DrugMAP Full Data Download File
Title - DrugMAP drug information in raw format
Version 1.01 (2022.07.20)
Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB)
            College of Pharmaceutical Sciences
            Zhejiang University
            https://idrblab.org/
Any question about data provided here, please contact with:
Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn)

ID: Drug ID
DN: Drug Name
HS: Highest Status
SN: Synonymous
CP: Company
TC: Therapeutic Class
DT: Drug Type
SQ: Sequence
PC: PubChem CID
MW: Molecular Weight
FM: Formula
IC: InChI
CS: Canonical SMILES
IK: InChIKey
IU: IUPAC Name
CA: CAS Number
CB: ChEBI ID
DE: Disease Entry

DMMHNU2	ID	DMMHNU2
DMMHNU2	DN	(S)-(+)-Dimethindene maleate
DMMHNU2	HS	Approved
DMMHNU2	SN	UNII-J43ZL3WTLN; J43ZL3WTLN; 136152-65-3; DSSTox_RID_83231; DSSTox_CID_28966; DSSTox_GSID_49040; Dimethindene maleate, (+)-; CAS-1217457-81-2; NCGC00025158-01; 121367-05-3; Dimethindene maleate, (S)-(+)-; DTXSID8049040; CHEMBL2356801; MolPort-023-276-095; HMS3267J12; Tox21_113582; AKOS024456589; Tox21_113582_1; NCGC00025158-02; 1H-Indene-2-ethanamine, N,N-dimethyl-3-((1S)-1-(2-pyridinyl)ethyl)-, (2Z)-2-butenedioate (1:1); B6734; (S)-(+)-Dimethindene maleate, > UNII-6LL60J9E0O component
DMMHNU2	TC	Antiinflammatory Agents
DMMHNU2	DT	Small molecular drug
DMMHNU2	PC	56972160
DMMHNU2	MW	408.5
DMMHNU2	FM	C24H28N2O4
DMMHNU2	IC	InChI=1S/C20H24N2.C4H4O4/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20;5-3(6)1-2-4(7)8/h4-10,12,15H,11,13-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m1./s1
DMMHNU2	CS	C[C@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C.C(=C\\C(=O)O)\\C(=O)O
DMMHNU2	IK	SWECWXGUJQLXJF-HFNHQGOYSA-N
DMMHNU2	IU	(Z)-but-2-enedioic acid;N,N-dimethyl-2-[3-[(1S)-1-pyridin-2-ylethyl]-1H-inden-2-yl]ethanamine
DMMHNU2	CA	CAS 136152-65-3
DMMHNU2	DE	Pruritus

DMIAHVU	ID	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	HS	Approved
DMIAHVU	SN	154-17-6; Deoxyglucose; 2-Deoxy-D-mannose; 2-Deoxy-D-arabinohexose; UNII-9G2MP84A8W; D-Arabino-hexose, 2-deoxy-; HSDB 5484; arabino-Hexose, 2-deoxy-; D-Glucose, 2-deoxy-; 9G2MP84A8W; (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal; AK-44445; 2 Deoxyglucose; 2 Deoxy D glucose; 2 Desoxy D glucose; D-arabino-2-desoxyhexose; d-2-glucodesose; D-2dGlc; deoxy-d-glucose, 2-; 2-DEOXYLGLUCOSE; 2-INNo-D-AEIIC; SCHEMBL7670; AC1L33KH; KSC175S5P; 4-01-00-04282 (Beilstein Handbook Reference); Jsp003004; CHEMBL2074932; CTK0H5957; MolPort-002-317-302; 2-deoxy-D-glucose
DMIAHVU	CP	Threshold Pharmaceuticals
DMIAHVU	DT	Small molecular drug
DMIAHVU	PC	108223
DMIAHVU	MW	164.16
DMIAHVU	FM	C6H12O5
DMIAHVU	IC	InChI=1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
DMIAHVU	CS	C(C=O)[C@H]([C@@H]([C@@H](CO)O)O)O
DMIAHVU	IK	VRYALKFFQXWPIH-PBXRRBTRSA-N
DMIAHVU	IU	(3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal
DMIAHVU	CA	CAS 154-17-6
DMIAHVU	DE	Solid tumour/cancer

DMYFBMS	ID	DMYFBMS
DMYFBMS	DN	99mTc-fanolesomab
DMYFBMS	HS	Approved
DMYFBMS	SN	LeuTech; NeutroSpec; RB5-IgM; Technetium (99mTc) fanolesomab; Anti-SSEA-1; Technetium-99m-fanolesomab; 99mTc RB5-IgM; 99mTc anti-SSEA-1; 99mTc-labeled anti-CD15 antibody
DMYFBMS	CP	Palatin Technologies
DMYFBMS	DT	Antibody
DMYFBMS	DE	Appendicitis

DMVZO01	ID	DMVZO01
DMVZO01	DN	99mTc-sestamibi
DMVZO01	HS	Approved
DMVZO01	SN	Sestamibi; RP-30; Tc-MIBI; Technetium-99m sestamibi
DMVZO01	CP	Bristol-Myers Squibb Pharma Co
DMVZO01	DT	Small molecular drug
DMVZO01	PC	9832136
DMVZO01	MW	777.9
DMVZO01	FM	C36H66N6O6Tc+7
DMVZO01	IC	InChI=1S/6C6H11NO.Tc/c6*1-6(2,8-4)5-7-3;/h6*5H2,1-2,4H3;/q;;;;;;+7/i;;;;;;1+1
DMVZO01	CS	CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.[99Tc+7]
DMVZO01	IK	ZGDBEIODOXIKGQ-KTTJZPQESA-N
DMVZO01	IU	1-isocyano-2-methoxy-2-methylpropane;technetium-99(7+)
DMVZO01	DE	Breast cancer

DMMN36E	ID	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	HS	Approved
DMMN36E	SN	Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC
DMMN36E	CP	GlaxoSmithKline
DMMN36E	TC	Anti-HIV Agents
DMMN36E	DT	Small molecular drug
DMMN36E	PC	441300
DMMN36E	MW	286.33
DMMN36E	FM	C14H18N6O
DMMN36E	IC	InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1
DMMN36E	CS	C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO
DMMN36E	IK	MCGSCOLBFJQGHM-SCZZXKLOSA-N
DMMN36E	IU	[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
DMMN36E	CA	CAS 136470-78-5
DMMN36E	CB	CHEBI:421707
DMMN36E	DE	Human immunodeficiency virus infection

DMOERGM	ID	DMOERGM
DMOERGM	DN	Abaloparatide
DMOERGM	HS	Approved
DMOERGM	SN	Tymlos
DMOERGM	CP	Radius Health
DMOERGM	DT	Recombinant protein
DMOERGM	SQ	Abaloparatide N-terminal peptide sequence: AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA
DMOERGM	PC	76943386
DMOERGM	MW	3961
DMOERGM	FM	C174H300N56O49
DMOERGM	IC	InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1
DMOERGM	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
DMOERGM	IK	BVISQZFBLRSESR-XSCWXTNMSA-N
DMOERGM	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMOERGM	CA	CAS 247062-33-5
DMOERGM	DE	Postmenopausal osteoporosis

DM2RX0I	ID	DM2RX0I
DM2RX0I	DN	Abametapir
DM2RX0I	HS	Approved
DM2RX0I	SN	5,5'-Dimethyl-2,2'-bipyridine; 1762-34-1; 5,5'-Dimethyl-2,2'-dipyridyl; 5,5'-Dimethyl-2,2'-bipyridyl; 6,6'-Bi-3-picoline; 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-; HA-44; 6,6'-Di-3-picolyl; 6,6'-Di-3-picoline; UNII-6UO390AMFB; 5-methyl-2-(5-methylpyridin-2-yl)pyridine; MFCD01740554; 6UO390AMFB; CHEMBL2205807; 5,5'-dimethyl-2,2'-bipyridinyl; 5,5 -Dimethyl-2,2 -bipyridine; Xeglyze; BRN 0123183; Abametapir [USAN:INN]; Xeglyze(Abametapir); Xeglyze (TN); PubChem24353; Abametapir (USAN/INN); ACMC-209eb4; SCHEMBL351152; HA44; 2,2 -Bis-(5-methylpyridyl); DTXSID00170095; ZINC403335; 9238AA; ANW-22814; BDBM50401351; LT0042; s5752; 5,5''-Dimethyl-2,2''-bipyridine; AKOS005257775; CS-W004546; DB11932; MCULE-8581798506; SB17220; 5,5 inverted exclamation marka-Dimethyl-2,2 inverted exclamation marka-dipyridyl; 5,5'-Dimethyl-2,2'-dipyridyl, 98%; AK-63331; DS-15219; SY052805; FT-0689891; D10687; W-108621; Q27265547; 5,5 inverted exclamation mark -Dimethyl-2,2 inverted exclamation mark -bipyridyl
DM2RX0I	DT	Small molecular drug
DM2RX0I	PC	15664
DM2RX0I	MW	184.24
DM2RX0I	FM	C12H12N2
DM2RX0I	IC	InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3
DM2RX0I	CS	CC1=CN=C(C=C1)C2=NC=C(C=C2)C
DM2RX0I	IK	PTRATZCAGVBFIQ-UHFFFAOYSA-N
DM2RX0I	IU	5-methyl-2-(5-methylpyridin-2-yl)pyridine
DM2RX0I	CA	CAS 1762-34-1
DM2RX0I	DE	Head and body lice

DM5WFNP	ID	DM5WFNP
DM5WFNP	DN	Abarelix
DM5WFNP	HS	Approved
DM5WFNP	SN	Plenaxis; Abarelix [USAN]; Plenaxis depot; PPI 149; R 3827; PPI-149; Plenaxis (TN); R-3827; Abarelix (USAN/INN); Abarelix-Depot-M; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(sup 6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N(6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-10
DM5WFNP	CP	Speciality European Pharma
DM5WFNP	TC	Anticancer Agents
DM5WFNP	DT	Small molecular drug
DM5WFNP	PC	16131215
DM5WFNP	MW	1416.1
DM5WFNP	FM	C72H95ClN14O14
DM5WFNP	IC	InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1
DM5WFNP	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM5WFNP	IK	AIWRTTMUVOZGPW-HSPKUQOVSA-N
DM5WFNP	IU	(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide
DM5WFNP	CA	CAS 183552-38-7
DM5WFNP	CB	CHEBI:337298
DM5WFNP	DE	Prostate cancer

DMSA8RU	ID	DMSA8RU
DMSA8RU	DN	Abatacept
DMSA8RU	HS	Approved
DMSA8RU	SN	Orencia (TN)
DMSA8RU	CP	Bristol-Myers Squibb
DMSA8RU	TC	Antirheumatic Agents
DMSA8RU	SQ	Abatacept monomer sequence: MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMSA8RU	DE	Rheumatoid arthritis

DMJO6GV	ID	DMJO6GV
DMJO6GV	DN	Abciximab
DMJO6GV	HS	Approved
DMJO6GV	SN	ReoPro (TN)
DMJO6GV	CP	Eli Lilly
DMJO6GV	TC	Anticoagulants
DMJO6GV	DT	Monoclonal antibody
DMJO6GV	SQ	1TXV:H ReoPro-like antibody Heavy Chain 1: EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;1TXV:L ReoPro-like antibody Light Chain 1DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC</sequence>    <sequence format="FASTA">&gt;1TXV:H ReoPro-like antibody Heavy Chain 2EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;1TXV:L ReoPro-like antibody Light Chain 2DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
DMJO6GV	DE	Angina pectoris

DM8V75C	ID	DM8V75C
DM8V75C	DN	ABIRATERONE
DM8V75C	HS	Approved
DM8V75C	SN	Abiraterone (AR inhibitor)
DM8V75C	DT	Small molecular drug
DM8V75C	PC	132971
DM8V75C	MW	349.5
DM8V75C	FM	C24H31NO
DM8V75C	IC	InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1
DM8V75C	CS	C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O
DM8V75C	IK	GZOSMCIZMLWJML-VJLLXTKPSA-N
DM8V75C	IU	(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DM8V75C	CA	CAS 154229-19-3
DM8V75C	CB	CHEBI:68642
DM8V75C	DE	Prostate cancer

DMANBZI	ID	DMANBZI
DMANBZI	DN	Abiraterone acetate
DMANBZI	HS	Approved
DMANBZI	SN	CB-7630; JNJ-212082; Zytiga
DMANBZI	TC	Anticancer Agents
DMANBZI	DT	Small molecular drug
DMANBZI	PC	9821849
DMANBZI	MW	391.5
DMANBZI	FM	C26H33NO2
DMANBZI	IC	InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
DMANBZI	CS	CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
DMANBZI	IK	UVIQSJCZCSLXRZ-UBUQANBQSA-N
DMANBZI	IU	[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMANBZI	CA	CAS 154229-18-2
DMANBZI	CB	CHEBI:68639
DMANBZI	DE	Prostate cancer

DMZT2P0	ID	DMZT2P0
DMZT2P0	DN	Abobotulinum toxin A
DMZT2P0	HS	Approved
DMZT2P0	SN	AbobotulinumtoxinA; Azzalure; Dysport; Reloxin; Abobotulinum toxin A for injection; CNT-52120
DMZT2P0	CP	Ipsen
DMZT2P0	DE	Cervical cancer

DM7GCVW	ID	DM7GCVW
DM7GCVW	DN	Acalabrutinib
DM7GCVW	HS	Approved
DM7GCVW	SN	Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326
DM7GCVW	CP	AstraZeneca/Acerta Pharma
DM7GCVW	PC	71226662
DM7GCVW	MW	465.5
DM7GCVW	FM	C26H23N7O2
DM7GCVW	IC	InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
DM7GCVW	CS	CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
DM7GCVW	IK	WDENQIQQYWYTPO-IBGZPJMESA-N
DM7GCVW	IU	4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
DM7GCVW	CA	CAS 1420477-60-6
DM7GCVW	DE	Chronic lymphocytic leukaemia; Mantle cell lymphoma

DMO381I	ID	DMO381I
DMO381I	DN	Acamprosate
DMO381I	HS	Approved
DMO381I	SN	AOTA; Acamprosato; Acamprosatum; Acamprostate; Aotal; Campral; Calcium acetyl homotaurinate; Calcium acetylhomotaurinate; Calcium acetylhomotaurine; Sodium acetylhomotaurine; Acamprosate 6473; Acamprosate (Campral); Acamprosate (INN); Acamprosate [INN:BAN]; Acamprosato [INN-Spanish]; Acamprosatum [INN-Latin]; Aotal (TN); Campral (TN); N-Acetylhomotaurine; 3-(Acetylamino)propanesulphonic acid; 3-Acetamido-1-propanesulfonic acid; 3-acetamidopropane-1-sulfonic acid
DMO381I	TC	Alcohol Deterrents
DMO381I	DT	Small molecular drug
DMO381I	PC	71158
DMO381I	MW	181.21
DMO381I	FM	C5H11NO4S
DMO381I	IC	InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10)
DMO381I	CS	CC(=O)NCCCS(=O)(=O)O
DMO381I	IK	AFCGFAGUEYAMAO-UHFFFAOYSA-N
DMO381I	IU	3-acetamidopropane-1-sulfonic acid
DMO381I	CA	CAS 77337-76-9
DMO381I	CB	CHEBI:51041
DMO381I	DE	Alcohol dependence

DMRM3AW	ID	DMRM3AW
DMRM3AW	DN	Acarbose
DMRM3AW	HS	Approved
DMRM3AW	SN	acarbose; 56180-94-0; Glucobay; Precose; Prandase; C25H43NO18; CHEBI:2376; CHEMBL3734896; BAY-g 5421; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1-&gt;4)-alpha-D-glucopyranosyl-(1-&gt;4)-D-glucopyranose; SMR000466376; SR-01000759407; Acarbose/; Acarbose [USAN:BAN:INN:JAN]; Acarbose,(S); Precose (TN); AC1L26GM; Acarbose (JAN/USAN/INN); MLS006011898; MLS000759506; MLS001424056; SPECTRUM1505172; SCHEMBL5316305; CHEMBL404271; BDBM23406; MolPort-002-507-369
DMRM3AW	CP	Bayer
DMRM3AW	TC	Hypoglycemic Agents
DMRM3AW	DT	Small molecular drug
DMRM3AW	PC	41774
DMRM3AW	MW	645.6
DMRM3AW	FM	C25H43NO18
DMRM3AW	IC	InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1
DMRM3AW	CS	C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO
DMRM3AW	IK	XUFXOAAUWZOOIT-UGEKTDRHSA-N
DMRM3AW	IU	(3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
DMRM3AW	CA	CAS 56180-94-0
DMRM3AW	CB	CHEBI:2376
DMRM3AW	DE	Diabetic complication; Cardiovascular disease

DM0TI4U	ID	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	HS	Approved
DM0TI4U	SN	Acebrutololum; Acebutololo; Acebutololum; Acetobutolol; Neptal; Prent; Sectral; Acebutolol HCL; RP 21823; Acebrutololum [INN-Latin]; Acebutololum [INN-Latin]; Acetobutolol [INN-Spanish]; Dl-Acebutolol; M & B 17803A; Prent (TN); Sectral (TN); Acebutolol (USAN/INN); Acebutolol [USAN:INN:BAN]; M&B-17803 A; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; (+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-Acebutolol; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone
DM0TI4U	CP	Promius Pharma Llc
DM0TI4U	TC	Antihypertensive Agents
DM0TI4U	DT	Small molecular drug
DM0TI4U	PC	1978
DM0TI4U	MW	336.4
DM0TI4U	FM	C18H28N2O4
DM0TI4U	IC	InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
DM0TI4U	CS	CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
DM0TI4U	IK	GOEMGAFJFRBGGG-UHFFFAOYSA-N
DM0TI4U	IU	N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide
DM0TI4U	CA	CAS 37517-30-9
DM0TI4U	CB	CHEBI:2379
DM0TI4U	DE	Hypertension

DMOLNCZ	ID	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	HS	Approved
DMOLNCZ	SN	(-)-aceclidine; R-(-)-aceclidine; GTPL288; ZB016005; [(8R)-1-azoniabicyclo[2.2.2]octan-8-yl] acetate
DMOLNCZ	DT	Small molecular drug
DMOLNCZ	PC	1979
DMOLNCZ	MW	169.22
DMOLNCZ	FM	C9H15NO2
DMOLNCZ	IC	InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3
DMOLNCZ	CS	CC(=O)OC1CN2CCC1CC2
DMOLNCZ	IK	WRJPSSPFHGNBMG-UHFFFAOYSA-N
DMOLNCZ	IU	1-azabicyclo[2.2.2]octan-3-yl acetate
DMOLNCZ	CA	CAS 827-61-2
DMOLNCZ	CB	CHEBI:93847
DMOLNCZ	DE	Glaucoma/ocular hypertension

DMZDF0B	ID	DMZDF0B
DMZDF0B	DN	Aceclofenac
DMZDF0B	HS	Approved
DMZDF0B	SN	Airtal; Barracan; Biofenac; Bristaflam; Falcol; Gerbin; Preservex; YT-919
DMZDF0B	CP	Almirall Prodesfarma SA
DMZDF0B	DT	Small molecular drug
DMZDF0B	PC	71771
DMZDF0B	MW	354.2
DMZDF0B	FM	C16H13Cl2NO4
DMZDF0B	IC	InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)
DMZDF0B	CS	C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl
DMZDF0B	IK	MNIPYSSQXLZQLJ-UHFFFAOYSA-N
DMZDF0B	IU	2-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxyacetic acid
DMZDF0B	CA	CAS 89796-99-6
DMZDF0B	CB	CHEBI:31159
DMZDF0B	DE	Inflammation

DMH75KV	ID	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	HS	Approved
DMH75KV	SN	Acenocoumarin; Acenocoumarolum; Acenocumarol; Acenocumarolo; Acenocumarolum; Acenokumarin; Ascumar; Minisintrom; Neositron;Nicoumalone; Nicumalon; Nitrovarfarian; Nitrowarfarin; Sincoumar; Sinkumar; Sinthrom; Sinthrome; Sintrom; Sintroma; Syncoumar; Syncumar; Synthrom; Syntrom; Zotil; Acenocoumarol Alliance Brand; Acenocoumarol Novartis Brand; Acenocoumarol [INN]; Acenocumarolo [DCIT]; Acenokumarin [Czech]; Alliance Brand of Acenocoumarol; Ciba Geigy Brand of Acenocoumarol; Mini Sintrom; Novartis Brand of Acenocoumarol; G 23350; Acenocoumarol (INN); Acenocoumarol Ciba-Geigy Brand; Acenocoumarolum [INN-Latin]; Ciba-Geigy Brand of Acenocoumarol; G-23350; Mini-sintrom; Sinthrome (TN); Sintrom (TN); AB-014/25000129; G-23,350; Mini-sintrom (TN); Nitrophenylacetylethyl-4-hydroxycoumarine; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-4h-chromen-4-one; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-4-one; 3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-para-nitrobenzyl)-4-hydroxy-coumarin; 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one;4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
DMH75KV	TC	Anticoagulants
DMH75KV	DT	Small molecular drug
DMH75KV	PC	54676537
DMH75KV	MW	353.3
DMH75KV	FM	C19H15NO6
DMH75KV	IC	InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3
DMH75KV	CS	CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(C3=CC=CC=C3OC2=O)O
DMH75KV	IK	VABCILAOYCMVPS-UHFFFAOYSA-N
DMH75KV	IU	4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-2-one
DMH75KV	CA	CAS 152-72-7
DMH75KV	CB	CHEBI:53766
DMH75KV	DE	Thrombosis

DM1SRQT	ID	DM1SRQT
DM1SRQT	DN	Aceprometazine
DM1SRQT	HS	Approved
DM1SRQT	SN	Aceprometazina; Aceprometazinum; Acepromethazine; Aceprometazina [INN-Spanish]; Aceprometazine [INN:DCF]; Aceprometazinum [INN-Latin]; Mepronizine (TN); KETONE, 10-(2-(DIMETHYLAMINO)PROPYL)PHENOTHIAZIN-2-YL METHYL; Ethanone, 1-(10-(2-(dimethylamino)propyl)-10H-phenothiazin-2-yl)-(9CI); 1-(10-(2-(Dimethylamino)propyl)-10H-phenothiazin-2-yl)ethanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone; 10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone; 1664 CB
DM1SRQT	TC	Antihistamines
DM1SRQT	DT	Small molecular drug
DM1SRQT	PC	26035
DM1SRQT	MW	326.5
DM1SRQT	FM	C19H22N2OS
DM1SRQT	IC	InChI=1S/C19H22N2OS/c1-13(20(3)4)12-21-16-7-5-6-8-18(16)23-19-10-9-15(14(2)22)11-17(19)21/h5-11,13H,12H2,1-4H3
DM1SRQT	CS	CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(=O)C)N(C)C
DM1SRQT	IK	XLOQNFNTQIRSOX-UHFFFAOYSA-N
DM1SRQT	IU	1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone
DM1SRQT	CA	CAS 13461-01-3
DM1SRQT	CB	CHEBI:53770
DM1SRQT	DE	Sleep-wake disorder

DMUIE76	ID	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	HS	Approved
DMUIE76	SN	acetaminophen; 4-Acetamidophenol; Paracetamol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Acetaminofen; Panadol; Datril; p-Hydroxyacetanilide; N-Acetyl-p-aminophenol; p-Acetamidophenol; Algotropyl; Naprinol; Lonarid; 4'-Hydroxyacetanilide; Multin; Acenol; Acamol; Anelix; p-Acetaminophenol; Liquagesic; Acetagesic; Gelocatil; Servigesic; Acetalgin; Abensanil; Pyrinazine; Injectapap; Clixodyne; Valgesic; Tussapap; Finimal; Paracet; Homoolan; Febrolin; Febrilix; Febridol; Dymadon; Anaflon; Apamide; Valadol; Tralgon; Tabalgin; Lestemp; Alvedon; Abenol; Abrol; Abrolet; Acephen; Acertol; Acetaco; Acetamol; Acetavance; Acetofen; Actamin; Actimol; Afebrin; Afebryl; Aferadol; Algesidal; Algina; Algomol; Alpiny; Alpinyl; Amadil; Aminofen; Analter; Anapap; Andox; Anhiba; Antidol; Anuphen; Apacet; Apadon; Apitrelal; Arfen; Arthralgen; Asetam; Asomal; Aspac; Asplin; Atasol; Atralidon; Babikan; Bacetamol; Banesin; Benmyo; Biocetamol; Cadafen; Calapol; Calmanticold; Calonal; Calpol; Capital; Captin; Causalon; Cefalex; Cetadol; Codabrol; Codalgin; Codapane; Codicet; Codisal; Codoliprane; Cofamol; Conacetol; Cosutone; Cuponol; Curadon; Curpol; Custodial; Dafalgan; Darocet; Darvocet; Daygrip; Deminofen; Democyl; Demogripal; Desfebre; Dhamol; Dimindol; Dirox; Disprol; Dolcor; Dolefin; Dolegrippin; Dolgesic; Doliprane; Dolko; Dolofugin; Doloreduct; Dolorfug; Dolorstop; Dolotec; Dolprone; Dorocoff; Dresan; Dristancito; Duaneo; Dularin; Duorol; Duracetamol; Durapan; Dypap; Ecosetol; Elixodyne; Empracet; Enelfa; Eneril; Excipain; Exdol; Fanalgic; Farmadol; Febranine; Febrectal; Febrectol; Febrex; Febricet; Febrin; Febrinol; Fendon; Fensum; Fepanil; Fevor; Finiweh; Fluparmol; Geluprane; Genapap; Genebs; Grippostad; Gynospasmine; Hedex; Ildamol; Inalgex; Infadrops; Janupap; Kataprin; Korum; Labamol; Lekadol; Lemgrip; Lemsip; Liqiprine; Lupocet; Lyteca; Magnidol; Malgis; Malidens; Maxadol; Medocodene; Mexalen; Minafen; Minoset; Miralgin; Momentum; NEBS; Napafen; Nealgyl; NeoCitran; Neodol; Neodolito; Neopap; Neotrend; Neuridon; NilnOcen; Nina; Nobedon; Nodolex; Noral; Ofirmev; Oltyl; Oralgan; Ortensan; Oxycocet; Paceco; Pacemo; Pacemol; Pacet; Pacimol; Paedialgon; Paedol; Painex; Paldesic; Pamol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorb; Panasorbe; Panets; Panex; Panodil; Panofen; Pantalgin; Paracemol; Paracenol; Paracetamole; Paracetamolo; Paracetanol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Parakapton; Parake; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parapan; Parasedol; Parasin; Paraspen; Parcetol; Parelan; Parmol; Parogal; Paroma; Pasolind; Pediapirin; Pediatrix; Pedric; Perfalgan; Phendon; Phenipirin; Phogoglandin; Pinex; Piramin; Pirinasol; Plicet; Polmofen; Predimol; Predualito; Prodol; Prompt; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Redutemp; Reliv; Remedol; Rivalgyl; Robigesic; Rounox; RubieMol; Rubophen; Rupemol; Salzone; Sanicet; Sanicopyrine; Scanol; Scentalgyl; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Setol; Sifenol; Sinaspril; Sinedol; Sinmol; Stanback; Stopain; Sunetheton; Supofen; Suppap; TYL; Tachiprina; Tapanol; Tapar; Tazamol; Temlo; Tempanal; Tempra; Termacet; Termalgin; Termalgine; Termofren; Tiffy; Titralgan; Treuphadol; Tricoton; Tylex; Tylol; Tymol; Upsanol; Utragin; Valorin; Veralgina; Vermidon; Verpol; Vips; Viruflu; Vivimed; Volpan; Zatinol; Zolben; Aceta Elixir; Actifed Plus; Aspirin free anacin; Bayer Select; D oliprane; Dymadon Co; Fortalidon P; Gattaphen T; Gripin Bebe; Helon N; Influbene N; Jin Gang; Lonarid Mono; Lyteca Syrup; Malex N; Panadeine Co; Panale ve; Pasolind N; Spalt N; Supadol mono; Toximer P; Treupel N; Treupel mon; Ty lenol; Tylex CD; Anacin 3; A-Per; Accu-Tap; Ultracet
DMUIE76	CP	Beximco Pharma
DMUIE76	TC	Analgesics
DMUIE76	DT	Small molecular drug
DMUIE76	PC	1983
DMUIE76	MW	151.16
DMUIE76	FM	C8H9NO2
DMUIE76	IC	InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)
DMUIE76	CS	CC(=O)NC1=CC=C(C=C1)O
DMUIE76	IK	RZVAJINKPMORJF-UHFFFAOYSA-N
DMUIE76	IU	N-(4-hydroxyphenyl)acetamide
DMUIE76	CA	CAS 103-90-2
DMUIE76	CB	CHEBI:46195
DMUIE76	DE	Pain

DM1AF5U	ID	DM1AF5U
DM1AF5U	DN	Acetazolamide
DM1AF5U	HS	Approved
DM1AF5U	SN	Acetadiazol; Acetamidothiadiazolesulfonamide; Acetamox; Acetazolam; Acetazolamid; Acetazolamida; Acetazolamidum; Acetazolamine; Acetazoleamide; Acetozalamide; AkZol; ApoAcetazolamide; Atenezol; Cidamex; Dazamide; Defiltran; Dehydratin; Diacarb; Diakarb; Diamox; Didoc; Diluran; Diuramid; Diuramide; Diuriwas; Diutazol; Donmox; Duiramid; Edemox; Eumicton; Fonurit; Glauconox; Glaumox; Glaupax; Glupax; HumaZolamide; Natrionex; Nephramid; Nephramide; Phonurit; Storzolamide; Vetamox; Acetazolamide Apotex Brand; Acetazolamide Chiesi Brand; Acetazolamide Dioptic Brand; Acetazolamide Grin Brand; Acetazolamide ICN Brand; Acetazolamide Jumer Brand; Acetazolamide Llorens Brand; Acetazolamide Medphano Brand; Acetazolamide Novopharm Brand; Acetazolamide Orion Brand; Acetazolamide Wassermann Brand; Ak Zol; Apo Acetazolamide; Apotex Brand of Acetazolamide; Chiesi Brand of Acetazolamide; Ciba Vision Brand of Acetazolamide; DiamoxSequels; Dioptic Brand of Acetazolamide; Grin Brand of Acetazolamide; Huma Zolamide; ICN Brand of Acetazolamide; Jumer Brand of Acetazolamide; Llorens Brand of Acetazolamide; Medphano Brand of Acetazolamide; Monosodium Salt Acetazolamide; Novopharm Brand of Acetazolamide; Orion Brand of Acetazolamide; Storz Brand of Acetazolamide Preparation; Wassermann Brand of Acetazolamide; Wyeth Brand of Acetazolamide Preparation; A 6011; Carbonic anhydrase inhibitor 6063; Acetazolamida [INN-Spanish]; Acetazolamide (AAZ); Acetazolamide, Monosodium Salt; Acetazolamidum [INN-Latin]; Ak-Zol; Apo-Acetazolamide; Carbonic Anhydrase Inhibitor No. 6063; Diamox (TN); Diureticum-holzinger; Huma-Zolamide; SK-acetazolamide; Acetazolamide Sodium, (Sterile); Acetazolamide [INN:BAN:JAN]; Acetazolamide (JP15/USP/INN); 4-Diamox
DM1AF5U	TC	Anticonvulsants
DM1AF5U	DT	Small molecular drug
DM1AF5U	PC	1986
DM1AF5U	MW	222.3
DM1AF5U	FM	C4H6N4O3S2
DM1AF5U	IC	InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)
DM1AF5U	CS	CC(=O)NC1=NN=C(S1)S(=O)(=O)N
DM1AF5U	IK	BZKPWHYZMXOIDC-UHFFFAOYSA-N
DM1AF5U	IU	N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide
DM1AF5U	CA	CAS 59-66-5
DM1AF5U	CB	CHEBI:27690
DM1AF5U	DE	Glaucoma/ocular hypertension

DM4SJ5Y	ID	DM4SJ5Y
DM4SJ5Y	DN	Acetic Acid, Glacial
DM4SJ5Y	HS	Approved
DM4SJ5Y	SN	ethanoic acid; 64-19-7; Ethylic acid; Acetic acid glacial; Acetic acid, glacial; Methanecarboxylic acid; Glacial acetic acid; Vinegar acid; Acetasol; Acide acetique; Essigsaeure; Aci-jel; Azijnzuur; Vinegar; Kyselina octova; Acido acetico; Octowy kwas; Pyroligneous acid; HOAc; Azijnzuur [Dutch]; Ethanoic acid monomer; acetyl alcohol; Aceticum acidum; Essigsaeure [German]; ethoic acid; Caswell No 003; Otic Tridesilon; Octowy kwas [Polish]; Otic Domeboro; Acetic acid (natural); Kyselina octova [Czech]; Acide acetique [French]; Orlex; Vosol; Acetic Acid 025% In Plastic Container
DM4SJ5Y	CP	Actavis Mid Atlantic Llc
DM4SJ5Y	TC	Antiinfective Agents
DM4SJ5Y	DT	Small molecular drug
DM4SJ5Y	PC	176
DM4SJ5Y	MW	60.05
DM4SJ5Y	FM	C2H4O2
DM4SJ5Y	IC	InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)
DM4SJ5Y	CS	CC(=O)O
DM4SJ5Y	IK	QTBSBXVTEAMEQO-UHFFFAOYSA-N
DM4SJ5Y	IU	acetic acid
DM4SJ5Y	CA	CAS 64-19-7
DM4SJ5Y	CB	CHEBI:15366
DM4SJ5Y	DE	infection in the ear canal

DMR6N7H	ID	DMR6N7H
DMR6N7H	DN	Acetohexamide
DMR6N7H	HS	Approved
DMR6N7H	SN	Acetohexamid; Acetohexamida; Acetohexamidum; Dimelin; Dimelor; Dymelor; Gamadiabet; Hypoglicil; Metaglucina; Minoral; Ordimel; Tsiklamid; Acetohexamide Lilly Brand; Acetohexamide Salvat Brand; Lilly Brand of Acetohexamide; Ord imel; Salvat Brand of Acetohexamide; U 14812; A-178; Acetohexamida [INN-Spanish]; Acetohexamidum [INN-Latin]; Dimelin (antidiabetic); Dymelor (TN); U-14812; Acetohexamide (JP15/USP/INN); Acetohexamide [USAN:INN:BAN:JAN]; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)-carbonyl]benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide
DMR6N7H	TC	Hypoglycemic Agents
DMR6N7H	DT	Small molecular drug
DMR6N7H	PC	1989
DMR6N7H	MW	324.4
DMR6N7H	FM	C15H20N2O4S
DMR6N7H	IC	InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)
DMR6N7H	CS	CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2
DMR6N7H	IK	VGZSUPCWNCWDAN-UHFFFAOYSA-N
DMR6N7H	IU	1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea
DMR6N7H	CA	CAS 968-81-0
DMR6N7H	CB	CHEBI:28052
DMR6N7H	DE	Diabetic complication

DMYX7NI	ID	DMYX7NI
DMYX7NI	DN	Acetohydroxamic Acid
DMYX7NI	HS	Approved
DMYX7NI	SN	AHA; Acethydroxamsaeure; Acethydroxamsaure; Acetohydroxamate; HAE; Lithostat; Acethydroxamic acid; Acethydroxamsaeure [German]; Acetohydroximic acid; Acetyl hydroxyamino; Acetylhydroxamic acid; Acide acetohydroxamique; Acide acetohydroxamique [French]; Acido acetohidroxamico; Acido acetohidroxamico [Spanish]; Acidum acetohydroxamicum; Acidum acetohydroxamicum [Latin]; Cetohyroxamic acid; Methylhydroxamic acid; SJX HLdmMAH; AHA (TN); Acetic acid, oxime; Acetohydroxamic acid [USAN:INN]; Lithostat (TN); N-Acetyl hydroxyacetamide; N-Acetylhydroxylamine; N-Hydroxyacetamide; N-hydroxyacetimidic acid; N-hydroxyethanimidic acid; S14-0751; Acetohydroxamic acid (USP/INN); Acetamide, N-hydroxy-(9CI)
DMYX7NI	TC	Antiinfective Agents
DMYX7NI	DT	Small molecular drug
DMYX7NI	PC	1990
DMYX7NI	MW	75.07
DMYX7NI	FM	C2H5NO2
DMYX7NI	IC	InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
DMYX7NI	CS	CC(=O)NO
DMYX7NI	IK	RRUDCFGSUDOHDG-UHFFFAOYSA-N
DMYX7NI	IU	N-hydroxyacetamide
DMYX7NI	CA	CAS 546-88-3
DMYX7NI	CB	CHEBI:27777
DMYX7NI	DE	Urinary tract infection

DMZV2PJ	ID	DMZV2PJ
DMZV2PJ	DN	Acetophenazine
DMZV2PJ	HS	Approved
DMZV2PJ	SN	Acephenazinum; Acetophenazina; Acetophenazinum; Tindal; Acetophenazine [INN]; Acetophenazina [INN-Spanish]; Acetophenazinum [INN-Latin]; Ketone, 10-(3-(4-(2-hydroxyethyl-1-piperazinyl)propyl)phenothiazin-2-yl methyl; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)ethanone; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone; 10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl methyl ketone; 2-acetyl-10-[3-[4-(b-hydroxyethyl)piperazinyl]propyl]phenothiazine
DMZV2PJ	TC	Antipsychotic Agents
DMZV2PJ	DT	Small molecular drug
DMZV2PJ	PC	17676
DMZV2PJ	MW	411.6
DMZV2PJ	FM	C23H29N3O2S
DMZV2PJ	IC	InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3
DMZV2PJ	CS	CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO
DMZV2PJ	IK	WNTYBHLDCKXEOT-UHFFFAOYSA-N
DMZV2PJ	IU	1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone
DMZV2PJ	CA	CAS 2751-68-0
DMZV2PJ	CB	CHEBI:2401
DMZV2PJ	DE	Bipolar disorder

DMDF79Z	ID	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	HS	Approved
DMDF79Z	SN	acetylcholine; Choline acetate; O-Acetylcholine; Acetyl choline ion; Acetylcholinum; 51-84-3; (2-Acetoxyethyl)trimethylammonium; Acetyl choline cation; Choline acetate (ester); 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Ach; Azetylcholin; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; UNII-N9YNS0M02X; BRN 1764436; CHEBI:15355; Bromoacetylcholine; EINECS 200-128-9; CHEMBL667; N9YNS0M02X; [2-(acetyloxy)ethyl]trimethylazanium; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- (9CI); 2-acetyloxyethyl-trimethylazanium; [3H]acetylcholine;  Miochol; Miochol-e
DMDF79Z	CP	Novartis Pharmaceuticals Corp
DMDF79Z	TC	Cardiovascular Agents
DMDF79Z	DT	Small molecular drug
DMDF79Z	PC	187
DMDF79Z	MW	146.21
DMDF79Z	FM	C7H16NO2+
DMDF79Z	IC	InChI=1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1
DMDF79Z	CS	CC(=O)OCC[N+](C)(C)C
DMDF79Z	IK	OIPILFWXSMYKGL-UHFFFAOYSA-N
DMDF79Z	IU	2-acetyloxyethyl(trimethyl)azanium
DMDF79Z	CA	CAS 51-84-3
DMDF79Z	CB	CHEBI:15355
DMDF79Z	DE	Cataract

DMHAUO0	ID	DMHAUO0
DMHAUO0	DN	Acetyldigitoxin
DMHAUO0	HS	Approved
DMHAUO0	SN	Acedigal; Acetildigitoxina; Acetyldiginatin; Acetyldigitoxinum; Acigoxin; Acylanid; Acylanide; Adicin; Acetyldigitoxin [INN]; Desglucolanatoside A; Acetildigitoxina [INN-Spanish]; Acetyldigitoxin (INN); Acetyldigitoxinum [INN-Latin]; Acylanid (TN); Alpha-Acetyldigitoxin; Alpha-Acetyldigitoxins; Alpha-Monoacetyldigitoxin; Acetyl-digitoxin-alpha; Digitoxin 3'''-acetate; Digitoxin, 3'''-acetate; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-{[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide; 3beta-[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide; [3-hydroxy-6-[4-hydroxy-6-[4-hydroxy-6-[[14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
DMHAUO0	CP	Norvatis Phamaceuticals Corporation
DMHAUO0	TC	Cardiotonic Agents
DMHAUO0	DT	Small molecular drug
DMHAUO0	PC	5284512
DMHAUO0	MW	807
DMHAUO0	FM	C43H66O14
DMHAUO0	IC	InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1
DMHAUO0	CS	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)OC(=O)C)O
DMHAUO0	IK	HPMZBILYSWLILX-UMDUKNJSSA-N
DMHAUO0	IU	[(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
DMHAUO0	CA	CAS 1111-39-3
DMHAUO0	CB	CHEBI:53773
DMHAUO0	DE	Congestive heart failure

DMYLOVR	ID	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	HS	Approved
DMYLOVR	SN	acyclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; Aciclovirum [Latin]; Sitavig; Aciclovier; Zyclir; 9-HYROXYETHOXYMETHYLGUANINE; Aciclovirum [INN-Latin]; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; W-248-U; 9-(2-Hydroxyethoxy)methylguanine; Acyclovir-side chain-2-3H; ACYCLOVIR SODIUM; 9-((2-Hydroxyethoxy)methyl)guanine; Acicloftal; Cargosil; BW-248U; UNII-X4HES1O11F; DRG-0008; NSC 645011; CHEBI:2453; CCRIS 1953; Iontophoretic acyclovir
DMYLOVR	CP	GlaxoSmithKline
DMYLOVR	TC	Antiviral Agents
DMYLOVR	DT	Small molecular drug
DMYLOVR	PC	135398513
DMYLOVR	MW	225.2
DMYLOVR	FM	C8H11N5O3
DMYLOVR	IC	InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)
DMYLOVR	CS	C1=NC2=C(N1COCCO)N=C(NC2=O)N
DMYLOVR	IK	MKUXAQIIEYXACX-UHFFFAOYSA-N
DMYLOVR	IU	2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one
DMYLOVR	CA	CAS 59277-89-3
DMYLOVR	CB	CHEBI:2453
DMYLOVR	DE	Virus infection; Herpes simplex virus infection

DM8BKU9	ID	DM8BKU9
DM8BKU9	DN	Acitretin
DM8BKU9	HS	Approved
DM8BKU9	SN	Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DM8BKU9	TC	Keratolytic Agents
DM8BKU9	DT	Small molecular drug
DM8BKU9	PC	5284513
DM8BKU9	MW	326.4
DM8BKU9	FM	C21H26O3
DM8BKU9	IC	InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
DM8BKU9	CS	CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC
DM8BKU9	IK	IHUNBGSDBOWDMA-AQFIFDHZSA-N
DM8BKU9	IU	(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DM8BKU9	CA	CAS 55079-83-9
DM8BKU9	CB	CHEBI:50173
DM8BKU9	DE	Psoriasis vulgaris

DMLFZHD	ID	DMLFZHD
DMLFZHD	DN	Aclarubicin
DMLFZHD	HS	Approved
DMLFZHD	SN	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A
DMLFZHD	TC	Anticancer Agents
DMLFZHD	DT	Small molecular drug
DMLFZHD	PC	451415
DMLFZHD	MW	811.9
DMLFZHD	FM	C42H53NO15
DMLFZHD	IC	InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
DMLFZHD	CS	CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O
DMLFZHD	IK	USZYSDMBJDPRIF-SVEJIMAYSA-N
DMLFZHD	IU	methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate
DMLFZHD	CA	CAS 57576-44-0
DMLFZHD	CB	CHEBI:77980
DMLFZHD	DE	Acute myeloid leukaemia

DM7JT24	ID	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	HS	Approved
DM7JT24	SN	Ouabain; Ouabagenin L-Rhamnoside; Ouabagenin L-rhamnoside; Acocantherin; Acocantherine; Acolongifloroside K; Astrobain; G-Strophanthin; G-Strophanthin (JAN); G-Strophicor; Gratibain; Gratus strophanthin; Kombetin; O 3125; OBN; Ouabagenin-L-rhamnosid; Ouabagenin-L-rhamnosid [German]; Ouabain (anhydrous); Ouabain anhydrous; Ouabain octahydrate; Ouabain, Octahydrate; Ouabaine; Oubain; Purostrophan; Quabain; Rectobaina; Solufantina; Strodival; Strophalen; Strophanthin G; Strophanthin-G; Strophoperm; Strophosan; Uabaina; Uabanin
DM7JT24	TC	Cardiotonic Agents
DM7JT24	DT	Small molecular drug
DM7JT24	PC	439501
DM7JT24	MW	584.7
DM7JT24	FM	C29H44O12
DM7JT24	IC	InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
DM7JT24	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
DM7JT24	IK	LPMXVESGRSUGHW-HBYQJFLCSA-N
DM7JT24	IU	3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DM7JT24	CA	CAS 630-60-4
DM7JT24	CB	CHEBI:472805
DM7JT24	DE	Heart failure; Atrial fibrillation

DMTIGA0	ID	DMTIGA0
DMTIGA0	DN	Acrivastine
DMTIGA0	HS	Approved
DMTIGA0	SN	Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
DMTIGA0	CP	Pfizer Pharmaceuticals
DMTIGA0	TC	Antiinflammatory Agents
DMTIGA0	DT	Small molecular drug
DMTIGA0	PC	5284514
DMTIGA0	MW	348.4
DMTIGA0	FM	C22H24N2O2
DMTIGA0	IC	InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
DMTIGA0	CS	CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC(=N3)/C=C/C(=O)O
DMTIGA0	IK	PWACSDKDOHSSQD-IUTFFREVSA-N
DMTIGA0	IU	(E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
DMTIGA0	CA	CAS 87848-99-5
DMTIGA0	CB	CHEBI:83168
DMTIGA0	DE	Allergic rhinitis

DMQMV1B	ID	DMQMV1B
DMQMV1B	DN	Adalimumab
DMQMV1B	HS	Approved
DMQMV1B	SN	Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)
DMQMV1B	CP	Abbott Laboratories
DMQMV1B	TC	Antirheumatic Agents
DMQMV1B	DT	Antibody
DMQMV1B	SQ	Light chain:: DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>    <sequence format="FASTA">&gt; Heavy chain:EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
DMQMV1B	DE	Rheumatoid arthritis

DMX2358	ID	DMX2358
DMX2358	DN	Adapalene
DMX2358	HS	Approved
DMX2358	SN	Adaferin; Adapaleno; Adapalenum; Differin; Differine; CD 271; CD271; Adaferin (TN); Adapaleno [INN-Spanish]; Adapalenum [INN-Latin]; CD-271; Differin (TN); Differin, Adapalene; KS-1196; Adapalene [USAN:BAN:INN]; Adapalene (JAN/USAN/INN); 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid; 6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid; 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid; 6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
DMX2358	CP	Galderma Laboratories
DMX2358	TC	Dermatologic Agents
DMX2358	DT	Small molecular drug
DMX2358	PC	60164
DMX2358	MW	412.5
DMX2358	FM	C28H28O3
DMX2358	IC	InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)
DMX2358	CS	COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5
DMX2358	IK	LZCDAPDGXCYOEH-UHFFFAOYSA-N
DMX2358	IU	6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
DMX2358	CA	CAS 106685-40-9
DMX2358	CB	CHEBI:31174
DMX2358	DE	Acne vulgaris

DMM278X	ID	DMM278X
DMM278X	DN	Adefovir
DMM278X	HS	Approved
DMM278X	SN	((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; 9-(2-(Phosphonomethoxy)ethyl)adenine; 9-(2-Phosphonylmethoxyethyl)adenine; ADEFOVIR; GS 0393; GS 393; GS-0393; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); N-(2-Phosphonylmethoxyethyl)adenine; PMEA; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid
DMM278X	DT	Small molecular drug
DMM278X	PC	60172
DMM278X	MW	273.189
DMM278X	FM	C12H14Cl2N2
DMM278X	IC	InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)
DMM278X	CS	C1=NC2=C(C(=N1)N)N=CN2CCOCP(=O)(O)O
DMM278X	IK	FIKAKWIAUPDISJ-UHFFFAOYSA-L
DMM278X	IU	2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid
DMM278X	CA	CAS 106941-25-7
DMM278X	CB	CHEBI:2469
DMM278X	DE	Hepatitis B virus infection; Herpes simplex virus infection

DMMAWY1	ID	DMMAWY1
DMMAWY1	DN	Adefovir dipivoxil
DMMAWY1	HS	Approved
DMMAWY1	SN	Adefovirdipivoxl; Hepsera; Preveon; YouHeDing; Adefovir depivoxil; Adefovir pivoxil; GS 0840; GS 840;Piv2PMEA; Adefovir dipivoxil (USAN); Adefovir pivoxil (JAN); Bis(pom)PMEA; Bis-POM PMEA; GS-0840; GS-840; Hepsera (TM); Hepsera (TN); Preveon (TN); Bis(POM)-PMEA; Bis-POM PMEA, Adefovir Dipivoxil; Bis-POM PMEA, Preveon, Hepsera, Adefovir Dipivoxil; Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine; [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; Propanoic acid,2,2-dimethyl-(((2-(6-amino-9H-purin-9-yl)ehtoxy)mehtyl)phosphinyldiene)bis(oxymehtylene)ester; Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester; (((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, diester with hydroxymethyl pivalate; 9-(2-((-Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; 9-(2-((Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; ADV
DMMAWY1	CP	Gilead Sciences
DMMAWY1	TC	Antiviral Agents
DMMAWY1	DT	Small molecular drug
DMMAWY1	PC	60871
DMMAWY1	MW	501.5
DMMAWY1	FM	C20H32N5O8P
DMMAWY1	IC	InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)
DMMAWY1	CS	CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N=CN=C21)N)OCOC(=O)C(C)(C)C
DMMAWY1	IK	WOZSCQDILHKSGG-UHFFFAOYSA-N
DMMAWY1	IU	[2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
DMMAWY1	CA	CAS 142340-99-6
DMMAWY1	CB	CHEBI:31175
DMMAWY1	DE	Hepatitis B virus infection

DMYQDBO	ID	DMYQDBO
DMYQDBO	DN	Ademetionine
DMYQDBO	HS	Approved
DMYQDBO	SN	Ceritan; Samyr; Transmetil; Ademetionine butandisulphonate; Ademetionine disulfate tosylate; Ademetionine sulfate tosilate; FD-1561; FO-1561
DMYQDBO	CP	Bioresearch SpA
DMYQDBO	DT	Small molecular drug
DMYQDBO	PC	34755
DMYQDBO	MW	398.4
DMYQDBO	FM	C15H22N6O5S
DMYQDBO	IC	InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1
DMYQDBO	CS	C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMYQDBO	IK	MEFKEPWMEQBLKI-AIRLBKTGSA-N
DMYQDBO	IU	(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylsulfonio]butanoate
DMYQDBO	CA	CAS 29908-03-0
DMYQDBO	CB	CHEBI:67040
DMYQDBO	DE	Cerebrovascular ischaemia; Hepatic fibrosis

DMZLHKJ	ID	DMZLHKJ
DMZLHKJ	DN	Adenine
DMZLHKJ	HS	Approved
DMZLHKJ	SN	ADE; ANE; Adenin; Adeninimine; Adenine [JAN]; Pedatisectine B; AD2; Vitamin B 4; Vitamin B4; ALBB-005925; Adenine (8CI); Adenine-ring; B 4, Vitamin; Leuco-4; Leucon (TN); Purine, 6; USAF CB-18; Vitamin-B4; Adenine (JAN/USP); Adenine-8-14C; 1,6-Dihydro-6-Imnopurine; 1,6-Dihydro-6-iminopurine; 1H-Purin-6-amine; 1H-Purin-6-amine (9CI); 1H-Purine, 6-amino; 2'-DEOXY-ADENOSINE-3'-5'-DIPHOSPHATE; 3,6-Dihydro-6-iminopurine; 4, Vitamin B; 6-Amino-1H-purine; 6-Amino-3H-purine; 6-Amino-7H-purine; 6-Amino-9H-purine; 6-Aminopurine; 7H-Purin-6-amine; 9H-Purin-6-amine
DMZLHKJ	TC	Dietary supplement
DMZLHKJ	DT	Small molecular drug
DMZLHKJ	PC	190
DMZLHKJ	MW	135.13
DMZLHKJ	FM	C5H5N5
DMZLHKJ	IC	InChI=1S/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10)
DMZLHKJ	CS	C1=NC2=NC=NC(=C2N1)N
DMZLHKJ	IK	GFFGJBXGBJISGV-UHFFFAOYSA-N
DMZLHKJ	IU	7H-purin-6-amine
DMZLHKJ	CA	CAS 73-24-5
DMZLHKJ	CB	CHEBI:16708
DMZLHKJ	DE	Malnutrition

DMM2NSK	ID	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	HS	Approved
DMM2NSK	SN	Adenosine, homopolymer; Adenine 9-beta-D-arabinofuranoside; Adenine-9-beta-D-ribofuranoside; Beta-D-Ribofuranoside, adenine-9; EA6C60C2-6AFB-4264-A2F0-541373DB950E; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 9-(beta-D-Arabinofuranosyl)adenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-D-Ribofuranosyladenine; 9beta-D-Ribofuranosyladenine
DMM2NSK	TC	Antiarrhythmic Agents
DMM2NSK	DT	Small molecular drug
DMM2NSK	PC	60961
DMM2NSK	MW	267.24
DMM2NSK	FM	C10H13N5O4
DMM2NSK	IC	InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
DMM2NSK	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DMM2NSK	IK	OIRDTQYFTABQOQ-KQYNXXCUSA-N
DMM2NSK	IU	(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMM2NSK	CA	CAS 5536-17-4
DMM2NSK	CB	CHEBI:16335
DMM2NSK	DE	Paroxysmal supraventricular tachycardia

DMNIJT0	ID	DMNIJT0
DMNIJT0	DN	Adenosine monophosphate
DMNIJT0	HS	Approved
DMNIJT0	SN	ASMP; Adenovite; Adenyl; Adenylate; Cardiomone; Lycedan; Monophosphadenine; Muskeladenylsaeure; Myoston; PAdo; Phosaden; Phosphaden; Phosphentaside; AMP dianion; Adenine polynucleotides; Adenosine phosphate; Adenosini phosphas; Adenylic acid; Ergadenylic acid; Fosfato de adenosina; Muscle adenylic acid; POLY A; Polyadenylic acids; Vitamin B8; A-5mp; AMP (VAN); AMP (nucleotide); Adenosine Monophosphate (Amp); Adenosine-monophosphate; Adenosine-phosphate; Adenosini phosphas [INN-Latin]; Adenyl (TN); Adenylic acid (VAN); Ado5'P; Fosfato de adenosina [INN-Spanish]; Muskeladenosin-phosphorsaeure; Phosphate d'adenosine; Adenosine 5'-monophosphate; Adenosine 5'-monophosphoric acid; Adenosine 5'-phosphate; Adenosine 5'-phosphoric acid; Adenosine phosphate (USAN/INN); Adenosine phosphate [USAN:BAN:INN]; Adenosine phosphate [USAN:INN:BAN]; Adenosine-5'P; Adenosine-5-monophosphate dianion; Adenosine-5-monophosphoric acid; Adenosine-5-phosphate; Formycin 5'-monophosphate hydrate; Formycin 5'-phosphate; Formycin 5'-phosphate hydrate; Formycin A 5'-monophosphate hydrate; My-B-Den; Phosphate d'adenosine [INN-French]; ADENOSINE-5'-PHOSPHATE; Adenosine 5'-(dihydrogen phosphate); Adenosine, mono(dihydrogen phosphate) (ester); Adenosine-5'-monophosphate; Adenosine-5'-monophosphoric acid; Adenosine-5-monophosphate(2-); GAMMA-ARSONO-BETA, GAMMA-METHYLENEADENOSINE-5'-DIPHOSPHATE; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate; (S)-1-C-(7-Amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-D-ribitol, 5-(dihydrogen phosphate); 1H-Pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-D-ribofuranosyl-, 5'-(dihydrogen phosphate)-, hydrate; 5'-Adenylic acid, homopolymer; 5'-Deoxy-5'-thioadenosine 5'-monophosphate; 5'-O-phosphonatoadenosine; 5'-O-phosphonoadenosine; 5'-Thio-5'-adenylic acid; 5'-adenosine monophosphate; 5'-adenylic acid; 7-Amino-3-beta-D-ribofuranosyl-1H-pyrazolo(4,3-d)pyrimidine 5'-(dihydrogen phosphate) hydrate; 7A8E6D15-9136-44C1-88C9-E1A224638E56; 7gpb; 8-Aminoadenosine 5'-monophosphate; 8gpb
DMNIJT0	TC	Dietary supplement
DMNIJT0	DT	Small molecular drug
DMNIJT0	PC	6083
DMNIJT0	MW	347.22
DMNIJT0	FM	C10H14N5O7P
DMNIJT0	IC	InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMNIJT0	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N
DMNIJT0	IK	UDMBCSSLTHHNCD-KQYNXXCUSA-N
DMNIJT0	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMNIJT0	CA	CAS 61-19-8
DMNIJT0	CB	CHEBI:16027
DMNIJT0	DE	Malnutrition

DM79F6G	ID	DM79F6G
DM79F6G	DN	Adenosine triphosphate
DM79F6G	HS	Approved
DM79F6G	SN	Adenylpyrophosphate; Triphosadenine; Triphosadenine (DCF); Adenosine 5'-triphosphate(4-); [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate; [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate; [[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid; 3b2q; 5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-ylmethoxy-hydroxy-phosphoryloxy-hydroxy-phosphoryl oxyphosphonic acid; 9H-purin-6-amine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]
DM79F6G	TC	Dietary supplement
DM79F6G	DT	Small molecular drug
DM79F6G	PC	5957
DM79F6G	MW	507.18
DM79F6G	FM	C10H16N5O13P3
DM79F6G	IC	InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DM79F6G	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N
DM79F6G	IK	ZKHQWZAMYRWXGA-KQYNXXCUSA-N
DM79F6G	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM79F6G	CA	CAS 56-65-5
DM79F6G	CB	CHEBI:15422
DM79F6G	DE	Bradycardia; Heart disease; Malnutrition

DMBHO9Y	ID	DMBHO9Y
DMBHO9Y	DN	Adinazolam
DMBHO9Y	HS	Approved
DMBHO9Y	SN	Adinazolamum; Deracyn; Adinazolam [USAN]; U 41123; Adinazolamum [INN-Latin]; Deracyn (TN); U 41,123;U-41123; Adinazolam (USAN/INN); Adinazolam [USAN:BAN:INN]; 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine; 8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-chloro-1-[(dimethylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine
DMBHO9Y	TC	Antidepressants
DMBHO9Y	DT	Small molecular drug
DMBHO9Y	PC	37632
DMBHO9Y	MW	351.8
DMBHO9Y	FM	C19H18ClN5
DMBHO9Y	IC	InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3
DMBHO9Y	CS	CN(C)CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
DMBHO9Y	IK	GJSLOMWRLALDCT-UHFFFAOYSA-N
DMBHO9Y	IU	1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine
DMBHO9Y	CA	CAS 37115-32-5
DMBHO9Y	CB	CHEBI:251412
DMBHO9Y	DE	Anxiety disorder

DMVWHTG	ID	DMVWHTG
DMVWHTG	DN	Afamelanotide
DMVWHTG	HS	Approved
DMVWHTG	SN	[Nle4,dPhe7]alpha-MSH; alpha-NDP-MSH; NDP-MSH
DMVWHTG	DT	Small molecular drug
DMVWHTG	PC	16197727
DMVWHTG	MW	1646.8
DMVWHTG	FM	C78H111N21O19
DMVWHTG	IC	InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1
DMVWHTG	CS	CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
DMVWHTG	IK	UAHFGYDRQSXQEB-LEBBXHLNSA-N
DMVWHTG	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMVWHTG	CA	CAS 75921-69-6
DMVWHTG	DE	Vitiligo; Erythropoietic porphyrias

DMT3D5I	ID	DMT3D5I
DMT3D5I	DN	Aflibercept
DMT3D5I	HS	Approved
DMT3D5I	SN	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
DMT3D5I	CP	Sanofi
DMT3D5I	SQ	Protein sequence for aflibercept: SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
DMT3D5I	DE	Metastatic colorectal cancer

DMPOD47	ID	DMPOD47
DMPOD47	DN	Ajmalicine
DMPOD47	HS	Approved
DMPOD47	SN	MLS000111555; methyl 19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylate; NSC72115; SMR000107477; Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (19.alpha.)-; 6474-90-4; WLN: T F6 D5 C666 EM ON SO TU&amp; TTTJ R1 UVO1; Isoarteril; Oxayohimban-16-carboxylic acid,17-didehydro-19-methyl-, methyl ester, (19
DMPOD47	DT	Small molecular drug
DMPOD47	PC	441975
DMPOD47	MW	352.4
DMPOD47	FM	C21H24N2O3
DMPOD47	IC	InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16+,19-/m0/s1
DMPOD47	CS	C[C@H]1[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45
DMPOD47	IK	GRTOGORTSDXSFK-XJTZBENFSA-N
DMPOD47	IU	methyl (1S,15R,16S,20S)-16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate
DMPOD47	CA	CAS 483-04-5
DMPOD47	CB	CHEBI:2524
DMPOD47	DE	Circulatory disorder

DMDJW5K	ID	DMDJW5K
DMDJW5K	DN	Ajmaline
DMDJW5K	HS	Approved
DMDJW5K	SN	(17R,21
DMDJW5K	DT	Small molecular drug
DMDJW5K	PC	6100671
DMDJW5K	MW	326.4
DMDJW5K	FM	C20H26N2O2
DMDJW5K	IC	InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16-,17-,18+,19+,20+/m0/s1
DMDJW5K	CS	CC[C@H]1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H]([C@H]2[C@H]5O)N3[C@@H]1O)C6=CC=CC=C6N4C
DMDJW5K	IK	CJDRUOGAGYHKKD-RQBLFBSQSA-N
DMDJW5K	IU	(1R,9R,10S,12R,13S,14R,16S,17S,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol
DMDJW5K	CA	CAS 4360-12-7
DMDJW5K	DE	Atrial fibrillation

DML6SRO	ID	DML6SRO
DML6SRO	DN	Alacepril
DML6SRO	HS	Approved
DML6SRO	SN	Cetapril (TN)
DML6SRO	CP	Dainippon
DML6SRO	DT	Small molecular drug
DML6SRO	PC	71992
DML6SRO	MW	406.5
DML6SRO	FM	C20H26N2O5S
DML6SRO	IC	InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1
DML6SRO	CS	C[C@H](CSC(=O)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O
DML6SRO	IK	FHHHOYXPRDYHEZ-COXVUDFISA-N
DML6SRO	IU	(2S)-2-[[(2S)-1-[(2S)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DML6SRO	CA	CAS 74258-86-9
DML6SRO	CB	CHEBI:31182
DML6SRO	DE	Cardiovascular disease

DMYZ57N	ID	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	HS	Approved
DMYZ57N	SN	Albendazol; Albendazolum; Albendoral; Albenza; Bendapar; Bilutac; Digezanol; Disthelm; Endoplus; Eskazole; Gascop; Lurdex; Metiazol; Proftril; Valbazen; Zental; Zentel; Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Armstrong Brand of Albendazole; Diba Brand of Albendazole; Fustery Brand of Albendazole; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Mediamix V Disthelm; Noe Socopharm Brand of Albendazole; Pfizer Brand of Albendazole; Sanicoopa Brand of Albendazole; SmithKline Beecham Brand of Albendazole; Valdecasas Brand of Albendazole; SKF 62979; SKF62979; Albendazol [INN-Spanish]; Albendazole Noe-Socopharm Brand; Albendazolum [INN-Latin]; Albenza (TN); Disthelm, Mediamix V; Eskazole (TN); Monohydrochloride, Albendazole; Noe-Socopharm Brand of Albendazole; SK&F 62979; SK&F62979; SKF-62979; Smith Kline & French Brand of Albendazole; V Disthelm, Mediamix; Zentel (TN); SK&F-62979; Albendazole (JAN/USP/INN); Albendazole [USAN:INN:BAN:JAN]; Albenza, Eskazole, Zentel, Andazol, Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole
DMYZ57N	CP	GlaxoSmithKline
DMYZ57N	TC	Antiprotozoal Agents
DMYZ57N	DT	Small molecular drug
DMYZ57N	PC	2082
DMYZ57N	MW	265.33
DMYZ57N	FM	C12H15N3O2S
DMYZ57N	IC	InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
DMYZ57N	CS	CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
DMYZ57N	IK	HXHWSAZORRCQMX-UHFFFAOYSA-N
DMYZ57N	IU	methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
DMYZ57N	CA	CAS 54965-21-8
DMYZ57N	CB	CHEBI:16664
DMYZ57N	DE	Worm infection

DM1JEGF	ID	DM1JEGF
DM1JEGF	DN	Albiglutide
DM1JEGF	HS	Approved
DM1JEGF	CP	GSK
DM1JEGF	SQ	Albiglutide sequence: HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
DM1JEGF	PC	122173812
DM1JEGF	MW	3284.6
DM1JEGF	FM	C148H223N39O46
DM1JEGF	IC	InChI=1S/C148H223N39O46/c1-16-76(10)119(144(229)165-79(13)124(209)173-103(59-85-62-157-90-35-24-23-34-88(85)90)134(219)175-99(55-73(4)5)135(220)184-117(74(6)7)142(227)172-91(36-25-27-51-149)126(211)159-66-111(197)168-97(147(232)233)38-29-53-156-148(153)154)186-136(221)101(56-82-30-19-17-20-31-82)176-131(216)96(46-50-115(203)204)171-130(215)92(37-26-28-52-150)169-123(208)78(12)163-122(207)77(11)164-129(214)95(43-47-108(152)194)167-110(196)65-160-128(213)94(45-49-114(201)202)170-132(217)98(54-72(2)3)174-133(218)100(58-84-39-41-87(193)42-40-84)177-139(224)105(68-188)180-141(226)107(70-190)181-143(228)118(75(8)9)185-138(223)104(61-116(205)206)178-140(225)106(69-189)182-146(231)121(81(15)192)187-137(222)102(57-83-32-21-18-22-33-83)179-145(230)120(80(14)191)183-112(198)67-161-127(212)93(44-48-113(199)200)166-109(195)64-158-125(210)89(151)60-86-63-155-71-162-86/h17-24,30-35,39-42,62-63,71-81,89,91-107,117-121,157,188-193H,16,25-29,36-38,43-61,64-70,149-151H2,1-15H3,(H2,152,194)(H,155,162)(H,158,210)(H,159,211)(H,160,213)(H,161,212)(H,163,207)(H,164,214)(H,165,229)(H,166,195)(H,167,196)(H,168,197)(H,169,208)(H,170,217)(H,171,215)(H,172,227)(H,173,209)(H,174,218)(H,175,219)(H,176,216)(H,177,224)(H,178,225)(H,179,230)(H,180,226)(H,181,228)(H,182,231)(H,183,198)(H,184,220)(H,185,223)(H,186,221)(H,187,222)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,232,233)(H4,153,154,156)/t76-,77-,78-,79-,80+,81+,89-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-/m0/s1
DM1JEGF	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CNC=N6)N
DM1JEGF	IK	OGWAVGNOAMXIIM-VTAHJYCESA-N
DM1JEGF	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM1JEGF	CB	CHEBI:78425
DM1JEGF	DE	Type-2 diabetes

DM5JTPU	ID	DM5JTPU
DM5JTPU	DN	Albumin Human
DM5JTPU	HS	Approved
DM5JTPU	SN	Albumin (Human); Kedbumin
DM5JTPU	CP	Ge Healthcare
DM5JTPU	DE	Hypoalbuminemia

DM5J1NH	ID	DM5J1NH
DM5J1NH	DN	Alcaftadine
DM5J1NH	HS	Approved
DM5J1NH	SN	Lastacaft (TN)
DM5J1NH	CP	Vistakon Pharmaceuticals
DM5J1NH	DT	Small molecular drug
DM5J1NH	PC	19371515
DM5J1NH	MW	307.4
DM5J1NH	FM	C19H21N3O
DM5J1NH	IC	InChI=1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-5-3-2-4-14(17)8-11-22-16(13-23)12-20-19(18)22/h2-5,12-13H,6-11H2,1H3
DM5J1NH	CS	CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1
DM5J1NH	IK	MWTBKTRZPHJQLH-UHFFFAOYSA-N
DM5J1NH	IU	11-(1-methylpiperidin-4-ylidene)-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carbaldehyde
DM5J1NH	CA	CAS 147084-10-4
DM5J1NH	CB	CHEBI:71023
DM5J1NH	DE	Allergic conjunctivitis

DMAE84F	ID	DMAE84F
DMAE84F	DN	Alclometasone
DMAE84F	HS	Approved
DMAE84F	SN	Aclometasone; Aclovate (TN); Alclometasone (INN); Alclometasone [INN:BAN]; (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7alpha-Chloro-16alpha-methylprednisolone
DMAE84F	CP	GlaxoSmithKline
DMAE84F	TC	Antiinflammatory Agents
DMAE84F	DT	Small molecular drug
DMAE84F	PC	5311000
DMAE84F	MW	408.9
DMAE84F	FM	C22H29ClO5
DMAE84F	IC	InChI=1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1
DMAE84F	CS	C[C@@H]1C[C@H]2[C@@H]3[C@@H](CC4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)Cl
DMAE84F	IK	FJXOGVLKCZQRDN-PHCHRAKRSA-N
DMAE84F	IU	(7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMAE84F	CA	CAS 67452-97-5
DMAE84F	CB	CHEBI:53776
DMAE84F	DE	Inflammation

DM2U4XQ	ID	DM2U4XQ
DM2U4XQ	DN	ALCURONIUM
DM2U4XQ	HS	Approved
DM2U4XQ	SN	Alcuronium
DM2U4XQ	DT	Small molecular drug
DM2U4XQ	PC	21158560
DM2U4XQ	MW	666.9
DM2U4XQ	FM	C44H50N4O2+2
DM2U4XQ	IC	InChI=1S/C44H50N4O2/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2/q+2/b29-13-,30-14-,33-25-,34-26-/t31-,32-,39-,40-,41-,42-,43+,44+,47-,48-/m0/s1
DM2U4XQ	CS	C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\\CO)/C1)CC2
DM2U4XQ	IK	MUQUYTSLDVKIOF-CHJKCJHBSA-N
DM2U4XQ	IU	(2E)-2-[(1S,9Z,11S,13S,14R,17S,25Z,27S,30R,33S,35S,36S,38E)-38-(2-hydroxyethylidene)-14,30-bis(prop-2-enyl)-8,24-diaza-14,30-diazoniaundecacyclo[25.5.2.211,14.11,26.110,17.02,7.013,17.018,23.030,33.08,35.024,36]octatriaconta-2,4,6,9,18,20,22,25-octaen-28-ylidene]ethanol
DM2U4XQ	CA	CAS 23214-96-2
DM2U4XQ	CB	CHEBI:55313
DM2U4XQ	DE	Anaesthesia

DM4YMIS	ID	DM4YMIS
DM4YMIS	DN	Aldesleukin
DM4YMIS	HS	Approved
DM4YMIS	SN	Proleukin (TN)
DM4YMIS	CP	Chiron
DM4YMIS	TC	Anticancer Agents
DM4YMIS	SQ	Aldesleukin sequence: MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
DM4YMIS	DE	Renal cell carcinoma; Non-hodgkin lymphoma

DM9S2JW	ID	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	HS	Approved
DM9S2JW	SN	ALDOSTERONE; 52-39-1; Electrocortin; Aldocortin; Aldocortene; Aldocorten; (+)-Aldosterone; Elektrocortin; d-Aldosterone; Reichstein X; 18-Oxocorticosterone; Aldosteronum; Aldosterona; Aldosteronum [INN-Latin]; Aldosterona [INN-Spanish]; [3H]aldosterone; 18-Aldocorticosterone; Aldosterone [INN:BAN:DCF]; 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al; NSC 73856; 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione; UNII-4964P6T9RB;  Aldocorten; D-Aldosterone; Aldosterone, (11 beta,17 alpha)-Isomer; Aldosterone, (+-)-Isomer; (11BETA)-11,21-DIHYDROXY-3,20-DIOXOPREGN-4-EN-18-AL; (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al, 18,11-halbacetal; 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al; 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al
DM9S2JW	TC	Antihypertensive Agents
DM9S2JW	DT	Small molecular drug
DM9S2JW	PC	5839
DM9S2JW	MW	360.4
DM9S2JW	FM	C21H28O5
DM9S2JW	IC	InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1
DM9S2JW	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C=O)O
DM9S2JW	IK	PQSUYGKTWSAVDQ-ZVIOFETBSA-N
DM9S2JW	IU	(8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde
DM9S2JW	CA	CAS 52-39-1
DM9S2JW	CB	CHEBI:27584
DM9S2JW	DE	Hypertension

DMP1I6Y	ID	DMP1I6Y
DMP1I6Y	DN	Alectinib
DMP1I6Y	HS	Approved
DMP1I6Y	SN	1256580-46-7; CH5424802; CH 5424802; AF-802; Alecensa; UNII-LIJ4CT1Z3Y; AF 802; LIJ4CT1Z3Y; Alectinib (CH5424802); 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; CHEMBL1738797; AF802; 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile; 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; AK170451; C30H34N4O2;  Alectinib; 9-ethyl-6,6-dimethyl-
DMP1I6Y	DT	Small molecular drug
DMP1I6Y	PC	49806720
DMP1I6Y	MW	482.6
DMP1I6Y	FM	C30H34N4O2
DMP1I6Y	IC	InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3
DMP1I6Y	CS	CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C
DMP1I6Y	IK	KDGFLJKFZUIJMX-UHFFFAOYSA-N
DMP1I6Y	IU	9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
DMP1I6Y	CA	CAS 1256580-46-7
DMP1I6Y	CB	CHEBI:90936
DMP1I6Y	DE	Lung cancer; Non-small-cell lung cancer

DMMYPWO	ID	DMMYPWO
DMMYPWO	DN	Alefacept
DMMYPWO	HS	Approved
DMMYPWO	SN	Amevive (TN)
DMMYPWO	TC	Analgesics
DMMYPWO	SQ	Alefacept heavy chain : CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Alefacept light chainMVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN
DMMYPWO	DE	Pain

DMZL3IV	ID	DMZL3IV
DMZL3IV	DN	Alemtuzumab
DMZL3IV	HS	Approved
DMZL3IV	SN	Campath (TN); MabCampath (TN); Campath-1H (TN)
DMZL3IV	CP	Bayer Schering Pharma
DMZL3IV	TC	Anticancer Agents
DMZL3IV	DT	Antibody
DMZL3IV	SQ	1CE1:H CAMPATH-1H:Heavy Chain 1: QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;1CE1:L CAMPATH-1H:Light Chain 1DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR</sequence>    <sequence format="FASTA">&gt;1CE1:H CAMPATH-1H:Heavy Chain 2QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;1CE1:L CAMPATH-1H:Light Chain 2DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR</sequence>    <sequence format="FASTA">&gt;1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV</sequence>    <sequence format="FASTA">&gt;1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>    <sequence format="FASTA">&gt;8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>    <sequence format="FASTA">&gt;1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE</sequence>    <sequence format="FASTA">&gt;1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMZL3IV	DE	Chronic lymphocytic leukaemia; Multiple sclerosis

DMY2KX9	ID	DMY2KX9
DMY2KX9	DN	Alendronate
DMY2KX9	HS	Approved
DMY2KX9	SN	Arendal; Fosamax; ALENDRONATE SODIUM; ALENDRONIC ACID; Acide alendronique; Acido alendronico; Acidum alendronicum; MK 217; Acide alendronique [INN-French]; Acido alendronico [INN-Spanish]; Acidum alendronicum [INN-Latin]; Alendronic acid (INN); Alendronic acid [INN:BAN]; Bisphosphonate, 65; Fosamax (TN); MK-217; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; (4-Amino-1-hydroxybutylidene)bisphosphonic acid; (4-Amino-1-hydroxybutylidene)diphosphonic acid; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); 4-Amino-1-hydroxybutane-1,1-diphosphonate; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
DMY2KX9	CP	Teva Pharmaceuticals 
DMY2KX9	TC	Bone Density Conservation Agents
DMY2KX9	DT	Small molecular drug
DMY2KX9	PC	2088
DMY2KX9	MW	249.1
DMY2KX9	FM	C4H13NO7P2
DMY2KX9	IC	InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
DMY2KX9	CS	C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
DMY2KX9	IK	OGSPWJRAVKPPFI-UHFFFAOYSA-N
DMY2KX9	IU	(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
DMY2KX9	CA	CAS 66376-36-1
DMY2KX9	CB	CHEBI:2567
DMY2KX9	DE	Paget's disease; Osteoporosis

DMCKPUR	ID	DMCKPUR
DMCKPUR	DN	Alfaferone
DMCKPUR	HS	Approved
DMCKPUR	SN	Alfaferon; Cilferon-A; Alpha-IFN, ASW; Interferon, ASW (alpha)
DMCKPUR	CP	Alfa Wassermann SpA
DMCKPUR	DE	Hairy cell leukaemia

DMVO0UB	ID	DMVO0UB
DMVO0UB	DN	Alfentanil
DMVO0UB	HS	Approved
DMVO0UB	SN	Alfenta; Alfentanilum; Alfentanyl; Alfenta (TN); Alfentanil (INN); Alfentanil [INN:BAN]; Alfentanilum [INN-Latin]; Rapifen (TN); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide
DMVO0UB	CP	Janssen Pharmaceutica
DMVO0UB	TC	Anesthetics
DMVO0UB	DT	Small molecular drug
DMVO0UB	PC	51263
DMVO0UB	MW	416.5
DMVO0UB	FM	C21H32N6O3
DMVO0UB	IC	InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3
DMVO0UB	CS	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC
DMVO0UB	IK	IDBPHNDTYPBSNI-UHFFFAOYSA-N
DMVO0UB	IU	N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide
DMVO0UB	CA	CAS 71195-58-9
DMVO0UB	CB	CHEBI:2569
DMVO0UB	DE	Anaesthesia

DMZVMKF	ID	DMZVMKF
DMZVMKF	DN	Alfuzosin
DMZVMKF	HS	Approved
DMZVMKF	SN	Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
DMZVMKF	CP	Sanofi-Aventis
DMZVMKF	TC	Antihypertensive Agents
DMZVMKF	DT	Small molecular drug
DMZVMKF	PC	2092
DMZVMKF	MW	389.4
DMZVMKF	FM	C19H27N5O4
DMZVMKF	IC	InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
DMZVMKF	CS	CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
DMZVMKF	IK	WNMJYKCGWZFFKR-UHFFFAOYSA-N
DMZVMKF	IU	N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
DMZVMKF	CA	CAS 81403-80-7
DMZVMKF	CB	CHEBI:51141
DMZVMKF	DE	Benign prostatic hyperplasia

DM4LOD0	ID	DM4LOD0
DM4LOD0	DN	Alglucosidase alfa
DM4LOD0	HS	Approved
DM4LOD0	SN	Lumizyme (TN); Myozyme (TN)
DM4LOD0	CP	Genzyme Corporation 
DM4LOD0	TC	Enzyme Replacement Agents
DM4LOD0	SQ	Alglucosidase alfa: AHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC
DM4LOD0	DE	Pompe disease

DM1BV7W	ID	DM1BV7W
DM1BV7W	DN	Aliskiren
DM1BV7W	HS	Approved
DM1BV7W	SN	Rasilez; SPP 100; Rasilez (TN); Tekturna (TN); Aliskiren (USAN/INN); (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]
DM1BV7W	CP	Norvatis Phamaceuticals Corporation
DM1BV7W	TC	Antihypertensive Agents
DM1BV7W	DT	Small molecular drug
DM1BV7W	PC	5493444
DM1BV7W	MW	551.8
DM1BV7W	FM	C30H53N3O6
DM1BV7W	IC	InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
DM1BV7W	CS	CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
DM1BV7W	IK	UXOWGYHJODZGMF-QORCZRPOSA-N
DM1BV7W	IU	(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide
DM1BV7W	CA	CAS 173334-57-1
DM1BV7W	CB	CHEBI:601027
DM1BV7W	DE	Hypertension

DMME8LH	ID	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	HS	Approved
DMME8LH	CP	Ligand Pharmaceuticals
DMME8LH	TC	Anticancer Agents
DMME8LH	DT	Small molecular drug
DMME8LH	PC	449171
DMME8LH	MW	300.4
DMME8LH	FM	C20H28O2
DMME8LH	IC	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+
DMME8LH	CS	CC1=C(C(CCC1)(C)C)/C=C/C(=C\\C=C\\C(=C\\C(=O)O)\\C)/C
DMME8LH	IK	SHGAZHPCJJPHSC-ZVCIMWCZSA-N
DMME8LH	IU	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DMME8LH	CA	CAS 5300-03-8
DMME8LH	CB	CHEBI:50648
DMME8LH	DE	Kaposi sarcoma

DMB4HFI	ID	DMB4HFI
DMB4HFI	DN	Alkavervir
DMB4HFI	HS	Approved
DMB4HFI	CP	3m Pharmaceuticals Inc
DMB4HFI	TC	Cardiovascular Agents
DMB4HFI	DE	High blood pressure

DMNLHAC	ID	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	HS	Approved
DMNLHAC	SN	516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102
DMNLHAC	DT	Small molecular drug
DMNLHAC	PC	92786
DMNLHAC	MW	318.5
DMNLHAC	FM	C21H34O2
DMNLHAC	IC	InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
DMNLHAC	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C
DMNLHAC	IK	AURFZBICLPNKBZ-SYBPFIFISA-N
DMNLHAC	IU	1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DMNLHAC	CA	CAS 516-54-1
DMNLHAC	CB	CHEBI:50169
DMNLHAC	DE	Postpartum depression; Essential tremor or related tremors; Status epilepticus seizure; Depression

DMLPAOB	ID	DMLPAOB
DMLPAOB	DN	Allopurinol
DMLPAOB	HS	Approved
DMLPAOB	SN	Adenock; Ailural; Ailurial; Allohexal; Allohexan; Alloprin; Allopur; Allopurin; Allopurinolum; Allorin; Allozym; Allpargin; Allural; Aloprim; Alopurinol; Aloral; Alositol; Aluline; Anoprolin; Anzief; Apulonga; Apurin; Apurol; Atisuril; Bleminol; Bloxanth; Caplenal; Capurate; Cellidrin; Cosuric; Dabrosin; Dabroson; Embarin; Epidropal; Epuric; Foligan; Geapur; Gichtex; Gotax; Hamarin; Hexanuret; Jenapurinol; Ketanrift; Ledopur; Lopurin; Lysuron; Milurit; Milurite; Miniplanor; Monarch; Nektrohan; Novopurol; Progout; Pureduct; Purinol; Remid; Riball; Rimapurinol; Roucol; Sigapurol; Suspendol; Takanarumin; Tipuric; Urbol; Uribenz; Uricemil; Uridocid; Uriprim; Uripurinol; Uritas; Urobenyl; Urolit; Urosin; Urtias; Xanthomax; Xanturat; Xanturic; Zygout; Zyloprim; Zyloric; Dura Al; Pan Quimica; A 8003; BW 56158; Urtias 100; AL-100; Allo-Puren; Allohexal (TN); Allopurinol(I); Allosig (TN); Apo-Allopurinol; BW 56-158; Ketobun-A; Progout (TN); Puricos (TN); Quimica, Pan; Zyloprim (TN); Zyloric (TN); BW-56-158; B. W. 56-158; 4-HPP
DMLPAOB	CP	GlaxoSmithKline
DMLPAOB	TC	Antimetabolites
DMLPAOB	DT	Small molecular drug
DMLPAOB	PC	135401907
DMLPAOB	MW	136.11
DMLPAOB	FM	C5H4N4O
DMLPAOB	IC	InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
DMLPAOB	CS	C1=NNC2=C1C(=O)NC=N2
DMLPAOB	IK	OFCNXPDARWKPPY-UHFFFAOYSA-N
DMLPAOB	IU	1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one
DMLPAOB	CA	CAS 315-30-0
DMLPAOB	CB	CHEBI:40279
DMLPAOB	DE	Hyperuricaemia

DM0SYAN	ID	DM0SYAN
DM0SYAN	DN	Almitrine
DM0SYAN	HS	Approved
DM0SYAN	SN	Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DM0SYAN	TC	Antiinflammatory Agents
DM0SYAN	DT	Small molecular drug
DM0SYAN	PC	33887
DM0SYAN	MW	477.6
DM0SYAN	FM	C26H29F2N7
DM0SYAN	IC	InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)
DM0SYAN	CS	C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C
DM0SYAN	IK	OBDOVFRMEYHSQB-UHFFFAOYSA-N
DM0SYAN	IU	6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DM0SYAN	CA	CAS 27469-53-0
DM0SYAN	CB	CHEBI:53778
DM0SYAN	DE	Chronic obstructive pulmonary disease

DM7I64Z	ID	DM7I64Z
DM7I64Z	DN	Almogran
DM7I64Z	HS	Approved
DM7I64Z	SN	Almotriptan; Axert; Almotriptan (USAN); Axert (TN); LAS-31416; PNU-180638; Almotriptan [USAN:INN:BAN]; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
DM7I64Z	CP	Almirall Prodesfarma
DM7I64Z	TC	Antimigraine Agents
DM7I64Z	DT	Small molecular drug
DM7I64Z	PC	123606
DM7I64Z	MW	335.5
DM7I64Z	FM	C17H25N3O2S
DM7I64Z	IC	InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
DM7I64Z	CS	CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3
DM7I64Z	IK	WKEMJKQOLOHJLZ-UHFFFAOYSA-N
DM7I64Z	IU	N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine
DM7I64Z	CA	CAS 154323-57-6
DM7I64Z	CB	CHEBI:520985
DM7I64Z	DE	Migraine

DMFG5ST	ID	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	HS	Approved
DMFG5ST	SN	Almotriptan; Almotriptan (malate); Almotriptan malate; Almotriptan malate (USAN); Almotriptan malate [USAN]; Almotriptan maleate; CHEBI:53781; LAS 31416; LAS 31416 D,L-malate acid; PNU 180638E; PNU-180638E; Almogran; Almotriptan [USAN:INN:BAN]; Axert; CHEBI:520985; DSSTox_CID_24289; DSSTox_GSID_44289; DSSTox_RID_80142; LAS-31416; N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethanamine; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; NCGC00095135-01; UNII-1O4XL5SN61; WKEMJKQOLOHJLZ-UHFFFAOYSA-N; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; 154323-57-6; 1O4XL5SN61; 1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedionate (1:1); 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine malate (1:1); 1-[[[2-(Dimethyl-amino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate; 181183-52-8; AK110510
DMFG5ST	PC	123607
DMFG5ST	MW	469.6
DMFG5ST	FM	C21H31N3O7S
DMFG5ST	IC	QHATUKWEVNMHRY-UHFFFAOYSA-N
DMFG5ST	CS	CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3.C(C(C(=O)O)O)C(=O)O
DMFG5ST	IK	1S/C17H25N3O2S.C4H6O5/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20;5-2(4(8)9)1-3(6)7/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3;2,5H,1H2,(H,6,7)(H,8,9)
DMFG5ST	IU	N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine;2-hydroxybutanedioic acid
DMFG5ST	CA	CAS 181183-52-8
DMFG5ST	CB	CHEBI:53781
DMFG5ST	DE	Migraine

DM8WI3R	ID	DM8WI3R
DM8WI3R	DN	Alogliptin
DM8WI3R	HS	Approved
DM8WI3R	SN	850649-61-5; UNII-JHC049LO86; alogliptina; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; SYR-322; JHC049LO86; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; CHEBI:72323; AK322010; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; vipidia; Alogliptin [INN]; Alogliptin (SYR-322); alogliptinum; alogliptine; HSDB 8203;  UNII-JHC049LO86
DM8WI3R	CP	Takeda
DM8WI3R	DT	Small molecular drug
DM8WI3R	PC	11450633
DM8WI3R	MW	339.4
DM8WI3R	FM	C18H21N5O2
DM8WI3R	IC	InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
DM8WI3R	CS	CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N
DM8WI3R	IK	ZSBOMTDTBDDKMP-OAHLLOKOSA-N
DM8WI3R	IU	2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
DM8WI3R	CA	CAS 850649-61-5
DM8WI3R	CB	CHEBI:72323
DM8WI3R	DE	Type-2 diabetes

DML2A03	ID	DML2A03
DML2A03	DN	Alosetron
DML2A03	HS	Approved
DML2A03	SN	Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride
DML2A03	CP	Prometheus Laboratories Inc
DML2A03	TC	Gastrointestinal Agents
DML2A03	DT	Small molecular drug
DML2A03	PC	2099
DML2A03	MW	294.35
DML2A03	FM	C17H18N4O
DML2A03	IC	InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)
DML2A03	CS	CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
DML2A03	IK	JSWZEAMFRNKZNL-UHFFFAOYSA-N
DML2A03	IU	5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one
DML2A03	CA	CAS 122852-42-0
DML2A03	CB	CHEBI:253342
DML2A03	DE	Irritable bowel syndrome

DMEXMYK	ID	DMEXMYK
DMEXMYK	DN	Alpelisib
DMEXMYK	HS	Approved
DMEXMYK	SN	alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide
DMEXMYK	CP	Novartis
DMEXMYK	DT	Small molecular drug
DMEXMYK	PC	56649450
DMEXMYK	MW	441.5
DMEXMYK	FM	C19H22F3N5O2S
DMEXMYK	IC	InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1
DMEXMYK	CS	CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
DMEXMYK	IK	STUWGJZDJHPWGZ-LBPRGKRZSA-N
DMEXMYK	IU	(2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
DMEXMYK	CA	CAS 1217486-61-7
DMEXMYK	CB	CHEBI:93752
DMEXMYK	DE	Solid tumour/cancer; Breast cancer

DMXC1K9	ID	DMXC1K9
DMXC1K9	DN	Alpha 1-PI
DMXC1K9	HS	Approved
DMXC1K9	SN	Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine
DMXC1K9	DT	Small molecular drug
DMXC1K9	PC	3689
DMXC1K9	MW	325.4
DMXC1K9	FM	C21H27NO2
DMXC1K9	IC	InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
DMXC1K9	CS	CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3
DMXC1K9	IK	UYNVMODNBIQBMV-UHFFFAOYSA-N
DMXC1K9	IU	4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol
DMXC1K9	CA	CAS 23210-56-2
DMXC1K9	CB	CHEBI:93829
DMXC1K9	DE	Alpha-1 antitrypsin deficiency; Cancer related pain

DMAS02L	ID	DMAS02L
DMAS02L	DN	Alpha-acetyldigoxin
DMAS02L	HS	Approved
DMAS02L	SN	Dioxanin (TN); Lanatilin (TN); Sandolanid (TN)
DMAS02L	DT	Small molecular drug
DMAS02L	PC	11765960
DMAS02L	MW	823
DMAS02L	FM	C43H66O15
DMAS02L	IC	InChI=1S/C43H66O15/c1-20-38(49)32(55-23(4)44)18-37(52-20)58-40-22(3)54-36(17-31(40)46)57-39-21(2)53-35(16-30(39)45)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(47)42(6)27(10-12-43(28,42)50)24-13-34(48)51-19-24/h13,20-22,25-33,35-40,45-47,49-50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1
DMAS02L	CS	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)OC(=O)C)O
DMAS02L	IK	HWKJSYYYURVNQU-DXJNJSHLSA-N
DMAS02L	IU	[(2R,3R,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-3-hydroxy-2-methyloxan-4-yl] acetate
DMAS02L	CA	CAS 5511-98-8
DMAS02L	DE	Cardiovascular disease

DMN7Y9K	ID	DMN7Y9K
DMN7Y9K	DN	Alpidem
DMN7Y9K	HS	Approved
DMN7Y9K	SN	ALPIDEM; 82626-01-5; Ananxyl; Alpidemum [Latin]; UNII-I93SC245QZ; SL 80.0342-00; 2-(6-Chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-dipropylacetamide; 6-Chloro-2-(p-chlorophenyl)-N,N-dipropylimidazo(1,2-a)pyridine-3-acetamide; CHEMBL54349; I93SC245QZ; S-800342; NCGC00182850-01; 6-Chlor-2-(4-chlorphenyl)-N,N-dipropylimidazol(1,2-a)pyridin-3-acetamid; DSSTox_RID_83237; DSSTox_CID_28972; DSSTox_GSID_49046; Alpidemum; 6-Chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-a]pyridine-3-acetamide
DMN7Y9K	DT	Small molecular drug
DMN7Y9K	PC	54897
DMN7Y9K	MW	404.3
DMN7Y9K	FM	C21H23Cl2N3O
DMN7Y9K	IC	InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3
DMN7Y9K	CS	CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMN7Y9K	IK	JRTIDHTUMYMPRU-UHFFFAOYSA-N
DMN7Y9K	IU	2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide
DMN7Y9K	CA	CAS 82626-01-5
DMN7Y9K	CB	CHEBI:135649
DMN7Y9K	DE	Anxiety disorder

DMC7XDN	ID	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	HS	Approved
DMC7XDN	SN	Alcelam; Algad; Alpaz; Alplax; Alpram; Alprax; Alprazolamum; Alprazolan; Alpronax; Alprox; Alviz; Alzam; Alzolam; Alzon;Anpress; ApoAlpraz; Azor; Bestrol; Cassadan; Constan; Esparon; Frontal; Helex; Intensol; Ksalol; Mialin; Neurol; Niravam; NovoAlprazol; NuAlpraz; Panistat; Panix; Pharnax; Prazam; Prazolan; Prinox; Ralozam; Relaxol; Restyl; Solanax; Tafil; Tensivan; Tranax; Trankimazin; Tranquinal; Tricalma; Unilan; Valeans; Xanagis; Xanax; Xanolam; Xanor; Zacetin; Zanapam; Zaxan; Zenax; Zolam; Zolan; Zolarem; Zoldac; Zoldax; Zopax; Zopic; Zotran; Alphapharm Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprazolam Apotex Brand; Alprazolam Kenral Brand; Alprazolam Novopharm Brand; Alprazolam Orion Brand; Alprazolam Pfizer Brand; Alprazolam Temmler Brand; Alprazolam extended release tablets; Alprazolam intensol; Alprazolam solution; Apo Alpraz; Apotex Brand of Alprazolam; Arzneimittelwerk Dresden Brand of Alprazolam; Kenral Brand of Alprazolam; Novo Alprazol; Novopharm Brand of Alprazolam; Nu Alpraz; Nu Pharm Brand of Alprazolam; Orion Brand of Alprazolam; Pfizer Brand of Alprazolam; Tafil D; Temmler Brand of Alprazolam; Xanax TS; Xanax XR; D 65MT; D65MT; TGAR01P; Tus 1; U 31889; AP-1002; AZ-002; Alprazolam Nu-Pharm Brand; Alprazolam-d5; Alprazolamum [INN-Latin]; Apo-Alpraz; D-65MT; Gen-Alprazolan; Niravam (TN); Novo-Alprazol; Nu-Alpraz; Nu-Pharm Brand of Alprazolam; Staccato-alprazolam; TUS-1; U-31889; U31,889; Xanax (TN); Xanor (TN); U-31,889; Alprazolam (JP15/USP/INN); Alprazolam [USAN:INN:BAN:JAN]; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
DMC7XDN	CP	Pfizer Pharmaceuticals
DMC7XDN	TC	Hypnotics and Sedatives
DMC7XDN	DT	Small molecular drug
DMC7XDN	PC	2118
DMC7XDN	MW	308.8
DMC7XDN	FM	C17H13ClN4
DMC7XDN	IC	InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3
DMC7XDN	CS	CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
DMC7XDN	IK	VREFGVBLTWBCJP-UHFFFAOYSA-N
DMC7XDN	IU	8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMC7XDN	CA	CAS 28981-97-7
DMC7XDN	CB	CHEBI:2611
DMC7XDN	DE	Anxiety disorder; Epilepsy

DMWH7NQ	ID	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	HS	Approved
DMWH7NQ	SN	Prostaglandin E1; alprostadil; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil
DMWH7NQ	CP	Pfizer Pharmaceuticals
DMWH7NQ	TC	Vasodilator Agents
DMWH7NQ	DT	Small molecular drug
DMWH7NQ	PC	5280723
DMWH7NQ	MW	354.5
DMWH7NQ	FM	C20H34O5
DMWH7NQ	IC	InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
DMWH7NQ	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O
DMWH7NQ	IK	GMVPRGQOIOIIMI-DWKJAMRDSA-N
DMWH7NQ	IU	7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
DMWH7NQ	CA	CAS 745-65-3
DMWH7NQ	CB	CHEBI:15544
DMWH7NQ	DE	Erectile dysfunction; Diabetic foot ulcer

DMB47TQ	ID	DMB47TQ
DMB47TQ	DN	Alseroxylon
DMB47TQ	HS	Approved
DMB47TQ	TC	Antihypertensive Agents
DMB47TQ	DE	Hypertension

DMRJ3YX	ID	DMRJ3YX
DMRJ3YX	DN	Alteplase
DMRJ3YX	HS	Approved
DMRJ3YX	SN	Activase (TN)
DMRJ3YX	CP	Boehringer Ingelheim Ltd
DMRJ3YX	TC	Thrombolytic Agents
DMRJ3YX	SQ	Alteplase sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DMRJ3YX	DE	Pulmonary embolism

DMKLAYG	ID	DMKLAYG
DMKLAYG	DN	Altretamine
DMKLAYG	HS	Approved
DMKLAYG	SN	Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
DMKLAYG	TC	Anticancer Agents
DMKLAYG	DT	Small molecular drug
DMKLAYG	PC	2123
DMKLAYG	MW	210.28
DMKLAYG	FM	C9H18N6
DMKLAYG	IC	InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
DMKLAYG	CS	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
DMKLAYG	IK	UUVWYPNAQBNQJQ-UHFFFAOYSA-N
DMKLAYG	IU	2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
DMKLAYG	CA	CAS 645-05-6
DMKLAYG	CB	CHEBI:24564
DMKLAYG	DE	Ovarian cancer

DMO9WDS	ID	DMO9WDS
DMO9WDS	DN	Altropane
DMO9WDS	HS	Approved
DMO9WDS	SN	Carbon-11-Altropane; Iodine-123-Altropane; 11C-Altropane; 123I-Altropane
DMO9WDS	CP	Harvard University
DMO9WDS	DT	Small molecular drug
DMO9WDS	PC	6440180
DMO9WDS	MW	429.3
DMO9WDS	FM	C18H21FINO2
DMO9WDS	IC	InChI=1S/C18H21FINO2/c1-23-18(22)17-15(12-3-5-13(19)6-4-12)11-14-7-8-16(17)21(14)10-2-9-20/h2-6,9,14-17H,7-8,10-11H2,1H3/b9-2+/t14-,15+,16+,17-/m0/s1
DMO9WDS	CS	COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/I)C[C@@H]1C3=CC=C(C=C3)F
DMO9WDS	IK	GTQLIPQFXVKRKJ-UNSMHXHVSA-N
DMO9WDS	IU	methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-[(E)-3-iodoprop-2-enyl]-8-azabicyclo[3.2.1]octane-2-carboxylate
DMO9WDS	CA	CAS 180468-34-2
DMO9WDS	CB	CHEBI:135696
DMO9WDS	DE	Attention deficit hyperactivity disorder

DM6ECN9	ID	DM6ECN9
DM6ECN9	DN	Aluminium
DM6ECN9	HS	Approved
DM6ECN9	SN	ALUMINUM; Adom; Aluminio; Metana; AO Al; Al alloy; Alaun [German]; Allbri aluminum paste and powder; Alumina fibre; Aluminium bronze; Aluminium flake; Aluminum alloy; Aluminum dehydrated; Aluminum dust; Aluminum metal; Aluminum powder; Aluminum production; Aluminum pyro powders; Aluminum soluble salts; Aluminum welding fumes; Emanay atomized aluminum powder; Metana aluminum paste; Noral Extra Fine Lining Grade; Noral Ink Grade Aluminum; Noral aluminium; Noral aluminum; Noral ink grade aluminium; A 00; A 95; A 99; A 995; A 999; AA 1099; AA1199; AD 1; AD1M; AO A1; AV00; AV000; Aa1193; Aluminum 27; Aluminum A00; Aluminum hydride [UN2463] [Dangerous when wet]; JISC 3108; JISC 3110; L16; NA9260; Pigment metal 1; ALUMINUM, ATOMIZED; Al(0); Aluminium(0); Aluminium, elementar; Aluminum (dust or fume); Aluminum (fume or dust); Aluminum (metal); Aluminum metal, alkyls; Aluminum metal, pyro powders; Aluminum metal, respirable fraction; Aluminum metal, soluble salts; Aluminum metal, total dust; Aluminum metal, welding fumes; Aluminum powder, coated [UN1309] [Flammable solid]; Aluminum powder, uncoated [UN1396] [Dangerous when wet]; Aluminum, elemental; Aluminum, molten [NA9260] [Class 9]; Aluminum, pyro powders; Aluminum, soluble salts; Aluminum, welding fumes; C-Pigment 1; C-Pigment 1 [German]; Noral non-leafing grade; Aluminum, pyro powders/welding fumes; C.I. 77000; ALUMINUM (SEE ALSO ALUMINUM OXIDE 1344-28-1); ALUMINUM, 99.999%; AQUANAL-plus aluminum (Al) 0.02-0.2 mg/L; AQUANAL(R)-plus aluminum (Al) 0.02-0.2 mg/L; 11008_ALDRICH; 11008_RIEDEL; 11009_ALDRICH; 11009_RIEDEL; 11010_ALDRICH; 11010_RIEDEL; 13Al
DM6ECN9	TC	Antiinflammatory Agents
DM6ECN9	DT	Small molecular drug
DM6ECN9	PC	5359268
DM6ECN9	MW	26.981
DM6ECN9	FM	Al
DM6ECN9	IC	InChI=1S/Al
DM6ECN9	CS	[Al]
DM6ECN9	IK	XAGFODPZIPBFFR-UHFFFAOYSA-N
DM6ECN9	IU	aluminum
DM6ECN9	CA	CAS 7429-90-5
DM6ECN9	CB	CHEBI:28984
DM6ECN9	DE	Hyperhidrosis

DMHR8KW	ID	DMHR8KW
DMHR8KW	DN	Alvimopan
DMHR8KW	HS	Approved
DMHR8KW	SN	Alvimopan anhydrous; LY 246736; LY246736; Adl 8-2698; Entereg (TN); Trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
DMHR8KW	CP	GSK
DMHR8KW	TC	Analgesics
DMHR8KW	DT	Small molecular drug
DMHR8KW	PC	5488548
DMHR8KW	MW	424.5
DMHR8KW	FM	C25H32N2O4
DMHR8KW	IC	InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1
DMHR8KW	CS	C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O
DMHR8KW	IK	UPNUIXSCZBYVBB-JVFUWBCBSA-N
DMHR8KW	IU	2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
DMHR8KW	CA	CAS 156053-89-3
DMHR8KW	CB	CHEBI:135686
DMHR8KW	DE	Gastrointestinal disease

DMS3YE9	ID	DMS3YE9
DMS3YE9	DN	Amantadine
DMS3YE9	HS	Approved
DMS3YE9	SN	Adamantamine; Adamantanamine; Adamantylamine; Amant; Amantadina; Amantadinum; Amantidine; Aminoadamantane; Endantadine; Mantadine; Symadine; Wiregyt; Amantadine Base; BIA4304; OR14310; Amantadina [INN-Spanish]; Amantadine (INN); Amantadine [INN:BAN]; Amantadinum [INN-Latin]; Gen-Amantadine; Pk-merz; Symmetrel (TN); TCMDC-125869; ADAMANTANE,1-AMINO; Adamantan-1-amine; Adamantan-1-ylamine; Tricyclo[3.3.1.1^3,7]decan-1-amine; Tricyclo(3.3.1.13,7)decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-ylamine; Tricyclo[3.3.1.1(3,7)]decane-1-amine; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; Tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo(3.3.1.1(3,7))-decan-1-amine; 1-Adamantamine; 1-Adamantanamine; 1-Adamantanamine (8CI); 1-Adamantylamine; 1-Aminoadamantane; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane
DMS3YE9	TC	Antiviral Agents
DMS3YE9	DT	Small molecular drug
DMS3YE9	PC	2130
DMS3YE9	MW	151.25
DMS3YE9	FM	C10H17N
DMS3YE9	IC	InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
DMS3YE9	CS	C1C2CC3CC1CC(C2)(C3)N
DMS3YE9	IK	DKNWSYNQZKUICI-UHFFFAOYSA-N
DMS3YE9	IU	adamantan-1-amine
DMS3YE9	CA	CAS 768-94-5
DMS3YE9	CB	CHEBI:2618
DMS3YE9	DE	Influenza A virus infection

DMOP0BL	ID	DMOP0BL
DMOP0BL	DN	Ambenonium
DMOP0BL	HS	Approved
DMOP0BL	SN	Ambenonum; Ambenonium Base; Ambenonium kation; Mytelase (TN); (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium; 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[n-(2-chlorobenzyl)-n,n-diethylethanaminium]
DMOP0BL	CP	Sanofi Aventis Us Llc
DMOP0BL	TC	Antiarrhythmic Agents
DMOP0BL	DT	Small molecular drug
DMOP0BL	PC	2131
DMOP0BL	MW	537.6
DMOP0BL	FM	C28H42Cl2N4O2+2
DMOP0BL	IC	InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2
DMOP0BL	CS	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl
DMOP0BL	IK	OMHBPUNFVFNHJK-UHFFFAOYSA-P
DMOP0BL	IU	(2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium
DMOP0BL	CA	CAS 7648-98-8
DMOP0BL	CB	CHEBI:2627
DMOP0BL	DE	Myasthenia gravis

DMD1QXW	ID	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	HS	Approved
DMD1QXW	SN	Letairis; Ambrisentan [INN]; Gilead brand of ambrisentan; BSF 208075; BSF208075; LU 208075; LU208075; BSF-208075; LU-208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
DMD1QXW	CP	GSK
DMD1QXW	DT	Small molecular drug
DMD1QXW	PC	6918493
DMD1QXW	MW	378.4
DMD1QXW	FM	C22H22N2O4
DMD1QXW	IC	InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
DMD1QXW	CS	CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
DMD1QXW	IK	OUJTZYPIHDYQMC-LJQANCHMSA-N
DMD1QXW	IU	(2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
DMD1QXW	CA	CAS 177036-94-1
DMD1QXW	CB	CHEBI:135949
DMD1QXW	DE	Pulmonary arterial hypertension

DMWJE9D	ID	DMWJE9D
DMWJE9D	DN	Ambroxol
DMWJE9D	HS	Approved
DMWJE9D	SN	Ambroxol hydrochloride; 23828-92-4; Ambroxol HCl; Mucosolvan; Mucoangin; Ambroxolhydrochloride; cis-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; UNII-CC995ZMV90; Ambroxol  hydrochloride; trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; Ambroxol Hydrochloride [JAN]; CC995ZMV90; 15942-05-9; Ambroxol hydrochloride (JAN); 2-Amino-3,5-dibromo-N-[trans-4-hydroxycyclohexyl]benzylamine; 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol hydrochloride
DMWJE9D	CP	Exsar
DMWJE9D	DT	Small molecular drug
DMWJE9D	PC	2132
DMWJE9D	MW	378.1
DMWJE9D	FM	C13H18Br2N2O
DMWJE9D	IC	InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2
DMWJE9D	CS	C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O
DMWJE9D	IK	JBDGDEWWOUBZPM-UHFFFAOYSA-N
DMWJE9D	IU	4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol
DMWJE9D	CA	CAS 18683-91-5
DMWJE9D	CB	CHEBI:92994
DMWJE9D	DE	Bronchitis

DMM1JL9	ID	DMM1JL9
DMM1JL9	DN	Amcinonide
DMM1JL9	HS	Approved
DMM1JL9	SN	Amcinonida; Amcinonido; Amcinonidum; Cyclocort; Cyclort; Triamcinolonacetatcyclopentanonid; Visderm; CL 34699; Amcinonido [INN-Spanish]; Amcinonidum [INN-Latin]; CL 34,699; CL-34699; Cyclocort (TN); Amcinonide (JAN/USP/INN); Amcinonide [USAN:INN:BAN:JAN]; Triamcinolone 16,17-cyclopentylidenedioxy-21-acetate; 1,4-Pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate; 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate; 19alpha-Fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclopentanone, 21-acetate
DMM1JL9	TC	Antiinflammatory Agents
DMM1JL9	DT	Small molecular drug
DMM1JL9	PC	443958
DMM1JL9	MW	502.6
DMM1JL9	FM	C28H35FO7
DMM1JL9	IC	InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1
DMM1JL9	CS	CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC6(O2)CCCC6
DMM1JL9	IK	ILKJAFIWWBXGDU-MOGDOJJUSA-N
DMM1JL9	IU	[2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] acetate
DMM1JL9	CA	CAS 51022-69-6
DMM1JL9	CB	CHEBI:31199
DMM1JL9	DE	Inflammation

DMIG6FY	ID	DMIG6FY
DMIG6FY	DN	Amdinocillin
DMIG6FY	HS	Approved
DMIG6FY	SN	Coactin; Hexacillin; Mecilinamo; Mecillinam; Mecillinamum; Selexidin; Amdinocillin Mecillinam; Amdinocillin [USAN]; Penicillin HX; FL 1060; Ro 109070; Amdinocillin (USAN); Coactin (TN); FL-1060; Mecilinamo [INN-Spanish]; Mecillinam (INN); Mecillinamum [INN-Latin]; Ro 10-9070; Ro-10-9070; Rel-(2R,6S)-6-{[(1E)-azepan-1-ylmethylene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-(((Hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1E)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((Hexahydro-1H-azepin-1-yl)methyleneamino)penicillanic acid; 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylic acid
DMIG6FY	CP	Leo Pharmaceutical 
DMIG6FY	TC	Antibiotics
DMIG6FY	DT	Small molecular drug
DMIG6FY	PC	36273
DMIG6FY	MW	325.4
DMIG6FY	FM	C15H23N3O3S
DMIG6FY	IC	InChI=1S/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)/t10-,11+,13-/m1/s1
DMIG6FY	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C
DMIG6FY	IK	BWWVAEOLVKTZFQ-NTZNESFSSA-N
DMIG6FY	IU	(2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIG6FY	CA	CAS 32887-01-7
DMIG6FY	DE	Bacterial infection

DM6I2WQ	ID	DM6I2WQ
DM6I2WQ	DN	Amezinium
DM6I2WQ	HS	Approved
DM6I2WQ	SN	Amezinium methyl sulfate
DM6I2WQ	DT	Small molecular drug
DM6I2WQ	PC	71927
DM6I2WQ	MW	202.23
DM6I2WQ	FM	C11H12N3O+
DM6I2WQ	IC	InChI=1S/C11H11N3O/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10/h2-8,12H,1H3/p+1
DM6I2WQ	CS	COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2
DM6I2WQ	IK	VXROHTDSRBRJLN-UHFFFAOYSA-O
DM6I2WQ	IU	6-methoxy-1-phenylpyridazin-1-ium-4-amine
DM6I2WQ	CA	CAS 41658-78-0
DM6I2WQ	CB	CHEBI:145698
DM6I2WQ	DE	Hypotension

DM9YSNQ	ID	DM9YSNQ
DM9YSNQ	DN	Amfepramone
DM9YSNQ	HS	Approved
DM9YSNQ	SN	Diethylpropion; DIETHYLPROPION; Diethylpropione; Amfepramon; Tepanil; Anorex; Nopropiophenone; Frekentine; Amphepramon; Amfepramonum; Amphepramone; Adiposon; Tylinal; Magrene; Dobesin; Neobes; Danylen; alpha-Benzoyltriethylamine; Anfepramona; Cegramine; Obesitex; Silutin; Regenon; Prefamone; Derfon; alpha-Diethylaminopropiophenone; 90-84-6; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; Amfepramone [INN]; Parabolin; Modulor; Keramik; Keramin; Anfamon; 2-(Diethylamino)propiophenone; 1-Phenyl-2-diethylamino-1-propanone;  Adiposon; Danylen;Derfon; Phepranon; Reginon; Amfepramone HCL; Amfepramone hydrochloride; Amphepramonum hydrochloride; Diethylpropion HCL; Diethylpropione hydrochloride; Tenuate hydrochloride; UR 1423; Alpha-Benzoyltriethylamine; Alpha-Diethylaminopropiophenone; Amfepramone (INN); Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton; Fenyl-(1-diethylaminoethyl)keton [Czech]; (+-)-diethylpropion; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; 2-Diethylaminopropiophenone
DM9YSNQ	DT	Small molecular drug
DM9YSNQ	PC	7029
DM9YSNQ	MW	205.3
DM9YSNQ	FM	C13H19NO
DM9YSNQ	IC	InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
DM9YSNQ	CS	CCN(CC)C(C)C(=O)C1=CC=CC=C1
DM9YSNQ	IK	XXEPPPIWZFICOJ-UHFFFAOYSA-N
DM9YSNQ	IU	2-(diethylamino)-1-phenylpropan-1-one
DM9YSNQ	CA	CAS 90-84-6
DM9YSNQ	CB	CHEBI:4530
DM9YSNQ	DE	Obesity; Migraine

DMK08L3	ID	DMK08L3
DMK08L3	DN	Amifampridine
DMK08L3	HS	Approved
DMK08L3	SN	3,4-DIAMINOPYRIDINE; pyridine-3,4-diamine; 3,4-Pyridinediamine; Firdapse; Diamino-3,4 pyridine; 4,5-Diaminopyridine; 3,4-DAP; SC10; amifampridin; Zenas; UNII-RU4S6E2G0J; EINECS 200-220-9; NSC 521760; BRN 0110232; RU4S6E2G0J; OYTKINVCDFNREN-UHFFFAOYSA-N; WT559; NCGC00167560-01; SMR000752913
DMK08L3	CP	Catalyst Pharmaceuticals
DMK08L3	PC	5918
DMK08L3	MW	109.13
DMK08L3	FM	C5H7N3
DMK08L3	IC	InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
DMK08L3	CS	C1=CN=CC(=C1N)N
DMK08L3	IK	OYTKINVCDFNREN-UHFFFAOYSA-N
DMK08L3	IU	pyridine-3,4-diamine
DMK08L3	CA	CAS 54-96-6
DMK08L3	CB	CHEBI:135948
DMK08L3	DE	LambertEaton myasthenic syndrome

DM5FL14	ID	DM5FL14
DM5FL14	DN	Amifostine
DM5FL14	HS	Approved
DM5FL14	SN	Ethiofos; Ethyol; Gammaphos; WR-1064; WR-2721; WR-2721C; YM-08310
DM5FL14	CP	Medimmune Oncology Inc
DM5FL14	DT	Small molecular drug
DM5FL14	PC	2141
DM5FL14	MW	214.23
DM5FL14	FM	C5H15N2O3PS
DM5FL14	IC	InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)
DM5FL14	CS	C(CN)CNCCSP(=O)(O)O
DM5FL14	IK	JKOQGQFVAUAYPM-UHFFFAOYSA-N
DM5FL14	IU	2-(3-aminopropylamino)ethylsulfanylphosphonic acid
DM5FL14	CA	CAS 20537-88-6
DM5FL14	CB	CHEBI:2636
DM5FL14	DE	Mucositis

DM5PDRB	ID	DM5PDRB
DM5PDRB	DN	Amikacin
DM5PDRB	HS	Approved
DM5PDRB	SN	Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A
DM5PDRB	CP	Abbott Laboratories
DM5PDRB	TC	Antibiotics
DM5PDRB	DT	Small molecular drug
DM5PDRB	PC	37768
DM5PDRB	MW	585.6
DM5PDRB	FM	C22H43N5O13
DM5PDRB	IC	InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
DM5PDRB	CS	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
DM5PDRB	IK	LKCWBDHBTVXHDL-RMDFUYIESA-N
DM5PDRB	IU	(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DM5PDRB	CA	CAS 37517-28-5
DM5PDRB	CB	CHEBI:2637
DM5PDRB	DE	Bacterial infection; Tuberculosis

DMRTSGP	ID	DMRTSGP
DMRTSGP	DN	Amiloride
DMRTSGP	HS	Approved
DMRTSGP	SN	Amiclaran; Amilorida; Amiloridum; Amipramidin; Amipramizid; Amipramizide; Amiprazidine; Amyloride; Guanamprazin; Guanamprazine; Midamor; Amiloride HCL; Amiloride hydrochloride hydrate; Amiclaran (TN); Amikal (Hydrochloride dihydrate); Amilorida [INN-Spanish]; Amiloride (INN); Amiloride [INN:BAN]; Amiloridum [INN-Latin]; Biduret (TN); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloride (Na-Ca chanel blocker)
DMRTSGP	CP	Tornett pharmaceutical
DMRTSGP	TC	Diuretics
DMRTSGP	DT	Small molecular drug
DMRTSGP	PC	16231
DMRTSGP	MW	229.63
DMRTSGP	FM	C6H8ClN7O
DMRTSGP	IC	InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)
DMRTSGP	CS	C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N
DMRTSGP	IK	XSDQTOBWRPYKKA-UHFFFAOYSA-N
DMRTSGP	IU	3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
DMRTSGP	CA	CAS 2609-46-3
DMRTSGP	CB	CHEBI:2639
DMRTSGP	DE	Congestive heart failure

DMFGND4	ID	DMFGND4
DMFGND4	DN	Aminocaproic acid
DMFGND4	HS	Approved
DMFGND4	SN	6-Aminohexanoic acid; 6-aminohexanoic acid; 6-Aminocaproic acid; aminocaproic acid; 60-32-2; amicar; Epsikapron; Caprocid; Capramol; Epsamon; EACA; Caprolisin; Acepramin; Hemocaprol; Epsicapron; Respramin; Amikar; EPSILON-AMINOCAPROIC ACID; Hexanoic acid, 6-amino-; Epsilcapramin; Aminokapron; Caplamin; Acepramine; Capracid; Hemopar; Ipsilon; Afibrin; Atsemin; Hepin; Epsilon S; Aminocaproic; Capralense; epsilon-Leucine; EACS; epsilon-Norleucine; epsilcapramine; 6-Amino-n-hexanoic acid; omega-Aminocaproic acid; epsilon-Aminohexanoic acid; 6-amino-hexanoic acid;  ACS; Amicar; Aminocaproate; Capranol; Caproamin; Epsicaprom; Epsilcapramine; Hemopar;Hepin; Acide aminocaproique; Acide aminocaproique [French]; Acide aminocaproque; Acido aminocaproico; Acidum aminocaproicum; Acidum aminocaproicum [Latin]; Aminocaproic Acid In Plastic Container; Aminocaproic Acids; Aminohexanoic acid; Eaca kabi; Epsilon Aminocaproic Acid; A 7824; CL 10304; CY 116; CY116; JD 177; Acide aminocaproique [INN-French]; Acido aminocaproico [DCIT,Spanish]; Acido aminocaproico [INN-Spanish]; Acidum aminocaproicum [INN-Latin]; Amicar (TN); Aminocaproic acid (USP); CL-10304; CY-116; Epsilon-Ahx; Epsilon-Aminocaproic acid; Epsilon-Aminocapronsaeure; Epsilon-Aminohexanoic acid; Epsilon-Leucine; Epsilon-Norleucine; Epsilon-aminocaproate; Epsilon-aminocapronzuur; Fullevir (TN); Kyselina omega-aminokapronova; Kyselina omega-aminokapronova [Czech]; Omega-Aminocaproic acid; Omega-Aminohexanoic acid; S04-0132; Acid, 6-Aminocaproic; Acid, 6-Aminohexanoic; Acid, epsilon-Aminocaproic; Aminocaproic acid (USP/INN); Aminocaproic acid [USAN:BAN:INN]; Aminocaproic acid [USAN:INN:BAN]; Epsilon-Aminocaproic acid (JAN); HEXANOIC ACID,6-AMINO; Epsilon-Amino-n-caproic acid; Epsilon-Amino-n-hexanoic acid; Amicar, A-amino caproic acid, A-Ahx, 6-aminohexanoic acid, Aminocaproic acid; 6 Aminocaproic Acid; 6 Aminohexanoic Acid; 6-amino-n-caproate; 6-amino-n-caproic acid; 6-aminohexanoate; 6-Amino Hexanoic Acid
DMFGND4	CP	Intelfarm Co.
DMFGND4	TC	Antifibrinolytic Agents
DMFGND4	DT	Small molecular drug
DMFGND4	PC	564
DMFGND4	MW	131.17
DMFGND4	FM	C6H13NO2
DMFGND4	IC	InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
DMFGND4	CS	C(CCC(=O)O)CCN
DMFGND4	IK	SLXKOJJOQWFEFD-UHFFFAOYSA-N
DMFGND4	IU	6-aminohexanoic acid
DMFGND4	CA	CAS 60-32-2
DMFGND4	CB	CHEBI:16586
DMFGND4	DE	Bleeding disorder; Postoperative hemorrhage

DMWFHMZ	ID	DMWFHMZ
DMWFHMZ	DN	Aminoglutethimide
DMWFHMZ	HS	Approved
DMWFHMZ	SN	Aminoglutethimidum; Aminoglutetimida; Cytadren; Elipten; Orimeten; Ciba Vision Brand of Aminoglutethimide; Novartis Brand of Aminoglutethimide; A 9657; Ba 16038; AG-1; Aminoglutethimide (AG); Aminoglutethimide [INN:BAN]; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Ba-16038; C 16038-BA; Cytadren (TN); Dl-Aminoglutethimide; P-Aminoglutethimide; Aminoglutethimide (USP/INN); Glutethimide, para-amino; Alpha-(p-Aminophenyl)-alpha-ethylglutarimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; (+/-)-p-AMINOGLUTETHIMIDE; (inverted question mark)-p-Aminoglutethimide; 2-(p-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine
DMWFHMZ	CP	Norvatis Phamaceuticals Corporation
DMWFHMZ	TC	Anticancer Agents
DMWFHMZ	DT	Small molecular drug
DMWFHMZ	PC	2145
DMWFHMZ	MW	232.28
DMWFHMZ	FM	C13H16N2O2
DMWFHMZ	IC	InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)
DMWFHMZ	CS	CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMWFHMZ	IK	ROBVIMPUHSLWNV-UHFFFAOYSA-N
DMWFHMZ	IU	3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione
DMWFHMZ	CA	CAS 125-84-8
DMWFHMZ	CB	CHEBI:2654
DMWFHMZ	DE	Cushing disease

DMS4BLQ	ID	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	HS	Approved
DMS4BLQ	SN	Aminolevulinic acid; 5-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid; 106-60-5; 5-Aminolevulinate; delta-aminolevulinic acid; Pentanoic acid, 5-amino-4-oxo-; Aladerm; 5-Amino-4-oxovaleric acid; Kerastick; Ameluz; Aminolevulinate; 5-ALA; delta-ALA; 5-Amino-4-oxopentanoate; 5-amino-levulinate; 5-amino-levulinic acid; 5-amino-4-oxo-pentanoic acid; CCRIS 8958; UNII-88755TAZ87; EINECS 203-414-1; Levulinic acid, 5-amino-; CHEMBL601; 4-oxo-5-amino-pentanoic acid; CHEBI:17549; ZGXJTSGNIOSYLO-UHFFFAOYSA-N; 88755TAZ87; Levulan (TN)
DMS4BLQ	DT	Small molecular drug
DMS4BLQ	PC	137
DMS4BLQ	MW	131.13
DMS4BLQ	FM	C5H9NO3
DMS4BLQ	IC	InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)
DMS4BLQ	CS	C(CC(=O)O)C(=O)CN
DMS4BLQ	IK	ZGXJTSGNIOSYLO-UHFFFAOYSA-N
DMS4BLQ	IU	5-amino-4-oxopentanoic acid
DMS4BLQ	CA	CAS 106-60-5
DMS4BLQ	CB	CHEBI:17549
DMS4BLQ	DE	Acne vulgaris; Actinic keratosis

DMWNHPC	ID	DMWNHPC
DMWNHPC	DN	Aminolevulinic Acid Hydrochloride
DMWNHPC	HS	Approved
DMWNHPC	SN	Levulan; Levulan Kerastick
DMWNHPC	CP	Dusa Pharmaceuticals Inc
DMWNHPC	DT	Small molecular drug
DMWNHPC	PC	123608
DMWNHPC	MW	167.59
DMWNHPC	FM	C5H10ClNO3
DMWNHPC	IC	InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H
DMWNHPC	CS	C(CC(=O)O)C(=O)CN.Cl
DMWNHPC	IK	ZLHFONARZHCSET-UHFFFAOYSA-N
DMWNHPC	IU	5-amino-4-oxopentanoic acid;hydrochloride
DMWNHPC	CA	CAS 5451-09-2
DMWNHPC	CB	CHEBI:132969
DMWNHPC	DE	Actinic keratosis

DML2NIB	ID	DML2NIB
DML2NIB	DN	Aminophylline
DML2NIB	HS	Approved
DML2NIB	SN	Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN)
DML2NIB	TC	Bronchodilator Agents
DML2NIB	DT	Small molecular drug
DML2NIB	PC	9433
DML2NIB	MW	420.43
DML2NIB	FM	C16H24N10O4
DML2NIB	IC	InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
DML2NIB	CS	CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N
DML2NIB	IK	FQPFAHBPWDRTLU-UHFFFAOYSA-N
DML2NIB	IU	1,3-dimethyl-7H-purine-2,6-dione;ethane-1,2-diamine
DML2NIB	CA	CAS 317-34-0
DML2NIB	CB	CHEBI:2659
DML2NIB	DE	Bronchial asthma; Asthma

DMENSL5	ID	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	HS	Approved
DMENSL5	SN	4-Aminosalicylic acid; 65-49-6; Aminosalicylic acid; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium
DMENSL5	CP	Panray Corp Sub Ormont Drug And Chemical Co Inc
DMENSL5	DT	Small molecular drug
DMENSL5	PC	4649
DMENSL5	MW	153.14
DMENSL5	FM	C7H7NO3
DMENSL5	IC	InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)
DMENSL5	CS	C1=CC(=C(C=C1N)O)C(=O)O
DMENSL5	IK	WUBBRNOQWQTFEX-UHFFFAOYSA-N
DMENSL5	IU	4-amino-2-hydroxybenzoic acid
DMENSL5	CA	CAS 65-49-6
DMENSL5	CB	CHEBI:27565
DMENSL5	DE	Pulmonary and extrapulmonary tuberculosis; Inflammatory bowel disease

DMUTEX3	ID	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	HS	Approved
DMUTEX3	SN	Amidorone; Aminodarone; Amiobeta; Amiodarex; Amiodarona; Amiodarons; Amiodaronum; Amiohexal; Amjodaronum; Ancar; Aratac;Arycor; Braxan; Corbionax; Cordarex; Cordarone; Kordaron; Labaz; Ortacrone; Pacerone; Rytmarone; Sedacoron; Sedacorone; Tachydaron; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amiodarone Base; Armstrong Brand of Amiodarone Hydrochloride; Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Cordarone Intravenous; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Leurquin Brand of Amiodarone Hydrochloride; Pharma Investi Brand of Amiodarone Hydrochloride; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Wyeth Brand of Amiodarone Hydrochloride; Ethylaminoethoxy)benzoyl]benzofuran; L 3428; L3428; SKF 33134A; Amio-Aqueous IV; Amiodarona [INN-Spanish]; Amiodaronum [INN-Latin]; Aratac (TN); Arycor (TN); Atlansil (TN); Cordarone (TN); L-3428; Pacerone (TN); Pms-Amiodarone; SKF 33134-A; Amiodarone (USAN/INN); Amiodarone [USAN:BAN:INN]; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); (2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
DMUTEX3	CP	Wyeth-Ayerst Laboratories
DMUTEX3	TC	Antiarrhythmic Agents
DMUTEX3	DT	Small molecular drug
DMUTEX3	PC	2157
DMUTEX3	MW	645.3
DMUTEX3	FM	C25H29I2NO3
DMUTEX3	IC	InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
DMUTEX3	CS	CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMUTEX3	IK	IYIKLHRQXLHMJQ-UHFFFAOYSA-N
DMUTEX3	IU	(2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone
DMUTEX3	CA	CAS 1951-25-3
DMUTEX3	CB	CHEBI:2663
DMUTEX3	DE	Tachyarrhythmias

DMSJVAM	ID	DMSJVAM
DMSJVAM	DN	Amisulpride
DMSJVAM	HS	Approved
DMSJVAM	SN	Aminosultopride; Amisulpiride; Amisulprida; Amisulpridum; Deniban; Socian; Solian; Amisulpride [INN]; DAN 2163; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpridum [INN-Latin]; DAN-2163; Deniban (TN); Solian (TN); Solian, Amisulpride; SL-91.1077; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMSJVAM	CP	Sanofi-Aventis
DMSJVAM	TC	Antipsychotic Agents
DMSJVAM	DT	Small molecular drug
DMSJVAM	PC	2159
DMSJVAM	MW	369.5
DMSJVAM	FM	C17H27N3O4S
DMSJVAM	IC	InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
DMSJVAM	CS	CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
DMSJVAM	IK	NTJOBXMMWNYJFB-UHFFFAOYSA-N
DMSJVAM	IU	4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMSJVAM	CA	CAS 71675-85-9
DMSJVAM	CB	CHEBI:64045
DMSJVAM	DE	Schizophrenia

DMK7F9S	ID	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	HS	Approved
DMK7F9S	SN	Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptylin; Amitriptylinum; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; Laroxyl; Proheptadiene; Redomex; Sarotex; Seroten; Sylvemid; Triptanol; Triptilin; Triptisol; Tryptanol; Amitriptilina [Italian]; Amitriptylin [German]; MK 230; N 750; TP0; Amitriptilina [INN-Spanish]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum [INN-Latin]; Elavil (TN); Laroxyl (TN); Ro 4-1575; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene
DMK7F9S	CP	Hoffmann La Roche Inc
DMK7F9S	TC	Analgesics
DMK7F9S	DT	Small molecular drug
DMK7F9S	PC	2160
DMK7F9S	MW	277.4
DMK7F9S	FM	C20H23N
DMK7F9S	IC	InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
DMK7F9S	CS	CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
DMK7F9S	IK	KRMDCWKBEZIMAB-UHFFFAOYSA-N
DMK7F9S	IU	N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
DMK7F9S	CA	CAS 50-48-6
DMK7F9S	CB	CHEBI:2666
DMK7F9S	DE	Depression

DM0DQM5	ID	DM0DQM5
DM0DQM5	DN	Amlexanox
DM0DQM5	HS	Approved
DM0DQM5	SN	ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid
DM0DQM5	CP	Access Pharmaceuticals
DM0DQM5	TC	Antiulcer Agents
DM0DQM5	DT	Small molecular drug
DM0DQM5	PC	2161
DM0DQM5	MW	298.29
DM0DQM5	FM	C16H14N2O4
DM0DQM5	IC	InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)
DM0DQM5	CS	CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N
DM0DQM5	IK	SGRYPYWGNKJSDL-UHFFFAOYSA-N
DM0DQM5	IU	2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid
DM0DQM5	CA	CAS 68302-57-8
DM0DQM5	CB	CHEBI:31205
DM0DQM5	DE	Respiratory tract inflammation

DMBDAZV	ID	DMBDAZV
DMBDAZV	DN	Amlodipine
DMBDAZV	HS	Approved
DMBDAZV	SN	Amlocard; Amlodipino; Amlodipinum; Amlodis; Amlopres; Amlor; Coroval; Intervask; Lipinox; AMLODIPINE BASE; Amlodipine Free Base; Amlodipino [Spanish]; Amlodipinum [Latin]; Racemic Amlodipine; Amlodipine (INN); Amlodipine [INN:BAN]; Dailyvasc (TN); Istin (TN); Norvasc (TN); Perivasc (TN); UK-4834011; R,S)-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMBDAZV	CP	Dainippon Sumitomo
DMBDAZV	TC	Antihypertensive Agents
DMBDAZV	DT	Small molecular drug
DMBDAZV	PC	2162
DMBDAZV	MW	408.9
DMBDAZV	FM	C20H25ClN2O5
DMBDAZV	IC	InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
DMBDAZV	CS	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
DMBDAZV	IK	HTIQEAQVCYTUBX-UHFFFAOYSA-N
DMBDAZV	IU	3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMBDAZV	CA	CAS 88150-42-9
DMBDAZV	CB	CHEBI:2668
DMBDAZV	DE	Hypertension

DMOEVK6	ID	DMOEVK6
DMOEVK6	DN	Ammonia
DMOEVK6	HS	Approved
DMOEVK6	SN	Ammonia N13
DMOEVK6	CP	Feinstein
DMOEVK6	DT	Small molecular drug
DMOEVK6	PC	222
DMOEVK6	MW	17.031
DMOEVK6	FM	H3N
DMOEVK6	IC	InChI=1S/H3N/h1H3
DMOEVK6	CS	N
DMOEVK6	IK	QGZKDVFQNNGYKY-UHFFFAOYSA-N
DMOEVK6	IU	azane
DMOEVK6	CA	CAS 7664-41-7
DMOEVK6	CB	CHEBI:16134
DMOEVK6	DE	Coronary artery disease

DM0GQ8N	ID	DM0GQ8N
DM0GQ8N	DN	Amobarbital
DM0GQ8N	HS	Approved
DM0GQ8N	SN	AMAL; Amasust; Amital; Amobarbitale; Amobarbitalum; Amobarbitone; Amospan; Amybal; Amylbarbitone; Amylobarbital; Amylobarbitone; Amytal; Barbamil; Barbamyl; Binoctal; Dorlotyn; Dormytal; Eunoctal; Isomyl; Isomytal; Mylodorm; Pentymal; Pentymalum; Robarb; Schiwanox; Sednotic; Somnal; Stadadorm; Sumital; Talamo; Amobarbital suppository dosage form; Amobarbitale [DCIT]; Barbamyl acid; Component of Dexamyl; Ethylisopentylbarbituric acid; Isoamylethylbarbituric acid; Amobarbital [INN:JAN]; Amobarbitalum [INN-Latin]; Component of 15-90; Component of Amo-Dextrosule; Component of Q-Caps; Isomytal (TN); Amobarbital (JP15/INN); 5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(3-methylbutyl)barbituric acid;5-Ethyl-5-isoamylbarbituric acid; 5-Ethyl-5-isoamylmalonyl urea; 5-Ethyl-5-isopentylbarbituric acid; 5-Ethyl-5-isopentylbarbitursaeure; 5-Isoamyl-5-ethylbarbituric acid; 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione
DM0GQ8N	TC	Hypnotics and Sedatives
DM0GQ8N	DT	Small molecular drug
DM0GQ8N	PC	2164
DM0GQ8N	MW	226.27
DM0GQ8N	FM	C11H18N2O3
DM0GQ8N	IC	InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DM0GQ8N	CS	CCC1(C(=O)NC(=O)NC1=O)CCC(C)C
DM0GQ8N	IK	VIROVYVQCGLCII-UHFFFAOYSA-N
DM0GQ8N	IU	5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione
DM0GQ8N	CA	CAS 57-43-2
DM0GQ8N	CB	CHEBI:2673
DM0GQ8N	DE	Insomnia

DME4RA8	ID	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	HS	Approved
DME4RA8	SN	Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquinum; Basoquin; CQA; Camochin; Camoquin; Camoquinal; Camoquine; Flavoquin; Flavoquine; Miaquin; Sunoquine; Amodiaquine hydrochloride; Amodiaquine USP24; SN 10751; AMODIAQUINE, FLAVOQUINE; Amodiaquina [INN-Spanish]; Amodiaquinum [INN-Latin]; CAM-AQ 1; CAM-AQI; Cam-AQ1; Camoquin (TN); Flavoquine (TN); SN 10,751; WR-002977; Amodiaquine (USAN/INN); Amodiaquine [USAN:INN:BAN]; Amodiaquine, ring-closed; S. N. 10751
DME4RA8	TC	Antimalarials
DME4RA8	DT	Small molecular drug
DME4RA8	PC	2165
DME4RA8	MW	355.9
DME4RA8	FM	C20H22ClN3O
DME4RA8	IC	InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)
DME4RA8	CS	CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O
DME4RA8	IK	OVCDSSHSILBFBN-UHFFFAOYSA-N
DME4RA8	IU	4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
DME4RA8	CA	CAS 86-42-0
DME4RA8	CB	CHEBI:2674
DME4RA8	DE	Malaria

DML8QSZ	ID	DML8QSZ
DML8QSZ	DN	Amosulalol
DML8QSZ	HS	Approved
DML8QSZ	SN	Lowgan; LY-137224; YM-09538
DML8QSZ	CP	Yamanouchi Pharmaceutical Co Ltd
DML8QSZ	DT	Small molecular drug
DML8QSZ	PC	2169
DML8QSZ	MW	380.5
DML8QSZ	FM	C18H24N2O5S
DML8QSZ	IC	InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23)
DML8QSZ	CS	CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N
DML8QSZ	IK	LVEXHFZHOIWIIP-UHFFFAOYSA-N
DML8QSZ	IU	5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-methylbenzenesulfonamide
DML8QSZ	CA	CAS 85320-68-9
DML8QSZ	CB	CHEBI:135592
DML8QSZ	DE	Hypertension

DMKITQE	ID	DMKITQE
DMKITQE	DN	Amoxapine
DMKITQE	HS	Approved
DMKITQE	SN	Amoxan; Amoxapina; Amoxapinum; Amoxepine; Ascendin; Asendin; Asendis; Defanyl; Demolox; Desmethylloxapin; Desmethylloxapine; Moxadil; CL 67772; A-129; Amoxapina [INN-Spanish]; Amoxapinum [INN-Latin]; Asendin (TN); Asendis (TN); CL-67772; Defanyl (TN); Demolox (TN); KS-1197; Moxadil (TN); CL-67,772; Amoxapine (JP15/USP/INN); Amoxapine [USAN:BAN:INN:JAN]; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
DMKITQE	TC	Antidepressants
DMKITQE	DT	Small molecular drug
DMKITQE	PC	2170
DMKITQE	MW	313.8
DMKITQE	FM	C17H16ClN3O
DMKITQE	IC	InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
DMKITQE	CS	C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
DMKITQE	IK	QWGDMFLQWFTERH-UHFFFAOYSA-N
DMKITQE	IU	8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
DMKITQE	CA	CAS 14028-44-5
DMKITQE	CB	CHEBI:2675
DMKITQE	DE	Major depressive disorder

DMUYNEI	ID	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	HS	Approved
DMUYNEI	SN	AMPC; Actimoxi; Amoclen; Amolin; Amopen; Amopenixin; Amoxi; Amoxibiotic; Amoxicaps; Amoxicilina; Amoxicillanyl; Amoxicilline; Amoxicillinum; Amoxiden; Amoxil; Amoxivet; Amoxycillin; Anemolin; Aspenil; Biomox; Bristamox; Cemoxin; Clamoxyl; Delacillin; DisperMox; Efpenix; Flemoxin; Hiconcil; Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Lamoxy; Larotid; Moxacin; Moxal; Moxatag; Ospamox; Pamoxicillin; Piramox; Polymox; Robamox; Sumox; Tolodina; Trimox; Unicillin; Utimox; Vetramox; Wymox; AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; Amoxicillin anhydrous; Amoxicilline [INN]; Amoxycillin Trihydrate; Metafarma capsules; Metifarma capsules; Sawamox PM; BLP 1410; AMK (TN); Actimoxi (TN); Alphamox (TN); Amoksibos (TN); Amoksiklav (TN); Amoxi-Mast; Amoxibiotic (TN); Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxil (TN); Amoxin (TN); Apo-Amoxi; Augmentin (TN); BL-P 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Cilamox (TN); Clamoxyl (TN); Curam (TN); D-Amoxicillin; Dedoxil (TN); Dispermox (TN); Duomox (TN); Enhancin (TN); Geramox (TN); Gimalxina (TN); Hiconcil (TN); Isimoxin (TN); Klavox (TN); Lamoxy (TN); Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Polymox (TN); Ro 10-8756; Samthongcillin (TN); Sandoz (TN); Senox (TN); Sinacilin (TN); Tolodina (TN); Trimox (TN); Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN); Apo-Amoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMUYNEI	CP	AstraZeneca
DMUYNEI	TC	Antibiotics
DMUYNEI	DT	Small molecular drug
DMUYNEI	PC	33613
DMUYNEI	MW	365.4
DMUYNEI	FM	C16H19N3O5S
DMUYNEI	IC	InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1
DMUYNEI	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C
DMUYNEI	IK	LSQZJLSUYDQPKJ-NJBDSQKTSA-N
DMUYNEI	IU	(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMUYNEI	CA	CAS 26787-78-0
DMUYNEI	CB	CHEBI:2676
DMUYNEI	DE	Bacterial infection

DMSZQAK	ID	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	HS	Approved
DMSZQAK	SN	Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore
DMSZQAK	CP	PharmacoFore Inc
DMSZQAK	DT	Small molecular drug
DMSZQAK	PC	3007
DMSZQAK	MW	135.21
DMSZQAK	FM	C9H13N
DMSZQAK	IC	InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
DMSZQAK	CS	CC(CC1=CC=CC=C1)N
DMSZQAK	IK	KWTSXDURSIMDCE-UHFFFAOYSA-N
DMSZQAK	IU	1-phenylpropan-2-amine
DMSZQAK	CA	CAS 300-62-9
DMSZQAK	CB	CHEBI:2679
DMSZQAK	DE	Attention deficit hyperactivity disorder

DMTAJQE	ID	DMTAJQE
DMTAJQE	DN	Amphotericin B
DMTAJQE	HS	Approved
DMTAJQE	SN	ABLC; Abelcet; Abelecet; Ambisome; Amphocin; Amphomoronal; Amphotec; Amphotericin; Amphotericinum; Amphotherizin; Amphozone; Fungilin; Fungisome; Fungisone; Fungizone; Halizon; SinuNase; Amfotericina B; Amophotericin B; Amphortericin B; Amphotericin B Cholesterol Dispersion; Amphotericin B Colloidal Dispersion; Amphotericin B liposomal; Amphotericin BETA; Amphotericine B; Amphotericinum B; Amphotherizin [German]; Liposomal Amphotericin B; NCI527017; NS 718; AMPH-B; Abelcet (TN); AmBisome (TN); Amfotericina B [INN-Spanish]; Ampho-Moronal; Amphocil (TN); Amphotec (TN); Amphotericin-B; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; Fungilin (TN); Fungisome (TN); Fungizone (TN); LNS-AmB; Mysteclin-F; NKTR-024; Amphotericin B [USAN:INN:JAN]; Amphotericin B, Lipid-based; Amphotericin B, Streptomyces sp.; Amphotericin B (JP15/USP/INN)
DMTAJQE	TC	Antifungal Agents
DMTAJQE	DT	Small molecular drug
DMTAJQE	PC	5280965
DMTAJQE	MW	924.1
DMTAJQE	FM	C47H73NO17
DMTAJQE	IC	InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
DMTAJQE	CS	C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
DMTAJQE	IK	APKFDSVGJQXUKY-INPOYWNPSA-N
DMTAJQE	IU	(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid
DMTAJQE	CA	CAS 1397-89-3
DMTAJQE	DE	Fungal infection; Mycoses

DMHWE7P	ID	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	HS	Approved
DMHWE7P	SN	ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMHWE7P	CP	Stadapharm GmbH
DMHWE7P	TC	Antibiotics
DMHWE7P	DT	Small molecular drug
DMHWE7P	PC	6249
DMHWE7P	MW	349.4
DMHWE7P	FM	C16H19N3O4S
DMHWE7P	IC	InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1
DMHWE7P	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C
DMHWE7P	IK	AVKUERGKIZMTKX-NJBDSQKTSA-N
DMHWE7P	IU	(2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMHWE7P	CA	CAS 69-53-4
DMHWE7P	CB	CHEBI:28971
DMHWE7P	DE	Bacterial infection

DM5BS98	ID	DM5BS98
DM5BS98	DN	Ampiroxicam
DM5BS98	HS	Approved
DM5BS98	SN	Flucam; Nacyl; Nasil; CP-65703
DM5BS98	CP	Pfizer Inc
DM5BS98	DT	Small molecular drug
DM5BS98	PC	2176
DM5BS98	MW	447.5
DM5BS98	FM	C20H21N3O7S
DM5BS98	IC	InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)
DM5BS98	CS	CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3
DM5BS98	IK	LSNWBKACGXCGAJ-UHFFFAOYSA-N
DM5BS98	IU	ethyl 1-[[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1lambda6,2-benzothiazin-4-yl]oxy]ethyl carbonate
DM5BS98	CA	CAS 99464-64-9
DM5BS98	CB	CHEBI:31210
DM5BS98	DE	Inflammation

DMLMXE0	ID	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	HS	Approved
DMLMXE0	SN	AMV; Agenerase; Amprenavir[usan]; Prozei; Vertex; Amprenavir [USAN]; VX 478; VX478; Vertex VX478; Agenerase (TM); Agenerase (TN); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; VX-478; Amprenavir (JAN/USAN/INN); Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide
DMLMXE0	CP	GlaxoSmithKline
DMLMXE0	TC	Anti-HIV Agents
DMLMXE0	DT	Small molecular drug
DMLMXE0	PC	65016
DMLMXE0	MW	505.6
DMLMXE0	FM	C25H35N3O6S
DMLMXE0	IC	InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1
DMLMXE0	CS	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
DMLMXE0	IK	YMARZQAQMVYCKC-OEMFJLHTSA-N
DMLMXE0	IU	[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMLMXE0	CA	CAS 161814-49-9
DMLMXE0	CB	CHEBI:40050
DMLMXE0	DE	Human immunodeficiency virus infection

DMZKYIV	ID	DMZKYIV
DMZKYIV	DN	Amsacrine
DMZKYIV	HS	Approved
DMZKYIV	SN	Acridinylanisidide; Amecrin; Amekrin; Amsacrina; Amsacrinum; Amsidine; Amsidyl; Amsine; Lamasine; MAMSA; NAMSA; Acridinyl Anisidide; SN 21429; SN11841; AMSA P-D; Acridinyl anisidide (TN); Amsacrina [INN-Spanish]; Amsacrinum [INN-Latin]; Amsidyl (TN); Cain's Acridine; M-AMSA; Meta-AMSA; Meta-Amsacrine; SN-11841; Amsacrine (USAN/INN); Amsacrine [USAN:BAN:INN]; M-AMSA (TN); N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; 4'-(9-Acridinylamino)methanesulphon-m-anisidide
DMZKYIV	CP	Travenol Laboratories Inc
DMZKYIV	TC	Anticancer Agents
DMZKYIV	DT	Small molecular drug
DMZKYIV	PC	2179
DMZKYIV	MW	393.5
DMZKYIV	FM	C21H19N3O3S
DMZKYIV	IC	InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)
DMZKYIV	CS	COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42
DMZKYIV	IK	XCPGHVQEEXUHNC-UHFFFAOYSA-N
DMZKYIV	IU	N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
DMZKYIV	CA	CAS 51264-14-3
DMZKYIV	CB	CHEBI:2687
DMZKYIV	DE	Acute lymphoblastic leukaemia

DMAWU35	ID	DMAWU35
DMAWU35	DN	Amtolmetin guacil
DMAWU35	HS	Approved
DMAWU35	SN	Artromed; Atromed; Eufans; Amtolmetin guacyl; MED-15; ST-679
DMAWU35	CP	Sigma-Tau Ind Farm Riunite SpA
DMAWU35	DT	Small molecular drug
DMAWU35	PC	65655
DMAWU35	MW	420.5
DMAWU35	FM	C24H24N2O5
DMAWU35	IC	InChI=1S/C24H24N2O5/c1-16-8-10-17(11-9-16)24(29)19-13-12-18(26(19)2)14-22(27)25-15-23(28)31-21-7-5-4-6-20(21)30-3/h4-13H,14-15H2,1-3H3,(H,25,27)
DMAWU35	CS	CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)NCC(=O)OC3=CC=CC=C3OC
DMAWU35	IK	CWJNMKKMGIAGDK-UHFFFAOYSA-N
DMAWU35	IU	(2-methoxyphenyl) 2-[[2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetyl]amino]acetate
DMAWU35	CA	CAS 87344-06-7
DMAWU35	CB	CHEBI:135678
DMAWU35	DE	Inflammation

DMJKO05	ID	DMJKO05
DMJKO05	DN	Amyl nitrite
DMJKO05	HS	Approved
DMJKO05	SN	Amyl nitrite; Pentyl nitrite; n-Amyl nitrite; 463-04-7; Nitramyl; n-Pentyl nitrite; Nitrous acid, pentyl ester; Pentyl alcohol, nitrite; UNII-H2HUX79FYK; CCRIS 763; EINECS 207-332-7; H2HUX79FYK; BRN 1701241; AI3-25184; CHEBI:55344; CSDTZUBPSYWZDX-UHFFFAOYSA-N; Pentylnitrite; n-pentylnitrite; amyl 1 nitrite; N-Phenyl nitrile; ACMC-1ACPW; nitrous acid pentyl ester; Nitrousacid, pentyl ester; DSSTox_CID_4522; UN 1113 (Related); Pentyl nitrite, AldrichCPR; AC1L1UC5; DSSTox_RID_77442; SCHEMBL34065; DSSTox_GSID_24522; KSC492M8F; 4-01-00-01644 
DMJKO05	DT	Small molecular drug
DMJKO05	PC	10026
DMJKO05	MW	117.15
DMJKO05	FM	C5H11NO2
DMJKO05	IC	InChI=1S/C5H11NO2/c1-2-3-4-5-8-6-7/h2-5H2,1H3
DMJKO05	CS	CCCCCON=O
DMJKO05	IK	CSDTZUBPSYWZDX-UHFFFAOYSA-N
DMJKO05	IU	pentyl nitrite
DMJKO05	CA	CAS 463-04-7
DMJKO05	CB	CHEBI:55344
DMJKO05	DE	Angina pectoris

DMJXIC9	ID	DMJXIC9
DMJXIC9	DN	Anagliptin
DMJXIC9	HS	Approved
DMJXIC9	SN	Anagliptin; 739366-20-2; UNII-K726J96838; suiny; CHEMBL1929396; (S)-N-(2-((2-(2-Cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; K726J96838; CHEMBL1929387; N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; Anagliptin [INN]; N-[2-({2-[(2s)-2-Cyanopyrrolidin-1-Yl]-2-Oxoethyl}amino)-2-Methylpropyl]-2-Methylpyrazolo[1,5-A]pyrimidine-6-Carboxamide; Anagliptin (JAN/INN); SCHEMBL905393; sk-0403
DMJXIC9	CP	Kowa Research Institute
DMJXIC9	DT	Small molecular drug
DMJXIC9	PC	44513473
DMJXIC9	MW	383.4
DMJXIC9	FM	C19H25N7O2
DMJXIC9	IC	InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
DMJXIC9	CS	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N
DMJXIC9	IK	LDXYBEHACFJIEL-HNNXBMFYSA-N
DMJXIC9	IU	N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
DMJXIC9	CA	CAS 739366-20-2
DMJXIC9	CB	CHEBI:136043
DMJXIC9	DE	Type-2 diabetes

DMSQ8MD	ID	DMSQ8MD
DMSQ8MD	DN	Anagrelide
DMSQ8MD	HS	Approved
DMSQ8MD	SN	Anagrelida; Anagrelidum; BL 416201; Agrylin (TN); Anagrelida [INN-Spanish]; Anagrelide [BAN:INN]; Anagrelide [INN:BAN]; Anagrelidum [INN-Latin]; Xagrid (TN); Anagrelide (INN/BAN); 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one
DMSQ8MD	CP	Shire Phamaceuticals
DMSQ8MD	TC	Antithrombotic Agents
DMSQ8MD	DT	Small molecular drug
DMSQ8MD	PC	135409400
DMSQ8MD	MW	256.079
DMSQ8MD	FM	C10H7Cl2N3O
DMSQ8MD	IC	InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
DMSQ8MD	CS	C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3
DMSQ8MD	IK	OTBXOEAOVRKTNQ-UHFFFAOYSA-N
DMSQ8MD	IU	6,7-dichloro-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
DMSQ8MD	CA	CAS 68475-42-3
DMSQ8MD	CB	CHEBI:142290
DMSQ8MD	DE	Thrombocythemia; Essential thrombocythemia

DMU8KOD	ID	DMU8KOD
DMU8KOD	DN	Anakinra
DMU8KOD	HS	Approved
DMU8KOD	SN	Kineret; Kineret (TN); Anakinra (USAN/INN)
DMU8KOD	CP	Amgen Inc
DMU8KOD	TC	Antiinflammatory Agents
DMU8KOD	SQ	DB00026 sequence: MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE
DMU8KOD	DE	Rheumatoid arthritis

DMV96ZH	ID	DMV96ZH
DMV96ZH	DN	Anapsos
DMV96ZH	HS	Approved
DMV96ZH	SN	Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC
DMV96ZH	CP	ASAC Pharmaceutical International AIE
DMV96ZH	DE	Atopic dermatitis

DMNP60F	ID	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	HS	Approved
DMNP60F	SN	Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
DMNP60F	CP	AstraZeneca
DMNP60F	TC	Anticancer Agents
DMNP60F	DT	Small molecular drug
DMNP60F	PC	2187
DMNP60F	MW	293.4
DMNP60F	FM	C17H19N5
DMNP60F	IC	InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
DMNP60F	CS	CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
DMNP60F	IK	YBBLVLTVTVSKRW-UHFFFAOYSA-N
DMNP60F	IU	2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
DMNP60F	CA	CAS 120511-73-1
DMNP60F	CB	CHEBI:2704
DMNP60F	DE	Breast cancer

DMLWQ27	ID	DMLWQ27
DMLWQ27	DN	Angiotensin Ii
DMLWQ27	HS	Approved
DMLWQ27	SN	Human angiotensin II; Angiotensin II human; 4474-91-3; Angiotensin II (mouse); Angiotensin II (human); Giapreza; Ang II; 5-Isoleucine-angiotensin II; 5-L-Isoleucineangiotensin II; Ile(5)-angiotensin II; 1-8-Angiotensin I; isoleucine(5)-angiotensin II;Angiotensin II, human; Isoleucine5-angiotensin II; Angiotensin II, ile(5)-; Angiotensin ii [INN:JAN]
DMLWQ27	CP	La Jolla Pharmaceutical Company
DMLWQ27	DT	Small molecular drug
DMLWQ27	PC	172198
DMLWQ27	MW	1046.2
DMLWQ27	FM	C50H71N13O12
DMLWQ27	IC	InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1
DMLWQ27	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DMLWQ27	IK	CZGUSIXMZVURDU-JZXHSEFVSA-N
DMLWQ27	IU	(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMLWQ27	CA	CAS 4474-91-3
DMLWQ27	CB	CHEBI:2719
DMLWQ27	DE	Increase blood pressure

DM8QM5U	ID	DM8QM5U
DM8QM5U	DN	Anidulafungin
DM8QM5U	HS	Approved
DM8QM5U	SN	Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002
DM8QM5U	CP	Pfizer Pharmaceuticals
DM8QM5U	TC	Antifungal Agents
DM8QM5U	DT	Small molecular drug
DM8QM5U	PC	166548
DM8QM5U	MW	1140.2
DM8QM5U	FM	C58H73N7O17
DM8QM5U	IC	InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1
DM8QM5U	CS	CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O
DM8QM5U	IK	JHVAMHSQVVQIOT-MFAJLEFUSA-N
DM8QM5U	IU	N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
DM8QM5U	CA	CAS 166663-25-8
DM8QM5U	CB	CHEBI:55346
DM8QM5U	DE	Convulsion

DMBAUED	ID	DMBAUED
DMBAUED	DN	Anileridine
DMBAUED	HS	Approved
DMBAUED	SN	Adopol; Alidine; Anileridina; Anileridinum; Apidol; Apodol; Leritin; Nipecotan; Anileridina [INN-Spanish]; Anileridine [INN:BAN]; Anileridinum [INN-Latin]; Leritine (TN); Anileridine (USP/INN); N-beta-(p-Aminophenyl)ethylnormeperidine; Ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate; Isonipecotic acid, 1-(p-aminophenethyl)-4-phenyl-, ethyl ester; Ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate; N-(beta-(p-Aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine; 1-(2-(4-Aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylisonipecotic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester; 1-[2-(4-Aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester; 4-Piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-[2-(4-aminophenyl)ethyl]-4-phenyl-, ethyl ester
DMBAUED	TC	Analgesics
DMBAUED	DT	Small molecular drug
DMBAUED	PC	8944
DMBAUED	MW	352.5
DMBAUED	FM	C22H28N2O2
DMBAUED	IC	InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3
DMBAUED	CS	CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3
DMBAUED	IK	LKYQLAWMNBFNJT-UHFFFAOYSA-N
DMBAUED	IU	ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
DMBAUED	CA	CAS 144-14-9
DMBAUED	CB	CHEBI:61203
DMBAUED	DE	Pain

DMC128O	ID	DMC128O
DMC128O	DN	Anileridine Hydrochloride
DMC128O	HS	Approved
DMC128O	SN	Anileridine Phosphate; Leritine
DMC128O	CP	Merck And Co Inc
DMC128O	TC	Neurology Agents
DMC128O	DT	Small molecular drug
DMC128O	PC	31338
DMC128O	MW	425.4
DMC128O	FM	C22H30Cl2N2O2
DMC128O	IC	InChI=1S/C22H28N2O2.2ClH/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18;;/h3-11H,2,12-17,23H2,1H3;2*1H
DMC128O	CS	CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3.Cl.Cl
DMC128O	IK	ZYTHLJLPPSSDIP-UHFFFAOYSA-N
DMC128O	IU	ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate;dihydrochloride
DMC128O	CA	CAS 126-12-5
DMC128O	CB	CHEBI:61208
DMC128O	DE	Pain

DMOIFW0	ID	DMOIFW0
DMOIFW0	DN	Aniracetam
DMOIFW0	HS	Approved
DMOIFW0	SN	aniracetam; 72432-10-1; Draganon; Sarpul; 1-(4-Methoxybenzoyl)-2-pyrrolidinone; Ampamet; 1-(4-methoxybenzoyl)pyrrolidin-2-one; 1-p-Anisoyl-2-pyrrolidinone; Ro 13-5057; Aniracetamun [INN-Latin]; Aniracetam [USAN:INN:JAN]; UNII-5L16LKN964; Ro 135057; BRN 4807205; Ro-13-5057; 1-p-anisoylpyrrolidin-2-one; 2-Pyrrolidinone, 1-(4-methoxybenzoyl)-; CHEMBL36994; MLS000079240; CHEBI:47943; 1-(p-Methoxybenzoyl)-2-pyrrolidinon [German]; ZXNRTKGTQJPIJK-UHFFFAOYSA-N; 5L16LKN964; NCGC00015116-10; SMR000038438
DMOIFW0	DT	Small molecular drug
DMOIFW0	PC	2196
DMOIFW0	MW	219.24
DMOIFW0	FM	C12H13NO3
DMOIFW0	IC	InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3
DMOIFW0	CS	COC1=CC=C(C=C1)C(=O)N2CCCC2=O
DMOIFW0	IK	ZXNRTKGTQJPIJK-UHFFFAOYSA-N
DMOIFW0	IU	1-(4-methoxybenzoyl)pyrrolidin-2-one
DMOIFW0	CA	CAS 72432-10-1
DMOIFW0	CB	CHEBI:47943
DMOIFW0	DE	Cerebrovascular ischaemia

DM2C48U	ID	DM2C48U
DM2C48U	DN	Anisindione
DM2C48U	HS	Approved
DM2C48U	SN	Anisindiona; Anisindionum; Miradon; Unidone; Anisin indandione; SPE 2792; Anisindiona [INN-Spanish]; Anisindione (INN); Anisindione [INN:BAN]; Anisindionum [INN-Latin]; Miradon (TN); 2-(4-Methoxy-phenyl)-indan-1,3-dione; 2-(4-Methoxyphenyl)-1H-indene-1,3(2H)-dione; 2-(4-Methoxyphenyl)indan-1,3-dione; 2-(4-methoxyphenyl)indene-1,3-dione; 2-(p-Methoxyphenyl)-1,3-indandione; 2-(p-Methoxyphenyl)indane-1,3-dione; 2-[4-(methyloxy)phenyl]-1H-indene-1,3(2H)-dione; 2-p-Anisyl-1,3-indandione; 2-para-Anisyl-1,3-indandione
DM2C48U	TC	Anticoagulants
DM2C48U	DT	Small molecular drug
DM2C48U	PC	2197
DM2C48U	MW	252.26
DM2C48U	FM	C16H12O3
DM2C48U	IC	InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3
DM2C48U	CS	COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
DM2C48U	IK	XRCFXMGQEVUZFC-UHFFFAOYSA-N
DM2C48U	IU	2-(4-methoxyphenyl)indene-1,3-dione
DM2C48U	CA	CAS 117-37-3
DM2C48U	CB	CHEBI:133809
DM2C48U	DE	Coagulation defect

DMW51AX	ID	DMW51AX
DMW51AX	DN	Anisodamine
DMW51AX	HS	Approved
DMW51AX	SN	anisodamine; racanisodamine; 55869-99-3; (6S)-6-Hydroxyhyoscyamine; (-)-Anisodamine; AC1O6SQS; AC1L4C7W; SCHEMBL620576; ZINC2112569; 8053AH; API0000388; 869A993; Q-100648; [(1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate; (S)-((1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; [(1R,3S,5R,6R)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate
DMW51AX	DT	Small molecular drug
DMW51AX	PC	6918612
DMW51AX	MW	305.4
DMW51AX	FM	C17H23NO4
DMW51AX	IC	InChI=1S/C17H23NO4/c1-18-12-7-13(9-15(18)16(20)8-12)22-17(21)14(10-19)11-5-3-2-4-6-11/h2-6,12-16,19-20H,7-10H2,1H3/t12-,13-,14+,15+,16-/m0/s1
DMW51AX	CS	CN1[C@H]2C[C@@H](C[C@@H]1[C@H](C2)O)OC(=O)[C@H](CO)C3=CC=CC=C3
DMW51AX	IK	WTQYWNWRJNXDEG-RBZJEDDUSA-N
DMW51AX	IU	[(1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMW51AX	CA	CAS 55869-99-3
DMW51AX	DE	Central and peripheral nervous disease

DMNOSWU	ID	DMNOSWU
DMNOSWU	DN	Anisodine
DMNOSWU	HS	Approved
DMNOSWU	SN	anisodine; 52646-92-1; SCHEMBL474045; AC1N31M8; 2,3-Dihydroxy-2-phenylpropanoic acid 9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonane-7alpha-yl ester
DMNOSWU	DT	Small molecular drug
DMNOSWU	PC	11616712
DMNOSWU	MW	319.4
DMNOSWU	FM	C17H21NO5
DMNOSWU	IC	InChI=1S/C17H21NO5/c1-18-12-7-11(8-13(18)15-14(12)23-15)22-16(20)17(21,9-19)10-5-3-2-4-6-10/h2-6,11-15,19,21H,7-9H2,1H3/t11?,12-,13+,14-,15+,17-/m1/s1
DMNOSWU	CS	CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@@](CO)(C4=CC=CC=C4)O
DMNOSWU	IK	JEJREKXHLFEVHN-QDXGGTILSA-N
DMNOSWU	IU	[(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-2,3-dihydroxy-2-phenylpropanoate
DMNOSWU	CA	CAS 52646-92-1
DMNOSWU	DE	Central and peripheral nervous disease

DMIJRF0	ID	DMIJRF0
DMIJRF0	DN	Anisotropine Methylbromide
DMIJRF0	HS	Approved
DMIJRF0	SN	Anisotropine; Endovalpin; Lytispasm; Valpin; Anisotropine methobromide; Anisotropine methyl bromide;Methyloctatropine bromide; Metilbromuro de octatropina; Octatropine methylbromide; Octatropini methylbromidum; Octatropone Bromide; Valpin 50; Anisotropine methylbromide (USAN); Anisotropine methylbromide [USAN:JAN]; Endovalpin (TN); Lytispasm (TN); Methylbromure d'octatropine; Methyloctatropine bromide (JAN); Metilbromuro de octatropina [INN-Spanish]; Octatropine methylbromide (INN); Octatropinimethylbromidum [INN-Latin]; Valpin (TN); Valpin 50 (TN); Methylbromure d'octatropine [INN-French]; Anisotropine methylbromide, (endo)-isomer; [(1R,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; Endo-8,8-Dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide; (1r,5r)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; (3-endo)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 1-alpha-H,5-alpha-H-Tropanium,3-alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 1alphaH,5alphaH-Tropanium, 3alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 2-Propylpentanoyltropinium methylbromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide 2-propylvalerate; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide 2-propylvalerate; 8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide; 8-Methyltropinium bromide 2-propylpentanoate; 8-Methyltropinium bromide 2-propylvalerate
DMIJRF0	TC	Anticholinergic Agents
DMIJRF0	DT	Small molecular drug
DMIJRF0	PC	657201
DMIJRF0	MW	362.3
DMIJRF0	FM	C17H32BrNO2
DMIJRF0	IC	InChI=1S/C17H32NO2.BrH/c1-5-7-13(8-6-2)17(19)20-16-11-14-9-10-15(12-16)18(14,3)4;/h13-16H,5-12H2,1-4H3;1H/q+1;/p-1/t14-,15+,16?;
DMIJRF0	CS	CCCC(CCC)C(=O)OC1C[C@H]2CC[C@@H](C1)[N+]2(C)C.[Br-]
DMIJRF0	IK	QSFKGMJOKUZAJM-JXMYBXCISA-M
DMIJRF0	IU	[(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate;bromide
DMIJRF0	CA	CAS 80-50-2
DMIJRF0	DE	Peptic ulcer

DM6Q4B0	ID	DM6Q4B0
DM6Q4B0	DN	Anistreplase
DM6Q4B0	HS	Approved
DM6Q4B0	TC	Thrombolytic Agents
DM6Q4B0	SQ	DB00029 sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DM6Q4B0	DE	Acute coronary syndrome

DMUMOEV	ID	DMUMOEV
DMUMOEV	DN	Ansuvimab
DMUMOEV	HS	Approved
DMUMOEV	DT	Antibody
DMUMOEV	DE	Ebola virus infection

DMA04JS	ID	DMA04JS
DMA04JS	DN	Antazoline
DMA04JS	HS	Approved
DMA04JS	SN	Analergine; Antastan; Antasten; Antazolin; Antazolina; Antazolinum; Antihistal; Antistin; Antistine; Azalone; Histostab;Imidamin; Imidamine; Phenazolin; Phenazoline; Antazolina [Spanish]; Antazolinum [Latin]; Antazolina [INN-Spanish]; Antazoline (INN); Antazoline [INN:BAN]; Antazolinum [INN-Latin]; Ben-A-hist; N-Benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline; N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-N-(phenylmethyl)aniline; 2-(N-Benzylanilinomethyl)-2-imidazoline; 2-(N-Phenyl-N-benzylaminomethyl)imidazoline; 2-Phenyl-benzyl-amino-methylimidazolin; 2-Phenyl-benzyl-amino-methylimidazolin [German]; 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine; 5512-M
DMA04JS	DT	Small molecular drug
DMA04JS	PC	2200
DMA04JS	MW	265.35
DMA04JS	FM	C17H19N3
DMA04JS	IC	InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)
DMA04JS	CS	C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3
DMA04JS	IK	REYFJDPCWQRWAA-UHFFFAOYSA-N
DMA04JS	IU	N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline
DMA04JS	CA	CAS 91-75-8
DMA04JS	CB	CHEBI:84115
DMA04JS	DE	Nasal congestion

DMNC64R	ID	DMNC64R
DMNC64R	DN	Antegren
DMNC64R	HS	Approved
DMNC64R	DT	Antibody
DMNC64R	DE	Multiple sclerosis

DMH4CFE	ID	DMH4CFE
DMH4CFE	DN	Antithymocyte globulin
DMH4CFE	HS	Approved
DMH4CFE	SN	Atgam (TN); Thymoglobulin (TN)
DMH4CFE	CP	Pfizer Pharmaceuticals
DMH4CFE	TC	Immunomodulatory Agents
DMH4CFE	DE	Aplastic anemia

DM89JLN	ID	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	HS	Approved
DM89JLN	SN	GG2; BMS 562247-01; BMS-562247; Eliquis (TN); BMS-562247-01; Apixaban (JAN/USAN/INN); BMS-562247-01, Apixaban; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd
DM89JLN	CP	Pfizer
DM89JLN	DT	Small molecular drug
DM89JLN	PC	10182969
DM89JLN	MW	459.5
DM89JLN	FM	C25H25N5O4
DM89JLN	IC	InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
DM89JLN	CS	COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
DM89JLN	IK	QNZCBYKSOIHPEH-UHFFFAOYSA-N
DM89JLN	IU	1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
DM89JLN	CA	CAS 503612-47-3
DM89JLN	CB	CHEBI:72296
DM89JLN	DE	Thrombosis

DMX38HQ	ID	DMX38HQ
DMX38HQ	DN	Apomorphine
DMX38HQ	HS	Approved
DMX38HQ	SN	Apomorphine (intranasal, Parkinson's disease)
DMX38HQ	CP	Archimedes Pharma Ltd
DMX38HQ	DT	Small molecular drug
DMX38HQ	PC	6005
DMX38HQ	MW	267.32
DMX38HQ	FM	C17H17NO2
DMX38HQ	IC	InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
DMX38HQ	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
DMX38HQ	IK	VMWNQDUVQKEIOC-CYBMUJFWSA-N
DMX38HQ	IU	(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMX38HQ	CA	CAS 58-00-4
DMX38HQ	CB	CHEBI:48538
DMX38HQ	DE	Parkinson disease; Sexual dysfunction; Idiopathic parkinson disease

DMO4PVE	ID	DMO4PVE
DMO4PVE	DN	Apraclonidine
DMO4PVE	HS	Approved
DMO4PVE	SN	Aplonidine; Apraclonidina; Apraclonidinum; Iopidine; Iopidine Eye; ALO 2145; Apraclonidina [INN-Spanish]; Apraclonidine (INN); Apraclonidine [INN:BAN]; Apraclonidinum [INN-Latin]; Iopidine (TN); P-aminoclonidine; Para-aminoclonidine; 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride; 2-(4-amino-2,6-dichloro)phenyliminoimidazolidine; 4-Aminoclonidine
DMO4PVE	CP	Alcon Canada Inc
DMO4PVE	TC	Antiglaucomic Agents
DMO4PVE	DT	Small molecular drug
DMO4PVE	PC	2216
DMO4PVE	MW	245.11
DMO4PVE	FM	C9H10Cl2N4
DMO4PVE	IC	InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)
DMO4PVE	CS	C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl
DMO4PVE	IK	IEJXVRYNEISIKR-UHFFFAOYSA-N
DMO4PVE	IU	2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
DMO4PVE	CA	CAS 66711-21-5
DMO4PVE	CB	CHEBI:2788
DMO4PVE	DE	Intra ocular pressure reduction

DMTWS9E	ID	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	HS	Approved
DMTWS9E	SN	Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
DMTWS9E	CP	Celgene
DMTWS9E	DT	Small molecular drug
DMTWS9E	PC	11561674
DMTWS9E	MW	460.5
DMTWS9E	FM	C22H24N2O7S
DMTWS9E	IC	InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
DMTWS9E	CS	CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
DMTWS9E	IK	IMOZEMNVLZVGJZ-QGZVFWFLSA-N
DMTWS9E	IU	N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide
DMTWS9E	CA	CAS 608141-41-9
DMTWS9E	CB	CHEBI:78540
DMTWS9E	DE	Psoriasis vulgaris

DM053KT	ID	DM053KT
DM053KT	DN	Aprepitant
DM053KT	HS	Approved
DM053KT	SN	Aprepitant [USAN]; L 754030; MK 0869; Emend (TN); L-754030; MK-0869; ONO-7436; Aprepitant (JAN/USAN/INN); MK-869, L-754030, Emend, Aprepitant; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
DM053KT	CP	Merck & Co
DM053KT	TC	Antiemetics
DM053KT	DT	Small molecular drug
DM053KT	PC	135413536
DM053KT	MW	534.4
DM053KT	FM	C23H21F7N4O3
DM053KT	IC	InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1
DM053KT	CS	C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F
DM053KT	IK	ATALOFNDEOCMKK-OITMNORJSA-N
DM053KT	IU	3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one
DM053KT	CA	CAS 170729-80-3
DM053KT	CB	CHEBI:499361
DM053KT	DE	Depression; Nausea; Solid tumour/cancer

DMBXWU8	ID	DMBXWU8
DMBXWU8	DN	Aprindine
DMBXWU8	HS	Approved
DMBXWU8	SN	Aprindin; Aprindina; Aprindinum; Aprinidine; Fibocil; AC 1802; Aprindina [INN-Spanish]; Aprindinum [INN-Latin]; Aprindine (USAN/INN); Aprindine [USAN:BAN:INN]; N-(3-(Diethylamino)propyl)-N-phenyl-2-indanamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediaminemonohydrochloride; N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine; N-(2,3-Dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-1,3-propanediamine; N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenylpropane-1,3-diamine
DMBXWU8	TC	Antiarrhythmic Agents
DMBXWU8	DT	Small molecular drug
DMBXWU8	PC	2218
DMBXWU8	MW	322.5
DMBXWU8	FM	C22H30N2
DMBXWU8	IC	InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3
DMBXWU8	CS	CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C3=CC=CC=C3
DMBXWU8	IK	NZLBHDRPUJLHCE-UHFFFAOYSA-N
DMBXWU8	IU	N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine
DMBXWU8	CA	CAS 37640-71-4
DMBXWU8	CB	CHEBI:135370
DMBXWU8	DE	Cardiac arrhythmias

DMOWK6B	ID	DMOWK6B
DMOWK6B	DN	Aprobarbital
DMOWK6B	HS	Approved
DMOWK6B	SN	Allional; Allonal; Allylisopropylmalonylurea; Allylpropymal; Allypropymal; Allypropymalum; Alurate; Aprobarbita; Aprobarbitale; Aprobarbitalum; Aprobarbitone; Aprozal; Numal; Allylisopropylbarbituric acid; Alurate elixir verdum; Aprobarbitale [DCIT]; Isopropylallylbarbituric acid; Alurate (TN); Aprobarbital (INN); Aprobarbital [INN:DCF]; Aprobarbitalum [INN-Latin]; Isonal (swedish); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-(9CI); 5-(1-Methylethyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione;5-(1-methylethyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(propan-2-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-5-isopropylbarbiturate; 5-Allyl-5-isopropylbarbituricacid; 5-Isopropyl-5-allylbarbituric acid; 5-allyl-5-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DMOWK6B	TC	Anticonvulsants
DMOWK6B	DT	Small molecular drug
DMOWK6B	PC	6464
DMOWK6B	MW	210.23
DMOWK6B	FM	C10H14N2O3
DMOWK6B	IC	InChI=1S/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15)
DMOWK6B	CS	CC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DMOWK6B	IK	UORJNBVJVRLXMQ-UHFFFAOYSA-N
DMOWK6B	IU	5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DMOWK6B	CA	CAS 77-02-1
DMOWK6B	CB	CHEBI:2791
DMOWK6B	DE	Anaesthesia; Insomnia

DM0QD4W	ID	DM0QD4W
DM0QD4W	DN	Aprotinin
DM0QD4W	HS	Approved
DM0QD4W	SN	Trasylol; Zymofren; Trazinin; Iniprol; Riker 52G; Bayer A 128; UNII-04XPW8C0FL; 04XPW8C0FL; APROTININ; RP-9921; Aprotininum; Aprotinina; Aprotinine; Antilysine; Repulson; Antagosan; Pantinol; Onquinin; Trascolan; Protimbin; Inhibin; Contrykal; Antilysin; Antikrein; Fosten; Tzalol; Gordox; Kir richter; Trypsin inhibitor; Aprotinin solution; 9087-70-1; BPTI; APROTININ BOVINE; Basic protease inhibitor; Aprotininum [INN-Latin]; Aprotinine [INN-French]; Aprotinina [INN-Spanish]; Pancreatic trypsin inhibitor; Kunitz and Northrop inhibitor
DM0QD4W	CP	Novo Nordisk A/S
DM0QD4W	DT	Small molecular drug
DM0QD4W	SQ	Aprotinin (bovine pancreatic trypsin inhibitor): RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
DM0QD4W	PC	146027575
DM0QD4W	MW	6511
DM0QD4W	FM	C284H432N84O79S7
DM0QD4W	IC	InChI=1S/C284H432N84O79S7/c1-21-144(9)222-271(439)337-174(68-46-105-309-282(300)301)239(407)340-187(120-160-77-85-164(374)86-78-160)251(419)341-185(116-156-55-29-24-30-56-156)250(418)342-188(121-161-79-87-165(375)88-80-161)252(420)346-191(123-208(291)378)246(414)322-149(14)230(398)326-168(62-35-39-98-285)234(402)319-146(11)227(395)314-132-215(385)324-181(113-141(3)4)247(415)354-199-137-452-453-138-200-263(431)336-179(97-112-448-20)242(410)331-176(70-48-107-311-284(304)305)244(412)363-226(154(19)372)274(442)358-197(233(401)316-129-212(382)312-130-213(383)318-151(16)278(446)447)135-449-451-139-201(355-253(421)186(117-157-57-31-25-32-58-157)344-256(424)195(127-220(393)394)350-267(435)204-72-50-109-366(204)275(443)167(289)61-43-102-306-279(294)295)265(433)339-182(114-142(5)6)248(416)338-180(93-96-218(389)390)276(444)368-111-52-74-206(368)277(445)367-110-51-73-205(367)268(436)349-189(122-162-81-89-166(376)90-82-162)259(427)362-224(152(17)370)269(437)317-133-216(386)365-108-49-71-203(365)266(434)357-202(264(432)333-169(63-36-40-99-286)235(403)320-148(13)229(397)328-175(69-47-106-310-283(302)303)243(411)360-223(145(10)22-2)272(440)361-222)140-454-450-136-198(325-214(384)131-313-211(381)128-315-232(400)183(119-159-75-83-163(373)84-76-159)351-270(438)221(143(7)8)359-258(426)190(118-158-59-33-26-34-60-158)352-273(441)225(153(18)371)364-245(413)177(335-262(199)430)91-94-207(290)377)261(429)334-172(66-44-103-307-280(296)297)236(404)321-147(12)228(396)327-170(64-37-41-100-287)237(405)330-173(67-45-104-308-281(298)299)238(406)345-192(124-209(292)379)255(423)347-193(125-210(293)380)254(422)343-184(115-155-53-27-23-28-54-155)249(417)332-171(65-38-42-101-288)240(408)353-196(134-369)260(428)323-150(15)231(399)329-178(92-95-217(387)388)241(409)348-194(126-219(391)392)257(425)356-200/h23-34,53-60,75-90,141-154,167-206,221-226,369-376H,21-22,35-52,61-74,91-140,285-289H2,1-20H3,(H2,290,377)(H2,291,378)(H2,292,379)(H2,293,380)(H,312,382)(H,313,381)(H,314,395)(H,315,400)(H,316,401)(H,317,437)(H,318,383)(H,319,402)(H,320,403)(H,321,404)(H,322,414)(H,323,428)(H,324,385)(H,325,384)(H,326,398)(H,327,396)(H,328,397)(H,329,399)(H,330,405)(H,331,410)(H,332,417)(H,333,432)(H,334,429)(H,335,430)(H,336,431)(H,337,439)(H,338,416)(H,339,433)(H,340,407)(H,341,419)(H,342,418)(H,343,422)(H,344,424)(H,345,406)(H,346,420)(H,347,423)(H,348,409)(H,349,436)(H,350,435)(H,351,438)(H,352,441)(H,353,408)(H,354,415)(H,355,421)(H,356,425)(H,357,434)(H,358,442)(H,359,426)(H,360,411)(H,361,440)(H,362,427)(H,363,412)(H,364,413)(H,387,388)(H,389,390)(H,391,392)(H,393,394)(H,446,447)(H4,294,295,306)(H4,296,297,307)(H4,298,299,308)(H4,300,301,309)(H4,302,303,310)(H4,304,305,311)/t144-,145-,146-,147+,148-,149-,150+,151-,152-,153+,154+,167+,168-,169+,170+,171+,172+,173+,174-,175-,176+,177-,178+,179-,180+,181-,182+,183-,184+,185+,186+,187+,188+,189+,190-,191+,192+,193+,194+,195-,196+,197+,198+,199-,200+,201+,202-,203-,204+,205+,206+,221-,222+,223+,224-,225-,226-/m1/s1
DM0QD4W	CS	CC[C@@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N6CCC[C@@H]6C(=O)N[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(=O)O)CCC(=O)O)C)CO)CCCCN)CC7=CC=CC=C7)CC(=O)N)CC(=O)N)CCCNC(=N)N)CCCCN)C)CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)CCC(=O)N)[C@H](C)O)CC8=CC=CC=C8)C(C)C)CC9=CC=C(C=C9)O)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CCCNC(=N)N)C)CCCCN)[C@@H](C)O)CC1=CC=C(C=C1)O)CCC(=O)O)CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)N)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(=O)O)[C@H](C)O)CCCNC(=N)N)CCSC)CC(C)C)C)CCCCN)C)CC(=O)N)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CC1=CC=C(C=C1)O)CCCNC(=N)N)[C@H](C)CC
DM0QD4W	IK	ZPNFWUPYTFPOJU-VKTQZXOTSA-N
DM0QD4W	IU	(3R)-4-[[(2S)-1-[[(1S,2aR,4R,5aR,8aR,11aR,13R,14aR,16S,17aS,19S,20aR,25S,26aR,29aR,31S,32aR,34S,35aS,37R,38aS,41aS,42R,44aS,45R,47aR,48S,50aS,51R,53aS,54R,56aR,57S,59aR,60S,62aS,63S,66S,69S,72S,75S,78S,81S,84S,87S,90S,93R)-29a,62a,69,84-tetrakis(4-aminobutyl)-35a,75,78-tris(2-amino-2-oxoethyl)-14a-(3-amino-3-oxopropyl)-8a,41a,72-tribenzyl-50a,53a-bis[(2R)-butan-2-yl]-47a,48,56a,81,90-pentakis(3-carbamimidamidopropyl)-31,60-bis(2-carboxyethyl)-42-[[2-[[2-[[(1R)-1-carboxyethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]carbamoyl]-57-(carboxymethyl)-11a,45-bis[(1S)-1-hydroxyethyl]-13-[(1R)-1-hydroxyethyl]-66-(hydroxymethyl)-2a,16,38a,44a-tetrakis[(4-hydroxyphenyl)methyl]-26a,32a,59a,63,87-pentamethyl-20a,34-bis(2-methylpropyl)-51-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,22a,24,25a,28a,30,31a,33,34a,36,37a,40a,43a,44,46a,47,49a,50,52a,53,55a,56,58a,59,61a,62,64a,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-5a-propan-2-yl-39,40,66a,67a,70a,71a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,21a,23,24a,27a,29,30a,32,33a,35,36a,39a,42a,43,45a,46,48a,49,51a,52,54a,55,57a,58,60a,61,63a,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazahexacyclo[91.71.4.454,117.04,8.019,23.025,29]doheptacontahectan-37-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoic acid
DM0QD4W	CA	CAS 9087-70-1
DM0QD4W	DE	Bleeding disorder

DMHTXSL	ID	DMHTXSL
DMHTXSL	DN	Arbekacin
DMHTXSL	HS	Approved
DMHTXSL	SN	Habekacin (TN)
DMHTXSL	CP	Meiji Seika
DMHTXSL	DT	Small molecular drug
DMHTXSL	PC	68682
DMHTXSL	MW	552.6
DMHTXSL	FM	C22H44N6O10
DMHTXSL	IC	InChI=1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1
DMHTXSL	CS	C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)N
DMHTXSL	IK	MKKYBZZTJQGVCD-XTCKQBCOSA-N
DMHTXSL	IU	(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DMHTXSL	CA	CAS 51025-85-5
DMHTXSL	CB	CHEBI:37922
DMHTXSL	DE	Bacterial infection

DMOQK8Z	ID	DMOQK8Z
DMOQK8Z	DN	Arbidol
DMOQK8Z	HS	Approved
DMOQK8Z	SN	Umifenovir; Arbidole; MC-101
DMOQK8Z	CP	Good Earth Medicine
DMOQK8Z	DT	Small molecular drug
DMOQK8Z	PC	131411
DMOQK8Z	MW	477.4
DMOQK8Z	FM	C22H25BrN2O3S
DMOQK8Z	IC	InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3
DMOQK8Z	CS	CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3
DMOQK8Z	IK	KCFYEAOKVJSACF-UHFFFAOYSA-N
DMOQK8Z	IU	ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate
DMOQK8Z	CA	CAS 131707-25-0
DMOQK8Z	CB	CHEBI:134730
DMOQK8Z	DE	Virus infection

DMCY8AF	ID	DMCY8AF
DMCY8AF	DN	Arbutamine
DMCY8AF	HS	Approved
DMCY8AF	SN	Arbutamina; Arbutaminum; Genesa; Arbutamina [INN-Spanish]; Arbutamine [INN:BAN]; Arbutaminum [INN-Latin]; 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol; 4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol; 4-[1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol
DMCY8AF	TC	Cardiotonic Agents
DMCY8AF	DT	Small molecular drug
DMCY8AF	PC	60789
DMCY8AF	MW	317.4
DMCY8AF	FM	C18H23NO4
DMCY8AF	IC	InChI=1S/C18H23NO4/c20-15-7-4-13(5-8-15)3-1-2-10-19-12-18(23)14-6-9-16(21)17(22)11-14/h4-9,11,18-23H,1-3,10,12H2/t18-/m0/s1
DMCY8AF	CS	C1=CC(=CC=C1CCCCNC[C@@H](C2=CC(=C(C=C2)O)O)O)O
DMCY8AF	IK	IIRWWTKISYTTBL-SFHVURJKSA-N
DMCY8AF	IU	4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol
DMCY8AF	CA	CAS 128470-16-6
DMCY8AF	CB	CHEBI:50580
DMCY8AF	DE	Coronary artery disease

DM9GH25	ID	DM9GH25
DM9GH25	DN	Arcitumomab
DM9GH25	HS	Approved
DM9GH25	SN	CEA-Scan; Arcitumomab (USAN/INN); Cea-Scan (TN)
DM9GH25	TC	Diagnostic Agents
DM9GH25	DT	Antibody
DM9GH25	DE	Breast cancer

DMYRX8B	ID	DMYRX8B
DMYRX8B	DN	Ardeparin
DMYRX8B	HS	Approved
DMYRX8B	SN	Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene
DMYRX8B	CP	Celcius Laboratories 
DMYRX8B	TC	Anticoagulants
DMYRX8B	DT	Small molecular drug
DMYRX8B	PC	772
DMYRX8B	MW	1134.9
DMYRX8B	FM	C26H42N2O37S5
DMYRX8B	IC	InChI=1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)
DMYRX8B	CS	CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
DMYRX8B	IK	HTTJABKRGRZYRN-UHFFFAOYSA-N
DMYRX8B	IU	6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
DMYRX8B	CA	CAS 9005-49-6
DMYRX8B	DE	Venous thrombosis; Thrombosis; Deep vein thrombosis; Venous thromboembolism

DMVMY7K	ID	DMVMY7K
DMVMY7K	DN	Arepanrix
DMVMY7K	HS	Approved
DMVMY7K	SN	H1N1 pandemic influenza vaccine (AS03 adjuvanted) 2, GlaxoSmithKline; H1N1 pandemic influenza vaccine2 (AS03 adjuvanted), GSK
DMVMY7K	CP	GlaxoSmithKline plc
DMVMY7K	DT	Vaccine
DMVMY7K	DE	Influenza virus infection

DMYM974	ID	DMYM974
DMYM974	DN	Arformoterol
DMYM974	HS	Approved
DMYM974	SN	67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate
DMYM974	CP	Sepracor phamaceuticals
DMYM974	TC	Bronchodilator Agents
DMYM974	DT	Small molecular drug
DMYM974	PC	3083544
DMYM974	MW	344.4
DMYM974	FM	C19H24N2O4
DMYM974	IC	InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
DMYM974	CS	C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O
DMYM974	IK	BPZSYCZIITTYBL-YJYMSZOUSA-N
DMYM974	IU	N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide
DMYM974	CA	CAS 67346-49-0
DMYM974	CB	CHEBI:408174
DMYM974	DE	Chronic obstructive pulmonary disease; Asthma

DMFI46A	ID	DMFI46A
DMFI46A	DN	Argatroban
DMFI46A	HS	Approved
DMFI46A	SN	Acova; Argatrobanum; MMTQAP; MPQA; Novastan; Argatrobanum [Latin]; MITSUBISHI INHIBITOR; MCI 9038; MD 805; MD805; Argatroban (anhydrous); Argatroban [INN:JAN]; GN-1600; MCI-9038; MD-805; MQI-ARG-MCP; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; (2R,4R)-4-Methyl-1[Nalpha-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperadinecarboxylic acid; (2r,4r)-4-methyl-1-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidinecarboxylic acid; 21R-Argatroban; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid
DMFI46A	TC	Anticoagulants
DMFI46A	DT	Small molecular drug
DMFI46A	PC	92722
DMFI46A	MW	508.6
DMFI46A	FM	C23H36N6O5S
DMFI46A	IC	InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1
DMFI46A	CS	C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C
DMFI46A	IK	KXNPVXPOPUZYGB-IOVMHBDKSA-N
DMFI46A	IU	(2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid
DMFI46A	CA	CAS 74863-84-6
DMFI46A	CB	CHEBI:94385
DMFI46A	DE	Thrombosis

DMRE4FC	ID	DMRE4FC
DMRE4FC	DN	Arginine
DMRE4FC	HS	Approved
DMRE4FC	SN	DL-Arginine hydrochloride; 32042-43-6; 2-Amino-5-guanidinopentanoic acid hydrochloride; argininhydrochlorid; DL-Arginine HCl; 220144-84-3; H-DL-Arg-OH.xHCl; DL-(+/-)-Arginine Hydrochloride; 1-Hydrochloride arginine; NSC7914; Arginine monochloride; 2-Amino-5-guanidinovaleric acid monohydrochloride; WLN: MUYZM3YZVQ &amp; DL-Arginine hydrochloride, 98%, anhydrous; Arginine monohydrochloride, L-(+)-; ARGININE, (L); L(+)-Arginine hydrochloride; D-Arginine, hydrochloride (1:1); EINECS 250-903-0; EINECS 239-674-8
DMRE4FC	DT	Small molecular drug
DMRE4FC	PC	6322
DMRE4FC	MW	174.2
DMRE4FC	FM	C6H14N4O2
DMRE4FC	IC	InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1
DMRE4FC	CS	C(C[C@@H](C(=O)O)N)CN=C(N)N
DMRE4FC	IK	ODKSFYDXXFIFQN-BYPYZUCNSA-N
DMRE4FC	IU	(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
DMRE4FC	CA	CAS 74-79-3
DMRE4FC	CB	CHEBI:16467
DMRE4FC	DE	Growth hormone deficiency

DM3NUMH	ID	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	HS	Approved
DM3NUMH	SN	129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236;  Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination
DM3NUMH	CP	Bristol-Myers Squibb; Otsuka Pharmaceutical Co., Ltd
DM3NUMH	TC	Antipsychotic Agents
DM3NUMH	DT	Small molecular drug
DM3NUMH	PC	60795
DM3NUMH	MW	448.4
DM3NUMH	FM	C23H27Cl2N3O2
DM3NUMH	IC	InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
DM3NUMH	CS	C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
DM3NUMH	IK	CEUORZQYGODEFX-UHFFFAOYSA-N
DM3NUMH	IU	7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
DM3NUMH	CA	CAS 129722-12-9
DM3NUMH	CB	CHEBI:31236
DM3NUMH	DE	Major depressive disorder; Schizophrenia; Bipolar disorder; Erythropoietic porphyrias

DMGB035	ID	DMGB035
DMGB035	DN	Armodafinil
DMGB035	HS	Approved
DMGB035	SN	Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, &gt; YFGHCGITMMYXAQ-LJQANCHMSA-N
DMGB035	CP	Cephalon
DMGB035	DT	Small molecular drug
DMGB035	PC	9690109
DMGB035	MW	273.4
DMGB035	FM	C15H15NO2S
DMGB035	IC	InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
DMGB035	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)[S@](=O)CC(=O)N
DMGB035	IK	YFGHCGITMMYXAQ-LJQANCHMSA-N
DMGB035	IU	2-[(R)-benzhydrylsulfinyl]acetamide
DMGB035	CA	CAS 112111-43-0
DMGB035	CB	CHEBI:77590
DMGB035	DE	Pediatric cancer

DMT81LZ	ID	DMT81LZ
DMT81LZ	DN	Arn-509
DMT81LZ	HS	Approved
DMT81LZ	SN	Arn-509 (AR inhibitor)
DMT81LZ	CP	Johnson & Johnson
DMT81LZ	DT	Small molecular drug
DMT81LZ	PC	24872560
DMT81LZ	MW	477.4
DMT81LZ	FM	C21H15F4N5O2S
DMT81LZ	IC	InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)
DMT81LZ	CS	CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F
DMT81LZ	IK	HJBWBFZLDZWPHF-UHFFFAOYSA-N
DMT81LZ	IU	4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide
DMT81LZ	CA	CAS 956104-40-8
DMT81LZ	DE	Acute myeloid leukaemia; Prostate cancer

DM1P6FR	ID	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	HS	Approved
DM1P6FR	SN	606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); D0C4LF; NVP-ME
DM1P6FR	CP	Array BioPharma
DM1P6FR	DT	Small molecular drug
DM1P6FR	PC	10288191
DM1P6FR	MW	441.2
DM1P6FR	FM	C17H15BrF2N4O3
DM1P6FR	IC	InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
DM1P6FR	CS	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
DM1P6FR	IK	ACWZRVQXLIRSDF-UHFFFAOYSA-N
DM1P6FR	IU	6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
DM1P6FR	CA	CAS 606143-89-9
DM1P6FR	CB	CHEBI:145371
DM1P6FR	DE	Melanoma

DMTL2Y1	ID	DMTL2Y1
DMTL2Y1	DN	Arsenic
DMTL2Y1	HS	Approved
DMTL2Y1	SN	Agent SA; Arsen [German,Polish]; Arsenic; Arsenic Black; Arsenic Lump (Metals Basis); Arsenic and arsenic compounds; Arsenic compounds; Arsenic hydride (AsH3); Arsenic, elemental; Arsenic, inorganic; Arsenic, organic compounds; Arsenic-75; Arsenicals; Arsenowodor [Polish]; Arsenwasserstoff [German]; Colloidal arsenic; Gray arsenic; Grey arsenic; Metallic arsenic; UN 2188; UN1558; UN2188; V1I29R0RJQ; 7440-38-2; Arsen; As; CCRIS 55; EINECS 231-148-6; EINECS 232-066-3; HSDB 509; HSDB 510; N712M78A8G; UNII-N712M78A8G; UNII-V1I29R0RJQ
DMTL2Y1	PC	5359596
DMTL2Y1	MW	74.921
DMTL2Y1	FM	As
DMTL2Y1	IC	RQNWIZPPADIBDY-UHFFFAOYSA-N
DMTL2Y1	CS	[As]
DMTL2Y1	IK	1S/As
DMTL2Y1	IU	arsenic
DMTL2Y1	CA	CAS 7440-38-2
DMTL2Y1	CB	CHEBI:27563
DMTL2Y1	DE	Acute myeloid leukaemia

DM61TA4	ID	DM61TA4
DM61TA4	DN	Arsenic trioxide
DM61TA4	HS	Approved
DM61TA4	SN	Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)
DM61TA4	TC	Anticancer Agents
DM61TA4	DT	Small molecular drug
DM61TA4	PC	14888
DM61TA4	MW	197.841
DM61TA4	FM	As2O3
DM61TA4	IC	InChI=1S/2As.3O/q2*+3;3*-2
DM61TA4	CS	[O-2].[O-2].[O-2].[As+3].[As+3]
DM61TA4	IK	QTLQKAJBUDWPIB-UHFFFAOYSA-N
DM61TA4	IU	arsenic(3+);oxygen(2-)
DM61TA4	CA	CAS 1327-53-3
DM61TA4	DE	Acute lymphoblastic leukaemia

DMQLX7O	ID	DMQLX7O
DMQLX7O	DN	Arteether
DMQLX7O	HS	Approved
DMQLX7O	SN	Beta arteether; Artecef (TN); Artemotil (TN)
DMQLX7O	CP	Artecef BV
DMQLX7O	DT	Small molecular drug
DMQLX7O	PC	3000469
DMQLX7O	MW	312.4
DMQLX7O	FM	C17H28O5
DMQLX7O	IC	InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1
DMQLX7O	CS	CCO[C@@H]1[C@@H]([C@@H]2CC[C@H]([C@H]3[C@]24[C@H](O1)O[C@@](CC3)(OO4)C)C)C
DMQLX7O	IK	NLYNIRQVMRLPIQ-XQLAAWPRSA-N
DMQLX7O	IU	(1R,4S,5R,8S,9R,10S,12R,13R)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
DMQLX7O	CA	CAS 75887-54-6
DMQLX7O	CB	CHEBI:135335
DMQLX7O	DE	Malaria

DM48QOT	ID	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	HS	Approved
DM48QOT	SN	Artemetero; Artemether[inn]; Artemetheri; Artemetherum; Artemos; Artenam; Artesaph; Artesian; Artimist; Artmether; Falcidol; Gvither; Malartem; Paluther; Rither; Arteannuin ether; Artemether [INN]; Artemisininelactol methyl ether; Dihydroartemisinin methyl ether; Dihydroquinghaosu methyl ether; SM 224; SM 229; Alpha-Artemether; Alpha-Dihydroartemisinin methyl ether; Artemetero [INN-Spanish]; Artemether (INN); Artemetherum [INN-Latin]; Beta-Artemether; Beta-Dihydroartemisinin methyl ether; Methyl-dihydroartemisinine; O-Methyldihydroartemisinine; SM-224; Beta-Methylether of 11-epi-dihydroartemisinin; Artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin; (3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether; (3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; (5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; 10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri
DM48QOT	DT	Small molecular drug
DM48QOT	PC	68911
DM48QOT	MW	298.37
DM48QOT	FM	C16H26O5
DM48QOT	IC	InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
DM48QOT	CS	C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C
DM48QOT	IK	SXYIRMFQILZOAM-HVNFFKDJSA-N
DM48QOT	IU	(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
DM48QOT	CA	CAS 71963-77-4
DM48QOT	CB	CHEBI:195280
DM48QOT	DE	Malaria

DMOY7W3	ID	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	HS	Approved
DMOY7W3	SN	Arteannuin; Artemisine; Artemisinina; Artemisinine; Artemisininum; Artesin; Huanghuahaosu; Qinghaosu; Qinghosu; Quinghaosu; Artemisinin [INN]; Artemisinina [Spanish]; Artemisinine [French]; Artemisininum [Latin]; Qing Hau SU; Qing Hau Sau; Qing Hau Sau [Chinese]; Qinghaosu [Chinese]; Quing Hau Sau; Artemisinin (INN); Coartem, Artemisinin; Artemisia annua L., extract; GNF-PF-5671; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (+)-Arteannuin; (+)-Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one
DMOY7W3	DT	Small molecular drug
DMOY7W3	PC	68827
DMOY7W3	MW	282.33
DMOY7W3	FM	C15H22O5
DMOY7W3	IC	InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
DMOY7W3	CS	C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)C
DMOY7W3	IK	BLUAFEHZUWYNDE-NNWCWBAJSA-N
DMOY7W3	IU	(1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
DMOY7W3	CA	CAS 63968-64-9
DMOY7W3	CB	CHEBI:223316
DMOY7W3	DE	Malaria

DMFETDK	ID	DMFETDK
DMFETDK	DN	Artemisinin SP
DMFETDK	HS	Approved
DMFETDK	SN	Isoguvacine; isoguvacine; 1,2,3,6-tetrahydropyridine-4-carboxylic acid; 64603-90-3; 1,2,3,6-Tetrahydro-pyridine-4-carboxylic acid; 1,2,3,6-Tetrahydro-4-pyridinecarboxylic acid; UNII-YTF580771Y; CHEMBL39071; CHEBI:34799; YTF580771Y; 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-; AC1OEMUS; 1,2,3,6-tetrahydropyridinium-4-carboxylate; 1,2,3,6-tetrahydropyridin-1-ium-4-carboxylate; Tocris-0235; Spectrum_001974; Lopac-G-002; AC1L1GNT; Spectrum3_001869; Biomol-NT_000254; AC1Q5QG1; Lopac0_000561; KBioSS_002540; BSPBio_003318; DivK1c_000115
DMFETDK	DT	Small molecular drug
DMFETDK	PC	3765
DMFETDK	MW	127.14
DMFETDK	FM	C6H9NO2
DMFETDK	IC	InChI=1S/C6H9NO2/c8-6(9)5-1-3-7-4-2-5/h1,7H,2-4H2,(H,8,9)
DMFETDK	CS	C1CNCC=C1C(=O)O
DMFETDK	IK	KRVDMABBKYMBHG-UHFFFAOYSA-N
DMFETDK	IU	1,2,3,6-tetrahydropyridine-4-carboxylic acid
DMFETDK	CA	CAS 64603-90-3
DMFETDK	CB	CHEBI:34799
DMFETDK	DE	Malaria

DMR27C8	ID	DMR27C8
DMR27C8	DN	Artesunate
DMR27C8	HS	Approved
DMR27C8	SN	Arinate; Arsumax; Artesunato; Artesunatum; Artsuna; Dihydroqinghaosusuccinate; Nuartez; Plasmotrim; Plasmotrin; Qinghaozhi; Artesunic acid; Dihydroqinghasu hemsuccinate; Quinghaosu reduced succinate ester; Succinyl dihydroartemisinin; SM 804; WR 256283; Arsumax (TN); Artesunate (USAN); Artesunate (superseded RN); Artesunato [INN-Spanish]; Artesunatum [INN-Latin]; WR-256283; Dihydroartemisinine-12-alpha-succinate; Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-oxo-4-{[(3r,5as,6r,8as,9r,10r,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid; 4-oxo-4-{[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid
DMR27C8	DT	Small molecular drug
DMR27C8	PC	6917864
DMR27C8	MW	384.4
DMR27C8	FM	C19H28O8
DMR27C8	IC	InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1
DMR27C8	CS	C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC(=O)CCC(=O)O)C
DMR27C8	IK	FIHJKUPKCHIPAT-AHIGJZGOSA-N
DMR27C8	IU	4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid
DMR27C8	CA	CAS 88495-63-0
DMR27C8	CB	CHEBI:63918
DMR27C8	DE	Malaria

DMOKCVI	ID	DMOKCVI
DMOKCVI	DN	ARZOXIFENE
DMOKCVI	HS	Approved
DMOKCVI	SN	Arzoxifene; 182133-25-1; UNII-E569WG6E60; LY 353381; E569WG6E60; 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol; 2-(4-methoxyphenyl)-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)benzo[b]thiophen-6-ol; Arzoxifene [INN]; LY-353381; SCHEMBL285277; CHEMBL226267; BDBM19442; DTXSID10171255; ZINC1544683; AC1L4522; AN-538; AKOS030631785; SB19713; KB-05502; FT-0751607; 124708-EP2295426A1; 124708-EP2295427A1; 124708-EP2292592A1; 124708-EP2292576A2; Benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl)
DMOKCVI	DT	Small molecular drug
DMOKCVI	PC	179337
DMOKCVI	MW	475.6
DMOKCVI	FM	C28H29NO4S
DMOKCVI	IC	InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3
DMOKCVI	CS	COC1=CC=C(C=C1)C2=C(C3=C(S2)C=C(C=C3)O)OC4=CC=C(C=C4)OCCN5CCCCC5
DMOKCVI	IK	MCGDSOGUHLTADD-UHFFFAOYSA-N
DMOKCVI	IU	2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol
DMOKCVI	CA	CAS 182133-25-1
DMOKCVI	DE	Breast cancer

DMV05SW	ID	DMV05SW
DMV05SW	DN	As-1670542
DMV05SW	HS	Approved
DMV05SW	SN	AVATROMBOPAG; 570406-98-3; AKR-501; UNII-3H8GSZ4SQL; 3H8GSZ4SQL; AKR 501; Avatrombopag [USAN:INN]; Doptelet; AS 1670542; Avatrombopag (USAN/INN); GTPL9953; DTXSID30205667; ZINC72190218; AKOS027323962; CS-3397; HY-13463; FT-0728753; D10306; AS1670542
DMV05SW	CP	Dova Pharmaceuticals
DMV05SW	DT	Small molecular drug
DMV05SW	PC	9852519
DMV05SW	MW	649.7
DMV05SW	FM	C29H34Cl2N6O3S2
DMV05SW	IC	InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)
DMV05SW	CS	C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
DMV05SW	IK	OFZJKCQENFPZBH-UHFFFAOYSA-N
DMV05SW	IU	1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
DMV05SW	CA	CAS 570406-98-3
DMV05SW	DE	Thrombocytopenia; Idiopathic thrombocytopenic purpura

DMCZIHT	ID	DMCZIHT
DMCZIHT	DN	Asasantin
DMCZIHT	HS	Approved
DMCZIHT	SN	Aggrenox; Aspirin mixture with Dipyridamole; 87653-67-6; Asasantin Retard; Aspirin / Dipyridamole; aspirin, dipyridamole drug combination; TX-3301; TX 3301; C24H40N8O4.C9H8O4; Aspirin/extended-release dipyridamole; AC1L3AE0; SCHEMBL456521; DTXSID40236543; LS-178622; Benzoic acid, 2-(acetyloxy)-, mixt. with 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis(ethanol)
DMCZIHT	CP	Boehringer Ingelheim Corp
DMCZIHT	DT	Small molecular drug
DMCZIHT	PC	137329
DMCZIHT	MW	684.8
DMCZIHT	FM	C33H48N8O8
DMCZIHT	IC	InChI=1S/C24H40N8O4.C9H8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30;1-6(10)13-8-5-3-2-4-7(8)9(11)12/h33-36H,1-18H2;2-5H,1H3,(H,11,12)
DMCZIHT	CS	CC(=O)OC1=CC=CC=C1C(=O)O.C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
DMCZIHT	IK	NOHUXXDTQJPXSB-UHFFFAOYSA-N
DMCZIHT	IU	2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
DMCZIHT	CA	CAS 87653-67-6
DMCZIHT	DE	Cerebrovascular ischaemia

DMSQZE2	ID	DMSQZE2
DMSQZE2	DN	Asenapine
DMSQZE2	HS	Approved
DMSQZE2	SN	Asenapi; Asenapine [INN:BAN]; Saphris (TN); [13C,2H3]-Asenipine; Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole
DMSQZE2	CP	Organon BioSciences
DMSQZE2	DT	Small molecular drug
DMSQZE2	PC	3036780
DMSQZE2	MW	285.8
DMSQZE2	FM	C17H16ClNO
DMSQZE2	IC	InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1
DMSQZE2	CS	CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
DMSQZE2	IK	VSWBSWWIRNCQIJ-GJZGRUSLSA-N
DMSQZE2	IU	(2R,6R)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
DMSQZE2	CA	CAS 65576-45-6
DMSQZE2	CB	CHEBI:71246
DMSQZE2	DE	Schizophrenia

DMM4FXA	ID	DMM4FXA
DMM4FXA	DN	Asfotase alfa
DMM4FXA	HS	Approved
DMM4FXA	SN	SPHEX, BioMep; SPHEX, Enobia; PHEX-based enzyme replacement therapy, BioMep; PHEX-based enzyme replacement therapy, Enobia; X-linked hypophosphatemic rickets therapy, BioMep; X-linked hypophosphatemic rickets therapy, Enobia
DMM4FXA	CP	Enobia Pharma Inc
DMM4FXA	SQ	Asfotase Alfa Sequence: LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSLKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIDDDDDDDDDD
DMM4FXA	DE	Genetic disease

DM672AH	ID	DM672AH
DM672AH	DN	Aspirin
DM672AH	HS	Approved
DM672AH	SN	ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard
DM672AH	CP	Bayer Pharmaceuticals Corporation
DM672AH	TC	Analgesics
DM672AH	DT	Small molecular drug
DM672AH	PC	2244
DM672AH	MW	180.16
DM672AH	FM	C9H8O4
DM672AH	IC	InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
DM672AH	CS	CC(=O)OC1=CC=CC=C1C(=O)O
DM672AH	IK	BSYNRYMUTXBXSQ-UHFFFAOYSA-N
DM672AH	IU	2-acetyloxybenzoic acid
DM672AH	CA	CAS 50-78-2
DM672AH	CB	CHEBI:15365
DM672AH	DE	Pain; Myocardial infarction; Cardiovascular disease

DMSYRBX	ID	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	HS	Approved
DMSYRBX	SN	198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; BMS 232632; Atazanavir [INN:BAN]; CGP 73547; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; HSDB 7339; Reyataz (TN); ATV; QZU4H47A3S; CHEMBL1163; CHEBI:37924; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; NCGC00182552-01; AK174307; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; DR7; atazanavirum; ATZ; Atazanavirum; Atazanavir (INN); Reyataz, BMS-232632, Atazanavir; Reyataz(TM) (*1:1 sulfate*); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide
DMSYRBX	CP	Bristol-Myers Squibb
DMSYRBX	TC	Anti-HIV Agents
DMSYRBX	DT	Small molecular drug
DMSYRBX	PC	148192
DMSYRBX	MW	704.9
DMSYRBX	FM	C38H52N6O7
DMSYRBX	IC	InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
DMSYRBX	CS	CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC
DMSYRBX	IK	AXRYRYVKAWYZBR-GASGPIRDSA-N
DMSYRBX	IU	methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
DMSYRBX	CA	CAS 198904-31-3
DMSYRBX	CB	CHEBI:37924
DMSYRBX	DE	Human immunodeficiency virus infection

DMNKG1Z	ID	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	HS	Approved
DMNKG1Z	SN	Aircrit; Alinor; Altol; Anselol; Antipressan; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenolin; Atenololum; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Selobloc; Serten; Servitenol; Stermin; Tenidon; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormine; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Betatop Ge; Scheinpharm Atenol; Seles beta; Tenormine [French]; A 7655; Atenol 1A pharma; Apo-Atenolol; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenololum [INN-Latin]; Felo-Bits; Lo-ten; Teno-basan; Tenormin (TN); Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide
DMNKG1Z	TC	Antihypertensive Agents
DMNKG1Z	DT	Small molecular drug
DMNKG1Z	PC	2249
DMNKG1Z	MW	266.34
DMNKG1Z	FM	C14H22N2O3
DMNKG1Z	IC	InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
DMNKG1Z	CS	CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
DMNKG1Z	IK	METKIMKYRPQLGS-UHFFFAOYSA-N
DMNKG1Z	IU	2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
DMNKG1Z	CA	CAS 29122-68-7
DMNKG1Z	CB	CHEBI:2904
DMNKG1Z	DE	Hypertension

DMMF8U0	ID	DMMF8U0
DMMF8U0	DN	Atezolizumab
DMMF8U0	HS	Approved
DMMF8U0	CP	Genentech South San Francisco, CA
DMMF8U0	DT	Monoclonal antibody
DMMF8U0	DE	Melanoma; Breast cancer; Bladder cancer; Colorectal cancer; Haematological malignancy; Myelodysplastic syndrome; Renal cell carcinoma; Squamous cell carcinoma; Urothelial carcinoma; Hepatocellular carcinoma; Ovarian cancer; Prostate cancer; Acute myeloid leukaemia; Follicular lymphoma; Gastric adenocarcinoma; Multiple myeloma; Pancreatic cancer; Small-cell lung cancer; Solid tumour/cancer; Bronchioalveolar carcinoma; Ulcer; Non-small cell lung cancer

DM5L6HI	ID	DM5L6HI
DM5L6HI	DN	Atomoxetine
DM5L6HI	HS	Approved
DM5L6HI	SN	Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
DM5L6HI	CP	Eli Lilly
DM5L6HI	DT	Small molecular drug
DM5L6HI	PC	54841
DM5L6HI	MW	255.35
DM5L6HI	FM	C17H21NO
DM5L6HI	IC	InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
DM5L6HI	CS	CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
DM5L6HI	IK	VHGCDTVCOLNTBX-QGZVFWFLSA-N
DM5L6HI	IU	(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
DM5L6HI	CA	CAS 83015-26-3
DM5L6HI	CB	CHEBI:127342
DM5L6HI	DE	Attention deficit hyperactivity disorder

DMF28YC	ID	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	HS	Approved
DMF28YC	SN	Atogal; Atorlip; Atorpic; Atorvastatina; Atorvastatine; Atorvastatinium; Atrovastin; Cardyl; Faboxim; Lipotropic; Lipovastatinklonal; Liprimar; Lowden; Sincol; Sortis; Sotis; Torvacard; Torvast; Totalip; Tozalip; Tulip; Vastina; Xanator; Xarator; Xavator; Zurinel; Atorvastatin (INN); Atorvastatin [INN:BAN]; Lipitor (TN); Lipitor(TM); Sortis (TN); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID
DMF28YC	CP	Pfizer Pharmaceuticals
DMF28YC	TC	Anticholesteremic Agents
DMF28YC	DT	Small molecular drug
DMF28YC	PC	60823
DMF28YC	MW	558.6
DMF28YC	FM	C33H35FN2O5
DMF28YC	IC	InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
DMF28YC	CS	CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMF28YC	IK	XUKUURHRXDUEBC-KAYWLYCHSA-N
DMF28YC	IU	(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
DMF28YC	CA	CAS 134523-00-5
DMF28YC	CB	CHEBI:39548
DMF28YC	DE	Cardiovascular disease

DMY4UMW	ID	DMY4UMW
DMY4UMW	DN	Atovaquone
DMY4UMW	HS	Approved
DMY4UMW	SN	Acuvel; Atavaquone; Mepron; Pron; Wellvone; Atovaquone GlaxoSmithKline brand; Glaxo Wellcome brand of atovaquone; GlaxoSmithKline brand of atovaquone; Malarone Pediatric; BW 566C; BW 566C80; Hydroxynaphthoquinone 566C80; Atovaquone & Interleukin 12; BW 556C-80; BW 566C-80; BW-A 566C; DRG-0084; Hydroxynaphthoquinone, 566C80; Mepron (TN); Mepron (antipneumocystic); ATO & IL-12; Atovaquone (USP/INN); Atovaquone [USAN:BAN:INN]; CRL-8131 & Atovaquone; 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; 566C80 hydroxynaphthoquinone; 566C80, hydroxynaphthoquinone; ATQ
DMY4UMW	CP	GlaxoSmithKline
DMY4UMW	TC	Antifungal Agents
DMY4UMW	DT	Small molecular drug
DMY4UMW	PC	74989
DMY4UMW	MW	366.8
DMY4UMW	FM	C22H19ClO3
DMY4UMW	IC	InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,24H,5-8H2
DMY4UMW	CS	C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O
DMY4UMW	IK	BSJMWHQBCZFXBR-UHFFFAOYSA-N
DMY4UMW	IU	3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione
DMY4UMW	CA	CAS 94015-53-9
DMY4UMW	CB	CHEBI:575568
DMY4UMW	DE	Fungal infection

DM42HXN	ID	DM42HXN
DM42HXN	DN	Atracurium
DM42HXN	HS	Approved
DM42HXN	SN	Atracurium Dibesylate; Tracrium (TN); 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]; 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DM42HXN	CP	Burroughs Wellcome Co
DM42HXN	TC	Neuromuscular Nondepolarizing Agents
DM42HXN	DT	Small molecular drug
DM42HXN	PC	47319
DM42HXN	MW	929.1
DM42HXN	FM	C53H72N2O12+2
DM42HXN	IC	InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2
DM42HXN	CS	C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
DM42HXN	IK	YXSLJKQTIDHPOT-UHFFFAOYSA-N
DM42HXN	IU	5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DM42HXN	CA	CAS 64228-79-1
DM42HXN	CB	CHEBI:2914
DM42HXN	DE	Anaesthesia

DMEN6X7	ID	DMEN6X7
DMEN6X7	DN	Atropine
DMEN6X7	HS	Approved
DMEN6X7	SN	dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate
DMEN6X7	CP	Pfizer Pharmaceuticals
DMEN6X7	TC	Antiarrhythmic Agents
DMEN6X7	DT	Small molecular drug
DMEN6X7	PC	174174
DMEN6X7	MW	289.4
DMEN6X7	FM	C17H23NO3
DMEN6X7	IC	InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16?
DMEN6X7	CS	CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
DMEN6X7	IK	RKUNBYITZUJHSG-PJPHBNEVSA-N
DMEN6X7	IU	[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
DMEN6X7	CA	CAS 51-55-8
DMEN6X7	CB	CHEBI:16684
DMEN6X7	DE	Organophosphate poisoning; Poison intoxication

DM79Y2T	ID	DM79Y2T
DM79Y2T	DN	ATryn antithrombin
DM79Y2T	HS	Approved
DM79Y2T	CP	Revo biologics
DM79Y2T	DE	Multiple sclerosis

DMWE2N4	ID	DMWE2N4
DMWE2N4	DN	Auranofin
DMWE2N4	HS	Approved
DMWE2N4	SN	Ridaura; Ridauran; Ridaura (TN); SK&F 39162; SK&F-39162; Gold, (1-thio-.beta.-D-glucopyranosato)(triethylphosphine)-, 2,3,4,6-tetraacetate; (1-Thio-.beta.-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
DMWE2N4	TC	Antirheumatic Agents
DMWE2N4	DT	Small molecular drug
DMWE2N4	PC	24199313
DMWE2N4	MW	678.5
DMWE2N4	FM	C20H34AuO9PS
DMWE2N4	IC	InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1
DMWE2N4	CS	CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]
DMWE2N4	IK	AUJRCFUBUPVWSZ-UHFFFAOYSA-M
DMWE2N4	IU	gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane
DMWE2N4	CA	CAS 34031-32-8
DMWE2N4	DE	Inflammatory arthritis

DM75CXN	ID	DM75CXN
DM75CXN	DN	Avanafil
DM75CXN	HS	Approved
DM75CXN	SN	Stendra (TN)
DM75CXN	CP	Vivus
DM75CXN	DT	Small molecular drug
DM75CXN	PC	9869929
DM75CXN	MW	483.9
DM75CXN	FM	C23H26ClN7O3
DM75CXN	IC	InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
DM75CXN	CS	COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl
DM75CXN	IK	WEAJZXNPAWBCOA-INIZCTEOSA-N
DM75CXN	IU	4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
DM75CXN	CA	CAS 330784-47-9
DM75CXN	CB	CHEBI:66876
DM75CXN	DE	Erectile dysfunction

DMK2GZX	ID	DMK2GZX
DMK2GZX	DN	Avapritinib
DMK2GZX	HS	Approved
DMK2GZX	SN	1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine
DMK2GZX	CP	Blueprint Medicines Cambridge, MA
DMK2GZX	PC	118023034
DMK2GZX	MW	498.6
DMK2GZX	FM	C26H27FN10
DMK2GZX	IC	InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1
DMK2GZX	CS	C[C@](C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N
DMK2GZX	IK	DWYRIWUZIJHQKQ-SANMLTNESA-N
DMK2GZX	IU	(1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine
DMK2GZX	CA	CAS 1703793-34-3
DMK2GZX	DE	Mast cell leukaemia; Systemic mastocytosis; Gastrointestinal stromal tumour

DMSZLJR	ID	DMSZLJR
DMSZLJR	DN	Avelumab
DMSZLJR	HS	Approved
DMSZLJR	CP	Merck KGaA/Pfizer
DMSZLJR	DT	Monoclonal antibody
DMSZLJR	SQ	Heavy chain: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Light chainQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
DMSZLJR	DE	Melanoma; Ovarian cancer; Solid tumour/cancer; Renal cell carcinoma; Merkel cell carcinoma

DM1AEH4	ID	DM1AEH4
DM1AEH4	DN	Avibactam
DM1AEH4	HS	Approved
DM1AEH4	SN	Avibactam; Avibactam (free acid); Avibactam [USAN:INN]; Avibactam free acid; AVE-1330A free acid; NXL 104; NXL104; Q15410251; SCHEMBL1666807; ZINC9302239; (2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; 1,6-Diazabicyclo(3.2.1)octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel-; 1192500-31-4; 396731-14-9; BDBM50339145; CHEBI:85984; CHEMBL1689063; CS-0593; DB09060; HY-14879; UNII-06MFO7817I component NDCUAPJVLWFHHB-UHNVWZDZSA-N; UNII-7352665165
DM1AEH4	PC	9835049
DM1AEH4	MW	265.25
DM1AEH4	FM	C7H11N3O6S
DM1AEH4	IC	NDCUAPJVLWFHHB-UHNVWZDZSA-N
DM1AEH4	CS	C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)N
DM1AEH4	IK	1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1
DM1AEH4	IU	[(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
DM1AEH4	CA	CAS 396731-14-9
DM1AEH4	CB	CHEBI:85984
DM1AEH4	DE	Infectious cystitis

DMYHN59	ID	DMYHN59
DMYHN59	DN	Axicabtagene ciloleucel
DMYHN59	HS	Approved
DMYHN59	CP	Masonic Cancer Center, University of Minnesota
DMYHN59	DT	CAR T Cell Therapy
DMYHN59	DE	Acute lymphoblastic leukaemia; Mantle cell lymphoma; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Primary mediastinal B-cell lymphoma; Large B-cell lymphoma

DMGVH6N	ID	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	HS	Approved
DMGVH6N	SN	AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)
DMGVH6N	CP	Pfizer
DMGVH6N	TC	Anticancer Agents
DMGVH6N	DT	Small molecular drug
DMGVH6N	PC	6450551
DMGVH6N	MW	386.5
DMGVH6N	FM	C22H18N4OS
DMGVH6N	IC	InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
DMGVH6N	CS	CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
DMGVH6N	IK	RITAVMQDGBJQJZ-FMIVXFBMSA-N
DMGVH6N	IU	N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
DMGVH6N	CA	CAS 319460-85-0
DMGVH6N	CB	CHEBI:66910
DMGVH6N	DE	Renal cell carcinoma

DMTA5OE	ID	DMTA5OE
DMTA5OE	DN	Azacitidine
DMTA5OE	HS	Approved
DMTA5OE	SN	Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC
DMTA5OE	CP	Celgene
DMTA5OE	TC	Anticancer Agents
DMTA5OE	DT	Small molecular drug
DMTA5OE	PC	9444
DMTA5OE	MW	244.2
DMTA5OE	FM	C8H12N4O5
DMTA5OE	IC	InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
DMTA5OE	CS	C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N
DMTA5OE	IK	NMUSYJAQQFHJEW-KVTDHHQDSA-N
DMTA5OE	IU	4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
DMTA5OE	CA	CAS 320-67-2
DMTA5OE	CB	CHEBI:2038
DMTA5OE	DE	Myelodysplastic syndrome

DMZ80SB	ID	DMZ80SB
DMZ80SB	DN	Azatadine
DMZ80SB	HS	Approved
DMZ80SB	SN	Azatadina; Azatadinum; Azatidine; Azatadine maleate; Azatadina [INN-Spanish]; Azatadine (INN); Azatadine [INN:BAN]; Azatadinum [INN-Latin]; 11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
DMZ80SB	TC	Antihistamines
DMZ80SB	DT	Small molecular drug
DMZ80SB	PC	19861
DMZ80SB	MW	290.4
DMZ80SB	FM	C20H22N2
DMZ80SB	IC	InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3
DMZ80SB	CS	CN1CCC(=C2C3=CC=CC=C3CCC4=C2N=CC=C4)CC1
DMZ80SB	IK	SEBMTIQKRHYNIT-UHFFFAOYSA-N
DMZ80SB	IU	2-(1-methylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaene
DMZ80SB	CA	CAS 3964-81-6
DMZ80SB	CB	CHEBI:2946
DMZ80SB	DE	Allergic rhinitis

DMMZSXQ	ID	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	HS	Approved
DMMZSXQ	SN	Azamun; Azanin; Azasan; Azathioprin; Azathioprinum; Azathiopurine; Azatioprin; Azatioprina; Azothioprine; Ccucol; Cytostatics; Immuran; Imuran; Imurek; Imurel; Methylnitroimidazolylmercaptopurine; Muran; Azamun [Czech]; Azathioprine sodium; Azatiopr in; A 4638; BW 57322; Azamun (TN); Azasan (TN); Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; BW 57-322; Imuran (TN); Imurel (TN); [Methyl(nitroimidazolyl)mercaptopurine]; AI-981/34845012; BW-57-322; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; B. W. 57-322; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
DMMZSXQ	CP	GlaxoSmithKline
DMMZSXQ	TC	Immunosuppressive Agents
DMMZSXQ	DT	Small molecular drug
DMMZSXQ	PC	2265
DMMZSXQ	MW	277.27
DMMZSXQ	FM	C9H7N7O2S
DMMZSXQ	IC	InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)
DMMZSXQ	CS	CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
DMMZSXQ	IK	LMEKQMALGUDUQG-UHFFFAOYSA-N
DMMZSXQ	IU	6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
DMMZSXQ	CA	CAS 446-86-6
DMMZSXQ	CB	CHEBI:2948
DMMZSXQ	DE	Organ transplant rejection

DMHVL0J	ID	DMHVL0J
DMHVL0J	DN	Azelaic Acid
DMHVL0J	HS	Approved
DMHVL0J	SN	AZA; Azelaic; Azelex; Finacea; Finevin; Skinorem; Skinoren; Acide azelaique; Acide azelaique [French]; Acido azelaico; Acido azelaico [Spanish]; Acidum azelaicum; Acidum azelaicum [Latin]; Anchoic acid; Azalaic Acid; Azelaic acid polyanhydride; Azelaic polyanhydride; Azelainic acid; Azleaic Acid; Heptanedicarboxylic acid; Lepargylic acid; NONANEDIOIC ACID; Nonanedioic acid; Polyazelaic anhydride; AZ1; Dicarboxylic acid C9; Emerox 1110; Emerox 1144; ZK 62498; A-9800; AGN-191861; Azelaic acid [USAN:INN]; Azelaic acid,technical grade; Azelex (TN); Finacea (TN); Finevin (TN); N-Nonanedioic acid; Nonanedioic acid, homopolymer; Poly(azelaic anhydride); SH-441; Skinoren (TN); ZK-62498; AZELAIC ACID, 95%; Azelaic acid (USAN/INN); Emery's L-110; 1,7-Heptanedicarboxylic acid; 1,9-Nonanedioic acid
DMHVL0J	TC	Dermatologic Agents
DMHVL0J	DT	Small molecular drug
DMHVL0J	PC	2266
DMHVL0J	MW	188.22
DMHVL0J	FM	C9H16O4
DMHVL0J	IC	InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)
DMHVL0J	CS	C(CCCC(=O)O)CCCC(=O)O
DMHVL0J	IK	BDJRBEYXGGNYIS-UHFFFAOYSA-N
DMHVL0J	IU	nonanedioic acid
DMHVL0J	CA	CAS 123-99-9
DMHVL0J	CB	CHEBI:48131
DMHVL0J	DE	Acne vulgaris

DMXTMBJ	ID	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	HS	Approved
DMXTMBJ	SN	Azelastina; Azelastinum; Optivar; Astelin (TN); Astepro (TN); Azelastina [INN-Spanish]; Azelastine (INN); Azelastine [INN:BAN]; Azelastinum [INN-Latin]; Optivar (TN); 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone HCl; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
DMXTMBJ	CP	Meda Pharmaceuticals Inc
DMXTMBJ	TC	Antiallergic Agents
DMXTMBJ	DT	Small molecular drug
DMXTMBJ	PC	2267
DMXTMBJ	MW	381.9
DMXTMBJ	FM	C22H24ClN3O
DMXTMBJ	IC	InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
DMXTMBJ	CS	CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
DMXTMBJ	IK	MBUVEWMHONZEQD-UHFFFAOYSA-N
DMXTMBJ	IU	4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
DMXTMBJ	CA	CAS 58581-89-8
DMXTMBJ	CB	CHEBI:2950
DMXTMBJ	DE	Allergic conjunctivitis

DMOIX5S	ID	DMOIX5S
DMOIX5S	DN	Azilsartan
DMOIX5S	HS	Approved
DMOIX5S	SN	TAK 536; TAK-536; Azilsartan (INN/USAN)
DMOIX5S	CP	Takeda
DMOIX5S	DT	Small molecular drug
DMOIX5S	PC	135415867
DMOIX5S	MW	456.4
DMOIX5S	FM	C25H20N4O5
DMOIX5S	IC	InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)
DMOIX5S	CS	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O
DMOIX5S	IK	KGSXMPPBFPAXLY-UHFFFAOYSA-N
DMOIX5S	IU	2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMOIX5S	CA	CAS 147403-03-0
DMOIX5S	CB	CHEBI:68850
DMOIX5S	DE	Hypertension

DMIR5QP	ID	DMIR5QP
DMIR5QP	DN	Azlocillin
DMIR5QP	HS	Approved
DMIR5QP	SN	Azlocilina; Azlocilline; Azlocillinum; Securopen; Bayer Brand of Azlocillin; Azlocilina [INN-Spanish]; Azlocillin Sodium (Sterile); Azlocilline [INN-French]; Azlocillinum [INN-Latin]; Bay-e 6905; Azlocillin (USAN/INN); Azlocillin [USAN:BAN:INN]; (2R,5R,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2R,5S,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-((R)-2-(2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2S)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2S)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5S,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2r,5s,6s)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]penam-3alpha-carboxylic acid; 3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-dimethyl-7-oxo-6-{[{[(2-oxoimidazolidin-1-yl)carbonyl]amino}(phenyl)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((R)-2-(2-Oxoimidazolidin-1-carboxamido)-2-phenylacetamido)penicillansaeure
DMIR5QP	CP	Bayer Pharmaceuticals Corp
DMIR5QP	TC	Antibiotics
DMIR5QP	DT	Small molecular drug
DMIR5QP	PC	6479523
DMIR5QP	MW	461.5
DMIR5QP	FM	C20H23N5O6S
DMIR5QP	IC	InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1
DMIR5QP	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C
DMIR5QP	IK	JTWOMNBEOCYFNV-NFFDBFGFSA-N
DMIR5QP	IU	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIR5QP	CA	CAS 37091-66-0
DMIR5QP	CB	CHEBI:2956
DMIR5QP	DE	Pseudomonas infection

DMDNJHG	ID	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	HS	Approved
DMDNJHG	SN	Azactam; Primbactam; Azactam (TN); SQ-26776; Monobactam, SQ 26776, Squibb 26776, Aztreonam; [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
DMDNJHG	CP	Bristol-Myers Squibb Company
DMDNJHG	TC	Antibiotics
DMDNJHG	DT	Small molecular drug
DMDNJHG	PC	5742832
DMDNJHG	MW	435.4
DMDNJHG	FM	C13H17N5O8S2
DMDNJHG	IC	InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1
DMDNJHG	CS	C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\\OC(C)(C)C(=O)O)/C2=CSC(=N2)N
DMDNJHG	IK	WZPBZJONDBGPKJ-VEHQQRBSSA-N
DMDNJHG	IU	2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
DMDNJHG	CA	CAS 78110-38-0
DMDNJHG	CB	CHEBI:161680
DMDNJHG	DE	Bacterial infection

DMP54C7	ID	DMP54C7
DMP54C7	DN	Bacampicillin
DMP54C7	HS	Approved
DMP54C7	SN	Bacampicilina; Bacampicilline; Bacampicillinum; Penglobe; Bacampicillin hydrochloride; Bacampicilina [INN-Spanish]; Bacampicillin (INN); Bacampicillin [INN:BAN]; Bacampicilline [INN-French]; Bacampicillinum [INN-Latin]; Penglobe (TN); Spectrobid (TN); (2S,5R,6R)-6((R)-(2-Amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid ester with ethyl 1-hydroxyethylcarbonate; 1'-Ethoxycarbonyloxyethyl-(6-D-alpha-aminophenylacetamido)penicillanate; 1-Ethoxycarbonyloxyethyl (2S,5R,6R)-6((R)-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylat; 1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-[(ethoxycarbonyl)oxy]ethyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 6-((R)-2-Amino-2-phenylacetamido)penicillansaeure-(1-(ethoxycarbonyloxy)ethylester
DMP54C7	CP	Pfizer Pharmaceuticals
DMP54C7	TC	Antibiotics
DMP54C7	DT	Small molecular drug
DMP54C7	PC	441397
DMP54C7	MW	465.5
DMP54C7	FM	C21H27N3O7S
DMP54C7	IC	InChI=1S/C21H27N3O7S/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25)/t11?,13-,14-,15+,18-/m1/s1
DMP54C7	CS	CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C
DMP54C7	IK	PFOLLRNADZZWEX-FFGRCDKISA-N
DMP54C7	IU	1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMP54C7	CA	CAS 50972-17-3
DMP54C7	CB	CHEBI:2968
DMP54C7	DE	Bacterial infection

DM5OHYE	ID	DM5OHYE
DM5OHYE	DN	Bacitracin
DM5OHYE	HS	Approved
DM5OHYE	SN	Altracin; Baciguent; Baciquent; Citracin; Fortracin; Bacitracin A; Bacitracin A1; Bacitracin A2a; Neosporin (TN); Solu-Tracin 50; Partyl-, (10.4)-lactam; L-Asparagine, N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-.alpha.-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-.alpha.-as; 11702_FLUKA; 11702_SIGMA
DM5OHYE	TC	Antibiotics
DM5OHYE	DT	Small molecular drug
DM5OHYE	PC	10909430
DM5OHYE	MW	1422.7
DM5OHYE	FM	C66H103N17O16S
DM5OHYE	IC	InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1
DM5OHYE	CS	CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4
DM5OHYE	IK	CLKOFPXJLQSYAH-ABRJDSQDSA-N
DM5OHYE	IU	(4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM5OHYE	CA	CAS 1405-87-4
DM5OHYE	CB	CHEBI:35862
DM5OHYE	DE	Skin infection

DMD2871	ID	DMD2871
DMD2871	DN	Bacitracin
DMD2871	HS	Approved
DMD2871	SN	Bacillus subtilis; Bacitracin Zinc free sample; Bacitracin zinc [USP]; Bacitracins zinc complex; Bacitracins, zinc complex; EPA Pesticide Chemical Code 006309; SC-18930; SCHEMBL543112; Ziba-RX; Zinc bacitracin; 5-((1-((9-((4H-imidazol-4-yl)methyl)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-(sec-butyl)-6-(carboxymethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopent; AKOS015896384; Albac; Caswell No. 909A; EINECS 215-787-8; FT-0622546; FT-0654564
DMD2871	PC	3083711
DMD2871	MW	1488.1
DMD2871	FM	C66H103N17O16SZn
DMD2871	IC	QSNOBVJFKSQBBD-UHFFFAOYSA-N
DMD2871	CS	CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCCCCC(C(=O)NC(C(=O)N1)CCCN)NC(=O)C(C(C)CC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C2CSC(=N2)C(C(C)CC)N)CC(=O)N)CC(=O)O)CC3C=NC=N3)CC4=CC=CC=C4.[Zn]
DMD2871	IK	1S/C66H103N17O16S.Zn/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90;/h12-14,18-19,31,33-37,39-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88);
DMD2871	IU	4-[[2-[[2-(1-amino-2-methylbutyl)-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[1-[[3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-butan-2-yl-6-(carboxymethyl)-9-(4H-imidazol-4-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid;zinc
DMD2871	CA	CAS 1405-89-6
DMD2871	DE	Pyothorax

DM0QV1J	ID	DM0QV1J
DM0QV1J	DN	Baclofen
DM0QV1J	HS	Approved
DM0QV1J	SN	Arbaclofen; (R)-Baclofen; 69308-37-8; (R)-4-Amino-3-(4-chlorophenyl)butanoic acid; d-Baclofen; (-)-Baclofen; (R)-(-)-Baclofen; R-Baclofen; R-(-)-Baclofen; STX209; (3R)-4-amino-3-(4-chlorophenyl)butanoic acid; UNII-NYU6UTW25B; l-Baclofen; STX 209; (R)-4-Amino-3-(4-chlorophenyl)butyric Acid; NYU6UTW25B; CHEMBL301742; AK109161; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-, (R)-; Benzeneporopanoic acid, (beta-(aminomethyl)-4-chloro-, (betaR)-; Arbaclofen [USAN:INN]; R-Baclofen RS; Arbaclofen (USAN); p-chlorophenyl GABA;  ApoBaclofen; Atrofen; Baclofene; BaclofeneIrex; Baclofeno; Baclofenum; Baclon; Baclophen; Baclospas; Clofen; Gabalon; GenBaclofen; Genpharm; Kemstro; Lebic; Lioresal; NuBaclo; PMSBaclofen; ASTA Medica Brand of Baclofen; Alphapharm Brand of Baclofen; Apo Baclofen; Apotex Brand of Baclofen; Ashbourne Brand of Baclofen; Athena Brand of Baclofen; Baclofen AWD; Baclofen Alphapharm Brand; Baclofen Apotex Brand; Baclofen Ashbourne Brand; Baclofen Athena Brand; Baclofen Irex Brand; Baclofen Isis Brand; Baclofen Medtronic Brand; Baclofen Novartis Brand; Baclofen Pharmascience Brand; Baclofene Irex; Chlorophenyl GABA; Ciba Geigy Brand of Baclofen; Gen Baclofen; Irex Brand of Baclofen; Isis Brand of Baclofen; Lioresal Intrathecal; Medtronic Brand of Baclofen; Novartis Brand of Baclofen; Nu Baclo; Nu Pharm Brand of Baclofen; PMS Baclofen; Pharmascience Brand of Baclofen; B 5399; Ba 34647; Ba34647; C 34647Ba; AWD, Baclofen; Apo-Baclofen; Ba-34647; Ba34,647; Baclofen Ciba-Geigy Brand; Baclofen Nu-Pharm Brand; Baclofene [INN-French]; Baclofene-Irex; Baclofeno [INN-Spanish]; Baclofenum [INN-Latin]; CIBA34,647BA; Ciba-Geigy Brand of Baclofen; DL-Baclofen; GABA, Chlorophenyl; Gen-Baclofen; Kemstro (TN); Lioresal (TN); Nu-Baclo; Nu-Baclofen; Nu-Pharm Brand of Baclofen; PCP-GABA; Pms-Baclofen; Ba-34,647; Baclofen (R,S); Ciba 34,647-Ba; Baclofen (JP15/USP/INN); Baclofen [USAN:INN:BAN:JAN]; Beta-(4-Chlorophenyl)gaba; CIBA-34,647-BA; Beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; Beta-(Aminomethyl)-p-chlorohydrocinnamic acid; Beta-(p-Chlorophenyl)-gamma-aminobutyric acid; DL-4-Amino-3-p-chlorophenylbutanoic acid; Gamma-Amino-beta-(p-chlorophenyl)butyric acid; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI); (+-)-Baclofen; (+/-)-BACLOFEN; (+/-)-beta-(Aminoethyl)-4-chlorobenzenepropanoic acid; (+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; (inverted question mark)-Baclofen; 4-Amino-3-(4-chlorophenyl)butanoic acid; 4-Amino-3-(4-chlorophenyl)butyric acid; (R)-4-Amino-3-(4-chloro-phenyl)-butyric acid
DM0QV1J	CP	Norvatis Phamaceuticals Corporation
DM0QV1J	TC	Muscle Relaxants
DM0QV1J	DT	Small molecular drug
DM0QV1J	PC	2284
DM0QV1J	MW	213.66
DM0QV1J	FM	C10H12ClNO2
DM0QV1J	IC	InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)
DM0QV1J	CS	C1=CC(=CC=C1C(CC(=O)O)CN)Cl
DM0QV1J	IK	KPYSYYIEGFHWSV-UHFFFAOYSA-N
DM0QV1J	IU	4-amino-3-(4-chlorophenyl)butanoic acid
DM0QV1J	CA	CAS 1134-47-0
DM0QV1J	CB	CHEBI:2972
DM0QV1J	DE	Multiple sclerosis; Fragile X syndrome

DMPWNDB	ID	DMPWNDB
DMPWNDB	DN	Balofloxacin
DMPWNDB	HS	Approved
DMPWNDB	SN	Baloxin; Balofloxacin [INN]; Q 35; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinoline arboxylic acid; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMPWNDB	CP	Chugai
DMPWNDB	DT	Small molecular drug
DMPWNDB	PC	65958
DMPWNDB	MW	389.4
DMPWNDB	FM	C20H24FN3O4
DMPWNDB	IC	InChI=1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27)
DMPWNDB	CS	CNC1CCCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
DMPWNDB	IK	MGQLHRYJBWGORO-UHFFFAOYSA-N
DMPWNDB	IU	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMPWNDB	CA	CAS 127294-70-6
DMPWNDB	DE	Gram-positive bacterial infection

DM1UV7F	ID	DM1UV7F
DM1UV7F	DN	Baloxavir marboxil
DM1UV7F	HS	Approved
DM1UV7F	SN	UNII-505CXM6OHG; 505CXM6OHG; Xofluza (TN); Baloxavir marboxil [INN]; Baloxavir marboxil (JAN/INN); SCHEMBL20108731; EX-A1867; HY-109025; CS-0030527
DM1UV7F	CP	Shionogi/Roche
DM1UV7F	PC	124081896
DM1UV7F	MW	571.6
DM1UV7F	FM	C27H23F2N3O7S
DM1UV7F	IC	InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
DM1UV7F	CS	COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
DM1UV7F	IK	RZVPBGBYGMDSBG-GGAORHGYSA-N
DM1UV7F	IU	[(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
DM1UV7F	CA	CAS 1985606-14-1
DM1UV7F	DE	Influenza virus infection

DMRJ9EN	ID	DMRJ9EN
DMRJ9EN	DN	Baloxavir marboxil
DMRJ9EN	HS	Approved
DMRJ9EN	SN	(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate; Baloxavir marboxil; Baloxavir marboxil (JAN/INN); Baloxavir marboxil [INN]; Xofluza (TN)
DMRJ9EN	TC	Antiviral Agents
DMRJ9EN	DT	Small molecular drug
DMRJ9EN	PC	124081896
DMRJ9EN	MW	571.552
DMRJ9EN	FM	C27H23F2N3O7S
DMRJ9EN	IC	InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
DMRJ9EN	CS	COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
DMRJ9EN	IK	RZVPBGBYGMDSBG-GGAORHGYSA-N
DMRJ9EN	IU	[(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
DMRJ9EN	CA	CAS 1985606-14-1
DMRJ9EN	DE	Influenza A infection

DM7I1T9	ID	DM7I1T9
DM7I1T9	DN	Balsalazide
DM7I1T9	HS	Approved
DM7I1T9	SN	Balsalazida; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazide [INN:BAN]; Balsalazido; Balsalazido [Spanish]; Balsalazidum; Balsalazidum [Latin]; BX-661A; Colazide; BALSALAZIDE; P80AL8J7ZP; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 80573-04-2; C17H15N3O6; CHEBI:267413; UNII-P80AL8J7ZP
DM7I1T9	PC	54585
DM7I1T9	MW	357.32
DM7I1T9	FM	C17H15N3O6
DM7I1T9	IC	IPOKCKJONYRRHP-UHFFFAOYSA-N
DM7I1T9	CS	C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DM7I1T9	IK	1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
DM7I1T9	IU	5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DM7I1T9	CA	CAS 80573-04-2
DM7I1T9	CB	CHEBI:267413
DM7I1T9	DE	Ulcerative colitis

DMO091F	ID	DMO091F
DMO091F	DN	Balsalazide
DMO091F	HS	Approved
DMO091F	SN	Balsalazida; Balsalazido; Balsalazidum; Colazal; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Balsalazide (INN); Balsalazide [INN:BAN]; Colazal (TN); Colazide (TN); (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
DMO091F	TC	Antiinflammatory Agents
DMO091F	DT	Small molecular drug
DMO091F	PC	54585
DMO091F	MW	357.32
DMO091F	FM	C17H15N3O6
DMO091F	IC	InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
DMO091F	CS	C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DMO091F	IK	IPOKCKJONYRRHP-UHFFFAOYSA-N
DMO091F	IU	5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DMO091F	CA	CAS 80573-04-2
DMO091F	CB	CHEBI:267413
DMO091F	DE	Inflammatory bowel disease

DMKLSHF	ID	DMKLSHF
DMKLSHF	DN	Bambuterol
DMKLSHF	HS	Approved
DMKLSHF	SN	Bambec; Bambuterolum; Oxeol; Bambuterolum [Latin]; Terbutaline bisdimethylcarbamate; Bambec (TN); Bambuterol (INN); Bambuterol [BAN:INN]; KWD-2183; Oxeol (TN); Terbutaline bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate); 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)
DMKLSHF	CP	AstraZeneca
DMKLSHF	TC	Bronchodilator Agents
DMKLSHF	DT	Small molecular drug
DMKLSHF	PC	54766
DMKLSHF	MW	367.4
DMKLSHF	FM	C18H29N3O5
DMKLSHF	IC	InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3
DMKLSHF	CS	CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O
DMKLSHF	IK	ANZXOIAKUNOVQU-UHFFFAOYSA-N
DMKLSHF	IU	[3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate
DMKLSHF	CA	CAS 81732-65-2
DMKLSHF	CB	CHEBI:553827
DMKLSHF	DE	Asthma

DMXLHYN	ID	DMXLHYN
DMXLHYN	DN	Bamifylline
DMXLHYN	HS	Approved
DMXLHYN	SN	Bamifylline hydrochloride; Trentadil; Pulmac; Bamifylline HCl; Bamiphylline hydrochloride; 20684-06-4; mono-HCl; Benzetamophylline hydrochloride; UNII-66466QLM3S; 8102 CB; BAX 2793Z; Bamifylline hydrochloride [USAN]; EINECS 243-967-6; AC 3810; CB 8102; 66466QLM3S; 8-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline monohydrochloride; 8'-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline hydrochloride; 8-Benzyl-7-(N-ethyl-N-(beta-hydroxyethyl)aminoethyl)theophylline hydrochloride
DMXLHYN	DT	Small molecular drug
DMXLHYN	PC	16229
DMXLHYN	MW	385.5
DMXLHYN	FM	C20H27N5O3
DMXLHYN	IC	InChI=1S/C20H27N5O3/c1-4-24(12-13-26)10-11-25-16(14-15-8-6-5-7-9-15)21-18-17(25)19(27)23(3)20(28)22(18)2/h5-9,26H,4,10-14H2,1-3H3
DMXLHYN	CS	CCN(CCN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=CC=C3)CCO
DMXLHYN	IK	VVUYEFBRTFASAH-UHFFFAOYSA-N
DMXLHYN	IU	8-benzyl-7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-1,3-dimethylpurine-2,6-dione
DMXLHYN	CA	CAS 2016-63-9
DMXLHYN	CB	CHEBI:135605
DMXLHYN	DE	Chronic obstructive pulmonary disease

DME1DJX	ID	DME1DJX
DME1DJX	DN	Baquting
DME1DJX	HS	Approved
DME1DJX	CP	China Nuokang Bio-Pharmaceutical Inc
DME1DJX	DE	Bleeding disorder

DMJ8NMC	ID	DMJ8NMC
DMJ8NMC	DN	Barbital
DMJ8NMC	HS	Approved
DMJ8NMC	SN	Barbitale; Barbitalum; Barbitone; Barbitonum; DEBA; Diemal; Diemalum; Diethylbarbitone; Diethylmalonylurea; Dormileno; Dormonal; Ethylbarbital; Hypnogene; Malonal; Medinal; Sedeval; Uronal; Veroletten; Verolettin; Veronal; Vesperal; Barbital Faes Brand; Barbitale [DCIT]; Diethylbarbituric acid; Faes Brand of Barbital; Barbital (TN); Barbital (VAN); Barbital [INN:JAN]; Barbitalum [INN-Latin]; Veronal (TN); Barbital (JP15/INN); Kyselina 5,5-diethylbarbiturova; Kyselina 5,5-diethylbarbiturova [Czech]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-(9CI); 5,5-Diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5,5-Diethylbarbituric acid; 5,5-diethyl-1,3-diazinane-2,4,6-trione; 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione; 7979P
DMJ8NMC	CP	Schering-Plough
DMJ8NMC	TC	Hypnotics and Sedatives
DMJ8NMC	DT	Small molecular drug
DMJ8NMC	PC	2294
DMJ8NMC	MW	184.19
DMJ8NMC	FM	C8H12N2O3
DMJ8NMC	IC	InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)
DMJ8NMC	CS	CCC1(C(=O)NC(=O)NC1=O)CC
DMJ8NMC	IK	FTOAOBMCPZCFFF-UHFFFAOYSA-N
DMJ8NMC	IU	5,5-diethyl-1,3-diazinane-2,4,6-trione
DMJ8NMC	CA	CAS 57-44-3
DMJ8NMC	CB	CHEBI:31252
DMJ8NMC	DE	Insomnia

DMJIA6T	ID	DMJIA6T
DMJIA6T	DN	Barbiturate
DMJIA6T	HS	Approved
DMJIA6T	SN	Barbituric acid; BARBITURIC ACID; 67-52-7; Malonylurea; 6-Hydroxyuracil; 2,4,6(1H,3H,5H)-Pyrimidinetrione; Pyrimidinetrione; pyrimidine-2,4,6(1H,3H,5H)-trione; 2,4,6-Pyrimidinetrione; Malonylharnstoff; 2,4,6-Trioxohexahydropyrimidine; 1,3-diazinane-2,4,6-trione; Barbitursaeure; Hexahydropyrimidine-2,4,6-trione; Hydrouracil, 6-hydroxy-; Barbituric acid (VAN); Urea, N,N'-(1,3-dioxo-1,3-propanediyl)-; NSC 7889; UNII-WQ92Y2793G; 2,4,6-Pyrimidinetrione(1H,3H,5H); Barbituric acid (VAN) (8CI); CHEBI:16294; EINECS 200-658-0;  Barbitursaeure; Pyrimidinetriol; Barbiturate anion; Sodiumbarbiturate; AG-670/31547005; Hexahydro-pyrimidine-2,4,6-trione; Pyrimidine-2,4,6(1H,3H,5H)-trione; 1,2,3,4,5,6-Hexahydro-2,4,6-pyrimidinetrione; 11709_FLUKA; 2,4,6-(1H,3H,5H)-Pyrimidinetrione; 2,4,6-Pyrimidinetriol; 2,4,6-Trihydroxypyrimidine; 2,4,6-trioxotetrahydro-2H-pyrimidin-1-ide; 4,6-dioxo-1H-pyrimidin-2-olate
DMJIA6T	DT	Small molecular drug
DMJIA6T	PC	6211
DMJIA6T	MW	128.09
DMJIA6T	FM	C4H4N2O3
DMJIA6T	IC	InChI=1S/C4H4N2O3/c7-2-1-3(8)6-4(9)5-2/h1H2,(H2,5,6,7,8,9)
DMJIA6T	CS	C1C(=O)NC(=O)NC1=O
DMJIA6T	IK	HNYOPLTXPVRDBG-UHFFFAOYSA-N
DMJIA6T	IU	1,3-diazinane-2,4,6-trione
DMJIA6T	CA	CAS 67-52-7
DMJIA6T	CB	CHEBI:16294
DMJIA6T	DE	Depression; Anaesthesia

DM4ONW5	ID	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	HS	Approved
DM4ONW5	SN	Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
DM4ONW5	CP	Incyte/Eli Lilly
DM4ONW5	DT	Small molecular drug
DM4ONW5	PC	44205240
DM4ONW5	MW	371.4
DM4ONW5	FM	C16H17N7O2S
DM4ONW5	IC	InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
DM4ONW5	CS	CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM4ONW5	IK	XUZMWHLSFXCVMG-UHFFFAOYSA-N
DM4ONW5	IU	2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DM4ONW5	CA	CAS 1187594-09-7
DM4ONW5	CB	CHEBI:95341
DM4ONW5	DE	Rheumatoid arthritis

DMWNRZT	ID	DMWNRZT
DMWNRZT	DN	Basiliximab
DMWNRZT	HS	Approved
DMWNRZT	SN	Simulect (TN)
DMWNRZT	CP	Norvatis Phamaceuticals Corporation
DMWNRZT	TC	Immunomodulatory Agents
DMWNRZT	DT	Monoclonal antibody
DMWNRZT	SQ	Basiliximab heavy chain: QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Basiliximab light chainQIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE
DMWNRZT	DE	Organ transplant rejection

DMU9C8F	ID	DMU9C8F
DMU9C8F	DN	Bavencio
DMU9C8F	HS	Approved
DMU9C8F	CP	EMD Serono Rockland, MA Pfizer New York, NY
DMU9C8F	DT	Monoclonal antibody
DMU9C8F	DE	Melanoma; Merkel cell carcinoma; Breast cancer; Gastric adenocarcinoma; Haematological malignancy; Head and neck cancer; Squamous cell carcinoma; Urothelial carcinoma; Colon cancer; Testicular cancer

DMLOS5R	ID	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	HS	Approved
DMLOS5R	SN	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS
DMLOS5R	CP	Bayer HealthCare Pharmaceuticals
DMLOS5R	DT	Small molecular drug
DMLOS5R	PC	135565596
DMLOS5R	MW	480.5
DMLOS5R	FM	C23H28N8O4
DMLOS5R	IC	InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)
DMLOS5R	CS	COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5
DMLOS5R	IK	MWYDSXOGIBMAET-UHFFFAOYSA-N
DMLOS5R	IU	2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide
DMLOS5R	CA	CAS 1032568-63-0
DMLOS5R	DE	Follicular lymphoma; Non-hodgkin lymphoma

DMY85QW	ID	DMY85QW
DMY85QW	DN	Bazedoxifene
DMY85QW	HS	Approved
DMY85QW	SN	Brilence; Conbriza; Viviant; Bazedoxifene acetate; TSE-424; WAY-140424; WAY-TES 424
DMY85QW	CP	Ligand Pharmaceuticals Inc
DMY85QW	DT	Small molecular drug
DMY85QW	PC	154257
DMY85QW	MW	470.6
DMY85QW	FM	C30H34N2O3
DMY85QW	IC	InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3
DMY85QW	CS	CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O
DMY85QW	IK	UCJGJABZCDBEDK-UHFFFAOYSA-N
DMY85QW	IU	1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
DMY85QW	CA	CAS 198481-32-2
DMY85QW	CB	CHEBI:135947
DMY85QW	DE	Osteopetrosis

DM1R5X4	ID	DM1R5X4
DM1R5X4	DN	Becaplermin
DM1R5X4	HS	Approved
DM1R5X4	SN	Regranex; Regranex (TN); Becaplermin (USAN/INN)
DM1R5X4	CP	Ortho-McNeil Pharmaceutical
DM1R5X4	TC	Antiulcer Agents
DM1R5X4	SQ	DB00102 sequence: SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT
DM1R5X4	DE	Diabetic complication

DMZPHIK	ID	DMZPHIK
DMZPHIK	DN	Beclomethasone
DMZPHIK	HS	Approved
DMZPHIK	SN	Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone
DMZPHIK	CP	Shire Pharmaceuticals
DMZPHIK	TC	Antiasthmatic Agents
DMZPHIK	DT	Small molecular drug
DMZPHIK	PC	20469
DMZPHIK	MW	408.9
DMZPHIK	FM	C22H29ClO5
DMZPHIK	IC	InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMZPHIK	CS	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C
DMZPHIK	IK	NBMKJKDGKREAPL-DVTGEIKXSA-N
DMZPHIK	IU	(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMZPHIK	CA	CAS 4419-39-0
DMZPHIK	CB	CHEBI:3001
DMZPHIK	DE	Allergic rhinitis; Asthma

DM3906J	ID	DM3906J
DM3906J	DN	Bedaquiline
DM3906J	HS	Approved
DM3906J	SN	SIRTURO (TN)
DM3906J	CP	Johnson & Johnson
DM3906J	DT	Small molecular drug
DM3906J	PC	5388906
DM3906J	MW	555.5
DM3906J	FM	C32H31BrN2O2
DM3906J	IC	InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1
DM3906J	CS	CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O
DM3906J	IK	QUIJNHUBAXPXFS-XLJNKUFUSA-N
DM3906J	IU	(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol
DM3906J	CA	CAS 843663-66-1
DM3906J	CB	CHEBI:72292
DM3906J	DE	Multi-drug resistant tuberculosis

DM8WCXM	ID	DM8WCXM
DM8WCXM	DN	Befunolol hci
DM8WCXM	HS	Approved
DM8WCXM	SN	Bentox (TN)
DM8WCXM	DT	Small molecular drug
DM8WCXM	PC	38286
DM8WCXM	MW	327.8
DM8WCXM	FM	C16H22ClNO4
DM8WCXM	IC	InChI=1S/C16H21NO4.ClH/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14;/h4-7,10,13,17,19H,8-9H2,1-3H3;1H
DM8WCXM	CS	CC(C)[NH2+]CC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O.[Cl-]
DM8WCXM	IK	TVVTWOGRPVJKDJ-UHFFFAOYSA-N
DM8WCXM	IU	[3-[(2-acetyl-1-benzofuran-7-yl)oxy]-2-hydroxypropyl]-propan-2-ylazanium;chloride
DM8WCXM	CA	CAS 39543-79-8
DM8WCXM	CB	CHEBI:31254
DM8WCXM	DE	Glaucoma/ocular hypertension

DMBT3AI	ID	DMBT3AI
DMBT3AI	DN	Belantamab mafodotin
DMBT3AI	HS	Approved
DMBT3AI	DT	Antibody drug conjugate
DMBT3AI	DE	Multiple myeloma

DMXLYQF	ID	DMXLYQF
DMXLYQF	DN	Belatacept
DMXLYQF	HS	Approved
DMXLYQF	SN	Nulojix (TN); Belatacept (USAN/INN)
DMXLYQF	CP	Bristol-Myers Squibb
DMXLYQF	SQ	sequence for belatacept: MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMXLYQF	DE	Kidney transplant rejection; Heart transplant rejection

DM3OBQF	ID	DM3OBQF
DM3OBQF	DN	Belimumab
DM3OBQF	HS	Approved
DM3OBQF	SN	Belimumab (USAN); LymphoStat-B; LymphoStat-B (TN)
DM3OBQF	CP	GSK
DM3OBQF	DT	Antibody
DM3OBQF	DE	Systemic lupus erythematosus

DM2RBWK	ID	DM2RBWK
DM2RBWK	DN	Belladonna
DM2RBWK	HS	Approved
DM2RBWK	DE	Colitis

DM3SRJZ	ID	DM3SRJZ
DM3SRJZ	DN	Belotecan hydrocholoride
DM3SRJZ	HS	Approved
DM3SRJZ	DE	Small-cell lung cancer

DM1CI9R	ID	DM1CI9R
DM1CI9R	DN	Bempedoic acid
DM1CI9R	HS	Approved
DM1CI9R	SN	ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-
DM1CI9R	CP	Esperion Therapeutics
DM1CI9R	DT	Small molecular drug
DM1CI9R	PC	10472693
DM1CI9R	MW	344.5
DM1CI9R	FM	C19H36O5
DM1CI9R	IC	InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)
DM1CI9R	CS	CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O
DM1CI9R	IK	HYHMLYSLQUKXKP-UHFFFAOYSA-N
DM1CI9R	IU	8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
DM1CI9R	CA	CAS 738606-46-7
DM1CI9R	CB	CHEBI:149601
DM1CI9R	DE	Cardiovascular disease; Familial hypercholesterolemia

DMH1M9B	ID	DMH1M9B
DMH1M9B	DN	Benazepril
DMH1M9B	HS	Approved
DMH1M9B	SN	Benazapril; Benazeprilum; Benzazepril; Benazepril Sandoz; Benazeprilum [Latin]; Forteekor [veterinary]; Benazepril (INN); Benazepril Sandoz (TN); Benazepril [INN:BAN]; Forteekor [veterinary] (TN); Fortekor (TN); Lotensin (TN); CGS-14824-A; [(3S)-3-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-({(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMH1M9B	CP	Norvatis Phamaceuticals Corporation
DMH1M9B	TC	Antihypertensive Agents
DMH1M9B	DT	Small molecular drug
DMH1M9B	PC	5362124
DMH1M9B	MW	424.5
DMH1M9B	FM	C24H28N2O5
DMH1M9B	IC	InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
DMH1M9B	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O
DMH1M9B	IK	XPCFTKFZXHTYIP-PMACEKPBSA-N
DMH1M9B	IU	2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMH1M9B	CA	CAS 86541-75-5
DMH1M9B	CB	CHEBI:3011
DMH1M9B	DE	Hypertension

DMFH15Z	ID	DMFH15Z
DMFH15Z	DN	Bendamustine hydrochloride
DMFH15Z	HS	Approved
DMFH15Z	SN	Treanda (TN)
DMFH15Z	CP	Cephalon
DMFH15Z	DT	Small molecular drug
DMFH15Z	PC	77082
DMFH15Z	MW	394.7
DMFH15Z	FM	C16H22Cl3N3O2
DMFH15Z	IC	InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H
DMFH15Z	CS	CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O.Cl
DMFH15Z	IK	ZHSKUOZOLHMKEA-UHFFFAOYSA-N
DMFH15Z	IU	4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrochloride
DMFH15Z	CA	CAS 3543-75-7
DMFH15Z	DE	leukaemia

DM7EVLC	ID	DM7EVLC
DM7EVLC	DN	Bendroflumethiazide
DM7EVLC	HS	Approved
DM7EVLC	SN	Aprinox; BHFT; Bendrofluazide; Bendroflumethazide; Bendroflumethiazidum; Bendroflumetiazida; Bendroflumetiazide; Bendrofumethiazide; Bentride; Benuron; Benzhydroflumethiazide; Benzydroflumethiazide; Benzylhydroflumethiazide; Benzylrodiuran; Berkozide; Bristuric; Bristuron; Centyl; Corzide; Flumersil; Flumesil; Intolex; Livesan; Naigaril; Nateretin; Naturetin; Naturine; Niagaril; Nikion; Orsile; Pluryl; Pluryle; Plusuril; Poliuron; Rauzide; Repicin; Salural; Salures; Sinesalin; Sodiuretic; Thiazidico; Urlea; Bendroflumethiazide [USP]; Bendroflumetiazide [DCIT]; Rautrax N; Relan beta; BL H368; FT 8; FT 81; Be 724-A; Bendroflumethiazidum [INN-Latin]; Bendroflumetiazida [INN-Spanish]; Benzy-rodiuran; NATURETIN-10; NATURETIN-5; Naturetin (TN); Neo-naclex; Neo-rontyl; Naturetin-2.5; Bendroflumethiazide (JAN/USP/INN); (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
DM7EVLC	CP	Crescent Pharmaceuticals
DM7EVLC	TC	Antihypertensive Agents
DM7EVLC	DT	Small molecular drug
DM7EVLC	PC	2315
DM7EVLC	MW	421.4
DM7EVLC	FM	C15H14F3N3O4S2
DM7EVLC	IC	InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
DM7EVLC	CS	C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2
DM7EVLC	IK	HDWIHXWEUNVBIY-UHFFFAOYSA-N
DM7EVLC	IU	3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DM7EVLC	CA	CAS 73-48-3
DM7EVLC	CB	CHEBI:3013
DM7EVLC	DE	High blood pressure

DM7P1J4	ID	DM7P1J4
DM7P1J4	DN	Benralizumab
DM7P1J4	HS	Approved
DM7P1J4	CP	AstraZeneca
DM7P1J4	DT	Monoclonal antibody
DM7P1J4	DE	Asthma; Chronic obstructive pulmonary disease

DMRVBWU	ID	DMRVBWU
DMRVBWU	DN	Bentazepam
DMRVBWU	HS	Approved
DMRVBWU	DT	Small molecular drug
DMRVBWU	PC	135412795
DMRVBWU	MW	296.4
DMRVBWU	FM	C17H16N2OS
DMRVBWU	IC	InChI=1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20)
DMRVBWU	CS	C1CCC2=C(C1)C3=C(S2)NC(=O)CN=C3C4=CC=CC=C4
DMRVBWU	IK	AIZFEOPQVZBNGH-UHFFFAOYSA-N
DMRVBWU	IU	5-phenyl-1,3,6,7,8,9-hexahydro-[1]benzothiolo[2,3-e][1,4]diazepin-2-one
DMRVBWU	CA	CAS 29462-18-8
DMRVBWU	CB	CHEBI:135252
DMRVBWU	DE	Anxiety disorder

DMF7EXL	ID	DMF7EXL
DMF7EXL	DN	Benzatropine
DMF7EXL	HS	Approved
DMF7EXL	SN	Benzatropina; Benzatropina [INN-Spanish]; Benzatropine; Benzatropinum; Benzatropinum [INN-Latin]; Benztropinum; Cobrentin; Cogentin; Cogentine; Akitan; Cogentinol; Tropine benzohydryl ether; benztropine; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 1NHL2J4X8K; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 86-13-5; CHEBI:3048; HSDB 3014; NCGC00159471-02; NK 02; UNII-1NHL2J4X8K
DMF7EXL	PC	1201549
DMF7EXL	MW	307.4
DMF7EXL	FM	C21H25NO
DMF7EXL	IC	GIJXKZJWITVLHI-YOFSQIOKSA-N
DMF7EXL	CS	CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMF7EXL	IK	1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20?
DMF7EXL	IU	(1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
DMF7EXL	CA	CAS 86-13-5
DMF7EXL	CB	CHEBI:3048
DMF7EXL	DE	Agitation/aggression

DMC3YUA	ID	DMC3YUA
DMC3YUA	DN	Benzbromarone
DMC3YUA	HS	Approved
DMC3YUA	SN	Acifugan; Azubromaron; Benzbromaron; Benzbromaronratiopharm; Benzbromaronum; Benzobromarona; Besuric; Desuric; Exurate; Harolan; Hipurik; Minuric; Narcaricin; Normurat; Uricovac; Urinorm; Uroleap; Aliud Brand of Benzbromarone; Benzbromaron AL; Benzbromaron ratiopharm; Benzbromarone Aliud Brand; Benzbromarone Heumann Brand; Benzbromarone Sanfer Brand; Benzbromarone ratiopharm Brand; Heumann Brand of Benzbromarone; Ratiopharm Brand of Benzbromarone; Sanfer Brand of Benzbromarone; Sanofi Winthrop Brand of Benzbromarone; L 2214; L2214; MJ 10061; NCI85433; AL, Benzbromaron; Benzbromaron-ratiopharm; Benzbromaronum [INN-Latin]; Benzobromarona [INN-Spanish]; L 2214-Labaz; L-2214; Uroleap (TN); Benzbromarone [USAN:INN:BAN]; Methanone, (3; Benzbromarone (JP15/USAN/INN); KETONE, 3,5-DIBROMO-4-HYDROXYPHENYL 2-ETHYL-3-BENZOFURANYL; Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl; (2-Ethyl-3-benzofuranyl)-(3,5-dibrom-4-hydroxyphenyl)keton; (3,5-Dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone; (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone; 2-Ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran; 3, 5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3,5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran; 3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-ETHYLBENZOFURAN
DMC3YUA	CP	Labaz Laboratories
DMC3YUA	DT	Small molecular drug
DMC3YUA	PC	2333
DMC3YUA	MW	424.1
DMC3YUA	FM	C17H12Br2O3
DMC3YUA	IC	InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3
DMC3YUA	CS	CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br
DMC3YUA	IK	WHQCHUCQKNIQEC-UHFFFAOYSA-N
DMC3YUA	IU	(3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone
DMC3YUA	CA	CAS 3562-84-3
DMC3YUA	CB	CHEBI:3023
DMC3YUA	DE	Gout

DMI18HW	ID	DMI18HW
DMI18HW	DN	Benzocaine
DMI18HW	HS	Approved
DMI18HW	SN	Aethoform; Americaine; Anaesthesin; Anaesthesinum; Anaesthin; Anestezin; Anesthesin; Anesthesine; Anesthone; Bensokain; Benzocaina; Benzocainum; Chloraseptic; Dermoplast; Ethoform; Ethoforme; Hurricaine; Identhesin; Keloform; Norcain; Norcaine; Norcainum; Orthesin; Otocain; Outgro; Parathesin; Parathesine; Solarcaine; Topcaine; Aethylium paraminobenzoicum; Amben ethyl ester; Anestezin [Russian]; Baby Anbesol; Benzocaine Acetate; Benzocaine Formate; Benzocaine Hydrobromide; Benzocaine Hydrochloride; Benzocaine Methanesulfonate; Ethyl PABA; Ethyl aminobenzoate; Ethylis aminobenzoas; Solu H; Acetate, Benzocaine; Anaesthan-syngala; Auralgan (TN); Benzocaina [INN-Spanish]; Benzocaine [INN:BAN]; Benzocainum [INN-Latin]; Ethyl 4-aminobenzoate; Ethyl 4-aminobenzoate hydrochloride; Ethyl aminobenzoate (JP15); Ethyl aminobenzoate (VAN); Ethyl p-aminobenzoate; Ethyl p-aminophenylcarboxylate; Ethylaminobenzoate-4; Ethylesterkyseliny p-aminobenzoove; Ethylester kyseliny p-aminobenzoove [Czech]; Formate, Benzocaine; Hydrobromide, Benzocaine; Hydrochloride, Benzocaine; Methanesulfonate, Benzocaine; Ora-jel; P-Aminobenzoic acid ethyl ester; P-Aminobenzoic ethyl ester; P-Carbethoxyaniline; P-Ethoxycarboxylic aniline; Parathesin (TN); AE-562/40377256; Benzocaine (USP/INN); ETHYL-P-AMINOBENZOATE; P-(Ethoxycarbonyl)aniline;P-Aminobenzoic acid, ethyl ester; Benzoic acid, amino-, ethyl ester; H-4-abz-oet; Benzoic acid, 4-amino-, ethyl ester; Benzoic acid, p-amino-, ethyl ester; Benzoic acid, 4-amino-, ethyl ester, hydrochloride; 112909_ALDRICH; 112909_SIAL; 4 Aminobenzoic Acid Ethyl Ester; 4-(Ethoxycarbonyl)aniline; 4-Aminobenzoic acid ethyl ester; 4-Aminobenzoic acid, ethyl ester; 4-Carbethoxyaniline; 4-amino-benzoic acid ethyl ester
DMI18HW	CP	Wyeth Pharmaceuticals
DMI18HW	TC	Anesthetics
DMI18HW	DT	Small molecular drug
DMI18HW	PC	2337
DMI18HW	MW	165.19
DMI18HW	FM	C9H11NO2
DMI18HW	IC	InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3
DMI18HW	CS	CCOC(=O)C1=CC=C(C=C1)N
DMI18HW	IK	BLFLLBZGZJTVJG-UHFFFAOYSA-N
DMI18HW	IU	ethyl 4-aminobenzoate
DMI18HW	CA	CAS 94-09-7
DMI18HW	CB	CHEBI:116735
DMI18HW	DE	Anaesthesia

DMKB9FI	ID	DMKB9FI
DMKB9FI	DN	Benzoic acid
DMKB9FI	HS	Approved
DMKB9FI	SN	Phenylformate; benzoate anion; Benzoic acid, ion(1-); 766-76-7; Benzeneformate; Tennplas; Phenylcarboxylate; Benzenemethanoate; Retarded BA; Benzenecarboxylate; Phenyl carboxylic acid; benzoic acid anion; Oracyclic acid; 4-Carboxybenzenide; Benzene formic acid; AC1Q1HDY; AC1Q22CA; AC1L18SS; GTPL4565; DTXSID4043771; CHEBI:16150; BDBM36181; CTK2H9612; WPYMKLBDIGXBTP-UHFFFAOYSA-M; STL483236; ZINC328578076; NCGC00247905-01; ZB000218; CJ-00025; LS-190261; 3230-EP2374454A1; 3230-EP2372017A1; 3230-EP2316825A1; 3230-EP2316457A1
DMKB9FI	DT	Small molecular drug
DMKB9FI	PC	243
DMKB9FI	MW	122.12
DMKB9FI	FM	C7H6O2
DMKB9FI	IC	InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)
DMKB9FI	CS	C1=CC=C(C=C1)C(=O)O
DMKB9FI	IK	WPYMKLBDIGXBTP-UHFFFAOYSA-N
DMKB9FI	IU	benzoic acid
DMKB9FI	CA	CAS 65-85-0
DMKB9FI	CB	CHEBI:30746
DMKB9FI	DE	Fungal infection

DM9U4FO	ID	DM9U4FO
DM9U4FO	DN	Benzonatate
DM9U4FO	HS	Approved
DM9U4FO	SN	Benzonatato; Benzonatatum; Benzononantin; Benzononatine; Exangit; Tesalon; Tessalin; Tessalon; Ventussin; Tessalon Perles; KM65; Benzonatato [INN-Spanish]; Benzonatatum [INN-Latin]; Tessalon Capsules (TN); Tessalon Perles (TN); Tessalon perles (TN); Tessalon-ciba; Ventussin-loz; Benzonatate (USP/INN); Benzonatate [USAN:INN:BAN];Nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; P-butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester; Polyethyleneglycol-p-n-butylaminobenzoate methyl ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [German]; Benzoic acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester (9CI); Benzoic acid, p-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)benzoate; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; 3,6,9,12,15,18,21,24,27-Nonaoxaoctacos-1-yl 4-(butylamino)benzoate; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester
DM9U4FO	TC	Antitussives
DM9U4FO	DT	Small molecular drug
DM9U4FO	PC	7699
DM9U4FO	MW	603.7
DM9U4FO	FM	C30H53NO11
DM9U4FO	IC	InChI=1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3
DM9U4FO	CS	CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC
DM9U4FO	IK	MAFMQEKGGFWBAB-UHFFFAOYSA-N
DM9U4FO	IU	2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate
DM9U4FO	CA	CAS 104-31-4
DM9U4FO	CB	CHEBI:3032
DM9U4FO	DE	Cough

DMIJATC	ID	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	HS	Approved
DMIJATC	SN	Benzaphetamine; Benzfetamina; Benzfetamine; Benzfetaminum; Benzofetamina; Benzphetaminum; Benzylamphetamine; Benzfetamina [DCIT]; Benzfetamina [Spanish]; Benzfetaminum [Latin]; U 0441; Benzfetamina [INN-Spanish]; Benzfetamine (INN); Benzfetamine [INN:BAN]; Benzfetaminum [INN-Latin]; Benzofetamina [INN-Spanish]; Benzphetaminum [INN-Latin]; D-Benzphetamine; Didrex (TN); N-Benzylmethamphetamin; N-Benzyl-N,alpha-dimethylphenethylamine; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; N-Benzyl-N-methyl-1-phenyl-2-propanamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-(9CI); (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; (+)-benzphetamine; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; (S)-(+)-benzphetamine; (S)-benzphetamine; (alphaS)-N,alpha-dimethylphenethylamine
DMIJATC	CP	Pharmacia
DMIJATC	DT	Small molecular drug
DMIJATC	PC	5311017
DMIJATC	MW	239.35
DMIJATC	FM	C17H21N
DMIJATC	IC	InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
DMIJATC	CS	C[C@@H](CC1=CC=CC=C1)N(C)CC2=CC=CC=C2
DMIJATC	IK	YXKTVDFXDRQTKV-HNNXBMFYSA-N
DMIJATC	IU	(2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine
DMIJATC	CA	CAS 156-08-1
DMIJATC	CB	CHEBI:3044
DMIJATC	DE	Obesity

DMU4D5Y	ID	DMU4D5Y
DMU4D5Y	DN	Benzquinamide
DMU4D5Y	HS	Approved
DMU4D5Y	SN	Benzchinamid; Benzchinamide; Benzchinamidum; Benzochinamide; Benzoquinamida; Benzoquinamide; Benzquinamid; Benzquinamida; Benzquinamidum; Emeticon; Promecon; Quantril; Quantryl; P 2647; Benzoquinamida [INN-Spanish]; Benzquinamide (USAN); Benzquinamidum [INN-Latin]; Emete-con; P-2647; Benzquinamide [USAN:INN:BAN]; [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamideacetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); N,N-Diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); 2-(Acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide; 2-(acetoxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-Acetoxy-3-(N,N-diethylcarboxamido)-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzopyridocoline; 2-Acetoxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11b-benzo(a)quinolizine; 2-Hydroxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzoquinolizine acetate; 2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-, (2alpha,3beta,11balpha)-(9CI); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo[a]quinolizine-3-carboxamide, N,N-diethyl-1,3.alpha.,4,6,7,11b.beta.-hexahydro-2.beta.-hydroxy-9,10-dimethoxy-, acetate (ester); 3-(diethylcarbamoyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate; 3-Diethylcarbamoyl-2,3,4,6,7,11b-hexahydro-9,10-dimethoxy-1H-benzo(a)chinolizin-2-yl acetat; 3-[(diethylamino)carbonyl]-9,10-bis(methyloxy)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate
DMU4D5Y	TC	Antiemetics
DMU4D5Y	DT	Small molecular drug
DMU4D5Y	PC	2342
DMU4D5Y	MW	404.5
DMU4D5Y	FM	C22H32N2O5
DMU4D5Y	IC	InChI=1S/C22H32N2O5/c1-6-23(7-2)22(26)17-13-24-9-8-15-10-20(27-4)21(28-5)11-16(15)18(24)12-19(17)29-14(3)25/h10-11,17-19H,6-9,12-13H2,1-5H3
DMU4D5Y	CS	CCN(CC)C(=O)C1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C)OC)OC
DMU4D5Y	IK	JSZILQVIPPROJI-UHFFFAOYSA-N
DMU4D5Y	IU	[3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate
DMU4D5Y	CA	CAS 63-12-7
DMU4D5Y	CB	CHEBI:27662
DMU4D5Y	DE	Nausea

DMQWZ0H	ID	DMQWZ0H
DMQWZ0H	DN	Benzthiazide
DMQWZ0H	HS	Approved
DMQWZ0H	SN	Aquapres; Aquasec; Aquatag; Benzothiazide; Benzotiazida; Benzthazide; Benzthiazidum; Benztiazide; Dihydrex; Diucen;Diucene; Edemex; Exna; Exosalt; Fouane; Fovane; Freeuril; HyDrine; Lemazide; Proaqua; Regulon; Urazide; Urese; Benztiazide [DCIT]; P 1393; Pfizer 1393; Aqua-Scrip; Aquatag (TN); Benzotiazida [INN-Spanish]; Benzthiazidum [INN-Latin]; Dihydrex (TN); Diucen (TN); Edemax (TN); Exna (TN); Foven (TN); Hy-drine; Pro-aqua; Rid-ema; S-Aqua; Benzthiazide (JAN/INN); Benzthiazide [USAN:INN:BAN]; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)menthyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)methyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(((phenylmethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-[[(phenylmethyl)thio]methyl]-, 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine-1,1-dioxide; 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1; 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 3-[(Benzylsulfanyl)methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(((phenylmethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide; 6-chloro-3-{[(phenylmethyl)thio]methyl}-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMQWZ0H	TC	Antihypertensive Agents
DMQWZ0H	DT	Small molecular drug
DMQWZ0H	PC	2343
DMQWZ0H	MW	431.9
DMQWZ0H	FM	C15H14ClN3O4S3
DMQWZ0H	IC	InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)
DMQWZ0H	CS	C1=CC=C(C=C1)CSCC2=NS(=O)(=O)C3=CC(=C(C=C3N2)Cl)S(=O)(=O)N
DMQWZ0H	IK	NDTSRXAMMQDVSW-UHFFFAOYSA-N
DMQWZ0H	IU	3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMQWZ0H	CA	CAS 91-33-8
DMQWZ0H	CB	CHEBI:3047
DMQWZ0H	DE	High blood pressure

DMGZOVN	ID	DMGZOVN
DMGZOVN	DN	Benztropine
DMGZOVN	HS	Approved
DMGZOVN	SN	Akitan; Benzatropina; Benzatropine; Benzatropinum; Benztropinum; Cobrentin; Cogentine; Cogentinol; Benzatropine [INN]; Benzatropine mesilate; Pms Benztropine; Tropine benzohydryl ether; NK 02; Apo-Benztropine; Benzatropina [INN-Spanish]; Benzatropine (INN); Benzatropine [INN:BAN]; Benzatropinum [INN-Latin]; Cogentin (TN); Benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether; (1R,5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; (1r,5r)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-[(diphenylmethyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane; (5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo-(9CI)
DMGZOVN	CP	Oak Pharmaceuticals Inc Sub Akorn Inc
DMGZOVN	TC	Antiparkinson Agents
DMGZOVN	DT	Small molecular drug
DMGZOVN	PC	1201549
DMGZOVN	MW	307.4
DMGZOVN	FM	C21H25NO
DMGZOVN	IC	InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20?
DMGZOVN	CS	CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMGZOVN	IK	GIJXKZJWITVLHI-YOFSQIOKSA-N
DMGZOVN	IU	(1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
DMGZOVN	CA	CAS 86-13-5
DMGZOVN	CB	CHEBI:3048
DMGZOVN	DE	Parkinson disease

DMBVYDI	ID	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	HS	Approved
DMBVYDI	SN	Ulesfia (TN)
DMBVYDI	CP	Sciele Pharma
DMBVYDI	DT	Small molecular drug
DMBVYDI	PC	244
DMBVYDI	MW	108.14
DMBVYDI	FM	C7H8O
DMBVYDI	IC	InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2
DMBVYDI	CS	C1=CC=C(C=C1)CO
DMBVYDI	IK	WVDDGKGOMKODPV-UHFFFAOYSA-N
DMBVYDI	IU	phenylmethanol
DMBVYDI	CA	CAS 100-51-6
DMBVYDI	CB	CHEBI:17987
DMBVYDI	DE	Head and body lice

DMDPYI5	ID	DMDPYI5
DMDPYI5	DN	Benzyl benzoate
DMDPYI5	HS	Approved
DMDPYI5	SN	BENZYL BENZOATE; 120-51-4; Benylate; Ascabiol; Novoscabin; Benzoic acid, phenylmethyl ester; Benzoic acid benzyl ester; Scobenol; Scabitox; Ascabin; Benzyl phenylformate; Phenylmethyl benzoate; Scabiozon; Scabagen; Peruscabin; Colebenz; Scabanca; Benzylets; Benzoic acid, benzyl ester; Vanzoate; Scabide; Benzyl benzenecarboxylate; benzylbenzoate; Antiscabiosum; Benzylis benzoas; Benzyl alcohol benzoic ester; Peruscabina; Venzonate; Spasmodin; Benzylum benzoicum; Benzylester kyseliny benzoove; Benzoesaeurebenzylester; Caswell No. 082
DMDPYI5	DT	Small molecular drug
DMDPYI5	PC	2345
DMDPYI5	MW	212.24
DMDPYI5	FM	C14H12O2
DMDPYI5	IC	InChI=1S/C14H12O2/c15-14(13-9-5-2-6-10-13)16-11-12-7-3-1-4-8-12/h1-10H,11H2
DMDPYI5	CS	C1=CC=C(C=C1)COC(=O)C2=CC=CC=C2
DMDPYI5	IK	SESFRYSPDFLNCH-UHFFFAOYSA-N
DMDPYI5	IU	benzyl benzoate
DMDPYI5	CA	CAS 120-51-4
DMDPYI5	CB	CHEBI:41237
DMDPYI5	DE	Infestations of lice and scabies

DMQHM2D	ID	DMQHM2D
DMQHM2D	DN	Benzylpenicilloyl Polylysine
DMQHM2D	HS	Approved
DMQHM2D	SN	Benzylpenicilloyl; Benzylpenicilloyl G; Benzylpenicilloyl G polylysine; Benzylpenicilloyl-polylysine; Penicilloyl-polylysine; 2-(2-((5-Carboxypentyl)amino)-2-oxo-1-((phenylacetyl)amino)ethyl)-5,5-dimethyl-4-thiazolidinecarboxylic acid; 2-[2-[(6-hydroxy-6-oxohexyl)amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
DMQHM2D	TC	Analgesics
DMQHM2D	DT	Small molecular drug
DMQHM2D	PC	45266800
DMQHM2D	MW	626.8
DMQHM2D	FM	C28H46N6O8S
DMQHM2D	IC	InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1
DMQHM2D	CS	CC1([C@@H](N[C@H](S1)C(C(=O)NCCCC[C@H](C(=O)O)N)NC(=O)CC2=CC=CC=C2)C(=O)O)C.C(CCN)C[C@H](C(=O)O)N
DMQHM2D	IK	IMPVZRLKKKXMKQ-SGDOCVTFSA-N
DMQHM2D	IU	(2R,4S)-2-[2-[[(5R)-5-amino-5-carboxypentyl]amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid;(2R)-2,6-diaminohexanoic acid
DMQHM2D	CA	CAS 31855-75-1
DMQHM2D	CB	CHEBI:59297
DMQHM2D	DE	Bacterial infection

DMXDZAQ	ID	DMXDZAQ
DMXDZAQ	DN	Bepotastine
DMXDZAQ	HS	Approved
DMXDZAQ	SN	Betotastine; Tau 284; TAU-284DS; Talion (TN); (S)-4-(4-((4-Chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid; 4-((4-Chlorophenyl)-2-pyridinylmethoxy)-1-piperidinebutanoic acid; 4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
DMXDZAQ	CP	Tanabe Seiyaku Co
DMXDZAQ	TC	Antiallergic Agents
DMXDZAQ	DT	Small molecular drug
DMXDZAQ	PC	164522
DMXDZAQ	MW	388.9
DMXDZAQ	FM	C21H25ClN2O3
DMXDZAQ	IC	InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)/t21-/m0/s1
DMXDZAQ	CS	C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O
DMXDZAQ	IK	YWGDOWXRIALTES-NRFANRHFSA-N
DMXDZAQ	IU	4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
DMXDZAQ	CA	CAS 125602-71-3
DMXDZAQ	CB	CHEBI:71204
DMXDZAQ	DE	Allergic rhinitis

DM0RKS4	ID	DM0RKS4
DM0RKS4	DN	Bepridil
DM0RKS4	HS	Approved
DM0RKS4	SN	Bepadin; Vascor; CERM 1978; Bepadin (TN); Bepridil (INN); Vascor (TN); N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; Beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline
DM0RKS4	TC	Antiarrhythmic Agents
DM0RKS4	DT	Small molecular drug
DM0RKS4	PC	2351
DM0RKS4	MW	366.5
DM0RKS4	FM	C24H34N2O
DM0RKS4	IC	InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
DM0RKS4	CS	CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3
DM0RKS4	IK	UIEATEWHFDRYRU-UHFFFAOYSA-N
DM0RKS4	IU	N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline
DM0RKS4	CA	CAS 64706-54-3
DM0RKS4	CB	CHEBI:3061
DM0RKS4	DE	Chronic/stable angina

DMEBY2D	ID	DMEBY2D
DMEBY2D	DN	Beriplast-P
DMEBY2D	HS	Approved
DMEBY2D	SN	Fibrin sealant, Aventis Behring
DMEBY2D	CP	Aventis Behring LLC
DMEBY2D	DE	Wound healing

DMWA2DZ	ID	DMWA2DZ
DMWA2DZ	DN	Berotralstat
DMWA2DZ	HS	Approved
DMWA2DZ	SN	UNII-XZA0KB1BDQ; XZA0KB1BDQ; 1809010-50-1; BCX7353; BCX-7353; Berotralstat (USAN); Berotralstat [USAN]; 1-[3-(aminomethyl)phenyl]-N-(5-{(R)-(3-; cyanophenyl)[(cyclopropylmethyl)amino]methyl}-2-; fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-; Orladeyo; Berotralstat [INN]; Berotralstat [USAN:INN]; SCHEMBL21974728; GTPL11347; WHO 10907; D11673; 1-(3-(Aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1H-pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl); 1H-Pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-; 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMWA2DZ	CP	BioCryst Pharmaceuticals
DMWA2DZ	DT	Small molecular drug
DMWA2DZ	PC	137528262
DMWA2DZ	MW	562.6
DMWA2DZ	FM	C30H26F4N6O
DMWA2DZ	IC	InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1
DMWA2DZ	CS	C1CC1CN[C@@H](C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N
DMWA2DZ	IK	UXNXMBYCBRBRFD-MUUNZHRXSA-N
DMWA2DZ	IU	2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMWA2DZ	CA	CAS 1809010-50-1
DMWA2DZ	DE	Hereditary angioedema

DMPHXMI	ID	DMPHXMI
DMPHXMI	DN	Besifloxacin
DMPHXMI	HS	Approved
DMPHXMI	SN	Besivance (TN)
DMPHXMI	CP	Bausch & Lomb
DMPHXMI	DT	Small molecular drug
DMPHXMI	PC	10178705
DMPHXMI	MW	393.8
DMPHXMI	FM	C19H21ClFN3O3
DMPHXMI	IC	InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1
DMPHXMI	CS	C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F
DMPHXMI	IK	QFFGVLORLPOAEC-SNVBAGLBSA-N
DMPHXMI	IU	7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMPHXMI	CA	CAS 141388-76-3
DMPHXMI	CB	CHEBI:135622
DMPHXMI	DE	Ocular inflammation

DM8L9D4	ID	DM8L9D4
DM8L9D4	DN	Bestatin
DM8L9D4	HS	Approved
DM8L9D4	SN	Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid
DM8L9D4	DT	Small molecular drug
DM8L9D4	PC	72172
DM8L9D4	MW	308.37
DM8L9D4	FM	C16H24N2O4
DM8L9D4	IC	InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1
DM8L9D4	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O
DM8L9D4	IK	VGGGPCQERPFHOB-RDBSUJKOSA-N
DM8L9D4	IU	(2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid
DM8L9D4	CA	CAS 58970-76-6
DM8L9D4	DE	Acute myeloid leukaemia

DMI6GKT	ID	DMI6GKT
DMI6GKT	DN	Beta-acetyldigoxin
DMI6GKT	HS	Approved
DMI6GKT	SN	Novodigal (TN)
DMI6GKT	DT	Small molecular drug
DMI6GKT	PC	10350481
DMI6GKT	MW	823
DMI6GKT	FM	C43H66O15
DMI6GKT	IC	InChI=1S/C43H66O15/c1-20-38(55-23(4)44)30(45)17-36(53-20)57-40-22(3)54-37(18-32(40)47)58-39-21(2)52-35(16-31(39)46)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(48)42(6)27(10-12-43(28,42)50)24-13-34(49)51-19-24/h13,20-22,25-33,35-40,45-48,50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1
DMI6GKT	CS	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)OC(=O)C)O)O
DMI6GKT	IK	NREAGDHHMSOWKZ-DXJNJSHLSA-N
DMI6GKT	IU	[(2R,3S,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl] acetate
DMI6GKT	CA	CAS 5355-48-6
DMI6GKT	CB	CHEBI:135892
DMI6GKT	DE	Cardiovascular disease

DM0RXBT	ID	DM0RXBT
DM0RXBT	DN	Beta-carotene
DM0RXBT	HS	Approved
DM0RXBT	SN	beta-carotene; 7235-40-7; beta Carotene; beta,beta-Carotene; Betacarotene; Provitamin A; Solatene; Carotaben; Provatene; all-trans-beta-Carotene; Serlabo; Natural Yellow 26; Karotin; KPMK; C.I. Food Orange 5; Solatene (caps); Karotin [Czech]; Food orange 5; Zlut prirodni 26; Betacarotenum [Latin]; Betacaroteno [Spanish]; Lucaratin; BetaVit; beta-Karotin; beta-Carotin; beta;-Carotene; beta-Carotene, all-trans-; .beta. Carotene; .beta.-Carotene; Betacarotenum [INN-Latin]; C.I. 75130; Betacaroteno [INN-Spanish]; Zlut prirodni 26 [Czech]
DM0RXBT	DT	Small molecular drug
DM0RXBT	PC	5280489
DM0RXBT	MW	536.9
DM0RXBT	FM	C40H56
DM0RXBT	IC	InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+
DM0RXBT	CS	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(CCCC2(C)C)C)\\C)\\C)/C)/C
DM0RXBT	IK	OENHQHLEOONYIE-JLTXGRSLSA-N
DM0RXBT	IU	1,3,3-trimethyl-2-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene
DM0RXBT	CA	CAS 7235-40-7
DM0RXBT	CB	CHEBI:17579
DM0RXBT	DE	Vitamin deficiency

DMGRZW2	ID	DMGRZW2
DMGRZW2	DN	Betaine
DMGRZW2	HS	Approved
DMGRZW2	SN	Cystadane
DMGRZW2	CP	Rare Disease Therapeutics Inc
DMGRZW2	DT	Small molecular drug
DMGRZW2	PC	247
DMGRZW2	MW	117.15
DMGRZW2	FM	C5H11NO2
DMGRZW2	IC	InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3
DMGRZW2	CS	C[N+](C)(C)CC(=O)[O-]
DMGRZW2	IK	KWIUHFFTVRNATP-UHFFFAOYSA-N
DMGRZW2	IU	2-(trimethylazaniumyl)acetate
DMGRZW2	CA	CAS 107-43-7
DMGRZW2	CB	CHEBI:17750
DMGRZW2	DE	Inborn error of metabolism

DMAHJEF	ID	DMAHJEF
DMAHJEF	DN	Betamethasone
DMAHJEF	HS	Approved
DMAHJEF	SN	betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate
DMAHJEF	TC	Antiinflammatory Agents
DMAHJEF	DT	Small molecular drug
DMAHJEF	PC	9782
DMAHJEF	MW	392.5
DMAHJEF	FM	C22H29FO5
DMAHJEF	IC	InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMAHJEF	CS	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
DMAHJEF	IK	UREBDLICKHMUKA-DVTGEIKXSA-N
DMAHJEF	IU	(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMAHJEF	CA	CAS 378-44-9
DMAHJEF	CB	CHEBI:3077
DMAHJEF	DE	Inflammation

DMRMS1A	ID	DMRMS1A
DMRMS1A	DN	Betamethasone Benzoate
DMRMS1A	HS	Approved
DMRMS1A	SN	Uticort
DMRMS1A	CP	Parke Davis Div Warner Lambert Co
DMRMS1A	DT	Small molecular drug
DMRMS1A	PC	5282492
DMRMS1A	MW	496.6
DMRMS1A	FM	C29H33FO6
DMRMS1A	IC	InChI=1S/C29H33FO6/c1-17-13-22-21-10-9-19-14-20(32)11-12-26(19,2)28(21,30)23(33)15-27(22,3)29(17,24(34)16-31)36-25(35)18-7-5-4-6-8-18/h4-8,11-12,14,17,21-23,31,33H,9-10,13,15-16H2,1-3H3/t17-,21-,22-,23-,26-,27-,28-,29-/m0/s1
DMRMS1A	CS	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)OC(=O)C5=CC=CC=C5)C)O)F)C
DMRMS1A	IK	SOQJPQZCPBDOMF-YCUXZELOSA-N
DMRMS1A	IU	[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] benzoate
DMRMS1A	CA	CAS 22298-29-9
DMRMS1A	CB	CHEBI:135798
DMRMS1A	DE	Inflammation

DMMIAXO	ID	DMMIAXO
DMMIAXO	DN	Betamethasone valerate
DMMIAXO	HS	Approved
DMMIAXO	SN	Beta-val; Betaderm; Betatrex; Dermabet; Valnac
DMMIAXO	CP	Schering Corp Sub Schering Plough Corp
DMMIAXO	DT	Small molecular drug
DMMIAXO	PC	16533
DMMIAXO	MW	476.6
DMMIAXO	FM	C27H37FO6
DMMIAXO	IC	InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1
DMMIAXO	CS	CCCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CO
DMMIAXO	IK	SNHRLVCMMWUAJD-SUYDQAKGSA-N
DMMIAXO	IU	[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate
DMMIAXO	CA	CAS 2152-44-5
DMMIAXO	CB	CHEBI:31277
DMMIAXO	DE	Dermatological disease

DM6EUL5	ID	DM6EUL5
DM6EUL5	DN	Betaxolol
DM6EUL5	HS	Approved
DM6EUL5	SN	Betaxololum; Betazolol; KERLEDEX; Kerlone; Betaxolol HCL; SL 75212; Betaxolol (INN); Betaxolol (TN); Betaxolol [INN:BAN]; Betaxololum [INN-Latin]; Betoptic (TN); Betoptic S (TN); Kerlone (TN); Lokren (TN); SL-75212; ALO-1401-02; (+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol
DM6EUL5	CP	Lorex Pharmaceuticals
DM6EUL5	TC	Antihypertensive Agents
DM6EUL5	DT	Small molecular drug
DM6EUL5	PC	2369
DM6EUL5	MW	307.4
DM6EUL5	FM	C18H29NO3
DM6EUL5	IC	InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
DM6EUL5	CS	CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O
DM6EUL5	IK	NWIUTZDMDHAVTP-UHFFFAOYSA-N
DM6EUL5	IU	1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
DM6EUL5	CA	CAS 63659-18-7
DM6EUL5	CB	CHEBI:3082
DM6EUL5	DE	Hypertension

DMUFGAY	ID	DMUFGAY
DMUFGAY	DN	Betazole
DMUFGAY	HS	Approved
DMUFGAY	SN	Ametazole; Betazol; Betazolo; Betazolum; Betazole [INN]; Betazolo [DCIT]; Lilly 96791; Betazol [INN-Spanish]; Betazolum [INN-Latin]; 1H-Pyrazole-3-ethanamine; 2-(1H-Pyrazol-3-yl)ethanamine; 2-(1H-pyrazol-5-yl)ethanamine; 2-(3-Pyrazolyl)ethylamine; 3-(2-Aminoethyl)pyrazole; 3-(beta-aminoethyl)pyrazole
DMUFGAY	CP	Eli Lilly And Co
DMUFGAY	TC	Antihistamines
DMUFGAY	DT	Small molecular drug
DMUFGAY	PC	7741
DMUFGAY	MW	111.15
DMUFGAY	FM	C5H9N3
DMUFGAY	IC	InChI=1S/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8)
DMUFGAY	CS	C1=C(NN=C1)CCN
DMUFGAY	IK	JXDFEQONERDKSS-UHFFFAOYSA-N
DMUFGAY	IU	2-(1H-pyrazol-5-yl)ethanamine
DMUFGAY	CA	CAS 105-20-4
DMUFGAY	CB	CHEBI:59170
DMUFGAY	DE	Gastric secretory disorder

DMCLHO0	ID	DMCLHO0
DMCLHO0	DN	Bethanechol
DMCLHO0	HS	Approved
DMCLHO0	SN	Amidopropyldimethylbetaine; Bethanecol; Urabeth; Myotonine chloride; Duvoid (TN); Myotonachol (TN); Urecholine (TN); Carbamoyl-beta-methylcholine; Carbamyl-beta-methylcholine; Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester); (2-Hydroxypropyl)trimethylammonium carbamate; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-(9CI); 2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; 2-carbamoyloxypropyl(trimethyl)azanium; 2-carbamoyloxypropyl-trimethylazanium
DMCLHO0	CP	Merck & Co
DMCLHO0	TC	Parasympathomimetics
DMCLHO0	DT	Small molecular drug
DMCLHO0	PC	2370
DMCLHO0	MW	161.22
DMCLHO0	FM	C7H17N2O2+
DMCLHO0	IC	InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1
DMCLHO0	CS	CC(C[N+](C)(C)C)OC(=O)N
DMCLHO0	IK	NZUPCNDJBJXXRF-UHFFFAOYSA-O
DMCLHO0	IU	2-carbamoyloxypropyl(trimethyl)azanium
DMCLHO0	CA	CAS 674-38-4
DMCLHO0	CB	CHEBI:3084
DMCLHO0	DE	Urinary retention

DM2C4RF	ID	DM2C4RF
DM2C4RF	DN	Betrixaban
DM2C4RF	HS	Approved
DM2C4RF	SN	Betrixaban; 330942-05-7; Bevyxxa; PRT054021; UNII-74RWP7W0J9; PRT 054021; 74RWP7W0J9; betrixaban maleate; Betrixaban [USAN:INN]; betrixaban/; Betrixaban (USAN); D0J0BU; SCHEMBL158591; QCR-99; GTPL9602; EX-A358; MolPort-009-682-948; ZINC3
DM2C4RF	CP	Portola Pharmaceuticals
DM2C4RF	DT	Small molecular drug
DM2C4RF	PC	10275777
DM2C4RF	MW	451.9
DM2C4RF	FM	C23H22ClN5O3
DM2C4RF	IC	InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)
DM2C4RF	CS	CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl
DM2C4RF	IK	XHOLNRLADUSQLD-UHFFFAOYSA-N
DM2C4RF	IU	N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
DM2C4RF	CA	CAS 330942-05-7
DM2C4RF	CB	CHEBI:140421
DM2C4RF	DE	Venous thromboembolism; Cerebrovascular ischaemia

DMSD1UN	ID	DMSD1UN
DMSD1UN	DN	Bevacizumab
DMSD1UN	HS	Approved
DMSD1UN	SN	Bevacizumab (ophthalmic slow-release tissue tablet)
DMSD1UN	CP	University of London
DMSD1UN	DT	Monoclonal antibody
DMSD1UN	SQ	Bevacizumab light chain: DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>    <sequence format="FASTA">&gt;"Bevacizumab heavy chain"EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMSD1UN	DE	Solid tumour/cancer; Colorectal cancer; Lung cancer; Metastatic colorectal cancer; Brain metastases; Ovarian cancer

DMZFICR	ID	DMZFICR
DMZFICR	DN	Bevantolol
DMZFICR	HS	Approved
DMZFICR	SN	Bevantololum; Bevantolol [INN:BAN]; Bevantololum [INN-Latin]; (+-)-bevantolol; 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol; 1-(3,4-dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol; 1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
DMZFICR	TC	Antihypertensive Agents
DMZFICR	DT	Small molecular drug
DMZFICR	PC	2372
DMZFICR	MW	345.4
DMZFICR	FM	C20H27NO4
DMZFICR	IC	InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
DMZFICR	CS	CC1=CC(=CC=C1)OCC(CNCCC2=CC(=C(C=C2)OC)OC)O
DMZFICR	IK	HXLAFSUPPDYFEO-UHFFFAOYSA-N
DMZFICR	IU	1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol
DMZFICR	CA	CAS 59170-23-9
DMZFICR	CB	CHEBI:238698
DMZFICR	DE	Hypertension

DMOBIKY	ID	DMOBIKY
DMOBIKY	DN	Bexarotene
DMOBIKY	HS	Approved
DMOBIKY	SN	Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA
DMOBIKY	CP	Eisai Inc
DMOBIKY	TC	Anticancer Agents
DMOBIKY	DT	Small molecular drug
DMOBIKY	PC	82146
DMOBIKY	MW	348.5
DMOBIKY	FM	C24H28O2
DMOBIKY	IC	InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
DMOBIKY	CS	CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
DMOBIKY	IK	NAVMQTYZDKMPEU-UHFFFAOYSA-N
DMOBIKY	IU	4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
DMOBIKY	CA	CAS 153559-49-0
DMOBIKY	CB	CHEBI:50859
DMOBIKY	DE	Cutaneous T-cell lymphoma

DMZDCS0	ID	DMZDCS0
DMZDCS0	DN	Bezafibrate
DMZDCS0	HS	Approved
DMZDCS0	SN	Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
DMZDCS0	TC	Antilipemic Agents
DMZDCS0	DT	Small molecular drug
DMZDCS0	PC	39042
DMZDCS0	MW	361.8
DMZDCS0	FM	C19H20ClNO4
DMZDCS0	IC	InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
DMZDCS0	CS	CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
DMZDCS0	IK	IIBYAHWJQTYFKB-UHFFFAOYSA-N
DMZDCS0	IU	2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
DMZDCS0	CA	CAS 41859-67-0
DMZDCS0	CB	CHEBI:47612
DMZDCS0	DE	Hyperlipidaemia

DMTZC5G	ID	DMTZC5G
DMTZC5G	DN	Bezlotoxumab
DMTZC5G	HS	Approved
DMTZC5G	SN	CDB1; Clostridium difficile toxin B monoclonal antibody; MBL-CDB1; MDX-1388; MK 6072; Zinplava
DMTZC5G	CP	Merck & Co.
DMTZC5G	DT	Monoclonal antibody
DMTZC5G	DE	C. difficile infection

DMTKD7Q	ID	DMTKD7Q
DMTKD7Q	DN	BIBW 2992
DMTKD7Q	HS	Approved
DMTKD7Q	SN	Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens
DMTKD7Q	CP	Boehringer Ingelheim
DMTKD7Q	DT	Small molecular drug
DMTKD7Q	PC	10184653
DMTKD7Q	MW	485.9
DMTKD7Q	FM	C24H25ClFN5O3
DMTKD7Q	IC	InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
DMTKD7Q	CS	CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4
DMTKD7Q	IK	ULXXDDBFHOBEHA-CWDCEQMOSA-N
DMTKD7Q	IU	(E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
DMTKD7Q	CA	CAS 850140-72-6
DMTKD7Q	CB	CHEBI:61390
DMTKD7Q	DE	Non-small-cell lung cancer

DMZMSPF	ID	DMZMSPF
DMZMSPF	DN	Bicalutamide
DMZMSPF	HS	Approved
DMZMSPF	SN	Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
DMZMSPF	CP	AstraZeneca plc
DMZMSPF	TC	Anticancer Agents
DMZMSPF	DT	Small molecular drug
DMZMSPF	PC	2375
DMZMSPF	MW	430.4
DMZMSPF	FM	C18H14F4N2O4S
DMZMSPF	IC	InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
DMZMSPF	CS	CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
DMZMSPF	IK	LKJPYSCBVHEWIU-UHFFFAOYSA-N
DMZMSPF	IU	N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
DMZMSPF	CA	CAS 90357-06-5
DMZMSPF	CB	CHEBI:91617
DMZMSPF	DE	Prostate cancer

DMG0H8K	ID	DMG0H8K
DMG0H8K	DN	Bictegravir, emtricitabine and tenofovir alafenamide
DMG0H8K	HS	Approved
DMG0H8K	SN	S900007760; Bictegravir mixture with emtricitabine and tenofovir alafenamide
DMG0H8K	CP	Gilead Sciences
DMG0H8K	PC	129626368
DMG0H8K	MW	1173.1
DMG0H8K	FM	C50H57F4N12O13PS
DMG0H8K	IC	InChI=1S/C21H18F3N3O5.C21H29N6O5P.C8H10FN3O3S/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28;1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30);5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1,5-6,13H,2-3H2,(H2,10,11,14)/t10-,11+,16+;15-,16+,33+;5-,6+/m010/s1
DMG0H8K	CS	C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3.C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F.C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
DMG0H8K	IK	GMIGIKGMWTUBHA-UKQLQXPXSA-N
DMG0H8K	IU	4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide;propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMG0H8K	DE	Human immunodeficiency virus infection

DM3KN7V	ID	DM3KN7V
DM3KN7V	DN	Bifonazole
DM3KN7V	HS	Approved
DM3KN7V	SN	Amycor; Azolmen; Bifokey; Bifomyk; Bifon; Bifonazol; Bifonazolum; Moldina; Mycospor; Trifonazole; Bayer brand of bifonazole; Bioglan brand of bifonazole; Canesten Extra Bifonazol; Canesten brand of bifonazole; Dermapharm brand of bifonazole; Inkeysa brand of bifonazole; Juventus brand of bifonazole; Merck Lipha Sante brand of bifonazole; Bay H-4502; Bifonazol [INN-Spanish]; Bifonazolum [INN-Latin]; Canespor (TN); Mycospor (TN); Bay-h-4502; Bifonazole (JP15/USAN/INN); Bifonazole [USAN:BAN:INN:JAN]; (+-)-1-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole; (+-)-1-(p,alpha-Diphenylbenzyl)imidazole; 1-((4-Biphenylyl)phenylmethyl)-1H-imidazole; 1-(alpha-(4-Biphenylyl)benzyl)imidazole; 1-(p,alpha-Diphenylbenzyl)imidazole; 1-[4,alpha-Diphenylbenzyl]-imidazole; 1-[biphenyl-4-yl(phenyl)methyl]-1H-imidazole; 1-[phenyl-(4-phenylphenyl)methyl]imidazole
DM3KN7V	CP	Bayer Pharmaceuticals Corporation
DM3KN7V	TC	Antifungal Agents
DM3KN7V	DT	Small molecular drug
DM3KN7V	PC	2378
DM3KN7V	MW	310.4
DM3KN7V	FM	C22H18N2
DM3KN7V	IC	InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H
DM3KN7V	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4
DM3KN7V	IK	OCAPBUJLXMYKEJ-UHFFFAOYSA-N
DM3KN7V	IU	1-[phenyl-(4-phenylphenyl)methyl]imidazole
DM3KN7V	CA	CAS 60628-96-8
DM3KN7V	CB	CHEBI:78692
DM3KN7V	DE	Fungal infection

DMX0E5B	ID	DMX0E5B
DMX0E5B	DN	Bimatoprost
DMX0E5B	HS	Approved
DMX0E5B	SN	Bimatoprost (topical, alopecia)
DMX0E5B	CP	Allergan Inc
DMX0E5B	DT	Small molecular drug
DMX0E5B	PC	5311027
DMX0E5B	MW	415.6
DMX0E5B	FM	C25H37NO4
DMX0E5B	IC	InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
DMX0E5B	CS	CCNC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O
DMX0E5B	IK	AQOKCDNYWBIDND-FTOWTWDKSA-N
DMX0E5B	IU	(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
DMX0E5B	CA	CAS 155206-00-1
DMX0E5B	CB	CHEBI:51230
DMX0E5B	DE	Alopecia; Glaucoma/ocular hypertension

DME78OA	ID	DME78OA
DME78OA	DN	Biperiden
DME78OA	HS	Approved
DME78OA	SN	Akineton; Beperiden; Biperidene; Biperideno; Biperidenum; Biperidine; Biperidene hydrochloride; KL 373; Akineton (TN);Biperidene [INN-French]; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperiden (JAN/USP/INN); Biperiden [USAN:BAN:INN:JAN]; Biperiden [USAN:INN:BAN:JAN]; Alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol
DME78OA	CP	Knoll Pharma
DME78OA	TC	Antiparkinson Agents
DME78OA	DT	Small molecular drug
DME78OA	PC	2381
DME78OA	MW	311.5
DME78OA	FM	C21H29NO
DME78OA	IC	InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
DME78OA	CS	C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O
DME78OA	IK	YSXKPIUOCJLQIE-UHFFFAOYSA-N
DME78OA	IU	1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol
DME78OA	CA	CAS 514-65-8
DME78OA	CB	CHEBI:3112
DME78OA	DE	Parkinson disease

DMTKU46	ID	DMTKU46
DMTKU46	DN	Bismuth
DMTKU46	HS	Approved
DMTKU46	SN	Bismut; Bismuto; Wismut; Bismuth standard for AAS; Bismuth standard for ICP; LTBB002773; Bismuth(III) nitrate solution; Bismuth, elemental; Bismuth-209; BISMUTH, 99.95%; BISMUTH, 99.999%; 83Bi
DMTKU46	TC	Antidiarrheals
DMTKU46	DT	Small molecular drug
DMTKU46	PC	5359367
DMTKU46	MW	208.98
DMTKU46	FM	Bi
DMTKU46	IC	InChI=1S/Bi
DMTKU46	CS	[Bi]
DMTKU46	IK	JCXGWMGPZLAOME-UHFFFAOYSA-N
DMTKU46	IU	bismuth
DMTKU46	CA	CAS 7440-69-9
DMTKU46	CB	CHEBI:33301
DMTKU46	DE	Diarrhea

DM3UZ95	ID	DM3UZ95
DM3UZ95	DN	Bisoprolol
DM3UZ95	HS	Approved
DM3UZ95	SN	Bisocor; Bisoprololum; Cardicor; Concor; Detensiel; Emconcor; Emcor; Euradal; Isoten; Monocor; Soloc; Soprol; Zebeta; Bisoprolol fumerate; Bisoprolol hemifumarate; Bisoprololum [Latin]; CL-297939; Concor (TN); Concore (TN); EMD-33512; Monocor (TN); Zebeta (TN); Bisoprolol (USAN/INN); Bisoprolol [USAN:BAN:INN]; EMD-33-512; (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol; (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol; 1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol
DM3UZ95	TC	Antihypertensive Agents
DM3UZ95	DT	Small molecular drug
DM3UZ95	PC	2405
DM3UZ95	MW	325.4
DM3UZ95	FM	C18H31NO4
DM3UZ95	IC	InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
DM3UZ95	CS	CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O
DM3UZ95	IK	VHYCDWMUTMEGQY-UHFFFAOYSA-N
DM3UZ95	IU	1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
DM3UZ95	CA	CAS 66722-44-9
DM3UZ95	CB	CHEBI:3127
DM3UZ95	DE	Hypertension

DMK6XAV	ID	DMK6XAV
DMK6XAV	DN	Bitolterol
DMK6XAV	HS	Approved
DMK6XAV	SN	Tornalate
DMK6XAV	CP	Sanofi Aventis Us Llc
DMK6XAV	DT	Small molecular drug
DMK6XAV	PC	35330
DMK6XAV	MW	461.5
DMK6XAV	FM	C28H31NO5
DMK6XAV	IC	InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3
DMK6XAV	CS	CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C
DMK6XAV	IK	FZGVEKPRDOIXJY-UHFFFAOYSA-N
DMK6XAV	IU	[4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyl)oxyphenyl] 4-methylbenzoate
DMK6XAV	CA	CAS 30392-40-6
DMK6XAV	CB	CHEBI:3133
DMK6XAV	DE	Chronic obstructive pulmonary disease; Asthma

DMECRX1	ID	DMECRX1
DMECRX1	DN	Bivalirudin
DMECRX1	HS	Approved
DMECRX1	SN	128270-60-0; Angiomax; Hirulog; bivalirudinum; bivalirudina; Bivalirudin Trifluoroacetate; BG-8967; UNII-TN9BEX005G; BG8967; Bivalirudin Trifluoacetate; TN9BEX005G; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; CHEBI:59173; Hirulog-1; Angiox; Bivalirudina; Bivalirudine; Bivalirudinum; The Medicines Company brand of bivalirudin; BG 8967; Angiomax (TN); HS-2004; Bivalirudin [USAN:BAN:INN]; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
DMECRX1	TC	Antithrombotic Agents
DMECRX1	DT	Small molecular drug
DMECRX1	PC	16129704
DMECRX1	MW	2180.3
DMECRX1	FM	C98H138N24O33
DMECRX1	IC	InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1
DMECRX1	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CC=CC=C6)N
DMECRX1	IK	OIRCOABEOLEUMC-GEJPAHFPSA-N
DMECRX1	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[2-[[2-[[2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
DMECRX1	CA	CAS 128270-60-0
DMECRX1	CB	CHEBI:59173
DMECRX1	DE	Thrombocytopenia

DMR8YD6	ID	DMR8YD6
DMR8YD6	DN	B-Lactams
DMR8YD6	HS	Approved
DMR8YD6	SN	Luteolin; luteolin; 491-70-3; Luteolol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Luteoline; Digitoflavone; Flacitran; Weld Lake; Cyanidenon 1470; Salifazide; Yama kariyasu; 5,7,3',4'-Tetrahydroxyflavone; UNII-KUX1ZNC9J2; CI Natural Yellow 2; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; 7-Tetrahydroxyflavone; CCRIS 3790; EINECS 207-741-0; KUX1ZNC9J2; CHEMBL151; BRN 0292084; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMR8YD6	DT	Small molecular drug
DMR8YD6	PC	5280445
DMR8YD6	MW	286.24
DMR8YD6	FM	C15H10O6
DMR8YD6	IC	InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H
DMR8YD6	CS	C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMR8YD6	IK	IQPNAANSBPBGFQ-UHFFFAOYSA-N
DMR8YD6	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMR8YD6	CA	CAS 491-70-3
DMR8YD6	CB	CHEBI:15864
DMR8YD6	DE	Bacterial infection

DMNER5S	ID	DMNER5S
DMNER5S	DN	Bleomycin
DMNER5S	HS	Approved
DMNER5S	SN	BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
DMNER5S	CP	Bristol-Myers Squibb
DMNER5S	TC	Anticancer Agents
DMNER5S	DT	Small molecular drug
DMNER5S	PC	5360373
DMNER5S	MW	1415.6
DMNER5S	FM	C55H84N17O21S3+
DMNER5S	IC	InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
DMNER5S	CS	CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
DMNER5S	IK	OYVAGSVQBOHSSS-WXFSZRTFSA-O
DMNER5S	IU	3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
DMNER5S	CA	CAS 11056-06-7
DMNER5S	DE	Hodgkin lymphoma

DMGECIJ	ID	DMGECIJ
DMGECIJ	DN	Blinatumomab
DMGECIJ	HS	Approved
DMGECIJ	SN	AMG 103; Blincyto
DMGECIJ	CP	Amgen
DMGECIJ	DT	Monoclonal antibody
DMGECIJ	SQ	single chain variable fragment fusion protein : DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH
DMGECIJ	DE	Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma

DMQTAGO	ID	DMQTAGO
DMQTAGO	DN	BMS-201038
DMQTAGO	HS	Approved
DMQTAGO	SN	AEGR 733; AEGR733; BMS 201038; BMS 201238; BMS201038; AEGR-733; BMS 201038-01
DMQTAGO	CP	Bristol-Myers Squibb
DMQTAGO	DT	Small molecular drug
DMQTAGO	PC	9853053
DMQTAGO	MW	693.7
DMQTAGO	FM	C39H37F6N3O2
DMQTAGO	IC	InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)
DMQTAGO	CS	C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
DMQTAGO	IK	MBBCVAKAJPKAKM-UHFFFAOYSA-N
DMQTAGO	IU	N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
DMQTAGO	CA	CAS 182431-12-5
DMQTAGO	CB	CHEBI:72297
DMQTAGO	DE	Familial hypercholesterolemia

DMBSHMF	ID	DMBSHMF
DMBSHMF	DN	Boceprevir
DMBSHMF	HS	Approved
DMBSHMF	SN	Boceprevir; Victrelis; 394730-60-0; SCH 503034; EBP 520; UNII-89BT58KELH; SCH-503034; 89BT58KELH; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
DMBSHMF	DT	Small molecular drug
DMBSHMF	PC	10324367
DMBSHMF	MW	519.7
DMBSHMF	FM	C27H45N5O5
DMBSHMF	IC	InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
DMBSHMF	CS	CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
DMBSHMF	IK	LHHCSNFAOIFYRV-DOVBMPENSA-N
DMBSHMF	IU	(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
DMBSHMF	CA	CAS 394730-60-0
DMBSHMF	CB	CHEBI:68621
DMBSHMF	DE	Hepatitis C virus infection

DM2EXC5	ID	DM2EXC5
DM2EXC5	DN	BOL-303259-X
DM2EXC5	HS	Approved
DM2EXC5	SN	Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb
DM2EXC5	CP	Bausch and Lomb/Valeant Pharmaceuticals
DM2EXC5	DT	Small molecular drug
DM2EXC5	PC	11156438
DM2EXC5	MW	507.6
DM2EXC5	FM	C27H41NO8
DM2EXC5	IC	InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
DM2EXC5	CS	C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O
DM2EXC5	IK	LOVMMUBRQUFEAH-UIEAZXIASA-N
DM2EXC5	IU	4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DM2EXC5	CA	CAS 860005-21-6
DM2EXC5	DE	Open-angle glaucoma; Renal cell carcinoma

DMIFYLX	ID	DMIFYLX
DMIFYLX	DN	Bopindolol
DMIFYLX	HS	Approved
DMIFYLX	SN	BOPINDOLOL; 62658-63-3; Sandonorm; (+-)-Bopindolol; 1-(tert-Butylamino)-3-((2-methyl-1H-indol-4-yl)oxy)propan-2-yl benzoate; Bopindololum [INN-Latin]; Bopindolol [INN]; UUOJIACWOAYWEZ-UHFFFAOYSA-N; Bopindolol (INN); Wandonorm; 69010-88-4; NCGC00163155-01; Sandonorm (TN); (+-)-4-(2-Benzoyloxy-3-tert-butylaminopropoxy)-2-methylindole; DSSTox_CID_2684; DSSTox_RID_76690; (+-)-1-(tert-Butylamino)-3-((2-methylindol-4-yl)oxy)-2-propanol benzoate (ester); DSSTox_GSID_22684
DMIFYLX	DT	Small molecular drug
DMIFYLX	PC	44112
DMIFYLX	MW	380.5
DMIFYLX	FM	C23H28N2O3
DMIFYLX	IC	InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3
DMIFYLX	CS	CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3
DMIFYLX	IK	UUOJIACWOAYWEZ-UHFFFAOYSA-N
DMIFYLX	IU	[1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl] benzoate
DMIFYLX	CA	CAS 62658-63-3
DMIFYLX	CB	CHEBI:143782
DMIFYLX	DE	Hypertension

DMNO38U	ID	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	HS	Approved
DMNO38U	SN	179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate
DMNO38U	CP	Takeda
DMNO38U	TC	Anticancer Agents
DMNO38U	DT	Small molecular drug
DMNO38U	PC	387447
DMNO38U	MW	384.2
DMNO38U	FM	C19H25BN4O4
DMNO38U	IC	InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
DMNO38U	CS	B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
DMNO38U	IK	GXJABQQUPOEUTA-RDJZCZTQSA-N
DMNO38U	IU	[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
DMNO38U	CA	CAS 179324-69-7
DMNO38U	CB	CHEBI:52717
DMNO38U	DE	Multiple myeloma; Non-hodgkin lymphoma; Mantle cell lymphoma

DMIOGBU	ID	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	HS	Approved
DMIOGBU	SN	Actelion; Bosentanum; Tracleer; Bosentan (INN); KS-5062; Ro 47-0203; Tracleer (TN); Bosentan [USAN:INN:BAN]; Ro 47-0203/039; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039; P-tert-Butyl-N-[6-(2-hydroxyethoxy); P-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
DMIOGBU	CP	Actelion Pharmaceuticals
DMIOGBU	TC	Antihypertensive Agents
DMIOGBU	DT	Small molecular drug
DMIOGBU	PC	104865
DMIOGBU	MW	551.6
DMIOGBU	FM	C27H29N5O6S
DMIOGBU	IC	InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
DMIOGBU	CS	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC
DMIOGBU	IK	GJPICJJJRGTNOD-UHFFFAOYSA-N
DMIOGBU	IU	4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
DMIOGBU	CA	CAS 147536-97-8
DMIOGBU	CB	CHEBI:51450
DMIOGBU	DE	Pulmonary arterial hypertension

DMTI8YE	ID	DMTI8YE
DMTI8YE	DN	Bosutinib
DMTI8YE	HS	Approved
DMTI8YE	SN	SKI 606; SKI606; Bosutinib (USAN); PF-5208763; SKI-606; Xy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor  3rd gen)
DMTI8YE	CP	Wyeth Research
DMTI8YE	TC	Anticancer Agents
DMTI8YE	DT	Small molecular drug
DMTI8YE	PC	5328940
DMTI8YE	MW	530.4
DMTI8YE	FM	C26H29Cl2N5O3
DMTI8YE	IC	InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
DMTI8YE	CS	CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
DMTI8YE	IK	UBPYILGKFZZVDX-UHFFFAOYSA-N
DMTI8YE	IU	4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
DMTI8YE	CA	CAS 380843-75-4
DMTI8YE	CB	CHEBI:39112
DMTI8YE	DE	Breast cancer

DMW67MU	ID	DMW67MU
DMW67MU	DN	Botulinum Toxin Type A
DMW67MU	HS	Approved
DMW67MU	SN	Botox; Botulinum toxin type A (JAN)
DMW67MU	SQ	Botulinum Toxin Type A Sequence: MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL
DMW67MU	DE	Blepharospasm

DM58QS1	ID	DM58QS1
DM58QS1	DN	Botulinum Toxin Type B
DM58QS1	HS	Approved
DM58QS1	SN	BTXA (TN); Dysport (TN); Myobloc (TN); Neurobloc (TN); Xeomin (TN)
DM58QS1	CP	Allergan Inc 
DM58QS1	TC	Antidystonic Agents
DM58QS1	SQ	Botulinum neurotoxin type B - Clostridium botulinum: MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSYSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE
DM58QS1	DE	Parkinson disease

DM20LIM	ID	DM20LIM
DM20LIM	DN	Bremelanotide
DM20LIM	HS	Approved
DM20LIM	SN	Bremelanotide (USAN/INN); PT-141; Rekynda
DM20LIM	CP	Palatin Technol
DM20LIM	DT	Small molecular drug
DM20LIM	PC	9941379
DM20LIM	MW	1025.2
DM20LIM	FM	C50H68N14O10
DM20LIM	IC	InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
DM20LIM	CS	CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C
DM20LIM	IK	FFHBJDQSGDNCIV-MFVUMRCOSA-N
DM20LIM	IU	(3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
DM20LIM	CA	CAS 189691-06-3
DM20LIM	DE	Erectile dysfunction; Hypoactive sexual desire dysfunction

DMWLC57	ID	DMWLC57
DMWLC57	DN	Brentuximab vedotin
DMWLC57	HS	Approved
DMWLC57	SN	Adcetris (TN)
DMWLC57	CP	Millennium Pharmaceuticals; Seattle Genetics
DMWLC57	DT	Monoclonal antibody
DMWLC57	DE	Hodgkin lymphoma

DM1FX74	ID	DM1FX74
DM1FX74	DN	Bretylium
DM1FX74	HS	Approved
DM1FX74	SN	Bretylum; Bretylium tolsylate; Bretylium tosylate(USAN); N-(2-bromobenzyl)-N,N-dimethylethanaminium; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1); (2-bromobenzyl)ethyldimethylaminium; (2-bromophenyl)methyl-ethyl-dimethylazanium; (o-Bromobenzyl)ethyldimethylammonium p-toluenesulfonate; 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium
DM1FX74	CP	Hospira Inc
DM1FX74	TC	Antiarrhythmic Agents
DM1FX74	DT	Small molecular drug
DM1FX74	PC	2431
DM1FX74	MW	243.16
DM1FX74	FM	C11H17BrN+
DM1FX74	IC	InChI=1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1
DM1FX74	CS	CC[N+](C)(C)CC1=CC=CC=C1Br
DM1FX74	IK	AAQOQKQBGPPFNS-UHFFFAOYSA-N
DM1FX74	IU	(2-bromophenyl)methyl-ethyl-dimethylazanium
DM1FX74	CA	CAS 59-41-6
DM1FX74	CB	CHEBI:3172
DM1FX74	DE	Ventricular fibrillation

DM7W94S	ID	DM7W94S
DM7W94S	DN	Brigatinib
DM7W94S	HS	Approved
DM7W94S	SN	1197953-54-0; UNII-HYW8DB273J; Brigatinib [USAN]; ALUNBRIG; HYW8DB273J; Brigatinib (USAN); Brigatiib; Alunbrig (TN); Brigatinib [USAN:INN]; Brigatinib (AP26113); SCHEMBL11916361; KS-00000TSQ; EX-A775; MolPort-044-561-640; BDBM50185140; ZINC148723177; AKOS030257612; CS-4278; DB12267; HY-12857; AC-29958
DM7W94S	CP	Ariad Pharmaceuticals/Takeda
DM7W94S	DT	Small molecular drug
DM7W94S	PC	68165256
DM7W94S	MW	584.1
DM7W94S	FM	C29H39ClN7O2P
DM7W94S	IC	InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)
DM7W94S	CS	CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC
DM7W94S	IK	AILRADAXUVEEIR-UHFFFAOYSA-N
DM7W94S	IU	5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine
DM7W94S	CA	CAS 1197953-54-0
DM7W94S	DE	Non-small-cell lung cancer; Anaplastic large cell lymphoma

DMBR01X	ID	DMBR01X
DMBR01X	DN	Brilinta
DMBR01X	HS	Approved
DMBR01X	SN	Ticagrelor; 274693-27-5; Brilique; AZD-6140; AZD6140; AZD 6140; AR-C126532XX; UNII-GLH0314RVC; [14C]-Ticagrelor; GLH0314RVC; CHEBI:68558; (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL]AMINO]-5-(PROPYLTHIO)-3H-1,2,3-TRIAZOLO[4,5-D]PYRIMIDIN-3-YL]-5-(2-HYDROXYETHOXY)-1,2-CYCLOPENTANEDIOL; (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;  Brilique; AR-C126532; Ticagrelor (USAN/INN); Brilinta/Brilique
DMBR01X	CP	AstraZeneca
DMBR01X	DT	Small molecular drug
DMBR01X	PC	9871419
DMBR01X	MW	522.6
DMBR01X	FM	C23H28F2N6O4S
DMBR01X	IC	InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
DMBR01X	CS	CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
DMBR01X	IK	OEKWJQXRCDYSHL-FNOIDJSQSA-N
DMBR01X	IU	(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
DMBR01X	CA	CAS 274693-27-5
DMBR01X	CB	CHEBI:68558
DMBR01X	DE	Myocardial infarction; Arterial thrombosis; Thrombosis

DMQLT4N	ID	DMQLT4N
DMQLT4N	DN	Brimonidine
DMQLT4N	HS	Approved
DMQLT4N	SN	brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; UK-14304; AGN 190342; UNII-E6GNX3HHTE; Brimonidine [INN:BAN]; UK 14304; C11H10BrN5; MLS000069370; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; E6GNX3HHTE; CHEMBL844; AGN-190342; BRN 0751629; SMR000058355; CHEBI:3175; LK 14304-18; Brimonidine, 98%; NCGC00016069-09; EN300-50880; DSSTox_RID_80758; Brimonidine (bioerodible, extended release); [3H]brimonidine
DMQLT4N	CP	PSivida Corp
DMQLT4N	DT	Small molecular drug
DMQLT4N	PC	2435
DMQLT4N	MW	292.13
DMQLT4N	FM	C11H10BrN5
DMQLT4N	IC	InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
DMQLT4N	CS	C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br
DMQLT4N	IK	XYLJNLCSTIOKRM-UHFFFAOYSA-N
DMQLT4N	IU	5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
DMQLT4N	CA	CAS 59803-98-4
DMQLT4N	CB	CHEBI:3175
DMQLT4N	DE	Ocular hypertension; Glaucoma/ocular hypertension

DMBAPFG	ID	DMBAPFG
DMBAPFG	DN	Brinzolamide
DMBAPFG	HS	Approved
DMBAPFG	SN	Azopt; Birnzolamide; Alcon brand of brinzolamide; Allphar brand of brinzolamide; Brinzolamide [USAN]; AL 4862; AL04862; BZ1; AL-4862; Azopt (TN); Brinzolamide (BRZ); Brinzolamide (JAN/USP/INN); (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R
DMBAPFG	CP	Alcon Laboratories
DMBAPFG	TC	Antiglaucomic Agents
DMBAPFG	DT	Small molecular drug
DMBAPFG	PC	68844
DMBAPFG	MW	383.5
DMBAPFG	FM	C12H21N3O5S3
DMBAPFG	IC	InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
DMBAPFG	CS	CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC
DMBAPFG	IK	HCRKCZRJWPKOAR-JTQLQIEISA-N
DMBAPFG	IU	(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMBAPFG	CA	CAS 138890-62-7
DMBAPFG	CB	CHEBI:3176
DMBAPFG	DE	Open-angle glaucoma

DMSEPK8	ID	DMSEPK8
DMSEPK8	DN	Brivaracetam
DMSEPK8	HS	Approved
DMSEPK8	SN	Rikelta; UCB-34714; Brivaracetam (USAN/INN)
DMSEPK8	CP	UCB
DMSEPK8	DT	Small molecular drug
DMSEPK8	PC	9837243
DMSEPK8	MW	212.29
DMSEPK8	FM	C11H20N2O2
DMSEPK8	IC	InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
DMSEPK8	CS	CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
DMSEPK8	IK	MSYKRHVOOPPJKU-BDAKNGLRSA-N
DMSEPK8	IU	(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
DMSEPK8	CA	CAS 357336-20-0
DMSEPK8	CB	CHEBI:133013
DMSEPK8	DE	Epilepsy; Pain; Complex partial seizure

DMASDQ6	ID	DMASDQ6
DMASDQ6	DN	Brodalumab
DMASDQ6	HS	Approved
DMASDQ6	SN	AMG 827
DMASDQ6	CP	Valeant Pharmaceuticals
DMASDQ6	DT	Monoclonal antibody
DMASDQ6	DE	Plaque psoriasis; Asthma; Psoriasis vulgaris

DMW8QNG	ID	DMW8QNG
DMW8QNG	DN	Brolucizumab
DMW8QNG	HS	Approved
DMW8QNG	CP	Alcon
DMW8QNG	DT	Antibody
DMW8QNG	DE	Wet age-related macular degeneration; Diabetic macular edema

DMY9TCW	ID	DMY9TCW
DMY9TCW	DN	Bromazepam
DMY9TCW	HS	Approved
DMY9TCW	SN	Bromazepamum; Calmepam; Compedium; Compendium; Creosedin; Durazanil; Lectopam; Lekotam; Lexaurin; Lexilium; Lexomil; Lexotan; Lexotanil; Normoc; Somalium; Ultramidol; Bromazepamum [Latin]; LA Xvii; KL 001; Ro 53350; Apo-Bromazepam; Brazepam (TN); Bromaze (TN); Bromazepam(USAN; Bromazepamum [INN-Latin]; Gen-Bromazepam; KL-001; Lectopam (TN); Lexotan (TN); Novo-bromazepam; Nu-Bromazepam; Ro 4-9253; Ro 5-3350; Bromazepam (JP15/USAN/INN); Bromazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-7-bromo-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzdiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one; 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one
DMY9TCW	CP	Hoffmann-La Roche pharmaceutical company
DMY9TCW	TC	Hypnotics and Sedatives
DMY9TCW	DT	Small molecular drug
DMY9TCW	PC	2441
DMY9TCW	MW	316.15
DMY9TCW	FM	C14H10BrN3O
DMY9TCW	IC	InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)
DMY9TCW	CS	C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=N3
DMY9TCW	IK	VMIYHDSEFNYJSL-UHFFFAOYSA-N
DMY9TCW	IU	7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one
DMY9TCW	CA	CAS 1812-30-2
DMY9TCW	CB	CHEBI:31302
DMY9TCW	DE	Panic attacks; Anxiety disorder

DMKB79O	ID	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	HS	Approved
DMKB79O	SN	Bromfenaco; Bromfenacum; Duract; Xibrom; BROMFENAC SODIUM; Bromfenac [INN]; Bromfenaco [Spanish]; Bromfenacum [Latin]; AHR-10282; Bromfenac (INN); Duract (TN); Xibrom (TN); Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid; [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
DMKB79O	TC	Antiinflammatory Agents
DMKB79O	DT	Small molecular drug
DMKB79O	PC	60726
DMKB79O	MW	334.16
DMKB79O	FM	C15H12BrNO3
DMKB79O	IC	InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)
DMKB79O	CS	C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O
DMKB79O	IK	ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
DMKB79O	IU	2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
DMKB79O	CA	CAS 91714-94-2
DMKB79O	CB	CHEBI:240107
DMKB79O	DE	Postoperative inflammation; Inflammation

DMVE3TK	ID	DMVE3TK
DMVE3TK	DN	Bromocriptine
DMVE3TK	HS	Approved
DMVE3TK	SN	Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptinum; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Ergoset; Parlodel; Bromocriptine [BAN]; Bromocriptine methanesulfonate; Parlodel Snaptabs; Alti-Bromocriptine; Apo-Bromocriptine; Bromocriptina [INN-Spanish]; Bromocriptinum [INN-Latin]; CB-154; Parlodel (TN); Bromocriptine (USAN/INN); Bromocriptine [USAN:BAN:INN]; Ergocryptine, 2-bromo-(8CI); (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine
DMVE3TK	CP	Norvatis Phamaceuticals Corporation
DMVE3TK	TC	Antiparkinson Agents
DMVE3TK	DT	Small molecular drug
DMVE3TK	PC	31101
DMVE3TK	MW	654.6
DMVE3TK	FM	C32H40BrN5O5
DMVE3TK	IC	InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
DMVE3TK	CS	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
DMVE3TK	IK	OZVBMTJYIDMWIL-AYFBDAFISA-N
DMVE3TK	IU	(6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMVE3TK	CA	CAS 25614-03-3
DMVE3TK	CB	CHEBI:3181
DMVE3TK	DE	Parkinson disease

DMNDJT5	ID	DMNDJT5
DMNDJT5	DN	Bromodiphenhydramine
DMNDJT5	HS	Approved
DMNDJT5	SN	Amodryl; Bromanautine; Bromazin; Bromazina; Bromazine; Bromazinum; Bromdiphenhydramine; Bromdiphenhydraminum; Deserol; Histabromamine; Ambodryl hydrochloride; Bromdiphenhydramine hydrochloride; Bromdiphenylhydramine hydrochloride; Bromodiphenhydramine hydrochloride; Ambrodyl (TN); Bromazina [INN-Spanish]; Bromazine [INN:BAN]; Bromazinum [INN-Latin]; Bromo-Benadryl; Bromo-Benzdryl; Neo-Benadryl; Beta-dimethylaminoethyl p-bromobenzhydryl ether; Beta-(p-Bromobenzhydryloxy)ethyldimethylamine; 2-(p-bromo-alpha-phenylbenzyloxy)-N,N-dimethylethylamine; 2-[(4-Bromophenyl)(phenyl)methoxy]-N,N-dimethylethanamine; 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine; 2-{[(4-bromophenyl)(phenyl)methyl]oxy}-N,N-dimethylethanamine
DMNDJT5	TC	Antihistamines
DMNDJT5	DT	Small molecular drug
DMNDJT5	PC	2444
DMNDJT5	MW	334.2
DMNDJT5	FM	C17H20BrNO
DMNDJT5	IC	InChI=1S/C17H20BrNO/c1-19(2)12-13-20-17(14-6-4-3-5-7-14)15-8-10-16(18)11-9-15/h3-11,17H,12-13H2,1-2H3
DMNDJT5	CS	CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)Br
DMNDJT5	IK	NUNIWXHYABYXKF-UHFFFAOYSA-N
DMNDJT5	IU	2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine
DMNDJT5	CA	CAS 118-23-0
DMNDJT5	CB	CHEBI:59177
DMNDJT5	DE	Hay fever

DM24XYQ	ID	DM24XYQ
DM24XYQ	DN	Bromperidol
DM24XYQ	HS	Approved
DM24XYQ	SN	bromperidol; 10457-90-6; Impromen; Bromoperidol; Tesoprel; Azurene; 4-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one; UNII-LYH6F7I22E; Bromperidolum [INN-Latin]; R 11333; EINECS 233-943-3; 4-(4-(4-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; CC 2489; BRN 1552256; LYH6F7I22E; 4-(4-(p-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; RKLNONIVDFXQRX-UHFFFAOYSA-N; 4-(4-(4-Bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone; NCGC00016692-01; CAS-10457-90-6
DM24XYQ	DT	Small molecular drug
DM24XYQ	PC	2448
DM24XYQ	MW	420.3
DM24XYQ	FM	C21H23BrFNO2
DM24XYQ	IC	InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
DM24XYQ	CS	C1CN(CCC1(C2=CC=C(C=C2)Br)O)CCCC(=O)C3=CC=C(C=C3)F
DM24XYQ	IK	RKLNONIVDFXQRX-UHFFFAOYSA-N
DM24XYQ	IU	4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
DM24XYQ	CA	CAS 10457-90-6
DM24XYQ	CB	CHEBI:31305
DM24XYQ	DE	Schizophrenia

DMFOVSD	ID	DMFOVSD
DMFOVSD	DN	Brompheniramine
DMFOVSD	HS	Approved
DMFOVSD	SN	Bromfed; Bromfenex; Bromfeniramina; Brotane; Parabromdylamine; BROMFED-DM; Bromfeniramina [INN-Spanish]; Brompheniramine (INN); Brompheniramine [INN:BAN]; Brompheniraminum [INN-Latin]; Brotane (TN); DIMETANE-DX; P-Bromdylamine; Para-Bromdylamine; Brompheniramine Maleate (1:1); [3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine; Gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine; 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine; 3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
DMFOVSD	CP	Alpharma Us Pharmaceuticals Division
DMFOVSD	TC	Antiallergic Agents
DMFOVSD	DT	Small molecular drug
DMFOVSD	PC	6834
DMFOVSD	MW	319.24
DMFOVSD	FM	C16H19BrN2
DMFOVSD	IC	InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
DMFOVSD	CS	CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2
DMFOVSD	IK	ZDIGNSYAACHWNL-UHFFFAOYSA-N
DMFOVSD	IU	3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMFOVSD	CA	CAS 86-22-6
DMFOVSD	CB	CHEBI:3183
DMFOVSD	DE	Allergic rhinitis

DMXKZT3	ID	DMXKZT3
DMXKZT3	DN	Buclizine
DMXKZT3	HS	Approved
DMXKZT3	SN	Bucladin; Buclifen; Buclina; Buclizina; Buclizinum; Buclodin; Histabuticine; Histabutizine; Histabutyzine; Hitabutyzyne; Posdel; Softran; Vibazine; Aphilan R; Buclizine dihydrochloride; Buclizine hydrochloride; Component of Softran; Histabutyzine dihydrochloride; Histabutyzine hydrochloride; Vibazine hydrochloride; AH 2526; UCB 4445; Aphilan-R base; Buclina (TN); Buclizina [INN-Spanish]; Buclizine (INN); Buclizine [INN:BAN]; Buclizine, hydrochloride; Buclizinum [INN-Latin]; Component of Bucladin-S; Migraleve (TN); Buclizine Hydrochloride (*dihydrochloride*); Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, dihydrochloride; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-(9CI); 1-(4-Tert-butylbenzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine; 1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine; 1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine; 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
DMXKZT3	CP	McNeil Laboratories
DMXKZT3	TC	Antihistamines
DMXKZT3	DT	Small molecular drug
DMXKZT3	PC	6729
DMXKZT3	MW	433
DMXKZT3	FM	C28H33ClN2
DMXKZT3	IC	InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3
DMXKZT3	CS	CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMXKZT3	IK	MOYGZHXDRJNJEP-UHFFFAOYSA-N
DMXKZT3	IU	1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
DMXKZT3	CA	CAS 82-95-1
DMXKZT3	CB	CHEBI:3205
DMXKZT3	DE	Nausea

DMJIBAW	ID	DMJIBAW
DMJIBAW	DN	Budesonide
DMJIBAW	HS	Approved
DMJIBAW	SN	Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
DMJIBAW	CP	AstraZeneca
DMJIBAW	TC	Antiinflammatory Agents
DMJIBAW	DT	Small molecular drug
DMJIBAW	PC	5281004
DMJIBAW	MW	430.5
DMJIBAW	FM	C25H34O6
DMJIBAW	IC	InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
DMJIBAW	CS	CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
DMJIBAW	IK	VOVIALXJUBGFJZ-KWVAZRHASA-N
DMJIBAW	IU	(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMJIBAW	CA	CAS 51333-22-3
DMJIBAW	CB	CHEBI:3207
DMJIBAW	DE	Asthma

DMODHQI	ID	DMODHQI
DMODHQI	DN	Budipine
DMODHQI	HS	Approved
DMODHQI	SN	Parkinsan; BY-701
DMODHQI	CP	ALTANA Pharma AG
DMODHQI	DT	Small molecular drug
DMODHQI	PC	68778
DMODHQI	MW	293.4
DMODHQI	FM	C21H27N
DMODHQI	IC	InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3
DMODHQI	CS	CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3
DMODHQI	IK	QIHLUZAFSSMXHQ-UHFFFAOYSA-N
DMODHQI	IU	1-tert-butyl-4,4-diphenylpiperidine
DMODHQI	CA	CAS 57982-78-2
DMODHQI	CB	CHEBI:135228
DMODHQI	DE	Migraine

DMG1OPF	ID	DMG1OPF
DMG1OPF	DN	Buflomedil
DMG1OPF	HS	Approved
DMG1OPF	SN	Loftyl; Buflomedil hydrochloride
DMG1OPF	CP	Laboratoire L Lafon SA
DMG1OPF	DT	Small molecular drug
DMG1OPF	PC	2467
DMG1OPF	MW	307.4
DMG1OPF	FM	C17H25NO4
DMG1OPF	IC	InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3
DMG1OPF	CS	COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC
DMG1OPF	IK	OWYLAEYXIQKAOL-UHFFFAOYSA-N
DMG1OPF	IU	4-pyrrolidin-1-yl-1-(2,4,6-trimethoxyphenyl)butan-1-one
DMG1OPF	CA	CAS 55837-25-7
DMG1OPF	CB	CHEBI:94538
DMG1OPF	DE	Peripheral vascular disease

DMX82DO	ID	DMX82DO
DMX82DO	DN	Buformin
DMX82DO	HS	Approved
DMX82DO	SN	Buformin; 1-Butylbiguanide; Buformine; Butyldiguanide; Butylbiguanide; Butformin; Butylbiguanidum; Glybigid; 1-Butyldiguanide; Glybigidum; N-Butylbiguanide; Buformina; Buforminum; Buformine [INN-French]; Buforminum [INN-Latin]; Buformina [INN-Spanish]; Silubin; Adebit; BIGUANIDE, 1-BUTYL-; Buformin [USAN:INN]; W 37; Buformin HCl; Imidodicarbonimidic diamide, N-butyl-; Sindiatil; Panformin; Diabrin; Biforon; Andere; UNII-W2115E9C7B; Buformine HCl; N-butylimidodicarbonimidic diamide; DBV hydrochloride; H 224
DMX82DO	PC	2468
DMX82DO	MW	157.22
DMX82DO	FM	C6H15N5
DMX82DO	IC	InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11)
DMX82DO	CS	CCCCN=C(N)N=C(N)N
DMX82DO	IK	XSEUMFJMFFMCIU-UHFFFAOYSA-N
DMX82DO	IU	2-butyl-1-(diaminomethylidene)guanidine
DMX82DO	CA	CAS 692-13-7
DMX82DO	CB	CHEBI:3209
DMX82DO	DE	Type 2 diabetes

DMJUVE6	ID	DMJUVE6
DMJUVE6	DN	Bulevirtide
DMJUVE6	HS	Approved
DMJUVE6	SN	Lipopeptide
DMJUVE6	CP	MYR Pharma
DMJUVE6	DT	Peptide
DMJUVE6	DE	Hepatitis D virus infection

DMRV7H0	ID	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	HS	Approved
DMRV7H0	SN	Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
DMRV7H0	CP	Hoffmann-La Roche pharmaceutical company
DMRV7H0	TC	Diuretics
DMRV7H0	DT	Small molecular drug
DMRV7H0	PC	2471
DMRV7H0	MW	364.4
DMRV7H0	FM	C17H20N2O5S
DMRV7H0	IC	InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
DMRV7H0	CS	CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
DMRV7H0	IK	MAEIEVLCKWDQJH-UHFFFAOYSA-N
DMRV7H0	IU	3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
DMRV7H0	CA	CAS 28395-03-1
DMRV7H0	CB	CHEBI:3213
DMRV7H0	DE	Congestive heart failure

DM4I8O7	ID	DM4I8O7
DM4I8O7	DN	Bunazosin
DM4I8O7	HS	Approved
DM4I8O7	SN	Andante; E 015; DE-070; Detantol-R; E-1015; E-643
DM4I8O7	CP	Eisai Co Ltd
DM4I8O7	DT	Small molecular drug
DM4I8O7	PC	2472
DM4I8O7	MW	373.4
DM4I8O7	FM	C19H27N5O3
DM4I8O7	IC	InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)
DM4I8O7	CS	CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
DM4I8O7	IK	RHLJLALHBZGAFM-UHFFFAOYSA-N
DM4I8O7	IU	1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one
DM4I8O7	CA	CAS 80755-51-7
DM4I8O7	CB	CHEBI:135576
DM4I8O7	DE	Glaucoma/ocular hypertension

DM4PRFC	ID	DM4PRFC
DM4PRFC	DN	Bupivacaine
DM4PRFC	HS	Approved
DM4PRFC	SN	Anekain; Bloqueina; Bucaine; Bupivacaina; Bupivacainum; Bupivan; CBupivacaine; Carbostesin; DepoBupivacaine; Marcaina; Marcaine; Sensorcaine; Bupivacaine Carbonate; Bupivacaine HCL; Bupivacaine HCL KIT; Marcaine HCL; Marcaine Spinal; AH 250; Win 11318; Win 11318 HCl; Bucaine (TN); Bupivacaina [INN-Spanish]; Bupivacaine (INN); Bupivacaine Monohydrochloride, Monohydrate; Bupivacaine [INN:BAN]; Bupivacainum [INN-Latin]; DL-Bupivacaine; DUR-843; Marcain (TN); Marcaine (TN); Sensorcaine (TN); Sensorcaine-MPF; Sensorcaine-MPFSpinal; Transdur-Bupivacaine; Vivacaine (TN); Dl-1-Butyl-2',6'-pipecoloxylidide; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (inverted exclamation markA)-bupivacaine; 1-Butyl-2',6'-pipecoloxylidide; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM4PRFC	CP	AstraZeneca
DM4PRFC	TC	Anesthetics
DM4PRFC	DT	Small molecular drug
DM4PRFC	PC	2474
DM4PRFC	MW	288.4
DM4PRFC	FM	C18H28N2O
DM4PRFC	IC	InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
DM4PRFC	CS	CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C
DM4PRFC	IK	LEBVLXFERQHONN-UHFFFAOYSA-N
DM4PRFC	IU	1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM4PRFC	CA	CAS 38396-39-3
DM4PRFC	CB	CHEBI:77431
DM4PRFC	DE	Anaesthesia; Pain

DMPRI8G	ID	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	HS	Approved
DMPRI8G	SN	Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone  (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M
DMPRI8G	CP	Reckitt; Colman
DMPRI8G	TC	Analgesics
DMPRI8G	DT	Small molecular drug
DMPRI8G	PC	644073
DMPRI8G	MW	467.6
DMPRI8G	FM	C29H41NO4
DMPRI8G	IC	InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
DMPRI8G	CS	C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
DMPRI8G	IK	RMRJXGBAOAMLHD-IHFGGWKQSA-N
DMPRI8G	IU	(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMPRI8G	CA	CAS 52485-79-7
DMPRI8G	CB	CHEBI:3216
DMPRI8G	DE	Pain; Migraine; Psychiatric disorder

DMBQEGT	ID	DMBQEGT
DMBQEGT	DN	Buprenorphine + naloxone
DMBQEGT	HS	Approved
DMBQEGT	SN	Buprenorphine/naloxone; [5 ,7 (S)]-17-(Cyclopropylmethyl)- -(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- -methyl-6,14-ethenomorphinan-7-methanol; SCHEMBL18085614; Buprenorphine 10 mg/ml in Methanol; Buprenorphine 01 mg/ml in Methanol; ALKS5461
DMBQEGT	CP	Orexo
DMBQEGT	DT	Small molecular drug
DMBQEGT	PC	6321408
DMBQEGT	MW	467.6
DMBQEGT	FM	C29H41NO4
DMBQEGT	IC	InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29?/m1/s1
DMBQEGT	CS	C[C@]([C@H]1C[C@@]23CCC1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
DMBQEGT	IK	RMRJXGBAOAMLHD-MLLHIGKASA-N
DMBQEGT	IU	(1S,2S,6R,14R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMBQEGT	CA	CAS 52485-79-7
DMBQEGT	DE	Opioid dependence; Major depressive disorder

DM5PCS7	ID	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	HS	Approved
DM5PCS7	SN	bupropion; Amfebutamone; 34911-55-2; Amfebutamon; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; amfebutamonum; Amfebutamona; (+-)-Bupropion; Wellbatrin; Bupropion [INN:BAN]; 34841-39-9; Elontril; Amfebutamonum [INN-Latin]; Zyban; Amfebutamona [INN-Spanish]; Bupropion SR; AMFEBUTAMONE HCl; alpha-(tert-butylamino)-m-chloropropiophenone; CHEMBL894; BRN 2101062; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; CHEBI:3219; SNPPWIUOZRMYNY-UHFFFAOYSA-N; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one;  Amfebutamon; Amfebutamonum; Elont; Bupropion Hcl; Bupropion hydrocloride; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone
DM5PCS7	CP	GlaxoSmithKline plc
DM5PCS7	DT	Small molecular drug
DM5PCS7	PC	444
DM5PCS7	MW	239.74
DM5PCS7	FM	C13H18ClNO
DM5PCS7	IC	InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
DM5PCS7	CS	CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DM5PCS7	IK	SNPPWIUOZRMYNY-UHFFFAOYSA-N
DM5PCS7	IU	2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
DM5PCS7	CA	CAS 34911-55-2
DM5PCS7	CB	CHEBI:3219
DM5PCS7	DE	Smoking dependence

DMKUOQV	ID	DMKUOQV
DMKUOQV	DN	Burosumab
DMKUOQV	HS	Approved
DMKUOQV	SN	Burosumab [USAN]; UNII-G9WJT6RD29; G9WJT6RD29
DMKUOQV	CP	Ultragenyx Pharmaceutical/Kyowa Hakko Kirin
DMKUOQV	DT	Antibody
DMKUOQV	DE	X-linked hypophosphataemia

DMBS632	ID	DMBS632
DMBS632	DN	Buspirone
DMBS632	HS	Approved
DMBS632	SN	Ansial; Ansiced; Anxiron; Axoren; Bespar; Buspirona; Buspironum; Buspisal; Ansial (TN); Ansiced (TN); Anxiron (TN); Axoren (TN); Bespar (TN); BuSpar (TN); Buspimen (TN); Buspinol (TN); Buspiron (TN); Buspirona [INN-Spanish]; Buspirone (INN); Buspirone [INN:BAN]; Buspirone-MDTS; Buspironum [INN-Latin]; Buspisal (TN); Gen-Buspirone; Narol (TN); Sorbon (TN); Spamilan (TN); Spitomin (TN); Gen-Buspirone (TN); MJ-9022-1; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
DMBS632	CP	Bristol-Myers Squibb
DMBS632	TC	Antianxiety Agents
DMBS632	DT	Small molecular drug
DMBS632	PC	2477
DMBS632	MW	385.5
DMBS632	FM	C21H31N5O2
DMBS632	IC	InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
DMBS632	CS	C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
DMBS632	IK	QWCRAEMEVRGPNT-UHFFFAOYSA-N
DMBS632	IU	8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
DMBS632	CA	CAS 36505-84-7
DMBS632	CB	CHEBI:3223
DMBS632	DE	Anxiety disorder

DMXYJ9C	ID	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	HS	Approved
DMXYJ9C	SN	Busulfano; Busulfanum; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Citosulfan; Glyzophrol; Leucosulfan; Mablin; Methanesulfonic; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum; Mylecytan; Myleran; Mylerlan; Sulfabutin; Sulphabutin; Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome; Busulfan Wellcome Brand; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Myleran tablets; Orphan Brand of Busulfan; Tetramethylene bis[methanesulfonate]; Tetramethylene dimethane sulfonate; Tetramethylenester kyseliny methansulfonove; Tetramethylenester kyseliny methansulfonove[Czech]; Wellcome Brand of Busulfan; AN 33501; CB 2041; GT 2041; GT 41; X 149; Acid, tetramethylene ester; Alkylating agent: crosslinks guanine residues; Busulfan [INN:JAN]; Busulfano [INN-Spanish]; Busulfanum [INN-Latin]; MYLERAN (TN); Methanesulfonic acid, tetram ethylene ester; Methanesulfonic acid, tetramethylene ester; Myleran (TN); Sulfabutin (VAN); Tetramethylene bis(methanesulfonate); Tetramethylene {bis[methanesulfonate]}; Wellcome, Busulfan; C.B. 2041; G.T. 41; Myleran, Busulfex, Busulfan; Busulfan (JP15/USP/INN); Butane-1,4-diyl dimethanesulfonate; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); N-Butane-1,3-di(methylsulfonate); 1,4-BUTANEDIOL DIMETHANESULFONATE; 1,4-Bis(methanesulfonoxy)butane; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Bis[methanesulfonoxy]butane; 1,4-Butanedi yl dimethanesulfonate; 1,4-Butanediol dimethanesulphonate; 1,4-Butanediol dimethylsulfonate; 1,4-Butanediol, dimethanesulfonate; 1,4-Butanediol, dimethanesulphonate; 1,4-Butanediyl dimethanesulfonate; 1,4-Di(methylsulfonoxy)butane; 1,4-Dimesyloxybutane; 1,4-Dimethane sulfonyl oxybutane; 1,4-Dimethanesulfonoxybutane; 1,4-Dimethanesulfonoxylbutane; 1,4-Dimethanesulfonyloxybutane; 1,4-Dimethanesulphonyloxybutane; 1,4-Dimethylsulfonoxybutane; 1,4-Dimethylsulfonyloxybutane; 1,{4-Bis[methanesulfonoxy]butane}; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 4-methylsulfonyloxybutyl methanesulfonate
DMXYJ9C	CP	GlaxoSmithKline
DMXYJ9C	TC	Anticancer Agents
DMXYJ9C	DT	Small molecular drug
DMXYJ9C	PC	2478
DMXYJ9C	MW	246.3
DMXYJ9C	FM	C6H14O6S2
DMXYJ9C	IC	InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
DMXYJ9C	CS	CS(=O)(=O)OCCCCOS(=O)(=O)C
DMXYJ9C	IK	COVZYZSDYWQREU-UHFFFAOYSA-N
DMXYJ9C	IU	4-methylsulfonyloxybutyl methanesulfonate
DMXYJ9C	CA	CAS 55-98-1
DMXYJ9C	CB	CHEBI:28901
DMXYJ9C	DE	Myeloproliferative syndrome

DMC5AST	ID	DMC5AST
DMC5AST	DN	Butabarbital
DMC5AST	HS	Approved
DMC5AST	SN	Butabarb; Butabarbitone; Butalan; Butatab; Butatal; Buticaps; Butisol; Butrate; Medarsed; Nilox; Sarisol; Secbubarbital; Secbutabarbital; Secbutabarbitale; Secbutabarbitalum; Secbutobarbital; Secbutobarbitone; Unicelles; Butabarbital [USAN]; Butisol sodium; Secbutabarbital [INN]; Secbutabarbitale [DCIT]; Sodium butabarbital;Butabarbital (USP); Butabarbital (VAN); Butisol (TN); Sec-Butobarbitone; Secbutabarbitalum [INN-Latin]; 5-(butan-2-yl)-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylpropyl)barbiturate; 5-Ethyl-5-(1-methylpropyl)barbituric acid; 5-Ethyl-5-isobutylbarbituric acid; 5-SEC-BUTYL-5-ETHYL-BARBITURIC ACID; 5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(1-methylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-sec-Butyl-5-ethylbarbituric acid; 5-sec-Butyl-5-ethylmalonyl urea; 5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
DMC5AST	TC	Antianxiety Agents
DMC5AST	DT	Small molecular drug
DMC5AST	PC	2479
DMC5AST	MW	212.25
DMC5AST	FM	C10H16N2O3
DMC5AST	IC	InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
DMC5AST	CS	CCC(C)C1(C(=O)NC(=O)NC1=O)CC
DMC5AST	IK	ZRIHAIZYIMGOAB-UHFFFAOYSA-N
DMC5AST	IU	5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione
DMC5AST	CA	CAS 125-40-6
DMC5AST	CB	CHEBI:3228
DMC5AST	DE	Insomnia

DM584TM	ID	DM584TM
DM584TM	DN	Butacaine
DM584TM	HS	Approved
DM584TM	SN	Butacaine sulfate; Butelline; Butyn; 149-15-5; Butacaine sulphate; Butacaine sulfate [USP]; UNII-PAU39W3CVB; EINECS 205-733-1; PAU39W3CVB; p-Aminobenzoyldibutylaminopropanol sulfate; Dibutylaminopropyl p-aminobenzoate sulfate; AI3-02405; 3'-Dibutylaminopropyl 4-aminobenzoate sulfate; 1-Propanol, 3-(dibutylamino)-, 4-aminobenzoate (ester), sulfate (2:1) (salt); 3-(p-Aminobenzoxy)-1-di-N-butylaminopropane sulfate; 3-(Dibutylamino)-1-propanol p-aminobenzoate (ester) sulfate (2:1)
DM584TM	DT	Small molecular drug
DM584TM	PC	2480
DM584TM	MW	306.4
DM584TM	FM	C18H30N2O2
DM584TM	IC	InChI=1S/C18H30N2O2/c1-3-5-12-20(13-6-4-2)14-7-15-22-18(21)16-8-10-17(19)11-9-16/h8-11H,3-7,12-15,19H2,1-2H3
DM584TM	CS	CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N
DM584TM	IK	HQFWVSGBVLEQGA-UHFFFAOYSA-N
DM584TM	IU	3-(dibutylamino)propyl 4-aminobenzoate
DM584TM	CA	CAS 149-16-6
DM584TM	CB	CHEBI:94820
DM584TM	DE	Pain

DM9J04X	ID	DM9J04X
DM9J04X	DN	Butalbital
DM9J04X	HS	Approved
DM9J04X	SN	Alisobumal; Alisobumalum; Allylbarbital; Allylbarbitone; Allylisobutylbarbital; Allylisobutylbarbiturate; Butalbarbital;Butalbitale; Butalbitalum; Itobarbital; Profundal; Sandoptal; Tetrallobarbital; Butalbitale [DCIT]; Axocet (TN); Axotal (TN); Bucet (TN); Bupap (TN); Butalbital [USAN:INN]; Butalbitalum [INN-Latin]; Cephadyn (TN); Dolgic (TN); Esgic (TN); Fioricet (TN); Fiorinal (TN); Fiormor (TN); Fiortal (TN); Fortabs (TN); IBS-L0126512; Iso-butylallylbarbituric acid; Laniroif (TN); Phrenilin (TN); Phrenilin Forte (TN); Sandoptal (TN); Sedapap (TN); Butalbital (USP/INN); Esgic-Plus (TN); 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; 5-Allyl-5-(2'-methyl-n-propyl) barbituric acid; 5-Allyl-5-(2-methylpropyl)barbituric acid; 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione; 5-Allyl-5-isobutylbarbituric acid
DM9J04X	TC	Analgesics
DM9J04X	DT	Small molecular drug
DM9J04X	PC	2481
DM9J04X	MW	224.26
DM9J04X	FM	C11H16N2O3
DM9J04X	IC	InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
DM9J04X	CS	CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C
DM9J04X	IK	UZVHFVZFNXBMQJ-UHFFFAOYSA-N
DM9J04X	IU	5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM9J04X	CA	CAS 77-26-9
DM9J04X	CB	CHEBI:102524
DM9J04X	DE	Anxiety disorder; Headache

DMOJ4ZI	ID	DMOJ4ZI
DMOJ4ZI	DN	Butenafine
DMOJ4ZI	HS	Approved
DMOJ4ZI	SN	Butenafina; Butenafinum; Mentax; Butenafine HCL; Butenafine [INN]; Butenafine hydrochloride; KP 363; Butenafina [INN-Spanish]; Butenafine (INN); Butenafinum [INN-Latin]; Butop (TN); KP-363; Mentax (TN); N-4-tert-butylbenzyl-N-methyl-1-naphthalene methylamine hydrochloride; N-p-tert-Butylbenzyl-N-methyl-1-naphthalenemethylamine; N-(p-tert-Butylbenzyl)-N-methyl-1-naphthalenemethylamine; 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine; 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
DMOJ4ZI	CP	Schering-Plough
DMOJ4ZI	TC	Antifungal Agents
DMOJ4ZI	DT	Small molecular drug
DMOJ4ZI	PC	2484
DMOJ4ZI	MW	317.5
DMOJ4ZI	FM	C23H27N
DMOJ4ZI	IC	InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3
DMOJ4ZI	CS	CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32
DMOJ4ZI	IK	ABJKWBDEJIDSJZ-UHFFFAOYSA-N
DMOJ4ZI	IU	1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine
DMOJ4ZI	CA	CAS 101828-21-1
DMOJ4ZI	CB	CHEBI:3238
DMOJ4ZI	DE	Dermatologic infection

DM7JHX0	ID	DM7JHX0
DM7JHX0	DN	Butethal
DM7JHX0	HS	Approved
DM7JHX0	SN	Aethylbutylbarbitursaeure; Budorm; Butabarbitol; Butobarbital; Butobarbitalum; Butobarbitone; Butobarbitural; Etoval; Hyperbutal; Longanoct; Meonal; Monodorm; Neonal; Sonerile; Soneryl; Butobarbital [BAN]; Butobarbital (BAN); Neonal (TN); Butyl,5-ethylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-butyl-5-ethyl-(9CI); 5-BUTYL-5-ETHYLBARBITURIC ACID; 5-Butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-butylbarbituric acid; 5-Ethyl-5-n-butylbarbituric acid; 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione
DM7JHX0	TC	Hypnotics and Sedatives
DM7JHX0	DT	Small molecular drug
DM7JHX0	PC	6473
DM7JHX0	MW	212.25
DM7JHX0	FM	C10H16N2O3
DM7JHX0	IC	InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15)
DM7JHX0	CS	CCCCC1(C(=O)NC(=O)NC1=O)CC
DM7JHX0	IK	STDBAQMTJLUMFW-UHFFFAOYSA-N
DM7JHX0	IU	5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione
DM7JHX0	CA	CAS 77-28-1
DM7JHX0	CB	CHEBI:134884
DM7JHX0	DE	Insomnia

DM8SY60	ID	DM8SY60
DM8SY60	DN	Butoconazole
DM8SY60	HS	Approved
DM8SY60	SN	Butaconazole; Butoconazol; Butoconazolum; Femstat; Gynofort; Duplicate RN for parent cpd; RS 35887; Butoconazol [INN-Spanish]; Butoconazole (INN); Butoconazole [INN:BAN]; Butoconazolum [INN-Latin]; Gynofort (TN); RS 35887-10-3; (+-)-1-[4-(4-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole; (+/-)-1-[4-(p-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]imidazole; (-)-1-((4-(p-Chlorophenyl)-2-((2,6-dichlorophenyl)thio)imidazole; 1-(4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl)-1H-imidazole; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole; 1-{4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl}-1H-imidazole; 1H-Imidazole; 1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, nitrate
DM8SY60	CP	Roche Palo Alto Llc
DM8SY60	TC	Antifungal Agents
DM8SY60	DT	Small molecular drug
DM8SY60	PC	47472
DM8SY60	MW	411.8
DM8SY60	FM	C19H17Cl3N2S
DM8SY60	IC	InChI=1S/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2
DM8SY60	CS	C1=CC(=C(C(=C1)Cl)SC(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)Cl
DM8SY60	IK	SWLMUYACZKCSHZ-UHFFFAOYSA-N
DM8SY60	IU	1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole
DM8SY60	CA	CAS 64872-76-0
DM8SY60	CB	CHEBI:3240
DM8SY60	DE	Candidiasis

DM5KYPJ	ID	DM5KYPJ
DM5KYPJ	DN	Butorphanol
DM5KYPJ	HS	Approved
DM5KYPJ	SN	Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL
DM5KYPJ	CP	Apotex Inc
DM5KYPJ	TC	Analgesics
DM5KYPJ	DT	Small molecular drug
DM5KYPJ	PC	5361092
DM5KYPJ	MW	327.5
DM5KYPJ	FM	C21H29NO2
DM5KYPJ	IC	InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
DM5KYPJ	CS	C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O
DM5KYPJ	IK	IFKLAQQSCNILHL-QHAWAJNXSA-N
DM5KYPJ	IU	(1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
DM5KYPJ	CA	CAS 42408-82-2
DM5KYPJ	CB	CHEBI:3242
DM5KYPJ	DE	Pain

DMZKXB7	ID	DMZKXB7
DMZKXB7	DN	Butylscopolamine
DMZKXB7	HS	Approved
DMZKXB7	SN	AC1LCV8Y
DMZKXB7	DT	Small molecular drug
DMZKXB7	PC	160883
DMZKXB7	MW	360.5
DMZKXB7	FM	C21H30NO4+
DMZKXB7	IC	InChI=1S/C21H30NO4/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14/h5-9,15-20,23H,3-4,10-13H2,1-2H3/q+1/t15?,16-,17-,18+,19-,20+,22?/m1/s1
DMZKXB7	CS	CCCC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C
DMZKXB7	IK	YBCNXCRZPWQOBR-MWGADRMYSA-N
DMZKXB7	IU	[(1S,2S,4R,5R)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMZKXB7	CA	CAS 7182-53-8
DMZKXB7	CB	CHEBI:145701
DMZKXB7	DE	Dysmenorrhea

DMPAZHC	ID	DMPAZHC
DMPAZHC	DN	Cabazitaxel
DMPAZHC	HS	Approved
DMPAZHC	SN	Jevtana; Taxoid XRP6258; Jevtana (TN)
DMPAZHC	CP	Sanofi-Aventis
DMPAZHC	DT	Small molecular drug
DMPAZHC	PC	9854073
DMPAZHC	MW	835.9
DMPAZHC	FM	C45H57NO14
DMPAZHC	IC	InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
DMPAZHC	CS	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
DMPAZHC	IK	BMQGVNUXMIRLCK-OAGWZNDDSA-N
DMPAZHC	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMPAZHC	CA	CAS 183133-96-2
DMPAZHC	CB	CHEBI:63584
DMPAZHC	DE	Breast cancer; Solid tumour/cancer

DMQ4HIN	ID	DMQ4HIN
DMQ4HIN	DN	Cabergoline
DMQ4HIN	HS	Approved
DMQ4HIN	SN	Cabaser; Cabaseril; Cabergolina; Cabergolinum; Dostinex; Galastop; Sogilen; Cabergolina [Spanish]; Cabergolinum [Latin]; CG-101; Cabaser (TN); Dostinex (TN); FCE-21336; Cabergoline [USAN:BAN:INN]; Cabergoline (JAN/USAN/INN); (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
DMQ4HIN	CP	Pfizer Pharmaceuticals
DMQ4HIN	TC	Anticancer Agents
DMQ4HIN	DT	Small molecular drug
DMQ4HIN	PC	54746
DMQ4HIN	MW	451.6
DMQ4HIN	FM	C26H37N5O2
DMQ4HIN	IC	InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
DMQ4HIN	CS	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
DMQ4HIN	IK	KORNTPPJEAJQIU-KJXAQDMKSA-N
DMQ4HIN	IU	(6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMQ4HIN	CA	CAS 81409-90-7
DMQ4HIN	CB	CHEBI:3286
DMQ4HIN	DE	Hyperprolactinaemia

DMIYDT4	ID	DMIYDT4
DMIYDT4	DN	Cabozantinib
DMIYDT4	HS	Approved
DMIYDT4	SN	Cabometyx; Cometriq
DMIYDT4	CP	Exelixis
DMIYDT4	DT	Small molecular drug
DMIYDT4	PC	25102847
DMIYDT4	MW	501.5
DMIYDT4	FM	C28H24FN3O5
DMIYDT4	IC	InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
DMIYDT4	CS	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
DMIYDT4	IK	ONIQOQHATWINJY-UHFFFAOYSA-N
DMIYDT4	IU	1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMIYDT4	CA	CAS 849217-68-1
DMIYDT4	CB	CHEBI:72317
DMIYDT4	DE	Thyroid cancer; Ovarian cancer

DMKBJWP	ID	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	HS	Approved
DMKBJWP	SN	CFF; Cafamil; Cafecon; Cafeina; Cafeine; Caffedrine; Caffein; Caffeina; Caffenium; Caffine; Cafipel; Coffein; Coffeine; Coffeinum; DHCplus; Dasin; Dexitac; Diurex; Durvitan; Enerjets; Ercatab; Guaranine; Hycomine; Kofein; Koffein; Mateina; Methyltheobromide; Methyltheobromine; Miudol; Nodaca; Organex; Percutafeine; Phensal; Stim; Teina; Thein; Theine; Tirend; Vivarin; Anacin Maximum Strength; Anhydrous caffeine; Caffedrine Caplets; Caffeina [Italian]; Caffeine Pure; Caffeine solution; Coffein [German]; Coffeinum N; Coffeinum Purrum; Component of Cafergot; DHC Plus; Dexitac Stay Alert Stimulant; Eldiatric C; GlaxoSmithKline Brand of Caffeine; Hycomine Compound; Keep Alert; Kofein [Czech]; Koffein [German]; Merck dura Brand of Caffeine; Methylxanthine theophylline; Midol Maximum Strength; Monomethyl derivative of Theophylline; Natural Caffeinum; Nix Nap; No Doz; Nodoz Maximum Strength Caplets; Passauer Brand of Caffeine; Percoffedrinol N; Pierre Fabre Brand of Caffeine; Quick Pep; Republic Drug Brand of Caffeine; Seid Brand of Caffeine; Theobromine Me; Theophylline Me; C 0750; Propoxyphene Compound 65; SK 65 Compound; TNP00310; Thompson Brand 1 of Caffeine; Thompson Brand 2 of Caffeine; Alert-pep; Anhydrous caffeine (JP15); Anhydrous caffeine (TN); Berlin-Chemie Brand of Caffeine; Bristol-Myers Squibb Brand of Caffeine; Cafcit (TN); Caffeine (USP); Caffeine (natural); Caffeine [BAN:JAN]; Caffeine, Monohydrate; Caffeine, anhydrous; Caffeine, synthetic; No-Doz; Pep-Back; Propoxyphene Compound-65; Quick-Pep; Refresh'n; SK-65 Compound; Tri-Aqua; Ultra Pep-Back; Wake-Up; CU-01000012617-3; P-A-C Analgesic Tablets; Theophylline, 7-methyl; Xanthine, 1,3,7-trimethyl; 1,3,7-Trimethyl-2,6-dioxopurine; 1,3,7-Trimethylpurine-2,6-dione; 1,3,7-Trimethylxanthine; 1-3-7-TRIMETHYLXANTHINE; 1-methyltheobromine; 3,7-dihydro-1,3,7-trimethyl-1H-purine; 7-Methyltheophylline
DMKBJWP	CP	Ben Venue Laboratories
DMKBJWP	TC	Antihypertensive Agents
DMKBJWP	DT	Small molecular drug
DMKBJWP	PC	2519
DMKBJWP	MW	194.19
DMKBJWP	FM	C8H10N4O2
DMKBJWP	IC	InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
DMKBJWP	CS	CN1C=NC2=C1C(=O)N(C(=O)N2C)C
DMKBJWP	IK	RYYVLZVUVIJVGH-UHFFFAOYSA-N
DMKBJWP	IU	1,3,7-trimethylpurine-2,6-dione
DMKBJWP	CA	CAS 58-08-2
DMKBJWP	CB	CHEBI:27732
DMKBJWP	DE	Orthostatic hypotension

DMQZBXI	ID	DMQZBXI
DMQZBXI	DN	Calaspargase pegol
DMQZBXI	HS	Approved
DMQZBXI	SN	UNII-T9FVH03HMZ; T9FVH03HMZ; Calaspargase pegol [USAN:INN]; EZN-2285
DMQZBXI	CP	Servier
DMQZBXI	DT	Antibody
DMQZBXI	DE	Acute lymphoblastic leukaemia; Acute lymphocytic leukaemia

DMN4CV5	ID	DMN4CV5
DMN4CV5	DN	Calcidiol
DMN4CV5	HS	Approved
DMN4CV5	SN	Calcifediolum; Calcifidiol; Delakmin; VDY; Calcifediol anhydrous; BML2-E02; Calcifediolum [INN-Latin]; Ro 8-8892; U-32070E; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 25(OH)D3; 25-(OH)Vitamin D3; 25-Hydroxycholecalciferol; 25-Hydroxycholecalciferol (Calcifediol); 25-Hydroxycholescalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3 monohydrate; 25-hydroxyvitamin D3; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 5,6-cis-25-Hydroxyvitamin D3; 5,6-trans-25-Hydroxycholescalciferol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol
DMN4CV5	CP	United Research Laboratories
DMN4CV5	TC	Vitamins
DMN4CV5	DT	Small molecular drug
DMN4CV5	PC	5283731
DMN4CV5	MW	400.6
DMN4CV5	FM	C27H44O2
DMN4CV5	IC	InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
DMN4CV5	CS	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMN4CV5	IK	JWUBBDSIWDLEOM-DTOXIADCSA-N
DMN4CV5	IU	(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMN4CV5	CA	CAS 19356-17-3
DMN4CV5	CB	CHEBI:17933
DMN4CV5	DE	Vitamin D deficiency

DM03CP7	ID	DM03CP7
DM03CP7	DN	Calcipotriol
DM03CP7	HS	Approved
DM03CP7	SN	Calcipotriene; Divonex; Dovonex; BMS-181161; Daivonex (TN); Dovonex (TN); MC-903; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3
DM03CP7	CP	LEO Pharma Inc
DM03CP7	TC	Antipsoriatic Agents
DM03CP7	DT	Small molecular drug
DM03CP7	PC	5288783
DM03CP7	MW	412.6
DM03CP7	FM	C27H40O3
DM03CP7	IC	InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1
DM03CP7	CS	C[C@H](/C=C/[C@H](C1CC1)O)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DM03CP7	IK	LWQQLNNNIPYSNX-UROSTWAQSA-N
DM03CP7	IU	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM03CP7	CA	CAS 112965-21-6
DM03CP7	CB	CHEBI:50749
DM03CP7	DE	Psoriasis vulgaris

DM0N9WA	ID	DM0N9WA
DM0N9WA	DN	Calcitonin Human
DM0N9WA	HS	Approved
DM0N9WA	CP	Novartis Pharmaceuticals Corp
DM0N9WA	TC	Anticancer Agents
DM0N9WA	PC	45055432
DM0N9WA	MW	3417.9
DM0N9WA	FM	C151H226N40O45S3
DM0N9WA	IC	InChI=1S/C151H226N40O45S3/c1-17-75(8)118(144(229)163-67-114(205)183-117(74(6)7)143(228)162-64-112(203)165-77(10)150(235)190-50-29-38-106(190)124(158)209)185-125(210)76(9)166-145(230)120(79(12)194)186-131(216)92(45-47-109(155)200)170-142(227)107-39-30-51-191(107)151(236)103(58-85-35-25-20-26-36-85)180-148(233)122(81(14)196)188-139(224)99(59-87-63-159-71-164-87)176-133(218)96(55-83-31-21-18-22-32-83)174-128(213)90(37-27-28-49-152)168-136(221)101(61-111(157)202)177-134(219)97(56-84-33-23-19-24-34-84)175-137(222)102(62-116(207)208)178-129(214)91(44-46-108(154)199)171-147(232)121(80(13)195)187-138(223)98(57-86-40-42-88(198)43-41-86)179-146(231)119(78(11)193)184-115(206)66-161-127(212)94(53-72(2)3)172-130(215)93(48-52-237-16)169-141(226)105-70-239-238-69-89(153)126(211)160-65-113(204)167-100(60-110(156)201)135(220)173-95(54-73(4)5)132(217)181-104(68-192)140(225)189-123(82(15)197)149(234)182-105/h18-26,31-36,40-43,63,71-82,89-107,117-123,192-198H,17,27-30,37-39,44-62,64-70,152-153H2,1-16H3,(H2,154,199)(H2,155,200)(H2,156,201)(H2,157,202)(H2,158,209)(H,159,164)(H,160,211)(H,161,212)(H,162,228)(H,163,229)(H,165,203)(H,166,230)(H,167,204)(H,168,221)(H,169,226)(H,170,227)(H,171,232)(H,172,215)(H,173,220)(H,174,213)(H,175,222)(H,176,218)(H,177,219)(H,178,214)(H,179,231)(H,180,233)(H,181,217)(H,182,234)(H,183,205)(H,184,206)(H,185,210)(H,186,216)(H,187,223)(H,188,224)(H,189,225)(H,207,208)/t75-,76-,77-,78+,79+,80+,81+,82+,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-,122-,123-/m0/s1
DM0N9WA	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]8CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)CO)CC(C)C)CC(=O)N)N
DM0N9WA	IK	LDVRMNJZLWXJPL-JKQNMTHDSA-N
DM0N9WA	IU	(3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10-(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DM0N9WA	CB	CHEBI:135973
DM0N9WA	DE	Postmenopausal osteoporosis; Pain; Paget's disease

DM8ZVJ7	ID	DM8ZVJ7
DM8ZVJ7	DN	Calcitriol
DM8ZVJ7	HS	Approved
DM8ZVJ7	SN	calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101;  Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)
DM8ZVJ7	CP	Cytotech Labs LLC
DM8ZVJ7	DT	Small molecular drug
DM8ZVJ7	PC	5280453
DM8ZVJ7	MW	416.6
DM8ZVJ7	FM	C27H44O3
DM8ZVJ7	IC	InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
DM8ZVJ7	CS	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM8ZVJ7	IK	GMRQFYUYWCNGIN-NKMMMXOESA-N
DM8ZVJ7	IU	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM8ZVJ7	CA	CAS 32222-06-3
DM8ZVJ7	CB	CHEBI:17823
DM8ZVJ7	DE	Congenital alopecia

DM3W15N	ID	DM3W15N
DM3W15N	DN	Calcium carbimide
DM3W15N	HS	Approved
DM3W15N	SN	Nitrolime; Alzodef; Aero cyanamid granular; USAF CY-2; Aero cyanamid special grade; Nitrolim; Cyanamid; Calcium cyanamid; Lime Nitroget; Cyanamid granular; NCI-C02937; CY-L 500; Cyanamid special grade; UN 1403, Nitrolime; WLN: CA NCN; NSC7078; NSC-7078
DM3W15N	DT	Small molecular drug
DM3W15N	PC	56955933
DM3W15N	MW	80.1
DM3W15N	FM	CCaN2
DM3W15N	IC	InChI=1S/CN2.Ca/c2-1-3;/q-2;+2
DM3W15N	CS	C(=[N-])=[N-].[Ca+2]
DM3W15N	IK	MYFXBBAEXORJNB-UHFFFAOYSA-N
DM3W15N	IU	calcium;azanidylidenemethylideneazanide
DM3W15N	CA	CAS 156-62-7
DM3W15N	CB	CHEBI:64301
DM3W15N	DE	Alcohol dependence

DMJ3CFY	ID	DMJ3CFY
DMJ3CFY	DN	Calcium phosphate dihydrate
DMJ3CFY	HS	Approved
DMJ3CFY	SN	Calcium phosphate dihydrate
DMJ3CFY	DT	Small molecular drug
DMJ3CFY	PC	22340838
DMJ3CFY	MW	346.204
DMJ3CFY	FM	Ca3H4O10P2
DMJ3CFY	IC	InChI=1S/3Ca.2H3O4P.2H2O/c;;;2*1-5(2,3)4;;/h;;;2*(H3,1,2,3,4);2*1H2/q3*+2;;;;/p-6
DMJ3CFY	CS	O.O.[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
DMJ3CFY	IK	WKMXOPXIVBEXRR-UHFFFAOYSA-H
DMJ3CFY	IU	tricalcium;diphosphate;dihydrate
DMJ3CFY	DE	Dental Caries

DMWIO46	ID	DMWIO46
DMWIO46	DN	Camphor
DMWIO46	HS	Approved
DMWIO46	SN	camphor; 76-22-2; 2-Camphanone; 2-Bornanone; DL-Camphor; (+)-Camphor; l-(-)-Camphor; (+/-)-Camphor; Root bark oil; 1,7,7-Trimethylbicyclo[2.2.1]heptan-2-one; Bornan-2-one; Alphanon; Kampfer; Gum camphor; Spirit of camphor; Formosa camphor; Laurel camphor; 2-Camphonone; Matricaria camphor; Camphor, synthetic; Bornane, 2-oxo-; 1,7,7-Trimethylnorcamphor; Root bark spirit; 2-Keto-1,7,7-trimethylnorcamphane; DL-Bornan-2-one; D-(+)-Camphor; Norcamphor, 1,7,7-trimethyl-; 21368-68-3; Camphor, (1R,4R)-(+)-; Bicyclo[2.2.1]heptan-2-one, 1,7,7-tri
DMWIO46	DT	Small molecular drug
DMWIO46	PC	2537
DMWIO46	MW	152.23
DMWIO46	FM	C10H16O
DMWIO46	IC	InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3
DMWIO46	CS	CC1(C2CCC1(C(=O)C2)C)C
DMWIO46	IK	DSSYKIVIOFKYAU-UHFFFAOYSA-N
DMWIO46	IU	1,7,7-trimethylbicyclo[2.2.1]heptan-2-one
DMWIO46	CA	CAS 76-22-2
DMWIO46	CB	CHEBI:36773
DMWIO46	DE	Acute or chronic pain

DMFRM1I	ID	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	HS	Approved
DMFRM1I	SN	842133-18-0; Invokana; Canagliflozin anhydrous; canagliflozin hemihydrate; UNII-6S49DGR869; JNJ-28431754; JNJ 24831754ZAE; Canagliflozin hydrate; TA-7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; 928672-86-0
DMFRM1I	CP	Johnson & Johnson
DMFRM1I	DT	Small molecular drug
DMFRM1I	PC	24812758
DMFRM1I	MW	444.5
DMFRM1I	FM	C24H25FO5S
DMFRM1I	IC	InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
DMFRM1I	CS	CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
DMFRM1I	IK	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
DMFRM1I	IU	(2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMFRM1I	CA	CAS 842133-18-0
DMFRM1I	CB	CHEBI:73274
DMFRM1I	DE	Type-2 diabetes; Diabetic nephropathy; Type-1 diabetes

DM8HLO5	ID	DM8HLO5
DM8HLO5	DN	Canakinumab
DM8HLO5	HS	Approved
DM8HLO5	SN	Ilaris (TN)
DM8HLO5	CP	Novartis
DM8HLO5	DT	Antibody
DM8HLO5	SQ	8836_H|canakinumab|Homo sapiens||H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217-231)+CH2(232-341)+CH3(342-448))|||||||448||||MW 49253.6|MW 49253.6|: QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;8836_L|canakinumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23357.9|MW 23357.9|QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLEIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM8HLO5	DE	Vasculitis; Urticaria; Rheumatoid arthritis; Cryopyrin-associated periodic syndromes

DMRK8OT	ID	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	HS	Approved
DMRK8OT	SN	candesartan; 139481-59-7; Blopress; Ratacand; CV-11974; 1-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid; CV 11974; UNII-S8Q36MD2XX; 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; CHEMBL1016; S8Q36MD2XX; 2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid; CHEBI:3347; C24H20N6O3; 2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid; NCGC00167474-01; AK-57139;  Blopress; Candesartan [BAN]; CV11974; Amias (TN); Atacand (TN); Blopress (TN); Candesartan [USAN:INN]; KS-5003; Ratacand (TN); Candesartan (USAN/INN); Atacand, Blopress, Amias, Ratacand,Candesartan; 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid; 2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole; [3H]candesartan
DMRK8OT	CP	AstraZeneca
DMRK8OT	TC	Antihypertensive Agents
DMRK8OT	DT	Small molecular drug
DMRK8OT	PC	2541
DMRK8OT	MW	440.5
DMRK8OT	FM	C24H20N6O3
DMRK8OT	IC	InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)
DMRK8OT	CS	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
DMRK8OT	IK	HTQMVQVXFRQIKW-UHFFFAOYSA-N
DMRK8OT	IU	2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMRK8OT	CA	CAS 139481-59-7
DMRK8OT	CB	CHEBI:3347
DMRK8OT	DE	Hypertension

DMNZSC1	ID	DMNZSC1
DMNZSC1	DN	Candicidin
DMNZSC1	HS	Approved
DMNZSC1	SN	(23E,25E,27E,29E,31E,33E,35E)-22-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid
DMNZSC1	TC	Antibiotics
DMNZSC1	DT	Small molecular drug
DMNZSC1	PC	10079874
DMNZSC1	MW	1109.3
DMNZSC1	FM	C59H84N2O18
DMNZSC1	IC	InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-56(74)54(61)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)/b6-5+,9-7+,10-8+,13-11+,14-12+,18-15+,21-16+/t35?,36?,37?,38-,43?,44?,45?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59?/m1/s1
DMNZSC1	CS	C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC\\2CC(C(C(CC(=O)CC(CC(CC(CC(=O)CCCC(=O)CC(=O)OC(C(/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C)C(C)CC(C)C(CC(=O)C3=CC=C(C=C3)N)O)O)O)O)O)C(=O)O)O)O)N)O
DMNZSC1	IK	OPGSFDUODIJJGF-JBUZINEHSA-N
DMNZSC1	IU	(23E,25E,27E,29E,31E,33E,35E)-22-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-38-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid
DMNZSC1	CA	CAS 1403-17-4
DMNZSC1	CB	CHEBI:3349
DMNZSC1	DE	Bacterial infection

DM8JRH0	ID	DM8JRH0
DM8JRH0	DN	Cangrelor
DM8JRH0	HS	Approved
DM8JRH0	SN	Cangrelor; 163706-06-7; Kengreal; UNII-6AQ1Y404U7; AR-C69931XX; CHEMBL334966; 6AQ1Y404U7; kengrexal; 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine; 5'-Adenylicacid,N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-,anhydridewithP,P'-(dichloromethylene)bis[phosphonicacid](1:1)
DM8JRH0	CP	The Medicines Company
DM8JRH0	DT	Small molecular drug
DM8JRH0	PC	9854012
DM8JRH0	MW	776.4
DM8JRH0	FM	C17H25Cl2F3N5O12P3S2
DM8JRH0	IC	InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1
DM8JRH0	CS	CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O
DM8JRH0	IK	PAEBIVWUMLRPSK-IDTAVKCVSA-N
DM8JRH0	IU	[dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
DM8JRH0	CA	CAS 163706-06-7
DM8JRH0	CB	CHEBI:90841
DM8JRH0	DE	Thrombosis

DM0659E	ID	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	HS	Approved
DM0659E	SN	cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; UNII-19GBJ60SN5; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; delta1(2)-trans-Cannabidiol; (-)-CBD; GWP42003-P; CBD; 19GBJ60SN5; QHMBSVQNZZTUGM-ZWKOTPCHSA-N
DM0659E	CP	GW Pharmaceuticals
DM0659E	DT	Small molecular drug
DM0659E	PC	644019
DM0659E	MW	314.5
DM0659E	FM	C21H30O2
DM0659E	IC	InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
DM0659E	CS	CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O
DM0659E	IK	QHMBSVQNZZTUGM-ZWKOTPCHSA-N
DM0659E	IU	2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
DM0659E	CA	CAS 13956-29-1
DM0659E	CB	CHEBI:69478
DM0659E	DE	LennoxGastaut syndrome; Dravet syndrome; Epilepsy; Infantile spasm

DMBP5N3	ID	DMBP5N3
DMBP5N3	DN	Cantharidin
DMBP5N3	HS	Approved
DMBP5N3	SN	DSSTox_CID_21752; DSSTox_RID_79835; DSSTox_GSID_41752; CAS-56-25-7; NCGC00016247-01; Spectrum_001114; SpecPlus_000537; Spectrum4_000920; Spectrum2_000630; Prestwick0_000885; Spectrum3_000621; Prestwick1_000885; Spectrum5_001618; Prestwick2_000885; KBioSS_001594; KBioGR_001420; BSPBio_002182; MLS002153505; SCHEMBL152261; DivK1c_006633; SPBio_002889; SPBio_000600; CHEMBL299846; DTXSID7041752; KBio2_006730; KBio3_001682; KBio2_004162; KBio2_001594; KBio1_001577; MolPort-003-665-556; HMS1570B12; Tox21_110326; CCG-39927; Tox21_110326_1
DMBP5N3	DT	Small molecular drug
DMBP5N3	PC	5944
DMBP5N3	MW	196.2
DMBP5N3	FM	C10H12O4
DMBP5N3	IC	InChI=1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3/t5-,6+,9+,10-
DMBP5N3	CS	C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3
DMBP5N3	IK	DHZBEENLJMYSHQ-XCVPVQRUSA-N
DMBP5N3	IU	(1S,2R,6S,7R)-2,6-dimethyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
DMBP5N3	CA	CAS 56-25-7
DMBP5N3	CB	CHEBI:64213
DMBP5N3	DE	Molluscum contagiosum infection

DMTS85L	ID	DMTS85L
DMTS85L	DN	Capecitabine
DMTS85L	HS	Approved
DMTS85L	SN	Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340;R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)
DMTS85L	CP	Roche
DMTS85L	TC	Anticancer Agents
DMTS85L	DT	Small molecular drug
DMTS85L	PC	60953
DMTS85L	MW	359.35
DMTS85L	FM	C15H22FN3O6
DMTS85L	IC	InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
DMTS85L	CS	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O
DMTS85L	IK	GAGWJHPBXLXJQN-UORFTKCHSA-N
DMTS85L	IU	pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
DMTS85L	CA	CAS 154361-50-9
DMTS85L	CB	CHEBI:31348
DMTS85L	DE	Colorectal cancer; Breast cancer

DMPUKA7	ID	DMPUKA7
DMPUKA7	DN	Caplacizumab
DMPUKA7	HS	Approved
DMPUKA7	DT	Antibody
DMPUKA7	DE	Thrombotic thrombocytopenic purpura

DMYCXKL	ID	DMYCXKL
DMYCXKL	DN	Capmatinib
DMYCXKL	HS	Approved
DMYCXKL	SN	1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O
DMYCXKL	CP	Incyte
DMYCXKL	DT	Small molecular drug
DMYCXKL	PC	25145656
DMYCXKL	MW	412.4
DMYCXKL	FM	C23H17FN6O
DMYCXKL	IC	InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
DMYCXKL	CS	CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
DMYCXKL	IK	LIOLIMKSCNQPLV-UHFFFAOYSA-N
DMYCXKL	IU	2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
DMYCXKL	CA	CAS 1029712-80-8
DMYCXKL	DE	Hepatocellular carcinoma; Recurrent glioblastoma; Non-small-cell lung cancer

DMNZBRY	ID	DMNZBRY
DMNZBRY	DN	Capreomycin
DMNZBRY	HS	Approved
DMNZBRY	SN	Capreomycin Sulfate Standard; Capreomycin sulphate; Caprocin (Disulfate); Ogostal (Disulfate); (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
DMNZBRY	TC	Antibiotics
DMNZBRY	DT	Small molecular drug
DMNZBRY	PC	3000502
DMNZBRY	MW	1321.4
DMNZBRY	FM	C50H88N28O15
DMNZBRY	IC	InChI=1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1
DMNZBRY	CS	C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N.C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N
DMNZBRY	IK	VCOPTHOUUNAYKQ-WBTCAYNUSA-N
DMNZBRY	IU	(3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
DMNZBRY	CA	CAS 11003-38-6
DMNZBRY	DE	Bacterial infection; Mycobacterium infection

DM346QI	ID	DM346QI
DM346QI	DN	Capreomycin Sulfate
DM346QI	HS	Approved
DM346QI	SN	Capastat Sulfate
DM346QI	CP	Akorn Inc
DM346QI	DE	Tuberculosis

DMHERIJ	ID	DMHERIJ
DMHERIJ	DN	Capromab
DMHERIJ	HS	Approved
DMHERIJ	SN	Prostascint (TN)
DMHERIJ	TC	Imaging Agents
DMHERIJ	DT	Antibody
DMHERIJ	DE	Prostate cancer

DMGMF6V	ID	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	HS	Approved
DMGMF6V	SN	Capsaicin (transdermal patch formulation, neuropathic pain)
DMGMF6V	CP	Samyang Corp
DMGMF6V	DT	Small molecular drug
DMGMF6V	PC	1548943
DMGMF6V	MW	305.4
DMGMF6V	FM	C18H27NO3
DMGMF6V	IC	InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+
DMGMF6V	CS	CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC
DMGMF6V	IK	YKPUWZUDDOIDPM-SOFGYWHQSA-N
DMGMF6V	IU	(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
DMGMF6V	CA	CAS 404-86-4
DMGMF6V	CB	CHEBI:3374
DMGMF6V	DE	Neuropathic pain

DM458UM	ID	DM458UM
DM458UM	DN	Captopril
DM458UM	HS	Approved
DM458UM	SN	Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Asisten; Capoten; Captolane; Captoprilum; Captopryl; Captoril; Captril; Cesplon; Dilabar; Garranil; Hipertil; Hypertil; Isopresol; Lopirin; Lopril; MCO; Tenosbon; Tensiomin; Tensobon; Tensoprel; Lopirin [Switzerland]; C 4042; SA 333; SQ 14225; X8Z; Apopril (TN); Capoten (TN); Captoprilum [INN-Latin]; Garranil (discontinued); L-Captopril; SQ 14,225; SQ-14225; SQ-14534; SQ-14,225; SQ-14,534; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; D-3-Mercapto-2-methylpropionylproline; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline
DM458UM	CP	Bristol-Myers Squibb
DM458UM	TC	Antihypertensive Agents
DM458UM	DT	Small molecular drug
DM458UM	PC	44093
DM458UM	MW	217.29
DM458UM	FM	C9H15NO3S
DM458UM	IC	InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
DM458UM	CS	C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
DM458UM	IK	FAKRSMQSSFJEIM-RQJHMYQMSA-N
DM458UM	IU	(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
DM458UM	CA	CAS 62571-86-2
DM458UM	CB	CHEBI:3380
DM458UM	DE	Hypertension

DMX9K8F	ID	DMX9K8F
DMX9K8F	DN	Carbachol
DMX9K8F	HS	Approved
DMX9K8F	SN	Carbach; Carbacholin; Carbacholine; Carbacholinum; Carbacholum; Carbacol; Carbacolina; Carbacolo; Carbamiotin; Carbamoylcholine; Carbastat; Carbochol; Carbocholin; Carbocholine; Carbyl; Carcholin; Coletyl; Doryl; Jestryl; Karbachol; Lentin; Lentine; Miostat; Moryl; Rilentol; Vasoperif; CARBACHOL CHLORIDE; Carbachol hydrochloride; Carbacholine chloride; Carbacholini chloridum; Carbacholinium chloratum; Carbacholum chloratum; Carbacolo [DCIT]; Carbaminocholine chloride; Carbaminoylcholine chloride; Carbamoylcholine chloride; Carbamylcholine chloride; Choline carbamate chloride; Choline chloride carbamate; Choline chlorine carbamate; Isopto Carbachol; Karbachol [Czech]; Karbamoylcholin chlorid; Karbamoylcholin chlorid [Czech]; Lentine [French]; Mistura C; C 4382; TL 457; C-1770; Carbacholum [INN-Latin]; Carbacol [INN-Spanish]; Carbamic acid, ester with choline chloride; Carbamoylcholine-hydrochloride; Carbastat (TN); Carboptic (TN); Choline chloride, carbamate; Doryl (VAN); Doryl (pharmaceutical); Gamma-Carbamoyl choline chloride; Isopto Carbachol (TN); Miostat (TN); Carbachol [INN:BAN:JAN]; Choline, chloride carbamate(ester); Choline, chloride, carbamate; P. V. Carbachol; Carbachol (JAN/USP/INN); Choline, chloride, carbamate, hydrochloride; Ethanaminium, 2-(aminocarbonyl)oxy-N,N,N-trimethyl-, chloride; Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride (1:1); (2-Carbamoyloxy-ethyl)-trimethyl-ammonium; (2-Carbamoyloxy-ethyl)-trimethyl-ammonium(Carbachol); (2-Carbamoyloxyethyl)trimethylammonium chloride; (2-Hydroxyethyl)trimethyl ammonium chloride carbamate; (2-Hydroxyethyl)trimethylammonium chloride carbamate; (carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammonium; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride; 2-(carbamoyloxy)-N,N,N-trimethylethanaminium chloride; 2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanaminium chloride; 2-carbamoyloxyethyl(trimethyl)azanium chloride
DMX9K8F	CP	Norvatis Phamaceuticals Corporation
DMX9K8F	TC	Cardiotonic Agents
DMX9K8F	DT	Small molecular drug
DMX9K8F	PC	5831
DMX9K8F	MW	182.65
DMX9K8F	FM	C6H15ClN2O2
DMX9K8F	IC	InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
DMX9K8F	CS	C[N+](C)(C)CCOC(=O)N.[Cl-]
DMX9K8F	IK	AIXAANGOTKPUOY-UHFFFAOYSA-N
DMX9K8F	IU	2-carbamoyloxyethyl(trimethyl)azanium;chloride
DMX9K8F	CA	CAS 51-83-2
DMX9K8F	CB	CHEBI:3385
DMX9K8F	DE	Glaucoma/ocular hypertension

DMZOLBI	ID	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	HS	Approved
DMZOLBI	SN	Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
DMZOLBI	CP	Lundbeck Inc
DMZOLBI	DT	Small molecular drug
DMZOLBI	PC	2554
DMZOLBI	MW	236.27
DMZOLBI	FM	C15H12N2O
DMZOLBI	IC	InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
DMZOLBI	CS	C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
DMZOLBI	IK	FFGPTBGBLSHEPO-UHFFFAOYSA-N
DMZOLBI	IU	benzo[b][1]benzazepine-11-carboxamide
DMZOLBI	CA	CAS 298-46-4
DMZOLBI	CB	CHEBI:3387
DMZOLBI	DE	Gastric adenocarcinoma; Epilepsy; Type-1 diabetes

DMLEDNK	ID	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	HS	Approved
DMLEDNK	SN	CBPC; Carbenicilina; Carbenicillina; Carbenicilline; Carbenicillinum; Carboxybenzylpenicillin; Pyopen; Carbenicillina [DCIT]; Carboxybenzyl Penicillin; Carboxybenzylpenicillin acid; Alpha-Carboxybenzylpencillin; Alpha-Carboxybenzylpenicillin solution; Carbenicilina [INN-Spanish]; Carbenicillin (INN); Carbenicillin [INN:BAN]; Carbenicilline [INN-French]; Carbenicillinum [INN-Latin]; Alpha-Phenyl(carboxymethylpenicillin); N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid;N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; (2S,5R,6R)-6-[(3-hydroxy-3-oxo-2-phenylpropanoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(alpha-Carboxyphenylacetamido)penicillanic acid; 6beta-(2-carboxy-2-phenylacetamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMLEDNK	CP	Roerig Div Pfizer Inc
DMLEDNK	TC	Antibiotics
DMLEDNK	DT	Small molecular drug
DMLEDNK	PC	20824
DMLEDNK	MW	378.4
DMLEDNK	FM	C17H18N2O6S
DMLEDNK	IC	InChI=1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1
DMLEDNK	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C
DMLEDNK	IK	FPPNZSSZRUTDAP-UWFZAAFLSA-N
DMLEDNK	IU	(2S,5R,6R)-6-[(2-carboxy-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMLEDNK	CA	CAS 4697-36-3
DMLEDNK	CB	CHEBI:3393
DMLEDNK	DE	Infection of the upper and lower urinary tract

DME2XG3	ID	DME2XG3
DME2XG3	DN	Carbenicillin Indanyl Sodium
DME2XG3	HS	Approved
DME2XG3	SN	Geocillin
DME2XG3	CP	Pfizer Laboratories Div Pfizer Inc
DME2XG3	TC	Antiinfective Agents
DME2XG3	DT	Small molecular drug
DME2XG3	PC	23676503
DME2XG3	MW	516.5
DME2XG3	FM	C26H25N2NaO6S
DME2XG3	IC	InChI=1S/C26H26N2O6S.Na/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17;/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32);/q;+1/p-1/t18?,19-,20+,23-;/m1./s1
DME2XG3	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)OC4=CC5=C(CCC5)C=C4)C(=O)[O-])C.[Na+]
DME2XG3	IK	QFWPXOXWAUAYAB-XZVIDJSISA-M
DME2XG3	IU	sodium;(2S,5R,6R)-6-[[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DME2XG3	CA	CAS 26605-69-6
DME2XG3	CB	CHEBI:31358
DME2XG3	DE	Bacterial infection

DMUSLW3	ID	DMUSLW3
DMUSLW3	DN	Carbetocin
DMUSLW3	HS	Approved
DMUSLW3	SN	Carbetocino [INN-Spanish]; Carbetocinum [INN-Latin]; Duratocin (TN); 1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin; 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-hydroxybenzyl)-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide
DMUSLW3	CP	Pfizer Pharmaceuticals
DMUSLW3	TC	Antitocolytic Agents
DMUSLW3	DT	Small molecular drug
DMUSLW3	PC	16681432
DMUSLW3	MW	988.2
DMUSLW3	FM	C45H69N11O12S
DMUSLW3	IC	InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
DMUSLW3	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMUSLW3	IK	NSTRIRCPWQHTIA-DTRKZRJBSA-N
DMUSLW3	IU	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide
DMUSLW3	CA	CAS 37025-55-1
DMUSLW3	CB	CHEBI:59204
DMUSLW3	DE	Postpartum haemorrhage

DMHRG8Q	ID	DMHRG8Q
DMHRG8Q	DN	Carbidopa
DMHRG8Q	HS	Approved
DMHRG8Q	SN	Atamet; Carbidopum; Lodosin; Lodosyn; Methyldopahydrazine; Stalevo; Carbidopa Monohydrate; Carbidopa anhydrous; Carbidopa hydrate; Carbidopum monohydricum; MK 486; Alpha-Methyldopahydrazine; C-126; C-DOPA; Carbidopa (anhydrous); Carbidopum [INN-Latin]; Lodosyn (TN); Lodosyn, Carbidopa; MK-485; MK-486; N-Aminomethyldopa; Carbidopa [USAN:INN:BAN]; Carbidopa-1-wasser; Hadrazino-alpha-methyldopa; L-alpha-Methyldopahydrazine; Carbidopa, (S)-Isomer; Carbidopa, Entacapone, & Levodopa; S(-)-CARBIDOPA; S-(-)-Carbidopa; L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate; Alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid; L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid; L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid; L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid; S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S); KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID; Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid-water (1/1); (S)-(-)-carbidopa; (S)-(-)-carbidopa hydrate; (S)-alpha-Hydrazino-3,4-dihydroxy-alpha-methyl-benzenepropanoic acid monohydrate; (S)-carbidopa; (S)-carbidopahydrate; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
DMHRG8Q	TC	Antiparkinson Agents
DMHRG8Q	DT	Small molecular drug
DMHRG8Q	PC	34359
DMHRG8Q	MW	226.23
DMHRG8Q	FM	C10H14N2O4
DMHRG8Q	IC	InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
DMHRG8Q	CS	C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN
DMHRG8Q	IK	TZFNLOMSOLWIDK-JTQLQIEISA-N
DMHRG8Q	IU	(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
DMHRG8Q	CA	CAS 28860-95-9
DMHRG8Q	CB	CHEBI:39585
DMHRG8Q	DE	Parkinson disease

DMULAI4	ID	DMULAI4
DMULAI4	DN	Carbimazole
DMULAI4	HS	Approved
DMULAI4	SN	Athyromazole; Atirozidina; Basolest; Carbethoxymethimazole; Carbimazol; Carbimazolum; Carbinazole; Carbotiroid; Mertiran; Neomercazole; TYRAZOL; Thyrostat; Carbimazol henning; Carbimazol spofa; CG1; Cg 1; Carbimazol henning (TN); Carbimazole (INN); Carbimazolum [INN-Latin]; Neo-Mercazole; Neo-Thyreostat; Neo-Tireol; Carbimazol [INN-Spanish, French]; Carbimazole [INN:BAN:DCF]; Ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate; Ethyl 3-methyl-2-thioimidazoline-1-carboxylate; Ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate; 1-Ethoxycarbonyl-3-methyl-2-thioimidazol; 1-Ethoxycarbonyl-3-methyl-2-thioxo-4-imidazoline; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo, ethyl ester; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester; 3-Methyl-2-thioxo-4-imidazoline-1-carboxylic acid ethyl ester; 4-Imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester
DMULAI4	TC	Antithyroid Agents
DMULAI4	DT	Small molecular drug
DMULAI4	PC	31072
DMULAI4	MW	186.23
DMULAI4	FM	C7H10N2O2S
DMULAI4	IC	InChI=1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3
DMULAI4	CS	CCOC(=O)N1C=CN(C1=S)C
DMULAI4	IK	CFOYWRHIYXMDOT-UHFFFAOYSA-N
DMULAI4	IU	ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate
DMULAI4	CA	CAS 22232-54-8
DMULAI4	CB	CHEBI:617099
DMULAI4	DE	Hyperthyroidism

DMCT31R	ID	DMCT31R
DMCT31R	DN	Carbinoxamine
DMCT31R	HS	Approved
DMCT31R	SN	Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine
DMCT31R	CP	McNeil Laboratories
DMCT31R	TC	Antihistamines
DMCT31R	DT	Small molecular drug
DMCT31R	PC	2564
DMCT31R	MW	290.79
DMCT31R	FM	C16H19ClN2O
DMCT31R	IC	InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
DMCT31R	CS	CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DMCT31R	IK	OJFSXZCBGQGRNV-UHFFFAOYSA-N
DMCT31R	IU	2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine
DMCT31R	CA	CAS 486-16-8
DMCT31R	CB	CHEBI:3398
DMCT31R	DE	Vasomotor/allergic rhinitis

DMG281S	ID	DMG281S
DMG281S	DN	Carboplatin
DMG281S	HS	Approved
DMG281S	SN	Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)
DMG281S	CP	Bristol-Myers Squibb
DMG281S	TC	Anticancer Agents
DMG281S	DT	Small molecular drug
DMG281S	PC	426756
DMG281S	MW	371.25
DMG281S	FM	C6H12N2O4Pt
DMG281S	IC	InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2
DMG281S	CS	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
DMG281S	IK	VSRXQHXAPYXROS-UHFFFAOYSA-N
DMG281S	IU	azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
DMG281S	CA	CAS 41575-94-4
DMG281S	CB	CHEBI:31355
DMG281S	DE	Ovarian cancer

DMS3508	ID	DMS3508
DMS3508	DN	Carboprost tromethamine
DMS3508	HS	Approved
DMS3508	SN	Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine
DMS3508	TC	Abortifacient Agents
DMS3508	DT	Small molecular drug
DMS3508	PC	5281074
DMS3508	MW	489.6
DMS3508	FM	C25H47NO8
DMS3508	IC	InChI=1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5-,14-12+;/t16-,17-,18+,19-,21+;/m1./s1
DMS3508	CS	CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
DMS3508	IK	UMMADZJLZAPZAW-XOWPVRJPSA-N
DMS3508	IU	2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid
DMS3508	CA	CAS 58551-69-2
DMS3508	DE	Abortion

DM48K0X	ID	DM48K0X
DM48K0X	DN	Carfilzomib
DM48K0X	HS	Approved
DM48K0X	SN	Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
DM48K0X	CP	Onyx Pharmaceuticals
DM48K0X	DT	Small molecular drug
DM48K0X	PC	11556711
DM48K0X	MW	719.9
DM48K0X	FM	C40H57N5O7
DM48K0X	IC	InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
DM48K0X	CS	CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
DM48K0X	IK	BLMPQMFVWMYDKT-NZTKNTHTSA-N
DM48K0X	IU	(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
DM48K0X	CA	CAS 868540-17-4
DM48K0X	CB	CHEBI:65347
DM48K0X	DE	Multiple myeloma; Small-cell lung cancer

DMCY0TI	ID	DMCY0TI
DMCY0TI	DN	Carglumic acid
DMCY0TI	HS	Approved
DMCY0TI	SN	Carbaglu (TN)
DMCY0TI	CP	Orphan Europe
DMCY0TI	DT	Small molecular drug
DMCY0TI	PC	121396
DMCY0TI	MW	190.15
DMCY0TI	FM	C6H10N2O5
DMCY0TI	IC	InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1
DMCY0TI	CS	C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N
DMCY0TI	IK	LCQLHJZYVOQKHU-VKHMYHEASA-N
DMCY0TI	IU	(2S)-2-(carbamoylamino)pentanedioic acid
DMCY0TI	CA	CAS 1188-38-1
DMCY0TI	CB	CHEBI:71028
DMCY0TI	DE	Acute hyperammonaemia

DMJYDVK	ID	DMJYDVK
DMJYDVK	DN	Cariprazine
DMJYDVK	HS	Approved
DMJYDVK	SN	Cariprazine; 839712-12-8; RGH-188; RGH 188; Cariprazine(RGH188); UNII-F6RJL8B278; F6RJL8B278; CHEMBL3085826; 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea; Cariprazine [USAN:INN]; Reagila; MP-214; MP 214; Cariprazine (USAN/INN); Cariprazine (RGH-188); C21H32Cl2N4O; SCHEMBL184342; SCHEMBL184343; GTPL7671; SCHEMBL7861573; CHEMBL2028019; CHEBI:90933; HSDB 8310; DTXSID80232867; KPWSJANDNDDRMB-QAQDUYKDSA-N; MolPort-039-139-594; BDBM263449; BCP14691; BDBM50443101; BDBM50382290; ZINC38309313; 3526AH
DMJYDVK	CP	Forest Laboratories; Gedeon Richter
DMJYDVK	DT	Small molecular drug
DMJYDVK	PC	11154555
DMJYDVK	MW	427.4
DMJYDVK	FM	C21H32Cl2N4O
DMJYDVK	IC	InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)
DMJYDVK	CS	CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl
DMJYDVK	IK	KPWSJANDNDDRMB-UHFFFAOYSA-N
DMJYDVK	IU	3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
DMJYDVK	CA	CAS 839712-12-8
DMJYDVK	CB	CHEBI:90933
DMJYDVK	DE	Bipolar disorder

DMWR1JC	ID	DMWR1JC
DMWR1JC	DN	Carisoprodol
DMWR1JC	HS	Approved
DMWR1JC	SN	carisoprodol; 78-44-4; Isomeprobamate; Carisoprodate; Carisoprodatum; Isoprotane; Isobamate; Isoprothane; Carisoma; Sanoma; Isopropyl meprobamate; SOMA; Somalgit; Atonalyt; Mioratrina; Mioartrina; Flexartal; Skutamil; Miolisodal; Mioril; Apesan; Relasom; Nospasm; Flexal; Arusal; Somanil; Carlsoprol; Carisoprodolum; Domarax; Stialgin; Somadril; Carsodal; Mioriodol; Mediquil; Izoprotan; Isoprotan; Carisol; Caprodat; Calenfa; Diolene; Carlsoma; Carlsodol; Brianil; Flexidon; Flexagilt; Caridolin; Meprodat; Listaflex; Flexagit; Fibrosona; Chinchen; Carsodol
DMWR1JC	DT	Small molecular drug
DMWR1JC	PC	2576
DMWR1JC	MW	260.329
DMWR1JC	FM	C12H24N2O4
DMWR1JC	IC	InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
DMWR1JC	CS	CCCC(C)(COC(=O)N)COC(=O)NC(C)C
DMWR1JC	IK	OFZCIYFFPZCNJE-UHFFFAOYSA-N
DMWR1JC	IU	[2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate
DMWR1JC	CA	CAS 78-44-4
DMWR1JC	CB	CHEBI:3419
DMWR1JC	DE	Musculoskeletal disorder

DMHTB31	ID	DMHTB31
DMHTB31	DN	Carphenazine
DMHTB31	HS	Approved
DMHTB31	SN	Carfenazine; Carphenazin; Procethazine; Proketazin; Carfenazina [INN-Spanish]; Carfenazine [INN:BAN]; Carfenazinum [INN-Latin]; 1-(10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl)-1-propanone; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)propan-1-one; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one
DMHTB31	CP	Wyeth Ayerst Laboratories
DMHTB31	TC	Antipsychotic Agents
DMHTB31	DT	Small molecular drug
DMHTB31	PC	18104
DMHTB31	MW	425.6
DMHTB31	FM	C24H31N3O2S
DMHTB31	IC	InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3
DMHTB31	CS	CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO
DMHTB31	IK	XZSMZRXAEFNJCU-UHFFFAOYSA-N
DMHTB31	IU	1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one
DMHTB31	CA	CAS 2622-30-2
DMHTB31	DE	Insomnia; Schizophrenia

DMHMP05	ID	DMHMP05
DMHMP05	DN	Carprofen
DMHMP05	HS	Approved
DMHMP05	SN	Carprofene; Carprofeno; Carprofenum; Imadyl; Ridamyl; Rimadyl; Carprofeno [Spanish]; C 5720; Ro 205720; C-5720; Carprofene [INN-French]; Carprofeno [INN-Spanish]; Carprofenum [INN-Latin]; Rimadyl (TN); Ro 20-5720; Carprofen (USAN/INN); Carprofen [USAN:INN:BAN]; Ro 20-5720/000; Ro-20-5720; Ro-20-5720/000; (+-)-6-Chloro-alpha-methylcarbazole-2-acetic acid; (+-)-isomer of carprofen; (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid; (+/-)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid; (-)-6-Chlor-alpha-methyl-2-carbazolessigsaeure; 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid; 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure [German]; 6-Chloro-alpha-methyl-9H-carbazole-2-acetic acid; 6-Chloro-alpha-methylcarbazole-2-acetic acid; 9H-Carbazole-2-acetic acid, 6-chloro-.al
DMHMP05	CP	Pfizer Pharmaceuticals
DMHMP05	TC	Analgesics
DMHMP05	DT	Small molecular drug
DMHMP05	PC	2581
DMHMP05	MW	273.71
DMHMP05	FM	C15H12ClNO2
DMHMP05	IC	InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)
DMHMP05	CS	CC(C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)Cl)C(=O)O
DMHMP05	IK	PUXBGTOOZJQSKH-UHFFFAOYSA-N
DMHMP05	IU	2-(6-chloro-9H-carbazol-2-yl)propanoic acid
DMHMP05	CA	CAS 53716-49-7
DMHMP05	CB	CHEBI:364453
DMHMP05	DE	Pain

DMFMDOB	ID	DMFMDOB
DMFMDOB	DN	Carteolol
DMFMDOB	HS	Approved
DMFMDOB	SN	Carteololum; Carteolol HCl; Carteolol Monohydrochloride; Arteolol (TN); Arteoptic (TN); Calte (TN); Carteol (TN); Carteolol (INN); Carteolol [INN:BAN]; Carteololum [INN-Latin]; Cartrol (TN); Elebloc (TN); Endak (TN); Glauteolol (TN); Mikelan (TN); Ocupress (TN); Poenglaucol (TN); Singlauc (TN); Teoptic (TN); 5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
DMFMDOB	CP	CIBA Vision Sterile Mfg
DMFMDOB	TC	Antihypertensive Agents
DMFMDOB	DT	Small molecular drug
DMFMDOB	PC	2583
DMFMDOB	MW	292.37
DMFMDOB	FM	C16H24N2O3
DMFMDOB	IC	InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)
DMFMDOB	CS	CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O
DMFMDOB	IK	LWAFSWPYPHEXKX-UHFFFAOYSA-N
DMFMDOB	IU	5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one
DMFMDOB	CA	CAS 51781-06-7
DMFMDOB	CB	CHEBI:3437
DMFMDOB	DE	Glaucoma/ocular hypertension

DMHTEAO	ID	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	HS	Approved
DMHTEAO	SN	Artist; Carvedilolum; Coreg; Coropres; Coropress; Dibloc; Dilatrend; Eucardic; Kredex; Querto; Atlana Pharma brand of carvedilol; Carvedilolum [Latin]; Coreg CR; GlaxoSmithKline brand of carvedilol; Lakeside brand of carvedilol; Roche brand of carvedilol; BM 14190; DQ 2466; SKF 105517; Artist (TN); BM-14190; Carloc (TN); Coreg (TN); DQ-2466; Dilatrend (TN); EG-P042; Eucardic (TN); BM-14-190; BM-14.190; Carvedilol, 14C-labeled; SK&F-105517; Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, (+-)-isomer; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
DMHTEAO	CP	GlaxoSmithKline plc
DMHTEAO	TC	Vasodilator Agents
DMHTEAO	DT	Small molecular drug
DMHTEAO	PC	2585
DMHTEAO	MW	406.5
DMHTEAO	FM	C24H26N2O4
DMHTEAO	IC	InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
DMHTEAO	CS	COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
DMHTEAO	IK	OGHNVEJMJSYVRP-UHFFFAOYSA-N
DMHTEAO	IU	1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
DMHTEAO	CA	CAS 72956-09-3
DMHTEAO	CB	CHEBI:3441
DMHTEAO	DE	Congestive heart failure

DMZPXRC	ID	DMZPXRC
DMZPXRC	DN	Carzinophilin
DMZPXRC	HS	Approved
DMZPXRC	SN	CARZINOPHILIN; Cardinophyllin; Cardinophillin; Azinomycin; CARZINOPHILIN A; Carzinophyllin; NSC 20088; Antibiotic from Streptomyces Sahachiroi; BRN 5721373; C31H33N3O11; 1403-28-7; Carzinophilin (8CI); AC1MHU1X; Carzinophilin (8CI)(9CI); LS-52587; LS-52588; 11002-20-3; [(1S)-2-[[(1E)-1-[(3R,4R,5S)-3-acetyloxy-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene]-2-[[(E)-1-hydroxy-3-oxobut-1-en-2-yl]amino]-2-oxoethyl]amino]-1-[(2S)-2-methyloxiran-2-yl]-2-oxoethyl] 3-methoxy-5-methylnaphthalene-1-carboxylate
DMZPXRC	DT	Small molecular drug
DMZPXRC	PC	227922
DMZPXRC	MW	639.6
DMZPXRC	FM	C31H33N3O12
DMZPXRC	IC	InChI=1S/C31H33N3O12/c1-14-7-6-8-18-19(14)9-17(43-5)10-20(18)26(40)32-13-30(4)24(39)28(41)45-31(46-30)25(23(38)22-11-34(22)16(3)37)44-27(33-29(31)42)21(12-35)15(2)36/h6-10,12,22-25,38-39H,11,13H2,1-5H3,(H,32,40)(H,33,42)
DMZPXRC	CS	CC1=C2C=C(C=C(C2=CC=C1)C(=O)NCC3(C(C(=O)OC4(O3)C(OC(=C(C=O)C(=O)C)NC4=O)C(C5CN5C(=O)C)O)O)C)OC
DMZPXRC	IK	GNGRYODSYNVRFD-UHFFFAOYSA-N
DMZPXRC	IU	N-[[7-[(1-acetylaziridin-2-yl)-hydroxymethyl]-9-(1,3-dioxobutan-2-ylidene)-3-hydroxy-4-methyl-2,11-dioxo-1,5,8-trioxa-10-azaspiro[5.5]undecan-4-yl]methyl]-3-methoxy-5-methylnaphthalene-1-carboxamide
DMZPXRC	DE	Solid tumour/cancer

DMGQIPT	ID	DMGQIPT
DMGQIPT	DN	Caspofungin
DMGQIPT	HS	Approved
DMGQIPT	SN	CASPO; Cancidas; Capsofungin; Caspofungin [INN]; M991; Cancidas (TM); Cancidas (TN); Caspofungin (INN); MK-0991; L-743,872; [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-(9CI); (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
DMGQIPT	CP	Merck & Co
DMGQIPT	TC	Antifungal Agents
DMGQIPT	DT	Small molecular drug
DMGQIPT	PC	2826718
DMGQIPT	MW	1093.3
DMGQIPT	FM	C52H88N10O15
DMGQIPT	IC	InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1
DMGQIPT	CS	CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O
DMGQIPT	IK	JYIKNQVWKBUSNH-OGZDCFRISA-N
DMGQIPT	IU	N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
DMGQIPT	CA	CAS 162808-62-0
DMGQIPT	CB	CHEBI:474180
DMGQIPT	DE	Fungal infection

DMRSZA5	ID	DMRSZA5
DMRSZA5	DN	Cefacetrile
DMRSZA5	HS	Approved
DMRSZA5	SN	Cefacetril; Cefacetrilo; Cefacetrilum; Celospor; Cephacetrile; Vetrimast [veterinary]; Cefacetrile (INN); Cefacetrilo [INN-Spanish]; Cefacetrilum [INN-Latin]; Celospor (TN); Celtol (TN); Cristacef (TN); Vetrimast [veterinary] (TN); C-36278-Ba; (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-Acetoxymethyl-7-(2-cyanacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-[(acetyloxy)methyl]-7-[(cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2-Cyanacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat acetat (ester); 7-Cyanacetylamino-cephalosporansaeure
DMRSZA5	TC	Antibiotics
DMRSZA5	DT	Small molecular drug
DMRSZA5	PC	91562
DMRSZA5	MW	339.33
DMRSZA5	FM	C13H13N3O6S
DMRSZA5	IC	InChI=1S/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1
DMRSZA5	CS	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC#N)SC1)C(=O)O
DMRSZA5	IK	RRYMAQUWDLIUPV-BXKDBHETSA-N
DMRSZA5	IU	(6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMRSZA5	CA	CAS 10206-21-0
DMRSZA5	CB	CHEBI:135437
DMRSZA5	DE	Bacterial infection

DMJXDGC	ID	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	HS	Approved
DMJXDGC	SN	Alenfral; Alfacet; Alfatil; CCL; Ceclor; Cefaclorum; Distaclor; Kefolor; Panacef; Panoral; Alfatil Kapseln; Cefaclor anhydrous; Cefaclor hydrate; Cefaclor monohydrate; Dystaclor MR; Kefolor Suspension; Muco Panoral; Lilly 99638 hydrate; Alenfral (TN); Ceclor (TN); Cefaclor (JP15); Cefaclor (USP); Distaclor (TN); Keflor (TN); L-Kefral; Raniclor (TN); S-6472; Cefaclor-1-wasser; Cefaclor [USAN:INN:BAN:JAN]; Ceclor, Distaclor, Keflor, Raniclor, Cefaclor; (6R,7R)-7-((R)-2-Amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate; 7-(2-Amino-2-phenyl-acetylamino)-3-chloro-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid
DMJXDGC	CP	Eli Lilly
DMJXDGC	TC	Antibiotics
DMJXDGC	DT	Small molecular drug
DMJXDGC	PC	51039
DMJXDGC	MW	367.8
DMJXDGC	FM	C15H14ClN3O4S
DMJXDGC	IC	InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
DMJXDGC	CS	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl
DMJXDGC	IK	QYIYFLOTGYLRGG-GPCCPHFNSA-N
DMJXDGC	IU	(6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJXDGC	CA	CAS 53994-73-3
DMJXDGC	CB	CHEBI:3478
DMJXDGC	DE	Bacterial infection

DMMC345	ID	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	HS	Approved
DMMC345	SN	CDX; Cefadroxilo; Cefadroxilum; Cephadroxil; Sumacef; Cefadroxil anhydrous; S 578; BL-S 578; BL-S578; Cefadroxil (JP15); Cefadroxilo [INN-Spanish]; Cefadroxilum [INN-Latin]; Curisafe (TN); D-Cefadroxil; S-578; Sumacef (TN); MJF-11567-3; (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid
DMMC345	CP	Pharco B international
DMMC345	TC	Antibiotics
DMMC345	DT	Small molecular drug
DMMC345	PC	47965
DMMC345	MW	363.4
DMMC345	FM	C16H17N3O5S
DMMC345	IC	InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1
DMMC345	CS	CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O
DMMC345	IK	BOEGTKLJZSQCCD-UEKVPHQBSA-N
DMMC345	IU	(6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMMC345	CA	CAS 50370-12-2
DMMC345	CB	CHEBI:3479
DMMC345	DE	Bacterial infection

DMVYSLE	ID	DMVYSLE
DMVYSLE	DN	Cefalotin
DMVYSLE	HS	Approved
DMVYSLE	SN	Cefalothin; Cefalotina; Cefalotine; Cefalotinum; Cemastin; Cephalothinum; Cephalotin; Coaxin; Cefalotina fabra; Cephalothin Monosodium Salt; Averon-1; Cefalotin (BAN); Cefalotina [INN-Spanish]; Cefalotina fabra (TN); Cefalotine [INN-French]; Cefalotinum [INN-Latin]; Keflin (TN); (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; 3-ACETOXYMETHYL-8-OXO-7-(2-THIOPHEN-2-YL-ACETYLAMINO)-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; 7-(2-Thienylacetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporin; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid
DMVYSLE	CP	Eli Lilly
DMVYSLE	TC	Antibiotics
DMVYSLE	DT	Small molecular drug
DMVYSLE	PC	6024
DMVYSLE	MW	396.4
DMVYSLE	FM	C16H16N2O6S2
DMVYSLE	IC	InChI=1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1
DMVYSLE	CS	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)O
DMVYSLE	IK	XIURVHNZVLADCM-IUODEOHRSA-N
DMVYSLE	IU	(6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMVYSLE	CA	CAS 153-61-7
DMVYSLE	CB	CHEBI:124991
DMVYSLE	DE	Bacterial infection

DMNEXZF	ID	DMNEXZF
DMNEXZF	DN	Cefamandole
DMNEXZF	HS	Approved
DMNEXZF	SN	Cefadole; Cefamandolum; Cefamandole (USAN/INN); (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
DMNEXZF	CP	Eli Lilly
DMNEXZF	TC	Antibiotics
DMNEXZF	DT	Small molecular drug
DMNEXZF	PC	456255
DMNEXZF	MW	462.5
DMNEXZF	FM	C18H18N6O5S2
DMNEXZF	IC	InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1
DMNEXZF	CS	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)O)SC2)C(=O)O
DMNEXZF	IK	OLVCFLKTBJRLHI-AXAPSJFSSA-N
DMNEXZF	IU	(6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMNEXZF	CA	CAS 34444-01-4
DMNEXZF	CB	CHEBI:3480
DMNEXZF	DE	Microorganisms infection

DMPDYFR	ID	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	HS	Approved
DMPDYFR	SN	CEZ; Cefamezin; Cefamezine; Cefazolina; Cefazoline; Cefazolinum; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; Elzogram; Cephazolin Sodium; Ancef (TN); Cefacidal (TN); Cefamezin (TN); Cefazolin (USP); Cefazolin [USAN:INN]; Cefazolin(usp); Cefazolina [INN-Spanish]; Cefazoline [INN-French]; Cefazolinum [INN-Latin]; Cefrina (TN); Elzogram (TN); Faxilen (TN); Gramaxin (TN); Kefazol (TN); Kefol (TN); Kefzol (TN); Kefzolan (TN); Kezolin (TN); Novaporin (TN); Zolicef (TN); (6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid; 7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid
DMPDYFR	CP	Fujisawa Pharmaceutical Co
DMPDYFR	TC	Antibiotics
DMPDYFR	DT	Small molecular drug
DMPDYFR	PC	33255
DMPDYFR	MW	454.5
DMPDYFR	FM	C14H14N8O4S3
DMPDYFR	IC	InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1
DMPDYFR	CS	CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O
DMPDYFR	IK	MLYYVTUWGNIJIB-BXKDBHETSA-N
DMPDYFR	IU	(6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMPDYFR	CA	CAS 25953-19-9
DMPDYFR	CB	CHEBI:474053
DMPDYFR	DE	Bacterial infection

DMJ7A0H	ID	DMJ7A0H
DMJ7A0H	DN	Cefdinir
DMJ7A0H	HS	Approved
DMJ7A0H	SN	CFDN; Cefdinirum; Cefdinyl; Cefdirnir; Cefzon; Omnicef; BMY 28488; FK 482; PD 134393; Cefdinir [USAN:INN]; Cefdinirum [INN-Latin]; Cefzon (TN); FK-482; FR-80482; KS-1038; Omnicef (TN); PD-134393; Cefdinir (JP15/USAN/INN); Omnicef, FK-482, BMY-28488, PD 134393, CI-983, Cefdinir; (-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
DMJ7A0H	CP	Abbott Laboratories
DMJ7A0H	TC	Antibiotics
DMJ7A0H	DT	Small molecular drug
DMJ7A0H	PC	6915944
DMJ7A0H	MW	395.4
DMJ7A0H	FM	C14H13N5O5S2
DMJ7A0H	IC	InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
DMJ7A0H	CS	C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\O)/C3=CSC(=N3)N)SC1)C(=O)O
DMJ7A0H	IK	RTXOFQZKPXMALH-GHXIOONMSA-N
DMJ7A0H	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJ7A0H	CA	CAS 91832-40-5
DMJ7A0H	CB	CHEBI:3485
DMJ7A0H	DE	Bacterial infection

DMSUVM1	ID	DMSUVM1
DMSUVM1	DN	Cefditoren
DMSUVM1	HS	Approved
DMSUVM1	SN	Cefditoren [USAN:INN]; Meiact (TN); Spectracef (TN); (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
DMSUVM1	CP	Cornerstone BioPharma
DMSUVM1	TC	Antibiotics
DMSUVM1	DT	Small molecular drug
DMSUVM1	PC	9870843
DMSUVM1	MW	506.6
DMSUVM1	FM	C19H18N6O5S3
DMSUVM1	IC	InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1
DMSUVM1	CS	CC1=C(SC=N1)/C=C\\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMSUVM1	IK	KMIPKYQIOVAHOP-YLGJWRNMSA-N
DMSUVM1	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSUVM1	CA	CAS 104145-95-1
DMSUVM1	CB	CHEBI:59343
DMSUVM1	DE	Bacterial infection

DMHVWIK	ID	DMHVWIK
DMHVWIK	DN	Cefepime
DMHVWIK	HS	Approved
DMHVWIK	SN	Axepim; CFPM; Cefepima; Cefepimum; Cepimax; Cepimex; Maxcef; Maxipime; Cefepima [Spanish]; Cefepimum [Latin]; BMY 28142; Axepim (TN); BMY-28142; Cefepime [USAN:INN]; Cepimax (TN); Cepimex (TN); Maxcef (TN); Maxipime (TN); Cefepime (USAN/INN); (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
DMHVWIK	CP	Bristol-Myers Squibb
DMHVWIK	TC	Antibiotics
DMHVWIK	DT	Small molecular drug
DMHVWIK	PC	5479537
DMHVWIK	MW	480.6
DMHVWIK	FM	C19H24N6O5S2
DMHVWIK	IC	InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1
DMHVWIK	CS	C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]
DMHVWIK	IK	HVFLCNVBZFFHBT-ZKDACBOMSA-N
DMHVWIK	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMHVWIK	CA	CAS 88040-23-7
DMHVWIK	CB	CHEBI:478164
DMHVWIK	DE	Bacterial infection

DMY60I8	ID	DMY60I8
DMY60I8	DN	Cefixime
DMY60I8	HS	Approved
DMY60I8	SN	CFIX; Cefixima; Cefiximum; Denvar; Necopen; Tricef; CL-284635; FK-027; FR-17027; Ofex (TN); Suprax (TN); Cefixime (JP15/USP/INN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b; 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
DMY60I8	CP	Wyeth Pharmaceuticals
DMY60I8	TC	Antibiotics
DMY60I8	DT	Small molecular drug
DMY60I8	PC	5362065
DMY60I8	MW	453.5
DMY60I8	FM	C16H15N5O7S2
DMY60I8	IC	InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1
DMY60I8	CS	C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCC(=O)O)/C3=CSC(=N3)N)SC1)C(=O)O
DMY60I8	IK	OKBVVJOGVLARMR-QSWIMTSFSA-N
DMY60I8	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMY60I8	CA	CAS 79350-37-1
DMY60I8	CB	CHEBI:472657
DMY60I8	DE	Bacterial infection

DMPLY7B	ID	DMPLY7B
DMPLY7B	DN	Cefmenoxime
DMPLY7B	HS	Approved
DMPLY7B	SN	Cefmax; Cefmenoxima; Cefmenoximum; Tacef; Cefmenoxime [INN]; A 50912; AB 50912; SCE 1365; Abbott-50192; Cefmenoxima [INN-Spanish]; Cefmenoxime (INN); Cefmenoximum [INN-Latin]; Cefmenoxime Hydrochloride (2:1); (6R,7R)-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (IUPAC); (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMPLY7B	TC	Antibiotics
DMPLY7B	DT	Small molecular drug
DMPLY7B	PC	9570757
DMPLY7B	MW	511.6
DMPLY7B	FM	C16H17N9O5S3
DMPLY7B	IC	InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1
DMPLY7B	CS	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMPLY7B	IK	HJJDBAOLQAWBMH-YCRCPZNHSA-N
DMPLY7B	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMPLY7B	CA	CAS 65085-01-0
DMPLY7B	CB	CHEBI:55490
DMPLY7B	DE	Bacterial infection

DM42W1B	ID	DM42W1B
DM42W1B	DN	Cefmetazole
DM42W1B	HS	Approved
DM42W1B	SN	CMZ; Cefmetazolo; Cefmetazolum; Cefmetazole Monosodium Salt; CS 1170; SKF 83088; U 72791; CS-1170; Cefmetazole [USAN:INN]; Cefmetazolo [INN-Spanish]; Cefmetazolum [INN-Latin]; U-72791A; Cefmetazole (USP/INN); (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, sodium salt; (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 6beta-{[(cyanomethyl)sulfanyl]acetamido}-6alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
DM42W1B	CP	Pharmacia And Upjohn Co
DM42W1B	TC	Antibiotics
DM42W1B	DT	Small molecular drug
DM42W1B	PC	42008
DM42W1B	MW	471.5
DM42W1B	FM	C15H17N7O5S3
DM42W1B	IC	InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1
DM42W1B	CS	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O
DM42W1B	IK	SNBUBQHDYVFSQF-HIFRSBDPSA-N
DM42W1B	IU	(6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM42W1B	CA	CAS 56796-20-4
DM42W1B	CB	CHEBI:3489
DM42W1B	DE	Bacterial infection

DMORSGU	ID	DMORSGU
DMORSGU	DN	Cefodizime
DMORSGU	HS	Approved
DMORSGU	SN	AC1NSFIB; CDZM; CHEBI:63214; CHEMBL2303613; Cefodizima; Cefodizima [INN-Spanish]; Cefodizime; Cefodizime (INN); Cefodizime Acid; Cefodizime [INN:BAN]; Cefodizimum; Cefodizimum [INN-Latin]; Cefodizme; DTXSID2022757; Diezime; EC 700-301-3; EX-A1379; HR 221 [AS SODIUM]; HR-221; HR-221 [As Sodium]; J-700161; Modivid; Neucef; S-771221B [As Sodium]; SCHEMBL151101; THR 221 [AS SODIUM]; THR-221; THR-221 [As Sodium]; Timecef; UNII-Z31298J4HQ; Z31298J4HQ
DMORSGU	TC	Anti-Bacterial Agents
DMORSGU	DT	Small molecular drug
DMORSGU	PC	5361871
DMORSGU	MW	584.655
DMORSGU	FM	C20H20N6O7S4
DMORSGU	IC	InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1
DMORSGU	CS	CC1=C(SC(=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O)CC(=O)O
DMORSGU	IK	XDZKBRJLTGRPSS-BGZQYGJUSA-N
DMORSGU	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMORSGU	CA	CAS 69739-16-8
DMORSGU	CB	CHEBI:63214
DMORSGU	DE	Bacterial infections

DMTX2BH	ID	DMTX2BH
DMTX2BH	DN	Cefonicid
DMTX2BH	HS	Approved
DMTX2BH	SN	Cefonicido; Cefonicidum; Monocef; Praticef; Cefonicid Monosodium Salt; Sodium Cefonicid; Cefonicid (INN); Cefonicid [INN:BAN]; Cefonicido [INN-Spanish]; Cefonicidum [INN-Latin]; Monocef (TN); SK&F-75073; SKF-75073-2; (6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7R)-7-(2-Hydroxy-2-phenylacetylamino)-6-oxo-3-{[1-(sulfomethyl)(1,2,3,4-tetraazol-5-ylthio)]methyl}-2H,7H,7aH-azetidino[2,1-b]1,3-thiazine-4-carboxylic acid; 6beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)ceph-3-em-4-carboxylic acid; 7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMTX2BH	CP	Glaxosmithkline
DMTX2BH	TC	Antibiotics
DMTX2BH	DT	Small molecular drug
DMTX2BH	PC	43594
DMTX2BH	MW	542.6
DMTX2BH	FM	C18H18N6O8S3
DMTX2BH	IC	InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1
DMTX2BH	CS	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O
DMTX2BH	IK	DYAIAHUQIPBDIP-AXAPSJFSSA-N
DMTX2BH	IU	(6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMTX2BH	CA	CAS 61270-58-4
DMTX2BH	CB	CHEBI:3491
DMTX2BH	DE	Bacterial infection

DM53PV8	ID	DM53PV8
DM53PV8	DN	Cefoperazone
DM53PV8	HS	Approved
DM53PV8	SN	Cefobid; Cefoperazon; Cefoperazono; Cefoperazonum; Cefoperazone sodium salt; Peracef [veterinary]; CP 52640; Cefazone (TN); Cefobid (TN); Cefoperazone (INN); Cefoperazone [INN:BAN]; Cefoperazono [INN-Spanish]; Cefoperazonum [INN-Latin]; Peracef [veterinary] (TN); (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid
DM53PV8	CP	Pfizer Pharmaceuticals
DM53PV8	TC	Antibiotics
DM53PV8	DT	Small molecular drug
DM53PV8	PC	44187
DM53PV8	MW	645.7
DM53PV8	FM	C25H27N9O8S2
DM53PV8	IC	InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1
DM53PV8	CS	CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
DM53PV8	IK	GCFBRXLSHGKWDP-XCGNWRKASA-N
DM53PV8	IU	(6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM53PV8	CA	CAS 62893-19-0
DM53PV8	CB	CHEBI:3493
DM53PV8	DE	Bacterial infection

DMSQVD6	ID	DMSQVD6
DMSQVD6	DN	Ceforanide
DMSQVD6	HS	Approved
DMSQVD6	SN	Ceforanido; Ceforanidum; Precef; Radacef; Bl s786; BL-S 786; BL-S786; Ceforanido [INN-Spanish]; Ceforanidum [INN-Latin]; Precef (TN); Ceforanide (USP/INN); Ceforanide [USAN:INN:BAN]; (6R,7R)-7-(2-(alpha-Amino-o-tolyl)acetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-7-(((2-(Aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 7-(o-(Aminomethyl)phenylacetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid; 7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid; 7beta-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid
DMSQVD6	TC	Antibiotics
DMSQVD6	DT	Small molecular drug
DMSQVD6	PC	43507
DMSQVD6	MW	519.6
DMSQVD6	FM	C20H21N7O6S2
DMSQVD6	IC	InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1
DMSQVD6	CS	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3CN)C(=O)O)CSC4=NN=NN4CC(=O)O
DMSQVD6	IK	SLAYUXIURFNXPG-CRAIPNDOSA-N
DMSQVD6	IU	(6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSQVD6	CA	CAS 60925-61-3
DMSQVD6	CB	CHEBI:3495
DMSQVD6	DE	Bacterial infection

DMEB837	ID	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	HS	Approved
DMEB837	SN	Cefotaxima; Cefotaxima [INN-Spanish]; Cefotaxime [INN:BAN]; Cefotaxime acid; Cefotaximum; Cefotaximum [INN-Latin]; Cephotaxime; E-cefotaxime; Omnatax; RU 24662; RU 24756; cefotaxime; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R,7R)-; 60846-21-1; 63527-52-6; C16H17N5O7S2; CHEBI:204928; EINECS 264-299-1; HR 756; N2GI8B1GK7; Taxim; UNII-N2GI8B1GK7
DMEB837	PC	5742673
DMEB837	MW	455.5
DMEB837	FM	C16H17N5O7S2
DMEB837	IC	GPRBEKHLDVQUJE-QSWIMTSFSA-N
DMEB837	CS	CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
DMEB837	IK	1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
DMEB837	IU	(6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMEB837	CA	CAS 60846-21-1
DMEB837	CB	CHEBI:204928
DMEB837	DE	Meningitis

DMMKHBJ	ID	DMMKHBJ
DMMKHBJ	DN	Cefotaxime
DMMKHBJ	HS	Approved
DMMKHBJ	SN	Cefotaxim; Cefotaxima; Cefotaximum; Cephotaxim; Cephotaxime; Claforan; Klaforan; Cefotaxim Hikma; Cefotaxime acid; CE3; RU 24662; Cefotaxim Hikma (TN); Cefotaxima [INN-Spanish]; Cefotaxime (INN); Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Claforan (TN); Ru-24756; Claforan (*Sodium salt*)
DMMKHBJ	CP	Roussel Uclaf 
DMMKHBJ	TC	Antibiotics
DMMKHBJ	DT	Small molecular drug
DMMKHBJ	PC	5742673
DMMKHBJ	MW	455.5
DMMKHBJ	FM	C16H17N5O7S2
DMMKHBJ	IC	InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
DMMKHBJ	CS	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O
DMMKHBJ	IK	GPRBEKHLDVQUJE-QSWIMTSFSA-N
DMMKHBJ	IU	(6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMMKHBJ	CA	CAS 63527-52-6
DMMKHBJ	CB	CHEBI:204928
DMMKHBJ	DE	Bacterial infection

DM07TX3	ID	DM07TX3
DM07TX3	DN	Cefotetan
DM07TX3	HS	Approved
DM07TX3	SN	Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DM07TX3	CP	AstraZeneca
DM07TX3	TC	Antibiotics
DM07TX3	DT	Small molecular drug
DM07TX3	PC	53025
DM07TX3	MW	575.6
DM07TX3	FM	C17H17N7O8S4
DM07TX3	IC	InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/t13?,15-,17+/m1/s1
DM07TX3	CS	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O
DM07TX3	IK	SRZNHPXWXCNNDU-RHBCBLIFSA-N
DM07TX3	IU	(6R,7S)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM07TX3	CA	CAS 69712-56-7
DM07TX3	CB	CHEBI:3499
DM07TX3	DE	Bacterial infection

DMF5HU6	ID	DMF5HU6
DMF5HU6	DN	Cefotiam
DMF5HU6	HS	Approved
DMF5HU6	SN	Aspil; CTM; Cefotiamum; Ceradolan; Haloapor; CEFOTIAM HYDROCHLORIDE; CGP 14221E; Abbott-48999; Aspil (TN); Cefotiam (INN); Cefotiam [INN:BAN]; Cefotiamum [INN-Latin]; SCE-963; CGP-14221-E; (6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}thio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7b-[2-(aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1h-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylic acid; 7beta-(2-amino-1,3-thiazol-4-yl)acetamido-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid
DMF5HU6	CP	Takeda
DMF5HU6	TC	Antibiotics
DMF5HU6	DT	Small molecular drug
DMF5HU6	PC	43708
DMF5HU6	MW	525.6
DMF5HU6	FM	C18H23N9O4S3
DMF5HU6	IC	InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1
DMF5HU6	CS	CN(C)CCN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CSC(=N4)N)SC2)C(=O)O
DMF5HU6	IK	QYQDKDWGWDOFFU-IUODEOHRSA-N
DMF5HU6	IU	(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMF5HU6	CA	CAS 61622-34-2
DMF5HU6	CB	CHEBI:355510
DMF5HU6	DE	Respiratory tract infection

DMY8NC4	ID	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	HS	Approved
DMY8NC4	SN	Cefoxitina; Cefoxitine; Cefoxitinum; Cefoxotin; Cenomycin; Mefoxin; Mefoxitin; Rephoxitin; cefoxitin; ceftoxitin; 35607-66-0; CEPHOXITIN; 4kow; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7S)-; 6OEV9DX57Y; AK118716; CAS-35607-66-0; CFX; CHEBI:209807; CHEMBL996; DSSTox_CID_2764; DSSTox_GSID_22764; DSSTox_RID_76721; NCGC00183034-01; UNII-6OEV9DX57Y
DMY8NC4	PC	441199
DMY8NC4	MW	427.5
DMY8NC4	FM	C16H17N3O7S2
DMY8NC4	IC	WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
DMY8NC4	CS	COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
DMY8NC4	IK	1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
DMY8NC4	IU	(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMY8NC4	CA	CAS 35607-66-0
DMY8NC4	CB	CHEBI:209807
DMY8NC4	DE	Peritonitis

DMYTXVR	ID	DMYTXVR
DMYTXVR	DN	Cefoxitin
DMYTXVR	HS	Approved
DMYTXVR	SN	Mefoxin; Mefoxitin; CEFOXITIN SODIUM; Cefoxitin sodium salt; Mefoxin (TN); Cefoxitin (USAN/INN); Cefoxitin sodium (JAN/USP); (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(thiophen-2-yl)acetamido]-3,4-didehydrocepham-4-carboxylic acid
DMYTXVR	CP	Merck & Co
DMYTXVR	TC	Antibiotics
DMYTXVR	DT	Small molecular drug
DMYTXVR	PC	441199
DMYTXVR	MW	427.5
DMYTXVR	FM	C16H17N3O7S2
DMYTXVR	IC	InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
DMYTXVR	CS	CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
DMYTXVR	IK	WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
DMYTXVR	IU	(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYTXVR	CA	CAS 35607-66-0
DMYTXVR	CB	CHEBI:209807
DMYTXVR	DE	Bacterial infection

DMKBTFG	ID	DMKBTFG
DMKBTFG	DN	Cefozopran
DMKBTFG	HS	Approved
DMKBTFG	SN	CZOP; Cefozopran [INN]; SCE 2787; Cefozopran (INN); (-)-1-(((6R,7R)-7-(2-(5-Amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1H-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7(sup 2)-(Z)-(O-methyloxime); Imidazo(1,2-b)pyridazinium, 1-((6R,7R)-7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt
DMKBTFG	CP	Takeda
DMKBTFG	DT	Small molecular drug
DMKBTFG	PC	9571080
DMKBTFG	MW	515.5
DMKBTFG	FM	C19H17N9O5S2
DMKBTFG	IC	InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1
DMKBTFG	CS	CO/N=C(/C1=NSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-]
DMKBTFG	IK	QDUIJCOKQCCXQY-WHJQOFBOSA-N
DMKBTFG	IU	(6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMKBTFG	CA	CAS 113359-04-9
DMKBTFG	CB	CHEBI:3502
DMKBTFG	DE	Gram-positive bacterial infection

DMZ2WL4	ID	DMZ2WL4
DMZ2WL4	DN	Cefpiramide
DMZ2WL4	HS	Approved
DMZ2WL4	SN	Cefpiramido; Cefpiramidum; WY 44635; Cefpiramide [USAN:INN]; Cefpiramido [INN-Spanish]; Cefpiramidum [INN-Latin]; WY44,635; Cefpiramide (USP/INN); (6R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-((R)-2-(4-Hydroxy-6-methylnicotinamido)-2-(p-hydroxyphe-nyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r)-7-{[(2r)-2-(4-hydroxyphenyl)-2-{[(6-methyl-4-oxo-1,4-dihydropyridin-3-yl)carbonyl]amino}acetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMZ2WL4	CP	Wyeth Ayerst Laboratories
DMZ2WL4	TC	Antibiotics
DMZ2WL4	DT	Small molecular drug
DMZ2WL4	PC	636405
DMZ2WL4	MW	612.6
DMZ2WL4	FM	C25H24N8O7S2
DMZ2WL4	IC	InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1
DMZ2WL4	CS	CC1=CC(=O)C(=CN1)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
DMZ2WL4	IK	PWAUCHMQEXVFJR-PMAPCBKXSA-N
DMZ2WL4	IU	(6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMZ2WL4	CA	CAS 70797-11-4
DMZ2WL4	CB	CHEBI:59213
DMZ2WL4	DE	Bacterial infection

DMJUNY5	ID	DMJUNY5
DMJUNY5	DN	Cefpodoxime
DMJUNY5	HS	Approved
DMJUNY5	SN	CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJUNY5	CP	Pfizer Pharmaceuticals
DMJUNY5	TC	Antibiotics
DMJUNY5	DT	Small molecular drug
DMJUNY5	PC	6335986
DMJUNY5	MW	427.5
DMJUNY5	FM	C15H17N5O6S2
DMJUNY5	IC	InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
DMJUNY5	CS	COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O
DMJUNY5	IK	WYUSVOMTXWRGEK-HBWVYFAYSA-N
DMJUNY5	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJUNY5	CA	CAS 80210-62-4
DMJUNY5	CB	CHEBI:3504
DMJUNY5	DE	Bacterial infection

DM7DSYP	ID	DM7DSYP
DM7DSYP	DN	Cefprozil
DM7DSYP	HS	Approved
DM7DSYP	SN	Arzimol; Brisoral; Cefprozilo; Cefprozilum; Cefzil; Cronocef; Procef; Serozil; Cefprozil anhydrous; BMY 28100; Cefprozil (INN); Cefprozil (TN); Cefprozilo [INN-Spanish]; Cefprozilum [INN-Latin]; Cefzil (TN); Procef (TN); (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7DSYP	CP	Bristol-Myers Squibb
DM7DSYP	TC	Antibiotics
DM7DSYP	DT	Small molecular drug
DM7DSYP	PC	5281006
DM7DSYP	MW	389.4
DM7DSYP	FM	C18H19N3O5S
DM7DSYP	IC	InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1
DM7DSYP	CS	C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O
DM7DSYP	IK	WDLWHQDACQUCJR-ZAMMOSSLSA-N
DM7DSYP	IU	(6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7DSYP	CA	CAS 92676-86-3
DM7DSYP	CB	CHEBI:3506
DM7DSYP	DE	Bacterial infection

DMUNSWV	ID	DMUNSWV
DMUNSWV	DN	Cefradine
DMUNSWV	HS	Approved
DMUNSWV	SN	Anspor; Cefradin; Cefradina; Cefradinum; Cephradin; Cephradine; Eskacef; Sefril; Velosef; CEPHRADINE SODIUM; SKF D 39304; SQ 11436; VELOSEF 125; VELOSEF 250; VELOSEF 500; Anspor (TN); Cefradina [INN-Spanish]; Cefradinum [INN-Latin]; Cephradine (USP); Cephradine (anhydrous); Cephradine [USAN:BAN]; SQ-11436; SQ-22022; Velosef (TN); Cefradine (JAN/INN); SK&F D-39304; SK-D-39304; (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid; 7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid
DMUNSWV	CP	Kent Pharms
DMUNSWV	TC	Antibiotics
DMUNSWV	DT	Small molecular drug
DMUNSWV	PC	38103
DMUNSWV	MW	349.4
DMUNSWV	FM	C16H19N3O4S
DMUNSWV	IC	InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
DMUNSWV	CS	CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O
DMUNSWV	IK	RDLPVSKMFDYCOR-UEKVPHQBSA-N
DMUNSWV	IU	(6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMUNSWV	CA	CAS 38821-53-3
DMUNSWV	CB	CHEBI:3547
DMUNSWV	DE	Bacterial infection

DMQXLF3	ID	DMQXLF3
DMQXLF3	DN	Cefsulodin
DMQXLF3	HS	Approved
DMQXLF3	SN	cefsulodin; (6R,7R)-3-{[4-(aminocarbonyl)pyridinium-1-yl]methyl}-8-oxo-7-{[phenyl(sulfo)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; AC1NR4MP; SCHEMBL65524; DTXSID6022769; Cefsulodin free acid (SCE-129), Antibiotic for Culture Media Use Only
DMQXLF3	DT	Small molecular drug
DMQXLF3	PC	656575
DMQXLF3	MW	532.6
DMQXLF3	FM	C22H20N4O8S2
DMQXLF3	IC	InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1
DMQXLF3	CS	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)S(=O)(=O)O)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N
DMQXLF3	IK	SYLKGLMBLAAGSC-QLVMHMETSA-N
DMQXLF3	IU	(6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMQXLF3	CA	CAS 62587-73-9
DMQXLF3	CB	CHEBI:3507
DMQXLF3	DE	Pseudomonas infection

DM41GRA	ID	DM41GRA
DM41GRA	DN	Ceftazidime
DM41GRA	HS	Approved
DM41GRA	SN	Ceftazidima; Ceftazidimum; Ceptaz; Fortaz; Ceftazidime Sodium In Plastic Container; Ceftazidime anhydrous; Ceftazidime pentahydrate; Fortaz In Plastic Container; SN 401; CEFTAZIDIME (ARGININE FORMULATION); Ceftazidima [INN-Spanish]; Ceftazidime (INN); Ceftazidime (TN); Ceftazidimum [INN-Latin]; Cefzim (TN); Ceptaz (TN); Fortaz (TN); Fortum (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
DM41GRA	CP	GlaxoSmithKline
DM41GRA	TC	Antibiotics
DM41GRA	DT	Small molecular drug
DM41GRA	PC	5481173
DM41GRA	MW	546.6
DM41GRA	FM	C22H22N6O7S2
DM41GRA	IC	InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1
DM41GRA	CS	CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]
DM41GRA	IK	ORFOPKXBNMVMKC-DWVKKRMSSA-N
DM41GRA	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM41GRA	CA	CAS 72558-82-8
DM41GRA	CB	CHEBI:3508
DM41GRA	DE	Bacterial infection

DMWV2AG	ID	DMWV2AG
DMWV2AG	DN	Ceftibuten
DMWV2AG	HS	Approved
DMWV2AG	SN	CETB; Cedax; Ceftem; Ceftibutene; Ceftibuteno; Ceftibutenum; Cephem; Ceprifran; Isocef; Keimax; Antibiotic 7432S; S 7432; Sch 39720; Cedax (TN); Ceftibutene [INN-French]; Ceftibuteno [INN-Spanish]; Ceftibutenum [INN-Latin]; Cephalosporin 7432-S; Cis-Ceftibutin; Cis-ceftibuten; Sch-39720; Trans-Ceftibuten; Ceftibuten(USAN/INN); Ceftibuten [USAN:INN:BAN]; (+)-(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7432-S; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid
DMWV2AG	CP	Shionogi USA
DMWV2AG	TC	Antibiotics
DMWV2AG	DT	Small molecular drug
DMWV2AG	PC	5282242
DMWV2AG	MW	410.4
DMWV2AG	FM	C15H14N4O6S2
DMWV2AG	IC	InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1
DMWV2AG	CS	C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=C\\CC(=O)O)/C3=CSC(=N3)N)C(=O)O
DMWV2AG	IK	UNJFKXSSGBWRBZ-BJCIPQKHSA-N
DMWV2AG	IU	(6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMWV2AG	CA	CAS 97519-39-6
DMWV2AG	CB	CHEBI:3510
DMWV2AG	DE	Chronic bronchitis

DMR2SOZ	ID	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	HS	Approved
DMR2SOZ	SN	Excede (TN)
DMR2SOZ	CP	Pfizer
DMR2SOZ	DT	Small molecular drug
DMR2SOZ	PC	6328657
DMR2SOZ	MW	523.6
DMR2SOZ	FM	C19H17N5O7S3
DMR2SOZ	IC	InChI=1S/C19H17N5O7S3/c1-30-23-11(9-7-34-19(20)21-9)14(25)22-12-15(26)24-13(17(27)28)8(5-32-16(12)24)6-33-18(29)10-3-2-4-31-10/h2-4,7,12,16H,5-6H2,1H3,(H2,20,21)(H,22,25)(H,27,28)/b23-11-/t12-,16-/m1/s1
DMR2SOZ	CS	CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4=CC=CO4)C(=O)O
DMR2SOZ	IK	ZBHXIWJRIFEVQY-IHMPYVIRSA-N
DMR2SOZ	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMR2SOZ	CA	CAS 80370-57-6
DMR2SOZ	DE	Bacterial infection

DM3VOGS	ID	DM3VOGS
DM3VOGS	DN	Ceftizoxime
DM3VOGS	HS	Approved
DM3VOGS	SN	Ceftix; Ceftizoxima; Ceftizoximum; Eposerin; Ceftizoxime Monosodium Salt; FK749; FR 13749; Cefizox (TN); Ceftizoxima[INN-Spanish]; Ceftizoxime (INN); Ceftizoxime [INN:BAN]; Ceftizoximum [INN-Latin]; FK-749; FR-13479; FR-13749; SKF-88373; SK&F 88373-2; Syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)-2Z-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxyamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2,3-didehydropenam-2-carboxylic acid
DM3VOGS	CP	Fujisawa Pharmaceutical Co
DM3VOGS	TC	Antibiotics
DM3VOGS	DT	Small molecular drug
DM3VOGS	PC	6533629
DM3VOGS	MW	383.4
DM3VOGS	FM	C13H13N5O5S2
DM3VOGS	IC	InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1
DM3VOGS	CS	CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O
DM3VOGS	IK	NNULBSISHYWZJU-LLKWHZGFSA-N
DM3VOGS	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM3VOGS	CA	CAS 68401-81-0
DM3VOGS	CB	CHEBI:553473
DM3VOGS	DE	Bacterial infection

DM9QWAH	ID	DM9QWAH
DM9QWAH	DN	Ceftolozane/tazobactam
DM9QWAH	HS	Approved
DM9QWAH	SN	CXA-101/tazobactam; CXA-201; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa
DM9QWAH	TC	Antiinfective Agents
DM9QWAH	DE	Discovery agent

DMCEW64	ID	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	HS	Approved
DMCEW64	SN	Biotrakson; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxonum; Ceftriazone; Longacef; Longaceph; Rocefin; Rocephin; Rocephine; CEFTRIAXONE SODIUM; Ceftriaxone intravenous; Ro 139904; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone, Disodium Salt; Ceftriaxonum [INN-Latin]; DRG-0071; Ro13-9904; Rocephin (TN); Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ro-13-9904; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMCEW64	CP	Hoffmann-La Roche pharmaceutical company
DMCEW64	TC	Antibiotics
DMCEW64	DT	Small molecular drug
DMCEW64	PC	5479530
DMCEW64	MW	554.6
DMCEW64	FM	C18H18N8O7S3
DMCEW64	IC	InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1
DMCEW64	CS	CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMCEW64	IK	VAAUVRVFOQPIGI-SPQHTLEESA-N
DMCEW64	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMCEW64	CA	CAS 73384-59-5
DMCEW64	CB	CHEBI:29007
DMCEW64	DE	Bacterial infection

DMSIMD8	ID	DMSIMD8
DMSIMD8	DN	Cefuroxime
DMSIMD8	HS	Approved
DMSIMD8	SN	Anaptivan; Biociclin; Biofuroksym; Bioxima; CXM; Cefofix; Cefumax; Cefurex; Cefuril; Cefuroxim; Cefuroximesodium; Cefuroximine; Cefuroximo; Cefuroximum; Cephuroxime; Cetroxil; Colifossim; Curocef; Curoxim; Curoxima; Curoxime; Froxal; Furoxil; Kesint; Ketocef; Lifurox; Medoxim; Sharox; Spectrazolr; Ultroxim; Zinacef;CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; CEFUROXIME SODIUM; Cefuroxim AJ; Cefuroxim Fresenius; Cefuroxim Genericsn; Cefuroxim Hexal; Cefuroxim Lilly; Cefuroxim MN; Cefuroxim Norcox; Cefuroxim curasan; Cefuroxima Fabra; Cefuroxima Richet; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime na; Cefuroxime sodium salt; KEFUROX IN PLASTIC CONTAINER; Sodium cefuroxime; ZINACEF IN PLASTIC CONTAINER; Zinacef Danmark; Ceftin (TN); Cefuroxim Norcox [inj.]; Cefuroxime (TN); Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]; Cetroxil [inj.]; Froxal [inj.]; KS-1040; Sharox [inj.]; Zinacef (TN); Zinnat (TN); Zinnat [inj.]; Cefuroxime (USAN/INN); Cefuroxime [USAN:INN:BAN]; Cefuroxime sodium (JP15/USP); Cefuroxime sodium [USAN:BAN:JAN]; Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid
DMSIMD8	CP	GlaxoSmithKline
DMSIMD8	TC	Antibiotics
DMSIMD8	DT	Small molecular drug
DMSIMD8	PC	5479529
DMSIMD8	MW	424.4
DMSIMD8	FM	C16H16N4O8S
DMSIMD8	IC	InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1
DMSIMD8	CS	CO/N=C(/C1=CC=CO1)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
DMSIMD8	IK	JFPVXVDWJQMJEE-IZRZKJBUSA-N
DMSIMD8	IU	(6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSIMD8	CA	CAS 55268-75-2
DMSIMD8	CB	CHEBI:3515
DMSIMD8	DE	Acute bronchitis

DM4CHN0	ID	DM4CHN0
DM4CHN0	DN	Cefuroxime axetil
DM4CHN0	HS	Approved
DM4CHN0	SN	cefuroxime axetil; Ceftin; Zinnat; Elobact; Zinat; Cefuroxime 1-acetoxyethyl ester; Bioracef; CXM-AX; Coliofossim; Furoxime; Cetoxil; Celocid; Cethixim; Nivador; Medoxm; Kalcef; Zoref; Sharox-500; UNII-Z49QDT0J8Z; DRG-0157; SN 407; CCI 15641; CCI-15641; Cepazine; CCI 1564; BRN 6854419; Z49QDT0J8Z; CHEBI:3516; (RS)-1-Hydroxyethyl (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), 1-acetate 3-carbamate; C20H22N4O10S; Cefazine; Altacef
DM4CHN0	PC	6321416
DM4CHN0	MW	510.5
DM4CHN0	FM	C20H22N4O10S
DM4CHN0	IC	InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1
DM4CHN0	CS	CC(OC(=O)C)OC(=O)C1=C(CSC2N1C(=O)C2NC(=O)C(=NOC)C3=CC=CO3)COC(=O)N
DM4CHN0	IK	KEJCWVGMRLCZQQ-YJBYXUATSA-N
DM4CHN0	IU	1-acetyloxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM4CHN0	CA	CAS 64544-07-6
DM4CHN0	CB	CHEBI:3516
DM4CHN0	DE	Bacterial infections

DM6LOQU	ID	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	HS	Approved
DM6LOQU	SN	CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM6LOQU	CP	Pfizer
DM6LOQU	TC	Analgesics
DM6LOQU	DT	Small molecular drug
DM6LOQU	PC	2662
DM6LOQU	MW	381.4
DM6LOQU	FM	C17H14F3N3O2S
DM6LOQU	IC	InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
DM6LOQU	CS	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
DM6LOQU	IK	RZEKVGVHFLEQIL-UHFFFAOYSA-N
DM6LOQU	IU	4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM6LOQU	CA	CAS 169590-42-5
DM6LOQU	CB	CHEBI:41423
DM6LOQU	DE	Rheumatoid arthritis; Pain

DMD5LBX	ID	DMD5LBX
DMD5LBX	DN	Celiprolol HCL
DMD5LBX	HS	Approved
DMD5LBX	SN	Selectol (TN)
DMD5LBX	DT	Small molecular drug
DMD5LBX	PC	42373
DMD5LBX	MW	416
DMD5LBX	FM	C20H34ClN3O4
DMD5LBX	IC	InChI=1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H
DMD5LBX	CS	CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl
DMD5LBX	IK	VKJHTUVLJYWAEY-UHFFFAOYSA-N
DMD5LBX	IU	3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea;hydrochloride
DMD5LBX	CA	CAS 57470-78-7
DMD5LBX	CB	CHEBI:31385
DMD5LBX	DE	Hypertension

DMYT2FP	ID	DMYT2FP
DMYT2FP	DN	Cellulose Sodium Phosphate
DMYT2FP	HS	Approved
DMYT2FP	SN	Calcibind
DMYT2FP	CP	Mission Pharmacal Co
DMYT2FP	DE	Hypercalciuria

DMTIUFA	ID	DMTIUFA
DMTIUFA	DN	Celtura
DMTIUFA	HS	Approved
DMTIUFA	SN	A/H1N1v; A/H1N1v vaccine (influenza virus infection), Novartis; H1N1 pandemic influenza A vaccine (MF59-adjuvanted, cell culture), Novartis
DMTIUFA	CP	Novartis AG
DMTIUFA	DT	Vaccine
DMTIUFA	DE	Influenza virus infection

DMKMJHE	ID	DMKMJHE
DMKMJHE	DN	Cemiplimab
DMKMJHE	HS	Approved
DMKMJHE	SN	REGN2810; REGN-2810; REGN 2810
DMKMJHE	CP	Regeneron/Sanofi
DMKMJHE	DT	Monoclonal antibody
DMKMJHE	DE	Cutaneous squamous cell carcinoma

DM8Y2RU	ID	DM8Y2RU
DM8Y2RU	DN	Cenegermin
DM8Y2RU	HS	Approved
DM8Y2RU	SN	cenegermin; Cenegermin [INN]; UNII-B6E7K36KT8; B6E7K36KT8; Human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli nerve growth factor
DM8Y2RU	CP	Domp
DM8Y2RU	DT	Antibody
DM8Y2RU	DE	Neurotrophic keratitis

DMXQS7K	ID	DMXQS7K
DMXQS7K	DN	Cenestin
DMXQS7K	HS	Approved
DMXQS7K	SN	Sodium equilin sulfate; Equilin sodium sulfate; Climopax; Estratab; 16680-47-0; Sodium equilin 3-monosulfate; Emopremarin; Novoconestron; Climestrone; Promarit; Primarin; Premarose; Premaril; Menotrol; Ganeake; Estropan; Estrifol; Premarina; Palopause; Menogen; Mannest; Hyphorin; Formatrix; Estromed; Equigyne; Prempak; Oestrilin; Menotab; Kestrin; Glyestrin; Estroate; Equilin 3-Sulfate Sodium Salt; Conjugen; Conestron; Ayerogen; Theogen; Sukingpo
DMXQS7K	CP	Duramed Pharmaceuticals Inc
DMXQS7K	DT	Small molecular drug
DMXQS7K	PC	23676225
DMXQS7K	MW	370.4
DMXQS7K	FM	C18H19NaO5S
DMXQS7K	IC	InChI=1S/C18H20O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3-5,10,14,16H,2,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,16+,18+;/m1./s1
DMXQS7K	CS	C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+]
DMXQS7K	IK	QTTMOCOWZLSYSV-QWAPEVOJSA-M
DMXQS7K	IU	sodium;[(9S,13S,14S)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate
DMXQS7K	CA	CAS 12126-59-9
DMXQS7K	CB	CHEBI:32143
DMXQS7K	DE	Menopause symptom; Osteoporosis

DM8KLU9	ID	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	HS	Approved
DM8KLU9	SN	Cenobamate; Cenobamate (USAN/INN); Cenobamate [INN]; Cenobamate [USAN:INN]; P85X70RZWS; SCHEMBL1682643; YKP3089; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; 913088-80-9; CHEMBL3989949; CS-0014686; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; HY-17607; UNII-P85X70RZWS
DM8KLU9	PC	11962412
DM8KLU9	MW	267.67
DM8KLU9	FM	C10H10ClN5O2
DM8KLU9	IC	GFHAXPJGXSQLPT-VIFPVBQESA-N
DM8KLU9	CS	C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl
DM8KLU9	IK	1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
DM8KLU9	IU	[(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
DM8KLU9	CA	CAS 913088-80-9
DM8KLU9	DE	Focal seizure

DMGOVHA	ID	DMGOVHA
DMGOVHA	DN	Cenobamate
DMGOVHA	HS	Approved
DMGOVHA	SN	Xcopri; UNII-P85X70RZWS; 913088-80-9; YKP3089; YKP-3089; P85X70RZWS; [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate; (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate; Cenobamate [INN]; Xcopri (TN); YKP-3089 Cenobamate; Cenobamate (USAN/INN); Cenobamate [USAN:INN]; SCHEMBL1682643; CHEMBL3989949; GTPL10773; EX-A3604; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; DB06119; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; HY-17607; CS-0014686; D11150; Q27286352
DMGOVHA	DT	Small molecular drug
DMGOVHA	PC	11962412
DMGOVHA	MW	267.67
DMGOVHA	FM	C10H10ClN5O2
DMGOVHA	IC	InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
DMGOVHA	CS	C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl
DMGOVHA	IK	GFHAXPJGXSQLPT-VIFPVBQESA-N
DMGOVHA	IU	[(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
DMGOVHA	CA	CAS 913088-80-9
DMGOVHA	DE	Complex partial seizure

DMD5JU8	ID	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	HS	Approved
DMD5JU8	SN	Adcadina; Ades[prex; Alcephin; Alexin; Alsporin; Ambal; Aristosporin; Azabort; Bactopenor; Beliam; Biocef; CEX; Carnosporin; Cefablan; Cefacet; Cefadal; Cefadin; Cefadina; Cefalekey; Cefaleksin; Cefalessina; Cefalexgobens; Cefalexin; Cefalexina; Cefalexine; Cefalexinum; Cefalin; Cefalival; Cefaloto; Cefaseptin; Cefax; Ceffanex; Cefibacter; Ceflax; Ceforal; Cefovit; Celexin; Cepastar; Cepexin; Cephacillin; Cephalexine; Cephalexinum; Cephalobene; Cephanasten; Cephaxin; Cephin; Cepol; Ceporex; Ceporexin; Ceporexine; Check; Cophalexin; Domucef; Doriman; Durantel; Efemida; Erocetin; Factagard; Felexin; Fexin; Ibilex; Ibrexin; Inphalex; Karilexina; Kefalospes; Keflet; Keflex; Kefolan; Keforal; Keftab; Kekrinal; Kidolex; Lafarine; Larixin; Lenocef; Lexibiotico; Loisine; Lonflex; Lopilexin; Losporal; Madlexin; Maksipor; Mamalexin; Mamlexin; Medolexin; Medoxine; Neokef; Neolexina; Noveol; Novolexin; Nufex; Oracef; Oriphex; Oroxin; Ortisporina; Ospexin; Palitrex; Pectril; Prindex; Pyassan; Rilexine; Roceph; Rogevil; Sanaxin; Sartosona; Sencephalin; Sepexin; Servicef; Servispor; Sialexin; Sinthecillin; Sintolexyn; Sporicef; Sporidex; Syncl; Syncle; Synecl; Tepaxin; Theratrex; Tokiolexin; Uphalexin; Viosporine; Voxxim; Winlex; Zabytrex; Zozarine; Cefalessina [DCIT]; Cefalexin Scand Pharm; Cefalexin Sodium; Cefalexin generics; Cefalexin hydrate; Cefalexin monohydrate; Cefalexina Northia; Cefalexina Richet; Cephalex von ct; Cephalexin hydrate; Cephalexin monohydrate; Ceporex Forte; Durantel DS; Henina Oral; Panixine Disperdose; Roceph Distab; Lilly 66873; S 6437; SQ 20248; Cefa-iskia; Cefalexin (JP15); Cefalexin.H2O; Cefalexina [INN-Spanish]; Cefalexine [INN-French]; Cefalexinum [INN-Latin]; Cephalexin(USP); Cephalexin (anhydrous); Cephalexin 1-hydrate; Cephalexin 1-wasser; Cephalexin [USAN:BAN]; Cephalexin.H2O; Ceporexin-E; Cusisporina-Cefalox; Ed A-Ceph; KS-1134; Keflex (TN); Keftab (TN); L-Keflex; Panixine disperdose (TN); Sporidex (TN); Cephalexin, (6R-(6alpha,7beta))-Isomer; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta (sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta3-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid
DMD5JU8	CP	Eli Lilly
DMD5JU8	TC	Antibiotics
DMD5JU8	DT	Small molecular drug
DMD5JU8	PC	27447
DMD5JU8	MW	347.4
DMD5JU8	FM	C16H17N3O4S
DMD5JU8	IC	InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
DMD5JU8	CS	CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
DMD5JU8	IK	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N
DMD5JU8	IU	(6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMD5JU8	CA	CAS 15686-71-2
DMD5JU8	CB	CHEBI:3534
DMD5JU8	DE	Bacterial infection

DMYZITL	ID	DMYZITL
DMYZITL	DN	Cephaloglycin
DMYZITL	HS	Approved
DMYZITL	SN	CEG; Cefaloglicina; Cefaloglycin; Cefaloglycine; Cefaloglycinum; Cephaloglycine; Kafocin; Kefglycin; Cephaloglycinanhdyous; Cephaloglycin anhydrous; Cephaoglycin acid; Lilly 39435; Cefaloglicina [INN-Spanish]; Cefaloglycin (JAN); Cefaloglycine [INN-French]; Cefaloglycinum [INN-Latin]; Cephaloglycin (anhydrous); D-Cephaloglycine; D-(-)-Cephaloglycin; (6R,7R)-3-(acetoxymethyl)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-((Acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-acetoxymethyl-7beta-[(2R)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic acid; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester); 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid, acetate inner salt; 7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid
DMYZITL	TC	Antibiotics
DMYZITL	DT	Small molecular drug
DMYZITL	PC	19150
DMYZITL	MW	405.4
DMYZITL	FM	C18H19N3O6S
DMYZITL	IC	InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1
DMYZITL	CS	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
DMYZITL	IK	FUBBGQLTSCSAON-PBFPGSCMSA-N
DMYZITL	IU	(6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYZITL	CA	CAS 3577-01-3
DMYZITL	CB	CHEBI:34613
DMYZITL	DE	Bacterial infection

DM79XDW	ID	DM79XDW
DM79XDW	DN	Cephalosporin
DM79XDW	HS	Approved
DM79XDW	SN	Cephalothin (TN)
DM79XDW	CP	Eli Lilly
DM79XDW	TC	Antibiotics
DM79XDW	DT	Small molecular drug
DM79XDW	PC	25058126
DM79XDW	MW	387.4
DM79XDW	FM	C15H21N3O7S
DM79XDW	IC	InChI=1S/C15H21N3O7S/c1-7-6-26-12(18-10(7)14(22)23)11(15(24)25)17-9(19)5-3-2-4-8(16)13(20)21/h8,11-12H,1-6,16H2,(H,17,19)(H,20,21)(H,22,23)(H,24,25)/t8-,11+,12-/m1/s1
DM79XDW	CS	C=C1CS[C@@H](N=C1C(=O)O)[C@@H](C(=O)O)NC(=O)CCCC[C@H](C(=O)O)N
DM79XDW	IK	JGKXEMYIHDYWCZ-JFUSQASVSA-N
DM79XDW	IU	(2R)-2-[(R)-[[(6R)-6-amino-6-carboxyhexanoyl]amino]-carboxymethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
DM79XDW	DE	Bacterial infection

DM51Z9E	ID	DM51Z9E
DM51Z9E	DN	Cephalothin sodium
DM51Z9E	HS	Approved
DM51Z9E	SN	Cephalothin Sodium W/ Dextrose In Plastic Container; Cephalothin Sodium W/ Sodium Chloride In Plastic Container; Keflin In Plastic Container
DM51Z9E	CP	Eli Lilly And Co
DM51Z9E	TC	Antiinfective Agents
DM51Z9E	DT	Small molecular drug
DM51Z9E	PC	23675321
DM51Z9E	MW	418.4
DM51Z9E	FM	C16H15N2NaO6S2
DM51Z9E	IC	InChI=1S/C16H16N2O6S2.Na/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10;/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23);/q;+1/p-1/t12-,15-;/m1./s1
DM51Z9E	CS	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)[O-].[Na+]
DM51Z9E	IK	VUFGUVLLDPOSBC-XRZFDKQNSA-M
DM51Z9E	IU	sodium;(6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM51Z9E	CA	CAS 58-71-9
DM51Z9E	CB	CHEBI:3542
DM51Z9E	DE	Bacterial infection

DMV2JNY	ID	DMV2JNY
DMV2JNY	DN	Cephapirin
DMV2JNY	HS	Approved
DMV2JNY	SN	CEPR; Cefa; Cefadyl; Cefapirin; Cefapirina; Cefapirine; Cefapirinum; Cefaprin; Cephapirine; Metricure; CEPHAPIRIN SODIUM; Cefaprinsodium; Cephapirin Monosodium Salt; ANTIBIOTIC BL-P1322; BL-P 1322; Cefa-ak; Cefadyl (TN); Cefapirin (BAN); Cefapirin [INN:BAN]; Cefapirina [INN-Spanish]; Cefapirine [INN-French]; Cefapirinum [INN-Latin]; Metricure (TN); (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-acetoxymethyl-7-[(pyridin-4-ylsulfanyl)acetamido]-3,4-didehydrocepham-4-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamidol-5-thia-1-azabicyclo(4.2.0)oct-2-en-2carbonsaeure acetat; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester); 7-(2-(4-Pyridylthio)acetamido)cephalosporanic acid
DMV2JNY	TC	Antibiotics
DMV2JNY	DT	Small molecular drug
DMV2JNY	PC	30699
DMV2JNY	MW	423.5
DMV2JNY	FM	C17H17N3O6S2
DMV2JNY	IC	InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1
DMV2JNY	CS	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)O
DMV2JNY	IK	UQLLWWBDSUHNEB-CZUORRHYSA-N
DMV2JNY	IU	(6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMV2JNY	CA	CAS 21593-23-7
DMV2JNY	CB	CHEBI:554446
DMV2JNY	DE	Sepsis

DM9Y5JB	ID	DM9Y5JB
DM9Y5JB	DN	Cepharanthine
DM9Y5JB	HS	Approved
DM9Y5JB	SN	CEPHARANTHINE; Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; CCRIS 6539; NSC 623442; BRN 0075231; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); NSC-623442; ecaene (non-preferred name); DSSTox_RID_81253; DSSTox_CID_25957; DSSTox_GSID_45957; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; CAS-481-49-2; SR-01000779734; Cepharanthin,(S)
DM9Y5JB	PC	10206
DM9Y5JB	MW	606.7
DM9Y5JB	FM	C37H38N2O6
DM9Y5JB	IC	InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1
DM9Y5JB	CS	CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3
DM9Y5JB	IK	YVPXVXANRNDGTA-WDYNHAJCSA-N
DM9Y5JB	IU	(14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.216,19.13,10.121,25.04,8.031,35.014,39]nonatriaconta-1(33),3(39),4(8),9,16(38),17,19(37),21,23,25(36),31,34-dodecaene
DM9Y5JB	CA	CAS 481-49-2
DM9Y5JB	CB	CHEBI:3546
DM9Y5JB	DE	Thrombocytopenia

DMB920Z	ID	DMB920Z
DMB920Z	DN	Ceritinib
DMB920Z	HS	Approved
DMB920Z	SN	ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337;  ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim
DMB920Z	DT	Small molecular drug
DMB920Z	PC	57379345
DMB920Z	MW	558.1
DMB920Z	FM	C28H36ClN5O3S
DMB920Z	IC	InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
DMB920Z	CS	CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
DMB920Z	IK	VERWOWGGCGHDQE-UHFFFAOYSA-N
DMB920Z	IU	5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
DMB920Z	CA	CAS 1032900-25-6
DMB920Z	CB	CHEBI:78432
DMB920Z	DE	Non-small-cell lung cancer

DMXCM7H	ID	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	HS	Approved
DMXCM7H	SN	cerivastatin; Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins
DMXCM7H	DT	Small molecular drug
DMXCM7H	PC	446156
DMXCM7H	MW	459.5
DMXCM7H	FM	C26H34FNO5
DMXCM7H	IC	InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
DMXCM7H	CS	CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O
DMXCM7H	IK	SEERZIQQUAZTOL-ANMDKAQQSA-N
DMXCM7H	IU	(E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
DMXCM7H	CA	CAS 145599-86-6
DMXCM7H	CB	CHEBI:3558
DMXCM7H	DE	Hyperlipidaemia; Multiple myeloma

DM0HAC8	ID	DM0HAC8
DM0HAC8	DN	Cerliponase Alfa
DM0HAC8	HS	Approved
DM0HAC8	SN	Brineura
DM0HAC8	CP	BioMarin Pharmaceutical
DM0HAC8	DT	Recombinant protein
DM0HAC8	SQ	Cerliponase alfa Sequence: SYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP
DM0HAC8	DE	Tripeptidyl peptidase 1 deficiency; Neuronal ceroid lipofuscinosis

DM5CL9Z	ID	DM5CL9Z
DM5CL9Z	DN	Certolizumab
DM5CL9Z	HS	Approved
DM5CL9Z	SN	CDP-870; Cimzia; PHA-738144; Simziya
DM5CL9Z	CP	UCB
DM5CL9Z	DT	Monoclonal antibody
DM5CL9Z	DE	Rheumatoid arthritis

DMUR94J	ID	DMUR94J
DMUR94J	DN	Certoparin sodium
DMUR94J	HS	Approved
DMUR94J	SN	Alphaparin (TN)
DMUR94J	DE	Deep vein thrombosis

DM6N4PR	ID	DM6N4PR
DM6N4PR	DN	Cerulenin
DM6N4PR	HS	Approved
DM6N4PR	SN	Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide
DM6N4PR	TC	Antiinfective Agents
DM6N4PR	DT	Small molecular drug
DM6N4PR	PC	5282054
DM6N4PR	MW	223.27
DM6N4PR	FM	C12H17NO3
DM6N4PR	IC	InChI=1S/C12H17NO3/c1-2-3-4-5-6-7-8-9(14)10-11(16-10)12(13)15/h2-3,5-6,10-11H,4,7-8H2,1H3,(H2,13,15)/b3-2+,6-5+/t10-,11-/m1/s1
DM6N4PR	CS	C/C=C/C/C=C/CCC(=O)[C@@H]1[C@@H](O1)C(=O)N
DM6N4PR	IK	GVEZIHKRYBHEFX-NQQPLRFYSA-N
DM6N4PR	IU	(2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide
DM6N4PR	CA	CAS 17397-89-6
DM6N4PR	CB	CHEBI:171741
DM6N4PR	DE	Weight loss

DM2WE5K	ID	DM2WE5K
DM2WE5K	DN	Ceruletide
DM2WE5K	HS	Approved
DM2WE5K	SN	Caerulein; Cerulein; Ceruletida; Ceruletidum; Ceruletida [INN-Spanish]; Ceruletidum [INN-Latin]; Ceruletide (USAN/INN); Ceruletide [USAN:INN:BAN]; 5-Oxo-L-prolyl-L-glutaminyl-L-alpha-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; 5-Oxo-L-prolyl-L-glutaminyl-L-aspartyl-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide 4-(hydrogen sulfate) (ester); 5-oxo-L-prolyl-L-glutaminyl-L-a-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide
DM2WE5K	CP	Pharmacia And Upjohn Co
DM2WE5K	TC	Diagnostic Agents
DM2WE5K	DT	Small molecular drug
DM2WE5K	PC	16129675
DM2WE5K	MW	1352.4
DM2WE5K	FM	C58H73N13O21S2
DM2WE5K	IC	InChI=1S/C58H73N13O21S2/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91)/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+/m1/s1
DM2WE5K	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]5CCC(=O)N5)O
DM2WE5K	IK	YRALAIOMGQZKOW-HYAOXDFASA-N
DM2WE5K	IU	(3S)-3-[[(2S)-5-amino-5-oxo-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-[[(2S)-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
DM2WE5K	CA	CAS 17650-98-5
DM2WE5K	CB	CHEBI:59219
DM2WE5K	DE	Caerulein stimulated gastric and pancreatic secretion; Solid tumour/cancer

DMOMP9U	ID	DMOMP9U
DMOMP9U	DN	Cetirizine
DMOMP9U	HS	Approved
DMOMP9U	SN	Cetiderm; Cetirizin; Cetirizina; Cetirizinum; Cetryn; Setir; Virlix; Ziptek; Zirtek; Zyrlex; Cetirizina [Spanish]; Cetirizinum [Latin]; Cetrizine Hcl; Hitrizin Film Tablet; Cetiderm (TN); Cetirizine (INN); Cetirizine [INN:BAN]; P-071; Reactine (TN); Zyrtec (TN); [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid; (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid; (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMOMP9U	CP	Pfizer Pharmaceuticals
DMOMP9U	TC	Antiallergic Agents
DMOMP9U	DT	Small molecular drug
DMOMP9U	PC	2678
DMOMP9U	MW	388.9
DMOMP9U	FM	C21H25ClN2O3
DMOMP9U	IC	InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)
DMOMP9U	CS	C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMOMP9U	IK	ZKLPARSLTMPFCP-UHFFFAOYSA-N
DMOMP9U	IU	2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMOMP9U	CA	CAS 83881-51-0
DMOMP9U	CB	CHEBI:3561
DMOMP9U	DE	Allergic rhinitis

DMSP4JX	ID	DMSP4JX
DMSP4JX	DN	Cetraxate
DMSP4JX	HS	Approved
DMSP4JX	SN	Neuer; NeuerCap; NeuerS; Cetraxate hydrochloride; DV-1006
DMSP4JX	CP	Daiichi Seiyaku Co Ltd
DMSP4JX	DT	Small molecular drug
DMSP4JX	PC	2680
DMSP4JX	MW	305.4
DMSP4JX	FM	C17H23NO4
DMSP4JX	IC	InChI=1S/C17H23NO4/c18-11-13-1-6-14(7-2-13)17(21)22-15-8-3-12(4-9-15)5-10-16(19)20/h3-4,8-9,13-14H,1-2,5-7,10-11,18H2,(H,19,20)
DMSP4JX	CS	C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O
DMSP4JX	IK	FHRSHSOEWXUORL-UHFFFAOYSA-N
DMSP4JX	IU	3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid
DMSP4JX	CA	CAS 34675-84-8
DMSP4JX	CB	CHEBI:17340
DMSP4JX	DE	Peptic ulcer

DMFD9Q6	ID	DMFD9Q6
DMFD9Q6	DN	Cetrorelix
DMFD9Q6	HS	Approved
DMFD9Q6	SN	Cetrorelixum; Cetrorelix (INN); Cetrotide (TN); HS-2008; Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide; N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide
DMFD9Q6	CP	Merck Serono
DMFD9Q6	TC	Infertility Agents
DMFD9Q6	DT	Small molecular drug
DMFD9Q6	PC	25074887
DMFD9Q6	MW	1431
DMFD9Q6	FM	C70H92ClN17O14
DMFD9Q6	IC	InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1
DMFD9Q6	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DMFD9Q6	IK	SBNPWPIBESPSIF-MHWMIDJBSA-N
DMFD9Q6	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMFD9Q6	CA	CAS 120287-85-6
DMFD9Q6	CB	CHEBI:59224
DMFD9Q6	DE	Ovarian stimulation

DMLNCE0	ID	DMLNCE0
DMLNCE0	DN	Cetuximab
DMLNCE0	HS	Approved
DMLNCE0	SN	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors
DMLNCE0	CP	Bristol-Myers Squibb
DMLNCE0	TC	Anticancer Agents
DMLNCE0	DT	Antibody
DMLNCE0	SQ	Cetuximab heavy chain: QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Cetuximab light chainDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMLNCE0	DE	Colorectal cancer

DMWSMND	ID	DMWSMND
DMWSMND	DN	Cevimeline
DMWSMND	HS	Approved
DMWSMND	SN	Evoxac; Saligren; Cevimeline [INN]; Cevimeline hydrochloride; Cevimeline hydrochloride [USAN]; Cevimeline hydrochloride hemihydrate; Cevimeline hydrochloride hydrate; AF 102B; AF102B; Fks 508; AF-102B; Cevimeline (INN); Cevimeline HCl 1/2H2O; Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN); Cevimeline.HCl; Evoxac (TN); FKS-508; SND-5008; SNI-2011; SNK-508; Saligren (TN); SND 5008, AF-102B, FKS-508; Cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); (+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate; (+/-)-cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride; 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
DMWSMND	CP	Daiichi Sankyo Pharma Development
DMWSMND	TC	Parasympathomimetics
DMWSMND	DT	Small molecular drug
DMWSMND	PC	83898
DMWSMND	MW	199.32
DMWSMND	FM	C10H17NOS
DMWSMND	IC	InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1
DMWSMND	CS	C[C@@H]1O[C@]2(CN3CCC2CC3)CS1
DMWSMND	IK	WUTYZMFRCNBCHQ-PSASIEDQSA-N
DMWSMND	IU	(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
DMWSMND	CA	CAS 107233-08-9
DMWSMND	DE	Sjogren syndrome

DMKN345	ID	DMKN345
DMKN345	DN	Charybdotoxin
DMKN345	HS	Approved
DMKN345	SN	ChTX; CTX Toxin; Quinquestriatus Toxin; Charybdotoxin (reduced); Toxin, CTX; Toxin, Quinquestriatus
DMKN345	DT	Small molecular drug
DMKN345	PC	56842037
DMKN345	MW	4296
DMKN345	FM	C176H277N57O55S7
DMKN345	IC	InChI=1S/C176H277N57O55S7/c1-81(2)58-106-149(263)213-110(62-91-67-191-80-197-91)152(266)215-112(64-127(183)246)156(270)231-135(85(8)240)170(284)219-114(69-234)157(271)200-95(36-25-54-192-174(185)186)138(252)196-68-130(249)199-96(32-17-21-50-177)139(253)222-120-75-291-295-79-124(226-159(273)116(71-236)218-167(281)132(82(3)4)228-155(269)113(65-128(184)247)216-169(283)134(84(7)239)230-154(268)108(59-88-28-13-12-14-29-88)210-145(259)102-44-47-129(248)198-102)166(280)232-137(87(10)242)172(286)233-136(86(9)241)171(285)220-115(70-235)158(272)204-98(34-19-23-52-179)141(255)206-104(45-48-131(250)251)147(261)225-122-77-292-290-74-119(223-143(257)99(35-20-24-53-180)201-140(254)97(33-18-22-51-178)203-153(267)111(63-126(182)245)214-148(262)105(49-57-289-11)208-162(120)276)161(275)205-101(38-27-56-194-176(189)190)144(258)224-121(164(278)211-107(60-89-39-41-92(243)42-40-89)150(264)221-118(73-238)173(287)288)76-293-294-78-123(163(277)207-103(43-46-125(181)244)146(260)202-100(142(256)209-106)37-26-55-193-175(187)188)227-168(282)133(83(5)6)229-160(274)117(72-237)217-151(265)109(212-165(122)279)61-90-66-195-94-31-16-15-30-93(90)94/h12-16,28-31,39-42,66-67,80-87,95-124,132-137,195,234-243H,17-27,32-38,43-65,68-79,177-180H2,1-11H3,(H2,181,244)(H2,182,245)(H2,183,246)(H2,184,247)(H,191,197)(H,196,252)(H,198,248)(H,199,249)(H,200,271)(H,201,254)(H,202,260)(H,203,267)(H,204,272)(H,205,275)(H,206,255)(H,207,277)(H,208,276)(H,209,256)(H,210,259)(H,211,278)(H,212,279)(H,213,263)(H,214,262)(H,215,266)(H,216,283)(H,217,265)(H,218,281)(H,219,284)(H,220,285)(H,221,264)(H,222,253)(H,223,257)(H,224,258)(H,225,261)(H,226,273)(H,227,282)(H,228,269)(H,229,274)(H,230,268)(H,231,270)(H,232,280)(H,233,286)(H,250,251)(H,287,288)(H4,185,186,192)(H4,187,188,193)(H4,189,190,194)/t84-,85-,86-,87-,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,132+,133+,134+,135+,136+,137+/m1/s1
DMKN345	CS	C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCCN)CCCCN)CC(=O)N)CCSC)CCCCN)CCCNC(=N)N)CO)[C@@H](C)O)CC(=O)N)CC6=CN=CN6)CC(C)C)CCCNC(=N)N)CCC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC7=CNC8=CC=CC=C87)CO)C(C)C)C(=O)N[C@@H](CC9=CC=C(C=C9)O)C(=O)N[C@@H](CO)C(=O)O)CCCNC(=N)N)CCC(=O)O)CCCCN)CO)[C@@H](C)O)O
DMKN345	IK	CNVQLPPZGABUCM-LIGYZCPXSA-N
DMKN345	IU	(2S)-3-hydroxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(1R,4S,7R,12R,15S,18S,21S,24S,27S,30S,33S,36S,42S,45R,50R,53S,56S,59S,62S,65S,68R,75S,78S,81S,84S,89S,92S,95S)-42,62,75,78-tetrakis(4-aminobutyl)-50-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-3-hydroxy-2-[[(2S)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-27,81-bis(2-amino-2-oxoethyl)-15-(3-amino-3-oxopropyl)-4,18,36-tris(3-carbamimidamidopropyl)-65-(2-carboxyethyl)-30,53,56-tris[(1R)-1-hydroxyethyl]-33,59,92-tris(hydroxymethyl)-24-(1H-imidazol-5-ylmethyl)-89-(1H-indol-3-ylmethyl)-21-(2-methylpropyl)-84-(2-methylsulfanylethyl)-2,5,13,16,19,22,25,28,31,34,37,40,43,51,54,57,60,63,66,74,77,80,83,86,87,90,93,96-octacosaoxo-95-propan-2-yl-9,10,47,48,70,71-hexathia-3,6,14,17,20,23,26,29,32,35,38,41,44,52,55,58,61,64,67,73,76,79,82,85,88,91,94,97-octacosazatricyclo[43.27.14.1112,68]heptanonacontane-7-carbonyl]amino]propanoyl]amino]propanoic acid
DMKN345	CA	CAS 95751-30-7
DMKN345	DE	Scorpion envenoming syndrome

DMQ8JIK	ID	DMQ8JIK
DMQ8JIK	DN	Chenodiol
DMQ8JIK	HS	Approved
DMQ8JIK	SN	474-25-9; Chenix; Chenic acid; Chenodeoxycholate; Gallodesoxycholic acid; Chendol; Chenodesoxycholic acid; Cdca; Chenofalk; Anthropodeoxycholic acid; Anthropodesoxycholic acid; Anthropododesoxycholic acid; Chenodesoxycholsaeure; Xenbilox; Henohol; Chenique Acid; Chenodiol [USAN]; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Sodium chenodeoxycholate; Acido chenodeoxicholico; Chenodesoxycholsaeure [German]; Acide chenodeoxycholique; 7-alpha-Hydroxylithocholic acid; Acidum chenodeoxycholicum
DMQ8JIK	CP	Sigma Tau Pharmaceuticals Inc
DMQ8JIK	DT	Small molecular drug
DMQ8JIK	PC	10133
DMQ8JIK	MW	392.6
DMQ8JIK	FM	C24H40O4
DMQ8JIK	IC	InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1
DMQ8JIK	CS	C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMQ8JIK	IK	RUDATBOHQWOJDD-BSWAIDMHSA-N
DMQ8JIK	IU	(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMQ8JIK	CA	CAS 474-25-9
DMQ8JIK	CB	CHEBI:16755
DMQ8JIK	DE	Cholelithiasis

DMXGJEI	ID	DMXGJEI
DMXGJEI	DN	Chlophedianol
DMXGJEI	HS	Approved
DMXGJEI	SN	Abehol; Antitussin; Calmotusin; Chlofedanol; Clofedano; Clofedanol; Clofedanolum; Clofedianolo; Dencyl; Eutus; Tussistop; Clofedianolo [Italian]; Clophedianol base; Ulo base; SL 501 base; Antitussin (TN); Clofedanol (INN); Clofedanol [INN:BAN]; Clofedanolum [INN-Latin]; Ulone (TN); Alpha-(Dimethylaminoethyl)-o-chlorobenzhydrol; Benzenemethanol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-alpha-phenyl-(9CI); 1-(2-Chlorophenyl)-1-phenyl-3-dimethylaminopropanol; 1-(2-Chlorophenyl)-3-(dimethylamino)-1-phenyl-1-propanol; 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol; 1-(2-chlorophenyl)-3-dimethylamino-1-phenylpropan-1-ol; 1-Phenyl-1-(o-chlorophenyl)-3-dimethylaminopropanol; 2-Chloro-.alpha.-(2-dimethylaminoethyl)benzhydrol; 2-Chloro-alpha-(2-(dimethylamino)ethyl)benzhydrol; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo [Italian]
DMXGJEI	CP	3m Pharmaceuticals Inc
DMXGJEI	TC	Anesthetics
DMXGJEI	DT	Small molecular drug
DMXGJEI	PC	2795
DMXGJEI	MW	289.8
DMXGJEI	FM	C17H20ClNO
DMXGJEI	IC	InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3
DMXGJEI	CS	CN(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2Cl)O
DMXGJEI	IK	WRCHFMBCVFFYEQ-UHFFFAOYSA-N
DMXGJEI	IU	1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol
DMXGJEI	CA	CAS 791-35-5
DMXGJEI	CB	CHEBI:135207
DMXGJEI	DE	Dry cough; Anaesthesia

DMRKE63	ID	DMRKE63
DMRKE63	DN	Chlorambucil
DMRKE63	HS	Approved
DMRKE63	SN	Ambochlorin; Amboclorin; Chlocambucil; Chloorambucol; Chlorambucilum; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucilo; Ecloril; Elcoril; Elcorin; Leukeran; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Clorambucile [DCIT]; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; Leuk ersan; Leukeran tablets; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil; C0253; CB 1348; CB1348; Cb l348; CB-1348; Chlorambucil [INN:BAN]; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; LEUKERAN (TN); Leukeran (TN); Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Chlorambucil (USP/INN)
DMRKE63	CP	GlaxoSmithKline
DMRKE63	TC	Anticancer Agents
DMRKE63	DT	Small molecular drug
DMRKE63	PC	2708
DMRKE63	MW	304.2
DMRKE63	FM	C14H19Cl2NO2
DMRKE63	IC	InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)
DMRKE63	CS	C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
DMRKE63	IK	JCKYGMPEJWAADB-UHFFFAOYSA-N
DMRKE63	IU	4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid
DMRKE63	CA	CAS 305-03-3
DMRKE63	CB	CHEBI:28830
DMRKE63	DE	Chronic lymphocytic leukaemia

DMFXEWT	ID	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	HS	Approved
DMFXEWT	SN	Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin&#174; D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol
DMFXEWT	CP	Aventis Pharmaceuticals Inc.
DMFXEWT	TC	Antibiotics
DMFXEWT	DT	Small molecular drug
DMFXEWT	PC	5959
DMFXEWT	MW	323.13
DMFXEWT	FM	C11H12Cl2N2O5
DMFXEWT	IC	InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1
DMFXEWT	CS	C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]
DMFXEWT	IK	WIIZWVCIJKGZOK-RKDXNWHRSA-N
DMFXEWT	IU	2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide
DMFXEWT	CA	CAS 56-75-7
DMFXEWT	CB	CHEBI:17698
DMFXEWT	DE	Bacterial infection

DMTN5XI	ID	DMTN5XI
DMTN5XI	DN	Chlordiazepoxide
DMTN5XI	HS	Approved
DMTN5XI	SN	Abboxide; Balance; Chloradiazepoxide; Chlordiazachel; Chlordiazepoxid; Chlordiazepoxidum; Chlordiazepoxydum; Chloridazepoxide; Chloridiazepide; Chloridiazepoxide; Chlorodiazepoxide; Chlozepid; Clopoxide; Clordiazepossido; Clordiazepoxido; Control; Decacil; Disarim; Eden; Elenium; Helogaphen; Ifibrium; Kalmocaps; Librelease; Librinin; Libritabs; Librium; Lygen; Menrium; Mesural; Methaminodiazepoxide; Mildmen; Multum; Napoton; Napton; Psicosan; Radepur; Risolid; Silibrin; Sonimen; Tropium; Viopsicol; Zeisin; Zetran; Chlordiazepoxide Base; Clordiazepossido [Italian]; A-Poxide; Apo-Chlordiazepoxide; Balance (pharmaceutical); Chlordiazepoxidum [INN-Latin]; Clordiazepoxido [INN-Spanish]; Eden-psich; Libritabs (TN); Librium (TN); MENRIUM 10-4; MENRIUM 5-4; Novapam (TN); Novo-Poxide; Tropium (TN); Chlordiazepoxide (JP15/USP/INN); Chlordiazepoxide [USAN:INN:BAN:JAN]; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide; 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide; 3H-1,4-benzodiazepin-2-amine,7-chloro-N-methyl-5-phenyl-,4-oxide; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid [German]; 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido [Italian]; 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
DMTN5XI	CP	Patheon Pharmaceuticals Inc
DMTN5XI	TC	Antianxiety Agents
DMTN5XI	DT	Small molecular drug
DMTN5XI	PC	2712
DMTN5XI	MW	299.75
DMTN5XI	FM	C16H14ClN3O
DMTN5XI	IC	InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9,21H,10H2,1H3
DMTN5XI	CS	CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O
DMTN5XI	IK	BUCORZSTKDOEKQ-UHFFFAOYSA-N
DMTN5XI	IU	7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
DMTN5XI	CA	CAS 58-25-3
DMTN5XI	CB	CHEBI:3611
DMTN5XI	DE	Anxiety disorder

DMQ9MVG	ID	DMQ9MVG
DMQ9MVG	DN	Chlorhexidine
DMQ9MVG	HS	Approved
DMQ9MVG	SN	AVAGARD; Chlorhexidin; Chlorhexidinum; Cloresidina; Clorhexidina; Fimeil; Hexadol; Hibiclens; Hibispray; Hibistat;Nolvasan; Novalsan; Peridex; Periogard; Rotersept; Savloclens; Soretol; Sterido; Sterilon; Superspray; Tubulicid; Chlorhexidin [Czech]; Chlorhexidine Base; Chlorhexidine gluconate; Cloresidina [DCIT]; Decanoylacetaldehyde Sodium Sulfide; Dentisept [veterinary]; Savlon babycare; Sebidin A; Sodium Houttuyfonamide; Avagard (TN); BIOPATCH (TN); ChloraPrep (TN); Chlorhexamed (TN); Chlorhexidine (INN);Chlorhexidine [INN:BAN]; Chlorhexidinum [INN-Latin]; Chlorohex (TN); Clohex (TN); Clorexil (TN); Clorhexidina [INN-Spanish]; Corsodyl (TN); Dentisept [veterinary] (TN); Dexidin (TN); Exidine (TN); Hibiclens (TN); Hibiscrub (TN); MK-412A; Merfen-incolore; Oro-Clense; Oronine (TN); Perichlor (TN); Peridex (TN); Peridont (TN); Periochip (TN); Periogard Oral Rinse (TN); Perioxidina (TN); Savacol (TN); Suthol (TN); Dejavu-MW (TN); Merfen-incolore (TN); Lisium (*Dihydrochloride*); Nolvasan (*Diacetate*); SOLU-I.V (TN); N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca-nediimidamide; N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; 1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]; 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane; 1,6-Bis(p-chlorophenyldiguanido)hexane; 1,6-Di(4'-chlorophenyldiguanido)hexane; 1,6-Di(N-p-chlorophenyldiguanido)hexane
DMQ9MVG	CP	G. D. Pharmaceuticals
DMQ9MVG	TC	Antibiotics
DMQ9MVG	DT	Small molecular drug
DMQ9MVG	PC	9552079
DMQ9MVG	MW	505.4
DMQ9MVG	FM	C22H30Cl2N10
DMQ9MVG	IC	InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)
DMQ9MVG	CS	C1=CC(=CC=C1N/C(=N/C(=NCCCCCCN=C(/N=C(/NC2=CC=C(C=C2)Cl)\\N)N)N)/N)Cl
DMQ9MVG	IK	GHXZTYHSJHQHIJ-UHFFFAOYSA-N
DMQ9MVG	IU	(1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine
DMQ9MVG	CA	CAS 55-56-1
DMQ9MVG	CB	CHEBI:3614
DMQ9MVG	DE	Bacterial infection

DMSF4PR	ID	DMSF4PR
DMSF4PR	DN	Chlormerodrin
DMSF4PR	HS	Approved
DMSF4PR	SN	Chlormerodrina; Chloromeridin; Neogidrin; Chlormerodrin Hg 197; Chlormerodrin Hg 203; Chlormerodrin (197Hg); Chlormerodrin (203Hg); Chlormerodrin Hg 197 (TN); Chlormerodrin Hg 197 (USAN); Chlormerodrin Hg 197 [USAN:USP XX]; Chlormerodrin Hg 203 (USAN); Hg-203 chlormerodrin; Loro-}; Neohydrin-203; Chlormerodrin (197Hg) (INN); Neohydrin-203 (TN); Mercury, [3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro; Urea, (2-methoxypropyl)-, mercury complex; [3-(carbamoylamino)-2-methoxypropyl](chloro)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury; {[3-(Chloromercuri)-2-methoxypropyl]urea}; {[3-[(Aminocarbonyl)amino]-2-hydroxypropyl]chloromercury}; [3-(carbamoylamino)-2-methoxypropyl](chloro)(203hg)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury-203; Chloro(2-methoxy-3-ureidopropyl)((203)Hg)mercury(II); Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro-}; [3-(carbamoylamino)-2-methoxypropyl](chloro)((203)Hg)mercury; Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl-C1,O3]ch; (3-(Chloromercuri)-2-methoxypropyl)urea; 3-Chloromercuri-2-methoxypropylurea; 3-ureido-2-methoxypropyl((203)Hg)mercury(II) chloride
DMSF4PR	TC	Diagnostic Agents
DMSF4PR	DT	Small molecular drug
DMSF4PR	PC	25210
DMSF4PR	MW	367.2
DMSF4PR	FM	C5H11ClHgN2O2
DMSF4PR	IC	InChI=1S/C5H11N2O2.ClH.Hg/c1-4(9-2)3-7-5(6)8;;/h4H,1,3H2,2H3,(H3,6,7,8);1H;/q;;+1/p-1
DMSF4PR	CS	COC(CNC(=O)N)C[Hg]Cl
DMSF4PR	IK	BJFGVYCULWBXKF-UHFFFAOYSA-M
DMSF4PR	IU	[3-(carbamoylamino)-2-methoxypropyl]-chloromercury
DMSF4PR	CA	CAS 10375-56-1
DMSF4PR	CB	CHEBI:59445
DMSF4PR	DE	Diagnostic imaging

DMTWUXR	ID	DMTWUXR
DMTWUXR	DN	Chlormezanone
DMTWUXR	HS	Approved
DMTWUXR	SN	Alinam; Banabin; Bisina; Chlomedinon; Chlormethazanone; Chlormethazone; Chlormezanon; Chlormezanona; Chlormezanonum; Clorilax; Clormetazanone; Clormetazon; Clormezanona; Clormezanone; Dichloromethazanone; Dichloromezanone; Lobak; Miorilax; Muskel; Myolespen; Phenarol; Rexan; Rilansyl; Rilaquil; Rilasol; Rilassol; Rilax; Rillasol; Supotran; Suprotan; Tanafol; Trancopal; Trancote; Tranrilax; Transanate; Clormezanone [DCIT]; WIN 4692; Banabil-sintyal; Banabin-sintyal; Banabin-syntyal; C-192; Chlormezanonum [INN-Latin]; Clormezanona [INN-Spanish]; Dl-Chlormezanone; Mio-sed; Muskel-Trancopal; TRANCOPAL (TN); Trancopal (TN); Chlormezanone (JAN/INN); Chlormezanone [BAN:INN:JAN]; Chlormezanone [INN:BAN:JAN]; (+-)-Chlormezanone; 2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide; 2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H,1,3-thiazin-4-one 1,1-Dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(4-Chlorphenyl)-3-methyl-4-metathiazanon-1,1-dioxid; 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one; 2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide; 2-(para-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1,-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide
DMTWUXR	TC	Analgesics
DMTWUXR	DT	Small molecular drug
DMTWUXR	PC	2717
DMTWUXR	MW	273.74
DMTWUXR	FM	C11H12ClNO3S
DMTWUXR	IC	InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3
DMTWUXR	CS	CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl
DMTWUXR	IK	WEQAYVWKMWHEJO-UHFFFAOYSA-N
DMTWUXR	IU	2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one
DMTWUXR	CA	CAS 80-77-3
DMTWUXR	CB	CHEBI:3619
DMTWUXR	DE	Anxiety disorder

DMSOQK1	ID	DMSOQK1
DMSOQK1	DN	Chloroprocaine
DMSOQK1	HS	Approved
DMSOQK1	SN	Chloroprocain; Chloroprocainum; Chlorprocaine; Chlorprocainum; Cloroprocaina; Halestyn; Nesacaine; Piocaine; Chloroprocaine [INN]; Chloroprocaine hydrochloride; Nesacaine MPF; Chlor-procaine; Chloroprocaine (INN); Chloroprocainum [INN-Latin]; Cloroprocaina [INN-Spanish]; Nesacaine (TN); Nesacaine-Ce; Nesacaine-MPF (TN); Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate; 2-(Diethylaminoethyl)-4-amino-2-chlorobenzoate; 2-Chloroprocaine; 2-diethylaminoethyl 4-amino-2-chlorobenzoate; 4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester
DMSOQK1	CP	Abbott Laboratories
DMSOQK1	TC	Anesthetics
DMSOQK1	DT	Small molecular drug
DMSOQK1	PC	8612
DMSOQK1	MW	270.75
DMSOQK1	FM	C13H19ClN2O2
DMSOQK1	IC	InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3
DMSOQK1	CS	CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl
DMSOQK1	IK	VDANGULDQQJODZ-UHFFFAOYSA-N
DMSOQK1	IU	2-(diethylamino)ethyl 4-amino-2-chlorobenzoate
DMSOQK1	CA	CAS 133-16-4
DMSOQK1	CB	CHEBI:3636
DMSOQK1	DE	Anaesthesia

DMSI5CB	ID	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	HS	Approved
DMSI5CB	SN	Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244
DMSI5CB	CP	Medreich Sterilab Ltd
DMSI5CB	TC	Antimalarials
DMSI5CB	DT	Small molecular drug
DMSI5CB	PC	2719
DMSI5CB	MW	319.9
DMSI5CB	FM	C18H26ClN3
DMSI5CB	IC	InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
DMSI5CB	CS	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
DMSI5CB	IK	WHTVZRBIWZFKQO-UHFFFAOYSA-N
DMSI5CB	IU	4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
DMSI5CB	CA	CAS 54-05-7
DMSI5CB	CB	CHEBI:3638
DMSI5CB	DE	Malaria

DMLHESP	ID	DMLHESP
DMLHESP	DN	Chlorothiazide
DMLHESP	HS	Approved
DMLHESP	SN	Aldoclor; Alurene; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazidum; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazide; Clotride; Diupres; Diuresal; Diuril; Diurilix; Diurite; Diutrid; Flumen; Minzil; Salisan; Salunil; Saluretil; Saluric; Thiazide; Urinex; Warduzide; Yadalan; Clorotiazide [DCIT]; Component of Aldoclor; Diuril Boluses; C 4911; Chlorothiazidum [INN-Latin]; Clorotiazida [INN-Spanish]; Diuril (TN); Diuril Boluses, Veterinary; Neo-Dema; Sk-chlorothiazide; Chlorothiazide [USAN:INN:BAN]; Diuril, Chlotride, Chlorothiazide; Chlorothiazide (JAN/USP/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMLHESP	CP	Oak Pharmaceuticals Inc Sub Akorn Inc
DMLHESP	TC	Antihypertensive Agents
DMLHESP	DT	Small molecular drug
DMLHESP	PC	2720
DMLHESP	MW	295.7
DMLHESP	FM	C7H6ClN3O4S2
DMLHESP	IC	InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
DMLHESP	CS	C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2
DMLHESP	IK	JBMKAUGHUNFTOL-UHFFFAOYSA-N
DMLHESP	IU	6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMLHESP	CA	CAS 58-94-6
DMLHESP	CB	CHEBI:3640
DMLHESP	DE	Congestive heart failure

DMFZBMQ	ID	DMFZBMQ
DMFZBMQ	DN	Chloroxine
DMFZBMQ	HS	Approved
DMFZBMQ	SN	chloroxine; 5,7-Dichloroquinolin-8-ol; 773-76-2; 5,7-Dichloro-8-hydroxyquinoline; Chlorquinol; Quixalin; Capitrol; Dichloroxin; Chloroxyquinoline; Dichloroquinolinol; Dikhloroskin; 5,7-Dichloro-8-quinolinol; Endiaron; Clofuzid; Quinolor; Dichlorohydroxyquinoline; Chlofucid; Quesyl; 5,7-Dichloroxine; 5,7-Dichlorooxine; Chlorohydroxyquinoline; 8-QUINOLINOL, 5,7-DICHLORO-; 5,7-Dichloro-8-oxyquinoline; Chloroxine [USAN]; 5,7-Dichlor-8-hydroxychinolin; C9H5Cl2NO; NSC 3904; UNII-2I8BD50I8B; CCRIS 5751; CHQ; Capitrol Cream Shampoo; EINECS 212-2
DMFZBMQ	DT	Small molecular drug
DMFZBMQ	PC	2722
DMFZBMQ	MW	214.04
DMFZBMQ	FM	C9H5Cl2NO
DMFZBMQ	IC	InChI=1S/C9H5Cl2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
DMFZBMQ	CS	C1=CC2=C(C(=C(C=C2Cl)Cl)O)N=C1
DMFZBMQ	IK	WDFKMLRRRCGAKS-UHFFFAOYSA-N
DMFZBMQ	IU	5,7-dichloroquinolin-8-ol
DMFZBMQ	CA	CAS 773-76-2
DMFZBMQ	CB	CHEBI:59477
DMFZBMQ	DE	Erythema

DM5URA2	ID	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	HS	Approved
DM5URA2	SN	Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine
DM5URA2	CP	Schering-Plough Corporation
DM5URA2	TC	Antiallergic Agents
DM5URA2	DT	Small molecular drug
DM5URA2	PC	2725
DM5URA2	MW	274.79
DM5URA2	FM	C16H19ClN2
DM5URA2	IC	InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
DM5URA2	CS	CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DM5URA2	IK	SOYKEARSMXGVTM-UHFFFAOYSA-N
DM5URA2	IU	3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DM5URA2	CA	CAS 113-92-8
DM5URA2	CB	CHEBI:52010
DM5URA2	DE	Allergic rhinitis

DMQRPOS	ID	DMQRPOS
DMQRPOS	DN	Chlorphentermine hydrochloride
DMQRPOS	HS	Approved
DMQRPOS	SN	Pre-sate
DMQRPOS	CP	Parke Davis Div Warner Lambert Co
DMQRPOS	DT	Small molecular drug
DMQRPOS	PC	65477
DMQRPOS	MW	220.14
DMQRPOS	FM	C10H15Cl2N
DMQRPOS	IC	InChI=1S/C10H14ClN.ClH/c1-10(2,12)7-8-3-5-9(11)6-4-8;/h3-6H,7,12H2,1-2H3;1H
DMQRPOS	CS	CC(C)(CC1=CC=C(C=C1)Cl)N.Cl
DMQRPOS	IK	WEJDYJKJPUPMLH-UHFFFAOYSA-N
DMQRPOS	IU	1-(4-chlorophenyl)-2-methylpropan-2-amine;hydrochloride
DMQRPOS	CA	CAS 151-06-4
DMQRPOS	DE	Appetite suppressant

DM1IFGT	ID	DM1IFGT
DM1IFGT	DN	Chlorproguanil
DM1IFGT	HS	Approved
DM1IFGT	SN	Chlorproguanilum; Clorpreguanile; Clorproguanil; Lapudrine; Clorpreguanile [DCIT]; Unspecified HCl of chlorproguanil; Chlorproguanil [INN:BAN]; Chlorproguanilum [INN-Latin]; Clorproguanil [INN-Spanish]; N-(3,4-dichlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; 1-(3,4-Dichlorophenyl)-5-isopropylbiguanide
DM1IFGT	DT	Small molecular drug
DM1IFGT	PC	9571037
DM1IFGT	MW	288.17
DM1IFGT	FM	C11H15Cl2N5
DM1IFGT	IC	InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)
DM1IFGT	CS	CC(C)N=C(N)/N=C(\\N)/NC1=CC(=C(C=C1)Cl)Cl
DM1IFGT	IK	ISZNZKHCRKXXAU-UHFFFAOYSA-N
DM1IFGT	IU	(1E)-1-[amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine
DM1IFGT	CA	CAS 537-21-3
DM1IFGT	CB	CHEBI:135192
DM1IFGT	DE	Malaria

DMBGZI3	ID	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	HS	Approved
DMBGZI3	SN	Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
DMBGZI3	CP	GlaxoSmithKline
DMBGZI3	TC	Antipsychotic Agents
DMBGZI3	DT	Small molecular drug
DMBGZI3	PC	2726
DMBGZI3	MW	318.9
DMBGZI3	FM	C17H19ClN2S
DMBGZI3	IC	InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
DMBGZI3	CS	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMBGZI3	IK	ZPEIMTDSQAKGNT-UHFFFAOYSA-N
DMBGZI3	IU	3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
DMBGZI3	CA	CAS 34468-21-8
DMBGZI3	CB	CHEBI:3647
DMBGZI3	DE	Schizophrenia

DMPHZQE	ID	DMPHZQE
DMPHZQE	DN	Chlorpropamide
DMPHZQE	HS	Approved
DMPHZQE	SN	Adiaben; Asucrol; Bioglumin; Catanil; Chlorodiabina; Chloronase; Chloropropamide; Chlorporpamide; Chlorpropamid; Chlorpropamidum; Clorpropamid; Clorpropamida; Clorpropamide; Diabaril; Diabechlor; Diabenal; Diabenese; Diabeneza; Diabetoral; Diabexan; Diabinese; Dynalase; Glisema; Glucamide; Insogen; Insulase; Meldian; Melitase; Mellinese; Millinese; Oradian; Prodiaben; Stabinol; Apotex Brand of Chlorpropamide; Byk Gulden Brand of Chlorpropamide; CHLORPROPAMIDE USP; Clorpropamide [DCIT]; Clorpropamide [Italian];Dia benese; Diamel Ex; Farmasierra Brand of Chlorpropamide; Pfizer Brand of Chlorpropamide; C 1290; P 607; Apo-Chlorpropamide; Chlorpropamide Bp/ Usp; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabet-Pages; Diabinese (TN); Novo-Propamide; U-3818; U-9818; Chlorpropamide [INN:BAN:JAN]; Chlorpropamide (JP15/USP/INN); N3-Butyl-N1-p-chlorobenzenesulfonylure a; N3-Butyl-N1-p-chlorobenzenesulfonylurea; N-Propyl-N'-p-chlorophenylsulfonylcarbamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-propyl-N'-p-chlorophenylsu lfonylcarbamide; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 1-(4-Chlorophenylsulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(p-Chlorobenzensulfonyl)-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-(para-Chlorophenylsulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide
DMPHZQE	TC	Hypoglycemic Agents
DMPHZQE	DT	Small molecular drug
DMPHZQE	PC	2727
DMPHZQE	MW	276.74
DMPHZQE	FM	C10H13ClN2O3S
DMPHZQE	IC	InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
DMPHZQE	CS	CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
DMPHZQE	IK	RKWGIWYCVPQPMF-UHFFFAOYSA-N
DMPHZQE	IU	1-(4-chlorophenyl)sulfonyl-3-propylurea
DMPHZQE	CA	CAS 94-20-2
DMPHZQE	CB	CHEBI:3650
DMPHZQE	DE	Non-insulin dependent diabetes

DMY0KGJ	ID	DMY0KGJ
DMY0KGJ	DN	Chlorprothixene
DMY0KGJ	HS	Approved
DMY0KGJ	SN	Chloroprothixene; Chlorprothixen; Chlorprothixenum; Chlorprothixine; Chlorprotixen; Chlorprotixene; Chlorprotixine; Chlothixen; Clorprotisene; Clorprotixeno; Iaractan; Paxyl; Rentovet; Tactaran; Taractan; Tarasan; Tardan; Traquilan; Trictal; Truxal; Truxaletten; Truxil; Vetacalm; Clorprotisene [DCIT]; MK 184; N 714; N 714C; NCI56378; Alpha-Chlorprothixene; Chlorprothixenum [INN-Latin]; Cis-Chlorprothixene; Clorprotixeno [INN-Spanish]; N-714; Ro 4-0403; Taractan (TN); Truxal (TN); Ro-4-0403;Trans(E)-Chlorprothixen; Chlorprothixene (JAN/USAN/INN); Chlorprothixene [USAN:INN:BAN:JAN]; Cloxan, Taractan, Truxal, Chlorprothixene; Cis-2-Chloro-9-(3-dimethylaminopropylidene)thioxanthene; {3-[2-Chloro-thioxanthen-(9Z)-ylidene]-propyl}-dimethyl-amine; Thioxanthene-delta9,gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)-(8CI); (3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (Z)-2-Chloro-9-(omega-dimethylaminopropylidene)thioxanthene; (Z)-2-Chloro-N,N-dimethylthioxanthene-.DELTA.(sup9),(sup.gamma.)-propylamine; (Z)-2-Chloro-N,N-dimethylthioxanthene-delta(sup 9,gamma)-propylamine; (alpha.-2-Chloro-9-.omega.-dimethylamino-propylamine)thioxanthene; 2-Chloro-9-[.omega.-(dimethylamino)propylidene]thioxanthene; 2-Chloro-9-[3-(dimethylamino)propylidene]thioxanthene; 2-Chloro-N,N-dimethylthioxanthene-.delta.(sup 9), .gamma.-propylamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-1-propanamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; 3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
DMY0KGJ	TC	Antipsychotic Agents
DMY0KGJ	DT	Small molecular drug
DMY0KGJ	PC	667467
DMY0KGJ	MW	315.9
DMY0KGJ	FM	C18H18ClNS
DMY0KGJ	IC	InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-
DMY0KGJ	CS	CN(C)CC/C=C\\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMY0KGJ	IK	WSPOMRSOLSGNFJ-AUWJEWJLSA-N
DMY0KGJ	IU	(3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
DMY0KGJ	CA	CAS 113-59-7
DMY0KGJ	CB	CHEBI:50931
DMY0KGJ	DE	Psychotic disorder

DM4DMBT	ID	DM4DMBT
DM4DMBT	DN	Chlorthalidone
DM4DMBT	HS	Approved
DM4DMBT	SN	Chlorothalidone; Chlorphthalidolone; Chlorphthalidone; Chlortalidone; Chlortalidonum; Chlorthalidon; Clortalidona; Clortalidone; Famolin; Higroton; Hygroton; Igroton; Isoren; Natriuran; Oradil; Oxodolin; Oxodoline; Phthalamodine; Phthalamudine; Renon; Saluretin; Thalitone; Urolin; Zambesil; Clortalidone [DCIT]; Racemic chlorthalidone; G 33182; Chlortalidonum [INN-Latin]; Chlorthalidone (USP); Clortalidona [INN-Spanish]; G-33182; Hydro-Long; Hygroton (TN); Oksodolin (oxodolin); Thalitone (TN); Chlortalidone (JAN/INN); Chlorthalidone [USAN:INN:BAN]; (+-)-Chlorthalidone; (+-)-Hygroton; 1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; 3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
DM4DMBT	TC	Antihypertensive Agents
DM4DMBT	DT	Small molecular drug
DM4DMBT	PC	2732
DM4DMBT	MW	338.8
DM4DMBT	FM	C14H11ClN2O4S
DM4DMBT	IC	InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
DM4DMBT	CS	C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O
DM4DMBT	IK	JIVPVXMEBJLZRO-UHFFFAOYSA-N
DM4DMBT	IU	2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide
DM4DMBT	CA	CAS 77-36-1
DM4DMBT	CB	CHEBI:3654
DM4DMBT	DE	Edema; Hypertension

DMCYVDT	ID	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	HS	Approved
DMCYVDT	SN	Biomioran; CLW; Chloroxazone; Chlorsoxazone; Chlorzoxane; Chlorzoxazon; Chlorzoxazona; Chlorzoxazonum; Clorzoxazona; Escoflex; Klorzoxazon; Mioran; Miotran; Myoflexin; Myoflexine; Neoflex; Nyoflex; Paraflex; Parafon; Pathorysin; Relaxazone; Remofleks; Remular; Solaxin; Component of Parafon Forte; McNeil Brand of Chlorzoxazone; Ortho Brand of Chlorzoxazone; Parafon Forte; Parafon Forte DSC; Strifon Forte Dsc; C 4397; Chlorzoxazonum [INN-Latin]; Clorzoxazona [INN-Spanish]; EZE-DS; Muscol (TN); Paraflex (TN); Parafon Forte (TN); Remular-S; Usaf ma-10; Chlorzoxazone [INN:BAN:JAN]; Chlorzoxazone (JAN/USP/INN); 2-Hydroxy-5-chlorobenzoxazole; 5-Chlorbenzoxazolin-2-on; 5-Chloro-1,3-benzoxazol-2(3H)-one; 5-Chloro-2(3H)-benzoxazolone; 5-Chloro-2-benzoxazolinone; 5-Chloro-2-benzoxazolol; 5-Chloro-2-benzoxazolone; 5-Chloro-2-hydroxybenzoxazole; 5-Chloro-3(H)-2-benzoxazolone; 5-Chlorobenzoksazolinon-2; 5-Chlorobenzoksazolinon-2 [Polish]; 5-Chlorobenzoksazolon-2; 5-Chlorobenzoksazolon-2 [Polish]; 5-Chlorobenzoxazol-2-one; 5-Chlorobenzoxazolidone; 5-Chlorobenzoxazolone; 5-chloro-1,3-benzoxazol-2-ol; 5-chloro-3H-1,3-benzoxazol-2-one; 5-chlorobenzoxazolin-2-one
DMCYVDT	TC	Analgesics
DMCYVDT	DT	Small molecular drug
DMCYVDT	PC	2733
DMCYVDT	MW	169.56
DMCYVDT	FM	C7H4ClNO2
DMCYVDT	IC	InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
DMCYVDT	CS	C1=CC2=C(C=C1Cl)NC(=O)O2
DMCYVDT	IK	TZFWDZFKRBELIQ-UHFFFAOYSA-N
DMCYVDT	IU	5-chloro-3H-1,3-benzoxazol-2-one
DMCYVDT	CA	CAS 95-25-0
DMCYVDT	CB	CHEBI:3655
DMCYVDT	DE	Acute pain

DMGU74E	ID	DMGU74E
DMGU74E	DN	Cholecalciferol
DMGU74E	HS	Approved
DMGU74E	SN	Arachitol; Calciol; Cholecalciferolum; Colecalciferol; Colecalciferolo; Colecalciferolum; Colecalcipherol; Delsterol; Deparal; Ebivit; FeraCol; Provitamine; Provitina; Rampage; Ricketon; Trivitan; Vigorsan; Colecalciferolo [DCIT]; VITAMIN D; Duphafral D3 1000; LT00244775; NEO Dohyfral D3; Oleovitamin D3; TNP00266; VITAMIN D3 POWDER; VITAMIN_D3; Vitamin D3; Vitamin D3 emulsifiable; Activated 7-dehydrocholesterol; Cholecalciferol (D3); Cholecalciferol, D3; Colecalciferol (INN); Colecalciferolum [INN-Latin]; D3-Vicotrat; D3-Vigantol; Delta-D; Irradiated 7-dehydrocholesterol; Micro-dee; Vitamin d-3; Cholecalciferol (JP15/USP); Cholecalciferol [USAN:BAN:JAN]; Delta-D (TN); Vitinc Dan-Dee-3; Vi-de-3-hydrosol; (+)-Vitamin D3; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; 25(OH)D; 7-Dehydrocholesterol activated; 7-Dehydrocholesterol, Activated; 7-Dehydrocholesterol, irradiated; 7-Dehydrocholestrol, activated; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(beta.)-ol; 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
DMGU74E	TC	Vitamins
DMGU74E	DT	Small molecular drug
DMGU74E	PC	5280795
DMGU74E	MW	384.6
DMGU74E	FM	C27H44O
DMGU74E	IC	InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
DMGU74E	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMGU74E	IK	QYSXJUFSXHHAJI-YRZJJWOYSA-N
DMGU74E	IU	(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMGU74E	CA	CAS 67-97-0
DMGU74E	CB	CHEBI:28940
DMGU74E	DE	Vitamin D deficiency

DM7OKQV	ID	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	HS	Approved
DM7OKQV	SN	cholic acid; 81-25-4; Cholalic acid; cholate; Cholalin; Colalin; Cholsaeure; NSC-6135; Cholic acid, 5beta-; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; UNII-G1JO7801AE; HSDB 982; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; Cholic acid [USAN]; 3,7,12-Trihydroxycholanic acid; G1JO7801AE; CHEMBL205596; CHEBI:16359; NSC6135; BHQCQFFYRZLCQQ-OELDTZBJSA-N
DM7OKQV	DT	Small molecular drug
DM7OKQV	PC	221493
DM7OKQV	MW	408.6
DM7OKQV	FM	C24H40O5
DM7OKQV	IC	InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1
DM7OKQV	CS	C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
DM7OKQV	IK	BHQCQFFYRZLCQQ-OELDTZBJSA-N
DM7OKQV	IU	(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM7OKQV	CA	CAS 81-25-4
DM7OKQV	CB	CHEBI:16359
DM7OKQV	DE	Synthesis disorder; Peroxisomal disorder

DMOI1ZF	ID	DMOI1ZF
DMOI1ZF	DN	Choline alfoscerate
DMOI1ZF	HS	Approved
DMOI1ZF	SN	Delecit (TN)
DMOI1ZF	DT	Small molecular drug
DMOI1ZF	PC	657272
DMOI1ZF	MW	257.22
DMOI1ZF	FM	C8H20NO6P
DMOI1ZF	IC	InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1
DMOI1ZF	CS	C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O
DMOI1ZF	IK	SUHOQUVVVLNYQR-MRVPVSSYSA-N
DMOI1ZF	IU	[(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMOI1ZF	CA	CAS 28319-77-9
DMOI1ZF	CB	CHEBI:16870
DMOI1ZF	DE	Amnesia

DM8P137	ID	DM8P137
DM8P137	DN	Choline salicylate
DM8P137	HS	Approved
DM8P137	SN	2016-36-6; Arthropan; Syrap; Mundisal; Satibon; Actasal; Salicol; Artrobione; Arret; Choline salicylate B; (2-Hydroxyethyl)trimethylammonium salicylate; UNII-KD510K1IQW; Choline salicylic acid salt; Salicylic acid choline salt; Cholini salicylas [INN-Latin]; Salicylic acid, ion(1-), choline; Salicylate de choline [INN-French]; Salicilato de colina [INN-Spanish]; EINECS 217-948-8; KD510K1IQW; Choline salicylate [USAN:INN:BAN:JAN]; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-hydroxybenzoic acid (1:1)
DM8P137	DT	Small molecular drug
DM8P137	PC	54686350
DM8P137	MW	241.28
DM8P137	FM	C12H19NO4
DM8P137	IC	InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1
DM8P137	CS	C[N+](C)(C)CCO.C1=CC=C(C(=C1)C(=O)O)[O-]
DM8P137	IK	UDKCHVLMFQVBAA-UHFFFAOYSA-M
DM8P137	IU	2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium
DM8P137	CA	CAS 2016-36-6
DM8P137	CB	CHEBI:3668
DM8P137	DE	Inflammation

DMFMZ3G	ID	DMFMZ3G
DMFMZ3G	DN	Choriogonadotropin alfa
DMFMZ3G	HS	Approved
DMFMZ3G	TC	Fertility Agents
DMFMZ3G	SQ	Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>    <sequence format="FASTA">&gt;Beta chainSKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ
DMFMZ3G	DE	Female infertility

DMFT73E	ID	DMFT73E
DMFT73E	DN	Chorionic Gonadotropin
DMFT73E	HS	Approved
DMFT73E	SN	A.P.L.; Chorionic Gonadotropin; Follutein; Pregnyl
DMFT73E	CP	Ferring Pharmaceuticals Inc
DMFT73E	DE	Fertility problem

DM2NA4K	ID	DM2NA4K
DM2NA4K	DN	Ciclesonide
DM2NA4K	HS	Approved
DM2NA4K	SN	Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
DM2NA4K	CP	Altana Pharma
DM2NA4K	TC	Antiallergic Agents
DM2NA4K	DT	Small molecular drug
DM2NA4K	PC	6918155
DM2NA4K	MW	540.7
DM2NA4K	FM	C32H44O7
DM2NA4K	IC	InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
DM2NA4K	CS	CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6
DM2NA4K	IK	LUKZNWIVRBCLON-GXOBDPJESA-N
DM2NA4K	IU	[2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate
DM2NA4K	CA	CAS 126544-47-6
DM2NA4K	CB	CHEBI:31397
DM2NA4K	DE	Obstructive airway disease; Asthma

DMN5T2A	ID	DMN5T2A
DMN5T2A	DN	Ciclopirox
DMN5T2A	HS	Approved
DMN5T2A	SN	Ciclopiroxum; Cyclopirox; Cyclopyroxolamine; Loprox; Penlac; Stieprox; Terit; Ciclopirox Olamin; Ciclopirox gel; Loprox Gel; Loprox Shampoo; Loprox cream; Penlac nail lacquer; HOE 296b; Batrafen (TN); Ciclopirox-Olamin; Ciclopiroxum [INN-Latin]; Dafnegin-CSC; HOE-296; HOE-296b; Loprox (TN); Penlac (TN); Stieprox (TN); Ciclopirox (USP/INN); Ciclopirox [USAN:BAN:INN]; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
DMN5T2A	TC	Antifungal Agents
DMN5T2A	DT	Small molecular drug
DMN5T2A	PC	2749
DMN5T2A	MW	207.27
DMN5T2A	FM	C12H17NO2
DMN5T2A	IC	InChI=1S/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3
DMN5T2A	CS	CC1=CC(=O)N(C(=C1)C2CCCCC2)O
DMN5T2A	IK	SCKYRAXSEDYPSA-UHFFFAOYSA-N
DMN5T2A	IU	6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
DMN5T2A	CA	CAS 29342-05-0
DMN5T2A	CB	CHEBI:453011
DMN5T2A	DE	Fungal infection

DMAZJFX	ID	DMAZJFX
DMAZJFX	DN	Ciclosporin
DMAZJFX	HS	Approved
DMAZJFX	SN	Ciclosporin; Ciclosporin (Ciclosporin A); Ciclosporina; Ciclosporina [INN-Spanish]; Ciclosporine; Ciclosporine [INN-French]; Ciclosporinum; Ciclosporinum [INN-Latin]; Cipol N; Consupren; Cyclosporin; Cyclosporine A; Equoral; Antibiotic S 7481F1; Gengraf; Neoplanta; Neoral; Ramihyphin A; Restasis; S-Neoral; Sandimmun; Sandimmun Neoral; Sandimmune; Sang 35; Sang-35; SangCyA; Sigmasporin Microoral; cyclosporin A; cyclosporine; 59865-13-3; 83HN0GTJ6D; CHEBI:4031; CSA; DSSTox_CID_365; DSSTox_RID_75541; MFCD00274558; MLS001333756; UNII-83HN0GTJ6D
DMAZJFX	PC	5284373
DMAZJFX	MW	1202.6
DMAZJFX	FM	C62H111N11O12
DMAZJFX	IC	PMATZTZNYRCHOR-CGLBZJNRSA-N
DMAZJFX	CS	CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMAZJFX	IK	1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
DMAZJFX	IU	(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMAZJFX	CA	CAS 59865-13-3
DMAZJFX	CB	CHEBI:4031
DMAZJFX	DE	Viral hepatitis

DMT2KRV	ID	DMT2KRV
DMT2KRV	DN	Ciclosporin
DMT2KRV	HS	Approved
DMT2KRV	SN	Cyclosporine A; CSA; CsA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin; Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine A; Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin
DMT2KRV	CP	Sandoz
DMT2KRV	TC	Immunosuppressive Agents
DMT2KRV	DT	Protein/peptide drug
DMT2KRV	PC	24883466
DMT2KRV	MW	1202.6
DMT2KRV	FM	C62H111N11O12
DMT2KRV	IC	InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1
DMT2KRV	CS	CC[C@@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMT2KRV	IK	PMATZTZNYRCHOR-VJRYSDSKSA-N
DMT2KRV	IU	(3R,6S,9S,12S,15S,18R,21S,24S,30R,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMT2KRV	CA	CAS 59865-13-3
DMT2KRV	DE	Psoriasis vulgaris; Xerophthalmia; Brain injury

DMA13GD	ID	DMA13GD
DMA13GD	DN	Cidofovir
DMA13GD	HS	Approved
DMA13GD	SN	CDV; Cidofovirum; Forvade; HPMPC; Vistide; Cidofovir anhydrous; GS 0504; GS 504; GS504; Cidofovir (Vistide); Cidofovir (anhydrous); GS-0504; GS-504; Vistide (TN); Vistide, Cidofovir; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; (S)-HPMPC; (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
DMA13GD	CP	Pfizer Pharmaceuticals
DMA13GD	TC	Anti-HIV Agents
DMA13GD	DT	Small molecular drug
DMA13GD	PC	60613
DMA13GD	MW	279.19
DMA13GD	FM	C8H14N3O6P
DMA13GD	IC	InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
DMA13GD	CS	C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O
DMA13GD	IK	VWFCHDSQECPREK-LURJTMIESA-N
DMA13GD	IU	[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
DMA13GD	CA	CAS 113852-37-2
DMA13GD	CB	CHEBI:3696
DMA13GD	DE	Cytomegalovirus infection

DME2H5T	ID	DME2H5T
DME2H5T	DN	Cilastatin
DME2H5T	HS	Approved
DME2H5T	SN	Cilastatina; Cilastatine; Cilastatinum; Cilastatin Monosodium Salt; Cilastatin acid; Cilastatina [Spanish]; Cilastatine [French]; Cilastatinum [Latin]; MK0791; Cilastatin (INN); Cilastatin [INN:BAN]; MK-791; (2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid; (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine; (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
DME2H5T	CP	Merck
DME2H5T	TC	Antibiotics
DME2H5T	DT	Small molecular drug
DME2H5T	PC	6435415
DME2H5T	MW	358.5
DME2H5T	FM	C16H26N2O5S
DME2H5T	IC	InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1
DME2H5T	CS	CC1(C[C@@H]1C(=O)N/C(=C\\CCCCSC[C@@H](C(=O)O)N)/C(=O)O)C
DME2H5T	IK	DHSUYTOATWAVLW-WFVMDLQDSA-N
DME2H5T	IU	(Z)-7-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
DME2H5T	CA	CAS 82009-34-5
DME2H5T	CB	CHEBI:3697
DME2H5T	DE	Bacterial infection

DM4V6JA	ID	DM4V6JA
DM4V6JA	DN	Cilazapril
DM4V6JA	HS	Approved
DM4V6JA	SN	Cilazaprilum; Cilazil; Dynorm; Inhibace; Inibace; Justor; Vascace; CILAZAPRIL MONOHYDRATE; Cilazapril anhydrous;Cilazapril hydrate; Cilazaprilum [Latin]; Cilazapril (INN); Cilazapril (USAN); Cilazapril (anhydrous); Cilazapril hydrate (JAN); Cilazapril, Anhydrous; Inhibace (TN); Ro 31-2848; Ro 31-2848 monohydrate; Ro 34-2848; Ro-312848; Ro-31-2848; Cilazapril [USAN:INN:BAN:JAN]; (1S,9S)-9-(((S)-1-Carboxy-3-phenylpropyl)amino)octahydro-10-oxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid 9-ethyl estermonohydrate; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid hydrate
DM4V6JA	TC	Antihypertensive Agents
DM4V6JA	DT	Small molecular drug
DM4V6JA	PC	56330
DM4V6JA	MW	417.5
DM4V6JA	FM	C22H31N3O5
DM4V6JA	IC	InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
DM4V6JA	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O
DM4V6JA	IK	HHHKFGXWKKUNCY-FHWLQOOXSA-N
DM4V6JA	IU	(4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid
DM4V6JA	CA	CAS 88768-40-5
DM4V6JA	CB	CHEBI:3698
DM4V6JA	DE	Congestive heart failure

DMZMSCT	ID	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	HS	Approved
DMZMSCT	SN	cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; Cilostazolum; OPC-13013; Cilostazolum [INN-Latin]; OPC-21; OPC 13013; OPC 21; UNII-N7Z035406B; CHEBI:31401; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; BRN 3632107; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS000028470;  Cilostazole; Otsuka brand of cilostazol; C 0737; CL23867; Cilostazol [INN:JAN]; Pleta (TN); Pletal (TN); Pletal, Cilostazol; Cilostazol (JP15/USAN/INN); 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
DMZMSCT	CP	Otsuka Pharmaceutical Co
DMZMSCT	TC	Vasodilator Agents
DMZMSCT	DT	Small molecular drug
DMZMSCT	PC	2754
DMZMSCT	MW	369.5
DMZMSCT	FM	C20H27N5O2
DMZMSCT	IC	InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
DMZMSCT	CS	C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
DMZMSCT	IK	RRGUKTPIGVIEKM-UHFFFAOYSA-N
DMZMSCT	IU	6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
DMZMSCT	CA	CAS 73963-72-1
DMZMSCT	CB	CHEBI:31401
DMZMSCT	DE	Intermittent claudication

DMH61ZB	ID	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	HS	Approved
DMH61ZB	SN	Acibilin; Acinil; Altramet; Brumetidina; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidinum; Cimetum; Dyspamet; Edalene; Eureceptor; Evicer; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; Peptol; Sigmetadine; Tagamet; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex; Ci metum; Cimetidine Hcl; Tagamet Hb; Biomet400; C 4522; FPF 1002; SKF 92334; Tagamet Hb 200; CIMETIDINE A/AB; Cimetidina [INN-Spanish]; Cimetidinum [INN-Latin]; DRG-0150; SKF-92334; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); SK&F-92334; Cimetidine (JP15/USP/INN); Cimetidine [USAN:INN:BAN:JAN]; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
DMH61ZB	CP	GlaxoSmithKline
DMH61ZB	TC	Antiulcer Agents
DMH61ZB	DT	Small molecular drug
DMH61ZB	PC	2756
DMH61ZB	MW	252.34
DMH61ZB	FM	C10H16N6S
DMH61ZB	IC	InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
DMH61ZB	CS	CC1=C(N=CN1)CSCCNC(=NC)NC#N
DMH61ZB	IK	AQIXAKUUQRKLND-UHFFFAOYSA-N
DMH61ZB	IU	1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
DMH61ZB	CA	CAS 51481-61-9
DMH61ZB	CB	CHEBI:3699
DMH61ZB	DE	Acid-reflux disorder

DMZHPNE	ID	DMZHPNE
DMZHPNE	DN	Cimetropium bromide
DMZHPNE	HS	Approved
DMZHPNE	SN	Alginor (TN)
DMZHPNE	CP	DeAngelini
DMZHPNE	DT	Small molecular drug
DMZHPNE	PC	20054870
DMZHPNE	MW	438.4
DMZHPNE	FM	C21H28BrNO4
DMZHPNE	IC	InChI=1S/C21H28NO4.BrH/c1-22(11-13-7-8-13)17-9-15(10-18(22)20-19(17)26-20)25-21(24)16(12-23)14-5-3-2-4-6-14;/h2-6,13,15-20,23H,7-12H2,1H3;1H/q+1;/p-1/t15?,16-,17-,18+,19-,20+,22?;/m1./s1
DMZHPNE	CS	C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)CC5CC5.[Br-]
DMZHPNE	IK	WDURTRGFUGAJHA-HNHWXVNLSA-M
DMZHPNE	IU	[(1R,2R,4S,5S)-9-(cyclopropylmethyl)-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DMZHPNE	CA	CAS 51598-60-8
DMZHPNE	DE	Spasm; Gastric motility disorder

DMCX0K3	ID	DMCX0K3
DMCX0K3	DN	Cinacalcet
DMCX0K3	HS	Approved
DMCX0K3	SN	Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
DMCX0K3	CP	Amgen
DMCX0K3	TC	Calcimimetics
DMCX0K3	DT	Small molecular drug
DMCX0K3	PC	156419
DMCX0K3	MW	357.4
DMCX0K3	FM	C22H22F3N
DMCX0K3	IC	InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
DMCX0K3	CS	C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F
DMCX0K3	IK	VDHAWDNDOKGFTD-MRXNPFEDSA-N
DMCX0K3	IU	N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
DMCX0K3	CA	CAS 226256-56-0
DMCX0K3	CB	CHEBI:48390
DMCX0K3	DE	Hyperparathyroidism; Kidney disease

DMFIC0M	ID	DMFIC0M
DMFIC0M	DN	Cinalukast
DMFIC0M	HS	Approved
DMFIC0M	SN	Cinalukast [USAN:INN]; Ro 24-5913; Cinalukast (USAN/INN); Ro-24-5913; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid
DMFIC0M	TC	Antiarrhythmic Agents
DMFIC0M	DT	Small molecular drug
DMFIC0M	PC	6436135
DMFIC0M	MW	412.5
DMFIC0M	FM	C23H28N2O3S
DMFIC0M	IC	InChI=1S/C23H28N2O3S/c1-3-23(4-2,22(27)28)14-20(26)24-18-10-5-7-16(13-18)11-12-21-25-19(15-29-21)17-8-6-9-17/h5,7,10-13,15,17H,3-4,6,8-9,14H2,1-2H3,(H,24,26)(H,27,28)/b12-11+
DMFIC0M	CS	CCC(CC)(CC(=O)NC1=CC=CC(=C1)/C=C/C2=NC(=CS2)C3CCC3)C(=O)O
DMFIC0M	IK	BZMKNPGKXJAIDV-VAWYXSNFSA-N
DMFIC0M	IU	4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid
DMFIC0M	CA	CAS 128312-51-6
DMFIC0M	CB	CHEBI:126598
DMFIC0M	DE	Asthma

DM7U5QJ	ID	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	HS	Approved
DM7U5QJ	SN	Aplactan; Aplexal; Apotomin; Artate; Carecin; Cerebolan; Cinaperazine; Cinarizina; Cinarizine; Cinazyn; Cinnacet; Cinnageron; Cinnarizinum; Corathiem; Denapol; Dimitron; Dimitronal; Eglen; Folcodal; Giganten; Glanil; Hilactan; Ixertol; Katoseran; Labyrin; Lazeta; Libotasin; Marisan; Midronal; Mitronal; Olamin; Processine; Sedatromin; Senoger; Sepan; Siptazin; Spaderizine; Stugeron; Stutgeron; Stutgin; Toliman; Votegol; Zepamol; Cinnarizine Stugeron; C 5270; MD 516; R 1575; R 516; Cero-Aterin; Cinarizina [INN-Spanish]; Cinnarizinum [INN-Latin]; R-516; Stugeron (TN); Stunarone (TN); Cinnarizine (JAN/USAN/INN); Cinnarizine [USAN:INN:BAN:JAN]; N-Benzhydryl-N'-cinnamylpiperazine; 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine; 1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; 1-Benzhydryl-4-cinnamylpiperazin; 1-Cinnamyl-4-(diphenylmethyl)piperazine; 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine; 1-trans-Cinnamyl-4-diphenylmethylpiperazine
DM7U5QJ	CP	Janssen Pharmaceutica
DM7U5QJ	TC	Antiallergic Agents
DM7U5QJ	DT	Small molecular drug
DM7U5QJ	PC	1547484
DM7U5QJ	MW	368.5
DM7U5QJ	FM	C26H28N2
DM7U5QJ	IC	InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+
DM7U5QJ	CS	C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4
DM7U5QJ	IK	DERZBLKQOCDDDZ-JLHYYAGUSA-N
DM7U5QJ	IU	1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine
DM7U5QJ	CA	CAS 16699-20-0
DM7U5QJ	CB	CHEBI:31403
DM7U5QJ	DE	Vertigo meniere disease

DMDX1ZC	ID	DMDX1ZC
DMDX1ZC	DN	Cinolazepam
DMDX1ZC	HS	Approved
DMDX1ZC	SN	Cinolazepamum; Gerodorm; Cinolazepam [INN]; OX 373; Cinolazepam (INN); Cinolazepamum [INN-Latin]; Gerodorm (TN); OX-373;1-(2-cyanoethyl)-7-chloro-3-hydroxy-5-(2'-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl]propanenitrile; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile; 7-Chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propionitrile; 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propanenitrile
DMDX1ZC	TC	Anticonvulsants
DMDX1ZC	DT	Small molecular drug
DMDX1ZC	PC	3033621
DMDX1ZC	MW	357.8
DMDX1ZC	FM	C18H13ClFN3O2
DMDX1ZC	IC	InChI=1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2
DMDX1ZC	CS	C1=CC=C(C(=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCC#N)O)F
DMDX1ZC	IK	XAXMYHMKTCNRRZ-UHFFFAOYSA-N
DMDX1ZC	IU	3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile
DMDX1ZC	CA	CAS 75696-02-5
DMDX1ZC	CB	CHEBI:59514
DMDX1ZC	DE	Muscle spasm

DM4EWNS	ID	DM4EWNS
DM4EWNS	DN	Cinoxacin
DM4EWNS	HS	Approved
DM4EWNS	SN	Cinobac; Cinobactin; Cinoxacine; Cinoxacino; Cinoxacinum; Cinx; Clinoxacin; Uronorm; Azolinic Acid; C 8645; Lilly 64716; TNP00246; Cinobac (TN); Cinoxacine [INN-French]; Cinoxacino [INN-Spanish]; Cinoxacinum [INN-Latin]; Cinoxacin (JAN/USP/INN); Cinoxacin [USAN:BAN:INN:JAN]; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
DM4EWNS	TC	Antiinfective Agents
DM4EWNS	DT	Small molecular drug
DM4EWNS	PC	2762
DM4EWNS	MW	262.22
DM4EWNS	FM	C12H10N2O5
DM4EWNS	IC	InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)
DM4EWNS	CS	CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3
DM4EWNS	IK	VDUWPHTZYNWKRN-UHFFFAOYSA-N
DM4EWNS	IU	1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
DM4EWNS	CA	CAS 28657-80-9
DM4EWNS	CB	CHEBI:3716
DM4EWNS	DE	Urinary tract infection

DMVIKJZ	ID	DMVIKJZ
DMVIKJZ	DN	Cinryze
DMVIKJZ	HS	Approved
DMVIKJZ	DE	Hereditary angioedema

DMGC5DB	ID	DMGC5DB
DMGC5DB	DN	Ciprofibrate
DMGC5DB	HS	Approved
DMGC5DB	SN	Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid
DMGC5DB	TC	Anticancer Agents
DMGC5DB	DT	Small molecular drug
DMGC5DB	PC	2763
DMGC5DB	MW	289.15
DMGC5DB	FM	C13H14Cl2O3
DMGC5DB	IC	InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)
DMGC5DB	CS	CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl
DMGC5DB	IK	KPSRODZRAIWAKH-UHFFFAOYSA-N
DMGC5DB	IU	2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid
DMGC5DB	CA	CAS 52214-84-3
DMGC5DB	CB	CHEBI:50867
DMGC5DB	DE	Hyperlipoproteinemia

DM2NLS9	ID	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	HS	Approved
DM2NLS9	SN	ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy
DM2NLS9	CP	Depomed Bayer
DM2NLS9	DT	Small molecular drug
DM2NLS9	PC	2764
DM2NLS9	MW	331.34
DM2NLS9	FM	C17H18FN3O3
DM2NLS9	IC	InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
DM2NLS9	CS	C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
DM2NLS9	IK	MYSWGUAQZAJSOK-UHFFFAOYSA-N
DM2NLS9	IU	1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DM2NLS9	CA	CAS 85721-33-1
DM2NLS9	CB	CHEBI:100241
DM2NLS9	DE	Bacterial infection; Gram-positive bacterial infection; Biliary cancer; Cystic fibrosis

DMZR26N	ID	DMZR26N
DMZR26N	DN	Ciprofloxacin+dexamethasone
DMZR26N	HS	Approved
DMZR26N	SN	CIPRODEX; Ciprofloxacin mixture with dexamethasone; 130244-48-3; Ciprodex Otic; Ciprofloxacin / dexamethasone; Ciprofloxacin and dexamethasone; Ciprofloxacin-dexamethasone Mixt.; SCHEMBL2523572; DTXSID50156420; NTRHYMXQWWPZDD-WKSAPEMMSA-N; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-, mixt. with 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
DMZR26N	CP	Alcon
DMZR26N	DT	Small molecular drug
DMZR26N	PC	9961920
DMZR26N	MW	723.8
DMZR26N	FM	C39H47F2N3O8
DMZR26N	IC	InChI=1S/C22H29FO5.C17H18FN3O3/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24;18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3;7-10,19H,1-6H2,(H,23,24)/t12-,15+,16+,17+,19+,20+,21+,22+;/m1./s1
DMZR26N	CS	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C.C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
DMZR26N	IK	NTRHYMXQWWPZDD-WKSAPEMMSA-N
DMZR26N	IU	1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMZR26N	CA	CAS 130244-48-3
DMZR26N	DE	Otitis externa; Acute otitis media

DMY7PED	ID	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	HS	Approved
DMY7PED	SN	cisapride; Propulsid; Prepulsid; Syspride; Pridesia; Risamal; Acenalin; Alimix; Propulsin; Propulsid Quicksolv; Enteropride; Kinestase; 81098-60-4; Cisawal; Vomiprid; Colinorm; Cisapron; Vomipride; Unipride; Kaudalit; Alipride; Acpulsif; Rapulid; Cipride; Pulsid; Esorid; Dispep; Presid; Unamol; Guptro; Alimix Forte; Cisapridum [Latin]; Cisaprida [Spanish]; R-51619; Cisapridum [INN-Latin]; R 51619; Cisaprida [INN-Spanish]; 104860-73-3; DCSUBABJRXZOMT-UHFFFAOYSA-N; T 1341; DSSTox_CID_2825;  Acenalin; Cisaprida; Cisapridum; Risamol; Prepulsid (TN); Propulsid (TN); Cisapride (USAN/INN); Cisapride [USAN:BAN:INN:JAN]; Cis-4-Amino-5-chloro-N-(1-(3-(p-fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-o-anisamide; (+-)-Cisapride; 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide; 4-amino-5-chloro-N-[1-{3-[(4-fluorophenyl)oxy]propyl}-3-(methyloxy)piperidin-4-yl]-2-(methyloxy)benzamide; 4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-methoxybenzamide; E-1454
DMY7PED	CP	Janssen Pharmaceutica
DMY7PED	TC	Gastrointestinal Agents
DMY7PED	DT	Small molecular drug
DMY7PED	PC	6917698
DMY7PED	MW	465.9
DMY7PED	FM	C23H29ClFN3O4
DMY7PED	IC	InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1
DMY7PED	CS	CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F
DMY7PED	IK	DCSUBABJRXZOMT-IRLDBZIGSA-N
DMY7PED	IU	4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide
DMY7PED	CA	CAS 81098-60-4
DMY7PED	CB	CHEBI:3720
DMY7PED	DE	Gastroesophageal reflux disease; Gastrointestinal disease

DMUZPJ5	ID	DMUZPJ5
DMUZPJ5	DN	Cisatracurium
DMUZPJ5	HS	Approved
DMUZPJ5	SN	Cisatracurium Besylate; Cisatracurium Besylate Preservative Free; Nimbex; Nimbex Preservative Free
DMUZPJ5	CP	Abbvie Inc
DMUZPJ5	DT	Small molecular drug
DMUZPJ5	PC	62887
DMUZPJ5	MW	929.1
DMUZPJ5	FM	C53H72N2O12+2
DMUZPJ5	IC	InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1
DMUZPJ5	CS	C[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
DMUZPJ5	IK	YXSLJKQTIDHPOT-LJCJQEJUSA-N
DMUZPJ5	IU	5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DMUZPJ5	CA	CAS 96946-41-7
DMUZPJ5	CB	CHEBI:140621
DMUZPJ5	DE	Muscle spasm

DMRHGI9	ID	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	HS	Approved
DMRHGI9	SN	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
DMRHGI9	CP	Bristol-Myers Squibb
DMRHGI9	TC	Anticancer Agents
DMRHGI9	DT	Small molecular drug
DMRHGI9	PC	5702198
DMRHGI9	MW	300.05
DMRHGI9	FM	Cl2H6N2Pt
DMRHGI9	IC	InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
DMRHGI9	CS	N.N.Cl[Pt]Cl
DMRHGI9	IK	LXZZYRPGZAFOLE-UHFFFAOYSA-L
DMRHGI9	IU	azane;dichloroplatinum
DMRHGI9	CA	CAS 15663-27-1
DMRHGI9	DE	Solid tumour/cancer; Osteosarcoma

DM2G9AE	ID	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	HS	Approved
DM2G9AE	SN	Akarin; Celapram; Celexa; Celius; Ciazil; Cilift; Cipram; Ciprapine; Citabax; Citadur; Citalec; Citalopramum; Citopam; Cytalopram; Dalsan; Humorup; Nitalapram; Oropram; Pramcit; Recital; Seropram; Talam; Talohexal; Temperax; Vodelax; Zentius; Zetalo; Citalopram [Celexa]; [3H]Citalopram; Akarin (TN); Celapram (TN); Celexa (TN); Celius (TN); Ciazil (TN); Cilift (TN); Cipram (TN); Cipramil (TN); Ciprapine (TN); Citabax (TN); Citadur (TN); Citalec (TN); Citalopram [INN:BAN]; Citalopramum [INN-Latin]; Citaxin (TN); Citol (TN); Citopam (TN); Citox (TN); Citrol (TN); Dalsan (TN); Lu 10-171; Recital (TN); Seropram (TN); Talam (TN); Zentius (TN); Zetalo (TN); AE-641/00603021; Citalopram (USP/INN); Lu-10-171; 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DM2G9AE	CP	Forest Laboratories, Inc
DM2G9AE	TC	Antidepressants
DM2G9AE	DT	Small molecular drug
DM2G9AE	PC	2771
DM2G9AE	MW	324.4
DM2G9AE	FM	C20H21FN2O
DM2G9AE	IC	InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
DM2G9AE	CS	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
DM2G9AE	IK	WSEQXVZVJXJVFP-UHFFFAOYSA-N
DM2G9AE	IU	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DM2G9AE	CA	CAS 59729-33-8
DM2G9AE	CB	CHEBI:77397
DM2G9AE	DE	Depression

DMI4XBM	ID	DMI4XBM
DMI4XBM	DN	Citicoline
DMI4XBM	HS	Approved
DMI4XBM	SN	Alphcolin; CerAxon; Citicholine; Hipercol; Neurex; Nicholin; Somazina; Trausan; Citicoline sodium; Cytidil diphosphocholine; CDP-choline; IP-302; Cytidine-5-diphosphocholine
DMI4XBM	CP	Ferrer Internacional SA
DMI4XBM	DT	Small molecular drug
DMI4XBM	PC	13804
DMI4XBM	MW	488.32
DMI4XBM	FM	C14H26N4O11P2
DMI4XBM	IC	InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1
DMI4XBM	CS	C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O
DMI4XBM	IK	RZZPDXZPRHQOCG-OJAKKHQRSA-N
DMI4XBM	IU	[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate
DMI4XBM	CA	CAS 987-78-0
DMI4XBM	CB	CHEBI:16436
DMI4XBM	DE	Cerebrovascular ischaemia

DMMEBWR	ID	DMMEBWR
DMMEBWR	DN	Citric acid, magnesium oxide, sodium picosulfate
DMMEBWR	HS	Approved
DMMEBWR	SN	Prepopik (TN)
DMMEBWR	CP	Ferring Pharmaceuticals
DMMEBWR	DT	Small molecular drug
DMMEBWR	PC	68654
DMMEBWR	MW	481.4
DMMEBWR	FM	C18H13NNa2O8S2
DMMEBWR	IC	InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25;;/h1-12,18H,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2
DMMEBWR	CS	C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)[O-])C3=CC=C(C=C3)OS(=O)(=O)[O-].[Na+].[Na+]
DMMEBWR	IK	GOZDTZWAMGHLDY-UHFFFAOYSA-L
DMMEBWR	IU	disodium;[4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate
DMMEBWR	CA	CAS 10040-45-6
DMMEBWR	CB	CHEBI:32147
DMMEBWR	DE	Crohn disease

DM3JDRP	ID	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	HS	Approved
DM3JDRP	SN	Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine
DM3JDRP	CP	EMD Serono Rockland, MA
DM3JDRP	TC	Anticancer Agents
DM3JDRP	DT	Small molecular drug
DM3JDRP	PC	20279
DM3JDRP	MW	285.69
DM3JDRP	FM	C10H12ClN5O3
DM3JDRP	IC	InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
DM3JDRP	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
DM3JDRP	IK	PTOAARAWEBMLNO-KVQBGUIXSA-N
DM3JDRP	IU	(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
DM3JDRP	CA	CAS 4291-63-8
DM3JDRP	CB	CHEBI:567361
DM3JDRP	DE	Multiple sclerosis; Relapsing-remitting multiple sclerosis; Hairy cell leukaemia

DM4M1SG	ID	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	HS	Approved
DM4M1SG	SN	Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a
DM4M1SG	CP	Abbott Laboratories
DM4M1SG	TC	Antibiotics
DM4M1SG	DT	Small molecular drug
DM4M1SG	PC	84029
DM4M1SG	MW	748
DM4M1SG	FM	C38H69NO13
DM4M1SG	IC	InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
DM4M1SG	CS	CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
DM4M1SG	IK	AGOYDEPGAOXOCK-KCBOHYOISA-N
DM4M1SG	IU	(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DM4M1SG	CA	CAS 81103-11-9
DM4M1SG	CB	CHEBI:3732
DM4M1SG	DE	Bacterial infection

DMPGR1E	ID	DMPGR1E
DMPGR1E	DN	Clascoterone
DMPGR1E	HS	Approved
DMPGR1E	SN	CB-03-01
DMPGR1E	CP	Cosmo Pharmaceuticals SpA
DMPGR1E	DT	Small molecular drug
DMPGR1E	PC	11750009
DMPGR1E	MW	402.5
DMPGR1E	FM	C24H34O5
DMPGR1E	IC	InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1
DMPGR1E	CS	CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)CO
DMPGR1E	IK	GPNHMOZDMYNCPO-PDUMRIMRSA-N
DMPGR1E	IU	[(8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate
DMPGR1E	CA	CAS 19608-29-8
DMPGR1E	DE	Acne vulgaris

DM2FGRT	ID	DM2FGRT
DM2FGRT	DN	Clavulanate
DM2FGRT	HS	Approved
DM2FGRT	SN	Clavulansaeure; Clavulox; Acide clavulanique; Acido clavulanico; Acidum clavulanicum; CLAVULANIC ACID; Clavulansaeure [INN]; Clavulinic Acid; Sodium Clavulanate; Antibiotic MM 14151; MM 14151; Acide clavulanique [INN-French]; Acido clavulanico [INN-Spanish]; Acidum clavulanicum [INN-Latin]; BRL-14151; Clavulanic acid (INN); Clavulanic acid [BAN:INN]; Clavulox (TN); MM-14151; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3008-B; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2alpha,3Z,5alpha))
DM2FGRT	CP	GlaxoSmithKline
DM2FGRT	TC	Antibiotics
DM2FGRT	DT	Small molecular drug
DM2FGRT	PC	5280980
DM2FGRT	MW	199.16
DM2FGRT	FM	C8H9NO5
DM2FGRT	IC	InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1
DM2FGRT	CS	C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)O
DM2FGRT	IK	HZZVJAQRINQKSD-PBFISZAISA-N
DM2FGRT	IU	(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM2FGRT	CA	CAS 58001-44-8
DM2FGRT	CB	CHEBI:48947
DM2FGRT	DE	Bacterial infection

DMBZWQL	ID	DMBZWQL
DMBZWQL	DN	Clemastine
DMBZWQL	HS	Approved
DMBZWQL	SN	Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin
DMBZWQL	CP	Norvatis Phamaceuticals Corporation
DMBZWQL	TC	Antiallergic Agents
DMBZWQL	DT	Small molecular drug
DMBZWQL	PC	26987
DMBZWQL	MW	343.9
DMBZWQL	FM	C21H26ClNO
DMBZWQL	IC	InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
DMBZWQL	CS	C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C
DMBZWQL	IK	YNNUSGIPVFPVBX-NHCUHLMSSA-N
DMBZWQL	IU	(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
DMBZWQL	CA	CAS 15686-51-8
DMBZWQL	CB	CHEBI:3738
DMBZWQL	DE	Allergic rhinitis

DMCKYZ5	ID	DMCKYZ5
DMCKYZ5	DN	Clenbuterol
DMCKYZ5	HS	Approved
DMCKYZ5	SN	Clenbuterolum; Contraspasmin; Planipart; Planipart [veterinary]; Clenbuterol (INN); Clenbuterol [BAN:INN]; Clenbuterolum [INN-Latin]; Contraspasmin (TN); NAB-365; Planipart [veterinary] (TN); (+)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; (+-)-clenbuterol; (-)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; 1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol; 1-(4-Amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol; 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol; 4-Amino-3,5-dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol; 4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol
DMCKYZ5	TC	Bronchodilator Agents
DMCKYZ5	DT	Small molecular drug
DMCKYZ5	PC	2783
DMCKYZ5	MW	277.19
DMCKYZ5	FM	C12H18Cl2N2O
DMCKYZ5	IC	InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3
DMCKYZ5	CS	CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O
DMCKYZ5	IK	STJMRWALKKWQGH-UHFFFAOYSA-N
DMCKYZ5	IU	1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol
DMCKYZ5	CA	CAS 37148-27-9
DMCKYZ5	CB	CHEBI:174690
DMCKYZ5	DE	Chronic breathing disorder

DMW4M97	ID	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	HS	Approved
DMW4M97	SN	Clevidipine; Cleviprex; 167221-71-8; Clevelox; rac-Clevidipine; H 324/38; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Cleviprex (TN); 3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; METHYL 5-{[(BUTANOYLOXY)METHOXY]CARBONYL}-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3
DMW4M97	CP	The Medicines Company
DMW4M97	DT	Small molecular drug
DMW4M97	PC	153994
DMW4M97	MW	456.3
DMW4M97	FM	C21H23Cl2NO6
DMW4M97	IC	InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
DMW4M97	CS	CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
DMW4M97	IK	KPBZROQVTHLCDU-UHFFFAOYSA-N
DMW4M97	IU	5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMW4M97	CA	CAS 167221-71-8
DMW4M97	CB	CHEBI:135738
DMW4M97	DE	Hypertension

DMUMQZ0	ID	DMUMQZ0
DMUMQZ0	DN	Clidinium
DMUMQZ0	HS	Approved
DMUMQZ0	SN	clidinium; N-Methyl quinuclidinyl benzilate; 7020-55-5; 3-hydroxy-1-methylquinuclidinium benzilate ester; 3-{[hydroxy(diphenyl)acetyl]oxy}-1-methyl-1-azoniabicyclo[222]octane; Ro-23773; 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[222]octane; 1-Azoniabicyclo(222)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl-; [3H]clidinium; (-)MQNB; Clidinium bromid; (1-methyl-1-azoniabicyclo[222]octan-8-yl) 2-hydroxy-2,2-di(phenyl)acetate; 3-Hydroxy-1-methylquinuclidinium benzilate (ester); Quinuclidinium,;  Librax (TN); Benzilic acid, ester with 3-hydroxy-1-methylquinuclidinium; Quinuclidinium, 3-hydroxy-1-methyl-, benzilate (ester); (1-methyl-1-azoniabicyclo[222]octan-3-yl) 2-hydroxy-2,2-diphenylacetate
DMUMQZ0	CP	Hoffmann La Roche Inc
DMUMQZ0	TC	Analgesics
DMUMQZ0	DT	Small molecular drug
DMUMQZ0	PC	2784
DMUMQZ0	MW	352.4
DMUMQZ0	FM	C22H26NO3+
DMUMQZ0	IC	InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1
DMUMQZ0	CS	C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMUMQZ0	IK	HOOSGZJRQIVJSZ-UHFFFAOYSA-N
DMUMQZ0	IU	(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) 2-hydroxy-2,2-diphenylacetate
DMUMQZ0	CA	CAS 7020-55-5
DMUMQZ0	CB	CHEBI:3743
DMUMQZ0	DE	Irritable bowel syndrome; Abdominal stomach pain

DM15HL8	ID	DM15HL8
DM15HL8	DN	Clindamycin
DM15HL8	HS	Approved
DM15HL8	SN	Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin
DM15HL8	CP	Pharmacia And Upjohn Co
DM15HL8	TC	Antibiotics
DM15HL8	DT	Small molecular drug
DM15HL8	PC	446598
DM15HL8	MW	425
DM15HL8	FM	C18H33ClN2O5S
DM15HL8	IC	InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
DM15HL8	CS	CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl
DM15HL8	IK	KDLRVYVGXIQJDK-AWPVFWJPSA-N
DM15HL8	IU	(2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
DM15HL8	CA	CAS 18323-44-9
DM15HL8	DE	Acne vulgaris

DMW1OQ0	ID	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	HS	Approved
DMW1OQ0	SN	Clobazam; Chlorepin; Urbanyl; Frisium; Clorepin; Urbadan; 22316-47-8; Clobazamum; Onfi; LM-2717; HR 376; RU-4723; Clobazamum [INN-Latin]; LM 2717; H-4723; H 4723; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; UNII-2MRO291B4U; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; NSC 336279; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; CCRIS 7506; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; EINECS 244-908-7; BRN 0758410;  Onfi
DMW1OQ0	TC	Neurology Agents
DMW1OQ0	DT	Small molecular drug
DMW1OQ0	PC	2789
DMW1OQ0	MW	300.74
DMW1OQ0	FM	C16H13ClN2O2
DMW1OQ0	IC	InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3
DMW1OQ0	CS	CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DMW1OQ0	IK	CXOXHMZGEKVPMT-UHFFFAOYSA-N
DMW1OQ0	IU	7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione
DMW1OQ0	CA	CAS 22316-47-8
DMW1OQ0	CB	CHEBI:31413
DMW1OQ0	DE	Anxiety disorder; Epilepsy

DMUXP52	ID	DMUXP52
DMUXP52	DN	Clobetasol
DMUXP52	HS	Approved
DMUXP52	SN	Clobetasolum; Clofenazon; Clobecort Amex; Butavate (TN); Clobecort Amex (TN); Clobetasol (INN); Clobetasol [INN:BAN]; Clobetasolum [INN-Latin]; Clobex (TN); Dermatovate (TN); Dermovate (TN); Movate (TN); Olux (TN); Temovate (TN); Tenovate (TN); (11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
DMUXP52	CP	Fougera Pharmaceuticals Inc
DMUXP52	TC	Antiinflammatory Agents
DMUXP52	DT	Small molecular drug
DMUXP52	PC	5311051
DMUXP52	MW	410.9
DMUXP52	FM	C22H28ClFO4
DMUXP52	IC	InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMUXP52	CS	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)F)C
DMUXP52	IK	FCSHDIVRCWTZOX-DVTGEIKXSA-N
DMUXP52	IU	(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMUXP52	CA	CAS 25122-41-2
DMUXP52	CB	CHEBI:205919
DMUXP52	DE	Rosacea; Oral lichen planus

DM9ZMQH	ID	DM9ZMQH
DM9ZMQH	DN	Clocortolone
DM9ZMQH	HS	Approved
DM9ZMQH	SN	Clocortolona; Clocortolonum; Clocortolone (INN); (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9-chloro-6alpha-fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione
DM9ZMQH	CP	Promius Pharma Llc
DM9ZMQH	DT	Small molecular drug
DM9ZMQH	PC	5311052
DM9ZMQH	MW	410.9
DM9ZMQH	FM	C22H28ClFO4
DM9ZMQH	IC	InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
DM9ZMQH	CS	C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)Cl)C)F
DM9ZMQH	IK	YMTMADLUXIRMGX-RFPWEZLHSA-N
DM9ZMQH	IU	(6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM9ZMQH	CA	CAS 4828-27-7
DM9ZMQH	CB	CHEBI:59582
DM9ZMQH	DE	Rosacea

DM9Y6X7	ID	DM9Y6X7
DM9Y6X7	DN	Clodronate
DM9Y6X7	HS	Approved
DM9Y6X7	SN	Bonefos; Clodronsaeure; Dichloromethanediphosphonate; Dichloromethylenebisphosphonate; Methanedichlorodiphosphonate; Acide clodronique; Acido clodronico; Acidum clodronicum; Clodronic Acid; Dichloromethanediphosphonic acid; Dichloromethylene Biphosphonate; Dichloromethylene Diphosphonate; Dichloromethylidene diphosphonate; Liposomes containing clodronic acid; Methanedichlorodiphosphonic acid; Acid, Clodronic; Acid, Dichloromethanediphosphonic; Acide clodronique [INN-French]; Acido clodronico [INN-Spanish]; Acidum clodronicum [INN-Latin]; Biphosphonate, Dichloromethylene; Bonefos (TN); Clodron (TN); Diphosphonate, Dichloromethane; Diphosphonate, Dichloromethylene; Disodium, Clodronate; Loron (TN); Sodium, Clodronate; [dichloro(phosphono)methyl]phosphonic acid; Clodronic acid (USAN/INN); Clodronic acid [USAN:BAN:INN]; Dichlormethylen-bis(phosphonsaeure); Dichloromethylene-1,1-bisphosphonic acid; Dichloromethylene-1,1-diphosphonic acid; Phosphonic acid, (dichloromethylene)di-(8CI); (Dichloro-phosphono-methyl)-phosphonic acid; (Dichloromethylene)bisphosphonic acid; (Dichloromethylene)diphosphonic acid; (Lip-C); (dichloromethanediyl)bis(phosphonic acid)
DM9Y6X7	TC	Antihypocalcemic Agents
DM9Y6X7	DT	Small molecular drug
DM9Y6X7	PC	25419
DM9Y6X7	MW	244.89
DM9Y6X7	FM	CH4Cl2O6P2
DM9Y6X7	IC	InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)
DM9Y6X7	CS	C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl
DM9Y6X7	IK	ACSIXWWBWUQEHA-UHFFFAOYSA-N
DM9Y6X7	IU	[dichloro(phosphono)methyl]phosphonic acid
DM9Y6X7	CA	CAS 10596-23-3
DM9Y6X7	CB	CHEBI:110423
DM9Y6X7	DE	Hypercalcaemia

DMCVJ86	ID	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	HS	Approved
DMCVJ86	SN	CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048
DMCVJ86	TC	Anticancer Agents
DMCVJ86	DT	Small molecular drug
DMCVJ86	PC	119182
DMCVJ86	MW	303.68
DMCVJ86	FM	C10H11ClFN5O3
DMCVJ86	IC	InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
DMCVJ86	CS	C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N
DMCVJ86	IK	WDDPHFBMKLOVOX-AYQXTPAHSA-N
DMCVJ86	IU	(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
DMCVJ86	CA	CAS 123318-82-1
DMCVJ86	CB	CHEBI:681569
DMCVJ86	DE	Acute lymphoblastic leukaemia; Myelodysplastic syndrome

DMEBOFW	ID	DMEBOFW
DMEBOFW	DN	Clofazimine
DMEBOFW	HS	Approved
DMEBOFW	SN	clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2;  CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine
DMEBOFW	CP	Norvatis Phamaceuticals Corporation
DMEBOFW	TC	Antiinflammatory Agents
DMEBOFW	DT	Small molecular drug
DMEBOFW	PC	2794
DMEBOFW	MW	473.4
DMEBOFW	FM	C27H22Cl2N4
DMEBOFW	IC	InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
DMEBOFW	CS	CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
DMEBOFW	IK	WDQPAMHFFCXSNU-UHFFFAOYSA-N
DMEBOFW	IU	N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine
DMEBOFW	CA	CAS 2030-63-9
DMEBOFW	CB	CHEBI:3749
DMEBOFW	DE	Crohn disease; Mycobacterium infection

DMPC1J7	ID	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	HS	Approved
DMPC1J7	SN	Amotril; Angiokapsul; Anparton; Antilipid; Antilipide; Apolan; Arterioflexin; Arterosol; Artevil; Ateculon; Ateriosan; Athebrate; Atheromide; Atheropront; Athromidin; Atrolen; Atromid; Atromida; Atromidin; Atrovis; Azionyl; Bioscleran; Bresit; CPIB; Cartagyl; Chlorfenisate; Chlorphenisate; Cinnarizin; Citiflus; Claripex; Cloberat; Clobrat; Clofar; Clofibate; Clofibram; Clofibrat; Clofibrato; Clofibratum; Clofinit; Clofipront; Delipid; Deliva; ELPI; EPIB; Fibralem; Gerastop; Hyclorate; Klofibrat; Klofiran; Levatrom; Lipamid; Lipavil; Lipavlon; Lipidsenker; Lipofacton; Lipomid; Liponorm; Liporeduct; Liporil; Liposid; Liprin; Liprinal; Lobetrin; Miscleron; Misclerone; Miskleron; Negalip; Normalip; Normat; Normet; Normolipol; Novofibrate; Persantinat; Recolip; Regardin; Regelan; Robigram; Scrobin; Serofinex; Serotinex; Skerolip; Sklerepmexe; Sklero; Sklerolip; Skleromex; Skleromexe; Ticlobran; Xyduril; Yoclo; Amotril S; Atromid S; Claripex CPIB; Clofibrato [Spanish]; Dura clofibrat; Ethyl chlorophenoxyisobutyrate; Ethyl clofibrate; Regelan N; Vincamin compositum; AY 61123; C 6643; Lipide 500; Oxan 600; AY-61123; Athranid-wirkstoff; Atromid-S; BML2-F02; Chlorophenoxyisobutyrate, Ethyl; Clobren-5F; Clobren-SF; Clofibrate (CLOF); Clofibrato [INN-Spanish]; Clofibratum [INN-Latin]; Clofibric Acid, Ethyl Ester; Ethyl p-chlorophenoxyisobutyrate; Ethyl para-chlorophenoxyisobutyrate; Neo-Atomid; Neo-Atromid; Sklero-Tablinen; Sklero-tablinene; Sklero-tabuls; ATROMID-S (TN); Atromid-S (TN); Atromid-S, Clofibrate; Ethyl alpha-p-chlorophenoxyisobutyrate; Clofibrate (JP15/USP/INN); Clofibrate [USAN:INN:BAN:JAN]; Ethyl 2-(4-chlorophenoxy)isobutyrate; Ethyl 2-(p-chlorophenoxy)isobutyrate; Ethyl alpha-(4-chlorophenoxy)isobutyrate; Ethyl alpha-(p-chlorophenoxy)isobutyrate; Ethyl-alpha-p-chlorophenoxy-isobutyrate
DMPC1J7	CP	Ayerst Laboratories Inc
DMPC1J7	TC	Antilipemic Agents
DMPC1J7	DT	Small molecular drug
DMPC1J7	PC	2796
DMPC1J7	MW	242.7
DMPC1J7	FM	C12H15ClO3
DMPC1J7	IC	InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3
DMPC1J7	CS	CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl
DMPC1J7	IK	KNHUKKLJHYUCFP-UHFFFAOYSA-N
DMPC1J7	IU	ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
DMPC1J7	CA	CAS 637-07-0
DMPC1J7	CB	CHEBI:3750
DMPC1J7	DE	Dysbetalipoproteinemia

DMKI7RB	ID	DMKI7RB
DMKI7RB	DN	Clomifene
DMKI7RB	HS	Approved
DMKI7RB	SN	Androxal; Chlomaphene; Chloramifene; Cisclomifenum; Cisclomiphene; Clomifen; Clomifeno; Clomifenum; Clomifert; Clomiphene; Clostilbegit; Enclomifene; Enclomifeno; Enclomifenum; Enclomiphen; Enclomiphene; Klostilbegit; Transclomifenum; Transclomiphene; Zuclomifene; Zuclomifeno; Zuclomifenum; Zuclomiphene; Clomiphene B;Enclomiphene [USAN]; ISOMER B; Zuclomiphene [USAN]; Cis-Clomifene; Cis-Clomiphene; Clomid (TN); Clomifene (INN); Clomifene (TN); Clomifene [INN:BAN]; Clomifeno [INN-Spanish]; Clomifenum [INN-Latin]; En-Clomiphene; Enclomifeno [INN-Spanish]; Enclomifenum [INN-Latin]; Enclomiphene (USAN); Milophene (TN); RMI 16,289; RMI-16289; RMI-16312; Serophene (TN); Trans-Clomifene; Trans-Clomiphene; Zuclomifeno [INN-Spanish]; Zuclomifenum [INN-Latin]; Zuclomiphene (USAN); Cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-isomer; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine
DMKI7RB	TC	Fertility Agents
DMKI7RB	DT	Small molecular drug
DMKI7RB	PC	1548953
DMKI7RB	MW	406
DMKI7RB	FM	C26H28ClNO
DMKI7RB	IC	InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+
DMKI7RB	CS	CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3
DMKI7RB	IK	GKIRPKYJQBWNGO-OCEACIFDSA-N
DMKI7RB	IU	2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine
DMKI7RB	CA	CAS 15690-57-0
DMKI7RB	CB	CHEBI:3752
DMKI7RB	DE	Female infertility

DMS51VC	ID	DMS51VC
DMS51VC	DN	Clomiphene citrate
DMS51VC	HS	Approved
DMS51VC	SN	Clomid; Milophene; Serophene
DMS51VC	CP	Sanofi Aventis Us Llc
DMS51VC	DT	Small molecular drug
DMS51VC	PC	3033832
DMS51VC	MW	598.1
DMS51VC	FM	C32H36ClNO8
DMS51VC	IC	InChI=1S/C26H28ClNO.C6H8O7/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,3-4,19-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
DMS51VC	CS	CCN(CC)CCOC1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\Cl)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMS51VC	IK	PYTMYKVIJXPNBD-OQKDUQJOSA-N
DMS51VC	IU	2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMS51VC	CA	CAS 7619-53-6
DMS51VC	DE	Female infertility

DMINRKW	ID	DMINRKW
DMINRKW	DN	Clomipramine
DMINRKW	HS	Approved
DMINRKW	SN	Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipraminum; Hydiphen; Monochlorimipramine; Anafranil base; G 34586; Anafranil (TN); Anafranil (free base); Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum [INN-Latin]; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI)
DMINRKW	CP	Norvatis Phamaceuticals Corporation
DMINRKW	TC	Antidepressants
DMINRKW	DT	Small molecular drug
DMINRKW	PC	2801
DMINRKW	MW	314.9
DMINRKW	FM	C19H23ClN2
DMINRKW	IC	InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
DMINRKW	CS	CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
DMINRKW	IK	GDLIGKIOYRNHDA-UHFFFAOYSA-N
DMINRKW	IU	3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
DMINRKW	CA	CAS 303-49-1
DMINRKW	CB	CHEBI:47780
DMINRKW	DE	Depression

DM0ZRMQ	ID	DM0ZRMQ
DM0ZRMQ	DN	Clomocycline
DM0ZRMQ	HS	Approved
DM0ZRMQ	SN	Chlormethylenecycline; Clomociclina; Clomocyclina; Clomocyclinum; Clomociclina [INN-Spanish]; Clomocycline (INN); Clomocycline [INN:BAN]; Clomocyclinum [INN-Latin]; N-2-Hydroxymethylchlortetracycline; N'-Methylolo-chlortetracycline; (2Z,4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(hydroxymethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
DM0ZRMQ	TC	Antibiotics
DM0ZRMQ	DT	Small molecular drug
DM0ZRMQ	PC	54680675
DM0ZRMQ	MW	508.9
DM0ZRMQ	FM	C23H25ClN2O9
DM0ZRMQ	IC	InChI=1S/C23H25ClN2O9/c1-22(34)8-6-9-16(26(2)3)18(30)14(21(33)25-7-27)20(32)23(9,35)19(31)12(8)17(29)13-11(28)5-4-10(24)15(13)22/h4-5,8-9,16,27-29,32,34-35H,6-7H2,1-3H3,(H,25,33)/t8-,9-,16-,22-,23-/m0/s1
DM0ZRMQ	CS	C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)NCO)N(C)C)O
DM0ZRMQ	IK	BXTHDFJCJQJHKD-KMVLDZISSA-N
DM0ZRMQ	IU	(4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DM0ZRMQ	CA	CAS 1181-54-0
DM0ZRMQ	CB	CHEBI:59589
DM0ZRMQ	DE	Bacterial infection

DMTO13J	ID	DMTO13J
DMTO13J	DN	Clonazepam
DMTO13J	HS	Approved
DMTO13J	SN	Antelepsin; Antilepsin; Chlonazepam; Cloazepam; Clonazepamum; Clonex; Clonopin; Iktorivil; Kenoket; Klonopin; Landsen; Lktorivil; Lonazep; Melzap; Paxam; Ravotril; Rivatril; Rivoril; Rivotril; Solfidin; Klonopin Rapidly Disintegrating; DF2374250; RO4023; Ro 4023; Ro 54023; Alti-Clonazepam; Clonazepamum [INN-Latin]; Klonopin (TN); Ravotril (TN); Rivatril (TN); Rivotril (TN); Ro 4-8180; Ro 5-4023; Ro-5-4023; Clonazepam (JP15/USP/INN); Clonazepam [USAN:INN:BAN:JAN]; Ro 5-4023/B-7; 1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one
DMTO13J	CP	Roche Pharmaceuticals
DMTO13J	TC	Anticonvulsants
DMTO13J	DT	Small molecular drug
DMTO13J	PC	2802
DMTO13J	MW	315.71
DMTO13J	FM	C15H10ClN3O3
DMTO13J	IC	InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
DMTO13J	CS	C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl
DMTO13J	IK	DGBIGWXXNGSACT-UHFFFAOYSA-N
DMTO13J	IU	5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
DMTO13J	CA	CAS 1622-61-3
DMTO13J	CB	CHEBI:3756
DMTO13J	DE	Epilepsy; Seizure disorder

DM6RZ9Q	ID	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	HS	Approved
DM6RZ9Q	SN	clonidine; Clonidin; Duraclon; Chlornidinum; 4205-90-7; Catapres-TTS; Catarpresan; Catarpres; Adesipress; Catapres; Catapressan; Catapresan; ST 155BS; ST-155-BS; Clonidinum; Clonidina; Clonidinum [INN-Latin]; Clonidinhydrochlorid; CATAPRES-TTS-3; CATAPRES-TTS-1; CATAPRES-TTS-2; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Isoglaucon; 2-(2,6-Dichloroanilino)-2-imidazoline; Dixarit; SKF 34427; Catapres- TTS; Clonidina [INN-Spanish]; M-5041T; Hemiton; CLORPRES; clonidine (amino form);  Adesipress; Clofenil; Clopheline; Duraclont; Gemiton; Klofelin; Klofenil; M 5041T; Catapres (TN); Catarpres-TTS; ST-155BS; Tenso-Timelets; Catarpres-TTS (TN); Clonidine [USAN:BAN:INN]; Clonidine (JAN/USAN/INN); 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE
DM6RZ9Q	CP	Intas Pharmaceuticals
DM6RZ9Q	TC	Antihypertensive Agents
DM6RZ9Q	DT	Small molecular drug
DM6RZ9Q	PC	2803
DM6RZ9Q	MW	230.09
DM6RZ9Q	FM	C9H9Cl2N3
DM6RZ9Q	IC	InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
DM6RZ9Q	CS	C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
DM6RZ9Q	IK	GJSURZIOUXUGAL-UHFFFAOYSA-N
DM6RZ9Q	IU	N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
DM6RZ9Q	CA	CAS 4205-90-7
DM6RZ9Q	CB	CHEBI:3757
DM6RZ9Q	DE	Hypertension; Diabetic neuropathy

DMOL54H	ID	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	HS	Approved
DMOL54H	SN	clopidogrel; 113665-84-2; (S)-Clopidogrel; Plavix; Clopidogrel [INN:BAN]; (+)-(S)-Clopidogrel; (+)-Clopidogrel; UNII-A74586SNO7; HSDB 7430; CLOPIDOGREL SULFATE; CHEBI:37941; GKTWGGQPFAXNFI-HNNXBMFYSA-N; A74586SNO7; CPD000550475; Zyllt; Clopidogrel (TN); SR-25990C; Plavix (TN); methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; Clopidogrelum; Thrombo; Clopidogrel BMS; Clopidogrel Hexal; Clopidogrel Acino; methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; PM-103; Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals
DMOL54H	CP	Prism Pharmaceuticals Inc
DMOL54H	DT	Small molecular drug
DMOL54H	PC	60606
DMOL54H	MW	321.8
DMOL54H	FM	C16H16ClNO2S
DMOL54H	IC	InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
DMOL54H	CS	COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
DMOL54H	IK	GKTWGGQPFAXNFI-HNNXBMFYSA-N
DMOL54H	IU	methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
DMOL54H	CA	CAS 113665-84-2
DMOL54H	CB	CHEBI:37941
DMOL54H	DE	Thrombosis

DMC3JST	ID	DMC3JST
DMC3JST	DN	Clorazepate
DMC3JST	HS	Approved
DMC3JST	SN	Chlorazepate; Tranxene; Cchlorazepic acid; Chlorazepic acid; Clorazepate dipotassium; Clorazepic acid; Clorazepic acid [BAN]; Gen-xene; Novo-Clopate; Tranxene (Cherazepate dipotasium); Tranxene (TN); Novo-Clopate (TN); (Chloromethyl)(dimethyl)(tridecyloxy)silane; 7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
DMC3JST	CP	Taro Pharmaceutical Industries Ltd
DMC3JST	TC	Hypnotics and Sedatives
DMC3JST	DT	Small molecular drug
DMC3JST	PC	2809
DMC3JST	MW	314.72
DMC3JST	FM	C16H11ClN2O3
DMC3JST	IC	InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)
DMC3JST	CS	C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O
DMC3JST	IK	XDDJGVMJFWAHJX-UHFFFAOYSA-N
DMC3JST	IU	7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid
DMC3JST	CA	CAS 23887-31-2
DMC3JST	CB	CHEBI:3761
DMC3JST	DE	Anxiety disorder

DMCEUJD	ID	DMCEUJD
DMCEUJD	DN	Clorgyline
DMCEUJD	HS	Approved
DMCEUJD	SN	Chlorgyline; Clorgilin; Clorgilina; Clorgiline; Clorgilinum; Clorgiline [INN]; M and B 9302; Clorgilina [INN-Spanish]; Clorgiline (INN); Clorgilinum [INN-Latin]; M & B 9302; N-methyl-n-propargyl-3-(2,4-dichlorophenoxy)propylamine; N-(3-(2,4-Dichlorophenoxy)propyl)-N-methyl-2-propynylamine; N-[3-(2,4-DICHLOROPHENOXY)PROPYL]-N-METHYL-N-PROP-2-YNYLAMINE; 2-Propyn-1-amine, N-(3-(2,4-dichlorophenoxy)propyl)-N-methyl-(9CI); 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine
DMCEUJD	TC	Antiparkinson Agents
DMCEUJD	DT	Small molecular drug
DMCEUJD	PC	4380
DMCEUJD	MW	272.17
DMCEUJD	FM	C13H15Cl2NO
DMCEUJD	IC	InChI=1S/C13H15Cl2NO/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15/h1,5-6,10H,4,7-9H2,2H3
DMCEUJD	CS	CN(CCCOC1=C(C=C(C=C1)Cl)Cl)CC#C
DMCEUJD	IK	BTFHLQRNAMSNLC-UHFFFAOYSA-N
DMCEUJD	IU	3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine
DMCEUJD	CA	CAS 17780-72-2
DMCEUJD	CB	CHEBI:3763
DMCEUJD	DE	Skin imperfections; Parkinson disease

DM6K1OA	ID	DM6K1OA
DM6K1OA	DN	Clothiapine
DM6K1OA	HS	Approved
DM6K1OA	SN	Clothiapine; Clotiapine; 2058-52-8; Entumine; Entumin; Etumine; HF 2159; Clotiapinum [INN-Latin]; Clotiapina [INN-Spanish]; UNII-Z05HCY0X1T; S-805C; Clothiapine [USAN]; EINECS 218-162-8; LW 2159; C18H18ClN3S; BRN 0568276; Z05HCY0X1T; CHEMBL304902; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)thiazepine; KAAZGXDPUNNEFN-UHFFFAOYSA-N; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo(b,f)(1,4)thiazepine; DIBENZO(b,f)(1,4)THIAZEPINE, 2-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-; Clothiapine (USAN); HF-2159; NCGC00160387-01
DM6K1OA	DT	Small molecular drug
DM6K1OA	PC	16351
DM6K1OA	MW	343.9
DM6K1OA	FM	C18H18ClN3S
DM6K1OA	IC	InChI=1S/C18H18ClN3S/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
DM6K1OA	CS	CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl
DM6K1OA	IK	KAAZGXDPUNNEFN-UHFFFAOYSA-N
DM6K1OA	IU	8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzothiazepine
DM6K1OA	CA	CAS 2058-52-8
DM6K1OA	CB	CHEBI:31424
DM6K1OA	DE	Schizophrenia

DM59AZT	ID	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	HS	Approved
DM59AZT	SN	Clotiazepamum; Clozan; Distensan; Rise; Rize; Rizen; Tienor; Trecalmo; Veratran; Y 6047; Clotiazepam [INN:JAN]; Clotiazepamum [INN-Latin]; Clozan (TN); Distensan (TN); Rize (TN); Rizen (TN); Trecalmo (TN); Veratran (TN); Y-6047; Clotiazepam (JP15/INN); 2H-Thieno(2,3e)(1,4)-diazepin-2-one, 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-(8CI); 5-(2-Chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno(2,3-e)(1,4)diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one; 5-(o-Chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2H-thieno(2,3-e)-1,4-diazepin-2-one
DM59AZT	TC	Hypnotics and Sedatives
DM59AZT	DT	Small molecular drug
DM59AZT	PC	2811
DM59AZT	MW	318.8
DM59AZT	FM	C16H15ClN2OS
DM59AZT	IC	InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3
DM59AZT	CS	CCC1=CC2=C(S1)N(C(=O)CN=C2C3=CC=CC=C3Cl)C
DM59AZT	IK	CHBRHODLKOZEPZ-UHFFFAOYSA-N
DM59AZT	IU	5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one
DM59AZT	CA	CAS 33671-46-4
DM59AZT	CB	CHEBI:31425
DM59AZT	DE	Anxiety disorder

DMMFCIH	ID	DMMFCIH
DMMFCIH	DN	Clotrimazole
DMMFCIH	HS	Approved
DMMFCIH	SN	Canesten; Canestene; Canestine; Canifug; Chlotrimazole; Cimitidine; Clomatin; Clotrimaderm; Clotrimazol; Clotrimazolum; Clotrimeizol; Cutistad; Empecid; Esparol; FemCare; Gynix; Kanesten; Klotrimazole; Lotrimax; Lotrimin; Monobaycuten; Mycelax; Mycelex; Mycofug; Mycosporin; Mykosporin; Nalbix; Pedisafe; Rimazole; Stiemazol; Tibatin; Trimysten; Canesten Cream; Canesten Solution; Clotrimazole Schering Brand; Desamix F; Fem Care; Gyne lotrimin; Lotrimin AF Cream; Lotrimin AF Lotion; Lotrimin AF Solution; Lotrimin Af; Lotrimin Cream; Lotrimin Lotion; Lotrimin Solution; Mycelex Cream; Mycelex G; Mycelex OTC; Mycelex Solution; Mycelex Troches; Mycelex Twin Pack; Myclo Cream; Myclo Solution; Myclo Spray Solution; Schering Brand of Clotrimazole; B 5097; Bay b 9057; Bayer Brand 1 of Clotrimazole; Bayer Brand 2 of Clotrimazole; C 6019; FB 5097; FB b 5097; Mycelex 7; Trivagizole 3; Bay-B 5097; Candid Vaginal (TN); Candinil (TN); Canesten (TN); Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; Clobrate VT (TN); Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; DRG-0072; Gino-Lotremine; Gyne-Lotrimin; Gyne-Lotrimin 3; Gyne-Lotrimin 3 Combination Pack; Gyne-Lotrimin Combination Pack; Lotrimin (TN); Lotrimin AF Jock-Itch Cream; Mono-baycuten; Mycelex (TN); Mycelex-7; Mycelex-7 Combination Pack; Mycelex-G; Mycelex: MycosporinRimazole; Myclo-Gyne; Neo-Zol Cream; Pan-Fungex; Cancap-VT (TN); Candid - V Gel (TN); Canesten 1-Day Cream Combi-Pak; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; Clotrimazole (JP15/USP/INN); Clotrimazole [USAN:INN:BAN:JAN]; (Chlorotrityl)imidazole; 1-(o-Chlorotrityl)imidazole
DMMFCIH	CP	Bayer Pharmaceuticals Corporation
DMMFCIH	TC	Antifungal Agents
DMMFCIH	DT	Small molecular drug
DMMFCIH	PC	2812
DMMFCIH	MW	344.8
DMMFCIH	FM	C22H17ClN2
DMMFCIH	IC	InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H
DMMFCIH	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4
DMMFCIH	IK	VNFPBHJOKIVQEB-UHFFFAOYSA-N
DMMFCIH	IU	1-[(2-chlorophenyl)-diphenylmethyl]imidazole
DMMFCIH	CA	CAS 23593-75-1
DMMFCIH	CB	CHEBI:3764
DMMFCIH	DE	Fungal infection

DMUTL7O	ID	DMUTL7O
DMUTL7O	DN	Cloxacillin
DMUTL7O	HS	Approved
DMUTL7O	SN	Chloroxacillin; Clossacillina; Cloxacilina; Cloxacilline; Cloxacillinum; MCIPC; Orbenin; Syntarpen; Tegopen; Clossacillina [DCIT]; Cloxacillin sodium; Methocillin S; BRL 1621; Cloxacilina [INN-Spanish]; Cloxacillin (INN); Cloxacillin [INN:BAN]; Cloxacilline [INN-French]; Cloxacillinum [INN-Latin]; Cloxapen (TN); Cloxapen (sodium monohydrate); Methylchlorphenylisoxazoryl-penicillin; Novo-Cloxin; Nu-Cloxi; Orbenin (TN); Tegopen (sodium monohydrate); BRL-1621 (sodium monohydrate); P-25 (sodium monohydrate); [3-(O-CHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL]PENICILLIN; (2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (3-(o-Chlorophenyl)-5-methyl-4-isoxazolyl)penicillin; 6-(((3-(2-Chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(o-Chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
DMUTL7O	CP	Beecham phamaceuticals
DMUTL7O	TC	Antibiotics
DMUTL7O	DT	Small molecular drug
DMUTL7O	PC	6098
DMUTL7O	MW	435.9
DMUTL7O	FM	C19H18ClN3O5S
DMUTL7O	IC	InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1
DMUTL7O	CS	CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMUTL7O	IK	LQOLIRLGBULYKD-JKIFEVAISA-N
DMUTL7O	IU	(2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMUTL7O	CA	CAS 61-72-3
DMUTL7O	CB	CHEBI:49566
DMUTL7O	DE	Bacterial infection

DMFC71L	ID	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	HS	Approved
DMFC71L	SN	Asaleptin; CLOZARIL; Clorazil; Clozapin; Clozapina; Clozapinum; Fazaclo; Iprox; Leponex; Lepotex; Fazaclo ODT; C 6305; HF1854; Clopine (TN); Clozapina [INN-Spanish]; Clozapine(tautomer); Clozapinum [INN-Latin]; Clozaril (TN); Denzapine (TN); Fazaclo (TN); Froidir (TN); HF-1854; KS-1166; Klozapol (TN); LEX-123; LX 100-129; Leponex (TN); W-801; Zaponex (TN); Clozapine [USAN:INN:BAN]; Clozapine (JAN/USP/INN); 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
DMFC71L	CP	Sandoz
DMFC71L	TC	Antipsychotic Agents
DMFC71L	DT	Small molecular drug
DMFC71L	PC	135398737
DMFC71L	MW	326.8
DMFC71L	FM	C18H19ClN4
DMFC71L	IC	InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
DMFC71L	CS	CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
DMFC71L	IK	QZUDBNBUXVUHMW-UHFFFAOYSA-N
DMFC71L	IU	3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine
DMFC71L	CA	CAS 5786-21-0
DMFC71L	CB	CHEBI:3766
DMFC71L	DE	Schizophrenia

DMPC2QY	ID	DMPC2QY
DMPC2QY	DN	CNTO-1959
DMPC2QY	HS	Approved
DMPC2QY	SN	Guselkumab
DMPC2QY	CP	Janssen/Johnson & Johnson
DMPC2QY	DT	Antibody
DMPC2QY	SQ	Heavy chain: EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Light chainQSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
DMPC2QY	DE	Plaque psoriasis; Asthma

DM8HBJI	ID	DM8HBJI
DM8HBJI	DN	Coagulation Factor IX
DM8HBJI	HS	Approved
DM8HBJI	TC	Anticoagulants
DM8HBJI	DE	Haemophilia B

DM6L4H2	ID	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	HS	Approved
DM6L4H2	SN	1004316-88-4; Cobicistat (GS-9350); GS 9350; GS-9350; UNII-LW2E03M5PG; Cobicistat,GS-9350; CHEBI:72291; LW2E03M5PG; Tybost; thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate; 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl
DM6L4H2	CP	GILEAD
DM6L4H2	DT	Small molecular drug
DM6L4H2	PC	25151504
DM6L4H2	MW	776
DM6L4H2	FM	C40H53N7O5S2
DM6L4H2	IC	InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1
DM6L4H2	CS	CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
DM6L4H2	IK	ZCIGNRJZKPOIKD-CQXVEOKZSA-N
DM6L4H2	IU	1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DM6L4H2	CA	CAS 1004316-88-4
DM6L4H2	CB	CHEBI:72291
DM6L4H2	DE	Human immunodeficiency virus infection

DMDKXTO	ID	DMDKXTO
DMDKXTO	DN	Cobicistat/darunavir
DMDKXTO	HS	Approved
DMDKXTO	SN	Prezcobix; Cobicistat / darunavir; Darunavir / Cobicistat; Cobicistat and darunavir; Cobicistat mixture with darunavir; Darunavir and cobicistat
DMDKXTO	CP	Gilead Sciences
DMDKXTO	DT	Small molecular drug
DMDKXTO	PC	57327017
DMDKXTO	MW	1323.7
DMDKXTO	FM	C67H90N10O12S3
DMDKXTO	IC	InChI=1S/C40H53N7O5S2.C27H37N3O7S/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35;1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49);3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t32-,33-,36+;22-,23-,24+,25-,26+/m10/s1
DMDKXTO	CS	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
DMDKXTO	IK	CXORHDVSJFELCV-HWDLLDTBSA-N
DMDKXTO	IU	[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate;1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMDKXTO	DE	Human immunodeficiency virus infection

DMSOX7I	ID	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	HS	Approved
DMSOX7I	SN	Allococaine; Allopseudococaine; Badrock; Bazooka; Benzoylethylecgonine; Benzoylmethylecgonine; Bernice; Bernies; Blast; Blizzard; Blow; Burese; COC; Cabello; Candy; Carrie; Caviar; Cecil; Charlie; Cholly; Coca; Cocain; Cocaina; Cocainum; Cocktail; Coke; Cola; Corine; Crack; Eritroxilina; Erytroxylin; Flake; Flex; Freeze; Girl; Goofball; Heaven; Hell; Jam; Kokain; Kokan; Kokayeen; Lady; Leaf; Moonrocks; Neurocaine; Pseudoallococaine; Rock; Sleighride; Snort; Snow; Toke; Toot; Trails; Yeyo; Bernice [Street Name]; Blow [Street Name]; Bouncing Powder; Cecil [Street Name]; Chicken Scratch; Cocaine [BAN]; Cocaine free base; Cocaine solution; Crack cocaine; Dama blanca; Ecgonine methyl ester benzoate; Ecgonine methyl ester benzoate solution; Flake [Street Name]; Florida Snow; Foo Foo; Girl [Street Name]; Gold dust; Gold dust [Street Name]; Green gold; Happy dust; Happy dust [Street Name]; Happy powder; Happy trails; Lady [Street Name]; Methyl Benzoylecgonine; Nose candy; Prime Time; Rock [Street Name]; Sweet Stuff; Toot [Street Name]; White girl or lady; Beta-Cocain; C" Carrie; Cocaine (TN); Cocaine (USP); Cocaine-M; G-Rock; Kibbles n' Bits; L-Cocain; L-Cocaine; Pimp's drug; Snow (birds); Star-spangled powder; Ecgonine, methyl ester, benzoate (ester); Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; (-)-Cocaine; (-)-Cocaine base; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; (R)-Cocaine; 1-Cocaine; 2-beta-Carbomethoxy-3-beta-benzoxytropane; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); 2beta-Carbomethoxy-3beta-benzoxytropane; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester)
DMSOX7I	TC	Anesthetics
DMSOX7I	DT	Small molecular drug
DMSOX7I	PC	446220
DMSOX7I	MW	303.35
DMSOX7I	FM	C17H21NO4
DMSOX7I	IC	InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1
DMSOX7I	CS	CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC
DMSOX7I	IK	ZPUCINDJVBIVPJ-LJISPDSOSA-N
DMSOX7I	IU	methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
DMSOX7I	CA	CAS 50-36-2
DMSOX7I	CB	CHEBI:27958
DMSOX7I	DE	Anaesthesia

DMJX6ZG	ID	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	HS	Approved
DMJX6ZG	SN	codeine; Methylmorphine; Codeine anhydrous; Codicept; l-Codeine; Coducept; Morphine monomethyl ether; Morphine 3-methyl ether; 76-57-3; (-)-Codeine; O3-Methylmorphine; codeinum; Morphine-3-methyl ether; Codein; Norcodine, N-methyl; Norcodeine, N-methyl; CODEINE BASE; Codeine polistirex; codeina; O(3)-methylmorphine; CCRIS 7555; Morphine-3-methyl ester; HSDB 3043; UNII-UX6OWY2V7J; CHEBI:16714; EINECS 200-969-1; UX6OWY2V7J; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; Codeine Anhydrate
DMJX6ZG	CP	Forest Pharmaceuticals
DMJX6ZG	TC	Analgesics
DMJX6ZG	DT	Small molecular drug
DMJX6ZG	PC	5284371
DMJX6ZG	MW	299.4
DMJX6ZG	FM	C18H21NO3
DMJX6ZG	IC	InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
DMJX6ZG	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O
DMJX6ZG	IK	OROGSEYTTFOCAN-DNJOTXNNSA-N
DMJX6ZG	IU	(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
DMJX6ZG	CA	CAS 76-57-3
DMJX6ZG	CB	CHEBI:16714
DMJX6ZG	DE	Pain; Cough

DM2POTE	ID	DM2POTE
DM2POTE	DN	Colchicine
DM2POTE	HS	Approved
DM2POTE	SN	Colchicin; Colchicina; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Kolkicin; LOC; Binds to tubulin; Colchicin [German]; Colchicina [Italian]; Colchicine [JAN]; Inhibits microtubular assembly; Spindle poison; C 9754; Colchicine (TN); Colchicine, Colchicum autumnale; MPC-004; N-Acetyl trimethylcolchicinic acid methylether; Colchicine (JP15/USP); Colchicine, (R)-Isomer; Benzo(a)heptalen-9(5H)-one; Colchicine, (+-)-Isomer; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine
DM2POTE	TC	Gout Suppressants
DM2POTE	DT	Small molecular drug
DM2POTE	PC	6167
DM2POTE	MW	399.4
DM2POTE	FM	C22H25NO6
DM2POTE	IC	InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1
DM2POTE	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
DM2POTE	IK	IAKHMKGGTNLKSZ-INIZCTEOSA-N
DM2POTE	IU	N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DM2POTE	CA	CAS 64-86-8
DM2POTE	CB	CHEBI:27882
DM2POTE	DE	Acute gouty arthritis

DMJ01D8	ID	DMJ01D8
DMJ01D8	DN	Colforsin daropate hci
DMJ01D8	HS	Approved
DMJ01D8	SN	Adehl (TN); Adele (TN)
DMJ01D8	CP	Nippon Kayaku
DMJ01D8	DT	Small molecular drug
DMJ01D8	PC	444028
DMJ01D8	MW	546.1
DMJ01D8	FM	C27H44ClNO8
DMJ01D8	IC	InChI=1S/C27H43NO8.ClH/c1-10-24(5)15-18(31)27(33)25(6)17(30)11-13-23(3,4)21(25)20(35-19(32)12-14-28(8)9)22(34-16(2)29)26(27,7)36-24;/h10,17,20-22,30,33H,1,11-15H2,2-9H3;1H/t17-,20-,21-,22-,24-,25-,26+,27-;/m0./s1
DMJ01D8	CS	CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)OC(=O)CCN(C)C.Cl
DMJ01D8	IK	VIRRLEDAYYYTOD-YHEOSNBFSA-N
DMJ01D8	IU	[(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-5-acetyloxy-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-6-yl] 3-(dimethylamino)propanoate;hydrochloride
DMJ01D8	CA	CAS 138605-00-2
DMJ01D8	CB	CHEBI:31429
DMJ01D8	DE	Asthma

DMZ9BMU	ID	DMZ9BMU
DMZ9BMU	DN	Colistimethate
DMZ9BMU	HS	Approved
DMZ9BMU	SN	Colimicina; Colimyscine; Colimycin M; Colistimethale Sodium; Colistimethate sodium; Colistin Sulfomethate; Colistin methanesulfonate sodium salt; Colistin sodium methanesulfonate; Colistin sodium methanesulfonate from bacillus colistinus; Colistin sulfomethate sodium; Colistinemethanesulfonate sodique; Colistrimethate sodium; Colymycin M; Pentasodium colistinmethanesulfonate; Sodium colistimethate; Sodium colistin methanesulfonate; Sodium colistinemethanesulfonate; W 1929; Colistimethate sodium [USAN:INN]; Colistinmethanesulfonic acid, sodium salt; Coly-Mycin M; Coly-Mycin M Parenteral; Coly-mycin injectable
DMZ9BMU	TC	Antibiotics
DMZ9BMU	DT	Small molecular drug
DMZ9BMU	PC	216258
DMZ9BMU	MW	1749.8
DMZ9BMU	FM	C58H105N16Na5O28S5
DMZ9BMU	IC	InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5
DMZ9BMU	CS	CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+]
DMZ9BMU	IK	IQWHCHZFYPIVRV-UHFFFAOYSA-I
DMZ9BMU	IU	pentasodium;[2-[17-(1-hydroxyethyl)-22-[[2-[[3-hydroxy-2-[[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate
DMZ9BMU	CA	CAS 8068-28-8
DMZ9BMU	DE	Respiratory tract infection

DMMD9QE	ID	DMMD9QE
DMMD9QE	DN	Colistin
DMMD9QE	HS	Approved
DMMD9QE	SN	Colistin sulphate; Polymyxin E; Colistin sulfate, nonsterile; Polymyxin E. Sulfate; Coly-Mycin M Parenteral (TN)
DMMD9QE	CP	Parkdale Pharmaceuticals
DMMD9QE	TC	Antibiotics
DMMD9QE	DT	Small molecular drug
DMMD9QE	PC	5311054
DMMD9QE	MW	1155.4
DMMD9QE	FM	C52H98N16O13
DMMD9QE	IC	InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1
DMMD9QE	CS	CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O
DMMD9QE	IK	YKQOSKADJPQZHB-QNPLFGSASA-N
DMMD9QE	IU	N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-5-methylheptanamide
DMMD9QE	CA	CAS 1066-17-7
DMMD9QE	DE	Pseudomonas infection

DMFJ2OG	ID	DMFJ2OG
DMFJ2OG	DN	Collagenase
DMFJ2OG	HS	Approved
DMFJ2OG	TC	Antiulcer Agents
DMFJ2OG	DE	Skin burns; Dermal ulcers

DM1V329	ID	DM1V329
DM1V329	DN	Conivaptan
DM1V329	HS	Approved
DM1V329	SN	Conivaptan [INN]; YM 087; YM087; Conivaptan (INN); Vaprisol (TN); YM-087; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
DM1V329	CP	Astellas Pharma Inc
DM1V329	DT	Small molecular drug
DM1V329	PC	151171
DM1V329	MW	498.6
DM1V329	FM	C32H26N4O2
DM1V329	IC	InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
DM1V329	CS	CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
DM1V329	IK	IKENVDNFQMCRTR-UHFFFAOYSA-N
DM1V329	IU	N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide
DM1V329	CA	CAS 210101-16-9
DM1V329	CB	CHEBI:681850
DM1V329	DE	Euvolemic hyponatremia

DMLT0E1	ID	DMLT0E1
DMLT0E1	DN	Conjugated estrogens
DMLT0E1	HS	Approved
DMLT0E1	SN	Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Evex; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt; Sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMLT0E1	CP	Wyeth Pharmaceuticals
DMLT0E1	TC	Estrogens
DMLT0E1	DT	Small molecular drug
DMLT0E1	PC	45357473
DMLT0E1	MW	372.4
DMLT0E1	FM	C18H21NaO5S
DMLT0E1	IC	InChI=1S/C18H22O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14?,15?,16?,18-;/m0./s1
DMLT0E1	CS	C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+]
DMLT0E1	IK	VUCAHVBMSFIGAI-TWCWWGPMSA-M
DMLT0E1	IU	sodium;[(13S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate
DMLT0E1	DE	Menopause symptom; Vasomotor symptom

DMTPIZC	ID	DMTPIZC
DMTPIZC	DN	Conjugated estrogens a
DMTPIZC	HS	Approved
DMTPIZC	SN	Conestin (TN)
DMTPIZC	DE	Hormone replacement therapy

DMU7SF8	ID	DMU7SF8
DMU7SF8	DN	Conjugated estrogens b
DMU7SF8	HS	Approved
DMU7SF8	SN	Enjuvia (TN)
DMU7SF8	DE	Hormone replacement therapy

DMF29Q5	ID	DMF29Q5
DMF29Q5	DN	Connexyn
DMF29Q5	HS	Approved
DMF29Q5	SN	Estulic; Intuniv; Tenex; GUANFACINE HCL; Guanfacine hydrochloride; G 1043; LON 798; BS 100-141; Guanfacine hydrochloride [USAN:JAN]; SPD-503; Tenex (TN); BS-100-141; Guanfacine hydrochloride (JAN/USP); N-(Aminoiminomethyl)-2,6-dichlorobenzeneacetamide hydrochloride; N-(Aminoiminomethyl)-2,6-dichlorophenylacetamide monohydrochloride; N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride; N-carbamimidoyl-2-(2,6-dichlorphenyl)acetamidhydrochlorid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, hydrochloride (1:1)
DMF29Q5	DT	Small molecular drug
DMF29Q5	PC	71401
DMF29Q5	MW	282.5
DMF29Q5	FM	C9H10Cl3N3O
DMF29Q5	IC	InChI=1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
DMF29Q5	CS	C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl
DMF29Q5	IK	DGFYECXYGUIODH-UHFFFAOYSA-N
DMF29Q5	IU	N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride
DMF29Q5	CA	CAS 29110-48-3
DMF29Q5	CB	CHEBI:5559
DMF29Q5	DE	Attention deficit hyperactivity disorder

DM26KR1	ID	DM26KR1
DM26KR1	DN	Copper dotatate Cu-64
DM26KR1	HS	Approved
DM26KR1	SN	UNII-N3858377KC; N3858377KC; Copper 64-DOTA-tate; Copper Cu-64 dotatate; 1426155-87-4; Cuprate(2-)-64Cu, (N-(2-(4,10-bis((carboxy-kappaO)methyl)-7-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN1,kappaN4,kappaN7,kappaN10)acetyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoni
DM26KR1	DT	Radioactive diagnostic agent
DM26KR1	PC	124220636
DM26KR1	MW	1497.5
DM26KR1	FM	C65H88CuN14O19S2
DM26KR1	IC	InChI=1S/C65H90N14O19S2.Cu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+2/p-2/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+0
DM26KR1	CS	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[64Cu+2]
DM26KR1	IK	IJRLLVFQGCCPPI-NVGRTJHCSA-L
DM26KR1	IU	2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-10-(carboxylatomethyl)-7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;copper-64(2+)
DM26KR1	CA	CAS 1426155-87-4
DM26KR1	DE	Diagnostic imaging

DMP9TWZ	ID	DMP9TWZ
DMP9TWZ	DN	Corticotropin
DMP9TWZ	HS	Approved
DMP9TWZ	SN	corticotropin; ACTH; Cortrophin; Corticotrophin; Adrenocorticotropic hormone; Corticotrophine; Corticotrofina; Acthargel; Corticotrophinum; beta-Corticotropin; Adrenocorticotrophin; Purified Cortrophin gel; Corticotropin [USP:INN]; 9002-60-2; CHEBI:3892; BDBM82408; ACTH-(1-39); 25-Asp-30-Gln-corticotropin porcine; NCGC00167127-01; CAS_12279-41-3; Adrenocorticotropic Hormone (1-39), human; LS-187380; SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF; J-004856; alpha1-39-Corticotropin (swine), 25-L-aspartic acid-30-L-glutamine
DMP9TWZ	CP	Questcor pharmaceuticals
DMP9TWZ	SQ	ACTH(1-39): SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF
DMP9TWZ	PC	16132265
DMP9TWZ	MW	4541
DMP9TWZ	FM	C207H308N56O58S
DMP9TWZ	IC	InChI=1S/C207H308N56O58S/c1-108(2)89-140(186(302)240-135(69-74-163(279)280)182(298)254-149(204(320)321)94-117-43-20-15-21-44-117)250-193(309)152-54-35-86-262(152)202(318)147(92-116-41-18-14-19-42-116)252-171(287)114(11)230-175(291)132(66-71-160(273)274)234-170(286)113(10)231-191(307)150(105-265)255-183(299)136(70-75-164(281)282)241-190(306)146(98-165(283)284)249-180(296)133(67-72-161(275)276)235-169(285)112(9)229-157(270)101-225-174(290)145(97-156(213)269)251-194(310)153-55-36-87-263(153)203(319)148(93-119-60-64-123(268)65-61-119)253-199(315)167(110(5)6)257-185(301)129(49-26-30-79-210)243-198(314)168(111(7)8)259-196(312)155-57-38-85-261(155)201(317)139(53-34-83-223-207(218)219)244-178(294)130(51-32-81-221-205(214)215)237-177(293)128(48-25-29-78-209)236-176(292)127(47-24-28-77-208)232-158(271)103-227-197(313)166(109(3)4)258-195(311)154-56-37-84-260(154)200(316)138(50-27-31-80-211)233-159(272)102-226-173(289)143(95-120-99-224-126-46-23-22-45-124(120)126)247-179(295)131(52-33-82-222-206(216)217)238-187(303)142(90-115-39-16-13-17-40-115)246-189(305)144(96-121-100-220-107-228-121)248-181(297)134(68-73-162(277)278)239-184(300)137(76-88-322-12)242-192(308)151(106-266)256-188(304)141(245-172(288)125(212)104-264)91-118-58-62-122(267)63-59-118/h13-23,39-46,58-65,99-100,107-114,125,127-155,166-168,224,264-268H,24-38,47-57,66-98,101-106,208-212H2,1-12H3,(H2,213,269)(H,220,228)(H,225,290)(H,226,289)(H,227,313)(H,229,270)(H,230,291)(H,231,307)(H,232,271)(H,233,272)(H,234,286)(H,235,285)(H,236,292)(H,237,293)(H,238,303)(H,239,300)(H,240,302)(H,241,306)(H,242,308)(H,243,314)(H,244,294)(H,245,288)(H,246,305)(H,247,295)(H,248,297)(H,249,296)(H,250,309)(H,251,310)(H,252,287)(H,253,315)(H,254,298)(H,255,299)(H,256,304)(H,257,301)(H,258,311)(H,259,312)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,320,321)(H4,214,215,221)(H4,216,217,222)(H4,218,219,223)/t112-,113-,114-,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,166-,167-,168-/m0/s1
DMP9TWZ	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N
DMP9TWZ	IK	IDLFZVILOHSSID-OVLDLUHVSA-N
DMP9TWZ	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]acetyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMP9TWZ	CA	CAS 12427-33-7
DMP9TWZ	CB	CHEBI:3892
DMP9TWZ	DE	Diabetic nephropathy; Cushing disease

DMU5QZX	ID	DMU5QZX
DMU5QZX	DN	Cortisone
DMU5QZX	HS	Approved
DMU5QZX	SN	11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone
DMU5QZX	DT	Small molecular drug
DMU5QZX	PC	222786
DMU5QZX	MW	360.4
DMU5QZX	FM	C21H28O5
DMU5QZX	IC	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
DMU5QZX	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C
DMU5QZX	IK	MFYSYFVPBJMHGN-ZPOLXVRWSA-N
DMU5QZX	IU	(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione
DMU5QZX	CA	CAS 53-06-5
DMU5QZX	CB	CHEBI:16962
DMU5QZX	DE	Atopic dermatitis

DMG8K57	ID	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	HS	Approved
DMG8K57	SN	Cortone
DMG8K57	CP	Pharmacia And Upjohn Co
DMG8K57	TC	Anticancer Agents
DMG8K57	DT	Small molecular drug
DMG8K57	PC	5745
DMG8K57	MW	402.5
DMG8K57	FM	C23H30O6
DMG8K57	IC	InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1
DMG8K57	CS	CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
DMG8K57	IK	ITRJWOMZKQRYTA-RFZYENFJSA-N
DMG8K57	IU	[2-[(8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3,11-dioxo-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DMG8K57	CA	CAS 50-04-4
DMG8K57	CB	CHEBI:3897
DMG8K57	DE	Solid tumour/cancer

DMUIASK	ID	DMUIASK
DMUIASK	DN	Cosyntropin
DMUIASK	HS	Approved
DMUIASK	SN	Cortrosyn; Tetracosactide; Cortrosyn (TN); Cosyntropin (USAN); Tetracosactide (INN)
DMUIASK	CP	Sandoz 
DMUIASK	TC	Diagnostic Agents
DMUIASK	PC	16129617
DMUIASK	MW	2933.4
DMUIASK	FM	C136H210N40O31S
DMUIASK	IC	InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86?,88-,89-,90+,91-,92+,93+,94+,95+,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,109+,110+,111+/m1/s1
DMUIASK	CS	CC(C)[C@@H](C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CNC=N8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C(CO)N
DMUIASK	IK	ZOEFCCMDUURGSE-CQVUSSRSSA-N
DMUIASK	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-amino-3-hydroxypropanoyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid
DMUIASK	CA	CAS 16960-16-0
DMUIASK	DE	Adrenocortical insufficiency

DMCEZ1B	ID	DMCEZ1B
DMCEZ1B	DN	Cotinine
DMCEZ1B	HS	Approved
DMCEZ1B	SN	cotinine; (-)-Cotinine; 486-56-6; Cotinina; Cotininum; (S)-(-)-Cotinine; (5S)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one; Cotinine (-); (S)-Cotinine; UNII-K5161X06LL; (S)-1-Methyl-5-(3-pyridinyl)-2-pyrrolidinone; 2-Pyrrolidinone, 1-methyl-5-(3-pyridinyl)-, (5S)-; CHEBI:68641; (S)-1-Methyl-5-(3-pyridyl)-2-pyrrolidinone; UIKROCXWUNQSPJ-VIFPVBQESA-N; K5161X06LL; Cotinine [INN]; MFCD00077696; Cotininum [INN-Latin]; Cotinina [INN-Spanish]; S(-)-1-Methyl-5-(3-pyridyl)-2-pyrrolidone; (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
DMCEZ1B	DT	Small molecular drug
DMCEZ1B	PC	854019
DMCEZ1B	MW	176.21
DMCEZ1B	FM	C10H12N2O
DMCEZ1B	IC	InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1
DMCEZ1B	CS	CN1[C@@H](CCC1=O)C2=CN=CC=C2
DMCEZ1B	IK	UIKROCXWUNQSPJ-VIFPVBQESA-N
DMCEZ1B	IU	(5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
DMCEZ1B	CA	CAS 486-56-6
DMCEZ1B	CB	CHEBI:68641
DMCEZ1B	DE	Insecticide

DMJ7IQX	ID	DMJ7IQX
DMJ7IQX	DN	Crestor/TriLipix
DMJ7IQX	HS	Approved
DMJ7IQX	CP	AstraZeneca
DMJ7IQX	DE	Dyslipidemia

DMNVKU6	ID	DMNVKU6
DMNVKU6	DN	Crisaborole
DMNVKU6	HS	Approved
DMNVKU6	SN	Crisaborole ointment 2%; PF-06930164
DMNVKU6	CP	Pfizer/Anacor Pharmaceuticals
DMNVKU6	DT	Small molecular drug
DMNVKU6	PC	44591583
DMNVKU6	MW	251.05
DMNVKU6	FM	C14H10BNO3
DMNVKU6	IC	InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2
DMNVKU6	CS	B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O
DMNVKU6	IK	USZAGAREISWJDP-UHFFFAOYSA-N
DMNVKU6	IU	4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile
DMNVKU6	CA	CAS 906673-24-3
DMNVKU6	CB	CHEBI:134677
DMNVKU6	DE	Atopic dermatitis

DMAHOVJ	ID	DMAHOVJ
DMAHOVJ	DN	Crizanlizumab
DMAHOVJ	HS	Approved
DMAHOVJ	SN	SEG101
DMAHOVJ	CP	Novartis
DMAHOVJ	DT	Antibody
DMAHOVJ	DE	Vaso-occlusive crisis; Sickle-cell disorder

DM4F29C	ID	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	HS	Approved
DM4F29C	SN	Xalkori (TN); novel ALK inhibitors
DM4F29C	CP	Pfizer New York, NY
DM4F29C	DT	Small molecular drug
DM4F29C	PC	11626560
DM4F29C	MW	450.3
DM4F29C	FM	C21H22Cl2FN5O
DM4F29C	IC	InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
DM4F29C	CS	C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
DM4F29C	IK	KTEIFNKAUNYNJU-GFCCVEGCSA-N
DM4F29C	IU	3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
DM4F29C	CA	CAS 877399-52-5
DM4F29C	CB	CHEBI:64310
DM4F29C	DE	Non-small-cell lung cancer

DM4AMQZ	ID	DM4AMQZ
DM4AMQZ	DN	Crofelemer
DM4AMQZ	HS	Approved
DM4AMQZ	SN	Fulyzaq (TN)
DM4AMQZ	CP	Salix
DM4AMQZ	DT	Small molecular drug
DM4AMQZ	PC	17397714
DM4AMQZ	MW	308.3
DM4AMQZ	FM	C18H16N2O3
DM4AMQZ	IC	InChI=1S/C18H16N2O3/c1-22-16-10-6-5-9-14(16)12-19-18(21)15-11-17(23-20-15)13-7-3-2-4-8-13/h2-11H,12H2,1H3,(H,19,21)
DM4AMQZ	CS	COC1=CC=CC=C1CNC(=O)C2=NOC(=C2)C3=CC=CC=C3
DM4AMQZ	IK	JDNAIBCYTQGWFC-UHFFFAOYSA-N
DM4AMQZ	IU	N-[(2-methoxyphenyl)methyl]-5-phenyl-1,2-oxazole-3-carboxamide
DM4AMQZ	DE	HIV-associated diarrhoea

DM74LZK	ID	DM74LZK
DM74LZK	DN	Cromoglicate
DM74LZK	HS	Approved
DM74LZK	SN	Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)
DM74LZK	CP	Zambon Group
DM74LZK	TC	Antiasthmatic Agents
DM74LZK	DT	Small molecular drug
DM74LZK	PC	2882
DM74LZK	MW	468.4
DM74LZK	FM	C23H16O11
DM74LZK	IC	InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)
DM74LZK	CS	C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O
DM74LZK	IK	IMZMKUWMOSJXDT-UHFFFAOYSA-N
DM74LZK	IU	5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid
DM74LZK	CA	CAS 16110-51-3
DM74LZK	CB	CHEBI:59773
DM74LZK	DE	Asthma; Allergic rhinitis

DMHCTAL	ID	DMHCTAL
DMHCTAL	DN	Cryptenamine Acetates
DMHCTAL	HS	Approved
DMHCTAL	SN	Unitensen; Cryptenamine Tannates
DMHCTAL	CP	Medpointe Pharmaceuticals Medpointe Healthcare Inc
DMHCTAL	TC	Cardiovascular Agents
DMHCTAL	DE	Hypertension

DMB8PF3	ID	DMB8PF3
DMB8PF3	DN	CT-102
DMB8PF3	HS	Approved
DMB8PF3	CP	Curative Health Services
DMB8PF3	DE	Diabetic foot ulcer

DMP0NFQ	ID	DMP0NFQ
DMP0NFQ	DN	Cupric Sulfate
DMP0NFQ	HS	Approved
DMP0NFQ	SN	Copper sulfate; 7758-98-7; CUPRIC SULFATE; Copper(II) sulfate; Cupric sulfate anhydrous; Copper sulphate; Copper(2+) sulfate; Cupricsulfate; Blue stone; Copper monosulfate; Copper II sulfate; Trinagle; Hylinec; Delcup; Cupric sulphate; Copper(ii) sulfate, anhydrous; Monocopper sulfate; Copper sulfate (1:1); Incracide 10A; Incracide E 51; Sulfuric acid copper(2+) salt (1:1); BCS copper fungicide; Blue copper (VAN); Copper Sulfate Powder; Bonide Root Destroyer; CuSO4; Kupfersulfat [German]; All Clear Root Destroyer; Copper sulfate (CuSO
DMP0NFQ	CP	Abraxis Pharmaceutical Products
DMP0NFQ	TC	Antiinfective Agents
DMP0NFQ	DT	Small molecular drug
DMP0NFQ	PC	24462
DMP0NFQ	MW	159.61
DMP0NFQ	FM	CuO4S
DMP0NFQ	IC	InChI=1S/Cu.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
DMP0NFQ	CS	[O-]S(=O)(=O)[O-].[Cu+2]
DMP0NFQ	IK	ARUVKPQLZAKDPS-UHFFFAOYSA-L
DMP0NFQ	IU	copper;sulfate
DMP0NFQ	CA	CAS 7758-98-7
DMP0NFQ	CB	CHEBI:23414
DMP0NFQ	DE	Pest attack; Fungal infection; Herbicide

DMHSJB4	ID	DMHSJB4
DMHSJB4	DN	Cyclacillin
DMHSJB4	HS	Approved
DMHSJB4	SN	Aminocyclohexylpenicillin; Bastcillin; Calthor; Ciclacilina; Ciclacillin; Ciclacilline; Ciclacillinum; Ciclacillum; Citosarin; Cyclapen; Noblicil; Orfilina; Peamezin; Syngacillin; Ultracillin; Vastcillin; Vipicil; Wyvital; Aminocyclohexyl penicillin; Cyclacillin [USAN]; AC 98; WY 4508; WY4508; C-12104; Ciclacilina [INN-Spanish]; Ciclacilline [INN-French]; Ciclacillinum [INN-Latin]; Cyclacillin (USAN); Cyclapen (TN); Cyclapen-W; Vastcillin (TN); Wy-4508; Ciclacillin (JP15/INN); Cyclapen-W (TN); (1-Aminocyclohexyl)penicillin; (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-(8CI); 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)penicillanic acid; 6-(1-Aminocyclohexylcarboxamido)penicillanic acid; 6beta-(1-aminocyclohexanecarboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMHSJB4	TC	Antibiotics
DMHSJB4	DT	Small molecular drug
DMHSJB4	PC	19003
DMHSJB4	MW	341.4
DMHSJB4	FM	C15H23N3O4S
DMHSJB4	IC	InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1
DMHSJB4	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C
DMHSJB4	IK	HGBLNBBNRORJKI-WCABBAIRSA-N
DMHSJB4	IU	(2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMHSJB4	CA	CAS 3485-14-1
DMHSJB4	CB	CHEBI:31444
DMHSJB4	DE	Bacterial infection

DMO0R76	ID	DMO0R76
DMO0R76	DN	Cyclandelate
DMO0R76	HS	Approved
DMO0R76	SN	cyclandelate; 456-59-7; Cyclolyt; Cyclomandol; Cyclospasmol; Spasmocyclon; Spasmocyclone; Ciclospasmol; Ciclandelato; Sancyclan; Saiclate; Sepyron; Perebral; Dilatan; Clandilon; Capilan; Spasmione; Arto-espasmol; 3,3,5-Trimethylcyclohexyl mandelate; Cyclandelatum; 3,5,5-Trimethylcyclohexyl amygdalate; Cyclobral; Cyclergine; Cyclandelatum [INN-Latin]; Ciclandelato [INN-Spanish]; 3,5,5-Trimethylcyclohexyl mandelate; Novodil; Natil; Mandelic Acid 3,3,5-Trimethylcyclohexyl Ester; Cyclandelic acid; BS 572; UNII-4139O1OAY2; HSDB 3046; EINECS 207
DMO0R76	DT	Small molecular drug
DMO0R76	PC	2893
DMO0R76	MW	276.4
DMO0R76	FM	C17H24O3
DMO0R76	IC	InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
DMO0R76	CS	CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O
DMO0R76	IK	WZHCOOQXZCIUNC-UHFFFAOYSA-N
DMO0R76	IU	(3,3,5-trimethylcyclohexyl) 2-hydroxy-2-phenylacetate
DMO0R76	CA	CAS 456-59-7
DMO0R76	CB	CHEBI:3988
DMO0R76	DE	Dementia

DM9G7BS	ID	DM9G7BS
DM9G7BS	DN	Cyclizine
DM9G7BS	HS	Approved
DM9G7BS	SN	Ciclizina; Cyclizinum; Emoquil; Marezine; Nautazine; Valoid; Wellcome; Cyclizine chloride; Cyclizine hydrochloride; Marezine hydrochloride; BW 47-83; Ciclizina [INN-Spanish]; Cyclizine (INN); Cyclizinum [INN-Latin]; Emoquil (TN); Marezine (TN); Marzine (TN); Ne-devomit; Neo-devomit; Reis-fit; Valoid (TN); Wellcome preparation 47-83; Wellcome prepn 47-83; Cyclizine [INN:BAN:DCF]; Wellcome prepn. 47-83; N-Benzhydryl-N'-methylpiperazine; N-Methyl-N'-benzhydrylpiperazine; N-Methyl-N'-benzyhydrylpiperazine; (+-)-1-diphenylmethyl-4-methylpiperazine; (-)-1-Diphenylmethyl-4-methylpiperazine; (N-Benzhydryl)(N'-methyl)diethylenediamine; 1-(Diphenylmethyl)-4-methylpiperazine; 1-Benzhydryl-4-methylpiperazin; 1-Benzhydryl-4-methylpiperazine; 1-Diphenylmethyl-4-methylpiperazine
DM9G7BS	CP	Seatrace Pharmaceuticals
DM9G7BS	TC	Antiemetics
DM9G7BS	DT	Small molecular drug
DM9G7BS	PC	6726
DM9G7BS	MW	266.4
DM9G7BS	FM	C18H22N2
DM9G7BS	IC	InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3
DM9G7BS	CS	CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3
DM9G7BS	IK	UVKZSORBKUEBAZ-UHFFFAOYSA-N
DM9G7BS	IU	1-benzhydryl-4-methylpiperazine
DM9G7BS	CA	CAS 82-92-8
DM9G7BS	CB	CHEBI:3994
DM9G7BS	DE	Nausea

DM1YBRM	ID	DM1YBRM
DM1YBRM	DN	Cyclobenzaprine
DM1YBRM	HS	Approved
DM1YBRM	SN	Ciclobenzaprina; Cyclobenz; Cyclobenzaprinum; Fexmid; Flexeril; Lisseril; Proeptatriene; Proheptatrien; Proheptatriene; Yurelax; Cyclobenzaprine [INN]; Flexeril hydrochloride; Proeptatriene [Italian]; MK 130; NCI78206; Amrix (TN); Ciclobenzaprina [INN-Spanish]; Cyclobenzaprine (INN); Cyclobenzaprinum [INN-Latin]; Fexmid(TN); Flexeril (TN); MK-130 HCl; Ro 4-1577; Apo-Cyclobenzaprine (TN); N,N-Dimethyl-3-(dibenzo(a,d)cycloheptene-4-ylidene)propylamine; N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine; N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine; 1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-(9CI); 10,11-Dehydroamitriptyline; 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene [Italian]; 9715 R.P; 9715 R.P.
DM1YBRM	CP	Janssen Research And Development Llc
DM1YBRM	TC	Antidepressants
DM1YBRM	DT	Small molecular drug
DM1YBRM	PC	2895
DM1YBRM	MW	275.4
DM1YBRM	FM	C20H21N
DM1YBRM	IC	InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
DM1YBRM	CS	CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31
DM1YBRM	IK	JURKNVYFZMSNLP-UHFFFAOYSA-N
DM1YBRM	IU	N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine
DM1YBRM	CA	CAS 303-53-7
DM1YBRM	CB	CHEBI:3996
DM1YBRM	DE	Depression

DMT5RMB	ID	DMT5RMB
DMT5RMB	DN	Cyclofenil
DMT5RMB	HS	Approved
DMT5RMB	SN	cyclofenil; 2624-43-3; Ondogyne; Cyclofenyl; Cyclophenyl; Cyclopenil; Fertodur; Sanocrisin; Cyclophenil; Sexovar; Rehibin; Sexadieno; Sexovid; Ondonid; Oginex; (Cyclohexylidenemethylene)bis(4,1-phenylene) diacetate; Neoclym; ICI 48213; Cyclofenilum [INN-Latin]; Ciclofenilo [INN-Spanish]; NSC 86464; H 3452; F 6066; UNII-J468V64WZ1; Cyclofenil [INN:BAN:DCF:JAN]; 4,4'-(Cyclohexylidenemethylene)diphenol diacetate ester; C23H24O4; EINECS 220-089-1; Bis(p-hydroxyphenyl)cyclohexyldienemethane diacetate; BRN 2014687; AI3-52271; F-6066
DMT5RMB	DT	Small molecular drug
DMT5RMB	PC	2898
DMT5RMB	MW	364.4
DMT5RMB	FM	C23H24O4
DMT5RMB	IC	InChI=1S/C23H24O4/c1-16(24)26-21-12-8-19(9-13-21)23(18-6-4-3-5-7-18)20-10-14-22(15-11-20)27-17(2)25/h8-15H,3-7H2,1-2H3
DMT5RMB	CS	CC(=O)OC1=CC=C(C=C1)C(=C2CCCCC2)C3=CC=C(C=C3)OC(=O)C
DMT5RMB	IK	GVOUFPWUYJWQSK-UHFFFAOYSA-N
DMT5RMB	IU	[4-[(4-acetyloxyphenyl)-cyclohexylidenemethyl]phenyl] acetate
DMT5RMB	CA	CAS 2624-43-3
DMT5RMB	CB	CHEBI:31446
DMT5RMB	DE	Infertility

DMA8LM5	ID	DMA8LM5
DMA8LM5	DN	Cyclopentolate
DMA8LM5	HS	Approved
DMA8LM5	SN	Ciclopentolato; Cyclopentoiate; Cyclopentolatum; Cyclopentylate; Cylate; Diopentolate; Mydrilate; Bell Pentolate; Minims Cyclopentolate; Bell Pentolate (TN); Ciclopentolato [INN-Spanish]; Cyclopentolate (INN); Cyclopentolate [INN:BAN]; Cyclopentolatum [INN-Latin]; Ocu-Pentolate; B-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; Beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; Alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; (+-)-cyclopentolate; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester
DMA8LM5	CP	Akorn Inc
DMA8LM5	TC	Parasympatholytics
DMA8LM5	DT	Small molecular drug
DMA8LM5	PC	2905
DMA8LM5	MW	291.4
DMA8LM5	FM	C17H25NO3
DMA8LM5	IC	InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
DMA8LM5	CS	CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O
DMA8LM5	IK	SKYSRIRYMSLOIN-UHFFFAOYSA-N
DMA8LM5	IU	2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate
DMA8LM5	CA	CAS 512-15-2
DMA8LM5	CB	CHEBI:4024
DMA8LM5	DE	Examination of eyes or vision

DM4O2Z7	ID	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	HS	Approved
DM4O2Z7	SN	ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide
DM4O2Z7	CP	Baxter International Inc
DM4O2Z7	TC	Anticancer Agents
DM4O2Z7	DT	Small molecular drug
DM4O2Z7	PC	2907
DM4O2Z7	MW	261.079
DM4O2Z7	FM	C7H15Cl2N2O2P
DM4O2Z7	IC	InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
DM4O2Z7	CS	C1CNP(=O)(OC1)N(CCCl)CCCl
DM4O2Z7	IK	CMSMOCZEIVJLDB-UHFFFAOYSA-N
DM4O2Z7	IU	N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DM4O2Z7	CA	CAS 50-18-0
DM4O2Z7	CB	CHEBI:4027
DM4O2Z7	DE	Solid tumour/cancer

DMT1I52	ID	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	HS	Approved
DMT1I52	SN	D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin;  Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One
DMT1I52	TC	Antiinfective Agents
DMT1I52	DT	Small molecular drug
DMT1I52	PC	6234
DMT1I52	MW	102.09
DMT1I52	FM	C3H6N2O2
DMT1I52	IC	InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1
DMT1I52	CS	C1[C@H](C(=O)NO1)N
DMT1I52	IK	DYDCUQKUCUHJBH-UWTATZPHSA-N
DMT1I52	IU	(4R)-4-amino-1,2-oxazolidin-3-one
DMT1I52	CA	CAS 68-41-7
DMT1I52	CB	CHEBI:40009
DMT1I52	DE	Tuberculosis; Bacterial infection; Obsessive compulsive disorder

DMJ4AWC	ID	DMJ4AWC
DMJ4AWC	DN	Cyclothiazide
DMJ4AWC	HS	Approved
DMJ4AWC	SN	Anhydron; Aquirel; Ciclotiazida; Ciclotiazide; Cyclothiazidum; Doburil; Fluidil; Renazide; Valmiran; Ciclotiazide [DCIT]; C 9847; MDi 193; Anhydron (TN); Ciclotiazida [INN-Spanish]; Cyclothiazidum [INN-Latin]; Lilly 35,483; Cyclothiazide [USAN:INN:BAN]; Cyclothiazide (JAN/USAN/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMJ4AWC	TC	Antihypertensive Agents
DMJ4AWC	DT	Small molecular drug
DMJ4AWC	PC	2910
DMJ4AWC	MW	389.9
DMJ4AWC	FM	C14H16ClN3O4S2
DMJ4AWC	IC	InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
DMJ4AWC	CS	C1C2CC(C1C=C2)C3NC4=CC(=C(C=C4S(=O)(=O)N3)S(=O)(=O)N)Cl
DMJ4AWC	IK	BOCUKUHCLICSIY-UHFFFAOYSA-N
DMJ4AWC	IU	3-(2-bicyclo[2.2.1]hept-5-enyl)-6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMJ4AWC	CA	CAS 2259-96-3
DMJ4AWC	CB	CHEBI:31448
DMJ4AWC	DE	Congestive heart failure

DM8C43Q	ID	DM8C43Q
DM8C43Q	DN	Cycrimine
DM8C43Q	HS	Approved
DM8C43Q	SN	Cicrimina; Cycriminum; Pagitane; Cicrimina [INN-Spanish]; Cycriminum [INN-Latin]; Alpha-Cyclopentyl-alpha-phenyl-1-Piperidinepropanol; (+-)-cycrimine; 1-Phenyl-1-cyclopentyl-3-piperidino-1-propanol; 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DM8C43Q	TC	Antiparkinson Agents
DM8C43Q	DT	Small molecular drug
DM8C43Q	PC	2911
DM8C43Q	MW	287.4
DM8C43Q	FM	C19H29NO
DM8C43Q	IC	InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
DM8C43Q	CS	C1CCN(CC1)CCC(C2CCCC2)(C3=CC=CC=C3)O
DM8C43Q	IK	SWRUZBWLEWHWRI-UHFFFAOYSA-N
DM8C43Q	IU	1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DM8C43Q	CA	CAS 77-39-4
DM8C43Q	CB	CHEBI:59692
DM8C43Q	DE	Parkinson disease

DMUY2OR	ID	DMUY2OR
DMUY2OR	DN	Cynarin
DMUY2OR	HS	Approved
DMUY2OR	SN	1,3-O-Dicaffeoylquinic acid; 19870-46-3; 1,3-Dicaffeoylquinic acid; Cynarin; 1,5-Dicaffeoylquinic acid; Cynarine; 1,5-di-O-Caffeoylquinic acid; 1,3-di-O-Caffeoylquinic acid; 30964-13-7; (1S,3R,4R,5R)-1,3-Bis[3-(3,4-dihydroxyphenyl)acryloyloxy]-4,5-dihydroxycyclohexanecarboxylic acid; (1S,3R,4R,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxy-cyclohexanecarboxylic acid; AC1O6FEM; 1,5-Dicaffeoylquinic-acid; 1,3-Dicaffeoyl quinic acid; 1,5-Dicaffeoylquinic acid ; CHEMBL478574; 1,5-DCQA
DMUY2OR	DT	Small molecular drug
DMUY2OR	PC	5281769
DMUY2OR	MW	516.4
DMUY2OR	FM	C25H24O12
DMUY2OR	IC	InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(31)36-20-12-25(24(34)35,11-19(30)23(20)33)37-22(32)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-30,33H,11-12H2,(H,34,35)/b7-3+,8-4+/t19-,20-,23+,25-/m1/s1
DMUY2OR	CS	C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O
DMUY2OR	IK	YDDUMTOHNYZQPO-RVXRWRFUSA-N
DMUY2OR	IU	(1R,3R,4S,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxycyclohexane-1-carboxylic acid
DMUY2OR	CA	CAS 212891-05-9
DMUY2OR	CB	CHEBI:520
DMUY2OR	DE	Vibrio cholerae infection

DM92AH3	ID	DM92AH3
DM92AH3	DN	Cyproheptadine
DM92AH3	HS	Approved
DM92AH3	SN	Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
DM92AH3	CP	Merck & Co
DM92AH3	TC	Antihistamines
DM92AH3	DT	Small molecular drug
DM92AH3	PC	2913
DM92AH3	MW	287.4
DM92AH3	FM	C21H21N
DM92AH3	IC	InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
DM92AH3	CS	CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1
DM92AH3	IK	JJCFRYNCJDLXIK-UHFFFAOYSA-N
DM92AH3	IU	1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine
DM92AH3	CA	CAS 129-03-3
DM92AH3	CB	CHEBI:4046
DM92AH3	DE	Rhinitis

DMQXLD2	ID	DMQXLD2
DMQXLD2	DN	Cyproterone
DMQXLD2	HS	Approved
DMQXLD2	SN	Ciproterona; Ciproterone; CyPat; Cyproteron; Cyproteronum; Ciproterona Servycal; Ciproterone [DCIT]; SH 80881; Apo-cyproterone; Ciproterona Servycal (TN); Ciproterona [INN-Spanish]; Cyproterone (INN); Cyproterone [INN:BAN]; Cyproteronum [INN-Latin]; Dianette (TN); Gen-Cyproterone; Novo-cyproterone; Diane-35 (TN); (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one; 6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]; 6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione
DMQXLD2	CP	Schering-Plough
DMQXLD2	TC	Anticancer Agents
DMQXLD2	DT	Small molecular drug
DMQXLD2	PC	5284537
DMQXLD2	MW	374.9
DMQXLD2	FM	C22H27ClO3
DMQXLD2	IC	InChI=1S/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12-,13+,14-,15-,16-,20-,21-,22-/m0/s1
DMQXLD2	CS	CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)O
DMQXLD2	IK	DUSHUSLJJMDGTE-ZJPMUUANSA-N
DMQXLD2	IU	(1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-15-hydroxy-2,16-dimethylpentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dien-6-one
DMQXLD2	CA	CAS 2098-66-0
DMQXLD2	CB	CHEBI:50742
DMQXLD2	DE	Prostate cancer

DMSYFM8	ID	DMSYFM8
DMSYFM8	DN	Cysteamine
DMSYFM8	HS	Approved
DMSYFM8	SN	Becaptan; Cisteamina; Cystavision; Cysteamide; Cysteamin; Cysteinamine; Decarboxycysteine; Ethanethiolamine; Lambraten; Lambratene; MEA; Mecramine; Mercamin; Mercamine; Mercaptamin; Mercaptamina; Mercaptamine; Mercaptaminum; Mercaptoethylamine; Merkamin; Riacon; Thioethanolamine; Aminoethyl mercaptan; Cisteamina [Italian]; Cysteamine bitartate; L 1573; WR 347; Beta-Aminoethanethiol; Beta-Aminoethylthiol; Beta-MEA; Beta-Mercaptoethylamine; C-9500; Cysteamine (USAN); Cysteamine [USAN:BAN]; L-1573; MEA (mercaptan); Mercaptamina [INN-Spanish]; Mercaptamine (INN); Mercaptaminum [INN-Latin]; (2-Mercaptoethyl)amine; (Mercaptoethyl)ammonium toluene-p-sulphonate; 1-Amino-2-mercaptoethylamine; 2-AMINO-ETHANETHIOL; 2-Amino-1-ethanethiol; 2-Aminoethanethiol; 2-Aminoethyl mercaptan; 2-Mercaptoethanamine; 2-Mercaptoethylamine; 2-Mercaptoethylamine, polymer-bound; 641022_ALDRICH
DMSYFM8	CP	Mylan Pharmaceuticals Inc
DMSYFM8	TC	Nephropathic cystinosis therapy
DMSYFM8	DT	Small molecular drug
DMSYFM8	PC	6058
DMSYFM8	MW	77.15
DMSYFM8	FM	C2H7NS
DMSYFM8	IC	InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2
DMSYFM8	CS	C(CS)N
DMSYFM8	IK	UFULAYFCSOUIOV-UHFFFAOYSA-N
DMSYFM8	IU	2-aminoethanethiol
DMSYFM8	CA	CAS 60-23-1
DMSYFM8	CB	CHEBI:17141
DMSYFM8	DE	Nephropathic cystinosis

DMZD5QR	ID	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	HS	Approved
DMZD5QR	SN	Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
DMZD5QR	CP	Upjohn Corporation
DMZD5QR	TC	Anticancer Agents
DMZD5QR	DT	Small molecular drug
DMZD5QR	PC	6253
DMZD5QR	MW	243.22
DMZD5QR	FM	C9H13N3O5
DMZD5QR	IC	InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
DMZD5QR	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
DMZD5QR	IK	UHDGCWIWMRVCDJ-CCXZUQQUSA-N
DMZD5QR	IU	4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMZD5QR	CA	CAS 147-94-4
DMZD5QR	CB	CHEBI:28680
DMZD5QR	DE	Acute lymphoblastic leukaemia

DMDI6R4	ID	DMDI6R4
DMDI6R4	DN	Dabigatran
DMDI6R4	HS	Approved
DMDI6R4	SN	Pradaxa (TN)
DMDI6R4	CP	Boehringer Ingelheim
DMDI6R4	DT	Small molecular drug
DMDI6R4	PC	216210
DMDI6R4	MW	471.5
DMDI6R4	FM	C25H25N7O3
DMDI6R4	IC	InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
DMDI6R4	CS	CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
DMDI6R4	IK	YBSJFWOBGCMAKL-UHFFFAOYSA-N
DMDI6R4	IU	3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
DMDI6R4	CA	CAS 211914-51-1
DMDI6R4	CB	CHEBI:70752
DMDI6R4	DE	Stroke

DMX6OE3	ID	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	HS	Approved
DMX6OE3	SN	1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436
DMX6OE3	DT	Small molecular drug
DMX6OE3	PC	44462760
DMX6OE3	MW	519.6
DMX6OE3	FM	C23H20F3N5O2S2
DMX6OE3	IC	InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
DMX6OE3	CS	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F
DMX6OE3	IK	BFSMGDJOXZAERB-UHFFFAOYSA-N
DMX6OE3	IU	N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
DMX6OE3	CA	CAS 1195765-45-7
DMX6OE3	CB	CHEBI:75045
DMX6OE3	DE	Melanoma

DMNPZL4	ID	DMNPZL4
DMNPZL4	DN	Dacarbazine
DMNPZL4	HS	Approved
DMNPZL4	SN	Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
DMNPZL4	CP	Bayer Pharmaceuticals Corporation
DMNPZL4	TC	Anticancer Agents
DMNPZL4	DT	Small molecular drug
DMNPZL4	PC	135398738
DMNPZL4	MW	182.18
DMNPZL4	FM	C6H10N6O
DMNPZL4	IC	InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+
DMNPZL4	CS	CN(C)/N=N/C1=C(NC=N1)C(=O)N
DMNPZL4	IK	FDKXTQMXEQVLRF-ZHACJKMWSA-N
DMNPZL4	IU	4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide
DMNPZL4	CA	CAS 4342-03-4
DMNPZL4	CB	CHEBI:94587
DMNPZL4	DE	Melanoma

DMSFK9V	ID	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	HS	Approved
DMSFK9V	SN	1009119-64-5; Daclatasvir (BMS-790052); 1214735-16-6; CHEBI:82977; C40H50N8O6; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; MLS006011140; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; KS-00000XPC; EX-A410
DMSFK9V	CP	Bristol-Myers Squibb
DMSFK9V	DT	Small molecular drug
DMSFK9V	PC	25154714
DMSFK9V	MW	738.9
DMSFK9V	FM	C40H50N8O6
DMSFK9V	IC	InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
DMSFK9V	CS	CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMSFK9V	IK	FKRSSPOQAMALKA-CUPIEXAXSA-N
DMSFK9V	IU	methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMSFK9V	CA	CAS 1009119-64-5
DMSFK9V	CB	CHEBI:82977
DMSFK9V	DE	Hepatitis C virus infection

DM6OZQV	ID	DM6OZQV
DM6OZQV	DN	Daclizumab
DM6OZQV	HS	Approved
DM6OZQV	SN	DAC HYP; Daclizumab HYP; Daclizumab High Yield Process; Daclizumab (subcutaneous, multiple sclerosis); Daclizumab (subcutaneous, multiple sclerosis), Abbott/Biogen Idec
DM6OZQV	CP	Biogen
DM6OZQV	DT	Monoclonal antibody
DM6OZQV	SQ	Humanized Anti-CD25 Heavy Chain 1: QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Humanized Anti-CD25 Light Chain 1DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DM6OZQV	DE	Multiple sclerosis

DMOH8VY	ID	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	HS	Approved
DMOH8VY	SN	PF-00299804
DMOH8VY	CP	Pfizer
DMOH8VY	DT	Small molecular drug
DMOH8VY	PC	11511120
DMOH8VY	MW	469.9
DMOH8VY	FM	C24H25ClFN5O2
DMOH8VY	IC	InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
DMOH8VY	CS	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
DMOH8VY	IK	LVXJQMNHJWSHET-AATRIKPKSA-N
DMOH8VY	IU	(E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
DMOH8VY	CA	CAS 1110813-31-4
DMOH8VY	CB	CHEBI:91466
DMOH8VY	DE	Non-small-cell lung cancer

DM2YGNW	ID	DM2YGNW
DM2YGNW	DN	Dactinomycin
DM2YGNW	HS	Approved
DM2YGNW	SN	Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
DM2YGNW	TC	Anticancer Agents
DM2YGNW	DT	Small molecular drug
DM2YGNW	PC	457193
DM2YGNW	MW	1255.4
DM2YGNW	FM	C62H86N12O16
DM2YGNW	IC	InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
DM2YGNW	CS	C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C
DM2YGNW	IK	RJURFGZVJUQBHK-IIXSONLDSA-N
DM2YGNW	IU	2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
DM2YGNW	CA	CAS 50-76-0
DM2YGNW	CB	CHEBI:27666
DM2YGNW	DE	Solid tumour/cancer

DMGMNH3	ID	DMGMNH3
DMGMNH3	DN	Dalbavancin
DMGMNH3	HS	Approved
DMGMNH3	SN	Zeven; Zeven (TN); Dalbavancin (USAN/INN); Dalvance; Xydalba
DMGMNH3	CP	Pfizer
DMGMNH3	DT	Small molecular drug
DMGMNH3	PC	16134627
DMGMNH3	MW	1816.7
DMGMNH3	FM	C88H100Cl2N10O28
DMGMNH3	IC	InChI=1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1
DMGMNH3	CS	CC(C)CCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O
DMGMNH3	IK	KGPGQDLTDHGEGT-SZUNQUCBSA-N
DMGMNH3	IU	(2S,3S,4R,5R,6S)-6-[[(1S,2R,19R,22R,34S,37R,40R,52S)-5,32-dichloro-52-[3-(dimethylamino)propylcarbamoyl]-2,26,31,44,49-pentahydroxy-22-(methylamino)-21,35,38,54,56,59-hexaoxo-47-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14(63),15,17(62),23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,65-henicosaen-64-yl]oxy]-3,4-dihydroxy-5-(10-methylundecanoylamino)oxane-2-carboxylic acid
DMGMNH3	CA	CAS 171500-79-1
DMGMNH3	CB	CHEBI:82721
DMGMNH3	DE	Bacterial infection

DMM0PDO	ID	DMM0PDO
DMM0PDO	DN	Dalfampridine
DMM0PDO	HS	Approved
DMM0PDO	SN	Ampyra (TN)
DMM0PDO	CP	Acorda Therapeutics
DMM0PDO	DT	Small molecular drug
DMM0PDO	PC	1727
DMM0PDO	MW	94.11
DMM0PDO	FM	C5H6N2
DMM0PDO	IC	InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)
DMM0PDO	CS	C1=CN=CC=C1N
DMM0PDO	IK	NUKYPUAOHBNCPY-UHFFFAOYSA-N
DMM0PDO	IU	pyridin-4-amine
DMM0PDO	CA	CAS 504-24-5
DMM0PDO	CB	CHEBI:34385
DMM0PDO	DE	Multiple sclerosis

DM4LTKV	ID	DM4LTKV
DM4LTKV	DN	Dalfopristin
DM4LTKV	HS	Approved
DM4LTKV	SN	5-(2-DIETHYLAMINO-ETHANESULFONYL)-21-HYDROXY-10-ISOPROPYL-11,19-DIMETHYL-9,26-DIOXA-3,15,28-TRIAZA-TRICYCLO[23.2.1.00,255]OCTACOSA-1(27),12,17,19,25(28)-PENTAENE-2,8,14,23-TETRAONE
DM4LTKV	TC	Antibiotics
DM4LTKV	DT	Small molecular drug
DM4LTKV	PC	6323289
DM4LTKV	MW	690.8
DM4LTKV	FM	C34H50N4O9S
DM4LTKV	IC	InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1
DM4LTKV	CS	CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C
DM4LTKV	IK	SUYRLXYYZQTJHF-VMBLUXKRSA-N
DM4LTKV	IU	(6R,7S,10R,11R,12E,17E,19E,21S)-6-[2-(diethylamino)ethylsulfonyl]-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone
DM4LTKV	CA	CAS 112362-50-2
DM4LTKV	CB	CHEBI:4309
DM4LTKV	DE	Bacterial infection

DM6CLBN	ID	DM6CLBN
DM6CLBN	DN	Danaparoid
DM6CLBN	HS	Approved
DM6CLBN	SN	Orgaran (TN)
DM6CLBN	CP	Schering-Plough
DM6CLBN	TC	Anticoagulants
DM6CLBN	DE	Deep venous clot

DML8KTN	ID	DML8KTN
DML8KTN	DN	Danazol
DML8KTN	HS	Approved
DML8KTN	SN	Anatrol; Chronogyn; Cyclomen; Danatrol; Danazant; Danazole; Danazolum; Danocrine; Danogen; Danokrin; Danol; Danoval; Danzol; Ladogal; Norciden; Panacrine; Winobanin; Alphapharm Brand of Danazol; Antigen Brand of Danazol; Kendrick Brand of Danazol; Ratiopharm Brand of Danazol; Sanofi Brand of Danazol; Sanofi Synthelabo Brand ofDanazol; Sanofi Winthrop Brand of Danazol; WIN 17757; Danazol-ratiopharm; Danazolum [INN-Latin]; Danocrine (TN); WIN 17,757; WIN-17757; Win 17, 757; Danazol (JAN/USP/INN); Danazol [USAN:BAN:INN:JAN];[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
DML8KTN	TC	Fertility Agents
DML8KTN	DT	Small molecular drug
DML8KTN	PC	28417
DML8KTN	MW	337.5
DML8KTN	FM	C22H27NO2
DML8KTN	IC	InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1
DML8KTN	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5
DML8KTN	IK	POZRVZJJTULAOH-LHZXLZLDSA-N
DML8KTN	IU	(1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
DML8KTN	CA	CAS 17230-88-5
DML8KTN	CB	CHEBI:4315
DML8KTN	DE	Menorrhagia; Breast cancer

DM1D8XY	ID	DM1D8XY
DM1D8XY	DN	Dantrolene
DM1D8XY	HS	Approved
DM1D8XY	SN	Dantrium; Dantroleno; Dantrolenum; DANTROLENE SODIUM; Dantrium Intravenous; Dantrium (TN); Dantrolen (TN); Dantroleno [INN-Spanish]; Dantrolenum [INN-Latin]; F-368; Dantrolene (USAN/INN); Dantrolene [USAN:BAN:INN]; 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin; 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
DM1D8XY	CP	Procter & Gamble
DM1D8XY	TC	Muscle Relaxants
DM1D8XY	DT	Small molecular drug
DM1D8XY	PC	6914273
DM1D8XY	MW	314.25
DM1D8XY	FM	C14H10N4O5
DM1D8XY	IC	InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+
DM1D8XY	CS	C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-]
DM1D8XY	IK	OZOMQRBLCMDCEG-VIZOYTHASA-N
DM1D8XY	IU	1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
DM1D8XY	CA	CAS 7261-97-4
DM1D8XY	DE	Hyperthermia

DM28UJG	ID	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	HS	Approved
DM28UJG	SN	BMS 512148; BMS-512148; BMS-512148, Dapagliflozin; Dapagliflozin (INN/USAN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
DM28UJG	CP	AstraZeneca
DM28UJG	DT	Small molecular drug
DM28UJG	PC	9887712
DM28UJG	MW	408.9
DM28UJG	FM	C21H25ClO6
DM28UJG	IC	InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
DM28UJG	CS	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl
DM28UJG	IK	JVHXJTBJCFBINQ-ADAARDCZSA-N
DM28UJG	IU	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DM28UJG	CA	CAS 461432-26-8
DM28UJG	CB	CHEBI:85078
DM28UJG	DE	Type-2 diabetes

DM34TXO	ID	DM34TXO
DM34TXO	DN	Dapagliflozin Propanediol; Saxagliptin Hydrochloride
DM34TXO	HS	Approved
DM34TXO	SN	Saxagliptin Hydrochloride; Qtern
DM34TXO	CP	Astrazeneca
DM34TXO	DT	Small molecular drug
DM34TXO	DE	Type-2 diabetes

DMOXJKF	ID	DMOXJKF
DMOXJKF	DN	Dapiprazole
DMOXJKF	HS	Approved
DMOXJKF	SN	Dapiprazol; Dapiprazolum; Dapirazol; Dapirazolum; Glamidolo; Remydrial; Reversil; Dapiprazol [German]; Dapiprazole [INN]; Dapiprazole (INN); Dapirazol [INN-Spanish]; Dapirazolum [INN-Latin]; Rev-Eyes; Rev-Eyes (TN); S-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-,hydrochloride; 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine hydrochloride; 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine; 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine; 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine
DMOXJKF	CP	Abbott Laboratories
DMOXJKF	TC	Ophthalmologicals
DMOXJKF	DT	Small molecular drug
DMOXJKF	PC	3033538
DMOXJKF	MW	325.5
DMOXJKF	FM	C19H27N5
DMOXJKF	IC	InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
DMOXJKF	CS	CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4
DMOXJKF	IK	RFWZESUMWJKKRN-UHFFFAOYSA-N
DMOXJKF	IU	3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
DMOXJKF	CA	CAS 72822-12-9
DMOXJKF	CB	CHEBI:51066
DMOXJKF	DE	Glaucoma/ocular hypertension

DM4LT8A	ID	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	HS	Approved
DM4LT8A	SN	Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline
DM4LT8A	TC	Antiinflammatory Agents
DM4LT8A	DT	Small molecular drug
DM4LT8A	PC	2955
DM4LT8A	MW	248.3
DM4LT8A	FM	C12H12N2O2S
DM4LT8A	IC	InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
DM4LT8A	CS	C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
DM4LT8A	IK	MQJKPEGWNLWLTK-UHFFFAOYSA-N
DM4LT8A	IU	4-(4-aminophenyl)sulfonylaniline
DM4LT8A	CA	CAS 80-08-0
DM4LT8A	CB	CHEBI:4325
DM4LT8A	DE	Pneumocystis pneumonia

DMFDQ3I	ID	DMFDQ3I
DMFDQ3I	DN	Daptomycin
DMFDQ3I	HS	Approved
DMFDQ3I	SN	Dapcin; Daptomicina; Daptomycine; Daptomycinum; LY 146032; LY-146032; LY146032; (2S)-daptomycin; 103060-53-3; C72H101N17O26; Cidecin; Cubicin; DAPTOMYCIN; CHEBI:600103; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]-L-alpha-asparagine; SCHEMBL28102
DMFDQ3I	PC	16134395
DMFDQ3I	MW	1620.7
DMFDQ3I	FM	C72H101N17O26
DMFDQ3I	IC	DOAKLVKFURWEDJ-RWDRXURGSA-N
DMFDQ3I	CS	CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
DMFDQ3I	IK	1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
DMFDQ3I	IU	(3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid
DMFDQ3I	CA	CAS 103060-53-3
DMFDQ3I	CB	CHEBI:600103
DMFDQ3I	DE	Methicillin-resistant staphylococcus infection

DMKDU16	ID	DMKDU16
DMKDU16	DN	Daptomycin
DMKDU16	HS	Approved
DMKDU16	SN	Cidecin; Cubicin; Dapcin; Daptomicina; Daptomycine; Daptomycinum; Deptomycin; Daptomicina [Spanish]; Daptomycine [French]; Daptomycinum [Latin]; LY146032; Cubicin (TN); LY-146032; MK-3009; Daptomycin [USAN:INN:BAN]; Daptomycin (JAN/USAN/INN); N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-ox
DMKDU16	CP	Cubist Pharmaceuticals
DMKDU16	TC	Antibiotics
DMKDU16	DT	Small molecular drug
DMKDU16	PC	16134395
DMKDU16	MW	1620.7
DMKDU16	FM	C72H101N17O26
DMKDU16	IC	InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
DMKDU16	CS	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@H](C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
DMKDU16	IK	DOAKLVKFURWEDJ-RWDRXURGSA-N
DMKDU16	IU	(3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid
DMKDU16	CA	CAS 103060-53-3
DMKDU16	CB	CHEBI:600103
DMKDU16	DE	Bacterial infection

DMKCIUZ	ID	DMKCIUZ
DMKCIUZ	DN	Daratumumab
DMKCIUZ	HS	Approved
DMKCIUZ	CP	Genmab Princeton, NJ
DMKCIUZ	DT	Antibody
DMKCIUZ	DE	Multiple myeloma

DMMJTYW	ID	DMMJTYW
DMMJTYW	DN	Darbepoetin alfa
DMMJTYW	HS	Approved
DMMJTYW	SN	Aranesp (TN)
DMMJTYW	CP	Amgen Inc
DMMJTYW	TC	Antianemic Agents
DMMJTYW	SQ	DB00012 sequence: APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR
DMMJTYW	DE	Anemia

DMWXLYZ	ID	DMWXLYZ
DMWXLYZ	DN	Darifenacin
DMWXLYZ	HS	Approved
DMWXLYZ	SN	Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN];  Emselex; Emselex (TN); Enablex (TN)
DMWXLYZ	CP	Norvatis Phamaceuticals Corporation
DMWXLYZ	TC	Urinary antispasmodics
DMWXLYZ	DT	Small molecular drug
DMWXLYZ	PC	444031
DMWXLYZ	MW	426.5
DMWXLYZ	FM	C28H30N2O2
DMWXLYZ	IC	InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
DMWXLYZ	CS	C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5
DMWXLYZ	IK	HXGBXQDTNZMWGS-RUZDIDTESA-N
DMWXLYZ	IU	2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
DMWXLYZ	CA	CAS 133099-04-4
DMWXLYZ	CB	CHEBI:391960
DMWXLYZ	DE	Overactive bladder

DMV7YFT	ID	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	HS	Approved
DMV7YFT	SN	1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen
DMV7YFT	CP	Bayer Pharmaceuticals Whippany, NJ
DMV7YFT	PC	67171867
DMV7YFT	MW	398.8
DMV7YFT	FM	C19H19ClN6O2
DMV7YFT	IC	InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1
DMV7YFT	CS	C[C@@H](CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O
DMV7YFT	IK	BLIJXOOIHRSQRB-PXYINDEMSA-N
DMV7YFT	IU	N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
DMV7YFT	CA	CAS 1297538-32-9
DMV7YFT	DE	Prostate cancer

DMN3GCH	ID	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	HS	Approved
DMN3GCH	SN	206361-99-1; TMC114; Prezista; TMC-114; UIC-94017; Darunavirum; TMC 114; Darunavirum [INN-Latin]; UNII-YO603Y8113; AIDS073035; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; CHEBI:367163; Darunavir-d9; YO603Y8113; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; NCGC00168773-01; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl;  Darunavirum; Darunavir [USAN]; UIC 94017; Prezista(TM); UIC-96017; Darunavir (USAN/INN); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
DMN3GCH	CP	Tibotec
DMN3GCH	TC	Antiviral Agents
DMN3GCH	DT	Small molecular drug
DMN3GCH	PC	213039
DMN3GCH	MW	547.7
DMN3GCH	FM	C27H37N3O7S
DMN3GCH	IC	InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1
DMN3GCH	CS	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N
DMN3GCH	IK	CJBJHOAVZSMMDJ-HEXNFIEUSA-N
DMN3GCH	IU	[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMN3GCH	CA	CAS 206361-99-1
DMN3GCH	CB	CHEBI:367163
DMN3GCH	DE	Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection

DMJV2EK	ID	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	HS	Approved
DMJV2EK	SN	Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
DMJV2EK	CP	Bristol Myers Squibb
DMJV2EK	TC	Anticancer Agents
DMJV2EK	DT	Small molecular drug
DMJV2EK	PC	3062316
DMJV2EK	MW	488
DMJV2EK	FM	C22H26ClN7O2S
DMJV2EK	IC	InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
DMJV2EK	CS	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
DMJV2EK	IK	ZBNZXTGUTAYRHI-UHFFFAOYSA-N
DMJV2EK	IU	N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DMJV2EK	CA	CAS 302962-49-8
DMJV2EK	CB	CHEBI:49375
DMJV2EK	DE	Chronic myelogenous leukaemia; Multiple myeloma

DM74SVE	ID	DM74SVE
DM74SVE	DN	Dasiglucagon
DM74SVE	HS	Approved
DM74SVE	SN	UNII-AD4J2O47FQ; AD4J2O47FQ; Dasiglucagon [INN]; Dasiglucagon [USAN]; Dasiglucagon [WHO-DD]; Dasiglucagon [USAN:INN]; ZP-GA-1; ZP4207; ZP-4207; 1544300-84-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-aib-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr; L-Threonine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-2-methylalanyl-L-alanyl-L-arginyl-L-alanyl-L-alpha-glutamyl-L-alpha
DM74SVE	CP	Zealand Pharma
DM74SVE	DT	Peptide
DM74SVE	PC	126961379
DM74SVE	MW	3381.6
DM74SVE	FM	C152H222N38O50
DM74SVE	IC	InChI=1S/C152H222N38O50/c1-73(2)55-99(133(222)171-98(47-51-116(206)207)132(221)183-111(71-194)144(233)189-122(80(11)197)149(238)239)174-137(226)105(61-85-65-161-91-32-21-20-31-89(85)91)178-129(218)93(34-23-25-53-154)172-146(235)119(75(5)6)187-139(228)103(57-81-27-16-14-17-28-81)176-131(220)97(46-50-115(204)205)170-130(219)96(45-49-114(202)203)167-123(212)76(7)164-127(216)94(35-26-54-160-151(157)158)166-124(213)77(8)165-150(240)152(12,13)190-145(234)107(64-118(210)211)180-134(223)100(56-74(3)4)173-135(224)101(59-83-36-40-87(198)41-37-83)175-128(217)92(33-22-24-52-153)168-142(231)109(69-192)184-136(225)102(60-84-38-42-88(199)43-39-84)177-138(227)106(63-117(208)209)179-143(232)110(70-193)185-148(237)121(79(10)196)188-140(229)104(58-82-29-18-15-19-30-82)181-147(236)120(78(9)195)186-113(201)67-162-126(215)95(44-48-112(156)200)169-141(230)108(68-191)182-125(214)90(155)62-86-66-159-72-163-86/h14-21,27-32,36-43,65-66,72-80,90,92-111,119-122,161,191-199H,22-26,33-35,44-64,67-71,153-155H2,1-13H3,(H2,156,200)(H,159,163)(H,162,215)(H,164,216)(H,165,240)(H,166,213)(H,167,212)(H,168,231)(H,169,230)(H,170,219)(H,171,222)(H,172,235)(H,173,224)(H,174,226)(H,175,217)(H,176,220)(H,177,227)(H,178,218)(H,179,232)(H,180,223)(H,181,236)(H,182,214)(H,183,221)(H,184,225)(H,185,237)(H,186,201)(H,187,228)(H,188,229)(H,189,233)(H,190,234)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,238,239)(H4,157,158,160)/t76-,77-,78+,79+,80+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,119-,120-,121-,122-/m0/s1
DM74SVE	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O
DM74SVE	IK	RZRMFQMNPDPAIX-AJTOSFMRSA-N
DM74SVE	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-2-methylpropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM74SVE	CA	CAS 1544300-84-6
DM74SVE	DE	Hypoglycemia; Hyperinsulinemia

DMLDQFV	ID	DMLDQFV
DMLDQFV	DN	Dasotraline
DMLDQFV	HS	Approved
DMLDQFV	SN	SEP-225289; SEP-289; Triple reuptake inhibitors (depression), Sepracor
DMLDQFV	CP	Sunovion pharmaceuticals
DMLDQFV	DT	Small molecular drug
DMLDQFV	PC	9947999
DMLDQFV	MW	292.2
DMLDQFV	FM	C16H15Cl2N
DMLDQFV	IC	InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1
DMLDQFV	CS	C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N
DMLDQFV	IK	SRPXSILJHWNFMK-MEDUHNTESA-N
DMLDQFV	IU	(1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
DMLDQFV	CA	CAS 675126-05-3
DMLDQFV	DE	Mood disorder; Attention deficit hyperactivity disorder; Eating disorder

DMQUSBT	ID	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	HS	Approved
DMQUSBT	SN	daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142;  Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline
DMQUSBT	TC	Anticancer Agents
DMQUSBT	DT	Small molecular drug
DMQUSBT	PC	30323
DMQUSBT	MW	527.5
DMQUSBT	FM	C27H29NO10
DMQUSBT	IC	InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
DMQUSBT	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
DMQUSBT	IK	STQGQHZAVUOBTE-VGBVRHCVSA-N
DMQUSBT	IU	(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMQUSBT	CA	CAS 20830-81-3
DMQUSBT	CB	CHEBI:41977
DMQUSBT	DE	Acute myeloid leukaemia; Solid tumour/cancer; Kaposi sarcoma

DMC50ME	ID	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	HS	Approved
DMC50ME	SN	Debrisochinum; Debrisoquina; Debrisoquine; Debrisoquinum; Declinax; Equitonil; Isocaramidine; Tendor; DEBRISOQUIN SULFATE; Debrisoquin hemisulfate; Debrisoquine sulfate; Isocaramidine sulfate; Debrisoquina [INN-Spanish]; Debrisoquine [INN:BAN]; Debrisoquinum [INN-Latin]; Ro 5-3307/1; Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-(7CI,8CI); 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 2-Amidino-1,2,3,4-tetrahydroisoquinoline; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; 3,4-Dihydro-2(1H;)-isoquinoline carboxamidine sulfate; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; 3,4-dihydroisoquinoline-2(1H)-carboximidamide
DMC50ME	TC	Antihypertensive Agents
DMC50ME	DT	Small molecular drug
DMC50ME	PC	2966
DMC50ME	MW	175.23
DMC50ME	FM	C10H13N3
DMC50ME	IC	InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
DMC50ME	CS	C1CN(CC2=CC=CC=C21)C(=N)N
DMC50ME	IK	JWPGJSVJDAJRLW-UHFFFAOYSA-N
DMC50ME	IU	3,4-dihydro-1H-isoquinoline-2-carboximidamide
DMC50ME	CA	CAS 1131-64-2
DMC50ME	CB	CHEBI:34665
DMC50ME	DE	Hypertension

DMSBRUW	ID	DMSBRUW
DMSBRUW	DN	Decamethonium
DMSBRUW	HS	Approved
DMSBRUW	SN	Decamethonum; Syncurine; DECAMETHONIUM ION; AIDS351484; AIDS-351484; Decamethylenebis(trimethylammonium)bromide; Syncurine (TN); Syncurine (*dibromide salt*); Trimethyl-[10-(trimethylazaniumyl)decyl]azanium; C 10 (VAN) (*dibromide salt*); N,N,N,N',N',N'-hexamethyldecane-1,10-diaminium; (DM)Br2; 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-(9CI); 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-, dibromide
DMSBRUW	TC	Neuromuscular Depolarizing Agents
DMSBRUW	DT	Small molecular drug
DMSBRUW	PC	2968
DMSBRUW	MW	258.49
DMSBRUW	FM	C16H38N2+2
DMSBRUW	IC	InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2
DMSBRUW	CS	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
DMSBRUW	IK	MTCUAOILFDZKCO-UHFFFAOYSA-N
DMSBRUW	IU	trimethyl-[10-(trimethylazaniumyl)decyl]azanium
DMSBRUW	CA	CAS 156-74-1
DMSBRUW	CB	CHEBI:41934
DMSBRUW	DE	Muscle spasm

DMQL8XJ	ID	DMQL8XJ
DMQL8XJ	DN	Decitabine
DMQL8XJ	HS	Approved
DMQL8XJ	SN	AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2&prime;-Deoxycytidine; 5-Aza-2'-deoxycytidine; 5-Azadeoxycytidine; 5-Deoxy-2&prime;-azacytidine; 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc
DMQL8XJ	TC	Anticancer Agents
DMQL8XJ	DT	Small molecular drug
DMQL8XJ	PC	451668
DMQL8XJ	MW	228.21
DMQL8XJ	FM	C8H12N4O4
DMQL8XJ	IC	InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
DMQL8XJ	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O
DMQL8XJ	IK	XAUDJQYHKZQPEU-KVQBGUIXSA-N
DMQL8XJ	IU	4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
DMQL8XJ	CA	CAS 2353-33-5
DMQL8XJ	CB	CHEBI:50131
DMQL8XJ	DE	Myelodysplastic syndrome

DM6ETS0	ID	DM6ETS0
DM6ETS0	DN	Deferasirox
DM6ETS0	HS	Approved
DM6ETS0	SN	Deferasirox; Deferasirox (Exjade); Deferasiroxum; Deferasiroxum [INN-Latin]; Exjade; V8G4MOF2V9; 201530-41-8; 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid; 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid; 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-; C21H15N3O4; CGP-72670; CHEBI:49005; DSSTox_CID_28522; DSSTox_RID_82794; ICL 670; ICL 670A; ICL-670; ICL-670A; ICL670; ICL670A; NCGC00181754-01; UNII-V8G4MOF2V9
DM6ETS0	PC	214348
DM6ETS0	MW	373.4
DM6ETS0	FM	C21H15N3O4
DM6ETS0	IC	BOFQWVMAQOTZIW-UHFFFAOYSA-N
DM6ETS0	CS	C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0	IK	C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0	IU	4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
DM6ETS0	CA	C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0	CB	CHEBI:49005
DM6ETS0	DE	Hyperphosphatemia

DMS2M7O	ID	DMS2M7O
DMS2M7O	DN	Deferiprone
DMS2M7O	HS	Approved
DMS2M7O	SN	Ferriprox (TN)
DMS2M7O	CP	ApoPharma
DMS2M7O	DT	Small molecular drug
DMS2M7O	PC	2972
DMS2M7O	MW	139.15
DMS2M7O	FM	C7H9NO2
DMS2M7O	IC	InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
DMS2M7O	CS	CC1=C(C(=O)C=CN1C)O
DMS2M7O	IK	TZXKOCQBRNJULO-UHFFFAOYSA-N
DMS2M7O	IU	3-hydroxy-1,2-dimethylpyridin-4-one
DMS2M7O	CA	CAS 30652-11-0
DMS2M7O	CB	CHEBI:68554
DMS2M7O	DE	Thalassemia

DMTUKZH	ID	DMTUKZH
DMTUKZH	DN	Deferoxamine mesylate
DMTUKZH	HS	Approved
DMTUKZH	SN	Desferal
DMTUKZH	CP	Novartis Pharmaceuticals Corp
DMTUKZH	DT	Small molecular drug
DMTUKZH	PC	62881
DMTUKZH	MW	656.8
DMTUKZH	FM	C26H52N6O11S
DMTUKZH	IC	InChI=1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4)
DMTUKZH	CS	CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O
DMTUKZH	IK	IDDIJAWJANBQLJ-UHFFFAOYSA-N
DMTUKZH	IU	N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;methanesulfonic acid
DMTUKZH	CA	CAS 138-14-7
DMTUKZH	CB	CHEBI:31460
DMTUKZH	DE	Acute iron or aluminum toxicity

DMV0RNS	ID	DMV0RNS
DMV0RNS	DN	Deflazacort
DMV0RNS	HS	Approved
DMV0RNS	SN	C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); D09WYX; AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927
DMV0RNS	CP	PTC Therapeutics
DMV0RNS	DT	Small molecular drug
DMV0RNS	PC	189821
DMV0RNS	MW	441.5
DMV0RNS	FM	C25H31NO6
DMV0RNS	IC	InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
DMV0RNS	CS	CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C
DMV0RNS	IK	FBHSPRKOSMHSIF-GRMWVWQJSA-N
DMV0RNS	IU	[2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate
DMV0RNS	CA	CAS 14484-47-0
DMV0RNS	CB	CHEBI:135720
DMV0RNS	DE	Duchenne dystrophy

DM3O8QY	ID	DM3O8QY
DM3O8QY	DN	Degarelix
DM3O8QY	HS	Approved
DM3O8QY	SN	Degarelix; 214766-78-6; UNII-SX0XJI3A11; SX0XJI3A11; CHEMBL415606; Uglypeptide1; Degarelix (INN/USAN); Degarelix [USAN:INN:BAN]; SCHEMBL1397034; GTPL5585; HSDB 7817; CHEBI:135961; HY-16168A; BDBM50102450; AKOS030526717; AN-5181; RL02641; DB06699; CS-5350; FE200486 (AS ACETATE SALT); QC-10170; Z-3147; D08901; 766D786; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2
DM3O8QY	DT	Small molecular drug
DM3O8QY	PC	16136245
DM3O8QY	MW	1632.3
DM3O8QY	FM	C82H103ClN18O16
DM3O8QY	IC	InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1
DM3O8QY	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DM3O8QY	IK	MEUCPCLKGZSHTA-XYAYPHGZSA-N
DM3O8QY	IU	(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DM3O8QY	CA	CAS 214766-78-6
DM3O8QY	CB	CHEBI:135961
DM3O8QY	DE	Prostate cancer

DM4Q80H	ID	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	HS	Approved
DM4Q80H	SN	Prasterone sulfate; DHEA sulfate; DEHYDROEPIANDROSTERONE SULFATE; Dehydroisoandrosterone sulfate; DHEAS; Dehydroepiandrosterone sulphate; Dehydroepiandrosterone monosulfate; 3-O-Sulfodehydroepiandrosterone; Dehydroepiandrosterone 3-sulfate; Dehydroandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; 17-Ketoandrost-5-en-3beta-yl sulfate; DHEA-S; Androst-5-en-17-on-3beta-yl sulfuric acid; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; CCRIS 6746; (3-beta)-3-(Sulfooxy)androst-5-en-17-one; DHEA sulphate
DM4Q80H	PC	12594
DM4Q80H	MW	368.5
DM4Q80H	FM	C19H28O5S
DM4Q80H	IC	InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1
DM4Q80H	CS	CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C
DM4Q80H	IK	CZWCKYRVOZZJNM-USOAJAOKSA-N
DM4Q80H	IU	[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DM4Q80H	CA	CAS 651-48-9
DM4Q80H	CB	CHEBI:16814
DM4Q80H	DE	Dyspareunia

DMVTU5Q	ID	DMVTU5Q
DMVTU5Q	DN	Delafloxacin Meglumine
DMVTU5Q	HS	Approved
DMVTU5Q	SN	Baxdela
DMVTU5Q	CP	Melinta Therapeutics
DMVTU5Q	DT	Small molecular drug
DMVTU5Q	PC	11578213
DMVTU5Q	MW	636
DMVTU5Q	FM	C25H29ClF3N5O9
DMVTU5Q	IC	InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
DMVTU5Q	CS	CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O
DMVTU5Q	IK	AHJGUEMIZPMAMR-WZTVWXICSA-N
DMVTU5Q	IU	1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
DMVTU5Q	CA	CAS 352458-37-8
DMVTU5Q	DE	Acute bacterial skin infection; Skin infection

DMXE76K	ID	DMXE76K
DMXE76K	DN	Delamanid
DMXE76K	HS	Approved
DMXE76K	SN	OPC-67683; Nitro-dihydroimidazo-oxazole derivatives (tuberculosis), Otsuka; 2-nitroimidazole derivatives (tuberculosis), Otsuka
DMXE76K	CP	Otsuka pharmaceutical
DMXE76K	DT	Small molecular drug
DMXE76K	PC	6480466
DMXE76K	MW	534.5
DMXE76K	FM	C25H25F3N4O6
DMXE76K	IC	InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1
DMXE76K	CS	C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F
DMXE76K	IK	XDAOLTSRNUSPPH-XMMPIXPASA-N
DMXE76K	IU	(2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole
DMXE76K	CA	CAS 681492-22-8
DMXE76K	CB	CHEBI:134742
DMXE76K	DE	Mycobacterium infection; Multi-drug resistant tuberculosis

DM7EUK3	ID	DM7EUK3
DM7EUK3	DN	Delapril
DM7EUK3	HS	Approved
DM7EUK3	SN	Adecut (TN)
DM7EUK3	CP	Takeda
DM7EUK3	DT	Small molecular drug
DM7EUK3	PC	5362116
DM7EUK3	MW	452.5
DM7EUK3	FM	C26H32N2O5
DM7EUK3	IC	InChI=1S/C26H32N2O5/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30)/t18-,23-/m0/s1
DM7EUK3	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2
DM7EUK3	IK	WOUOLAUOZXOLJQ-MBSDFSHPSA-N
DM7EUK3	IU	2-[2,3-dihydro-1H-inden-2-yl-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]amino]acetic acid
DM7EUK3	CA	CAS 83435-66-9
DM7EUK3	CB	CHEBI:135735
DM7EUK3	DE	Cardiovascular disease

DM3NF5G	ID	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	HS	Approved
DM3NF5G	SN	DLV; Rescriptor; SPP; DELAVIRDINE MESYLATE; Delavirdine [INN]; U 90152; BHAP-U 90152; Delavirdine (INN); Rescriptor (TM);Rescriptor (TN); U-90152; U-90152S; PNU-90152-T; Delavirdine (*Mesylate salt*); U90152S (*Mesylate salt*); Delavirdine(U-90152) & .a.IFN; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon; (1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
DM3NF5G	CP	Pfizer Pharmaceuticals
DM3NF5G	TC	Anti-HIV Agents
DM3NF5G	DT	Small molecular drug
DM3NF5G	PC	5625
DM3NF5G	MW	456.6
DM3NF5G	FM	C22H28N6O3S
DM3NF5G	IC	InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3
DM3NF5G	CS	CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C
DM3NF5G	IK	WHBIGIKBNXZKFE-UHFFFAOYSA-N
DM3NF5G	IU	N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
DM3NF5G	CA	CAS 136817-59-9
DM3NF5G	CB	CHEBI:119573
DM3NF5G	DE	Human immunodeficiency virus infection

DMAYEU1	ID	DMAYEU1
DMAYEU1	DN	Demecarium bromide
DMAYEU1	HS	Approved
DMAYEU1	SN	Demecarium; Demecastigmine; Frumtosnil; Humorsol; Tonilen; Tosmicil; Tosmilen; Tosmilene; Visumatic; Visumiotic;Bromure de demecarium; Bromuro de demecario; Demecarii bromidum; Demekarium bromide; Demekastigmine bromide; BC 48; Bromure de demecarium [INN-French]; Bromuro de demecario [INN-Spanish]; Demecarii bromidum [INN-Latin]; Demecarium bromide [INN:BAN]; Humorsol (TN); Decamethylenebis[m-dimethylaminophenyl n-methylcarbamate] dimethobromide; Demecarium bromide (USP/INN); Decamethylenebis(N-methylcarbamic acid m-dimethylaminophenyl ester) bromomethylate; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate) dimethobromide; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate)dimethobromide;Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate); Trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium dibromide; Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate) (2:1); N,N'-Bis(3-trimethylammoniumphenoxycarbonyl)-N,N'-dimethyldecamethylenediamine dibromide; Benzenaminium,3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(N,N,N-trimethyl-, dibromide; (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (2:1); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (7CI); 3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(N,N,N-trimethylanilinium) dibromide
DMAYEU1	TC	Parasympathomimetics
DMAYEU1	DT	Small molecular drug
DMAYEU1	PC	5965
DMAYEU1	MW	716.6
DMAYEU1	FM	C32H52Br2N4O4
DMAYEU1	IC	InChI=1S/C32H52N4O4.2BrH/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8;;/h17-22,25-26H,9-16,23-24H2,1-8H3;2*1H/q+2;;/p-2
DMAYEU1	CS	CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-].[Br-]
DMAYEU1	IK	YHKBUDZECQDYBR-UHFFFAOYSA-L
DMAYEU1	IU	trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium;dibromide
DMAYEU1	CA	CAS 56-94-0
DMAYEU1	CB	CHEBI:4391
DMAYEU1	DE	Open-angle glaucoma

DMZEPFJ	ID	DMZEPFJ
DMZEPFJ	DN	Demeclocycline
DMZEPFJ	HS	Approved
DMZEPFJ	SN	Bioterciclin; Clortetrin; DMCT; DMCTC; Declomycin; Deganol; Demeclociclina; Demeclocyclinum; Demeclor; Demethylchlorotetracycline; Demethylchlortetracyclin; Demethylchlortetracycline; Demethylchlortetracyclinum; Demetraclin; Diuciclin; Ledermycin; Methylchlorotetracycline; Mexocine; Novotriclina; Perciclina; Sumaclina; Demeclocycline Monohydrochloride; Demethylchlortetracycline base; Ledermycin hydrochloride; RP 10192; DMCT (antibiotic); Declomycin (TN); Declostatin (TN); Demeclociclina [INN-Spanish]; Demeclocycline (USP); Demeclocycline [USAN:BAN]; Demeclocyclinum [INN-Latin]; Demethylchlortetracycline (JAN); Ledermycin (TN); Tri-demethylchlortetracycline; [4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (2E)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6R,12aR)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; 6-Demethyl-7-chlorotetracycline; 6-Demethyl-7-chlortetracycline; 6-Demethylchlorotetracycline; 6-Demethylchlortetracycline; 6-Demetil-7-clorotetraciclina; 6-Demetil-7-clorotetraciclina [Italian]; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide; 7-Chloro-6-demethyltetracycline
DMZEPFJ	CP	Patheon Pharmaceuticals Inc
DMZEPFJ	TC	Antibiotics
DMZEPFJ	DT	Small molecular drug
DMZEPFJ	PC	54680690
DMZEPFJ	MW	464.9
DMZEPFJ	FM	C21H21ClN2O8
DMZEPFJ	IC	InChI=1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-27,30,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1
DMZEPFJ	CS	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O
DMZEPFJ	IK	GUXHBMASAHGULD-SEYHBJAFSA-N
DMZEPFJ	IU	(4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMZEPFJ	CA	CAS 127-33-3
DMZEPFJ	CB	CHEBI:4392
DMZEPFJ	DE	Bronchitis; Acne vulgaris; Lyme disease

DMCZQGK	ID	DMCZQGK
DMCZQGK	DN	Demecolcine
DMCZQGK	HS	Approved
DMCZQGK	SN	colcemid; 1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one; demecolcine,colcemid, n-deacetyl-n-methylcolchicine, n-methyl-n-desacetylcolchicine; Demicolcine; NSC3096; 1,2,3,10-Tetramethoxy-7-(methylamino)-6,7-dihydrobenzo[a]heptalen-9(5H)-one; NCGC00166035-01; AC1L1EKK; MolMap_000011; SCHEMBL8160; AC1Q698E; CHEMBL433632; CTK8E8505; MolPort-003-846-192; 6,7-Dihydro-1,2,3,10-Tetramethoxy-7-(Methylamino) Benzo (alpha) Heptalen-9(5H)-one; HMS3374M04; HSCI1_000384; BBL027927; STL377913; CD0013
DMCZQGK	DT	Small molecular drug
DMCZQGK	PC	220401
DMCZQGK	MW	371.4
DMCZQGK	FM	C21H25NO5
DMCZQGK	IC	InChI=1S/C21H25NO5/c1-22-15-8-6-12-10-18(25-3)20(26-4)21(27-5)19(12)13-7-9-17(24-2)16(23)11-14(13)15/h7,9-11,15,22H,6,8H2,1-5H3/t15-/m0/s1
DMCZQGK	CS	CN[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
DMCZQGK	IK	NNJPGOLRFBJNIW-HNNXBMFYSA-N
DMCZQGK	IU	(7S)-1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one
DMCZQGK	CA	CAS 477-30-5
DMCZQGK	CB	CHEBI:4393
DMCZQGK	DE	Solid tumour/cancer

DMMHR1U	ID	DMMHR1U
DMMHR1U	DN	Denileukin diftitox
DMMHR1U	HS	Approved
DMMHR1U	CP	Louisville
DMMHR1U	TC	Anticancer Agents
DMMHR1U	SQ	DB00004 sequence: MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
DMMHR1U	DE	leukaemia; Non-small-cell lung cancer

DM8C3GN	ID	DM8C3GN
DM8C3GN	DN	Denopamine
DM8C3GN	HS	Approved
DM8C3GN	SN	Kalgut (TN)
DM8C3GN	DT	Small molecular drug
DM8C3GN	PC	5311064
DM8C3GN	MW	317.4
DM8C3GN	FM	C18H23NO4
DM8C3GN	IC	InChI=1S/C18H23NO4/c1-22-17-8-3-13(11-18(17)23-2)9-10-19-12-16(21)14-4-6-15(20)7-5-14/h3-8,11,16,19-21H,9-10,12H2,1-2H3/t16-/m0/s1
DM8C3GN	CS	COC1=C(C=C(C=C1)CCNC[C@@H](C2=CC=C(C=C2)O)O)OC
DM8C3GN	IK	VHSBBVZJABQOSG-INIZCTEOSA-N
DM8C3GN	IU	4-[(1R)-2-[2-(3,4-dimethoxyphenyl)ethylamino]-1-hydroxyethyl]phenol
DM8C3GN	CA	CAS 71771-90-9
DM8C3GN	CB	CHEBI:135359
DM8C3GN	DE	Cardiac disease

DMNI0KO	ID	DMNI0KO
DMNI0KO	DN	Denosumab
DMNI0KO	HS	Approved
DMNI0KO	SN	Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)
DMNI0KO	CP	Amgen
DMNI0KO	DT	Antibody
DMNI0KO	SQ	Denosumab OPGL-1 heavy chain sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt; Denosumab OPGL-1 light chain sequenceEIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMNI0KO	DE	Postmenopausal osteoporosis; Rheumatoid arthritis; Prostate cancer

DM3GYAL	ID	DM3GYAL
DM3GYAL	DN	Deoxycholic acid
DM3GYAL	HS	Approved
DM3GYAL	SN	(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-oic acid; 3,12-Dihydroxycholanic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 5-beta-Deoxycholic acid; 7-Deoxycholic acid; 7alpha-Deoxycholic acid; ATX-101; Choleic acid; Cholerebic; Cholic acid, deoxy-; Cholorebic; DEOXYCHOLIC ACID; Degalol; Deoxy cholic acid; Deoxycholatic acid; Desoxycholic acid; Desoxycholsaeure; Dihydroxycholanoic acid; Droxolan; Pyrochol; Septochol; Sodium deoxycholate; deoxycholate
DM3GYAL	DT	Small molecular drug
DM3GYAL	PC	222528
DM3GYAL	MW	392.58
DM3GYAL	FM	C24H40O4
DM3GYAL	IC	InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
DM3GYAL	CS	CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C
DM3GYAL	IK	KXGVEGMKQFWNSR-LLQZFEROSA-N
DM3GYAL	IU	(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM3GYAL	CA	CAS 83-44-3
DM3GYAL	CB	CHEBI:28834
DM3GYAL	DE	Fat below the chin

DMYE5LJ	ID	DMYE5LJ
DMYE5LJ	DN	DEOXYCYTIDINE
DMYE5LJ	HS	Approved
DMYE5LJ	SN	Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993
DMYE5LJ	DT	Small molecular drug
DMYE5LJ	PC	13711
DMYE5LJ	MW	227.22
DMYE5LJ	FM	C9H13N3O4
DMYE5LJ	IC	InChI=1S/C9H13N3O4/c10-7-1-2-12(9(15)11-7)8-3-5(14)6(4-13)16-8/h1-2,5-6,8,13-14H,3-4H2,(H2,10,11,15)/t5-,6+,8+/m0/s1
DMYE5LJ	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O
DMYE5LJ	IK	CKTSBUTUHBMZGZ-SHYZEUOFSA-N
DMYE5LJ	IU	4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMYE5LJ	CA	CAS 951-77-9
DMYE5LJ	CB	CHEBI:15698
DMYE5LJ	DE	Acute myeloid leukaemia

DMRH7CV	ID	DMRH7CV
DMRH7CV	DN	Deserpidine
DMRH7CV	HS	Approved
DMRH7CV	SN	Canescin; Canescine; Deresperine; Desepridine; Deserpidin; Deserpidina; Deserpidinum; Desmethoxyreserpine; Halmonyl; Harmonyl; Raunormin; Raunormine; Recanescin; Recanescine; Reserpidine; Tranquinil; Lilly 22641; ORETICYL 50; A-11025; Deserpidina [INN-Spanish]; Deserpidine (INN); Deserpidine [INN:BAN]; Deserpidinum [INN-Latin]; Halmonyl (TN); MD-0232; Deserpidic acid, methyl ester, 3,4,5-trimethoxybenzoate; Methyl 17alpha-methoxy-18beta-(3,4,5-trimethoxybenzoyloxy)-3beta,20alpha-yohimban-16beta-carboxylat; Methyl 17alpha-methoxy-18beta-((3,4,5-trimethoxybenzoyl)oxy)-3beta,20alpha-yohimban-16beta-carboxylate; Methyl 18beta-hydroxy-17alpha-methoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester); Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate; Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate; Benz[g]indolo[2,3-a]quinolizine-1-carboxylic acid, 1,2,3,4,4a,5,7,8,-13,13b,14,14a-dodecahydro-3-hydroxy-2-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate; (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; 11-Demethoxyreserpine; 11-Desmethoxyreserpine; 17.alpha.-Methoxy-18.beta.-[(3,4,5-trimethoxybenzoyl)oxy]-3.beta.,20.alpha.-yohimban-16.beta.-carboxylic acid methyl ester; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester); 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester)
DMRH7CV	TC	Antihypertensive Agents
DMRH7CV	DT	Small molecular drug
DMRH7CV	PC	8550
DMRH7CV	MW	578.7
DMRH7CV	FM	C32H38N2O8
DMRH7CV	IC	InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1
DMRH7CV	CS	CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
DMRH7CV	IK	CVBMAZKKCSYWQR-WCGOZPBSSA-N
DMRH7CV	IU	methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMRH7CV	CA	CAS 131-01-1
DMRH7CV	CB	CHEBI:27478
DMRH7CV	DE	Hypertension

DM2TO9R	ID	DM2TO9R
DM2TO9R	DN	Desflurane
DM2TO9R	HS	Approved
DM2TO9R	SN	Desflurano; Desfluranum; Suprane; I 653; I653; PC6781E; Desflurane [USAN:INN]; Desflurano [INN-Spanish]; Desfluranum [INN-Latin]; I-653; R-e 236ea1; Suprane (TN); Desflurane (JAN/USP/INN); Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane; 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
DM2TO9R	TC	Anesthetics
DM2TO9R	DT	Small molecular drug
DM2TO9R	PC	42113
DM2TO9R	MW	168.04
DM2TO9R	FM	C3H2F6O
DM2TO9R	IC	InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H
DM2TO9R	CS	C(C(F)(F)F)(OC(F)F)F
DM2TO9R	IK	DPYMFVXJLLWWEU-UHFFFAOYSA-N
DM2TO9R	IU	2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
DM2TO9R	CA	CAS 57041-67-5
DM2TO9R	CB	CHEBI:4445
DM2TO9R	DE	Anaesthesia

DMT2FDC	ID	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	HS	Approved
DMT2FDC	SN	Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipraminum; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; Norimipramine; Norpramine; Pentofran; Pertrofane; Sertofran; Desipramine Hcl; DMI 50475; DMI (pharmaceutical); Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Norpramin (TN); Pertofrane (TN); ZERO/006017; N-(3-Methylaminopropyl)iminobibenzyl; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl
DMT2FDC	CP	Sanofi Aventis Us Llc
DMT2FDC	TC	Antidepressants
DMT2FDC	DT	Small molecular drug
DMT2FDC	PC	2995
DMT2FDC	MW	266.4
DMT2FDC	FM	C18H22N2
DMT2FDC	IC	InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
DMT2FDC	CS	CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
DMT2FDC	IK	HCYAFALTSJYZDH-UHFFFAOYSA-N
DMT2FDC	IU	3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
DMT2FDC	CA	CAS 50-47-5
DMT2FDC	CB	CHEBI:47781
DMT2FDC	DE	Attention deficit hyperactivity disorder; Depression

DM2BTFN	ID	DM2BTFN
DM2BTFN	DN	Desirudin Recombinant
DM2BTFN	HS	Approved
DM2BTFN	SN	Iprivask
DM2BTFN	CP	Valeant Pharmaceuticals North America Llc
DM2BTFN	TC	Cardiovascular Agents
DM2BTFN	DE	Coagulation defect

DMB3ZSK	ID	DMB3ZSK
DMB3ZSK	DN	Deslanoside
DMB3ZSK	HS	Approved
DMB3ZSK	SN	Ceglunat; Desace; Deslanosido; Deslanosidum; Glucodigoxin; Lekozid; Sediranido; Deacetyllanatoside C; DesacetylLanatoside; Desacetyldigilanide C; Desacetyllanatoside C; Deslanatoside C; Deslanosidum C; Lanatosid C; Cedilanid-D; Desacetyl-Lanatoside C; Deslanosido [INN-Spanish]; Deslanosidum [INN-Latin]; Cedilanid-d (TN); Deslanoside (JP15/USP/INN); Deslanoside [USAN:BAN:INN:JAN]; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
DMB3ZSK	TC	Antiarrhythmic Agents
DMB3ZSK	DT	Small molecular drug
DMB3ZSK	PC	28620
DMB3ZSK	MW	943.1
DMB3ZSK	FM	C47H74O19
DMB3ZSK	IC	InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
DMB3ZSK	CS	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O
DMB3ZSK	IK	OBATZBGFDSVCJD-LALPQLPRSA-N
DMB3ZSK	IU	3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMB3ZSK	CA	CAS 17598-65-1
DMB3ZSK	CB	CHEBI:31468
DMB3ZSK	DE	Heart failure; Arrhythmia; Congestive cardiac insufficiency

DM56YN7	ID	DM56YN7
DM56YN7	DN	Desloratadine
DM56YN7	HS	Approved
DM56YN7	SN	Aerius; Allex; Azomyr; Claramax; Clarinex; Denosin; Desalex; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratidine; Neoclarityn; Opulis; Clarinex RediTabs; Desloratadine [USAN]; Essex brand of desloratadine; Schering brand of desloratadine; Sch 34117; Aerius (TN); Claramax (TN); Clarinex (TN); NeoClarityn (TN); Sch-34117; Schering-Plough brand of desloratadine; Desloratadine (USAN/INN); 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
DM56YN7	CP	Schering-Plough
DM56YN7	TC	Antiallergic Agents
DM56YN7	DT	Small molecular drug
DM56YN7	PC	124087
DM56YN7	MW	310.8
DM56YN7	FM	C19H19ClN2
DM56YN7	IC	InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
DM56YN7	CS	C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
DM56YN7	IK	JAUOIFJMECXRGI-UHFFFAOYSA-N
DM56YN7	IU	13-chloro-2-piperidin-4-ylidene-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
DM56YN7	CA	CAS 100643-71-8
DM56YN7	CB	CHEBI:291342
DM56YN7	DE	Allergic rhinitis

DMS3GVE	ID	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	HS	Approved
DMS3GVE	SN	Ddavp; DESMOPRESSIN; DDAVP; dAVP; Minirin; Adiuretin SD; Noctiva; Adiuretin; Deamino Arginine Vasopressin; Desmopressinum; deamino-vasopressin; [deamino1]AVP; Desmopressin [INN:BAN]; [deamino-Cys1]AVP; Desmopressinum [INN-Latin]; Desmopressine [INN-French]; Desmopresina [INN-Spanish]; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; desnopressin; Vasopressin, Deamino Arginine; EINECS 240-726-7; 1-Desamino-8-D-arginine vasopressin; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin;  Desmopressin Melt; Minrin Melt; FE-992026; Desmopressin (fast-dissolving, nocturia/diabetes insipidus); Desmopressin (fast-dissolving, nocturia/diabetes insipidus), Ferring Pharmaceuticals
DMS3GVE	CP	Ferring Pharmaceuticals Inc
DMS3GVE	DT	Small molecular drug
DMS3GVE	PC	5311065
DMS3GVE	MW	1069.2
DMS3GVE	FM	C46H64N14O12S2
DMS3GVE	IC	InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1
DMS3GVE	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMS3GVE	IK	NFLWUMRGJYTJIN-PNIOQBSNSA-N
DMS3GVE	IU	(2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMS3GVE	CA	CAS 16679-58-6
DMS3GVE	CB	CHEBI:4450
DMS3GVE	DE	Diabetic complication

DM27U4Y	ID	DM27U4Y
DM27U4Y	DN	Desogestrel
DM27U4Y	HS	Approved
DM27U4Y	SN	Cerazette; Desogen; Desogestrelum; Organon Brand of Desogestrel; ORG 2969; Desogestrelum [INN-Latin]; Desogestrel (USAN/INN); Desogestrel [USAN:BAN:INN]; Alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17; (17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol; (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol; 13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol; 13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol; 13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol; 17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol
DM27U4Y	TC	Contraceptive Agents
DM27U4Y	DT	Small molecular drug
DM27U4Y	PC	40973
DM27U4Y	MW	310.5
DM27U4Y	FM	C22H30O
DM27U4Y	IC	InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
DM27U4Y	CS	CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34
DM27U4Y	IK	RPLCPCMSCLEKRS-BPIQYHPVSA-N
DM27U4Y	IU	(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
DM27U4Y	CA	CAS 54024-22-5
DM27U4Y	CB	CHEBI:4453
DM27U4Y	DE	Contraception

DMTP2NJ	ID	DMTP2NJ
DMTP2NJ	DN	Desonide
DMTP2NJ	HS	Approved
DMTP2NJ	SN	Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide
DMTP2NJ	TC	Antiinflammatory Agents
DMTP2NJ	DT	Small molecular drug
DMTP2NJ	PC	5311066
DMTP2NJ	MW	416.5
DMTP2NJ	FM	C24H32O6
DMTP2NJ	IC	InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMTP2NJ	CS	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O
DMTP2NJ	IK	WBGKWQHBNHJJPZ-LECWWXJVSA-N
DMTP2NJ	IU	(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMTP2NJ	CA	CAS 638-94-8
DMTP2NJ	CB	CHEBI:204734
DMTP2NJ	DE	Atopic dermatitis

DM4PXF6	ID	DM4PXF6
DM4PXF6	DN	Desoximetasone
DM4PXF6	HS	Approved
DM4PXF6	SN	Desoximetasona; Desoximetasonum; Topicort; HOE-304; R-2113; Topicort (TN); Topicort Emollient (TN); A-41-304; Desoximetasone (USP/INN); (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9alpha-fluoro-16alpha-methyl-Delta(1)-corticosterone
DM4PXF6	TC	Antiinflammatory Agents
DM4PXF6	DT	Small molecular drug
DM4PXF6	PC	5311067
DM4PXF6	MW	376.5
DM4PXF6	FM	C22H29FO4
DM4PXF6	IC	InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1
DM4PXF6	CS	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C
DM4PXF6	IK	VWVSBHGCDBMOOT-IIEHVVJPSA-N
DM4PXF6	IU	(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM4PXF6	CA	CAS 140218-14-0
DM4PXF6	CB	CHEBI:691037
DM4PXF6	DE	Inflammation

DMS0AFE	ID	DMS0AFE
DMS0AFE	DN	Desoxycorticosterone acetate
DMS0AFE	HS	Approved
DMS0AFE	SN	Doca
DMS0AFE	CP	Organon Usa Inc
DMS0AFE	DT	Small molecular drug
DMS0AFE	PC	5952
DMS0AFE	MW	372.5
DMS0AFE	FM	C23H32O4
DMS0AFE	IC	InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1
DMS0AFE	CS	CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMS0AFE	IK	VPGRYOFKCNULNK-ACXQXYJUSA-N
DMS0AFE	IU	[2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DMS0AFE	CA	CAS 56-47-3
DMS0AFE	CB	CHEBI:34671
DMS0AFE	DE	Discovery agent

DMSA4B3	ID	DMSA4B3
DMSA4B3	DN	Desoxycorticosterone pivalate
DMSA4B3	HS	Approved
DMSA4B3	SN	DOCP; DTMA; Cortexone M; Deoxycorticosterone pivalate; Deoxycorticosterone trimethylacetate; Deoxycortolone Pivalate; Deoxycortone pivalate; Deoxycortone trimethylacetate; Desoxycorticosterone trimethylacetate; Desoxycortone pivalate; Percorten M; Percorten Pivalate; Desoxycorticosterone pivalate (USP); Neodin-depositum; Percorten (TN); Corticosterone, deoxy-, pivalate (6CI,7CI); [2-(10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] 2,2-dimethylpropanoate; 11-Deoxycorticosterone pivalate; 11-Deoxycorticosterone, pivalate; 11-Deoxycorticosterone, pivalate (8CI); 21-(2,2-Dimethyl-1-oxopropoxy)pregn-4-ene-3,20-dione; 3,20-dioxopregn-4-en-21-yl 2,2-dimethylpropanoate
DMSA4B3	TC	Antiaddison Agents
DMSA4B3	DT	Small molecular drug
DMSA4B3	PC	11876263
DMSA4B3	MW	414.6
DMSA4B3	FM	C26H38O4
DMSA4B3	IC	InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1
DMSA4B3	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CC[C@]34C
DMSA4B3	IK	VVOIQBFMTVCINR-WWMZEODYSA-N
DMSA4B3	IU	[2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
DMSA4B3	CA	CAS 808-48-0
DMSA4B3	CB	CHEBI:50782
DMSA4B3	DE	Addison disease

DMEZFXR	ID	DMEZFXR
DMEZFXR	DN	Desoxyribonuclease
DMEZFXR	HS	Approved
DMEZFXR	DE	Female genital tract inflammation

DMJE6KO	ID	DMJE6KO
DMJE6KO	DN	Desvenalfaxine succinate
DMJE6KO	HS	Approved
DMJE6KO	SN	386750-22-7; Desvenlafaxine succinate monohydrate; Desvenlafaxine (succinate hydrate); Desvenlafaxine succinate hydrate; Desvenlafaxine Succinate [USAN]; Desvenlafaxine succinate (USAN); O-desmethylvenlafaxine Succinate Monohydrate; Desvenlafaxine Succinate Monohydrate (O-Desmethylvenlafaxine Succinate Monohydrate); Pristiq (TN); AC1OCFPN; Desvenlafaxine(succinatehydrate); SCHEMBL1278407; CTK8E8387; HY-B0602A; MolPort-021-783-032
DMJE6KO	CP	Wyeth
DMJE6KO	DT	Small molecular drug
DMJE6KO	PC	6918664
DMJE6KO	MW	399.5
DMJE6KO	FM	C20H33NO7
DMJE6KO	IC	InChI=1S/C16H25NO2.C4H6O4.H2O/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;5-3(6)1-2-4(7)8;/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1-2H2,(H,5,6)(H,7,8);1H2
DMJE6KO	CS	CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O
DMJE6KO	IK	PWPDEXVGKDEKTE-UHFFFAOYSA-N
DMJE6KO	IU	butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol;hydrate
DMJE6KO	CA	CAS 386750-22-7
DMJE6KO	DE	Fibromyalgia

DMHD4PE	ID	DMHD4PE
DMHD4PE	DN	Desvenlafaxine
DMHD4PE	HS	Approved
DMHD4PE	SN	Norvenlafaxine; Desvenlafaxine (INN); Desvenlafaxine [INN:BAN]; O-Desmethylvenlafaxine; WY 45,233; O-DESMETHYLVENLAFAXINE (ODV); WY-45,233
DMHD4PE	CP	Wyeth
DMHD4PE	DT	Small molecular drug
DMHD4PE	PC	125017
DMHD4PE	MW	263.37
DMHD4PE	FM	C16H25NO2
DMHD4PE	IC	InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
DMHD4PE	CS	CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
DMHD4PE	IK	KYYIDSXMWOZKMP-UHFFFAOYSA-N
DMHD4PE	IU	4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
DMHD4PE	CA	CAS 93413-62-8
DMHD4PE	CB	CHEBI:83527
DMHD4PE	DE	Major depressive disorder; Menopause symptom

DMUPFLI	ID	DMUPFLI
DMUPFLI	DN	Deutetrabenazine
DMUPFLI	HS	Approved
DMUPFLI	SN	Dutetrabenazine; Austedo; SD809; SD-809; SD 809; 1392826-25-3; Deutetrabenazine [USAN:INN]
DMUPFLI	CP	Teva
DMUPFLI	DT	Small molecular drug
DMUPFLI	PC	73437646
DMUPFLI	MW	323.5
DMUPFLI	FM	C19H27NO3
DMUPFLI	IC	InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3
DMUPFLI	CS	[2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]
DMUPFLI	IK	MKJIEFSOBYUXJB-VFJJUKLQSA-N
DMUPFLI	IU	(3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMUPFLI	CA	CAS 1392826-25-3
DMUPFLI	DE	Tardive dyskinesia; Huntington disease

DMMWZET	ID	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	HS	Approved
DMMWZET	SN	Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone
DMMWZET	CP	Swiss Pharma
DMMWZET	TC	Antiinflammatory Agents
DMMWZET	DT	Small molecular drug
DMMWZET	PC	5743
DMMWZET	MW	392.5
DMMWZET	FM	C22H29FO5
DMMWZET	IC	InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
DMMWZET	CS	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
DMMWZET	IK	UREBDLICKHMUKA-CXSFZGCWSA-N
DMMWZET	IU	(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMMWZET	CA	CAS 50-02-2
DMMWZET	CB	CHEBI:41879
DMMWZET	DE	Rheumatoid arthritis

DMIG8DW	ID	DMIG8DW
DMIG8DW	DN	Dexamethasone sodium phosphate
DMIG8DW	HS	Approved
DMIG8DW	SN	EryDex; Dexamethasone sodium phosphate (erythrocyte encapsulated); Dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; Dex 21-P (red blood cell encapsulated), Urbino University/EryDel; Intra-erythrocyte dexamethasone (inflammatory diseases), Urbino University/EryDel
DMIG8DW	CP	Universita' Degli Studi Di Urbino
DMIG8DW	DT	Small molecular drug
DMIG8DW	PC	16961
DMIG8DW	MW	516.4
DMIG8DW	FM	C22H28FNa2O8P
DMIG8DW	IC	InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1
DMIG8DW	CS	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+]
DMIG8DW	IK	PLCQGRYPOISRTQ-FCJDYXGNSA-L
DMIG8DW	IU	disodium;[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate
DMIG8DW	CA	CAS 2392-39-4
DMIG8DW	CB	CHEBI:4462
DMIG8DW	DE	Ataxia-telangiectasia

DMKVWGE	ID	DMKVWGE
DMKVWGE	DN	Dexbrompheniramine
DMKVWGE	HS	Approved
DMKVWGE	SN	Dexbromfeniramina; Dexbrompheniraminum; Ilvin; Parabromodylamine; D-Brompheniramine; Dexbromfeniramina [INN-Spanish]; Dexbrompheniramine [INN:BAN]; Dexbrompheniraminum [INN-Latin]; N,N-Dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin; (3-p-Bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; (S)-(+)-brompheniramine; (S)-brompheniramine
DMKVWGE	CP	Schering Corp Sub Schering Plough Corp
DMKVWGE	TC	Antihistamines
DMKVWGE	DT	Small molecular drug
DMKVWGE	PC	16960
DMKVWGE	MW	319.24
DMKVWGE	FM	C16H19BrN2
DMKVWGE	IC	InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
DMKVWGE	CS	CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2
DMKVWGE	IK	ZDIGNSYAACHWNL-HNNXBMFYSA-N
DMKVWGE	IU	(3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMKVWGE	CA	CAS 132-21-8
DMKVWGE	CB	CHEBI:59269
DMKVWGE	DE	Hay fever

DMA8DPN	ID	DMA8DPN
DMA8DPN	DN	Dexchlorpheniramine maleate
DMA8DPN	HS	Approved
DMA8DPN	SN	Polaramine
DMA8DPN	CP	Schering Corp Sub Schering Plough Corp
DMA8DPN	DT	Small molecular drug
DMA8DPN	PC	5281070
DMA8DPN	MW	390.9
DMA8DPN	FM	C20H23ClN2O4
DMA8DPN	IC	InChI=1S/C16H19ClN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1
DMA8DPN	CS	CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\\C(=O)O)\\C(=O)O
DMA8DPN	IK	DBAKFASWICGISY-DASCVMRKSA-N
DMA8DPN	IU	(Z)-but-2-enedioic acid;(3S)-3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMA8DPN	CA	CAS 2438-32-6
DMA8DPN	CB	CHEBI:4465
DMA8DPN	DE	Rhinitis

DMFYBD0	ID	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	HS	Approved
DMFYBD0	SN	(S)-(+)-Ibuprofen; 51146-56-6; DEXIBUPROFEN; S(+)-Ibuprofen; (S)-2-(4-Isobutylphenyl)propanoic acid; (S)-Ibuprofen; d-Ibuproten; (S)-(+)-2-(4-Isobutylphenyl)propionic acid; (+)-(S)-p-Isobutylhydratropic acid; Seractil; (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid; (S)-(+)-4-Isobutyl-alpha-methylphenylacetic acid; UNII-671DKG7P5S; S-(+)-ibuprofen; (2S)-2-(4-isobutylphenyl)propanoic acid; CHEMBL175; 671DKG7P5S; CHEBI:43415; (S)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid; NCGC00016861-05
DMFYBD0	DT	Small molecular drug
DMFYBD0	PC	39912
DMFYBD0	MW	206.28
DMFYBD0	FM	C13H18O2
DMFYBD0	IC	InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
DMFYBD0	CS	C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
DMFYBD0	IK	HEFNNWSXXWATRW-JTQLQIEISA-N
DMFYBD0	IU	(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
DMFYBD0	CA	CAS 51146-56-6
DMFYBD0	CB	CHEBI:43415
DMFYBD0	DE	Ankylosing spondylitis

DM1DBV5	ID	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	HS	Approved
DM1DBV5	SN	dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; dexilant; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; UNII-UYE4T5I70X; TAK-390; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; AK170558; TAK-390MR; T-168390; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; Dexlansoprazole (INN/USAN);  Kapidex; KS-1075; Lansoprazole
DM1DBV5	CP	Takeda
DM1DBV5	DT	Small molecular drug
DM1DBV5	PC	9578005
DM1DBV5	MW	369.4
DM1DBV5	FM	C16H14F3N3O2S
DM1DBV5	IC	InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
DM1DBV5	CS	CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
DM1DBV5	IK	MJIHNNLFOKEZEW-RUZDIDTESA-N
DM1DBV5	IU	2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DM1DBV5	CA	CAS 138530-94-6
DM1DBV5	CB	CHEBI:135931
DM1DBV5	DE	Non-erosive gastro-esophageal reflux disease; Erosive esophagitis; Peptic ulcer; NSAID-associated gastric ulcer

DM93L4X	ID	DM93L4X
DM93L4X	DN	Dexmedetomidine
DM93L4X	HS	Approved
DM93L4X	SN	Dexmedetomidina; Dexmedetomidinum; MPV 1440; MPV-1440; Precedex (TN); Dexmedetomidine (USAN/INN); (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DM93L4X	CP	Hospira
DM93L4X	TC	Hypnotics and Sedatives
DM93L4X	DT	Small molecular drug
DM93L4X	PC	5311068
DM93L4X	MW	200.28
DM93L4X	FM	C13H16N2
DM93L4X	IC	InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1
DM93L4X	CS	CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C
DM93L4X	IK	CUHVIMMYOGQXCV-NSHDSACASA-N
DM93L4X	IU	5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DM93L4X	CA	CAS 113775-47-6
DM93L4X	CB	CHEBI:4466
DM93L4X	DE	Irritability

DMUQE2A	ID	DMUQE2A
DMUQE2A	DN	Dexmethylphenidate
DMUQE2A	HS	Approved
DMUQE2A	SN	Dexmethylphenidate; Dexmethylphenidate (INN); Dexmethylphenidate [INN]; Focalin; Focalin XR; M32RH9MFGP; Methyl D-phenidate; d-Methylphenidate; Attenade; Dex methylphenidate; d-threo-Methylphenidate; dex-methylphenidate; dexmethylphenidatum; dexmetilfenidato; threo-(+)-Methylphenidate; (+)-threo-Methylphenidate; 40431-64-9; CHEBI:51860; CHEMBL827; D-MPH; D-TMP; UNII-M32RH9MFGP; methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate; methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate; methyl (R)-phenyl[(R)-piperidin-2-yl]acetate
DMUQE2A	PC	154101
DMUQE2A	MW	233.31
DMUQE2A	FM	C14H19NO2
DMUQE2A	IC	DUGOZIWVEXMGBE-CHWSQXEVSA-N
DMUQE2A	CS	COC(=O)C(C1CCCCN1)C2=CC=CC=C2
DMUQE2A	IK	1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1
DMUQE2A	IU	methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate
DMUQE2A	CA	CAS 40431-64-9
DMUQE2A	CB	CHEBI:51860
DMUQE2A	DE	Attention deficit hyperactivity disorder

DM8WBAH	ID	DM8WBAH
DM8WBAH	DN	Dexmethylphenidate hydrochloride
DM8WBAH	HS	Approved
DM8WBAH	SN	Dexmethylphenidate hydrochloride; Focalin; D-threo-Methylphenidate hydrochloride; Dexmethylphenidate HCl; Focalin XR; UNII-1678OK0E08; Dexmethylphenidate hydrochloride [USAN]; 19262-68-1; 1678OK0E08; 23655-65-4; CHEMBL904; Methyl (2R)-phenyl((2R)-piperidin-2-yl)acetate hydrochloride; dl-threo-Methylphenidate Hydrochloride; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R-(R*,R*))-; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (alphaR,2R)-; Dexmethylphenidate; NWP06
DM8WBAH	DT	Small molecular drug
DM8WBAH	PC	154100
DM8WBAH	MW	269.77
DM8WBAH	FM	C14H20ClNO2
DM8WBAH	IC	InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1
DM8WBAH	CS	COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2.Cl
DM8WBAH	IK	JUMYIBMBTDDLNG-OJERSXHUSA-N
DM8WBAH	IU	methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate;hydrochloride
DM8WBAH	CA	CAS 19262-68-1
DM8WBAH	DE	Attention deficit hyperactivity disorder

DMD7X1O	ID	DMD7X1O
DMD7X1O	DN	Dexrazoxane
DMD7X1O	HS	Approved
DMD7X1O	SN	24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dexrazoxano; Dexrazoxanum; Dextrorazoxane; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; Desrazoxane; Eucardion; ADR 529; ICRF 187; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazone; ADR-529; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; HSDB 7319; UNII-048L81261F; NSC169780; dyzoxane; BRN 5759131; CHEBI:50223; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; NSC 169780; AK-72797; Razoxanum;  Cardioxane; Dyzoxane; Savene; TopoTect; Totect; Dexrazoxane HCl; Dexrazoxane hydrochloride; ICRF 187 hydrochloride; Cardioxane (TN); Dexrazoxane (TN); Totect (TN); Zinecard (TN); Dexrazoxane (USAN/INN); Dexrazoxane [USAN:BAN:INN]; Soluble ICRF (L-isosomer); Razoxane, (S)-Isomer; Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride;(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-(9CI); 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride; Icrf-187
DMD7X1O	CP	Pfizer Pharmaceuticals
DMD7X1O	TC	Anticancer Agents
DMD7X1O	DT	Small molecular drug
DMD7X1O	PC	71384
DMD7X1O	MW	268.27
DMD7X1O	FM	C11H16N4O4
DMD7X1O	IC	InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1
DMD7X1O	CS	C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
DMD7X1O	IK	BMKDZUISNHGIBY-ZETCQYMHSA-N
DMD7X1O	IU	4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
DMD7X1O	CA	CAS 24584-09-6
DMD7X1O	CB	CHEBI:50223
DMD7X1O	DE	Breast cancer; Chemoprotection; Respiratory tract disease

DMMIHVP	ID	DMMIHVP
DMMIHVP	DN	Dextroamphetamine
DMMIHVP	HS	Approved
DMMIHVP	SN	D-Amphetamine; dextroamphetamine; Dexamphetamine; Dexamfetamine; (S)-Amphetamine; Dexadrine; (+)-(S)-Amphetamine; Dexedrine; (2S)-1-phenylpropan-2-amine; (S)-(+)-Amphetamine; Dextrostat; Desamfetamina; (S)-1-Phenyl-2-propylamine; Dexidrine; Sympamin; Dephadren; Amsustain; (+)-Phenaminum; (+)-alpha-Methylphenethylamine; (S)-1-Phenyl-2-aminopropane; (+)-alpha-Methylphenylethylamine; D-(S)-Amphetamine; (S)-(+)-beta-Phenylisopropylamine; 51-64-9; (S)-alpha-Phenylethylamine; (2S)-(+)-Amphetamine; Benzedrine; Dexacaps; Dexamfetamina; Dexamfetaminum; Dexamphetaminum; Dexanfetamina; Isoamycin; Propisamine; Psychedrine; Raphetamine; Rhinalator; Simpatedrin; Sympamine; Sympatedrine; Weckamine; Desamfetamina [DCIT]; Dexedrine Spansule; Dextroamphetamine [USAN]; Dextroamphetamine resin complex; D-AM; Dexamfetamina [INN-Spanish]; Dexamfetamine (INN); Dexamfetaminum [INN-Latin]; Dexamphetaminum [INN-Latin]; Dexanfetamina [INN-Spanish]; Dexedrine (TN); Dextro-Amphetamine; Dextro-Amphetamine Sulfate; Dextroamphetamine (USAN); Dextrostat (TN); Dl-Amphetamine; Dl-Benzedrine; Fenylo-izopropylaminyl; Beta-phenyl-isopropylamine; D-alpha-methylphenethylamine; Alpha-Methylphenethylamine, d-form; S(+)-Amphetamine; D-(+)-Amphetamine; D-1-Phenyl-2-aminopropan; D-1-Phenyl-2-aminopropan [German]; D-1-Phenyl-2-aminopropane; D-2-Amino-1-phenylpropane; Dl-1-Phenyl-2-aminopropane; Benzeneethanamine, alpha-methyl-, (aS)-(9CI); Phenethylamine, alpha-methyl-, (+)-(8CI); (+/-)-Benzedrine; (+/-)-Desoxynorephedrine; (+/-)-beta-Phenylisopropylamine; (S)-1-Phenyl-2-propanamine; (S)-alpha-Methylphenethylamine; (S)-alpha-methylbenzeneethanamine; (alphaS)-alpha-methylbenzeneethanamine; dextroamphetamine sulfate (oral liquid, ADHD), Auriga
DMMIHVP	CP	GlaxoSmithKline
DMMIHVP	TC	Central Nervous System Stimulants
DMMIHVP	DT	Small molecular drug
DMMIHVP	PC	5826
DMMIHVP	MW	135.21
DMMIHVP	FM	C9H13N
DMMIHVP	IC	InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
DMMIHVP	CS	C[C@@H](CC1=CC=CC=C1)N
DMMIHVP	IK	KWTSXDURSIMDCE-QMMMGPOBSA-N
DMMIHVP	IU	(2S)-1-phenylpropan-2-amine
DMMIHVP	CA	CAS 51-64-9
DMMIHVP	CB	CHEBI:4469
DMMIHVP	DE	Narcolepsy; Attention deficit hyperactivity disorder

DMUDJZM	ID	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	HS	Approved
DMUDJZM	SN	Albutussin; Canfodion; Cosylan; Demorphine; Destrometerfano; Dextromethorfan; Dextromethorphane; Dextromethorphanum; Dextrometorfano; Dextrometorphan; Dextromorphan; Dexyromethorphan; Dormetan; Levomethorphan; Levomethorphane; Levomethorphanum; Levometorfano; Methorphan; RACEMETHORPHAN; Trocal; Balminil DM; Balminil DM Children; Benylin Adult Formula Cough Suppressant; Benylin DM for Children; Benylin Pediatric Cough Suppressant; Delsym Cough Formula; Demorphan hydrobromide; Destrometerfano [DCIT]; Dextromethorfan [Czech]; Dextromethorphan Bromhydrate; Hold DM; Koffex DM; Novahistex DM; Novahistine DM; Pertussin DM Extra Strength; Robitussin Maximum Strength Cough Suppressant; Robitussin Pediatric; Robitussin Pediatric Cough Suppressant; Triaminic DM Long Lasting for Children; BA 2666; Benylin DM 12 Hour; Benylin DM for Children 12 Hour; Sucrets 4 Hour Cough Suppressant; Vicks 44 Cough Relief; Calmylin #1; Cough-X; Creo-Terpin; D-Methorphan; Delta-Methorphan; Dextromethorphan (USP); Dextromethorphane [INN-French]; Dextromethorphanum [INN-Latin]; Dextrometorfano [INN-Spanish]; Diabe-Tuss DM Syrup; Hihustan M.; L-Methorphan; Levomethorphane [INN-French]; Levomethorphanum [INN-Latin]; Levometorfano [INN-Spanish]; Neurodex (TN); Pertussin CS Children's Strength; Romilar (TN); Dextromethorphan [USP:INN:BAN]; Levomethorphan [BAN:DCF:INN]; Levomethorphan [INN:BAN:DCF]; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)-(9CI); Cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren; (+)-3-Methoxy-17-methylmorphinan; (-)-3-Methoxy-N-methylmorphinan; (9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan; 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan; 3-Methoxy-17-methylmorphinan; 3-Methoxy-N-methylmorphinon; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl-(8CI)
DMUDJZM	TC	Analgesics
DMUDJZM	DT	Small molecular drug
DMUDJZM	PC	5360696
DMUDJZM	MW	271.4
DMUDJZM	FM	C18H25NO
DMUDJZM	IC	InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
DMUDJZM	CS	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
DMUDJZM	IK	MKXZASYAUGDDCJ-NJAFHUGGSA-N
DMUDJZM	IU	(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DMUDJZM	CA	CAS 125-71-3
DMUDJZM	CB	CHEBI:4470
DMUDJZM	DE	Cough

DMEHCY5	ID	DMEHCY5
DMEHCY5	DN	Dextromethorphan polistirex
DMEHCY5	HS	Approved
DMEHCY5	CP	Reckitt Benckiser Llc
DMEHCY5	PC	5464025
DMEHCY5	MW	352.3
DMEHCY5	FM	C18H26BrNO
DMEHCY5	IC	InChI=1S/C18H25NO.BrH/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H/t15-,17+,18+;/m1./s1
DMEHCY5	CS	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC.Br
DMEHCY5	IK	MISZALMBODQYFT-URVXVIKDSA-N
DMEHCY5	IU	(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrobromide
DMEHCY5	CA	CAS 125-69-9
DMEHCY5	DE	Dry cough

DM23HCX	ID	DM23HCX
DM23HCX	DN	Dextropropoxyphene
DM23HCX	HS	Approved
DM23HCX	SN	Algafan; Antalvic; Destropropossifene; Dextropropoxifeno; Dextropropoxyphen; Dextropropoxyphenum; Dextroproxifeno; Femadol; Levopropoxyphene; Propoxyphene; Proxagesic; Proxyphen; Destropropossifene [DCIT]; Dextroproxifeno [Spanish]; SK 65; D-Propoxyphene; Dextropropoxifeno [INN-Spanish]; Dextropropoxyphene[INN:BAN]; Dextropropoxyphenum [INN-Latin]; Bulk dextropropoxyphene (non-dosage forms); Alpha-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat [German]; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane; [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate; (+)-1,2-Diphenyl-2-propionoxy-3-methyl-4-dimethylaminobutane; (+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxybutane; (1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate; (D)-PROPOXYPHENE; (S)-alpha-(2-(Dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate; 4-Dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane
DM23HCX	TC	Analgesics
DM23HCX	DT	Small molecular drug
DM23HCX	PC	10100
DM23HCX	MW	339.5
DM23HCX	FM	C22H29NO2
DM23HCX	IC	InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1
DM23HCX	CS	CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C
DM23HCX	IK	XLMALTXPSGQGBX-GCJKJVERSA-N
DM23HCX	IU	[(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate
DM23HCX	CA	CAS 469-62-5
DM23HCX	CB	CHEBI:51173
DM23HCX	DE	Pain

DMBVEC7	ID	DMBVEC7
DMBVEC7	DN	Dextrothyroxine Sodium
DMBVEC7	HS	Approved
DMBVEC7	SN	Choloxin
DMBVEC7	CP	Abbvie Inc
DMBVEC7	DT	Small molecular drug
DMBVEC7	PC	23690433
DMBVEC7	MW	798.85
DMBVEC7	FM	C15H10I4NNaO4
DMBVEC7	IC	InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m1./s1
DMBVEC7	CS	C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@H](C(=O)[O-])N.[Na+]
DMBVEC7	IK	YDTFRJLNMPSCFM-UTONKHPSSA-M
DMBVEC7	IU	sodium;(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
DMBVEC7	CA	CAS 137-53-1
DMBVEC7	DE	High blood cholesterol level

DMJDB0Y	ID	DMJDB0Y
DMJDB0Y	DN	Dezocine
DMJDB0Y	HS	Approved
DMJDB0Y	SN	SCHEMBL1369581; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol
DMJDB0Y	TC	Analgesics
DMJDB0Y	DT	Small molecular drug
DMJDB0Y	PC	3033053
DMJDB0Y	MW	245.36
DMJDB0Y	FM	C16H23NO
DMJDB0Y	IC	InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1
DMJDB0Y	CS	C[C@]12CCCCC[C@H]([C@@H]1N)CC3=C2C=C(C=C3)O
DMJDB0Y	IK	VTMVHDZWSFQSQP-VBNZEHGJSA-N
DMJDB0Y	IU	(1R,9S,15S)-15-amino-1-methyltricyclo[7.5.1.02,7]pentadeca-2(7),3,5-trien-4-ol
DMJDB0Y	CA	CAS 53648-55-8
DMJDB0Y	CB	CHEBI:4474
DMJDB0Y	DE	Pain

DMU3FGB	ID	DMU3FGB
DMU3FGB	DN	Dhaq diacetate
DMU3FGB	HS	Approved
DMU3FGB	SN	Mitoxantrone diacetate; Anthraquinone, 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-, 1,4-diacetate (salt); 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione diacetate; 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-9,10-anthracenedione diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone 1,4-diaceate
DMU3FGB	TC	Anticancer Agents
DMU3FGB	DT	Small molecular drug
DMU3FGB	PC	51151
DMU3FGB	MW	564.6
DMU3FGB	FM	C26H36N4O10
DMU3FGB	IC	InChI=1S/C22H28N4O6.2C2H4O2/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;2*1-2(3)4/h1-4,23-30H,5-12H2;2*1H3,(H,3,4)
DMU3FGB	CS	CC(=O)[O-].CC(=O)[O-].C1=CC(=C2C(=C1NCC[NH2+]CCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCC[NH2+]CCO
DMU3FGB	IK	ZWCKUVMZBKQQRG-UHFFFAOYSA-N
DMU3FGB	IU	2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium;diacetate
DMU3FGB	CA	CAS 70711-41-0
DMU3FGB	DE	Solid tumour/cancer

DM08E9O	ID	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	HS	Approved
DM08E9O	SN	diazepam; Valium; 439-14-5; Diazemuls; Ansiolisina; Sibazon; Relanium; Faustan; Apaurin; Stesolid; Seduxen; Methyldiazepinone; Valitran; Tranqdyn; Seduksen; Relaminal; Quiatril; Quetinil; Dipezona; Diazetard; Diazepan; Calmpose; Tranimul; Tensopam; Serenack; Paranten; Kiatrium; Domalium; Condition; Bialzepam; Ansiolin; Unisedil; Stesolin; Serenamin; Ruhsitus; Renborin; Quievita; Tranquirit; Serenzin; Neurolytril; Liberetas; Diacepan; Ceregulart; Calmocitene; Bensedin; Atensine; Apozepam; Umbrium; Sonacon; Sedipam; Levium; Diapam; Atilen; Assival; Amiprol;  Diazepam (intranasal, epilepsy)
DM08E9O	CP	Archimedes Pharma Ltd
DM08E9O	DT	Small molecular drug
DM08E9O	PC	3016
DM08E9O	MW	284.74
DM08E9O	FM	C16H13ClN2O
DM08E9O	IC	InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
DM08E9O	CS	CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DM08E9O	IK	AAOVKJBEBIDNHE-UHFFFAOYSA-N
DM08E9O	IU	7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM08E9O	CA	CAS 439-14-5
DM08E9O	CB	CHEBI:49575
DM08E9O	DE	Epilepsy

DML1538	ID	DML1538
DML1538	DN	Diazoxide
DML1538	HS	Approved
DML1538	SN	Aroglycem; Diazossido; Diazoxido; Diazoxidum; Dizoxide; Eudemine; Hyperstat; Hypertonalum; Mutabase; Proglicem; Proglycem; Diazossido [DCIT]; Diazossido [Italian]; D 9035; SRG 95213; Sch 6783; Diazoxido [INN-Spanish]; Diazoxidum [INN-Latin]; Hyperstat (TN); SRG-95213; Sch-6783; Diazoxide [USAN:INN:BAN]; Diazoxide (JAN/USP/INN); 2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide; 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]; 7-chloro-3-methyl-4H-1
DML1538	TC	Antihypertensive Agents
DML1538	DT	Small molecular drug
DML1538	PC	3019
DML1538	MW	230.67
DML1538	FM	C8H7ClN2O2S
DML1538	IC	InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)
DML1538	CS	CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl
DML1538	IK	GDLBFKVLRPITMI-UHFFFAOYSA-N
DML1538	IU	7-chloro-3-methyl-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide
DML1538	CA	CAS 364-98-7
DML1538	CB	CHEBI:4495
DML1538	DE	Hypertension

DMF9G7L	ID	DMF9G7L
DMF9G7L	DN	Dibucaine
DMF9G7L	HS	Approved
DMF9G7L	SN	Cincainum; Cinchocaine; Cinchocainum; Cincocaina; Cincocainio; Dermacaine; Dibucain; Dibucainum; Nupercainal; Nupercaine; Percamine; Sovcaine; Cinchocaine HCL; Cinchocaine hydrochloride; Cincocaina [DCIT]; Dibucaine Base; Dibucaine [USP]; Alpha-Butyloxycinchoninic acid diethylethylenediamide; Cincain (TN); Cinchocaine (INN);Cinchocainum [INN-Latin]; Cincocainio [INN-Spanish]; Dibucaine (USP); Nupercainal (TN); Nupercainal (VAN); Nupercaine (TN); Sovcaine (TN); Alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine; N-[2-(Diethylamino)ethyl]-2-butoxycinchoninamide; N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide; QUINOLINE,2-BUTOXY,4-CARBOXY,(N-TRIETHYLAMINO) AMIDE CINCHOCAIN; 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide; 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-(beta.-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide; 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide; 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide; 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide; 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide; 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide; 2-butoxy-N-(alpha-diethylaminoethyl)cinchoninamide; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
DMF9G7L	CP	Novartis Pharmaceuticals Corp
DMF9G7L	TC	Anesthetics
DMF9G7L	DT	Small molecular drug
DMF9G7L	PC	3025
DMF9G7L	MW	343.5
DMF9G7L	FM	C20H29N3O2
DMF9G7L	IC	InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
DMF9G7L	CS	CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
DMF9G7L	IK	PUFQVTATUTYEAL-UHFFFAOYSA-N
DMF9G7L	IU	2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
DMF9G7L	CA	CAS 85-79-0
DMF9G7L	CB	CHEBI:247956
DMF9G7L	DE	Anaesthesia

DMH7IDQ	ID	DMH7IDQ
DMH7IDQ	DN	Dichlorphenamide
DMH7IDQ	HS	Approved
DMH7IDQ	SN	dichlorphenamide; Diclofenamide; 120-97-8; 4,5-dichlorobenzene-1,3-disulfonamide; Dichlofenamide; Dichlorophenamide; Daranide; Dichlorphenamid; Glauconide; Antidrasi; Glaucol; Oratrol; Diclofenamidum; Diclofenamida; Diclofenamid; Barastonin; Glaumid; Glafco; Glajust; 4,5-Dichloro-m-benzenedisulfonamide; 1,3-Benzenedisulfonamide, 4,5-dichloro-; Diclofenamidum [INN-Latin]; 4,5-Dichloro-1,3-disulfamoylbenzene; 1,3-Disulfamoyl-4,5-dichlorobenzene; Diclofenamida [INN-Spanish]; 1,3-Disulfamyl-4,5-dichlorobenzene; Dasanide; Keveyis;  Antidrasi; Dichlorphenamide [BAN]; Llorens Brand of Dichlorphenamide; Merck Brand of Dichlorphenamide; CB 8000; I7A; Daranide (TN); Dichlorophenamide (DCP); Dichlorphenamide (USP); Diclofenamide (JP15/INN); 3,4-Dichloro-5-sulfamylbenzenesulfonamide; 4,5-Dichloro-1,3-benzenedisulfonamide; 4,5-Dichloro-benzene-1,3-disulfonic acid diamide; 4,5-DICHLOROBENZENE-1,3-DISULFONAMIDE
DMH7IDQ	TC	Antiglaucomic Agents
DMH7IDQ	DT	Small molecular drug
DMH7IDQ	PC	3038
DMH7IDQ	MW	305.2
DMH7IDQ	FM	C6H6Cl2N2O4S2
DMH7IDQ	IC	InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)
DMH7IDQ	CS	C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
DMH7IDQ	IK	GJQPMPFPNINLKP-UHFFFAOYSA-N
DMH7IDQ	IU	4,5-dichlorobenzene-1,3-disulfonamide
DMH7IDQ	CA	CAS 120-97-8
DMH7IDQ	CB	CHEBI:101085
DMH7IDQ	DE	Chronic glaucoma

DMPIHLS	ID	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	HS	Approved
DMPIHLS	SN	Diclofenac (sodium matrix patch, pain)
DMPIHLS	CP	Novartis Pharmaceuticals Corp
DMPIHLS	TC	Neurology Agents
DMPIHLS	DT	Small molecular drug
DMPIHLS	PC	3033
DMPIHLS	MW	296.1
DMPIHLS	FM	C14H11Cl2NO2
DMPIHLS	IC	InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)
DMPIHLS	CS	C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl
DMPIHLS	IK	DCOPUUMXTXDBNB-UHFFFAOYSA-N
DMPIHLS	IU	2-[2-(2,6-dichloroanilino)phenyl]acetic acid
DMPIHLS	CA	CAS 15307-86-5
DMPIHLS	CB	CHEBI:47381
DMPIHLS	DE	Osteoarthritis

DM8EU0Z	ID	DM8EU0Z
DM8EU0Z	DN	Dicloxacillin
DM8EU0Z	HS	Approved
DM8EU0Z	SN	Dichloroxacillin; Diclossacillina; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilline; Dicloxacillinum; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; Diclossacillina [DCIT]; Dicloxacillin sodium; BRL 1702; Diclocil (TN); Dicloxacilina [INN-Spanish]; Dicloxacilline [INN-French]; Dicloxacillinum [INN-Latin]; R-13423; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin, Monosodium Salt, Mono-Hydrate; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid
DM8EU0Z	CP	Sandoz Inc
DM8EU0Z	TC	Antibiotics
DM8EU0Z	DT	Small molecular drug
DM8EU0Z	PC	18381
DM8EU0Z	MW	470.3
DM8EU0Z	FM	C19H17Cl2N3O5S
DM8EU0Z	IC	InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
DM8EU0Z	CS	CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DM8EU0Z	IK	YFAGHNZHGGCZAX-JKIFEVAISA-N
DM8EU0Z	IU	(2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM8EU0Z	CA	CAS 3116-76-5
DM8EU0Z	CB	CHEBI:4511
DM8EU0Z	DE	Bacterial infection

DMFQCB1	ID	DMFQCB1
DMFQCB1	DN	Dicumarol
DMFQCB1	HS	Approved
DMFQCB1	SN	Acadyl; Acavyl; Anathrombase; Antitrombosin; Apekumarol; Baracoumin; Bishydroxycoumarin; Cuma; Cumid; Dicoumal; Dicoumarin; Dicoumarol; Dicoumarolum; Dicoumerol; Dicuman; Dicumarine; Dicumarinum; Dicumarolo; Dicumarolum; Dicumol; Dikumarol; Dufalone; Dwukumarol; Kumoran; Melitoxin; Temparin; Trombosan; Dicumaol R; Dicumarol [USAN]; Dicumarolo [DCIT]; Dwukumarol [Polish]; Uncoupler of oxidative respiration; M0216; NC 034; Bis-hydroxycoumarin; Dicoumarol (INN); Dicoumarolum [INN-Latin]; Dicumarol (TN); Dicumarol (USAN); Dicumarol [INN-Spanish]; Symmetric dicoumarol analogue, 1; Bis(4-hydroxycoumarin-3-yl)methane; Di-(4-hydroxy-3-coumarinyl)methane; Bis-3,3'-(4-hydroxycoumarinyl)methane; Bis-3,3'-(4-oxycoumarinyl)ethylacetate; Di-4-hydroxy-3,3'-methylenedicoumarin; Coumarin, 3,3'-methylenebis[4-hydroxy-(8CI); 2-hydroxy-3-[(2-hydroxy-4-oxochromen-3-yl)methyl]chromen-4-one; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy-(9CI); 3,3&prime;-Methylenebis(4-hydroxycoumarin); 3,3'-Methyleen-bis(4-hydroxy-cumarine); 3,3'-Methyleen-bis(4-hydroxy-cumarine) [Dutch]; 3,3'-Methylen-bis(4-hydroxy-cumarin); 3,3'-Methylen-bis(4-hydroxy-cumarin) [German]; 3,3'-Methylene-bis(4-hydroxycoumarin); 3,3'-Methylene-bis(4-hydroxycoumarine); 3,3'-Methylene-bis(4-hydroxycoumarine) [French]; 3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone); 3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one); 3,3'-Methylenebis(4-hydroxycoumarin); 3,3'-Methylenebis[4-hydroxy-1,2-benzopyrone]; 3,3'-Methylenebis[4-hydroxy-2H-1-benzopyran-2-one]; 3,3'-Methylenebis[4-hydroxycoumarin]; 3,3'-Metilen-bis(4-idrossi-cumarina); 3,3'-Metilen-bis(4-idrossi-cumarina) [Italian]; 3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one); 3,3'-methylenebis(2-hydroxy-4h-chromen-4-one); 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); 3,3-Methylene-bis[4-hydroxycoumarin]; 4,4'-Dihydroxy-3,3'-methylene bis coumarin
DMFQCB1	TC	Anticoagulants
DMFQCB1	DT	Small molecular drug
DMFQCB1	PC	54676038
DMFQCB1	MW	336.3
DMFQCB1	FM	C19H12O6
DMFQCB1	IC	InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2
DMFQCB1	CS	C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O
DMFQCB1	IK	DOBMPNYZJYQDGZ-UHFFFAOYSA-N
DMFQCB1	IU	4-hydroxy-3-[(4-hydroxy-2-oxochromen-3-yl)methyl]chromen-2-one
DMFQCB1	CA	CAS 66-76-2
DMFQCB1	CB	CHEBI:4513
DMFQCB1	DE	Thrombosis; Bleeding disorder

DMZSDGX	ID	DMZSDGX
DMZSDGX	DN	Dicyclomine
DMZSDGX	HS	Approved
DMZSDGX	SN	Atumin; Bentomine; Bentylol; Dicicloverina; Dicycloverin; Dicycloverine; Dicycloverinum; Dicymine; Diocyl; Dyspas; Formulex; Mamiesan; Merbentyl; Procyclomin; Sawamin; Spasmoban; Wyovin; Bentyl hydrochloride; Bentylol hydrochloride; Dicyclomine Hcl; Dicycloverin hydrochloride; Diethylaminocarbethoxybicyclohexyl hydrochloride; Diocyl hydrochloride; Kolantyl hydrochloride; Wyovin hydrochloride; GU8471000; Bentyl (TN); Bentylol (TN); Byclomine (TN); Di-syntramine; Dibent (TN); Dicicloverina [INN-Spanish]; Dicycloverine (INN); Dicycloverine [INN:BAN]; Dicycloverinum [INN-Latin]; Dicymine (TN); Dilomine (TN); Formulex (TN); Lomine (TN); Merbentyl (TN); Oxityl-P; Beta-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; Di-Spaz (TN); J.L. 998; Beta-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; Cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 1-Cyclohexylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride
DMZSDGX	CP	Peckforton Pharmaceuticals
DMZSDGX	TC	Anticholinergic Agents
DMZSDGX	DT	Small molecular drug
DMZSDGX	PC	3042
DMZSDGX	MW	309.5
DMZSDGX	FM	C19H35NO2
DMZSDGX	IC	InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
DMZSDGX	CS	CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
DMZSDGX	IK	CURUTKGFNZGFSE-UHFFFAOYSA-N
DMZSDGX	IU	2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate
DMZSDGX	CA	CAS 77-19-0
DMZSDGX	CB	CHEBI:4514
DMZSDGX	DE	Functional bowel syndrome

DMI2QPE	ID	DMI2QPE
DMI2QPE	DN	Didanosine
DMI2QPE	HS	Approved
DMI2QPE	SN	didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927
DMI2QPE	CP	Bristol-Myers Squibb
DMI2QPE	TC	Anti-HIV Agents
DMI2QPE	DT	Small molecular drug
DMI2QPE	PC	135398739
DMI2QPE	MW	236.23
DMI2QPE	FM	C10H12N4O3
DMI2QPE	IC	InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
DMI2QPE	CS	C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O
DMI2QPE	IK	BXZVVICBKDXVGW-NKWVEPMBSA-N
DMI2QPE	IU	9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DMI2QPE	CA	CAS 69655-05-6
DMI2QPE	CB	CHEBI:490877
DMI2QPE	DE	Human immunodeficiency virus infection

DMBSXI0	ID	DMBSXI0
DMBSXI0	DN	Dienestrol
DMBSXI0	HS	Approved
DMBSXI0	SN	Agaldog; Cycladiene; Dehydrostilbestrol; Dehydrostilboestrol; Dienesterol; Dienestrolo; Dienestrolum; Dienoestrol; Dienol; Dinestrol; Dinovex; Estragard; Estraguard; Estrodienol; Estroral; Follidiene; Follormon; Gynefollin; Hormofemin; Isodienestrol; Oestrasid; Oestrodiene; Oestrodienol; Oestroral; Oestrovis; Restrol; Retalon; Sexadien; Synestrol; Teserene; Willnestrol; Dienestrolo [DCIT]; Dienoestrol [Nonsteroidal oestrogens]; Dienoestrol bp; Alpha-Dienestrol; DV (TN); Dienestrolum [INN-Latin]; Para-Dien; Restrol, Dienestrol; Dienestrol (E,E); Dienestrol (USP/INN); Dienestrol, (E,E)-Isomer; P,p'-(Diethylideneethylene)diphenol; Para,para'-(Diethylideneethylene)diphenol; Di(p-oxyphenyl)-2,4-hexadiene; Di(para-oxyphenyl)-2,4-hexadiene; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, (E,E-(9CI); (E,E)-Dienestrol; 3,4-Bis(4-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(p-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(para-hydroxyphenyl)-2,4-hexadiene; 4,4'-(1,2-Diethylidene-1,2-ethanediyl)bisphenol; 4,4'-(2E,4E)-hexa-2,4-diene-3,4-diyldiphenol; 4,4'-(Diethylideneethylene)diphenol; 4,4'-Dihydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-Hydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-hexa-2,4-diene-3,4-diyldiphenol; 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
DMBSXI0	TC	Estrogens
DMBSXI0	DT	Small molecular drug
DMBSXI0	PC	667476
DMBSXI0	MW	266.3
DMBSXI0	FM	C18H18O2
DMBSXI0	IC	InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+
DMBSXI0	CS	C/C=C(/C(=C/C)/C1=CC=C(C=C1)O)\\C2=CC=C(C=C2)O
DMBSXI0	IK	NFDFQCUYFHCNBW-SCGPFSFSSA-N
DMBSXI0	IU	4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
DMBSXI0	CA	CAS 13029-44-2
DMBSXI0	CB	CHEBI:4518
DMBSXI0	DE	Atrophic vaginitis

DM1TJ8F	ID	DM1TJ8F
DM1TJ8F	DN	Diethylcarbamazine
DM1TJ8F	HS	Approved
DM1TJ8F	SN	Bitirazine; Camin; Caracide; Carbamazine; Carbilazine; Caricide; Cypip; Decacide; Diaethylcarbamazinum; Diethylcarbamazinum; Dietilcarbamazina; Ethodryl; Luxuran; Notezine; Spatonin; Diethyl carbamazine; Ditrazine Base; Banocide (TN); Camin (TN); Carbilazine (TN); Caricide (TN); Cypip (TN); Diethylcarbamazine (INN); Diethylcarbamazine [INN:BAN]; Diethylcarbamazinum [INN-Latin]; Dietilcarbamazina [INN-Spanish]; Ethodryl (TN); FR-1031; Filaribits (TN); Forte (TN); Hetrazan (TN); Spatonin (TN); N,N-Diethyl-4-methyl-1-piperazinecarboxamide; N,N-diethyl-4-methylpiperazine-1-carboxamide; 1-Diethylcarbamyl-4-methylpiperazine; 84L
DM1TJ8F	CP	Lederle Laboratories Div American Cyanamid Co
DM1TJ8F	TC	Anthelmintics
DM1TJ8F	DT	Small molecular drug
DM1TJ8F	PC	3052
DM1TJ8F	MW	199.29
DM1TJ8F	FM	C10H21N3O
DM1TJ8F	IC	InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3
DM1TJ8F	CS	CCN(CC)C(=O)N1CCN(CC1)C
DM1TJ8F	IK	RCKMWOKWVGPNJF-UHFFFAOYSA-N
DM1TJ8F	IU	N,N-diethyl-4-methylpiperazine-1-carboxamide
DM1TJ8F	CA	CAS 90-89-1
DM1TJ8F	CB	CHEBI:4527
DM1TJ8F	DE	Lymphatic filariasis

DMN3UXQ	ID	DMN3UXQ
DMN3UXQ	DN	Diethylstilbestrol
DMN3UXQ	HS	Approved
DMN3UXQ	SN	Acnestrol; Agostilben; Antigestil; Apstil; Bufon; Climaterine; Comestrol; Cyren; DES; Desma; Destrol; Diaethylstilboestrolum; Diastyl; Dibestrol; Dicorvin; Diethylstilbesterol; Diethylstilbestrolum; Diethylstilboesterol; Dietilestilbestrol; Dietilstilbestrolo; Distilbene; Domestrol; Dyestrol; Estril; Estrobene; Estrogenine; Estromenin; Estrosyn; Fonatol; Grafestrol; Gynopharm; Hibestrol; Idroestril; Iscovesco; Makarol; Menostilbeen; Micrest; Microest; Milestrol; OeKolp; Oestrogenine; Oestrolmensil; Oestromenin; Oestromensil; Oestromensyl; Oestromienin; Oestromon; Pabestrol; Palestrol; Protectona; Sedestran; Serral; Sexocretin; Sibol; Sintestrol; Stibilium; Stilbestroform; Stilbestrol; Stilbestrone; Stilbetin; Stilboefral; Stilboestroform; Stilboestrol; Stilbofolin; Stilbofollin; Stilbol; Stilkap; Strobene; Synestrin; Synthestrin; Synthoestrin; Synthofolin; Syntofolin; Tampovagan; Tylosterone; Vagestrol; APS Brand of Diethylstilbestrol; Anti gestil; Co Pharma Brand of Diethylstilbestrol; Comestrol estrobene; Cyren A; Diethylstilbestrol BP; Dietilestilbestrol [Spanish]; Dietilstilbestrolo [DCIT]; Estilbin MCO; Gerda Brand of Diethylstilbestrol; Oestrol vetag; Percutatrine oestrogenique iscovesco; ST IL; Stilbene Estrogen; Tampovagan stilboestrol; DiBestrol 2 Premix; MG 137; Rumestrol 1; Rumestrol 2; Cis-Des; Cis-Diethylstilbesterol; Cis-Diethylstilbestrol; Co-Pharma Brand of Diethylstilbestrol; DES (synthetic estrogen); Dawe's destrol; Di-Estryl; Diethylstilbestrol (DES); Diethylstilbestrol [USAN:INN]; Diethylstilbestrol, Disodium Salt; Diethylstilbestrolum [INN-Latin]; Dietilestilbestrol [INN-Spanish]; E-Diethylstilbestrol; Estilbin (MCO); Estrogen, Stilbene; Hi-Bestrol; Neo-Oestranol 1; Neo-Oestranol I; Neo-oe stranol 1; New-Estranol 1; Stil-Rol; Stilbestrol (TN); TRANS-DIETHYSTILBESTEROL; TRANSGENIC MODEL EVALUATION (DES); Trans-Diethylstilbesterol; Trans-Diethylstilbestrol; Trans-Diethylstilboesterol; DiBestrol "2" Premix; Dibestrol '2' premix; Diethylstilbestrol (USP/INN); Alpha,alpha'-Diethylstilbenediol; Diethylstilbestrol, (Z)-Isomer; Alpha,alpha'-Diethyl-4,4'-stilbenediol; (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene; (E)-4,4'-(hex-3-ene-3,4-diyl)diphenol; (E)-Diethylstilbestrol; 3,4'(4,4'-Dihydroxyphenyl)hex-3-ene; 3,4-Bis(p-hydroxyphenyl)-3-hexene; 3,4-bis(4-hydroxyphenyl)hex-3-ene; 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol; 4,4'-Dihydroxydiethylstilbene; 4,4'-hex-3-ene-3,4-diyldiphenol
DMN3UXQ	CP	Bayer Pharmaceuticals Corp
DMN3UXQ	TC	Anticancer Agents
DMN3UXQ	DT	Small molecular drug
DMN3UXQ	PC	448537
DMN3UXQ	MW	268.3
DMN3UXQ	FM	C18H20O2
DMN3UXQ	IC	InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+
DMN3UXQ	CS	CC/C(=C(/CC)\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O
DMN3UXQ	IK	RGLYKWWBQGJZGM-ISLYRVAYSA-N
DMN3UXQ	IU	4-[(E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol
DMN3UXQ	CA	CAS 56-53-1
DMN3UXQ	CB	CHEBI:41922
DMN3UXQ	DE	Gonorrheal vaginitis

DMI9PRJ	ID	DMI9PRJ
DMI9PRJ	DN	Diflorasone
DMI9PRJ	HS	Approved
DMI9PRJ	SN	Diflorasona; Diflorasonum; Maxiflor; Murode; U 34865; Diflorasona [INN-Spanish]; Diflorasone (INN); Diflorasone [INN:BAN]; Diflorasonum [INN-Latin]; Murode (TN); (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 6a,9a-difluoro-16b-methylprednisolone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
DMI9PRJ	CP	Pharmacia And Upjohn Co
DMI9PRJ	TC	Antiinflammatory Agents
DMI9PRJ	DT	Small molecular drug
DMI9PRJ	PC	71415
DMI9PRJ	MW	410.5
DMI9PRJ	FM	C22H28F2O5
DMI9PRJ	IC	InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1
DMI9PRJ	CS	C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F
DMI9PRJ	IK	WXURHACBFYSXBI-XHIJKXOTSA-N
DMI9PRJ	IU	(6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMI9PRJ	CA	CAS 2557-49-5
DMI9PRJ	CB	CHEBI:59750
DMI9PRJ	DE	Rosacea

DM7EN8I	ID	DM7EN8I
DM7EN8I	DN	Diflunisal
DM7EN8I	HS	Approved
DM7EN8I	SN	Adomal; Algobid; Citidol; Difludol; Diflunisalum; Dolisal; Dolobid; Dolobil; Dolobis; Dolocid; Flovacil; Fluniget; Fluodonil; Flustar; Noaldol; Reuflos; Unisal; Apotex Brand of Diflunisal; Cahill May Roberts Brand of Diflunisal; Diflunisal Novopharm Brand; Frosst SA Brand of Diflunisal; Merck Brand of Diflunisal; Novopharm Brand of Diflunisal; Nu Pharm Brand of Diflunisal; MK 647; MK647; Apo-Diflunisal; Diflunisalum [INN-Latin]; Dolobid (TN); MK-647; Merck Sharp & Dohme Brand of Diflunisal; Novo-Diflunisal; Nu-Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal (JAN/USP/INN); Diflunisal [USAN:INN:BAN:JAN]; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 5-(2,4-Difluorophenyl)salicylic acid; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-[2,4-Difluorophenyl]salicylic acid
DM7EN8I	CP	Merck & Co
DM7EN8I	TC	Analgesics
DM7EN8I	DT	Small molecular drug
DM7EN8I	PC	3059
DM7EN8I	MW	250.2
DM7EN8I	FM	C13H8F2O3
DM7EN8I	IC	InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
DM7EN8I	CS	C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O
DM7EN8I	IK	HUPFGZXOMWLGNK-UHFFFAOYSA-N
DM7EN8I	IU	5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
DM7EN8I	CA	CAS 22494-42-4
DM7EN8I	CB	CHEBI:39669
DM7EN8I	DE	Pain

DMMFVB3	ID	DMMFVB3
DMMFVB3	DN	Difluprednate
DMMFVB3	HS	Approved
DMMFVB3	SN	Durezol (TN)
DMMFVB3	CP	Sirion
DMMFVB3	DT	Small molecular drug
DMMFVB3	PC	443936
DMMFVB3	MW	508.5
DMMFVB3	FM	C27H34F2O7
DMMFVB3	IC	InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1
DMMFVB3	CS	CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C(=O)COC(=O)C
DMMFVB3	IK	WYQPLTPSGFELIB-JTQPXKBDSA-N
DMMFVB3	IU	[(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
DMMFVB3	CA	CAS 23674-86-4
DMMFVB3	CB	CHEBI:31485
DMMFVB3	DE	Ocular pain

DMWVIGP	ID	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	HS	Approved
DMWVIGP	SN	Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystodigin; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitoxina; Digitoxine; Digitoxinum; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Lanatoxin; Lanostabil; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purpurid; Tardigal; Unidigin; Crystalline digitalin; Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; LT00244784; Crystodigin (TN); De-Tone; Digitalin, crystalline; Digitaline (TN); Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxina [INN-Spanish]; Digitoxine [INN-French]; Digitoxinum [INN-Latin]; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Purodigin, crystalline; Tri-digitoxoside; Tri-digitoxoside [German]; Digitoxin [INN:BAN:JAN]; Digitoxin (JP15/USP/INN); Inhibits Na+/K+ ATPase; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]
DMWVIGP	TC	Antiarrhythmic Agents
DMWVIGP	DT	Small molecular drug
DMWVIGP	PC	441207
DMWVIGP	MW	764.9
DMWVIGP	FM	C41H64O13
DMWVIGP	IC	InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
DMWVIGP	CS	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O
DMWVIGP	IK	WDJUZGPOPHTGOT-XUDUSOBPSA-N
DMWVIGP	IU	3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMWVIGP	CA	CAS 71-63-6
DMWVIGP	CB	CHEBI:28544
DMWVIGP	DE	Heart failure; Arrhythmia; Congestive cardiac insufficiency

DMQCTIH	ID	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	HS	Approved
DMQCTIH	SN	digoxin; 20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674;  Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin
DMQCTIH	CP	GlaxoSmithKline
DMQCTIH	TC	Antiarrhythmic Agents
DMQCTIH	DT	Small molecular drug
DMQCTIH	PC	2724385
DMQCTIH	MW	780.9
DMQCTIH	FM	C41H64O14
DMQCTIH	IC	InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
DMQCTIH	CS	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
DMQCTIH	IK	LTMHDMANZUZIPE-PUGKRICDSA-N
DMQCTIH	IU	3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMQCTIH	CA	CAS 20830-75-5
DMQCTIH	CB	CHEBI:4551
DMQCTIH	DE	Heart failure; Arrhythmia; Congestive cardiac insufficiency

DMZIXU9	ID	DMZIXU9
DMZIXU9	DN	Dihydralazine
DMZIXU9	HS	Approved
DMZIXU9	SN	Dihydralazine sulfate; 7327-87-9; Dihydralazine sulphate; 1,4-Dihydrazinophthalazine sulfate; Depressan; Hydralazine sulfate; Ophthazin Sulfate; UNII-1C2B1W91NK; CCRIS 5386; Sulfate de dihydralazine [French]; 1,4-Dihydrazinylphthalazine Sulfate; EINECS 230-808-0; 1C2B1W91NK; Phthalazine, 1,4-dihydrazino-, sulfate (1:1); 1,4-Dihydrazinophthalazine hydrogen sulfate; W-104459; Sulfate de dihydralazine; 1,4-dihydrazinophthalazine sulfate(1:1); Dihydralazinsulfat; C8H10N6.H2O4S; Nepresol (TN); Dihydralazine Sulfate,(S); AC1Q6XE2
DMZIXU9	DT	Small molecular drug
DMZIXU9	PC	10230
DMZIXU9	MW	190.21
DMZIXU9	FM	C8H10N6
DMZIXU9	IC	InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)
DMZIXU9	CS	C1=CC=C2C(=C1)C(=NN=C2NN)NN
DMZIXU9	IK	VQKLRVZQQYVIJW-UHFFFAOYSA-N
DMZIXU9	IU	(4-hydrazinylphthalazin-1-yl)hydrazine
DMZIXU9	CA	CAS 484-23-1
DMZIXU9	CB	CHEBI:134841
DMZIXU9	DE	Hypertension

DMBXVMZ	ID	DMBXVMZ
DMBXVMZ	DN	Dihydroartemisinin
DMBXVMZ	HS	Approved
DMBXVMZ	SN	Artenimol; Cotecxin; Dihydroartemisinine; Dihydroqinghaosu; Dihydroquinghaosu; Dihydroquinghoasu; VM3352; Artenimol (INN); JAV-110; GNF-PF-5634; (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol; [3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin; 1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin)
DMBXVMZ	DT	Small molecular drug
DMBXVMZ	PC	3000518
DMBXVMZ	MW	284.35
DMBXVMZ	FM	C15H24O5
DMBXVMZ	IC	InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1
DMBXVMZ	CS	C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C
DMBXVMZ	IK	BJDCWCLMFKKGEE-ISOSDAIHSA-N
DMBXVMZ	IU	(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
DMBXVMZ	CA	CAS 71939-50-9
DMBXVMZ	CB	CHEBI:135921
DMBXVMZ	DE	Malaria

DM5SQ1G	ID	DM5SQ1G
DM5SQ1G	DN	Dihydroergocristine
DM5SQ1G	HS	Approved
DM5SQ1G	SN	Nehydrin
DM5SQ1G	CP	Sanochemia Pharmazeutika AG
DM5SQ1G	DT	Small molecular drug
DM5SQ1G	PC	107715
DM5SQ1G	MW	611.7
DM5SQ1G	FM	C35H41N5O5
DM5SQ1G	IC	InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1
DM5SQ1G	CS	CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
DM5SQ1G	IK	DEQITUUQPICUMR-HJPBWRTMSA-N
DM5SQ1G	IU	(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM5SQ1G	CA	CAS 17479-19-5
DM5SQ1G	CB	CHEBI:59912
DM5SQ1G	DE	Alcohol dependence

DM5IKUF	ID	DM5IKUF
DM5IKUF	DN	Dihydroergotamine
DM5IKUF	HS	Approved
DM5IKUF	SN	Migranal (TN)
DM5IKUF	CP	Pfizer Pharmaceuticals
DM5IKUF	TC	Antimigraine Agents
DM5IKUF	DT	Small molecular drug
DM5IKUF	PC	10531
DM5IKUF	MW	583.7
DM5IKUF	FM	C33H37N5O5
DM5IKUF	IC	InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
DM5IKUF	CS	C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
DM5IKUF	IK	LUZRJRNZXALNLM-JGRZULCMSA-N
DM5IKUF	IU	(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM5IKUF	CA	CAS 511-12-6
DM5IKUF	CB	CHEBI:4562
DM5IKUF	DE	Migraine

DM5D6WZ	ID	DM5D6WZ
DM5D6WZ	DN	Dihydroergotoxine
DM5D6WZ	HS	Approved
DM5D6WZ	SN	Ergotamine, dihydro, methanesulfonate (salt)
DM5D6WZ	TC	Vasodilator Agents
DM5D6WZ	DT	Small molecular drug
DM5D6WZ	PC	6420006
DM5D6WZ	MW	679.8
DM5D6WZ	FM	C34H41N5O8S
DM5D6WZ	IC	InChI=1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1
DM5D6WZ	CS	C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5CC6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O
DM5D6WZ	IK	ADYPXRFPBQGGAH-WVVAGBSPSA-N
DM5D6WZ	IU	(6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
DM5D6WZ	CA	CAS 11032-41-0
DM5D6WZ	DE	Alzheimer disease

DMFB97P	ID	DMFB97P
DMFB97P	DN	Dihydrotachysterol
DMFB97P	HS	Approved
DMFB97P	SN	Antitanil; Calcamine; Dichystrolum; Dihidrotaquisterol; Dihydral; Dihydrotachysterolum; Diidrotachisterolo; Dygratyl; Hytakerol; Parterol; Tachyrol; Tachystin; Dht Intensol; Diidrotachisterolo [DCIT]; AT 10; DHT2; Anti-tetany substance 10; Dht(sub 2); Dihidrotaquisterol [INN-Spanish]; Dihydrotachysterol(sub 2); Dihydrotachysterolum [INN-Latin]; Dihydrotachysterol [INN:BAN:JAN]; (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol; (3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; 9,10-Secoergosta-5,7,22-trien-3beta-ol
DMFB97P	TC	Antihypoparathyroid Agents
DMFB97P	DT	Small molecular drug
DMFB97P	PC	5311071
DMFB97P	MW	398.7
DMFB97P	FM	C28H46O
DMFB97P	IC	InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1
DMFB97P	CS	C[C@H]\\1CC[C@@H](C/C1=C\\C=C\\2/CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C)O
DMFB97P	IK	ILYCWAKSDCYMBB-OPCMSESCSA-N
DMFB97P	IU	(1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
DMFB97P	CA	CAS 67-96-9
DMFB97P	CB	CHEBI:4591
DMFB97P	DE	Hypocalcemia

DMM1LG2	ID	DMM1LG2
DMM1LG2	DN	Dihydroxyacetone
DMM1LG2	HS	Approved
DMM1LG2	SN	1,3-dihydroxyacetone; Dihydroxyacetone; 96-26-4; 1,3-Dihydroxypropan-2-one; Chromelin; 1,3-Dihydroxy-2-propanone; glycerone; Triulose; Viticolor; Soleal; Oxatone; Dihyxal; Oxantin; Otan; 2-Propanone, 1,3-dihydroxy-; 1,3-Dihydroxypropanone; 1,3-Dihydroxydimethyl ketone; NSC-24343; Ketochromin; Bis(hydroxymethyl) ketone; UNII-O10DDW6JOO; dihydroxy-acetone; 2-Propanone, 1,3-dihydroxy; BRN 1740268; CCRIS 4899; AI3-24477; Dihydroxyacetone [USP]; EINECS 202-494-5; O10DDW6JOO; 1,2-Dihydroxy-2-propanone; CHEBI:16016; RXKJFZQQPQGTFL-UHFFFAOYSA-N
DMM1LG2	DT	Small molecular drug
DMM1LG2	PC	670
DMM1LG2	MW	90.08
DMM1LG2	FM	C3H6O3
DMM1LG2	IC	InChI=1S/C3H6O3/c4-1-3(6)2-5/h4-5H,1-2H2
DMM1LG2	CS	C(C(=O)CO)O
DMM1LG2	IK	RXKJFZQQPQGTFL-UHFFFAOYSA-N
DMM1LG2	IU	1,3-dihydroxypropan-2-one
DMM1LG2	CA	CAS 96-26-4
DMM1LG2	CB	CHEBI:16016
DMM1LG2	DE	Sunburn

DM8YXKW	ID	DM8YXKW
DM8YXKW	DN	Dihydroxyaluminium
DM8YXKW	HS	Approved
DM8YXKW	SN	(2-Aminoacetoxy)dihydroxyaluminum; Dihydroxyaluminium glycinate; Dihydroxyaluminum aminoacetate; 41354-48-7; Robalate; Prodexin; Hyperacid; Alilac; (Glycinato)dihydroxyaluminum; Alminate; (T-4)-(Glycinato-N,O)dihydroxyaluminum; Dihydroxyaluminum aminoacetate [USAN:USP]; C2H6AlNO4; Dihydroxoaluminium glycinat; Aluminum glycinate, AldrichCPR; DTXSID3044546; (Glycinato-N,O)dihydroxyaluminum; 51484-68-5 (proacid); MolPort-023-220-319; 13682-92-3 (Parent); (Glycinato)dihydroxyaluminum hydrate; EINECS 237-193-8; Aluminum, (glycinato-N
DM8YXKW	TC	Antiinflammatory Agents
DM8YXKW	DT	Small molecular drug
DM8YXKW	PC	16683036
DM8YXKW	MW	137.07
DM8YXKW	FM	C2H8AlNO4
DM8YXKW	IC	InChI=1S/C2H5NO2.Al.2H2O/c3-1-2(4)5;;;/h1,3H2,(H,4,5);;2*1H2/q;+1;;/p-1
DM8YXKW	CS	C(C(=O)O[Al])N.O.O
DM8YXKW	IK	RBNPZEHAODHBPZ-UHFFFAOYSA-M
DM8YXKW	CA	CAS 13682-92-3
DM8YXKW	DE	Skin inflammation

DMAI7ZV	ID	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	HS	Approved
DMAI7ZV	SN	Acalix; Adizem; Aldizem; Anoheal; Cardil; Cardizem; Citizem; Dilacor; Dilcontin; Dilren; Diltia; Diltiazemum; Dilticard; Diltzac; Dilzen; Endrydil; Viazem; Cardizen LA; Incoril AP; Tiazac Tildiem; Tiazac XC; Adizem (TN); Altiazem (TN); Angiozem (TN); Angizem (TN); Angizem CD (TN); Apo-Diltiaz; Cardizem (Hydrochloride); Cardizem (TN); Cartia XT (TN); Dilacor-XR; Dilatam (TN); Dilatem (TN); Dilcardia (TN); Dilcontin SR (TN); Dilt-cd; Dilta-Hexal; Diltelan (TN); Diltiazem (INN); Diltiazem [INN:BAN]; Diltiazemum [INN-Latin]; Diltime (TN); Dilzem (TN); Dyalec (TN); Filazem (TN); Herben (TN); Nu-Diltiaz; Progor (TN); RG 83606 (Hydrochloride); Surazem (TN); Tiamate (TN); Tiazac (TN); Tiazac XC (TN); Tildiem (TN); Vasmulax (TN); Viazem (TN); Zandil (TN); Zemtrial (TN); D-cis-Diltiazem; MK-793 (Malate); [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
DMAI7ZV	CP	Valeant International Barbados Srl
DMAI7ZV	TC	Antihypertensive Agents
DMAI7ZV	DT	Small molecular drug
DMAI7ZV	PC	39186
DMAI7ZV	MW	414.5
DMAI7ZV	FM	C22H26N2O4S
DMAI7ZV	IC	InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
DMAI7ZV	CS	CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DMAI7ZV	IK	HSUGRBWQSSZJOP-RTWAWAEBSA-N
DMAI7ZV	IU	[(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMAI7ZV	CA	CAS 56209-45-1
DMAI7ZV	CB	CHEBI:101278
DMAI7ZV	DE	Hypertension

DM264B3	ID	DM264B3
DM264B3	DN	Dimenhydrinate
DM264B3	HS	Approved
DM264B3	SN	Gravamin (TN); Gravol (TN); Vertirosan (TN); Dimenhydrinate (JP15/USP/INN); 2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide; 2-benzhydryloxyethyl(dimethyl)azanium; 8-chloro-1,3-dimethyl-2-oxopurin-6-olate; 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione-2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
DM264B3	CP	Carter-Horner Corp.
DM264B3	TC	Antiemetics
DM264B3	DT	Small molecular drug
DM264B3	PC	10660
DM264B3	MW	470
DM264B3	FM	C24H28ClN5O3
DM264B3	IC	InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10)
DM264B3	CS	CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
DM264B3	IK	NFLLKCVHYJRNRH-UHFFFAOYSA-N
DM264B3	IU	2-benzhydryloxy-N,N-dimethylethanamine;8-chloro-1,3-dimethyl-7H-purine-2,6-dione
DM264B3	CA	CAS 523-87-5
DM264B3	CB	CHEBI:94848
DM264B3	DE	Nausea

DM32YAI	ID	DM32YAI
DM32YAI	DN	Dimethindene
DM32YAI	HS	Approved
DM32YAI	SN	Dimethpyrindene; Dimethylpyrindene; Dimetindene; Dimetindeno; Dimetindenum; Fengel; Fenistil; Forhistal; Foristal; Pecofenil; Triten; Z 2001; Dimetindene (INN); Dimetindene [INN:BAN]; Dimetindeno [INN-Spanish]; Dimetindenum [INN-Latin]; Fenistil (TN); Dimethyl{2-[3-(2-pyridylethyl)inden-2-yl]ethyl}amine; N,N-Dimethyl-3-(1-(2-pyridyl)ethyl)inden-2-ethylamin; N,N-Dimethyl-N-(3-(1-(2-pyridyl)ethyl)-2-indenylethyl)amin; N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine; 1H-Indene-2-ethanamine, N,N-dimethyl-3-(1-(2-pyridinyl)ethyl)-(9CI); 2-(1-(2-(2-Dimethylaminoethyl)inden-3-yl)ethyl)pyridine
DM32YAI	TC	Antiallergic Agents
DM32YAI	DT	Small molecular drug
DM32YAI	PC	21855
DM32YAI	MW	292.4
DM32YAI	FM	C20H24N2
DM32YAI	IC	InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3
DM32YAI	CS	CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C
DM32YAI	IK	MVMQESMQSYOVGV-UHFFFAOYSA-N
DM32YAI	IU	N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine
DM32YAI	CA	CAS 5636-83-9
DM32YAI	CB	CHEBI:135222
DM32YAI	DE	Respiratory allergy

DMXQKSL	ID	DMXQKSL
DMXQKSL	DN	Dinoprost Tromethamine
DMXQKSL	HS	Approved
DMXQKSL	SN	Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt
DMXQKSL	TC	Abortifacient Agents
DMXQKSL	DT	Small molecular drug
DMXQKSL	PC	5282415
DMXQKSL	MW	475.6
DMXQKSL	FM	C24H45NO8
DMXQKSL	IC	InChI=1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1
DMXQKSL	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
DMXQKSL	IK	IYGXEHDCSOYNKY-RZHHZEQLSA-N
DMXQKSL	IU	2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
DMXQKSL	CA	CAS 38562-01-5
DMXQKSL	CB	CHEBI:31502
DMXQKSL	DE	Abortion

DMTYOPD	ID	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	HS	Approved
DMTYOPD	SN	Cervidil; Dinoproston; Dinoprostona; Dinoprostonum; Prepidil; Propess; Prostenon; Prostin; Prepidil Gel; Prostarmon E;Prostin E; Dinoprostone Prostaglandin E2; Minprositin E2; Minprostin E2; PGE2; PGE2 alpha; PGE2alpha; Prostaglandin E2; Prostaglandin E2 alpha; Prostaglandin E2alpha; Prostarmon E2; Prostin E2; U 12062; [3H]PGE2; Alpha, PGE2; Alpha, Prostaglandin E2; BML1-F07; Cervidil (TN); Dinoprostona [INN-Spanish]; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostonum [INN-Latin]; E2 alpha, Prostaglandin; E2, Prostaglandin; E2alpha, Prostaglandin; Gel, Prepidil; L-PGE2; L-Prostaglandin E2; Prepidil (TN); Propess (TN); Prostin E2 (TN); U-12062; BMS-279654 & PGE2; Dinoprostone (JAN/USP/INN); Dinoprostone [USAN:INN:BAN:JAN]; L-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; (15S)-Prostaglandin E2; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI); 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
DMTYOPD	CP	Pfizer Pharmaceuticals
DMTYOPD	TC	Prostaglandins
DMTYOPD	DT	Small molecular drug
DMTYOPD	PC	5280360
DMTYOPD	MW	352.5
DMTYOPD	FM	C20H32O5
DMTYOPD	IC	InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1
DMTYOPD	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O
DMTYOPD	IK	XEYBRNLFEZDVAW-ARSRFYASSA-N
DMTYOPD	IU	(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMTYOPD	CA	CAS 363-24-6
DMTYOPD	CB	CHEBI:15551
DMTYOPD	DE	Medical abortion

DMXVU6D	ID	DMXVU6D
DMXVU6D	DN	Diphemanil Methylsulfate
DMXVU6D	HS	Approved
DMXVU6D	SN	Demotil; Diphemanil; Diphemanilum; Diphenatil; Diphenmethanil; Nivelon; Nivelona; Prantal; Prantil; Prentol; Talpran; Vagophemanil; Variton; Diphemanil methosulfate; Diphemanil methyl sulfate; Diphemanil methylsulphate; Diphemanil metilsulfate; Diphemanili metilsulfas; Diphenmanil methyl sulfate; Diphenmanil methylsulfate; Diphenmethanil methyl sulfate; Diphenmethanil methylsulfate; Metilsulfate de diphemanil; Metilsulfato de difemanilo; Prantal methylsulfate; Vagophemanil methyl sulfate; Ban-guard; Diphemanil methylsulfate [INN:BAN]; Diphemanil metilsulfate (INN); Diphemanili metilsulfas [INN-Latin]; Metilsulfate de diphemanil [INN-French]; Metilsulfato de difemanilo [INN-Spanish]; Prantal (TN); Ban-Guard (Veterinary); P-(alpha-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; N,N-Dimethyl-4-piperidylidene-1,1-diphenylmethane methylsulfate; P-(alpha.-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; Piperidinium, 4-(diphenylmethylene)-1,1-dimethyl-, methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methylsulfate; 4-(diphenylmethylidene)-1,1-dimethylpiperidinium methyl sulfate; 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium
DMXVU6D	TC	Parasympatholytics
DMXVU6D	DT	Small molecular drug
DMXVU6D	PC	6126
DMXVU6D	MW	389.5
DMXVU6D	FM	C21H27NO4S
DMXVU6D	IC	InChI=1S/C20H24N.CH4O4S/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;1-5-6(2,3)4/h3-12H,13-16H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
DMXVU6D	CS	C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C.COS(=O)(=O)[O-]
DMXVU6D	IK	BREMLQBSKCSNNH-UHFFFAOYSA-M
DMXVU6D	IU	4-benzhydrylidene-1,1-dimethylpiperidin-1-ium;methyl sulfate
DMXVU6D	CA	CAS 62-97-5
DMXVU6D	CB	CHEBI:59782
DMXVU6D	DE	Peptic ulcer

DMKQTBA	ID	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	HS	Approved
DMKQTBA	SN	diphenhydramine; 58-73-1; Benadryl; Benzhydramine; Probedryl; Alledryl; Antistominum; Dihidral; 2-(Benzhydryloxy)-N,N-dimethylethanamine; Benzhydraminum; Benzhydroamina; Diphantine; Difenhydramin; Ibiodral; Difedryl; Dibondrin; Mephadryl; Desentol; Dermistina; Betramin; Benzhydril; Benzantine; Benachlor; Bagodryl; Syntedril; Novamina; Medidryl; Hyadrine; Histaxin; Etanautine; Drylistan; Diabylen; Diabenyl; Dermodrin; Benodine; Baramine; Allergical; Debendrin; Benadrin; Dabylen; Antomin; Nausen; Benapon; Dylamon; Benylin; Benylan; Benodin; Amidryl;  Aleryl; Allerdryl; Allergeval; Allergina; Allergival; Antitussive; Automin; Banophen; Beldin; Belix; Bena; Benhydramin; Benzhydryl; Compoz; Dibendrin; Dibenil; Difenhidramina; Difenidramina; Dimedrol; Dimedryl; Dimehydrinate; Diphen; Diphenhist; Diphenhydraminum; Diphenylhydramin; Diphenylhydramine; Dryistan; Genahist; Hydramine; Hyrexin; Restamin; Rigidil; Siladryl; Silphen; Syntodril; Allergan B; Allermax Caplets; BENADRYL HCl; Banophen Caplets; Benadryl Allergy; Difenidramina [Italian]; Dimedrol base; Diphen Cough; Diphenhist Captabs; Diphenhydramine Base; Diphenhydramine HCl; Nytol Quickcaps; Nytol Quickgels;Twilite Caplets; Unisom Sleepgels Maximum Strength; Dormarex 2; FAR 90X2; PM 255; S51; Aller-Med; Ben-allergin; Benadryl (TN); Benadryl (hydrochloride); Beta-Dimethylaminoethanol diphenylmethyl ether; Beta-Dimethylaminoethylbenzhydrylether; Beta-dimethylaminoethyl benzhydryl ether; Difenhidramina [INN-Spanish]; Dimedrol (TN); Diphenhydraminum [INN-Latin]; Nervine Nighttime Sleep-Aid; Nytol (TN); O-Benzhydryldimethylaminoethanol; Restamin (TN); Sleep-Eze D; Sleep-Eze D Extra Strength; DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE; Diphenhydramine (JP15/INN); Diphenhydramine [INN:BAN:JAN]; Alpha-(2-Dimethylaminoethoxy)diphenylmethane; N-(Benzhydryloksy-etylo)dwumetyloamina; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; Beta-Dimethylamino-aethyl-benzhydryl-aether; Beta-Dimethylamino-aethyl-benzhydryl-aether [German]; N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; 2-(diphenylmethoxy)-N,N-dimethylethanamine; 2-Diphenylmethoxy-N,N-dimethylethylamine; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; 2-benzhydryloxy-N,N-dimethylethanamine; 2-benzhydryloxyethyl-N,N-dimethylammonium; 2-diphenylmethoxy-N,N-demthylethanamine; 2PM
DMKQTBA	CP	Johnson & Johnson 
DMKQTBA	TC	Antiallergic Agents
DMKQTBA	DT	Small molecular drug
DMKQTBA	PC	3100
DMKQTBA	MW	255.35
DMKQTBA	FM	C17H21NO
DMKQTBA	IC	InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
DMKQTBA	CS	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
DMKQTBA	IK	ZZVUWRFHKOJYTH-UHFFFAOYSA-N
DMKQTBA	IU	2-benzhydryloxy-N,N-dimethylethanamine
DMKQTBA	CA	CAS 58-73-1
DMKQTBA	CB	CHEBI:4636
DMKQTBA	DE	Meniere disease

DMHPWOM	ID	DMHPWOM
DMHPWOM	DN	Diphenidol
DMHPWOM	HS	Approved
DMHPWOM	SN	Avomol; Defenidol; Difenidol; Difenidolo; Difenidolum; Nometic; Vontrol; Difenidol HCl; Difenidolo [DCIT]; SKF 478; Difenidolum [INN-Latin]; Diphenidol [USAN:BAN]; SK-478; Diphenidol (USAN/INN); SK&F-478; Alpha,alpha-Diphenyl-1-piperidinebutanol; Diphenyl(3-(1-piperidyl)propyl)carbinol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol hydrochloride
DMHPWOM	DT	Small molecular drug
DMHPWOM	PC	3055
DMHPWOM	MW	309.4
DMHPWOM	FM	C21H27NO
DMHPWOM	IC	InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2
DMHPWOM	CS	C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O
DMHPWOM	IK	OGAKLTJNUQRZJU-UHFFFAOYSA-N
DMHPWOM	IU	1,1-diphenyl-4-piperidin-1-ylbutan-1-ol
DMHPWOM	CA	CAS 972-02-1
DMHPWOM	CB	CHEBI:4638
DMHPWOM	DE	Nausea

DMO5SZX	ID	DMO5SZX
DMO5SZX	DN	Diphenoxylate
DMO5SZX	HS	Approved
DMO5SZX	SN	Difenossilato; Difenoxilato; Diphenoxalate; Diphenoxylatum; Difenossilato [DCIT]; Difenoxilato [Spanish]; Diphenoxylate HCl; Diphenoxylate Monohydrochloride; Diphenoxylate hydrochloride; Diphenoxylatum [Latin]; NIH 7562; R 1132; Difenoxilato [INN-Spanish]; Diphenoxylate (INN); Diphenoxylate [INN:BAN]; Diphenoxylate hydrochloride (USP); Diphenoxylate hydrochloride(usp); Diphenoxylatum [INN-Latin]; R 1132 (antiperistaltic); R-1132; Co-phenotrope (TN); Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride; 1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride; 2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile; 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI); 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride; 4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride
DMO5SZX	CP	Janssen Pharmaceutica
DMO5SZX	TC	Analgesics
DMO5SZX	DT	Small molecular drug
DMO5SZX	PC	13505
DMO5SZX	MW	452.6
DMO5SZX	FM	C30H32N2O2
DMO5SZX	IC	InChI=1S/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3
DMO5SZX	CS	CCOC(=O)C1(CCN(CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMO5SZX	IK	HYPPXZBJBPSRLK-UHFFFAOYSA-N
DMO5SZX	IU	ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate
DMO5SZX	CA	CAS 915-30-0
DMO5SZX	CB	CHEBI:4639
DMO5SZX	DE	Diarrhea

DMW4X37	ID	DMW4X37
DMW4X37	DN	Diphenylpyraline
DMW4X37	HS	Approved
DMW4X37	SN	Allergen; Belfene; Dafen; Dayfen; Diafen; Difenilpiralina; Diphenylpyralamine; Diphenylpyralinum; Diphenylpyrilene; Hispril; Histryl; Histyn; Hystryl; Lergobine; Lyssipoll; Mepiben; Neargal; AN 1041; Difenilpiralina [INN-Spanish]; Diphenylpyraline (INN); Diphenylpyraline [INN:BAN]; Diphenylpyralinum [INN-Latin];Diphenylpyraline maleate (2:1); N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze; N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze [German]; 1-Methyl-4-piperidyl benzhydryl ether; 1-methyl-4-hydroxypiperidine benzhydryl ether; 4-(Benzhydryloxy)-1-methylpiperidine; 4-(Diphenylmethoxy)-1-methylpiperidine; 4-(benzhydryloxy)-N-methylpiperidine; 4-DIPHENYLMETHOXY-1-METHYLPIPERIDINE; 4-[(diphenylmethyl)oxy]-1-methylpiperidine; 4-benzhydryloxy-1-methylpiperidine
DMW4X37	TC	Antihistamines
DMW4X37	DT	Small molecular drug
DMW4X37	PC	3103
DMW4X37	MW	281.4
DMW4X37	FM	C19H23NO
DMW4X37	IC	InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3
DMW4X37	CS	CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3
DMW4X37	IK	OWQUZNMMYNAXSL-UHFFFAOYSA-N
DMW4X37	IU	4-benzhydryloxy-1-methylpiperidine
DMW4X37	CA	CAS 147-20-6
DMW4X37	CB	CHEBI:59788
DMW4X37	DE	Allergic rhinitis

DM0FSIM	ID	DM0FSIM
DM0FSIM	DN	Diphtheria-tetanus vaccine
DM0FSIM	HS	Approved
DM0FSIM	SN	Diphtheria-tetanus vaccine (im suspension), Finlay Institute
DM0FSIM	CP	Finlay Institute
DM0FSIM	DT	Vaccine
DM0FSIM	DE	Clostridium infection

DMH5W0G	ID	DMH5W0G
DMH5W0G	DN	Dipivefrin
DMH5W0G	HS	Approved
DMH5W0G	SN	AKPro; Dipivefrina; Dipivefrine; Dipivefrinum; Propine; Dipivalyl epinephrine; Dipivefrin HCL; Dipivefrin [USAN]; K 30081; Dipivefrin (USAN); Dipivefrina [INN-Spanish]; Dipivefrine (INN); Dipivefrinum [INN-Latin]; Ophtho-Dipivefrin; Propine C Cap B.I.D.; [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate; (+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate; (+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; (-)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester; (-)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat; (RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol; 2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate)
DMH5W0G	CP	Allergan Pharmaceutical
DMH5W0G	TC	Ophthalmologicals
DMH5W0G	DT	Small molecular drug
DMH5W0G	PC	3105
DMH5W0G	MW	351.4
DMH5W0G	FM	C19H29NO5
DMH5W0G	IC	InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3
DMH5W0G	CS	CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C
DMH5W0G	IK	OCUJLLGVOUDECM-UHFFFAOYSA-N
DMH5W0G	IU	[2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate
DMH5W0G	CA	CAS 52365-63-6
DMH5W0G	CB	CHEBI:4646
DMH5W0G	DE	Chronic open-angle glaucoma

DMXY30O	ID	DMXY30O
DMXY30O	DN	Dipyridamole
DMXY30O	HS	Approved
DMXY30O	SN	Agilease; Anginal; Antistenocardin; Apricor; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; Dipiridamol; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamolum; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Justpertin; Kurantil; Miosen; Natyl; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Protangix; Stenocardil; Stenocardiol; Stimolcardio; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; IPRAD Brand of Dipyridamole; Iv Persantine; Novopharm Brand of Dipyridamole; Cleridium 150; D 9766; Prandiol 75; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Berlin-Chemie Brand of Dipyridamole; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Novo-Dipiradol; Persantine (TN); RA-8; Usaf Ge-12; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Permole, Persantine, Dipyridan, Dipyridamole; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
DMXY30O	CP	FISCHER and ROCH
DMXY30O	TC	Vasodilator Agents
DMXY30O	DT	Small molecular drug
DMXY30O	PC	3108
DMXY30O	MW	504.6
DMXY30O	FM	C24H40N8O4
DMXY30O	IC	InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
DMXY30O	CS	C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
DMXY30O	IK	IZEKFCXSFNUWAM-UHFFFAOYSA-N
DMXY30O	IU	2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
DMXY30O	CA	CAS 58-32-2
DMXY30O	CB	CHEBI:4653
DMXY30O	DE	Hypertension

DM0D9YJ	ID	DM0D9YJ
DM0D9YJ	DN	Dirithromycin
DM0D9YJ	HS	Approved
DM0D9YJ	SN	Dirithromycine; Dirithromycinum; Diritromicina; Divitross; Dynabac; Noriclan; Valodin; Dirithromycine [French]; Dirithromycinum [Latin]; Diritromicina [Spanish]; LY 237216; AS-E 136; ASE-136; Dynabac (TN); LY-237216; Dirithromycin (USP/INN); Dirithromycin [USAN:BAN:INN]; (9S)-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]erythromycin
DM0D9YJ	TC	Antibiotics
DM0D9YJ	DT	Small molecular drug
DM0D9YJ	PC	6473883
DM0D9YJ	MW	835.1
DM0D9YJ	FM	C42H78N2O14
DM0D9YJ	IC	InChI=1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37-,39+,40-,41-,42-/m1/s1
DM0D9YJ	CS	CC[C@@H]1[C@@]([C@H]2[C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)(C)O)C)N[C@H](O2)COCCOC)C)(C)O
DM0D9YJ	IK	WLOHNSSYAXHWNR-DWIOZXRMSA-N
DM0D9YJ	IU	(1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2,10-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one
DM0D9YJ	CA	CAS 62013-04-1
DM0D9YJ	CB	CHEBI:474014
DM0D9YJ	DE	Bacterial infection

DM5SYZP	ID	DM5SYZP
DM5SYZP	DN	Disopyramide
DM5SYZP	HS	Approved
DM5SYZP	SN	Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
DM5SYZP	CP	Gd Searle Llc
DM5SYZP	TC	Antiarrhythmic Agents
DM5SYZP	DT	Small molecular drug
DM5SYZP	PC	3114
DM5SYZP	MW	339.5
DM5SYZP	FM	C21H29N3O
DM5SYZP	IC	InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
DM5SYZP	CS	CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C
DM5SYZP	IK	UVTNFZQICZKOEM-UHFFFAOYSA-N
DM5SYZP	IU	4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
DM5SYZP	CA	CAS 3737-09-5
DM5SYZP	CB	CHEBI:4657
DM5SYZP	DE	Ventricular arrhythmias; Urinary incontinence

DMCL2OK	ID	DMCL2OK
DMCL2OK	DN	Disulfiram
DMCL2OK	HS	Approved
DMCL2OK	SN	Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
DMCL2OK	CP	Odyssey Pharmaceuticals
DMCL2OK	TC	Alcohol Deterrents
DMCL2OK	DT	Small molecular drug
DMCL2OK	PC	3117
DMCL2OK	MW	296.5
DMCL2OK	FM	C10H20N2S4
DMCL2OK	IC	InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
DMCL2OK	CS	CCN(CC)C(=S)SSC(=S)N(CC)CC
DMCL2OK	IK	AUZONCFQVSMFAP-UHFFFAOYSA-N
DMCL2OK	IU	diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate
DMCL2OK	CA	CAS 97-77-8
DMCL2OK	CB	CHEBI:4659
DMCL2OK	DE	Alcohol dependence

DM4RK0G	ID	DM4RK0G
DM4RK0G	DN	Divalproex sodium
DM4RK0G	HS	Approved
DM4RK0G	SN	Delepsine; Depakote; Divalproate; Divalproex; Epilex; Epival; Sprinkle; Valcote; Valdisoval; Valparin; Depakote CP; Depakote ER; Depakote Sprinkle; Divalproex sodium [USAN]; Sodium divalproate; Sodium hydrogen divalproate; Valproate semisodique; Valproate semisodique [French]; Valproate semisodium; Valproato semisodico; Valproato semisodico [Spanish]; Valproatum seminatricum; Valproatum seminatricum [Latin]; Abbott 50711; Abbott-50711; Depacon (TN); Depakote (TN); Depakote ER (TN); Divalproex sodium (USP); Epival (TN); Ergenyl Chrono (TN); Valance (TN); Valproate semisodium (INN); Divalproex sodium, Depakote, Epival; Natrium hydrogen bis(2-propylvalerat); Sodium hydrogen bis(2-propylpentanoate); Sodium hydrogen bis(2-propylvalerate); Valproic acid semisodium salt (2:1); Zalkote. (TN); Sodium hydrogen bis(2-propylvalerate), oligomer; Sodium 2-propylpentanoate-2-propylpentanoic acid (1:1); Pentanoic acid, 2-propyl-, sodium salt (2:1); Pentanoic acid, 2-propyl-, sodium salt(2:1); 2-propylpentanoate
DM4RK0G	CP	Abbott Laboratories
DM4RK0G	TC	Anticonvulsants
DM4RK0G	DT	Small molecular drug
DM4RK0G	PC	23663956
DM4RK0G	MW	310.4
DM4RK0G	FM	C16H31NaO4
DM4RK0G	IC	InChI=1S/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1
DM4RK0G	CS	CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]
DM4RK0G	IK	MSRILKIQRXUYCT-UHFFFAOYSA-M
DM4RK0G	IU	sodium;2-propylpentanoate;2-propylpentanoic acid
DM4RK0G	CA	CAS 76584-70-8
DM4RK0G	CB	CHEBI:4667
DM4RK0G	DE	Seizure disorder

DMD1B8Z	ID	DMD1B8Z
DMD1B8Z	DN	Dobutamine
DMD1B8Z	HS	Approved
DMD1B8Z	SN	Dobutamina; Dobutaminum; Dobutamine Hcl; Dobutamine [USAN]; Dobutamine hydrobromide; LY 81929; Lilly 81929; DL-dobutamine; Dobutamina [INN-Spanish]; Dobutamine Hcl in Dextrose 5%; Dobutamine(usp); Dobutaminum [INN-Latin]; Rac-dobutamine; Racemic-Dobutamine; Dobutamine (USP/INN); Dobutamine [USAN:BAN:INN]; Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer; (+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine; 4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol; 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol; 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
DMD1B8Z	CP	Ben Venue Laboratories
DMD1B8Z	TC	Cardiotonic Agents
DMD1B8Z	DT	Small molecular drug
DMD1B8Z	PC	36811
DMD1B8Z	MW	301.4
DMD1B8Z	FM	C18H23NO3
DMD1B8Z	IC	InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
DMD1B8Z	CS	CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
DMD1B8Z	IK	JRWZLRBJNMZMFE-UHFFFAOYSA-N
DMD1B8Z	IU	4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
DMD1B8Z	CA	CAS 34368-04-2
DMD1B8Z	CB	CHEBI:4670
DMD1B8Z	DE	Heart failure

DMS5IEB	ID	DMS5IEB
DMS5IEB	DN	Docarpamine
DMS5IEB	HS	Approved
DMS5IEB	SN	Tanadopa (TN)
DMS5IEB	DT	Small molecular drug
DMS5IEB	PC	71137
DMS5IEB	MW	470.5
DMS5IEB	FM	C21H30N2O8S
DMS5IEB	IC	InChI=1S/C21H30N2O8S/c1-5-28-20(26)30-17-8-7-15(13-18(17)31-21(27)29-6-2)9-11-22-19(25)16(10-12-32-4)23-14(3)24/h7-8,13,16H,5-6,9-12H2,1-4H3,(H,22,25)(H,23,24)/t16-/m0/s1
DMS5IEB	CS	CCOC(=O)OC1=C(C=C(C=C1)CCNC(=O)[C@H](CCSC)NC(=O)C)OC(=O)OCC
DMS5IEB	IK	ZLVMAMIPILWYHQ-INIZCTEOSA-N
DMS5IEB	IU	[4-[2-[[(2S)-2-acetamido-4-methylsulfanylbutanoyl]amino]ethyl]-2-ethoxycarbonyloxyphenyl] ethyl carbonate
DMS5IEB	CA	CAS 74639-40-0
DMS5IEB	CB	CHEBI:31513
DMS5IEB	DE	Hypertension

DMDI269	ID	DMDI269
DMDI269	DN	Docetaxel
DMDI269	HS	Approved
DMDI269	SN	EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
DMDI269	CP	Sanofi-Aventis
DMDI269	TC	Anticancer Agents
DMDI269	DT	Small molecular drug
DMDI269	PC	148124
DMDI269	MW	807.9
DMDI269	FM	C43H53NO14
DMDI269	IC	InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
DMDI269	CS	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
DMDI269	IK	ZDZOTLJHXYCWBA-VCVYQWHSSA-N
DMDI269	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMDI269	CA	CAS 114977-28-5
DMDI269	CB	CHEBI:4672
DMDI269	DE	Solid tumour/cancer

DMOHK1E	ID	DMOHK1E
DMOHK1E	DN	Docosanol
DMOHK1E	HS	Approved
DMOHK1E	SN	Abreva; Debat; Doconsanol; Erazaban; Healip; Herepair; Lidakol; Lidavol; Tadenan; Behenic alcohol; Behenyl alcohol; Docosanol [USAN]; Docosyl alcohol; IK 2; Lanette 22; NAA 422; Stenol 1822; Stenol 1822A; Abreva (TN); Docosanol (USAN); Docosanol (VAN); Erazaban (TN); IK.2; N-Docosanol; Nacol 22-97; V-1326;BEHENYL ALCOHOL, 98%; Docosan-1-ol; Behenyl alcohol, Abreva, 1-Docosanol, Docosanol; Behenyl alcohol, AI3-36489, Behenic alcohol, 1-Docosanol, Docosyl alcohol, IK-2, Tadenan; 1-DOCOSANOL
DMOHK1E	CP	Avanir Pharmaceuticals 
DMOHK1E	TC	Antiviral Agents
DMOHK1E	DT	Small molecular drug
DMOHK1E	PC	12620
DMOHK1E	MW	326.6
DMOHK1E	FM	C22H46O
DMOHK1E	IC	InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
DMOHK1E	CS	CCCCCCCCCCCCCCCCCCCCCCO
DMOHK1E	IK	NOPFSRXAKWQILS-UHFFFAOYSA-N
DMOHK1E	IU	docosan-1-ol
DMOHK1E	CA	CAS 661-19-8
DMOHK1E	CB	CHEBI:31000
DMOHK1E	DE	Herpes simplex virus infection

DMPN1TW	ID	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	HS	Approved
DMPN1TW	SN	Dofetilida; Dofetilidum; Tikosyn; Xelide; UK 68798; Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin];Tikosyn (TN); UK 68,798; UK-68798; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; UK-68,798; Dofetilide (JAN/USAN/INN); Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE
DMPN1TW	CP	Pfizer Pharmaceuticals
DMPN1TW	TC	Antiarrhythmic Agents
DMPN1TW	DT	Small molecular drug
DMPN1TW	PC	71329
DMPN1TW	MW	441.6
DMPN1TW	FM	C19H27N3O5S2
DMPN1TW	IC	InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
DMPN1TW	CS	CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
DMPN1TW	IK	IXTMWRCNAAVVAI-UHFFFAOYSA-N
DMPN1TW	IU	N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
DMPN1TW	CA	CAS 115256-11-6
DMPN1TW	CB	CHEBI:4681
DMPN1TW	DE	Sinus rhythm disorder

DMMG26Z	ID	DMMG26Z
DMMG26Z	DN	Dolasetron
DMMG26Z	HS	Approved
DMMG26Z	SN	Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate
DMMG26Z	CP	Aventis Pharmaceuticals Inc.
DMMG26Z	TC	Antiemetics
DMMG26Z	DT	Small molecular drug
DMMG26Z	PC	3033818
DMMG26Z	MW	324.4
DMMG26Z	FM	C19H20N2O3
DMMG26Z	IC	InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11?,12-,13+,14?
DMMG26Z	CS	C1[C@@H]2CC(C[C@H]3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54
DMMG26Z	IK	UKTAZPQNNNJVKR-AKJUYKBHSA-N
DMMG26Z	IU	[(3S,7R)-10-oxo-8-azatricyclo[5.3.1.03,8]undecan-5-yl] 1H-indole-3-carboxylate
DMMG26Z	CA	CAS 115956-12-2
DMMG26Z	CB	CHEBI:94561
DMMG26Z	DE	Nausea

DMCZGRE	ID	DMCZGRE
DMCZGRE	DN	Dolutegravir
DMCZGRE	HS	Approved
DMCZGRE	SN	1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium (
DMCZGRE	CP	GlaxoSmithKline
DMCZGRE	DT	Small molecular drug
DMCZGRE	PC	54726191
DMCZGRE	MW	419.4
DMCZGRE	FM	C20H19F2N3O5
DMCZGRE	IC	InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
DMCZGRE	CS	C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
DMCZGRE	IK	RHWKPHLQXYSBKR-BMIGLBTASA-N
DMCZGRE	IU	(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
DMCZGRE	CA	CAS 1051375-16-6
DMCZGRE	CB	CHEBI:76010
DMCZGRE	DE	Human immunodeficiency virus infection

DMBDPY0	ID	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	HS	Approved
DMBDPY0	SN	Domperidon; Domperidona; Domperidonum; Motilium; Nauzelin; KW 5338; NCI299589; Costi (TN); D-122; Domperidona [INN-Spanish]; Domperidonum [INN-Latin]; HS-0067; KW-5338; Motilium (TN); Motillium (TN); Motinorm (TN); R 33,812; R-33812; R-33,812; Domperidone (JAN/USAN/INN); Domperidone [USAN:BAN:INN:JAN]; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMBDPY0	CP	Janssen Pharmaceutica
DMBDPY0	TC	Antiemetics
DMBDPY0	DT	Small molecular drug
DMBDPY0	PC	3151
DMBDPY0	MW	425.9
DMBDPY0	FM	C22H24ClN5O2
DMBDPY0	IC	InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
DMBDPY0	CS	C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O
DMBDPY0	IK	FGXWKSZFVQUSTL-UHFFFAOYSA-N
DMBDPY0	IU	6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMBDPY0	CA	CAS 57808-66-9
DMBDPY0	CB	CHEBI:31515
DMBDPY0	DE	Gastrointestinal disease

DMIYG7Z	ID	DMIYG7Z
DMIYG7Z	DN	Donepezil
DMIYG7Z	HS	Approved
DMIYG7Z	SN	Donepezil (transdermal patch, Alzheimer's disease)
DMIYG7Z	CP	Nitto Denko Corp
DMIYG7Z	TC	Neurology Agents
DMIYG7Z	DT	Small molecular drug
DMIYG7Z	PC	3152
DMIYG7Z	MW	379.5
DMIYG7Z	FM	C24H29NO3
DMIYG7Z	IC	InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
DMIYG7Z	CS	COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC
DMIYG7Z	IK	ADEBPBSSDYVVLD-UHFFFAOYSA-N
DMIYG7Z	IU	2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
DMIYG7Z	CA	CAS 120014-06-4
DMIYG7Z	CB	CHEBI:53289
DMIYG7Z	DE	Alzheimer disease

DMPGUCF	ID	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	HS	Approved
DMPGUCF	SN	Dopamin; Dopamina; Dopaminum; Dophamine; Hydroxytyramin; Hydroxytyramine; Intropin; LDP; Oxytyramine; Revimine; ASL 279; IP 498; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine [INN:BAN]; Dopaminum [INN-Latin]; L-DOPAMINE; M-Hydroxytyramine hydrochloride; Medopa (TN); Intropin [*hydrochloride*]; KW-3-060; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamine (USAN)(*hydrochloride*); A-(3,4-Dihydroxyphenyl)-b-aminoethane; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; (3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol
DMPGUCF	CP	Baxter Healthcare Corp Anesthesia And Critical Care
DMPGUCF	TC	Cardiotonic Agents
DMPGUCF	DT	Small molecular drug
DMPGUCF	PC	681
DMPGUCF	MW	153.18
DMPGUCF	FM	C8H11NO2
DMPGUCF	IC	InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
DMPGUCF	CS	C1=CC(=C(C=C1CCN)O)O
DMPGUCF	IK	VYFYYTLLBUKUHU-UHFFFAOYSA-N
DMPGUCF	IU	4-(2-aminoethyl)benzene-1,2-diol
DMPGUCF	CA	CAS 51-61-6
DMPGUCF	CB	CHEBI:18243
DMPGUCF	DE	Parkinson disease; Hypotension

DMSCIKZ	ID	DMSCIKZ
DMSCIKZ	DN	Dopexamine
DMSCIKZ	HS	Approved
DMSCIKZ	SN	Dopacard (TN)
DMSCIKZ	DT	Small molecular drug
DMSCIKZ	PC	55483
DMSCIKZ	MW	356.5
DMSCIKZ	FM	C22H32N2O2
DMSCIKZ	IC	InChI=1S/C22H32N2O2/c25-21-11-10-20(18-22(21)26)13-17-24-15-7-2-1-6-14-23-16-12-19-8-4-3-5-9-19/h3-5,8-11,18,23-26H,1-2,6-7,12-17H2
DMSCIKZ	CS	C1=CC=C(C=C1)CCNCCCCCCNCCC2=CC(=C(C=C2)O)O
DMSCIKZ	IK	RYBJORHCUPVNMB-UHFFFAOYSA-N
DMSCIKZ	IU	4-[2-[6-(2-phenylethylamino)hexylamino]ethyl]benzene-1,2-diol
DMSCIKZ	CA	CAS 86197-47-9
DMSCIKZ	CB	CHEBI:135507
DMSCIKZ	DE	Cardiac failure

DM9UCJK	ID	DM9UCJK
DM9UCJK	DN	Doripenem
DM9UCJK	HS	Approved
DM9UCJK	SN	Doribax; S 4661; S-4661; Doripenem (USAN/INN); (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9UCJK	CP	Shionogi; penisula
DM9UCJK	DT	Small molecular drug
DM9UCJK	PC	73303
DM9UCJK	MW	420.5
DM9UCJK	FM	C15H24N4O6S2
DM9UCJK	IC	InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1
DM9UCJK	CS	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O
DM9UCJK	IK	AVAACINZEOAHHE-VFZPANTDSA-N
DM9UCJK	IU	(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9UCJK	CA	CAS 148016-81-3
DM9UCJK	CB	CHEBI:135928
DM9UCJK	DE	Urinary tract infection; Gram-positive bacterial infection

DM3XU74	ID	DM3XU74
DM3XU74	DN	Dornase Alfa
DM3XU74	HS	Approved
DM3XU74	SN	Pulmozyme (TN)
DM3XU74	CP	Genentech
DM3XU74	TC	Enzyme Replacement Agents
DM3XU74	SQ	Dornase alfa sequence: LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVMLK
DM3XU74	DE	Cystic fibrosis

DMA17D0	ID	DMA17D0
DMA17D0	DN	Dorzolamide
DMA17D0	HS	Approved
DMA17D0	SN	Trusopt; Dorzolamide (DZA); Dorzolamide (INN); Trusopt (TN); (4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide; (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE
DMA17D0	CP	Merck & Co
DMA17D0	TC	Antihypertensive Agents
DMA17D0	DT	Small molecular drug
DMA17D0	PC	5284549
DMA17D0	MW	324.4
DMA17D0	FM	C10H16N2O4S3
DMA17D0	IC	InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1
DMA17D0	CS	CCN[C@H]1C[C@@H](S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
DMA17D0	IK	IAVUPMFITXYVAF-XPUUQOCRSA-N
DMA17D0	IU	(4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
DMA17D0	CA	CAS 120279-96-1
DMA17D0	CB	CHEBI:4702
DMA17D0	DE	Open-angle glaucoma

DM78NWP	ID	DM78NWP
DM78NWP	DN	Dostarlimab
DM78NWP	HS	Approved
DM78NWP	CP	AnaptysBio; GlaxoSmithKline
DM78NWP	DT	Antibody
DM78NWP	DE	Endometrial cancer; Multiple myeloma; Breast cancer; Neoplasm

DMKE7L9	ID	DMKE7L9
DMKE7L9	DN	Doxacurium
DMKE7L9	HS	Approved
DMKE7L9	SN	Nuromax; Chlorure de doxacurium; Chlorure de doxacurium [French]; Cloruro de doxacurio; Cloruro de doxacurio [Spanish]; Doxacurii chloridum; Doxacurii chloridum [Latin]; Doxacurium chloride(no stereochemistry); Nuromax (TN); Doxacurium chloride (USAN/INN); Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate; Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate dichloride
DMKE7L9	CP	Abbott Laboratories
DMKE7L9	TC	Analgesics
DMKE7L9	DT	Small molecular drug
DMKE7L9	PC	60169
DMKE7L9	MW	1035.2
DMKE7L9	FM	C56H78N2O16+2
DMKE7L9	IC	InChI=1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2
DMKE7L9	CS	C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C
DMKE7L9	IK	GBLRQXKSCRCLBZ-UHFFFAOYSA-N
DMKE7L9	IU	bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate
DMKE7L9	CA	CAS 133814-18-3
DMKE7L9	CB	CHEBI:4706
DMKE7L9	DE	Spasm

DMCYANK	ID	DMCYANK
DMCYANK	DN	Doxapram
DMCYANK	HS	Approved
DMCYANK	SN	Docatone; Dopram; Doxapramum; Doxapram HCL; Doxapram hydrochloride; Docatone (TN); Dopram (TN); Doxapram (INN); Doxapram [USP:JAN]; Doxapramum [INN-Latin]; (+-)-doxapram; 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one; 1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-(9CI)
DMCYANK	TC	Central Nervous System Stimulants
DMCYANK	DT	Small molecular drug
DMCYANK	PC	3156
DMCYANK	MW	378.5
DMCYANK	FM	C24H30N2O2
DMCYANK	IC	InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3
DMCYANK	CS	CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4
DMCYANK	IK	XFDJYSQDBULQSI-UHFFFAOYSA-N
DMCYANK	IU	1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one
DMCYANK	CA	CAS 309-29-5
DMCYANK	CB	CHEBI:681848
DMCYANK	DE	Respiratory disease

DM9PLRH	ID	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	HS	Approved
DM9PLRH	SN	Doxazosina; Doxazosine; Doxazosinum; Normothen; Doxazosina [Spanish]; Doxazosine [French]; Doxazosinum [Latin]; UK 33274; Cardura (TN); Cardura XL (TN); Cardura-1; Cardura-2; Cardura-4; Carduran (TN); Doxazosin (INN); Doxazosin [INN:BAN]; UK-33274; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
DM9PLRH	CP	Pfizer Pharmaceuticals
DM9PLRH	TC	Antihypertensive Agents
DM9PLRH	DT	Small molecular drug
DM9PLRH	PC	3157
DM9PLRH	MW	451.5
DM9PLRH	FM	C23H25N5O5
DM9PLRH	IC	InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
DM9PLRH	CS	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
DM9PLRH	IK	RUZYUOTYCVRMRZ-UHFFFAOYSA-N
DM9PLRH	IU	[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
DM9PLRH	CA	CAS 74191-85-8
DM9PLRH	CB	CHEBI:4708
DM9PLRH	DE	Hypertension

DMPI98T	ID	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	HS	Approved
DMPI98T	SN	Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin;  Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin
DMPI98T	CP	Pfizer Pharmaceuticals
DMPI98T	TC	Antidepressants
DMPI98T	DT	Small molecular drug
DMPI98T	PC	667477
DMPI98T	MW	279.4
DMPI98T	FM	C19H21NO
DMPI98T	IC	InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+
DMPI98T	CS	CN(C)CC/C=C/1\\C2=CC=CC=C2COC3=CC=CC=C31
DMPI98T	IK	ODQWQRRAPPTVAG-GZTJUZNOSA-N
DMPI98T	IU	(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
DMPI98T	CA	CAS 1668-19-5
DMPI98T	DE	Depression

DM6FG1P	ID	DM6FG1P
DM6FG1P	DN	Doxercalciferol
DM6FG1P	HS	Approved
DM6FG1P	SN	Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)
DM6FG1P	CP	Genzyme
DM6FG1P	DT	Small molecular drug
DM6FG1P	PC	5281107
DM6FG1P	MW	412.6
DM6FG1P	FM	C28H44O2
DM6FG1P	IC	InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
DM6FG1P	CS	C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM6FG1P	IK	HKXBNHCUPKIYDM-CGMHZMFXSA-N
DM6FG1P	IU	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM6FG1P	CA	CAS 54573-75-0
DM6FG1P	CB	CHEBI:4712
DM6FG1P	DE	Chronic kidney disease

DMEDKZH	ID	DMEDKZH
DMEDKZH	DN	Doxofylline
DMEDKZH	HS	Approved
DMEDKZH	SN	Ansimar (TN)
DMEDKZH	CP	ABC S.p.A.
DMEDKZH	DT	Small molecular drug
DMEDKZH	PC	50942
DMEDKZH	MW	266.25
DMEDKZH	FM	C11H14N4O4
DMEDKZH	IC	InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
DMEDKZH	CS	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3
DMEDKZH	IK	HWXIGFIVGWUZAO-UHFFFAOYSA-N
DMEDKZH	IU	7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
DMEDKZH	CA	CAS 69975-86-6
DMEDKZH	CB	CHEBI:94714
DMEDKZH	DE	Asthma

DMVP5YE	ID	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	HS	Approved
DMVP5YE	SN	doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin
DMVP5YE	CP	Sequus Pharmaceuticals Inc
DMVP5YE	TC	Anticancer Agents
DMVP5YE	DT	Small molecular drug
DMVP5YE	PC	31703
DMVP5YE	MW	543.5
DMVP5YE	FM	C27H29NO11
DMVP5YE	IC	InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
DMVP5YE	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
DMVP5YE	IK	AOJJSUZBOXZQNB-TZSSRYMLSA-N
DMVP5YE	IU	(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMVP5YE	CA	CAS 23214-92-8
DMVP5YE	CB	CHEBI:28748
DMVP5YE	DE	Solid tumour/cancer; Tumour; Breast cancer; Hepatocellular carcinoma

DM7ICNU	ID	DM7ICNU
DM7ICNU	DN	Doxycycline
DM7ICNU	HS	Approved
DM7ICNU	SN	Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline
DM7ICNU	CP	Collagenex
DM7ICNU	TC	Antiinflammatory Agents
DM7ICNU	DT	Small molecular drug
DM7ICNU	PC	54671203
DM7ICNU	MW	444.4
DM7ICNU	FM	C22H24N2O8
DM7ICNU	IC	InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
DM7ICNU	CS	C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
DM7ICNU	IK	SGKRLCUYIXIAHR-AKNGSSGZSA-N
DM7ICNU	IU	(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DM7ICNU	CA	CAS 564-25-0
DM7ICNU	CB	CHEBI:50845
DM7ICNU	DE	Chronic periodontitis; Advanced gum disease; Diabetic foot ulcer

DMKOXFE	ID	DMKOXFE
DMKOXFE	DN	Doxylamine
DMKOXFE	HS	Approved
DMKOXFE	SN	Dossilamina; Doxilamina; Doxilminio; Doxylaminum; Dossilamina [DCIT]; Diclectin (TN); Dolased (TN); Donormyl (TN); Dormidina (TN); Doxilminio [INN-Spanish]; Doxylamine (INN); Doxylamine [INN:BAN]; Doxylaminum [INN-Latin]; Dozile (TN); Evanorm (TN); Mersyndol (TN); Restavit (TN); Somnil (TN); Syndol (TN); Unisom-2 (TN); Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; 2-Dimethylaminoethoxyphenylmethyl-2-picoline
DMKOXFE	CP	Ion Healthcare
DMKOXFE	TC	Hypnotics and Sedatives
DMKOXFE	DT	Small molecular drug
DMKOXFE	PC	3162
DMKOXFE	MW	270.37
DMKOXFE	FM	C17H22N2O
DMKOXFE	IC	InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
DMKOXFE	CS	CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C
DMKOXFE	IK	HCFDWZZGGLSKEP-UHFFFAOYSA-N
DMKOXFE	IU	N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
DMKOXFE	CA	CAS 469-21-6
DMKOXFE	CB	CHEBI:51380
DMKOXFE	DE	Morning sickness

DMGOXPQ	ID	DMGOXPQ
DMGOXPQ	DN	DP-VPA
DMGOXPQ	HS	Approved
DMGOXPQ	SN	TVA; RAP-valproate; SPD-421; Valproic acid prodrug, Shire; RAP-valproate, D-Pharm
DMGOXPQ	CP	D-Pharm Ltd
DMGOXPQ	DE	Bipolar disorder

DMF2JDG	ID	DMF2JDG
DMF2JDG	DN	Dromostanolone
DMF2JDG	HS	Approved
DMF2JDG	SN	Drostanolo; Drostanolon; Drostanolona; Drostanolone; Drostanolonum; Medrosteron; Medrotestron; Methalone; Metholone; Prometholone; Drostanolo [DCIT]; SKI 27719; Drolban (TN); Drostanolona [INN-Spanish]; Drostanolone [INN:BAN]; Drostanolonum [INN-Latin]; Dihydro-2alpha-methyltestosterone; Dihydro-2-alpha-methyltestosterone; Dihydro-2.alpha.-methyltestosterone; Androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)-(9CI); (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one; 17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one; 17-beta-Hydroxy-2-alpha-methyl-5-alpha-androstan-3-one; 17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one; 2-alpha-Methyl-17-beta-hydroxy-5-alpha-androstan-3-one; 2-alpha-Methyldihydrotestosterone; 2.alpha.-Methyldihydrotestosterone; 2a-methylandrostan-17b-ol-3-one; 2alpha-Methyldihydrotestosterone
DMF2JDG	CP	Eli Lilly And Co
DMF2JDG	TC	Anabolic Agents
DMF2JDG	DT	Small molecular drug
DMF2JDG	PC	6011
DMF2JDG	MW	304.5
DMF2JDG	FM	C20H32O2
DMF2JDG	IC	InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1
DMF2JDG	CS	C[C@@H]1C[C@]2([C@@H](CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C)CC1=O)C
DMF2JDG	IK	IKXILDNPCZPPRV-RFMGOVQKSA-N
DMF2JDG	IU	(2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
DMF2JDG	CA	CAS 58-19-5
DMF2JDG	CB	CHEBI:34838
DMF2JDG	DE	Mammary tumour

DMA8FS5	ID	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	HS	Approved
DMA8FS5	SN	Multaq; Dronedarone [INN]; SR 33589; SR 33589B; Dronedarone (INN); Sanofi-Aventis brand of dronedarone; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide
DMA8FS5	CP	Sanofi-Synthelabo
DMA8FS5	DT	Small molecular drug
DMA8FS5	PC	208898
DMA8FS5	MW	556.8
DMA8FS5	FM	C31H44N2O5S
DMA8FS5	IC	InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3
DMA8FS5	CS	CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC
DMA8FS5	IK	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
DMA8FS5	IU	N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide
DMA8FS5	CA	CAS 141626-36-0
DMA8FS5	CB	CHEBI:50659
DMA8FS5	DE	Angina pectoris; Atrial fibrillation

DM0DXA8	ID	DM0DXA8
DM0DXA8	DN	Droperidol
DM0DXA8	HS	Approved
DM0DXA8	SN	DHBP; Dehidrobenzperidol; Dehydrobenzoperidol; Dehydrobenzperidol; Deidrobenzperidolo; Dihidrobenzperidol; Dridol; Droleptan; Droperidolo; Droperidolum; Halkan; Inappin; Inapsin; Inapsine; Innovan; Inopsin; Inoval; Leptanal; Leptofen; Properidol; Sintodril; Sintosian; Thalamanol; Thalamonal; Vetkalm; Component of Innovar; Droperidolo [DCIT]; Janssen Brand of Droperidol; Kern Brand of Droperidol; Taylor Brand of Droperidol; R 4749; R4749; Dridol (TN); Droleptan (TN); Droperidolum [INN-Latin]; Dropletan (TN); HS-0065; INAPSINE (TN); Inapsine (TN); Innovar-vet; McN-JR 4749; R-4749; Ina.psi.n; Ina.psi.ne; Ino.psi.n; McN-JR-4749; Droperidol (JP15/USP/INN); Droperidol [USAN:INN:BAN:JAN]; Luorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-(1-(4-(4-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-F; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenz; 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
DM0DXA8	CP	Janssen Pharmaceutica
DM0DXA8	TC	Antipsychotic Agents
DM0DXA8	DT	Small molecular drug
DM0DXA8	PC	3168
DM0DXA8	MW	379.4
DM0DXA8	FM	C22H22FN3O2
DM0DXA8	IC	InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
DM0DXA8	CS	C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
DM0DXA8	IK	RMEDXOLNCUSCGS-UHFFFAOYSA-N
DM0DXA8	IU	3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
DM0DXA8	CA	CAS 548-73-2
DM0DXA8	CB	CHEBI:4717
DM0DXA8	DE	Nausea

DM1A9W3	ID	DM1A9W3
DM1A9W3	DN	Drospirenone
DM1A9W3	HS	Approved
DM1A9W3	SN	DRSP; Dehydrospirorenone; Dihydrospirorenone; Drospirenona; Drospirenonum; Drospirenone [INN]; ZK 30595; ZK30595; Angeliq, Drospirenone; Drospirenona [INN-Spanish]; Drospirenonum [INN-Latin]; SH-470; ZK-30595; Drospirenone (JAN/USAN/INN); (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimethylspiro-(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione; 1,2-Dihydrospirorenone; 1,2-dihydro-spirorenone; 17-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone; 3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'H,16'H-dicyclopropa[6,7;15,16]-17alpha-pregn-4-ene-21,17-carbolactone; 6-beta,7-beta;15-beta,16-beta-Dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone; 6beta,7beta,15beta,16beta-dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton; 6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone; 6beta,7beta;15beta,16beta-Dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; Spiro(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta
DM1A9W3	TC	Contraceptive Agents
DM1A9W3	DT	Small molecular drug
DM1A9W3	PC	68873
DM1A9W3	MW	366.5
DM1A9W3	FM	C24H30O3
DM1A9W3	IC	InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
DM1A9W3	CS	C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C
DM1A9W3	IK	METQSPRSQINEEU-HXCATZOESA-N
DM1A9W3	IU	(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione
DM1A9W3	CA	CAS 67392-87-4
DM1A9W3	CB	CHEBI:50838
DM1A9W3	DE	Contraception

DM59JCN	ID	DM59JCN
DM59JCN	DN	Drotrecogin alfa
DM59JCN	HS	Approved
DM59JCN	SN	Xigris; Drotrecogin alfa (activated); Xigris (TN); Drotrecogin alfa (activated) (USAN)
DM59JCN	CP	Eli Lilly
DM59JCN	TC	Antisepsis Agents
DM59JCN	SQ	Heavy chain: LIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP</sequence>    <sequence format="FASTA">&gt;Light chainSKHVDGDQCLVLPLEHPCASLCCGHGTCIXGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHL
DM59JCN	DE	Cerebrovascular ischaemia; Severe sepsis

DM5YF4M	ID	DM5YF4M
DM5YF4M	DN	Droxidopa
DM5YF4M	HS	Approved
DM5YF4M	SN	droxidopa; 23651-95-8; L-DOPS; Northera; (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid; threo-Dopaserine; 3916-18-5; DOPS; DL-threo-DOPS; L-Threodops; DL-threo-3,4-Dihydroxyphenylserine; DL-threo-Droxidopa; DL-threo-Dihydroxyphenylserine; UNII-J7A92W69L7; SM 5688; CHEBI:31524; Droxidopa (L-DOPS); threo-beta,3-Dihydroxy-DL-tyrosine; EINECS 223-480-5; beta,3-Dihydroxy-DL-tyrosine threo-; BRN 2852792; L-threo-dihydroxyphenylserine; DL-threo-3-(3,4-Dihydroxyphenyl)serine; Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo-
DM5YF4M	CP	Chelsea Therapeutics
DM5YF4M	DT	Small molecular drug
DM5YF4M	PC	92974
DM5YF4M	MW	213.19
DM5YF4M	FM	C9H11NO5
DM5YF4M	IC	InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
DM5YF4M	CS	C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O
DM5YF4M	IK	QXWYKJLNLSIPIN-JGVFFNPUSA-N
DM5YF4M	IU	(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
DM5YF4M	CA	CAS 23651-95-8
DM5YF4M	CB	CHEBI:31524
DM5YF4M	DE	Neurogenic orthostatic hypotension

DMXZRW0	ID	DMXZRW0
DMXZRW0	DN	DTI-015
DMXZRW0	HS	Approved
DMXZRW0	SN	Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK;  BCNU; Injectable carmustine, Direct Therapeutics
DMXZRW0	CP	Direct Therapeutics Inc
DMXZRW0	DT	Small molecular drug
DMXZRW0	PC	2578
DMXZRW0	MW	214.05
DMXZRW0	FM	C5H9Cl2N3O2
DMXZRW0	IC	InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)
DMXZRW0	CS	C(CCl)NC(=O)N(CCCl)N=O
DMXZRW0	IK	DLGOEMSEDOSKAD-UHFFFAOYSA-N
DMXZRW0	IU	1,3-bis(2-chloroethyl)-1-nitrosourea
DMXZRW0	CA	CAS 154-93-8
DMXZRW0	CB	CHEBI:3423
DMXZRW0	DE	Liver cancer; Brain cancer

DMCIJBH	ID	DMCIJBH
DMCIJBH	DN	DU-176B
DMCIJBH	HS	Approved
DMCIJBH	SN	Edoxaban
DMCIJBH	CP	Daiichi Sankyo
DMCIJBH	DT	Small molecular drug
DMCIJBH	PC	25022378
DMCIJBH	MW	738.3
DMCIJBH	FM	C31H40ClN7O8S2
DMCIJBH	IC	InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1
DMCIJBH	CS	CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O
DMCIJBH	IK	PSMMNJNZVZZNOI-SJILXJHISA-N
DMCIJBH	IU	N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;4-methylbenzenesulfonic acid;hydrate
DMCIJBH	CA	CAS 1229194-11-9
DMCIJBH	CB	CHEBI:85974
DMCIJBH	DE	Atrial fibrillation

DMYXBV3	ID	DMYXBV3
DMYXBV3	DN	Dulaglutide
DMYXBV3	HS	Approved
DMYXBV3	SN	GLP-1 analog
DMYXBV3	CP	Eli Lilly
DMYXBV3	SQ	Dulaglutide Sequence: HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
DMYXBV3	DE	Type-2 diabetes

DM9BI7M	ID	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	HS	Approved
DM9BI7M	SN	Yentreve; LY 248686; Cymbalta (TN); Duloxetine (INN); Duloxetine [INN:BAN]; Yentreve (TN); Duloxetine, (+)-isomer; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; (S)-Duloxetine; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine
DM9BI7M	CP	Eli Lilly
DM9BI7M	TC	Antidepressants
DM9BI7M	DT	Small molecular drug
DM9BI7M	PC	60835
DM9BI7M	MW	297.4
DM9BI7M	FM	C18H19NOS
DM9BI7M	IC	InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
DM9BI7M	CS	CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
DM9BI7M	IK	ZEUITGRIYCTCEM-KRWDZBQOSA-N
DM9BI7M	IU	(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
DM9BI7M	CA	CAS 116539-59-4
DM9BI7M	CB	CHEBI:36795
DM9BI7M	DE	Depression

DMOAD2Y	ID	DMOAD2Y
DMOAD2Y	DN	Dupilumab
DMOAD2Y	HS	Approved
DMOAD2Y	SN	REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis
DMOAD2Y	CP	Regeneron/Sanofi
DMOAD2Y	DT	Antibody
DMOAD2Y	DE	Atopic dermatitis; Asthma

DM4PVDY	ID	DM4PVDY
DM4PVDY	DN	Durvalumab
DM4PVDY	HS	Approved
DM4PVDY	CP	AstraZeneca
DM4PVDY	DT	Monoclonal antibody
DM4PVDY	SQ	Durvalumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Durvalumab light chainEIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM4PVDY	DE	Pancreatic ductal carcinoma; Solid tumour/cancer; Biliary tract cancer; Diffuse large B-cell lymphoma; Hepatocellular carcinoma; Melanoma; Urothelial carcinoma

DMQ4TJK	ID	DMQ4TJK
DMQ4TJK	DN	Dutasteride
DMQ4TJK	HS	Approved
DMQ4TJK	SN	Avodart; Avolve; Duagen; Dutasteride [USAN]; GG 745; GI 198745; Avidart (TN); Avodart (TN); Avodart, Dutasteride; Avolve (TN); Duagen (TN); Duprost (TN); Dutagen (TN); Dutas (TN); GG-745; GI-198745; GI-198745X; Dutasteride (JAN/USAN/INN); N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
DMQ4TJK	CP	GSK
DMQ4TJK	TC	Anticancer Agents
DMQ4TJK	DT	Small molecular drug
DMQ4TJK	PC	6918296
DMQ4TJK	MW	528.5
DMQ4TJK	FM	C27H30F6N2O2
DMQ4TJK	IC	InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
DMQ4TJK	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
DMQ4TJK	IK	JWJOTENAMICLJG-QWBYCMEYSA-N
DMQ4TJK	IU	(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
DMQ4TJK	CA	CAS 164656-23-9
DMQ4TJK	CB	CHEBI:521033
DMQ4TJK	DE	Benign prostatic hyperplasia; Prostate cancer

DMU6OFP	ID	DMU6OFP
DMU6OFP	DN	Dyclonine
DMU6OFP	HS	Approved
DMU6OFP	SN	Diclonia; Diclonina; Dyclocaine; Dyclocainum; Dyclonin; Dycloninum; Dyclothane; Tanaclone; Diclonina [INN-Spanish]; Dyclonine (INN); Dyclonine [INN:BAN]; Dycloninum [INN-Latin]; 1-(4-Butoxy-phenyl)-3-piperidin-1-yl-propan-1-one; 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone; 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one; 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-(9CI); 2-(1-piperidyl)ethyl p-butoxyphenyl ketone; 3-Piperidino-4'-butoxypropiophenone; 4'-Butoxy-3-piperidinopropiophenone; 4-butoxy-beta-piperidinopropiophenone; 4-n-butoxy-beta-(1-piperidyl)propiophenone
DMU6OFP	CP	Astrazeneca Lp
DMU6OFP	TC	Anesthetics
DMU6OFP	DT	Small molecular drug
DMU6OFP	PC	3180
DMU6OFP	MW	289.4
DMU6OFP	FM	C18H27NO2
DMU6OFP	IC	InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
DMU6OFP	CS	CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2
DMU6OFP	IK	BZEWSEKUUPWQDQ-UHFFFAOYSA-N
DMU6OFP	IU	1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one
DMU6OFP	CA	CAS 586-60-7
DMU6OFP	CB	CHEBI:4724
DMU6OFP	DE	Pain

DMAKIDV	ID	DMAKIDV
DMAKIDV	DN	Dydrogesterone
DMAKIDV	HS	Approved
DMAKIDV	SN	Dehydrogesterone; Didrogesterona; Didrogesterone; Diphaston; Dufaston; Duphaston; Duvaron; Dydrogesterona; Dydrogesteronum; Gestatron; Gynorest; Hydrogesterone; Hydrogestrone; Isopregnenone; Prodel; Retrone; Terolut; Didrogesterone [DCIT]; Solvay Brand of Dydrogesterone; DELTA6-Retroprogesterone; Duphaston (TN); Dydrogesterona [INN-Spanish]; Dydrogesteronum [INN-Latin]; Gynorest (TN); Delta(6)-Retroprogesterone; Delta(sup 6)-Retroprogesterone; Retro-6-dehydroprogesterone; Dydrogesterone (JP15/USP/INN); Dydrogesterone [USAN:INN:BAN:JAN]; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-(9CI); (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one; (9-beta,10-alpha)-Pregna-4,6-diene-3,20-dione; (9beta,10alpha)-pregna-4,6-diene-3,20-dione; 10alpha-Isopregnenone; 6 Dehydro 9 beta 10 alpha progesterone; 6-Dehydro-9 beta-10 alpha-progesterone; 6-Dehydro-9.beta.,10.alpha.-progesterone; 6-Dehydro-9beta,10alpha-progesterone; 6-Dehydro-retro-progesterone; 6-Dehydroretroprogesterone; 9-.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9-beta,10-alpha-Pregna-4,6-diene-3,20-dione; 9-beta,10alpha-Pregna-4,6-diene-3,20-dione; 9.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione (8CI)
DMAKIDV	CP	Solvay Pharmaceuticals
DMAKIDV	TC	Progesterones
DMAKIDV	DT	Small molecular drug
DMAKIDV	PC	9051
DMAKIDV	MW	312.4
DMAKIDV	FM	C21H28O2
DMAKIDV	IC	InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1
DMAKIDV	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3[C@H]2C=CC4=CC(=O)CC[C@@]34C)C
DMAKIDV	IK	JGMOKGBVKVMRFX-HQZYFCCVSA-N
DMAKIDV	IU	(8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMAKIDV	CA	CAS 152-62-5
DMAKIDV	CB	CHEBI:31527
DMAKIDV	DE	Menstrual disorder

DM8DZC1	ID	DM8DZC1
DM8DZC1	DN	Dyphylline
DM8DZC1	HS	Approved
DM8DZC1	SN	Aristophyllin; Asthmolysin; Astmamasit; Astrophyllin; Circain; Circair; Coronal; Coronarin; Corphyllin; Dihydroxypropyltheophylline; Diprofilina; Diprofillin; Diprofillina; Diprofilline; Diprophyllin; Diprophylline; Diprophyllinum; Dipropylline; Droxine; Dyflex; Glyfyllin; Glyphyllin; Glyphylline; Glyphyllinum; Hidroxiteofillina; Hiphyllin; Hyphylline; Iphyllin; Isophyllen; Liactemin; Lufyllin; Neophyl; Neophyllin; Neophylline; Neostenovasan; Neothylline; Neotilina; Neufil; Neutrafil; Neutrafillina; Neutraphyllin; Neutraphylline; Neutroxantina; Propyphyllin; Protheophylline; Purifilin; Silbephyllin; Silbephylline; Solufilin; Solufyllin; Soluphyllin; Synthophylline; Tefilan; Teofen; Tesfen; Theal; Thefylan; Dihydroxypropyl theophylline; Dihydroxypropyl theopylin; Dilor G; Diprofillina [DCIT]; Dyphylline [USAN]; Neophyllin M; Theal ampules; AFI-Phyllin; COR-theophylline; Dihydroxypropyl theopylin (german); Dilor-400; Diphyllin (VAN); Diprofilina [INN-Spanish]; Diprophyllinum [INN-Latin]; Dyphylline (USP); Lufyllin (TN); Neo-Vasophylline; Diprophylline (JAN/INN); Neothylline, Lufyllin, diprophylline,Dyphylline; (+-)-7-(2,3-Dihydroxypropyl)theophylline; (+-)-diprophylline; (+-)-dyphylline; (1,2-Dihydroxy-3-propyl)thiophyllin; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)theophylline; 7-(2,3-Dioxypropyl)theophylline; 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; 7-(beta,gamma-Dihydroxypropyl)theophylline; 7-(beta.,.gamma.-Dihydroxypropyl)theophylline; 7-DIHYDROXYPROPYLTHEOPHYLLINE; 7-[2,3-Dihydroxypropyl]-theophylline
DM8DZC1	TC	Bronchodilator Agents
DM8DZC1	DT	Small molecular drug
DM8DZC1	PC	3182
DM8DZC1	MW	254.24
DM8DZC1	FM	C10H14N4O4
DM8DZC1	IC	InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3
DM8DZC1	CS	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O
DM8DZC1	IK	KSCFJBIXMNOVSH-UHFFFAOYSA-N
DM8DZC1	IU	7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione
DM8DZC1	CA	CAS 479-18-5
DM8DZC1	CB	CHEBI:4728
DM8DZC1	DE	Acute bronchial asthma

DMJDYNQ	ID	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	HS	Approved
DMJDYNQ	SN	Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
DMJDYNQ	CP	Eisai Co. Ltd.
DMJDYNQ	DT	Small molecular drug
DMJDYNQ	PC	9924495
DMJDYNQ	MW	349.4
DMJDYNQ	FM	C23H15N3O
DMJDYNQ	IC	InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H
DMJDYNQ	CS	C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4
DMJDYNQ	IK	PRMWGUBFXWROHD-UHFFFAOYSA-N
DMJDYNQ	IU	2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile
DMJDYNQ	CA	CAS 380917-97-5
DMJDYNQ	CB	CHEBI:71013
DMJDYNQ	DE	Diabetic neuropathy; Parkinson disease

DMOF2C6	ID	DMOF2C6
DMOF2C6	DN	Ecallantide
DMOF2C6	HS	Approved
DMOF2C6	SN	FOV-2302; Retinal venous occlusion therapy, Fovea; Ecallantide (ophthalmic formulation/retinal disease); Ecallantide (ophthalmic formulation/retinal disease), Dyax/Fovea; DX-88 (ophthalmic formulation/retinal disease), Dyax/Fovea
DMOF2C6	CP	Dyax Corp
DMOF2C6	DT	Small molecular drug
DMOF2C6	PC	44152182
DMOF2C6	MW	7054
DMOF2C6	FM	C305H442N88O91S8
DMOF2C6	IC	InChI=1S/C305H442N88O91S8/c1-16-152(5)241-295(478)377-195(124-168-80-82-172(398)83-81-168)252(435)334-137-227(404)333-138-228(405)345-214-143-487-491-147-218-291(474)351-179(73-47-107-327-301(315)316)255(438)341-154(7)245(428)339-155(8)249(432)379-210(127-171-136-326-150-338-171)299(482)393-113-53-79-221(393)294(477)361-181(75-49-109-329-303(319)320)260(443)372-203(125-169-134-332-175-69-40-39-68-173(169)175)277(460)370-198(119-163-58-29-20-30-59-163)274(457)369-199(120-164-60-31-21-32-61-164)275(458)375-207(130-226(314)403)284(467)389-242(153(6)17-2)296(479)378-202(123-167-66-37-24-38-67-167)283(466)390-243(159(12)396)297(480)362-182(76-50-110-330-304(321)322)258(441)353-186(86-94-223(311)400)267(450)383-217(290(473)359-188(89-98-234(414)415)263(446)354-189(90-99-235(416)417)265(448)368-201(282(465)388-241)122-166-64-35-23-36-65-166)146-490-489-145-216(384-268(451)191(92-101-237(420)421)355-262(445)187(88-97-233(412)413)357-271(454)194(116-151(3)4)366-285(468)212(141-394)381-266(449)190(91-100-236(418)419)358-273(456)197(118-162-56-27-19-28-57-162)367-259(442)180(74-48-108-328-302(317)318)349-280(463)206(129-225(313)402)374-264(447)185(85-93-222(310)399)356-279(462)205(128-224(312)401)344-229(406)139-335-251(434)184(352-288(214)471)87-96-232(410)411)289(472)350-178(72-43-46-106-308)256(439)347-177(71-42-45-105-307)257(440)360-193(103-115-486-15)270(453)385-219(292(475)391-244(160(13)397)298(481)363-183(77-51-111-331-305(323)324)261(444)380-211(300(483)484)133-240(426)427)148-492-488-144-215(386-276(459)200(121-165-62-33-22-34-63-165)371-286(469)213(142-395)382-278(461)204(126-170-135-325-149-337-170)373-269(452)192(102-114-485-14)346-246(429)156(9)340-250(433)174(309)84-95-231(408)409)287(470)343-158(11)247(430)364-196(117-161-54-25-18-26-55-161)272(455)348-176(70-41-44-104-306)254(437)342-157(10)248(431)365-209(132-239(424)425)281(464)376-208(131-238(422)423)253(436)336-140-230(407)392-112-52-78-220(392)293(476)387-218/h18-40,54-69,80-83,134-136,149-160,174,176-221,241-244,332,394-398H,16-17,41-53,70-79,84-133,137-148,306-309H2,1-15H3,(H2,310,399)(H2,311,400)(H2,312,401)(H2,313,402)(H2,314,403)(H,325,337)(H,326,338)(H,333,404)(H,334,435)(H,335,434)(H,336,436)(H,339,428)(H,340,433)(H,341,438)(H,342,437)(H,343,470)(H,344,406)(H,345,405)(H,346,429)(H,347,439)(H,348,455)(H,349,463)(H,350,472)(H,351,474)(H,352,471)(H,353,441)(H,354,446)(H,355,445)(H,356,462)(H,357,454)(H,358,456)(H,359,473)(H,360,440)(H,361,477)(H,362,480)(H,363,481)(H,364,430)(H,365,431)(H,366,468)(H,367,442)(H,368,448)(H,369,457)(H,370,460)(H,371,469)(H,372,443)(H,373,452)(H,374,447)(H,375,458)(H,376,464)(H,377,478)(H,378,479)(H,379,432)(H,380,444)(H,381,449)(H,382,461)(H,383,450)(H,384,451)(H,385,453)(H,386,459)(H,387,476)(H,388,465)(H,389,467)(H,390,466)(H,391,475)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,483,484)(H4,315,316,327)(H4,317,318,328)(H4,319,320,329)(H4,321,322,330)(H4,323,324,331)/t152-,153-,154-,155-,156-,157-,158-,159-,160-,174-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,241-,242-,243-,244-/m0/s1
DMOF2C6	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N5CCC[C@H]5C(=O)N3)CC(=O)O)CC(=O)O)C)CCCCN)CC6=CC=CC=C6)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)CCSC)CCCCN)CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCC(=O)O)CC(=O)N)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CC9=CC=CC=C9)CCC(=O)O)CO)CC(C)C)CCC(=O)O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC1=CC=CC=C1)CCC(=O)O)CCC(=O)O)CCC(=O)N)CCCNC(=N)N)[C@H](C)O)CC1=CC=CC=C1)[C@@H](C)CC)CC(=O)N)CC1=CC=CC=C1)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CCCNC(=N)N)CC1=CN=CN1)C)C)CCCNC(=N)N)CC1=CC=C(C=C1)O
DMOF2C6	IK	VBGWSQKGUZHFPS-VGMMZINCSA-N
DMOF2C6	IU	(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(1R,2aS,4S,5aS,8aS,11aR,13S,14aS,16S,17aS,19S,20aS,22S,23aS,25S,26aS,28S,29aS,31R,32aS,35aS,36R,38aS,39S,41aS,42S,44aS,45S,48R,50aS,51S,53aS,54S,56aS,57S,59aS,60S,63S,66S,69S,72S,75S,78S,84S,87R,96S,99S)-22,42,45-tris(4-aminobutyl)-31-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-29a,72,78-tris(2-amino-2-oxoethyl)-14a,75-bis(3-amino-3-oxopropyl)-2a,23a,25,32a,35a,66-hexabenzyl-26a,99-bis[(2S)-butan-2-yl]-17a,41a,59a,69-tetrakis(3-carbamimidamidopropyl)-5a,8a,51,54,63,84-hexakis(2-carboxyethyl)-13,16-bis(carboxymethyl)-20a-[(1S)-1-hydroxyethyl]-60-(hydroxymethyl)-96-[(4-hydroxyphenyl)methyl]-50a-(1H-imidazol-5-ylmethyl)-38a-(1H-indol-3-ylmethyl)-19,28,53a,56a-tetramethyl-57-(2-methylpropyl)-39-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,21,22a,24,25a,27,28a,30,31a,34a,37a,38,40a,41,43a,44,47,49a,50,52a,53,55a,56,58a,59,61a,62,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-33,34,63a,64a,67a,68a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,20,21a,23,24a,26,27a,29,30a,33a,36a,37,39a,40,42a,43,46,48a,49,51a,52,54a,55,57a,58,60a,61,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazapentacyclo[85.74.4.448,111.04,8.0144,148]nonahexacontahectane-36-carbonyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]butanedioic acid
DMOF2C6	CA	CAS 460738-38-9
DMOF2C6	DE	Retina venous occlusion

DMSNVGB	ID	DMSNVGB
DMSNVGB	DN	Echothiophate Iodide
DMSNVGB	HS	Approved
DMSNVGB	SN	Echodide; Phospholine; Diethoxyphosphinylthiocholine iodide; ECOTHIOPATE IODIDE; Ecostigmini jodidum; Ecothiopati iodidum; Ecothiophate iodide; Ioduro de ecotiopato; Phospholine iodide; Diethoxyphosphoryl-thiocholine iodide; Echothiophate iodide (USP); Ecothiopati iodidum [INN-Latin]; Iodide, Echothiophate; Iodide, Ecothiopate; Iodide, Ecothiophate; Iodide, Phospholine; Iodure d'ecothiopate; Ioduro de ecotiopato [INN-Spanish]; Phospholine (the pharmaceutical); Phospholine Iodide (TN); Phospholine iodide (TN); Ecothiopate iodide (JP15/INN); Iodure d'ecothiopate [INN-French]; N-(2-(Diethoxyphosphinylthio)ethyl)trimethylammonium iodide; O,O-Diethyl S-2-trimethylammonium ethylphosphonothiolate iodide; S-Ester of (2-mercaptoethyl)trimethylammonium iodide with O,O-diethyl phosphorothioate; S-beta-dimethylaminoethyl-O,O-diethylthionophosphate methiodide; S-(2-Dimethylaminoethyl)-O.O-diethylphosphorothioate methiodide; S-(2-dimethylaminoethyl)-O,O-diethylphosphorothioate methiodide; Ammonium, (2-(O,O-diethylphosphorothio)ethyl)trimethyl-, iodide; Ammonium, (2-mercaptoethyl)trimethyl-, iodide, S-ester with O,O-diethylphosphorothioate; S-(2-(N,N,N-Trimethylammonio)ethyl) O,O-diethylphosphorothiolate iodide; Ethanaminium, 2-((diethoxyphosphinyl)thio)-N,N,N-trimethyl-, iodide; (2-Mercaptoethyl)trimethylammonium iodide S-ester with O,O-diethyl phosphorothioate; (2-mercaptoethyl)trimethylammonium iodidie O,O-diethyl phosphorothioate; 2-((Diethoxyphosphinyl)thio)-N,N,N,-trimethylethanaminium iodide; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid [German]; 2-Diethoxy-phosphinylthioethyl-trimethylammonium iodide; 2-[(diethoxyphosphinyl)thio]-N,N,N-trimethylethanaminium iodide; 2-[(diethoxyphosphoryl)sulfanyl]-N,N,N-trimethylethanaminium iodide; 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium iodide; 2-{[bis(ethyloxy)phosphoryl]thio}-N,N,N-trimethylethanaminium iodide; 217 MI; 217-mi
DMSNVGB	CP	Wyeth Pharmaceuticals
DMSNVGB	TC	Parasympathomimetics
DMSNVGB	DT	Small molecular drug
DMSNVGB	PC	10547
DMSNVGB	MW	383.23
DMSNVGB	FM	C9H23INO3PS
DMSNVGB	IC	InChI=1S/C9H23NO3PS.HI/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5;/h6-9H2,1-5H3;1H/q+1;/p-1
DMSNVGB	CS	CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-]
DMSNVGB	IK	OVXQHPWHMXOFRD-UHFFFAOYSA-M
DMSNVGB	IU	2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium;iodide
DMSNVGB	CA	CAS 513-10-0
DMSNVGB	CB	CHEBI:59849
DMSNVGB	DE	Chronic glaucoma

DMFSWGH	ID	DMFSWGH
DMFSWGH	DN	Econazole
DMFSWGH	HS	Approved
DMFSWGH	SN	Ecostatin; Palavale; Pevaryl; Ecostatin Vaginal Ovules; Ecostatin cream; Spectazole cream; SQ 13050; Ecostatin (TN); Gyno-Pevaryl 150; Gyno-pevaryl; Pevaryl (TN); Spectazole (TN); Econazole (USAN/INN); 1-[2,4-Dichloro-.beta.-[(p-chlorobenzyl)oxy]phenethyl]imidazole; 1-[2-[(4-Chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
DMFSWGH	CP	Merz Pharmaceuticals Llc
DMFSWGH	TC	Antifungal Agents
DMFSWGH	DT	Small molecular drug
DMFSWGH	PC	3198
DMFSWGH	MW	381.7
DMFSWGH	FM	C18H15Cl3N2O
DMFSWGH	IC	InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2
DMFSWGH	CS	C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
DMFSWGH	IK	LEZWWPYKPKIXLL-UHFFFAOYSA-N
DMFSWGH	IU	1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMFSWGH	CA	CAS 27220-47-9
DMFSWGH	CB	CHEBI:82873
DMFSWGH	DE	Tinea versicolor; Cutaneous candidiasis; Tinea corporis; Tinea cruris; Tinea pedis

DMCRQHB	ID	DMCRQHB
DMCRQHB	DN	Edrophonium
DMCRQHB	HS	Approved
DMCRQHB	SN	EDR; Edrophonum; Edroponium; Reversol; Tensilon; EDROPHONIUM ION; Edrophone Chloride; Enlon Plus; ENLON-PLUS; Enlon (TN); Reversol (TN); Tensilon (TN); Ethyl-(3-hydroxyphenyl)-dimethylazanium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylanilinium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; (3-hydroxyphenyl)dimethylethylammonium; 3-hydroxy-N,N-dimethyl-N-ethylanilinium
DMCRQHB	TC	Antidotes
DMCRQHB	DT	Small molecular drug
DMCRQHB	PC	3202
DMCRQHB	MW	166.24
DMCRQHB	FM	C10H16NO+
DMCRQHB	IC	InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1
DMCRQHB	CS	CC[N+](C)(C)C1=CC(=CC=C1)O
DMCRQHB	IK	VWLHWLSRQJQWRG-UHFFFAOYSA-O
DMCRQHB	IU	ethyl-(3-hydroxyphenyl)-dimethylazanium
DMCRQHB	CA	CAS 312-48-1
DMCRQHB	CB	CHEBI:251408
DMCRQHB	DE	Myasthenia gravis

DMCKL5V	ID	DMCKL5V
DMCKL5V	DN	Efalizumab
DMCKL5V	HS	Approved
DMCKL5V	SN	Raptiva; Raptiva (TN); Efalizumab (USAN/INN)
DMCKL5V	CP	Roche
DMCKL5V	TC	Immunomodulatory Agents
DMCKL5V	DT	Antibody
DMCKL5V	SQ	Heavy Chain Variable Region: EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETRYNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTLVTVSS</sequence>    <sequence format="FASTA">&gt;Light Chain Variable RegionDIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWXQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIKR
DMCKL5V	DE	Psoriasis vulgaris; Renal transplantation

DMC0GSJ	ID	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	HS	Approved
DMC0GSJ	SN	EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
DMC0GSJ	TC	Anti-HIV Agents
DMC0GSJ	DT	Small molecular drug
DMC0GSJ	PC	64139
DMC0GSJ	MW	315.67
DMC0GSJ	FM	C14H9ClF3NO2
DMC0GSJ	IC	InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
DMC0GSJ	CS	C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
DMC0GSJ	IK	XPOQHMRABVBWPR-ZDUSSCGKSA-N
DMC0GSJ	IU	(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
DMC0GSJ	CA	CAS 154598-52-4
DMC0GSJ	CB	CHEBI:119486
DMC0GSJ	DE	Human immunodeficiency virus infection

DMFA9MV	ID	DMFA9MV
DMFA9MV	DN	Efinaconazole
DMFA9MV	HS	Approved
DMFA9MV	SN	IDP-108; KP-103
DMFA9MV	CP	Dow
DMFA9MV	DT	Small molecular drug
DMFA9MV	PC	489181
DMFA9MV	MW	348.4
DMFA9MV	FM	C18H22F2N4O
DMFA9MV	IC	InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1
DMFA9MV	CS	C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
DMFA9MV	IK	NFEZZTICAUWDHU-RDTXWAMCSA-N
DMFA9MV	IU	(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
DMFA9MV	CA	CAS 164650-44-6
DMFA9MV	CB	CHEBI:82718
DMFA9MV	DE	Fungal infection

DMJOQM3	ID	DMJOQM3
DMJOQM3	DN	Eflornithine
DMJOQM3	HS	Approved
DMJOQM3	SN	EFLORNITHINE; Ornidyl; 70052-12-9; 2-(Difluoromethyl)ornithine; alpha-Difluoromethylornithine; Difluromethylornithine; Eflornitina [Spanish]; Eflornithinum [Latin]; 2,5-diamino-2-(difluoromethyl)pentanoic acid; alpha-(Difluoromethyl)-DL-ornithine; N-Difluoromethylornithine; DFMO (growth regulator); 67037-37-0; Eflornithine [INN:BAN]; 2-(Difluoromethyl)-DL-ornithine; DL-alpha-(Difluoromethyl)ornithine; MDL 71782; CCRIS 3295; Ornithine, 2-(difluoromethyl)-; Eflornithinum; Eflornitina; DFMO hydrochloride; DFMO hydrochloride hydrate; EFLORNITHINE HYDROCHLORIDE; BMS 203522; Alpha-DFMO HCl; Alpha-Difluoromethylornithine; Alpha-Difluoromethylornithine hydrochloride; CPP-1X; Eflornithine (INN); Ornidyl (TN); DL-alpha-Difluoromethylornithine; DL-alpha-Difluoromethylornithine hydrochloride hydrate; D,L-alpha-Difluoromethylornithine; Alpha-(Difluoromethyl)-DL-ornithine; Alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate; 2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride; 2-(Difluoromethyl)-DL-ornithine HCl; 2-(Difluoromethyl)-DL-ornithine hydrochloride; 2-(Difluoromethyl)-DL-ornithine monohydrochloride; 2-(Difluoromethyl)ornithine hydrochloride hydrate
DMJOQM3	CP	Sanofi-Aventis
DMJOQM3	TC	Anticancer Agents
DMJOQM3	DT	Small molecular drug
DMJOQM3	PC	3009
DMJOQM3	MW	182.17
DMJOQM3	FM	C6H12F2N2O2
DMJOQM3	IC	InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)
DMJOQM3	CS	C(CC(C(F)F)(C(=O)O)N)CN
DMJOQM3	IK	VLCYCQAOQCDTCN-UHFFFAOYSA-N
DMJOQM3	IU	2,5-diamino-2-(difluoromethyl)pentanoic acid
DMJOQM3	CA	CAS 70052-12-9
DMJOQM3	CB	CHEBI:41948
DMJOQM3	DE	African trypanosomiasis; Trypanosomiasis

DMMUCG4	ID	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	HS	Approved
DMMUCG4	SN	Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149;  Espanova (TN); DOCOSAHEXAENOIC ACID
DMMUCG4	CP	Omthera Pharmaceutials
DMMUCG4	DT	Small molecular drug
DMMUCG4	PC	445580
DMMUCG4	MW	328.5
DMMUCG4	FM	C22H32O2
DMMUCG4	IC	InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-
DMMUCG4	CS	CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O
DMMUCG4	IK	MBMBGCFOFBJSGT-KUBAVDMBSA-N
DMMUCG4	IU	(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
DMMUCG4	CA	CAS 6217-54-5
DMMUCG4	CB	CHEBI:28125
DMMUCG4	DE	Hypertriglyceridemia; Alzheimer disease

DMRDUC0	ID	DMRDUC0
DMRDUC0	DN	Elagolix sodium
DMRDUC0	HS	Approved
DMRDUC0	SN	Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336
DMRDUC0	CP	AbbVie
DMRDUC0	PC	24785956
DMRDUC0	MW	653.6
DMRDUC0	FM	C32H29F5N3NaO5
DMRDUC0	IC	InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1
DMRDUC0	CS	CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+]
DMRDUC0	IK	DQYGXRQUFSRDCH-UQIIZPHYSA-M
DMRDUC0	IU	sodium;4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate
DMRDUC0	CA	CAS 832720-36-2
DMRDUC0	DE	Endometriosis

DMS7OU8	ID	DMS7OU8
DMS7OU8	DN	Elapegademase
DMS7OU8	HS	Approved
DMS7OU8	SN	Elapegademase [INN]; UNII-9R3D3Y0UHS; Elapegademase [USAN:INN]; 9R3D3Y0UHS
DMS7OU8	CP	Leadiant Biosciences
DMS7OU8	DE	Immunodeficiency; Adenosine deaminase defciency

DMJLE18	ID	DMJLE18
DMJLE18	DN	Elbasvir
DMJLE18	HS	Approved
DMJLE18	SN	Elbasvir; Elbasvir [USAN:INN]; Elbasvir(MK-8742); MK 8742; MK-8742; MK8742; SB16741; ZINC150588351; 1370468-36-2; 632L571YDK; A16855; CHEBI:132967; CHEMBL3039514; CS-5332; Carbamic acid, N,N'-(((6S)-6-phenyl-6H-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; DB11574; EX-A2889; HY-15789; SCHEMBL17429773; UNII-632L571YDK
DMJLE18	PC	71661251
DMJLE18	MW	882
DMJLE18	FM	C49H55N9O7
DMJLE18	IC	BVAZQCUMNICBAQ-PZHYSIFUSA-N
DMJLE18	CS	CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC
DMJLE18	IK	1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1
DMJLE18	IU	methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMJLE18	CA	CAS 1370468-36-2
DMJLE18	CB	CHEBI:132967
DMJLE18	DE	Viral hepatitis

DMW649X	ID	DMW649X
DMW649X	DN	Eletriptan
DMW649X	HS	Approved
DMW649X	SN	Eletriptanum; Relpax; UK 116044; UK116044; Eletriptan (INN); Eletriptan [INN:BAN]; Relpax (TN); UK-116044; UK-116044-04; (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
DMW649X	CP	Pfizer Inc
DMW649X	TC	Antimigraine Agents
DMW649X	DT	Small molecular drug
DMW649X	PC	77993
DMW649X	MW	382.5
DMW649X	FM	C22H26N2O2S
DMW649X	IC	InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
DMW649X	CS	CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
DMW649X	IK	PWVXXGRKLHYWKM-LJQANCHMSA-N
DMW649X	IU	5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
DMW649X	CA	CAS 143322-58-1
DMW649X	CB	CHEBI:50922
DMW649X	DE	Migraine

DMSRZAO	ID	DMSRZAO
DMSRZAO	DN	Eliglustat tartrate
DMSRZAO	HS	Approved
DMSRZAO	SN	Fabrazyme (TN)
DMSRZAO	CP	Genzyme
DMSRZAO	DT	Small molecular drug
DMSRZAO	PC	52918379
DMSRZAO	MW	959.2
DMSRZAO	FM	C50H78N4O14
DMSRZAO	IC	InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1
DMSRZAO	CS	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMSRZAO	IK	KUBARPMUNHKBIQ-VTHUDJRQSA-N
DMSRZAO	IU	N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide;(2R,3R)-2,3-dihydroxybutanedioic acid
DMSRZAO	CA	CAS 928659-70-5
DMSRZAO	CB	CHEBI:83353
DMSRZAO	DE	Metabolic disorder

DMZC6GT	ID	DMZC6GT
DMZC6GT	DN	Elliptinium acetate
DMZC6GT	HS	Approved
DMZC6GT	SN	Celiptium (TN)
DMZC6GT	CP	Sanofi
DMZC6GT	DT	Small molecular drug
DMZC6GT	PC	42722
DMZC6GT	MW	336.4
DMZC6GT	FM	C20H20N2O3
DMZC6GT	IC	InChI=1S/C18H16N2O.C2H4O2/c1-10-15-9-20(3)7-6-13(15)11(2)18-17(10)14-8-12(21)4-5-16(14)19-18;1-2(3)4/h4-9,21H,1-3H3;1H3,(H,3,4)
DMZC6GT	CS	CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C)C.CC(=O)[O-]
DMZC6GT	IK	BOMZMNZEXMAQQW-UHFFFAOYSA-N
DMZC6GT	IU	2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate
DMZC6GT	CA	CAS 58337-35-2
DMZC6GT	DE	Solid tumour/cancer

DMRCX8K	ID	DMRCX8K
DMRCX8K	DN	Eloctate
DMRCX8K	HS	Approved
DMRCX8K	SN	Recombinant human factor VIII-FC
DMRCX8K	CP	Biogen Idec
DMRCX8K	DE	Haemophilia A

DMA9REV	ID	DMA9REV
DMA9REV	DN	Elosulfase alfa
DMA9REV	HS	Approved
DMA9REV	SN	Vimizim
DMA9REV	CP	Biomarin
DMA9REV	SQ	Elosulfase-alfa: APQPPNILLLLMDDMGWGDLGVYGEPSRETPLCSPSRAALLTGRLPIRNGFYTTNAHARNLLKKAGYVSKIVGKWHLGHRPQFHPLKHGFNIPVYRDWEMVGRYYEEFPINLKTGEANLTFLYWAVDATHAPVYASKPFLGTSQRGRYGDVADNTFVFFTSDNGAALISAPEQGGSNGPFPGHVTAGQVSHQLGSIMDLFTTSLALAGLTLMDRPIFYYRGDTLMAATLGQHKAHFWTWTVTTHNLEDHTKLPLIFHLGRDPGERFPLSFEALVPAQPQLNVCNWAVMNWAPPGCEKLGKPNLDRMAAEGLLFPNFYSANAYTPQEIVGGIPDSEQLLPEDEWFGSPNCHFGPYDNKARPQIYLQEALDFIKRQARHHPFAVREIDDSIGKILELLQDLHLCGKQTTFEGGMREPALAWWPPSDRAIDGLNLLPTLLQGRNSWENFRQGIDFCPGQNVSGASAEYQEALSRITSVVQQHQCLTPPESIPKKCLWSH
DMA9REV	DE	Mucopolysaccharidosis

DMEYHG9	ID	DMEYHG9
DMEYHG9	DN	Elotuzumab
DMEYHG9	HS	Approved
DMEYHG9	SN	BMS-901608
DMEYHG9	CP	Bristol-Myers Squibb
DMEYHG9	DT	Antibody
DMEYHG9	SQ	Elotuzumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Elotuzumab light chainDIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMEYHG9	DE	Multiple myeloma

DMOGFIX	ID	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	HS	Approved
DMOGFIX	SN	Eltrombopag [INN]; SB 497115; SB497115; SB-497115; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dime; Thylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-(9CI); (E)-3\'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2\'-hydroxybiphenyl-3-carboxylic acid
DMOGFIX	CP	GlaxoSmithKline
DMOGFIX	DT	Small molecular drug
DMOGFIX	PC	135449332
DMOGFIX	MW	442.5
DMOGFIX	FM	C25H22N4O4
DMOGFIX	IC	InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)
DMOGFIX	CS	CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
DMOGFIX	IK	SVOQIEJWJCQGDQ-UHFFFAOYSA-N
DMOGFIX	IU	3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid
DMOGFIX	CA	CAS 496775-61-2
DMOGFIX	CB	CHEBI:85010
DMOGFIX	DE	Thrombocytopenia; Idiopathic thrombocytopenic purpura

DMYZ0P1	ID	DMYZ0P1
DMYZ0P1	DN	Eluxadoline
DMYZ0P1	HS	Approved
DMYZ0P1	SN	MuDelta
DMYZ0P1	CP	Furiex pharmaceuticals
DMYZ0P1	DT	Small molecular drug
DMYZ0P1	PC	11250029
DMYZ0P1	MW	569.6
DMYZ0P1	FM	C32H35N5O5
DMYZ0P1	IC	InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1
DMYZ0P1	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)[C@@H](C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N
DMYZ0P1	IK	QFNHIDANIVGXPE-FNZWTVRRSA-N
DMYZ0P1	IU	5-[[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid
DMYZ0P1	CA	CAS 864821-90-9
DMYZ0P1	CB	CHEBI:85980
DMYZ0P1	DE	Diarrhea-predominant irritable bowel syndrome

DMG9B1U	ID	DMG9B1U
DMG9B1U	DN	Elvitegravir
DMG9B1U	HS	Approved
DMG9B1U	SN	EVG
DMG9B1U	DT	Small molecular drug
DMG9B1U	PC	5277135
DMG9B1U	MW	447.9
DMG9B1U	FM	C23H23ClFNO5
DMG9B1U	IC	InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1
DMG9B1U	CS	CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O
DMG9B1U	IK	JUZYLCPPVHEVSV-LJQANCHMSA-N
DMG9B1U	IU	6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid
DMG9B1U	CA	CAS 697761-98-1
DMG9B1U	CB	CHEBI:72289
DMG9B1U	DE	Human immunodeficiency virus infection

DMZG5WL	ID	DMZG5WL
DMZG5WL	DN	Emapalumab
DMZG5WL	HS	Approved
DMZG5WL	SN	emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X
DMZG5WL	CP	Novimmune
DMZG5WL	DT	Antibody
DMZG5WL	DE	Primary haemophagocytic lymphohistiocytosis

DM36LAJ	ID	DM36LAJ
DM36LAJ	DN	Emedastine
DM36LAJ	HS	Approved
DM36LAJ	SN	Emadine; Emedastina; Emedastinum; Emedastine [INN]; Emedastine difumarate; KB 2413; KG 2413; Emadine (TN); Emedastina [INN-Spanish]; Emedastine (INN); Emedastine [INN:BAN]; Emedastinum [INN-Latin]; KB-2413; KG-2413; 1-(2-Ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate; 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole; 1-Methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazo)-2-yl)(1,4)diazepane; 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
DM36LAJ	TC	Antiallergic Agents
DM36LAJ	DT	Small molecular drug
DM36LAJ	PC	3219
DM36LAJ	MW	302.4
DM36LAJ	FM	C17H26N4O
DM36LAJ	IC	InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3
DM36LAJ	CS	CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C
DM36LAJ	IK	KBUZBQVCBVDWKX-UHFFFAOYSA-N
DM36LAJ	IU	1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole
DM36LAJ	CA	CAS 87233-61-2
DM36LAJ	CB	CHEBI:4779
DM36LAJ	DE	Allergic conjunctivitis

DMCOAVT	ID	DMCOAVT
DMCOAVT	DN	Emepronium
DMCOAVT	HS	Approved
DMCOAVT	SN	Emepronium Bromide; Restenacht; Cetiprin; Emeprone bromide; Emepron bromide; 3614-30-0; Emeproniumbromid [German]; Emepronium bromide [INN:BAN]; Emepronii bromidum [INN-Latin]; Bromure d'emepronium [INN-French]; Bromuro de emepronio [INN-Spanish]; EINECS 222-786-6; Ethyldimethyl(1-methyl-3,3-diphenylpropyl)ammonium bromide; Dimethylethyl(beta-benzhydrylisopropyl)ammonium bromide; C20H28N; Ammonium, ethyldimethyl(1-methyl-3,3-diphenylpropyl)-, bromide; Emeproniumbromid; Emepronii bromidum; Bromure d'emepronium; Bromuro de emep
DMCOAVT	DT	Small molecular drug
DMCOAVT	PC	34055
DMCOAVT	MW	282.4
DMCOAVT	FM	C20H28N+
DMCOAVT	IC	InChI=1S/C20H28N/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20H,5,16H2,1-4H3/q+1
DMCOAVT	CS	CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2
DMCOAVT	IK	JEJBJBKVPOWOQK-UHFFFAOYSA-N
DMCOAVT	IU	4,4-diphenylbutan-2-yl-ethyl-dimethylazanium
DMCOAVT	CA	CAS 27892-33-7
DMCOAVT	CB	CHEBI:135169
DMCOAVT	DE	Urinary incontinence

DMCT2YF	ID	DMCT2YF
DMCT2YF	DN	Emetine
DMCT2YF	HS	Approved
DMCT2YF	SN	Emetine hydrochloride; EMETINE; 14198-59-5; MLS000028478; SMR000058444; NSC-33669; NSC33669; Emetine monohydrochloride; Opera_ID_1460; Cephaeline methyl ether HCl; AC1O7FP4; SCHEMBL636599; CHEMBL513000; DTXSID80424947; MolPort-004-964-890; Cephaeline methyl ether hydrochloride; NSC752340; AKOS024374935; NSC-752340; ST51014995; Emetan,7',10,11-tetramethoxy-, dihydrochloride; Q-100155; 10-[((1R)-6,7-dimethoxy(1,2,3,4-tetrahydroisoquinolyl))methyl](10S,11aS,9R)-9- ethyl-2,3-dimethoxy-5,6,7,11a-tetrahydropiperidino[2,1-a]isoquinolin
DMCT2YF	DT	Small molecular drug
DMCT2YF	PC	10219
DMCT2YF	MW	480.6
DMCT2YF	FM	C29H40N2O4
DMCT2YF	IC	InChI=1S/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3/t18-,21-,24+,25-/m0/s1
DMCT2YF	CS	CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC
DMCT2YF	IK	AUVVAXYIELKVAI-CKBKHPSWSA-N
DMCT2YF	IU	(2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine
DMCT2YF	CA	CAS 483-18-1
DMCT2YF	CB	CHEBI:4781
DMCT2YF	DE	Hepatitis virus infection

DM0AQ83	ID	DM0AQ83
DM0AQ83	DN	Emicizumab
DM0AQ83	HS	Approved
DM0AQ83	CP	Roche/Genentech
DM0AQ83	DT	Antibody
DM0AQ83	DE	Factor VIII deficiency

DMRF9YK	ID	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	HS	Approved
DMRF9YK	SN	864070-44-0; JARDIANCE; BI 10773; UNII-HDC1R2M35U; Empagliflozin (BI 10773); BI-10773; BI10773; HDC1R2M35U; CHEBI:82720; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; AK160980; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
DMRF9YK	CP	Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DMRF9YK	DT	Small molecular drug
DMRF9YK	PC	11949646
DMRF9YK	MW	450.9
DMRF9YK	FM	C23H27ClO7
DMRF9YK	IC	InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
DMRF9YK	CS	C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
DMRF9YK	IK	OBWASQILIWPZMG-QZMOQZSNSA-N
DMRF9YK	IU	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMRF9YK	CA	CAS 864070-44-0
DMRF9YK	CB	CHEBI:82720
DMRF9YK	DE	Type-1 diabetes

DMBMUWZ	ID	DMBMUWZ
DMBMUWZ	DN	Emtricitabine
DMBMUWZ	HS	Approved
DMBMUWZ	SN	Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC
DMBMUWZ	CP	Gilead; Bristol-Myers Squibb
DMBMUWZ	TC	Anti-HIV Agents
DMBMUWZ	DT	Small molecular drug
DMBMUWZ	PC	60877
DMBMUWZ	MW	247.25
DMBMUWZ	FM	C8H10FN3O3S
DMBMUWZ	IC	InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1
DMBMUWZ	CS	C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
DMBMUWZ	IK	XQSPYNMVSIKCOC-NTSWFWBYSA-N
DMBMUWZ	IU	4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
DMBMUWZ	CA	CAS 143491-57-0
DMBMUWZ	CB	CHEBI:31536
DMBMUWZ	DE	Human immunodeficiency virus infection; Hepatitis virus infection; Hepatitis B virus infection

DMNFUZR	ID	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	HS	Approved
DMNFUZR	SN	Vasotec; Enalapril (INN); Enalapril (TN); N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMNFUZR	CP	Merck & Co
DMNFUZR	TC	Antihypertensive Agents
DMNFUZR	DT	Small molecular drug
DMNFUZR	PC	5388962
DMNFUZR	MW	376.4
DMNFUZR	FM	C20H28N2O5
DMNFUZR	IC	InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
DMNFUZR	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O
DMNFUZR	IK	GBXSMTUPTTWBMN-XIRDDKMYSA-N
DMNFUZR	IU	(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMNFUZR	CA	CAS 75847-73-3
DMNFUZR	CB	CHEBI:4784
DMNFUZR	DE	Hypertension

DMFYAM1	ID	DMFYAM1
DMFYAM1	DN	Enalaprilat
DMFYAM1	HS	Approved
DMFYAM1	SN	Extract of ginger root; Ginger extract; Ginger root extract; Ginger, ext; LS-3194; Zingiber officinale extract; Zingiber officinale root extract; CCRIS 7641; EINECS 283-634-2; FEMA No. 2520; FEMA No. 2521; FEMA No. 2523; Ginger extract (Zingiber officinale); ginger, extract (zingiber officinale rosc.)
DMFYAM1	PC	6850776
DMFYAM1	MW	568.8
DMFYAM1	FM	C35H52O6
DMFYAM1	IC	QCVRFSPGUWEKFC-ILHSMLOTSA-N
DMFYAM1	CS	CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC.CCCCCC(C)CC(=O)CCC1=CC(=C(C=C1)O)OC
DMFYAM1	IK	1S/C18H28O3.C17H24O3/c1-4-5-6-7-14(2)12-16(19)10-8-15-9-11-17(20)18(13-15)21-3;1-3-4-5-6-7-8-15(18)11-9-14-10-12-16(19)17(13-14)20-2/h9,11,13-14,20H,4-8,10,12H2,1-3H3;7-8,10,12-13,19H,3-6,9,11H2,1-2H3/b;8-7+
DMFYAM1	IU	(E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one;1-(4-hydroxy-3-methoxyphenyl)-5-methyldecan-3-one
DMFYAM1	CA	CAS 84696-15-1
DMFYAM1	DE	Essential hypertension

DMPRBQV	ID	DMPRBQV
DMPRBQV	DN	Enalaprilat
DMPRBQV	HS	Approved
DMPRBQV	SN	EAL; Enalaprilate; Enalaprilatum; ENALAPRILAT INHIBITOR; Enalapril acid; Enalapril diacid; Enalaprilat anhydrous; Enalaprilic acid; Enalprilat hydrate; Enalprilate hydrate; Enalaprilat (USP); MK-422; Vasotec I.V.; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline-water (1/2); (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate; 1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
DMPRBQV	CP	Merck & Co
DMPRBQV	TC	Antihypertensive Agents
DMPRBQV	DT	Small molecular drug
DMPRBQV	PC	5462501
DMPRBQV	MW	348.4
DMPRBQV	FM	C18H24N2O5
DMPRBQV	IC	InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
DMPRBQV	CS	C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O
DMPRBQV	IK	LZFZMUMEGBBDTC-QEJZJMRPSA-N
DMPRBQV	IU	(2S)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMPRBQV	CA	CAS 76420-72-9
DMPRBQV	CB	CHEBI:4786
DMPRBQV	DE	Hypertension

DM8QXOC	ID	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	HS	Approved
DM8QXOC	SN	Enasidenib; Enasidenib mesylate; IDHIFA; 1446502-11-9; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 3T1SS4E7AG; AG-221; CC-90007; CC-90007 Free Base; UNII-3T1SS4E7AG
DM8QXOC	PC	89683805
DM8QXOC	MW	473.4
DM8QXOC	FM	C19H17F6N7O
DM8QXOC	IC	DYLUUSLLRIQKOE-UHFFFAOYSA-N
DM8QXOC	CS	CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O
DM8QXOC	IK	1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)
DM8QXOC	IU	2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DM8QXOC	CA	CAS 1446502-11-9
DM8QXOC	CB	CHEBI:145374
DM8QXOC	DE	Acute myeloid leukaemia

DMPOU5H	ID	DMPOU5H
DMPOU5H	DN	ENASIDENIB MESYLATE
DMPOU5H	HS	Approved
DMPOU5H	SN	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541
DMPOU5H	CP	Celgene/Agios
DMPOU5H	PC	90480031
DMPOU5H	MW	569.5
DMPOU5H	FM	C20H21F6N7O4S
DMPOU5H	IC	InChI=1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4)
DMPOU5H	CS	CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O
DMPOU5H	IK	ORZHZQZYWXEDDL-UHFFFAOYSA-N
DMPOU5H	IU	methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DMPOU5H	CA	CAS 1650550-25-6
DMPOU5H	DE	Acute myeloid leukaemia

DM7RNP3	ID	DM7RNP3
DM7RNP3	DN	Enbrel
DM7RNP3	HS	Approved
DM7RNP3	DE	Arthritis

DM0YJSB	ID	DM0YJSB
DM0YJSB	DN	Enflurane
DM0YJSB	HS	Approved
DM0YJSB	SN	Alyrane; Efrane; Enflurano; Enfluranum; Enfran; Enlirane; Ethrane; Etran; Methylflurether; Abbott Brand of Enflurane; AstraZeneca Brand of Enflurane; Baxter Anaesthesia Brand of Enflurane; Pisa Brand of Enflurane; Zeneca Brand of Enflurane; Anesthetic 347; C 347; OHIO 347; Anesthetic Compound No. 347; Enflurane [Anaesthetics,volatile]; Enflurano [INN-Spanish]; Enfluranum [INN-Latin]; Ethrane (TN); Enflurane (JP15/USP/INN); Enflurane [USAN:BAN:INN:JAN]; Ether, 2-chloro-1,1,2-trifluoroethyl difluoromethyl; (+-)-2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane
DM0YJSB	TC	Anesthetics
DM0YJSB	DT	Small molecular drug
DM0YJSB	PC	3226
DM0YJSB	MW	184.49
DM0YJSB	FM	C3H2ClF5O
DM0YJSB	IC	InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H
DM0YJSB	CS	C(C(OC(F)F)(F)F)(F)Cl
DM0YJSB	IK	JPGQOUSTVILISH-UHFFFAOYSA-N
DM0YJSB	IU	2-chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane
DM0YJSB	CA	CAS 13838-16-9
DM0YJSB	CB	CHEBI:4792
DM0YJSB	DE	Anaesthesia

DMFS63G	ID	DMFS63G
DMFS63G	DN	Enfortumab
DMFS63G	HS	Approved
DMFS63G	SN	ASG-2ME
DMFS63G	CP	Astellas Northbrook, IL Seattle Genetics Bothell, WA
DMFS63G	DT	Antibody drug conjugate
DMFS63G	DE	Urothelial carcinoma

DM7YPM1	ID	DM7YPM1
DM7YPM1	DN	Enfuvirtide
DM7YPM1	HS	Approved
DM7YPM1	SN	Fuzeon; Pentafuside; Enfuvirtide [USAN]; Roche brand of pentafuside; DP178; Dp 178; Peptide T20; T 20; T20 peptide; Fuzeon (TN); T 20 (peptide); T-20; T-20 cpd
DM7YPM1	CP	Hoffmann-La Roche pharmaceutical company
DM7YPM1	TC	Anti-HIV Agents
DM7YPM1	DT	Small molecular drug
DM7YPM1	SQ	DB00109 sequence: YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
DM7YPM1	PC	24847866
DM7YPM1	MW	4565
DM7YPM1	FM	C206H304N52O66
DM7YPM1	IC	InChI=1S/C206H304N52O66/c1-20-103(15)168(254-197(315)137(75-101(11)12)239-202(320)151(94-261)252-192(310)143(82-113-90-216-96-221-113)249-205(323)169(104(16)21-2)255-198(316)138(76-102(13)14)240-203(321)152(95-262)253-206(324)170(106(18)263)256-199(317)148(258-257-107(19)264)78-109-45-47-114(265)48-46-109)204(322)234-132(58-68-165(283)284)180(298)229-131(57-67-164(281)282)184(302)251-150(93-260)200(318)233-126(52-62-156(212)269)181(299)246-145(84-158(214)271)193(311)230-125(51-61-155(211)268)177(295)225-123(49-59-153(209)266)175(293)227-127(53-63-160(273)274)178(296)223-121(43-31-33-69-207)174(292)245-144(83-157(213)270)194(312)232-128(54-64-161(275)276)179(297)226-124(50-60-154(210)267)176(294)228-129(55-65-162(277)278)182(300)235-134(72-98(5)6)187(305)237-133(71-97(3)4)186(304)231-130(56-66-163(279)280)183(301)236-135(73-99(7)8)189(307)248-147(86-166(285)286)196(314)224-122(44-32-34-70-208)173(291)242-140(79-110-87-217-118-40-28-25-37-115(110)118)185(303)222-105(17)171(289)250-149(92-259)201(319)238-136(74-100(9)10)188(306)243-142(81-112-89-219-120-42-30-27-39-117(112)120)191(309)247-146(85-159(215)272)195(313)244-141(80-111-88-218-119-41-29-26-38-116(111)119)190(308)241-139(172(290)220-91-167(287)288)77-108-35-23-22-24-36-108/h22-30,35-42,45-48,87-90,96-106,121-152,168-170,217-219,258-263,265H,20-21,31-34,43-44,49-86,91-95,207-208H2,1-19H3,(H2,209,266)(H2,210,267)(H2,211,268)(H2,212,269)(H2,213,270)(H2,214,271)(H2,215,272)(H,216,221)(H,220,290)(H,222,303)(H,223,296)(H,224,314)(H,225,295)(H,226,297)(H,227,293)(H,228,294)(H,229,298)(H,230,311)(H,231,304)(H,232,312)(H,233,318)(H,234,322)(H,235,300)(H,236,301)(H,237,305)(H,238,319)(H,239,320)(H,240,321)(H,241,308)(H,242,291)(H,243,306)(H,244,313)(H,245,292)(H,246,299)(H,247,309)(H,248,307)(H,249,323)(H,250,289)(H,251,302)(H,252,310)(H,253,324)(H,254,315)(H,255,316)(H,256,317)(H,257,264)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)/t103-,104-,105-,106+,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,168-,169-,170-/m0/s1
DM7YPM1	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)NCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NNC(=O)C
DM7YPM1	IK	BWVBEUNZTQWGMR-CKVIKZOTSA-N
DM7YPM1	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-(2-acetylhydrazinyl)-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-(carboxymethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DM7YPM1	DE	Human immunodeficiency virus infection

DMYTE6L	ID	DMYTE6L
DMYTE6L	DN	Enoxacin
DMYTE6L	HS	Approved
DMYTE6L	SN	Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
DMYTE6L	TC	Antiinfective Agents
DMYTE6L	DT	Small molecular drug
DMYTE6L	PC	3229
DMYTE6L	MW	320.32
DMYTE6L	FM	C15H17FN4O3
DMYTE6L	IC	InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
DMYTE6L	CS	CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
DMYTE6L	IK	IDYZIJYBMGIQMJ-UHFFFAOYSA-N
DMYTE6L	IU	1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
DMYTE6L	CA	CAS 74011-58-8
DMYTE6L	CB	CHEBI:157175
DMYTE6L	DE	Urinary tract infection

DMQVZJD	ID	DMQVZJD
DMQVZJD	DN	Enoximone
DMQVZJD	HS	Approved
DMQVZJD	SN	ENOXIMONE; Perfan; 77671-31-9; Fenoximone; Enoximonum [Latin]; MDL-17043; Enoximona [Spanish]; MDL 17,043; UNII-C7Z4ITI7L7; MDL-17,043; RMI-17043; 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one; C7Z4ITI7L7; 4-Methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one; CHEMBL249856; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-; NCGC00015400-02; Enoximonum; Enoximona; 1,3-Dihydro-4-methyl-5-[4-methylthiobenzoyl]-2H-imidazol-2-one; DSSTox_RID_80702; DSSTox_CID_25147; DSSTox_GSID_45147; Perfane;  Enoximona; E 1279; Perfan (TN); Enoximone (USAN/INN); Enoximone [USAN:BAN:INN]; 1,3-Dihydro-4-methyl-5-(4-methylthiobenzoyl)-2H-imidazol-2-one; FENOXIMONE
DMQVZJD	TC	Cardiotonic Agents
DMQVZJD	DT	Small molecular drug
DMQVZJD	PC	53708
DMQVZJD	MW	248.3
DMQVZJD	FM	C12H12N2O2S
DMQVZJD	IC	InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)
DMQVZJD	CS	CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)SC
DMQVZJD	IK	ZJKNESGOIKRXQY-UHFFFAOYSA-N
DMQVZJD	IU	4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one
DMQVZJD	CA	CAS 77671-31-9
DMQVZJD	CB	CHEBI:135010
DMQVZJD	DE	Congestive heart failure

DMFYZKN	ID	DMFYZKN
DMFYZKN	DN	Enprofylline
DMFYZKN	HS	Approved
DMFYZKN	SN	Enprofilina; Enprofyllinum; Nilyph; Oxeze; P 5679; D-4028; Enprofilina [INN-Spanish]; Enprofylline [USAN:INN]; Enprofyllinum [INN-Latin]; Enprofylline (USAN/INN); 3,7-Dihydro-3-propyl-1H-purine-2,6-dione; 3-Propyl-3,7-dihydro-purine-2,6-dione; 3-Propylxanthine; 3-n-Propylxanthine; 3-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-propyl-7H-purine-2,6-dione
DMFYZKN	TC	Antiinflammatory Agents
DMFYZKN	DT	Small molecular drug
DMFYZKN	PC	1676
DMFYZKN	MW	194.19
DMFYZKN	FM	C8H10N4O2
DMFYZKN	IC	InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)
DMFYZKN	CS	CCCN1C2=C(C(=O)NC1=O)NC=N2
DMFYZKN	IK	SIQPXVQCUCHWDI-UHFFFAOYSA-N
DMFYZKN	IU	3-propyl-7H-purine-2,6-dione
DMFYZKN	CA	CAS 41078-02-8
DMFYZKN	CB	CHEBI:126237
DMFYZKN	DE	Asthma

DMLBVKQ	ID	DMLBVKQ
DMLBVKQ	DN	Entacapone
DMLBVKQ	HS	Approved
DMLBVKQ	SN	Comtan; Comtess; Entacapona; Entacaponum; Novartis brand of entacapone; Orion brand of entacapone; KB475572; OR 611; COM-998; Comtan (TN); Entacapona [INN-Spanish]; Entacapone [USAN:INN]; Entacaponum [INN-Latin]; OR-611; Stalevo (TN); Entacapone (JAN/USAN/INN); N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
DMLBVKQ	CP	Norvatis Phamaceuticals Corporation
DMLBVKQ	TC	Antiparkinson Agents
DMLBVKQ	DT	Small molecular drug
DMLBVKQ	PC	5281081
DMLBVKQ	MW	305.29
DMLBVKQ	FM	C14H15N3O5
DMLBVKQ	IC	InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
DMLBVKQ	CS	CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N
DMLBVKQ	IK	JRURYQJSLYLRLN-BJMVGYQFSA-N
DMLBVKQ	IU	(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
DMLBVKQ	CA	CAS 130929-57-6
DMLBVKQ	CB	CHEBI:4798
DMLBVKQ	DE	Parkinson disease

DM7VTQO	ID	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	HS	Approved
DM7VTQO	SN	Baraclude; ETV; Entecavir hydrate; Entecavir monohydrate; BMS-200475; Baraclude (TN); Entecavir (INN); Entecavir (USAN); Entecavir hydrate (JAN); SQ-34676; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate
DM7VTQO	CP	Bristol-Myers Squibb
DM7VTQO	TC	Antiviral Agents
DM7VTQO	DT	Small molecular drug
DM7VTQO	PC	135398508
DM7VTQO	MW	277.28
DM7VTQO	FM	C12H15N5O3
DM7VTQO	IC	InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1
DM7VTQO	CS	C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2N=C(NC3=O)N
DM7VTQO	IK	QDGZDCVAUDNJFG-FXQIFTODSA-N
DM7VTQO	IU	2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one
DM7VTQO	CA	CAS 142217-69-4
DM7VTQO	CB	CHEBI:473990
DM7VTQO	DE	Hepatitis B virus infection

DMK659W	ID	DMK659W
DMK659W	DN	Enteric-coated mycophenolate sodium
DMK659W	HS	Approved
DMK659W	SN	Myfortic; Mycophenolate sodium; ERL-080; Enteric-coated MPA, Novartis; Enteric-coated mycophenolate sodium, Novartis
DMK659W	CP	Novartis AG
DMK659W	DE	Transplant rejection

DMMPTLH	ID	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	HS	Approved
DMMPTLH	SN	1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
DMMPTLH	CP	Ignyta
DMMPTLH	DT	Small molecular drug
DMMPTLH	PC	25141092
DMMPTLH	MW	560.6
DMMPTLH	FM	C31H34F2N6O2
DMMPTLH	IC	InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)
DMMPTLH	CS	CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6
DMMPTLH	IK	HAYYBYPASCDWEQ-UHFFFAOYSA-N
DMMPTLH	IU	N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
DMMPTLH	CA	CAS 1108743-60-7
DMMPTLH	DE	Solid tumour/cancer; Colorectal cancer; Neuroblastoma; Mammary analogue secretory carcinoma; Non-small cell lung cancer

DMGL19D	ID	DMGL19D
DMGL19D	DN	Enzalutamide
DMGL19D	HS	Approved
DMGL19D	SN	MDV3100; Enzalutamide (AR inhibitor)
DMGL19D	CP	Astellas Pharma
DMGL19D	DT	Small molecular drug
DMGL19D	SQ	5'-CTCCAACATCAAGGAAGATGGCATTTCTAG
DMGL19D	PC	15951529
DMGL19D	MW	464.4
DMGL19D	FM	C21H16F4N4O2S
DMGL19D	IC	InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
DMGL19D	CS	CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
DMGL19D	IK	WXCXUHSOUPDCQV-UHFFFAOYSA-N
DMGL19D	IU	4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
DMGL19D	CA	CAS 915087-33-1
DMGL19D	CB	CHEBI:68534
DMGL19D	DE	Prostate cancer

DM5OGK0	ID	DM5OGK0
DM5OGK0	DN	Epalrestat
DM5OGK0	HS	Approved
DM5OGK0	SN	epalrestat; 82159-09-9; Kinedak; Epalrestatum; Ono 2235; Ono-2235; Epalrestat [INN]; Epalrestatum [Latin]; ONO-2; 2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid; ONO 2; UNII-424DV0807X; C15H13NO3S2; CHEMBL56337; 5-((1Z,2E)-2-Methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; CHEBI:31539; 5-((Z,E)-beta-Methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; 424DV0807X;  Epalrestatum; Aldorin (TN); Kinedak (TN); Epalrestat (JAN/INN); {5-[(E)-2-Methyl-3-phenyl-prop-2-en-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid; 3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine; Ono 2
DM5OGK0	CP	Eskayef Bangladesh Limited
DM5OGK0	TC	Hypoglycemic Agents
DM5OGK0	DT	Small molecular drug
DM5OGK0	PC	1549120
DM5OGK0	MW	319.4
DM5OGK0	FM	C15H13NO3S2
DM5OGK0	IC	InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
DM5OGK0	CS	C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)O
DM5OGK0	IK	CHNUOJQWGUIOLD-NFZZJPOKSA-N
DM5OGK0	IU	2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
DM5OGK0	CA	CAS 82159-09-9
DM5OGK0	CB	CHEBI:31539
DM5OGK0	DE	Diabetic neuropathy; Pain

DMHEAGL	ID	DMHEAGL
DMHEAGL	DN	Epanova
DMHEAGL	HS	Approved
DMHEAGL	SN	Omefas; Anti-hypertriglycemic (oral/capsule, hypertriglyceridemia/crohn's disease), Omthera
DMHEAGL	CP	Tillotts Pharma AG
DMHEAGL	DT	Small molecular drug
DMHEAGL	PC	56842239
DMHEAGL	MW	909.4
DMHEAGL	FM	C60H92O6
DMHEAGL	IC	InChI=1S/C22H32O2.C20H30O2.C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24);3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22);3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-;4-3-,7-6-,10-9-,13-12-,16-15-;4-3-,7-6-,10-9-
DMHEAGL	CS	CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O
DMHEAGL	IK	QPEOIOLHJXXJFN-GNGJDXFDSA-N
DMHEAGL	IU	(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid;(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid;(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid
DMHEAGL	DE	Hypertriglyceridemia

DMMV0KW	ID	DMMV0KW
DMMV0KW	DN	Ephedrine
DMMV0KW	HS	Approved
DMMV0KW	SN	Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin
DMMV0KW	CP	Ben Venue Laboratories Inc
DMMV0KW	TC	Central Nervous System Stimulants
DMMV0KW	DT	Small molecular drug
DMMV0KW	PC	9294
DMMV0KW	MW	165.23
DMMV0KW	FM	C10H15NO
DMMV0KW	IC	InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1
DMMV0KW	CS	C[C@@H]([C@@H](C1=CC=CC=C1)O)NC
DMMV0KW	IK	KWGRBVOPPLSCSI-WPRPVWTQSA-N
DMMV0KW	IU	(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol
DMMV0KW	CA	CAS 299-42-3
DMMV0KW	CB	CHEBI:15407
DMMV0KW	DE	Asthma

DMVONE6	ID	DMVONE6
DMVONE6	DN	Epidermal growth factor
DMVONE6	HS	Approved
DMVONE6	SN	62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1;  Gentel (TN); EGF
DMVONE6	DT	Small molecular drug
DMVONE6	PC	56841751
DMVONE6	MW	6046
DMVONE6	FM	C257H381N73O83S7
DMVONE6	IC	InChI=1S/C257H381N73O83S7/c1-20-123(15)203(245(404)283-103-192(351)285-157(80-127-42-52-135(339)53-43-127)222(381)313-171(104-331)210(369)281-101-191(350)287-167(92-198(360)361)228(387)290-146(37-27-70-273-255(265)266)213(372)318-177(110-414)238(397)292-148(62-65-185(259)344)217(376)327-205(125(17)337)249(408)294-147(38-28-71-274-256(267)268)212(371)309-168(93-199(362)363)229(388)298-153(76-117(3)4)218(377)289-145(36-26-69-272-254(263)264)211(370)303-162(86-133-96-277-144-35-25-23-33-141(133)144)226(385)304-161(85-132-95-276-143-34-24-22-32-140(132)143)225(384)291-149(63-66-195(354)355)214(373)297-154(77-118(5)6)219(378)296-152(253(412)413)39-29-72-275-257(269)270)326-247(406)202(122(13)14)324-242(401)181(114-418)320-227(386)165(90-188(262)347)307-241(400)180(113-417)322-250(409)206(126(18)338)328-231(390)160(83-130-48-58-138(342)59-49-130)302-234(393)174(107-334)315-230(389)169(94-200(364)365)310-221(380)155(78-119(7)8)299-233(392)173(106-333)314-215(374)150(64-67-196(356)357)295-248(407)204(124(16)21-2)325-232(391)163(87-134-97-271-116-284-134)305-216(375)151(68-75-420-19)293-239(398)179(112-416)321-246(405)201(121(11)12)323-194(353)99-278-189(348)98-279-208(367)164(89-187(261)346)306-220(379)156(79-120(9)10)300-240(399)178(111-415)319-223(382)158(81-128-44-54-136(340)55-45-128)286-190(349)100-280-209(368)166(91-197(358)359)308-224(383)159(82-129-46-56-137(341)57-47-129)301-235(394)175(108-335)316-237(396)176(109-336)317-244(403)184-41-31-74-330(184)252(411)182(115-419)288-193(352)102-282-243(402)183-40-30-73-329(183)251(410)170(84-131-50-60-139(343)61-51-131)311-236(395)172(105-332)312-207(366)142(258)88-186(260)345/h22-25,32-35,42-61,95-97,116-126,142,145-184,201-206,276-277,331-343,414-419H,20-21,26-31,36-41,62-94,98-115,258H2,1-19H3,(H2,259,344)(H2,260,345)(H2,261,346)(H2,262,347)(H,271,284)(H,278,348)(H,279,367)(H,280,368)(H,281,369)(H,282,402)(H,283,404)(H,285,351)(H,286,349)(H,287,350)(H,288,352)(H,289,377)(H,290,387)(H,291,384)(H,292,397)(H,293,398)(H,294,408)(H,295,407)(H,296,378)(H,297,373)(H,298,388)(H,299,392)(H,300,399)(H,301,394)(H,302,393)(H,303,370)(H,304,385)(H,305,375)(H,306,379)(H,307,400)(H,308,383)(H,309,371)(H,310,380)(H,311,395)(H,312,366)(H,313,381)(H,314,374)(H,315,389)(H,316,396)(H,317,403)(H,318,372)(H,319,382)(H,320,386)(H,321,405)(H,322,409)(H,323,353)(H,324,401)(H,325,391)(H,326,406)(H,327,376)(H,328,390)(H,354,355)(H,356,357)(H,358,359)(H,360,361)(H,362,363)(H,364,365)(H,412,413)(H4,263,264,272)(H4,265,266,273)(H4,267,268,274)(H4,269,270,275)/t123-,124-,125+,126+,142-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,201-,202-,203-,204-,205-,206-/m0/s1
DMVONE6	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N
DMVONE6	IK	VBEQCZHXXJYVRD-GACYYNSASA-N
DMVONE6	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-sulfanylpropanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMVONE6	CA	CAS 62229-50-9
DMVONE6	DE	Vulnerary; Wound healing

DMX0K3Q	ID	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	HS	Approved
DMX0K3Q	SN	Epinastina; Epinastinum; Purivist; Epinastina [Spanish]; Epinastine [INN]; Epinastinum [Latin]; WAL 80; WAL 801; WAL 801CL; Elestat (TN); Epinastine (INN); Purivist (TN); Relestat (TN); WAL-80 Cl; (+-)-Epinastine; 3-Amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; 3-amino-9,13b-dihydro-1H-benz(c,f)imidazo(1,5a)azepine; 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine
DMX0K3Q	CP	Allergan Pharmaceuticals
DMX0K3Q	TC	Antihistamines
DMX0K3Q	DT	Small molecular drug
DMX0K3Q	PC	3241
DMX0K3Q	MW	249.31
DMX0K3Q	FM	C16H15N3
DMX0K3Q	IC	InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)
DMX0K3Q	CS	C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N
DMX0K3Q	IK	WHWZLSFABNNENI-UHFFFAOYSA-N
DMX0K3Q	IU	2,4-diazatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine
DMX0K3Q	CA	CAS 80012-43-7
DMX0K3Q	CB	CHEBI:51032
DMX0K3Q	DE	Allergic conjunctivitis

DM3KJBC	ID	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	HS	Approved
DM3KJBC	SN	ADROP; Adnephrine; Adrenal; Adrenalin; Adrenalina; Adrenaline; Adrenalinum; Adrenamine; Adrenan; Adrenapax; Adrenasol; Adrenatrate; Adrenine; Adrenodis; Adrenohorma; Adrenosan; Adrenutol; Adrin; Adrine; Antiasthmatique; Asthmanefrin; Astmahalin; Astminhal; Balmadren; Bernarenin; Biorenine; Bosmin; Brevirenin; Bronkaid; Chelafrin; Corisol; Drenamist; Dylephrin; Epifrin; Epiglaufrin; Epinefrin; Epinefrina; Epinephran; Epinephrin; Epinephrinum; Epipen; Epirenamine; Epirenan; Epirenin; Epitrate; Eppy; Esphygmogenina; Exadrin; Glaucon; Glaucosan; Glauposine; Glycirenan; Haemostasin; Haemostatin; Hektalin; Hemisine; Hemostasin; Hemostatin; Hypernephrin; Hyporenin; IOP; Intranefrin; Iontocaine; Isoptoepinal; Kidoline; Levoadrenaline; Levoepinephrine; Levorenen; Levorenin; Levorenine; Lyophrin; Metanephrin; Methylaminoethanolcatechol; Methylarterenol; Micronefrin; Micronephrine; Mucidrina; Myosthenine; Mytrate; Nephridine; Nieraline; Paranephrin; Primatene; Racepinephrine; Renagladin; Renaglandin; Renaglandulin; Renaleptine; Renalina; Renoform; Renostypricin; Renostypticin; Renostyptin; Scurenaline; Septocaine; Simplene; Sindrenina; Soladren; Sphygmogenin; Stryptirenal; Styptirenal; Supracapsulin; Supradin; Supranefran; Supranephrane; Supranephrine; Supranol; Suprarenaline; Suprarenin; Suprel; Surenine; Surrenine; Susphrine; Takamina; Takamine; Tokamina; Tonogen; Twinject; Vaponefrin; Vasoconstrictine; Vasoconstrictor; Vasodrine; Vasoton; Vasotonin; ADR ADRENALINE; Adrenalin in Oil; Adrenalina [DCIT]; Asmatane Mist; Asthma meter mist; Asthmahaler Mist; Bronkaid Mist; Bronkaid Suspension Mist; Bupivacaine Hcl and Epinephrine; Citanest Forte; EPI E Z PEN JR; EPIPEN E Z PEN; EPIPEN JR; Epi EZ Pen Jr; Epinefrin [Czech]; Epinephrine hydrochloride; Epipen EZ Pen; Primatene Mist; Racemic Epinephrine; Sympathin I; Adrenalin (TN); Adrenalin-Medihaler; Adrenaline (JP15); Adrenaline/Epinephrine; Ana-Guard; Asthma-nefrin; D-Adrenaline; D-Epifrin; D-Epinephrine; Dyspne-Inhal; Epinefrina [INN-Spanish]; Epinephrine (USP); Epinephrinum [INN-Latin]; Epipen (TN); Epipen Auto-Injector; Epipen Jr.; L-Adrenalin; L-Adrenaline; L-Adrenaline Base; L-Epinehphrine; L-Epinephine; L-Epirenamine; L-Methylaminoethanolcatechol; L-epinephrine; Levo-Methylaminoethanolcatechol; Medihaler-Epi; R-Adrenaline; Sus-Phrine; Twinject 0.15; Twinject 0.3; Twinject 0.30; Epinephrine (USP/INN); Epinephrine [USAN:INN:JAN]; Epipen Jr. Auto-Injector; L-Epinephrine (synthetic); SUS-PHRINE SULFITE-FREE; R-(-)-Epinephrine; L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; (-)-(R)-Epinephrine; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; (-)-Adrenalin; (-)-Adrenaline; (-)-R-Epinephrine; (R)-(-)-Adnephrine; (R)-(-)-Adrenaline; (R)-(-)-Epinephrine; (R)-(-)-Epirenamine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; (R)-Adrenaline; (R)-Epinephrine; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; 1-Adrenalin; 1-Epinephrine; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
DM3KJBC	TC	Vasoconstrictor Agents
DM3KJBC	DT	Small molecular drug
DM3KJBC	PC	5816
DM3KJBC	MW	183.2
DM3KJBC	FM	C9H13NO3
DM3KJBC	IC	InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1
DM3KJBC	CS	CNC[C@@H](C1=CC(=C(C=C1)O)O)O
DM3KJBC	IK	UCTWMZQNUQWSLP-VIFPVBQESA-N
DM3KJBC	IU	4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
DM3KJBC	CA	CAS 51-43-4
DM3KJBC	CB	CHEBI:28918
DM3KJBC	DE	Allergy

DMPDW6T	ID	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	HS	Approved
DMPDW6T	SN	Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin
DMPDW6T	CP	Pfizer Pharmaceuticals
DMPDW6T	TC	Anticancer Agents
DMPDW6T	DT	Small molecular drug
DMPDW6T	PC	41867
DMPDW6T	MW	543.5
DMPDW6T	FM	C27H29NO11
DMPDW6T	IC	InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
DMPDW6T	CS	C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
DMPDW6T	IK	AOJJSUZBOXZQNB-VTZDEGQISA-N
DMPDW6T	IU	(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMPDW6T	CA	CAS 56420-45-2
DMPDW6T	CB	CHEBI:47898
DMPDW6T	DE	Solid tumour/cancer

DMF0NQR	ID	DMF0NQR
DMF0NQR	DN	Eplerenone
DMF0NQR	HS	Approved
DMF0NQR	SN	Epoxymexrenone; Inspra; Selara; CGP-30083; Inspra (TN); SC-66110; Eplerenone (JAN/USAN/INN); Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone; 7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
DMF0NQR	CP	Pfizer Pharmaceuticals
DMF0NQR	TC	Antihypertensive Agents
DMF0NQR	DT	Small molecular drug
DMF0NQR	PC	443872
DMF0NQR	MW	414.5
DMF0NQR	FM	C24H30O6
DMF0NQR	IC	InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
DMF0NQR	CS	C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC
DMF0NQR	IK	JUKPWJGBANNWMW-VWBFHTRKSA-N
DMF0NQR	IU	methyl (1R,2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate
DMF0NQR	CA	CAS 107724-20-9
DMF0NQR	CB	CHEBI:31547
DMF0NQR	DE	Heart failure

DMKWB73	ID	DMKWB73
DMKWB73	DN	Epoetin alfa
DMKWB73	HS	Approved
DMKWB73	SN	Epogen (TN); Procrit (TN)
DMKWB73	CP	Amgen Inc
DMKWB73	TC	Antianemic Agents
DMKWB73	DE	Anemia

DMUTYR2	ID	DMUTYR2
DMUTYR2	DN	Epoprostenol
DMUTYR2	HS	Approved
DMUTYR2	SN	Epoprostanol; Epoprostenolum; Flolan; PGX; Prostacyclin; Prostacycline; Prostacyclins; Vasocyclin; ProstaglandinI; Prostaglandin X; Prostaglandins X; PGI2; Prostacyclin I2; Prostaglandin I2; TRY 200; Epoprostenol (TN); Epoprostenol [USAN:INN]; Epoprostenolum [INN-Latin]; PG-I2; PGI(sub 2); Prostaglandin I(2); Try-200; U 53,217; U-53217; Epoprostenol (USAN/INN); KB-IV-24; (5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate; (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid; (5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid; (5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid; (Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
DMUTYR2	TC	Antihypertensive Agents
DMUTYR2	DT	Small molecular drug
DMUTYR2	PC	5282411
DMUTYR2	MW	352.5
DMUTYR2	FM	C20H32O5
DMUTYR2	IC	InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1
DMUTYR2	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O
DMUTYR2	IK	KAQKFAOMNZTLHT-OZUDYXHBSA-N
DMUTYR2	IU	(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
DMUTYR2	CA	CAS 35121-78-9
DMUTYR2	CB	CHEBI:15552
DMUTYR2	DE	Pulmonary hypertension

DM07K2I	ID	DM07K2I
DM07K2I	DN	Eprosartan
DM07K2I	HS	Approved
DM07K2I	SN	133040-01-4; Teveten; F-108566; F 108566; UNII-2KH13Z0S0Y; (E)-4-((2-Butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; CHEMBL813; SK-108566; 2KH13Z0S0Y; CHEBI:4814; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; SK&F 108566; SKF-108566; Teveten (TN); Eprosartan (USAN/INN); Eprosartan [USAN:BAN:INN]; SK&F-108566; (4-carboxybenzyl)imidazole-5-acrylic acid; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; [3H]eprosartan
DM07K2I	CP	Abbott Laboratories
DM07K2I	TC	Antihypertensive Agents
DM07K2I	DT	Small molecular drug
DM07K2I	PC	5281037
DM07K2I	MW	424.5
DM07K2I	FM	C23H24N2O4S
DM07K2I	IC	InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
DM07K2I	CS	CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)/C=C(\\CC3=CC=CS3)/C(=O)O
DM07K2I	IK	OROAFUQRIXKEMV-LDADJPATSA-N
DM07K2I	IU	4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid
DM07K2I	CA	CAS 133040-01-4
DM07K2I	CB	CHEBI:4814
DM07K2I	DE	Hypertension

DMQXTJS	ID	DMQXTJS
DMQXTJS	DN	Eptifibatide
DMQXTJS	HS	Approved
DMQXTJS	SN	Integrelin; Integrilin; Intrifiban; HS-2011; Integrilin (TN); SB-1; Sch-60936; N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]; L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide; L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide; [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid; 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid; 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
DMQXTJS	CP	Millennium Pharmaceuticals
DMQXTJS	TC	Anticoagulants
DMQXTJS	DT	Small molecular drug
DMQXTJS	PC	448812
DMQXTJS	MW	832
DMQXTJS	FM	C35H49N11O9S2
DMQXTJS	IC	InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1
DMQXTJS	CS	C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N
DMQXTJS	IK	CZKPOZZJODAYPZ-LROMGURASA-N
DMQXTJS	IU	2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
DMQXTJS	CA	CAS 188627-80-7
DMQXTJS	CB	CHEBI:291902
DMQXTJS	DE	Acute cardiac ischemic events

DM5LJCI	ID	DM5LJCI
DM5LJCI	DN	Eptinezumab
DM5LJCI	HS	Approved
DM5LJCI	CP	Alder Biopharmaceuticals Bothell, WA
DM5LJCI	DE	Migraine

DMI782S	ID	DMI782S
DMI782S	DN	Erdafitinib
DMI782S	HS	Approved
DMI782S	SN	1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino
DMI782S	CP	Janssen Research & Development Raritan, NJ
DMI782S	PC	67462786
DMI782S	MW	446.5
DMI782S	FM	C25H30N6O2
DMI782S	IC	InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3
DMI782S	CS	CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC
DMI782S	IK	OLAHOMJCDNXHFI-UHFFFAOYSA-N
DMI782S	IU	N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine
DMI782S	CA	CAS 1346242-81-6
DMI782S	DE	Lymphoma; Urothelial carcinoma; Bladder cancer; Solid tumour/cancer

DM6QFSV	ID	DM6QFSV
DM6QFSV	DN	Erdosteine
DM6QFSV	HS	Approved
DM6QFSV	SN	Asdigan; Biopulmin; Dostin; Dostol; Drupsan; Ectrin; Edirel; Erdomed; Erdopect; Erdos; Erdotin; Esteclin; Fluidasa; Flusten; Mucoflux; Mucofor; Mucotec; Mucothera; Mukial; Secresolv; Theovix; Tusselin; Vectrine; KW-9144; RV-144
DM6QFSV	CP	Edmond Pharma
DM6QFSV	DT	Small molecular drug
DM6QFSV	PC	65632
DM6QFSV	MW	249.3
DM6QFSV	FM	C8H11NO4S2
DM6QFSV	IC	InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)
DM6QFSV	CS	C1CSC(=O)C1NC(=O)CSCC(=O)O
DM6QFSV	IK	QGFORSXNKQLDNO-UHFFFAOYSA-N
DM6QFSV	IU	2-[2-oxo-2-[(2-oxothiolan-3-yl)amino]ethyl]sulfanylacetic acid
DM6QFSV	CA	CAS 84611-23-4
DM6QFSV	CB	CHEBI:135014
DM6QFSV	DE	Bronchitis

DMWMCN0	ID	DMWMCN0
DMWMCN0	DN	Erenumab
DMWMCN0	HS	Approved
DMWMCN0	SN	Aimovig; Erenumab [USAN]; UNII-I5I8VB78VT; I5I8VB78VT
DMWMCN0	CP	Amgen/Novartis
DMWMCN0	DE	Hyperprolactinaemia

DMHO0AR	ID	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	HS	Approved
DMHO0AR	SN	Calciferol; Calciferolum; Condacaps; Condocaps; Condol; Crtron; Crystallina; Daral; Davitin; Decaps; Deltalin; Deratol; Detalup; Diactol; Drisdol; Ercalciol; Ergocalciferolo; Ergocalciferols; Ergocalciferolum; Ergorone; Ertron; Fortodyl; Geltabs; Haliver; Hyperkil; Infron; Metadee; Mulsiferol; Mykostin; Ostelin; Radiostol; Radstein; Radsterin; Rodinec; Sterogyl; Vigantol; Viostdrol; Viosterol; CALCIFEROL IN A GELATIN MATRIX; Component of Geltabs Vitamin D; Davitamon D; Divit urto; Ergocalciferolo [DCIT]; Ergosterol activated; Ergosterol irradiated; Geltabs Vitamin D; Irradiated ergosterol; Oleovitamin D; Rodine C; Synthetic Vitamin D; Viosterol in Oil; Calciferon 2; Mina D2; Oleovitamin D2; VITAMIN D2; VITAMIN_D2; Vitamina D2; Buco-D; Calciferol (TN); Calciferol (vitamin D2); D-Arthin; D-Tracetten; De-rat concentrate; Dee-Osterol; Dee-Ron; Dee-Ronal; Dee-Roual; Deltalin (TN); Drisdol (TN); Ergocalciferol (D2); Ergocalciferol: Vitamin D; Ergocalciferolum [INN-Latin]; Ergosterol, irradiated; Hi-Deratol; Novovitamin-D; Oleovitamin D, Synthetic; Shock-ferol; Shock-ferol sterogyl; Sorex C.R; Uvesterol-D; Vio-D; Vitamin d-2; Vitamin-D2; Vitavel-D; Ergocalciferol (JP15/USP); Ergocalciferol [INN:BAN:JAN]; Sorex C.R.; VITAMIN D2 WATER DISPERSABLE U.S.P.; CALCIFEROL, U.S.P.; Irradiated ergosta-5,7,22-trien-3-beta-ol; Irradiated ergosta-5,7,22-trien-3.beta.-ol; (+)-Vitamin D2; (3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol; (3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; 7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87; 9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol;9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol; 9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
DMHO0AR	CP	Eli Lilly
DMHO0AR	TC	Vitamins
DMHO0AR	DT	Small molecular drug
DMHO0AR	PC	5280793
DMHO0AR	MW	396.6
DMHO0AR	FM	C28H44O
DMHO0AR	IC	InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
DMHO0AR	CS	C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMHO0AR	IK	MECHNRXZTMCUDQ-RKHKHRCZSA-N
DMHO0AR	IU	(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMHO0AR	CA	CAS 50-14-6
DMHO0AR	CB	CHEBI:28934
DMHO0AR	DE	Hypoparathyroidism

DMORPBA	ID	DMORPBA
DMORPBA	DN	Ergoloid mesylate
DMORPBA	HS	Approved
DMORPBA	SN	Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN)
DMORPBA	CP	Sandoz
DMORPBA	TC	Vasodilator Agents
DMORPBA	DT	Small molecular drug
DMORPBA	PC	592735
DMORPBA	MW	591.7
DMORPBA	FM	C33H45N5O5
DMORPBA	IC	InChI=1S/C33H45N5O5/c1-7-31(4,5)27-29(40)37-13-9-12-25(37)33(42)38(27)30(41)32(43-33,18(2)3)35-28(39)20-14-22-21-10-8-11-23-26(21)19(16-34-23)15-24(22)36(6)17-20/h8,10-11,16,18,20,22,24-25,27,34,42H,7,9,12-15,17H2,1-6H3,(H,35,39)
DMORPBA	CS	CCC(C)(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O
DMORPBA	IK	YLXBZBPHTNJZQE-UHFFFAOYSA-N
DMORPBA	IU	N-[2-hydroxy-7-(2-methylbutan-2-yl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMORPBA	DE	Alzheimer disease

DM0VEC1	ID	DM0VEC1
DM0VEC1	DN	Ergonovine
DM0VEC1	HS	Approved
DM0VEC1	SN	Basergin; Ergobasin; Ergobasine; Ergoklinine; Ergometrin; Ergometrina; Ergometrine; Ergometrinum; Ergostetrine; Ergotocine; Ergotrate; Margonovine; Neofemergen; Secacornin; Secometrin; Ergotrate Maleate; Lysergic acid propanolamide; Ergometrina [INN-Spanish]; Ergometrine (INN); Ergometrine [INN:BAN]; Ergometrinum[INN-Latin]; D-Lysergic acid 1-hydroxymethylethylamide; D-Lysergic acid-L-propanolamide; L-Lysergic-L(beta-hydroxyisopropylamide); N-(1-(Hydroxymethyl)ethyl)-D-lysergamide; N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide; N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide; N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-9,10-didehydroergoline-8beta-carboxamide; [8beta(S)]-9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide
DM0VEC1	CP	Pfizer Pharmaceuticals
DM0VEC1	TC	Oxytocics
DM0VEC1	DT	Small molecular drug
DM0VEC1	PC	443884
DM0VEC1	MW	325.4
DM0VEC1	FM	C19H23N3O2
DM0VEC1	IC	InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1
DM0VEC1	CS	C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DM0VEC1	IK	WVVSZNPYNCNODU-XTQGRXLLSA-N
DM0VEC1	IU	(6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM0VEC1	CA	CAS 60-79-7
DM0VEC1	CB	CHEBI:4822
DM0VEC1	DE	Postpartum haemorrhage

DMKR3C5	ID	DMKR3C5
DMKR3C5	DN	Ergotamine
DMKR3C5	HS	Approved
DMKR3C5	SN	Avetol; Cornutamin; Cornutamine; ETIN; Ergam; Ergate; Ergomar; Ergonsvine; Ergostat; Ergotamin; Ergotartrate; Exmigra; Femergin;Gynergen; Lingraine; Lingran; Migretamine; Rigetamin; Secagyn; Secupan; Temigran; Wigrettes; Ergotamine bitartrate; Ergotamine hemitartrate; Ergotamine tartrate; Gotamine tartrate; Medihaler ergotamine; Ergomar (TN); Ergotamina [INN-Spanish]; Ergotamine (INN); Ergotamine [INN:BAN]; Ergotamine tartrate (VAN); Ergotaminum [INN-Latin]; Ergoton-A; Neo-ergotin; Ergotamine, tartrate (2:1); Ergotamine tartrate, Avetol, Cornutamin, Ergam, Ergotartrate; ERGOTAMINE (SEE ALSO: ERGOTAMINE TARTRATE (CAS 379-79-3)); Ergotamine, tartrate (2:1) (salt) (8CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)-(9CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt); (5'A)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman 2,3-dihydroxybutanedioate(2:1); 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione
DMKR3C5	CP	Eli Lilly
DMKR3C5	TC	Analgesics
DMKR3C5	DT	Small molecular drug
DMKR3C5	PC	8223
DMKR3C5	MW	581.7
DMKR3C5	FM	C33H35N5O5
DMKR3C5	IC	InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1
DMKR3C5	CS	C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
DMKR3C5	IK	XCGSFFUVFURLIX-VFGNJEKYSA-N
DMKR3C5	IU	(6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMKR3C5	CA	CAS 379-79-3
DMKR3C5	CB	CHEBI:64318
DMKR3C5	DE	Headache

DM78IME	ID	DM78IME
DM78IME	DN	Ergotidine
DM78IME	HS	Approved
DM78IME	SN	Eramin; Ergamine; Histamine; Histaminum; Istamina; Theramine; Free histamine; Histamine Base; Histamine [USAN]; Istamina [Italian]; H7125_SIGMA; [3H]histamine; ALBB-005968; Beta-Aminoethylglyoxaline; Beta-Aminoethylimidazole; Beta-aminothethylglyoxaline; Histamine (DCF); Histamine, Free Base; Histaminum (TN); L-histamine; ZERO/004089; Imidazole-4-ethylamine; Beta-Imidazolyl-4-ethylamine; F411C768-A159-4FC0-A195-291A08BB03AA; 1H-Imidazole-4-ethanamine; 1H-Imidazole-5-ethanamine; 2-(1H-Imidazol-4-yl)ethanamine; 2-(1H-imidazol-4-yl)ethan-1-amine; 2-(1H-imidazol-5-yl)ethanamine; 2-(3H-Imidazol-4-yl)-ethylamine; 2-(4-Imidazolyl)ethylamine; 2-Imidazol-4-ylethylamine; 2-[4-Imidazolyl]ethylamine; 4-(2-Aminoethyl)-1H-imidazole; 4-Imidazoleethylamine; 5-Imidazoleethylamine
DM78IME	TC	Antiallergic Agents
DM78IME	DT	Small molecular drug
DM78IME	PC	774
DM78IME	MW	111.15
DM78IME	FM	C5H9N3
DM78IME	IC	InChI=1S/C5H9N3/c6-2-1-5-3-7-4-8-5/h3-4H,1-2,6H2,(H,7,8)
DM78IME	CS	C1=C(NC=N1)CCN
DM78IME	IK	NTYJJOPFIAHURM-UHFFFAOYSA-N
DM78IME	IU	2-(1H-imidazol-5-yl)ethanamine
DM78IME	CA	CAS 51-45-6
DM78IME	CB	CHEBI:18295
DM78IME	DE	Respiratory allergy

DM1DX4Q	ID	DM1DX4Q
DM1DX4Q	DN	Eribulin
DM1DX4Q	HS	Approved
DM1DX4Q	CP	Eisai
DM1DX4Q	DT	Small molecular drug
DM1DX4Q	PC	11354606
DM1DX4Q	MW	729.9
DM1DX4Q	FM	C40H59NO11
DM1DX4Q	IC	InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1
DM1DX4Q	CS	C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O
DM1DX4Q	IK	UFNVPOGXISZXJD-JBQZKEIOSA-N
DM1DX4Q	IU	(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one
DM1DX4Q	CA	CAS 253128-41-5
DM1DX4Q	CB	CHEBI:63587
DM1DX4Q	DE	Breast cancer

DMCMBHA	ID	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	HS	Approved
DMCMBHA	SN	Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
DMCMBHA	CP	OSI Pharma
DMCMBHA	TC	Anticancer Agents
DMCMBHA	DT	Small molecular drug
DMCMBHA	PC	176870
DMCMBHA	MW	393.4
DMCMBHA	FM	C22H23N3O4
DMCMBHA	IC	InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
DMCMBHA	CS	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
DMCMBHA	IK	AAKJLRGGTJKAMG-UHFFFAOYSA-N
DMCMBHA	IU	N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
DMCMBHA	CA	CAS 183321-74-6
DMCMBHA	CB	CHEBI:114785
DMCMBHA	DE	Non-small-cell lung cancer; Colon cancer; Pancreatic cancer

DM4S3O8	ID	DM4S3O8
DM4S3O8	DN	Ertapenem
DM4S3O8	HS	Approved
DM4S3O8	SN	Ertapenem [INN]; Ertapenem (INN); Invanz (TN); (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM4S3O8	CP	Merck & Co
DM4S3O8	TC	Antibiotics
DM4S3O8	DT	Small molecular drug
DM4S3O8	PC	150610
DM4S3O8	MW	475.5
DM4S3O8	FM	C22H25N3O7S
DM4S3O8	IC	InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1
DM4S3O8	CS	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)[C@@H](C)O
DM4S3O8	IK	JUZNIMUFDBIJCM-ANEDZVCMSA-N
DM4S3O8	IU	(4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM4S3O8	CA	CAS 153832-46-3
DM4S3O8	CB	CHEBI:404903
DM4S3O8	DE	Bacterial infection

DMFGQ2S	ID	DMFGQ2S
DMFGQ2S	DN	Erythrityl Tetranitrate
DMFGQ2S	HS	Approved
DMFGQ2S	SN	Cardilate; Cardiloid; Cardivell; Cardiwell; Erythritetranitrat; Nitroerythrit; Nitroerythrite; Nitroerythrol; Tetranitrin; Tetranitrol; Eritritile tetranitrato; Eritritile tetranitrato [DCIT]; Eritrityl tetranitrate; Eritrityli tetranitras; Erythritol tetranitrate; Erythrityl tetranitrate [USAN]; Erythrol tetranitrate; Tetranitrato de eritritilo; Eritrityli tetranitras [INN-Latin]; Erythritol, tetranitrate; Meso-Erythritol tetranitrate; Tetranitrate d'erithrityle; Tetranitrate d'eritrityle; Tetranitrato de eritritilo [INN-Spanish]; Erythritol, tetranitrate (8CI); Tetranitrate d'eritrityle [INN-French]; 1,2,3,4-Butanetetralyl tetranitrate; 1,3,4-trinitrooxybutan-2-yl nitrate
DMFGQ2S	TC	Vasodilator Agents
DMFGQ2S	DT	Small molecular drug
DMFGQ2S	PC	5284553
DMFGQ2S	MW	302.11
DMFGQ2S	FM	C4H6N4O12
DMFGQ2S	IC	InChI=1S/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+
DMFGQ2S	CS	C([C@H]([C@H](CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
DMFGQ2S	IK	SNFOERUNNSHUGP-ZXZARUISSA-N
DMFGQ2S	IU	[(2R,3S)-1,3,4-trinitrooxybutan-2-yl] nitrate
DMFGQ2S	CA	CAS 7297-25-8
DMFGQ2S	CB	CHEBI:60072
DMFGQ2S	DE	Angina pectoris

DM4K7GQ	ID	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	HS	Approved
DM4K7GQ	SN	Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery
DM4K7GQ	CP	Eli Lilly
DM4K7GQ	TC	Antibiotics
DM4K7GQ	DT	Small molecular drug
DM4K7GQ	PC	12560
DM4K7GQ	MW	733.9
DM4K7GQ	FM	C37H67NO13
DM4K7GQ	IC	InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
DM4K7GQ	CS	CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
DM4K7GQ	IK	ULGZDMOVFRHVEP-RWJQBGPGSA-N
DM4K7GQ	IU	(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DM4K7GQ	CA	CAS 114-07-8
DM4K7GQ	CB	CHEBI:42355
DM4K7GQ	DE	Bacterial infection

DMFK9HG	ID	DMFK9HG
DMFK9HG	DN	Escitalopram
DMFK9HG	HS	Approved
DMFK9HG	SN	Esertia; Escitalopram [INN]; Cipralex (TN); Escitalopram (INN); Esertia (TN); Lexapro (TN); S(+)-Citalopram; (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; (S)-Citalopram
DMFK9HG	CP	Forest Laboratories 
DMFK9HG	TC	Antidepressants
DMFK9HG	DT	Small molecular drug
DMFK9HG	PC	146570
DMFK9HG	MW	324.4
DMFK9HG	FM	C20H21FN2O
DMFK9HG	IC	InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
DMFK9HG	CS	CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
DMFK9HG	IK	WSEQXVZVJXJVFP-FQEVSTJZSA-N
DMFK9HG	IU	(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DMFK9HG	CA	CAS 128196-01-0
DMFK9HG	CB	CHEBI:36791
DMFK9HG	DE	Major depressive disorder

DMZREFQ	ID	DMZREFQ
DMZREFQ	DN	Eslicarbazepine
DMZREFQ	HS	Approved
DMZREFQ	SN	Aptiom; BIA 2-093; Exalief; SEP-0002093; Sep-93; Stedesa; Zebinix
DMZREFQ	TC	Neurology Agents
DMZREFQ	DT	Small molecular drug
DMZREFQ	PC	9881504
DMZREFQ	MW	254.28
DMZREFQ	FM	C15H14N2O2
DMZREFQ	IC	InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
DMZREFQ	CS	C1[C@@H](C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
DMZREFQ	IK	BMPDWHIDQYTSHX-AWEZNQCLSA-N
DMZREFQ	IU	(5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMZREFQ	CA	CAS 104746-04-5
DMZREFQ	DE	Seizure disorder

DMREUZV	ID	DMREUZV
DMREUZV	DN	Eslicarbazepine acetate
DMREUZV	HS	Approved
DMREUZV	SN	Eslicarbazepine acetate; BIA 2-093; Aptiom; Zebinix; Stedesa; Exalief; Eslicarbazepine (acetate); UNII-BEA68ZVB2K; BIA-2-093; (S)-5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; Sep 0002093; BIA 2093; BEA68ZVB2K; SEP-0002093; CHEMBL87992; Eslicarbazepine acetate [USAN]; CHEBI:87016; exelief; (S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate; Eslicarbazepine acetate (USAN)
DMREUZV	PC	179344
DMREUZV	MW	296.32
DMREUZV	FM	C17H16N2O3
DMREUZV	IC	InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1
DMREUZV	CS	CC(=O)OC1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N
DMREUZV	IK	QIALRBLEEWJACW-INIZCTEOSA-N
DMREUZV	IU	[(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate
DMREUZV	CA	CAS 236395-14-5
DMREUZV	CB	CHEBI:87016
DMREUZV	DE	Partial seizures

DM51TYR	ID	DM51TYR
DM51TYR	DN	Esmolol
DM51TYR	HS	Approved
DM51TYR	SN	ASL 8052-001; Brevibloc (TN); Esmolol (INN); Esmolol [INN:BAN]; Methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate; Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; Methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; (+-)-Esmolol; (+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
DM51TYR	CP	Bedford Laboratories
DM51TYR	TC	Antihypertensive Agents
DM51TYR	DT	Small molecular drug
DM51TYR	PC	59768
DM51TYR	MW	295.37
DM51TYR	FM	C16H25NO4
DM51TYR	IC	InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3
DM51TYR	CS	CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O
DM51TYR	IK	AQNDDEOPVVGCPG-UHFFFAOYSA-N
DM51TYR	IU	methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate
DM51TYR	CA	CAS 81147-92-4
DM51TYR	CB	CHEBI:88206
DM51TYR	DE	Acute supraventricular tachycardia

DM7BN0X	ID	DM7BN0X
DM7BN0X	DN	Esomeprazole
DM7BN0X	HS	Approved
DM7BN0X	SN	Esomeprazolum; Nexiam; Inexium paranova; Axagon (TN); Esomeprazole (INN); Esomeprazole [INN:BAN]; Esopral (TN); Inexium paranova (TN); Lucen (TN); Nexiam (TN); Nexium (TN); Sompraz (TN); Zoleri (TN); (S)-(-)-Omeprazole; (S)-Omeprazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
DM7BN0X	CP	AstraZeneca
DM7BN0X	TC	Antiulcer Agents
DM7BN0X	DT	Small molecular drug
DM7BN0X	PC	9568614
DM7BN0X	MW	345.4
DM7BN0X	FM	C17H19N3O3S
DM7BN0X	IC	InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1
DM7BN0X	CS	CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC
DM7BN0X	IK	SUBDBMMJDZJVOS-DEOSSOPVSA-N
DM7BN0X	IU	6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DM7BN0X	CA	CAS 119141-88-7
DM7BN0X	CB	CHEBI:50275
DM7BN0X	DE	Peptic ulcer

DMZGXUM	ID	DMZGXUM
DMZGXUM	DN	Estazolam
DMZGXUM	HS	Approved
DMZGXUM	SN	Cannoc; Esilgan; Estazolamum; Eurodin; Julodin; Nemurel; Nuctalon; ProSom; Somnatrol; Tasedan; Abbott Brand of Estazolam; HormonaBrand of Estazolam; Takeda Brand of Estazolam; Abbott 47631; D 40TA; D40TA; U 33737; D-40TA; Estazolamum [INN-Latin]; Eurodin (TN); ProSom (TN); Prosom (TN); Estazolam [USAN:INN:JAN]; Estazolam (JP15/USAN/INN); 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl; 8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine (IUPAC); 8-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-6-phenyl-4H-s-triazolo[4,3-(alpha)] [1,4]benzodiazepine
DMZGXUM	TC	Anticonvulsants
DMZGXUM	DT	Small molecular drug
DMZGXUM	PC	3261
DMZGXUM	MW	294.74
DMZGXUM	FM	C16H11ClN4
DMZGXUM	IC	InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2
DMZGXUM	CS	C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4
DMZGXUM	IK	CDCHDCWJMGXXRH-UHFFFAOYSA-N
DMZGXUM	IU	8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMZGXUM	CA	CAS 29975-16-4
DMZGXUM	CB	CHEBI:4858
DMZGXUM	DE	Insomnia

DM9KZDO	ID	DM9KZDO
DM9KZDO	DN	Esterified estrogens
DM9KZDO	HS	Approved
DM9KZDO	DE	Breast cancer

DMUNTE3	ID	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	HS	Approved
DMUNTE3	SN	Aerodiol; Alora; Altrad; Aquadiol; Bardiol; Climaderm; Climara; Compudose; Corpagen; Dermestril; Destradiol; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyesterin; Dihydroxyestrin; Dihydroxyoestrin; Dimenformon; Diogyn; Diogynets; Divigel; Elestrin; Encore; Esclim; Estrace; Estraderm; Estradiolo; Estradiolum; Estradot; Estraldine; Estrasorb; Estreva; Estrifam; Estring; Estroclim; Estrodiolum; Estrogel; Estrovite; Evamist; Evorel; Extrasorb; Femanest; Femestral; Femestrol; Fempatch; Femtran; Follicyclin; Gelestra; Ginedisc; Ginosedol; GynPolar; Gynergon; Gynestrel; Gynodiol; Gynoestryl; Innofem; Lamdiol; Macrodiol; Macrol; Menest; Menorest; Microdiol; Nordicol; Oesclim; Oestergon; Oestradiol; Oestradiolum; Oestrogel; Oestroglandol; Oestrogynal; Ovahormon; Ovasterol; Ovastevol; Ovociclina; Ovocyclin; Ovocycline; Ovocylin; Perlatanol; Polyestradiol; Primofol; Profoliol; Progynon; Syndiol; Systen; Tradelia; Trocosone; Vagifem; Vivelle; Zerella; Zesteem; Zesteen; Zumenon; Climara Forte; Component of Menrium; Estraderm MX; Estraderm TTS; Estradiolo [DCIT]; Estradiolum [INN]; Estring vaginal ring; Estrofem Forte; Oestradiol Berco; Oestradiol R; Progynon DH; Sandrena Gel; Sisare Gel; Trial SAT; CMC_11154; Compudose 200; Compudose 365; E 2; E 8875; E0025; Epiestriol 50; Estraderm TTS 100; Estraderm TTS 50; Estrapak 50; Estroclim 50; Estrofem 2; Sandrena 1; [3H]]estradiol; Activella (TN); Alora (TN); Alpha-Oestradiol; AngeliQ (TN); B-Estradiol; Beta-Estradiol; Beta-Oestradiol; Beta-estradiol; Cis-Estradiol; Cis-Oestradiol; Climara (TN); D-Estradiol; D-Oestradiol; Divigel (TN); E(sub 2); Elestrin (TN); Estrace (TN); Estraderm (TN); Estraderm TTS (TN); Estradiol [USAN:INN]; Estradiol acetate (TN); Estradiol cypionate (TN); Estradiol valerate (TN); Estradiol-17 beta; Estradiol-17beta; Estrasorb (TN); Estrasorb Topical (TN); Estring (TN); Estrofem (TN); Estrogel (TN); EvaMist (TN); Femring (TN); Innofem (TN); Menostar (TN); Oestradiol-17beta; Progynon-DH; Progynova (TN); S-21400; SK-Estrogens; SL-1100; VIVELLE-DOT; Vagifem (TN); Vivelle (TN); [3H]-estradiol; Estradiol-17-beta; Estradiol-3,17beta; Oestradiol-17-beta; Vivelle-Dot (TN); D-3,17beta-Estradiol; [2,4,6,7-3H]-E2; 17 beta-Estradiol; 17-.BETA.-Estradiol; 17-beta-OH-estradiol; 17-beta-estradiol; 17.beta.-Estradiol; 17.beta.-Oestradiol; 17b-Oestradiol; 17beta oestradiol; 17beta-Estradiol; 17beta-Oestradiol; 3,17-beta-Estradiol; 3,17-beta-Oestradiol; 3,17.beta.-Estradiol; 3,17beta-Estradiol
DMUNTE3	TC	Estrogens
DMUNTE3	DT	Small molecular drug
DMUNTE3	PC	5757
DMUNTE3	MW	272.4
DMUNTE3	FM	C18H24O2
DMUNTE3	IC	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
DMUNTE3	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O
DMUNTE3	IK	VOXZDWNPVJITMN-ZBRFXRBCSA-N
DMUNTE3	IU	(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMUNTE3	CA	CAS 17916-67-5
DMUNTE3	CB	CHEBI:16469
DMUNTE3	DE	Breast cancer

DM07U2A	ID	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	HS	Approved
DM07U2A	SN	Femring
DM07U2A	CP	Warner Chilcott Ireland Ltd
DM07U2A	DT	Small molecular drug
DM07U2A	PC	9818306
DM07U2A	MW	314.4
DM07U2A	FM	C20H26O3
DM07U2A	IC	InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1
DM07U2A	CS	CC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4O)C
DM07U2A	IK	FHXBMXJMKMWVRG-SLHNCBLASA-N
DM07U2A	IU	[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] acetate
DM07U2A	CA	CAS 4245-41-4
DM07U2A	CB	CHEBI:135981
DM07U2A	DE	Hormone replacement therapy

DM27Z5T	ID	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	HS	Approved
DM27Z5T	SN	Depo-estradiol
DM27Z5T	CP	Pharmacia And Upjohn Co
DM27Z5T	DT	Small molecular drug
DM27Z5T	PC	9403
DM27Z5T	MW	396.6
DM27Z5T	FM	C26H36O3
DM27Z5T	IC	InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1
DM27Z5T	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=C3C=CC(=C5)O
DM27Z5T	IK	UOACKFBJUYNSLK-XRKIENNPSA-N
DM27Z5T	IU	[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
DM27Z5T	CA	CAS 313-06-4
DM27Z5T	CB	CHEBI:34745
DM27Z5T	DE	Hormone replacement therapy

DM8MC6O	ID	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	HS	Approved
DM8MC6O	SN	Delestrogen
DM8MC6O	CP	Par Sterile Products Llc
DM8MC6O	DT	Small molecular drug
DM8MC6O	PC	13791
DM8MC6O	MW	356.5
DM8MC6O	FM	C23H32O3
DM8MC6O	IC	InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1
DM8MC6O	CS	CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C
DM8MC6O	IK	RSEPBGGWRJCQGY-RBRWEJTLSA-N
DM8MC6O	IU	[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate
DM8MC6O	CA	CAS 979-32-8
DM8MC6O	CB	CHEBI:31561
DM8MC6O	DE	Hormone replacement therapy

DMLNMEA	ID	DMLNMEA
DMLNMEA	DN	Estradiol valerate/dienogest
DMLNMEA	HS	Approved
DMLNMEA	SN	Climodien; Climodiene; Dienogest/estradiol valerate; DNG/E2V; E2V/DNG; Klimodien; Lafamme
DMLNMEA	DT	Small molecular drug
DMLNMEA	PC	9874560
DMLNMEA	MW	667.9
DMLNMEA	FM	C43H57NO5
DMLNMEA	IC	InChI=1S/C23H32O3.C20H25NO2/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2;1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3;12,17-18,23H,2-10H2,1H3/t18-,19-,20+,21+,23+;17-,18+,19+,20-/m11/s1
DMLNMEA	CS	CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C.C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O
DMLNMEA	IK	LRHSUZNWLAJWRT-GAJBHWORSA-N
DMLNMEA	IU	[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate;2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile
DMLNMEA	CA	CAS 307334-58-3
DMLNMEA	DE	Discovery agent

DMWTAOI	ID	DMWTAOI
DMWTAOI	DN	Estramustine
DMWTAOI	HS	Approved
DMWTAOI	SN	Estramustina; Estramustinum; Emcyt (TN); Estramustine (USAN/INN); Estradiol 3-[bis(2-chloroethyl)carbamate]; Ro-22-2296/000; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]; [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate; (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate; 17.beta.-Estradiol 3-[bis(2-chloroethyl)carbamate]
DMWTAOI	CP	Pfizer Pharmaceuticals
DMWTAOI	TC	Anticancer Agents
DMWTAOI	DT	Small molecular drug
DMWTAOI	PC	259331
DMWTAOI	MW	440.4
DMWTAOI	FM	C23H31Cl2NO3
DMWTAOI	IC	InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1
DMWTAOI	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl
DMWTAOI	IK	FRPJXPJMRWBBIH-RBRWEJTLSA-N
DMWTAOI	IU	[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate
DMWTAOI	CA	CAS 2998-57-4
DMWTAOI	CB	CHEBI:4868
DMWTAOI	DE	Prostate cancer

DMOEM2I	ID	DMOEM2I
DMOEM2I	DN	Estriol
DMOEM2I	HS	Approved
DMOEM2I	SN	Aacifemine; Destriol; Estratriol; Estriel; Estriolo; Gynaesan; Hemostyptanon; Holin; Hormomed; Hormonin; Klimoral; Oestratriol; Oestriol; Oestriolum; Orestin; Orgastyptin; Overstin; Ovestin; Ovestrion; Stiptanon; Synapause; Theelol; Thulol; Tridestrin; Trihydroxyestrin; Trihydroxyoestrin; Triodurin; Triovex; Deuslon A; Estriolo [Italian]; Folicular hormone; Follicular hormone hydrate; Oestriol [Steroidal oestrogens]; A 13610; E0218; OE3; Deuslon-A; Estriel (TN); Estriol [USAN:JAN]; Estriol, unconjugated; Ortho-Gynest; Estriol (JP15/USP); Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; Estra-1,3,5(10)-triene-3,16,17-triol; Estra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol; Estra-1,3,5(10)-trien-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; (16.alpha.,17.beta.)-Estra-1,3,5(10)-triene-3,16,17-triol; (16.alpha.,17.beta.)-Oestra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol; 1,3,5(10)-ESTRATRIENE-3,16,17-TRIOL; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; 1,3,5(10)-Estratriene-3,16.alpha., 17.beta.-triol; 1,3,5(10)-Estratriene-3,16.alpha.,17.beta.-triol; 1,3,5(10)-Estratriene-3,16alpha,17beta-Triol; 1,3,5-Estratriene-3.beta.,16-.alpha.,17-.beta.-triol; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3-.beta.,16.alpha.,17.beta.-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; 16,17-Epiestriol; 16-Epiestriol; 16-Hydroxyestradiol; 16-alpha,17-beta-Estriol; 16-alpha,17-beta-Oestriol; 16-alpha-Hydroxyestradiol; 16-alpha-Hydroxyoestradiol; 16.alpha.,17.beta.-Estriol; 16.alpha.,17.beta.-Oestriol; 16.alpha.-Estriol; 16.alpha.-Hydroxy-17.beta.-estradiol; 16.alpha.-Hydroxyestradiol; 16.alpha.-Hydroxyoestradiol; 16alpha,17beta-Estriol; 16alpha,17beta-Oestriol; 16alpha-Hydroxy-17beta-estradiol; 16alpha-Hydroxyestradiol; 16alpha-Hydroxyoestradiol; 3,16-alpha,17-beta-Estriol; 3,16-alpha,17-beta-Oestriol; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-estratriene; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16-alpha,17-beta-Trihydroxyestra-1,3,5(10)-triene; 3,16-alpha,17-beta-Trihydroxyoestra-1,3,5(10)-triene; 3,16.alpha.,17.beta.-Estriol; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-estratriene; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-oestratriene; 3,16.alpha.,17.beta.-Trihydroxy-1,3,5(10)-estratriene; 3,16.alpha.,17.beta.-Trihydroxyestra-1,3,5(10)-triene; 3,16alpha,17beta-Estriol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 3,16alpha,17beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16alpha,17beta-trihydroxy-Delta(1,3,5)-estratriene
DMOEM2I	CP	Pipex Pharmaceuticals
DMOEM2I	TC	Estrogens
DMOEM2I	DT	Small molecular drug
DMOEM2I	PC	5756
DMOEM2I	MW	288.4
DMOEM2I	FM	C18H24O3
DMOEM2I	IC	InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1
DMOEM2I	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O
DMOEM2I	IK	PROQIPRRNZUXQM-ZXXIGWHRSA-N
DMOEM2I	IU	(8R,9S,13S,14S,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol
DMOEM2I	CA	CAS 50-27-1
DMOEM2I	CB	CHEBI:27974
DMOEM2I	DE	Hormone deficiency; Multiple sclerosis

DMGY0UT	ID	DMGY0UT
DMGY0UT	DN	Estrogen
DMGY0UT	HS	Approved
DMGY0UT	DE	Menopause symptom

DM5T6US	ID	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	HS	Approved
DM5T6US	SN	Aquacrine; Crinovaryl; Cristallovar; Crystogen; Destrone; Disynformon; Endofolliculina; Esterone; Estrin; Estrol; Estron; Estrona; Estronum; Estrovarin; Estrugenone; Estrusol; Femidyn; Fermidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculin; Folliculine; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormofollin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Ketophydroxyestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelestrin; Thelykinin; Thynestron; Tokokin; Unden; Unigen; Wehgen; Wynestron; Estrogenic Substance; Estrona [Spanish]; Femestrone injection; Follicular hormone; Folliculine benzoate; Hauck Brand of Estrone; Hyrex Brand of Estrone; Menformon A; Oestrone [Steroidal oestrogens]; Penncap M; Vortech Brand of Estrone; WynestronPencap M; CMC_13458; E 9750; E0026; E(sub 1); Estrona [INN-Spanish]; Estrone (E1); Estrone (TN); Estrone [USAN:INN]; Estrone-A; Estronum [INN-Latin]; Femestrone inj.; Ketohydroxy-Estratriene; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; Oestrone, Estrone; Ovex (tablets); Unden (pharmaceutical); Unden (pharmaceutical) (VAN); Estrone (JAN/USP/INN); Estrone, (8 alpha)-Isomer; Estrone, (9 beta)-Isomer; Estrone, (+-)-Isomer; [2,4,6,7-3H]-E1; Delta-1,3,5-Estratrien-3beta-ol-17-one; Delta-1,3,5-Oestratrien-3beta-ol-17-one; Delta-1,3,5-estratrien-3-beta-ol-17-one; Delta-1,3,5-oestratrien-3-beta-ol-17-one; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; 1,3,5(10)-Estratrien-3-ol-17-one; 1,3,5(10)-Oestratrien-3-ol-17-one; 3-Hydroxy-1,3,5(10)-estratrien-17-one; 3-Hydroxy-17-keto-estra-1,3,5-triene; 3-Hydroxy-17-keto-oestra-1,3,5-triene; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-triene-17-one; 3-hydroxy-estra-1,3,5(10)-trien-17-one
DM5T6US	TC	Antimenopausal Agents
DM5T6US	DT	Small molecular drug
DM5T6US	PC	5870
DM5T6US	MW	270.4
DM5T6US	FM	C18H22O2
DM5T6US	IC	InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1
DM5T6US	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O
DM5T6US	IK	DNXHEGUUPJUMQT-CBZIJGRNSA-N
DM5T6US	IU	(8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
DM5T6US	CA	CAS 53-16-7
DM5T6US	CB	CHEBI:17263
DM5T6US	DE	Menopausal and postmenopausal disorder

DMVBIZL	ID	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	HS	Approved
DMVBIZL	SN	Estrone 3-sulfate; Estrone hydrogen sulfate; Estrone sulphate; [3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate; [3H]estrone-3-sulphate
DMVBIZL	DT	Small molecular drug
DMVBIZL	PC	3001028
DMVBIZL	MW	350.429
DMVBIZL	FM	C18H22O5S
DMVBIZL	IC	InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1
DMVBIZL	CS	CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O
DMVBIZL	IK	JKKFKPJIXZFSSB-CBZIJGRNSA-N
DMVBIZL	IU	[(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMVBIZL	CA	CAS 481-97-0
DMVBIZL	CB	CHEBI:17474
DMVBIZL	DE	Menopausal symptoms

DMRMDWA	ID	DMRMDWA
DMRMDWA	DN	Estropipate
DMRMDWA	HS	Approved
DMRMDWA	SN	Estropipate; 7280-37-7; Piperazine estrone sulfate; Harmogen; Ogen; Ortho-Est; UNII-SVI38UY019; Piperazine estronesulfate; Sulestrex; SVI38UY019; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1); OGEN 2.5; Estropipate (USP); OGEN 5; Ogen (TN); OGEN .625; OGEN 1.25; EINECS 230-696-3; piperazine (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl sulfate; Piperazine oestrone sulphate; Conjugated estrogens: piperazine estrone sulfate; Estrone hydrogen sulf
DMRMDWA	DT	Small molecular drug
DMRMDWA	PC	5284555
DMRMDWA	MW	436.6
DMRMDWA	FM	C22H32N2O5S
DMRMDWA	IC	InChI=1S/C18H22O5S.C4H10N2/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;1-2-6-4-3-5-1/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);5-6H,1-4H2/t14-,15-,16+,18+;/m1./s1
DMRMDWA	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1
DMRMDWA	IK	HZEQBCVBILBTEP-ZFINNJDLSA-N
DMRMDWA	IU	[(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;piperazine
DMRMDWA	CA	CAS 7280-37-7
DMRMDWA	CB	CHEBI:4873
DMRMDWA	DE	Hypogonadism

DM8RZ9H	ID	DM8RZ9H
DM8RZ9H	DN	Eszopiclone
DM8RZ9H	HS	Approved
DM8RZ9H	SN	Esopiclone; Estorra; Lunesta; Lunivia; Estorra (TN); Eszopiclone [USAN:INN]; KS-1055; SEP-0227018; SEP-0227108; SEP-190; SEP-225441; Eszopiclone (JAN/USAN/INN); [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (S)-Zopiclone; (plus)-Zopiclone; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester
DM8RZ9H	CP	GSK
DM8RZ9H	TC	Hypnotics and Sedatives
DM8RZ9H	DT	Small molecular drug
DM8RZ9H	PC	969472
DM8RZ9H	MW	388.8
DM8RZ9H	FM	C17H17ClN6O3
DM8RZ9H	IC	InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1
DM8RZ9H	CS	CN1CCN(CC1)C(=O)O[C@H]2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
DM8RZ9H	IK	GBBSUAFBMRNDJC-INIZCTEOSA-N
DM8RZ9H	IU	[(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
DM8RZ9H	CA	CAS 138729-47-2
DM8RZ9H	CB	CHEBI:53760
DM8RZ9H	DE	Insomnia

DMCV109	ID	DMCV109
DMCV109	DN	Etanercept
DMCV109	HS	Approved
DMCV109	SN	Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon
DMCV109	CP	AstraZeneca
DMCV109	DT	Monoclonal antibody
DMCV109	SQ	Etanercept Sequence: LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMCV109	DE	Arthritis; Pemphigus vulgaris; Sciatica

DMHP9BL	ID	DMHP9BL
DMHP9BL	DN	Etelcalcetide
DMHP9BL	HS	Approved
DMHP9BL	SN	Velcalcetide; Parsabiv; UNII-60ME133FJB; 1262780-97-1; 60ME133FJB; etelcalcetide HCl; Etelcalcetide [USAN:INN]; Etelcalcetide (USAN/INN); Etelcalcetide Hydrochloride(AMG-416)
DMHP9BL	CP	Amgen/Kai Pharmaceuticals
DMHP9BL	DT	Small molecular drug
DMHP9BL	PC	71511839
DMHP9BL	MW	1048.3
DMHP9BL	FM	C38H73N21O10S2
DMHP9BL	IC	InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1
DMHP9BL	CS	C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C
DMHP9BL	IK	ANIAZGVDEUQPRI-ZJQCGQFWSA-N
DMHP9BL	IU	(2R)-3-[[(2S)-2-acetamido-3-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]-2-aminopropanoic acid
DMHP9BL	CA	CAS 1262780-97-1
DMHP9BL	CB	CHEBI:134700
DMHP9BL	DE	Secondary hyperparathyroidism; Myelodysplastic syndrome

DM2QBHP	ID	DM2QBHP
DM2QBHP	DN	Eteplirsen
DM2QBHP	HS	Approved
DM2QBHP	SN	AVI-4658
DM2QBHP	CP	Sarepta Therapeutics
DM2QBHP	DE	Duchenne dystrophy

DM5M4NT	ID	DM5M4NT
DM5M4NT	DN	Ethacrynate sodium
DM5M4NT	HS	Approved
DM5M4NT	CP	Aton Pharma Inc
DM5M4NT	TC	Cardiovascular Agents
DM5M4NT	DT	Small molecular drug
DM5M4NT	PC	23668825
DM5M4NT	MW	325.12
DM5M4NT	FM	C13H11Cl2NaO4
DM5M4NT	IC	InChI=1S/C13H12Cl2O4.Na/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17;/h4-5H,2-3,6H2,1H3,(H,16,17);/q;+1/p-1
DM5M4NT	CS	CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])Cl)Cl.[Na+]
DM5M4NT	IK	CWCSCNSKBSCYCS-UHFFFAOYSA-M
DM5M4NT	IU	sodium;2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetate
DM5M4NT	CA	CAS 6500-81-8
DM5M4NT	DE	High blood pressure

DM60QMR	ID	DM60QMR
DM60QMR	DN	Ethacrynic acid
DM60QMR	HS	Approved
DM60QMR	SN	Crinuryl; Edecril; Edecrina; Endecril; Ethacrynate; Hidromedin; Hydromedin; Mingit; Otacril; Reomax; Taladren; Uregit; Acide etacrynique; Acido etacrinico; Acidum etacrynicum; Etacrinic acid; Etacrynic Acid; Etakrinic acid; Ethacrinic acid; Ethacryinic Acid; Kyselina ethakrynova; Kyselina ethakrynova [Czech]; Methylenebutyryl phenoxyacetic acid; Methylenebutyrylphenoxyacetic acid; E0526; MK 595; Acide etacrynique [INN-French]; Acido etacrinico [INN-Spanish]; Acidum etacrynicum [INN-Latin]; Edecrin (TN); Ethacrinique (acide); Ethacrynic Acid, Sodium Salt; Ethacrynic acid (USP); Ethacrynic acid [USAN:BAN]; MK-595; Etacrynic acid (JP15/INN); [2,3-Dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; [4-(2-Methylenebutyryl)-2,3-dichlorophenoxy]acetic acid; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [Czech]; [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid; (2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid; (4-(2-Methylenebutyryl)-2,3-dichlorophenoxy)acetic acid; 2,3-Dichloro-4(2-methylene-butyryl)phenoxy] acetic acid; 2,3-Dichloro-4-(2-methylenebutyl)phenoxyacetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxy acetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxyacetic acid; 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
DM60QMR	TC	Diuretics
DM60QMR	DT	Small molecular drug
DM60QMR	PC	3278
DM60QMR	MW	303.13
DM60QMR	FM	C13H12Cl2O4
DM60QMR	IC	InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
DM60QMR	CS	CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl
DM60QMR	IK	AVOLMBLBETYQHX-UHFFFAOYSA-N
DM60QMR	IU	2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
DM60QMR	CA	CAS 58-54-8
DM60QMR	CB	CHEBI:4876
DM60QMR	DE	High blood pressure

DMR87LC	ID	DMR87LC
DMR87LC	DN	Ethambutol
DMR87LC	HS	Approved
DMR87LC	SN	Aethambutolum; Diambutol; EMB; Etambutol; Etambutolo; Ethambutolum; Etibi; Miambutol; Myambutol; Purderal; Servambutol; Tibutol; Etambutolo [DCIT]; CL 40881 (dihydrochloride); D-Ethambutol; Etambutol [INN-Spanish]; Ethambutol & EEP; Ethambutol & Propolis; Ethambutol (INN); Ethambutol [INN:BAN]; Ethambutol, meso form; Ethambutol, racemic mixture; Ethambutolum [INN-Latin]; Myambutol (TN); Myambutol (dihydrochloride); Servambutol (TN); Ethambutol, (-)-isomer; D,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-2,2'-(Ethylenediimino)bis(1-butanol); D-2,2'-(Ethylenediimino)di-1-butanol; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (+)-2,2'-(Ethylenediimino)di-1-butanol; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; (+)-S,S-Ethambutol; (+)-ethambutol; (-)-(R,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (2'S)-2,2'-[Ethane-1,2-diyldi(imino)]dibutan-1-ol; (2R)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2R)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2S)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; (S,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (S,S)-ethambutol; 2,2'-(1,2-Ethylenediimino)-di-1-butanol; 2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; 2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol
DMR87LC	CP	Macleods Pharmaceutical. Ltd
DMR87LC	TC	Antitubercular Agents
DMR87LC	DT	Small molecular drug
DMR87LC	PC	14052
DMR87LC	MW	204.31
DMR87LC	FM	C10H24N2O2
DMR87LC	IC	InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1
DMR87LC	CS	CC[C@@H](CO)NCCN[C@@H](CC)CO
DMR87LC	IK	AEUTYOVWOVBAKS-UWVGGRQHSA-N
DMR87LC	IU	(2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol
DMR87LC	CA	CAS 74-55-5
DMR87LC	CB	CHEBI:4877
DMR87LC	DE	Pulmonary tuberculosis

DMDRQZU	ID	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	HS	Approved
DMDRQZU	SN	Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA
DMDRQZU	TC	Analgesics
DMDRQZU	DT	Small molecular drug
DMDRQZU	PC	702
DMDRQZU	MW	46.07
DMDRQZU	FM	C2H6O
DMDRQZU	IC	InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3
DMDRQZU	CS	CCO
DMDRQZU	IK	LFQSCWFLJHTTHZ-UHFFFAOYSA-N
DMDRQZU	IU	ethanol
DMDRQZU	CA	CAS 64-17-5
DMDRQZU	CB	CHEBI:16236
DMDRQZU	DE	Cystitis; Chronic pain

DM3B654	ID	DM3B654
DM3B654	DN	Ethanolamine oleate
DM3B654	HS	Approved
DM3B654	SN	Ethamolin (TN)
DM3B654	DT	Small molecular drug
DM3B654	PC	5282489
DM3B654	MW	343.5
DM3B654	FM	C20H41NO3
DM3B654	IC	InChI=1S/C18H34O2.C2H7NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;3-1-2-4/h9-10H,2-8,11-17H2,1H3,(H,19,20);4H,1-3H2/b10-9-;
DM3B654	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)O.C(CO)N
DM3B654	IK	KGWDUNBJIMUFAP-KVVVOXFISA-N
DM3B654	IU	2-aminoethanol;(Z)-octadec-9-enoic acid
DM3B654	CA	CAS 2272-11-9
DM3B654	DE	Bleeding disorder

DM53IP1	ID	DM53IP1
DM53IP1	DN	Ethchlorvynol
DM53IP1	HS	Approved
DM53IP1	SN	Alvinol; Arvynol; Etchlorvinolo; Etclorvinol; Ethchlorovynol; Ethchlorvinol; Ethchlorvinyl; Ethchlorvynolum;Ethclorvynol; Ethochlorvynol; Ethychlorvynol; Normonson; Normosan; Normoson; Nostel; Nromoson; Placidil; Placidyl; Roeridorm; Serenesil; Serenil; Serensil; Serensiloline; A 71; Aethyl-chlorvynol; Beta-Chlorovinyl ethyl ethynyl carbinol; Beta-Chlorvinyl ethyl ethynyl carbinol; Etclorvinol [INN-Spanish]; Ethchlorvynolum [INN-Latin]; Ethyl beta-chlorovinyl ethynyl carbinol; Placidyl (TN); Ethchlorvynol [USAN:INN:BAN]; Ethchlorvynol (JAN/USP/INN); (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol; 1-Chloro-3-ethyl-1-penten-4-yn-3-ol; 1-Chloro-3-ethylpent-1-4-yn-3-ol; 1-chloro-3-ethylpent-1-en-4-yn-3-ol; 3-(beta-Chlorovinyl)-1-pentyn-3-ol; 5-Chloro-3-ethylpent-1-yn-4-en-3-ol
DM53IP1	CP	Abbott Laboratories
DM53IP1	TC	Hypnotics and Sedatives
DM53IP1	DT	Small molecular drug
DM53IP1	PC	5281077
DM53IP1	MW	144.6
DM53IP1	FM	C7H9ClO
DM53IP1	IC	InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+
DM53IP1	CS	CCC(/C=C/Cl)(C#C)O
DM53IP1	IK	ZEHYJZXQEQOSON-AATRIKPKSA-N
DM53IP1	IU	(E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol
DM53IP1	CA	CAS 113-18-8
DM53IP1	CB	CHEBI:4882
DM53IP1	DE	Insomnia

DMK57GB	ID	DMK57GB
DMK57GB	DN	Ethinamate
DMK57GB	HS	Approved
DMK57GB	SN	Ethinamat; Ethinamatum; Ethinimate; Etinamate; Etinamato; Valamid; Valamin; Valaminetta; Valaminettae; Valaminetten; Valmid; Valmidate; Volamin; Ethynylcyclohexyl carbamate; Carbamate de L'ethinylcyclohexanol; Carbamate de l'ethinylcyclohexanol [French]; Ethinamatum [INN-Latin]; Etinamato [INN-Spanish]; USAF EL-42; Valamin (TN); Valmid (TN); Aethinyl-cyclohexyl-carbamat; Aethinyl-cyclohexyl-carbamat [German]; Carbamic acid, 1-ethynylcyclohexyl ester; Ethinamate (JAN/INN); Ethinamate [INN:BAN:JAN]; Cyclohexanol, 1-ethynyl-, carbamate; Cyclohexanol, 1-ethynyl-, 1-carbamate; (1-ethynylcyclohexyl) carbamate; 1-Ethinylcyclohexyl carbamate; 1-Ethinylcyclohexyl carbonate; 1-Ethynylcyclohexanol carbamate; 1-Ethynylcyclohexyl carbamate; 1-ethynylcyclohexylcarbamate
DMK57GB	TC	Hypnotics and Sedatives
DMK57GB	DT	Small molecular drug
DMK57GB	PC	3284
DMK57GB	MW	167.2
DMK57GB	FM	C9H13NO2
DMK57GB	IC	InChI=1S/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11)
DMK57GB	CS	C#CC1(CCCCC1)OC(=O)N
DMK57GB	IK	GXRZIMHKGDIBEW-UHFFFAOYSA-N
DMK57GB	IU	(1-ethynylcyclohexyl) carbamate
DMK57GB	CA	CAS 126-52-3
DMK57GB	CB	CHEBI:4884
DMK57GB	DE	Insomnia

DMODJ40	ID	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	HS	Approved
DMODJ40	SN	Aethinyloestradiolum; Aethinyoestradiol; Amenoron; Amenorone; Anovlar; Certostat; Cyclosa; Dicromil; Diprol; Dyloform; Ertonyl; Esteed; Estigyn; Estinyl; Estopherol; Estoral; Estorals; Ethidol; Ethinoral; Ethinylestradiolum; Ethinylestriol; Ethinyloestradiol; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol; Etinilestradiolo; Etinoestryl; Etistradiol; Etivex; Feminone; Follicoral; Ginestrene; Inestra; Kolpolyn; Linoral; Lynoral; Menolyn; Microfollin; Novestrol; Oradiol; Orestralyn; Orestrayln; Palonyl; Perovex; Primogyn; Prosexol; Spanestrin; Ylestrol; Aethinyoestradiol [German]; Component of Demulen; Component of Oracon; Component of Ortrel; Diogyn E; Effik Brand of Ethinyl Estradiol; Estoral [Orion]; Ethinyl Estradiol Hemihydrate; Ethinyl Estradiol [USP]; Ethinyl Oestradiol Effik; Ethinylestradiol Jenapharm; Ethinyloestradiol [Steroidal oestrogens]; Ethynyl estradiol; Etinilestradiolo [DCIT]; Jenapharm Brand of Ethinyl Estradiol; Microfollin Forte; Organon Brand of Ethinyl Estradiol; PUBERTAL ETHINYL ESTRADIOL STUDY; Primogyn C; Primogyn M; Progynon C; Progynon M; Schering Brand of Ethinyl Estradiol; EE2; Ethinyl E2; Ethy 11; Diognat-E; Diogyn-E; EE(sub 2); Estinyl (TN); Eston-E; Estoral (Orion); Estoral (VAN); Estradiol, Ethinyl; Estradiol, Ethynyl; Ethinyl estradiol (USP); Ethinyl-Oestradiol Effik; Ethinyl-oestranol; Ethinylestradiolum [INN-Latin]; Ethynylestradiol, Ethinyl Estradiol; Etinilestradiol [INN-Spanish]; Hemihydrate, Ethinyl Estradiol; Jenapharm, Ethinylestradiol; Neo-Estrone; Nogest-S; OVULEN-21; OVULEN-28; Ortho-Cyclen; Chee-O-Gen; Chee-O-Genf; Ethinylestradiol (JP15/INN); Ethinylestradiol [INN:BAN:JAN]; Ethinyl Estradiol, (8 alpha)-Isomer; 17 alpha-Ethinylestradiol; 17 alpha-Ethynylestradiol; 17 alpha-Ethynyloestradiol; 17 alpha-ethinyestradiol; 17-Ethinyl-3,17-estradiol; 17-Ethinyl-3,17-oestradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17-Ethynyloestradiol; 17-alpha-Ethinyl-17-beta-estradiol; 17-alpha-Ethynyl-17-beta-oestradiol; 17-alpha-Ethynylestradiol; 17-alpha-Ethynylestradiol-17-beta; 17-alpha-Ethynylestradiol-l7-beta; 17-alpha-Ethynyloestradiol-17-beta; 17-alpha-ethynyl estradiol; 17.alpha.-Ethinyl-17.beta.-estradiol; 17.alpha.-Ethinylestradiol; 17.alpha.-Ethynyl-17.beta.-oestradiol; 17.alpha.-Ethynylestradiol; 17.alpha.-Ethynyloestradiol; 17a-Ethynylestradiol; 17alpha-Ethinyl estradiol; 17alpha-Ethinylestradiol; 17alpha-Ethinylestradiol-17beta; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; 17alpha-Ethynyloestradiol-17beta
DMODJ40	CP	Schering-Plough
DMODJ40	TC	Estrogens
DMODJ40	DT	Small molecular drug
DMODJ40	PC	5991
DMODJ40	MW	296.4
DMODJ40	FM	C20H24O2
DMODJ40	IC	InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
DMODJ40	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O
DMODJ40	IK	BFPYWIDHMRZLRN-SLHNCBLASA-N
DMODJ40	IU	(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMODJ40	CA	CAS 57-63-6
DMODJ40	CB	CHEBI:4903
DMODJ40	DE	Female hypogonadism

DM8K3EI	ID	DM8K3EI
DM8K3EI	DN	Ethionamide
DM8K3EI	HS	Approved
DM8K3EI	SN	Aethionamidum; Aetina; Aetiva; Amidazin; Amidazine; Atina; Ethatyl; Ethimide; Ethina; Ethinamide; Ethionamidum; Ethioniamide; Ethylisothiamide; Ethyonomide; Etimid; Etiocidan; Etionamid; Etionamida; Etionamide; Etioniamid; Etionid; Etionizin; Etionizina; Etionizine; Fatoliamid; Iridocin; Iridozin; Isothin; Isotiamida; Itiocide; Nicotion; Nisotin; Nizotin; Rigenicid; Sertinon; Teberus; Thianid; Thianide; Thioamide; Thiomid; Thioniden; Tianid; Tiomid; Trecator; Trekator; Trescatyl; Trescazide; Tubenamide; Tubermin; Tuberoid; Tuberoson; Ethionamid prothionamid; Etionamide [DCIT]; Iridocin Bayer; Trecator SC; Wyeth Brand of Ethionamide; Bayer 5312; Bayer5312; E0695; TH 1314; Alpha-Ethylisonicotinic acid thioamide; Alpha-Ethylisonicotinoylthioamide; Alpha-Ethylisothionicotinamide; Alpha-Ethylthioisonicotinamide; Alpha-ethylt hioisonicotinamide; Ethina (VAN); Ethionamidum [INN-Latin]; Etionamida [INN-Spanish]; Tio-Mid; Trecator-SC; Alpha-Ethyl-thioisonicotinamide; Trecator-SC (TN); Ethionamide (JP15/USP/INN); Ethionamide [USAN:INN:BAN:JAN]; 2-ETHYL-4-PYRIDINECARBOTHIOAMIDE; 2-Ethyl-4-thioamidylpyridine; 2-Ethyl-4-thiocarbamoylpyridine; 2-Ethyl-thioisonicotinamide; 2-Ethylisonicotinic acid thioamide; 2-Ethylisonicotinic thioamide; 2-Ethylisonicotinothioamide; 2-Ethylisonicotinoylthioamide; 2-Ethylisothionicotinamide; 2-Ethylthioisonicotinamide; 2-e thylisothionicotinamide; 2-ethyl-4-aminothiocarbonylpyridine; 2-ethylisonicotinic acid thiomide; 2-ethylpyridine-4-carbothioamide; 2-ethylthioisonicotinamide, Trecator SC, Amidazine, Ethionamide; 3-Ethylisothionicotinamide
DM8K3EI	TC	Antituberculosis Agents
DM8K3EI	DT	Small molecular drug
DM8K3EI	PC	2761171
DM8K3EI	MW	166.25
DM8K3EI	FM	C8H10N2S
DM8K3EI	IC	InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)
DM8K3EI	CS	CCC1=NC=CC(=C1)C(=S)N
DM8K3EI	IK	AEOCXXJPGCBFJA-UHFFFAOYSA-N
DM8K3EI	IU	2-ethylpyridine-4-carbothioamide
DM8K3EI	CA	CAS 536-33-4
DM8K3EI	CB	CHEBI:4885
DM8K3EI	DE	Tuberculosis

DM0N3L7	ID	DM0N3L7
DM0N3L7	DN	Ethopropazine
DM0N3L7	HS	Approved
DM0N3L7	SN	Aethopropropazin; Athapropazine; Athopropazin; Ethapropazine; Ethopromazine; Etopropezina; Fempropazine; Fenpropazina; Isopthazine; Isotazin; Isothazine; Isothiazine; Lysivane; Parcidol; Pardidol; Parfezine; Parkin; Parkisol; Parsidan; Parsidol; Parsitan; Parsotil; Phenopropazine; Phenoprozine; Prodictazin; Prodierazine; Profenamina; Profenamine; Profenaminum; Prophenamine; Prophenaminum; Rochipel; Rocipel; Rodipal; Profenamina [Italian]; RP 3356; SC 2538; SKF 2538; W 483; Parkin (TN); Parsidan (TN); Parsidol(TN); Profenamina [INN-Spanish]; Profenamine (INN); Profenamine [INN:BAN]; Profenaminum [INN-Latin]; N,N-Diethyl-alpha-methyl-10H-phenothiazine-10-ethanamine; N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine; N,N-Diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine; N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine; 10-(2-Diethylaminopropyl)phenothiazine; 10-[2-(Diethylamino)-1-Propyl]phenothiazine;10-[2-(Diethylamino)-2-methylethyl]phenothiazine; 10-[2-(Diethylamino)propyl]phenothiazine; 2-Diethylamino-1-propyl-N-dibenzoparathiazine
DM0N3L7	TC	Antiparkinson Agents
DM0N3L7	DT	Small molecular drug
DM0N3L7	PC	3290
DM0N3L7	MW	312.5
DM0N3L7	FM	C19H24N2S
DM0N3L7	IC	InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3
DM0N3L7	CS	CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31
DM0N3L7	IK	CDOZDBSBBXSXLB-UHFFFAOYSA-N
DM0N3L7	IU	N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine
DM0N3L7	CA	CAS 522-00-9
DM0N3L7	CB	CHEBI:313639
DM0N3L7	DE	Parkinson disease

DMDZ9LT	ID	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	HS	Approved
DMDZ9LT	SN	Aethosuccimidum; Aethosuximide; Asamid; Atysmal; Capitus; Emeside; Ethosuccimid; Ethosuccimide; Ethosuccinimide; Ethosuxide; Ethosuximidum; Ethylmethylsuccimide; Ethymal; Etomal; Etosuccimide; Etosuximid; Etosuximida; Etosuximide; Mesentol; Pemal; Pemalin; Pentinimid; Peptinimid; Petinimid; Petnidan; Piknolepsin; Pyknolepsinum; Ronton; Simatin; Succimal; Succimitin; Suksilep; Suxilep; Suximal; Suxin; Suxinutin; Thetamid; Thilopemal; Zaraondan; Zarodan; Zarondan; Zarontin; Zartalin; Aethosuximide [German]; Desitin Brand of Ethosuximide; Epileo Petit MAL; Etosuccimide [DCIT]; Etosuximida Faes; Faes Brand of Ethosuximide; Fortbenton Brand of Ethosuximide; Jenapharm Brand of Ethosuximide; Katwijk Brand of Ethosuximide; LAB Brand of Ethosuximide; Parke Davis Brand of Ethosuximide; Pfizer Brand of Ethosuximide; United Drug Brand of Ethosuximide; Warner Lambert Brand of Ethosuximide; Wernigerode Brand of Ethosuximide; Cl 366; E 7138; E0746; H 940; PM 671; CN-10395; Ethosuximidum [INN-Latin]; Etosuximida [INN-Spanish]; Faes, Etosuximida; H-490; N-Ethyl methylsuccinimide; PM-671; Simatin(E); Warner-Lambert Brand of Ethosuximide; Zarondan-Saft; Zarontin (TN); C.I. 366; CN-10,395; Piknole.psi.n; Pyknole.psi.num; Alpha-Ethyl-alpha-methylsuccinimide; Alpha-Methyl-alpha-ethylsuccinimide; Ethosuximide (JP15/USP/INN); Ethosuximide [USAN:INN:BAN:JAN]; Gamma-Methyl-gamma-ethylsuccinimide; Gamma-Methyl-gamma-ethyl-succinimide; Gamma-ethyl-gamma-methyl-succinimide; (+-)-2-Ethyl-2-methylsuccinimide; 2-Ethyl-2-methylsuccinimide; 2-Methyl-2-ethylsuccinimide; 3-Ethyl-3-methyl-2, 5-pyrrolidinedion; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; 3-Ethyl-3-methylpyrrolidine-2,5-dione; 3-Ethyl-3-methylpyrroline-2,5-dione; 3-Ethyl-3-methylsuccinimide; 3-Methyl-3-ethylpyrrolidine-2,5-dione; 3-Methyl-3-ethylsuccinimide
DMDZ9LT	CP	Pfizer
DMDZ9LT	TC	Analgesics
DMDZ9LT	DT	Small molecular drug
DMDZ9LT	PC	3291
DMDZ9LT	MW	141.17
DMDZ9LT	FM	C7H11NO2
DMDZ9LT	IC	InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
DMDZ9LT	CS	CCC1(CC(=O)NC1=O)C
DMDZ9LT	IK	HAPOVYFOVVWLRS-UHFFFAOYSA-N
DMDZ9LT	IU	3-ethyl-3-methylpyrrolidine-2,5-dione
DMDZ9LT	CA	CAS 77-67-8
DMDZ9LT	CB	CHEBI:4887
DMDZ9LT	DE	Epilepsy

DMXWOCP	ID	DMXWOCP
DMXWOCP	DN	Ethotoin
DMXWOCP	HS	Approved
DMXWOCP	SN	Accenon; Ethotoine; Ethotoinum; Etotoina; Peganone; Pegoanone; Abbott brand of ethotoin; Accenon (TN); Ethotoine [INN-French]; Ethotoinum [INN-Latin]; Etotoina [INN-Spanish]; Peganone (TN); Ethotoin [INN:BAN:JAN]; Ethotoin (JAN/USP/INN); (+-)-3-Ethyl-5-phenylhydantoin; 1-Ethyl-2,5-dioxo-4-phenylimidazolidine; 3-Ethyl-5-phenyl-2,4-imidazolidinedione; 3-Ethyl-5-phenylhydantoin; 3-Ethyl-5-phenylimidazolidin-2,4-dione; 3-ethyl-5-phenylimidazolidine-2,4-dione
DMXWOCP	CP	Ovation Pharmaceuticals 
DMXWOCP	TC	Anticonvulsants
DMXWOCP	DT	Small molecular drug
DMXWOCP	PC	3292
DMXWOCP	MW	204.22
DMXWOCP	FM	C11H12N2O2
DMXWOCP	IC	InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
DMXWOCP	CS	CCN1C(=O)C(NC1=O)C2=CC=CC=C2
DMXWOCP	IK	SZQIFWWUIBRPBZ-UHFFFAOYSA-N
DMXWOCP	IU	3-ethyl-5-phenylimidazolidine-2,4-dione
DMXWOCP	CA	CAS 86-35-1
DMXWOCP	CB	CHEBI:4888
DMXWOCP	DE	Complex partial seizure

DMVO4ED	ID	DMVO4ED
DMVO4ED	DN	Ethoxzolamide
DMVO4ED	HS	Approved
DMVO4ED	SN	ethoxzolamide; Ethoxyzolamide; Ethoxazolamide; Ethamide; Etoxzolamide; Cardrase; 6-Ethoxy-2-benzothiazolesulfonamide; 452-35-7; Glaucotensil; Diuretic C; 6-Ethoxy-1,3-benzothiazole-2-sulfonamide; Mingoral; 2-Benzothiazolesulfonamide, 6-ethoxy-; Redupresin; 6-Ethoxybenzo[d]thiazole-2-sulfonamide; 6-Ethoxyzolamide; 6-Ethoxybenzothiazole-2-sulfonamide; 6-Ethoxybenzothiazole-2-sulphonamide; U-4191; NSC 10679; UNII-Z52H4811WX; C9H10N2O3S2; HSDB 3268; CHEMBL18; EINECS 207-199-5; BRN 0212240; MLS000028637; AI3-50805;  Cardrase; EZL; Cardrase (TN); Ethoxzolamide (EZA); 6-(ethyloxy)-1,3-benzothiazole-2-sulfonamide; 6-Ethoxy-benzothiazole-2-sulfonic acid amide; 6-ethoxy-1,3-benzothiazole-2-sulfonamide
DMVO4ED	TC	Diuretics
DMVO4ED	DT	Small molecular drug
DMVO4ED	PC	3295
DMVO4ED	MW	258.3
DMVO4ED	FM	C9H10N2O3S2
DMVO4ED	IC	InChI=1S/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13)
DMVO4ED	CS	CCOC1=CC2=C(C=C1)N=C(S2)S(=O)(=O)N
DMVO4ED	IK	OUZWUKMCLIBBOG-UHFFFAOYSA-N
DMVO4ED	IU	6-ethoxy-1,3-benzothiazole-2-sulfonamide
DMVO4ED	CA	CAS 452-35-7
DMVO4ED	CB	CHEBI:101096
DMVO4ED	DE	Glaucoma/ocular hypertension; Duodenal ulcer

DM20VMW	ID	DM20VMW
DM20VMW	DN	Ethylestrenol
DM20VMW	HS	Approved
DM20VMW	SN	Maxibolin
DM20VMW	CP	Organon Usa Inc
DM20VMW	DT	Small molecular drug
DM20VMW	PC	13765
DM20VMW	MW	288.5
DM20VMW	FM	C20H32O
DM20VMW	IC	InChI=1S/C20H32O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h6,15-18,21H,3-5,7-13H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1
DM20VMW	CS	CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O
DM20VMW	IK	AOXRBFRFYPMWLR-XGXHKTLJSA-N
DM20VMW	IU	(8R,9S,10R,13S,14S,17S)-17-ethyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
DM20VMW	CA	CAS 965-90-2
DM20VMW	CB	CHEBI:31578
DM20VMW	DE	Testosterone deficiency

DMZM84R	ID	DMZM84R
DMZM84R	DN	Ethynodiol diacetate
DMZM84R	HS	Approved
DMZM84R	SN	Cervicundin; Continuin; Femulen; Luteonorm; Metrodiol; Ethinodiol diacetate; Ethyndiol Diacetate; Ethynodiol diacetate [Progestins]; Ethynodiol diacetate [USAN]; Etynodiol Acetate; Metrodiol diacetate; Ovulen 50; SC 11800; Etynodiol di(acetate); Luto-metrodiol; SC-11800; Ethynodiol diacetate (JAN/USP);[(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; (3 beta, 17 alpha)-19-Norpregn-4-en-20-yne-3,17 diolDiacetate; (3-beta,17-alpha)-19-Norpregn-4-en-20-yne-3,17-diol diacetate; (3beta,17beta)-17-ethynylestr-4-ene-3,17-diyl diacetate; 17-alpha-Ethynyl-19-norandrost-4-ene-3-beta,17-beta-diol diacetate; 17-alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; 17-alpha-Ethynyl-4-estrene-3-beta,17-beta-diol diacetate; 17-alpha-Ethynylestr-4-ene-3-beta,17-beta-diol acetate; 17alpha-Ethynyl-19-norandrost-4-ene-3beta,17-beta-diol diacetate; 17alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; 17alpha-Ethynyl-4-estrene-3beta,17beta-diol diacetate; 17alpha-Ethynylestr-4-ene-3beta,17beta-diol acetate; 17alpha-ethynylestr-4-ene-3beta,17beta-diyl diacetate; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol diacetate; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol, diacetate; 19-Nor-17alpha-pregn-4-en-20-yne-3beta,17-diol diacetate; 3-beta, 17-beta-Diacetoxy-17-alpha-ethynyl-4-oestrene; 3-beta,17-beta-Diacetoxy-19-nor-17-alpha-pregn-4-en-20-yne; 3beta, 17beta-Diacetoxy-17alpha-ethynyl-4-oestrene; 3beta,17beta-Diacetoxy-17alpha-ethynyl-4-estrene; 3beta,17beta-Diacetoxy-19-nor-17alpha-pregn-4-en-20-yne
DMZM84R	TC	Contraceptive Agents
DMZM84R	DT	Small molecular drug
DMZM84R	PC	9270
DMZM84R	MW	384.5
DMZM84R	FM	C24H32O4
DMZM84R	IC	InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1
DMZM84R	CS	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C
DMZM84R	IK	ONKUMRGIYFNPJW-KIEAKMPYSA-N
DMZM84R	IU	[(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMZM84R	CA	CAS 297-76-7
DMZM84R	CB	CHEBI:31580
DMZM84R	DE	Contraception

DMBIYNH	ID	DMBIYNH
DMBIYNH	DN	ETI-204
DMBIYNH	HS	Approved
DMBIYNH	CP	Elusys Therapeutics
DMBIYNH	DT	Antibody
DMBIYNH	DE	Anthrax

DMAWJIN	ID	DMAWJIN
DMAWJIN	DN	Etidronate Disodium
DMAWJIN	HS	Approved
DMAWJIN	SN	Didronel
DMAWJIN	CP	Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
DMAWJIN	DT	Small molecular drug
DMAWJIN	PC	23894
DMAWJIN	MW	249.99
DMAWJIN	FM	C2H6Na2O7P2
DMAWJIN	IC	InChI=1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2
DMAWJIN	CS	CC(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+]
DMAWJIN	IK	GWBBVOVXJZATQQ-UHFFFAOYSA-L
DMAWJIN	IU	disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]ethyl]phosphinate
DMAWJIN	CA	CAS 7414-83-7
DMAWJIN	CB	CHEBI:4906
DMAWJIN	DE	Osteoporosis

DM1XHYJ	ID	DM1XHYJ
DM1XHYJ	DN	Etidronic acid
DM1XHYJ	HS	Approved
DM1XHYJ	SN	EHDP; Etidronate; Etidronsaeure; HEDP; Osteoscan; Acetodiphosphonic acid; Acide etidronique; Acido etidronico; Acidumetidronicum; Didronel IV; Etidronic acid monohydrate; Hydroxyethanediphosphonic acid; Oxyethylidenediphosphonic acid; Turpinal SL; Dequest2010; Dequest 2015; Dequest Z 010; Ferrofos 510; RP 61; Acide etidronique [INN-French]; Acido etidronico [INN-Spanish]; Acidum etidronicum [INN-Latin]; Diphosphonate (base); Etidronic acid (USAN/INN); Etidronic acid [USAN:INN:BAN]; Hydroxyethane-1,1-diphosphonic acid; Ethane-1-hydroxy-1,1-bisphosphonate; Ethane-1-hydroxy-1,1-bisphosphonic acid; Ethane-1-hydroxy-1,1-diphosphonate; Ethane-1-hydroxy-1,1-diphosphonic acid; Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester; (1-Hydroxyethylene)diphosphonic acid; (1-Hydroxyethylidene)bis(phosphonic acid); (1-Hydroxyethylidene)bisphosphonic acid; (1-Hydroxyethylidene)diphoshonic acid; (1-Hydroxyethylidene)diphosphonic acid; (1-hydroxy-1-phosphonoethyl)phosphonic acid; (1-hydroxyethane-1,1-diyl)bis(phosphonic acid); (Hydroxyethylidene)diphosphonic acid; 1,1,1-Ethanetriol diphosphonate; 1-HYDROXY-1,1-DIPHOSPHONOETHANE; 1-Hydroxyethane-1,1,-diphosphonic acid; 1-Hydroxyethane-1,1-bisphosphonic acid; 1-Hydroxyethane-1,1-diphosphonate; 1-Hydroxyethane-1,1-diphosphonic acid; 1-Hydroxyethanediphosphonic acid; 1-Hydroxyethylidene 1,1-diphosphonic acid; 1-Hydroxyethylidene-1,1-biphosphonate; 1-Hydroxyethylidene-1,1-bisphosphonate; 1-Hydroxyethylidene-1,1-diphosphonic acid; 1-Hydroxyethylidenediphosphonic acid; 1000SL
DM1XHYJ	TC	Bone Density Conservation Agents
DM1XHYJ	DT	Small molecular drug
DM1XHYJ	PC	3305
DM1XHYJ	MW	206.03
DM1XHYJ	FM	C2H8O7P2
DM1XHYJ	IC	InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
DM1XHYJ	CS	CC(O)(P(=O)(O)O)P(=O)(O)O
DM1XHYJ	IK	DBVJJBKOTRCVKF-UHFFFAOYSA-N
DM1XHYJ	IU	(1-hydroxy-1-phosphonoethyl)phosphonic acid
DM1XHYJ	CA	CAS 2809-21-4
DM1XHYJ	CB	CHEBI:4907
DM1XHYJ	DE	Paget's disease

DM6WJO9	ID	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	HS	Approved
DM6WJO9	SN	etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1
DM6WJO9	CP	Meda Pharmaceuticals 
DM6WJO9	TC	Analgesics
DM6WJO9	DT	Small molecular drug
DM6WJO9	PC	3308
DM6WJO9	MW	287.35
DM6WJO9	FM	C17H21NO3
DM6WJO9	IC	InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
DM6WJO9	CS	CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O
DM6WJO9	IK	NNYBQONXHNTVIJ-UHFFFAOYSA-N
DM6WJO9	IU	2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
DM6WJO9	CA	CAS 41340-25-4
DM6WJO9	CB	CHEBI:4909
DM6WJO9	DE	Pain

DMZI3WO	ID	DMZI3WO
DMZI3WO	DN	Etomidate
DMZI3WO	HS	Approved
DMZI3WO	SN	Absele; Amidate; Ethnor; Ethomidate; Etomidato; Etomidatum; Hypnomidate; Radenarcon; Radenarkon; Etomidic acid; R 16659; R 26490; R26490; Amidate (TN); Amidate (pharmaceutical); Amidate, Etomidate; D-Etomidate; Etomidato [INN-Spanish]; Etomidatum [INN-Latin]; R-26490; Etomidate (USAN/INN); Etomidate [USAN:BAN:INN]; Ethyl 3-(1-phenylethyl)imidazole-4-carboxylate; Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate; (+)-Etomidate; (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester; (d)-Etomidate; 1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester; 1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester; 3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
DMZI3WO	CP	Janssen Pharmaceutica
DMZI3WO	TC	Analgesics
DMZI3WO	DT	Small molecular drug
DMZI3WO	PC	667484
DMZI3WO	MW	244.29
DMZI3WO	FM	C14H16N2O2
DMZI3WO	IC	InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1
DMZI3WO	CS	CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2
DMZI3WO	IK	NPUKDXXFDDZOKR-LLVKDONJSA-N
DMZI3WO	IU	ethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate
DMZI3WO	CA	CAS 33125-97-2
DMZI3WO	CB	CHEBI:4910
DMZI3WO	DE	Anaesthesia

DMKA8J4	ID	DMKA8J4
DMKA8J4	DN	Etonogestrel
DMKA8J4	HS	Approved
DMKA8J4	SN	Etonogestrelum; Implanon; Implanon (TN); NuvaRing (TN); Etonogestrel (USAN/INN); (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; 17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one; 3-Ketodesogestrel; 3-Oxodesogestrel
DMKA8J4	TC	Contraceptive Agents
DMKA8J4	DT	Small molecular drug
DMKA8J4	PC	6917715
DMKA8J4	MW	324.5
DMKA8J4	FM	C22H28O2
DMKA8J4	IC	InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
DMKA8J4	CS	CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DMKA8J4	IK	GCKFUYQCUCGESZ-BPIQYHPVSA-N
DMKA8J4	IU	(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMKA8J4	CA	CAS 54048-10-1
DMKA8J4	CB	CHEBI:50777
DMKA8J4	DE	Contraception

DMNH3PG	ID	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	HS	Approved
DMNH3PG	SN	etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
DMNH3PG	CP	Bristol Myers Squibb Co Pharmaceutical Research Institute
DMNH3PG	TC	Anticancer Agents
DMNH3PG	DT	Small molecular drug
DMNH3PG	PC	36462
DMNH3PG	MW	588.6
DMNH3PG	FM	C29H32O13
DMNH3PG	IC	InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
DMNH3PG	CS	C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
DMNH3PG	IK	VJJPUSNTGOMMGY-MRVIYFEKSA-N
DMNH3PG	IU	(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
DMNH3PG	CA	CAS 33419-42-0
DMNH3PG	CB	CHEBI:4911
DMNH3PG	DE	Solid tumour/cancer

DM6A4NW	ID	DM6A4NW
DM6A4NW	DN	Etoricoxib
DM6A4NW	HS	Approved
DM6A4NW	SN	Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH
DM6A4NW	CP	Merck & Co
DM6A4NW	TC	Antiinflammatory Agents
DM6A4NW	DT	Small molecular drug
DM6A4NW	PC	123619
DM6A4NW	MW	358.8
DM6A4NW	FM	C18H15ClN2O2S
DM6A4NW	IC	InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
DM6A4NW	CS	CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
DM6A4NW	IK	MNJVRJDLRVPLFE-UHFFFAOYSA-N
DM6A4NW	IU	5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
DM6A4NW	CA	CAS 202409-33-4
DM6A4NW	CB	CHEBI:6339
DM6A4NW	DE	Rheumatoid arthritis

DMGV8QU	ID	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	HS	Approved
DMGV8QU	SN	Intelence; DAPY deriv; Diaminopyrimidine deriv; R 165335; R165335; TMC 125; TMC125; Intelence (TN); Intelence(TM); R-165335; R165335-TMC125; TMC-125; Etravirine (JAN/USAN/INN); TMC-125/R-165335; 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile; 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE; 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile; 65B; ETR
DMGV8QU	DT	Small molecular drug
DMGV8QU	PC	193962
DMGV8QU	MW	435.3
DMGV8QU	FM	C20H15BrN6O
DMGV8QU	IC	InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)
DMGV8QU	CS	CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N
DMGV8QU	IK	PYGWGZALEOIKDF-UHFFFAOYSA-N
DMGV8QU	IU	4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile
DMGV8QU	CA	CAS 269055-15-4
DMGV8QU	CB	CHEBI:63589
DMGV8QU	DE	Human immunodeficiency virus-1 infection

DM2CZFA	ID	DM2CZFA
DM2CZFA	DN	Etretinate
DM2CZFA	HS	Approved
DM2CZFA	SN	etretinate; 54350-48-0; Tegison; Ethyl etrinoate; Retinoid; Etretinatum; Etretinato; Ro 10-9359; Etretinatum [INN-Latin]; Etretinato [INN-Spanish]; UNII-65M2UDR9AG; CCRIS 3615; HSDB 7185; EINECS 259-119-3; NSC 297936; 65M2UDR9AG; Ro-10-9359; Tigason; CHEBI:4913; C23H30O3; Ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; Ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; 3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonanetetraenoic acid ethy
DM2CZFA	DT	Small molecular drug
DM2CZFA	PC	5282375
DM2CZFA	MW	354.5
DM2CZFA	FM	C23H30O3
DM2CZFA	IC	InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+
DM2CZFA	CS	CCOC(=O)/C=C(\\C)/C=C/C=C(\\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C
DM2CZFA	IK	HQMNCQVAMBCHCO-DJRRULDNSA-N
DM2CZFA	IU	ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
DM2CZFA	CA	CAS 54350-48-0
DM2CZFA	CB	CHEBI:4913
DM2CZFA	DE	Keratosis

DM5GT1M	ID	DM5GT1M
DM5GT1M	DN	EVANS BLUE
DM5GT1M	HS	Approved
DM5GT1M	SN	tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonatonaphthalen-2-ylidene)hydrazinyl]-3-methylphenyl]-2-methylphenyl]hydrazinylidene]-5-oxonaphthalene-1,3-disulfonate; AC1NUWHB; AC1O426Q; AN-23389; tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonato-2-naphthylidene)hydrazino]-3-methyl-phenyl]-2-methyl-phenyl]hydrazono]-5-oxo-naphthalene-1,3-disulfonate; 6,6-[(3,3'-Dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)bis[4-amino-5-hydroxy-1,3-naphthalenedisulphonic acid]tetrasodium sa
DM5GT1M	DT	Small molecular drug
DM5GT1M	PC	9409
DM5GT1M	MW	960.8
DM5GT1M	FM	C34H24N6Na4O14S4
DM5GT1M	IC	InChI=1S/C34H28N6O14S4.4Na/c1-15-11-17(3-7-21(15)37-39-23-9-5-19-25(55(43,44)45)13-27(57(49,50)51)31(35)29(19)33(23)41)18-4-8-22(16(2)12-18)38-40-24-10-6-20-26(56(46,47)48)14-28(58(52,53)54)32(36)30(20)34(24)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4
DM5GT1M	CS	CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)[O-])S(=O)(=O)[O-])O)C)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+].[Na+]
DM5GT1M	IK	ATNOAWAQFYGAOY-UHFFFAOYSA-J
DM5GT1M	IU	tetrasodium;4-amino-6-[[4-[4-[(8-amino-1-hydroxy-5,7-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-5-hydroxynaphthalene-1,3-disulfonate
DM5GT1M	CA	CAS 314-13-6
DM5GT1M	CB	CHEBI:82467
DM5GT1M	DE	Abdominal aortic aneurysm

DM8X2EH	ID	DM8X2EH
DM8X2EH	DN	Everolimus
DM8X2EH	HS	Approved
DM8X2EH	SN	Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
DM8X2EH	CP	Novartis
DM8X2EH	TC	Anticancer Agents
DM8X2EH	DT	Small molecular drug
DM8X2EH	PC	6442177
DM8X2EH	MW	958.2
DM8X2EH	FM	C53H83NO14
DM8X2EH	IC	InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
DM8X2EH	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC
DM8X2EH	IK	HKVAMNSJSFKALM-GKUWKFKPSA-N
DM8X2EH	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM8X2EH	CA	CAS 159351-69-6
DM8X2EH	CB	CHEBI:68478
DM8X2EH	DE	Renal cell carcinoma; Kidney cancer

DMBLX7U	ID	DMBLX7U
DMBLX7U	DN	Evinacumab
DMBLX7U	HS	Approved
DMBLX7U	SN	REGN1500; ANGPTL-1 antibody
DMBLX7U	CP	Regeneron Pharmaceuticals Tarrytown, NY
DMBLX7U	DE	Elevated C-reactive protein; Familial hypercholesterolemia; Hypercholesterolaemia

DM9HPW3	ID	DM9HPW3
DM9HPW3	DN	Exemestane
DM9HPW3	HS	Approved
DM9HPW3	SN	Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione
DM9HPW3	TC	Anticancer Agents
DM9HPW3	DT	Small molecular drug
DM9HPW3	PC	60198
DM9HPW3	MW	296.4
DM9HPW3	FM	C20H24O2
DM9HPW3	IC	InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1
DM9HPW3	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C
DM9HPW3	IK	BFYIZQONLCFLEV-DAELLWKTSA-N
DM9HPW3	IU	(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
DM9HPW3	CA	CAS 107868-30-4
DM9HPW3	CB	CHEBI:4953
DM9HPW3	DE	Hormonally-responsive breast cancer

DMYHBKN	ID	DMYHBKN
DMYHBKN	DN	Exenatide
DMYHBKN	HS	Approved
DMYHBKN	SN	Exenatide Synthetic; AC 2993 LAR; Ex4 peptide; Byetta (TN); Exendin 4 (Heloderma suspectum); Extendin-4; L-Serinamide
DMYHBKN	CP	Eli Lilly
DMYHBKN	TC	Hypoglycemic Agents
DMYHBKN	DT	Small molecular drug
DMYHBKN	SQ	Exenatide: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
DMYHBKN	PC	45588096
DMYHBKN	MW	4187
DMYHBKN	FM	C184H282N50O60S
DMYHBKN	IC	InChI=1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1
DMYHBKN	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC9=CNC=N9)N
DMYHBKN	IK	HTQBXNHDCUEHJF-XWLPCZSASA-N
DMYHBKN	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMYHBKN	CA	CAS 141758-74-9
DMYHBKN	DE	Cardiovascular disease; Type-2 diabetes

DMHPRWG	ID	DMHPRWG
DMHPRWG	DN	Exjade
DMHPRWG	HS	Approved
DMHPRWG	SN	Deferasirox
DMHPRWG	CP	Novartis
DMHPRWG	DT	Small molecular drug
DMHPRWG	PC	214348
DMHPRWG	MW	373.4
DMHPRWG	FM	C21H15N3O4
DMHPRWG	IC	InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
DMHPRWG	CS	C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
DMHPRWG	IK	BOFQWVMAQOTZIW-UHFFFAOYSA-N
DMHPRWG	IU	4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
DMHPRWG	CA	CAS 201530-41-8
DMHPRWG	CB	CHEBI:49005
DMHPRWG	DE	Iron overload disease

DM7A8TW	ID	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	HS	Approved
DM7A8TW	SN	Ezedoc; Ezetimib; Ezetrol; Zetia; Zient; Essex brand of ezetimibe; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH58235; Sch 58235; Ezetimibe [USAN:INN]; Inegy (TN); MK-0653; SCH-58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia (TN); Zetia , Ezetrol, Ezetimibe; Ezetimibe (JAN/USAN/INN); (-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
DM7A8TW	CP	Schering-Plough
DM7A8TW	TC	Anticholesteremic Agents
DM7A8TW	DT	Small molecular drug
DM7A8TW	PC	150311
DM7A8TW	MW	409.4
DM7A8TW	FM	C24H21F2NO3
DM7A8TW	IC	InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1
DM7A8TW	CS	C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O
DM7A8TW	IK	OLNTVTPDXPETLC-XPWALMASSA-N
DM7A8TW	IU	(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
DM7A8TW	CA	CAS 163222-33-1
DM7A8TW	CB	CHEBI:49040
DM7A8TW	DE	Hypercholesterolaemia

DMAB6PM	ID	DMAB6PM
DMAB6PM	DN	Factor 8
DMAB6PM	HS	Approved
DMAB6PM	SN	Wilate (TN)
DMAB6PM	DE	Hemophilia

DMZUW6P	ID	DMZUW6P
DMZUW6P	DN	Factor viia
DMZUW6P	HS	Approved
DMZUW6P	SN	Novoseven (TN)
DMZUW6P	DE	Hemophilia

DM3C5GZ	ID	DM3C5GZ
DM3C5GZ	DN	FADROZOLE
DM3C5GZ	HS	Approved
DM3C5GZ	SN	102676-47-1; CGS-16949A; Fadrozole [INN]; Fadrozolum [INN-Latin]; Fadrozol [INN-Spanish]; CHEMBL9298; Fadrozole (INN); 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-; Fadrozolum; Fadrozol; 4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-
DM3C5GZ	DT	Small molecular drug
DM3C5GZ	PC	59693
DM3C5GZ	MW	223.27
DM3C5GZ	FM	C14H13N3
DM3C5GZ	IC	InChI=1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2
DM3C5GZ	CS	C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N
DM3C5GZ	IK	CLPFFLWZZBQMAO-UHFFFAOYSA-N
DM3C5GZ	IU	4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
DM3C5GZ	CA	CAS 102676-47-1
DM3C5GZ	CB	CHEBI:94355
DM3C5GZ	DE	Breast cancer

DMBI9ZJ	ID	DMBI9ZJ
DMBI9ZJ	DN	Falecalcitrol
DMBI9ZJ	HS	Approved
DMBI9ZJ	SN	Falecalcitriol; falecalcitriol; Flocalcitriol; 83805-11-2; calcitriol hexafluoride; Hornel, Fulstan; Falecalcitriol [INN]; ST-630; ST 630; Fulstan; Ro 23-4194; UNII-G70A8514T8; C27H38F6O3; Hornel; 26,26,26,27,27,27-Hexafluoro-1,25-dihydroxyvitamin D3; G70A8514T8; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; Hexafluorocalcitriol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol,;  Fulstan (TN); Horner (TN)
DMBI9ZJ	DT	Small molecular drug
DMBI9ZJ	PC	5282190
DMBI9ZJ	MW	524.6
DMBI9ZJ	FM	C27H38F6O3
DMBI9ZJ	IC	InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24-/m1/s1
DMBI9ZJ	CS	C[C@H](CCCC(C(F)(F)F)(C(F)(F)F)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DMBI9ZJ	IK	XPYGGHVSFMUHLH-UUSULHAXSA-N
DMBI9ZJ	IU	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMBI9ZJ	CA	CAS 83805-11-2
DMBI9ZJ	DE	Hyperparathyroidism

DMJHLSD	ID	DMJHLSD
DMJHLSD	DN	Famciclovir
DMJHLSD	HS	Approved
DMJHLSD	SN	FCV; Famciclovirum; Famvir; Oravir; BRL 42810; IN1338; Anti-Farnesyl Rabbit pAb; BRL-42810; Famciclovirum [INN-Latin]; Famvir (TN); Famciclovir [USAN:BAN:INN]; Famciclovir (JAN/USAN/INN); [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
DMJHLSD	CP	Schering-Plough
DMJHLSD	TC	Antiviral Agents
DMJHLSD	DT	Small molecular drug
DMJHLSD	PC	3324
DMJHLSD	MW	321.33
DMJHLSD	FM	C14H19N5O4
DMJHLSD	IC	InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)
DMJHLSD	CS	CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C
DMJHLSD	IK	GGXKWVWZWMLJEH-UHFFFAOYSA-N
DMJHLSD	IU	[2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate
DMJHLSD	CA	CAS 104227-87-4
DMJHLSD	CB	CHEBI:4974
DMJHLSD	DE	Virus infection

DMRL3AB	ID	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	HS	Approved
DMRL3AB	SN	Pepcid; famotidine; 76824-35-6; Pepcid AC; Pepcidine; Quamatel; Gastridin; Famodil; Dispromil; Pepdine; Digervin; Gaster; Fluxid; Pepdul; Pepcid RPD; Famulcer; Supertidine; Pepcidina; Fagastine; Whitidin; Farmotex; Peptifam; Ferotine; Dispronil; Tairal; Sigafam; Famtac; Durater; Yamarin; Pepzan; Famoxal; Evatin; Weimok; Pepdif; Fudone; Fanosin; Fanobel; Duovel; Fibonel; Fadine; Dipsin; Ganor; Fadin; Dinul; Fanox; Fadyn; Famox; Famo; Nu-Famotidine; Pepcidin Rapitab; Sedanium-R; Dibrit 40; Famotidinum [Latin]; PEPCID; Famotidina [Spanish]; Apogastine; Antodine; Bestidine;  Amfamox; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Famocid; Famodar; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Gastridan; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; Panalba; Pepcidac; Pepcidin; Pepfamin; Peptan; Peptidin; Purifam; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC Gelcaps; PepcidRPD; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Pepcid (TN); Pepcidine (TN); YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
DMRL3AB	CP	Astellas Pharma
DMRL3AB	TC	Antiulcer Agents
DMRL3AB	DT	Small molecular drug
DMRL3AB	PC	5702160
DMRL3AB	MW	337.5
DMRL3AB	FM	C8H15N7O2S3
DMRL3AB	IC	InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
DMRL3AB	CS	C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N
DMRL3AB	IK	XUFQPHANEAPEMJ-UHFFFAOYSA-N
DMRL3AB	IU	3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
DMRL3AB	CA	CAS 76824-35-6
DMRL3AB	CB	CHEBI:4975
DMRL3AB	DE	Peptic ulcer

DMX7A5V	ID	DMX7A5V
DMX7A5V	DN	Faropenem
DMX7A5V	HS	Approved
DMX7A5V	SN	FPM; Fropenem; (+)-(5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-((2R)-tetrahydro-2-furyl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 6alpha-[(1R)-1-hydroxyethyl]-2-[(2R)-tetrahydrofuran-2-yl]-2,3-didehydropenam-3-carboxylic acid
DMX7A5V	CP	Suntory
DMX7A5V	TC	Respiratory Agents
DMX7A5V	DT	Small molecular drug
DMX7A5V	PC	65894
DMX7A5V	MW	285.32
DMX7A5V	FM	C12H15NO5S
DMX7A5V	IC	InChI=1S/C12H15NO5S/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6/h5-7,11,14H,2-4H2,1H3,(H,16,17)/t5-,6-,7+,11-/m1/s1
DMX7A5V	CS	C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)[C@H]3CCCO3)C(=O)O)O
DMX7A5V	IK	HGGAKXAHAYOLDJ-FHZUQPTBSA-N
DMX7A5V	IU	(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMX7A5V	CA	CAS 106560-14-9
DMX7A5V	CB	CHEBI:51257
DMX7A5V	DE	Gram-positive bacterial infection

DMDEXQ0	ID	DMDEXQ0
DMDEXQ0	DN	Febuxostat
DMDEXQ0	HS	Approved
DMDEXQ0	SN	Adenuric; TEI; Uloric; Febuxostat [USAN]; S1547; TMX 67; Tei 6720; TMX-67; Tei-6720; Uloric (TN); Febuxostat (JAN/USAN/INN); TMX-67, Adenuric, Uloric, Febuxostat; 111GE013; 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
DMDEXQ0	CP	Takeda
DMDEXQ0	DT	Small molecular drug
DMDEXQ0	PC	134018
DMDEXQ0	MW	316.4
DMDEXQ0	FM	C16H16N2O3S
DMDEXQ0	IC	InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)
DMDEXQ0	CS	CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O
DMDEXQ0	IK	BQSJTQLCZDPROO-UHFFFAOYSA-N
DMDEXQ0	IU	2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
DMDEXQ0	CA	CAS 144060-53-7
DMDEXQ0	CB	CHEBI:31596
DMDEXQ0	DE	Hyperuricaemia

DM4ZBK6	ID	DM4ZBK6
DM4ZBK6	DN	Fedratinib
DM4ZBK6	HS	Approved
DM4ZBK6	SN	TG101348
DM4ZBK6	CP	Targen
DM4ZBK6	DT	Small molecular drug
DM4ZBK6	PC	16722836
DM4ZBK6	MW	524.7
DM4ZBK6	FM	C27H36N6O3S
DM4ZBK6	IC	InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)
DM4ZBK6	CS	CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4
DM4ZBK6	IK	JOOXLOJCABQBSG-UHFFFAOYSA-N
DM4ZBK6	IU	N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
DM4ZBK6	CA	CAS 936091-26-8
DM4ZBK6	CB	CHEBI:91408
DM4ZBK6	DE	Myelofibrosis

DML2DCR	ID	DML2DCR
DML2DCR	DN	Fedratinib hydrochloride
DML2DCR	HS	Approved
DML2DCR	SN	Fedratinib hydrochloride (USAN); TG101348(2ClH.H2O); UH9J2HBQWJ; 1374744-69-0; BCP24783; D11296; Fedratinib dihydrochloride monohydrate; UNII-UH9J2HBQWJ
DML2DCR	PC	67517580
DML2DCR	MW	615.6
DML2DCR	FM	C27H40Cl2N6O4S
DML2DCR	IC	QAFZLTVOFJHYDF-UHFFFAOYSA-N
DML2DCR	CS	CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl
DML2DCR	IK	1S/C27H36N6O3S.2ClH.H2O/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4;;;/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31);2*1H;1H2
DML2DCR	IU	N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide;hydrate;dihydrochloride
DML2DCR	CA	CAS 1374744-69-0
DML2DCR	DE	Myelofibrosis

DM1V5ZS	ID	DM1V5ZS
DM1V5ZS	DN	Felbamate
DM1V5ZS	HS	Approved
DM1V5ZS	SN	Felbamato; Felbamatum; Felbamyl; Felbatol; Taloxa; Essex brand of felbamate; Felbamato [Spanish]; Felbamatum [Latin]; Schering brand of felbamate; F 0778; W 554; Wallace brand 1 of felbamate; Wallace brand 2 of felbamate; ADD-03055; Carbamic acid 2-phenyltrimethylene ester; Felbamate [USAN:INN]; Felbatol (TN); Schering-Plough brand of felbamate; W-554; Carbamic acid, 2-phenyltrimethylene ester; Felbamate (USAN/INN); (3-carbamoyloxy-2-phenyl-propyl) carbamate; (3-carbamoyloxy-2-phenylpropyl) carbamate; 1,3-Propanediol, 2-phenyl-, dicarbamate; 2-Phenyl-1,3-propanediol dicarbamate; 2-Phenylpropane-1,3-diyl dicarbamate
DM1V5ZS	CP	MedPointe
DM1V5ZS	TC	Antiepileptic Agents
DM1V5ZS	DT	Small molecular drug
DM1V5ZS	PC	3331
DM1V5ZS	MW	238.24
DM1V5ZS	FM	C11H14N2O4
DM1V5ZS	IC	InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
DM1V5ZS	CS	C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N
DM1V5ZS	IK	WKGXYQFOCVYPAC-UHFFFAOYSA-N
DM1V5ZS	IU	(3-carbamoyloxy-2-phenylpropyl) carbamate
DM1V5ZS	CA	CAS 25451-15-4
DM1V5ZS	CB	CHEBI:4995
DM1V5ZS	DE	Epilepsy

DMKZEIB	ID	DMKZEIB
DMKZEIB	DN	Felbinac
DMKZEIB	HS	Approved
DMKZEIB	SN	Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda
DMKZEIB	CP	Takeda Pharmaceutical Co Ltd
DMKZEIB	DT	Small molecular drug
DMKZEIB	PC	3332
DMKZEIB	MW	212.24
DMKZEIB	FM	C14H12O2
DMKZEIB	IC	InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16)
DMKZEIB	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O
DMKZEIB	IK	QRZAKQDHEVVFRX-UHFFFAOYSA-N
DMKZEIB	IU	2-(4-phenylphenyl)acetic acid
DMKZEIB	CA	CAS 5728-52-9
DMKZEIB	CB	CHEBI:31597
DMKZEIB	DE	Arthritis

DMOSW35	ID	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	HS	Approved
DMOSW35	SN	Agon; Felobeta; Felocor; Feloday; Felodipina; Felodipinum; Felodur; Felogamma; Felogard; Fensel; Flodil; Hydac; Lexxel; Logimax; Modip; Munobal; Penedil; Perfudal; Plandil; Plendil; Preslow; Prevex; Renedil; Splendil; AGON SR; AbZ Brand of Felodipine; Aliud Brand of Felodipine; Alphapharm Brand of Felodipine; Alpharma Brand of Felodipine; Astra Brand of Felodipine; AstraZeneca Brand of Felodipine; Aventis Brand of Felodipine; Azupharma Brand of Felodipine; BC Brand of Felodipine; Betapharm Brand of Felodipine; Ct Arzneimittel Brand of Felodipine; Felo Biochemie; Felo Puren; Felodipin AL; Felodipin AZU; Felodipin AbZ; Felodipin Heumann; Felodipin Stada; Felodipin dura; Felodipin ratiopharm; Felodipin von ct; FelodurER; Heumann Brand of Felodipine; Hexal Brand of Felodipine; Hoechst Brand of Felodipine; Merck dura Brand of Felodipine; Munobal Retard; Pharmaceutica Astra Brand of Felodipine; Pharmacia Spain Brandof Felodipine; Plendil Depottab; Plendil ER; Plendil Retard; Promed Brand of Felodipine; Ratiopharm Brand of Felodipine; Stadapharm Brand of Felodipine; TheraPharm Brand of Felodipine; Worwag Brand of Felodipine; F 9677; Felodipin 1A Pharma; H 154 82; H 15482; CGH-869; Ct-Arzneimittel Brand of Felodipine; Dl-Felodipine; Felo-Puren; Felodipin-ratiopharm; Felodipina [INN-Spanish]; Felodipinum [INN-Latin]; H 154-82; H 154/82; Heumann, Felodipin; Plendil (TN); AE-641/11429675; Felodipine [USAN:BAN:INN]; Felodipine [USAN:INN:BAN]; H-154/82; Felodipine (JAN/USP/INN); Plendil, Renedil, Feloday, Felodipine; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethylmethyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 1A Brand of Felodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methylester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMOSW35	CP	AstraZeneca
DMOSW35	TC	Antihypertensive Agents
DMOSW35	DT	Small molecular drug
DMOSW35	PC	3333
DMOSW35	MW	384.2
DMOSW35	FM	C18H19Cl2NO4
DMOSW35	IC	InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3
DMOSW35	CS	CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
DMOSW35	IK	RZTAMFZIAATZDJ-UHFFFAOYSA-N
DMOSW35	IU	5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMOSW35	CA	CAS 72509-76-3
DMOSW35	CB	CHEBI:585948
DMOSW35	DE	Hypertension

DMHLP9C	ID	DMHLP9C
DMHLP9C	DN	Felypressin
DMHLP9C	HS	Approved
DMHLP9C	SN	Felipresina; Felipressina; Felypressine; Felypressinum; Octapressin; Octopressin; Phelypressin; Felipressina [DCIT]; Phenylalanine Lysine Vasopressin; Felipresina [INN-Spanish]; Felypressine [INN-French]; Felypressinum [INN-Latin]; Octapressin (TN); PLV-2; Felypressin [USAN:INN:BAN]; Vasopressin, Phenylalanyl-Lysyl; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1-6)disulfide; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1->6)disulfide; 1-{[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyllysylglycinamide; 2-(L-Phenylalanine)-8-L-lysinevasopressin; N-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMHLP9C	CP	AstraZeneca
DMHLP9C	TC	Vasoconstrictor Agents
DMHLP9C	DT	Small molecular drug
DMHLP9C	PC	14257662
DMHLP9C	MW	1040.2
DMHLP9C	FM	C46H65N13O11S2
DMHLP9C	IC	InChI=1S/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DMHLP9C	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=CC=C4)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DMHLP9C	IK	SFKQVVDKFKYTNA-DZCXQCEKSA-N
DMHLP9C	IU	(2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMHLP9C	CA	CAS 56-59-7
DMHLP9C	CB	CHEBI:60564
DMHLP9C	DE	Localisation

DMXGDFK	ID	DMXGDFK
DMXGDFK	DN	Fenbufen
DMXGDFK	HS	Approved
DMXGDFK	SN	fenbufen; 36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a
DMXGDFK	DT	Small molecular drug
DMXGDFK	PC	3335
DMXGDFK	MW	254.28
DMXGDFK	FM	C16H14O3
DMXGDFK	IC	InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
DMXGDFK	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCC(=O)O
DMXGDFK	IK	ZPAKPRAICRBAOD-UHFFFAOYSA-N
DMXGDFK	IU	4-oxo-4-(4-phenylphenyl)butanoic acid
DMXGDFK	CA	CAS 36330-85-5
DMXGDFK	CB	CHEBI:31599
DMXGDFK	DE	Arthritis

DM0LRU9	ID	DM0LRU9
DM0LRU9	DN	Fendrix
DM0LRU9	HS	Approved
DM0LRU9	SN	Fendrix Extra Strength; New hepatitis B prophylactic vaccine, GlaxoSmithKline; HBV prophylactic vaccine (new), GlaxoSmithKline; Hepatitis B prophylactic vaccine (extra strength), GlaxoSmithKline; MPL hepatitis B vaccine, GSK/Corixa; SBAS4-adjuvanted hepatitis B vaccine, GlaxoSmithKline; SBAS4-adjuvanted hepatitis B vaccine, SmithKline Beecham; SBAS4/MPL (HBV vaccine), GlaxoSmithKline/Ribi; SBAS4/MPL (HBV vaccine), SmithKline Beecham/Ribi
DM0LRU9	CP	GlaxoSmithKline Biologicals
DM0LRU9	DT	Vaccine
DM0LRU9	DE	Hepatitis B virus infection

DMFKXDY	ID	DMFKXDY
DMFKXDY	DN	Fenofibrate
DMFKXDY	HS	Approved
DMFKXDY	SN	Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate
DMFKXDY	CP	Abbott Laboratories
DMFKXDY	TC	Antilipemic Agents
DMFKXDY	DT	Small molecular drug
DMFKXDY	PC	3339
DMFKXDY	MW	360.8
DMFKXDY	FM	C20H21ClO4
DMFKXDY	IC	InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
DMFKXDY	CS	CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
DMFKXDY	IK	YMTINGFKWWXKFG-UHFFFAOYSA-N
DMFKXDY	IU	propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
DMFKXDY	CA	CAS 49562-28-9
DMFKXDY	CB	CHEBI:5001
DMFKXDY	DE	High cholesterol level

DMGO2MC	ID	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	HS	Approved
DMGO2MC	SN	Fenofibric acid; 42017-89-0; Procetofenic acid; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; alpha 1081; NSC 281318; LF 178 acid; UNII-BGF9MN2HU1; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; LF 153; FNF Acid; C17H15ClO4; Trilipix; CCRIS 7302; EINECS 255-626-9; BGF9MN2HU1; CHEMBL981; BRN 2058973; CHEBI:83469; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; AK117112; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; W-106287
DMGO2MC	DT	Small molecular drug
DMGO2MC	PC	64929
DMGO2MC	MW	318.7
DMGO2MC	FM	C17H15ClO4
DMGO2MC	IC	InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
DMGO2MC	CS	CC(C)(C(=O)O)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
DMGO2MC	IK	MQOBSOSZFYZQOK-UHFFFAOYSA-N
DMGO2MC	IU	2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid
DMGO2MC	CA	CAS 42017-89-0
DMGO2MC	CB	CHEBI:83469
DMGO2MC	DE	Cardiovascular disease

DMFAOKP	ID	DMFAOKP
DMFAOKP	DN	Fenoldopam
DMFAOKP	HS	Approved
DMFAOKP	SN	Carlacor; Fenoldopamum; Fenodopam mesylate; Fenoldopamum [Latin]; SKF 82526; Carlacor (TN); Corlopam (TN); Fenoldopam (INN);Fenoldopam [INN:BAN]; SKF 82526-J; SKF-82526J; SK&F-82526; 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DMFAOKP	CP	Ben Venue Laboratories
DMFAOKP	TC	Antihypertensive Agents
DMFAOKP	DT	Small molecular drug
DMFAOKP	PC	3341
DMFAOKP	MW	305.75
DMFAOKP	FM	C16H16ClNO3
DMFAOKP	IC	InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2
DMFAOKP	CS	C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O
DMFAOKP	IK	TVURRHSHRRELCG-UHFFFAOYSA-N
DMFAOKP	IU	9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DMFAOKP	CA	CAS 67227-56-9
DMFAOKP	CB	CHEBI:5002
DMFAOKP	DE	Hypertension

DML5VQ0	ID	DML5VQ0
DML5VQ0	DN	Fenoprofen
DML5VQ0	HS	Approved
DML5VQ0	SN	Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid
DML5VQ0	CP	Typharm Limited
DML5VQ0	TC	Antiinflammatory Agents
DML5VQ0	DT	Small molecular drug
DML5VQ0	PC	3342
DML5VQ0	MW	242.27
DML5VQ0	FM	C15H14O3
DML5VQ0	IC	InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)
DML5VQ0	CS	CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O
DML5VQ0	IK	RDJGLLICXDHJDY-UHFFFAOYSA-N
DML5VQ0	IU	2-(3-phenoxyphenyl)propanoic acid
DML5VQ0	CA	CAS 29679-58-1
DML5VQ0	CB	CHEBI:5004
DML5VQ0	DE	Rheumatoid arthritis

DMIP3ZV	ID	DMIP3ZV
DMIP3ZV	DN	Fenoterol
DMIP3ZV	HS	Approved
DMIP3ZV	SN	Berotec; Berotek; Fenoterolum; Phenoterol; TH 1165A; Berotec (TN); Fenoterolum [INN-Latin]; P-Hydroxyphenylorciprenaline; Th-1165a; Fenoterol (USAN/INN); Fenoterol [USAN:BAN:INN]; P-Hydroxyphenyl-orciprenaline; 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane; 1-(p-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane; 3,5-Dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol; 5-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)benzene-1,3-diol; 5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol; 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol; 5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol
DMIP3ZV	CP	Boehriger Ingelheim
DMIP3ZV	TC	Bronchodilator Agents
DMIP3ZV	DT	Small molecular drug
DMIP3ZV	PC	3343
DMIP3ZV	MW	303.35
DMIP3ZV	FM	C17H21NO4
DMIP3ZV	IC	InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3
DMIP3ZV	CS	CC(CC1=CC=C(C=C1)O)NCC(C2=CC(=CC(=C2)O)O)O
DMIP3ZV	IK	LSLYOANBFKQKPT-UHFFFAOYSA-N
DMIP3ZV	IU	5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol
DMIP3ZV	CA	CAS 13392-18-2
DMIP3ZV	CB	CHEBI:149226
DMIP3ZV	DE	Asthma

DM8WAHT	ID	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	HS	Approved
DM8WAHT	SN	fentanyl; Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT];  Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals
DM8WAHT	CP	Janssen Pharmaceuticals Inc
DM8WAHT	TC	Neurology Agents
DM8WAHT	DT	Small molecular drug
DM8WAHT	PC	3345
DM8WAHT	MW	336.5
DM8WAHT	FM	C22H28N2O
DM8WAHT	IC	InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
DM8WAHT	CS	CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
DM8WAHT	IK	PJMPHNIQZUBGLI-UHFFFAOYSA-N
DM8WAHT	IU	N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
DM8WAHT	CA	CAS 437-38-7
DM8WAHT	CB	CHEBI:119915
DM8WAHT	DE	Analgesia; Pain; Cancer related pain; Chronic pain

DM13495	ID	DM13495
DM13495	DN	Fesoterodine fumarate
DM13495	HS	Approved
DM13495	SN	Toviaz (TN)
DM13495	CP	Pfizer
DM13495	DT	Small molecular drug
DM13495	PC	9849808
DM13495	MW	527.6
DM13495	FM	C30H41NO7
DM13495	IC	InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1
DM13495	CS	CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\\C(=O)O
DM13495	IK	MWHXMIASLKXGBU-RNCYCKTQSA-N
DM13495	IU	(E)-but-2-enedioic acid;[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
DM13495	CA	CAS 286930-03-8
DM13495	DE	Overactive bladder

DM17ONX	ID	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	HS	Approved
DM17ONX	SN	Carboxyterfenadine; Fexofendine; Terfenadine acid metabolite; Terfenadine carboxylate; F 9427; MDL 16455; Allegra (TN); Fastofen (TN); Fexofenadine (INN); Fexofenadine [INN:BAN]; Telfast (TN); Terfenadine-COOH; Terfenidine carboxylate, MDL 16455; Tilfur (TN); 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid
DM17ONX	CP	Sanofi-Aventis
DM17ONX	TC	Antiallergic Agents
DM17ONX	DT	Small molecular drug
DM17ONX	PC	3348
DM17ONX	MW	501.7
DM17ONX	FM	C32H39NO4
DM17ONX	IC	InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
DM17ONX	CS	CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
DM17ONX	IK	RWTNPBWLLIMQHL-UHFFFAOYSA-N
DM17ONX	IU	2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
DM17ONX	CA	CAS 83799-24-0
DM17ONX	CB	CHEBI:5050
DM17ONX	DE	Allergic rhinitis

DM9Q8SO	ID	DM9Q8SO
DM9Q8SO	DN	Fibrinolysin
DM9Q8SO	HS	Approved
DM9Q8SO	SQ	Fibrinolysin heavy chain: DLLDDYVNTQGASLLSLSRKNLAGRSVEDCAAKCEEETDFVCRAFQYHSKEQQCVVMAENSKNTPVFRMRDVILYEKRIYLLECKTGNGQTYRGTTAETKSGVTCQKWSATSPHVPKFSPEKFPLAGLEENYCRNPDNDENGPWCYTTDPDKRYDYCDIPECEDKCMHCSGENYEGKIAKTMSGRDCQAWDSQSPHAHGYIPSKFPNKNLKMNYCRNPDGEPRPWCFTTDPQKRWEFCDIPRCTTPPPSSGPKYQCLKGTGKNYGGTVAVTESGHTCQRWSEQTPHKHNRTPENFPCKNLEENYCRNPNGEKAPWCYTTNSEVRWEYCTIPSCESSPLSTERMDVPVPPEQTPVPQDCYHGNGQSYRGTSSTTITGRKCQSWSSMTPHRHLKTPENYPNAGLTMNYCRNPDADKSPWCYTTDPRVRWEFCNLKKCSETPEQVPAAPQAPGVENPPEADCMIGTGKSYRGKKATTVAGVPCQEWAAQEPHQHSIFTPETNPQSGLERNYCRNPDGDVNGPWCYTMNPRKPFDYCDVPQCESSFDCGKPKVEPKKCSGR</sequence>    <sequence format="FASTA">&gt;Fibrinolysin light chainIVGGCVSKPHSWPWQVSLRRSSRHFCGGTLISPKWVLTAAHCLDNILALSFYKVILGAHNEKVREQSVQEIPVSRLFREPSQADIALLKLSRPAIITKEVIPACLPPPNYMVAARTECYITGWGETQGTFGEGLLKEAHLPVIENKVCNRNEYLDGRVKPTELCAGHLIGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSPYVPWIEETMRRN
DM9Q8SO	DE	Wound healing

DMFP6MV	ID	DMFP6MV
DMFP6MV	DN	Fidaxomicin
DMFP6MV	HS	Approved
DMFP6MV	SN	Dificid (TN)
DMFP6MV	CP	Astellas
DMFP6MV	DT	Small molecular drug
DMFP6MV	PC	10034073
DMFP6MV	MW	1058
DMFP6MV	FM	C52H74Cl2O18
DMFP6MV	IC	InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1
DMFP6MV	CS	CC[C@H]1/C=C(/[C@H](C/C=C/C=C(/C(=O)O[C@@H](C/C=C(/C=C(/[C@@H]1O[C@H]2[C@H]([C@H]([C@@H](C(O2)(C)C)OC(=O)C(C)C)O)O)\\C)\\C)[C@@H](C)O)\\CO[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)\\C
DMFP6MV	IK	ZVGNESXIJDCBKN-UUEYKCAUSA-N
DMFP6MV	IU	[(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate
DMFP6MV	CA	CAS 873857-62-6
DMFP6MV	DE	Clostridium difficile associated diarrhea

DMZEONG	ID	DMZEONG
DMZEONG	DN	Finafloxacin
DMZEONG	HS	Approved
DMZEONG	SN	Finafloxacin hydrochloride; Antibacterial (Helicobacter pylori infection/ bacterial urinary tract infection), Combinature; Finafloxacin (iv, bacterial infection), MerLion/Alcon; Finafloxacin (oral, bacterial infection), MerLion/Alcon
DMZEONG	CP	Alcon
DMZEONG	DT	Small molecular drug
DMZEONG	PC	11567473
DMZEONG	MW	398.4
DMZEONG	FM	C20H19FN4O4
DMZEONG	IC	InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1
DMZEONG	CS	C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O
DMZEONG	IK	FYMHQCNFKNMJAV-HOTGVXAUSA-N
DMZEONG	IU	7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMZEONG	CA	CAS 209342-40-5
DMZEONG	CB	CHEBI:85176
DMZEONG	DE	Urinary tract infection

DMWV3TZ	ID	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	HS	Approved
DMWV3TZ	SN	Andozac; Eucoprost; FIT; Finasterida; Finasteridum; Finastid; Finpecia; Propecia; Propeshia; Proscar; Prostide; Cahill May Roberts Brand of Finasteride; Chibro Proscar; Frosst Iberica Brand of Finasteride; Lipha Brand of Finasteride; MSD Brand of Finasteride; MSD Chibropharm Brand of Finasteride; MK 0906; MK 906; MK906; Merck Brand 1 of Finasteride; Merck Brand 2 of Finasteride; Merck Frosst Brand 1 of Finasteride; Merck Frosst Brand 2 of Finasteride; Alternova (TN); Appecia (TN); Chibro-Proscar; Finalo (TN); Finara (TN); Finast (TN); Finasterid (TN); Finasterid IVAX (TN); Finasterida [INN-Spanish]; Finasteridum [INN-Latin]; Finax (TN); Fincar (TN); Finpecia (TN); Gefina (TN); KS-1058; MK-0906; MK-906; Merck Sharp & Dhome Brand 2 of Finasteride; Merck Sharp & Dohme Brand 1 of Finasteride; Propecia (TN); Proscar (TN); Prosteride (TN); YM-152; Finasteride (USP/INN); Finasteride [USAN:INN:BAN]; L-652,931; Proscar, Propecia, Finasteride; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
DMWV3TZ	CP	Merck
DMWV3TZ	TC	Antihyperplasia Agents
DMWV3TZ	DT	Small molecular drug
DMWV3TZ	PC	57363
DMWV3TZ	MW	372.5
DMWV3TZ	FM	C23H36N2O2
DMWV3TZ	IC	InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
DMWV3TZ	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C
DMWV3TZ	IK	DBEPLOCGEIEOCV-WSBQPABSSA-N
DMWV3TZ	IU	(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
DMWV3TZ	CA	CAS 98319-26-7
DMWV3TZ	CB	CHEBI:5062
DMWV3TZ	DE	Benign prostatic hyperplasia

DM5JVAN	ID	DM5JVAN
DM5JVAN	DN	Fingolimod
DM5JVAN	HS	Approved
DM5JVAN	SN	2-Amino-2-(4-octylphenethyl)propane-1,3-diol
DM5JVAN	CP	Novartis
DM5JVAN	DT	Small molecular drug
DM5JVAN	PC	107970
DM5JVAN	MW	307.5
DM5JVAN	FM	C19H33NO2
DM5JVAN	IC	InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
DM5JVAN	CS	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
DM5JVAN	IK	KKGQTZUTZRNORY-UHFFFAOYSA-N
DM5JVAN	IU	2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
DM5JVAN	CA	CAS 162359-55-9
DM5JVAN	CB	CHEBI:63115
DM5JVAN	DE	Primary progressive multiple sclerosis

DMKV4NL	ID	DMKV4NL
DMKV4NL	DN	Flavoxate
DMKV4NL	HS	Approved
DMKV4NL	SN	Bladuril; Flavossato; Flavoxato; Flavoxatum; Urispas; Flavossato [DCIT]; Flavoxate HCI; Flavoxate HCL; Spasuret hydrochloride; AK 123; Bladderon (TN); Bladuril (TN); DW-61; Flavoxate (INN); Flavoxate [INN:BAN]; Flavoxato [INN-Spanish]; Flavoxatum [INN-Latin]; Urispas (TN); Uritac (TN); Zopyran-8-carboxylate; Beta-piperidinoethyl 3-methylflavone-8-carboxylate; Piperidinoethyl-3-methylflavone-8-carboxylate; 1-Piperidinoethanol, 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylat; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-Piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-ben; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate; 2-piperidinoethyl 3-methylflavone-8-carboxylate; 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester
DMKV4NL	CP	Nippon Shinyaku
DMKV4NL	TC	Parasympatholytics
DMKV4NL	DT	Small molecular drug
DMKV4NL	PC	3354
DMKV4NL	MW	391.5
DMKV4NL	FM	C24H25NO4
DMKV4NL	IC	InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3
DMKV4NL	CS	CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4
DMKV4NL	IK	SPIUTQOUKAMGCX-UHFFFAOYSA-N
DMKV4NL	IU	2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
DMKV4NL	CA	CAS 15301-69-6
DMKV4NL	CB	CHEBI:5088
DMKV4NL	DE	Suprapubic pain; Nocturia; Urgency; Dysuria

DMSQDLE	ID	DMSQDLE
DMSQDLE	DN	Flecainide
DMSQDLE	HS	Approved
DMSQDLE	SN	flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide;  Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide
DMSQDLE	CP	3M pharmaceuticals
DMSQDLE	TC	Antiarrhythmic Agents
DMSQDLE	DT	Small molecular drug
DMSQDLE	PC	3356
DMSQDLE	MW	414.34
DMSQDLE	FM	C17H20F6N2O3
DMSQDLE	IC	InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
DMSQDLE	CS	C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F
DMSQDLE	IK	DJBNUMBKLMJRSA-UHFFFAOYSA-N
DMSQDLE	IU	N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
DMSQDLE	CA	CAS 54143-55-4
DMSQDLE	CB	CHEBI:75984
DMSQDLE	DE	Tachyarrhythmias; Atrial fibrillation; Paroxysmal atrial fibrillation

DMXGQYZ	ID	DMXGQYZ
DMXGQYZ	DN	Fleroxacin
DMXGQYZ	HS	Approved
DMXGQYZ	SN	FLRX; Fleroxacine; Fleroxacino; Fleroxacinum; Fleroxicin; Megalocin; Megalone; Megalosin; Quinodis; Fleroxacine [French]; Fleroxacino [Spanish]; Fleroxacinum [Latin]; AM 833; F0646; AM-833; Megalocin (TN); Megalone (TN); Quinodis (TN); Ro 23-6240; Ro-236240; Ro 23-6240/000; Fleroxacin (JAN/USAN/INN); Fleroxacin [USAN:BAN:INN:JAN]; Ro-23-6240/000; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMXGQYZ	TC	Antiinfective Agents
DMXGQYZ	DT	Small molecular drug
DMXGQYZ	PC	3357
DMXGQYZ	MW	369.34
DMXGQYZ	FM	C17H18F3N3O3
DMXGQYZ	IC	InChI=1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)
DMXGQYZ	CS	CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F
DMXGQYZ	IK	XBJBPGROQZJDOJ-UHFFFAOYSA-N
DMXGQYZ	IU	6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMXGQYZ	CA	CAS 79660-72-3
DMXGQYZ	CB	CHEBI:31810
DMXGQYZ	DE	Bacterial infection

DM70DTN	ID	DM70DTN
DM70DTN	DN	Flibanserin
DM70DTN	HS	Approved
DM70DTN	SN	Flibanserin [USAN]; Bimt 17; Bimt-17; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
DM70DTN	CP	Boehringer Ingelheim
DM70DTN	DT	Small molecular drug
DM70DTN	PC	6918248
DM70DTN	MW	390.4
DM70DTN	FM	C20H21F3N4O
DM70DTN	IC	InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
DM70DTN	CS	C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F
DM70DTN	IK	PPRRDFIXUUSXRA-UHFFFAOYSA-N
DM70DTN	IU	3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
DM70DTN	CA	CAS 167933-07-5
DM70DTN	CB	CHEBI:90865
DM70DTN	DE	Mood disorder; Female sexual arousal dysfunction

DMJ8A3Z	ID	DMJ8A3Z
DMJ8A3Z	DN	Florbetapir F-18
DMJ8A3Z	HS	Approved
DMJ8A3Z	SN	Amyvid (TN)
DMJ8A3Z	CP	Avid Radiopharmaceuticals
DMJ8A3Z	DT	Small molecular drug
DMJ8A3Z	PC	24822371
DMJ8A3Z	MW	359.4
DMJ8A3Z	FM	C20H25FN2O3
DMJ8A3Z	IC	InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1
DMJ8A3Z	CS	CNC1=CC=C(C=C1)/C=C/C2=CN=C(C=C2)OCCOCCOCC[18F]
DMJ8A3Z	IK	YNDIAUKFXKEXSV-CRYLGTRXSA-N
DMJ8A3Z	IU	4-[(E)-2-[6-[2-[2-(2-(18F)fluoranylethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-N-methylaniline
DMJ8A3Z	CA	CAS 956103-76-7
DMJ8A3Z	CB	CHEBI:66880
DMJ8A3Z	DE	Diagnostic imaging

DM04LR2	ID	DM04LR2
DM04LR2	DN	Floxuridine
DM04LR2	HS	Approved
DM04LR2	SN	floxuridine; 50-91-9; 2'-Deoxy-5-fluorouridine; 5-Fluorodeoxyuridine; Fluorodeoxyuridine; Floxuridin; FUDR; Fluoruridine deoxyribose; Deoxyfluorouridine; 5-Fluoro-2'-deoxyuridine; FdUrd; Floxuridinum; Floxiridina; 5FdU; 5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione; 5-Fluoro-2-desoxyuridine; 5 Fluorodeoxyuridine; Floxuridinum [INN-Latin]; FDUR; Floxiridina [INN-Spanish]; beta-5-Fluoro-2'-deoxyuridine; 5-Fluoro-2-deoxyuridine; 5-FdUrd; 5-Fluorouracil deoxyriboside;  Sterile fudr (TN); Floxuridine/5-fluorouracil
DM04LR2	CP	Heidelberger
DM04LR2	DT	Small molecular drug
DM04LR2	PC	5790
DM04LR2	MW	246.19
DM04LR2	FM	C9H11FN2O5
DM04LR2	IC	InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DM04LR2	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O
DM04LR2	IK	ODKNJVUHOIMIIZ-RRKCRQDMSA-N
DM04LR2	IU	5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DM04LR2	CA	CAS 50-91-9
DM04LR2	CB	CHEBI:60761
DM04LR2	DE	Solid tumour/cancer; Colorectal cancer

DMNUWST	ID	DMNUWST
DMNUWST	DN	Flucloxacillin
DMNUWST	HS	Approved
DMNUWST	SN	FLOXACILLIN; Floxapen; Fluclox; Flucloxacilina; Flucloxacilline; Flucloxacillinum; Fluorochloroxacillin; MFIPC; Floxacillin [USAN]; Flucloxacillin sodium; BRL 2039; Flopen (TN); Floxacillin (USAN); Floxapen (TN); Flucloxacilina [INN-Spanish]; Flucloxacillin (INN); Flucloxacillin-Sodium; Flucloxacilline [INN-French]; Flucloxacillinum [INN-Latin]; Rel-(2R,6S)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylato; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S(2alpha,5alpha,6beta)); 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMNUWST	CP	GlaxoSmithKline
DMNUWST	TC	Antibiotics
DMNUWST	DT	Small molecular drug
DMNUWST	PC	21319
DMNUWST	MW	453.9
DMNUWST	FM	C19H17ClFN3O5S
DMNUWST	IC	InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
DMNUWST	CS	CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMNUWST	IK	UIOFUWFRIANQPC-JKIFEVAISA-N
DMNUWST	IU	(2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMNUWST	CA	CAS 5250-39-5
DMNUWST	CB	CHEBI:5098
DMNUWST	DE	Bacterial infection

DMOWZ6B	ID	DMOWZ6B
DMOWZ6B	DN	Fluconazole
DMOWZ6B	HS	Approved
DMOWZ6B	SN	Afungil; Alflucoz; Baten; Beagyne; Biocanol; Biozolene; Canzol; Cryptal; Diflazon; Diflucan; Dimycon; Elazor; FCZ; FLCZ; Flucazol; FlucoLich; Flucobeta; Fluconazol; Fluconazolum; Flucostat; Flukezol; Flunazul; Flunizol; Fluzone; Forcan; Fuconal; Fungata; Lavisa; Loitin; Mutum; Neofomiral; Oxifugol; Oxifungol; Pritenzol; Solacap; Syscan; TPF; Triflucan; Zemyc; Zoltec; Zonal; AbZ Brand of Fluconazole; Aliud Brand of Fluconazole; Alpharma Brand of Fluconazole; Apo Fluconazole; Apotex Brand of Fluconazole; Armstrong Brand of Fluconazole; Betapharm Brand of Fluconazole; Chemia Brand of Fluconazole; Ct Arzneimittel Brand of Fluconazole; Effik Brand of Fluconazole; Fluc Hexal; Fluconazol AL; Fluconazol AbZ; Fluconazol Isis; Fluconazol Stada; Fluconazol [Spanish]; Fluconazol ratiopharm; Fluconazol von ct; Fluconazolum [Latin]; Hexal Brand of Fluconazole; Lesvi Brand of Fluconazole; Lichtenstein Brand of Fluconazole; Mack Brand of Fluconazole; Pfizer Brand of Fluconazole; Pfleger Brand of Fluconazole; Ratiopharm Brand of Fluconazole; SAT Brand of Fluconazole; Silanes Brand of Fluconazole; Stada Brand of Fluconazole; Vita Brand of Fluconazole; F0677; Fluconazole in combination with MGCD290; UK 49858; UK49858; Alfumet (TN); Apo-Fluconazole; Ct-Arzneimittel Brand of Fluconazole; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; DRG-0005; Diflucan (TN); Fluconazol-Isis; Fluconazol-ratiopharm; Fluconazole & Bovine Lactoferrin; Fluconazole & Human recombinant granulocyte colony stimulating factor; Fluconazole & hGCSF; Fluconazole in dextrose 5% in plastic container; Flucytosine & Nyotran; GL663142 & Fluconazole; KS-1059; Trican (TN); UK-49858; DIFLUCAN IN SODIUM CHLORIDE 0.9%; DIFLUCAN IN SODIUM CHLORIDE 0.9%IN PLASTIC CONTAINER; Fluconazole in sodium chloride 0.9%; Fluconazole in sodium chloride 0.9% in plastic container; Flucytosine & Nyotran(Liposomal Nystatin); XMP.284 & Fluconazole; XMP.366 & Fluconazole; XMP.391 & Fluconazole; Diflucan, Trican, Alfumet, Fluconazole; Fluconazole & MC-510,011; Fluconazole (JAN/USAN/INN); Fluconazole [USAN:INN:BAN:JAN]; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
DMOWZ6B	CP	Pfizer
DMOWZ6B	TC	Antifungal Agents
DMOWZ6B	DT	Small molecular drug
DMOWZ6B	PC	3365
DMOWZ6B	MW	306.27
DMOWZ6B	FM	C13H12F2N6O
DMOWZ6B	IC	InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
DMOWZ6B	CS	C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O
DMOWZ6B	IK	RFHAOTPXVQNOHP-UHFFFAOYSA-N
DMOWZ6B	IU	2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
DMOWZ6B	CA	CAS 86386-73-4
DMOWZ6B	CB	CHEBI:46081
DMOWZ6B	DE	Fungal infection

DM13VTW	ID	DM13VTW
DM13VTW	DN	Flucytosine
DM13VTW	HS	Approved
DM13VTW	SN	Alcobon; Ancobon; Ancotil; Ancotyl; Flucitosina; Flucystine; Flucytosin; Flucytosinum; Flucytosone; Fluocytosine; Fluorcytosine; Fluorocytosine; Flucitosina [DCIT]; F0321; LT00771985; Ancobon (TN); Flucytosinum [INN-Latin]; GL663142 & 5FC; Ro 2-9915; Ro 29915 E/265601; Ro-2-9915; Flucytosine (JP15/USP/INN); Flucytosine [USAN:INN:BAN:JAN]; Cytosine, 5-fluoro-(6CI,7CI,8CI); GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-); 2-Hydroxy-4-amino-5-fluoropyrimidine; 4-Amino-5-fluoro-2(1H)-pyrimidinone; 4-Amino-5-fluoro-2-hydroxypyrimidine; 4-Amino-5-fluoro-2-hyroxypyrimidine; 4-Amino-5-fluoropyrimidin-2(1H)-one; 5-FC; 5-Flucytosine; 5-Fluorocystosine; 5-Fluorocytosin; 5-Fluorocytosine; 5-Fluorocytosine-6-3H; 5-Flurocytosine; 5-fluoro cytosine; 5987P; 6-Amino-2-oxo-5-fluoropyrimidine; 6-amino-5-fluoro-1H-pyrimidin-2-one; 9074P
DM13VTW	TC	Antifungal Agents
DM13VTW	DT	Small molecular drug
DM13VTW	PC	3366
DM13VTW	MW	129.09
DM13VTW	FM	C4H4FN3O
DM13VTW	IC	InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
DM13VTW	CS	C1=NC(=O)NC(=C1F)N
DM13VTW	IK	XRECTZIEBJDKEO-UHFFFAOYSA-N
DM13VTW	IU	6-amino-5-fluoro-1H-pyrimidin-2-one
DM13VTW	CA	CAS 2022-85-7
DM13VTW	CB	CHEBI:5100
DM13VTW	DE	Endocarditis

DMVRLT7	ID	DMVRLT7
DMVRLT7	DN	Fludarabine
DMVRLT7	HS	Approved
DMVRLT7	SN	FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)
DMVRLT7	CP	Genzyme Corp
DMVRLT7	TC	Anticancer Agents
DMVRLT7	DT	Small molecular drug
DMVRLT7	PC	657237
DMVRLT7	MW	285.23
DMVRLT7	FM	C10H12FN5O4
DMVRLT7	IC	InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1
DMVRLT7	CS	C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N
DMVRLT7	IK	HBUBKKRHXORPQB-FJFJXFQQSA-N
DMVRLT7	IU	(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMVRLT7	CA	CAS 21679-14-1
DMVRLT7	CB	CHEBI:94701
DMVRLT7	DE	Haematological malignancy

DMD2K4I	ID	DMD2K4I
DMD2K4I	DN	Fludiazepam
DMD2K4I	HS	Approved
DMD2K4I	SN	Erispan; Fludiazepamum; ID 540; Erispan (TN); Fludiazepam [INN:JAN]; Fludiazepamum [INN-Latin]; ID-540; Fludiazepam (JP15/INN); 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-(9CI); 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMD2K4I	CP	Dainippon Sumitomo Pharma
DMD2K4I	TC	Antianxiety Agents
DMD2K4I	DT	Small molecular drug
DMD2K4I	PC	3369
DMD2K4I	MW	302.73
DMD2K4I	FM	C16H12ClFN2O
DMD2K4I	IC	InChI=1S/C16H12ClFN2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3
DMD2K4I	CS	CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
DMD2K4I	IK	ROYOYTLGDLIGBX-UHFFFAOYSA-N
DMD2K4I	IU	7-chloro-5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMD2K4I	CA	CAS 3900-31-0
DMD2K4I	CB	CHEBI:31618
DMD2K4I	DE	Anxiety disorder

DMUDIR8	ID	DMUDIR8
DMUDIR8	DN	Fludrocortisone
DMUDIR8	HS	Approved
DMUDIR8	SN	fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF;  Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone
DMUDIR8	TC	Antiinflammatory Agents
DMUDIR8	DT	Small molecular drug
DMUDIR8	PC	31378
DMUDIR8	MW	380.4
DMUDIR8	FM	C21H29FO5
DMUDIR8	IC	InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
DMUDIR8	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O)F
DMUDIR8	IK	AAXVEMMRQDVLJB-BULBTXNYSA-N
DMUDIR8	IU	(8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMUDIR8	CA	CAS 127-31-1
DMUDIR8	CB	CHEBI:50885
DMUDIR8	DE	Cerebral salt-wasting syndrome

DMC8VNH	ID	DMC8VNH
DMC8VNH	DN	Flufenamic Acid
DMC8VNH	HS	Approved
DMC8VNH	SN	flufenamic acid; 530-78-9; Fluphenamic acid; Nichisedan; Achless; Arlef; Tecramine; Paraflu; Lanceat; Flufacid; Plostene; Fullsafe; Parlef; Surika; Parlif; Flufenaminsaeure; Reumajust A; Acido flufenamico; N-(3-Trifluoromethylphenyl)anthranilic acid; Ristogen; Sastridex; Meralen; Ansatin; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; Fluore-200; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; ANT-1; Acide flufenamique; Acidum flufenamicum; TVX 916; INF 1837; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; NSC-82699; CI 440
DMC8VNH	DT	Small molecular drug
DMC8VNH	PC	3371
DMC8VNH	MW	281.23
DMC8VNH	FM	C14H10F3NO2
DMC8VNH	IC	InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)
DMC8VNH	CS	C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F
DMC8VNH	IK	LPEPZBJOKDYZAD-UHFFFAOYSA-N
DMC8VNH	IU	2-[3-(trifluoromethyl)anilino]benzoic acid
DMC8VNH	CA	CAS 530-78-9
DMC8VNH	CB	CHEBI:42638
DMC8VNH	DE	Dysmenorrhea

DMPCG2L	ID	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	HS	Approved
DMPCG2L	SN	flumazenil; 78755-81-4; Anexate; Flumazepil; Romazicon; Lanexat; Mazicon; Ro 15-1788; Flumazenilum; Flumazenilo; Flumazenilum [Latin]; Flumazenilo [Spanish]; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate; [11C]flumazenil; Ro 151788; Flumazenil (Ro 15-1788); Ro-15-1788; UNII-40P7XK9392; C15H14FN3O3; CHEMBL407; Ro15-1788; BRN 4763661; MLS000028850; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; CHEBI:5103; OFBIFZUFASYYRE-UHFFFAOYSA-N;  FlumUP TD; Flumazenil (transdermal patch formulation); Flumazenil (transdermal patch formulation), Coeruleus
DMPCG2L	CP	Coeruleus Ltd
DMPCG2L	DT	Small molecular drug
DMPCG2L	PC	3373
DMPCG2L	MW	303.29
DMPCG2L	FM	C15H14FN3O3
DMPCG2L	IC	InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3
DMPCG2L	CS	CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C
DMPCG2L	IK	OFBIFZUFASYYRE-UHFFFAOYSA-N
DMPCG2L	IU	ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMPCG2L	CA	CAS 78755-81-4
DMPCG2L	CB	CHEBI:5103
DMPCG2L	DE	Benzodiazepine overdose

DMUNG4A	ID	DMUNG4A
DMUNG4A	DN	Flumethasone
DMUNG4A	HS	Approved
DMUNG4A	SN	Flucorticin; Flumetasona; Flumetasona [INN-Spanish]; Flumetasone; Flumetasone [INN]; Flumetasonum; Flumetasonum [INN-Latin]; Flumethason; Flumethasonum; Fluvet; LR3CD8SX89; Methagon; RS 2177; RS-2177; U-10974; flumethasone; 2135-17-3; Anaprime; Aniprime; Cortexilar; Flucort (Veterinary); 6-alpha-Fluorodexamethasone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 6alpha,9alpha-Difluoro-16alpha-methylprednisolone; 6alpha-Fluorodexamethasone; CHEBI:34764; MLS000028618; NSC 54702; UNII-LR3CD8SX89
DMUNG4A	PC	16490
DMUNG4A	MW	410.5
DMUNG4A	FM	C22H28F2O5
DMUNG4A	IC	WXURHACBFYSXBI-GQKYHHCASA-N
DMUNG4A	CS	CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C)F
DMUNG4A	IK	1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
DMUNG4A	IU	(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMUNG4A	CA	CAS 2135-17-3
DMUNG4A	CB	CHEBI:34764
DMUNG4A	DE	Atopic dermatitis

DMU0YP6	ID	DMU0YP6
DMU0YP6	DN	Flumethasone Pivalate
DMU0YP6	HS	Approved
DMU0YP6	SN	Locacorten; Locorten; Lorinden; Flumetasone pivalate; Flumethasone pivalate (USP); KS-1138; Locorten (TN); Flumetasone pivalate (JAN/BAN); Lpha.-methylpregna-1,4-diene-3,20-dione 21-pivalate; [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate; 6,9-Difluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl pivalate; 6.Alpha.,9-Difluoro-11.beta.,17,21-trihydroxy-16.a; 6.Alpha.,9.alpha.-Difluoro-16.alpha.-methylprednisolone 21-pivalate; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-(2,2-dimethylpropionate); 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate
DMU0YP6	TC	Antiinflammatory Agents
DMU0YP6	DT	Small molecular drug
DMU0YP6	PC	443980
DMU0YP6	MW	494.6
DMU0YP6	FM	C27H36F2O6
DMU0YP6	IC	InChI=1S/C27H36F2O6/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-24(18,5)26(17,29)20(31)12-25(16,6)27(14,34)21(32)13-35-22(33)23(2,3)4/h7-8,10,14,16-17,19-20,31,34H,9,11-13H2,1-6H3/t14-,16+,17+,19+,20+,24+,25+,26+,27+/m1/s1
DMU0YP6	CS	C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F
DMU0YP6	IK	JWRMHDSINXPDHB-OJAGFMMFSA-N
DMU0YP6	IU	[2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
DMU0YP6	CA	CAS 2002-29-1
DMU0YP6	CB	CHEBI:31620
DMU0YP6	DE	Contact dermatitis

DMZU5JP	ID	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	HS	Approved
DMZU5JP	SN	Flufenal; Flunarizin; Flunarizina; Flunarizinum; Fluvert; Issium; Sibelium; Vertix; Zinasen; Apo-flunarizine capsules; Flunarizina [INN-Spanish]; Flunarizine (INN); Flunarizine [INN:BAN]; Flunarizinum [INN-Latin]; Novo-Flunarizine; R-14950; Sibelium (TN); (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-en-1-yl)piperazine; 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine
DMZU5JP	CP	Janssen Pharmaceutica
DMZU5JP	TC	Anticonvulsants
DMZU5JP	DT	Small molecular drug
DMZU5JP	PC	941361
DMZU5JP	MW	404.5
DMZU5JP	FM	C26H26F2N2
DMZU5JP	IC	InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
DMZU5JP	CS	C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMZU5JP	IK	SMANXXCATUTDDT-QPJJXVBHSA-N
DMZU5JP	IU	1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine
DMZU5JP	CA	CAS 52468-60-7
DMZU5JP	CB	CHEBI:92209
DMZU5JP	DE	Migraine

DMZSWQC	ID	DMZSWQC
DMZSWQC	DN	Flunisolide
DMZSWQC	HS	Approved
DMZSWQC	SN	Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione
DMZSWQC	TC	Antiasthmatic Agents
DMZSWQC	DT	Small molecular drug
DMZSWQC	PC	82153
DMZSWQC	MW	434.5
DMZSWQC	FM	C24H31FO6
DMZSWQC	IC	InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMZSWQC	CS	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O
DMZSWQC	IK	XSFJVAJPIHIPKU-XWCQMRHXSA-N
DMZSWQC	IU	(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMZSWQC	CA	CAS 3385-03-3
DMZSWQC	CB	CHEBI:5106
DMZSWQC	DE	Allergic rhinitis

DMGR5Z3	ID	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	HS	Approved
DMGR5Z3	SN	Flunibeta; Flunimerck; Fluninoc; Flunitrazepamum; Fluridrazepam; Narcozep; Primun; Rohipnol; Rohypnol; Roipnol; Betapharm Brand of Flunitrazepam; Ct Arzneimittel Brand of Flunitrazepam; Flunitrazepam Teva; Flunitrazepam neuraxpharm; Flunitrazepam ratiopharm; Flunizep von ct; Hexal Brand of Flunitrazepam; Merck dura Brand ofFlunitrazepam; Neuraxpharm Brand of Flunitrazepam; Ratiopharm Brand of Flunitrazepam; Roche Brand of Flunitrazepam; Teva Brand of Flunitrazepam; Fluni 1A Pharma; RO54200; [3H]flunitrazepam; Ct-Arzneimittel Brand of Flunitrazepam; Darkene (TN); Flunipam (TN); Flunitrazepam-Teva; Flunitrazepam-neuraxpharm; Flunitrazepam-ratiopharm; Flunitrazepamum [INN-Latin]; Hipnosedon (TN); Hypnodorm (TN); Ilman(TN); Insom (TN); Nilium (TN); Ro 5-4200; Rohypnol (TN); Rufinol (TN); Silece (TN); Vulbegal (TN); RO-5-4200; Flunitrazepam (JP15/USAN/INN); Flunitrazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; 1-Methyl-7-nitro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2(1H)-one; 1A Brand of Flunitrazepam; 5-(2-Fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one; 5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one
DMGR5Z3	CP	Roche Laboratories Inc
DMGR5Z3	TC	Hypnotics and Sedatives
DMGR5Z3	DT	Small molecular drug
DMGR5Z3	PC	3380
DMGR5Z3	MW	313.28
DMGR5Z3	FM	C16H12FN3O3
DMGR5Z3	IC	InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3
DMGR5Z3	CS	CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3F
DMGR5Z3	IK	PPTYJKAXVCCBDU-UHFFFAOYSA-N
DMGR5Z3	IU	5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one
DMGR5Z3	CA	CAS 1622-62-4
DMGR5Z3	CB	CHEBI:31622
DMGR5Z3	DE	Insomnia

DMG2KI4	ID	DMG2KI4
DMG2KI4	DN	Fluocinolone acetonide
DMG2KI4	HS	Approved
DMG2KI4	SN	Coriphate; Cortiplastol; Dermalar; Flucinar; Flucinolone; Flucort; Fluocet; Fluocinolonacetonidum; Fluonid; Fluotrex; Fluovitif; Flupollon; Jellin; Localyn; Medidur; Omniderm; Percutina; Prodermin; Radiocin; Retisert; Sinalar; Synalar; Synamol; Synandone; Synandrone; Synemol; Synotic; Synsac; Tefunote;Acetonida de fluocinolona; Acetonide de fluocinolone; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; Fluortriamcinolone Acetonide; Fs Shampoo; Localyn Syntex; F0657; RS 1401AT; Acetonida de fluocinolona [INN-Spanish]; Acetonide de fluocinolone [INN-French]; Component of Neo-Synalar; Dermatin (steroid); Fluocet (TN); Fluocinoloni acetonidum [INN-Latin]; Neo-Synalar; RS-1401 AT; Retisert (TN); Synalar (TN); Synalar-HP; Derma-smoothe/fs; Flucort-N (TN); Fluocinolone 16,17-acetonide; Fluocinolone acetonide [USAN:INN:JAN]; Ydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; 6.Alpha.,9-Difluoro; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; 6alpha-Fluorotriamcinolone acetonide
DMG2KI4	TC	Antiinflammatory Agents
DMG2KI4	DT	Small molecular drug
DMG2KI4	PC	6215
DMG2KI4	MW	452.5
DMG2KI4	FM	C24H30F2O6
DMG2KI4	IC	InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
DMG2KI4	CS	C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O
DMG2KI4	IK	FEBLZLNTKCEFIT-VSXGLTOVSA-N
DMG2KI4	IU	(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMG2KI4	CA	CAS 67-73-2
DMG2KI4	CB	CHEBI:31623
DMG2KI4	DE	Inflammation

DM65KL8	ID	DM65KL8
DM65KL8	DN	Fluocinonide
DM65KL8	HS	Approved
DM65KL8	SN	Bestasone; Biscosal; Cortalar; Fluocinolide; Fluocinonido; Fluocinonidum; Fluonex; Fluzon; Lidex; Lonide; Lyderm;Metosyn; Straderm; Topsymin; Topsyn; Vanos; Fluocinolide acetate; Fluocinolone acetonide acetate; Fluocinonide Emulsified Base; Fluocinonide FAPG; Lidex E; Synalar acetate; Fluocinolone acetonide 21-acetate; Fluocinonido [INN-Spanish]; Fluocinonidum [INN-Latin]; Fluonex (TN); LIDEX (TN); LIDEX-E; Lidex (TN); Lonide (TN); Lyderm (TN); Vanos (TN); Lidex-E (TN); Fluocinonide (JP15/USP/INN); Fluocinonide [USAN:BAN:INN:JAN]; Fluocinonide [USAN:INN:BAN:JAN]; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate (8CI); Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate
DM65KL8	CP	Taro Pharmaceuticals Inc
DM65KL8	TC	Antiinflammatory Agents
DM65KL8	DT	Small molecular drug
DM65KL8	PC	9642
DM65KL8	MW	494.5
DM65KL8	FM	C26H32F2O7
DM65KL8	IC	InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
DM65KL8	CS	CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C
DM65KL8	IK	WJOHZNCJWYWUJD-IUGZLZTKSA-N
DM65KL8	IU	[2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] acetate
DM65KL8	CA	CAS 356-12-7
DM65KL8	CB	CHEBI:5109
DM65KL8	DE	Inflammation

DMQTFAO	ID	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	HS	Approved
DMQTFAO	SN	Ful-Glo; Fluoreseptic; 41935-48-2; NSC5070
DMQTFAO	DT	Small molecular drug
DMQTFAO	PC	16850
DMQTFAO	MW	332.3
DMQTFAO	FM	C20H12O5
DMQTFAO	IC	InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H
DMQTFAO	CS	C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O
DMQTFAO	IK	GNBHRKFJIUUOQI-UHFFFAOYSA-N
DMQTFAO	IU	3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
DMQTFAO	CA	CAS 2321-07-5
DMQTFAO	CB	CHEBI:31624
DMQTFAO	DE	Ocular disease

DM2HKC4	ID	DM2HKC4
DM2HKC4	DN	Fluorometholone
DM2HKC4	HS	Approved
DM2HKC4	SN	Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Fml (TN); Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
DM2HKC4	CP	Alcon Laboratories
DM2HKC4	TC	Antiallergic Agents
DM2HKC4	DT	Small molecular drug
DM2HKC4	PC	9878
DM2HKC4	MW	376.5
DM2HKC4	FM	C22H29FO4
DM2HKC4	IC	InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
DM2HKC4	CS	C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O
DM2HKC4	IK	FAOZLTXFLGPHNG-KNAQIMQKSA-N
DM2HKC4	IU	(6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DM2HKC4	CA	CAS 426-13-1
DM2HKC4	CB	CHEBI:31625
DM2HKC4	DE	Chronic obstructive pulmonary disease

DMUM7HZ	ID	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	HS	Approved
DMUM7HZ	SN	5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-;  Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU
DMUM7HZ	CP	Hoffmann-La Roche pharmaceutical company
DMUM7HZ	TC	Immunosuppressive Agents
DMUM7HZ	DT	Small molecular drug
DMUM7HZ	PC	3385
DMUM7HZ	MW	130.08
DMUM7HZ	FM	C4H3FN2O2
DMUM7HZ	IC	InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
DMUM7HZ	CS	C1=C(C(=O)NC(=O)N1)F
DMUM7HZ	IK	GHASVSINZRGABV-UHFFFAOYSA-N
DMUM7HZ	IU	5-fluoro-1H-pyrimidine-2,4-dione
DMUM7HZ	CA	CAS 51-21-8
DMUM7HZ	CB	CHEBI:46345
DMUM7HZ	DE	Solid tumour/cancer; Tumour; Colorectal cancer

DM3PD2C	ID	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	HS	Approved
DM3PD2C	SN	Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetinum; Fluval; Fontex; Portal; Pulvules; Reconcile; Reneuron; Fluoxetina [Spanish]; Fluoxetine Hcl; Prozac Weekly; Animex-On; Fluoxetina [INN-Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetinum [INN-Latin]; Lilly-110140; Prozac (TN); Fluoxetine (USAN/INN); Fluoxetine [USAN:INN:BAN]; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
DM3PD2C	CP	Eli Lilly
DM3PD2C	TC	Antidepressants
DM3PD2C	DT	Small molecular drug
DM3PD2C	PC	3386
DM3PD2C	MW	309.33
DM3PD2C	FM	C17H18F3NO
DM3PD2C	IC	InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
DM3PD2C	CS	CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
DM3PD2C	IK	RTHCYVBBDHJXIQ-UHFFFAOYSA-N
DM3PD2C	IU	N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
DM3PD2C	CA	CAS 54910-89-3
DM3PD2C	CB	CHEBI:86990
DM3PD2C	DE	Depression

DMUHCF1	ID	DMUHCF1
DMUHCF1	DN	Fluoxymesterone
DMUHCF1	HS	Approved
DMUHCF1	SN	Androfluorene; Androfluorone; Androsterolo; Fluossimesterone; Fluosterone; Fluotestin; Fluoximesteron; Fluoximesterona; Fluoximesterone; Fluoximesteronum; Fluoxymesteronum; Fluoxymestrone; Flusteron; Flutestos; Halotestin; Oralsterone; Oratestin; Testoral; Ultandren; Ultandrene; Component of Halodrin; Fluossimesterone [DCIT]; Ora Testryl; U 6040; Anadroid-F; Android-f; Fluoximesterona [INN-Spanish]; Fluoxymesteronum [INN-Latin]; Halotestin (TN); Neo-Ormonal; Ora-Testryl; Fluoxymesterone [INN:BAN:JAN]; Fluoxymesterone (JP15/USP/INN); Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN); Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN) (8CI); (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one;9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta-hydroxy-17alpha-methyltestosterone; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one
DMUHCF1	TC	Anabolic Agents
DMUHCF1	DT	Small molecular drug
DMUHCF1	PC	6446
DMUHCF1	MW	336.4
DMUHCF1	FM	C20H29FO3
DMUHCF1	IC	InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1
DMUHCF1	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@]4(C)O)C)O)F
DMUHCF1	IK	YLRFCQOZQXIBAB-RBZZARIASA-N
DMUHCF1	IU	(8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMUHCF1	CA	CAS 76-43-7
DMUHCF1	CB	CHEBI:5120
DMUHCF1	DE	Breast cancer

DM0DJ9O	ID	DM0DJ9O
DM0DJ9O	DN	Flupentixol
DM0DJ9O	HS	Approved
DM0DJ9O	SN	2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 53772-82-0; ALPHA-FLUPENTHIXOL; EINECS 220-304-9; EINECS 258-756-4; Emergil; FA0UYH6QUO; FLUPENTHIXOL; Fluanxol; Flupenthixole; Flupentixol; Flupentixolum [INN-Latin]; Fluphenthixol; Fluxanxol; LC 44; N 7009; Siplaril; Siplarol; UNII-FA0UYH6QUO; cis-(Z)-Flupenthixol; cis-(Z)-Flupenthixol dihydrochloride; cis-Flupenthixol; cis-Flupentixol; flupentixolum
DM0DJ9O	TC	Antipsychotic Neuroleptic drug
DM0DJ9O	DT	Small molecular drug
DM0DJ9O	PC	5281881
DM0DJ9O	MW	434.521
DM0DJ9O	FM	C23H25F3N2OS
DM0DJ9O	IC	InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
DM0DJ9O	CS	C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DM0DJ9O	IK	NJMYODHXAKYRHW-DVZOWYKESA-N
DM0DJ9O	IU	2-[4-[(3Z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DM0DJ9O	CA	CAS 2709-56-0
DM0DJ9O	CB	CHEBI:10454
DM0DJ9O	DE	Depression; Schizophrenia

DMIT8LX	ID	DMIT8LX
DMIT8LX	DN	Fluphenazine
DMIT8LX	HS	Approved
DMIT8LX	SN	FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334;  Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)
DMIT8LX	CP	Bristol-Myers Squibb
DMIT8LX	TC	Antipsychotic Agents
DMIT8LX	DT	Small molecular drug
DMIT8LX	PC	3372
DMIT8LX	MW	437.5
DMIT8LX	FM	C22H26F3N3OS
DMIT8LX	IC	InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
DMIT8LX	CS	C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DMIT8LX	IK	PLDUPXSUYLZYBN-UHFFFAOYSA-N
DMIT8LX	IU	2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol
DMIT8LX	CA	CAS 69-23-8
DMIT8LX	CB	CHEBI:5123
DMIT8LX	DE	Psychotic disorder

DMZWBKG	ID	DMZWBKG
DMZWBKG	DN	Fluprednisolone
DMZWBKG	HS	Approved
DMZWBKG	SN	Alphadrol
DMZWBKG	CP	Pharmacia And Upjohn Co
DMZWBKG	DT	Small molecular drug
DMZWBKG	PC	5876
DMZWBKG	MW	378.4
DMZWBKG	FM	C21H27FO5
DMZWBKG	IC	InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1
DMZWBKG	CS	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O
DMZWBKG	IK	MYYIMZRZXIQBGI-HVIRSNARSA-N
DMZWBKG	IU	(6S,8S,9S,10R,11S,13S,14S,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMZWBKG	CA	CAS 53-34-9
DMZWBKG	CB	CHEBI:34474
DMZWBKG	DE	Asthma

DMHCI9S	ID	DMHCI9S
DMHCI9S	DN	Flurandrenolide
DMHCI9S	HS	Approved
DMHCI9S	SN	Cordran; Drenison; Drocort; Floudroxycortide; Fludrossicortide; Fludroxicortida; Fludroxicortidum; Fludroxycortide; Fludroxycortidum; Fluorandrenolone; Fluradrenolide; Flurandrenolone; Haelan; Sermaka; CORDRAN SP; Fludrossicortide [DCIT]; Fluorandrenolone acetonide; Flurandrenolide [USAN]; Flurandrenolone acetonide; L 33379; Alondra-F; CORDRAN (TN); Cordran tape (TN); Fludroxicortida [INN-Spanish]; Fludroxycortidum [INN-Latin]; Flurandrenolide (USP); Haldrone-F; Fludroxycortide (JAN/INN); Acetonide of 6alpha-fluoro-16alpha-hydroxyhydrocortisone; Pregn-4-ene-3,20-dione, 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregn-4-ene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxyprogesterone cyclic 16,17-acetal with acetone; 6alpha-Fluoro-16alpha-hydroxyhydrocortisone 16,17-acetonide
DMHCI9S	CP	Watson Laboratories
DMHCI9S	TC	Antiinflammatory Agents
DMHCI9S	DT	Small molecular drug
DMHCI9S	PC	15209
DMHCI9S	MW	436.5
DMHCI9S	FM	C24H33FO6
DMHCI9S	IC	InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMHCI9S	CS	C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F
DMHCI9S	IK	POPFMWWJOGLOIF-XWCQMRHXSA-N
DMHCI9S	IU	(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DMHCI9S	CA	CAS 1524-88-5
DMHCI9S	CB	CHEBI:5127
DMHCI9S	DE	Inflammation

DMAL4G0	ID	DMAL4G0
DMAL4G0	DN	Flurazepam
DMAL4G0	HS	Approved
DMAL4G0	SN	Dalmadorm; Dalmane; Felison; Felmane; Flunox; Flurazepamum; Insumin; Noctosom; Paxane; Somnol; Stauroderm; Valdorm; Flurazepam HCL; Flurazepam hydrochloride; Dalmadorm (TN); Dalmane (TN); Dalmane-R; Flurazepamum [INN-Latin]; Insumin (TN); Flurazepam (JP15/INN); Flurazepam [INN:BAN:JAN]; Ro-5-6901/3; 2H-1,4-Benzodiazepin-2-one,7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
DMAL4G0	CP	West-ward Pharmaceutical Corp
DMAL4G0	TC	Hypnotics and Sedatives
DMAL4G0	DT	Small molecular drug
DMAL4G0	PC	3393
DMAL4G0	MW	387.9
DMAL4G0	FM	C21H23ClFN3O
DMAL4G0	IC	InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
DMAL4G0	CS	CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
DMAL4G0	IK	SAADBVWGJQAEFS-UHFFFAOYSA-N
DMAL4G0	IU	7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
DMAL4G0	CA	CAS 17617-23-1
DMAL4G0	CB	CHEBI:5128
DMAL4G0	DE	Insomnia

DMGN4BY	ID	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	HS	Approved
DMGN4BY	SN	Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid
DMGN4BY	CP	Abbott Laboratories
DMGN4BY	TC	Antiinflammatory Agents
DMGN4BY	DT	Small molecular drug
DMGN4BY	PC	3394
DMGN4BY	MW	244.26
DMGN4BY	FM	C15H13FO2
DMGN4BY	IC	InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
DMGN4BY	CS	CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
DMGN4BY	IK	SYTBZMRGLBWNTM-UHFFFAOYSA-N
DMGN4BY	IU	2-(3-fluoro-4-phenylphenyl)propanoic acid
DMGN4BY	CA	CAS 5104-49-4
DMGN4BY	CB	CHEBI:5130
DMGN4BY	DE	Rheumatoid arthritis

DMFO843	ID	DMFO843
DMFO843	DN	Fluspirilene
DMFO843	HS	Approved
DMFO843	SN	Fluspirilen; Fluspirileno; Fluspirilenum; Imap; Redeptin; Spirodiflamine; R 6218; F-100; Fluspirileno [INN-Spanish]; Fluspirilenum [INN-Latin]; Imap (TN); Spiropiperidine analogue, 1; Fluspirilene (USAN/INN); Fluspirilene [USAN:INN:BAN]; McN-JR-6218; 1-Phenyl-4-oxo-8-(4,4-bis(4-fluorophenyl)butyl)-1,3,8-triazaspiro(4,5)decane; 8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro-(4.5)decan-4-one; 8-[4,4-bis (p-fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4,5]decan-4-one; 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one; 8-[4,4-bis(4-fluorophenyl)butyl]-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one; 8-[4,4-bis(p-Fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4.5]decan-4-one
DMFO843	CP	Janssen Pharmaceutica
DMFO843	TC	Antipsychotic Agents
DMFO843	DT	Small molecular drug
DMFO843	PC	3396
DMFO843	MW	475.6
DMFO843	FM	C29H31F2N3O
DMFO843	IC	InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)
DMFO843	CS	C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
DMFO843	IK	QOYHHIBFXOOADH-UHFFFAOYSA-N
DMFO843	IU	8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DMFO843	CA	CAS 1841-19-6
DMFO843	CB	CHEBI:93369
DMFO843	DE	Schizophrenia

DMK0O7U	ID	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	HS	Approved
DMK0O7U	SN	Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)
DMK0O7U	CP	Schering-Plough Corporation
DMK0O7U	TC	Anticancer Agents
DMK0O7U	DT	Small molecular drug
DMK0O7U	PC	3397
DMK0O7U	MW	276.21
DMK0O7U	FM	C11H11F3N2O3
DMK0O7U	IC	InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
DMK0O7U	CS	CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
DMK0O7U	IK	MKXKFYHWDHIYRV-UHFFFAOYSA-N
DMK0O7U	IU	2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMK0O7U	CA	CAS 13311-84-7
DMK0O7U	CB	CHEBI:5132
DMK0O7U	DE	Prostate cancer

DMGCSVF	ID	DMGCSVF
DMGCSVF	DN	Fluticasone
DMGCSVF	HS	Approved
DMGCSVF	SN	Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
DMGCSVF	CP	Fougera Pharmaceuticals Inc
DMGCSVF	TC	Antiinflammatory Agents
DMGCSVF	DT	Small molecular drug
DMGCSVF	PC	5311101
DMGCSVF	MW	444.5
DMGCSVF	FM	C22H27F3O4S
DMGCSVF	IC	InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
DMGCSVF	CS	C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)O)C)O)F)C)F
DMGCSVF	IK	MGNNYOODZCAHBA-GQKYHHCASA-N
DMGCSVF	IU	S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
DMGCSVF	CA	CAS 90566-53-3
DMGCSVF	CB	CHEBI:5134
DMGCSVF	DE	Allergic rhinitis

DMRWLB2	ID	DMRWLB2
DMRWLB2	DN	Fluticasone propionate
DMRWLB2	HS	Approved
DMRWLB2	SN	FLUTICASONE PROPIONATE; Flovent; Cutivate; Flixotide; Flonase; Flixonase; Flovent HFA; Flunase; Flutide; Fluspiral; Flusonal; atemur; Flutivate; Fluinol; Axotide; Asmatil; Brethal; Flovent Diskus 50; Flixotide Disks; Flixotide Disk; Flovent Diskus; Flovent Diskus 100; Flovent Diskus 250; Flixotide Inhaler; Trialona; Rinosone; Inalacor; Cultivate; Ubizol; Zoflut; Flixonase Nasal Spray; Flonase Aq; Fluticasonpropionat Allen; Fluticasone (propionate); UNII-O2GMZ0LF5W; CCI-18781; CCI 18781; MFCD00866007; O2GMZ0LF5W
DMRWLB2	PC	444036
DMRWLB2	MW	500.6
DMRWLB2	FM	C25H31F3O5S
DMRWLB2	IC	InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
DMRWLB2	CS	CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF
DMRWLB2	IK	WMWTYOKRWGGJOA-CENSZEJFSA-N
DMRWLB2	IU	[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
DMRWLB2	CA	CAS 80474-14-2
DMRWLB2	CB	CHEBI:31441
DMRWLB2	DE	Asthma

DMU54C3	ID	DMU54C3
DMU54C3	DN	Flutropium bromide
DMU54C3	HS	Approved
DMU54C3	SN	Flubron (TN)
DMU54C3	DT	Small molecular drug
DMU54C3	PC	656602
DMU54C3	MW	478.4
DMU54C3	FM	C24H29BrFNO3
DMU54C3	IC	InChI=1S/C24H29FNO3.BrH/c1-26(15-14-25)20-12-13-21(26)17-22(16-20)29-23(27)24(28,18-8-4-2-5-9-18)19-10-6-3-7-11-19;/h2-11,20-22,28H,12-17H2,1H3;1H/q+1;/p-1/t20-,21+,22?,26?;
DMU54C3	CS	C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCF.[Br-]
DMU54C3	IK	FNUZASGZEHGWQM-QCERWEEGSA-M
DMU54C3	IU	[(1S,5R)-8-(2-fluoroethyl)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide
DMU54C3	CA	CAS 63516-07-4
DMU54C3	CB	CHEBI:31630
DMU54C3	DE	Cough

DM4MDJY	ID	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	HS	Approved
DM4MDJY	SN	Canef; Cranoc; Fluindostatin; Fluvas; Fluvastatina; Fluvastatine; Fluvastatinum; Lescol; Lescol XL; XU 62320; Canef(TN); Fluvas (TN); Fluvastatin & Primycin; Fluvastatin (INN); Fluvastatin [INN:BAN]; Fluvastatina [INN-Spanish]; Fluvastatine [INN-French]; Fluvastatinum [INN-Latin]; Lescol (TN); Vastin (TN); XU-62320; (+)-(3R,5S)-fluvastatin; (-)-(3S,5R)-fluvastatin; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
DM4MDJY	TC	Anticholesteremic Agents
DM4MDJY	DT	Small molecular drug
DM4MDJY	PC	446155
DM4MDJY	MW	411.5
DM4MDJY	FM	C24H26FNO4
DM4MDJY	IC	InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1
DM4MDJY	CS	CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F
DM4MDJY	IK	FJLGEFLZQAZZCD-MCBHFWOFSA-N
DM4MDJY	IU	(E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
DM4MDJY	CA	CAS 93957-54-1
DM4MDJY	CB	CHEBI:38565
DM4MDJY	DE	Hypercholesterolaemia

DMQTJSX	ID	DMQTJSX
DMQTJSX	DN	Fluvoxamine
DMQTJSX	HS	Approved
DMQTJSX	SN	Dumyrox; Fluvoxamina; Fluvoxaminum; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum [INN-Latin]; Luvox (TN); (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
DMQTJSX	CP	IVAX Pharmaceuticals
DMQTJSX	TC	Antidepressants
DMQTJSX	DT	Small molecular drug
DMQTJSX	PC	5324346
DMQTJSX	MW	318.33
DMQTJSX	FM	C15H21F3N2O2
DMQTJSX	IC	InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
DMQTJSX	CS	COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F
DMQTJSX	IK	CJOFXWAVKWHTFT-XSFVSMFZSA-N
DMQTJSX	IU	2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
DMQTJSX	CA	CAS 54739-18-3
DMQTJSX	CB	CHEBI:5138
DMQTJSX	DE	Depression

DM2PSBE	ID	DM2PSBE
DM2PSBE	DN	Focetria A(H1N1)
DM2PSBE	HS	Approved
DM2PSBE	SN	Focetria (H1N1); H1N1 pandemic influenza A vaccine (MF59-adjuvanted, egg-based), Novartis
DM2PSBE	CP	Novartis AG
DM2PSBE	DT	Vaccine
DM2PSBE	DE	Influenza virus infection

DMEMBJC	ID	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	HS	Approved
DMEMBJC	SN	folic acid; 59-30-3; Folate; Pteroylglutamic acid; Vitamin M; Folacin; Folacid; PteGlu; Vitamin B9; Folvite; Pteroyl-L-glutamic acid; Vitamin Bc; Acifolic; Cytofol; Incafolic; Foliamin; Folsaure; Folicet; Millafol; Folipac; Folettes; Folsan; Folbal; Folsav; Vitamin Be; Pteroyl-L-monoglutamic acid; Mittafol; Folan; Facid; Pteroylmonoglutamic acid; Antianemia factor; Factor U; Folico (Italy); Folina (Italy); Foldine [France]; Pteroylmonoglutamate; Acfol (Spain); Foldine; Folcysteine; Folasic (Australia); Folcidin; Folaemin [Netherlands]; Nifolin; [3H]folic acid
DMEMBJC	TC	Vitamins
DMEMBJC	DT	Small molecular drug
DMEMBJC	PC	135398658
DMEMBJC	MW	441.4
DMEMBJC	FM	C19H19N7O6
DMEMBJC	IC	InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
DMEMBJC	CS	C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
DMEMBJC	IK	OVBPIULPVIDEAO-LBPRGKRZSA-N
DMEMBJC	IU	(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMEMBJC	CA	CAS 59-30-3
DMEMBJC	CB	CHEBI:27470
DMEMBJC	DE	Vitamin deficiency; Folate-deficiency anemia

DM2JTS5	ID	DM2JTS5
DM2JTS5	DN	Follitropin beta
DM2JTS5	HS	Approved
DM2JTS5	TC	Fertility Agents
DM2JTS5	SQ	Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>    <sequence format="FASTA">&gt;Beta chainNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
DM2JTS5	DE	Female infertility

DM6VOWQ	ID	DM6VOWQ
DM6VOWQ	DN	Fomepizole
DM6VOWQ	HS	Approved
DM6VOWQ	SN	Antizol; Fomepizol; Fomepizolum; Orphan brand of fomepizole; Paladin brand of fomepizole; M0774; Antizol (TN); Fomepizol [INN-Spanish]; Fomepizole [USAN:INN]; Fomepizolum [INN-Latin]; S14-0570; Fomepizole (USAN/INN); 4-Methyl-1H-pyrazole; 4-Methylpyrazol; 4-Methylpyrazole; 4-methylpyrazole monohydrochloride
DM6VOWQ	TC	Antidotes
DM6VOWQ	DT	Small molecular drug
DM6VOWQ	PC	3406
DM6VOWQ	MW	82.1
DM6VOWQ	FM	C4H6N2
DM6VOWQ	IC	InChI=1S/C4H6N2/c1-4-2-5-6-3-4/h2-3H,1H3,(H,5,6)
DM6VOWQ	CS	CC1=CNN=C1
DM6VOWQ	IK	RIKMMFOAQPJVMX-UHFFFAOYSA-N
DM6VOWQ	IU	4-methyl-1H-pyrazole
DM6VOWQ	CA	CAS 7554-65-6
DM6VOWQ	CB	CHEBI:5141
DM6VOWQ	DE	Athylene glycol or methanol poisoning

DMBEP7G	ID	DMBEP7G
DMBEP7G	DN	Fomivirsen sodium
DMBEP7G	HS	Approved
DMBEP7G	SN	Vitravene; Vitravene Preservative Free; DRG-0234; Vitravene (TN); DNA, d(P-thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G), eicosasodium salt
DMBEP7G	CP	Novartis AG; Isis Pharmaceuticals
DMBEP7G	TC	Antisense
DMBEP7G	DT	Small molecular drug
DMBEP7G	PC	71587550
DMBEP7G	MW	7122
DMBEP7G	FM	C204H243N63Na20O114P20S20
DMBEP7G	IC	InChI=1S/C204H263N63O114P20S20.20Na/c1-80-44-253(195(291)237-169(80)270)145-31-98(119(349-145)62-328-387(306,407)367-97-30-144(252-22-16-137(210)226-194(252)290)348-118(97)61-327-400(319,420)380-109-42-157(266-78-219-162-167(266)230-187(214)235-182(162)283)361-131(109)74-340-398(317,418)378-107-40-154(262-53-89(10)178(279)246-204(262)300)357-127(107)70-336-395(314,415)375-104-37-151(259-50-86(7)175(276)243-201(259)297)355-125(104)68-334-396(315,416)376-105-38-152(260-51-87(8)176(277)244-202(260)298)358-128(105)71-337-401(320,421)381-110-43-158(267-79-220-163-168(267)231-188(215)236-183(163)284)359-129(110)72-338-388(307,408)368-93-26-140(248-18-12-133(206)222-190(248)286)343-113(93)56-322-383(302,403)362-91-24-155(341-111(91)54-268)264-76-217-160-165(264)228-185(212)233-180(160)281)369-389(308,409)323-58-115-94(27-141(345-115)249-19-13-134(207)223-191(249)287)364-384(303,404)329-63-120-101(34-148(350-120)256-47-83(4)172(273)240-198(256)294)372-392(311,412)332-66-123-99(32-146(353-123)254-45-81(2)170(271)238-196(254)292)370-390(309,410)324-59-116-95(28-142(346-116)250-20-14-135(208)224-192(250)288)365-385(304,405)330-64-121-102(35-149(351-121)257-48-84(5)173(274)241-199(257)295)373-393(312,413)333-67-124-100(33-147(354-124)255-46-82(3)171(272)239-197(255)293)371-391(310,411)325-60-117-96(29-143(347-117)251-21-15-136(209)225-193(251)289)366-386(305,406)331-65-122-103(36-150(352-122)258-49-85(6)174(275)242-200(258)296)374-394(313,414)335-69-126-106(39-153(356-126)261-52-88(9)177(278)245-203(261)299)377-397(316,417)339-73-130-108(41-156(360-130)265-77-218-161-166(265)229-186(213)234-181(161)282)379-399(318,419)326-57-114-92(25-139(344-114)247-17-11-132(205)221-189(247)285)363-382(301,402)321-55-112-90(269)23-138(342-112)263-75-216-159-164(263)227-184(211)232-179(159)280;;;;;;;;;;;;;;;;;;;;/h11-22,44-53,75-79,90-131,138-158,268-269H,23-43,54-74H2,1-10H3,(H,301,402)(H,302,403)(H,303,404)(H,304,405)(H,305,406)(H,306,407)(H,307,408)(H,308,409)(H,309,410)(H,310,411)(H,311,412)(H,312,413)(H,313,414)(H,314,415)(H,315,416)(H,316,417)(H,317,418)(H,318,419)(H,319,420)(H,320,421)(H2,205,221,285)(H2,206,222,286)(H2,207,223,287)(H2,208,224,288)(H2,209,225,289)(H2,210,226,290)(H,237,270,291)(H,238,271,292)(H,239,272,293)(H,240,273,294)(H,241,274,295)(H,242,275,296)(H,243,276,297)(H,244,277,298)(H,245,278,299)(H,246,279,300)(H3,211,227,232,280)(H3,212,228,233,281)(H3,213,229,234,282)(H3,214,230,235,283)(H3,215,231,236,284);;;;;;;;;;;;;;;;;;;;/q;20*+1/p-20/t90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,382?,383?,384?,385?,386?,387?,388?,389?,390?,391?,392?,393?,394?,395?,396?,397?,398?,399?,400?,401?;;;;;;;;;;;;;;;;;;;;/m0..................../s1
DMBEP7G	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=S)([O-])O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)O)[S-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMBEP7G	IK	DLKYYJFLRUUGHJ-SSJCJZGYSA-A
DMBEP7G	IU	icosasodium;1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-sulfidophosphoryl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMBEP7G	CA	CAS 160369-77-7
DMBEP7G	DE	Cytomegalovirus retinitis

DMWS3FH	ID	DMWS3FH
DMWS3FH	DN	Fondaparinux sodium
DMWS3FH	HS	Approved
DMWS3FH	SN	Arixtra; Quixidar; Fondaparin sodium; Arixtra (TN); GSK-576428; SR-90107; SR-90107A; Fondaparinux sodium (JAN/USAN/INN)
DMWS3FH	CP	GSK
DMWS3FH	TC	Anticoagulants
DMWS3FH	DT	Small molecular drug
DMWS3FH	PC	636380
DMWS3FH	MW	1728.1
DMWS3FH	FM	C31H43N3Na10O49S8
DMWS3FH	IC	InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1
DMWS3FH	CS	CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMWS3FH	IK	XEKSTYNIJLDDAZ-JASSWCPGSA-D
DMWS3FH	IU	decasodium;(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dihydroxyoxane-2-carboxylate
DMWS3FH	CA	CAS 114870-03-0
DMWS3FH	DE	Venous thrombosis

DMRBJNZ	ID	DMRBJNZ
DMRBJNZ	DN	Forasartan
DMRBJNZ	HS	Approved
DMRBJNZ	SN	SC 52458; SC-52458; Forasartan (USAN/INN); 5-((3,5-Dibutyl-1H-1,2,4-triazol-1-yl)methyl)-2-(2-(1H-tetrazol-5-ylphenyl))pyridine; 5-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol-5-yl)phenyl]pyridine
DMRBJNZ	TC	Antihypertensive Agents
DMRBJNZ	DT	Small molecular drug
DMRBJNZ	PC	132706
DMRBJNZ	MW	416.5
DMRBJNZ	FM	C23H28N8
DMRBJNZ	IC	InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30)
DMRBJNZ	CS	CCCCC1=NN(C(=N1)CCCC)CC2=CN=C(C=C2)C3=CC=CC=C3C4=NNN=N4
DMRBJNZ	IK	YONOBYIBNBCDSJ-UHFFFAOYSA-N
DMRBJNZ	IU	5-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol-5-yl)phenyl]pyridine
DMRBJNZ	CA	CAS 145216-43-9
DMRBJNZ	CB	CHEBI:141552
DMRBJNZ	DE	Hypertension

DMSOURV	ID	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	HS	Approved
DMSOURV	SN	Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate
DMSOURV	CP	Norvatis Phamaceuticals Corporation
DMSOURV	TC	Sympathomimetics
DMSOURV	DT	Small molecular drug
DMSOURV	PC	3410
DMSOURV	MW	344.4
DMSOURV	FM	C19H24N2O4
DMSOURV	IC	InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)
DMSOURV	CS	CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O
DMSOURV	IK	BPZSYCZIITTYBL-UHFFFAOYSA-N
DMSOURV	IU	N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide
DMSOURV	CA	CAS 73573-87-2
DMSOURV	CB	CHEBI:63082
DMSOURV	DE	Asthma

DM4W9B3	ID	DM4W9B3
DM4W9B3	DN	Fosamprenavir
DM4W9B3	HS	Approved
DM4W9B3	SN	Telzir; Amprenavir phosphate; Fosamprenavir [INN]; GW 433908; GW433908; VX 175; Fosamprenavir (INN); Lexiva (TM); Lexiva (TN); Telzir (TN); Telzir(TM); VX-175; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester
DM4W9B3	CP	GlaxoSmithKline
DM4W9B3	TC	Anti-HIV Agents
DM4W9B3	DT	Small molecular drug
DM4W9B3	PC	131536
DM4W9B3	MW	585.6
DM4W9B3	FM	C25H36N3O9PS
DM4W9B3	IC	InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1
DM4W9B3	CS	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N
DM4W9B3	IK	MLBVMOWEQCZNCC-OEMFJLHTSA-N
DM4W9B3	IU	[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate
DM4W9B3	CA	CAS 226700-79-4
DM4W9B3	CB	CHEBI:82941
DM4W9B3	DE	Human immunodeficiency virus infection

DM9KJLZ	ID	DM9KJLZ
DM9KJLZ	DN	Foscavir
DM9KJLZ	HS	Approved
DM9KJLZ	SN	Foscarmet; Foscarnet; Phosphonoformate; Triapten; Virudin; Carboxyphosphonic acid; Dihydroxyphosphanecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide trisodium salt; Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate; FOSCARNET SODIUM; Forscarnet sodium; Foscarnet sodico; Foscarnet sodico [Spanish]; Foscarnet sodique; Foscarnet sodique [French]; Foscarnet sodium hexahydrate; Foscarnet sodium hydrate; Foscarneto sodico; Foscarnetum natricum; Foscarnetum natricum [Latin]; Phgosphonocarboxylic acid; Phosphonoformic acid; Phosphonomethanoic acid; Trisodium carboxyphosphate; Trisodium dioxidophosphanecarboxylate oxide; Trisodium dioxidophosphinecarboxylate oxide; Trisodium phosphonatoformate; Trisodium phosphonatoformate hexahydrate; Trisodium phosphonoformate; Trisodium phosphonoformate hexahydrate; Trisodium phosphonoformte hexahydrate; A 29622; EHB 776; A-29622; DRG-0017; Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody; EHB-776; Foscarnet sodique [INN-French]; Foscarnet sodium hydrate (JAN); Foscarneto sodico [INN-Spanish]; Foscarnetum natricum [INN-Latin]; Foscavir (TN); HS-0008; MSL & PFA; Phosphonoformic acid, trisodium salt; Trisodium carboxyphosphate (anhydrous); Trisodium phosphonoformate (anhydrous); Foscarnet & IFN-ALPHA; Foscarnet sodium (USAN/INN); Foscarnet sodium [USAN:INN:BAN]; Phosphonoformic acid & IFN-ALPHA; Phosphonoformic acid, trisodium salt, hexahydrate; PFA & rIFN.alpha.A; Phosphinecarboxylic acid, dihydroxy-, oxide; Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon; Sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6); Formic acid, phosphono-, trisodium salt, hexahydrate; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate
DM9KJLZ	CP	AstraZeneca
DM9KJLZ	TC	Antiviral Agents
DM9KJLZ	DT	Small molecular drug
DM9KJLZ	PC	44561
DM9KJLZ	MW	191.95
DM9KJLZ	FM	CNa3O5P
DM9KJLZ	IC	InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3
DM9KJLZ	CS	C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]
DM9KJLZ	IK	DFHAXXVZCFXGOQ-UHFFFAOYSA-K
DM9KJLZ	IU	trisodium;phosphonatoformate
DM9KJLZ	CA	CAS 63585-09-1
DM9KJLZ	CB	CHEBI:141644
DM9KJLZ	DE	Cytomegalovirus retinitis

DMR0TYK	ID	DMR0TYK
DMR0TYK	DN	Fosdenopterin
DMR0TYK	HS	Approved
DMR0TYK	SN	CPMP; CPMP (molybdenum cofactor deficiency), Alexion; CPMP (molybdenum cofactor deficiency), Orphatec
DMR0TYK	CP	Orphatec Pharmaceuticals GmbH
DMR0TYK	DT	Small molecular drug
DMR0TYK	PC	135463437
DMR0TYK	MW	363.22
DMR0TYK	FM	C10H14N5O8P
DMR0TYK	IC	InChI=1S/C10H14N5O8P/c11-9-14-6-3(7(16)15-9)12-4-8(13-6)22-2-1-21-24(19,20)23-5(2)10(4,17)18/h2,4-5,8,12,17-18H,1H2,(H,19,20)(H4,11,13,14,15,16)/t2-,4-,5+,8-/m1/s1
DMR0TYK	CS	C1[C@@H]2[C@@H](C([C@H]3[C@@H](O2)NC4=C(N3)C(=O)NC(=N4)N)(O)O)OP(=O)(O1)O
DMR0TYK	IK	CZAKJJUNKNPTTO-AJFJRRQVSA-N
DMR0TYK	IU	(1R,10R,12S,17R)-5-amino-11,11,14-trihydroxy-14-oxo-13,15,18-trioxa-2,4,6,9-tetraza-14lambda5-phosphatetracyclo[8.8.0.03,8.012,17]octadeca-3(8),4-dien-7-one
DMR0TYK	CA	CAS 150829-29-1
DMR0TYK	CB	CHEBI:60210
DMR0TYK	DE	Encephalopathy; Molybdenum cofactor deficiency

DMD072M	ID	DMD072M
DMD072M	DN	Fosfestrol
DMD072M	HS	Approved
DMD072M	SN	fosfestrol; Diethylstilbestrol diphosphate; 522-40-7; Phosphestrol; Phosphoestrolum; Honvan; Stilbestrol diphosphate; Desdp; Diethylstilbestryl diphosphate; Diethylstilbesterol diphosphate; ST52-Asta; Fosfestrolum [INN-Latin]; UNII-A0E0NMA80F; CCRIS 2778; (E)-Hex-3-ene-3,4-diylbis(4,1-phenylene) bis(dihydrogen phosphate); C18H22O8P2; EINECS 208-328-8; A0E0NMA80F; CHEBI:4532; Diethylstilbestrol diphosphate [USP]; NCGC00181335-01; Stilphostrol (TN); alpha,alpha'-Diethyl-(E)-4,4'-stilbenediol bis(dihydrogen phosphate)
DMD072M	DT	Small molecular drug
DMD072M	PC	3032325
DMD072M	MW	428.3
DMD072M	FM	C18H22O8P2
DMD072M	IC	InChI=1S/C18H22O8P2/c1-3-17(13-5-9-15(10-6-13)25-27(19,20)21)18(4-2)14-7-11-16(12-8-14)26-28(22,23)24/h5-12H,3-4H2,1-2H3,(H2,19,20,21)(H2,22,23,24)/b18-17+
DMD072M	CS	CC/C(=C(/CC)\\C1=CC=C(C=C1)OP(=O)(O)O)/C2=CC=C(C=C2)OP(=O)(O)O
DMD072M	IK	NLORYLAYLIXTID-ISLYRVAYSA-N
DMD072M	IU	[4-[(E)-4-(4-phosphonooxyphenyl)hex-3-en-3-yl]phenyl] dihydrogen phosphate
DMD072M	CA	CAS 522-40-7
DMD072M	CB	CHEBI:4532
DMD072M	DE	Solid tumour/cancer

DMVGPMX	ID	DMVGPMX
DMVGPMX	DN	Fosfomycin
DMVGPMX	HS	Approved
DMVGPMX	SN	FCM; Phosphomycin; Phosphonemycin; Phosphonomycin; Priomicina; Veramina; Disodium fosfomycin; Disodium phosphonomycin; Fosfocina disodium salt; Fosfomycin disodium; Fosfomycin disodium salt; Fosfomycin sodium; Fosfomycin sodium salt; Fosmicin S; Phosphomycin disodium salt; Phosphonomycin disodium salt; Phosphonomycin sodium; Sodium fosfomycin; MK 955; FOM-Na; Fosfomycin sodium (JP15); Fosmicin S (TN); Fosfomycin (USAN/INN); L-cis-1,2-epoxypropylphosphonic acid; Disodium (1R,2S)-(1,2-epoxypropyl)phosphonate; Disodium[(2r,3s)-3-methyloxiran-2-yl]phosphonate; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; Phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2R-cis)-(9CI); (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonicacid; (1R,2S)(-)-(1,2-Epoxypropyl)phosphonic acid disodium salt; (1R,2S)-(1,2-Epoxypropyl)phosphonic acid; (1R,2S)-epoxypropylphosphonate; (1R,2S)-epoxypropylphosphonic acid; (2R-cis)-(3-Methyloxiranyl)phosphonic acid disodium salt
DMVGPMX	TC	Antibiotics
DMVGPMX	DT	Small molecular drug
DMVGPMX	PC	446987
DMVGPMX	MW	138.06
DMVGPMX	FM	C3H7O4P
DMVGPMX	IC	InChI=1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1
DMVGPMX	CS	C[C@H]1[C@H](O1)P(=O)(O)O
DMVGPMX	IK	YMDXZJFXQJVXBF-STHAYSLISA-N
DMVGPMX	IU	[(2R,3S)-3-methyloxiran-2-yl]phosphonic acid
DMVGPMX	CA	CAS 23155-02-4
DMVGPMX	CB	CHEBI:28915
DMVGPMX	DE	Bacterial infection

DMDIC39	ID	DMDIC39
DMDIC39	DN	Fosfosal
DMDIC39	HS	Approved
DMDIC39	SN	Disdolen (TN)
DMDIC39	DT	Small molecular drug
DMDIC39	PC	3418
DMDIC39	MW	218.1
DMDIC39	FM	C7H7O6P
DMDIC39	IC	InChI=1S/C7H7O6P/c8-7(9)5-3-1-2-4-6(5)13-14(10,11)12/h1-4H,(H,8,9)(H2,10,11,12)
DMDIC39	CS	C1=CC=C(C(=C1)C(=O)O)OP(=O)(O)O
DMDIC39	IK	FFKUDWZICMJVPA-UHFFFAOYSA-N
DMDIC39	IU	2-phosphonooxybenzoic acid
DMDIC39	CA	CAS 6064-83-1
DMDIC39	CB	CHEBI:94564
DMDIC39	DE	Pain

DM9NJ52	ID	DM9NJ52
DM9NJ52	DN	Fosinopril
DM9NJ52	HS	Approved
DM9NJ52	SN	Acecor; Fosenopril; Monopril; Staril; FOSINOPRIL SODIUM; Fosinopril (INN); Fosinopril [INN:BAN]; Monopril (TN); SQ-28555; SQ-28,555; Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; (4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline; (4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline; 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
DM9NJ52	CP	Bristol-Myers Squibb
DM9NJ52	TC	Antihypertensive Agents
DM9NJ52	DT	Small molecular drug
DM9NJ52	PC	55891
DM9NJ52	MW	563.7
DM9NJ52	FM	C30H46NO7P
DM9NJ52	IC	InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
DM9NJ52	CS	CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3
DM9NJ52	IK	BIDNLKIUORFRQP-FKDWWROVSA-N
DM9NJ52	IU	(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
DM9NJ52	CA	CAS 98048-97-6
DM9NJ52	CB	CHEBI:5163
DM9NJ52	DE	Hypertension

DM7G0EP	ID	DM7G0EP
DM7G0EP	DN	Fosmidomycin
DM7G0EP	HS	Approved
DM7G0EP	SN	FOM; Fosmidomycina; Fosmidomycine; Fosmidomycinum; FR-31564; Fosmidomycina [INN-Spanish]; Fosmidomycine [INN-French]; Fosmidomycinum [INN-Latin]; {3-[formyl(hydroxy)amino]propyl}phosphonic acid; (3-(Formylhydroxyamino)propyl)phosphonic acid, monosodium salt; (3-(N-Hydroxyformamido)propyl)phosphonic acid; 3-(Formyl-hydroxy-amino)propylphosphonic acid; 3-(N-Formyl-N-hydroxyamino)-propylphosphonic acid; 3-(N-hydroxyformamido)propylphosphonic acid; 3-[FORMYL(HYDROXY)AMINO]PROPYLPHOSPHONIC ACID
DM7G0EP	TC	Antimalarials
DM7G0EP	DT	Small molecular drug
DM7G0EP	PC	572
DM7G0EP	MW	183.1
DM7G0EP	FM	C4H10NO5P
DM7G0EP	IC	InChI=1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
DM7G0EP	CS	C(CN(C=O)O)CP(=O)(O)O
DM7G0EP	IK	GJXWDTUCERCKIX-UHFFFAOYSA-N
DM7G0EP	IU	3-[formyl(hydroxy)amino]propylphosphonic acid
DM7G0EP	CA	CAS 66508-53-0
DM7G0EP	CB	CHEBI:443725
DM7G0EP	DE	Malaria

DMOX3LB	ID	DMOX3LB
DMOX3LB	DN	Fosphenytoin
DMOX3LB	HS	Approved
DMOX3LB	SN	Fosfenitoina; Fosphenytoine; Fosphenytoinum; HMPDP; Prodilantin; ACC-9653; Cerebyx (TN); Fosfenitoina [INN-Spanish]; Fosphenytoin (INN); Fosphenytoin [INN:BAN]; Fosphenytoine [INN-French]; Fosphenytoinum [INN-Latin]; Prodilantin (TN); (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate; (3-Phosphoryloxymethyl)phenytoin; 3-(hydroxymethyl)phenytoin disodium phosphate; 3-(hydroxymethyl)phenytoin phosphate ester
DMOX3LB	CP	Pfizer Pharmaceuticals
DMOX3LB	TC	Anticonvulsants
DMOX3LB	DT	Small molecular drug
DMOX3LB	PC	56339
DMOX3LB	MW	362.27
DMOX3LB	FM	C16H15N2O6P
DMOX3LB	IC	InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)
DMOX3LB	CS	C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3
DMOX3LB	IK	XWLUWCNOOVRFPX-UHFFFAOYSA-N
DMOX3LB	IU	(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate
DMOX3LB	CA	CAS 93390-81-9
DMOX3LB	CB	CHEBI:5165
DMOX3LB	DE	Epilepsy

DM8J5XT	ID	DM8J5XT
DM8J5XT	DN	Fospropofol
DM8J5XT	HS	Approved
DM8J5XT	SN	Fospropofol; Fospropofol [INN]; LZ257RZP7K; SCHEMBL3821874; ZINC2519740; 258516-89-1; AC1MI4YI; ACM258516891; CHEBI:135193; CHEMBL1201766; DB06716; DEA No. 2138; DTXSID50870295; FT-0727559; GTPL7475; UNII-LZ257RZP7K; [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate
DM8J5XT	PC	3038498
DM8J5XT	MW	288.28
DM8J5XT	FM	C13H21O5P
DM8J5XT	IC	QVNNONOFASOXQV-UHFFFAOYSA-N
DM8J5XT	CS	CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)(O)O
DM8J5XT	IK	1S/C13H21O5P/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16)
DM8J5XT	IU	[2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate
DM8J5XT	CA	CAS 258516-89-1
DM8J5XT	CB	CHEBI:135193
DM8J5XT	DE	Neuropathic pain

DMKLJRD	ID	DMKLJRD
DMKLJRD	DN	Fospropofol disodium
DMKLJRD	HS	Approved
DMKLJRD	SN	Lusedra (TN)
DMKLJRD	CP	Eisai
DMKLJRD	DT	Small molecular drug
DMKLJRD	PC	3038497
DMKLJRD	MW	332.24
DMKLJRD	FM	C13H19Na2O5P
DMKLJRD	IC	InChI=1S/C13H21O5P.2Na/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16;;/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16);;/q;2*+1/p-2
DMKLJRD	CS	CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)([O-])[O-].[Na+].[Na+]
DMKLJRD	IK	LWYLQNWMSGFCOZ-UHFFFAOYSA-L
DMKLJRD	IU	disodium;[2,6-di(propan-2-yl)phenoxy]methyl phosphate
DMKLJRD	CA	CAS 258516-87-9
DMKLJRD	DE	Monitored anaesthesia care

DM6AUHV	ID	DM6AUHV
DM6AUHV	DN	Fostamatinib
DM6AUHV	HS	Approved
DM6AUHV	SN	901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]
DM6AUHV	CP	Rigel Pharmaceuticals
DM6AUHV	DT	Small molecular drug
DM6AUHV	PC	11671467
DM6AUHV	MW	580.5
DM6AUHV	FM	C23H26FN6O9P
DM6AUHV	IC	InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)
DM6AUHV	CS	CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C
DM6AUHV	IK	GKDRMWXFWHEQQT-UHFFFAOYSA-N
DM6AUHV	IU	[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate
DM6AUHV	CA	CAS 901119-35-5
DM6AUHV	DE	Immune thrombocytopenic purpura; Rheumatoid arthritis

DM50ILT	ID	DM50ILT
DM50ILT	DN	Fostemsavir
DM50ILT	HS	Approved
DM50ILT	SN	BMS-216; BMS-248; BMS-378806; BMS-626529; BMS-705; BMS-806; BMS-806 series; BMS-853; HIV-1 attachment inhibitors, BMS; HIV-1 entry inhibitors, BMS; BMS-488043 follow-on compounds, BMS; HIV-1 attachment inhibitors, Bristol-Myers Squibb
DM50ILT	CP	Bristol-myers squibb
DM50ILT	DT	Small molecular drug
DM50ILT	PC	11319217
DM50ILT	MW	583.5
DM50ILT	FM	C25H26N7O8P
DM50ILT	IC	InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38)
DM50ILT	CS	CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC
DM50ILT	IK	SWMDAPWAQQTBOG-UHFFFAOYSA-N
DM50ILT	IU	[3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
DM50ILT	CA	CAS 864953-29-7
DM50ILT	DE	Human immunodeficiency virus infection

DMV62ED	ID	DMV62ED
DMV62ED	DN	Fotemustine
DMV62ED	HS	Approved
DMV62ED	SN	Fotemustine; 92118-27-9; Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; Muphoran; Mustophorane; Servier-10036; Fotemustinum [Latin]; Fotemustina [Spanish]; S 10036; C9H19ClN3O5P; CCRIS 6337; S-10036; Fotemustinum; Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate; (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; Mustoforan; 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea; Fotemustine [BAN:INN]
DMV62ED	DT	Small molecular drug
DMV62ED	PC	104799
DMV62ED	MW	315.69
DMV62ED	FM	C9H19ClN3O5P
DMV62ED	IC	InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
DMV62ED	CS	CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC
DMV62ED	IK	YAKWPXVTIGTRJH-UHFFFAOYSA-N
DMV62ED	IU	1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea
DMV62ED	CA	CAS 92118-27-9
DMV62ED	CB	CHEBI:131852
DMV62ED	DE	Solid tumour/cancer

DMF8DNE	ID	DMF8DNE
DMF8DNE	DN	Framycetin
DMF8DNE	HS	Approved
DMF8DNE	SN	Neomycin; neomycin; NEOMYCIN B; Soframycin; Actiline; Mycifradin; Fradiomycin; Soframycine; Framycetinum; Framycetine; Framicetina; Neomas; Fradiomycinum; Antibiotique; Nivemycin; Actilin; Neolate; Enterfram; Myacyne; Framygen; Caswell No 595; Vonamycin powder V; Neomycin B sulfate; Neomin; Neomcin; Fradiomycin B; Neo-Rx; Neomicina [DCIT]; Framycetinum [INN-Latin]; PIMAVECORT; Neobrettin; Neo-Fradin; 119-04-0; Neomycine [INN-French]; Neomycinum [INN-Latin]; Framycetine [INN-French]; Framicetina [INN-Spanish]; USAF CB-19; Endomixin; Fraquinol; Myacine; Myciguent; NMY; Neobiotic; Neomicina; Neomycinum; Tuttomycin; VONAMYCIN; NEOMYCIN AND POLYMYXIN B SULFATES; NEOMYCIN SULFATE; Neomycin solution; Soframycin Ophthalmic; Antibiotic 10676; Antibiotic produced by Streptomyces decaris Neomycin B; Framycetin (INN); Soframycin (TN); Framycetin [INN:BAN:DCF]; Sofra-Tulle (TN); BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; D-Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy
DMF8DNE	TC	Antibiotics
DMF8DNE	DT	Small molecular drug
DMF8DNE	PC	8378
DMF8DNE	MW	614.6
DMF8DNE	FM	C23H46N6O13
DMF8DNE	IC	InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
DMF8DNE	CS	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
DMF8DNE	IK	PGBHMTALBVVCIT-VCIWKGPPSA-N
DMF8DNE	IU	(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
DMF8DNE	CA	CAS 119-04-0
DMF8DNE	CB	CHEBI:7508
DMF8DNE	DE	Alcoholic cirrhosis of liver; Acute liver failure; Bacterial infection

DMDZY54	ID	DMDZY54
DMDZY54	DN	Fremanezumab
DMDZY54	HS	Approved
DMDZY54	SN	Fremanezumab [INN]; Fremanezumab [USAN]; UNII-PF8K38CG54; PF8K38CG54; TEV-48125; PF-04472429
DMDZY54	CP	Teva
DMDZY54	DT	Antibody
DMDZY54	DE	Hyperprolactinaemia

DM7RE8P	ID	DM7RE8P
DM7RE8P	DN	Frovatriptan
DM7RE8P	HS	Approved
DM7RE8P	SN	Allegro; Auradol; Frova; Frovelan; Migard; Miguard; Rilamig; Allergo filmtabletten; SB 209509; Allergo filmtabletten(TN); Frova (TN); Frovatriptan (INN); SB-209509; (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide; (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide; (R)-5,6,7,8-Tetrahydro-6-(methylamino)carbazole-3-carboxamide
DM7RE8P	CP	Vernalis
DM7RE8P	TC	Antimigraine Agents
DM7RE8P	DT	Small molecular drug
DM7RE8P	PC	77992
DM7RE8P	MW	243.3
DM7RE8P	FM	C14H17N3O
DM7RE8P	IC	InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1
DM7RE8P	CS	CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N
DM7RE8P	IK	XPSQPHWEGNHMSK-SECBINFHSA-N
DM7RE8P	IU	(6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
DM7RE8P	CA	CAS 158747-02-5
DM7RE8P	CB	CHEBI:134991
DM7RE8P	DE	Migraine

DM43AN2	ID	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	HS	Approved
DM43AN2	SN	D-(-)-Fructose; 57-48-7; D(-)-Fructose; (3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-one; 53188-23-1; D-(-)-Levulose; D-Levulose; Nevulose; Furucton; arabino-Hexulose; Sugar, fruit; Fructose, D-; Krystar 300; Hi-Fructo 970; keto-D-fructose; Fructose, pure; Fructose solution; CCRIS 3335; 30237-26-4; EINECS 200-333-3; AI3-23514; DL-Fructose; MFCD00148910; D(-)-Fructose, 99%; Fructon; D-(-)-Fructose, &gt; Methose; Levulosa; Levulosa Baxter; Levulosa Braun; Apir Levulosa; Levulosa Mein; Levulosa Ibys; Levulosa Ife; Levulosado Braun; D-fructose
DM43AN2	DT	Small molecular drug
DM43AN2	PC	2723872
DM43AN2	MW	180.16
DM43AN2	FM	C6H12O6
DM43AN2	IC	InChI=1S/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4-,5+,6?/m1/s1
DM43AN2	CS	C1[C@H]([C@H]([C@@H](C(O1)(CO)O)O)O)O
DM43AN2	IK	LKDRXBCSQODPBY-VRPWFDPXSA-N
DM43AN2	IU	(3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM43AN2	CA	CAS 6347-01-9
DM43AN2	CB	CHEBI:37714
DM43AN2	DE	Vomiting

DM0YZC6	ID	DM0YZC6
DM0YZC6	DN	Fulvestrant
DM0YZC6	HS	Approved
DM0YZC6	SN	Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI
DM0YZC6	CP	AstraZeneca
DM0YZC6	TC	Anticancer Agents
DM0YZC6	DT	Small molecular drug
DM0YZC6	PC	104741
DM0YZC6	MW	606.8
DM0YZC6	FM	C32H47F5O3S
DM0YZC6	IC	InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
DM0YZC6	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
DM0YZC6	IK	VWUXBMIQPBEWFH-WCCTWKNTSA-N
DM0YZC6	IU	(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DM0YZC6	CA	CAS 129453-61-8
DM0YZC6	CB	CHEBI:31638
DM0YZC6	DE	Breast cancer

DM3P6V7	ID	DM3P6V7
DM3P6V7	DN	Furazolidone
DM3P6V7	HS	Approved
DM3P6V7	SN	Bifuron; Corizium; Coryzium; Diafuron; Enterotoxon; Furall; Furaxon; Furaxone; Furazol; Furazolidine; Furazolidon; Furazolidona; Furazolidonum; Furazolum; Furazon; Furidon; Furovag; Furox; Furoxal; Furoxane; Furoxon; Furoxone; Furozolidine; Giardil; Giarlam; Medaron; Neftin; Nicolen; Nifulidone; Nifuran; Nifurazolidone; Nifurazolidonum; Nitrofurazolidone; Nitrofurazolidonum; Nitrofuroxon; Optazol; Ortazol; Puradin; Roptazol; Sclaventerol; Tikofuran; Topazone; Trichofuron; Tricofuron; Tricoron; Trifurox; Viofuragyn; Fiurox aerosol powder; Furoxone Liquid; Furoxone Swine Mix; NF 180 custom mix ten; F-8900; Furazolidona [INN-Spanish]; Furazolidone [INN:BAN]; Furazolidonum [INN-Latin]; Furox Aerosol Powder (Veterinary); Furoxone (TN); NF-180; Usaf ea-1; Dependal-M (TN); Furazolidone (USP/INN); N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone; N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one; 3-(((5-Nitro-2-furanyl)methylene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidone; 3-((5-Nitrofurylidene)amino)-2-oxazolidone; 3-(5'-Nitrofurfuralamino)-2-oxazolidone; 3-(5-Nitrofurfurylideneamino)-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone; 3-[(5-Nitrofurylidene)amino]-2-oxazolidone; 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; 3-{[(5-Nitro-2-furanyl)methylene]amino}-2-oxazolidinone; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; 3-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
DM3P6V7	CP	GlaxoSmithKline
DM3P6V7	TC	Antiinfective Agents
DM3P6V7	DT	Small molecular drug
DM3P6V7	PC	5323714
DM3P6V7	MW	225.16
DM3P6V7	FM	C8H7N3O5
DM3P6V7	IC	InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
DM3P6V7	CS	C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
DM3P6V7	IK	PLHJDBGFXBMTGZ-WEVVVXLNSA-N
DM3P6V7	IU	3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
DM3P6V7	CA	CAS 67-45-8
DM3P6V7	CB	CHEBI:5195
DM3P6V7	DE	Diarrhea

DMMQ8ZG	ID	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	HS	Approved
DMMQ8ZG	SN	Aisemide; Aldalix; Aldic; Aluzine; Anfuramaide; Aquarid; Aquasin; Arasemide; Beronald; Bioretic; Cetasix; Depix; Desal; Desdemin; Dirine; Disal; Discoid; Disemide; Diural; Diurapid; Diurin; Diurolasa; Diusemide; Diusil; Diuzol; Dranex; Dryptal; Durafurid; Edemid; Edenol; Eliur; Endural; Errolon; Eutensin; FUN; Farsix; Fluidrol; Fluss; Franyl; Frumex; Frumide; Frusedan; Frusema; Frusemid; Frusemide; Frusemin; Frusenex; Frusetic; Frusid; Fulsix; Fuluvamide; Fuluvamine; Fulvamide; Furanthril; Furanthryl; Furantral; Furantril; Furanturil; Furesis; Furetic; Furex; Furfan; Furix; Furmid; Furobeta; Furocot; Furodiurol; Furodrix; Furomen; Furomex; Furorese; Furosan; Furose; Furosedon; Furosemid; Furosemida; Furosemidu; Furosemidum; Furosemix; Furoside; Furosifar; Furosix; Furoter; Furovite; Fursemid; Fursemida; Fursemide; Fursol; Fusid; Golan; Hissuflux; Hydrex; Hydro; Hydroled; Impugan; Jenafusid; Katlex; Kofuzon; Kolkin; Kutrix; Lasemid; Lasex; Lasiletten; Lasilix; Lasix; Laxur; Lazix; Liside; Logirene; Lowpston; Lowpstron; Luscek; Macasirool; Marsemide; Mirfat; Mita; Moilarorin; Myrosemide; Nadis; Nelsix; Novosemide; Odemase; Odemex; Oedemex; Prefemin; Profemin; Promedes; Promide; Protargen; Puresis; Radisemide; Radonna; Radouna; Retep; Rosemide; Rosis; Rusyde; Salinex; Salix; Salurex; Salurid; Seguril; Selectofur; Sigasalur; Spirofur; Synephron; Transit; Trofurit; Uremide; Uresix; Urian; Uridon; Uritol; Urosemide; Vesix; Yidoli; Zafimida; FUROSEMIDE USP; Fu sid; Furosemide Monohydrochloride; Furosemide Monosodium Salt; Furosemidu [Polish]; Lasix Retard; Lasix Special; Less Diur; Polysquall A; Sal diureticum; F0182; F4381_SIGMA; LB 502; Aisemide (TN); Apo-Frusemide; Apo-Furosemide; Beronald (TN); Desdemin (TN); Discoid (TN); Diumide-K; Diural (TN); Diurapid (TN); Dryptal (TN); Durafurid (TN); Errolon (TN); Eutensin (TN); Frudix (TN); Frusetic (TN); Frusid (TN); Fulsix (TN); Fuluvamide (TN); Furesis (TN); Furix (TN); Furo-Basan; Furo-puren; Furomide M.D; Furosedon (TN); Furosemida [INN-Spanish]; Furosemide (mita); Furosemidum [INN-Latin]; Hoe-058A; Hydro-rapid; Impugan (TN); Katlex (TN); LB-502; Lasilix (TN); Lasix (TN); Lodix (TN); Lowpston (TN); Macasirool (TN); Mirfat (TN); Neo-renal; Nicorol (TN); Odemase (TN); Oedemex (TN); Profemin (TN); Rosemide (TN); Rusyde (TN); Salix (TN); Salix (brand of furosemide); Trofurit (TN); Urex (TN); Urex-M; Apo-Furosemide (TN); Furo-Puren (TN); Furomide M.D.; Furosemide [USAN:INN:JAN]; Hydro-rapid(TN); Lasix, Frusemide, Furosemide; Furosemide (JP15/USP/INN); Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
DMMQ8ZG	CP	Sanofi-Aventis
DMMQ8ZG	TC	Diuretics
DMMQ8ZG	DT	Small molecular drug
DMMQ8ZG	PC	3440
DMMQ8ZG	MW	330.74
DMMQ8ZG	FM	C12H11ClN2O5S
DMMQ8ZG	IC	InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
DMMQ8ZG	CS	C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
DMMQ8ZG	IK	ZZUFCTLCJUWOSV-UHFFFAOYSA-N
DMMQ8ZG	IU	4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
DMMQ8ZG	CA	CAS 54-31-9
DMMQ8ZG	CB	CHEBI:47426
DMMQ8ZG	DE	Congestive heart failure

DMWVCF3	ID	DMWVCF3
DMWVCF3	DN	Fusidic acid
DMWVCF3	HS	Approved
DMWVCF3	SN	FUCIDIN; Fucidate; Fucithalmic; Fusidate; Fusidine; Ramycin; Diethanolamine fusidate; Fucidate Sodium; Fucidic acid; Fucidin acid; Fuci (TN); Fucibet (TN); Fucicort (TN); Fucidin (TN); Fucidin Cream 2%; Fucidine (TN); Fucithalmic (TN); Fucizon (TN); Fudic (TN); Fusiderm (TN); Fusidin (TN); SQ 16,603; Fusidic acid (USAN/INN); C.A.S. 62,602; (2Z)-2-[(17Z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; 16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; 3.alpha.,11.alpha.,16.beta.-Trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate
DMWVCF3	CP	Leo Laboratories 
DMWVCF3	TC	Antibiotics
DMWVCF3	DT	Small molecular drug
DMWVCF3	PC	3000226
DMWVCF3	MW	516.7
DMWVCF3	FM	C31H48O6
DMWVCF3	IC	InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
DMWVCF3	CS	C[C@H]1[C@@H]2CC[C@]3([C@H]([C@]2(CC[C@H]1O)C)[C@@H](C[C@@H]\\4[C@@]3(C[C@@H](/C4=C(/CCC=C(C)C)\\C(=O)O)OC(=O)C)C)O)C
DMWVCF3	IK	IECPWNUMDGFDKC-MZJAQBGESA-N
DMWVCF3	IU	(2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
DMWVCF3	CA	CAS 6990-06-3
DMWVCF3	CB	CHEBI:29013
DMWVCF3	DE	Bacterial infection; MRSA infection

DMZ0P95	ID	DMZ0P95
DMZ0P95	DN	Ga-68-DOTATOC
DMZ0P95	HS	Approved
DMZ0P95	DT	radioactive diagnostic agent
DMZ0P95	DE	Diagnostic imaging

DM6T924	ID	DM6T924
DM6T924	DN	Gabapentin
DM6T924	HS	Approved
DM6T924	SN	Aclonium; GBN; Gabapen; Gabapentina; Gabapentine; Gabapentinium; Gabapentino; Gabapentinum; Gabapetin; Neurontin; Serada; Vultin; Apotex brand of gabapentin; Aventis brand of gabapentin; Gabapentin GR; Gabapentin Hexal; Gabapentin Stada; Gabapentino [Spanish]; Hexal brand of gabapentin; Novopharm brand of gabapentin; Parke Davis brand of gabapentin; Pfizer brand of gabapentin; Pharmascience brand of gabapentin; Ratiopharm brand of gabapentin; Stadapharm brand of gabapentin; GOE 2450; Go 3450; Apo-Gabapentin; DDS-2003; DM-1796; DM-5689; G-154; Gabapentin (Neurontin); Gabapentin-ratiopharm; Gabapentine [INN-French]; Gabapentino [INN-Spanish]; Gabapentinum [INN-Latin]; Goe-3450; Neurontin (TN); Novo-Gabapentin; PMS-Gabapentin; Warner-Lambert brand of gabapentin; Gabapentin [USAN:INN:BAN]; [1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID; Gabapentin (JAN/USAN/INN); 1-(Aminomethyl)-cyclohexaneacetic acid; 1-(Aminomethyl)cyclohexaneacetic acid; 2-[1-(aminomethyl)cyclohexyl]acetic acid
DM6T924	CP	Pfizer
DM6T924	TC	Analgesics
DM6T924	DT	Small molecular drug
DM6T924	PC	3446
DM6T924	MW	171.24
DM6T924	FM	C9H17NO2
DM6T924	IC	InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
DM6T924	CS	C1CCC(CC1)(CC(=O)O)CN
DM6T924	IK	UGJMXCAKCUNAIE-UHFFFAOYSA-N
DM6T924	IU	2-[1-(aminomethyl)cyclohexyl]acetic acid
DM6T924	CA	CAS 60142-96-3
DM6T924	CB	CHEBI:42797
DM6T924	DE	Complex partial seizure; Solid tumour/cancer

DMU9D2F	ID	DMU9D2F
DMU9D2F	DN	Gabexate
DMU9D2F	HS	Approved
DMU9D2F	SN	gabexate; Gabexate [INN]; 39492-01-8; Gabexatum [INN-Latin]; Gabexato [INN-Spanish]; UNII-4V7M9137X9; CHEMBL87563; C16H23N3O4; Gabexate (INN); 4V7M9137X9; Ethyl p-hydroxybenzoate 6-guanidinohexanoate; ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate; Gabexatum; Gabexato; Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester; p-carbethoxyphenyl e-guanidinocaproate; AC1L1FYH; Prestwick3_001008; Prestwick2_001008; Prestwick0_001008; Prestwick1_001008; BSPBio_001135; SCHEMBL446024; SPBio_003016; GTPL7863
DMU9D2F	DT	Small molecular drug
DMU9D2F	PC	3447
DMU9D2F	MW	321.37
DMU9D2F	FM	C16H23N3O4
DMU9D2F	IC	InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)
DMU9D2F	CS	CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N
DMU9D2F	IK	YKGYIDJEEQRWQH-UHFFFAOYSA-N
DMU9D2F	IU	ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate
DMU9D2F	CA	CAS 39492-01-8
DMU9D2F	CB	CHEBI:93036
DMU9D2F	DE	Pancreatitis

DMI53FU	ID	DMI53FU
DMI53FU	DN	Gaboxadol
DMI53FU	HS	Approved
DMI53FU	SN	Gaboxadolum; Gaboxadolum [Latin]; LU 2030; Gaboxadol [USAN:INN]; Lu 02-030; MK-0928; Gaboxadol (USAN/INN); LU-2-030; Lu-02-030; Isoxazolo(5,4-c)pyridin-3(2H)-one, 4,5,6,7-tetrahydro-, hydrate; 4,5,6,7-Tetrahydroisoxazole(5,4-c)pyridin-3-ol; 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one
DMI53FU	CP	Merck & Co
DMI53FU	TC	Hypnotics and Sedatives
DMI53FU	DT	Small molecular drug
DMI53FU	PC	3448
DMI53FU	MW	140.14
DMI53FU	FM	C6H8N2O2
DMI53FU	IC	InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9)
DMI53FU	CS	C1CNCC2=C1C(=O)NO2
DMI53FU	IK	ZXRVKCBLGJOCEE-UHFFFAOYSA-N
DMI53FU	IU	4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one
DMI53FU	CA	CAS 64603-91-4
DMI53FU	CB	CHEBI:34373
DMI53FU	DE	Insomnia

DM4VAOG	ID	DM4VAOG
DM4VAOG	DN	Gadobenate dimeglumine
DM4VAOG	HS	Approved
DM4VAOG	SN	Hydron; Multihance; Gadobenate Dimeglumine [USAN]; Gadobenic acid; Gadobenic acid dimeglumine salt; Meglumine gadobenate; Multihance Multipack; B 1903617; E-7155; Gadobenate dimeglumine (USAN); Gd-BOPTA; Meglumine gadobenate (JAN); Multihance (TN); B-19036/7; Gadolinium(3+); Gd-Bopta/dimeg; Dihydrogen ((+-)-4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))gadolinate(2-), compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2); (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2); 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]-3-phenylmethoxypropanoate; 2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; D-Glucitol, 1-deoxy-1-(methylamino)-, (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8), O(sup 11),O(sup 13)-gadolinate(2-) (2:1); Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8),O(sup 11),O(sup 13))-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2)
DM4VAOG	TC	Contrast Media
DM4VAOG	DT	Small molecular drug
DM4VAOG	PC	6918204
DM4VAOG	MW	1058.1
DM4VAOG	FM	C36H62GdN5O21
DM4VAOG	IC	InChI=1S/C22H31N3O11.2C7H17NO5.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;2*1-8-2-4(10)6(12)7(13)5(11)3-9;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);2*4-13H,2-3H2,1H3;/q;;;+3/p-3/t;2*4-,5+,6+,7+;/m.00./s1
DM4VAOG	CS	CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC=C(C=C1)COCC(C(=O)[O-])N(CCN(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-])CC(=O)O.[Gd+3]
DM4VAOG	IK	OCDAWJYGVOLXGZ-VPVMAENOSA-K
DM4VAOG	IU	2-[2-[carboxylatomethyl-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl]amino]ethyl-(carboxymethyl)amino]-3-phenylmethoxypropanoate;gadolinium(3+);(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
DM4VAOG	CA	CAS 127000-20-8
DM4VAOG	DE	Schizophrenia

DM5V9U1	ID	DM5V9U1
DM5V9U1	DN	Gadofosveset
DM5V9U1	HS	Approved
DM5V9U1	SN	Vasovist (TN)
DM5V9U1	CP	Epix
DM5V9U1	DT	Small molecular drug
DM5V9U1	PC	73415770
DM5V9U1	MW	891.9
DM5V9U1	FM	C33H41GdN3O14P
DM5V9U1	IC	InChI=1S/C33H44N3O14P.Gd/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);/q;+3/p-3/t26-;/m1./s1
DM5V9U1	CS	[H+].[H+].[H+].C1CC(CCC1OP(=O)([O-])OC[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-])(C2=CC=CC=C2)C3=CC=CC=C3.[Gd+3]
DM5V9U1	IK	ZSDLYSDDELEVDD-UFTMZEDQSA-K
DM5V9U1	IU	2-[[(2R)-2-[bis(carboxylatomethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron
DM5V9U1	CA	CAS 201688-00-8
DM5V9U1	DE	Imaging

DMEO794	ID	DMEO794
DMEO794	DN	Galantamine
DMEO794	HS	Approved
DMEO794	SN	GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
DMEO794	CP	Janssen Pharmaceutica
DMEO794	TC	Parasympathomimetics
DMEO794	DT	Small molecular drug
DMEO794	PC	9651
DMEO794	MW	287.35
DMEO794	FM	C17H21NO3
DMEO794	IC	InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
DMEO794	CS	CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
DMEO794	IK	ASUTZQLVASHGKV-JDFRZJQESA-N
DMEO794	IU	(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
DMEO794	CA	CAS 357-70-0
DMEO794	CB	CHEBI:42944
DMEO794	DE	Alzheimer disease

DMIZ1E8	ID	DMIZ1E8
DMIZ1E8	DN	Galcanezumab
DMIZ1E8	HS	Approved
DMIZ1E8	SN	Galcanezumab [USAN:INN]; UNII-55KHL3P693; 55KHL3P693
DMIZ1E8	CP	Eli Lilly
DMIZ1E8	DT	Antibody
DMIZ1E8	DE	Hyperprolactinaemia

DMPO0MS	ID	DMPO0MS
DMPO0MS	DN	Gallamine Triethiodide
DMPO0MS	HS	Approved
DMPO0MS	SN	Benzkurin; Flaxedil; Gallaflex; Parexyl; Pirolakson; Pyrolaxon; Relaxan; Remyolan; Retensin; Sincurarine; Syncurarine; Tricuran; Benzcurine iodide; Gallamin triethiodide; Gallamina triodoetilato; Gallamina triodoetilato [DCIT]; Gallamine iodide; Gallamine triethiodide [INN]; Gallamine triiodoethylate; Gallamini triethiodidum; Gallaminii iodidum; Gallaminum triaethjodidum; Gallaminum triaethoiodatum; Gallamone triethiodide; Gallamoni jodidum; Miowas G; Triethiodure de gallamine; Triethiodurode galamina; Triiodoethylate de gallamine; Triiodoethylate de gallamine [French]; F 2559; Fourneau 2559; G 8134; HL 8583; RP 3697; Flaxedil (TN); Gallamine triethiodide (USP); Gallamine-3ETI; Gallamini triethiodidum [INN-Latin]; Triethiodure de gallamine [INN-French]; Triethioduro de galamina [INN-Spanish]; Pyrogallol 1,2,3-(diethylaminoethyl ether) trisethyl iodide; Pyrogallol 1,2,3-(diethylaminoethyl ether) tris(ethyliodide); Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene; Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene [French]; Triiodoethylate of tri(diethylaminoethyloxy)-1,2,3-benzene; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene [French]; Ammonium, (v-phenenyltris(oxyethylene))tris(triethyl-, triiodide; Ammonium, (v-phenenyltris(oxyethylene)tris(triethyl-, triiodide; Tri(beta-diethylaminoethoxy)-1,2,3-benzene tri-iodoethylate; Ethanaminium, 2,2',2'-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl-, triiodide; (v-Phenenyltris(oxyethylene))tris(triethylammonium iodide); (v-Phenenyltris(oxyethylene))tris(triethylammonium) triiodide; (v-Phenenyltris(oxyethylene))tris(triethylammoniumiodide); 1,2,3-Tri(beta-diethylaminoethoxy)benzene triethiodide; 1,2,3-Tris(2-diethylaminoethoxy)benzene triethiodide; 1,2,3-Tris(2-diethylaminoethoxy)benzene tris(ethyliodide); 1,2,3-Tris(2-triethylammonium ethoxy)benzene triiodide; 1,2,3-Tris(diethylaminoethoxy)benzene triethiodide; 2,2',2''-(1,2,3-Benzenetriyltris(oxy))tris(N,N,N-triethylethanaminium) triiodide; 2,2',2''-[benzene-1,2,3-triyltris(oxy)]tris(N,N,N-triethylethanaminium) triiodide; 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium triiodide
DMPO0MS	TC	Skeletal Muscle Relaxants
DMPO0MS	DT	Small molecular drug
DMPO0MS	PC	6172
DMPO0MS	MW	891.5
DMPO0MS	FM	C30H60I3N3O3
DMPO0MS	IC	InChI=1S/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3
DMPO0MS	CS	CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-]
DMPO0MS	IK	REEUVFCVXKWOFE-UHFFFAOYSA-K
DMPO0MS	IU	2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium;triiodide
DMPO0MS	CA	CAS 65-29-2
DMPO0MS	DE	Stabilize muscle contraction

DMF9O6B	ID	DMF9O6B
DMF9O6B	DN	Gallium nitrate
DMF9O6B	HS	Approved
DMF9O6B	SN	Ganite (TN)
DMF9O6B	TC	Anticancer Agents
DMF9O6B	DT	Small molecular drug
DMF9O6B	PC	61635
DMF9O6B	MW	255.74
DMF9O6B	FM	GaN3O9
DMF9O6B	IC	InChI=1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1
DMF9O6B	CS	[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ga+3]
DMF9O6B	IK	CHPZKNULDCNCBW-UHFFFAOYSA-N
DMF9O6B	IU	gallium;trinitrate
DMF9O6B	CA	CAS 13494-90-1
DMF9O6B	DE	Hypercalcaemia

DMER9YA	ID	DMER9YA
DMER9YA	DN	Galsulfase
DMER9YA	HS	Approved
DMER9YA	SN	Aryplase; Aryplase (TN); Galsulfase (genetical recombination); Galsulfase (USAN/INN); Galsulfase (genetical recombination) (JAN)
DMER9YA	TC	Enzyme Replacement Agents
DMER9YA	SQ	Galsulfase: SGAGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTNGTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM
DMER9YA	DE	Mucopolysaccharidosis

DMGBKVD	ID	DMGBKVD
DMGBKVD	DN	Gamma hydroxybutyric acid
DMGBKVD	HS	Approved
DMGBKVD	SN	Anetamin; GHB; Hydroxyb; Oxybate; SHB; Somsanit; Xyrem; Gamma OH; Oxybate sodium; Utyric acid monosodium salt; EB 27; WY 3478; Gam-OH; Gamma-Hydroxy butyrate; Gamma-Hydroxy sodium butyrate; Gamma-Hydroxybutanoic acid; Gamma-Hydroxybutyrate sodium; Gamma-Hydroxybutyric acid; Gamma-Hydroxybutyric acid decomposition product; Gamma-Hydroxybutyric acid monosodium salt; Gamma-OH; Xyrem (TN); Gamma-Hydroxybutyric acid, sodium salt; Oxy-n-butyric acid; Sodium Oxybate (4-hydroxybutanoic acid); Sodium .gamma.-hydroxybutyrate; Sodium .gamma.-oxybutyrate; AA3E2AF0-AB7A-4A1E-A391-199C049D7162; Butanoic acid, 4-hydroxy-, monosodium salt; Butanoic acid, 4-hydroxy-, sodium salt; Butyric acid, 4-hydroxy-, monosodium salt; Butyric acid, 4-hydroxy-, sodium salt; 3-carboxypropoxy acid; 4 HB; 4-Hydroxy; 4-Hydroxyacid; 4-Hydroxyalkanoic acid; 4-Hydroxybutanoic acid; 4-Hydroxybuttersaeure; 4-Hydroxybutyrate sodium; 4-Hydroxybutyric acid; 4-Hydroxybutyric acid monosodium salt; 4-Hydroxycarboxylic acid; 4-OHB; 4-hydroxy-butyric acid
DMGBKVD	CP	Jazz Pharmaceuticals
DMGBKVD	TC	Anesthetics
DMGBKVD	DT	Small molecular drug
DMGBKVD	PC	10413
DMGBKVD	MW	104.1
DMGBKVD	FM	C4H8O3
DMGBKVD	IC	InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7)
DMGBKVD	CS	C(CC(=O)O)CO
DMGBKVD	IK	SJZRECIVHVDYJC-UHFFFAOYSA-N
DMGBKVD	IU	4-hydroxybutanoic acid
DMGBKVD	CA	CAS 591-81-1
DMGBKVD	CB	CHEBI:30830
DMGBKVD	DE	Narcolepsy

DMSXKYG	ID	DMSXKYG
DMSXKYG	DN	Gamma-homolinolenic acid
DMSXKYG	HS	Approved
DMSXKYG	SN	DGLA; BML3-B11; Ro 12-1989; Star GLA (GNC); Bishomo-gamma-linolenic acid; C 20:3 n-6; Dihomo-gamma-linolenic acid; Homo-gamma-linolenic acid; Homo-gamma-linolensaeure; Tona-lean 1000 CLA (Action Labs); Cis-8,11,14-Eicosatrienoic Acid; Eicosa-8Z,11Z,14Z-trienoic acid; All-cis-8,11,14-Eicosatrienoic acid; All-cis-8,11,14-icosatrienoic acid; All-cis-Eicosa-8,11,14-triensaeure; Cis,cis,cis-8,11,14-Eicosatrienoic acid; Cis-8,cis-11,cis-14-Eicosatrienoic acid; (8E,11E,14E)-8,11,14-Icosatrienoic acid; (8Z,11Z,14Z)-Icosatrienoic acid; (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid; (Z,Z,Z)-8,11,14-Eicosatrienoate; (Z,Z,Z)-8,11,14-Eicosatrienoic acid; (Z,Z,Z)-8,11,14-Icosatrienoate; (Z,Z,Z)-8,11,14-Icosatrienoicacid; 20:3, n-6,9,12 all-cis; 8, 11, 14-eicosatrienoic acid; 8,11,14-Eicosatrienoate; 8,11,14-Eicosatrienoic acid; 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)-(9CI); 8,11,14-Eicosatrienoic acid, (Z,Z,Z)-(8CI); 8,11,14-Icosatrienoate; 8,11,14-all-cis-Eicosatrienoic acid; 8c,11c,14c-Eicosatriensaeure; 8c,11c,14c-eicosatrienoic acid
DMSXKYG	TC	Dietary supplement
DMSXKYG	DT	Small molecular drug
DMSXKYG	PC	5280581
DMSXKYG	MW	306.5
DMSXKYG	FM	C20H34O2
DMSXKYG	IC	InChI=1S/C20H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13H,2-5,8,11,14-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-
DMSXKYG	CS	CCCCC/C=C\\C/C=C\\C/C=C\\CCCCCCC(=O)O
DMSXKYG	IK	HOBAELRKJCKHQD-QNEBEIHSSA-N
DMSXKYG	IU	(8Z,11Z,14Z)-icosa-8,11,14-trienoic acid
DMSXKYG	CA	CAS 1783-84-2
DMSXKYG	CB	CHEBI:53486
DMSXKYG	DE	Malnutrition

DMQN30Z	ID	DMQN30Z
DMQN30Z	DN	Gamolenic acid
DMQN30Z	HS	Approved
DMQN30Z	SN	gamma-Linolenic acid; GAMOLENIC ACID; 506-26-3; (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid; (Z,Z,Z)-6,9,12-Octadecatrienoic acid; CCRIS 7668; UNII-78YC2MAX4O; Acidum gamolenicum [Latin]; Acido gamolenico [Spanish]; Acide gamolenique [French]; 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-; Gamolenic acid [INN:BAN]; (6,9,12)-linolenic acid; all-cis-6,9,12-Octadecatrienoic acid; cis,cis,cis-6,9,12-Octadecatrienoic acid; 6Z,9Z,12Z-octadecatrienoic acid; 78YC2MAX4O; cis-Delta(6,9,12)-octadecatrienoic acid; CHEMBL464982; CHEBI:28661; Epogam (TN); gamma-linolenic acid
DMQN30Z	DT	Small molecular drug
DMQN30Z	PC	5280933
DMQN30Z	MW	278.4
DMQN30Z	FM	C18H30O2
DMQN30Z	IC	InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-
DMQN30Z	CS	CCCCC/C=C\\C/C=C\\C/C=C\\CCCCC(=O)O
DMQN30Z	IK	VZCCETWTMQHEPK-QNEBEIHSSA-N
DMQN30Z	IU	(6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid
DMQN30Z	CA	CAS 506-26-3
DMQN30Z	CB	CHEBI:28661
DMQN30Z	DE	Allergy

DM1MBYQ	ID	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	HS	Approved
DM1MBYQ	SN	ganciclovir; 82410-32-0; Gancyclovir; Cytovene; Vitrasert; Hydroxyacyclovir; Ganciclovirum; Zirgan; RS-21592; Cymevene; HHEMG; Biolf 62; BW-759U; Ganciclovirum [Latin]; 2'-NDG; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; BW 759U; BIOLF-62; 2'-Nor-2'-deoxyguanosine; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BW-B 759U; UNII-P9G3CKZ4P5; DRG-0018; BW 759; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; CCRIS 9212; GA2; Cytovene-IV; HSDB 6512
DM1MBYQ	CP	Bausch & Lomb Pharmaceuticals, Inc.
DM1MBYQ	TC	Antiviral Agents
DM1MBYQ	DT	Small molecular drug
DM1MBYQ	PC	135398740
DM1MBYQ	MW	255.23
DM1MBYQ	FM	C9H13N5O4
DM1MBYQ	IC	InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
DM1MBYQ	CS	C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
DM1MBYQ	IK	IRSCQMHQWWYFCW-UHFFFAOYSA-N
DM1MBYQ	IU	2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one
DM1MBYQ	CA	CAS 82410-32-0
DM1MBYQ	CB	CHEBI:465284
DM1MBYQ	DE	Virus infection

DMGMB30	ID	DMGMB30
DMGMB30	DN	Ganirelix
DMGMB30	HS	Approved
DMGMB30	SN	Ganirelixum; Orgalutran; Ganirelix acetate; Antagon (TN); Ganirelix (INN); Ganirelix [INN:BAN]; Ganirelixum [INN-Latin]; Orgalutran (TN); RS-26306
DMGMB30	CP	Organon International
DMGMB30	TC	Abortifacient Agents
DMGMB30	DT	Small molecular drug
DMGMB30	PC	16130957
DMGMB30	MW	1570.3
DMGMB30	FM	C80H113ClN18O13
DMGMB30	IC	InChI=1S/C80H113ClN18O13/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89)/t50-,60-,61+,62+,63-,64+,65-,66-,67+,68+/m1/s1
DMGMB30	CS	CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC
DMGMB30	IK	GJNXBNATEDXMAK-PFLSVRRQSA-N
DMGMB30	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMGMB30	CA	CAS 124904-93-4
DMGMB30	CB	CHEBI:135910
DMGMB30	DE	Ovulation dysfunction

DMSL679	ID	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	HS	Approved
DMSL679	SN	Bonoq; GTFX; Gaity; Gatiflo; Gatilox; Gatiquin; Gatispan; Tequin; Zymar; Zymaxid; Zymer; AM 1155; CG 5501;PD 135432; PD135432; AM-1155; BMS 206584-01; BMS-206584; CG-5501; Gatiflo (TN); Gatifloxacin & Gamma Interferon; Gatifloxacin (INN); Gatifloxacin (TN); Gatifloxacin [USAN:INN]; PD-135432; Tequin (TN); Tequin in dextrose 5% in plastic container; Zymar (TN); Zymer (TN); BMS-206584-01; Gatiflo,Tequin and Zymar, Gatifloxacin; AM-1155 (*Sesquihydrate*); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMSL679	CP	Bristol-Myers Squibb
DMSL679	TC	Antiinfective Agents
DMSL679	DT	Small molecular drug
DMSL679	PC	5379
DMSL679	MW	375.4
DMSL679	FM	C19H22FN3O4
DMSL679	IC	InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
DMSL679	CS	CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
DMSL679	IK	XUBOMFCQGDBHNK-UHFFFAOYSA-N
DMSL679	IU	1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMSL679	CA	CAS 112811-59-3
DMSL679	CB	CHEBI:5280
DMSL679	DE	Respiratory tract infection

DMH0QKA	ID	DMH0QKA
DMH0QKA	DN	GDC-0199
DMH0QKA	HS	Approved
DMH0QKA	CP	AbbVie
DMH0QKA	DT	Small molecular drug
DMH0QKA	PC	49846579
DMH0QKA	MW	868.4
DMH0QKA	FM	C45H50ClN7O7S
DMH0QKA	IC	InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
DMH0QKA	CS	CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
DMH0QKA	IK	LQBVNQSMGBZMKD-UHFFFAOYSA-N
DMH0QKA	IU	4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
DMH0QKA	CA	CAS 1257044-40-8
DMH0QKA	CB	CHEBI:133021
DMH0QKA	DE	Chronic lymphocytic leukaemia; Solid tumour/cancer

DM15F0X	ID	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	HS	Approved
DM15F0X	SN	Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
DM15F0X	CP	AstraZeneca
DM15F0X	TC	Anticancer Agents
DM15F0X	DT	Small molecular drug
DM15F0X	PC	123631
DM15F0X	MW	446.9
DM15F0X	FM	C22H24ClFN4O3
DM15F0X	IC	InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
DM15F0X	CS	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
DM15F0X	IK	XGALLCVXEZPNRQ-UHFFFAOYSA-N
DM15F0X	IU	N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
DM15F0X	CA	CAS 184475-35-2
DM15F0X	CB	CHEBI:49668
DM15F0X	DE	Solid tumour/cancer; Urethral cancer; Head and neck cancer

DMSE3I7	ID	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	HS	Approved
DMSE3I7	SN	Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)
DMSE3I7	CP	Eli Lilly
DMSE3I7	TC	Anticancer Agents
DMSE3I7	DT	Small molecular drug
DMSE3I7	PC	60750
DMSE3I7	MW	263.2
DMSE3I7	FM	C9H11F2N3O4
DMSE3I7	IC	InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
DMSE3I7	CS	C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
DMSE3I7	IK	SDUQYLNIPVEERB-QPPQHZFASA-N
DMSE3I7	IU	4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMSE3I7	CA	CAS 95058-81-4
DMSE3I7	CB	CHEBI:175901
DMSE3I7	DE	Solid tumour/cancer

DMD8Q3J	ID	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	HS	Approved
DMD8Q3J	SN	ApoGemfibrozil; Ausgem; Bolutol; Brozil; Cholespid; Clearol; Decrelip; Elmogan; Fetinor; Fibratol; Fibrocit; GFZ; Gemd; Gemfibril; Gemfibromax; Gemfibrosil; Gemfibrozilo; Gemfibrozilum; Gemhexal; Gemlipid; Gemnpid; GenGemfibrozil; Genlip; Gozid; Hidil; Hipolixan; Innogem; Innogen; Ipolipid; Jezil; Lanaterom; Lifibron; Lipazil; Lipigem; Lipira; Lipizyl; Lipozid; Lipur; Litarek; Lopid; Micolip; Normolip; NuGemfibrozil; Pilder; Polyxit; Progemzal; Reducel; Regulip; Renabrazin; Sinelip; Synbrozil; Taborcil; Tentroc; Trialmin; Alphapharm Brand of Gemfibrozil; Apo Gemfibrozil; Apotex Brand of Gemfibrozil; Bayvit Brand of Gemfibrozil; Bexal Brand of Gemfibrozil; Biochemie Brand of Gemfibrozil; Bull Brand of Gemfibrozil; Cantabria Brand of Gemfibrozil; Chem mart Brand of Gemfibrozil; Chem mart Gemfibrozil; DBL Gemfibrozil; Douglas Brand of Gemfibrozil; Farmasierra Brand of Gemfibrozil; Faulding Brand of Gemfibrozil;Ferrer Brand of Gemfibrozil; Gemfibrozilo Bayvit; Gemfibrozilo Bexal; Gemfibrozilo Ur; Gen Gemfibrozil; GenRX Gemfibrozil; Genpharm Brand of Gemfibrozil; Gevilon Uno; Healthsense Brand of Gemfibrozil; Healthsense Gemfibrozil; Hexal Brand of Gemfibrozil; Ipsen Brand of Gemfibrozil; Lipox Gemfi; Lopid R; Menarini Brand of Gemfibrozil; Novo Gemfibrozil; Novopharm Brand of Gemfibrozil; Nu Gemfibrozil; Nu Pharm Brand of Gemfibrozil; PMS Gemfibrozil; Parke Davis Brand of Gemfibrozil; Pfizer Brand of Gemfibrozil; Pharmascience Brand of Gemfibrozil; Quimifar Brand of Gemfibrozil; SBPA Gemfibrozil; Sigma Brand of Gemfibrozil; TAD Brand of Gemfibrozil; Terry White Chemists Brand of Gemfibrozil; Terry White Chemists Gemfibrozil; United Drug Brand of Gemfibrozil; Warner Lambert Brand of Gemfibrozil; CI719; Gemfi 1A Pharma; Apo-Gemfibrozil; Bayvit, Gemfibrozilo; Gem-S; Gemfibrozil, GenRX; Gemfibrozil, Healthsense; Gemfibrozil, SBPA; Gemfibrozilo [INN-Spanish]; Gemfibrozilum [INN-Latin]; Gen-Fibro;Gen-Gemfibrozil; Jezil (TN); Lopid (TN); Low-Lip; Novo-Gemfibrozil; Nu-Gemfibrozil; Nu-Pharm Brand of Gemfibrozil; PMS-Gemfibrozil; TEVA-A; WL-Gemfibrozil; Warner-Lambert Brand of Gemfibrozil; GEMFIBROZIL (SEE ALSO PEROXISOME PROJECT (GEMFIBROZIL)); Gemfibrozil [USAN:BAN:INN]; Gen-Fibro (TN); PEROXISOME PROJECT (GEMFIBROZIL) (SEE ALSO GEMFIBROZIL); Gemfibrozil (JAN/USP/INN); Gemcor, Lopid, Jezil,Gen-Fibro, Gemfibrozil; 1A Brand of Gemfibrozil; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; 5-(2,5-Dimethyl-Phenoxy)-2,2-Dimethyl-Pentanoic Acid; 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid
DMD8Q3J	CP	Pfizer Pharmaceuticals
DMD8Q3J	TC	Antilipemic Agents
DMD8Q3J	DT	Small molecular drug
DMD8Q3J	PC	3463
DMD8Q3J	MW	250.33
DMD8Q3J	FM	C15H22O3
DMD8Q3J	IC	InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)
DMD8Q3J	CS	CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O
DMD8Q3J	IK	HEMJJKBWTPKOJG-UHFFFAOYSA-N
DMD8Q3J	IU	5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
DMD8Q3J	CA	CAS 25812-30-0
DMD8Q3J	CB	CHEBI:5296
DMD8Q3J	DE	Hyperlipidaemia

DMHT34O	ID	DMHT34O
DMHT34O	DN	Gemifloxacin
DMHT34O	HS	Approved
DMHT34O	SN	Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
DMHT34O	CP	Oscient Pharmaceuticals
DMHT34O	TC	Antibiotics
DMHT34O	DT	Small molecular drug
DMHT34O	PC	9571107
DMHT34O	MW	389.4
DMHT34O	FM	C18H20FN5O4
DMHT34O	IC	InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
DMHT34O	CS	CO/N=C/1\\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F
DMHT34O	IK	ZRCVYEYHRGVLOC-HYARGMPZSA-N
DMHT34O	IU	7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMHT34O	CA	CAS 175463-14-6
DMHT34O	CB	CHEBI:101853
DMHT34O	DE	Bacterial infection

DMJ2O7B	ID	DMJ2O7B
DMJ2O7B	DN	Gemtuzumab ozogamicin
DMJ2O7B	HS	Approved
DMJ2O7B	SN	Mylotarg (TN)
DMJ2O7B	CP	Wyeth Pharmaceuticals
DMJ2O7B	TC	Anticancer Agents
DMJ2O7B	DT	Antibody
DMJ2O7B	SQ	Light Chain No. 1: QIVLTQSPAIMSASPGEKVTITCSASSSISYMHWFQQKPGTSPKLWIYTTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCHQRSTYPLTFGSGTKLELK</sequence>    <sequence format="FASTA">&gt; Light Chain No. 2DIQMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPKLLMYKASSLESGVPSRFIGSGSGTEFTLTISSLQPDDFATYYCQQYNSDSKMFGQGTKVEVK</sequence>    <sequence format="FASTA">&gt; Heavy Chain No. 1QVQLQQSGAELAKPGASVKMSCKASGYTFTSYRMHWVKQRPGQGLEWIGYINPSTGYTEYNQKFKDKATLTADKSSSTAYMQLSSLTFEDSAVYYCARGGGVFDYWGQGTTLTVSS</sequence>    <sequence format="FASTA">&gt; Heavy Chain No. 2QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAIIWVRQAPGQGLEWMGGIVPMFGPPNYAQKFQGRVTITADESTNTAYMELSSLRSEDTAFYFCAGGYGIYSPEEYNGGLVTVSS
DMJ2O7B	DE	Acute myeloid leukaemia

DMKINJO	ID	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	HS	Approved
DMKINJO	SN	Alcomicin; Apogen; Bristagen; Cidomycin; GENTAMYCIN; Garamycin; Garasol; Gentacidin; Gentacycol; Gentafair; Gentak; Gentamar; Gentamicina; Gentamicine; Gentamicins; Gentamicinum; Gentamycinum; Gentavet; Gentocin; Jenamicin; Refobacin; Uromycine; Garamycin Otic Solution; Genoptic Liquifilm; Gentamcin Sulfate; Gentamicin sulphate sterile; Refobacin TM; Gentamicin C1; G-Mycin; G-Myticin; Garamycin (TN); Gentamicin (BAN); Gentamicin (TN); Gentamicina [INN-Spanish]; Gentamicine [INN-French]; Gentamicinum [INN-Latin];Gentamycin-creme; Gentamycin-creme [German]; Ocu-Mycin; Spectro-Genta; U-Gencin; Genoptic S.O.P.; O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; (1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-beta-L-lyxo-heptopyranoside; (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside
DMKINJO	CP	Sandoz
DMKINJO	TC	Antibiotics
DMKINJO	DT	Small molecular drug
DMKINJO	PC	3467
DMKINJO	MW	477.6
DMKINJO	FM	C21H43N5O7
DMKINJO	IC	InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3
DMKINJO	CS	CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
DMKINJO	IK	CEAZRRDELHUEMR-UHFFFAOYSA-N
DMKINJO	IU	2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMKINJO	CA	CAS 1403-66-3
DMKINJO	DE	Bacterial infection

DMBT7MI	ID	DMBT7MI
DMBT7MI	DN	Gentamicine sulfate
DMBT7MI	HS	Approved
DMBT7MI	SN	SCH-9724; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMBT7MI	TC	Antibiotics
DMBT7MI	DT	Small molecular drug
DMBT7MI	PC	6419933
DMBT7MI	MW	1488.8
DMBT7MI	FM	C60H125N15O25S
DMBT7MI	IC	InChI=1S/C21H43N5O7.C20H41N5O7.C19H39N5O7.H2O4S/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20;1-8(21)12-5-4-9(22)18(30-12)31-15-10(23)6-11(24)16(13(15)26)32-19-14(27)17(25-3)20(2,28)7-29-19;1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17;1-5(2,3)4/h9-20,25-29H,5-8,22-24H2,1-4H3;8-19,25-28H,4-7,21-24H2,1-3H3;8-18,24-27H,3-7,20-23H2,1-2H3;(H2,1,2,3,4)/t9-,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+;8-,9-,10+,11-,12+,13+,14-,15-,16+,17-,18-,19-,20+;8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-;/m110./s1
DMBT7MI	CS	C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O.OS(=O)(=O)O
DMBT7MI	IK	RDEIXVOBVLKYNT-HDZPSJEVSA-N
DMBT7MI	IU	(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid
DMBT7MI	CA	CAS 1405-41-0
DMBT7MI	DE	Bacterial infection

DMP0OVQ	ID	DMP0OVQ
DMP0OVQ	DN	Gestrinone
DMP0OVQ	HS	Approved
DMP0OVQ	SN	Dimetrose (TN)
DMP0OVQ	CP	Sarsa
DMP0OVQ	DT	Small molecular drug
DMP0OVQ	PC	27812
DMP0OVQ	MW	308.4
DMP0OVQ	FM	C21H24O2
DMP0OVQ	IC	InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1
DMP0OVQ	CS	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C#C)O
DMP0OVQ	IK	BJJXHLWLUDYTGC-ANULTFPQSA-N
DMP0OVQ	IU	(8S,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMP0OVQ	CA	CAS 16320-04-0
DMP0OVQ	CB	CHEBI:89642
DMP0OVQ	DE	Breast cancer

DMKGH0R	ID	DMKGH0R
DMKGH0R	DN	GHRP-2
DMKGH0R	HS	Approved
DMKGH0R	SN	Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy
DMKGH0R	DT	Small molecular drug
DMKGH0R	PC	6918245
DMKGH0R	MW	818
DMKGH0R	FM	C45H55N9O6
DMKGH0R	IC	InChI=1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1
DMKGH0R	CS	C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N
DMKGH0R	IK	HRNLPPBUBKMZMT-RDRUQFPZSA-N
DMKGH0R	IU	(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
DMKGH0R	CA	CAS 158861-67-7
DMKGH0R	CB	CHEBI:135890
DMKGH0R	DE	Growth hormone deficiency

DMTI0ZO	ID	DMTI0ZO
DMTI0ZO	DN	Gilteritinib
DMTI0ZO	HS	Approved
DMTI0ZO	SN	6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; ASP 2215; Gilteritinib; Gilteritinib (ASP-2215); Gilteritinib (ASP2215); Gilteritinib (USAN/INN); Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Xospata
DMTI0ZO	TC	Anticancer Agents
DMTI0ZO	DT	Small molecular drug
DMTI0ZO	PC	49803313
DMTI0ZO	MW	552.724
DMTI0ZO	FM	C29H44N8O3
DMTI0ZO	IC	InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
DMTI0ZO	CS	CCC1=NC(=C(N=C1NC2CCOCC2)NC3=CC(=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC)C(=O)N
DMTI0ZO	IK	GYQYAJJFPNQOOW-UHFFFAOYSA-N
DMTI0ZO	IU	6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
DMTI0ZO	CA	CAS 1254053-43-4
DMTI0ZO	DE	Acute myeloid leukemia

DMWQ4MZ	ID	DMWQ4MZ
DMWQ4MZ	DN	Gilteritinib
DMWQ4MZ	HS	Approved
DMWQ4MZ	SN	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199
DMWQ4MZ	CP	Astellas
DMWQ4MZ	PC	49803313
DMWQ4MZ	MW	552.7
DMWQ4MZ	FM	C29H44N8O3
DMWQ4MZ	IC	InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
DMWQ4MZ	CS	CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5
DMWQ4MZ	IK	GYQYAJJFPNQOOW-UHFFFAOYSA-N
DMWQ4MZ	IU	6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
DMWQ4MZ	CA	CAS 1254053-43-4
DMWQ4MZ	CB	CHEBI:145372
DMWQ4MZ	DE	Acute myeloid leukaemia

DM5PFIJ	ID	DM5PFIJ
DM5PFIJ	DN	Givosiran
DM5PFIJ	HS	Approved
DM5PFIJ	SN	1639325-43-1; N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide; Fitusiran; Givlaari; Givosiran [INN]; Givosiran [USAN]; Givosiran [USAN:INN]; ALN-AS1; UNII-ROV204583W; ROV204583W; WHO 10280
DM5PFIJ	CP	Alnylam Pharmaceuticals
DM5PFIJ	DT	Small interfering RNA
DM5PFIJ	PC	119058042
DM5PFIJ	MW	1711
DM5PFIJ	FM	C78H139N11O30
DM5PFIJ	IC	InChI=1S/C78H139N11O30/c1-50-42-54(96)43-89(50)65(104)26-12-10-8-6-5-7-9-11-25-64(103)88-78(47-111-39-27-61(100)82-33-19-30-79-58(97)22-13-16-36-114-75-66(85-51(2)93)72(108)69(105)55(44-90)117-75,48-112-40-28-62(101)83-34-20-31-80-59(98)23-14-17-37-115-76-67(86-52(3)94)73(109)70(106)56(45-91)118-76)49-113-41-29-63(102)84-35-21-32-81-60(99)24-15-18-38-116-77-68(87-53(4)95)74(110)71(107)57(46-92)119-77/h50,54-57,66-77,90-92,96,105-110H,5-49H2,1-4H3,(H,79,97)(H,80,98)(H,81,99)(H,82,100)(H,83,101)(H,84,102)(H,85,93)(H,86,94)(H,87,95)(H,88,103)/t50-,54-,55-,56-,57-,66-,67-,68-,69+,70+,71+,72-,73-,74-,75-,76-,77-/m1/s1
DM5PFIJ	CS	C[C@@H]1C[C@H](CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCO[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)NC(=O)C)O
DM5PFIJ	IK	RUPXJRIDSUCQAN-PQNNUJSWSA-N
DM5PFIJ	IU	N-[1,3-bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide
DM5PFIJ	CA	CAS 1639325-43-1
DM5PFIJ	DE	Acute intermittent hepatic porphyria

DM83MOK	ID	DM83MOK
DM83MOK	DN	Glassia
DM83MOK	HS	Approved
DM83MOK	SN	Glassia (TN)
DM83MOK	CP	Baxter
DM83MOK	DE	Emphysema

DMAPV1B	ID	DMAPV1B
DMAPV1B	DN	Glatiramer acetate
DMAPV1B	HS	Approved
DMAPV1B	SN	Glatiramer acetate; Copaxone; 147245-92-9; Copolymer 1; Copolymer-1; COP-1; Protiramer; Glatopa; L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt); L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1); (2S)-2,6-diaminohexanoic acid; TV 5010; UNII-5M691HL4BO; Glatirameracetat; Glatiramer acetate [USAN:BAN]; AC1MIXQC; 5M691HL4BO
DMAPV1B	CP	Teva Pharmaceuticals
DMAPV1B	TC	Immunosuppressive Agents
DMAPV1B	DT	Small molecular drug
DMAPV1B	SQ	Example Glatiramer peptide: EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK
DMAPV1B	PC	3081884
DMAPV1B	MW	623.7
DMAPV1B	FM	C25H45N5O13
DMAPV1B	IC	InChI=1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)/t8-;5-;3-;2-;/m0000./s1
DMAPV1B	CS	C[C@@H](C(=O)O)N.CC(=O)O.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N
DMAPV1B	IK	FHEAIOHRHQGZPC-KIWGSFCNSA-N
DMAPV1B	IU	acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid
DMAPV1B	CA	CAS 147245-92-9
DMAPV1B	DE	Multiple sclerosis

DM31YVO	ID	DM31YVO
DM31YVO	DN	Glecaprevir
DM31YVO	HS	Approved
DM31YVO	SN	Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; glecaprevirum; 1365970-03-1; A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CHEMBL3545363; CS-8098; D10814; DB13879; EX-A1940; HY-17634; UNII-K6BUU8J72P
DM31YVO	PC	66828839
DM31YVO	MW	838.9
DM31YVO	FM	C38H46F4N6O9S
DM31YVO	IC	MLSQGNCUYAMAHD-ITNVBOSISA-N
DM31YVO	CS	CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
DM31YVO	IK	1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
DM31YVO	IU	(1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide
DM31YVO	CA	CAS 1365970-03-1
DM31YVO	DE	Viral hepatitis

DMF6Z5T	ID	DMF6Z5T
DMF6Z5T	DN	Glecaprevir; pibrentasvir
DMF6Z5T	HS	Approved
DMF6Z5T	SN	pibrentasvir; Maviret; Mavyret; Glecaprevir / pibrentasvir; Glecaprevir and pibrentasvir; ABT-493/ABT-530; Glecaprevir mixture with pibrentasvir; ABT-493 / ABT-530; S900007520
DMF6Z5T	CP	AbbVie
DMF6Z5T	DT	Combination drug
DMF6Z5T	PC	66828839; 58031952
DMF6Z5T	DE	Hepatitis C virus infection

DM8JXPZ	ID	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	HS	Approved
DM8JXPZ	SN	Abbenclamide; Adiab; Azuglucon; Bastiverit; Benclamin; Betanase; Calabren; Cytagon; Daonil; Debtan; Diabeta; Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglykon; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Glibenbeta; Glibenclamida; Glibenclamidum; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glycolande; Glycomin; Glynase; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Melix; Micronase; Miglucan; Nadib; Neogluconin; Normoglucon; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Sugril; Suraben; Tiabet; Yuglucon; Euglucon N; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glyburide [USAN]; Micronized glyburide; Betanese 5; Euglucon 5; G 0639; GBN 5; HB 419; HB 420; HB419; HB420; Norglicem 5; U 26452; UR 606; Apo-Glibenclamide; Daonil (TN); Dia-basan; Diabeta (TN); Euglucon (TN); Gen-Glybe; Gliben-Puren N; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida [INN-Spanish]; Glibenclamidum [INN-Latin]; Gluco-Tablimen; Glyburide (USP); Glyburide (micronized); Glynase (TN); HB-419; HB-420; Hemi-Daonil; Med-Glionil; Micronase (TN); Novo-Glyburide; Semi-Euglucon; Semi-daonil; U-26452; Glibenclamide (JP15/INN); Semi-Daonil (TN); Semi-Gliben-Puren N; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
DM8JXPZ	CP	Nigerian-German Chemicals
DM8JXPZ	TC	Hypoglycemic Agents
DM8JXPZ	DT	Small molecular drug
DM8JXPZ	PC	3488
DM8JXPZ	MW	494
DM8JXPZ	FM	C23H28ClN3O5S
DM8JXPZ	IC	InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
DM8JXPZ	CS	COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
DM8JXPZ	IK	ZNNLBTZKUZBEKO-UHFFFAOYSA-N
DM8JXPZ	IU	5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
DM8JXPZ	CA	CAS 10238-21-8
DM8JXPZ	CB	CHEBI:5441
DM8JXPZ	DE	Diabetic complication; Stroke

DMN6QO5	ID	DMN6QO5
DMN6QO5	DN	Gliclazide
DMN6QO5	HS	Approved
DMN6QO5	SN	Diaikron; Diamicron; Gliclazida; Gliclazidum; Gliklazid; Glimicron; Glyclazide; Nordialex; S 1702; S 852; SE 1702; Diamicron (TN); Dianorm (TN); Gliclazida [INN-Spanish]; Gliclazidum [INN-Latin]; Glimicron (TN); S-1702; S-852; Gliclazide (JAN/INN); Glubitor-OD (TN); Gliclazide [BAN:INN:DCF:JAN]; N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide; N-[(hexahydrocyclopenta[c]pyrrol-2(1H)-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea; 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea; 1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea; 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea; 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea
DMN6QO5	TC	Hypoglycemic Agents
DMN6QO5	DT	Small molecular drug
DMN6QO5	PC	3475
DMN6QO5	MW	323.4
DMN6QO5	FM	C15H21N3O3S
DMN6QO5	IC	InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
DMN6QO5	CS	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
DMN6QO5	IK	BOVGTQGAOIONJV-UHFFFAOYSA-N
DMN6QO5	IU	1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea
DMN6QO5	CA	CAS 21187-98-4
DMN6QO5	CB	CHEBI:31654
DMN6QO5	DE	Diabetic complication

DM5FSJA	ID	DM5FSJA
DM5FSJA	DN	Glimepiride
DM5FSJA	HS	Approved
DM5FSJA	SN	Amarel; Amaryl; Endial; Glimepirid; Glimepirida; Glimepiridum; Glimepride; Glimer; Glymepirid; Roname; Solosa; Glimepirida [Spanish]; Glimepiridum [Latin]; Sandoz glimepiride; HOE 490; Amaryl (TN); Hoe-490; Novo-glimepiride; PMS-glimepiride; Ratio-glimepiride; Amaryl, Glista OD, Glimepiride; Glimepiride [USAN:BAN:INN]; Glimepiride (JAN/USP/INN); 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; 64598P
DM5FSJA	CP	Sanofi-Aventis
DM5FSJA	TC	Hypoglycemic Agents
DM5FSJA	DT	Small molecular drug
DM5FSJA	PC	3476
DM5FSJA	MW	490.6
DM5FSJA	FM	C24H34N4O5S
DM5FSJA	IC	InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)
DM5FSJA	CS	CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C
DM5FSJA	IK	WIGIZIANZCJQQY-UHFFFAOYSA-N
DM5FSJA	IU	4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
DM5FSJA	CA	CAS 261361-60-8
DM5FSJA	CB	CHEBI:5383
DM5FSJA	DE	Diabetic complication

DMZA5PQ	ID	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	HS	Approved
DMZA5PQ	SN	Aldiab; Digrin; Dipazide; Glibenese; Glibetin; Glican; Glide; Glidiab; Glidiazinamide; Glipid; Glipizida; Glipizidum; Glucolip; Glucotrol; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; Glypidizine; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Semiglynase; Sucrazide; Alphapharm Brand of Glipizide; Glibenese Brand of Glipizide; Glipizide Kenfarma Brand; Glucotrol XL; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; CP 28720; K 4024; K4024; PfizerBrand 1 of Glipizide; Pfizer Brand 2 of Glipizide; TK 1320; CP 28,720; CP-28720; G-117; Glipizida [INN-Spanish]; Glipizide Extended-Release Tablets; Glipizidum [INN-Latin]; Gluco-Rite; Glucotrol (TN); K-4024; KS-1068; Samarium(III) ionophore I; Glipizide (USP/INN); Glipizide [USAN:BAN:INN]; Glucotrol XL, Glucotrol, Glipizide; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea
DMZA5PQ	CP	Pfizer Pharmaceuticals
DMZA5PQ	TC	Hypoglycemic Agents
DMZA5PQ	DT	Small molecular drug
DMZA5PQ	PC	3478
DMZA5PQ	MW	445.5
DMZA5PQ	FM	C21H27N5O4S
DMZA5PQ	IC	InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
DMZA5PQ	CS	CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
DMZA5PQ	IK	ZJJXGWJIGJFDTL-UHFFFAOYSA-N
DMZA5PQ	IU	N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide
DMZA5PQ	CA	CAS 29094-61-9
DMZA5PQ	CB	CHEBI:5384
DMZA5PQ	DE	Diabetic complication

DMB0EUX	ID	DMB0EUX
DMB0EUX	DN	Gliquidone
DMB0EUX	HS	Approved
DMB0EUX	SN	Beglynor; Beglynora; Glikvidon; Gliquidona; Gliquidonum; Glurenorm; Glycvidon; ARDF 26; ARDF 26 SE; AR-DF 26; Gliquidona [INN-Spanish]; Gliquidone (INN); Gliquidone [BAN:INN]; Gliquidonum [INN-Latin]; Glurenorm (TN); N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide; 1-Cyclohexyl-3-((p-(2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolyl)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea
DMB0EUX	CP	Boehriger Ingelheim
DMB0EUX	TC	Hypoglycemic Agents
DMB0EUX	DT	Small molecular drug
DMB0EUX	PC	91610
DMB0EUX	MW	527.6
DMB0EUX	FM	C27H33N3O6S
DMB0EUX	IC	InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)
DMB0EUX	CS	CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C
DMB0EUX	IK	LLJFMFZYVVLQKT-UHFFFAOYSA-N
DMB0EUX	IU	1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea
DMB0EUX	CA	CAS 33342-05-1
DMB0EUX	CB	CHEBI:93416
DMB0EUX	DE	Diabetic complication

DMJPR2B	ID	DMJPR2B
DMJPR2B	DN	Glisoxepide
DMJPR2B	HS	Approved
DMJPR2B	SN	Glisepin; Glisoxepid; Glisoxepida; Glisoxepidum; Glisoxepida [Spanish]; BS 4231; Bay B 4231; FBB 4231; RP22410; Glisoxepida [INN-Spanish]; Glisoxepide (INN); Glisoxepidum [INN-Latin]; Pro-Diaban; Glisoxepide [INN:BAN:DCF]; N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide; N-{2-[4-({[(azepan-1-ylamino)carbonyl]amino}sulfonyl)phenyl]ethyl}-5-methylisoxazole-3-carboxamide; 1-(Hexahydro-1H-azepin-1-yl)-3-((p-(2-(5-methyl-3-isoxazolecarboxamido)ethyl)phenyl)sulfonyl)urea
DMJPR2B	TC	Hypoglycemic Agents
DMJPR2B	DT	Small molecular drug
DMJPR2B	PC	32778
DMJPR2B	MW	449.5
DMJPR2B	FM	C20H27N5O5S
DMJPR2B	IC	InChI=1S/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)
DMJPR2B	CS	CC1=CC(=NO1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NN3CCCCCC3
DMJPR2B	IK	ZKUDBRCEOBOWLF-UHFFFAOYSA-N
DMJPR2B	IU	N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide
DMJPR2B	CA	CAS 25046-79-1
DMJPR2B	CB	CHEBI:135731
DMJPR2B	DE	Non-insulin dependent diabetes

DMFLUTR	ID	DMFLUTR
DMFLUTR	DN	Glucagon recombinant
DMFLUTR	HS	Approved
DMFLUTR	SN	Glucagon recombinant; GTPL1136; CHEMBL266481
DMFLUTR	TC	Antihypoglycemic Agents
DMFLUTR	DT	Small molecular drug
DMFLUTR	SQ	Glucagon for Injection Sequence : HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
DMFLUTR	PC	44278361
DMFLUTR	MW	3482.7
DMFLUTR	FM	C153H225N43O49S
DMFLUTR	IC	InChI=1S/C153H225N43O49S/c1-72(2)52-97(133(226)176-96(47-51-246-11)132(225)184-104(60-115(159)209)143(236)196-123(78(10)203)151(244)245)179-137(230)103(58-83-64-167-89-29-19-18-28-87(83)89)183-131(224)95(43-46-114(158)208)177-148(241)120(74(5)6)194-141(234)101(54-79-24-14-12-15-25-79)182-138(231)105(61-117(211)212)185-130(223)94(42-45-113(157)207)171-124(217)75(7)170-127(220)91(31-22-49-165-152(160)161)172-128(221)92(32-23-50-166-153(162)163)174-146(239)110(69-199)191-140(233)107(63-119(215)216)186-134(227)98(53-73(3)4)178-135(228)99(56-81-33-37-85(204)38-34-81)180-129(222)90(30-20-21-48-154)173-145(238)109(68-198)190-136(229)100(57-82-35-39-86(205)40-36-82)181-139(232)106(62-118(213)214)187-147(240)111(70-200)192-150(243)122(77(9)202)195-142(235)102(55-80-26-16-13-17-27-80)188-149(242)121(76(8)201)193-116(210)66-168-126(219)93(41-44-112(156)206)175-144(237)108(67-197)189-125(218)88(155)59-84-65-164-71-169-84/h12-19,24-29,33-40,64-65,71-78,88,90-111,120-123,167,197-205H,20-23,30-32,41-63,66-70,154-155H2,1-11H3,(H2,156,206)(H2,157,207)(H2,158,208)(H2,159,209)(H,164,169)(H,168,219)(H,170,220)(H,171,217)(H,172,221)(H,173,238)(H,174,239)(H,175,237)(H,176,226)(H,177,241)(H,178,228)(H,179,230)(H,180,222)(H,181,232)(H,182,231)(H,183,224)(H,184,225)(H,185,223)(H,186,227)(H,187,240)(H,188,242)(H,189,218)(H,190,229)(H,191,233)(H,192,243)(H,193,210)(H,194,234)(H,195,235)(H,196,236)(H,211,212)(H,213,214)(H,215,216)(H,244,245)(H4,160,161,165)(H4,162,163,166)/t75-,76+,77+,78+,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-/m0/s1
DMFLUTR	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O
DMFLUTR	IK	MASNOZXLGMXCHN-ZLPAWPGGSA-N
DMFLUTR	IU	(3S)-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMFLUTR	CB	CHEBI:5391
DMFLUTR	DE	Hypoglycemia

DM6EL5Q	ID	DM6EL5Q
DM6EL5Q	DN	Glucarpidase
DM6EL5Q	HS	Approved
DM6EL5Q	SN	Voraxaze (TN)
DM6EL5Q	CP	BTG International
DM6EL5Q	DT	Small molecular drug
DM6EL5Q	SQ	Glucarpidase: ALAQKRDNVLFQAATDEQPAVIKTLEKLVNIETGTGDAEGIAAAGNFLEAELKNLGFTVTRSKSAGLVVGDNIVGKIKGRGGKNLLLMSHMDTVYLKGILAKAPFRVEGDKAYGPGIADDKGGNAVILHTLKLLKEYGVRDYGTITVLFNTDEEKGSFGSRDLIQEEAKLADYVLSFEPTSAGDEKLSLGTSGIAYVQVNITGKASHAGAAPELGVNALVEASDLVLRTMNIDDKAKNLRFNWTIAKAGNVSNIIPASATLNADVRYARNEDFDAAMKTLEERAQQKKLPEADVKVIVTRGRPAFNAGEGGKKLVDKAVAYYKEAGGTLGVEERTGGGTDAAYAALSGKPVIESLGLPGFGYHSDKAEYVDISAIPRRLYMAARLIMDLGAGK
DM6EL5Q	PC	21195079
DM6EL5Q	MW	261.5
DM6EL5Q	FM	Zn4+8
DM6EL5Q	IC	InChI=1S/4Zn/q4*+2
DM6EL5Q	CS	[Zn+2].[Zn+2].[Zn+2].[Zn+2]
DM6EL5Q	IK	LZQXMCNBQHANEY-UHFFFAOYSA-N
DM6EL5Q	IU	zinc(2+)
DM6EL5Q	DE	Delayed methotrexate clearance

DM4ZLFD	ID	DM4ZLFD
DM4ZLFD	DN	Glucosamine
DM4ZLFD	HS	Approved
DM4ZLFD	SN	Chitosamine; GCS; Glucosamina; Glucosaminum; D-glucosamine; Glucosamina [INN-Spanish]; Glucosamine [USAN:INN]; Glucosaminum [INN-Latin]; Viartril-S; Beta-D-Glucosamine; Glucosamine (USAN/INN); Partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 2-Amino-2-deoxy-D-glucose; 2-Amino-2-deoxy-beta-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose; 2-amino-2-deoxyglucose
DM4ZLFD	TC	Antiinflammatory Agents
DM4ZLFD	DT	Small molecular drug
DM4ZLFD	PC	439213
DM4ZLFD	MW	179.17
DM4ZLFD	FM	C6H13NO5
DM4ZLFD	IC	InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6?/m1/s1
DM4ZLFD	CS	C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)N)O)O)O
DM4ZLFD	IK	MSWZFWKMSRAUBD-IVMDWMLBSA-N
DM4ZLFD	IU	(3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
DM4ZLFD	CA	CAS 3416-24-8
DM4ZLFD	CB	CHEBI:47977
DM4ZLFD	DE	Osteoarthritis

DMAHMT9	ID	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	HS	Approved
DMAHMT9	SN	glutathione; 70-18-8; Glutathion; Isethion; Tathion; Glutathione-SH; Glutinal; reduced glutathione; Neuthion; Deltathione; Copren; L-Glutathione reduced; Glutide; Tathione; Triptide; Ledac; Glutatione; GSH; Glutatiol; Panaron; gamma-L-Glutamyl-L-cysteinylglycine; Glutathione SH; L-Glutatione; Glutathione (reduced); Agifutol S; L-gamma-glutamyl-L-cysteinylglycine; gamma-L-glutamyl-L-cysteinyl-glycine; 5-L-Glutamyl-L-cysteinylglycine; Glutathione [JAN]; glutathione red; gamma-L-Glutamylcysteinylglycine; red. glutathione
DMAHMT9	DT	Small molecular drug
DMAHMT9	PC	124886
DMAHMT9	MW	307.33
DMAHMT9	FM	C10H17N3O6S
DMAHMT9	IC	InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1
DMAHMT9	CS	C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)N
DMAHMT9	IK	RWSXRVCMGQZWBV-WDSKDSINSA-N
DMAHMT9	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
DMAHMT9	CA	CAS 70-18-8
DMAHMT9	CB	CHEBI:16856
DMAHMT9	DE	Human immunodeficiency virus infection

DMGE0CW	ID	DMGE0CW
DMGE0CW	DN	Glutethimide
DMGE0CW	HS	Approved
DMGE0CW	SN	Alfimid; Doriden; Dorimide; Elrodorm; Gimid; Glimid; Glutathimid; Glutethimid; Glutethimidum; Glutetimid; Glutetimida; Glutetimide; Glutetimidu; Gluthetimide; Noxiron; Noxyron; Ondasil; Rigenox; Sarodormin; Glutetimide [DCIT]; Glutetimidu [Polish]; CC 11511; LT00114358; Doriden (TN); Doriden-sed; Glutethimide [INN:BAN]; Glutethimidum [INN-Latin]; Glutetimida [INN-Spanish]; Glutethimide (JAN/INN); Phenyl-aethyl-glutarsaeureimid; Phenyl-aethyl-glutarsaeureimid [German]; Alpha-Ethyl-alpha-phenylglutarimide; Alpha-Phenyl-alpha-ethylglutaric acid imide; Alpha-Phenyl-alpha-ethylglutarimide; 2-Ethyl-2-phenylglutarimide; 2-Phenyl-2-ethylglutaric acid imide; 3-Ethyl-3-phenyl-2,6-diketopiperidine; 3-Ethyl-3-phenyl-2,6-dioxopiperidine; 3-Ethyl-3-phenyl-2,6-piperidinedione; 3-Phenyl-3-ethyl-2,6-diketopiperidine; 3-Phenyl-3-ethyl-2,6-dioxopiperidine; 3-ethyl-3-phenylpiperidine-2,6-dione
DMGE0CW	TC	Hypnotics and Sedatives
DMGE0CW	DT	Small molecular drug
DMGE0CW	PC	3487
DMGE0CW	MW	217.26
DMGE0CW	FM	C13H15NO2
DMGE0CW	IC	InChI=1S/C13H15NO2/c1-2-13(10-6-4-3-5-7-10)9-8-11(15)14-12(13)16/h3-7H,2,8-9H2,1H3,(H,14,15,16)
DMGE0CW	CS	CCC1(CCC(=O)NC1=O)C2=CC=CC=C2
DMGE0CW	IK	JMBQKKAJIKAWKF-UHFFFAOYSA-N
DMGE0CW	IU	3-ethyl-3-phenylpiperidine-2,6-dione
DMGE0CW	CA	CAS 77-21-4
DMGE0CW	CB	CHEBI:5439
DMGE0CW	DE	Insomnia

DMDGRQO	ID	DMDGRQO
DMDGRQO	DN	Glycerol phenylbutyrate
DMDGRQO	HS	Approved
DMDGRQO	SN	GT4P; HPN-100; Glyceryl tri-(4-phenylbutyrate)
DMDGRQO	CP	Ucyclyd Pharma Inc
DMDGRQO	DT	Small molecular drug
DMDGRQO	PC	10482134
DMDGRQO	MW	530.6
DMDGRQO	FM	C33H38O6
DMDGRQO	IC	InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2
DMDGRQO	CS	C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3
DMDGRQO	IK	ZSDBFLMJVAGKOU-UHFFFAOYSA-N
DMDGRQO	IU	2,3-bis(4-phenylbutanoyloxy)propyl 4-phenylbutanoate
DMDGRQO	CA	CAS 611168-24-2
DMDGRQO	CB	CHEBI:134745
DMDGRQO	DE	Hepatic encephalopathy

DMIOZ29	ID	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	HS	Approved
DMIOZ29	SN	Aciport; Aminoazijnzuur; Aminoessigsaeure; Amitone; Corilin; Glicina; Glicoamin; Gly; Glycin; Glycinum; Glycocoll; Glycolixir; Glycosthene; Glykokoll; Glyzin; Hgly; Leimzucker; Padil; Polyglycine; Acide aminoacetique; Acido aminoacetico; Acidum aminoaceticum; Aminoacetic acid; Aminoethanoic acid; An alpha amino acid ester; Glycine [INN]; Hampshire glycine; Polyglycine II; Sucre de gelatine; Acide aminoacetique [INN-French]; Acido aminoacetico [INN-Spanish]; Acidum aminoaceticum [INN-Latin]; GLY (IUPAC abbrev); GLYCINE, ACS; Glicina [INN-Spanish]; Glycinum [INN-Latin]; Gyn-hydralin; L-Glycine; S04-0135; AB-131/40217813; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; GLYCINE 1.5% IN PLASTIC CONTAINER; Glycine (JP15/USP); Glycine iron sulphate (1:1); Glycine, homopolymer (VAN); Glycine, labeled with carbon-14; Glycine, non-medical; Glycine-UL-14C hydrochloride; H-Gly-OH; H2N-CH2-COOH; L-alpha-amino acids; (1-13c)glycinato; (15N)Glycine; 2,2-dialkylglycines; 2-Aminoacetic acid
DMIOZ29	TC	Dietary supplement
DMIOZ29	DT	Small molecular drug
DMIOZ29	PC	750
DMIOZ29	MW	75.07
DMIOZ29	FM	C2H5NO2
DMIOZ29	IC	InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)
DMIOZ29	CS	C(C(=O)O)N
DMIOZ29	IK	DHMQDGOQFOQNFH-UHFFFAOYSA-N
DMIOZ29	IU	2-aminoacetic acid
DMIOZ29	CA	CAS 56-40-6
DMIOZ29	CB	CHEBI:15428
DMIOZ29	DE	Malnutrition

DM1WL9O	ID	DM1WL9O
DM1WL9O	DN	Glycodiazine
DM1WL9O	HS	Approved
DM1WL9O	SN	GLYMIDINE; Glidiazine; Glycodiazin; Glymidinum; Glycodiazin [German]; Gondafon (TN); N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulphonamide; N-(5-{[2-(methyloxy)ethyl]oxy}pyrimidin-2-yl)benzenesulfonamide; 2-Benzolsulfonamido-5-.beta.-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine [German]; 5-beta-(Methoxyethoxy)-2-(phenylsulfonylamido)pyrimidine
DM1WL9O	TC	Hypoglycemic Agents
DM1WL9O	DT	Small molecular drug
DM1WL9O	PC	9565
DM1WL9O	MW	309.34
DM1WL9O	FM	C13H15N3O4S
DM1WL9O	IC	InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16)
DM1WL9O	CS	COCCOC1=CN=C(N=C1)NS(=O)(=O)C2=CC=CC=C2
DM1WL9O	IK	QFWPJPIVLCBXFJ-UHFFFAOYSA-N
DM1WL9O	IU	N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide
DM1WL9O	CA	CAS 339-44-6
DM1WL9O	CB	CHEBI:146188
DM1WL9O	DE	Diabetic complication

DM2M3ZA	ID	DM2M3ZA
DM2M3ZA	DN	Glycopyrrolate
DM2M3ZA	HS	Approved
DM2M3ZA	SN	GLYCOPYRROLATE; 596-51-0; Glycopyrrolate bromide; Robinul; Gastrodyn; Tarodyl; Nodapton; Tarodyn; Asecryl; Copyrrolate; Cuvposa; Glycopyrronii bromidum; AHR-504; ROBINUL FORTE; Robinal; Robanul; Bromuro de glicopirronio; Bromure de glycopyrronium; NVA-237; AHR 504; Glycopyrronii bromidum [INN-Latin]; EINECS 209-887-0; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio [INN-Spanish]; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide
DM2M3ZA	CP	Novartis
DM2M3ZA	TC	Anticholinergic Agents
DM2M3ZA	DT	Small molecular drug
DM2M3ZA	PC	11693
DM2M3ZA	MW	398.3
DM2M3ZA	FM	C19H28BrNO3
DM2M3ZA	IC	InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1
DM2M3ZA	CS	C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
DM2M3ZA	IK	VPNYRYCIDCJBOM-UHFFFAOYSA-M
DM2M3ZA	IU	(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
DM2M3ZA	CA	CAS 596-51-0
DM2M3ZA	CB	CHEBI:90972
DM2M3ZA	DE	Anaesthesia; Chronic obstructive pulmonary disease

DMGVJLB	ID	DMGVJLB
DMGVJLB	DN	GMA-161
DMGVJLB	HS	Approved (orphan drug)
DMGVJLB	CP	MacroGenics & Genzyme
DMGVJLB	DE	Idiopathic thrombocytopenic purpura

DMHZV7X	ID	DMHZV7X
DMHZV7X	DN	Golimumab
DMHZV7X	HS	Approved
DMHZV7X	SN	Simponi (TN); Golimumab (USAN/INN)
DMHZV7X	CP	Takeda
DMHZV7X	DT	Antibody
DMHZV7X	DE	Rheumatoid arthritis; Inflammatory bowel disease

DMAQ469	ID	DMAQ469
DMAQ469	DN	Gonadorelin
DMAQ469	HS	Approved
DMAQ469	SN	Dirigestran; Factrel; Fertagyl; Gonadorelina; Gonadorelinum; Hypocrine; Kryptocur; LFRH; LHFSHRH; Luforan; Luliberin; Lutal; Lutamin; Lutrefact; Relefact; Relisorm; Dirigestran Spofa; Gonadoliberin I; Gonadotropin releasing hormone; LHFSH Releasing Hormone; LUTEINIZING HORMONE; Lutrepulse KIT; MammalianGnRH; Relisorm l; Synthetic LRF; Synthetic gonadoliberin; HOE 471; AY-24031; FSH-Releasing Hormone; Fertagyl (TN); GnRH-I; Gonadorelin (INN); Gonadorelin [INN:BAN]; Gonadorelina [INN-Spanish]; Gonadorelinum [INN-Latin]; Gonadotropin-releasing factor; Gonadotropin-releasing hormone; Gonadotropin-releasing hormone I; Human LH-RH; LH-FSH Releasing Hormone; LH-Releasing hormone; Luteinizing hormone-releasing hormone; Mammalian LH-RH; Mammalian gonadotropin-releasing hormone; Ovine LH-RH; Ovine gonadotropin-releasing hormone; Porchine LH-RH; Porcine LH-releasing factor; Synthetic Gn-RH; Synthetic LH-FSH releasing hormone; Synthetic LH-RF; Synthetic LH-RH; Synthetic LH-releasing factor; Synthetic LH-releasing hormone; Synthetic gonadotropic hormone-releasing hormone; Synthetic gonadotropin-releasing hormone; LH-RH (swine); LH-Releasing factor (pig); LH-Releasing hormone (porcine); Luteinizing hormone-releasing factor (human); Luteinizing hormone-releasing factor (pig); Luteinizing hormone-releasing factor (rat); Luteinizing hormone-releasing factor (sheep); Luteinizing hormone-releasing factor (swine); Luteinizing hormone-releasing hormone (swin); Synthetic LH-FSH-RH; Synthetic decapeptide FSH/LH-RH; Follicle-stimulating hormone-releasing factor (pig); Gonadotropin, luteinizing hormone-releasing hormone, synthetic; Synthetic LH-RH/FSH-RH; Synthetic LH-releasing hormone/FSH-releasing hormone; PyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
DMAQ469	CP	Hikma (Maple) Ltd
DMAQ469	TC	Fertility Agents
DMAQ469	DT	Small molecular drug
DMAQ469	PC	638793
DMAQ469	MW	1182.3
DMAQ469	FM	C55H75N17O13
DMAQ469	IC	InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1
DMAQ469	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
DMAQ469	IK	XLXSAKCOAKORKW-AQJXLSMYSA-N
DMAQ469	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMAQ469	CA	CAS 9034-40-6
DMAQ469	CB	CHEBI:5520
DMAQ469	DE	Hypothalamic hypogonadism

DMAT8CG	ID	DMAT8CG
DMAT8CG	DN	Goserelin
DMAT8CG	HS	Approved
DMAT8CG	SN	AstraZeneca (TN); HS-2015; ZD-9393; Zoladex (TN)
DMAT8CG	CP	Zeneca Pharmaceuticals
DMAT8CG	TC	Anticancer Agents
DMAT8CG	DT	Small molecular drug
DMAT8CG	PC	5311128
DMAT8CG	MW	1269.4
DMAT8CG	FM	C59H84N18O14
DMAT8CG	IC	InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1
DMAT8CG	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
DMAT8CG	IK	BLCLNMBMMGCOAS-URPVMXJPSA-N
DMAT8CG	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMAT8CG	CA	CAS 65807-02-5
DMAT8CG	CB	CHEBI:5523
DMAT8CG	DE	Breast cancer

DMPT74U	ID	DMPT74U
DMPT74U	DN	Gramicidin D
DMPT74U	HS	Approved
DMPT74U	SN	Gramicidins; Gramoderm; Gramacidine S; Gramicidin C; Gramicidin Dubos; Gramicidin J; Gramicidin K; Gramicidin P; Gramicidin S; Gramicidin S [INN]; Gramicidina D; Gramicidina S; Gramicidinum S; Neosporin Ophthalmic Solution; Gramicin S 1; Gramacidine S [INN-French]; Gramicidin A(1); Gramicidin [INN:BAN]; Gramicidina S [INN-Spanish]; Gramicidina [INN-Spanish]; Gramicidine [INN-French]; Gramicidinum S [INN-Latin]; Gramicidinum [INN-Latin]; Gramicin S-A; Cyclo(L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl); 1,10-anhydro(L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithine)
DMPT74U	TC	Antibiotics
DMPT74U	DT	Small molecular drug
DMPT74U	PC	45267103
DMPT74U	MW	1811.2
DMPT74U	FM	C96H135N19O16
DMPT74U	IC	InChI=1S/C96H135N19O16/c1-50(2)36-71(105-79(118)48-102-93(128)80(54(9)10)103-49-117)86(121)104-58(17)84(119)113-82(56(13)14)95(130)115-83(57(15)16)96(131)114-81(55(11)12)94(129)112-78(43-62-47-101-70-33-25-21-29-66(62)70)92(127)108-74(39-53(7)8)89(124)111-77(42-61-46-100-69-32-24-20-28-65(61)69)91(126)107-73(38-52(5)6)88(123)110-76(41-60-45-99-68-31-23-19-27-64(60)68)90(125)106-72(37-51(3)4)87(122)109-75(85(120)97-34-35-116)40-59-44-98-67-30-22-18-26-63(59)67/h18-33,44-47,49-58,71-78,80-83,98-101,116H,34-43,48H2,1-17H3,(H,97,120)(H,102,128)(H,103,117)(H,104,121)(H,105,118)(H,106,125)(H,107,126)(H,108,127)(H,109,122)(H,110,123)(H,111,124)(H,112,129)(H,113,119)(H,114,131)(H,115,130)/t58-,71+,72+,73+,74+,75-,76-,77-,78-,80-,81+,82+,83-/m0/s1
DMPT74U	CS	C[C@@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)NCCO)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@H](C(C)C)NC=O
DMPT74U	IK	NDAYQJDHGXTBJL-MWWSRJDJSA-N
DMPT74U	IU	(2R)-2-[[2-[[(2S)-2-formamido-3-methylbutanoyl]amino]acetyl]amino]-N-[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-(2-hydroxyethylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]-4-methylpentanamide
DMPT74U	CA	CAS 1405-97-6
DMPT74U	DE	Bacterial infection

DMIUW25	ID	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	HS	Approved
DMIUW25	SN	BRL-43694; Kytril (TN); Granisetron (USAN/INN); 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide; 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
DMIUW25	CP	Roche Pharmaceuticals
DMIUW25	TC	Antiemetics
DMIUW25	DT	Small molecular drug
DMIUW25	PC	5284566
DMIUW25	MW	312.4
DMIUW25	FM	C18H24N4O
DMIUW25	IC	InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12?,13-,14+
DMIUW25	CS	CN1[C@@H]2CCC[C@H]1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
DMIUW25	IK	MFWNKCLOYSRHCJ-AGUYFDCRSA-N
DMIUW25	IU	1-methyl-N-[(1R,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
DMIUW25	CA	CAS 109889-09-0
DMIUW25	CB	CHEBI:5537
DMIUW25	DE	Nausea and vomiting

DMGLX0T	ID	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	HS	Approved
DMGLX0T	SN	Raxar; Grepafloxacin [INN]; Grepafloxacin (unspecified); Raxar (TN); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMGLX0T	CP	GlaxoSmithKline
DMGLX0T	TC	Antibiotics
DMGLX0T	DT	Small molecular drug
DMGLX0T	PC	72474
DMGLX0T	MW	359.4
DMGLX0T	FM	C19H22FN3O3
DMGLX0T	IC	InChI=1S/C19H22FN3O3/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26)
DMGLX0T	CS	CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F
DMGLX0T	IK	AIJTTZAVMXIJGM-UHFFFAOYSA-N
DMGLX0T	IU	1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMGLX0T	CA	CAS 119914-60-2
DMGLX0T	CB	CHEBI:5543
DMGLX0T	DE	Chronic bronchitis; Bacterial infection

DMK54YG	ID	DMK54YG
DMK54YG	DN	Griseofulvin
DMK54YG	HS	Approved
DMK54YG	SN	Amudane; Delmofulvina; Fulcin; Fulcine; Fulvicin; FulvicinUF; Fulvina; Fulvinil; Fulvistatin; Fungivin; Greosin;Gresfeed; Gricin; Grifulin; Grifulvin; GrisPEG; Grisactin; Griscofulvin; Grisefuline; Griseo; Griseofulvina; Griseofulvine; Griseofulvinum; Griseomix; Griseostatin; Grisetin; Grisofulvin; Grisovin; Grizeofulvin; Grysio; Guservin; Lamoryl; Likuden; Likunden; Murfulvin; Poncyl; Spirofulvin; Sporostatin; Xuanjing; Curling fact or; Curling factor; Fulvican grisactin; Fulvicin U F; Grifulvin V; Gris PEG; Grisactin Ultra; Grise ostatin; Griseofulvin forte; Grisovin FP; Interacts with polymerized microtubules and associated proteins; Sporostatin xan; Biogrisin-FP; FULVICIN P/G 165; FULVICIN P/G 330;Fulvicin Bolus (Veterinary); Fulvicin P/G; Fulvicin U/F; Fulvidex (Veterinary); GRISEOFULVIN, MICROCRYSTALLINE; GRISEOFULVIN, ULTRAMICROCRYSTALLINE; Gris-PEG; Griseofulvin and Alpha-IFN; Griseofulvin-forte; Griseofulvina [INN-Spanish]; Griseofulvine [INN-French]; Griseofulvinum [INN-Latin]; Grisovin (TN); NP-002466; Neo-Fulcin; ULTRAGRIS-165; ULTRAGRIS-330; USAF SC-2; Fulvicin-P/G; Fulvicin-U-F; Fulvicin-U/F; Fulvicin-U/F (Veterinary); Griseofulvin [USAN:INN:BAN:JAN]; (+)-Griseofulvin; 7-Chloro-4,6,2'-trimethoxy-6'-methylgris-2'-en-3,4'-dione
DMK54YG	TC	Antifungal Agents
DMK54YG	DT	Small molecular drug
DMK54YG	PC	441140
DMK54YG	MW	352.8
DMK54YG	FM	C17H17ClO6
DMK54YG	IC	InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1
DMK54YG	CS	C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC
DMK54YG	IK	DDUHZTYCFQRHIY-RBHXEPJQSA-N
DMK54YG	IU	(2S,5'R)-7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
DMK54YG	CA	CAS 126-07-8
DMK54YG	CB	CHEBI:27779
DMK54YG	DE	Ringworm infection

DM1ECNJ	ID	DM1ECNJ
DM1ECNJ	DN	GS-7340
DM1ECNJ	HS	Approved
DM1ECNJ	SN	Tenofovir alafenamide; Vemlidy
DM1ECNJ	CP	Gilead Sciences
DM1ECNJ	DT	Small molecular drug
DM1ECNJ	PC	9574768
DM1ECNJ	MW	476.5
DM1ECNJ	FM	C21H29N6O5P
DM1ECNJ	IC	InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
DM1ECNJ	CS	C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3
DM1ECNJ	IK	LDEKQSIMHVQZJK-CAQYMETFSA-N
DM1ECNJ	IU	propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DM1ECNJ	CA	CAS 379270-37-8
DM1ECNJ	CB	CHEBI:90926
DM1ECNJ	DE	Human immunodeficiency virus infection; Hepatitis B virus infection

DM8QB0T	ID	DM8QB0T
DM8QB0T	DN	GSK2592984A
DM8QB0T	HS	Approved
DM8QB0T	SN	GSK-2340269A; GSK-2340272A; Pandemrix (H1N1); H1N1 pandemic influenzavaccine (AS03 adjuvanted) 1, GlaxoSmithKline; H1N1 pandemic influenza vaccine 1 (AS03 adjuvanted), GSK; Influenza vaccines (intramuscular, influenza virus infection), GlaxoSmithKline
DM8QB0T	CP	GlaxoSmithKline plc
DM8QB0T	DT	Vaccine
DM8QB0T	DE	Influenza virus infection

DM5QWEL	ID	DM5QWEL
DM5QWEL	DN	Guanabenz
DM5QWEL	HS	Approved
DM5QWEL	SN	GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
DM5QWEL	CP	Eon Labs Manufacturing
DM5QWEL	TC	Sympatholytics
DM5QWEL	DT	Small molecular drug
DM5QWEL	PC	5702063
DM5QWEL	MW	231.08
DM5QWEL	FM	C8H8Cl2N4
DM5QWEL	IC	InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+
DM5QWEL	CS	C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl
DM5QWEL	IK	WDZVGELJXXEGPV-YIXHJXPBSA-N
DM5QWEL	IU	2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
DM5QWEL	CA	CAS 60329-03-5
DM5QWEL	CB	CHEBI:5553
DM5QWEL	DE	High blood pressure

DM6S157	ID	DM6S157
DM6S157	DN	Guanadrel Sulfate
DM6S157	HS	Approved
DM6S157	SN	Hylorel; Hyloride; Guanadrel sulfate [USAN]; CL 1388R; U 28288D; CL-1388R; Guanadrel sulfate (USP); Hylorel (TN); U 28,288D; U-28288D; Guanadrel sulfate (2:1); Guanidine (1,4-dioxaspiro(4.5)dec-2-ylmethyl)-, sulfate (2:1); (1,4-Dioxaspiro(4.5)dec-2-ylmethyl)guanidine sulfate (2:1); 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine
DM6S157	TC	Antihypertensive Agents
DM6S157	DT	Small molecular drug
DM6S157	PC	68552
DM6S157	MW	524.6
DM6S157	FM	C20H40N6O8S
DM6S157	IC	InChI=1S/2C10H19N3O2.H2O4S/c2*11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10;1-5(2,3)4/h2*8H,1-7H2,(H4,11,12,13);(H2,1,2,3,4)
DM6S157	CS	C1CCC2(CC1)OCC(O2)CN=C(N)N.C1CCC2(CC1)OCC(O2)CN=C(N)N.OS(=O)(=O)O
DM6S157	IK	RTEVGQJRTFFMLL-UHFFFAOYSA-N
DM6S157	IU	2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine;sulfuric acid
DM6S157	CA	CAS 22195-34-2
DM6S157	CB	CHEBI:5556
DM6S157	DE	Hypertension

DM9NSWT	ID	DM9NSWT
DM9NSWT	DN	Guanethidine
DM9NSWT	HS	Approved
DM9NSWT	SN	Abapresin; Dopam; Dopom; Eutensol; Guanethidinum; Guanetidina; Ismelin; Isobarin; Octadin; Octadine; Octatensin; Octatensine; Oktadin; Oktatensin; Oktatenzin; Sanotensin; Guanethidine Sulphae; Guanethidine sulfate; Ismelin sulfate; Apo-Guanethidine; Guanethidine (INN); Guanethidine [INN:BAN]; Guanethidinum [INN-Latin]; Guanetidina [INN-Spanish]; Apo-Guanethidine (TN); Beta-1-Azacyclooctylethylguanidine; Guanethidine Sulfate (1:1); Guanethidine Sulfate (2:1); Su 5864 sulfate (1:1); N-(2-Perhydroazocin-1-ylethyl)guanidine; ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine; (2-(Octahydro-1-azocinyl)ethyl)guanidine; 1-(2-azocan-1-ylethyl)guanidine; 1-[2-(azocan-1-yl)ethyl]guanidine; 2-(1'-Azacyclooctyl)ethylguanidine; 2-(1-N,N-Heptamethyleneimino)ethylguanidine; 2-[2-(azocan-1-yl)ethyl]guanidine
DM9NSWT	CP	Norvatis Phamaceuticals Corporation
DM9NSWT	TC	Antihypertensive Agents
DM9NSWT	DT	Small molecular drug
DM9NSWT	PC	3518
DM9NSWT	MW	198.31
DM9NSWT	FM	C10H22N4
DM9NSWT	IC	InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)
DM9NSWT	CS	C1CCCN(CCC1)CCN=C(N)N
DM9NSWT	IK	ACGDKVXYNVEAGU-UHFFFAOYSA-N
DM9NSWT	IU	2-[2-(azocan-1-yl)ethyl]guanidine
DM9NSWT	CA	CAS 55-65-2
DM9NSWT	CB	CHEBI:5557
DM9NSWT	DE	Moderate and severe hypertension

DMB1CZ8	ID	DMB1CZ8
DMB1CZ8	DN	Guanfacine extended release
DMB1CZ8	HS	Approved
DMB1CZ8	SN	Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Impulsin; Palmitamide MEA; Hydroxyethylpalmitamide; N-palmitoylethanolamine; N-(2-Hydroxyethyl)palmitamide; Palmitic acid monoethanolamide; Palmitoyl-EA; Loramine P 256; Palmitoyl ethanolamide; Palmidrolum; palmitylethanolamide; HEXADECANAMIDE, N-(2-HYDROXYETHYL)-; Palmidrol [INN]; Palmidrolum [INN-Latin]; UNII-6R8T1UDM3V; Palmitinsaeure-beta-hydroxyethylamid; Monoethanolamine palmitic acid amide; NSC 23320; hexadecanoyl ethanolamide; Anandamide (16:0)
DMB1CZ8	CP	Shire
DMB1CZ8	DT	Small molecular drug
DMB1CZ8	PC	4671
DMB1CZ8	MW	299.5
DMB1CZ8	FM	C18H37NO2
DMB1CZ8	IC	InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
DMB1CZ8	CS	CCCCCCCCCCCCCCCC(=O)NCCO
DMB1CZ8	IK	HXYVTAGFYLMHSO-UHFFFAOYSA-N
DMB1CZ8	IU	N-(2-hydroxyethyl)hexadecanamide
DMB1CZ8	CA	CAS 544-31-0
DMB1CZ8	CB	CHEBI:71464
DMB1CZ8	DE	Attention deficit hyperactivity disorder

DM0P63W	ID	DM0P63W
DM0P63W	DN	Guanidine Hydrochloride
DM0P63W	HS	Approved
DM0P63W	SN	Guanidine hydrochloride; 1950/1/1; Guanidinium chloride; Guanidine, monohydrochloride; guanidine HCl; Aminoformamidine hydrochloride; Aminomethanamidine hydrochloride; GUANIDINE MONOHYDROCHLORIDE; Guanidine chloride; Iminourea hydrochloride; Carbamidine hydrochloride; Guanidinium hydrochloride; Guanidine (hydrochloride); UNII-3YQC9ZY4YB; Guanidium chloride; USAF EK-749; Guanidine, hydrochloride (1:1); EINECS 200-002-3; 3YQC9ZY4YB; AI3-19014; MFCD00013026; Guanidine Hydrochloride, ULTROL&amp; Grade; Guanidinehydrochloride
DM0P63W	CP	Merck Sharp And Dohme Corp
DM0P63W	TC	Neurology Agents
DM0P63W	DT	Small molecular drug
DM0P63W	PC	5742
DM0P63W	MW	95.53
DM0P63W	FM	CH6ClN3
DM0P63W	IC	InChI=1S/CH5N3.ClH/c2-1(3)4;/h(H5,2,3,4);1H
DM0P63W	CS	C(=N)(N)N.Cl
DM0P63W	IK	PJJJBBJSCAKJQF-UHFFFAOYSA-N
DM0P63W	IU	guanidine;hydrochloride
DM0P63W	CA	CAS 50-01-1
DM0P63W	CB	CHEBI:32735
DM0P63W	DE	Muscle fatigue

DMP7LK1	ID	DMP7LK1
DMP7LK1	DN	Guggulsterone
DMP7LK1	HS	Approved
DMP7LK1	SN	Guggulsterone E; (E)-Guggulsterone; E-Guggulsterone; Guggulsterones E; trans-Guggulsterone; 39025-24-6; Pregna-4,17-diene-3,16-dione; UNII-9B259YE66O; (17E)-Pregna-4,17(20)-diene-3,16-dione; Z-Guggulsterone; CHEMBL402063; 95975-55-6; 9B259YE66O; (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; E-Guggulsteron; Pregna-4,17(20)-diene-3,16-dione; Guggulsterone, (E)-; Guglip; Z/E-Guggulsterone; Pregna-4,17(20)-diene-3,16-dione, (17E)-;  Guggulsterone E; Guggulsterones Z; Cis-Guggulsterone; Trans-Guggulsterone; (17E)-pregna-4,17-diene-3,16-dione; (17Z)-Pregna-4,17(20)-diene-3,16-dione; (17Z)-pregna-4,17-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; (Z)-Guggulsterone; 4,17(20)-cis-Pregnadiene-3,16-dione; E-GUGGULSTERONE
DMP7LK1	TC	Antiinflammatory Agents
DMP7LK1	DT	Small molecular drug
DMP7LK1	PC	6450278
DMP7LK1	MW	312.4
DMP7LK1	FM	C21H28O2
DMP7LK1	IC	InChI=1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4,11,15,17-18H,5-10,12H2,1-3H3/b16-4+/t15-,17+,18+,20+,21-/m1/s1
DMP7LK1	CS	C/C=C/1\\C(=O)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMP7LK1	IK	WDXRGPWQVHZTQJ-OSJVMJFVSA-N
DMP7LK1	IU	(8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione
DMP7LK1	CA	CAS 39025-23-5
DMP7LK1	CB	CHEBI:135338
DMP7LK1	DE	Osteoarthritis

DMV4KOA	ID	DMV4KOA
DMV4KOA	DN	GW642444
DMV4KOA	HS	Approved
DMV4KOA	SN	Fumagillinum; Fumagilline; Fumagilina; Fumidil; Fugillin; UNII-7OW73204U1; Amebacillin; Fugilin; CHEMBL32838; Fumagillin DCH; CHEBI:48635; Fumagillina [DCIT]; 7OW73204U1; Fumagillinum [INN-Latin]; Fumagilline [INN-French]; Fumagilina [INN-Spanish]; DSSTox_RID_79580; DSSTox_CID_20736; DSSTox_GSID_40736; Fumagillin [INN:BAN:DCF]; 2,4,6,8-Decatetraenedioic acid, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-yl ester
DMV4KOA	CP	GSK
DMV4KOA	DT	Small molecular drug
DMV4KOA	PC	21880659
DMV4KOA	MW	486.4
DMV4KOA	FM	C24H33Cl2NO5
DMV4KOA	IC	InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2
DMV4KOA	CS	C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl
DMV4KOA	IK	DAFYYTQWSAWIGS-UHFFFAOYSA-N
DMV4KOA	IU	4-[2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DMV4KOA	DE	Asthma

DML72VJ	ID	DML72VJ
DML72VJ	DN	GW685698X
DML72VJ	HS	Approved
DML72VJ	SN	Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate
DML72VJ	CP	GSK
DML72VJ	DT	Small molecular drug
DML72VJ	PC	9854489
DML72VJ	MW	538.6
DML72VJ	FM	C27H29F3O6S
DML72VJ	IC	InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1
DML72VJ	CS	C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
DML72VJ	IK	XTULMSXFIHGYFS-VLSRWLAYSA-N
DML72VJ	IU	[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
DML72VJ	CA	CAS 397864-44-7
DML72VJ	CB	CHEBI:74899
DML72VJ	DE	Asthma

DMFUAXT	ID	DMFUAXT
DMFUAXT	DN	H1N1 pandemic influenza A vaccine
DMFUAXT	HS	Approved
DMFUAXT	SN	Panflu; H1N1 pandemic influenza A vaccine, Sinovac; Panflu.1; Split viron vaccine (H1N1 influenza), Sinovac; Split viron vaccine + adjuvant (H1N1 influenza), Sinovac; Whole viron vaccine + adjuvant (H1N1 influenza), Sinovac
DMFUAXT	CP	Sinovac Biotech Ltd
DMFUAXT	DT	Vaccine
DMFUAXT	DE	Influenza virus infection

DMMHYLB	ID	DMMHYLB
DMMHYLB	DN	H5N1 influenza vaccine
DMMHYLB	HS	Approved
DMMHYLB	SN	IPSIV; Inactivated Polymer-Subunit H5N1 Influenza Vaccine; H5N1 influenza vaccine (protein subunit, Polyoxidonium adjuvant); H5N1 influenza vaccine (protein subunit, Polyoxidonium adjuvant), Microgen
DMMHYLB	CP	Glaxosmithkline; novavax; vaxart
DMMHYLB	DT	Vaccine
DMMHYLB	DE	Human immunodeficiency virus infection

DM7JNTV	ID	DM7JNTV
DM7JNTV	DN	Halaven
DM7JNTV	HS	Approved
DM7JNTV	SN	Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent
DM7JNTV	CP	Eisai Woodcliff Lake, NJ
DM7JNTV	PC	17755248
DM7JNTV	MW	826
DM7JNTV	FM	C41H63NO14S
DM7JNTV	IC	InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1
DM7JNTV	CS	C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O.CS(=O)(=O)O
DM7JNTV	IK	QAMYWGZHLCQOOJ-WRNBYXCMSA-N
DM7JNTV	IU	(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one;methanesulfonic acid
DM7JNTV	CA	CAS 441045-17-6
DM7JNTV	CB	CHEBI:70710
DM7JNTV	DE	Bladder cancer; Breast cancer

DMPFWO6	ID	DMPFWO6
DMPFWO6	DN	Halazepam
DMPFWO6	HS	Approved
DMPFWO6	SN	Halazepamum; Pacinone; Paxipam; Sch 12041; Schering 12041; Alapryl (TN); Halazepamum [INN-Latin]; Pacinone (TN); Paxipam (TN); Sch-12041; Halazepam (USAN/INN); Halazepam [USAN:BAN:INN]; 7-Chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one; 7=Chlor-5-phenyl-1-(2,2,2-trifluorethyl)-1H-1,4-benzodiazepin-2(3H)-on
DMPFWO6	TC	Antianxiety Agents
DMPFWO6	DT	Small molecular drug
DMPFWO6	PC	31640
DMPFWO6	MW	352.7
DMPFWO6	FM	C17H12ClF3N2O
DMPFWO6	IC	InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2
DMPFWO6	CS	C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3)CC(F)(F)F
DMPFWO6	IK	WYCLKVQLVUQKNZ-UHFFFAOYSA-N
DMPFWO6	IU	7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one
DMPFWO6	CA	CAS 23092-17-3
DMPFWO6	CB	CHEBI:5603
DMPFWO6	DE	Anxiety disorder

DMGLAX1	ID	DMGLAX1
DMGLAX1	DN	Halcinonide
DMGLAX1	HS	Approved
DMGLAX1	SN	Halog; Halog-e
DMGLAX1	CP	Ranbaxy Laboratories Inc
DMGLAX1	DT	Small molecular drug
DMGLAX1	PC	443943
DMGLAX1	MW	455
DMGLAX1	FM	C24H32ClFO5
DMGLAX1	IC	InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1
DMGLAX1	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F
DMGLAX1	IK	MUQNGPZZQDCDFT-JNQJZLCISA-N
DMGLAX1	IU	(1S,2S,4R,8S,9S,11S,12R,13S)-8-(2-chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DMGLAX1	CA	CAS 3093-35-4
DMGLAX1	CB	CHEBI:31663
DMGLAX1	DE	Skin disease

DM3GB6S	ID	DM3GB6S
DM3GB6S	DN	Halobetasol propionate
DM3GB6S	HS	Approved
DM3GB6S	SN	Halobetasol; Miracorten; Ultravate; Halobetasol propionate [USAN]; Ulobetasol cream; Ulobetasol propionate; BMY 30056; CGP 14 458; CGP 14458; BMY-30056; CGP-14458; Halobetasol propionate (USAN); Ultravate (TN); [(6S,9R,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; 6 alpha-fluoroclobetasol 17-propionate; 6-fluoroclobetasol 17-propionate
DM3GB6S	TC	Antiinflammatory Agents
DM3GB6S	DT	Small molecular drug
DM3GB6S	PC	6918178
DM3GB6S	MW	485
DM3GB6S	FM	C25H31ClF2O5
DM3GB6S	IC	InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1
DM3GB6S	CS	CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCl
DM3GB6S	IK	BDSYKGHYMJNPAB-LICBFIPMSA-N
DM3GB6S	IU	[(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
DM3GB6S	CA	CAS 66852-54-8
DM3GB6S	CB	CHEBI:135782
DM3GB6S	DE	Inflammation

DMOMK1V	ID	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	HS	Approved
DMOMK1V	SN	Halfan; Halofantrino; HALOFANTRINE HYDROCHLORIDE; Halofantrine HCl; Halofantrine Hydrochloride [USAN]; Halofantrine [USAN]; Halofantrino [Spanish]; WR 171669; Dl-WR 171669; Halfan (TN); Halofantrine hydrochloride (USAN); WR 171,699; WR-171669; WR-171699; SK&F-102866; WR-171,669; (+-)-Halofantrine hydrochloride; (1)-Halofantrine; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride
DMOMK1V	CP	GlaxoSmithKline
DMOMK1V	TC	Antimalarials
DMOMK1V	DT	Small molecular drug
DMOMK1V	PC	37393
DMOMK1V	MW	500.4
DMOMK1V	FM	C26H30Cl2F3NO
DMOMK1V	IC	InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3
DMOMK1V	CS	CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O
DMOMK1V	IK	FOHHNHSLJDZUGQ-UHFFFAOYSA-N
DMOMK1V	IU	3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol
DMOMK1V	CA	CAS 69756-53-2
DMOMK1V	CB	CHEBI:94392
DMOMK1V	DE	Malaria

DM96SE0	ID	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	HS	Approved
DM96SE0	SN	Aldo; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Bioperidolo; Brotopon; Dozic; Dozix; Eukystol; Fortunan; Galoperidol; Haldol; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidolum; Halopidol; Halopoidol; Halosten; Keselan; Linton; Mixidol; Pekuces; Peluces; Peridol; Pernox; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium; Aloperidolo [DCIT]; Aloperidolo [Italian]; Einalon S; Haldol La; Haldol Solutab; Lealgin compositum; Pms Haloperidol; H 1512; R 1625; Aloperidin (TN); Apo-Haloperidol; Bioperidolo (TN); Brotopon (TN); Dozic (TN); Duraperidol (TN); Einalon S (TN); Eukystol (TN); Haldol (TN); Haloperidolum [INN-Latin]; Halosten (TN); Keselan (TN); Linton (TN);Novo-Peridol; Peluces (TN); R-1625; Serenace (TN); Serenase (TN); Sigaperidol (TN); Haloperidol (JP15/USP); McN-JR-1625; Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]
DM96SE0	CP	Janssen Pharmaceutica
DM96SE0	TC	Antipsychotic Agents
DM96SE0	DT	Small molecular drug
DM96SE0	PC	3559
DM96SE0	MW	375.9
DM96SE0	FM	C21H23ClFNO2
DM96SE0	IC	InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
DM96SE0	CS	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
DM96SE0	IK	LNEPOXFFQSENCJ-UHFFFAOYSA-N
DM96SE0	IU	4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
DM96SE0	CA	CAS 52-86-8
DM96SE0	CB	CHEBI:5613
DM96SE0	DE	Schizophrenia

DMH4IVU	ID	DMH4IVU
DMH4IVU	DN	Haloprogin
DMH4IVU	HS	Approved
DMH4IVU	SN	Aloprogen; Haloprogina; Haloprogine; Haloproginum; Halotex; Mycanden; Mycilan; Polik; Component of Halotex; M 1028; Haloprogina [INN-Spanish]; Haloprogine [INN-French]; Haloproginum [INN-Latin]; Halotex (TN); Mycanden (TN); Mycilan (TN); Polik (TN); Haloprogin [USAN:INN:JAN]; M-1028 (Meiji); Haloprogin (JAN/USAN/INN); Ether, 3-iodo-2-propynyl 2,4,5-trichlorophenyl; Benzene,1,2,4-trichloro-5-[(3-iodo-2-propynyl)oxy]; (3-Iod-2-propinyl)-(2,4,5-trichlorphenyl)ether; 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene; 1,2,4-trichloro-5-[(3-iodo-2-propynyl) oxy]benzene; 2,4,5-Trichlorophenyl .gamma.-iodopropargil ether; 2,4,5-Trichlorophenyl .gamma.-iodopropargyl ether; 2,4,5-Trichlorophenyl gamma-iodopropargil ether; 2,4,5-Trichlorophenyl iodopropargyl ether; 2,4,5-Trichlorophenyl-gamma-iodopropargyl ether; 3-Iodo-2-propynyl 2,4,5-trichlorophenyl ether
DMH4IVU	TC	Antifungal Agents
DMH4IVU	DT	Small molecular drug
DMH4IVU	PC	3561
DMH4IVU	MW	361.4
DMH4IVU	FM	C9H4Cl3IO
DMH4IVU	IC	InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2
DMH4IVU	CS	C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI
DMH4IVU	IK	CTETYYAZBPJBHE-UHFFFAOYSA-N
DMH4IVU	IU	1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene
DMH4IVU	CA	CAS 777-11-7
DMH4IVU	CB	CHEBI:5614
DMH4IVU	DE	Dermatophytosis; Candidiasis

DM80OZ5	ID	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	HS	Approved
DM80OZ5	SN	Alotano; Anestan; Bromchlortrifluoraethanum; Bromochlorotrifluoroethane; Chalothane; Fluktan; Fluorotane; Fluothane; Ftorotan; Ftuorotan; Halan; Halotan; Halotano; Halothan; Halothanum; Halsan; Narcotan; Narcotane; Narkotan; Phthorothanum; Rhodialothan; Alotano [DCIT]; Ftorotan [Russian]; CF3CHClBr; Freon 123B1; Fluothane (TN); Halotano [INN-Spanish]; Halothane [Anaesthetics, volatile]; Halothanum [INN-Latin]; Narcotann NE-spofa [Russian]; Narcotann ne-spofa; Halothane [INN:BAN:JAN]; Halothane (JP15/USP/INN); (+-)-2-Bromo-2-chloro-1,1,1-trifluoroethane; 1,1,1-Trifluoro-2-bromo-2-chloroethane; 1,1,1-Trifluoro-2-chloro-2-bromoethane; 1-Bromo-1-chloro-2,2,2-trifluoroethane; 2,2,2-Trifluoro-1-chloro-1-bromoethane; 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE; 2-Brom-2-chlor-1,1,1-trifluorethan
DM80OZ5	TC	Anesthetics
DM80OZ5	DT	Small molecular drug
DM80OZ5	PC	3562
DM80OZ5	MW	197.38
DM80OZ5	FM	C2HBrClF3
DM80OZ5	IC	InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H
DM80OZ5	CS	C(C(F)(F)F)(Cl)Br
DM80OZ5	IK	BCQZXOMGPXTTIC-UHFFFAOYSA-N
DM80OZ5	IU	2-bromo-2-chloro-1,1,1-trifluoroethane
DM80OZ5	CA	CAS 151-67-7
DM80OZ5	CB	CHEBI:5615
DM80OZ5	DE	Anaesthesia

DMN0S1G	ID	DMN0S1G
DMN0S1G	DN	HEGF
DMN0S1G	HS	Approved
DMN0S1G	CP	Bharat Biotech
DMN0S1G	DE	Diabetic foot ulcer

DMEVXY6	ID	DMEVXY6
DMEVXY6	DN	Heparin Calcium
DMEVXY6	HS	Approved
DMEVXY6	SN	Calciparine
DMEVXY6	CP	Sanofi Aventis Us Llc
DMEVXY6	TC	Cardiovascular Agents
DMEVXY6	DE	Coagulation defect

DM9KHZL	ID	DM9KHZL
DM9KHZL	DN	Heparin Sodium
DM9KHZL	HS	Approved
DM9KHZL	SN	(2S,3S,4R,5R,6R)-6-{[(2S,3S,4S,5R,6S)-6-{[(2R,3S,4S,5R)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid; HepFlush; GTPL4214; CHEMBL526514; Heparin Sodium 10,000 Units And Dextrose 5% In Plastic Container
DM9KHZL	CP	Hospira Inc
DM9KHZL	TC	Cardiovascular Agents
DM9KHZL	PC	92044406
DM9KHZL	MW	1157.9
DM9KHZL	FM	C26H42N2NaO37S5+
DM9KHZL	IC	InChI=1S/C26H42N2O37S5.Na/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36;/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);/q;+1
DM9KHZL	CS	CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.[Na+]
DM9KHZL	IK	JRTRSJGZMRQDHI-UHFFFAOYSA-N
DM9KHZL	IU	sodium;6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
DM9KHZL	DE	Deep vein thrombosis; Coagulation defect

DMOB2F3	ID	DMOB2F3
DMOB2F3	DN	Heptabarbital
DMOB2F3	HS	Approved
DMOB2F3	SN	Cycloheptenylethylmalonylurea; Heptabarb; Heptabarbe; Heptabarbitone; Heptabarbo; Heptabarbum; Heptadorm; Heptamal; Heptamalum; Heptbarbital; Medapan; Medomin; Medomine; Noctyn; Cycloheptenylethylbarbituric acid; G 475; Heptabarbe [INN-French]; Heptabarbo [INN-Spanish]; Heptabarbum [INN-Latin]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohepten-1-yl)-5-ethyl-(9CI); 5-(1-CYCLOHEPTEN-1-YL)-5-ETHYLBARBITURIC ACID; 5-(1-Cyclohepten-1-yl)-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-Cycloheptenyl)-5-ethylbarbitursaeure; 5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione; 5-Ethyl-5-(1'-cycloheptenyl)-barbituric acid; 5-Ethyl-5-cycloheptenylbarbituric acid
DMOB2F3	DT	Small molecular drug
DMOB2F3	PC	10518
DMOB2F3	MW	250.29
DMOB2F3	FM	C13H18N2O3
DMOB2F3	IC	InChI=1S/C13H18N2O3/c1-2-13(9-7-5-3-4-6-8-9)10(16)14-12(18)15-11(13)17/h7H,2-6,8H2,1H3,(H2,14,15,16,17,18)
DMOB2F3	CS	CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2
DMOB2F3	IK	PAZQYDJGLKSCSI-UHFFFAOYSA-N
DMOB2F3	IU	5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione
DMOB2F3	CA	CAS 509-86-4
DMOB2F3	CB	CHEBI:81297
DMOB2F3	DE	Anaesthesia

DM6YWBF	ID	DM6YWBF
DM6YWBF	DN	Herbimycin A
DM6YWBF	HS	Approved
DM6YWBF	SN	Herbimycin; Herbimycin A from Streptomyces hygroscopicus; Antibiotic Tan 420F; [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(2R,3S,5S,6R,7S,8E,10S,11S,12Z,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate
DM6YWBF	TC	Anticancer Agents
DM6YWBF	DT	Small molecular drug
DM6YWBF	PC	5311102
DM6YWBF	MW	574.7
DM6YWBF	FM	C30H42N2O9
DM6YWBF	IC	InChI=1S/C30H42N2O9/c1-16-10-9-11-23(37-5)28(41-30(31)36)18(3)12-17(2)27(40-8)24(38-6)13-19(4)26(39-7)21-14-20(33)15-22(25(21)34)32-29(16)35/h9-12,14-15,17,19,23-24,26-28H,13H2,1-8H3,(H2,31,36)(H,32,35)/b11-9-,16-10+,18-12+/t17-,19-,23-,24-,26+,27+,28-/m0/s1
DM6YWBF	CS	C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C=C([C@@H]1OC)C2=O)/C)OC)OC(=O)N)\\C)C)OC)OC
DM6YWBF	IK	MCAHMSDENAOJFZ-BVXDHVRPSA-N
DM6YWBF	IU	[(4E,6Z,8S,9S,10E,12S,13R,14S,16S,17R)-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DM6YWBF	CA	CAS 70563-58-5
DM6YWBF	CB	CHEBI:5674
DM6YWBF	DE	Solid tumour/cancer

DMDBWHY	ID	DMDBWHY
DMDBWHY	DN	Heroin diacetylmorphine
DMDBWHY	HS	Approved
DMDBWHY	SN	Diamorphine (TN)
DMDBWHY	CP	Bayer company
DMDBWHY	DT	Small molecular drug
DMDBWHY	PC	5462328
DMDBWHY	MW	369.4
DMDBWHY	FM	C21H23NO5
DMDBWHY	IC	InChI=1S/C21H23NO5/c1-11(23)25-16-6-4-13-10-15-14-5-7-17(26-12(2)24)20-21(14,8-9-22(15)3)18(13)19(16)27-20/h4-7,14-15,17,20H,8-10H2,1-3H3/t14-,15+,17-,20-,21-/m0/s1
DMDBWHY	CS	CC(=O)O[C@H]1C=C[C@H]2[C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)OC(=O)C)CCN3C
DMDBWHY	IK	GVGLGOZIDCSQPN-PVHGPHFFSA-N
DMDBWHY	IU	[(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate
DMDBWHY	CA	CAS 561-27-3
DMDBWHY	CB	CHEBI:27808
DMDBWHY	DE	Neurological disorder

DMKER83	ID	DMKER83
DMKER83	DN	Hesperetin
DMKER83	HS	Approved
DMKER83	SN	Hesperin; Hesperitin; TNP00238; YSO2; Cyanidanon 4'-methyl ether 1626; Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN); Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN) (8CI); (-)-hesperetin; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',5,7-Trihydroxy-4'-methoxyflavanone; 3',5,7-Trihydroxy-4-methoxyflavanone; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-(9CI); 5,7,3'-Trihydroxy-4'-methoxyflavanone
DMKER83	TC	Anticholesteremic Agents
DMKER83	DT	Small molecular drug
DMKER83	PC	72281
DMKER83	MW	302.28
DMKER83	FM	C16H14O6
DMKER83	IC	InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1
DMKER83	CS	COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O
DMKER83	IK	AIONOLUJZLIMTK-AWEZNQCLSA-N
DMKER83	IU	(2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMKER83	CA	CAS 520-33-2
DMKER83	CB	CHEBI:28230
DMKER83	DE	High blood cholesterol level

DMI5DW1	ID	DMI5DW1
DMI5DW1	DN	Hesperidin
DMI5DW1	HS	Approved
DMI5DW1	SN	hesperidin; 520-26-3; Cirantin; Hesperidoside; Hesper bitabs; Hesperetin-rutinosid; Hesperidine; UNII-E750O06Y6O; CCRIS 3940; (S)-(-)-Hesperidin; EINECS 208-288-1; NSC 44184; BRN 0075140; Hesperidin, (2S)-; Hesperetin 7-rutinoside; MLS001304066; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one; CHEBI:28775; USAF CF-3; Hesperidin, (S)-(-)-; Hesperitin-7-rhamnoglucoside; E750O06Y6O; C28H34O15; HESPERIDINE
DMI5DW1	DT	Small molecular drug
DMI5DW1	PC	10621
DMI5DW1	MW	610.6
DMI5DW1	FM	C28H34O15
DMI5DW1	IC	InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1
DMI5DW1	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O
DMI5DW1	IK	QUQPHWDTPGMPEX-QJBIFVCTSA-N
DMI5DW1	IU	(2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
DMI5DW1	CA	CAS 520-26-3
DMI5DW1	CB	CHEBI:28775
DMI5DW1	DE	Vascular purpura

DMPXITB	ID	DMPXITB
DMPXITB	DN	Hetacillin
DMPXITB	HS	Approved
DMPXITB	SN	Etacillina; Hetacilina; Hetacilline; Hetacillinum; Phenazacillin; Versapen; Etacillina [DCIT]; HETACILLIN POTASSIUM; BRL 804; BL-P 804; BRL-804; Hetacilina [INN-Spanish]; Hetacilline [INN-French]; Hetacillinum [INN-Latin]; Versapen (TN); Hetacillin (USAN/INN); Hetacillin [USAN:INN:BAN]; N,N'-Isopropylidene-A-amino-benzyl penicillin; (2S,%R,6R)-6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (2S,5R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)penicillansaeure; 6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid
DMPXITB	CP	Bristol Laboratories Inc Div Bristol Myers Co
DMPXITB	TC	Antibiotics
DMPXITB	DT	Small molecular drug
DMPXITB	PC	443387
DMPXITB	MW	389.5
DMPXITB	FM	C19H23N3O4S
DMPXITB	IC	InChI=1S/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)/t11-,12-,13+,16-/m1/s1
DMPXITB	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)C4=CC=CC=C4)C(=O)O)C
DMPXITB	IK	DXVUYOAEDJXBPY-NFFDBFGFSA-N
DMPXITB	IU	(2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMPXITB	CA	CAS 3511-16-8
DMPXITB	CB	CHEBI:5683
DMPXITB	DE	Bacterial infection

DMGUC9T	ID	DMGUC9T
DMGUC9T	DN	HEV-239
DMGUC9T	HS	Approved
DMGUC9T	SN	Hecolin; Bacterially-expressed hepatitis E vaccine, Xiamen Innovax Biotech; Hepatitis E vaccine (recombinant), Xiamen Innovax Biotech; Hepatitis E vaccine (alum-adjuvanted), Xiamen Innovax Biotech
DMGUC9T	CP	Beijing Wantai Biological Pharmacy Enterprise Co Ltd
DMGUC9T	DT	Vaccine
DMGUC9T	DE	Hepatitis E virus infection

DMLKSE0	ID	DMLKSE0
DMLKSE0	DN	Hexachlorophene
DMLKSE0	HS	Approved
DMLKSE0	SN	Acigena; Almederm; Armohex; Bilevon; Bivelon; Cotofilm; Dermadex; Distodin; Eleven; Esaclorofene; Exofene; Fascol; Fomac; Fostril; Gamophen; Gamophene; Hexabalm; Hexachlorofen; Hexachlorophane; Hexachlorophen; Hexachlorophenum; Hexaclorofeno; Hexafen; Hexascrub; Hexide; Hexophene; Hexosan; Isobac; Nabac; PHisoHex; Phisodan; Ritosept; Septisol; Septofen; Steral; Steraskin; Surofene; TRICHLOROPHENE; Tersaseptic; Trisophen; Turgex; Blockade Anti Bacterial Finish; Brevity Blue Liquid Bacteriostatic Scouring Cream; Brevity Blue Liquid Sanitizing Scouring Cream; Enditch Pet Shampoo; Esaclorofene [DCIT]; Fo stril; Hexachlorofen [Czech]; Hexachlorophene [INN]; Hilo Cat Flea Powder; Hilo Flea Powder; Neosept V; Pedigree Dog Shampoo Bar; Scrubteam Surgical Spongebrush; Staphene O; AT 7; B 32; H3P; Hexachlorophene [UN2875] [Poison]; KUC106447N; M0219; Nabac 25 ec; AT-7; AT17 (TN); AT7 (TN); Acigena (TN); Almederm (TN); At-17; B & b Flea Kontroller for Dogs Only; B 32 (VAN); Bilevon (TN); E-Z Scrub; En-Viron D Concentrated Phenolic Disinfectant; Exofene (TN); Fesia-sin; Fostril (TN); G-11; G-Eleven; G-II; Gamophen (TN); Germa-Medica; Hexa-Germ; Hexachlorophene, Pharma; Hexachlorophenum [INN-Latin]; Hexaclorofeno [INN-Spanish]; Hexaphene-LV; Hexosan (TN); PRE-OP II; Phiso-Scrub; Phisohex(TN); Pre-Op; Septi-Soft; Septisol (TN); Solu-Heks; Soy-dome; Ster-zac; Surgi-Cen; Surgi-Cin; Surofene (TN); Thera-Groom Pet Shampoo for Dogs for Veterinary Use Only; G-11 (TN); GERMA-MEDICA (MG); Germa-Medica (TN); Hexachlorophene (USP/INN); KSC-19-051; Methylenebis(3,4,6-trichlorophenol); Bis(2,3,5-tric hloro-6-hydroxyphenyl)methane; Bis(2,3,5-trichloro-6-hydroxyphenyl)methane; Bis(2-hydroxy-3,5,6-trichlorophenyl)methane; Bis(3,5,6-trichloro-2-hydroxyphenyl)methane; Bis-2,3,5-trichlor-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan [Czech]; Bis(3,5,6-trichloro-2-hydroxyphenyl)-methane; Methane, bis(2,3,5-trichloro-6-hydroxyphenyl); 2,2',3,3',5,5'-Hexachloro-6,6'-dihydroxydiphenylmethane; 2,2'-Dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane; 2,2'-Methylene bis(3,4,6-trichlorophenol); 2,2'-Methylenebis(3,4,6-trichlorophenol); 2,2'-Methylenebis[3,4,6-trichlorophenol]; 2,2'-methanediylbis(3,4,6-trichlorophenol); 2,2-Methylene-bis-[3,4,6-trichlorophenol]; 3,3',5,5',6,6'-Hexachloro-2,2'-dihydroxydiphenylmethane; 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol
DMLKSE0	TC	Antiinfective Agents
DMLKSE0	DT	Small molecular drug
DMLKSE0	PC	3598
DMLKSE0	MW	406.9
DMLKSE0	FM	C13H6Cl6O2
DMLKSE0	IC	InChI=1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2
DMLKSE0	CS	C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl
DMLKSE0	IK	ACGUYXCXAPNIKK-UHFFFAOYSA-N
DMLKSE0	IU	3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol
DMLKSE0	CA	CAS 70-30-4
DMLKSE0	CB	CHEBI:5693
DMLKSE0	DE	Bacterial infection

DMFY307	ID	DMFY307
DMFY307	DN	Hexafluronium bromide
DMFY307	HS	Approved
DMFY307	SN	Hexafluorenium; Milaxen; Mylaxen; Bromuro de hexafluronio; Esafluronio bromuro; Esafluronio bromuro [DCIT]; Hexafluorenium bromide; Hexafluorenium bromide [USAN]; Hexafluorenium dibromide; Hexafluorenium dibromide salt; Hexafluronii bromidum; Bromure d'hexafluronium; Bromuro de hexafluronio [INN-Spanish]; Hexafluorenium bromide (USAN); Hexafluronii bromidum [INN-Latin]; Hexafluronium bromide (INN); IN-117; Mylaxen (TN); Bromure d'hexafluronium [INN-French]; Hexamethylene bis(9-fluorenyldimethylammonium)dibromide; Hexamethylenebis(9-fluorenyldimethylammonium bromide); Hexamethylenebis(dimethyl-9-fluorenylammonium bromide); Hexamethylenebis(fluoren-9-yldimethylammonium) dibromide; AMMONIUM, HEXAMETHYLENEBIS(FLUOREN-9-YLDIMETHYL-, DIBROMIDE; Ammonium, hexamethylenebis(fluoren-9-yldimethyl-, bromide; N,N'-Di(9-fluorenyl)-N,N,N',N'-tetramethyly-hexamethylendi(ammoniumbromid); 1,6-Bis(9 fluorenyldimethyl-ammonium)hexane bromide; 1,6-Hexanediaminium, N,N'-di-9H-fluoren-9-yl-N,N,N',N'-tetramethyl-, dibromide; 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium dibromide
DMFY307	TC	Analgesics
DMFY307	DT	Small molecular drug
DMFY307	PC	9434
DMFY307	MW	662.5
DMFY307	FM	C36H42Br2N2
DMFY307	IC	InChI=1S/C36H42N2.2BrH/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36;;/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3;2*1H/q+2;;/p-2
DMFY307	CS	C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-]
DMFY307	IK	WDEFPRUEZRUYNW-UHFFFAOYSA-L
DMFY307	IU	9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium;dibromide
DMFY307	CA	CAS 317-52-2
DMFY307	DE	Spasm

DMQ314B	ID	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	HS	Approved
DMQ314B	SN	Barbidorm; Citodon; Citopan; Cyclonal; Cyclopan; Dorico; Enhexymal; Enhexymalum; Esobarbitale; Evipal; Evipan; Hexabarbital;Hexobarbitalum; Hexobarbitone; Hexobarbitonum; Methexenyl; Methylhexabarbital; Methylhexabital; Narcosan; Noctivane; Sombucaps; Sombulex; Somnalert; Esobarbitale [DCIT]; Esobarbitale [Italian]; Hexanastab oral; Sodium hexobarbital; Citopan (TN); Evipan (TN); Hexenal (barbiturate); Hexobarbital (VAN); Hexobarbital [INN:JAN]; Hexobarbitalum [INN-Latin]; Hexobarbital (JAN/INN); N-Methyl-5-cyclohexenyl-5-methylbarbituric acid; (+-)-Hexobarbital; 1,5-Dimethyl-5-(1-cyclohexenyl)barbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl; 5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYLBARBITURIC ACID; 5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-Cyclohexenyl)-1,5-dimethylbarbituric acid; 5-(1-Cyclohexenyl-1)-1-methyl-5-methylbarbituric acid; 5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione; 5-(delta-1,2-Cyclohexenyl)-5-methyl-N-methyl-barbitursaeure [German]; 5-(delta-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-(delta.-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-cyclohex-1-en-1-yl-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-cyclohex-1-en-1-yl-2-hydroxy-1,5-dimethylpyrimidine-4,6(1H,5H)-dione
DMQ314B	TC	Hypnotics and Sedatives
DMQ314B	DT	Small molecular drug
DMQ314B	PC	3608
DMQ314B	MW	236.27
DMQ314B	FM	C12H16N2O3
DMQ314B	IC	InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
DMQ314B	CS	CC1(C(=O)NC(=O)N(C1=O)C)C2=CCCCC2
DMQ314B	IK	UYXAWHWODHRRMR-UHFFFAOYSA-N
DMQ314B	IU	5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
DMQ314B	CA	CAS 56-29-1
DMQ314B	CB	CHEBI:5706
DMQ314B	DE	Anaesthesia

DMEADRK	ID	DMEADRK
DMEADRK	DN	Hexylcaine
DMEADRK	HS	Approved
DMEADRK	SN	Hexilcaina; Hexylcainum; Osmocaine; Hexylcaine [INN]; Cyclaine (TN); Hexilcaina [INN-Spanish]; Hexylcainum [INN-Latin]; Osmocaine (TN); (2-Cyclohexylamino-1-methylethyl) benzoate; 1-(Cyclohexylamino)-2-propanol benzoate (ester); 1-(cyclohexylamino)propan-2-yl benzoate; 2-Propanol, 1-(cyclohexylamino)-, benzoate (ester)
DMEADRK	CP	Merck & Co
DMEADRK	TC	Anesthetics
DMEADRK	DT	Small molecular drug
DMEADRK	PC	10770
DMEADRK	MW	261.36
DMEADRK	FM	C16H23NO2
DMEADRK	IC	InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3
DMEADRK	CS	CC(CNC1CCCCC1)OC(=O)C2=CC=CC=C2
DMEADRK	IK	DKLKMKYDWHYZTD-UHFFFAOYSA-N
DMEADRK	IU	1-(cyclohexylamino)propan-2-yl benzoate
DMEADRK	CA	CAS 532-77-4
DMEADRK	CB	CHEBI:34791
DMEADRK	DE	Anaesthesia

DMV7IM6	ID	DMV7IM6
DMV7IM6	DN	Histamine Phosphate
DMV7IM6	HS	Approved
DMV7IM6	SN	Histamine acid phosphate; Histamine biphosphate; Histamine dihydrogen phosphate; Histamine diphosphate; Histamine phosphate [USP]; Histamine positive; H0147; Histamine phosphate (TN); Histamine phosphate (USP); Histamine phosphate (1:2); 1H-Imidazole-4-ethanamine, phosphate (1:2); 2-Imidazol-4-ylethylamine orthophosphoric acid (1:2); 4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate); 4-(2-Aminoethyl)imidazole di-acid phosphate; 4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
DMV7IM6	TC	Diagnostic Agents
DMV7IM6	DT	Small molecular drug
DMV7IM6	PC	65513
DMV7IM6	MW	307.14
DMV7IM6	FM	C5H15N3O8P2
DMV7IM6	IC	InChI=1S/C5H9N3.2H3O4P/c6-2-1-5-3-7-4-8-5;2*1-5(2,3)4/h3-4H,1-2,6H2,(H,7,8);2*(H3,1,2,3,4)
DMV7IM6	CS	C1=C(NC=N1)CCN.OP(=O)(O)O.OP(=O)(O)O
DMV7IM6	IK	ZHIBQGJKHVBLJJ-UHFFFAOYSA-N
DMV7IM6	IU	2-(1H-imidazol-5-yl)ethanamine;phosphoric acid
DMV7IM6	CA	CAS 51-74-1
DMV7IM6	CB	CHEBI:51193
DMV7IM6	DE	Diagnostic imaging

DMGBPSH	ID	DMGBPSH
DMGBPSH	DN	Homatropine Methylbromide
DMGBPSH	HS	Approved
DMGBPSH	SN	Arkitropin; Camatropine; Equipin; Esopin; Homapin; Homatromide; Malcotran; Mesopin; Methylhomatropine; Novatrin; Novatrine; Novatropine; Npvatropine; Sethyl; Homatropine methobromide; Homatropine methyl bromide; Homatropini methylbromidum; Humulon lead salt; Methyl Bromide Homatropine; Methylhomatropine bromide; Methylhomatropinum bromatum; Metilbromuro de homatropina; Omatropina metilbromuro; Omatropina metilbromuro [DCIT]; Tropinium methobromide mandelate; DL-Homatropine methyl bromide; DL-Methylbromide; Equipin (TN); Homapin-10; Homapin-5; Homatropine DL-methylbromide; Homatropine methylbromide (USP); Homatropine methylbromide [INN:BAN]; Homatropini methylbromidum [INN-Latin]; Hycodan, probilagol; Isopto Homatropine (TN); Methylbromure d'homatropine; Metilbromuro de homatropina [INN-Spanish]; N-Methylhomatropinium Bromide; Sed-Tems; Methylbromure d'homatropine [INN-French]; HOMATROPINIUM, 8-METHYL-, BROMIDE; [(5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate bromide; (8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 2-hydroxy-2-phenylacetate bromide; 3-[2-hydroxy(phenyl)acetoxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate; 3-{[hydroxy(phenyl)acetyl]oxy}-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide mandelate; 8-Methylhomatropinium bromide
DMGBPSH	TC	Antiulcer Agents
DMGBPSH	DT	Small molecular drug
DMGBPSH	PC	10429215
DMGBPSH	MW	370.3
DMGBPSH	FM	C17H24BrNO3
DMGBPSH	IC	InChI=1S/C17H24NO3.BrH/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12;/h3-7,13-16,19H,8-11H2,1-2H3;1H/q+1;/p-1/t13-,14+,15?,16?;
DMGBPSH	CS	C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-]
DMGBPSH	IK	FUFVKLQESJNNAN-ZZJGABIISA-M
DMGBPSH	IU	[(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate;bromide
DMGBPSH	CA	CAS 80-49-9
DMGBPSH	DE	Uveitis; Peptic ulcer

DM78G6F	ID	DM78G6F
DM78G6F	DN	HTF 919
DM78G6F	HS	Approved
DM78G6F	DT	Small molecular drug
DM78G6F	PC	60918
DM78G6F	MW	301.39
DM78G6F	FM	C16H23N5O
DM78G6F	IC	InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)
DM78G6F	CS	CCCCCN=C(N)NN=CC1=CNC2=C1C=C(C=C2)OC
DM78G6F	IK	IKBKZGMPCYNSLU-UHFFFAOYSA-N
DM78G6F	IU	1-[(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine
DM78G6F	CA	CAS 145158-71-0
DM78G6F	DE	Constipation

DMA5OBU	ID	DMA5OBU
DMA5OBU	DN	Human neutral insulin
DMA5OBU	HS	Approved
DMA5OBU	DT	Small molecular drug
DMA5OBU	PC	16129672
DMA5OBU	MW	5808
DMA5OBU	FM	C257H383N65O77S6
DMA5OBU	IC	InChI=1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1
DMA5OBU	CS	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMA5OBU	IK	PBGKTOXHQIOBKM-FHFVDXKLSA-N
DMA5OBU	IU	(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMA5OBU	DE	Diabetic complication

DMPHVQ1	ID	DMPHVQ1
DMPHVQ1	DN	Human prothrombin complex concentrate
DMPHVQ1	HS	Approved
DMPHVQ1	CP	Octapharma usa
DMPHVQ1	SQ	sp|P00734|THRB_HUMAN Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2: MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE
DMPHVQ1	DE	Bleeding disorder

DMMAWLU	ID	DMMAWLU
DMMAWLU	DN	Huperzine A
DMMAWLU	HS	Approved
DMMAWLU	SN	Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680
DMMAWLU	DT	Small molecular drug
DMMAWLU	PC	854026
DMMAWLU	MW	242.32
DMMAWLU	FM	C15H18N2O
DMMAWLU	IC	InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)/b11-3+/t10-,15+/m0/s1
DMMAWLU	CS	C/C=C/1\\[C@@H]2CC3=C([C@]1(CC(=C2)C)N)C=CC(=O)N3
DMMAWLU	IK	ZRJBHWIHUMBLCN-YQEJDHNASA-N
DMMAWLU	IU	(1R,9R,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one
DMMAWLU	CA	CAS 102518-79-6
DMMAWLU	CB	CHEBI:78330
DMMAWLU	DE	Alzheimer disease

DMX8M26	ID	DMX8M26
DMX8M26	DN	Hyaluronate sodium
DMX8M26	HS	Approved
DMX8M26	DT	Small molecular drug
DMX8M26	PC	3084049
DMX8M26	MW	799.6
DMX8M26	FM	C28H44N2NaO23+
DMX8M26	IC	InChI=1S/C28H44N2O23.Na/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43;/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45);/q;+1/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19-,20+,21+,22+,25-,26+,27-,28-;/m1./s1
DMX8M26	CS	CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O.[Na+]
DMX8M26	IK	YWIVKILSMZOHHF-QJZPQSOGSA-N
DMX8M26	IU	sodium;(2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMX8M26	CA	CAS 9067-32-7
DMX8M26	DE	Joint lubricant; Pancytopenia; Enthesopathy

DMETWAU	ID	DMETWAU
DMETWAU	DN	Hyaluronidase (ovine)
DMETWAU	HS	Approved
DMETWAU	SN	Hyaluronidase; Hydase; Vitragan; Vitrase; Hyaluronidase Injection; Hyaluronidase (vitreous hemorrhage), ISTA
DMETWAU	CP	PrimaPharm; Primapharm
DMETWAU	SQ	Hyaluronidase Sequence: MWTGLGPAVTLALVLVVAWATELKPTAPPIFTGRPFVVAWDVPTQDCGPRHKMPLDPKDMKAFDVQASPNEGFVNQNITIFYRDRLGMYPHFNSVGGSVHGGVPQNGSLWVHLEMLKGHVEHYIRTQEPAGLAVIDWEDWRPVWVRNWQDKDVYRRLSRQLVASHHPDWPPERIVKEAQYEFEFAARQFMLETLRFVKAFRPRHLWGFYLFPDCYNHDYVQNWETYTGRCPDVEVSRNDQLSWLWAESTALFPSVYLEETLASSTHGRNFVSFRVQEALRVADVHHANHALPVYVFTRPTYSRGLTGLSEMDLISTIGESAALGAAGVILWGDAGFTTSNETCRRLKDYLTRSLVPYVVNVSWAAQYCSWAQCHGHGRCVRRDPNAHTFLHLSASSFRLVPSHAPDEPRLRPEGELSWADRNHLQTHFRCQCYLGWGGEQCQWDRRRAAGGASGAWAGFHLTGLLAVAVLAFTWTS
DMETWAU	DE	Resorption of radiopaque agents

DMU8JGH	ID	DMU8JGH
DMU8JGH	DN	Hydralazine
DMU8JGH	HS	Approved
DMU8JGH	SN	Apresolin; Apresoline; Apressin; Apressoline; Aprezolin; HLZ; Hidral; Hidralazin; Hidralazina; Hipoftalin; Hydralazin; Hydralazinum; Hydrallazin; Hydrallazine; Hydrazinophthalazine; Hypophthalin; Idralazina; Hidralazina [Spanish]; Idralazina [DCIT]; Idralazina [Italian]; BA 5968; C 5968; Ciba 5968; Praparat 5968; Apresoline (TN); Apressin (pharmaceutical); C-5068; C-5968; Hidral (TN); Hidralazina [INN-Spanish]; Hydralazine (INN); Hydralazine [INN:BAN]; Hydralazinum [INN-Latin]; Hydrazone 1(2H)-phthalazinone; Phthalazin-1-ylhydrazine; [2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride; (1Z)-1(2H)-Phthalazinone hydrazone; (2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone, hydrazone; 1-Hydrazinophthalazine; 1-Phthalazinylhydrazine; 6-Hydralazine
DMU8JGH	TC	Antihypertensive Agents
DMU8JGH	DT	Small molecular drug
DMU8JGH	PC	3637
DMU8JGH	MW	160.18
DMU8JGH	FM	C8H8N4
DMU8JGH	IC	InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
DMU8JGH	CS	C1=CC=C2C(=C1)C=NN=C2NN
DMU8JGH	IK	RPTUSVTUFVMDQK-UHFFFAOYSA-N
DMU8JGH	IU	phthalazin-1-ylhydrazine
DMU8JGH	CA	CAS 86-54-4
DMU8JGH	CB	CHEBI:5775
DMU8JGH	DE	Hypertension

DMUSZHD	ID	DMUSZHD
DMUSZHD	DN	Hydrochlorothiazide
DMUSZHD	HS	Approved
DMUSZHD	SN	Acesistem; Acuilix; Acuretic; Aldazida; Aldoril; Apresazide; Aquarills; Aquarius; Bremil; Briazide; Caplaril; Carozide; Catiazida; Chlorizide; Chlorosulthiadil; Chlorzide; Chlothia; Cidrex; Clorana; Condiuren; Diaqua; Dichlorosal; Dichlorotride; Dichlothiazide; Dichlotiazid; Dichlotride; Diclotride; Dicyclotride; Didral; Dihydran; Dihydrochlorothiazid; Dihydrochlorothiazide; Dihydrochlorothiazidum; Dihydrochlorurit; Dihydrochlorurite; Dihydroxychlorothiazidum; Direma; Disalunil; Disothiazid; Diurogen; Dixidrasi; Drenol; Esidrex; Esidrix; Esoidrina; Fluvin; HCT; HCTZ; HCZ; Hidril; Hidrochlortiazid; Hidroclorotiazida; Hidroronol; Hidrosaluretil; Hidrotiazida; Hyclosid; Hydril; HydroDIURIL; Hydrochlorat; Hydrochlorot; Hydrochlorothiazid; Hydrochlorothiazidum; Hydrochlorthiazide; Hydrochlorthiazidum; Hydrocot; Hydrodiuretic; Hydropres; Hydrosaluric; Hydrothide; Hydrozide; Hypothiazid; Hypothiazide; Hytrid; Idroclorotiazide; Idrotiazide; Indroclor; Ivaugan; Manuril; Maschitt; Medozide; Megadiuril; Microzide; Mictrin; Mikorten; Modurcen; Moduretic; Natrinax; Nefrix; Nefrol; Neoflumen; Newtolide; Novodiurex; Oretic; Pantemon; Panurin; Roxane; Saldiuril; Sectrazide; Selozide; Servithiazid; Spironazide; Tandiur; Thiaretic; Thiuretic; Thlaretic; Timolide; Unazid; Urodiazin; Urozide; Vaseretic; Vetidrex; Aquazide H; Chlorsulfonamidodihydrobenzothiadiazine dioxide; Component of Aldactazide; Component of Aldoril; Component of Butizide Prestabs; Component of Caplaril; Component of Cyclex; Component of Dyazide; Component of Esimil; Concor Plus; Diclot ride; Hydro Par; Hydrochlorothiazide Intensol; Idroclorotiazide [DCIT]; Lotensin HCT; Panurin dichloride; Raunova Plus; Diu 25 Vigt; H 4759; MaybridgeCompound 10; Mazide 25 mg; Su 5879; Aldactazide 25/25; Aldectazide 50/50; Apo-Hydro; Aquazide H (TN); Aquazide-H; Dichlotride (TN); Diu-melusin; Esidrex (TN); Esidrix (TN); HCT-Isis; Hidro-Niagrin; Hidroclorotiazida [INN-Spanish]; Hydrex-semi; Hydro-Aquil; Hydro-D; Hydro-Diuril; Hydro-Saluric; Hydro-T; Hydro-chlor; HydroSaluric (TN); Hydrochlorothiazidum [INN-Latin]; Hydrodiuril (TN); Hydrozide Injection, Veterinary; Jen-Diril; Microzide (TN); Neo-Flumen; Neo-Minzil; Neo-codema; Oretic (TN); Ro-hydrazide; AF-614/30832002; Apo-Hydro (TN); Hydrochlorothiazide [INN:BAN:JAN]; Hydrochlorothiazide (JP15/USP/INN); Dro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi; 3,4-Dihydrochlorothiazide; 6-Chloro-7-sulfamoyl-3, 4-dihy
DMUSZHD	TC	Diuretics
DMUSZHD	DT	Small molecular drug
DMUSZHD	PC	3639
DMUSZHD	MW	297.7
DMUSZHD	FM	C7H8ClN3O4S2
DMUSZHD	IC	InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
DMUSZHD	CS	C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
DMUSZHD	IK	JZUFKLXOESDKRF-UHFFFAOYSA-N
DMUSZHD	IU	6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMUSZHD	CA	CAS 58-93-5
DMUSZHD	CB	CHEBI:5778
DMUSZHD	DE	Hypertension

DMQ2JO5	ID	DMQ2JO5
DMQ2JO5	DN	Hydrocodone
DMQ2JO5	HS	Approved
DMQ2JO5	SN	HYDROCODONE; Dihydrocodeinone; Hydrocodon; Hydrocone; Hydroconum; Codinovo; Dicodid; Multacodin; Bekadid; hidrocodona; Idrocodone; Hydrocodonum; Idrocodone [DCIT]; DICO; (-)-Dihydrocodeinone; Hydrocodonum [INN-Latin]; 125-29-1; Hidrocodona [INN-Spanish]; Codeinone, dihydro-; Hydrocodone polistirex; Hydrocodone [INN:BAN]; UNII-6YKS4Y3WQ7; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; HSDB 3097; EINECS 204-733-9; BRN 0094193;  Bekadid; Hidrocodona; Hydrocodeinonebitartrate; Hydrocon; Anexsia (TN); Dicodid (TN); Duodin (TN); Hycet (TN); Hycodan (TN); Hycomine (TN); Hydrocodone (INN); Hydrokon (TN); Hydrovo (TN); Kolikodol (TN); Lorcet (TN); Lortab (TN); Mercodinone (TN); Norco (TN); Norgan (TN); Novahistex (TN); Orthoxycol (TN); Symtan (TN); Synkonin (TN); Vicodin (TN); Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-(8CI); Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-(9CI); (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; KP-201 hydrocodone prodrug
DMQ2JO5	CP	Abbott Laboratories
DMQ2JO5	TC	Analgesics
DMQ2JO5	DT	Small molecular drug
DMQ2JO5	PC	5284569
DMQ2JO5	MW	299.4
DMQ2JO5	FM	C18H21NO3
DMQ2JO5	IC	InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
DMQ2JO5	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4
DMQ2JO5	IK	LLPOLZWFYMWNKH-CMKMFDCUSA-N
DMQ2JO5	IU	(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMQ2JO5	CA	CAS 125-29-1
DMQ2JO5	CB	CHEBI:5779
DMQ2JO5	DE	Pain

DMIAPBE	ID	DMIAPBE
DMIAPBE	DN	Hydrocodone bitartrate
DMIAPBE	HS	Approved
DMIAPBE	SN	Hydrocodon; Hydrocodone [INN:BAN]; Hydrocodone polistirex; Hydrocodonum; Hydrocodonum [INN-Latin]; Hydrocone; Hydroconum; Idrocodone; Idrocodone [DCIT]; Multacodin; hidrocodona; (-)-Dihydrocodeinone; 125-29-1; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; BRN 0094193; DICO; EINECS 204-733-9; HSDB 3097; UNII-6YKS4Y3WQ7; Bekadid; Codeinone, dihydro-; Codinovo; Dicodid; Dihydrocodeinone; HYDROCODONE; Hidrocodona [INN-Spanish]; HYDROCODONE BITARTRATE; OJHZNMVJJKMFGX-RNWHKREASA-N; SCHEMBL154972; .codon; 143-71-5; API0002943; CHEMBL2062267; MFCD00078557
DMIAPBE	PC	20831824
DMIAPBE	MW	449.4
DMIAPBE	FM	C22H27NO9
DMIAPBE	IC	OJHZNMVJJKMFGX-RNWHKREASA-N
DMIAPBE	CS	CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4.C(C(C(=O)O)O)(C(=O)O)O
DMIAPBE	IK	1S/C18H21NO3.C4H6O6/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;5-1(3(7)8)2(6)4(9)10/h3,6,11-12,17H,4-5,7-9H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-,12+,17-,18-;/m0./s1
DMIAPBE	IU	(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2,3-dihydroxybutanedioic acid
DMIAPBE	CA	CAS 143-71-5
DMIAPBE	DE	Neuropathic pain

DM8K1XO	ID	DM8K1XO
DM8K1XO	DN	Hydrocortamate
DM8K1XO	HS	Approved
DM8K1XO	SN	Hidrocortamato; Hydrocortamatum; Idrocortamato; Magnacort; Hydrocortamate [INN]; Idrocortamato [DCIT]; Hidrocortamato [INN-Spanish]; Hydrocortamatum [INN-Latin]; Hydrocortisone 21-(diethylamino)acetate; Hyddrocortison-21-(beta-diethylaminoacetat); Glycine, N,N-diethyl-, 21-ester with cortisol; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; 17-Hydroxycorticosterone, 21-(diethylamino)acetate
DM8K1XO	TC	Antiinflammatory Agents
DM8K1XO	DT	Small molecular drug
DM8K1XO	PC	84088
DM8K1XO	MW	475.6
DM8K1XO	FM	C27H41NO6
DM8K1XO	IC	InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1
DM8K1XO	CS	CCN(CC)CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O
DM8K1XO	IK	FWFVLWGEFDIZMJ-FOMYWIRZSA-N
DM8K1XO	IU	[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate
DM8K1XO	CA	CAS 76-47-1
DM8K1XO	CB	CHEBI:50851
DM8K1XO	DE	Inflammation

DMGEMB7	ID	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	HS	Approved
DMGEMB7	SN	Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone
DMGEMB7	CP	Merck And Co Inc
DMGEMB7	TC	Antiinflammatory Agents
DMGEMB7	DT	Small molecular drug
DMGEMB7	PC	5754
DMGEMB7	MW	362.5
DMGEMB7	FM	C21H30O5
DMGEMB7	IC	InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
DMGEMB7	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O
DMGEMB7	IK	JYGXADMDTFJGBT-VWUMJDOOSA-N
DMGEMB7	IU	(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMGEMB7	CA	CAS 50-23-7
DMGEMB7	CB	CHEBI:17650
DMGEMB7	DE	Inflammation; Congenital adrenal hyperplasia

DMVPUQI	ID	DMVPUQI
DMVPUQI	DN	Hydroflumethiazide
DMVPUQI	HS	Approved
DMVPUQI	SN	Bristab; Bristurin; Dihydroflumethazide; Dihydroflumethiazide; Diucardin; Diuredemina; Diurometon; Elodrin; Elodrine; Enjit; Finuret; Flutizide; Glomerulin; HFZ; Hidroalogen; Hidroflumetiazid; Hidroflumetiazida; Hydol; Hydrenox; Hydroflumethazide; Hydroflumethiazidum; Hydroflumethizide; Idroflumetiazide; Leodrine; Metflorylthiazidine; Metforylthiadiazin; Metforylthiazidin; Methforylthiazidine; NaClex; Olmagran; Rivosil; Robezon; Rodiuran; Rontyl; Saluron; Sisuril; Spandiuril; Trifluoromethylhydrazide; Trifluoromethylhydrothiazide; Vergonil; Component of Salutensin; Idroflumetiazide [DCIT]; SB01887; Di-ademil; Di-adenil; Hidroflumetiazida [INN-Spanish]; Hydroflumethiazidum [INN-Latin]; Naciex (glaxo); Saluron (TN); Hydroflumethiazide [INN:BAN:JAN]; Hydroflumethiazide (JAN/USP/INN); Ethyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Fluoromethyl-3, 4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 3, 4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 3, 4-Dihydro-6-trifluorom; 3, 4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1, 1-dioxide; 3,4-Dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2, 4-benzothi; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-(Trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Trifluoromethyl-3, 4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2, 4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 7-Sulfamoyl-6-tri; 7-Sulfamoyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1, 1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
DMVPUQI	TC	Diuretics
DMVPUQI	DT	Small molecular drug
DMVPUQI	PC	3647
DMVPUQI	MW	331.3
DMVPUQI	FM	C8H8F3N3O4S2
DMVPUQI	IC	InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)
DMVPUQI	CS	C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1
DMVPUQI	IK	DMDGGSIALPNSEE-UHFFFAOYSA-N
DMVPUQI	IU	1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMVPUQI	CA	CAS 135-09-1
DMVPUQI	CB	CHEBI:5784
DMVPUQI	DE	Congestive heart failure

DM1NG5W	ID	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	HS	Approved
DM1NG5W	SN	perhydrol; oxydol; 7722-84-1; Superoxol; Interox; Hydrogen dioxide; hydroperoxide; Peroxaan; Inhibine; Kastone; Hioxyl; Albone; Albone 35; Dihydrogen dioxide; Albone DS; T-Stuff; Lensept; Perone; Elawox; Albone 70; Perone 50; Albone 50; Albone 35CG; Albone 70CG; Albone 50CG; H2O2; Hydrogen peroxide (H2O2); Peroxide; Peroxan; Hydrogen peroxide, 30%; Hydrogen dioxide solution; Hydrogen peroxide, 90%; Perone 35; Perone 30; Hydrogen peroxide, solution; Waterstofperoxyde; Wasserstoffperoxid; Hydrogen peroxide, 3%; Caswell No. 486AA
DM1NG5W	DT	Small molecular drug
DM1NG5W	PC	784
DM1NG5W	MW	34.015
DM1NG5W	FM	H2O2
DM1NG5W	IC	InChI=1S/H2O2/c1-2/h1-2H
DM1NG5W	CS	OO
DM1NG5W	IK	MHAJPDPJQMAIIY-UHFFFAOYSA-N
DM1NG5W	IU	hydrogen peroxide
DM1NG5W	CA	CAS 7722-84-1
DM1NG5W	CB	CHEBI:16240
DM1NG5W	DE	Infectious disease

DMHP21E	ID	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	HS	Approved
DMHP21E	SN	hydromorphone; Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one;  DiMo; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug
DMHP21E	CP	Knoll
DMHP21E	TC	Analgesics
DMHP21E	DT	Small molecular drug
DMHP21E	PC	5284570
DMHP21E	MW	285.34
DMHP21E	FM	C17H19NO3
DMHP21E	IC	InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1
DMHP21E	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4
DMHP21E	IK	WVLOADHCBXTIJK-YNHQPCIGSA-N
DMHP21E	IU	(4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMHP21E	CA	CAS 466-99-9
DMHP21E	CB	CHEBI:5790
DMHP21E	DE	Pain; Chronic pain

DM6AVR4	ID	DM6AVR4
DM6AVR4	DN	Hydroquinone
DM6AVR4	HS	Approved
DM6AVR4	SN	hydroquinone; 1,4-benzenediol; Benzene-1,4-diol; 123-31-9; 1,4-Dihydroxybenzene; Quinol; p-Benzenediol; p-Hydroxyphenol; p-Hydroquinone; 4-Hydroxyphenol; Eldoquin; Benzoquinol; p-Dihydroxybenzene; hydroquinol; Eldopaque; Phiaquin; p-Dioxybenzene; Hydroquinole; Dihydroquinone; Tecquinol; Idrochinone; Benzohydroquinone; Tequinol; Hidroquinone; Arctuvin; Dihydroxybenzene; Solaquin forte; Derma-Blanch; Tenox HQ; Hydrochinone; Hydrochinon; Artra; Eldoquin Forte; Eldopaque Forte; Diak 5; Benzene, p-dihydroxy-; 1,4-Dihydroxy-benzol; Usaf ek-356; Accutin
DM6AVR4	DT	Small molecular drug
DM6AVR4	PC	785
DM6AVR4	MW	110.11
DM6AVR4	FM	C6H6O2
DM6AVR4	IC	InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H
DM6AVR4	CS	C1=CC(=CC=C1O)O
DM6AVR4	IK	QIGBRXMKCJKVMJ-UHFFFAOYSA-N
DM6AVR4	IU	benzene-1,4-diol
DM6AVR4	CA	CAS 123-31-9
DM6AVR4	CB	CHEBI:17594
DM6AVR4	DE	Melasma

DMGKV9D	ID	DMGKV9D
DMGKV9D	DN	Hydroxocobalamin
DMGKV9D	HS	Approved
DMGKV9D	SN	AlphaRedisol; Axion; Axlon; Cobalex; Codroxomin; Cyanokit; Depogamma; Docclan; Docelan; Docelvita; Docevita; Duradoce; Hidroxocobalamina; Hydrobamine; Hydrocobalamin; Hydrogrisevit; Hydrovit; Hydroxocobalaminacetat; Hydroxocobalamine; Hydroxocobalaminum; Hydroxocobemine; Hydroxomin; Hydroxycobalamin; Hydroxycobalamine; Hyxobamine; Idrogrisevit; Idrossocobalamina; Oxobemin; Vibeden; Vitadurin; Alpha Cobione; Ciplamin H; Hydro Cobex; Hydroxocobalamin acetate; Hydroxocobalamin monohydrochloride; Hydroxy Cobal; Idrossocobalamina [DCIT]; Primabalt RP; Hydroxocobalamin Vitamin B12; Hydroxy vitamin B12; Ohb12; Vitamin B12a; Vitamin B12b; Acti-B12; AlphaRedisol (TN); Benzimidazolyl ribofuranosyl phosphate deriv.; Cyanokit (TN); Ducobee-Hy; Duralta-12; Hidroxocobalamina [INN-Spanish]; Hydroxocobalamine [INN-French]; Hydroxocobalaminum [INN-Latin]; Hydroxycob(lll)alamin; Lyovit-H; Neo-Betalin 12; Neo-cytamen; Neo-macrabin; Neo-rojamin; OH-Cbl; OH-Duphar; Oxolamine (arcum); Redisol-H; Sytobex-H; Vitamin B(sub 12a); Vitamin B-12b; Hydroxocobalamin (JAN/USP/INN); Hydroxocobalamin [USAN:INN:BAN:JAN]; Alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide; Hydroxocobalamin(alkaline soln.), OH-replaces CN-in Cyanocobalamin); Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-hydroxocobamide; Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole inner salt; Cobinamide dihydroxide dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono (inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, Co-hydroxy-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3); Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)
DMGKV9D	TC	Vitamins
DMGKV9D	DT	Small molecular drug
DMGKV9D	PC	70689311
DMGKV9D	MW	1347.4
DMGKV9D	FM	C62H90CoN13O15P
DMGKV9D	IC	InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+2;/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1
DMGKV9D	CS	CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@@]\\4([C@H]([C@@H]5[C@]6([C@@]([C@@H](C(=N6)/C(=C\\7/[C@@]([C@@H](C(=N7)/C=C\\8/C([C@@H](C(=N8)/C(=C4\\[N-]5)/C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co+2]
DMGKV9D	IK	DQOCFCZRZOAIBN-WZHZPDAFSA-L
DMGKV9D	IU	cobalt(2+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1H-corrin-21-id-3-yl]propanoylamino]propan-2-yl] phosphate;hydrate
DMGKV9D	CA	CAS 13422-51-0
DMGKV9D	DE	Vitamin B12 deficiency; Lung injury

DMJAS3O	ID	DMJAS3O
DMJAS3O	DN	Hydroxyamphetamine
DMJAS3O	HS	Approved
DMJAS3O	SN	Hydroxyamfetamine; Hydroxyamphetamide; Norpholedrine; Norveritol; Nov-Pholedrin; Oksamfetamin; Oxamfetamin; Oxamphetamine; Oxamphetaminium; Paradrine; Paredrine; Paredrinex; Pedrolon; Phenol, 4-(2-aminopropyl)-; Phenol, p-(2-aminopropyl)-; Phenol,4-(2-aminopropyl)-; Pulsoton; alpha-Methyltyramine; hydroxyamphetamine; p-(2-Aminopropyl)phenol; p-HYDROXYAMPHETAMINE; .alpha.-Methyltyramine; 1-p-Hydroxyphenyl-2-propylamine; 103-86-6; 2-Amino-1-(p-hydroxyphenyl)propane; 4-(2-Aminopropyl)phenol; 4-Hydroxyamphetamine
DMJAS3O	PC	3651
DMJAS3O	MW	151.21
DMJAS3O	FM	C9H13NO
DMJAS3O	IC	GIKNHHRFLCDOEU-UHFFFAOYSA-N
DMJAS3O	CS	CC(CC1=CC=C(C=C1)O)N
DMJAS3O	IK	1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3
DMJAS3O	IU	4-(2-aminopropyl)phenol
DMJAS3O	CA	CAS 103-86-6
DMJAS3O	CB	CHEBI:103855
DMJAS3O	DE	Horner syndrome

DMQSGM0	ID	DMQSGM0
DMQSGM0	DN	Hydroxyamphetamine Hydrobromide
DMQSGM0	HS	Approved
DMQSGM0	SN	Paredrine; 4-hydroxyamphetamine
DMQSGM0	CP	Pharmics Inc
DMQSGM0	DT	Small molecular drug
DMQSGM0	PC	9377
DMQSGM0	MW	232.12
DMQSGM0	FM	C9H14BrNO
DMQSGM0	IC	InChI=1S/C9H13NO.BrH/c1-7(10)6-8-2-4-9(11)5-3-8;/h2-5,7,11H,6,10H2,1H3;1H
DMQSGM0	CS	CC(CC1=CC=C(C=C1)O)N.Br
DMQSGM0	IK	RZCJLMTXBMNRAD-UHFFFAOYSA-N
DMQSGM0	IU	4-(2-aminopropyl)phenol;hydrobromide
DMQSGM0	CA	CAS 306-21-8
DMQSGM0	DE	Horner syndrome

DMSIVND	ID	DMSIVND
DMSIVND	DN	Hydroxychloroquine
DMSIVND	HS	Approved
DMSIVND	SN	Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258
DMSIVND	CP	Concordia Pharmaceuticals Inc
DMSIVND	TC	Antimalarials
DMSIVND	DT	Small molecular drug
DMSIVND	PC	3652
DMSIVND	MW	335.9
DMSIVND	FM	C18H26ClN3O
DMSIVND	IC	InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
DMSIVND	CS	CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
DMSIVND	IK	XXSMGPRMXLTPCZ-UHFFFAOYSA-N
DMSIVND	IU	2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
DMSIVND	CA	CAS 118-42-3
DMSIVND	CB	CHEBI:5801
DMSIVND	DE	Malaria

DMGIZF5	ID	DMGIZF5
DMGIZF5	DN	Hydroxyflutamide
DMGIZF5	HS	Approved
DMGIZF5	SN	HFT; Hydroxyniphtholide; PC1193; Sch 16423; Hydroxy-flutamide; OH-flutamide; Sch-16423; Alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide; Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMGIZF5	TC	Anticancer Agents
DMGIZF5	DT	Small molecular drug
DMGIZF5	PC	91649
DMGIZF5	MW	292.21
DMGIZF5	FM	C11H11F3N2O4
DMGIZF5	IC	InChI=1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)
DMGIZF5	CS	CC(C)(C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F)O
DMGIZF5	IK	YPQLFJODEKMJEF-UHFFFAOYSA-N
DMGIZF5	IU	2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMGIZF5	CA	CAS 52806-53-8
DMGIZF5	DE	Prostate cancer

DMIKQH5	ID	DMIKQH5
DMIKQH5	DN	Hydroxyprogesterone
DMIKQH5	HS	Approved
DMIKQH5	SN	Delalutin (TN); Proluton depot (TN)
DMIKQH5	CP	Bristol Myers Squibb
DMIKQH5	DT	Small molecular drug
DMIKQH5	PC	6238
DMIKQH5	MW	330.5
DMIKQH5	FM	C21H30O3
DMIKQH5	IC	InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1
DMIKQH5	CS	CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
DMIKQH5	IK	DBPWSSGDRRHUNT-CEGNMAFCSA-N
DMIKQH5	IU	(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMIKQH5	CA	CAS 68-96-2
DMIKQH5	CB	CHEBI:17252
DMIKQH5	DE	Solid tumour/cancer

DMR5QS6	ID	DMR5QS6
DMR5QS6	DN	Hydroxystilbamidine Isethionate
DMR5QS6	HS	Approved
DMR5QS6	SN	Hydroxystilbamide; Hydroxystilbamidine diisethionate; FluoroGold (TN); Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1); Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1) (8CI); Benzenecarboximidamide, 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxy-, bis(2-hydroxyethanesulfonate) (salt); Ethanesulfonic acid, 2-hydroxy-, compd. with 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxybenzenecarboximidamide (2:1); (4E)-4-[2-[4-(diaminomethylidene)cyclohexa-2,5-dien-1-ylidene]ethylidene]-3-oxocyclohexa-1,5-diene-1-carboximidamide; 2-Hydroxy-4,4'-diamidinostilbene di(beta-hydroxyethanesulfonate); 2-Hydroxy-4,4'-diguanylstilbene diisethionate; 2-Hydroxy-4,4'-stilbenedicarboxamidine bis(2-hydroxyethanesulfonate) (salt); 2-Hydroxy-4,4'-stilbenedicarboxamidine diisethionate; 2-Hydroxyethanesulphonic acid, compoundwith 4-(2-(4-amidinophenyl)vinyl)-3-hydroxybenzenecarboxamidine (2:1); 2-Hydroxystilbamidine diisethionate; 2-Hydroxystilbamidine isethionate; 2-hydroxyethanesulfonic acid
DMR5QS6	TC	Antifungal Agents
DMR5QS6	DT	Small molecular drug
DMR5QS6	PC	135460345
DMR5QS6	MW	406.5
DMR5QS6	FM	C18H22N4O5S
DMR5QS6	IC	InChI=1S/C16H16N4O.C2H6O4S/c17-15(18)12-5-2-10(3-6-12)1-4-11-7-8-13(16(19)20)9-14(11)21;3-1-2-7(4,5)6/h1-9,21H,(H3,17,18)(H3,19,20);3H,1-2H2,(H,4,5,6)/b4-1+;
DMR5QS6	CS	C1=CC(=CC=C1/C=C/C2=C(C=C(C=C2)C(=N)N)O)C(=N)N.C(CS(=O)(=O)O)O
DMR5QS6	IK	HPLUMRXCPMTSQW-DYVSEJHDSA-N
DMR5QS6	IU	4-[(E)-2-(4-carbamimidoylphenyl)ethenyl]-3-hydroxybenzenecarboximidamide;2-hydroxyethanesulfonic acid
DMR5QS6	CA	CAS 533-22-2
DMR5QS6	DE	Blastomycosis

DMOQVU9	ID	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	HS	Approved
DMOQVU9	SN	Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA
DMOQVU9	TC	Anticancer Agents
DMOQVU9	DT	Small molecular drug
DMOQVU9	PC	3657
DMOQVU9	MW	76.055
DMOQVU9	FM	CH4N2O2
DMOQVU9	IC	InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
DMOQVU9	CS	C(=O)(N)NO
DMOQVU9	IK	VSNHCAURESNICA-UHFFFAOYSA-N
DMOQVU9	IU	hydroxyurea
DMOQVU9	CA	CAS 127-07-1
DMOQVU9	CB	CHEBI:44423
DMOQVU9	DE	Chronic myelogenous leukaemia

DMF8Y74	ID	DMF8Y74
DMF8Y74	DN	Hydroxyzine
DMF8Y74	HS	Approved
DMF8Y74	SN	Atara; Atarax; Ataraxoid; Atarazoid; Atarox; Atazina; Aterax; Deinait; Durrax; Hidroxizina; Hychotine; Hydroksyzyny; Hydroxine; Hydroxizine; Hydroxizinum; Hydroxycine; Hydroxyzin; Hydroxyzinum; Hydroxyzyne; Idrossizina; Neurozina; Nevrolaks; Orgatrax; Pamazone; Parenteral; Paxistil; Placidol; Plaxidol; Tranquizine; Traquizine; Vistaril; Atarax base; Hydroksyzyny [Polish]; Hydroxyzine Hcl; Hydroxyzine base; Hydroxyzine hydrochloride; Idrossizina [DCIT]; NP 212; UCB 4492; UCB 492; Atarax (TN); Hidroxizina [INN-Spanish]; Hy-Pam 25; Hydroxyzine (INN); Hydroxyzine [INN:BAN]; Hydroxyzinum [INN-Latin]; Marex (TN); Neo-Calma; Tran-Q; U.CB 4492; Vesparaz-Wirkstoff; Vistaril (TN); U.C.B 4492; N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine; N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-(9CI); 1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol; 2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
DMF8Y74	CP	Pfizer Pharmaceuticals
DMF8Y74	TC	Hypnotics and Sedatives
DMF8Y74	DT	Small molecular drug
DMF8Y74	PC	3658
DMF8Y74	MW	374.9
DMF8Y74	FM	C21H27ClN2O2
DMF8Y74	IC	InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2
DMF8Y74	CS	C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMF8Y74	IK	ZQDWXGKKHFNSQK-UHFFFAOYSA-N
DMF8Y74	IU	2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
DMF8Y74	CA	CAS 68-88-2
DMF8Y74	CB	CHEBI:5818
DMF8Y74	DE	Anxiety disorder

DMVAIH4	ID	DMVAIH4
DMVAIH4	DN	Hylenex
DMVAIH4	HS	Approved
DMVAIH4	CP	Halozyme therapeutics; baxter healthcare
DMVAIH4	DE	Solid tumour/cancer

DM804UR	ID	DM804UR
DM804UR	DN	Hyoscyamine
DM804UR	HS	Approved
DM804UR	SN	L-Hyoscyamine; hyoscyamine; 101-31-5; (-)-Hyoscyamine; Daturine; Duboisine; (-)-Atropine; L-Tropine tropate; (S)-Atropine; (S)-(-)-Hyoscyamine; Hyoscyamine (L); UNII-PX44XO846X; Tropine, (-)-tropate; Levbid; PX44XO846X; Levsinex SR; CHEBI:17486; Hyoscyamine, l-; [3(S)-endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; (2S)-(1R,5S)-8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropanoate; (1R,5S)-8-METHYL-8-AZABICYCLO[321]OCT-3-YL (2R)-3-HYDROXY-2-PHENYLPROPANOATE; Hyocyamine
DM804UR	TC	Antiarrhythmic Agents
DM804UR	DT	Small molecular drug
DM804UR	PC	154417
DM804UR	MW	289.4
DM804UR	FM	C17H23NO3
DM804UR	IC	InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1
DM804UR	CS	CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3
DM804UR	IK	RKUNBYITZUJHSG-VFSICIBPSA-N
DM804UR	IU	[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate
DM804UR	CA	CAS 101-31-5
DM804UR	CB	CHEBI:17486
DM804UR	DE	Gastrointestinal disease

DM0RXF5	ID	DM0RXF5
DM0RXF5	DN	Hyqvia
DM0RXF5	HS	Approved
DM0RXF5	SN	Immunoglobulin infusion with recombinant hyaluronidase
DM0RXF5	CP	Baxter
DM0RXF5	DE	Immunodeficiency

DMV67QO	ID	DMV67QO
DMV67QO	DN	Ibalizumab 
DMV67QO	HS	Approved
DMV67QO	SN	Hu5A8; TNX-355
DMV67QO	CP	TaiMed Biologics/Theratechnologies
DMV67QO	DT	Antibody
DMV67QO	DE	Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection

DM0QZBN	ID	DM0QZBN
DM0QZBN	DN	Ibandronate
DM0QZBN	HS	Approved
DM0QZBN	SN	BFQ; Acid ibandronico; Ibandronic Acid; Bisphosphonate 2; R484; RPR 102289A; Bondronat (TN); Boniva (TN); Bonviva (TN); Ibandronic acid (INN); Ibandronic acid [INN:BAN]; RPR-102289A; Ibandronic acid, sodium salt, monohydrate; Roche brand of ibandronic acid, sodium salt, monohydrate; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate; 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate
DM0QZBN	CP	Roche; GlaxoSmithKline
DM0QZBN	TC	Bone Density Conservation Agents
DM0QZBN	DT	Small molecular drug
DM0QZBN	PC	60852
DM0QZBN	MW	319.23
DM0QZBN	FM	C9H23NO7P2
DM0QZBN	IC	InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
DM0QZBN	CS	CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
DM0QZBN	IK	MPBVHIBUJCELCL-UHFFFAOYSA-N
DM0QZBN	IU	[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid
DM0QZBN	CA	CAS 114084-78-5
DM0QZBN	DE	Osteoporosis

DMGUX67	ID	DMGUX67
DMGUX67	DN	Ibopamine hci
DMGUX67	HS	Approved
DMGUX67	SN	Inopamil (TN); Scandine (TN)
DMGUX67	DT	Small molecular drug
DMGUX67	PC	156320
DMGUX67	MW	343.8
DMGUX67	FM	C17H26ClNO4
DMGUX67	IC	InChI=1S/C17H25NO4.ClH/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4;/h6-7,10-12,18H,8-9H2,1-5H3;1H
DMGUX67	CS	CC(C)C(=O)OC1=C(C=C(C=C1)CCNC)OC(=O)C(C)C.Cl
DMGUX67	IK	ALIXRWKJZYLBJI-UHFFFAOYSA-N
DMGUX67	IU	[4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate;hydrochloride
DMGUX67	CA	CAS 75011-65-3
DMGUX67	DE	Cardiac disease

DMG594T	ID	DMG594T
DMG594T	DN	Ibritumomab
DMG594T	HS	Approved
DMG594T	SN	Zevalin (TN)
DMG594T	CP	Bayer Pharmaceuticals Corporation
DMG594T	TC	Anticancer Agents
DMG594T	DT	Antibody
DMG594T	SQ	Ibritumomab tiuxetan heavy chain: QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR</sequence>    <sequence format="FASTA">&gt;Ibritumomab tiuxetan light chainQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRADAAPTVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN
DMG594T	DE	Non-hodgkin lymphoma; Mantle cell lymphoma

DMHZCPO	ID	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	HS	Approved
DMHZCPO	SN	PCI-32765; Ibrutinib (BTK inhibitor)
DMHZCPO	CP	Janssen Biotech; Pharmacyclics
DMHZCPO	DT	Small molecular drug
DMHZCPO	PC	24821094
DMHZCPO	MW	440.5
DMHZCPO	FM	C25H24N6O2
DMHZCPO	IC	InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
DMHZCPO	CS	C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
DMHZCPO	IK	XYFPWWZEPKGCCK-GOSISDBHSA-N
DMHZCPO	IU	1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
DMHZCPO	CA	CAS 936563-96-1
DMHZCPO	CB	CHEBI:76612
DMHZCPO	DE	B-cell non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Non-hodgkin lymphoma; Pancreatic cancer; Solid tumour/cancer

DM4LSPN	ID	DM4LSPN
DM4LSPN	DN	Ibudilast
DM4LSPN	HS	Approved
DM4LSPN	SN	Eyevinal; Ibudilastum; Ketas; Ibudilastum [Latin]; Ke Tas; AV 411; I 0157; KC 404; AV-411; Ibudilast [INN:JAN]; KC-404; Ketas (TN); MN-166; Ibudilast (JAN/INN); 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine
DM4LSPN	CP	Avigen
DM4LSPN	DT	Small molecular drug
DM4LSPN	PC	3671
DM4LSPN	MW	230.31
DM4LSPN	FM	C14H18N2O
DM4LSPN	IC	InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3
DM4LSPN	CS	CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C
DM4LSPN	IK	ZJVFLBOZORBYFE-UHFFFAOYSA-N
DM4LSPN	IU	2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one
DM4LSPN	CA	CAS 50847-11-5
DM4LSPN	CB	CHEBI:31684
DM4LSPN	DE	Amyotrophic lateral sclerosis; Alcohol dependence; Methamphetamine dependence; Opioid dependence; Multiple sclerosis; Castleman's disease

DM8VCBE	ID	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	HS	Approved
DM8VCBE	SN	ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid;  Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol;Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid;Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN
DM8VCBE	TC	Analgesics
DM8VCBE	DT	Small molecular drug
DM8VCBE	PC	3672
DM8VCBE	MW	206.28
DM8VCBE	FM	C13H18O2
DM8VCBE	IC	InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
DM8VCBE	CS	CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
DM8VCBE	IK	HEFNNWSXXWATRW-UHFFFAOYSA-N
DM8VCBE	IU	2-[4-(2-methylpropyl)phenyl]propanoic acid
DM8VCBE	CA	CAS 15687-27-1
DM8VCBE	CB	CHEBI:5855
DM8VCBE	DE	Pain

DMFJ8LT	ID	DMFJ8LT
DMFJ8LT	DN	Ibutamoren
DMFJ8LT	HS	Approved
DMFJ8LT	SN	L 163191; MK-0667; MK-677; 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
DMFJ8LT	CP	Merck
DMFJ8LT	DT	Small molecular drug
DMFJ8LT	PC	178024
DMFJ8LT	MW	528.7
DMFJ8LT	FM	C27H36N4O5S
DMFJ8LT	IC	InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1
DMFJ8LT	CS	CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N
DMFJ8LT	IK	UMUPQWIGCOZEOY-JOCHJYFZSA-N
DMFJ8LT	IU	2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
DMFJ8LT	CA	CAS 159634-47-6
DMFJ8LT	DE	Fibromyalgia

DMKXY2R	ID	DMKXY2R
DMKXY2R	DN	Ibutilide
DMKXY2R	HS	Approved
DMKXY2R	SN	Corvert; Ibutilida; Ibutilidum; Butilide fumarate; IBUTILIDE FUMARATE; Ibutilide Fumarate [USAN]; U 70226E; U82208E; U82209E; Corvert (TN); Ibutilida [INN-Spanish]; Ibutilide (INN); Ibutilide [BAN:INN]; Ibutilide [INN:BAN]; Ibutilide fumarate (USAN); Ibutilidum [INN-Latin]; U-70226E; U-82208E; U-82209E; Ibutilide, (+-)-isomer; N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide; Ibutilide, fumarate salt (2:1), (+-)-isomer; N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide; N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-,(E)-2-butenedioate (2:1) (salt); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-butenedioate (2:1); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide fumarate (2:1) (salt); (+-)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-butenedioate
DMKXY2R	CP	Pfizer Pharmaceuticals
DMKXY2R	TC	Antiarrhythmic Agents
DMKXY2R	DT	Small molecular drug
DMKXY2R	PC	60753
DMKXY2R	MW	384.6
DMKXY2R	FM	C20H36N2O3S
DMKXY2R	IC	InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3
DMKXY2R	CS	CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
DMKXY2R	IK	ALOBUEHUHMBRLE-UHFFFAOYSA-N
DMKXY2R	IU	N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide
DMKXY2R	CA	CAS 122647-31-8
DMKXY2R	CB	CHEBI:5856
DMKXY2R	DE	Atrial fibrillation

DMQPTOZ	ID	DMQPTOZ
DMQPTOZ	DN	Icatibant
DMQPTOZ	HS	Approved
DMQPTOZ	SN	Firazyr; Icatibant [INN]; HOE 140; HOE140; JE049; WIN 65365; Hoe-140; WIN-65365; D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK
DMQPTOZ	CP	Jerini AG
DMQPTOZ	TC	Antiinflammatory Agents
DMQPTOZ	DT	Small molecular drug
DMQPTOZ	PC	6918173
DMQPTOZ	MW	1304.5
DMQPTOZ	FM	C59H89N19O13S
DMQPTOZ	IC	InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1
DMQPTOZ	CS	C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@H]3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DMQPTOZ	IK	QURWXBZNHXJZBE-SKXRKSCCSA-N
DMQPTOZ	IU	(2S)-2-[[(2S,3aS,7aS)-1-[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMQPTOZ	CA	CAS 130308-48-4
DMQPTOZ	DE	Hereditary angioedema

DM648X9	ID	DM648X9
DM648X9	DN	Icodextrin
DM648X9	HS	Approved
DM648X9	SN	Extraneal
DM648X9	CP	Innovata plc
DM648X9	DT	Small molecular drug
DM648X9	PC	3517
DM648X9	MW	231.08
DM648X9	FM	C8H8Cl2N4
DM648X9	IC	InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)
DM648X9	CS	C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl
DM648X9	IK	WDZVGELJXXEGPV-UHFFFAOYSA-N
DM648X9	IU	2-[(2,6-dichlorophenyl)methylideneamino]guanidine
DM648X9	CA	CAS 5051-62-7
DM648X9	DE	Kidney disease

DMJHN0A	ID	DMJHN0A
DMJHN0A	DN	Icosapent
DMJHN0A	HS	Approved
DMJHN0A	TC	Dietary supplement
DMJHN0A	DT	Small molecular drug
DMJHN0A	PC	446284
DMJHN0A	MW	302.5
DMJHN0A	FM	C20H30O2
DMJHN0A	IC	InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-
DMJHN0A	CS	CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O
DMJHN0A	IK	JAZBEHYOTPTENJ-JLNKQSITSA-N
DMJHN0A	IU	(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
DMJHN0A	CA	CAS 10417-94-4
DMJHN0A	CB	CHEBI:28364
DMJHN0A	DE	Thrombin deficiency; Hyperglyceridemia; Hypertriglyceridemia

DMM0XGL	ID	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	HS	Approved
DMM0XGL	SN	DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin
DMM0XGL	CP	Ben Venue Laboratories
DMM0XGL	TC	Anticancer Agents
DMM0XGL	DT	Small molecular drug
DMM0XGL	PC	42890
DMM0XGL	MW	497.5
DMM0XGL	FM	C26H27NO9
DMM0XGL	IC	InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
DMM0XGL	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O
DMM0XGL	IK	XDXDZDZNSLXDNA-TZNDIEGXSA-N
DMM0XGL	IU	(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
DMM0XGL	CA	CAS 58957-92-9
DMM0XGL	CB	CHEBI:42068
DMM0XGL	DE	Acute myeloid leukaemia

DMXEACF	ID	DMXEACF
DMXEACF	DN	Idarucizumab
DMXEACF	HS	Approved
DMXEACF	SN	Praxbind
DMXEACF	CP	Boehringer Ingelheim
DMXEACF	DT	Antibody
DMXEACF	DE	Reversal of the anticoagulant effects of dabigatran

DMQFDRC	ID	DMQFDRC
DMQFDRC	DN	Idebenone
DMQFDRC	HS	Approved
DMQFDRC	SN	idebenone; 58186-27-9; Idebenona; Idebenonum; CV 2619; Idebenonum [Latin]; Idebenona [Spanish]; Idebenone [INN:JAN]; CV-2619; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; UNII-HB6PN45W4J; BRN 2001459; 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone; HB6PN45W4J; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone; CHEBI:31687; JGPMMRGNQUBGND-UHFFFAOYSA-N; 2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-; NCGC00160514-01; AK161748
DMQFDRC	CP	Santhera Pharmaceuticals
DMQFDRC	DT	Small molecular drug
DMQFDRC	PC	3686
DMQFDRC	MW	338.4
DMQFDRC	FM	C19H30O5
DMQFDRC	IC	InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3
DMQFDRC	CS	CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO
DMQFDRC	IK	JGPMMRGNQUBGND-UHFFFAOYSA-N
DMQFDRC	IU	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
DMQFDRC	CA	CAS 58186-27-9
DMQFDRC	CB	CHEBI:31687
DMQFDRC	DE	Cognitive impairment; Friedreich's ataxia

DMP1QTS	ID	DMP1QTS
DMP1QTS	DN	Idecabtagene vicleucel
DMP1QTS	HS	Approved
DMP1QTS	SN	Bb2121
DMP1QTS	CP	Celgene
DMP1QTS	DT	CAR T Cell Therapy
DMP1QTS	DE	Multiple myeloma

DM602WT	ID	DM602WT
DM602WT	DN	Idelalisib
DM602WT	HS	Approved
DM602WT	SN	Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL101; CAL 101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; UNII-YG57I8T5M0; CAL-101 (Idelalisib, GS-1101); YG57I8T5M0; CHEMBL2216870; CHEBI:82701; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; Idelalisib; CAL-101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE
DM602WT	CP	Gilead Sciences
DM602WT	DT	Small molecular drug
DM602WT	PC	11625818
DM602WT	MW	415.4
DM602WT	FM	C22H18FN7O
DM602WT	IC	InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
DM602WT	CS	CC[C@@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DM602WT	IK	IFSDAJWBUCMOAH-HNNXBMFYSA-N
DM602WT	IU	5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one
DM602WT	CA	CAS 870281-82-6
DM602WT	CB	CHEBI:82701
DM602WT	DE	Chronic lymphocytic leukaemia

DMDRT0E	ID	DMDRT0E
DMDRT0E	DN	Idoxuridine
DMDRT0E	HS	Approved
DMDRT0E	SN	Emanil; Herpesil; Herpidu; Idossuridina; Iododeoxyuridine; Kerecide; Ophthalmadine; Synmiol; ID2; LT00440811; SKF 14287; Dendrid (TN); HERPLEX (TN); Herpe-Gel; Herpes-Gel; Iododeoxyuridine-125I; Oftan-IDU; SK&F 14287; SK&F-14287; Idoxuridine (JP15/USP/INN); Idoxuridine [USAN:INN:BAN:JAN]; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 1-(2-deoxypentofuranosyl)-4-hydroxy-5-iodopyrimidin-2(1H)-one; 1-(2-deoxypentofuranosyl)-5-iodopyrimidine-2,4(1h,3h)-dione; 1-(4-Hydroxy-5-hydroxymethyltetrahydrofuran-2-yl)-5-iodo-1H-pyrimidine-2,4-dione; 1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 1.beta.-D-2'-Deoxyribofuranosyl-5-iodouracil; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 2'-Deoxy-5-(iodo-125I)uridine; 2'-deoxy-5-(125i)iodouridine; 5-(125-I)-Iodo-2-deoxyuridine; 5-I-2'-dUrd; 5-Iododesoxyuridine; 5IdU
DMDRT0E	TC	Antiviral Agents
DMDRT0E	DT	Small molecular drug
DMDRT0E	PC	5905
DMDRT0E	MW	354.1
DMDRT0E	FM	C9H11IN2O5
DMDRT0E	IC	InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DMDRT0E	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O
DMDRT0E	IK	XQFRJNBWHJMXHO-RRKCRQDMSA-N
DMDRT0E	IU	1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
DMDRT0E	CA	CAS 54-42-2
DMDRT0E	CB	CHEBI:147675
DMDRT0E	DE	Herpes simplex virus infection

DM30SXV	ID	DM30SXV
DM30SXV	DN	Idursulfase
DM30SXV	HS	Approved
DM30SXV	SN	Elaprase (TN)
DM30SXV	SQ	Idursulfase heavy chain: SETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPVDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQREDVQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPG</sequence>    <sequence format="FASTA">&gt;Idursulfase light chainNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP
DM30SXV	DE	Infertility; Hunter syndrome

DMCT3I8	ID	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	HS	Approved
DMCT3I8	SN	Cyfos; Holoxan; Ifex; Ifosfamid; Ifosfamida; Ifosfamidum; Ifosphamide; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; Isosfamide; Mitoxana; Naxamide; Ifosfamide Sterile; Iso Endoxan; A 4942; ASTA Z 4942; Holoxan 1000; MJF 9325; Z 4942; Z4942; I-Phosphamide; IFEX (TN); Ifex (TN); Ifosfamida [INN-Spanish]; Ifosfamidum [INN-Latin]; Iphosphamid(e); Iso-Endoxan; MJF-9325; Mitoxana (TN); NPFAPI-04; Z-4942; Mitoxana, Ifex, Ifosfamide; Ifosfamide (JAN/USP/INN); Ifosfamide [USAN:INN:BAN:JAN]; N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; (+-)-Ifosfamid; (+-)-Ifosphamide; (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; (D,L)-Ifosfamide; (R,S)-Ifosphamide; (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI); 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 3,} 2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
DMCT3I8	TC	Anticancer Agents
DMCT3I8	DT	Small molecular drug
DMCT3I8	PC	3690
DMCT3I8	MW	261.079
DMCT3I8	FM	C7H15Cl2N2O2P
DMCT3I8	IC	InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
DMCT3I8	CS	C1CN(P(=O)(OC1)NCCCl)CCCl
DMCT3I8	IK	HOMGKSMUEGBAAB-UHFFFAOYSA-N
DMCT3I8	IU	N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DMCT3I8	CA	CAS 3778-73-2
DMCT3I8	CB	CHEBI:5864
DMCT3I8	DE	Solid tumour/cancer

DM6AUFY	ID	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	HS	Approved
DM6AUFY	SN	Fanapt; Fanapta; Fiapta; Zomaril; HP 873; Fanapt (TN); HP-873; ILO-522; Iloperidone [USAN:INN]; Fanapta, Zomaril, Iloperidone; Iloperidone (USAN/INN); 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
DM6AUFY	CP	Vanda Pharmaceuticals
DM6AUFY	DT	Small molecular drug
DM6AUFY	PC	71360
DM6AUFY	MW	426.5
DM6AUFY	FM	C24H27FN2O4
DM6AUFY	IC	InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3
DM6AUFY	CS	CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
DM6AUFY	IK	XMXHEBAFVSFQEX-UHFFFAOYSA-N
DM6AUFY	IU	1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone
DM6AUFY	CA	CAS 133454-47-4
DM6AUFY	CB	CHEBI:65173
DM6AUFY	DE	Schizophrenia

DMVPZBE	ID	DMVPZBE
DMVPZBE	DN	Iloprost
DMVPZBE	HS	Approved
DMVPZBE	SN	Ciloprost; Endoprost; Ilomedin; Ilomedine; Iloprostum; Ventavis; Iloprostum [Latin]; ZK 36374; E-1030; Iloprost (INN); Iloprost [BAN:INN]; SH-401; Ventavis (TN); ZK-36374; ZK-363775; [3H]-Iloprost; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
DMVPZBE	CP	Actelion Pharmaceuticals
DMVPZBE	TC	Antihypertensive Agents
DMVPZBE	DT	Small molecular drug
DMVPZBE	PC	5311181
DMVPZBE	MW	360.5
DMVPZBE	FM	C22H32O4
DMVPZBE	IC	InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
DMVPZBE	CS	CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O
DMVPZBE	IK	HIFJCPQKFCZDDL-ACWOEMLNSA-N
DMVPZBE	IU	(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
DMVPZBE	CA	CAS 78919-13-8
DMVPZBE	CB	CHEBI:63916
DMVPZBE	DE	Pulmonary arterial hypertension

DM7RJXL	ID	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	HS	Approved
DM7RJXL	SN	Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
DM7RJXL	CP	Novartis AG
DM7RJXL	TC	Anticancer Agents
DM7RJXL	DT	Small molecular drug
DM7RJXL	PC	5291
DM7RJXL	MW	493.6
DM7RJXL	FM	C29H31N7O
DM7RJXL	IC	InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
DM7RJXL	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DM7RJXL	IK	KTUFNOKKBVMGRW-UHFFFAOYSA-N
DM7RJXL	IU	4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DM7RJXL	CA	CAS 152459-95-5
DM7RJXL	CB	CHEBI:45783
DM7RJXL	DE	Chronic myelogenous leukaemia; Systemic mastocytosis; Lung cancer; Intestinal cancer; Acute lymphoblastic leukaemia

DMUL7T1	ID	DMUL7T1
DMUL7T1	DN	Imidapril
DMUL7T1	HS	Approved
DMUL7T1	SN	Tanatil (TN)
DMUL7T1	CP	Tanabe
DMUL7T1	DT	Small molecular drug
DMUL7T1	PC	5464343
DMUL7T1	MW	405.4
DMUL7T1	FM	C20H27N3O6
DMUL7T1	IC	InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
DMUL7T1	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O
DMUL7T1	IK	KLZWOWYOHUKJIG-BPUTZDHNSA-N
DMUL7T1	IU	(4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
DMUL7T1	CA	89371-37-9
DMUL7T1	DE	Cardiovascular disease

DM3VS7Z	ID	DM3VS7Z
DM3VS7Z	DN	Imidazole salicylate
DM3VS7Z	HS	Approved
DM3VS7Z	SN	Salizolo; Selezen; ITF-182
DM3VS7Z	CP	Italfarmaco SpA
DM3VS7Z	DT	Small molecular drug
DM3VS7Z	PC	37425
DM3VS7Z	MW	206.2
DM3VS7Z	FM	C10H10N2O3
DM3VS7Z	IC	InChI=1S/C7H6O3.C3H4N2/c8-6-4-2-1-3-5(6)7(9)10;1-2-5-3-4-1/h1-4,8H,(H,9,10);1-3H,(H,4,5)
DM3VS7Z	CS	C1=CC=C(C(=C1)C(=O)O)O.C1=CN=CN1
DM3VS7Z	IK	XCHHJFVNQPPLJK-UHFFFAOYSA-N
DM3VS7Z	IU	2-hydroxybenzoic acid;1H-imidazole
DM3VS7Z	CA	CAS 36364-49-5
DM3VS7Z	DE	Inflammation

DMI9FBP	ID	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	HS	Approved
DMI9FBP	SN	Imipemide; Tienamycin; Imipenem anhydrous; Imipenem (INN); N-Formimidoylthienamycin; Primaxin (TN); Imipenem, N-Formimidoyl thienamycin; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMI9FBP	CP	Merck & Co
DMI9FBP	TC	Antibiotics
DMI9FBP	DT	Small molecular drug
DMI9FBP	PC	104838
DMI9FBP	MW	299.35
DMI9FBP	FM	C12H17N3O4S
DMI9FBP	IC	InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1
DMI9FBP	CS	C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O
DMI9FBP	IK	ZSKVGTPCRGIANV-ZXFLCMHBSA-N
DMI9FBP	IU	(5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMI9FBP	CA	CAS 64221-86-9
DMI9FBP	CB	CHEBI:471744
DMI9FBP	DE	Bacterial infection

DM2NUH3	ID	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	HS	Approved
DM2NUH3	SN	Antideprin; Berkomine; Censtim; Censtin; Declomipramine; Dimipressin; Dpid; Dynaprin; Eupramin; Imavate; Imidobenzyle; Imipramin; Imipramina; Imipraminum; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Janimine; Melipramin; Melipramine; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; Surplix; Timolet; Tofranil; Imipramina [Italian]; Tofraniln A; Antideprin (TN); Deprimin (TN); Deprinol (TN); Depsonil (TN); Dyna-zina; Dynaprin (TN); Eupramin (TN); G-22355; Imipramil (TN); Imipramina [INN-Spanish]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum [INN-Latin]; Irmin (TN); Janimine (TN); Janimine (hydrochloride); Melipramin (TN); SK-Pramine; Surplix (TN); Tofranil(TN); Tofranil (free base); Tofranil (hydrochloride); Tofranil, base; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI)
DM2NUH3	CP	Novartis Pharmaceuticals Corp
DM2NUH3	TC	Antidepressants
DM2NUH3	DT	Small molecular drug
DM2NUH3	PC	3696
DM2NUH3	MW	280.4
DM2NUH3	FM	C19H24N2
DM2NUH3	IC	InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
DM2NUH3	CS	CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
DM2NUH3	IK	BCGWQEUPMDMJNV-UHFFFAOYSA-N
DM2NUH3	IU	3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
DM2NUH3	CA	CAS 50-49-7
DM2NUH3	CB	CHEBI:47499
DM2NUH3	DE	Depression

DM1TMA3	ID	DM1TMA3
DM1TMA3	DN	Imiquimod
DM1TMA3	HS	Approved
DM1TMA3	SN	Aldara; Beselna; Zartra; Zyclara; Imiquimod acetate; R 837; S 26308; Aldara (TN); Aldara, Imiquimod; Beselna (TN); DZ-2636; Imiquimod [USAN:INN]; MTD-39; R-837; S-26308; TMX-101; Imiquimod (JAN/USAN/INN); 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 3M Brand of Imiquimod; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
DM1TMA3	CP	INova Pharmaceuticals 
DM1TMA3	TC	Antiviral Agents
DM1TMA3	DT	Small molecular drug
DM1TMA3	PC	57469
DM1TMA3	MW	240.3
DM1TMA3	FM	C14H16N4
DM1TMA3	IC	InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
DM1TMA3	CS	CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
DM1TMA3	IK	DOUYETYNHWVLEO-UHFFFAOYSA-N
DM1TMA3	IU	1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
DM1TMA3	CA	CAS 99011-02-6
DM1TMA3	CB	CHEBI:36704
DM1TMA3	DE	Skin cancer

DMRMFP4	ID	DMRMFP4
DMRMFP4	DN	Inamrinone Lactate
DMRMFP4	HS	Approved
DMRMFP4	SN	Amrinone; inamrinone; 60719-84-8; Wincoram; Inocor; Cordemcura; Cartonic; 5-Amino-[3,4'-bipyridin]-6(1H)-one; Amrinonum [INN-Latin]; Amrinonum; Amrinona; Amrinona [INN-Spanish]; 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone; Win-40680; Amcoral; 5-Amino-(3,4'-bipyridin)-6(1H)-one; WIN 40680; AWD 08-250; 3-amino-5-pyridin-4-yl-1H-pyridin-2-one; UNII-JUT23379TN; CCRIS 3794; Amrinone lactate; MLS000069829; EINECS 262-390-0; 5-amino-3,4'-bipyridin-6(1H)-one; BRN 0744819; 5-Amino(3,4'-bipyridin)-6(1H)-one; SMR000058850; CHEMBL12856; JUT23379TN;  Amrinone Lactate
DMRMFP4	CP	Sanofi Aventis Us Llc
DMRMFP4	TC	Cardiovascular Agents
DMRMFP4	DT	Small molecular drug
DMRMFP4	PC	3035194
DMRMFP4	MW	277.28
DMRMFP4	FM	C13H15N3O4
DMRMFP4	IC	InChI=1S/C10H9N3O.C3H6O3/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7;1-2(4)3(5)6/h1-6H,11H2,(H,13,14);2,4H,1H3,(H,5,6)
DMRMFP4	CS	CC(C(=O)O)O.C1=CN=CC=C1C2=CNC(=O)C(=C2)N
DMRMFP4	IK	DOSIONJFGDSKCQ-UHFFFAOYSA-N
DMRMFP4	IU	3-amino-5-pyridin-4-yl-1H-pyridin-2-one;2-hydroxypropanoic acid
DMRMFP4	CA	CAS 75898-90-7
DMRMFP4	DE	Congestive heart failure; Cardiac disease

DM3DSVJ	ID	DM3DSVJ
DM3DSVJ	DN	Incadronate
DM3DSVJ	HS	Approved
DM3DSVJ	SN	Incadronate; 138330-18-4; Disodium Cycloheptylaminomethylene diphosphonate; Bisphonal; Cimadronate sodium; AC1OCF1R; Incadronic acid sodium salt; C8H17NNa2O6P2; CTK8F9264; RT-012376; YM-21175-1; J-007120; disodium [(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate
DM3DSVJ	DT	Small molecular drug
DM3DSVJ	PC	6918123
DM3DSVJ	MW	331.15
DM3DSVJ	FM	C8H17NNa2O6P2
DM3DSVJ	IC	InChI=1S/C8H19NO6P2.2Na/c10-16(11,12)8(17(13,14)15)9-7-5-3-1-2-4-6-7;;/h7-9H,1-6H2,(H2,10,11,12)(H2,13,14,15);;/q;2*+1/p-2
DM3DSVJ	CS	C1CCCC(CC1)NC(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+]
DM3DSVJ	IK	PCSJAAWOSGCAFV-UHFFFAOYSA-L
DM3DSVJ	IU	disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate
DM3DSVJ	DE	Hypercalcaemia

DMKE6YT	ID	DMKE6YT
DMKE6YT	DN	Incobotulinum toxin A
DMKE6YT	HS	Approved
DMKE6YT	SN	IncobotulinumtoxinA; Xeomin; NT-201; Botulinum toxin type A extract (blepharospasm), Merz/BioteCon
DMKE6YT	CP	Merz
DMKE6YT	DE	Cervical cancer

DM32GSJ	ID	DM32GSJ
DM32GSJ	DN	Incruse ellipta
DM32GSJ	HS	Approved
DM32GSJ	SN	Umeclidinium bromide; 869113-09-7; Umeclidinium (bromide); GSK573719A; Incruse Ellipta; UNII-7AN603V4JV; 7AN603V4JV; GSK-573719; 1-[2-(Benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-quinuclidinium Bromide; 1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide; CHEMBL523299; Umeclidinium brom; Umeclidinium bromide [USAN:INN]; umeclidinii bromidum; 1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1); 1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2
DM32GSJ	CP	Glaxosmithkline
DM32GSJ	DT	Small molecular drug
DM32GSJ	PC	11519069
DM32GSJ	MW	508.5
DM32GSJ	FM	C29H34BrNO2
DM32GSJ	IC	InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
DM32GSJ	CS	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-]
DM32GSJ	IK	PEJHHXHHNGORMP-UHFFFAOYSA-M
DM32GSJ	IU	diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide
DM32GSJ	CA	CAS 869113-09-7
DM32GSJ	CB	CHEBI:79040
DM32GSJ	DE	Chronic obstructive pulmonary disease

DMQJHR7	ID	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	HS	Approved
DMQJHR7	SN	312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one;  QAB-149; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone
DMQJHR7	CP	Novartis
DMQJHR7	DT	Small molecular drug
DMQJHR7	PC	6918554
DMQJHR7	MW	392.5
DMQJHR7	FM	C24H28N2O3
DMQJHR7	IC	InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
DMQJHR7	CS	CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
DMQJHR7	IK	QZZUEBNBZAPZLX-QFIPXVFZSA-N
DMQJHR7	IU	5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
DMQJHR7	CA	CAS 312753-06-3
DMQJHR7	CB	CHEBI:68575
DMQJHR7	DE	Chronic obstructive pulmonary disease; Asthma

DMGN1PW	ID	DMGN1PW
DMGN1PW	DN	Indapamide
DMGN1PW	HS	Approved
DMGN1PW	SN	Arifon; Bajaten; Cormil; Damide; Fludex; Idapamide; Indaflex; Indamol; Indapamida; Indapamidum; Ipamix; Lozide; Lozol; Metindamide; Natrilix; Natrix; Noranat; Pressurai; Tandix; Tertensif; Veroxil; RHC 2555; SE 1520; USV 2555; Apo-Indapamide; Indapamida [INN-Spanish]; Indapamide (USP); Indapamidum [INN-Latin]; Lozol (TN); Natrilix (TN); Natrix (TN); Novo-Indapamide; Nu-Indapamide; S-1520; SE-1520; Indapamide (JAN/USP); Indapamide [USAN:INN:BAN:JAN]; N-[4-Chloro-3-sulfamoylbenzamido]-2-methylindoline; NLozol, Arifon, Fludex, Noranat, Veroxil, Tertensif, Indapamide; N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-(9CI); 1-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide; 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide; 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
DMGN1PW	CP	Servier Laboratories
DMGN1PW	TC	Antihypertensive Agents
DMGN1PW	DT	Small molecular drug
DMGN1PW	PC	3702
DMGN1PW	MW	365.8
DMGN1PW	FM	C16H16ClN3O3S
DMGN1PW	IC	InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
DMGN1PW	CS	CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N
DMGN1PW	IK	NDDAHWYSQHTHNT-UHFFFAOYSA-N
DMGN1PW	IU	4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
DMGN1PW	CA	CAS 26807-65-8
DMGN1PW	CB	CHEBI:5893
DMGN1PW	DE	Hypertension

DMUV8OR	ID	DMUV8OR
DMUV8OR	DN	Indecainide
DMUV8OR	HS	Approved
DMUV8OR	SN	Indecainida; Indecainidum; Ricainid; Ricainide; Indecainida [Spanish]; Indecainide [INN]; Indecainidum [Latin]; Decabid (TN); LY-135837; 9-(3-((1-methylethyl)amino)propyl)-9H-fluorene-9-carboxamide; 9-(3-(Isopropylamino)propyl))fluorene-9-carboxamide; 9-(3-(Isopropylamino)propyl)-9-fluorenylcarboxamid; 9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide
DMUV8OR	CP	Eli Lilly And Co
DMUV8OR	TC	Antidysrhythmic Agents
DMUV8OR	DT	Small molecular drug
DMUV8OR	PC	52195
DMUV8OR	MW	308.4
DMUV8OR	FM	C20H24N2O
DMUV8OR	IC	InChI=1S/C20H24N2O/c1-14(2)22-13-7-12-20(19(21)23)17-10-5-3-8-15(17)16-9-4-6-11-18(16)20/h3-6,8-11,14,22H,7,12-13H2,1-2H3,(H2,21,23)
DMUV8OR	CS	CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N
DMUV8OR	IK	UCEWGESNIULAGX-UHFFFAOYSA-N
DMUV8OR	IU	9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide
DMUV8OR	CA	CAS 74517-78-5
DMUV8OR	CB	CHEBI:135314
DMUV8OR	DE	Dysrhythmias

DMWO3N6	ID	DMWO3N6
DMWO3N6	DN	Indeloxazine
DMWO3N6	HS	Approved
DMWO3N6	SN	Elen; Noin; Indeloxazine hydrochloride; YM-08054
DMWO3N6	CP	Yamanouchi Pharmaceutical Co Ltd
DMWO3N6	DT	Small molecular drug
DMWO3N6	PC	3704
DMWO3N6	MW	231.29
DMWO3N6	FM	C14H17NO2
DMWO3N6	IC	InChI=1S/C14H17NO2/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12/h1-4,6,12,15H,5,7-10H2
DMWO3N6	CS	C1COC(CN1)COC2=CC=CC3=C2CC=C3
DMWO3N6	IK	MADRVGBADLFHMO-UHFFFAOYSA-N
DMWO3N6	IU	2-(3H-inden-4-yloxymethyl)morpholine
DMWO3N6	CA	CAS 60929-23-9
DMWO3N6	CB	CHEBI:5894
DMWO3N6	DE	Dementia

DM0T3YH	ID	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	HS	Approved
DM0T3YH	SN	Crixivan; IDV; Indinavir [USAN]; L 735524; Crixivan (TM); Crixivan (TN); L-735 524; L-735524; MK-639; Propolis+Indinavir; RS-253; L-735,524; Indinavir, Sulfate (1:1); Indinavir (*1:1 Sulfate salt*); N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
DM0T3YH	CP	Merck & Co
DM0T3YH	TC	Anti-HIV Agents
DM0T3YH	DT	Small molecular drug
DM0T3YH	PC	5362440
DM0T3YH	MW	613.8
DM0T3YH	FM	C36H47N5O4
DM0T3YH	IC	InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1
DM0T3YH	CS	CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5
DM0T3YH	IK	CBVCZFGXHXORBI-PXQQMZJSSA-N
DM0T3YH	IU	(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
DM0T3YH	CA	CAS 150378-17-9
DM0T3YH	CB	CHEBI:44032
DM0T3YH	DE	Human immunodeficiency virus infection

DMOPGHQ	ID	DMOPGHQ
DMOPGHQ	DN	Indiplon
DMOPGHQ	HS	Approved
DMOPGHQ	SN	NBI 34060; NBI-34060; Indiplon (USAN/INN); N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide
DMOPGHQ	CP	Neurocrine Biosciences
DMOPGHQ	DT	Small molecular drug
DMOPGHQ	PC	6450813
DMOPGHQ	MW	376.4
DMOPGHQ	FM	C20H16N4O2S
DMOPGHQ	IC	InChI=1S/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3
DMOPGHQ	CS	CC(=O)N(C)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4
DMOPGHQ	IK	CBIAWPMZSFFRGN-UHFFFAOYSA-N
DMOPGHQ	IU	N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide
DMOPGHQ	CA	CAS 325715-02-4
DMOPGHQ	DE	Insomnia; Fibromyalgia

DM2NQUY	ID	DM2NQUY
DM2NQUY	DN	Indocyanine green
DM2NQUY	HS	Approved
DM2NQUY	SN	indocyanine green; Cardiogreen; 3599-32-4; AC1L2DMU; GTPL4844; KS-00000YFZ; MOLI001001; F9995-0163; sodium 4-(2-((1E,3E,5E,7E)-7-(1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-2(3H)-ylidene)hepta-1,3,5-trienyl)-1,1-dimethyl-1H-benzo[e]indolium-3-yl)butane-1-sulfonate; sodium 4-[2-[(1E,3E,5E,7Z)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]butane-1-sulfonate; sodium 4-[2-[7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4
DM2NQUY	DT	Small molecular drug
DM2NQUY	PC	11967809
DM2NQUY	MW	775
DM2NQUY	FM	C43H47N2NaO6S2
DM2NQUY	IC	InChI=1S/C43H48N2O6S2.Na/c1-42(2)38(44(28-14-16-30-52(46,47)48)36-26-24-32-18-10-12-20-34(32)40(36)42)22-8-6-5-7-9-23-39-43(3,4)41-35-21-13-11-19-33(35)25-27-37(41)45(39)29-15-17-31-53(49,50)51;/h5-13,18-27H,14-17,28-31H2,1-4H3,(H-,46,47,48,49,50,51);/q;+1/p-1
DM2NQUY	CS	CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)[O-])/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCCCS(=O)(=O)[O-])C=CC6=CC=CC=C65)(C)C)C.[Na+]
DM2NQUY	IK	MOFVSTNWEDAEEK-UHFFFAOYSA-M
DM2NQUY	IU	sodium;4-[(2E)-2-[(2E,4E,6E)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonate
DM2NQUY	CA	CAS 3599-32-4
DM2NQUY	DE	Gastrointestinal disease

DMSC4A7	ID	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	HS	Approved
DMSC4A7	SN	Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin
DMSC4A7	CP	Recordati Rare Diseases Inc
DMSC4A7	TC	Antiinflammatory Agents
DMSC4A7	DT	Small molecular drug
DMSC4A7	PC	3715
DMSC4A7	MW	357.8
DMSC4A7	FM	C19H16ClNO4
DMSC4A7	IC	InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
DMSC4A7	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O
DMSC4A7	IK	CGIGDMFJXJATDK-UHFFFAOYSA-N
DMSC4A7	IU	2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
DMSC4A7	CA	CAS 53-86-1
DMSC4A7	CB	CHEBI:49662
DMSC4A7	DE	Rheumatoid arthritis

DMI0RHA	ID	DMI0RHA
DMI0RHA	DN	Inebilizumab
DMI0RHA	HS	Approved
DMI0RHA	CP	MedImmune Gaithersburg, MD
DMI0RHA	DE	Neuromyelitis optica spectrum disorder

DMH7OIA	ID	DMH7OIA
DMH7OIA	DN	Infliximab
DMH7OIA	HS	Approved
DMH7OIA	SN	Remicade (TN)
DMH7OIA	CP	Samsung Bioepsis
DMH7OIA	TC	Immunosuppressive Agents
DMH7OIA	DT	Antibody
DMH7OIA	DE	Plaque psoriasis; Rheumatoid arthritis; Asthma

DMK1CZJ	ID	DMK1CZJ
DMK1CZJ	DN	Ingenol mebutate
DMK1CZJ	HS	Approved
DMK1CZJ	SN	Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A
DMK1CZJ	CP	LEO Pharma
DMK1CZJ	DT	Small molecular drug
DMK1CZJ	PC	6918670
DMK1CZJ	MW	430.5
DMK1CZJ	FM	C25H34O6
DMK1CZJ	IC	InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16+,17-,18+,19-,21+,24+,25+/m1/s1
DMK1CZJ	CS	C/C=C(/C)\\C(=O)O[C@H]1C(=C[C@@]23[C@@]1([C@@H](C(=C[C@H](C2=O)[C@H]4[C@H](C4(C)C)C[C@H]3C)CO)O)O)C
DMK1CZJ	IK	VDJHFHXMUKFKET-WDUFCVPESA-N
DMK1CZJ	IU	[(1S,4S,5S,6R,9S,10R,12R,14R)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyl-15-oxo-4-tetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dienyl] (Z)-2-methylbut-2-enoate
DMK1CZJ	CA	CAS 75567-37-2
DMK1CZJ	CB	CHEBI:66913
DMK1CZJ	DE	Actinic keratosis; Melanoma

DMJ93CT	ID	DMJ93CT
DMJ93CT	DN	Inotersen
DMJ93CT	HS	Approved
DMJ93CT	SN	UNII-0IEO0F56LV; 0IEO0F56LV; Inotersen [USAN]; ISIS 420915
DMJ93CT	CP	Ionis Pharmaceuticals
DMJ93CT	PC	121492004
DMJ93CT	MW	7183
DMJ93CT	FM	C230H318N69O121P19S19
DMJ93CT	IC	InChI=1S/C230H318N69O121P19S19/c1-98-53-280(219(312)262-178(98)231)140-43-110(121(382-140)66-364-425(328,444)406-114-47-144(292-90-254-150-183(236)244-85-249-188(150)292)387-126(114)71-368-423(326,442)404-112-45-142(282-59-104(7)197(303)274-225(282)318)383-122(112)67-363-421(324,440)403-111-44-141(281-58-103(6)196(302)273-224(281)317)385-124(111)69-366-427(330,446)410-119-52-149(297-95-260-156-194(297)268-217(242)271-204(156)310)391-130(119)75-372-431(334,450)419-167-139(401-215(177(167)362-42-32-352-22)299-97-261-157-195(299)269-218(243)272-205(157)311)84-381-438(341,457)418-165-136(398-213(175(165)360-40-30-350-20)291-64-109(12)202(308)279-230(291)323)82-379-437(340,456)417-163-135(397-211(173(163)358-38-28-348-18)289-62-107(10)200(306)277-228(289)321)81-378-435(338,454)414-161-132(394-209(171(161)356-36-26-346-16)286-56-101(4)181(234)265-222(286)315)78-375-433(336,452)412-159-120(65-300)392-207(169(159)354-34-24-344-14)288-61-106(9)199(305)276-227(288)320)402-422(325,441)367-70-125-115(48-145(386-125)293-91-255-151-184(237)245-86-250-189(151)293)407-426(329,445)365-68-123-113(46-143(384-123)283-60-105(8)198(304)275-226(283)319)405-424(327,443)371-74-129-118(51-148(390-129)296-94-259-155-193(296)267-216(241)270-203(155)309)409-429(332,448)370-72-127-116(49-146(388-127)294-92-256-152-185(238)246-87-251-190(152)294)408-428(331,447)369-73-128-117(50-147(389-128)295-93-257-153-186(239)247-88-252-191(153)295)411-430(333,449)374-77-138-166(176(361-41-31-351-21)214(400-138)298-96-258-154-187(240)248-89-253-192(154)298)420-439(342,458)380-83-137-164(174(359-39-29-349-19)212(399-137)290-63-108(11)201(307)278-229(290)322)416-436(339,455)377-80-134-162(172(357-37-27-347-17)210(396-134)287-57-102(5)182(235)266-223(287)316)415-434(337,453)376-79-133-160(170(355-35-25-345-15)208(395-133)285-55-100(3)180(233)264-221(285)314)413-432(335,451)373-76-131-158(301)168(353-33-23-343-13)206(393-131)284-54-99(2)179(232)263-220(284)313/h53-64,85-97,110-149,158-177,206-215,300-301H,23-52,65-84H2,1-22H3,(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H,342,458)(H2,231,262,312)(H2,232,263,313)(H2,233,264,314)(H2,234,265,315)(H2,235,266,316)(H2,236,244,249)(H2,237,245,250)(H2,238,246,251)(H2,239,247,252)(H2,240,248,253)(H,273,302,317)(H,274,303,318)(H,275,304,319)(H,276,305,320)(H,277,306,321)(H,278,307,322)(H,279,308,323)(H3,241,267,270,309)(H3,242,268,271,310)(H3,243,269,272,311)/t110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,206+,207+,208+,209+,210+,211+,212+,213+,214+,215+,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?/m0/s1
DMJ93CT	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OCCOC)N6C=NC7=C6N=C(NC7=O)N)COP(=S)(O)O[C@@H]8[C@H](O[C@H]([C@@H]8OCCOC)N9C=C(C(=O)NC9=O)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)(O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)CO)S)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O
DMJ93CT	IK	KLEGMTRDCCDFJK-XDQSQZFTSA-N
DMJ93CT	IU	1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[hydroxy-[(2R,3R,4R,5R)-2-(hydroxymethyl)-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMJ93CT	CA	CAS 1492984-65-2
DMJ93CT	DE	Hereditary amyloidosis

DMAC130	ID	DMAC130
DMAC130	DN	Inotuzumab ozogamicin
DMAC130	HS	Approved
DMAC130	CP	Pfizer
DMAC130	DT	Antibody
DMAC130	DE	Acute lymphocytic leukaemia; Acute lymphoblastic leukaemia

DMB7CE0	ID	DMB7CE0
DMB7CE0	DN	Insulin
DMB7CE0	HS	Approved
DMB7CE0	SN	BrioDurance; Insulin (agglomerated vesicle technology, diabetes), Cense Biosciences; Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes); Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes), Cense Biosciences
DMB7CE0	CP	Cense Biosciences Inc
DMB7CE0	SQ	A chain: GIVEQCCTSICSLYQLENYCN</sequence>    <sequence format="FASTA">&gt;B chainFVNQHLCGSHLVEALYLVCGERGFFYTPKT
DMB7CE0	DE	Diabetic complication

DMPL395	ID	DMPL395
DMPL395	DN	Insulin degludec
DMPL395	HS	Approved
DMPL395	SN	Tresiba (TN)
DMPL395	CP	Novo Nordisk
DMPL395	SQ	A Chain: FVNQHLCGSHLVEALYLVCGERGFFYTPK</sequence>    <sequence format="FASTA">&gt;B ChainGIVEQCCTSICSLYQLENYCN
DMPL395	PC	118984462
DMPL395	MW	6104
DMPL395	FM	C274H411N65O81S6
DMPL395	IC	InChI=1S/C274H411N65O81S6/c1-28-146(23)223(331-210(357)119-275)268(412)335-222(145(21)22)264(408)305-172(89-97-218(369)370)234(378)300-169(84-92-204(279)351)238(382)326-198-131-424-425-132-199-259(403)323-193(126-341)256(400)312-177(103-138(7)8)241(385)313-183(110-154-66-74-160(345)75-67-154)244(388)301-167(82-90-202(277)349)235(379)308-176(102-137(5)6)239(383)303-171(88-96-217(367)368)237(381)320-189(116-205(280)352)251(395)316-185(112-156-70-78-162(347)79-71-156)247(391)327-197(258(402)322-191(273(419)420)118-207(282)354)130-423-422-129-196(231(375)290-122-211(358)295-166(86-94-215(363)364)233(377)299-165(62-53-99-288-274(283)284)229(373)289-123-212(359)297-181(108-152-57-45-41-46-58-152)243(387)315-182(109-153-59-47-42-48-60-153)246(390)317-186(113-157-72-80-163(348)81-73-157)254(398)338-226(150(27)344)270(414)339-100-54-63-201(339)262(406)306-173(271(415)416)61-51-52-98-287-208(355)93-85-174(272(417)418)296-209(356)64-49-38-36-34-32-30-31-33-35-37-39-50-65-214(361)362)329-266(410)221(144(19)20)334-252(396)179(105-140(11)12)310-245(389)184(111-155-68-76-161(346)77-69-155)314-240(384)175(101-136(3)4)307-227(371)148(25)294-232(376)170(87-95-216(365)366)304-263(407)220(143(17)18)333-253(397)180(106-141(13)14)311-249(393)188(115-159-121-286-135-293-159)319-255(399)192(125-340)298-213(360)124-291-230(374)195(128-421-426-133-200(328-260(198)404)261(405)337-225(149(26)343)269(413)324-194(127-342)257(401)336-224(147(24)29-2)267(411)330-199)325-242(386)178(104-139(9)10)309-248(392)187(114-158-120-285-134-292-158)318-236(380)168(83-91-203(278)350)302-250(394)190(117-206(281)353)321-265(409)219(142(15)16)332-228(372)164(276)107-151-55-43-40-44-56-151/h40-48,55-60,66-81,120-121,134-150,164-201,219-226,340-348H,28-39,49-54,61-65,82-119,122-133,275-276H2,1-27H3,(H2,277,349)(H2,278,350)(H2,279,351)(H2,280,352)(H2,281,353)(H2,282,354)(H,285,292)(H,286,293)(H,287,355)(H,289,373)(H,290,375)(H,291,374)(H,294,376)(H,295,358)(H,296,356)(H,297,359)(H,298,360)(H,299,377)(H,300,378)(H,301,388)(H,302,394)(H,303,383)(H,304,407)(H,305,408)(H,306,406)(H,307,371)(H,308,379)(H,309,392)(H,310,389)(H,311,393)(H,312,400)(H,313,385)(H,314,384)(H,315,387)(H,316,395)(H,317,390)(H,318,380)(H,319,399)(H,320,381)(H,321,409)(H,322,402)(H,323,403)(H,324,413)(H,325,386)(H,326,382)(H,327,391)(H,328,404)(H,329,410)(H,330,411)(H,331,357)(H,332,372)(H,333,397)(H,334,396)(H,335,412)(H,336,401)(H,337,405)(H,338,398)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,415,416)(H,417,418)(H,419,420)(H4,283,284,288)/t146-,147-,148-,149+,150+,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,219-,220-,221-,222-,223-,224-,225-,226-/m0/s1
DMPL395	CS	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMPL395	IK	FYZPCMFQCNBYCY-WIWKJPBBSA-N
DMPL395	IU	16-[[(1S)-4-[[(5S)-5-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carboxypentyl]amino]-1-carboxy-4-oxobutyl]amino]-16-oxohexadecanoic acid
DMPL395	CA	CAS 844439-96-9
DMPL395	DE	Type-1/2 diabetes

DM79NZ5	ID	DM79NZ5
DM79NZ5	DN	Insulin determir
DM79NZ5	HS	Approved
DM79NZ5	SN	Levemir (TN)
DM79NZ5	DE	Diabetic complication

DM5XHVR	ID	DM5XHVR
DM5XHVR	DN	Insulin Lyspro recombinant
DM5XHVR	HS	Approved
DM5XHVR	TC	Hypoglycemic Agents
DM5XHVR	DE	Diabetic complication

DMYVP5G	ID	DMYVP5G
DMYVP5G	DN	Insulin recombinant
DMYVP5G	HS	Approved
DMYVP5G	SN	9004-10-8; Exubera; Insulin recombinant; Endopancrine; Humilin; Dermulin; Decurvon; Musulin; Iszilin; Insulyl; Insular; Iletin; insulin-human; Dal-insulinum; Intesulin B; Insulin, dalanated; Insulina dalanatada; AERx; Insulinum dalanatum; insulin (recombinant); Imusay-131; INSULIN INJECTION; Insulini injectio neutralis; Insulina iniettabile neutra; Injectable insulini neutrale; Inyectable neutro de insulina; CHEBI:5931; CCRIS 5464; Insulinum dalanatum [INN-Latin]; HSDB 3102; Insulin, dalanated [USAN:INN]; AERx [Insulin management system]
DMYVP5G	TC	Hypoglycemic Agents
DMYVP5G	DT	Small molecular drug
DMYVP5G	PC	70678557
DMYVP5G	MW	5794
DMYVP5G	FM	C256H381N65O77S6
DMYVP5G	IC	InChI=1S/C256H381N65O77S6/c1-29-130(23)202(311-190(337)103-258)250(391)315-200(128(19)20)246(387)286-158(75-82-197(347)348)216(357)281-154(70-77-186(261)333)220(361)306-181-115-402-403-116-182-241(382)303-176(110-323)238(379)293-161(88-122(7)8)224(365)294-167(95-139-53-61-145(328)62-54-139)227(368)282-153(69-76-185(260)332)217(358)289-160(87-121(5)6)222(363)283-157(74-81-196(345)346)219(360)301-173(101-188(263)335)233(374)297-169(97-141-57-65-147(330)66-58-141)230(371)307-180(240(381)302-174(254(395)396)102-189(264)336)114-401-400-113-179(213(354)272-106-191(338)277-152(72-79-194(341)342)215(356)280-150(51-42-84-270-256(266)267)211(352)271-107-192(339)278-165(93-137-46-36-32-37-47-137)226(367)296-166(94-138-48-38-33-39-49-138)229(370)298-170(98-142-59-67-148(331)68-60-142)236(377)318-205(134(27)326)253(394)321-85-43-52-184(321)244(385)284-151(50-40-41-83-257)221(362)319-206(135(28)327)255(397)398)309-247(388)199(127(17)18)314-234(375)163(90-124(11)12)291-228(369)168(96-140-55-63-146(329)64-56-140)295-223(364)159(86-120(3)4)288-209(350)132(25)276-214(355)156(73-80-195(343)344)285-245(386)198(126(15)16)313-235(376)164(91-125(13)14)292-232(373)172(100-144-105-269-119-275-144)300-237(378)175(109-322)279-193(340)108-273-212(353)178(112-399-404-117-183(308-242(181)383)243(384)317-204(133(26)325)251(392)304-177(111-324)239(380)316-203(131(24)30-2)249(390)310-182)305-225(366)162(89-123(9)10)290-231(372)171(99-143-104-268-118-274-143)299-218(359)155(71-78-187(262)334)287-252(393)207(208(265)349)320-248(389)201(129(21)22)312-210(351)149(259)92-136-44-34-31-35-45-136/h31-39,44-49,53-68,104-105,118-135,149-184,198-207,322-331H,29-30,40-43,50-52,69-103,106-117,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,349)(H,268,274)(H,269,275)(H,271,352)(H,272,354)(H,273,353)(H,276,355)(H,277,338)(H,278,339)(H,279,340)(H,280,356)(H,281,357)(H,282,368)(H,283,363)(H,284,385)(H,285,386)(H,286,387)(H,287,393)(H,288,350)(H,289,358)(H,290,372)(H,291,369)(H,292,373)(H,293,379)(H,294,365)(H,295,364)(H,296,367)(H,297,374)(H,298,370)(H,299,359)(H,300,378)(H,301,360)(H,302,381)(H,303,382)(H,304,392)(H,305,366)(H,306,361)(H,307,371)(H,308,383)(H,309,388)(H,310,390)(H,311,337)(H,312,351)(H,313,376)(H,314,375)(H,315,391)(H,316,380)(H,317,384)(H,318,377)(H,319,362)(H,320,389)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,395,396)(H,397,398)(H4,266,267,270)/t130-,131-,132+,133+,134+,135+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182-,183+,184+,198+,199+,200+,201+,202+,203+,204+,205+,206+,207+/m1/s1
DMYVP5G	CS	CC[C@@H](C)[C@H]1C(=O)N[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@H](C)CC)NC(=O)CN
DMYVP5G	IK	YAJCHEVQCOHZDC-QMMNLEPNSA-N
DMYVP5G	IU	(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-3-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-oxopropanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2R)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1S)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S,2S)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMYVP5G	CA	CAS 9004-10-8
DMYVP5G	DE	Diabetic complication

DMW8KI7	ID	DMW8KI7
DMW8KI7	DN	Insulin Susp Isophane Recombinant Human
DMW8KI7	HS	Approved
DMW8KI7	SN	Nph Insulin; Nph Iletin I (Beef-pork); Nph Iletin Ii; Insulin Insulatard Nph Nordisk; Nph Iletin Ii (Pork); Nph Purified Pork Isophane Insulin; Humulin N; Novolin N; Insulatard Nph Human; Insulin Susp Isophane Beef; Insulin Susp Isophane Beef/Pork; Insulin Susp Isophane Purified Beef; Insulin Susp Isophane Purified Pork; Insulin Susp Isophane Semisynthetic Purified Human
DMW8KI7	CP	Eli Lilly And Co
DMW8KI7	DE	Diabetic complication

DM0NATE	ID	DM0NATE
DM0NATE	DN	Insulin Susp Protamine Zinc Beef/Pork
DM0NATE	HS	Approved
DM0NATE	SN	Protamine Zinc & Iletin I (Beef-pork); Protamine Zinc And Iletin Ii; Protamine Zinc Insulin; Protamine Zinc And Iletin Ii (Pork); Insulin Susp Protamine Zinc Purified Beef; Insulin Susp Protamine Zinc Purified Pork
DM0NATE	CP	Eli Lilly And Co
DM0NATE	DE	Diabetic complication

DM6MO9X	ID	DM6MO9X
DM6MO9X	DN	Insulin Zinc Susp Recombinant Human
DM6MO9X	HS	Approved
DM6MO9X	SN	Humulin L; Humulin U; Lentard; Lente; Lente Iletin Ii; Lente Iletin Ii (Pork); Lente Insulin; Novolin L; Semilente; Semilente Insulin; Ultralente; Ultralente Insulin; Insulin Zinc Susp Beef; Insulin Zinc Susp Extended Beef; Insulin Zinc Susp Extended Purified Beef; Insulin Zinc Susp Extended Recombinant Human; Insulin Zinc Susp Prompt Beef; Insulin Zinc Susp Prompt Purified Pork; Insulin Zinc Susp Purified Beef; Insulin Zinc Susp Purified Beef/Pork; Insulin Zinc Susp Purified Pork; Insulin Zinc Susp Semisynthetic Purified Human
DM6MO9X	CP	Eli Lilly And Co
DM6MO9X	DE	Diabetic complication

DMO95XI	ID	DMO95XI
DMO95XI	DN	Insulin, porcine
DMO95XI	HS	Approved
DMO95XI	SN	Velosulin; Hog insulin; Insulin [pig]; Insulin porcine; Neutral insulin; Pig insulin; Porcine insulin; Swine insulin; A neutral, buffered solution of pork insulin; Insulin (Alopex lagopus); Insulin (Canis familiaris); Insulin (Physeter catodon); Insulin (dog); Insulin (ox); Insulin (pig); Insulin (porcine); Insulin (sperm whale); Insulin (swine); Insulin [USAN:JAN]; Insulin, neutral; Insulin,pig; Insulin (Ox), 8A-L-threonine-10A-L-isoleucine-(9CI); 8A-L-Threonine-10A-L-isoleucineinsulin (ox)
DMO95XI	TC	Hypoglycemic Agents
DMO95XI	DT	Small molecular drug
DMO95XI	PC	16131098
DMO95XI	MW	5778
DMO95XI	FM	C256H381N65O76S6
DMO95XI	IC	InChI=1S/C256H381N65O76S6/c1-29-131(23)205(313-193(337)104-258)251(391)317-204(130(21)22)247(387)288-159(75-82-200(347)348)217(357)282-156(71-78-189(262)333)221(361)308-183-116-401-402-117-184-242(382)305-178(111-323)239(379)294-162(88-123(7)8)224(364)295-168(95-140-53-61-146(327)62-54-140)227(367)283-154(69-76-187(260)331)218(358)290-161(87-122(5)6)222(362)285-158(74-81-199(345)346)220(360)302-174(101-190(263)334)234(374)298-170(97-142-57-65-148(329)66-58-142)230(370)309-182(241(381)304-176(255(396)397)103-192(265)336)115-400-399-114-181(213(353)272-107-194(338)278-153(72-79-197(341)342)216(356)281-151(51-42-84-270-256(266)267)211(351)271-108-195(339)279-166(93-138-46-36-32-37-47-138)226(366)297-167(94-139-48-38-33-39-49-139)229(369)299-171(98-143-59-67-149(330)68-60-143)237(377)320-208(136(28)326)253(393)321-85-43-52-186(321)245(385)286-152(50-40-41-83-257)214(354)277-134(26)254(394)395)311-249(389)203(129(19)20)316-235(375)164(90-125(11)12)292-228(368)169(96-141-55-63-147(328)64-56-141)296-223(363)160(86-121(3)4)289-209(349)133(25)276-215(355)157(73-80-198(343)344)287-246(386)202(128(17)18)315-236(376)165(91-126(13)14)293-232(372)173(100-145-106-269-120-275-145)301-238(378)177(110-322)280-196(340)109-273-212(352)180(113-398-403-118-185(310-243(183)383)244(384)319-207(135(27)325)252(392)306-179(112-324)240(380)318-206(132(24)30-2)250(390)312-184)307-225(365)163(89-124(9)10)291-231(371)172(99-144-105-268-119-274-144)300-219(359)155(70-77-188(261)332)284-233(373)175(102-191(264)335)303-248(388)201(127(15)16)314-210(350)150(259)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-208,322-330H,29-30,40-43,50-52,69-104,107-118,257-259H2,1-28H3,(H2,260,331)(H2,261,332)(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H,268,274)(H,269,275)(H,271,351)(H,272,353)(H,273,352)(H,276,355)(H,277,354)(H,278,338)(H,279,339)(H,280,340)(H,281,356)(H,282,357)(H,283,367)(H,284,373)(H,285,362)(H,286,385)(H,287,386)(H,288,387)(H,289,349)(H,290,358)(H,291,371)(H,292,368)(H,293,372)(H,294,379)(H,295,364)(H,296,363)(H,297,366)(H,298,374)(H,299,369)(H,300,359)(H,301,378)(H,302,360)(H,303,388)(H,304,381)(H,305,382)(H,306,392)(H,307,365)(H,308,361)(H,309,370)(H,310,383)(H,311,389)(H,312,390)(H,313,337)(H,314,350)(H,315,376)(H,316,375)(H,317,391)(H,318,380)(H,319,384)(H,320,377)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,394,395)(H,396,397)(H4,266,267,270)/t131-,132-,133-,134-,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1
DMO95XI	CS	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMO95XI	IK	NOESYZHRGYRDHS-ZYCCASTOSA-N
DMO95XI	IU	(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S)-1-carboxyethyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMO95XI	CA	CAS 12584-58-6
DMO95XI	DE	Diabetic complication

DMX7V28	ID	DMX7V28
DMX7V28	DN	Insulin-aspart
DMX7V28	HS	Approved
DMX7V28	SN	Aspart; NovoLog; NovoRapid; Aspart insulin; Insulin aspart; Insulin aspart [USAN]; Insulin X14; NovoMix 30; NovoRapid 30 Mix; INA-X 14; Novolog mix 70/30; AspB28-insulin (human); B28-Asp-insulin; (AspB28)-human insulin; 28(sup B)-L-Aspartic acid-insulin (human)
DMX7V28	TC	Hypoglycemic Agents
DMX7V28	DT	Small molecular drug
DMX7V28	SQ	A chain: GIVEQCCTSICSLYQLENYCN</sequence>    <sequence format="FASTA">&gt;B chainFVNQHLCGSHLVEALYLVCGERGFFYTDKT
DMX7V28	PC	118984445
DMX7V28	MW	5826
DMX7V28	FM	C256H381N65O79S6
DMX7V28	IC	InChI=1S/C256H381N65O79S6/c1-29-129(23)204(313-191(338)102-258)251(394)317-203(128(21)22)247(390)287-157(73-80-198(348)349)216(359)282-154(69-76-187(262)334)220(363)308-182-114-404-405-115-183-243(386)305-177(109-323)240(383)293-160(85-121(7)8)224(367)294-166(92-138-51-59-144(328)60-52-138)227(370)283-152(67-74-185(260)332)217(360)289-159(84-120(5)6)222(365)285-156(72-79-197(346)347)219(362)301-172(98-188(263)335)234(377)297-168(94-140-55-63-146(330)64-56-140)230(373)309-181(242(385)304-175(254(397)398)100-190(265)337)113-403-402-112-180(213(356)272-105-192(339)277-151(70-77-195(342)343)215(358)280-149(50-42-82-270-256(266)267)211(354)271-106-193(340)278-164(90-136-45-36-32-37-46-136)226(369)296-165(91-137-47-38-33-39-48-137)229(372)298-169(95-141-57-65-147(331)66-58-141)238(381)319-206(132(26)325)252(395)303-174(101-199(350)351)235(378)281-150(49-40-41-81-257)221(364)321-208(134(28)327)255(399)400)311-249(392)202(127(19)20)316-236(379)162(87-123(11)12)291-228(371)167(93-139-53-61-145(329)62-54-139)295-223(366)158(83-119(3)4)288-209(352)131(25)276-214(357)155(71-78-196(344)345)286-246(389)201(126(17)18)315-237(380)163(88-124(13)14)292-232(375)171(97-143-104-269-118-275-143)300-239(382)176(108-322)279-194(341)107-273-212(355)179(111-401-406-116-184(310-244(182)387)245(388)320-207(133(27)326)253(396)306-178(110-324)241(384)318-205(130(24)30-2)250(393)312-183)307-225(368)161(86-122(9)10)290-231(374)170(96-142-103-268-117-274-142)299-218(361)153(68-75-186(261)333)284-233(376)173(99-189(264)336)302-248(391)200(125(15)16)314-210(353)148(259)89-135-43-34-31-35-44-135/h31-39,43-48,51-66,103-104,117-134,148-184,200-208,322-331H,29-30,40-42,49-50,67-102,105-116,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H,268,274)(H,269,275)(H,271,354)(H,272,356)(H,273,355)(H,276,357)(H,277,339)(H,278,340)(H,279,341)(H,280,358)(H,281,378)(H,282,359)(H,283,370)(H,284,376)(H,285,365)(H,286,389)(H,287,390)(H,288,352)(H,289,360)(H,290,374)(H,291,371)(H,292,375)(H,293,383)(H,294,367)(H,295,366)(H,296,369)(H,297,377)(H,298,372)(H,299,361)(H,300,382)(H,301,362)(H,302,391)(H,303,395)(H,304,385)(H,305,386)(H,306,396)(H,307,368)(H,308,363)(H,309,373)(H,310,387)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,380)(H,316,379)(H,317,394)(H,318,384)(H,319,381)(H,320,388)(H,321,364)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,266,267,270)/t129-,130-,131-,132+,133+,134+,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,200-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1
DMX7V28	CS	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC8=CC=C(C=C8)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC9=CNC=N9)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMX7V28	IK	WEDIKSVWBUKTRA-WTKGVUNUSA-N
DMX7V28	IU	(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMX7V28	CA	CAS 116094-23-6
DMX7V28	DE	Diabetic complication

DMOA4VW	ID	DMOA4VW
DMOA4VW	DN	Insulin-detemir
DMOA4VW	HS	Approved
DMOA4VW	SN	Insulin detemir; UNII-4FT78T86XV; 4FT78T86XV; NN-304; Levemir; Levemir Penfill; Levemir Insulin; Levemir Innolet; Levemir Flexpen; 169148-63-4; Insulin detemir [USAN:INN:BAN]; NN304; NN 304; CHEMBL2104391; INSULIN DETEMIR RECOMBINANT; 29B-(N6-Myristoyl-L-lysine)-30B-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-Myristoyl-L-lysine)-30(sup B)-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-(1-Oxotetradecyl)-L-lysine)-(1(sup A)-21(sup A)),(1(sup B)-29(sup B))-insulin (human); 270588-25-5
DMOA4VW	TC	Hypoglycemic Agents
DMOA4VW	DT	Small molecular drug
DMOA4VW	SQ	GIVEQCCTSICSLYQLENYCNFVNQHLCGSHLVEALYLVCGERGFFYTPK
DMOA4VW	PC	16137271
DMOA4VW	MW	5917
DMOA4VW	FM	C267H402N64O76S6
DMOA4VW	IC	InChI=1S/C267H402N64O76S6/c1-29-32-33-34-35-36-37-38-39-40-50-64-204(347)280-95-52-51-61-170(265(404)405)298-256(395)197-63-54-97-331(197)264(403)220(147(28)336)330-248(387)182(110-154-71-79-160(340)80-72-154)309-240(379)178(106-150-59-48-43-49-60-150)307-237(376)177(105-149-57-46-42-47-58-149)289-207(350)120-282-223(362)162(62-53-96-281-267(276)277)291-227(366)163(84-91-209(352)353)288-206(349)119-283-225(364)192-126-409-410-127-193(252(391)314-187(266(406)407)115-203(275)346)319-241(380)181(109-153-69-77-159(339)78-70-153)308-245(384)185(113-201(273)344)312-231(370)168(86-93-211(356)357)295-233(372)172(99-134(6)7)300-229(368)164(81-88-198(270)341)293-238(377)179(107-151-65-73-157(337)74-66-151)305-235(374)173(100-135(8)9)304-250(389)189(123-333)315-253(392)195-129-412-411-128-194(318-232(371)166(83-90-200(272)343)292-228(367)169(87-94-212(358)359)297-258(397)216(142(22)23)327-262(401)217(143(24)30-2)323-205(348)116-268)254(393)320-196(255(394)329-219(146(27)335)263(402)316-190(124-334)251(390)328-218(144(25)31-3)261(400)322-195)130-413-408-125-191(317-236(375)174(101-136(10)11)301-242(381)183(111-155-117-278-131-285-155)310-230(369)165(82-89-199(271)342)294-244(383)186(114-202(274)345)313-259(398)213(139(16)17)324-222(361)161(269)104-148-55-44-41-45-56-148)224(363)284-121-208(351)290-188(122-332)249(388)311-184(112-156-118-279-132-286-156)243(382)303-176(103-138(14)15)247(386)325-214(140(18)19)257(396)296-167(85-92-210(354)355)226(365)287-145(26)221(360)299-171(98-133(4)5)234(373)306-180(108-152-67-75-158(338)76-68-152)239(378)302-175(102-137(12)13)246(385)326-215(141(20)21)260(399)321-192/h41-49,55-60,65-80,117-118,131-147,161-197,213-220,332-340H,29-40,50-54,61-64,81-116,119-130,268-269H2,1-28H3,(H2,270,341)(H2,271,342)(H2,272,343)(H2,273,344)(H2,274,345)(H2,275,346)(H,278,285)(H,279,286)(H,280,347)(H,282,362)(H,283,364)(H,284,363)(H,287,365)(H,288,349)(H,289,350)(H,290,351)(H,291,366)(H,292,367)(H,293,377)(H,294,383)(H,295,372)(H,296,396)(H,297,397)(H,298,395)(H,299,360)(H,300,368)(H,301,381)(H,302,378)(H,303,382)(H,304,389)(H,305,374)(H,306,373)(H,307,376)(H,308,384)(H,309,379)(H,310,369)(H,311,388)(H,312,370)(H,313,398)(H,314,391)(H,315,392)(H,316,402)(H,317,375)(H,318,371)(H,319,380)(H,320,393)(H,321,399)(H,322,400)(H,323,348)(H,324,361)(H,325,386)(H,326,385)(H,327,401)(H,328,390)(H,329,394)(H,330,387)(H,352,353)(H,354,355)(H,356,357)(H,358,359)(H,404,405)(H,406,407)(H4,276,277,281)/t143-,144-,145-,146+,147+,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,213-,214-,215-,216-,217-,218-,219-,220-/m0/s1
DMOA4VW	CS	CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]5CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)C(C)C)CC(C)C)CC7=CC=C(C=C7)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC8=CNC=N8)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC9=CNC=N9)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N6)[C@@H](C)CC)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN)CO)CC(C)C)CC1=CC=C(C=C1)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O
DMOA4VW	IK	UGOZVNFCFYTPAZ-IOXYNQHNSA-N
DMOA4VW	IU	(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-6-(tetradecanoylamino)hexanoic acid
DMOA4VW	CA	CAS 169148-63-4
DMOA4VW	DE	Type-1/2 diabetes

DMR4HIW	ID	DMR4HIW
DMR4HIW	DN	Insulin-glargine
DMR4HIW	HS	Approved
DMR4HIW	SN	Glargine; Lantus; SoloStar; SoloStar [Insulin delivery pen]; A21-Gly-B31-Arg-B32-Arg-insulin
DMR4HIW	TC	Hypoglycemic Agents
DMR4HIW	DT	Small molecular drug
DMR4HIW	SQ	A chain: GIVEQCCTSICSLYQLENYCG</sequence>    <sequence format="FASTA">&gt;B chainFVNQHLCGSHLVEALYLVCGERGFFYTPKTRR
DMR4HIW	PC	118984454
DMR4HIW	MW	6063
DMR4HIW	FM	C267H404N72O78S6
DMR4HIW	IC	InChI=1S/C267H404N72O78S6/c1-29-137(23)212(330-199(355)109-269)260(412)334-211(136(21)22)256(408)305-166(79-86-206(365)366)226(378)298-163(75-82-196(273)352)230(382)326-190-122-421-422-123-191-251(403)322-185(117-341)249(401)312-170(94-129(7)8)234(386)313-176(101-146-57-65-152(346)66-58-146)237(389)299-161(73-80-194(271)350)227(379)308-169(93-128(5)6)232(384)301-165(78-85-205(363)364)229(381)320-182(107-197(274)353)244(396)316-178(103-148-61-69-154(348)70-62-148)240(392)325-188(222(374)290-115-207(367)368)120-418-420-121-189(221(373)288-112-200(356)294-160(76-83-203(359)360)225(377)297-157(53-42-88-284-265(276)277)219(371)287-113-201(357)295-174(99-144-48-36-32-37-49-144)236(388)315-175(100-145-50-38-33-39-51-145)239(391)317-179(104-149-63-71-155(349)72-64-149)247(399)338-216(142(28)345)263(415)339-91-45-56-193(339)254(406)302-158(52-40-41-87-268)231(383)336-214(140(26)343)261(413)303-159(54-43-89-285-266(278)279)224(376)306-167(264(416)417)55-44-90-286-267(280)281)328-258(410)210(135(19)20)333-245(397)172(96-131(11)12)310-238(390)177(102-147-59-67-153(347)68-60-147)314-233(385)168(92-127(3)4)307-217(369)139(25)293-223(375)164(77-84-204(361)362)304-255(407)209(134(17)18)332-246(398)173(97-132(13)14)311-242(394)181(106-151-111-283-126-292-151)319-248(400)184(116-340)296-202(358)114-289-220(372)187(119-419-423-124-192(327-252(190)404)253(405)337-215(141(27)344)262(414)323-186(118-342)250(402)335-213(138(24)30-2)259(411)329-191)324-235(387)171(95-130(9)10)309-241(393)180(105-150-110-282-125-291-150)318-228(380)162(74-81-195(272)351)300-243(395)183(108-198(275)354)321-257(409)208(133(15)16)331-218(370)156(270)98-143-46-34-31-35-47-143/h31-39,46-51,57-72,110-111,125-142,156-193,208-216,340-349H,29-30,40-45,52-56,73-109,112-124,268-270H2,1-28H3,(H2,271,350)(H2,272,351)(H2,273,352)(H2,274,353)(H2,275,354)(H,282,291)(H,283,292)(H,287,371)(H,288,373)(H,289,372)(H,290,374)(H,293,375)(H,294,356)(H,295,357)(H,296,358)(H,297,377)(H,298,378)(H,299,389)(H,300,395)(H,301,384)(H,302,406)(H,303,413)(H,304,407)(H,305,408)(H,306,376)(H,307,369)(H,308,379)(H,309,393)(H,310,390)(H,311,394)(H,312,401)(H,313,386)(H,314,385)(H,315,388)(H,316,396)(H,317,391)(H,318,380)(H,319,400)(H,320,381)(H,321,409)(H,322,403)(H,323,414)(H,324,387)(H,325,392)(H,326,382)(H,327,404)(H,328,410)(H,329,411)(H,330,355)(H,331,370)(H,332,398)(H,333,397)(H,334,412)(H,335,402)(H,336,383)(H,337,405)(H,338,399)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,416,417)(H4,276,277,284)(H4,278,279,285)(H4,280,281,286)/t137-,138-,139-,140+,141+,142+,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,208-,209-,210-,211-,212-,213-,214-,215-,216-/m0/s1
DMR4HIW	CS	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMR4HIW	IK	COCFEDIXXNGUNL-RFKWWTKHSA-N
DMR4HIW	IU	(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-47-(carboxymethylcarbamoyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMR4HIW	CA	CAS 160337-95-1
DMR4HIW	DE	Malaria; Type-1 diabetes; Type-2 diabetes; Diabetic complication

DMQI0FU	ID	DMQI0FU
DMQI0FU	DN	Insulin-glulisine
DMQI0FU	HS	Approved
DMQI0FU	TC	Hypoglycemic Agents
DMQI0FU	SQ	A chain: GIVEQCCTSICSLYQLENYCN</sequence>    <sequence format="FASTA">&gt;B chainFVKQHLCGSHLVEALYLVCGERGFFYTPET
DMQI0FU	PC	16136701
DMQI0FU	MW	5823
DMQI0FU	FM	C258H384N64O78S6
DMQI0FU	IC	InChI=1S/C258H384N64O78S6/c1-29-132(23)206(313-193(338)105-260)253(394)317-205(131(21)22)250(391)289-160(75-83-200(348)349)219(360)283-157(71-79-190(264)335)223(364)308-184-117-404-405-118-185-244(385)305-179(112-324)241(382)295-164(90-124(7)8)227(368)296-170(97-141-53-61-147(329)62-54-141)230(371)284-156(70-78-189(263)334)220(361)291-163(89-123(5)6)225(366)285-159(74-82-199(346)347)222(363)303-176(103-191(265)336)236(377)299-172(99-143-57-65-149(331)66-58-143)233(374)309-183(243(384)304-177(256(397)398)104-192(266)337)116-403-402-115-182(215(356)273-108-194(339)278-154(72-80-197(342)343)218(359)281-152(51-42-86-271-258(267)268)213(354)272-109-195(340)279-168(95-139-46-36-32-37-47-139)229(370)298-169(96-140-48-38-33-39-49-140)232(373)300-173(100-144-59-67-150(332)68-60-144)239(380)320-209(136(27)327)255(396)322-87-43-52-187(322)247(388)286-161(76-84-201(350)351)224(365)321-210(137(28)328)257(399)400)311-251(392)204(130(19)20)316-237(378)166(92-126(11)12)293-231(372)171(98-142-55-63-148(330)64-56-142)297-226(367)162(88-122(3)4)290-211(352)134(25)277-216(357)158(73-81-198(344)345)288-249(390)203(129(17)18)315-238(379)167(93-127(13)14)294-235(376)175(102-146-107-270-121-276-146)302-240(381)178(111-323)280-196(341)110-274-214(355)181(114-401-406-119-186(310-245(184)386)246(387)319-208(135(26)326)254(395)306-180(113-325)242(383)318-207(133(24)30-2)252(393)312-185)307-228(369)165(91-125(9)10)292-234(375)174(101-145-106-269-120-275-145)301-221(362)155(69-77-188(262)333)282-217(358)153(50-40-41-85-259)287-248(389)202(128(15)16)314-212(353)151(261)94-138-44-34-31-35-45-138/h31-39,44-49,53-68,106-107,120-137,151-187,202-210,323-332H,29-30,40-43,50-52,69-105,108-119,259-261H2,1-28H3,(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H2,266,337)(H,269,275)(H,270,276)(H,272,354)(H,273,356)(H,274,355)(H,277,357)(H,278,339)(H,279,340)(H,280,341)(H,281,359)(H,282,358)(H,283,360)(H,284,371)(H,285,366)(H,286,388)(H,287,389)(H,288,390)(H,289,391)(H,290,352)(H,291,361)(H,292,375)(H,293,372)(H,294,376)(H,295,382)(H,296,368)(H,297,367)(H,298,370)(H,299,377)(H,300,373)(H,301,362)(H,302,381)(H,303,363)(H,304,384)(H,305,385)(H,306,395)(H,307,369)(H,308,364)(H,309,374)(H,310,386)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,379)(H,316,378)(H,317,394)(H,318,383)(H,319,387)(H,320,380)(H,321,365)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,267,268,271)/t132-,133-,134-,135+,136+,137+,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,202-,203-,204-,205-,206-,207-,208-,209-,210-/m0/s1
DMQI0FU	CS	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMQI0FU	IK	RCHHVVGSTHAVPF-ZPHPLDECSA-N
DMQI0FU	IU	(4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-4-carboxy-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMQI0FU	CA	CAS 207748-29-6
DMQI0FU	DE	Diabetic complication

DM4O90W	ID	DM4O90W
DM4O90W	DN	Insulin-lispro
DM4O90W	HS	Approved
DM4O90W	SN	WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN];  Humalog (TN); Insulin Lispro
DM4O90W	CP	Eli Lilly
DM4O90W	TC	Hypoglycemic Agents
DM4O90W	DT	Small molecular drug
DM4O90W	PC	16132438
DM4O90W	MW	5814
DM4O90W	FM	C257H389N65O77S6
DM4O90W	IC	InChI=1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1
DM4O90W	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN.C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC8=CC=CC=C8)N)O
DM4O90W	IK	WNRQPCUGRUFHED-DETKDSODSA-N
DM4O90W	IU	(4S)-4-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid;(4S)-4-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM4O90W	CA	CAS 133107-64-9
DM4O90W	DE	Diabetic complication

DMSTA36	ID	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	HS	Approved
DMSTA36	SN	Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate
DMSTA36	CP	Boehringer Ingelheim Pharmaceuticals
DMSTA36	DT	Small molecular drug
DMSTA36	PC	135423438
DMSTA36	MW	539.6
DMSTA36	FM	C31H33N5O4
DMSTA36	IC	InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3
DMSTA36	CS	CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
DMSTA36	IK	CPMDPSXJELVGJG-UHFFFAOYSA-N
DMSTA36	IU	methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate
DMSTA36	CA	CAS 656247-17-5
DMSTA36	CB	CHEBI:85164
DMSTA36	DE	Colorectal cancer; Idiopathic pulmonary fibrosis; Ovarian cancer; Non-small-cell lung cancer; Mesothelioma

DMUTZ8S	ID	DMUTZ8S
DMUTZ8S	DN	Interferon Alfa-2a, Recombinant
DMUTZ8S	HS	Approved
DMUTZ8S	SN	Roferon A (TN)
DMUTZ8S	TC	Anticancer Agents
DMUTZ8S	SQ	DB00034 sequence: CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMUTZ8S	DE	Chronic HCV-1 infection

DMWCQP4	ID	DMWCQP4
DMWCQP4	DN	Interferon alfa-2B
DMWCQP4	HS	Approved
DMWCQP4	SN	Intron A; Viraferon
DMWCQP4	CP	Schering-plough
DMWCQP4	TC	Anticancer Agents
DMWCQP4	DT	Small molecular drug
DMWCQP4	PC	71306834
DMWCQP4	MW	746.5
DMWCQP4	FM	C16H17Cl3I2N3NaO5S
DMWCQP4	IC	InChI=1S/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1
DMWCQP4	CS	CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+]
DMWCQP4	IK	MIXCUJKCXRNYFM-UHFFFAOYSA-M
DMWCQP4	IU	sodium;diiodomethanesulfonate;N-propyl-N-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide
DMWCQP4	CA	CAS 98530-12-2
DMWCQP4	DE	Melanoma

DM3TPY8	ID	DM3TPY8
DM3TPY8	DN	Interferon Alfa-2b, Recombinant
DM3TPY8	HS	Approved
DM3TPY8	SN	Alpharona (TN); Genferon (TN); Gerpferon (TN); Grippferon (TN); Infagel (TN); Intron A (TN); Kipferon (TN); Realderon (TN); Recolin (TN); Teva (TN); Viferon (TN)
DM3TPY8	CP	Schering-Plough
DM3TPY8	TC	Anticancer Agents
DM3TPY8	SQ	DB00105 sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DM3TPY8	DE	Hairy cell leukaemia

DM90WJH	ID	DM90WJH
DM90WJH	DN	Interferon alfacon-1
DM90WJH	HS	Approved
DM90WJH	SN	Advaferon; Infergen; Advaferon (TN); Infergen (TN); Interferon alfacon-1 (genetical recombination); Interferon alfacon-1 (USAN/INN); Interferon alfacon-1 (genetical recombination) (JAN)
DM90WJH	TC	Anticancer Agents
DM90WJH	SQ	Interferon alfacon-1: MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE
DM90WJH	DE	Hepatitis C

DM4AK0Q	ID	DM4AK0Q
DM4AK0Q	DN	Interferon alfa-n1
DM4AK0Q	HS	Approved
DM4AK0Q	SN	Well-feron; Interferon alfa-n1 (USAN); Well-feron (TN)
DM4AK0Q	TC	Antiviral Agents
DM4AK0Q	SQ	DB00011 sequence: CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DM4AK0Q	DE	Chronic myelogenous leukaemia

DMTZNQ9	ID	DMTZNQ9
DMTZNQ9	DN	Interferon alfa-n3
DMTZNQ9	HS	Approved
DMTZNQ9	SN	Alferon LDO; Interferon alfa-n3 (oral); Interferon alfa-n3 (oral), Hemispherx; Interferon alfa-n3 (oral), InterferonSciences
DMTZNQ9	CP	Interferon Sciences Inc
DMTZNQ9	SQ	DB00018 sequence (alpha-2A): CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>    <sequence format="FASTA">&gt;DB00018 sequence (alpha-2B)CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>    <sequence format="FASTA">&gt;DB00018 sequence (alpha-2C)CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRRDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMTZNQ9	DE	Human immunodeficiency virus infection

DM1A6RV	ID	DM1A6RV
DM1A6RV	DN	Interferon beta-1a
DM1A6RV	HS	Approved
DM1A6RV	SN	Avonex; Avonex (TN); Cinnovex (TN); Interferon beta-1a (USAN); Interferon beta-1a (genetical recombination); Interferon beta-1a (genetical recombination) (JAN); Rebif (TN)
DM1A6RV	TC	Immunomodulatory Agents
DM1A6RV	DT	Protein/peptide drug
DM1A6RV	SQ	MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
DM1A6RV	DE	Multiple sclerosis

DMCN61Z	ID	DMCN61Z
DMCN61Z	DN	Interferon beta-1b
DMCN61Z	HS	Approved
DMCN61Z	SN	Betaferon (TN); Betaseron (TN)
DMCN61Z	TC	Immunomodulatory Agents
DMCN61Z	SQ	DB00068 sequence: SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
DMCN61Z	DE	Multiple sclerosis

DMWUMRL	ID	DMWUMRL
DMWUMRL	DN	Interferon gamma-1b
DMWUMRL	HS	Approved
DMWUMRL	TC	Immunomodulatory Agents
DMWUMRL	SQ	DB00033 sequence: CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ
DMWUMRL	DE	Chronic granulomatous disease

DM1Y69Q	ID	DM1Y69Q
DM1Y69Q	DN	Interleukin-3
DM1Y69Q	HS	Approved
DM1Y69Q	DE	Aplastic anemia

DM1Y2JH	ID	DM1Y2JH
DM1Y2JH	DN	Inulin
DM1Y2JH	HS	Approved
DM1Y2JH	SN	Inulin [BAN]; Inulin and sodium chloride; Inulin from Jerusalem artichokes; Inulin USP 27
DM1Y2JH	TC	Hypoglycemic Agents
DM1Y2JH	DT	Small molecular drug
DM1Y2JH	PC	24763
DM1Y2JH	MW	6179
DM1Y2JH	FM	C228H382O191
DM1Y2JH	IC	InChI=1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1
DM1Y2JH	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O)CO[C@]4([C@H]([C@@H]([C@H](O4)CO)O)O)CO[C@]5([C@H]([C@@H]([C@H](O5)CO)O)O)CO[C@]6([C@H]([C@@H]([C@H](O6)CO)O)O)CO[C@]7([C@H]([C@@H]([C@H](O7)CO)O)O)CO[C@]8([C@H]([C@@H]([C@H](O8)CO)O)O)CO[C@]9([C@H]([C@@H]([C@H](O9)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO)O)O)O)O
DM1Y2JH	IK	JYJIGFIDKWBXDU-MNNPPOADSA-N
DM1Y2JH	IU	(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM1Y2JH	CA	CAS 9005-80-5
DM1Y2JH	DE	Measure kidney function

DMS6ZI0	ID	DMS6ZI0
DMS6ZI0	DN	Inulin
DMS6ZI0	HS	Approved
DMS6ZI0	SN	Inulin [BAN]; Inulin [USP:BAN]; Inulin and sodium chloride; Inulin-oligofructose enriched; JOS53KRJ01; LS-186416; LS-187349; Liquid Agave Inulin; Agave Inulin; Inulin - Liquid; Inulin Powder; 78089-EP2272846A1; 78089-EP2277868A1; 78089-EP2277869A1; 78089-EP2308866A1; 78089-EP2374791A1; AI3-19506; DB00638; EINECS 232-684-3; UNII-JOS53KRJ01
DMS6ZI0	PC	24763
DMS6ZI0	MW	6179
DMS6ZI0	FM	C228H382O191
DMS6ZI0	IC	JYJIGFIDKWBXDU-MNNPPOADSA-N
DMS6ZI0	CS	C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)COC3(C(C(C(O3)CO)O)O)COC4(C(C(C(O4)CO)O)O)COC5(C(C(C(O5)CO)O)O)COC6(C(C(C(O6)CO)O)O)COC7(C(C(C(O7)CO)O)O)COC8(C(C(C(O8)CO)O)O)COC9(C(C(C(O9)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)CO)O)O)O)O
DMS6ZI0	IK	1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1
DMS6ZI0	IU	(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMS6ZI0	CA	CAS 9005-80-5
DMS6ZI0	DE	Acute kidney failure

DM80OEZ	ID	DM80OEZ
DM80OEZ	DN	Iobenguane I-123
DM80OEZ	HS	Approved
DM80OEZ	SN	Iobenguane (123I); UNII-P2TH1XYZ84; m-Iodobenzylguanidine-123I; P2TH1XYZ84; Adreview; Iobenguane I 123; 123I-MIBG; 2-[(3-iodanylphenyl)methyl]guanidine; 76924-93-1; Iodine-123 metaiodobenzylguanidine; m-(123I)Iodobenzylguanidine; Iobenguane I 123 [USAN]; MyoMIBG-I 123 (TN); (123I)-m-Iodobenzylguanidine; AC1L367T; AC1Q50E3; CHEMBL1615777; SCHEMBL13158600; (123)I-MIBG; CHEBI:135134; 123 iodine metaiodobenzylguanidine; MOLI000966; 3-Iodobenzylguanidine (123I) (JAN); Guanidine, ((3-iodo(123I)phenyl)methyl)-; D01729
DM80OEZ	CP	GE Healthcare
DM80OEZ	DT	Small molecular drug
DM80OEZ	PC	135326
DM80OEZ	MW	271.09
DM80OEZ	FM	C8H10IN3
DM80OEZ	IC	InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9-4
DM80OEZ	CS	C1=CC(=CC(=C1)[123I])CN=C(N)N
DM80OEZ	IK	PDWUPXJEEYOOTR-IUAIQHPESA-N
DM80OEZ	IU	2-[(3-(123I)iodanylphenyl)methyl]guanidine
DM80OEZ	CA	CAS 76924-93-1
DM80OEZ	CB	CHEBI:135134
DM80OEZ	DE	Neuroendocrine cancer

DMXIQYS	ID	DMXIQYS
DMXIQYS	DN	Iodipamide
DMXIQYS	HS	Approved
DMXIQYS	SN	Adipiodon; Adipiodona; Adipiodone; Adipiodonum; Bilignost; Bilignostum; Biligrafin; Cholografin; Cholospect; IDB; Transbilix; Iodipamic acid; Iodipamide [USAN]; Adipiodona [INN-Spanish]; Adipiodonum [INN-Latin]; Iodipamide (USP); Adipiodone (JAN/INN); N,N''-Adipoyl-bis(3-amino-2,4,6-triiodbenzoesaeure); 3,3'(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-Adipoyldiiminobis(2,4,6-triiodobenzoic Acid); 3,3'-[(1,6-DIOXOHEXANE-1,6-DIYL)DIIMINO]BIS(2,4,6-TRIIODOBENZOIC ACID); 3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]-2,4,6-TRIIODO-BENZOIC ACID; 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid
DMXIQYS	TC	Contrast Media
DMXIQYS	DT	Small molecular drug
DMXIQYS	PC	3739
DMXIQYS	MW	1139.8
DMXIQYS	FM	C20H14I6N2O6
DMXIQYS	IC	InChI=1S/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34)
DMXIQYS	CS	C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I
DMXIQYS	IK	FFINMCNLQNTKLU-UHFFFAOYSA-N
DMXIQYS	IU	3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid
DMXIQYS	CA	CAS 606-17-7
DMXIQYS	CB	CHEBI:31176
DMXIQYS	DE	Gallbladder disease

DMNARJT	ID	DMNARJT
DMNARJT	DN	Ioflupane I-123
DMNARJT	HS	Approved
DMNARJT	SN	Datscan (TN)
DMNARJT	CP	GE Healthcare
DMNARJT	DT	Small molecular drug
DMNARJT	PC	3086674
DMNARJT	MW	427.3
DMNARJT	FM	C18H23FINO2
DMNARJT	IC	InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4
DMNARJT	CS	COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCCF)C[C@@H]1C3=CC=C(C=C3)[123I]
DMNARJT	IK	HXWLAJVUJSVENX-HFIFKADTSA-N
DMNARJT	IU	methyl (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-(4-(123I)iodanylphenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
DMNARJT	CA	CAS 155798-07-5
DMNARJT	CB	CHEBI:68855
DMNARJT	DE	Parkinson disease

DMLZTP9	ID	DMLZTP9
DMLZTP9	DN	Ipecac
DMLZTP9	HS	Approved
DMLZTP9	SN	Ipecac syrup
DMLZTP9	DE	Poison intoxication

DMWA24P	ID	DMWA24P
DMWA24P	DN	IPI-145
DMWA24P	HS	Approved
DMWA24P	SN	Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;
DMWA24P	CP	Verastem
DMWA24P	DT	Small molecular drug
DMWA24P	PC	50905713
DMWA24P	MW	416.9
DMWA24P	FM	C22H17ClN6O
DMWA24P	IC	InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
DMWA24P	CS	C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DMWA24P	IK	SJVQHLPISAIATJ-ZDUSSCGKSA-N
DMWA24P	IU	8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
DMWA24P	CA	CAS 1201438-56-3
DMWA24P	CB	CHEBI:131169
DMWA24P	DE	Small lymphocytic lymphoma; Follicular lymphoma; Arthritis

DMJTIYK	ID	DMJTIYK
DMJTIYK	DN	Ipilimumab
DMJTIYK	HS	Approved
DMJTIYK	SN	BMS-734016; MDX-010; MDX-101; Yervoy (TN)
DMJTIYK	CP	Bristol-Myers Squibb
DMJTIYK	DT	Monoclonal antibody
DMJTIYK	SQ	Ipilimumab heavy chain (patent appl. US20150283234) : QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Ipilimumab light chain EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMJTIYK	DE	Melanoma

DMFQ320	ID	DMFQ320
DMFQ320	DN	Ipratropium
DMFQ320	HS	Approved
DMFQ320	SN	Aerodose; Atrovent; Atrovent Hfa; Ipatropium Bromide; Ipratropium bromide; X8M; Apo-Ipravent; Apovent (TN); Atrovent (TN); Kendral-Ipratropium; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane
DMFQ320	TC	Bronchodilator Agents
DMFQ320	DT	Small molecular drug
DMFQ320	PC	657309
DMFQ320	MW	332.5
DMFQ320	FM	C20H30NO3+
DMFQ320	IC	InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18?,19?,21?
DMFQ320	CS	CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C
DMFQ320	IK	OEXHQOGQTVQTAT-BZQJJPTISA-N
DMFQ320	IU	[(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
DMFQ320	CA	CAS 60205-81-4
DMFQ320	CB	CHEBI:5956
DMFQ320	DE	Obstructive lung disease

DM0IO13	ID	DM0IO13
DM0IO13	DN	Ipriflavone
DM0IO13	HS	Approved
DM0IO13	SN	Osten (TN)
DM0IO13	DT	Small molecular drug
DM0IO13	PC	3747
DM0IO13	MW	280.3
DM0IO13	FM	C18H16O3
DM0IO13	IC	InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
DM0IO13	CS	CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3
DM0IO13	IK	SFBODOKJTYAUCM-UHFFFAOYSA-N
DM0IO13	IU	3-phenyl-7-propan-2-yloxychromen-4-one
DM0IO13	CA	CAS 35212-22-7
DM0IO13	CB	CHEBI:31719
DM0IO13	DE	Osteoporosis

DMTP1DC	ID	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	HS	Approved
DMTP1DC	SN	irbesartan; 138402-11-6; Aprovel; Avapro; Karvea; SR-47436; BMS-186295; BMS 186295; Irbesartan [USAN:INN]; SR 47436; UNII-J0E2756Z7N; CHEMBL1513; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[44]non-8-en-6-one; CHEBI:5959; C25H28N6O; YOSHYTLCDANDAN-UHFFFAOYSA-N; J0E2756Z7N; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[44]non-1-en-4-one; NCGC00095122-01; AK-57149; DSSTox_CID_3169;  Aprovel; Irbesarran; Irbetan; Lrbesartan; BMS Brand of Irbesartan; Bristol Myers Brand of Irbesartan; SanofiWinthrop Brand of Irbesartan; Aprovel (TN); Avalide (TN); Avapro (TN); Karvea (TN); Irbesartan (JAN/USAN/INN); BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(44)non-1-en-4-one; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[44]non-1-en-4-one; 2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[44]non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; [3H]irbesartan
DMTP1DC	CP	Bristol-Myers Squibb
DMTP1DC	TC	Antihypertensive Agents
DMTP1DC	DT	Small molecular drug
DMTP1DC	PC	3749
DMTP1DC	MW	428.5
DMTP1DC	FM	C25H28N6O
DMTP1DC	IC	InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
DMTP1DC	CS	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMTP1DC	IK	YOSHYTLCDANDAN-UHFFFAOYSA-N
DMTP1DC	IU	2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
DMTP1DC	CA	CAS 138402-11-6
DMTP1DC	CB	CHEBI:5959
DMTP1DC	DE	Hypertension

DMP6SC2	ID	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	HS	Approved
DMP6SC2	SN	Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde
DMP6SC2	CP	Pfizer Pharmaceuticals
DMP6SC2	TC	Anticancer Agents
DMP6SC2	DT	Small molecular drug
DMP6SC2	PC	60838
DMP6SC2	MW	586.7
DMP6SC2	FM	C33H38N4O6
DMP6SC2	IC	InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
DMP6SC2	CS	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
DMP6SC2	IK	UWKQSNNFCGGAFS-XIFFEERXSA-N
DMP6SC2	IU	[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
DMP6SC2	CA	CAS 97682-44-5
DMP6SC2	CB	CHEBI:80630
DMP6SC2	DE	Colorectal cancer

DMAP8MV	ID	DMAP8MV
DMAP8MV	DN	Iron
DMAP8MV	HS	Approved
DMAP8MV	SN	Eisen; Feronate; Ferretts; Ferrousal; Ferrum; Hemocyte; Hierro; LOHA; PZhO; Remko; Siderol; Yieronia; Ancor B; Armco iron; Carbonyl iron; Ferrous iron; Ferrovac E; Hoeganaes EH; Iron monocation; Iron standard for AAS; ATW 230; ATW 432; Atomel 28; Atomel 300M200; Atomel 500M; Atomel 95; Atomiron 44MR; Atomiron 5M; Atomiron AFP 25; Atomiron AFP 5; DSP 1000; DSP 128B; DSP 135; DSP 135C; DSP 138; EF 1000; EF 250; EFV 250; GS 6; HS 4849; Hoeganaes ATW 230; NC 100; PZh1M1; PZh2M; PZh2M1; PZh2M2; PZh3; PZh3M; PZh4M; Ancoren 80/150; Copy Powder CS 105-175; Diseases, iron overload; EFV 200/300; EFV 250/400; F 60 (metal); FT 3 (element); Fe-40; Fe1+; Ferro-Caps; Ferro-Time; HF 2 (element); HL (iron); HQ (metal); HS (iron); Iron (Fe); Iron(III) nitrate solution; Iron, elemental; PZh-1M3; PZh-2; SUY-B 2; Vitedyn-Slo; Diseases (animal), iron overload; Ed-In-Sol; Iron (Fe1+); Iron ion (Fe+); Iron ion(1+); Iron(1+); Iron(1+) ion; Iron, ion (Fe1+); Iron, ion (Fe1+) (8CI,9CI); 3ZhP
DMAP8MV	TC	Iron Supplement
DMAP8MV	DT	Small molecular drug
DMAP8MV	PC	23925
DMAP8MV	MW	55.84
DMAP8MV	FM	Fe
DMAP8MV	IC	InChI=1S/Fe
DMAP8MV	CS	[Fe]
DMAP8MV	IK	XEEYBQQBJWHFJM-UHFFFAOYSA-N
DMAP8MV	IU	iron
DMAP8MV	CA	CAS 7439-89-6
DMAP8MV	CB	CHEBI:18248
DMAP8MV	DE	Iron-deficiency anemia

DM5OY70	ID	DM5OY70
DM5OY70	DN	Iron Dextran
DM5OY70	HS	Approved
DM5OY70	SN	Chinofer; Dexferrum; Dextrofer; Eisendextran; Fenate; Ferridextran; Ferrodextran; Ferroglucin; Hematran; Icar; Imfergen; Imferon; Imperon; Imposil; Infed; Norferan; Polyfer; Proferdex; Prolongal; Ursoferran; Dextran iron complex; Eisendextran [German]; Fero Gradumet; Ferric dextran; Iron dextran complex; Iron dextran injection; Iron hydrogenated dextran; Ironorm injection; B 75; Dextrofer 75; Ferdex 100; Ferroglukin 75; Myofer 100; A 100 (Pharmaceutical); American Regent Brand of Iron-Dextran Complex; Dextran-Iron Complex; Fe-Dextran; GlaxoSmithKline Brand of Iron-Dextran Complex; Goldline Brand of Iron-Dextran Complex; Hauck Brand of Iron-Dextran Complex; Hawthron Brand of Iron-Dextran Complex; Iro-Jex; Iron-dextran complex; Sanofi Brand of Iron-Dextran Complex; Sulfuric acid, iron salt; Sulphuric acid, iron salt; Vortech Brand of Iron-Dextran Complex; Watson Brand of Iron-Dextran Complex; Sulfuric acid iron salt (1:1); Sulfuric acid, iron salt (1:); Sulfuric acid iron(2+) salt (1:1)
DM5OY70	TC	Iron Supplement
DM5OY70	DT	Small molecular drug
DM5OY70	PC	105075
DM5OY70	MW	153.93
DM5OY70	FM	FeH2O4S
DM5OY70	IC	InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)
DM5OY70	CS	OS(=O)(=O)O.[Fe]
DM5OY70	IK	MVZXTUSAYBWAAM-UHFFFAOYSA-N
DM5OY70	IU	iron;sulfuric acid
DM5OY70	CA	CAS 9004-66-4
DM5OY70	DE	Iron-deficiency anemia

DMD45S9	ID	DMD45S9
DMD45S9	DN	Isavuconazonium
DMD45S9	HS	Approved
DMD45S9	SN	Isavuconazonium; Isavuconazonium (USAN); Isavuconazonium [USAN]; Isavuconazonium ion; VH2L779W8Q; 742049-41-8; AC1OCFMR; ACN-048059; BCP23773; BAL 8557-000; BAL-8557; BAL8557-000; CHEBI:85978; CHEMBL1183349; DB06636; DTXSID70225203; Glycine, N-methyl-, (2-(((1-(1-((2R,3R)-3-(4-(4-cyanophenyl)-2-thiazolyl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-1H-1,2,4-triazolium-4-yl)ethoxy)carbonyl)methylamino)-3-pyridinyl)methyl ester; SCHEMBL13133195; UNII-VH2L779W8Q
DMD45S9	PC	6918606
DMD45S9	MW	717.8
DMD45S9	FM	C35H35F2N8O5S+
DMD45S9	IC	RSWOJTICKMKTER-QXLBVTBOSA-N
DMD45S9	CS	CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O
DMD45S9	IK	1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1
DMD45S9	IU	[2-[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]pyridin-3-yl]methyl 2-(methylamino)acetate
DMD45S9	CA	CAS 742049-41-8
DMD45S9	CB	CHEBI:85978
DMD45S9	DE	Allergic bronchopulmonary aspergillosis

DMJ9G23	ID	DMJ9G23
DMJ9G23	DN	ISIS 1570
DMJ9G23	HS	Approved
DMJ9G23	CP	Isis Pharmaceuticals
DMJ9G23	DT	Antisense drug
DMJ9G23	DE	Lleum inflammation

DMAF1NB	ID	DMAF1NB
DMAF1NB	DN	Isocarboxazid
DMAF1NB	HS	Approved
DMAF1NB	SN	BMIH; Benazide; Enerzer; Isocarbonazid; Isocarbossazide; Isocarboxazida; Isocarboxazide; Isocarboxazidum; Isocarboxyzid; Maraplan; Marplan; Marplon; Isocarbossazide [DCIT]; Isocarboxazid (INN); Isocarboxazid [INN:BAN]; Isocarboxazida [INN-Spanish]; Isocarboxazide [INN-French]; Isocarboxazidum [INN-Latin]; Marplan (TN); Ro5-0831; Ro 5-0831/1; N'-Benzyl N-methyl-5-isoxazolecarboxylhydrazide-3; N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide; 1-Benzyl-2-(5-methyl-3-isoxazolyl-carbonyl)hydrazine; 1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzylhydrazide; 5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide; 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide
DMAF1NB	CP	Hoffmann-La Roche pharmaceutical company
DMAF1NB	TC	Antidepressants
DMAF1NB	DT	Small molecular drug
DMAF1NB	PC	3759
DMAF1NB	MW	231.25
DMAF1NB	FM	C12H13N3O2
DMAF1NB	IC	InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
DMAF1NB	CS	CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2
DMAF1NB	IK	XKFPYPQQHFEXRZ-UHFFFAOYSA-N
DMAF1NB	IU	N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
DMAF1NB	CA	CAS 59-63-2
DMAF1NB	CB	CHEBI:93635
DMAF1NB	DE	Depression

DMITSEH	ID	DMITSEH
DMITSEH	DN	Isoetharine
DMITSEH	HS	Approved
DMITSEH	SN	Bronkosol; Dilabron; Etyprenaline; Etyprenalinum; Isoetarin; Isoetarina; Isoetarine; Isoetarinum; Neoisuprel; Isoetharine Hcl; Win 3406; Bronkometer (TN); Bronkosol (TN); Dey-Lute Isoetharine; Isoetarina [INN-Spanish]; Isoetarine (INN); Isoetarinum [INN-Latin]; Isoetharine (USP); Isoetharine HCl S/F; Isoetharine [USAN:BAN]; 3,4-Dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol; 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol
DMITSEH	TC	Bronchodilator Agents
DMITSEH	DT	Small molecular drug
DMITSEH	PC	3762
DMITSEH	MW	239.31
DMITSEH	FM	C13H21NO3
DMITSEH	IC	InChI=1S/C13H21NO3/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9/h5-8,10,13-17H,4H2,1-3H3
DMITSEH	CS	CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C
DMITSEH	IK	HUYWAWARQUIQLE-UHFFFAOYSA-N
DMITSEH	IU	4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol
DMITSEH	CA	CAS 530-08-5
DMITSEH	CB	CHEBI:6005
DMITSEH	DE	Asthma

DMY6T31	ID	DMY6T31
DMY6T31	DN	Isoflurane
DMY6T31	HS	Approved
DMY6T31	SN	Aerrane; Forane; Forene; IsoFlo; Isoflurano; Isofluranum; AErrane (Veterinary); Forane (TN); Isoflurane [Anaesthetics, volatile]; Isoflurano [INN-Spanish]; Isofluranum [INN-Latin]; R-E 235dal; Isoflurane (JP15/USP/INN); Isoflurane [USAN:BAN:INN:JAN]; Isoflurane [USAN:INN:BAN:JAN]; Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl; 1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether; 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane; 2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane
DMY6T31	TC	Anesthetics
DMY6T31	DT	Small molecular drug
DMY6T31	PC	3763
DMY6T31	MW	184.49
DMY6T31	FM	C3H2ClF5O
DMY6T31	IC	InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H
DMY6T31	CS	C(C(F)(F)F)(OC(F)F)Cl
DMY6T31	IK	PIWKPBJCKXDKJR-UHFFFAOYSA-N
DMY6T31	IU	2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane
DMY6T31	CA	CAS 26675-46-7
DMY6T31	CB	CHEBI:6015
DMY6T31	DE	Anaesthesia

DMBSK7X	ID	DMBSK7X
DMBSK7X	DN	Isoflurophate
DMBSK7X	HS	Approved
DMBSK7X	SN	DFP; DIFP; Diflupyl; Diflurophate; Diisopropylfluorfosfat; Diisopropylfluorophosphate; Diisopropylfluorphosphorsaeureester; Diisopropylphosphofluoridate; Diisopropylphosphorofluoridate; Dyflos; Floropryl; Fluoropryl; Fluorostigmine; Fluostigmine; Fluropryl; Isofluorophate; Isofluorphate; Isoflurophosphate; Neoglaucit; Di isopropylphosphorofluoridate; Diisopropoxyphosphoryl fluoride; Diisopropyl fluoridophosphate; Diisopropyl fluorophosphate; Diisopropyl fluorophosphonate; Diisopropyl phosphofluoridate; Diisopropyl phosphorofluoridate; Diisopropylfluorfosfat [Czech]; Diisopropylfluorophosphoric acid ester; Diisopropylfluorphosphorsaeureester [German]; Disiopropyl fluorophosphonate; Fluorodiisopropyl phosphate; Isoflurophate [USP]; Isopropyl fluophosphate; Isopropyl phosphorofluoridate; Merck Brand of Isoflurophate; Phosphoric acid diisopropyl ester fluoride; EA 1152; TL 466; DIISOPROPYL-FLUOROPHOSPHATE; Di-isopropylphosphorofluoridate; Floropryl (TN); Fluophosphoric acid, diisopropyl ester; Fluorophosphoric acid, diisopropyl ester; Isoflurophate (USP); PF-3; Phosphorofluoridic acid, diisopropyl ester; T-1703; Bis(1-methylethyl) Phosphorofluoridate; Dipropan-2-yl phosphorofluoridoate; O,O-Diisopropyl fluorophosphate; Bis(propan-2-yl) fluorophosphate; O,O'-Diisopropyl phosphoryl fluoride; Phosphorofluoridic acid, bis(1-methylethyl) ester; 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane
DMBSK7X	TC	Antiglaucomic Agents
DMBSK7X	DT	Small molecular drug
DMBSK7X	PC	5936
DMBSK7X	MW	184.15
DMBSK7X	FM	C6H14FO3P
DMBSK7X	IC	InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3
DMBSK7X	CS	CC(C)OP(=O)(OC(C)C)F
DMBSK7X	IK	MUCZHBLJLSDCSD-UHFFFAOYSA-N
DMBSK7X	IU	2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane
DMBSK7X	CA	CAS 55-91-4
DMBSK7X	CB	CHEBI:17941
DMBSK7X	DE	Glaucoma/ocular hypertension

DM5JVS3	ID	DM5JVS3
DM5JVS3	DN	Isoniazid
DM5JVS3	HS	Approved
DM5JVS3	SN	Abdizide; Andrazide; Anidrasona; Antimicina; Antituberkulosum; Armacide; Armazid; Armazide; Atcotibine; Azuren; Bacillen; Bacillin; Cedin; Cemidon; Chemiazid; Chemidon; Continazine; Cortinazine; Cotinazin; Cotinizin; Defonin; Dibutin; Diforin; Dinacrin; Ditubin; Ebidene; Eralon; Ertuban; Eutizon; Evalon; Fetefu; Fimalene; HIA; Hidranizil; Hidrasonil; Hidrulta; Hidrun; Hycozid; Hydra; Hydrazid; Hydrazide; Hyozid; Hyzyd; INH; Idrazil; Inah; Inizid; Iscotin; Isidrina; Ismazide; Isobicina; Isocid; Isocidene; Isocotin; Isohydrazide; Isokin; Isolyn; Isonerit; Isonex; Isoniacid; Isoniazida; Isoniazide; Isoniazidum; Isonicazide; Isonicid; Isonico; Isonicotan; Isonicotil; Isonicotinhydrazid; Isonicotinohydrazide; Isonide; Isonidrin; Isonikazid; Isonilex; Isonin; Isonindon; Isonirit; Isoniton; Isonizida; Isonizide; Isotamine; Isotebe; Isotebezid; Isotinyl; Isozid; Isozide; Isozyd; LANIZID; Laniazid; Laniozid; Mybasan; Neoteben; Neoxin; Neumandin; Nevin; Niadrin; Nicazide; Nicetal; Nicizina; Niconyl; Nicotibina; Nicotibine; Nicotisan; Nicozide; Nidaton; Nidrazid; Nikozid; Niplen; Nitadon; Niteban; Nydrazid; Nyscozid; Pelazid; Percin; Phthisen; Pycazide; Pyreazid; Pyricidin; Pyridicin; Pyrizidin; Raumanon; Razide; Retozide; Rimicid; Rimifon; Rimiphone; Rimitsid; Robiselin; Robisellin; Roxifen; Sanohidrazina; Sauterazid; Sauterzid; Stanozide; Tebecid; Tebemid; Tebenic; Tebexin; Tebilon; Tebos; Teebaconin; Tekazin; Tibazide; Tibemid; Tibiazide; Tibinide; Tibison; Tibivis; Tibizide; Tibusan; Tisin; Tisiodrazida; Tizide; Tubazid; Tubazide; Tubeco; Tubecotubercid; Tubercid; Tuberian; Tubicon; Tubilysin; Tubizid; Tubomel; Tyvid; Unicocyde; Unicozyde; Vazadrine; Vederon; Zidafimia; Zinadon; Zonazide; Hid rasonil; Isoco tin; Isoniazid SA; Isozid e; Nidra zid; Rimif on; BP 5015; Bp 5 015; FSR 3; I0138; INHd20; L 1945; Nitebannsc 9659; Preparation 6424; RP 5015; AZT + Isoniazid; Cedin (Aerosol); Dow-Isoniazid; FRS-3; FSR-3; Ido-tebin; In-73; Inh-Burgthal; Isoniazid & EEP; Isoniazid & Propolis; Laniazid (TN); Neo-Tizide; Nydrazid (TN); RP-5015; TB-Phlogin; TB-Razide; TB-Vis; Usaf cb-2; I.A.I; RU-EF-Tb; RY-EF-Tb; I.A.I.
DM5JVS3	CP	Roche Pharmaceuticals
DM5JVS3	TC	Antitubercular Agents
DM5JVS3	DT	Small molecular drug
DM5JVS3	PC	3767
DM5JVS3	MW	137.14
DM5JVS3	FM	C6H7N3O
DM5JVS3	IC	InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
DM5JVS3	CS	C1=CN=CC=C1C(=O)NN
DM5JVS3	IK	QRXWMOHMRWLFEY-UHFFFAOYSA-N
DM5JVS3	IU	pyridine-4-carbohydrazide
DM5JVS3	CA	CAS 54-85-3
DM5JVS3	CB	CHEBI:6030
DM5JVS3	DE	Tuberculosis

DMQYV60	ID	DMQYV60
DMQYV60	DN	Isopropamide iodide
DMQYV60	HS	Approved
DMQYV60	SN	Isopropamide Iodide; 71-81-8; Darbid; Isoproponum iodide; Priamide Eupharma; Priamide; Tyrimide; Dipramide; Priazimide; Piaccamide; Sanulcin; Dipramid; Isamid; Marygin-M; UNII-E0KNA372SZ; Isopropamide ioduro [DCIT]; Isopropamidi iodidum [INN-Latin]; SKF 4740; Iodure d'isopropamide [INN-French]; EINECS 200-766-8; NSC 15521; Ioduro de isopropamida [INN-Spanish]; 5579 MD; E0KNA372SZ; R 79; MLS000069749; (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; Benzenepropanaminium, gamma-(aminocarbonyl)-N-methyl-N,N-bis(1-methyl
DMQYV60	DT	Small molecular drug
DMQYV60	PC	6284
DMQYV60	MW	480.4
DMQYV60	FM	C23H33IN2O
DMQYV60	IC	InChI=1S/C23H32N2O.HI/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21;/h6-15,18-19H,16-17H2,1-5H3,(H-,24,26);1H
DMQYV60	CS	CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C.[I-]
DMQYV60	IK	BFSMWENDZZIWPW-UHFFFAOYSA-N
DMQYV60	IU	(4-amino-4-oxo-3,3-diphenylbutyl)-methyl-di(propan-2-yl)azanium;iodide
DMQYV60	CA	CAS 71-81-8
DMQYV60	CB	CHEBI:6044
DMQYV60	DE	Allergic rhinitis

DMK7MEY	ID	DMK7MEY
DMK7MEY	DN	Isoproterenol
DMK7MEY	HS	Approved
DMK7MEY	SN	isoproterenol; Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isadrine; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Neo-Epinine; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409
DMK7MEY	CP	Abbott Laboratories
DMK7MEY	TC	Cardiotonic Agents
DMK7MEY	DT	Small molecular drug
DMK7MEY	PC	3779
DMK7MEY	MW	211.26
DMK7MEY	FM	C11H17NO3
DMK7MEY	IC	InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3
DMK7MEY	CS	CC(C)NCC(C1=CC(=C(C=C1)O)O)O
DMK7MEY	IK	JWZZKOKVBUJMES-UHFFFAOYSA-N
DMK7MEY	IU	4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol
DMK7MEY	CA	CAS 7683-59-2
DMK7MEY	CB	CHEBI:64317
DMK7MEY	DE	Heart block; Melanoma

DMBI4JG	ID	DMBI4JG
DMBI4JG	DN	Isosorbide dinitrate
DMBI4JG	HS	Approved
DMBI4JG	SN	Angidil; Astridine; BiDil; Cardis; Carvanil; Carvasin; Cedocard; Claodical; Cornilat; Coronex; Corosorbide; Corovliss; Difutrat; Dignionitrat; Dilatrate; Diniket; Dinitroisosorbide; Dinitrosorbide; Disorlon; Emoper; EureCor; Flindix; Frandol; Harrical; ISD; ISDN; IsoBid; Isochron; Isodinit; Isoket; Isorbid; Isordil; Isostat; Isotrate; Korodil; Langoran; Laserdil; Lomilan; Maycor; Myorexon; Nitrosorbid; Nitrosorbide; Nitrosorbon; Nosim; Resoidan; Rigedal; Sorbangil; Sorbide; Sorbidilat; Sorbidinitrate; Sorbidnitrate; Sorbislo; Sorbitrate; Sorbonit; Sorquad; Sorquat; Tinidil; Titradose; Vascardin; Vasodilat; Vasorbate; Xanyl; Cedocard Retard; Dilatrate SR; Dinitrato de isosorbida; Iso Bid; Isomak R; Isordil Tembids; Isosorbide dinitrato; Isosorbide dinitrato [DCIT]; Isosorbidi dinitras; Isosorbidi nitras; Rifloc Retard; Sorbide nitrate; Sorbidi nitras; Cardio 10; Cardonit 40; IBD 20; Isoket Retard 120; Isoket Retard120; Isoket retard 40; TYB 3215; Cedocard (TN); D-Isosorbide dinitrate; Dilatrate-SR; Dinitrate d'isosorbide; Dinitrate, Isosorbide; Dinitrato de isosorbida [INN-Spanish]; Iso-Bid; Iso-Mack; Iso-Puren; Isoket Retard-120; Isordil (TN); Isosorbidi dinitras [INN-Latin]; SDM No. 40; SDM No. 50; SST-101; Sorate-10; Sorate-5; Sorbide, dinitrate; Sorbitrate (TN); D-Isosorbide dinitrate-Lactose mixture; Dianhydrosorbitol 2,5-dinitrate; Dilatrate-sr (TN); Dinitrate d'isosorbide [INN-French]; Isosorbide 2,5-dinitrate; Sorbide T.D.; Glucitol, 1,4:3; Isosorbide dinitrate (JP15/USP/INN); Isosorbide dinitrate [USAN:INN:BAN:JAN]; Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]; D-Glucitol, 1,4:3,6-dianhydro-, dinitrate; D-Glucitol, 1,4:3,6-dianhydro-, 2,5-dinitrate; [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3, 6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydrosorbitol 2, 5-dinitrate; 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate; 1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol
DMBI4JG	CP	Biovail Corporation 
DMBI4JG	TC	Vasodilator Agents
DMBI4JG	DT	Small molecular drug
DMBI4JG	PC	6883
DMBI4JG	MW	236.14
DMBI4JG	FM	C6H8N2O8
DMBI4JG	IC	InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1
DMBI4JG	CS	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O[N+](=O)[O-])O[N+](=O)[O-]
DMBI4JG	IK	MOYKHGMNXAOIAT-JGWLITMVSA-N
DMBI4JG	IU	[(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
DMBI4JG	CA	CAS 87-33-2
DMBI4JG	CB	CHEBI:6061
DMBI4JG	DE	Anal fissure; Angina pectoris

DMYLMU0	ID	DMYLMU0
DMYLMU0	DN	Isosorbide mononitrate
DMYLMU0	HS	Approved
DMYLMU0	SN	Conpin; Corangin; Duride; Edistol; Elantan; Epicordin; Etimonis; IHD; ISMN; ISMO; Imazin; Imdur; Imodur; Imtrate; Ismexin; Ismox; Isomon; Isomonat; Isomonit; Iturol; Medocor; Monicor; Monis; Monisid; Monit; Monizid; MonoSigma; Monocedocard; Monocinque; Monoclair; Monocord; Monoket; Monolong; Monomax; Mononit; Monopront; Monosorb; Monosorbitrate; Monosordil; Monotrate; Multitab; Nitex; Nitramin; Olicard; Olicardin; Orasorbil; Percorina; Pertil; Plodin; Promocard; Sigacora; Sorbimon; Titarane; Turimonit; Uniket; Vasdilat; Vasotrate; Conpin Retardkaps; Corangin SR; Elantan Long; Elantan Retard; ISMN AL; ISMN AbZ; ISMN Apogepha; ISMN Atid; ISMN Basics; ISMN Heumann; ISMN Hexal; ISMN Lannacher; ISMN Stada; Imdur Durules; Isosorbidi mononitras; Isosorbidi mononitras [Latin]; Mono Corax; Mono Corax Retard; Mono Mack; Monodur Durules; Monoket OD; Monoket Retard; Mononitrato de isosorbida; Mononitrato de isosorbida [Spanish]; AHR 4698; IS 5MN; Imdur 60; Monit 20; Mono Mac 50D; Monocord 20; Monocord 40; Monocord 50 SR; Monolong 40; Monolong 60; Mononit 20; Mononit 40; Mononit Retard 50; Monosorb XL 60;Olicard 40; Pentacard 20; AHR-4698; BM 22-145; BM 22.145; Chemydur (TN); Fem-Mono; IS 5-MN; Imdur (TN); Ismo (TN); Ismo-20; Isopen-20; Isosorbide 5-mononitrate; Isosorbide 5-nitrate; Mono-Mack; Mono-Sanorania; Mononitrate d'isosorbide; Mononitrate d'isosorbide [French]; Olicard-retard; BM-22-145; Isosobide-5-mononitrate [UN3251] [Flammable solid]; Isosorbide-5-mononitrate; Isosorbide-5-nitrate; Isosorbide mononitrate (JAN/USP/INN); Isosorbide mononitrate [USAN:BAN:INN:JAN]; Isosorbide mononitrate [USAN:INN:BAN:JAN]; D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate; [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3,6-Dianhydro-D-glucitol 5-nitrate; 1,4:3,6-dianhydro-5-O-nitro-D-glucitol; 5-ISMN Durules; 5-Ismn
DMYLMU0	CP	AstraZeneca
DMYLMU0	TC	Vasodilator Agents
DMYLMU0	DT	Small molecular drug
DMYLMU0	PC	27661
DMYLMU0	MW	191.14
DMYLMU0	FM	C6H9NO6
DMYLMU0	IC	InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1
DMYLMU0	CS	C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O
DMYLMU0	IK	YWXYYJSYQOXTPL-SLPGGIOYSA-N
DMYLMU0	IU	[(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
DMYLMU0	CA	CAS 16051-77-7
DMYLMU0	CB	CHEBI:6062
DMYLMU0	DE	Hydrocephalus

DM4QTBN	ID	DM4QTBN
DM4QTBN	DN	Isotretinoin
DM4QTBN	HS	Approved
DM4QTBN	SN	Accutane; Amnesteem; Claravis; Isotane; Isotretinoine; Isotretinoino; Isotretinoinum; Isotrex; Roaccutan; Roaccutane; Roacutan; Sotret; Teriosal; Neovitamin A acid; R 3255; Ro 4 3780; Ro 43780; Accutane (TN); Amnesteem (TN); BML2-E07; CIP-Isotretinoin; Claravi (TN); Clarus (TN); Decutan (TN); Isotane (TN); Isotretinoin (USP); Isotretinoin Zinc Salt, 13 cis Isomer; Isotretinoine [INN-French]; Isotretinoino [INN-Spanish]; Isotretinoinum [INN-Latin]; Izotek (TN); Oratane (TN); Ro 4-3780; Ro-43780; Roaccutane (TN); Sotret (TN); Isotretinoin [USAN:INN:BAN]; Ro-4-3780; Isotretinoin Zinc Salt, 13-cis-Isomer; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; (2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; (7E,9E,11E,13Z)-retinoic acid; 13-RA; 13-cis RA; 13-cis-Vitamin A acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
DM4QTBN	CP	Roche Pharmaceuticals
DM4QTBN	TC	Antiacne Agents
DM4QTBN	DT	Small molecular drug
DM4QTBN	PC	5282379
DM4QTBN	MW	300.4
DM4QTBN	FM	C20H28O2
DM4QTBN	IC	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-
DM4QTBN	CS	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\\C(=O)O)/C)/C
DM4QTBN	IK	SHGAZHPCJJPHSC-XFYACQKRSA-N
DM4QTBN	IU	(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DM4QTBN	CA	CAS 4759-48-2
DM4QTBN	CB	CHEBI:6067
DM4QTBN	DE	Acne vulgaris

DMX7LKS	ID	DMX7LKS
DMX7LKS	DN	Isovanillin
DMX7LKS	HS	Approved
DMX7LKS	SN	Isovanilin; Isovanilline; Iso-Vanillin; Oxy-3 methoxy-4 benzaldehyde; Oxy-3 methoxy-4 benzaldehyde [French]; P-Anisaldehyde, 3-hydroxy-(8CI); 3-Hydroxy-4-methoxybenzaldehyde; 3-Hydroxy-p-anisaldehyde; 3-Hydroxyanisaldehyde; 3-hydroxy-4-anisaldehyde; 4-Methoxy-3-hydroxybenzaldehyde; 5-Formylguaiacol
DMX7LKS	TC	Anticancer Agents
DMX7LKS	DT	Small molecular drug
DMX7LKS	PC	12127
DMX7LKS	MW	152.15
DMX7LKS	FM	C8H8O3
DMX7LKS	IC	InChI=1S/C8H8O3/c1-11-8-3-2-6(5-9)4-7(8)10/h2-5,10H,1H3
DMX7LKS	CS	COC1=C(C=C(C=C1)C=O)O
DMX7LKS	IK	JVTZFYYHCGSXJV-UHFFFAOYSA-N
DMX7LKS	IU	3-hydroxy-4-methoxybenzaldehyde
DMX7LKS	CA	CAS 621-59-0
DMX7LKS	DE	Solid tumour/cancer

DMJL10P	ID	DMJL10P
DMJL10P	DN	Isoxyl
DMJL10P	HS	Approved
DMJL10P	SN	Tiocarlide; Thiocarlide; Tiocarlid; 910-86-1; Disocarban; Datanil; Tiocarlidum [INN-Latin]; Tiocarlida [INN-Spanish]; 4,4'-Diisoamyloxythiocarbanilide; 4,4'-Bis(isopentyloxy)thiocarbanilide; Tiocarlide [INN:BAN:DCF]; UNII-43M23X81Y2; C23H32N2O2S; N,N'-Bis(4-(3-methylbutoxy)phenyl)thiourea; EINECS 213-006-5; CARBANILIDE, 4,4'-BIS(ISOPENTYLOXY)THIO-; BRN 2546347; Thiourea, N,N'-bis[4-(3-methylbutoxy)phenyl]-; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)-; NSC742400; 43M23X81Y2; Amixyl; Disoxyl; Tiocarlida; Tiocarlidum; BRN2546347; Tiocarlide (INN); Tiocarlide [INN:DCF]; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)-(9CI)
DMJL10P	DT	Small molecular drug
DMJL10P	PC	3001386
DMJL10P	MW	400.6
DMJL10P	FM	C23H32N2O2S
DMJL10P	IC	InChI=1S/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28)
DMJL10P	CS	CC(C)CCOC1=CC=C(C=C1)NC(=S)NC2=CC=C(C=C2)OCCC(C)C
DMJL10P	IK	BWBONKHPVHMQHE-UHFFFAOYSA-N
DMJL10P	IU	1,3-bis[4-(3-methylbutoxy)phenyl]thiourea
DMJL10P	CA	CAS 910-86-1
DMJL10P	CB	CHEBI:135637
DMJL10P	DE	Bacterial infection

DMWCRN1	ID	DMWCRN1
DMWCRN1	DN	Ispaghula
DMWCRN1	HS	Approved
DMWCRN1	SN	Fiberall; Metamucil; PSYLLIUM; Plantaglucide; Psyllium Husk [USP]; Psyllium gum; Psyllium seed gum; Psyllium seed husk
DMWCRN1	CP	Reckitt; Colman
DMWCRN1	DE	Irritable bowel syndrome

DMA5XGH	ID	DMA5XGH
DMA5XGH	DN	Isradipine
DMA5XGH	HS	Approved
DMA5XGH	SN	Clivoten; DynaCirc; DynaCire; Dynacrine; Esradin; Icaz; Isradipin; Isradipino; Isradipinum; Isrodipine; Lomir; Prescal; Rebriden; DynaCire CR; Dynacirc CR; Isradipino [Spanish]; Isradipinum [Latin]; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; DynaCirc (TN); PN 200-110; PN 205-033; PN 205-034; PN-200110; Prescal (TN); Isradipine (USP/INN); Isradipine [USAN:INN:BAN]; PN-200-110; PN-205-033; PN-205-034; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Isradipine, (+-)-Isomer; DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; Methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isradipine; (+/-)-Isradipine; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
DMA5XGH	CP	Norvatis Phamaceuticals Corporation
DMA5XGH	TC	Antihypertensive Agents
DMA5XGH	DT	Small molecular drug
DMA5XGH	PC	3784
DMA5XGH	MW	371.4
DMA5XGH	FM	C19H21N3O5
DMA5XGH	IC	InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
DMA5XGH	CS	CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC
DMA5XGH	IK	HMJIYCCIJYRONP-UHFFFAOYSA-N
DMA5XGH	IU	3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMA5XGH	CA	CAS 75695-93-1
DMA5XGH	CB	CHEBI:6073
DMA5XGH	DE	Hypertension; Herpes simplex virus infection

DM20VSK	ID	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	HS	Approved
DM20VSK	SN	KW 6002; Istradefylline [USAN:INN]; Istradefylline (JAN/USAN/INN); (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 8-((1E)-2-(3,4-Dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione
DM20VSK	CP	Kyowa Hakko Pharmaceuticals
DM20VSK	DT	Small molecular drug
DM20VSK	PC	5311037
DM20VSK	MW	384.4
DM20VSK	FM	C20H24N4O4
DM20VSK	IC	InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+
DM20VSK	CS	CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)/C=C/C3=CC(=C(C=C3)OC)OC)C
DM20VSK	IK	IQVRBWUUXZMOPW-PKNBQFBNSA-N
DM20VSK	IU	8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione
DM20VSK	CA	CAS 155270-99-8
DM20VSK	CB	CHEBI:134726
DM20VSK	DE	Substance use disorder; Parkinson disease

DMCR1MV	ID	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	HS	Approved
DMCR1MV	SN	Canadiol; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazolum; Itrizole; Oriconazole; Orungal; Prokanazol; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporonox; Triasporn; Itraconazol [Spanish]; Itraconazole oral solution; Itraconazolum [Latin]; R 51211; Cis-Itraconazole; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itrizole (TN); R-51211; Sporanox (TN); Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Oriconazole, R51211, Sporanox; Itraconazole [USAN:BAN:INN:JAN]; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
DMCR1MV	CP	Janssen Pharmaceutica
DMCR1MV	TC	Antifungal Agents
DMCR1MV	DT	Small molecular drug
DMCR1MV	PC	55283
DMCR1MV	MW	705.6
DMCR1MV	FM	C35H38Cl2N8O4
DMCR1MV	IC	InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
DMCR1MV	CS	CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
DMCR1MV	IK	VHVPQPYKVGDNFY-ZPGVKDDISA-N
DMCR1MV	IU	2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
DMCR1MV	CA	CAS 84625-61-6
DMCR1MV	CB	CHEBI:6076
DMCR1MV	DE	Fungal infection

DM0L594	ID	DM0L594
DM0L594	DN	Ivabradine
DM0L594	HS	Approved
DM0L594	SN	Ivabradine; 155974-00-8; Procoralan; Corlanor; Corlentor; UNII-3H48L0LPZQ; S 16257; S-16257; S-16257-2; S 16257-2; 3H48L0LPZQ; CHEMBL471737; CHEBI:85966; C27H36N2O5; 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one; S-16260-2; s16257; (S)-3-(3-(((3,4-Dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one; Ivabradine [INN]
DM0L594	CP	Servier
DM0L594	DT	Small molecular drug
DM0L594	PC	132999
DM0L594	MW	468.6
DM0L594	FM	C27H36N2O5
DM0L594	IC	InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1
DM0L594	CS	CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC
DM0L594	IK	ACRHBAYQBXXRTO-OAQYLSRUSA-N
DM0L594	IU	3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
DM0L594	CA	CAS 155974-00-8
DM0L594	CB	CHEBI:85966
DM0L594	DE	Angina pectoris

DMZC1HS	ID	DMZC1HS
DMZC1HS	DN	Ivacaftor
DMZC1HS	HS	Approved
DMZC1HS	SN	Kalydeco (TN)
DMZC1HS	CP	Vertex
DMZC1HS	DT	Small molecular drug
DMZC1HS	PC	16220172
DMZC1HS	MW	392.5
DMZC1HS	FM	C24H28N2O3
DMZC1HS	IC	InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)
DMZC1HS	CS	CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C
DMZC1HS	IK	PURKAOJPTOLRMP-UHFFFAOYSA-N
DMZC1HS	IU	N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide
DMZC1HS	CA	CAS 873054-44-5
DMZC1HS	CB	CHEBI:66901
DMZC1HS	DE	Cystic fibrosis

DMDBX5F	ID	DMDBX5F
DMDBX5F	DN	Ivermectin
DMDBX5F	HS	Approved
DMDBX5F	SN	I 8898; Ivexterm (TN); MK-933; Mectizan (TN); Stromectol (TN)
DMDBX5F	CP	Merck & Co
DMDBX5F	TC	Antiprotozoal Agents
DMDBX5F	DT	Small molecular drug
DMDBX5F	PC	6321424
DMDBX5F	MW	875.1
DMDBX5F	FM	C48H74O14
DMDBX5F	IC	InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1
DMDBX5F	CS	CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\\C)C
DMDBX5F	IK	AZSNMRSAGSSBNP-XPNPUAGNSA-N
DMDBX5F	IU	(1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6'-[(2S)-butan-2-yl]-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
DMDBX5F	CA	CAS 71827-03-7
DMDBX5F	CB	CHEBI:63941
DMDBX5F	DE	Intestinal strongyloidiasis due to nematode parasite

DM8S6T7	ID	DM8S6T7
DM8S6T7	DN	Ivosidenib
DM8S6T7	HS	Approved
DM8S6T7	SN	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767
DM8S6T7	CP	Agios Pharmaceuticals
DM8S6T7	PC	71657455
DM8S6T7	MW	583
DM8S6T7	FM	C28H22ClF3N6O3
DM8S6T7	IC	InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
DM8S6T7	CS	C1CC(=O)N([C@@H]1C(=O)N(C2=CC(=CN=C2)F)[C@@H](C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
DM8S6T7	IK	WIJZXSAJMHAVGX-DHLKQENFSA-N
DM8S6T7	IU	(2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
DM8S6T7	CA	CAS 1448347-49-6
DM8S6T7	CB	CHEBI:145430
DM8S6T7	DE	Haematological malignancy; Acute myeloid leukaemia; Cholangiocarcinoma

DMRVITQ	ID	DMRVITQ
DMRVITQ	DN	Ivosidenib
DMRVITQ	HS	Approved
DMRVITQ	SN	(2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; Ivosidenib; Ivosidenib (USAN/INN); Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; Tibsovo
DMRVITQ	TC	Anticancer Agents
DMRVITQ	DT	Small molecular drug
DMRVITQ	PC	71657455
DMRVITQ	MW	582.968
DMRVITQ	FM	C28H22ClF3N6O3
DMRVITQ	IC	InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
DMRVITQ	CS	C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
DMRVITQ	IK	WIJZXSAJMHAVGX-DHLKQENFSA-N
DMRVITQ	IU	(2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
DMRVITQ	CA	CAS 1448347-49-6
DMRVITQ	DE	Acute myeloid leukemia; Cholangiocarcinoma

DM2OZ3G	ID	DM2OZ3G
DM2OZ3G	DN	Ixabepilone
DM2OZ3G	HS	Approved
DM2OZ3G	SN	Azaepothilone B; BMS-247550; Ixempra (TN)
DM2OZ3G	CP	Bristol-Myers Squibb
DM2OZ3G	DT	Small molecular drug
DM2OZ3G	PC	6445540
DM2OZ3G	MW	506.7
DM2OZ3G	FM	C27H42N2O5S
DM2OZ3G	IC	InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1
DM2OZ3G	CS	C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](NC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C
DM2OZ3G	IK	FABUFPQFXZVHFB-PVYNADRNSA-N
DM2OZ3G	IU	(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione
DM2OZ3G	CA	CAS 219989-84-1
DM2OZ3G	CB	CHEBI:63605
DM2OZ3G	DE	Breast cancer

DMXW92T	ID	DMXW92T
DMXW92T	DN	Ixekizumab
DMXW92T	HS	Approved
DMXW92T	SN	LY2439821
DMXW92T	CP	Eli Lilly
DMXW92T	DT	Monoclonal antibody
DMXW92T	SQ	Heavy Chain Sequence: QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG</sequence>    <sequence format="FASTA">&gt;Light Chain SequenceDIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMXW92T	DE	Plaque psoriasis; Psoriatic arthritis

DMKJ8LB	ID	DMKJ8LB
DMKJ8LB	DN	Josamycin
DMKJ8LB	HS	Approved
DMKJ8LB	SN	Josacine; Josamicina; Josamycine; Josamycinum; EN 141; Kitasamycin A3; Leucomycin A3; Turimycin A5; Antibiotic yl-704 A3; Iosalide (TN); Josacine (TN); Josalid (TN); Josamicina [INN-Spanish]; Josamina (TN); Josamy (TN); Josamycin (TN); Josamycine [INN-French]; Josamycinum [INN-Latin]; Wilprafen (TN); Yl-704 A3; Josamycin [USAN:INN:JAN]; Josamycin (JP15/USAN/INN); Dro-2H-pyran-3-yl 3-methylbutanoate; Leucomycin V, 3-acetate 4B-(3-methylbutanoate); Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate); Leucomycin V,3-acetate 4(sup beta)-(3-methylbutanoate)
DMKJ8LB	TC	Antibiotics
DMKJ8LB	DT	Small molecular drug
DMKJ8LB	PC	5282165
DMKJ8LB	MW	828
DMKJ8LB	FM	C42H69NO15
DMKJ8LB	IC	InChI=1S/C42H69NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29-31,34-41,46,49-50H,15,17,19-22H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1
DMKJ8LB	CS	C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O
DMKJ8LB	IK	XJSFLOJWULLJQS-NGVXBBESSA-N
DMKJ8LB	IU	[(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4-acetyloxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 3-methylbutanoate
DMKJ8LB	CA	CAS 16846-24-5
DMKJ8LB	CB	CHEBI:31739
DMKJ8LB	DE	Bacterial infection

DM2DMPO	ID	DM2DMPO
DM2DMPO	DN	Kanamycin
DM2DMPO	HS	Approved
DM2DMPO	SN	Aspidium; KAN; Kanamicina; Kanamycine; Kanamycinum; Kantrex; Klebcil; KANAMYCIN A; Kanamicina [Italian]; Kanamycin A tetracation; Kanamycin Base; Kanamycin monosulfate; Kanamycin sulfate; Kenamycin A; Liposomal Kanamycin; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin monosulfate (JP15); Kanamycinsulfate (JP15); Kanamycin sulfate (TN); Kanamycin sulfate (USP); Kanamycine [INN-French]; Kanamycinum [INN-Latin]; Kantrex (TN); Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diazaniumyl-3-(6-azaniumyl-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-azaniumyl-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside
DM2DMPO	CP	Sigma Chemical Company
DM2DMPO	TC	Antibiotics
DM2DMPO	DT	Small molecular drug
DM2DMPO	PC	6032
DM2DMPO	MW	484.5
DM2DMPO	FM	C18H36N4O11
DM2DMPO	IC	InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
DM2DMPO	CS	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N
DM2DMPO	IK	SBUJHOSQTJFQJX-NOAMYHISSA-N
DM2DMPO	IU	(2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
DM2DMPO	CA	CAS 59-01-8
DM2DMPO	CB	CHEBI:17630
DM2DMPO	DE	Bacterial infection

DMITFB8	ID	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	HS	Approved
DMITFB8	SN	Kanamicina; Kanamicina [Italian]; Kanamycin Base; EQK9Q303C5; KANAMYCIN A; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin sulfate; Kanamycine; Kanamycine [INN-French]; Kanamycinum; Kanamycinum [INN-Latin]; kanamycin; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; BRN 0061647; C18H36N4O11; CHEBI:17630; EINECS 200-411-7; Glucopyranoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-, D-; HSDB 3107; KAN; UNII-EQK9Q303C5
DMITFB8	PC	6032
DMITFB8	MW	484.5
DMITFB8	FM	C18H36N4O11
DMITFB8	IC	SBUJHOSQTJFQJX-NOAMYHISSA-N
DMITFB8	CS	C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N
DMITFB8	IK	1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
DMITFB8	IU	(2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
DMITFB8	CA	CAS 59-01-8
DMITFB8	CB	CHEBI:17630
DMITFB8	DE	Pulmonary tuberculosis

DMT5HA4	ID	DMT5HA4
DMT5HA4	DN	Ketamine
DMT5HA4	HS	Approved
DMT5HA4	SN	Calypsol; Cetamina; Green; Ketaject; Ketalar; Ketaminum; Ketanest; Ketoject; Ketolar; Tekam; KETAMINE HCL; Ketalar base; Ketamine Base; Special K; Special K [street name]; CLSTA 20; T385; Cetamina [INN-Spanish]; Dl-Ketamine; Ketalar (TN); Ketamine (INN); Ketamine [INN:BAN]; Ketaminum [INN-Latin]; Ketanest (TN); Ketaset (TN); Tekam (TN); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-(9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)-(9CI); Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)-(8CI); (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
DMT5HA4	CP	Pfizer Pharmaceuticals
DMT5HA4	TC	Analgesics
DMT5HA4	DT	Small molecular drug
DMT5HA4	PC	3821
DMT5HA4	MW	237.72
DMT5HA4	FM	C13H16ClNO
DMT5HA4	IC	InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3
DMT5HA4	CS	CNC1(CCCCC1=O)C2=CC=CC=C2Cl
DMT5HA4	IK	YQEZLKZALYSWHR-UHFFFAOYSA-N
DMT5HA4	IU	2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
DMT5HA4	CA	CAS 6740-88-1
DMT5HA4	CB	CHEBI:6121
DMT5HA4	DE	Anaesthesia

DMVLMW6	ID	DMVLMW6
DMVLMW6	DN	Ketanserin
DMVLMW6	HS	Approved
DMVLMW6	SN	Ketanserina; Ketanserine; Ketanserinum; Ketaserin; Perketal; Serefrex; Sufrexal; Taseron; Ketanserina [INN-Spanish]; Ketanserine [INN-French]; Ketanserinum [INN-Latin]; R 41,468; R-41468; [3H]-Ketanserin; Ketanserin (USAN/INN); Ketanserin [USAN:BAN:INN]; R-41,468; (+)-3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2,4-(1H,3H)-quinazolinedione; 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)quinazoline-2,4(1H,3H)-dione; 3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1H-quinazoline-2,4-dione; 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione
DMVLMW6	CP	Janssen Pharmaceutica
DMVLMW6	TC	Antihypertensive Agents
DMVLMW6	DT	Small molecular drug
DMVLMW6	PC	3822
DMVLMW6	MW	395.4
DMVLMW6	FM	C22H22FN3O3
DMVLMW6	IC	InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
DMVLMW6	CS	C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O
DMVLMW6	IK	FPCCSQOGAWCVBH-UHFFFAOYSA-N
DMVLMW6	IU	3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione
DMVLMW6	CA	CAS 74050-98-9
DMVLMW6	CB	CHEBI:6123
DMVLMW6	DE	Hypertension

DMM3L6Z	ID	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	HS	Approved
DMM3L6Z	SN	Ketobemidone hydrochloride; Cliradon hydrochloride; Ketobimedon hydrochloride; UNII-U9U6LTV80K; 5965-49-1; EINECS 227-749-8; U9U6LTV80K; 1-Methyl-4-(m-hydroxyphenyl)piperidine-4-ethylketone hydrochloride; Ketobemidone HCl; 1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-, hydrochloride; Ketogan (TN); AC1L2YOJ; 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one hydrochloride(1:1); AC1Q5G7W; SCHEMBL9706814; 469-79-4 (Parent); DTXSID00208327; LS-123062; D08101
DMM3L6Z	DT	Small molecular drug
DMM3L6Z	PC	10101
DMM3L6Z	MW	247.33
DMM3L6Z	FM	C15H21NO2
DMM3L6Z	IC	InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3
DMM3L6Z	CS	CCC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)O
DMM3L6Z	IK	ALFGKMXHOUSVAD-UHFFFAOYSA-N
DMM3L6Z	IU	1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one
DMM3L6Z	CA	CAS 469-79-4
DMM3L6Z	CB	CHEBI:6125
DMM3L6Z	DE	Pain

DMPZI3Q	ID	DMPZI3Q
DMPZI3Q	DN	Ketoconazole
DMPZI3Q	HS	Approved
DMPZI3Q	SN	KCZ; KTZ; K 1003; R 41400; R41400; KS-1205; KW-1414; Perkhotal (TN); R 41,400; R-41400; R41,400; Ketoconazole [USAN:INN:BAN:JAN]; Nizoral, Extina, Xolegel, Kuric, Ketoconazole; Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
DMPZI3Q	CP	Johnson & Johnson 
DMPZI3Q	TC	Antifungal Agents
DMPZI3Q	DT	Small molecular drug
DMPZI3Q	PC	456201
DMPZI3Q	MW	531.4
DMPZI3Q	FM	C26H28Cl2N4O4
DMPZI3Q	IC	InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1
DMPZI3Q	CS	CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl
DMPZI3Q	IK	XMAYWYJOQHXEEK-OZXSUGGESA-N
DMPZI3Q	IU	1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
DMPZI3Q	CA	CAS 65277-42-1
DMPZI3Q	CB	CHEBI:48336
DMPZI3Q	DE	Fungal infection

DMRKXPT	ID	DMRKXPT
DMRKXPT	DN	Ketoprofen
DMRKXPT	HS	Approved
DMRKXPT	SN	Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid
DMRKXPT	CP	ProEthic Pharmaceuticals
DMRKXPT	TC	Analgesics
DMRKXPT	DT	Small molecular drug
DMRKXPT	PC	3825
DMRKXPT	MW	254.28
DMRKXPT	FM	C16H14O3
DMRKXPT	IC	InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
DMRKXPT	CS	CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
DMRKXPT	IK	DKYWVDODHFEZIM-UHFFFAOYSA-N
DMRKXPT	IU	2-(3-benzoylphenyl)propanoic acid
DMRKXPT	CA	CAS 22071-15-4
DMRKXPT	CB	CHEBI:6128
DMRKXPT	DE	Pain; Osteoarthritis; Musculoskeletal pain; Migraine

DMI4EL5	ID	DMI4EL5
DMI4EL5	DN	Ketorolac
DMI4EL5	HS	Approved
DMI4EL5	SN	Ketoralac; Ketorolaco; Ketorolacum; Macril; Ketorolaco [Spanish]; Ketorolacum [Latin]; RS 37619; Acular (TN); Ketorolac (INN); Ketorolac [INN:BAN]; RS-37619; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; (+-)-isomer; (+/-)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
DMI4EL5	CP	Laboratorios Syntex SA 
DMI4EL5	TC	Analgesics
DMI4EL5	DT	Small molecular drug
DMI4EL5	PC	3826
DMI4EL5	MW	255.27
DMI4EL5	FM	C15H13NO3
DMI4EL5	IC	InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)
DMI4EL5	CS	C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O
DMI4EL5	IK	OZWKMVRBQXNZKK-UHFFFAOYSA-N
DMI4EL5	IU	5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
DMI4EL5	CA	CAS 74103-06-3
DMI4EL5	CB	CHEBI:76223
DMI4EL5	DE	Postoperative inflammation

DM74XKS	ID	DM74XKS
DM74XKS	DN	Ketotifen
DM74XKS	HS	Approved
DM74XKS	SN	Ketotifen [INN:BAN]; Ketotifene; Ketotifene [INN-French]; Ketotifeno; Ketotifeno [INN-Spanish]; Ketotifenum; Ketotifenum [INN-Latin]; HC 20-511; ZCVMWBYGMWKGHF-UHFFFAOYSA-N; Zaditor; ketotifen; 34580-13-7; 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one; BRN 3983897; CHEMBL534; EINECS 252-099-7; HSDB 7283; UNII-X49220T18G
DM74XKS	PC	3827
DM74XKS	MW	309.4
DM74XKS	FM	C19H19NOS
DM74XKS	IC	ZCVMWBYGMWKGHF-UHFFFAOYSA-N
DM74XKS	CS	CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
DM74XKS	IK	1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3
DM74XKS	IU	2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
DM74XKS	CA	CAS 34580-13-7
DM74XKS	CB	CHEBI:92511
DM74XKS	DE	Conjunctivitis

DMOVY05	ID	DMOVY05
DMOVY05	DN	Ketotifen
DMOVY05	HS	Approved
DMOVY05	SN	Ketotifene; Ketotifeno; Ketotifenum; Ketotifin; Ketotiphen; Ketotiphene; Zaditor; Ketotifene fumarate; Alaway (TN); HC 20-511; Ketotifen (INN); Ketotifen [INN:BAN]; Ketotifene [INN-French]; Ketotifeno [INN-Spanish]; Ketotifenum [INN-Latin]; Zaditor (TN); 10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (2E)-2-butenedioate (1:1); 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one; 4-(1-Methyl-4-piperidylidene)-9-hydrobenzo[a]thiopheno[3,2-d][7]annulen-10-one; 4-(1-Methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
DMOVY05	CP	Norvatis Phamaceuticals Corporation
DMOVY05	TC	Antiallergic Agents
DMOVY05	DT	Small molecular drug
DMOVY05	PC	3827
DMOVY05	MW	309.4
DMOVY05	FM	C19H19NOS
DMOVY05	IC	InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3
DMOVY05	CS	CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
DMOVY05	IK	ZCVMWBYGMWKGHF-UHFFFAOYSA-N
DMOVY05	IU	2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
DMOVY05	CA	CAS 34580-13-7
DMOVY05	CB	CHEBI:92511
DMOVY05	DE	Allergic conjunctivitis

DM0KAE6	ID	DM0KAE6
DM0KAE6	DN	Kombiglyze XR/Komboglyze FDC
DM0KAE6	HS	Approved
DM0KAE6	SN	Metformin mixture with saxagliptin; 1198772-17-6; Kombiglyze; Komboglyze; Kombiglyze XR; Saxagliptin / metformin; Metformin / saxagliptin
DM0KAE6	CP	AstraZeneca
DM0KAE6	DT	Small molecular drug
DM0KAE6	PC	56842229
DM0KAE6	MW	444.6
DM0KAE6	FM	C22H36N8O2
DM0KAE6	IC	InChI=1S/C18H25N3O2.C4H11N5/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17;1-9(2)4(7)8-3(5)6/h10-15,23H,1-7,9,20H2;1-2H3,(H5,5,6,7,8)/t10?,11?,12?,13-,14-,15+,17?,18?;/m1./s1
DM0KAE6	CS	CN(C)C(=N)N=C(N)N.C1[C@@H](N([C@H]2C1C2)C(=O)[C@@H](C34CC5CC(C3)CC(C5)(C4)O)N)C#N
DM0KAE6	IK	QUKZWYNGKYRRKE-RIKNOMPASA-N
DM0KAE6	IU	(1R,3R)-2-[(2R)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;3-(diaminomethylidene)-1,1-dimethylguanidine
DM0KAE6	CA	CAS 1198772-17-6
DM0KAE6	DE	Diabetic complication

DMSA4HZ	ID	DMSA4HZ
DMSA4HZ	DN	KU-0058948
DMSA4HZ	HS	Approved
DMSA4HZ	SN	CHEMBL380648; KU-0058948; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
DMSA4HZ	DT	Small molecular drug
DMSA4HZ	PC	11291932
DMSA4HZ	MW	380.4
DMSA4HZ	FM	C21H21FN4O2
DMSA4HZ	IC	InChI=1S/C21H21FN4O2/c22-18-7-6-14(12-17(18)21(28)26-10-3-8-23-9-11-26)13-19-15-4-1-2-5-16(15)20(27)25-24-19/h1-2,4-7,12,23H,3,8-11,13H2,(H,25,27)
DMSA4HZ	CS	C1CNCCN(C1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F
DMSA4HZ	IK	HGEPGGJUGUMFHT-UHFFFAOYSA-N
DMSA4HZ	IU	4-[[3-(1,4-diazepane-1-carbonyl)-4-fluorophenyl]methyl]-2H-phthalazin-1-one
DMSA4HZ	DE	Ovarian cancer

DMK8U72	ID	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	HS	Approved
DMK8U72	SN	Albetol; Ibidomide; Labetalolum; Labetolol; NORMOZIDE; AH 5158; AH-5158; Labetalol (INN); Labetalol [INN:BAN]; Labetalolum [INN-Latin]; Normodyne (TN); Sch-19927; Trandate (TN); 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
DMK8U72	CP	Allen & Handbury
DMK8U72	TC	Antihypertensive Agents
DMK8U72	DT	Small molecular drug
DMK8U72	PC	3869
DMK8U72	MW	328.4
DMK8U72	FM	C19H24N2O3
DMK8U72	IC	InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)
DMK8U72	CS	CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O
DMK8U72	IK	SGUAFYQXFOLMHL-UHFFFAOYSA-N
DMK8U72	IU	2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide
DMK8U72	CA	CAS 36894-69-6
DMK8U72	CB	CHEBI:6343
DMK8U72	DE	Hypertension

DMVM6QR	ID	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	HS	Approved
DMVM6QR	SN	Erlosamide; Harkoseride; Vimpat; Erlosamide [INN]; Lacosamide [USAN]; ADD 234037; SPM 927; ADD-234037; SPM-927; SPM-929; Erlosamide, Vimpat, Lacosamide; Lacosamide (USAN/INN); (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-acetamido-N-benzyl-3-methoxypropanamide
DMVM6QR	CP	Schwarz Pharma
DMVM6QR	TC	Analgesics
DMVM6QR	DT	Small molecular drug
DMVM6QR	PC	219078
DMVM6QR	MW	250.29
DMVM6QR	FM	C13H18N2O3
DMVM6QR	IC	InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
DMVM6QR	CS	CC(=O)N[C@H](COC)C(=O)NCC1=CC=CC=C1
DMVM6QR	IK	VPPJLAIAVCUEMN-GFCCVEGCSA-N
DMVM6QR	IU	(2R)-2-acetamido-N-benzyl-3-methoxypropanamide
DMVM6QR	CA	CAS 175481-36-4
DMVM6QR	CB	CHEBI:135939
DMVM6QR	DE	Convulsion; Diabetic neuropathy; Epilepsy

DMA7QTC	ID	DMA7QTC
DMA7QTC	DN	Lactoferrin
DMA7QTC	HS	Approved
DMA7QTC	SN	Lactoferroxin B; Lactoferroxin-B; AC1L4UTC; Arg-tyr-tyr-gly-tyr-och3; AC1Q5JP4; methyl n5-(diaminomethylidene)-l-ornithyl-l-tyrosyl-l-tyrosylglycyl-l-tyrosinate; 117667-26-2; L-Tyrosine, N-(N-(N-(N-L-arginyl-L-tyrosyl)-L-tyrosyl)glycyl)-, methyl ester; methyl (2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoate
DMA7QTC	DT	Small molecular drug
DMA7QTC	PC	126456119
DMA7QTC	MW	3125.8
DMA7QTC	FM	C141H226N46O29S3
DMA7QTC	IC	InChI=1S/C141H226N46O29S3/c1-11-77(6)111(133(212)186-112(80(9)189)134(213)183-106(74-218)130(209)184-110(76(4)5)132(211)176-97(49-32-61-161-141(155)156)120(199)170-93(45-28-57-157-137(147)148)116(195)166-78(7)113(192)180-103(136(215)216)66-82-36-16-13-17-37-82)185-128(207)104(72-188)181-131(210)107-50-33-62-187(107)135(214)79(8)165-109(191)71-164-115(194)100(64-75(2)3)177-121(200)92(44-24-27-56-144)168-117(196)91(43-23-26-55-143)169-125(204)99(53-63-219-10)175-119(198)94(46-29-58-158-138(149)150)172-126(205)101(67-83-69-162-88-40-20-18-38-85(83)88)179-124(203)98(51-52-108(146)190)174-127(206)102(68-84-70-163-89-41-21-19-39-86(84)89)178-122(201)96(48-31-60-160-140(153)154)171-118(197)95(47-30-59-159-139(151)152)173-129(208)105(73-217)182-123(202)90(42-22-25-54-142)167-114(193)87(145)65-81-34-14-12-15-35-81/h12-21,34-41,69-70,75-80,87,90-107,110-112,162-163,188-189,217-218H,11,22-33,42-68,71-74,142-145H2,1-10H3,(H2,146,190)(H,164,194)(H,165,191)(H,166,195)(H,167,193)(H,168,196)(H,169,204)(H,170,199)(H,171,197)(H,172,205)(H,173,208)(H,174,206)(H,175,198)(H,176,211)(H,177,200)(H,178,201)(H,179,203)(H,180,192)(H,181,210)(H,182,202)(H,183,213)(H,184,209)(H,185,207)(H,186,212)(H,215,216)(H4,147,148,157)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t77-,78-,79-,80+,87-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,110-,111-,112-/m0/s1
DMA7QTC	CS	CC[C@H](C)[C@@H](C(=N[C@@H]([C@@H](C)O)C(=N[C@@H](CS)C(=N[C@@H](C(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](C)C(=N[C@@H](CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C([C@H](CO)N=C([C@@H]2CCCN2C(=O)[C@H](C)N=C(CN=C([C@H](CC(C)C)N=C([C@H](CCCCN)N=C([C@H](CCCCN)N=C([C@H](CCSC)N=C([C@H](CCCNC(=N)N)N=C([C@H](CC3=CNC4=CC=CC=C43)N=C([C@H](CCC(=N)O)N=C([C@H](CC5=CNC6=CC=CC=C65)N=C([C@H](CCCNC(=N)N)N=C([C@H](CCCNC(=N)N)N=C([C@H](CS)N=C([C@H](CCCCN)N=C([C@H](CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O
DMA7QTC	IK	CSSYQJWUGATIHM-IKGCZBKSSA-N
DMA7QTC	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-4-methylsulfanylbutylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-4-methylpentylidene]amino]-1-hydroxyethylidene]amino]propanoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-methylpentylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxypropylidene]amino]-3-phenylpropanoic acid
DMA7QTC	CA	CAS 151186-19-5
DMA7QTC	DE	Solid tumour/cancer

DMV7OPN	ID	DMV7OPN
DMV7OPN	DN	Lactulose
DMV7OPN	HS	Approved
DMV7OPN	SN	Lactulosa; Lactulosa [INN-Spanish]; Lactulosa [Spanish]; Lactulosum; Lactulosum [INN-Latin]; Lactulosum [Latin]; Laevolac; Lattulosio [Italian]; Laxilose; Portalac; lactulose; 4-O-beta-D-Galactopyranosyl-D-fructofuranose; 4-O-beta-D-Galactopyranosyl-D-fructose; Acilac; Bifiteral; Cephulac; Cholac; Chronulac; Constilac; Constulose; D-Lactulose; Duphalac; Enulose; Generlac; Heptalac; Isolactose; 4-O-beta-D-galactopyranosyl-beta-D-fructofuranose; 9XH2P2N8EP; BRN 0093773; BRN 6278818; EINECS 225-027-7; UNII-9XH2P2N8EP
DMV7OPN	PC	11333
DMV7OPN	MW	342.3
DMV7OPN	FM	C12H22O11
DMV7OPN	IC	JCQLYHFGKNRPGE-FCVZTGTOSA-N
DMV7OPN	CS	C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O
DMV7OPN	IK	1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12-/m1/s1
DMV7OPN	IU	(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMV7OPN	CA	CAS 4618-18-2
DMV7OPN	CB	CHEBI:6359
DMV7OPN	DE	Hepatic encephalopathy

DMZDN4W	ID	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	HS	Approved
DMZDN4W	SN	ALA; Alaninum; LPG; Polyalanine; A-Alanine; A-Aminopropionic acid; Alanina [DCIT,Spanish]; Alanine (USP); L-A-Aminopropionicacid; L-Alanine (9CI); L-Alanine (JAN); L-Alanine, homopolymer; L-Alanine, labeled with tritium; L-a-Alanine; L-a-Aminopropionic acid; Poly-DL-alanine; L-Alanine, labeled with carbon-14; Alanine, L-(7CI,8CI); F4F207FF-8FF8-4789-99A1-147AE0A36673; L-Alanine, N-coco alkyl derivs.; Propanoic acid, 2-amino-, (S); (C14)L-Alanine; (S)-2-Aminopropionic acid; 14C-L-Alanine
DMZDN4W	TC	Dietary supplement
DMZDN4W	DT	Small molecular drug
DMZDN4W	PC	5950
DMZDN4W	MW	89.09
DMZDN4W	FM	C3H7NO2
DMZDN4W	IC	InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1
DMZDN4W	CS	C[C@@H](C(=O)O)N
DMZDN4W	IK	QNAYBMKLOCPYGJ-REOHCLBHSA-N
DMZDN4W	IU	(2S)-2-aminopropanoic acid
DMZDN4W	CA	CAS 56-41-7
DMZDN4W	CB	CHEBI:16977
DMZDN4W	DE	Glioma; Dietary shortage

DMANBR7	ID	DMANBR7
DMANBR7	DN	L-alanyl-l-glutamine
DMANBR7	HS	Approved
DMANBR7	SN	Dipeptiven (TN)
DMANBR7	DT	Small molecular drug
DMANBR7	PC	123935
DMANBR7	MW	217.22
DMANBR7	FM	C8H15N3O4
DMANBR7	IC	InChI=1S/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)/t4-,5-/m0/s1
DMANBR7	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DMANBR7	IK	HJCMDXDYPOUFDY-WHFBIAKZSA-N
DMANBR7	IU	(2S)-5-amino-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoic acid
DMANBR7	CA	CAS 39537-23-0
DMANBR7	CB	CHEBI:73788
DMANBR7	DE	Mucositis

DMI347A	ID	DMI347A
DMI347A	DN	Lamivudine
DMI347A	HS	Approved
DMI347A	SN	lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; Heptivir; CIS-LAMIVUDINE; (-)-2'-Deoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; (-)-BCH-189; Lamivudine [USAN:BAN:INN]; GR109714X; beta-L-3'-Thia-2',3'-dideoxycytidine; beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)NGPB-21; 136891-12-8; 2',3'-Dideoxy-3'-thiacytidine; (-)-BCH 189; UNII-2T8Q726O95; HSDB 7155; GR 109714X;  DTHC; LMV; Lamivir; Zefix; BCH 189; BCH189; BCH-790; DRG-0126; Epivir (TN); Epivir(TM); GG-714; HHA & 3TC; HHA & Lamivudine; Heptovir (TN); Lamivudine & GNA; Zeffix (TN); Epivir-HBV (TN); Lamivudine [USAN:INN:BAN]; Lamivudine (JAN/USP/INN); Lamivudine, (2S-cis)-Isomer; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Efavirenz/lamivudine/tenofovir fumarate
DMI347A	CP	Glaxo Smith Kline Pharmaceuticals
DMI347A	TC	Anti-HIV Agents
DMI347A	DT	Small molecular drug
DMI347A	PC	60825
DMI347A	MW	229.26
DMI347A	FM	C8H11N3O3S
DMI347A	IC	InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
DMI347A	CS	C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N
DMI347A	IK	JTEGQNOMFQHVDC-NKWVEPMBSA-N
DMI347A	IU	4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
DMI347A	CA	CAS 134678-17-4
DMI347A	CB	CHEBI:63577
DMI347A	DE	Chronic HBV infection; Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection

DM8SXYG	ID	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	HS	Approved
DM8SXYG	SN	Crisomet; Labileno; Lamictal; Lamictin; Lamiktal; Lamitor; Lamotrigina; Lamotriginum; Desitin Brand of Lamotrigine; Faes Brand of Lamotrigine; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; Lamictal Cd; Lamictal ODT; Lamictal XR; Lamotrigina [Spanish]; Lamotriginum [Latin]; BW 430C; GI 267119X; GW 273293; L 3791; BW-430C; EUR-1048; Lamictal (TN); Lamictin (TN); Lamotrigine [USAN:INN:BAN]; Lamotrigine (JAN/USAN/INN); 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
DM8SXYG	CP	GSK
DM8SXYG	TC	Anticonvulsants
DM8SXYG	DT	Small molecular drug
DM8SXYG	PC	3878
DM8SXYG	MW	256.089
DM8SXYG	FM	C9H7Cl2N5
DM8SXYG	IC	InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
DM8SXYG	CS	C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
DM8SXYG	IK	PYZRQGJRPPTADH-UHFFFAOYSA-N
DM8SXYG	IU	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
DM8SXYG	CA	CAS 84057-84-1
DM8SXYG	CB	CHEBI:6367
DM8SXYG	DE	Bipolar disorder; Epilepsy

DMEH7YU	ID	DMEH7YU
DMEH7YU	DN	Lanadelumab
DMEH7YU	HS	Approved
DMEH7YU	SN	Lanadelumab [USAN]; UNII-2372V1TKXK; 2372V1TKXK; DX-2930
DMEH7YU	CP	Dyax/Shire
DMEH7YU	DE	Hereditary angioedema

DMG6ZU4	ID	DMG6ZU4
DMG6ZU4	DN	Lanreotide acetate
DMG6ZU4	HS	Approved
DMG6ZU4	SN	Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide;  Somatuline lp (TN); Lanreotide Autogel
DMG6ZU4	CP	Beaufour-Ipsen
DMG6ZU4	DT	Small molecular drug
DMG6ZU4	PC	71349
DMG6ZU4	MW	1096.3
DMG6ZU4	FM	C54H69N11O10S2
DMG6ZU4	IC	InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)
DMG6ZU4	CS	CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N
DMG6ZU4	IK	PUDHBTGHUJUUFI-UHFFFAOYSA-N
DMG6ZU4	IU	10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMG6ZU4	CA	CAS 108736-35-2
DMG6ZU4	DE	Acromegaly

DMXYLQ3	ID	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	HS	Approved
DMXYLQ3	SN	Lancid; Lanproton; Lansopep; Lansoprazol; Lansoprazol [INN-Spanish]; Lansoprazole [USAN:BAN:INN]; Lansoprazolum; Lansoprazolum [INN-Latin]; Lansox; Lanston; Lanzol-30; Lanzopral; Lanzor; Lasoprol; Limpidex; Mesactol; Monolitum; Ogastro; Opiren; Agopton; Aprazol; Bamalite; Blason; Compraz; Ilsatec; Ketian; Prevacid; Prevacid 24HR; Prevacid Iv; Prevacid NapraPAC; Prevacid SoluTab; Prezal; Pro Ulco; Prosogan; Suprecid; Takepron; Zoprol; lansoprazole; 103577-45-3; A-65006; AG 1749; AG-1749; CHEBI:6375; Dakar; HSDB 7204; Lanz; Lanzo; Ogast; Promp; Ulpax; Zoton
DMXYLQ3	PC	3883
DMXYLQ3	MW	369.4
DMXYLQ3	FM	C16H14F3N3O2S
DMXYLQ3	IC	MJIHNNLFOKEZEW-UHFFFAOYSA-N
DMXYLQ3	CS	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
DMXYLQ3	IK	1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
DMXYLQ3	IU	2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DMXYLQ3	CA	CAS 103577-45-3
DMXYLQ3	CB	CHEBI:6375
DMXYLQ3	DE	Duodenal ulcer

DMMJQSH	ID	DMMJQSH
DMMJQSH	DN	Lanthanum carbonate
DMMJQSH	HS	Approved
DMMJQSH	SN	Fosrenol; Foznol; Lambda; Lanthanum; Phosphate binding agent, Shire/Johnson Matthey; Project Lambda, Shire/Johnson Matthey
DMMJQSH	CP	Shire Pharm
DMMJQSH	DT	Small molecular drug
DMMJQSH	PC	168924
DMMJQSH	MW	457.84
DMMJQSH	FM	C3La2O9
DMMJQSH	IC	InChI=1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6
DMMJQSH	CS	C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3]
DMMJQSH	IK	NZPIUJUFIFZSPW-UHFFFAOYSA-H
DMMJQSH	IU	lanthanum(3+);tricarbonate
DMMJQSH	CA	CAS 587-26-8
DMMJQSH	DE	Hypophosphatasia

DM3BH1Y	ID	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	HS	Approved
DM3BH1Y	SN	FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)
DM3BH1Y	CP	GlaxoSmithKline
DM3BH1Y	TC	Anticancer Agents
DM3BH1Y	DT	Small molecular drug
DM3BH1Y	PC	208908
DM3BH1Y	MW	581.1
DM3BH1Y	FM	C29H26ClFN4O4S
DM3BH1Y	IC	InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
DM3BH1Y	CS	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
DM3BH1Y	IK	BCFGMOOMADDAQU-UHFFFAOYSA-N
DM3BH1Y	IU	N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
DM3BH1Y	CA	CAS 231277-92-2
DM3BH1Y	CB	CHEBI:49603
DM3BH1Y	DE	Breast cancer

DM26CQR	ID	DM26CQR
DM26CQR	DN	Larotrectinib
DM26CQR	HS	Approved
DM26CQR	SN	UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470
DM26CQR	CP	Loxo Oncology/Bayer
DM26CQR	PC	46188928
DM26CQR	MW	428.4
DM26CQR	FM	C21H22F2N6O2
DM26CQR	IC	InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1
DM26CQR	CS	C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C=CC(=C5)F)F
DM26CQR	IK	NYNZQNWKBKUAII-KBXCAEBGSA-N
DM26CQR	IU	(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
DM26CQR	CA	CAS 1223403-58-4
DM26CQR	DE	Solid tumour/cancer

DMSQ1JV	ID	DMSQ1JV
DMSQ1JV	DN	LAS-34273
DMSQ1JV	HS	Approved
DMSQ1JV	SN	Bretaris; Eklira; Aclidinium bromide; LAS-W-330; [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oct-8-yl] 2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide
DMSQ1JV	CP	Almirall
DMSQ1JV	DT	Small molecular drug
DMSQ1JV	PC	11519741
DMSQ1JV	MW	564.6
DMSQ1JV	FM	C26H30BrNO4S2
DMSQ1JV	IC	InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1
DMSQ1JV	CS	C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-]
DMSQ1JV	IK	XLAKJQPTOJHYDR-QTQXQZBYSA-M
DMSQ1JV	IU	[(3R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide
DMSQ1JV	CA	CAS 320345-99-1
DMSQ1JV	CB	CHEBI:65344
DMSQ1JV	DE	Chronic obstructive pulmonary disease

DMXLVDT	ID	DMXLVDT
DMXLVDT	DN	Lasmiditan
DMXLVDT	HS	Approved
DMXLVDT	SN	COL-144; LY-573144; Migraine therapy, CoLucid
DMXLVDT	CP	Colucid pharmaceuticals
DMXLVDT	DT	Small molecular drug
DMXLVDT	PC	11610526
DMXLVDT	MW	377.4
DMXLVDT	FM	C19H18F3N3O2
DMXLVDT	IC	InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)
DMXLVDT	CS	CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F
DMXLVDT	IK	XEDHVZKDSYZQBF-UHFFFAOYSA-N
DMXLVDT	IU	2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide
DMXLVDT	CA	CAS 439239-90-4
DMXLVDT	DE	Migraine

DMHA18P	ID	DMHA18P
DMHA18P	DN	Lasofoxifene
DMHA18P	HS	Approved
DMHA18P	SN	Oporia; 180916-16-9; rac-Lasofoxifene; CP 336156; Fablyn; UNII-337G83N988; (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; CHEMBL328190; 337G83N988; (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol; 180915-78-0; CP-336,156; LASOFOXIFENE HCL; Lasofoxifene [INN:BAN]; AC1L50OI; SCHEMBL26815; GTPL7542; CTK8F1062; BDBM20606; DTXSID50171037; GXESHMAMLJKROZ-IAPPQJPRSA-N; ZINC3918428; BCP03626; AKOS030241621; AN-3516; BCP9000842; DB06202;  Oporia; Lasofoxifene [INN]; Cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; AZD9639
DMHA18P	CP	Pfizer
DMHA18P	DT	Small molecular drug
DMHA18P	PC	216416
DMHA18P	MW	413.5
DMHA18P	FM	C28H31NO2
DMHA18P	IC	InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1
DMHA18P	CS	C1CCN(C1)CCOC2=CC=C(C=C2)[C@H]3[C@H](CCC4=C3C=CC(=C4)O)C5=CC=CC=C5
DMHA18P	IK	GXESHMAMLJKROZ-IAPPQJPRSA-N
DMHA18P	IU	(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
DMHA18P	CA	CAS 180916-16-9
DMHA18P	CB	CHEBI:135938
DMHA18P	DE	Osteoporosis; Virus infection

DMANL0D	ID	DMANL0D
DMANL0D	DN	Latamoxef
DMANL0D	HS	Approved
DMANL0D	SN	Festamoxin; LMOX; Lamoxactam; Latamoxefum; Moxalactam; Disodium Moxalactam; Lilly 127935; Ly127935; Sid 734787; Latamoxef (INN); Latamoxef [INN:BAN]; Latamoxefum [INN-Latin]; Oxa-cephem; S-6059; (6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxopropanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 1-Oxacephalosporin; 7b-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7a-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid
DMANL0D	TC	Antibiotics
DMANL0D	DT	Small molecular drug
DMANL0D	PC	47499
DMANL0D	MW	520.5
DMANL0D	FM	C20H20N6O9S
DMANL0D	IC	InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1
DMANL0D	CS	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O
DMANL0D	IK	JWCSIUVGFCSJCK-CAVRMKNVSA-N
DMANL0D	IU	(6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMANL0D	CA	CAS 64952-97-2
DMANL0D	CB	CHEBI:599928
DMANL0D	DE	Bacterial infection

DMI5OXG	ID	DMI5OXG
DMI5OXG	DN	Latanoprost
DMI5OXG	HS	Approved
DMI5OXG	SN	Catioprost; Xalatan; Latanoprost free acid; L1167_SIGMA; PhXA41; XA41; AR-202; Nova-21027; PHXA-41; XA-41; Xalatan (TN); Latanoprost (JAN/USAN/INN); PhXA34 [as 15(R,S)-isomer]; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
DMI5OXG	CP	Pfizer Pharmaceuticals
DMI5OXG	TC	Antihypertensive Agents
DMI5OXG	DT	Small molecular drug
DMI5OXG	PC	5311221
DMI5OXG	MW	432.6
DMI5OXG	FM	C26H40O5
DMI5OXG	IC	InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1
DMI5OXG	CS	CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O
DMI5OXG	IK	GGXICVAJURFBLW-CEYXHVGTSA-N
DMI5OXG	IU	propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DMI5OXG	CA	CAS 130209-82-4
DMI5OXG	CB	CHEBI:6384
DMI5OXG	DE	Open-angle glaucoma; Glaucoma/ocular hypertension; Ocular disease

DMLFX7K	ID	DMLFX7K
DMLFX7K	DN	LCZ696
DMLFX7K	HS	Approved
DMLFX7K	SN	DTXSID50239500
DMLFX7K	CP	Novartis Pharmaceuticals
DMLFX7K	DT	Small molecular drug
DMLFX7K	PC	71300864
DMLFX7K	MW	970
DMLFX7K	FM	C48H64N6Na3O11+3
DMLFX7K	IC	InChI=1S/C24H29N5O3.C24H29NO5.3Na.3H2O/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;3*1H2/q;;3*+1;;;/t22-;17-,21+;;;;;;/m01....../s1
DMLFX7K	CS	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O.CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O.O.O.O.[Na+].[Na+].[Na+]
DMLFX7K	IK	ACXLNSLRLQLEAL-HWSDWTSLSA-N
DMLFX7K	IU	trisodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid;trihydrate
DMLFX7K	DE	Heart failure

DME6G97	ID	DME6G97
DME6G97	DN	Lefamulin
DME6G97	HS	Approved
DME6G97	SN	UNII-21904A5386; 1061337-51-6; CHEMBL3291398; 21904A5386; Lefamulin [INN]; Acetic acid, 2-(((1R,2R,4R)-4-amino-2-hydroxycyclohexyl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3ah-cyclopentacycloocten-8-yl ester; Lefamulin(BC-3781); Lefamulin [USAN:INN]; Acetic acid, 2-[[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten
DME6G97	CP	Nabriva Therapeutics King of Prussia, PA
DME6G97	PC	25185057
DME6G97	MW	507.7
DME6G97	FM	C28H45NO5S
DME6G97	IC	InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18-,20-,21-,22-,24+,25+,26-,27+,28+/m1/s1
DME6G97	CS	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C
DME6G97	IK	KPVIXBKIJXZQJX-FCEONZPQSA-N
DME6G97	IU	[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanylacetate
DME6G97	CA	CAS 1061337-51-6
DME6G97	DE	Acute bacterial skin infection; Community-acquired pneumonia

DMR8ONJ	ID	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	HS	Approved
DMR8ONJ	SN	Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
DMR8ONJ	CP	Sanofi-Aventis
DMR8ONJ	TC	Antiinflammatory Agents
DMR8ONJ	DT	Small molecular drug
DMR8ONJ	PC	3899
DMR8ONJ	MW	270.21
DMR8ONJ	FM	C12H9F3N2O2
DMR8ONJ	IC	InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
DMR8ONJ	CS	CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
DMR8ONJ	IK	VHOGYURTWQBHIL-UHFFFAOYSA-N
DMR8ONJ	IU	5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
DMR8ONJ	CA	CAS 75706-12-6
DMR8ONJ	CB	CHEBI:6402
DMR8ONJ	DE	Arthritis; Multiple sclerosis

DM6Q7U4	ID	DM6Q7U4
DM6Q7U4	DN	Lenalidomide
DM6Q7U4	HS	Approved
DM6Q7U4	SN	Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
DM6Q7U4	CP	Celgene Corporation 
DM6Q7U4	TC	Anticancer Agents
DM6Q7U4	DT	Small molecular drug
DM6Q7U4	PC	216326
DM6Q7U4	MW	259.26
DM6Q7U4	FM	C13H13N3O3
DM6Q7U4	IC	InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
DM6Q7U4	CS	C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
DM6Q7U4	IK	GOTYRUGSSMKFNF-UHFFFAOYSA-N
DM6Q7U4	IU	3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
DM6Q7U4	CA	CAS 191732-72-6
DM6Q7U4	CB	CHEBI:63791
DM6Q7U4	DE	Multiple myeloma

DMB1IU4	ID	DMB1IU4
DMB1IU4	DN	Lenvatinib
DMB1IU4	HS	Approved
DMB1IU4	SN	E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
DMB1IU4	CP	Eisai Co. Ltd.
DMB1IU4	DT	Small molecular drug
DMB1IU4	PC	9823820
DMB1IU4	MW	426.9
DMB1IU4	FM	C21H19ClN4O4
DMB1IU4	IC	InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
DMB1IU4	CS	COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
DMB1IU4	IK	WOSKHXYHFSIKNG-UHFFFAOYSA-N
DMB1IU4	IU	4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
DMB1IU4	CA	CAS 417716-92-8
DMB1IU4	CB	CHEBI:85994
DMB1IU4	DE	Ovarian cancer; Hepatocellular carcinoma; Melanoma; Solid tumour/cancer; Non-small-cell lung cancer; Renal cell carcinoma; Thyroid cancer

DM1I3D5	ID	DM1I3D5
DM1I3D5	DN	Lepirudin
DM1I3D5	HS	Approved
DM1I3D5	SN	Refludan; Refludin; Aventis Behring Brand of Lepirudin; Aventis Brand Lepirudin; Aventis Pharma Brand of Lepirudin; Berlex Brand of Lepirudin; Hoechst Brand of Lepirudin; Lepirudin recombinant; Pharmion Brand of Lepirudin; Schering Brand of Lepirudin; Hbw 023; Hbw-023; 1-L-Leucine-2-L-threonine-63-desulfohirudin (Hirudomedicinalis isoform HV1); 1-Leu-2-thr-63-desulfohirudin
DM1I3D5	TC	Antithrombotic Agents
DM1I3D5	DT	Small molecular drug
DM1I3D5	SQ	DB00001 sequence: LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ
DM1I3D5	PC	118856773
DM1I3D5	MW	6979
DM1I3D5	FM	C287H440N80O111S6
DM1I3D5	IC	InChI=1S/C287H440N80O111S6/c1-24-132(17)225-280(470)345-162(87-126(5)6)236(426)306-111-209(396)320-181(116-370)267(457)344-176(101-220(416)417)238(428)307-105-203(390)316-152(61-74-213(402)403)243(433)321-146(40-29-32-80-288)241(431)339-171(96-198(298)385)259(449)326-153(56-69-194(294)381)250(440)351-186(121-482-479-118-183-240(430)310-107-202(389)313-148(54-67-192(292)379)233(423)303-108-206(393)317-170(95-197(297)384)258(448)322-147(41-30-33-81-289)242(432)350-187(272(462)359-225)122-483-480-119-184(269(459)323-150(60-73-212(400)401)235(425)304-110-208(395)319-180(115-369)266(456)342-174(99-201(301)388)265(455)357-223(130(13)14)278(468)355-183)352-254(444)165(90-129(11)12)335-270(460)185-120-481-484-123-188(354-263(453)178(103-222(420)421)347-283(473)230(137(22)375)362-264(454)168(93-141-48-52-144(378)53-49-141)346-282(472)228(135(20)373)361-232(422)145(291)86-125(3)4)273(463)363-229(136(21)374)281(471)330-158(65-78-217(410)411)249(439)348-179(114-368)239(429)309-106-204(391)315-151(55-68-193(293)380)244(434)340-172(97-199(299)386)260(450)334-164(89-128(9)10)253(443)353-185)271(461)358-224(131(15)16)279(469)364-227(134(19)372)277(467)311-112-205(392)314-149(59-72-211(398)399)234(424)305-113-210(397)356-231(138(23)376)286(476)367-85-37-45-191(367)276(466)331-160(42-31-34-82-290)284(474)365-83-35-43-189(365)274(464)328-154(57-70-195(295)382)248(438)349-182(117-371)268(458)338-169(94-142-104-302-124-312-142)257(447)341-173(98-200(300)387)261(451)343-175(100-219(414)415)237(427)308-109-207(394)318-177(102-221(418)419)262(452)337-166(91-139-38-27-26-28-39-139)255(445)327-155(62-75-214(404)405)245(435)325-159(66-79-218(412)413)251(441)360-226(133(18)25-2)285(475)366-84-36-44-190(366)275(465)329-157(64-77-216(408)409)246(436)324-156(63-76-215(406)407)247(437)336-167(92-140-46-50-143(377)51-47-140)256(446)333-163(88-127(7)8)252(442)332-161(287(477)478)58-71-196(296)383/h26-28,38-39,46-53,104,124-138,145-191,223-231,368-378H,24-25,29-37,40-45,54-103,105-123,288-291H2,1-23H3,(H2,292,379)(H2,293,380)(H2,294,381)(H2,295,382)(H2,296,383)(H2,297,384)(H2,298,385)(H2,299,386)(H2,300,387)(H2,301,388)(H,302,312)(H,303,423)(H,304,425)(H,305,424)(H,306,426)(H,307,428)(H,308,427)(H,309,429)(H,310,430)(H,311,467)(H,313,389)(H,314,392)(H,315,391)(H,316,390)(H,317,393)(H,318,394)(H,319,395)(H,320,396)(H,321,433)(H,322,448)(H,323,459)(H,324,436)(H,325,435)(H,326,449)(H,327,445)(H,328,464)(H,329,465)(H,330,471)(H,331,466)(H,332,442)(H,333,446)(H,334,450)(H,335,460)(H,336,437)(H,337,452)(H,338,458)(H,339,431)(H,340,434)(H,341,447)(H,342,456)(H,343,451)(H,344,457)(H,345,470)(H,346,472)(H,347,473)(H,348,439)(H,349,438)(H,350,432)(H,351,440)(H,352,444)(H,353,443)(H,354,453)(H,355,468)(H,356,397)(H,357,455)(H,358,461)(H,359,462)(H,360,441)(H,361,422)(H,362,454)(H,363,463)(H,364,469)(H,398,399)(H,400,401)(H,402,403)(H,404,405)(H,406,407)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,477,478)/t132-,133-,134+,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1
DM1I3D5	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CNC=N7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C
DM1I3D5	IK	FIBJDTSHOUXTKV-BRHMIFOHSA-N
DM1I3D5	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-15,76-bis(4-aminobutyl)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9,67-bis(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-18,47-bis(2-carboxyethyl)-24-(carboxymethyl)-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DM1I3D5	CA	CAS 138068-37-8
DM1I3D5	CB	CHEBI:142437
DM1I3D5	DE	Thrombocytopenia

DMPWSEM	ID	DMPWSEM
DMPWSEM	DN	Lercanidipine
DMPWSEM	HS	Approved
DMPWSEM	SN	Lercanil; Masnidipine; Lercanidipine [INN]; Lercanidipine (INN); Lercanil (TN); REC 15-2375; Zanidip (TN); REC-15-2375; Methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-2-((3,3-Diphenylpropyl)methylamino)-1,1-dimethylethyl methyl1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester; 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMPWSEM	CP	Forest Laboratories
DMPWSEM	TC	Antihypertensive Agents
DMPWSEM	DT	Small molecular drug
DMPWSEM	PC	65866
DMPWSEM	MW	611.7
DMPWSEM	FM	C36H41N3O6
DMPWSEM	IC	InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
DMPWSEM	CS	CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMPWSEM	IK	ZDXUKAKRHYTAKV-UHFFFAOYSA-N
DMPWSEM	IU	5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMPWSEM	CA	CAS 100427-26-7
DMPWSEM	CB	CHEBI:135930
DMPWSEM	DE	Hypertension

DMUR64T	ID	DMUR64T
DMUR64T	DN	Lesinurad
DMUR64T	HS	Approved
DMUR64T	SN	LESINURAD; 878672-00-5; RDEA594; Zurampic; RDEA 594; UNII-09ERP08I3W; RDEA-594; 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid; 09ERP08I3W; AK323774; C17H14BrN3O2S; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid; 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
DMUR64T	CP	Ardea Biosciences
DMUR64T	DT	Small molecular drug
DMUR64T	PC	53465279
DMUR64T	MW	404.3
DMUR64T	FM	C17H14BrN3O2S
DMUR64T	IC	InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)
DMUR64T	CS	C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O
DMUR64T	IK	FGQFOYHRJSUHMR-UHFFFAOYSA-N
DMUR64T	IU	2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
DMUR64T	CA	CAS 878672-00-5
DMUR64T	CB	CHEBI:90929
DMUR64T	DE	Hyperuricaemia

DMQ2AIJ	ID	DMQ2AIJ
DMQ2AIJ	DN	Lestaurtinib
DMQ2AIJ	HS	Approved (orphan drug)
DMQ2AIJ	SN	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)
DMQ2AIJ	CP	Cephalon; Kyowa Hakko Kogyo
DMQ2AIJ	TC	Anticancer Agents
DMQ2AIJ	DT	Small molecular drug
DMQ2AIJ	PC	126565
DMQ2AIJ	MW	439.5
DMQ2AIJ	FM	C26H21N3O4
DMQ2AIJ	IC	InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1
DMQ2AIJ	CS	C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O
DMQ2AIJ	IK	UIARLYUEJFELEN-LROUJFHJSA-N
DMQ2AIJ	IU	(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one
DMQ2AIJ	CA	CAS 111358-88-4
DMQ2AIJ	CB	CHEBI:91471
DMQ2AIJ	DE	Acute myeloid leukaemia; Psoriasis vulgaris; Myeloid leukaemia

DMH07Y3	ID	DMH07Y3
DMH07Y3	DN	Letrozole
DMH07Y3	HS	Approved
DMH07Y3	SN	Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
DMH07Y3	TC	Anticancer Agents
DMH07Y3	DT	Small molecular drug
DMH07Y3	PC	3902
DMH07Y3	MW	285.3
DMH07Y3	FM	C17H11N5
DMH07Y3	IC	InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
DMH07Y3	CS	C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
DMH07Y3	IK	HPJKCIUCZWXJDR-UHFFFAOYSA-N
DMH07Y3	IU	4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
DMH07Y3	CA	CAS 112809-51-5
DMH07Y3	CB	CHEBI:6413
DMH07Y3	DE	Hormonally-responsive breast cancer

DMUAZWG	ID	DMUAZWG
DMUAZWG	DN	Leucovorin
DMUAZWG	HS	Approved
DMUAZWG	SN	5-formyltetrahydrofolate; Citrovorum factor; Folinic acid
DMUAZWG	TC	Vitamins
DMUAZWG	DT	Small molecular drug
DMUAZWG	PC	135403648
DMUAZWG	MW	473.446
DMUAZWG	FM	C20H23N7O7
DMUAZWG	IC	InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1
DMUAZWG	CS	C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DMUAZWG	IK	VVIAGPKUTFNRDU-ABLWVSNPSA-N
DMUAZWG	IU	(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMUAZWG	CA	CAS 58-05-9
DMUAZWG	CB	CHEBI:15640
DMUAZWG	DE	Colorectal cancer

DMNWZJG	ID	DMNWZJG
DMNWZJG	DN	Leucovorin Calcium
DMNWZJG	HS	Approved
DMNWZJG	SN	Leucovorin Calcium Preservative Free; Wellcovorin
DMNWZJG	CP	Hospira Inc
DMNWZJG	TC	Anticancer Agents
DMNWZJG	DT	Small molecular drug
DMNWZJG	PC	135403647
DMNWZJG	MW	511.5
DMNWZJG	FM	C20H21CaN7O7
DMNWZJG	IC	InChI=1S/C20H23N7O7.Ca/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);/q;+2/p-2/t12?,13-;/m0./s1
DMNWZJG	CS	C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Ca+2]
DMNWZJG	IK	KVUAALJSMIVURS-ZEDZUCNESA-L
DMNWZJG	IU	calcium;(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioate
DMNWZJG	CA	CAS 1492-18-8
DMNWZJG	CB	CHEBI:31340
DMNWZJG	DE	Solid tumour/cancer

DMZT4N7	ID	DMZT4N7
DMZT4N7	DN	Leucovorin/5-fluorouracil
DMZT4N7	HS	Approved
DMZT4N7	TC	Vitamins
DMZT4N7	DT	Small molecular drug
DMZT4N7	PC	54575
DMZT4N7	DE	Colon cancer

DM5XPIJ	ID	DM5XPIJ
DM5XPIJ	DN	Leuprolide
DM5XPIJ	HS	Approved
DM5XPIJ	SN	Enantone; Eligard (TN); Leuprorelin (INN); Viadur (TN); 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide
DM5XPIJ	CP	Abbott Laboratories
DM5XPIJ	TC	Anticancer Agents
DM5XPIJ	DT	Small molecular drug
DM5XPIJ	SQ	Leuprolide: PHWSYLLR
DM5XPIJ	PC	657181
DM5XPIJ	MW	1209.4
DM5XPIJ	FM	C59H84N16O12
DM5XPIJ	IC	InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1
DM5XPIJ	CS	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
DM5XPIJ	IK	GFIJNRVAKGFPGQ-LIJARHBVSA-N
DM5XPIJ	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM5XPIJ	CA	CAS 53714-56-0
DM5XPIJ	CB	CHEBI:6427
DM5XPIJ	DE	Prostate cancer

DM15HAT	ID	DM15HAT
DM15HAT	DN	Leuprorelin acetate
DM15HAT	HS	Approved
DM15HAT	SN	Leuprolide acetate; Leuplin (TN); Leuprorelin acetate (JAN); 5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate
DM15HAT	CP	Takeda
DM15HAT	DT	Small molecular drug
DM15HAT	PC	657180
DM15HAT	MW	1269.4
DM15HAT	FM	C61H88N16O14
DM15HAT	IC	InChI=1S/C59H84N16O12.C2H4O2/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40;1-2(3)4/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64);1H3,(H,3,4)/t40-,41-,42-,43+,44-,45-,46-,47-,48-;/m0./s1
DM15HAT	CS	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O
DM15HAT	IK	RGLRXNKKBLIBQS-XNHQSDQCSA-N
DM15HAT	IU	acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM15HAT	CA	CAS 74381-53-6
DM15HAT	CB	CHEBI:63597
DM15HAT	DE	Prostate cancer

DMJBOCR	ID	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	HS	Approved
DMJBOCR	SN	Levocarnitine; L-carnitine; 541-15-1; vitamin BT; (R)-Carnitine; Carnitor; (-)-Carnitine; Carnitine; Karnitin; (-)-L-Carnitine; L-(-)-Carnitine; Levocarnitina; Carnitene; Levocarnitinum; Metina; L-Carnitine inner salt; Carniking; Carnovis; Carnitolo; Carnilean; Carrier; Lefcar; Carnitine, (-)-; L-carnitine Base; Levocarnitinum [Latin]; Levocarnitina [Spanish]; ST 198; L(-)-Carnitine; Carniking 50; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; Levocarnitine [USAN:INN]; gamma-Trimethyl-beta-hydroxybutyrobetaine; bicarnesine;  Nicetile (TN); L-Carnitine
DMJBOCR	DT	Small molecular drug
DMJBOCR	PC	10917
DMJBOCR	MW	161.2
DMJBOCR	FM	C7H15NO3
DMJBOCR	IC	InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1
DMJBOCR	CS	C[N+](C)(C)C[C@@H](CC(=O)[O-])O
DMJBOCR	IK	PHIQHXFUZVPYII-ZCFIWIBFSA-N
DMJBOCR	IU	(3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate
DMJBOCR	CA	CAS 541-15-1
DMJBOCR	CB	CHEBI:16347
DMJBOCR	DE	Nutritional deficiency; Cognitive impairment

DM5YBO1	ID	DM5YBO1
DM5YBO1	DN	Levalbuterol
DM5YBO1	HS	Approved
DM5YBO1	SN	Levosalbutamol; 34391-04-3; (R)-salbutamol; Xopenex; R-Salbutamol; R-Albuterol; (r)-(-)-salbutamol; UNII-EDN2NBH5SS; 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; EDN2NBH5SS; CHEBI:8746; Levosalbutamol (INN); Levosalbutamol [INN]; (R)-albuterol; m-Xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (R)-(-)-; (-)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol
DM5YBO1	DT	Small molecular drug
DM5YBO1	PC	123600
DM5YBO1	MW	239.31
DM5YBO1	FM	C13H21NO3
DM5YBO1	IC	InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m0/s1
DM5YBO1	CS	CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O
DM5YBO1	IK	NDAUXUAQIAJITI-LBPRGKRZSA-N
DM5YBO1	IU	4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DM5YBO1	CA	CAS 34391-04-3
DM5YBO1	CB	CHEBI:8746
DM5YBO1	DE	Asthma

DMCOLUP	ID	DMCOLUP
DMCOLUP	DN	Levallorphan
DMCOLUP	HS	Approved
DMCOLUP	SN	Levallofano; Levallorphane; Levallorphanum; Levalorfano; Naloxiphan; Levallofano [DCIT]; Levallorphan [INN:BAN]; Levallorphane [INN-French]; Levallorphanum [INN-Latin]; Levalorfano [INN-Spanish]; Lorfan (TN); Ro-1-7700; N-Allyl-3-hydroxymorphinan; L-N-Allyl-3-hydroxymorphinan; Levo-3-hydroxy-N-allyl morphinan; (-)-3-Hydroxy-N-allylmorphinan; 17-Allylmorphinan-3-ol; 17-prop-2-en-1-ylmorphinan-3-ol
DMCOLUP	CP	Hoffmann La Roche Inc
DMCOLUP	TC	Antinarcotic Agents
DMCOLUP	DT	Small molecular drug
DMCOLUP	PC	5359371
DMCOLUP	MW	283.4
DMCOLUP	FM	C19H25NO
DMCOLUP	IC	InChI=1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1
DMCOLUP	CS	C=CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O
DMCOLUP	IK	OZYUPQUCAUTOBP-QXAKKESOSA-N
DMCOLUP	IU	(1R,9R,10R)-17-prop-2-enyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMCOLUP	CA	CAS 152-02-3
DMCOLUP	CB	CHEBI:6431
DMCOLUP	DE	Narcotic depression

DM5EN79	ID	DM5EN79
DM5EN79	DN	Levamisole
DM5EN79	HS	Approved
DM5EN79	SN	Ketrax; LEVOMYSOL; Lepuron; Levamisol; Levamisolum; Levotetramisole; Tetramisol; Wormicid; Levamisole Base;Nilverm base; P00039; Vermisol 150; Dl-Tetramisol; Dl-Tetramisole; Ergamisol (TN); Ketrax (TN); L-Tetramisole; Levamisol [INN-Spanish]; Levamisole (INN); Levamisole [INN:BAN]; Levamisolum [INN-Latin]; TCMDC-125847; L(-)-Levamisole; L-2,3,5,6-Tetrahyro-6-phenylimidazo(2,1-b)thiazole; (-)-Tetramisole; (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole; (S)-(-)-Levamisole
DM5EN79	CP	Janssen Pharmaceutica
DM5EN79	TC	Anticancer Agents
DM5EN79	DT	Small molecular drug
DM5EN79	PC	26879
DM5EN79	MW	204.29
DM5EN79	FM	C11H12N2S
DM5EN79	IC	InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1
DM5EN79	CS	C1CSC2=N[C@H](CN21)C3=CC=CC=C3
DM5EN79	IK	HLFSDGLLUJUHTE-SNVBAGLBSA-N
DM5EN79	IU	(6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole
DM5EN79	CA	CAS 14769-73-4
DM5EN79	CB	CHEBI:6432
DM5EN79	DE	Parasitic infection; Colon cancer

DMTGDN8	ID	DMTGDN8
DMTGDN8	DN	Levetiracetam
DMTGDN8	HS	Approved
DMTGDN8	SN	102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,;  Keppra; Leviteracetam; Torleva; Levetiracetam [INN]; Ucb L060; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam
DMTGDN8	CP	UCB Pharmaceuticals Inc
DMTGDN8	TC	Anticonvulsants
DMTGDN8	DT	Small molecular drug
DMTGDN8	PC	5284583
DMTGDN8	MW	170.21
DMTGDN8	FM	C8H14N2O2
DMTGDN8	IC	InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
DMTGDN8	CS	CC[C@@H](C(=O)N)N1CCCC1=O
DMTGDN8	IK	HPHUVLMMVZITSG-LURJTMIESA-N
DMTGDN8	IU	(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
DMTGDN8	CA	CAS 102767-28-2
DMTGDN8	CB	CHEBI:6437
DMTGDN8	DE	Fibromyalgia; Epilepsy

DMSREPX	ID	DMSREPX
DMSREPX	DN	Levobetaxolol
DMSREPX	HS	Approved
DMSREPX	SN	Levobetaxolol [INN]; Betaxon (TN); (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; (2S)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; (2s)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol; (S)-(-)-Betaxolol; (S)-1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; (S)-Betaxolol
DMSREPX	CP	Alcon Pharmaceuticals Ltd
DMSREPX	TC	Cardiotonic Agents
DMSREPX	DT	Small molecular drug
DMSREPX	PC	60657
DMSREPX	MW	307.4
DMSREPX	FM	C18H29NO3
DMSREPX	IC	InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1
DMSREPX	CS	CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O
DMSREPX	IK	NWIUTZDMDHAVTP-KRWDZBQOSA-N
DMSREPX	IU	(2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMSREPX	CA	CAS 93221-48-8
DMSREPX	CB	CHEBI:59254
DMSREPX	DE	Chronic open-angle glaucoma

DMTNFCQ	ID	DMTNFCQ
DMTNFCQ	DN	Levobunolol
DMTNFCQ	HS	Approved
DMTNFCQ	SN	Akbeta; Betagan; Levobunololum; Levobunolol HCl; Betegan (TN); Levobunolol (INN); Levobunolol [INN:BAN]; Levobunololum [INN-Latin]; Liquifilm (TN); W-6412A; W-7000A; AK-Beta (TN); (-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one
DMTNFCQ	CP	Allergan Pharmaceuticals
DMTNFCQ	TC	Sympatholytics
DMTNFCQ	DT	Small molecular drug
DMTNFCQ	PC	39468
DMTNFCQ	MW	291.4
DMTNFCQ	FM	C17H25NO3
DMTNFCQ	IC	InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1
DMTNFCQ	CS	CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O
DMTNFCQ	IK	IXHBTMCLRNMKHZ-LBPRGKRZSA-N
DMTNFCQ	IU	5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one
DMTNFCQ	CA	CAS 47141-42-4
DMTNFCQ	CB	CHEBI:6438
DMTNFCQ	DE	Open-angle glaucoma

DM783CH	ID	DM783CH
DM783CH	DN	Levobupivacaine
DM783CH	HS	Approved
DM783CH	SN	Novabupi; Chirocaine (TN); Levobupivacaine (INN); Levobupivacaine [INN:BAN]; Novabupi (TN); L(-)-Bupivacaine; L-(-)-bupivacaine; L-(-)-1-Butyl-2',6'-pipecoloxylidide; (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (S)-1-Butyl-2',6'-pipecoloxylidide; (S)-bupivacaine
DM783CH	CP	AstraZeneca
DM783CH	TC	Anesthetics
DM783CH	DT	Small molecular drug
DM783CH	PC	92253
DM783CH	MW	288.4
DM783CH	FM	C18H28N2O
DM783CH	IC	InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1
DM783CH	CS	CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C
DM783CH	IK	LEBVLXFERQHONN-INIZCTEOSA-N
DM783CH	IU	(2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM783CH	CA	CAS 27262-47-1
DM783CH	CB	CHEBI:6149
DM783CH	DE	Anaesthesia

DMMZPWT	ID	DMMZPWT
DMMZPWT	DN	Levocabastine
DMMZPWT	HS	Approved
DMMZPWT	SN	Levocabastin; Levocabastina; Levocabastinum; Livostin; Levocabastina [Spanish]; Levocabastinum [Latin]; Levocabastine (INN); Levocabastine [INN:BAN]; Livostin (TN); (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid; 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-4-piperidinecarboxylic acid
DMMZPWT	CP	Janssen Pharmaceutica
DMMZPWT	TC	Antiallergic Agents
DMMZPWT	DT	Small molecular drug
DMMZPWT	PC	54385
DMMZPWT	MW	420.5
DMMZPWT	FM	C26H29FN2O2
DMMZPWT	IC	InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23?,25?,26-/m1/s1
DMMZPWT	CS	C[C@@H]1CN(CC[C@@]1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F
DMMZPWT	IK	ZCGOMHNNNFPNMX-YHYDXASRSA-N
DMMZPWT	IU	(3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid
DMMZPWT	CA	CAS 79449-98-2
DMMZPWT	CB	CHEBI:92584
DMMZPWT	DE	Allergic conjunctivitis

DMQYLGP	ID	DMQYLGP
DMQYLGP	DN	Levocetirizine
DMQYLGP	HS	Approved
DMQYLGP	SN	(-)-Cetirizine; (-)-Cetirizine Dihydrochloride; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Levocetirizine; Levocetirizine HCl; UNII-6U5EA9RT2O; Xarlin; Xyzal; cetirizine-d4; levocetrizine
DMQYLGP	DT	Small molecular drug
DMQYLGP	PC	1549000
DMQYLGP	MW	388.892
DMQYLGP	FM	C21H25ClN2O3
DMQYLGP	IC	InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
DMQYLGP	CS	C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMQYLGP	IK	ZKLPARSLTMPFCP-OAQYLSRUSA-N
DMQYLGP	IU	2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMQYLGP	CA	CAS 130018-77-8
DMQYLGP	CB	CHEBI:94559
DMQYLGP	DE	Allergy

DMW6ZJI	ID	DMW6ZJI
DMW6ZJI	DN	Levocetirizine dihydrochloride
DMW6ZJI	HS	Approved
DMW6ZJI	SN	Xyzal; Xyzall; Levocetirizine HCl; Levocetirizine dihydrochloride [USAN]; Levocetirizine hydrochloride; Levocetirizine 2HCl; KS-1177; Levocetirizine hydrochloride (JAN); Vozet (TN); Xozal (TN); Xusal (TN); Xuzal (TN); Xyzal (TN); Xyzall (TN); Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride; (2-(4-((R)-(4-Chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
DMW6ZJI	CP	GlaxoSmithKline
DMW6ZJI	TC	Antiallergic Agents
DMW6ZJI	DT	Small molecular drug
DMW6ZJI	PC	9955977
DMW6ZJI	MW	461.8
DMW6ZJI	FM	C21H27Cl3N2O3
DMW6ZJI	IC	InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H/t21-;;/m1../s1
DMW6ZJI	CS	C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl
DMW6ZJI	IK	PGLIUCLTXOYQMV-GHVWMZMZSA-N
DMW6ZJI	IU	2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
DMW6ZJI	CA	CAS 130018-87-0
DMW6ZJI	DE	Allergic rhinitis

DMN3E57	ID	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	HS	Approved
DMN3E57	SN	Levodopa (optimized formulation, Parkinson's disease); More effective levodopa (Parkinson's disease), Orion; Levodopa (optimized formulation, Parkinson's disease), Orion
DMN3E57	CP	Orion Corp
DMN3E57	DT	Small molecular drug
DMN3E57	PC	6047
DMN3E57	MW	197.19
DMN3E57	FM	C9H11NO4
DMN3E57	IC	InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
DMN3E57	CS	C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O
DMN3E57	IK	WTDRDQBEARUVNC-LURJTMIESA-N
DMN3E57	IU	(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
DMN3E57	CA	CAS 59-92-7
DMN3E57	CB	CHEBI:15765
DMN3E57	DE	Parkinson disease

DMS60RB	ID	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	HS	Approved
DMS60RB	SN	Aeroquin; Cravit; Elequine; Floxacin; Floxel; Iquix; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levofloxacine; Levofloxacino; Levofloxacinum; Levokacin; Levox; Levoxacin; Mosardal; Nofaxin; Oftaquix; Quixin; Reskuin; Tavanic; Volequin; Cravit Ophthalmic; DR 3354; DR3355; HR 355; Cravit (TN); D-Levofloxacin; DR-3355; HR-355; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Levaquin (TN); Levofloxacin (INN); Levofloxacin tablet, suspension or intravenous; Levofloxacine [INN-French]; Levofloxacino [INN-Spanish]; Levofloxacinum [INN-Latin]; MP-376; Oftaquix (TN); Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Tavanic (TN); Levofloxacin [USAN:INN:JAN]; DR-3355: L-isomer of ofloxacin; Ofloxacin S-(-)-form; S-(-)-Ofloxacin; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin
DMS60RB	CP	Sanofi-Aventis
DMS60RB	TC	Antibiotics
DMS60RB	DT	Small molecular drug
DMS60RB	PC	149096
DMS60RB	MW	361.4
DMS60RB	FM	C18H20FN3O4
DMS60RB	IC	InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
DMS60RB	CS	C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
DMS60RB	IK	GSDSWSVVBLHKDQ-JTQLQIEISA-N
DMS60RB	IU	(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMS60RB	CA	CAS 100986-85-4
DMS60RB	CB	CHEBI:63598
DMS60RB	DE	Bacterial infection

DMUV5JB	ID	DMUV5JB
DMUV5JB	DN	Levomefolic acid
DMUV5JB	HS	Approved
DMUV5JB	SN	Levomefolic acid; Levomefolinic acid; Metafolin; Metafolin (TN); L-5-Methyltetrahydrofolate; LEVOMEFOLATE; (6s)-5-methyltetrahydrofolic acid; (S)-2-(4-((((S)-2-Amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzamido)pentanedioic acid; 31690-09-2; 5-METHYL-5,6,7,8-TETRAHYDROFOLIC ACID; 5-Methyltetrahydrofolate; 8S95DH25XC; C20H25N7O6; CHEBI:15641; LMSR; N-(5-methyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid; UNII-8S95DH25XC; [(6S)-5-methyl-5,6,7,8-tetrahydropteroyl]glutamate
DMUV5JB	PC	135398561
DMUV5JB	MW	459.5
DMUV5JB	FM	C20H25N7O6
DMUV5JB	IC	ZNOVTXRBGFNYRX-STQMWFEESA-N
DMUV5JB	CS	CN1C(CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DMUV5JB	IK	1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1
DMUV5JB	IU	(2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
DMUV5JB	CA	CAS 31690-09-2
DMUV5JB	CB	CHEBI:15641
DMUV5JB	DE	Contraception

DMIKFEL	ID	DMIKFEL
DMIKFEL	DN	Levomepromazine
DMIKFEL	HS	Approved
DMIKFEL	SN	METHOTRIMEPRAZINE; Nozinan; 60-99-1; Levoprome; Levomepromazina; Levomepromazinum; Levomepromazin; Nosinan; UNII-9G0LAW7ATQ; 2-Methoxytrimeprazine; Neozine; Levotomin; Minozinan; Milezin; 9G0LAW7ATQ; RP-7044; Levopromazioni; Veractil; Nomizan; Hirnamine; Dedoran; Nocinan; Nirnamine; CHEBI:6838; XP03; Methoxytrimeprazine; F-5116; Methotrimeprazine [USP]; Methotrimeprazine (USP); Bayer 1213; Arc-VI-C-5; CL 36467; CL 39743; Levomepromazinum [INN-Latin]; Levomepromazina [INN-Spanish]; EINECS 200-495-5; Methotrimeprazine
DMIKFEL	CP	Immunex Corp
DMIKFEL	DT	Small molecular drug
DMIKFEL	PC	72287
DMIKFEL	MW	328.5
DMIKFEL	FM	C19H24N2OS
DMIKFEL	IC	InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
DMIKFEL	CS	C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C
DMIKFEL	IK	VRQVVMDWGGWHTJ-CQSZACIVSA-N
DMIKFEL	IU	(2R)-3-(2-methoxyphenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine
DMIKFEL	CA	CAS 60-99-1
DMIKFEL	CB	CHEBI:6838
DMIKFEL	DE	Psychotic disorder; Bipolar disorder

DM06HG5	ID	DM06HG5
DM06HG5	DN	Levomethadyl Acetate
DM06HG5	HS	Approved
DM06HG5	SN	LAAM; Levacetilmetadol; Levacetylmethadol; Levacetylmethadolum; Levomethadyl; Orlaam; Levacetylmethadol [INN]; Levacetilmetadol [INN-Spanish]; Levacetylmethadol (INN); Levacetylmethadolum [INN-Latin]; Levo-Alphacetylmethadol; Levo-Methadyl acetate; Levomethadyl acetate (USAN); Orlaam (TN); A-l-acetylmethadol; Alpha-l-Acetylmethadol; L-alpha-Acetylmethadol; Levo-alpha-Acetylmethadol; N-alpha-Acetylmethadol; Alpha-(-)-Acetylmethadol; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-(9CI); (-)-alpha-Acetylmethadol; (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; 1-alpha-Acetylmethadol; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)-(8CI)
DM06HG5	CP	Roxane Laboratories
DM06HG5	TC	Analgesics
DM06HG5	DT	Small molecular drug
DM06HG5	PC	15130
DM06HG5	MW	353.5
DM06HG5	FM	C23H31NO2
DM06HG5	IC	InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1
DM06HG5	CS	CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
DM06HG5	IK	XBMIVRRWGCYBTQ-AVRDEDQJSA-N
DM06HG5	IU	[(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
DM06HG5	CA	CAS 1477-40-3
DM06HG5	CB	CHEBI:6441
DM06HG5	DE	Opioid dependence

DM429AE	ID	DM429AE
DM429AE	DN	Levomethadyl acetate hydrochloride
DM429AE	HS	Approved
DM429AE	SN	Levacetilmetadol; Levacetilmetadol [INN-Spanish]; Levacetylmethadol; Levacetylmethadol (INN); Levacetylmethadol [INN]; Levacetylmethadolum; Levacetylmethadolum [INN-Latin]; Levomethadyl; Levomethadyl acetate; Levacetyl methadol hydrochloride; LAAM hydrochloride; Levomethadyl acetate HCl; MK 790; MK-790 hydrochloride; ORLAAM hydrochloride; l-Acetylmethadol hydrochloride; (-)-(3S,6S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester), hydrochloride; 43033-72-3; 6-Dimethylamino-4,4-diphenyl-3-heptanolacetate.HCl; B54CW5KG52; CCRIS 3321; Levomethadyl acetate hydrochloride; Levomethadyl acetate hydrochloride [USAN]; UNII-B54CW5KG52; alpha-l-Acetylmethadol hydrochloride; l-alpha-Acetylmethadol hydrochloride; N-alpha-Acetylmethadol; Orlaam; alpha-l-Acetylmethadol; l-alpha-Acetylmethadol; levo-Alphacetylmethadol; levo-Methadyl acetate; levo-alpha-Acetylmethadol; (-)-alpha-Acetylmethadol; 1-alpha-Acetylmethadol; 1477-40-3; DEA No. 9648; LAAM; UNII-R3B637Y991; alpha-(-)-Acetylmethadol
DM429AE	PC	39371
DM429AE	MW	390
DM429AE	FM	C23H32ClNO2
DM429AE	IC	UXBPQRGCVJOTNT-COBSGTNCSA-N
DM429AE	CS	CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.Cl
DM429AE	IK	1S/C23H31NO2.ClH/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21;/h7-16,18,22H,6,17H2,1-5H3;1H/t18-,22-;/m0./s1
DM429AE	IU	[(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate;hydrochloride
DM429AE	CA	CAS 43033-72-3
DM429AE	CB	CHEBI:6442
DM429AE	DE	Opiate dependence

DMV26S8	ID	DMV26S8
DMV26S8	DN	Levomilnacipran
DMV26S8	HS	Approved
DMV26S8	SN	Fetzima; UNII-UGM0326TXX; Levomilnacipran HCl; 96847-54-0; UGM0326TXX; CHEMBL99946; F-2695; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; Levomilnacipran [USAN:INN]; Milnacipram; AC1OCEN8; F 2695; Levomilnacipran (USAN/INN); ZINC506; SCHEMBL1414867; GTPL7435; GJJFMKBJSRMPLA-DZGCQCFKSA-N; CHEBI:136040; BDBM50032379; SB17447; DB08918; f2-695; D10072
DMV26S8	CP	Forest Laboratories
DMV26S8	DT	Small molecular drug
DMV26S8	PC	6917779
DMV26S8	MW	246.35
DMV26S8	FM	C15H22N2O
DMV26S8	IC	InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1
DMV26S8	CS	CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2
DMV26S8	IK	GJJFMKBJSRMPLA-DZGCQCFKSA-N
DMV26S8	IU	(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DMV26S8	CA	CAS 96847-54-0
DMV26S8	CB	CHEBI:136040
DMV26S8	DE	Fibromyalgia

DM1DP7T	ID	DM1DP7T
DM1DP7T	DN	Levonorgestrel
DM1DP7T	HS	Approved
DM1DP7T	SN	norgestrel; 797-63-7; D-Norgestrel; (-)-Norgestrel; Microval; Levonova; Postinor; Mirena; Ovrette; Neogest; Jadelle; Plan B; NORPLANT; Norplant 2; Microlution; Follistrel; Trivora; Monovar; Triciclor; Microgyn; Ovranette; Triagynon; Microlut; Nordet; Trigoa; 18-Methylnorethisterone; Levonorgestrelum; Microgynon CD; Microgest ED; Norplant II; Ovral-Lo; Logynon ED; Levlen ED; Trinordiol 28; Trinordiol 21; Microgynon 28; Microgynon 21; d(-)-Norgestrel; Neogynon 21; Monofeme 28; Nordette 28; Minivlar 30; Stediril 30; Nordette 21; Trifeme;  Capronor; DNorgestrel; Levlen; Levonelle; Methylnorethindrone; Microluton; NorLevo; Norgeston; Norgestrel; Norgestrelum; Preven; Tetragynon; LD norgestrel [French]; Ld norgestrel; Levonorgestrel implants; Norgestrel [Progestins]; Norplant System in Plastic Container; Triquilar ED; Microgynon 30 ED; SH 70850; SH 850; Trifeme 28; Triphasil 21; Triphasil 28; Wy 3707; Alpha-Norgestrel; Component of Lo/ovral; Dl-Norgestrel; FH 122-A; LO/Ovral; Levonorgestrelum [INN-Latin]; Levora-21; Levora-28; Mirena (TN); Norgestrelum [INN-Latin]; Norplant (TN); Norplant-2; Ovoplex 30-150; Ovrette (TN); Postinor-2; Rigevidon 21+7; SOH-075; Tri-Levlen 21; Wy-3707; Wy-5104; E-Gen-C; Levonorgestrel [USAN:INN:BAN]; D(-)-Norgestrel; Levonorgestrel (JAN/USP/INN); Norgestrel (JP15/USP/INN); Norgestrel [USAN:BAN:INN:JAN]; Norgestrel [USAN:INN:BAN:JAN]; D-(-)-Norgestrel; Levonelle, D-Norgestrel, Levonova, Levonorgestrel; Norgestrel-(-)-D; Dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; 13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE; 13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 17-Ethynyl-18-methyl-19-nortestosterone; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; 17alpha-Ethynyl-18-homo-19-nor-testosterone; 17alpha-Ethynyl-18-homo-19-nortestosterone; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; 18,19-Dinor-4-pregnen-20-yn-3-one; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; 72-HOURS
DM1DP7T	TC	Contraceptive Agents
DM1DP7T	DT	Small molecular drug
DM1DP7T	PC	13109
DM1DP7T	MW	312.4
DM1DP7T	FM	C21H28O2
DM1DP7T	IC	InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
DM1DP7T	CS	CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DM1DP7T	IK	WWYNJERNGUHSAO-XUDSTZEESA-N
DM1DP7T	IU	(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DM1DP7T	CA	CAS 797-63-7
DM1DP7T	CB	CHEBI:6443
DM1DP7T	DE	Contraception

DMECB4H	ID	DMECB4H
DMECB4H	DN	Levopropoxyphene Napsylate Anhydrous
DMECB4H	HS	Approved
DMECB4H	SN	Novrad
DMECB4H	CP	Eli Lilly Industries Inc
DMECB4H	DT	Small molecular drug
DMECB4H	PC	6604497
DMECB4H	MW	547.7
DMECB4H	FM	C32H37NO5S
DMECB4H	IC	InChI=1S/C22H29NO2.C10H8O3S/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h6-15,18H,5,16-17H2,1-4H3;1-7H,(H,11,12,13)/t18-,22+;/m0./s1
DMECB4H	CS	CCC(=O)O[C@@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@@H](C)CN(C)C.C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)O
DMECB4H	IK	VZPXFHVJUUSVLH-VNJAQMQMSA-N
DMECB4H	IU	[(2R,3S)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;naphthalene-2-sulfonic acid
DMECB4H	CA	CAS 5714-90-9
DMECB4H	DE	Cough

DM2XVNI	ID	DM2XVNI
DM2XVNI	DN	Levormeloxifene
DM2XVNI	HS	Approved
DM2XVNI	SN	Centchroman; Centron; Levormeloxifene; Ormeloxifene; Saheli; NNC-46-0020; Non-steroidal (oral, contraception/cancer); Non-steroidal (oral, contraception/cancer), Central Drug Research Institute (CDRI)
DM2XVNI	CP	Novo Nordisk A/S; Central Drug Research Institute
DM2XVNI	DT	Small molecular drug
DM2XVNI	PC	35805
DM2XVNI	MW	457.6
DM2XVNI	FM	C30H35NO3
DM2XVNI	IC	InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1
DM2XVNI	CS	CC1([C@H]([C@@H](C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C
DM2XVNI	IK	XZEUAXYWNKYKPL-WDYNHAJCSA-N
DM2XVNI	IU	1-[2-[4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine
DM2XVNI	CA	78994-23-7
DM2XVNI	DE	Breast cancer

DMGS80V	ID	DMGS80V
DMGS80V	DN	Levorphanol
DMGS80V	HS	Approved
DMGS80V	SN	levorphanol; Levorphan; Methorphinan; Aromarone; Racemethorphanum; Dromoran; Cetarin; Antalgin; Levo-Dromoran; Racemic dromoran; Methorfinan [Czech]; Levorfanolo [DCIT]; Levorphanolum; Levorfanol; Orphan; Levorfanol [INN-Spanish]; Levorphanolum [INN-Latin]; Racemorfano [INN-Spanish]; 17-Methylmorphinan-3-ol; N-Methyl-3-hydroxymorphinan; Racemorphan; Racemorphan [INN:BAN]; Racemorphane [INN-French]; Racemorphanum [INN-Latin]; (-)-N-Methylmorphinan-3-ol; Morphinan-3-ol, 17-methyl-; Levorphanal; dl-3-Hydroxy-N-methylmorphinan; DEA No;  Antalgin; DEXTRORPHAN; Levodroman; Levorfanolo; Methorfinan; Racemorfano; Racemorphane; Racemorphanum; NU 2206; L-Dromoran; Levorphanol (INN); Ro 1-5431; Levo-Dromoran (TN); Dl-3-Hydroxy-N-methylmorphinan; (+)-3-Hydroxy-17-methylmorphinan; (+-)-17-Methylmorphinan-3-ol; (+-)-3-Hydroxy-N-methylmorphinan; (-)-3-Hydroxy-N-methylmorphinan; 1,3,4,9,10,10a-Hexahydro-11-methyl-2H-10,4a-iminoethanophenanthren-6-ol, dl-mixture; 1,3,4,9,10,10a-Hexahydro-6-hydroxy-2H-10,4a-(iminoethano)-11-methylphenanthrene; 3-Hydroxy-N-methylmorphinan; Dextrorphan
DMGS80V	CP	Roxane Laboratories
DMGS80V	TC	Analgesics
DMGS80V	DT	Small molecular drug
DMGS80V	PC	5359272
DMGS80V	MW	257.37
DMGS80V	FM	C17H23NO
DMGS80V	IC	InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1
DMGS80V	CS	CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O
DMGS80V	IK	JAQUASYNZVUNQP-USXIJHARSA-N
DMGS80V	IU	(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMGS80V	CA	CAS 297-90-5
DMGS80V	CB	CHEBI:6444
DMGS80V	DE	Pain; Ischemic stroke

DMKBOS2	ID	DMKBOS2
DMKBOS2	DN	Levosimendan
DMKBOS2	HS	Approved
DMKBOS2	SN	Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
DMKBOS2	CP	Abbott Laboratories
DMKBOS2	TC	Cardiotonic Agents
DMKBOS2	DT	Small molecular drug
DMKBOS2	PC	3033825
DMKBOS2	MW	280.28
DMKBOS2	FM	C14H12N6O
DMKBOS2	IC	InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1
DMKBOS2	CS	C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N
DMKBOS2	IK	WHXMKTBCFHIYNQ-SECBINFHSA-N
DMKBOS2	IU	2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
DMKBOS2	CA	CAS 141505-33-1
DMKBOS2	CB	CHEBI:50567
DMKBOS2	DE	Cardiac output syndrome; Pulmonary hypertension; Congestive heart failure; Heart failure

DMHN027	ID	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	HS	Approved
DMHN027	SN	Eltroxin; Euthyrox; Forthyron; Laevothyroxinum; Laevoxin; Levolet; Levothroid; Levothyrox; Levothyroxin; Levoxyl; Oroxine; Synthroid; THX; Tetraiodothyronine; Thyratabs; Thyrax; Thyreoideum; Thyroxevan; Thyroxin; Thyroxinal; Levothyroxine sodium; Synthroid sodium; Thyroxine [BAN]; Thyroxine iodine; LT00440967; T4 levothyroxine; DL-Thyroxin; Eltroxin (TN); Euthyrox (TN); Eutirox (TN); Forthyron (TN); L-Thryoxin; L-Thyroxin; L-thyroxine; Laevothyroxinum (acid); Levaxin (TN); Levo-T; Levothyroxine (BAN); Levothyroxinum (acid); Levoxyl (TN); Synthroid (TN); T-3850; T4 (Hormone); Thyrax (TN); Thyrox (TN); Thyroxine (VAN); Thyroxine (l); L-thyroxine (TN); Levothyroxine Sodium (L-thyroxine); Levothroid (*Sodiumsalt*); Synthroid (*Sodium salt*); Thyroxine, L-(8CI); L-3,5,3',5'-Tetraiodothyronine; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; Beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine; O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; (-)-Thyroxine; (125I)T4; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; 3,3',5,5"-Tetraiodo-L-thyronine; 3,3',5,5''-Tetraiodo-L-thyronine; 3,3',5,5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodothyronine; 3,5,3'5'-Tetraiodo-L-thyronine; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine
DMHN027	CP	Abbott Laboratories
DMHN027	TC	Antithyroid Agents
DMHN027	DT	Small molecular drug
DMHN027	PC	5819
DMHN027	MW	776.87
DMHN027	FM	C15H11I4NO4
DMHN027	IC	InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1
DMHN027	CS	C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N
DMHN027	IK	XUIIKFGFIJCVMT-LBPRGKRZSA-N
DMHN027	IU	(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
DMHN027	CA	CAS 51-48-9
DMHN027	CB	CHEBI:18332
DMHN027	DE	Hypothyroidism

DM4PUDW	ID	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	HS	Approved
DM4PUDW	SN	Aciglut; Glu; Glusate; Glut; Glutacid; Glutamicol; Glutamidex; Glutaminol; Glutaton; Gulutamine; Acide glutamique; Acido glutamico; Acidum glutamicum; Acidum glutaminicum; Glutamic acid polymer; Glutaminic acid; E 620; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique [INN-French]; Acido glutamico [INN-Spanish]; Acidum glutamicum [INN-Latin]; D-Glutamiensuur; Glutamic Acid [USAN:INN]; Glutamic acid (VAN); Glutaminic acid (VAN); Gulutamine (USP); L-Glutamic acid hydrochloride; L-Glutaminic acid; L-Glutaminsaeure; L-glu; L-glutamate; Alpha-Aminoglutaric acid (VAN); Alpha-L-Glutamic acid polymer; Glutamic Acid (L-glutamic acid); Glutamic acid (H-3); H-Glu-OH; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid, homopolymer; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid); Glutamic acid, L-, peptides; L-Glutamic acid, homopolymer (9CI); Poly(alpha-L-glutamic acid); Glutamic acid, L-(7CI,8CI); L-(+)-glutamic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid
DM4PUDW	TC	Dietary supplement
DM4PUDW	DT	Small molecular drug
DM4PUDW	PC	33032
DM4PUDW	MW	147.13
DM4PUDW	FM	C5H9NO4
DM4PUDW	IC	InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
DM4PUDW	CS	C(CC(=O)O)[C@@H](C(=O)O)N
DM4PUDW	IK	WHUUTDBJXJRKMK-VKHMYHEASA-N
DM4PUDW	IU	(2S)-2-aminopentanedioic acid
DM4PUDW	CA	CAS 56-86-0
DM4PUDW	CB	CHEBI:16015
DM4PUDW	DE	Schizophrenia

DM69G8X	ID	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	HS	Approved
DM69G8X	SN	NutreStore; AES-14; Aesgen-14; Glutamine (INN); L-glutamine (oral, short bowel syndrome), Emmaus; L-glutamine (topical, chemotherapy-induced mucositis), Aesgen; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus/University of California Los Angeles
DM69G8X	CP	Nutritional Restart
DM69G8X	DT	Small molecular drug
DM69G8X	PC	5961
DM69G8X	MW	146.14
DM69G8X	FM	C5H10N2O3
DM69G8X	IC	InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1
DM69G8X	CS	C(CC(=O)N)[C@@H](C(=O)O)N
DM69G8X	IK	ZDXPYRJPNDTMRX-VKHMYHEASA-N
DM69G8X	IU	(2S)-2,5-diamino-5-oxopentanoic acid
DM69G8X	CA	CAS 56-85-9
DM69G8X	CB	CHEBI:18050
DM69G8X	DE	Short bowel syndrome

DMNQXV8	ID	DMNQXV8
DMNQXV8	DN	LGX818
DMNQXV8	HS	Approved
DMNQXV8	SN	Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)
DMNQXV8	CP	Array BioPharma
DMNQXV8	DT	Small molecular drug
DMNQXV8	PC	50922675
DMNQXV8	MW	540
DMNQXV8	FM	C22H27ClFN7O4S
DMNQXV8	IC	InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
DMNQXV8	CS	C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=C(C(=CC(=C3)Cl)NS(=O)(=O)C)F)C(C)C)NC(=O)OC
DMNQXV8	IK	CMJCXYNUCSMDBY-ZDUSSCGKSA-N
DMNQXV8	IU	methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
DMNQXV8	CA	CAS 1269440-17-6
DMNQXV8	DE	Melanoma

DML4ZOT	ID	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	HS	Approved
DML4ZOT	SN	Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
DML4ZOT	CP	Endo Pharmaceuticals
DML4ZOT	TC	Anesthetics
DML4ZOT	DT	Small molecular drug
DML4ZOT	PC	3676
DML4ZOT	MW	234.34
DML4ZOT	FM	C14H22N2O
DML4ZOT	IC	InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)
DML4ZOT	CS	CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
DML4ZOT	IK	NNJVILVZKWQKPM-UHFFFAOYSA-N
DML4ZOT	IU	2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
DML4ZOT	CA	CAS 137-58-6
DML4ZOT	CB	CHEBI:6456
DML4ZOT	DE	Anaesthesia; Dysmenorrhea

DMV23GL	ID	DMV23GL
DMV23GL	DN	Lidoflazine
DMV23GL	HS	Approved
DMV23GL	SN	LIDOFLAZINE; Ordiflazine; Corflazine; Clinium; Lidoflazinum; Lidoflazin; 3416-26-0; Klinium; Angex; Lidoflazina [Italian]; McN-JR 7904; UNII-J4ZHN3HBTE; Lidoflazinum [INN-Latin]; Lidoflazina [INN-Spanish]; Lidoflazine [USAN:INN:BAN]; C30H35F2N3O; J4ZHN3HBTE; EINECS 222-312-8; R 7904; BRN 0904339; CHEMBL92870; MCN-JR-7904; 4-(4,4-Bis(p-fluorophenyl)butyl)-1-piperazineaceto-2',6'-xylidide; 1-Piperazineacetamide, 4-(4,4-bis(4-fluorophenyl)butyl)-N-(2,6-dimethylphenyl)-; NCGC00016627-01; NCGC00016627-04; CAS-3416-26-0
DMV23GL	DT	Small molecular drug
DMV23GL	PC	3926
DMV23GL	MW	491.6
DMV23GL	FM	C30H35F2N3O
DMV23GL	IC	InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)
DMV23GL	CS	CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMV23GL	IK	ZBIAKUMOEKILTF-UHFFFAOYSA-N
DMV23GL	IU	2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
DMV23GL	CA	CAS 3416-26-0
DMV23GL	CB	CHEBI:93095
DMV23GL	DE	Angina pectoris

DM4WVC5	ID	DM4WVC5
DM4WVC5	DN	Lifitegrast
DM4WVC5	HS	Approved
DM4WVC5	SN	Lifitegrast; Xiidra; 1025967-78-5; SAR-1118; SAR 1118; UNII-038E5L962W; CHEMBL2048028; 038E5L962W; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;  SAR-1118; SAR-1119; SHP606; SPD606
DM4WVC5	CP	Shire Pharmaceuticals
DM4WVC5	DT	Small molecular drug
DM4WVC5	PC	11965427
DM4WVC5	MW	615.5
DM4WVC5	FM	C29H24Cl2N2O7S
DM4WVC5	IC	InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
DM4WVC5	CS	CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
DM4WVC5	IK	JFOZKMSJYSPYLN-QHCPKHFHSA-N
DM4WVC5	IU	(2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
DM4WVC5	CA	CAS 1025967-78-5
DM4WVC5	CB	CHEBI:133023
DM4WVC5	DE	Dry eye disease; Allergic conjunctivitis

DM4EGV0	ID	DM4EGV0
DM4EGV0	DN	Linaclotide
DM4EGV0	HS	Approved
DM4EGV0	SN	Linaclotide (USAN)
DM4EGV0	CP	Microbia
DM4EGV0	DT	Small molecular drug
DM4EGV0	PC	16158208
DM4EGV0	MW	1526.8
DM4EGV0	FM	C59H79N15O21S6
DM4EGV0	IC	InChI=1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1
DM4EGV0	CS	C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O
DM4EGV0	IK	KXGCNMMJRFDFNR-WDRJZQOASA-N
DM4EGV0	IU	(2S)-2-[[(1R,4S,7S,13S,16R,21R,24R,27S,30S,33R,38R,44S)-21-amino-13-(2-amino-2-oxoethyl)-27-(2-carboxyethyl)-44-[(1R)-1-hydroxyethyl]-30-[(4-hydroxyphenyl)methyl]-4-methyl-3,6,12,15,22,25,28,31,40,43,46,51-dodecaoxo-18,19,35,36,48,49-hexathia-2,5,11,14,23,26,29,32,39,42,45,52-dodecazatetracyclo[22.22.4.216,33.07,11]dopentacontane-38-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM4EGV0	CA	CAS 851199-59-2
DM4EGV0	CB	CHEBI:68551
DM4EGV0	DE	Irritable bowel syndrome

DMWFJTR	ID	DMWFJTR
DMWFJTR	DN	Linagliptin
DMWFJTR	HS	Approved
DMWFJTR	SN	Ondero; BI 1356; BI-1356; Ondero (TN); BI-1356-BS; (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
DMWFJTR	CP	Boehringer Ingelheim
DMWFJTR	DT	Small molecular drug
DMWFJTR	PC	10096344
DMWFJTR	MW	472.5
DMWFJTR	FM	C25H28N8O2
DMWFJTR	IC	InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
DMWFJTR	CS	CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
DMWFJTR	IK	LTXREWYXXSTFRX-QGZVFWFLSA-N
DMWFJTR	IU	8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
DMWFJTR	CA	CAS 668270-12-0
DMWFJTR	CB	CHEBI:68610
DMWFJTR	DE	Type-2 diabetes

DMVTHER	ID	DMVTHER
DMVTHER	DN	Lincomycin
DMVTHER	HS	Approved
DMVTHER	SN	Cillimycin; Epilincomycin; Jiemycin; LCM; Lincocin; Lincocine; Lincolcina; Lincolnensin; Lincomicina; Lincomix; Lincomycine; Lincomycinum; Lincomyocin; Lincorex; Mycivin; Lincomycin A; Lincomycine [French]; CBMicro_021584; Lincomix 20; Pura Ject 100; Lincocin (TN); Lincomicina [INN-Spanish]; Lincomycine [INN-French]; Lincomycinum [INN-Latin]; U 10,149A; Lincomycin (USAN/INN); Lincomycin [USAN:INN:BAN]; Lincomycin, (2S-cis)-Isomer; Methyl 6,8-dideoxy-6-[(1-methyl-4-propylprolyl)amino]-1-thiooctopyranoside
DMVTHER	TC	Antibiotics
DMVTHER	DT	Small molecular drug
DMVTHER	PC	3000540
DMVTHER	MW	406.5
DMVTHER	FM	C18H34N2O6S
DMVTHER	IC	InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1
DMVTHER	CS	CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O
DMVTHER	IK	OJMMVQQUTAEWLP-KIDUDLJLSA-N
DMVTHER	IU	(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
DMVTHER	CA	CAS 154-21-2
DMVTHER	CB	CHEBI:6472
DMVTHER	DE	Gram-positive bacterial infection

DMB8CNL	ID	DMB8CNL
DMB8CNL	DN	Lindane
DMB8CNL	HS	Approved
DMB8CNL	SN	Aalindan; Aficide; Agrocide; Agronexit; Ameisenatod; Ameisentod; Aparasin; Aphtiria; Aphtitria; Aplidal; Arbitex; BBH; Benhexachlor; Benhexol; Benzanex; Benzex; Bexol; Celanex; Chloresene; Codechine; Devoran; Dolmix; Entomoxan; Esoderm; Exagama; Forlin; Gallogama; Gamacarbatox; Gamacid; Gamacide; Gamaphex; Gamene; Gamiso; Gammahexa; Gammahexane; Gammalin; Gammasan; Gammaterr; Gammex; Gammexane; Gammopaz; Gamtox; Geobilan; Gexane; Gyben; HCH; Hcch; Heclotox; Hecoltox; Hexa; Hexablanc; Hexachlor; Hexachloran; Hexachlorane; Hexamul; Hexapoudre; Hexatox; Hexaverm; Hexcidum; Hexicide; Hexit; Hexyclan; Hilbeech; Hortex; Inexit; Isatox; Isotox; Jacutin; Kokotine; Kwell; Lasochron; Lendine; Lentox; Lidenal; Lindafor; Lindagam; Lindagrain; Lindagranox; Lindalo; Lindamul; Lindan; Lindano; Lindanum; Lindapoudre; Lindaterra; Lindatox; Lindex; Lindosep; Lintox; Linvur; Lorexane; Mszycol; Nexit; Nicochloran; Novigam; Novigan; Omnitox; Ovadziak; Owadziak; PLK; Pedraczak; Pflanzol; Quellada; Scabene; Silvanol; Streunex; Submar; Viton; Agrocide III; Agrocide WP; Am eisenatod; Arcotal S; BHCor HCH; Borer Spray; DOL GRANULE; Eso derm; Gamma BHC; HCH [BSI]; HCH [ISO]; Hilbeec h; Isot ox; Lacco HI lin; Lindam ul; Mglawik L; New kotol; Nexen fb; PMS Lindane; Sang gamma; Agrocide 2; Agrocide6G; Agrocide 7; Bentox 10; Detox 25; Gamacide 20; Gammalin 20; Geolin G 3; Hungaria L7; Latka 666; Milbol 49; PS71_SUPELCO; TAP 85; Agrisol G-20; Alpha-BHC; Alpha-HCH; Ben-Hex; Beta-BHC; Beta-HCH; Beta-Lindane; Beta-isomer; D-BHC; Delta-BHC; Delta-HCH; ENT 7,796; ENT 8,601; ENT 9,232; ENT 9,233; ENT 9,234; Epsilon-HCH; Forst-nexen; Gamma-BHC; Gamma-HCH; Gamma-col; HCH (alpha); HCH (beta); KWELL (TN); Kwell-R; Nexen-fb; Nexi t-stark; Nexit-stark; Nexol-E; Sang-gamma; T-HCH; TRI-6; Trives-T
DMB8CNL	CP	Morton Grove Pharmaceuticals
DMB8CNL	TC	Antiscabies Agent
DMB8CNL	DT	Small molecular drug
DMB8CNL	PC	727
DMB8CNL	MW	290.8
DMB8CNL	FM	C6H6Cl6
DMB8CNL	IC	InChI=1S/C6H6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H
DMB8CNL	CS	C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl
DMB8CNL	IK	JLYXXMFPNIAWKQ-UHFFFAOYSA-N
DMB8CNL	IU	1,2,3,4,5,6-hexachlorocyclohexane
DMB8CNL	CB	CHEBI:24536
DMB8CNL	DE	Infestations of lice and scabies

DMGFPU2	ID	DMGFPU2
DMGFPU2	DN	Linezolid
DMGFPU2	HS	Approved
DMGFPU2	SN	Linezlid; ZLD; Zyvox; Zyvoxa; Zyvoxam; Zyvoxid; PNU 100766; U 100766; Linezolid & VRC3375; Linezolid [USAN:INN]; PNU-100766; U-100766; Zyvox (TN); Zyvoxam (TN); Zyvoxid (TN); NDA 21-130 Zyvox (linezolid tablets); NDA 21-131 Zyvox for injection (linezolid injection); NDA 21-132 Zyvox oral suspension (linzolid oral suspension); Linezolid (JAN/USAN/INN); PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; 111GE017
DMGFPU2	CP	Pfizer Pharmaceuticals
DMGFPU2	TC	Antibiotics
DMGFPU2	DT	Small molecular drug
DMGFPU2	PC	441401
DMGFPU2	MW	337.35
DMGFPU2	FM	C16H20FN3O4
DMGFPU2	IC	InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
DMGFPU2	CS	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F
DMGFPU2	IK	TYZROVQLWOKYKF-ZDUSSCGKSA-N
DMGFPU2	IU	N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
DMGFPU2	CA	CAS 165800-03-3
DMGFPU2	CB	CHEBI:63607
DMGFPU2	DE	Bacterial infection

DM6IR3P	ID	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	HS	Approved
DM6IR3P	SN	liothyronine; 3,3',5-Triiodo-L-thyronine; 6893/2/3; Liothyronin; Tresitope; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; triothyrone; Liothyroninum; Liotironina; 3,5,3'-Triiodo-L-thyronine; L-T3; T3; 3,3',5-Triiodothyronine; Triiodo-L-thyronine; Lyothyronine; 3,5,3'TRIIODOTHYRONINE; L-3,5,3'-Triiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; T3 (amino acid); T3 (Hormone); L-3,3',5-TriioDOThyronine; Liothyronine [INN:BAN]; Rathyronine; Triothyrone; THYROID HORMONE; Liothyronine I 131; Liothyronine I 131 [USAN]; T3 liothyronine; Cytomel (TN); Euthroid-1; Euthroid-2; Euthroid-3; Liothyronine (INN); Liothyroninum[INN-Latin]; Liotironina [INN-Spanish]; T3 (Triiodothyronine); T3 (VAN); Tertroxin (TN); Thyrolar-1; Thyrolar-2; Thyrolar-3; Tri-Thyrotope; Triiodothyronine (T3); Triomet-131; Euthroid-05; Thyrolar-025; Thyrolar-05; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Thyronine, 3,3',5-triiodo-, L-(6CI); L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-(9CI); 3,3'5-Triiodo-L-thyronine; 3,5,3'-Tri-iodo-L-thyronine; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
DM6IR3P	CP	King Pharmaceuticals, Inc
DM6IR3P	TC	Hormone Replacement Agents
DM6IR3P	DT	Small molecular drug
DM6IR3P	PC	5920
DM6IR3P	MW	650.97
DM6IR3P	FM	C15H12I3NO4
DM6IR3P	IC	InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1
DM6IR3P	CS	C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O
DM6IR3P	IK	AUYYCJSJGJYCDS-LBPRGKRZSA-N
DM6IR3P	IU	(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
DM6IR3P	CA	CAS 15785-49-6
DM6IR3P	CB	CHEBI:18258
DM6IR3P	DE	Hypothyroidism; Congestive heart failure

DMSTXWR	ID	DMSTXWR
DMSTXWR	DN	Liotrix
DMSTXWR	HS	Approved
DMSTXWR	SN	Liotrix; Novothyral; Thyrolar; Combithyrex; Diotroxin; Euthroid; W 1782; 8065-29-0; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt, mixt. with O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine monosodium salt; Levothyroxine Sodium mixture with Liothyronine Sodium; Liothyronine Sodium and Levothyroxine Sodium; Monosodium L-thyroxine hydrate mixt. with monosodium L-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine
DMSTXWR	PC	71371
DMSTXWR	MW	1471.8
DMSTXWR	FM	C30H21I7N2Na2O8
DMSTXWR	IC	LKYWLLWWYBVUPP-XOCLESOZSA-L
DMSTXWR	CS	C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)[O-])N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)[O-])N.[Na+].[Na+]
DMSTXWR	IK	1S/C15H11I4NO4.C15H12I3NO4.2Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);1-4,6,12,20H,5,19H2,(H,21,22);;/q;;2*+1/p-2/t2*12-;;/m00../s1
DMSTXWR	IU	disodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
DMSTXWR	CA	CAS 8065-29-0
DMSTXWR	CB	CHEBI:6485
DMSTXWR	DE	Hypothyroidism

DM3FXPS	ID	DM3FXPS
DM3FXPS	DN	Liraglutide
DM3FXPS	HS	Approved
DM3FXPS	SN	Liraglutida; Liraglutidum; Victoza; NN 2211; NN2211; Liraglutida [INN-Spanish]; Liraglutide [USAN:INN]; Liraglutidum [INN-Latin]; NN-2211; Victoza (TN); N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
DM3FXPS	CP	Novo Nordisk Massachusetts General Hospital
DM3FXPS	DT	Small molecular drug
DM3FXPS	SQ	Liraglutide Sequence: HAEGTFTSDVSSYLEGQAAKEEFIIAWLVKGRG
DM3FXPS	PC	16134956
DM3FXPS	MW	3751
DM3FXPS	FM	C172H265N43O51
DM3FXPS	IC	InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1
DM3FXPS	CS	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O
DM3FXPS	IK	YSDQQAXHVYUZIW-QCIJIYAXSA-N
DM3FXPS	IU	(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
DM3FXPS	CA	CAS 204656-20-2
DM3FXPS	CB	CHEBI:71193
DM3FXPS	DE	Type-2 diabetes; Obesity

DM6W8V5	ID	DM6W8V5
DM6W8V5	DN	Lisdexamfetamine
DM6W8V5	HS	Approved
DM6W8V5	SN	NRP104; Lisdexamfetamine (INN); Vyvanse (TN)
DM6W8V5	CP	New River Pharmaceuticals
DM6W8V5	DT	Small molecular drug
DM6W8V5	PC	11597698
DM6W8V5	MW	263.38
DM6W8V5	FM	C15H25N3O
DM6W8V5	IC	InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
DM6W8V5	CS	C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N
DM6W8V5	IK	VOBHXZCDAVEXEY-JSGCOSHPSA-N
DM6W8V5	IU	(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
DM6W8V5	CA	CAS 608137-32-2
DM6W8V5	CB	CHEBI:135925
DM6W8V5	DE	Attention deficit hyperactivity disorder

DMUOK4C	ID	DMUOK4C
DMUOK4C	DN	Lisinopril
DMUOK4C	HS	Approved
DMUOK4C	SN	Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)
DMUOK4C	CP	Merck & Co
DMUOK4C	TC	Antihypertensive Agents
DMUOK4C	DT	Small molecular drug
DMUOK4C	PC	5362119
DMUOK4C	MW	405.5
DMUOK4C	FM	C21H31N3O5
DMUOK4C	IC	InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
DMUOK4C	CS	C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
DMUOK4C	IK	RLAWWYSOJDYHDC-BZSNNMDCSA-N
DMUOK4C	IU	(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
DMUOK4C	CA	CAS 76547-98-3
DMUOK4C	CB	CHEBI:43755
DMUOK4C	DE	Hypertension

DMP45ME	ID	DMP45ME
DMP45ME	DN	Lisocabtagene maraleucel
DMP45ME	HS	Approved
DMP45ME	SN	JCAR017
DMP45ME	CP	Celgene
DMP45ME	DT	CAR T Cell Therapy
DMP45ME	DE	Central nervous system lymphoma; Precursor B-lymphoblastic neoplasm; Follicular lymphoma; Richter syndrome; Non-hodgkin lymphoma; Large B-cell lymphoma

DMCME17	ID	DMCME17
DMCME17	DN	Lisuride
DMCME17	HS	Approved
DMCME17	SN	Lisurida; Lisuridum; Lysurid; Lysuride; Lisuride [INN]; Lysuride Hydrogen Maleate; Methylergol Carbamide; Arolac (TN); Cuvalit (TN); Dipergon (TN); Dopergin (TN); Dopergine (TN); Lisurida [INN-Spanish]; Lisuride (INN); Lisuridum [INN-Latin]; Lysenyl Forte (TN); Prolacam (TN); Revanil (TN); Lisuride Maleate (1:1); N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea; 1,1-diethyl-3-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea; 3-(9,10-Didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea
DMCME17	CP	IVAX Pharmaceuticals
DMCME17	TC	Antiparkinson Agents
DMCME17	DT	Small molecular drug
DMCME17	PC	28864
DMCME17	MW	338.4
DMCME17	FM	C20H26N4O
DMCME17	IC	InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1
DMCME17	CS	CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMCME17	IK	BKRGVLQUQGGVSM-KBXCAEBGSA-N
DMCME17	IU	3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
DMCME17	CA	CAS 18016-80-3
DMCME17	CB	CHEBI:51164
DMCME17	DE	Parkinson disease; Fibrosis

DMX9PIA	ID	DMX9PIA
DMX9PIA	DN	Live attenuated influenza vaccine
DMX9PIA	HS	Approved
DMX9PIA	SN	Influenza vaccine, BioDiem; Influenza vaccine, St Petersburg Institute of Experimental Medicine; Live attenuated influenza vaccine (CoVaccine adjuvant); SCH-900795; Cold-adapted flu virus vaccine, St Petersburg Institute of Experimental Medicine; Influenza vaccine (live attenuated, nasal), BioDiem; Influenza vaccine, BioDiem/Merck & Co; LAIV (CoVaccine adjuvant), Nobilon/NV Organon; Live attenuated influenza vaccine (CoVaccine adjuvant), BioDiem/ Serum Institute of India; Live attenuated influenza vaccine (CoVaccine adjuvant), Schering Plough/BioDiem; Live attenuated influenza vaccine (CoVaccine adjuvant), Merck & Co/BioDiem
DMX9PIA	CP	St Petersburg Institute of Experimental Medicine
DMX9PIA	DT	Vaccine
DMX9PIA	DE	Influenza virus infection

DM0QJDC	ID	DM0QJDC
DM0QJDC	DN	Lixisenatide
DM0QJDC	HS	Approved
DM0QJDC	SN	Lyxumia (TN)
DM0QJDC	CP	Sanofi
DM0QJDC	DT	Small molecular drug
DM0QJDC	PC	90472060
DM0QJDC	MW	4858
DM0QJDC	FM	C215H347N61O65S
DM0QJDC	IC	InChI=1S/C215H347N61O65S/c1-16-115(10)173(210(337)256-141(68-74-170(299)300)194(321)261-148(94-122-98-232-126-50-24-23-49-124(122)126)199(326)258-143(89-111(2)3)196(323)247-134(58-32-40-83-223)189(316)262-149(96-160(226)285)180(307)235-100-161(286)233-104-165(290)274-85-42-60-156(274)207(334)267-154(108-280)206(333)265-151(105-277)181(308)237-101-162(287)239-117(12)213(340)276-87-44-62-158(276)214(341)275-86-43-61-157(275)208(335)268-153(107-279)204(331)249-132(56-30-38-81-221)187(314)246-131(55-29-37-80-220)186(313)245-130(54-28-36-79-219)185(312)244-129(53-27-35-78-218)184(311)243-128(52-26-34-77-217)183(310)242-127(176(227)303)51-25-33-76-216)272-201(328)146(92-120-45-19-17-20-46-120)260-197(324)144(90-112(4)5)257-190(317)135(59-41-84-231-215(228)229)255-209(336)172(114(8)9)271-177(304)116(11)240-182(309)138(65-71-167(293)294)251-192(319)139(66-72-168(295)296)252-193(320)140(67-73-169(297)298)253-195(322)142(75-88-342-15)254-191(318)137(63-69-159(225)284)250-188(315)133(57-31-39-82-222)248-203(330)152(106-278)266-198(325)145(91-113(6)7)259-200(327)150(97-171(301)302)263-205(332)155(109-281)269-212(339)175(119(14)283)273-202(329)147(93-121-47-21-18-22-48-121)264-211(338)174(118(13)282)270-164(289)103-236-179(306)136(64-70-166(291)292)241-163(288)102-234-178(305)125(224)95-123-99-230-110-238-123/h17-24,45-50,98-99,110-119,125,127-158,172-175,232,277-283H,16,25-44,51-97,100-109,216-224H2,1-15H3,(H2,225,284)(H2,226,285)(H2,227,303)(H,230,238)(H,233,286)(H,234,305)(H,235,307)(H,236,306)(H,237,308)(H,239,287)(H,240,309)(H,241,288)(H,242,310)(H,243,311)(H,244,312)(H,245,313)(H,246,314)(H,247,323)(H,248,330)(H,249,331)(H,250,315)(H,251,319)(H,252,320)(H,253,322)(H,254,318)(H,255,336)(H,256,337)(H,257,317)(H,258,326)(H,259,327)(H,260,324)(H,261,321)(H,262,316)(H,263,332)(H,264,338)(H,265,333)(H,266,325)(H,267,334)(H,268,335)(H,269,339)(H,270,289)(H,271,304)(H,272,328)(H,273,329)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H4,228,229,231)/t115-,116-,117-,118+,119+,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,172-,173-,174-,175-/m0/s1
DM0QJDC	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N
DM0QJDC	IK	XVVOERDUTLJJHN-IAEQDCLQSA-N
DM0QJDC	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM0QJDC	CA	CAS 320367-13-3
DM0QJDC	CB	CHEBI:85662
DM0QJDC	DE	Type-2 diabetes

DMJPD06	ID	DMJPD06
DMJPD06	DN	Lmw heparin
DMJPD06	HS	Approved
DMJPD06	SN	Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN)
DMJPD06	DT	Small molecular drug
DMJPD06	PC	25244225
DMJPD06	MW	591.5
DMJPD06	FM	C12H17NO20S3-4
DMJPD06	IC	InChI=1S/C12H21NO20S3/c14-4-3(13-34(20,21)22)11(19)30-2(1-29-35(23,24)25)7(4)31-12-9(33-36(26,27)28)6(16)5(15)8(32-12)10(17)18/h2-9,11-16,19H,1H2,(H,17,18)(H,20,21,22)(H,23,24,25)(H,26,27,28)/p-4/t2-,3?,4-,5?,6+,7?,8?,9?,11?,12-/m1/s1
DMJPD06	CS	C([C@@H]1C([C@@H](C(C(O1)O)NS(=O)(=O)[O-])O)O[C@H]2C([C@H](C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]
DMJPD06	IK	OHJKXVLJWUPWQG-IUYNYSEKSA-J
DMJPD06	IU	(4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
DMJPD06	DE	Hematologic disease; Coagulation defect

DMHY3IP	ID	DMHY3IP
DMHY3IP	DN	Lobeglitazone
DMHY3IP	HS	Approved
DMHY3IP	SN	Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang
DMHY3IP	CP	Chong Kun Dang Pharmaceutical Corp
DMHY3IP	DT	Small molecular drug
DMHY3IP	PC	9826451
DMHY3IP	MW	480.5
DMHY3IP	FM	C24H24N4O5S
DMHY3IP	IC	InChI=1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30)
DMHY3IP	CS	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC
DMHY3IP	IK	CHHXEZSCHQVSRE-UHFFFAOYSA-N
DMHY3IP	IU	5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMHY3IP	CA	CAS 607723-33-1
DMHY3IP	CB	CHEBI:136052
DMHY3IP	DE	Type-2 diabetes

DM1WXA6	ID	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	HS	Approved
DM1WXA6	SN	Britlofex; Lofexidina; Lofexidinum; Britlofex (TN); Lofexidina [INN-Spanish]; Lofexidine (INN); Lofexidine [INN:BAN]; Lofexidinum [INN-Latin]; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-(9CI); 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole
DM1WXA6	CP	US WorldMeds
DM1WXA6	TC	Antihypertensive Agents
DM1WXA6	DT	Small molecular drug
DM1WXA6	PC	30668
DM1WXA6	MW	259.13
DM1WXA6	FM	C11H12Cl2N2O
DM1WXA6	IC	InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)
DM1WXA6	CS	CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl
DM1WXA6	IK	KSMAGQUYOIHWFS-UHFFFAOYSA-N
DM1WXA6	IU	2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole
DM1WXA6	CA	CAS 31036-80-3
DM1WXA6	CB	CHEBI:51368
DM1WXA6	DE	Opioid dependence; Heroin and opiate withdrawal

DMVRH9C	ID	DMVRH9C
DMVRH9C	DN	Lomefloxacin
DMVRH9C	HS	Approved
DMVRH9C	SN	LFLX; Lomefloxacine; Lomefloxacino; Lomefloxacinum; Lomefloxacine [French]; Lomefloxacino [Spanish]; Lomefloxacinum[Latin]; SC 4711; SC 47111A; DM 10 (bactericide); DM-10; Lomefloxacin (USAN); Maxaquin (TN); Maxaquin (hydrochloride); Okacyn (TN); SC-4711; SC-47111A; Uniquin (TN); Lomefloxacin [USAN:BAN:INN]; NY-198 (hydrochloride); SC-47111 (hydrochloride); SC-47111B (mesylate); (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride
DMVRH9C	CP	Pharmacia Corp
DMVRH9C	TC	Antibiotics
DMVRH9C	DT	Small molecular drug
DMVRH9C	PC	3948
DMVRH9C	MW	351.35
DMVRH9C	FM	C17H19F2N3O3
DMVRH9C	IC	InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)
DMVRH9C	CS	CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O
DMVRH9C	IK	ZEKZLJVOYLTDKK-UHFFFAOYSA-N
DMVRH9C	IU	1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMVRH9C	CA	CAS 98079-51-7
DMVRH9C	CB	CHEBI:116278
DMVRH9C	DE	Bacterial infection

DME0TC8	ID	DME0TC8
DME0TC8	DN	Lomerizine
DME0TC8	HS	Approved
DME0TC8	SN	lomerizine; 101477-55-8; Lomerizine [INN]; UNII-DEE37CY4VO; 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine; C27H30F2N2O3; DEE37CY4VO; CHEMBL29188; Terranas; 1-(Bis(p-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine; 1-(Bis(p-fluorophenyl)-methyl)-4-(2,3,4-trimethoxybenzyl)piperazine; NCGC00164543-01; iomerizine; 1-(2,3,4-trimethoxybenzyl)-4-[bis(4-fluorophenyl)methyl]piperazine; 1-(2,3,4-trimethoxybenzyl)-4-(bis(4-fluorophenyl)methyl)piperazine; AC1Q4NME
DME0TC8	DT	Small molecular drug
DME0TC8	PC	3949
DME0TC8	MW	468.5
DME0TC8	FM	C27H30F2N2O3
DME0TC8	IC	InChI=1S/C27H30F2N2O3/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20/h4-13,25H,14-18H2,1-3H3
DME0TC8	CS	COC1=C(C(=C(C=C1)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC)OC
DME0TC8	IK	JQSAYKKFZOSZGJ-UHFFFAOYSA-N
DME0TC8	IU	1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine
DME0TC8	CA	CAS 101477-55-8
DME0TC8	CB	CHEBI:94682
DME0TC8	DE	Migraine

DMLB4PE	ID	DMLB4PE
DMLB4PE	DN	Lomitapide mesylate
DMLB4PE	HS	Approved
DMLB4PE	SN	Lomitapide (mesylate); Lomitapide mesylate; Lomitapide mesylate (USAN); Lomitapide mesylate [USAN]; X4S83CP54E; lomitapide-mesylate; 202914-84-9; BMS 201038-04; BMS-201038-04; CHEBI:72299; N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)biphenyl-2-ylcarboxamido)piperidin-1-yl)butyl)-9H-fluorene-9-carboxamide methanesulfonate; UNII-X4S83CP54E; Juxtapid (TN)
DMLB4PE	PC	11274333
DMLB4PE	MW	789.8
DMLB4PE	FM	C40H41F6N3O5S
DMLB4PE	IC	QKVKOFVWUHNEBX-UHFFFAOYSA-N
DMLB4PE	CS	CS(=O)(=O)O.C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
DMLB4PE	IK	1S/C39H37F6N3O2.CH4O3S/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45;1-5(2,3)4/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49);1H3,(H,2,3,4)
DMLB4PE	IU	methanesulfonic acid;N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
DMLB4PE	CA	CAS 202914-84-9
DMLB4PE	CB	CHEBI:72299
DMLB4PE	DE	Hypertriglyceridaemia

DMMWSUL	ID	DMMWSUL
DMMWSUL	DN	Lomustine
DMMWSUL	HS	Approved
DMMWSUL	SN	Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea
DMMWSUL	TC	Anticancer Agents
DMMWSUL	DT	Small molecular drug
DMMWSUL	PC	3950
DMMWSUL	MW	233.69
DMMWSUL	FM	C9H16ClN3O2
DMMWSUL	IC	InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)
DMMWSUL	CS	C1CCC(CC1)NC(=O)N(CCCl)N=O
DMMWSUL	IK	GQYIWUVLTXOXAJ-UHFFFAOYSA-N
DMMWSUL	IU	1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
DMMWSUL	CA	CAS 13010-47-4
DMMWSUL	CB	CHEBI:6520
DMMWSUL	DE	Brain cancer

DMGM2Z6	ID	DMGM2Z6
DMGM2Z6	DN	Lonafarnib
DMGM2Z6	HS	Approved
DMGM2Z6	SN	Sarasar; Lonafarnib [USAN]; Sch 66336; Sch66336; SCH-066336; Sch-66336; Lonafarnib (USAN/INN); (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; (+)-4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; (+)-4[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE
DMGM2Z6	CP	Schering-Plough
DMGM2Z6	TC	Anticancer Agents
DMGM2Z6	DT	Small molecular drug
DMGM2Z6	PC	148195
DMGM2Z6	MW	638.8
DMGM2Z6	FM	C27H31Br2ClN4O2
DMGM2Z6	IC	InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1
DMGM2Z6	CS	C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
DMGM2Z6	IK	DHMTURDWPRKSOA-RUZDIDTESA-N
DMGM2Z6	IU	4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide
DMGM2Z6	CA	CAS 193275-84-2
DMGM2Z6	CB	CHEBI:47097
DMGM2Z6	DE	Non-small-cell lung cancer; Hepatitis D virus infection; Myelodysplastic syndrome; Hutchinson-Gilford progeria syndrome

DMXSVGI	ID	DMXSVGI
DMXSVGI	DN	Loncastuximab tesirine
DMXSVGI	HS	Approved
DMXSVGI	CP	ADC Therapeutics
DMXSVGI	DT	Antibody drug conjugate
DMXSVGI	DE	Diffuse large B-cell lymphoma; Follicular lymphoma

DMOJZQ9	ID	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	HS	Approved
DMOJZQ9	SN	Ioperamide; Loperacap; Loperamida; Loperamidum; Kaopectate II; Loperamide Monohydrochloride; Pepto Diarrhea Control; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide [INN:BAN]; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); R-18553; Rho-Loperamide
DMOJZQ9	CP	Janssen Pharmaceutica
DMOJZQ9	TC	Antidiarrheals
DMOJZQ9	DT	Small molecular drug
DMOJZQ9	PC	3955
DMOJZQ9	MW	477
DMOJZQ9	FM	C29H33ClN2O2
DMOJZQ9	IC	InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
DMOJZQ9	CS	CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4
DMOJZQ9	IK	RDOIQAHITMMDAJ-UHFFFAOYSA-N
DMOJZQ9	IU	4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
DMOJZQ9	CA	CAS 53179-11-6
DMOJZQ9	CB	CHEBI:6532
DMOJZQ9	DE	Diarrhea

DMITQS0	ID	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	HS	Approved
DMITQS0	SN	AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346; A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378
DMITQS0	CP	Abbott Laboratories
DMITQS0	TC	Anti-HIV Agents
DMITQS0	DT	Small molecular drug
DMITQS0	PC	92727
DMITQS0	MW	628.8
DMITQS0	FM	C37H48N4O5
DMITQS0	IC	InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
DMITQS0	CS	CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
DMITQS0	IK	KJHKTHWMRKYKJE-SUGCFTRWSA-N
DMITQS0	IU	(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
DMITQS0	CA	CAS 192725-17-0
DMITQS0	CB	CHEBI:31781
DMITQS0	DE	Human immunodeficiency virus infection

DM4L8H3	ID	DM4L8H3
DM4L8H3	DN	Loracarbef
DM4L8H3	HS	Approved
DM4L8H3	SN	Lorabid; Loracarbefum; Lorafem; Loracarbef hydrate; KT-3777; LY-163892; Lorabid (TN); (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-ammonio-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylic acid; 7beta-[(2R)-2-ammonio-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate
DM4L8H3	CP	Eli Lilly
DM4L8H3	TC	Antibiotics
DM4L8H3	DT	Small molecular drug
DM4L8H3	PC	5284585
DM4L8H3	MW	349.77
DM4L8H3	FM	C16H16ClN3O4
DM4L8H3	IC	InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12+/m1/s1
DM4L8H3	CS	C1CC(=C(N2[C@H]1[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl
DM4L8H3	IK	JAPHQRWPEGVNBT-UTUOFQBUSA-N
DM4L8H3	IU	(6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM4L8H3	CA	CAS 76470-66-1
DM4L8H3	CB	CHEBI:47544
DM4L8H3	DE	Bacterial infection

DMF3AN7	ID	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	HS	Approved
DMF3AN7	SN	Aerotina; Alarin; Alavert; Alerpriv; Allertidin; Anhissen; Biloina; Bonalerg; Civeran; Claratyne; Clarinase; Claritin; Claritine; Clarityn; Clarityne; Clarium; Fristamin; Histaloran; Lergy; Lertamine; Lesidas; Lisino; Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratadina; Loratadinum; Loratidine; Loratyne; Loraver; Lorfast; Loritine; Lowadina; Nularef; Optimin; Polaratyne; Pylor; Restamine; Rhinase; Rinomex; Roletra; Sanelor; Sensibit; Sohotin; Tadine; Velodan; Versal; Zeos; Bedix Loratadina; Claratyne Cold; Claratyne Decongestant; Clarinase Reperabs; Claritin D; Claritin Hives Relief; Claritin Hives Relief Reditab; Claritin Reditabs; Claritin reditab; Clarityne Dy Repetabs; Loratadina [Spanish]; Loratadine Redidose; Loratadine Wyeth Brand; Loratadinum [Latin]; Sinhistan Dy; Talorat Dy; Wyeth Brand of Loratadine; L 9664; Sch 29851; Sch29851; Alavert (TN); AllergyX (TN); Children's Claritin; Claritin (TN); Claritine (TN); Clarityn (TN); Clarityne (TN); Clarityne-D; Flonidan (TN); Fristamin (TN); Lomilan (TN); Lorfast (TN); Rinolan (TN); Roletra (TN); Sch-29851; Symphoral (TN); Tidilor (TN); Alavert, Claritin, Loratadine; Loratadine [USAN:BAN:INN]; Loratadine (JAN/USAN/INN); Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate; Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate; 1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester; 1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester; 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acidethyl ester; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
DMF3AN7	CP	Schering-Plough Corporation
DMF3AN7	TC	Antihistamines
DMF3AN7	DT	Small molecular drug
DMF3AN7	PC	3957
DMF3AN7	MW	382.9
DMF3AN7	FM	C22H23ClN2O2
DMF3AN7	IC	InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
DMF3AN7	CS	CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
DMF3AN7	IK	JCCNYMKQOSZNPW-UHFFFAOYSA-N
DMF3AN7	IU	ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate
DMF3AN7	CA	CAS 79794-75-5
DMF3AN7	CB	CHEBI:6538
DMF3AN7	DE	Allergy; Allergic rhinitis

DM84ZXF	ID	DM84ZXF
DM84ZXF	DN	Lorazepam
DM84ZXF	HS	Approved
DM84ZXF	SN	Almazine; Alzapam; Anxiedin; Anxira; Anzepam; Aplacasse; Aplacassee; ApoLorazepam; Aripax; Ativan; Azurogen; Bonatranquan; Bonton; Delormetazepam; Demethyllormetazepam; Donix; Duralozam; Durazolam; Efasedan; Emotion; Emotival; Equitam; Idalprem; Kalmalin; Larpose; Laubeel; Lomesta; Lopam; Lorabenz; Lorafen; Loram; Lorans; Lorapam; Lorat; Lorax; Loraz; Lorazene; Lorazep; Lorazepamum; Lorazin; Lorazon; Lorenin; Loridem; Lorivan; Lorsedal; Lorsilan; Lorzem; Lozepam; Merlit; Nervistopl; Norlormetazepam; Novhepar; Novolorazem; NuLoraz; Orfidal; Punktyl; Quait; Renaquil; Rocosgen; Securit; Sedatival; Sedazin; Sedicepan; Sedizepan; Sidenar; Silence; Sinestron; Somagerol; Stapam; Tavor; Temesta; Tolid; Tranqipam; Trapax; Upan; Vigiten; Wypax; AHP Brand of Lorazepam; Apo Lorazepam; Apotex Brand of Lorazepam; Baxter Brand of Lorazepam; Ct Arzneimittel Brand of Lorazepam; Desitin Brand of Lorazepam; Dolorgiet Brand of Lorazepam; Llorens Brand of Lorazepam; Lorazep von ct; Lorazepam AHP Brand; Lorazepam Apotex Brand; Lorazepam Baxter Brand; Lorazepam Desitin Brand; Lorazepam Dolorgiet Brand; Lorazepam Fabra; Lorazepam Genericon; Lorazepam Intensol; Lorazepam Lannacher; Lorazepam Llorens Brand; Lorazepam Medical; Lorazepam Medical Brand; Lorazepam Medix Brand; Lorazepam Novartis Brand; Lorazepam Novopharm Brand; Lorazepam Riemser Brand; Lorazepam Wyeth Brand; Lorazepam neuraxpharm; Lorazepam neuraxpharm Brand; Lorazepam preservative free; Lorazepam ratiopharm; Lorazepam ratiopharm Brand; Lorazepan Chobet; Lorazepan Richet; Max Pax; Medical Brand of Lorazepam; Medix Brand of Lorazepam; Merck dura Brand of Lorazepam; Nervistop L; Neuraxpharm Brand of Lorazepam; Novartis Brand of Lorazepam; Novo Lorazem; Novopharm Brand of Lorazepam; Nu Loraz; Nu Pharm Brand of Lorazepam; Orfidal Wyeth; Pro dorm; Ratiopharm Brand of Lorazepam; Riemser Brand of Lorazepam; Serra Pamies Brand of Lorazepam; Wyeth Brand of Lorazepam; L1764_SIGMA; WY4036; Wy 4036; Apo-Lorazepam; Ativan (TN); Ct-Arzneimittel Brand of Lorazepam; Lorazepam (Ativan); Lorazepam Nu-Pharm Brand; Lorazepam ct-Arzneimittel Brand; Lorazepam-Efeka; Lorazepam-neuraxpharm; Lorazepam-ratiopharm; Lorazepamum [INN-Latin]; Medical, Lorazepam; Novo-Lorazem; Nu-Loraz; Nu-Pharm Brand of Lorazepam; O-Chlorooxazepam; O-Chloroxazepam; Temesta (TN); Wy-4036; Wyeth, Orfidal; Lorazepam (JP15/USP/INN); Lorazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; (+/-)-Lorazepam; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
DM84ZXF	CP	Wyeth Pharmaceuticals
DM84ZXF	TC	Antianxiety Agents
DM84ZXF	DT	Small molecular drug
DM84ZXF	PC	3958
DM84ZXF	MW	321.2
DM84ZXF	FM	C15H10Cl2N2O2
DM84ZXF	IC	InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)
DM84ZXF	CS	C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
DM84ZXF	IK	DIWRORZWFLOCLC-UHFFFAOYSA-N
DM84ZXF	IU	7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
DM84ZXF	CA	CAS 846-49-1
DM84ZXF	CB	CHEBI:6539
DM84ZXF	DE	Anxiety disorder

DMG6OYJ	ID	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	HS	Approved
DMG6OYJ	SN	APD 356; APD356; AR-10A; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 10-chloro-2-methyl-4-azabicyclo[5.4.0]undeca-8,10,12-triene
DMG6OYJ	CP	Arena Pharmaceuticals Inc.
DMG6OYJ	DT	Small molecular drug
DMG6OYJ	PC	11658860
DMG6OYJ	MW	195.69
DMG6OYJ	FM	C11H14ClN
DMG6OYJ	IC	InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1
DMG6OYJ	CS	C[C@H]1CNCCC2=C1C=C(C=C2)Cl
DMG6OYJ	IK	XTTZERNUQAFMOF-QMMMGPOBSA-N
DMG6OYJ	IU	(5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
DMG6OYJ	CA	CAS 616202-92-7
DMG6OYJ	CB	CHEBI:65353
DMG6OYJ	DE	Obesity; Drug abuse

DMICDLV	ID	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	HS	Approved
DMICDLV	SN	Loratinib; UNII-OSP71S83EU; Lorlatinib,PF-06463922; OSP71S83EU; lorlantinib; 4clj; 4cli; Lorlatinib [USAN:INN]; Lorlatinib (JAN/USAN/INN); PF06463922(Lorlatinib); GTPL7476; SCHEMBL15261807; EX-A828; MolPort-035-789-724; KS-00000T6C; 2641AH; ZINC98208524; s7536; MFCD28144520; BDBM50018830; AKOS027250753; DB12130; CS-39
DMICDLV	CP	Pfizer
DMICDLV	PC	71731823
DMICDLV	MW	406.4
DMICDLV	FM	C21H19FN6O2
DMICDLV	IC	InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
DMICDLV	CS	C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
DMICDLV	IK	IIXWYSCJSQVBQM-LLVKDONJSA-N
DMICDLV	IU	(16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
DMICDLV	CA	CAS 1454846-35-5
DMICDLV	CB	CHEBI:143117
DMICDLV	DE	Non-small-cell lung cancer

DMYZFXN	ID	DMYZFXN
DMYZFXN	DN	Lornoxicam
DMYZFXN	HS	Approved
DMYZFXN	SN	CTX; Chlortenoxicam; Lorcam; Safem; Telos; Xefo; Xefo Rapid; HN-10000; TS-110; Ro-13-9297
DMYZFXN	CP	Roche Holding AG
DMYZFXN	DT	Small molecular drug
DMYZFXN	PC	54690031
DMYZFXN	MW	371.8
DMYZFXN	FM	C13H10ClN3O4S2
DMYZFXN	IC	InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)
DMYZFXN	CS	CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3
DMYZFXN	IK	WLHQHAUOOXYABV-UHFFFAOYSA-N
DMYZFXN	IU	6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide
DMYZFXN	CA	CAS 70374-39-9
DMYZFXN	CB	CHEBI:31783
DMYZFXN	DE	Migraine

DM72JXH	ID	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	HS	Approved
DM72JXH	SN	Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan
DM72JXH	CP	Merck & Co
DM72JXH	TC	Antihypertensive Agents
DM72JXH	DT	Small molecular drug
DM72JXH	PC	3961
DM72JXH	MW	422.9
DM72JXH	FM	C22H23ClN6O
DM72JXH	IC	InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
DM72JXH	CS	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
DM72JXH	IK	PSIFNNKUMBGKDQ-UHFFFAOYSA-N
DM72JXH	IU	[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
DM72JXH	CA	CAS 114798-26-4
DM72JXH	CB	CHEBI:6541
DM72JXH	DE	Hypertension

DM8QTJI	ID	DM8QTJI
DM8QTJI	DN	Loteprednol etabonate
DM8QTJI	HS	Approved
DM8QTJI	SN	Alrex; Locort; Loteflam; Lotemax; Loterox; CDDD-5604; HGP-1; IDR-90102; IDR-90103; Lotemax (TN); P-5604; Alrex, Lotemax, Loteprednol etabonate; Loteprednol etabonate (JAN/USAN); Chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate; Chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
DM8QTJI	CP	Bausch & Lomb Pharmaceuticals, Inc.
DM8QTJI	TC	Antiallergic Agents
DM8QTJI	DT	Small molecular drug
DM8QTJI	PC	444025
DM8QTJI	MW	466.9
DM8QTJI	FM	C24H31ClO7
DM8QTJI	IC	InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1
DM8QTJI	CS	CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl
DM8QTJI	IK	DMKSVUSAATWOCU-HROMYWEYSA-N
DM8QTJI	IU	chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
DM8QTJI	CA	CAS 82034-46-6
DM8QTJI	CB	CHEBI:31784
DM8QTJI	DE	Eye inflammation

DM9OZWQ	ID	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	HS	Approved
DM9OZWQ	SN	lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD;  Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination
DM9OZWQ	CP	Atos Pharma
DM9OZWQ	TC	Anticholesteremic Agents
DM9OZWQ	DT	Small molecular drug
DM9OZWQ	PC	53232
DM9OZWQ	MW	404.5
DM9OZWQ	FM	C24H36O5
DM9OZWQ	IC	InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
DM9OZWQ	CS	CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
DM9OZWQ	IK	PCZOHLXUXFIOCF-BXMDZJJMSA-N
DM9OZWQ	IU	[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
DM9OZWQ	CA	CAS 75330-75-5
DM9OZWQ	CB	CHEBI:40303
DM9OZWQ	DE	Hypercholesterolaemia; Cardiovascular disease

DMGCQ4E	ID	DMGCQ4E
DMGCQ4E	DN	Lovastatin acid
DMGCQ4E	HS	Approved
DMGCQ4E	SN	Lovastatin acid; Mevinolinic acid; Monacolinic K acid; MSD 803 acid; MSD 803 free acid; UNII-5CLV35Y90C; MK 819; L-154819; L 154819; 5CLV35Y90C; CHEBI:82985; (3R,5R)-7-((1R,2R,6S,8R,8AS)-2,6-DIMETHYL-8-{[(2R)-2-METHYLBUTANOYL]OXY}-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DMGCQ4E	PC	64727
DMGCQ4E	MW	422.6
DMGCQ4E	FM	C24H38O6
DMGCQ4E	IC	InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28)/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
DMGCQ4E	CS	CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)C
DMGCQ4E	IK	QLJODMDSTUBWDW-BXMDZJJMSA-N
DMGCQ4E	IU	(3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DMGCQ4E	CA	CAS 75225-51-3
DMGCQ4E	CB	CHEBI:82985
DMGCQ4E	DE	Hypercholesterolemia

DM8AI9U	ID	DM8AI9U
DM8AI9U	DN	Loxapine
DM8AI9U	HS	Approved
DM8AI9U	SN	Cloxazepine; Dibenzacepin; Dibenzoazepine; Lossapina; Loxapin; Loxapina; Loxapinsuccinate; Loxapinum; Loxepine; Oxilapine; Lossapina [DCIT]; Loxitane IM; CL 62362; HF 3170; HF3170; Hydrofluoride 3170; LW 3170; S 805; SUM 3170; CL-62362; Loxapac (TN); Loxapina [INN-Spanish]; Loxapinum [INN-Latin]; Loxitane (TN); S-805;SUM-3170; CL-71,563; Loxapine (USAN/INN); Loxapine [USAN:BAN:INN]; Loxapine [USAN:INN:BAN]; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine
DM8AI9U	CP	Watson Laboratories
DM8AI9U	TC	Antipsychotic Agents
DM8AI9U	DT	Small molecular drug
DM8AI9U	PC	3964
DM8AI9U	MW	327.8
DM8AI9U	FM	C18H18ClN3O
DM8AI9U	IC	InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
DM8AI9U	CS	CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
DM8AI9U	IK	XJGVXQDUIWGIRW-UHFFFAOYSA-N
DM8AI9U	IU	8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
DM8AI9U	CA	CAS 1977-10-2
DM8AI9U	CB	CHEBI:50841
DM8AI9U	DE	Schizophrenia

DMQMGXV	ID	DMQMGXV
DMQMGXV	DN	Loxoprofen gel
DMQMGXV	HS	Approved
DMQMGXV	SN	Loxonin; Loxoprofen; Loxonin Pap; Loxonin Tape; CS-600G; LX-A; LX-P; Loxonin Gel 1%; Lipoxin A, Daiichi Sankyo/Lead Chemical; Lipoxin A, Sankyo/ Lead Chemical; Loxoprofen (gel, pain/ inflammation), Daiichi Sankyo; Loxoprofen (gel, pain/ inflammation), Sankyo; Loxoprofen (patch, pain/inflammation), Daiichi Sankyo/ Lead Chemical; Loxoprofen (patch, pain/inflammation), Sankyo/ Lead Chemical
DMQMGXV	CP	Sankyo Co Ltd
DMQMGXV	DT	Small molecular drug
DMQMGXV	PC	3965
DMQMGXV	MW	246.3
DMQMGXV	FM	C15H18O3
DMQMGXV	IC	InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
DMQMGXV	CS	CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
DMQMGXV	IK	YMBXTVYHTMGZDW-UHFFFAOYSA-N
DMQMGXV	IU	2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid
DMQMGXV	CA	68767-14-6
DMQMGXV	DE	Inflammation

DMQXI9F	ID	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	HS	Approved
DMQXI9F	SN	Endophenyl; Fenilalanina; Phe; Phenylalanine; Phenylalaninum; Fenilalanina [Spanish]; Phenylalaninum [Latin]; Antibiotic FN 1636; CB 3208; NCI9959; Alpha-Aminohydrocinnamic acid; Beta-Phenylalanine; L-Antibiotic FN 1636; L-PHENYLALININE; N-Formylmelphalan; Phenylalanine (VAN); H-Phe-OH; L-Phenylalanine (JP15); Phenylalanine (USP/INN); Phenylalanine [USAN:INN:JAN]; Beta-Phenyl-L-alanine; N-Formyl-L-sarcolysin; N-Formyl-L-p-sarcolysin; L-PHENYL ALANINE (SEE ALSO 22839-47-0, ASPARTAME; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)-N-formylalanine; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-N-formyl-(9CI); (2S)-2-amino-3-phenylpropanoic acid; (L)-Phenylalanine; (S)-(-)-Phenylalanine; (S)-2-Amino-3-phenylpropanoic acid; (S)-2-Amino-3-phenylpropionic acid; (S)-Phenylalanine; (S)-alpha-Amino-benzenepropanoic acid; (S)-alpha-Amino-beta-phenylpropionic acid; (S)-alpha-Aminohydrocinnamic acid; 1F9436B3-8B0D-4AC6-A004-4249B0BDA436; 3-Phenyl-L-alanine; 3-Phenylalanine; 3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid
DMQXI9F	TC	Dietary supplement
DMQXI9F	DT	Small molecular drug
DMQXI9F	PC	6140
DMQXI9F	MW	165.19
DMQXI9F	FM	C9H11NO2
DMQXI9F	IC	InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1
DMQXI9F	CS	C1=CC=C(C=C1)C[C@@H](C(=O)O)N
DMQXI9F	IK	COLNVLDHVKWLRT-QMMMGPOBSA-N
DMQXI9F	IU	(2S)-2-amino-3-phenylpropanoic acid
DMQXI9F	CA	CAS 63-91-2
DMQXI9F	CB	CHEBI:17295
DMQXI9F	DE	Malnutrition

DMKSTWR	ID	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	HS	Approved
DMKSTWR	SN	Carboxypyrrolidine; Pro; Prolina; Prolinum; Prolina [Spanish]; Prolinum [Latin]; CB 1707; L-Prolin; PRO (IUPACabbreviation); Proline (USP); Proline (VAN); Proline [USAN:INN]; H-Pro-OH; L-Proline (JAN); L-Proline-15N; L-alpha-Pyrrolidinecarboxylic acid; L-Proline, labeled with carbon-14; L-Pyrrolidine-2-carboxylic acid; L-(2,3-3H)Proline; (-)-(S)-Proline; (-)-2-Pyrrolidinecarboxylic acid; (-)-Proline (S)-2-Carboxypyrrolidine; (2S)-pyrrolidine-2-carboxylic acid; (S)-2-Carboxypyrrolidine; (S)-2-Pyrrolidinecarboxylic acid; (S)-Proline; (S)-Pyrrolidine-2-carboxylic acid; 2-pyrrolidinecarboxylic acid
DMKSTWR	TC	Dietary supplement
DMKSTWR	DT	Small molecular drug
DMKSTWR	PC	145742
DMKSTWR	MW	115.13
DMKSTWR	FM	C5H9NO2
DMKSTWR	IC	InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
DMKSTWR	CS	C1C[C@H](NC1)C(=O)O
DMKSTWR	IK	ONIBWKKTOPOVIA-BYPYZUCNSA-N
DMKSTWR	IU	(2S)-pyrrolidine-2-carboxylic acid
DMKSTWR	CA	CAS 4305-67-3
DMKSTWR	CB	CHEBI:17203
DMKSTWR	DE	Malnutrition

DMIBH7M	ID	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	HS	Approved
DMIBH7M	SN	Ardeytropin; Kalma; LTR; Lyphan; Optimax; Pacitron; Sedanoct; Triptofano; Trofan; Trp; Tryptacin; Tryptan; Tryptophane; Tryptophanum; Triptofano [Spanish]; Tryptophane [French]; Tryptophanum [Latin]; EH 121; MT1; T 0254; Alti-Tryptophan; L-TRYPTOPHAN SIGMA GRADE; L-Trp; L-Tryptofan; L-Tryptophane; L-Ttp; TRP NH3+ COOH; TRP-01; Tryptophan (VAN); Tryptophan [USAN:INN]; H-Trp-oh; Indole-3-alanine; L-Tryptophan (9CI); L-Tryptophan (JP15); Tryptophan (H-3); Tryptophan (USP/INN); L-b-3-Indolylalanine; L-beta-3-Indolylalanine; Tryptophan, L-(8CI); Alanine, 3-indol-3-yl; Alpha'-Amino-3-indolepropionic acid; L-(-)-Tryptophan; L-(-)-Tryptophane; L-a-Aminoindole-3-propionic acid; L-alpha-Aminoindole-3-propionic acid; L-alpha-amino-3-indolepropionic acid; Alpha-Amino-beta-(3-indolyl)-propionic acid; Alpha-amino-beta-(3-indolyl)-pr opionic acid; Propionic acid, 2-amino-3-indol-3-yl; S(-)-1-alpha-Aminoindole-3-propionic acid; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; (L)-TRYPTOPHAN; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-(-)-Tryptopha n; (S)-(-)-Tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; (S)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; (S)-alpha-Aminoindole-3-propionic acid; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; 1-beta-3-Indolylalanine; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; 1H-Indole-3-alanine; 1H-Indole-3-alanine (VAN); 1beta-3-Indolylalanine; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; 2-Amino-3-indolylpropanoic acid; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine
DMIBH7M	TC	Antidepressants
DMIBH7M	DT	Small molecular drug
DMIBH7M	PC	6305
DMIBH7M	MW	204.22
DMIBH7M	FM	C11H12N2O2
DMIBH7M	IC	InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1
DMIBH7M	CS	C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N
DMIBH7M	IK	QIVBCDIJIAJPQS-VIFPVBQESA-N
DMIBH7M	IU	(2S)-2-amino-3-(1H-indol-3-yl)propanoic acid
DMIBH7M	CA	CAS 73-22-3
DMIBH7M	CB	CHEBI:16828
DMIBH7M	DE	Depression

DM9O8DT	ID	DM9O8DT
DM9O8DT	DN	L-tyrosine
DM9O8DT	HS	Approved
DM9O8DT	SN	DTY; Rxosine; Tirosina; Tyr; Tyrosine; Tyrosinum; Tirosina [Spanish]; Tyrosine Power; Tyrosinum [Latin]; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; L-Tyrosin; L-Tyrosine hydrochloride; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; P-Tyrosine; TYR NH3+ COOH; Tyrosine (VAN); Tyrosine [USAN:INN]; Free-Form L-Tyrosine; H-Tyr-OH; L-Tyrosine (9CI); L-Tyrosine (JAN); L-Tyrosine, homopolymer; L-Tyrosine, monomer; L-p-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; Tyrosine (USP/INN); Beta-(p-Hydroxyphenyl)alanine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; Tyrosine, L-(8CI); DD69927C-C6A8-4BC6-8E9A-0AB423B176E7; L-(-)-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; Alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; L-2-Amino-3-p-hydroxyphenylpropanoic acid; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; (S)-3-(p-Hydroxyphenyl)alanine; (S)-Tyrosine; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; 2-Amino-3-(p-hydroxyphenyl)propionic acid; 3-(4-Hydroxyphenyl)-L-alanine; 3-(p-Hydroxyphenyl)alanine; 4-Hydroxy-L-phenylalanine; 4ts1
DM9O8DT	TC	Dietary supplement
DM9O8DT	DT	Small molecular drug
DM9O8DT	PC	6057
DM9O8DT	MW	181.19
DM9O8DT	FM	C9H11NO3
DM9O8DT	IC	InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1
DM9O8DT	CS	C1=CC(=CC=C1C[C@@H](C(=O)O)N)O
DM9O8DT	IK	OUYCCCASQSFEME-QMMMGPOBSA-N
DM9O8DT	IU	(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
DM9O8DT	CA	CAS 60-18-4
DM9O8DT	CB	CHEBI:17895
DM9O8DT	DE	Malnutrition

DMMJVXZ	ID	DMMJVXZ
DMMJVXZ	DN	LU302146
DMMJVXZ	HS	Approved
DMMJVXZ	DE	Pulmonary hypertension

DMJTEMW	ID	DMJTEMW
DMJTEMW	DN	Lubiprostone
DMJTEMW	HS	Approved
DMJTEMW	SN	Amitiza; Lubiprostone [USAN]; RU 0211; RU0211; SPI 0211; SPI0211; AMITIZA (TN); RU-0211; SPI-0211; Amitiza, RU-0211, SPI-0211, Lubiprostone; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta (b)pyran-5-yl)heptanoic acid; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid; 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid; 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
DMJTEMW	CP	Takeda
DMJTEMW	TC	Anticonstipation Agents
DMJTEMW	DT	Small molecular drug
DMJTEMW	PC	157920
DMJTEMW	MW	390.5
DMJTEMW	FM	C20H32F2O5
DMJTEMW	IC	InChI=1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15-,17-,20-/m1/s1
DMJTEMW	CS	CCCCC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@@H]2CCCCCCC(=O)O)O)(F)F
DMJTEMW	IK	WGFOBBZOWHGYQH-MXHNKVEKSA-N
DMJTEMW	IU	7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
DMJTEMW	CA	CAS 333963-40-9
DMJTEMW	DE	Chronic idiopathic constipation

DMZLBUO	ID	DMZLBUO
DMZLBUO	DN	Lucanthone
DMZLBUO	HS	Approved
DMZLBUO	SN	Lucanthon; Lucanthonum; Lucantona; Miracol; Nilodin; Scapuren; Tixantone; LUCANTHONE HYDROCHLORIDE; Lucanthone monohydrochloride; Miracil D; BW 57223; CBC 900139; DR-15771; Lucanthone [INN:BAN]; Lucanthonum [INN-Latin]; Lucantona [INN-Spanish]; 1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one; 1-(2-diethylaminoethylamino)-4-methylthioxanthen-9-one; 1-[[2-(Diethylamino)ethyl]amino]-4-methylthioxanthone; 1-{[2-(Diethylamino)ethyl]amino}-4-methyl-9H-thioxanthen-9-one; 9H-Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl-(9CI)
DMZLBUO	CP	Spectrum
DMZLBUO	TC	Anticancer Agents
DMZLBUO	DT	Small molecular drug
DMZLBUO	PC	10180
DMZLBUO	MW	340.5
DMZLBUO	FM	C20H24N2OS
DMZLBUO	IC	InChI=1S/C20H24N2OS/c1-4-22(5-2)13-12-21-16-11-10-14(3)20-18(16)19(23)15-8-6-7-9-17(15)24-20/h6-11,21H,4-5,12-13H2,1-3H3
DMZLBUO	CS	CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O
DMZLBUO	IK	FBQPGGIHOFZRGH-UHFFFAOYSA-N
DMZLBUO	IU	1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one
DMZLBUO	CA	CAS 479-50-5
DMZLBUO	CB	CHEBI:51052
DMZLBUO	DE	Solid tumour/cancer

DMT73J8	ID	DMT73J8
DMT73J8	DN	Luliconazole
DMT73J8	HS	Approved
DMT73J8	SN	Lulicon; Lulifin; JA-004; JA-005; NND-502; PR-2699
DMT73J8	CP	Medicis
DMT73J8	DT	Small molecular drug
DMT73J8	PC	3003141
DMT73J8	MW	354.3
DMT73J8	FM	C14H9Cl2N3S2
DMT73J8	IC	InChI=1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1
DMT73J8	CS	C1[C@H](S/C(=C(\\C#N)/N2C=CN=C2)/S1)C3=C(C=C(C=C3)Cl)Cl
DMT73J8	IK	YTAOBBFIOAEMLL-REQDGWNSSA-N
DMT73J8	IU	(2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile
DMT73J8	CA	CAS 187164-19-8
DMT73J8	CB	CHEBI:34825
DMT73J8	DE	Tinea pedis; Dry eye disease

DMUPOGR	ID	DMUPOGR
DMUPOGR	DN	Lumacaftor + Ivacaftor
DMUPOGR	HS	Approved
DMUPOGR	CP	Vertex
DMUPOGR	DE	Cystic fibrosis; Acute lung injury

DMEBQAO	ID	DMEBQAO
DMEBQAO	DN	Lumasiran
DMEBQAO	HS	Approved
DMEBQAO	CP	Alnylam Pharmaceuticals
DMEBQAO	DT	Small interfering RNA
DMEBQAO	DE	Hyperoxaluria

DMQ8HOJ	ID	DMQ8HOJ
DMQ8HOJ	DN	lumateperone tosylate
DMQ8HOJ	HS	Approved
DMQ8HOJ	SN	lumateperone Tosylate; lumateperone (Tosylate); 1187020-80-9; UNII-JIE88N006O; ITI-007 tosylate; JIE88N006O; 1187020-80-9 (tosylate); ITI007; ITI 007; ITI-007; Lumateperone tosylate (USAN); Lumateperone tosylate [USAN]; CHEMBL3233142; 1-(4-fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]butan-1-one toluenesulfonic acid; Caplyta (TN); SCHEMBL1769664; CS-5540; HY-19733; D11170; Q27281520; 1-(4-Fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one tosylate salt
DMQ8HOJ	DT	Small molecular drug
DMQ8HOJ	PC	44241743
DMQ8HOJ	MW	565.7
DMQ8HOJ	FM	C31H36FN3O4S
DMQ8HOJ	IC	InChI=1S/C24H28FN3O.C7H8O3S/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17;1-6-2-4-7(5-3-6)11(8,9)10/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3;2-5H,1H3,(H,8,9,10)/t20-,21-;/m0./s1
DMQ8HOJ	CS	CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
DMQ8HOJ	IK	LHAPOGAFBLSJJQ-GUTACTQSSA-N
DMQ8HOJ	IU	1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one;4-methylbenzenesulfonic acid
DMQ8HOJ	CA	CAS 1187020-80-9
DMQ8HOJ	DE	Schizophrenia

DM29GAD	ID	DM29GAD
DM29GAD	DN	Lumefantrine
DM29GAD	HS	Approved
DM29GAD	SN	Benflumetol; Coartem; Dl-Benflumelol; Lumefantrine (INN); Lumefantrine [INN:BAN]; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol; 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol; 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
DM29GAD	DT	Small molecular drug
DM29GAD	PC	6437380
DM29GAD	MW	528.9
DM29GAD	FM	C30H32Cl3NO
DM29GAD	IC	InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-
DM29GAD	CS	CCCCN(CCCC)CC(C1=CC(=CC\\2=C1C3=C(/C2=C/C4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O
DM29GAD	IK	DYLGFOYVTXJFJP-MYYYXRDXSA-N
DM29GAD	IU	2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol
DM29GAD	CA	CAS 82186-77-4
DM29GAD	CB	CHEBI:156095
DM29GAD	DE	Malaria

DM1S4AG	ID	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	HS	Approved
DM1S4AG	SN	Joicela; Prexige; Novartis brand of lumiracoxib; COX 189; COX189; COX-189; Lumiracoxib [USAN:INN]; Prexige (Novartis); Prexige (TN); Lumiracoxib (USAN/INN); 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
DM1S4AG	CP	Norvatis Phamaceuticals Corporation
DM1S4AG	TC	Antiinflammatory Agents
DM1S4AG	DT	Small molecular drug
DM1S4AG	PC	151166
DM1S4AG	MW	293.72
DM1S4AG	FM	C15H13ClFNO2
DM1S4AG	IC	InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
DM1S4AG	CS	CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O
DM1S4AG	IK	KHPKQFYUPIUARC-UHFFFAOYSA-N
DM1S4AG	IU	2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
DM1S4AG	CA	CAS 220991-20-8
DM1S4AG	CB	CHEBI:73044
DM1S4AG	DE	Knee osteoarthritis

DMCVPXO	ID	DMCVPXO
DMCVPXO	DN	Lurasidone hydrochloride
DMCVPXO	HS	Approved
DMCVPXO	SN	Lurasidone HCl; SM 13496; Lurasidone hydrochloride (USAN); MK-3756; SM-13496; SMP-13496; N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide
DMCVPXO	CP	Sumitomo
DMCVPXO	DT	Small molecular drug
DMCVPXO	PC	11237860
DMCVPXO	MW	529.1
DMCVPXO	FM	C28H37ClN4O2S
DMCVPXO	IC	InChI=1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1
DMCVPXO	CS	C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O.Cl
DMCVPXO	IK	NEKCRUIRPWNMLK-SCIYSFAVSA-N
DMCVPXO	IU	(1S,2R,6S,7R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione;hydrochloride
DMCVPXO	CA	CAS 367514-88-3
DMCVPXO	CB	CHEBI:70732
DMCVPXO	DE	Schizophrenia

DMEFRTZ	ID	DMEFRTZ
DMEFRTZ	DN	Lurbinectedin
DMEFRTZ	HS	Approved
DMEFRTZ	SN	UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B
DMEFRTZ	CP	PharmaMar
DMEFRTZ	DT	Small molecular drug
DMEFRTZ	PC	57327016
DMEFRTZ	MW	784.9
DMEFRTZ	FM	C41H44N4O10S
DMEFRTZ	IC	InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
DMEFRTZ	CS	CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
DMEFRTZ	IK	YDDMIZRDDREKEP-HWTBNCOESA-N
DMEFRTZ	IU	[(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate
DMEFRTZ	CA	CAS 497871-47-3
DMEFRTZ	DE	leukaemia; Solid tumour/cancer; Endometrial cancer; Ovarian cancer; Small-cell lung cancer

DMH6IKO	ID	DMH6IKO
DMH6IKO	DN	Lusutrombopag
DMH6IKO	HS	Approved
DMH6IKO	SN	LUSUTROMBOPAG; mulpleta; UNII-6LL5JFU42F; 6LL5JFU42F; 2-Propenoic acid, Lusutrombopag [USAN:INN]; SCHEMBL3062
DMH6IKO	CP	Shionogi
DMH6IKO	PC	49843517
DMH6IKO	MW	591.5
DMH6IKO	FM	C29H32Cl2N2O5S
DMH6IKO	IC	InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1
DMH6IKO	CS	CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\\C)/C(=O)O)Cl
DMH6IKO	IK	NOZIJMHMKORZBA-KJCUYJGMSA-N
DMH6IKO	IU	(E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
DMH6IKO	CA	CAS 1110766-97-6
DMH6IKO	CB	CHEBI:136051
DMH6IKO	DE	Thrombocytopenia; Liver disease

DMN1XVC	ID	DMN1XVC
DMN1XVC	DN	Lutetium Lu 177 dotatate
DMN1XVC	HS	Approved
DMN1XVC	SN	UNII-AE221IM3BB; Dotatate lutenium Lu-177; AE221IM3BB; Lu-DOTA-TATE; 177Lu-DOTA-octreotate; Lutetium Lu 177 Dotatate; 177Lu-DOTA-Tyr3-octreotate
DMN1XVC	CP	Advanced Accelerator Applications/Novartis
DMN1XVC	PC	132274234
DMN1XVC	MW	1609.5
DMN1XVC	FM	C65H87LuN14O19S2
DMN1XVC	IC	InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2
DMN1XVC	CS	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[177Lu+3]
DMN1XVC	IK	MXDPZUIOZWKRAA-PRDSJKGBSA-K
DMN1XVC	IU	2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+)
DMN1XVC	CA	CAS 437608-50-9
DMN1XVC	DE	Neuroendocrine cancer

DM7K5GD	ID	DM7K5GD
DM7K5GD	DN	Lutropin alfa
DM7K5GD	HS	Approved
DM7K5GD	SN	Luveris; Luveris (TN); Lutropin alfa (USAN/INN)
DM7K5GD	TC	Fertility Agents
DM7K5GD	SQ	Alpha Chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>    <sequence format="FASTA">&gt;Beta Chain (LH)SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYRDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLFL
DM7K5GD	DE	Female infertility

DMJKROX	ID	DMJKROX
DMJKROX	DN	Luvox
DMJKROX	HS	Approved
DMJKROX	SN	FLUVOXAMINE MALEATE; 61718-82-9; Fevarin; Luvox CR; Fluvoxamine (maleate); UNII-5LGN83G74V; DU23000; DU-23000; SME 3110; 5LGN83G74V; MK-264; 54739-18-3; 5-Methoxy-4'-trifluoromethylvalerophenone (E)-O-2-aminoethyloxime monomaleate; 5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1); 54739-20-7; 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-, (Z)-2-butenedioate (1:1); C19H25F3N2O6
DMJKROX	DT	Small molecular drug
DMJKROX	PC	9560989
DMJKROX	MW	434.4
DMJKROX	FM	C19H25F3N2O6
DMJKROX	IC	InChI=1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-
DMJKROX	CS	COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F.C(=C\\C(=O)O)\\C(=O)O
DMJKROX	IK	LFMYNZPAVPMEGP-PIDGMYBPSA-N
DMJKROX	IU	(Z)-but-2-enedioic acid;2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
DMJKROX	CA	CAS 61718-82-9
DMJKROX	CB	CHEBI:5139
DMJKROX	DE	Anxiety disorder

DM93VBZ	ID	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	HS	Approved
DM93VBZ	SN	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);
DM93VBZ	CP	Eli Lilly
DM93VBZ	DT	Small molecular drug
DM93VBZ	PC	46220502
DM93VBZ	MW	506.6
DM93VBZ	FM	C27H32F2N8
DM93VBZ	IC	InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)
DM93VBZ	CS	CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
DM93VBZ	IK	UZWDCWONPYILKI-UHFFFAOYSA-N
DM93VBZ	IU	N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
DM93VBZ	CA	CAS 1231929-97-7
DM93VBZ	DE	Breast cancer; Solid tumour/cancer

DMOMLHJ	ID	DMOMLHJ
DMOMLHJ	DN	Lymecycline
DMOMLHJ	HS	Approved
DMOMLHJ	SN	Aureociclin; Aureomicina; Aurofac; Biovetin; Centraureo; Chlortetracyclin; Chrusomykine; Limeciclina; Lymecyclinum; Orospray; Acronize PD; Aurofac 10; Tetrlysal 300; Lymecycline (INN); Tetralysal 300 (TN); N(2)-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline; N(6)-[({[(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-yl]carbonyl}amino)methyl]-L-lysine; (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide
DMOMLHJ	CP	Galderma
DMOMLHJ	TC	Antibiotics
DMOMLHJ	DT	Small molecular drug
DMOMLHJ	PC	54707177
DMOMLHJ	MW	602.6
DMOMLHJ	FM	C29H38N4O10
DMOMLHJ	IC	InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34-35,38,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14-,15-,16-,21-,28+,29-/m0/s1
DMOMLHJ	CS	C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCNCCCC[C@@H](C(=O)O)N)N(C)C)O
DMOMLHJ	IK	PZTCVADFMACKLU-UEPZRUIBSA-N
DMOMLHJ	IU	(2S)-6-[[[(4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carbonyl]amino]methylamino]-2-aminohexanoic acid
DMOMLHJ	CA	CAS 992-21-2
DMOMLHJ	CB	CHEBI:59040
DMOMLHJ	DE	Bacterial infection

DM154EB	ID	DM154EB
DM154EB	DN	Lypressin
DM154EB	HS	Approved
DM154EB	SN	Lysine-vasopressin; Lysine-8-vasopressin
DM154EB	DT	Small molecular drug
DM154EB	PC	644076
DM154EB	MW	1056.2
DM154EB	FM	C46H65N13O12S2
DM154EB	IC	InChI=1S/C46H65N13O12S2/c47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DM154EB	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DM154EB	IK	BJFIDCADFRDPIO-DZCXQCEKSA-N
DM154EB	IU	(2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM154EB	CA	CAS 50-57-7
DM154EB	CB	CHEBI:94802
DM154EB	DE	Amnesia

DMQYJIR	ID	DMQYJIR
DMQYJIR	DN	Macimorelin
DMQYJIR	HS	Approved
DMQYJIR	SN	Solorel; AEZS-130; ARD-07; ARD-0705; EP-01572; EP-1572; JMV-1843
DMQYJIR	CP	Aeterna Zentaris
DMQYJIR	DT	Small molecular drug
DMQYJIR	PC	9804938
DMQYJIR	MW	474.6
DMQYJIR	FM	C26H30N6O3
DMQYJIR	IC	InChI=1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1
DMQYJIR	CS	CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)NC=O)N
DMQYJIR	IK	UJVDJAPJQWZRFR-DHIUTWEWSA-N
DMQYJIR	IU	2-amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
DMQYJIR	CA	CAS 381231-18-1
DMQYJIR	DE	Somatotropin deficiency; Growth hormone deficiency

DMP79A1	ID	DMP79A1
DMP79A1	DN	Macitentan
DMP79A1	HS	Approved
DMP79A1	SN	Macitentan; 441798-33-0; Opsumit; ACT-064992; ACT 064992; UNII-Z9K9Y9WMVL; ACT064992; Z9K9Y9WMVL; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide; CHEBI:76607; Actelion-1; Macitentan [USAN:INN]; macitentanum; zlchem 5; Opsumit (TN); Macitentan (JAN/USAN); (non-labelled)Macitentan-d7; MLS006011174; C19H20Br2N6O4S; SCHEMBL1445625; GTPL7352; CHEMBL2103873; ZLA0005; EX-A544; DTXSID50196063
DMP79A1	CP	Actelion Pharmaceuticals
DMP79A1	DT	Small molecular drug
DMP79A1	PC	16004692
DMP79A1	MW	588.3
DMP79A1	FM	C19H20Br2N6O4S
DMP79A1	IC	InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)
DMP79A1	CS	CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br
DMP79A1	IK	JGCMEBMXRHSZKX-UHFFFAOYSA-N
DMP79A1	IU	5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine
DMP79A1	CA	CAS 441798-33-0
DMP79A1	CB	CHEBI:76607
DMP79A1	DE	Cardiovascular disease

DM3BS97	ID	DM3BS97
DM3BS97	DN	Macrolides
DM3BS97	HS	Approved
DM3BS97	SN	Tylosin; tylosin tartrate; Tilosina; Tylosinum; UNII-YEF4JXN031; Tylosine; Tylocine; Tylan; Tylosin A; 1401-69-0; YEF4JXN031; Fradizine; CHEBI:17658; Vubityl 200; Tylosinum [INN-Latin]; Tylosine [INN-French]; Tilosina [INN-Spanish]; HSDB 7022; EINECS 215-754-8; AI3-29799; SR-05000002057; Tylosin [USP:INN:BAN]; Tylan (TN); Tylosin (USP/INN); AC1NQX0W
DM3BS97	DT	Small molecular drug
DM3BS97	PC	5280440
DM3BS97	MW	916.1
DM3BS97	FM	C46H77NO17
DM3BS97	IC	InChI=1S/C46H77NO17/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3/b15-14+,23-18+/t24-,25+,26-,27-,28+,29+,30-,32-,33-,35+,36-,37-,38-,39-,40-,41-,42-,43+,44+,45-,46-/m1/s1
DM3BS97	CS	CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)\\C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC
DM3BS97	IK	WBPYTXDJUQJLPQ-VMXQISHHSA-N
DM3BS97	IU	2-[(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13-trimethyl-2,10-dioxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
DM3BS97	CA	CAS 1401-69-0
DM3BS97	CB	CHEBI:17658
DM3BS97	DE	Bacterial infection

DMU4ORS	ID	DMU4ORS
DMU4ORS	DN	Magnesium
DMU4ORS	HS	Approved
DMU4ORS	SN	Magnesio; Magnesio [Italian]; Magnesium Matrix Modifier; Magnesium modifier; Magnesium powdered; Magnesium preparation; Magnesium sheet; LTBB002624; Magnesium hydride [UN2010] [Dangerous when wet]; MAGNESIUM NITRATE, ACS; Magnesium nitrate-nitric acid solution; Rieke's active magnesium; MAGNESIUM, ATOMIZED POWDER,18MICRON; Magnesium granules, coated particle size not50% magnesium in pellets, turnings or ribbons [UN1869] [Flammable solid]; Magnesium, powder or magnesium alloys, powder [UN1418] [Dangerous when wet, Spontaneously combustible]; AQUANAL-plus magnesium (Mg) 100-1500 mg/L; AQUANAL(R)-plus magnesium (Mg) 100-1500 mg/L;12Mg
DMU4ORS	CP	AstraZeneca
DMU4ORS	DT	Small molecular drug
DMU4ORS	PC	5462224
DMU4ORS	MW	24.305
DMU4ORS	FM	Mg
DMU4ORS	IC	InChI=1S/Mg
DMU4ORS	CS	[Mg]
DMU4ORS	IK	FYYHWMGAXLPEAU-UHFFFAOYSA-N
DMU4ORS	IU	magnesium
DMU4ORS	CA	CAS 7439-95-4
DMU4ORS	CB	CHEBI:25107
DMU4ORS	DE	Ischemic stroke

DMVEK07	ID	DMVEK07
DMVEK07	DN	Magnesium Sulfate
DMVEK07	HS	Approved
DMVEK07	SN	Magnesiumsulfat; Bitter salt; Epsom salt; Hair salt; Heptahydrate Magnesium Sulfate; Kieserite [as monohydrate]; Magnesium Sulfate In Plastic Container; Magnesium Sulphate Hydrate; Magnesium bisulfate; Magnesium hydrogensulphate; Magnesium sulfate anhydrous; Magnesium sulfate dried; Magnesium sulfate hexahydrate; Magnesium sulfate solution; Magnesium sulphate; Sal Angalis; Sal De sedlitz; Sal amarum; Sal anglicum; Sal catharticum; Sal seidlitense; Salts of england; Sulfuric acid magnesium salt; Tomix OT; MgSO4; Epsom Sa (TN); Magnesium Sulfate, Heptahydrate; Magnesium sulfate in dextrose 5% in plastic container; Magnesium(II) sulfate; OT-S; Sel d'angleterre; Sulfate, Magnesium; Sulfuric acid magnesium salt (VAN); Sulfuric acid, magnesium salt; Magnesium sulfate (1:1); Magnesium(2+) ion sulfate; OT-S (drying agent); SDA 15-062-07; Sulfuric acid magnesium salt (1:1); Sulfuric acid, C10-16 alkyl ester, magnesium salt; Sulfuric acid, magnesium salt (1:1); Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts; (C10-C16) Alkylalcohol sulfuric acid, magnesium salt
DMVEK07	CP	Mitsuwa Kinzoku Co
DMVEK07	TC	Analgesics
DMVEK07	DT	Small molecular drug
DMVEK07	PC	24083
DMVEK07	MW	120.37
DMVEK07	FM	MgO4S
DMVEK07	IC	InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
DMVEK07	CS	[O-]S(=O)(=O)[O-].[Mg+2]
DMVEK07	IK	CSNNHWWHGAXBCP-UHFFFAOYSA-L
DMVEK07	IU	magnesium;sulfate
DMVEK07	CA	CAS 7487-88-9
DMVEK07	CB	CHEBI:32599
DMVEK07	DE	Acute pain

DMXZ84M	ID	DMXZ84M
DMXZ84M	DN	Malathion
DMXZ84M	HS	Approved
DMXZ84M	SN	Calmathion; Camathion; Carbafos; Carbetovur; Carbetox; Carbofos; Carbophos; Celthion; Chemathion; Cimexan; Cleensheen; Cythion; Dorthion; Emmatos; Ethiolacar; Etiol; Extermathion; Flair; Forthion; Fosfothion; Fosfotion; Fyfanon; Hilthion; Karbofos; Kypfos; Malacide; Malafor; Malagran; Malakill; Malamar; Malaphele; Malaphos; Malasol; Malaspray; Malataf; Malathiazol; Malathione; Malathiozoo; Malathon; Malathyl; Malation; Malatol; Malatox; Maldison; Malmed; Malphos; Maltox; Mercaptothion; Mercaptotion; Moscarda; Oleophosphothion; Organoderm; Ovide; Paladin; Phosphothion; Prioderm; Sadofos; Sadophos; Sumitox; TAK; Taskil; Vetiol; Zithiol; Carbethoxy malathion; Detm ol ma; Detmol MA; Emmatos extra; Lice Rid;Malathion LV Concentrate; Malathion [USP]; Malation [Polish]; Maltox MLT; Mercaptosuccinic acid diethyl ester; Mercaptotion [Spanish]; Ortho Malathion; Siptox I; Vegfru malatox; AC 26691; EL 4049; Experimental insecticide 4049; Fog 3; Fosfotion 550; Hilthion 25wdp; IFO 13140; Latka 4049; Latka 4049 [Czech]; MET86C_SUPELCO; Malamar 50; Malathion 60; Malathion E50; OMS 1; PS86_SUPELCO; SF 60; Sadofos 30; American cyanamid 4,049; Derbac-M; ENT 17,034; Four thousand forty-nine; Insecticide no. 4049; Kop-Thionkypfosmalacide; Kop-thion; Malathion (USP); Malathion (old ID); Ovide (TN); Staeubol-Puder; Suleo-M; TM-4049; Kill-A-Mite; MALATHION, 96%; Malathion-2,3-14C; 8059HC
DMXZ84M	TC	Parasympathomimetics
DMXZ84M	DT	Small molecular drug
DMXZ84M	PC	4004
DMXZ84M	MW	330.4
DMXZ84M	FM	C10H19O6PS2
DMXZ84M	IC	InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3
DMXZ84M	CS	CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC
DMXZ84M	IK	JXSJBGJIGXNWCI-UHFFFAOYSA-N
DMXZ84M	IU	diethyl 2-dimethoxyphosphinothioylsulfanylbutanedioate
DMXZ84M	CA	CAS 121-75-5
DMXZ84M	CB	CHEBI:6651
DMXZ84M	DE	Pediculus capitis infestation

DMSCDY9	ID	DMSCDY9
DMSCDY9	DN	Mannitol
DMSCDY9	HS	Approved
DMSCDY9	SN	Diosmol; Hexahydroxyhexane; Invenex; Isotol; MTL; Manita; Mannazucker; Mannidex; Mannigen; Mannistol; Mannit; Mannite; Osmitrol; Osmofundin; Osmosal; Resectisol; Cordycepic acid; Cpd without stereochemical designation; Manna sugar; Mannitol [USAN]; Marine Crystal; Resectisol In Plastic Container; M0044; Mannidex 16700; Mannogem 2080; D-mannite; D-mannitol; DL-Mannitol; MANNITOL 25%; Maniton-S; Mannitol (USP); Mannitol (VAN); Mannitol 10%; Mannitol 10% In Plastic Container; Mannitol 15%; Mannitol 15% In Plastic Container; Mannitol 20%; Mannitol 20% In Plastic Container; Mannitol 5%; Mannitol 5% In Plastic Container; OSMITROL 10% IN WATER IN PLASTIC CONTAINER; OSMITROL 15% IN WATER IN PLASTIC CONTAINER; OSMITROL 20% IN WATER IN PLASTIC CONTAINER; OSMITROL 5% IN WATER IN PLASTIC CONTAINER; Osmitrol (TN); Osmitrol 10% In Water; Osmitrol 15% In Water; Osmitrol 20% In Water; Osmitrol 5% In Water; SDM No. 35; SORBITOL-MANNITOL IN PLASTIC CONTAINER; Sorbitol-Mannitol; D-Mannitol (JP15); MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER; D-(-)-Mannitol; ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D; MANNITOL 15% DEXTROSE 5% IN SODIUM CHLORIDE 0.45%; MANNITOL 5% DEXTROSE 5% IN SODIUM CHLORIDE 0.12%; (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol; (L)-Mannitol
DMSCDY9	TC	Sweetening Agents
DMSCDY9	DT	Small molecular drug
DMSCDY9	PC	6251
DMSCDY9	MW	182.17
DMSCDY9	FM	C6H14O6
DMSCDY9	IC	InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
DMSCDY9	CS	C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O
DMSCDY9	IK	FBPFZTCFMRRESA-KVTDHHQDSA-N
DMSCDY9	IU	(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
DMSCDY9	CA	CAS 69-65-8
DMSCDY9	CB	CHEBI:16899
DMSCDY9	DE	Bronchiectasis; Renal failure

DMPWB7T	ID	DMPWB7T
DMPWB7T	DN	Maprotiline
DMPWB7T	HS	Approved
DMPWB7T	SN	Deprilept; Dibencycladine; Maprotilin; Maprotilina; Maprotilinum; Maprotylina; Maprotylina [Polish]; TBB066626; BA-34276; Deprilept (TN); Ludiomil (TN); Maprotilina [INN-Spanish]; Maprotiline (USAN); Maprotilinum [INN-Latin]; Psymion (TN); Ba-34,276; Maprotiline [USAN:BAN:INN]; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)propylmethylamine; 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine
DMPWB7T	CP	Norvatis Phamaceuticals Corporation
DMPWB7T	TC	Antidepressants
DMPWB7T	DT	Small molecular drug
DMPWB7T	PC	4011
DMPWB7T	MW	277.4
DMPWB7T	FM	C20H23N
DMPWB7T	IC	InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
DMPWB7T	CS	CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
DMPWB7T	IK	QSLMDECMDJKHMQ-UHFFFAOYSA-N
DMPWB7T	IU	N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine
DMPWB7T	CA	CAS 10262-69-8
DMPWB7T	CB	CHEBI:6690
DMPWB7T	DE	Major depressive disorder

DMTL94F	ID	DMTL94F
DMTL94F	DN	Maraviroc
DMTL94F	HS	Approved
DMTL94F	SN	376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc
DMTL94F	CP	Pfizer; AstraZeneca
DMTL94F	TC	Anti-HIV Agents
DMTL94F	DT	Small molecular drug
DMTL94F	PC	3002977
DMTL94F	MW	513.7
DMTL94F	FM	C29H41F2N5O
DMTL94F	IC	InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
DMTL94F	CS	CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
DMTL94F	IK	GSNHKUDZZFZSJB-HLMSNRGBSA-N
DMTL94F	IU	4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
DMTL94F	CA	CAS 376348-65-1
DMTL94F	CB	CHEBI:63608
DMTL94F	DE	Human immunodeficiency virus infection; Chronic obstructive pulmonary disease

DMKEY6S	ID	DMKEY6S
DMKEY6S	DN	Margetuximab
DMKEY6S	HS	Approved
DMKEY6S	CP	Macrogenics
DMKEY6S	DT	Antibody
DMKEY6S	DE	Gastrointestinal cancer; Gastric adenocarcinoma; HER2-positive breast cancer

DM70IK5	ID	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	HS	Approved
DM70IK5	SN	Dronabinol; TETRAHYDROCANNABINOL; delta9-Tetrahydrocannabinol; delta9-THC; Deltanyne; Dronabinolum; delta-9-tetrahydrocannabinol; Abbott 40566; delta-9-THC; delta(9)-THC; 1972/8/3; delta1-THC; delta(sup 1)-Thc; delta(sup 9)-Thc; 1-trans-delta-9-Tetrahydrocannabinol; THC; Namisol; Dronabinolum [Latin]; 9-tetrahydrocannabinol; delta(9)-Tetrahydrocannabinol; delta(1)-Tetrahydrocannabinol; (-)-delta9-trans-Tetrahydrocannabinol; delta1-Tetrahydrocannabinol; 1-trans-delta9-Tetrahydrocannabinol; delta(9)-Tetrahydrocannibinol; SP;  Compassia; Ganja; Hashish; Marincap; MaxEPA; Omegaven; Promega; Relivar; Sonergx; Tetranabinex; Cannabis resin; Drona binol; QCD 84924; SP 104; Tetrahydrocannabinol delta9; CAT-310; DELTA1-THC; DELTA1-Tetrahydrocannabinol;DELTA9-THC; DRG-0138; Delta-THC; Delta1-THC; Delta1-Tetrahydrocannabinol; Delta9-THC; Delta9-Tetrahydrocannabinol; Delta9-Tetrahydrocannabinol solution; Dronabinol [USAN:INN]; Marinol (TN); Pro-Mega;QCD-84924; Trans-tetrahydrocannabinol; DELTA9-trans-Tetrahydrocannabinol; Delta(1)-THC; Delta(1)-Tetrahydrocannabinol; Delta(9)-THC; Delta(9)-Tetrahydrocannabinol; Delta(9)-Tetrahydrocannibinol; Delta(sup 1)-Tetrahydrocannabinol; Delta(sup 1)-Thc; Delta(sup 9)-Tetrahydrocannabinol; Delta(sup 9)-Thc; Delta(sup9)-THC; Delta-9-THC; Delta-9-tetrahydrocannabinol; Delta1-Tetrahydrocannabinol (VAN); Delta9-Tetrahydrocannabinol (VAN); Delta9-trans-Tetrahydrocannabinol; Dronabinol (USP/INN); Omega-3-Fatty acid; THC-delta-9; Trans-delta9-Tetrahydrocannabinol; Cannabinol, tetrahydro-(6CI); Fish oils, n-3 fatty acid-high; Fish oils, omega-3 fatty acid-high; L-delta(sup 1)-tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol; L-trans-delta9-Tetrahydrocannabinol; Trans-delta-9-Tetrahydrocannabinol; Cannabinol, Delta1-tetrahydro-(7CI); Fats and Glyceridic oils, fish, n-3 fatty acid-high; L-delta1-Tetrahydrocannabinol; Trans-DELTA9-Tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol;L-trans-delta9-Tetrahydrocannabinol; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; (-)-DELTA1-Tetrahydrocannabinol; (-)-DELTA9-THC; (-)-DELTA9-Tetrahydrocannabinol; (-)-DELTA9-trans-Tetrahydrocannabinol; (-)-delta(sup9)-trans-Tetrahydrocannabinol; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; (-)-delta1-Tetrahydrocannabinol; (-)-delta9-(trans)-Tetrahydrocannabinol; (-)-delta9-Tetrahydrocannabinol; (-)-trans-DELTA9-Tetrahydrocannabinol; (-)-trans-Delta1-Tetrahydrocannabinol; (-)-trans-Delta9-THC; (-)-trans-delta9-Tetrahydrocannabinol; (L)-delta1-Tetrahydrocannabinol; (l)-delta(sup 1)-Tetrahydrocannabinol; (l)-delta1-Tetrahydrocannabinol; 1-trans-delta(sup9)-tetrahydrocannabinol; 1-trans-D9-Tetrahydrocannabinol; 1-trans-delta(sup 9)-Tetrahydrocannabinol; 14C-DELTA1-Tetrahydrocannabinol; 6H-Dibenzo; 9-delta-Tetrahydrocannabinol; 9-ene-Tetrahydrocannabinol; Delta(9)-tetrahydrocannabinol
DM70IK5	CP	Unimed Pharmaceuticals
DM70IK5	TC	Analgesics
DM70IK5	DT	Small molecular drug
DM70IK5	PC	16078
DM70IK5	MW	314.5
DM70IK5	FM	C21H30O2
DM70IK5	IC	InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1
DM70IK5	CS	CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
DM70IK5	IK	CYQFCXCEBYINGO-IAGOWNOFSA-N
DM70IK5	IU	(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
DM70IK5	CA	CAS 1972-08-3
DM70IK5	CB	CHEBI:66964
DM70IK5	DE	Anorexia nervosa cachexia; Chemotherapy-induced nausea

DMMVNZ0	ID	DMMVNZ0
DMMVNZ0	DN	Masoprocol
DMMVNZ0	HS	Approved
DMMVNZ0	SN	NDGA; N 5023; TNP00263; Actinex (TN); Nordihydroguaiaretic acid (meso-form); (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol; 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
DMMVNZ0	TC	Anticancer Agents
DMMVNZ0	DT	Small molecular drug
DMMVNZ0	PC	71398
DMMVNZ0	MW	302.4
DMMVNZ0	FM	C18H22O4
DMMVNZ0	IC	InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+
DMMVNZ0	CS	C[C@H](CC1=CC(=C(C=C1)O)O)[C@@H](C)CC2=CC(=C(C=C2)O)O
DMMVNZ0	IK	HCZKYJDFEPMADG-TXEJJXNPSA-N
DMMVNZ0	IU	4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
DMMVNZ0	CA	CAS 27686-84-6
DMMVNZ0	CB	CHEBI:73468
DMMVNZ0	DE	Prostate cancer

DMZ36RN	ID	DMZ36RN
DMZ36RN	DN	Mazindol
DMZ36RN	HS	Approved
DMZ36RN	SN	mazindol; Mazanor; Sanorex; Teronac; Mazildene; 22232-71-9; Magrilon; Dimagrir; Mazindolum; Mazindole; Mazindolum [INN-Latin]; Terenac; AN 448; Mazindol [USAN:BAN:INN]; SAH 42548; CCRIS 3152; DEA No 1605; 5-(4-Chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol; 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; HSDB 3112; SA 42-548; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole; EINECS 244-857-0; S 42548; CHEMBL781; 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; BRN 0546547;  Diestet; Sanjorex; Solucaps; Teronak; Mazindol Medix Brand; Mazindol Novartis Brand; Mazindol Searle Brand; Mazindol Wyeth Brand; Medix Brand of Mazindol; Novartis Brand of Mazindol; Searle Brand of Mazindol; Wyeth Brand of Mazindol; AN 448;AN448; AN-448; Mazanor (TN); SANOREX (TN); Sanorex (TN); Mazindol (JAN/USP/INN); (+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole; 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol; 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; [3H]mazindol
DMZ36RN	TC	Central Nervous System Stimulants
DMZ36RN	DT	Small molecular drug
DMZ36RN	PC	4020
DMZ36RN	MW	284.74
DMZ36RN	FM	C16H13ClN2O
DMZ36RN	IC	InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
DMZ36RN	CS	C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O
DMZ36RN	IK	ZPXSCAKFGYXMGA-UHFFFAOYSA-N
DMZ36RN	IU	5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol
DMZ36RN	CA	CAS 22232-71-9
DMZ36RN	CB	CHEBI:6702
DMZ36RN	DE	Obesity

DM0R4Z5	ID	DM0R4Z5
DM0R4Z5	DN	MCB-3837
DM0R4Z5	HS	Approved
DM0R4Z5	SN	Oxaquin
DM0R4Z5	CP	Biovertis
DM0R4Z5	DT	Small molecular drug
DM0R4Z5	PC	44201350
DM0R4Z5	MW	706.6
DM0R4Z5	FM	C31H33F2N4O11P
DM0R4Z5	IC	InChI=1S/C31H33F2N4O11P/c1-17(38)34-13-20-14-37(30(42)47-20)19-4-5-27(24(33)10-19)46-16-31(48-49(43,44)45)6-8-35(9-7-31)26-12-25-21(11-23(26)32)28(39)22(29(40)41)15-36(25)18-2-3-18/h4-5,10-12,15,18,20H,2-3,6-9,13-14,16H2,1H3,(H,34,38)(H,40,41)(H2,43,44,45)/t20-/m0/s1
DM0R4Z5	CS	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)OCC3(CCN(CC3)C4=C(C=C5C(=C4)N(C=C(C5=O)C(=O)O)C6CC6)F)OP(=O)(O)O)F
DM0R4Z5	IK	MNABRWLVTSGIMU-FQEVSTJZSA-N
DM0R4Z5	IU	7-[4-[[4-[(5S)-5-(acetamidomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenoxy]methyl]-4-phosphonooxypiperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DM0R4Z5	CA	CAS 790704-50-6
DM0R4Z5	DE	Malaria

DM8ZHP1	ID	DM8ZHP1
DM8ZHP1	DN	MCI-186
DM8ZHP1	HS	Approved
DM8ZHP1	SN	Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one
DM8ZHP1	CP	Mitsubishi Tanabe
DM8ZHP1	DT	Small molecular drug
DM8ZHP1	PC	4021
DM8ZHP1	MW	174.2
DM8ZHP1	FM	C10H10N2O
DM8ZHP1	IC	InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3
DM8ZHP1	CS	CC1=NN(C(=O)C1)C2=CC=CC=C2
DM8ZHP1	IK	QELUYTUMUWHWMC-UHFFFAOYSA-N
DM8ZHP1	IU	5-methyl-2-phenyl-4H-pyrazol-3-one
DM8ZHP1	CA	CAS 89-25-8
DM8ZHP1	CB	CHEBI:31530
DM8ZHP1	DE	Amyotrophic lateral sclerosis

DM4IAKR	ID	DM4IAKR
DM4IAKR	DN	MD-1100
DM4IAKR	HS	Approved
DM4IAKR	SN	Linaclotide acetate; Linaclotide acetate (USAN); MM-416775
DM4IAKR	CP	Microbia
DM4IAKR	DT	Small molecular drug
DM4IAKR	PC	16158207
DM4IAKR	MW	1586.8
DM4IAKR	FM	C61H83N15O23S6
DM4IAKR	IC	InChI=1S/C59H79N15O21S6.C2H4O2/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29;1-2(3)4/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95);1H3,(H,3,4)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-;/m0./s1
DM4IAKR	CS	C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O.CC(=O)O
DM4IAKR	IK	KWFNVZFWXXEJKL-YZDVLOIKSA-N
DM4IAKR	IU	acetic acid;(2S)-2-[[(1R,4S,7S,13S,16R,21R,24R,27S,30S,33R,38R,44S)-21-amino-13-(2-amino-2-oxoethyl)-27-(2-carboxyethyl)-44-[(1R)-1-hydroxyethyl]-30-[(4-hydroxyphenyl)methyl]-4-methyl-3,6,12,15,22,25,28,31,40,43,46,51-dodecaoxo-18,19,35,36,48,49-hexathia-2,5,11,14,23,26,29,32,39,42,45,52-dodecazatetracyclo[22.22.4.216,33.07,11]dopentacontane-38-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM4IAKR	CA	CAS 851199-60-5
DM4IAKR	DE	Constipation; Irritable bowel syndrome

DMO14SG	ID	DMO14SG
DMO14SG	DN	Mebendazole
DMO14SG	HS	Approved
DMO14SG	SN	Bantenol; Banworm; Besantin; Lomper; MBDZ; Madicure; Mebendan; Mebendazol; Mebendazolum; Mebenoazole; Mebenvet; Mebex; Mebutar; Noverme; Ovitelmin; Pantelmin; Sqworm; Sufil; Surfont; Telmin; Vermicidin; Vermicol; Vermidil; Vermin; Vermirax; Vermox; Verpanyl; Versid; Wormkuur; Abello Farmacia Brand of Mebendazole; Anti Worm; Ardeypharm Brand of Mebendazole; Boots Brand of Mebendazole; Boots Threadworm Treatment; Diba Brand of Mebendazole; Elfar Brand of Mebendazole; Equivurm Plus; Esteve Brand of Mebendazole; Healthypharm Brand of Mebendazole; Janssen Brand of Mebendazole; Leidapharm Brand of Mebendazole; Norgine Brand of Mebendazole; Pfizer Brand of Mebendazole; Pripsen Mebendazole; SSL Brand of Mebendazole; Streger Brand of Mebendazole; Taxandria Brand of Mebendazole; Tedec Meiji Brand of Mebendazole; R 17635; R17635; Anti-Worm; Antiox (TN); Degort's Brand of Mebendazole; Mebendazol [INN-Spanish]; Mebendazole(USAN); Mebendazolum [INN-Latin]; Ovex (TN); Pripsen (TN); R 17,635; R-17635; Vermox (TN); MEBENDAZOLE, 99%; Mebendazole (JAN/USP); Mebendazole (JAN/USP/INN); Mebendazole [USAN:INN:BAN:JAN]; Methyl5-benzoyl benzimidazole-2-carbamate; Methyl 5-benzoyl-2-benzimidazolecarbamate; Methyl 5-benzoyl-2-benzimidazolylcarbamate; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; Methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; Methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester
DMO14SG	CP	Janssen Pharmaceutica
DMO14SG	TC	Antinematodal Agents
DMO14SG	DT	Small molecular drug
DMO14SG	PC	4030
DMO14SG	MW	295.29
DMO14SG	FM	C16H13N3O3
DMO14SG	IC	InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
DMO14SG	CS	COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3
DMO14SG	IK	OPXLLQIJSORQAM-UHFFFAOYSA-N
DMO14SG	IU	methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate
DMO14SG	CA	CAS 31431-39-7
DMO14SG	CB	CHEBI:6704
DMO14SG	DE	Worm infection

DMNOBFQ	ID	DMNOBFQ
DMNOBFQ	DN	Mebeverine
DMNOBFQ	HS	Approved
DMNOBFQ	SN	Arluy; Mebeverina; Mebeverinum; Arluy (TN); Mebeverina [INN-Spanish]; Mebeverine (INN); Mebeverine [INN:BAN]; Mebeverinum [INN-Latin]; Mebeverine (USAN)(*hydrochloride*); Veratric acid, 4-[ethyl(p-me; Veratric acid, 4-((ethyl(p-methoxy-alpha-methylphenethyl))amino)butyl ester; Veratric acid, 4-((ethyl(p-methoxy-.alpha.-methylphenethyl))amino)butyl ester; Benzoic acid, 3,4-dimethoxy-, 4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl ester; Benzoic acid, 3,4-dimethoxy-, {4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl} ester; Benzoic acid, 3,4-dimethoxy-, 4-(ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl ester; 4-(Ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl 3,4-dimethoxybenzoate;4-(ethyl-(4-methoxy-alpha-methylphenethyl)aminobutyl) veratrate; 4-(ethyl{1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)butyl 3,4-bis(methyloxy)benzoate; 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate
DMNOBFQ	CP	Reckitt; Colman
DMNOBFQ	DT	Small molecular drug
DMNOBFQ	PC	4031
DMNOBFQ	MW	429.5
DMNOBFQ	FM	C25H35NO5
DMNOBFQ	IC	InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
DMNOBFQ	CS	CCN(CCCCOC(=O)C1=CC(=C(C=C1)OC)OC)C(C)CC2=CC=C(C=C2)OC
DMNOBFQ	IK	VYVKHNNGDFVQGA-UHFFFAOYSA-N
DMNOBFQ	IU	4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate
DMNOBFQ	CA	CAS 3625-06-7
DMNOBFQ	CB	CHEBI:91514
DMNOBFQ	DE	Irritable bowel syndrome

DM0KYI4	ID	DM0KYI4
DM0KYI4	DN	Mebutamate
DM0KYI4	HS	Approved
DM0KYI4	SN	Dormate
DM0KYI4	CP	Medpointe Pharmaceuticals Medpointe Healthcare Inc
DM0KYI4	DT	Small molecular drug
DM0KYI4	PC	6151
DM0KYI4	MW	232.28
DM0KYI4	FM	C10H20N2O4
DM0KYI4	IC	InChI=1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14)
DM0KYI4	CS	CCC(C)C(C)(COC(=O)N)COC(=O)N
DM0KYI4	IK	LEROTMJVBFSIMP-UHFFFAOYSA-N
DM0KYI4	IU	[2-(carbamoyloxymethyl)-2,3-dimethylpentyl] carbamate
DM0KYI4	CA	CAS 64-55-1
DM0KYI4	CB	CHEBI:31804
DM0KYI4	DE	Anxiety disorder

DMGQFYB	ID	DMGQFYB
DMGQFYB	DN	Mecamylamine
DMGQFYB	HS	Approved
DMGQFYB	SN	Mecamilamina; Mecamine; Mecamylaminum; Mekamine; Mevasine; Revertina; Versamine; Inversine hydrochloride; Mecamilamina [DCIT]; Mecamilamina [Italian]; Mevasin hydrochloride; Inversine (TN); Mecamylamine [INN:BAN]; Mecamylaminum [INN-Latin]; N-Methyl-2-isocamphanamine; N,2,3,3-Tetramethyl-2-norbornamine; N,2,3,3-Tetramethyl-2-norcamphanamine; N,2,2,3-tetramethylbicyclo[2.2.1]heptan-3-amine; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine; 2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 3-Methylaminoisocamphane; 3-Methylaminoisokamfan; 3-Methylaminoisokamfan [Czech]; 3-beta-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane
DMGQFYB	CP	Mecamylamine
DMGQFYB	TC	Antihypertensive Agents
DMGQFYB	DT	Small molecular drug
DMGQFYB	PC	4032
DMGQFYB	MW	167.29
DMGQFYB	FM	C11H21N
DMGQFYB	IC	InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3
DMGQFYB	CS	CC1(C2CCC(C2)C1(C)NC)C
DMGQFYB	IK	IMYZQPCYWPFTAG-UHFFFAOYSA-N
DMGQFYB	IU	N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
DMGQFYB	CA	CAS 60-40-2
DMGQFYB	CB	CHEBI:6706
DMGQFYB	DE	Essential hypertension

DM1O3BY	ID	DM1O3BY
DM1O3BY	DN	Mecasermin
DM1O3BY	HS	Approved
DM1O3BY	SN	Increlex (TN)
DM1O3BY	TC	Immunomodulatory Agents
DM1O3BY	SQ	Mecasermin: GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA
DM1O3BY	DE	Growth failure

DM0CVXA	ID	DM0CVXA
DM0CVXA	DN	Mechlorethamine
DM0CVXA	HS	Approved
DM0CVXA	SN	Antimit; Carolysine; Caryolysin; Caryolysine; Chlorethazine; Chlormethine; Cloramin; Clormetina; Dichloren; Embechine; Embichin; MBA; Mebichloramine; Mechlorethanamine; Mechloroethamine; Mecloretamina; Mustargen; Mustine; Mutagen; Nitrogranulogen; Thyldiethylamine; Dichlor amine; Me chloroethamine; Mecloretamina [Italian]; Mustine note; Nitrogen mustard; HN2; T 1024; TL 146; Chloramine (the nitrogen mustard); Chlormethine (INN); Chlormethine [INN:BAN]; Chlormethinum [INN-Latin]; Clormetina [INN-Spanish]; ENT-25294; HN-2; IBS-L0033631; Mustargen (TN); N-Lost; N-Methyl lost; Stickstofflost (ebewe); T-1024; Bis(2-chloroethyl)methylamine; Bis(beta-chloroethyl) methylamine; Bis(beta-chloroethyl)methylamine; Di(2-chloroethyl)methylamine; Methylbis(2-chloroethyl)amine; Methylbis(beta-chloroethyl)amine; Methyldi(2-chloroethyl)amine; N-Methyl-lost; N-Methyl-lost [German]; Nitrogen mustard (HN-2); Mitoxine (*Hydrochloride*); N,N-Di(chloroethyl)methylamine; N-Methyl-bis-chloraethylamin; N-Methyl-bis-chloraethylamin [German]; Nitol (*Hydrochloride*); Stickstofflost (*Hydrochloride*); N,N-Bis(2-chloroethyl)methylamine; N-Methyl-bis(2-chloroethyl)amine; N-Methyl-bis(beta-chloroethyl)amine; Beta,beta'-Dichlorodiethyl-N-methylamine; N-Methyl-2,2'-dichlorodiethylamine; N,N-Bis(2-chloroethyl)-N-methylamine; 1,5-Dichloro-3-methyl-3-azapentane hydrochloride; 2,2'-Dichloro-N-me; 2,2'-Dichloro-N-methyldiethylamine; 2,2'-Dichlorodiethyl-methylamine; 2-Chloro-N-(2-chloroethyl)-N-methylethanamine
DM0CVXA	CP	Recordati Rare Diseases Inc
DM0CVXA	TC	Anticancer Agents
DM0CVXA	DT	Small molecular drug
DM0CVXA	PC	4033
DM0CVXA	MW	156.05
DM0CVXA	FM	C5H11Cl2N
DM0CVXA	IC	InChI=1S/C5H11Cl2N/c1-8(4-2-6)5-3-7/h2-5H2,1H3
DM0CVXA	CS	CN(CCCl)CCCl
DM0CVXA	IK	HAWPXGHAZFHHAD-UHFFFAOYSA-N
DM0CVXA	IU	2-chloro-N-(2-chloroethyl)-N-methylethanamine
DM0CVXA	CA	CAS 51-75-2
DM0CVXA	CB	CHEBI:28925
DM0CVXA	DE	T-cell lymphoma; Hodgkin lymphoma

DMS7T13	ID	DMS7T13
DMS7T13	DN	Meclizine
DMS7T13	HS	Approved
DMS7T13	SN	Ancolan; Ancolon; Antivert; Bonadettes; Bonine; Calmonal; Chiclida; Diadril; Histamethine; Histamethizine; Histametizine; Histametizyn; Histametizyne; Itinerol; Marex; Meclicot; Meclozina; Meclozine; Meclozinum; Medivert; Monamine; Navicalm; Nevidoxine; Parachloramine; Peremesin; Postafene; Ravelon; Sabari; Siguran; Subari; Suprimal; Travelon; Veritab; Vomisseis; Vomissels; Dramamine II; Meclizine Hcl; UCB 170; UCB 5052; UCB 5062; Antivert (TN); Antivert/25; Antivert/50; Bonamine (TN); Bonine (TN); Meclizine [INN:BAN]; Meclozina [INN-Spanish]; Meclozine (BAN); Meclozinum [INN-Latin]; Neo-istafene; Neo-suprimal; Neo-suprimel; Nevidoxine (TN); Postafen (TN); Sea-Legs; Ru-Vert-M; U. C. B. 5062; U.C.B. 5062; (+-)-Meclizine; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine
DMS7T13	CP	Citron Pharma Llc
DMS7T13	TC	Antiallergic Agents
DMS7T13	DT	Small molecular drug
DMS7T13	PC	4034
DMS7T13	MW	390.9
DMS7T13	FM	C25H27ClN2
DMS7T13	IC	InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
DMS7T13	CS	CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMS7T13	IK	OCJYIGYOJCODJL-UHFFFAOYSA-N
DMS7T13	IU	1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine
DMS7T13	CA	CAS 569-65-3
DMS7T13	CB	CHEBI:6709
DMS7T13	DE	Dizziness

DMSFQ8I	ID	DMSFQ8I
DMSFQ8I	DN	Meclocycline
DMSFQ8I	HS	Approved
DMSFQ8I	SN	Meclociclina; Meclocyclinum; Meclosorb; Samil; Meclociclina [Italian]; GS 2989; GS-2989; Meclociclina [INN-Spanish]; Meclocycline(USAN); Meclocyclinum [INN-Latin]; Meclocycline (USAN/INN); Meclocycline [USAN:INN:BAN]; (2E,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4aR,5S,5aS,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,12a.alpha.)]-(9CI); 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4aal; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-6-methylene-5-oxytetracycline; 7-Cloro-6-metilene-5-ossitetraciclina; 7-Cloro-6-metilene-5-ossitetraciclina [Italian]; 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacene carboxamide
DMSFQ8I	CP	Johnson And Johnson Consumer Companies Inc
DMSFQ8I	TC	Antibiotics
DMSFQ8I	DT	Small molecular drug
DMSFQ8I	PC	54676539
DMSFQ8I	MW	476.9
DMSFQ8I	FM	C22H21ClN2O8
DMSFQ8I	IC	InChI=1S/C22H21ClN2O8/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30/h4-5,10,14-15,17,26-28,31,33H,1H2,2-3H3,(H2,24,32)/t10-,14-,15+,17+,22+/m1/s1
DMSFQ8I	CS	CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O
DMSFQ8I	IK	RNIADBXQDMCFEN-IWVLMIASSA-N
DMSFQ8I	IU	(4S,4aR,5S,5aR,12aR)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMSFQ8I	CA	CAS 2013-58-3
DMSFQ8I	CB	CHEBI:135772
DMSFQ8I	DE	Bacterial infection

DMNL98G	ID	DMNL98G
DMNL98G	DN	Meclofenamate sodium
DMNL98G	HS	Approved
DMNL98G	CP	Parke Davis Div Warner Lambert Co
DMNL98G	DT	Small molecular drug
DMNL98G	PC	4038
DMNL98G	MW	318.1
DMNL98G	FM	C14H10Cl2NNaO2
DMNL98G	IC	InChI=1S/C14H11Cl2NO2.Na/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;/h2-7,17H,1H3,(H,18,19);/q;+1/p-1
DMNL98G	CS	CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl.[Na+]
DMNL98G	IK	OGPIIGMUPMPMNT-UHFFFAOYSA-M
DMNL98G	IU	sodium;2-(2,6-dichloro-3-methylanilino)benzoate
DMNL98G	CA	CAS 6385-02-0
DMNL98G	CB	CHEBI:6711
DMNL98G	DE	Arthritis

DM05FXR	ID	DM05FXR
DM05FXR	DN	Meclofenamic acid
DM05FXR	HS	Approved
DM05FXR	SN	Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
DM05FXR	TC	Analgesics
DM05FXR	DT	Small molecular drug
DM05FXR	PC	4037
DM05FXR	MW	296.1
DM05FXR	FM	C14H11Cl2NO2
DM05FXR	IC	InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
DM05FXR	CS	CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl
DM05FXR	IK	SBDNJUWAMKYJOX-UHFFFAOYSA-N
DM05FXR	IU	2-(2,6-dichloro-3-methylanilino)benzoic acid
DM05FXR	CA	CAS 644-62-2
DM05FXR	CB	CHEBI:6710
DM05FXR	DE	Ankylosing spondylitis; Joint pain

DMBGWPH	ID	DMBGWPH
DMBGWPH	DN	Medroxyprogesterone
DMBGWPH	HS	Approved
DMBGWPH	SN	Asconale; Colirest; Hematrol; Hydroxymethylprogesterone; Lunelle; Medrossiprogesterone; Medroxiprogesterona; Medroxiprogesteronum; Medroxyprogesteron; Medroxyprogesteronum; Methylhydroxyprogesterone; Adgyn Medro; Farlutal inyectable; Medroprogesterone Acetate; Medrossiprogesterone [DCIT]; Medroxyprogesteron acetate; Medroxyprogesterone Strakan Brand; Sodelut G; Strakan Brand of Medroxyprogesterone; MPA Gyn 5; U 8840; CBP-1011; Farlutal inyectable (TN); G-Farlutal; Medroxiprogesterona [INN-Spanish]; Medroxyprogesterone (INN); Medroxyprogesterone [INN:BAN]; Medroxyprogesteronum [INN-Latin]; Novo-Medrone; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-(9CI); Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)-(9CI); (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; (6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione; 17 alpha Hydroxy 6 alpha Methylprogesterone; 17 alpha-Hydroxy-6 alpha-Methylprogesterone; 17-Hydroxy-6.alpha.-methylprogesterone; 17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione; 17-Hydroxy-6alpha-methylprogesterone; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone; 17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 17alpha-Hydroxy-6alpha-methylprogesterone; 6-Dihydromegestrol; 6-alpha-Methyl-17-alpha-hydroxyprogesterone; 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone; 6alpha-Methyl-17alpha-hydroxyprogesterone; 6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione; 6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione
DMBGWPH	CP	Pharmacia And Upjohn Co
DMBGWPH	TC	Contraceptive Agents
DMBGWPH	DT	Small molecular drug
DMBGWPH	PC	10631
DMBGWPH	MW	344.5
DMBGWPH	FM	C22H32O3
DMBGWPH	IC	InChI=1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1
DMBGWPH	CS	C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C
DMBGWPH	IK	FRQMUZJSZHZSGN-HBNHAYAOSA-N
DMBGWPH	IU	(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMBGWPH	CA	CAS 520-85-4
DMBGWPH	CB	CHEBI:6715
DMBGWPH	DE	Solid tumour/cancer

DMJ90O5	ID	DMJ90O5
DMJ90O5	DN	Medrysone
DMJ90O5	HS	Approved
DMJ90O5	SN	Hydroxymesterone; Medrifar; Medritonic; Medrocort; Visudrisone; Medrysone (USAN); U-8471; (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 11.beta.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; 11.beta.-Hydroxy-6.alpha.-methylprogesterone; 11beta-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; 6.alpha.-Methyl-11.beta.-hydroxyprogesterone
DMJ90O5	DT	Small molecular drug
DMJ90O5	PC	247839
DMJ90O5	MW	344.5
DMJ90O5	FM	C22H32O3
DMJ90O5	IC	InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1
DMJ90O5	CS	C[C@H]1C[C@H]2[C@@H]3CC[C@@H]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)CC4)C)O)C)C(=O)C
DMJ90O5	IK	GZENKSODFLBBHQ-ILSZZQPISA-N
DMJ90O5	IU	(6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMJ90O5	CA	CAS 2668-66-8
DMJ90O5	CB	CHEBI:34829
DMJ90O5	DE	Eye inflammation

DMK7HFI	ID	DMK7HFI
DMK7HFI	DN	Mefenamic acid
DMK7HFI	HS	Approved
DMK7HFI	SN	ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid
DMK7HFI	TC	Antiinflammatory Agents
DMK7HFI	DT	Small molecular drug
DMK7HFI	PC	4044
DMK7HFI	MW	241.28
DMK7HFI	FM	C15H15NO2
DMK7HFI	IC	InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
DMK7HFI	CS	CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C
DMK7HFI	IK	HYYBABOKPJLUIN-UHFFFAOYSA-N
DMK7HFI	IU	2-(2,3-dimethylanilino)benzoic acid
DMK7HFI	CA	CAS 61-68-7
DMK7HFI	CB	CHEBI:6717
DMK7HFI	DE	Dysmenorrhea

DMWT905	ID	DMWT905
DMWT905	DN	Mefloquine
DMWT905	HS	Approved
DMWT905	SN	Lariam; Mefloquin; Mefloquina; Mefloquinone; Mefloquinum; Mephloquine; Racemic mefloquine; Ro 215998; WR 142490; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquina [INN-Spanish]; Mefloquinum [INN-Latin]; RO 13-7224; RO 13-7225; Ro 21-5998; SPB-80406; WR-142490; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Ro 21-5998 (Hydrochloride); WR-142,490; WR-177,602; Ro-21-5998-001; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; (+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol
DMWT905	CP	Hoffmann-La Roche pharmaceutical company
DMWT905	TC	Antimalarials
DMWT905	DT	Small molecular drug
DMWT905	PC	4046
DMWT905	MW	378.31
DMWT905	FM	C17H16F6N2O
DMWT905	IC	InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2
DMWT905	CS	C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
DMWT905	IK	XEEQGYMUWCZPDN-UHFFFAOYSA-N
DMWT905	IU	[2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol
DMWT905	CA	CAS 49752-90-1
DMWT905	CB	CHEBI:63681
DMWT905	DE	Malaria

DMDH9KX	ID	DMDH9KX
DMDH9KX	DN	Megestrol
DMDH9KX	HS	Approved
DMDH9KX	SN	Chronopil; Megestrolo; Megestrolo [DCIT]; Chronopil (TN); Megace (TN); Megestrol (INN); Megestrol [INN:BAN]; Megestrolum [INN-Latin]; (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
DMDH9KX	CP	Bristol Myers Squibb
DMDH9KX	TC	Anticancer Agents
DMDH9KX	DT	Small molecular drug
DMDH9KX	PC	19090
DMDH9KX	MW	342.5
DMDH9KX	FM	C22H30O3
DMDH9KX	IC	InChI=1S/C22H30O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h11-12,16-18,25H,5-10H2,1-4H3/t16-,17+,18+,20-,21+,22+/m1/s1
DMDH9KX	CS	CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C
DMDH9KX	IK	VXIMPSPISRVBPZ-NWUMPJBXSA-N
DMDH9KX	IU	(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
DMDH9KX	CA	CAS 3562-63-8
DMDH9KX	DE	Breast cancer

DM1OFHN	ID	DM1OFHN
DM1OFHN	DN	Meglitinides
DM1OFHN	HS	Approved
DM1OFHN	DT	Small molecular drug
DM1OFHN	PC	3033769
DM1OFHN	MW	347.2
DM1OFHN	FM	C15H20Cl2N2O3
DM1OFHN	IC	InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1
DM1OFHN	CS	CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2OC)Cl)Cl)O
DM1OFHN	IK	WAOQONBSWFLFPE-VIFPVBQESA-N
DM1OFHN	IU	3,5-dichloro-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide
DM1OFHN	CA	CAS 84225-95-6
DM1OFHN	CB	CHEBI:92070
DM1OFHN	DE	Type-2 diabetes; Psychotic disorder

DMGUZ0W	ID	DMGUZ0W
DMGUZ0W	DN	MELARSOPROL
DMGUZ0W	HS	Approved
DMGUZ0W	SN	MELARSOPROL; Mel B; Arsobal; 494-79-1; Melarsoprolum [INN-Latin]; EINECS 207-793-4; Melarsoprol [INN:BAN:DCF]; RP 3854; CHEBI:6729; [2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol; 1,3,2-Dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-; Melarsoprolum; Melarsenoxid-BAL; 2-(p-(4,6-Diamino-s-triazin-2-ylamino)phenyl)-1,3,2-dithiarsolane-4-methanol; C12H15AsN6OS2; Specia; UNII-ZF3786Q2E8; Melarsoprol (INN); AC1L1UXN; Mel B (TN); CHEMBL166; SCHEMBL61707; ZF3786Q2E8
DMGUZ0W	DT	Small molecular drug
DMGUZ0W	PC	10311
DMGUZ0W	MW	398.3
DMGUZ0W	FM	C12H15AsN6OS2
DMGUZ0W	IC	InChI=1S/C12H15AsN6OS2/c14-10-17-11(15)19-12(18-10)16-8-3-1-7(2-4-8)13-21-6-9(5-20)22-13/h1-4,9,20H,5-6H2,(H5,14,15,16,17,18,19)
DMGUZ0W	CS	C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO
DMGUZ0W	IK	JCYZMTMYPZHVBF-UHFFFAOYSA-N
DMGUZ0W	IU	[2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol
DMGUZ0W	CA	CAS 494-79-1
DMGUZ0W	CB	CHEBI:6729
DMGUZ0W	DE	Trypanosomiasis

DMKWFBT	ID	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	HS	Approved
DMKWFBT	SN	73-31-4; Melatonine; N-Acetyl-5-methoxytryptamine; Circadin; 5-Methoxy-N-acetyltryptamine; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; Melatol; Melovine; Melatonex; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; UNII-JL5DK93RCL; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; N-acetyl-5-methoxy-tryptamine; NSC 113928; CCRIS 3472; CHEMBL45; EINECS 200-797-7; JL5DK93RCL; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; BRN 0205542;  Circadin; Melapure; Melatonina; Posidorm; Vivitas; Night Rest; Pineal Hormone; Revital Melatonin; Rx Balance; Sleep Right; IN1244; M 5250; M1105; ML1; MT6; TNP00300; M-1200; M-1250; Mela-T; Melatonex, Melatonin; Melatonina (TN); NMR/14327425; Nature'S Harmony; PREVENTION 2 (MELATONIN); PREVENTION 3 (MELATONIN); PREVENTION 4 (MELATONIN); PREVENTION 5 (MELATONIN); PREVENTION 1 (MELATONIN) (PREVENTION 1); Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]-(6CI,8CI); N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-(9CI); Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}; Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-(9CI); 4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID; [3H]melatonin; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKWFBT	TC	Central Nervous System Stimulants
DMKWFBT	DT	Small molecular drug
DMKWFBT	PC	896
DMKWFBT	MW	232.28
DMKWFBT	FM	C13H16N2O2
DMKWFBT	IC	InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)
DMKWFBT	CS	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC
DMKWFBT	IK	DRLFMBDRBRZALE-UHFFFAOYSA-N
DMKWFBT	IU	N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKWFBT	CA	CAS 73-31-4
DMKWFBT	CB	CHEBI:16796
DMKWFBT	DE	Insomnia

DM2AR7L	ID	DM2AR7L
DM2AR7L	DN	Meloxicam
DM2AR7L	HS	Approved
DM2AR7L	SN	Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica
DM2AR7L	CP	Iroko pharmaceuticals
DM2AR7L	DT	Small molecular drug
DM2AR7L	PC	54677470
DM2AR7L	MW	351.4
DM2AR7L	FM	C14H13N3O4S2
DM2AR7L	IC	InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
DM2AR7L	CS	CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
DM2AR7L	IK	ZRVUJXDFFKFLMG-UHFFFAOYSA-N
DM2AR7L	IU	4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
DM2AR7L	CA	CAS 71125-38-7
DM2AR7L	CB	CHEBI:6741
DM2AR7L	DE	Arthritis

DMOLNHF	ID	DMOLNHF
DMOLNHF	DN	Melphalan
DMOLNHF	HS	Approved
DMOLNHF	SN	Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); Alkeran (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
DMOLNHF	TC	Anticancer Agents
DMOLNHF	DT	Small molecular drug
DMOLNHF	PC	460612
DMOLNHF	MW	305.2
DMOLNHF	FM	C13H18Cl2N2O2
DMOLNHF	IC	InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1
DMOLNHF	CS	C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl
DMOLNHF	IK	SGDBTWWWUNNDEQ-LBPRGKRZSA-N
DMOLNHF	IU	(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
DMOLNHF	CA	CAS 148-82-3
DMOLNHF	CB	CHEBI:28876
DMOLNHF	DE	Multiple myeloma; Intrahepatic cholangiocarcinoma

DMWF5R4	ID	DMWF5R4
DMWF5R4	DN	Melphalan flufenamide
DMWF5R4	HS	Approved
DMWF5R4	SN	J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides
DMWF5R4	CP	Oncopeptides AB
DMWF5R4	DT	Small molecular drug
DMWF5R4	PC	9935639
DMWF5R4	MW	498.4
DMWF5R4	FM	C24H30Cl2FN3O3
DMWF5R4	IC	InChI=1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1
DMWF5R4	CS	CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N
DMWF5R4	IK	YQZNKYXGZSVEHI-VXKWHMMOSA-N
DMWF5R4	IU	ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate
DMWF5R4	CA	CAS 380449-51-4
DMWF5R4	DE	Ovarian cancer; Plasma cell myeloma; Multiple myeloma

DMD9WSC	ID	DMD9WSC
DMD9WSC	DN	Memantine
DMD9WSC	HS	Approved
DMD9WSC	SN	Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest
DMD9WSC	CP	Merz & Co GmbH
DMD9WSC	DT	Small molecular drug
DMD9WSC	PC	4054
DMD9WSC	MW	179.3
DMD9WSC	FM	C12H21N
DMD9WSC	IC	InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
DMD9WSC	CS	CC12CC3CC(C1)(CC(C3)(C2)N)C
DMD9WSC	IK	BUGYDGFZZOZRHP-UHFFFAOYSA-N
DMD9WSC	IU	3,5-dimethyladamantan-1-amine
DMD9WSC	CA	CAS 19982-08-2
DMD9WSC	CB	CHEBI:64312
DMD9WSC	DE	Alzheimer disease

DMP9N85	ID	DMP9N85
DMP9N85	DN	Menadiol sodium diphosphate
DMP9N85	HS	Approved
DMP9N85	SN	Kappadione; Synkavit; Procoagulo; Synkavite; Thylokay; Kipca water soluble; Synkayvite; Menadiol sodium diphosphate; Menadione sodium phosphate; Sodium menadione diphosphate; Menadiol Sodium Diphosphate Anhydrous; UNII-R2L46WE615; Menadiol tetrasodium diphosphate; EINECS 205-012-1; Menadione diphosphate tetrasodium salt; 1:4-Naphthaquinol-bisdisodium phosphate; 131-13-5; Menadiol sodium diphosphate anhydrous [USAN]; R2L46WE615; 2-Methyl-1,4-naphthaquinol bis(disodium phosphate); Tetrasodium 2-methyl-1,4-naphthalenediol diphosp
DMP9N85	DT	Small molecular drug
DMP9N85	PC	8555
DMP9N85	MW	422.08
DMP9N85	FM	C11H8Na4O8P2
DMP9N85	IC	InChI=1S/C11H12O8P2.4Na/c1-7-6-10(18-20(12,13)14)8-4-2-3-5-9(8)11(7)19-21(15,16)17;;;;/h2-6H,1H3,(H2,12,13,14)(H2,15,16,17);;;;/q;4*+1/p-4
DMP9N85	CS	CC1=C(C2=CC=CC=C2C(=C1)OP(=O)([O-])[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+]
DMP9N85	IK	GZBACHSOZNEZOG-UHFFFAOYSA-J
DMP9N85	IU	tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate
DMP9N85	CA	CAS 131-13-5
DMP9N85	DE	Coagulation defect

DMSJDTY	ID	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	HS	Approved
DMSJDTY	SN	menadione; 58-27-5; Vitamin K3; 2-Methyl-1,4-naphthoquinone; Menaphthone; 2-methylnaphthalene-1,4-dione; 2-Methylnaphthoquinone; Thyloquinone; Panosine; Klottone; Kayquinone; Kappaxin; Kayklot; Kolklot; 2-Methyl-1,4-naphthalenedione; Menaphthon; Menadion; Kipca; Kanone; Mitenone; Kativ-G; Kaergona; Aquinone; Prokayvit; Mitenon; Koaxin; Kaykot; Kareon; Hemodal; Aquakay; Synkay; Karcon; K-Thrombyl; K-Vitan; Kipca-Oil Soluble; Juva-K; Vitamin K2(0); Vitamin K0; Menaquinone 0; Vitamin K 3; Menaphtone; Menadionum; 2-Methyl-1,4-naphthochinon; Usaf;  Aquakay; Klottone;Koaxin; Memodol; Methylnaphthoquinone; Vicasol; Menadione semiquinone; M0373; VK3; Kappaxan (VAN); Kappaxin (TN); Kipca, oil soluble; Menadione (K3); Menadione (USP); Menadione [USAN:BAN]; Usaf ek-5185; Vitamin-K3; Methyl-1,4-naphthalenedione; Methyl-1,4-naphthoquinone; Vitamin K3 : 2-Methyl-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-,radical ion(1-); 2-Methyl-1,4-naftochinon; 2-Methyl-1,4-naftochinon [Czech]; 2-Methyl-1,4-naphthochinon [German]; 2-methyl-1,4-naphthoquinone, 5; 3-Methyl-1,4-naphthoquinone; Ascorbic acid/menadione; Triglycyl-lysine-vasopressin
DMSJDTY	TC	Vitamins
DMSJDTY	DT	Small molecular drug
DMSJDTY	PC	4055
DMSJDTY	MW	172.18
DMSJDTY	FM	C11H8O2
DMSJDTY	IC	InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3
DMSJDTY	CS	CC1=CC(=O)C2=CC=CC=C2C1=O
DMSJDTY	IK	MJVAVZPDRWSRRC-UHFFFAOYSA-N
DMSJDTY	IU	2-methylnaphthalene-1,4-dione
DMSJDTY	CA	CAS 58-27-5
DMSJDTY	CB	CHEBI:28869
DMSJDTY	DE	Vitamin K deficiency; Prostate cancer

DM2SR1J	ID	DM2SR1J
DM2SR1J	DN	Meningococcal groups A, C, Y and W-135 conjugate vaccine
DM2SR1J	HS	Approved
DM2SR1J	SN	Menveo (TN)
DM2SR1J	CP	Novartis
DM2SR1J	DE	Meningococcal infection

DM4CF18	ID	DM4CF18
DM4CF18	DN	Menotropins
DM4CF18	HS	Approved
DM4CF18	SN	Humegon; Human Menopausal Gonadotrophin; Human Menopausal Gonadotrophin (JP15); Humegon (TN); Menotropins (USP)
DM4CF18	TC	Fertility Agents
DM4CF18	SQ	AlphaChain (LH): APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>    <sequence format="FASTA">&gt;BetaChain (LH)SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYRDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLFL</sequence>    <sequence format="FASTA">&gt;AlphaChain (FSH)APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>    <sequence format="FASTA">&gt;BetaChain (FSH)NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
DM4CF18	DE	Female infertility

DMG2KW7	ID	DMG2KW7
DMG2KW7	DN	Menthol
DMG2KW7	HS	Approved
DMG2KW7	SN	Hexahydrothymol; Levomenthol; Levomentholum; Menthacamphor; Menthomenthol; Neoisomenthol; Racementhol; Racementholum; Racementol; Headache crystals; Menthol natural; Menthol racemic; Menthol racemique; Menthol racemique [French]; Menthol solution; Menthyl alcohol; Peppermint camphor; Racemic menthol; Robitussin Cough Drops; M0321; M0545; D-Menthol; D-Neomenthol; Dl-Menthol; Fisherman's friend lozenges; L-Menthol; Levomenthol [INN:BAN]; Levomentholum [INN-Latin]; Menthol (USP); Menthol (VAN); Menthol natural, brazilian; NOOLISFMXDJSKH-KXUCPTDWBX; Rac-Menthol; Racementhol [INN:BAN]; Racementholum [INN-Latin]; Racementol [INN-Spanish]; Tra-kill tracheal mite killer; D,l-Menthol; Dl-Menthol (JP15); Fisherman's friendlozenges (TN); L-Menthol (JP15); L-Menthol (TN); L-Menthol (natural); Dl-3-p-Menthanol; P-Menthan-3-ol; RACEMIC MENTHOL U.S.P.; U.S.P. Menthol; D-(-)-Menthol; D-p-Menthan-3-ol; L-(-)-Menthol; Menthol, (1alpha,2beta,5alpha)-Isomer; Cis-1 ,3-trans-1,4-(+-)-menthol; Cis-1,3-trans-1,4-(+-)-menthol; (+)-Neo-menthol; (+)-p-Menthan-3-ol; (+-)-(1R*,3R*,4S*)-Menthol; (+-)-Menthol; (+/-)-Menthol; (+/-)-p-Menthan-3-ol; (-)-(1R,3R,4S)-Menthol; (-)-Menthyl alcohol; (-)-menthol; (-)-p-Menthan-3-ol; (-)-trans-p-Menthan-cis-ol; (1R)-(-)-Menthol; (1R,2S,5R)-Menthol; (1R,3R,4S)-(-)-MENTHOL; (1S, 2S, 5R)-(+)-Neomenthol; (1S,2R,5R)-(+)-Isomenthol; (1S,2R,5S)-(+)-Menthol; (1S,2R,5S)-Menthol; (1r,2s,5r)-(-)-menthol; (L)-MENTHOL; (R)-(-)-Menthol; 2-Isopropyl-5-methylcyclohexanol; 3-p-Menthol; 4-Isopropyl-1-methylcyclohexan-3-ol; 5-Methyl-2-(1-methylethyl)-cyclohexanol; 5-Methyl-2-(1-methylethyl)cyclohexanol; 5-methyl-2-(propan-2-yl)cyclohexanol; 5-methyl-2-propan-2-ylcyclohexan-1-ol
DMG2KW7	TC	Antipruritics
DMG2KW7	DT	Small molecular drug
DMG2KW7	PC	1254
DMG2KW7	MW	156.26
DMG2KW7	FM	C10H20O
DMG2KW7	IC	InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3
DMG2KW7	CS	CC1CCC(C(C1)O)C(C)C
DMG2KW7	IK	NOOLISFMXDJSKH-UHFFFAOYSA-N
DMG2KW7	IU	5-methyl-2-propan-2-ylcyclohexan-1-ol
DMG2KW7	CA	CAS 89-78-1
DMG2KW7	CB	CHEBI:25187
DMG2KW7	DE	Throat irritation

DM8YU2F	ID	DM8YU2F
DM8YU2F	DN	Mepenzolate
DM8YU2F	HS	Approved
DM8YU2F	SN	Cantil; Cantilaque; Cantilon; Cantril; Colibantil; Colopiril; Colum; Delevil; Eftoron; Gastropidil; Glycophenylate; Mepenzolon; Tralanta; Trancolon; Trokonil; Bromure de mepenzolate; Bromuro de mepenzolato; MEPENZOLATE BROMIDE; Mepenzolate Methylbromide; Mepenzolati bromidum; Mepenzolic acid; Mepenzolone Bromide; JB 340; Bromure de mepenzolate [INN-French]; Bromuro de mepenzolato [INN-Spanish]; Cantil (TN); Mepenzolati bromidum [INN-Latin]; Mepenzolic acid, bromine salt; Mepenzolate bromide (JP15/INN); Mepenzolate bromide [INN:BAN:JAN]; N-Methyl-3-piperidyl benzilate methobromide; N-Methyl-3-piperidyl benzilate methyl bromide; N-Methyl-3-piperidyldiphenylglycolate methobromide; N-methyl-3-piperidylbenzilate methyl bromide; Benzilic acid, 1-methyl-3-piperidyl ester methobromide; Benzilic acid, ester with 3-hydroxy-1,1-dimethylpiperidinium bromide; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-, bromide; Piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester); Piperidinium, 3-hydroxy-1,1-dimethyl-, bromide, benzilate; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-(VAN); Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-, bromide; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide; 1-Methyl-3-piperidyl benzilate methyl bromide; 1-Methyl-3-piperidyl benzilate methylbromide; 2-(1,1-dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate; 2-[(1,1-dimethylpiperidinium-3-yl)oxy]-2-oxo-1,1-diphenylethanolate; 3-((Hydroxydiphenylacetyl)oxy)-1,1-dimethylpiperidinium bromide; 3-Hydroxy-1,1-dimethylpiperidinium bromide benzilate; 3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide
DM8YU2F	TC	Parasympatholytics
DM8YU2F	DT	Small molecular drug
DM8YU2F	PC	4057
DM8YU2F	MW	340.4
DM8YU2F	FM	C21H26NO3+
DM8YU2F	IC	InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1
DM8YU2F	CS	C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C
DM8YU2F	IK	GKNPSSNBBWDAGH-UHFFFAOYSA-N
DM8YU2F	IU	(1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate
DM8YU2F	CA	CAS 25990-43-6
DM8YU2F	CB	CHEBI:94411
DM8YU2F	DE	Gastrointestinal disease; Peptic ulcer

DMX4GND	ID	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	HS	Approved
DMX4GND	SN	Demarol; Demerol; Dolcontral; Dolosal; Dolsin; Isonipecain; Isonipecaine; Lidol; Lydol; Meperidol; Nemerol; Pethanol; Pethidin; Pethidine; Pethidineter; Pethidinum; Petidina; Petydyna; Phetidine; Piperosal; Pipersal; Meperidine solution; Methyl phenylpiperidine carbonic acid ethyl ester; Operidine EPJ I; Pethidine DBL; Petydyna [Polish]; Demerol (TN); Operidine EPJ-I; Pethidine (INN); Pethidine DBL (TN); Pethidinum [INN-Latin]; Petidina [INN-Spanish]; Ethyl 1-methyl-4-phenylisonipecotate; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; N-Methyl-4-phenyl-4-carbethoxypiperidine; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI); 1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; 1-Methyl-4-phenylisonipecotic acid, ethyl ester;1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; 4-Carbethoxy-1-methyl-4-phenylpiperidine; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester
DMX4GND	CP	Apotex Inc
DMX4GND	TC	Anesthetics
DMX4GND	DT	Small molecular drug
DMX4GND	PC	4058
DMX4GND	MW	247.33
DMX4GND	FM	C15H21NO2
DMX4GND	IC	InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3
DMX4GND	CS	CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2
DMX4GND	IK	XADCESSVHJOZHK-UHFFFAOYSA-N
DMX4GND	IU	ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
DMX4GND	CA	CAS 57-42-1
DMX4GND	CB	CHEBI:6754
DMX4GND	DE	Pain

DMFJH5Q	ID	DMFJH5Q
DMFJH5Q	DN	Mephentermine
DMFJH5Q	HS	Approved
DMFJH5Q	SN	Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane
DMFJH5Q	CP	Baxter Healthcare Corp Anesthesia Critical Care
DMFJH5Q	TC	Vasoconstrictor Agents
DMFJH5Q	DT	Small molecular drug
DMFJH5Q	PC	3677
DMFJH5Q	MW	163.26
DMFJH5Q	FM	C11H17N
DMFJH5Q	IC	InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
DMFJH5Q	CS	CC(C)(CC1=CC=CC=C1)NC
DMFJH5Q	IK	RXQCGGRTAILOIN-UHFFFAOYSA-N
DMFJH5Q	IU	N,2-dimethyl-1-phenylpropan-2-amine
DMFJH5Q	CA	CAS 100-92-5
DMFJH5Q	CB	CHEBI:6755
DMFJH5Q	DE	High blood pressure

DM5UGDK	ID	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	HS	Approved
DM5UGDK	SN	Epiazin; Epilan; Fenantoin; Insulton; Mefenetoin; Mefenitoina; Mephenetoinum; Mephentoin; Mephenytoine; Mephenytoinum; Mesantoin; Mesdontoin; Mesontoin; Methoin; Methylphenetoin; Metydan; Phenantoin; Phenylethylmethylhydantoin; Sacerno; Sedantional; Sedantoin; Sedantoinal; Triantoin; Ydantoin; Methyl Phenetoin; Methyl hydantoin; MU2276000; Gerot-epilan; L-Mephenytoin; Mefenitoina [INN-Spanish]; Mephenytoin [USAN:INN]; Mephenytoine [INN-French]; Mephenytoinum [INN-Latin]; Mesantoin (TN); Phenetoin, Methyl;Mephenytoin (USP/INN); L-3-Methyl-5-ethyl-5-phenylhydantoin; (+-)-5-Ethyl-3-methyl-5-phenylhydantoin; (+-)-Mephenytoin; (-)-5-Ethyl-3-methyl-5-phenylhydantoin; 3-Ethylnirvanol; 3-Methyl-5, 5-ethylphenylhydantoin; 3-Methyl-5,5-ethylphenylhydantoin; 3-Methyl-5,5-phenylethylhydantoin; 3-Methyl-5-ethyl-5-phenylh; 3-Methyl-5-ethyl-5-phenylhydantoin; 5 Ethyl 3 Methyl 5 Phenylhydantoin; 5-Ethyl-3-methyl-5-phenyl-2,4(3H,5H)-imidazoledione; 5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione; 5-Ethyl-3-methyl-5-phenylhydantoin; 5-Ethyl-3-methyl-5-phenylimidazolidin-2,4-dione; 5-Ethyl-5-fenyl-3-methylhydantoin; 5-Ethyl-5-fenyl-3-methylhydantoin [Czech]; 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
DM5UGDK	CP	Norvatis Phamaceuticals Corporation
DM5UGDK	TC	Anticonvulsants
DM5UGDK	DT	Small molecular drug
DM5UGDK	PC	4060
DM5UGDK	MW	218.25
DM5UGDK	FM	C12H14N2O2
DM5UGDK	IC	InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)
DM5UGDK	CS	CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2
DM5UGDK	IK	GMHKMTDVRCWUDX-UHFFFAOYSA-N
DM5UGDK	IU	5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
DM5UGDK	CA	CAS 50-12-4
DM5UGDK	CB	CHEBI:6757
DM5UGDK	DE	Epilepsy

DMUDWP9	ID	DMUDWP9
DMUDWP9	DN	Mepindolol
DMUDWP9	HS	Approved
DMUDWP9	SN	Mepindolol Bio Tsd; PH-851; Mepindolol, Pharmed/SB
DMUDWP9	CP	Pharmed Dr Liedtke GmbH
DMUDWP9	DT	Small molecular drug
DMUDWP9	PC	71698
DMUDWP9	MW	262.35
DMUDWP9	FM	C15H22N2O2
DMUDWP9	IC	InChI=1S/C15H22N2O2/c1-10(2)16-8-12(18)9-19-15-6-4-5-14-13(15)7-11(3)17-14/h4-7,10,12,16-18H,8-9H2,1-3H3
DMUDWP9	CS	CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)C)O
DMUDWP9	IK	NXWGWUVGUSFQJC-UHFFFAOYSA-N
DMUDWP9	IU	1-[(2-methyl-1H-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol
DMUDWP9	CA	CAS 23694-81-7
DMUDWP9	CB	CHEBI:135082
DMUDWP9	DE	Angina pectoris

DMH2NMY	ID	DMH2NMY
DMH2NMY	DN	Mepivacaine
DMH2NMY	HS	Approved
DMH2NMY	SN	Carbocaine; Mepivacaina; Mepivacainum; Mepivicaine; Scandicain; Scandicaine; Scandicane; Arestocaine HCL; Carboplyin Dental; Isocaine HCL; Carbocaine (TN); Carboplyin Dental (TN); D-mepivacaine; DL-Mepivacaine; Mepivacaina [INN-Spanish]; Mepivacaine (INN); Mepivacaine [INN:BAN]; Mepivacainum [INN-Latin]; Polocaine (TN); Polocaine-Mpf; S-Ropivacaine Mesylate; D(-)-Mepivacaine; N-Methyl-2-pipecolic acid, 2,6-dimethylanilide; N-Methyl-2-pipecolic acid, 2,6-xylidide; N-Methylhexahydro-2-picolinic acid, 2,6-dimethylanilide; N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide; N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide; (+-)-1-Methyl-2',6'-pipecoloxylidide; 1-METHYL-2',6'-PIPECOLOXYLIDIDE
DMH2NMY	CP	Eastman Kodak Co
DMH2NMY	TC	Anesthetics
DMH2NMY	DT	Small molecular drug
DMH2NMY	PC	4062
DMH2NMY	MW	246.35
DMH2NMY	FM	C15H22N2O
DMH2NMY	IC	InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)
DMH2NMY	CS	CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C
DMH2NMY	IK	INWLQCZOYSRPNW-UHFFFAOYSA-N
DMH2NMY	IU	N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
DMH2NMY	CA	CAS 96-88-8
DMH2NMY	CB	CHEBI:6759
DMH2NMY	DE	Analgesia

DMW2GEJ	ID	DMW2GEJ
DMW2GEJ	DN	Mepolizumab
DMW2GEJ	HS	Approved
DMW2GEJ	SN	Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid
DMW2GEJ	CP	MedImmune
DMW2GEJ	DT	Monoclonal antibody
DMW2GEJ	DE	Severe asthma; Asthma

DMTL9IP	ID	DMTL9IP
DMTL9IP	DN	Meprednisone
DMTL9IP	HS	Approved
DMTL9IP	SN	Betapar
DMTL9IP	CP	Schering Corp Sub Schering Plough Corp
DMTL9IP	DT	Small molecular drug
DMTL9IP	PC	5284587
DMTL9IP	MW	372.5
DMTL9IP	FM	C22H28O5
DMTL9IP	IC	InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1
DMTL9IP	CS	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)CO)O)C)C
DMTL9IP	IK	PIDANAQULIKBQS-RNUIGHNZSA-N
DMTL9IP	IU	(8S,9S,10R,13S,14S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
DMTL9IP	CA	CAS 1247-42-3
DMTL9IP	CB	CHEBI:135573
DMTL9IP	DE	Chronic obstructive pulmonary disease

DMHM93Y	ID	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	HS	Approved
DMHM93Y	SN	meprobamate; Meprospan; Meprobamat; Equanil; Miltown; Amepromat; Meprocompren; Meproban; Tranmep; Meprobam; Dapaz; Metractyl; Meprotabs; Meprosin; Meprodil; Mepiosine; Libiolan; Crestanil; Calmiren; Ayeramate; Andaksin; Anatimon; Anathylmon; Holbamate; Despasmol; Cirponyl; Biobamat; Neuramate; Metranquil; Meprocon; Mepantin; Lepetown; Ipsotian; Equilium; Equatrate; Carbaxin; Biobamate; Ansiatan; Anastress; Miltamato; Meprotil; Meprotan; Meprosan; Meproleaf; Meprindon; Mepranil; Mepavlon; Margonil; Harmonin; Dicandiol; Calmadin; Auxietil; Anxietil; Ansiowas;  Amepromat; Amosene; Andaxin; Aneural; Aneurol; Aneusral; Aneuxal; Aneuxral; Ansietan; Ansil; Anural; Anzil; Apascil; Apasil; Appetrol; Arcoban; Arpon; Artolon; Ataraxine; Atraxin; Ayermate; Bamate; Brobamate; Calmax; Cirpon; Coprobate; Cypron; Cyrpon; Deprol; Diron; Diurnal; Diurnaldiverondormabrol; Diveron; Dormabrol; Ecuanil; Edenal; Enorden; Epicur; Epikur; Equinil; Equitar; Erina; Estasil; Gadexyl; Gagexyl; Hartol; Kessobamate; Klort; Larten; Lepenil; Letyl; Mendel; Mepamtin; Meposed; Mepriam; Meprin; Meprobamato; Meprobamatum; Meprodiol; Meprol; Meprosa; Meprotanum; Meproten; Meprovan; Meprovanmeprozine; Meprozine; Meptran; Meptranactylmilprem; Micrainin; Milpath; Milprem; Miltann; Miltaun; Miltuan; Miltwon; Misedant; Morbam; Multaun; Nephentine; Nervonus; Oasil; Optarket;Orlevol; Orolevol; Pancalma; Panediol; Pankalma; Pathibamate; Paxin; Pensive; Perequietil; Perequil; Perquietil; Pertranquil; Pimal; Placidon; Placitate; Prequil; Probamato; Probamyl; Probate; Procalmadiol; Procalmadol; Procalmidol; Procarbamide; Promate; Promato; Proquanil; Protran; Quaname; Quanane; Quanil; Quietidon; Quivet; Rastenil; Reostral; Restenil; Restenyl; Restinal; Restinil; Robamate;Sadanyl; Scolazil; Sedabamate; Sedanil; Sedanyl; Sedazil; Sedoquil; Sedoselecta; Selene; Seril; Setran; Shalvaton; Sowell; Spantran; Stensolo; Tamate; Tensol; Tensonal; Trancot; Trankvilan; Tranlisant; Tranquilan; Tranquilate; Tranquilax; Tranquiline; Tranquilsan; Tranquinol; Trelmar; Urbil; Urbilat; Vistabamate; Wardamate; Wyseals; Zirpon; Component of Appetrol; Component of Bamadex; Component of Equalysen; Component of Milpath; Component of Milprem; Component of Miltrate; Equanil suspension; Meprobamat [German]; Meprobamate and Aspirin Tablets; Meprobamato [Italian]; Meprobamic acid; Meprocon CMC; Solevione anastress; Bamd 400; Bamo 400; Canquil 400; Miltown 600; PMB 200; PMB 400; Apo-Meprobamate; Appetrol-Sr; Canquil-400; Component of PMB-400; Equanil (TN); Equazine-M; Fas-Cile; Fas-Cile 200; Kesso-Bamate; Mar-Bate; Meprin (VAN); Mepro-Aspirin; Mepro-analgesic; Meprobamato [INN-Spanish]; Meprobamatum [INN-Latin]; Meprospan (TN); Meprospan-200; Meprospan-400; Milprem-200; Milprem-400; Miltown (TN); My-trans; Neo-Tran; PMB-200; PMB-400; Pan-tranquil; Q-Gesic; SK-Bamate; Tranquiline (Intra); Vio-Bamate; Cap-O-Tran; Carbamic acid 2-methyl-2-propyltrimethylene ester; Meprobamate (JAN/USP/INN); Meprobamate [USAN:INN:BAN:JAN]; Carbamic acid, 2-methyl-2-propyltrimethylene ester; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate; {2-[(carbamoyloxy)methyl]-2-methylpentyl} carbamate; 1,3-Propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate; 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate; 2,2-Di(carbamoyloxymethyl)pentane; 2-Methyl-2-n-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propylpropane-1,3-diol dicarbamate; 2-Methyl-2-propyltrimethylene carbamate; 2-Metil-2-n-propil-1,3-propanediol dicarbamato; 2-Metil-2-n-propil-1,3-propanediol dicarbamato [Spanish]; 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate; 3P Bamate; KAI-1455
DMHM93Y	CP	Wyeth Pharmaceuticals
DMHM93Y	TC	Antianxiety Agents
DMHM93Y	DT	Small molecular drug
DMHM93Y	PC	4064
DMHM93Y	MW	218.25
DMHM93Y	FM	C9H18N2O4
DMHM93Y	IC	InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
DMHM93Y	CS	CCCC(C)(COC(=O)N)COC(=O)N
DMHM93Y	IK	NPPQSCRMBWNHMW-UHFFFAOYSA-N
DMHM93Y	IU	[2-(carbamoyloxymethyl)-2-methylpentyl] carbamate
DMHM93Y	CA	CAS 57-53-4
DMHM93Y	CB	CHEBI:6761
DMHM93Y	DE	Malaria; Anxiety disorder; Ischemic reperfusion injury

DMPSB8F	ID	DMPSB8F
DMPSB8F	DN	MEPTAZINOL
DMPSB8F	HS	Approved
DMPSB8F	SN	MEPTAZINOL HYDROCHLORIDE; 59263-76-2; Meptazinol HCl; Meptazinol (hydrochloride); 3-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Meptazinol hydrochloride [USAN]; EINECS 261-683-0; WY-22811 hydrochloride; IL-22811 hydrochloride; WY 22811; IL 22811; 3-(3-ethyl-1-methylazepan-3-yl)phenol hydrochloride; m-(3-Ethyl-1-methyl-hexahydro-1H-azepin-3-yl)phenol hydrochloride; m-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Phenol, m-(3-ethyl-1-methyl-hexahydro-1H-azepin-3-yl)-, hydrochloride
DMPSB8F	DT	Small molecular drug
DMPSB8F	PC	41049
DMPSB8F	MW	233.35
DMPSB8F	FM	C15H23NO
DMPSB8F	IC	InChI=1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3
DMPSB8F	CS	CCC1(CCCCN(C1)C)C2=CC(=CC=C2)O
DMPSB8F	IK	JLICHNCFTLFZJN-UHFFFAOYSA-N
DMPSB8F	IU	3-(3-ethyl-1-methylazepan-3-yl)phenol
DMPSB8F	CA	CAS 54340-58-8
DMPSB8F	CB	CHEBI:91484
DMPSB8F	DE	Pain

DMB4SFH	ID	DMB4SFH
DMB4SFH	DN	Mepyramine
DMB4SFH	HS	Approved
DMB4SFH	SN	Anhistabs; Anhistol; Antalergan; Antallergan; Antamine; Anthisan; Copsamine; Coradon; Dipane; Dorantamin; Harvamine; Histacap; Histalon; Histapyran; Histasan; Isamin; Kriptin; Maranhist; Mepiramina; Mepiramine; Mepyramin; Mepyraminum; Mepyren; Neoantergan; Neobridal; Nyscaps; PYRA; Paraminyl; Parmal; Pyramal; Pyranisamine; Pyrilamide; Pyrilamine; Stamine; Stangen; Statomin; Thylogen; Mepyramin [German]; Pyrilamine salt with fine resin; RP 2786; [3H]mepyramine; [3H]pyrilamine; Afko-Hist; Mepiramina [INN-Spanish]; Mepyramine (INN); Mepyramine [INN:BAN]; Mepyraminum [INN-Latin]; Neo-Bridal; Wait's green mountain antihistamine; R.d. 2786; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin [German]; P-Methoxy-benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-para-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N-(para-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N',N'-Dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Dimethylamino-aethyl-N-p-methoxy-benzyl-.alpha.-amino-pyridin-maleat; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha.-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridyl-1,2-ethanediamine; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-((4-Methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine; 2-((2-(Dimethylamino)ethyl)-(p-methoxybenzyl)amino)pyridine; 2-((p-Methoxybenzyl)(2-(dimethylamino)ethyl)amino)pyridine; 2-[(p-Methoxybenzyl)[2-(dimethylamino)ethyl]amino]pyridine; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine; 2-[[2-(Dimethylamino)ethyl]-(p-methoxybenzyl)amino]pyridine; 2-dimethylaminoethyl-p-anisyl-(2-pyridyl)amine
DMB4SFH	TC	Antiasthmatic Agents
DMB4SFH	DT	Small molecular drug
DMB4SFH	PC	4992
DMB4SFH	MW	285.4
DMB4SFH	FM	C17H23N3O
DMB4SFH	IC	InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3
DMB4SFH	CS	CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
DMB4SFH	IK	YECBIJXISLIIDS-UHFFFAOYSA-N
DMB4SFH	IU	N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
DMB4SFH	CA	CAS 91-84-9
DMB4SFH	CB	CHEBI:6762
DMB4SFH	DE	Allergy

DM7F5OW	ID	DM7F5OW
DM7F5OW	DN	Mepyramine maleate
DM7F5OW	HS	Approved
DM7F5OW	SN	Pyrilamine maleate; PYRILAMINE MALEATE; 59-33-6; Anisopyradamine; Histosol; Minihist; Diaminide maleate; Paraminyl maleate; Renstamin; Histatex; Pyraninyl; Pymafed; Paramal; Histine; Antihist; Histan; Pyramal maleate; Stangen maleate; Thylogen maleate; Anthisan maleate; Statomin maleate; Pyra-Maleate; Pyrilamine maleate salt; Neoantergan maleate; Pyranisamine maleate; Pyranilamine maleate; Kriptin maleate; Neo-Antergan maleate; Pyra maleate; Prefrin A; Dorantamin maleate; 2786 RP maleate; Histavet-P (veterinary); Mepyramine hydrogen; Enrumay; Pyma; Component of Pyrdex; Mepiramine maleate; Mepyramine hydrogen maleinate; Mepyramine maleate salt; Midol Maximum Strength PMS; Pyranilamine m aleate; Pyrilamine maleate [USAN]; P 5514; Component of Endotussin-NN; Histavet-P; Pymafed (TN); Pyrilamine maleate (USP); PYRILAMINE MALEATE (SEE ALSO PYRILAMINE, CAS 91-84-9); N-Dimethylaminoethyl-N-p-methoxy-alpha-aminopyridine maleate; N-(dimethylaminoethyl)-N-(p-methoxyphenyl)-alpha-aminopyridine maleate; N-(Dimethylamino)ethyl-N-(p-methoxy)-alpha-aminopyridine maleate; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine maleate; Pyridine, 2-[[2-(dimethylamino)ethyl](p-methoxybenzyl)amino]-, maleate (1:1); N,N-Dimethyl-N'-(4-methoxybenzyl)-N'-(2-pyridyl)ethylenediamine maleate; N-(p-me thoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; N-(p-methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; Pyridine, 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)-, maleate (1:1); N-(4-Methoxyphenyl)methyl-N inverted exclamation marka,Ninverted exclamation marka-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-alpha-pyridylethylenediamine maleate; N-(p-Methoxybenzyl)-N,N'-dimethyl-N-2-pyridyl-1,2-ethanediamine, maleic acid salt; N-(4-Methoxyphenyl)methyl-N',N'-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine but-2-enedioate; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine (2Z)-but-2-enedioate; 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (2Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N1-((4-methoxyphenyl)methyl)-N2,N2-dimethyl-N1-2-pyridinyl-, (2Z)-2-butenedioate (1:1); 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine bimaleate; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate (1:1); 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine bimaleate; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine maleate; Pyrilamine Maleate
DM7F5OW	TC	Antiasthmatic Agents
DM7F5OW	DT	Small molecular drug
DM7F5OW	PC	5284451
DM7F5OW	MW	401.5
DM7F5OW	FM	C21H27N3O5
DM7F5OW	IC	InChI=1S/C17H23N3O.C4H4O4/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15;5-3(6)1-2-4(7)8/h4-11H,12-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DM7F5OW	CS	CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\\C(=O)O)\\C(=O)O
DM7F5OW	IK	JXYWFNAQESKDNC-BTJKTKAUSA-N
DM7F5OW	IU	(Z)-but-2-enedioic acid;N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
DM7F5OW	CA	CAS 59-33-6
DM7F5OW	DE	Headache; Allergy

DMAFBCY	ID	DMAFBCY
DMAFBCY	DN	Mequitazine
DMAFBCY	HS	Approved
DMAFBCY	SN	Butix; Instotal; Kitazemin; Mequitazina; Mequitazinum; Metaplexan; Mircol; Primalan; Quitadrill; Vigigan; Virginan; Zesulan; Italfarmaco brand of mequitazine; Mequitazina [Spanish]; Mequitazine hydrochloride; Pierre Fabre brand of mequitazine; LM 209; Kitazemin (TN); LM-209; Mequitazina [INN-Spanish]; Mequitazinum [INN-Latin]; Mequitazine (JP15/INN); Mequitazine [INN:BAN:DCF:JAN]; Mequitazine tartrate, (R-(R*,R*))-isomer; 10-(1-Azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine; 10-(1-azabicyclo(2.2.2)oct-8-ylmethyl)phenothiazine; 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine; 10-(3-Quinuclidinylmethyl)phenothiazine; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)-(9CI); 3-Methylquinuclidinyl-10-phenothiazine
DMAFBCY	CP	Pierre Fabre SA
DMAFBCY	TC	Antihistamines
DMAFBCY	DT	Small molecular drug
DMAFBCY	PC	4066
DMAFBCY	MW	322.5
DMAFBCY	FM	C20H22N2S
DMAFBCY	IC	InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2
DMAFBCY	CS	C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
DMAFBCY	IK	HOKDBMAJZXIPGC-UHFFFAOYSA-N
DMAFBCY	IU	10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine
DMAFBCY	CA	CAS 29216-28-2
DMAFBCY	CB	CHEBI:31821
DMAFBCY	DE	Allergic rhinitis; Respiratory disease

DMTM2IK	ID	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	HS	Approved
DMTM2IK	SN	6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog)
DMTM2IK	CP	Novopharm
DMTM2IK	TC	Anticancer Agents
DMTM2IK	DT	Small molecular drug
DMTM2IK	PC	667490
DMTM2IK	MW	152.18
DMTM2IK	FM	C5H4N4S
DMTM2IK	IC	InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
DMTM2IK	CS	C1=NC2=C(N1)C(=S)N=CN2
DMTM2IK	IK	GLVAUDGFNGKCSF-UHFFFAOYSA-N
DMTM2IK	IU	3,7-dihydropurine-6-thione
DMTM2IK	CA	CAS 50-44-2
DMTM2IK	CB	CHEBI:2208
DMTM2IK	DE	Acute lymphoblastic leukaemia; Crohn disease

DM0HS92	ID	DM0HS92
DM0HS92	DN	Merimepodib
DM0HS92	HS	Approved
DM0HS92	SN	Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
DM0HS92	CP	GSK
DM0HS92	DT	Small molecular drug
DM0HS92	PC	153241
DM0HS92	MW	452.5
DM0HS92	FM	C23H24N4O6
DM0HS92	IC	InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1
DM0HS92	CS	COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4
DM0HS92	IK	JBPUGFODGPKTDW-SFHVURJKSA-N
DM0HS92	IU	[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
DM0HS92	CA	CAS 198821-22-6
DM0HS92	DE	Hepatitis C virus infection; Breast cancer; Hepatitis virus infection; Head and neck cancer; Gastric adenocarcinoma

DM62UHC	ID	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	HS	Approved
DM62UHC	SN	MEPM; MERONEM; Meropen; Merrem; Meropenem anhydrous; Mepem (TN); Meronem (TN); Meropen (TN); Meropenem (INN); Merrem (TN); Neopenem (TN); SM-7338; Meronem; Merrem I.V. (TN); (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
DM62UHC	CP	AstraZeneca
DM62UHC	TC	Antibiotics
DM62UHC	DT	Small molecular drug
DM62UHC	PC	441130
DM62UHC	MW	383.5
DM62UHC	FM	C17H25N3O5S
DM62UHC	IC	InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
DM62UHC	CS	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
DM62UHC	IK	DMJNNHOOLUXYBV-PQTSNVLCSA-N
DM62UHC	IU	(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM62UHC	CA	CAS 96036-03-2
DM62UHC	CB	CHEBI:43968
DM62UHC	DE	Bacterial infection

DMOVAIX	ID	DMOVAIX
DMOVAIX	DN	Meropenem + vaborbactam
DMOVAIX	HS	Approved
DMOVAIX	SN	Vabomere; Meropenem / vaborbactam; Meropenem and vaborbactam; Meropenem mixture with vaborbactam; Carbavance
DMOVAIX	CP	The Medicines Company/Rempex Pharmaceuticals
DMOVAIX	PC	86298703
DMOVAIX	MW	680.6
DMOVAIX	FM	C29H41BN4O10S2
DMOVAIX	IC	InChI=1S/C17H25N3O5S.C12H16BNO5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t7-,8-,9+,10+,11-,12-;8-,10-/m10/s1
DMOVAIX	CS	B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O.C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
DMOVAIX	IK	SDJYWZHQLNEXKV-SSHSFQATSA-N
DMOVAIX	IU	(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid
DMOVAIX	CA	CAS 2031124-72-6
DMOVAIX	DE	Urinary tract infection; Intra-abdominal infection

DMOL5IU	ID	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	HS	Approved
DMOL5IU	SN	Apriso; Asacol; Asacolitin; Asacolon; Asalit; Ascolitin; Canasa; Claversal; Fisalamine; Fivasa; Iialda; Ipocol; Lialda; Lixacol; Mesacol; Mesalamine; Mesalazina; Mesalazinum; Mesasal; Mesavance; Mesavancol; Mezavant; Pentacol; Pentasa; Rowasa; Salofalk; Salozinal; SfRowasa; Allphar Brand of Mesalamine; Antigen Brand of Mesalamine; Asacol HD; Axcan Brand of Mesalamine; Byk Brand of Mesalamine; Celltech Brand of Mesalamine; Falk Brand of Mesalamine; Farmasa Brand of Mesalamine; Ferring Brand of Mesalamine; GlaxoSmithKline Brand of Mesalamine; Henning Berlin Brand of Mesalamine; M Aminosalicylic Acid; Merckle Brand of Mesalamine; Mesalamine Hydrochloride; Mesalamine Monosodium Salt; Mesalamine [USAN]; Mesalazina[Spanish]; Mesalazine MMX; Mesalazinum [Latin]; Meta Aminosalicylic Acid; Mezavant XL; Minosalicylic acid; Norgine Brand of Mesalamine; Novopharm Brand of Mesalamine; Provalis Brand of Mesalamine; Sanofi Synthelabo Brand of Mesalamine; Schering Plough Brand of Mesalamine; SmithKline Brand of Mesalamine; Solvay Brand of Mesalamine; Yamanouchi Brand of Mesalamine; Novo 5 ASA; Novo5 ASA; AJG-501; Apriso (TN); Asacol (TN); Canasa (TN); Hydrochloride, Mesalamine; Iialda (TN); Ipocal (TN); Lialda (TN); M-A; M-Aminosalicylic acid; MAX-002; MD-0901; Masacol (TN); Mesalamine (USP); Meta-AminosalicylicAcid; Monosodium Salt, Mesalamine; Novo-5 ASA; P-Aminosalicylsaeure; P-Aminosalicylsaeure [German]; Pentasa (TN); Procter & Gamble Brand of Mesalamine; Rowasa (TN); SPD-476; SPD-480; Salofalk (TN); Salofalk Granu-Stix; Schering-Plough Brand of Mesalamine; Z-206; Mesalazine (JAN/INN); Salicylic acid, 5-amino-(8CI); 2-Hydroxy-5-aminobenzoic acid; 3-carboxy-4-hydroxyaniline; 5 Aminosalicylate; 5 Aminosalicylic Acid; 5-AS; 5-ASA; 5-Amino-2-hydroxybenzoic acid; 5-Aminosalicylate; 5-Aminosalicylic acid; 5-amino-2-hydroxy-benzoic acid; 5-aminosalicylic acid, Mesalazine, Asacol, Pentasa, Canasa, Mesalamine
DMOL5IU	TC	Antiinflammatory Agents
DMOL5IU	DT	Small molecular drug
DMOL5IU	PC	4075
DMOL5IU	MW	153.14
DMOL5IU	FM	C7H7NO3
DMOL5IU	IC	InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
DMOL5IU	CS	C1=CC(=C(C=C1N)C(=O)O)O
DMOL5IU	IK	KBOPZPXVLCULAV-UHFFFAOYSA-N
DMOL5IU	IU	5-amino-2-hydroxybenzoic acid
DMOL5IU	CA	CAS 89-57-6
DMOL5IU	CB	CHEBI:6775
DMOL5IU	DE	Ulcerative colitis

DM2ZGAN	ID	DM2ZGAN
DM2ZGAN	DN	Mesoridazine
DM2ZGAN	HS	Approved
DM2ZGAN	SN	Calodal; Lidanar; Lidanil; Mesoridazina; Mesoridazinum; Serentil; Serentil Concentrate; Thioridazien thiomethyl sulfoxide; Thioridazine monosulfoxide analog; Thioridazine thiomethyl sulfoxide; TPS 23; Tps23; Lidanar (TN); Mesoridazina [INN-Spanish]; Mesoridazinum [INN-Latin]; NC-123; Serentil (TN); TPS-23; Mesoridazine (USAN/INN); Mesoridazine [USAN:BAN:INN]; T-2-SO; THD-2-SO; Thioridazine-2-sulfoxide; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
DM2ZGAN	CP	Norvatis Phamaceuticals Corporation
DM2ZGAN	TC	Antipsychotic Agents
DM2ZGAN	DT	Small molecular drug
DM2ZGAN	PC	4078
DM2ZGAN	MW	386.6
DM2ZGAN	FM	C21H26N2OS2
DM2ZGAN	IC	InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
DM2ZGAN	CS	CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C
DM2ZGAN	IK	SLVMESMUVMCQIY-UHFFFAOYSA-N
DM2ZGAN	IU	10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
DM2ZGAN	CA	CAS 5588-33-0
DM2ZGAN	CB	CHEBI:6780
DM2ZGAN	DE	Schizophrenia

DMG3F94	ID	DMG3F94
DMG3F94	DN	Mestranol
DMG3F94	HS	Approved
DMG3F94	SN	Devocin; Menophase; Mestranolo; Mestranolum; Norquen; Ovastol; Component of Norinyl; Component of Norquen; Component of Ovulen; Ethynylestradiol methyl ether; Mestranol [Steroidal oestrogens]; Mestranolo [DCIT]; EE3ME; Ethinyl Estradiol 3 Methyl Ether; SC 4725; Component of Ortho-Novum; Delta-MVE; EE(sub3)ME; EthinylEstradiol 3-Methyl Ether; Ethinylestradiol 3-methyl ether; Ethinyloestradiol 3-methyl ether; Ethynylestradiol 3-methyl ether; Ethynyloestradiol 3-methyl ether; Inostral (steroid); Mestranolum [INN-Latin]; Mestranol (JP15/USP/INN); Mestranol [USAN:INN:BAN:JAN]; Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 17-Ethynylestradiol 3-methyl ether; 17-Ethynyloestradiol 3-methyl ether; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-alpha-Ethinyl oestradiol 3-methyl ether; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; 17-alpha-Ethynyloestradiol methyl ether; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; 17alpha-Ethinyl estradiol 3-methyl ether; 17alpha-Ethinyl oestradiol 3-methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; 17alpha-Ethynylestradiol 3-methyl ether; 17alpha-Ethynylestradiol methyl ether; 17alpha-Ethynyloestradiol 3-methyl ether; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-17-alpha-ethinylestradiol; 3-Methoxy-17-alpha-ethinyloestradiol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynylestradiol; 3-Methoxy-17-alpha-ethynyloestradiol; 3-Methoxy-17-ethynyloestradiol-17-beta; 3-Methoxy-17alpha-ethinylestradiol; 3-Methoxy-17alpha-ethinyloestradiol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; 3-Methoxy-17alpha-ethynylestradiol; 3-Methoxy-17alpha-ethynyloestradiol; 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; 3-Methoxyethynylestradiol; 3-Methoxyethynyloestradiol; 3-Methylethynylestradiol; 3-Methylethynyloestradiol; 3-O-Methylethynylestradiol
DMG3F94	TC	Estrogens
DMG3F94	DT	Small molecular drug
DMG3F94	PC	6291
DMG3F94	MW	310.4
DMG3F94	FM	C21H26O2
DMG3F94	IC	InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1
DMG3F94	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC
DMG3F94	IK	IMSSROKUHAOUJS-MJCUULBUSA-N
DMG3F94	IU	(8R,9S,13S,14S,17R)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol
DMG3F94	CA	CAS 72-33-3
DMG3F94	CB	CHEBI:6784
DMG3F94	DE	Contraception

DMM4QOJ	ID	DMM4QOJ
DMM4QOJ	DN	Metadoxine
DMM4QOJ	HS	Approved
DMM4QOJ	SN	MG01CI; Metadoxine (oral sustained release, ADHD); Metadoxine (oral extended release, ADHD), Alcobra; Metadoxine (oral sustained release, ADHD), Alcobra
DMM4QOJ	CP	Alcobra
DMM4QOJ	DT	Small molecular drug
DMM4QOJ	PC	115198
DMM4QOJ	MW	298.29
DMM4QOJ	FM	C13H18N2O6
DMM4QOJ	IC	InChI=1S/C8H11NO3.C5H7NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5;7-4-2-1-3(6-4)5(8)9/h2,10-12H,3-4H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t;3-/m.0/s1
DMM4QOJ	CS	CC1=NC=C(C(=C1O)CO)CO.C1CC(=O)N[C@@H]1C(=O)O
DMM4QOJ	IK	RYKKQQUKJJGFMN-HVDRVSQOSA-N
DMM4QOJ	IU	4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2S)-5-oxopyrrolidine-2-carboxylic acid
DMM4QOJ	CA	CAS 74536-44-0
DMM4QOJ	DE	Multiple myeloma

DMTQS9A	ID	DMTQS9A
DMTQS9A	DN	Metaproterenol sulfate
DMTQS9A	HS	Approved
DMTQS9A	SN	Metaproterenol; metaproterenol; ORCIPRENALINE; Alupent; 586-06-1; Orciprenalinum; Metaproterenol sulfate; Orciprenalina; Orciprenalinum [INN-Latin]; Orciprenalina [INN-Spanish]; Metaproterenol polistirex; Metaprel; Alotec; Prometa; Orciprenaline [INN]; CCRIS 9017; Orciprenaline (INN); EINECS 209-569-1; CHEMBL776; BRN 2807247; (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; CHEBI:6792; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol;  Alupent; Orciprenaline
DMTQS9A	CP	Boehringer Ingelheim Pharmaceuticals Inc
DMTQS9A	DT	Small molecular drug
DMTQS9A	PC	441333
DMTQS9A	MW	520.6
DMTQS9A	FM	C22H36N2O10S
DMTQS9A	IC	InChI=1S/2C11H17NO3.H2O4S/c2*1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8;1-5(2,3)4/h2*3-5,7,11-15H,6H2,1-2H3;(H2,1,2,3,4)
DMTQS9A	CS	CC(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O
DMTQS9A	IK	MKFFGUZYVNDHIH-UHFFFAOYSA-N
DMTQS9A	IU	5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol;sulfuric acid
DMTQS9A	CA	CAS 5874-97-5
DMTQS9A	DE	Asthma

DMWIX23	ID	DMWIX23
DMWIX23	DN	Metaraminol
DMWIX23	HS	Approved
DMWIX23	SN	Araminol; Hydroxynorephedrine; Isophenylephrine; Metaradrin; Metaradrine; Metaraminolum; Pressonex; Pressorol; Icoral B; Metaraminolum [Latin]; Aramine (TN); L-Metaraminol; M-Hydroxy norephedrine; M-Hydroxynorephedrine; M-Hydroxyphenylpropanolamine; M-Hydroxypropadrine; Meta-Hydroxynorephedrine; Metaraminol (INN); Metaraminol [INN:BAN]; Metaraminolum [INN-Latin]; Alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol; Alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; Alpha-(m-Hydroxyphenyl)-beta-aminopropanol; M-Hydroxy-alpha-(1-aminoethyl)-benzyl alcohol; Benzenemethanol, alpha-(1-aminoethyl)-3-hydroxy-, (R-(R*,S*))-(9CI); (-)-Erythro-metaraminol; 1-(m-Hydroxyphenyl)-2-amino-1-propanol; 1-Metaraminol; 1-alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; 2-Amino-1-(m-hydroxyphenyl)-1-propanol; 3-Hydroxyphenylisopropanolamine; 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol
DMWIX23	CP	Merck Sharp & Dohme Pharmaceuticals
DMWIX23	TC	Antihypertensive Agents
DMWIX23	DT	Small molecular drug
DMWIX23	PC	5906
DMWIX23	MW	167.2
DMWIX23	FM	C9H13NO2
DMWIX23	IC	InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1
DMWIX23	CS	C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N
DMWIX23	IK	WXFIGDLSSYIKKV-RCOVLWMOSA-N
DMWIX23	IU	3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol
DMWIX23	CA	CAS 54-49-9
DMWIX23	CB	CHEBI:6794
DMWIX23	DE	Hypotension

DMJFP6G	ID	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	HS	Approved
DMJFP6G	SN	Metergoline; metergoline; Liserdol; 17692-51-2; Methergoline; Metergolina; Metergolinum; Metergolina [DCIT]; Metergolinum [Latin]; Metergolina [Spanish]; Substance 355/255; Metergoline [INN:BAN]; Metergolinum [INN-Latin]; 1-Methyl-N-carbobenzyloxydihydro-D-lysergamin; FI-6337; MLS000069437; UNII-1501393LY5; C25H29N3O2; AHR 3009; 1-Methyl-8-beta-carbobenzyloxyaminomethyl-10-alpha-ergoline; EINECS 241-686-3; 1,6-Dimethyl-8-beta-carbobenzyloxaminomethyl-10-alpha-ergoline; FI 6337;  Liserdol (TN)
DMJFP6G	DT	Small molecular drug
DMJFP6G	PC	28693
DMJFP6G	MW	403.5
DMJFP6G	FM	C25H29N3O2
DMJFP6G	IC	InChI=1S/C25H29N3O2/c1-27-14-18(13-26-25(29)30-16-17-7-4-3-5-8-17)11-21-20-9-6-10-22-24(20)19(12-23(21)27)15-28(22)2/h3-10,15,18,21,23H,11-14,16H2,1-2H3,(H,26,29)/t18-,21+,23+/m0/s1
DMJFP6G	CS	CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5
DMJFP6G	IK	WZHJKEUHNJHDLS-QTGUNEKASA-N
DMJFP6G	IU	benzyl N-[[(6aR,9S,10aR)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinolin-9-yl]methyl]carbamate
DMJFP6G	CA	CAS 17692-51-2
DMJFP6G	CB	CHEBI:64216
DMJFP6G	DE	Hyperprolactinaemia

DM89QE1	ID	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	HS	Approved
DM89QE1	SN	657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin
DM89QE1	CP	Bristol-Myers Squibb
DM89QE1	TC	Hypoglycemic Agents
DM89QE1	DT	Small molecular drug
DM89QE1	PC	4091
DM89QE1	MW	129.16
DM89QE1	FM	C4H11N5
DM89QE1	IC	InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
DM89QE1	CS	CN(C)C(=N)N=C(N)N
DM89QE1	IK	XZWYZXLIPXDOLR-UHFFFAOYSA-N
DM89QE1	IU	3-(diaminomethylidene)-1,1-dimethylguanidine
DM89QE1	CA	CAS 657-24-9
DM89QE1	CB	CHEBI:6801
DM89QE1	DE	Type-2 diabetes

DMTPAM3	ID	DMTPAM3
DMTPAM3	DN	Metformin arginine-hemisuccinimide
DMTPAM3	HS	Approved
DMTPAM3	SN	Diap-2; Metformin arginine-hemisuccinate-hemisuccinamide; Metformin arginine-hemisuccinimide (type 2 diabetes); Diap-2 (type 2 diabetes), Arteria; Metformin arginine-hemisuccinimide (type 2 diabetes), Arteria
DMTPAM3	CP	Boehringer Ingelheim Pharmaceuticals; Merck; Depomed; Janssen Research & Development; AstraZeneca; Bristol-Myers Squibb
DMTPAM3	DE	Type-2 diabetes

DMGS4QH	ID	DMGS4QH
DMGS4QH	DN	Methacholine Chloride
DMGS4QH	HS	Approved
DMGS4QH	SN	Methacholine; methacholine; Acetylmethylcholine; Methacholin; Mecholine; Mecholin; Provocholine; Methacholinum; beta-Methylacetylcholine; 55-92-5; Choline, acetyl-beta-methyl-; Acetyl-beta-methylcholine; BRN 1769932; CHEBI:6804; 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; AMMONIUM, (2-HYDROXYPROPYL)TRIMETHYL-, ACETATE (ESTER); 2-acetyloxypropyl(trimethyl)azanium; C8H18NO2; AC1Q5XYD; AC1L1COQ; Prestwick2_000759; Prestwick0_000759; Prestwick3_000759; Prestwick1_000759; CHEMBL978; 2-(acetyloxy)-n,n,n-trimethylpropan-1-aminium; METHACHOLINE
DMGS4QH	CP	Methapharm Inc
DMGS4QH	DT	Small molecular drug
DMGS4QH	PC	6114
DMGS4QH	MW	195.69
DMGS4QH	FM	C8H18ClNO2
DMGS4QH	IC	InChI=1S/C8H18NO2.ClH/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1
DMGS4QH	CS	CC(C[N+](C)(C)C)OC(=O)C.[Cl-]
DMGS4QH	IK	JHPHVAVFUYTVCL-UHFFFAOYSA-M
DMGS4QH	IU	2-acetyloxypropyl(trimethyl)azanium;chloride
DMGS4QH	CA	CAS 62-51-1
DMGS4QH	CB	CHEBI:50142
DMGS4QH	DE	bronchial hyperreactivity; Asthma

DMAY96V	ID	DMAY96V
DMAY96V	DN	Methacycline
DMAY96V	HS	Approved
DMAY96V	SN	Bialatan; Metaciclina; Metacycline; Metacyclinum; Methacyclin; Methacyclinum; Methylenecycline; Methyleneoxytetracycline; Rondomycin; Methacycline amphoteric; Methacycline base; GS 2876; GS-2876; Metaciclina [INN-Spanish]; Metacycline (INN); Metacyclinum [INN-Latin]; Methacycline (USAN); Methacycline [USAN:BAN]; Tri-methacycline; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; 6-Demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline; 6-Deoxy-6-demethyl-6-methylene-5-oxytetracycline; 6-Methylene-5-hydroxytetracycline; 6-Methylene-5-oxytetracycline; 6-Methyleneoxytetracycline
DMAY96V	TC	Antibiotics
DMAY96V	DT	Small molecular drug
DMAY96V	PC	54675785
DMAY96V	MW	442.4
DMAY96V	FM	C22H22N2O8
DMAY96V	IC	InChI=1S/C22H22N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-6,10,14-15,17,25-27,30,32H,1H2,2-3H3,(H2,23,31)/t10-,14-,15+,17+,22+/m1/s1
DMAY96V	CS	CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O
DMAY96V	IK	XIYOPDCBBDCGOE-IWVLMIASSA-N
DMAY96V	IU	(4S,4aR,5S,5aR,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMAY96V	CA	CAS 914-00-1
DMAY96V	CB	CHEBI:6805
DMAY96V	DE	Bacterial infection

DMTW6IU	ID	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	HS	Approved
DMTW6IU	SN	Adanon; Algovetin; Althose; Amidon; Amidone; Biscuits; Dextromethadone; Diaminon; Dollies; Dolly; Dolophin; Dolophine; Heptadone; Heptanon; Ketalgin; Levometadona; Levomethadonum; Levothyl; Metadona; Metadone; Metasedin; Methadon; Methadona; Methadonum; Methaquaione; Phenadone; Polamidone; Polamivet; Westadone; Dolophine HCL; Levomethadone [INN]; Metadona [Spanish]; Metadone [DCIT]; Methadona [Spanish]; Methadone HCL Intensol; Methadone M; Methadonum [Latin]; Racemic methadone; A 4624; AN 148; Hoechst 10820; K 174; Amidone (TN); D-Methadone; Dl-Methadone; Dolophine (TN); Heptadon (TN); Heptanon (pharmaceutical); L-Methadone; L-Polamidon; L-Polamivet; Levometadona [INN-Spanish]; Levomethadonum [INN-Latin]; Metadona [INN-Spanish]; Methadone (BAN); Methadone [INN:BAN]; Methadonum [INN-Latin]; Methadose (TN); Physeptone (TN); Sedo-Rapide; Symoron (TN); Dolophine (*Hydrochloride*); Fenadone (*Hydrochloride*); Heptadone (*Hydrochloride*); Heptanon (*Hydrochloride*); Hoescht 10820 (*Hydrochloride*); Phenadone (*Hydrochloride*); AN-148 (*Hydrochloride*); L-(+)-Methadone; S-(+)-Methadone; D-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (+)-Methadone; (+-)-Methadone; (+/-)-Methadone; (+/-)-Tussal; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-(9CI); 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; 6-(dimethylamino)-4,4-diphenylheptan-3-one; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; 6S-Methadone
DMTW6IU	CP	Eli Lilly
DMTW6IU	TC	Analgesics
DMTW6IU	DT	Small molecular drug
DMTW6IU	PC	4095
DMTW6IU	MW	309.4
DMTW6IU	FM	C21H27NO
DMTW6IU	IC	InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
DMTW6IU	CS	CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
DMTW6IU	IK	USSIQXCVUWKGNF-UHFFFAOYSA-N
DMTW6IU	IU	6-(dimethylamino)-4,4-diphenylheptan-3-one
DMTW6IU	CA	CAS 76-99-3
DMTW6IU	CB	CHEBI:6807
DMTW6IU	DE	Dry cough

DMIRMVB	ID	DMIRMVB
DMIRMVB	DN	Methadyl Acetate
DMIRMVB	HS	Approved
DMIRMVB	SN	ALPHACETYLMETHADOL; Acemethadone; Acetilmetadol; Acetylmethadol; Acetylmethadolum; Amidolacetate; Levamethadyl; Acetilmetadol [INN-Spanish]; Acetylmethadol (INN); Acetylmethadolum [INN-Latin]; Methadyl acetate (USAN); Methadyl acetate [USAN:BAN]; N-LAMM; Race-Acetylmethadol; [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester); Benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate; (R,S)-4-Dimethylamino-1-ethyl-2,2-diphenylpentyl acetat; 1-Ethyl-4-dimethylamino-2,2-diphenylpentylacetat; 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane; 4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; 6-(Dimethylamino)-4,4-Diphenyl-3-Heptanol Acetate
DMIRMVB	TC	Narcotics
DMIRMVB	DT	Small molecular drug
DMIRMVB	PC	10517
DMIRMVB	MW	353.5
DMIRMVB	FM	C23H31NO2
DMIRMVB	IC	InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3
DMIRMVB	CS	CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
DMIRMVB	IK	XBMIVRRWGCYBTQ-UHFFFAOYSA-N
DMIRMVB	IU	[6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
DMIRMVB	CA	CAS 509-74-0
DMIRMVB	CB	CHEBI:135491
DMIRMVB	DE	Opioid dependence

DMPM4SK	ID	DMPM4SK
DMPM4SK	DN	Methamphetamine
DMPM4SK	HS	Approved
DMPM4SK	SN	METHAMPHETAMINE; Metamfetamine; d-Deoxyephedrine; d-Desoxyephedrine; d-Methamphetamine; d-N-Methylamphetamine; Metamphetamine; L-Methamphetamine; d-Methylamphetamine; Methylamphetamine; d-Phenylisopropylmethylamine; N-Methylamphetamine; (S)-Methamphetamine; Norodin; (+)-Methylamphetamine; d-(S)-Methamphetamine; D-1-Phenyl-2-methylaminopropane; Metamfetaminum; Desyphed; (+)-N-Methylamphetamine; (S)-Methylamphetamine; (+)-(S)-Deoxyephedrine; Methyl-beta-phenylisopropylamine; 1-Phenyl-2-methylaminopropane; (S)-(+)-Deoxyephedrine;  Crank; Desohyephedrine; Metamfetamina; Meth; Methamphetaminum; Speed; Stimulex; Crank [Street Name]; Crystal Meth; Crystal Meth [Street Name]; Desyphed hydrochloride; ICE [Street Name]; Metamfetamine [INN];Metamfetaminum [Latin]; Metanfetamina [Spanish]; Methamphetaminum [JP]; Speed [Street Name]; D-Deoxyephedrine; D-Desoxyephedrine; D-Methamphetamine; D-Methylamphetamine; D-Phenylisopropylmethylamine;Desoxyn (TN); Metamfetamina [INN-Spanish]; Metamfetamine (INN); Metamfetamine-m; Metamfetaminum [INN-Latin]; Metanfetamina [INN-Spanish]; Meth (Street Name); Methamphetaminum [INN-Latin]; D-N-Methylamphetamine; D-(S)-Methamphetamine; D-N,alpha-dimethylphenethylamine; Methamphetamine, its salts, isomers, and salts of its isomers; N-Methyl-beta-phenylisopropylamin; N-Methyl-beta-phenylisopropylamin [German]; N-Methyl-beta-phenylisopropylamine; D-1-Phenyl-2-methylaminopropan; D-1-Phenyl-2-methylaminopropan [German]; S-(+)-Methamphetamine; D-N,alpha-Dimethylphenethylamine; N-Methyl-1-phenyl-2-propanamine; Benzeneethanamine, N,alpha-dimethyl-, (S)-(9CI); Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-(9CI); Phenethylamine, N,alpha-dimethyl-, (S)-(+)-(8CI); (+)-(S)-N-alpha-Dimethylphenethylamine; (+)-2-(N-Methylamino)-1-phenylpropane; (+)-N,alpha-Dimethyl-beta-phenylethylamine; (+)-N,alpha-Dimethylphenethylamine; (+)-methamphetamine; (2S)-N-methyl-1-phenylpropan-2-amine; (S)-(+)-Methamphetamine; (S)-(+)-N,alpha,dimethylphenethylamine; (S)-N,alpha-Dimethylbenzeneethanamine; (S)-N,alpha-Dimethylbenzeneethanoamine; (alphaS)-N,alpha-dimethylbenzeneethanamine; 1-Phenyl-2-methylamino-propan; 1-Phenyl-2-methylamino-propan [German]; 2S-(+)-Methamphetamine; Methamfetamine
DMPM4SK	CP	Ovation Pharma
DMPM4SK	TC	Central Nervous System Stimulants
DMPM4SK	DT	Small molecular drug
DMPM4SK	PC	10836
DMPM4SK	MW	149.23
DMPM4SK	FM	C10H15N
DMPM4SK	IC	InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1
DMPM4SK	CS	C[C@@H](CC1=CC=CC=C1)NC
DMPM4SK	IK	MYWUZJCMWCOHBA-VIFPVBQESA-N
DMPM4SK	IU	(2S)-N-methyl-1-phenylpropan-2-amine
DMPM4SK	CA	CAS 537-46-2
DMPM4SK	CB	CHEBI:6809
DMPM4SK	DE	Pain; Attention deficit hyperactivity disorder

DMO2JBC	ID	DMO2JBC
DMO2JBC	DN	Methamphetamine hydrochloride
DMO2JBC	HS	Approved
DMO2JBC	SN	Methamphetamine HCL; Methamphetamine hydrochloride; Methamphetaminium chloride; Methylamphetamine hydrochloride; Methylisomyn; Norodin hydrochloride; Adipex; Chestox; Deofed; Des-O-E; Desepin; Desodex; Desoxo-5; Desoxyfed; Desoxyne; Destim; Dexoval; Dexstim; Dextim; Dosoxy; Doxyfed; Drinalfa; Efroxine; Eufodrinal; Gerovit; Hyphet; Isophen; Isophen (VAN); Obedrin-LA; Pervitin; Philopon; Soxysympamine; Syndrox; Tonedron; d-Methaphetamine hydrochloride; (+)-Methamphetamine hydrochloride; 51-57-0; S-(+)-Methamphetamine hydrochloride
DMO2JBC	PC	66124
DMO2JBC	MW	185.69
DMO2JBC	FM	C10H16ClN
DMO2JBC	IC	TWXDDNPPQUTEOV-FVGYRXGTSA-N
DMO2JBC	CS	CC(CC1=CC=CC=C1)NC.Cl
DMO2JBC	IK	1S/C10H15N.ClH/c1-9(11-2)8-10-6-4-3-5-7-10;/h3-7,9,11H,8H2,1-2H3;1H/t9-;/m0./s1
DMO2JBC	IU	(2S)-N-methyl-1-phenylpropan-2-amine;hydrochloride
DMO2JBC	CA	CAS 51-57-0
DMO2JBC	CB	CHEBI:35340
DMO2JBC	DE	Attention deficit hyperactivity disorder

DM8X4A1	ID	DM8X4A1
DM8X4A1	DN	Methantheline
DM8X4A1	HS	Approved
DM8X4A1	SN	Mantheline; Methanide; Methanthelinium; Methanthelinum; Banthine bromide; Gastrin I; Methanthine bromide; Gastrin-1 Human; Diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; N,N-Diethyl-N-methyl-2-[(9H-xanthen-9-ylcarbonyl)oxy]ethanaminium
DM8X4A1	CP	Shire Development Inc
DM8X4A1	TC	Anticholinergic Agents
DM8X4A1	DT	Small molecular drug
DM8X4A1	PC	4097
DM8X4A1	MW	340.4
DM8X4A1	FM	C21H26NO3+
DM8X4A1	IC	InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1
DM8X4A1	CS	CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13
DM8X4A1	IK	GZHFODJQISUKAY-UHFFFAOYSA-N
DM8X4A1	IU	diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
DM8X4A1	CA	CAS 5818-17-7
DM8X4A1	CB	CHEBI:6817
DM8X4A1	DE	Gastritis; Pancreatitis; Irritable bowel syndrome; Peptic ulcer

DM5A38V	ID	DM5A38V
DM5A38V	DN	Metharbital
DM5A38V	HS	Approved
DM5A38V	SN	Endiemal; Endiemalum; Gemonal; Gemonil; Gemonit; Metabarbital; Metarbital; Metarbitale; Methabarbital; Methabarbitone; Metharbitalum; Metharbitone; Metharbutal; Methylbarbital; Metarbitale [DCIT]; AN 23; Sch 412; Gemonil (TN); Metarbital [INN-Spanish]; Metharbital [INN:JAN]; Metharbitalum [INN-Latin]; N-Methylbarbital; Metharbital (JAN/INN); 1-Methylbarbital; 5,5-Diethyl-1-methyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5,5-Diethyl-1-methylbarbituric acid; 5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione; 5,5-diethyl-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione
DM5A38V	CP	Abbott Laboratories
DM5A38V	TC	Anticonvulsants
DM5A38V	DT	Small molecular drug
DM5A38V	PC	4099
DM5A38V	MW	198.22
DM5A38V	FM	C9H14N2O3
DM5A38V	IC	InChI=1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14)
DM5A38V	CS	CCC1(C(=O)NC(=O)N(C1=O)C)CC
DM5A38V	IK	FWJKNZONDWOGMI-UHFFFAOYSA-N
DM5A38V	IU	5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione
DM5A38V	CA	CAS 50-11-3
DM5A38V	CB	CHEBI:31827
DM5A38V	DE	Epilepsy

DM7J2TA	ID	DM7J2TA
DM7J2TA	DN	Methazolamide
DM7J2TA	HS	Approved
DM7J2TA	SN	Methazolamide (oral, sustained release)
DM7J2TA	CP	Effcon Laboratories Inc
DM7J2TA	DT	Small molecular drug
DM7J2TA	PC	4100
DM7J2TA	MW	236.3
DM7J2TA	FM	C5H8N4O3S2
DM7J2TA	IC	InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)
DM7J2TA	CS	CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C
DM7J2TA	IK	FLOSMHQXBMRNHR-UHFFFAOYSA-N
DM7J2TA	IU	N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide
DM7J2TA	CA	CAS 554-57-4
DM7J2TA	CB	CHEBI:6822
DM7J2TA	DE	Glaucoma/ocular hypertension

DMAUHQX	ID	DMAUHQX
DMAUHQX	DN	Methdilazine
DMAUHQX	HS	Approved
DMAUHQX	SN	Disyncram; Methdilazinum; Methodilazine; Metodilazina; Tacaryl; Tacazyl; Tacryl; Methilazine hydrochloride; Methdilazine (INN); Methdilazinum [INN-Latin]; Metodilazina [INN-Spanish]; Tacaryl (TN); Methdilazine [USAN:INN:BAN]; 10-((1-Methyl-3-pyrrolidinyl)methyl)phenothiazine; 10-((1-methyl-3-pyrrolidinyl)methyl)-10H-phenothiazine; 10-[(1-Methylpyrrolidin-3-yl)methyl]phenothiazine; 10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine
DMAUHQX	TC	Antihistamines
DMAUHQX	DT	Small molecular drug
DMAUHQX	PC	14677
DMAUHQX	MW	296.4
DMAUHQX	FM	C18H20N2S
DMAUHQX	IC	InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3
DMAUHQX	CS	CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42
DMAUHQX	IK	HTMIBDQKFHUPSX-UHFFFAOYSA-N
DMAUHQX	IU	10-[(1-methylpyrrolidin-3-yl)methyl]phenothiazine
DMAUHQX	CA	CAS 1982-37-2
DMAUHQX	CB	CHEBI:6823
DMAUHQX	DE	Allergic rhinitis

DM25FL8	ID	DM25FL8
DM25FL8	DN	Methimazole
DM25FL8	HS	Approved
DM25FL8	SN	methimazole; 60-56-0; thiamazole; Tapazole; 2-Mercapto-1-methylimidazole; Mercazolyl; 1-Methylimidazole-2-thiol; Thymidazole; Mercazole; Methimazol; Thymidazol; Thiamazol; Metazolo; Thycapzol; Metothyrine; Metothyrin; Merkazolil; Mercaptazole; Strumazol; Favistan; Basolan; Thycapsol; Metotirin; Danantizol; Thacapzol; Merkastan; Frentirox; Metizol; Tiamazol; Mercasolyl; 1-Methyl-1H-imidazole-2-thiol; Methylmercaptoimidazole; 1-Methyl-2-mercaptoimidazole; Methiamazole; Usaf el-30; Methimazolum; Mercazolylum; Tapuzole; Metimazol; Thimazole;  Basolan; MMZ; Mercazol; Methamazole; Methizol; Methymazol; Metisol; Strumazole; Thiamazole; Thiamazolum; Thimazol; Thyrozol; Tiamazolo; Tirodril; EliLilly Brand of Methimazole; Estedi Brand of Methimazole; Henning Berlin Brand of Methimazole; Hexal Brand of Methimazole; Jones Brand of Methimazole; Merck Brand of Methimazole; Nourypharma Brand of Methimazole; Philopharm Brand of Methimazole; Sanofi Synthelabo Brand of Methimazole; Temmler Brand of Methimazole; Thiamazol Henning; Thiamazol Hexal; Tiamazolo [DCIT]; M0868; Henning, Thiamazol; Hexal, Thiamazol; Methimazole (USP); Methimazole [USAN:BAN]; Tapazole (TN); Thiamazol [INN-French]; Thiamazolum [INN-Latin]; Tiamazol [INN-Spanish]; Mestinon, Regonol, Pyridostigmine Bromide;Thiamazole (JP15/INN); N-Methyl-2-mercaptoimidazole; 1 Methyl 2 mercaptoimidazole; 1,3-Dihydro-1-Methyl-2H-Imidazol-2-Thione; 1,3-Dihydro-1-methyl-2H-imidazole-2-thione; 1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE; 1-Methyl-1,3-dihydroimidazole-2-thione; 1-Methyl-2-Imidazolethione; 1-Methyl-2-imidazolethiol; 1-Methyl-imidazole-2-thiol; 1-Methylimidazole-2(3H)-thione; 1-Metylo 2 merkaptoimidazolem; 1-Metylo 2 merkaptoimidazolem [Polish]; 2-Mercaptomethylimidazole; 3-methyl-1H-imidazole-2-thione
DM25FL8	TC	Antithyroid Agents
DM25FL8	DT	Small molecular drug
DM25FL8	PC	1349907
DM25FL8	MW	114.17
DM25FL8	FM	C4H6N2S
DM25FL8	IC	InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
DM25FL8	CS	CN1C=CNC1=S
DM25FL8	IK	PMRYVIKBURPHAH-UHFFFAOYSA-N
DM25FL8	IU	3-methyl-1H-imidazole-2-thione
DM25FL8	CA	CAS 60-56-0
DM25FL8	CB	CHEBI:50673
DM25FL8	DE	Hyperthyroidism

DM3Z217	ID	DM3Z217
DM3Z217	DN	Methimazole
DM3Z217	HS	Approved
DM3Z217	SN	Mercaptazole; Mercasolyl; Mercazole; Mercazolyl; Mercazolylum; Merkastan; Merkazolil; Metazolo; Methiamazole; Methimazol; Methimazolum; Methylmercaptoimidazole; Metizol; Metothyrin; Metothyrine; Metotirin; Strumazol; Tapazole; Thacapzol; Basolan; Danantizol; Favistan; Frentirox; Thiamazol; Thycapsol; Thycapzol; Thymidazol; Thymidazole; Tiamazol; Usaf el-30; methimazole; thiamazole; 1-Methyl-1H-imidazole-2-thiol; 1-Methyl-2-mercaptoimidazole; 1-Methylimidazole-2-thiol; 2-Mercapto-1-methylimidazole; 3-methyl-1H-imidazole-2-thione; 60-56-0
DM3Z217	PC	1349907
DM3Z217	MW	114.17
DM3Z217	FM	C4H6N2S
DM3Z217	IC	PMRYVIKBURPHAH-UHFFFAOYSA-N
DM3Z217	CS	CN1C=CNC1=S
DM3Z217	IK	1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
DM3Z217	IU	3-methyl-1H-imidazole-2-thione
DM3Z217	CA	CAS 60-56-0
DM3Z217	CB	CHEBI:50673
DM3Z217	DE	Thyrotoxicosis

DM7YMIT	ID	DM7YMIT
DM7YMIT	DN	Methohexital
DM7YMIT	HS	Approved
DM7YMIT	SN	Brevital; Brietal; Enallynymall; Enallynymalum; Methodrexitone; Methohexitalum; Methohexitone; Metoesital; Metohexital; Metoesital [DCIT]; Brevital (TN); Methohexital, Monosodium Salt; Methohexitalum [INN-Latin]; Metohexital [INN-Spanish]; Methohexital (USP/INN); Alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituricacid; (+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione; 5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid; 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM7YMIT	CP	Par Sterile Products Llc
DM7YMIT	TC	Anesthetics
DM7YMIT	DT	Small molecular drug
DM7YMIT	PC	9034
DM7YMIT	MW	262.3
DM7YMIT	FM	C14H18N2O3
DM7YMIT	IC	InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)
DM7YMIT	CS	CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C
DM7YMIT	IK	NZXKDOXHBHYTKP-UHFFFAOYSA-N
DM7YMIT	IU	5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM7YMIT	CA	CAS 151-83-7
DM7YMIT	CB	CHEBI:102216
DM7YMIT	DE	Anaesthesia

DM2TEOL	ID	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	HS	Approved
DM2TEOL	SN	methotrexate; 1959/5/2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate
DM2TEOL	DT	Small molecular drug
DM2TEOL	PC	126941
DM2TEOL	MW	454.4
DM2TEOL	FM	C20H22N8O5
DM2TEOL	IC	InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
DM2TEOL	CS	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM2TEOL	IK	FBOZXECLQNJBKD-ZDUSSCGKSA-N
DM2TEOL	IU	(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
DM2TEOL	CA	CAS 59-05-2
DM2TEOL	CB	CHEBI:44185
DM2TEOL	DE	leukaemia; Solid tumour/cancer; Prostate cancer; Rheumatoid arthritis; Proliferative vitreoretinopathy

DM5XH2C	ID	DM5XH2C
DM5XH2C	DN	Methotrexate Sodium
DM5XH2C	HS	Approved
DM5XH2C	SN	Methotrexate disodium salt; 7413-34-5; Sodium methotrexate; MTX disodium; methotrexate disodium; UNII-3IG1E710ZN; 3IG1E710ZN; CHEBI:50679; Amethopterin sodium; Disodium methotrexate; Methotrexat dinatrium; Mexate-Aq Preserved; Methotrexate sodium salt; EINECS 231-022-0; 59-05-2 (Parent); Methotrexate Preservative Free; 4-Amino-N(sup 10)-methylpteroylglutamic acid disodium salt; METHOTREXATE SODIUM PRESERVATIVE FREE
DM5XH2C	CP	Hospira Inc
DM5XH2C	TC	Anticancer Agents
DM5XH2C	DT	Small molecular drug
DM5XH2C	PC	11329481
DM5XH2C	MW	498.4
DM5XH2C	FM	C20H20N8Na2O5
DM5XH2C	IC	InChI=1S/C20H22N8O5.2Na/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);;/q;2*+1/p-2/t13-;;/m0../s1
DM5XH2C	CS	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+]
DM5XH2C	IK	DASQOOZCTWOQPA-GXKRWWSZSA-L
DM5XH2C	IU	disodium;(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioate
DM5XH2C	CA	CAS 7413-34-5
DM5XH2C	CB	CHEBI:50679
DM5XH2C	DE	Solid tumour/cancer

DMF5XQH	ID	DMF5XQH
DMF5XQH	DN	Methoxamine
DMF5XQH	HS	Approved
DMF5XQH	SN	Methoxamedrin; Methoxamedrine; Methoxamin; Methoxaminum; Metossamina; Metoxamina; Pseudomethoxamine; Vasoxin; Vasoxine; Metossamina [DCIT]; Methoxamine (BAN); Methoxamine [INN:BAN]; Methoxaminum [INN-Latin]; Metoxamina [INN-Spanish]; AQ-387/40213491; Alpha-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; DL-2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol; 2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; 2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol
DMF5XQH	CP	Glaxosmithkline
DMF5XQH	TC	Antihypertensive Agents
DMF5XQH	DT	Small molecular drug
DMF5XQH	PC	6082
DMF5XQH	MW	211.26
DMF5XQH	FM	C11H17NO3
DMF5XQH	IC	InChI=1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3
DMF5XQH	CS	CC(C(C1=C(C=CC(=C1)OC)OC)O)N
DMF5XQH	IK	WJAJPNHVVFWKKL-UHFFFAOYSA-N
DMF5XQH	IU	2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol
DMF5XQH	CA	CAS 390-28-3
DMF5XQH	CB	CHEBI:6839
DMF5XQH	DE	Hypertension

DME8FZ9	ID	DME8FZ9
DME8FZ9	DN	Methoxsalen
DME8FZ9	HS	Approved
DME8FZ9	SN	Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one
DME8FZ9	TC	Anticancer Agents
DME8FZ9	DT	Small molecular drug
DME8FZ9	PC	4114
DME8FZ9	MW	216.19
DME8FZ9	FM	C12H8O4
DME8FZ9	IC	InChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3
DME8FZ9	CS	COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2
DME8FZ9	IK	QXKHYNVANLEOEG-UHFFFAOYSA-N
DME8FZ9	IU	9-methoxyfuro[3,2-g]chromen-7-one
DME8FZ9	CA	CAS 298-81-7
DME8FZ9	CB	CHEBI:18358
DME8FZ9	DE	Cutaneous T-cell lymphoma; Psoriasis vulgaris

DMK1LZD	ID	DMK1LZD
DMK1LZD	DN	Methoxy polyethylene glycol-epoetin beta
DMK1LZD	HS	Approved
DMK1LZD	SN	Mircera (TN)
DMK1LZD	DE	Kidney transplant rejection

DML0RAE	ID	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	HS	Approved
DML0RAE	SN	Analgizer; Anecotan; Ingalan; Inhalan; Methofane; Methoflurane; Methofluranum; Methoxane; Methoxiflurane; Methoxifluranum;Methoxyfluoran; Methoxyfluorane; Methoxyfluran; Methoxyfluranum; Metofane; Metossiflurano; Metoxfluran; Metoxifluran; Metoxiflurano; Penthrane; Pentran; Pentrane; Metossiflurano [DCIT]; Methoxyflurane [Anaesthetics, volatile]; Methoxyfluranum [INN-Latin]; Metofane (VAN); Metoxiflurano [INN-Spanish]; Penthrane (TN); Penthrane (VAN); Methoxyflurane (USP/INN); Methoxyflurane [USAN:INN:BAN]; Methyl 1,1-difluoro-2,2-dichloroethyl ether; Ether, 2,2-dichloro-1,1-difluoroethyl methyl; (2,2-dichloro-1,1-difluoroethyl) methyl ether; 2,2-Dichloro-1,1-difluoro-1-methoxyethane; 2,2-Dichloro-1,1-difluoroethyl methyl ether
DML0RAE	TC	Anesthetics
DML0RAE	DT	Small molecular drug
DML0RAE	PC	4116
DML0RAE	MW	164.96
DML0RAE	FM	C3H4Cl2F2O
DML0RAE	IC	InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3
DML0RAE	CS	COC(C(Cl)Cl)(F)F
DML0RAE	IK	RFKMCNOHBTXSMU-UHFFFAOYSA-N
DML0RAE	IU	2,2-dichloro-1,1-difluoro-1-methoxyethane
DML0RAE	CA	CAS 76-38-0
DML0RAE	CB	CHEBI:6843
DML0RAE	DE	Anaesthesia

DMHP8FI	ID	DMHP8FI
DMHP8FI	DN	Methscopolamine bromide
DMHP8FI	HS	Approved
DMHP8FI	SN	Pamine Forte
DMHP8FI	CP	Private Formulations Inc
DMHP8FI	DT	Small molecular drug
DMHP8FI	PC	5459110
DMHP8FI	MW	398.3
DMHP8FI	FM	C18H24BrNO4
DMHP8FI	IC	InChI=1S/C18H24NO4.BrH/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11;/h3-7,12-17,20H,8-10H2,1-2H3;1H/q+1;/p-1/t12?,13-,14-,15+,16-,17+;/m1./s1
DMHP8FI	CS	C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-]
DMHP8FI	IK	CXYRUNPLKGGUJF-OZVSTBQFSA-M
DMHP8FI	IU	[(1R,2R,4S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DMHP8FI	CA	CAS 155-41-9
DMHP8FI	CB	CHEBI:61276
DMHP8FI	DE	Nausea and vomiting

DM6L5VO	ID	DM6L5VO
DM6L5VO	DN	Methsuximide
DM6L5VO	HS	Approved
DM6L5VO	SN	Celontin; Mesuximid; Mesuximida; Mesuximide; Mesuximidum; Methsuximid; Metosuccimmide; Metsuccimide; Petinutin; Methsuximide [BAN]; Metosuccimmide [DCIT]; PM 396; Alpha-Methylphensuximide; Celontin (TN); Mesuximida [INN-Spanish]; Mesuximide (INN); Mesuximidum [INN-Latin]; Methsuximide (USP); Petinutin (TN); Alpha-Methyl-alpha-phenyl N-methyl succinimide; N,2-Dimethyl-2-phenylsuccinimide; N-Methyl-alpha-methyl-alpha-phenylsuccinimide; (+-)-N,2-Dimethyl-2-phenylsuccinimide; (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion; 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine; 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione; 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione; 1,3-Dimethyl-3-phenylsuccinimide; 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
DM6L5VO	CP	Pfizer Pharmaceuticals
DM6L5VO	TC	Anticonvulsants
DM6L5VO	DT	Small molecular drug
DM6L5VO	PC	6476
DM6L5VO	MW	203.24
DM6L5VO	FM	C12H13NO2
DM6L5VO	IC	InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
DM6L5VO	CS	CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2
DM6L5VO	IK	AJXPJJZHWIXJCJ-UHFFFAOYSA-N
DM6L5VO	IU	1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
DM6L5VO	CA	CAS 77-41-8
DM6L5VO	CB	CHEBI:6846
DM6L5VO	DE	Epileptic seizures

DMN7SDE	ID	DMN7SDE
DMN7SDE	DN	Methyclothiazide
DMN7SDE	HS	Approved
DMN7SDE	SN	Aquaresen; Aquatensen; Duretic; Enduron; Enduronum; METHYLCLOTHIAZIDE; Methychlothiazide; Methyclothiazid; Methyclothiazidum;Methycyclothiazide; Methylchlorothiazide; Methylcyclothiazide; Meticlotiazida; Meticlotiazide; Naturon; Meticlotiazide [DCIT]; Ciba 7272-Su; Enduron (TN); Methyclothiazidum [INN-Latin]; Meticlotiazida [INN-Spanish]; Naturon (VAN); Methyclothiazide (JAN/USP/INN); Methyclothiazide [USAN:INN:BAN:JAN]; (+-)-6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxid;2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide; 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-chloromethyl-2-methyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1
DMN7SDE	TC	Antihypertensive Agents
DMN7SDE	DT	Small molecular drug
DMN7SDE	PC	4121
DMN7SDE	MW	360.2
DMN7SDE	FM	C9H11Cl2N3O4S2
DMN7SDE	IC	InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)
DMN7SDE	CS	CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CCl
DMN7SDE	IK	CESYKOGBSMNBPD-UHFFFAOYSA-N
DMN7SDE	IU	6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMN7SDE	CA	CAS 135-07-9
DMN7SDE	CB	CHEBI:6847
DMN7SDE	DE	Edema; Hypertension

DMIUX3D	ID	DMIUX3D
DMIUX3D	DN	Methyl aminolevulinate
DMIUX3D	HS	Approved
DMIUX3D	SN	Metvix; Aminolevulinic acid methyl ester; Methyl 5-aminolevulinate; Methyl delta-aminolevulinate; Methyl5-amino-4-oxopentanoate; Levulinic acid, 5-amino-, methyl ester; Pentanoic acid, 5-amino-4-oxo-, methyl ester; 5-Aminolevulinic acid methyl ester
DMIUX3D	TC	Anticancer Agents
DMIUX3D	DT	Small molecular drug
DMIUX3D	PC	157922
DMIUX3D	MW	145.16
DMIUX3D	FM	C6H11NO3
DMIUX3D	IC	InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3
DMIUX3D	CS	COC(=O)CCC(=O)CN
DMIUX3D	IK	YUUAYBAIHCDHHD-UHFFFAOYSA-N
DMIUX3D	IU	methyl 5-amino-4-oxopentanoate
DMIUX3D	CA	CAS 33320-16-0
DMIUX3D	CB	CHEBI:724125
DMIUX3D	DE	Acne vulgaris

DM5I621	ID	DM5I621
DM5I621	DN	Methyldopa
DM5I621	HS	Approved
DM5I621	SN	AMD; Aldometil; Aldomin; Alphamethyldopa; Baypresol; Becanta; Dopamet; Dopamethyperpax; Dopatec; Dopegit; Dopegyt; Dopergit; Grospisk; Hyperpax; Hypolag; Medomet; Medopa; Medopal; Medopren; Methoplain; Methyldopum; Metildopa; Novomedopa; Presinol; Presolisin; Sedometil; Sembrina; Alpha medopa; Methyl dopa; Methyldopa anhydrous; Aldoril D30; Aldoril D50; Bayer 1440 L; LT00847269; MK 351; Aldomet (TN); Aldoril (TN); Alpha-Methyl dopa; Alpha-Methyldihydroxyphenylalanine; Alpha-Methyldopa; Apo-Methyldopa; Dopamet (TN); Dopegyt (TN); L-Methyl Dopa; L-Methyldopa; METHYL DOPA (SEE ALSO METHYL DOPA SESQUIHYDRATE); MK-351; Methyldopa (INN); Methyldopa (anhydrous); Methyldopum [INN-Latin]; Metildopa [INN-Spanish]; Mk. b51; Nr.C 2294; Nu-Medopa; Alpha-Methyldopa (VAN); L-alpha-Methyl DOPA; L-alpha-Methyldopa; Methyl-L-dopa; Aldoril, Dopamet, Dopegyt, Methyldopa; L-(alpha-Md); Methyldopa (L,-); Alpha-Methyl-L-3,4-dihydroxyphenylalanine; L-alpha-Methyl-3,4-dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine; L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine; L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid; L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine; L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine; (-)-3-(3,4-Dihydroxyphenyl)-2-Methyl-L-Alanine Sesqui-Hydrate; (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; (S)-(-)-alpha-Methyldopa; 3-(3,4-DIHYDROXYPHENYL)-2-METHYL-L-ALANINE; 3-Hydroxy-.alpha.-methyl-L-tyrosine; 3-Hydroxy-alpha-methyl-L-tyrosine
DM5I621	CP	Ivax pharmaceutical
DM5I621	TC	Antihypertensive Agents
DM5I621	DT	Small molecular drug
DM5I621	PC	38853
DM5I621	MW	211.21
DM5I621	FM	C10H13NO4
DM5I621	IC	InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1
DM5I621	CS	C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N
DM5I621	IK	CJCSPKMFHVPWAR-JTQLQIEISA-N
DM5I621	IU	(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid
DM5I621	CA	CAS 555-30-6
DM5I621	CB	CHEBI:61058
DM5I621	DE	Hypertension

DM8XI09	ID	DM8XI09
DM8XI09	DN	Methyldopate Hydrochloride
DM8XI09	HS	Approved
DM8XI09	CP	Merck And Co Inc
DM8XI09	TC	Cardiovascular Agents
DM8XI09	DT	Small molecular drug
DM8XI09	PC	17276
DM8XI09	MW	275.73
DM8XI09	FM	C12H18ClNO4
DM8XI09	IC	InChI=1S/C12H17NO4.ClH/c1-3-17-11(16)12(2,13)7-8-4-5-9(14)10(15)6-8;/h4-6,14-15H,3,7,13H2,1-2H3;1H/t12-;/m0./s1
DM8XI09	CS	CCOC(=O)[C@](C)(CC1=CC(=C(C=C1)O)O)N.Cl
DM8XI09	IK	QSRVZCCJDKYRRF-YDALLXLXSA-N
DM8XI09	IU	ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoate;hydrochloride
DM8XI09	CA	CAS 2508-79-4
DM8XI09	DE	Hypertension

DMJAPE7	ID	DMJAPE7
DMJAPE7	DN	Methylene blue
DMJAPE7	HS	Approved
DMJAPE7	SN	methylene blue; 61-73-4; Methylthioninium chloride; Swiss Blue; Chromosmon; Methylene Blue N; Methylenium ceruleum; Urolene blue; Methylene Blue chloride; Solvent blue 8; Bleu de methylene; Methylene Blue G; Methylene Blue A; External Blue 1; Methylene Blue D; Methylene Blue B; Methylene Blue anhydrous; CI Basic Blue 9; Methylene Blue ZF; Methylene Blue SP; Methylene Blue NZ; Methylene Blue BX; Methylene Blue BD; Methylene Blue SG; Tetramethylene Blue; Methylene Blue ZX; Methylene Blue FZ; Methylene Blue BP; Calcozine; 3,7-Bis-dimethylamino-phenothiazin-5-ylium
DMJAPE7	PC	6099
DMJAPE7	MW	319.9
DMJAPE7	FM	C16H18ClN3S
DMJAPE7	IC	InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1
DMJAPE7	CS	CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-]
DMJAPE7	IK	CXKWCBBOMKCUKX-UHFFFAOYSA-M
DMJAPE7	IU	[7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride
DMJAPE7	CA	CAS 61-73-4
DMJAPE7	CB	CHEBI:6872
DMJAPE7	DE	Acquired methemoglobinemia

DMBEX4O	ID	DMBEX4O
DMBEX4O	DN	Methylergonovine
DMBEX4O	HS	Approved
DMBEX4O	SN	Basofortina; Ergotyl; Metenarin; Methergen; Methergin; Methergine; Methylergobasin; Methylergobasine; Methylergobrevin; Methylergometrin; Methylergometrine; Methylergometrinum; Methylergonovin; Metilergometrina; Metilergometrinio; Partergin; Ryegonovin; Lysergic acid butanolamide; Methylergometrine maleate; Metilergometrina [DCIT]; ME 277; Ergotyl (TN); Methergine (TN); Methylergometrine (INN); Methylergometrine [INN:BAN]; Methylergometrinum [INN-Latin]; Metilergometrinio [INN-Spanish]; Spametrin-M; D-Lysergic acid-dl-hydroxybutylamide-2; N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide; D-Lysergic acid-(+)-butanolamide-(2); (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide
DMBEX4O	CP	Edison Therapeutics Llc
DMBEX4O	TC	Oxytocics
DMBEX4O	DT	Small molecular drug
DMBEX4O	PC	8226
DMBEX4O	MW	339.4
DMBEX4O	FM	C20H25N3O2
DMBEX4O	IC	InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1
DMBEX4O	CS	CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMBEX4O	IK	UNBRKDKAWYKMIV-QWQRMKEZSA-N
DMBEX4O	IU	(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMBEX4O	CA	CAS 113-42-8
DMBEX4O	CB	CHEBI:92607
DMBEX4O	DE	Spontaneous abortion

DMZTGN2	ID	DMZTGN2
DMZTGN2	DN	Methylnaltrexone bromide
DMZTGN2	HS	Approved
DMZTGN2	SN	Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, &gt; W-5330; CHIR-01020
DMZTGN2	CP	Progenics
DMZTGN2	DT	Small molecular drug
DMZTGN2	PC	5361917
DMZTGN2	MW	436.3
DMZTGN2	FM	C21H26BrNO4
DMZTGN2	IC	InChI=1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22?;/m1./s1
DMZTGN2	CS	C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.[Br-]
DMZTGN2	IK	IFGIYSGOEZJNBE-KNLJMPJLSA-N
DMZTGN2	IU	(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one;bromide
DMZTGN2	CA	CAS 73232-52-7
DMZTGN2	DE	Opioid-induced constipation; Obesity

DM7SJD6	ID	DM7SJD6
DM7SJD6	DN	Methylphenidate
DM7SJD6	HS	Approved
DM7SJD6	SN	Calocain; Centedein; Centedrin; Centredin; Concerta; Daytrana; Meridil; Metadate; Methylfenidan; Methylin; Methylofenidan; Methylphen; Methylphenidan; Methylphenidatum; Metilfenidato; Phenidylate; Plimasine; Riphenidate; Ritalin; Ritaline; Tsentedrin; Metadate CD; Metadate ER; Methyl phenidate; Methyl phenidyl acetate; Methyl phenidylacetate; Methylin ER; Metilfenidato [Italian]; Ritalin LA; Ritalin SR; Ritcher works; C 4311; Attenta (TN); Biphentin (TN); Concerta (TN); D-methylphenidate HCl; Daytrana (TN); Equasym (TN); Metadate ER (TN); Methylin (TN); Methylphenidate [INN:BAN]; Methylphenidatum [INN-Latin]; Metilfenidato [INN-Spanish]; Motiron (TN); PMS-Methylphenidate; Ritalin (TN); Ritalin LA (TN); Ritalin-SR; Rubifen (TN); Methylphenidate (USAN/INN); Alpha-Phenyl-2-piperidineacetic acid methyl ester; Methyl phenyl(piperidin-2-yl)acetate; Methyl alpha-phenyl-alpha-2-piperidinylacetate; Alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester; Methyl 2-phenyl-2-piperidin-2-ylacetate; Methyl alpha-phenyl-alpha-(2-piperidyl)acetate; Methyl (2-phenyl-2-(2-piperidyl)acetate); METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R); 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester
DM7SJD6	CP	Novartis
DM7SJD6	TC	Central Nervous System Stimulants
DM7SJD6	DT	Small molecular drug
DM7SJD6	PC	4158
DM7SJD6	MW	233.31
DM7SJD6	FM	C14H19NO2
DM7SJD6	IC	InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
DM7SJD6	CS	COC(=O)C(C1CCCCN1)C2=CC=CC=C2
DM7SJD6	IK	DUGOZIWVEXMGBE-UHFFFAOYSA-N
DM7SJD6	IU	methyl 2-phenyl-2-piperidin-2-ylacetate
DM7SJD6	CA	CAS 113-45-1
DM7SJD6	CB	CHEBI:84276
DM7SJD6	DE	Attention deficit hyperactivity disorder; Traumatic brain injury

DMDSWAG	ID	DMDSWAG
DMDSWAG	DN	Methylphenobarbital
DMDSWAG	HS	Approved
DMDSWAG	SN	Enfenemal; Enphenemal; Enphenemalum; Mebaral; Meberal; Mebroin; Mephobarbital; Mephobarbitone; Mephytal; Methylphenobarbitalum; Methylphenobarbitone; Methylphenobarbitonum; Methylphenolbarbital; Metilfenobarbital; Metilfenobarbitale; Metylfenemal; Metyna; Morbusan; Phemetone; Phemiton; Phemitone; Phenmiton; Prominal; Prominaletten; Prominalum; Mephobarbital [JAN]; Methyl phenobarbitone; Methylphenylbarbituric acid; Metilfenobarbitale [DCIT]; Sanofi Brand of Mephobarbital; Sanofi Synthelabo Brand of Mephobarbital; Isonal (roussel); Mebaral (TN); Menta-Bal; Methyl-calminal; Methylphenobarbital (INN); Methylphenobarbitalum [INN-Latin]; Metilfenobarbital [INN-Spanish]; N-Ethylmethylphenylbarbituric acid; N-Methylethylphenylbarbituric acid; N-Methylphenobarbital; N-Methylphenolbarbitol; Mephobarbital (JAN/USP); N-Methyl-5-phenyl-5-ethylbarbital; 1-Methyl-5-ethyl-5-phenylbarbituric acid; 1-Methyl-5-phenyl-5-ethylbarbituric acid; 1-Methylphenobarbital; 5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-1-methyl-5-phenylbarbituric acid; 5-Ethyl-5-phenyl-N-methyl-bartituric acid; 5-Ethyl-N-methyl-5-phenylbarbituric acid; 5-Phenyl-5-ethyl-3-methylbarbituric acid; 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-1-methyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
DMDSWAG	CP	Ovation Pharmaceuticals 
DMDSWAG	TC	Hypnotics and Sedatives
DMDSWAG	DT	Small molecular drug
DMDSWAG	PC	8271
DMDSWAG	MW	246.26
DMDSWAG	FM	C13H14N2O3
DMDSWAG	IC	InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)
DMDSWAG	CS	CCC1(C(=O)NC(=O)N(C1=O)C)C2=CC=CC=C2
DMDSWAG	IK	ALARQZQTBTVLJV-UHFFFAOYSA-N
DMDSWAG	IU	5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMDSWAG	CA	CAS 115-38-8
DMDSWAG	CB	CHEBI:6758
DMDSWAG	DE	Anxiety disorder

DM4BDON	ID	DM4BDON
DM4BDON	DN	Methylprednisolone
DM4BDON	HS	Approved
DM4BDON	SN	Depo-medrol; M-predrol; Medrol; Medrol Acetate
DM4BDON	CP	Pharmacia And Upjohn Co
DM4BDON	TC	Anticancer Agents
DM4BDON	DT	Small molecular drug
DM4BDON	PC	6741
DM4BDON	MW	374.5
DM4BDON	FM	C22H30O5
DM4BDON	IC	InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
DM4BDON	CS	C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
DM4BDON	IK	VHRSUDSXCMQTMA-PJHHCJLFSA-N
DM4BDON	IU	(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM4BDON	CA	CAS 83-43-2
DM4BDON	CB	CHEBI:6888
DM4BDON	DE	Solid tumour/cancer; Spinal cord injury

DM5VWOB	ID	DM5VWOB
DM5VWOB	DN	Methylscopolamine
DM5VWOB	HS	Approved
DM5VWOB	SN	Methscopolamine; methscopolamine; N-Methylscopolamine; N-methyl scopolamine; UNII-VDR09VTQ8U; VDR09VTQ8U; 13265-10-6; CHEMBL376897; (1r,2r,4s,5s)-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane; Metylskopolamin; 56552-70-6; 3-Oxa-9-azoniatricyclo[33102,4]nonane, 7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, (1a,2b,4b,5a,7b); HSDB 5420; [3H]N-methylscopolamine; [3H]N-methyl scopolamine; [3H]NMS; Methyl scopolamine; 3C0
DM5VWOB	TC	Anticholinergic Agents
DM5VWOB	DT	Small molecular drug
DM5VWOB	PC	71183
DM5VWOB	MW	318.4
DM5VWOB	FM	C18H24NO4+
DM5VWOB	IC	InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12?,13-,14-,15+,16-,17+/m1/s1
DM5VWOB	CS	C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C
DM5VWOB	IK	LZCOQTDXKCNBEE-XJMZPCNVSA-N
DM5VWOB	IU	[(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DM5VWOB	CA	CAS 13265-10-6
DM5VWOB	CB	CHEBI:135361
DM5VWOB	DE	Peptic ulcer

DMWLFGO	ID	DMWLFGO
DMWLFGO	DN	Methyltestosterone
DMWLFGO	HS	Approved
DMWLFGO	SN	Android (TN)
DMWLFGO	CP	Valeant Pharmaceuticals
DMWLFGO	DT	Small molecular drug
DMWLFGO	PC	6010
DMWLFGO	MW	302.5
DMWLFGO	FM	C20H30O2
DMWLFGO	IC	InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1
DMWLFGO	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C
DMWLFGO	IK	GCKMFJBGXUYNAG-HLXURNFRSA-N
DMWLFGO	IU	(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMWLFGO	CA	CAS 58-18-4
DMWLFGO	CB	CHEBI:27436
DMWLFGO	DE	Solid tumour/cancer

DMBW7VH	ID	DMBW7VH
DMBW7VH	DN	Methyprylon
DMBW7VH	HS	Approved
DMBW7VH	SN	Dimerin; Methprylon; Methyprolon; Methyprylone; Methyprylonum; Metiprilon; Metiprilona; Metiprilone; Noctan; Nodular; Noludar; Methyprylon [INN]; Methyprylone [INN-French]; Methyprylonum [INN-Latin]; Metiprilona [INN-Spanish]; Noludar (TN); Ro 1-6463; Methyprylon (JAN/INN); 2,4-Dioxo-3,3-diethyl-5-methylpiperidine; 2,4-Dioxy-3,3-diethyl-5-methylpiperidine; 3,3-Diethyl-2,4-dioxo-5-methylpiperidine; 3,3-Diethyl-5-methyl-2,4-piperidinedione; 3,3-Diethyl-5-methylpiperidine-2,4-dione
DMBW7VH	TC	Sedatives and Hypnotics
DMBW7VH	DT	Small molecular drug
DMBW7VH	PC	4162
DMBW7VH	MW	183.25
DMBW7VH	FM	C10H17NO2
DMBW7VH	IC	InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13)
DMBW7VH	CS	CCC1(C(=O)C(CNC1=O)C)CC
DMBW7VH	IK	SIDLZWOQUZRBRU-UHFFFAOYSA-N
DMBW7VH	IU	3,3-diethyl-5-methylpiperidine-2,4-dione
DMBW7VH	CA	CAS 125-64-4
DMBW7VH	CB	CHEBI:31837
DMBW7VH	DE	Insomnia

DM1EF73	ID	DM1EF73
DM1EF73	DN	Methysergide
DM1EF73	HS	Approved
DM1EF73	SN	Deseril; Desernil; Desernyl; Deseryl; Desril; Dimethylergometrin; Methylmethylergonovine; Methysergid; Methysergidum; Metisergide; Metisergido; Sansert; Methyllysergic acid butanolamide; Metisergide [DCIT]; UML 491; Deseril (TN); Methysergidum [INN-Latin]; Metisergido [INN-Spanish]; Sansert (TN); UML-491; Methysergide (USAN/INN); Methysergide [USAN:INN:BAN]; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; 1-Methyl-D-lysergic acid butanolamide; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 1-Methylmethylergonovine; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide
DM1EF73	CP	Norvatis Phamaceuticals Corporation
DM1EF73	TC	Vasoconstrictor Agents
DM1EF73	DT	Small molecular drug
DM1EF73	PC	9681
DM1EF73	MW	353.5
DM1EF73	FM	C21H27N3O2
DM1EF73	IC	InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15+,19-/m1/s1
DM1EF73	CS	CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C
DM1EF73	IK	KPJZHOPZRAFDTN-ZRGWGRIASA-N
DM1EF73	IU	(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
DM1EF73	CA	CAS 361-37-5
DM1EF73	CB	CHEBI:92629
DM1EF73	DE	Migraine

DMIKHN0	ID	DMIKHN0
DMIKHN0	DN	Meticillin
DMIKHN0	HS	Approved
DMIKHN0	SN	Dimocillin; MII; Metacillin; Methicillin; Methicillinum; Methycillin; Meticilina; Meticillina; Meticilline; Meticillinum; Staphcillin; Methicillin [BAN]; Meticillin [INN]; Meticillina [DCIT]; BRL 1241; Methicillin Monohydrate, Monosodium Salt; Meticilina [INN-Spanish]; Meticilline [INN-French]; Meticillinum [INN-Latin]; Penicillin, Dimethoxyphenyl; (2,6-Dimethoxyphenyl)penicillin; (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2,6-dimethoxyphenyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,3-Dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,6-Dimethoxybenzamido)penicillanic acid; 6beta-(2,6-dimethoxybenzamido)-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-(2,6-dimethoxybenzamido)penicillanic acid
DMIKHN0	CP	Beecham phamaceuticals
DMIKHN0	TC	Antibiotics
DMIKHN0	DT	Small molecular drug
DMIKHN0	PC	6087
DMIKHN0	MW	380.4
DMIKHN0	FM	C17H20N2O6S
DMIKHN0	IC	InChI=1S/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)/t11-,12+,15-/m1/s1
DMIKHN0	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C
DMIKHN0	IK	RJQXTJLFIWVMTO-TYNCELHUSA-N
DMIKHN0	IU	(2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIKHN0	CA	CAS 61-32-5
DMIKHN0	CB	CHEBI:6827
DMIKHN0	DE	Bacterial infection; Neurological disorder

DMJMVKI	ID	DMJMVKI
DMJMVKI	DN	Metipranolol
DMJMVKI	HS	Approved
DMJMVKI	SN	Disorat; Methypranol; Metipranololum; Trimepranol; Turoptin; BM-01004; Betanol (TN); Disorat (TN); Metipranololum [INN-Latin]; OptiPranolol (TN); Trimepranol (TN); VUAB-6453; VUFB-6453; Metipranolol (USAN/INN); Metipranolol [USAN:BAN:INN]; [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate (9CI); Phenol,4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, (+-)-, 1-acetate; (+-)-1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; (RS)-4-(2-Hydroxy-3-isopropylaminopropoxy)-2,3,6-trimethylphenyl acetat; 1-(4-Acetoxy-2,3,5-Trimethylphenoxy)-3-Isopropylamino-2-Propanol; 1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; 2-Propanol, 1-(4-hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-, 4-acetate; 4-(2-Hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate; 4-[2-hydroxy-3-(isopropylamino)propoxy]-2,3,6-trimethylphenyl acetate; 62164P
DMJMVKI	TC	Antihypertensive Agents
DMJMVKI	DT	Small molecular drug
DMJMVKI	PC	31477
DMJMVKI	MW	309.4
DMJMVKI	FM	C17H27NO4
DMJMVKI	IC	InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3
DMJMVKI	CS	CC1=CC(=C(C(=C1OC(=O)C)C)C)OCC(CNC(C)C)O
DMJMVKI	IK	BQIPXWYNLPYNHW-UHFFFAOYSA-N
DMJMVKI	IU	[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate
DMJMVKI	CA	CAS 22664-55-7
DMJMVKI	CB	CHEBI:6897
DMJMVKI	DE	Open-angle glaucoma

DM0JE6N	ID	DM0JE6N
DM0JE6N	DN	Metixene
DM0JE6N	HS	Approved
DM0JE6N	SN	Atosil; Contalyl; Dalpan; METHIXENE; Methixart; Methixen; Methyloxan; Metisene; Metixeno; Metixenum; Raunana; Tremaril;Tremarit; Tremonil; Tremoquil; Trest; Methixen [German]; Methixene hydrochloride; Metisene [DCIT]; Metixene hydrochloride; Tremaril hydrochloride; Metixene (INN); Metixene (TN); Metixene [INN:BAN]; Metixeno [INN-Spanish]; Metixenum [INN-Latin]; Methixene (*hydrochloride*); Metixene (*hydrochloride*); Tremonil (*hydrochloride*); 1-Methyl-3-(9H-thioxanthen-9-yl-methyl)piperidine; 1-Methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine; 1-Methyl-3-(thioxanthen-9-ylmethyl) piperidine; 1-Methyl-3-(thioxanthen-9-ylmethyl)-1-piperidine; 1-methyl-3-(thioxanthen-9-ylmethyl)-piperidine hydrochloride; 60 SJ 1977; 60 SJ 1977 (*hydrochloride*); 9-(1'-Methylpiperidine-3'-methyl)thioxanthene
DM0JE6N	CP	Norvatis Phamaceuticals Corporation
DM0JE6N	TC	Antiparkinson Agents
DM0JE6N	DT	Small molecular drug
DM0JE6N	PC	4167
DM0JE6N	MW	309.5
DM0JE6N	FM	C20H23NS
DM0JE6N	IC	InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3
DM0JE6N	CS	CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24
DM0JE6N	IK	MJFJKKXQDNNUJF-UHFFFAOYSA-N
DM0JE6N	IU	1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine
DM0JE6N	CA	CAS 4969-02-2
DM0JE6N	CB	CHEBI:51024
DM0JE6N	DE	Parkinson disease

DMFA5MY	ID	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	HS	Approved
DMFA5MY	SN	Cerucal; Clopra; Clopromate; Duraclamid; Elieten; Emetid; Emitasol; Emperal; Eucil; Gastrese; Gastrobid; Gastromax; Gastronerton; Gastrosil; Gastrotablinen; Gastrotem; Imperan; Maxeran; Maxolon; Meclopran; Metaclopramide; Metaclopromide; Metamide; Methochlopramide; Methoclopramide; Metochlopramide; Metoclol; Metoclopramida; Metoclopramidum; Metocobil; Metramid; Moriperan; Mygdalon; Octamide; Parmid; Paspertin; Peraprin; Plasil; Pramidin; Pramiel; Pramin; Primperan; Reclomide; Reglan; Reliveran; Terperan; Metoclopramide Omega; DEL 1267; Apo-Metoclop; CLOPRA-YELLOW; Clopra-Yellow; Degan (TN); Elieten (TN); Gastro-Timelets; Maxeran (TN); Maxolon (TN); Metoclopramida [INN-Spanish]; Metoclopramide Monohydrochloride, Monohydrate; Metoclopramidum [INN-Latin]; Neu-Sensamide; Nu-Metoclopramide; Plasil (pharmaceutical); Pms-Metoclopramide; Primperan (TN); Pylomid (TN); Reglan (TN); Terperan (TN); Metoclopramide (JP15/INN); Metoclopramide [INN:BAN:JAN]; N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide; O-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-(8CI); Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-(9CI); (metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; (metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one; 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide; 2-Methoxy-5-chloroprocainamide; 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide; 4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide); 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide; 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide; 5-Chloro-2-methoxyprocainamide
DMFA5MY	CP	Sanofi-Aventis
DMFA5MY	TC	Antiemetics
DMFA5MY	DT	Small molecular drug
DMFA5MY	PC	4168
DMFA5MY	MW	299.79
DMFA5MY	FM	C14H22ClN3O2
DMFA5MY	IC	InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
DMFA5MY	CS	CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
DMFA5MY	IK	TTWJBBZEZQICBI-UHFFFAOYSA-N
DMFA5MY	IU	4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
DMFA5MY	CA	CAS 364-62-5
DMFA5MY	CB	CHEBI:107736
DMFA5MY	DE	Nausea

DMZJYBW	ID	DMZJYBW
DMZJYBW	DN	Metocurine Iodide
DMZJYBW	HS	Approved
DMZJYBW	SN	Metokuriinijodidi; Metokurinjodid; Metubine; Dimethyl tubocurarine iodide; Dimethylchondrocurarine iodide; Dimethyltubocurarine Iodide; Metocurine diiodide; Metocurine iodide [USAN]; Metocurini Iodidum; Metubine iodide; Mutubine Iodide; Trimethyltubocurarine Iodide; Dimethylether of d-tubocurarine iodide; Dimetiltubocurarinio, ioduro de; Methyl-curarin; Methyl-curarin [German]; Metocurine iodide (USAN); Metubine iodide (TN); O,O'-Dimethylchondrocurarine diiodide; Tubocurarine, O,O'-dimethyl-, diiodide; Tubocuraranium, 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl-, diiodide; (+)-O,O'-Dimethylchondrocurarine Di-iodide; (+)-O,O'-Dimethylchondrocurarine diiodide; 2,2,2',2'-tetramethyl-6,6',7',12'-tetrakis(methyloxy)tubocuraran-2,2'-diium diiodide; 6,6',7',12'-Tetramethoxy-2,2,2',2'-tetramethyltubocuraranium diiodide
DMZJYBW	TC	Anesthetics
DMZJYBW	DT	Small molecular drug
DMZJYBW	PC	24244
DMZJYBW	MW	906.6
DMZJYBW	FM	C40H48I2N2O6
DMZJYBW	IC	InChI=1S/C40H48N2O6.2HI/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1
DMZJYBW	CS	C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[I-].[I-]
DMZJYBW	IK	DIGFQJFCDPKEPF-OIUSMDOTSA-L
DMZJYBW	IU	(1S,16R)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene;diiodide
DMZJYBW	CA	CAS 7601-55-0
DMZJYBW	CB	CHEBI:6901
DMZJYBW	DE	Anaesthesia

DMB39LO	ID	DMB39LO
DMB39LO	DN	Metolazone
DMB39LO	HS	Approved
DMB39LO	SN	Diulo; Metalazone; Metalozone; Metenix; Metolazona; Metolazonum; Microx; Mykrox; Oldren; Xuret; Zaroxolyn; Metolazona [INN-Spanish]; Metolazonum [INN-Latin]; Mykrox (TN); SR 720-22; Zaroxolyn (TN); SR-720-22; Metolazone (JAN/USP/INN); Metolazone [USAN:BAN:INN:JAN]; Mykrox, Zaroxolyn, Diulo, Metolazone; 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide; 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
DMB39LO	TC	Antihypertensive Agents
DMB39LO	DT	Small molecular drug
DMB39LO	PC	4170
DMB39LO	MW	365.8
DMB39LO	FM	C16H16ClN3O3S
DMB39LO	IC	InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
DMB39LO	CS	CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl
DMB39LO	IK	AQCHWTWZEMGIFD-UHFFFAOYSA-N
DMB39LO	IU	7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
DMB39LO	CA	CAS 17560-51-9
DMB39LO	CB	CHEBI:64354
DMB39LO	DE	Edema; Hypertension

DMOJ0V6	ID	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	HS	Approved
DMOJ0V6	SN	Beatrolol; BelocDuriles; Betaloc; BetalocAstra; Betalok; Dutoprol; LOPRESSIDONE; Lopresor; Lopresoretic; Lopressor; Meijoprolol; Metohexal; Metoprololum; Metroprolol; Preblok; Presolol; Seloken; Seroken; Spesicor; Spesikor; Toprol; AstraZeneca Brand of Metaoprolol Tartrate; AstraZeneca Brand of Seloken; Beloc Duriles; Betaloc Astra; Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate; Metoprolol succinate; Novartis Brand of Metprolol Tartrate; Seloken AstraZeneca Brand; CGP 2175; CGP2175; H 93 26; H 9326; Beloc-Duriles; Betaloc (TN); Betaloc-Astra; CGP-2175; Corvitol (TN); Dl-Metoprolol; H 93-26; Lopressor (TN); Metoprololum [INN-Latin]; Metrol (TN); Minax (TN); Neobloc (TN); Selo-Zok; Selokeen (TN); TOPROL-XL; Tartrate, Metoprolol; Metoprolol (USAN/INN); Metoprolol [USAN:INN:BAN]; Toprol-XL (TN); (RS)-Metoprolol; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; 3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
DMOJ0V6	CP	AstraZeneca
DMOJ0V6	TC	Antihypertensive Agents
DMOJ0V6	DT	Small molecular drug
DMOJ0V6	PC	4171
DMOJ0V6	MW	267.36
DMOJ0V6	FM	C15H25NO3
DMOJ0V6	IC	InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
DMOJ0V6	CS	CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
DMOJ0V6	IK	IUBSYMUCCVWXPE-UHFFFAOYSA-N
DMOJ0V6	IU	1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMOJ0V6	CA	CAS 51384-51-1
DMOJ0V6	CB	CHEBI:6904
DMOJ0V6	DE	Hypertension

DM1NOEK	ID	DM1NOEK
DM1NOEK	DN	Metreleptin
DM1NOEK	HS	Approved
DM1NOEK	CP	Amylin Pharmaceuticals
DM1NOEK	SQ	Peptide Sequence : MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPGC
DM1NOEK	DE	Diabetic complication

DMTIVEN	ID	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	HS	Approved
DMTIVEN	SN	APMN; Acromona; Anagiardil; Arilin; Atrivyl; Bexon; CONT; Clont; Danizol; Deflamon; Efloran; Elyzol; Entizol; Eumin; Flagemona; Flagesol; Flagil; Flagyl; Flegyl; Florazole; Fossyol; Giatricol; Gineflavir; Giniflavir; Klion; Klont; Meronidal; Methronidazole; Metric; MetroCream; MetroGel; MetroLotion; Metrodzhil; Metrogyl; Metrolag; Metrolyl; Metromidol; Metronidaz; Metronidazol; Metronidazolo; Metronidazolum; Metrotop; Metrozine; Metryl; Mexibol; Monagyl; Monasin; NIDA; Nalox; Nidagel; Noritate; Novonidazol; Orvagil; Protostat; Rathimed; Rosased; Sanatrichom; Satric; Takimetol; Trichazol; Trichex; Trichocide; Trichomol; Trichopal; Trichopol; Tricocet; Tricom; Trikacide; Trikamon; Trikojol; Trikozol; Trimeks; Trivazol; Vagilen; Vagimid; Vandazole; Vertisal; Wagitran; Zadstat; Zidoval; Flagyl Er; Ginefla vir; METRONIDAZOLE USP; Metro Cream; Metro Gel; Metronidazole Monohydrochloride; Metronidazole Phosphoester; Metronidazole in Plastic Container; Metronidazolo [DCIT]; Tricho cordes; Trichomonacid pharmachim; Tricowas B; Bayer 5360; Flagyl 375; M0924; Metric 21; RP 8823; SC 10295; Anabact (TN); Apo-Metronidazole; Deflamon-wirkstoff; Flagyl (TN); IDR-90105; METRO I.V; MetroGel (TN); MetroGel-Vaginal; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Mexibol (silanes); Neo-Tric; Noritate (TN); RP-8823; Rozex (TN); Tricho-gynaedron; ZERO/004064; CB-01-14 MMX; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Flagyl I.V.; Flagyl I.V. RTU; Metro I.V.; Metro I.V. In Plastic Container; Metrogel-vaginal (TN); Metronidazole (JP15/USP/INN); Metronidazole [USAN:INN:BAN:JAN]; Methyl-5-nitroimidazole-1-ethanol; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; 2-Methyl-5-nitro-1-imidazoleethanol; 2-Methyl-5-nitroimidazole-1-ethanol; MNZ
DMTIVEN	CP	Pfizer Pharmaceuticals
DMTIVEN	TC	Antiinfective Agents
DMTIVEN	DT	Small molecular drug
DMTIVEN	PC	4173
DMTIVEN	MW	171.15
DMTIVEN	FM	C6H9N3O3
DMTIVEN	IC	InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
DMTIVEN	CS	CC1=NC=C(N1CCO)[N+](=O)[O-]
DMTIVEN	IK	VAOCPAMSLUNLGC-UHFFFAOYSA-N
DMTIVEN	IU	2-(2-methyl-5-nitroimidazol-1-yl)ethanol
DMTIVEN	CA	CAS 443-48-1
DMTIVEN	CB	CHEBI:6909
DMTIVEN	DE	Amoebiasis; Crohn disease; Perianal crohn disease

DMI7FVQ	ID	DMI7FVQ
DMI7FVQ	DN	Metyrapone
DMI7FVQ	HS	Approved
DMI7FVQ	SN	MYT; Mepyrapone; Metapirone; Metapyron; Methapyrapone; Methbipyranone; Methopirapone; Methopyrapone; Methopyrinine; Methopyrone; Metirapona; Metopiron; Metopirone; Metopyrone; Metroprione; Metyrapon; Metyraponum; Alliance Brand of Metyrapone; Metyrapone Alliance Brand; Metyrapone Novartis Brand; Novartis Brand of Metyrapone; Su 4885; METOPIRONE (TN); Metirapona [INN-Spanish]; Metopirone (TN); Metyraponum [INN-Latin]; Su-4885; Metyrapone (JP15/USP/INN); Metyrapone [USAN:INN:BAN:JAN]; 1,2-Di-3-pyridyl-2-methyl-1-propanone; 2-Methyl-1,2-bis(3-pyridyl)-1-propanone; 2-Methyl-1,2-di-3-pyridinyl-1-propanone; 2-Methyl-1,2-di-3-pyridyl-1-propanone; 2-methyl-1,2-dipyridin-3-yl-propan-1-one; 2-methyl-1,2-dipyridin-3-ylpropan-1-one
DMI7FVQ	CP	Norvatis Phamaceuticals Corporation
DMI7FVQ	TC	Antimetabolites
DMI7FVQ	DT	Small molecular drug
DMI7FVQ	PC	4174
DMI7FVQ	MW	226.27
DMI7FVQ	FM	C14H14N2O
DMI7FVQ	IC	InChI=1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3
DMI7FVQ	CS	CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2
DMI7FVQ	IK	FJLBFSROUSIWMA-UHFFFAOYSA-N
DMI7FVQ	IU	2-methyl-1,2-dipyridin-3-ylpropan-1-one
DMI7FVQ	CA	CAS 54-36-4
DMI7FVQ	CB	CHEBI:44241
DMI7FVQ	DE	Cushing disease

DMBYCU0	ID	DMBYCU0
DMBYCU0	DN	Metyrosine
DMBYCU0	HS	Approved
DMBYCU0	SN	Demser; Methyltyrosine; Metirosina; Metirosine; Metirosinum; Racemetirosina; Racemetirosine; Racemetirosinum; Metyrosine[USAN]; Racemetirosine [INN]; M 8131; MK 781; Alpha-MPT; Alpha-Methyltyrosine; Demser (TN); H 9/88; L 588357-0; L-AMPT; M-5185; MK-781; Metirosina [INN-Spanish]; Metirosine (INN); Metirosinum [INN-Latin]; Metyrosine (USP); Racemetirosina [INN-Spanish]; Racemetirosinum [INN-Latin]; DL-alpha-Methyltyrosine; L-588357-0; Alpha-Methyl-L-tyrosine; Alpha-Methyl-dl-tyrosine; Alpha-Methyl-p-tyrosine; Alpha-Methyl-para-tyrosine; A-methyl-L-p-tyrosine; Alpha-Methyl-L-P-Tyrosine; Alpha-Methyltyrosine, (L)-Isomer; DL-alpha-Methyl-p-tyrosine; L-alpha-Methyl-p-tyrosine; Alpha-Methyltyrosine, (D,L)-Isomer; DL-2-Methyl-3-(4-hydroxyphenyl)alanine; Alpha-Methyltyrosine, (+,-)-Isomer; L-2-Methyl-3-(4-hydroxy-phenyl)alanine; (+-)-alpha-Methyl-DL-tyrosine; (-)-(S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (-)-alpha-Methyl-DL-tyrosine; (-)-alpha-Methyl-L-tyrosine; (2R)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (R,S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (S)-alpha-Methyltyrosine; 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; 4-Hydroxy-alpha-methylphenylalanine
DMBYCU0	TC	Anticancer Agents
DMBYCU0	DT	Small molecular drug
DMBYCU0	PC	441350
DMBYCU0	MW	195.21
DMBYCU0	FM	C10H13NO3
DMBYCU0	IC	InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1
DMBYCU0	CS	C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N
DMBYCU0	IK	NHTGHBARYWONDQ-JTQLQIEISA-N
DMBYCU0	IU	(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
DMBYCU0	CA	CAS 672-87-7
DMBYCU0	CB	CHEBI:6912
DMBYCU0	DE	Pheochromocytoma

DMCTE9R	ID	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	HS	Approved
DMCTE9R	SN	Mexiletene; Mexiletina; Mexiletinum; Mexilitine; Mexityl; Mexiletine HCL; KO1173; KO-1173; KOE-1173; Mexiletina [INN-Spanish]; Mexiletine (INN); Mexiletine [INN:BAN]; Mexiletinum [INN-Latin]; Mexitil (TN); (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; 1-(2,6-Dimethylphenoxy)-2-propanamine; 1-(2,6-dimethylphenoxy)propan-2-amine; 1-Methyl-2-(2,6-xylyloxy)ethylamine; 1-methyl-2-(2,6-xylyloxy)ethanamine; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; 2-(2-aminopropoxy)-1,3-dimethylbenzene
DMCTE9R	CP	Boehringer Ingelheim
DMCTE9R	TC	Antiarrhythmic Agents
DMCTE9R	DT	Small molecular drug
DMCTE9R	PC	4178
DMCTE9R	MW	179.26
DMCTE9R	FM	C11H17NO
DMCTE9R	IC	InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3
DMCTE9R	CS	CC1=C(C(=CC=C1)C)OCC(C)N
DMCTE9R	IK	VLPIATFUUWWMKC-UHFFFAOYSA-N
DMCTE9R	IU	1-(2,6-dimethylphenoxy)propan-2-amine
DMCTE9R	CA	CAS 31828-71-4
DMCTE9R	CB	CHEBI:6916
DMCTE9R	DE	Ventricular tachycardia

DMY5JEP	ID	DMY5JEP
DMY5JEP	DN	Mezlocillin
DMY5JEP	HS	Approved
DMY5JEP	SN	Mezlin; Mezlocilina; Mezlocillinum; Mezlocillin (USAN/INN); (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid
DMY5JEP	TC	Antibiotics
DMY5JEP	DT	Small molecular drug
DMY5JEP	PC	656511
DMY5JEP	MW	539.6
DMY5JEP	FM	C21H25N5O8S2
DMY5JEP	IC	InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1
DMY5JEP	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)O)C
DMY5JEP	IK	YPBATNHYBCGSSN-VWPFQQQWSA-N
DMY5JEP	IU	(2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMY5JEP	CA	CAS 51481-65-3
DMY5JEP	CB	CHEBI:6919
DMY5JEP	DE	Urinary tract infection

DMVKA4O	ID	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	HS	Approved
DMVKA4O	SN	Mianserina; Mianserine; Mianserinum; Mianseryna; Norval; Tolvan; Tolvon; Mianserin Monohydrochloride; Mianseryna [Polish]; Bolvidon (TN); Mianserin (INN); Mianserin [INN:BAN]; Mianserina [INN-Spanish]; Mianserine [INN-French]; Mianserinum [INN-Latin]; Norval (TN); Tolvin (TN); Tolvon (TN); 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; 2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
DMVKA4O	CP	GlaxoSmithKline
DMVKA4O	TC	Antidepressants
DMVKA4O	DT	Small molecular drug
DMVKA4O	PC	4184
DMVKA4O	MW	264.4
DMVKA4O	FM	C18H20N2
DMVKA4O	IC	InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
DMVKA4O	CS	CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
DMVKA4O	IK	UEQUQVLFIPOEMF-UHFFFAOYSA-N
DMVKA4O	IU	5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene
DMVKA4O	CA	CAS 24219-97-4
DMVKA4O	CB	CHEBI:51137
DMVKA4O	DE	Depression

DM6Y3AN	ID	DM6Y3AN
DM6Y3AN	DN	Micafungin
DM6Y3AN	HS	Approved
DM6Y3AN	SN	Mycamine; FK463; FK-463; Mycamine (TN); Mycamine(TM)
DM6Y3AN	CP	Astellas Pharma
DM6Y3AN	TC	Antifungal Agents
DM6Y3AN	DT	Small molecular drug
DM6Y3AN	PC	477468
DM6Y3AN	MW	1270.3
DM6Y3AN	FM	C56H71N9O23S
DM6Y3AN	IC	InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1
DM6Y3AN	CS	CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O
DM6Y3AN	IK	PIEUQSKUWLMALL-YABMTYFHSA-N
DM6Y3AN	IU	[5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] hydrogen sulfate
DM6Y3AN	CA	CAS 235114-32-6
DM6Y3AN	CB	CHEBI:600520
DM6Y3AN	DE	Candidiasis

DM3O6CY	ID	DM3O6CY
DM3O6CY	DN	Micardis telmisartan
DM3O6CY	HS	Approved
DM3O6CY	CP	Boehringer-Ingelheim Pharmaceuticals
DM3O6CY	DE	Hypertension

DMPMYE8	ID	DMPMYE8
DMPMYE8	DN	Miconazole
DMPMYE8	HS	Approved
DMPMYE8	SN	Dactarin; MCZ; Miconazol; Miconazolo; Miconazolum; Micozole; Minostate; Monistat; Vusion; Zimycan; Daktarin IV; Miconasil Nitrate; Miconazole nitrate salt; Miconazolo [DCIT]; Monistat IV; MJR 1762; Miconazole 3; Miconazole 3 Combination Pack; Miconazole 7 Combination Pack; Monazole 7; Monistat 1 Combination Pack; Monistat 3 Vaginal Ovules; Monistat 5 Tampon; Monistat 7 Vaginal Suppositories; R 18134; Aflorix(nitrate); Albistat(nitrate); Andergin(nitrate); Conofite(nitrate); Daktarin (TN); Femizol (TN); Femizol-M; Florid(nitrate); Lotrimin AF(nitrate); Micantin (nitrate); Micatin (TN); Miconazex (TN); Miconazol [INN-Spanish]; Miconazole-7; Miconazolum [INN-Latin]; Monista (nitrate); Monistat (TN); Monistat 3 Dual-Pak; Monistat 7 Dual-Pak; Monistat Dual-PAK; Monistat iv (TN); Monistat-Derm; Novo-Miconazole Vaginal Ovules; Epi-Monistat(nitrate); Gyno-Daktar(nitrate); Monistat-Derm (TN); R-14,889; Miconazole (JP15/USP/INN); Miconazole [USAN:BAN:INN:JAN]; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)-(9CI); Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-(9CI); (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole; 1-[2,4-Dichloro-beta-([2,4-dichloro-benzyl]oxy)phenethyl]imidazole; 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole; 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole; 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
DMPMYE8	CP	Janssen Pharmaceutica
DMPMYE8	TC	Antifungal Agents
DMPMYE8	DT	Small molecular drug
DMPMYE8	PC	4189
DMPMYE8	MW	416.1
DMPMYE8	FM	C18H14Cl4N2O
DMPMYE8	IC	InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
DMPMYE8	CS	C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl
DMPMYE8	IK	BYBLEWFAAKGYCD-UHFFFAOYSA-N
DMPMYE8	IU	1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
DMPMYE8	CA	CAS 22916-47-8
DMPMYE8	CB	CHEBI:82892
DMPMYE8	DE	Fungal infection

DMXOELT	ID	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	HS	Approved
DMXOELT	SN	Dazolam; Dormicum; Midanium; Midazolamum; Midosed; Versed; Midazolam Base; Dormicum (TN); Hypnovel (TN); Midacum (TN); Midazolamum [INN-Latin]; Ro 21-3981; Versed (TN); Midazolam (JAN/INN); Midazolam [INN:BAN:JAN]; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
DMXOELT	CP	Roche Pharmaceuticals
DMXOELT	TC	Hypnotics and Sedatives
DMXOELT	DT	Small molecular drug
DMXOELT	PC	4192
DMXOELT	MW	325.8
DMXOELT	FM	C18H13ClFN3
DMXOELT	IC	InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3
DMXOELT	CS	CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F
DMXOELT	IK	DDLIGBOFAVUZHB-UHFFFAOYSA-N
DMXOELT	IU	8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
DMXOELT	CA	CAS 59467-70-8
DMXOELT	CB	CHEBI:6931
DMXOELT	DE	Irritability; Epilepsy

DME2PY5	ID	DME2PY5
DME2PY5	DN	Midodrine
DME2PY5	HS	Approved
DME2PY5	SN	Alphamine; Amatine; Gutron; Hipertan; Metligene; Midamine; Midodrin; Midodrina; Midodrinum; ProAmatine; MIDODRINE HYDROCHLORIDE; Midodrine HCL; Midodrine Monohydrochloride; Midodrine hydrochloride [USAN]; A 4020 Linz; St 1085; TS 701; A-4020 Linz; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride [USAN:JAN]; Midodrinum [INN-Latin]; Pro-Amatine; Proamatine (TN); ST-1085; St. Peter 224; Midodrine hydrochloride (JAN/USAN); Pro-Amatine (TN); DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; (+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride
DME2PY5	CP	Shire Canada Inc
DME2PY5	TC	Vasoconstrictor Agents
DME2PY5	DT	Small molecular drug
DME2PY5	PC	4195
DME2PY5	MW	254.28
DME2PY5	FM	C12H18N2O4
DME2PY5	IC	InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)
DME2PY5	CS	COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O
DME2PY5	IK	PTKSEFOSCHHMPD-UHFFFAOYSA-N
DME2PY5	IU	2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide
DME2PY5	CA	CAS 42794-76-3
DME2PY5	CB	CHEBI:6933
DME2PY5	DE	Orthostatic hypotension

DMI6E0R	ID	DMI6E0R
DMI6E0R	DN	Midostaurin
DMI6E0R	HS	Approved
DMI6E0R	SN	PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN);  CPG 41251
DMI6E0R	CP	Novartis
DMI6E0R	TC	Anticancer Agents
DMI6E0R	DT	Small molecular drug
DMI6E0R	PC	9829523
DMI6E0R	MW	570.6
DMI6E0R	FM	C35H30N4O4
DMI6E0R	IC	InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
DMI6E0R	CS	C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
DMI6E0R	IK	BMGQWWVMWDBQGC-IIFHNQTCSA-N
DMI6E0R	IU	N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide
DMI6E0R	CA	CAS 120685-11-2
DMI6E0R	CB	CHEBI:63452
DMI6E0R	DE	Acute myeloid leukaemia; Systemic mastocytosis; Colorectal cancer; Chronic myelomonocytic leukaemia

DMGZQEF	ID	DMGZQEF
DMGZQEF	DN	Mifepristone
DMGZQEF	HS	Approved
DMGZQEF	SN	Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma
DMGZQEF	CP	HRA Pharma
DMGZQEF	DT	Small molecular drug
DMGZQEF	PC	55245
DMGZQEF	MW	429.6
DMGZQEF	FM	C29H35NO2
DMGZQEF	IC	InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
DMGZQEF	CS	CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
DMGZQEF	IK	VKHAHZOOUSRJNA-GCNJZUOMSA-N
DMGZQEF	IU	(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMGZQEF	CA	CAS 84371-65-3
DMGZQEF	CB	CHEBI:50692
DMGZQEF	DE	Cushing disease

DMFIQ2H	ID	DMFIQ2H
DMFIQ2H	DN	Migalastat
DMFIQ2H	HS	Approved
DMFIQ2H	SN	DDIG; D-Galactitol, 1,5-dideoxy-1,5-imino; (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-iminogalactitol; 2-(Hydroxymethyl)-3,4,5-piperidinetriol hydrochloride
DMFIQ2H	CP	Amicus Therapeutics
DMFIQ2H	DT	Small molecular drug
DMFIQ2H	PC	176077
DMFIQ2H	MW	163.17
DMFIQ2H	FM	C6H13NO4
DMFIQ2H	IC	InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1
DMFIQ2H	CS	C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O
DMFIQ2H	IK	LXBIFEVIBLOUGU-DPYQTVNSSA-N
DMFIQ2H	IU	(2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
DMFIQ2H	CA	CAS 108147-54-2
DMFIQ2H	CB	CHEBI:135923
DMFIQ2H	DE	Fabry disease

DMXBQAM	ID	DMXBQAM
DMXBQAM	DN	Miglitol
DMXBQAM	HS	Approved
DMXBQAM	SN	Diastabol; Glyset; Plumarol; Seibule; Glyset (TN); SK-983; Bay-m-1099; Miglitol (JAN/USAN/INN); (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
DMXBQAM	TC	Hypoglycemic Agents
DMXBQAM	DT	Small molecular drug
DMXBQAM	PC	441314
DMXBQAM	MW	207.22
DMXBQAM	FM	C8H17NO5
DMXBQAM	IC	InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1
DMXBQAM	CS	C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O
DMXBQAM	IK	IBAQFPQHRJAVAV-ULAWRXDQSA-N
DMXBQAM	IU	(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
DMXBQAM	CA	CAS 72432-03-2
DMXBQAM	CB	CHEBI:6935
DMXBQAM	DE	Diabetic complication

DM5J64S	ID	DM5J64S
DM5J64S	DN	Miglustat
DM5J64S	HS	Approved
DM5J64S	SN	BuDNJ; Butyldeoxynojirimycin; Miglustatum; NBV; Vevesca; Zavesca; Miglustat [USAN]; OGT 918; SC 48334; SC48334; Miglustat, Hydrochloride; N-Butyl deoxynojirimycin; N-Butyl dnj; N-Butyldeoxynojirimycin; N-Butylmoranoline; NB-DNJ; OGT-918; SC-48334; Zavesca (TN); Miglustat (USAN/INN); N-Bu-DNJ; N-Butyl-DNJ; N-Butyl-deoxynojirimycin; N-(n-Butyl)deoxynojirimycin; N-butyl-1-deoxynojirimycin; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-N-butylimino-D-glucitol
DM5J64S	TC	Anti-HIV Agents
DM5J64S	DT	Small molecular drug
DM5J64S	PC	51634
DM5J64S	MW	219.28
DM5J64S	FM	C10H21NO4
DM5J64S	IC	InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
DM5J64S	CS	CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O
DM5J64S	IK	UQRORFVVSGFNRO-UTINFBMNSA-N
DM5J64S	IU	(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
DM5J64S	CA	CAS 72599-27-0
DM5J64S	CB	CHEBI:50381
DM5J64S	DE	Type 1 gaucher disease

DMBFE74	ID	DMBFE74
DMBFE74	DN	Milnacipran
DMBFE74	HS	Approved
DMBFE74	SN	Ixel; Midalcipran; Milnacipranum; Toledomin; Milnacipran [INN]; Milnacipranum [Latin]; F 2207; F-2207; Ixel (TN); Milnacipran(INN); Savella (TN); (+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; 1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl
DMBFE74	CP	Silesia Laboratories
DMBFE74	TC	Antidepressants
DMBFE74	DT	Small molecular drug
DMBFE74	PC	65833
DMBFE74	MW	246.35
DMBFE74	FM	C15H22N2O
DMBFE74	IC	InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1
DMBFE74	CS	CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2
DMBFE74	IK	GJJFMKBJSRMPLA-HIFRSBDPSA-N
DMBFE74	IU	(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DMBFE74	CA	CAS 96847-55-1
DMBFE74	CB	CHEBI:94468
DMBFE74	DE	Depression

DM8TUPF	ID	DM8TUPF
DM8TUPF	DN	Milrinone
DM8TUPF	HS	Approved
DM8TUPF	SN	Corotrop; Corotrope; Milrila; Milrinona; Milrinonum; Primacor; Milrinona [Spanish]; Milrinonum [Latin]; M 4659; M1663; YM 018; MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER; Milrila (TN); PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER; Primacor (TN); WIN 47203-2; Win-47203; Milrinone [USAN:BAN:INN]; Win-47203-2; Milrinone (JAN/USAN/INN); 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4&prime;-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; 111GE027; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
DM8TUPF	CP	Sanofi-Synthelabo Inc
DM8TUPF	TC	Cardiotonic Agents
DM8TUPF	DT	Small molecular drug
DM8TUPF	PC	4197
DM8TUPF	MW	211.22
DM8TUPF	FM	C12H9N3O
DM8TUPF	IC	InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)
DM8TUPF	CS	CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2
DM8TUPF	IK	PZRHRDRVRGEVNW-UHFFFAOYSA-N
DM8TUPF	IU	6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
DM8TUPF	CA	CAS 78415-72-2
DM8TUPF	CB	CHEBI:50693
DM8TUPF	DE	Congestive heart failure

DMND304	ID	DMND304
DMND304	DN	Miltefosine
DMND304	HS	Approved
DMND304	SN	HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
DMND304	CP	Aeterna Zentaris
DMND304	TC	Antifungal Agents
DMND304	DT	Small molecular drug
DMND304	PC	3599
DMND304	MW	407.6
DMND304	FM	C21H46NO4P
DMND304	IC	InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3
DMND304	CS	CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C
DMND304	IK	PQLXHQMOHUQAKB-UHFFFAOYSA-N
DMND304	IU	hexadecyl 2-(trimethylazaniumyl)ethyl phosphate
DMND304	CA	CAS 58066-85-6
DMND304	CB	CHEBI:75283
DMND304	DE	Leishmaniasis; Visceral leishmaniasis

DM0EP7M	ID	DM0EP7M
DM0EP7M	DN	Minaprine
DM0EP7M	HS	Approved
DM0EP7M	SN	Brantur; Cantor; Minaprina; Minaprinum; Minaprine dihydrochloride; AGR 1240; CB 30038; Cantor (TN); Minaprina [INN-Spanish]; Minaprinum [INN-Latin]; Minaprine (USAN/INN); Minaprine [USAN:BAN:INN]; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine; 3-(morpholinoethyl)amino-4-methyl-6-phenylpyridazine; 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
DM0EP7M	TC	Antidepressants
DM0EP7M	DT	Small molecular drug
DM0EP7M	PC	4199
DM0EP7M	MW	298.4
DM0EP7M	FM	C17H22N4O
DM0EP7M	IC	InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)
DM0EP7M	CS	CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3
DM0EP7M	IK	LDMWSLGGVTVJPG-UHFFFAOYSA-N
DM0EP7M	IU	4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
DM0EP7M	CA	CAS 25905-77-5
DM0EP7M	CB	CHEBI:51038
DM0EP7M	DE	Depression

DMVN5OH	ID	DMVN5OH
DMVN5OH	DN	Minocycline
DMVN5OH	HS	Approved
DMVN5OH	SN	Borymycin; MINO; MIY; Minociclina; Minociclinum; Minocin; Minocline; Minocyclin; Minocyclinum; Minocycline Monohydrochloride; CL 59806; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minociclina [INN-Spanish]; Minocin (Hydrochloride); Minocin (TN); Minocyclinum [INN-Latin]; Vectrin (Hydrochloride); CRL-1605 & Minocycline; Minocycline (USAN/INN); Minocycline [USAN:BAN:INN]; (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Dimethylamino-6-demethyl-6-deoxytetracycline
DMVN5OH	CP	Lederle Laboratories
DMVN5OH	TC	Antibiotics
DMVN5OH	DT	Small molecular drug
DMVN5OH	PC	54675783
DMVN5OH	MW	457.5
DMVN5OH	FM	C23H27N3O7
DMVN5OH	IC	InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
DMVN5OH	CS	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C
DMVN5OH	IK	FFTVPQUHLQBXQZ-KVUCHLLUSA-N
DMVN5OH	IU	(4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMVN5OH	CA	CAS 10118-90-8
DMVN5OH	CB	CHEBI:50694
DMVN5OH	DE	Bacterial infection; Rosacea

DM50PMY	ID	DM50PMY
DM50PMY	DN	Minodronate
DM50PMY	HS	Approved
DM50PMY	SN	Minodronic acid; 180064-38-4; (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid; Recalbon; Bonoteo; BPH 261; ONO 5920; YH 529; Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-; UNII-40SGR63TGL; YM 529; 40SGR63TGL; Ono-5920; NSC725590; YH-529; 127657-42-5; NCGC00183829-01; AK119862; Phosphonic acid, (1-hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)bis-; (1-hydroxy-2-{imidazo[1,2-a]pyridin-3-yl}-1-phosphonoethyl)phosphonic acid; minodronic acid
DM50PMY	DT	Small molecular drug
DM50PMY	PC	130956
DM50PMY	MW	322.15
DM50PMY	FM	C9H12N2O7P2
DM50PMY	IC	InChI=1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)
DM50PMY	CS	C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DM50PMY	IK	VMMKGHQPQIEGSQ-UHFFFAOYSA-N
DM50PMY	IU	(1-hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid
DM50PMY	CA	CAS 180064-38-4
DM50PMY	DE	Osteoporosis

DMA2Z4F	ID	DMA2Z4F
DMA2Z4F	DN	Minoxidil
DMA2Z4F	HS	Approved
DMA2Z4F	SN	Alopexil; Alostil; Loniten; Lonolox; Minodyl; Minossidile; Minoxidilum; Minoxigaine; Minoximen; Neoxidil; Normoxidil; Pierminox; Prexidil; Regaine; RiUP; Rogaine; Theroxidil; Tricoxidil; Trocoxidil; MINOXIDIL EXTRA STRENGTH FOR MEN; Men s Rogaine Foam; Mens Rogaine Foam; Minossidile [Italian]; Minoxidil Pfizer Brand; PfizerBrand of Minoxidil; Rogaine Extra Strength for Men; Rogaine for Men; Rogaine for Women; M 4145; M1389; U 10858; Apo-Gain; Gen-Minoxidil; Loniten (TN); MINOXIDIL (FOR MEN); MINOXIDIL (FOR WOMEN); MINOXIDIL EXTRA STRENGTH (FOR MEN); Men's Rogaine; Minoxidilum [INN-Latin]; ROGAINE (FOR MEN); ROGAINE (FOR WOMEN); ROGAINE EXTRA STRENGTH (FOR MEN); Regaine (TN); Riup (TN); Rogaine (TN); TM-160; U-10858; Minoxidil (USP/INN); Minoxidil [USAN:BAN:INN]; U-10,858; Rogaine, Regaine, Avacor and Mintop, Minoxidil; Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide; 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; 2,4-Diamino-6-piperidinilpirimidina-3-ossido; 2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]; 2,4-Diamino-6-piperidino-pyrimidine-3-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; 2,6-Diamino-4-piperidinopyrimidin-1-oxid; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; 6-Piperidino-2,4-diaminopyrimidine 3-oxide; 6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide
DMA2Z4F	CP	Upjohn Corporation
DMA2Z4F	TC	Antihypertensive Agents
DMA2Z4F	DT	Small molecular drug
DMA2Z4F	PC	4201
DMA2Z4F	MW	209.25
DMA2Z4F	FM	C9H15N5O
DMA2Z4F	IC	InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2
DMA2Z4F	CS	C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
DMA2Z4F	IK	ZIMGGGWCDYVHOY-UHFFFAOYSA-N
DMA2Z4F	IU	3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
DMA2Z4F	CA	CAS 38304-91-5
DMA2Z4F	CB	CHEBI:6942
DMA2Z4F	DE	Hypertension

DMGSRN1	ID	DMGSRN1
DMGSRN1	DN	Mipomersen
DMGSRN1	HS	Approved
DMGSRN1	SN	Mipomersen
DMGSRN1	CP	Isis Pharmaceuticals
DMGSRN1	TC	Antisense
DMGSRN1	DT	Antisense drug
DMGSRN1	SQ	5'-GCCUCAGTCTGCTTCGCACC
DMGSRN1	PC	71301230
DMGSRN1	MW	7158
DMGSRN1	FM	C230H305N67O122P19S19-19
DMGSRN1	IC	InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-131(112(400-141)70-381-422(327,328)442-136-50-146(283-66-108(12)196(302)275-228(283)320)406-118(136)76-387-427(337,338)448-140-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)409-120(140)78-389-428(339,340)446-138-52-148(292-91-250-151-186(240)246-89-248-188(151)292)407-121(138)79-390-430(343,344)450-169-124(413-204(160(169)373-37-27-363-17)286-59-101(5)181(235)260-221(286)313)83-394-435(353,354)455-174-128(417-209(165(174)378-42-32-368-22)291-68-110(14)198(304)277-230(291)322)87-396-434(351,352)453-172-126(415-207(163(172)376-40-30-366-20)289-62-104(8)184(238)263-224(289)316)85-395-433(349,350)452-171-123(412-206(162(171)375-39-29-365-19)288-61-103(7)183(237)262-223(288)315)82-393-432(347,348)449-168-111(69-298)410-211(159(168)372-36-26-362-16)296-95-254-155-192(296)267-215(244)271-201(155)307)439-420(323,324)384-74-117-137(51-147(405-117)284-67-109(13)197(303)276-229(284)321)444-425(333,334)388-77-119-139(53-149(408-119)293-92-252-153-190(293)265-213(242)269-199(153)305)447-426(335,336)386-71-113-132(46-142(401-113)279-56-98(2)178(232)257-218(279)310)440-421(325,326)383-73-115-135(49-145(403-115)282-65-107(11)195(301)274-227(282)319)443-424(331,332)385-75-116-134(48-144(404-116)281-64-106(10)194(300)273-226(281)318)441-423(329,330)382-72-114-133(47-143(402-114)280-57-99(3)179(233)258-219(280)311)445-429(341,342)392-81-129-176(167(380-44-34-370-24)212(419-129)297-96-255-156-193(297)268-216(245)272-202(156)308)457-438(359,360)398-86-127-173(164(377-41-31-367-21)208(416-127)290-63-105(9)185(239)264-225(290)317)454-436(355,356)399-88-130-175(166(379-43-33-369-23)210(418-130)295-94-251-152-187(241)247-90-249-189(152)295)456-437(357,358)397-84-125-170(161(374-38-28-364-18)205(414-125)287-60-102(6)182(236)261-222(287)314)451-431(345,346)391-80-122-157(299)158(371-35-25-361-15)203(411-122)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,324)(H,325,326)(H,327,328)(H,329,330)(H,331,332)(H,333,334)(H,335,336)(H,337,338)(H,339,340)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,355,356)(H,357,358)(H,359,360)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/p-19/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122+,123-,124-,125+,126-,127+,128-,129-,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,157+,158+,159-,160-,161+,162-,163-,164+,165-,166+,167-,168-,169-,170+,171-,172-,173+,174-,175+,176-,203+,204-,205+,206-,207-,208+,209-,210+,211-,212-/m1/s1
DMGSRN1	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)([O-])S[C@H]3C[C@@H](O[C@@H]3COP(=O)([O-])S[C@H]4C[C@@H](O[C@@H]4COP(=O)([O-])S[C@H]5C[C@@H](O[C@@H]5COP(=O)([O-])S[C@H]6C[C@@H](O[C@@H]6COP(=O)([O-])S[C@H]7C[C@@H](O[C@@H]7COP(=O)([O-])S[C@H]8C[C@@H](O[C@@H]8COP(=O)([O-])S[C@H]9C[C@@H](O[C@@H]9COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O
DMGSRN1	IK	TZRFSLHOCZEXCC-HIVFKXHNSA-A
DMGSRN1	IU	[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4R,5S)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4S,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-[(2R,3R,4S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]sulfanylphosphinate
DMGSRN1	CA	CAS 1000120-98-8
DMGSRN1	DE	Familial hypercholesterolemia

DMS1GYT	ID	DMS1GYT
DMS1GYT	DN	Mirabegron
DMS1GYT	HS	Approved
DMS1GYT	SN	Myrbetriq (TN)
DMS1GYT	CP	Astellas
DMS1GYT	DT	Small molecular drug
DMS1GYT	PC	9865528
DMS1GYT	MW	396.5
DMS1GYT	FM	C21H24N4O2S
DMS1GYT	IC	InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
DMS1GYT	CS	C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
DMS1GYT	IK	PBAPPPCECJKMCM-IBGZPJMESA-N
DMS1GYT	IU	2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
DMS1GYT	CA	CAS 223673-61-8
DMS1GYT	CB	CHEBI:65349
DMS1GYT	DE	Overactive bladder

DML53ZJ	ID	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	HS	Approved
DML53ZJ	SN	Avanza; Axit; Azamianserin; Mepirzapin; Mepirzepine; Mirtabene; Mirtaz; Mirtazapina; Mirtazapinum; Mirtazepine; Mirtazipine; Mirtazon; Norset; Promyrtil; Remergil; Remergon; Remeron; Rexer; Zispin; Celltech brand of mirtazapine; Mundogen brand of mirtazapine; Organon brand of mirtazapine; Remeron SolTab; ORG 3770; Afloyan (TN); Alphamirt (TN); Alphazagen (TN); Amirel (TN); Arintapin (TN); Arintapina (TN); Avanza (TN); Axit (TN); Bexzis (TN); Calixta (TN); Ciblex (TN); Combar (TN); Comenter (TN); Divaril (TN); Esprital (TN); Finmirtaza (TN); Finpharma (TN); Finscope (TN); Genamirt (TN); Hexazipin (TN); Loxozapin (TN); ME-2040; Medizapin (TN); Miralix (TN); Mirap (TN); Mirazep (TN); Miro (TN); Miron (TN); Mirta (TN); Mirtabene (TN); Mirtachem (TN); Mirtacur (TN); Mirtadepi (TN); Mirtagamma (TN); Mirtal (TN); Mirtalich (TN); Mirtalphagen (TN); Mirtamed (TN); Mirtamerck (TN); Mirtapax (TN); Mirtapharm (TN); Mirtapin(TN); Mirtaratio (TN); Mirtaril (TN); Mirtaron (TN); Mirtascope (TN); Mirtasole (TN); Mirtastad (TN); Mirtastada (TN); Mirtatifi (TN); Mirtatsapiini (TN); Mirtawin (TN); Mirtaz (TN); Mirtazapin (TN);Mirtazapina (TN); Mirtazapina [INN-Spanish]; Mirtazapinum [INN-Latin]; Mirtazelon (TN); Mirtazen (TN); Mirtazep (TN); Mirtazepin (TN); Mirtazon (TN); Mirtazza (TN); Mirtel (TN); Mirtoral (TN); Mirzagen (TN); Mirzalux (TN); Mirzaten (TN); Mitrazen (TN); Mizapin (TN); Mizapin Sol (TN); Norset (TN); Noxibel (TN); Pharmasole (TN); Pharmazepine (TN); Promyrtil (TN); Remergil (TN); Remergon (TN); Remeron (TN); Remeron SolTab (TN); Remirta (TN); Rexer (TN); SolTab (TN); Tarzapine (TN); Tazamel (TN); Tazapin (TN); Tazascope (TN); Tirzamed (TN); Valdren (TN); Vastat (TN); Zapex (TN); Zicomber (TN); Zismirt (TN); Zispin (TN); Zispin SolTab (TN); Zuleptan (TN); Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirzaten Q-Tab (TN); Zistap. (TN); Mirtazapine (JAN/USAN/INN); (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; (N-methyl-11C)mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; 6-Azamianserin
DML53ZJ	CP	Organon International
DML53ZJ	TC	Antidepressants
DML53ZJ	DT	Small molecular drug
DML53ZJ	PC	4205
DML53ZJ	MW	265.35
DML53ZJ	FM	C17H19N3
DML53ZJ	IC	InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
DML53ZJ	CS	CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
DML53ZJ	IK	RONZAEMNMFQXRA-UHFFFAOYSA-N
DML53ZJ	IU	5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
DML53ZJ	CA	CAS 85650-52-8
DML53ZJ	CB	CHEBI:6950
DML53ZJ	DE	Depression

DMHVJFK	ID	DMHVJFK
DMHVJFK	DN	Misoprostol
DMHVJFK	HS	Approved
DMHVJFK	SN	Cytotec; GyMiso; Isprelor; Misopess; Misoprostolum; Misotol; SC 29333; Cytotec (TN); Misoprostolum [INN-Latin]; SC-29333; XP-16J; Misoprostol (JAN/USAN/INN); Methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate; (+/-)-15-Deoxy-(16RS)-16-hydroxy-16-methylprostaglandin E1 methyl ester; (11-alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester
DMHVJFK	CP	Pfizer Pharmaceuticals
DMHVJFK	TC	Abortifacient Agents
DMHVJFK	DT	Small molecular drug
DMHVJFK	PC	5282381
DMHVJFK	MW	382.5
DMHVJFK	FM	C22H38O5
DMHVJFK	IC	InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
DMHVJFK	CS	CCCCC(C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O
DMHVJFK	IK	OJLOPKGSLYJEMD-URPKTTJQSA-N
DMHVJFK	IU	methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate
DMHVJFK	CA	CAS 59122-46-2
DMHVJFK	CB	CHEBI:94387
DMHVJFK	DE	Medical abortion

DMP8HEL	ID	DMP8HEL
DMP8HEL	DN	Mitiglinide
DMP8HEL	HS	Approved
DMP8HEL	SN	Mitiglinide calcium; Mitiglinide calcium hydrate; KAD 1229; S21403; Glufast (TN); Kad-1229; Calcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate; Calcium (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate; (2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid; 2-Benzyl-3-(hexahydro-2-isoindolinylcarbonyl)propionate
DMP8HEL	CP	Elixir Pharmaceuticals
DMP8HEL	TC	Hypoglycemic Agents
DMP8HEL	DT	Small molecular drug
DMP8HEL	PC	121891
DMP8HEL	MW	315.4
DMP8HEL	FM	C19H25NO3
DMP8HEL	IC	InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1
DMP8HEL	CS	C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O
DMP8HEL	IK	WPGGHFDDFPHPOB-BBWFWOEESA-N
DMP8HEL	IU	(2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid
DMP8HEL	CA	CAS 145375-43-5
DMP8HEL	CB	CHEBI:135349
DMP8HEL	DE	Diabetic complication

DMH0ZJE	ID	DMH0ZJE
DMH0ZJE	DN	Mitomycin
DMH0ZJE	HS	Approved
DMH0ZJE	SN	Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,;  Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free
DMH0ZJE	TC	Anticancer Agents
DMH0ZJE	DT	Small molecular drug
DMH0ZJE	PC	5746
DMH0ZJE	MW	334.33
DMH0ZJE	FM	C15H18N4O5
DMH0ZJE	IC	InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
DMH0ZJE	CS	CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
DMH0ZJE	IK	NWIBSHFKIJFRCO-WUDYKRTCSA-N
DMH0ZJE	IU	[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
DMH0ZJE	CA	CAS 50-07-7
DMH0ZJE	CB	CHEBI:27504
DMH0ZJE	DE	Breast cancer; Gastrointestinal cancer; Solid tumour/cancer

DM4PF81	ID	DM4PF81
DM4PF81	DN	Mitomycin A
DM4PF81	HS	Approved
DM4PF81	SN	Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester); [(1ar,8r,8as,8br)-6,8a-dimethoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, (1aR-(1aalpha,8beta,8aalpha,8balpha))-(9CI)
DM4PF81	TC	Anticancer Agents
DM4PF81	DT	Small molecular drug
DM4PF81	PC	19972
DM4PF81	MW	349.34
DM4PF81	FM	C16H19N3O6
DM4PF81	IC	InChI=1S/C16H19N3O6/c1-6-11(20)10-9(12(21)13(6)23-2)7(5-25-15(17)22)16(24-3)14-8(18-14)4-19(10)16/h7-8,14,18H,4-5H2,1-3H3,(H2,17,22)/t7-,8+,14+,16-/m1/s1
DM4PF81	CS	CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)OC
DM4PF81	IK	HYFMSAFINFJTFH-NGSRAFSJSA-N
DM4PF81	IU	[(4S,6S,7R,8S)-7,11-dimethoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
DM4PF81	CA	CAS 4055-39-4
DM4PF81	CB	CHEBI:85412
DM4PF81	DE	Solid tumour/cancer

DMU1GX0	ID	DMU1GX0
DMU1GX0	DN	Mitotane
DMU1GX0	HS	Approved
DMU1GX0	SN	Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane
DMU1GX0	CP	Bristol Myers Squibb
DMU1GX0	TC	Anticancer Agents
DMU1GX0	DT	Small molecular drug
DMU1GX0	PC	4211
DMU1GX0	MW	320
DMU1GX0	FM	C14H10Cl4
DMU1GX0	IC	InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
DMU1GX0	CS	C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl
DMU1GX0	IK	JWBOIMRXGHLCPP-UHFFFAOYSA-N
DMU1GX0	IU	1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene
DMU1GX0	CA	CAS 53-19-0
DMU1GX0	CB	CHEBI:6954
DMU1GX0	DE	Adrenocortical carcinoma

DMM39BF	ID	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	HS	Approved
DMM39BF	SN	DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)
DMM39BF	CP	Serono
DMM39BF	TC	Analgesics
DMM39BF	DT	Small molecular drug
DMM39BF	PC	4212
DMM39BF	MW	444.5
DMM39BF	FM	C22H28N4O6
DMM39BF	IC	InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
DMM39BF	CS	C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
DMM39BF	IK	KKZJGLLVHKMTCM-UHFFFAOYSA-N
DMM39BF	IU	1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
DMM39BF	CA	CAS 65271-80-9
DMM39BF	CB	CHEBI:50729
DMM39BF	DE	Solid tumour/cancer; Non-hodgkin lymphoma

DM473VD	ID	DM473VD
DM473VD	DN	Mivacurium
DM473VD	HS	Approved
DM473VD	SN	Mivacron; Chlorure de mivacurium; Chlorure de mivacurium [French]; Cloruro de mivacurio; Cloruro de mivacurio [Spanish]; MIVACURIUM CHLORIDE; Mivacurii chloridum; Mivacurii chloridum [Latin]; BW B109OU dichloride; BWB109OU; BW-B1090U; BW-B109OU; MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER; Mivacron (TN); Mivacurium chloride(USAN/INN); Mivacurium chloride [USAN:INN:BAN]; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride; (R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1)
DM473VD	TC	Neuromuscular Nondepolarizing Agents
DM473VD	DT	Small molecular drug
DM473VD	PC	5281042
DM473VD	MW	1029.3
DM473VD	FM	C58H80N2O14+2
DM473VD	IC	InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1
DM473VD	CS	C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C
DM473VD	IK	ILVYCEVXHALBSC-OTBYEXOQSA-N
DM473VD	IU	bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate
DM473VD	CA	CAS 133814-19-4
DM473VD	CB	CHEBI:6958
DM473VD	DE	Anaesthesia

DM1FDN8	ID	DM1FDN8
DM1FDN8	DN	Mizolastine
DM1FDN8	HS	Approved
DM1FDN8	SN	Mistalin; Mistamine; Mizolastina; Mizolastinum; Mizolen; Mizollen; Zolim; Zolistam; Zolistan; Allphar brand of mizolastine; Galderma brand of mizolastine; Mizolastine [INN]; Novag brand of mizolastine; Sanofi Synthelabo brand of mizolastine; Schwarz brand of mizolastine; MKC-431; Mizolastina [INN-Spanish]; Mizolastinum [INN-Latin]; Mizollen (TN); SL 85.0324; Mizolastine (JAN/INN); SL-85.0324; 2-((1-(1-(p-Fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3H)-pyrimidinone; 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
DM1FDN8	TC	Antiallergic Agents
DM1FDN8	DT	Small molecular drug
DM1FDN8	PC	65906
DM1FDN8	MW	432.5
DM1FDN8	FM	C24H25FN6O
DM1FDN8	IC	InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)
DM1FDN8	CS	CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5
DM1FDN8	IK	PVLJETXTTWAYEW-UHFFFAOYSA-N
DM1FDN8	IU	2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
DM1FDN8	CA	CAS 108612-45-9
DM1FDN8	CB	CHEBI:31857
DM1FDN8	DE	Allergic rhinitis

DMW6F0S	ID	DMW6F0S
DMW6F0S	DN	Mizoribine
DMW6F0S	HS	Approved
DMW6F0S	SN	Bredinin; Bredinine; MZR; Mizoribina; Mizoribinum; M 3047; Bredinin (TN); HE-69; HS-0046; Mizoribina [INN-Spanish]; Mizoribine [INN:JAN]; Mizoribinum [INN-Latin]; Mizoribine (JAN/INN); Bredinin, HE 69, NSC 289637, MZB, Mizoribine; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide; N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; N'-(beta-D-Ribofuranosyl)-5-hydroxy-imida-zole-4-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide;4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate; 4-carbamoyl-1-b-d-ribofuranosylimidazolium-5-olate; 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide
DMW6F0S	TC	Antimetabolites
DMW6F0S	DT	Small molecular drug
DMW6F0S	PC	104762
DMW6F0S	MW	259.22
DMW6F0S	FM	C9H13N3O6
DMW6F0S	IC	InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1
DMW6F0S	CS	C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)N
DMW6F0S	IK	HZQDCMWJEBCWBR-UUOKFMHZSA-N
DMW6F0S	IU	1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide
DMW6F0S	CA	CAS 50924-49-7
DMW6F0S	CB	CHEBI:31858
DMW6F0S	DE	Transplant rejection

DM215WE	ID	DM215WE
DM215WE	DN	MK-1439
DM215WE	HS	Approved
DM215WE	SN	Doravirine; 1338225-97-0; UNII-913P6LK81M; MK1439; 913P6LK81M; MK 1439
DM215WE	CP	Merck & Co.
DM215WE	DT	Small molecular drug
DM215WE	PC	58460047
DM215WE	MW	425.7
DM215WE	FM	C17H11ClF3N5O3
DM215WE	IC	InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)
DM215WE	CS	CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F
DM215WE	IK	ZIAOVIPSKUPPQW-UHFFFAOYSA-N
DM215WE	IU	3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile
DM215WE	CA	CAS 1338225-97-0
DM215WE	DE	Human immunodeficiency virus infection

DMBYNW0	ID	DMBYNW0
DMBYNW0	DN	MK-3475
DMBYNW0	HS	Approved
DMBYNW0	CP	Merck
DMBYNW0	DT	Monoclonal antibody
DMBYNW0	DE	Melanoma

DMOB58Q	ID	DMOB58Q
DMOB58Q	DN	MK-8228
DMOB58Q	HS	Approved
DMOB58Q	SN	Letermovir
DMOB58Q	CP	Merck & Co.
DMOB58Q	DT	Small molecular drug
DMOB58Q	PC	45138674
DMOB58Q	MW	572.5
DMOB58Q	FM	C29H28F4N4O4
DMOB58Q	IC	InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1
DMOB58Q	CS	COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
DMOB58Q	IK	FWYSMLBETOMXAG-QHCPKHFHSA-N
DMOB58Q	IU	2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
DMOB58Q	CA	CAS 917389-32-3
DMOB58Q	DE	Cytomegalovirus Disease; Cytomegalovirus infection

DMP2LZ8	ID	DMP2LZ8
DMP2LZ8	DN	MLN0002
DMP2LZ8	HS	Approved
DMP2LZ8	SN	Vedolizumab
DMP2LZ8	CP	Takeda
DMP2LZ8	SQ	Heavy Chain Sequence: QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Light Chain SequenceDVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMP2LZ8	DE	Crohn disease

DMCMETN	ID	DMCMETN
DMCMETN	DN	MLN9708
DMCMETN	HS	Approved
DMCMETN	CP	Millennium Pharmaceuticals
DMCMETN	DT	Small molecular drug
DMCMETN	PC	49867936
DMCMETN	MW	517.1
DMCMETN	FM	C20H23BCl2N2O9
DMCMETN	IC	InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)/t14-,20?/m0/s1
DMCMETN	CS	B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)[C@H](CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl
DMCMETN	IK	YTXSYWAKVMZICI-PVCZSOGJSA-N
DMCMETN	IU	4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid
DMCMETN	CA	CAS 1201902-80-8
DMCMETN	DE	Amyloidosis; Multiple myeloma

DMNZWL7	ID	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	HS	Approved
DMNZWL7	SN	Arima; Aurorex; Aurorix; Deprenorm; Feraken; Manerix; Moclaime; Moclamide; Moclamine; Moclix; Moclobamide; Moclobemid; Moclobemida; Moclobemidum; Moclobeta; Moclodura; Moclonorm; NovoMoclobemide; NuMoclobemide; Rimoc; Alphapharm Brand of Moclobemide; Alpharma Brand of Moclobemide; Apo Moclobemide; Apotex Brand of Moclobemide; Azupharma Brand of Moclobemide; BC Brand of Moclobemide; Betapharm Brand of Moclobemide; Bull Brand of Moclobemide; Chem mart Brand of Moclobemide; Chem mart Moclobemide; Ct Arzneimittel Brand of Moclobemide; DBL Moclobemide; Esparma Brand of Moclobemide; Faulding Brand of Moclobemide; GenRX Moclobemide; Healthsense Brand of Moclobemide; Healthsense Moclobemide; Hexal Brand of Moclobemide; Hoffmann La Roche Brand of Moclobemide; Kendrick Brand of Moclobemide; Merck dura Brand of Moclobemide; Moclobemid AZU; Moclobemid Puren; Moclobemid Stada; Moclobemid ratiopharm; Moclobemid von ct; Moclobemide Alphapharm Brand; Moclobemide Alpharma Brand; Moclobemide Apotex Brand; Moclobemide Azupharma Brand; Moclobemide BC Brand; Moclobemide Bull Brand; Moclobemide Faulding Brand; Moclobemide Healthsense Brand; Moclobemide Hexal Brand; Moclobemide Kendrick Brand; Moclobemide Novopharm Brand; Moclobemide Pharmascience Brand; Moclobemide Roche Brand; Moclobemide Stadapharm Brand; Moclobemide Temmler Brand; Moclobemide betapharm Brand; Moclobemide esparma Brand; Moclobemide ratiopharm Brand; Novo Moclobemide; Novopharm Brand of Moclobemide; Nu Moclobemide; Nu Pharm Brand of Moclobemide; PMS Moclobemide; Pharmascience Brand of Moclobemide; Ratiopharm Brand of Moclobemide; Roche Brand of Moclobemide; Stadapharm Brand of Moclobemide; Temmler Brand of Moclobemide; Terry White Chemists Brand of Moclobemide; Terry White Chemists Moclobemide; CBMicro_048319; Moclobemid 1A Pharma; Moclobemid1A Pharma; Moclobemide 1A Brand; Ro 11 1163; AZU, Moclobemid; Apo-Moclobemide; Aurorix (TN); Ct-Arzneimittel Brand of Moclobemide; Hoffmann-La Roche Brand of Moclobemide; Manerix (TN); Moclobemid-1A Pharma; Moclobemid-Puren; Moclobemid-ratiopharm; Moclobemida [INN-Spanish]; Moclobemide Nu-Pharm Brand; Moclobemide ct-Arzneimittel Brand; Moclobemide, Chem mart; Moclobemide, DBL; Moclobemide, GenRX; Moclobemide, Healthsense; Moclobemidum [INN-Latin]; Novo-Moclobemide; Nu-Moclobemide; Nu-Pharm Brand of Moclobemide; PMS-Moclobemide; Ro 11-1163; Stada, Moclobemid; Von ct, Moclobemid; GNF-PF-695; Moclobemide (USAN/INN); Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Ro 11-1163/000; Ro-11-1163; P-Chloro-N-(2-morpholinoethyl)benzamide; 1A Brand of Moclobemide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
DMNZWL7	CP	Hoffmann-La Roche pharmaceutical company
DMNZWL7	TC	Antidepressants
DMNZWL7	DT	Small molecular drug
DMNZWL7	PC	4235
DMNZWL7	MW	268.74
DMNZWL7	FM	C13H17ClN2O2
DMNZWL7	IC	InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
DMNZWL7	CS	C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
DMNZWL7	IK	YHXISWVBGDMDLQ-UHFFFAOYSA-N
DMNZWL7	IU	4-chloro-N-(2-morpholin-4-ylethyl)benzamide
DMNZWL7	CA	CAS 71320-77-9
DMNZWL7	CB	CHEBI:83531
DMNZWL7	DE	Skin imperfections; Depression

DMYILBE	ID	DMYILBE
DMYILBE	DN	Modafinil
DMYILBE	HS	Approved
DMYILBE	SN	Provigil; Modiodal
DMYILBE	CP	Cephalon Inc
DMYILBE	TC	Neurology Agents
DMYILBE	DT	Small molecular drug
DMYILBE	PC	4236
DMYILBE	MW	273.4
DMYILBE	FM	C15H15NO2S
DMYILBE	IC	InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)
DMYILBE	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
DMYILBE	IK	YFGHCGITMMYXAQ-UHFFFAOYSA-N
DMYILBE	IU	2-benzhydrylsulfinylacetamide
DMYILBE	CA	CAS 68693-11-8
DMYILBE	CB	CHEBI:77585
DMYILBE	DE	Narcolepsy; Brain injury; Bipolar disorder

DM26E4B	ID	DM26E4B
DM26E4B	DN	Moexipril
DM26E4B	HS	Approved
DM26E4B	SN	Moexiprilum; Uniretic; Moexipril (INN); Moexipril [INN:BAN]; Moexiprilum [INN-Latin]; Perdix (TN); Univasc (TN); (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DM26E4B	CP	Ucb Inc
DM26E4B	TC	Antihypertensive Agents
DM26E4B	DT	Small molecular drug
DM26E4B	PC	91270
DM26E4B	MW	498.6
DM26E4B	FM	C27H34N2O7
DM26E4B	IC	InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
DM26E4B	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC
DM26E4B	IK	UWWDHYUMIORJTA-HSQYWUDLSA-N
DM26E4B	IU	(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DM26E4B	CA	CAS 103775-10-6
DM26E4B	CB	CHEBI:6960
DM26E4B	DE	Hypertension

DMISH0Z	ID	DMISH0Z
DMISH0Z	DN	Mogamulizumab
DMISH0Z	HS	Approved
DMISH0Z	CP	Kyowa Hakko Kirin
DMISH0Z	DT	Monoclonal antibody
DMISH0Z	DE	Cutaneous T-cell lymphoma; Solid tumour/cancer; T-cell leukaemia; Sezary syndrome; Mycosis fungoides

DMAH70G	ID	DMAH70G
DMAH70G	DN	Molindone
DMAH70G	HS	Approved
DMAH70G	SN	Molindona; Molindonum; Molindone Monohydrochloride; Molindona [INN-Spanish]; Molindone (INN); Molindone (MOL); Molindone [INN:BAN]; Molindonum [INN-Latin]; (+-)-Molindone; 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one; 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one
DMAH70G	TC	Antipsychotic Agents
DMAH70G	DT	Small molecular drug
DMAH70G	PC	23897
DMAH70G	MW	276.37
DMAH70G	FM	C16H24N2O2
DMAH70G	IC	InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
DMAH70G	CS	CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C
DMAH70G	IK	KLPWJLBORRMFGK-UHFFFAOYSA-N
DMAH70G	IU	3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one
DMAH70G	CA	CAS 7416-34-4
DMAH70G	CB	CHEBI:6965
DMAH70G	DE	Schizophrenia

DM9MA8O	ID	DM9MA8O
DM9MA8O	DN	Molsidomine
DM9MA8O	HS	Approved
DM9MA8O	SN	molsidomine; morsydomine; Corvaton; 25717-80-0; Molsidolat; Motazomin; SIN-10; Sydnopharm; Morial; N-Ethoxycarbonyl-3-morpholinosydnonimine; Molsidominum [INN-Latin]; Molsidomina [INN-Spanish]; Molsidomin; MLS000028573; UNII-D46583G77X; CAS 276; EINECS 247-207-4; BRN 3999414; SMR000058990; Sydnone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)-; N-Carboxy-3-morpholinosydnonimine ethyl ester; N-Carboxy-3-morpholinosydnone imine ethyl ester; N-(Ethoxycarbonyl)-3-(4-morpholino)sydnone imine; Corvasal; Coruno; Sydnone imine, N-carboxy-3-m
DM9MA8O	DT	Small molecular drug
DM9MA8O	PC	5353788
DM9MA8O	MW	242.23
DM9MA8O	FM	C9H14N4O4
DM9MA8O	IC	InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3
DM9MA8O	CS	CCO/C(=N/C1=C[N+](=NO1)N2CCOCC2)/[O-]
DM9MA8O	IK	XLFWDASMENKTKL-UHFFFAOYSA-N
DM9MA8O	IU	(1E)-1-ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate
DM9MA8O	CA	CAS 25717-80-0
DM9MA8O	CB	CHEBI:92623
DM9MA8O	DE	Angina pectoris

DM45OJN	ID	DM45OJN
DM45OJN	DN	Mometasone
DM45OJN	HS	Approved
DM45OJN	SN	Elocom; Mometasona; Mometasonum; Mometasona [Spanish]; Mometasonum [Latin]; Asmanex (TN); Elocon (TN); Mometasone (INN); Nasonex (TN); Twisthaler (TN); (+)-Mometasone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
DM45OJN	CP	Schering-Plough
DM45OJN	TC	Antiinflammatory Agents
DM45OJN	DT	Small molecular drug
DM45OJN	PC	441335
DM45OJN	MW	427.4
DM45OJN	FM	C22H28Cl2O4
DM45OJN	IC	InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
DM45OJN	CS	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)Cl)C
DM45OJN	IK	QLIIKPVHVRXHRI-CXSFZGCWSA-N
DM45OJN	IU	(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DM45OJN	CA	CAS 105102-22-5
DM45OJN	CB	CHEBI:6970
DM45OJN	DE	Skin allergy

DMVJS2K	ID	DMVJS2K
DMVJS2K	DN	Monobenzone
DMVJS2K	HS	Approved
DMVJS2K	SN	Agerite; Alba; Benoquin; Benzoquin; Carmifal; Depigman; Dermochinona; Leucodinine; Monobenzon; Monobenzona; Monobenzonum; PBP; Pigmex; Superlite; Agerite alba; Benzyl hydroquinone; Hydrochinon monobenzylether; Hydrochinon monobenzylether [Czech]; Hydroquinone benzyl ether; Hydroquinone monobenzyl ether; ICN brand of monobenzone; Monobenzone [INN]; Monobenzyl Ether of Hydroquinone; Monobenzyl ether hydroquinone; Monobenzyl hydroquinone; Alba-Dome; Benoquin (TN); Benoquin, Monobenzone; Benzyl p-hydroxyphenyl ether; Carmifal(TN); Depigman (TN); Dermochinona (TN); HYDROQUINONE MONOBENZYL ETHER, N F; Leucodinine (TN); Monobenzon (TN); Monobenzona [INN-Spanish]; Monobenzonum [INN-Latin]; Novo-depigman; P-BENZYLOXYPHENOL; P-Hydroxyphenyl benzyl ether; Pigmex (TN); Superlite (TN); Superlite (antioxidant); Monobenzone (USP/INN); P-(BENZYLOXY)PHENOL; 4-(Benzyl-Oxy)Phenol; 4-(Benzyloxy)phenol; 4-(Benzyloxyl)phenol; 4-(Phenylmethoxy)phenol; 4-Benzyloxyphenol; 4-benzyloxy phenol; 4-phenylmethoxy-phenol; 4-phenylmethoxyphenol
DMVJS2K	TC	Dermatologic Agents
DMVJS2K	DT	Small molecular drug
DMVJS2K	PC	7638
DMVJS2K	MW	200.23
DMVJS2K	FM	C13H12O2
DMVJS2K	IC	InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2
DMVJS2K	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)O
DMVJS2K	IK	VYQNWZOUAUKGHI-UHFFFAOYSA-N
DMVJS2K	IU	4-phenylmethoxyphenol
DMVJS2K	CA	CAS 103-16-2
DMVJS2K	CB	CHEBI:34380
DMVJS2K	DE	Vitiligo

DMD157S	ID	DMD157S
DMD157S	DN	Montelukast
DMD157S	HS	Approved
DMD157S	SN	Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
DMD157S	CP	Schering-Plough Corporation
DMD157S	TC	Antiasthmatic Agents
DMD157S	DT	Small molecular drug
DMD157S	PC	5281040
DMD157S	MW	586.2
DMD157S	FM	C35H36ClNO3S
DMD157S	IC	InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
DMD157S	CS	CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
DMD157S	IK	UCHDWCPVSPXUMX-TZIWLTJVSA-N
DMD157S	IU	2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
DMD157S	CA	CAS 158966-92-8
DMD157S	CB	CHEBI:50730
DMD157S	DE	Asthma

DM560Y3	ID	DM560Y3
DM560Y3	DN	Morantel tartrate
DM560Y3	HS	Approved
DM560Y3	SN	Paratect; Banminth II; MORANTEL TARTRATE SALT; Morantel tartrate [USAN]; Morantel tartrate hydrate; CP 12009-18; Morantel tartrate (USP); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-, tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-,tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-,(R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); (E)-1,4,5,6-Tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)pyrimidine tartrate (1:1); 1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine; 2,3-dihydroxybutanedioic acid
DM560Y3	TC	Anthelmintics
DM560Y3	DT	Small molecular drug
DM560Y3	PC	6433951
DM560Y3	MW	370.4
DM560Y3	FM	C16H22N2O6S
DM560Y3	IC	InChI=1S/C12H16N2S.C4H6O6/c1-10-6-9-15-11(10)4-5-12-13-7-3-8-14(12)2;5-1(3(7)8)2(6)4(9)10/h4-6,9H,3,7-8H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/b5-4+;/t;1-,2-/m.1/s1
DM560Y3	CS	CC1=C(SC=C1)/C=C/C2=NCCCN2C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DM560Y3	IK	GGXQONWGCAQGNA-UUSVNAAPSA-N
DM560Y3	IU	(2R,3R)-2,3-dihydroxybutanedioic acid;1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine
DM560Y3	CA	CAS 26155-31-7
DM560Y3	DE	Mature gastrointestinal nematode infection

DMOMBJW	ID	DMOMBJW
DMOMBJW	DN	Moricizine
DMOMBJW	HS	Approved
DMOMBJW	SN	Moracizin; Moracizina; Moracizine; Moracizinum; Moricizine [USAN]; G 214; EN-313; Moracizina [INN-Spanish]; Moracizine (INN); Moracizinum [INN-Latin]; Moricizine (USAN); Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate; Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate; Ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate; Phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester; Ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate; Ethyl {10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl N-{10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)carbamate; Carbamic acid, (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)-, ethyl ester
DMOMBJW	CP	Shire Development Inc
DMOMBJW	TC	Antiarrhythmic Agents
DMOMBJW	DT	Small molecular drug
DMOMBJW	PC	34633
DMOMBJW	MW	427.5
DMOMBJW	FM	C22H25N3O4S
DMOMBJW	IC	InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)
DMOMBJW	CS	CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4
DMOMBJW	IK	FUBVWMNBEHXPSU-UHFFFAOYSA-N
DMOMBJW	IU	ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate
DMOMBJW	CA	CAS 31883-05-3
DMOMBJW	CB	CHEBI:6997
DMOMBJW	DE	Arrhythmia; Heart arrhythmia

DM9UTDE	ID	DM9UTDE
DM9UTDE	DN	Morniflumate
DM9UTDE	HS	Approved
DM9UTDE	SN	morniflumate; 65847-85-0; UNII-R133MWH7X1; 2-Morpholinoethyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate; R133MWH7X1; Morniflumatum; Morniflumato; 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate; Morniflumate [USAN:INN]; Morniflumatum [INN-Latin]; Morniflumato [INN-Spanish]; Nifluminsaeure 2-morpholinoethylester; UP 164; Morniflumate (USAN); Niflumic acid beta-morpholinoethyl ester; AC1Q4JLB; AC1L2HFJ; DSSTox_RID_97471; DSSTox_CID_31587; DSSTox_GSID_57798; SCHEMBL50683; CHEMBL2105059; DTXSID6057798
DM9UTDE	DT	Small molecular drug
DM9UTDE	PC	72106
DM9UTDE	MW	395.4
DM9UTDE	FM	C19H20F3N3O3
DM9UTDE	IC	InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24)
DM9UTDE	CS	C1COCCN1CCOC(=O)C2=C(N=CC=C2)NC3=CC=CC(=C3)C(F)(F)F
DM9UTDE	IK	LDXSPUSKBDTEKA-UHFFFAOYSA-N
DM9UTDE	IU	2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate
DM9UTDE	CA	CAS 65847-85-0
DM9UTDE	CB	CHEBI:136018
DM9UTDE	DE	Otitis media

DMRMS0L	ID	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	HS	Approved
DMRMS0L	SN	Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr
DMRMS0L	CP	Eurohealth International Sarl
DMRMS0L	TC	Analgesics
DMRMS0L	DT	Small molecular drug
DMRMS0L	PC	5288826
DMRMS0L	MW	285.34
DMRMS0L	FM	C17H19NO3
DMRMS0L	IC	InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
DMRMS0L	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O
DMRMS0L	IK	BQJCRHHNABKAKU-KBQPJGBKSA-N
DMRMS0L	IU	(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
DMRMS0L	CA	CAS 57-27-2
DMRMS0L	CB	CHEBI:17303
DMRMS0L	DE	Chronic pain

DMEJKRF	ID	DMEJKRF
DMEJKRF	DN	Motexafin gadolinium
DMEJKRF	HS	Approved
DMEJKRF	SN	Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)
DMEJKRF	CP	Pharmacyclics, Inc
DMEJKRF	TC	Anticancer Agents
DMEJKRF	DT	Small molecular drug
DMEJKRF	PC	158385
DMEJKRF	MW	1148.4
DMEJKRF	FM	C52H72GdN5O14
DMEJKRF	IC	InChI=1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2
DMEJKRF	CS	CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].[Gd+3]
DMEJKRF	IK	VAZLWPAHMORDGR-UHFFFAOYSA-L
DMEJKRF	IU	3-[4,5-diethyl-24-(3-hydroxypropyl)-16,17-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-10,23-dimethyl-13,20,25,26-tetraza-27-azanidapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1(25),2,4,6,8(26),9,11,13,15,17,19,21,23-tridecaen-9-yl]propan-1-ol;gadolinium(3+);diacetate
DMEJKRF	CA	CAS 246252-06-2
DMEJKRF	DE	Brain cancer; Human immunodeficiency virus infection

DMYKUNR	ID	DMYKUNR
DMYKUNR	DN	Moxalactam Disodium
DMYKUNR	HS	Approved
DMYKUNR	SN	Moxam; Shiomarin
DMYKUNR	CP	Eli Lilly And Co
DMYKUNR	TC	Antiinfective Agents
DMYKUNR	DT	Small molecular drug
DMYKUNR	PC	441242
DMYKUNR	MW	564.4
DMYKUNR	FM	C20H18N6Na2O9S
DMYKUNR	IC	InChI=1S/C20H20N6O9S.2Na/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9;;/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32);;/q;2*+1/p-2/t12?,18-,20+;;/m1../s1
DMYKUNR	CS	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)[O-])OC)OC2)C(=O)[O-].[Na+].[Na+]
DMYKUNR	IK	GRIXGZQULWMCLU-HUTAOCTPSA-L
DMYKUNR	IU	disodium;(6R,7R)-7-[[2-carboxylato-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMYKUNR	CA	CAS 64953-12-4
DMYKUNR	DE	Bacterial infection

DMN63DZ	ID	DMN63DZ
DMN63DZ	DN	Moxetumomab pasudotox
DMN63DZ	HS	Approved
DMN63DZ	SN	CAT-8015; GCR-8015; HA22; UNII-2NDX4B6N8F; Moxetumomab pasudotox [USAN]; Immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 heavy chain variable region fragment) fusion protein with exotoxin PE38 (Pseudomonas fragment), disulfide with immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 light chain fragment)
DMN63DZ	CP	AstraZeneca
DMN63DZ	TC	Anticancer Agents
DMN63DZ	DT	Monoclonal antibody
DMN63DZ	SQ	RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1)
DMN63DZ	DE	Haematological malignancy; Hairy cell leukaemia

DMYGHX5	ID	DMYGHX5
DMYGHX5	DN	Moxidectin 
DMYGHX5	HS	Approved
DMYGHX5	SN	Moxidectin; ProHeart 6; UNII-NGU5H31YO9; Cydectin; NGU5H31YO9; Moxidectine [INN-French]; Moxidectinum [INN-Latin]; Moxidectina [INN-Spanish]; C37H53NO8; Moxidectina; Moxidectine; Moxidectinum; Moxidectin [USAN:INN:BAN]
DMYGHX5	CP	Medicines Development for Global Health
DMYGHX5	PC	9832912
DMYGHX5	MW	639.8
DMYGHX5	FM	C37H53NO8
DMYGHX5	IC	InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1
DMYGHX5	CS	C[C@@H]\\1C/C(=C/C[C@@H]2C[C@@H](C[C@@]3(O2)C/C(=N\\OC)/[C@@H]([C@H](O3)/C(=C/C(C)C)/C)C)OC(=O)[C@@H]4C=C([C@H]([C@@H]5[C@]4(/C(=C/C=C1)/CO5)O)O)C)/C
DMYGHX5	IK	YZBLFMPOMVTDJY-LSGXYNIPSA-N
DMYGHX5	IU	(1R,4S,4'E,5'S,6R,6'S,8R,10E,13R,14E,16E,20R,21R,24S)-21,24-dihydroxy-4'-methoxyimino-5',11,13,22-tetramethyl-6'-[(E)-4-methylpent-2-en-2-yl]spiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
DMYGHX5	CA	CAS 113507-06-5
DMYGHX5	DE	River blindness; Onchocerciasis

DMU8V4S	ID	DMU8V4S
DMU8V4S	DN	Moxifloxacin
DMU8V4S	HS	Approved
DMU8V4S	SN	Avelox; MFX; MXF; MXFX; Vigamox; Avalox (TN); Avelon (TN); Avelox (TN); Moxifloxacin [INN:BAN]; Vigamox (TN); Avelox I.V.; Actira (*Hydrochloride*); Avelox (*Hydrochloride*); (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMU8V4S	CP	Bayer AG
DMU8V4S	TC	Antibiotics
DMU8V4S	DT	Small molecular drug
DMU8V4S	PC	152946
DMU8V4S	MW	401.4
DMU8V4S	FM	C21H24FN3O4
DMU8V4S	IC	InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
DMU8V4S	CS	COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
DMU8V4S	IK	FABPRXSRWADJSP-MEDUHNTESA-N
DMU8V4S	IU	7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMU8V4S	CA	CAS 151096-09-2
DMU8V4S	CB	CHEBI:63611
DMU8V4S	DE	Bacterial infection

DMFCLYW	ID	DMFCLYW
DMFCLYW	DN	Moxisylyte
DMFCLYW	HS	Approved
DMFCLYW	SN	Thymoxamine
DMFCLYW	DT	Small molecular drug
DMFCLYW	PC	4260
DMFCLYW	MW	279.37
DMFCLYW	FM	C16H25NO3
DMFCLYW	IC	InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3
DMFCLYW	CS	CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C
DMFCLYW	IK	VRYMTAVOXVTQEF-UHFFFAOYSA-N
DMFCLYW	IU	[4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] acetate
DMFCLYW	CA	CAS 54-32-0
DMFCLYW	CB	CHEBI:94754
DMFCLYW	DE	Erectile dysfunction

DMGFB0E	ID	DMGFB0E
DMGFB0E	DN	MOXONIDINE
DMGFB0E	HS	Approved
DMGFB0E	SN	BDF-5895; BE-5895; Normoxin; AC1OCENE; SCHEMBL1230620; Moxonidine hydrochloride hydrate; moxonidine hydrochloride monohydrate; LY-326869; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine hydrate hydrochloride
DMGFB0E	DT	Small molecular drug
DMGFB0E	PC	4810
DMGFB0E	MW	241.68
DMGFB0E	FM	C9H12ClN5O
DMGFB0E	IC	InChI=1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)
DMGFB0E	CS	CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC
DMGFB0E	IK	WPNJAUFVNXKLIM-UHFFFAOYSA-N
DMGFB0E	IU	4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine
DMGFB0E	CA	CAS 75438-57-2
DMGFB0E	CB	CHEBI:7009
DMGFB0E	DE	Alcohol dependence

DMZ905C	ID	DMZ905C
DMZ905C	DN	Mozavaptan
DMZ905C	HS	Approved
DMZ905C	SN	137975-06-5; Opc-31260; Opc 31260; Mozavaptan [INN]; CHEMBL420762; OPC31260; 5-Dimethylamino-1-(4-(2-methylbenzoylamino)benzoyl)-2,3,4,5-tetrahydro-1H-benzazepine; N-(4-(5-(dimethylamino)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-2-methylbenzamide; N-(4-((5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; N-(4-(((5RS)-5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; C27H29N3O2; OPC-31260
DMZ905C	DT	Small molecular drug
DMZ905C	PC	119369
DMZ905C	MW	427.5
DMZ905C	FM	C27H29N3O2
DMZ905C	IC	InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
DMZ905C	CS	CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
DMZ905C	IK	WRNXUQJJCIZICJ-UHFFFAOYSA-N
DMZ905C	IU	N-[4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]phenyl]-2-methylbenzamide
DMZ905C	CA	CAS 137975-06-5
DMZ905C	CB	CHEBI:135694
DMZ905C	DE	Hyponatraemia

DMWX683	ID	DMWX683
DMWX683	DN	Mupirocin
DMWX683	HS	Approved
DMWX683	SN	Bactoderm; Bactroban; Centany; MRC; Mupirocina; Mupirocine; Mupirocinum; Plasimine; Bactroban Nasal; Mupirocina [Spanish]; Mupirocine [French]; Mupirocinum [Latin]; Pseudomonic acid; Pseudomonic acid A; BRL 4910A; BRL-4910A; Bactroban (TN); Centany (TN); Mupirocin (USP/INN); Mupirocin, 14C-Labeled; 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S); 8-Carboxyoctyl (E)-4-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2H-pyran-2-yl)-3-methylcrotonat; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
DMWX683	CP	GlaxoSmithKline
DMWX683	TC	Antibiotics
DMWX683	DT	Small molecular drug
DMWX683	PC	446596
DMWX683	MW	500.6
DMWX683	FM	C26H44O9
DMWX683	IC	InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1
DMWX683	CS	C[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)C/C(=C/C(=O)OCCCCCCCCC(=O)O)/C)[C@H](C)O
DMWX683	IK	MINDHVHHQZYEEK-HBBNESRFSA-N
DMWX683	IU	9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
DMWX683	CA	CAS 12650-69-0
DMWX683	CB	CHEBI:7025
DMWX683	DE	Bacterial infection

DM8ANCF	ID	DM8ANCF
DM8ANCF	DN	Muromonab
DM8ANCF	HS	Approved
DM8ANCF	TC	Immunomodulatory Agents
DM8ANCF	SQ	Muromonab-CD3 light chain: QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINRADTAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC</sequence>    <sequence format="FASTA">&gt;Muromonab-CD3 heavy chainQVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSAKTTAPSVYPLAPVCGGTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DM8ANCF	DE	Organ transplant rejection

DMPQAGE	ID	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	HS	Approved
DMPQAGE	SN	mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; RS-61443; Munoloc; Mycophenolic acid morpholinoethyl ester; TM-MMF; Mycophenylate mofetil; Mycophenolatemofetil; UNII-9242ECW6R0; HSDB 7436; Cellcept (TN); 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; CHEBI:8764; C23H31NO7; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Myfenax; RS-61443-190;  CellCept; MMF; CellCept (TN); ME-MPA; MMF CellCept(TM); R-99; Mycophenolate mofetil (JAN/USAN); CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
DMPQAGE	CP	Roche
DMPQAGE	TC	Immunosuppressive Agents
DMPQAGE	DT	Small molecular drug
DMPQAGE	PC	5281078
DMPQAGE	MW	433.5
DMPQAGE	FM	C23H31NO7
DMPQAGE	IC	InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
DMPQAGE	CS	CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)OCCN3CCOCC3)O
DMPQAGE	IK	RTGDFNSFWBGLEC-SYZQJQIISA-N
DMPQAGE	IU	2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
DMPQAGE	CA	CAS 128794-94-5
DMPQAGE	CB	CHEBI:8764
DMPQAGE	DE	Organ transplant rejection; Immune System disease; Pemphigus vulgaris

DMRBMAU	ID	DMRBMAU
DMRBMAU	DN	Mycophenolic acid
DMRBMAU	HS	Approved
DMRBMAU	SN	Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; mycophenolic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; Lilly-68618; Ly 68618; Melbex; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 24280-93-1; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; CCRIS 5565; NSC 129185; NSC-129185; UNII-HU9DX48N0T
DMRBMAU	PC	446541
DMRBMAU	MW	320.3
DMRBMAU	FM	C17H20O6
DMRBMAU	IC	HPNSFSBZBAHARI-RUDMXATFSA-N
DMRBMAU	CS	CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O
DMRBMAU	IK	1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
DMRBMAU	IU	(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
DMRBMAU	CA	CAS 483-60-3
DMRBMAU	CB	CHEBI:168396
DMRBMAU	DE	Crohn disease

DMYTN18	ID	DMYTN18
DMYTN18	DN	Mycophenolic acid
DMYTN18	HS	Approved
DMYTN18	SN	(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; CCRIS 5565; Lilly-68618; Ly 68618; Melbex; Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; NSC 129185; NSC-129185; UNII-HU9DX48N0T; mycophenolic acid
DMYTN18	DT	Small molecular drug
DMYTN18	PC	446541
DMYTN18	MW	320.341
DMYTN18	FM	C17H20O6
DMYTN18	IC	InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
DMYTN18	CS	CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)O)OC
DMYTN18	IK	HPNSFSBZBAHARI-RUDMXATFSA-N
DMYTN18	IU	(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
DMYTN18	CA	CAS 483-60-3
DMYTN18	CB	CHEBI:168396
DMYTN18	DE	Organ transplant rejection

DMSOAJ2	ID	DMSOAJ2
DMSOAJ2	DN	N-0923
DMSOAJ2	HS	Approved
DMSOAJ2	SN	ent-Rotigotine; 92206-54-7; N-0437; 6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; 112835-48-0; 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-; 2-(N-n-Propyl-N-2-thienylethylamino)-5-hydroxytetralin; PubChem16422; AC1Q7ALS; rotigotine transdermal patch; AC1L1N7C; SCHEMBL50425; CHEMBL104383; CTK8E7910
DMSOAJ2	CP	National Cancer Institute (NCI)
DMSOAJ2	DT	Small molecular drug
DMSOAJ2	PC	57537
DMSOAJ2	MW	315.5
DMSOAJ2	FM	C19H25NOS
DMSOAJ2	IC	InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3
DMSOAJ2	CS	CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
DMSOAJ2	IK	KFQYTPMOWPVWEJ-UHFFFAOYSA-N
DMSOAJ2	IU	6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMSOAJ2	CA	CAS 92206-54-7
DMSOAJ2	DE	Parkinson disease

DMHJVOL	ID	DMHJVOL
DMHJVOL	DN	Nabi-HB
DMHJVOL	HS	Approved
DMHJVOL	SN	Reformulated HBV therapy, Nabi; Hepatitis B virus immune globulin (intramuscular), Nabi; H-BIG 5%iv formulation, Nabi
DMHJVOL	CP	Nabi Biologics
DMHJVOL	DE	Hepatitis B virus infection

DMVRYT2	ID	DMVRYT2
DMVRYT2	DN	Nabilone
DMVRYT2	HS	Approved
DMVRYT2	SN	Nabilone; Nabilona; Nabilonum; Cesamet; 51022-71-0; CHEMBL947; GECBBEABIDMGGL-RTBURBONSA-N; Nabilonum [Latin]; Nabilona [Spanish]; Nabilone [USAN:INN:BAN]; DEA No. 7379; Nabilon; CPD 109514; CPD-109514; 9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-; 9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-
DMVRYT2	DT	Small molecular drug
DMVRYT2	PC	5284592
DMVRYT2	MW	372.5
DMVRYT2	FM	C24H36O3
DMVRYT2	IC	InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1
DMVRYT2	CS	CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=O)CC[C@H]3C(OC2=C1)(C)C)O
DMVRYT2	IK	GECBBEABIDMGGL-RTBURBONSA-N
DMVRYT2	IU	(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one
DMVRYT2	CA	CAS 51022-71-0
DMVRYT2	DE	Insomnia

DMAT2XH	ID	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	HS	Approved
DMAT2XH	SN	NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex
DMAT2XH	CP	Nobex Corp
DMAT2XH	DT	Small molecular drug
DMAT2XH	PC	4409
DMAT2XH	MW	228.29
DMAT2XH	FM	C15H16O2
DMAT2XH	IC	InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
DMAT2XH	CS	CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
DMAT2XH	IK	BLXXJMDCKKHMKV-UHFFFAOYSA-N
DMAT2XH	IU	4-(6-methoxynaphthalen-2-yl)butan-2-one
DMAT2XH	CA	CAS 42924-53-8
DMAT2XH	CB	CHEBI:7443
DMAT2XH	DE	Pain

DM1XBWR	ID	DM1XBWR
DM1XBWR	DN	N-acetyl-D-glucosamine
DM1XBWR	HS	Approved
DM1XBWR	SN	Aflexa; GlcNAc; NAcGlc; NDG; Crab Shell Chitin; Glucosamine Complex; Maxi GS; Natures Blend Glucosamine; Pharmaceutical aid; JFD00446; SB01966; GS-500; N-Acetylchitosamine; N-Acetylchondrosamine; N-Acetylgalactosamine; N-Acetylhexosamine; Glucosamine, N-acetyl; N-Acetyl-D-Allosamine; N-Acetyl-D-galactosamine; N-Acetyl-D-hexosamine; N-acetyl-D-mannosamine; N-Acetyl-D-glucosamine-Agarose; N-Acetyl-alpha-D-glucosamine; N-acetyl-alpha-D-glucosaminides; N-[2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; 2-(Acetylamino)-2-deoxyhexopyranose; 2-ACETAMIDO-2-DEOXY-D-ALLOSE; 2-Acetamido-2-deoxy-D-glucose; 2-Acetamido-2-deoxyglucose; 2-Acetamido-D-glucose; 2-acetamido-2-deoxy-D-glucopyranose; 2-acetamido-2-deoxyhexopyranose; 6-Acetamido-6-deoxy-.alpha.-D-glucopyranose; 6-Acetamido-6-deoxy-acpha-D-glucopyranose
DM1XBWR	TC	Antiinflammatory Agents
DM1XBWR	DT	Small molecular drug
DM1XBWR	PC	439174
DM1XBWR	MW	221.21
DM1XBWR	FM	C8H15NO6
DM1XBWR	IC	InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8?/m1/s1
DM1XBWR	CS	CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O
DM1XBWR	IK	OVRNDRQMDRJTHS-RTRLPJTCSA-N
DM1XBWR	IU	N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DM1XBWR	CA	CAS 72-87-7
DM1XBWR	CB	CHEBI:506227
DM1XBWR	DE	Autoimmune diabetes

DM5NM6E	ID	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	HS	Approved
DM5NM6E	SN	DPNH; Dihydrodiphosphopyridine nucleotide; Dihydronicotinamide adenine dinucleotide; Diphosphopyridine nucleotide reduced; NADH dianion; Nicotinamide adenine dinucleotide reduced; Reduced Nicotinamide Adenine Dinucleotide; NADH2; Beta-DPNH; Beta-NADH; Coenzyme I, reduced; Cozymase I, reduced; Diphosphopyridine nucleotide,reduced form; NAD-reduced; Nicotinamide adenine dinucleotide, reduced form; Reduced nicotinamide-adenine dinucleotide; Beta-Nicotinamide adenine dinucleotide, reduced dipotassium salt; NADH+H+; Nicotinaminde-Adenine-Dinucleotide; Adenosine pyrophosphate, 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (7CI); Adenosine 5'-(trihydrogen pyrophosphate), 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (8CI); Adenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide (9CI); Adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] dihydrogen diphosphate}; Adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] diphosphate}; [5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-[[(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-phosphinic acid
DM5NM6E	TC	Dietary supplement
DM5NM6E	DT	Small molecular drug
DM5NM6E	PC	439153
DM5NM6E	MW	665.4
DM5NM6E	FM	C21H29N7O14P2
DM5NM6E	IC	InChI=1S/C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1
DM5NM6E	CS	C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O
DM5NM6E	IK	BOPGDPNILDQYTO-NNYOXOHSSA-N
DM5NM6E	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM5NM6E	CA	CAS 58-68-4
DM5NM6E	CB	CHEBI:16908
DM5NM6E	DE	Parkinson disease

DMW6GVL	ID	DMW6GVL
DMW6GVL	DN	Nadolol
DMW6GVL	HS	Approved
DMW6GVL	SN	Anabet; Corgard; Corgaretic; Nadic; Nadololum; Solgol; SQ 11725; SQ11725; Anabet (TN); Corgard (TN); Corzide (TN); Nadololum [INN-Latin]; SQ-11725; Solgol (TN); Alti-Nadolol (TN); Apo-Nadol (TN); Novo-Nadolol (TN); Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol
DMW6GVL	CP	Apotex Inc
DMW6GVL	TC	Antihypertensive Agents
DMW6GVL	DT	Small molecular drug
DMW6GVL	PC	39147
DMW6GVL	MW	309.4
DMW6GVL	FM	C17H27NO4
DMW6GVL	IC	InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
DMW6GVL	CS	CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O
DMW6GVL	IK	VWPOSFSPZNDTMJ-UCWKZMIHSA-N
DMW6GVL	IU	(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
DMW6GVL	CA	CAS 220045-89-6
DMW6GVL	DE	High blood pressure

DMBNKST	ID	DMBNKST
DMBNKST	DN	Nadroparin calcium
DMBNKST	HS	Approved
DMBNKST	SN	Fraxiparine (TN)
DMBNKST	DE	Coagulation defect

DMU1XOD	ID	DMU1XOD
DMU1XOD	DN	Nafamostat
DMU1XOD	HS	Approved
DMU1XOD	SN	FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum
DMU1XOD	DT	Small molecular drug
DMU1XOD	PC	4413
DMU1XOD	MW	347.4
DMU1XOD	FM	C19H17N5O2
DMU1XOD	IC	InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
DMU1XOD	CS	C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
DMU1XOD	IK	MQQNFDZXWVTQEH-UHFFFAOYSA-N
DMU1XOD	IU	(6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
DMU1XOD	CA	CAS 81525-10-2
DMU1XOD	CB	CHEBI:135466
DMU1XOD	DE	Pancreatitis; Sepsis

DMAHEFY	ID	DMAHEFY
DMAHEFY	DN	Nafarelin
DMAHEFY	HS	Approved
DMAHEFY	SN	Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig)
DMAHEFY	CP	Pfizer Pharmaceuticals
DMAHEFY	TC	Fertility Agents
DMAHEFY	DT	Small molecular drug
DMAHEFY	PC	25077405
DMAHEFY	MW	1322.5
DMAHEFY	FM	C66H83N17O13
DMAHEFY	IC	InChI=1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1
DMAHEFY	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
DMAHEFY	IK	RWHUEXWOYVBUCI-ITQXDASVSA-N
DMAHEFY	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMAHEFY	CA	CAS 76932-56-4
DMAHEFY	DE	Endometriosis

DMN9RPO	ID	DMN9RPO
DMN9RPO	DN	Nafcillin
DMN9RPO	HS	Approved
DMN9RPO	SN	Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMN9RPO	TC	Antibiotics
DMN9RPO	DT	Small molecular drug
DMN9RPO	PC	8982
DMN9RPO	MW	414.5
DMN9RPO	FM	C21H22N2O5S
DMN9RPO	IC	InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1
DMN9RPO	CS	CCOC1=C(C2=CC=CC=C2C=C1)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMN9RPO	IK	GPXLMGHLHQJAGZ-JTDSTZFVSA-N
DMN9RPO	IU	(2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMN9RPO	CA	CAS 147-52-4
DMN9RPO	CB	CHEBI:7447
DMN9RPO	DE	Arthritis

DMVMQ1L	ID	DMVMQ1L
DMVMQ1L	DN	Nafronyl
DMVMQ1L	HS	Approved
DMVMQ1L	SN	Nafronyl oxalate; 3200-06-4; Naftidrofuryl oxalate; Nafronyl oxalate salt; 2-(Diethylamino)ethyl 3-(naphthalen-1-yl)-2-((tetrahydrofuran-2-yl)methyl)propanoate oxalate; Naftidrofuryl (oxalate); Dusodril; Dubimax; Praxilene; Iridus; LS-121; EU-1806; DSSTox_RID_80935; DSSTox_CID_25533; DSSTox_GSID_45533; naftidrofuryl hydrogen oxalate; CHEMBL1439099; alpha-[1-Naphthylmethyl]-2-tetrahydrofuranpropionic acid diethylaminoethyl ester; SMR000539007; Nafronyl oxalate salt, analytical standard; CAS-3200-06-4; NSC225233; LS 121
DMVMQ1L	DT	Small molecular drug
DMVMQ1L	PC	4417
DMVMQ1L	MW	383.5
DMVMQ1L	FM	C24H33NO3
DMVMQ1L	IC	InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3
DMVMQ1L	CS	CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32
DMVMQ1L	IK	KBAFPSLPKGSANY-UHFFFAOYSA-N
DMVMQ1L	IU	2-(diethylamino)ethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate
DMVMQ1L	CA	CAS 31329-57-4
DMVMQ1L	CB	CHEBI:91817
DMVMQ1L	DE	Cerebrovascular ischaemia

DMHVBG1	ID	DMHVBG1
DMHVBG1	DN	Naftifine
DMHVBG1	HS	Approved
DMHVBG1	SN	Naftifin; Naftifina; Naftifinum; Naftifine HCl; Naftifina [INN-Spanish]; Naftifine (INN); Naftifine [INN:BAN]; Naftifinum[INN-Latin]; Naftin (TN); SN 105-843; N-cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride; N-Methyl-N-(1-naphthyl methyl)-3-phenyl-2-propen-1-amine(E), hydrochloride; (2E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine; (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine; (E)-N-Cinnamyl-N-methyl-1-naphthalinmethylamin; (E)-N-Cinnamyl-N-methyl-1-naphthylmethylamin; (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
DMHVBG1	CP	Merz Pharmaceuticals Llc
DMHVBG1	TC	Antifungal Agents
DMHVBG1	DT	Small molecular drug
DMHVBG1	PC	47641
DMHVBG1	MW	287.4
DMHVBG1	FM	C21H21N
DMHVBG1	IC	InChI=1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3/b11-8+
DMHVBG1	CS	CN(C/C=C/C1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32
DMHVBG1	IK	OZGNYLLQHRPOBR-DHZHZOJOSA-N
DMHVBG1	IU	(E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
DMHVBG1	CA	CAS 65472-88-0
DMHVBG1	CB	CHEBI:7451
DMHVBG1	DE	Dermatomycosis

DMQ8R4E	ID	DMQ8R4E
DMQ8R4E	DN	Naftopidil
DMQ8R4E	HS	Approved
DMQ8R4E	SN	naftopidil; 57149-07-2; Flivas; KT-611; Naftopidil [INN]; Avishot; Naftopidilum [Latin]; Naftopidil (Flivas); BM-15275; Naftopidil (unspecified); BRN 0629965; CHEMBL142635; C24H28N2O3; 1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol; NCGC00015718-06; (+-)-1-(4-(2-Methoxyphenyl)piperazinyl)-3-(1-naphthyloxy)propan-2-ol; 4-(2-Methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)-1-pioerazineethanol; (RS)-1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol; DSSTox_RID_80725; DSSTox_CID_25176
DMQ8R4E	DT	Small molecular drug
DMQ8R4E	PC	4418
DMQ8R4E	MW	392.5
DMQ8R4E	FM	C24H28N2O3
DMQ8R4E	IC	InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3
DMQ8R4E	CS	COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O
DMQ8R4E	IK	HRRBJVNMSRJFHQ-UHFFFAOYSA-N
DMQ8R4E	IU	1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol
DMQ8R4E	CA	CAS 57149-07-2
DMQ8R4E	CB	CHEBI:31891
DMQ8R4E	DE	Hypertension

DMOSQGU	ID	DMOSQGU
DMOSQGU	DN	Nalbuphine
DMOSQGU	HS	Approved
DMOSQGU	SN	Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol
DMOSQGU	CP	Endo Pharmaceuticals
DMOSQGU	TC	Analgesics
DMOSQGU	DT	Small molecular drug
DMOSQGU	PC	5311304
DMOSQGU	MW	357.4
DMOSQGU	FM	C21H27NO4
DMOSQGU	IC	InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1
DMOSQGU	CS	C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O
DMOSQGU	IK	NETZHAKZCGBWSS-CEDHKZHLSA-N
DMOSQGU	IU	(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
DMOSQGU	CA	CAS 20594-83-6
DMOSQGU	CB	CHEBI:7454
DMOSQGU	DE	Prurigo nodularis; Uremic pruritus; Pain

DMGD3YH	ID	DMGD3YH
DMGD3YH	DN	Naldemedine Tosylate
DMGD3YH	HS	Approved
DMGD3YH	CP	Shionogi
DMGD3YH	DT	Small molecular drug
DMGD3YH	PC	56837137
DMGD3YH	MW	742.8
DMGD3YH	FM	C39H42N4O9S
DMGD3YH	IC	InChI=1S/C32H34N4O6.C7H8O3S/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17;1-6-2-4-7(5-3-6)11(8,9)10/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39);2-5H,1H3,(H,8,9,10)/t22-,26+,31+,32-;/m1./s1
DMGD3YH	CS	CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O
DMGD3YH	IK	WCYDLROFMZJJLE-RTMHEQJQSA-N
DMGD3YH	IU	(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide;4-methylbenzenesulfonic acid
DMGD3YH	CA	CAS 1345728-04-2
DMGD3YH	DE	Opioid-induced constipation

DMA9DHW	ID	DMA9DHW
DMA9DHW	DN	Nalfurafine hcl
DMA9DHW	HS	Approved
DMA9DHW	SN	Nalfurafine hydrochloride; Nalfurafine HCl; TRK-820; Remitch; Nalfurafine (hydrochloride); 152658-17-8; UNII-25CC4N0P8J; 25CC4N0P8J; CHEMBL490665; AC 820; Nalfurafine hydrochloride [USAN:JAN]; (-)-17-(Cyclopropylmethyl)-3,14; A-dihydroxy-4,5; A-epoxy-6; A-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan Hydrochloride; (2E)-N-[(5; A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide Hydrochloride; SCHEMBL19856501; DTXSID70426071; DJSFYNINGIMKAG-FQJQBBMWSA-N; BCP15625; Remitch (TN)
DMA9DHW	DT	Small molecular drug
DMA9DHW	PC	6918287
DMA9DHW	MW	513
DMA9DHW	FM	C28H33ClN2O5
DMA9DHW	IC	InChI=1S/C28H32N2O5.ClH/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17;/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3;1H/b7-4+;/t20-,22-,26+,27+,28-;/m1./s1
DMA9DHW	CS	CN([C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)/C=C/C7=COC=C7.Cl
DMA9DHW	IK	DJSFYNINGIMKAG-FQJQBBMWSA-N
DMA9DHW	IU	(E)-N-[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]-3-(furan-3-yl)-N-methylprop-2-enamide;hydrochloride
DMA9DHW	CA	CAS 152658-17-8
DMA9DHW	DE	Uremic pruritus

DMRM0JV	ID	DMRM0JV
DMRM0JV	DN	Nalidixic acid
DMRM0JV	HS	Approved
DMRM0JV	SN	Betaxina; Cybis; Dixiben; Dixinal; Eucistin; Innoxalon; Jicsron; Kusnarin; Nalidicron; Nalidixan; Nalidixane; Nalidixate; Nalidixic; Nalidixin; Nalitucsan; Nalix; Nalurin; Narigix; Naxuril; NegGram; Negram; Nevigramon; Nicelate; Nogram; Poleon; Sicmylon; Specifen; Specifin; Unaserus; Uralgin; Uriben; Uriclar; Urisal; Urodixin; Uroman; Uroneg; Uronidix; Uropan; Wintomylon; Wintron; Acide nalidixico; Acide nalidixico [Italian]; Acide nalidixique; Acide nalidixique [French]; Acido nalidissico; Acido nalidissico [DCIT]; Acido nalidixico; Acidum nalidixicum; NALIDIXATE SODIUM; Naladixic acid; Naldixic acid; Nalidic acid; Nalidixinic acid; Nalidixic acid USP27; WIN 183203; Acid, Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; N-1200; NegGram (TN); Neggram (TN); Sodium Nalidixic Acid, Anhydrous; Sodium Nalidixic Acid, Monohydrate; Sodium,Nalidixate; WIN 18,320; WIN-18320; Wil 18,320; Wintomylon (TN); ZERO/002632; WIN-18320 (TN); Nalidixic acid (JP15/USP/INN); Nalidixic acid [USAN:INN:BAN:JAN]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one
DMRM0JV	TC	Antibiotics
DMRM0JV	DT	Small molecular drug
DMRM0JV	PC	4421
DMRM0JV	MW	232.23
DMRM0JV	FM	C12H12N2O3
DMRM0JV	IC	InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
DMRM0JV	CS	CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O
DMRM0JV	IK	MHWLWQUZZRMNGJ-UHFFFAOYSA-N
DMRM0JV	IU	1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMRM0JV	CA	CAS 389-08-2
DMRM0JV	CB	CHEBI:100147
DMRM0JV	DE	Urinary tract infection

DM4YWCZ	ID	DM4YWCZ
DM4YWCZ	DN	Nalmefene
DM4YWCZ	HS	Approved
DM4YWCZ	SN	Alcofene; Arthene; Cervene; Cessal; Incystene; Nalmefeno; Nalmefenum; Nalmetrene; Nalmetreno; Nalmetrenum; Revex; Soberal; JF 1; ORF 11676; JF-1; NIH-10365; Nalmefeno [INN-Spanish]; Nalmefenum [INN-Latin]; Nalmetreno [INN-Spanish]; Nalmetrenum [INN-Latin]; ORF-11676; Revex (TN); Nalmefene (USAN/INN); Nalmefene [USAN:BAN:INN]; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; 6-Desoxy-6-methylenenaltrexone; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol
DM4YWCZ	CP	Eurohealth International Sarl
DM4YWCZ	TC	Anticraving Agents
DM4YWCZ	DT	Small molecular drug
DM4YWCZ	PC	5284594
DM4YWCZ	MW	339.4
DM4YWCZ	FM	C21H25NO3
DM4YWCZ	IC	InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1
DM4YWCZ	CS	C=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O
DM4YWCZ	IK	WJBLNOPPDWQMCH-MBPVOVBZSA-N
DM4YWCZ	IU	(4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DM4YWCZ	CA	CAS 55096-26-9
DM4YWCZ	CB	CHEBI:7457
DM4YWCZ	DE	Opioid dependence

DML0B41	ID	DML0B41
DML0B41	DN	Naloxegol
DML0B41	HS	Approved
DML0B41	SN	NKTR-118
DML0B41	CP	AstraZeneca
DML0B41	DT	Small molecular drug
DML0B41	PC	56959087
DML0B41	MW	651.8
DML0B41	FM	C34H53NO11
DML0B41	IC	InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1
DML0B41	CS	COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC=C)O
DML0B41	IK	XNKCCCKFOQNXKV-ZRSCBOBOSA-N
DML0B41	IU	(4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DML0B41	CA	CAS 854601-70-0
DML0B41	CB	CHEBI:82975
DML0B41	DE	Opioid-induced constipation

DM3FXMA	ID	DM3FXMA
DM3FXMA	DN	Naloxone
DM3FXMA	HS	Approved
DM3FXMA	SN	Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one
DM3FXMA	CP	Bristol Meyers Squibb
DM3FXMA	TC	Antinarcotic Agents
DM3FXMA	DT	Small molecular drug
DM3FXMA	PC	5284596
DM3FXMA	MW	327.4
DM3FXMA	FM	C19H21NO4
DM3FXMA	IC	InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
DM3FXMA	CS	C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
DM3FXMA	IK	UZHSEJADLWPNLE-GRGSLBFTSA-N
DM3FXMA	IU	(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM3FXMA	CA	CAS 465-65-6
DM3FXMA	CB	CHEBI:7459
DM3FXMA	DE	Narcotic depression; Opioid dependence; Respiratory depression; Pruritus

DMUL45H	ID	DMUL45H
DMUL45H	DN	Naltrexone
DMUL45H	HS	Approved
DMUL45H	SN	Depotrex; Naltrel; Vivitrex; Vivitrol; Naltrexone Depot; IBS therapy, Pain Therapeutics; Irritable bowel syndrome therapy, Pain Therapeutics; PTI-901; XR-NTX; Naltrexone (sustained release), DAS; Naltrexone (sustained release), elbion; Naltrexone depot (injectable suspension), DrugAbuse Sciences; Naltrexone depot (injectable suspension), elbion; Opioid antagonists (irritable bowel syndrome), Pain Therapeutics; Naltrexone (low-dose), Pain Therapeutics; Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek; Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma; Naltrexone (once-monthly controlled-release, Medisorb), Alkermes
DMUL45H	CP	Tni biotech; DrugAbuse Sciences; Alkermes Inc
DMUL45H	DT	Small molecular drug
DMUL45H	PC	5360515
DMUL45H	MW	341.4
DMUL45H	FM	C20H23NO4
DMUL45H	IC	InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
DMUL45H	CS	C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
DMUL45H	IK	DQCKKXVULJGBQN-XFWGSAIBSA-N
DMUL45H	IU	(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMUL45H	CA	CAS 16590-41-3
DMUL45H	CB	CHEBI:7465
DMUL45H	DE	Alcohol dependence; Human immunodeficiency virus infection

DMFWKG1	ID	DMFWKG1
DMFWKG1	DN	Nandrolone
DMFWKG1	HS	Approved
DMFWKG1	SN	Decadura; Estrenolone; Menidrabol; Nadrolone; Nandrolon; Nandrolona; Nandrolonum; Norandrostenolon;Norandrostenolone; Nortestonate; Nortestosterone; Nortestosteronum; Oestrenolon; LT03330030; U 2410; Decadura (TN); Durabolin (TN); Nandrolona [INN-Spanish]; Nandrolone (INN); Nandrolonum [INN-Latin]; Estr-4-en-3-one, 17beta-hydroxy-(8CI); Estr-4-en-3-one, 17-hydroxy-, (17beta)-(9CI); Estr-4-en-3-one, 17-hydroxy-, (17-beta)-(9CI); (17-beta)-17-Hydroxyestr-4-en-3-one; (17beta)-17-hydroxyestr-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-Estr-4-Ene-3-One; 17-beta-Hydroestr-4-en-3-one; 17beta-Hydroxy-19-nor-4-androsten-3-one; 17beta-Hydroxy-19-norandrost-4-en-3-one; 17beta-Hydroxy-4-estren-3-one; 17beta-hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxy-4-estren-3-one; 17beta-hydroxyestr-4-en-3-one; 19-Norandrostenolone; 19-Nortestosterone; 4-Estren-17beta-ol-3-one; 4-estren-17beta-ol-3-one
DMFWKG1	CP	Aspen Global Inc
DMFWKG1	TC	Anabolic Agents
DMFWKG1	DT	Small molecular drug
DMFWKG1	PC	9904
DMFWKG1	MW	274.4
DMFWKG1	FM	C18H26O2
DMFWKG1	IC	InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1
DMFWKG1	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34
DMFWKG1	IK	NPAGDVCDWIYMMC-IZPLOLCNSA-N
DMFWKG1	IU	(8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
DMFWKG1	CA	CAS 434-22-0
DMFWKG1	CB	CHEBI:7466
DMFWKG1	DE	Osteoporosis

DMJFZDL	ID	DMJFZDL
DMJFZDL	DN	Naphazoline
DMJFZDL	HS	Approved
DMJFZDL	SN	Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole
DMJFZDL	CP	Allergan Inc
DMJFZDL	TC	Anticancer Agents
DMJFZDL	DT	Small molecular drug
DMJFZDL	PC	4436
DMJFZDL	MW	210.27
DMJFZDL	FM	C14H14N2
DMJFZDL	IC	InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)
DMJFZDL	CS	C1CN=C(N1)CC2=CC=CC3=CC=CC=C32
DMJFZDL	IK	CNIIGCLFLJGOGP-UHFFFAOYSA-N
DMJFZDL	IU	2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole
DMJFZDL	CA	CAS 835-31-4
DMJFZDL	CB	CHEBI:93363
DMJFZDL	DE	Itching; Hyperaemia

DMZ5RGV	ID	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	HS	Approved
DMZ5RGV	SN	NAPROXEN; 22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex
DMZ5RGV	CP	Iroko pharmaceuticals; PLx Pharma; CeNeS Pharmaceuticals plc
DMZ5RGV	DT	Small molecular drug
DMZ5RGV	PC	156391
DMZ5RGV	MW	230.26
DMZ5RGV	FM	C14H14O3
DMZ5RGV	IC	InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
DMZ5RGV	CS	C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
DMZ5RGV	IK	CMWTZPSULFXXJA-VIFPVBQESA-N
DMZ5RGV	IU	(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
DMZ5RGV	CA	CAS 22204-53-1
DMZ5RGV	CB	CHEBI:7476
DMZ5RGV	DE	Osteoarthritis; Endometriosis; Pain

DMO50U2	ID	DMO50U2
DMO50U2	DN	Naratriptan
DMO50U2	HS	Approved
DMO50U2	SN	Colatan; Naramig; Naratriptanum; Amerge (TN); Naramig (TN); Naratriptan (INN); Amerge, Naramig,Naratriptan; N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide; N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide; N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
DMO50U2	CP	GlaxoSmithKline
DMO50U2	TC	Vasoconstrictor Agents
DMO50U2	DT	Small molecular drug
DMO50U2	PC	4440
DMO50U2	MW	335.5
DMO50U2	FM	C17H25N3O2S
DMO50U2	IC	InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3
DMO50U2	CS	CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
DMO50U2	IK	AMKVXSZCKVJAGH-UHFFFAOYSA-N
DMO50U2	IU	N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
DMO50U2	CA	CAS 121679-13-8
DMO50U2	CB	CHEBI:7478
DMO50U2	DE	Migraine

DMFEHXD	ID	DMFEHXD
DMFEHXD	DN	Natamycin
DMFEHXD	HS	Approved
DMFEHXD	SN	Delvocid; Delvolan; Delvopos; Mycophyt; Myprozine; Natacyn; Natafucin; Natamicina; Natamycine; Natamycinum; Pimafucin; Pimaricin; Pimaricine; Pimarizin; Synogil; Tennecetin; Natamycin preparation; Pimaricin preparation; Pimarizin [German]; CL 12625; Antibiotic A-5283; CL 12,625; CL-12625; Natacyn (TN); Natamicina [INN-Spanish]; Natamycine [INN-French]; Natamycinum [INN-Latin]; Pimaricin (JP15); Natamycin (USP/INN); Natamycin [USAN:INN:BAN]; Stereoisomer of 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.0(sup 5,7))octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; 16-(3-Amino-3,6-didesoxy-beta-D-mannopyranosyloxy)-5,6-epoxy-8,12,14-trihydroxy-26-methyl-2,10-dioxo-1-oxacyclohexacosa-3,17,19,21,23-pentaen-13-carbonsaeure; 6,11,28-Trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 22-[(3-amino-3,6-dideoxy-.beta.-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-, (1R,3S,5R,7R,8E,12R,14
DMFEHXD	TC	Antifungal Agents
DMFEHXD	DT	Small molecular drug
DMFEHXD	PC	5284447
DMFEHXD	MW	665.7
DMFEHXD	FM	C33H47NO13
DMFEHXD	IC	InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32+,33-/m1/s1
DMFEHXD	CS	C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O
DMFEHXD	IK	NCXMLFZGDNKEPB-FFPOYIOWSA-N
DMFEHXD	IU	(1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
DMFEHXD	CA	CAS 7681-93-8
DMFEHXD	DE	Conjunctivitis

DMLK2QH	ID	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	HS	Approved
DMLK2QH	SN	Fastic; IPCCPA; Senaglinide; Starlix; Starsis; Trazec; Nateglinide [INN]; Novartis brand of nateglinide; DJN 608; A-4166; AY-4166; DJN-608; Nate-glinide; Starlix (TN); YM-026; SDZ-DJN-608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
DMLK2QH	CP	Norvatis Phamaceuticals Corporation
DMLK2QH	TC	Hypoglycemic Agents
DMLK2QH	DT	Small molecular drug
DMLK2QH	PC	5311309
DMLK2QH	MW	317.4
DMLK2QH	FM	C19H27NO3
DMLK2QH	IC	InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1
DMLK2QH	CS	CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O
DMLK2QH	IK	OELFLUMRDSZNSF-OFLPRAFFSA-N
DMLK2QH	IU	(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
DMLK2QH	CA	CAS 105816-04-4
DMLK2QH	CB	CHEBI:31897
DMLK2QH	DE	Diabetic complication

DM7F1PA	ID	DM7F1PA
DM7F1PA	DN	Nebivolol
DM7F1PA	HS	Approved
DM7F1PA	SN	Bystolic; Lobivon; Nebilet; Nebilong; Nebipill; Nebivololum; Nubeta; Nebivololum [Latin]; R 67555; Bystolic (TN); Nebicard-5;Nebilet (TN); Nebilong (TN); Nodon (TN); Nubeta (TN); PI-21858; R-67555; R65,824; Nebicard-5 (TN); Nebivolol (USAN/INN); Nebivolol [USAN:INN:BAN]; Alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol); Alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol); Alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol; 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol; 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
DM7F1PA	CP	Forest Laboratories
DM7F1PA	TC	Antihypertensive Agents
DM7F1PA	DT	Small molecular drug
DM7F1PA	PC	71301
DM7F1PA	MW	405.4
DM7F1PA	FM	C22H25F2NO4
DM7F1PA	IC	InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2
DM7F1PA	CS	C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O
DM7F1PA	IK	KOHIRBRYDXPAMZ-UHFFFAOYSA-N
DM7F1PA	IU	1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
DM7F1PA	CA	CAS 99200-09-6
DM7F1PA	CB	CHEBI:64019
DM7F1PA	DE	Hypertension

DMKOJSN	ID	DMKOJSN
DMKOJSN	DN	Necitumumab
DMKOJSN	HS	Approved
DMKOJSN	SN	LY3012211
DMKOJSN	CP	Lilly
DMKOJSN	DT	Monoclonal antibody
DMKOJSN	SQ	Sequence A: QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Sequence A'QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Sequence BEIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>    <sequence format="FASTA">&gt;Sequence B'EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMKOJSN	DE	Colorectal cancer

DM4ZS8M	ID	DM4ZS8M
DM4ZS8M	DN	Nefazodone
DM4ZS8M	HS	Approved
DM4ZS8M	SN	Nefazodona; Nefazodonum; Nefazodona [Spanish]; Nefazodone Hcl; Nefazodonum [Latin]; Nefadar (TN); Nefazodone (INN); Nefazodone [INN:BAN]; Serzone (TN); 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
DM4ZS8M	CP	Bristol-Myers Squibb
DM4ZS8M	TC	Antidepressants
DM4ZS8M	DT	Small molecular drug
DM4ZS8M	PC	4449
DM4ZS8M	MW	470
DM4ZS8M	FM	C25H32ClN5O2
DM4ZS8M	IC	InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
DM4ZS8M	CS	CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
DM4ZS8M	IK	VRBKIVRKKCLPHA-UHFFFAOYSA-N
DM4ZS8M	IU	2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
DM4ZS8M	CA	CAS 83366-66-9
DM4ZS8M	CB	CHEBI:7494
DM4ZS8M	DE	Major depressive disorder; Depression

DMB6VEG	ID	DMB6VEG
DMB6VEG	DN	Nelarabine
DMB6VEG	HS	Approved
DMB6VEG	SN	Arranon; ArranonG; Atriance; Nelzarabine; Nelarabine [USAN]; Nelzarabine [USAN]; GW 506U78; GW506U78; U78; Arranon (GlaxoSmithKline); Arranon (TN); Arranon, Nelarabine; Atriance (TN); GW-506U; GW-506U78; Nelarabine (INN); Nelzarabine (USAN); O-Methoxydeoxyguanosine; O-Methylguanosine; Nelarabine (JAN/USAN); (2R,3R,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; 2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-Amino-6-methoxypurine arabinoside; 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine; 6'-O-Methylguanosine; 9-beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; 9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
DMB6VEG	CP	GlaxoSmithKline
DMB6VEG	TC	Anticancer Agents
DMB6VEG	DT	Small molecular drug
DMB6VEG	PC	3011155
DMB6VEG	MW	297.27
DMB6VEG	FM	C11H15N5O5
DMB6VEG	IC	InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1
DMB6VEG	CS	COC1=NC(=NC2=C1N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N
DMB6VEG	IK	IXOXBSCIXZEQEQ-UHTZMRCNSA-N
DMB6VEG	IU	(2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMB6VEG	CA	CAS 121032-29-9
DMB6VEG	CB	CHEBI:63612
DMB6VEG	DE	leukaemia

DMFX6G8	ID	DMFX6G8
DMFX6G8	DN	Nelfinavir mesylate
DMFX6G8	HS	Approved
DMFX6G8	SN	Nelfin; Nelfinavir (Mesylate); Nelfinavir Mesylate [USAN]; Nelfinavir Methanesulfonate; Nelfinavir mesilate; Nelfinavir mesylate; Nelfinavir mesylate hydrate; Nelfinavir; NELFINAVIR MESYLATE AG1343; Nelfinavir [INN:BAN]; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; 159989-64-7; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; C32H45N3O4S; CHEBI:7496; HO3OGH5D7I; NLF; UNII-HO3OGH5D7I; 98D603VP8V; C32H45N3O4S.CH4O3S; CHEBI:7497; CHEMBL1205; DSSTox_CID_10777; DSSTox_GSID_33736; DSSTox_RID_79093; HSDB 7159; MFCD00931436; Nelfinavir methanesulfonate hydrate; UNII-98D603VP8V
DMFX6G8	PC	64142
DMFX6G8	MW	663.9
DMFX6G8	FM	C33H49N3O7S2
DMFX6G8	IC	NQHXCOAXSHGTIA-SKXNDZRYSA-N
DMFX6G8	CS	CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O
DMFX6G8	IK	1S/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1
DMFX6G8	IU	(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide;methanesulfonic acid
DMFX6G8	CA	CAS 159989-65-8
DMFX6G8	CB	CHEBI:7497
DMFX6G8	DE	Human immunodeficiency virus infection

DMY0EKH	ID	DMY0EKH
DMY0EKH	DN	Nemonapride
DMY0EKH	HS	Approved
DMY0EKH	SN	Emilace (TN); Nemonapride (JAN/INN); Nemonapride, (cis)-isomer
DMY0EKH	CP	Astellas
DMY0EKH	DT	Small molecular drug
DMY0EKH	PC	156333
DMY0EKH	MW	387.9
DMY0EKH	FM	C21H26ClN3O2
DMY0EKH	IC	InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)/t14-,18-/m1/s1
DMY0EKH	CS	C[C@@H]1[C@@H](CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl
DMY0EKH	IK	KRVOJOCLBAAKSJ-RDTXWAMCSA-N
DMY0EKH	IU	N-[(2R,3R)-1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-(methylamino)benzamide
DMY0EKH	CA	CAS 187139-87-3
DMY0EKH	CB	CHEBI:64219
DMY0EKH	DE	Schizophrenia

DM0S9Z1	ID	DM0S9Z1
DM0S9Z1	DN	Nemonoxacin
DM0S9Z1	HS	Approved
DM0S9Z1	SN	Nemonoxacin; 378746-64-6; UNII-P94L0PVO94; TG-873870; P94L0PVO94; Nemonoxacin [INN]; 7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-[(3S,5S)-3-Amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; SCHEMBL1006373; CHEMBL1213456; CHEBI:136053; ZINC40435195; SB16570; FT-0700967; 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid
DM0S9Z1	CP	TaiGen Biotechnology
DM0S9Z1	DT	Small molecular drug
DM0S9Z1	PC	11993740
DM0S9Z1	MW	371.4
DM0S9Z1	FM	C20H25N3O4
DM0S9Z1	IC	InChI=1S/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1
DM0S9Z1	CS	C[C@H]1C[C@@H](CN(C1)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)OC)N
DM0S9Z1	IK	AVPQPGFLVZTJOR-RYUDHWBXSA-N
DM0S9Z1	IU	7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid
DM0S9Z1	CA	CAS 378746-64-6
DM0S9Z1	CB	CHEBI:136053
DM0S9Z1	DE	infection associated with diabetic foot ulcers; Community-acquired pneumonia

DMPWCTH	ID	DMPWCTH
DMPWCTH	DN	Neocarzinostatin
DMPWCTH	HS	Approved
DMPWCTH	SN	ZINOSTATIN; Neocarzinostatin (JAN); Zinostatin (USAN/INN); SCHEMBL1347615; D02046; 33862-EP2311453A1; 33862-EP2298765A1; 33862-EP2295426A1; 33862-EP2298764A1; 33862-EP2298748A2; 33862-EP2295427A1; 33862-EP2295055A2; 33862-EP2272832A1; 33862-EP2311829A1; 33862-EP2305642A2; 33862-EP2275420A1; 33862-EP2311808A1; 33862-EP2298768A1; 33862-EP2295416A2; 120130-EP2272832A1
DMPWCTH	DT	Small molecular drug
DMPWCTH	PC	5282473
DMPWCTH	MW	661.6
DMPWCTH	FM	C35H35NO12
DMPWCTH	IC	InChI=1S/C35H35NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h8-9,12-14,17,21,24-26,28-31,33,36-39H,6,15H2,1-4H3/t17-,21?,24-,25-,26-,28-,29+,30-,31-,33-,35+/m1/s1
DMPWCTH	CS	C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H](C=C3C2CC#C[C@@H]4[C@@](O4)(C#C3)[C@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)O)NC)O)O
DMPWCTH	IK	BLXZMHNVKCEIJX-PNKAXBHOSA-N
DMPWCTH	IU	[(4S,6R,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4R)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]tridec-1(13)-en-2,7-diyn-12-yl] 2-hydroxy-7-methoxy-5-methylnaphthalene-1-carboxylate
DMPWCTH	CA	CAS 9014-02-2
DMPWCTH	DE	Solid tumour/cancer

DM6T2J3	ID	DM6T2J3
DM6T2J3	DN	Neostigmine
DM6T2J3	HS	Approved
DM6T2J3	SN	Eustigmin; Eustigmine; Intrastigmina; Juvastigmin; Neostigmin; Neostigminum; Prostigmin; Prostigmine; Prozerin; Sulfonatooxymethane; Synstigmin; Syntostigmine; Vagostigmin; Vagostigmine; Neostigmine [BAN]; Neostigmine omega; M-Trimethylammoniumphenyldimethylcarbamate; Neostigmine (BAN); Prostigmin (TN); Vagostigmin (TN); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-(9CI); (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium
DM6T2J3	TC	Parasympathomimetics
DM6T2J3	DT	Small molecular drug
DM6T2J3	PC	4456
DM6T2J3	MW	223.29
DM6T2J3	FM	C12H19N2O2+
DM6T2J3	IC	InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
DM6T2J3	CS	CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
DM6T2J3	IK	ALWKGYPQUAPLQC-UHFFFAOYSA-N
DM6T2J3	IU	[3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium
DM6T2J3	CA	CAS 59-99-4
DM6T2J3	CB	CHEBI:7514
DM6T2J3	DE	Myasthenia gravis

DMYK490	ID	DMYK490
DMYK490	DN	Nepafenac
DMYK490	HS	Approved
DMYK490	SN	Nevanac; AHR-9434; AL-6515
DMYK490	CP	Alcon
DMYK490	DT	Small molecular drug
DMYK490	PC	151075
DMYK490	MW	254.28
DMYK490	FM	C15H14N2O2
DMYK490	IC	InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
DMYK490	CS	C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N
DMYK490	IK	QEFAQIPZVLVERP-UHFFFAOYSA-N
DMYK490	IU	2-(2-amino-3-benzoylphenyl)acetamide
DMYK490	CA	CAS 78281-72-8
DMYK490	CB	CHEBI:75922
DMYK490	DE	Osteoarthritis

DMEDU7B	ID	DMEDU7B
DMEDU7B	DN	NERATINIB MALEATE
DMEDU7B	HS	Approved
DMEDU7B	SN	Neratinib maleate; UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892
DMEDU7B	CP	Puma Biotechnology
DMEDU7B	PC	67307512
DMEDU7B	MW	673.1
DMEDU7B	FM	C34H33ClN6O7
DMEDU7B	IC	InChI=1S/C30H29ClN6O3.C4H4O4/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22;5-3(6)1-2-4(7)8/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38);1-2H,(H,5,6)(H,7,8)/b9-7+;2-1-
DMEDU7B	CS	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C.C(=C\\C(=O)O)\\C(=O)O
DMEDU7B	IK	VXZCUHNJXSIJIM-MEBGWEOYSA-N
DMEDU7B	IU	(Z)-but-2-enedioic acid;(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
DMEDU7B	CA	CAS 915942-22-2
DMEDU7B	DE	HER2/NEU overexpressing breast cancer

DMMPG5V	ID	DMMPG5V
DMMPG5V	DN	NERIDRONIC ACID
DMMPG5V	HS	Approved
DMMPG5V	SN	Neridronic acid; 79778-41-9; Nerixia; Neridronic acid [INN]; (6-Amino-1-hydroxyhexane-1,1-diyl)diphosphonic acid; UNII-8U27U3RIN4; Acide neridronique [INN-French]; Acido neridronico [INN-Spanish]; Acidum neridronicum [INN-Latin]; CHEMBL55214; 8U27U3RIN4; NERIDRONATE SODIUM HYDRATE; (6-Amino-1-hydroxyhexylidene)diphosphonic acid; 6-Amino-1-hydroxyhexane-1,1-diphosphonate; 6-amino-1-hydroxyhexane-1,1-diyldiphosphonic acid; W-203821; Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis-
DMMPG5V	DT	Small molecular drug
DMMPG5V	PC	71237
DMMPG5V	MW	277.15
DMMPG5V	FM	C6H17NO7P2
DMMPG5V	IC	InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
DMMPG5V	CS	C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN
DMMPG5V	IK	PUUSSSIBPPTKTP-UHFFFAOYSA-N
DMMPG5V	IU	(6-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid
DMMPG5V	CA	CAS 79778-41-9
DMMPG5V	CB	CHEBI:135145
DMMPG5V	DE	Bone disease; Complex regional pain syndrome

DMFOIA8	ID	DMFOIA8
DMFOIA8	DN	Nesiritide
DMFOIA8	HS	Approved
DMFOIA8	SN	Natrecor (TN)
DMFOIA8	CP	Scios Llc
DMFOIA8	DT	Small molecular drug
DMFOIA8	SQ	DB04899: Natriuretic peptides B: SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH
DMFOIA8	PC	71308561
DMFOIA8	MW	3464
DMFOIA8	FM	C143H244N50O42S4
DMFOIA8	IC	InChI=1S/C143H244N50O42S4/c1-13-76(10)112-137(232)189-99(68-199)131(226)188-98(67-198)130(225)187-97(66-197)129(224)186-96(65-196)117(212)166-59-105(202)169-90(52-72(2)3)114(209)163-61-107(204)171-100(132(227)177-83(32-19-22-44-146)124(219)190-111(75(8)9)136(231)184-91(53-73(4)5)127(222)175-84(34-24-46-159-141(151)152)121(216)174-85(35-25-47-160-142(153)154)122(217)185-94(139(234)235)55-78-57-157-71-167-78)69-238-239-70-101(172-108(205)62-165-116(211)95(64-195)170-106(203)60-162-113(208)87(38-39-103(148)200)181-135(230)110(74(6)7)191-126(221)89(41-51-237-12)179-120(215)82(31-18-21-43-145)180-134(229)102-37-27-49-193(102)138(233)79(147)63-194)133(228)182-92(54-77-28-15-14-16-29-77)115(210)164-58-104(201)168-80(33-23-45-158-140(149)150)118(213)173-81(30-17-20-42-144)119(214)178-88(40-50-236-11)123(218)183-93(56-109(206)207)128(223)176-86(125(220)192-112)36-26-48-161-143(155)156/h14-16,28-29,57,71-76,79-102,110-112,194-199H,13,17-27,30-56,58-70,144-147H2,1-12H3,(H2,148,200)(H,157,167)(H,162,208)(H,163,209)(H,164,210)(H,165,211)(H,166,212)(H,168,201)(H,169,202)(H,170,203)(H,171,204)(H,172,205)(H,173,213)(H,174,216)(H,175,222)(H,176,223)(H,177,227)(H,178,214)(H,179,215)(H,180,229)(H,181,230)(H,182,228)(H,183,218)(H,184,231)(H,185,217)(H,186,224)(H,187,225)(H,188,226)(H,189,232)(H,190,219)(H,191,221)(H,192,220)(H,206,207)(H,234,235)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t76-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,110-,111-,112-/m0/s1
DMFOIA8	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CNC=N4)C(=O)O)CC(C)C)CO)CO)CO)CO
DMFOIA8	IK	HPNRHPKXQZSDFX-OAQDCNSJSA-N
DMFOIA8	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(4R,10S,16S,19S,22S,25S,28S,31S,34S,37S,40S,43S,49S,52R)-52-[[2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid
DMFOIA8	CB	CHEBI:135919
DMFOIA8	DE	Congestive heart failure

DM0LPI9	ID	DM0LPI9
DM0LPI9	DN	Netarsudil
DM0LPI9	HS	Approved
DM0LPI9	SN	UNII-W6I5QDT7QI; W6I5QDT7QI; Netarsudil mesylate; Netarsudil [USAN]; AR-11324 free base; Netarsudil [USAN:INN]; Netarsudil (USAN/INN); GTPL9322; SCHEMBL16036278; ZINC113149554; AR11324; AR-11324; ester 60; 1628418-15-4
DM0LPI9	CP	Aerie Pharmaceuticals
DM0LPI9	PC	66599893
DM0LPI9	MW	453.5
DM0LPI9	FM	C28H27N3O3
DM0LPI9	IC	InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1
DM0LPI9	CS	CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
DM0LPI9	IK	OURRXQUGYQRVML-AREMUKBSSA-N
DM0LPI9	IU	[4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate
DM0LPI9	CA	CAS 1254032-66-0
DM0LPI9	DE	Open-angle glaucoma; Glaucoma/ocular hypertension

DMRD1QK	ID	DMRD1QK
DMRD1QK	DN	Netilmicin
DMRD1QK	HS	Approved
DMRD1QK	SN	NTL; Netilmicina; Netilmicine; Netilmicinum; Netilyn; Netira; Nettacin; Vectacin; NETILMICIN SULFATE; Sch 20569; Netilmicin (INN); Netilmicin [INN:BAN]; Netilmicina [INN-Spanish]; Netilmicine [INN-French]; Netilmicinum [INN-Latin]; Netira (TN); Nettacin (TN); Sch-20569; O-(2,6-Diamino-2,3,4,6-tetradesoxy-alpha-glycero-4-hexenopyranosyl-(1-4)-O-(3-desoxy-4-C-methyl-3-methylamino-beta-L-arabinopyranosyl-(1-6)-2-desoxy-N1-ethyl-D-streptamin; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3S,4S,5S)-2-[(1S,2R,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 1-N-Aethylsisomicin; 1-N-Ethylsisomicin; 2-[4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4-amino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)pentopyranoside
DMRD1QK	CP	Abbott Laboratories
DMRD1QK	TC	Antibiotics
DMRD1QK	DT	Small molecular drug
DMRD1QK	PC	441306
DMRD1QK	MW	475.6
DMRD1QK	FM	C21H41N5O7
DMRD1QK	IC	InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1
DMRD1QK	CS	CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N
DMRD1QK	IK	CIDUJQMULVCIBT-MQDUPKMGSA-N
DMRD1QK	IU	(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMRD1QK	CA	CAS 56391-56-1
DMRD1QK	DE	Bacterial infection

DM6HX9B	ID	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	HS	Approved
DM6HX9B	SN	NEV; NVP; Viramune; Cahill May Roberts Brand of Nevirapine; Promeco Brand of Nevirapine; BI RG 587; BIRG 0587; BIRG 587; BIRG587; BIRG-0587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Nevirapine & PRO 140; Nevirapine [USAN:INN]; Viramune (TN); Viramune(TM); BI-RG-587; Nevirapine & CD4-IgG; Nevirapine (JAN/USP/INN); Viramune, BI-RG 587, Nevirapine; BI-RG-587 & CD4-IgG; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
DM6HX9B	CP	Boehringer Ingelheim
DM6HX9B	TC	Anti-HIV Agents
DM6HX9B	DT	Small molecular drug
DM6HX9B	PC	4463
DM6HX9B	MW	266.3
DM6HX9B	FM	C15H14N4O
DM6HX9B	IC	InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
DM6HX9B	CS	CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
DM6HX9B	IK	NQDJXKOVJZTUJA-UHFFFAOYSA-N
DM6HX9B	IU	2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
DM6HX9B	CA	CAS 129618-40-2
DM6HX9B	CB	CHEBI:63613
DM6HX9B	DE	Human immunodeficiency virus infection

DMCDYW7	ID	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	HS	Approved
DMCDYW7	SN	Nicardipino; Nicardipinum; Cardene IV; Nicardipine LA; Cardene (TN); Nicardipine (INN); Nicardipine [INN:BAN]; Nicardipino [INN-Spanish]; Nicardipinum [INN-Latin]; Y-93; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMCDYW7	CP	Chiesi Usa Inc
DMCDYW7	TC	Antihypertensive Agents
DMCDYW7	DT	Small molecular drug
DMCDYW7	PC	4474
DMCDYW7	MW	479.5
DMCDYW7	FM	C26H29N3O6
DMCDYW7	IC	InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3
DMCDYW7	CS	CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMCDYW7	IK	ZBBHBTPTTSWHBA-UHFFFAOYSA-N
DMCDYW7	IU	5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMCDYW7	CA	CAS 55985-32-5
DMCDYW7	CB	CHEBI:7550
DMCDYW7	DE	High blood pressure

DMBCM8L	ID	DMBCM8L
DMBCM8L	DN	Nicergoline
DMBCM8L	HS	Approved
DMBCM8L	SN	MNE; Nargoline; Nicergolin; Nicergolina; Nicergolinum; Nicotergoline; Nimergoline; Sermion; Nicergolin [German]; Nicergolina [DCIT]; Nimergoline base; FI 6714; RP 19651; Nicergolinum [INN-Latin]; Sermion (TN); Nicergoline (JP15/USAN/INN); Nicergoline [USAN:BAN:INN:JAN]; Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester) (8CI); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester); Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8beta)-, 5-bromo-3-pyridinecarboxylate (ester); (+)-10-Methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; 1-Methyl-lumilysergol 8-(5-bromonicotinate) 10-methyl ether; 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat); 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat) [German]; 10-Methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyrindinecarboxylate (ester); 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate; 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate (ester); 5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester; 8-beta-((5-Bromonicotinoyloxy)methyl)-1,6-dimethyl-10-alpha-methoxyergoline
DMBCM8L	TC	Vasodilator Agents
DMBCM8L	DT	Small molecular drug
DMBCM8L	PC	34040
DMBCM8L	MW	484.4
DMBCM8L	FM	C24H26BrN3O3
DMBCM8L	IC	InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1
DMBCM8L	CS	CN1C[C@@H](C[C@]2([C@H]1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br
DMBCM8L	IK	YSEXMKHXIOCEJA-FVFQAYNVSA-N
DMBCM8L	IU	[(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate
DMBCM8L	CA	CAS 27848-84-6
DMBCM8L	CB	CHEBI:31902
DMBCM8L	DE	Brain ischaemia; Senile dementia

DMJAGXQ	ID	DMJAGXQ
DMJAGXQ	DN	Niclosamide
DMJAGXQ	HS	Approved
DMJAGXQ	SN	niclosamide; 50-65-7; Niclocide; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; Tredemine; Bayluscid; Phenasal; Yomesan; Fenasal; Dichlosale; Helmiantin; Sagimid; Iomezan; Devermine; Atenase; Vermitid; Radeverm; Mansonil; Iomesan; Devermin; Cestocid; Sulqui; Lintex; Nasemo; Mato; Fedal-Telmin; Bayer 73; Radewerm; Zestocarp; Bayer 2353; 2',5-Dichloro-4'-nitrosalicylanilide; Chemagro 2353; BAY 2353; Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-; 5-Chloro-2'-chloro-4'-nitrosalicylanilide; nicolsamide; HL 2447; Niclosamidum [I
DMJAGXQ	DT	Small molecular drug
DMJAGXQ	PC	4477
DMJAGXQ	MW	327.12
DMJAGXQ	FM	C13H8Cl2N2O4
DMJAGXQ	IC	InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)
DMJAGXQ	CS	C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O
DMJAGXQ	IK	RJMUSRYZPJIFPJ-UHFFFAOYSA-N
DMJAGXQ	IU	5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide
DMJAGXQ	CA	CAS 50-65-7
DMJAGXQ	CB	CHEBI:7553
DMJAGXQ	DE	Cestodes infection

DMIYJFV	ID	DMIYJFV
DMIYJFV	DN	Nicorandil
DMIYJFV	HS	Approved
DMIYJFV	SN	Adancor; Dancor; Ikorel; Nicorandilum; Sigmart; Aventis Brand of Nicorandil; Aventis Pharma Brand of Nicorandil; Merck Brand of Nicorandil; Merck Lipha Sante Brand of Nicorandil; Nicorandil Aventis Brand; Nicorandil Merck Brand; Rhone Poulenc Rorer Brand of Nicorandil; SG 75; SG75; Ikorel (TN); Nicorandilum [INN-Latin]; RP-46417; Rhone-Poulenc Rorer Brand of Nicorandil; SG-75; Sigmart (TN); Nitrate, 2-Nicotinamidethyl; Nitrate, 2-Nicotinamidoethyl; N-(2-Hydroxyethyl)nicotinamide nitrate; Nicorandil (JP15/USAN/INN); Nicorandil [USAN:BAN:INN:JAN]; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; 2 Nicotinamidethyl Nitrate; 2 Nicotinamidoethyl Nitrate; 2-(Nicotinamido)ethyl nitrat; 2-(Pyridine-3-carboxamido)ethyl Nitrate; 2-(pyridine-3-carbonylamino)ethyl nitrate; 2-Nicotinamidethyl Nitrate; 2-Nicotinamidoethyl nitrate; 2-[(pyridin-3-ylcarbonyl)amino]ethylnitrat
DMIYJFV	CP	Chugai; Roche; Sanofi-Aventis; Merk KGaA; Pfizer; 3M Pharmaceutical
DMIYJFV	TC	Vasodilator Agents
DMIYJFV	DT	Small molecular drug
DMIYJFV	PC	47528
DMIYJFV	MW	211.17
DMIYJFV	FM	C8H9N3O4
DMIYJFV	IC	InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)
DMIYJFV	CS	C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]
DMIYJFV	IK	LBHIOVVIQHSOQN-UHFFFAOYSA-N
DMIYJFV	IU	2-(pyridine-3-carbonylamino)ethyl nitrate
DMIYJFV	CA	CAS 65141-46-0
DMIYJFV	CB	CHEBI:31905
DMIYJFV	DE	Angina pectoris

DMUPE07	ID	DMUPE07
DMUPE07	DN	Nicotinamide
DMUPE07	HS	Approved
DMUPE07	SN	Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide
DMUPE07	TC	Antiinflammatory Agents
DMUPE07	DT	Small molecular drug
DMUPE07	PC	936
DMUPE07	MW	122.12
DMUPE07	FM	C6H6N2O
DMUPE07	IC	InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)
DMUPE07	CS	C1=CC(=CN=C1)C(=O)N
DMUPE07	IK	DFPAKSUCGFBDDF-UHFFFAOYSA-N
DMUPE07	IU	pyridine-3-carboxamide
DMUPE07	CA	CAS 98-92-0
DMUPE07	CB	CHEBI:17154
DMUPE07	DE	Inflammatory skin condition

DMWX5CO	ID	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	HS	Approved
DMWX5CO	SN	Habitrol; Micotine; NCT; NICOTINE AND SALTS; Nicoderm Patch; Nicotina [Italian]; Nicotine Patch; Nicotine [USAN]; Nicotine replacement patch; Nicotine solution; Nictoine patch; Nikotin [German]; Nikotyna [Polish]; Transdermal Nicotine; Nicotine [UN1654] [Poison]; ENT 3,424; Habitrol (TN); Nicorette (TN); Nicotine (USP); Nicotine (compounds related to); Nicotine [BSI:ISO]; L(-)-nicotine; Beta-Pyridyl-alpha-N-methyl pyrrolidine; (-)-Nicotine solution; (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; (S)-(-)-Nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; (S)-Nicotine; 3-(2-(N-methylpyrrolidinyl))pyridine; 3-(N-Methylpyrollidino)pyridine; 3-(N-Methylpyrrolidino)pyridine; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
DMWX5CO	CP	Upjohn Corporation
DMWX5CO	DT	Small molecular drug
DMWX5CO	PC	89594
DMWX5CO	MW	162.23
DMWX5CO	FM	C10H14N2
DMWX5CO	IC	InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1
DMWX5CO	CS	CN1CCC[C@H]1C2=CN=CC=C2
DMWX5CO	IK	SNICXCGAKADSCV-JTQLQIEISA-N
DMWX5CO	IU	3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
DMWX5CO	CA	CAS 54-11-5
DMWX5CO	CB	CHEBI:17688
DMWX5CO	DE	Nicotine dependence; Tobacco dependence

DMSVOZT	ID	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	HS	Approved
DMSVOZT	SN	Adalat; Adalate; Adapine; Adapress; Afeditab; Alat; Aldipin; Alfadal; Alonix; Angipec; Anifed; Anpine; Aprical; Bonacid; Calcibloc; Calcigard; Calcilat; Camont; Cardifen; Cardilat; Cardionorm; Chronadalate; Citilat; Coracten; Coral; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Cordipin; Cordipine; Corinfar; Corotrend; Corynphar; Depin; Dignokonstant; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Emaberin; Fedcor; Fenamon; Fenigidin; Fenihidin; Fenihidine; Glopir; Hadipin; Hexadilat; Infedipin; Introcar; Kordafen; Korinfar; Macorel; Megalat; Myogard; Nedipin; Nicardia; Nifangin; Nifar; Nifdemin; Nifebene; Nifecard; Nifecor; Nifedepat; Nifediac; Nifedical; Nifedicor; Nifedin; Nifedine; Nifedipino; Nifedipinum; Nifedipres; Nifelan; Nifelat; Nifelate; Nificard; Nifidine; Nifipen; Niphedipine; Orix; Oxcord; Pidilat; Procardia; Sepamit; Tibricol; Vascard; Zenusin; AWD Pharma Brand of Nifedipine; Adalat CC; Adalat CR; Adalat Crono; Adalat FT; Adalat GITS; Adalat LA; Adalat LP; Adalat Oros; Adalat PA; Adalat Retard; Adalat XL; Adalate LP; Adcock Ingram Brand of Nifedipine; Adipine XL; Afeditab CR; Alonix S; Aprical long; Bayer Brand of Nifedipine; Chronadalate LP; Coracten XL; Ecodipin E; Fedcor Retard; Fenamon SR; Fortipine LA; KRKA Brand of Nifedipine; Nifedical XL; Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Monohydrochloride; Nifedipine Orion Brand; Nifedipine Pfizer Brand; Nifedipine Retard; Nifedirex LP; Nifelat Q; Nifensar XL; Orion Brand of Nifedipine; Pfizer Brand of Nifedipine; Procardia XL; Slofedipine XL; Tensipine MR; Adalat 10; Adalat 20; Adalat 5; Adalat GITS 30; Bay1040; N 7634; N1fedilat; Adalat (TN); Afeditab CR (TN); Alpha-Nifedipine Retard;Apo-Nifed; Bay-1040; KB-1712P; Monohydrochloride, Nifedipine; Nifedical (TN); Nifedipine-GTIS; Nifedipino [INN-Spanish]; Nifedipinum [INN-Latin]; Procardia (TN); Bay-a-1040; Nifedipine (JP15/USP/INN); Nifedipine [USAN:BAN:INN:JAN]
DMSVOZT	CP	Bayer
DMSVOZT	TC	Analgesics
DMSVOZT	DT	Small molecular drug
DMSVOZT	PC	4485
DMSVOZT	MW	346.3
DMSVOZT	FM	C17H18N2O6
DMSVOZT	IC	InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
DMSVOZT	CS	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
DMSVOZT	IK	HYIMSNHJOBLJNT-UHFFFAOYSA-N
DMSVOZT	IU	dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMSVOZT	CA	CAS 21829-25-4
DMSVOZT	CB	CHEBI:7565
DMSVOZT	DE	Angina pectoris

DMJ3I1Q	ID	DMJ3I1Q
DMJ3I1Q	DN	Niflumic acid
DMJ3I1Q	HS	Approved
DMJ3I1Q	SN	Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A
DMJ3I1Q	TC	Antiinflammatory Agents
DMJ3I1Q	DT	Small molecular drug
DMJ3I1Q	PC	4488
DMJ3I1Q	MW	282.22
DMJ3I1Q	FM	C13H9F3N2O2
DMJ3I1Q	IC	InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
DMJ3I1Q	CS	C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F
DMJ3I1Q	IK	JZFPYUNJRRFVQU-UHFFFAOYSA-N
DMJ3I1Q	IU	2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid
DMJ3I1Q	CA	CAS 4394-00-7
DMJ3I1Q	CB	CHEBI:34888
DMJ3I1Q	DE	Rheumatoid arthritis

DMSQLZJ	ID	DMSQLZJ
DMSQLZJ	DN	Nifurtimox
DMSQLZJ	HS	Approved
DMSQLZJ	SN	NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide
DMSQLZJ	CP	Bayer healthcare pharmaceuticals
DMSQLZJ	DT	Small molecular drug
DMSQLZJ	PC	6842999
DMSQLZJ	MW	287.29
DMSQLZJ	FM	C10H13N3O5S
DMSQLZJ	IC	InChI=1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+
DMSQLZJ	CS	CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-]
DMSQLZJ	IK	ARFHIAQFJWUCFH-IZZDOVSWSA-N
DMSQLZJ	IU	(E)-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine
DMSQLZJ	CA	CAS 23256-30-6
DMSQLZJ	CB	CHEBI:7566
DMSQLZJ	DE	Trypanosomiasis; Chagas disease

DM7HXWT	ID	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	HS	Approved
DM7HXWT	SN	NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)
DM7HXWT	CP	Novartis AG
DM7HXWT	TC	Anticancer Agents
DM7HXWT	DT	Small molecular drug
DM7HXWT	PC	644241
DM7HXWT	MW	529.5
DM7HXWT	FM	C28H22F3N7O
DM7HXWT	IC	InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
DM7HXWT	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DM7HXWT	IK	HHZIURLSWUIHRB-UHFFFAOYSA-N
DM7HXWT	IU	4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
DM7HXWT	CA	CAS 641571-10-0
DM7HXWT	CB	CHEBI:52172
DM7HXWT	DE	Chronic myelogenous leukaemia

DMFN07X	ID	DMFN07X
DMFN07X	DN	Nilutamide
DMFN07X	HS	Approved
DMFN07X	SN	Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
DMFN07X	CP	Aventis Pharmaceuticals Inc.
DMFN07X	TC	Anticancer Agents
DMFN07X	DT	Small molecular drug
DMFN07X	PC	4493
DMFN07X	MW	317.22
DMFN07X	FM	C12H10F3N3O4
DMFN07X	IC	InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
DMFN07X	CS	CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C
DMFN07X	IK	XWXYUMMDTVBTOU-UHFFFAOYSA-N
DMFN07X	IU	5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
DMFN07X	CA	CAS 63612-50-0
DMFN07X	CB	CHEBI:7573
DMFN07X	DE	Prostate cancer

DMQ0RKZ	ID	DMQ0RKZ
DMQ0RKZ	DN	Nimodipine
DMQ0RKZ	HS	Approved
DMQ0RKZ	SN	Admon; Brainal; Calnit; Kenesil; Modus; NimoGel; NimodipinISIS; Nimodipino; Nimodipinum; Nimotop; Periplum; Remontal; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Cantabria Brand of Nimodipine; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Nimodipin Hexal; Nimodipin ISIS; Nimodipino Bayvit; Vita Brand of Nimodipine; Bay-E 9736; DRG-0139; EG-1961; N-149; NIMOTOP (TN); Nimodipin-ISIS; Nimodipino [INN-Spanish]; Nimodipinum [INN-Latin]; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Bay-e-9736; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Periplum, Nimotop, BRN 0459792, DRG-0139; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3&prime;-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide
DMQ0RKZ	CP	Bayer Pharmaceuticals Corporation
DMQ0RKZ	TC	Vasodilator Agents
DMQ0RKZ	DT	Small molecular drug
DMQ0RKZ	PC	4497
DMQ0RKZ	MW	418.4
DMQ0RKZ	FM	C21H26N2O7
DMQ0RKZ	IC	InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
DMQ0RKZ	CS	CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
DMQ0RKZ	IK	UIAGMCDKSXEBJQ-UHFFFAOYSA-N
DMQ0RKZ	IU	3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMQ0RKZ	CA	CAS 66085-59-4
DMQ0RKZ	CB	CHEBI:7575
DMQ0RKZ	DE	Cerebral vasospasm

DMA65ER	ID	DMA65ER
DMA65ER	DN	Nipradilol
DMA65ER	HS	Approved
DMA65ER	SN	Nipradilol; Nipradolol; Hypadil; 81486-22-8; Nipradilolum [Latin]; Nipradilol [INN:JAN]; UNII-FVM336I71Y; Hypadil (TN); CCRIS 2515; K 351; BRN 3566879; FVM336I71Y; 8-(2-Hydroxy-3-(isopropylamino)propoxy)chroman-3-yl nitrate; C15H22N2O6; 8-(2-Hydroxy-3-(isopropylamino)propoxy)-3-chromanyl nitrat; 8-(2-Hydroxy-3-(isopropylamino)propoxy)-3-chromanol 3-nitrate; K-351; 3,4-Dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2H-1-benzopyran; 3,4-Dihydro-8-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2H-1-benzopyran-3-ol 3-nitra
DMA65ER	DT	Small molecular drug
DMA65ER	PC	72006
DMA65ER	MW	326.34
DMA65ER	FM	C15H22N2O6
DMA65ER	IC	InChI=1S/C15H22N2O6/c1-10(2)16-7-12(18)8-21-14-5-3-4-11-6-13(23-17(19)20)9-22-15(11)14/h3-5,10,12-13,16,18H,6-9H2,1-2H3
DMA65ER	CS	CC(C)NCC(COC1=CC=CC2=C1OCC(C2)O[N+](=O)[O-])O
DMA65ER	IK	OMCPLEZZPVJJIS-UHFFFAOYSA-N
DMA65ER	IU	[8-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3,4-dihydro-2H-chromen-3-yl] nitrate
DMA65ER	CA	CAS 81486-22-8
DMA65ER	CB	CHEBI:31682
DMA65ER	DE	Angina pectoris

DMLPSWQ	ID	DMLPSWQ
DMLPSWQ	DN	Niraparib Tosylate
DMLPSWQ	HS	Approved
DMLPSWQ	SN	1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059
DMLPSWQ	CP	Tesaro
DMLPSWQ	TC	Antihypertensive Agents
DMLPSWQ	DT	Small molecular drug
DMLPSWQ	PC	78357761
DMLPSWQ	MW	492.6
DMLPSWQ	FM	C26H28N4O4S
DMLPSWQ	IC	InChI=1S/C19H20N4O.C7H8O3S/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10)/t14-;/m1./s1
DMLPSWQ	CS	CC1=CC=C(C=C1)S(=O)(=O)O.C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
DMLPSWQ	IK	LCPFHXWLJMNKNC-PFEQFJNWSA-N
DMLPSWQ	IU	4-methylbenzenesulfonic acid;2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
DMLPSWQ	CA	CAS 1038915-73-9
DMLPSWQ	DE	Peritoneal cancer; Fallopian tube cancer

DM7ISKJ	ID	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	HS	Approved
DM7ISKJ	SN	Baymycard; Nisocor; Nisoldipin; Nisoldipino; Nisoldipinum; Sular; Syscor; Zadipina; Bay k 5552; Nisoldipino [INN-Spanish]; Nisoldipinum [INN-Latin]; Sular (TN); Bay-k-5552; Nisoldipine (JAN/USAN/INN); Nisoldipine [USAN:BAN:INN:JAN]; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat;Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM7ISKJ	TC	Antihypertensive Agents
DM7ISKJ	DT	Small molecular drug
DM7ISKJ	PC	4499
DM7ISKJ	MW	388.4
DM7ISKJ	FM	C20H24N2O6
DM7ISKJ	IC	InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3
DM7ISKJ	CS	CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
DM7ISKJ	IK	VKQFCGNPDRICFG-UHFFFAOYSA-N
DM7ISKJ	IU	3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM7ISKJ	CA	CAS 63675-72-9
DM7ISKJ	CB	CHEBI:76917
DM7ISKJ	DE	Hypertension

DMOWLVG	ID	DMOWLVG
DMOWLVG	DN	Nitazoxanide
DMOWLVG	HS	Approved
DMOWLVG	SN	Alinia; Colufase; Cryptaz; Daxon; Heliton; Nitazoxanid; Nitazoxanida; Nitazoxanidum; Taenitaz; Tizoxanide glucuronide; AZT + Nitazoxanide; Alinia (TN); Annita (TN); Azt+ nitazoxanide; Daxon (TN); Dexidex (TN); Kidonax (TN); Nitax (TN); Nitazox (TN); Nitazoxanida [INN-Spanish]; Nitazoxanide [USAN:INN]; Nitazoxanidum [INN-Latin]; Pacovanton (TN); Paramix (TN); Phavic-1; Zox (TN); Nitazoxanide (USAN/INN); Daxon, Dexidex, Kidonax, Pacovanton, Paramix, Nitax, Zox, Nitazoxanide
DMOWLVG	CP	Unimed Pharmaceuticals
DMOWLVG	TC	Antiparasitic Agents
DMOWLVG	DT	Small molecular drug
DMOWLVG	PC	41684
DMOWLVG	MW	307.28
DMOWLVG	FM	C12H9N3O5S
DMOWLVG	IC	InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)
DMOWLVG	CS	CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-]
DMOWLVG	IK	YQNQNVDNTFHQSW-UHFFFAOYSA-N
DMOWLVG	IU	[2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate
DMOWLVG	CA	CAS 55981-09-4
DMOWLVG	CB	CHEBI:94807
DMOWLVG	DE	Diarrhea

DMVS9WQ	ID	DMVS9WQ
DMVS9WQ	DN	Nitisinone
DMVS9WQ	HS	Approved
DMVS9WQ	SN	Nitisinona; Nitisinonum; Nitisone; Orfadin; Nitisinone [INN]; SC 0735; FE-0200; Nitisinone (NTBC); Nitisinone [USAN:INN]; Orfadin (TN); Nitisinone (JAN/USAN/INN); 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione; 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; 2-(Alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione; 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione; 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione
DMVS9WQ	TC	Anticancer Agents
DMVS9WQ	DT	Small molecular drug
DMVS9WQ	PC	115355
DMVS9WQ	MW	329.23
DMVS9WQ	FM	C14H10F3NO5
DMVS9WQ	IC	InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2
DMVS9WQ	CS	C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]
DMVS9WQ	IK	OUBCNLGXQFSTLU-UHFFFAOYSA-N
DMVS9WQ	IU	2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
DMVS9WQ	CA	CAS 104206-65-7
DMVS9WQ	CB	CHEBI:50378
DMVS9WQ	DE	Hereditary tyrosinemia type 1

DMEGIQ6	ID	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	HS	Approved
DMEGIQ6	SN	Alodorm; Apodorm; Benzalin; Calsamin; Calsmin; Cerson; Dormalon; Dumolid; Eatan; Epibenzalin; Epinelbon; Eunoctin; Eunoktin; Gerson; Hipnax; Hipsal; Ibrovek; Imadorm; Imeson; Imesont; Ipersed; Magadon; Megadon; Mitidin; Mogadan; Mogadon; Mogadone; Nelbon; Nelmat; Neozepam; Neuchlonic; Nitrados; Nitravet; Nitrazadon; Nitrazep; Nitrazepamum; Nitrempax; Nitrenpax; Nitrodiazepam; Noctesed; Novanox; Pacisyn; Paxisyn; Pelson; Persopit; Radedorm; Relact; Remnos; Serenade; Somitran; Somnased; Somnibel; Somnite; Sonebon; Sonnolin; Surem; Trazenin; Unisomnia; Aliud Brand of Nitrazepam; Allphar Brand of Nitrazepam; Alphapharma Brand of Nitrazepam; Alpharma Brand of Nitrazepam; Alter Brand of Nitrazepam; CSP Brand of Nitrazepam; DDSA Brand of Nitrazepam; Dermatech Brand of Nitrazepam; Desitin Brand of Nitrazepam; Dormicum Brand of Nitrazepam; Eatan N; ICN Brand of Nitrazepam; Neuraxpharm Brand of Nitrazepam; Nitrazepam AL; Norgine Brand of Nitrazepam; Pfleger Brand of Nitrazepam; Protea Brand of Nitrazepam; Rhoxalpharma Brand of Nitrazepam; Sandoz nitrazepam; Scheurich Brand of Nitrazepam; Sonebon Tofraniln A; Taurus Brandof Nitrazepam; United Drug Brand of Nitrazepam; Wernigerode Brand of Nitrazepam; LA 1; S 2000; Alodorm (TN); Apo-nitrazepam tablets BP; Apodorm (TN); Arem (TN); Benzalin (TN); Cavodan (TN); Ct-Arzneimittel Brand of Nitrazepam; Dima (TN); Dormalon (TN); Dormicum (anticonvulsant); Dormigen (TN); Dormin-5; Dormo-Puren; Dumolid (TN); Eatan N (TN); Eunoctin (TN); Hypnotex (TN); ISOPROPYLACETATE/NITRAZEPAM; Imeson (TN); Insoma (TN); Insomin (TN); Ipersed (TN); LA 1 (VAN); Mitidin (TN); Mogadan (TN); Mogadon (TN); N-Desmethylnimetazepam; Nitavan (TN); Nitepam (TN); Nitrados (TN); Nitrapan (TN); Nitravet (TN); Nitrazadon (TN); Nitrazep (TN); Nitrazepam (TN); Nitrazepam Capsules BP 1993 (TN); Nitrazepam Oral Suspension BP 1993 (TN); Nitrazepam Tablets BP 1993 (TN); Nitrazepam-10; Nitrazepam-5; Nitrazepam-neuraxpharm; Nitrazepamum [INN-Latin]; Nitrazepan (TN); Nitrazepol (TN); Nitredon (TN); Nitrosun (TN); Novanox (TN); Numbon (TN); Onirema (TN); Ormodon (TN); Pacisyn (TN); Paxadorm (TN); Pelson (TN); Pelsonfilina (TN); Protraz (TN); Radedorm (TN); Remnos (TN); Rhoxal-nitrazepam; Ro 4-5360; Ro 5-3059; Ro 53-60; Serenade (TN); Somnibel N (TN); Somnipar (TN); Somnite (TN); Sonebon (TN); Sonotrat (TN); Surem (TN); Tri (TN); Unisomnia (TN); Dormo-Puren (TN); Nitrazepam (JP15/USAN/INN); Nitrazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 2,3-Dihydro-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2-on; 7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMEGIQ6	TC	Antianxiety Agents
DMEGIQ6	DT	Small molecular drug
DMEGIQ6	PC	4506
DMEGIQ6	MW	281.27
DMEGIQ6	FM	C15H11N3O3
DMEGIQ6	IC	InChI=1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)
DMEGIQ6	CS	C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3
DMEGIQ6	IK	KJONHKAYOJNZEC-UHFFFAOYSA-N
DMEGIQ6	IU	7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMEGIQ6	CA	CAS 146-22-5
DMEGIQ6	CB	CHEBI:7581
DMEGIQ6	DE	Epilepsy; Insomnia

DM21C09	ID	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	HS	Approved
DM21C09	SN	Baylotensin; Bayotensin; Baypress; Bylotensin; Deiten; Gericin; Jutapress; Nidrel; Niprina; NitrePuren; Nitregamma; Nitrendepat; Nitrendidoc; Nitrendimerck; Nitrendipin; Nitrendipincorax; Nitrendipino; Nitrendipinum; Nitrensal; Nitrepin; Nitrepress; Tensogradal; Trendinol; Vastensium; Nitre AbZ; Nitre Puren; Nitren Lich;Nitren acis; Nitrend KSK; Nitrendi Biochemie; Nitrendipin AL; Nitrendipin Apogepha; Nitrendipin Atid; Nitrendipin Basics; Nitrendipin Heumann; Nitrendipin Lindo; Nitrendipin Stada; Nitrendipin beta; Nitrendipin corax; Nitrendipin von ct; Nitrendipino Bayvit; Nitren 1A Pharma; AL, Nitrendipin; AbZ, Nitre; Acis, Nitren; Atid, Nitrendipin; Basics, Nitrendipin; Baypress (TN); Bayvit, Nitrendipino; Beta, Nitrendipin; Biochemie, Nitrendi; Ct, nitrendipin von; Heumann, Nitrendipin; KSK, Nitrend; Lich, Nitren; Lindo, Nitrendipin; N-144; Nitre-Puren; Nitrendipin-corax; Pharma, Nitren 1A; Stada, Nitrendipin; Von ct, nitrendipin; Bay-e-5009; 1A Pharma, Nitren
DM21C09	TC	Antihypertensive Agents
DM21C09	DT	Small molecular drug
DM21C09	PC	4507
DM21C09	MW	360.4
DM21C09	FM	C18H20N2O6
DM21C09	IC	InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
DM21C09	CS	CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C
DM21C09	IK	PVHUJELLJLJGLN-UHFFFAOYSA-N
DM21C09	IU	5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM21C09	CA	CAS 39562-70-4
DM21C09	CB	CHEBI:7582
DM21C09	DE	Hypertension

DM1RBYG	ID	DM1RBYG
DM1RBYG	DN	Nitric Oxide
DM1RBYG	HS	Approved
DM1RBYG	SN	Nitric oxide; nitric oxide; nitrogen monoxide; Mononitrogen monoxide; 10102-43-9; nitrogen monooxide; nitrogen protoxide; nitrosyl; Nitrosyl radical; EDRF; CHEBI:16480; endothelium-derived relaxing factor; monoxyde d'azote; oxoazanyl; oxyde azotique; oxido nitrico; Stickstoffmonoxid; Nitric oxide trimer; monoxido de nitrogeno; Stickstoff(II)-oxid; Nitric oxide (JAN); INOmax (TN); oxido de nitrogeno(II); Nitrosoradical; [NO]; oxidonitrogen(); Nitrogen(II) oxide; OHM 11771; AC1L3QHF; Nitric oxide, 985%; DTXSID1020938; CHEMBL1200689; CTK0H7679; ()NO;  HNO; INOmax; Nitrosyl; Nitroxyl; Oxoazanyl; Stickmonoxyd; Endogenous Nitrate Vasodilator; Monoxido de nitrogeno; Nitrogen monooxide; Nitrogen monoxide; Nitrosyl hydride; Nitroxide radical; Oxido nitrico; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd [German]; Bioxyde d'azote; Bioxyde d'azote [French]; Endothelium-Derived Nitric Oxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric oxide 10% by volume or more; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen oxide (NO); Oxide, Nitric; Oxido de nitrogeno(II); Oxidonitrogen(); Vasodilator, Endogenous Nitrate; Nitric Oxide, Endothelium-Derived; Nitrosyl hydride ((NO)H); Endothelium-derived relaxing factor (EDRF)
DM1RBYG	CP	NB therapeutics; University of Akron
DM1RBYG	TC	Bronchodilator Agents
DM1RBYG	DT	Small molecular drug
DM1RBYG	PC	145068
DM1RBYG	MW	30.006
DM1RBYG	FM	NO
DM1RBYG	IC	InChI=1S/NO/c1-2
DM1RBYG	CS	[N]=O
DM1RBYG	IK	MWUXSHHQAYIFBG-UHFFFAOYSA-N
DM1RBYG	IU	nitric oxide
DM1RBYG	CA	CAS 10102-43-9
DM1RBYG	CB	CHEBI:16480
DM1RBYG	DE	Respiratory failure; Solid tumour/cancer; Tinea pedis

DM7PQIK	ID	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	HS	Approved
DM7PQIK	SN	Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Furabid; Furachel; Furadantin; Furadantine; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Gerofuran; Ituran; Macpac; Macrobid; Macrodantin; Macrodantina; Macrofuran; Macrofurin; NITROFURANTION; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitrofuradantin; Nitrofurantoina; Nitrofurantoine; Nitrofurantoinum; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Siraliden; Trantoin; Uerineks; Urantoin; Urizept; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Welfurin; Zoofurin; Fua Med; Furadantin Retard; Furadantina MC; Furadantine mc; Furophen T; NITROFURANTOIN MACROCRYSTALLINE; Nitrofurantoina [DCIT]; Fua-med; Fur-ren; Furadantin (TN); Furadantine-MC; Macrobid (TN); Macrodantin (TN); N-Toin; ND-3320; ND-7248; NITROFURANTOIN, MACROCRYSTALLINE; Nitro Macro (TN); Nitrofur-C; Nitrofurantoine [INN-French]; Nitrofurantoinum [INN-Latin]; Ro-Antoin; Urantoin (TN); Uro-Selz; Uro-Tablinen; Uro-tablineu; Usaf ea-2; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; 1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin
DM7PQIK	CP	Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
DM7PQIK	TC	Antiinfective Agents
DM7PQIK	DT	Small molecular drug
DM7PQIK	PC	6604200
DM7PQIK	MW	238.16
DM7PQIK	FM	C8H6N4O5
DM7PQIK	IC	InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+
DM7PQIK	CS	C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
DM7PQIK	IK	NXFQHRVNIOXGAQ-YCRREMRBSA-N
DM7PQIK	IU	1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione
DM7PQIK	CA	CAS 67-20-9
DM7PQIK	CB	CHEBI:71415
DM7PQIK	DE	Urinary tract infection

DMSM2KE	ID	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	HS	Approved
DMSM2KE	SN	nitrofurazone; Nitrofural; Furacilin; 59-87-0; Furacin; Furacillin; Furacine; Aldomycin; Furaldon; Nifuzon; Actin-N; Furacycline; Furacoccid; Otofuran; Nitrofurazan; Monafuracin; Furaziline; Furacinetten; Babrocid; Nitrozone; Mastofuran; Furazone; Chemofuran; Mammex; Amifur; Alfucin; Furesol; Furazol W; 5-Nitro-2-furaldehyde semicarbazone; Monofuracin; Dermofural; Monafuracis; Furaseptyl; Furatsilin; Nitrofurol; Fuvacillin; Furametral; Biofuracina; Becafurazone; Nifucin; Ibiofural; Hemofuran; Furalone; Furacort; Eldezol; Vadrocid; Vabrocid; Furazyme
DMSM2KE	DT	Small molecular drug
DMSM2KE	PC	5447130
DMSM2KE	MW	198.14
DMSM2KE	FM	C6H6N4O4
DMSM2KE	IC	InChI=1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+
DMSM2KE	CS	C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N
DMSM2KE	IK	IAIWVQXQOWNYOU-FPYGCLRLSA-N
DMSM2KE	IU	[(E)-(5-nitrofuran-2-yl)methylideneamino]urea
DMSM2KE	CA	CAS 59-87-0
DMSM2KE	CB	CHEBI:44368
DMSM2KE	DE	Skin burns; Bacterial infection

DMQ2491	ID	DMQ2491
DMQ2491	DN	Nitroglycerin
DMQ2491	HS	Approved
DMQ2491	SN	nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong;  Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Nitro-dur (TN); Transderm-nitro (TN); DWP-401
DMQ2491	TC	Vasodilator Agents
DMQ2491	DT	Small molecular drug
DMQ2491	PC	4510
DMQ2491	MW	227.09
DMQ2491	FM	C3H5N3O9
DMQ2491	IC	InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
DMQ2491	CS	C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
DMQ2491	IK	SNIOPGDIGTZGOP-UHFFFAOYSA-N
DMQ2491	IU	1,3-dinitrooxypropan-2-yl nitrate
DMQ2491	CA	CAS 55-63-0
DMQ2491	CB	CHEBI:28787
DMQ2491	DE	Diabetic foot ulcer; Angina pectoris

DMLUA2J	ID	DMLUA2J
DMLUA2J	DN	Nitroprusside
DMLUA2J	HS	Approved
DMLUA2J	SN	Nitropress (TN); Nitroprusside sodium; Sodium nitroprusside (USP); Tox21_110314; Tox21_110314_1; 13755-38-9; 7304AF; A-8282; C07695; NITROPRUSSIDE SODIUM DIHYDRATE; C5FeN6O.2Na.2H2O; CAS-13755-38-9; CHEBI:9179; D00614; DSSTox_CID_21126; DSSTox_GSID_41126; DSSTox_RID_79630; DTXSID7041126; MFCD00149192; NCGC00166055-03; Na2[Fe(CN)5(NO)].2H2O; Sodium nitroferricyanide dihydrate, 99+%; Sodium nitroferricyanide dihydrate, reagent ACS; Sodium nitroferricyanide(III) dihydrate; Sodium nitroprusside hydrate (JAN)
DMLUA2J	PC	11953895
DMLUA2J	MW	297.95
DMLUA2J	FM	C5H4FeN6Na2O3
DMLUA2J	IC	XRKMNJXYOFSTBE-UHFFFAOYSA-N
DMLUA2J	CS	[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]
DMLUA2J	IK	1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q5*-1;+4;-1;2*+1;;
DMLUA2J	IU	disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate
DMLUA2J	CA	CAS 13755-38-9
DMLUA2J	CB	CHEBI:9179
DMLUA2J	DE	Congestive heart failure

DMM765C	ID	DMM765C
DMM765C	DN	Nitroprusside
DMM765C	HS	Approved
DMM765C	SN	C07269; LS-187044
DMM765C	TC	Antihypertensive Agents
DMM765C	DT	Small molecular drug
DMM765C	PC	11953891
DMM765C	MW	215.94
DMM765C	FM	C5FeN6O
DMM765C	IC	InChI=1S/5CN.Fe.NO/c5*1-2;;1-2/q5*-1;+6;-1
DMM765C	CS	[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.[Fe+6]
DMM765C	IK	CDLSWOALPINAJL-UHFFFAOYSA-N
DMM765C	IU	iron(6+);nitroxyl anion;pentacyanide
DMM765C	DE	Hypertension

DMTHWBI	ID	DMTHWBI
DMTHWBI	DN	Nitrous oxide
DMTHWBI	HS	Approved
DMTHWBI	SN	Distickstoffmonoxid; Lachgas; Stickdioxyd; Dinitrogen monoxide; Dinitrogen oxide; Factitious air; Gaz hilarant; Hyponitrous acid anhydride; Laughing gas; Nitrogen hypoxide; Nitrogenium oxydulatum; Nitrous oxide [JAN]; Oxido nitroso; Oxido nitroso [Spanish]; Oxyde nitreux; Stickdioxyd [German]; N2O; Nitrous oxide [UN1070] [Nonflammable gas]; Diazyne 1-oxide; Gas, Laughing; NITROUS-OXIDE; Nitrogen oxide (N2O); Nitrous oxide (TN); Nitrous oxide [Anaesthetics, volatile]; Nitrous oxide, compressed; Nitrous oxide, refrigerated liquid; Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]; Oxide, Nitrous; Protoxyde d'azote; Protoxyde d'azote [French]; Nitrous oxide (JP15/USP); Oxidodinitrogen(N-N); Stickstoff(I)-oxid
DMTHWBI	DT	Small molecular drug
DMTHWBI	PC	948
DMTHWBI	MW	44.013
DMTHWBI	FM	N2O
DMTHWBI	IC	InChI=1S/N2O/c1-2-3
DMTHWBI	CS	[N-]=[N+]=O
DMTHWBI	IK	GQPLMRYTRLFLPF-UHFFFAOYSA-N
DMTHWBI	IU	nitrous oxide
DMTHWBI	CA	CAS 10024-97-2
DMTHWBI	CB	CHEBI:17045
DMTHWBI	DE	Anxiety disorder

DMAB9QE	ID	DMAB9QE
DMAB9QE	DN	Nivolumab
DMAB9QE	HS	Approved
DMAB9QE	CP	Bristol-Myers Squibb
DMAB9QE	DT	Monoclonal antibody
DMAB9QE	SQ	Heavy Chain Sequence: QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK</sequence>    <sequence format="FASTA">&gt;Light Chain SequenceEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMAB9QE	DE	Central nervous system lymphoma; Chronic myelogenous leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Malignant pleural mesothelioma; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small-cell lung cancer; Esophageal cancer; Gastric adenocarcinoma; Recurrent glioblastoma; Renal cell carcinoma; Triple negative breast cancer; Melanoma; Non-small-cell lung cancer

DMGFV3Z	ID	DMGFV3Z
DMGFV3Z	DN	Nizatidine
DMGFV3Z	HS	Approved
DMGFV3Z	SN	Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
DMGFV3Z	CP	Eli Lilly
DMGFV3Z	TC	Antiulcer Agents
DMGFV3Z	DT	Small molecular drug
DMGFV3Z	PC	3033637
DMGFV3Z	MW	331.5
DMGFV3Z	FM	C12H21N5O2S2
DMGFV3Z	IC	InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
DMGFV3Z	CS	CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C
DMGFV3Z	IK	SGXXNSQHWDMGGP-IZZDOVSWSA-N
DMGFV3Z	IU	(E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
DMGFV3Z	CA	CAS 76963-41-2
DMGFV3Z	CB	CHEBI:7601
DMGFV3Z	DE	Acid-reflux disorder

DMRJ7D1	ID	DMRJ7D1
DMRJ7D1	DN	Nomegestrol acetate
DMRJ7D1	HS	Approved
DMRJ7D1	SN	Lutenyl (TN)
DMRJ7D1	CP	Theramex
DMRJ7D1	DT	Small molecular drug
DMRJ7D1	PC	91668
DMRJ7D1	MW	370.5
DMRJ7D1	FM	C23H30O4
DMRJ7D1	IC	InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1
DMRJ7D1	CS	CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@H]4C1=CC(=O)CC4
DMRJ7D1	IK	IIVBFTNIGYRNQY-YQLZSBIMSA-N
DMRJ7D1	IU	[(8S,9S,10R,13S,14S,17R)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
DMRJ7D1	CA	CAS 58652-20-3
DMRJ7D1	CB	CHEBI:135564
DMRJ7D1	DE	Breast cancer

DMOUC09	ID	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	HS	Approved
DMOUC09	SN	norepinephrine; L-Noradrenaline; Levarterenol; 51-41-2; L-Norepinephrine; Levophed; (-)-Norepinephrine; L-arterenol; (R)-Noradrenaline; (R)-Norepinephrine; Levonor; Levonorepinephrine; Adrenor; Aktamin; Levonoradrenaline; Sympathin E; (R)-(-)-Norepinephrine; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; Noradrenalin; Norepirenamine; norepinephrinum; Noradrenalinum; Levoarterenol; Norartrinal; Nor-Epirenan; L-3,4-dihydroxyphenylethanolamine; Levarterenolo; Noreinefrina; Norepinefrina; Norepinephrinum; Levarterenolo [DCIT]; Nor adrenalin; Noradrenalina [Italian]; Norepinephrine Noradrenalin; LT03330026; ALBB-006229; Nor adrenalin (TN); Noradrenaline (JP15); Noreinefrina [INN-Spanish]; Norepinephrine (INN); Norepinephrine [INN:JAN]; Norepinephrinum [INN-Latin]; Norepinephrine l-Tartrate (1:1); D-(-)-Noradrenaline; D53D5E3A-2360-4CA9-8031-6C2CD4062FD5; L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol; L-1-(3,4-Dihydroxyphenyl)-2-aminoethanol; L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol; (-)-(R)-Norepinephrine; (-)-Arterenol free base; (-)-alpha-(Aminomethyl)protocatechuyl alcohol; (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(9CI); 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Ecteinascidins
DMOUC09	CP	Bedford Laboratories
DMOUC09	TC	Vasoconstrictor Agents
DMOUC09	DT	Small molecular drug
DMOUC09	PC	439260
DMOUC09	MW	169.18
DMOUC09	FM	C8H11NO3
DMOUC09	IC	InChI=1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-/m0/s1
DMOUC09	CS	C1=CC(=C(C=C1[C@H](CN)O)O)O
DMOUC09	IK	SFLSHLFXELFNJZ-QMMMGPOBSA-N
DMOUC09	IU	4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
DMOUC09	CA	CAS 51-41-2
DMOUC09	CB	CHEBI:18357
DMOUC09	DE	Sepsis

DMTY169	ID	DMTY169
DMTY169	DN	Norethindrone
DMTY169	HS	Approved
DMTY169	SN	Activella; Anhydrohydroxynorprogesterone; Anovulatorio; Anovule; Brevicon; Brevinor; Camila; Ciclovulan; Conceplan;Conludaf; Conludag; Demulen; Errin; Estrinor; Ethinylnortestosterone; Ethynylmortestosterone; Ethynylnortestosterone; Gencept; Genora; Gestest; Jenest; Loestrin; Menzol; Microneth; Micronett; Micronor; Micronovum; Milli; Minovlar; Nelova; Nodiol; Noraethisteronum; Noralutin; Norcept; Norcolut; Norcolute; Noresthisterone; Norethadrone; Norethin; Norethindirone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Noretisterone; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Normapause; Norpregneninlone; Norpregneninolone; Norpregneninotone; Orlest; Proluteasi; Synphase; Triella; Utovlan; Utovlar; Component of Noriday; Norethindrone Norethisterone; Norethindrone [USAN]; Norethisterone [Progestins]; Noretisterone [DCIT]; Primolut N; Brevinor 21; Brevinor 28; Noriday 28; Ortho 1 35; Ortho 7 7 7; Ovysmen 1 35; SC 4640; Synphasic 28; Trinovum 21; Brevinor-1 21; Brevinor-1 28; Camila (TN); Jenest-28; Micronor (TN); Mini-Pe; Mini-pill; Nor-QD; Nora-BE; Norcept-E; Norethin 1/35 E; Norethin 1/50 M; Norethindrone (USP); Norethisterone (JP15); Norethisteronum [INN-Latin]; Noretisterona [INN-Spanish]; Ortho-Novum 1 35; Ortho-Novum 1 50; Ortho-Novum 7 7 7; Ovysmen 0.5 35; Primolut-N; Tri-Norinyl; Ethinyl-19-nortestosterone; Nor-Q.D; Primolut-N (TN); Nor-Q.D.; 17-Ethinyl-19-nortestosterone; 17-Ethynyl-17-hydroxyestr-4-en-3-one; 17-alpha-Ethynyl-19-nortestosterone; 17-alpha-Ethynyl-4-estren-17-ol-3-one; 17-ethynyl-17beta-hydroxyestr-4-en-3-one; 17.alpha.-Ethinyl-19-nortestosterone; 17.alpha.-Ethynyl-19-nortestosterone; 17.alpha.-Ethynyl-4-estren-17-ol-3-one; 17alpha-Ethinyl-19-nortestosterone; 17alpha-Ethynyl-19-nortestosterone; 17alpha-Ethynyl-4-estren-17-ol-3-one; 19-Nor-17-alpha-ethynyltestosterone; 19-Nor-17-ethinyltestosterone; 19-Nor-17.alpha.-ethynyltestosterone; 19-Nor-17alpa-ethynyltestosterone; 19-Nor-17alpha-ethynyltestosterone; 19-Nor-ethindrone; 19-Nor-ethinyl-4,5-testosterone; 19-Norethindrone; 19-Norethinyltestosterone; 19-Norethisterone; 4-Estren-17alpha-ethynyl-17beta-ol-3-one
DMTY169	CP	Parke Davis Div Warner Lambert Co
DMTY169	TC	Contraceptive Agents
DMTY169	DT	Small molecular drug
DMTY169	PC	6230
DMTY169	MW	298.4
DMTY169	FM	C20H26O2
DMTY169	IC	InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
DMTY169	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DMTY169	IK	VIKNJXKGJWUCNN-XGXHKTLJSA-N
DMTY169	IU	(8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DMTY169	CA	CAS 68-22-4
DMTY169	CB	CHEBI:7627
DMTY169	DE	Solid tumour/cancer

DMDGCQP	ID	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	HS	Approved
DMDGCQP	SN	Noresthisterone; Norethadrone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Norpregneninlone; Norpregneninolone; Primolut-N; Proluteasi; Synphase; Triella; Utovlan; Utovlar; norethindrone; 19-Nor-ethindrone; 19-Norethisterone; 68-22-4; Anovulatorio; Anovule; Camila; Ciclovulan; Conludaf; Conludag; Ethinylnortestosterone; Gestest; Microneth; Micronett; Micronor; Micronovum; Mini-Pe; Mini-pill; Minovlar; Nor-QD; Noralutin; Norcolut; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
DMDGCQP	PC	5832
DMDGCQP	MW	340.5
DMDGCQP	FM	C22H28O3
DMDGCQP	IC	IMONTRJLAWHYGT-ZCPXKWAGSA-N
DMDGCQP	CS	CC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C#C
DMDGCQP	IK	1S/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,13,17-20H,5-12H2,2-3H3/t17-,18+,19+,20-,21-,22-/m0/s1
DMDGCQP	IU	[(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
DMDGCQP	CA	CAS 51-98-9
DMDGCQP	CB	CHEBI:7628
DMDGCQP	DE	Menorrhagia

DMIZ6W2	ID	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	HS	Approved
DMIZ6W2	SN	Baccidal; Barazan; Chibroxin; Fulgram; Lexinor; NFLX; Norflo; Norfloxacine; Norfloxacino; Norfloxacinum; Noroxin; Sebercim; Merck Brand of Norfloxacin; Norfloxacin Merck Brand; AM 0715; AM 715; AM0715; MK 0366; MK 366; MK0366; MK366; AM-0715; AM-715; Chibroxin (TN); Insensye (TN); MK-0366; MK-366; Norflohexal (TN); Norfloxacine [INN-French]; Norfloxacino [INN-Spanish]; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin (TN); Nufloxib (TN); Roxin (TN); Utin (TN); Utinor (TN); Apo-Norflox (TN); Norfloxacin (JP15/USP/INN); Norfloxacin [USAN:BAN:INN:JAN]; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DMIZ6W2	TC	Antibiotics
DMIZ6W2	DT	Small molecular drug
DMIZ6W2	PC	4539
DMIZ6W2	MW	319.33
DMIZ6W2	FM	C16H18FN3O3
DMIZ6W2	IC	InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
DMIZ6W2	CS	CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
DMIZ6W2	IK	OGJPXUAPXNRGGI-UHFFFAOYSA-N
DMIZ6W2	IU	1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DMIZ6W2	CA	CAS 70458-96-7
DMIZ6W2	CB	CHEBI:100246
DMIZ6W2	DE	Bacterial infection

DMYP4XC	ID	DMYP4XC
DMYP4XC	DN	Norgestimate
DMYP4XC	HS	Approved
DMYP4XC	SN	Norgestimato; Norgestimatum; Dexnorgestrel acetime; Norgestrel oxime acetate; D 138; ORF 10131; RWJ 10131; Norgestimato [INN-Spanish]; Norgestimatum [INN-Latin]; ORF-10131; Ortho-Prefest; RWJ-10131; Norgestimate (USP/INN); Norgestimate [USAN:INN:BAN]; D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-oneoxime; D-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime; [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate; (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester); (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate
DMYP4XC	TC	Contraceptive Agents
DMYP4XC	DT	Small molecular drug
DMYP4XC	PC	6540478
DMYP4XC	MW	369.5
DMYP4XC	FM	C23H31NO3
DMYP4XC	IC	InChI=1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1
DMYP4XC	CS	CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)C)CCC4=C/C(=N/O)/CC[C@H]34
DMYP4XC	IK	KIQQMECNKUGGKA-NMYWJIRASA-N
DMYP4XC	IU	[(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
DMYP4XC	CA	CAS 20799-27-3
DMYP4XC	CB	CHEBI:50815
DMYP4XC	DE	Contraception

DM4KDYJ	ID	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	HS	Approved
DM4KDYJ	SN	Acetexa; Allegron; Altilev; Ateben; Avantyl; Aventyl; Demethylamitriptylene; Demethylamitriptyline; Demethylamitryptyline; Desitriptilina; Desitriptyline; Desmethylamitriptylin; Desmethylamitriptyline; Lumbeck; Noramitriptyline; Noritren; Nortrilen; Nortriptilina; Nortriptylinum; Nortryptiline; Nortryptyline; Pamelor; Psychostyl; Sensaval; Sesaval; Vividyl; AVENTYL HCL; Nortriptilina [DCIT]; Nortriptylene hydrochloride; Pamelor hydrochloride; Sensival Ventyl; NCI169453; Allegron (TN); Aventyl (TN); Norpress (TN); Nortrilen (TN); Nortriptyline (INN); Nortriptyline [INN:BAN]; Nortriptylinum [INN-Latin]; Pamelor (TN); Sensoval (TN); N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin; (2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene
DM4KDYJ	TC	Antidepressants
DM4KDYJ	DT	Small molecular drug
DM4KDYJ	PC	4543
DM4KDYJ	MW	263.4
DM4KDYJ	FM	C19H21N
DM4KDYJ	IC	InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
DM4KDYJ	CS	CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
DM4KDYJ	IK	PHVGLTMQBUFIQQ-UHFFFAOYSA-N
DM4KDYJ	IU	N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
DM4KDYJ	CA	CAS 72-69-5
DM4KDYJ	CB	CHEBI:7640
DM4KDYJ	DE	Depression

DMRFWGK	ID	DMRFWGK
DMRFWGK	DN	Novobiocin
DMRFWGK	HS	Approved
DMRFWGK	SN	Albamix; Albamycin; Cardelmycin; Cathocin; Cathomycin; Inamycin; NOV; Novobiocina; Novobiocine; Novobiocinum; Robiocina; Sirbiocina; Spheromycin; Stilbiocina; Streptonivicin; Crystallinic acid; Novobiocin sodium salt; PA 93; U 6391; Albamycin (TN); Antibiotic PA-93; Novo-R; Novobiocin [INN:BAN]; Novobiocina [INN-Spanish]; Novobiocine [INN-French]; Novobiocinum [INN-Latin]; Streptonivicin (*Sodium salt*); [(3R,4S,5R,6R)-5-hydroxy-6-[2-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate; N-[7-[[3-O-(Aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-.beta.-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl); (3R,4S,5R,6R)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2H-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate; (3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]amino}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate(non-preferred name); 7-(3-(O-Carbamoyl)-4-(O-methyl)-5,5-dimethyl-alpha-L-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin; 7-(Carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2H-chromen-2-one
DMRFWGK	CP	Pfizer Pharmaceuticals
DMRFWGK	TC	Antibiotics
DMRFWGK	DT	Small molecular drug
DMRFWGK	PC	54675769
DMRFWGK	MW	612.6
DMRFWGK	FM	C31H36N2O11
DMRFWGK	IC	InChI=1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1
DMRFWGK	CS	CC1=C(C=CC2=C1OC(=O)C(=C2O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)OC(=O)N)O
DMRFWGK	IK	YJQPYGGHQPGBLI-KGSXXDOSSA-N
DMRFWGK	IU	[(3R,4S,5R,6R)-5-hydroxy-6-[4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate
DMRFWGK	CA	CAS 303-81-1
DMRFWGK	CB	CHEBI:28368
DMRFWGK	DE	Bacterial infection

DM6ZPLQ	ID	DM6ZPLQ
DM6ZPLQ	DN	Novolimus
DM6ZPLQ	HS	Approved
DM6ZPLQ	CP	Elixir Medical
DM6ZPLQ	PC	9854320
DM6ZPLQ	MW	900.1
DM6ZPLQ	FM	C50H77NO13
DM6ZPLQ	IC	InChI=1S/C50H77NO13/c1-29-15-11-10-12-16-30(2)40(53)27-37-20-18-35(7)50(60,64-37)47(57)48(58)51-22-14-13-17-38(51)49(59)63-42(32(4)25-36-19-21-39(52)43(26-36)61-8)28-41(54)31(3)24-34(6)45(56)46(62-9)44(55)33(5)23-29/h10-12,15-16,24,29,31-33,35-40,42-43,45-46,52-53,56,60H,13-14,17-23,25-28H2,1-9H3/b12-10+,15-11+,30-16+,34-24+/t29-,31-,32-,33-,35-,36+,37+,38+,39-,40+,42+,43-,45-,46+,50-/m1/s1
DM6ZPLQ	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)O
DM6ZPLQ	IK	ZHYGVVKSAGDVDY-QQQXYHJWSA-N
DM6ZPLQ	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18,30-trihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM6ZPLQ	CA	CAS 151519-50-5
DM6ZPLQ	DE	Artery stenosis

DMRSX53	ID	DMRSX53
DMRSX53	DN	nusinersen
DMRSX53	HS	Approved
DMRSX53	SN	BIIB 058; IONIS-SMNRx; ISIS-396443; Spinraza
DMRSX53	CP	Biogen/Ionis Pharmaceuticals
DMRSX53	DT	Antisense drug
DMRSX53	SQ	5'-UCACUUUCAUAAUGCUGG
DMRSX53	DE	Spinal muscular atrophy

DM63QS9	ID	DM63QS9
DM63QS9	DN	Nystatin
DM63QS9	HS	Approved
DM63QS9	SN	Biofanal; Comycin; Diastatin; Fungicidin; Herniocid; Korostatin; Moronal; Myconystatin; Mycostatin; Mykinac; Mykostatyna; Nilstat; Nistatin; Nistatina; Nyamyc; Nyotran; Nystaform; Nystan; Nystatine; Nystatinum; Nystatyna; Nystavescent; Nystex; Nystop; Stamicin; Stamycin; Terrastatin; Candex Lotion; Mycostatin Pastilles; Nystatin A; Nystatin G; Nystatin preparation; Nystatyna [Polish]; Zydin E; Barstatin 100; Mycostatin 20; Nystatin A1; Nystatin A2; Nystatin A3; Animax (TN); Candio-hermal; Flagystatin II (TN); Infestat (TN); Korostatin (TN); Lystin (TN); Moronal (antibiotic); Mycostatin (TN); Mykacet (TN); Mykinac (TN); Mytrex (TN); Nidoflor (TN); Nilstat (TN); Nistatina (TN); Nistatina [INN-Spanish]; Nysert (TN);Nystaform (TN); Nystalocal (TN); Nystamont (TN); Nystan (TN); Nystatin LF (liposome); Nystatine [INN-French]; Nystatinum [INN-Latin]; Nystex (TN); Nystop (TN); O-V Statin; Myco-Triacet II (TN); Mycolog-II (TN); Nystatin A1, A2, A3 complex; Nystatin [INN:BAN:JAN]; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-a-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-alpha-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (4E,6E,8E,10E,14E,16E)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,35S)-3-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,21S,35S)-3-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid
DM63QS9	CP	Bristol-Myers Squibb
DM63QS9	TC	Antifungal Agents
DM63QS9	DT	Small molecular drug
DM63QS9	PC	6433272
DM63QS9	MW	926.1
DM63QS9	FM	C47H75NO17
DM63QS9	IC	InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1
DM63QS9	CS	C[C@H]1/C=C/C=C/CC/C=C/C=C/C=C/C=C/C(CC2C(C(C[C@](O2)(CC(C(CCC(CC(CC(CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
DM63QS9	IK	VQOXZBDYSJBXMA-RKEBNKJGSA-N
DM63QS9	IU	(1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid
DM63QS9	CA	CAS 1400-61-9
DM63QS9	CB	CHEBI:473992
DM63QS9	DE	Fungal infection

DM3Q1SM	ID	DM3Q1SM
DM3Q1SM	DN	Obeticholic acid
DM3Q1SM	HS	Approved
DM3Q1SM	SN	INT747; INT-747; 6-ethylchenodeoxycholic acid; 6-ECDCA; OCA; 6-Et CDCA
DM3Q1SM	CP	Intercept
DM3Q1SM	DT	Small molecular drug
DM3Q1SM	PC	447715
DM3Q1SM	MW	420.6
DM3Q1SM	FM	C26H44O4
DM3Q1SM	IC	InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1
DM3Q1SM	CS	CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O
DM3Q1SM	IK	ZXERDUOLZKYMJM-ZWECCWDJSA-N
DM3Q1SM	IU	(4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM3Q1SM	CA	CAS 459789-99-2
DM3Q1SM	CB	CHEBI:43602
DM3Q1SM	DE	Primary biliary cholangitis; Insomnia

DM3BVAE	ID	DM3BVAE
DM3BVAE	DN	Obinutuzumab
DM3BVAE	HS	Approved
DM3BVAE	SN	GA101/RG7159
DM3BVAE	CP	Biogen Idec; Genentech
DM3BVAE	DT	Antibody
DM3BVAE	DE	Chronic lymphocytic leukaemia; Haematological malignancy

DMEZ2KH	ID	DMEZ2KH
DMEZ2KH	DN	Ocrelizumab
DMEZ2KH	HS	Approved
DMEZ2KH	SN	Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)
DMEZ2KH	CP	Roche/Genentech
DMEZ2KH	DT	Antibody
DMEZ2KH	DE	Multiple sclerosis; Diffuse large B-cell lymphoma

DM7AVGW	ID	DM7AVGW
DM7AVGW	DN	Ocriplasmin
DM7AVGW	HS	Approved
DM7AVGW	CP	ThromboGenics
DM7AVGW	SQ	Protein sequence for the truncated heavy chain: APSFDCGKPQVEPKKCPGR</sequence>    <sequence format="FASTA">&gt;Protein sequence for the light chain VVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN
DM7AVGW	DE	Symptomatic vitreomacular adhesion

DMHIDCJ	ID	DMHIDCJ
DMHIDCJ	DN	Octreotide
DMHIDCJ	HS	Approved
DMHIDCJ	SN	Longastatin; Octreotida; Octreotidum; Sandostatine; Octreotida [Spanish]; Octreotide Acetate Salt; Octreotidum [Latin]; DRG-0115; HS-2020; Octreotide-LAR; SAN 201-995; SM 201-995; SMS 201-995; Sandostatin (TN); Sandoz 201-995; Octreotide (USAN/INN); Octreotide [USAN:INN:BAN]; SMS-201-995; Zacycloicosane-4-carboxamide acetate; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMHIDCJ	CP	Norvatis Phamaceuticals Corporation
DMHIDCJ	TC	Anabolic Agents
DMHIDCJ	DT	Small molecular drug
DMHIDCJ	PC	448601
DMHIDCJ	MW	1019.2
DMHIDCJ	FM	C49H66N10O10S2
DMHIDCJ	IC	InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1
DMHIDCJ	CS	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O
DMHIDCJ	IK	DEQANNDTNATYII-OULOTJBUSA-N
DMHIDCJ	IU	(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMHIDCJ	CA	CAS 83150-76-9
DMHIDCJ	DE	Acromegaly

DMZK0FQ	ID	DMZK0FQ
DMZK0FQ	DN	Oestradiol valerate and dienogest
DMZK0FQ	HS	Approved
DMZK0FQ	SN	Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one;  Natazia (TN)
DMZK0FQ	CP	Bayer
DMZK0FQ	DT	Small molecular drug
DMZK0FQ	PC	68861
DMZK0FQ	MW	311.4
DMZK0FQ	FM	C20H25NO2
DMZK0FQ	IC	InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1
DMZK0FQ	CS	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O
DMZK0FQ	IK	AZFLJNIPTRTECV-FUMNGEBKSA-N
DMZK0FQ	IU	2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile
DMZK0FQ	CA	CAS 65928-58-7
DMZK0FQ	CB	CHEBI:70708
DMZK0FQ	DE	Endometriosis; Contraception

DM295PR	ID	DM295PR
DM295PR	DN	Ofatumumab
DM295PR	HS	Approved
DM295PR	SN	Arzerra (TN)
DM295PR	CP	GlaxoSmithKline
DM295PR	DT	Antibody
DM295PR	SQ	Ofatumumab Heavy Chain: EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPGSSKSTSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP</sequence>    <sequence format="FASTA">&gt;Ofatumumab Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DM295PR	DE	Chronic lymphocytic leukaemia; Rheumatoid arthritis; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma

DM0VQN3	ID	DM0VQN3
DM0VQN3	DN	Ofloxacin
DM0VQN3	HS	Approved
DM0VQN3	SN	Bactocin; DEXTROFLOXACINE; Danoflox; Effexin; Exocin; Exocine; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxstat; Fugacin; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Medofloxine; Mergexin; Novecin; Nufafloqo; OFLX; OFX; Obide; Occidal; Ocuflox; Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacina; Ofloxacine; Ofloxacino; Ofloxacinum; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Viotisone; Visiren; XED; Zanocin; Floxin otic; Ofloxacin Otic; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacino [Spanish]; Ofloxacinum [Latin]; Uro Tarivid; DL 8280; HOE 280; O 8757; ORF 18489; PT 01; DL-8280; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Floxin Otic (TN); HOE-280; Hoe-280; Marfloxacin (TN); O-Flox; ORF-28489; Ocuflox (TN); Ru-43280; WP-0405; Ofloxacin (JP15/USP/INN); Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
DM0VQN3	CP	Janssen Pharmaceutica
DM0VQN3	TC	Antibiotics
DM0VQN3	DT	Small molecular drug
DM0VQN3	PC	4583
DM0VQN3	MW	361.4
DM0VQN3	FM	C18H20FN3O4
DM0VQN3	IC	InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
DM0VQN3	CS	CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
DM0VQN3	IK	GSDSWSVVBLHKDQ-UHFFFAOYSA-N
DM0VQN3	IU	7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DM0VQN3	CA	CAS 82419-36-1
DM0VQN3	CB	CHEBI:7731
DM0VQN3	DE	Bacterial infection

DMQ4PKA	ID	DMQ4PKA
DMQ4PKA	DN	Olamufloxacin
DMQ4PKA	HS	Approved
DMQ4PKA	SN	Olamufloxacin; HSR-903; UNII-LJG8KL1435; HSR 903; LJG8KL1435; J-502473; (S)-5-Amino-7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-(-)-5-Amino-7-(7-amino-5-azaspiro[2,4]hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid; 5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-quinoline-3-carboxylic acid; Olamufloxacin [INN]; AC1Q5RCW; AC1L9XAZ; SCHEMBL1851976
DMQ4PKA	PC	477670
DMQ4PKA	MW	386.4
DMQ4PKA	FM	C20H23FN4O3
DMQ4PKA	IC	InChI=1S/C20H23FN4O3/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28)/t12-/m1/s1
DMQ4PKA	CS	CC1=C2C(=C(C(=C1N3CC(C4(C3)CC4)N)F)N)C(=O)C(=CN2C5CC5)C(=O)O
DMQ4PKA	IK	LEILBPMISZFZQK-GFCCVEGCSA-N
DMQ4PKA	IU	5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid
DMQ4PKA	CA	CAS 167887-97-0
DMQ4PKA	DE	Bacterial infections

DMPFN6Y	ID	DMPFN6Y
DMPFN6Y	DN	Olanzapine
DMPFN6Y	HS	Approved
DMPFN6Y	SN	Lanzac; Midax; Olansek; Olanzapina; Olanzapinum; Symbyax; Zalasta; Zydis; Zyprexa; Eli Lilly brand of olanzapine; Lilly brand of olanzapine; Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis; LY 170053; ALKS-7921; KS-1090; LY-170052; LY-170053; Olanzapine (OLA); Olanzapine [USAN:INN]; Olzapin (TN); Rexapin (TN); Zalasta (TN); Zolafren (TN); Zydis (TN); Zyprexa (TN); Olanzapine (JAN/USAN/INN); 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
DMPFN6Y	CP	Eli Lilly
DMPFN6Y	TC	Antipsychotic Agents
DMPFN6Y	DT	Small molecular drug
DMPFN6Y	PC	135398745
DMPFN6Y	MW	312.4
DMPFN6Y	FM	C17H20N4S
DMPFN6Y	IC	InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
DMPFN6Y	CS	CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
DMPFN6Y	IK	KVWDHTXUZHCGIO-UHFFFAOYSA-N
DMPFN6Y	IU	2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
DMPFN6Y	CA	CAS 132539-06-1
DMPFN6Y	CB	CHEBI:7735
DMPFN6Y	DE	Schizophrenia

DM0Y49P	ID	DM0Y49P
DM0Y49P	DN	Olanzapine/fluoxetine combination
DM0Y49P	HS	Approved
DM0Y49P	SN	Symbyax (Zyprexa/Prozac)
DM0Y49P	CP	Eli Lilly; Eli Lilly & Co
DM0Y49P	DT	Small molecular drug
DM0Y49P	PC	24848071
DM0Y49P	DE	Depression

DM8QB1D	ID	DM8QB1D
DM8QB1D	DN	Olaparib
DM8QB1D	HS	Approved
DM8QB1D	SN	AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
DM8QB1D	CP	AstraZeneca
DM8QB1D	DT	Small molecular drug
DM8QB1D	PC	23725625
DM8QB1D	MW	434.5
DM8QB1D	FM	C24H23FN4O3
DM8QB1D	IC	InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
DM8QB1D	CS	C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
DM8QB1D	IK	FDLYAMZZIXQODN-UHFFFAOYSA-N
DM8QB1D	IU	4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
DM8QB1D	CA	CAS 763113-22-0
DM8QB1D	CB	CHEBI:83766
DM8QB1D	DE	Ovarian cancer; Pancreatic cancer; Prostate cancer

DMNYOIX	ID	DMNYOIX
DMNYOIX	DN	Olaratumab
DMNYOIX	HS	Approved
DMNYOIX	SN	LY3012207
DMNYOIX	CP	Eli Lilly
DMNYOIX	DT	Monoclonal antibody
DMNYOIX	SQ	Heavy Chain: QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMNYOIX	DE	Soft tissue sarcoma; Non-small-cell lung cancer

DM6MDCF	ID	DM6MDCF
DM6MDCF	DN	Oliceridine
DM6MDCF	HS	Approved
DM6MDCF	SN	TRV130A
DM6MDCF	DT	Small molecular drug
DM6MDCF	PC	66553195
DM6MDCF	MW	386.6
DM6MDCF	FM	C22H30N2O2S
DM6MDCF	IC	InChI=1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1
DM6MDCF	CS	COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
DM6MDCF	IK	DMNOVGJWPASQDL-OAQYLSRUSA-N
DM6MDCF	IU	N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine
DM6MDCF	CA	CAS 1401028-24-7
DM6MDCF	DE	Thyroid disease; Acute pain

DMWBHRY	ID	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	HS	Approved
DMWBHRY	SN	Benevas; Benicar; Olmetec; Olvance; Forest Brand of Olmesartan Medoxomil; Olmesartan medoximil; Sankyo Brand of Olmesartan Medoxomil; Cs 866; Benicar (TN); Berlin-Chemie Brand of Olmesartan Medoxomil; CS-866; CS-866DM; CS-866RN; DE-092; KS-1182; Olmetec (TN); Benicar, Olmetec,Olmesartan; Olmesartan medoxomil (JAN/USAN); (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; 1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
DMWBHRY	TC	Antihypertensive Agents
DMWBHRY	DT	Small molecular drug
DMWBHRY	PC	130881
DMWBHRY	MW	558.6
DMWBHRY	FM	C29H30N6O6
DMWBHRY	IC	InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
DMWBHRY	CS	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
DMWBHRY	IK	UQGKUQLKSCSZGY-UHFFFAOYSA-N
DMWBHRY	IU	(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
DMWBHRY	CA	CAS 144689-63-4
DMWBHRY	CB	CHEBI:31932
DMWBHRY	DE	High blood pressure

DM62B78	ID	DM62B78
DM62B78	DN	Olodaterol
DM62B78	HS	Approved
DM62B78	SN	BI-1744
DM62B78	CP	Boehringer Ingelheim Pharmaceuticals
DM62B78	DT	Small molecular drug
DM62B78	PC	11504295
DM62B78	MW	386.4
DM62B78	FM	C21H26N2O5
DM62B78	IC	InChI=1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1
DM62B78	CS	CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C(=CC(=C2)O)NC(=O)CO3)O
DM62B78	IK	COUYJEVMBVSIHV-SFHVURJKSA-N
DM62B78	IU	6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one
DM62B78	CA	CAS 868049-49-4
DM62B78	CB	CHEBI:82700
DM62B78	DE	Chronic obstructive pulmonary disease

DMKMWQG	ID	DMKMWQG
DMKMWQG	DN	Olopatadine
DMKMWQG	HS	Approved
DMKMWQG	SN	Allelock; Opatanol; Pataday; Patanase; Patanol; OLOPATADINE HCl; OLOPATADINE HYDROCHLORIDE; ALO4943A; HCl of KW 4679; KW 4679; O0361; AL-4943A; ALO-4943A; Allelock (TN); KW-4679; KW-4943A; Olopatadine [INN:BAN]; Pataday (TN); Patanase (TN); Patanol S (TN); {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride
DMKMWQG	CP	Alcon
DMKMWQG	TC	Antiallergic Agents
DMKMWQG	DT	Small molecular drug
DMKMWQG	PC	5281071
DMKMWQG	MW	337.4
DMKMWQG	FM	C21H23NO3
DMKMWQG	IC	InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
DMKMWQG	CS	CN(C)CC/C=C\\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O
DMKMWQG	IK	JBIMVDZLSHOPLA-LSCVHKIXSA-N
DMKMWQG	IU	2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
DMKMWQG	CA	CAS 113806-05-6
DMKMWQG	CB	CHEBI:94593
DMKMWQG	DE	Allergic conjunctivitis; Ocular allergy

DMWBQKU	ID	DMWBQKU
DMWBQKU	DN	Olprinone
DMWBQKU	HS	Approved
DMWBQKU	SN	Olprinone; 106730-54-5; loprinone; Coretec; Olprinone [INN]; UNII-4Y8BMI9YGC; 4Y8BMI9YGC; C14H10N4O; Olprinone (INN); 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile; 1,2-Dihydro-5-imidazo(1,2-alpha)pyridin-6-yl-6-methyl-2-oxonicotinonitrile; 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridinecarbonitrile; AC1L1IIG; AC1Q4Q1U; SCHEMBL27661; DTXSID1048461; CHEMBL1474900; KS-00000EYK; MolPort-006-394-808; JPAWFIIYTJQOKW-UHFFFAOYSA-N; CHEBI:135019; BCP09781; ZINC38192538; HY-14254A; 3950AH
DMWBQKU	DT	Small molecular drug
DMWBQKU	PC	4593
DMWBQKU	MW	250.25
DMWBQKU	FM	C14H10N4O
DMWBQKU	IC	InChI=1S/C14H10N4O/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10/h2-6,8H,1H3,(H,17,19)
DMWBQKU	CS	CC1=C(C=C(C(=O)N1)C#N)C2=CN3C=CN=C3C=C2
DMWBQKU	IK	JPAWFIIYTJQOKW-UHFFFAOYSA-N
DMWBQKU	IU	5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile
DMWBQKU	CA	CAS 106730-54-5
DMWBQKU	CB	CHEBI:135019
DMWBQKU	DE	Heart failure

DMZW9HA	ID	DMZW9HA
DMZW9HA	DN	Olsalazine
DMZW9HA	HS	Approved
DMZW9HA	SN	Azodisal; Dipentum; Olsalazine sodium; Di-mesalazine
DMZW9HA	CP	Pharmacia & Upjohn AB
DMZW9HA	DT	Small molecular drug
DMZW9HA	PC	22419
DMZW9HA	MW	302.24
DMZW9HA	FM	C14H10N2O6
DMZW9HA	IC	InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)
DMZW9HA	CS	C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
DMZW9HA	IK	QQBDLJCYGRGAKP-UHFFFAOYSA-N
DMZW9HA	IU	5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid
DMZW9HA	CA	CAS 15722-48-2
DMZW9HA	CB	CHEBI:7770
DMZW9HA	DE	Ulcerative colitis

DMPU2WX	ID	DMPU2WX
DMPU2WX	DN	Omacetaxine mepesuccinate
DMPU2WX	HS	Approved
DMPU2WX	SN	Synribo (TN)
DMPU2WX	CP	Ivax
DMPU2WX	DT	Small molecular drug
DMPU2WX	PC	285033
DMPU2WX	MW	545.6
DMPU2WX	FM	C29H39NO9
DMPU2WX	IC	InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1
DMPU2WX	CS	CC(C)(CCC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O
DMPU2WX	IK	HYFHYPWGAURHIV-JFIAXGOJSA-N
DMPU2WX	IU	1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
DMPU2WX	CA	CAS 26833-87-4
DMPU2WX	CB	CHEBI:71019
DMPU2WX	DE	Chronic myeloid leukaemia

DMR2J95	ID	DMR2J95
DMR2J95	DN	Omadacycline
DMR2J95	HS	Approved
DMR2J95	SN	UNII-090IP5RV8F; 090IP5RV8F; Omadacycline [USAN:INN]; Omadacycline (USAN); AC1NUY3H; Amadacycline methanesulfonate; SCHEMBL152
DMR2J95	CP	Paratek Pharmaceuticals
DMR2J95	PC	54697325
DMR2J95	MW	556.6
DMR2J95	FM	C29H40N4O7
DMR2J95	IC	InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1
DMR2J95	CS	CC(C)(C)CNCC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
DMR2J95	IK	VJYKVCURWJGLPG-IQZGDKDPSA-N
DMR2J95	IU	(4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMR2J95	CA	CAS 389139-89-3
DMR2J95	DE	Acute bacterial skin infection; Bacterial pneumonia; Bacterial infection

DMU5G01	ID	DMU5G01
DMU5G01	DN	Omadacycline
DMU5G01	HS	Approved
DMU5G01	SN	Amadacycline; Amadacycline (intravenous), Merck & Co; Amadacycline (intravenous), Paratek/Novartis; Amadacycline (oral), Merck & Co; Amadacycline (oral), Paratek/ Novartis; Antibacterial aminomethycyclines, Paratek/Bayer; MK-2764; Omadacycline; Omadacycline (intravenous), Merck & Co; Omadacycline (intravenous), Paratek; Omadacycline (intravenous), Paratek/ Novartis; Omadacycline (oral), Merck & Co; Omadacycline (oral), Paratek; Omadacycline (oral), Paratek/ Novartis; Omadacycline tosylate; P-000538; P-000642; P-001075; P-001207; P-001221; P-00136; P-002352; PTK-0796; PTK-796; Sancycline derivatives, Paratek; Tetracycline analogs, GlaxoSmithKline/Paratek; Tetracycline analogs, Paratek/Merck & Co;Tetracycline analogs (multi-drug-resistant infections), Paratek/Bayer
DMU5G01	TC	Antibiotics
DMU5G01	DT	Small molecular drug
DMU5G01	PC	54697325
DMU5G01	MW	556.66
DMU5G01	FM	C29H40N4O7
DMU5G01	IC	InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1
DMU5G01	CS	CC(C)(C)CNCC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
DMU5G01	IK	VJYKVCURWJGLPG-IQZGDKDPSA-N
DMU5G01	IU	(4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMU5G01	CA	CAS 389139-89-3
DMU5G01	DE	Acute skin infections; Community-acquired bacterial pneumonia

DMETVFJ	ID	DMETVFJ
DMETVFJ	DN	Omalizumab
DMETVFJ	HS	Approved
DMETVFJ	SN	Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)
DMETVFJ	CP	National University Hospital, Singapore|National University, Singapore
DMETVFJ	TC	Antiasthmatic Agents
DMETVFJ	DT	Monoclonal antibody
DMETVFJ	SQ	Omalizumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Omalizumab light chainDIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMETVFJ	DE	Asthma; Chronic idiopathic urticaria

DML9TI0	ID	DML9TI0
DML9TI0	DN	Ombitasvir + paritaprevir + ritonavir
DML9TI0	HS	Approved
DML9TI0	SN	ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); Viekirax
DML9TI0	TC	Antiinfective Agents
DML9TI0	DE	Hepatitis C virus infection

DM471KJ	ID	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	HS	Approved
DM471KJ	SN	Losec (TN)
DM471KJ	CP	AstraZeneca
DM471KJ	TC	Antiulcer Agents
DM471KJ	DT	Small molecular drug
DM471KJ	PC	4594
DM471KJ	MW	345.4
DM471KJ	FM	C17H19N3O3S
DM471KJ	IC	InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
DM471KJ	CS	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
DM471KJ	IK	SUBDBMMJDZJVOS-UHFFFAOYSA-N
DM471KJ	IU	6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DM471KJ	CA	CAS 73590-58-6
DM471KJ	CB	CHEBI:77260
DM471KJ	DE	Gastroesophageal reflux disease

DMOTQ1I	ID	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	HS	Approved
DMOTQ1I	SN	DESMETHYLONDANSETRON; Zofran; Zophren; Zudan; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran ODT; GR 38032; GR 38032X; GR38032F; Apo-ondansetron; GR-38032F; Novo-ondansetron; Ondansetron (Zofran); PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Zofran (TN); Zofran ODT (TN); Ondansetron [USAN:INN:BAN]; Ondansetron (JAN/USP/INN); Ondansetron, (+,-)-Isomer; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
DMOTQ1I	CP	GlaxoSmithKline
DMOTQ1I	TC	Antiemetics
DMOTQ1I	DT	Small molecular drug
DMOTQ1I	PC	4595
DMOTQ1I	MW	293.4
DMOTQ1I	FM	C18H19N3O
DMOTQ1I	IC	InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
DMOTQ1I	CS	CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
DMOTQ1I	IK	FELGMEQIXOGIFQ-UHFFFAOYSA-N
DMOTQ1I	IU	9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
DMOTQ1I	CA	CAS 99614-02-5
DMOTQ1I	CB	CHEBI:7773
DMOTQ1I	DE	Chemotherapy-induced nausea; Alcohol dependence

DMHG57U	ID	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	HS	Approved
DMHG57U	SN	Brexpiprazole
DMHG57U	CP	Lundbeck; Otsuka America Pharmaceutical
DMHG57U	DT	Small molecular drug
DMHG57U	PC	11978813
DMHG57U	MW	433.6
DMHG57U	FM	C25H27N3O2S
DMHG57U	IC	InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)
DMHG57U	CS	C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4
DMHG57U	IK	ZKIAIYBUSXZPLP-UHFFFAOYSA-N
DMHG57U	IU	7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one
DMHG57U	CA	CAS 913611-97-9
DMHG57U	CB	CHEBI:134716
DMHG57U	DE	Major depressive disorder

DM1BKA6	ID	DM1BKA6
DM1BKA6	DN	Opicapone
DM1BKA6	HS	Approved
DM1BKA6	SN	BIA-9-1067
DM1BKA6	CP	Portela & Ca SA
DM1BKA6	PC	135565903
DM1BKA6	MW	413.2
DM1BKA6	FM	C15H10Cl2N4O6
DM1BKA6	IC	InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3
DM1BKA6	CS	CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
DM1BKA6	IK	ASOADIZOVZTJSR-UHFFFAOYSA-N
DM1BKA6	IU	5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
DM1BKA6	CA	CAS 923287-50-7
DM1BKA6	CB	CHEBI:134699
DM1BKA6	DE	Parkinson disease

DMPUOXF	ID	DMPUOXF
DMPUOXF	DN	Opipramol
DMPUOXF	HS	Approved
DMPUOXF	SN	Opipramolo; Opipramolum; Opipramol dihydrochloride; Opipramol hydrochloride; Opipramoli hydrochloridum; G 33 040
DMPUOXF	DT	Small molecular drug
DMPUOXF	PC	9417
DMPUOXF	MW	363.5
DMPUOXF	FM	C23H29N3O
DMPUOXF	IC	InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2
DMPUOXF	CS	C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO
DMPUOXF	IK	YNZFUWZUGRBMHL-UHFFFAOYSA-N
DMPUOXF	IU	2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol
DMPUOXF	CA	CAS 315-72-0
DMPUOXF	CB	CHEBI:94614
DMPUOXF	DE	Anxiety disorder

DMTSRI6	ID	DMTSRI6
DMTSRI6	DN	Oprelvekin
DMTSRI6	HS	Approved
DMTSRI6	SN	Neumega; Neumega (TN); Oprelvekin (genetical recombination); Oprelvekin (USAN/INN); Oprelvekin (genetical recombination) (JAN)
DMTSRI6	CP	Wyeth Pharmaceuticals
DMTSRI6	TC	Anticoagulants
DMTSRI6	SQ	DB00038 sequence: GPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQLLMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL
DMTSRI6	DE	Thrombocytopenia

DM28D05	ID	DM28D05
DM28D05	DN	Oritavancin
DM28D05	HS	Approved
DM28D05	SN	Nuvocid; Oritavancin [INN]; LY333328; Chlorobiphenyl-chloroeremomycin; (3S,6R,7R,22R,23S,26S,36R,38aR)-22-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-mannopyranosyloxy)-3-(carbamoylmethyl)-10,19-dichloro-44-[2-O-[3-(4'-chlorobiphenyl-4-ylmethylamino)-2,3,6-trideoxy-3-C-me; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-(4'-chloro[1,1'-biphenyl]-4-ylmethyl)vancomycin; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin
DM28D05	CP	Eli Lilly
DM28D05	DT	Small molecular drug
DM28D05	PC	16136912
DM28D05	MW	1793.1
DM28D05	FM	C86H97Cl3N10O26
DM28D05	IC	InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1
DM28D05	CS	C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O
DM28D05	IK	VHFGEBVPHAGQPI-LXKZPTCJSA-N
DM28D05	IU	(1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
DM28D05	CA	CAS 171099-57-3
DM28D05	CB	CHEBI:82699
DM28D05	DE	Bacterial infection; Gram-positive bacterial infection

DMRJSP8	ID	DMRJSP8
DMRJSP8	DN	Orlistat
DMRJSP8	HS	Approved
DMRJSP8	SN	orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Alli; Orlipastat; (-)-Tetrahydrolipstatin; Orlipastatum; Orlipastatum [INN-Latin]; THLP; Ro-18-0647; UNII-95M8R751W8; C29H53NO5; Ro 18-0647/002; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate; Orlistat (Alli, Xenical); MLS002207022; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; CHEMBL175247;  Alli; GlaxoSmithKline brand of orlistat; Roche brand of orlistat; Alli (TN); Hoffmann-La Roche brand of orlistat; KS-1183; Orlistat [USAN:INN]; R-212; Xenical (TN); Orlistat (USAN/INN); Ro 18-0647/008; Alli, Xenical, Tetrahydrolipstatin, Orlistat; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; TETRAHYDROLIPSTATIN
DMRJSP8	CP	GlaxoSmithKline plc
DMRJSP8	TC	Antiobesity Agents
DMRJSP8	DT	Small molecular drug
DMRJSP8	PC	3034010
DMRJSP8	MW	495.7
DMRJSP8	FM	C29H53NO5
DMRJSP8	IC	InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
DMRJSP8	CS	CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
DMRJSP8	IK	AHLBNYSZXLDEJQ-FWEHEUNISA-N
DMRJSP8	IU	[(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate
DMRJSP8	CA	CAS 96829-58-2
DMRJSP8	CB	CHEBI:94686
DMRJSP8	DE	Obesity

DM6QHDJ	ID	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	HS	Approved
DM6QHDJ	DT	Small molecular drug
DM6QHDJ	PC	28061
DM6QHDJ	MW	219.62
DM6QHDJ	FM	C7H10ClN3O3
DM6QHDJ	IC	InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3
DM6QHDJ	CS	CC1=NC=C(N1CC(CCl)O)[N+](=O)[O-]
DM6QHDJ	IK	IPWKIXLWTCNBKN-UHFFFAOYSA-N
DM6QHDJ	IU	1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
DM6QHDJ	CA	CAS 16773-42-5
DM6QHDJ	CB	CHEBI:75176
DM6QHDJ	DE	Amoebiasis

DMW542E	ID	DMW542E
DMW542E	DN	Orphenadrine
DMW542E	HS	Approved
DMW542E	SN	Antiflex; Biorphen; Brocadisipal; Brocasipal; Disipal; Lysantin; Mefenamine; Mephenamine; Methyldiphenylhydramine; Myolin; Myotrol; ORP; Orfenadrina; Orfro; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrinum; Orphenate; Orphenedrine; Norflex Orphenadrine Citrate; Sodium Mefenamine; WS 2434; Banflex (TN); Biorphen (TN); Brocasipal (TN); Disipal (TN); Flexon (TN); Mephenamin (TN); Mialgin (TN); Norflex (TN); O-Methyldiphenhydramine; O-Monomethyldiphenhydramine; Orfenadrina [INN-Spanish]; Orphenadrine(INN); Orphenadrine [INN:BAN]; Orphenadrinum [INN-Latin]; Beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Phenyl-o-tolylmethyl dimethyaminoethyl ether; Beta-Dimethylaminoethyl-2-methylbenzhydryl ether; N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamin; N,N-Dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine; N,N-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine; N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine; N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine; N,N-Dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine; N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine
DMW542E	CP	3M Pharmaceuticals
DMW542E	TC	Antiparkinson Agents
DMW542E	DT	Small molecular drug
DMW542E	PC	4601
DMW542E	MW	269.4
DMW542E	FM	C18H23NO
DMW542E	IC	InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3
DMW542E	CS	CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C
DMW542E	IK	QVYRGXJJSLMXQH-UHFFFAOYSA-N
DMW542E	IU	N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine
DMW542E	CA	CAS 83-98-7
DMW542E	CB	CHEBI:7789
DMW542E	DE	Parkinson disease

DMFIQ20	ID	DMFIQ20
DMFIQ20	DN	Orphenadrine citrate
DMFIQ20	HS	Approved
DMFIQ20	SN	Orfenadrina; Orfenadrina [INN-Spanish]; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrine [INN:BAN]; Orphenadrinum; Orphenadrinum [INN-Latin]; Orphenate; Orphenedrine; WS 2434; o-Methyldiphenhydramine; o-Monomethyldiphenhydramine; orphenadrine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine; 83-98-7; EINECS 201-509-2; HSDB 3139; Phenyl-o-tolylmethyl dimethyaminoethyl ether; beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Biorphen; Brocadisipal; Brocasipal; Disipal; Invagesic; Mephenamine; Norgesic; Banflex; Euflex; Flexoject; Flexon; Flexor; Norflex; Norflex (pharmaceutical); Orphenadrine (Citrate); Orphenadrine citrate; Orphenadrine citrate (Norflex); Orphenadrine citrate [USP]; Orphenadrine citrate salt; Orphenadrine dihydrogen citrate; Plenactol; Tega-Flex; X-Otag; 2-hydroxypropane-1,2,3-tricarboxylic acid; 4596-23-0; 4682-36-4; CHEBI:7790; EINECS 225-137-5; N,N-Dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine citrate (1:1); NCGC00094745-01; dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine
DMFIQ20	PC	83823
DMFIQ20	MW	461.5
DMFIQ20	FM	C24H31NO8
DMFIQ20	IC	MMMNTDFSPSQXJP-UHFFFAOYSA-N
DMFIQ20	CS	CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMFIQ20	IK	1S/C18H23NO.C6H8O7/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-12,18H,13-14H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMFIQ20	IU	N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMFIQ20	CA	CAS 4682-36-4
DMFIQ20	CB	CHEBI:7790
DMFIQ20	DE	Myalgia

DMGO72P	ID	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	HS	Approved
DMGO72P	SN	Tamiflu (*Phosphate salt 1:1*); Agucort; Oseltamivirum; Tamvir; GS 4104; GS4104; Agucort (TN); GS-4104; Oseltamivir (INN); Oseltamivir [INN:BAN]; Ro-640796; Tamiflu (TN); Tamiflu-Free; Ro-64-0796; OTV
DMGO72P	CP	Hoffmann-La Roche pharmaceutical company
DMGO72P	TC	Antiviral Agents
DMGO72P	DT	Small molecular drug
DMGO72P	PC	65028
DMGO72P	MW	312.4
DMGO72P	FM	C16H28N2O4
DMGO72P	IC	InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1
DMGO72P	CS	CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC
DMGO72P	IK	VSZGPKBBMSAYNT-RRFJBIMHSA-N
DMGO72P	IU	ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate
DMGO72P	CA	CAS 196618-13-0
DMGO72P	CB	CHEBI:7798
DMGO72P	DE	Influenza virus infection

DMIJC9X	ID	DMIJC9X
DMIJC9X	DN	Osilodrostat
DMIJC9X	HS	Approved
DMIJC9X	SN	LCI699; 928134-65-0; LCI-699; UNII-5YL4IQ1078; CHEMBL3099695; 5YL4IQ1078; Osilodrostat;4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile; 1304733-26-3; Osilodrostat [USAN:INN]; LCI 699; Osilodrostat (USAN/INN); LCI699-NX; GTPL8310; SCHEMBL12460772; DTXSID40156570; MolPort-044-560-410; EX-A1397; ZINC72318114; s7456; BDBM50444549; AKOS027323750; DB11837; CS-6896; HY-16276; KB-78108; Z-3271; D11061; 4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzo nitrile
DMIJC9X	CP	Novartis Pharmaceuticals
DMIJC9X	DT	Small molecular drug
DMIJC9X	PC	44139752
DMIJC9X	MW	227.24
DMIJC9X	FM	C13H10FN3
DMIJC9X	IC	InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1
DMIJC9X	CS	C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F
DMIJC9X	IK	USUZGMWDZDXMDG-CYBMUJFWSA-N
DMIJC9X	IU	4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile
DMIJC9X	CA	CAS 928134-65-0
DMIJC9X	DE	Cushing disease

DMRJLAT	ID	DMRJLAT
DMRJLAT	DN	Osimertinib
DMRJLAT	HS	Approved
DMRJLAT	SN	Tagrisso
DMRJLAT	CP	Astrazeneca
DMRJLAT	DT	Small molecular drug
DMRJLAT	PC	71496458
DMRJLAT	MW	499.6
DMRJLAT	FM	C28H33N7O2
DMRJLAT	IC	InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
DMRJLAT	CS	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
DMRJLAT	IK	DUYJMQONPNNFPI-UHFFFAOYSA-N
DMRJLAT	IU	N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
DMRJLAT	CA	CAS 1421373-65-0
DMRJLAT	CB	CHEBI:90943
DMRJLAT	DE	Non-small-cell lung cancer; Melanoma

DMF5ZB3	ID	DMF5ZB3
DMF5ZB3	DN	OspA lipoprotein
DMF5ZB3	HS	Approved
DMF5ZB3	TC	Vaccines
DMF5ZB3	DT	Vaccine
DMF5ZB3	SQ	OspA lipoprotein: MKKYLLGIGLILALIACKQNVSSLDEKNSVSVDVPGGMKVLVSKEKNKDGKYDLMATVDNVDLKGTSDKNNGSGILEGVKADKSKVKLTVADDLSKTTLEVLKEDGTVVSRKVTSKDKSTTEAKFNEKGELSEKTMTRANGTTLEYSQMTNEDNAAKAVETLKNGIKFEGNLASGKTAVEIKEGTVTLKREIDKNGKVTVSLNDTASGSKKTASWQESTSTLTISANSKKTKDLVFLTNGTITVQNYDSAGTKLEGSAAEIKKLDELKNALR
DMF5ZB3	DE	Lyme disease

DMC4GEI	ID	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	HS	Approved
DMC4GEI	SN	Ospemifene; 128607-22-7; Osphena; FC-1271a; Deamino-hydroxytoremifene; Fc-1271; 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol; UNII-B0P231ILBK; CCRIS 9205; B0P231ILBK; CHEBI:73275; 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol; senshio; Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethanol; Ophena; Ospemifene [USAN:INN:BAN]; Deaminotoremifene; Osphena (TN); Deaminohydroxytoremifene; AC1MI19T; C24H23ClO2
DMC4GEI	CP	Shionogi; QuatRx
DMC4GEI	DT	Small molecular drug
DMC4GEI	PC	3036505
DMC4GEI	MW	378.9
DMC4GEI	FM	C24H23ClO2
DMC4GEI	IC	InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-
DMC4GEI	CS	C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\C3=CC=C(C=C3)OCCO)/CCCl
DMC4GEI	IK	LUMKNAVTFCDUIE-VHXPQNKSSA-N
DMC4GEI	IU	2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol
DMC4GEI	CA	CAS 128607-22-7
DMC4GEI	CB	CHEBI:73275
DMC4GEI	DE	Dyspareunia; Postmenopausal vaginal atrophy

DM05968	ID	DM05968
DM05968	DN	Otilonium bromide
DM05968	HS	Approved
DM05968	SN	Otilonium Bromide; 26095-59-0; Octylonium bromide; Spasmomen; Octylonium; Otilonium (bromide); SP63; Ottilonio bromuro [Italian]; UNII-21HN3N72PV; Otilonium bromide [INN:BAN]; Otilonii bromidum [INN-Latin]; Bromure d'otilonium [INN-French]; Bromuro de otilonio [INN-Spanish]; EINECS 247-457-4; 21HN3N72PV; Diethyl(2-hydroxyethyl)methylammonium bromide p-(o-(octyloxy)benzamido)benzoate; Ethanaminium, N,N-diethyl-N-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-, bromide; DSSTox_CID_26357; DSSTox_RID_81559
DM05968	CP	Menarini
DM05968	DT	Small molecular drug
DM05968	PC	72092
DM05968	MW	563.6
DM05968	FM	C29H43BrN2O4
DM05968	IC	InChI=1S/C29H42N2O4.BrH/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3;/h12-13,15-20H,5-11,14,21-23H2,1-4H3;1H
DM05968	CS	CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.[Br-]
DM05968	IK	VWZPIJGXYWHBOW-UHFFFAOYSA-N
DM05968	IU	diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium;bromide
DM05968	CA	CAS 26095-59-0
DM05968	DE	Gastric motility disorder

DMQNI7O	ID	DMQNI7O
DMQNI7O	DN	OTL-200
DMQNI7O	HS	Approved
DMQNI7O	SN	Libmeldy
DMQNI7O	CP	Orchard Therapeutics
DMQNI7O	DT	Gene therapy
DMQNI7O	DE	Metachromatic leukodystrophy

DME0F98	ID	DME0F98
DME0F98	DN	Ovine corticotropin-releasing hormone
DME0F98	HS	Approved
DME0F98	SN	Ovine CRF; Ovine CRH; Ovine CRF 41; Ovine corticotropin-releasing factor; Ovine ACTH releasing factor; 79804-71-0; Corticotropin-releasing factor (sheep); Sheep corticotropin-releasing factor (1-41); Corticotropin-releasing factor (sheep hypothalamus); Amunine; Amunin; Corticorelin ovine; oCRH; Corticorelin triflutate; AC1Q2C7A; CRF(OVINE)TRIFLUOROACETATE; Sheep corticotropin-releasing factor; Corticotropin-releasing hormone, ovine; Corticotropin-releasing f
DME0F98	DT	Small molecular drug
DME0F98	PC	16132344
DME0F98	MW	4670
DME0F98	FM	C205H339N59O63S
DME0F98	IC	InChI=1S/C205H339N59O63S/c1-30-104(21)159(198(322)225-106(23)163(214)287)259-193(317)142(87-157(285)286)253-184(308)132(77-99(11)12)246-182(306)130(75-97(7)8)244-172(296)117(46-36-38-67-207)231-170(294)118(47-39-68-221-204(215)216)233-189(313)139(84-151(213)274)251-194(318)143(91-266)256-188(312)137(82-113-88-219-93-223-113)241-165(289)108(25)227-169(293)120(51-58-147(209)270)234-173(297)121(52-59-148(210)271)229-164(288)107(24)228-179(303)128(73-95(3)4)243-176(300)123(54-61-150(212)273)236-190(314)140(85-155(281)282)242-166(290)109(26)226-168(292)116(45-35-37-66-206)239-200(324)161(110(27)268)261-178(302)126(65-72-328-29)238-174(298)124(55-62-152(275)276)237-181(305)134(79-101(15)16)254-197(321)158(103(19)20)258-177(301)125(56-63-153(277)278)235-171(295)119(48-40-69-222-205(217)218)232-180(304)129(74-96(5)6)245-183(307)131(76-98(9)10)247-187(311)138(83-114-89-220-94-224-114)250-186(310)136(81-112-43-33-32-34-44-112)255-201(325)162(111(28)269)262-192(316)135(80-102(17)18)248-191(315)141(86-156(283)284)252-185(309)133(78-100(13)14)249-195(319)144(92-267)257-199(323)160(105(22)31-2)260-196(320)145-49-41-70-263(145)203(327)146-50-42-71-264(146)202(326)127(57-64-154(279)280)240-175(299)122(53-60-149(211)272)230-167(291)115(208)90-265/h32-34,43-44,88-89,93-111,115-146,158-162,265-269H,30-31,35-42,45-87,90-92,206-208H2,1-29H3,(H2,209,270)(H2,210,271)(H2,211,272)(H2,212,273)(H2,213,274)(H2,214,287)(H,219,223)(H,220,224)(H,225,322)(H,226,292)(H,227,293)(H,228,303)(H,229,288)(H,230,291)(H,231,294)(H,232,304)(H,233,313)(H,234,297)(H,235,295)(H,236,314)(H,237,305)(H,238,298)(H,239,324)(H,240,299)(H,241,289)(H,242,290)(H,243,300)(H,244,296)(H,245,307)(H,246,306)(H,247,311)(H,248,315)(H,249,319)(H,250,310)(H,251,318)(H,252,309)(H,253,308)(H,254,321)(H,255,325)(H,256,312)(H,257,323)(H,258,301)(H,259,317)(H,260,320)(H,261,302)(H,262,316)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H4,215,216,221)(H4,217,218,222)/t104-,105-,106-,107-,108-,109-,110+,111+,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,158-,159-,160-,161-,162-/m0/s1
DME0F98	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N
DME0F98	IK	QEEJLLNYQOBRRM-KSHGRFHLSA-N
DME0F98	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoic acid
DME0F98	CA	CAS 79804-71-0
DME0F98	DE	Cushing disease; Diagnostic imaging

DMTAFY4	ID	DMTAFY4
DMTAFY4	DN	Oxacillin
DMTAFY4	HS	Approved
DMTAFY4	SN	Bactocill; Ossacillina; Oxacilina; Oxacilline; Oxacillinum; Oxazocillin; Oxazocilline; Prostaphlin; Prostaphlyn; OXACILLIN SODIUM; Ossacillina [DCIT]; Sodium oxacillin; Bactocill (TN); MPI-penicillin; MPi-PC; Oxacilina (TN); Oxacilina [INN-Spanish]; Oxacillin (INN); Oxacillin [INN:BAN]; Oxacilline [INN-French]; Oxacillinum [INN-Latin]; Penicillin, Methylphenylisoxazolyl; Oxacillin, Monosodium Salt, Anhydrous; (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylic acid; 5-Methyl-3-phenyl-4-isoxazolyl-penicillin; 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid
DMTAFY4	CP	Sandoz Inc
DMTAFY4	TC	Antibiotics
DMTAFY4	DT	Small molecular drug
DMTAFY4	PC	6196
DMTAFY4	MW	401.4
DMTAFY4	FM	C19H19N3O5S
DMTAFY4	IC	InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1
DMTAFY4	CS	CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMTAFY4	IK	UWYHMGVUTGAWSP-JKIFEVAISA-N
DMTAFY4	IU	(2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMTAFY4	CA	CAS 66-79-5
DMTAFY4	CB	CHEBI:7809
DMTAFY4	DE	Bacterial infection

DMQNWRD	ID	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	HS	Approved
DMQNWRD	SN	Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)
DMQNWRD	CP	Sanofi-Aventis
DMQNWRD	TC	Anticancer Agents
DMQNWRD	DT	Small molecular drug
DMQNWRD	PC	9887053
DMQNWRD	MW	397.29
DMQNWRD	FM	C8H14N2O4Pt
DMQNWRD	IC	InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1
DMQNWRD	CS	C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
DMQNWRD	IK	DRMCATBEKSVAPL-BNTLRKBRSA-N
DMQNWRD	IU	[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)
DMQNWRD	CA	CAS 61825-94-3
DMQNWRD	DE	Colorectal cancer

DM2QDX1	ID	DM2QDX1
DM2QDX1	DN	Oxamniquine
DM2QDX1	HS	Approved
DM2QDX1	SN	Mansil; Oxaminiquine; Oxamniquina; Oxamniquinum; Vansil; UK 4261; UK 4271; Mansil (TN); Oxamniquina [INN-Spanish]; Oxamniquinum [INN-Latin]; UK-4271; Vansil (TN); Oxamniquine (USAN/INN); Oxamniquine [USAN:BAN:INN]; {2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol; [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol; (2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol; 1,2,3,4-Tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol; 2-((Isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydro-6-quinolinemethanol; 2-(Isopropylaminomethyl)-7-nitro-1,2,3,4-tetrahydroquinoline-6-methanol; 6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline
DM2QDX1	CP	Pfizer Pharmaceuticals
DM2QDX1	TC	Schistosomicides
DM2QDX1	DT	Small molecular drug
DM2QDX1	PC	4612
DM2QDX1	MW	279.33
DM2QDX1	FM	C14H21N3O3
DM2QDX1	IC	InChI=1S/C14H21N3O3/c1-9(2)15-7-12-4-3-10-5-11(8-18)14(17(19)20)6-13(10)16-12/h5-6,9,12,15-16,18H,3-4,7-8H2,1-2H3
DM2QDX1	CS	CC(C)NCC1CCC2=CC(=C(C=C2N1)[N+](=O)[O-])CO
DM2QDX1	IK	XCGYUJZMCCFSRP-UHFFFAOYSA-N
DM2QDX1	IU	[7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol
DM2QDX1	CA	CAS 21738-42-1
DM2QDX1	CB	CHEBI:78416
DM2QDX1	DE	Schistosomiasis

DMU9MYJ	ID	DMU9MYJ
DMU9MYJ	DN	Oxandrolone
DMU9MYJ	HS	Approved
DMU9MYJ	SN	Anavar; Lonavar; Ossandrolone; Oxandrin; Oxandrolona; Oxandrolonum; Protivar; Provitar; Vasorome; Ossandrolone [DCIT]; SC 11585; Anavar (TN); Oxandrin (TN); Oxandrolona [INN-Spanish]; Oxandrolonum [INN-Latin]; SC-11585; Oxandrin, Anavar, Oxandrolone; Oxandrolone (JAN/USP/INN); Oxandrolone [USAN:INN:BAN:JAN]; Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone; (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one; (4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI); 17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one; 17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-(8CI); 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-(9CI)
DMU9MYJ	CP	Pfizer Pharmaceuticals
DMU9MYJ	DT	Small molecular drug
DMU9MYJ	PC	5878
DMU9MYJ	MW	306.4
DMU9MYJ	FM	C19H30O3
DMU9MYJ	IC	InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1
DMU9MYJ	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C
DMU9MYJ	IK	QSLJIVKCVHQPLV-PEMPUTJUSA-N
DMU9MYJ	IU	(1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one
DMU9MYJ	CA	CAS 53-39-4
DMU9MYJ	CB	CHEBI:7820
DMU9MYJ	DE	Alcoholic hepatitis

DMZ30JT	ID	DMZ30JT
DMZ30JT	DN	Oxantel pamoate
DMZ30JT	HS	Approved
DMZ30JT	SN	Telopar; Oxantel embonate; CP-14445; Oxantel pamoate (USAN); Telopar (TN); CP-14445-16; Phenol, 3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl), (E)-, 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1) (salt); 4,4'-Methylenebis(3-hydroxy-2-naphthoic) acid, compound with (E)-3-(2-(1,4,5,6-tetrahydro-1-methylpyrimidin-2-yl)vinyl)phenol (1:1)
DMZ30JT	TC	Anthelmintics
DMZ30JT	DT	Small molecular drug
DMZ30JT	PC	5281086
DMZ30JT	MW	604.6
DMZ30JT	FM	C36H32N2O7
DMZ30JT	IC	InChI=1S/C23H16O6.C13H16N2O/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-15-9-3-8-14-13(15)7-6-11-4-2-5-12(16)10-11/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2,4-7,10,16H,3,8-9H2,1H3/b;7-6+
DMZ30JT	CS	CN1CCCN=C1/C=C/C2=CC(=CC=C2)O.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O
DMZ30JT	IK	CCOAINFUFGBHBA-UETGHTDLSA-N
DMZ30JT	IU	4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-[(E)-2-(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)ethenyl]phenol
DMZ30JT	CA	CAS 68813-55-8
DMZ30JT	CB	CHEBI:7821
DMZ30JT	DE	Trichuris trichiura infection

DM9UB0P	ID	DM9UB0P
DM9UB0P	DN	Oxaprozin
DM9UB0P	HS	Approved
DM9UB0P	SN	Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid
DM9UB0P	CP	Gd Searle Llc
DM9UB0P	TC	Antiinflammatory Agents
DM9UB0P	DT	Small molecular drug
DM9UB0P	PC	4614
DM9UB0P	MW	293.3
DM9UB0P	FM	C18H15NO3
DM9UB0P	IC	InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
DM9UB0P	CS	C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
DM9UB0P	IK	OFPXSFXSNFPTHF-UHFFFAOYSA-N
DM9UB0P	IU	3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
DM9UB0P	CA	CAS 21256-18-8
DM9UB0P	CB	CHEBI:7822
DM9UB0P	DE	Rheumatoid arthritis

DM1F42Z	ID	DM1F42Z
DM1F42Z	DN	Oxatomide
DM1F42Z	HS	Approved
DM1F42Z	SN	Celtect; Oxatimide; Oxatomida; Oxatomidum; Oxetal; Tinset; CBMicro_024634; KW 4354; O 9387; R 35443; R35443; Celtect (TN); KW-4354; McN-JR 35443; Oxatomida [INN-Spanish]; Oxatomide (tinset); Oxatomidum [INN-Latin]; R 35,443; R-35443; Oxatomide (JAN/USAN/INN); Oxatomide [USAN:BAN:INN:JAN]; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone; 1-[3-(4-Benzhydryl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone; 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
DM1F42Z	CP	Janssen Pharmaceutica
DM1F42Z	TC	Antiallergic Agents
DM1F42Z	DT	Small molecular drug
DM1F42Z	PC	4615
DM1F42Z	MW	426.6
DM1F42Z	FM	C27H30N4O
DM1F42Z	IC	InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
DM1F42Z	CS	C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM1F42Z	IK	BAINIUMDFURPJM-UHFFFAOYSA-N
DM1F42Z	IU	3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
DM1F42Z	CA	CAS 60607-34-3
DM1F42Z	CB	CHEBI:31943
DM1F42Z	DE	Hay fever

DMXNZM4	ID	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	HS	Approved
DMXNZM4	SN	Abboxampam; Abboxapam; Adumbran; Alepam; Ansioxacepam; Anxiolit; Aplakil; Astress; Azutranguil; Azutranquil; Bonare; Drimuel; Droxacepam; Durazepam; Hilong; Isodin; Lederpam; Limbial; Murelax; Nesontil; Noctazepam; Nortemazepam; Nozepam; Ossazepam; Oxanid; Oxazepamum; Oxazipam; Oxozepam; Pacienx; Praxiten; Propax; Psicopax; Psiquiwas; QUEN; Quilibrex; Rondar; Sedigoa; Serax; Serenal; Serenid; Serepax; Seresta; Serpax; Sigacalm; Sobril; Tacepam; Tarchomin; Tazepam; Uskan; Vaben; Zaxopam; Anxiolit retard; Ossazepam [DCIT]; P acienx; CB 8092; DF2371850; O5254_SIGMA; Wy 3498; Z 10 tr; Alepam (TN); Apo-astress; Hi-Long; Medopam (TN); Murelax (TN); N-Desmethyltemazepam; Noripam (TN); Oxa-puren; Oxazepamum [INN-Latin]; Purata (TN); Ro 5-6789; Serax (TN); Serenid-D; Serepax (TN); WY-3498; Wy-3498 stic; Z10-Tr; Ox-Pam (TN); Tranquo-buscopan-wirkstoff; Oxazepam (JAN/USP/INN); Oxazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; (+-)-Oxazepam; (RS)-Oxazepam; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-1,4(2H)-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one; 7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMXNZM4	CP	Genus Pharms
DMXNZM4	TC	Hypnotics and Sedatives
DMXNZM4	DT	Small molecular drug
DMXNZM4	PC	4616
DMXNZM4	MW	286.71
DMXNZM4	FM	C15H11ClN2O2
DMXNZM4	IC	InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)
DMXNZM4	CS	C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O
DMXNZM4	IK	ADIMAYPTOBDMTL-UHFFFAOYSA-N
DMXNZM4	IU	7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMXNZM4	CA	CAS 604-75-1
DMXNZM4	CB	CHEBI:7823
DMXNZM4	DE	Anxiety disorder

DM5PU6O	ID	DM5PU6O
DM5PU6O	DN	Oxcarbazepine
DM5PU6O	HS	Approved
DM5PU6O	SN	Epilexter; Epliga; Oxacarbazepine; Oxcarbamazepine; Oxcarbazepime; Oxcarbazepina; Oxcarbazepinum; Timox; Trileptal; Desitin brand of oxcarbazepine; Novartis brand of oxcarbazepine; Oxcarbazepine [INN]; GP 47680; O0363; GP-47680; KIN-493; Oxaleptal (TN); Oxcarbazepina [INN-Spanish]; Oxcarbazepinum [INN-Latin]; SPN-804; Trileptal (TN); Oxcarbazepine (USAN/INN); 10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
DM5PU6O	CP	Norvatis Phamaceuticals Corporation
DM5PU6O	TC	Anticonvulsants
DM5PU6O	DT	Small molecular drug
DM5PU6O	PC	34312
DM5PU6O	MW	252.27
DM5PU6O	FM	C15H12N2O2
DM5PU6O	IC	InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)
DM5PU6O	CS	C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
DM5PU6O	IK	CTRLABGOLIVAIY-UHFFFAOYSA-N
DM5PU6O	IU	5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
DM5PU6O	CA	CAS 28721-07-5
DM5PU6O	CB	CHEBI:7824
DM5PU6O	DE	Epilepsy

DME7KRM	ID	DME7KRM
DME7KRM	DN	Oxiconazole
DME7KRM	HS	Approved
DME7KRM	SN	Oxiconazol; Oxiconazolum; Oxyconazole; Oxiconazol [INN-Spanish]; Oxiconazole (INN); Oxiconazole [INN:BAN]; Oxiconazolum [INN-Latin]; Ro 13-8996; Sgd 301-76; RO-13-8996; (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-O-(2,4-dichlorobenzyl) ethanone oxime nitrate; 1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine; 2',4'-Dichlor-O-(2,4-dichlorbenzyl)-2-(1-imidazolyl)-(Z)-acetophenonoxim; 2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-(O-(2,4-dichlorobenzyl)oxime)
DME7KRM	CP	Fougera Pharmaceuticals Inc
DME7KRM	TC	Antifungal Agents
DME7KRM	DT	Small molecular drug
DME7KRM	PC	5353853
DME7KRM	MW	429.1
DME7KRM	FM	C18H13Cl4N3O
DME7KRM	IC	InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18+
DME7KRM	CS	C1=CC(=C(C=C1Cl)Cl)CO/N=C(\\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl
DME7KRM	IK	QRJJEGAJXVEBNE-HKOYGPOVSA-N
DME7KRM	IU	(Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine
DME7KRM	CA	CAS 64211-45-6
DME7KRM	CB	CHEBI:7825
DME7KRM	DE	Tinea pedis

DM9EQC0	ID	DM9EQC0
DM9EQC0	DN	Oxidized glutathione
DM9EQC0	HS	Approved
DM9EQC0	DT	Small molecular drug
DM9EQC0	PC	65359
DM9EQC0	MW	612.6
DM9EQC0	FM	C20H32N6O12S2
DM9EQC0	IC	InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1
DM9EQC0	CS	C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N
DM9EQC0	IK	YPZRWBKMTBYPTK-BJDJZHNGSA-N
DM9EQC0	IU	(2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM9EQC0	CA	CAS 27025-41-8
DM9EQC0	CB	CHEBI:17858
DM9EQC0	DE	Breast cancer; Bacterial infection

DMRKOS1	ID	DMRKOS1
DMRKOS1	DN	Oxilofrine
DMRKOS1	HS	Approved
DMRKOS1	SN	Oxilofrine hydrochloride; Carnigen (TN)
DMRKOS1	DT	Small molecular drug
DMRKOS1	PC	688009
DMRKOS1	MW	181.23
DMRKOS1	FM	C10H15NO2
DMRKOS1	IC	InChI=1S/C10H15NO2/c1-7(11-2)10(13)8-3-5-9(12)6-4-8/h3-7,10-13H,1-2H3/t7-,10-/m0/s1
DMRKOS1	CS	C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NC
DMRKOS1	IK	OXFGTKPPFSCSMA-XVKPBYJWSA-N
DMRKOS1	IU	4-[(1R,2S)-1-hydroxy-2-(methylamino)propyl]phenol
DMRKOS1	CA	CAS 365-26-4
DMRKOS1	CB	CHEBI:134822
DMRKOS1	DE	Orthostatic hypotension

DM9FKSR	ID	DM9FKSR
DM9FKSR	DN	Oxitropium bromide
DM9FKSR	HS	Approved
DM9FKSR	SN	Oxivent (TN)
DM9FKSR	CP	Dieckmann
DM9FKSR	DT	Small molecular drug
DM9FKSR	PC	6917865
DM9FKSR	MW	412.3
DM9FKSR	FM	C19H26BrNO4
DM9FKSR	IC	InChI=1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1/t13?,14-,15-,16+,17-,18+,20?;/m1./s1
DM9FKSR	CS	CC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-]
DM9FKSR	IK	LCELQERNWLBPSY-YAYGZGPXSA-M
DM9FKSR	IU	[(1R,2R,4S,5S)-9-ethyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DM9FKSR	CA	CAS 30286-75-0
DM9FKSR	DE	Asthma

DM51OQW	ID	DM51OQW
DM51OQW	DN	Oxprenolol
DM51OQW	HS	Approved
DM51OQW	SN	Coretal; Koretal; Laracor; Osprenololo; Oxprenololum; Tevacor; Trasacor; Trasicor; Osprenololo [DCIT]; Slow Trasicor; Trasicor 80; Captol (TN); Corbeton (TN); Coretal (TN); Dl-Alprenolol; Dl-Oxprenolol; Laracor (TN); Oxprenolol (INN); Oxprenolol (TN); Oxprenolol [INN:BAN]; Oxprenololum [INN-Latin]; Slow-pren; Tevacor (TN);Trasacor (TN); Trasicor (TN); Trasidex (TN); Trasitensin (TN); Slow-Pren (TN); Slow-Trasicor (TN); Coretal (*hydrochloride*); Laracor (*hydrochloride*); Oxprenolol Ba 39089 (*hydrochloride*); Trasacor (*hydrochloride*); Trasicor (*hydrochloride*); Slow-Pren (*hydrochloride*); (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-Oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)-2-propanol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol
DM51OQW	TC	Antihypertensive Agents
DM51OQW	DT	Small molecular drug
DM51OQW	PC	4631
DM51OQW	MW	265.35
DM51OQW	FM	C15H23NO3
DM51OQW	IC	InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3
DM51OQW	CS	CC(C)NCC(COC1=CC=CC=C1OCC=C)O
DM51OQW	IK	CEMAWMOMDPGJMB-UHFFFAOYSA-N
DM51OQW	IU	1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol
DM51OQW	CA	CAS 6452-71-7
DM51OQW	CB	CHEBI:91704
DM51OQW	DE	Hypertension

DMLHSE3	ID	DMLHSE3
DMLHSE3	DN	Oxtriphylline
DMLHSE3	HS	Approved
DMLHSE3	SN	Choledyl; Cholegyl; Cholinophyllin; Cholinophylline; Filoral; Oxtrimethylline; Sabidal; Soliphylline; Teofilcolina; Teokolin; Theoxylline; Choline theophylline salt; Cholini theophyllinas; Colina teofillinato; Colina teofillinato [DCIT]; Oxtriphylline [USAN]; Oxtriphylline pediatric; Teofilinato de colina; Theophyllinate de choline; Theophylline cholinate; Theophylline salt of choline; Choledyl SA 400; Zy 15061; Choledyl (TN); Cholini theophyllinas [INN-Latin]; Teofilinato de colina [INN-Spanish]; Theophyllinate de choline[INN-French]; Choline salt with theophylline (1:1); Theophylline, compd. with choline; Choline, compd. with theophylline (1:1); Choline, hydroxide, compd. with theophylline (1:1); Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethylpurine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1); (2-Hydroxyethyl)trimethylammonium compound with theophylline; 1,3-dimethyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, ion(1-), 2-hydroxy-N,N,N-trimethylethanaminium
DMLHSE3	TC	Bronchodilator Agents
DMLHSE3	DT	Small molecular drug
DMLHSE3	PC	656652
DMLHSE3	MW	283.33
DMLHSE3	FM	C12H21N5O3
DMLHSE3	IC	InChI=1S/C7H8N4O2.C5H14NO/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;1-6(2,3)4-5-7/h3,12H,1-2H3;7H,4-5H2,1-3H3/q;+1/p-1
DMLHSE3	CS	CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO
DMLHSE3	IK	SOELXOBIIIBLRJ-UHFFFAOYSA-M
DMLHSE3	IU	1,3-dimethyl-2-oxopurin-6-olate;2-hydroxyethyl(trimethyl)azanium
DMLHSE3	CA	CAS 4499-40-5
DMLHSE3	DE	Cough

DMI0GDH	ID	DMI0GDH
DMI0GDH	DN	Oxybuprocaine
DMI0GDH	HS	Approved
DMI0GDH	SN	Benoxil; Benoxinate; Butoxyaminobenzoyldiethylaminoethanol; Butoxyprocaine; Conjucain; Dorsacain; Novescine; Novesinol; Oxibuprocaina; Oxibuprocainum; Oxibuprokain; Oxybucaine; Oxybuprocainum; Oxyriprocaine; Prescaina; Benoxinate hydrochloride; Monofree oxybuprocaine; Oxybuprocaine HCL; Oxybuprocaine hydrochloride; S 749;Monofree oxybuprocaine (TN); Novesin (TN); Novesine (TN); Oxibuprocaina [INN-Spanish]; Oxybuprocaine (INN); Oxybuprocaine [INN:BAN]; Oxybuprocainum [INN-Latin]; Diethylaminoethyl-4-amino-3-butoxybenzoate; BENZOIC ACID, 4-AMINO-3-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7CI,8CI,9CI); 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate; 2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate; 2-Diethylaminoethyl 4-amino-3-butoxybenzoate; 3-Butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester; 3-Butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester; 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid; 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester; 4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester; 4-Amino-3-butoxybenzoicacid 2-diethylaminoethyl ester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [German]
DMI0GDH	CP	Norvatis Phamaceuticals Corporation
DMI0GDH	TC	Anesthetics
DMI0GDH	DT	Small molecular drug
DMI0GDH	PC	4633
DMI0GDH	MW	308.4
DMI0GDH	FM	C17H28N2O3
DMI0GDH	IC	InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3
DMI0GDH	CS	CCCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N
DMI0GDH	IK	CMHHMUWAYWTMGS-UHFFFAOYSA-N
DMI0GDH	IU	2-(diethylamino)ethyl 4-amino-3-butoxybenzoate
DMI0GDH	CA	CAS 99-43-4
DMI0GDH	CB	CHEBI:309594
DMI0GDH	DE	Anaesthesia

DMF2KLU	ID	DMF2KLU
DMF2KLU	DN	Oxybutynin hydrochloride
DMF2KLU	HS	Approved
DMF2KLU	SN	HOB-294; Oxybutynin hydrochloride (transdermal patch, overactive bladder); Oxybutynin hydrochloride (transdermal patch, overactive bladder), Hisamitsu
DMF2KLU	CP	Watson Pharmaceuticals
DMF2KLU	DT	Small molecular drug
DMF2KLU	PC	91505
DMF2KLU	MW	393.9
DMF2KLU	FM	C22H32ClNO3
DMF2KLU	IC	InChI=1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H
DMF2KLU	CS	CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl
DMF2KLU	IK	SWIJYDAEGSIQPZ-UHFFFAOYSA-N
DMF2KLU	IU	4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate;hydrochloride
DMF2KLU	CA	CAS 1508-65-2
DMF2KLU	CB	CHEBI:7857
DMF2KLU	DE	Urinary incontinence

DMXLKHV	ID	DMXLKHV
DMXLKHV	DN	Oxycodone
DMXLKHV	HS	Approved
DMXLKHV	CP	Watson Laboratories
DMXLKHV	TC	Analgesics
DMXLKHV	DT	Small molecular drug
DMXLKHV	PC	5284603
DMXLKHV	MW	315.4
DMXLKHV	FM	C18H21NO4
DMXLKHV	IC	InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
DMXLKHV	CS	CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
DMXLKHV	IK	BRUQQQPBMZOVGD-XFKAJCMBSA-N
DMXLKHV	IU	(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMXLKHV	CA	CAS 76-42-6
DMXLKHV	CB	CHEBI:7852
DMXLKHV	DE	Pain; Back pain

DM8ZXT6	ID	DM8ZXT6
DM8ZXT6	DN	Oxymetazoline
DM8ZXT6	HS	Approved
DM8ZXT6	SN	Hazol; Iliadin; Nafrine; Navasin; Navisin; Nezeril; Oximetazolina; Oximetazolinum; Oxylazine; Oxymetazolinum; Oxymethazoline; Oxymetozoline; Rhinofrenol; Rhinolitan; Sinerol; Dristan Long Lasting Mentholated Nasal Spray; Dristan Long Lasting Nasal Mist; Drixoral Nasal Solution; Oxymeta zoline; Oxymetazoline hydrochloride crystalline; Afrin Cherry 12 Hour Nasal Spray; Afrin Extra Moisturizing 12 Hour Nasal Spray; Afrin Original 12 Hour Nasal Spray; Afrin Original 12 Hour Nose Drops; Afrin Original 12 Hour Pump Mist; Afrin Sinus 12 Hour Nasal Spray; Duramist Plus Up To 12 Hour Nasal Decongestant Spray; Genasal Nasal Spray Up to 12 Hour Relief; H 990; Nasal Relief 12 Hour Nasal Spray; Nostrilla 12 Hour Nasal Decongestant; Vicks Sinex 12 Hour Nasal Spray; Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief; Decongestant (TN); Neo-Synephrine 12 Hour Spray; Operil (TN); Oximetazolina [INN-Spanish]; Oxymetazoline (INN); Oxymetazoline [INN:BAN]; Oxymetazolinum [INN-Latin]; Visine L.R; Visine L.R.; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-(7CI,8CI); Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-(9CI); 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline; 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol; 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol; 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
DM8ZXT6	CP	Schein Pharmaceutical
DM8ZXT6	TC	Nasal Decongestants
DM8ZXT6	DT	Small molecular drug
DM8ZXT6	PC	4636
DM8ZXT6	MW	260.37
DM8ZXT6	FM	C16H24N2O
DM8ZXT6	IC	InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)
DM8ZXT6	CS	CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C
DM8ZXT6	IK	WYWIFABBXFUGLM-UHFFFAOYSA-N
DM8ZXT6	IU	6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
DM8ZXT6	CA	CAS 1491-59-4
DM8ZXT6	CB	CHEBI:7862
DM8ZXT6	DE	Eye inflammation; Nasal congestion

DMFXUT8	ID	DMFXUT8
DMFXUT8	DN	Oxymetholone
DMFXUT8	HS	Approved
DMFXUT8	SN	oxymetholone; Anasterone; 434-07-1; HMS3393H15
DMFXUT8	CP	Solvay Pharmaceuticals
DMFXUT8	DT	Small molecular drug
DMFXUT8	PC	5281034
DMFXUT8	MW	332.5
DMFXUT8	FM	C21H32O3
DMFXUT8	IC	InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1
DMFXUT8	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C
DMFXUT8	IK	ICMWWNHDUZJFDW-DHODBPELSA-N
DMFXUT8	IU	(2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DMFXUT8	CA	CAS 434-07-1
DMFXUT8	CB	CHEBI:7864
DMFXUT8	DE	Aplastic anemia

DM65AGJ	ID	DM65AGJ
DM65AGJ	DN	Oxymorphone
DM65AGJ	HS	Approved
DM65AGJ	SN	Oxymorphone (abuse-resistant, pain); Oxymorphone (abuse-resistant, pain), Pain Therapeutics/ King Pharmaceuticals; Oxymorphone (abuse-resistant, pain), Pain Therapeutics/Pfizer
DM65AGJ	CP	Pain Therapeutics Inc
DM65AGJ	TC	Neurology Agents
DM65AGJ	DT	Small molecular drug
DM65AGJ	PC	5284604
DM65AGJ	MW	301.34
DM65AGJ	FM	C17H19NO4
DM65AGJ	IC	InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1
DM65AGJ	CS	CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
DM65AGJ	IK	UQCNKQCJZOAFTQ-ISWURRPUSA-N
DM65AGJ	IU	(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM65AGJ	CA	CAS 76-41-5
DM65AGJ	CB	CHEBI:7865
DM65AGJ	DE	Pain

DMPZS7U	ID	DMPZS7U
DMPZS7U	DN	Oxyphenbutazone
DMPZS7U	HS	Approved
DMPZS7U	SN	Tandearil
DMPZS7U	CP	Novartis Pharmaceuticals Corp
DMPZS7U	DT	Small molecular drug
DMPZS7U	PC	4641
DMPZS7U	MW	324.4
DMPZS7U	FM	C19H20N2O3
DMPZS7U	IC	InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
DMPZS7U	CS	CCCCC1C(=O)N(N(C1=O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMPZS7U	IK	HFHZKZSRXITVMK-UHFFFAOYSA-N
DMPZS7U	IU	4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
DMPZS7U	CA	CAS 129-20-4
DMPZS7U	CB	CHEBI:76258
DMPZS7U	DE	Arthritis

DM3TABW	ID	DM3TABW
DM3TABW	DN	Oxyphencyclimine
DM3TABW	HS	Approved
DM3TABW	SN	Antulcus; Caridan; Daricol; Manir; Naridan; Oxifencicliminum; Oxiphencycliminum; Oxyphencycliminum; Zamanil; Oxifencicliminum [INN-Spanish]; Oxyphencyclimine (INN); Oxyphencyclimine [INN:BAN]; Oxyphencycliminum [INN-Latin]; Benzeneacetic acid, .alpha.-cyclohexyl-.alpha.-hydroxy-, (1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)methyl ester; (1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl cyclohexyl(hydroxy)phenylacetate; (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate; 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinemethanol-alpha-phenylcyclohexaneglycolate; 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat; 1-Methyl-1,4,5,6-tetrahydro-2-pyrimidinylmethyl-alpha-cyclohexylmandelat
DM3TABW	CP	Pfizer Laboratories Div Pfizer Inc
DM3TABW	TC	Anticholinergic Agents
DM3TABW	DT	Small molecular drug
DM3TABW	PC	4642
DM3TABW	MW	344.4
DM3TABW	FM	C20H28N2O3
DM3TABW	IC	InChI=1S/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3
DM3TABW	CS	CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O
DM3TABW	IK	DUDKAZCAISNGQN-UHFFFAOYSA-N
DM3TABW	IU	(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
DM3TABW	CA	CAS 125-53-1
DM3TABW	CB	CHEBI:7868
DM3TABW	DE	Peptic ulcer

DMMQHOZ	ID	DMMQHOZ
DMMQHOZ	DN	Oxyphenonium
DMMQHOZ	HS	Approved
DMMQHOZ	SN	Argicillin; Atrenyl; Hydroxymethylgramicidin; Methacin; Methocidin; Methocidine; Methocidinum; Metocidina; Oxiphenonum; Spastrex;Oxyphenonium Chloride; Oxyphenonium Iodide; Methocidin [DCF:INN]; Methocidine [INN-French]; Methocidinum [INN-Latin]; Metocidina [INN-Spanish]; [2-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-ethyl]-diethyl-methyl-ammonium; 2-((Cyclohexylhydroxyphenylacetyl)oxy)-N,N-diethyl-N-methylethanaminium; 2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium; 2-[2-cyclohexyl(hydroxy)phenylacetoxy]-n,n-diethyl-n-methylethanaminium
DMMQHOZ	CP	Novartis Pharmaceuticals Corp
DMMQHOZ	TC	Parasympatholytics
DMMQHOZ	DT	Small molecular drug
DMMQHOZ	PC	5749
DMMQHOZ	MW	348.5
DMMQHOZ	FM	C21H34NO3+
DMMQHOZ	IC	InChI=1S/C21H34NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3/q+1
DMMQHOZ	CS	CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
DMMQHOZ	IK	GFRUPHOKLBPHTQ-UHFFFAOYSA-N
DMMQHOZ	IU	2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium
DMMQHOZ	CA	CAS 14214-84-7
DMMQHOZ	CB	CHEBI:94329
DMMQHOZ	DE	Visceral spasms

DMOVH1M	ID	DMOVH1M
DMOVH1M	DN	Oxytetracycline
DMOVH1M	HS	Approved
DMOVH1M	SN	Adamycin; Biostat; Dabicycline; Dalimycin; Fanterrin; Geomycin; Geotilin; Hydroxytetracycline; Imperacin; Lenocycline; Macocyn; OTC; Oksisyklin; Ossitetraciclina; Oxacycline; Oxitetraciclina; Oxitetracyclin; Oxitetracycline; Oxitetracyclinum; Oxymycin; Oxymykoin; Oxypam; Oxyterracin; Oxyterracine; Oxyterracyne; Oxytetracid; Oxytetracyclin; Oxytetracyclinum; Proteroxyna; Riomitsin; Ryomycin; Solkaciclina; Tarocyn; Tarosin; Teravit; Terrafungine; Terramitsin; Terramycin; Tetran; Unimycin; Ursocyclin; Ursocycline; Vendarcin; Biostat PA; Ossitetraciclina [DCIT]; Oxytetracycline HCl; Oxytetracycline [INN]; Oxytetracycline amphoteric; Oxytetracycline anhydrous; Oxytetracycline calcium; Terramycin im; Antibiotic TM 25; LA 200; Liquamycin LA 200; Mycoshield TMQTHC 20; Pennox 200; TM 5; Terramycin Q50; Geomycin (Streptomyces vimosus); OTC (antibiotic); Oxitetraciclina [INN-Spanish]; Oxytetracycline (anhydrous); Oxytetracycline (internal use); Oxytetracyclinum [INN-Latin]; Terramycin, Liquamycin, Oxytetracycline; (2E,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4S,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 5-Hydroxytetracycline
DMOVH1M	CP	Pfizer Pharmaceuticals
DMOVH1M	TC	Antibiotics
DMOVH1M	DT	Small molecular drug
DMOVH1M	PC	54675779
DMOVH1M	MW	460.4
DMOVH1M	FM	C22H24N2O9
DMOVH1M	IC	InChI=1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,12-14,17,25-26,28,30,32-33H,1-3H3,(H2,23,31)/t12-,13-,14+,17+,21-,22+/m1/s1
DMOVH1M	CS	C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O
DMOVH1M	IK	OWFJMIVZYSDULZ-PXOLEDIWSA-N
DMOVH1M	IU	(4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMOVH1M	CA	CAS 2058-46-0
DMOVH1M	CB	CHEBI:27701
DMOVH1M	DE	Bacterial infection

DMDL27I	ID	DMDL27I
DMDL27I	DN	Oxytocin
DMDL27I	HS	Approved
DMDL27I	SN	OXYTOCIN; Pitocin; 50-56-6; Ocytocin; Endopituitrina; Orasthin; Syntocinon; Oxytocine; Oxitocina; Oxytocinum; (1-Hemicystine)oxytocin; Piton S; Oxytocic hormone; UNII-1JQS135EYN; 3-Isoleucine-8-leucine vasopressin; Partocon; Oxystin; alpha-Hypophamine; Synthetic oxytocin; 1JQS135EYN; Ocytocinum; Syntocinone; Utedrin; Oxtocin; Uteracon; Syntocin; Synpitan; Presoxin; Di-sipidin; CHEMBL395429; CHEBI:7872; Nobitocin S; Atonin O; Oxetakain [Czech]; Ossitocina [DCIT]; Oxytocine [INN-French]; Oxytocinum [INN-Latin]; Oxitocina [INN-Spanish]; Posterior;  Oxytocin (intranasal/ muco system, autism); [3H]OT (human, mouse, rat)
DMDL27I	CP	Pastorus Pharma Llc
DMDL27I	DT	Small molecular drug
DMDL27I	SQ	DB00107 sequence: CYIQNCPLG
DMDL27I	PC	439302
DMDL27I	MW	1007.2
DMDL27I	FM	C43H66N12O12S2
DMDL27I	IC	InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1
DMDL27I	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMDL27I	IK	XNOPRXBHLZRZKH-DSZYJQQASA-N
DMDL27I	IU	(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMDL27I	CA	CAS 50-56-6
DMDL27I	CB	CHEBI:7872
DMDL27I	DE	Autism spectrum disorder; Lactation failure

DM1YB0R	ID	DM1YB0R
DM1YB0R	DN	OZ277
DM1YB0R	HS	Approved
DM1YB0R	SN	Arterolane; UNII-3N1TN351VB; 664338-39-0; OZ277; 3N1TN351VB; OZ-277; C22H36N2O4; Arterolane [INN]; RBx11160; OZ 277; SCHEMBL4547841; CHEMBL404431; CHEMBL580910; CHEMBL221773; SCHEMBL12612733; CHEMBL1197433; SCHEMBL13951812; SCHEMBL11379522; SCHEMBL10307589; VXYZBLXGCYNIHP-BBMJWGJISA-N; VXYZBLXGCYNIHP-CAGINOIPSA-N; ZINC14191464; RBX-11160; NCGC00274173-01; HY-10852; Y1261
DM1YB0R	DT	Small molecular drug
DM1YB0R	PC	10475633
DM1YB0R	MW	392.5
DM1YB0R	FM	C22H36N2O4
DM1YB0R	IC	InChI=1S/C22H36N2O4/c1-20(2,23)13-24-19(25)12-14-3-5-21(6-4-14)26-22(28-27-21)17-8-15-7-16(10-17)11-18(22)9-15/h14-18H,3-13,23H2,1-2H3,(H,24,25)
DM1YB0R	CS	CC(C)(CNC(=O)CC1CCC2(CC1)OC3(C4CC5CC(C4)CC3C5)OO2)N
DM1YB0R	IK	VXYZBLXGCYNIHP-UHFFFAOYSA-N
DM1YB0R	CA	CAS 664338-39-0
DM1YB0R	CB	CHEBI:136054
DM1YB0R	DE	Malaria

DMT6AM2	ID	DMT6AM2
DMT6AM2	DN	Ozanimod
DMT6AM2	HS	Approved
DMT6AM2	SN	1306760-87-1; Ozanimod (RPC1063); UNII-Z80293URPV; Z80293URPV; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile; Ozanimod [USAN:INN]; Ozanimod (USAN/INN); SCHEMBL2195490; GTPL8709; CHEMBL3707247; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile; EX-A1316; s7952; ZINC116109867; AKOS026674086; DB12612; CS-5070; HY-12288; AC-29883; Benzonitrile, 5-(3-((1
DMT6AM2	CP	Receptos San Diego, CA
DMT6AM2	PC	52938427
DMT6AM2	MW	404.5
DMT6AM2	FM	C23H24N4O3
DMT6AM2	IC	InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
DMT6AM2	CS	CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@@H](C4=CC=C3)NCCO)C#N
DMT6AM2	IK	XRVDGNKRPOAQTN-FQEVSTJZSA-N
DMT6AM2	IU	5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile
DMT6AM2	CA	CAS 1306760-87-1
DMT6AM2	DE	Crohn disease; Ulcerative colitis; Non-small-cell lung cancer; Multiple sclerosis

DM6KZMG	ID	DM6KZMG
DM6KZMG	DN	Ozenoxacin
DM6KZMG	HS	Approved
DM6KZMG	SN	T-3912; GF-001001-00; Non-fluorinated quinolone (Gram positive bacterial infection), Ferrer
DM6KZMG	CP	Ferrer Internacional
DM6KZMG	PC	9863827
DM6KZMG	MW	363.4
DM6KZMG	FM	C21H21N3O3
DM6KZMG	IC	InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
DM6KZMG	CS	CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C
DM6KZMG	IK	XPIJWUTXQAGSLK-UHFFFAOYSA-N
DM6KZMG	IU	1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid
DM6KZMG	CA	CAS 245765-41-7
DM6KZMG	CB	CHEBI:136050
DM6KZMG	DE	Impetigo; Bacterial infection

DMNKT8Z	ID	DMNKT8Z
DMNKT8Z	DN	Pachycarpine
DMNKT8Z	HS	Approved
DMNKT8Z	SN	(+)-sparteine
DMNKT8Z	DT	Small molecular drug
DMNKT8Z	PC	7014
DMNKT8Z	MW	234.38
DMNKT8Z	FM	C15H26N2
DMNKT8Z	IC	InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m1/s1
DMNKT8Z	CS	C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4
DMNKT8Z	IK	SLRCCWJSBJZJBV-TUVASFSCSA-N
DMNKT8Z	IU	(1R,2S,9R,10R)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane
DMNKT8Z	CA	CAS 492-08-0
DMNKT8Z	DE	Postpartum haemorrhage

DMLB81S	ID	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	HS	Approved
DMLB81S	SN	5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-b; 7-epi-Paclitaxel; ABI-007; Abraxane; Capxol; Ebetaxel; EmPAC; Genaxol; Genetaxyl; Genexol; Intaxel; LipoPac; OncoGel; Onxol; Paclitaxel (Taxol); Paxceed; Paxene; Plaxicel; TAXOL; TaxAlbin; Taxol A; Xorane; Yewtaxan; Zisu; nab-paclitaxel; paclitaxel
DMLB81S	TC	Anticancer Agents
DMLB81S	DT	Small molecular drug
DMLB81S	PC	36314
DMLB81S	MW	853.918
DMLB81S	FM	C47H51NO14
DMLB81S	IC	InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
DMLB81S	CS	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
DMLB81S	IK	RCINICONZNJXQF-MZXODVADSA-N
DMLB81S	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMLB81S	CA	CAS 33069-62-4
DMLB81S	CB	ChEBI:45863
DMLB81S	DE	Breast cancer

DMD7L94	ID	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	HS	Approved
DMD7L94	SN	571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE;  LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934
DMD7L94	CP	Onyx Pharmaceuticals; Pfizer
DMD7L94	TC	Anticancer Agents
DMD7L94	DT	Small molecular drug
DMD7L94	PC	5330286
DMD7L94	MW	447.5
DMD7L94	FM	C24H29N7O2
DMD7L94	IC	InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
DMD7L94	CS	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
DMD7L94	IK	AHJRHEGDXFFMBM-UHFFFAOYSA-N
DMD7L94	IU	6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
DMD7L94	CA	CAS 571190-30-2
DMD7L94	CB	CHEBI:85993
DMD7L94	DE	Solid tumour/cancer; Schizophrenia; Breast cancer

DM9JOYP	ID	DM9JOYP
DM9JOYP	DN	Palifermin
DM9JOYP	HS	Approved
DM9JOYP	SN	Kepivance; Kepivance (TN); Palifermin (USAN/INN)
DM9JOYP	TC	Antimucositis Agents
DM9JOYP	SQ	Palifermin sequence: SYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT
DM9JOYP	DE	Oral mucositis

DM7NPJS	ID	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	HS	Approved
DM7NPJS	SN	Xeplion; Invega Sustenna; Paliperidone palmitate; JNS-010; Paliperidone (depot injection, NanoCrystal); Paliperidone (injectable, NanoCrystal), Elan; Paliperidone (depot injection, NanoCrystal), Johnson & Johnson
DM7NPJS	CP	Johnson & Johnson
DM7NPJS	DT	Small molecular drug
DM7NPJS	PC	115237
DM7NPJS	MW	426.5
DM7NPJS	FM	C23H27FN4O3
DM7NPJS	IC	InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
DM7NPJS	CS	CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
DM7NPJS	IK	PMXMIIMHBWHSKN-UHFFFAOYSA-N
DM7NPJS	IU	3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
DM7NPJS	CA	CAS 144598-75-4
DM7NPJS	CB	CHEBI:83804
DM7NPJS	DE	Schizophrenia

DMQM9S0	ID	DMQM9S0
DMQM9S0	DN	Palivizumab
DMQM9S0	HS	Approved
DMQM9S0	SN	Synagis; Abbosynagis (TN); Palivizumab (INN); Palivizumab (genetical recombination); Synagis (TN); Palivizumab (genetical recombination) (JAN)
DMQM9S0	CP	Medlmmune
DMQM9S0	TC	Antiviral Agents
DMQM9S0	DT	Monoclonal antibody
DMQM9S0	SQ	VH region MEDI-493: QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS</sequence>    <sequence format="FASTA">&gt;VH RegionQVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS
DMQM9S0	DE	Respiratory syncytial virus infection

DMBHMOX	ID	DMBHMOX
DMBHMOX	DN	Palonosetron
DMBHMOX	HS	Approved
DMBHMOX	SN	Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one
DMBHMOX	CP	Eisai Inc
DMBHMOX	TC	Antiemetics
DMBHMOX	DT	Small molecular drug
DMBHMOX	PC	6337614
DMBHMOX	MW	296.4
DMBHMOX	FM	C19H24N2O
DMBHMOX	IC	InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1
DMBHMOX	CS	C1C[C@@H]2CN(C(=O)C3=CC=CC(=C23)C1)[C@@H]4CN5CCC4CC5
DMBHMOX	IK	CPZBLNMUGSZIPR-NVXWUHKLSA-N
DMBHMOX	IU	(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one
DMBHMOX	CA	CAS 135729-61-2
DMBHMOX	CB	CHEBI:85161
DMBHMOX	DE	Nausea

DMK2PBD	ID	DMK2PBD
DMK2PBD	DN	Palonosetron + fosnetupitant
DMK2PBD	HS	Approved
DMK2PBD	CP	Helsinn Group
DMK2PBD	DT	Antibody
DMK2PBD	DE	Chemotherapy-induced nausea

DMB4AVP	ID	DMB4AVP
DMB4AVP	DN	Pamidronate
DMB4AVP	HS	Approved
DMB4AVP	SN	AHPrBP; Amidronate; Aminomux; Aminopropanehydroxydiphosphonate; Aredia; Ribodroat; Acide pamidronique; Acido pamidronico; Acidum pamidronicum; Aminohydroxypropylidene diphosphonate; Novartis brand of pamidronate disodium salt; PAMIDRONATE DISODIUM; PAMIDRONIC ACID; Pamidronate calcium; Pamidronate monosodium; Bisphosphonate 6; Acide pamidronique [INN-French]; Acido pamidronico [INN-Spanish]; Acidum pamidronicum [INN-Latin]; Pamidronic acid (INN); Pamidronic acid [INN:BAN]; Ribodroat (TN); Amino-1-hydroxypropane-1,1-diphosphonate; (3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID; (3-Amino-1-hydroxypropylidene)bisphosphonic acid; (3-Amino-1-hydroxypropylidene)diphosphonic acid; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid); (3-amino-1-hydroxypropylidene)-1,1-biphosphonate; (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate; 1-hydroxy-3-aminopropane-1,1-diphosphonic acid; 3-Amino-1-hydroxypropylidene-1,1-diphosphonate
DMB4AVP	TC	Antiinflammatory Agents
DMB4AVP	DT	Small molecular drug
DMB4AVP	PC	4674
DMB4AVP	MW	235.07
DMB4AVP	FM	C3H11NO7P2
DMB4AVP	IC	InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)
DMB4AVP	CS	C(CN)C(O)(P(=O)(O)O)P(=O)(O)O
DMB4AVP	IK	WRUUGTRCQOWXEG-UHFFFAOYSA-N
DMB4AVP	IU	(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
DMB4AVP	CA	CAS 40391-99-9
DMB4AVP	CB	CHEBI:7903
DMB4AVP	DE	Hypercalcaemia

DMB0VY8	ID	DMB0VY8
DMB0VY8	DN	Pancuronium
DMB0VY8	HS	Approved
DMB0VY8	SN	Mioblock; Pavulon; Bromure de pancuronium; Bromuro de pancuronio; PANCURONIUM BROMIDE; Pancuronii bromidum; Pancuronium dibromide; Poncuronium bromide; NA 97; ORG NA 97; P 1918; Bromure de pancuronium [INN-French]; Bromuro de pancuronio [INN-Spanish]; ORG-NA 97; Pancuronii bromidum [INN-Latin]; Pavulon (TN); Pancuronium bromide (JP15/USAN/INN); Pancuronium bromide [USAN:BAN:INN:JAN]; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate (8CI); Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, dibromide; Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-, dibromide; Piperidinium, 1,1'-(2-beta,16-beta-(3-alpha,17-beta-dihydroxy-5-alpha-androstanylene))bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-[(2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl-, dibromide; (2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2,16-bis(1-methylpiperidinium-1-yl)androstane dibromide; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate dibromide; 1,1'-(3,17-Bis(acetyloxy)androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Bis(acetyloxy)-5alpha-androstane-2beta,16beta-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methylpiperidinium) dibromide diacetate; 1,1'-([2beta,3alpha,5alpha,16beta,17beta]-3,17-Bis[acetyloxy]androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(Acetyloxy)androstane-2,16-diyl]bis(1-methylpiperidinium) dibromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-diol diacetate dimethobromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-dioldiacetatedimethobromide; 3-alpha,17-beta-Diacetoxy-2-beta,16-beta-dipiperidino-5-alpha-androstane dimethobromide; 3alpha,17beta-Diacetoxy-2beta,16beta-dipiperidino-5alpha-androstane dimethobromide; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane dibromide; 5alpha-Androstan-3alpha,17beta-diol, 2beta,16beta-dipipecolinio-, dibromide, diacetate
DMB0VY8	CP	Organon International
DMB0VY8	TC	Neuromuscular Nondepolarizing Agents
DMB0VY8	DT	Small molecular drug
DMB0VY8	PC	441289
DMB0VY8	MW	572.9
DMB0VY8	FM	C35H60N2O4+2
DMB0VY8	IC	InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DMB0VY8	CS	CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C
DMB0VY8	IK	GVEAYVLWDAFXET-XGHATYIMSA-N
DMB0VY8	IU	[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMB0VY8	CA	CAS 16974-53-1
DMB0VY8	CB	CHEBI:7907
DMB0VY8	DE	Anaesthesia

DMQPD1F	ID	DMQPD1F
DMQPD1F	DN	Panitumumab
DMQPD1F	HS	Approved
DMQPD1F	SN	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)
DMQPD1F	CP	Amgen & Takeda
DMQPD1F	TC	Anticancer Agents
DMQPD1F	DT	Monoclonal antibody
DMQPD1F	DE	Colorectal cancer; Head and neck cancer

DM58WKG	ID	DM58WKG
DM58WKG	DN	Panobinostat
DM58WKG	HS	Approved
DM58WKG	SN	Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
DM58WKG	CP	Novartis
DM58WKG	DT	Small molecular drug
DM58WKG	PC	6918837
DM58WKG	MW	349.4
DM58WKG	FM	C21H23N3O2
DM58WKG	IC	InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
DM58WKG	CS	CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO
DM58WKG	IK	FPOHNWQLNRZRFC-ZHACJKMWSA-N
DM58WKG	IU	(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
DM58WKG	CA	CAS 404950-80-7
DM58WKG	CB	CHEBI:85990
DM58WKG	DE	Multiple myeloma; Primary myelofibrosis; Type-2 diabetes

DMSVOCZ	ID	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	HS	Approved
DMSVOCZ	SN	Astropan; Pantoprazol; Pantoprazolum; Pantoprozole; Pantor; Pantozol; Protium; Protonix; Somac; Pantoprazole Na; Pantoprazole Sodium; Protonix IV; BY 1023; Astropan (TN); BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol [INN-Spanish]; Pantoprazolum [INN-Latin]; Pantor (TN); Pantotab (TN); Pantozol (TN); Protium (TN); Protonix (TN); SK&F 96022; SK-96022; SKF-96022; Somac (TN); Ulcepraz (TN); Pantoprazole (USAN/INN); Pantoprazole [USAN:BAN:INN]; SK&F-96022; 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DMSVOCZ	CP	Wyeth; Altana; Solvay
DMSVOCZ	TC	Antiulcer Agents
DMSVOCZ	DT	Small molecular drug
DMSVOCZ	PC	4679
DMSVOCZ	MW	383.4
DMSVOCZ	FM	C16H15F2N3O4S
DMSVOCZ	IC	InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
DMSVOCZ	CS	COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
DMSVOCZ	IK	IQPSEEYGBUAQFF-UHFFFAOYSA-N
DMSVOCZ	IU	6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DMSVOCZ	CA	CAS 102625-70-7
DMSVOCZ	CB	CHEBI:7915
DMSVOCZ	DE	Gastroesophageal reflux disease

DM091H2	ID	DM091H2
DM091H2	DN	Pantothenic acid
DM091H2	HS	Approved
DM091H2	SN	D-pantothenic acid; pantothenic acid; vitamin B5; 79-83-4; pantothenate; Chick antidermatitis factor; (+)-Pantothenic acid; PANTOTHENOIC ACID; (R)-pantothenate; (D)-(+)-Pantothenic acid; Kyselina pantothenova [Czech]; HSDB 1020; Pantothenic Acid [BAN]; D(+)-N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-beta-alanine; BRN 1727064; UNII-19F5HK2737; (R)-pantothenic acid; beta-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (R)-; EINECS 201-229-0; (D,+)-N(alpha-gamma-Dihydroxy-beta,beta-dimethylbutyryl)-beta-alanine
DM091H2	DT	Small molecular drug
DM091H2	PC	6613
DM091H2	MW	219.23
DM091H2	FM	C9H17NO5
DM091H2	IC	InChI=1S/C9H17NO5/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13)/t7-/m0/s1
DM091H2	CS	CC(C)(CO)[C@H](C(=O)NCCC(=O)O)O
DM091H2	IK	GHOKWGTUZJEAQD-ZETCQYMHSA-N
DM091H2	IU	3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid
DM091H2	CA	CAS 79-83-4
DM091H2	CB	CHEBI:46905
DM091H2	DE	Vitamin deficiency

DMCA9QP	ID	DMCA9QP
DMCA9QP	DN	Papaverine
DMCA9QP	HS	Approved
DMCA9QP	SN	papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; Pavatym; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Cerespan; Papaverine [BAN]; Pavacot; Papaverina [Italian]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverine Hcl; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); Pamelon; Chlorhydrate de papaverine; Qua bid; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; Alapav; Cardiospan; Cardoverina; Ceraspan; Cerebid; Delapav; Dilaves; Dispamil; Drapavel; Durapav; Dynovas; Forpavin; Genabid; Mesotina; Myobid; Pameion; Panergon; Papacon; Papalease; Papaversan; Pavacap; Pavacels; Pavacen; Pavagen; Pavarine; Pavatest; Pavatine; Paverolan; Paveron; Pavnell; Vasal; PAP H; Papavarine chlorhydrate; Papaverine chlorohydrate; Papaverine monohydrochloride; Papaverinium chloride; Pavabid Hp; RS 47; TNP00305; Alapav (TN); Albatran (TN); Artegodan (TN); Cardiospan (TN); Cardioverina (TN); Cepaverin (TN); Cerebid (TN); Cerespan (TN); Delapav (TN); Dicertan (TN); Dilaves (TN); Dispamil (TN); Drapavel (TN); Durapav (TN); Dynovas (TN); Forpaven (TN); Houde (TN); Mesotina (TN); Myobid (TN); Opdensit (TN); Optenyl (TN); Pameion (TN); Pamelon (TN); Panergon (TN); Papacon (TN); Papalease (TN); Papanerin-hcl; Papaversan (TN); Pavabid (TN); Pavacap (TN); Pavacen (TN); Pavadel (TN); Pavadyl (TN); Pavagen (TN); Pavakey (TN); Pavased (TN); Pavatest (TN); Paverina (TN); Paverolan (TN); Paveron (TN); Pavnell (TN); Qua bid (TN); Ro-Papav; Therapav (TN); Vasal (TN); Vaso-Pav; Vasospan (TN); Papanerin-hcl (TN); Papaverin-Hamelin (TN); Papital TR; Paptial TR; Ro-Papav (TN); Spasmo-Nit (TN); Vaso-Pav (TN); Pap-Kaps-150 (TN); Papital TR (TN); Paptial TR (TN); Isoquinoline,6,7-dimethoxy-1-veratryl-(8CI); Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE
DMCA9QP	TC	Vasodilator Agents
DMCA9QP	DT	Small molecular drug
DMCA9QP	PC	4680
DMCA9QP	MW	339.4
DMCA9QP	FM	C20H21NO4
DMCA9QP	IC	InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
DMCA9QP	CS	COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
DMCA9QP	IK	XQYZDYMELSJDRZ-UHFFFAOYSA-N
DMCA9QP	IU	1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
DMCA9QP	CA	CAS 58-74-2
DMCA9QP	CB	CHEBI:28241
DMCA9QP	DE	Spasm

DMOC1BX	ID	DMOC1BX
DMOC1BX	DN	Paraldehyde
DMOC1BX	HS	Approved
DMOC1BX	SN	UNII-S6M3YBG8QA; S6M3YBG8QA
DMOC1BX	DT	Small molecular drug
DMOC1BX	PC	31264
DMOC1BX	MW	132.16
DMOC1BX	FM	C6H12O3
DMOC1BX	IC	InChI=1S/C6H12O3/c1-4-7-5(2)9-6(3)8-4/h4-6H,1-3H3
DMOC1BX	CS	CC1OC(OC(O1)C)C
DMOC1BX	IK	SQYNKIJPMDEDEG-UHFFFAOYSA-N
DMOC1BX	IU	2,4,6-trimethyl-1,3,5-trioxane
DMOC1BX	CA	CAS 123-63-7
DMOC1BX	CB	CHEBI:27909
DMOC1BX	DE	Insomnia

DMR5ZUP	ID	DMR5ZUP
DMR5ZUP	DN	Paramethadione
DMR5ZUP	HS	Approved
DMR5ZUP	SN	Isoethadione; Paradione; Parametadiona; Parametadione; Paramethadionum; Parametadione [DCIT]; A 348; Paradione (TN); Parametadiona [INN-Spanish]; Paramethadione (INN); Paramethadione [BAN:INN]; Paramethadione [INN:BAN]; Paramethadionum [INN-Latin]; 3,5-Dimethyl-5-ethyloxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-2,4-oxazolidinedione
DMR5ZUP	TC	Anticonvulsants
DMR5ZUP	DT	Small molecular drug
DMR5ZUP	PC	8280
DMR5ZUP	MW	157.17
DMR5ZUP	FM	C7H11NO3
DMR5ZUP	IC	InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3
DMR5ZUP	CS	CCC1(C(=O)N(C(=O)O1)C)C
DMR5ZUP	IK	VQASKUSHBVDKGU-UHFFFAOYSA-N
DMR5ZUP	IU	5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione
DMR5ZUP	CA	CAS 115-67-3
DMR5ZUP	CB	CHEBI:7921
DMR5ZUP	DE	Seizure disorder; Fetal trimethadione syndrome

DM6PR40	ID	DM6PR40
DM6PR40	DN	Paramethasone
DM6PR40	HS	Approved
DM6PR40	SN	Cassenne; Cortiden; Dillar; Flumethone; Metilar; Parametasona; Parametasone; Paramethasonum; Paramezone; Parametasone [DCIT]; CS 1483; Dillar (TN); Parametasona [INN-Spanish]; Paramethasone (INN); Paramethasone [INN:BAN]; Paramethasonum [INN-Latin]; (6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (6alpha,11beta,16alpha)-6-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 16alpha-Methyl-6alpha-fluoroprednisolone; 6alpha-Fluoro-16alpha-methylprednisolone
DM6PR40	CP	Eli Lilly And Co
DM6PR40	TC	Antiinflammatory Agents
DM6PR40	DT	Small molecular drug
DM6PR40	PC	5875
DM6PR40	MW	392.5
DM6PR40	FM	C22H29FO5
DM6PR40	IC	InChI=1S/C22H29FO5/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-20(15,2)19(13)17(26)9-21(14,3)22(11,28)18(27)10-24/h4-5,7,11,13-14,16-17,19,24,26,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20+,21+,22+/m1/s1
DM6PR40	CS	C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)F
DM6PR40	IK	MKPDWECBUAZOHP-AFYJWTTESA-N
DM6PR40	IU	(6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM6PR40	CA	CAS 53-33-8
DM6PR40	CB	CHEBI:7922
DM6PR40	DE	Inflammation; Diabetic macular edema

DMM0HR1	ID	DMM0HR1
DMM0HR1	DN	Pargyline
DMM0HR1	HS	Approved
DMM0HR1	SN	Benzylmethylpropargylamine; Benzylmethylpropynylamine; Eudatin; Eutron; Methylbenzylpropynylamine; Paragyline; Pargilina; Pargylamine; Pargylin; Pargylinum; Supirdyl; A 19120; MO 911; Pargilina [INN-Spanish]; Pargyline (INN); Pargyline [INN:BAN]; Pargylinum [INN-Latin]; Benzyl-methyl-2-propinylamin; Benzyl-methyl-2-propinylamin [Czech]; N-Methyl-N-benzylpropynylamine; N-Methyl-N-propargylbenzylamine; N-Methyl-N-2-propynylbenzylamine; N-Benzyl-N-methyl-2-propynylamine; N-Benzyl-N-methyl-2-propyn-1; N-Benzyl-N-methyl-2-propyn-1-amine; N-benzyl-N-methylprop-2-yn-1-amine; N-methyl-N-(phenylmethyl)prop-2-yn-1-amine
DMM0HR1	CP	Abbott Laboratories Pharmaceutical Products Div
DMM0HR1	TC	Antihypertensive Agents
DMM0HR1	DT	Small molecular drug
DMM0HR1	PC	4688
DMM0HR1	MW	159.23
DMM0HR1	FM	C11H13N
DMM0HR1	IC	InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3
DMM0HR1	CS	CN(CC#C)CC1=CC=CC=C1
DMM0HR1	IK	DPWPWRLQFGFJFI-UHFFFAOYSA-N
DMM0HR1	IU	N-benzyl-N-methylprop-2-yn-1-amine
DMM0HR1	CA	CAS 555-57-7
DMM0HR1	CB	CHEBI:7930
DMM0HR1	DE	Skin imperfections; Muscular dystrophy; Hypertension

DMYBV3G	ID	DMYBV3G
DMYBV3G	DN	Paricalcitol
DMYBV3G	HS	Approved
DMYBV3G	SN	Paracalcin; Zemplar; Abbott brand of paricalcitol; Paricalcitol [USAN]; Ab 122358; ABT-358; Zemplar (TN); Paricalcitol (USAN/INN); Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; 19-Nor-1,25-(OH)2D2; 19-Nor-1-alpha,25-dihydroxyvitamin D2; 19-Nor-1alpha,25-dihydroxyvitamin D2; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E)
DMYBV3G	CP	Abbott Laboratories
DMYBV3G	TC	Parasympathomimetics
DMYBV3G	DT	Small molecular drug
DMYBV3G	PC	5281104
DMYBV3G	MW	416.6
DMYBV3G	FM	C27H44O3
DMYBV3G	IC	InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
DMYBV3G	CS	C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C[C@@H](C3)O)O)C
DMYBV3G	IK	BPKAHTKRCLCHEA-UBFJEZKGSA-N
DMYBV3G	IU	(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
DMYBV3G	CA	CAS 131918-61-1
DMYBV3G	CB	CHEBI:7931
DMYBV3G	DE	Hyperparathyroidism

DM1AGXN	ID	DM1AGXN
DM1AGXN	DN	Paromomycin
DM1AGXN	HS	Approved
DM1AGXN	SN	Aminosidin; Catenulin; Humatin; Hydroxymycin sulfate; Paramomycin Sulfate; Paromomycin I; Paromomycin sulfate Rx346208; Aminosidine, sulfate; HATT & Paromomycin; Humatin (TN); Paromomycin (INN); Paromomycin (TN); Paromomycin (complex); PA1-PA2-PA3-PA4; Human .alpha.-1-antitrypsin & Paromomyin; PAROMOMYCIN I, AMMINOSIDIN, CATENULIN, CRESTOMYCIN, MONOMYCIN A, NEOMYCIN E; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine
DM1AGXN	CP	King Pharmaceuticals
DM1AGXN	TC	Antibiotics
DM1AGXN	DT	Small molecular drug
DM1AGXN	PC	165580
DM1AGXN	MW	615.6
DM1AGXN	FM	C23H45N5O14
DM1AGXN	IC	InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
DM1AGXN	CS	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
DM1AGXN	IK	UOZODPSAJZTQNH-LSWIJEOBSA-N
DM1AGXN	IU	(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol
DM1AGXN	CA	CAS 7542-37-2
DM1AGXN	CB	CHEBI:7934
DM1AGXN	DE	Intestinal amebiasis

DM5PVQE	ID	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	HS	Approved
DM5PVQE	SN	Seroxat (TN)
DM5PVQE	CP	GlaxoSmithKline
DM5PVQE	TC	Antidepressants
DM5PVQE	DT	Small molecular drug
DM5PVQE	PC	43815
DM5PVQE	MW	329.4
DM5PVQE	FM	C19H20FNO3
DM5PVQE	IC	InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
DM5PVQE	CS	C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
DM5PVQE	IK	AHOUBRCZNHFOSL-YOEHRIQHSA-N
DM5PVQE	IU	(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
DM5PVQE	CA	CAS 61869-08-7
DM5PVQE	CB	CHEBI:7936
DM5PVQE	DE	Depression

DMHM7JS	ID	DMHM7JS
DMHM7JS	DN	Pasireotide
DMHM7JS	HS	Approved
DMHM7JS	SN	Signifor; UNII-I4P76SY3N4; Pasireotide diaspartate; I4P76SY3N4; SOM230; 820232-50-6; pasireotide aspartate; Pasireotide diaspartate [EMA EPAR]; CHEBI:72313; Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate;  Signifor (TN); SOM 230; SOM-230
DMHM7JS	CP	Novartis
DMHM7JS	DT	Small molecular drug
DMHM7JS	PC	9941444
DMHM7JS	MW	1047.2
DMHM7JS	FM	C58H66N10O9
DMHM7JS	IC	InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1
DMHM7JS	CS	C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
DMHM7JS	IK	VMZMNAABQBOLAK-DBILLSOUSA-N
DMHM7JS	IU	[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
DMHM7JS	CA	CAS 396091-73-9
DMHM7JS	CB	CHEBI:72312
DMHM7JS	DE	Cushing disease

DMMIQ20	ID	DMMIQ20
DMMIQ20	DN	Patiromer calcium
DMMIQ20	HS	Approved
DMMIQ20	SN	Patiromer; RLY-5016; Potassium binder (hyperkalemia), Relypsa
DMMIQ20	CP	Relypsa Inc
DMMIQ20	DE	Hyperkalemia

DMWSA0V	ID	DMWSA0V
DMWSA0V	DN	Patisiran
DMWSA0V	HS	Approved
DMWSA0V	SN	Patisiran [INN]; Patisiran [USAN:INN]; UNII-50FKX8CB2Y; 50FKX8CB2Y; ALN-18328
DMWSA0V	CP	Alnylam Pharmaceuticals
DMWSA0V	DT	siRNA drug
DMWSA0V	SQ	RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1)
DMWSA0V	DE	Amyloidosis; Amyloid cardiomyopathy; Hereditary amyloidosis; Transthyretin familial amyloid cardiomyopathy

DMF57DM	ID	DMF57DM
DMF57DM	DN	Pazopanib
DMF57DM	HS	Approved
DMF57DM	SN	Pazopanib; Pazopanib (GW-786034); 444731-52-6; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; CHEBI:71219; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; UNII-7RN5DR86CK
DMF57DM	PC	10113978
DMF57DM	MW	437.5
DMF57DM	FM	C21H23N7O2S
DMF57DM	IC	CUIHSIWYWATEQL-UHFFFAOYSA-N
DMF57DM	CS	CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
DMF57DM	IK	1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
DMF57DM	IU	5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
DMF57DM	CA	CAS 444731-52-6
DMF57DM	CB	CHEBI:71219
DMF57DM	DE	Renal cell carcinoma

DM6U9CQ	ID	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	HS	Approved
DM6U9CQ	SN	Votrient (TN)
DM6U9CQ	CP	GlaxoSmithKline
DM6U9CQ	DT	Small molecular drug
DM6U9CQ	PC	11525740
DM6U9CQ	MW	474
DM6U9CQ	FM	C21H24ClN7O2S
DM6U9CQ	IC	InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
DM6U9CQ	CS	CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
DM6U9CQ	IK	MQHIQUBXFFAOMK-UHFFFAOYSA-N
DM6U9CQ	IU	5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride
DM6U9CQ	CA	CAS 635702-64-6
DM6U9CQ	CB	CHEBI:71217
DM6U9CQ	DE	Renal cell carcinoma

DM49IGF	ID	DM49IGF
DM49IGF	DN	Pefloxacin
DM49IGF	HS	Approved
DM49IGF	SN	Abactal; Labocton; PERFLOXACIN; PFLX; Peflacine; Pefloxacine; Pefloxacino; Pefloxacinum; Pefloxacin methanesulfonate; Silver Pefloxacin; AM-725; EU-5306; Pefloxacin [INN-French]; Pefloxacino [INN-Spanish]; Pefloxacinum [INN-Latin]; Pefloxacin (USAN/INN); Pefloxacin [USAN:BAN:INN]; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo
DM49IGF	TC	Antiinfective Agents
DM49IGF	DT	Small molecular drug
DM49IGF	PC	51081
DM49IGF	MW	333.36
DM49IGF	FM	C17H20FN3O3
DM49IGF	IC	InChI=1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24)
DM49IGF	CS	CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O
DM49IGF	IK	FHFYDNQZQSQIAI-UHFFFAOYSA-N
DM49IGF	IU	1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DM49IGF	CA	CAS 70458-92-3
DM49IGF	CB	CHEBI:50199
DM49IGF	DE	Gonococcal urethritis

DMOWEBU	ID	DMOWEBU
DMOWEBU	DN	Pegaptanib
DMOWEBU	HS	Approved
DMOWEBU	SN	Macugen (TN); Pegaptanib Octasodium; Pegaptanib sodium; EYE 001; NX 1838; NX1838
DMOWEBU	CP	Eyetech pharmaceuticals and Pfizer
DMOWEBU	TC	Antiangiogenic Agents
DMOWEBU	DT	Aptamer
DMOWEBU	PC	56603655
DMOWEBU	MW	541.6
DMOWEBU	FM	C22H44N3O10P
DMOWEBU	IC	InChI=1S/C22H44N3O10P/c1-31-15-17-33-21(27)24-13-9-7-11-19(25-22(28)34-18-16-32-2)20(26)23-12-8-5-4-6-10-14-35-36(3,29)30/h19H,4-18H2,1-3H3,(H,23,26)(H,24,27)(H,25,28)(H,29,30)/t19-/m0/s1
DMOWEBU	CS	COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC
DMOWEBU	IK	WLCZTRVUXYALDD-IBGZPJMESA-N
DMOWEBU	IU	7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid
DMOWEBU	DE	Neovascular age-related macular degeneration

DM7UP8X	ID	DM7UP8X
DM7UP8X	DN	Pegfilgrastim
DM7UP8X	HS	Approved
DM7UP8X	SN	Neulasta; Neulasta (TN); Pegfilgrastim (INN)
DM7UP8X	CP	Amgen Inc
DM7UP8X	TC	Immunomodulatory Agents
DM7UP8X	DT	Small molecular drug
DM7UP8X	SQ	Pegfilgrastim sequence: MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP
DM7UP8X	PC	70683024
DM7UP8X	MW	730.7
DM7UP8X	FM	C27H46N4O19
DM7UP8X	IC	InChI=1S/C27H46N4O19/c1-10(16(28)23(40)41)48-24-18(30-11(2)33)21(39)20(38)14(49-24)9-47-27(25(42)43)6-12(34)17(22(50-27)19(37)13(35)8-32)31-15(36)7-29-26(44)46-5-4-45-3/h10,12-14,16-22,24,32,34-35,37-39H,4-9,28H2,1-3H3,(H,29,44)(H,30,33)(H,31,36)(H,40,41)(H,42,43)/t10-,12+,13-,14-,16+,17-,18-,19-,20+,21-,22-,24+,27-/m1/s1
DM7UP8X	CS	C[C@H]([C@@H](C(=O)O)N)O[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO[C@@]2(C[C@@H]([C@H]([C@@H](O2)[C@@H]([C@@H](CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C
DM7UP8X	IK	GAQMWPRWVIGRRV-IVDGIBIRSA-N
DM7UP8X	IU	(2R,4S,5R,6R)-2-[[(2R,3R,4R,5R,6S)-5-acetamido-6-[(1S,2R)-1-amino-1-carboxypropan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]methoxy]-4-hydroxy-5-[[2-(2-methoxyethoxycarbonylamino)acetyl]amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DM7UP8X	DE	Malignant solid tumour

DMJI3BA	ID	DMJI3BA
DMJI3BA	DN	Peginterferon alfa-2a
DMJI3BA	HS	Approved
DMJI3BA	SN	Pegasys; Peginterferon alfa-2a (genetical recombination); Peginterferon alfa-2a (USAN/INN); Peginterferon alfa-2a (genetical recombination) (JAN)
DMJI3BA	CP	Hoffmann-La Roche pharmaceutical company
DMJI3BA	TC	Anticancer Agents
DMJI3BA	SQ	Peginterferon alfa-2a sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMJI3BA	DE	Hairy cell leukaemia

DMAP58Y	ID	DMAP58Y
DMAP58Y	DN	Peginterferon alfa-2b
DMAP58Y	HS	Approved
DMAP58Y	SN	PegIntron; Peginterferon alfa-2b (INN); Peginterferon alfa-2b (generical recombination); Peginterferon alfa-2b (generical recombination) (JAN)
DMAP58Y	CP	Schering-Plough
DMAP58Y	TC	Antiviral Agents
DMAP58Y	SQ	DB00022 sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMAP58Y	DE	Hepatitis C virus infection

DMCLR6G	ID	DMCLR6G
DMCLR6G	DN	Pegloticase
DMCLR6G	HS	Approved
DMCLR6G	SN	Krystexxa (TN)
DMCLR6G	CP	Savient
DMCLR6G	SQ	Pegloticase: TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL
DMCLR6G	DE	Gout

DM6NZ2P	ID	DM6NZ2P
DM6NZ2P	DN	Pegvaliase
DM6NZ2P	HS	Approved
DM6NZ2P	SN	BMN 165; Pegvaliase [INN]; UNII-N6UAH27EUV; N6UAH27EUV
DM6NZ2P	CP	BioMarin Pharmaceutical
DM6NZ2P	PC	86278362
DM6NZ2P	MW	318.41
DM6NZ2P	FM	C15H30N2O5
DM6NZ2P	IC	InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1
DM6NZ2P	CS	COCCOCCCCCC(=O)NCCCC[C@@H](C(=O)O)N
DM6NZ2P	IK	NPOCDVAOUKODSQ-ZDUSSCGKSA-N
DM6NZ2P	IU	(2S)-2-amino-6-[6-(2-methoxyethoxy)hexanoylamino]hexanoic acid
DM6NZ2P	CA	CAS 1585984-95-7
DM6NZ2P	DE	Phenylketonuria

DMDEZI3	ID	DMDEZI3
DMDEZI3	DN	Pegvisomant
DMDEZI3	HS	Approved
DMDEZI3	SN	Somavent; Pegvisomant (genetical recombination); Somavent (TN); Somavert (TN); Pegvisomant (USAN/INN); Pegvisomant (genetical recombination) (JAN)
DMDEZI3	CP	Abbott Laboratories
DMDEZI3	TC	Anabolic Agents
DMDEZI3	SQ	DB00082 sequence: FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF
DMDEZI3	DE	Acromegaly

DMRH0D5	ID	DMRH0D5
DMRH0D5	DN	PEGylated IFN beta 1-a
DMRH0D5	HS	Approved
DMRH0D5	SN	BIIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis); PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idec; PEGylated interferon beta 1-a (multiple sclerosis), Biogen Idec
DMRH0D5	CP	Biogen idec
DMRH0D5	DE	Type-2 diabetes

DM8DQV9	ID	DM8DQV9
DM8DQV9	DN	Pelubiprofen
DM8DQV9	HS	Approved
DM8DQV9	SN	Pelubi; Rubione; CS-670; DW-330; RS-2131
DM8DQV9	CP	Sankyo Co Ltd
DM8DQV9	DT	Small molecular drug
DM8DQV9	PC	5282203
DM8DQV9	MW	258.31
DM8DQV9	FM	C16H18O3
DM8DQV9	IC	InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+
DM8DQV9	CS	CC(C1=CC=C(C=C1)/C=C/2\\CCCCC2=O)C(=O)O
DM8DQV9	IK	AUZUGWXLBGZUPP-GXDHUFHOSA-N
DM8DQV9	IU	2-[4-[(E)-(2-oxocyclohexylidene)methyl]phenyl]propanoic acid
DM8DQV9	CA	CAS 69956-77-0
DM8DQV9	DE	Back pain

DMD1VZL	ID	DMD1VZL
DMD1VZL	DN	Pemafibrate
DMD1VZL	HS	Approved
DMD1VZL	SN	K-877
DMD1VZL	CP	Kowa Co Ltd
DMD1VZL	PC	11526038
DMD1VZL	MW	490.5
DMD1VZL	FM	C28H30N2O6
DMD1VZL	IC	InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1
DMD1VZL	CS	CC[C@H](C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3
DMD1VZL	IK	ZHKNLJLMDFQVHJ-RUZDIDTESA-N
DMD1VZL	IU	(2R)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid
DMD1VZL	CA	CAS 848259-27-8
DMD1VZL	DE	Lipid metabolism disorder; Cardiovascular disease; Hyperlipidemia

DMFQEA6	ID	DMFQEA6
DMFQEA6	DN	Pembrolizumab
DMFQEA6	HS	Approved
DMFQEA6	CP	Merck Kenilworth, NJ
DMFQEA6	DT	Monoclonal antibody
DMFQEA6	SQ	Heavy Chain Sequence: QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK</sequence>    <sequence format="FASTA">&gt;Light Chain SequenceEIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMFQEA6	DE	Solid tumour/cancer; Hepatocellular carcinoma; Ovarian cancer; Primary mediastinal B-cell lymphoma; Prostate cancer; Renal cell carcinoma; Small-cell lung cancer; Breast cancer; Colorectal cancer; Cutaneous squamous cell carcinoma; Esophageal cancer; Melanoma

DMMX2E6	ID	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	HS	Approved
DMMX2E6	SN	Alimta; LYA; LY 231514; LY231514; Alimta (TN); LY 231,514; LY-2315; LY-231514; Pemetrexed (INN); Pemetrexed [INN:BAN]; LY-231,514; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
DMMX2E6	CP	Eli Lilly
DMMX2E6	TC	Anticancer Agents
DMMX2E6	DT	Small molecular drug
DMMX2E6	PC	135410875
DMMX2E6	MW	427.4
DMMX2E6	FM	C20H21N5O6
DMMX2E6	IC	InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
DMMX2E6	CS	C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMMX2E6	IK	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
DMMX2E6	IU	(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
DMMX2E6	CA	CAS 137281-23-3
DMMX2E6	CB	CHEBI:63616
DMMX2E6	DE	Malignant pleural mesothelioma

DM819JF	ID	DM819JF
DM819JF	DN	Pemigatinib
DM819JF	HS	Approved
DM819JF	SN	Unii-Y6BX7BL23K; UNII-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828
DM819JF	CP	Incyte Wilmington, DE
DM819JF	PC	86705695
DM819JF	MW	487.5
DM819JF	FM	C24H27F2N5O4
DM819JF	IC	InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)
DM819JF	CS	CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5
DM819JF	IK	HCDMJFOHIXMBOV-UHFFFAOYSA-N
DM819JF	IU	11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
DM819JF	CA	CAS 1513857-77-6
DM819JF	DE	Bladder cancer; Myeloproliferative syndrome; Cholangiocarcinoma

DML97WV	ID	DML97WV
DML97WV	DN	Pemirolast
DML97WV	HS	Approved
DML97WV	SN	Pemirolastum; Pemirox; Pemirolast [INN]; Pemiroplast Potassium; Alamast (TN); Alegysal (TN); Pemirolast (INN); Pemirolastum [INN-Latin]; Pemirox (TN); 9-TBX; 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
DML97WV	TC	Antiallergic Agents
DML97WV	DT	Small molecular drug
DML97WV	PC	57697
DML97WV	MW	228.21
DML97WV	FM	C10H8N6O
DML97WV	IC	InChI=1S/C10H8N6O/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8/h2-5H,1H3,(H,12,13,14,15)
DML97WV	CS	CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3
DML97WV	IK	HIANJWSAHKJQTH-UHFFFAOYSA-N
DML97WV	IU	9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
DML97WV	CA	CAS 69372-19-6
DML97WV	CB	CHEBI:134936
DML97WV	DE	Allergic conjunctivitis

DM4ES8F	ID	DM4ES8F
DM4ES8F	DN	Penbutolol
DM4ES8F	HS	Approved
DM4ES8F	SN	Betapressin; Levatol; Levatolol; Levopenbutol; Lobeta; Paginol; Penbutololum; PENBUTOLOL SULFATE; HOE 893; HOE 893d; Betapressin (TN); Hostabloc (TN); L-Penbutolol; Levatol (TN); Levatolol (TN); Lobeta (TN); Paginol (TN); Penbutolol (INN); Penbutolol [INN:BAN]; Penbutololum [INN-Latin]; Penbutolol Sulfate (2:1); S(-)-Penbutolol; (-)-Penbutolol; (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol; 1-(tert-Butylamino)-3-(o-cyclopentylphenoxy)propan-2-ol
DM4ES8F	TC	Antihypertensive Agents
DM4ES8F	DT	Small molecular drug
DM4ES8F	PC	37464
DM4ES8F	MW	291.4
DM4ES8F	FM	C18H29NO2
DM4ES8F	IC	InChI=1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1
DM4ES8F	CS	CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O
DM4ES8F	IK	KQXKVJAGOJTNJS-HNNXBMFYSA-N
DM4ES8F	IU	(2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol
DM4ES8F	CA	CAS 38363-40-5
DM4ES8F	CB	CHEBI:7954
DM4ES8F	DE	Hypertension

DMOUMDV	ID	DMOUMDV
DMOUMDV	DN	Penciclovir
DMOUMDV	HS	Approved
DMOUMDV	SN	penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2
DMOUMDV	TC	Antiviral Agents
DMOUMDV	DT	Small molecular drug
DMOUMDV	PC	135398748
DMOUMDV	MW	253.26
DMOUMDV	FM	C10H15N5O3
DMOUMDV	IC	InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)
DMOUMDV	CS	C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N
DMOUMDV	IK	JNTOCHDNEULJHD-UHFFFAOYSA-N
DMOUMDV	IU	2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one
DMOUMDV	CA	CAS 39809-25-1
DMOUMDV	CB	CHEBI:7956
DMOUMDV	DE	Human immunodeficiency virus infection

DMG1DTE	ID	DMG1DTE
DMG1DTE	DN	Penfluridol
DMG1DTE	HS	Approved
DMG1DTE	SN	PENFLURIDOL; 26864-56-2; Semap; 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol; TLP-607; McN-JR-16,341; 1-[4,4-Bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol; Penfluridolum [INN-Latin]; C28H27ClF5NO; UNII-25TLU22Q8H; R 16341; EINECS 248-074-5; R-16341; BRN 1558826; CHEMBL47050; 25TLU22Q8H; MDLAAYDRRZXJIF-UHFFFAOYSA-N; 4-Piperidinol, 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)-; 4-Piperidinol,; Hydroxamates
DMG1DTE	DT	Small molecular drug
DMG1DTE	PC	33630
DMG1DTE	MW	524
DMG1DTE	FM	C28H27ClF5NO
DMG1DTE	IC	InChI=1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2
DMG1DTE	CS	C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMG1DTE	IK	MDLAAYDRRZXJIF-UHFFFAOYSA-N
DMG1DTE	IU	1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol
DMG1DTE	CA	CAS 26864-56-2
DMG1DTE	CB	CHEBI:92278
DMG1DTE	DE	Schizophrenia

DM40EF6	ID	DM40EF6
DM40EF6	DN	Penicillamine
DM40EF6	HS	Approved
DM40EF6	SN	D-Penicillamine; penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Beta-Thiovaline; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; Beta,beta-Dimethylcysteine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine; D-penicillamine
DM40EF6	TC	Antidotes
DM40EF6	DT	Small molecular drug
DM40EF6	PC	5852
DM40EF6	MW	149.21
DM40EF6	FM	C5H11NO2S
DM40EF6	IC	InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1
DM40EF6	CS	CC(C)([C@H](C(=O)O)N)S
DM40EF6	IK	VVNCNSJFMMFHPL-VKHMYHEASA-N
DM40EF6	IU	(2S)-2-amino-3-methyl-3-sulfanylbutanoic acid
DM40EF6	CA	CAS 771431-20-0
DM40EF6	CB	CHEBI:7959
DM40EF6	DE	Rheumatoid arthritis

DMNMHBV	ID	DMNMHBV
DMNMHBV	DN	Penicillin
DMNMHBV	HS	Approved
DMNMHBV	SN	Cillin; Pentids; 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Phenylmethyl)penicillin; 7005-30-3; NSC131815; (Phenylmethyl)penicillinic acid; 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; AC1L1DHC; AC1Q5UVJ; Penicilline G sodium salt; Oprea1_713794; Oprea1_861345; CHEMBL300052; SCHEMBL2109546; CTK2H5530
DMNMHBV	DT	Small molecular drug
DMNMHBV	PC	2349
DMNMHBV	MW	334.4
DMNMHBV	FM	C16H18N2O4S
DMNMHBV	IC	InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)
DMNMHBV	CS	CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
DMNMHBV	IK	JGSARLDLIJGVTE-UHFFFAOYSA-N
DMNMHBV	IU	3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMNMHBV	CA	CAS 61-33-6
DMNMHBV	DE	Bacterial infection

DM49VEW	ID	DM49VEW
DM49VEW	DN	Penicillin G Benzathine
DM49VEW	HS	Approved
DM49VEW	SN	Bicillin L-a; Permapen; Bicillin
DM49VEW	CP	King Pharmaceuticals Inc
DM49VEW	TC	Antiinfective Agents
DM49VEW	DT	Small molecular drug
DM49VEW	PC	656811
DM49VEW	MW	981.2
DM49VEW	FM	C48H64N6O12S2
DM49VEW	IC	InChI=1S/2C16H18N2O4S.C16H20N2.4H2O/c2*1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-7-15(8-4-1)13-17-11-12-18-14-16-9-5-2-6-10-16;;;;/h2*3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);1-10,17-18H,11-14H2;4*1H2/t2*11-,12+,14-;;;;;/m11...../s1
DM49VEW	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.C1=CC=C(C=C1)CNCCNCC2=CC=CC=C2.O.O.O.O
DM49VEW	IK	WIDKTXGNSOORHA-CJHXQPGBSA-N
DM49VEW	IU	N,N'-dibenzylethane-1,2-diamine;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate
DM49VEW	CA	CAS 41372-02-5
DM49VEW	DE	Bacterial infection

DMU4JLB	ID	DMU4JLB
DMU4JLB	DN	Penicillin G Procaine
DMU4JLB	HS	Approved
DMU4JLB	SN	Duracillin A.S.; Pfizerpen-as
DMU4JLB	CP	Eli Lilly And Co
DMU4JLB	TC	Antiinfective Agents
DMU4JLB	DT	Small molecular drug
DMU4JLB	PC	22502
DMU4JLB	MW	588.7
DMU4JLB	FM	C29H40N4O7S
DMU4JLB	IC	InChI=1S/C16H18N2O4S.C13H20N2O2.H2O/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);5-8H,3-4,9-10,14H2,1-2H3;1H2/t11-,12+,14-;;/m1../s1
DMU4JLB	CS	CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.O
DMU4JLB	IK	KZDCMKVLEYCGQX-UDPGNSCCSA-N
DMU4JLB	IU	2-(diethylamino)ethyl 4-aminobenzoate;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate
DMU4JLB	CA	CAS 6130-64-9
DMU4JLB	DE	Bacterial infection

DMY18XK	ID	DMY18XK
DMY18XK	DN	Penicillin G Sodium
DMY18XK	HS	Approved
DMY18XK	SN	Penicillin G sodium salt; 69-57-8; Benzylpenicillin sodium; Crystapen; American penicillin; Pencillin G sodium; Sodium penicillin G; BENZYLPENICILLIN SODIUM SALT; Sodium penicillin; Sodium benzylpenicillinate; Sodium penicillin II; Veticillin; Penilaryn; Mycofarm; Novocillin; Sodium benzylpenicillin; Kesso-Pen; Pen-A-Brasive; Sodium benzylpenicillin G; Monosodium benzylpenicillin; Benzylpenicillinic acid sodium salt; Sugracillin sodium salt; Penicillin G Sodium, Crystalline; Sodium benzylp
DMY18XK	CP	Bristol Myers Squibb Spa
DMY18XK	TC	Antiinfective Agents
DMY18XK	DT	Small molecular drug
DMY18XK	PC	23668834
DMY18XK	MW	356.4
DMY18XK	FM	C16H17N2NaO4S
DMY18XK	IC	InChI=1S/C16H18N2O4S.Na/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1
DMY18XK	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)[O-])C.[Na+]
DMY18XK	IK	FCPVYOBCFFNJFS-LQDWTQKMSA-M
DMY18XK	IU	sodium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMY18XK	CA	CAS 69-57-8
DMY18XK	CB	CHEBI:51765
DMY18XK	DE	Bacterial infection

DMKVOYF	ID	DMKVOYF
DMKVOYF	DN	Penicillin V
DMKVOYF	HS	Approved
DMKVOYF	SN	Apocillin; Apopen; Beromycin; Calcipen; Fenacilin; Fenospen; Fenossimetilpenicillina; Fenoximetilpenicilina; Fenoxymethylpenicillin; Fenoxypen; Meropenin; Oracillin; Oratren; Ospen; PNV; PVA; Phenocillin; Phenomycilline; Phenopenicillin; Phenoximethylpenicillinum; Phenoxomethylpenicillanyl; Phenoxomethylpenicillin; Phenoxymethylpenicillanyl; Phenoxymethylpenicillin; Phenoxymethylpenicilline; Phenoxymethylpenicillinum; Robicillin; Rocilin; Stabicillin; Vebecillin; Vegacillin; Acipen V; Compocillin V; Crystapen V; Distaquaine V; Eskacillian V; Eskacillin V; Fenossimetilpenicillina [DCIT]; Penicillin V [USAN]; Penicillin phenoxymethyl; Phenoxymethyl penicillin; Phenoxymethylenepenicillinic acid; Phenoxymethylpenicillinic acid; Phenoxymethylpenicillinic acid potassium salt; Acipen-v; Beromycin, Penicillin; Berromycin, Penicillin; Fenoximetilpenicilina [INN-Spanish]; Pen-Oral; Pen-V; Pen-vee; Penicillin V (USP); Penicillin, Phenoxymethyl; Phenoxymethylpenicillin (INN); Phenoxymethylpenicilline [INN-French]; Phenoxymethylpenicillinum [INN-Latin]; V-Cil; V-Cillin; V-Cylina; V-Cyline; V-Tablopen; P-Mega-Tablinen; V-Cillin (TN); (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carbonyl; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid; 3,3-Dimethyl-7-oxo-6-((phenyloxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN); 6-Phenoxyacetamidopenicillanic acid
DMKVOYF	TC	Antibiotics
DMKVOYF	DT	Small molecular drug
DMKVOYF	PC	6869
DMKVOYF	MW	350.4
DMKVOYF	FM	C16H18N2O5S
DMKVOYF	IC	InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1
DMKVOYF	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C
DMKVOYF	IK	BPLBGHOLXOTWMN-MBNYWOFBSA-N
DMKVOYF	IU	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMKVOYF	CA	CAS 87-08-1
DMKVOYF	CB	CHEBI:27446
DMKVOYF	DE	Bacterial infection

DM8LX76	ID	DM8LX76
DM8LX76	DN	Penicillin V Potassium
DM8LX76	HS	Approved
DM8LX76	SN	Ledercillin Vk; Pen-vee K; Pfizerpen Vk; Veetids; Veetids '125'; Veetids '250'; Uticillin Vk; Veetids '500'
DM8LX76	CP	Glaxosmithkline
DM8LX76	TC	Antiinfective Agents
DM8LX76	DT	Small molecular drug
DM8LX76	PC	23676814
DM8LX76	MW	388.5
DM8LX76	FM	C16H17KN2O5S
DM8LX76	IC	InChI=1S/C16H18N2O5S.K/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1
DM8LX76	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+]
DM8LX76	IK	HCTVWSOKIJULET-LQDWTQKMSA-M
DM8LX76	IU	potassium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DM8LX76	CA	CAS 132-98-9
DM8LX76	CB	CHEBI:7967
DM8LX76	DE	Bacterial infection

DMZ9MO5	ID	DMZ9MO5
DMZ9MO5	DN	Pentaerythritol tetranitrate
DMZ9MO5	HS	Approved
DMZ9MO5	SN	PENTAERYTHRITOL TETRANITRATE; PETN; Penthrite; Nitropentaerythrite; Nitropentaerythritol; Nitropenta; Pentaerithrityl tetranitrate; Vasodiatol; Pentanitrine; Pentanitrol; Quintrate; Corpent; Baritrate; Angicap; Perityl; Peritrate; Penthrit; Antora; Erinit; Peridex-LA; 78-11-5; Deltrate-20; Neopentanetetrayl nitrate; Tetrasule; Pergitral; Pentritol; Pentrite; Nitrotalans; Kaytrate; Duotrate; Subicard; Rythritol; Prevangor; Pentryate; Nitropenton; Nitropent; Pentrate; Pentitrate; Pentafin; Nitrinal; Niperyth; Mycardol; Metranil; Lowetrate; Arcotrate
DMZ9MO5	DT	Small molecular drug
DMZ9MO5	PC	6518
DMZ9MO5	MW	316.14
DMZ9MO5	FM	C5H8N4O12
DMZ9MO5	IC	InChI=1S/C5H8N4O12/c10-6(11)18-1-5(2-19-7(12)13,3-20-8(14)15)4-21-9(16)17/h1-4H2
DMZ9MO5	CS	C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O[N+](=O)[O-]
DMZ9MO5	IK	TZRXHJWUDPFEEY-UHFFFAOYSA-N
DMZ9MO5	IU	[3-nitrooxy-2,2-bis(nitrooxymethyl)propyl] nitrate
DMZ9MO5	CA	CAS 78-11-5
DMZ9MO5	CB	CHEBI:25879
DMZ9MO5	DE	Angina pectoris

DMRCLZB	ID	DMRCLZB
DMRCLZB	DN	Pentagastrin
DMRCLZB	HS	Approved
DMRCLZB	SN	Peptavlon; Peptavlon (TN); Pentagastrin (JAN/USAN/INN); (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-(2-methylpropoxycarbonylamino)propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DMRCLZB	TC	Diagnostic Agents
DMRCLZB	DT	Small molecular drug
DMRCLZB	PC	9853654
DMRCLZB	MW	767.9
DMRCLZB	FM	C37H49N7O9S
DMRCLZB	IC	InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1
DMRCLZB	CS	CC(C)(C)OC(=O)NCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N
DMRCLZB	IK	NEYNJQRKHLUJRU-DZUOILHNSA-N
DMRCLZB	IU	(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DMRCLZB	CA	CAS 5534-95-2
DMRCLZB	CB	CHEBI:31974
DMRCLZB	DE	Diagnostic imaging

DMHZJCG	ID	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	HS	Approved
DMHZJCG	SN	Lomidine; Nebupent; PENTAM; PNT; Pentacarinat; Pentamide; Pentamidin; Pentamidina; Pentamidinum; Pneumopent; PENTAMIDINE ISETHIONATE; Pentamidina [DCIT]; Pentamidine isetionate; Pentamidine mesylate; MB 800; Pentam 300; Lomidine (TN); MB-800; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamidine (INN); Pentamidinum [INN-Latin]; RP-2512; Nebupent (*Isethionate); Pentacarinat (*Isethionate); Pentam 300 (*Isethionate); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid;Pentamidine [INN:BAN:DCF]; RP 2512 (*Isethionate); P,p'-(Pentamethylenedioxy)bis[benzamidine]; P,p'-(Pentamethylenedioxy)dibenzamidine; P,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-(9CI); 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; 4, 4'-Diamidinodiphenoxypentane; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(Pentamethylenedioxy)dibenzamide; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; 4,4'-Diamidinodiphenoxypentane; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
DMHZJCG	TC	Antifungal Agents
DMHZJCG	DT	Small molecular drug
DMHZJCG	PC	4735
DMHZJCG	MW	340.4
DMHZJCG	FM	C19H24N4O2
DMHZJCG	IC	InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
DMHZJCG	CS	C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N
DMHZJCG	IK	XDRYMKDFEDOLFX-UHFFFAOYSA-N
DMHZJCG	IU	4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
DMHZJCG	CA	CAS 100-33-4
DMHZJCG	CB	CHEBI:45081
DMHZJCG	DE	Fungal infection; Human immunodeficiency virus infection

DM1XBHS	ID	DM1XBHS
DM1XBHS	DN	Pentazocine
DM1XBHS	HS	Approved
DM1XBHS	SN	Fortalgesic; Fortalin; Fortral; Lexir; Liticon; Pentagin; Pentazocaine; Pentazocin; Pentazocina; Pentazocinum; Sosegon; Soseton; Sosigon; Talacen; Talwan; Pentazocina [DCIT]; NIH 7958; WIN 20228; Algopent (free base); Fortal (TN); Fortral (TN); Fortwin (TN); KF-1820; L-pentazocine; Pentazocinum [INN-Latin]; Talacen (TN); Talwin (TN); Talwin NX (TN); Talwin PX (TN); II-C-2; Pentazocine (JP15/USP/INN); Pentazocine [USAN:INN:BAN:JAN]; Pentazocine, Pentazocin, Sosegon, WIN 20228; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; 2-(3,3-Dimethylallyl)cyclazocine; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol
DM1XBHS	CP	Sterling Drug Company
DM1XBHS	TC	Anesthetics
DM1XBHS	DT	Small molecular drug
DM1XBHS	PC	441278
DM1XBHS	MW	285.4
DM1XBHS	FM	C19H27NO
DM1XBHS	IC	InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1
DM1XBHS	CS	C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O
DM1XBHS	IK	VOKSWYLNZZRQPF-GDIGMMSISA-N
DM1XBHS	IU	(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DM1XBHS	CA	CAS 359-83-1
DM1XBHS	CB	CHEBI:7982
DM1XBHS	DE	Pain

DMFNH7L	ID	DMFNH7L
DMFNH7L	DN	Pentobarbital
DMFNH7L	HS	Approved
DMFNH7L	SN	Aethaminalum; Dorsital; Etaminal; Ethaminal; Mebubarbital; Mebumal; Nebralin; Nembutal; Neodorm; Pentabarbital; Pentabarbitone; Pentobarbitale; Pentobarbitalum; Pentobarbitone; Pentobarbiturate; Rivadorm; Pentobarbital calcium; Pentobarbital suppository dosage form; Pentobarbitale [DCIT]; Pentobarbituric acid; Ethyl-propylmethylcarbinylbarbituric acid; Nembutal (TN); Nembutal (VAN); Neodorm (VAN); Neodorm (new); Pentobarbital (VAN); Pentobarbital [USP:INN]; Pentobarbital, Monosodium Salt; Pentobarbitalum [INN-Latin]; Pentobarbitone (VAN); Pentobarbital (USP/INN); (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)malonylurea; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
DMFNH7L	CP	Oak Pharmaceuticals Inc
DMFNH7L	TC	Hypnotics and Sedatives
DMFNH7L	DT	Small molecular drug
DMFNH7L	PC	4737
DMFNH7L	MW	226.27
DMFNH7L	FM	C11H18N2O3
DMFNH7L	IC	InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DMFNH7L	CS	CCCC(C)C1(C(=O)NC(=O)NC1=O)CC
DMFNH7L	IK	WEXRUCMBJFQVBZ-UHFFFAOYSA-N
DMFNH7L	IU	5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
DMFNH7L	CA	CAS 76-74-4
DMFNH7L	CB	CHEBI:7983
DMFNH7L	DE	Insomnia

DM38VYQ	ID	DM38VYQ
DM38VYQ	DN	Pentolinium
DM38VYQ	HS	Approved
DM38VYQ	SN	Pentolineum; Pentolonium; Pentolonum; 1,1'-pentane-1,5-diylbis(1-methylpyrrolidinium); 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium
DM38VYQ	CP	Wyeth Ayerst Laboratories
DM38VYQ	TC	Antihypertensive Agents
DM38VYQ	DT	Small molecular drug
DM38VYQ	PC	5850
DM38VYQ	MW	240.43
DM38VYQ	FM	C15H32N2+2
DM38VYQ	IC	InChI=1S/C15H32N2/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17/h3-15H2,1-2H3/q+2
DM38VYQ	CS	C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C
DM38VYQ	IK	XSBSKEQEUFOSDD-UHFFFAOYSA-N
DM38VYQ	IU	1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium
DM38VYQ	CA	CAS 144-44-5
DM38VYQ	CB	CHEBI:347401
DM38VYQ	DE	Hypotension

DM2HRKE	ID	DM2HRKE
DM2HRKE	DN	Pentosan polysulfate
DM2HRKE	HS	Approved
DM2HRKE	SN	Elmiron; Pentosan sulfuric polyester; Polypentose sulfate; Elmiron (TN); Xylan,hydrogen sulfate; [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate
DM2HRKE	CP	Ortho-McNeil Pharmaceutical
DM2HRKE	TC	Anticoagulants
DM2HRKE	DT	Small molecular drug
DM2HRKE	PC	37720
DM2HRKE	MW	602.5
DM2HRKE	FM	C10H18O21S4
DM2HRKE	IC	InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1
DM2HRKE	CS	C1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2CO[C@H]([C@@H]([C@H]2OS(=O)(=O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)O
DM2HRKE	IK	FCCNSUIJIOOXEZ-SJYYZXOBSA-N
DM2HRKE	IU	[(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate
DM2HRKE	CA	CAS 37300-21-3
DM2HRKE	DE	Painful bladder syndrome; Interstitial cystitis

DM0HXDS	ID	DM0HXDS
DM0HXDS	DN	Pentostatin
DM0HXDS	HS	Approved
DM0HXDS	SN	Coforin; Covidarabine; Deoxycoformycin; Nipent; Oncopent; Vidarbine; Vira A deaminase inhibitor; CL-67310465; CO-Vidarabine; Co-V; Nipent (TN); PD-81565; PD-ADI; Pentostatin (JAN/USAN/INN); (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol; (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; 2'-DCF; 2'-Deoxycoformycin; 2'-Dexoycoformycin
DM0HXDS	TC	Anticancer Agents
DM0HXDS	DT	Small molecular drug
DM0HXDS	PC	439693
DM0HXDS	MW	268.27
DM0HXDS	FM	C11H16N4O4
DM0HXDS	IC	InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1
DM0HXDS	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC=NC[C@H]3O)CO)O
DM0HXDS	IK	FPVKHBSQESCIEP-JQCXWYLXSA-N
DM0HXDS	IU	(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol
DM0HXDS	CA	CAS 53910-25-1
DM0HXDS	DE	Hairy cell leukaemia

DMU3DNC	ID	DMU3DNC
DMU3DNC	DN	Pentoxifylline
DMU3DNC	HS	Approved
DMU3DNC	SN	Agapurin; Azupentat; Dimethyloxohexylxanthine; Durapental; Hemovas; Ikomio; Oxpentifylline; PENTOXYPHYLINE;PNX; Pentoxifilina; Pentoxifyllin; Pentoxifyllinum; Pentoxil; Pentoxiphyllin; Pentoxiphylline; Pentoxiphyllium; Pentoxyfylline; Pentoxyphyllin; Pentoxyphylline; Ralofect; Rentylin; Torental; Trental;Vasofirin; Vazofirin; Agapurin Retard; BL 191; BL191; EHT 0201; EHT0201; IN1161; P 1784; Artal (TN); BL-191; EHT-0201; EHT-201; Flexital (TN); Pentox (TN); Pentoxifilina [INN-Spanish]; Pentoxifyllinum [INN-Latin]; Pentoxil (TN); Pentoxin (TN); Trental (TN); Cis-9-Octadecenoyl coenzyme A; Pentoxifylline [USAN:INN:JAN]; Pentoxifylline (JAN/USP/INN); 1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion; 1-(5-Oxohexyl)-3,7-dimethylxanthine; 1-(5-Oxohexyl)theobromine; 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl) xantine; 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)xanthine; 3,7-Dimethyl-1-(5-oxohexyl)xantine; 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
DMU3DNC	CP	Aventis Pharmaceuticals Inc.
DMU3DNC	TC	Vasodilator Agents
DMU3DNC	DT	Small molecular drug
DMU3DNC	PC	4740
DMU3DNC	MW	278.31
DMU3DNC	FM	C13H18N4O3
DMU3DNC	IC	InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
DMU3DNC	CS	CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
DMU3DNC	IK	BYPFEZZEUUWMEJ-UHFFFAOYSA-N
DMU3DNC	IU	3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
DMU3DNC	CA	CAS 6493-05-6
DMU3DNC	CB	CHEBI:7986
DMU3DNC	DE	Intermittent claudication

DMNXY5K	ID	DMNXY5K
DMNXY5K	DN	Peramivir
DMNXY5K	HS	Approved
DMNXY5K	SN	PeramiFlu; S-021812; (1S,2S,3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; PRV
DMNXY5K	CP	BioCryst Pharmaceuticals
DMNXY5K	DT	Small molecular drug
DMNXY5K	PC	154234
DMNXY5K	MW	328.41
DMNXY5K	FM	C15H28N4O4
DMNXY5K	IC	InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1
DMNXY5K	CS	CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)N=C(N)N)NC(=O)C
DMNXY5K	IK	XRQDFNLINLXZLB-CKIKVBCHSA-N
DMNXY5K	IU	(1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
DMNXY5K	CA	CAS 330600-85-6
DMNXY5K	CB	CHEBI:85202
DMNXY5K	DE	Influenza virus infection

DM2AOTZ	ID	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	HS	Approved
DM2AOTZ	SN	Perazine maleate; Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, maleate; 84-97-9 (Parent); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, (Z)-2-butenedioate; SCHEMBL220704; AC1O6123; LS-105593; 10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DM2AOTZ	DT	Small molecular drug
DM2AOTZ	PC	4744
DM2AOTZ	MW	339.5
DM2AOTZ	FM	C20H25N3S
DM2AOTZ	IC	InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3
DM2AOTZ	CS	CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=CC=CC=C42
DM2AOTZ	IK	WEYVCQFUGFRXOM-UHFFFAOYSA-N
DM2AOTZ	IU	10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DM2AOTZ	CA	CAS 84-97-9
DM2AOTZ	CB	CHEBI:59118
DM2AOTZ	DE	Psychotic disorder

DM14MAE	ID	DM14MAE
DM14MAE	DN	Pergolide
DM14MAE	HS	Approved
DM14MAE	SN	Pergolida; Pergolidum; Permax; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum [INN-Latin]; Permax (TN); LY-127,809; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; (8beta)-8-[(methylthio)methyl]-6-propylergoline
DM14MAE	CP	Valeant Pharmaceuticals
DM14MAE	TC	Antiparkinson Agents
DM14MAE	DT	Small molecular drug
DM14MAE	PC	47811
DM14MAE	MW	314.5
DM14MAE	FM	C19H26N2S
DM14MAE	IC	InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1
DM14MAE	CS	CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
DM14MAE	IK	YEHCICAEULNIGD-MZMPZRCHSA-N
DM14MAE	IU	(6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
DM14MAE	CA	CAS 66104-22-1
DM14MAE	CB	CHEBI:63617
DM14MAE	DE	Parkinson disease

DM5GKOV	ID	DM5GKOV
DM5GKOV	DN	Pergolide mesylate
DM5GKOV	HS	Approved
DM5GKOV	SN	Pergolida; Pergolide (mesylate); Pergolide Methanesulfonate; Pergolide mesilate; Permax (TN); LY127809; PERGOLIDE MESYLATE; PERGOLIDE MESYLATE SALT; 55B9HQY616; 66104-23-2; 8-beta-((Methylthio)methyl)-6-propylergoline methanesulfonate; 8-beta-((Methylthio)methyl)-6-propylergoline monomethane sulfonate; 8beta-((Methylthio)methyl)-6-propylergoline monomethanesulfonate; CHEBI:8021; CHEMBL1275; CPD000058504; DSSTox_CID_20583; DSSTox_GSID_40583; DSSTox_RID_77029; MLS000069837; MPE; SMR000058504; UNII-55B9HQY616; LY-127,809; LY-127809; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum; Pergolidum [INN-Latin]; Permax; Prestwick0_000295; Prestwick1_000295; Prestwick2_000295; Prestwick3_000295; SR-01000721840; Spectrum2_001970; Spectrum4_000835; Spectrum5_001649; Spectrum_001647; TNP00315; pergolide; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; 24MJ822NZ9; 66104-22-1; CHEBI:63617; CHEMBL531; Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-; NCGC00017366-04; UNII-24MJ822NZ9
DM5GKOV	PC	47812
DM5GKOV	MW	410.6
DM5GKOV	FM	C20H30N2O3S2
DM5GKOV	IC	UWCVGPLTGZWHGS-ZORIOUSZSA-N
DM5GKOV	CS	CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O
DM5GKOV	IK	1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1
DM5GKOV	IU	(6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline;methanesulfonic acid
DM5GKOV	CA	CAS 66104-23-2
DM5GKOV	CB	CHEBI:8021
DM5GKOV	DE	Parkinsonism

DMINO7Z	ID	DMINO7Z
DMINO7Z	DN	Perhexiline
DMINO7Z	HS	Approved
DMINO7Z	SN	Perhexilene; Perhexilina; Perhexilinum; Perhexilline; Perhexilina [INN-Spanish]; Perhexiline (INN); Perhexiline [INN:BAN]; Perhexilinum [INN-Latin]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine
DMINO7Z	TC	Vasodilator Agents
DMINO7Z	DT	Small molecular drug
DMINO7Z	PC	4746
DMINO7Z	MW	277.5
DMINO7Z	FM	C19H35N
DMINO7Z	IC	InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2
DMINO7Z	CS	C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
DMINO7Z	IK	CYXKNKQEMFBLER-UHFFFAOYSA-N
DMINO7Z	IU	2-(2,2-dicyclohexylethyl)piperidine
DMINO7Z	CA	CAS 39648-47-0
DMINO7Z	CB	CHEBI:35553
DMINO7Z	DE	Angina pectoris

DMOPZDT	ID	DMOPZDT
DMOPZDT	DN	Perindopril
DMOPZDT	HS	Approved
DMOPZDT	SN	ACEON; Coverex; Coversum; Coversyl; Prestarium; Coverene Cor; Cpd with unspecified MF; Aceon (TN); Acertil (TN); Armix (TN); Coverene (TN); Coverex (TN); Coversum (TN); DW-7950; Prestarium (TN); Prexanil (TN); Prexum (TN); Procaptan (TN); S-9490; SED-9490; McN-A-2833; Perindopril (USAN/INN); Ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate; (2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid
DMOPZDT	TC	Antihypertensive Agents
DMOPZDT	DT	Small molecular drug
DMOPZDT	PC	107807
DMOPZDT	MW	368.5
DMOPZDT	FM	C19H32N2O5
DMOPZDT	IC	InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1
DMOPZDT	CS	CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O
DMOPZDT	IK	IPVQLZZIHOAWMC-QXKUPLGCSA-N
DMOPZDT	IU	(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
DMOPZDT	CA	CAS 82834-16-0
DMOPZDT	CB	CHEBI:8024
DMOPZDT	DE	Hypertension

DMZ0Q1G	ID	DMZ0Q1G
DMZ0Q1G	DN	Permethrin
DMZ0Q1G	HS	Approved
DMZ0Q1G	SN	Ambush; PerFoam; Transpermethrin; Acticin Cream; Elimite Cream; Nix Cream Rinse; Transpermethrin [ISO];FMC 35171; NRDC 146; NRDC 148; PS758_SUPELCO; Permethrin (isomers); Permethrin (isomers) solution; Permethrine,c&t; Trans-(+-)-Permethrin; [3-(phenyloxy)phenyl]methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; (+)-CIS-PERMETHRIN; (+)-trans-Permethrin; (+-)-cis-Fmc 33297; (+-)-cis-Permethrin; (+-)-trans-Permethrin; (3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; (3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate; 1RS,cis-Permethrin; 1RS-trans-Permethrin; 3-Phenoxybenzyle (1RS)-cis, trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylate; 3-phenoxybenzyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
DMZ0Q1G	TC	Insecticides
DMZ0Q1G	DT	Small molecular drug
DMZ0Q1G	PC	40326
DMZ0Q1G	MW	391.3
DMZ0Q1G	FM	C21H20Cl2O3
DMZ0Q1G	IC	InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3
DMZ0Q1G	CS	CC1(C(C1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C
DMZ0Q1G	IK	RLLPVAHGXHCWKJ-UHFFFAOYSA-N
DMZ0Q1G	IU	(3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate
DMZ0Q1G	CA	CAS 52645-53-1
DMZ0Q1G	CB	CHEBI:34911
DMZ0Q1G	DE	Sarcoptes scabiei infection

DMVHJLX	ID	DMVHJLX
DMVHJLX	DN	Perospirone
DMVHJLX	HS	Approved
DMVHJLX	SN	Lullan; SM-9018
DMVHJLX	CP	Sumitomo Pharmaceuticals Co Ltd
DMVHJLX	DT	Small molecular drug
DMVHJLX	PC	115368
DMVHJLX	MW	426.6
DMVHJLX	FM	C23H30N4O2S
DMVHJLX	IC	InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+
DMVHJLX	CS	C1CC[C@H]2[C@@H](C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54
DMVHJLX	IK	FBVFZWUMDDXLLG-HDICACEKSA-N
DMVHJLX	IU	(3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione
DMVHJLX	CA	CAS 150915-41-6
DMVHJLX	CB	CHEBI:94777
DMVHJLX	DE	Psychotic disorder

DMA4MRX	ID	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	HS	Approved
DMA4MRX	SN	Chlorperphenazine; Chlorpiprazine; Decentan; Emesinal; Etaperazin; Etaperazine; Ethaperazine; Fentazin;PZC; Perfenazina; Perfenazine; Perphenan; Perphenazin; Perphenazinum; Thilatazin; Tranquisan; Trifaron; Trilafon; Trilifan; Triphenot; Perfenazina [Italian]; Perphenazine [Trilafon]; Perphenazine maleate; P 6402; Sch 3940; Apo-Perphenazine; F-mon; Perfenazina [INN-Spanish]; Perphenazinum [INN-Latin]; SCH-3940; Siquil (TN); Triavil (TN); Perphenazine [INN:BAN:JAN]; Perphenazine (JP15/USP/INN); Gamma-[4-(beta-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine; Gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]; 1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine; 1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-, trihydrochloride; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; 2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; 2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine; 2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol; 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
DMA4MRX	CP	Schering-Plough Corporation
DMA4MRX	TC	Antipsychotic Agents
DMA4MRX	DT	Small molecular drug
DMA4MRX	PC	4748
DMA4MRX	MW	404
DMA4MRX	FM	C21H26ClN3OS
DMA4MRX	IC	InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2
DMA4MRX	CS	C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
DMA4MRX	IK	RGCVKNLCSQQDEP-UHFFFAOYSA-N
DMA4MRX	IU	2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol
DMA4MRX	CA	CAS 58-39-9
DMA4MRX	CB	CHEBI:8028
DMA4MRX	DE	Schizophrenia

DMHJV0X	ID	DMHJV0X
DMHJV0X	DN	Pertuzumab
DMHJV0X	HS	Approved
DMHJV0X	SN	Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)
DMHJV0X	CP	Roche; Genentech
DMHJV0X	DT	Monoclonal antibody
DMHJV0X	SQ	Amino acid sequence for pertuzumab light chain : DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>    <sequence format="FASTA">&gt;Amino acid sequence for pertuzumab heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
DMHJV0X	DE	Breast cancer

DMS2J0Z	ID	DMS2J0Z
DMS2J0Z	DN	Pexidartinib
DMS2J0Z	HS	Approved
DMS2J0Z	SN	PLX-3397
DMS2J0Z	CP	Plexxikon Inc
DMS2J0Z	PC	25151352
DMS2J0Z	MW	417.8
DMS2J0Z	FM	C20H15ClF3N5
DMS2J0Z	IC	InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)
DMS2J0Z	CS	C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F
DMS2J0Z	IK	JGWRKYUXBBNENE-UHFFFAOYSA-N
DMS2J0Z	IU	5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine
DMS2J0Z	CA	CAS 1029044-16-3
DMS2J0Z	CB	CHEBI:145373
DMS2J0Z	DE	Alzheimer disease; Pigmented villonodular synovitis; Neurofibromatosis type 1; Tenosynovial giant cell tumour

DMSB068	ID	DMSB068
DMSB068	DN	PF-04449913
DMSB068	HS	Approved
DMSB068	SN	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2
DMSB068	CP	Pfizer
DMSB068	DT	Small molecular drug
DMSB068	PC	25166913
DMSB068	MW	374.4
DMSB068	FM	C21H22N6O
DMSB068	IC	InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1
DMSB068	CS	CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N
DMSB068	IK	SFNSLLSYNZWZQG-VQIMIIECSA-N
DMSB068	IU	1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea
DMSB068	CA	CAS 1095173-27-5
DMSB068	CB	CHEBI:145428
DMSB068	DE	Chronic myelomonocytic leukaemia; Solid tumour/cancer

DM79VXT	ID	DM79VXT
DM79VXT	DN	PF-04971729
DM79VXT	HS	Approved
DM79VXT	SN	Ertugliflozin; 1210344-57-2; PF04971729; UNII-6C282481IP; PF 04971729; CHEMBL1770248; 6C282481IP; AK174928; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; Steglatro; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; Ertugliflozin [USAN:INN]; C22H25ClO7;  PF-4971729; SGLT2 inhibitor (oral, type 2 diabetes), Pfizer; Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer; Ertugliflozin/PF-04971729
DM79VXT	CP	Merck & Co./Pfizer
DM79VXT	DT	Small molecular drug
DM79VXT	PC	44814423
DM79VXT	MW	436.9
DM79VXT	FM	C22H25ClO7
DM79VXT	IC	InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
DM79VXT	CS	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)CO)O)O)O)Cl
DM79VXT	IK	MCIACXAZCBVDEE-CUUWFGFTSA-N
DM79VXT	IU	(1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
DM79VXT	CA	CAS 1210344-57-2
DM79VXT	DE	Type-2 diabetes

DMOHS9P	ID	DMOHS9P
DMOHS9P	DN	Phenacemide
DMOHS9P	HS	Approved
DMOHS9P	SN	Acetylureum; Carbanmide; Cetylureum; Comitiadone; Eferon; Efron; Epheron; Epiclase; Felurea; Fenacemid; Fenacemida; Fenacemide;Fenacetamide; Fenilep; Fenised; Fenostenyl; Fenural; Fenurea; Fenurone; Fenylacetylmocovina; Fenytan; Neophedan; Neophenal; Phacetur; Phenacalum; Phenacemidum; Phenacereum; Phenacerum; Phenacetur; Phenacetylcarbamide; Phenacetylurea; Phenarone; Phenicarb; Phenuron; Phenurone; Phenutal; Phenylacetylurea; Phenylacetyluree; Phenyrit; Phetylureum; Carbamide phenylacetate; Fenacemide [DCIT]; Fenylacetylmocovina [Czech]; Phenylacetyluree [French]; A-1348; Alpha-Phenylacetylurea; Fenacemida [INN-Spanish]; Fenacetil-karbamide; Phenacemide [INN:BAN]; Phenacemidum [INN-Latin]; Phenurone (TN); Sym-PHENYLACETYLUREA; N-(Aminocarbonyl)benzeneacetamide; Phenacemide (JAN/INN); N-carbamoyl-2-phenylacetamide; N-(aminocarbonyl)-2-phenylacetamide; (2-phenylacetyl)urea; (Phenylacetyl)urea
DMOHS9P	TC	Anticonvulsants
DMOHS9P	DT	Small molecular drug
DMOHS9P	PC	4753
DMOHS9P	MW	178.19
DMOHS9P	FM	C9H10N2O2
DMOHS9P	IC	InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)
DMOHS9P	CS	C1=CC=C(C=C1)CC(=O)NC(=O)N
DMOHS9P	IK	XPFRXWCVYUEORT-UHFFFAOYSA-N
DMOHS9P	IU	N-carbamoyl-2-phenylacetamide
DMOHS9P	CA	CAS 63-98-9
DMOHS9P	CB	CHEBI:8049
DMOHS9P	DE	Epilepsy

DM6TS1N	ID	DM6TS1N
DM6TS1N	DN	Phendimetrazine
DM6TS1N	HS	Approved
DM6TS1N	SN	Adphen; Antapentan; Dyrexan; Fendimetrazina; Hyrex; Mephenmetrazine; Phendimetrazinum; Sedafamen; Wehless; Adipost (TN); Adphen (base); Appecon (TN); Bontril PDM (TN); Fendimetrazina [INN-Spanish]; Melfiat (TN); Obezine (TN); Phendiet (TN); Phendimetrazine (INN); Phendimetrazine [INN:BAN]; Phendimetrazinum [INN-Latin]; Plegine (TN); Statobex (TN); X-Trozine; Anorex-SR (TN); Prelu-2 (TN); Phendimetrazine, (2S-trans)-isomer; D-2-Phenyl-3,4-dimethylmorpholine; Morpholine, 3,4-dimethyl-2-phenyl; (+)-3,4-Dimethyl-2-phenylmorpholine; (+)-Phendimetrazine; (2R-trans)-3,4-Dimethyl-2-phenylmorpholine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenyltetrahydro-1,4-oxazine; 3-Phenyl-2-methylmorpholine
DM6TS1N	CP	Sandoz Inc
DM6TS1N	TC	Anorexigenic Agents
DM6TS1N	DT	Small molecular drug
DM6TS1N	PC	30487
DM6TS1N	MW	191.27
DM6TS1N	FM	C12H17NO
DM6TS1N	IC	InChI=1S/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3/t10-,12+/m0/s1
DM6TS1N	CS	C[C@H]1[C@@H](OCCN1C)C2=CC=CC=C2
DM6TS1N	IK	MFOCDFTXLCYLKU-CMPLNLGQSA-N
DM6TS1N	IU	(2S,3S)-3,4-dimethyl-2-phenylmorpholine
DM6TS1N	CA	CAS 634-03-7
DM6TS1N	CB	CHEBI:8059
DM6TS1N	DE	Obesity

DMHIDUE	ID	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	HS	Approved
DMHIDUE	SN	Fenelzina; Fenelzyna; Fenelzyne; Phenelezine; Phenelzinum; Phenethylhydrazine; Phenylethylhydrazine; Fenelzyna [Polish]; Fenelzyne [Polish]; W1544; Beta-Phenylethylhydrazine; Fenelzina [INN-Spanish]; Nardelzine (TN); Nardil (TN); Phenelzine (BAN); Phenelzine [INN:BAN]; Phenelzinum [INN-Latin]; Phenylethyl hydrazine-HCl; W 1544-A; 1-Hydrazino-2-phenylethane; 2-Phenethylhydrazine; 2-Phenylethylhydrazine
DMHIDUE	CP	Parke Davis Div Warner Lambert Co
DMHIDUE	TC	Antidepressants
DMHIDUE	DT	Small molecular drug
DMHIDUE	PC	3675
DMHIDUE	MW	136.19
DMHIDUE	FM	C8H12N2
DMHIDUE	IC	InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
DMHIDUE	CS	C1=CC=C(C=C1)CCNN
DMHIDUE	IK	RMUCZJUITONUFY-UHFFFAOYSA-N
DMHIDUE	IU	2-phenylethylhydrazine
DMHIDUE	CA	CAS 51-71-8
DMHIDUE	CB	CHEBI:8060
DMHIDUE	DE	Skin imperfections; Depression

DMDTC7R	ID	DMDTC7R
DMDTC7R	DN	Phenindamine
DMDTC7R	HS	Approved
DMDTC7R	SN	Fenindamina; Phenindaminum; Phenindiamine; Thephorin; NU 1504; Fenindamina [INN-Spanish]; Nolahist (TN); Phenindamine (INN); Phenindamine [INN:BAN]; Phenindaminum [INN-Latin]; Thephorin (TN); 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-1H-indeno(2,1-c)pyridine; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-lH-indeno(2,1-c)pyridine; 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lH-indeno-(2,1-c)pyridine; 2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine; 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
DMDTC7R	CP	Amarin Pharmaceuticals
DMDTC7R	TC	Antihistamines
DMDTC7R	DT	Small molecular drug
DMDTC7R	PC	11291
DMDTC7R	MW	261.399
DMDTC7R	FM	C19H19N
DMDTC7R	IC	InChI=1S/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3
DMDTC7R	CS	CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4
DMDTC7R	IK	ISFHAYSTHMVOJR-UHFFFAOYSA-N
DMDTC7R	IU	2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
DMDTC7R	CA	CAS 82-88-2
DMDTC7R	CB	CHEBI:8065
DMDTC7R	DE	Common cold

DM2PYNR	ID	DM2PYNR
DM2PYNR	DN	Phenindione
DM2PYNR	HS	Approved
DM2PYNR	SN	Athrombon; Bindan; Cronodione; Danedion; Danilon; Danilone; Diadilan; Dindevan; Dineval; Diophindane; Emandion; Emandione; Eridione; Fenhydren; Fenilin; Fenindion; Fenindiona; Hedulin; Hemolidione; Indema; Indion; Indon; Phenhydren; Phenillin; Phenindionum; Phenylen; Phenylin; Phenylindanedione; Phenylindione; Phenyline; Phenyllin; Pindione; Rectadione; Theradione; Thrombasal; Tromazal; Trombol; Boots Brand of Phenindione; Goldshield Brand of Phenindione; Merck Lipha Sante Brand of Phenindione; P1029; P26406_ALDRICH; Fenindiona [INN-Spanish]; Hedulin (TN); Phenindione (INN); Phenindione [INN:BAN]; Phenindionum [INN-Latin]; 2 Phenyl 1,3 indandione; 2-Fenyloindandion-1,3; 2-Fenyloindandion-1,3 [Polish]; 2-Phenyl-1,3-diketohydrindene; 2-Phenyl-1,3-indandione; 2-Phenyl-1,3-indanedione; 2-Phenyl-1H-indene-1,3(2H)-dione; 2-Phenylindan-1,3-dione; 2-Phenylindandione; 2-phenyl-1,3(2H)-Indenedione; 2-phenyl-2,3-dihydro-1H-indene-1,3-dione; 2-phenylindene-1,3-dione
DM2PYNR	TC	Anticoagulants
DM2PYNR	DT	Small molecular drug
DM2PYNR	PC	4760
DM2PYNR	MW	222.24
DM2PYNR	FM	C15H10O2
DM2PYNR	IC	InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H
DM2PYNR	CS	C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
DM2PYNR	IK	NFBAXHOPROOJAW-UHFFFAOYSA-N
DM2PYNR	IU	2-phenylindene-1,3-dione
DM2PYNR	CA	CAS 83-12-5
DM2PYNR	CB	CHEBI:8066
DM2PYNR	DE	Coagulation defect; Pulmonary embolism

DMCH7RU	ID	DMCH7RU
DMCH7RU	DN	Pheniramine
DMCH7RU	HS	Approved
DMCH7RU	SN	Avil; Feniramina; Feniramine; Histapyridamine; Metron; Pheniraminum; Propheniramine; Prophenpyridamine; Pyriton; Trimeton; Tripoton; Pheniramine Bimaleate; Avil (TN); Feniramina [INN-Spanish]; P-Aminosalicylsaures salz; Pheniramine (INN); Pheniramine [INN:BAN]; Pheniraminum [INN-Latin]; PHENIRAMINE (SEE ALSO PHENIRAMINE MALEATE 132-20-7); Dimethyl(3-phenyl-3-(2-pyridyl)propyl)amine; N,N-Dimethyl-3-phenyl-3-(2-pyridyl)propylamine; N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine; 1-Phenyl-1-(2-pyridyl)-3-dimethylaminopropane; 2-(3-Dimethylamino-1-phenylpropyl)pyridine; 2-(alpha-(2-Dimethylaminoethyl)benzyl)pyridine; 2-Pyridinepropanamine, N,N-dimethyl-gamma-phenyl-(9CI); 2-[.alpha.-(2-Dimethylaminoethyl)benzyl]pyridine; 2-[.alpha.-[2-(Dimethylamino)ethyl]benzyl]pyridine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylamine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylanine
DMCH7RU	CP	Aventis Pharmaceuticals Inc.
DMCH7RU	TC	Antiallergic Agents
DMCH7RU	DT	Small molecular drug
DMCH7RU	PC	4761
DMCH7RU	MW	240.34
DMCH7RU	FM	C16H20N2
DMCH7RU	IC	InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3
DMCH7RU	CS	CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2
DMCH7RU	IK	IJHNSHDBIRRJRN-UHFFFAOYSA-N
DMCH7RU	IU	N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine
DMCH7RU	CA	CAS 86-21-5
DMCH7RU	CB	CHEBI:91591
DMCH7RU	DE	Hay fever

DMXYTN9	ID	DMXYTN9
DMXYTN9	DN	Phenmetrazine
DMXYTN9	HS	Approved
DMXYTN9	SN	Cafilon; Defenmetrazin; Dexphenmetrazine; Fenmetrazin; Fenmetrazina; Oxazimedrine; Phenmetraline; Phenmetrazin; Phenmetrazinum; Preludin hydrochloride; A 66; Psychamine A 66; Defenmetrazin (TN); Fenmetrazin (TN); Fenmetrazina [INN-Spanish]; Oxazimedrine (TN); Phenmetraline (TN); Phenmetrazine [INN:BAN]; Phenmetrazinum [INN-Latin]; Dl-2-Phenyl-3-methyltetrahydro-1,4-oxazine; 2-Fenyl-3-methylmorfolin; 2-Fenyl-3-methylmorfolin [Czech]; 2-Phenyl-3-methylmorpholine; 3-Methyl-2-phenylmorpholine; 3-Methyl-2-phenyltetrahydro-2H-1,4-oxazine
DMXYTN9	CP	Boehringer Ingelheim GmbH 
DMXYTN9	TC	Appetite Depressants
DMXYTN9	DT	Small molecular drug
DMXYTN9	PC	4762
DMXYTN9	MW	177.24
DMXYTN9	FM	C11H15NO
DMXYTN9	IC	InChI=1S/C11H15NO/c1-9-11(13-8-7-12-9)10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3
DMXYTN9	CS	CC1C(OCCN1)C2=CC=CC=C2
DMXYTN9	IK	OOBHFESNSZDWIU-UHFFFAOYSA-N
DMXYTN9	IU	3-methyl-2-phenylmorpholine
DMXYTN9	CA	CAS 134-49-6
DMXYTN9	CB	CHEBI:8067
DMXYTN9	DE	Obesity

DMXZOCG	ID	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	HS	Approved
DMXZOCG	SN	Adonal; Aephenal; Agrypnal; Amylofene; Antrocol; Aphenylbarbit; Aphenyletten; Austrominal; Barbapil; Barbellen; Barbellon; Barbenyl; Barbilehae; Barbinal; Barbipenyl; Barbiphen; Barbiphenyl; Barbipil; Barbita; Barbivis; Barbonal; Barbophen; Bardorm; Bartol; Bialminal; Cabronal; Calmetten; Calminal; Cardenal; Chinoin; Codibarbita; Coronaletta; Cratecil; Damoral; Dezibarbitur; Donphen; Dormina; Dormiral; Dormital; Doscalun; Duneryl; Ensobarb; Ensodorm; Epanal; Epidorm; Epilol; Episedal; Epsylone; Eskabarb; Etilfen; Euneryl; Ezibarbitur; Fenbital; Fenemal; Fenobarbital; Fenobarbitale; Fenosed; Fenylettae; Gardenal; Gardepanyl; Glysoletten; Haplopan; Haplos; Helional; Hennoletten; Henotal; Hypnaletten; Hypnette; Hypnogen; Hypnolone; Hypnoltol; Hysteps; Lefebar; Leonal; Lephebar; Lepinal; Lepinaletten; Linasen; Liquital; Lixophen; Lubergal; Lubrokal; Lumen; Lumesettes; Lumesyn; Luminal; Lumofridetten; Luphenil; Luramin; Molinal; Neurobarb; Nirvonal; Noptil; Nunol; PHOB; Parkotal; Pharmetten; Phenaemal; Phenemal; Phenemalum; Phenobal; Phenobarb; Phenobarbitalum; Phenobarbitol; Phenobarbitone; Phenobarbitonum; Phenobarbyl; Phenoluric; Phenolurio; Phenomet; Phenonyl; Phenoturic; Phenylaethylbarbitursaeure; Phenylethylbarbiturate; Phenylethylbarbitursaeure; Phenylethylmalonylurea; Phenyletten; Phenylral; Phenyral; Polcominal; Promptonal; Sedabar; Sedicat; Sedizorin; Sedlyn; Sedofen; Sedonal; Sedonettes; Sedophen; Sevenal; Solfoton; Sombutol; Somnolens; Somnoletten; Somnosan; Somonal; Spasepilin; Starifen; Starilettae; Stental; Talpheno; Teolaxin; Teoloxin; Thenobarbital; Theoloxin; Theominal; Triabarb; Tridezibarbitur; Triphenatol; Versomnal; Zadoletten; Zadonal; Aephe nal; Component of Antrocol; Component of Bronkotabs; Component of Hecadrol; Component of Primatene P; Component of Slowten; Component of Tedral; Elixir of phenobarbital; Fen osed; Fenobarbitale [DCIT]; Le phebar; Levsin PB Drops and Tablets; PUBERTAL PHENOBARBITAL STUDY; Pamine PB; Phenobarbitalum [INN]; Phenobarbituric acid; Phenylethyl barbituric acid; Phenylethylbarbituric acid; Solfoton talpheno; Stental Extentabs; Stental exte ntabs; Arco-Lase Plus; Barbilehae (barbilettae); Blu-phen; Chardonna-2; Component of Valpin 50-PB; Fenobarbital [INN-Spanish]; Gustase-Plus; Hypno-Tablinetten; Luminal (TN); Nova-Pheno; Phazyme-PB; Phen-Bar; Phenobarbital (PB); Phenobarbital, Monosodium Salt; Phenobarbitalum [INN-Latin]; SK-Phenobarbital; Seda-Tablinen; Seda-tabl inen; Sedonal (sedative); Solu-Barb; Valprin 50-PB; Phenobarbital [USAN:INN:JAN]; Phenyl-ethyl-barbituric acid; Acido 5-fenil-5-etilbarbiturico; Acido 5-fenil-5-etilbarbiturico [Italian]; Phenobarbital (JP15/USP/INN); 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione;5-Ethyl-5-phenyl-2,4,6-(1H,3H,5H)pyrimidinetrione; 5-Ethyl-5-phenyl-2,4,6-pyrimidinetrione; 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione; 5-Ethyl-5-phenylbarbituric acid; 5-Phenyl-5-ethylbarbituric acid;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
DMXZOCG	CP	FISCHER and ROCH
DMXZOCG	TC	Anticonvulsants
DMXZOCG	DT	Small molecular drug
DMXZOCG	PC	4763
DMXZOCG	MW	232.23
DMXZOCG	FM	C12H12N2O3
DMXZOCG	IC	InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
DMXZOCG	CS	CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
DMXZOCG	IK	DDBREPKUVSBGFI-UHFFFAOYSA-N
DMXZOCG	IU	5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMXZOCG	CA	CAS 50-06-6
DMXZOCG	CB	CHEBI:8069
DMXZOCG	DE	Seizure disorder

DM8KSQH	ID	DM8KSQH
DM8KSQH	DN	Phenoxybenzamine
DM8KSQH	HS	Approved
DM8KSQH	SN	Bensylyt; Bensylyte; Benzylyt; Dibenylene; Dibenylin; Dibenyline; Dibenziran; Dibenzylene; Dibenzylin; Dibenzyran; Fenossibenzamina; Fenoxibenzamina; Phenoxybenzaminum; Bensylyt NEN; Fenossibenzamina [DCIT]; POB HCl; Phenoxybenzamine Hcl; A 688; Dibenzyline (TN); Fenoxibenzamina [INN-Spanish]; Phenoxybenzamine (INN);Phenoxybenzamine [INN:BAN]; Phenoxybenzaminum [INN-Latin]; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; 688A
DM8KSQH	CP	Concordia Pharmaceuticals Inc
DM8KSQH	TC	Antihypertensive Agents
DM8KSQH	DT	Small molecular drug
DM8KSQH	PC	4768
DM8KSQH	MW	303.8
DM8KSQH	FM	C18H22ClNO
DM8KSQH	IC	InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
DM8KSQH	CS	CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2
DM8KSQH	IK	QZVCTJOXCFMACW-UHFFFAOYSA-N
DM8KSQH	IU	N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine
DM8KSQH	CA	CAS 59-96-1
DM8KSQH	CB	CHEBI:8077
DM8KSQH	DE	Malignant essential hypertension

DMDO279	ID	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	HS	Approved
DMDO279	SN	Falithiom; Falithrom; Fencumar; Fenprocoumona; Fenprocumon; Fenprocumone; Liquamar; Marcoumar; Marcumar; Marcuphen; Phenprocoumalol; Phenprocoumarol; Phenprocoumarole; Phenprocoumone; Phenprocoumonum; Phenprocumone; Phenprocumonum; Phenprogramma; Phenylpropylhydroxycumarinum; Fenprocumone [DCIT]; Hexal Brand of Phenprocoumon; Roche Brand of Phenprocoumon; Worwag Brand of Phenprocoumon; U29342; Falithrom (TN); Fenprocoumona [INN-Spanish]; Liquamar (TN); Marcoumar (TN); Marcumar (TN); Phenprocoumone [INN-French]; Phenprocoumonum [INN-Latin]; Ro 1-4849; Phenprocoumon (USAN/INN); Phenprocoumon [USAN:INN:BAN]; 2-hydroxy-3-(1-phenylpropyl)chromen-4-one; 3-(1'-Phenyl-propyl)-4-oxycoumarin; 3-(1'-Phenyl-propyl)-4-oxycoumarin [German]; 3-(1-Phenylpropyl)-4-hydroxycoumarin; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; 3-(alpha-Phenylpropyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one
DMDO279	TC	Anticoagulants
DMDO279	DT	Small molecular drug
DMDO279	PC	54680692
DMDO279	MW	280.3
DMDO279	FM	C18H16O3
DMDO279	IC	InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3
DMDO279	CS	CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
DMDO279	IK	DQDAYGNAKTZFIW-UHFFFAOYSA-N
DMDO279	IU	4-hydroxy-3-(1-phenylpropyl)chromen-2-one
DMDO279	CA	CAS 435-97-2
DMDO279	CB	CHEBI:50438
DMDO279	DE	Thrombosis

DMG60XN	ID	DMG60XN
DMG60XN	DN	Phentermine
DMG60XN	HS	Approved
DMG60XN	SN	Duromine; Fastin; Fentermina; Inoamin; Ionamin; Ionamine; Linyl; Lipopill; Lonamin; Mirapront; Normephentermine; Obenix; Obermine; Omnibex; Ortetamin; Ortetamina; Ortetaminum; Phentercot; Phenterminum; Phentride; Phentrol; Wilpo; Zantryl; Ona Mast; Ortetamine [INN]; Phentermine HCl; Phentermine resin complex; AmbkkkkK744; Phentermine Resin 30; Phentrol 2; Phentrol 3; Phentrol 4; Adipex P (TN); Adipex-P; Alpha-Benzylisopropylamine; Duromine (TN); Fastin (TN); Fentermina [INN-Spanish]; Ionamin (TN); Mirapront (TN); Obenix (TN); Obephen (TN); Obermine (TN); Oby-Trim; Panbesy (TN); Phenterex (TN); Phentermine (TN); Phenterminum [INN-Latin]; Phentremene (TN); Phentrol (TN); Phentromin (TN); Pro-Fast; Redusa (TN); Sinpet (TN); Supremin (TN); Teramine (TN); Trenker (TN); Umine (TN); Weltmine (TN); Zantryl (TN); Alpha,alpha-Dimethylbenzeneethanamine; Alpha,alpha-Dimethylphenethylamine; Anoxine-AM (TN); Obestin-30 (TN); Oby-Trim (TN); Phentermine (USAN/INN); Phentermine [USAN:INN:BAN]; Phenyl-tert-butylamine; Phenyl-tertiary-butylamine; Pro-Fast SA (TN); Alpha,alpha-Dimethyl-beta-phenylethylamine; Alpha.,.alpha.-dimethyl-Benzeneethanamine; (alpha,alpha)-Dimethylphenethylamine; 1,1-Dimethyl-2-phenylethylamine; 1-(2-Methylphenyl)-2-propylamin; 1-(2-Tolyl)-2-propylamine; 2-Amino-2-methyl-1-phenylpropane; 2-Methyl-1-phenyl-2-propanamine; 2-Phenyl-tert-butylamine
DMG60XN	CP	Medeva Pharmaceuticals
DMG60XN	TC	Appetite Depressants
DMG60XN	DT	Small molecular drug
DMG60XN	PC	4771
DMG60XN	MW	149.23
DMG60XN	FM	C10H15N
DMG60XN	IC	InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3
DMG60XN	CS	CC(C)(CC1=CC=CC=C1)N
DMG60XN	IK	DHHVAGZRUROJKS-UHFFFAOYSA-N
DMG60XN	IU	2-methyl-1-phenylpropan-2-amine
DMG60XN	CA	CAS 122-09-8
DMG60XN	CB	CHEBI:8080
DMG60XN	DE	Obesity

DMXYJOB	ID	DMXYJOB
DMXYJOB	DN	Phentolamine
DMXYJOB	HS	Approved
DMXYJOB	SN	Dibasin; Fentolamin; Fentolamina; Phenotolamine; Phentalamine; Phentolaminum; Regitin; Regitine; Regitipe; Regityn; Rogitine; Phentolamine mesylate [USAN]; Phentolamine methanesulfonate; C 7337; C 7337 Ciba; Fentolamina [INN-Spanish]; Phentolamine (INN); Phentolamine [INN:BAN]; Phentolamine, methyl sulfonate; Phentolaminum [INN-Latin]; Vasomax (TN); 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
DMXYJOB	CP	Bedford Laboratories
DMXYJOB	TC	Antihypertensive Agents
DMXYJOB	DT	Small molecular drug
DMXYJOB	PC	5775
DMXYJOB	MW	281.35
DMXYJOB	FM	C17H19N3O
DMXYJOB	IC	InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
DMXYJOB	CS	CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
DMXYJOB	IK	MRBDMNSDAVCSSF-UHFFFAOYSA-N
DMXYJOB	IU	3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
DMXYJOB	CA	CAS 50-60-2
DMXYJOB	CB	CHEBI:8081
DMXYJOB	DE	Dermal necrosis

DMQ95GE	ID	DMQ95GE
DMQ95GE	DN	Phenylacetic acid
DMQ95GE	HS	Approved
DMQ95GE	SN	.alpha.-Toluic acid; .omega.-Phenylacetic acid; 2-Phenylacetic acid; Acetic acid, phenyl-; Benzenacetic acid; Benzeneacetic acid; Benzylcarboxylic acid; Benzylformic acid; Kyselina fenyloctova; Kyselina fenyloctova [Czech]; PHENYL ACETIC ACID; PHENYL-ACETIC ACID; PHENYLACETIC ACID; Phenylacetic acid (natural); Phenylethanoic acid; Phenyllacetic acid; alpha-Toluic acid; omega-Phenylacetic acid; phenylacetate
DMQ95GE	DT	Small molecular drug
DMQ95GE	PC	999
DMQ95GE	MW	136.15
DMQ95GE	FM	C8H8O2
DMQ95GE	IC	InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)
DMQ95GE	CS	C1=CC=C(C=C1)CC(=O)O
DMQ95GE	IK	WLJVXDMOQOGPHL-UHFFFAOYSA-N
DMQ95GE	IU	2-phenylacetic acid
DMQ95GE	CA	CAS 103-82-2
DMQ95GE	CB	ChEBI:30745
DMQ95GE	DE	Hyperammonemia

DMAYL0T	ID	DMAYL0T
DMAYL0T	DN	Phenylbutazone
DMAYL0T	HS	Approved
DMAYL0T	SN	Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione
DMAYL0T	TC	Analgesics
DMAYL0T	DT	Small molecular drug
DMAYL0T	PC	4781
DMAYL0T	MW	308.4
DMAYL0T	FM	C19H20N2O2
DMAYL0T	IC	InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3
DMAYL0T	CS	CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3
DMAYL0T	IK	VYMDGNCVAMGZFE-UHFFFAOYSA-N
DMAYL0T	IU	4-butyl-1,2-diphenylpyrazolidine-3,5-dione
DMAYL0T	CA	CAS 50-33-9
DMAYL0T	CB	CHEBI:48574
DMAYL0T	DE	Chronic pain

DMZHUO5	ID	DMZHUO5
DMZHUO5	DN	Phenylephrine
DMZHUO5	HS	Approved
DMZHUO5	SN	Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
DMZHUO5	CP	Alcon Canada Inc
DMZHUO5	TC	Ophthalmologicals
DMZHUO5	DT	Small molecular drug
DMZHUO5	PC	6041
DMZHUO5	MW	167.2
DMZHUO5	FM	C9H13NO2
DMZHUO5	IC	InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
DMZHUO5	CS	CNC[C@@H](C1=CC(=CC=C1)O)O
DMZHUO5	IK	SONNWYBIRXJNDC-VIFPVBQESA-N
DMZHUO5	IU	3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
DMZHUO5	CA	CAS 61-76-7
DMZHUO5	CB	CHEBI:8093
DMZHUO5	DE	Fecal incontinence; Ophthalmic graves disease

DMKAEQW	ID	DMKAEQW
DMKAEQW	DN	Phenyltoloxamine
DMKAEQW	HS	Approved
DMKAEQW	SN	Bristamin hydrochloride; Phenyltoloxamine hydrochloride; HL 2153; (2-(Dimethylamino)ethyl) (o-benzylphenoxy)ether hydrochloride; N,N-Dimethyl-2-(alpha-phenyl-o-toloxy)-ethylamine hydrochloride; ETHYLAMINE, 2-(o-BENZYLPHENOXY)-N,N-DIMETHYL-, HYDROCHLORIDE; Ethylamine, N,N-dimethyl-2-((alpha-phenyl-o-tolyl)oxy)-, hydrochloride; N-(2'-Dimethylaminoaethyl)-(o-benzylphenol)-aether hydrochlorid [German]; AC1L2KJQ; 92-12-6 (Parent); LS-67923; 2-(2-benzylphenoxy)ethyl-dimethylazanium chloride
DMKAEQW	DT	Small molecular drug
DMKAEQW	PC	7077
DMKAEQW	MW	255.35
DMKAEQW	FM	C17H21NO
DMKAEQW	IC	InChI=1S/C17H21NO/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3
DMKAEQW	CS	CN(C)CCOC1=CC=CC=C1CC2=CC=CC=C2
DMKAEQW	IK	IZRPKIZLIFYYKR-UHFFFAOYSA-N
DMKAEQW	IU	2-(2-benzylphenoxy)-N,N-dimethylethanamine
DMKAEQW	CA	CAS 92-12-6
DMKAEQW	CB	CHEBI:135047
DMKAEQW	DE	Allergy

DMNOKBV	ID	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	HS	Approved
DMNOKBV	SN	Aleviatin; Antisacer; Auranile; Causoin; Citrullamon; Citrulliamon; Comital; Comitoina; Convul; Danten; Dantinal; Dantoinal; Dantoine; Denyl; Difenilhidantoina; Difenin; Difetoin; Difhydan; Dihycon; Dihydantoin; Dilabid; Dilantin; Dilantine; Dillantin; Dintoin; Dintoina; Diphantoin; Diphedal; Diphedan; Diphenat; Diphenin; Diphenine; Diphentoin; Diphentyn; Diphenylan; Diphenylhydantoin; Diphenylhydantoine; Diphenylhydatanoin; Ditoinate; Ekko; Elepsindon; Enkelfel; Epamin; Epanutin; Epelin; Epifenyl; Epihydan; Epilantin; Epinat; Epised; Eptal; Eptoin; Fenitoin; Fenitoina; Fentoin; Fenylepsin; Fenytoine; Hidan; Hidantal; Hidantilo; Hidantina; Hidantomin; Hindatal; Hydantal; Hydantin; Hydantoinal; Hydantol; Idantoil; Idantoin; Iphenylhydantoin; Kessodanten; Labopal; Lehydan; Lepitoin; Lepsin; Minetoin; Neosidantoina; Novantoina; Novophenytoin; Oxylan; PHENYTEK; Phanantin; Phanatine; Phenatine; Phenatoine; Phenhydan; Phenhydanin; Phenitoin; Phentoin; Phentytoin; Phenytex; Phenytoine; Phenytoinum; Ritmenal; Saceril; Sanepil; Silantin; Sinergina; Sodanthon; Sodantoin; Sodanton; Solantin; Solantoin; Solantyl; Sylantoic;TOIN; Tacosal; Thilophenyl; Zentronal; Zentropil; Component of Mebroin; Dantoinal klinos; Difenilhidantoina [Spanish]; Dihydan toin; Dilantin acid; Diphenylhydantoine [French]; Ekko capsules; Elepsi ndon; Epdantoin Simple; Epdantoine simple; Epilan D; Extended Phenytoin Sodium; Fen toin; Fenantoin Mn Pharma; Fenidantoin s; Fenytoin Dak; Hidantina senosian; Hidantina vitoria; Ictalis simp le; Ictalis simple; Om hidantoina simple; Phenat ine; Phenytoin AWD; Sodium Diphenylhydantoinate; Taco sal; Toin unicelles; CL12003; D 4007; D4007_SIGMA; Didan TDC 250; Epasmir 5; IFLab1_000214; DILANTIN-30; DPH (VAN); Di-Hydan; Di-Lan; Di-Phetine; Dilantin (TN); Dilantin Infatabs (TN); Dilantin Kapseals (TN); Dilantin-125; Diphenylhydantoin (VAN); Epanutin (TN); Epasmir (5); Epilan-D; Eptoin (TN); Fenidantoin (s); Fenitoina [INN-Spanish]; Neos-Hidantoina; Om-Hydantoine; PHENYTOIN SODIUM, EXTENDED; Phenytek (TN); Phenytoin (PHN); Phenytoin-Gerot; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Di-Lan (VAN); Didan-tdc-250; Gerot-epilan-D; PHENYTOIN (5,5-DIPHENYLHYDANTOIN); Phenytoin (JP15/USP/INN); Phenytoin [USAN:INN:BAN:JAN]; Hydantoin, 5,5-diphenyl-(8CI); 2,4-Imidazolidinedione, 5,5-diphenyl-(9CI); 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; 5,5-DIPHENYLHYDANTOIN; 5,5-Diphenyl-2,4-imidazolidinedione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); 5,5-Diphenylhydantoin (phenytoin); 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Dwufenylohydantoina; 5,5-Dwufenylohydantoina [Polish]; 5,5-diphenylimidazolidine-2,4-dione
DMNOKBV	CP	Mylan Laboratories
DMNOKBV	TC	Anticonvulsants
DMNOKBV	DT	Small molecular drug
DMNOKBV	PC	1775
DMNOKBV	MW	252.27
DMNOKBV	FM	C15H12N2O2
DMNOKBV	IC	InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)
DMNOKBV	CS	C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
DMNOKBV	IK	CXOFVDLJLONNDW-UHFFFAOYSA-N
DMNOKBV	IU	5,5-diphenylimidazolidine-2,4-dione
DMNOKBV	CA	CAS 57-41-0
DMNOKBV	CB	CHEBI:8107
DMNOKBV	DE	Epilepsy

DMUKMC8	ID	DMUKMC8
DMUKMC8	DN	Phloroglucinol
DMUKMC8	HS	Approved
DMUKMC8	SN	phloroglucinol; 108-73-6; Benzene-1,3,5-triol; 1,3,5-trihydroxybenzene; 1,3,5-benzenetriol; Phloroglucin; Phloroglucine; Spasfon-Lyoc; s-Trihydroxybenzene; 5-Hydroxyresorcinol; Benzene-s-triol; 3,5-Dihydroxyphenol; Benzene, trihydroxy; sym-Trihydroxybenzene; 5-Oxyresorcinol; Dilospan S; Floroglucinol; Floroglucin; Phloroglucinol anhydrous; 5-Oxyresorcinolphloroglucin; 1,3,5-THB; 1,3,5-Trihydroxycyclohexatriene; 1,3,5-Triol; Floroglucin [Czech]; Floroglucinol [Czech]; Benzene, 1,3,5-trihydroxy-; UNII-DHD7FFG6YS; 5-Benzenetriol; NSC 157
DMUKMC8	DT	Small molecular drug
DMUKMC8	PC	359
DMUKMC8	MW	126.11
DMUKMC8	FM	C6H6O3
DMUKMC8	IC	InChI=1S/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9H
DMUKMC8	CS	C1=C(C=C(C=C1O)O)O
DMUKMC8	IK	QCDYQQDYXPDABM-UHFFFAOYSA-N
DMUKMC8	IU	benzene-1,3,5-triol
DMUKMC8	CA	CAS 108-73-6
DMUKMC8	CB	CHEBI:16204
DMUKMC8	DE	Urinary tract disease

DMUXQG7	ID	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	HS	Approved
DMUXQG7	SN	orthophosphate; Phosphate ion; 14265-44-2; O-Phosphate; UNII-NK08V8K8HR; NK08V8K8HR; Phosphates; Phosphate ions; PO4; a phosphate group; tetraoxophosphate(V); tetraoxophosphate(3-); Phosphoric acid trianion; tetraoxidophosphate(3-); phosphoric acid, ion(3-); AC1L1AN2; DTXSID7039672; CHEBI:18367; CTK0H5978; NBIIXXVUZAFLBC-UHFFFAOYSA-K; BDBM50155537; AKOS015903596; PO4(3-); CREATINE PHOSPHATE; N-PHOSPHOCREATINE; [PO4](3-); I14-18227
DMUXQG7	DT	Small molecular drug
DMUXQG7	PC	1061
DMUXQG7	MW	94.971
DMUXQG7	FM	O4P-3
DMUXQG7	IC	InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3
DMUXQG7	CS	[O-]P(=O)([O-])[O-]
DMUXQG7	IK	NBIIXXVUZAFLBC-UHFFFAOYSA-K
DMUXQG7	IU	phosphate
DMUXQG7	CA	CAS 14265-44-2
DMUXQG7	CB	CHEBI:18367
DMUXQG7	DE	Constipation

DM8HDOL	ID	DM8HDOL
DM8HDOL	DN	Phytonadione
DM8HDOL	HS	Approved
DM8HDOL	SN	Phyllochinon; Phyllohydroquinone; Phytomenadione; Fitomenadione [DCIT]; Phyllochinon [German]; LT00452032; Fitomenadiona [INN-Spanish]; Mephyton (TN); Phylloquinone (8CI); Phytomenadione (INN); Phytomenadionum [INN-Latin]; Phytonadione [USAN:JAN]; Vitamin K1 (TN); Vitamin K1 (VAN); Vitamin K1 (generic); Phythyl-menadion (GERMAN); Phytonadione (JP15/USP); 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-); 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened-ione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; 2-Methyl-3-phythyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon [German]; 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 3-Phytylmenadione
DM8HDOL	TC	Vitamins
DM8HDOL	DT	Small molecular drug
DM8HDOL	PC	5284607
DM8HDOL	MW	450.7
DM8HDOL	FM	C31H46O2
DM8HDOL	IC	InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1
DM8HDOL	CS	CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C
DM8HDOL	IK	MBWXNTAXLNYFJB-NKFFZRIASA-N
DM8HDOL	IU	2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
DM8HDOL	CA	CAS 79083-00-4
DM8HDOL	CB	CHEBI:18067
DM8HDOL	DE	Bleeding disorder; Vitamin K deficiency

DM27BL1	ID	DM27BL1
DM27BL1	DN	Pibrentasvir
DM27BL1	HS	Approved
DM27BL1	SN	2WU922TK3L; A-1325912.0; ABT 530; ABT-530; ABT-530;Pibrentasvir; CHEMBL3545123; CS-8135; D10816; DB13878; Dimethyl N,N'-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis((6-fluoro-1H-benzimidazole-5,2-diyl)((2S)-pyrrolidine-2,1-diyl)((2S,3R)-3-methoxy-1-oxobutane-1,2-diyl)))biscarbamate; EX-A865; J-690144; J3.646.121G; Pibrentasvir; Pibrentasvir (JAN/USAN/INN); Pibrentasvir [USAN]; SCHEMBL17639956; SCHEMBL2756579; UNII-2WU922TK3L
DM27BL1	TC	Antiviral Agent
DM27BL1	DT	Small molecular drug
DM27BL1	PC	58031952
DM27BL1	MW	1113.201
DM27BL1	FM	C57H65F5N10O8
DM27BL1	IC	InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1
DM27BL1	CS	CC(C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C(=C3)F)C4CCC(N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)C1CCCN1C(=O)C(C(C)OC)NC(=O)OC)NC(=O)OC)OC
DM27BL1	IK	VJYSBPDEJWLKKJ-NLIMODCCSA-N
DM27BL1	IU	methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2S)-1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate
DM27BL1	CA	CAS 1353900-92-1
DM27BL1	DE	Hepatitis C virus infection

DMIBNG2	ID	DMIBNG2
DMIBNG2	DN	Picrotoxin
DMIBNG2	HS	Approved
DMIBNG2	SN	Cocculin; Cocculus; Picrotox; Picrotoxine; Picrotoxinum; Sesquiterpene; Coques du levant; Coques du levant [French];Fish berry; Indian berry; Oriental berry; P 1675; Picrotin-Picrotoxinin; Picrotoxin (Compound of one mole Picrotoxinin and one mole Picrotin); Picrotoxinin-picrotin; Picrotin, compound with picrotoxinin (1:1); Picrotin, compd. with picrotoxinin (1:1); Picrotoxinin, compd. with picrotin (1:1); 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR,2aR,3S,6R,6aS,8aS,8bR,9S)-& (1aR,2aR,3S,6R,6aS,8aS,8bR,9R; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, [1aR-(1a.alpha.,2
DMIBNG2	TC	Central Nervous System Stimulants
DMIBNG2	DT	Small molecular drug
DMIBNG2	PC	31304
DMIBNG2	MW	602.6
DMIBNG2	FM	C30H34O13
DMIBNG2	IC	InChI=1S/C15H18O7.C15H16O6/c1-12(2,18)6-7-10(16)20-8(6)9-13(3)14(7,19)4-5-15(13,22-5)11(17)21-9;1-5(2)7-8-11(16)19-9(7)10-13(3)14(8,18)4-6-15(13,21-6)12(17)20-10/h5-9,18-19H,4H2,1-3H3;6-10,18H,1,4H2,2-3H3/t5-,6+,7?,8?,9-,13-,14-,15+;6?,7-,8?,9?,10+,13+,14+,15-/m10/s1
DMIBNG2	CS	CC(=C)[C@@H]1C2[C@@H]3[C@@]4([C@](C1C(=O)O2)(CC5[C@]4(O5)C(=O)O3)O)C.C[C@@]12[C@H]3C4[C@H](C([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O
DMIBNG2	IK	VJKUPQSHOVKBCO-ZTYBEOBUSA-N
DMIBNG2	IU	(1R,3R,5S,8S,13R,14S)-1-hydroxy-14-(2-hydroxypropan-2-yl)-13-methyl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione;(1R,5S,8S,13R,14R)-1-hydroxy-13-methyl-14-prop-1-en-2-yl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione
DMIBNG2	CA	CAS 124-87-8
DMIBNG2	DE	Respiratory distress syndrome

DMV9ADG	ID	DMV9ADG
DMV9ADG	DN	Pilocarpine
DMV9ADG	HS	Approved
DMV9ADG	SN	Adsorbocarpine; Almocarpine; Epicar; Isopilocarpine; Isoptocarpine; Miocarpine; Ocusert; Pilagan; Pilocarpin; Pilocarpol; Pilokarpin; Pilokarpol; Pilostat; Salagen; Spersacarpine; Syncarpine; Amistura P; Isopto carpine; Minims Pilocarpine; Ocusert pilo; Pilocarpine HCl; Pilocarpine chloride; Pilocarpine nitrate; Ocusert P 20;Beta-Pilocarpine hydrochloride; Diocarpine (TN); Isopto Carpine (TN); Mi-Pilo; Miocarpine (TN); Ocu-Carpine; Ocusert Pilo-40; Ocusert pilo-20; Pilocarpine (TN); Pilopine HS (TN); Piloptic-1; Piloptic-2; Piloptic-3; Piloptic-4; Piloptic-6; Salagen (TN); Scheinpharm (TN); Timpilo (TN); Ocusert Pilo-20 (TN); Ocusert pilo-20 (TN); P.V. Carpine Liquifilm; Pilocarpine (JAN/USP); Pilocarpine [USAN:BAN:JAN]; Piloptic-1/2; Pilocarpine Mononitrate, (3S-cis)-Isomer; Pilocarpine, Monohydrochloride, (3S-cis)-Isomer; Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone; (+)-Pilocarpine; (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one; (3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone; 3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; 3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone; 3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
DMV9ADG	CP	Alcon Laboratories
DMV9ADG	TC	Cholinergic Agents
DMV9ADG	DT	Small molecular drug
DMV9ADG	PC	5910
DMV9ADG	MW	208.26
DMV9ADG	FM	C11H16N2O2
DMV9ADG	IC	InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1
DMV9ADG	CS	CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C
DMV9ADG	IK	QCHFTSOMWOSFHM-WPRPVWTQSA-N
DMV9ADG	IU	(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
DMV9ADG	CA	CAS 92-13-7
DMV9ADG	CB	CHEBI:8207
DMV9ADG	DE	Glaucoma/ocular hypertension

DMZ65K8	ID	DMZ65K8
DMZ65K8	DN	Pilsicainide
DMZ65K8	HS	Approved
DMZ65K8	SN	SUNRYTHM; Sunrhythm; Pilsicainide hydrochloride; DU-6552; SUN-1165; SUN-1165i
DMZ65K8	CP	Suntory Ltd
DMZ65K8	DT	Small molecular drug
DMZ65K8	PC	4820
DMZ65K8	MW	272.4
DMZ65K8	FM	C17H24N2O
DMZ65K8	IC	InChI=1S/C17H24N2O/c1-13-6-3-7-14(2)16(13)18-15(20)12-17-8-4-10-19(17)11-5-9-17/h3,6-7H,4-5,8-12H2,1-2H3,(H,18,20)
DMZ65K8	CS	CC1=C(C(=CC=C1)C)NC(=O)CC23CCCN2CCC3
DMZ65K8	IK	BCQTVJKBTWGHCX-UHFFFAOYSA-N
DMZ65K8	IU	N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide
DMZ65K8	CA	CAS 88069-67-4
DMZ65K8	CB	CHEBI:135127
DMZ65K8	DE	Heart arrhythmia

DMR7IVC	ID	DMR7IVC
DMR7IVC	DN	Pimavanserin
DMR7IVC	HS	Approved
DMR7IVC	SN	ST51054136; AC-5273; I14-1981; 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
DMR7IVC	CP	Acadia Pharmaceuticals
DMR7IVC	DT	Small molecular drug
DMR7IVC	PC	10071196
DMR7IVC	MW	427.6
DMR7IVC	FM	C25H34FN3O2
DMR7IVC	IC	InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
DMR7IVC	CS	CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C
DMR7IVC	IK	RKEWSXXUOLRFBX-UHFFFAOYSA-N
DMR7IVC	IU	1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
DMR7IVC	CA	CAS 706779-91-1
DMR7IVC	CB	CHEBI:133017
DMR7IVC	DE	Parkinson disease

DMZLGRB	ID	DMZLGRB
DMZLGRB	DN	Pimecrolimus
DMZLGRB	HS	Approved
DMZLGRB	SN	Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin
DMZLGRB	CP	Norvatis Phamaceuticals Corporation
DMZLGRB	TC	Dermatologic Agents
DMZLGRB	DT	Small molecular drug
DMZLGRB	PC	6509979
DMZLGRB	MW	810.4
DMZLGRB	FM	C43H68ClNO11
DMZLGRB	IC	InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
DMZLGRB	CS	CC[C@@H]1/C=C(/C[C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@@H]([C@@H](C4)OC)Cl)/C)O)C)OC)OC)C)\\C
DMZLGRB	IK	KASDHRXLYQOAKZ-XDSKOBMDSA-N
DMZLGRB	IU	(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(E)-1-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMZLGRB	CA	CAS 137071-32-0
DMZLGRB	CB	CHEBI:135888
DMZLGRB	DE	Atopic dermatitis

DMW83TP	ID	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	HS	Approved
DMW83TP	SN	Antalon; Neoperidole; Opiran; Orap; Pimozida; Pimozidum; Primozida; ASTA Medica Brand of Pimozide; Janssen Brand of Pimozide;Orap forte; Pharmascience Brand of Pimozide; P 1793; R 6238; McN-JR 6238; Orap (TN); Pimozida [INN-Spanish]; Pimozidum [INN-Latin]; Primozida [INN-Spanish]; R-6238; McN-JR-6238; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMW83TP	CP	Janssen Pharmaceutica
DMW83TP	TC	Antipsychotic Agents
DMW83TP	DT	Small molecular drug
DMW83TP	PC	16362
DMW83TP	MW	461.5
DMW83TP	FM	C28H29F2N3O
DMW83TP	IC	InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
DMW83TP	CS	C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
DMW83TP	IK	YVUQSNJEYSNKRX-UHFFFAOYSA-N
DMW83TP	IU	3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMW83TP	CA	CAS 2062-78-4
DMW83TP	CB	CHEBI:8212
DMW83TP	DE	Schizophrenia

DMRADYL	ID	DMRADYL
DMRADYL	DN	Pinacidil
DMRADYL	HS	Approved
DMRADYL	SN	Pinacidilum; P 1134; S 1230; P-154; Pinacidil (anhydrous); Pinacidilum [INN-Latin]; S-1230; N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)guanidine; Guanidine, 2-cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)-, monohydrate; Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-, monohydrate; (+-)-Pinacidil; (+/-)-N-Cyano-N'-4-pyridinyl-N"-(1,2,2-trimethylpropyl)guanidine; (R,S)-Pinacidil; (inverted question mark)-N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-guanidine; 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine; 2-Cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine; 2-Cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)guanidine monohydrate
DMRADYL	TC	Antihypertensive Agents
DMRADYL	DT	Small molecular drug
DMRADYL	PC	4826
DMRADYL	MW	245.32
DMRADYL	FM	C13H19N5
DMRADYL	IC	InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)
DMRADYL	CS	CC(C(C)(C)C)N=C(NC#N)NC1=CC=NC=C1
DMRADYL	IK	IVVNZDGDKPTYHK-UHFFFAOYSA-N
DMRADYL	IU	1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine
DMRADYL	CA	CAS 60560-33-0
DMRADYL	CB	CHEBI:91706
DMRADYL	DE	High blood pressure

DMD2NV7	ID	DMD2NV7
DMD2NV7	DN	Pindolol
DMD2NV7	HS	Approved
DMD2NV7	SN	Betapindol; Blocklin; Calvisken; Carvisken; Decreten; Durapindol; Pectobloc; Pinbetol; Pindololum; Prindolol; Prinodolol; Pynastin; Visken; Blockin L; Blocklin L; LB 46; LB46; P 0778; Betapindol (TN); Blockin L (TN); Blocklin L (TN); Blocklin-L; Calvisken (TN); Cardilate (TN); Carvisken (TN); DL-LB 46; DL-Pindolol; Decreten (TN); Durapindol (TN); Glauco-Viskin; Glauco-visken; LB-46; P-6820; Pectobloc (TN); Pinbetol (TN); Pindololum [INN-Latin]; Prindolol (TN); Pynastin (TN); Visken (TN); Blocklin-L (TN); Glauco-Visken (TN); Pindolol (JP15/USP/INN); Pindolol [USAN:INN:BAN:JAN]; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; (+-)-Pindolol; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole
DMD2NV7	CP	Tocris Bioscience
DMD2NV7	TC	Antihypertensive Agents
DMD2NV7	DT	Small molecular drug
DMD2NV7	PC	4828
DMD2NV7	MW	248.32
DMD2NV7	FM	C14H20N2O2
DMD2NV7	IC	InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
DMD2NV7	CS	CC(C)NCC(COC1=CC=CC2=C1C=CN2)O
DMD2NV7	IK	JZQKKSLKJUAGIC-UHFFFAOYSA-N
DMD2NV7	IU	1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
DMD2NV7	CA	CAS 13523-86-9
DMD2NV7	CB	CHEBI:8214
DMD2NV7	DE	Hypertension

DMKJ485	ID	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	HS	Approved
DMKJ485	SN	111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A;  Actos; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1
DMKJ485	CP	Takeda Pharmaceuticals
DMKJ485	TC	Hypoglycemic Agents
DMKJ485	DT	Small molecular drug
DMKJ485	PC	4829
DMKJ485	MW	356.4
DMKJ485	FM	C19H20N2O3S
DMKJ485	IC	InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
DMKJ485	CS	CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMKJ485	IK	HYAFETHFCAUJAY-UHFFFAOYSA-N
DMKJ485	IU	5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMKJ485	CA	CAS 111025-46-8
DMKJ485	CB	CHEBI:8228
DMKJ485	DE	Diabetic complication; Obesity; Type-2 diabetes

DM5F84A	ID	DM5F84A
DM5F84A	DN	Pipecuronium
DM5F84A	HS	Approved
DM5F84A	SN	Arduan; Pipecurium; Arduan (TN); Piperazinium, 4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl); [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DM5F84A	TC	Analgesics
DM5F84A	DT	Small molecular drug
DM5F84A	PC	50192
DM5F84A	MW	602.9
DM5F84A	FM	C35H62N4O4+2
DM5F84A	IC	InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DM5F84A	CS	CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C
DM5F84A	IK	OWWLUIWOFHMHOQ-XGHATYIMSA-N
DM5F84A	IU	[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DM5F84A	CA	CAS 68399-58-6
DM5F84A	CB	CHEBI:8230
DM5F84A	DE	Spasm

DMGQU0Y	ID	DMGQU0Y
DMGQU0Y	DN	Piperacetazine
DMGQU0Y	HS	Approved
DMGQU0Y	SN	Quide
DMGQU0Y	CP	Dow Pharmaceutical Corp Sub Dow Chemical Co
DMGQU0Y	DT	Small molecular drug
DMGQU0Y	PC	19675
DMGQU0Y	MW	410.6
DMGQU0Y	FM	C24H30N2O2S
DMGQU0Y	IC	InChI=1S/C24H30N2O2S/c1-18(28)20-7-8-24-22(17-20)26(21-5-2-3-6-23(21)29-24)13-4-12-25-14-9-19(10-15-25)11-16-27/h2-3,5-8,17,19,27H,4,9-16H2,1H3
DMGQU0Y	CS	CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO
DMGQU0Y	IK	BTFMCMVEUCGQDX-UHFFFAOYSA-N
DMGQU0Y	IU	1-[10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]phenothiazin-2-yl]ethanone
DMGQU0Y	CA	CAS 3819-00-9
DMGQU0Y	CB	CHEBI:92293
DMGQU0Y	DE	Schizophrenia

DMTBKF3	ID	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	HS	Approved
DMTBKF3	SN	PIPC; Peperacillin; Peracin; Pipercillin; Pipracil; Pipril; PIPERACILLIN SODIUM; Piperacillin Monosodium Salt; Piperacillin anhydrous; Cl-227193; Peracin (TN); Piperacillin (INN); Piperacillin (anhydrous); Pipracil, Piper; T-1220; Zobactin (TN); (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-ethyl-2,3-dioxopiperazine carbonyl ampicillin; 6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanicacid; 6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
DMTBKF3	CP	Wyeth
DMTBKF3	TC	Antibiotics
DMTBKF3	DT	Small molecular drug
DMTBKF3	PC	43672
DMTBKF3	MW	517.6
DMTBKF3	FM	C23H27N5O7S
DMTBKF3	IC	InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1
DMTBKF3	CS	CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMTBKF3	IK	IVBHGBMCVLDMKU-GXNBUGAJSA-N
DMTBKF3	IU	(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMTBKF3	CA	CAS 61477-96-1
DMTBKF3	CB	CHEBI:8232
DMTBKF3	DE	Bacterial infection

DMT70RC	ID	DMT70RC
DMT70RC	DN	Piperaquine
DMT70RC	HS	Approved
DMT70RC	SN	Piperaquinoline; Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-); Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-(9CI); 1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane; 1,3-bis(4-(7'-chloro-4'-quinoline)-1-piperazine); 4,4'-(propane-1,3-diyldipiperazine-4,1-diyl)bis(7-chloroquinoline); 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
DMT70RC	DT	Small molecular drug
DMT70RC	PC	122262
DMT70RC	MW	535.5
DMT70RC	FM	C29H32Cl2N6
DMT70RC	IC	InChI=1S/C29H32Cl2N6/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29/h2-9,20-21H,1,10-19H2
DMT70RC	CS	C1CN(CCN1CCCN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl)C5=C6C=CC(=CC6=NC=C5)Cl
DMT70RC	IK	UCRHFBCYFMIWHC-UHFFFAOYSA-N
DMT70RC	IU	7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
DMT70RC	CA	CAS 4085-31-8
DMT70RC	CB	CHEBI:91231
DMT70RC	DE	Malaria

DMTY9LU	ID	DMTY9LU
DMTY9LU	DN	Piperazine
DMTY9LU	HS	Approved
DMTY9LU	SN	Anthalazine; Antiren; Diethylenediamine; Diethyleneimine; Dispermine; Eraverm; Hexahydropyrazine; Lumbrical; PZE; Piperazidine; Piperazin; Pipersol; Upixon; Uvilon; Vermex; Vermizine; Wurmirazin; Piperazin [German]; Piperazin [Germany]; Piperazine Dihydrochloride Dihydrochloride Hydrate; Piperazine [USAN]; Piperazine anhydrous; Piperazinium oleate; Pyrazine hexahydride; LTBB000432; Piperazine [UN2579] [Corrosive]; Eraverm (VAN); PIPERAZINE (HEXAHYDRATE); Piperazine (USP); Piperazine Hexa-Hydrate; Piperazine, anhydrous; Pyrazine, hexahy; Vermizine (TN); Worm-away; Asca-Trol No. 3; Worm-A-Ton; Hexahydro-1,4-diazine; 1,4-Diazacyclohexane; 1,4-Diethylenediamine; 1,4-Piperazine
DMTY9LU	CP	Glaxosmithkline
DMTY9LU	TC	Antinematodal Agents
DMTY9LU	DT	Small molecular drug
DMTY9LU	PC	4837
DMTY9LU	MW	86.14
DMTY9LU	FM	C4H10N2
DMTY9LU	IC	InChI=1S/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2
DMTY9LU	CS	C1CNCCN1
DMTY9LU	IK	GLUUGHFHXGJENI-UHFFFAOYSA-N
DMTY9LU	IU	piperazine
DMTY9LU	CA	CAS 110-85-0
DMTY9LU	CB	CHEBI:28568
DMTY9LU	DE	Enterobiasis; Ascariasis

DMNL0E6	ID	DMNL0E6
DMNL0E6	DN	Pipobroman
DMNL0E6	HS	Approved
DMNL0E6	SN	Amedel; Pipobromanum; Vercyte; A 1803; A-8103; Pipobroman [USAN:INN]; Pipobromanum [INN-Latin]; VERCYTE (TN); Pipobroman (JAN/USAN/INN); N,N'-Bis(3-bromopropionyl)piperazine; N,N-Bis-(3-bromopropionyl)-piperazine; 1,4-Bis(3-bromopropanoyl)piperazine; 1,4-Bis(3-bromopropionyl)piperazine; 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
DMNL0E6	TC	Anticancer Agents
DMNL0E6	DT	Small molecular drug
DMNL0E6	PC	4842
DMNL0E6	MW	356.05
DMNL0E6	FM	C10H16Br2N2O2
DMNL0E6	IC	InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2
DMNL0E6	CS	C1CN(CCN1C(=O)CCBr)C(=O)CCBr
DMNL0E6	IK	NJBFOOCLYDNZJN-UHFFFAOYSA-N
DMNL0E6	IU	3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
DMNL0E6	CA	CAS 54-91-1
DMNL0E6	CB	CHEBI:8242
DMNL0E6	DE	Refractory chronic myeloid leukaemia

DMC68DF	ID	DMC68DF
DMC68DF	DN	Pipotiazine
DMC68DF	HS	Approved
DMC68DF	SN	Pipotiazine; Pipothiazine; Pipotiazina; Pipotiazinum; 39860-99-6; Piportil; Pipotiazinum [INN-Latin]; Pipotiazina [INN-Spanish]; UNII-L903J9JPYV; L903J9JPYV; 10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]-N,N-dimethylphenothiazine-2-sulfonamide; Pipotiazine [INN:BAN]; Piportil depot; Piportil (TN); Pipotiazine (INN); EINECS 254-659-6; Pipotiazine; ; ; Piportil; AC1L1XY4; SCHEMBL123275; GTPL7557; CHEMBL398880; BDBM81798; DTXSID40192913; ZINC3813024; BCP23973; PDSP2_000525; PDSP1_000527; NSC_62867; AKOS030527554; DB01621; ACM39860996
DMC68DF	DT	Small molecular drug
DMC68DF	PC	62867
DMC68DF	MW	475.7
DMC68DF	FM	C24H33N3O3S2
DMC68DF	IC	InChI=1S/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3
DMC68DF	CS	CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO
DMC68DF	IK	JOMHSQGEWSNUKU-UHFFFAOYSA-N
DMC68DF	IU	10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]-N,N-dimethylphenothiazine-2-sulfonamide
DMC68DF	CA	CAS 39860-99-6
DMC68DF	DE	Schizophrenia

DMGTW1I	ID	DMGTW1I
DMGTW1I	DN	Pirarubicin
DMGTW1I	HS	Approved
DMGTW1I	SN	Pinorubicin (TN); Therarubucin (TN)
DMGTW1I	CP	Sanraku and Meiji Seika
DMGTW1I	DT	Small molecular drug
DMGTW1I	PC	636397
DMGTW1I	MW	627.6
DMGTW1I	FM	C32H37NO12
DMGTW1I	IC	InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1
DMGTW1I	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O[C@H]6CCCCO6
DMGTW1I	IK	KMSKQZKKOZQFFG-HSUXVGOQSA-N
DMGTW1I	IU	(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2S)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMGTW1I	CA	CAS 72496-41-4
DMGTW1I	CB	CHEBI:32011
DMGTW1I	DE	Breast cancer

DMI5678	ID	DMI5678
DMI5678	DN	Pirbuterol
DMI5678	HS	Approved
DMI5678	SN	Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
DMI5678	CP	3M Pharmaceuticals
DMI5678	TC	Bronchodilator Agents
DMI5678	DT	Small molecular drug
DMI5678	PC	4845
DMI5678	MW	240.3
DMI5678	FM	C12H20N2O3
DMI5678	IC	InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3
DMI5678	CS	CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O
DMI5678	IK	VQDBNKDJNJQRDG-UHFFFAOYSA-N
DMI5678	IU	6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
DMI5678	CA	CAS 38677-81-5
DMI5678	CB	CHEBI:8245
DMI5678	DE	Asthma

DMP6M1N	ID	DMP6M1N
DMP6M1N	DN	Pirenzepine
DMP6M1N	HS	Approved
DMP6M1N	SN	Gasteril; Gastrotsepin; Gastrozepin; Pirenzepin; Pirenzepina; Pirenzepinum; Pyrenzepine; Ulcosan; Pirenzepine Gastrozepin; Gastrozepin (TN); L-S 519; Pirenzepina [INN-Spanish]; Pirenzepine (INN); Pirenzepine [INN:BAN]; Pirenzepinum [INN-Latin]; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one
DMP6M1N	CP	Boehringer Ingelheim 
DMP6M1N	TC	Antiulcer Agents
DMP6M1N	DT	Small molecular drug
DMP6M1N	PC	4848
DMP6M1N	MW	351.4
DMP6M1N	FM	C19H21N5O2
DMP6M1N	IC	InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)
DMP6M1N	CS	CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMP6M1N	IK	RMHMFHUVIITRHF-UHFFFAOYSA-N
DMP6M1N	IU	11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMP6M1N	CA	CAS 28797-61-7
DMP6M1N	CB	CHEBI:8247
DMP6M1N	DE	Peptic ulcer

DM6VZFQ	ID	DM6VZFQ
DM6VZFQ	DN	Pirfenidone
DM6VZFQ	HS	Approved
DM6VZFQ	SN	Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one
DM6VZFQ	CP	InterMune
DM6VZFQ	DT	Small molecular drug
DM6VZFQ	PC	40632
DM6VZFQ	MW	185.22
DM6VZFQ	FM	C12H11NO
DM6VZFQ	IC	InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
DM6VZFQ	CS	CC1=CN(C(=O)C=C1)C2=CC=CC=C2
DM6VZFQ	IK	ISWRGOKTTBVCFA-UHFFFAOYSA-N
DM6VZFQ	IU	5-methyl-1-phenylpyridin-2-one
DM6VZFQ	CA	CAS 53179-13-8
DM6VZFQ	CB	CHEBI:32016
DM6VZFQ	DE	Idiopathic pulmonary fibrosis

DMBCYF5	ID	DMBCYF5
DMBCYF5	DN	Pirmenol
DMBCYF5	HS	Approved
DMBCYF5	SN	Pimenol; Pirmavar; Pirmenol hydrochloride
DMBCYF5	CP	Pfizer Inc
DMBCYF5	DT	Small molecular drug
DMBCYF5	PC	65502
DMBCYF5	MW	338.5
DMBCYF5	FM	C22H30N2O
DMBCYF5	IC	InChI=1S/C22H30N2O/c1-18-10-8-11-19(2)24(18)17-9-15-22(25,20-12-4-3-5-13-20)21-14-6-7-16-23-21/h3-7,12-14,16,18-19,25H,8-11,15,17H2,1-2H3/t18-,19+,22?
DMBCYF5	CS	C[C@@H]1CCC[C@@H](N1CCCC(C2=CC=CC=C2)(C3=CC=CC=N3)O)C
DMBCYF5	IK	APUDBKTWDCXQJA-QIDMFYOTSA-N
DMBCYF5	IU	4-[(2S,6R)-2,6-dimethylpiperidin-1-yl]-1-phenyl-1-pyridin-2-ylbutan-1-ol
DMBCYF5	CA	CAS 68252-19-7
DMBCYF5	CB	CHEBI:135436
DMBCYF5	DE	Heart arrhythmia

DMTK234	ID	DMTK234
DMTK234	DN	Piroxicam
DMTK234	HS	Approved
DMTK234	SN	Akten; Artroxicam; Bruxicam; Caliment; Erazon; Felden; Feldene; Flogobene; Geldene; Improntal; Larapam; Pipoxicam; Pirkam; Piroflex; Piroftal; Piroxicamum; Pyroxycam; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Zunden; Feldene Fast; Feldene Gel; Piroxicam usp; AK1015; CHF 1251; CP 16171; CP16171; P 5654; Apo-Piroxicam; Brexidol (TN); Brexin (TN); CP-16171; Erazon (TN); Exipan (TN); Felden (TN); Feldene (TN); Feldoral (TN); Hotemin (TN); Mobilis (TN); Pirox von ct (TN); Piroxicamum [INN-Latin]; Proponol (TN); Reumador (TN); Tracam (TN); Veral (TN); Vurdon (TN); Feldene, Roxam, Piroxicam; Piroxicam (JP15/USP/INN); Piroxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxo-1; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy(pyridin-2-ylamino)methylidene]-2-methyl-3,4-dihydro-2H-1; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
DMTK234	CP	Pfizer Pharmaceuticals
DMTK234	TC	Analgesics
DMTK234	DT	Small molecular drug
DMTK234	PC	54676228
DMTK234	MW	331.3
DMTK234	FM	C15H13N3O4S
DMTK234	IC	InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
DMTK234	CS	CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
DMTK234	IK	QYSPLQLAKJAUJT-UHFFFAOYSA-N
DMTK234	IU	4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide
DMTK234	CA	CAS 36322-90-4
DMTK234	CB	CHEBI:8249
DMTK234	DE	Pain

DMMOFHT	ID	DMMOFHT
DMMOFHT	DN	Pirprofen
DMMOFHT	HS	Approved
DMMOFHT	SN	Pirprofen; Rengasil; 31793-07-4; Pirprofenum [INN-Latin]; Pirprofene [INN-French]; Pirprofeno [INN-Spanish]; SU-21524; EINECS 250-805-8; BRN 1686438; SU 21524; Hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)-; 3-CHLORO-4-(3-PYRROLIN-1-YL)HYDRATROPIC ACID; C13H14ClNO2; Pirprofenum; Pirprofeno; Pirprofene; Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-alpha-methyl-; Pirprofen [USAN:INN:BAN]; Pirprofen [USAN:BAN:INN]; pirprofen[usan:ban:inn]; Pirprofen (USAN/INN); AC1Q5RRJ; AC1L1UQD; SCHEMBL24311; 5-20-04-00276 (Beilstei
DMMOFHT	DT	Small molecular drug
DMMOFHT	PC	35935
DMMOFHT	MW	251.71
DMMOFHT	FM	C13H14ClNO2
DMMOFHT	IC	InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)
DMMOFHT	CS	CC(C1=CC(=C(C=C1)N2CC=CC2)Cl)C(=O)O
DMMOFHT	IK	PIDSZXPFGCURGN-UHFFFAOYSA-N
DMMOFHT	IU	2-[3-chloro-4-(2,5-dihydropyrrol-1-yl)phenyl]propanoic acid
DMMOFHT	CA	CAS 31793-07-4
DMMOFHT	CB	CHEBI:135028
DMMOFHT	DE	Dysmenorrhea

DMJH792	ID	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	HS	Approved
DMJH792	SN	Pitavastatin; Itavastatin; Livalo; NK 104; Pitavastatin [INN]; Pitavastatin calcium; UNII-M5681Q5F9P; NK-104; C25H24FNO4; M5681Q5F9P; Zypitamag; Flovas; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; P 872441; P-872441; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; NK 104 (acid); Pitavastatin calcium (JAN)
DMJH792	PC	5282452
DMJH792	MW	421.5
DMJH792	FM	C25H24FNO4
DMJH792	IC	InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1
DMJH792	CS	C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F
DMJH792	IK	VGYFMXBACGZSIL-MCBHFWOFSA-N
DMJH792	IU	(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
DMJH792	CA	CAS 147511-69-1
DMJH792	CB	CHEBI:32020
DMJH792	DE	Primary hyperlipidemia and mixed dyslipidemia

DM1UJO0	ID	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	HS	Approved
DM1UJO0	SN	Livalo; Pitavastatin calcium; 147526-32-7; Pitavastatin hemicalcium; NK-104; Nisvastatin; UNII-IYD54XEG3W; Flovas; IYD54XEG3W; 2C25H23FNO4Ca; CHEBI:71258; NK 104 (acid); Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; AK-50694; Itavastatin calcium; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; Pitavastatin calcium (JAN); Alipza; Livazo; P-872441; P 872441; 6-Heptenoic acid,
DM1UJO0	DT	Small molecular drug
DM1UJO0	PC	5282451
DM1UJO0	MW	881
DM1UJO0	FM	C50H46CaF2N2O8
DM1UJO0	IC	InChI=1S/2C25H24FNO4.Ca/c2*26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h2*1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;;+2/p-2/b2*12-11+;/t2*18-,19-;/m11./s1
DM1UJO0	CS	C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2]
DM1UJO0	IK	RHGYHLPFVJEAOC-FFNUKLMVSA-L
DM1UJO0	IU	calcium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
DM1UJO0	CA	CAS 147526-32-7
DM1UJO0	CB	CHEBI:71258
DM1UJO0	DE	Dyslipidemia

DM8RFNJ	ID	DM8RFNJ
DM8RFNJ	DN	Pitolisant
DM8RFNJ	HS	Approved
DM8RFNJ	SN	Pitolisant; 362665-56-3; TIPROLISANT; BF2.649; UNII-4BC83L4PIY; 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine; Pitolisant (BF2.649); 1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidine; 4BC83L4PIY; Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-; CHEMBL462605; wakix; 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride; 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine; Tirolisant; Pitolisant (INN); tiprolisant [USAN]; Wakix (TN); Pitolisant [USAN:INN]; SCHEMBL117648; GTPL8924; CTK1B6404; HBS-101
DM8RFNJ	CP	Bioprojet; Ferrer
DM8RFNJ	DT	Small molecular drug
DM8RFNJ	PC	9948102
DM8RFNJ	MW	295.8
DM8RFNJ	FM	C17H26ClNO
DM8RFNJ	IC	InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2
DM8RFNJ	CS	C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl
DM8RFNJ	IK	NNACHAUCXXVJSP-UHFFFAOYSA-N
DM8RFNJ	IU	1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
DM8RFNJ	CA	CAS 362665-56-3
DM8RFNJ	CB	CHEBI:134709
DM8RFNJ	DE	Schizophrenia; Excessive daytime sleepiness

DMX8CVY	ID	DMX8CVY
DMX8CVY	DN	Pivampicillin
DMX8CVY	HS	Approved
DMX8CVY	SN	Pivaloylampicillin; Pivampicilina; Pivampicilline; Pivampicillinum; Pondocillin; Ampicillin Pivaloyl Ester; Ampicillin pivaloyloxymethyl ester; Pivaloyloxymethyl ampicillinate; Pivampicillin Monohydrochloride; MK 191; Pivampicilina [INN-Spanish]; Pivampicillin (INN); Pivampicillin [INN:BAN]; Pivampicilline [INN-French]; Pivampicillinum [INN-Latin]; Pondocillin (TN); [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMX8CVY	TC	Antibiotics
DMX8CVY	DT	Small molecular drug
DMX8CVY	PC	33478
DMX8CVY	MW	463.5
DMX8CVY	FM	C22H29N3O6S
DMX8CVY	IC	InChI=1S/C22H29N3O6S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26)/t13-,14-,15+,18-/m1/s1
DMX8CVY	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)OCOC(=O)C(C)(C)C)C
DMX8CVY	IK	ZEMIJUDPLILVNQ-ZXFNITATSA-N
DMX8CVY	IU	2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMX8CVY	CA	CAS 33817-20-8
DMX8CVY	CB	CHEBI:8255
DMX8CVY	DE	Bacterial infection

DMDU0BV	ID	DMDU0BV
DMDU0BV	DN	Pivmecillinam
DMDU0BV	HS	Approved
DMDU0BV	SN	Coactabs; PMPC; Pivamdinocillin; Pivmecilinamo; Pivmecillinamum; Selexid; Amdinocillin Pivoxil; Amdinocillin pivoxil [USAN]; Mecillinam Pivaloyl Ester; Amdinocillin pivoxil (USAN); Amdinocillin, pivaloyloxymethyl ester; Coactabs (TN); Penomax (TN); Pivmecilinamo [INN-Spanish]; Pivmecillinam (INN); Pivmecillinamum [INN-Latin]; Ro 10-9071; Selexid (TN); [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylate; [(2,2-dimethylpropanoyl)oxy]methyl (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; [(2,2-dimethylpropanoyl)oxy]methyl(2s,5r,6r)-6-{[(e)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; Hydroxymethyl (2S,5R,6R)-6-(((hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate pivalate (ester); 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 2,2-dimethylpropanoyloxymethyl (5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMDU0BV	TC	Antibiotics
DMDU0BV	DT	Small molecular drug
DMDU0BV	PC	115163
DMDU0BV	MW	439.6
DMDU0BV	FM	C21H33N3O5S
DMDU0BV	IC	InChI=1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3/t14-,15+,17-/m1/s1
DMDU0BV	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C
DMDU0BV	IK	NPGNOVNWUSPMDP-HLLBOEOZSA-N
DMDU0BV	IU	2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMDU0BV	CA	CAS 32886-97-8
DMDU0BV	CB	CHEBI:51210
DMDU0BV	DE	Urinary tract infection

DMV74ZH	ID	DMV74ZH
DMV74ZH	DN	Pizotyline
DMV74ZH	HS	Approved
DMV74ZH	SN	Pizotifen; PIZOTYLINE; 15574-96-6; Sandomigran; Litec; Sandomygran; Pizotifenum; Pizotifeno; Polomigran; Pizotifene; BC-105; BC 105; Pizotyline [USAN]; Pizotifan; Pizotifene [INN-French]; Pizotifenum [INN-Latin]; Pizotifeno [INN-Spanish]; UNII-0BY8440V3N; EINECS 239-632-9; BRN 0753534; C19H21NS; CHEBI:50212; FIADGNVRKBPQEU-UHFFFAOYSA-N; Pizotifen (INN); Pizotifen [INN]; 0BY8440V3N; Pizotyline (USAN); 4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene)-1-methylpiperidine
DMV74ZH	DT	Small molecular drug
DMV74ZH	PC	27400
DMV74ZH	MW	295.4
DMV74ZH	FM	C19H21NS
DMV74ZH	IC	InChI=1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3
DMV74ZH	CS	CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1
DMV74ZH	IK	FIADGNVRKBPQEU-UHFFFAOYSA-N
DMV74ZH	IU	1-methyl-4-(6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene)piperidine
DMV74ZH	CA	CAS 15574-96-6
DMV74ZH	CB	CHEBI:50212
DMV74ZH	DE	Headache

DMKMBES	ID	DMKMBES
DMKMBES	DN	Plazomicin
DMKMBES	HS	Approved
DMKMBES	SN	ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN);  ZINC68150640; DB12615; D10151; D-Streptamine,
DMKMBES	CP	Achaogen
DMKMBES	DT	Small molecular drug
DMKMBES	PC	42613186
DMKMBES	MW	592.7
DMKMBES	FM	C25H48N6O10
DMKMBES	IC	InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1
DMKMBES	CS	C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CNCCO)N)N)NC(=O)[C@H](CCN)O)O
DMKMBES	IK	IYDYFVUFSPQPPV-PEXOCOHZSA-N
DMKMBES	IU	(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DMKMBES	CA	CAS 1154757-24-0
DMKMBES	DE	Urinary tract infection; Prostate disease; Bronchitis; Pancreatic cancer

DMKEX7O	ID	DMKEX7O
DMKEX7O	DN	Plecanatide
DMKEX7O	HS	Approved
DMKEX7O	SN	Trulance
DMKEX7O	CP	Synergy Pharmaceuticals
DMKEX7O	DT	Small molecular drug
DMKEX7O	PC	70693500
DMKEX7O	MW	1681.9
DMKEX7O	FM	C65H104N18O26S4
DMKEX7O	IC	InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1
DMKEX7O	CS	C[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CC(=O)N)C(C)C)CC(C)C)CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N
DMKEX7O	IK	NSPHQWLKCGGCQR-DLJDZFDSSA-N
DMKEX7O	IU	(2S)-2-[[(1R,4S,7S,10S,13S,16R,19S,22S,25R,32S,38R)-10-(2-amino-2-oxoethyl)-25-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-22-(2-carboxyethyl)-32-[(1R)-1-hydroxyethyl]-4-methyl-19-(2-methylpropyl)-3,6,9,12,15,18,21,24,30,33,36-undecaoxo-7,13-di(propan-2-yl)-27,28,40,41-tetrathia-2,5,8,11,14,17,20,23,31,34,37-undecazabicyclo[14.13.13]dotetracontane-38-carbonyl]amino]-4-methylpentanoic acid
DMKEX7O	CA	CAS 467426-54-6
DMKEX7O	DE	Irritable bowel syndrome; Chronic idiopathic constipation; Crohn disease

DMAKXW9	ID	DMAKXW9
DMAKXW9	DN	PLEGRIDY
DMAKXW9	HS	Approved
DMAKXW9	SN	Peginterferon beta-1a
DMAKXW9	CP	Biogen Idec
DMAKXW9	SQ	Sequence: MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
DMAKXW9	DE	Multiple sclerosis

DMCJN1P	ID	DMCJN1P
DMCJN1P	DN	Plerixafor
DMCJN1P	HS	Approved
DMCJN1P	SN	Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
DMCJN1P	CP	Genzyme
DMCJN1P	DT	Small molecular drug
DMCJN1P	PC	65015
DMCJN1P	MW	502.8
DMCJN1P	FM	C28H54N8
DMCJN1P	IC	InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
DMCJN1P	CS	C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
DMCJN1P	IK	YIQPUIGJQJDJOS-UHFFFAOYSA-N
DMCJN1P	IU	1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
DMCJN1P	CA	CAS 110078-46-1
DMCJN1P	CB	CHEBI:125354
DMCJN1P	DE	Non-hodgkin lymphoma

DM7C8YV	ID	DM7C8YV
DM7C8YV	DN	Plicamycin
DM7C8YV	HS	Approved
DM7C8YV	SN	A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01
DM7C8YV	DT	Small molecular drug
DM7C8YV	PC	163659
DM7C8YV	MW	1085.1
DM7C8YV	FM	C52H76O24
DM7C8YV	IC	InChI=1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1
DM7C8YV	CS	C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)OC3=CC4=CC5=C(C(=O)[C@H]([C@@H](C5)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7C[C@H]([C@H]([C@H](O7)C)O)O[C@H]8C[C@]([C@@H]([C@H](O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O
DM7C8YV	IK	CFCUWKMKBJTWLW-BKHRDMLASA-N
DM7C8YV	IU	(2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-7-methyl-3,4-dihydro-2H-anthracen-1-one
DM7C8YV	CA	CAS 18378-89-7
DM7C8YV	CB	CHEBI:31856
DM7C8YV	DE	Lung cancer; Ovarian cancer; Testicular cancer; Hypercalcaemia; Solid tumour/cancer

DMG8MLJ	ID	DMG8MLJ
DMG8MLJ	DN	Pneumococcal 13-valent conjugate vaccine
DMG8MLJ	HS	Approved
DMG8MLJ	SN	Prevnar 13 (TN)
DMG8MLJ	CP	Pfizer
DMG8MLJ	DE	Streptococcus infection

DMT2EJP	ID	DMT2EJP
DMT2EJP	DN	Podofilox
DMT2EJP	HS	Approved
DMT2EJP	SN	podophyllotoxin; 518-28-5; Condylox; Condyline; Wartec; Podophyllotoxin 7; Podophyllinic acid lactone; Warticon; (-)-Podophyllotoxin; Podofilox [USAN]; CCRIS 565; UNII-L36H50F353; Podophyllotoxin, 95%; HSDB 7238; NSC24818; CHEMBL61; EINECS 208-250-4; NSC 24818; (5R,5aR,8aR,9R)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one; MLS000069495; AI3-50456; CHEBI:50305; Podofilox (USAN); L36H50F353; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one,; Podophyllotoxin
DMT2EJP	CP	Actavis Laboratories Ut Inc
DMT2EJP	DT	Small molecular drug
DMT2EJP	PC	10607
DMT2EJP	MW	414.4
DMT2EJP	FM	C22H22O8
DMT2EJP	IC	InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1
DMT2EJP	CS	COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O
DMT2EJP	IK	YJGVMLPVUAXIQN-XVVDYKMHSA-N
DMT2EJP	IU	(5R,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMT2EJP	CA	CAS 518-28-5
DMT2EJP	CB	CHEBI:50305
DMT2EJP	DE	External genital and perianal wart; Condyloma; Verruca vulgaris

DMF6Y0L	ID	DMF6Y0L
DMF6Y0L	DN	Polatuzumab vedotin
DMF6Y0L	HS	Approved
DMF6Y0L	CP	Genentech
DMF6Y0L	DT	Antibody
DMF6Y0L	DE	Follicular lymphoma; Haematological malignancy; Diffuse large B-cell lymphoma

DMH1KMT	ID	DMH1KMT
DMH1KMT	DN	Polidocanol
DMH1KMT	HS	Approved
DMH1KMT	SN	Asclera (TN)
DMH1KMT	CP	Chemisch FBRK KRSSLR
DMH1KMT	DT	Small molecular drug
DMH1KMT	PC	656641
DMH1KMT	MW	582.8
DMH1KMT	FM	C30H62O10
DMH1KMT	IC	InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3
DMH1KMT	CS	CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
DMH1KMT	IK	ONJQDTZCDSESIW-UHFFFAOYSA-N
DMH1KMT	IU	2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
DMH1KMT	CA	CAS 3055-99-0
DMH1KMT	CB	CHEBI:46859
DMH1KMT	DE	Reticular veins; Spider veins

DMUCWEX	ID	DMUCWEX
DMUCWEX	DN	Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co
DMUCWEX	HS	Approved
DMUCWEX	SN	Aethoxysklerol; Asclera
DMUCWEX	DT	Small molecular drug
DMUCWEX	PC	24750
DMUCWEX	MW	230.39
DMUCWEX	FM	C14H30O2
DMUCWEX	IC	InChI=1S/C14H30O2/c1-2-3-4-5-6-7-8-9-10-11-13-16-14-12-15/h15H,2-14H2,1H3
DMUCWEX	CS	CCCCCCCCCCCCOCCO
DMUCWEX	IK	SFNALCNOMXIBKG-UHFFFAOYSA-N
DMUCWEX	IU	2-dodecoxyethanol
DMUCWEX	CA	CAS 4536-30-5
DMUCWEX	CB	CHEBI:78770
DMUCWEX	DE	Varicose veins

DM0PMGJ	ID	DM0PMGJ
DM0PMGJ	DN	Polyestradiol Phosphate
DM0PMGJ	HS	Approved
DM0PMGJ	SN	Estradurin
DM0PMGJ	CP	Wyeth Ayerst Laboratories
DM0PMGJ	TC	Anticancer Agents
DM0PMGJ	DT	Small molecular drug
DM0PMGJ	PC	66435
DM0PMGJ	MW	352.4
DM0PMGJ	FM	C18H25O5P
DM0PMGJ	IC	InChI=1S/C18H25O5P/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)23-24(20,21)22/h3,5,10,14-17,19H,2,4,6-9H2,1H3,(H2,20,21,22)/t14-,15-,16+,17+,18+/m1/s1
DM0PMGJ	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)O
DM0PMGJ	IK	BBWXLCKRYRQQPL-ZBRFXRBCSA-N
DM0PMGJ	IU	[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] dihydrogen phosphate
DM0PMGJ	CA	CAS 4995-43-1
DM0PMGJ	DE	Prostate cancer

DM4I1JP	ID	DM4I1JP
DM4I1JP	DN	Polyethylene glycol
DM4I1JP	HS	Approved
DM4I1JP	SN	ETHYLENE GLYCOL; Ethane-1,2-diol; 1,2-ethanediol; 107-21-1; glycol; monoethylene glycol; 1,2-Dihydroxyethane; 2-hydroxyethanol; Glycol alcohol; polyethylene glycol; Ethylene alcohol; Macrogol; Fridex; Tescol; Ethylene dihydrate; Norkool; Macrogol 400 BPC; Dowtherm SR 1; Zerex; Ucar 17; Lutrol-9; ethyleneglycol; ethanediol; Aethylenglykol; Polyethylene glycol 200; Glycol, ethylene-; 1,2-Ethandiol; Glycols, polyethylene; Caswell No. 441; Ethylenglycol; Lutrol; Aethylenglykol [German]; Polyethylene glycol 600; 146AR; UNII-FC72KVT52F
DM4I1JP	DT	Small molecular drug
DM4I1JP	PC	174
DM4I1JP	MW	62.07
DM4I1JP	FM	C2H6O2
DM4I1JP	IC	InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2
DM4I1JP	CS	C(CO)O
DM4I1JP	IK	LYCAIKOWRPUZTN-UHFFFAOYSA-N
DM4I1JP	IU	ethane-1,2-diol
DM4I1JP	CA	CAS 107-21-1
DM4I1JP	CB	CHEBI:30742
DM4I1JP	DE	Constipation

DMN0LP8	ID	DMN0LP8
DMN0LP8	DN	Polymyxin B Sulfate
DMN0LP8	HS	Approved
DMN0LP8	SN	Aerosporin; Polimixina B; Polymixin B sulfate; Polymxin B sulfate; Polymyxin b; Polymyxine B; Polymyxinum B; Terramycin Ophthalmic; Polimixina B [INN-Spanish]; Polymyxin B Sulfate [USAN:JAN]; Polymyxin B, sulfate; Polymyxine B [INN-French]; Polymyxinum B [INN-Latin]; Aerosporin, PMB, Poly-RX,Polymyxin B sulphate; 4-amino-N-[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(2-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-4-hydroxy-1-oxobutan-2-yl]-2-formamidobutanamide
DMN0LP8	TC	Antibiotics
DMN0LP8	DT	Small molecular drug
DMN0LP8	PC	5702105
DMN0LP8	MW	1301.6
DMN0LP8	FM	C56H100N16O17S
DMN0LP8	IC	InChI=1S/C56H98N16O13.H2O4S/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79;1-5(2,3)4/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80);(H2,1,2,3,4)
DMN0LP8	CS	CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)C(C)O.OS(=O)(=O)O
DMN0LP8	IK	HFMDLUQUEXNBOP-UHFFFAOYSA-N
DMN0LP8	IU	N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide;sulfuric acid
DMN0LP8	CA	CAS 1405-20-5
DMN0LP8	DE	Pseudomonas infection

DMJAOT1	ID	DMJAOT1
DMJAOT1	DN	Polyoxidonium
DMJAOT1	HS	Approved
DMJAOT1	CP	Immutic Group
DMJAOT1	DE	Infectious disease

DMCH80F	ID	DMCH80F
DMCH80F	DN	Polythiazide
DMCH80F	HS	Approved
DMCH80F	SN	Drenusil; Nephril; Politiazida; Polythiazidum; Renese; P 2525; P-2525; Politiazida [INN-Spanish]; Polythiazidum [INN-Latin]; Renese (TN); Polythiazide (JAN/USAN/INN); Polythiazide [USAN:INN:BAN:JAN]; 2-Methyl-3-(beta,beta,beta-trifluoroethylthiomethyl)-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide (8CI, 9CI); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-, 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-7-sulphamoyl-3-(2,2,2-trifluoroethylthiomethyl)-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1; 6-chloro-2-methyl-3-{[(2,2,2-trifluoroethyl)thio]methyl}-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMCH80F	TC	Antihypertensive Agents
DMCH80F	DT	Small molecular drug
DMCH80F	PC	4870
DMCH80F	MW	439.9
DMCH80F	FM	C11H13ClF3N3O4S3
DMCH80F	IC	InChI=1S/C11H13ClF3N3O4S3/c1-18-10(4-23-5-11(13,14)15)17-7-2-6(12)8(24(16,19)20)3-9(7)25(18,21)22/h2-3,10,17H,4-5H2,1H3,(H2,16,19,20)
DMCH80F	CS	CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F
DMCH80F	IK	CYLWJCABXYDINA-UHFFFAOYSA-N
DMCH80F	IU	6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMCH80F	CA	CAS 346-18-9
DMCH80F	CB	CHEBI:8327
DMCH80F	DE	Edema; Hypertension

DMTGBAX	ID	DMTGBAX
DMTGBAX	DN	Pomalidomide
DMTGBAX	HS	Approved
DMTGBAX	SN	Actimid (TN); Pomalidomide (Immunomodulator)
DMTGBAX	CP	Celgene
DMTGBAX	DT	Small molecular drug
DMTGBAX	PC	134780
DMTGBAX	MW	273.24
DMTGBAX	FM	C13H11N3O4
DMTGBAX	IC	InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
DMTGBAX	CS	C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
DMTGBAX	IK	UVSMNLNDYGZFPF-UHFFFAOYSA-N
DMTGBAX	IU	4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
DMTGBAX	CA	CAS 19171-19-8
DMTGBAX	CB	CHEBI:72690
DMTGBAX	DE	Systemic sclerosis

DMYGJQO	ID	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	HS	Approved
DMYGJQO	SN	Iclusig (TN)
DMYGJQO	CP	ARIAD Pharmaceuticals
DMYGJQO	DT	Small molecular drug
DMYGJQO	PC	24826799
DMYGJQO	MW	532.6
DMYGJQO	FM	C29H27F3N6O
DMYGJQO	IC	InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
DMYGJQO	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
DMYGJQO	IK	PHXJVRSECIGDHY-UHFFFAOYSA-N
DMYGJQO	IU	3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
DMYGJQO	CA	CAS 943319-70-8
DMYGJQO	CB	CHEBI:78543
DMYGJQO	DE	Acute lymphoblastic leukaemia

DMEAOYJ	ID	DMEAOYJ
DMEAOYJ	DN	Ponesimod
DMEAOYJ	HS	Approved
DMEAOYJ	SN	854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-
DMEAOYJ	CP	Actelion Pharmaceuticals South San Francisco, CA
DMEAOYJ	DT	Small molecular drug
DMEAOYJ	PC	11363176
DMEAOYJ	MW	461
DMEAOYJ	FM	C23H25ClN2O4S
DMEAOYJ	IC	InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1
DMEAOYJ	CS	CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
DMEAOYJ	IK	LPAUOXUZGSBGDU-ULCCENQXSA-N
DMEAOYJ	IU	(5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
DMEAOYJ	CA	CAS 854107-55-4
DMEAOYJ	DE	Psoriasis vulgaris; Multiple sclerosis

DM7ZWNY	ID	DM7ZWNY
DM7ZWNY	DN	Porfimer Sodium
DM7ZWNY	HS	Approved
DM7ZWNY	SN	Photofrin
DM7ZWNY	CP	Concordia Laboratories Inc
DM7ZWNY	DT	Small molecular drug
DM7ZWNY	DE	Non-small-cell lung cancer

DMUL5EW	ID	DMUL5EW
DMUL5EW	DN	Posaconazole
DMUL5EW	HS	Approved
DMUL5EW	SN	Noxafil; Spriafil; Posaconazole SP; Posaconazole in combination with MGCD290; SCH56592; Sch 56592; X2N; Noxafil (TN); Noxafil, Posaconazole; SCH-56592; Posaconazole (USAN/INN); Posaconazole [USAN:INN:BAN]; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
DMUL5EW	CP	Schering-Plough
DMUL5EW	TC	Antifungal Agents
DMUL5EW	DT	Small molecular drug
DMUL5EW	PC	468595
DMUL5EW	MW	700.8
DMUL5EW	FM	C37H42F2N8O4
DMUL5EW	IC	InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
DMUL5EW	CS	CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
DMUL5EW	IK	RAGOYPUPXAKGKH-XAKZXMRKSA-N
DMUL5EW	IU	4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
DMUL5EW	CA	CAS 171228-49-2
DMUL5EW	CB	CHEBI:64355
DMUL5EW	DE	Aspergillosis

DMMTAJC	ID	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	HS	Approved
DMMTAJC	SN	Acronitol; Celeka; Chloropotassuril; Chlorvescent; Durekal; Durules; Enpott; Enseal; Infalyte; KCL; KSR; Kadalex; Kalcorid; Kaleorid; Kaleorod; Kaliduron; Kaliglutol; Kalilente; Kalinorm; Kaliolite; Kalipor; Kalipoz; Kalitabs; Kaliumchlorid; Kaochlor; Kaskay; Kato; Kayback; Kayciel; Kaysiel; Keylyte; Kloren; Klorvess; Klotrix; Kolyum; Miopotasio; Neobakasal; Pfiklor; Potasion; Potasol; Potavescent; Rekawan; Selora; Steropotassium; Sylvite; [KCl]; Chlorid draselny; Chlorid draselny [Czech]; Chloride of potash; Conductance standard solution; Dipotassium dichloride; Emplets potassium chloride; K Tab; KCL Retard; KM potassium chloride; Kalinorm Depottab; Kalitrans Retard; Kalium Duriles; Kalium Durules; Kalium Retard; Kalium SR; Kaon Cl; Kaon Ultra; Kay Ciel; Kelp salt; Leo K; Monopotassium chloride; Muriate of potash; Natural sylvite; Plus Kalium Retard; Potassium Chloride BP; Potassium Chloride in Plastic Container; Potassium Cl; Potassium chloride [JAN]; Potassium chloride solution; Potassium chloride standard; Potassium monochloride; Potassium muriate; Rekawan Retard; Repone K; Sal digestnum sylvii; Super K; Tripotassium trichloride; Trona muriate of potash; Trona potassium chloride; Ultra K Chlor; IN2900; Potassium Chloride 10meq in Plastic Container; Potassium chloride 20meq inplastic container; Potassium chloride 30meq in plastic container; Potassium chloride 40meq in plastic container; Addi-K; Apo-K; Cena-K; Chloride, Potassium; Chloropotassuril diffu-K; Diffu-K; Duffi-K; Durules-K; K+10; K+8; K-10; K-Care; K-Contin; K-Dur; K-Grad; K-Lease; K-Lor; K-Lyte Cl; K-Norm; K-SR; K-Sol; K-Tab; K. tab; KCL (TN); KCl-retard Zyma; Kalinor-Retard P; Kalium S.R; Kalium-Durettes; Kalium-R; Kalium-duriles; Kaon Cl-10; Kaon-Cl; Kaon-Cl 10; Kaon-Cl TABS; Kaon-ci; Kay-Ciel; Kay-EM; Klor-Con; Klor-Con M10; Klor-Con M15; Klor-Con M20; Klor-Lyte; Klotrix (TN); Lento-K; Lento-Kalium; Leo-K; Micro-K; Micro-K 10; Micro-K Extentcaps; Micro-K LS; Micro-Kalium Retard; Nu-K; POTASSIUM CHLORIDE, ACS; Peter-kal; Potassium atomic spectroscopy standard concentrate 1.00 g K; Potassium chloride (K3Cl3); Potassium chloride (KCl); Potassium standard concentrate 10.00 g K; Potassium thallium chloride (KTlCl); Repone-K; Rum-K; Sando-K; Slow-K; Slow-K tablets; Span-K; Super K (salt); Ten-K; Clor-K-Zaf; Hydrochloric acid potassium salt (1:1); ISA (ionic strength adjustment solution: 1 M KCl); K-Lyte/Cl; K-Predne-Dome; K-dur (TN); K-lyte/C1; Kalium S.R.; Kaon-Cl (TN); Kay-Cee-L; Klor-con (TN); Potassium chloride (JP15/USP); Ultra-K-Chlor; Conductivity Standard Solution, 1413-S/cm; Conductivity Standard Solution, 500-S/cm; POTASSIUM CHLORIDE, U.S.P.; 11118_FLUKA
DMMTAJC	TC	Dietary supplement
DMMTAJC	DT	Small molecular drug
DMMTAJC	PC	4873
DMMTAJC	MW	74.55
DMMTAJC	FM	ClK
DMMTAJC	IC	InChI=1S/ClH.K/h1H;/q;+1/p-1
DMMTAJC	CS	[Cl-].[K+]
DMMTAJC	IK	WCUXLLCKKVVCTQ-UHFFFAOYSA-M
DMMTAJC	IU	potassium;chloride
DMMTAJC	CA	CAS 7447-40-7
DMMTAJC	CB	CHEBI:32588
DMMTAJC	DE	Hypokalemia

DMGLZ26	ID	DMGLZ26
DMGLZ26	DN	Practolol
DMGLZ26	HS	Approved
DMGLZ26	SN	Dalzic; Eraldin; Practololo; Practololum; Praktololu; Teranol; Eralzdin Practolol; Practololo [DCIT]; Praktololu [Polish]; AY 21011; Cardiol (TN); Cordialina (TN); Dalzic (TN); Eraldin (TN); Eraldina (TN); Practololum [INN-Latin]; Praktol (TN); Pralon (TN); Teranol (TN); Practolol [USAN:BAN:INN]; N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide; N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; N-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; N-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide; (+-)-Practolol; 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol; 4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide
DMGLZ26	TC	Antiarrhythmic Agents
DMGLZ26	DT	Small molecular drug
DMGLZ26	PC	4883
DMGLZ26	MW	266.34
DMGLZ26	FM	C14H22N2O3
DMGLZ26	IC	InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)
DMGLZ26	CS	CC(C)NCC(COC1=CC=C(C=C1)NC(=O)C)O
DMGLZ26	IK	DURULFYMVIFBIR-UHFFFAOYSA-N
DMGLZ26	IU	N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
DMGLZ26	CA	CAS 6673-35-4
DMGLZ26	CB	CHEBI:258351
DMGLZ26	DE	Cardiac arrhythmias

DMAO80I	ID	DMAO80I
DMAO80I	DN	Pralatrexate
DMAO80I	HS	Approved
DMAO80I	SN	Folotyn (TN)
DMAO80I	CP	Allos Therapeutics
DMAO80I	DT	Small molecular drug
DMAO80I	PC	148121
DMAO80I	MW	477.5
DMAO80I	FM	C23H23N7O5
DMAO80I	IC	InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1
DMAO80I	CS	C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMAO80I	IK	OGSBUKJUDHAQEA-WMCAAGNKSA-N
DMAO80I	IU	(2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid
DMAO80I	CA	CAS 146464-95-1
DMAO80I	CB	CHEBI:71223
DMAO80I	DE	Breast cancer; Peripheral T-cell lymphoma

DMGQ0ZI	ID	DMGQ0ZI
DMGQ0ZI	DN	Pralidoxime chloride
DMGQ0ZI	HS	Approved
DMGQ0ZI	SN	Protopam Chloride
DMGQ0ZI	CP	Baxter Healthcare Corp Anesthesia And Critical Care
DMGQ0ZI	DT	Small molecular drug
DMGQ0ZI	PC	135445761
DMGQ0ZI	MW	172.61
DMGQ0ZI	FM	C7H9ClN2O
DMGQ0ZI	IC	InChI=1S/C7H8N2O.ClH/c1-9-5-3-2-4-7(9)6-8-10;/h2-6H,1H3;1H
DMGQ0ZI	CS	C[N+]1=CC=CC=C1/C=N/O.[Cl-]
DMGQ0ZI	IK	HIGSLXSBYYMVKI-UHFFFAOYSA-N
DMGQ0ZI	IU	(NE)-N-[(1-methylpyridin-1-ium-2-yl)methylidene]hydroxylamine;chloride
DMGQ0ZI	CA	CAS 51-15-0
DMGQ0ZI	CB	CHEBI:8355
DMGQ0ZI	DE	Poisoning due to pesticides and chemicals

DMWU0I2	ID	DMWU0I2
DMWU0I2	DN	Pralsetinib
DMWU0I2	HS	Approved
DMWU0I2	SN	GBLBJPZSROAGMF-SIYOEGHHSA-N; Blu667; 2097132-94-8; SCHEMBL18806610; SCHEMBL18789229; SCHEMBL18789228; GTPL10033; BLU-668; EX-A1944; HY-112301; CS-0044766; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
DMWU0I2	CP	Blueprint Medicines Cambridge, MA
DMWU0I2	PC	129073603
DMWU0I2	MW	533.6
DMWU0I2	FM	C27H32FN9O2
DMWU0I2	IC	InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1
DMWU0I2	CS	CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
DMWU0I2	IK	GBLBJPZSROAGMF-SIYOEGHHSA-N
DMWU0I2	IU	N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
DMWU0I2	CA	CAS 2097132-94-8
DMWU0I2	DE	Solid tumour/cancer; Non-small-cell lung cancer

DMNMW9R	ID	DMNMW9R
DMNMW9R	DN	Pramipexole
DMNMW9R	HS	Approved
DMNMW9R	SN	Mirapex; Pramipexol; Pramipexolum; SUD919CL2Y; Mirapex (TN); Mirapexin (TN); Pramipexole [USAN:INN]; SND-919; Sifrol(TN); U-98528E; Pramipexole (USAN/INN); (-)-Pramipexole; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; 111GE001; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; 2-amino-6-propylaminotetrahydrobenzothiazole
DMNMW9R	CP	Intas Pharma
DMNMW9R	TC	Antiparkinson Agents
DMNMW9R	DT	Small molecular drug
DMNMW9R	PC	119570
DMNMW9R	MW	211.33
DMNMW9R	FM	C10H17N3S
DMNMW9R	IC	InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
DMNMW9R	CS	CCCN[C@H]1CCC2=C(C1)SC(=N2)N
DMNMW9R	IK	FASDKYOPVNHBLU-ZETCQYMHSA-N
DMNMW9R	IU	(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMNMW9R	CA	CAS 104632-26-0
DMNMW9R	CB	CHEBI:8356
DMNMW9R	DE	Parkinson disease

DM2FHG3	ID	DM2FHG3
DM2FHG3	DN	Pramiracetam
DM2FHG3	HS	Approved (orphan drug)
DM2FHG3	SN	Amacetam; Ectapram; Neupramir; Remen; Amacetam hydrochloride; Amacetam sulfate; Pramiracetam hydrochloride; Pramiracetam sulfate; CNS-1879
DM2FHG3	CP	Warner-Lambert Co
DM2FHG3	DT	Small molecular drug
DM2FHG3	PC	51712
DM2FHG3	MW	269.38
DM2FHG3	FM	C14H27N3O2
DM2FHG3	IC	InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18)
DM2FHG3	CS	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C
DM2FHG3	IK	ZULJGOSFKWFVRX-UHFFFAOYSA-N
DM2FHG3	IU	N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide
DM2FHG3	CA	CAS 68497-62-1
DM2FHG3	CB	CHEBI:135110
DM2FHG3	DE	Brain disease

DM0EZ9Q	ID	DM0EZ9Q
DM0EZ9Q	DN	Pramlintide
DM0EZ9Q	HS	Approved
DM0EZ9Q	SN	Symlin; Triproamylin; Pramlintide [USAN]; Pramlintide acetate; Pramlintide acetate [USAN]; Pramlintide acetate hydrate; AC 0137
DM0EZ9Q	CP	Amylin Pharmaceuticals
DM0EZ9Q	DT	Small molecular drug
DM0EZ9Q	SQ	Pramlintide: KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY
DM0EZ9Q	PC	70691388
DM0EZ9Q	MW	3949
DM0EZ9Q	FM	C171H267N51O53S2
DM0EZ9Q	IC	InChI=1S/C171H267N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114-73-276-277-74-115(210-140(245)95(173)38-28-29-49-172)158(263)204-108(65-124(179)237)153(258)217-131(85(16)226)164(269)191-84(15)139(244)216-133(87(18)228)168(273)211-114/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231H,21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,233)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,260)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,251)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,182,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,134-,135-/m0/s1
DM0EZ9Q	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N
DM0EZ9Q	IK	TZIRZGBAFTZREM-MKAGXXMWSA-N
DM0EZ9Q	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]pentanediamide
DM0EZ9Q	CA	CAS 151126-32-8
DM0EZ9Q	CB	CHEBI:135922
DM0EZ9Q	DE	Type-1/2 diabetes

DMYHDCA	ID	DMYHDCA
DMYHDCA	DN	Pranlukast
DMYHDCA	HS	Approved
DMYHDCA	SN	Azlaire; Azlaire (TN); Pranlukast (INN); N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
DMYHDCA	TC	Antiasthmatic Agents
DMYHDCA	DT	Small molecular drug
DMYHDCA	PC	4887
DMYHDCA	MW	481.5
DMYHDCA	FM	C27H23N5O4
DMYHDCA	IC	InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
DMYHDCA	CS	C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4=C3OC(=CC4=O)C5=NNN=N5
DMYHDCA	IK	NBQKINXMPLXUET-UHFFFAOYSA-N
DMYHDCA	IU	N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
DMYHDCA	CA	CAS 103177-37-3
DMYHDCA	CB	CHEBI:94810
DMYHDCA	DE	Asthma

DM67VKL	ID	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	HS	Approved
DM67VKL	SN	Dehydroepiandrosterone; DHEA; 53-43-0; PRASTERONE; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone
DM67VKL	DT	Small molecular drug
DM67VKL	PC	5881
DM67VKL	MW	288.4
DM67VKL	FM	C19H28O2
DM67VKL	IC	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1
DM67VKL	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)O)C
DM67VKL	IK	FMGSKLZLMKYGDP-USOAJAOKSA-N
DM67VKL	IU	(3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
DM67VKL	CA	CAS 53-43-0
DM67VKL	CB	CHEBI:28689
DM67VKL	DE	Chronic obstructive pulmonary disease; Cardiovascular disease

DM7MT6E	ID	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	HS	Approved
DM7MT6E	SN	Effient (TN)
DM7MT6E	CP	Lilly; Daiichi Sankyo
DM7MT6E	DT	Small molecular drug
DM7MT6E	PC	6918456
DM7MT6E	MW	373.4
DM7MT6E	FM	C20H20FNO3S
DM7MT6E	IC	InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3
DM7MT6E	CS	CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
DM7MT6E	IK	DTGLZDAWLRGWQN-UHFFFAOYSA-N
DM7MT6E	IU	[5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate
DM7MT6E	CA	CAS 150322-43-3
DM7MT6E	CB	CHEBI:87723
DM7MT6E	DE	Acute coronary syndrome

DM6A0X7	ID	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	HS	Approved
DM6A0X7	SN	Eptastatin; Oliprevin; Pravastatina; Pravastatine; Pravastatinum; Pravator; Vasten; Pravastatin Sodium Salt; Pravastatina [Spanish]; Pravastatine [French]; Pravastatinum [Latin]; KS-5015; Pravachol (TN); Pravastatin (INN); Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravator (TN); RMS-431; Selektine (TN); SQ-31,000; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
DM6A0X7	CP	Bristol-Myers Squibb
DM6A0X7	TC	Anticholesteremic Agents
DM6A0X7	DT	Small molecular drug
DM6A0X7	PC	54687
DM6A0X7	MW	424.5
DM6A0X7	FM	C23H36O7
DM6A0X7	IC	InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
DM6A0X7	CS	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O
DM6A0X7	IK	TUZYXOIXSAXUGO-PZAWKZKUSA-N
DM6A0X7	IU	(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DM6A0X7	CA	CAS 81093-37-0
DM6A0X7	CB	CHEBI:63618
DM6A0X7	DE	Hypercholesterolaemia

DMEWC7N	ID	DMEWC7N
DMEWC7N	DN	Prazepam
DMEWC7N	HS	Approved
DMEWC7N	SN	Centrax; Demetrin; Lysanxia; Prazeene; Prazene; Prazepamum; Sedapran; Settima; Trepidan; Verstran; W 4020; Centrac (TN); Centrax (TN); Demetrin (TN); K-373; Lysanxia (TN); Mono Demetrin (TN); Pozapam (TN); Prasepine (TN); Prazene (TN); Prazepamum [INN-Latin]; Reapam (TN); Trepidan (TN); W-4020; Prazepam (JP15/USAN/INN); Prazepam [USAN:INN:BAN:JAN]; 7-Chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-cyclopropylmethyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one; 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
DMEWC7N	TC	Antianxiety Agents
DMEWC7N	DT	Small molecular drug
DMEWC7N	PC	4890
DMEWC7N	MW	324.8
DMEWC7N	FM	C19H17ClN2O
DMEWC7N	IC	InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
DMEWC7N	CS	C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4
DMEWC7N	IK	MWQCHHACWWAQLJ-UHFFFAOYSA-N
DMEWC7N	IU	7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
DMEWC7N	CA	CAS 2955-38-6
DMEWC7N	CB	CHEBI:8362
DMEWC7N	DE	Anxiety disorder

DMOU1PK	ID	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	HS	Approved
DMOU1PK	SN	Azinox; Biliricide; Biltricide; Cesol; Cisticid; Cutter; Cysticide; Droncit; Drontsit; Prasiquantel; Praziquantelum; Pyquiton; Traziquantel; Bayer Brand of Praziquantel; Cutter Tape Tabs; Merck Brand of Praziquantel; Embay 8440; P 4668; Bay-8440; Biltricide (TN); EMBAY-8440; NPFAPI-02; Praziquantelum [INN-Latin]; Biltricide, Droncit, Praziquantel; Praziquantel (JAN/USP/INN); Praziquantel [USAN:INN:BAN:JAN]; Praziquantel, (R)-Isomer; Praziquantel, (S)-Isomer; Praziquantel, (+-)-Isomer; (+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; (11bS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a) isoquinolin-4-one; 8440, EMBAY
DMOU1PK	CP	Bayer Pharmaceuticals Corporation
DMOU1PK	TC	Anthelmintics
DMOU1PK	DT	Small molecular drug
DMOU1PK	PC	4891
DMOU1PK	MW	312.4
DMOU1PK	FM	C19H24N2O2
DMOU1PK	IC	InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2
DMOU1PK	CS	C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2
DMOU1PK	IK	FSVJFNAIGNNGKK-UHFFFAOYSA-N
DMOU1PK	IU	2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one
DMOU1PK	CA	CAS 55268-74-1
DMOU1PK	CB	CHEBI:91583
DMOU1PK	DE	Flatworm infection

DMCD9YG	ID	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	HS	Approved
DMCD9YG	SN	Furazosin; Justac; Lentopres; Prazocin; Prazosina; Prazosine; Prazosinum; Prazosin HCl; TNP00312; CP-12299; Hypovase (TN); Minipress (TN); Prazosin (INN); Prazosin [INN:BAN]; Prazosina [INN-Spanish]; Prazosine [INN-French]; Prazosinum [INN-Latin]; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone; Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); 1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone
DMCD9YG	CP	Pfizer Pharmaceuticals
DMCD9YG	TC	Antihypertensive Agents
DMCD9YG	DT	Small molecular drug
DMCD9YG	PC	4893
DMCD9YG	MW	383.4
DMCD9YG	FM	C19H21N5O4
DMCD9YG	IC	InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
DMCD9YG	CS	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC
DMCD9YG	IK	IENZQIKPVFGBNW-UHFFFAOYSA-N
DMCD9YG	IU	[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
DMCD9YG	CA	CAS 19216-56-9
DMCD9YG	CB	CHEBI:8364
DMCD9YG	DE	Congestive heart failure; Benign prostatic hyperplasia; Hypertension

DMBUNVW	ID	DMBUNVW
DMBUNVW	DN	Prednicarbate
DMBUNVW	HS	Approved
DMBUNVW	SN	Dermatop; Peitel; Dermatop (TN); Hoe-777; S-77 0777; S-770777; Prednicarbate (USP/INN); [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
DMBUNVW	TC	Antiinflammatory Agents
DMBUNVW	DT	Small molecular drug
DMBUNVW	PC	6714002
DMBUNVW	MW	488.6
DMBUNVW	FM	C27H36O8
DMBUNVW	IC	InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1
DMBUNVW	CS	CCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)OCC
DMBUNVW	IK	FNPXMHRZILFCKX-KAJVQRHHSA-N
DMBUNVW	IU	[2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
DMBUNVW	CA	CAS 73771-04-7
DMBUNVW	CB	CHEBI:135791
DMBUNVW	DE	Inflammation

DMQ8FR2	ID	DMQ8FR2
DMQ8FR2	DN	Prednisolone
DMQ8FR2	HS	Approved
DMQ8FR2	SN	Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos
DMQ8FR2	CP	Schering Corp Sub Schering Plough Corp
DMQ8FR2	TC	Anticancer Agents
DMQ8FR2	DT	Small molecular drug
DMQ8FR2	PC	5755
DMQ8FR2	MW	360.4
DMQ8FR2	FM	C21H28O5
DMQ8FR2	IC	InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
DMQ8FR2	CS	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O
DMQ8FR2	IK	OIGNJSKKLXVSLS-VWUMJDOOSA-N
DMQ8FR2	IU	(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMQ8FR2	CA	CAS 50-24-8
DMQ8FR2	CB	CHEBI:8378
DMQ8FR2	DE	Solid tumour/cancer; Multiple sclerosis

DM2HG4X	ID	DM2HG4X
DM2HG4X	DN	Prednisone
DM2HG4X	HS	Approved
DM2HG4X	SN	Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
DM2HG4X	CP	Schering-Plough
DM2HG4X	TC	Antiinflammatory Agents
DM2HG4X	DT	Small molecular drug
DM2HG4X	PC	5865
DM2HG4X	MW	358.4
DM2HG4X	FM	C21H26O5
DM2HG4X	IC	InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
DM2HG4X	CS	C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C
DM2HG4X	IK	XOFYZVNMUHMLCC-ZPOLXVRWSA-N
DM2HG4X	IU	(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
DM2HG4X	CA	CAS 53-03-2
DM2HG4X	CB	CHEBI:8382
DM2HG4X	DE	Atopic dermatitis; Eczema; Inflammation

DMDVP3B	ID	DMDVP3B
DMDVP3B	DN	Pregabalin
DMDVP3B	HS	Approved
DMDVP3B	SN	Pregabalin CR; Pregabalin (controlled-release, oral); Pregabalin (controlled-release, oral), Pfizer
DMDVP3B	CP	Pfizer
DMDVP3B	DT	Small molecular drug
DMDVP3B	PC	5486971
DMDVP3B	MW	159.23
DMDVP3B	FM	C8H17NO2
DMDVP3B	IC	InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1
DMDVP3B	CS	CC(C)C[C@@H](CC(=O)O)CN
DMDVP3B	IK	AYXYPKUFHZROOJ-ZETCQYMHSA-N
DMDVP3B	IU	(3S)-3-(aminomethyl)-5-methylhexanoic acid
DMDVP3B	CA	CAS 148553-50-8
DMDVP3B	CB	CHEBI:64356
DMDVP3B	DE	Chronic obstructive pulmonary disease

DMYQVGN	ID	DMYQVGN
DMYQVGN	DN	Premarin/Trimegestone
DMYQVGN	HS	Approved
DMYQVGN	SN	Conjugated estrogen tablets
DMYQVGN	CP	Wyeth
DMYQVGN	DE	Menopause symptom

DMDYA31	ID	DMDYA31
DMDYA31	DN	Pretomanid
DMDYA31	HS	Approved
DMDYA31	SN	PA-824; 187235-37-6; Pretomanid; PA 824; PA824; UNII-2XOI31YC4N; (S)-PA 824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; 2XOI31YC4N; CHEMBL227875; MMV688755; AK161427; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid [USAN:INN]; C14H12F3N3O5; PA-824(Pretomanid); AC1L9UFX; Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011
DMDYA31	DT	Small molecular drug
DMDYA31	PC	456199
DMDYA31	MW	359.26
DMDYA31	FM	C14H12F3N3O5
DMDYA31	IC	InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1
DMDYA31	CS	C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
DMDYA31	IK	ZLHZLMOSPGACSZ-NSHDSACASA-N
DMDYA31	IU	(6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
DMDYA31	CA	CAS 187235-37-6
DMDYA31	DE	Mycobacterium infection; Tuberculosis

DMQ0C2Z	ID	DMQ0C2Z
DMQ0C2Z	DN	Prevnar
DMQ0C2Z	HS	Approved
DMQ0C2Z	SN	Prevenar; PNCRM7; PCV-7; Polyvalent pneumococcal vaccine, Praxis; Pneumococcus/CRM-197 conjugate vaccine, Pfizer; Vaccine (pneumococcal), Praxis/American Home Products; 7vPnC, Pfizer
DMQ0C2Z	CP	Pfizer Vaccines
DMQ0C2Z	DT	Vaccine
DMQ0C2Z	DE	Otitis media

DMMZB0K	ID	DMMZB0K
DMMZB0K	DN	Prifinium
DMMZB0K	HS	Approved
DMMZB0K	SN	Prifinium; 10236-81-4; 3-(Benzhydrylidene)-1,1-diethyl-2-methylpyrrolidinium; Prifinum; NCGC00183859-01; EINECS 233-568-5; AC1Q1ITK; AC1L1J7T; SCHEMBL14672576; 3-benzhydrylidene-1,1-diethyl-2-methylpyrrolidin-1-ium; CHEMBL1229214; CTK4A0968; 3-Diphenylmethylene-1,1-diethyl-2-methylpyrrolidinium
DMMZB0K	DT	Small molecular drug
DMMZB0K	PC	4905
DMMZB0K	MW	306.5
DMMZB0K	FM	C22H28N+
DMMZB0K	IC	InChI=1S/C22H28N/c1-4-23(5-2)17-16-21(18(23)3)22(19-12-8-6-9-13-19)20-14-10-7-11-15-20/h6-15,18H,4-5,16-17H2,1-3H3/q+1
DMMZB0K	CS	CC[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)C1C)CC
DMMZB0K	IK	ZYEPZINLLPPBMI-UHFFFAOYSA-N
DMMZB0K	IU	3-benzhydrylidene-1,1-diethyl-2-methylpyrrolidin-1-ium
DMMZB0K	CA	CAS 10236-81-4
DMMZB0K	DE	Irritable bowel syndrome

DMI7DZ2	ID	DMI7DZ2
DMI7DZ2	DN	Prilocaine
DMI7DZ2	HS	Approved
DMI7DZ2	SN	Citanest; Prilocaina; Prilocainum; Propitocaine; Prilocaine [USAN]; Prilocaine base; Astra 1512; Astra 1515; L 67; Citanest (TN); Prilocaina [INN-Spanish]; Prilocainum [INN-Latin]; Propitocaine (JAN); Prilocaine (USP/INN); O-Methyl-2-propylaminopropionanilide; O-Methyl-alpha-propylaminopropionanilide; Alpha-n-Propylamino-2-methylpropionanilide; N-[2-Methylphenyl]-2-[propylamino]propanamide; N-(2-methylphenyl)-N2-propylalaninamide; N-(2-Methylphenyl)-2-(propylamino)propanamide; N-(2-methylphenyl)-N(2)-propylalaninamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)-(9CI); 2-(Propylamino)-o-propionotoluidide; 2-Methyl-.alpha.-propylaminopropionanilide; 2-Methyl-alpha-propylaminopropionanilide
DMI7DZ2	CP	Astrazeneca Lp
DMI7DZ2	TC	Anesthetics
DMI7DZ2	DT	Small molecular drug
DMI7DZ2	PC	4906
DMI7DZ2	MW	220.31
DMI7DZ2	FM	C13H20N2O
DMI7DZ2	IC	InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)
DMI7DZ2	CS	CCCNC(C)C(=O)NC1=CC=CC=C1C
DMI7DZ2	IK	MVFGUOIZUNYYSO-UHFFFAOYSA-N
DMI7DZ2	IU	N-(2-methylphenyl)-2-(propylamino)propanamide
DMI7DZ2	CA	CAS 721-50-6
DMI7DZ2	CB	CHEBI:8404
DMI7DZ2	DE	Pain

DMWQ16I	ID	DMWQ16I
DMWQ16I	DN	Primaquine
DMWQ16I	HS	Approved
DMWQ16I	SN	Kanaprim; Primachin; Primachina; Primachinum; Primaquin; Primaquina; Primaquinum; Primachina [DCIT]; SN 13272; WR 2975; Dl-Primaquine; Kanaprim (TN); Neo-Quipenyl; Primaquina [INN-Spanish]; Primaquine (INN); Primaquine Bis-Phosphoric Acid; Primaquine [INN:BAN]; Primaquinum [INN-Latin]; SN 13,272; TG1-296; TG1-297; Ethylbutylamino)-6-methoxyquinoline; S. N. 13272; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-(6CI,8CI); (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (+)-Primaquine; (+/-)-Primaquine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-Primaquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-(9CI); 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; 6-Methoxy-8-[4-amino-1-methylbutylamino]quinoline; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; 8-(4-Amino-1-m; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline
DMWQ16I	CP	Sanofi-Aventis
DMWQ16I	TC	Antimalarials
DMWQ16I	DT	Small molecular drug
DMWQ16I	PC	4908
DMWQ16I	MW	259.35
DMWQ16I	FM	C15H21N3O
DMWQ16I	IC	InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3
DMWQ16I	CS	CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
DMWQ16I	IK	INDBQLZJXZLFIT-UHFFFAOYSA-N
DMWQ16I	IU	4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
DMWQ16I	CA	CAS 90-34-6
DMWQ16I	CB	CHEBI:8405
DMWQ16I	DE	Malaria

DM0WX6I	ID	DM0WX6I
DM0WX6I	DN	Primidone
DM0WX6I	HS	Approved
DM0WX6I	SN	Cyral; Desoxyphenobarbital; Desoxyphenobarbitone; Hexadiona; Lepimidin; Lepsiral; Liskantin; Majsolin; Midone; Milepsin; Misodine; Misolyne; Mizodin; Mizolin; Myidone; Mylepsin; Mylepsinum; Mysedon; Mysoline; Neurosyn; Prilepsin; Primacione; Primaclone; Primacone; Primakton; Primidon; Primidona; Primidonum; Primoline; Prysoline; Resimatil; Sertan; Apotex Brand of Primidone; Astra Brand of Primidone; AstraZeneca Brand of Primidone; Desitin Brand of Primidone; Draxis Brand of Primidone; Holsten Brand of Primidone; Pms Primidone; Primidon Holsten; Primidone Methanol Solution; Xcel Brand of Primidone; Zeneca Brand of Primidone; P 7295; Roe 101; Apo-Primidone; Hexamidine (the antispasmodic); Hexamidine(the antispasmodic); Liskantin (TN); Medi-Pets; Mylepsinum (TN); Mysoline (TN); Primidona [INN-Spanish]; Primidone (primaclone); Primidonum [INN-Latin]; Prysoline (TN); Pyrimidone Medi-pets; Resimatil (TN); Sanofi-Synthelabo Brand of Primidone; Sertan (TN); Apo-Primidone (TN); Pyrimidone (Medi-pets); Primidone (JP15/USP/INN); Primidone [USAN:INN:BAN:JAN]; 2-Deoxyphenobarbital; 2-Desoxyphenobarbital; 4,4'-(Hexamethylenedioxy)dibenzamidine; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion [German]; 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione; 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione; 5-Ethylhexahydro-4,6-dioxo-5-phenylpyrimidine; 5-Ethylhexahydro-5-phenylpyrimidine-4,6-dione; 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6); 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6) [German]; 5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione; 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione; 5-ethyl-5-phenyldihydropyrimidine-4,6(1H,5H)-dione; 5-ethylhe xahydro-4,6-dioxo-5-phenylpyrimidine
DM0WX6I	CP	Rekah Pharmaceutical
DM0WX6I	TC	Anticonvulsants
DM0WX6I	DT	Small molecular drug
DM0WX6I	PC	4909
DM0WX6I	MW	218.25
DM0WX6I	FM	C12H14N2O2
DM0WX6I	IC	InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)
DM0WX6I	CS	CCC1(C(=O)NCNC1=O)C2=CC=CC=C2
DM0WX6I	IK	DQMZLTXERSFNPB-UHFFFAOYSA-N
DM0WX6I	IU	5-ethyl-5-phenyl-1,3-diazinane-4,6-dione
DM0WX6I	CA	CAS 125-33-7
DM0WX6I	CB	CHEBI:8412
DM0WX6I	DE	Epilepsy

DM9HOKG	ID	DM9HOKG
DM9HOKG	DN	Prinomastat
DM9HOKG	HS	Approved
DM9HOKG	SN	AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
DM9HOKG	CP	Pfizer
DM9HOKG	TC	Anticancer Agents
DM9HOKG	DT	Small molecular drug
DM9HOKG	PC	466151
DM9HOKG	MW	423.5
DM9HOKG	FM	C18H21N3O5S2
DM9HOKG	IC	InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1
DM9HOKG	CS	CC1([C@@H](N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=NC=C3)C(=O)NO)C
DM9HOKG	IK	YKPYIPVDTNNYCN-INIZCTEOSA-N
DM9HOKG	IU	(3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
DM9HOKG	CA	CAS 192329-42-3
DM9HOKG	CB	CHEBI:138885
DM9HOKG	DE	Lung cancer; Brain cancer

DMMFWOJ	ID	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	HS	Approved
DMMFWOJ	SN	Apurina; Bencid; Benecid; Benemid; Benemide; Benuryl; Panuric; Parabenem; Probalan; Probampacin; Probecid; Proben; Probenecida; Probenecide; Probenecidum; Probenemid; Probenicid; Probenid; Probexin; Prolongine; Robenecid; Sulprin; Tubophan; Uricosid; Urocid; Biokanol Brand of Probenecid; ICN Brand of Probenecid; IDIS Brand of Probenecid; Major Brand of Probenecid; Martec Brand of Probenecid; Merck Brand of Probenecid; Ophthalmic Brand of Probenecid; Parmed Brand of Probenecid; Probenecid Major Brand; Probenecid Martec Brand; Probenecid Parmed Brand; Probenecid Weimer; Probenecid Zenith Brand; Probenecid acid; Synergid R; Valdecasas Brand of Probenecid; Zenith Brand of Probenecid; Benemid (TN); Benuryl (TN); Col-BENEMID; ColBenemid (co mponent of); ColBenemid (component of); P-[Dipropylsulfamoyl]benzoic acid; Polycillin-BRB; Pro-Cid; Probenecida [INN-Spanish]; Probenecide [INN-French]; Probenecidum [INN-Latin]; P-(Dipropylsulfamoyl)benzoic acid; P-(Dipropylsulfamyl)benzoic acid; Polycillin-PRB (component of); Probenecid [INN:BAN:JAN]; Probenecid (JP15/USP/INN); 4-((Dipropylamino)sulfonyl)benzoic acid;4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(Dipropylsulfamoyl)benzoic acid; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; 4-[(dipropylamino)sulfonyl]benzoic acid
DMMFWOJ	TC	Uricosuric Agents
DMMFWOJ	DT	Small molecular drug
DMMFWOJ	PC	4911
DMMFWOJ	MW	285.36
DMMFWOJ	FM	C13H19NO4S
DMMFWOJ	IC	InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)
DMMFWOJ	CS	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O
DMMFWOJ	IK	DBABZHXKTCFAPX-UHFFFAOYSA-N
DMMFWOJ	IU	4-(dipropylsulfamoyl)benzoic acid
DMMFWOJ	CA	CAS 57-66-9
DMMFWOJ	CB	CHEBI:8426
DMMFWOJ	DE	Hyperuricaemia; Gout

DMVZQ2M	ID	DMVZQ2M
DMVZQ2M	DN	Probucol
DMVZQ2M	HS	Approved
DMVZQ2M	SN	Biphenabid; Bisbid; Bisphenabid; Lesterol; Lorelco; Lursell; Lurselle; Panavir; Probucolum; Sinlestal; Superlipid; Almirall Brand of Probucol; Aventis Brand of Probucol; Hoechst Brand of Probucol; DH 581; DH581; DE-3872; DH-581; LORELCO (TN); Probucolum [INN-Latin]; ZERO/001429; Probucol (JAN/USP/INN); Probucol [USAN:BAN:INN:JAN]; Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol; 4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]; 4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol]; 4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol); 4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]
DMVZQ2M	TC	Anticholesteremic Agents
DMVZQ2M	DT	Small molecular drug
DMVZQ2M	PC	4912
DMVZQ2M	MW	516.799
DMVZQ2M	FM	C31H48O2S2
DMVZQ2M	IC	InChI=1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3
DMVZQ2M	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C
DMVZQ2M	IK	FYPMFJGVHOHGLL-UHFFFAOYSA-N
DMVZQ2M	IU	2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol
DMVZQ2M	CA	CAS 23288-49-5
DMVZQ2M	CB	CHEBI:8427
DMVZQ2M	DE	Coronary artery disease

DMNMXR8	ID	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	HS	Approved
DMNMXR8	SN	Biocoryl; Novocainamid; Novocainamide; Novocamid; Procainamida; Procainamidum; Procamide; Procan; Procanbid; Procapan; Pronestyl; Novocaine amide; Procaine amide; P-Aminobenzoic diethylaminoethylamide; Procainamida [INN-Spanish]; Procainamide (INN); Procainamide [INN:BAN]; Procainamidum [INN-Latin]; Procan (TN); Procanbid (TN); Procapan (free base); Pronestyl (TN); Pronestyl-Sr; P-Amino-N-(2-diethylaminoethyl)benzamide; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-(9CI); 2-Diethylaminoethylamid kyseliny p-aminobenzoove; 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech]; 4-Amino-N-(2-(Diethylamino)Ethyl)Benzamide Sulfate; 4-Amino-N-(2-(diethylamino)ethyl)benzamide; 4-Amino-N-[2-(diethylamino)ethyl]benzamide; 4-amino-N-(2-diethylaminoethyl)-benzamide; 4-amino-N-(2-diethylaminoethyl)benzamide
DMNMXR8	TC	Antiarrhythmic Agents
DMNMXR8	DT	Small molecular drug
DMNMXR8	PC	4913
DMNMXR8	MW	235.33
DMNMXR8	FM	C13H21N3O
DMNMXR8	IC	InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)
DMNMXR8	CS	CCN(CC)CCNC(=O)C1=CC=C(C=C1)N
DMNMXR8	IK	REQCZEXYDRLIBE-UHFFFAOYSA-N
DMNMXR8	IU	4-amino-N-[2-(diethylamino)ethyl]benzamide
DMNMXR8	CA	CAS 51-06-9
DMNMXR8	CB	CHEBI:8428
DMNMXR8	DE	Ventricular arrhythmias

DM4LSNE	ID	DM4LSNE
DM4LSNE	DN	Procaine
DM4LSNE	HS	Approved
DM4LSNE	SN	Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester
DM4LSNE	CP	Wyeth Pharmaceuticals
DM4LSNE	TC	Anesthetics
DM4LSNE	DT	Small molecular drug
DM4LSNE	PC	4914
DM4LSNE	MW	236.31
DM4LSNE	FM	C13H20N2O2
DM4LSNE	IC	InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3
DM4LSNE	CS	CCN(CC)CCOC(=O)C1=CC=C(C=C1)N
DM4LSNE	IK	MFDFERRIHVXMIY-UHFFFAOYSA-N
DM4LSNE	IU	2-(diethylamino)ethyl 4-aminobenzoate
DM4LSNE	CA	CAS 59-46-1
DM4LSNE	CB	CHEBI:8430
DM4LSNE	DE	Anaesthesia

DMIK367	ID	DMIK367
DMIK367	DN	Procarbazine
DMIK367	HS	Approved
DMIK367	SN	Ibenzmethyzin; Ibenzmethyzine; MBH; MIH; Natulan; Natulanar; PCX; Procarbazin; Procarbazina; Procarbazinum; Procarbazin [German]; Procarbazine Monohydrochloride; CB 400-497; Indicarb (TN); Matulane (TN); Natulan (TN); Procarbazina [INN-Spanish]; Procarbazine (INN); Procarbazine [INN:BAN]; Procarbazinum [INN-Latin];Ro 4-6467; SRI-10847; Ro 4-6467/1; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; P-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-(9CI); 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
DMIK367	CP	Sigma-Tau Pharmaceuticals
DMIK367	TC	Anticancer Agents
DMIK367	DT	Small molecular drug
DMIK367	PC	4915
DMIK367	MW	221.3
DMIK367	FM	C12H19N3O
DMIK367	IC	InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)
DMIK367	CS	CC(C)NC(=O)C1=CC=C(C=C1)CNNC
DMIK367	IK	CPTBDICYNRMXFX-UHFFFAOYSA-N
DMIK367	IU	4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
DMIK367	CA	CAS 671-16-9
DMIK367	CB	CHEBI:71417
DMIK367	DE	Hodgkin lymphoma

DM1M0Q4	ID	DM1M0Q4
DM1M0Q4	DN	Procaterol
DM1M0Q4	HS	Approved
DM1M0Q4	SN	Meptin; Procaterolo; Procaterolum; Procaterol Monohydrochloride; Procaterolo [DCIT]; Procaterolum [Latin]; Meptin (TN); OPC-2009; Procaterol (INN); Procaterol [INN:BAN]; Procaterolum [INN-Latin]; (R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinoline-2,8-diol; 8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one
DM1M0Q4	TC	Bronchodilator Agents
DM1M0Q4	DT	Small molecular drug
DM1M0Q4	PC	4916
DM1M0Q4	MW	290.36
DM1M0Q4	FM	C16H22N2O3
DM1M0Q4	IC	InChI=1S/C16H22N2O3/c1-4-12(17-9(2)3)16(21)11-5-7-13(19)15-10(11)6-8-14(20)18-15/h5-9,12,16-17,19,21H,4H2,1-3H3,(H,18,20)
DM1M0Q4	CS	CCC(C(C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C
DM1M0Q4	IK	FKNXQNWAXFXVNW-UHFFFAOYSA-N
DM1M0Q4	IU	8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one
DM1M0Q4	CA	CAS 60443-17-6
DM1M0Q4	CB	CHEBI:91585
DM1M0Q4	DE	Asthma

DM53SRA	ID	DM53SRA
DM53SRA	DN	Prochlorperazine
DM53SRA	HS	Approved
DM53SRA	SN	CHLOPERAZINE; Capazine; Chlormeprazine; Chlorperazine; Combid; Compazine; Compro; Emelent; Eskatrol; Kronocin; Meterazin; Meterazine; Nipodal; Novamin; Prochloroperazine; Prochlorpemazine; Prochlorperazin; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Proclorperazine; Stemetil; Tementil; Temetid; Vertigon; Compazine Suppositories; Prochlorperazine Edisylate Salt; Prochlorperazine dihydrobromide; Prochlorperazine dimaleate; Prochlorperazine maleate; Prochlorperazine mesilate; Bayer A 173; P77; RP 6140; SKF 4657; Buccastem (TN); Compazine (TN); Compro (TN); Phenotil (TN); Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Stemetil (TN); Stemzine (TN); Compazine (*Maleate*); Prochlorperazine (JAN/USP/INN); Prochlorperazine [USAN:INN:BAN:JAN]; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-Chloro-10-[3-(4-methyl-1-piper-azinyl)propyl]-10H-pheno-thiazine dimaleate; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP
DM53SRA	CP	GlaxoSmithKline
DM53SRA	TC	Antipsychotic Agents
DM53SRA	DT	Small molecular drug
DM53SRA	PC	4917
DM53SRA	MW	373.9
DM53SRA	FM	C20H24ClN3S
DM53SRA	IC	InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
DM53SRA	CS	CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
DM53SRA	IK	WIKYUJGCLQQFNW-UHFFFAOYSA-N
DM53SRA	IU	2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DM53SRA	CA	CAS 58-38-8
DM53SRA	CB	CHEBI:8435
DM53SRA	DE	Nausea

DMHFJDT	ID	DMHFJDT
DMHFJDT	DN	Procyclidine
DMHFJDT	HS	Approved
DMHFJDT	SN	Arpicolin; Elorine; Kemadrin; Kemadrine; Lergine; Metanin; Osnervan; Prociclidina; Procidlidina; Procyclid; Procyclidinum; Procyklidin; Prosyklidin; Spamol; Triciclidina; Triciloid; Tricoloid; Tricyclamol; Vagosin; Prociclidina [INN-Spanish]; Procyclidine (INN); Procyclidine [INN:BAN]; Procyclidinum [INN-Latin]; 1-Cyclohexyl-1-phenyl-3-(1-pyrrolidinyl)-1-propanol; 1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol; 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol
DMHFJDT	TC	Antiparkinson Agents
DMHFJDT	DT	Small molecular drug
DMHFJDT	PC	4919
DMHFJDT	MW	287.4
DMHFJDT	FM	C19H29NO
DMHFJDT	IC	InChI=1S/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
DMHFJDT	CS	C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O
DMHFJDT	IK	WYDUSKDSKCASEF-UHFFFAOYSA-N
DMHFJDT	IU	1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol
DMHFJDT	CA	CAS 77-37-2
DMHFJDT	CB	CHEBI:8448
DMHFJDT	DE	Parkinson disease

DMF1X5P	ID	DMF1X5P
DMF1X5P	DN	Proflavine
DMF1X5P	HS	Approved
DMF1X5P	SN	PRL; Proflavin; Proflavina; Proflavinum; Profura; Progarmed; Isoflav base; Proflavine [INN]; Proflavine hemisulfate; Proflavina [INN-Spanish]; Proflavine Hemi-Sulfate; Proflavinum [INN-Latin]; AE-562/12222295; Acridine-3,6-diamine; 2,8-Diaminoacridine; 2,8-Diaminoacridine (European); 2,8-Diaminoacridinium; 3,6-ACRIDINEDIAMINE; 3,6-Acridinediamine hydrochloride; 3,6-Diamino-acridinium; 3,6-Diaminoacridine; 3,6-Diaminoacridine sulfate; 3,6-Diaminoacridinium; 3,7-Diamino-5-azaanthracene
DMF1X5P	TC	Antiinfective Agents
DMF1X5P	DT	Small molecular drug
DMF1X5P	PC	7099
DMF1X5P	MW	209.25
DMF1X5P	FM	C13H11N3
DMF1X5P	IC	InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2
DMF1X5P	CS	C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N
DMF1X5P	IK	WDVSHHCDHLJJJR-UHFFFAOYSA-N
DMF1X5P	IU	acridine-3,6-diamine
DMF1X5P	CA	CAS 92-62-6
DMF1X5P	CB	CHEBI:8452
DMF1X5P	DE	Sepsis

DM671NG	ID	DM671NG
DM671NG	DN	Progabide
DM671NG	HS	Approved
DM671NG	SN	Gabren; Gabrene; Halogabide; Progabida; Progabidum; SL 76002; Gabren (TN); Gabrene (TN); Progabida [INN-Spanish]; Progabidum [INN-Latin]; SL 76-002; SL-76002; Progabide (USAN/INN); Progabide [USAN:BAN:INN]; Progabide [USAN:INN:BAN]; 4-(((4-Chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)butanamide; 4-((alpha-(p-Chlorophenyl)-5-fluorosalicylidene)amino)butyramide; 4-(alpha-(p-Chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)butyramide; 4-[[(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(E)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(Z)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide
DM671NG	CP	Sanofi-Aventis
DM671NG	TC	Antidepressants
DM671NG	DT	Small molecular drug
DM671NG	PC	44115
DM671NG	MW	334.8
DM671NG	FM	C17H16ClFN2O2
DM671NG	IC	InChI=1S/C17H16ClFN2O2/c18-12-5-3-11(4-6-12)17(21-9-1-2-16(20)23)14-10-13(19)7-8-15(14)22/h3-8,10,22H,1-2,9H2,(H2,20,23)
DM671NG	CS	C1=CC(=CC=C1C(=NCCCC(=O)N)C2=C(C=CC(=C2)F)O)Cl
DM671NG	IK	IBALRBWGSVJPAP-UHFFFAOYSA-N
DM671NG	IU	4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylidene]amino]butanamide
DM671NG	CA	CAS 62666-20-0
DM671NG	CB	CHEBI:135422
DM671NG	DE	Depression

DMUY35B	ID	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	HS	Approved
DMUY35B	SN	progesterone; 57-83-0; Agolutin; Pregn-4-ene-3,20-dione; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Utrogestan; Syngesterone; Progestin; Luteol; Corpus luteum hormone; Progesterol; Progesteronum; Pregnenedione; Glanducorpin; Prometrium; Corlutin; Cyclogest; Progestron; Gestormone; Progestone; Gestone; Progestasert; Progestronol; Methylpregnone; Hormoflaveine; Syngestrets; Proluton; Progekan; Nalutron; Lutoform; Gynlutin; Gesterol; Fologenon; Corporin; Corlutina; Syntolutan; Prolidon; Membrettes; Lutocyclin; Luteodyn; Lucorteum; Corluvite;  LPCN-1107; Progesterone (oral, preterm labor); Progesterone (oral, preterm labor), Lipocine
DMUY35B	CP	Lipocine Inc
DMUY35B	DT	Small molecular drug
DMUY35B	PC	5994
DMUY35B	MW	314.5
DMUY35B	FM	C21H30O2
DMUY35B	IC	InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
DMUY35B	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMUY35B	IK	RJKFOVLPORLFTN-LEKSSAKUSA-N
DMUY35B	IU	(8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMUY35B	CA	CAS 57-83-0
DMUY35B	CB	CHEBI:17026
DMUY35B	DE	Premature labour; Contraception

DMBL79I	ID	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	HS	Approved
DMBL79I	SN	Bigumal; Chlorguanid; Chlorguanide; Chloriguane; Chloroguanide; Paludrin; Proguanile; Proguanilum; Proguanile [DCIT]; Diguanyl (hydrochloride); Drinupal (hydrochloride); Paludrine (TN); Paludrine (hydrochloride); Palusil (hydrochloride); Proguanil [INN:BAN]; Proguanilum [INN-Latin]; RP-3359; Tirian (hydrochloride); M-4888 (hydrochloride); SN-12837 (hydrochloride); N1-p-Chlorophenyl-N5-isopropylbiguanide; N-(4-Chlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; N-(4-Chlorophenyl)-N'-(isopropyl)-imidodicarbonimidic diamide; N-(4-chlorophenyl)-N'-(propan-2-yl)imidodicarbonimidic diamide; (1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine; 1-(p-Chlorophenyl)-5-isopropylbiguanide; 1-Isopropyl-5-(4-chlorophenyl)biguanide
DMBL79I	CP	AstraZeneca
DMBL79I	TC	Antimalarials
DMBL79I	DT	Small molecular drug
DMBL79I	PC	6178111
DMBL79I	MW	253.73
DMBL79I	FM	C11H16ClN5
DMBL79I	IC	InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)
DMBL79I	CS	CC(C)N=C(N)/N=C(\\N)/NC1=CC=C(C=C1)Cl
DMBL79I	IK	SSOLNOMRVKKSON-UHFFFAOYSA-N
DMBL79I	IU	(1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine
DMBL79I	CA	CAS 500-92-5
DMBL79I	CB	CHEBI:8455
DMBL79I	DE	Malaria

DMYSCIL	ID	DMYSCIL
DMYSCIL	DN	Prolastin
DMYSCIL	HS	Approved
DMYSCIL	SN	Prolastin-C; TAL-6004; Alpha-1 antitrypsin, Bayer; Alpha-1 antitrypsin, Talecris/Crucell; Alpha-1 proteinaseinhibitor (human), Bayer
DMYSCIL	CP	Bayer AG
DMYSCIL	DE	Alpha-1 antitrypsin deficiency

DMMJ1IS	ID	DMMJ1IS
DMMJ1IS	DN	Prolixin decanoate
DMMJ1IS	HS	Approved
DMMJ1IS	SN	Modecate; Dapotum D; Flufenazine decanoate; Fluorophenazine decanoate; Fluphenaline decanoate; Fluphenazine decanoate; Fluphenazine depot; Moditen depot; Fluphenazine O-decanoate; Moditen-depo; Prolixin decanoate (TN); SQ 10,733; Fluphenazine decanoate (JAN/USP); Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate
DMMJ1IS	TC	Antipsychotic Agents
DMMJ1IS	DT	Small molecular drug
DMMJ1IS	PC	3388
DMMJ1IS	MW	591.8
DMMJ1IS	FM	C32H44F3N3O2S
DMMJ1IS	IC	InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3
DMMJ1IS	CS	CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
DMMJ1IS	IK	VIQCGTZFEYDQMR-UHFFFAOYSA-N
DMMJ1IS	IU	2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate
DMMJ1IS	CA	CAS 5002-47-1
DMMJ1IS	CB	CHEBI:5124
DMMJ1IS	DE	Schizophrenia

DMZAL7W	ID	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	HS	Approved
DMZAL7W	SN	Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride
DMZAL7W	CP	Wyeth Pharmaceuticals
DMZAL7W	TC	Antipsychotic Agents
DMZAL7W	DT	Small molecular drug
DMZAL7W	PC	4926
DMZAL7W	MW	284.4
DMZAL7W	FM	C17H20N2S
DMZAL7W	IC	InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
DMZAL7W	CS	CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
DMZAL7W	IK	ZGUGWUXLJSTTMA-UHFFFAOYSA-N
DMZAL7W	IU	N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine
DMZAL7W	CA	CAS 58-40-2
DMZAL7W	CB	CHEBI:8459
DMZAL7W	DE	Psychomotor agitation

DMK4S8I	ID	DMK4S8I
DMK4S8I	DN	Promegestone
DMK4S8I	HS	Approved
DMK4S8I	SN	Surgestone (TN)
DMK4S8I	CP	Labs. Cassenne
DMK4S8I	DT	Small molecular drug
DMK4S8I	PC	36709
DMK4S8I	MW	326.5
DMK4S8I	FM	C22H30O2
DMK4S8I	IC	InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1
DMK4S8I	CS	CCC(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C
DMK4S8I	IK	QFFCYTLOTYIJMR-XMGTWHOFSA-N
DMK4S8I	IU	(8S,13S,14S,17S)-13,17-dimethyl-17-propanoyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMK4S8I	CA	CAS 34184-77-5
DMK4S8I	CB	CHEBI:73390
DMK4S8I	DE	Gynecological disease

DMU92F8	ID	DMU92F8
DMU92F8	DN	Promestriene
DMU92F8	HS	Approved
DMU92F8	SN	BCP9000134; VA11593; A824465; I06-0300
DMU92F8	DT	Small molecular drug
DMU92F8	PC	9883915
DMU92F8	MW	328.5
DMU92F8	FM	C22H32O2
DMU92F8	IC	InChI=1S/C22H32O2/c1-4-13-24-16-6-8-17-15(14-16)5-7-19-18(17)11-12-22(2)20(19)9-10-21(22)23-3/h6,8,14,18-21H,4-5,7,9-13H2,1-3H3/t18-,19-,20+,21+,22+/m1/s1
DMU92F8	CS	CCCOC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4OC)C
DMU92F8	IK	IUWKNLFTJBHTSD-AANPDWTMSA-N
DMU92F8	IU	(8R,9S,13S,14S,17S)-17-methoxy-13-methyl-3-propoxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene
DMU92F8	CA	CAS 39219-28-8
DMU92F8	CB	CHEBI:135402
DMU92F8	DE	Acne vulgaris

DM6I5GR	ID	DM6I5GR
DM6I5GR	DN	Promethazine
DM6I5GR	HS	Approved
DM6I5GR	SN	Antiallersin; Aprobit; Avomine; Camergan; Dimapp; Diphergan; Diprazin; Diprazine; Diprozin; Fargan; Fenazil; Fenetazina; Fenetazine; Genphen; Hiberna; Histargan; Iergigan; Isophenergan; Isopromethazine; Lercigan; Lergigan; Metaryl; Pelpica; Phargan; Phenargan; Phenerzine; Phensedyl; Pilothia; Pilpophen; Pipolphene; Proazaimine; Proazamine; Procit; Promacot; Promazinamide; Promergan; Promesan; Prometasin; Prometazin; Prometazina; Prometazine; Prometh; Promethacon; Promethaine; Promethazin; PromethazineHcl; Promethazinum; Promethegan; Promethiazine; Promezathine; Prorex; Protazine; Prothazin; Prothazine; Provigan; Pyrethia; Pyrethiazine; Remsed; Romergan; Rumergan; Tanidil; Thiergan; Valergine; Vallergine; Lilly 01516; Lilly 1516; RP 3277; SKF 1498; WY 509; A-91033; Atosil (TN); Avomine (TN); Fargan (TN); Farganesse (TN); Lergigan (TN); Phenergan (TN); Phenoject-50; Pro-50; Prometazina [INN-Spanish]; Promethazine [INN:BAN]; Promethazinum [INN-Latin]; Promethegan (TN); Prothiazine (TN); Receptozine (TN); Romergan (TN); Zipan-25; Dimethylamino-isopropyl-phenthiazin; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN)
DM6I5GR	CP	Wyeth Pharmaceuticals
DM6I5GR	TC	Antiallergic Agents
DM6I5GR	DT	Small molecular drug
DM6I5GR	PC	4927
DM6I5GR	MW	284.4
DM6I5GR	FM	C17H20N2S
DM6I5GR	IC	InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
DM6I5GR	CS	CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
DM6I5GR	IK	PWWVAXIEGOYWEE-UHFFFAOYSA-N
DM6I5GR	IU	N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
DM6I5GR	CA	CAS 60-87-7
DM6I5GR	CB	CHEBI:8461
DM6I5GR	DE	Nausea

DMPIBJK	ID	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	HS	Approved
DMPIBJK	SN	Propafenona; Propafenonum; Rythmol; Propafenon Hexal; Propafenon hexal (TN); Propafenona [INN-Spanish]; Propafenone (INN); Propafenone [INN:BAN]; Propafenone-HCl; Propafenonum [INN-Latin]; Rythmol SR (TN); Rytmonorm (TN); 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; 1-[2-(2-Hydroxy-3-[propylamino]-propoxy)phenyl]-3-phenyl-1-propanone; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
DMPIBJK	CP	Reliant Pharmaceuticals
DMPIBJK	TC	Antiarrhythmic Agents
DMPIBJK	DT	Small molecular drug
DMPIBJK	PC	4932
DMPIBJK	MW	341.4
DMPIBJK	FM	C21H27NO3
DMPIBJK	IC	InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3
DMPIBJK	CS	CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
DMPIBJK	IK	JWHAUXFOSRPERK-UHFFFAOYSA-N
DMPIBJK	IU	1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
DMPIBJK	CA	CAS 54063-53-5
DMPIBJK	CB	CHEBI:63619
DMPIBJK	DE	Tachyarrhythmias

DM2EN6G	ID	DM2EN6G
DM2EN6G	DN	Propantheline
DM2EN6G	HS	Approved
DM2EN6G	SN	Corrigast; Ercorax; Ercotina; Ketaman; Kivatin; Neometantyl; Neopepulsan; Pantas; Pantheline; Pervagal; Probanthine; Probantine; Prodixamon; Propantel; Propanthel; Propanthelinium; Propanthelinum; Bromure de propantheline; Bromuro de proantelina; PROPANTHELINE BROMIDE; Propantelina bromuro; Propantelina bromuro [DCIT];Propanthelini bromidum; P 8891; Bromure de propantheline [INN-French]; Bromuro de proantelina [INN-Spanish]; Pro-Banthine; Pro-Gastron; Propanthelini bromidum [INN-Latin]; SC-3171; Pro-Banthine (TN);Propantheline bromide (JP15/USP/INN); Propantheline bromide [USAN:INN:BAN:JAN]; Diisopropyl(2-hydroxyethyl)methylammonium bromide xanthene-9-carboxylate; Xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethylammonium bromide; Ammonium, (2-hydroxyethyl)diisopropylmethyl-, xanthene-9-carboxylate (ester); Ammonium, diisopropyl(2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide; N-methyl-N-(1-methylethyl)-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate bromide; 2-Hydroxyethyl]diisopropylmethyl-ammonium bromide xanthene-9-carboxylate; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide (1:1)
DM2EN6G	TC	Antispasmodics
DM2EN6G	DT	Small molecular drug
DM2EN6G	PC	4934
DM2EN6G	MW	368.5
DM2EN6G	FM	C23H30NO3+
DM2EN6G	IC	InChI=1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1
DM2EN6G	CS	CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C
DM2EN6G	IK	VVWYOYDLCMFIEM-UHFFFAOYSA-N
DM2EN6G	IU	methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
DM2EN6G	CA	CAS 298-50-0
DM2EN6G	CB	CHEBI:8481
DM2EN6G	DE	Stomach ulcer; Excessive sweating

DMLS39E	ID	DMLS39E
DMLS39E	DN	Proparacaine
DMLS39E	HS	Approved
DMLS39E	SN	Alcaine; Diocaine; Kainair; Ophthaine; Ophthetic; Paracaine; Prossimetacaina; Proximetacaina; Proximetacainum; Proxymetacaine; Proxymetacainum; Prossimetacaina [DCIT]; Proxymetacaine Hcl; Ak-taine; Alcaine (TN); Ocu-Caine; Proximetacaina [INN-Spanish]; Proxymetacaine (INN); Proxymetacaine [INN:BAN]; Proxymetacainum [INN-Latin]; Spectro-Caine; Ak-Taine (TN); Beta-(Diethylamino)ethyl 4-n-propoxybenzoate; BENZOIC ACID, 3-AMINO-4-PROPOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate; 2-diethylaminoethyl 3-amino-4-propoxybenzoate; 3-Amino-4-propoxybenzoic acid 2-(diethylamino)ethyl ester
DMLS39E	TC	Anesthetics
DMLS39E	DT	Small molecular drug
DMLS39E	PC	4935
DMLS39E	MW	294.39
DMLS39E	FM	C16H26N2O3
DMLS39E	IC	InChI=1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3
DMLS39E	CS	CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N
DMLS39E	IK	KCLANYCVBBTKTO-UHFFFAOYSA-N
DMLS39E	IU	2-(diethylamino)ethyl 3-amino-4-propoxybenzoate
DMLS39E	CA	CAS 499-67-2
DMLS39E	CB	CHEBI:8485
DMLS39E	DE	Anaesthesia

DM6JQ2I	ID	DM6JQ2I
DM6JQ2I	DN	Propentofylline propionate
DM6JQ2I	HS	Approved
DM6JQ2I	SN	Hextol (TN)
DM6JQ2I	DT	Small molecular drug
DM6JQ2I	PC	4938
DM6JQ2I	MW	306.36
DM6JQ2I	FM	C15H22N4O3
DM6JQ2I	IC	InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
DM6JQ2I	CS	CCCN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(=O)C
DM6JQ2I	IK	RBQOQRRFDPXAGN-UHFFFAOYSA-N
DM6JQ2I	IU	3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione
DM6JQ2I	CA	CAS 55242-55-2
DM6JQ2I	CB	CHEBI:32061
DM6JQ2I	DE	Alzheimer disease

DME9JNL	ID	DME9JNL
DME9JNL	DN	Propericiazine
DME9JNL	HS	Approved
DME9JNL	SN	Aolept; Nemactil; Neulactil; Neuleptil; PERICYAZINE; Periciazina; Periciazine; Periciazinum; Piperocyanomazine;Periciazine [INN]; Bayer 1409; IC 6002; RP 8908; WH 7508; Neulactil (TN); Neuleptil (TN); Periciazina [INN-Spanish]; Periciazinum [INN-Latin]; Propericiazine (JAN); Propericiazine(jan); SKF 20,716; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine [French]; 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile; 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine; 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine; 6909 RP
DME9JNL	CP	Sanofi-Aventis
DME9JNL	TC	Antipsychotic Agents
DME9JNL	DT	Small molecular drug
DME9JNL	PC	4747
DME9JNL	MW	365.5
DME9JNL	FM	C21H23N3OS
DME9JNL	IC	InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
DME9JNL	CS	C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N
DME9JNL	IK	LUALIOATIOESLM-UHFFFAOYSA-N
DME9JNL	IU	10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile
DME9JNL	CA	CAS 2622-26-6
DME9JNL	CB	CHEBI:31981
DME9JNL	DE	Psychiatric disorder

DMWDHUZ	ID	DMWDHUZ
DMWDHUZ	DN	Propicillin
DMWDHUZ	HS	Approved
DMWDHUZ	SN	Propicillin; propicilline; Propicilina; Propicillinum; 551-27-9; UNII-8X1R260V33; phenoxypropylpenicillin; CHEBI:52429; 8X1R260V33; 6beta-(2-phenoxybutanamido)-2,2-dimethylpenam-3alpha-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxybutanoyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (1-Phenoxypropyl)penicillin; Propicillinum [INN-Latin]; Propicilina [INN-Spanish]; Propicilline [INN-French]; Propicillin [INN:BAN:DCF]; Propicillin (BAN); EINECS 208-995-5; AC1Q5QWR; NCGC00160673-01; AC1L3P0Y
DMWDHUZ	DT	Small molecular drug
DMWDHUZ	PC	92879
DMWDHUZ	MW	378.4
DMWDHUZ	FM	C18H22N2O5S
DMWDHUZ	IC	InChI=1S/C18H22N2O5S/c1-4-11(25-10-8-6-5-7-9-10)14(21)19-12-15(22)20-13(17(23)24)18(2,3)26-16(12)20/h5-9,11-13,16H,4H2,1-3H3,(H,19,21)(H,23,24)/t11?,12-,13+,16-/m1/s1
DMWDHUZ	CS	CCC(C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)OC3=CC=CC=C3
DMWDHUZ	IK	HOCWPKXKMNXINF-XQERAMJGSA-N
DMWDHUZ	IU	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxybutanoylamino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMWDHUZ	CA	CAS 551-27-9
DMWDHUZ	CB	CHEBI:52429
DMWDHUZ	DE	Bacterial infection

DMKY8V1	ID	DMKY8V1
DMKY8V1	DN	Propiomazine
DMKY8V1	HS	Approved
DMKY8V1	SN	Phenoctyl; Propiomazina; Propiomazinum; Propionylpromethazine; Dorevan (TN); Dorevane (TN); Indorm (TN); Largon (TN); Propavan (TN); Propiomazina [INN-Spanish]; Propiomazinum [INN-Latin]; Serentin (TN); Wy-1359; Propiomazine (USAN/INN); Propiomazine [USAN:BAN:INN]; Propiomazine [USAN:INN:BAN]; 1-(10-(2-(Dimethylamino)propyl)phenothiazin-2-yl)-1-propanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one; 10-(2-Dimethylaminopropyl)-2-propionylphenothiazine; 10-Dimethylaminoisopropyl-2-propionylphenothiazine; 2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine; 3-Propionyl-10-dimethylaminoisopropylphenothiazine
DMKY8V1	CP	Hikma Maple Ltd
DMKY8V1	TC	Sedatives and Hypnotics
DMKY8V1	DT	Small molecular drug
DMKY8V1	PC	4940
DMKY8V1	MW	340.5
DMKY8V1	FM	C20H24N2OS
DMKY8V1	IC	InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3
DMKY8V1	CS	CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)N(C)C
DMKY8V1	IK	UVOIBTBFPOZKGP-UHFFFAOYSA-N
DMKY8V1	IU	1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one
DMKY8V1	CA	CAS 362-29-8
DMKY8V1	CB	CHEBI:8491
DMKY8V1	DE	Insomnia

DMUWBIJ	ID	DMUWBIJ
DMUWBIJ	DN	Propiverine
DMUWBIJ	HS	Approved
DMUWBIJ	SN	propiverine hydrochloride; 54556-98-8; Propiverine HCl; Mictonorm; Propiverine Hydrochlorride; UNII-DC4GZD10H3; (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride; DSSTox_RID_81957; DSSTox_CID_26847; DSSTox_GSID_46847; C23H29NO3.HCl; DC4GZD10H3; CAS-54556-98-8; NCGC00181103-01; Mictonetten; Pollarine; Mictonorm (TN); propiverin hydrochloride; Bup-4 (TN); AC1L9B4A; CHEBI:8494; SCHEMBL1034248; DTXSID1046847; CHEMBL2359059; Propiverine hydrochloride (JP17); KFUJMHHNLGCTIJ-UHFFFAOYSA-N; BCP09576; Tox21_112719; NSC172140
DMUWBIJ	DT	Small molecular drug
DMUWBIJ	PC	4942
DMUWBIJ	MW	367.5
DMUWBIJ	FM	C23H29NO3
DMUWBIJ	IC	InChI=1S/C23H29NO3/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21/h4-13,21H,3,14-18H2,1-2H3
DMUWBIJ	CS	CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C
DMUWBIJ	IK	QPCVHQBVMYCJOM-UHFFFAOYSA-N
DMUWBIJ	IU	(1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate
DMUWBIJ	CA	CAS 60569-19-9
DMUWBIJ	CB	CHEBI:8493
DMUWBIJ	DE	Urinary incontinence

DMB4OLE	ID	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	HS	Approved
DMB4OLE	SN	Ampofol; Aquafol; Diisopropylphenol; Dipravan; Diprivan; Disoprivan; Disoprofol; Fresofol; Ivofol; PFL; Propofolum; Rapinovet; Recofol; Abbott Brand of Propofol; Alpha Brand of Propofol; Astra Brand of Propofol; AstraZeneca Brand of Propofol; Braun Brand of Propofol; Curamed Brand of Propofol; Diprivan Injectable emulsion; Fresenius Brand of Propofol; Fresenius Kabi Brand of Propofol; Juste Brand of Propofol; Parnell Brand of Propofol; Pisa Brand of Propofol; Propofol Abbott; Propofol Fresenius; Propofol MCT; Propofol Rovi; Propofolum [Latin]; Rovi Brand of Propofol; Schering Brand of Propofol; Zeneca Brand of Propofol; AM-149; DDS-04F; Diprivan (TN); Propofol IDD-D; Propofol-Lipuro; ZD-0859; Ghl.PD_Mitscher_leg0.558; Propofol [USAN:INN:BAN]; Propofol (JAN/USAN/INN); Propofol(2,6-Diisopropylphenol); 2, 6-Diisopropylphenol; 2,6 Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; 2,6-Bis(Isopropyl)-phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-Diisopropylphenol; 2,6-bis(1-methylethyl)-phenol; 2,6-di(propan-2-yl)phenol
DMB4OLE	CP	AstraZeneca
DMB4OLE	TC	Hypnotics and Sedatives
DMB4OLE	DT	Small molecular drug
DMB4OLE	PC	4943
DMB4OLE	MW	178.27
DMB4OLE	FM	C12H18O
DMB4OLE	IC	InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
DMB4OLE	CS	CC(C)C1=C(C(=CC=C1)C(C)C)O
DMB4OLE	IK	OLBCVFGFOZPWHH-UHFFFAOYSA-N
DMB4OLE	IU	2,6-di(propan-2-yl)phenol
DMB4OLE	CA	CAS 2078-54-8
DMB4OLE	CB	CHEBI:44915
DMB4OLE	DE	Anaesthesia

DMMSOLA	ID	DMMSOLA
DMMSOLA	DN	Propoxyphene Hydrochloride
DMMSOLA	HS	Approved
DMMSOLA	SN	Darvon; Dolene; Kesso-gesic; Prophene 65; Propoxyphene Hydrochloride 65; Darvon-n; Propoxyphene Napsylate
DMMSOLA	CP	Xanodyne Pharmaceutics Inc
DMMSOLA	TC	Neurology Agents
DMMSOLA	DT	Small molecular drug
DMMSOLA	PC	15424
DMMSOLA	MW	375.9
DMMSOLA	FM	C22H30ClNO2
DMMSOLA	IC	InChI=1S/C22H29NO2.ClH/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;/h6-15,18H,5,16-17H2,1-4H3;1H/t18-,22+;/m1./s1
DMMSOLA	CS	CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C.Cl
DMMSOLA	IK	QMQBBUPJKANITL-MYXGOWFTSA-N
DMMSOLA	IU	[(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;hydrochloride
DMMSOLA	CA	CAS 1639-60-7
DMMSOLA	CB	CHEBI:8498
DMMSOLA	DE	Pain

DM79NTF	ID	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	HS	Approved
DM79NTF	SN	Anaprilin; Anapriline; Avlocardyl; Bedranol; Berkolol; Betachron; Betadren; Betalong; Caridolol; Corpendol; Dociton; Efektolol; Etalong; Euprovasin; Herzbase; Ikopal; Inderal; Inderalici; Inderex; Inderol; Intermigran; Kemi; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propranalol; Propranololo; Propranololum; Proprasylyt; Reducor; Sawatal; Servanolol; Sumial; Beta Neg; Inderal hydrochloride; Kemi S; Propranolol Hcl Intensol; Propranololo [DCIT]; Racemic propranolol; Reducorline; AY 64043; AY-20694; Anaprilinum (TN); Avlocardyl (TN); Beta-Propranolol; Beta-Tablinen; Beta-Timelets; DL-Propranolol hydrochloride; Deralin (TN); Dociton (TN); Inderal (TN); Inderal LA (TN); Inderalici (TN); InnoPran XL (TN); Propanolol [INN-Spanish]; Propranolol (INN); Propranolol (TN); Propranolol [INN:BAN]; Propranololum [INN-Latin]; Sumial (TN); D,L-Propranolol; INDERIDE-40/25; R,S-Propranolol Hydrochloride; (+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
DM79NTF	CP	AstraZeneca plc
DM79NTF	TC	Antianxiety Agents
DM79NTF	DT	Small molecular drug
DM79NTF	PC	4946
DM79NTF	MW	259.339
DM79NTF	FM	C16H21NO2
DM79NTF	IC	InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
DM79NTF	CS	CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
DM79NTF	IK	AQHHHDLHHXJYJD-UHFFFAOYSA-N
DM79NTF	IU	1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
DM79NTF	CA	CAS 525-66-6
DM79NTF	CB	CHEBI:8499
DM79NTF	DE	Migraine

DMTBW2O	ID	DMTBW2O
DMTBW2O	DN	Propylhexedrine
DMTBW2O	HS	Approved
DMTBW2O	SN	Propylhexedrine hydrochloride; Eggobesin; Eventin hydrochloride; Benzedrex hydrochloride; Pernsator-wirkstoff; dl-Propylhexedrine Hydrochloride; 1007-33-6; Cyclohexylisopropylmethylamine hydrochloride; NSC 27110; NSC 170998; Cyclohexyl(isopropyl)methylammonium chloride; 1-Cyclohexyl-2-methylaminopropane hydrochloride; EINECS 213-753-7; (+-)-Propylhexedrine hydrochloride; N,alpha-Dimethylcyclohexaneethylamine hydrochloride; Propylhexedrine dl-form hydrochloride; Cyclohexaneethylamine, N,alpha-dimethyl-, hydrochloride
DMTBW2O	DT	Small molecular drug
DMTBW2O	PC	7558
DMTBW2O	MW	155.28
DMTBW2O	FM	C10H21N
DMTBW2O	IC	InChI=1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3
DMTBW2O	CS	CC(CC1CCCCC1)NC
DMTBW2O	IK	JCRIVQIOJSSCQD-UHFFFAOYSA-N
DMTBW2O	IU	1-cyclohexyl-N-methylpropan-2-amine
DMTBW2O	CA	CAS 101-40-6
DMTBW2O	CB	CHEBI:134783
DMTBW2O	DE	Obesity

DM6D7N8	ID	DM6D7N8
DM6D7N8	DN	Propylthiouracil
DM6D7N8	HS	Approved
DM6D7N8	SN	propylthiouracil; 51-52-5; 6-Propyl-2-thiouracil; Propacil; Prothyran; Prothiurone; Procasil; Propycil; Thiuragyl; Protiural; Prothiucil; Prothycil; Propyl-Thiorist; Propyl-Thyracil; 2-Mercapto-6-propylpyrimidin-4-ol; 6-N-Propylthiouracil; Propythiouracil; Propilthiouracil; Propyl-Thiorit; Propylthiorit; 6-Propylthiouracil; Propylthiouracile; Thyreostat II; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; Propiltiouracilo; 6-N-Propyl-2-thiouracil; 6-Thio-4-propyluracil; PTU (thyreostatic); Propylthiouracilum; 4-Propyl-2-thiouracil;  Procasil; Propiltiouracile; PROPYL THIOURACIL; Propiltiouracile [DCIT]; Thyreos tat ii; HC210060; Propiltiouracilo [INN-Spanish]; Propylthiouracil (TN); Propylthiouracile [INN-French]; Propylthiouracilum [INN-Latin]; Ptu(thyreostatic); T0517-6237; Thyreostat propyl-thyracil; Propylthiouracil [INN:BAN:JAN]; Propylthiouracil (JP15/USP/INN); 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone; 2-Mercapto-4-hydroxy-6-n-propylpyrimidine; 2-Mercapto-6-propyl-4-pyrimidone; 2-Mercapto-6-propylpyrimid-4-one; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 4-Hydroxy-2-mercapto-6-propylpyrimidine; 6 Propyl 2 Thiouracil; 6-(n-Propyl)-2-thiouracil; 6-Prop yl-2-thiouracil; 6-Propil-tiouracile; 6-Propil-tiouracile [Italian]; 6-Propyl-2-thio-2,4(1H,3H)-pyrimidinedione; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; 6-n-PROPYL-2-MERCAPTO-4-HYDROXYPYRIMIDINE; 6-propyl-2 thiouracil; 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one; 6-propyl-2-thiopyrimidine-2,4(1H,3H)-dione; Propyl thiouracile
DM6D7N8	TC	Antithyroid Agents
DM6D7N8	DT	Small molecular drug
DM6D7N8	PC	657298
DM6D7N8	MW	170.23
DM6D7N8	FM	C7H10N2OS
DM6D7N8	IC	InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)
DM6D7N8	CS	CCCC1=CC(=O)NC(=S)N1
DM6D7N8	IK	KNAHARQHSZJURB-UHFFFAOYSA-N
DM6D7N8	IU	6-propyl-2-sulfanylidene-1H-pyrimidin-4-one
DM6D7N8	CA	CAS 51-52-5
DM6D7N8	CB	CHEBI:8502
DM6D7N8	DE	Hyperthyroidism

DMX0EZJ	ID	DMX0EZJ
DMX0EZJ	DN	Prothionamide
DMX0EZJ	HS	Approved
DMX0EZJ	SN	Ektebin; Peteha; Prothionamidum; Protionamid; Protionamida; Protionamide; Protionamidum; Protionizina; Tebeform; Trevintix; Tuberex; RP 9778; TH 1321; Prothionamide (JP15); Protionamida [INN-Spanish]; Protionamide (INN); Protionamide [INN:DCF]; Protionamidum [INN-Latin]; TH-1321; Trevintix (TN); 2-Propyl-4-pyridinecarbothioamide; 2-Propyl-4-thiocarbamoylpyridine; 2-Propyl-thioisonicotinamide; 2-Propylisonicotinylthioamide; 2-Propylthioisonicotinamide; 2-propylpyridine-4-carbothioamide; 4-Pyridinecarbothioamide, 2-propyl-(9CI); 9778 R.P; 9778 R.P.
DMX0EZJ	TC	Antituberculosis Agents
DMX0EZJ	DT	Small molecular drug
DMX0EZJ	PC	666418
DMX0EZJ	MW	180.27
DMX0EZJ	FM	C9H12N2S
DMX0EZJ	IC	InChI=1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12)
DMX0EZJ	CS	CCCC1=NC=CC(=C1)C(=S)N
DMX0EZJ	IK	VRDIULHPQTYCLN-UHFFFAOYSA-N
DMX0EZJ	IU	2-propylpyridine-4-carbothioamide
DMX0EZJ	CA	CAS 14222-60-7
DMX0EZJ	CB	CHEBI:32066
DMX0EZJ	DE	Tuberculosis

DMGN5QD	ID	DMGN5QD
DMGN5QD	DN	Protirelin
DMGN5QD	HS	Approved
DMGN5QD	SN	24305-27-9; Hirtonin; TRH-SR, Takeda; protirelin
DMGN5QD	CP	Abbott Laboratories Pharmaceutical Products Div
DMGN5QD	TC	Neurology Agents
DMGN5QD	DT	Small molecular drug
DMGN5QD	PC	638678
DMGN5QD	MW	362.38
DMGN5QD	FM	C16H22N6O4
DMGN5QD	IC	InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1
DMGN5QD	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N
DMGN5QD	IK	XNSAINXGIQZQOO-SRVKXCTJSA-N
DMGN5QD	IU	(2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMGN5QD	CA	CAS 24305-27-9
DMGN5QD	CB	CHEBI:35940
DMGN5QD	DE	Central nervous system disease

DMAHZKR	ID	DMAHZKR
DMAHZKR	DN	Protokylol Hydrochloride
DMAHZKR	HS	Approved
DMAHZKR	SN	Ventaire
DMAHZKR	CP	Sanofi Aventis Us Llc
DMAHZKR	DT	Small molecular drug
DMAHZKR	PC	8699
DMAHZKR	MW	367.8
DMAHZKR	FM	C18H22ClNO5
DMAHZKR	IC	InChI=1S/C18H21NO5.ClH/c1-11(6-12-2-5-17-18(7-12)24-10-23-17)19-9-16(22)13-3-4-14(20)15(21)8-13;/h2-5,7-8,11,16,19-22H,6,9-10H2,1H3;1H
DMAHZKR	CS	CC(CC1=CC2=C(C=C1)OCO2)NCC(C3=CC(=C(C=C3)O)O)O.Cl
DMAHZKR	IK	LOVXREQUMZKFCM-UHFFFAOYSA-N
DMAHZKR	IU	4-[2-[1-(1,3-benzodioxol-5-yl)propan-2-ylamino]-1-hydroxyethyl]benzene-1,2-diol;hydrochloride
DMAHZKR	CA	CAS 136-69-6
DMAHZKR	DE	Asthma

DMNHTZI	ID	DMNHTZI
DMNHTZI	DN	Protriptyline
DMNHTZI	HS	Approved
DMNHTZI	SN	Amimetilina; Impril; Maximed; Novopramine; Protriptilina; Protriptylinum; Protryptyline; Rhotrimine; Triptil; Triptyl; Vivactil; Vivactyl; Triptil hydrochloride; Normethyl EX4442; Triadapin 5; Apo-Imipramine; Apo-Trimip; Novo-Doxepin; Novo-Tripramine; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum [INN-Latin]; Vivactil (TN); N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
DMNHTZI	CP	Teva Womens Health Inc
DMNHTZI	TC	Antidepressants
DMNHTZI	DT	Small molecular drug
DMNHTZI	PC	4976
DMNHTZI	MW	263.4
DMNHTZI	FM	C19H21N
DMNHTZI	IC	InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
DMNHTZI	CS	CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13
DMNHTZI	IK	BWPIARFWQZKAIA-UHFFFAOYSA-N
DMNHTZI	IU	N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyl)propan-1-amine
DMNHTZI	CA	CAS 438-60-8
DMNHTZI	CB	CHEBI:8597
DMNHTZI	DE	Depression

DMGKT2L	ID	DMGKT2L
DMGKT2L	DN	Pro-urokinase
DMGKT2L	HS	Approved
DMGKT2L	SN	Thrombolyse (TN)
DMGKT2L	DE	Thrombin deficiency

DMOK965	ID	DMOK965
DMOK965	DN	Prulifloxacin
DMOK965	HS	Approved
DMOK965	SN	123447-62-1; NM441; NM 441; NM-441; Prulifloxacin (hydrochloride); 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; NCGC00164615-01; Quisnon; DSSTox_CID_26480; DSSTox_RID_81651; DSSTox_GSID_46480; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-; 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; Prulifloxacin [INN]; Pruvel; Sword; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; CCRIS 7686; CAS-123447-62-1; Pufloxacin dioxolil; 6-fluoro-1-methyl-7-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; MLS006011767; CHEMBL422648; NAD-441A; OPT-99; SCHEMBL1650794; DTXSID0046480; CHEBI:32071; AOB5600; BCP12727; HY-B0024; Tox21_112235; BBL034010; MFCD00864847; s2071; STK626148; AKOS005559236; Prulifloxacin (NM441, AF 3013); Tox21_112235_1; AC-2012; DB11892; MCULE-8435182996; SB18983; NCGC00164615-02; NCGC00164615-03; (+-)-7-(4-((Z)-2,3-Dihydroxy-2-butenyl)-1-piperazinyl)-6-fluoro-1-methyl-4-oxo-1H,4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, cyclic carbonate; AK144730; AS-13607; I926; SMR000046722; AB0013936; FT-0651733; P2058; Prulifloxacin 100 microg/mL in Acetonitrile; K-1771; 447P621; Prulifloxacin, >=98% (perchloric acid titration); SR-01000872596; Prulifloxacin, Antibiotic for Culture Media Use Only; Q-101929; Q3924793; SR-01000872596-1; BRD-A92341659-001-01-6
DMOK965	DT	Small molecular drug
DMOK965	PC	65947
DMOK965	MW	461.5
DMOK965	FM	C21H20FN3O6S
DMOK965	IC	InChI=1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)
DMOK965	CS	CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C
DMOK965	IK	PWNMXPDKBYZCOO-UHFFFAOYSA-N
DMOK965	IU	6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
DMOK965	CA	CAS 123447-62-1
DMOK965	CB	CHEBI:32071
DMOK965	DE	Urinary tract infection

DMIVJ0D	ID	DMIVJ0D
DMIVJ0D	DN	Pseudoephedrine
DMIVJ0D	HS	Approved
DMIVJ0D	SN	Balminil Decongestant Syrup; Dimetapp Decongestant; Dimetapp Decongestant Pediatric Drops; Drixoral Nasal Decongestant; Pseudoephedrine Ephedrine; Sudafed Decongestant Extra Strength; Triaminic AM Decongestant Formula; Triaminic Infant Oral Decongestant Drops; Efidac 24 PseudoephedrineHcl; Sudafed Decongestant 12 Hour; Pseudoefedrina [INN-Spanish]; Pseudoephedrine (INN); Pseudoephedrine [INN:BAN]; Pseudoephedrine d-form; Pseudoephedrinum [INN-Latin]; Sudafed (TN); Alpha-(1-(Methylamino)ethyl)benzyl alcohol; D-psi-2-Methylamino-1-phenyl-1-propanol; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-(9CI); (+)-(1S,2S)-Pseudoephedrine; (1S,2S)-(+)-Pseudoephedrine; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; (1S,2S)-2-Methylamino-1-phenyl-1-propanol; (1S,2S)-Pseudoephedrine; (1S,2S)-Pseudoephedrine, polymer-bound
DMIVJ0D	CP	Pfizer Pharmaceuticals
DMIVJ0D	DT	Small molecular drug
DMIVJ0D	PC	7028
DMIVJ0D	MW	165.23
DMIVJ0D	FM	C10H15NO
DMIVJ0D	IC	InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1
DMIVJ0D	CS	C[C@@H]([C@H](C1=CC=CC=C1)O)NC
DMIVJ0D	IK	KWGRBVOPPLSCSI-WCBMZHEXSA-N
DMIVJ0D	IU	(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
DMIVJ0D	CA	CAS 90-82-4
DMIVJ0D	CB	CHEBI:51209
DMIVJ0D	DE	Nasal congestion

DMLSUWZ	ID	DMLSUWZ
DMLSUWZ	DN	PSI-7977
DMLSUWZ	HS	Approved
DMLSUWZ	SN	1190307-88-0; SOVALDI; PSI 7977; GS-7977; GS 7977; UNII-WJ6CA3ZU8B; WJ6CA3ZU8B; CHEBI:85083; Sofosbuvir (PSI-7977, GS-7977); Hepcvir; Hepcinat; HSDB 8226; 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; Sofosbuvir [USAN:INN]; Resof; SoviHep; Sovaldi (TN); Sofosbuvir (JAN/USAN); Sofosbuvir(PSI-7977); GTPL7368; SCHEMBL2010114; CHEMBL1259059; AMMD00019; EX-A389; MolPort-028-720-482; isopropyl (2S)-2-[[[(2R,
DMLSUWZ	CP	Gilead Sciences
DMLSUWZ	DT	Small molecular drug
DMLSUWZ	PC	45375808
DMLSUWZ	MW	529.5
DMLSUWZ	FM	C22H29FN3O9P
DMLSUWZ	IC	InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
DMLSUWZ	CS	C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DMLSUWZ	IK	TTZHDVOVKQGIBA-IQWMDFIBSA-N
DMLSUWZ	IU	propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMLSUWZ	CA	CAS 1190307-88-0
DMLSUWZ	CB	CHEBI:85083
DMLSUWZ	DE	HCV 1-6 infection; Hepatitis C virus infection

DMWLTU2	ID	DMWLTU2
DMWLTU2	DN	PSMA-11 Ga-68
DMWLTU2	HS	Approved
DMWLTU2	SN	UNII-ZJ0EKR6M10; ZJ0EKR6M10; Prostamedix; (68Ga)Hbed-psma; 68ga-psma-hbed-cc; (68ga)psma-hbed-cc; 68Ga-Psma-11; Gallium Ga-68 gozetotide; Gallium gozetotide Ga-68; Ga-Psma-hbed-CC Ga-68; Gallium (68Ga) gozetotide; Ga-68-Labeled PSMA-11; Ga-68 PSMA-11; PSMA-11 Ga 68; DKFZ-PSMA-11 GA-68; Gallium (68Ga) gozetotide [INN]; Glu-urea-Lys(ahx)-hbed-CC Ga-68; (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-Labelled Glu-urea-Lys(ahx)-hbed-CC; Glu-NH-CO-NH-Lys-(ahx)-(68Ga(hbed-CC)); (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC; Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC; 1906894-20-9
DMWLTU2	DT	Radioactive diagnostic agent
DMWLTU2	PC	154572876
DMWLTU2	MW	1011.9
DMWLTU2	FM	C44H59GaN6O17
DMWLTU2	IC	InChI=1S/C44H62N6O17.Ga/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58;/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67);/q;+3/p-3/t32-,33-;/m0./s1/i;1-2
DMWLTU2	CS	[H+].C1=CC(=C(C=C1CCC(=O)NCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CN(CCN(CC2=C(C=CC(=C2)CCC(=O)O)[O-])CC(=O)[O-])CC(=O)[O-])[O-].[68Ga+3]
DMWLTU2	IK	AEBYHKKMCWUMKX-LNTZDJBBSA-K
DMWLTU2	IU	2-[[5-[3-[[6-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-6-oxohexyl]amino]-3-oxopropyl]-2-oxidophenyl]methyl-[2-[[5-(2-carboxyethyl)-2-oxidophenyl]methyl-(carboxylatomethyl)amino]ethyl]amino]acetate;gallium-68(3+);hydron
DMWLTU2	CA	CAS 1906894-20-9
DMWLTU2	DE	Diagnostic imaging

DMG2X3E	ID	DMG2X3E
DMG2X3E	DN	Pyrantel
DMG2X3E	HS	Approved
DMG2X3E	SN	PYRANTEL; Pyrequan; 15686-83-6; Strongid; Pirantele [DCIT]; Pyrantelum; Pirantel; Pyrantel [INN:BAN]; Pyrantelum [INN-Latin]; Pirantel [INN-Spanish]; UNII-4QIH0N49E7; HSDB 3252; EINECS 239-774-1; CHEBI:8654; 4QIH0N49E7; (E)-1-Methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine; E-1,4,5,6-Tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine; Pirantele; 1-methyl-2-[(E)-2-(2-thienyl)vinyl]-5,6-dihydro-4H-pyrimidine; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)-, (E)-; Pin-X
DMG2X3E	DT	Small molecular drug
DMG2X3E	PC	708857
DMG2X3E	MW	206.31
DMG2X3E	FM	C11H14N2S
DMG2X3E	IC	InChI=1S/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3/b6-5+
DMG2X3E	CS	CN1CCCN=C1/C=C/C2=CC=CS2
DMG2X3E	IK	YSAUAVHXTIETRK-AATRIKPKSA-N
DMG2X3E	IU	1-methyl-2-[(E)-2-thiophen-2-ylethenyl]-5,6-dihydro-4H-pyrimidine
DMG2X3E	CA	CAS 15686-83-6
DMG2X3E	CB	CHEBI:8654
DMG2X3E	DE	Worm infection

DM4IF32	ID	DM4IF32
DM4IF32	DN	Pyrazinamide
DM4IF32	HS	Approved
DM4IF32	SN	Aldinamid; Aldinamide; Braccopiral; Corsazinmid; Dipimide; Eprazin; Farmizina; Isopas; Lynamide; Novamid; Pezetamid; Pharozinamide; Piraldina; Pirazimida; Pirazinamid; Pirazinamida; Pirazinamide; Prazina; Pyrafat; Pyramide; Pyrazide; Pyrazinamdie; Pyrazinamidum; Pyrazineamide; Pyrazinecarboxamide; Rozide; Tebrazid; Tebrazio; Tisamid; Unipyranamide; Zinamide; Zinastat; P ezetamid; Pirazinamide [DCIT]; Pyrazine carboxamide; Pyrazine carboxylamide; Pyrazinecarboxylic acid amide; Pyrazinoic acid am ide; Pyrazinoic acid amide; DRG 0124; MK 56; P 7136; Pyrazinamide BP 2000; T 165; AZT + Pyrazinamide combination; D-50; Pirazinamida [INN-Spanish]; Pms-Pyrazinamide; Pyrazinamide (TN); Pyrazinamidum [INN-Latin]; D-50 (VAN); Pyrazinamide [INN:BAN:JAN]; Pyrazine-2-carboxamide; Pyrazinamide (JP15/USP/INN); Pyrazinoic acid amide, Pezetamid, Pyrafat, Zinamide, Tebrazid, Pyrafat, Pyrazinamide; 2-Carbamylpyrazine; 2-carbamyl pyrazine
DM4IF32	TC	Antitubercular Agents
DM4IF32	DT	Small molecular drug
DM4IF32	PC	1046
DM4IF32	MW	123.11
DM4IF32	FM	C5H5N3O
DM4IF32	IC	InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
DM4IF32	CS	C1=CN=C(C=N1)C(=O)N
DM4IF32	IK	IPEHBUMCGVEMRF-UHFFFAOYSA-N
DM4IF32	IU	pyrazine-2-carboxamide
DM4IF32	CA	CAS 98-96-4
DM4IF32	CB	CHEBI:45285
DM4IF32	DE	Mycobacterium infection

DM8HO1L	ID	DM8HO1L
DM8HO1L	DN	Pyridostigmine
DM8HO1L	HS	Approved
DM8HO1L	SN	Pyridostigminum; Pyridostigmine Bromine; Mestinon (TN); Mestinon-SR; Regonol (TN); AQ-776/42801589; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-(9CI); (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate; 1-methyl-3-pyridiniumyl dimethylcarbamate; 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium
DM8HO1L	CP	Valeant Pharmaceuticals
DM8HO1L	TC	Parasympathomimetics
DM8HO1L	DT	Small molecular drug
DM8HO1L	PC	4991
DM8HO1L	MW	181.21
DM8HO1L	FM	C9H13N2O2+
DM8HO1L	IC	InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1
DM8HO1L	CS	C[N+]1=CC=CC(=C1)OC(=O)N(C)C
DM8HO1L	IK	RVOLLAQWKVFTGE-UHFFFAOYSA-N
DM8HO1L	IU	(1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate
DM8HO1L	CA	CAS 155-97-5
DM8HO1L	CB	CHEBI:8665
DM8HO1L	DE	Myasthenia gravis

DMO2K0J	ID	DMO2K0J
DMO2K0J	DN	Pyridoxal Phosphate
DMO2K0J	HS	Approved
DMO2K0J	SN	Pyridoxal phosphate; pyridoxal phosphate; Codecarboxylase; pyridoxal 5-phosphate; 54-47-7; pyridoxal 5'-phosphate; Pyridoxal P; Pyromijin; Hairoxal; Vitazechs; Biosechs; Pyridoxal-5'-phosphate; Hiadelon; Pidopidon; Himitan; Phosphopyridoxal; Sechvitan; Pydoxal; Piodel; Pyridoxyl phosphate; Apolon B6; (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate; HI-Pyridoxin; Pal-P; PYRIDOXAL-5-PHOSPHATE; pyridoxal-P; Phosphopyridoxal coenzyme; Vitahexin P; Hexermin P; Coenzyme B6; Pyridoxal monophosphate; Pyridoxaldehyde phosphate; Apolon B(sub 6);  Biosechs; PLP; Pyrido; Phosphoridoxal coenzyme; Pyridoxal phosphate [JAN]; SRI 2392; VITAMIN B6 COMPLEX; Vitamin B6 phosphate; Hexermin-P; Pyridoxal 5-monophosphoric acid ester; Pyridoxal 5-phosphate; Pyridoxal phosphate (6CI); Pyridoxal-5P; Pyridoxal-P; Sechvitan, Vitahexin P; Vitahexin-P; Vitamin B6 phosphate (ester); Pyridoxal 5'-phosphate; Pyridoxal 5'-phosphate hydrate; Pyridoxal-5-Phosphate Hydrate; Pyridoxal-5-monophosphate; P-5'-P; Pyridoxal 5'-(dihydrogen phosphate); Pyridoxal 5'-phosphate monohydrate, vitamin B6; Pyridoxal 5'-phosphate monohydrate-Vitamin B6; Pyridoxal phosphate treated beta-lactoglobulin from bovine whey; Pyridoxal, 5-(dihydrogen phosphate); Pyridoxal, 5-(dihydrogenphosphate); Pyridoxal, 5-(dihydrogen phosphate) (8CI); Phosphoric acid mono-(4-formyl-5-hydroxy-6-methyl-pyridin-3-ylmethyl) ester; Isonicotinaldehyde, 3-hydroxy-5-(hydroxymethyl)-2-methyl-, 5-(dihydrogen phosphate); (4-Formyl-5-hydroxy-6-methyl(3-pyridyl))methyl dihydrogen phosphate; (4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl dihydrogen phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate trihydrate; 2-Methyl-3-hydroxy-4-formyl-5-pyridylmethylphosphoric acid; 3-Hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde; 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate; 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde; 4-Formyl-5-hydroxy-6-methyl-pyridin-3-yl)methoxyphosphonic acid; 4-Pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-(9CI); Lepirudine
DMO2K0J	TC	Dietary supplement
DMO2K0J	DT	Small molecular drug
DMO2K0J	PC	1051
DMO2K0J	MW	247.14
DMO2K0J	FM	C8H10NO6P
DMO2K0J	IC	InChI=1S/C8H10NO6P/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14/h2-3,11H,4H2,1H3,(H2,12,13,14)
DMO2K0J	CS	CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O
DMO2K0J	IK	NGVDGCNFYWLIFO-UHFFFAOYSA-N
DMO2K0J	IU	(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate
DMO2K0J	CA	CAS 54-47-7
DMO2K0J	CB	CHEBI:18405
DMO2K0J	DE	Malnutrition

DM5X7VY	ID	DM5X7VY
DM5X7VY	DN	Pyrimethamine
DM5X7VY	HS	Approved
DM5X7VY	SN	Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprime; Daraprin; Diaminopyritamin; Erbaprelina; Ethylpyrimidine; Khloridin; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethaminum; Tindurin; Tindurine; Tinduring; Aventis Brand of Pyrimethamine; Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; M alocid; Pirimetamina [Spanish]; Pyrimethamine Hcl; Wellcome Brand of Pyrimethamine; BW 5063; RP 4753; WR 2978; AZT + Pyrimethamine combination; BW 50-63; Daraprim (TN); EXR-101; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; Pirimetamina [INN-Spanish]; Pyrimethamine (Pyr); Pyrimethaminum [INN-Latin]; TCMDC-123831; TCMDC-125860; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Fansidar (Pyrimethamine/Sulfadoxine); Pyrimethamine (JAN/USP/INN); Pyrimethamine [USAN:INN:BAN:JAN]; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine
DM5X7VY	TC	Antimalarials
DM5X7VY	DT	Small molecular drug
DM5X7VY	PC	4993
DM5X7VY	MW	248.71
DM5X7VY	FM	C12H13ClN4
DM5X7VY	IC	InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)
DM5X7VY	CS	CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl
DM5X7VY	IK	WKSAUQYGYAYLPV-UHFFFAOYSA-N
DM5X7VY	IU	5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
DM5X7VY	CA	CAS 58-14-0
DM5X7VY	CB	CHEBI:8673
DM5X7VY	DE	Malaria

DMNA8HM	ID	DMNA8HM
DMNA8HM	DN	Pyrithione Zinc
DMNA8HM	HS	Approved
DMNA8HM	SN	Head & Shoulders Conditioner
DMNA8HM	CP	Warner Chilcott Co Llc
DMNA8HM	DT	Small molecular drug
DMNA8HM	PC	3005837
DMNA8HM	MW	317.7
DMNA8HM	FM	C10H8N2O2S2Zn
DMNA8HM	IC	InChI=1S/2C5H4NOS.Zn/c2*7-6-4-2-1-3-5(6)8;/h2*1-4H;/q2*-1;+2
DMNA8HM	CS	C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[Zn+2]
DMNA8HM	IK	PICXIOQBANWBIZ-UHFFFAOYSA-N
DMNA8HM	IU	zinc;1-oxidopyridine-2-thione
DMNA8HM	CA	CAS 13463-41-7
DMNA8HM	CB	CHEBI:32076
DMNA8HM	DE	Seborrhoeic dermatitis

DMUWAM2	ID	DMUWAM2
DMUWAM2	DN	Pyronaridine
DMUWAM2	HS	Approved
DMUWAM2	SN	Malaridine; Pyronaridine phosphate salt; Benzonaphthyridine 7351; 2-Methoxy-7-chloro-10-(3',5'-bis(pyrrolin-1-ylmethyl)-4'-hydroxyphenylamino)benzo(b)-1,5-naphthyridine; 4-((7-Chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)phenol; 4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one; 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
DMUWAM2	DT	Small molecular drug
DMUWAM2	PC	107771
DMUWAM2	MW	518
DMUWAM2	FM	C29H32ClN5O2
DMUWAM2	IC	InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)
DMUWAM2	CS	COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CC(=C(C(=C4)CN5CCCC5)O)CN6CCCC6
DMUWAM2	IK	DJUFPMUQJKWIJB-UHFFFAOYSA-N
DMUWAM2	IU	4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
DMUWAM2	CA	CAS 74847-35-1
DMUWAM2	CB	CHEBI:135951
DMUWAM2	DE	Malaria

DM7Q41G	ID	DM7Q41G
DM7Q41G	DN	Pyruvic acid
DM7Q41G	HS	Approved
DM7Q41G	SN	BTS; Brenztraubensaeure; Acetylformic acid; Acide pyruvique; Pyroracemic acid; CH3COCOOH; A-Ketopropionic acid; Alpha-Ketopropionic acid; Alpha-Oxopropionsaeure; Alpha-keto propionic acid; Alpha-ketopropionic acid; P-9250; Pyruvic acid (8CI); Pyruvic acid (natural); Propanoic acid, 2-oxo-(9CI); 2-Ketopropionic acid; 2-Oxopropanoate; 2-Oxopropanoic acid; 2-Oxopropansaeure; 2-Oxopropionic acid; 2-Oxopropionsaeure; 2-oxo(1-14c)propanoic acid; 2-oxo-propionic acid
DM7Q41G	TC	Dietary supplement
DM7Q41G	DT	Small molecular drug
DM7Q41G	PC	1060
DM7Q41G	MW	88.06
DM7Q41G	FM	C3H4O3
DM7Q41G	IC	InChI=1S/C3H4O3/c1-2(4)3(5)6/h1H3,(H,5,6)
DM7Q41G	CS	CC(=O)C(=O)O
DM7Q41G	IK	LCTONWCANYUPML-UHFFFAOYSA-N
DM7Q41G	IU	2-oxopropanoic acid
DM7Q41G	CA	CAS 127-17-3
DM7Q41G	CB	CHEBI:32816
DM7Q41G	DE	Malnutrition

DMGAZHU	ID	DMGAZHU
DMGAZHU	DN	Quattvaxem
DMGAZHU	HS	Approved
DMGAZHU	SN	DTwPHib-CRM197 conjugate vaccine; DPT-Hib vaccine, Chiron; DTP-Hib vaccine, Chiron; Diphtheria, tetanus, pertussis, Haemophilus influenzae b vaccine (CRM-197 adjuvant), Chiron
DMGAZHU	CP	Chiron Corp
DMGAZHU	DT	Vaccine
DMGAZHU	DE	Bordetella pertussis infection

DMY4D87	ID	DMY4D87
DMY4D87	DN	Quazepam
DMY4D87	HS	Approved
DMY4D87	SN	Cetrane; Doral; Dormalin; Oniria; Prosedar; Quazapam; Quazepamum; Quazium; Selepam; Sch 16134; Doral (TN); Dormalin (TN); Quazepamum [INN-Latin]; Sch-161; Sch-16134; Quazepam (JAN/USP); Quazepam [USAN:BAN:INN]; Quazepam (JAN/USP/INN); 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-Chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione
DMY4D87	CP	Schering-Plough
DMY4D87	TC	Hypnotics and Sedatives
DMY4D87	DT	Small molecular drug
DMY4D87	PC	4999
DMY4D87	MW	386.8
DMY4D87	FM	C17H11ClF4N2S
DMY4D87	IC	InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2
DMY4D87	CS	C1C(=S)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F
DMY4D87	IK	IKMPWMZBZSAONZ-UHFFFAOYSA-N
DMY4D87	IU	7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione
DMY4D87	CA	CAS 36735-22-5
DMY4D87	CB	CHEBI:8694
DMY4D87	DE	Insomnia

DM3NC4M	ID	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	HS	Approved
DM3NC4M	SN	Kvercetin; Meletin; QUE; Quercetine; Quercetol; Quercitin; Quertin; Quertine; Sophoretin; Xanthaurine; Flavin meletin; Kvercetin [Czech]; Quercetin content; Quercetin dihydrate; CI Natural Yellow 10; Cyanidelonon 1522; KUC104418N; KUC107684N; MixCom3_000183; Natural Yellow 10; P0042; Q 0125; TNP00070; TNP00089; LIM-5662; LNS-5662; C.I . natural yellow 10; C.I. 75670; C.I. Natural Yellow 10; C.I. Natural red 1; CU-01000012502-3; KSC-10-126; KSC-23-76; T-Gelb bzw. grun 1; C.I. Natural yellow 10 & 13; 2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,3',4',5,7-Pentahydroxyflavone dihydrate; 3,5,7,3',4'-Pentahydroxyflavone; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one
DM3NC4M	TC	Hypoglycemic Agents
DM3NC4M	DT	Small molecular drug
DM3NC4M	PC	5280343
DM3NC4M	MW	302.23
DM3NC4M	FM	C15H10O7
DM3NC4M	IC	InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H
DM3NC4M	CS	C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
DM3NC4M	IK	REFJWTPEDVJJIY-UHFFFAOYSA-N
DM3NC4M	IU	2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
DM3NC4M	CA	CAS 117-39-5
DM3NC4M	CB	CHEBI:16243
DM3NC4M	DE	Obesity

DM1N62C	ID	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	HS	Approved
DM1N62C	SN	quetiapine; 111974-69-7; Quetiapine [INN:BAN]; UNII-BGL0JSY5SI; BGL0JSY5SI; CHEMBL716; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; CHEBI:8707; C21H25N3O2S; URKOMYMAXPYINW-UHFFFAOYSA-N; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; NCGC00095911-03; Co-Quetiapine; Norsic; Quetiapina; Quetiapinum; Quetiapine hemifumarate; Ketipinor (TN); Norsic (TN); Quetiapine (INN); Seroquel (Fumarate); Seroquel (TN); 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; PD-172760
DM1N62C	CP	AstraZeneca
DM1N62C	TC	Antipsychotic Agents
DM1N62C	DT	Small molecular drug
DM1N62C	PC	5002
DM1N62C	MW	383.5
DM1N62C	FM	C21H25N3O2S
DM1N62C	IC	InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
DM1N62C	CS	C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
DM1N62C	IK	URKOMYMAXPYINW-UHFFFAOYSA-N
DM1N62C	IU	2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol
DM1N62C	CA	CAS 111974-69-7
DM1N62C	CB	CHEBI:8707
DM1N62C	DE	Schizophrenia; Alcohol dependence

DM7WI4Q	ID	DM7WI4Q
DM7WI4Q	DN	Quinagolide
DM7WI4Q	HS	Approved
DM7WI4Q	SN	Norprolac; 87056-78-8; Quinagolidum; SDZ 205-502; Quinagolide (INN/BAN); AC1MJ64J; SCHEMBL143485; CHEMBL290962; CHEBI:135627; ZINC3778441; BDBM50225362; DB09097; D07217; 056Q788; UNII-80Q9QWN15M component GDFGTRDCCWFXTG-ZIFCJYIRSA-N; (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
DM7WI4Q	CP	Ferring Pharmaceuticals
DM7WI4Q	TC	Fertility Agents
DM7WI4Q	DT	Small molecular drug
DM7WI4Q	PC	3086401
DM7WI4Q	MW	395.6
DM7WI4Q	FM	C20H33N3O3S
DM7WI4Q	IC	InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1
DM7WI4Q	CS	CCCN1C[C@H](C[C@H]2[C@H]1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC
DM7WI4Q	IK	GDFGTRDCCWFXTG-ZIFCJYIRSA-N
DM7WI4Q	IU	(3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
DM7WI4Q	CA	CAS 87056-78-8
DM7WI4Q	CB	CHEBI:135627
DM7WI4Q	DE	Hyperprolactinaemia

DMR8H31	ID	DMR8H31
DMR8H31	DN	Quinapril
DMR8H31	HS	Approved
DMR8H31	SN	Ectren; Koretic; Quinaprilum; QUINAPRIL HCL; Quinaprilum [Latin]; Accupril (TN); Quinapril [INN:BAN]; Quinapril (USP/INN); [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-Isoquinolinecarboxylic acid; (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; (3S)-2-{(2S)-2-[(1S)-1-ethoxycarbonyl-3-phenylpropylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
DMR8H31	CP	Pfizer Pharmaceuticals
DMR8H31	TC	Antihypertensive Agents
DMR8H31	DT	Small molecular drug
DMR8H31	PC	54892
DMR8H31	MW	438.5
DMR8H31	FM	C25H30N2O5
DMR8H31	IC	InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1
DMR8H31	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O
DMR8H31	IK	JSDRRTOADPPCHY-HSQYWUDLSA-N
DMR8H31	IU	(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMR8H31	CA	CAS 85441-61-8
DMR8H31	CB	CHEBI:8713
DMR8H31	DE	Hypertension

DMJ6H1Z	ID	DMJ6H1Z
DMJ6H1Z	DN	Quinestrol
DMJ6H1Z	HS	Approved
DMJ6H1Z	SN	EECPE; Eston; Estrovis; Estrovister; Plestrovis; Quilea; Quinestrolo; Quinestrolum; Quinestrolo [DCIT]; Estrovis 4000; W 3566; Estrovis (TN); Ethinyl Estradiol 3-Cyclopentyl Ether; Qui-Lea; Quinestrolum [INN-Latin]; W-3566; Quinestrol (USAN/INN); Quinestrol [USAN:INN:BAN]; Estradiol-17-beta 3-cyclopentyl ether; (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol; 17-alpha-Ethinylestradiol 3-cyclopentyl ether; 17ALPHA-ETHYLNYL-1,3,5[10]ESTRATRIENE-3,17BETA-DIOL 3-CYCLOPENTYL ETHER; 17alpha-Ethynyl-1,3,5(10)-estratriene-3,17beta-diol 3-cyclopentyl ether; 17alpha-Ethynylestradiol 3-cyclopentyl ether; 3-(Cyclopentyloxy)-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(Cyclopentyloxy)-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(cyclopentyloxy)-17beta-ethynylestra-1,3,5(10)-trien-17-ol; 3-Cyclopentyloxy-17alpha-ethynylestra-1,3,5(10)-trien-17beta-ol
DMJ6H1Z	TC	Anticancer Agents
DMJ6H1Z	DT	Small molecular drug
DMJ6H1Z	PC	9046
DMJ6H1Z	MW	364.5
DMJ6H1Z	FM	C25H32O2
DMJ6H1Z	IC	InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1
DMJ6H1Z	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC5CCCC5
DMJ6H1Z	IK	PWZUUYSISTUNDW-VAFBSOEGSA-N
DMJ6H1Z	IU	(8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol
DMJ6H1Z	CA	CAS 152-43-2
DMJ6H1Z	CB	CHEBI:8716
DMJ6H1Z	DE	Breast cancer

DMWCOSR	ID	DMWCOSR
DMWCOSR	DN	Quinethazone
DMWCOSR	HS	Approved
DMWCOSR	SN	Aquamox; Chinetazone; Chinethazone; Chinethazonum; Hydromox; Idrokin; Quinetazona; Quinethazon; Quinethazonum; Chinetazone[DCIT]; CL 36010; Hydromox (TN); Quinetazona [INN-Spanish]; Quinethazone (aquamox); Quinethazonum [INN-Latin]; Quinethazone (JAN/INN); Quinethazone [INN:BAN:JAN]; 2-Ethyl-7-chloro-1,2,3,4-tetrahydro-4-oxochinazolin-6-sulfonamid; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamide; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-sulfamoylquinazoline; 7-Chloro-2-ethyl-6-sulfamoyl-1,2,3,4-tetrahydro-4-quinazolinone; 7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide; 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide
DMWCOSR	TC	Antihypertensive Agents
DMWCOSR	DT	Small molecular drug
DMWCOSR	PC	6307
DMWCOSR	MW	289.74
DMWCOSR	FM	C10H12ClN3O3S
DMWCOSR	IC	InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)
DMWCOSR	CS	CCC1NC2=CC(=C(C=C2C(=O)N1)S(=O)(=O)N)Cl
DMWCOSR	IK	AGMMTXLNIQSRCG-UHFFFAOYSA-N
DMWCOSR	IU	7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide
DMWCOSR	CA	CAS 73-49-4
DMWCOSR	CB	CHEBI:8717
DMWCOSR	DE	Hypertension

DMLPICK	ID	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	HS	Approved
DMLPICK	SN	Quinact; Quinaglute; Quinalan; Quinatime; Quindine; Quinicardine; Quinidex; Quinidine sulfate; Quiniduran; Quinora; beta-Quinine; Cardioquin; Chinidin; Chinidine; Cin-Quin; Cinchonan-9-ol, 6'-methoxy-, (9S)-; Conchinin; Conchinine; Conquinine; Duraquin; ITX08688JL; Kinidin; Pitayine; chinidinum; quinidina; quinidine; (+)-Quinidine; (8R,9S)-Quinidine; (9S)-6'-Methoxycinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; 56-54-2; CHEBI:28593; CHEMBL1294; MFCD00135581; UNII-ITX08688JL
DMLPICK	PC	441074
DMLPICK	MW	324.4
DMLPICK	FM	C20H24N2O2
DMLPICK	IC	LOUPRKONTZGTKE-LHHVKLHASA-N
DMLPICK	CS	COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
DMLPICK	IK	1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1
DMLPICK	IU	(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
DMLPICK	CA	CAS 56-54-2
DMLPICK	CB	CHEBI:28593
DMLPICK	DE	Ventricular tachyarrhythmia

DMSWYF5	ID	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	HS	Approved
DMSWYF5	SN	Aflukin; Chinin; Chinine; Chininum; Conchinin; Conquinine; Quindan; Quinidex; Quinidine; Quinimax; Quinina; Quinineanhydrous; Quinora; Quniacridine; Chinin [German]; Kinder Quinina; QUININE MONO HCL; Quinine Dab; Quinine [BAN]; Quinine anhydrous; Quinine bisulfate; Quinine sulfate; Quinine sulphate; Quinoline alkaloid; LT00645788;Q0028; SB01652; Beta-Quinine; Cin-Quin; Coco-Quinine; IBS-L0034250; Kinder Quinina (TN); Legatrin (TN); Quinine (BAN); Quinine, Anhydrous; Quinine, polymers; Quinine, tannate; Biquinate (*Bisulfate heptathydrate*); Dentojel (*Bisulfate heptathydrate*); Quinamm (*2:1 Sulfate salt*), dihydrate; Quine (*2:1 Sulfate salt*, dihydrate); Quinsan (*2:1 Sulfate salt*), dihydrate; Alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; (+)-Quinidine; (-)-Quinine; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (3A,8A,9r)-6'-methoxycinchonan-9-ol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-Quinine; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-(-)-Quinine, 6-methoxycinchonidine; (R)-(-)-quinine; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine
DMSWYF5	CP	Pfizer Pharmaceuticals
DMSWYF5	TC	Antimalarials
DMSWYF5	DT	Small molecular drug
DMSWYF5	PC	3034034
DMSWYF5	MW	324.4
DMSWYF5	FM	C20H24N2O2
DMSWYF5	IC	InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1
DMSWYF5	CS	COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O
DMSWYF5	IK	LOUPRKONTZGTKE-WZBLMQSHSA-N
DMSWYF5	IU	(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
DMSWYF5	CA	CAS 72402-53-0
DMSWYF5	CB	CHEBI:15854
DMSWYF5	DE	Malaria

DM5GVHU	ID	DM5GVHU
DM5GVHU	DN	Quinolones
DM5GVHU	HS	Approved
DM5GVHU	SN	AC1MI0KP
DM5GVHU	DT	Small molecular drug
DM5GVHU	PC	6038
DM5GVHU	MW	145.16
DM5GVHU	FM	C9H7NO
DM5GVHU	IC	InChI=1S/C9H7NO/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-6H,(H,10,11)
DM5GVHU	CS	C1=CC=C2C(=C1)C=CC(=O)N2
DM5GVHU	IK	LISFMEBWQUVKPJ-UHFFFAOYSA-N
DM5GVHU	IU	1H-quinolin-2-one
DM5GVHU	CA	CAS 59-31-4
DM5GVHU	CB	CHEBI:16365
DM5GVHU	DE	Bacterial infection; Tuberculosis

DMLKFC4	ID	DMLKFC4
DMLKFC4	DN	Quinupristin
DMLKFC4	HS	Approved
DMLKFC4	SN	Quinupristina; Quinupristine; Quinupristinum; SYB; RP 57669; Quinupristin [USAN:INN]; Quinupristina [INN-Spanish]; Quinupristine [INN-French]; Quinupristinum [INN-Latin]; RP-57669; Synercid (TN); Quinupristin (JAN/USAN/INN); 4-[4-(DIMETHYLAMINO)-N-METHYL-L-PHENYLALANINE]-5-[(2S,5R)-5-[[[(3S)-1-AZABICYCLO-[2.2.2]OCT-3-YL]THIO]METHYL]-4-OXO-2-PIPERIDINECARBOXYLIC ACID]VIRGINIAMYCIN; 5delta-(3-quinuclidinyl)thiomethylpristinamycin IA
DMLKFC4	TC	Antibiotics
DMLKFC4	DT	Small molecular drug
DMLKFC4	PC	5388937
DMLKFC4	MW	1022.2
DMLKFC4	FM	C53H67N9O10S
DMLKFC4	IC	InChI=1S/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35+,37-,38+,39+,40+,43-,44+,45+/m1/s1
DMLKFC4	CS	CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3C[C@H](C(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C
DMLKFC4	IK	WTHRRGMBUAHGNI-LCYNINFDSA-N
DMLKFC4	IU	N-[(3S,6S,12R,15S,16R,19S,22S,25R)-25-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]sulfanylmethyl]-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide
DMLKFC4	CA	CAS 120138-50-3
DMLKFC4	DE	Bacterial infection

DMM4U9G	ID	DMM4U9G
DMM4U9G	DN	R0-93877
DMM4U9G	HS	Approved
DMM4U9G	SN	Prucalopride; 179474-81-8; UNII-0A09IUW5TP; 4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide; 0A09IUW5TP; C18H26ClN3O3; CHEMBL117287; R-093877; 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide; R 093877; 4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide; 4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide; R093877; Motegrity; Prucalopride [USAN:INN:BAN]
DMM4U9G	CP	Shire/Takeda
DMM4U9G	DT	Small molecular drug
DMM4U9G	PC	3052762
DMM4U9G	MW	367.9
DMM4U9G	FM	C18H26ClN3O3
DMM4U9G	IC	InChI=1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23)
DMM4U9G	CS	COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl
DMM4U9G	IK	ZPMNHBXQOOVQJL-UHFFFAOYSA-N
DMM4U9G	IU	4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide
DMM4U9G	CA	CAS 179474-81-8
DMM4U9G	CB	CHEBI:135552
DMM4U9G	DE	Irritable bowel syndrome; Constipation

DMMZXIW	ID	DMMZXIW
DMMZXIW	DN	Rabeprazole
DMMZXIW	HS	Approved
DMMZXIW	SN	Dexrabeprazole; Eraloc; Rebeprazole sodium; CL23619; LY307640; Aciphex (TN); Eraloc (TN); Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DMMZXIW	CP	Eisai; Johnson & Johnson
DMMZXIW	TC	Antiulcer Agents
DMMZXIW	DT	Small molecular drug
DMMZXIW	PC	5029
DMMZXIW	MW	359.4
DMMZXIW	FM	C18H21N3O3S
DMMZXIW	IC	InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
DMMZXIW	CS	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
DMMZXIW	IK	YREYEVIYCVEVJK-UHFFFAOYSA-N
DMMZXIW	IU	2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DMMZXIW	CA	CAS 117976-89-3
DMMZXIW	CB	CHEBI:8768
DMMZXIW	DE	Bacterial infection

DMFOTZ7	ID	DMFOTZ7
DMFOTZ7	DN	Racecadotril
DMFOTZ7	HS	Approved
DMFOTZ7	SN	Acetorphan; Hidrasec; Tiorfan
DMFOTZ7	CP	BioProjet; Societe Civile de Recherche
DMFOTZ7	DT	Small molecular drug
DMFOTZ7	PC	107751
DMFOTZ7	MW	385.5
DMFOTZ7	FM	C21H23NO4S
DMFOTZ7	IC	InChI=1S/C21H23NO4S/c1-16(23)27-15-19(12-17-8-4-2-5-9-17)21(25)22-13-20(24)26-14-18-10-6-3-7-11-18/h2-11,19H,12-15H2,1H3,(H,22,25)
DMFOTZ7	CS	CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC2=CC=CC=C2
DMFOTZ7	IK	ODUOJXZPIYUATO-UHFFFAOYSA-N
DMFOTZ7	IU	benzyl 2-[[2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]acetate
DMFOTZ7	CA	CAS 81110-73-8
DMFOTZ7	CB	CHEBI:91508
DMFOTZ7	DE	Diarrhea

DMXTCVF	ID	DMXTCVF
DMXTCVF	DN	Radium-223-Dichloride
DMXTCVF	HS	Approved
DMXTCVF	CP	Bayer HealthCare Pharmaceuticals
DMXTCVF	DE	Prostate cancer

DMDKF3M	ID	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	HS	Approved
DMDKF3M	SN	Raloxifene (extended-release, CDT)
DMDKF3M	CP	SCOLR Pharma Inc
DMDKF3M	DT	Small molecular drug
DMDKF3M	PC	5035
DMDKF3M	MW	473.6
DMDKF3M	FM	C28H27NO4S
DMDKF3M	IC	InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
DMDKF3M	CS	C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
DMDKF3M	IK	GZUITABIAKMVPG-UHFFFAOYSA-N
DMDKF3M	IU	[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
DMDKF3M	CA	CAS 84449-90-1
DMDKF3M	CB	CHEBI:8772
DMDKF3M	DE	Osteoporosis

DMYURI6	ID	DMYURI6
DMYURI6	DN	Raltegravir
DMYURI6	HS	Approved
DMYURI6	SN	RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL
DMYURI6	CP	Merck
DMYURI6	DT	Small molecular drug
DMYURI6	PC	54671008
DMYURI6	MW	444.4
DMYURI6	FM	C20H21FN6O5
DMYURI6	IC	InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)
DMYURI6	CS	CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
DMYURI6	IK	CZFFBEXEKNGXKS-UHFFFAOYSA-N
DMYURI6	IU	N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide
DMYURI6	CA	CAS 518048-05-0
DMYURI6	DE	Human immunodeficiency virus infection

DMT9K8G	ID	DMT9K8G
DMT9K8G	DN	Raltitrexed
DMT9K8G	HS	Approved
DMT9K8G	SN	Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ZD 1694; ICI D1694; UNII-FCB9EGG971; D1694; D 1694; CHEBI:5847; Raltitrexed (Tomudex); C21H22N4O6S; ZD-16; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; FCB9EGG971; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_RID_81653; DSSTox_CID_26482; DSSTox_GSID_46482
DMT9K8G	CP	AstraZeneca
DMT9K8G	TC	Anticancer Agents
DMT9K8G	DT	Small molecular drug
DMT9K8G	PC	135400182
DMT9K8G	MW	458.5
DMT9K8G	FM	C21H22N4O6S
DMT9K8G	IC	InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1
DMT9K8G	CS	CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N1
DMT9K8G	IK	IVTVGDXNLFLDRM-HNNXBMFYSA-N
DMT9K8G	IU	(2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid
DMT9K8G	CA	CAS 112887-68-0
DMT9K8G	CB	CHEBI:5847
DMT9K8G	DE	Rectal adenocarcinoma

DM7IW9J	ID	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	HS	Approved
DM7IW9J	SN	Rozerem; Ramelteon [USAN]; Rozerem (TN); TAK-375; Ramelteon (JAN/USAN/INN); Rozerem, TAK-375, Ramelteon; N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide; N-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide
DM7IW9J	CP	Takeda
DM7IW9J	TC	Hypnotics and Sedatives
DM7IW9J	DT	Small molecular drug
DM7IW9J	PC	208902
DM7IW9J	MW	259.339
DM7IW9J	FM	C16H21NO2
DM7IW9J	IC	InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1
DM7IW9J	CS	CCC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3
DM7IW9J	IK	YLXDSYKOBKBWJQ-LBPRGKRZSA-N
DM7IW9J	IU	N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide
DM7IW9J	CA	CAS 196597-26-9
DM7IW9J	CB	CHEBI:109549
DM7IW9J	DE	Insomnia; Circadian rhythm sleep disorder

DM2R68E	ID	DM2R68E
DM2R68E	DN	Ramipril
DM2R68E	HS	Approved
DM2R68E	SN	Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
DM2R68E	CP	Sanofi-Aventis
DM2R68E	TC	Antihypertensive Agents
DM2R68E	DT	Small molecular drug
DM2R68E	PC	5362129
DM2R68E	MW	416.5
DM2R68E	FM	C23H32N2O5
DM2R68E	IC	InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
DM2R68E	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
DM2R68E	IK	HDACQVRGBOVJII-JBDAPHQKSA-N
DM2R68E	IU	(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
DM2R68E	CA	CAS 87333-19-5
DM2R68E	CB	CHEBI:8774
DM2R68E	DE	Congestive heart failure

DMH7GN8	ID	DMH7GN8
DMH7GN8	DN	Ramosetron
DMH7GN8	HS	Approved
DMH7GN8	SN	132036-88-5; UNII-7ZRO0SC54Y; Ramosetron [INN]; 7ZRO0SC54Y; CHEMBL1643895; Ramosetron (INN); (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone; Nor-YM 060; SCHEMBL16701; GTPL2301; DTXSID0043842; NTHPAPBPFQJABD-LLVKDONJSA-N; MolPort-019-991-383; CHEBI:135156; ZINC5116719; AC1L3355; BDBM50334454; 8235AH; AKOS015896003; SB19072; DB09290; SC-92398; AJ-53160; LS-187182; TL8000762; R-146; FT-0651831; D08466; A806353; (-)-(R)-1-Methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl ketone;  Nasea (TN); YM060
DMH7GN8	DT	Small molecular drug
DMH7GN8	PC	108000
DMH7GN8	MW	279.34
DMH7GN8	FM	C17H17N3O
DMH7GN8	IC	InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1
DMH7GN8	CS	CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
DMH7GN8	IK	NTHPAPBPFQJABD-LLVKDONJSA-N
DMH7GN8	IU	(1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone
DMH7GN8	CA	CAS 132036-88-5
DMH7GN8	CB	CHEBI:135156
DMH7GN8	DE	Nausea and vomiting; Irritable bowel syndrome

DMWUFQ4	ID	DMWUFQ4
DMWUFQ4	DN	Ramucirumab
DMWUFQ4	HS	Approved
DMWUFQ4	SN	LY3009806
DMWUFQ4	CP	Lilly
DMWUFQ4	DT	Monoclonal antibody
DMWUFQ4	SQ	9098_H|ramucirumab|Homo sapiens||H-GAMMA-1 (VH(1-116)+CH1(117-214)+HINGE-REGION(215-229)+CH2(230-339)+CH3(340-446))|||||||446||||MW 48696.0|MW 48696.0|: EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;9098_L|ramucirumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(109-214))|||||||214||||MW 23124.7|MW 23124.7|DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIKGTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMWUFQ4	DE	Gastric adenocarcinoma

DMSYPNW	ID	DMSYPNW
DMSYPNW	DN	Ranibizumab
DMSYPNW	HS	Approved
DMSYPNW	SN	Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)
DMSYPNW	CP	Genentech Inc
DMSYPNW	DT	Antibody
DMSYPNW	SQ	Ranibizumab Light Chain: DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>    <sequence format="FASTA">&gt;Ranibizumab Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL
DMSYPNW	DE	Hereditary hemorrhagic telangiectasia

DM0GUSX	ID	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	HS	Approved
DM0GUSX	SN	Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
DM0GUSX	CP	GlaxoSmithKline
DM0GUSX	TC	Antiulcer Agents
DM0GUSX	DT	Small molecular drug
DM0GUSX	PC	3001055
DM0GUSX	MW	314.41
DM0GUSX	FM	C13H22N4O3S
DM0GUSX	IC	InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
DM0GUSX	CS	CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C
DM0GUSX	IK	VMXUWOKSQNHOCA-UKTHLTGXSA-N
DM0GUSX	IU	(E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
DM0GUSX	CA	CAS 82530-72-1
DM0GUSX	CB	CHEBI:8776
DM0GUSX	DE	Peptic ulcer

DM0C9IL	ID	DM0C9IL
DM0C9IL	DN	Ranolazine
DM0C9IL	HS	Approved
DM0C9IL	SN	RANOLAZINE; 95635-55-5; Ranexa; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; CVT-303; (-)-Ranolazine; Ranolazine (Ranexa); Ranolazine 2HCl; RS-43285-003; 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; CHEBI:87690; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; C24H33N3O4; NCGC00015897-02; DSSTox_RID_80743; DSSTox_CID_25196; DSSTox_GSID_45196; Ran4; CVT 303; Latixa; RAN D;  Latixa; Ranolazine dihydrochloride; KEG-1295; RS-43285; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine extended-release; Ranolazine/Dronedarone Fixed-Dose Combination
DM0C9IL	CP	CV Therapeutics
DM0C9IL	TC	Analgesics
DM0C9IL	DT	Small molecular drug
DM0C9IL	PC	56959
DM0C9IL	MW	427.5
DM0C9IL	FM	C24H33N3O4
DM0C9IL	IC	InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)
DM0C9IL	CS	CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
DM0C9IL	IK	XKLMZUWKNUAPSZ-UHFFFAOYSA-N
DM0C9IL	IU	N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
DM0C9IL	CA	CAS 95635-55-5
DM0C9IL	CB	CHEBI:87690
DM0C9IL	DE	Chronic/stable angina; Paroxysmal atrial fibrillation

DM3WKQ4	ID	DM3WKQ4
DM3WKQ4	DN	Rasagiline
DM3WKQ4	HS	Approved
DM3WKQ4	SN	RAS; Rasagiline [INN]; Azilect (TN); Rasagiline (INN); (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; (R)-N-2-Propynyl-1-indanamine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
DM3WKQ4	CP	Teva Pharmaceutical Industries Ltd
DM3WKQ4	TC	Antiparkinson Agents
DM3WKQ4	DT	Small molecular drug
DM3WKQ4	PC	3052776
DM3WKQ4	MW	171.24
DM3WKQ4	FM	C12H13N
DM3WKQ4	IC	InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
DM3WKQ4	CS	C#CCN[C@@H]1CCC2=CC=CC=C12
DM3WKQ4	IK	RUOKEQAAGRXIBM-GFCCVEGCSA-N
DM3WKQ4	IU	(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
DM3WKQ4	CA	CAS 136236-51-6
DM3WKQ4	CB	CHEBI:63620
DM3WKQ4	DE	Skin cancer; Skin imperfections; Parkinson disease

DMWTVAN	ID	DMWTVAN
DMWTVAN	DN	Rauwolfia serpentina root
DMWTVAN	HS	Approved
DMWTVAN	SN	Raubasine; 483-04-5; Ajmalicin; Circolene; Sarpan; py-Tetrahydroserpentine; Tetrahydroserpentine; UNII-4QJL8OX71Z; EINECS 207-589-5; BRN 0097268; 4QJL8OX71Z; CHEBI:2524; CHEMBL123325; Methyl 16,17-didehydro-19alpha-methyl-18-oxayohimban-16-carboxylat; 16,17-Didehydro-19-methyloxayohimban-16-carboxylic acid m
DMWTVAN	DT	Small molecular drug
DMWTVAN	DE	Discovery agent

DMSWNJF	ID	DMSWNJF
DMSWNJF	DN	Ravulizumab
DMSWNJF	HS	Approved
DMSWNJF	SN	Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210
DMSWNJF	CP	Alexion
DMSWNJF	DT	Antibody
DMSWNJF	DE	Paroxysmal nocturnal haemoglobinuria

DM7QG0M	ID	DM7QG0M
DM7QG0M	DN	Raxibacumab
DM7QG0M	HS	Approved
DM7QG0M	CP	GlaxoSmithKline
DM7QG0M	DT	Monoclonal antibody
DM7QG0M	DE	Anthrax

DM26PRD	ID	DM26PRD
DM26PRD	DN	Reboxetine
DM26PRD	HS	Approved
DM26PRD	SN	71620-89-8; (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine; Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,R*)-; Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-; Reboxetine [INN:BAN]; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; HSDB 7701; Edronax (TN); (R,R)-Reboxetine; AC1L2RJ0; SCHEMBL34533; CHEMBL383921; DTXSID1048257; MolPort-005-943-618; CHEBI:135342; ZINC3996032; BCP12060; AKOS015966368; DB00234; AN-34535; AK431803; AJ-47614
DM26PRD	CP	Pfizer Pharmaceuticals
DM26PRD	TC	Antidepressants
DM26PRD	DT	Small molecular drug
DM26PRD	PC	127151
DM26PRD	MW	313.4
DM26PRD	FM	C19H23NO3
DM26PRD	IC	InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
DM26PRD	CS	CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3
DM26PRD	IK	CBQGYUDMJHNJBX-RTBURBONSA-N
DM26PRD	IU	(2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
DM26PRD	CA	CAS 71620-89-8
DM26PRD	CB	CHEBI:135342
DM26PRD	DE	Depression

DMY7ESM	ID	DMY7ESM
DMY7ESM	DN	Recombinant Factor IX
DMY7ESM	HS	Approved
DMY7ESM	SN	RFIX, Baxter; Recombinant Factor IX, Baxter
DMY7ESM	CP	Baxter 1nternational
DMY7ESM	DE	Factor IX deficiency; Bleeding disorder

DMMPCFX	ID	DMMPCFX
DMMPCFX	DN	Recombinant human endostatin
DMMPCFX	HS	Approved
DMMPCFX	SN	Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn
DMMPCFX	CP	Shandong Simcere Medgenn Bio- Pharmaceutical Co Ltd
DMMPCFX	DE	Solid tumour/cancer

DM76VHG	ID	DM76VHG
DM76VHG	DN	Regadenoson
DM76VHG	HS	Approved
DM76VHG	SN	Lexiscan (TN)
DM76VHG	CP	CV Therapeutics
DM76VHG	DT	Small molecular drug
DM76VHG	PC	219024
DM76VHG	MW	390.35
DM76VHG	FM	C15H18N8O5
DM76VHG	IC	InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1
DM76VHG	CS	CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DM76VHG	IK	LZPZPHGJDAGEJZ-AKAIJSEGSA-N
DM76VHG	IU	1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide
DM76VHG	CA	CAS 313348-27-5
DM76VHG	CB	CHEBI:135613
DM76VHG	DE	Radionuclide imaging

DM87XSN	ID	DM87XSN
DM87XSN	DN	REGN-727
DM87XSN	HS	Approved
DM87XSN	SN	Alirocumab; Alirocumab); RENG-727; Anti-PCSK9 antibody (hypercholesterolemia), Regeneron/sanofi-aventis
DM87XSN	CP	Sanofi; Novo Nordisk
DM87XSN	DT	Antibody
DM87XSN	DE	Familial hypercholesterolemia; Hypercholesterolaemia

DMHSY1I	ID	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	HS	Approved
DMHSY1I	SN	Regorafenib; 755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
DMHSY1I	CP	Bayer HealthCare Pharmaceuticals
DMHSY1I	DT	Small molecular drug
DMHSY1I	PC	11167602
DMHSY1I	MW	482.8
DMHSY1I	FM	C21H15ClF4N4O3
DMHSY1I	IC	InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)
DMHSY1I	CS	CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F
DMHSY1I	IK	FNHKPVJBJVTLMP-UHFFFAOYSA-N
DMHSY1I	IU	4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
DMHSY1I	CA	CAS 755037-03-7
DMHSY1I	CB	CHEBI:68647
DMHSY1I	DE	Metastatic colorectal cancer

DMK7IWL	ID	DMK7IWL
DMK7IWL	DN	Relugolix
DMK7IWL	HS	Approved
DMK7IWL	SN	737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917
DMK7IWL	CP	Takeda
DMK7IWL	DT	Small molecular drug
DMK7IWL	PC	10348973
DMK7IWL	MW	623.6
DMK7IWL	FM	C29H27F2N7O5S
DMK7IWL	IC	InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)
DMK7IWL	CS	CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
DMK7IWL	IK	AOMXMOCNKJTRQP-UHFFFAOYSA-N
DMK7IWL	IU	1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
DMK7IWL	CA	CAS 737789-87-6
DMK7IWL	DE	Endometriosis; Prostate cancer

DMBFZ6L	ID	DMBFZ6L
DMBFZ6L	DN	Remdesivir
DMBFZ6L	HS	Approved
DMBFZ6L	SN	L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
DMBFZ6L	CP	Gilead Sciences, Foster City, CA
DMBFZ6L	DT	Small molecular drug
DMBFZ6L	PC	121304016
DMBFZ6L	MW	602.6
DMBFZ6L	FM	C27H35N6O8P
DMBFZ6L	IC	InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
DMBFZ6L	CS	CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
DMBFZ6L	IK	RWWYLEGWBNMMLJ-YSOARWBDSA-N
DMBFZ6L	IU	2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMBFZ6L	CA	CAS 1809249-37-3
DMBFZ6L	CB	CHEBI:145994
DMBFZ6L	DE	Ebola virus infection; Coronavirus Disease 2019 (COVID-19)

DMZTXCH	ID	DMZTXCH
DMZTXCH	DN	Remifentanil
DMZTXCH	HS	Approved
DMZTXCH	SN	Remifentanyl; Ultiva; GI 87084B; GI 87084X; GI87084B; Remifentanil (INN); Remifentanil [INN:BAN]; Ultiva (TN); Methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate; 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester; 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester; 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
DMZTXCH	CP	Abbott Laboratories
DMZTXCH	TC	Hypnotics and Sedatives
DMZTXCH	DT	Small molecular drug
DMZTXCH	PC	60815
DMZTXCH	MW	376.4
DMZTXCH	FM	C20H28N2O5
DMZTXCH	IC	InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3
DMZTXCH	CS	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC
DMZTXCH	IK	ZTVQQQVZCWLTDF-UHFFFAOYSA-N
DMZTXCH	IU	methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
DMZTXCH	CA	CAS 132875-61-7
DMZTXCH	CB	CHEBI:8802
DMZTXCH	DE	Anaesthesia

DMNAKLY	ID	DMNAKLY
DMNAKLY	DN	Remikiren
DMNAKLY	HS	Approved
DMNAKLY	SN	REM; Remikiren [INN]; Remikiren (INN); Ro 42-5892; Ro-42-5892; (2R)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; (2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; (S)-alpha-((S)-alpha-((t-butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; (alphaS)-alpha-((alphaS)-alpha-((tert-Butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; 2-benzyl-3-tert-butylsulfonyl-N-[1-[(1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl)amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide
DMNAKLY	CP	Hoffmann-La Roche pharmaceutical company
DMNAKLY	TC	Antihypertensive Agents
DMNAKLY	DT	Small molecular drug
DMNAKLY	PC	6324659
DMNAKLY	MW	630.8
DMNAKLY	FM	C33H50N4O6S
DMNAKLY	IC	InChI=1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28+,29+,30-/m1/s1
DMNAKLY	CS	CC(C)(C)S(=O)(=O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3CCCCC3)[C@H]([C@H](C4CC4)O)O
DMNAKLY	IK	UXIGZRQVLGFTOU-VQXQMPIVSA-N
DMNAKLY	IU	(2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide
DMNAKLY	CA	CAS 126222-34-2
DMNAKLY	CB	CHEBI:8803
DMNAKLY	DE	Hypertension

DMLVSYX	ID	DMLVSYX
DMLVSYX	DN	Remimazolam
DMLVSYX	HS	Approved
DMLVSYX	SN	CNS-7054; CNS-7056; CNS-7056B; CNS-7056X; GW-351564X; GW-418259X; GW-457837A; GW-502056X; ONO-2745; Short-acting sedatives, Therasci; GABA A agonist (anesthesia, sedation) CeNeS/Ono; Sedatives (short acting), CeNeS/Ono; Sedatives (short acting), PAION/Ono; Sedatives (short-acting), TheraSci; Short-acting sedatives, Therasci/GSK; Sedatives (short-acting), TheraSci/GSK
DMLVSYX	CP	GlaxoSmithKline plc
DMLVSYX	DT	Small molecular drug
DMLVSYX	PC	9867812
DMLVSYX	MW	439.3
DMLVSYX	FM	C21H19BrN4O2
DMLVSYX	IC	InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1
DMLVSYX	CS	CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4
DMLVSYX	IK	CYHWMBVXXDIZNZ-KRWDZBQOSA-N
DMLVSYX	IU	methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate
DMLVSYX	CA	CAS 308242-62-8
DMLVSYX	DE	Anaesthesia; Procedural sedation

DM5SXUV	ID	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	HS	Approved
DM5SXUV	SN	Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid
DM5SXUV	CP	Novo Nordisk
DM5SXUV	TC	Hypoglycemic Agents
DM5SXUV	DT	Small molecular drug
DM5SXUV	PC	65981
DM5SXUV	MW	452.6
DM5SXUV	FM	C27H36N2O4
DM5SXUV	IC	InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
DM5SXUV	CS	CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O
DM5SXUV	IK	FAEKWTJYAYMJKF-QHCPKHFHSA-N
DM5SXUV	IU	2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
DM5SXUV	CA	CAS 135062-02-1
DM5SXUV	CB	CHEBI:8805
DM5SXUV	DE	Diabetic complication

DM6KI0D	ID	DM6KI0D
DM6KI0D	DN	Repirinast
DM6KI0D	HS	Approved
DM6KI0D	SN	MY-1250; MY-5116; MY-6116
DM6KI0D	CP	Mitsubishi-Tokyo Pharmaceuticals Inc
DM6KI0D	DT	Small molecular drug
DM6KI0D	PC	5050
DM6KI0D	MW	355.4
DM6KI0D	FM	C20H21NO5
DM6KI0D	IC	InChI=1S/C20H21NO5/c1-10(2)7-8-25-20(24)15-9-14(22)16-18(26-15)13-6-5-11(3)12(4)17(13)21-19(16)23/h5-6,9-10H,7-8H2,1-4H3,(H,21,23)
DM6KI0D	CS	CC1=C(C2=C(C=C1)C3=C(C(=O)C=C(O3)C(=O)OCCC(C)C)C(=O)N2)C
DM6KI0D	IK	NFQIAEMCQGTTIR-UHFFFAOYSA-N
DM6KI0D	IU	3-methylbutyl 7,8-dimethyl-4,5-dioxo-6H-pyrano[3,2-c]quinoline-2-carboxylate
DM6KI0D	CA	CAS 73080-51-0
DM6KI0D	CB	CHEBI:32092
DM6KI0D	DE	Asthma

DMG7SQK	ID	DMG7SQK
DMG7SQK	DN	Rescinnamine
DMG7SQK	HS	Approved
DMG7SQK	SN	Anapral; Anaprel; Apolon; Apoterin; Cartric; Cinamine; Cinatabs; Cinnaloid; Cinnasil; Moderil; Normorescina; Paresinan; Raupyrol; Raurescin; Raurescine; Recinnamine; Recitensina; Rescaloid; Rescamin; Rescidan; Rescin; Rescinamina; Rescinnamin; Rescinnamina; Rescinnaminum; Rescinpal; Rescisan; Rescitens; Resealoid; Reserpinene; Reserpinin; Reserpinine; Resipal; Reskinnamin; Rozex; Scinnamina; Tenamine; Tuareg; Apoterin S; Methyl trimethoxycinnamoylreserpate; Rescinnamina [DCIT]; Trimethoxy cinnamoyl reserpate de methyl; Trimethoxy cinnamoyl reserpate de methyl [French]; Trimethoxycinnamoyl methyl reserpate; Tsuruselpi S; Anaprel (TN); Cinnasil (TN); Moderil (TN); NP-011016; Rescinamina [INN-Spanish]; Rescinnamine (VAN); Rescinnaminum [INN-Latin]; Resepinine (C35 alkaloid); Reserpinine (C35 alkaloid); Reserpinine (VAN); Tsuruselpi S (TN); Rescinnamine (JAN/INN); Rescinnamine [BAN:INN:JAN]; Methyl reserpate 3,4,5-trimethoxycinnamic acid ester; Reserpic acid methyl ester 3,4,5-trimethoxycinnamate; Methyl 18-O-(3,4,5-trimethoxycinnamoyl)reserpate; O-(3,4,5-Trimethoxy-trans-cinnamoyl) methyl reserpate; 3,4,5-Trimethoxycinnamic acid, methyl reserpate; 3,4,5-Trimethoxycinnamoyl methyl reserpate; 3,4,5-Trimethylcinnamic acid, ester with methyl reserpate; 3,4,5-Trimethylcinnamoyl methyl reserpate
DMG7SQK	TC	Antihypertensive Agents
DMG7SQK	DT	Small molecular drug
DMG7SQK	PC	5280954
DMG7SQK	MW	634.7
DMG7SQK	FM	C35H42N2O9
DMG7SQK	IC	InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
DMG7SQK	CS	CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)/C=C/C6=CC(=C(C(=C6)OC)OC)OC
DMG7SQK	IK	SZLZWPPUNLXJEA-QEGASFHISA-N
DMG7SQK	IU	methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMG7SQK	CA	CAS 24815-24-5
DMG7SQK	CB	CHEBI:28572
DMG7SQK	DE	Hypertension

DM6VM38	ID	DM6VM38
DM6VM38	DN	Reserpine
DM6VM38	HS	Approved
DM6VM38	SN	Abesta; Abicol; Adelfan; Adelphin; Alkarau; Alkaserp; Alserin; Apoplon; Apsical; Ascoserp; Ascoserpina; Austrapine; Banasil; Banisil; Benazyl; Bioserpine; Brinderdin; Briserine; Broserpine; Cardioserpin; Carditivo; Carpacil; Carrserp; Darebon; Deserpine; Dralserp; Eberpine; Eberspine; Ebserpine; Elfanex; Elserpine; Enipresser; Escaspere; Eserpine; Eskaserp; Eskaserpine; Gammaserpine; Gilucard; Helfoserpin; Hexaplin; Hiposerpil; Hiserpia; Hydropine; Hydroserp; Hypersil; Hypersine; Hypertensan; Idoserp; Idsoserp; Interpina; Kitine; Klimanosid; Lemiserp; Loweserp; Mallopress; Maviserpin; Mayserpine; Mephaserpin; Modenol; Naquival; Nembuserpin; Neoserfin; Neoserp; Neoslowten; Orthoserpina; Perskleran; Pressimedin; Purserpine; Quiescin; Raucap; Raudiford; Raudixin; Raudixoid; Raugal; Raulen; Rauloydin; Raumorine; Raunervil; Raunorine; Raunova; Raupasil; Raupoid; Raurine; Rausan; Rausedan; Rausedil; Rausedyl; Rauserpin; Rauserpine; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwasedin; Rauwilid; Rauwiloid; Rauwipur; Rauwita; Rauwoleaf; Rawilid; Recipin; Regroton; Resaltex; Resedrex; Resedril; Reserbal; Resercaps; Resercen; Reserfia; Reserjen; Reserlor; Reserp; Reserpal; Reserpamed; Reserpanca; Reserpene; Reserpex; Reserpidefe; Reserpil; Reserpin; Reserpina; Reserpinum; Reserpka; Reserpoid; Reserpur; Reserutin; Resiatric; Residin; Residine; Resine; Resocalm; Resperin; Resperine; Respital; Restran; Rezerpin; Riserpa; Rivased; Rivasin; Rolserp; Roxel; Roxinoid; Roxynoid; Ryser; Salupres; Sandril; Sandron; Sedaraupin; Sedaraupina; Sederaupin; Sedserp; Seominal; Serfin; Serfolia; Serolfia; Serpalan; Serpaloid; Serpaneurona; Serpanray; Serpasil; Serpasol; Serpate; Serpazil; Serpazol; Serpedin; Serpen; Serpena; Serpentil; Serpentin; Serpentina; Serpicon; Serpil; Serpiloid; Serpilum; Serpine; Serpipur; Serpivate; Serpivite; Serpogen; Serpoid; Serpone; Serpyrit; Sertabs; Sertens; Sertensin; Sertina; Supergan; Tefaserpina; Temposerpine; Tensanyl; Tenserpinie; Tensional; Tensionorme; Tepserpine; Terbolan; Transerpin; Triserpin; Tylandril; Unilord; Unipres; VIXO; Esc aspere; Hydromox R; Hypercal B; Loweser p; Neose rfin; Rau sedyl; Renese R; Rese rpamed; Se rpate; V Serp; VI XO; Diupres 250; Diupres 500; ENT 50146; H 520; Hydropres 25; Hydropres 50; Hydrosine 25; R 0875; Apoplon (TN); Diupres-250; Diupres-500; Diurese-R; Diutensen-R; HYDRO-RESERP; Hydrap-ES; Hydromox-R; Key-serpine; L-Carpserp; Neo-serp; Rau-Sed; Renese-R; Rese-lar; Reser-ar; SK-Reserpine; T-Serp; Usaf cb-27; V-Serp; Vio-Serpine; Cam-Ap-Es; L"-Carpserp; R-e-s; Ser-A-Gen; 3P Reserp
DM6VM38	TC	Antihypertensive Agents
DM6VM38	DT	Small molecular drug
DM6VM38	PC	5770
DM6VM38	MW	608.7
DM6VM38	FM	C33H40N2O9
DM6VM38	IC	InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1
DM6VM38	CS	CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
DM6VM38	IK	QEVHRUUCFGRFIF-MDEJGZGSSA-N
DM6VM38	IU	methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DM6VM38	CA	CAS 50-55-5
DM6VM38	CB	CHEBI:28487
DM6VM38	DE	Hypertension

DM0AUCH	ID	DM0AUCH
DM0AUCH	DN	Reslizumab
DM0AUCH	HS	Approved
DM0AUCH	CP	Teva
DM0AUCH	DT	Monoclonal antibody
DM0AUCH	DE	Severe asthma; Asthma; Eosinophilic asthma

DM9JXB7	ID	DM9JXB7
DM9JXB7	DN	Retapamulin
DM9JXB7	HS	Approved
DM9JXB7	SN	Altabax; Altargo; SB 275833; Altabax (Glaxo); Altabax (TN); Altargo (TN); Retapamulin (USAN/INN)
DM9JXB7	CP	GlaxoSmithKline
DM9JXB7	TC	Antibiotics
DM9JXB7	DT	Small molecular drug
DM9JXB7	PC	6918462
DM9JXB7	MW	517.799
DM9JXB7	FM	C30H47NO4S
DM9JXB7	IC	InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22?,24-,26+,27+,28-,29+,30+/m1/s1
DM9JXB7	CS	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C
DM9JXB7	IK	STZYTFJPGGDRJD-FJJJPKKESA-N
DM9JXB7	IU	[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate
DM9JXB7	CA	CAS 224452-66-8
DM9JXB7	CB	CHEBI:166679
DM9JXB7	DE	Impetigo

DML0D1P	ID	DML0D1P
DML0D1P	DN	Reteplase
DML0D1P	HS	Approved
DML0D1P	SN	Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)
DML0D1P	TC	Thrombolytic Agents
DML0D1P	SQ	DB00015 sequence: SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DML0D1P	DE	Heart attack

DMGNYIH	ID	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	HS	Approved
DMGNYIH	SN	Ezogabine; Potiga; Trobalt; Retigabine [USAN]; D 20443; D 23129; ADD-230001; D-20443; D-23129; GKE-841; KE-0201; Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate; Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate; [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate; Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride; N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester; Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate; N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester; Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester
DMGNYIH	CP	GSK
DMGNYIH	TC	Anticonvulsants
DMGNYIH	DT	Small molecular drug
DMGNYIH	PC	121892
DMGNYIH	MW	303.33
DMGNYIH	FM	C16H18FN3O2
DMGNYIH	IC	InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
DMGNYIH	CS	CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N
DMGNYIH	IK	PCOBBVZJEWWZFR-UHFFFAOYSA-N
DMGNYIH	IU	ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate
DMGNYIH	CA	CAS 150812-12-7
DMGNYIH	CB	CHEBI:68584
DMGNYIH	DE	Epilepsy; Behcet disease

DMMP5SI	ID	DMMP5SI
DMMP5SI	DN	Revefenacin
DMMP5SI	HS	Approved
DMMP5SI	SN	UNII-G2AE2VE07O; G2AE2VE07O; Revefenacin [INN]; Revefenacin [WHO-DD]; Revefenacin [USAN:INN]; Revefenacin (USAN/INN); SCHEMBL356480; EX-A1722; DB11855; GSK1160724; CS-7743; GSK-1160724; HY-15851; D10978; 1211931-83-7
DMMP5SI	CP	Theravance Biopharma/Mylan
DMMP5SI	PC	11753673
DMMP5SI	MW	597.7
DMMP5SI	FM	C35H43N5O4
DMMP5SI	IC	InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
DMMP5SI	CS	CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
DMMP5SI	IK	FYDWDCIFZSGNBU-UHFFFAOYSA-N
DMMP5SI	IU	[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate
DMMP5SI	CA	CAS 864750-70-9
DMMP5SI	DE	Chronic obstructive pulmonary disease

DM8LRU2	ID	DM8LRU2
DM8LRU2	DN	Revolade/Promacta
DM8LRU2	HS	Approved
DM8LRU2	SN	AC1OC7GM
DM8LRU2	CP	GSK
DM8LRU2	DT	Small molecular drug
DM8LRU2	PC	6913084
DM8LRU2	MW	330.9
DM8LRU2	FM	C22H31Cl
DM8LRU2	IC	InChI=1S/C22H31Cl/c23-22-17-19(12-8-11-18-9-4-1-2-5-10-18)15-16-21(22)20-13-6-3-7-14-20/h8,12,15-18,20H,1-7,9-11,13-14H2/b12-8-
DM8LRU2	CS	C1CCCC(CC1)C/C=C\\C2=CC(=C(C=C2)C3CCCCC3)Cl
DM8LRU2	IK	NDXQJQCGBAIFER-WQLSENKSSA-N
DM8LRU2	IU	[(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]cycloheptane
DM8LRU2	DE	Idiopathic thrombocytopenic purpura; Thrombocytopenia; Chronic liver disease

DM69XMQ	ID	DM69XMQ
DM69XMQ	DN	RG-7446
DM69XMQ	HS	Approved
DM69XMQ	CP	Genentech
DM69XMQ	DT	Monoclonal antibody
DM69XMQ	DE	Urothelial carcinoma; Bladder cancer

DMNF0G8	ID	DMNF0G8
DMNF0G8	DN	Rh-alphaglucosidase
DMNF0G8	HS	Approved
DMNF0G8	SN	Pompase (TN)
DMNF0G8	DE	Pompe disease

DM3ADGP	ID	DM3ADGP
DM3ADGP	DN	Rhucin
DM3ADGP	HS	Approved
DM3ADGP	SN	sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; BNRNXUUZRGQAQC-UHFFFAOYSA-N; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; Sildenafil
DM3ADGP	CP	Pfizer
DM3ADGP	DT	Small molecular drug
DM3ADGP	PC	135398744
DM3ADGP	MW	474.6
DM3ADGP	FM	C22H30N6O4S
DM3ADGP	IC	InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
DM3ADGP	CS	CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
DM3ADGP	IK	BNRNXUUZRGQAQC-UHFFFAOYSA-N
DM3ADGP	IU	5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DM3ADGP	CA	CAS 139755-83-2
DM3ADGP	CB	CHEBI:9139
DM3ADGP	DE	Hereditary angioedema; Erectile dysfunction

DMALNG0	ID	DMALNG0
DMALNG0	DN	RHuEPO
DMALNG0	HS	Approved
DMALNG0	CP	Bio-Gal Advanced Biotechnology
DMALNG0	DE	Solid tumour/cancer

DMEYLH9	ID	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	HS	Approved
DMEYLH9	SN	ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Ribavirine; Copegus; Vilona; Ribamide; Ribasphere; Ribamidil; Viramid; Ribamidyl; Ribavirinum; Ribavirina; Rebetron; Varazid; RTCA; Ribavirin Capsules; Ribavirinum [INN-Latin]; Ribavirine [INN-French]; Ribavirina [INN-Spanish]; ICN-1229; Rebretron; Virazid; Ribav; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; DRG-0028; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; UNII-49717AWG6K; Ribavirin (Copegus);  Copegus; Cotronak; RBV; RTC; Ravanex; Ribacine; Ribovirin; Viramide; Virazide; R 9644; SCH 18908; C-Virin; Copegus (TN); Drug: Ribavirin; KS-1104; R-964; RG-964; Rebetol (TN); Ribasphere (TN); Ribavirin [USAN:INN]; Vilona (TN); Virazole (Ribavirin) Inhalation Solution; Virazole (TN); AA-504/07617051; Ro 20-9963/000; Ro-20-9963; Ribavirin (JAN/USP/INN); 1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; RBI034 (2-5A antisense compound) + Ribavirin
DMEYLH9	CP	Hoffmann-La Roche pharmaceutical company
DMEYLH9	TC	Antiviral Agents
DMEYLH9	DT	Small molecular drug
DMEYLH9	PC	37542
DMEYLH9	MW	244.2
DMEYLH9	FM	C8H12N4O5
DMEYLH9	IC	InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
DMEYLH9	CS	C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DMEYLH9	IK	IWUCXVSUMQZMFG-AFCXAGJDSA-N
DMEYLH9	IU	1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
DMEYLH9	CA	CAS 36791-04-5
DMEYLH9	CB	CHEBI:63580
DMEYLH9	DE	Hepatitis C virus infection

DM9CIUW	ID	DM9CIUW
DM9CIUW	DN	Ribociclib succinate
DM9CIUW	HS	Approved
DM9CIUW	SN	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739
DM9CIUW	CP	Novartis
DM9CIUW	DT	Small molecular drug
DM9CIUW	PC	57334219
DM9CIUW	MW	552.6
DM9CIUW	FM	C27H36N8O5
DM9CIUW	IC	InChI=1S/C23H30N8O.C4H6O4/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30;5-3(6)1-2-4(7)8/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28);1-2H2,(H,5,6)(H,7,8)
DM9CIUW	CS	CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5.C(CC(=O)O)C(=O)O
DM9CIUW	IK	NHANOMFABJQAAH-UHFFFAOYSA-N
DM9CIUW	IU	butanedioic acid;7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
DM9CIUW	CA	CAS 1374639-75-4
DM9CIUW	DE	Hormone receptor positive and HER2-negative advanced or metastatic breast cancer; Breast cancer

DM8YMWE	ID	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	HS	Approved
DM8YMWE	SN	riboflavin; vitamin B2; Lactoflavin; Riboflavine; Vitamin G; 83-88-5; Lactoflavine; (-)-riboflavin; Beflavine; Beflavin; Riboflavina; Flavaxin; Vitaflavine; Riboflavinum; Ribocrisina; Ribovel; Lactobene; Ribotone; Flaxain; Ribosyn; Riboderm; Ribipca; Flavin BB; Vitasan B2; Fiboflavin; Dermadram; Hyflavin; HYRE; Vitamin Bi; Aqua-Flave; 7,8-Dimethyl-10-ribitylisoalloxazine; Russupteridine Yellow III; 6,7-Dimethyl-9-D-ribitylisoalloxazine; Riboflavinequinone; Riboflavinum [INN-Latin]; Riboflavine [INN-French]; Riboflavina [INN-Spanish]
DM8YMWE	DT	Small molecular drug
DM8YMWE	PC	493570
DM8YMWE	MW	376.4
DM8YMWE	FM	C17H20N4O6
DM8YMWE	IC	InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1
DM8YMWE	CS	CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O
DM8YMWE	IK	AUNGANRZJHBGPY-SCRDCRAPSA-N
DM8YMWE	IU	7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione
DM8YMWE	CA	CAS 83-88-5
DM8YMWE	CB	CHEBI:17015
DM8YMWE	DE	Acne vulgaris

DMWH9CN	ID	DMWH9CN
DMWH9CN	DN	Ridogrel
DMWH9CN	HS	Approved
DMWH9CN	SN	Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
DMWH9CN	TC	Gastrointestinal Agents
DMWH9CN	DT	Small molecular drug
DMWH9CN	PC	5362391
DMWH9CN	MW	366.3
DMWH9CN	FM	C18H17F3N2O3
DMWH9CN	IC	InChI=1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+
DMWH9CN	CS	C1=CC(=CC(=C1)C(F)(F)F)/C(=N\\OCCCCC(=O)O)/C2=CN=CC=C2
DMWH9CN	IK	GLLPUTYLZIKEGF-HAVVHWLPSA-N
DMWH9CN	IU	5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
DMWH9CN	CA	CAS 110140-89-1
DMWH9CN	CB	CHEBI:135542
DMWH9CN	DE	Acute myocardial infarction

DM1YBHK	ID	DM1YBHK
DM1YBHK	DN	Rifabutin
DM1YBHK	HS	Approved
DM1YBHK	SN	Alfacid; Ansamycin; Ansatipin; Ansatipine; Assatipin; Mycobutin; RBT; Rifabutina; Rifabutine; Rifabutinum; Grunenthal Brand of Rifabutin; Kenfarma Brand of Rifabutin; Pfizer Brand of Rifabutin; Rifabutin Pfizer Brand; Rifabutina [Spanish]; Rifabutine [French]; Rifabutinum [Latin]; Antibiotic LM 427; LM 427; LM427; DRG-0085; LM-427; Mycobutin (TN); Rifabutin [USAN:BAN:INN]; Rifabutin (JAN/USP/INN); Mycobutin, Ansamycin, LM 427, Ansatipine, Rifabutin; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin; Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptameth; 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; 4-N-isobutylspiropiperidylrifamycin S
DM1YBHK	CP	Adria Laboratories 
DM1YBHK	TC	Antibiotics
DM1YBHK	DT	Small molecular drug
DM1YBHK	PC	135398743
DM1YBHK	MW	847
DM1YBHK	FM	C46H62N4O11
DM1YBHK	IC	InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,48,52-55H,16-19,21H2,1-11H3/b13-12+,20-15+,24-14-,47-36?/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
DM1YBHK	CS	C[C@H]1/C=C/C=C(\\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C
DM1YBHK	IK	ZWBTYMGEBZUQTK-PVLSIAFMSA-N
DM1YBHK	IU	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate
DM1YBHK	CA	CAS 72559-06-9
DM1YBHK	DE	Mycobacterium infection; Tuberculosis

DM5DSFZ	ID	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	HS	Approved
DM5DSFZ	SN	Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifamor; Rifampicin; Rifampicin SV; Rifampicina; Rifampicina [INN-Spanish]; Rifampicine [French]; Rifampicinum; Rifampicinum [INN-Latin]; Rifamycin AMP; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Sinerdol; Tubocin; Archidyn; Arficin; Arzide; Benemicin; Dione 21-acetate; Doloresum; Eremfat; Fenampicin; L-5103 Lepetit; rifampin; 13292-46-1; Abrifam; Ba 41166/E; R/AMP; Rifa; Rifam
DM5DSFZ	PC	135398735
DM5DSFZ	MW	822.9
DM5DSFZ	FM	C43H58N4O12
DM5DSFZ	IC	JQXXHWHPUNPDRT-WLSIYKJHSA-N
DM5DSFZ	CS	CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C
DM5DSFZ	IK	1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
DM5DSFZ	IU	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DM5DSFZ	CA	CAS 13292-46-1
DM5DSFZ	CB	CHEBI:27470
DM5DSFZ	DE	Osteoporosis

DMA8J1G	ID	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	HS	Approved
DMA8J1G	SN	Abrifam; Archidyn; Arficin; Arzide; Benemicin; Benemycin; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; RFP; RMP; Ramp; Rifa; Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamor; Rifampicin; Rifampicina; Rifampicine; Rifampicinum; Rifamsolin; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Rimycin; Sinerdol; Tubocin; Rifamicin AMP; Rifampicin SV; Rifampicine [French]; Rifampin [USAN]; Rifamycin AMP; Ba 41166; AZT + Rifampin; BA-41166E; Ba 41166/E; DRG-0109; Dione 21-acetate; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; Reserpine & Rifampicin; Rifadin (TN); Rifadin I.V; Rifampicin & EEP; Rifampicin & Propolis; Rifampicina [INN-Spanish]; Rifampicinum [INN-Latin]; Rifampin (USP); Rimactan (TN); Rimactane (TN); Rimycin (TN); Sinerdol (TN); Tubocin (TN); Rifadin I.V.; Rifampicin (JP15/INN); Rifampicin[INN:BAN:JAN]; Rifadin, Rimactane, Rifampicin, Rifampin; 1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI)
DMA8J1G	CP	Norvatis Phamaceuticals Corporation
DMA8J1G	TC	Antituberculosis Agents
DMA8J1G	DT	Small molecular drug
DMA8J1G	PC	135398735
DMA8J1G	MW	822.9
DMA8J1G	FM	C43H58N4O12
DMA8J1G	IC	InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
DMA8J1G	CS	C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C
DMA8J1G	IK	JQXXHWHPUNPDRT-WLSIYKJHSA-N
DMA8J1G	IU	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DMA8J1G	CA	CAS 13292-46-1
DMA8J1G	CB	CHEBI:28077
DMA8J1G	DE	Tuberculosis

DMEH3O7	ID	DMEH3O7
DMEH3O7	DN	Rifamycin
DMEH3O7	HS	Approved
DMEH3O7	SN	Rifamycin SV; Rifamycin SV MMX; Rifamycin sodium; CB-01-11; Rifamycin (oral controlled-release, gastrointestinal-specific); Rifamycin (oral controlled-release, gastrointestinal-specific), Cosmo/Dr Falk/Santarus
DMEH3O7	CP	Cosmo Technologies
DMEH3O7	DT	Small molecular drug
DMEH3O7	PC	6324616
DMEH3O7	MW	697.8
DMEH3O7	FM	C37H47NO12
DMEH3O7	IC	InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1
DMEH3O7	CS	C[C@H]1/C=C/C=C(\\C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C
DMEH3O7	IK	HJYYPODYNSCCOU-ODRIEIDWSA-N
DMEH3O7	IU	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DMEH3O7	CA	CAS 6998-60-3
DMEH3O7	CB	CHEBI:29673
DMEH3O7	DE	Diarrhea; Infectious disease

DMCHV4I	ID	DMCHV4I
DMCHV4I	DN	Rifapentine
DMCHV4I	HS	Approved
DMCHV4I	SN	RIFAPENTINE; Rifapentina; Rifapentinum; Cyclopentylrifampicin; Rifamycin AF/ACPP; Antibiotic DL 473IT; KTC 1; 61379-65-5; MDL 473; DRG-0283; DL 473; R-773; R 77-3; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Rifapentin,(S); NCGC00167431-01; ZINC169621228; NCGC00167431-03; AN-15578; RPE
DMCHV4I	CP	Sanofi-Aventis
DMCHV4I	TC	Antituberculosis Agents
DMCHV4I	DT	Small molecular drug
DMCHV4I	PC	135403821
DMCHV4I	MW	877
DMCHV4I	FM	C47H64N4O12
DMCHV4I	IC	InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1
DMCHV4I	CS	C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C
DMCHV4I	IK	WDZCUPBHRAEYDL-GZAUEHORSA-N
DMCHV4I	IU	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DMCHV4I	CA	CAS 61379-65-5
DMCHV4I	CB	CHEBI:45304
DMCHV4I	DE	Tuberculosis; Macular degeneration

DMW1TV2	ID	DMW1TV2
DMW1TV2	DN	Rifaximin
DMW1TV2	HS	Approved
DMW1TV2	SN	RCIFAX; Rifaximin (bioadhesive/ gastrointestinal extended release); Rifaximin (bioadhesive/ gastrointestinal extended release), Salix Pharmaceuticals
DMW1TV2	CP	Salix Pharmaceuticals Ltd
DMW1TV2	DT	Small molecular drug
DMW1TV2	PC	6436173
DMW1TV2	MW	785.9
DMW1TV2	FM	C43H51N3O11
DMW1TV2	IC	InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1
DMW1TV2	CS	C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C
DMW1TV2	IK	NZCRJKRKKOLAOJ-XRCRFVBUSA-N
DMW1TV2	IU	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate
DMW1TV2	CA	CAS 80621-81-4
DMW1TV2	CB	CHEBI:75246
DMW1TV2	DE	Bacterial infection

DM13PQW	ID	DM13PQW
DM13PQW	DN	Rilmenidine
DM13PQW	HS	Approved
DM13PQW	SN	Rilmenidine phosphate; 85409-38-7; Rilmenidine dihydrogen phosphate; UNII-59QD64Q32M; EINECS 287-106-2; 59QD64Q32M; S 3341-3; 4,5-Dihydro-N-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1); 2-Oxazolamine, 4,5-dihydro-N-(dicyclopropylmethyl)-, phosphate (1:1); (Dicyclopropylmethyl)(4,5-dihydro-2-oxazolyl)ammonium dihydrogen phosphate; W-104082; 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, phosphate (1:1); N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; phosphoric acid
DM13PQW	DT	Small molecular drug
DM13PQW	PC	68712
DM13PQW	MW	180.25
DM13PQW	FM	C10H16N2O
DM13PQW	IC	InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
DM13PQW	CS	C1CC1C(C2CC2)NC3=NCCO3
DM13PQW	IK	CQXADFVORZEARL-UHFFFAOYSA-N
DM13PQW	IU	N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine
DM13PQW	CA	CAS 54187-04-1
DM13PQW	CB	CHEBI:8862
DM13PQW	DE	Hypertension

DMGLUQS	ID	DMGLUQS
DMGLUQS	DN	Rilonacept
DMGLUQS	HS	Approved
DMGLUQS	SN	Rilonacept (USAN/INN)
DMGLUQS	CP	Regeneron
DMGLUQS	SQ	8750_M|rilonacept|Homo sapiens||FUSION-IL1RAP-IL1R1-GAMMA-1 (IL1RAP+(Pr21-359)(1-339)+IL1R1+(Pr22-333)(340-651)+HINGE-REGION(652-663)+CH2(664-773)+CH3(774-880))|||||||880||||MW 100630.6|MW 100630.6|: SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMDSRNEVWWTIDGKKPDDITIDVTINESISHSRTEDETRTQILSIKKVTSEDLKRSYVCHARSAKGEVAKAAKVKQKVPAPRYTVEKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMGLUQS	DE	Arthritis; Acute gout flare

DMJ0QOW	ID	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	HS	Approved
DMJ0QOW	SN	500287-72-9; TMC278; Edurant; TMC 278; UNII-FI96A8X663; R278474; TMC-278; 4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile; CHEBI:68606; FI96A8X663; R 278474; 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; (E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile; W-202888;  RPV; Mu O-conotoxin
DMJ0QOW	DT	Small molecular drug
DMJ0QOW	PC	6451164
DMJ0QOW	MW	366.4
DMJ0QOW	FM	C22H18N6
DMJ0QOW	IC	InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+
DMJ0QOW	CS	CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)/C=C/C#N
DMJ0QOW	IK	YIBOMRUWOWDFLG-ONEGZZNKSA-N
DMJ0QOW	IU	4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile
DMJ0QOW	CA	CAS 500287-72-9
DMJ0QOW	CB	CHEBI:68606
DMJ0QOW	DE	Human immunodeficiency virus infection; Pain

DMECBWN	ID	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	HS	Approved
DMECBWN	SN	Rilutek; Riluzol; Riluzolum; Riluzole HCl; RP 54274; ALBB-006046; BF-37; PK-26124; R-116; RP-54274; Rilutek (TN); Riluzol [INN-Spanish]; Riluzole [USAN:INN]; Riluzolum [INN-Latin]; ZERO/001785; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; Riluzole (JAN/USAN/INN); PK-26124, RP-54274, Rilutek, Riluzole; 2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine
DMECBWN	CP	Sanofi-Aventis
DMECBWN	TC	Anticonvulsants
DMECBWN	DT	Small molecular drug
DMECBWN	PC	5070
DMECBWN	MW	234.2
DMECBWN	FM	C8H5F3N2OS
DMECBWN	IC	InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
DMECBWN	CS	C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
DMECBWN	IK	FTALBRSUTCGOEG-UHFFFAOYSA-N
DMECBWN	IU	6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
DMECBWN	CA	CAS 1744-22-5
DMECBWN	CB	CHEBI:8863
DMECBWN	DE	Amyotrophic lateral sclerosis

DM5DWMU	ID	DM5DWMU
DM5DWMU	DN	Rimantadine
DM5DWMU	HS	Approved
DM5DWMU	SN	Remantadine; Riamantadine; Rimant; Rimantadina; Rimantadinum; Enamine_005755; Alpha-Methyladamantanemethylamine; Flumadine (TN); Rimantadina [INN-Spanish]; Rimantadine (INN); Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; Alpha-Methyl-1-adamantanemethylamine; Rimant & .alpha. IFN; Rimantidine & .alpha.IFN; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-& IFN.alpha; 1-(1-Adamantyl)ethanamine; 1-(1-Adamantyl)ethylamin; 1-(1-adamantyl)-ethylamine; 1-(1-adamantyl)ethylamine; 1-(adamantan-1-yl)ethan-1-amine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; 1-Adamantan-1-yl-ethylamine; 1-Adamantan-1-ylethylamine; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine
DM5DWMU	CP	Forest Laboratories Inc
DM5DWMU	TC	Antiviral Agents
DM5DWMU	DT	Small molecular drug
DM5DWMU	PC	5071
DM5DWMU	MW	179.3
DM5DWMU	FM	C12H21N
DM5DWMU	IC	InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3
DM5DWMU	CS	CC(C12CC3CC(C1)CC(C3)C2)N
DM5DWMU	IK	UBCHPRBFMUDMNC-UHFFFAOYSA-N
DM5DWMU	IU	1-(1-adamantyl)ethanamine
DM5DWMU	CA	CAS 13392-28-4
DM5DWMU	CB	CHEBI:94440
DM5DWMU	DE	Influenza A virus infection

DMHOAUG	ID	DMHOAUG
DMHOAUG	DN	Rimegepant
DMHOAUG	HS	Approved
DMHOAUG	SN	BMS-927711; 1289023-67-1; UNII-997WVV895X; BMS 927711; CHEMBL2178422; 997WVV895X; (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate; Rimegepant [USAN:INN]; Rimegepant (USAN/INN); SCHEMBL1670580; DTXSID70156003; C28H28F2N6O3; EX-A1922; 3504AH; ZINC68267814; BDBM50400098; AKOS030526382; DB12457; CS-1027; NCGC00378677-01; HY-15498; KB-145921; W-5991
DMHOAUG	CP	Labrys Biologics
DMHOAUG	DT	Small molecular drug
DMHOAUG	PC	51049968
DMHOAUG	MW	534.6
DMHOAUG	FM	C28H28F2N6O3
DMHOAUG	IC	InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1
DMHOAUG	CS	C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6
DMHOAUG	IK	KRNAOFGYEFKHPB-ANJVHQHFSA-N
DMHOAUG	IU	[(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
DMHOAUG	CA	CAS 1289023-67-1
DMHOAUG	DE	Migraine

DMTAREC	ID	DMTAREC
DMTAREC	DN	Rimexolone
DMTAREC	HS	Approved
DMTAREC	SN	Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)
DMTAREC	CP	Auritec Pharmaceuticals Inc
DMTAREC	DT	Small molecular drug
DMTAREC	PC	5311412
DMTAREC	MW	370.5
DMTAREC	FM	C24H34O3
DMTAREC	IC	InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1
DMTAREC	CS	CCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C)C
DMTAREC	IK	QTTRZHGPGKRAFB-OOKHYKNYSA-N
DMTAREC	IU	(8S,9S,10R,11S,13S,14S,16R,17S)-11-hydroxy-10,13,16,17-tetramethyl-17-propanoyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMTAREC	CA	CAS 49697-38-3
DMTAREC	CB	CHEBI:135566
DMTAREC	DE	Arthritis

DMA47C6	ID	DMA47C6
DMA47C6	DN	Rimiterol
DMA47C6	HS	Approved
DMA47C6	SN	Rimiterol Hydrobromide; EINECS 250-834-6; WG-253; 31842-61-2; R 798; (R*,S*)-4-(Hydroxypiperidin-2-ylmethyl)pyrocatechol hydrobromide; erythro-alpha-(3,4-Dihydroxyphenyl)-2-piperidinemethanol hydrobromide; 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol hydrobromide; 2-Piperidinemethanol, alpha-(3,4-dihydroxyphenyl)-, (R*,S*)-, hydrobromide; API0025612; UNII-I29DRR8S3R component QPYZEEKXUYXZBK-PKKHVXKMSA-N; 1,2-Benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, hydrobromide, (R*,S*)- (9CI)
DMA47C6	DT	Small molecular drug
DMA47C6	PC	36283
DMA47C6	MW	223.27
DMA47C6	FM	C12H17NO3
DMA47C6	IC	InChI=1S/C12H17NO3/c14-10-5-4-8(7-11(10)15)12(16)9-3-1-2-6-13-9/h4-5,7,9,12-16H,1-3,6H2/t9-,12+/m1/s1
DMA47C6	CS	C1CCN[C@H](C1)[C@H](C2=CC(=C(C=C2)O)O)O
DMA47C6	IK	IYMMESGOJVNCKV-SKDRFNHKSA-N
DMA47C6	IU	4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol
DMA47C6	CA	CAS 32953-89-2
DMA47C6	DE	Asthma

DMXBLMP	ID	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	HS	Approved
DMXBLMP	SN	Riociguat; 625115-55-1; Adempas; Riociguat (BAY 63-2521); BAY 63-2521; riociguatum; UNII-RU3FE2Y4XI; RU3FE2Y4XI; CHEBI:76018; Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate; Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate; N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester
DMXBLMP	CP	Bayer HealthCare Pharmaceuticals
DMXBLMP	DT	Small molecular drug
DMXBLMP	PC	11304743
DMXBLMP	MW	422.4
DMXBLMP	FM	C20H19FN8O2
DMXBLMP	IC	InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)
DMXBLMP	CS	CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC
DMXBLMP	IK	WXXSNCNJFUAIDG-UHFFFAOYSA-N
DMXBLMP	IU	methyl N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-N-methylcarbamate
DMXBLMP	CA	CAS 625115-55-1
DMXBLMP	CB	CHEBI:76018
DMXBLMP	DE	Pulmonary arterial hypertension

DM958QB	ID	DM958QB
DM958QB	DN	Ripretinib
DM958QB	HS	Approved
DM958QB	SN	1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-
DM958QB	CP	Deciphera Pharmaceuticals Waltham, MA
DM958QB	PC	71584930
DM958QB	MW	510.4
DM958QB	FM	C24H21BrFN5O2
DM958QB	IC	InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)
DM958QB	CS	CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
DM958QB	IK	CEFJVGZHQAGLHS-UHFFFAOYSA-N
DM958QB	IU	1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea
DM958QB	CA	CAS 1442472-39-0
DM958QB	DE	Glioma; Solid tumour/cancer; Systemic mastocytosis; Gastrointestinal stromal tumour

DMM32GT	ID	DMM32GT
DMM32GT	DN	Risankizumab
DMM32GT	HS	Approved
DMM32GT	CP	AbbVie North Chicago, IL Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DMM32GT	DE	Psoriatic arthritis; Plaque psoriasis

DMIMF8J	ID	DMIMF8J
DMIMF8J	DN	Risdiplam
DMIMF8J	HS	Approved
DMIMF8J	SN	UNII-76RS4S2ET1; 76RS4S2ET1; 1825352-65-5; Risdiplam [INN]; SCHEMBL17260852; EX-A2074; RG-7916; HY-109101; RO7034067; CS-0039501; 4H-Pyrido(1,2-a)pyrimidin-4-one, 7-(4,7-diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-; 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
DMIMF8J	CP	PTC Therapeutics South Plainfield, NJ Roche Basel, Switzerland
DMIMF8J	PC	118513932
DMIMF8J	MW	401.5
DMIMF8J	FM	C22H23N7O
DMIMF8J	IC	InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3
DMIMF8J	CS	CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6
DMIMF8J	IK	ASKZRYGFUPSJPN-UHFFFAOYSA-N
DMIMF8J	IU	7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one
DMIMF8J	CA	CAS 1825352-65-5
DMIMF8J	DE	Spinal muscular atrophy

DM5FLTY	ID	DM5FLTY
DM5FLTY	DN	Risedronate
DM5FLTY	HS	Approved
DM5FLTY	SN	Risedronic acid; 105462-24-6; Actonel; Atelvia; Acido risedronico; Acidum risedronicum; Benet; Risedronic acid [INN:BAN]; Acidum risedronicum [INN-Latin]; Acido risedronico [INN-Spanish]; Acide risedronique [INN-French]; Risedronic acid monohydrate; NE-58095; UNII-KM2Z91756Z; C7H11NO7P2; NE 58019; HSDB 7326; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid,;  Benet; RIS; Ridron; Acide risedronique; Bisphosphonate 1; Actonel (TN); Ridron (TN); Risedronic acid (INN); (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID
DM5FLTY	CP	Procter & Gamble; Sanofi-Aventis
DM5FLTY	TC	Bone Density Conservation Agents
DM5FLTY	DT	Small molecular drug
DM5FLTY	PC	5245
DM5FLTY	MW	283.11
DM5FLTY	FM	C7H11NO7P2
DM5FLTY	IC	InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
DM5FLTY	CS	C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DM5FLTY	IK	IIDJRNMFWXDHID-UHFFFAOYSA-N
DM5FLTY	IU	(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
DM5FLTY	CA	CAS 105462-24-6
DM5FLTY	CB	CHEBI:8869
DM5FLTY	DE	Paget's disease

DMN6DXL	ID	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	HS	Approved
DMN6DXL	SN	Belivon; Risperdal; Risperdone; Risperidal; Risperidona; Risperidonum; Risperin; Rispolept; Rispolin; Sequinan; Risperdal Consta; Risperidona [Spanish]; Risperidonum [Latin]; R 62 766; R 64766; R64766; Consta, Risperdal; KS-1106; R 64,766; R-118; R-64766; R64,766; Risperdal (TN); Risperdal M-Tab; Risperidal M-Tab; Risperidone (RIS); Risperidone, placebo; R 64 766, Risperdal, Risperidone; R-64,766; R-64-766; Risperidone [USAN:BAN:INN]; Risperidone (JAN/USAN/INN); 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
DMN6DXL	CP	Janssen-Cilag
DMN6DXL	TC	Antipsychotic Agents
DMN6DXL	DT	Small molecular drug
DMN6DXL	PC	5073
DMN6DXL	MW	410.5
DMN6DXL	FM	C23H27FN4O2
DMN6DXL	IC	InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
DMN6DXL	CS	CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
DMN6DXL	IK	RAPZEAPATHNIPO-UHFFFAOYSA-N
DMN6DXL	IU	3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
DMN6DXL	CB	CHEBI:8871
DMN6DXL	DE	Schizophrenia

DM4V6RL	ID	DM4V6RL
DM4V6RL	DN	Ritodrine
DM4V6RL	HS	Approved
DM4V6RL	SN	Prepar; Ritodrina; Ritodrinium; Utopar; Yutopar; RITODRINE HCL; DU-21220; Ritodrina [INN-Spanish]; Ritodrinium [INN-Latin]; Yutopar (TN); Yutopar S.R; Ritodrine (USAN/INN); Ritodrine [USAN:BAN:INN]; P-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; Erythro-p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; 2-(4-Hydroxyphenethylamino)-1-(4-hydroxyphenyl)propanol; 4-[2-[[(1R,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
DM4V6RL	TC	Sympathomimetics
DM4V6RL	DT	Small molecular drug
DM4V6RL	PC	33572
DM4V6RL	MW	287.35
DM4V6RL	FM	C17H21NO3
DM4V6RL	IC	InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1
DM4V6RL	CS	C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O
DM4V6RL	IK	IOVGROKTTNBUGK-SJCJKPOMSA-N
DM4V6RL	IU	4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
DM4V6RL	CA	CAS 26652-09-5
DM4V6RL	CB	CHEBI:8872
DM4V6RL	DE	Premature labour

DMU764S	ID	DMU764S
DMU764S	DN	Ritonavir
DMU764S	HS	Approved
DMU764S	SN	Norvir; RIT; RTV; Norvir Sec; Ritonavir [USAN]; ABT 538; ABT 84538; ABT538; Abbott 84538; A-84538; ABBOTT-84538; ABT-538; DRG-0244; Norvir (TM); Norvir (TN); Ritonavir (JAN/USAN/INN); N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 538, ABT
DMU764S	CP	Abbott Laboratories
DMU764S	TC	Anti-HIV Agents
DMU764S	DT	Small molecular drug
DMU764S	PC	392622
DMU764S	MW	720.9
DMU764S	FM	C37H48N6O5S2
DMU764S	IC	InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
DMU764S	CS	CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
DMU764S	IK	NCDNCNXCDXHOMX-XGKFQTDJSA-N
DMU764S	IU	1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMU764S	CA	CAS 155213-67-5
DMU764S	CB	CHEBI:45409
DMU764S	DE	Human immunodeficiency virus infection

DM1YVZT	ID	DM1YVZT
DM1YVZT	DN	Rituximab
DM1YVZT	HS	Approved
DM1YVZT	CP	Genentech
DM1YVZT	DT	Antibody
DM1YVZT	DE	Non-hodgkin lymphoma; Pemphigus vulgaris

DMBUH26	ID	DMBUH26
DMBUH26	DN	Rituximab
DMBUH26	HS	Approved
DMBUH26	SN	MAbThera (TN)
DMBUH26	CP	Roche
DMBUH26	TC	Anticancer Agents
DMBUH26	DT	Antibody
DMBUH26	SQ	Rituximab heavy chain chimeric: QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Rituximab light chain chimericQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMBUH26	DE	Non-hodgkin lymphoma; Haematological malignancy

DMQMBZ1	ID	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	HS	Approved
DMQMBZ1	SN	XARELTO (TN)
DMQMBZ1	CP	Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development
DMQMBZ1	DT	Small molecular drug
DMQMBZ1	PC	9875401
DMQMBZ1	MW	435.9
DMQMBZ1	FM	C19H18ClN3O5S
DMQMBZ1	IC	InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
DMQMBZ1	CS	C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl
DMQMBZ1	IK	KGFYHTZWPPHNLQ-AWEZNQCLSA-N
DMQMBZ1	IU	5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
DMQMBZ1	CA	CAS 366789-02-8
DMQMBZ1	CB	CHEBI:68579
DMQMBZ1	DE	Deep vein thrombosis

DMG629M	ID	DMG629M
DMG629M	DN	Rivastigmine
DMG629M	HS	Approved
DMG629M	SN	Rivastigmine (transdermal patch)
DMG629M	CP	Samyang Corp
DMG629M	DT	Small molecular drug
DMG629M	PC	77991
DMG629M	MW	250.34
DMG629M	FM	C14H22N2O2
DMG629M	IC	InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
DMG629M	CS	CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
DMG629M	IK	XSVMFMHYUFZWBK-NSHDSACASA-N
DMG629M	IU	[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
DMG629M	CA	CAS 123441-03-2
DMG629M	CB	CHEBI:8874
DMG629M	DE	Alzheimer disease

DMDJMA3	ID	DMDJMA3
DMDJMA3	DN	Rizatriptan
DMDJMA3	HS	Approved
DMDJMA3	SN	Risatriptan; Rizatriptanum; Rizatriptan benzoat; MK 462 free base; Maxalt (TN); Rizaliv (TN); Rizalt (TN); Rizatriptan (INN); Rizatriptan [INN:BAN]; N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine; N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine; N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
DMDJMA3	CP	Merck & Co
DMDJMA3	TC	Antiinflammatory Agents
DMDJMA3	DT	Small molecular drug
DMDJMA3	PC	5078
DMDJMA3	MW	269.34
DMDJMA3	FM	C15H19N5
DMDJMA3	IC	InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
DMDJMA3	CS	CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3
DMDJMA3	IK	ULFRLSNUDGIQQP-UHFFFAOYSA-N
DMDJMA3	IU	N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
DMDJMA3	CA	CAS 144034-80-0
DMDJMA3	CB	CHEBI:48273
DMDJMA3	DE	Migraine

DMY9BMK	ID	DMY9BMK
DMY9BMK	DN	Rocuronium
DMY9BMK	HS	Approved
DMY9BMK	SN	Esmeron (TN); Zemuron (TN); (2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMY9BMK	CP	Gland Pharma Ltd
DMY9BMK	TC	Neuromuscular Nondepolarizing Agents
DMY9BMK	DT	Small molecular drug
DMY9BMK	PC	441290
DMY9BMK	MW	529.8
DMY9BMK	FM	C32H53N2O4+
DMY9BMK	IC	InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1
DMY9BMK	CS	CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C
DMY9BMK	IK	YXRDKMPIGHSVRX-OOJCLDBCSA-N
DMY9BMK	IU	[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMY9BMK	CA	CAS 143558-00-3
DMY9BMK	CB	CHEBI:8884
DMY9BMK	DE	Muscle spasm

DM3P5DA	ID	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	HS	Approved
DM3P5DA	SN	Ceoxx; Refecoxib; Vioxx; Cahill May Roberts brand of rofecoxib; MSD brand of rofecoxib; Merck Frosst brandof rofecoxib; Merck brand of rofecoxib; Vioxx Dolor; MK 0966; MK 0996; MK 966; MK0966; Ceeoxx (TN); Ceoxx (TN); KS-1107; MK-0966; MK-966; Merck Sharp & Dhome brand of rofecoxib; Vioxx (TN); Vioxx (trademark); Rofecoxib (JAN/USAN/INN); 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one
DM3P5DA	CP	Merck & Co
DM3P5DA	TC	Antiinflammatory Agents
DM3P5DA	DT	Small molecular drug
DM3P5DA	PC	5090
DM3P5DA	MW	314.4
DM3P5DA	FM	C17H14O4S
DM3P5DA	IC	InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
DM3P5DA	CS	CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3
DM3P5DA	IK	RZJQGNCSTQAWON-UHFFFAOYSA-N
DM3P5DA	IU	3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one
DM3P5DA	CA	CAS 162011-90-7
DM3P5DA	CB	CHEBI:8887
DM3P5DA	DE	Osteoarthritis

DMPGHY8	ID	DMPGHY8
DMPGHY8	DN	Roflumilast
DMPGHY8	HS	Approved
DMPGHY8	SN	162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide;  DAXAS; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast
DMPGHY8	CP	Nycomed US Inc; Altana
DMPGHY8	DT	Small molecular drug
DMPGHY8	PC	449193
DMPGHY8	MW	403.2
DMPGHY8	FM	C17H14Cl2F2N2O3
DMPGHY8	IC	InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
DMPGHY8	CS	C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
DMPGHY8	IK	MNDBXUUTURYVHR-UHFFFAOYSA-N
DMPGHY8	IU	3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
DMPGHY8	CA	CAS 162401-32-3
DMPGHY8	CB	CHEBI:47657
DMPGHY8	DE	Asthma; Atopic dermatitis; Type-2 diabetes; Chronic obstructive pulmonary disease

DMCZWOK	ID	DMCZWOK
DMCZWOK	DN	Rokitamycin
DMCZWOK	HS	Approved
DMCZWOK	SN	Ricamycin (TN)
DMCZWOK	CP	Toyo Jozo Co Ltd
DMCZWOK	DT	Small molecular drug
DMCZWOK	PC	5282211
DMCZWOK	MW	828
DMCZWOK	FM	C42H69NO15
DMCZWOK	IC	InChI=1S/C42H69NO15/c1-11-16-32(48)55-40-27(6)53-34(23-42(40,7)58-31(47)12-2)56-37-26(5)54-41(36(50)35(37)43(8)9)57-38-28(19-20-44)21-24(3)29(45)18-15-13-14-17-25(4)52-33(49)22-30(46)39(38)51-10/h13-15,18,20,24-30,34-41,45-46,50H,11-12,16-17,19,21-23H2,1-10H3/b14-13+,18-15+/t24-,25-,26-,27+,28+,29+,30-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1
DMCZWOK	CS	CCCC(=O)O[C@H]1[C@@H](O[C@H](C[C@@]1(C)OC(=O)CC)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2N(C)C)O)O[C@H]3[C@H](C[C@H]([C@H](/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]3OC)O)C)O)C)CC=O)C)C
DMCZWOK	IK	VYWWNRMSAPEJLS-MDWYKHENSA-N
DMCZWOK	IU	[(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-2,4-dimethyl-4-propanoyloxyoxan-3-yl] butanoate
DMCZWOK	CA	CAS 74014-51-0
DMCZWOK	CB	CHEBI:32103
DMCZWOK	DE	Bacterial infection

DM8XP26	ID	DM8XP26
DM8XP26	DN	Rolapitant
DM8XP26	HS	Approved
DM8XP26	SN	Rolapitant; 552292-08-7; Sch 619734; Varubi; UNII-NLE429IZUC; SCH-619734; NLE429IZUC; 914462-92-3; (5S,8S)-8-(((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one; (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one; Rolapitant [USAN:INN]; Varuby; Varubi (TN); Rolapitant (USAN/INN); Rolapitant(sch619734); SCHEMBL354305; GTPL5749; CHEMBL3707331; CHEBI:90908; DTXSID90203740; MolPort-035-942-975; EX-A1288; BCP09609; ZINC3816514
DM8XP26	CP	TESARO
DM8XP26	DT	Small molecular drug
DM8XP26	PC	10311306
DM8XP26	MW	500.5
DM8XP26	FM	C25H26F6N2O2
DM8XP26	IC	InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1
DM8XP26	CS	C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@]3(CCC(=O)N3)CN2)C4=CC=CC=C4
DM8XP26	IK	FIVSJYGQAIEMOC-ZGNKEGEESA-N
DM8XP26	IU	(5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one
DM8XP26	CA	CAS 552292-08-7
DM8XP26	CB	CHEBI:90908
DM8XP26	DE	Chemotherapy-induced nausea

DMBR5Q7	ID	DMBR5Q7
DMBR5Q7	DN	Rolitetracycline
DMBR5Q7	HS	Approved
DMBR5Q7	SN	Bristacin; Kinteto; Pyrrolidinomethyltetracycline; Reverin; Revrin; Rolitetraciclina; Rolitetracyclinum; Solvocillin; Superciclin; Synotodecin; Synterin; Syntetrex; Syntetrin; Tetraverin; Transcycline; Velacicline; Velacycline; AAT 4; SQ 15659; Pirrolidinometil-tetraciclina; Pirrolidinometil-tetraciclina [Italian]; Prm-TC; Rolitetraciclina [INN-Spanish]; Rolitetracyclinum [INN-Latin]; SQ 15,659; Synterin (TN); N-(Pyrrolidinomethyl)tetracycline; Pyrrolidino-methyl-tetracycline; N-Pyrrolidino-methyl-tetracycline; Rolitetracycline (JAN/USAN/INN); Rolitetracycline [USAN:INN:BAN:JAN]; N-(1-Pyrrolidinylmethyl)-tetracycline; (2Z,4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide
DMBR5Q7	TC	Antibiotics
DMBR5Q7	DT	Small molecular drug
DMBR5Q7	PC	54682938
DMBR5Q7	MW	527.6
DMBR5Q7	FM	C27H33N3O8
DMBR5Q7	IC	InChI=1S/C27H33N3O8/c1-26(37)13-7-6-8-16(31)17(13)21(32)18-14(26)11-15-20(29(2)3)22(33)19(24(35)27(15,38)23(18)34)25(36)28-12-30-9-4-5-10-30/h6-8,14-15,20,31-32,35,37-38H,4-5,9-12H2,1-3H3,(H,28,36)/t14-,15-,20-,26+,27-/m0/s1
DMBR5Q7	CS	C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCN5CCCC5)N(C)C)O
DMBR5Q7	IK	IKQRPFTXKQQLJF-IAHYZSEUSA-N
DMBR5Q7	IU	(4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-N-(pyrrolidin-1-ylmethyl)-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMBR5Q7	CA	CAS 751-97-3
DMBR5Q7	CB	CHEBI:63334
DMBR5Q7	DE	Acne vulgaris

DMT5GNL	ID	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	HS	Approved
DMT5GNL	SN	Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
DMT5GNL	CP	Gloucester Pharmaceuticals; Fujisawa Pharmaceutical Ltd.
DMT5GNL	DT	Small molecular drug
DMT5GNL	PC	5352062
DMT5GNL	MW	540.7
DMT5GNL	FM	C24H36N4O6S2
DMT5GNL	IC	InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
DMT5GNL	CS	C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C
DMT5GNL	IK	OHRURASPPZQGQM-GCCNXGTGSA-N
DMT5GNL	IU	(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
DMT5GNL	CA	CAS 128517-07-7
DMT5GNL	CB	CHEBI:61080
DMT5GNL	DE	Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; Renal cell carcinoma

DM3U7SZ	ID	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	HS	Approved
DM3U7SZ	CP	Amgen
DM3U7SZ	DT	Small molecular drug
DM3U7SZ	SQ	Thrombopoietin receptor binding domain amino acid sequence : IEGPTLRQWLAARA</sequence>    <sequence format="FASTA">&gt;Amino acid sequence for Fc fusion compoundMDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGIEGPTLRQWLAARAGGGGGGGGIEGPTLRQWLAARA
DM3U7SZ	PC	5329098
DM3U7SZ	MW	238.28
DM3U7SZ	FM	C15H14N2O
DM3U7SZ	IC	InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
DM3U7SZ	CS	CC1=CC(=C(N1)/C=C\\2/C3=CC=CC=C3NC2=O)C
DM3U7SZ	IK	WUWDLXZGHZSWQZ-WQLSENKSSA-N
DM3U7SZ	IU	(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
DM3U7SZ	CA	CAS 194413-58-6
DM3U7SZ	CB	CHEBI:91083
DM3U7SZ	DE	Thrombocytopenia; Multiple myeloma; Myelodysplastic syndrome

DMFJZN0	ID	DMFJZN0
DMFJZN0	DN	Romosozumab
DMFJZN0	HS	Approved
DMFJZN0	SN	AMG 785
DMFJZN0	CP	Amgen
DMFJZN0	DT	Antibody
DMFJZN0	DE	Postmenopausal osteoporosis

DMA6S1D	ID	DMA6S1D
DMA6S1D	DN	Ropinirole
DMA6S1D	HS	Approved
DMA6S1D	SN	Ropinirol; Ropinirolum; Ropitor; ReQuip CR; ReQuip XL; SKF 101468; Adartrel (TN); Requip (TN); Ropark (TN); Ropinirol[INN-Spanish]; Ropinirole (INN); Ropinirole [INN:BAN]; Ropinirolum [INN-Latin]; Ropitor (TN); SK&F 101468; SK&F-101,468; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
DMA6S1D	CP	GlaxoSmithKline plc
DMA6S1D	TC	Antiparkinson Agents
DMA6S1D	DT	Small molecular drug
DMA6S1D	PC	5095
DMA6S1D	MW	260.37
DMA6S1D	FM	C16H24N2O
DMA6S1D	IC	InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
DMA6S1D	CS	CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
DMA6S1D	IK	UHSKFQJFRQCDBE-UHFFFAOYSA-N
DMA6S1D	IU	4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
DMA6S1D	CA	CAS 91374-21-9
DMA6S1D	CB	CHEBI:8888
DMA6S1D	DE	Parkinson disease

DMSPJG2	ID	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	HS	Approved
DMSPJG2	SN	Naropin; ROPIVACAINE HCl; Ropivacaine hydrochloride; Ropivacaine monohydrochloride; Naropin (TN); Ropivacaine monohydrochloride, (S)-isomer; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
DMSPJG2	CP	AstraZeneca
DMSPJG2	TC	Anesthetics
DMSPJG2	DT	Small molecular drug
DMSPJG2	PC	175805
DMSPJG2	MW	274.4
DMSPJG2	FM	C17H26N2O
DMSPJG2	IC	InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1
DMSPJG2	CS	CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C
DMSPJG2	IK	ZKMNUMMKYBVTFN-HNNXBMFYSA-N
DMSPJG2	IU	(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
DMSPJG2	CA	CAS 84057-95-4
DMSPJG2	CB	CHEBI:8890
DMSPJG2	DE	Anaesthesia

DMILWZR	ID	DMILWZR
DMILWZR	DN	Rosiglitazone
DMILWZR	HS	Approved
DMILWZR	PC	77999
DMILWZR	FM	C18H19N3O3S
DMILWZR	IC	InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
DMILWZR	CS	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
DMILWZR	IK	YASAKCUCGLMORW-UHFFFAOYSA-N
DMILWZR	IU	5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMILWZR	CA	CAS 122320-73-4
DMILWZR	CB	CHEBI:50122
DMILWZR	DE	Type 2 diabetes

DMY6EAO	ID	DMY6EAO
DMY6EAO	DN	Rosiglitazone
DMY6EAO	HS	Approved
DMY6EAO	SN	Rosigilitazone; Rosiglitazone [INN:BAN]; Rosiglitazone maleate; Rosiglizole; TDZ 01; YASAKCUCGLMORW-UHFFFAOYSA-N; Avandamet; Avandaryl; Avandia; rosiglitazona; rosiglitazone; rosiglitazone (Avandia); rosiglitazonum; 122320-73-4; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; BRL49653; Brl 49653; Brl-49653; C18H19N3O3S; CHEBI:50122
DMY6EAO	PC	77999
DMY6EAO	MW	357.4
DMY6EAO	FM	C18H19N3O3S
DMY6EAO	IC	YASAKCUCGLMORW-UHFFFAOYSA-N
DMY6EAO	CS	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
DMY6EAO	IK	1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
DMY6EAO	IU	5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMY6EAO	CA	CAS 122320-73-4
DMY6EAO	CB	CHEBI:50122
DMY6EAO	DE	Diabetes mellitus

DMT45MU	ID	DMT45MU
DMT45MU	DN	Rosiglitazone XR
DMT45MU	HS	Approved
DMT45MU	SN	Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate
DMT45MU	CP	GSK
DMT45MU	DT	Small molecular drug
DMT45MU	PC	5281055
DMT45MU	MW	473.5
DMT45MU	FM	C22H23N3O7S
DMT45MU	IC	InChI=1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-
DMT45MU	CS	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3.C(=C\\C(=O)O)\\C(=O)O
DMT45MU	IK	SUFUKZSWUHZXAV-BTJKTKAUSA-N
DMT45MU	IU	(Z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMT45MU	CA	CAS 155141-29-0
DMT45MU	CB	CHEBI:8892
DMT45MU	DE	Type-2 diabetes; Alzheimer disease

DMVOIK1	ID	DMVOIK1
DMVOIK1	DN	Rosoxacin
DMVOIK1	HS	Approved
DMVOIK1	SN	Acrosoxacin; Eracine; Eradacil; Eradacin; Rosoxacine; Rosoxacino; Rosoxacinum; Roxadyl; Winuron; PD 107522; WIN 35213;Eradacil (TN); Rosoxacin [USAN:INN]; Rosoxacine [INN-French]; Rosoxacino [INN-Spanish]; Rosoxacinum [INN-Latin]; Roxadyl (TN); Win 35,213; Win-35123; Rosoxacin (USAN/INN); 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid; 1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
DMVOIK1	CP	Sanofi-Aventis
DMVOIK1	TC	Antiinfective Agents
DMVOIK1	DT	Small molecular drug
DMVOIK1	PC	287180
DMVOIK1	MW	294.3
DMVOIK1	FM	C17H14N2O3
DMVOIK1	IC	InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)
DMVOIK1	CS	CCN1C=C(C(=O)C2=C1C=C(C=C2)C3=CC=NC=C3)C(=O)O
DMVOIK1	IK	XBPZXDSZHPDXQU-UHFFFAOYSA-N
DMVOIK1	IU	1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
DMVOIK1	CA	CAS 40034-42-2
DMVOIK1	CB	CHEBI:131715
DMVOIK1	DE	Bacterial infection

DMMIQ7G	ID	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	HS	Approved
DMMIQ7G	SN	Astende; Cirantan; Cresadex; Creston; Crestor; Provisacor; Razel; Rosedex; Rosimol; Rosumed; Rosustatin; Rosuvas; Rosuvast; Rosvel; Rovartal; Simestat; Sinlip; Vivacor; Rosuvastatin [INN]; Rosuvastatin calcium; Rosuvastatin calcium [USAN]; Rosuvastatin hemicalcium; S 4522; ZD 4522; ZD4522; AZD-4522; Creston (TN);Crestor (TN); Pyrimidine Compound, 26; Rosuvastatin (INN); S-4522; ZD 4522, calcium salt; ZD-4522; Rosuvastatin calcium (JAN/USAN); Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhelpt-6-enoic acid] calcium salt; Calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (S-((R*,S*-(E)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); (S-(R*,S*-(E)))-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)
DMMIQ7G	CP	AstraZeneca
DMMIQ7G	TC	Anticholesteremic Agents
DMMIQ7G	DT	Small molecular drug
DMMIQ7G	PC	446157
DMMIQ7G	MW	481.5
DMMIQ7G	FM	C22H28FN3O6S
DMMIQ7G	IC	InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1
DMMIQ7G	CS	CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
DMMIQ7G	IK	BPRHUIZQVSMCRT-VEUZHWNKSA-N
DMMIQ7G	IU	(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
DMMIQ7G	CA	CAS 287714-41-4
DMMIQ7G	CB	CHEBI:38545
DMMIQ7G	DE	Hypercholesterolaemia; Elevated C-reactive protein

DMP7X6Q	ID	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	HS	Approved
DMP7X6Q	SN	Rotigotine; Rotigotine CDS; Rotigotine CDS Patch; SPM 962; SPM-962; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; Leganto; N 0923; Neupro; (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; (S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; 87T4T8BO2E; 99755-59-6; C19H25NOS; CHEMBL1303; DSSTox_CID_26772; DSSTox_RID_81893; NCGC00168748-01; UNII-87T4T8BO2E
DMP7X6Q	PC	59227
DMP7X6Q	MW	315.5
DMP7X6Q	FM	C19H25NOS
DMP7X6Q	IC	KFQYTPMOWPVWEJ-INIZCTEOSA-N
DMP7X6Q	CS	CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
DMP7X6Q	IK	1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
DMP7X6Q	IU	(6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMP7X6Q	CA	CAS 99755-59-6
DMP7X6Q	CB	CHEBI:135351
DMP7X6Q	DE	Parkinsonism

DM9PVX8	ID	DM9PVX8
DM9PVX8	DN	Rucaparib
DM9PVX8	HS	Approved
DM9PVX8	SN	RUCAPARIB; 283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one
DM9PVX8	CP	Clovis Oncology
DM9PVX8	DT	Small molecular drug
DM9PVX8	PC	9931954
DM9PVX8	MW	323.4
DM9PVX8	FM	C19H18FN3O
DM9PVX8	IC	InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
DM9PVX8	CS	CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2
DM9PVX8	IK	HMABYWSNWIZPAG-UHFFFAOYSA-N
DM9PVX8	IU	6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
DM9PVX8	CA	CAS 283173-50-2
DM9PVX8	CB	CHEBI:94311
DM9PVX8	DE	Ovarian cancer

DMWE60C	ID	DMWE60C
DMWE60C	DN	Rufinamide
DMWE60C	HS	Approved
DMWE60C	SN	106308-44-5; Inovelon; Banzel; 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide; CGP-33101; Cgp 33101; Xilep; 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide; RUF-331; UNII-WFW942PR79; RUF 331; 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide; WFW942PR79; C10H8F2N4O; E 2080; POGQSBRIGCQNEG-UHFFFAOYSA-N; 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-; NCGC00165883-02; E2080; DSSTox_CID_26506; DSSTox_RID_81675; DSSTox_GSID_46506;  Banzel; Banzel, Rufinamide; E-2080; SYN-111; Rufinamide (USAN/INN); Inovelon/Banzel
DMWE60C	CP	Eisai
DMWE60C	DT	Small molecular drug
DMWE60C	PC	129228
DMWE60C	MW	238.19
DMWE60C	FM	C10H8F2N4O
DMWE60C	IC	InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
DMWE60C	CS	C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F
DMWE60C	IK	POGQSBRIGCQNEG-UHFFFAOYSA-N
DMWE60C	IU	1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
DMWE60C	CA	CAS 106308-44-5
DMWE60C	CB	CHEBI:134966
DMWE60C	DE	Seizure disorder; Pediatric lennox-gastaut syndrome; Epilepsy

DM7Q98D	ID	DM7Q98D
DM7Q98D	DN	Ruxolitinib
DM7Q98D	HS	Approved
DM7Q98D	SN	Ruxolitinib (JAK inhibitor)
DM7Q98D	CP	Incyte
DM7Q98D	DT	Small molecular drug
DM7Q98D	PC	25126798
DM7Q98D	MW	306.4
DM7Q98D	FM	C17H18N6
DM7Q98D	IC	InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
DM7Q98D	CS	C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM7Q98D	IK	HFNKQEVNSGCOJV-OAHLLOKOSA-N
DM7Q98D	IU	(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
DM7Q98D	CA	CAS 941678-49-5
DM7Q98D	CB	CHEBI:66919
DM7Q98D	DE	High-risk myelofibrosis; Pancreatic cancer; Essential thrombocythemia; Atopic dermatitis; Vitiligo

DMOFP18	ID	DMOFP18
DMOFP18	DN	Ryzodeq
DMOFP18	HS	Approved
DMOFP18	CP	Novo nordisk
DMOFP18	DE	Type-2 diabetes

DM0YWJC	ID	DM0YWJC
DM0YWJC	DN	Safinamide
DM0YWJC	HS	Approved
DM0YWJC	SN	133865-89-1; Xadago; (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide; Fce-26743; UNII-90ENL74SIG; (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide; EMD 1195686; 90ENL74SIG; CHEMBL396778; EMD-1195686; AK-77847; 2(s)-(4-(3-fluorobenzyloxy)benzylamino)propionamide; CHEMBL48582; Safinamide [USAN:INN]; 2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide; AC1L2ZLK; Safinamide (USAN/INN); (S)-2-(((4-((3-Fluorophenyl)methoxy)phenyl)methyl)amino)propanamide; EC 603-772-2; SCHEMBL69350; Fce 26743; ON 019190.Na
DM0YWJC	CP	Us Worldmeds
DM0YWJC	DT	Small molecular drug
DM0YWJC	PC	131682
DM0YWJC	MW	302.34
DM0YWJC	FM	C17H19FN2O2
DM0YWJC	IC	InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DM0YWJC	CS	C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F
DM0YWJC	IK	NEMGRZFTLSKBAP-LBPRGKRZSA-N
DM0YWJC	IU	(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DM0YWJC	CA	CAS 133865-89-1
DM0YWJC	CB	CHEBI:134718
DM0YWJC	DE	Parkinson disease; Idiopathic parkinson disease

DM0J2ZT	ID	DM0J2ZT
DM0J2ZT	DN	Safinamide mesylate
DM0J2ZT	HS	Approved
DM0J2ZT	SN	Safinamide mesylate; Safinamide mesilate; PNU-151774E; UNII-YS90V3DTX0; FCE-28073; NW-1015; Safinamide mesylate [USAN]; YS90V3DTX0; FCE-28073(R-isomer); Safinamide mesylate (USAN); safinamide methanesulfonate; PNU 151774E; Xadago (TN); NW 1015; AC1MI4YU; Safinamide mesilate (JAN)
DM0J2ZT	CP	US WorldMeds
DM0J2ZT	PC	3038502
DM0J2ZT	MW	398.5
DM0J2ZT	FM	C18H23FN2O5S
DM0J2ZT	IC	InChI=1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m0./s1
DM0J2ZT	CS	C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F.CS(=O)(=O)O
DM0J2ZT	IK	YKOCHIUQOBQIAC-YDALLXLXSA-N
DM0J2ZT	IU	(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid
DM0J2ZT	CA	CAS 202825-46-5
DM0J2ZT	DE	Parkinson disease

DMN9CWF	ID	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	HS	Approved
DMN9CWF	SN	Aerolin; Airomir; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmaven; Asmidon; Asmol; Asthalin; Asthavent; Broncovaleas; Bronter; Bugonol; Bumol; Butamol; Butohaler; Butotal; Butovent; Buventol; Cetsim; Cobutolin; Dilatamol; Ecovent; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Mozal; Novosalmol; Parasma; Pneumolat; Proventil; Respax; Respolin; Rotahaler; Sabutal; Sabutamol; Salamol; Salbetol; Salbron; Salbuhexal; Salbulin; Salbupur; Salbusian; Salbutalan; Salbutamolum; Salbutan; Salbutard; Salbutine; Salbutol; Salbuven; Salbuvent; Sallbupp; Salmaplon; Salomol; Salvent; Saventol; Servitamol; Solbutamol; Spreor; Sultanol; Suprasma; Suxar; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Ventiloboi; Ventodisks; Ventoline; Volma; Volmax; Zaperin; Albuterol Sulphate; Albuterol [USAN]; Albuterol hemisulfate; Proventil HFA; Proventil Inhaler; Salbutamol Sulphate; Salbutamol sulfate; Sultanol N; Ventalin inhaler; Ventolin Inhaler; Ventolin Rotacaps; Volare albuterol HFA; AH 3365; S 8260; Aerolin (TN); Albuterol (USP); Alti-Salbutamol; Arubendol-Salbutamol; Asmol Uni-Dose; Asthalin (TN); Broncho-Spray; Buto-Asma; Dl-Albuterol; Dl-Salbutamol; ProAi (TN); Proventil (TN); Racemic-Salbutamol; Salbu-BASF; Salbu-Fatol; Salbutamolum [INN-Latin]; Ventolin (TN); Volare easi-breathe; R,S-Albuterol; Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol; Alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
DMN9CWF	CP	GlaxoSmithKline
DMN9CWF	TC	Bronchodilator Agents
DMN9CWF	DT	Small molecular drug
DMN9CWF	PC	2083
DMN9CWF	MW	239.31
DMN9CWF	FM	C13H21NO3
DMN9CWF	IC	InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
DMN9CWF	CS	CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
DMN9CWF	IK	NDAUXUAQIAJITI-UHFFFAOYSA-N
DMN9CWF	IU	4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DMN9CWF	CA	CAS 18559-94-9
DMN9CWF	CB	CHEBI:2549
DMN9CWF	DE	Acute asthma

DM1T2LS	ID	DM1T2LS
DM1T2LS	DN	Salicin
DM1T2LS	HS	Approved
DM1T2LS	SN	salicin; 138-52-3; Salicoside; Salicine; Salicyl alcohol glucoside; D-(-)-Salicin; (2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-(2-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triol; 2-(Hydroxymethyl)phenyl beta-D-glucopyranoside; Saligenin beta-D-glucopyranoside; D-Salicin; Saligenin-beta-D-glucopyranoside; 2-(Hydroxymethyl)phenyl-beta-d-glucopyranoside; Salicin (6CI,8CI); D(-)-Salicin; o-(Hydroxymethyl)phenyl beta-D-glucopyranoside; Benzyl alcohol, o-hydroxy-, o-glucoside; UNII-4649620TBZ; AI3-19099; alpha-Hydroxy-o-tolyl beta
DM1T2LS	DT	Small molecular drug
DM1T2LS	PC	439503
DM1T2LS	MW	286.28
DM1T2LS	FM	C13H18O7
DM1T2LS	IC	InChI=1S/C13H18O7/c14-5-7-3-1-2-4-8(7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-4,9-18H,5-6H2/t9-,10-,11+,12-,13-/m1/s1
DM1T2LS	CS	C1=CC=C(C(=C1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM1T2LS	IK	NGFMICBWJRZIBI-UJPOAAIJSA-N
DM1T2LS	IU	(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triol
DM1T2LS	CA	CAS 138-52-3
DM1T2LS	CB	CHEBI:17814
DM1T2LS	DE	Analgesia

DM2F8XZ	ID	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	HS	Approved
DM2F8XZ	SN	Salicylic acid; salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Salonil; Rutranex; Retarder W; Keralyt; Freezone; Duoplant; Saligel; Ionil; Psoriacid-S-stift; salicylate; Stri-Dex; Salicylic acid soap; Benzoic acid, 2-hydroxy-; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech; Kyselina salicylova; Clear away wart remover; Duofil wart;  Domerine; Duofilm; Occlusal; SAX; Salicylate; Sebucare; Sebulex; Acido salicilico [Italian]; Advanced pain relief callus removers; Advanced pain relief corn removers; Akurza Cream; Akurza Lotion; DHS Sal Shampoo; DuoPlant Gel; Duofil wart remover; Hydrisalic Gel; Ionil plus; Kyselina salicylova [Czech]; Mediplast pads; O Hydroxybenzoic Acid; Ortho Hydroxybenzoic Acid; Retarder SAX; Salex Cream; Salex Lotion; CMC_13852; K 537; ATA fraction 10, ammonium salt; Acid, Salicylic; Acido o-idrossibenzoico; Acido o-idrossibenzoico [Italian]; Kyselina 2-hydroxybenzoova; Kyselina 2-hydroxybenzoova [Czech]; O-Carboxyphenol; O-hydroxybenzoic acid; Ortho-Hydroxybenzoic Acid; P&S Shampoo; Phenol derivative, 7; Propa pH Peel-Off Acne Mask; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); SALICYLIC ACID, ACS; Salicylic acid & Sulfur Soap; Salicylic acid (TN); Salicylic acid [USAN:JAN]; Acid, 2-Hydroxybenzoic; Acid, o-Hydroxybenzoic; Acid, ortho-Hydroxybenzoic; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; Dr Scholl's callus removers; Dr Scholl's corn removers; Dr Scholl's wart remover kit; Salicylic acid (6CI,8CI); Salicylic acid (JP15/USP); Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); Salicylic acid-ring-UL-14C; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); Benzoic acid, 2-hydroxy-(9CI); E9A559BE-383B-4F83-BC02-3031D03D558A; 2 Hydroxybenzoic Acid; 2-hydroxy(1-14c)benzoic acid; SALICYLATE
DM2F8XZ	TC	Antiinflammatory Agents
DM2F8XZ	DT	Small molecular drug
DM2F8XZ	PC	338
DM2F8XZ	MW	138.12
DM2F8XZ	FM	C7H6O3
DM2F8XZ	IC	InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
DM2F8XZ	CS	C1=CC=C(C(=C1)C(=O)O)O
DM2F8XZ	IK	YGSDEFSMJLZEOE-UHFFFAOYSA-N
DM2F8XZ	IU	2-hydroxybenzoic acid
DM2F8XZ	CA	CAS 69-72-7
DM2F8XZ	CB	CHEBI:16914
DM2F8XZ	DE	Seborrhoeic dermatitis

DMIEU69	ID	DMIEU69
DMIEU69	DN	Salmeterol
DMIEU69	HS	Approved
DMIEU69	SN	Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
DMIEU69	CP	GlaxoSmithKline
DMIEU69	TC	Bronchodilator Agents
DMIEU69	DT	Small molecular drug
DMIEU69	PC	5152
DMIEU69	MW	415.6
DMIEU69	FM	C25H37NO4
DMIEU69	IC	InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2
DMIEU69	CS	C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O
DMIEU69	IK	GIIZNNXWQWCKIB-UHFFFAOYSA-N
DMIEU69	IU	2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
DMIEU69	CA	CAS 89365-50-4
DMIEU69	CB	CHEBI:64064
DMIEU69	DE	Chronic obstructive pulmonary disease

DMEWUPF	ID	DMEWUPF
DMEWUPF	DN	Salmon Calcitonin
DMEWUPF	HS	Approved
DMEWUPF	SN	Astronin; Biocalcin; Bionocalcin; Cadens; Calciben; Calcihexal; Calcimar; Calcimonta; Calcinil; Calcioton; Calcitonina; Calcitoran; Calco; Calogen; Calsynar; Caltine; Casalm; Catonin; Cibacalcine; Citonina; Eptacalcin; Forcaltonin; Fortical; Ipocalcin; Kalsimin; Karil; Miacalcic; Miacalcin; Miracalcic; Oseototal; Osseocalcina; Osteobion; Osteovis; Ostosalm; Ostostabil; Porostenina; Prontocalcin; Quosten; Riostin; Rulicalcin; Salcat; Salcatonin; Salcatyn; Salmocalcin; Salmofar; Sical; Stalcin; Staporos; Steocin; Tonocalcin; Ucecal; Calcitonin salmon; Calcitonin vom lachs; Calcitonine de saumon; Calsynar Lyo L; Recombinant salmon calcitonin; Salmon calcitonin I; Synthetic salmon calcitonin; CALCITONIN, SALMON; Calcimar (TN); Calcitonin (salmon); Calcitonin salmon (synthesis); Calcitonin, salmar; Calcitonin,salmon; Calcitonin-salmon; Fortical (TN); Isi-calcin; Miacalcin (TN); TZ-CT; Thyrocalcitonin (salmon); Calcitonin salmon (USAN/INN); Calcitonin salmon (synthesis) (JAN); Calcitonin, salmon, for bioassay; Salmon calcitonin (1-32); Calcitonin [USAN:INN:BAN:JAN]; Salmon calcitonin-(I-32)
DMEWUPF	TC	Antiosteporotic Agents
DMEWUPF	DT	Small molecular drug
DMEWUPF	SQ	DB00017 sequence: CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP
DMEWUPF	PC	16129616
DMEWUPF	MW	3431.9
DMEWUPF	FM	C145H240N44O48S2
DMEWUPF	IC	InChI=1S/C145H240N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99-63-239-238-62-79(148)117(210)178-96(59-191)134(227)174-92(52-104(151)202)131(224)172-90(49-69(9)10)129(222)180-98(61-193)135(228)187-114(74(16)197)142(235)181-99)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)
DMEWUPF	CS	CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)N)CO)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO
DMEWUPF	IK	BBBFJLBPOGFECG-UHFFFAOYSA-N
DMEWUPF	IU	4-[[5-amino-2-[[2-[[2-[[6-amino-2-[[2-[[2-[[2-[[22-amino-16-(2-amino-2-oxoethyl)-7-(1-hydroxyethyl)-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[1-[[1-[[6-amino-1-[[1-[[5-amino-1-[[1-[[1-[2-[[1-[[1-[[4-amino-1-[[1-[[2-[[1-[[2-[[1-(2-carbamoylpyrrolidin-1-yl)-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMEWUPF	CA	CAS 9007-12-9
DMEWUPF	DE	Osteoporosis

DM13P4C	ID	DM13P4C
DM13P4C	DN	Salsalate
DM13P4C	HS	Approved
DM13P4C	SN	Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid
DM13P4C	TC	Antiinflammatory Agents
DM13P4C	DT	Small molecular drug
DM13P4C	PC	5161
DM13P4C	MW	258.23
DM13P4C	FM	C14H10O5
DM13P4C	IC	InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
DM13P4C	CS	C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O
DM13P4C	IK	WVYADZUPLLSGPU-UHFFFAOYSA-N
DM13P4C	IU	2-(2-hydroxybenzoyl)oxybenzoic acid
DM13P4C	CA	CAS 552-94-3
DM13P4C	CB	CHEBI:9014
DM13P4C	DE	Rheumatoid arthritis

DM62MUZ	ID	DM62MUZ
DM62MUZ	DN	Samarium Sm-153 Lexidronam Pentasodium
DM62MUZ	HS	Approved
DM62MUZ	CP	Lantheus Medical Imaging Inc
DM62MUZ	TC	Neurology Agents
DM62MUZ	DT	Small molecular drug
DM62MUZ	PC	9810246
DM62MUZ	MW	695.93
DM62MUZ	FM	C6H12N2Na5O12P4Sm
DM62MUZ	IC	InChI=1S/C6H20N2O12P4.5Na.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;;;;;;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);;;;;;/q;5*+1;+3/p-8/i;;;;;;1+3
DM62MUZ	CS	C(CN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])N(CP(=O)([O-])[O-])CP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[153Sm+3]
DM62MUZ	IK	SZZACTGRBZTAKY-NKNBZPHVSA-F
DM62MUZ	IU	pentasodium;samarium-153(3+);N,N,N',N'-tetrakis(phosphonatomethyl)ethane-1,2-diamine
DM62MUZ	DE	Cancer related pain

DMDINFS	ID	DMDINFS
DMDINFS	DN	Sanguinarine
DMDINFS	HS	Approved
DMDINFS	SN	SANGUINARINE; 2447-54-3; Pseudochelerythrine; Sanguinarin; sangvinarin; Veadent; Sanguiritrin; SANGUINARIUM; Dimethylenedioxy benzphenanthridine; UNII-AV9VK043SS; C20H14NO4; EINECS 219-503-3; Benzophenanthridine alkaloid; BRN 3915507; AV9VK043SS; CHEBI:17183; NCGC00015959-03; CAS-2447-54-3; [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-; DSSTox_RID_80748; DSSTox_CID_25204; DSSTox_GSID_45204; 13-Methyl[1,3]benzodioxolo[5,6-C][1,3]dioxolo[4,5-I]phenanthridin-13-Ium; Sangrovit; y-Chelerythrine; SR-01000075650
DMDINFS	DT	Small molecular drug
DMDINFS	PC	5154
DMDINFS	MW	332.3
DMDINFS	FM	C20H14NO4+
DMDINFS	IC	InChI=1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1
DMDINFS	CS	C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6
DMDINFS	IK	INVGWHRKADIJHF-UHFFFAOYSA-N
DMDINFS	IU	24-methyl-5,7,18,20-tetraoxa-24-azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene
DMDINFS	CA	CAS 2447-54-3
DMDINFS	CB	CHEBI:17183
DMDINFS	DE	Dental plaque

DM5VP0F	ID	DM5VP0F
DM5VP0F	DN	Saphris
DM5VP0F	HS	Approved
DM5VP0F	SN	Asenapine maleate; Saphris; Asenapine (maleate); Org 5222; Sycrest; Org-5222; Asenapine maleate [USAN]; C17H16ClNO.C4H4O4; Asenapine/; Saphris (TN); EINECS 288-064-8; Org 5222 maleate; trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate; (S,S)-Asenapine Maleate; SCHEMBL175228; Asenapine maleate (JAN/USAN); CHEBI:71248; GMDCDXMAFMEDAG-CHHFXETESA-N; ABP000604; s1283; MFCD00900588; Asenapine maleate, &gt;=98% (HPLC); AKOS015951084; SCH-900274; MK-8274; CS-0859; HY-11100; AC-24116
DM5VP0F	PC	6917875
DM5VP0F	MW	401.8
DM5VP0F	FM	C21H20ClNO5
DM5VP0F	IC	InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-;/m1./s1
DM5VP0F	CS	CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24.C(=CC(=O)O)C(=O)O
DM5VP0F	IK	GMDCDXMAFMEDAG-CHHFXETESA-N
DM5VP0F	IU	(Z)-but-2-enedioic acid;(2S,6S)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
DM5VP0F	CA	CAS 85650-56-2
DM5VP0F	CB	CHEBI:71248
DM5VP0F	DE	Schizophrenia

DM4087K	ID	DM4087K
DM4087K	DN	Saprisartan
DM4087K	HS	Approved
DM4087K	SN	Saprisartan potassium; GR 138950; GR-138950; GR-138950C; GR-138950X; 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide
DM4087K	TC	Antihypertensive Agents
DM4087K	DT	Small molecular drug
DM4087K	PC	60921
DM4087K	MW	611.4
DM4087K	FM	C25H22BrF3N4O4S
DM4087K	IC	InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34)
DM4087K	CS	CCC1=NC(=C(N1CC2=CC3=C(C=C2)OC(=C3Br)C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)C(=O)N)C5CC5
DM4087K	IK	DUEWVPTZCSAMNB-UHFFFAOYSA-N
DM4087K	IU	3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide
DM4087K	CA	CAS 146623-69-0
DM4087K	DE	Hypertension

DM90TJP	ID	DM90TJP
DM90TJP	DN	Sapropterin hydrochloride
DM90TJP	HS	Approved
DM90TJP	SN	Biopten (TN)
DM90TJP	DT	Small molecular drug
DM90TJP	PC	135409471
DM90TJP	MW	314.17
DM90TJP	FM	C9H17Cl2N5O3
DM90TJP	IC	InChI=1S/C9H15N5O3.2ClH/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7;;/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17);2*1H/t3-,4+,6-;;/m0../s1
DM90TJP	CS	C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O.Cl.Cl
DM90TJP	IK	RKSUYBCOVNCALL-NTVURLEBSA-N
DM90TJP	IU	(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one;dihydrochloride
DM90TJP	CA	CAS 69056-38-8
DM90TJP	CB	CHEBI:32120
DM90TJP	DE	Hyperphenylalaninemia

DMG814N	ID	DMG814N
DMG814N	DN	Saquinavir
DMG814N	HS	Approved
DMG814N	SN	Fortovase; Invirase; ROC; SQV; Saguinavir; Ro 318959; Fortovase (TN); Fortovase(TM); Invirase (TN); Ro 31-8959; Invirase(TM)(monomesylate); Ro-31-8959; Saquinavir (JAN/USP/INN); QNC-ASN-HPH-DIQ-NTB; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide
DMG814N	CP	Hoffmann-La Roche pharmaceutical company
DMG814N	TC	Anti-HIV Agents
DMG814N	DT	Small molecular drug
DMG814N	PC	441243
DMG814N	MW	670.8
DMG814N	FM	C38H50N6O5
DMG814N	IC	InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1
DMG814N	CS	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O
DMG814N	IK	QWAXKHKRTORLEM-UGJKXSETSA-N
DMG814N	IU	(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
DMG814N	CA	CAS 127779-20-8
DMG814N	CB	CHEBI:63621
DMG814N	DE	Human immunodeficiency virus infection

DMKS1DV	ID	DMKS1DV
DMKS1DV	DN	SARALASIN
DMKS1DV	HS	Approved
DMKS1DV	SN	Saralasin; 34273-10-4; UNII-H2AFV2HE66; (Sar1,Val5,Ala8)-Angiotensin II; CHEMBL938; H2AFV2HE66; Saralasinum [INN-Latin]; Saralasin [INN:BAN]; Saralasine [INN-French]; Saralasina [INN-Spanish]; Saralasinum; Saralasine; Saralasina; (1-(N-Methylglycin) 5-L-valin, 8-L-alanin)angiotensin II; Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-; NCGC00166135-01; N-(1-(N-(N-(N-(N-(N2-(N-methylglycly)-L-arginyl)-L-valyl)-L-tyrosyl)-L-valyl)-L-histidyl)-L-prolyl)-L-alanine; SCHEMBL23; AC1O44IX; DSSTox_RID_81710
DMKS1DV	DT	Small molecular drug
DMKS1DV	PC	6324663
DMKS1DV	MW	912
DMKS1DV	FM	C42H65N13O10
DMKS1DV	IC	InChI=1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1
DMKS1DV	CS	C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMKS1DV	IK	PFGWGEPQIUAZME-NXSMLHPHSA-N
DMKS1DV	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid
DMKS1DV	CA	CAS 34273-10-4
DMKS1DV	CB	CHEBI:135894
DMKS1DV	DE	Hypertension

DMKZROL	ID	DMKZROL
DMKZROL	DN	Saralasin Acetate
DMKZROL	HS	Approved
DMKZROL	SN	Saralasin acetate; Sarenin; Saralasin acetate [USAN]; Saralasin acetate (USAN); 39698-78-7; UNII-FO21Z580M4; Sarenin (TN); SCHEMBL2200145; CHEMBL1200670; FO21Z580M4; 34273-10-4 (Parent); D04126; [Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate; [Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate, &gt
DMKZROL	CP	Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
DMKZROL	DT	Small molecular drug
DMKZROL	PC	11954381
DMKZROL	MW	990.1
DMKZROL	FM	C44H71N13O13
DMKZROL	IC	InChI=1S/C42H65N13O10.C2H4O2.H2O/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65;1-2(3)4;/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47);1H3,(H,3,4);1H2/t24-,28-,29-,30-,31-,33-,34-;;/m0../s1
DMKZROL	CS	C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC.CC(=O)O.O
DMKZROL	IK	YBZYNINTWCLDQA-UHKVWXOHSA-N
DMKZROL	IU	acetic acid;(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid;hydrate
DMKZROL	CA	CAS 39698-78-7
DMKZROL	DE	Hypertension

DMLZNIQ	ID	DMLZNIQ
DMLZNIQ	DN	Sarecycline 
DMLZNIQ	HS	Approved
DMLZNIQ	SN	Sarecycline; UNII-94O110CX2E; 94O110CX2E; Sarecycline [USAN:INN]; Sarecycline (USAN/INN); P005672; SCHEMBL2699170; ZINC72319783; ZINC198637385; DB12035; FT-0772434; D10666
DMLZNIQ	CP	Allergan
DMLZNIQ	PC	54681908
DMLZNIQ	MW	487.5
DMLZNIQ	FM	C24H29N3O8
DMLZNIQ	IC	InChI=1S/C24H29N3O8/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33/h5-6,11,13,18,28-29,32,34H,7-9H2,1-4H3,(H2,25,33)/t11-,13-,18-,24-/m0/s1
DMLZNIQ	CS	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC
DMLZNIQ	IK	AYUMVPHUMFKFPJ-SBAJWEJLSA-N
DMLZNIQ	IU	(4S,4aS,5aR,12aR)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMLZNIQ	CA	CAS 1035654-66-0
DMLZNIQ	DE	Acne vulgaris

DMY0M8J	ID	DMY0M8J
DMY0M8J	DN	Sargramostim
DMY0M8J	HS	Approved
DMY0M8J	SN	Leukine; Leukine (TN); Sargramostim (genetical recombination); Sargramostim (USAN/INN); Sargramostim (genetical recombination) (JAN)
DMY0M8J	CP	Bayer Pharmaceuticals Corporation
DMY0M8J	TC	Immunomodulatory Agents
DMY0M8J	SQ	DB00020 sequence: APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE
DMY0M8J	DE	Bone marrow transplantation

DMOGNXY	ID	DMOGNXY
DMOGNXY	DN	Sarilumab
DMOGNXY	HS	Approved
DMOGNXY	SN	Kevzara
DMOGNXY	CP	Sanofi/Regeneron
DMOGNXY	DT	Monoclonal antibody
DMOGNXY	SQ	Heavy chain: EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Light chainDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMOGNXY	DE	Rheumatoid arthritis

DMGLP6S	ID	DMGLP6S
DMGLP6S	DN	Sarpogrelate
DMGLP6S	HS	Approved
DMGLP6S	SN	Sarpogrelate [INN]; Sarpogrelate (INN); Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester; 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid; 4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid
DMGLP6S	TC	Hypoglycemic Agents
DMGLP6S	DT	Small molecular drug
DMGLP6S	PC	5160
DMGLP6S	MW	429.5
DMGLP6S	FM	C24H31NO6
DMGLP6S	IC	InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)
DMGLP6S	CS	CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O
DMGLP6S	IK	FFYNAVGJSYHHFO-UHFFFAOYSA-N
DMGLP6S	IU	4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid
DMGLP6S	CA	CAS 125926-17-2
DMGLP6S	CB	CHEBI:135697
DMGLP6S	DE	Diabetic complication

DMRSKMZ	ID	DMRSKMZ
DMRSKMZ	DN	Satumomab Pendetide
DMRSKMZ	HS	Approved
DMRSKMZ	TC	Imaging Agents
DMRSKMZ	DT	Monoclonal antibody
DMRSKMZ	DE	Breast cancer

DMGXENV	ID	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	HS	Approved
DMGXENV	SN	Onglyza; BMS 477118-11; BMS-477118; Kombiglyze XR (TN); OPC-262; Onglyza (TN); BMS-477118-11; (1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3
DMGXENV	CP	Bristol-Myers Squibb; AstraZeneca
DMGXENV	DT	Small molecular drug
DMGXENV	PC	11243969
DMGXENV	MW	315.4
DMGXENV	FM	C18H25N3O2
DMGXENV	IC	InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1
DMGXENV	CS	C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N
DMGXENV	IK	QGJUIPDUBHWZPV-SGTAVMJGSA-N
DMGXENV	IU	(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
DMGXENV	CA	CAS 361442-04-8
DMGXENV	CB	CHEBI:71272
DMGXENV	DE	Type-2 diabetes

DMDK7T9	ID	DMDK7T9
DMDK7T9	DN	SBC-102
DMDK7T9	HS	Approved
DMDK7T9	SN	Sebelipase alfa; Enzyme replacement therapy (protein recombinant, lysosomal acid lipase deficiency), Synageva BioPharma
DMDK7T9	CP	Synageva biopharma
DMDK7T9	SQ	Sebelipase alfa protein sequence: SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ
DMDK7T9	DE	Enzyme deficiency

DMOM8AL	ID	DMOM8AL
DMOM8AL	DN	Scopolamine
DMOM8AL	HS	Approved
DMOM8AL	SN	Atroscine; Euscopol; Hyosceine; Hysco; Isoscopil; Kwells; SEE; Scop; Scopamin; Scopolaminhydrobromid; Scopos; Sereen; Tranaxine; Transcop; Triptone; Atroscine Hydrobromide; Hydroscine hydrobromide; Hyocine F hydrobromide; Hyoscine bromide; Hyoscyine hydrobromide; SCOPOLAMINE BROMIDE; Scopolamine Hyoscine; Scopolaminium bromide; Scopolammonium bromide; Tropane alkaloid; MOLI001381; NCI61806; Borrachero (TN); Burundanga (TN); Hyoscine (TN); L-Hyoscine hydrobromide; Scopoderm-TTS; Scopolamine (INN); Transderm scop (TN); Levo-duboisine (TN); Xy-, (-)-tropate (ester); (-)-Scopolamine hydrobromide trihydrate; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epo; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl tropate
DMOM8AL	CP	Norvatis Phamaceuticals Corporation
DMOM8AL	TC	Antispasmodics
DMOM8AL	DT	Small molecular drug
DMOM8AL	PC	3000322
DMOM8AL	MW	303.35
DMOM8AL	FM	C17H21NO4
DMOM8AL	IC	InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1
DMOM8AL	CS	CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4
DMOM8AL	IK	STECJAGHUSJQJN-USLFZFAMSA-N
DMOM8AL	IU	[(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMOM8AL	CA	CAS 114-49-8
DMOM8AL	CB	CHEBI:16794
DMOM8AL	DE	Addictive disorder; Nausea

DMJ18YL	ID	DMJ18YL
DMJ18YL	DN	Secnidazole
DMJ18YL	HS	Approved
DMJ18YL	SN	3366-95-8; Secnidazol; Secnidazolum; Flagentyl; Secnidazolum [INN-Latin]; Solosec; RP 14539; Secnidazol [INN-Spanish]; PM 185184;Secnidazole (Flagentyl); SYM-1219; EINECS 222-134-0; seknidazol; MLS000559043; PM-185184; NCGC00095158-01; SMR000149359; RP-14539
DMJ18YL	CP	Lupin
DMJ18YL	DT	Small molecular drug
DMJ18YL	PC	71815
DMJ18YL	MW	185.18
DMJ18YL	FM	C7H11N3O3
DMJ18YL	IC	InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3
DMJ18YL	CS	CC1=NC=C(N1CC(C)O)[N+](=O)[O-]
DMJ18YL	IK	KPQZUUQMTUIKBP-UHFFFAOYSA-N
DMJ18YL	IU	1-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
DMJ18YL	CA	CAS 3366-95-8
DMJ18YL	CB	CHEBI:94433
DMJ18YL	DE	Bacterial vaginosis; Amoebiasis

DM14RF5	ID	DM14RF5
DM14RF5	DN	Secobarbital
DM14RF5	HS	Approved
DM14RF5	SN	Barbosec; Evronal; Hypotrol; Hyptran; Meballymal; Meballymalum; Pramil; Quinalbarbital; Quinalbarbitone; Secobarbitale; Secobarbitalum; Secobarbitone; Seconal; Seotal; Somosal; Secobarbital solution; Secobarbital suppository dosage form; Secobarbitale [DCIT]; Secobarbital [USAN:INN]; Secobarbitalum [INN-Latin]; Seconal (TN);Secobarbital (USP/INN); (+-)-5-Allyl-5-(1-methylbutyl)-barbituric acid; (+-)-Secobarbital; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)-(9CI); 5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione; 5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID; 5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-(1-methylbutyl)barbiturate; 5-Allyl-5-(1-methylbutyl)malonylurea; 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM14RF5	CP	Eli Lilly
DM14RF5	TC	Hypnotics and Sedatives
DM14RF5	DT	Small molecular drug
DM14RF5	PC	5193
DM14RF5	MW	238.28
DM14RF5	FM	C12H18N2O3
DM14RF5	IC	InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
DM14RF5	CS	CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DM14RF5	IK	KQPKPCNLIDLUMF-UHFFFAOYSA-N
DM14RF5	IU	5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM14RF5	CA	CAS 76-73-3
DM14RF5	CB	CHEBI:9073
DM14RF5	DE	Intractable insomnia

DMDKE4N	ID	DMDKE4N
DMDKE4N	DN	Secretin
DMDKE4N	HS	Approved
DMDKE4N	SN	SECREFLO; SecreFlow; Secrepan; Secretina; Secretine; Secretinum; Secretolin; Vitrum; Hormone of the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level; Human secretin; RG 1068; L-Valinamide; SECRETIN-FERRING; Secretin (human); Secretin (porcine); Secretin-Kabi; Secretina [INN-Spanish]; Secretine [INN-French]; Secretinum [INN-Latin]; Secretin [INN:BAN:DCF:JAN]
DMDKE4N	TC	Diagnostic Agents
DMDKE4N	DT	Small molecular drug
DMDKE4N	SQ	DB00021 sequence: HSDGTFTSELSRLRDSARLQRLLQGLV
DMDKE4N	PC	16129665
DMDKE4N	MW	3056.4
DMDKE4N	FM	C130H219N43O42
DMDKE4N	IC	InChI=1S/C130H219N43O42/c1-59(2)43-78(118(206)172-99(65(13)14)126(214)215)151-94(182)53-148-104(192)75(31-34-91(132)180)156-113(201)81(46-62(7)8)163-115(203)82(47-63(9)10)161-107(195)72(28-22-38-145-128(136)137)153-110(198)76(32-35-92(133)181)157-114(202)80(45-61(5)6)159-106(194)71(27-21-37-144-127(134)135)152-102(190)66(15)150-120(208)87(55-174)168-117(205)86(52-98(188)189)165-109(197)73(29-23-39-146-129(138)139)154-112(200)79(44-60(3)4)160-108(196)74(30-24-40-147-130(140)141)155-121(209)89(57-176)169-116(204)83(48-64(11)12)162-111(199)77(33-36-96(184)185)158-122(210)90(58-177)170-125(213)101(68(17)179)173-119(207)84(49-69-25-19-18-20-26-69)166-124(212)100(67(16)178)171-95(183)54-149-105(193)85(51-97(186)187)164-123(211)88(56-175)167-103(191)70(131)50-93-142-41-42-143-93/h18-20,25-26,41-42,59-68,70-90,99-101,174-179H,21-24,27-40,43-58,131H2,1-17H3,(H2,132,180)(H2,133,181)(H,142,143)(H,148,192)(H,149,193)(H,150,208)(H,151,182)(H,152,190)(H,153,198)(H,154,200)(H,155,209)(H,156,201)(H,157,202)(H,158,210)(H,159,194)(H,160,196)(H,161,195)(H,162,199)(H,163,203)(H,164,211)(H,165,197)(H,166,212)(H,167,191)(H,168,205)(H,169,204)(H,170,213)(H,171,183)(H,172,206)(H,173,207)(H,184,185)(H,186,187)(H,188,189)(H,214,215)(H4,134,135,144)(H4,136,137,145)(H4,138,139,146)(H4,140,141,147)
DMDKE4N	CS	CC(C)CC(C(=O)NC(C(C)C)C(=O)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=NC=CN2)N
DMDKE4N	IK	KKNIUBFRGPFELP-UHFFFAOYSA-N
DMDKE4N	IU	5-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[5-amino-1-[[2-[[1-[(1-carboxy-2-methylpropyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-amino-3-(1H-imidazol-2-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DMDKE4N	CA	CAS 1393-25-5
DMDKE4N	DE	Pancreatic exocrine dysfunction; Gastrinoma

DMFEGB0	ID	DMFEGB0
DMFEGB0	DN	Segesterone acetate; ethinyl estradiol
DMFEGB0	HS	Approved
DMFEGB0	CP	TherapeuticsMD
DMFEGB0	DE	Contraception

DM6034S	ID	DM6034S
DM6034S	DN	Selegiline
DM6034S	HS	Approved
DM6034S	SN	selegiline; L-Deprenalin; Emsam; (-)-selegiline; Selegilinum; Selegilina; Carbex; 14611-51-9; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; UNII-2K1V7GP655; l-E 250; CHEMBL972; CHEBI:9086; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; 2K1V7GP655; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; selgene; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; Selegyline; Zalapar; Selegiline (transdermal, Parkinson's/depression); Zunrisa/Rezonic
DM6034S	CP	Syntropharma
DM6034S	DT	Small molecular drug
DM6034S	PC	26757
DM6034S	MW	187.28
DM6034S	FM	C13H17N
DM6034S	IC	InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1
DM6034S	CS	C[C@H](CC1=CC=CC=C1)N(C)CC#C
DM6034S	IK	MEZLKOACVSPNER-GFCCVEGCSA-N
DM6034S	IU	(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
DM6034S	CA	CAS 14611-51-9
DM6034S	CB	CHEBI:9086
DM6034S	DE	Skin imperfections; Major depressive disorder; Chemotherapy-induced nausea

DM3VR1L	ID	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	HS	Approved
DM3VR1L	SN	Selegiline hydrochloride; 14611-52-0; Selegiline Hcl; (-)-Deprenyl hydrochloride; l-Deprenyl hydrochloride; Jumex hydrochloride; Eldepryl hydrochloride; (-)-Deprenil hydrochloride; (R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine hydrochloride; (-)-E-250 hydrochloride; UNII-6W731X367Q; HSDB 7183; R-(-)-Deprenyl (hydrochloride); FPF1100; (-)-Phenylisopropylmethylpropynylamine; 6W731X367Q; (-)-(R)-N,alpha-Dimethyl-N-2-propynylphenethylamine hydrochloride; Zydis selegiline
DM3VR1L	CP	Somerset Pharmaceuticals Inc
DM3VR1L	TC	Neurology Agents
DM3VR1L	DT	Small molecular drug
DM3VR1L	PC	26758
DM3VR1L	MW	223.74
DM3VR1L	FM	C13H18ClN
DM3VR1L	IC	InChI=1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1
DM3VR1L	CS	C[C@H](CC1=CC=CC=C1)N(C)CC#C.Cl
DM3VR1L	IK	IYETZZCWLLUHIJ-UTONKHPSSA-N
DM3VR1L	IU	(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride
DM3VR1L	CA	CAS 14611-52-0
DM3VR1L	CB	CHEBI:9087
DM3VR1L	DE	Parkinson disease; Motor symptoms

DM25CGV	ID	DM25CGV
DM25CGV	DN	Selenium
DM25CGV	HS	Approved
DM25CGV	SN	Selenium; Selenium alloy; Selenium and compounds; Selenium anhydride; Selenium base; Selenium dihydride; Selenium dust; Selenium elemental; Selenium homopolymer; Selenium hydride; Selenium metallicum; Selenium, colloidal; Selenium, elemental; Selenium, metallic; Vandex; selenio; 7782-49-2; CCRIS 4250; Caswell No. 732; EINECS 231-957-4; Colloidal selenium; Electronic E-2; Elemental selenium; Gray selenium; Hydrogen selenide (H2Se); SELENIUM ATOM; SELENIUM COMPOUNDS; SELENIUM POWDER; Selen [Polish]; HSDB 4493; Se; Selen; UNII-H6241UJ22B
DM25CGV	PC	6326970
DM25CGV	MW	78.97
DM25CGV	FM	Se
DM25CGV	IC	BUGBHKTXTAQXES-UHFFFAOYSA-N
DM25CGV	CS	[Se]
DM25CGV	IK	1S/Se
DM25CGV	IU	selenium
DM25CGV	CA	CAS 7782-49-2
DM25CGV	CB	CHEBI:27568
DM25CGV	DE	Seborrhoeic dermatitis

DMAHSU0	ID	DMAHSU0
DMAHSU0	DN	Selexipag
DMAHSU0	HS	Approved
DMAHSU0	SN	Selexipag; NS-304; 475086-01-2; Uptravi; NS 304; ACT-293987; UNII-5EXC0E384L; Selexipag(NS-304); ACT 293987; 5EXC0E384L; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; Selexipag [USAN:INN]; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; Uptravi (TN)
DMAHSU0	CP	Actelion Pharmaceuticals
DMAHSU0	DT	Small molecular drug
DMAHSU0	PC	9913767
DMAHSU0	MW	496.6
DMAHSU0	FM	C26H32N4O4S
DMAHSU0	IC	InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
DMAHSU0	CS	CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMAHSU0	IK	QXWZQTURMXZVHJ-UHFFFAOYSA-N
DMAHSU0	IU	2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide
DMAHSU0	CA	CAS 475086-01-2
DMAHSU0	CB	CHEBI:90844
DMAHSU0	DE	Pulmonary arterial hypertension

DMZR15V	ID	DMZR15V
DMZR15V	DN	Selpercatinib
DMZR15V	HS	Approved
DMZR15V	SN	MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636
DMZR15V	CP	Loxo Oncology Stamford, CT
DMZR15V	PC	134823904
DMZR15V	MW	542.6
DMZR15V	FM	C29H34N8O3
DMZR15V	IC	InChI=1S/C29H34N8O3/c1-19-9-34-37-17-23(40-18-24-11-30-5-6-39-24)8-25(29(19)37)26-12-32-27(13-31-26)35-15-21-7-22(16-35)36(21)14-20-3-4-28(38-2)33-10-20/h3-4,8-10,12-13,17,21-22,24,30H,5-7,11,14-16,18H2,1-2H3/t21?,22?,24-/m0/s1
DMZR15V	CS	CC1=C2C(=CC(=CN2N=C1)OC[C@@H]3CNCCO3)C4=CN=C(C=N4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC
DMZR15V	IK	MFOVQWYFURMVKU-IWAAJCSBSA-N
DMZR15V	IU	(2S)-2-[[4-[5-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyrazin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-yl]oxymethyl]morpholine
DMZR15V	DE	Non-small-cell lung cancer; Colon cancer; Thyroid cancer

DMAGFOD	ID	DMAGFOD
DMAGFOD	DN	Semaglutide
DMAGFOD	HS	Approved
DMAGFOD	SN	NN9535
DMAGFOD	CP	Novo Nordisk
DMAGFOD	DT	Small molecular drug
DMAGFOD	PC	56843331
DMAGFOD	MW	4114
DMAGFOD	FM	C187H291N45O59
DMAGFOD	IC	InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1
DMAGFOD	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
DMAGFOD	IK	DLSWIYLPEUIQAV-CCUURXOWSA-N
DMAGFOD	IU	18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
DMAGFOD	CA	CAS 910463-68-2
DMAGFOD	DE	Type-2 diabetes

DM25HP1	ID	DM25HP1
DM25HP1	DN	Sermorelin
DM25HP1	HS	Approved
DM25HP1	SN	Sermorelina; Sermoreline; Sermorelinum; Sermorelina [Spanish]; Sermoreline [French]; Sermorelinum [Latin]; Geref (TN); Sermorelin (INN); Sermorelin [INN:BAN]; GROWTH HORMONE RELEASING FACTOR, Fragment 1-29 Amide; Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
DM25HP1	CP	Emd Serono Inc
DM25HP1	TC	Hormone Replacement Agents
DM25HP1	DT	Small molecular drug
DM25HP1	SQ	DB00010 sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSRQ
DM25HP1	PC	16132413
DM25HP1	MW	3357.9
DM25HP1	FM	C149H246N44O42S
DM25HP1	IC	InChI=1S/C149H246N44O42S/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-/m0/s1
DM25HP1	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM25HP1	IK	WGWPRVFKDLAUQJ-MITYVQBRSA-N
DM25HP1	IU	(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
DM25HP1	CA	CAS 86168-78-7
DM25HP1	DE	Pediatric growth disorder

DM1A9XO	ID	DM1A9XO
DM1A9XO	DN	Sertaconazole
DM1A9XO	HS	Approved
DM1A9XO	SN	Sertaconazol; Sertaconazolum; Sertaconazol [Spanish]; Sertaconazole [INN]; Sertaconazolum [Latin]; FI-7045; Sertaconazole (INN); (+-)-1-(2,4-Dichloro-beta-((7-chlorobenzo(b)thien-3-yl)methoxy)phenethyl)imidazole; (inverted exclamation markA)-1-[2,4-dichloro-b-[(7-chlorobenzo[b]thien-3-yl)methoxy]phenethyl]imidazole;1-(2-((7-Chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole; 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 7-Chloro-3-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl)benzo(b)thiophene; 7-Chloro-3-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno [Spanish]
DM1A9XO	TC	Antifungal Agents
DM1A9XO	DT	Small molecular drug
DM1A9XO	PC	65863
DM1A9XO	MW	437.8
DM1A9XO	FM	C20H15Cl3N2OS
DM1A9XO	IC	InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2
DM1A9XO	CS	C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl
DM1A9XO	IK	JLGKQTAYUIMGRK-UHFFFAOYSA-N
DM1A9XO	IU	1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DM1A9XO	CA	CAS 99592-32-2
DM1A9XO	CB	CHEBI:83682
DM1A9XO	DE	Fungal infection

DM0FB1J	ID	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	HS	Approved
DM0FB1J	SN	Lustral; SRE; Sertralina; Sertralinum; Sertralina [Spanish]; Sertraline [Zoloft]; Sertralinum [Latin]; CP 51974; Cp 51974; Apo-Sertraline; Lustral (TN); Sertraline (INN); Sertraline (Zoloft); Sertraline [INN:BAN]; Zoloft (TN); (+)-Sertraline; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
DM0FB1J	CP	Pfizer Inc
DM0FB1J	TC	Antidepressants
DM0FB1J	DT	Small molecular drug
DM0FB1J	PC	68617
DM0FB1J	MW	306.2
DM0FB1J	FM	C17H17Cl2N
DM0FB1J	IC	InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1
DM0FB1J	CS	CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
DM0FB1J	IK	VGKDLMBJGBXTGI-SJCJKPOMSA-N
DM0FB1J	IU	(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
DM0FB1J	CA	CAS 79617-96-2
DM0FB1J	CB	CHEBI:9123
DM0FB1J	DE	Depression

DMPVRN9	ID	DMPVRN9
DMPVRN9	DN	Setmelanotide
DMPVRN9	HS	Approved
DMPVRN9	SN	RM-493; UNII-N7T15V1FUY; BIM-22493; N7T15V1FUY; 920014-72-8; Setmelanotide [USAN:INN]; GTPL9272; CHEMBL3301624; CS-6399; DB11700; HY-19870; L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-&gt; 8)-disulfide; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-d
DMPVRN9	CP	Rhythm Metabolics Boston, MA
DMPVRN9	PC	11993702
DMPVRN9	MW	1117.3
DMPVRN9	FM	C49H68N18O9S2
DMPVRN9	IC	InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1
DMPVRN9	CS	C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DMPVRN9	IK	HDHDTKMUACZDAA-PHNIDTBTSA-N
DMPVRN9	IU	(4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide
DMPVRN9	CA	CAS 920014-72-8
DMPVRN9	DE	Diabetic complication; Obesity; Prader-Willi syndrome; Bardet biedl syndrome

DMC9O43	ID	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	HS	Approved
DMC9O43	SN	Sevofluran; Sevoflurano; Sevofluranum; Sevofrane; Sevorane; Sojourn; Ultane; Fluoromethyl hexafluoroisopropyl ether; Bax 3084; F0691; MR6S4; MR_6S4; PC4681; Sevoflurano [INN-Spanish]; Sevofluranum [INN-Latin]; Ultane (TN); Sevoflurane (JAN/USAN/INN); Sevoflurane [USAN:INN:BAN:JAN]; Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether; Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
DMC9O43	CP	Abbott Laboratories
DMC9O43	TC	Anesthetics
DMC9O43	DT	Small molecular drug
DMC9O43	PC	5206
DMC9O43	MW	200.05
DMC9O43	FM	C4H3F7O
DMC9O43	IC	InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2
DMC9O43	CS	C(OC(C(F)(F)F)C(F)(F)F)F
DMC9O43	IK	DFEYYRMXOJXZRJ-UHFFFAOYSA-N
DMC9O43	IU	1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
DMC9O43	CA	CAS 28523-86-6
DMC9O43	CB	CHEBI:9130
DMC9O43	DE	Anaesthesia

DMFJTDI	ID	DMFJTDI
DMFJTDI	DN	Sibutramine
DMFJTDI	HS	Approved
DMFJTDI	SN	Butramin; Medaria; Meridia; Reductil; Sibutramina; Sibutraminum; Sibutramina [Spanish]; Sibutraminum [Latin]; BTS-54524; Butramin (TN); Ectiva (TN); Meridia (TN); Reductil (TN); Sibutramine (INN); Sibutramine [INN:BAN]; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
DMFJTDI	CP	Abbott Laboratories
DMFJTDI	TC	Appetite Depressants
DMFJTDI	DT	Small molecular drug
DMFJTDI	PC	5210
DMFJTDI	MW	279.8
DMFJTDI	FM	C17H26ClN
DMFJTDI	IC	InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3
DMFJTDI	CS	CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C
DMFJTDI	IK	UNAANXDKBXWMLN-UHFFFAOYSA-N
DMFJTDI	IU	1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
DMFJTDI	CA	CAS 106650-56-0
DMFJTDI	CB	CHEBI:9137
DMFJTDI	DE	Obesity

DM1BS03	ID	DM1BS03
DM1BS03	DN	Sifalimumab
DM1BS03	HS	Approved
DM1BS03	SN	Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
DM1BS03	CP	AstraZeneca; MedImmune
DM1BS03	DT	Antibody
DM1BS03	DE	Renal cell carcinoma; Systemic lupus erythematosus

DMSWJ5X	ID	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	HS	Approved
DMSWJ5X	SN	Sildenafil (citrate); Sildenafil citrate; Sildenafil citrate [USAN]; Sildenafil citrate salt; UK 92480; UK-92480-10; UNII-BW9B0ZE037; Sildenafilcitrate; Sildenafil; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; 139755-83-2; 3M7OB98Y7H; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; BNRNXUUZRGQAQC-UHFFFAOYSA-N; C22H30N6O4S; CHEBI:9139; CHEMBL192; HSDB 7305; Sildenafil [INN:BAN]; UK-92,480-10; UK-92480; UNII-3M7OB98Y7H; 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate (1:1); 171599-83-0; BW9B0ZE037; CHEBI:58987; Caverta; DSSTox_CID_26076; DSSTox_GSID_46076; DSSTox_RID_81321
DMSWJ5X	PC	135413523
DMSWJ5X	MW	666.7
DMSWJ5X	FM	C28H38N6O11S
DMSWJ5X	IC	DEIYFTQMQPDXOT-UHFFFAOYSA-N
DMSWJ5X	CS	CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMSWJ5X	IK	1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMSWJ5X	IU	5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one;2-hydroxypropane-1,2,3-tricarboxylic acid
DMSWJ5X	CA	CAS 171599-83-0
DMSWJ5X	CB	CHEBI:31307
DMSWJ5X	DE	Erectile dysfunction

DMJSBT6	ID	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	HS	Approved
DMJSBT6	SN	Silodosin; 160970-54-7; Rapaflo; Urief; Silodyx; Urorec; KMD-3213; Silodosin-d6; UNII-CUZ39LUY82; KMD 3213; KAD 3213; CUZ39LUY82; CHEMBL24778; KAD-3213; (R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide; 160970-64-9; Q-102517; Rapflo
DMJSBT6	DT	Small molecular drug
DMJSBT6	PC	5312125
DMJSBT6	MW	495.5
DMJSBT6	FM	C25H32F3N3O4
DMJSBT6	IC	InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
DMJSBT6	CS	C[C@H](CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F
DMJSBT6	IK	PNCPYILNMDWPEY-QGZVFWFLSA-N
DMJSBT6	IU	1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide
DMJSBT6	CA	CAS 160970-54-7
DMJSBT6	CB	CHEBI:135929
DMJSBT6	DE	Benign prostatic hyperplasia

DMGEATB	ID	DMGEATB
DMGEATB	DN	Siltuximab
DMGEATB	HS	Approved
DMGEATB	CP	Janssen Biotech
DMGEATB	DT	Antibody
DMGEATB	SQ	Heavy Chain Sequence: EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Light Chain SequenceQIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMGEATB	DE	Anemia; Multiple myeloma

DMVTHWQ	ID	DMVTHWQ
DMVTHWQ	DN	Silver sulfadiazine
DMVTHWQ	HS	Approved
DMVTHWQ	SN	Brandiazin; Dermazin; Dermazine; Flamazine; Flammazine; Geben; Sicazine; Silbertone; Silvederma; Silver; Sulfargen; Abbott Brand of Silver Sulfadiazine; Aldo Brand of Silver Sulfadiazine; Major Brand of Silver Sulfadiazine; Medphano Brand of Silver Sulfadiazine; MonarchBrand of Silver Sulfadiazine; Pharmascience Brand of Silver Sulfadiazine; Rhone Poulenc Rorer Brand of Silver Sulfadiazine; SSD AF; SULFADIAZINE SILVER; Sherwood Brand of Silver Sulfadiazine; Silver Sulfafdiazine; Silver sulfadiazinate; Silver sulphadiazine; Solvay Brand of Silver Sulfadiazine; Sulfadiazin silber; Sulfadiazine silver salt; Sulfadiazine silverSilvadene; Zenith Brand of Silver Sulfadiazine; Par Brand 1 of Silver Sulfadiazine; Par Brand 2 of Silver Sulfadiazine; Par Brand 3 of Silver Sulfadiazine; Flamazine (TN); Rhone-Poulenc Rorer Brand of Silver Sulfadiazine; Silvadene (TN); Silver(I) sulfadiazine; Smith & Nephew Brand of Silver Sulfadiazine; Sulfadiazin, silbersalz; Sulfadiazine silver (JP15); Sulfadiazine, Silver [USAN]; Sulfadiazine, silver; Sulfafdiazine, Silver; Thermazene (TN); SSD (1% Silver Sulfadiazine Cream USP); Sulfadiazine, silver (USP); N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt; N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt; Silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide; Silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex; Silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide; Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt; Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt; (4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
DMVTHWQ	TC	Antiinfective Agents
DMVTHWQ	DT	Small molecular drug
DMVTHWQ	PC	441244
DMVTHWQ	MW	357.14
DMVTHWQ	FM	C10H9AgN4O2S
DMVTHWQ	IC	InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1
DMVTHWQ	CS	C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+]
DMVTHWQ	IK	UEJSSZHHYBHCEL-UHFFFAOYSA-N
DMVTHWQ	IU	silver;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
DMVTHWQ	CA	CAS 22199-08-2
DMVTHWQ	CB	CHEBI:9142
DMVTHWQ	DE	Bacterial infection

DMLUA9D	ID	DMLUA9D
DMLUA9D	DN	Simeprevir
DMLUA9D	HS	Approved
DMLUA9D	SN	TMC436
DMLUA9D	CP	Johnson & Johnson
DMLUA9D	TC	Antiinfective Agents
DMLUA9D	DT	Small molecular drug
DMLUA9D	PC	24873435
DMLUA9D	MW	749.9
DMLUA9D	FM	C38H47N5O7S2
DMLUA9D	IC	InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1
DMLUA9D	CS	CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C\\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC
DMLUA9D	IK	JTZZSQYMACOLNN-VDWJNHBNSA-N
DMLUA9D	IU	(1R,4R,6S,7Z,15R,17R)-N-cyclopropylsulfonyl-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxamide
DMLUA9D	CA	CAS 923604-59-5
DMLUA9D	CB	CHEBI:134743
DMLUA9D	DE	Chronic HCV-1 infection

DM30SGU	ID	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	HS	Approved
DM30SGU	SN	Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
DM30SGU	CP	Merck & Co
DM30SGU	TC	Anticholesteremic Agents
DM30SGU	DT	Small molecular drug
DM30SGU	PC	54454
DM30SGU	MW	418.6
DM30SGU	FM	C25H38O5
DM30SGU	IC	InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
DM30SGU	CS	CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
DM30SGU	IK	RYMZZMVNJRMUDD-HGQWONQESA-N
DM30SGU	IU	[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
DM30SGU	CA	CAS 79902-63-9
DM30SGU	CB	CHEBI:9150
DM30SGU	DE	Hypercholesterolaemia

DMGWR0C	ID	DMGWR0C
DMGWR0C	DN	Sintilimab
DMGWR0C	HS	Approved
DMGWR0C	SN	Tyvyt
DMGWR0C	CP	Innovent Biologics
DMGWR0C	DT	Antibody
DMGWR0C	DE	Hodgkin lymphoma

DM2R86O	ID	DM2R86O
DM2R86O	DN	Siponimod
DM2R86O	HS	Approved
DM2R86O	SN	BAF312
DM2R86O	CP	Novartis
DM2R86O	DT	Small molecular drug
DM2R86O	PC	44599207
DM2R86O	MW	516.6
DM2R86O	FM	C29H35F3N2O3
DM2R86O	IC	InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+
DM2R86O	CS	CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O
DM2R86O	IK	KIHYPELVXPAIDH-HNSNBQBZSA-N
DM2R86O	IU	1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid
DM2R86O	CA	CAS 1230487-00-9
DM2R86O	DE	Hepatocellular carcinoma; Rheumatoid arthritis; Multiple sclerosis

DMVCMUJ	ID	DMVCMUJ
DMVCMUJ	DN	Siponimod
DMVCMUJ	HS	Approved
DMVCMUJ	SN	Siponimod; Siponimod [INN]; Siponimod [WHO-DD]; BAF-312; BAF312; BAF312 (Siponimod); RR6P8L282I; 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid; 1230487-00-9; 3-Azetidinecarboxylic acid, 1-((4-((1E)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)-; CHEMBL2336071; UNII-RR6P8L282I
DMVCMUJ	PC	44599207
DMVCMUJ	MW	516.6
DMVCMUJ	FM	C29H35F3N2O3
DMVCMUJ	IC	KIHYPELVXPAIDH-HNSNBQBZSA-N
DMVCMUJ	CS	CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O
DMVCMUJ	IK	1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+
DMVCMUJ	IU	1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid
DMVCMUJ	CA	CAS 1230487-00-9
DMVCMUJ	DE	Multiple sclerosis

DMGW1ID	ID	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	HS	Approved
DMGW1ID	SN	53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
DMGW1ID	CP	Wyeth
DMGW1ID	TC	Immunosuppressive Agents
DMGW1ID	DT	Small molecular drug
DMGW1ID	PC	5284616
DMGW1ID	MW	914.2
DMGW1ID	FM	C51H79NO13
DMGW1ID	IC	InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
DMGW1ID	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
DMGW1ID	IK	QFJCIRLUMZQUOT-HPLJOQBZSA-N
DMGW1ID	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMGW1ID	CA	CAS 53123-88-9
DMGW1ID	CB	CHEBI:9168
DMGW1ID	DE	Organ transplant rejection; Dutch elm disease; Multiple myeloma

DM92P0F	ID	DM92P0F
DM92P0F	DN	Sisomicin
DM92P0F	HS	Approved
DM92P0F	SN	Siseptin; Sisomicin sulfate; Sisomicina [INN-Spanish]; Sisomicine; Sisomicine [INN-French]; Sisomicinum; Sisomicinum [INN-Latin]; Sisomin; Sisomycin; Sissomicin; X55XSL74YQ; sisomicin; 32385-11-8; BRN 1357913; C19H37N5O7; Antibiotic 66-40; Antibiotic 6640; Dehydrogentamicin Cla; Rickamicin; Sch 13475; Sch-13475; CHEBI:9169; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-; EINECS 251-018-2; UNII-X55XSL74YQ
DM92P0F	PC	36119
DM92P0F	MW	447.5
DM92P0F	FM	C19H37N5O7
DM92P0F	IC	URWAJWIAIPFPJE-YFMIWBNJSA-N
DM92P0F	CS	CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CC=C(O3)CN)N)N)N)O
DM92P0F	IK	1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1
DM92P0F	IU	(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DM92P0F	CA	CAS 32385-11-8
DM92P0F	CB	CHEBI:9169
DM92P0F	DE	Infectious cystitis

DMGDKXN	ID	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	HS	Approved
DMGDKXN	SN	486460-32-6; Januvia; Xelevia; Sitagliptan; MK-0431; UNII-QFP0P1DV7Z; Tesavel; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; CHEBI:40237; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE;  Janumet; Sitagliptin phosphate; Januvia (TN); Sitagliptin (PropINN); Januvia (merck & Co); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin/atovastatin
DMGDKXN	CP	Merck & Co
DMGDKXN	TC	Hypoglycemic Agents
DMGDKXN	DT	Small molecular drug
DMGDKXN	PC	4369359
DMGDKXN	MW	407.31
DMGDKXN	FM	C16H15F6N5O
DMGDKXN	IC	InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
DMGDKXN	CS	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
DMGDKXN	IK	MFFMDFFZMYYVKS-SECBINFHSA-N
DMGDKXN	IU	(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
DMGDKXN	CA	CAS 486460-32-6
DMGDKXN	CB	CHEBI:40237
DMGDKXN	DE	Type-2 diabetes; Peripheral arterial disease

DMQ8E9R	ID	DMQ8E9R
DMQ8E9R	DN	SKI-758
DMQ8E9R	HS	Approved
DMQ8E9R	SN	SCHEMBL3992463; CHEMBL219557; BDBM13047; SKI-758; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile
DMQ8E9R	DT	Small molecular drug
DMQ8E9R	PC	11341869
DMQ8E9R	MW	552.4
DMQ8E9R	FM	C28H27Cl2N5O3
DMQ8E9R	IC	InChI=1S/C28H27Cl2N5O3/c1-34-4-6-35(7-5-34)15-19-8-17(16-38-19)20-9-24-21(10-26(20)36-2)28(18(13-31)14-32-24)33-25-12-27(37-3)23(30)11-22(25)29/h8-12,14,16H,4-7,15H2,1-3H3,(H,32,33)
DMQ8E9R	CS	CN1CCN(CC1)CC2=CC(=CO2)C3=C(C=C4C(=C3)N=CC(=C4NC5=CC(=C(C=C5Cl)Cl)OC)C#N)OC
DMQ8E9R	IK	ANUHLKPVOXDYSK-UHFFFAOYSA-N
DMQ8E9R	IU	4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl]quinoline-3-carbonitrile
DMQ8E9R	DE	Ischemia

DMDIZCS	ID	DMDIZCS
DMDIZCS	DN	S-licarbazepine
DMDIZCS	HS	Approved
DMDIZCS	SN	Eslicarbazepine; (S)-10-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; S-licarbazepine; UNII-S5VXA428R4; BIA 2-194; S-10-Monohydroxy-dihydro-carbamazepin; S5VXA428R4; S-(+)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide; (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide; (10S)-10,11-Dihydro-10-hydroxy-5H-Dibenz[b,f]azepine-5-carboxamide; (S)-Licarbazepine; S(+)-Liscarbazepine; (10S)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide
DMDIZCS	PC	9881504
DMDIZCS	MW	254.28
DMDIZCS	FM	15H14N2O2
DMDIZCS	IC	InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
DMDIZCS	CS	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
DMDIZCS	IK	BMPDWHIDQYTSHX-AWEZNQCLSA-N
DMDIZCS	IU	(5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMDIZCS	CA	CAS 104746-04-5
DMDIZCS	DE	Partial seizures

DMFX9O6	ID	DMFX9O6
DMFX9O6	DN	SM-101
DMFX9O6	HS	Approved (orphan drug)
DMFX9O6	SN	SMP-534
DMFX9O6	CP	SuppreMol
DMFX9O6	DT	Small molecular drug
DMFX9O6	PC	445629
DMFX9O6	DE	Idiopathic thrombocytopenic purpura; Diabetic nephropathy; Systemic lupus erythematosus

DM1I93C	ID	DM1I93C
DM1I93C	DN	SMT-D002
DM1I93C	HS	Approved
DM1I93C	SN	DL-06003
DM1I93C	CP	DanioLabs Ltd
DM1I93C	DE	Seborrhea

DMH21E0	ID	DMH21E0
DMH21E0	DN	Sodium acetate anhydrous
DMH21E0	HS	Approved
DMH21E0	SN	Sodium Acetate In Plastic Container
DMH21E0	CP	Hospira Inc
DMH21E0	DT	Small molecular drug
DMH21E0	PC	517045
DMH21E0	MW	82.03
DMH21E0	FM	C2H3NaO2
DMH21E0	IC	InChI=1S/C2H4O2.Na/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1
DMH21E0	CS	CC(=O)[O-].[Na+]
DMH21E0	IK	VMHLLURERBWHNL-UHFFFAOYSA-M
DMH21E0	IU	sodium;acetate
DMH21E0	CA	CAS 127-09-3
DMH21E0	CB	CHEBI:32954
DMH21E0	DE	Hyponatraemia

DMMU6BJ	ID	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	HS	Approved
DMMU6BJ	SN	Acidosan; Colovage; Glycoprep; Golytely; Jusonin; Meylon; Natriumhydrogenkarbonat; Natron; Neut; Nulytely; Soludal; BSS plus; Baking soda; Bicarbonate of soda; Carbonic acid monosodium salt; Gripe water; Lithium bicarbonate; Monosodium hydrogen carbonate; Natrii hydrogencarbonas; Natrium bicarbonicum; Natrium hydrogencarbonicum; Natrum bicarbonicum; Sandoz sodium bicarbonate; Sel De vichy; Soda Mint; Sodium acid carbonate; Sodium bicarbonate in plastic container; Sodium bicarbonate liquid concentrate; Sodium bicarbonate solution; Sodium hydrocarbonate; Sodium hydrogen carbonate; Sodium hydrogencarbonate; NaHCO3; Bicarbonate, Sodium; Carbonic acid, monosodium salt; Co-lav; Col-evac; Go-evac; Hema BP-38; Hydrogen Carbonate, Sodium; Meylon (TN); Neut (TN); Peg-lyte; Soda (van); Soda, Baking; Sodium bicarbonate [USAN:JAN]; Carbonic acid sodium salt (1:1); E-Z-EM Prep Lyte; Sodium bicarbonate (1:1); Sodium bicarbonate (JP15/USP); Sodium carbonate (Na(HCO3)); 800 Sodium Bicarbonate Powder
DMMU6BJ	TC	Antidiarrheals
DMMU6BJ	DT	Small molecular drug
DMMU6BJ	PC	516892
DMMU6BJ	MW	84.007
DMMU6BJ	FM	CHNaO3
DMMU6BJ	IC	InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
DMMU6BJ	CS	C(=O)(O)[O-].[Na+]
DMMU6BJ	IK	UIIMBOGNXHQVGW-UHFFFAOYSA-M
DMMU6BJ	IU	sodium;hydrogen carbonate
DMMU6BJ	CA	CAS 144-55-8
DMMU6BJ	CB	CHEBI:32139
DMMU6BJ	DE	Metabolic acidosis

DMM3950	ID	DMM3950
DMM3950	DN	Sodium chloride
DMM3950	HS	Approved
DMM3950	SN	sodium chloride; 7647-14-5; Halite; Salt; Table salt; Saline; Rock salt; Common salt; Dendritis; Purex; Sodium chloric; Top flake; Sodium chloride (NaCl); Hyposaline; Flexivial; Gingivyl; Iodized salt; Slow Sodium; Sea salt; SS salt; Sodium monochloride; Natriumchlorid; Hypersal; Adsorbanac; Trisodium trichloride; White crystal; NaCl; HG blending; Salt (ingredient); sodiumchloride; Colyte; Sodium chloride (Na4Cl4); Caswell No 754; Extra Fine 325 Salt; Extra Fine 200 Salt; Sodium chloride brine, purified; Arm-A-Vial; CCRIS 982; sterling
DMM3950	DT	Small molecular drug
DMM3950	PC	5234
DMM3950	MW	58.44
DMM3950	FM	ClNa
DMM3950	IC	InChI=1S/ClH.Na/h1H;/q;+1/p-1
DMM3950	CS	[Na+].[Cl-]
DMM3950	IK	FAPWRFPIFSIZLT-UHFFFAOYSA-M
DMM3950	IU	sodium;chloride
DMM3950	CA	CAS 7647-14-5
DMM3950	CB	CHEBI:26710
DMM3950	DE	Skin burns

DMLJ634	ID	DMLJ634
DMLJ634	DN	Sodium lauryl sulfate
DMLJ634	HS	Approved
DMLJ634	SN	Anticerumen; Dreft; Dupanal; Duponal; Duponol; Gardinol; Irium; NALS; Natriumlaurylsulfat; Neutrazyme; SDS; SLS; Syntapon; WAQE; Akyposal SDS; Aquarex ME; Aquarex methyl; Carsonol SLS; Carsonol SLS Paste B; Carsonol SLS Special; Conco Sulfate WAG; Conco Sulfate WAN; Conco Sulfate WAS; Conco sulfate WA; Conco sulfate WN; DODECYL SULFATE; Dupanol WAQ; Duponal WAQE; Duponol C; Duponol Me; Duponol QC; Duponol WA; Duponol WA dry; Duponol WAQ; Duponol WAQE; Duponol WAQM; Duponol methyl; Duponol qx; Duponol waqa; EMAL O; Empicol LPZ; Hexamol SLS; Incronol SLS; Laurylsiran sodny; Lauyl sodium sulfate; Maprobix NEU; Maprofix LK; Maprofix NEU; Maprofix WAC; Melanol CL; Montopol La Paste; Nikkol SLS; Orvus WA Paste; Perlandrol L; Perlankrol L; Richonol A; Richonol C; Richonol af; SDS Running Buffer; Sintapon L; Sipex OP; Sipex SP; Sipex UB; Sipex sb; Sipex sd; Sipon LS; Sipon LSB; Sipon PD; Sipon WD; Sodium Laurylsulfate; Solsol needles; Standapol WAQ; Stepanol ME; Stepanol ME Dry AW; Stepanol WA; Stepanol WA Paste; Stepanol me dry; Stepanol methyl; Stepanol wac; Stepanol waq; Sterling wa paste; Sulfotex wa; Texapon DL; Trepenol WA; Avirol 101; Avirol 118; Avirol 118 conc; Berol 452; CP 75424; Cycloryl 21; Cycloryl 31; Cycloryl 580; Cycloryl 585N; Detergent 66; Emal 10; Emersal 6400; Empicol LS 30; Empicol LX 28; Finasol osr2; MP SILICA RP 18; Maprofix 563; Melanol CL 30; Monagen Y 100; Monogen Y 100; Odoripon Al 95; Perklankrol ESD 60; Rewopol NLS 30; Sinnopon LS 100; Sinnopon LS 95; Sipon LS 100; Standapol 112; Standapol 112 conc; Standapol was 100; Steinapol NLS 90; Stepanol T 28; Sulfetal L 95; Sulfopon wa 1; Swascol 3L; Tarapon K 12; Tvm 474; Emulsifier no. 104; Finasol osr(sub 2); IPC-SDS;Jordanol SL-300; Lanette Wax-S; Maprofix WAC-LA; Product no. 161; Product no. 75; Quolac EX-UB; S-4600; Standapol wa-ac; Stepanol WA-100; Sterling WAQ-CH; Ultra sulfate sl-1
DMLJ634	DT	Small molecular drug
DMLJ634	PC	3423265
DMLJ634	MW	288.38
DMLJ634	FM	C12H25NaO4S
DMLJ634	IC	InChI=1S/C12H26O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15;/h2-12H2,1H3,(H,13,14,15);/q;+1/p-1
DMLJ634	CS	CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
DMLJ634	IK	DBMJMQXJHONAFJ-UHFFFAOYSA-M
DMLJ634	IU	sodium;dodecyl sulfate
DMLJ634	CA	CAS 151-21-3
DMLJ634	CB	CHEBI:8984
DMLJ634	DE	Constipation

DMGA9X0	ID	DMGA9X0
DMGA9X0	DN	Sodium nitroprusside
DMGA9X0	HS	Approved
DMGA9X0	SN	Nitroprusside (Sodium); Sodium nitroprusside anhydrous; 14402-89-2; C5FeN6O.2Na; Nitropruss; Nitroprusid-natrium; Sodium nitroprussate; Nitroprussidnatrium [German]; C5FeN6O.2H2O.2Na; Sodium nitroprusside [USAN]; Na2[Fe(CN)5(NO)]; Sodium nitroprussiate dihydrate; Sodium nitrosylpentacyanoferrate; SCHEMBL3020702; CCRIS 1912; Sodium Nitroprusside (anhydrous); Disodium nitrosylpentacyanoferrate; Disodium pentacyanonitrosylferrate; CHEBI:29321; Nitroprussiate de sodium [French]; MolPort-003-926-312; disodium pentacyanidonitrosylfer
DMGA9X0	DT	Small molecular drug
DMGA9X0	PC	11953895
DMGA9X0	MW	297.95
DMGA9X0	FM	C5H4FeN6Na2O3
DMGA9X0	IC	InChI=1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q5*-1;+4;-1;2*+1;;
DMGA9X0	CS	[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]
DMGA9X0	IK	XRKMNJXYOFSTBE-UHFFFAOYSA-N
DMGA9X0	IU	disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate
DMGA9X0	CA	CAS 13755-38-9
DMGA9X0	CB	CHEBI:9179
DMGA9X0	DE	Hypertension

DMCIWZL	ID	DMCIWZL
DMCIWZL	DN	Sodium oxybate
DMCIWZL	HS	Approved
DMCIWZL	SN	Sodium Oxybate [USAN]; Sodium gamma-hydroxybutyrate; Sodium oxybate; Sodium-4-hydroxybutyrate; Somsanit; gamma-Hydroxy sodium butyrate; Anetamin; Gamma OH; Natrium 4-hydroxybutyrat; Oxybate (sodium); Oxybate sodium; Sodium 4-hydroxybutyrate; gamma-Hydroxybutyrate sodium; gamma-Hydroxybutyrate sodium salt; sodium 4-hydroxybutanoate; 4-Hydroxybuttersaeure natriumsalz; 4-Hydroxybutyrate sodium; 4-Hydroxybutyric acid sodium salt; 502-85-2; Butanoic acid, 4-hydroxy-, monosodium salt; EINECS 207-953-3; NSC 84223; UNII-7G33012534
DMCIWZL	PC	23663870
DMCIWZL	MW	126.09
DMCIWZL	FM	C4H7NaO3
DMCIWZL	IC	XYGBKMMCQDZQOZ-UHFFFAOYSA-M
DMCIWZL	CS	C(CC(=O)[O-])CO.[Na+]
DMCIWZL	IK	1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1
DMCIWZL	IU	sodium;4-hydroxybutanoate
DMCIWZL	CA	CAS 502-85-2
DMCIWZL	DE	Narcolepsy

DMXLBCQ	ID	DMXLBCQ
DMXLBCQ	DN	Sodium phenylbutyrate
DMXLBCQ	HS	Approved
DMXLBCQ	SN	Ammonaps; Buphenyl; EL-532; Sodium 4-phenylbutyrate; Sodium phenylbutyrate, Elan; Sodium phenylbutyrate, Medicis; Sodium phenylbutyrate, Ucyclyd; VP-101; Sodium 4-phenylbutyrate, Elan; Sodium 4-phenylbutyrate, Ucyclyd; Sodium phenylbutyrate (cancer), MacroChem/Access; Sodium phenylbutyrate (cancer), Virium/ Somanta; Sodium phenylbutyrate (cancer), Virium/Access Pharmaceuticals; Sodium 4-phenyibutyrate (cancer), MacroChem/Access; Sodium 4-phenylbutyrate (cancer), Virium/ Somanta; Sodium 4-phenylbutyrate (cancer), Virium/Access Pharmaceuticals
DMXLBCQ	CP	Ucyclyd Pharma Inc; Elan Corp plc
DMXLBCQ	DT	Small molecular drug
DMXLBCQ	PC	5258
DMXLBCQ	MW	186.18
DMXLBCQ	FM	C10H11NaO2
DMXLBCQ	IC	InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
DMXLBCQ	CS	C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]
DMXLBCQ	IK	VPZRWNZGLKXFOE-UHFFFAOYSA-M
DMXLBCQ	IU	sodium;4-phenylbutanoate
DMXLBCQ	CA	CAS 1716-12-7
DMXLBCQ	CB	CHEBI:75316
DMXLBCQ	DE	Spinal muscular atrophy

DMKY27B	ID	DMKY27B
DMKY27B	DN	Sodium phosphate dibasic/sodium phosphate monobasic
DMKY27B	HS	Approved
DMKY27B	SN	Anhydrous sodium acid phosphate; Dipotassium phosphate anhydrous; Monobasic potassium acid phosphate; Monobasic sodium phosphate; Potassium phosphate; Sodium phosphate
DMKY27B	DE	Multiple sclerosis

DM4QFXJ	ID	DM4QFXJ
DM4QFXJ	DN	Sodium Tetradecyl Sulfate
DM4QFXJ	HS	Approved
DM4QFXJ	SN	STDS; Trombavar; Monotetradecylsulfate sodium salt; Natri tetradecylsulfas; Natrii tetradecyclis sulfas; Sodium myristyl sulfate; Sodium tetradecyl sulphate; Sodium tetradecylsulfate; Sotradecol Sodium; Tetradecyl sodium sulfate; Niaproof 4; Tesapon K 14; Texapon K 14; Myristyl sulfate, sodium salt; Natrii tetradecyclis sulfas [INN-Latin]; Tetradecilsulfato sodico [INN-Spanish]; Tetradecyl sulfate de sodium [INN-French]; Tetradecyl sulfate, sodium salt; Fibro-Vein (TN); S.T.D; Sulfuric acid, monotetradecyl ester, sodium salt; Sulfuric acid, myristyl ester, sodium salt; S.T.D.; 1-Tetradecanol, 1-(hydrogen sulfate), sodium salt (1:1); 1-Tetradecanol, hydrogen sulfate, sodium salt
DM4QFXJ	TC	Sclerosing Agents
DM4QFXJ	DT	Small molecular drug
DM4QFXJ	PC	23665770
DM4QFXJ	MW	316.43
DM4QFXJ	FM	C14H29NaO4S
DM4QFXJ	IC	InChI=1S/C14H30O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-19(15,16)17;/h2-14H2,1H3,(H,15,16,17);/q;+1/p-1
DM4QFXJ	CS	CCCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
DM4QFXJ	IK	UPUIQOIQVMNQAP-UHFFFAOYSA-M
DM4QFXJ	IU	sodium;tetradecyl sulfate
DM4QFXJ	CA	CAS 1191-50-0
DM4QFXJ	DE	Hemangioma; Varicose and spider veins of leg

DMCSLZ4	ID	DMCSLZ4
DMCSLZ4	DN	Sodium zirconium cyclosilicate
DMCSLZ4	HS	Approved
DMCSLZ4	SN	UZSi 9; ZS-9 compound; Sodium zirconium silicate (Na2ZrSi3O9); UZSi-9; CBTCHTJSGLCFMY-UHFFFAOYSA-N; 543686-27-7
DMCSLZ4	CP	AstraZeneca
DMCSLZ4	PC	91799284
DMCSLZ4	MW	371.5
DMCSLZ4	FM	H6Na2O9Si3Zr+2
DMCSLZ4	IC	InChI=1S/2Na.H6O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/h;;1-6H;/q2*+1;;
DMCSLZ4	CS	O[Si]1(O[Si](O[Si](O1)(O)O)(O)O)O.[Na+].[Na+].[Zr]
DMCSLZ4	IK	CBTCHTJSGLCFMY-UHFFFAOYSA-N
DMCSLZ4	IU	disodium;2,2,4,4,6,6-hexahydroxy-1,3,5,2,4,6-trioxatrisilinane;zirconium
DMCSLZ4	CA	CAS 17141-74-1
DMCSLZ4	DE	Hyperkalemia

DMQI86A	ID	DMQI86A
DMQI86A	DN	Sofosbuvir
DMQI86A	HS	Approved
DMQI86A	SN	HSDB 8226; Hepcinat; Hepcvir; Resof; SOFOSBUVIR; Sofosbuvir (PSI-7977, GS-7977); Sofosbuvir [USAN:INN]; Sovaldi (TN); SoviHep
DMQI86A	TC	Antiviral Agents
DMQI86A	DT	Small molecular drug
DMQI86A	PC	45375808
DMQI86A	MW	529.458
DMQI86A	FM	C22H29FN3O9P
DMQI86A	IC	InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
DMQI86A	CS	CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DMQI86A	IK	TTZHDVOVKQGIBA-IQWMDFIBSA-N
DMQI86A	IU	propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMQI86A	CA	CAS 1190307-88-0
DMQI86A	CB	CHEBI:85083
DMQI86A	DE	Chronic hepatitis C infection

DM5F47O	ID	DM5F47O
DM5F47O	DN	Sofosbuvir + velpatasvir + voxilaprevir
DM5F47O	HS	Approved
DM5F47O	SN	Vosevi; Sofosbuvir / velpatasvir / voxilaprevir; Sofosbuvir mixture with velpatasvir and voxilaprevir; S900007740
DM5F47O	CP	Gilead Sciences
DM5F47O	PC	129011857
DM5F47O	MW	2281.4
DM5F47O	FM	C111H135F5N17O26PS
DM5F47O	IC	InChI=1S/C49H54N8O8.C40H52F4N6O9S.C22H29FN3O9P/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29;1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29;1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61);11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53);5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t27-,28-,38-,39-,41-,42+;20-,22-,23+,26-,27+,28+,30-,39-;14-,16+,18+,20+,22+,36-/m010/s1
DM5F47O	CS	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C.C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)COC.C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DM5F47O	IK	FMWRYUBVSONSCK-ZYTFCPLVSA-N
DM5F47O	IU	(1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide;methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate;propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DM5F47O	DE	Hepatitis C virus infection

DMG592Q	ID	DMG592Q
DMG592Q	DN	Solifenacin
DMG592Q	HS	Approved
DMG592Q	SN	Vesicare; Vesikur; Solifenacin succinate; Solifenacin succinate [USAN]; YM 905; Solifenacin (INN); Solifenacin [INN:BAN]; Vesicare (TN); YM-53705; YM-67905; YM-905; Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1)
DMG592Q	CP	GlaxoSmithKline
DMG592Q	TC	Antispasmodics
DMG592Q	DT	Small molecular drug
DMG592Q	PC	154059
DMG592Q	MW	362.5
DMG592Q	FM	C23H26N2O2
DMG592Q	IC	InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
DMG592Q	CS	C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5
DMG592Q	IK	FBOUYBDGKBSUES-VXKWHMMOSA-N
DMG592Q	IU	[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
DMG592Q	CA	CAS 242478-37-1
DMG592Q	CB	CHEBI:135530
DMG592Q	DE	Overactive bladder

DMZ9FAO	ID	DMZ9FAO
DMZ9FAO	DN	Somatomedin-1
DMZ9FAO	HS	Approved
DMZ9FAO	SN	Igef (TN)
DMZ9FAO	DE	Hormone deficiency

DMF3GM2	ID	DMF3GM2
DMF3GM2	DN	Somatropin recombinant
DMF3GM2	HS	Approved
DMF3GM2	SN	Genotropin (TN); Humatrope (TN); Norditropin (TN); Nutropin (TN); Saizen (TN)
DMF3GM2	CP	Pfizer Pharmaceuticals
DMF3GM2	TC	Hormone Replacement Agents
DMF3GM2	DE	Growth hormone deficiency

DM72409	ID	DM72409
DM72409	DN	Sonidegib phosphate
DM72409	HS	Approved
DM72409	SN	Sonidegib phosphate; Sonidegib phosphate (USAN); Sonidegib phosphate [USAN:INN]; UNII-W421AI34UW; W421AI34UW; sonidegib bisphosphate; sonidegib diphosphate; 1218778-77-8; 3888AH; AKOS015994565; AOB87343; BCP11860; C26H26F3N3O3.2H3O4P; CHEBI:90864; CHEMBL3137317; CS-1175; DTXSID90669468; EX-A1556; Erismodegib Diphosphate; FE-0016; HY-16582; KS-00002WSZ; LDE-225 Diphosphate; LDE225 (Diphosphate); LDE225 Diphosphate; NVP-LDE225 Diphosphate; NVP-LDE225 Diphosphate salt; Odomzo (TN); SB16677
DM72409	PC	45138699
DM72409	MW	681.5
DM72409	FM	C26H32F3N3O11P2
DM72409	IC	RWIVSVMMGFFZIJ-VWDRLOGHSA-N
DM72409	CS	CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F.OP(=O)(O)O.OP(=O)(O)O
DM72409	IK	1S/C26H26F3N3O3.2H3O4P/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29;2*1-5(2,3)4/h4-13,16-17H,14-15H2,1-3H3,(H,31,33);2*(H3,1,2,3,4)/t16-,17+;;
DM72409	IU	N-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide;phosphoric acid
DM72409	CA	CAS 1218778-77-8
DM72409	CB	CHEBI:90864
DM72409	DE	Basal cell carcinoma

DMS8IFC	ID	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	HS	Approved
DMS8IFC	SN	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
DMS8IFC	CP	Bayer AG; Onyx Pharmaceuticals
DMS8IFC	TC	Anticancer Agents
DMS8IFC	DT	Small molecular drug
DMS8IFC	PC	216239
DMS8IFC	MW	464.8
DMS8IFC	FM	C21H16ClF3N4O3
DMS8IFC	IC	InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
DMS8IFC	CS	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
DMS8IFC	IK	MLDQJTXFUGDVEO-UHFFFAOYSA-N
DMS8IFC	IU	4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
DMS8IFC	CA	CAS 284461-73-0
DMS8IFC	CB	CHEBI:50924
DMS8IFC	DE	Renal cell carcinoma; Myelodysplastic syndrome; Hepatocellular carcinoma

DMAN0DE	ID	DMAN0DE
DMAN0DE	DN	Sorbitol
DMAN0DE	HS	Approved
DMAN0DE	SN	D-Sorbitol; sorbitol; D-Glucitol; 50-70-4; glucitol; L-Gulitol; (-)-Sorbitol; Glucarine; Sorbilande; Diakarmon; Sorbostyl; Multitol; Nivitin; Karion; Esasorb; Neosorb; D-(-)-Sorbitol; Sorbol; Cholaxine; Sorbite; Sionit; Sionite; Siosan; Sionon; Karion instant; Sorbitol F; Sorbitol FP; Sorbex Rp; Sorbitol syrup C; Sorbex X; Sorbex R; Sorbex M; Sorbex S; Sionit K; D-Sorbol; Hexahydric alcohol; Sorbicolan; Sorvilande; Neosorb P 60; D-Sorbite; Foodol D 70; Neosorb 20/60DC; Neosorb 70/70; Neosorb 70/02; Neosorb P 20/60; d-Sorbit; Karion (carbohydrate)
DMAN0DE	CP	Pharmaxis
DMAN0DE	DT	Small molecular drug
DMAN0DE	PC	5780
DMAN0DE	MW	182.17
DMAN0DE	FM	C6H14O6
DMAN0DE	IC	InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1
DMAN0DE	CS	C([C@H]([C@H]([C@@H]([C@H](CO)O)O)O)O)O
DMAN0DE	IK	FBPFZTCFMRRESA-JGWLITMVSA-N
DMAN0DE	IU	(2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol
DMAN0DE	CA	CAS 50-70-4
DMAN0DE	CB	CHEBI:17924
DMAN0DE	DE	Constipation

DMUJGR1	ID	DMUJGR1
DMUJGR1	DN	Sorivudine
DMUJGR1	HS	Approved
DMUJGR1	SN	Usevir (TN)
DMUJGR1	DT	Small molecular drug
DMUJGR1	PC	5282192
DMUJGR1	MW	349.13
DMUJGR1	FM	C11H13BrN2O6
DMUJGR1	IC	InChI=1S/C11H13BrN2O6/c12-2-1-5-3-14(11(19)13-9(5)18)10-8(17)7(16)6(4-15)20-10/h1-3,6-8,10,15-17H,4H2,(H,13,18,19)/b2-1+/t6-,7-,8+,10-/m1/s1
DMUJGR1	CS	C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)/C=C/Br
DMUJGR1	IK	GCQYYIHYQMVWLT-HQNLTJAPSA-N
DMUJGR1	IU	5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMUJGR1	CA	CAS 77181-69-2
DMUJGR1	CB	CHEBI:32152
DMUJGR1	DE	Virus infection

DML60TN	ID	DML60TN
DML60TN	DN	Sotalol
DML60TN	HS	Approved
DML60TN	SN	Sotalolum; Darob mite; Sotalol Monohydrochloride; Beta-Cardone; Betapace (TN); Betapace AF (TN); Darob mite (TN); MJ-1999; Sotacor (TN); Sotalex (TN); Sotalol (INN); Sotalol [INN:BAN]; Sotalolum [INN-Latin]; D,l-Sotalol; N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide; N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide; N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-(9CI); 4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; 4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid
DML60TN	CP	Bristol-Myers Squibb
DML60TN	TC	Antiarrhythmic Agents
DML60TN	DT	Small molecular drug
DML60TN	PC	5253
DML60TN	MW	272.37
DML60TN	FM	C12H20N2O3S
DML60TN	IC	InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
DML60TN	CS	CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
DML60TN	IK	ZBMZVLHSJCTVON-UHFFFAOYSA-N
DML60TN	IU	N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide
DML60TN	CA	CAS 3930-20-9
DML60TN	CB	CHEBI:63622
DML60TN	DE	Sinus rhythm disorder

DMB4HCT	ID	DMB4HCT
DMB4HCT	DN	Sparfloxacin
DMB4HCT	HS	Approved
DMB4HCT	SN	Esparfloxacino; SPFX; Spara; Sparfloxacine; Sparfloxacinum; Zagam; AT 4140; CP 103826; PD 131501; PD131501; AT-4140; CP-103826; DRG-0143; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD-131501; RP-64206; Respipac (TN); Sparfloxacin & RU 40555; Sparfloxacine [INN-French]; Sparfloxacinum [INN-Latin]; Zagam (TN); Sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
DMB4HCT	CP	Square pharma
DMB4HCT	TC	Antibiotics
DMB4HCT	DT	Small molecular drug
DMB4HCT	PC	60464
DMB4HCT	MW	392.4
DMB4HCT	FM	C19H22F2N4O3
DMB4HCT	IC	InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
DMB4HCT	CS	C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F
DMB4HCT	IK	DZZWHBIBMUVIIW-DTORHVGOSA-N
DMB4HCT	IU	5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
DMB4HCT	CA	CAS 110871-86-8
DMB4HCT	CB	CHEBI:9212
DMB4HCT	DE	Bacterial infection

DM0MQ35	ID	DM0MQ35
DM0MQ35	DN	Spectinomycin
DM0MQ35	HS	Approved
DM0MQ35	SN	Actinospectacin; Actinospectacina; Adspec; Espectinomicina; Prospec; SCM; SPCM; Spectam; Spectinomicina; Spectinomycine; Spectinomycinum; Spectogard; Stanilo; Togamycin; Trobicin; Actinospectacina [Italian]; Spectam Scour Halt; Spectinomicina [Italian]; Spectinomycin Di HCl; Spectinomycin HCl; Spectinomycin dihydrochloride; Spectinomycin hydrochloride; Spectinomycin hydrochloride anhydrous; Spectinomycin monohydrochloride; Spectinomycin sulfate; Antibiotic 2233wp; M 141; U 18409; U 18409 E; Actinospectacin, hydrochloride; Adspec (TN); Espectinomicina [INN-Spanish]; M-141; Prospec (TN); Spectinomycin (INN); Spectinomycin Dihydrochloride, Anhydrous; Spectinomycin Dihydrochloride, Pentahydrate; SpectinomycinHCl/ Sulphate; Spectinomycin Hydrochloride (anhydrous); Spectinomycin [INN:BAN]; Spectinomycine [INN-French]; Spectinomycinum [INN-Latin]; Trobicin (TN); U-18409AE; XK 43-1; Togamycin sulfate (1:1); ACTINOSPECTACIN, ESPECTINOMICINA, CHX-3101; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-Decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4H-pyrano(2,3-b)(1,4)benzodioxin-4-one monohydrochloride; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, [2R-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.)]-, sulfate (1:1) (salt)
DM0MQ35	CP	Pharmacia & Upjohn Company
DM0MQ35	TC	Antibiotics
DM0MQ35	DT	Small molecular drug
DM0MQ35	PC	15541
DM0MQ35	MW	332.35
DM0MQ35	FM	C14H24N2O7
DM0MQ35	IC	InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
DM0MQ35	CS	C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O
DM0MQ35	IK	UNFWWIHTNXNPBV-WXKVUWSESA-N
DM0MQ35	IU	(1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one
DM0MQ35	CA	CAS 1695-77-8
DM0MQ35	CB	CHEBI:9215
DM0MQ35	DE	Bacterial infection

DM6CMJD	ID	DM6CMJD
DM6CMJD	DN	Spectinomycin
DM6CMJD	HS	Approved
DM6CMJD	SN	Specitinomycin; Spectam; Spectinomicina; Spectinomicina [Italian]; Spectinomycin; Spectinomycin [INN:BAN]; Spectinomycin hydrochloride; Spectinomycine; Spectinomycine [INN-French]; Spectinomycinum; Spectinomycinum [INN-Latin]; Togamycin; Actinospectacina [Italian]; Antibiotic 2233wp; CHX-3101; Espectinomicina; Espectinomicina [INN-Spanish]; Trobicin; U 18409 E; UNFWWIHTNXNPBV-WXKVUWSESA-N; actinospectacin; 1695-77-8; 93AKI1U6QF; BRN 2171701; C14H24N2O7; CHEBI:9215; EINECS 216-911-3; M-141; SCM; UNII-93AKI1U6QF
DM6CMJD	PC	15541
DM6CMJD	MW	332.35
DM6CMJD	FM	C14H24N2O7
DM6CMJD	IC	UNFWWIHTNXNPBV-WXKVUWSESA-N
DM6CMJD	CS	CC1CC(=O)C2(C(O1)OC3C(C(C(C(C3O2)NC)O)NC)O)O
DM6CMJD	IK	1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
DM6CMJD	IU	(1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one
DM6CMJD	CA	CAS 1695-77-8
DM6CMJD	CB	CHEBI:9215
DM6CMJD	DE	Gonococcal infection

DM6XFHS	ID	DM6XFHS
DM6XFHS	DN	SPI-1005
DM6XFHS	HS	Approved
DM6XFHS	SN	Ebselen [INN]; Ebselene; Ebselene [French]; Ebseleno; Ebseleno [Spanish]; Ebselenum; Ebselenum [Latin]; Harmokisane; PZ 51; PZ-51; PZ51; RP 60931; SPI-1005; SPI-3005; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-Phenyl-1,2-benzisoselenazolin-3-one; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; 2-phenyl-1,2-benzoselenazol-3-one; DR 3305; DR-3305; E 3520
DM6XFHS	TC	Fibrinolytic Agents
DM6XFHS	DT	Small molecular drug
DM6XFHS	PC	3194
DM6XFHS	MW	274.19
DM6XFHS	FM	C13H9NOSe
DM6XFHS	IC	InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
DM6XFHS	CS	C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
DM6XFHS	IK	DYEFUKCXAQOFHX-UHFFFAOYSA-N
DM6XFHS	IU	2-phenyl-1,2-benzoselenazol-3-one
DM6XFHS	CA	CAS 60940-34-3
DM6XFHS	CB	CHEBI:77543
DM6XFHS	DE	Reperfusion injury

DM0BQRS	ID	DM0BQRS
DM0BQRS	DN	Spinosad
DM0BQRS	HS	Approved
DM0BQRS	SN	Natroba (TN)
DM0BQRS	CP	ParaPRO
DM0BQRS	DT	Small molecular drug
DM0BQRS	PC	24721309
DM0BQRS	MW	732
DM0BQRS	FM	C41H65NO10
DM0BQRS	IC	InChI=1S/C41H65NO10/c1-10-26-12-11-13-34(52-36-17-16-33(42(5)6)23(3)48-36)22(2)37(44)32-20-30-28(31(32)21-35(43)50-26)15-14-25-18-27(19-29(25)30)51-41-40(47-9)39(46-8)38(45-7)24(4)49-41/h14-15,20,22-31,33-34,36,38-41H,10-13,16-19,21H2,1-9H3/t22-,23-,24+,25-,26+,27-,28+,29-,30-,31?,33+,34+,36+,38+,39-,40-,41+/m1/s1
DM0BQRS	CS	CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C
DM0BQRS	IK	SRJQTHAZUNRMPR-MGGCLMNKSA-N
DM0BQRS	IU	(2S,5S,7R,9R,10S,14R,15S,19S)-15-[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-19-ethyl-14-methyl-7-[(2R,3R,4R,5S,6S)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy-20-oxatetracyclo[10.10.0.02,10.05,9]docosa-3,11-diene-13,21-dione
DM0BQRS	CA	CAS 168316-95-8
DM0BQRS	DE	Head and body lice

DM20R5F	ID	DM20R5F
DM20R5F	DN	Spiramycin
DM20R5F	HS	Approved
DM20R5F	SN	spiramycin; 8025-81-8; ST075006; Spiramycinum; Spiramycine; Provamycin; Sequamycin; Espiramicin; Rovamycin; Antibiotic 799; NSC-64393; RP 5337; Rovamycine; Prestwick_121; 5337 R.P.; Prestwick2_000745; Prestwick3_000745; AC1O4WG0; Spiramycin antibiotic complex; BPBio1_000804; SCHEMBL5032756; AKOS015896378; K430; SR-01000872632; SR-01000872632-1; I06-1973; Spiramycin, European Pharmacopoeia (EP) Reference Standard; Spiramycin from Streptomyces sp., VETRANAL(TM), analytical standard; Spiramycin, Pharmaceutical Secondary Standard
DM20R5F	DT	Small molecular drug
DM20R5F	PC	6419898
DM20R5F	MW	843.1
DM20R5F	FM	C43H74N2O14
DM20R5F	IC	InChI=1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26?,27?,28?,29+,30?,31-,32+,34?,35?,36?,37?,38?,39+,40+,41?,42?,43?/m1/s1
DM20R5F	CS	C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C
DM20R5F	IK	ACTOXUHEUCPTEW-JMRHEKERSA-N
DM20R5F	IU	2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
DM20R5F	CA	CAS 8025-81-8
DM20R5F	DE	Bacterial infection

DM5XLTY	ID	DM5XLTY
DM5XLTY	DN	Spirapril
DM5XLTY	HS	Approved
DM5XLTY	SN	Renormax; Sandopril; Setrilan; Espirapril [Spanish]; Not established; Spiraprilum [Latin]; Sch-33844; Spirapril (INN); Spirapril [INN:BAN]; TI-211-950; (2S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,9-dithia-3-azaspiro[4.4]nonane-2-carboxylic acid
DM5XLTY	TC	Antihypertensive Agents
DM5XLTY	DT	Small molecular drug
DM5XLTY	PC	5311447
DM5XLTY	MW	466.6
DM5XLTY	FM	C22H30N2O5S2
DM5XLTY	IC	InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1
DM5XLTY	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3
DM5XLTY	IK	HRWCVUIFMSZDJS-SZMVWBNQSA-N
DM5XLTY	IU	(8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
DM5XLTY	CA	CAS 83647-97-6
DM5XLTY	CB	CHEBI:135756
DM5XLTY	DE	Hypertension

DM2AQ5N	ID	DM2AQ5N
DM2AQ5N	DN	Spironolactone
DM2AQ5N	HS	Approved
DM2AQ5N	SN	Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
DM2AQ5N	CP	Pfizer Pharmaceuticals
DM2AQ5N	TC	Diuretics
DM2AQ5N	DT	Small molecular drug
DM2AQ5N	PC	5833
DM2AQ5N	MW	416.6
DM2AQ5N	FM	C24H32O4S
DM2AQ5N	IC	InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
DM2AQ5N	CS	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C
DM2AQ5N	IK	LXMSZDCAJNLERA-ZHYRCANASA-N
DM2AQ5N	IU	S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
DM2AQ5N	CA	CAS 52-01-7
DM2AQ5N	CB	CHEBI:9241
DM2AQ5N	DE	Congestive heart failure

DMCO5JZ	ID	DMCO5JZ
DMCO5JZ	DN	SR141716A
DMCO5JZ	HS	Approved
DMCO5JZ	SN	Riobant; Slimona; [3H]SR141716A; Acomplia (TN); Bethin (TN); Monaslim (TN); Remonabent (TN); Rimonabant [USAN:INN]; Rimoslim (TN); Riobant (TN); Riomont (TN); Slimona (TN); Zimulti (TN); Rimonabant (JAN/USAN/INN); 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; 5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
DMCO5JZ	CP	Sanofi-Aventis
DMCO5JZ	TC	Antiobesity Agents
DMCO5JZ	DT	Small molecular drug
DMCO5JZ	PC	104850
DMCO5JZ	MW	463.8
DMCO5JZ	FM	C22H21Cl3N4O
DMCO5JZ	IC	InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMCO5JZ	CS	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMCO5JZ	IK	JZCPYUJPEARBJL-UHFFFAOYSA-N
DMCO5JZ	IU	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMCO5JZ	CA	CAS 168273-06-1
DMCO5JZ	CB	CHEBI:34967
DMCO5JZ	DE	Obesity

DM6DEK9	ID	DM6DEK9
DM6DEK9	DN	Stavudine
DM6DEK9	HS	Approved
DM6DEK9	SN	DdeThd; DdeTyd; Dideoxydidehydrothymidine; Estavudina; STV; Sanilvudine; Stavudinum; Zent; Zerit; Zerit Xr; Zerut XR; BMY 27857; BMY27857; D 1413; D 4T; BMY-27857; Bristol-Myers Brand of Stavudine; Bristol-Myers Squibb Brand of Stavudine; D 4T (nucleoside); Estavudina [INN-Spanish]; Sanilvudine (JAN); Stavudine, Monosodium Salt; Stavudinum [INN-Latin]; Zerit (TN); Zerit(TM); D4T & GM-CSF; D4TMBY-27857-3; Stavudine (USAN/INN); Stavudine [USAN:BAN:INN]; Stavudine [USAN:INN:BAN]; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-(7CI,8CI); 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; 2',3' Didehydro 3' deoxythymidine; 2',3'-Anhydrothymidine; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI); 2',3'-Didehydro-2',3'-dideoxythmidine; 2',3'-Didehydro-3'-deoxythimidine; 2',3'-Didehydro-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Deoxy-2',3'-didehydrothymidine; 3'-Deoxy-2'-thymidinene; D4T
DM6DEK9	CP	Aurobindo Pharma
DM6DEK9	TC	Anti-HIV Agents
DM6DEK9	DT	Small molecular drug
DM6DEK9	PC	18283
DM6DEK9	MW	224.21
DM6DEK9	FM	C10H12N2O4
DM6DEK9	IC	InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1
DM6DEK9	CS	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO
DM6DEK9	IK	XNKLLVCARDGLGL-JGVFFNPUSA-N
DM6DEK9	IU	1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
DM6DEK9	CA	CAS 3056-17-5
DM6DEK9	CB	CHEBI:63581
DM6DEK9	DE	Human immunodeficiency virus infection

DMMSDOY	ID	DMMSDOY
DMMSDOY	DN	Stiripentol
DMMSDOY	HS	Approved
DMMSDOY	SN	Diacomit; ME-2080; Stiripentol (oral); Stiripentol (oral), Laboratoires Biocodex
DMMSDOY	CP	Biocodex
DMMSDOY	DT	Small molecular drug
DMMSDOY	PC	5311454
DMMSDOY	MW	234.29
DMMSDOY	FM	C14H18O3
DMMSDOY	IC	InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+
DMMSDOY	CS	CC(C)(C)C(/C=C/C1=CC2=C(C=C1)OCO2)O
DMMSDOY	IK	IBLNKMRFIPWSOY-FNORWQNLSA-N
DMMSDOY	IU	(E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
DMMSDOY	CA	CAS 49763-96-4
DMMSDOY	CB	CHEBI:94435
DMMSDOY	DE	Dravet syndrome; Epilepsy

DM5JQ0D	ID	DM5JQ0D
DM5JQ0D	DN	Streptokinase
DM5JQ0D	HS	Approved
DM5JQ0D	SN	Awelysin; Estreptoquinasa; Kabikinase; Streptase; Streptochinasi; Streptokinasum; Streptochinasi [DCIT]; Streptococcal fibrinolysin; Estreptoquinasa [INN-Spanish]; Streptase (TN); Streptokinasum [INN-Latin]; 4-cyclohexylpyrrolidine-2-carboxylic Acid
DM5JQ0D	CP	Alpes Selection
DM5JQ0D	TC	Thrombolytic Agents
DM5JQ0D	DT	Small molecular drug
DM5JQ0D	SQ	Streptokinase Sequence DB00086: MKNYLSFGMFALLFALTFGTVNSVQAIAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDISLKFFEIDLTSRPAHGGKTEQGLSPKSKPFATDSGAMSHKLEKADLLKAIQEQLIANVHSNDDYFEVIDFASDATITDRNGKVYFADKDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQAKSVDVEYTVQFTPLNPDDDFRPGLKDTKLLKTLAIGDTITSQELLAQAQSILNKNHPGYTIYERDSSIVTHDNDIFRTILPMDQEFTYRVKNREQAYRINKKSGLNEEINNTDLISEKYYVLKKGEKPYDPFDRSHLKLFTIKYVDVDTNELLKSEQLLTASERNLDFRDLYDPRDKAKLLYNNLDAFGIMDYTLTGKVEDNHDDTNRIITVYMGKRPEGENASYHLAYDKDRYTEEEREVYSYLRYTGTPIPDNPNDK
DM5JQ0D	PC	9815560
DM5JQ0D	MW	197.27
DM5JQ0D	FM	C11H19NO2
DM5JQ0D	IC	InChI=1S/C11H19NO2/c13-11(14)10-6-9(7-12-10)8-4-2-1-3-5-8/h8-10,12H,1-7H2,(H,13,14)
DM5JQ0D	CS	C1CCC(CC1)C2CC(NC2)C(=O)O
DM5JQ0D	IK	XRZWVSXEDRYQGC-UHFFFAOYSA-N
DM5JQ0D	IU	4-cyclohexylpyrrolidine-2-carboxylic acid
DM5JQ0D	CA	CAS 9002-01-1
DM5JQ0D	DE	Pulmonary embolism

DME1LQN	ID	DME1LQN
DME1LQN	DN	Streptomycin
DME1LQN	HS	Approved
DME1LQN	SN	Agrept; Agrimycin; Gerox; Neodiestreptopab; SRY; Strepcen; Streptomicina; Streptomycine; Streptomycinum; Streptomyzin; Liposomal Streptomycin; Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin Sesquisulfate Hydrate; Streptomycin sulfate; Streptomycin sulphate; Streptomyzin [German]; Agrept (TN); Estreptomicina [INN-Spanish]; Hokko-mycin; Plantomycin (TN); Rimosidin (TN); Streptomycin & EEP; Streptomycin & Propolis; Streptomycin (INN); Streptomycin (TN); Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; AS-50 (TN); STREPTOMYCIN SULFATE (2:3) SALT; Agri-mycin-17 (TN); O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2S,3S,4S,5R)-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,4S)-5-(diaminomethylideneamino)-2-[(2R,5S)-3-[(2S,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}
DME1LQN	CP	Merck & Co
DME1LQN	TC	Antibiotics
DME1LQN	DT	Small molecular drug
DME1LQN	PC	19649
DME1LQN	MW	581.6
DME1LQN	FM	C21H39N7O12
DME1LQN	IC	InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
DME1LQN	CS	C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O
DME1LQN	IK	UCSJYZPVAKXKNQ-HZYVHMACSA-N
DME1LQN	IU	2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
DME1LQN	CA	CAS 57-92-1
DME1LQN	CB	CHEBI:17076
DME1LQN	DE	Bacterial infection

DMSRXVM	ID	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	HS	Approved
DMSRXVM	SN	Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin [INN:BAN]; Streptomycin sulfate; Streptomycin sulphate; Streptomycine; Streptomycinum; Streptomyzin [German]; Agrept; Agrimycin; Chemform; Estreptomicina [INN-Spanish]; Hokko-mycin; Neodiestreptopab; Strepcen; Y45QSO73OB; streptomycin; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 57-92-1; CHEBI:17076; Caswell No. 804; Gerox; NSC-14083; UNII-Y45QSO73OB
DMSRXVM	PC	19649
DMSRXVM	MW	581.6
DMSRXVM	FM	C21H39N7O12
DMSRXVM	IC	UCSJYZPVAKXKNQ-HZYVHMACSA-N
DMSRXVM	CS	CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O
DMSRXVM	IK	1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
DMSRXVM	IU	2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
DMSRXVM	CA	CAS 57-92-1
DMSRXVM	CB	CHEBI:17076
DMSRXVM	DE	Infectious endocarditis

DMOF7AT	ID	DMOF7AT
DMOF7AT	DN	Streptozocin
DMOF7AT	HS	Approved
DMOF7AT	SN	Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose
DMOF7AT	CP	Pfizer Pharmaceuticals
DMOF7AT	TC	Anticancer Agents
DMOF7AT	DT	Small molecular drug
DMOF7AT	PC	29327
DMOF7AT	MW	265.22
DMOF7AT	FM	C8H15N3O7
DMOF7AT	IC	InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1
DMOF7AT	CS	CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O
DMOF7AT	IK	ZSJLQEPLLKMAKR-GKHCUFPYSA-N
DMOF7AT	IU	1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
DMOF7AT	CA	CAS 18883-66-4
DMOF7AT	CB	CHEBI:9288
DMOF7AT	DE	Pancreatic cancer

DME81IY	ID	DME81IY
DME81IY	DN	Succimer
DME81IY	HS	Approved
DME81IY	SN	Succimer; meso-2,3-Dimercaptosuccinic acid; 304-55-2; DMSA; (2R,3S)-rel-2,3-Dimercaptosuccinic acid; meso-Dimercaptosuccinic acid; Chemet; Dim-sa; Succimerum; Succimero; Dimercaptosuccinic acid; Succimerum [INN-Latin]; Succimero [INN-Spanish]; (R*,S*)-2,3-Dimercaptobutanedioic acid; Butanedioic acid, 2,3-dimercapto-, (2R,3S)-rel-; UNII-DX1U2629QE; Succimer [USAN:INN:BAN]; HSDB 6783; EINECS 206-155-2; Ro 1-7977; BRN 1725150; DX1U2629QE; CHEBI:63623; Butanedioic acid, 2,3-dimercapto-, (R*,S*)-; meso-2,3-Dimercaptobernsteinsaeure
DME81IY	DT	Small molecular drug
DME81IY	PC	2724354
DME81IY	MW	182.2
DME81IY	FM	C4H6O4S2
DME81IY	IC	InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)/t1-,2+
DME81IY	CS	[C@@H]([C@@H](C(=O)O)S)(C(=O)O)S
DME81IY	IK	ACTRVOBWPAIOHC-XIXRPRMCSA-N
DME81IY	IU	(2S,3R)-2,3-bis(sulfanyl)butanedioic acid
DME81IY	CA	CAS 304-55-2
DME81IY	CB	CHEBI:63623
DME81IY	DE	Metal intoxication

DMDWICP	ID	DMDWICP
DMDWICP	DN	Succinic acid
DMDWICP	HS	Approved
DMDWICP	SN	Asuccin; Bernsteinsaeure; Bernsteinsaure; Butandisaeure; Katasuccin; SIN; Succ; Succinellite; Wormwood; Acid of amber; Acide butanedioique; Acide succinique; Acidum succinicum; Amber acid; Bernsteinsaure [German]; Butanedioic acid diammonium salt; Butanedionic acid; Dihydrofumaric acid; Ethanedicarboxylic acid; Ethylene dicarboxylic acid; Ethylene succinic acid; Ethylenesuccinic acid; Kyselina jantarova; Kyselina jantarova [Czech]; Potassium Succinate; Sal succini; Spirit of amber; Succinicum acidum; Succinicun acidum; Wormwood acid; A 12084; Butanedioic acid (9CI); SUCCINIC ACID, ACS; Succinate, 9; Succinic acid (8CI); Amber acid, Butanedioic acid, Ethylenesuccinic acid; 1,2-Ethanedicarboxylic acid; 1,4-BUTANEDIOIC ACID (SUCCINIC ACID); 1,4-Butanedioic acid
DMDWICP	TC	Dietary supplement
DMDWICP	DT	Small molecular drug
DMDWICP	PC	1110
DMDWICP	MW	118.09
DMDWICP	FM	C4H6O4
DMDWICP	IC	InChI=1S/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)
DMDWICP	CS	C(CC(=O)O)C(=O)O
DMDWICP	IK	KDYFGRWQOYBRFD-UHFFFAOYSA-N
DMDWICP	IU	butanedioic acid
DMDWICP	CA	CAS 110-15-6
DMDWICP	CB	CHEBI:15741
DMDWICP	DE	Malnutrition

DM2ET1M	ID	DM2ET1M
DM2ET1M	DN	Succinylcholine
DM2ET1M	HS	Approved
DM2ET1M	SN	Anectine; Diacetylcholine; Ditilin; Ditiline; Listenon; Lysthenon; Quelicin; SCK; Succicuran; Succinocholine; Succinoylcholine; Succinylbischoline; Succinyldicholine; Sucostrin; Suxamethonium; Dicholine succinate; Succinyl choline; Anectine (TN); Scoline (TN); Succinic acid, diester with choline; Succinic acid, diester with choline chloride; Choline, succinate (ester); Choline, succinate (2:1) (ester); Trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio; Trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium; 2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
DM2ET1M	CP	Sandoz Canada Inc
DM2ET1M	TC	Analgesics
DM2ET1M	DT	Small molecular drug
DM2ET1M	PC	5314
DM2ET1M	MW	290.4
DM2ET1M	FM	C14H30N2O4+2
DM2ET1M	IC	InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
DM2ET1M	CS	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
DM2ET1M	IK	AXOIZCJOOAYSMI-UHFFFAOYSA-N
DM2ET1M	IU	trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
DM2ET1M	CA	CAS 306-40-1
DM2ET1M	CB	CHEBI:45652
DM2ET1M	DE	Spasm

DMP9HBO	ID	DMP9HBO
DMP9HBO	DN	Sucralfate
DMP9HBO	HS	Approved
DMP9HBO	SN	SUL; Ulcerlmin; Sucralfate, Chugai; Sucralfate, Scios Nova
DMP9HBO	CP	Scios Inc
DMP9HBO	PC	121494085
DMP9HBO	MW	1577.9
DMP9HBO	FM	C12H54Al9O55S8
DMP9HBO	IC	InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1
DMP9HBO	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]
DMP9HBO	IK	YZPQNHUVIVIUCT-JTJNLBSYSA-F
DMP9HBO	CA	CAS 54182-58-0
DMP9HBO	DE	Acne vulgaris

DMU7YEL	ID	DMU7YEL
DMU7YEL	DN	Sufentanil
DMU7YEL	HS	Approved
DMU7YEL	SN	Chronogesic; Sufentanilum; Sufentanyl; Sulfentanil; Sulfentanyl; R 30730; R-30730; Sufenta (TN); Sufentanilum [INN-Latin]; Sufentil (TN); Sufentanil (USAN/INN); Sufentanil [USAN:BAN:INN]; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
DMU7YEL	CP	Janssen Pharmaceutica
DMU7YEL	TC	Anesthetics
DMU7YEL	DT	Small molecular drug
DMU7YEL	PC	41693
DMU7YEL	MW	386.6
DMU7YEL	FM	C22H30N2O2S
DMU7YEL	IC	InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
DMU7YEL	CS	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC
DMU7YEL	IK	GGCSSNBKKAUURC-UHFFFAOYSA-N
DMU7YEL	IU	N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
DMU7YEL	CA	CAS 56030-54-7
DMU7YEL	CB	CHEBI:9316
DMU7YEL	DE	Analgesia

DMZ6VEY	ID	DMZ6VEY
DMZ6VEY	DN	Sulfacetamide
DMZ6VEY	HS	Approved
DMZ6VEY	SN	Acetocid; Acetosulfamin; Acetosulfamine; Albamine; Albucid; Alesten; Cetamide; Formosulfacetamide; Klaron; Oclucid; Ophthacet; Region; SULSTER; Sebizon; Solfacetamide; Steramide; Sulamyd; Sulfacet; Sulfacetamida; Sulfacetamidum; Sulfacetimide; Sulfacil; Sulfacyl; Sulfacylum; Sulfair; Sulfanilacetamide; Sulfanilazetamid; Sulphacetamide; Sulphacetamidum; Sulphasil; Sultrin; Urosulfon; Urosulfone; Isopto cetamide; Sodium sulamyd; Sodium sulfacetamide; Solfacetamide [DCIT]; Sulfacetamide Monosodium Salt; Sulfacetamide Sodium Usp; Sulfacetamide sodium; Sulfacetamide sodium anhydrous; Sulfanilazetamid [German]; Sulphacetamide sodium; Sulfair 15; A-500; Ak-Sulf; Bleph-10; Bleph-10 liquifilm; FML-S; I-Sulfacet; Isopto-Cetamide; Klaron (TN); N-Acetylsulfanilamide; N-Acetylsulfanilamine; N-Sulfanilylacetamide; N-Sulphanilylacetamide; N1-Acetylsulfanilamide; OP-Sulfa 30; Ocusulf-10; Ophthel-S; P-Aminobenzenesulfonacetamide; P-Aminobenzenesulfonoacetamide; Steri-Units Sulfacetamide; Sulf-10; Sulf-15; Sulfacel-15; Sulfacetamida [INN-Spanish]; Sulfacetamide [USAN:INN]; Sulfacetamidum [INN-Latin]; Sulfacyl (VAN); Sulfair-15; Sulten-10; N'-Acetylsulfanilamide; N(sup 1)-Acetylsulfanilamide; N(sup1)-Acetylsulfanilamide; Sulfacetamide (USP/INN); N-(4-Aminobenzenesulfonyl)acetamide; N-(4-Aminophenylsulfonyl)acetamide; N-(4-aminophenyl)sulfonylacetamide; N-Acetyl-4-aminobenzenesulfonamide; N-[(4-Aminophenyl)sulfonyl]acetamide; N-[(p-Aminophenyl)sulfonyl]acetamide; N(sup 1)-Acetyl-4-aminophenylsulfonamide; N-((4-Aminophenyl)sulfonyl)acetamide; N-((p-Aminophenyl)sulfonyl)acetamide
DMZ6VEY	TC	Antibiotics
DMZ6VEY	DT	Small molecular drug
DMZ6VEY	PC	5320
DMZ6VEY	MW	214.24
DMZ6VEY	FM	C8H10N2O3S
DMZ6VEY	IC	InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)
DMZ6VEY	CS	CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N
DMZ6VEY	IK	SKIVFJLNDNKQPD-UHFFFAOYSA-N
DMZ6VEY	IU	N-(4-aminophenyl)sulfonylacetamide
DMZ6VEY	CA	CAS 144-80-9
DMZ6VEY	CB	CHEBI:63845
DMZ6VEY	DE	Acne vulgaris

DMKI2XC	ID	DMKI2XC
DMKI2XC	DN	Sulfacytine
DMKI2XC	HS	Approved
DMKI2XC	SN	Renoquid; Sulfacitina; Sulfacitine; Sulfacitinum; CL 636; Renoquid (TN); Sulfacitina [INN-Spanish]; Sulfacitinum [INN-Latin]; Sulfacytine (USAN); Sulfacytine [USAN:BAN]; N-Sulfanilyl-l-ethylcytosine; Nl-sulfanilyl-1-ethylcytosine; N(sup 1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; N(sup1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-(8CI); 1-Ethyl N4-sulfanilylcytosin; 1-Ethyl-N-sulfanilylcytosine; 4-amino-N-(1-ethyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzenesulfonamide; 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide
DMKI2XC	TC	Antiinfective Agents
DMKI2XC	DT	Small molecular drug
DMKI2XC	PC	5322
DMKI2XC	MW	294.33
DMKI2XC	FM	C12H14N4O3S
DMKI2XC	IC	InChI=1S/C12H14N4O3S/c1-2-16-8-7-11(14-12(16)17)15-20(18,19)10-5-3-9(13)4-6-10/h3-8H,2,13H2,1H3,(H,14,15,17)
DMKI2XC	CS	CCN1C=CC(=NC1=O)NS(=O)(=O)C2=CC=C(C=C2)N
DMKI2XC	IK	SIBQAECNSSQUOD-UHFFFAOYSA-N
DMKI2XC	IU	4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide
DMKI2XC	CA	CAS 17784-12-2
DMKI2XC	CB	CHEBI:135230
DMKI2XC	DE	Cystitis; Urinary tract infection

DMTW3R8	ID	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	HS	Approved
DMTW3R8	SN	Adiazin; Adiazine; CocoDiazine; Codiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazovit; Diazyl; Eskadiazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Sanodiazine; Solfadiazina; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfadiazina; Sulfadiazinum; Sulfanilamidopyrimidine; Sulfapirimidin; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Trifonamide; Trisem; Truozine; Honey diazine; Solfadiazina [DCIT]; Sulfapyrimidin [German]; Sulfonamides Duplex; Sulphadiazine E; Triple Sulfas; Zinc Sulfadiazine; A 306; RP 2616; A-306; Coco-Diazine; Lantrisul (TN); Lipo-Diazine; Lipo-Levazine; Metha-Meridiazine; Neotrizine (TN); Pecta-Diazine; RBPI21 & Sulfa; Sulfadiazina [INN-Spanish]; Sulfadiazine (TN); Sulfadiazine, Zinc; Sulfadiazinum [INN-Latin]; Sulfaloid (TN); Sulfonamides Duplex (TN); Sulfose (TN); Terfonyl (TN); Tri-Sulfameth; Triple Sulfa (TN); Triple Sulfas (TN); Triple Sulfoid (TN); Trisulfapyrimidine, oral suspension; A-306 (VAN); CRL-8131 & Sulfadiazine; Di-Azo-Mul; Mixture of sulfadiazine, sulfamerazine, and sulfamethazine; Pecta-diazine, suspension; S. N. 112; S.N. 112; Sulfadiazine [USAN:INN:JAN]; Thi-Di-Mer; N(1)-2-pyrimidinylsulfanilamide; N(1)-2-pyrimidylsulfanilamide; N(sup 1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidylsulfanilamide; N-(2-Pyrimidinyl)sulfanilamide; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; Sulfa-Triple #2 (TN); Sulfadiazine (JAN/USP/INN); N1-(Pyrimidin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyrimidinyl-(8CI); Adiazin, Adiazine, Debenal, Liquadiazine, Microsulfon, Sulfazine, Sulfolex, Sulfadiazine; 2-Sulfanilamido-pyrimidine; 2-Sulfanilamidopyrimidin; 2-Sulfanilamidopyrimidin [German]; 2-Sulfanilamidopyrimidine; 2-Sulfanilylaminopyrimidine; 2-Sulfapyrimidine; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; SDZ
DMTW3R8	CP	Lilly
DMTW3R8	TC	Antiinfective Agents
DMTW3R8	DT	Small molecular drug
DMTW3R8	PC	5215
DMTW3R8	MW	250.28
DMTW3R8	FM	C10H10N4O2S
DMTW3R8	IC	InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
DMTW3R8	CS	C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMTW3R8	IK	SEEPANYCNGTZFQ-UHFFFAOYSA-N
DMTW3R8	IU	4-amino-N-pyrimidin-2-ylbenzenesulfonamide
DMTW3R8	CA	CAS 68-35-9
DMTW3R8	CB	CHEBI:9328
DMTW3R8	DE	Rheumatic fever

DMKM3SX	ID	DMKM3SX
DMKM3SX	DN	Sulfamerazine
DMKM3SX	HS	Approved
DMKM3SX	SN	Cremomerazine; Kelamerazine; Mebacid; Mesulfa; Methylpyrimal; Methylsulfadiazine; Methylsulfazin; Methylsulfazine;Metilsulfadiazin; Metilsulfazin; Percoccide; Pyralcid; Romezin; Septacil; Septosyl; Solfamerazina; Solumedin; Sulfameradine; Sulfamerazin; Sulfamerazina; Sulfamerazinum; Sulfamethyldiazine; Sulphamerazine; Sumedine; Pyrimal M; Solfamerazina [DCIT]; RP 2632; A-310; Debenal-M; Pirimal-M; Sulfamerazina [INN-Spanish]; Sulfamerazine (INN); Sulfamerazinum [INN-Latin]; Veta-Merazine; Sulfamerazine [USAN:INN:BAN]; N-(4-Methyl-2-pyrimidyl)sulfanilamide; N1-(4-Methyl-2-pyrimidinyl)sulfanilamide; N1-(4-Methylpyrimidin-2-yl)sulfanilamide; N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(4-methyl-2-pyrimidinyl)-(8CI); (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin [German]; 2(p-Aminobenzolsulfonamido)-4-methylpyrimidin; 2-(4-Aminobenzenesulfonamido)-4-methylpyrimidine; 2-(Sulfanilamido)-4-methylpyrimidine; 2-(p-Aminobenzolsulfonamido)-4-methylpyrimidine; 2-Sulfa-4-methylpyrimidine; 2-Sulfanilamido-4-methylpyrimidine; 2643-RP; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide (9CI); 4-Amino-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4-methyl-pyrimidin-2-yl)-benzenesulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide
DMKM3SX	TC	Antiinfective Agents
DMKM3SX	DT	Small molecular drug
DMKM3SX	PC	5325
DMKM3SX	MW	264.31
DMKM3SX	FM	C11H12N4O2S
DMKM3SX	IC	InChI=1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)
DMKM3SX	CS	CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMKM3SX	IK	QPPBRPIAZZHUNT-UHFFFAOYSA-N
DMKM3SX	IU	4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide
DMKM3SX	CA	CAS 127-79-7
DMKM3SX	CB	CHEBI:102130
DMKM3SX	DE	Bacterial infection

DMRGZ16	ID	DMRGZ16
DMRGZ16	DN	Sulfamethazine
DMRGZ16	HS	Approved
DMRGZ16	SN	Azolmetazin; Cremomethazine; Diazil; Dimezathine; Intradine; Kelametazine; Mermeth; Neasina; Neazina; Pirmazin; Primazin; Solfadimidina; Spanbolet; Sulfadimerazine; Sulfadimesin; Sulfadimesine; Sulfadimethyldiazine; Sulfadimethylpyrimidine; Sulfadimezin; Sulfadimezine; Sulfadimezinum; Sulfadimidin; Sulfadimidina; Sulfadimidine; Sulfadimidinum; Sulfadine; Sulfametazina; Sulfametazyny; Sulfamethiazine; Sulfamezathine; Sulfodimesin; Sulfodimezine; Sulphadimethylpyrimidine; Sulphadimidine; Sulphamethasine; Sulphamethazine; Sulphamezathine; Sulphamidine; Sulphodimezine; Superseptil; Superseptyl; Vertolan; Calfspan Tablets; Sa III; Solfadimidina [DCIT]; SulfaSURE SR Bolus; Sulfadimidine solution; Sulfametazina[Italian]; Sulfametazyny [Polish]; Sulfamethazine solution; Sulka S Boluses; BN 2409; HC210279; A-502; Diazil (the sulfanilamide); Dimidin-R; Hava-Span; Sulfa-Isodimerazine; Sulfadimidina [INN-Spanish]; Sulfadimidine (INN); Sulfadimidine [INN:BAN]; Sulfadimidinum [INN-Latin]; Sulfamethazine (USP); Sulfamezathine (TN); N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup1)-(2,6-Dimethylpyrimid-4-yl)sulfanilamide; [(4-Aminophenyl)sulfonyl](4,6-dimethylpyrimidin-2-yl)amine; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin [German]; 2-(4-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-(p-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-Sulfanilamido-4,6-dimethylpyrimidine; 4,6-Dimethyl-2-sulfanilamidopyrimidine; 4,6-Dimethylsulfadiazine; 4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide; 4-Amino-N-[4,6-dimethyl-2-pyrimidinyl]-benzenesulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin [German]
DMRGZ16	TC	Antiinfective Agents
DMRGZ16	DT	Small molecular drug
DMRGZ16	PC	5327
DMRGZ16	MW	278.33
DMRGZ16	FM	C12H14N4O2S
DMRGZ16	IC	InChI=1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)
DMRGZ16	CS	CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C
DMRGZ16	IK	ASWVTGNCAZCNNR-UHFFFAOYSA-N
DMRGZ16	IU	4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
DMRGZ16	CA	CAS 57-68-1
DMRGZ16	CB	CHEBI:102265
DMRGZ16	DE	Bacterial infection

DMGCHDS	ID	DMGCHDS
DMGCHDS	DN	Sulfamethizole
DMGCHDS	HS	Approved
DMGCHDS	SN	Ayerlucil; Famet; Lucosil; Methazol; Microsul; Proklar; Renasul; Rufol; SULFAMETHIAZOLE; Salimol; Solfametizolo; Sulamethizole; Sulfamethazole; Sulfamethizol; Sulfamethizolum; Sulfamethylthiadiazole; Sulfametizol; Sulfapyelon; Sulfstat; Sulfurine; Sulphamethizole; Sulphamethyltiadiazole; Tetracid; Thidicur;Thiosulfil; Ultrasul; Urocydal; Urodiaton; Urolucosil; Urosulfin; Uroz; Solfametizolo [DCIT]; Sulfa gram; Thiosulfil Forte; RP 2145; VK 53; Sulfamethizolum [INN-Latin]; Sulfametizol [INN-Spanish]; Thiosulfil (TN); Sulfamethizole [USAN:INN:JAN]; Thiosulfil-A-Forte; Sulfamethizole (JP15/USP/INN); N1-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)-sulfanilamide; 2-(p-Aminobenzenesulfonamido)-5-methylthiadiazole; 2-Methyl-5-sulfanilamido-1,3,4-thiadiazole; 2-Sulfanilamido-5-methyl-1,3,4-thiadiazole; 4-Amino-N-(5-Methyl-1,3,4-Thiadiazol-2-Yl)Benzene-1-Sulfonamide; 4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide; 4-Amino-N-[5-methyl-1,3,4-thiadiazol-2-yl]benzenesulfonamide; 5-Methyl-2-sulfanilamido-1,3,4-thiadiazole
DMGCHDS	TC	Antiinfective Agents
DMGCHDS	DT	Small molecular drug
DMGCHDS	PC	5328
DMGCHDS	MW	270.3
DMGCHDS	FM	C9H10N4O2S2
DMGCHDS	IC	InChI=1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)
DMGCHDS	CS	CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N
DMGCHDS	IK	VACCAVUAMIDAGB-UHFFFAOYSA-N
DMGCHDS	IU	4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide
DMGCHDS	CA	CAS 144-82-1
DMGCHDS	CB	CHEBI:9331
DMGCHDS	DE	Urinary tract infection

DMB08GE	ID	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	HS	Approved
DMB08GE	SN	sulfamethoxazole; 723-46-6; Gantanol; Sulphamethoxazole; Sulfisomezole; Sulfamethoxazol; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Sulpha-methoxizole; Sulfamethalazole; Azo-gantanol; Sulphamethylisoxazole; Urobak; Sulfamethoxizole; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Bactrimel; Gamazole; Sulphisomezole; Sulfametoxazol; Solfametossazolo; Sulfamethoxazolum; Ro 4-2130; SMX; Septran; Sulphamethalazole; Trib; Solfametossazolo [DCIT]; Sulfamethoxazole sodium; MS 53; Sulphamethoxazole BP 98; ALBB-002089; Apo-Sulfamethoxazole; Bactrim (TN); Septra (TN); Septrin (TN); Sulfamethoxazolum [INN-Latin]; Sulfametoxazol [INN-Spanish]; Ro 6-2580/11; Ro-4-2130; Sulfamethoxazole [USAN:INN:JAN]; Sulfamethoxazole (JP15/USP/INN); N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methylisoxazol-3-yl)sulfanilamide; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); N'-(5-Methyl-3-isoxazole)sulfanilamide; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-(8CI); 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; 3-Sulphanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; 4-Amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; 5-Methyl-3-sulphanil-amidoisoxazole; Sulphameth oxazole
DMB08GE	TC	Antiinfective Agents
DMB08GE	DT	Small molecular drug
DMB08GE	PC	5329
DMB08GE	MW	253.28
DMB08GE	FM	C10H11N3O3S
DMB08GE	IC	InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)
DMB08GE	CS	CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N
DMB08GE	IK	JLKIGFTWXXRPMT-UHFFFAOYSA-N
DMB08GE	IU	4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
DMB08GE	CA	CAS 723-46-6
DMB08GE	CB	CHEBI:9332
DMB08GE	DE	Bacterial infection; Infection of P. falciparum

DMIO1K0	ID	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	HS	Approved
DMIO1K0	SN	Mafenide; mafenide; 138-39-6; 4-(Aminomethyl)benzenesulfonamide; 4-Aminomethylbenzenesulfonamide; Ambamide; Emilene; Maphenide; Maphenid; Malfamin; Homosul; Homonal; Benzamsulfonamide; Homosulfanilamide; Marprontil; Mesudrin; Septicid; Neofamid; Mesudin; Paramenyl; 4-Homosulfanilamide; Benzenesulfonamide, 4-(aminomethyl)-; Homosulfaminum; 4-(aminomethyl)benzene-1-sulfonamide; p-(Aminomethyl)benzenesulfonamide; 4-sulfamoylbenzylamine; Bensulfamide; Mafenidum [INN-Latin]; Mafenida [INN-Spanish]; 4-(aminosulfonyl)benzylamine;  Mafenide acetate; MAFENIDE
DMIO1K0	CP	Mylan Inc
DMIO1K0	DT	Small molecular drug
DMIO1K0	PC	3998
DMIO1K0	MW	186.23
DMIO1K0	FM	C7H10N2O2S
DMIO1K0	IC	InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)
DMIO1K0	CS	C1=CC(=CC=C1CN)S(=O)(=O)N
DMIO1K0	IK	TYMRLRRVMHJFTF-UHFFFAOYSA-N
DMIO1K0	IU	4-(aminomethyl)benzenesulfonamide
DMIO1K0	CA	CAS 138-39-6
DMIO1K0	CB	CHEBI:6633
DMIO1K0	DE	Bacterial infection

DMABVE9	ID	DMABVE9
DMABVE9	DN	Sulfanilamide
DMABVE9	HS	Approved
DMABVE9	SN	AAS; AVC; Albexan; Albosal; Ambeside; Antistrept; Astreptine; Astrocid; Bactesid; Collomide; Colsulanyde; Copticide; Deseptyl; Desseptyl; Dipron; Ergaseptine; Gerison; Gombardol; Infepan; Lusil; Lysococcine; Neococcyl; Orgaseptine; PABS; Prontalbin; Prontylin; Proseptal; Proseptine; Pysococcine; SAN; Sanamid; Septanilam; Septolix; Septoplex; Septoplix; Solfanilamide; Stramid; Strepamide; Streptagol; Streptamid; Streptocid; Streptocide; Streptocidum; Streptocom; Streptol; Strepton; Streptopan; Streptrocide; Sulfanilamida; Sulfanilamidum; Sulfocidin; Therapol; Tolder; Prontosil I; Prontosil White; Pronzin Album; Rubiazol A; Septamide Album; Solfanilamide [DCIT]; Stopton Album; Streptocid album; Streptocide White; Sulfanilamide Vaginal Cream; Sulphanilamide Extra Pure; Sulphanilamide Gr; White streptocide; F 1162; Fourneau 1162; Ro13354; A-349; AVC (TN); Aromatic/heteroaromatic sulfonamide 2; F-1162; P-Aminobenzenesulfonylamide; P-Aminobenzensulfonamide; Streptocid (TN); Streptocide (VAN); Sulfanilamida [INN-Spanish]; Sulfanilamide (INN); Sulfanilamide [INN:DCF]; Sulfanilamidum [INN-Latin]; Aniline-p-sulfonic amide; I.C. 56; BENZENESULFONIC ACID,4-AMINO,AMIDE SULFANILAMIDE; N4,N4-Bis(2-bromoethyl)sulfanilamide; N(sup 4),N(sup 4)-Bis(2-bromoethyl)sulfanilamide; N(sup4),N(sup4)-Bis(2-bromoethyl)sulfanilamide; Benzenesulfonamide, 4-(bis(2-bromoethyl)amino)-(9CI); Sulfanilamide, N4,N4-bis(2-bromoethyl)-(8CI); 1162 F; 4-(Bis(2-bromoethyl)amino)benzenesulfonamide; 4-Aminobenzene-1-Sulfonamide; 4-Aminophenylsulfonamide; 4-Sulfamoylaniline; 4-[bis(2-bromoethyl)amino]benzenesulfonamide
DMABVE9	TC	Antibiotics
DMABVE9	DT	Small molecular drug
DMABVE9	PC	5333
DMABVE9	MW	172.21
DMABVE9	FM	C6H8N2O2S
DMABVE9	IC	InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
DMABVE9	CS	C1=CC(=CC=C1N)S(=O)(=O)N
DMABVE9	IK	FDDDEECHVMSUSB-UHFFFAOYSA-N
DMABVE9	IU	4-aminobenzenesulfonamide
DMABVE9	CA	CAS 63-74-1
DMABVE9	CB	CHEBI:45373
DMABVE9	DE	Bacterial infection

DMFNAEM	ID	DMFNAEM
DMFNAEM	DN	Sulfaphenazole
DMFNAEM	HS	Approved
DMFNAEM	SN	Sulfabid
DMFNAEM	CP	Pharmaceutical Research Assoc Inc
DMFNAEM	TC	Antiinfective Agents
DMFNAEM	DT	Small molecular drug
DMFNAEM	PC	5335
DMFNAEM	MW	314.4
DMFNAEM	FM	C15H14N4O2S
DMFNAEM	IC	InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2
DMFNAEM	CS	C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N
DMFNAEM	IK	QWCJHSGMANYXCW-UHFFFAOYSA-N
DMFNAEM	IU	4-amino-N-(2-phenylpyrazol-3-yl)benzenesulfonamide
DMFNAEM	CA	CAS 526-08-9
DMFNAEM	CB	CHEBI:77780
DMFNAEM	DE	Bacterial infection

DMIUYFH	ID	DMIUYFH
DMIUYFH	DN	Sulfapyridine
DMIUYFH	HS	Approved
DMIUYFH	SN	Adiplon; Coccoclase; Dagenan; Eubasin; Eubasinum; Haptocil; Piridazol; Plurazol; Pyriamid; Pyridazol; Relbapiridina; Ronin;Septipulmon; Solfapiridina; Streptosilpyridine; Sulfapiridina; Sulfapyridinum; Sulfidin; Sulfidine; Sulphapyridin; Sulphapyridine; Thioseptal; Trianon; Solfapiridina [DCIT]; M and B 693; A-499; ALBB-006215; M + B 693; M&B 693; M+B 693; Sulfapiridina [INN-Spanish]; Sulfapyridine (TN); Sulfapyridinum [INN-Latin]; AO-801/41077453; N(1)-Pyridylsulfanilamide; N(sup1)-Pyridylsulfanilamide; N-2-Pyridylsulfanilamide; N1-2-Pyridylsulfanilamide; Sulfapyridine (USP/INN); Sulfapyridine [USAN:INN:BAN]; N'-2-Pyridylsulfanilide; N(1)-2-Pyridylsulfanilamide; N(sup 1)-2-Pyridylsulfanilamide; N1-(Pyridin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyridyl-(8CI); 2-(4-Aminobenzenesulfonamido)pyridine; 2-(p-Aminobenzenesulphonamido)pyridine; 2-Sulfanilamidopyridin; 2-Sulfanilamidopyridin [German]; 2-Sulfanilamidopyridine; 2-Sulfanilyl aminopyridine; 2-Sulfanilylaminopyridine; 2-Sulfapyridine; 4-(2-Pyridinylsulfonyl)aniline; 4-AMINO-N-2-PYRIDINYLBENZENESULFONAMIDE; 4-Amino-N,2-pyridinylbenzenesulfonamide; 4-Amino-N-2-pyridinyl-benzenesulfonamide; 4-Amino-N-[2-pyridyl]benzene sulfonamide; 4-[(2-Pyridylamino)sulfonyl]aniline; 4-amino-N-(pyridin-2-yl)benzenesulfonamide; 4-amino-N-pyridin-2-yl-benzenesulfonamide; 4-amino-N-pyridin-2-ylbenzenesulfonamide
DMIUYFH	TC	Dermatologic Agents
DMIUYFH	DT	Small molecular drug
DMIUYFH	PC	5336
DMIUYFH	MW	249.29
DMIUYFH	FM	C11H11N3O2S
DMIUYFH	IC	InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)
DMIUYFH	CS	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMIUYFH	IK	GECHUMIMRBOMGK-UHFFFAOYSA-N
DMIUYFH	IU	4-amino-N-pyridin-2-ylbenzenesulfonamide
DMIUYFH	CA	CAS 144-83-2
DMIUYFH	CB	CHEBI:132842
DMIUYFH	DE	Dermatitis herpetiformis

DMICA9H	ID	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	HS	Approved
DMICA9H	SN	sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine
DMICA9H	CP	Watson Laboratories
DMICA9H	TC	Antiinflammatory Agents
DMICA9H	DT	Small molecular drug
DMICA9H	PC	5339
DMICA9H	MW	398.4
DMICA9H	FM	C18H14N4O5S
DMICA9H	IC	InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)
DMICA9H	CS	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
DMICA9H	IK	NCEXYHBECQHGNR-UHFFFAOYSA-N
DMICA9H	IU	2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid
DMICA9H	CA	CAS 599-79-1
DMICA9H	CB	CHEBI:9334
DMICA9H	DE	Rheumatoid arthritis; Irritable bowel syndrome

DMEV954	ID	DMEV954
DMEV954	DN	Sulfinpyrazone
DMEV954	HS	Approved
DMEV954	SN	Anturan; Anturane; Anturanil; Anturano; Anturen; Anturidin; Diphenylpyrazone; Enturan; Enturen; Novopyrazone; Sulfinpirazona; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazonum; Sulfoxyphenylpyrazolidin; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; Apo Sulfinpyrazone; Apotex Brand of Sulfinpyrazone; Novartis Brand of Sulfinpyrazone; Nu Pharm Brand of Sulfinpyrazone; Nu Sulfinpyrazone; G 28315; Anturane (TN); Apo-Sulfinpyrazone; G 28,315; Nu-Pharm Brand of Sulfinpyrazone; Nu-Sulfinpyrazone; Sulfinpirazona [INN-Spanish]; Sulfinpyrazone (SPZ); Sulfinpyrazonum [INN-Latin]; USAF GE-13; Sulfinpyrazone [USAN:INN:JAN]; Sulfinpyrazone (JP15/USP/INN); (+/-)-SULFINPYRAZONE; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl) pyrazolidine; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
DMEV954	TC	Uricosuric Agents
DMEV954	DT	Small molecular drug
DMEV954	PC	5342
DMEV954	MW	404.5
DMEV954	FM	C23H20N2O3S
DMEV954	IC	InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
DMEV954	CS	C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4
DMEV954	IK	MBGGBVCUIVRRBF-UHFFFAOYSA-N
DMEV954	IU	4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
DMEV954	CA	CAS 57-96-5
DMEV954	CB	CHEBI:9342
DMEV954	DE	Gout

DMXLT8C	ID	DMXLT8C
DMXLT8C	DN	Sulfisoxazole
DMXLT8C	HS	Approved
DMXLT8C	SN	Accuzole; Alphazole; Amidoxal; Astrazolo; Azosulfizin; Bactesulf; Barazae; Chemouag; Cosoxazole; Dorsulfan; ERYZOLE; Entusil; Entusul; Ganda; Gantrisin; Gantrisine; Gantrisona; Gantrosan; Isoxamin; Neazolin; Neoxazoi; Neoxazol; Novazolo; Novosaxazole; Pancid; Renosulfan; Resoxol; Roxosul; Roxoxol; SOXO; Saxosozine; Sodizole; Solfafurazolo; Sosol; Soxamide; Soxazole; Soxisol; Soxitabs; Soxomide; Stansin; Sulbio; Sulfadimethylisoxazole; Sulfafurazol; Sulfafurazole; Sulfafurazolum; Sulfagan; Sulfagen; Sulfaisoxazole; Sulfalar; Sulfapolar; Sulfasol; Sulfasoxazole; Sulfasoxizole; Sulfazin; Sulfisin; Sulfisonazole; Sulfisoxasole; Sulfisoxazol; Sulfisoxazolum; Sulfizin; Sulfizol; Sulfizole; Sulfofurazole; Sulfoxol; Suloxsol; Sulphadimethylisoxazole; Sulphafuraz; Sulphafurazol; Sulphafurazole; Sulphafurazolum; Sulphaisoxazole; Sulphisoxazol; Sulphisoxazole; Sulphofurazole; Sulsoxin; Thiasin; Unisulf; Urisoxin; Uritrisin; Urogan; Vagilia; Azo Gantrisin; Component of Azo Gantrisin; Component of Azo Gantrisin Accuzole; Dorsulfan warthausen; Roxosul tablets; Solfafurazolo [DCIT]; Sulfafuraz ole; Sulfisoxazole [USAN]; Sulfisoxazole dialamine; NU 445; Component of Azo-Sulfizin; G-sox; Gantrisin (TN); J-Sul; Koro-sulf; Norilgan-S; SK-Soxazole; Sulfafurazole (INN); Sulfafurazolum [INN-Latin]; Sulfazin (VAN); Sulfisoxazole-Carc; Tl-azole; US-67; V-Sul; Sulfisoxazole (JP15/USP); U.S.-67; 3,4-Dimethyl-5-sulfanilamidoisoxazole; 3,4-Dimethyl-5-sulfonamidoisoxazole; 3,4-Dimethyl-5-sulphanilamidoisoxazole; 3,4-Dimethyl-5-sulphonamidoisoxazole; 3,4-Dimethylisoxale-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulphanilamide; 3,4-dimethylisoaxazole-5-sulfanilimide; 5-Sulfanilamido-3,4-dimethyl-isoxazole; 5-Sulfanilamido-3,4-dimethylisoxazole; 5-Sulphanilamido-3,4-dimethyl-isoxazole
DMXLT8C	CP	Hoffmann La Roche Inc
DMXLT8C	TC	Antiinfective Agents
DMXLT8C	DT	Small molecular drug
DMXLT8C	PC	5344
DMXLT8C	MW	267.31
DMXLT8C	FM	C11H13N3O3S
DMXLT8C	IC	InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
DMXLT8C	CS	CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N
DMXLT8C	IK	NHUHCSRWZMLRLA-UHFFFAOYSA-N
DMXLT8C	IU	4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide
DMXLT8C	CA	CAS 127-69-5
DMXLT8C	CB	CHEBI:102484
DMXLT8C	DE	Urinary tract infection

DM1YA7M	ID	DM1YA7M
DM1YA7M	DN	Sulfonamides
DM1YA7M	HS	Approved
DM1YA7M	SN	Sulfonamide Mixtures; Mixtures, Sulfonamide
DM1YA7M	DT	Small molecular drug
DM1YA7M	PC	91392493
DM1YA7M	MW	347.4
DM1YA7M	FM	C17H17NO5S
DM1YA7M	IC	InChI=1S/C17H17NO5S/c1-2-23-17(20)12-18(16-11-7-6-8-14(16)13-19)24(21,22)15-9-4-3-5-10-15/h3-11,13H,2,12H2,1H3
DM1YA7M	CS	CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2
DM1YA7M	IK	DFRPGUIKXDWHSA-UHFFFAOYSA-N
DM1YA7M	IU	ethyl 2-[N-(benzenesulfonyl)-2-formylanilino]acetate
DM1YA7M	DE	Bacterial infection

DMAYX6P	ID	DMAYX6P
DMAYX6P	DN	Sulfoxone
DMAYX6P	HS	Approved
DMAYX6P	SN	Aldapsone; Aldesulfon; Diamidin; Diason; Diazon; Novotrone; Adesulfone sodium; Diasone sodium enterab; Sodium aldesulphone; Sodium sulfoxone; [4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid; [sulfonylbis(4,1-phenyleneimino)]dimethanesulfinic acid
DMAYX6P	CP	Abbvie Inc
DMAYX6P	TC	Antibiotics
DMAYX6P	DT	Small molecular drug
DMAYX6P	PC	5351
DMAYX6P	MW	404.5
DMAYX6P	FM	C14H16N2O6S3
DMAYX6P	IC	InChI=1S/C14H16N2O6S3/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20)
DMAYX6P	CS	C1=CC(=CC=C1NCS(=O)O)S(=O)(=O)C2=CC=C(C=C2)NCS(=O)O
DMAYX6P	IK	NEDPPCHNEOMTJV-UHFFFAOYSA-N
DMAYX6P	IU	[4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid
DMAYX6P	CA	CAS 144-76-3
DMAYX6P	CB	CHEBI:135651
DMAYX6P	DE	Dermatitis herpetiformis

DM2QHZU	ID	DM2QHZU
DM2QHZU	DN	Sulindac
DM2QHZU	HS	Approved
DM2QHZU	SN	Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
DM2QHZU	CP	Merck & Co
DM2QHZU	TC	Antiinflammatory Agents
DM2QHZU	DT	Small molecular drug
DM2QHZU	PC	1548887
DM2QHZU	MW	356.4
DM2QHZU	FM	C20H17FO3S
DM2QHZU	IC	InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
DM2QHZU	CS	CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O
DM2QHZU	IK	MLKXDPUZXIRXEP-MFOYZWKCSA-N
DM2QHZU	IU	2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
DM2QHZU	CA	CAS 38194-50-2
DM2QHZU	CB	CHEBI:9352
DM2QHZU	DE	Rheumatoid arthritis

DMNUC42	ID	DMNUC42
DMNUC42	DN	Sulodexide
DMNUC42	HS	Approved
DMNUC42	TC	Antithrombotic Agents
DMNUC42	PC	6453528
DMNUC42	MW	295.29
DMNUC42	FM	C12H17N5O4
DMNUC42	IC	InChI=1S/C12H17N5O4/c1-13-10-7-11(15-4-14-10)17(5-16-7)12-9(20-2)8(19)6(3-18)21-12/h4-6,8-9,12,18-19H,3H2,1-2H3,(H,13,14,15)/t6-,8-,9-,12-/m1/s1
DMNUC42	CS	CNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)OC
DMNUC42	IK	GRYSXUXXBDSYRT-WOUKDFQISA-N
DMNUC42	IU	(2R,3R,4R,5R)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol
DMNUC42	CA	CAS 57817-83-1
DMNUC42	DE	Tinnitus

DMZI2UF	ID	DMZI2UF
DMZI2UF	DN	Sulphadoxine
DMZI2UF	HS	Approved
DMZI2UF	SN	2447-57-6; Sulforthomidine; Fanasil; Sulphormethoxine; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Sulfadoxinum; Sulfadoxina; Sulfadoxin; Fanzil; Solfadossina; Ro 4-4393; Solfadossina [DCIT]; Sulfadoxinum [INN-Latin]; Sulfadoxina [INN-Spanish]; 4-Sulfanilamido-5,6-dimethoxypyrimidine; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-; WR 4873; N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide; UNII-88463U4SM5; Orthosulfin; Sulformethoxine; Sulformetoxine; Sulphormetoxin; Sulphorthodimethoxine; WR 4073; Ro-4-4393; Sanasil: Sulfadoxine: Sulformetoxin; Sulfadoxine (JAN/USP/INN); Sulfadoxine [USAN:INN:BAN:JAN]; N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine; RS-1653
DMZI2UF	DT	Small molecular drug
DMZI2UF	PC	17134
DMZI2UF	MW	310.33
DMZI2UF	FM	C12H14N4O4S
DMZI2UF	IC	InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)
DMZI2UF	CS	COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N
DMZI2UF	IK	PJSFRIWCGOHTNF-UHFFFAOYSA-N
DMZI2UF	IU	4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
DMZI2UF	CA	CAS 2447-57-6
DMZI2UF	CB	CHEBI:9329
DMZI2UF	DE	Malaria

DMF54ZG	ID	DMF54ZG
DMF54ZG	DN	Sulpiride
DMF54ZG	HS	Approved
DMF54ZG	SN	Abilit; Aiglonyl; Alimoral; Arminol; Calmoflorine; Championyl; Coolspan; Darleton; Deponerton; Desisulpid; Desmenat; Digton; Dobren; Dogmatil; Dogmatyl; Dolmatil; Dresent; Eglonil; Eglonyl; Ekilid; Enimon; Equilid; Eusulpid; Fardalan; Fidelan; Guastil; Isnamide; Kylistro; Lebopride; Levobren; Levopraid; Levosulpirida; Levosulpiridum; Lisopiride; Mariastel; Meresa; Miradol; Mirbanil; Misulvan; Neogama; Norestran; Normum; Nufarol; Omiryl; Omperan; Ozoderpin; Pontiride; Psicocen; Pyrikappl; Pyrkappl; Restful; Sernevin; Splotin; Stamonevrol; Sulp; Sulperide; Sulpirid; Sulpirida; Sulpiridum; Sulpitil; Sulpivert; Sulpor; Sulpride; Sulpyrid; Suprium; Sursumid; Synedil; Tepavil; Valirem; Zemorcon; Allphar Brand of Sulpiride; Almirall Brand of Sulpiride; Areu Brand of Sulpiride; Centrum Brand of Sulpiride; Desitin Brand of Sulpiride; Dolorgiet Brand of Sulpiride; Erempharma Brand of Sulpiride; Fumouzer Brand of Sulpiride; Hennig Brand of Sulpiride; Hexal Brand of Sulpiride; Hoechst Brand of Sulpiride; Hormosan Brand of Sulpiride; Krewel Brand of Sulpiride; Levosulpiride [INN]; Magnetic resonance imaging sulpiride; Pharmacia Brand of Sulpiride; Psicofarma Brand of Sulpiride; Rosemont Brand of Sulpiride; Sanofi Synthelabo Brand of Sulpiride; Spyfarma Brand of Sulpiride; Uriach Brand of Sulpiride; Vertigo Meresa; Vertigo neogama; RD 1403; S 8010; Bosnyl (TN); Dogmatil (TN); Dogmatyl (TN); Eglonyl (TN); Levosulpirida [INN-Spanish]; Levosulpiridum [INN-Latin]; Meresa (TN); Neuraxpharm (TN); RV-12309; Ratiopharm (TN); Sanofi-Synthelabo Brand of Sulpiride; Sulpirid (TN); Sulpirida [INN-Spanish]; Sulpiridum [INN-Latin]; Sulpiryd (TN); Vertigo-Meresa; Vertigo-neogama; R. D. 1403; R.D. 1403; Sulpiride (JP15/USAN/INN); Sulpiride [USAN:INN:BAN:JAN]; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; (+/-)-Sulpiride; (RS)-(+/-)-sulpiride; (inverted question mark)-Sulpiride
DMF54ZG	CP	Arrow Generics
DMF54ZG	TC	Antipsychotic Agents
DMF54ZG	DT	Small molecular drug
DMF54ZG	PC	5355
DMF54ZG	MW	341.4
DMF54ZG	FM	C15H23N3O4S
DMF54ZG	IC	InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
DMF54ZG	CS	CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
DMF54ZG	IK	BGRJTUBHPOOWDU-UHFFFAOYSA-N
DMF54ZG	IU	N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
DMF54ZG	CA	CAS 15676-16-1
DMF54ZG	CB	CHEBI:32168
DMF54ZG	DE	Schizophrenia

DMVYXR8	ID	DMVYXR8
DMVYXR8	DN	Sumatriptan
DMVYXR8	HS	Approved
DMVYXR8	SN	Sumatran; Sumatriptanum; Sumax; GR 43175; GR 43175X; NP101; GR-43175; Imigran (TN); Imitrex (TN); KS-1116; Sumatriptanum [INN-Latin]; Sumatriptan (JAN/USP/INN); (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide
DMVYXR8	CP	GlaxoSmithKline
DMVYXR8	TC	Vasoconstrictor Agents
DMVYXR8	DT	Small molecular drug
DMVYXR8	PC	5358
DMVYXR8	MW	295.4
DMVYXR8	FM	C14H21N3O2S
DMVYXR8	IC	InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3
DMVYXR8	CS	CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
DMVYXR8	IK	KQKPFRSPSRPDEB-UHFFFAOYSA-N
DMVYXR8	IU	1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
DMVYXR8	CA	CAS 103628-46-2
DMVYXR8	CB	CHEBI:10650
DMVYXR8	DE	Migraine

DMCBJSR	ID	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	HS	Approved
DMCBJSR	SN	Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
DMCBJSR	CP	Pfizer
DMCBJSR	TC	Anticancer Agents
DMCBJSR	DT	Small molecular drug
DMCBJSR	PC	5329102
DMCBJSR	MW	398.5
DMCBJSR	FM	C22H27FN4O2
DMCBJSR	IC	InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
DMCBJSR	CS	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C
DMCBJSR	IK	WINHZLLDWRZWRT-ATVHPVEESA-N
DMCBJSR	IU	N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DMCBJSR	CA	CAS 557795-19-4
DMCBJSR	CB	CHEBI:38940
DMCBJSR	DE	Gastrointestinal stromal tumour; Gastrointestinal cancer

DMN8E5D	ID	DMN8E5D
DMN8E5D	DN	Sunitinib malate
DMN8E5D	HS	Approved
DMN8E5D	SN	(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate; LVX8N1UT73; MFCD08282795; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; PHA-290940AD; SU 011248; SU010398; SU011248; SU011248 L-malate salt; SUNITINIB MALEATE; Sunitinib malate; Sunitinib malate [USAN]; UNII-LVX8N1UT73
DMN8E5D	TC	Anticancer Agents
DMN8E5D	DT	Small molecular drug
DMN8E5D	PC	6456015
DMN8E5D	MW	532.569
DMN8E5D	FM	C26H33FN4O7
DMN8E5D	IC	InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1
DMN8E5D	CS	CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O
DMN8E5D	IK	LBWFXVZLPYTWQI-IPOVEDGCSA-N
DMN8E5D	IU	N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid
DMN8E5D	CA	CAS 341031-54-7
DMN8E5D	DE	Gastrointestinal stromal tumor; Renal cell carcinoma

DMOGREH	ID	DMOGREH
DMOGREH	DN	Suplatast tosilate
DMOGREH	HS	Approved
DMOGREH	SN	IPD; IPD-1151T; YM-672
DMOGREH	CP	Taiho Pharmaceutical Co Ltd
DMOGREH	DT	Small molecular drug
DMOGREH	PC	71773
DMOGREH	MW	499.6
DMOGREH	FM	C23H33NO7S2
DMOGREH	IC	InChI=1S/C16H25NO4S.C7H8O3S/c1-4-20-11-14(18)12-21-15-7-5-13(6-8-15)17-16(19)9-10-22(2)3;1-6-2-4-7(5-3-6)11(8,9)10/h5-8,14,18H,4,9-12H2,1-3H3;2-5H,1H3,(H,8,9,10)
DMOGREH	CS	CCOCC(COC1=CC=C(C=C1)NC(=O)CC[S+](C)C)O.CC1=CC=C(C=C1)S(=O)(=O)[O-]
DMOGREH	IK	RYVJQEZJUFRANT-UHFFFAOYSA-N
DMOGREH	IU	[3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate
DMOGREH	CA	CAS 94055-76-2
DMOGREH	DE	Allergy

DMKXJZ7	ID	DMKXJZ7
DMKXJZ7	DN	Suprofen
DMKXJZ7	HS	Approved
DMKXJZ7	SN	Maldocil; Masterfen; Profenal; Srendam; Sulproltin; Suprocil; Suprofene; Suprofenum; Suprol; Sutoprofen; R 25061; R25061; TN 762; TN762; Profenal (TN); R-25061; Suprofene [INN-French]; Suprofenum [INN-Latin]; TN-762; TYN-762P; P-2-Thenoylhydratropic acid; R-25,061; Suprofen (JAN/USP/INN); Suprofen [USAN:BAN:INN:JAN]; Alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (+-)-2-(p-(2-Thenoyl)phenyl)propionic acid; (-)-alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (R)-(Thien-2-ylcarbonyl)propionic acid; (S)-2-(4-(Thien-2-ylcarbonyl)phenyl)butyric acid; 2-(4-(2-Thenoyl)phenyl)propionsaeure; 2-(4-(2-Thienylcarbonyl)phenyl)propanoic acid; 2-[4-(thiophen-2-ylcarbonyl)phenyl]propanoic acid; 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid; 4-(2-Thenoyl)hydratropsaeure
DMKXJZ7	TC	Antiinflammatory Agents
DMKXJZ7	DT	Small molecular drug
DMKXJZ7	PC	5359
DMKXJZ7	MW	260.31
DMKXJZ7	FM	C14H12O3S
DMKXJZ7	IC	InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
DMKXJZ7	CS	CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O
DMKXJZ7	IK	MDKGKXOCJGEUJW-UHFFFAOYSA-N
DMKXJZ7	IU	2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid
DMKXJZ7	CA	CAS 40828-46-4
DMKXJZ7	CB	CHEBI:9362
DMKXJZ7	DE	Miosis

DM0E6S3	ID	DM0E6S3
DM0E6S3	DN	Suvorexant
DM0E6S3	HS	Approved
DM0E6S3	SN	Suvorexant; 1030377-33-3; MK-4305; BELSOMRA; MK 4305; MK4305; UNII-081L192FO9; Suvorexant (MK-4305); [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone; (R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; CHEMBL1083659; CHEBI:82698; 081L192FO9; C23H23ClN6O2; ((7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
DM0E6S3	DT	Small molecular drug
DM0E6S3	PC	24965990
DM0E6S3	MW	450.9
DM0E6S3	FM	C23H23ClN6O2
DM0E6S3	IC	InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1
DM0E6S3	CS	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
DM0E6S3	IK	JYTNQNCOQXFQPK-MRXNPFEDSA-N
DM0E6S3	IU	[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
DM0E6S3	CA	CAS 1030377-33-3
DM0E6S3	CB	CHEBI:82698
DM0E6S3	DE	Insomnia

DM6S0HB	ID	DM6S0HB
DM6S0HB	DN	TachoComb
DM6S0HB	HS	Approved
DM6S0HB	SN	Collagen fleece, Nycomed; Collagen fleece, Torii; TO-193; Fibrin/thrombin/aprotinin collagen fleece, Nycomed/Torii
DM6S0HB	CP	Nycomed
DM6S0HB	DE	Wound healing

DM51FY6	ID	DM51FY6
DM51FY6	DN	Tacrine
DM51FY6	HS	Approved
DM51FY6	SN	Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine
DM51FY6	TC	Parasympathomimetics
DM51FY6	DT	Small molecular drug
DM51FY6	PC	1935
DM51FY6	MW	198.26
DM51FY6	FM	C13H14N2
DM51FY6	IC	InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)
DM51FY6	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)N
DM51FY6	IK	YLJREFDVOIBQDA-UHFFFAOYSA-N
DM51FY6	IU	1,2,3,4-tetrahydroacridin-9-amine
DM51FY6	CA	CAS 321-64-2
DM51FY6	CB	CHEBI:45980
DM51FY6	DE	Alzheimer disease

DMZ7XNQ	ID	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	HS	Approved
DMZ7XNQ	SN	Advagraf; Fujimycin; Graceptor; Modigraf; Prograf; Protopic; Protopy; Tacarolimus; Tsukubaenolide; Tacrolimus anhydrous; FK 506; FK5; FK506; FR 900506; FR900506; K506; L 679934; Advagraf (TN); FR-900506; Fk-506; L-679934; LCP-Tacro; Prograf (TN); Protopic (TN); Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); (-)-FK 506; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
DMZ7XNQ	CP	Fujisawa; Sucampo
DMZ7XNQ	TC	Immunosuppressive Agents
DMZ7XNQ	DT	Small molecular drug
DMZ7XNQ	PC	445643
DMZ7XNQ	MW	804
DMZ7XNQ	FM	C44H69NO12
DMZ7XNQ	IC	InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
DMZ7XNQ	CS	C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
DMZ7XNQ	IK	QJJXYPPXXYFBGM-LFZNUXCKSA-N
DMZ7XNQ	IU	(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMZ7XNQ	CA	CAS 104987-11-3
DMZ7XNQ	CB	CHEBI:61049
DMZ7XNQ	DE	Organ transplant rejection; Ocular allergy

DMJZHT1	ID	DMJZHT1
DMJZHT1	DN	Tadalafil
DMJZHT1	HS	Approved
DMJZHT1	SN	ADCIRCA; Acdirca; Cialis; Tadanafil; Lilly brand of tadalafil; Tadalafil [USAN]; GF 196960; IC 351; ICOS 351; Ic351; Cialis (TN); GF-196960; IC-351; KS-1117; Tadalafil (JAN/USAN/INN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
DMJZHT1	CP	Eli Lilly
DMJZHT1	TC	Antiimpotence Agents
DMJZHT1	DT	Small molecular drug
DMJZHT1	PC	110635
DMJZHT1	MW	389.4
DMJZHT1	FM	C22H19N3O4
DMJZHT1	IC	InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1
DMJZHT1	CS	CN1CC(=O)N2[C@@H](C1=O)CC3=C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36
DMJZHT1	IK	WOXKDUGGOYFFRN-IIBYNOLFSA-N
DMJZHT1	IU	(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione
DMJZHT1	CA	CAS 171596-29-5
DMJZHT1	CB	CHEBI:71940
DMJZHT1	DE	Erectile dysfunction

DM1XT4N	ID	DM1XT4N
DM1XT4N	DN	Tafenoquine
DM1XT4N	HS	Approved
DM1XT4N	SN	106635-80-7; WR-238605; WR 238605; Etaquine; WR238605; Tafenoquine [INN:BAN
DM1XT4N	CP	Medicines for Malaria Venture/GlaxoSmithKline
DM1XT4N	DT	Small molecular drug
DM1XT4N	PC	115358
DM1XT4N	MW	463.5
DM1XT4N	FM	C24H28F3N3O3
DM1XT4N	IC	InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3
DM1XT4N	CS	CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC
DM1XT4N	IK	LBHLFPGPEGDCJG-UHFFFAOYSA-N
DM1XT4N	IU	4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine
DM1XT4N	CA	CAS 106635-80-7
DM1XT4N	CB	CHEBI:141487
DM1XT4N	DE	Plasmodium vivax malaria; Malaria

DMFC41K	ID	DMFC41K
DMFC41K	DN	Tafluprost
DMFC41K	HS	Approved
DMFC41K	SN	Zioptan (TN)
DMFC41K	CP	Merck
DMFC41K	DT	Small molecular drug
DMFC41K	PC	9868491
DMFC41K	MW	452.5
DMFC41K	FM	C25H34F2O5
DMFC41K	IC	InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1
DMFC41K	CS	CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(COC2=CC=CC=C2)(F)F)O)O
DMFC41K	IK	WSNODXPBBALQOF-VEJSHDCNSA-N
DMFC41K	IU	propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
DMFC41K	CA	CAS 209860-87-7
DMFC41K	CB	CHEBI:66899
DMFC41K	DE	Glaucoma/ocular hypertension

DM9HQ5U	ID	DM9HQ5U
DM9HQ5U	DN	Tagraxofusp
DM9HQ5U	HS	Approved
DM9HQ5U	SN	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DM9HQ5U	CP	Stemline Therapeutics
DM9HQ5U	DE	Blastic plasmacytoid dendritic cell neoplasm; Acute myeloid leukaemia

DM1KS78	ID	DM1KS78
DM1KS78	DN	Talazoparib
DM1KS78	HS	Approved
DM1KS78	SN	Talazoparib (BMN 673); UNII-9QHX048FRV; 9QHX048FRV; Talazoparib [USAN:INN]; Talzenna; 4pjt; 2YQ
DM1KS78	CP	Pfizer
DM1KS78	DT	Small molecular drug
DM1KS78	PC	135565082
DM1KS78	MW	380.4
DM1KS78	FM	C19H14F2N6O
DM1KS78	IC	InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
DM1KS78	CS	CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
DM1KS78	IK	HWGQMRYQVZSGDQ-HZPDHXFCSA-N
DM1KS78	IU	(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
DM1KS78	CA	CAS 1207456-01-6
DM1KS78	DE	Breast cancer; Psoriatic arthritis

DM2M3OC	ID	DM2M3OC
DM2M3OC	DN	Talazoparib
DM2M3OC	HS	Approved
DM2M3OC	SN	(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one; (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One; LT-673; Talazoparib; Talazoparib (BMN 673); Talazoparib [USAN:INN]
DM2M3OC	TC	Poly (ADP-ribose) polymerase (PARP) inhibitor
DM2M3OC	DT	Small molecular drug
DM2M3OC	PC	135565082
DM2M3OC	MW	380.359
DM2M3OC	FM	C19H14F2N6O
DM2M3OC	IC	InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
DM2M3OC	CS	CN1C(=NC=N1)C2C(NC3=C4C2=NNC(=O)C4=CC(=C3)F)C5=CC=C(C=C5)F
DM2M3OC	IK	HWGQMRYQVZSGDQ-HZPDHXFCSA-N
DM2M3OC	IU	(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
DM2M3OC	CA	CAS 1207456-01-6
DM2M3OC	DE	Breast cancer

DM214Q8	ID	DM214Q8
DM214Q8	DN	Talbutal
DM214Q8	HS	Approved
DM214Q8	SN	Lotusate; Profundol; Talbumalum; Talbutale; Talbutalum; Talbutal [INN]; Talbutale [DCIT]; WIN 5095; Lotusate (TN); Sec-Butyl allylbarbituric acid; Talbutal (INN); Talbutalum [INN-Latin]; 5-(1-Methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-5-(1-methylpropyl) barbituric acid; 5-Allyl-5-sec-butylbarbituric acid; 5-Isobutyl-5-allylbarbituric acid; 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM214Q8	TC	Hypnotics and Sedatives
DM214Q8	DT	Small molecular drug
DM214Q8	PC	8275
DM214Q8	MW	224.26
DM214Q8	FM	C11H16N2O3
DM214Q8	IC	InChI=1S/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
DM214Q8	CS	CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DM214Q8	IK	BJVVMKUXKQHWJK-UHFFFAOYSA-N
DM214Q8	IU	5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM214Q8	CA	CAS 115-44-6
DM214Q8	CB	CHEBI:134923
DM214Q8	DE	Irritability

DM3PZXN	ID	DM3PZXN
DM3PZXN	DN	Taliglucerase alfa
DM3PZXN	HS	Approved
DM3PZXN	SN	Elelyso (TN)
DM3PZXN	CP	Pfizer
DM3PZXN	DE	Metabolic disorder

DMKBW5C	ID	DMKBW5C
DMKBW5C	DN	Talimogene Laherparepvec
DMKBW5C	HS	Approved
DMKBW5C	SN	IMLYGIC
DMKBW5C	CP	Amgen
DMKBW5C	TC	Anticancer Agents
DMKBW5C	DT	Vaccine
DMKBW5C	DE	Melanoma

DMLB0EZ	ID	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	HS	Approved
DMLB0EZ	SN	tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene;  Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen
DMLB0EZ	CP	AstraZeneca plc
DMLB0EZ	TC	Anticancer Agents
DMLB0EZ	DT	Small molecular drug
DMLB0EZ	PC	2733526
DMLB0EZ	MW	371.5
DMLB0EZ	FM	C26H29NO
DMLB0EZ	IC	InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
DMLB0EZ	CS	CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
DMLB0EZ	IK	NKANXQFJJICGDU-QPLCGJKRSA-N
DMLB0EZ	IU	2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
DMLB0EZ	CA	CAS 10540-29-1
DMLB0EZ	CB	CHEBI:41774
DMLB0EZ	DE	Breast cancer

DM5QF9V	ID	DM5QF9V
DM5QF9V	DN	Tamsulosin
DM5QF9V	HS	Approved
DM5QF9V	SN	Flomax; Flowmax; Harnal; Tamsolusin; Tamsulon; Tamsulosina; Tamsulosine; Tamsulosinum; Flomax (TN); Flomaxtra (TN); Tamsulon (TN); Tamsulosin (INN); Tamsulosin [INN:BAN]; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; Tamsulosinum [INN-Latin]; Urimax (TN); (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
DM5QF9V	CP	Yamanouchi Pharmaceuticals 
DM5QF9V	TC	Anticancer Agents
DM5QF9V	DT	Small molecular drug
DM5QF9V	PC	129211
DM5QF9V	MW	408.5
DM5QF9V	FM	C20H28N2O5S
DM5QF9V	IC	InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1
DM5QF9V	CS	CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N
DM5QF9V	IK	DRHKJLXJIQTDTD-OAHLLOKOSA-N
DM5QF9V	IU	5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
DM5QF9V	CA	CAS 106133-20-4
DM5QF9V	CB	CHEBI:9398
DM5QF9V	DE	Benign prostatic hyperplasia

DMPHWU6	ID	DMPHWU6
DMPHWU6	DN	Tandospirone
DMPHWU6	HS	Approved
DMPHWU6	SN	Sediel (TN)
DMPHWU6	DT	Small molecular drug
DMPHWU6	PC	91273
DMPHWU6	MW	383.5
DMPHWU6	FM	C21H29N5O2
DMPHWU6	IC	InChI=1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-18H,1-2,4-5,8-14H2/t15-,16+,17+,18-
DMPHWU6	CS	C1C[C@H]2C[C@@H]1[C@H]3[C@@H]2C(=O)N(C3=O)CCCCN4CCN(CC4)C5=NC=CC=N5
DMPHWU6	IK	CEIJFEGBUDEYSX-FZDBZEDMSA-N
DMPHWU6	IU	(1S,2R,6S,7R)-4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione
DMPHWU6	CA	CAS 87760-53-0
DMPHWU6	CB	CHEBI:145673
DMPHWU6	DE	Anxiety disorder

DMXLSH3	ID	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	HS	Approved
DMXLSH3	SN	Tapentadol; 175591-23-8; Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL
DMXLSH3	CP	Ortho-McNell Pharmaceutical
DMXLSH3	DT	Small molecular drug
DMXLSH3	PC	9838021
DMXLSH3	MW	257.8
DMXLSH3	FM	C14H24ClNO
DMXLSH3	IC	InChI=1S/C14H23NO.ClH/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12;/h6-9,11,14,16H,5,10H2,1-4H3;1H/t11-,14+;/m0./s1
DMXLSH3	CS	CC[C@@H](C1=CC(=CC=C1)O)[C@@H](C)CN(C)C.Cl
DMXLSH3	IK	ZELFLGGRLLOERW-YECZQDJWSA-N
DMXLSH3	IU	3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride
DMXLSH3	CA	CAS 175591-09-0
DMXLSH3	DE	Acute pain

DMLOQ1V	ID	DMLOQ1V
DMLOQ1V	DN	Tasimelteon
DMLOQ1V	HS	Approved
DMLOQ1V	SN	Tasimelteon; 609799-22-6; Hetlioz; VEC-162; BMS-214778; VEC 162; UNII-SHS4PU80D9; BMS 214778; SHS4PU80D9; CHEBI:79042; N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide; Tasimelteon [USAN:INN]; tasimelteonum; N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide; N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide; N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide; Hetlioz (TN); Tasimelteon (USAN/INN); SCHEMBL3505912; GTPL7393
DMLOQ1V	CP	Vanda Pharmaceuticals
DMLOQ1V	DT	Small molecular drug
DMLOQ1V	PC	10220503
DMLOQ1V	MW	245.32
DMLOQ1V	FM	C15H19NO2
DMLOQ1V	IC	InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
DMLOQ1V	CS	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2
DMLOQ1V	IK	PTOIAAWZLUQTIO-GXFFZTMASA-N
DMLOQ1V	IU	N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
DMLOQ1V	CA	CAS 609799-22-6
DMLOQ1V	CB	CHEBI:79042
DMLOQ1V	DE	Insomnia

DMM13DI	ID	DMM13DI
DMM13DI	DN	Tasosartan
DMM13DI	HS	Approved
DMM13DI	SN	Verdia; ANA-756; WAY-126756; Tasosartan (USAN/INN); WAY-ANA-756; 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one; 2,4-dimethyl-8-{[2'-(2h-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6h)-one
DMM13DI	TC	Antihypertensive Agents
DMM13DI	DT	Small molecular drug
DMM13DI	PC	60919
DMM13DI	MW	411.5
DMM13DI	FM	C23H21N7O
DMM13DI	IC	InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29)
DMM13DI	CS	CC1=C2CCC(=O)N(C2=NC(=N1)C)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMM13DI	IK	ADXGNEYLLLSOAR-UHFFFAOYSA-N
DMM13DI	IU	2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one
DMM13DI	CA	CAS 145733-36-4
DMM13DI	CB	CHEBI:135666
DMM13DI	DE	Hypertension

DM3ED1A	ID	DM3ED1A
DM3ED1A	DN	Tavaborole
DM3ED1A	HS	Approved
DM3ED1A	SN	Kerydin; AN2690; AN-2690; AN-2690); SCH-900340; Topical antifungal (onychomycosis), Merck & Co; Trichophyton-targeting antifungal (onychomycosis), Merck & Co; Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough; Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor; Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough
DM3ED1A	CP	Anacor; Anacor Pharmaceuticals Inc
DM3ED1A	DT	Small molecular drug
DM3ED1A	PC	11499245
DM3ED1A	MW	151.93
DM3ED1A	FM	C7H6BFO2
DM3ED1A	IC	InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
DM3ED1A	CS	B1(C2=C(CO1)C=C(C=C2)F)O
DM3ED1A	IK	LFQDNHWZDQTITF-UHFFFAOYSA-N
DM3ED1A	IU	5-fluoro-1-hydroxy-3H-2,1-benzoxaborole
DM3ED1A	CA	CAS 174671-46-6
DM3ED1A	CB	CHEBI:77942
DM3ED1A	DE	Onychomycosis

DMUOT9V	ID	DMUOT9V
DMUOT9V	DN	Taxol
DMUOT9V	HS	Approved
DMUOT9V	SN	C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
DMUOT9V	DT	Small molecular drug
DMUOT9V	PC	36314
DMUOT9V	MW	853.9
DMUOT9V	FM	C47H51NO14
DMUOT9V	IC	InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
DMUOT9V	CS	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
DMUOT9V	IK	RCINICONZNJXQF-MZXODVADSA-N
DMUOT9V	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMUOT9V	CA	CAS 33069-62-4
DMUOT9V	CB	CHEBI:45863
DMUOT9V	DE	Gastric adenocarcinoma; Ovarian cancer; Solid tumour/cancer; Breast cancer; Pancreatic cancer

DM8SMD1	ID	DM8SMD1
DM8SMD1	DN	Tazarotene
DM8SMD1	HS	Approved
DM8SMD1	SN	Avage; Suretin; Tazaroteno; Tazarotenum; Tazorac; Tazoral; Zorac; AGN 190168; AGN-190168; Avage (TN); Tazarotene [USAN:INN]; Tazorac (TN); Zorac (TN); Tazarotene (JAN/USAN/INN); Tazorac, Avage, Zora, Tazarotene; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester
DM8SMD1	CP	Allergan Pharmaceuticals
DM8SMD1	TC	Dermatologic Agents
DM8SMD1	DT	Small molecular drug
DM8SMD1	PC	5381
DM8SMD1	MW	351.5
DM8SMD1	FM	C21H21NO2S
DM8SMD1	IC	InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3
DM8SMD1	CS	CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
DM8SMD1	IK	OGQICQVSFDPSEI-UHFFFAOYSA-N
DM8SMD1	IU	ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
DM8SMD1	CA	CAS 118292-40-3
DM8SMD1	CB	CHEBI:32184
DM8SMD1	DE	Psoriasis vulgaris

DMWP1BH	ID	DMWP1BH
DMWP1BH	DN	Tazemetostat
DMWP1BH	HS	Approved
DMWP1BH	SN	EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-
DMWP1BH	CP	Epizyme
DMWP1BH	DT	Small molecular drug
DMWP1BH	PC	66558664
DMWP1BH	MW	572.7
DMWP1BH	FM	C34H44N4O4
DMWP1BH	IC	InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)
DMWP1BH	CS	CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5
DMWP1BH	IK	NSQSAUGJQHDYNO-UHFFFAOYSA-N
DMWP1BH	IU	N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide
DMWP1BH	CA	CAS 1403254-99-8
DMWP1BH	DE	Malignant rhabdoid tumour; Brain and central nervous system tumour; Diffuse large B-cell lymphoma; Mesothelioma; Solid tumour/cancer; Synovial sarcoma; Follicular lymphoma

DM3XNUI	ID	DM3XNUI
DM3XNUI	DN	Tazobactam
DM3XNUI	HS	Approved
DM3XNUI	SN	TAZ; CL298741; YTR830H; CL-298741; Piprataz (TN); YTR-830H; Tazobactam (JAN/USAN/INN); (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4; (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
DM3XNUI	CP	Gepach International
DM3XNUI	TC	Antiinfective Agents
DM3XNUI	DT	Small molecular drug
DM3XNUI	PC	123630
DM3XNUI	MW	300.29
DM3XNUI	FM	C10H12N4O5S
DM3XNUI	IC	InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1
DM3XNUI	CS	C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
DM3XNUI	IK	LPQZKKCYTLCDGQ-WEDXCCLWSA-N
DM3XNUI	IU	(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM3XNUI	CA	CAS 89786-04-9
DM3XNUI	CB	CHEBI:9421
DM3XNUI	DE	Bacterial infection

DML6OE7	ID	DML6OE7
DML6OE7	DN	Tbo-Filgrastim
DML6OE7	HS	Approved
DML6OE7	SN	Neutroval (TN)
DML6OE7	CP	Sicor Biotech
DML6OE7	DE	Neutropenia

DMQ5S6C	ID	DMQ5S6C
DMQ5S6C	DN	Tebipenem pivoxil
DMQ5S6C	HS	Approved
DMQ5S6C	SN	161715-24-8; Orapenem; TBPM-PI; L-084; ME1211; UNII-95AK1A52I8; LJC 11,084; 95AK1A52I8; LJC-11084; ME-1211; 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; Tebipenempivoxil; Tebipenem [INN]; (4R,5S,6S)-(Pivaloyloxy)methyl 3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)-; Tebipenem pivoxil (L-084); Tebipenem pivoxil(L-084); Orapenem (TN); (1R,5S,6S)-6-[1(R)-Hydroxyethyl]-1-methyl-2-[1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl]-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester; MLS006011128; SCHEMBL305541; Tebipenem pivoxil [USAN:INN]; CHEMBL2107486; GTPL10864; DTXSID00167228; CHEBI:135799; EX-A1256; HY-B0396; WHO 7924; ZINC4217736; Tebipenem pivoxil (JAN/USAN/INN); 2748AH; CT0255; LJC 11084; MFCD17215369; s2159; AKOS015899532; CCG-269673; LJC-11,084; NCGC00346570-01; NCGC00346570-04; (pivaloyloxy)methyl (4R,5S,6S)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; [(4R,5S,6S)-3-{[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carbonyloxy]methyl 2,2-dimethylpropanoate; AC-22712; AS-75334; L-084;ME1211; SMR004702908; L 084; D09598; AB01566835_01; Q1623593; (4R,5R,6S)-3-((1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy) methyl ester; 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMQ5S6C	CP	Meiji Seika Pharma
DMQ5S6C	DT	Small molecular drug
DMQ5S6C	PC	9892071
DMQ5S6C	MW	497.6
DMQ5S6C	FM	C22H31N3O6S2
DMQ5S6C	IC	InChI=1S/C22H31N3O6S2/c1-11-15-14(12(2)26)18(27)25(15)16(19(28)30-10-31-20(29)22(3,4)5)17(11)33-13-8-24(9-13)21-23-6-7-32-21/h11-15,26H,6-10H2,1-5H3/t11-,12-,14-,15-/m1/s1
DMQ5S6C	CS	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)OCOC(=O)C(C)(C)C)[C@@H](C)O
DMQ5S6C	IK	SNUDIPVBUUXCDG-QHSBEEBCSA-N
DMQ5S6C	IU	2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMQ5S6C	CA	CAS 161715-24-8
DMQ5S6C	CB	CHEBI:135799
DMQ5S6C	DE	Respiratory tract infection

DMYQCWT	ID	DMYQCWT
DMYQCWT	DN	Tecartus
DMYQCWT	HS	Approved
DMYQCWT	SN	Brexucabtagene autoleucel; KTE-X19
DMYQCWT	CP	Gilead Sciences; Kite Pharma
DMYQCWT	DT	CAR T Cell Therapy
DMYQCWT	DE	Mantle cell lymphoma

DM2OVDT	ID	DM2OVDT
DM2OVDT	DN	Tecfidera
DM2OVDT	HS	Approved
DM2OVDT	SN	DIMETHYL FUMARATE
DM2OVDT	CP	Biogen Idec
DM2OVDT	DT	Small molecular drug
DM2OVDT	PC	637568
DM2OVDT	MW	144.12
DM2OVDT	FM	C6H8O4
DM2OVDT	IC	InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+
DM2OVDT	CS	COC(=O)/C=C/C(=O)OC
DM2OVDT	IK	LDCRTTXIJACKKU-ONEGZZNKSA-N
DM2OVDT	IU	dimethyl (E)-but-2-enedioate
DM2OVDT	CA	CAS 624-49-7
DM2OVDT	CB	CHEBI:76004
DM2OVDT	DE	Multiple sclerosis

DMUEWM3	ID	DMUEWM3
DMUEWM3	DN	Technetium (99MTC) mebrofenin
DMUEWM3	HS	Approved
DMUEWM3	SN	F2NQ468L52; Glycine, N-(2-((3-bromo-2,4,6-trimethylphenyl)amino)-2-oxoethyl)-N-(carboxymethyl)-, technetium-99Tc salt; Mebrofenin / 99Tc; Mebrofenin / technetium-99Tc; Mebrofenin mixture with technetium-99Tc; TECHNETIUM TC-99M MEBROFENIN KIT; Technetium (99Mtc) Mebrofenin; Technetium TC-99M mebrofenin kit; Technetium Tc 99m DISIDA; Technetium Tc 99m diisopropyl-iminodiacetic acid; Technetium Tc 99m mebrofenin; Technetium Tc-99m mebrofenin; UNII-F2NQ468L52
DMUEWM3	TC	Diagnostic Radiopharmaceutical Agents
DMUEWM3	DT	Small molecular drug
DMUEWM3	PC	11431716
DMUEWM3	MW	486.136
DMUEWM3	FM	C15H19BrN2O5Tc
DMUEWM3	IC	InChI=1S/C15H19BrN2O5.Tc/c1-8-4-9(2)15(10(3)14(8)16)17-11(19)5-18(6-12(20)21)7-13(22)23;/h4H,5-7H2,1-3H3,(H,17,19)(H,20,21)(H,22,23);/i;1+1
DMUEWM3	CS	CC1=CC(=C(C(=C1NC(=O)CN(CC(=O)O)CC(=O)O)C)Br)C.[Tc]
DMUEWM3	IK	JLJSYHOPCNWUNE-IEOVAKBOSA-N
DMUEWM3	IU	2-[[2-(3-bromo-2,4,6-trimethylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid;technetium-99
DMUEWM3	CA	CAS 1415247-71-0
DMUEWM3	DE	Imaging of liver and gallbladder

DMW5ML9	ID	DMW5ML9
DMW5ML9	DN	Tecovirimat 
DMW5ML9	HS	Approved
DMW5ML9	SN	Tecovirimat; ST 246; SIGA-246; UNII-F925RR824R; 816458-31-8; F925RR824R; ST-246; TPOXX; Tecovirimat [USAN:INN]; SIGA 246
DMW5ML9	CP	SIGA Technologies
DMW5ML9	PC	16124688
DMW5ML9	MW	376.3
DMW5ML9	FM	C19H15F3N2O3
DMW5ML9	IC	InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+
DMW5ML9	CS	C1[C@@H]2[C@H]1[C@@H]3C=C[C@H]2[C@@H]4[C@H]3C(=O)N(C4=O)NC(=O)C5=CC=C(C=C5)C(F)(F)F
DMW5ML9	IK	CSKDFZIMJXRJGH-VWLPUNTISA-N
DMW5ML9	IU	N-[(1S,2S,6R,7R,8R,10S)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide
DMW5ML9	CA	CAS 869572-92-9
DMW5ML9	DE	Virus infection; Smallpox

DMG2SKR	ID	DMG2SKR
DMG2SKR	DN	Tedizolid
DMG2SKR	HS	Approved
DMG2SKR	SN	Tedizolid; Torezolid; 856866-72-3; TR-700; Da 7157; UNII-97HLQ82NGL; DA-7157; TR 700; 97HLQ82NGL; CHEBI:82717; (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)-3-pyridyl]phenyl]-5-(hydroxymethyl)oxazolidin-2-one; Tedizolid [USAN:INN]; Tedizolid (USAN/INN); SCHEMBL440398; CHEMBL1257051; DTXSID10234975; XFALPSLJIHVRKE-GFCCVEGCSA-N; MolPort-042-624-220; AI025; BCP02830; ZINC43100956; AKOS025401974; CS-0687; NCGC00379072-02; AN-27109; AK322133; AC-27738; BC600578; HY-14855
DMG2SKR	CP	Bayer HealthCare Pharmaceuticals
DMG2SKR	DT	Small molecular drug
DMG2SKR	PC	11234049
DMG2SKR	MW	370.3
DMG2SKR	FM	C17H15FN6O3
DMG2SKR	IC	InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1
DMG2SKR	CS	CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4C[C@@H](OC4=O)CO)F
DMG2SKR	IK	XFALPSLJIHVRKE-GFCCVEGCSA-N
DMG2SKR	IU	(5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
DMG2SKR	CA	CAS 856866-72-3
DMG2SKR	CB	CHEBI:82717
DMG2SKR	DE	Skin infection

DMYOAKS	ID	DMYOAKS
DMYOAKS	DN	Teduglutide
DMYOAKS	HS	Approved
DMYOAKS	SN	Gattex (TN)
DMYOAKS	CP	NPS
DMYOAKS	DT	Small molecular drug
DMYOAKS	SQ	Protein sequence for teduglutide: HGDGSFSDEMNTILDNLAARDFINWLIQTKITD
DMYOAKS	PC	16139605
DMYOAKS	MW	3752.1
DMYOAKS	FM	C164H252N44O55S
DMYOAKS	IC	InChI=1S/C164H252N44O55S/c1-21-77(11)126(156(255)187-95(44-46-114(167)214)141(240)206-130(83(17)211)160(259)186-93(42-33-34-49-165)140(239)202-129(80(14)24-4)159(258)208-131(84(18)212)161(260)200-111(163(262)263)66-125(230)231)203-151(250)100(54-76(9)10)189-145(244)103(57-88-67-175-92-41-32-31-40-90(88)92)192-147(246)105(60-116(169)216)199-157(256)127(78(12)22-2)204-152(251)102(56-87-38-29-26-30-39-87)190-149(248)109(64-123(226)227)195-137(236)94(43-35-50-174-164(171)172)183-134(233)82(16)179-133(232)81(15)180-142(241)98(52-74(5)6)188-146(245)104(59-115(168)215)194-150(249)110(65-124(228)229)196-143(242)99(53-75(7)8)198-158(257)128(79(13)23-3)205-162(261)132(85(19)213)207-153(252)106(61-117(170)217)193-139(238)97(48-51-264-20)185-138(237)96(45-47-120(220)221)184-148(247)108(63-122(224)225)197-155(254)113(72-210)201-144(243)101(55-86-36-27-25-28-37-86)191-154(253)112(71-209)182-119(219)70-177-136(235)107(62-121(222)223)181-118(218)69-176-135(234)91(166)58-89-68-173-73-178-89/h25-32,36-41,67-68,73-85,91,93-113,126-132,175,209-213H,21-24,33-35,42-66,69-72,165-166H2,1-20H3,(H2,167,214)(H2,168,215)(H2,169,216)(H2,170,217)(H,173,178)(H,176,234)(H,177,235)(H,179,232)(H,180,241)(H,181,218)(H,182,219)(H,183,233)(H,184,247)(H,185,237)(H,186,259)(H,187,255)(H,188,245)(H,189,244)(H,190,248)(H,191,253)(H,192,246)(H,193,238)(H,194,249)(H,195,236)(H,196,242)(H,197,254)(H,198,257)(H,199,256)(H,200,260)(H,201,243)(H,202,239)(H,203,250)(H,204,251)(H,205,261)(H,206,240)(H,207,252)(H,208,258)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,262,263)(H4,171,172,174)/t77-,78-,79-,80-,81-,82-,83+,84+,85+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,126-,127-,128-,129-,130-,131-,132-/m0/s1
DMYOAKS	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CN=CN5)N
DMYOAKS	IK	CILIXQOJUNDIDU-ASQIGDHWSA-N
DMYOAKS	IU	(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]butanedioic acid
DMYOAKS	CA	CAS 197922-42-2
DMYOAKS	DE	Short bowel syndrome

DM31ZQM	ID	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	HS	Approved
DM31ZQM	SN	Tegafur (Fluoropyrimidine)
DM31ZQM	DT	Small molecular drug
DM31ZQM	PC	5386
DM31ZQM	MW	200.17
DM31ZQM	FM	C8H9FN2O3
DM31ZQM	IC	InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)
DM31ZQM	CS	C1CC(OC1)N2C=C(C(=O)NC2=O)F
DM31ZQM	IK	WFWLQNSHRPWKFK-UHFFFAOYSA-N
DM31ZQM	IU	5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione
DM31ZQM	CA	CAS 17902-23-7
DM31ZQM	CB	CHEBI:32188
DM31ZQM	DE	Solid tumour/cancer

DM3XYD1	ID	DM3XYD1
DM3XYD1	DN	Tegaserod
DM3XYD1	HS	Approved
DM3XYD1	SN	Tegaserod (USAN/INN); 1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine
DM3XYD1	CP	Novartis
DM3XYD1	DT	Small molecular drug
DM3XYD1	PC	135409453
DM3XYD1	MW	301.39
DM3XYD1	FM	C16H23N5O
DM3XYD1	IC	InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+
DM3XYD1	CS	CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC
DM3XYD1	IK	IKBKZGMPCYNSLU-RGVLZGJSSA-N
DM3XYD1	IU	1-[(E)-(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine
DM3XYD1	CA	CAS 145158-71-0
DM3XYD1	CB	CHEBI:51043
DM3XYD1	DE	Irritable bowel syndrome; Gastro-oesophageal reflux; Dyspepsia

DMAQ2LK	ID	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	HS	Approved
DMAQ2LK	SN	Targocid (TN)
DMAQ2LK	CP	Sanofi-Aventis
DMAQ2LK	DT	Small molecular drug
DMAQ2LK	PC	133065662
DMAQ2LK	MW	1879.7
DMAQ2LK	FM	C88H97Cl2N9O33
DMAQ2LK	IC	InChI=1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88?/m1/s1
DMAQ2LK	CS	CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O
DMAQ2LK	IK	BJNLLBUOHPVGFT-CAYRISATSA-N
DMAQ2LK	IU	(1S,2R,19R,22R,34S,37R,40R,52S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-amino-5,15-dichloro-64-[(2S,3R,4R,5S,6R)-3-(decanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylic acid
DMAQ2LK	CA	CAS 61036-62-2
DMAQ2LK	DE	Bacterial infection

DMMRV29	ID	DMMRV29
DMMRV29	DN	Telaprevir
DMMRV29	HS	Approved
DMMRV29	SN	402957-28-2; VX-950; Incivek; Telaprevir (VX-950); Incivo; MP-424; VX 950; Telavic; VX-950(Telaprevir); LY-570310; UNII-655M5O3W0U; VRT-111950; CHEMBL231813; CHEBI:68595; 655M5O3W0U; S-Telaprevir; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide
DMMRV29	DT	Small molecular drug
DMMRV29	PC	3010818
DMMRV29	MW	679.8
DMMRV29	FM	C36H53N7O6
DMMRV29	IC	InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1
DMMRV29	CS	CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5
DMMRV29	IK	BBAWEDCPNXPBQM-GDEBMMAJSA-N
DMMRV29	IU	(3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide
DMMRV29	CA	CAS 402957-28-2
DMMRV29	CB	CHEBI:68595
DMMRV29	DE	Hepatitis C virus infection

DM58VQX	ID	DM58VQX
DM58VQX	DN	Telavancin
DM58VQX	HS	Approved
DM58VQX	SN	telavancinum; telavancina; telavancine; 372151-71-8; UNII-XK134822Z0; CHEBI:71229; XK134822Z0; Telavancin [INN]; HSDB 8194; AC1MIWRX; SCHEMBL8287015; CHEMBL507870; DB06402; LS-192933; T-1455; Telavancin, Antibiotic for Culture Media Use Only; Vancomycin, N3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-
DM58VQX	DT	Small molecular drug
DM58VQX	PC	3081362
DM58VQX	MW	1755.6
DM58VQX	FM	C80H106Cl2N11O27P
DM58VQX	IC	InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1
DM58VQX	CS	CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)C
DM58VQX	IK	ONUMZHGUFYIKPM-MXNFEBESSA-N
DM58VQX	IU	(1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-[2-(decylamino)ethylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-36-[(phosphonomethylamino)methyl]-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
DM58VQX	CA	CAS 372151-71-8
DM58VQX	CB	CHEBI:71229
DM58VQX	DE	Staphylococcus infection

DMSWUGE	ID	DMSWUGE
DMSWUGE	DN	Telbivudine
DMSWUGE	HS	Approved
DMSWUGE	SN	Epavudine; LLT; LdT; Sebivo; Telbivudin; Tyzeka; Telbivudine [USAN]; LDT600; NB 02B; NV 02B; L-Deoxythymidine; L-Thymidine; L-dT; LDT-600; NV-02B; Tyzeka (TN); Beta-L-Thymidine; Telbivudine (USAN/INN); Tyzake/Sebivo (TN); Tyzeka, Sebivo, Telbivudine; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 2'-Deoxy-L-thymidine
DMSWUGE	CP	Idenix
DMSWUGE	TC	Antiviral Agents
DMSWUGE	DT	Small molecular drug
DMSWUGE	PC	159269
DMSWUGE	MW	242.23
DMSWUGE	FM	C10H14N2O5
DMSWUGE	IC	InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1
DMSWUGE	CS	CC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O
DMSWUGE	IK	IQFYYKKMVGJFEH-CSMHCCOUSA-N
DMSWUGE	IU	1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMSWUGE	CA	CAS 3424-98-4
DMSWUGE	CB	CHEBI:63624
DMSWUGE	DE	Hepatitis B virus infection

DMZ4P3A	ID	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	HS	Approved
DMZ4P3A	SN	Ketek; Levviax; TEL; HMR 3647; HMR3647; RU 66647; RU66647; HMR-3647; Ketek (TN); RU-66647; Telithromycin [USAN:BAN:INN]; Telithromycin (JAN/USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A
DMZ4P3A	CP	Sanofi-Aventis
DMZ4P3A	TC	Antibiotics
DMZ4P3A	DT	Small molecular drug
DMZ4P3A	PC	3002190
DMZ4P3A	MW	812
DMZ4P3A	FM	C43H65N5O10
DMZ4P3A	IC	InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1
DMZ4P3A	CS	CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
DMZ4P3A	IK	LJVAJPDWBABPEJ-PNUFFHFMSA-N
DMZ4P3A	IU	(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMZ4P3A	CA	CAS 191114-48-4
DMZ4P3A	CB	CHEBI:29688
DMZ4P3A	DE	Bacterial infection

DMS3GX2	ID	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	HS	Approved
DMS3GX2	SN	Kinzal; Kinzalmono; Micardis; Pritor; Abbott brand of telmisartan; Boehringer Ingelheim brand of telmisartan; Glaxo Wellcome brand of telmisartan; GlaxoSmithKline brand of telmisartan; BIBR 277; BIBR 277SE; BIBR-277; BIBR-277SE; Bay 68-9291; Micardis (TN); Telmisartan [USAN:INN]; YM-086; BIBR-277-SE; Telmisartan (JAN/USAN/INN); Micardis, Targit, Temax, BIBR277, Telmisartan; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid; 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
DMS3GX2	CP	Boehringer Ingelheim
DMS3GX2	TC	Antihypertensive Agents
DMS3GX2	DT	Small molecular drug
DMS3GX2	PC	65999
DMS3GX2	MW	514.6
DMS3GX2	FM	C33H30N4O2
DMS3GX2	IC	InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
DMS3GX2	CS	CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C
DMS3GX2	IK	RMMXLENWKUUMAY-UHFFFAOYSA-N
DMS3GX2	IU	2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
DMS3GX2	CA	CAS 144701-48-4
DMS3GX2	CB	CHEBI:9434
DMS3GX2	DE	Hypertension

DMDIYFZ	ID	DMDIYFZ
DMDIYFZ	DN	Telotristat ethyl
DMDIYFZ	HS	Approved
DMDIYFZ	SN	Telotristat; Telotristat etiprate; LP-778902; LX-1032; LX-1606; Serotonin modulator (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon; Tryptophan hydroxylase inhibitor (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon
DMDIYFZ	CP	Lexicon Pharmaceuticals
DMDIYFZ	DT	Small molecular drug
DMDIYFZ	PC	25181577
DMDIYFZ	MW	575
DMDIYFZ	FM	C27H26ClF3N6O3
DMDIYFZ	IC	InChI=1S/C27H26ClF3N6O3/c1-3-39-25(38)20(32)12-16-4-6-17(7-5-16)21-14-23(35-26(33)34-21)40-24(27(29,30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37/h4-11,13-14,20,24H,3,12,32H2,1-2H3,(H2,33,34,35)/t20-,24+/m0/s1
DMDIYFZ	CS	CCOC(=O)[C@H](CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)O[C@H](C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N
DMDIYFZ	IK	MDSQOJYHHZBZKA-GBXCKJPGSA-N
DMDIYFZ	IU	ethyl (2S)-2-amino-3-[4-[2-amino-6-[(1R)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]pyrimidin-4-yl]phenyl]propanoate
DMDIYFZ	CA	CAS 1033805-22-9
DMDIYFZ	DE	Carcinoid syndrome diarrhea; Carcinoid syndrome

DM02A65	ID	DM02A65
DM02A65	DN	Temazepam
DM02A65	HS	Approved
DM02A65	SN	Cerepax; Crisonar; Dasuen; Euhypnos; Euipnos; Gelthix; Hydroxydiazepam; Lenal; Levanxene; Levanxol; Levanzene; Mabertin; Methyloxazepam; Nocturne; Nomapam; Normison; Normitab; Nortem; Oxydiazepam; Perdorm; Planum; Remestan; Restoril; Signopam; Temador; Temaz; Temaze; Temazepamum; Temtabs; Tenox; AHP Brand of Temazepam; Alphapharm Brand of Temazepam; Apo Temazepam; Apotex Brand of Temazepam; Ct Arzneimittel Brand of Temazepam; Desitin Brand of Temazepam; Gen Temazepam; Genopharm Brand of Temazepam; Genpharm Brand of Temazepam; ICN Brand of Temazepam; Katwijk Brand of Temazepam; Knoll Brand of Temazepam; Mallinckrodt Brand of Temazepam; Neodorm SP; Norkotral Tema; Norton Brand of Temazepam; Novartis Brand of Temazepam; Novo Temazepam; Novopharm Brand of Temazepam; Nu Pharm Brand of Temazepam; Nu Temazepam; Orion Brand of Temazepam; PMS Temazepam; Pharmascience Brand of Temazepam; Pronervon T; Scheffler Brand of Temazepam; Sigma Brand of Temazepam; Temazep von ct; Uvamin Retard; Wyeth Brand of Temazepam; ER 115; K3917; Pfizer Brand 1 of Temazepam; Pfizer Brand 2 of Temazepam; Ro 5 5345; Ro55345; SaH 47 603; SaH 47603; WY 2917; WY 3917; WY3917; Apo-Temazepam; Ct-Arzneimittel Brand of Temazepam; Euhypnos (TN); Gen-Temazepam; K-3917; N-Methyloxazepam; Norkotral (TN); Normison (TN); Novo-Temazepam; Nu-Pharm Brand of Temazepam; Nu-Temazepam; PMS-Temazepam; Remestan (TN); Restoril (TN); Ro 5-5345; SaH 47-603; Tema, Norkotral; Temazepam, pharmaceutical grade; Temazepamum [INN-Latin]; Temtabs (TN); Tenox (TN); Wy-3917; Ro-5-5345; Temazepam (USP/INN); Temazepam [USAN:INN:BAN]; 1,3-Dihydro-7-chloro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 3 Hydroxydiazepam; 3-Hydroxydiazepam; 7-CHLORO-1,3-DIHYDRO-3-HYDROXY-1-METHYL-5-PHENYL-2H-1,4-BENZODIAZEPIN-2-ONE; 7-Chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM02A65	CP	Mylan Inc
DM02A65	TC	Hypnotics and Sedatives
DM02A65	DT	Small molecular drug
DM02A65	PC	5391
DM02A65	MW	300.74
DM02A65	FM	C16H13ClN2O2
DM02A65	IC	InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3
DM02A65	CS	CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3
DM02A65	IK	SEQDDYPDSLOBDC-UHFFFAOYSA-N
DM02A65	IU	7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM02A65	CA	CAS 846-50-4
DM02A65	CB	CHEBI:9435
DM02A65	DE	Insomnia

DM1A79H	ID	DM1A79H
DM1A79H	DN	Temocapril
DM1A79H	HS	Approved
DM1A79H	SN	Temocapril; Temocaprilum; 2-((2S,6R)-6-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl)acetic acid; UNII-18IZ008EU6; 18IZ008EU6; Temocapril [INN:BAN]; Temocaprilum [INN-Latin]; C23H28N2O5S2; 2-((2S,6R)-6-((S)-1-ETHOXY-1-OXO-4-PHENYLBUTAN-2-YLAMINO)-5-OXO-2-(THIOPHEN-2-YL)-1,4-THIAZEPAN-4-YL)ACETIC ACID; (2S-(2alpha,6beta(R*)))-6-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid; Temocapril (INN); AC1L9FDI
DM1A79H	PC	443874
DM1A79H	MW	476.6
DM1A79H	FM	C23H28N2O5S2
DM1A79H	IC	InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1
DM1A79H	CS	CCOC(=O)C(CCC1=CC=CC=C1)NC2CSC(CN(C2=O)CC(=O)O)C3=CC=CS3
DM1A79H	IK	FIQOFIRCTOWDOW-BJLQDIEVSA-N
DM1A79H	IU	2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
DM1A79H	CA	CAS 111902-57-9
DM1A79H	CB	CHEBI:135771
DM1A79H	DE	High blood pressure

DM0JXFL	ID	DM0JXFL
DM0JXFL	DN	Temocapril hydrochloride
DM0JXFL	HS	Approved
DM0JXFL	SN	Acecol (TN)
DM0JXFL	CP	Sankyo
DM0JXFL	DT	Small molecular drug
DM0JXFL	PC	443873
DM0JXFL	MW	513.1
DM0JXFL	FM	C23H29ClN2O5S2
DM0JXFL	IC	InChI=1S/C23H28N2O5S2.ClH/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27;/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27);1H/t17-,18-,20-;/m0./s1
DM0JXFL	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3.Cl
DM0JXFL	IK	XDDQNOKKZKHBIX-ASBZXGSUSA-N
DM0JXFL	IU	2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid;hydrochloride
DM0JXFL	CA	CAS 110221-44-8
DM0JXFL	CB	CHEBI:32190
DM0JXFL	DE	Cardiovascular disease

DMNX2QI	ID	DMNX2QI
DMNX2QI	DN	Temocaprilate
DMNX2QI	HS	Approved
DMNX2QI	SN	(+)-(2S,6R)-6-(((1S)-1-carboxy-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid; 2-(4-Carboxymethyl-5-oxo-2-thiophen-2-yl-[1,4]thiazepan-6-ylamino)-4-phenyl-butyric acid; 2D6A12Q12R; AC1L9E45; AJ-48035; AK116088; AKOS016010295; API0000849; AX8152551; BDBM50024710; O437; RNH 5139; RNH-5139; RS 5139; RS-5139; RT-015901; SCHEMBL498916; TL8000320; Temocapril Diacid; Temocaprilat; Temocaprilat [INN:BAN]; ZINC4099102; temocaprilate
DMNX2QI	PC	443151
DMNX2QI	MW	448.552
DMNX2QI	FM	C21H24N2O5S2
DMNX2QI	IC	InChI=1S/C21H24N2O5S2/c24-19(25)12-23-11-18(17-7-4-10-29-17)30-13-16(20(23)26)22-15(21(27)28)9-8-14-5-2-1-3-6-14/h1-7,10,15-16,18,22H,8-9,11-13H2,(H,24,25)(H,27,28)/t15-,16-,18-/m0/s1
DMNX2QI	CS	C1C(SCC(C(=O)N1CC(=O)O)NC(CCC2=CC=CC=C2)C(=O)O)C3=CC=CS3
DMNX2QI	IK	KZVWEOXAPZXAFB-BQFCYCMXSA-N
DMNX2QI	IU	(2S)-2-[[(2S,6R)-4-(carboxymethyl)-5-oxo-2-thiophen-2-yl-1,4-thiazepan-6-yl]amino]-4-phenylbutanoic acid
DMNX2QI	CA	CAS 110221-53-9
DMNX2QI	CB	CHEBI:9436
DMNX2QI	DE	High blood pressure

DMKECZD	ID	DMKECZD
DMKECZD	DN	Temozolomide
DMKECZD	HS	Approved
DMKECZD	SN	Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ
DMKECZD	CP	Schering-Plough
DMKECZD	TC	Anticancer Agents
DMKECZD	DT	Small molecular drug
DMKECZD	PC	5394
DMKECZD	MW	194.15
DMKECZD	FM	C6H6N6O2
DMKECZD	IC	InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
DMKECZD	CS	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
DMKECZD	IK	BPEGJWRSRHCHSN-UHFFFAOYSA-N
DMKECZD	IU	3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
DMKECZD	CA	CAS 85622-93-1
DMKECZD	CB	CHEBI:72564
DMKECZD	DE	Grade IV astrocytoma

DMS104F	ID	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	HS	Approved
DMS104F	SN	Torisel
DMS104F	CP	Wyeth
DMS104F	DT	Small molecular drug
DMS104F	PC	6918289
DMS104F	MW	1030.3
DMS104F	FM	C56H87NO16
DMS104F	IC	InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
DMS104F	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC
DMS104F	IK	CBPNZQVSJQDFBE-FUXHJELOSA-N
DMS104F	IU	[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
DMS104F	CA	CAS 162635-04-3
DMS104F	CB	CHEBI:79699
DMS104F	DE	Renal cell carcinoma

DMCOZJY	ID	DMCOZJY
DMCOZJY	DN	Tenapanor
DMCOZJY	HS	Approved
DMCOZJY	SN	1234423-95-0; UNII-WYD79216A6; AZD 1722; WYD79216A6; AZD-1722; 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide; Tenapanor [USAN:INN]; Tenapanor(free base); GTPL8449; CHEMBL3304485; SCHEMBL15267600; DTXSID40154016; BCP24892; BCP28554; EX-A2506
DMCOZJY	CP	AstraZeneca
DMCOZJY	DT	Small molecular drug
DMCOZJY	PC	71587953
DMCOZJY	MW	1145
DMCOZJY	FM	C50H66Cl4N8O10S2
DMCOZJY	IC	InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1
DMCOZJY	CS	CN1C[C@H](C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)[C@@H]5CN(CC6=C5C=C(C=C6Cl)Cl)C
DMCOZJY	IK	DNHPDWGIXIMXSA-CXNSMIOJSA-N
DMCOZJY	IU	1-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea
DMCOZJY	CA	CAS 1234423-95-0
DMCOZJY	DE	Kidney disease; Constipation; Irritable bowel syndrome

DMJYN25	ID	DMJYN25
DMJYN25	DN	Tenecteplase
DMJYN25	HS	Approved
DMJYN25	SN	Tnkase; Tnkase (TN); Tenecteplase (USAN/INN)
DMJYN25	TC	Thrombolytic Agents
DMJYN25	SQ	DB00031 sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGNWSTAESGAECTNWQSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAAAAASPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DMJYN25	DE	Myocardial infarction

DMLW57T	ID	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	HS	Approved
DMLW57T	SN	PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside
DMLW57T	TC	Anticancer Agents
DMLW57T	DT	Small molecular drug
DMLW57T	PC	452548
DMLW57T	MW	656.7
DMLW57T	FM	C32H32O13S
DMLW57T	IC	InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
DMLW57T	CS	COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O
DMLW57T	IK	NRUKOCRGYNPUPR-QBPJDGROSA-N
DMLW57T	IU	(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
DMLW57T	CA	CAS 29767-20-2
DMLW57T	DE	Acute lymphoblastic leukaemia

DM1IS6U	ID	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	HS	Approved
DM1IS6U	SN	Apropovir; PMPA; TFV; Tenefovir; GS 1275; GS 1278; GS1278; GNA & Tenofovir; HHA & Tenofovir; KS-5021; Viread (TN); Viread, Tenofovir; D,L-Tenofovir; PMPA-(R); Phosphonic acid, [[2-(6-amino-9H-purin-9; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA
DM1IS6U	CP	Gilead Sciences
DM1IS6U	TC	Anti-HIV Agents
DM1IS6U	DT	Small molecular drug
DM1IS6U	PC	464205
DM1IS6U	MW	287.21
DM1IS6U	FM	C9H14N5O4P
DM1IS6U	IC	InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1
DM1IS6U	CS	C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
DM1IS6U	IK	SGOIRFVFHAKUTI-ZCFIWIBFSA-N
DM1IS6U	IU	[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
DM1IS6U	CA	CAS 147127-20-6
DM1IS6U	CB	CHEBI:63625
DM1IS6U	DE	Human immunodeficiency virus infection

DMTQF4A	ID	DMTQF4A
DMTQF4A	DN	Tenofovir alafenamide
DMTQF4A	HS	Approved
DMTQF4A	SN	Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy; Tenofovir; UNII-W4HFE001U5; W4HFE001U5; (R)-(((1-(6-AMINO-9H-PURIN-9-YL)PROPAN-2-YL)OXY)METHYL)PHOSPHONIC ACID; (R)-(1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid; (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-[2-(Phosphonomethoxy)propyl]adenine; (R)-PMPA; ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid; 147127-20-6; 9-[(R)-2-(phosphonomethoxy)propyl]adenine; Apropovir; CHEBI:63625; D,L-Tenofovir; GS-1278; PMPA; PMPA gel; (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; 379270-37-8; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE
DMTQF4A	PC	9574768
DMTQF4A	MW	476.5
DMTQF4A	FM	C21H29N6O5P
DMTQF4A	IC	LDEKQSIMHVQZJK-CAQYMETFSA-N
DMTQF4A	CS	CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OC3=CC=CC=C3
DMTQF4A	IK	1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
DMTQF4A	IU	propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMTQF4A	CA	CAS 379270-37-8
DMTQF4A	CB	CHEBI:90926
DMTQF4A	DE	Viral hepatitis

DMSY4ZG	ID	DMSY4ZG
DMSY4ZG	DN	Tenofovir disoproxil fumarate
DMSY4ZG	HS	Approved
DMSY4ZG	SN	Bis-POC-PMPA; GSK548470; PMPA-oral; Tenofovir DF; Tenozet; Viread
DMSY4ZG	TC	Antiinfective Agents
DMSY4ZG	DT	Small molecular drug
DMSY4ZG	PC	6398764
DMSY4ZG	MW	635.5
DMSY4ZG	FM	C23H34N5O14P
DMSY4ZG	IC	InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1
DMSY4ZG	CS	C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\\C(=O)O
DMSY4ZG	IK	VCMJCVGFSROFHV-WZGZYPNHSA-N
DMSY4ZG	IU	[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(E)-but-2-enedioic acid
DMSY4ZG	CA	CAS 202138-50-9
DMSY4ZG	CB	CHEBI:63718
DMSY4ZG	DE	Discovery agent

DMVAZP9	ID	DMVAZP9
DMVAZP9	DN	Tenoxicam
DMVAZP9	HS	Approved
DMVAZP9	SN	Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide
DMVAZP9	CP	Roche Laboratories Inc
DMVAZP9	TC	Antiinflammatory Agents
DMVAZP9	DT	Small molecular drug
DMVAZP9	PC	54677971
DMVAZP9	MW	337.4
DMVAZP9	FM	C13H11N3O4S2
DMVAZP9	IC	InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)
DMVAZP9	CS	CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3
DMVAZP9	IK	LZNWYQJJBLGYLT-UHFFFAOYSA-N
DMVAZP9	IU	4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide
DMVAZP9	CA	CAS 59804-37-4
DMVAZP9	CB	CHEBI:32192
DMVAZP9	DE	Rheumatoid arthritis

DMUQ0E8	ID	DMUQ0E8
DMUQ0E8	DN	Tepotinib
DMUQ0E8	HS	Approved
DMUQ0E8	SN	1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo
DMUQ0E8	CP	EMD Serono
DMUQ0E8	DT	Small molecular drug
DMUQ0E8	PC	25171648
DMUQ0E8	MW	492.6
DMUQ0E8	FM	C29H28N6O2
DMUQ0E8	IC	InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3
DMUQ0E8	CS	CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N
DMUQ0E8	IK	AHYMHWXQRWRBKT-UHFFFAOYSA-N
DMUQ0E8	IU	3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile
DMUQ0E8	CA	CAS 1100598-32-0
DMUQ0E8	DE	Solid tumour/cancer; Hepatocellular carcinoma; Non-small cell lung cancer

DM4L59B	ID	DM4L59B
DM4L59B	DN	Teprotumumab
DM4L59B	HS	Approved
DM4L59B	SN	RV001
DM4L59B	CP	River vision
DM4L59B	DE	Diabetic macular edema; Graves disease

DM3JCVS	ID	DM3JCVS
DM3JCVS	DN	Terazosin
DM3JCVS	HS	Approved
DM3JCVS	SN	Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Terazosabb; Terazosina; Terazosine; Terazosinum; Vasomet; Trazosin HCl; A 45975; Abbott 45975; A-45975; Hytrin (TN); Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina [INN-Spanish]; Terazosine [INN-French]; Terazosinum [INN-Latin]; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
DM3JCVS	CP	Abbott Laboratories
DM3JCVS	TC	Anticancer Agents
DM3JCVS	DT	Small molecular drug
DM3JCVS	PC	5401
DM3JCVS	MW	387.4
DM3JCVS	FM	C19H25N5O4
DM3JCVS	IC	InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
DM3JCVS	CS	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
DM3JCVS	IK	VCKUSRYTPJJLNI-UHFFFAOYSA-N
DM3JCVS	IU	[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
DM3JCVS	CA	CAS 63590-64-7
DM3JCVS	CB	CHEBI:9445
DM3JCVS	DE	Benign prostatic hyperplasia

DMI6HUW	ID	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	HS	Approved
DMI6HUW	SN	Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride
DMI6HUW	CP	Celtic Pharma
DMI6HUW	TC	Antifungal Agents
DMI6HUW	DT	Small molecular drug
DMI6HUW	PC	1549008
DMI6HUW	MW	291.4
DMI6HUW	FM	C21H25N
DMI6HUW	IC	InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+
DMI6HUW	CS	CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21
DMI6HUW	IK	DOMXUEMWDBAQBQ-WEVVVXLNSA-N
DMI6HUW	IU	(E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
DMI6HUW	CA	CAS 91161-71-6
DMI6HUW	CB	CHEBI:9448
DMI6HUW	DE	Fungal infection; Onychomycosis

DMD4381	ID	DMD4381
DMD4381	DN	Terbutaline
DMD4381	HS	Approved
DMD4381	SN	Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol
DMD4381	CP	Ben Venue Laboratories
DMD4381	TC	Bronchodilator Agents
DMD4381	DT	Small molecular drug
DMD4381	PC	5403
DMD4381	MW	225.28
DMD4381	FM	C12H19NO3
DMD4381	IC	InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3
DMD4381	CS	CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O
DMD4381	IK	XWTYSIMOBUGWOL-UHFFFAOYSA-N
DMD4381	IU	5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
DMD4381	CA	CAS 23031-25-6
DMD4381	CB	CHEBI:9449
DMD4381	DE	Asthma

DMVPWLZ	ID	DMVPWLZ
DMVPWLZ	DN	Terbutyline
DMVPWLZ	HS	Approved
DMVPWLZ	DE	Hypertension

DMJ13KI	ID	DMJ13KI
DMJ13KI	DN	Terconazole
DMJ13KI	HS	Approved
DMJ13KI	SN	Fungistat; Terazol; Terconazol; Terconazolum; Tercospor; Triaconazole; Zazole; R 42470; Terazol 3; Terazol 7; Terazol 73; Tetrazol 3; Tetrazol 7; Gyno-Terazol; R 42,470; R-42470; Terazol 3 (TN); Terazol 7 & 3; Terazol Cream & Suppositories; Terconazol [INN-Spanish]; Terconazolum [INN-Latin]; Terconazole (USAN/INN); Terconazole [USAN:INN:BAN]; Cis-1-(p-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-isopropylpiperazine; Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, rel-(2R,4S); 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine; 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine
DMJ13KI	TC	Antifungal Agents
DMJ13KI	DT	Small molecular drug
DMJ13KI	PC	441383
DMJ13KI	MW	532.5
DMJ13KI	FM	C26H31Cl2N5O3
DMJ13KI	IC	InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1
DMJ13KI	CS	CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl
DMJ13KI	IK	BLSQLHNBWJLIBQ-OZXSUGGESA-N
DMJ13KI	IU	1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine
DMJ13KI	CA	CAS 67915-31-5
DMJ13KI	CB	CHEBI:82980
DMJ13KI	DE	Candidiasis

DMQ2FKJ	ID	DMQ2FKJ
DMQ2FKJ	DN	Teriflunomide
DMQ2FKJ	HS	Approved
DMQ2FKJ	CP	Sanofi-Aventis
DMQ2FKJ	DT	Small molecular drug
DMQ2FKJ	PC	54684141
DMQ2FKJ	MW	270.21
DMQ2FKJ	FM	C12H9F3N2O2
DMQ2FKJ	IC	InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
DMQ2FKJ	CS	C/C(=C(\\C#N)/C(=O)NC1=CC=C(C=C1)C(F)(F)F)/O
DMQ2FKJ	IK	UTNUDOFZCWSZMS-YFHOEESVSA-N
DMQ2FKJ	IU	(Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide
DMQ2FKJ	CA	CAS 163451-81-8
DMQ2FKJ	CB	CHEBI:68540
DMQ2FKJ	DE	Hyperlipidaemia; Multiple sclerosis; Hepatitis B virus infection; Rheumatoid arthritis

DMMC45B	ID	DMMC45B
DMMC45B	DN	Teriparatide
DMMC45B	HS	Approved
DMMC45B	SN	Forteo; Forteo (TN); Teriparatide (genetical recombination); Teriparatide (USAN/INN); Teriparatide (genetical recombination) (JAN)
DMMC45B	CP	Eli Lilly
DMMC45B	TC	Bone Density Conservation Agents
DMMC45B	DT	Peptide
DMMC45B	SQ	Parathyroid hormone precursor - Homo sapiens (1-34): SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF
DMMC45B	PC	16133850
DMMC45B	MW	4118
DMMC45B	FM	C181H291N55O51S2
DMMC45B	IC	InChI=1S/C181H291N55O51S2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97/h22-26,35-38,77-80,85-96,103,105-132,143-146,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,191,192,198)(H4,193,194,199)/t96-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,143-,144-,145-,146-/m0/s1
DMMC45B	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N
DMMC45B	IK	OGBMKVWORPGQRR-UMXFMPSGSA-N
DMMC45B	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMMC45B	CA	CAS 52232-67-4
DMMC45B	CB	CHEBI:135983
DMMC45B	DE	Osteogenesis imperfecta; Psoriatic disorder

DMT9FH3	ID	DMT9FH3
DMT9FH3	DN	Terlipressin
DMT9FH3	HS	Approved
DMT9FH3	SN	Glypressin; Lucassin; Terlipressina; Terlipressine; Terlipressinum; Glypressin (TN); HS-2028; Terlipressin [BAN:INN]; Terlipressina [INN-Spanish]; Terlipressine [INN-French]; Terlipressinum [INN-Latin]; N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin
DMT9FH3	CP	Ferring Pharmaceuticals
DMT9FH3	TC	Vasoconstrictor Agents
DMT9FH3	DT	Small molecular drug
DMT9FH3	PC	72081
DMT9FH3	MW	1227.4
DMT9FH3	FM	C52H74N16O15S2
DMT9FH3	IC	InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1
DMT9FH3	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DMT9FH3	IK	BENFXAYNYRLAIU-QSVFAHTRSA-N
DMT9FH3	IU	(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
DMT9FH3	CA	CAS 14636-12-5
DMT9FH3	CB	CHEBI:135905
DMT9FH3	DE	Hypertension

DM2L3D5	ID	DM2L3D5
DM2L3D5	DN	Tertatolol
DM2L3D5	HS	Approved
DM2L3D5	SN	(-)-tertatolol; (+)-Tertatolol; GTPL64; ZINC748; PDSP2_001696; PDSP1_001713; 117305-34-7; UNII-9ZO341YQXP component HTWFXPCUFWKXOP-CYBMUJFWSA-N
DM2L3D5	DT	Small molecular drug
DM2L3D5	PC	36920
DM2L3D5	MW	295.4
DM2L3D5	FM	C16H25NO2S
DM2L3D5	IC	InChI=1S/C16H25NO2S/c1-16(2,3)17-10-13(18)11-19-14-8-4-6-12-7-5-9-20-15(12)14/h4,6,8,13,17-18H,5,7,9-11H2,1-3H3
DM2L3D5	CS	CC(C)(C)NCC(COC1=CC=CC2=C1SCCC2)O
DM2L3D5	IK	HTWFXPCUFWKXOP-UHFFFAOYSA-N
DM2L3D5	IU	1-(tert-butylamino)-3-(3,4-dihydro-2H-thiochromen-8-yloxy)propan-2-ol
DM2L3D5	CA	CAS 83688-84-0
DM2L3D5	CB	CHEBI:135244
DM2L3D5	DE	Hypertension

DM9GP85	ID	DM9GP85
DM9GP85	DN	Tesamorelin
DM9GP85	HS	Approved
DM9GP85	SN	Egrifta (TN)
DM9GP85	CP	Theratechnologies
DM9GP85	DT	Small molecular drug
DM9GP85	PC	16137828
DM9GP85	MW	5136
DM9GP85	FM	C221H366N72O67S
DM9GP85	IC	InChI=1S/C221H366N72O67S/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)179(324)276-150(96-169(316)317)199(344)256-117(22)180(325)291-172(111(16)26-2)214(359)284-147(91-119-43-31-29-32-44-119)206(351)293-174(118(23)298)215(360)285-149(95-162(230)307)205(350)289-155(104-297)210(355)280-146(93-121-56-60-123(300)61-57-121)203(348)267-130(51-41-83-248-220(240)241)186(331)266-126(46-34-36-78-223)197(342)290-171(110(14)15)212(357)283-141(87-106(6)7)183(328)252-100-166(311)258-133(63-70-157(225)302)190(335)278-144(90-109(12)13)202(347)288-152(101-294)208(353)257-115(20)178(323)262-128(49-39-81-246-218(236)237)185(330)265-125(45-33-35-77-222)189(334)277-143(89-108(10)11)201(346)279-142(88-107(8)9)200(345)272-137(66-73-160(228)305)195(340)282-151(97-170(318)319)207(352)292-173(112(17)27-3)213(358)274-139(76-85-361-24)196(341)287-153(102-295)209(354)268-131(52-42-84-249-221(242)243)187(332)270-135(64-71-158(226)303)192(337)269-132(62-69-156(224)301)182(327)251-99-165(310)259-134(67-74-167(312)313)191(336)286-154(103-296)211(356)281-148(94-161(229)306)204(349)273-136(65-72-159(227)304)193(338)271-138(68-75-168(314)315)194(339)264-124(47-37-79-244-216(232)233)181(326)250-98-164(309)253-113(18)176(321)261-127(48-38-80-245-217(234)235)184(329)254-114(19)177(322)263-129(50-40-82-247-219(238)239)188(333)275-140(175(231)320)86-105(4)5/h28-32,43-44,54-61,105-118,124-155,171-174,294-300H,25-27,33-42,45-53,62-104,222-223H2,1-24H3,(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,307)(H2,231,320)(H,250,326)(H,251,327)(H,252,328)(H,253,309)(H,254,329)(H,255,343)(H,256,344)(H,257,353)(H,258,311)(H,259,310)(H,260,308)(H,261,321)(H,262,323)(H,263,322)(H,264,339)(H,265,330)(H,266,331)(H,267,348)(H,268,354)(H,269,337)(H,270,332)(H,271,338)(H,272,345)(H,273,349)(H,274,358)(H,275,333)(H,276,324)(H,277,334)(H,278,335)(H,279,346)(H,280,355)(H,281,356)(H,282,340)(H,283,357)(H,284,359)(H,285,360)(H,286,336)(H,287,341)(H,288,347)(H,289,350)(H,290,342)(H,291,325)(H,292,352)(H,293,351)(H,312,313)(H,314,315)(H,316,317)(H,318,319)(H4,232,233,244)(H4,234,235,245)(H4,236,237,246)(H4,238,239,247)(H4,240,241,248)(H4,242,243,249)/b30-28+/t111-,112-,113-,114-,115-,116-,117-,118+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,171-,172-,173-,174-/m0/s1
DM9GP85	CS	CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N
DM9GP85	IK	QBEPNUQJQWDYKU-BMGKTWPMSA-N
DM9GP85	IU	(4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM9GP85	CA	CAS 804475-66-9
DM9GP85	DE	HIV-associated lipodystrophy

DMVY4GN	ID	DMVY4GN
DMVY4GN	DN	Testolactone
DMVY4GN	HS	Approved
DMVY4GN	SN	Fludestrin; Teolit; Teslac; Teslak; Testolacton; Testolactona; Testolactonum; Testolattone; Bristol Myers SquibbBrand of Testolactone; Testolattone [DCIT]; SQ 9538; Bristol-Myers Squibb Brand of Testolactone; DELTA1-Dehydrotestolactone; DELTA1-Dehydrotestololactone; DELTA1-Testololactone; SQ-9538; TESLAC (TN);Teslac (TN); Testolactona [INN-Spanish]; Testolactone [USAN:INN]; Testolactonum [INN-Latin]; Delta(1)-Dehydrotestolactone; Delta(1)-Testolactone; Delta(1)-Testololactone; Delta(1)-testololactone; Delta-1-testololactone; Testolactone (USP/INN); D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione; D-homo-17a-oxaandrosta-1,4-diene-3,17-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione; 1 Dehydrotestolactone; 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone; 1,2-Dehydrotestololactone; 1,2-Didehydrotestololactone; 1,2-didehydrotestololactone; 1-Dehydrotestolactone; 1-Dehydrotestololactone; 1-dehydrotestololactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI); 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione; 17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione; 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone; 3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone
DMVY4GN	TC	Anticancer Agents
DMVY4GN	DT	Small molecular drug
DMVY4GN	PC	13769
DMVY4GN	MW	300.4
DMVY4GN	FM	C19H24O3
DMVY4GN	IC	InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1
DMVY4GN	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC(=O)O2)CCC4=CC(=O)C=C[C@]34C
DMVY4GN	IK	BPEWUONYVDABNZ-DZBHQSCQSA-N
DMVY4GN	IU	(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione
DMVY4GN	CA	CAS 968-93-4
DMVY4GN	CB	CHEBI:9460
DMVY4GN	DE	Breast cancer

DM7HUNW	ID	DM7HUNW
DM7HUNW	DN	Testosterone
DM7HUNW	HS	Approved
DM7HUNW	SN	AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one
DM7HUNW	CP	Ardana Bioscience
DM7HUNW	DT	Small molecular drug
DM7HUNW	PC	6013
DM7HUNW	MW	288.4
DM7HUNW	FM	C19H28O2
DM7HUNW	IC	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
DM7HUNW	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C
DM7HUNW	IK	MUMGGOZAMZWBJJ-DYKIIFRCSA-N
DM7HUNW	IU	(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DM7HUNW	CA	CAS 58-22-0
DM7HUNW	CB	CHEBI:17347
DM7HUNW	DE	Osteoporosis; Male hormonal deficiency; Hormone deficiency

DMC1TEV	ID	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	HS	Approved
DMC1TEV	SN	Testodrin prolongatum; Testosterone 17beta-cyclopentylpropionate; Testosterone 17beta-cypionate; Testosterone cyclopentanepropionate; Testosterone cyclopentylpropionate; Testosterone cypionate [USP]; Testandrone; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testoviron Schering; Testoviron T; Testrone; Testryl; Virormone; Virosterone; testosterone; trans-Testosterone; 58-22-0; AndroGel; Androderm; Androlin; Andronaq; Andropatch; Andrusol; Cristerona T; Cristerone T; Homosteron; Homosterone; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Sustanon; Sustanone; Synandrol F; Teslen; UNII-M0XW1UBI14; depAndro 100; depAndro 200; 58-20-8; Andro-Cyp; Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17b)-; CHEBI:9463; DEPO; Dep-Test; Depo-Testadiol; Depo-Testosterone; Depotest; Depovirin; Durandro; Jectatest; M0XW1UBI14; Malogen CYP; NSC 9157; Pertestis; T-Ionate-P.A; TESTOSTERONE CYPIONATE
DMC1TEV	PC	441404
DMC1TEV	MW	412.6
DMC1TEV	FM	C27H40O3
DMC1TEV	IC	HPFVBGJFAYZEBE-ZLQWOROUSA-N
DMC1TEV	CS	CC12CCC3C(C1CCC2OC(=O)CCC4CCCC4)CCC5=CC(=O)CCC35C
DMC1TEV	IK	1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1
DMC1TEV	IU	[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
DMC1TEV	CA	CAS 58-20-8
DMC1TEV	CB	CHEBI:9463
DMC1TEV	DE	Testosterone deficiency

DMB6871	ID	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	HS	Approved
DMB6871	SN	Testanthate; Testate; Testenate; Testinon; Testoenant; Testonenant; Testosterone 17-enanthate; Testosterone enantate; Testosterone heptanoate; Testosterone heptoate; Testosterone heptylate; Testosterone oenanthate; Testostroval; testosterone enanthate; 17-Hydroxyandrost-4-en-3-one, 17-heptanoate; 315-37-7; Andro L.A. 200; Andropository; Androtardyl; Atlatest; DePatestrye; Delatest; Depo-Testro Med; Ditate; Durathate; Everone; Exten test; Malogen L.A.; Malogen L.A.200; NSC-17591; Orquisteron-E; Primotestone; Reposo TMD; Reposo-TMD
DMB6871	PC	9416
DMB6871	MW	400.6
DMB6871	FM	C26H40O3
DMB6871	IC	VOCBWIIFXDYGNZ-IXKNJLPQSA-N
DMB6871	CS	CCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
DMB6871	IK	1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1
DMB6871	IU	[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate
DMB6871	CA	CAS 315-37-7
DMB6871	CB	CHEBI:9464
DMB6871	DE	Testosterone deficiency

DMZO10Y	ID	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	HS	Approved
DMZO10Y	SN	Restandol (TN)
DMZO10Y	CP	Organon Greece
DMZO10Y	DT	Small molecular drug
DMZO10Y	PC	65157
DMZO10Y	MW	456.7
DMZO10Y	FM	C30H48O3
DMZO10Y	IC	InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1
DMZO10Y	CS	CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMZO10Y	IK	UDSFVOAUHKGBEK-CNQKSJKFSA-N
DMZO10Y	IU	[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate
DMZO10Y	CA	CAS 5949-44-0
DMZO10Y	CB	CHEBI:135741
DMZO10Y	DE	Hypogonadism

DMYWQ0O	ID	DMYWQ0O
DMYWQ0O	DN	Tetrabenazine
DMYWQ0O	HS	Approved
DMYWQ0O	SN	Nitoman; Rubigen; Tetrabenazina; Tetrabenazinum; Tetrabenzaine; Tetrabenzine; Xenazine; Tetra Benazin; Nitoman (TN); Ro 1-9569; Tetrabenazina [INN-Spanish]; Tetrabenazine (INN); Tetrabenazine [INN:BAN]; Tetrabenazinum [INN-Latin]; Xenazine (TN); Nitoman, Xenazine, Tetrabenazine; Ro 1-9569/12; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-(9CI); 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMYWQ0O	TC	Nephropathic cystinosis therapy
DMYWQ0O	DT	Small molecular drug
DMYWQ0O	PC	6018
DMYWQ0O	MW	317.4
DMYWQ0O	FM	C19H27NO3
DMYWQ0O	IC	InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
DMYWQ0O	CS	CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC
DMYWQ0O	IK	MKJIEFSOBYUXJB-UHFFFAOYSA-N
DMYWQ0O	IU	9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMYWQ0O	CA	CAS 718635-93-9
DMYWQ0O	CB	CHEBI:64028
DMYWQ0O	DE	Hyperkinetic movement disorder; Huntington disease

DM9J6C2	ID	DM9J6C2
DM9J6C2	DN	Tetracaine
DM9J6C2	HS	Approved
DM9J6C2	SN	Amethocaine; Anetain; Contralgin; Dicain; Dicaine; Dikain; Fissucain; Intercain; Laudocaine; Medicaine; Meethobalm; Metraspray; Mucaesthin; Niphanoid; Pontocaine; Rexocaine; Tetracaina; Tetracainum; Tetrakain; Uromucaesthin; Tetrakain [Czech]; Amethocaine (TN); Diaethylaminoaethanol ester der p-butylaminobenzoesaeure;Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Medihaler-Tetracaine; Pontocaine (TN); Tetracaina [INN-Spanish]; Tetracaine [USAN:INN]; Tetracainum [INN-Latin]; Dimethylaminoethyl p-butyl-aminobenzoate; Tetracaine (USP/INN); P-Butylaminobenzoyl-2-dimethylaminoethanol; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE; P-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; 2-dimethylaminoethyl 4-(butylamino)benzoate; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester
DM9J6C2	TC	Anesthetics
DM9J6C2	DT	Small molecular drug
DM9J6C2	PC	5411
DM9J6C2	MW	264.36
DM9J6C2	FM	C15H24N2O2
DM9J6C2	IC	InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3
DM9J6C2	CS	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
DM9J6C2	IK	GKCBAIGFKIBETG-UHFFFAOYSA-N
DM9J6C2	IU	2-(dimethylamino)ethyl 4-(butylamino)benzoate
DM9J6C2	CA	CAS 94-24-6
DM9J6C2	CB	CHEBI:9468
DM9J6C2	DE	Spinal anesthesia; Pain

DMZA017	ID	DMZA017
DMZA017	DN	Tetracycline
DMZA017	HS	Approved
DMZA017	SN	Amycin; Biocycline; Bristaciclin; Bristaciclina; Bristacycline; Ciclibion; Copharlan; Cyclomycin; Cytome; Dumocyclin; Enterocycline; Medocycline; Resteclin; Robitet; Sanclomycine; Tetrachel; Veracin; Bristaciclin alpha; Cefracycline suspension; Component of Tetrastatin; Sumycin syrup; Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Achromycin (naphthacene derivative); Achromycin, naphthacene derivative; Centet (base); Lemtrex (base); Liquamycin (Veterinary); Liquamycin, veterinary; Panmycin (TN); Piracaps (base); Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; SK-Tetracycline; Sumycin (TN); T-125; Tetra-Co; Tetraciclina [INN-Spanish]; Tetracycline & VRC3375; Tetracycline (internal use); Tetracyclinum [INN-Latin]; Tetracyn (TN); Vetquamycin-324 (free base); Tetracycline (JAN/USP/INN); Tetracycline [USAN:INN:BAN:JAN]; Methyl-1,11-dioxo-2-naphthacenecarboxamide; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide
DMZA017	CP	Pfizer Inc
DMZA017	TC	Antibiotics
DMZA017	DT	Small molecular drug
DMZA017	PC	54675776
DMZA017	MW	444.4
DMZA017	FM	C22H24N2O8
DMZA017	IC	InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1
DMZA017	CS	C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
DMZA017	IK	NWXMGUDVXFXRIG-WESIUVDSSA-N
DMZA017	IU	(4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMZA017	CA	CAS 60-54-8
DMZA017	CB	CHEBI:27902
DMZA017	DE	Bacterial infection

DMINZ4W	ID	DMINZ4W
DMINZ4W	DN	Tetrahydrobiopterin
DMINZ4W	HS	Approved
DMINZ4W	SN	tetrahydrobiopterin; 17528-72-2; 5,6,7,8-tetrahydrobiopterin; BRN 0544742; CHEBI:15372; 5,6,7,8-Tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone; L-erythro-2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinon; (1R,2S)-(2-Amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)-1,2-propandiol; 5,6,7,8-erythro-tetrahydrobiopterin; 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(3H)-one; Dapropterin; Phenoptin
DMINZ4W	TC	Dietary supplement
DMINZ4W	DT	Small molecular drug
DMINZ4W	PC	135402045
DMINZ4W	MW	241.25
DMINZ4W	FM	C9H15N5O3
DMINZ4W	IC	InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)
DMINZ4W	CS	CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DMINZ4W	IK	FNKQXYHWGSIFBK-UHFFFAOYSA-N
DMINZ4W	IU	2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-3H-pteridin-4-one
DMINZ4W	CA	CAS 17528-72-2
DMINZ4W	CB	CHEBI:15372
DMINZ4W	DE	Malnutrition

DMH15UV	ID	DMH15UV
DMH15UV	DN	Tetrahydrofolic acid
DMH15UV	HS	Approved
DMH15UV	SN	Tetrahydrafolate; Tetrahydrofolate; Tetrahydropteroylglutamate; Tetrahydropteroylglutamic acid; BIT3012; FH4; H4PteGlu; Folate-H4; Th-folate; Tetra-H-folate; Tetrahydropteroyl mono-L-glutamate; N-(5,6,7,8-tetrahydropteroyl)-L-glutamic acid; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)glutamic acid; N-[4-{[(2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}benzoyl]-L-glutamic acid; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; N-[4-({[(6S)-2-AMINO-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID; N-[4-({[(6S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid; (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid; (6S)-5,6,7,8-tetrahydropteroylglutamate; (6S)-H4folate; (6S)-THFA; (6S)-Tetrahydrofolic acid; (6S)-tetrahydrofolate; 2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 5,6,7,8-Tetrahydropteroyl-L-glutamic acid; 5,6,7,8-tetrahydrofolate; 5,6,7,8-tetrahydrofolic acid
DMH15UV	TC	Dietary supplement
DMH15UV	DT	Small molecular drug
DMH15UV	PC	135444742
DMH15UV	MW	445.4
DMH15UV	FM	C19H23N7O6
DMH15UV	IC	InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11?,12-/m0/s1
DMH15UV	CS	C1C(NC2=C(N1)N=C(NC2=O)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMH15UV	IK	MSTNYGQPCMXVAQ-KIYNQFGBSA-N
DMH15UV	IU	(2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMH15UV	CA	CAS 135-16-0
DMH15UV	CB	CHEBI:20506
DMH15UV	DE	Malnutrition

DMT57WC	ID	DMT57WC
DMT57WC	DN	Tetrahydrozoline
DMT57WC	HS	Approved
DMT57WC	SN	Tyzine
DMT57WC	CP	Fougera Pharmaceuticals Inc
DMT57WC	DT	Small molecular drug
DMT57WC	PC	5419
DMT57WC	MW	200.28
DMT57WC	FM	C13H16N2
DMT57WC	IC	InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)
DMT57WC	CS	C1CC(C2=CC=CC=C2C1)C3=NCCN3
DMT57WC	IK	BYJAVTDNIXVSPW-UHFFFAOYSA-N
DMT57WC	IU	2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole
DMT57WC	CA	CAS 84-22-0
DMT57WC	CB	CHEBI:28674
DMT57WC	DE	Ocular disease

DMWMPRG	ID	DMWMPRG
DMWMPRG	DN	Tetrodotoxin
DMWMPRG	HS	Approved
DMWMPRG	SN	Maculotoxin; Spheroidine; TTX; Tarichatoxin; Tetradotoxin; Tetrodontoxin; Tetrodotoxine; Tetrodoxin; Fugu Toxin; Fugu poison; BJT 1; Babylonia japonica toxin 1; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10adimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; (1R,5R,6R,7R,9S,11R,12R,13S,14S)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1(7,11).0(1,6)]tetradecane-5,9,12,13,14-pentol; (1r,5r,6r,9r,11s,13s,14s)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol(non-preferred name); (4R-(4alpha,4aalpha,5alpha,7alpha,9alpha,10alpha,10abeta,11S*,12S*))-Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d) pyrimidine-4,7,10,11,12-pentol
DMWMPRG	TC	Antibiotics
DMWMPRG	DT	Small molecular drug
DMWMPRG	PC	11174599
DMWMPRG	MW	319.27
DMWMPRG	FM	C11H17N3O8
DMWMPRG	IC	InChI=1S/C11H17N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-20H,1H2,(H3,12,13,14)/t2-,3-,4-,5+,6-,7+,9+,10-,11+/m1/s1
DMWMPRG	CS	C([C@@]1([C@H]2[C@@H]3[C@H](N=C(N[C@@]34[C@@H]([C@@H]1O[C@]([C@H]4O)(O2)O)O)N)O)O)O
DMWMPRG	IK	CFMYXEVWODSLAX-QOZOJKKESA-N
DMWMPRG	IU	(1R,5R,6R,7R,9S,11S,12S,13S,14S)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol
DMWMPRG	CA	CAS 4368-28-9
DMWMPRG	DE	Bacterial infection

DMY62FC	ID	DMY62FC
DMY62FC	DN	Tezacaftor And Ivacaftor
DMY62FC	HS	Approved
DMY62FC	SN	Ivacaftor / Tezacaftor; Tezacaftor / Ivacaftor; Ivacaftor and Tezacaftor; Ivacaftor regimen with Tezacaftor
DMY62FC	CP	Vertex Pharmaceuticals
DMY62FC	PC	72722243
DMY62FC	MW	913
DMY62FC	FM	C50H55F3N4O9
DMY62FC	IC	InChI=1S/C26H27F3N2O6.C24H28N2O3/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20;1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35);7-13,27H,1-6H3,(H,25,28)(H,26,29)/t16-;/m1./s1
DMY62FC	CS	CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C.CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
DMY62FC	IK	NETGOEWJJZQLCO-PKLMIRHRSA-N
DMY62FC	IU	N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide;1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
DMY62FC	CA	CAS 1969264-35-4
DMY62FC	DE	Acute lung injury

DM70BU5	ID	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	HS	Approved
DM70BU5	SN	Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
DM70BU5	TC	Immunosuppressive Agents
DM70BU5	DT	Small molecular drug
DM70BU5	PC	5426
DM70BU5	MW	258.23
DM70BU5	FM	C13H10N2O4
DM70BU5	IC	InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
DM70BU5	CS	C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
DM70BU5	IK	UEJJHQNACJXSKW-UHFFFAOYSA-N
DM70BU5	IU	2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
DM70BU5	CA	CAS 50-35-1
DM70BU5	CB	CHEBI:74947
DM70BU5	DE	Multiple myeloma

DMM8D3F	ID	DMM8D3F
DMM8D3F	DN	Theobromine
DMM8D3F	HS	Approved
DMM8D3F	SN	theobromine; 83-67-0; 3,7-Dimethylxanthine; Diurobromine; Teobromin; Theostene; Theosalvose; Santheose; Thesodate; Thesal; 3,7-dimethylpurine-2,6-dione; 3,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; Theobromin; Xanthine, 3,7-dimethyl-; 3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-; SC 15090; 2,6-Dihydroxy-3,7-dimethylpurine; Theobromine (natural); UNII-OBD445WZ5P; NSC 5039; 7-Dimethylxanthine; 2,6-Dihydroxy-3,7-dimethyl-purine; BRN 0016464; FEMA No. 3591; CCRIS 2350; HSDB 7332
DMM8D3F	DT	Small molecular drug
DMM8D3F	PC	5429
DMM8D3F	MW	180.16
DMM8D3F	FM	C7H8N4O2
DMM8D3F	IC	InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13)
DMM8D3F	CS	CN1C=NC2=C1C(=O)NC(=O)N2C
DMM8D3F	IK	YAPQBXQYLJRXSA-UHFFFAOYSA-N
DMM8D3F	IU	3,7-dimethylpurine-2,6-dione
DMM8D3F	CA	CAS 83-67-0
DMM8D3F	CB	CHEBI:28946
DMM8D3F	DE	Asthma

DMRJFN9	ID	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	HS	Approved
DMRJFN9	SN	Bronchoretard; Cetraphylline; Chronophyllin; Dimethylxanthine; Elixophylline; Liquophylline; Pseudotheophylline; Afonilum Retard; Bronchodid Duracap; Elixophyllin SR; Somophyllin CRT; Spophyllin retard; Telbans DrySyrup; Teofilina [Polish]; Theal tablets; Theobid Duracap; Theodur Dry Syrup; Uniphyllin continus; Elixophyllin (TN); Elixophyllin(e); Pulmo-Timelets; Somophyllin-CRT; Somophyllin-DF; Theo-Organidin; Theoclear-200; Theodur G (TN); Theolair (TN); Theophylline (JP15); Theophylline-SR; Quibron-t (TN); Theo-Dur-Sprinkle; Theophylline-[8-3H; Theoclear L.A.-130; 1,3 Dimethylxanthine; 1,3-Dimethylxanthine; 1H-purine-2,6-dione
DMRJFN9	CP	Purdue Pharma
DMRJFN9	TC	Bronchodilator Agents
DMRJFN9	DT	Small molecular drug
DMRJFN9	PC	2153
DMRJFN9	MW	180.16
DMRJFN9	FM	C7H8N4O2
DMRJFN9	IC	InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)
DMRJFN9	CS	CN1C2=C(C(=O)N(C1=O)C)NC=N2
DMRJFN9	IK	ZFXYFBGIUFBOJW-UHFFFAOYSA-N
DMRJFN9	IU	1,3-dimethyl-7H-purine-2,6-dione
DMRJFN9	CA	CAS 58-55-9
DMRJFN9	CB	CHEBI:28177
DMRJFN9	DE	Chronic obstructive pulmonary disease

DM7YCK3	ID	DM7YCK3
DM7YCK3	DN	Thiabendazole
DM7YCK3	HS	Approved
DM7YCK3	SN	Biogard; Bioguard; Bovizole; Cropasal; Drawipas; Eprofil; Equizole; Hymush; Lombristop; Mertec; Mertect; Mintesol; Mintezol; Mintezole; Minzolum; Mycozol; Nemacin; Nemapan; Omnizole; Ormogal; Pitrizet; Polival; RPH; Sistesan; Storite; Tbdz; Tebuzate; Tecto; Testo; Thiaben; Thiabendazol; Thiabendazolum; Thiabendole; Thiabenzazole; Thiabenzole; Thibendole; Thibenzol; Thibenzole; Thiprazole; Tiabenda; Tiabendazol; Tiabendazole; Tiabendazolum; Tobaz; Tresaderm; Triasox; Tubazole; Captan T; Equivet TZ; Equizole A; Helmindrax octelmin; Hokustar HP; Mertect lsp; RTU Flowable Fungicide; Tecto B; Tecto rph; Thibenzole att; Top Form Wormer; Chemviron TK 100; G 491; MK 360; Mertect 160; Mertect 340f; Metasol TK 100; Metasol tk 10; PS1057_SUPELCO; Sanaizol 100; Syntol M100; TBZ 6; TBZ 60W; Tecto 10P; Tecto 40F; Tecto 60; Thibenzole 200; Tibimix 20; APL-luster; Arbotect (TN); MK-360; Metasol TK-100; Mintezol (TN); TBZ-6; Thiabendazole (USP); Thiabendazole [BSI:ISO]; Thiabendazole [USAN:BAN]; Tiabendazolum [INN-Latin]; Tresaderm (TN); E-Z-Ex; Mintezol, Equizole, Thiabendazole; Tiabendazol [INN-Spanish, French]; Tiabendazole (JAN/INN); 2-(1,3-Thiazol-4-yl)-1H-benzimidazole; 2-(1,3-Thiazol-4-yl)benzimidazole; 2-(1,3-thiazol-4-yl)-1H-1,3-benzodiazole; 2-(4'-Thiazolyl)benzimidazole; 2-(4-Thiazolyl)-1H-benzimidazole; 2-(4-Thiazolyl)benzimidazole; 2-(Thiazol-4-yl)benzimidazole; 2-Thiazol-4-yl-1H-benzoimidazole; 2-Thiazole-4-ylbenzimidazole; 2-[4-Thiazoly]benzimidazole; 4-(1H-benzimidazol-2-yl)-1,3-thiazole; 4-(2-Benzimidazolyl)thiazole
DM7YCK3	TC	Antinematodal Agents
DM7YCK3	DT	Small molecular drug
DM7YCK3	PC	5430
DM7YCK3	MW	201.25
DM7YCK3	FM	C10H7N3S
DM7YCK3	IC	InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)
DM7YCK3	CS	C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3
DM7YCK3	IK	WJCNZQLZVWNLKY-UHFFFAOYSA-N
DM7YCK3	IU	4-(1H-benzimidazol-2-yl)-1,3-thiazole
DM7YCK3	CA	CAS 148-79-8
DM7YCK3	CB	CHEBI:45979
DM7YCK3	DE	Helminth infection; Dutch elm disease

DMDRKH2	ID	DMDRKH2
DMDRKH2	DN	Thiamphenicol
DMDRKH2	HS	Approved
DMDRKH2	SN	thiamphenicol; 15318-45-3; Thiophenicol; Thiamcol; (+)-Thiamphenicol; Raceophenidol; Dextrosulphenidol; Thiamphenicolum; D-Thiocymetin; D-Thiophenicol; Thiocymetin (TN); Armai (TN); Thiocymetin; Tiamfenicolo [DCIT]; UNII-FLQ7571NPM; Tiamfenicol [INN-Spanish]; Thiamphenicol (Thiophenicol); Macphenicol; C12H15Cl2NO5S; Urfamycine; Igralin; Hyrazin; Dexawin; Rincrol; Neomyson; Urfamicina; Thiamphenicolum [INN-Latin]; Descocin; Masatirin; Efnicol; SW 5063; Unaseran-D; Thiamphenicol [USAN:INN:BAN:JAN]; EINECS 239-355-3; RACEPHENICOL; WIN-5063-2
DMDRKH2	DT	Small molecular drug
DMDRKH2	PC	27200
DMDRKH2	MW	356.2
DMDRKH2	FM	C12H15Cl2NO5S
DMDRKH2	IC	InChI=1S/C12H15Cl2NO5S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-16)15-12(18)11(13)14/h2-5,9-11,16-17H,6H2,1H3,(H,15,18)/t9-,10-/m1/s1
DMDRKH2	CS	CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O
DMDRKH2	IK	OTVAEFIXJLOWRX-NXEZZACHSA-N
DMDRKH2	IU	2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide
DMDRKH2	CA	CAS 15318-45-3
DMDRKH2	CB	CHEBI:32215
DMDRKH2	DE	Bacterial infection

DMHDF7B	ID	DMHDF7B
DMHDF7B	DN	Thiamylal
DMHDF7B	HS	Approved
DMHDF7B	SN	Surital; Thioquinalbarbitone; Thioseconal; Thiamylal [USAN]; Surital (TN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN) (8CI); Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione; Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6-(1H,5H)-pyrimidinedione; 4,6(1H,5H)-Pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-(9CI); 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione; 5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-Allyl-5-(1-methylbutyl)-2-thiobarbitursaeure; 5-Allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione; 5-allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMHDF7B	TC	Hypnotics and Sedatives
DMHDF7B	DT	Small molecular drug
DMHDF7B	PC	3032285
DMHDF7B	MW	254.35
DMHDF7B	FM	C12H18N2O2S
DMHDF7B	IC	InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
DMHDF7B	CS	CCCC(C)C1(C(=O)NC(=S)NC1=O)CC=C
DMHDF7B	IK	XLOMZPUITCYLMJ-UHFFFAOYSA-N
DMHDF7B	IU	5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMHDF7B	CA	CAS 77-27-0
DMHDF7B	CB	CHEBI:9536
DMHDF7B	DE	Anaesthesia

DMC1NBW	ID	DMC1NBW
DMC1NBW	DN	Thiazolidinedione
DMC1NBW	HS	Approved
DMC1NBW	SN	2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487
DMC1NBW	DT	Small molecular drug
DMC1NBW	PC	5437
DMC1NBW	MW	117.13
DMC1NBW	FM	C3H3NO2S
DMC1NBW	IC	InChI=1S/C3H3NO2S/c5-2-1-7-3(6)4-2/h1H2,(H,4,5,6)
DMC1NBW	CS	C1C(=O)NC(=O)S1
DMC1NBW	IK	ZOBPZXTWZATXDG-UHFFFAOYSA-N
DMC1NBW	IU	1,3-thiazolidine-2,4-dione
DMC1NBW	CA	CAS 2295-31-0
DMC1NBW	CB	CHEBI:50992
DMC1NBW	DE	Alzheimer disease

DMU3IET	ID	DMU3IET
DMU3IET	DN	Thiethylperazine
DMU3IET	HS	Approved
DMU3IET	SN	ETHYLTHIOPERAZINE; Theithylperazine; Thiethylperazinum; Thiethylpipezazine; Thioethylperazine; Tietilperazina; Torecan; Tietilperazina [DCIT]; Thiethylperazinum [INN-Latin]; Torecan (TN); Thiethylperazine (USAN/INN); Thiethylperazine [USAN:INN:BAN]; Norzine (*Dimaleate*); GS-95 (*Dimaleate*)
DMU3IET	CP	Norvatis Phamaceuticals Corporation
DMU3IET	TC	Antiemetics
DMU3IET	DT	Small molecular drug
DMU3IET	PC	5440
DMU3IET	MW	399.6
DMU3IET	FM	C22H29N3S2
DMU3IET	IC	InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3
DMU3IET	CS	CCSC1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C
DMU3IET	IK	XCTYLCDETUVOIP-UHFFFAOYSA-N
DMU3IET	IU	2-ethylsulfanyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DMU3IET	CA	CAS 1420-55-9
DMU3IET	CB	CHEBI:9544
DMU3IET	DE	Nausea

DMEPWYA	ID	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	HS	Approved
DMEPWYA	SN	Thiocolchicoside; 602-41-5; Coltramyl; UNII-T1X8S697GT; Thiocolchicine 2-glucoside analog; NSC 147755; Musco-ril; T1X8S697GT; 10-Thiocolchicoside; Tiocolchicoside [DCIT]; Colchicoside, 10-thio-; Thiocolchicoside [INN:DCF]; Q-201823; Thiocolchicosidum [INN-Latin]; Tiocolchicosido [INN-Spanish]; C27H33NO10S; Tiocolchicosido; Tiocolchicoside; Muscoril; Thiocolchicosidum; EINECS 210-017-7; BRN 0072205; R. 271; 2-10-Di(demethoxy)-2-glucosyloxy-10-methylthiocolchicine; Miotens; Coltrax; NSC147755; Coltramyl (TN); NCGC00016519-01
DMEPWYA	DT	Small molecular drug
DMEPWYA	PC	9915886
DMEPWYA	MW	563.6
DMEPWYA	FM	C27H33NO10S
DMEPWYA	IC	InChI=1S/C27H33NO10S/c1-12(30)28-16-7-5-13-9-18(37-27-24(34)23(33)22(32)19(11-29)38-27)25(35-2)26(36-3)21(13)14-6-8-20(39-4)17(31)10-15(14)16/h6,8-10,16,19,22-24,27,29,32-34H,5,7,11H2,1-4H3,(H,28,30)/t16-,19+,22+,23-,24+,27+/m0/s1
DMEPWYA	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DMEPWYA	IK	LEQAKWQJCITZNK-AXHKHJLKSA-N
DMEPWYA	IU	N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMEPWYA	CA	CAS 602-41-5
DMEPWYA	CB	CHEBI:94557
DMEPWYA	DE	Muscle spasm

DM7NKEV	ID	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	HS	Approved
DM7NKEV	SN	6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)
DM7NKEV	CP	Glaxo Smith Kline Pharmaceuticals
DM7NKEV	TC	Anticancer Agents
DM7NKEV	DT	Small molecular drug
DM7NKEV	PC	2723601
DM7NKEV	MW	167.19
DM7NKEV	FM	C5H5N5S
DM7NKEV	IC	InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
DM7NKEV	CS	C1=NC2=C(N1)C(=S)N=C(N2)N
DM7NKEV	IK	WYWHKKSPHMUBEB-UHFFFAOYSA-N
DM7NKEV	IU	2-amino-3,7-dihydropurine-6-thione
DM7NKEV	CA	CAS 154-42-7
DM7NKEV	CB	CHEBI:9555
DM7NKEV	DE	Acute myeloid leukaemia

DMGP8AX	ID	DMGP8AX
DMGP8AX	DN	Thiopental
DMGP8AX	HS	Approved
DMGP8AX	SN	Intraval; Penthiobarbital; Pentothiobarbital; Thiomebumal; Thionembutal; Thiopentobarbital; Thiopentobarbitone; Thiopentone; Thiothal; Tiopentale; Trapanal; Thiopental [BAN]; Thiopental solution; Thiopentobarbituric acid; Tiopentale [Italian]; Sodium Pentothal (TN); Thiopental (TN); Thiopentone sodium (TN); Trapanal (TN); (+-)-Thiopental; (+/-)-THIOPENTAL; (+/-)-Thiopental solution; 2-Thio-5-ethyl-5-sec-pentylbarbituric acid; 4,6,(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-(9CI); 5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione; 5-Ethyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-ethyl-2-mercapto-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMGP8AX	CP	Abbott Laboratories
DMGP8AX	TC	Hypnotics and Sedatives
DMGP8AX	DT	Small molecular drug
DMGP8AX	PC	3000715
DMGP8AX	MW	242.34
DMGP8AX	FM	C11H18N2O2S
DMGP8AX	IC	InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DMGP8AX	CS	CCCC(C)C1(C(=O)NC(=S)NC1=O)CC
DMGP8AX	IK	IUJDSEJGGMCXSG-UHFFFAOYSA-N
DMGP8AX	IU	5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMGP8AX	CA	CAS 76-75-5
DMGP8AX	CB	CHEBI:102166
DMGP8AX	DE	Anaesthesia

DM35M8J	ID	DM35M8J
DM35M8J	DN	Thioridazine
DM35M8J	HS	Approved
DM35M8J	SN	Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine
DM35M8J	CP	Norvatis Phamaceuticals Corporation
DM35M8J	TC	Antipsychotic Agents
DM35M8J	DT	Small molecular drug
DM35M8J	PC	5452
DM35M8J	MW	370.6
DM35M8J	FM	C21H26N2S2
DM35M8J	IC	InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
DM35M8J	CS	CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
DM35M8J	IK	KLBQZWRITKRQQV-UHFFFAOYSA-N
DM35M8J	IU	10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine
DM35M8J	CA	CAS 50-52-2
DM35M8J	CB	CHEBI:9566
DM35M8J	DE	Schizophrenia

DMIZKOP	ID	DMIZKOP
DMIZKOP	DN	Thiotepa
DMIZKOP	HS	Approved
DMIZKOP	SN	thiotepa; THIO-TEPA; 52-24-4; Triethylenethiophosphoramide; Thiophosphamide; Tiofosyl; Tiofosfamid; Thiofozil; Tiofozil; Thioplex; Tespamin; Oncotepa; Tespamine; Girostan; Thiotef; Stepa; Tio-tef; Thio-Tep; Oncotiotepa; Tifosyl; Oncothio-tepa; TESPA; TSPA; Thio-tepa S; Ledertepa; Thiotriethylenephosphoramide; TIO TEF; N,N',N''-Triethylenethiophosphoramide; Tris(1-aziridinyl)phosphine sulfide; Thiophosphamidum; 1,1',1''-phosphorothioyltriaziridine; Triethylene thiophosphoramide; Triaziridinylphosphine sulfide
DMIZKOP	DT	Small molecular drug
DMIZKOP	PC	5453
DMIZKOP	MW	189.22
DMIZKOP	FM	C6H12N3PS
DMIZKOP	IC	InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2
DMIZKOP	CS	C1CN1P(=S)(N2CC2)N3CC3
DMIZKOP	IK	FOCVUCIESVLUNU-UHFFFAOYSA-N
DMIZKOP	IU	tris(aziridin-1-yl)-sulfanylidene-lambda5-phosphane
DMIZKOP	CA	CAS 52-24-4
DMIZKOP	CB	CHEBI:9570
DMIZKOP	DE	Breast cancer

DMDINC4	ID	DMDINC4
DMDINC4	DN	Thiothixene
DMDINC4	HS	Approved
DMDINC4	SN	Navan; Navane; Navaron; Orbinamon; Thiothixine; Tiotixene; Tiotixeno; Tiotixenum; Thiothixene hydrochloride; P 4657B; CP 12252-1; Cis-Thiothixene; Navane (TN); P-4657 B; P-4657A; P-4657B; Thiothixene (USP); Thiothixene (Z); Thiothixene Hydrochloride (base); Thiothixene [USAN:BAN]; Tiotixene (JAN); Tiotixeno [INN-Spanish]; Tiotixenum [INN-Latin]; Trans-Thiothixene; P-4657-B; CP-12,252-1; CP-12,252-1 base; {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide; N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (E)-Thiothixene; 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene
DMDINC4	CP	Pfizer Pharmaceuticals
DMDINC4	TC	Antipsychotic Agents
DMDINC4	DT	Small molecular drug
DMDINC4	PC	941651
DMDINC4	MW	443.6
DMDINC4	FM	C23H29N3O2S2
DMDINC4	IC	InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-
DMDINC4	CS	CN1CCN(CC1)CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
DMDINC4	IK	GFBKORZTTCHDGY-UWVJOHFNSA-N
DMDINC4	IU	(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide
DMDINC4	CA	CAS 3313-26-6
DMDINC4	CB	CHEBI:9571
DMDINC4	DE	Schizophrenia

DM2P6VD	ID	DM2P6VD
DM2P6VD	DN	Thrombin/fibrinogen matrix patch
DM2P6VD	HS	Approved
DM2P6VD	SN	Evicel; Thrombin; Biological Hemostatic Dressing; Fibrin Fleece; Fibrin Pad; Fibrin Patch; Fleece Fibrin Patch; Fibrin sealant, Omrix/ Ethicon; Fibrinogen, Omrix/Ethicon; Thrombin/fibrinogen matrix patch (surgical bleeding); Fibrin matrix patch (surgical bleeding), Omrix/Ethicon; Thrombin/fibrinogen matrixpatch (surgical bleeding), Omrix/Ethicon
DM2P6VD	CP	OMRIX Biopharmaceuticals SA
DM2P6VD	DE	Bleeding disorder

DMJ47QC	ID	DMJ47QC
DMJ47QC	DN	Thyrotropin
DMJ47QC	HS	Approved
DMJ47QC	SN	Thytropar
DMJ47QC	CP	Sanofi Aventis Us Llc
DMJ47QC	DE	Hypothyroidism

DMMYLTI	ID	DMMYLTI
DMMYLTI	DN	Thyrotropin Alfa
DMMYLTI	HS	Approved
DMMYLTI	TC	Diagnostic Agents
DMMYLTI	SQ	Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>    <sequence format="FASTA">&gt;Beta chainFCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYRTVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY
DMMYLTI	DE	Thyroid cancer

DMKSQG0	ID	DMKSQG0
DMKSQG0	DN	Tiagabine
DMKSQG0	HS	Approved
DMKSQG0	SN	tiagabine; 115103-54-3; Gabitril; Tiagabinum; Tiagabina; (R)-Tiagabine; Tiagabinum [INN-Latin]; Tiagabina [INN-Spanish]; Tiagabine [INN:BAN]; Tiagabine [INN]; Abbott-70569; UNII-Z80I64HMNP; Tiagabine (INN); ABBOTT-70569-1; Gabitril (TN); CHEMBL1027; Z80I64HMNP; ABT-569; CHEBI:9586; NO-328; (-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid; A-70569-1; (R)-1-(4,4-Bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid; Gabatril; NO 329;  Gabitril; NO-329; Tiagabina [INN-Spanish];Tiagabine (INN); N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid; (3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid; (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid; [3H]tiagabine
DMKSQG0	CP	Cephalon
DMKSQG0	TC	Anticonvulsants
DMKSQG0	DT	Small molecular drug
DMKSQG0	PC	60648
DMKSQG0	MW	375.6
DMKSQG0	FM	C20H25NO2S2
DMKSQG0	IC	InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1
DMKSQG0	CS	CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(=O)O)C3=C(C=CS3)C
DMKSQG0	IK	PBJUNZJWGZTSKL-MRXNPFEDSA-N
DMKSQG0	IU	(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid
DMKSQG0	CA	CAS 115103-54-3
DMKSQG0	CB	CHEBI:9586
DMKSQG0	DE	Epilepsy; Anxiety disorder

DMYN8MA	ID	DMYN8MA
DMYN8MA	DN	Tianeptine
DMYN8MA	HS	Approved
DMYN8MA	SN	Tianeptina; Tianeptinum; Tianeptine Acid; Tianeptine [INN]; Stablon (TN); Tianeptine (INN); (1)-7-((3-Chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid S,S-dioxide; 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid; 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid
DMYN8MA	DT	Small molecular drug
DMYN8MA	PC	68870
DMYN8MA	MW	437
DMYN8MA	FM	C21H25ClN2O4S
DMYN8MA	IC	InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26)
DMYN8MA	CS	CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O
DMYN8MA	IK	JICJBGPOMZQUBB-UHFFFAOYSA-N
DMYN8MA	IU	7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid
DMYN8MA	CA	CAS 72797-41-2
DMYN8MA	CB	CHEBI:91749
DMYN8MA	DE	Major depressive disorder

DMN6CAG	ID	DMN6CAG
DMN6CAG	DN	Tiapride
DMN6CAG	HS	Approved
DMN6CAG	SN	tiapride; 51012-32-9; Thiapride; Tiapridal; N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)benzamide; Tiapridum [INN-Latin]; Tiaprida [INN-Spanish]; UNII-LAH70H9JPH; FLO 1347; Tiapride [INN:BAN:DCF]; Tiapride HCl; EINECS 256-907-9; LAH70H9JPH; BRN 2390588; JTVPZMFULRWINT-UHFFFAOYSA-N; BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-2-METHOXY-5-(METHYLSULFONYL)-; N-(2-(Diethylamino)ethyl)-5-(methylsulfonyl)-o-anisamide; Tiapridum; Tiaprida; Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)-; NCGC00015996-02; SPI-860
DMN6CAG	DT	Small molecular drug
DMN6CAG	PC	5467
DMN6CAG	MW	328.4
DMN6CAG	FM	C15H24N2O4S
DMN6CAG	IC	InChI=1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)
DMN6CAG	CS	CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC
DMN6CAG	IK	JTVPZMFULRWINT-UHFFFAOYSA-N
DMN6CAG	IU	N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide
DMN6CAG	CA	CAS 51012-32-9
DMN6CAG	CB	CHEBI:94666
DMN6CAG	DE	Alcohol dependence; Neuropathic pain

DM23D7J	ID	DM23D7J
DM23D7J	DN	Tiaprofenic acid
DM23D7J	HS	Approved
DM23D7J	SN	Surgam; Tiaprofensaeure; Acide tiaprofenique; Acido tiaprofenico; Acidum tiaprofenicum; Surgam SR; FC 3001; RU 15060; Acide tiaprofenique [INN-French]; Acido tiaprofenico [INN-Spanish]; Acidum tiaprofenicum [INN-Latin]; Apo-Tiaprofenic Tablets; Dom-tiaprofenic; Surgam (TN); Surgamyl (TN); Tiaprofen (TN); Tiaprofenic acid (JAN/INN); Tiaprofenic-200-Tab; Tiaprofenic-300-Tab; Tiaprofenic acid [INN:BAN:DCF:JAN]; Alpha-methyl-5-benzoyl-2-thienylacetic acid; 2-(5-Benzyl-2-thienyl)propionsaeure; 2-(5-benzoylthiophen-2-yl)propanoic acid; 2-[5-(phenylcarbonyl)-2-thienyl]propanoic acid; 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid; 5-benzoyl-alpha-methylthiophene-2-acetic acid
DM23D7J	TC	Analgesics
DM23D7J	DT	Small molecular drug
DM23D7J	PC	5468
DM23D7J	MW	260.31
DM23D7J	FM	C14H12O3S
DM23D7J	IC	InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)
DM23D7J	CS	CC(C1=CC=C(S1)C(=O)C2=CC=CC=C2)C(=O)O
DM23D7J	IK	GUHPRPJDBZHYCJ-UHFFFAOYSA-N
DM23D7J	IU	2-(5-benzoylthiophen-2-yl)propanoic acid
DM23D7J	CA	CAS 33005-95-7
DM23D7J	CB	CHEBI:32221
DM23D7J	DE	Pain

DM5JWV9	ID	DM5JWV9
DM5JWV9	DN	Tiazofurin
DM5JWV9	HS	Approved
DM5JWV9	SN	Riboxamide; TCAR; TIZ; Tiazofurina; Tiazofurine; Tiazofurinum; Tiazole; Tiazofurin [USAN]; Tiazofurina [Spanish]; Tiazofurinum [Latin]; Cpd-5825; Tiazofurin (USAN); Tiazofurine (INN); 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide; 2-beta-D-Ribofuranosyl-4-thiazolecarboxamide; 2-ribofuranosylthiazole-4-carboxamide
DM5JWV9	TC	Anticancer Agents
DM5JWV9	DT	Small molecular drug
DM5JWV9	PC	457954
DM5JWV9	MW	260.269
DM5JWV9	FM	C9H12N2O5S
DM5JWV9	IC	InChI=1S/C9H12N2O5S/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1
DM5JWV9	CS	C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DM5JWV9	IK	FVRDYQYEVDDKCR-DBRKOABJSA-N
DM5JWV9	IU	2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide
DM5JWV9	CA	CAS 60084-10-8
DM5JWV9	CB	CHEBI:90239
DM5JWV9	DE	Solid tumour/cancer

DM78XFG	ID	DM78XFG
DM78XFG	DN	Tibolone
DM78XFG	HS	Approved
DM78XFG	SN	Livial (TN)
DM78XFG	DT	Small molecular drug
DM78XFG	PC	444008
DM78XFG	MW	312.4
DM78XFG	FM	C21H28O2
DM78XFG	IC	InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1
DM78XFG	CS	C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O
DM78XFG	IK	WZDGZWOAQTVYBX-XOINTXKNSA-N
DM78XFG	IU	(7R,8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DM78XFG	CA	CAS 5630-53-5
DM78XFG	CB	CHEBI:32223
DM78XFG	DE	Anabolic metabolism

DM4ME02	ID	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	HS	Approved
DM4ME02	SN	TIPC; Ticarcilina; Ticarcilline; Ticarcillinum; Ticarcillin Supplement; Ticillin [veterinary]; BRL-2288; Ticarcilina[INN-Spanish]; Ticarcillin (INN); Ticarcillin [INN:BAN]; Ticarcilline [INN-French]; Ticarcillinum [INN-Latin]; Ticillin [veterinary] (TN); Timentin (TN); A-carboxy-3-thienylmethylpenicillin; Alpha-carboxy-3-thienylmethylpenicillin; (2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-thiophen-3-ylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-2,2-dimethylpenam-3alpha-carboxylic acid
DM4ME02	CP	GlaxoSmithKline
DM4ME02	TC	Antibiotics
DM4ME02	DT	Small molecular drug
DM4ME02	PC	36921
DM4ME02	MW	384.4
DM4ME02	FM	C15H16N2O6S2
DM4ME02	IC	InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1
DM4ME02	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CSC=C3)C(=O)O)C(=O)O)C
DM4ME02	IK	OHKOGUYZJXTSFX-KZFFXBSXSA-N
DM4ME02	IU	(2S,5R,6R)-6-[[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM4ME02	CA	CAS 34787-01-4
DM4ME02	CB	CHEBI:9587
DM4ME02	DE	Bacterial infection

DMO946V	ID	DMO946V
DMO946V	DN	Ticlopidine
DMO946V	HS	Approved
DMO946V	SN	Ticlid; Ticlopidina; Ticlopidinum; PCR 5332; Ticlid (TN); Ticlopidin-Puren; Ticlopidina [INN-Spanish]; Ticlopidine (INN); Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidin-Puren (TN); 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
DMO946V	TC	Fibrinolytic Agents
DMO946V	DT	Small molecular drug
DMO946V	PC	5472
DMO946V	MW	263.8
DMO946V	FM	C14H14ClNS
DMO946V	IC	InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
DMO946V	CS	C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
DMO946V	IK	PHWBOXQYWZNQIN-UHFFFAOYSA-N
DMO946V	IU	5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
DMO946V	CA	CAS 55142-85-3
DMO946V	CB	CHEBI:9588
DMO946V	DE	Stroke

DMLE7IO	ID	DMLE7IO
DMLE7IO	DN	Tigecycline
DMLE7IO	HS	Approved
DMLE7IO	SN	Tigilcycline; Tygacil; Tigecycline [USAN]; GAR 936; GAR-936; TBG-MINO; Tygacil (TN); Tygacil(TM); GAR-936,Tigecycline; Tigecycline (JAN/USAN); WAY-GAR-936; Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline; N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide; (4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide; (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 9-t-Butylglycylamido minocycline
DMLE7IO	CP	Wyeth Pharmaceuticals
DMLE7IO	TC	Antibiotics
DMLE7IO	DT	Small molecular drug
DMLE7IO	PC	54686904
DMLE7IO	MW	585.6
DMLE7IO	FM	C29H39N5O8
DMLE7IO	IC	InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36-37,40,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1
DMLE7IO	CS	CC(C)(C)NCC(=O)NC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
DMLE7IO	IK	SOVUOXKZCCAWOJ-HJYUBDRYSA-N
DMLE7IO	IU	(4S,4aS,5aR,12aR)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMLE7IO	CA	CAS 220620-09-7
DMLE7IO	CB	CHEBI:149836
DMLE7IO	DE	Skin infection

DMLW9HG	ID	DMLW9HG
DMLW9HG	DN	Tildrakizumab
DMLW9HG	HS	Approved
DMLW9HG	SN	UNII-DEW6X41BEK; DEW6X41BEK; Tildrakizumab [USAN:INN]; SCH 900222
DMLW9HG	CP	Sun Pharma
DMLW9HG	DT	Antibody
DMLW9HG	DE	Plaque psoriasis

DMJW0VS	ID	DMJW0VS
DMJW0VS	DN	Tilidine
DMJW0VS	HS	Approved
DMJW0VS	SN	Valoron; Tilidine hydrochloride hemihydrate; 255733-17-6; Tilidine hydrochloride hemihydrate [EP]; DTXSID70180262; Ethyl (1RS,2SR)-2-(dimethylamino)-1-phenylcyclohex-3-enecarboxylate hydrochloride hemihydrate; 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, hydrochloride, hydrate (2:2:1), (1R,2S)-rel-; UNII-Y757T3419R component WHYVWQHDUOALSV-UMJMSJQKSA-N
DMJW0VS	DT	Small molecular drug
DMJW0VS	PC	30131
DMJW0VS	MW	273.37
DMJW0VS	FM	C17H23NO2
DMJW0VS	IC	InChI=1S/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m1/s1
DMJW0VS	CS	CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2=CC=CC=C2
DMJW0VS	IK	WDEFBBTXULIOBB-WBVHZDCISA-N
DMJW0VS	IU	ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate
DMJW0VS	CA	CAS 51931-66-9
DMJW0VS	CB	CHEBI:77822
DMJW0VS	DE	Pain

DM3NXRU	ID	DM3NXRU
DM3NXRU	DN	Timolol
DM3NXRU	HS	Approved
DM3NXRU	SN	Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol
DM3NXRU	CP	Merck Frosst
DM3NXRU	TC	Antiarrhythmic Agents
DM3NXRU	DT	Small molecular drug
DM3NXRU	PC	33624
DM3NXRU	MW	316.42
DM3NXRU	FM	C13H24N4O3S
DM3NXRU	IC	InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
DM3NXRU	CS	CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O
DM3NXRU	IK	BLJRIMJGRPQVNF-JTQLQIEISA-N
DM3NXRU	IU	(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
DM3NXRU	CA	CAS 26839-75-8
DM3NXRU	CB	CHEBI:9599
DM3NXRU	DE	High blood pressure

DM3OWT4	ID	DM3OWT4
DM3OWT4	DN	Tindamax
DM3OWT4	HS	Approved
DM3OWT4	SN	Tinidazole (oral), Mission Pharmacal
DM3OWT4	CP	Presutti Laboratories
DM3OWT4	DT	Small molecular drug
DM3OWT4	PC	5479
DM3OWT4	MW	247.27
DM3OWT4	FM	C8H13N3O4S
DM3OWT4	IC	InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3
DM3OWT4	CS	CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C
DM3OWT4	IK	HJLSLZFTEKNLFI-UHFFFAOYSA-N
DM3OWT4	IU	1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole
DM3OWT4	CA	CAS 148159-84-6
DM3OWT4	CB	CHEBI:63627
DM3OWT4	DE	Bacterial infection

DMNYPGS	ID	DMNYPGS
DMNYPGS	DN	Tioconazole
DMNYPGS	HS	Approved
DMNYPGS	SN	Fungibacid; GyneCure; Tioconazol; Tioconazolum; Trosyd; Trosyl; Vagistat; Zoniden; Trosyd AF; Trosyd J; Monistat 1; UK 20349; Gyno-trosyd; Tioconazol [INN-Spanish]; Tioconazolum [INN-Latin]; Tz-3; UK 20,349; UK-20349; Vagistat-1; Vagistat-1 (TN); Tioconazole (JAN/USP/INN); Tioconazole [USAN:BAN:INN:JAN]; (+-)-1-(2,4-Dichloro-beta-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole; (+-)-1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-(2,4-Dichloro-(beta-(2-chloro-3-thenyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2-chloro-3-thenyl)-oxy)phenethyl)imidazole; 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMNYPGS	TC	Antifungal Agents
DMNYPGS	DT	Small molecular drug
DMNYPGS	PC	5482
DMNYPGS	MW	387.7
DMNYPGS	FM	C16H13Cl3N2OS
DMNYPGS	IC	InChI=1S/C16H13Cl3N2OS/c17-12-1-2-13(14(18)7-12)15(8-21-5-4-20-10-21)22-9-11-3-6-23-16(11)19/h1-7,10,15H,8-9H2
DMNYPGS	CS	C1=CC(=C(C=C1Cl)Cl)C(CN2C=CN=C2)OCC3=C(SC=C3)Cl
DMNYPGS	IK	QXHHHPZILQDDPS-UHFFFAOYSA-N
DMNYPGS	IU	1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMNYPGS	CA	CAS 65899-73-2
DMNYPGS	CB	CHEBI:77898
DMNYPGS	DE	Onychomycosis

DMFDC0Q	ID	DMFDC0Q
DMFDC0Q	DN	Tiotropium
DMFDC0Q	HS	Approved
DMFDC0Q	SN	186691-13-4; UNII-0EB439235F; 0EB439235F; [3H]tiotropium; (1r,2r,4s,5s,7s)-7-{[hydroxy(Dithiophen-2-Yl)acetyl]oxy}-9,9-Dimethyl-3-Oxa-9-Azoniatricyclo[3310~2,4~]nonane; NCGC00167971-01; 0HK; (1R,2R,4S,5S)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3310^{2,4}]nonan-9-ium; GTPL367; SCHEMBL4662461; GTPL8592; DTXSID5044281; CHEMBL3305968; Spiriva (TN); Tiotropium bromide [USAN:INN]; (1A,2A,4A,5A,7A)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatri-cyclo[331024]nonane bromide; (1a,2,4,5a,7)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide; 7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide
DMFDC0Q	CP	Boehringer Ingelheim
DMFDC0Q	TC	Bronchodilator Agents
DMFDC0Q	DT	Small molecular drug
DMFDC0Q	PC	5487427
DMFDC0Q	MW	392.5
DMFDC0Q	FM	C19H22NO4S2+
DMFDC0Q	IC	InChI=1S/C19H22NO4S2/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15/h3-8,11-13,16-17,22H,9-10H2,1-2H3/q+1/t11?,12-,13+,16-,17+
DMFDC0Q	CS	C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C
DMFDC0Q	IK	LERNTVKEWCAPOY-FPISHFTHSA-N
DMFDC0Q	IU	[(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate
DMFDC0Q	CA	CAS 186691-13-4
DMFDC0Q	CB	CHEBI:90960
DMFDC0Q	DE	Chronic obstructive pulmonary disease

DM8HJX6	ID	DM8HJX6
DM8HJX6	DN	Tipranavir
DM8HJX6	HS	Approved
DM8HJX6	SN	Aptivus; TPV; PNU 140690; U 140690; Aptivus (Boehringer Ingelheim); Aptivus (TN); Aptivus(TM); PNU-140690; PNU-140690E; Tipranavir (INN); U-140690; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE
DM8HJX6	CP	Boehriger Ingelheim
DM8HJX6	TC	Anti-HIV Agents
DM8HJX6	DT	Small molecular drug
DM8HJX6	PC	54682461
DM8HJX6	MW	602.7
DM8HJX6	FM	C31H33F3N2O5S
DM8HJX6	IC	InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
DM8HJX6	CS	CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4
DM8HJX6	IK	SUJUHGSWHZTSEU-FYBSXPHGSA-N
DM8HJX6	IU	N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
DM8HJX6	CA	CAS 174484-41-4
DM8HJX6	CB	CHEBI:63628
DM8HJX6	DE	Human immunodeficiency virus infection

DMJNV4O	ID	DMJNV4O
DMJNV4O	DN	Tirbanibulin
DMJNV4O	HS	Approved
DMJNV4O	SN	KX2-391; 897016-82-9; KX-01; UNII-4V9848RS5G; N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide; KX-2-391; CHEMBL571546; 4V9848RS5G; KX2391; KX 01; KX-2391; MLS006011272; SCHEMBL153779; KX01; GTPL7957; DTXSID30237862; MolPort-023-293-512; HUNGUWOZPQBXGX-UHFFFAOYSA-N; HMS3656J15; EX-A2434; BCP02845; ZINC43152787; s2700; BDBM50303801; AKOS027276392; KX2-391; KX-01; SB16619; CS-0248; KX2-391 (KX01); BCP9000828; 2-Pyridineacetamide, 5-(4-(2-(4-morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-; NCGC00346644-05; NCGC00346644-01; KX 2
DMJNV4O	CP	Kinex Pharmaceuticals
DMJNV4O	DT	Small molecular drug
DMJNV4O	PC	23635314
DMJNV4O	MW	431.5
DMJNV4O	FM	C26H29N3O3
DMJNV4O	IC	InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)
DMJNV4O	CS	C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
DMJNV4O	IK	HUNGUWOZPQBXGX-UHFFFAOYSA-N
DMJNV4O	IU	N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide
DMJNV4O	CA	CAS 897016-82-9
DMJNV4O	DE	Prostate cancer; Actinic keratosis

DMQG17S	ID	DMQG17S
DMQG17S	DN	Tirofiban
DMQG17S	HS	Approved
DMQG17S	SN	AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
DMQG17S	CP	Medicure Pharma
DMQG17S	TC	Fibrinolytic Agents
DMQG17S	DT	Small molecular drug
DMQG17S	PC	60947
DMQG17S	MW	440.6
DMQG17S	FM	C22H36N2O5S
DMQG17S	IC	InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
DMQG17S	CS	CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O
DMQG17S	IK	COKMIXFXJJXBQG-NRFANRHFSA-N
DMQG17S	IU	(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
DMQG17S	CA	CAS 144494-65-5
DMQG17S	CB	CHEBI:9605
DMQG17S	DE	Acute coronary syndrome

DMM9BJD	ID	DMM9BJD
DMM9BJD	DN	Tisagenlecleucel
DMM9BJD	HS	Approved
DMM9BJD	SN	Tisagenlecleucel-T
DMM9BJD	CP	Novartis Pharmaceuticals East Hanover, NJ
DMM9BJD	DT	CAR T Cell Therapy
DMM9BJD	DE	Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Acute lymphoblastic leukaemia; Acute myeloid leukaemia

DMGVUO5	ID	DMGVUO5
DMGVUO5	DN	Tislelizumab
DMGVUO5	HS	Approved
DMGVUO5	CP	BeiGene
DMGVUO5	DT	Monoclonal antibody
DMGVUO5	DE	Hepatocellular carcinoma; Hodgkin lymphoma

DMUKC5L	ID	DMUKC5L
DMUKC5L	DN	Tivozanib
DMUKC5L	HS	Approved
DMUKC5L	SN	ASP4130/AV-951
DMUKC5L	CP	Astellas Pharma US; AVEO Pharmaceuticals
DMUKC5L	DT	Small molecular drug
DMUKC5L	PC	9911830
DMUKC5L	MW	454.9
DMUKC5L	FM	C22H19ClN4O5
DMUKC5L	IC	InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
DMUKC5L	CS	CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
DMUKC5L	IK	SPMVMDHWKHCIDT-UHFFFAOYSA-N
DMUKC5L	IU	1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea
DMUKC5L	CA	CAS 475108-18-0
DMUKC5L	CB	CHEBI:91327
DMUKC5L	DE	Renal cell carcinoma

DMR2IQ4	ID	DMR2IQ4
DMR2IQ4	DN	Tizanidine
DMR2IQ4	HS	Approved
DMR2IQ4	SN	Sirdalud; Ternelin; Tizanidina; Tizanidinum; Sirdalud (TN); Tizanidina [INN-Spanish]; Tizanidine (INN); Tizanidine [INN:BAN]; Tizanidinum [INN-Latin]; Zanaflex (TN); 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole; 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole; 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
DMR2IQ4	CP	Elan Pharmaceuticals
DMR2IQ4	TC	Analgesics
DMR2IQ4	DT	Small molecular drug
DMR2IQ4	PC	5487
DMR2IQ4	MW	253.71
DMR2IQ4	FM	C9H8ClN5S
DMR2IQ4	IC	InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)
DMR2IQ4	CS	C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
DMR2IQ4	IK	XFYDIVBRZNQMJC-UHFFFAOYSA-N
DMR2IQ4	IU	5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
DMR2IQ4	CA	CAS 51322-75-9
DMR2IQ4	CB	CHEBI:63629
DMR2IQ4	DE	Spasm

DMUI0CH	ID	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	HS	Approved
DMUI0CH	SN	Aktob; Brulamycin; Distobram; Gotabiotic; NEBRAMYCIN; Nebcin; Nebicin; Obracin; Obramycin; Sybryx; TOY; Tenebrimycin;Tenemycin; Tobacin; Tobi; Tobracin; Tobradex; Tobradistin; Tobralex; Tobramaxin; Tobramicin; Tobramicina; Tobramitsetin; Tobramycetin; Tobramycine; Tobramycinum; Tobrased; Tobrasone; Tobrex; Deoxykanamycin B; Nebramycin VI; TOBRAMYCIN SULFATE; Tobramycin for Inhalation; Tobramycin solution for inhalation; A 12253A; Lilly 47663; NF 6; Nebramycin 6; Nebramycin factir 6; Nebramycin factor 6; Nebcin (Sulfate); SPRC-AB01; TobraDex (TN); Tobracin (TN); Tobramicina [INN-Spanish]; Tobramycin, Free Base; Tobramycine [INN-French]; Tobramycinum [INN-Latin]; Tobrex (TN); Tobramycin (JP15/USP); Tobramycin[USAN:BAN:INN:JAN]; TOA-(1-6)2TB-(4-1)TOC; TOA-(1-6)TOB-(4-1)TOC; 1-Epitobramycin; 3'-Deoxykanamycin B
DMUI0CH	CP	Bausch & Lomb Pharmaceuticals, Inc.
DMUI0CH	TC	Antibiotics
DMUI0CH	DT	Small molecular drug
DMUI0CH	PC	36294
DMUI0CH	MW	467.5
DMUI0CH	FM	C18H37N5O9
DMUI0CH	IC	InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
DMUI0CH	CS	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N
DMUI0CH	IK	NLVFBUXFDBBNBW-PBSUHMDJSA-N
DMUI0CH	IU	(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
DMUI0CH	CA	CAS 32986-56-4
DMUI0CH	CB	CHEBI:28864
DMUI0CH	DE	Bacterial infection

DMYNMDP	ID	DMYNMDP
DMYNMDP	DN	Tocainide
DMYNMDP	HS	Approved
DMYNMDP	SN	Taquidil; Tocainida; Tocainidum; Tonocard; Astra W 36095; Tocainida [INN-Spanish]; Tocainidum [INN-Latin]; W-36095; Tocainide (USAN/INN); Tocainide [USAN:BAN:INN]; Alanyl-2,6-xylidide; N-(2,6-dimethylphenyl)alaninamide; (-)-2-Amino-N-(2,6-dimethylphenyl)propanamide; 2-AMINO-N-(2,6-DIMETHYLPHENYL)PROPANAMIDE; 2-Amino-2',6'-propionoxylidide; 2-Amino-N-(2,6-dimethylphenyl)propionamid
DMYNMDP	TC	Antiarrhythmic Agents
DMYNMDP	DT	Small molecular drug
DMYNMDP	PC	38945
DMYNMDP	MW	192.26
DMYNMDP	FM	C11H16N2O
DMYNMDP	IC	InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14)
DMYNMDP	CS	CC1=C(C(=CC=C1)C)NC(=O)C(C)N
DMYNMDP	IK	BUJAGSGYPOAWEI-UHFFFAOYSA-N
DMYNMDP	IU	2-amino-N-(2,6-dimethylphenyl)propanamide
DMYNMDP	CA	CAS 41708-72-9
DMYNMDP	CB	CHEBI:9611
DMYNMDP	DE	Ventricular arrhythmias

DM7J6OR	ID	DM7J6OR
DM7J6OR	DN	Tocilizumab
DM7J6OR	HS	Approved
DM7J6OR	SN	Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody
DM7J6OR	CP	Roche; Genentech
DM7J6OR	DT	Monoclonal antibody
DM7J6OR	DE	Rheumatoid arthritis; Juvenile idiopathic arthritis

DM1UE67	ID	DM1UE67
DM1UE67	DN	TOCOTRIENOL
DM1UE67	HS	Approved
DM1UE67	SN	2-Methyl-2-[[4,8,12-trimethyl-3(E),7(E),11(E)]-tridecatrienyl]-3,4-dihydro-2H-benzo[b]pyran-6-ol
DM1UE67	DT	Small molecular drug
DM1UE67	PC	9929901
DM1UE67	MW	382.6
DM1UE67	FM	C26H38O2
DM1UE67	IC	InChI=1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+
DM1UE67	CS	CC(=CCC/C(=C/CC/C(=C/CCC1(CCC2=C(O1)C=CC(=C2)O)C)/C)/C)C
DM1UE67	IK	GJJVAFUKOBZPCB-ZGRPYONQSA-N
DM1UE67	IU	2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol
DM1UE67	CA	CAS 6829-55-6
DM1UE67	DE	Hyperlipidaemia

DMBS370	ID	DMBS370
DMBS370	DN	Tofacitinib
DMBS370	HS	Approved
DMBS370	SN	Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200;  Xeljanz (TN)
DMBS370	CP	Pfizer
DMBS370	DT	Small molecular drug
DMBS370	PC	9926791
DMBS370	MW	312.37
DMBS370	FM	C16H20N6O
DMBS370	IC	InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
DMBS370	CS	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
DMBS370	IK	UJLAWZDWDVHWOW-YPMHNXCESA-N
DMBS370	IU	3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
DMBS370	CA	CAS 477600-75-2
DMBS370	CB	CHEBI:71200
DMBS370	DE	Rheumatoid arthritis

DMIHRNA	ID	DMIHRNA
DMIHRNA	DN	Tolazamide
DMIHRNA	HS	Approved
DMIHRNA	SN	Diabewas; Norglycin; Tolamide; Tolanase; Tolazamida; Tolazamidum; Tolazolamide; Tolinase; Pharmacia Brand of Tolazamide; T 2408; U 17835; Tolazamida [INN-Spanish]; Tolazamidum [INN-Latin]; Tolinase (TN); U-17835; Tolazamide (JP15/USP/INN); Tolazamide [USAN:INN:BAN:JAN]; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea; 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea; 4-(p-Tolylsulfonyl)-1,1-hexamethylene; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; 59866P
DMIHRNA	TC	Hypoglycemic Agents
DMIHRNA	DT	Small molecular drug
DMIHRNA	PC	5503
DMIHRNA	MW	311.4
DMIHRNA	FM	C14H21N3O3S
DMIHRNA	IC	InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)
DMIHRNA	CS	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2
DMIHRNA	IK	OUDSBRTVNLOZBN-UHFFFAOYSA-N
DMIHRNA	IU	1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea
DMIHRNA	CA	CAS 1156-19-0
DMIHRNA	CB	CHEBI:9613
DMIHRNA	DE	Diabetic complication

DMI40NL	ID	DMI40NL
DMI40NL	DN	Tolazoline
DMI40NL	HS	Approved
DMI40NL	SN	Artonil; Benzalolin; Benzazoline; Benzidazol; Benzolin; Benzylimidazoline; Divascol; Imidalin; Imidaline; Kasimid;Lambril; Olitensol; Peripherine; Phenylmethylimidazoline; Prefaxil; Pridazole; Priscol; Priscoline; Tolazolin; Tolazolina; Tolazolinum; Vasimid; Vasodil; Vasodilatan; Dilatol ASI; Tolazine [veterinary]; Tolazoline Monohydrochloride; Ciba 3259; Benzolin (VAN); Benzolin (vasodilator); Tolazine [veterinary] (TN); Tolazolina [INN-Spanish]; Tolazoline (INN); Tolazoline [INN:BAN]; Tolazolinum [INN-Latin]; Benzolin (vasodilator) (VAN); 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-(9CI); 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; 2-BENZYL-4,5-IMIDAZOLINE HCl; 2-Benzyl-2-imidazoline; 2-Benzyl-4,5-dihydro-1H-imidazole; 2-Benzyl-4,5-imidazoline; 2-Benzylimidazoline; 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole
DMI40NL	TC	Vasodilator Agents
DMI40NL	DT	Small molecular drug
DMI40NL	PC	5504
DMI40NL	MW	160.22
DMI40NL	FM	C10H12N2
DMI40NL	IC	InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)
DMI40NL	CS	C1CN=C(N1)CC2=CC=CC=C2
DMI40NL	IK	JIVZKJJQOZQXQB-UHFFFAOYSA-N
DMI40NL	IU	2-benzyl-4,5-dihydro-1H-imidazole
DMI40NL	CA	CAS 59-98-3
DMI40NL	CB	CHEBI:28502
DMI40NL	DE	Pulmonary hypertension

DM02AWV	ID	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	HS	Approved
DM02AWV	SN	Aglicid; Arcosal; Arkozal; Artosin; Artozin; Beglucin; Butamid; Butamide; Butamidum; Diaben; Diabesan; Diabetamid; Diabetol; Diabuton; Diasulfon; Diaval; Dirastan; Dolipol; Drabet; Glyconon; Ipoglicone; Mobenol; Orabet; Oralin; Oramide; Orezan; Orinase; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Tarasina; Tolbet;Tolbusal; Tolbutamid; Tolbutamida; Tolbutamidum; Tolbutone; Toluina; Tolumid; Toluran; Toluvan; Tolylsulfonylbutylurea; Willbutamide; Apotex Brand of Tolbutamide; Aventis Brand of Tolbutamide; BerlinChemie Brand of Tolbutamide; Butamide Brand of Tolbutamide; Hoechst Brand of Tolbutamide; Pfizer Brand of Tolbutamide; TOLBUTAMIDE USP; Tolbutamide Aventis Brand; Tolbutamide Butamide Brand; Tolbutamide Hoechst Brand; Tolbutamide Pfizer Brand; Valdecasas Brand of Tolbutamide; Yamanouchi Brand of Tolbutamide; D 860; HLS 831; T 0891; U 2043; Apo-Tolbutamide; Berlin-Chemie Brand of Tolbutamide; Novo-Butamide; Orinase (TN); Sk-tolbutamide; Tol-Tab; Tolbutamida [INN-Spanish]; Tolbutamidum [INN-Latin]; Tolbutamide [INN:BAN:JAN]; R.A.N. Brand of Tolbutamide; Tolbutamid R.A.N.; Tolbutamide (JP15/USP/INN); N-4-Methylbenzolsulfonyl-N-butylurea; N-4-(Methylbenzolsulfonyl)-n-butylurea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-(para-tolylsulfonyl) urea; 1-Butyl-3-tosylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; 3-(p-tolylsulfonyl)-1-butylurea; 3-[p-Tolyl-4-sulfonyl]-1-butylurea
DM02AWV	CP	Pharmacia And Upjohn Co
DM02AWV	TC	Hypoglycemic Agents
DM02AWV	DT	Small molecular drug
DM02AWV	PC	5505
DM02AWV	MW	270.35
DM02AWV	FM	C12H18N2O3S
DM02AWV	IC	InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
DM02AWV	CS	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C
DM02AWV	IK	JLRGJRBPOGGCBT-UHFFFAOYSA-N
DM02AWV	IU	1-butyl-3-(4-methylphenyl)sulfonylurea
DM02AWV	CA	CAS 64-77-7
DM02AWV	CB	CHEBI:27999
DM02AWV	DE	Non-insulin dependent diabetes

DM8MNVO	ID	DM8MNVO
DM8MNVO	DN	Tolcapone
DM8MNVO	HS	Approved
DM8MNVO	SN	Tasmar; Roche brand of tolcapone; Ro 40-7592; Tasmar (TN); Tolcapone [USAN:INN]; Ro-40-7592; Tolcapone (JAN/USAN/INN); Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl); (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone; (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone; 3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone; 3,4-dihydroxy-5'-methyl-5-nitrobenzophenone
DM8MNVO	TC	Antiparkinson Agents
DM8MNVO	DT	Small molecular drug
DM8MNVO	PC	4659569
DM8MNVO	MW	273.24
DM8MNVO	FM	C14H11NO5
DM8MNVO	IC	InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
DM8MNVO	CS	CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
DM8MNVO	IK	MIQPIUSUKVNLNT-UHFFFAOYSA-N
DM8MNVO	IU	(3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone
DM8MNVO	CA	CAS 134308-13-7
DM8MNVO	CB	CHEBI:63630
DM8MNVO	DE	Parkinson disease

DMWUIJE	ID	DMWUIJE
DMWUIJE	DN	Tolmetin
DMWUIJE	HS	Approved
DMWUIJE	SN	Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid
DMWUIJE	CP	Ortho Mcneil Janssen Pharmaceuticals Inc
DMWUIJE	TC	Antiinflammatory Agents
DMWUIJE	DT	Small molecular drug
DMWUIJE	PC	5509
DMWUIJE	MW	257.279
DMWUIJE	FM	C15H15NO3
DMWUIJE	IC	InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
DMWUIJE	CS	CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O
DMWUIJE	IK	UPSPUYADGBWSHF-UHFFFAOYSA-N
DMWUIJE	IU	2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid
DMWUIJE	CA	CAS 26171-23-3
DMWUIJE	CB	CHEBI:71941
DMWUIJE	DE	Rheumatoid arthritis

DM28MU7	ID	DM28MU7
DM28MU7	DN	Tolnaftate
DM28MU7	HS	Approved
DM28MU7	SN	Aftate; Breezee; Chinofungin; Dermoxin; Dungistop; Focusan; Fungistop; Genaspor; Micoisdin; Phytoderm; Pitrex; Separin; Sorgoa; Sporiline; Timoped; Tinactin; Tinaderm; Tinatox; Tinavet; Ting; Tniaderm; Tolnaftato; Tolnaftatum; Tolnaphthate; Tolsanil; Tonoftal; Tritin; ZeaSorb; Aftate for jock itch aerosol spray powder; Aftate for jock itch gel; Aftate for jock itch sprinkle powder; Bioglan Brand of Tolnaftate; Carter Wallace Brand of Tolnaftate; Chinosol Brand of Tolnaftate; Douglas Brand of Tolnaftate; Essex Brand of Tolnaftate; Genaspore cream; Insight Brand of Tolnaftate; Isdin Brand of Tolnaftate; Naphthiomate T; Ony Clear; Pitrex cream; Schering Brand of Tolnaftate; Stiefel Brand of Tolnaftate; Thompson Brand of Tolnaftate; Tinactin aerosol liquid; Tinactin aerosol powder; Tinactin antifungal deodorant powder aerosol; Tinactin cream; Tinactin jock itch aerosol powder; Tinactin jock itch cream;Tinactin jock itch spray powder; Tinactin plus aerosol powder; Tinactin plus powder; Tinactin powder; Tinactin solution; Ting Products; Ting antifungal cream; Ting antifungal powder; Ting antifungal spray liquid; Ting antifungal spray powder; Tolnaftat Purder N; Tolnaftate Douglas Brand; Tolnaftate Schering Brand; Tolnaftato [DCIT]; Wernigerode Brand of Tolnaftate; Zenith Brand of Tolnaftate; NP 27; NP27; Pedinol Brand 1 of Tolnaftate; Pedinol Brand 2 of Tolnaftate; Sch 10144; Absorbine (TN); Aftate (TN); Aftate for athlete's foot aerosol spray liquid; Aftate for athlete's foot aerosol spray powder; Aftate for athlete's foot gel; Aftate for athlete's foot sprinkle powder; Genaspor (TN); HI-Alazin; Hi-alarzin; Lamasil AF (TN); NP 27 (TN); NP-27 Cream; NP-27 Powder; NP-27 Solution; NP-27 Spray Powder; Naphthiomate-T; Odor Eaters (TN); Ony-Clear; Purder N, Tolnaftat; Schering-Plough Brand 1 of Tolnaftate; Schering-Plough Brand 2 of Tolnaftate; Scholl (TN); Separin (TN); Tinactin (TN); Tinavet (Veterinary); Ting (TN); Tolnaftate(USAN); Tolnaftato [INN-Spanish]; Tolnaftatum [INN-Latin]; Zeasorb-AF powder; Tolnaftate (JP14/USP); Tolnaftate (JP15/USP); Dr. Scholl's athlete's foot spray; Tolnaftate (JP15/USP/INN); Tolnaftate [USAN:BAN:INN:JAN]; Tolnaftate [USAN:INN:BAN:JAN]; M,N-Dimethylthiocarbanilic acid O-2-naphthyl ester; Methyl (3-methylphenyl)carbamothioic acid O-2-naphthalenyl ester; O-2-Naphthyl N,N-dimethylthiocarbanilate; O-2-Naphthyl m,N-dimethylthiocarbanilate; Methyl-(3-methylphenyl)carbamothioic acid O-2-naphthyl ester; Methyl-[3-methylphenyl]-carbamothioic acid O-2-naphthyl ester; O-(2-Naphthyl) methyl(3-methylphenyl)thiocarbamate; O-naphthalen-2-yl methyl(3-methylphenyl)carbamothioate; Carbamothioic acid, methyl(3-methylphenyl)-, O-2-naphthalenyl ester; Carbanilic acid, N,m-dimethylthio-, O-2-naphthyl ester; Carbanilic acid, m,N-dimethylthio-, O-2-naphthyl ester; N-Methyl-(3-methylphenyl)-carbamothioic acid, O-2-naphthalenyl ester; O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate; Carbamothioic acid, N-methyl-N-(3-methylphenyl)-, O-2-naphthalenyl ester; 2-Naphthyl N-methyl-N-(3-tolyl)thionocarbamate
DM28MU7	CP	Schering-Plough
DM28MU7	TC	Antifungal Agents
DM28MU7	DT	Small molecular drug
DM28MU7	PC	5510
DM28MU7	MW	307.4
DM28MU7	FM	C19H17NOS
DM28MU7	IC	InChI=1S/C19H17NOS/c1-14-6-5-9-17(12-14)20(2)19(22)21-18-11-10-15-7-3-4-8-16(15)13-18/h3-13H,1-2H3
DM28MU7	CS	CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2
DM28MU7	IK	FUSNMLFNXJSCDI-UHFFFAOYSA-N
DM28MU7	IU	O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate
DM28MU7	CA	CAS 2398-96-1
DM28MU7	CB	CHEBI:9620
DM28MU7	DE	Dermatophytosis; Jock itch

DMA2GHJ	ID	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	HS	Approved
DMA2GHJ	SN	Agileo; Viveo; AV-650; SPH-3047; Tolperisone (controlled-release); Tolperisone (controlled-release), Sanochemia; Tolperisone (controlled-release), Sanochemia/Avigen
DMA2GHJ	CP	Sanochemia Pharmazeutika AG
DMA2GHJ	DT	Small molecular drug
DMA2GHJ	PC	5511
DMA2GHJ	MW	245.36
DMA2GHJ	FM	C16H23NO
DMA2GHJ	IC	InChI=1S/C16H23NO/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17/h6-9,14H,3-5,10-12H2,1-2H3
DMA2GHJ	CS	CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
DMA2GHJ	IK	FSKFPVLPFLJRQB-UHFFFAOYSA-N
DMA2GHJ	IU	2-methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-one
DMA2GHJ	CA	CAS 728-88-1
DMA2GHJ	CB	CHEBI:93835
DMA2GHJ	DE	Muscle spasm

DMSHPW8	ID	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	HS	Approved
DMSHPW8	SN	Tolterodina; Tolterodinum; Detrol (TN); Detrusitol (TN); Kabi-2234; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol
DMSHPW8	CP	Pfizer Pharmaceuticals
DMSHPW8	TC	Antispasmodics
DMSHPW8	DT	Small molecular drug
DMSHPW8	PC	443879
DMSHPW8	MW	325.5
DMSHPW8	FM	C22H31NO
DMSHPW8	IC	InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1
DMSHPW8	CS	CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2
DMSHPW8	IK	OOGJQPCLVADCPB-HXUWFJFHSA-N
DMSHPW8	IU	2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
DMSHPW8	CA	CAS 124937-51-5
DMSHPW8	CB	CHEBI:9622
DMSHPW8	DE	Overactive bladder

DMIWFRL	ID	DMIWFRL
DMIWFRL	DN	Tolvaptan
DMIWFRL	HS	Approved
DMIWFRL	SN	Samsca; OPC 41061; Benzazepine derivative, 32; OPC-41061; Samsca (TN); N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide; (-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide; 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine
DMIWFRL	CP	Otsuka; Winston Laboratories & Otsuka
DMIWFRL	DT	Small molecular drug
DMIWFRL	PC	216237
DMIWFRL	MW	448.9
DMIWFRL	FM	C26H25ClN2O3
DMIWFRL	IC	InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
DMIWFRL	CS	CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C
DMIWFRL	IK	GYHCTFXIZSNGJT-UHFFFAOYSA-N
DMIWFRL	IU	N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
DMIWFRL	CA	CAS 150683-30-0
DMIWFRL	CB	CHEBI:32246
DMIWFRL	DE	Hyponatraemia; Heart failure

DMAE6LK	ID	DMAE6LK
DMAE6LK	DN	Topetecan
DMAE6LK	HS	Approved
DMAE6LK	SN	TOPOTECAN HYDROCHLORIDE; 119413-54-6; Topotecan Hcl; Hycamptamine hydrochloride; Topotecan (Hydrochloride); Topotecan monohydrochloride; UNII-956S425ZCY; Topotecan hydrochloride [USAN]; Nogitecan hydrochloride; DRG-0288; F S-104864-A; NSC-609699; NSC 609699; NSC609699; 956S425ZCY; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione monohydrochloride; NCGC00095189-01; AK-48920; DSSTox_RID_81248; DSSTox_CID_25952
DMAE6LK	CP	GSK
DMAE6LK	DT	Small molecular drug
DMAE6LK	PC	60699
DMAE6LK	MW	457.9
DMAE6LK	FM	C23H24ClN3O5
DMAE6LK	IC	InChI=1S/C23H23N3O5.ClH/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20;/h5-8,27,30H,4,9-11H2,1-3H3;1H/t23-;/m0./s1
DMAE6LK	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl
DMAE6LK	IK	DGHHQBMTXTWTJV-BQAIUKQQSA-N
DMAE6LK	IU	(19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione;hydrochloride
DMAE6LK	CA	CAS 119413-54-6
DMAE6LK	DE	Small-cell lung cancer

DM82Z30	ID	DM82Z30
DM82Z30	DN	Topiramate
DM82Z30	HS	Approved
DM82Z30	SN	Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta
DM82Z30	CP	Ortho-McNell Pharmaceutical
DM82Z30	TC	Anticonvulsants
DM82Z30	DT	Small molecular drug
DM82Z30	PC	5284627
DM82Z30	MW	339.36
DM82Z30	FM	C12H21NO8S
DM82Z30	IC	InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
DM82Z30	CS	CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C
DM82Z30	IK	KJADKKWYZYXHBB-XBWDGYHZSA-N
DM82Z30	IU	[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate
DM82Z30	CA	CAS 97240-79-4
DM82Z30	CB	CHEBI:63631
DM82Z30	DE	Alcohol dependence; Epilepsy; Seizure disorder

DMP6G8T	ID	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	HS	Approved
DMP6G8T	SN	Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin
DMP6G8T	CP	GlaxoSmithKline
DMP6G8T	TC	Anticancer Agents
DMP6G8T	DT	Small molecular drug
DMP6G8T	PC	60700
DMP6G8T	MW	421.4
DMP6G8T	FM	C23H23N3O5
DMP6G8T	IC	InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
DMP6G8T	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
DMP6G8T	IK	UCFGDBYHRUNTLO-QHCPKHFHSA-N
DMP6G8T	IU	(19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DMP6G8T	CA	CAS 123948-87-8
DMP6G8T	CB	CHEBI:63632
DMP6G8T	DE	Small-cell lung cancer; Ovarian cancer; Solid tumour/cancer

DMXKJ6C	ID	DMXKJ6C
DMXKJ6C	DN	Torasemide
DMXKJ6C	HS	Approved
DMXKJ6C	SN	Demadex; Dilutol; Luprac; Presoril; Sutril; TORSEMIDE; Toradiur; Torasemida; Torasemidum; Torem; Torocard; Torrem; Unat; Torasemide N; Torsemide [USAN]; AC 4464; BM 02015; JDL 464; BM-02015; Demadex (TN); Demadex, Torsemide; GJ-1090; JDL-464; KS-1123; Luprac (TN); PW-2132; Torasemida [INN-Spanish]; Torasemidum [INN-Latin]; Torsemide (USP); Torasemide (JAN/INN); N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl]urea
DMXKJ6C	TC	Diuretics
DMXKJ6C	DT	Small molecular drug
DMXKJ6C	PC	41781
DMXKJ6C	MW	348.4
DMXKJ6C	FM	C16H20N4O3S
DMXKJ6C	IC	InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
DMXKJ6C	CS	CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C
DMXKJ6C	IK	NGBFQHCMQULJNZ-UHFFFAOYSA-N
DMXKJ6C	IU	1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea
DMXKJ6C	CA	CAS 56211-40-6
DMXKJ6C	CB	CHEBI:9637
DMXKJ6C	DE	Congestive heart failure

DMQYUWG	ID	DMQYUWG
DMQYUWG	DN	Toremifene
DMQYUWG	HS	Approved
DMQYUWG	SN	Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
DMQYUWG	CP	Prostrakan Inc
DMQYUWG	TC	Anticancer Agents
DMQYUWG	DT	Small molecular drug
DMQYUWG	PC	3005573
DMQYUWG	MW	406
DMQYUWG	FM	C26H28ClNO
DMQYUWG	IC	InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
DMQYUWG	CS	CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\\C2=CC=CC=C2)/C3=CC=CC=C3
DMQYUWG	IK	XFCLJVABOIYOMF-QPLCGJKRSA-N
DMQYUWG	IU	2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
DMQYUWG	CA	CAS 89778-26-7
DMQYUWG	CB	CHEBI:9635
DMQYUWG	DE	Breast cancer

DMMYZ3D	ID	DMMYZ3D
DMMYZ3D	DN	Tositumomab
DMMYZ3D	HS	Approved
DMMYZ3D	SN	Bexxar (TN)
DMMYZ3D	CP	GlaxoSmithKline
DMMYZ3D	TC	Anticancer Agents
DMMYZ3D	DT	Antibody
DMMYZ3D	SQ	Mouse-Human chimeric Anti-CD20 Heavy Chain 1: QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Mouse-Human chimeric Anti-CD20 Light Chain 1QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR</sequence>    <sequence format="FASTA">&gt;Mouse-Human chimeric Anti-CD20 Heavy Chain 2QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Mouse-Human chimeric Anti-CD20 Light Chain 2QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMMYZ3D	DE	Non-hodgkin lymphoma

DM5A31S	ID	DM5A31S
DM5A31S	DN	TP-434
DM5A31S	HS	Approved
DM5A31S	SN	TP-038; TP-120; TP-170; TP-221; TP-271; TP-787; Tetracycline analogs (bacterial infection), Tetraphase Pharmaceuticals; Tetracycline derivatives (bacterial infection), Tetraphase Pharmaceuticals; Fluorocycline antibiotic (oral, bacterial infection), Tetraphase Pharmaceuticals; Tetracycline analogs (iv, antibiotic), Tetraphase Pharmaceuticals; TP-434 (oral, multidrug-resistant bacterial infections); TP-434 (oral, multidrug-resistant bacterial infections), Tetraphase Pharmaceuticals
DM5A31S	CP	Tetraphase Pharmaceuticals
DM5A31S	DT	Small molecular drug
DM5A31S	PC	54726192
DM5A31S	MW	558.6
DM5A31S	FM	C27H31FN4O8
DM5A31S	IC	InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1
DM5A31S	CS	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F
DM5A31S	IK	AKLMFDDQCHURPW-ISIOAQNYSA-N
DM5A31S	IU	(4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DM5A31S	CA	CAS 1207283-85-9
DM5A31S	DE	Intra-abdominal infection; Influenza virus infection

DMG3Y89	ID	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	HS	Approved
DMG3Y89	SN	Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)
DMG3Y89	CP	PharmaMar
DMG3Y89	DT	Small molecular drug
DMG3Y89	PC	108150
DMG3Y89	MW	761.8
DMG3Y89	FM	C39H43N3O11S
DMG3Y89	IC	InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1
DMG3Y89	CS	CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O
DMG3Y89	IK	PKVRCIRHQMSYJX-AIFWHQITSA-N
DMG3Y89	IU	[(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate
DMG3Y89	CA	CAS 114899-77-3
DMG3Y89	CB	CHEBI:84050
DMG3Y89	DE	Solid tumour/cancer; Ovarian cancer

DMRQD04	ID	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	HS	Approved
DMRQD04	SN	Conzip; Ryzolt; Tramadol Hydrochloride; Ultram Er; Rybix Odt; Ultram
DMRQD04	CP	Chemie Grunenthal of Stolberg-am-Rhein
DMRQD04	TC	Analgesics
DMRQD04	DT	Small molecular drug
DMRQD04	PC	33741
DMRQD04	MW	263.37
DMRQD04	FM	C16H25NO2
DMRQD04	IC	InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1
DMRQD04	CS	CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
DMRQD04	IK	TVYLLZQTGLZFBW-ZBFHGGJFSA-N
DMRQD04	IU	(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol
DMRQD04	CA	CAS 123154-38-1
DMRQD04	CB	CHEBI:75725
DMRQD04	DE	Pain

DM2JGQ3	ID	DM2JGQ3
DM2JGQ3	DN	Trametinib
DM2JGQ3	HS	Approved
DM2JGQ3	SN	GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN
DM2JGQ3	CP	GlaxoSmithKline
DM2JGQ3	DT	Small molecular drug
DM2JGQ3	PC	11707110
DM2JGQ3	MW	615.4
DM2JGQ3	FM	C26H23FIN5O4
DM2JGQ3	IC	InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
DM2JGQ3	CS	CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5
DM2JGQ3	IK	LIRYPHYGHXZJBZ-UHFFFAOYSA-N
DM2JGQ3	IU	N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
DM2JGQ3	CA	CAS 871700-17-3
DM2JGQ3	CB	CHEBI:75998
DM2JGQ3	DE	Melanoma

DM4L6EU	ID	DM4L6EU
DM4L6EU	DN	Trandolapril
DM4L6EU	HS	Approved
DM4L6EU	SN	Gopten; Mavik; Odric; Odrik; Preran; Trandolaprilum; Udrik; Trandolaprilum [Latin]; RU 44570; RU44570; Mavik (TN); RU-44570; Trandolapril [INN:BAN]; Trandolapril (JAN/INN); (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid; 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid
DM4L6EU	CP	Abbott Laboratories
DM4L6EU	TC	Antihypertensive Agents
DM4L6EU	DT	Small molecular drug
DM4L6EU	PC	5484727
DM4L6EU	MW	430.5
DM4L6EU	FM	C24H34N2O5
DM4L6EU	IC	InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
DM4L6EU	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(=O)O
DM4L6EU	IK	VXFJYXUZANRPDJ-WTNASJBWSA-N
DM4L6EU	IU	(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
DM4L6EU	CA	CAS 87679-37-6
DM4L6EU	CB	CHEBI:9649
DM4L6EU	DE	Hypertension

DMFI8A7	ID	DMFI8A7
DMFI8A7	DN	Tranexamic acid
DMFI8A7	HS	Approved
DMFI8A7	SN	AMCA; AMCHA; AMH; Amikapron; Amstat; Anvitoff; Carxamin; Cyclocapron; Cyklokapron; Emorhalt; Exacyl; Frenolyse; Hexapromin; Hexatron; Mastop; Rikavarin; Spiramin; Tamcha; Tranex; Tranexamsaeure; Tranexan; Transamin; Transamlon; Trasamlon; Ugurol; Acide tranexamique; Acido tranexamico; Acidum tranexamicum; Tranexmic acid; Tranhexamic acid; Trans AMCHA; CL 65336; DV 79; DV79; KABI 2161; LT00159441; ALBB-006013; Acide tranexamique [INN-French]; Acido tranexamico [INN-Spanish]; Acidum tranexamicum [INN-Latin]; CL-65336; Cis-AMCHA; Cyklokapron (TN); DV-79; RP 18,429; Rikavarin (TN); Rikavarin-S; T-AMCHA; Tranexamic acid cis-form; Trans-Amcha; Trans-Tranexamic acid; Cis-4-(Aminomethyl)cyclohexanecarboxylic acid; Tranexamic acid (JP15/USAN/INN); Tranexamic acid [USAN:INN:BAN:JAN]; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester; Trans-p-(Aminomethyl)cyclohexanecarboxylic; Trans-p-(Aminomethyl)cyclohexanecarboxylic acid; Cis-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-Aminomethylcyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)cyclohexane-carboxylic acid; Trans-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid; 4-(Aminomethyl)-Cyclohexanecarboxylic Acid; 4-(Aminomethyl)cyclohexanecarboxylic acid; 4-(aminomethyl)cyclohexane-1-carboxylic acid
DMFI8A7	CP	Daiichi Sankyo Pharma Development
DMFI8A7	TC	Antifibrinolytic Agents
DMFI8A7	DT	Small molecular drug
DMFI8A7	PC	5526
DMFI8A7	MW	157.21
DMFI8A7	FM	C8H15NO2
DMFI8A7	IC	InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)
DMFI8A7	CS	C1CC(CCC1CN)C(=O)O
DMFI8A7	IK	GYDJEQRTZSCIOI-UHFFFAOYSA-N
DMFI8A7	IU	4-(aminomethyl)cyclohexane-1-carboxylic acid
DMFI8A7	CA	CAS 701-54-2
DMFI8A7	CB	CHEBI:48669
DMFI8A7	DE	Excessive bleeding

DME5Y64	ID	DME5Y64
DME5Y64	DN	Tranilast
DME5Y64	HS	Approved
DME5Y64	SN	tranilast; 53902-12-8; Rizaben; trans-Tranilast; Tranilastum; 70806-55-2; MK 341; N-(3,4-Dimethoxycinnamoyl)anthranilic acid; Tranilastum [INN-Latin]; Tranilast [USAN:INN:JAN]; Tranpro; UNII-HVF50SMY6E; SB-252218; MK-341; Tranilast (SB 252218); 3,4-DAA; n-(3',4'-dimethoxycinnamoyl) anthranilic acid; HVF50SMY6E; MLS000028468; CHEBI:77572; C18H17NO5; Anthranilic acid, N-(3,4-dimethoxycinnamoyl)-; NZHGWWWHIYHZNX-CSKARUKUSA-N; 2-((3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid; MFCD00864787; T 0318; NU-3450; Rizaben (TN); Tranilast (JAN/USAN/INN); Rizaben, SB 252218, MK 341, Tranpro ,Tranilast; N-(3',4'-dimethoxycinnamoyl) anthranilic acid; N-(3&prime; -Dimethoxycinnamoyl)anthranilic Acid; 2-({(2E)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic acid; 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid; 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid; Molecule 20
DME5Y64	CP	Kissei
DME5Y64	DT	Small molecular drug
DME5Y64	PC	5282230
DME5Y64	MW	327.3
DME5Y64	FM	C18H17NO5
DME5Y64	IC	InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
DME5Y64	CS	COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC
DME5Y64	IK	NZHGWWWHIYHZNX-CSKARUKUSA-N
DME5Y64	IU	2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid
DME5Y64	CA	CAS 53902-12-8
DME5Y64	CB	CHEBI:77572
DME5Y64	DE	Ocular allergy

DMGB5RE	ID	DMGB5RE
DMGB5RE	DN	Tranylcypromine
DMGB5RE	HS	Approved
DMGB5RE	SN	GJZ; Jatrosom; Parnate; Parnitene; Tranilcipromina; Transamine; Tranylcyprominum; Allphar Brand of Tranylcypromine Sulfate; Esparma Brand of Tranylcypromine Sulfate; GlaxoSmithKline Brand of Tranylcypromine Sulfate; Goldshield Brand of Tranylcypromine Sulfate; Link Brand of Tranylcypromine Sulfate; Racemic Tranylcypromine; SmithKline Brand of Tranylcypromine Sulfate; SKF 385; Trans 2 Phenylcyclopropylamine; D-Tranylcypromine; Dl-Tranylcypromine; Jatrosom (TN); L-Tranylcypromine; Parmodalin (TN); Parnate (TN); Parstelin (TN); SKF Trans-385; Sicoton (TN); Sulfate, Tranylcypromine; Tranilcipromina [INN-Spanish]; Transamine (TN); Transapin (TN); Tranylcypromine (INN); Tranylcypromine [INN:BAN]; Tranylcyprominum [INN-Latin]; Tylciprine (TN); Trans-2-Phenylcyclopropylamine; Trans-DL-2-Phenylcyclopropylamine; Trans-(-)-2-Phenylcyclopropanamine; Cyclopropanamine, 2-phenyl-, (1R-trans)-(9CI); (+)-(R)-Tranylcypromine; (+)-Tranylcypromine; (+)-trans-2-Phenylcyclopropylamine; (-)-Tranylcypromine; (1R)-2-phenylcyclopropan-1-amine; (1R,2R)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropanamine; (1S)-2-phenylcyclopropan-1-amine; (1S,2R)-2-phenylcyclopropan-1-amine; (1S,2S)-2-phenylcyclopropan-1-amine; (2S)-2-phenylcyclopropan-1-amine; 2-Phenylcyclopropanamine; 2-phenylcyclopropan-1-amine
DMGB5RE	CP	GlaxoSmithKline plc
DMGB5RE	TC	Antidepressants
DMGB5RE	DT	Small molecular drug
DMGB5RE	PC	19493
DMGB5RE	MW	133.19
DMGB5RE	FM	C9H11N
DMGB5RE	IC	InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1
DMGB5RE	CS	C1[C@H]([C@@H]1N)C2=CC=CC=C2
DMGB5RE	IK	AELCINSCMGFISI-DTWKUNHWSA-N
DMGB5RE	IU	(1R,2S)-2-phenylcyclopropan-1-amine
DMGB5RE	CA	CAS 3721-26-4
DMGB5RE	CB	CHEBI:94631
DMGB5RE	DE	Prostate cancer; Major depressive disorder

DMZQOUX	ID	DMZQOUX
DMZQOUX	DN	Trastuzumab
DMZQOUX	HS	Approved
DMZQOUX	SN	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
DMZQOUX	CP	Roche; Genentech
DMZQOUX	TC	Anticancer Agents
DMZQOUX	DT	Antibody
DMZQOUX	SQ	Anti-HER2 Light chain (1 and 2): DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>    <sequence format="FASTA">&gt;Anti-HER2 Heavy chain (1 and 2)EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMZQOUX	DE	Breast cancer; Gastric adenocarcinoma; HER2-positive breast cancer

DM20K91	ID	DM20K91
DM20K91	DN	Travoprost
DM20K91	HS	Approved
DM20K91	SN	Travatan; Travatanz; Travatan Alcon; Travatan Z; Travoprost [USAN]; AL6221; AL-6221; Travatan (TN); Travatan Z (TN); Travatan, Travoprost; Travoprost (JAN/USAN/INN); Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (+)-Fluprostenol isopropyl ester; (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate; 5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
DM20K91	CP	Alcon Canada Inc
DM20K91	TC	Ophthalmologicals
DM20K91	DT	Small molecular drug
DM20K91	PC	5282226
DM20K91	MW	500.5
DM20K91	FM	C26H35F3O6
DM20K91	IC	InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
DM20K91	CS	CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O
DM20K91	IK	MKPLKVHSHYCHOC-AHTXBMBWSA-N
DM20K91	IU	propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
DM20K91	CA	CAS 157283-68-6
DM20K91	CB	CHEBI:746859
DM20K91	DE	Open-angle glaucoma

DMK1GBJ	ID	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	HS	Approved
DMK1GBJ	SN	Beneficat; Desirel; Sideril; Tradozone; Trazalon; Trazodil; Trazodon; Trazodona; Trazodonum; Trazolan; Trazonil; Trialodine; Trittico; Desyrel Dividose; Trazodona [Spanish]; Trazodone Hcl; Trazodonum [Latin]; Beneficat (TN); Deprax (TN); Desirel (TN); Desyrel (TN); Desyrel(trazodone hcl salt); Molipaxin (TN); Thombran (TN); Trazodona [INN-Spanish]; Trazodone (Desyrel); Trazodone (INN); Trazodone [INN:BAN]; Trazodonum [INN-Latin]; Trazorel (TN); Trialodine (TN); Trittico (TN); 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 8-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride
DMK1GBJ	CP	Angelini research laboratories
DMK1GBJ	TC	Antidepressants
DMK1GBJ	DT	Small molecular drug
DMK1GBJ	PC	5533
DMK1GBJ	MW	371.9
DMK1GBJ	FM	C19H22ClN5O
DMK1GBJ	IC	InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2
DMK1GBJ	CS	C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
DMK1GBJ	IK	PHLBKPHSAVXXEF-UHFFFAOYSA-N
DMK1GBJ	IU	2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one
DMK1GBJ	CA	CAS 19794-93-5
DMK1GBJ	CB	CHEBI:9654
DMK1GBJ	DE	Depression

DMTIQF3	ID	DMTIQF3
DMTIQF3	DN	Treprostinil
DMTIQF3	HS	Approved
DMTIQF3	SN	Treprostinilo; Treprostinilum; Uniprost; Viveta; Treprostinil sodium; LRX 15; U 62840; Remodulin (TN); Treprostinil [USAN:INN]; UT-15; Treprostinil (USAN/INN); U-62,840; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 15 AU81; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
DMTIQF3	TC	Antihypertensive Agents
DMTIQF3	DT	Small molecular drug
DMTIQF3	PC	6918140
DMTIQF3	MW	390.5
DMTIQF3	FM	C23H34O5
DMTIQF3	IC	InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
DMTIQF3	CS	CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
DMTIQF3	IK	PAJMKGZZBBTTOY-ZFORQUDYSA-N
DMTIQF3	IU	2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
DMTIQF3	CA	CAS 81846-19-7
DMTIQF3	CB	CHEBI:50861
DMTIQF3	DE	Pulmonary arterial hypertension

DM49DUI	ID	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	HS	Approved
DM49DUI	SN	Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid
DM49DUI	CP	Roche Pharmaceuticals
DM49DUI	TC	Keratolytic Agents
DM49DUI	DT	Small molecular drug
DM49DUI	PC	444795
DM49DUI	MW	300.4
DM49DUI	FM	C20H28O2
DM49DUI	IC	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
DM49DUI	CS	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
DM49DUI	IK	SHGAZHPCJJPHSC-YCNIQYBTSA-N
DM49DUI	IU	(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DM49DUI	CA	CAS 302-79-4
DM49DUI	CB	CHEBI:15367
DM49DUI	DE	Acne vulgaris; Acute promyelocytic leukaemia

DMU54QB	ID	DMU54QB
DMU54QB	DN	Treximet
DMU54QB	HS	Approved
DMU54QB	SN	Trexima; Naproxen mixture with sumatriptan; Naproxen sodium mixture with sumatriptan succinate; Sumatriptan mixture with naproxen;Sumatriptan succinate and naproxen sodium; Sumatriptan succinate mixture with naproxen sodium; Naproxen / sumatriptan
DMU54QB	CP	GSK
DMU54QB	DT	Small molecular drug
DMU54QB	PC	23709079
DMU54QB	MW	665.7
DMU54QB	FM	C32H40N3NaO9S
DMU54QB	IC	InChI=1S/C14H21N3O2S.C14H14O3.C4H6O4.Na/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;5-3(6)1-2-4(7)8;/h4-5,8-9,15-16H,6-7,10H2,1-3H3;3-9H,1-2H3,(H,15,16);1-2H2,(H,5,6)(H,7,8);/q;;;+1/p-1/t;9-;;/m.0../s1
DMU54QB	CS	C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-].CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O.[Na+]
DMU54QB	IK	IGRAQVLKCQVBQA-DBQHITQZSA-M
DMU54QB	IU	sodium;butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DMU54QB	CA	CAS 811794-26-0
DMU54QB	DE	Migraine

DM0AEPG	ID	DM0AEPG
DM0AEPG	DN	Triacetin
DM0AEPG	HS	Approved
DM0AEPG	SN	triacetin; 102-76-1; Glyceryl triacetate; Glycerol triacetate; Enzactin; Glycerin triacetate; Triacetine; Triacetylglycerol; Fungacetin; Glyped; Triacetyl glycerine; Vanay; Kesscoflex TRA; Kodaflex triacetin; 1,2,3-Propanetriol, triacetate; Acetin, tri-; Triacetinum; Triacetina; 1,2,3-triacetoxypropane; 1,2,3-Propanetriol triacetate; propane-1,2,3-triyl triacetate; Triacetyl glycerin; Triacetyl glycerol; 1,2,3-Propanetriyl triacetate; Triacetin [INN]; 1,2,3-Triacetylglycerol; 1,2,3-Propanetriol, 1,2,3-triacetate; FEMA Number 2007
DM0AEPG	DT	Small molecular drug
DM0AEPG	PC	5541
DM0AEPG	MW	218.2
DM0AEPG	FM	C9H14O6
DM0AEPG	IC	InChI=1S/C9H14O6/c1-6(10)13-4-9(15-8(3)12)5-14-7(2)11/h9H,4-5H2,1-3H3
DM0AEPG	CS	CC(=O)OCC(COC(=O)C)OC(=O)C
DM0AEPG	IK	URAYPUMNDPQOKB-UHFFFAOYSA-N
DM0AEPG	IU	2,3-diacetyloxypropyl acetate
DM0AEPG	CA	CAS 102-76-1
DM0AEPG	CB	CHEBI:9661
DM0AEPG	DE	Onychomycosis

DM98IXF	ID	DM98IXF
DM98IXF	DN	Triamcinolone
DM98IXF	HS	Approved
DM98IXF	SN	Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone
DM98IXF	CP	Aventis Pharmaceuticals Inc.
DM98IXF	TC	Antiinflammatory Agents
DM98IXF	DT	Small molecular drug
DM98IXF	PC	31307
DM98IXF	MW	394.4
DM98IXF	FM	C21H27FO6
DM98IXF	IC	InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
DM98IXF	CS	C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O
DM98IXF	IK	GFNANZIMVAIWHM-OBYCQNJPSA-N
DM98IXF	IU	(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DM98IXF	CA	CAS 124-94-7
DM98IXF	CB	CHEBI:9667
DM98IXF	DE	Allergic rhinitis

DM7LRKD	ID	DM7LRKD
DM7LRKD	DN	Triamcinolone diacetate
DM7LRKD	HS	Approved
DM7LRKD	SN	Aristocort diacetate; Polcortolon; Tedarol; Aristocort Forte; Triamcinolone 16,21-diacetate; Orion; Aristocort Parenterals; Kenacort Diacetate Syrup; Aristocort diacetate forte; Aristocort Forte Parenteral; TRIAMCINOLONE DIACETATE; UNII-A73MM2Q32P; Kenacourt; Aristocort syrup; CHEBI:9669; 357RP; EINECS 200-669-0; Triamcinolone 16-alpha,21-di(acetate); A73MM2Q32P; 16alpha-Hydroxy-9alpha-fluoroprednisolone diacetate; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone diacetate; NCGC00159320-03; delta1,9alpha-Fluoro-16alpha-hydroxyhydrocortisone diacetate; delta11,16alpha-Hydroxy-9alpha-fluorohydrocortisone diacetate; 16alpha,21-Diacetoxy-9alpha-fluoro-11beta,17alpha-dihydroxy-1,4-pregnadiene-3,20-dione; 9-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate; DSSTox_CID_28639; DSSTox_RID_82909; DSSTox_GSID_48713; Pregna-1,4-diene-3,20-dione, 16,21-bis(acetyloxy)-9-fluoro-11,17-dihydroxy-, (11beta,16alpha)-; Polcartolone; CAS-67-78-7; Triamcinolone diacetate [JAN]; Triamcinolone diacetate [USP:JAN]; SCHEMBL12549; 67-78-7
DM7LRKD	PC	6216
DM7LRKD	MW	478.5
DM7LRKD	FM	C25H31FO8
DM7LRKD	IC	XGMPVBXKDAHORN-RBWIMXSLSA-N
DM7LRKD	CS	CC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)OC(=O)C)O
DM7LRKD	IK	1S/C25H31FO8/c1-13(27)33-12-20(31)25(32)21(34-14(2)28)10-18-17-6-5-15-9-16(29)7-8-22(15,3)24(17,26)19(30)11-23(18,25)4/h7-9,17-19,21,30,32H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22-,23-,24-,25+/m0/s1
DM7LRKD	IU	[2-[(8S,9R,10S,11S,13S,14S,16R,17S)-16-acetyloxy-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DM7LRKD	CA	CAS 67-78-7
DM7LRKD	CB	CHEBI:9669
DM7LRKD	DE	Allergy

DM2HU9I	ID	DM2HU9I
DM2HU9I	DN	Triamterene
DM2HU9I	HS	Approved
DM2HU9I	SN	Ademin; Ademine; Amteren; Anjal; Dazid; Diarol; Dinazide; Diren; Ditak; Diucelpin; Diurene; Diutensat; Diuteren; Dyberzide; Dyren; Dyrenium; Dytac; Dytenzide; Esiteren; Hidiurese; Hydrene; Hypertorr; Isobar; Jatropur; Jenateren; Kalspare; Masuharmin; Nephral; Noridil; Noridyl; Pterofen; Pterophene; Renezide; Reviten; Taturil; Teriam; Teridin; Triamizide; Triampur; Triamteren; Triamterena; Triamterenum; Triamteril; Triamterine; Triamthiazid; Tricilone; Trispan; Triteren; Triurene; Trizid; Turfa; Uretren; Urocaudal; Goldshield Brand of Triamterene; Jorba Brand of Triamterene; Pter ophene; SmithKline Beecham Brand of Triamterene; TRIAMTERENE USP; Thiazid Wolff; Triamteril complex; Wellspring Brand of Triamterene; Fluss 40; SKF 8542; T 4143; Ademin(e); Apo-triazide; Dyrenium (TN); Pteridine deriv. 11; SALI-PUREN; SK&F 8542; SK-8542; Tri-Span; Triamterena [INN-Spanish]; Triamterenum [INN-Latin]; SK&F-8542; Triamterene (JP15/USP/INN); Triamterene [USAN:INN:BAN:JAN]; 2,4,7-Triamino-6-fenilpteridina; 2,4,7-Triamino-6-fenilpteridina [Italian]; 2,4,7-Triamino-6-phenylpteridine; 6-PHENYL-2,4,7-TRIAMINO PTERIDINE; 6-Phenyl-2,4,7-pteridinetriamine; 6-Phenyl-2,4,7-triaminopteridine; 6-phenylpteridine-2,4,7-triamine
DM2HU9I	TC	Diuretics
DM2HU9I	DT	Small molecular drug
DM2HU9I	PC	5546
DM2HU9I	MW	253.26
DM2HU9I	FM	C12H11N7
DM2HU9I	IC	InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
DM2HU9I	CS	C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N
DM2HU9I	IK	FNYLWPVRPXGIIP-UHFFFAOYSA-N
DM2HU9I	IU	6-phenylpteridine-2,4,7-triamine
DM2HU9I	CA	CAS 396-01-0
DM2HU9I	CB	CHEBI:9671
DM2HU9I	DE	Congestive heart failure; Edema; Hypertension

DMETYK5	ID	DMETYK5
DMETYK5	DN	Triazolam
DMETYK5	HS	Approved
DMETYK5	SN	Clorazolam; Halcion; Hypnostat; Novidorm; Novodorm; Songar; Triazolamum; Trilam; Apo Triazo; Apotex Brand of Triazolam; Gen Triazolam; Genpharm Brand of Triazolam; Gerard Brand of Triazolam; Pfizer Brand of Triazolam; Triazolam Pfizer Brand; TGAR01H; U 33030; Alti-Triazolam; Apo-Triazo; Gen-Triazolam; Halcion (TN); Halcion (triazolam); Hypam (TN); Novo-Triolam; Triazolamum [INN-Latin]; Trilam (TN); U 33,030; U-33030; U33,030; Apo-Triazo (TN); U-33,030; Triazolam (JAN/USP/INN); Triazolam [USAN:BAN:INN:JAN]; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMETYK5	CP	Upjohn Corporation
DMETYK5	TC	Hypnotics and Sedatives
DMETYK5	DT	Small molecular drug
DMETYK5	PC	5556
DMETYK5	MW	343.2
DMETYK5	FM	C17H12Cl2N4
DMETYK5	IC	InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
DMETYK5	CS	CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl
DMETYK5	IK	JOFWLTCLBGQGBO-UHFFFAOYSA-N
DMETYK5	IU	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMETYK5	CA	CAS 28911-01-5
DMETYK5	CB	CHEBI:9674
DMETYK5	DE	Insomnia

DMHAQCO	ID	DMHAQCO
DMHAQCO	DN	Trichlormethiazide
DMHAQCO	HS	Approved
DMHAQCO	SN	Achletin; Anistadin; Aponorin; Aquazide; Carvacron; Chlopolidine; Cretonin; Diurazida; Diurese; Diuroral;Esmarin; Eurinol; Fluitran; Flurese; Flutra; Gangesol; Hydrotrichlorothiazide; Intromene; Isestran; Kubacron; Metahydrin; Metatensin; Nakva; Naqua; Naquasone; Schebitran; Tachionin; Tolcasone; Trichlordiuride; Trichlorex; Trichlormas; Trichlormetazid; Trichlormethiazid; Trichlormethiazidum; Trichloromethiadiazide; Trichloromethiazide; Triclordiuride; Triclormetiazida; Triclormetiazide; Triflumen;American Urologicals Brand of Trichloromethiazide; Jones Brand of Trichloromethiazide; Schering Brand of Trichlormethiazide; Triclormetiazide [DCIT]; Triclormetiazide [Italian]; Achletin (TN); Ciba 7057-Su; Diu-Hydrin; Flurese (VAN); Naqua (TN); Salurin (wadel); Trichlormethiazide W/ Reserpine; Trichlormethiazide [INN:JAN]; Trichlormethiazidum [INN-Latin]; Trichloromethiazide, 6; Triclormetiazida[INN-Spanish]; Triflumen (TN); Diu-Hydrin (TN); Trichlormethiazide (JP15/USP/INN); (+-)-6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-,1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide; 3-Dichloromethylhydrochlorothiazide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-[dichloromethyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-Chloro-3-dichloromethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; 6-Chloro-3-dichloromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide
DMHAQCO	CP	Hoechst Marion Roussel
DMHAQCO	TC	Antihypertensive Agents
DMHAQCO	DT	Small molecular drug
DMHAQCO	PC	5560
DMHAQCO	MW	380.7
DMHAQCO	FM	C8H8Cl3N3O4S2
DMHAQCO	IC	InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)
DMHAQCO	CS	C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl
DMHAQCO	IK	LMJSLTNSBFUCMU-UHFFFAOYSA-N
DMHAQCO	IU	6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMHAQCO	CA	CAS 133-67-5
DMHAQCO	CB	CHEBI:9683
DMHAQCO	DE	Hypertension

DMPWGBR	ID	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	HS	Approved
DMPWGBR	SN	Triclabendazole; 68786-66-3; Fasinex; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; C14H9Cl3N2OS; Triclabendazolum [INN-Latin]; Triclabendazol [INN-Spanish]; CCRIS 8988; UNII-4784C8E03O; CGA 89317; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole; CPD000466357; MLS001424101; CHEMBL1086440; 6-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole; 4784C8E03O; NCGC00164610-01; Triclabendazole, 98%; SMR000466357; AK-68238; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole
DMPWGBR	DT	Small molecular drug
DMPWGBR	PC	50248
DMPWGBR	MW	359.7
DMPWGBR	FM	C14H9Cl3N2OS
DMPWGBR	IC	InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)
DMPWGBR	CS	CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl
DMPWGBR	IK	NQPDXQQQCQDHHW-UHFFFAOYSA-N
DMPWGBR	IU	6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole
DMPWGBR	CA	CAS 68786-66-3
DMPWGBR	CB	CHEBI:94759
DMPWGBR	DE	Helminth infection

DMZUR4N	ID	DMZUR4N
DMZUR4N	DN	Triclosan
DMZUR4N	HS	Approved
DMZUR4N	SN	triclosan; 3380-34-5; 5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL; 2,4,4'-Trichloro-2'-hydroxydiphenyl ether; Irgasan; Cloxifenolum; Triclosanum; Irgasan DP300; Stri-Dex Face Wash; Phenol, 5-chloro-2-(2,4-dichlorophenoxy)-; Lexol 300; Stri-Dex Cleansing Bar; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Triclosanum [INN-Latin]; CH 3565; DP-300; Caswell No 186A; C12H7Cl3O2; UNII-4NM5039Y5X; HSDB 7194; CHEBI:164200; Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl; Phenyl ether, 2'-hydroxy-2,4,4'-trichloro-; EINECS 222-182-2; CHEMBL849; EPA;  Aquasept; Cliniclean; Cloxifenol; Manusept; Sapoderm; TCL; Trisan; Clearasil DailyFace Wash; Dermtek Brand of Triclosan; GlaxoSmithKline Brand of Triclosan; Microshield T; Oxy Skin Wash; Pharmachem Brand of Triclosan; Reckitt Brand of Triclosan; SSL Brand of Triclosan; Ster Zac Bath Concentrate; SterZac Bath Concentrate; Trans Canaderm Brand of Triclosan; Triclosan Pharmachem Brand; Triclosan Reckitt Brand; IN1424; Irgasan DP 300; CH-3565; Johnson & Johnson Brand of Triclosan; Procter & Gamble Brand of Triclosan; Ster-Zac Bath Concentrate; Stri-Dex cleansing bar (TN); Triclosan (USP/INN); Triclosan [USAN:BAN:INN]; 2,4,4'-Trichloro-2'-hydroxy diphenyl ether; 2-Hydroxy-2',4,4'-trichlorodiphenyl Ether; WL-1001
DMZUR4N	TC	Antibiotics
DMZUR4N	DT	Small molecular drug
DMZUR4N	PC	5564
DMZUR4N	MW	289.5
DMZUR4N	FM	C12H7Cl3O2
DMZUR4N	IC	InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H
DMZUR4N	CS	C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl
DMZUR4N	IK	XEFQLINVKFYRCS-UHFFFAOYSA-N
DMZUR4N	IU	5-chloro-2-(2,4-dichlorophenoxy)phenol
DMZUR4N	CA	CAS 3380-34-5
DMZUR4N	CB	CHEBI:164200
DMZUR4N	DE	Trypanosomiasis; Infection of P. falciparum; Malaria

DMVLHNI	ID	DMVLHNI
DMVLHNI	DN	Tridihexethyl
DMVLHNI	HS	Approved
DMVLHNI	SN	Pathilon; Propethonum; (3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium; 3-cyclohexyl-N,N,N-triethyl-3-hydroxy-3-phenylpropan-1-aminium
DMVLHNI	TC	Anticholinergic Agents
DMVLHNI	DT	Small molecular drug
DMVLHNI	PC	20299
DMVLHNI	MW	318.5
DMVLHNI	FM	C21H36NO+
DMVLHNI	IC	InChI=1S/C21H36NO/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3/q+1
DMVLHNI	CS	CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O
DMVLHNI	IK	NPRHVSBSZMAEIN-UHFFFAOYSA-N
DMVLHNI	IU	(3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium
DMVLHNI	CA	CAS 60-49-1
DMVLHNI	CB	CHEBI:9701
DMVLHNI	DE	Acquired nystagmus

DMD2WPG	ID	DMD2WPG
DMD2WPG	DN	Trientine
DMD2WPG	HS	Approved
DMD2WPG	SN	Trientine HCl; 21121-06-2; triethylenetetramine HCl; SMR000058543; AC1NUQ0M; MLS000069683; SCHEMBL205201; CHEMBL1200783; CTK0I9735; DTXSID80419994; XPVOJYDIBHYVFL-UHFFFAOYSA-N; Pharmakon1600-01505675; NSC759164; NSC158271; AKOS027276425; NSC-158271; NSC-759164; 1, N,N'-bis(2-aminoethyl)-, tetrahydrochloride; 1,2-Ethanediamine, N,N'-bis(2-aminoethyl)-, hydrochloride; N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine hydrochloride
DMD2WPG	DT	Small molecular drug
DMD2WPG	PC	5565
DMD2WPG	MW	146.23
DMD2WPG	FM	C6H18N4
DMD2WPG	IC	InChI=1S/C6H18N4/c7-1-3-9-5-6-10-4-2-8/h9-10H,1-8H2
DMD2WPG	CS	C(CNCCNCCN)N
DMD2WPG	IK	VILCJCGEZXAXTO-UHFFFAOYSA-N
DMD2WPG	IU	N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine
DMD2WPG	CA	CAS 112-24-3
DMD2WPG	CB	CHEBI:39501
DMD2WPG	DE	Inborn error of metabolism

DMOL793	ID	DMOL793
DMOL793	DN	Trifarotene
DMOL793	HS	Approved
DMOL793	SN	Trifarotene; UNII-0J8RN2W0HK; 895542-09-3; CD5789; 0J8RN2W0HK; Trifarotene [USAN:INN]; CD 5789; SCHEMBL381493; GTPL9962; CHEMBL3707313; DTXSID30237781; EX-A2704; DB12808; compound 15b [PMID: 29706423]; 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic acid; HY-100256; CS-0018407; 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid; [1,1':3',1''-Terphenyl]-4-carboxylic acid, 3''-(1,1-dimethylethyl)-4'-(2-hydroxyethoxy)-4''-(1-pyrrolidinyl)-
DMOL793	CP	Galderma
DMOL793	DT	Small molecular drug
DMOL793	PC	11518241
DMOL793	MW	459.6
DMOL793	FM	C29H33NO4
DMOL793	IC	InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
DMOL793	CS	CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4
DMOL793	IK	MFBCDACCJCDGBA-UHFFFAOYSA-N
DMOL793	IU	4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid
DMOL793	CA	CAS 895542-09-3
DMOL793	DE	Acne vulgaris

DMKBYWI	ID	DMKBYWI
DMKBYWI	DN	Trifluoperazine
DMKBYWI	HS	Approved
DMKBYWI	SN	Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
DMKBYWI	CP	GlaxoSmithKline plc
DMKBYWI	TC	Antipsychotic Agents
DMKBYWI	DT	Small molecular drug
DMKBYWI	PC	5566
DMKBYWI	MW	407.5
DMKBYWI	FM	C21H24F3N3S
DMKBYWI	IC	InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
DMKBYWI	CS	CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
DMKBYWI	IK	ZEWQUBUPAILYHI-UHFFFAOYSA-N
DMKBYWI	IU	10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine
DMKBYWI	CA	CAS 117-89-5
DMKBYWI	CB	CHEBI:45951
DMKBYWI	DE	Schizophrenia

DMKFQJP	ID	DMKFQJP
DMKFQJP	DN	Triflupromazine
DMKFQJP	HS	Approved
DMKFQJP	SN	Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN)
DMKFQJP	CP	Bristol-Myers Squibb
DMKFQJP	TC	Antipsychotic Agents
DMKFQJP	DT	Small molecular drug
DMKFQJP	PC	5568
DMKFQJP	MW	352.4
DMKFQJP	FM	C18H19F3N2S
DMKFQJP	IC	InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
DMKFQJP	CS	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F
DMKFQJP	IK	XSCGXQMFQXDFCW-UHFFFAOYSA-N
DMKFQJP	IU	N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine
DMKFQJP	CA	CAS 146-54-3
DMKFQJP	CB	CHEBI:9711
DMKFQJP	DE	Psychotic disorder

DMG2YBD	ID	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	HS	Approved
DMG2YBD	SN	Fluridine; TFDU; TRIFLUOROTHYMIDINE; Trifluoridine; Trifluoromethyldeoxyuridine; Trifluridina; Trifluridinum; Virophta; Viroptic; Trifluorothymine deoxyriboside; CF3dUrd; F3DThd; F3T; F3TDR; HS-0007; Trifluridina [INN-Spanish]; Trifluridine [USAN:INN]; Trifluridinum [INN-Latin]; Viroptic (TN); Trifluridine (USP/INN);Viroptic, Trifluorothymidine, Trifluridine; Alpha,alpha,alpha-Trifluorothymidine; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2'-Deoxy-5-(trifluoromethyl)uridine; 2'-Deoxy-5-trifluoromethyluridine; 5-(Trifluoromethyl)-2'-deoxyuridine; 5-(Trifluoromethyl)deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoromethyl-2-deoxyuridine; 5-Trifluorothymidine
DMG2YBD	CP	Monarch Pharmaceuticals
DMG2YBD	TC	Antiviral Agents
DMG2YBD	DT	Small molecular drug
DMG2YBD	PC	6256
DMG2YBD	MW	296.2
DMG2YBD	FM	C10H11F3N2O5
DMG2YBD	IC	InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
DMG2YBD	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
DMG2YBD	IK	VSQQQLOSPVPRAZ-RRKCRQDMSA-N
DMG2YBD	IU	1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
DMG2YBD	CA	CAS 70-00-8
DMG2YBD	CB	CHEBI:75179
DMG2YBD	DE	Virus infection

DMB19L8	ID	DMB19L8
DMB19L8	DN	Trihexyphenidyl
DMB19L8	HS	Approved
DMB19L8	SN	trihexyphenidyl; Benzhexol; Triphenidyl; Trihexyphenidyle; Parkinane retard; Benzhexolum; 144-11-6; Trihexyphenidylum; Sedrena (free base); Trihexifenidilo; Trihexyphenidyle [INN-French]; Trihexifenidilo [INN-Spanish]; Trihexyphenidylum [INN-Latin]; Artane; Trihexylphenizyl; Trihexylphenidyl; Trihexylphenidyle; Trihexyphenidyl [INN:BAN]; Trihexylphenedyl; HSDB 3196; EINECS 205-614-4; NSC 12268; 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-; 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol; BRN 0088959;  Benzhexol; Trihexane; Trihexy; Artane Sequels; PMS Trihexyphenidyl; Apo-Trihex; Artane (TN); Trihexyphenidyl (INN); Apo-Trihex (TN); Apo-trihex (TN); SWR-0342SA
DMB19L8	CP	Lederle Laboratories Div American Cyanamid Co
DMB19L8	TC	Antiparkinson Agents
DMB19L8	DT	Small molecular drug
DMB19L8	PC	5572
DMB19L8	MW	301.5
DMB19L8	FM	C20H31NO
DMB19L8	IC	InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2
DMB19L8	CS	C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O
DMB19L8	IK	HWHLPVGTWGOCJO-UHFFFAOYSA-N
DMB19L8	IU	1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DMB19L8	CA	CAS 144-11-6
DMB19L8	CB	CHEBI:9720
DMB19L8	DE	Dystonia; Parkinson disease; Obesity

DMP5A4T	ID	DMP5A4T
DMP5A4T	DN	Trilaciclib
DMP5A4T	HS	Approved
DMP5A4T	SN	G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra
DMP5A4T	CP	G1 Therapeutics Research Triangle Park, NC
DMP5A4T	PC	68029831
DMP5A4T	MW	446.5
DMP5A4T	FM	C24H30N8O
DMP5A4T	IC	InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
DMP5A4T	CS	CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
DMP5A4T	IK	PDGKHKMBHVFCMG-UHFFFAOYSA-N
DMP5A4T	IU	4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
DMP5A4T	CA	CAS 1374743-00-6
DMP5A4T	DE	Triple negative breast cancer; Small-cell lung cancer

DMQZ9GF	ID	DMQZ9GF
DMQZ9GF	DN	Trilostane
DMQZ9GF	HS	Approved
DMQZ9GF	SN	Desopan; Desopan (TN); Modrenal (TN); Vetoryl (TN); Vetoryl, Trilostane; Win-24540; Trilostane (JAN/USAN); (4alpha,5alpha,17beta)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile; 3,17beta-dihydroxy-4alpha,5-epoxy-5alpha-androst-2-ene-2-carbonitrile
DMQZ9GF	CP	Dechra Pharmaceuticals
DMQZ9GF	DT	Small molecular drug
DMQZ9GF	PC	656583
DMQZ9GF	MW	329.4
DMQZ9GF	FM	C20H27NO3
DMQZ9GF	IC	InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1
DMQZ9GF	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@]45[C@@]3(CC(=C([C@H]4O5)O)C#N)C
DMQZ9GF	IK	KVJXBPDAXMEYOA-CXANFOAXSA-N
DMQZ9GF	IU	(1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile
DMQZ9GF	CA	CAS 13647-35-3
DMQZ9GF	CB	CHEBI:32260
DMQZ9GF	DE	Cushing disease

DM1QLST	ID	DM1QLST
DM1QLST	DN	Trimazosin
DM1QLST	HS	Approved
DM1QLST	SN	Trimazosin hydrochloride; Trimazosin HCl; 53746-46-6; UNII-827T79ILE7; Trimazosin hydrochloride [USAN]; 827T79ILE7; Trimazosin hydrochloride monohydrate; Trimazosin hydrochloride (USAN); 35795-16-5 (Parent); Cardovar; Supres; Trimazosin hydrochlorid-1-wasser; AC1Q3ECH; CP 19106-1; AC1L21UN; SCHEMBL10363255; CHEMBL3989848; DTXSID40202021; Trimazosin monohydrochloride monohydrate; 2-Hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylate monohydrochloride monohydrate; 1-Piperazinecarboxylic aci
DM1QLST	DT	Small molecular drug
DM1QLST	PC	37264
DM1QLST	MW	435.5
DM1QLST	FM	C20H29N5O6
DM1QLST	IC	InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)
DM1QLST	CS	CC(C)(COC(=O)N1CCN(CC1)C2=NC3=C(C(=C(C=C3C(=N2)N)OC)OC)OC)O
DM1QLST	IK	YNZXWQJZEDLQEG-UHFFFAOYSA-N
DM1QLST	IU	(2-hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
DM1QLST	CA	CAS 35795-16-5
DM1QLST	CB	CHEBI:135710
DM1QLST	DE	Congestive heart failure

DMPYQ7B	ID	DMPYQ7B
DMPYQ7B	DN	Trimebutine
DMPYQ7B	HS	Approved
DMPYQ7B	SN	Trimebutine maleate; Trimedat; Dromostat; Ibutin; Digerent polifarma; EINECS 251-845-9; TM 906; (1-Ethyl-1-phenyl-2-(3,4,5-trimethoxybenzoyloxy)ethyl)dimethylammonium hydrogen maleate; AC1O5HFA; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethylphenethyl ester, maleate (1:1); 34140-59-5; SCHEMBL1652810; C22H29NO5.C4H4O4; AKOS026750056; LS-38470; dimethyl-[2-phenyl-1-(3,4,5-trimethoxybenzoyl)oxybutan-2-yl]azanium; (E)-4-hydroxy-4-oxobut-2-enoate; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethyl
DMPYQ7B	DT	Small molecular drug
DMPYQ7B	PC	5573
DMPYQ7B	MW	387.5
DMPYQ7B	FM	C22H29NO5
DMPYQ7B	IC	InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3
DMPYQ7B	CS	CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C
DMPYQ7B	IK	LORDFXWUHHSAQU-UHFFFAOYSA-N
DMPYQ7B	IU	[2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate
DMPYQ7B	CA	CAS 58997-89-0
DMPYQ7B	CB	CHEBI:94458
DMPYQ7B	DE	Irritable bowel syndrome

DMEMV9D	ID	DMEMV9D
DMEMV9D	DN	Trimeprazine
DMEMV9D	HS	Approved
DMEMV9D	SN	Alimemazina; Alimemazine; Alimemazinum; Alimezine; Isobutrazine; Methylpromazine; Oxomemazin; Repetin; Teralen; Trimeperazine; Trimeprazine Tartrat; Bayer 1219; Alimemazina [INN-Spanish]; Alimemazine (INN); Alimemazine [INN:BAN]; Alimemazinum [INN-Latin]; Dl-Trimeprazine; Nedeltran (TN); Oxomemazine [DCF:INN]; Panectyl (TN); Repeltin (TN); Temaril (TN); Therafene (TN); Theralen (TN); Theralene (TN); Trimeprazine (BAN); Vallergan (TN); Vanectyl (TN); Trimeprazine 5,5-dioxide; Trimeprazine hemi-(+)-tartrate; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; (+-)-Alimemazine; (+-)-Trimeprazine; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine
DMEMV9D	CP	Allergan Herbert Skin Care Div Allergan Inc
DMEMV9D	TC	Antihistamines
DMEMV9D	DT	Small molecular drug
DMEMV9D	PC	5574
DMEMV9D	MW	298.4
DMEMV9D	FM	C18H22N2S
DMEMV9D	IC	InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
DMEMV9D	CS	CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C
DMEMV9D	IK	ZZHLYYDVIOPZBE-UHFFFAOYSA-N
DMEMV9D	IU	N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine
DMEMV9D	CA	CAS 84-96-8
DMEMV9D	CB	CHEBI:9725
DMEMV9D	DE	Allergic rhinitis

DM0Q8MZ	ID	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	HS	Approved
DM0Q8MZ	SN	Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]
DM0Q8MZ	TC	Anticonvulsants
DM0Q8MZ	DT	Small molecular drug
DM0Q8MZ	PC	5576
DM0Q8MZ	MW	143.14
DM0Q8MZ	FM	C6H9NO3
DM0Q8MZ	IC	InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
DM0Q8MZ	CS	CC1(C(=O)N(C(=O)O1)C)C
DM0Q8MZ	IK	IRYJRGCIQBGHIV-UHFFFAOYSA-N
DM0Q8MZ	IU	3,5,5-trimethyl-1,3-oxazolidine-2,4-dione
DM0Q8MZ	CA	CAS 127-48-0
DM0Q8MZ	CB	CHEBI:9727
DM0Q8MZ	DE	Pancreatic cancer; Epilepsy

DMHF4IQ	ID	DMHF4IQ
DMHF4IQ	DN	Trimethaphan
DMHF4IQ	HS	Approved
DMHF4IQ	SN	Thimethaphan; Trimetaphan; Trimetaphanum; Arfonad (TN); Thieno(1',2':1,2)thieno(3,4-d)imidazol-5-ium, decahydro-2-oxo-1,3-bis(phenylmethyl)-(VAN); 1,3-dibenzyl-2-oxodecahydrothieno[1',2':1,2]thieno[3,4-d]imidazol-5-ium
DMHF4IQ	CP	Hoffmann La Roche Inc
DMHF4IQ	TC	Antihypertensive Agents
DMHF4IQ	DT	Small molecular drug
DMHF4IQ	PC	23576
DMHF4IQ	MW	365.5
DMHF4IQ	FM	C22H25N2OS+
DMHF4IQ	IC	InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1
DMHF4IQ	CS	C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5
DMHF4IQ	IK	CHQOEHPMXSHGCL-UHFFFAOYSA-N
DMHF4IQ	IU	3,5-dibenzyl-8-thionia-3,5-diazatricyclo[6.3.0.02,6]undecan-4-one
DMHF4IQ	CA	CAS 7187-66-8
DMHF4IQ	CB	CHEBI:9728
DMHF4IQ	DE	Aneurysm; Hypertensive emergency

DMM7CHK	ID	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	HS	Approved
DMM7CHK	SN	Abaprim; Alprim; Anitrim; Antrima; Antrimox; Bacdan; Bacidal; Bacide; Bacin; Bacta; Bacterial; Bacticel; Bactin; Bactoprim; Bactramin; Bencole; Bethaprim; Biosulten; Briscotrim; Chemotrin; Cidal; Colizole; Conprim; Cotrimel; Deprim; Duocide; Esbesul; Espectrin; Euctrim; Exbesul; Fermagex; Fortrim; Futin; Idotrim; Ikaprim; Instalac; Kombinax; Lagatrim; Lastrim; Methoprim; Metoprim; Monoprim; Monotrim; Monotrimin; Novotrimel; Omstat; Oraprim; Pancidim; Polytrim; Priloprim; Primosept; Primsol; Proloprim; Protrin; Purbal; Resprim; Roubac; Roubal; Salvatrim; Setprin; Sinotrim; Stopan; Streptoplus; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Sulmeprim; Sulthrim; Sultrex; Syraprim; Tiempe; Toprim; Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimethopriom; Trimetoprim; Trimetoprima; Trimexazole; Trimexol; Trimezol; Trimogal; Trimono; Trimopan; Trimpex; Triprim; Trisul; Trisulcom; Trisulfam; Trisural; Uretrim; Urobactrim; Utetrin; Velaten; Wellcoprim; Wellcoprin; Xeroprim; Zamboprim; Bacterial [Antibiotic]; Colizole DS; Component of Bactrim; Component of Septra; Lagatrim Forte; ResprimForte; Septrin DS; Septrin Forte; Septrin S; Trimetoprim [DCIT]; Trimetoprim [Polish]; BW 5672; KUC103659N; NIH 204; T 7883; Trimpex 200; WR 5949; Alcorim-F; Apo-Sulfatrim; BW 56-72; Co-Trimoxizole; Monotrim (TN); NIH 204 (VAN); Proloprim (TN); Smz-Tmp; Sulfamethoxazole & Trimethoprim; TCMDC-125538; Tmp-Ratiopharm; Trimeth/Sulfa; Trimethopim(TMP); Trimethoprim & VRC3375; Trimethoprime [INN-French]; Trimethoprimum [INN-Latin]; Trimetoprima [INN-Spanish]; Trimez-IFSA; Trimpex (TN); Triprim (TN); U-Prin; Uro-D S; BW-56-72; KSC-4-158; AZT + TMP/SMX (mixture) combination; Trimethoprim (JAN/USP/INN); Trimethoprim [USAN:BAN:INN:JAN]
DMM7CHK	CP	GlaxoSmithKline
DMM7CHK	TC	Antiinfective Agents
DMM7CHK	DT	Small molecular drug
DMM7CHK	PC	5578
DMM7CHK	MW	290.32
DMM7CHK	FM	C14H18N4O3
DMM7CHK	IC	InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
DMM7CHK	CS	COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N
DMM7CHK	IK	IEDVJHCEMCRBQM-UHFFFAOYSA-N
DMM7CHK	IU	5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
DMM7CHK	CA	CAS 738-70-5
DMM7CHK	CB	CHEBI:45924
DMM7CHK	DE	Urinary tract infection

DMDEA85	ID	DMDEA85
DMDEA85	DN	Trimetrexate
DMDEA85	HS	Approved
DMDEA85	SN	TMQ; Trimetrexato; Trimetrexatum; JB 11; Jb-11; Trimetrexato [INN-Spanish]; Trimetrexatum [INN-Latin]; Trimetrexate (USAN/INN); Trimetrexate [USAN:BAN:INN]; 2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline; 5-Methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine; 5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine; 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; 6-[((3,4,5-Trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine
DMDEA85	CP	Medimmune Oncology Inc
DMDEA85	TC	Antifungal Agents
DMDEA85	DT	Small molecular drug
DMDEA85	PC	5583
DMDEA85	MW	369.4
DMDEA85	FM	C19H23N5O3
DMDEA85	IC	InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)
DMDEA85	CS	CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC
DMDEA85	IK	NOYPYLRCIDNJJB-UHFFFAOYSA-N
DMDEA85	IU	5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine
DMDEA85	CA	CAS 52128-35-5
DMDEA85	CB	CHEBI:9737
DMDEA85	DE	Toxoplasmosis

DM1SC8M	ID	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	HS	Approved
DM1SC8M	SN	Sapilent; Stangyl; Surmontil; Surmontyl; Trimeprimina; Trimeprimine; Trimeproprimin; Trimeproprimine; Trimipramina; Trimipraminum; Trimeprimina [Italian]; FI 6120; IL 6001; Beta-Methylimipramine; IL-6001; RP-7162; Rhotrimine (TN); Stangyl (TN); Surmontil (TN); Trimipramina [INN-Spanish]; Trimipraminum [INN-Latin]; Trimipramine (USAN/INN); Trimipramine [USAN:INN:BAN]; Trimipramine, (-)-Isomer; (+)-Trimipramine; (-)-Trimipramine; 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-(9CI); 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-(9CI); 7162 RP
DM1SC8M	CP	Odyssey Pharmaceuticals Inc
DM1SC8M	TC	Antidepressants
DM1SC8M	DT	Small molecular drug
DM1SC8M	PC	5584
DM1SC8M	MW	294.4
DM1SC8M	FM	C20H26N2
DM1SC8M	IC	InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
DM1SC8M	CS	CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C
DM1SC8M	IK	ZSCDBOWYZJWBIY-UHFFFAOYSA-N
DM1SC8M	IU	3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
DM1SC8M	CA	CAS 3564-75-8
DM1SC8M	CB	CHEBI:9738
DM1SC8M	DE	Major depressive disorder

DMZBU15	ID	DMZBU15
DMZBU15	DN	Tripelennamine
DMZBU15	HS	Approved
DMZBU15	SN	Benzoxale; Cizaron; Dehistin; Piribenzil; Pyribenzamin; Pyribenzamine; Pyridbenzamine; Resistamine; Tonaril; Tripelannamine; Tripelenamina; Tripelenamine; Tripelennamin; Tripelennamina; Tripelennaminum; Tripellenamine; Triplennamine; Vetibenzamina; Pyrinamine base; Tripelennamina [Italian]; Tripelennamine [BAN]; Tripelennamine [INN]; Ts and Blues; Pyribenzamine (TN); Pyristine (piristina); Tripelenamina [INN-Spanish]; Tripelennamine (INN); Tripelennaminum [INN-Latin]; Tripelennamine Citrate (1:1); Beta-Dimethylaminoethyl-2-pyridylaminotoluene; Beta-Dimethylaminoethyl-2-pyridylbenzylamine; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin [German]; Benzyl-(alpha.-pyridyl)-dimethylaethylendiamin; Benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine; N-Benzyl-N',N'-dimethyl-N-2-pyridylethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(2-pyridyl)ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Benzyl-N-(2-pyridyl)-N',N'-dimethyl ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha.-pyridyl)ethylenediamine; N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; N,N-Dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-1,2-ethanediamine; N,N-dimethyl-N'-(phenylmethyl)-N'-pyridin-2-ylethane-1,2-diamine; N-Benzyl-N',N'-Dimethyl-N-Pyridin-2-Yl-Ethane-1,2-Diamine Hydrochloride; 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-(9CI); 2-(Benzyl(2-dimethylaminoethyl)amino)pyridine; 2-(N-Benzyl-N-(2-dimethylaminoethyl)amino)pyridine; 2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine; 2-[Benzyl(2-dimethylaminoethyl)amino]pyridine; 2-[N-Benzyl-N-(2-dimethylaminoethyl)amino]pyridine
DMZBU15	CP	Norvatis Phamaceuticals Corporation
DMZBU15	TC	Antiallergic Agents
DMZBU15	DT	Small molecular drug
DMZBU15	PC	5587
DMZBU15	MW	255.36
DMZBU15	FM	C16H21N3
DMZBU15	IC	InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3
DMZBU15	CS	CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2
DMZBU15	IK	UFLGIAIHIAPJJC-UHFFFAOYSA-N
DMZBU15	IU	N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
DMZBU15	CA	CAS 91-81-6
DMZBU15	CB	CHEBI:9741
DMZBU15	DE	Hypersensitivity

DM7SWIA	ID	DM7SWIA
DM7SWIA	DN	Triprolidine
DM7SWIA	HS	Approved
DM7SWIA	SN	Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride
DM7SWIA	TC	Antiallergic Agents
DM7SWIA	DT	Small molecular drug
DM7SWIA	PC	5282443
DM7SWIA	MW	278.4
DM7SWIA	FM	C19H22N2
DM7SWIA	IC	InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
DM7SWIA	CS	CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC=N3
DM7SWIA	IK	CBEQULMOCCWAQT-WOJGMQOQSA-N
DM7SWIA	IU	2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine
DM7SWIA	CA	CAS 486-12-4
DM7SWIA	CB	CHEBI:84116
DM7SWIA	DE	Hay fever

DMTK4LS	ID	DMTK4LS
DMTK4LS	DN	Triptorelin
DMTK4LS	HS	Approved
DMTK4LS	SN	Gonapeptyl depot (TN)
DMTK4LS	CP	Tulane University
DMTK4LS	DT	Small molecular drug
DMTK4LS	PC	25074470
DMTK4LS	MW	1311.4
DMTK4LS	FM	C64H82N18O13
DMTK4LS	IC	InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1
DMTK4LS	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
DMTK4LS	IK	VXKHXGOKWPXYNA-PGBVPBMZSA-N
DMTK4LS	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMTK4LS	CA	CAS 57773-63-4
DMTK4LS	CB	CHEBI:63633
DMTK4LS	DE	Solid tumour/cancer; Prostate cancer

DMHB2C3	ID	DMHB2C3
DMHB2C3	DN	Trofosfamide
DMHB2C3	HS	Approved
DMHB2C3	SN	Trofosfamide; Trophosphamide; Ixoten; 22089-22-1; Trofosfamid; Triphosphamide; Trilofosfamida; Trifosfamide; Trisfosfamide; Trilophosphamide; Trofosfamidum; Z 4828; Trofosfamide [INN]; ASTA Z 4828; Trofosfamida [Spanish]; A-4828; Trofosfamidum [INN-Latin]; NSC 109723; Trofosfamido [INN-Spanish]; MLS002704177; CCRIS 4442; Z-4828; EINECS 244-770-8; Trofosfamide (INN); BRN 0532530; N,N,3-Tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N,N-3'-Tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine, 2-oxide
DMHB2C3	DT	Small molecular drug
DMHB2C3	PC	65702
DMHB2C3	MW	323.6
DMHB2C3	FM	C9H18Cl3N2O2P
DMHB2C3	IC	InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2
DMHB2C3	CS	C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl
DMHB2C3	IK	UMKFEPPTGMDVMI-UHFFFAOYSA-N
DMHB2C3	IU	N,N,3-tris(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DMHB2C3	CA	CAS 22089-22-1
DMHB2C3	CB	CHEBI:135381
DMHB2C3	DE	Non-hodgkin lymphoma

DM3VFPD	ID	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	HS	Approved
DM3VFPD	SN	Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
DM3VFPD	CP	Daiichi Sankyo Pharma Development
DM3VFPD	TC	Antiinflammatory Agents
DM3VFPD	DT	Small molecular drug
DM3VFPD	PC	5591
DM3VFPD	MW	441.5
DM3VFPD	FM	C24H27NO5S
DM3VFPD	IC	InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)
DM3VFPD	CS	CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C
DM3VFPD	IK	GXPHKUHSUJUWKP-UHFFFAOYSA-N
DM3VFPD	IU	5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM3VFPD	CA	CAS 97322-87-7
DM3VFPD	CB	CHEBI:9753
DM3VFPD	DE	Diabetic complication

DMUZNIG	ID	DMUZNIG
DMUZNIG	DN	Troleandomycin
DMUZNIG	HS	Approved
DMUZNIG	SN	Aovine; Cyclamycin; Evramicina; Matromicina; Oleandocetin; Oleandocetine; TAO; Treolmicina; Triacetyloleandomycin; Triacetyloleandomycinum; Tribiocillina; Triocetin; Triolan; Troleandomicina; Troleandomycine; Troleandomycinum; Viamicina; Wytrion; Matromycin T; Oleandomycin triacetate; Oleandomycin triacetyl ester; Triacetyl ester of oleandomycin; WY 651; Tao (TN); Tao (VAN); Tekmisin (TN); Treis-Micina; Triacetyloleandomycin (JAN); Triocetin (TN); Troleandomicina [INN-Spanish]; Troleandomycin (TAO); Troleandomycin [USAN:INN]; Troleandomycine [INN-French]; Troleandomycinum [INN-Latin]; Oleandomycin, triacetate (ester); T.A.O; Troleandomycin (USP/INN); T.A.O.
DMUZNIG	CP	Bayer Pharmaceuticals Corporation
DMUZNIG	TC	Antibiotics
DMUZNIG	DT	Small molecular drug
DMUZNIG	PC	202225
DMUZNIG	MW	814
DMUZNIG	FM	C41H67NO15
DMUZNIG	IC	InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1
DMUZNIG	CS	C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C
DMUZNIG	IK	LQCLVBQBTUVCEQ-QTFUVMRISA-N
DMUZNIG	IU	[(3R,5S,6S,7R,8S,9R,12R,13S,14S,15R)-6-[(2S,3R,4S,6R)-3-acetyloxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-8-[(2R,4S,5S,6S)-5-acetyloxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-10,16-dioxo-1,11-dioxaspiro[2.13]hexadecan-14-yl] acetate
DMUZNIG	CA	CAS 2751-09-9
DMUZNIG	CB	CHEBI:45735
DMUZNIG	DE	Bacterial infection

DMOBLGK	ID	DMOBLGK
DMOBLGK	DN	Tromethamine
DMOBLGK	HS	Approved
DMOBLGK	SN	Trometamol; 77-86-1; TROMETHAMINE; Tris; Tris(Hydroxymethyl)aminomethane; Tham; Trisamine; 2-Amino-2-(hydroxymethyl)-1,3-propanediol; Trizma; Tris buffer; Tris base; Tromethane; Trisaminol; Talatrol; Trispuffer; Trisamin; Pehanorm; Tutofusin tris; Tris-steril; Apiroserum Tham; Addex-tham; Tris-base; Tris, free base; Trimethylolaminomethane; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-; Tris Amino; Aminotrimethylolmethane; Aminotris(hydroxymethyl)methane; THAM-E; Tris (buffering agent); Tris(Hydroxymethyl)Aminomethane
DMOBLGK	DT	Small molecular drug
DMOBLGK	PC	6503
DMOBLGK	MW	121.14
DMOBLGK	FM	C4H11NO3
DMOBLGK	IC	InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2
DMOBLGK	CS	C(C(CO)(CO)N)O
DMOBLGK	IK	LENZDBCJOHFCAS-UHFFFAOYSA-N
DMOBLGK	IU	2-amino-2-(hydroxymethyl)propane-1,3-diol
DMOBLGK	CA	CAS 77-86-1
DMOBLGK	CB	CHEBI:9754
DMOBLGK	DE	Acidosis

DM1D90W	ID	DM1D90W
DM1D90W	DN	Tropicamide
DM1D90W	HS	Approved
DM1D90W	SN	Bistropamide; Epitromina; Mydral; Mydriacyl; Mydriafair; Mydriaticum; Mydrum; OcuTropic; Opticyl; Paremyd; Tropicacyl; Tropicamida; Tropicamidum; Tropikamid; Tropimil; Visumidriatic; Akorn Brand of Tropicamide; Alcon Brand of Tropicamide; Bournonville Brand of Tropicamide; Cahill May Roberts Brand of Tropicamide; Chauvin Brand of Tropicamide; Colircusi Tropicamida; Medical Ophthalmics Brand of Tropicamide; Minims tropicamide; Novartis Brand of Tropicamide; Ocu Tropic; Ocumed Brand of Tropicamide; Ocusoft Brand of Tropicamide; Pharmafair Brand of Tropicamide; Rivex Brand of Tropicamide; Triaminic DM; Tropicamide Alcon Brand; Tropicamide Chauvin Brand; Tropicamide Faure; Tropicamide Minims; Tropicamide Monofree; Tropicamide Novartis Brand; Tropicamide Ocumed Brand; Tropicamide Pharmafair Brand; Tropicamide Rivex Brand; Stulln Brand 1 of Tropicamide; Stulln Brand 2 of Tropicamide; T 9778; I-Picamide; Mydriacyl (TN); Ocu-Tropic; Ro 1-7683; Spectro-Cyl; Tropicamida [INN-Spanish]; Tropicamidum [INN-Latin]; Tropicamide [USAN:INN:BANJAN]; Tropicamide (JP15/USP/INN); Tropicamide Monohydrochloride, (R)-Isomer; Tropicamide Monohydrochloride, (S)-Isomer; Tropicamide, (R)-Isomer; Tropicamide, (S)-Isomer; N-Ethyl-N-(4-pyridylmethyl)tropamid; N-Ethyl-N-(4-pyridylmethyl)tropamide; N-ethyl-n-(g-picolyl)tropamide; Tropicamide, (+-)-Isomer; N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; N-Ethyl-2-phenyl-N-4-[-pyridyl-methyl]hydracrylamide; N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide; N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide; (+-)-N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide
DM1D90W	CP	Alcon Laboratories Inc
DM1D90W	TC	Diagnostic Agents
DM1D90W	DT	Small molecular drug
DM1D90W	PC	5593
DM1D90W	MW	284.35
DM1D90W	FM	C17H20N2O2
DM1D90W	IC	InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3
DM1D90W	CS	CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2
DM1D90W	IK	BGDKAVGWHJFAGW-UHFFFAOYSA-N
DM1D90W	IU	N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide
DM1D90W	CA	CAS 1508-75-4
DM1D90W	CB	CHEBI:9757
DM1D90W	DE	Mydriasis

DMNSJ7V	ID	DMNSJ7V
DMNSJ7V	DN	Tropisetron
DMNSJ7V	HS	Approved
DMNSJ7V	SN	Navoban; Novaban; TKT; ICS-205930; Navoban (TN); Tropisetron (INN); [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate
DMNSJ7V	CP	Novartis International AG
DMNSJ7V	DT	Small molecular drug
DMNSJ7V	PC	656665
DMNSJ7V	MW	284.35
DMNSJ7V	FM	C17H20N2O2
DMNSJ7V	IC	InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13?
DMNSJ7V	CS	CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43
DMNSJ7V	IK	ZNRGQMMCGHDTEI-FUNVUKJBSA-N
DMNSJ7V	IU	[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate
DMNSJ7V	CA	CAS 89565-68-4
DMNSJ7V	CB	CHEBI:32269
DMNSJ7V	DE	Fibromyalgia

DMX6RTG	ID	DMX6RTG
DMX6RTG	DN	Trospium
DMX6RTG	HS	Approved
DMX6RTG	SN	Spasmex; Spasmoplex; Trosec; Regurin (TN); Sanctura (TN); Spasmex (TN); Spasmoplex (TN); Trosec (TN); Trospium chloride (JAN/USAN/INN); Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-hydroxy-, chloride, benzilate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate chloride; 3-Hydroxyspiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium) chloride benzilate; 6,10-Ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate; 8-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride
DMX6RTG	CP	Allergan Pharmaceuticals
DMX6RTG	TC	Parasympatholytics
DMX6RTG	DT	Small molecular drug
DMX6RTG	PC	5284632
DMX6RTG	MW	392.5
DMX6RTG	FM	C25H30NO3+
DMX6RTG	IC	InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23?
DMX6RTG	CS	C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O
DMX6RTG	IK	OYYDSUSKLWTMMQ-AIZNXBIQSA-N
DMX6RTG	IU	[(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate
DMX6RTG	CA	CAS 47608-32-2
DMX6RTG	CB	CHEBI:145791
DMX6RTG	DE	Spasm; Overactive bladder

DM32XZT	ID	DM32XZT
DM32XZT	DN	Trospium chloride
DM32XZT	HS	Approved
DM32XZT	SN	Regurin; Sanctura
DM32XZT	TC	Respiratory Agents
DM32XZT	DT	Small molecular drug
DM32XZT	PC	5284631
DM32XZT	MW	428
DM32XZT	FM	C25H30ClNO3
DM32XZT	IC	InChI=1S/C25H30NO3.ClH/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26;/h1-6,9-12,21-23,28H,7-8,13-18H2;1H/q+1;/p-1/t21-,22+,23?;
DM32XZT	CS	C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-]
DM32XZT	IK	RVCSYOQWLPPAOA-DHWZJIOFSA-M
DM32XZT	IU	[(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride
DM32XZT	CA	CAS 10405-02-4
DM32XZT	CB	CHEBI:32270
DM32XZT	DE	Discovery agent

DM6AN32	ID	DM6AN32
DM6AN32	DN	Trovafloxacin
DM6AN32	HS	Approved
DM6AN32	SN	TVFX; Trovan; Fluorinated quinolone; Trovafloxacin [INN]; CP 99219; CP99219; CP 99,219; CP-99219;Trovafloxacin (INN); Trovan (TN); Trovan (oral); Turvel (TN); CP-99,219; (1alpha,5alpha,6alpha)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-((1R,5S)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
DM6AN32	CP	Pfizer Pharmaceuticals
DM6AN32	TC	Antiinfective Agents
DM6AN32	DT	Small molecular drug
DM6AN32	PC	62959
DM6AN32	MW	416.4
DM6AN32	FM	C20H15F3N4O3
DM6AN32	IC	InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16?
DM6AN32	CS	C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
DM6AN32	IK	WVPSKSLAZQPAKQ-SOSAQKQKSA-N
DM6AN32	IU	7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DM6AN32	CA	CAS 147059-72-1
DM6AN32	CB	CHEBI:9763
DM6AN32	DE	Bacterial infection

DMDHCK9	ID	DMDHCK9
DMDHCK9	DN	Trumenba
DMDHCK9	HS	Approved
DMDHCK9	SN	Meningococcal Group B Vaccine
DMDHCK9	CP	Wyeth; pfizer
DMDHCK9	DT	Vaccine
DMDHCK9	DE	Meningitis

DM4NTMO	ID	DM4NTMO
DM4NTMO	DN	TRYPAN BLUE
DM4NTMO	HS	Approved
DM4NTMO	SN	AC1O6WJ7; tetrasodium (3E)-5-amino-3-[[4-[4-[(2Z)-2-(8-amino-1-oxo-3,6-disulfonatonaphthalen-2-ylidene)hydrazinyl]-3-methylphenyl]-2-methylphenyl]hydrazinylidene]-4-oxonaphthalene-2,7-disulfonate; 3,3',3,3'-[(3,3'-Dimethylbiphenyl-4,4'-diyl)bis(iminonitrilo)]bis(3,4-dihydro-4-oxo-5-amino-2,7-naphthalenedisulfonic acid disodium) salt
DM4NTMO	DT	Small molecular drug
DM4NTMO	PC	6296
DM4NTMO	MW	960.8
DM4NTMO	FM	C34H24N6Na4O14S4
DM4NTMO	IC	InChI=1S/C34H28N6O14S4.4Na/c1-15-7-17(3-5-25(15)37-39-31-27(57(49,50)51)11-19-9-21(55(43,44)45)13-23(35)29(19)33(31)41)18-4-6-26(16(2)8-18)38-40-32-28(58(52,53)54)12-20-10-22(56(46,47)48)14-24(36)30(20)34(32)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4
DM4NTMO	CS	CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-])N)O)C)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O-])S(=O)(=O)[O-])N)O.[Na+].[Na+].[Na+].[Na+]
DM4NTMO	IK	GLNADSQYFUSGOU-UHFFFAOYSA-J
DM4NTMO	IU	tetrasodium;5-amino-3-[[4-[4-[(8-amino-1-hydroxy-3,6-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonate
DM4NTMO	CA	CAS 72-57-1
DM4NTMO	CB	CHEBI:78897
DM4NTMO	DE	Ophthalmic surgery injury

DMBZIVP	ID	DMBZIVP
DMBZIVP	DN	Tubocurarine
DMBZIVP	HS	Approved
DMBZIVP	SN	Amelizol; Delacurarine; Jexin; Tubadil; Tubaine; Tubarine; Tubocurarin; Tubocurarinum; Chlorure de tubocurarine; Cloruro de tubocurarina; Dextrotubocurarine chloride; Intocostrine T; Isoquinoline alkaloid; Tubocurarina cloruro; Tubocurarina cloruro [DCIT]; Tubocurarine chloride; Tubocurarine hydrochloride; Tubocurarini chloridum; Chlorure de tubocurarine [INN-French]; Cloruro de tubocurarina [INN-Spanish]; Curarin-haf; D-Paracurarine chloride; D-Tubocurarine; D-Tubocurarine chloride; D-Tubocurarine dichloride; D-Tubocurarine hydrochloride; Delacurarine (TN); Jex (TN); Metubine (TN); Tubaine (TN); Tubarine (TN); Tubocurarine chloride (INN); Tubocurarine chloride (TN); Tubocurarine chloride (anhydrous); Tubocurarini chloridum [INN-Latin]; Tubocurarinum (TN); D-(+)-Tubocurarine chloride; Tubocurarine, chloride, hydrochloride, (+)-(8CI); D-7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium chloride; Tubocuraranium, 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyl-, chloride, hydrochloride; (+)-Tubocurarine; (+)-Tubocurarine chloride; (+)-Tubocurarine chloride hydrochloride; 2,2',2'-trimethyl-6,6'-bis(methyloxy)tubocuraran-2,2'-diium-7',12'-diol dichloride; 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium; 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium
DMBZIVP	TC	Neuromuscular Nondepolarizing Agents
DMBZIVP	DT	Small molecular drug
DMBZIVP	PC	6000
DMBZIVP	MW	609.7
DMBZIVP	FM	C37H41N2O6+
DMBZIVP	IC	InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1
DMBZIVP	CS	CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC
DMBZIVP	IK	JFJZZMVDLULRGK-URLMMPGGSA-O
DMBZIVP	IU	(1S,16R)-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-30-aza-15-azoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol
DMBZIVP	CA	CAS 57-95-4
DMBZIVP	CB	CHEBI:9774
DMBZIVP	DE	Anaesthesia; Smoking dependence

DMBESUA	ID	DMBESUA
DMBESUA	DN	Tucatinib
DMBESUA	HS	Approved
DMBESUA	SN	Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE
DMBESUA	CP	Seattle Genetics Bothell, WA
DMBESUA	PC	51039094
DMBESUA	MW	480.5
DMBESUA	FM	C26H24N8O2
DMBESUA	IC	InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)
DMBESUA	CS	CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5
DMBESUA	IK	SDEAXTCZPQIFQM-UHFFFAOYSA-N
DMBESUA	IU	6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
DMBESUA	CA	CAS 937263-43-9
DMBESUA	DE	Gastric adenocarcinoma; HER2-positive breast cancer

DM749I3	ID	DM749I3
DM749I3	DN	Ubrogepant
DM749I3	HS	Approved
DM749I3	SN	1374248-77-7; UNII-AD0O8X2QJR; MK-1602; AD0O8X2QJR; Ubrogepant [USAN:INN]; Ubrogepant (USAN/INN); SCHEMBL3698428; CHEMBL2364638; GTPL10176; DTXSID00160178; DDOOFTLHJSMHLN-ZQHRPCGSSA-N; MK1602; ZINC95598454; SB19741; HY-12366; CS-0011109; D10673; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DM749I3	CP	Merck
DM749I3	DT	Small molecular drug
DM749I3	PC	68748835
DM749I3	MW	549.5
DM749I3	FM	C29H26F3N5O3
DM749I3	IC	InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1
DM749I3	CS	C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6
DM749I3	IK	DDOOFTLHJSMHLN-ZQHRPCGSSA-N
DM749I3	IU	(3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DM749I3	CA	CAS 1374248-77-7
DM749I3	DE	Migraine

DM1IQRP	ID	DM1IQRP
DM1IQRP	DN	Udenafil
DM1IQRP	HS	Approved
DM1IQRP	SN	Zydena; DA 8159; DA-8159; Zydena (TN); 3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide; 5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one
DM1IQRP	CP	Dong-A Pharmaceutical
DM1IQRP	TC	Vasodilator Agents
DM1IQRP	DT	Small molecular drug
DM1IQRP	PC	135413547
DM1IQRP	MW	516.7
DM1IQRP	FM	C25H36N6O4S
DM1IQRP	IC	InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
DM1IQRP	CS	CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C
DM1IQRP	IK	IYFNEFQTYQPVOC-UHFFFAOYSA-N
DM1IQRP	IU	3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
DM1IQRP	CA	CAS 268203-93-6
DM1IQRP	CB	CHEBI:135926
DM1IQRP	DE	Erectile dysfunction

DMX3O0D	ID	DMX3O0D
DMX3O0D	DN	UFT
DMX3O0D	HS	Approved
DMX3O0D	SN	Futraful; Orzel; UFUR; Tegafur + uracil; UFT + leucovorin; BMS-200604-01; Tegafur + uracil, Taiho/Bristol-Myers Squibb
DMX3O0D	CP	Taiho Pharmaceutical Co Ltd
DMX3O0D	DT	Small molecular drug
DMX3O0D	PC	104747
DMX3O0D	MW	312.25
DMX3O0D	FM	C12H13FN4O5
DMX3O0D	IC	InChI=1S/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8)
DMX3O0D	CS	C1CC(OC1)N2C=C(C(=O)NC2=O)F.C1=CNC(=O)NC1=O
DMX3O0D	IK	DHMYGZIEILLVNR-UHFFFAOYSA-N
DMX3O0D	IU	5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione
DMX3O0D	CA	CAS 74578-38-4
DMX3O0D	DE	Solid tumour/cancer

DMBNI20	ID	DMBNI20
DMBNI20	DN	Ulipristal
DMBNI20	HS	Approved
DMBNI20	SN	Ella (TN)
DMBNI20	CP	HRA Pharma
DMBNI20	DT	Small molecular drug
DMBNI20	PC	13559281
DMBNI20	MW	433.6
DMBNI20	FM	C28H35NO3
DMBNI20	IC	InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1
DMBNI20	CS	CC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
DMBNI20	IK	HKDLNTKNLJPAIY-WKWWZUSTSA-N
DMBNI20	IU	(8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMBNI20	CA	CAS 159811-51-5
DMBNI20	DE	Contraception

DMYRBO1	ID	DMYRBO1
DMYRBO1	DN	Umbralisib
DMYRBO1	HS	Approved
DMYRBO1	SN	RP5264; TGR-1202
DMYRBO1	CP	Tg therapeutics
DMYRBO1	PC	72950888
DMYRBO1	MW	571.5
DMYRBO1	FM	C31H24F3N5O3
DMYRBO1	IC	InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
DMYRBO1	CS	C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N
DMYRBO1	IK	IUVCFHHAEHNCFT-INIZCTEOSA-N
DMYRBO1	IU	2-[(1S)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one
DMYRBO1	CA	CAS 1532533-67-7
DMYRBO1	DE	Chronic lymphocytic leukaemia; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Marginal zone lymphoma

DM4E8O9	ID	DM4E8O9
DM4E8O9	DN	Umeclidinium
DM4E8O9	HS	Approved
DM4E8O9	SN	573719
DM4E8O9	CP	GlaxoSmithKline
DM4E8O9	DT	Small molecular drug
DM4E8O9	PC	11519070
DM4E8O9	MW	428.6
DM4E8O9	FM	C29H34NO2+
DM4E8O9	IC	InChI=1S/C29H34NO2/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25/h1-15,31H,16-24H2/q+1
DM4E8O9	CS	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5
DM4E8O9	IK	FVTWTVQXNAJTQP-UHFFFAOYSA-N
DM4E8O9	IU	diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol
DM4E8O9	CA	CAS 869185-19-3
DM4E8O9	CB	CHEBI:79041
DM4E8O9	DE	Chronic obstructive pulmonary disease

DMXNR04	ID	DMXNR04
DMXNR04	DN	Unoprostone
DMXNR04	HS	Approved
DMXNR04	DT	Small molecular drug
DMXNR04	PC	5311236
DMXNR04	MW	382.5
DMXNR04	FM	C22H38O5
DMXNR04	IC	InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1
DMXNR04	CS	CCCCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O
DMXNR04	IK	TVHAZVBUYQMHBC-SNHXEXRGSA-N
DMXNR04	IU	(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid
DMXNR04	CA	CAS 120373-36-6
DMXNR04	CB	CHEBI:39455
DMXNR04	DE	Glaucoma/ocular hypertension

DM32B5U	ID	DM32B5U
DM32B5U	DN	Upadacitinib
DM32B5U	HS	Approved
DM32B5U	SN	ABT-494
DM32B5U	CP	Abbvie
DM32B5U	PC	58557659
DM32B5U	MW	380.4
DM32B5U	FM	C17H19F3N6O
DM32B5U	IC	InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
DM32B5U	CS	CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
DM32B5U	IK	WYQFJHHDOKWSHR-MNOVXSKESA-N
DM32B5U	IU	(3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
DM32B5U	CA	CAS 1310726-60-3
DM32B5U	DE	Atopic dermatitis; Psoriatic arthritis; Crohn disease; Ulcerative colitis; Rheumatoid arthritis

DM8T2OI	ID	DM8T2OI
DM8T2OI	DN	Upadacitinib
DM8T2OI	HS	Approved
DM8T2OI	SN	Upadacitinib, ABT-494; J3.590.729G; Rinvoq; SB19218; SCHEMBL9991056; Upadacitinib; Upadacitinib (USAN/INN); Upadacitinib [USAN:INN]; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-; 1310726-59-0; 1310726-60-3; 4RA0KN46E0; ABT 494; ABT-494; ABT-494 enantiomer; AC-30326; BCP19011; CHEMBL3622821; CS-6150; D10994; EX-A1628; GTPL9246; HY-19569; MFCD30502663; UNII-4RA0KN46E0
DM8T2OI	PC	58557659
DM8T2OI	MW	380.4
DM8T2OI	FM	C17H19F3N6O
DM8T2OI	IC	WYQFJHHDOKWSHR-MNOVXSKESA-N
DM8T2OI	CS	CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
DM8T2OI	IK	1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
DM8T2OI	IU	(3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
DM8T2OI	CA	CAS 1310726-60-3
DM8T2OI	DE	Rheumatoid arthritis

DMHL7OB	ID	DMHL7OB
DMHL7OB	DN	Uracil mustard
DMHL7OB	HS	Approved
DMHL7OB	SN	Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol
DMHL7OB	TC	Anticancer Agents
DMHL7OB	DT	Small molecular drug
DMHL7OB	PC	6194
DMHL7OB	MW	252.09
DMHL7OB	FM	C8H11Cl2N3O2
DMHL7OB	IC	InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)
DMHL7OB	CS	C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl
DMHL7OB	IK	IDPUKCWIGUEADI-UHFFFAOYSA-N
DMHL7OB	IU	5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione
DMHL7OB	CA	CAS 66-75-1
DMHL7OB	CB	CHEBI:9884
DMHL7OB	DE	Acute myeloid leukaemia

DMD59GI	ID	DMD59GI
DMD59GI	DN	Urapidil
DMD59GI	HS	Approved
DMD59GI	SN	urapidil; 34661-75-1; Ebrantil; Eupressyl; Mediatensyl; Uraprene; Urapidilum [INN-Latin]; UNII-A78GF17HJS; NSC 310405; B-66256; C20H29N5O3; EINECS 252-130-4; BRN 0725782; A78GF17HJS; MLS003115907; 6-(3-(4-(o-Methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil; 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil; NCGC00016066-07; Ebrantil (TN); 6-((3-(4-(o-Methoxyphenyl)-1-piperazinyl)propyl)amino)-1,3-dimethyluracil; W-106718; Urapidilum; urapidil(jan); TgAAV-TNFR:Fc
DMD59GI	DT	Small molecular drug
DMD59GI	PC	5639
DMD59GI	MW	387.5
DMD59GI	FM	C20H29N5O3
DMD59GI	IC	InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
DMD59GI	CS	CN1C(=CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC
DMD59GI	IK	ICMGLRUYEQNHPF-UHFFFAOYSA-N
DMD59GI	IU	6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethylpyrimidine-2,4-dione
DMD59GI	CA	CAS 34661-75-1
DMD59GI	CB	CHEBI:32278
DMD59GI	DE	Hypertension; Inflammation

DMUK75B	ID	DMUK75B
DMUK75B	DN	Urea
DMUK75B	HS	Approved
DMUK75B	SN	carbamide; 57-13-6; Isourea; Carbonyldiamide; Ureophil; Carbonyldiamine; Carbamimidic acid; Pseudourea; Ureaphil; Urevert; Carbaderm; Alphadrate; Keratinamin; Calmurid; Aquadrate; Carbonyl diamide; Pastaron; Urepearl; Carbamide resin; Ultra Mide; Varioform ii; Aqua Care; Prespersion, 75 urea; carmol; basodexan; Harnstoff; Nutraplus; Mocovina; Urea solution; Supercel 3000; Aqua Care HP; Ureacin-20; Ureacin-40 Creme; Ureacin-10 lotion; Polyurea; Panafil; Onychomal; Hyanit; Caswell No. 902; Carbonyl Diamine; Mocovina [Czech]; Harnstoff [Ge
DMUK75B	DT	Small molecular drug
DMUK75B	PC	1176
DMUK75B	MW	60.056
DMUK75B	FM	CH4N2O
DMUK75B	IC	InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4)
DMUK75B	CS	C(=O)(N)N
DMUK75B	IK	XSQUKJJJFZCRTK-UHFFFAOYSA-N
DMUK75B	IU	urea
DMUK75B	CA	CAS 57-13-6
DMUK75B	CB	CHEBI:16199
DMUK75B	DE	Dermatological disease

DMQTREB	ID	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	HS	Approved
DMQTREB	SN	uridine; 58-96-8; Uridin; Uracil riboside; beta-Uridine; d-uridine; CHEBI:16704; b-Uridine; UNII-WHI7HQ7H85; Urd; AI3-52690; EINECS 200-407-5; WHI7HQ7H85; MLS000069625; Uracil-1-beta-d-ribofuranoside; C9H12N2O6; DRTQHJPVMGBUCF-XVFCMESISA-N; SMR000058222; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 1-beta-D-ribofuranosylpyrimidine-2,4(1H,3H)-dione
DMQTREB	DT	Small molecular drug
DMQTREB	PC	6029
DMQTREB	MW	244.2
DMQTREB	FM	C9H12N2O6
DMQTREB	IC	InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1
DMQTREB	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
DMQTREB	IK	DRTQHJPVMGBUCF-XVFCMESISA-N
DMQTREB	IU	1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMQTREB	CA	CAS 58-96-8
DMQTREB	CB	CHEBI:16704
DMQTREB	DE	Depression

DMG9HIA	ID	DMG9HIA
DMG9HIA	DN	Urofollitropin
DMG9HIA	HS	Approved
DMG9HIA	SN	Bravelle; Fertinex; Metrodin; Urofollitrophin; Fertinorm HP; Bravelle (TN); Fertinex (TN); Follistim (TN); Gonal-F(TN); (4-Threonine)oxytocin; 1,2-Dithia-5,8,11,14,17-penaazacycloeicosane, cyclic peptide deriv.; 4-(L-Threonine)oxytocin
DMG9HIA	TC	Fertility Agents
DMG9HIA	DT	Small molecular drug
DMG9HIA	SQ	Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>    <sequence format="FASTA">&gt;Beta chainNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
DMG9HIA	PC	62819
DMG9HIA	MW	980.2
DMG9HIA	FM	C42H65N11O12S2
DMG9HIA	IC	InChI=1S/C42H65N11O12S2/c1-6-21(4)33-40(63)52-34(22(5)54)41(64)49-28(16-31(44)56)37(60)50-29(19-67-66-18-25(43)35(58)47-27(38(61)51-33)15-23-9-11-24(55)12-10-23)42(65)53-13-7-8-30(53)39(62)48-26(14-20(2)3)36(59)46-17-32(45)57/h9-12,20-22,25-30,33-34,54-55H,6-8,13-19,43H2,1-5H3,(H2,44,56)(H2,45,57)(H,46,59)(H,47,58)(H,48,62)(H,49,64)(H,50,60)(H,51,61)(H,52,63)
DMG9HIA	CS	CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O
DMG9HIA	IK	ZDRRIRUAESZNIH-UHFFFAOYSA-N
DMG9HIA	IU	1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMG9HIA	DE	Female infertility

DM0GOUD	ID	DM0GOUD
DM0GOUD	DN	Urokinase
DM0GOUD	HS	Approved
DM0GOUD	TC	Thrombolytic Agents
DM0GOUD	SQ	DB00013 sequence: KPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL
DM0GOUD	DE	Myocardial infarction

DMCUT21	ID	DMCUT21
DMCUT21	DN	Ursodeoxycholic acid
DMCUT21	HS	Approved
DMCUT21	SN	Actigall; Antigall; Arsacol; Delursan; Destolit; Deursil; Litursol; Lyeton; Peptarom; Solutrat; UDCA; UDCS; UrSO; Urosiol; Ursacol; Ursobilin; Ursochol; Ursodamor; Ursodeoxycholate; Ursodiol; Ursofalk; Ursolvan; Ursosan; Acide ursodesoxycholique; Acido ursodeossicolico; Acido ursodeossicolico [Italian]; Acido ursodeoxicolico; Acidum ursodeoxycholicum; Deoxyursocholic Acid; Sodium Ursodeoxycholate; Ursacholic Acid; Urso DS; Urso Forte; Ursodeoxy cholic acid; Ursodesoxycholicacid; Ursodexycholic Acid; Ursodiol [USAN]; IU5; U0030; Urso 250; Acide ursodesoxycholique [INN-French]; Acido ursodeoxicolico [INN-Spanish]; Acidum ursodeoxycholicum [INN-Latin]; Actigall (TN); Cholit-ursan; Deursil (TN); Dom-ursodiol c; ISO-URSODEOXYCHOLIC ACID; PHL-ursodiol c; PMS-ursodiol c; U-9000; Urso (TN); Urso Forte (TN); Ursodiol (USP); Ursosan (TN); Ursodeoxycholic acid (JP15/INN); Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)-(9CI); (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol; 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid; 3,7-Dihydroxycholan-24-oic acid; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; 3-alpha,7-beta-Dihydroxycholanic acid; 3-alpha,7-beta-Dioxycholanic acid; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,7beta-Dihydroxy-5beta-cholanic acid; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; 5beta-Cholanic Acid-3alpha,7beta-diol; 7-beta-Hydroxylithocholic acid; 7beta-Hydroxylithocholic acid
DMCUT21	CP	Axcan Pharma
DMCUT21	TC	Cholagogues and Choleretics
DMCUT21	DT	Small molecular drug
DMCUT21	PC	31401
DMCUT21	MW	392.6
DMCUT21	FM	C24H40O4
DMCUT21	IC	InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1
DMCUT21	CS	C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMCUT21	IK	RUDATBOHQWOJDD-UZVSRGJWSA-N
DMCUT21	IU	(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMCUT21	CA	CAS 128-13-2
DMCUT21	CB	CHEBI:9907
DMCUT21	DE	Primary biliary cirrhosis

DMHTYK3	ID	DMHTYK3
DMHTYK3	DN	Ustekinumab
DMHTYK3	HS	Approved
DMHTYK3	SN	6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine; WR99210; WR-99210; 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE; 47326-86-3; BRN 0629517; WR 99210; 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-; WR-99,210; CHEMBL129788; BRL 6231; 1,6-Dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine; 1-(2',4',5'-Trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine;  Stelara (TN)
DMHTYK3	CP	Centocor Ortho Biotech
DMHTYK3	DT	Antibody
DMHTYK3	DE	Plaque psoriasis; Malaria; Inflammatory bowel disease; Psoriasis vulgaris

DMA630M	ID	DMA630M
DMA630M	DN	Vaccinia immune globulin
DMA630M	HS	Approved
DMA630M	CP	DynPort Vaccine Company LLC
DMA630M	DE	Vaccination

DMHKS94	ID	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	HS	Approved
DMHKS94	SN	Talavir; VACV; ValACV; Valacyclovir; Virval; Zelitrex; Valaciclovir Hcl; Valacyclover Hydrochloric; Valacyclover Hydrochloride; BW256U87; TBB067866; Acyclovir-valine; BW-256U; Valaciclovir (INN); Valaciclovir [INN:BAN]; Valaciclovir, Valtrex; Valtrex (TN); Zelitrex (TN); Valacyclovir, (L)-isomer; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9 H-purin-9-yl)methoxy]ethyl ester, monohydrochloride; 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate
DMHKS94	CP	GlaxoSmithKline
DMHKS94	TC	Antiviral Agents
DMHKS94	DT	Small molecular drug
DMHKS94	PC	135398742
DMHKS94	MW	324.34
DMHKS94	FM	C13H20N6O4
DMHKS94	IC	InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1
DMHKS94	CS	CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N
DMHKS94	IK	HDOVUKNUBWVHOX-QMMMGPOBSA-N
DMHKS94	IU	2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate
DMHKS94	CA	CAS 124832-26-4
DMHKS94	CB	CHEBI:35854
DMHKS94	DE	Virus infection

DM5I1CE	ID	DM5I1CE
DM5I1CE	DN	Valacyclovir Hydrochloride
DM5I1CE	HS	Approved
DM5I1CE	CP	Glaxosmithkline
DM5I1CE	TC	Antiinfective Agents
DM5I1CE	DT	Small molecular drug
DM5I1CE	PC	135398741
DM5I1CE	MW	360.8
DM5I1CE	FM	C13H21ClN6O4
DM5I1CE	IC	InChI=1S/C13H20N6O4.ClH/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20;/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20);1H/t8-;/m0./s1
DM5I1CE	CS	CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N.Cl
DM5I1CE	IK	ZCDDBUOENGJMLV-QRPNPIFTSA-N
DM5I1CE	IU	2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DM5I1CE	CA	CAS 124832-27-5
DM5I1CE	CB	CHEBI:9919
DM5I1CE	DE	Herpes simplex virus infection

DMQSA2V	ID	DMQSA2V
DMQSA2V	DN	Valbenazine tosylate
DMQSA2V	HS	Approved
DMQSA2V	SN	Valbenazine ditosylate; UNII-5SML1T733B; 5SML1T733B; Valbenazine tosylate [USAN]; Valbenazine tosylate (USAN); 1639208-54-0; NBI-98854 ditosylate
DMQSA2V	CP	Neurocrine Biosciences
DMQSA2V	DT	Small molecular drug
DMQSA2V	PC	92042922
DMQSA2V	MW	763
DMQSA2V	FM	C38H54N2O10S2
DMQSA2V	IC	InChI=1S/C24H38N2O4.2C7H8O3S/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4;2*1-6-2-4-7(5-3-6)11(8,9)10/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3;2*2-5H,1H3,(H,8,9,10)/t17-,19-,20-,23+;;/m1../s1
DMQSA2V	CS	CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC
DMQSA2V	IK	BXGKAGLZHGYAMW-TZYFFPFWSA-N
DMQSA2V	IU	[(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate;4-methylbenzenesulfonic acid
DMQSA2V	CA	CAS 1639208-54-0
DMQSA2V	DE	Tardive dyskinesia

DMAY7H4	ID	DMAY7H4
DMAY7H4	DN	Valdecoxib
DMAY7H4	HS	Approved
DMAY7H4	SN	Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide
DMAY7H4	TC	Antiinflammatory Agents
DMAY7H4	DT	Small molecular drug
DMAY7H4	PC	119607
DMAY7H4	MW	314.4
DMAY7H4	FM	C16H14N2O3S
DMAY7H4	IC	InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
DMAY7H4	CS	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N
DMAY7H4	IK	LNPDTQAFDNKSHK-UHFFFAOYSA-N
DMAY7H4	IU	4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide
DMAY7H4	CA	CAS 181695-72-7
DMAY7H4	CB	CHEBI:63634
DMAY7H4	DE	Osteoarthritis

DMS2IUH	ID	DMS2IUH
DMS2IUH	DN	Valganciclovir
DMS2IUH	HS	Approved
DMS2IUH	SN	Cymeval; RS 79070; RO1079070/194; Valcyte (TN); Valganciclovir (INN); Valganciclovir (Oral); Valganciclovir [INN:BAN]; L-Valine, ester with ganciclovir; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
DMS2IUH	CP	Roche Laboratories Inc
DMS2IUH	TC	Antiviral Agents
DMS2IUH	DT	Small molecular drug
DMS2IUH	PC	135413535
DMS2IUH	MW	354.36
DMS2IUH	FM	C14H22N6O5
DMS2IUH	IC	InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1
DMS2IUH	CS	CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
DMS2IUH	IK	WPVFJKSGQUFQAP-GKAPJAKFSA-N
DMS2IUH	IU	[2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
DMS2IUH	CA	CAS 175865-60-8
DMS2IUH	CB	CHEBI:63635
DMS2IUH	DE	Virus infection

DMCFE9I	ID	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	HS	Approved
DMCFE9I	SN	99-66-1; Dipropylacetic acid; Depakine; Depakene; 2-Propylvaleric acid; Ergenyl; Di-n-propylacetic acid; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; Propylvaleric acid; n-Dipropylacetic acid; Myproic Acid; Di-n-propylessigsaure; n-DPA; Dipropylacetate; Convulex; Depakin; Vupral; Acido valproico; Acide valproique; Acidum valproicum; Stavzor; Avugane; Baceca; Kyselina 2-propylvalerova; 2-n-Propyl-n-valeric acid; Acetic acid, dipropyl-; Abbott 44090; Valproinsaeure; Savicol; Convulsofin; Deproic; VPA; Depakin chrono; Dipropyl Acetate; Med Valproic; Valproic acid USP; Valproic acid USP24; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; Alti-Valproic; Depakote (TM); Dom-Valproic; G2M-777; Kyselina 2-propylvalerova [Czech]; N-DPA; N-Dipropylacetic acid; Novo-Valproic; Nu-Valproic; PMS-Valproic Acid; Penta-Valproic; Valproic acid (USP); Di-n-propylessigsaeure; Di-n-propylessigsaure [German]; Valproic acid [USAN:INN:BAN]; Valproic Acid, SodiumSalt (2:1); 2 PP (base)
DMCFE9I	CP	Abbot Phamaceuticals
DMCFE9I	TC	Neurology Agents
DMCFE9I	DT	Small molecular drug
DMCFE9I	PC	3121
DMCFE9I	MW	144.21
DMCFE9I	FM	C8H16O2
DMCFE9I	IC	InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
DMCFE9I	CS	CCCC(CCC)C(=O)O
DMCFE9I	IK	NIJJYAXOARWZEE-UHFFFAOYSA-N
DMCFE9I	IU	2-propylpentanoic acid
DMCFE9I	CA	CAS 99-66-1
DMCFE9I	CB	CHEBI:39867
DMCFE9I	DE	Epilepsy; Alcohol dependence

DMOYJFK	ID	DMOYJFK
DMOYJFK	DN	Valrubicin
DMOYJFK	HS	Approved
DMOYJFK	SN	Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester
DMOYJFK	TC	Anticancer Agents
DMOYJFK	DT	Small molecular drug
DMOYJFK	PC	454216
DMOYJFK	MW	723.6
DMOYJFK	FM	C34H36F3NO13
DMOYJFK	IC	InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1
DMOYJFK	CS	CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(=O)C(F)(F)F)O
DMOYJFK	IK	ZOCKGBMQLCSHFP-KQRAQHLDSA-N
DMOYJFK	IU	[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate
DMOYJFK	CA	CAS 56124-62-0
DMOYJFK	CB	CHEBI:135876
DMOYJFK	DE	Bladder cancer; Psoriasis vulgaris

DMREUQ6	ID	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	HS	Approved
DMREUQ6	SN	valsartan; 137862-53-4; Diovan; Tareg; Provas; L-Valsartan; CGP 48933; Exforge; CGP-48933; (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; UNII-80M03YXJ7I; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; CHEMBL1069; 80M03YXJ7I; CHEBI:9927; C24H29N5O3; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; 137863-60-6; AK-58790; Kalpress; Miten; Nisis;  Diovan; Vals; Valsarran; Walsartan; Aventis brand of valsartan; CEPA brand of valsartan; Esteve brand of valsartan; Lacer brand of valsartan; Novartis brand of valsartan; Sanol brand of valsartan; Schwarz brand of valsartan; Diovan (TN); Diovan, Valsartan; Valsartan [USAN:INN]; Valtan (TN); Valzaar (TN); Valsartan (JAN/USAN/INN); N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; [3H]valsartan
DMREUQ6	CP	Norvatis Phamaceuticals Corporation
DMREUQ6	TC	Antihypertensive Agents
DMREUQ6	DT	Small molecular drug
DMREUQ6	PC	60846
DMREUQ6	MW	435.5
DMREUQ6	FM	C24H29N5O3
DMREUQ6	IC	InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
DMREUQ6	CS	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O
DMREUQ6	IK	ACWBQPMHZXGDFX-QFIPXVFZSA-N
DMREUQ6	IU	(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
DMREUQ6	CA	CAS 137862-53-4
DMREUQ6	CB	CHEBI:9927
DMREUQ6	DE	Hypertension

DMK7T1Q	ID	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	HS	Approved
DMK7T1Q	SN	Vancocin; Vancoled; Vancomicina; Vancomicina [INN-Spanish]; Vancomycin (USP); Vancomycin [USAN:INN:BAN]; Vancomycin [USP:INN:BAN]; Vancomycine; Vancomycine [INN-French]; Vancomycinum; Vancomycinum [INN-Latin]; Viomycin derivative; VANCOMYCIN; VANCOR; vancomicin; vanomycin; 1404-90-6; 6Q205EH1VU; C66H75Cl2N9O24; CHEBI:28001; CHEMBL262777; EINECS 215-772-6; HSDB 3262; UNII-6Q205EH1VU; Vancomycin hydrochloride from Streptomyces orientalis
DMK7T1Q	PC	14969
DMK7T1Q	MW	1449.2
DMK7T1Q	FM	C66H75Cl2N9O24
DMK7T1Q	IC	MYPYJXKWCTUITO-LYRMYLQWSA-N
DMK7T1Q	CS	CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
DMK7T1Q	IK	1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1
DMK7T1Q	IU	(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
DMK7T1Q	CA	CAS 1404-90-6
DMK7T1Q	CB	CHEBI:28001
DMK7T1Q	DE	Methicillin-resistant staphylococcus infection

DMRICNP	ID	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	HS	Approved
DMRICNP	SN	Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)
DMRICNP	CP	AstraZeneca
DMRICNP	TC	Anticancer Agents
DMRICNP	DT	Small molecular drug
DMRICNP	PC	3081361
DMRICNP	MW	475.4
DMRICNP	FM	C22H24BrFN4O2
DMRICNP	IC	InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
DMRICNP	CS	CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC
DMRICNP	IK	UHTHHESEBZOYNR-UHFFFAOYSA-N
DMRICNP	IU	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
DMRICNP	CA	CAS 443913-73-3
DMRICNP	CB	CHEBI:49960
DMRICNP	DE	Solid tumour/cancer

DMTBGW8	ID	DMTBGW8
DMTBGW8	DN	Vardenafil
DMTBGW8	HS	Approved
DMTBGW8	SN	VDN; Levitra (TN); VARDENAFIL, LEVITRA; Vardenafil (INN); 1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one; 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4-ol
DMTBGW8	CP	Bayer Pharmaceuticals Corporation
DMTBGW8	TC	Antiimpotence Agents
DMTBGW8	DT	Small molecular drug
DMTBGW8	PC	135400189
DMTBGW8	MW	488.6
DMTBGW8	FM	C23H32N6O4S
DMTBGW8	IC	InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)
DMTBGW8	CS	CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C
DMTBGW8	IK	SECKRCOLJRRGGV-UHFFFAOYSA-N
DMTBGW8	IU	2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
DMTBGW8	CA	CAS 224785-90-4
DMTBGW8	CB	CHEBI:46295
DMTBGW8	DE	Erectile dysfunction

DMMUOLJ	ID	DMMUOLJ
DMMUOLJ	DN	Varenicline
DMMUOLJ	HS	Approved
DMMUOLJ	SN	CP 526555; Champix (TN); Chantix (TN); Varenicline (INN); 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline
DMMUOLJ	CP	Pfizer Pharmaceuticals
DMMUOLJ	DT	Small molecular drug
DMMUOLJ	PC	170361
DMMUOLJ	MW	211.26
DMMUOLJ	FM	C13H13N3
DMMUOLJ	IC	InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2
DMMUOLJ	CS	C1C2CNCC1C3=CC4=NC=CN=C4C=C23
DMMUOLJ	IK	JQSHBVHOMNKWFT-UHFFFAOYSA-N
DMMUOLJ	IU	5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
DMMUOLJ	CA	CAS 249296-44-4
DMMUOLJ	DE	Smoking dependence

DMQ2FPC	ID	DMQ2FPC
DMQ2FPC	DN	Vasopressin
DMQ2FPC	HS	Approved
DMQ2FPC	SN	Leiormone; Pitressin; Pituitrin; Tonephin; Vasopressina; Vasopressine; Vasopressins; Vasopressinum; American Pharmaceutical Brand of Vasopressin; American Regent Brand of Vasopressin; Antidiuretic Hormones; Antidiuretic hormone; Beta Hypophamine; Inyectable de vasopresina; Monarch Brand of Vasopressin; Solute injectable de vasopressine; Vasopressin Monarch Brand; Vasopressin injection; Vasopressina [DCIT]; Vasopressini injectio; ADH (hormone); Beta-Hypophamine; Inyectable de vasopresina [INN-Spanish]; Pitressin (TN); Solute injectable de vasopressine [INN-French]; Vasopressin (USP); Vasopressini injectio [INN-Latin]; Parke-Davis Brand of Vasopressin (USP); Vasopressin (JP15/USP)
DMQ2FPC	CP	Astellas Pharma
DMQ2FPC	TC	Vasoconstrictor Agents
DMQ2FPC	DT	Small molecular drug
DMQ2FPC	PC	644077
DMQ2FPC	MW	1084.2
DMQ2FPC	FM	C46H65N15O12S2
DMQ2FPC	IC	InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DMQ2FPC	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMQ2FPC	IK	KBZOIRJILGZLEJ-LGYYRGKSSA-N
DMQ2FPC	IU	(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMQ2FPC	CA	CAS 113-79-1
DMQ2FPC	CB	CHEBI:34543
DMQ2FPC	DE	Diabetes insipidus; Polyuria; Enuresis

DMP0UK2	ID	DMP0UK2
DMP0UK2	DN	Vecuronium
DMP0UK2	HS	Approved
DMP0UK2	SN	Norcuron (TN); (2A,3A,5A,16A,17A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMP0UK2	CP	Bedford Laboratories
DMP0UK2	TC	Analgesics
DMP0UK2	DT	Small molecular drug
DMP0UK2	PC	39765
DMP0UK2	MW	557.8
DMP0UK2	FM	C34H57N2O4+
DMP0UK2	IC	InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DMP0UK2	CS	CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C
DMP0UK2	IK	BGSZAXLLHYERSY-XQIGCQGXSA-N
DMP0UK2	IU	[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMP0UK2	CA	CAS 86029-43-8
DMP0UK2	CB	CHEBI:9939
DMP0UK2	DE	Spasm

DMV3YMX	ID	DMV3YMX
DMV3YMX	DN	Vedolizmab
DMV3YMX	HS	Approved
DMV3YMX	SN	4168-17-6
DMV3YMX	CP	Millennium Pharmaceuticals
DMV3YMX	DT	Monoclonal antibody
DMV3YMX	DE	Crohn disease; Ulcerative colitis

DM4BOAS	ID	DM4BOAS
DM4BOAS	DN	Velaglucerase alfa
DM4BOAS	HS	Approved
DM4BOAS	SN	Vpriv (TN)
DM4BOAS	CP	Shire
DM4BOAS	SQ	VPRIV Sequence: ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ
DM4BOAS	DE	Metabolic disorder

DMGF8ZQ	ID	DMGF8ZQ
DMGF8ZQ	DN	Velpatasvir
DMGF8ZQ	HS	Approved
DMGF8ZQ	SN	Velpatasvir; Velpatasvir [USAN:INN]; Verpatasvir; KCU0C7RS7Z; 1377049-84-7; GS 5816; GS-5816; GS5816; UNII-KCU0C7RS7Z; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
DMGF8ZQ	PC	67683363
DMGF8ZQ	MW	883
DMGF8ZQ	FM	C49H54N8O8
DMGF8ZQ	IC	FHCUMDQMBHQXKK-CDIODLITSA-N
DMGF8ZQ	CS	CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC
DMGF8ZQ	IK	1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
DMGF8ZQ	IU	methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
DMGF8ZQ	CA	CAS 1377049-84-7
DMGF8ZQ	CB	CHEBI:133009
DMGF8ZQ	DE	Viral hepatitis

DM62UG5	ID	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	HS	Approved
DM62UG5	SN	PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)
DM62UG5	CP	Daiichi Sankyo group; Genentech
DM62UG5	DT	Small molecular drug
DM62UG5	PC	42611257
DM62UG5	MW	489.9
DM62UG5	FM	C23H18ClF2N3O3S
DM62UG5	IC	InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
DM62UG5	CS	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
DM62UG5	IK	GPXBXXGIAQBQNI-UHFFFAOYSA-N
DM62UG5	IU	N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide
DM62UG5	CA	CAS 918504-65-1
DM62UG5	CB	CHEBI:63637
DM62UG5	DE	Melanoma

DM8I94Y	ID	DM8I94Y
DM8I94Y	DN	Venetoclax
DM8I94Y	HS	Approved
DM8I94Y	SN	Venclexta
DM8I94Y	DT	Small molecular drug
DM8I94Y	PC	49846579
DM8I94Y	MW	868.447
DM8I94Y	FM	C45H50ClN7O7S
DM8I94Y	IC	InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
DM8I94Y	CS	CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
DM8I94Y	IK	LQBVNQSMGBZMKD-UHFFFAOYSA-N
DM8I94Y	IU	4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
DM8I94Y	CA	CAS 1257044-40-8
DM8I94Y	CB	CHEBI:133021
DM8I94Y	DE	Chronic lymphocytic leukemia

DMR6QH0	ID	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	HS	Approved
DMR6QH0	SN	Efectin; Elafax; Venlafaxina; VenlafaxineXR; Venlafaxinum; Venlafaxine ER; Wy 45030; Efectin (TN); Venlafaxina [INN-Spanish];Venlafaxine (Effexor); Venlafaxine (INN); Venlafaxine [BAN:INN]; Venlafaxine [INN:BAN]; Venlafaxinum [INN-Latin]; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; 1-[(1R)-2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol
DMR6QH0	CP	Wyeth
DMR6QH0	TC	Antidepressants
DMR6QH0	DT	Small molecular drug
DMR6QH0	PC	5656
DMR6QH0	MW	277.4
DMR6QH0	FM	C17H27NO2
DMR6QH0	IC	InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3
DMR6QH0	CS	CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
DMR6QH0	IK	PNVNVHUZROJLTJ-UHFFFAOYSA-N
DMR6QH0	IU	1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol
DMR6QH0	CA	CAS 93413-69-5
DMR6QH0	CB	CHEBI:9943
DMR6QH0	DE	Depression

DMA7PEW	ID	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	HS	Approved
DMA7PEW	SN	Arpamyl; Calan; Calcan; Cordilox; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isotopin; Vasolan; Veracim; Verapamilo; Verapamilum; Veraptin; Verexamil; Bosoptin (TN); Calan (TN); D-365; Isoptin (TN); Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verelan (TN); CP-16533-1; Covera-HS (TN); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; (+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Verapamil (Na-Ca chanel blocker)
DMA7PEW	CP	Pfizer Inc
DMA7PEW	TC	Analgesics
DMA7PEW	DT	Small molecular drug
DMA7PEW	PC	2520
DMA7PEW	MW	454.6
DMA7PEW	FM	C27H38N2O4
DMA7PEW	IC	InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
DMA7PEW	CS	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DMA7PEW	IK	SGTNSNPWRIOYBX-UHFFFAOYSA-N
DMA7PEW	IU	2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DMA7PEW	CA	CAS 52-53-9
DMA7PEW	CB	CHEBI:77733
DMA7PEW	DE	Hypertension

DM7MDBE	ID	DM7MDBE
DM7MDBE	DN	Vericiguat
DM7MDBE	HS	Approved
DM7MDBE	SN	Vericiguat; 1350653-20-1; UNII-LV66ADM269; BAY-1021189; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate; BAY1021189; LV66ADM269; MK-1242; Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate; methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridin-3-yl)pyrimidin-5-yl)carbam
DM7MDBE	CP	Bayer HealthCare Pharmaceuticals
DM7MDBE	DT	Small molecular drug
DM7MDBE	PC	54674461
DM7MDBE	MW	426.4
DM7MDBE	FM	C19H16F2N8O2
DM7MDBE	IC	InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
DM7MDBE	CS	COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
DM7MDBE	IK	QZFHIXARHDBPBY-UHFFFAOYSA-N
DM7MDBE	IU	methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
DM7MDBE	CA	CAS 1350653-20-1
DM7MDBE	CB	CHEBI:142432
DM7MDBE	DE	Heart failure

DMIY6DB	ID	DMIY6DB
DMIY6DB	DN	Verteporfin
DMIY6DB	HS	Approved
DMIY6DB	SN	Visudyne (TN)
DMIY6DB	DT	Small molecular drug
DMIY6DB	PC	11980904
DMIY6DB	MW	1437.6
DMIY6DB	FM	C82H84N8O16
DMIY6DB	IC	InChI=1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t2*38-,41+/m00/s1
DMIY6DB	CS	CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C
DMIY6DB	IK	NJLRKAMQPVVOIU-IDLGWYNRSA-N
DMIY6DB	IU	3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid;3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-5-yl]propanoic acid
DMIY6DB	DE	Psoriasis vulgaris

DMBKX3C	ID	DMBKX3C
DMBKX3C	DN	VESNARINONE
DMBKX3C	HS	Approved
DMBKX3C	SN	vesnarinone; 81840-15-5; Arkin-Z; Piteranometozine; OPC-8212; Arkin; Vesnarinonum [Latin]; Vesnarinona [Spanish]; UNII-5COW40EV8M; OPC 8212; Vesnarinone [USAN:INN:JAN]; CCRIS 1451; DRG-0210; BRN 5644229; 5COW40EV8M; CHEMBL17423; 6-(4-(3,4-Dimethoxybenzoyl)-1-piperazinyl)-3,4-dihydro-2(1H)-; 1-(1,2,3,4-Tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine; 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one; 3,4-Dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-2(1H)-quinolinone
DMBKX3C	DT	Small molecular drug
DMBKX3C	PC	5663
DMBKX3C	MW	395.5
DMBKX3C	FM	C22H25N3O4
DMBKX3C	IC	InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)
DMBKX3C	CS	COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC
DMBKX3C	IK	ZVNYJIZDIRKMBF-UHFFFAOYSA-N
DMBKX3C	IU	6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
DMBKX3C	CA	CAS 81840-15-5
DMBKX3C	CB	CHEBI:31237
DMBKX3C	DE	Cardiac failure

DM4UHZF	ID	DM4UHZF
DM4UHZF	DN	Vestronidase alfa
DM4UHZF	HS	Approved
DM4UHZF	CP	Ultragenyx
DM4UHZF	DE	Mucopolysaccharidosis

DMFR201	ID	DMFR201
DMFR201	DN	Vibegron
DMFR201	HS	Approved
DMFR201	SN	MK-4618
DMFR201	CP	Merck
DMFR201	PC	44472635
DMFR201	MW	444.5
DMFR201	FM	C26H28N4O3
DMFR201	IC	InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
DMFR201	CS	C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)[C@@H](C5=CC=CC=C5)O
DMFR201	IK	DJXRIQMCROIRCZ-XOEOCAAJSA-N
DMFR201	IU	(6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
DMFR201	CA	CAS 1190389-15-1
DMFR201	CB	CHEBI:142418
DMFR201	DE	Overactive bladder

DM0N85H	ID	DM0N85H
DM0N85H	DN	Vidarabine
DM0N85H	HS	Approved
DM0N85H	SN	Araadenosine; Arabinosyladenine; Armes; RAB; Spongoadenosine; VIRDARABINE; Vidarabin; Vidarabina; Vidarabinum; Xylosyladenine; Adenine arabinoside; Adenine xyloside; Adenosine arabinose; Ara A; Arabinoside adenine; Arabinosyl adenine; Vidarabina [DCIT]; Vidarabine anhydrous; Vira ATM; Xylosyl A; A 9251; ARA-A NSC 247519; Alpha-Ara A; Ara-A; Arabinosyl-adenine; Arasena-A; Armes (TN); Beta-Ara A; Vidarabine (JAN); Vira-A; Adenosine-8-14C; Vira-A, Vidarabine; ADENOSINE, U.S.P.; (+)-Cyclaradine; 9-Arabinosyladenine
DM0N85H	TC	Antiviral Agents
DM0N85H	DT	Small molecular drug
DM0N85H	PC	21704
DM0N85H	MW	267.24
DM0N85H	FM	C10H13N5O4
DM0N85H	IC	InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1
DM0N85H	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N
DM0N85H	IK	OIRDTQYFTABQOQ-UHTZMRCNSA-N
DM0N85H	IU	(2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM0N85H	CA	CAS 5536-17-4
DM0N85H	CB	CHEBI:45327
DM0N85H	DE	Herpes simplex virus infection

DMYT0OG	ID	DMYT0OG
DMYT0OG	DN	Vigabatrin
DMYT0OG	HS	Approved
DMYT0OG	SN	GVG; Sabril; Sabrilex; Vigabatrina; Vigabatrine; Vigabatrinum; Aventis Brand of Vigabatrin; Gamma Vinyl GABA; Gamma Vinyl gamma Aminobutyric Acid; Hoechst Brand of Vigabatrin; Vigabatrin Aventis Brand; Vigabatrin Hoechst Brand; Vigabatrin Yamanouchi Brand; Vigabatrina [Spanish]; Vigabatrine [French]; Vigabatrinum [Latin]; Yamanouchi Brand of Vigabatrin; M071754; MDL 71754; RMI 71754; V 8261; V8261_SIGMA; CPP-109; Gamma-Vinyl GABA; MDL 71,754; MDL-71754; RMI-71754; RMI-71890; Sabril (TN); Sabrilex (TN); Gamma-Vinyl-GABA; Hexenoic acid, 4-amino; Vigabatrin [USAN:BAN:INN]; Vigabatrin [USAN:INN:BAN]; Gamma-Vinyl-gamma-Aminobutyric Acid; Gamma-Vinyl-gamma-aminobutyric acid; Vigabatrin (JAN/USAN/INN); Acid, gamma-Vinyl-gamma-Aminobutyric; (R,S)-4-Amino-5-hexenoic acid; (inverted question mark)-gamma-Vinyl GABA; 4-Amino-5-hexenoic acid; 4-Aminohexenoic acid; 4-aminohex-5-enoic acid
DMYT0OG	CP	Ovation Pharma; Lundbeck
DMYT0OG	TC	Anticonvulsants
DMYT0OG	DT	Small molecular drug
DMYT0OG	PC	5665
DMYT0OG	MW	129.16
DMYT0OG	FM	C6H11NO2
DMYT0OG	IC	InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
DMYT0OG	CS	C=CC(CCC(=O)O)N
DMYT0OG	IK	PJDFLNIOAUIZSL-UHFFFAOYSA-N
DMYT0OG	IU	4-aminohex-5-enoic acid
DMYT0OG	CA	CAS 68506-86-5
DMYT0OG	CB	CHEBI:63638
DMYT0OG	DE	Complex partial seizure; Infantile spasm; Epilepsy

DMF5EK1	ID	DMF5EK1
DMF5EK1	DN	Vilanterol
DMF5EK1	HS	Approved
DMF5EK1	SN	503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair
DMF5EK1	CP	GlaxoSmithKline
DMF5EK1	DT	Small molecular drug
DMF5EK1	PC	10184665
DMF5EK1	MW	486.4
DMF5EK1	FM	C24H33Cl2NO5
DMF5EK1	IC	InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
DMF5EK1	CS	C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNC[C@@H](C2=CC(=C(C=C2)O)CO)O)Cl
DMF5EK1	IK	DAFYYTQWSAWIGS-DEOSSOPVSA-N
DMF5EK1	IU	4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DMF5EK1	CA	CAS 503068-34-6
DMF5EK1	CB	CHEBI:75037
DMF5EK1	DE	Chronic obstructive pulmonary disease

DM4LECQ	ID	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	HS	Approved
DM4LECQ	SN	Vilazodone [INN]; Vilazodone (TN); 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide
DM4LECQ	CP	Genaissance and Merck KGaA
DM4LECQ	DT	Small molecular drug
DM4LECQ	PC	6918314
DM4LECQ	MW	441.5
DM4LECQ	FM	C26H27N5O2
DM4LECQ	IC	InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
DM4LECQ	CS	C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N
DM4LECQ	IK	SGEGOXDYSFKCPT-UHFFFAOYSA-N
DM4LECQ	IU	5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide
DM4LECQ	CA	CAS 163521-12-8
DM4LECQ	CB	CHEBI:70707
DM4LECQ	DE	Major depressive disorder

DMYN59P	ID	DMYN59P
DMYN59P	DN	Vildagliptin
DMYN59P	HS	Approved
DMYN59P	SN	Equa; Galvu; Galvus; Jalra; Xiliarx; Galvus (TN); Vidagliptin (see Vildagliptin); Vildagliptin (JAN/USAN/INN); (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI)
DMYN59P	CP	Novartis
DMYN59P	DT	Small molecular drug
DMYN59P	PC	6918537
DMYN59P	MW	303.4
DMYN59P	FM	C17H25N3O2
DMYN59P	IC	InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
DMYN59P	CS	C1C[C@H](N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
DMYN59P	IK	SYOKIDBDQMKNDQ-XWTIBIIYSA-N
DMYN59P	IU	(2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
DMYN59P	CA	CAS 274901-16-5
DMYN59P	CB	CHEBI:135285
DMYN59P	DE	Type-2 diabetes

DM5TVS3	ID	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	HS	Approved
DM5TVS3	SN	Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid
DM5TVS3	CP	Eli Lilly And Co
DM5TVS3	TC	Anticancer Agents
DM5TVS3	DT	Small molecular drug
DM5TVS3	PC	13342
DM5TVS3	MW	811
DM5TVS3	FM	C46H58N4O9
DM5TVS3	IC	InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1
DM5TVS3	CS	CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
DM5TVS3	IK	JXLYSJRDGCGARV-CFWMRBGOSA-N
DM5TVS3	IU	methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
DM5TVS3	CA	CAS 865-21-4
DM5TVS3	DE	Solid tumour/cancer

DMK1ZOR	ID	DMK1ZOR
DMK1ZOR	DN	Vincamine
DMK1ZOR	HS	Approved
DMK1ZOR	SN	vincamine; 1617-90-9; Pervincamine; Devincan; Minorine; Vincamidol; Novicet; Monorin; Methyl vincaminate; Arteriovinca; Vincasaunier; Vinkametrin; Devinkan; Decincan; Vincapront; Vincafolina; Vincadar; Tripervan; Angiopac; Anasclerol; (+)-Vincamine; Equipur; Pervone; Oxygeron; Vincafor; Perval; Ocu-vinc; Vincamina [DCIT]; Vincimax; Vincamine base; Vincaminum [INN-Latin]; UNII-996XVD0JHT; Vincamine [INN:BAN:DCF]; Minorin; Vincachron; Vincapan; Vincamin; Vincagil; Vinca; Vinodrel retard; Vinca-Minor; Vinca-Ecobi; HSDB 7150; Anasclerol (base)
DMK1ZOR	DT	Small molecular drug
DMK1ZOR	PC	15376
DMK1ZOR	MW	354.4
DMK1ZOR	FM	C21H26N2O3
DMK1ZOR	IC	InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1
DMK1ZOR	CS	CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@](C2)(C(=O)OC)O
DMK1ZOR	IK	RXPRRQLKFXBCSJ-GIVPXCGWSA-N
DMK1ZOR	IU	methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
DMK1ZOR	CA	CAS 1617-90-9
DMK1ZOR	CB	CHEBI:9985
DMK1ZOR	DE	Cerebrovascular disease

DMINOX3	ID	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	HS	Approved
DMINOX3	SN	LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine
DMINOX3	CP	Mayne Pharma Limited
DMINOX3	TC	Anticancer Agents
DMINOX3	DT	Small molecular drug
DMINOX3	PC	5978
DMINOX3	MW	825
DMINOX3	FM	C46H56N4O10
DMINOX3	IC	InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
DMINOX3	CS	CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
DMINOX3	IK	OGWKCGZFUXNPDA-XQKSVPLYSA-N
DMINOX3	IU	methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
DMINOX3	CA	CAS 57-22-7
DMINOX3	CB	CHEBI:28445
DMINOX3	DE	Acute lymphoblastic leukaemia

DMVR628	ID	DMVR628
DMVR628	DN	Vindesine
DMVR628	HS	Approved
DMVR628	SN	DAVA; Vindesin; Vindesina; Vindesinum; Desacetylvinblastine amide; Lilly 112531; Vindesina [INN-Spanish]; Vindesinum [INN-Latin]; Vindesine (USAN/INN); Vindesine [USAN:BAN:INN]; Vindesine [USAN:INN:BAN]; 3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; Methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
DMVR628	TC	Anticancer Agents
DMVR628	DT	Small molecular drug
DMVR628	PC	40839
DMVR628	MW	753.9
DMVR628	FM	C43H55N5O7
DMVR628	IC	InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1
DMVR628	CS	CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
DMVR628	IK	HHJUWIANJFBDHT-KOTLKJBCSA-N
DMVR628	IU	methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate
DMVR628	CA	CAS 53643-48-4
DMVR628	CB	CHEBI:36373
DMVR628	DE	Acute lymphoblastic leukaemia

DMVXFYE	ID	DMVXFYE
DMVXFYE	DN	Vinorelbine
DMVXFYE	HS	Approved
DMVXFYE	SN	Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
DMVXFYE	CP	GlaxoSmithKline
DMVXFYE	TC	Anticancer Agents
DMVXFYE	DT	Small molecular drug
DMVXFYE	PC	5311497
DMVXFYE	MW	778.9
DMVXFYE	FM	C45H54N4O8
DMVXFYE	IC	InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1
DMVXFYE	CS	CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
DMVXFYE	IK	GBABOYUKABKIAF-IELIFDKJSA-N
DMVXFYE	IU	methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
DMVXFYE	CA	CAS 71486-22-1
DMVXFYE	CB	CHEBI:480999
DMVXFYE	DE	Solid tumour/cancer

DMVN2E6	ID	DMVN2E6
DMVN2E6	DN	Vinpocetine
DMVN2E6	HS	Approved
DMVN2E6	SN	Bravinton; Cavinton; Ceractin; Vinpocetinum; Apovincaminic acid ethyl ester; AY 27255; RGH 4405; TCV 3B; V 6383; V6383_SIGMA; AY 27,255; Apovincaminate d'ethyle; Apovincaminate d'ethyle [French]; Cavinton (TN); Cis-Apovincaminic acid ethyl ester; Intelectol (TN); RGH-4405; TCV-3B; Ultra-Vinca; Vinpocetine-ethyl apovincaminate; Vinpocetinum [INN-Latin]; Eburnamenine-14-carboxylic acid ethyl ester; Ethyl apovincamin-22-oate; Vinpocetine [USAN:INN:JAN]; Ethyl (+)-apovincaminate; Vinpocetine (JAN/USAN/INN); Ethyl(+)-cis-apovincaminate; Ethyl apovincaminate, (3alpha,16alpha)-isomer; Ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate; (+)-Apovincaminic acid ethyl ester; (+)-cis-Apovincaminic acid ethyl ester; (3alpha, 16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; 1H-Indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine, eburnamenine-14-carboxylic acid deriv.; 3-alpha,16-alpha-Apovincaminic acid ethyl ester
DMVN2E6	TC	Vasodilator Agents
DMVN2E6	DT	Small molecular drug
DMVN2E6	PC	443955
DMVN2E6	MW	350.5
DMVN2E6	FM	C22H26N2O2
DMVN2E6	IC	InChI=1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1
DMVN2E6	CS	CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC
DMVN2E6	IK	DDNCQMVWWZOMLN-IRLDBZIGSA-N
DMVN2E6	IU	ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate
DMVN2E6	CA	CAS 42971-09-5
DMVN2E6	CB	CHEBI:32297
DMVN2E6	DE	Ischemic stroke

DMZYLFC	ID	DMZYLFC
DMZYLFC	DN	Viomycin sulfate
DMZYLFC	HS	Approved
DMZYLFC	SN	Viocin (TN)
DMZYLFC	DT	Small molecular drug
DMZYLFC	PC	135524783
DMZYLFC	MW	783.8
DMZYLFC	FM	C25H45N13O14S
DMZYLFC	IC	InChI=1S/C25H43N13O10.H2O4S/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43;1-5(2,3)4/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48);(H2,1,2,3,4)/b13-7-;/t10-,11+,12-,14-,15-,17-,18-;/m0./s1
DMZYLFC	CS	C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N.OS(=O)(=O)O
DMZYLFC	IK	AQONYROJHRNYQQ-QMAPKBLTSA-N
DMZYLFC	IU	(3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R,6S)-2-amino-6-hydroxy-1,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide;sulfuric acid
DMZYLFC	CA	CAS 37883-00-4
DMZYLFC	DE	Bacterial infection

DM0REZS	ID	DM0REZS
DM0REZS	DN	Virulizin
DM0REZS	HS	Approved
DM0REZS	SN	Virulizin (TN)
DM0REZS	CP	Lorus Therapeutics
DM0REZS	DE	Breast cancer

DM5IXKQ	ID	DM5IXKQ
DM5IXKQ	DN	Vismodegib
DM5IXKQ	HS	Approved
DM5IXKQ	SN	879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide;  Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449
DM5IXKQ	CP	Genentech
DM5IXKQ	DT	Small molecular drug
DM5IXKQ	PC	24776445
DM5IXKQ	MW	421.3
DM5IXKQ	FM	C19H14Cl2N2O3S
DM5IXKQ	IC	InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)
DM5IXKQ	CS	CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
DM5IXKQ	IK	BPQMGSKTAYIVFO-UHFFFAOYSA-N
DM5IXKQ	IU	2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
DM5IXKQ	CA	CAS 879085-55-9
DM5IXKQ	CB	CHEBI:66903
DM5IXKQ	DE	Basal cell carcinoma; Primitive neuroectodermal tumour medulloblastoma

DMJ2AH4	ID	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	HS	Approved
DMJ2AH4	SN	Retinol; retinol; all-trans-Retinol; 68-26-8; Vitamin A1; Alphalin; Axerophthol; Afaxin; Oleovitamin A; Chocola A; Ophthalamin; Epiteliol; Biosterol; Aquasynth; Apostavit; Alphasterol; Veroftal; Testavol; Anatola; Prepalin; Myvpack; Agoncal; Agiolan; Vogan; Axerol; Vitpex; Avibon; Apexol; Aoral; Vaflol; Dofsol; Avitol; Vitamin A alcohol; Disatabs Tabs; Lard Factor; Bentavit A; Dohyfral A; all-trans-Retinyl alcohol; Alcovit A; Vogan-Neu; Anatola A; Plivit A; A-Mulsal; Vi-Alpha; A-Vitan; All-trans retinol; Atars; Vafol; trans-retinol; all-trans-Vitamin A;  ACON; ATAV; Alin; Avita; Axerophtholum; Cylasphere; LPK; Retinolo; Retinolum; TROL; Thalasphere; Wachstumsvitamin; All Trans Retinol; Antixerophthalmic vitamin; Antixerophthalmisches Vitamin; Aquasol A Parenteral; Homagenets Aoral; Homagenets aorl; Hydrovit A; Mvc Plus; Retinol solution; Retinolo [DCIT]; Retrovitamin A; Sehkraft A; Super A; Testavol S; Vitamin A cryst; Vitamine A; Vitaminum A; Vitavel A; Zinosan N; Rovimix A 500; Vitamin A1 alcohol; A-Sol; Anti-infective vitamin; Beta-Retinol; Retinol [INN:BAN]; Retinolum [INN-Latin]; Solu-A; Trans-Vitamin A alcohol; Trans-retinol; Vi-a; Vi-alpha; Vio-A; Vitamin A (Feed); Vitamin A (USP); Vitamin A alcohol (VAN); Vitamin A1 alcohol, all trans; Vitamin-A; Vitamin-A alcohol; Vitamin-A alcohol solution; Vitamin-A1; Vitavel-A; Vogan-nu; A-Vi-Pel; ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1); All-trans-Retinol; All-trans-Retinyl alcohol; All-trans-Vitamin A; All-trans-Vitamin A alcohol; All-trans-Vitamin A1; Del-VI-A; Hi-A-Vita; Nio-A-Let; Ro-a-vit; Trans-Retinol acid (Vitamin A); Vi-Dom-A; [11,12-3H]-Retinol; MVC 9+3; MVI-12; Retinol, all-trans-(8CI); Retin-11,12-t2-ol (9CI); Retinol-(cellular-retinol-binding-protein); Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol; All-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol; 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer; Tricyclics
DMJ2AH4	TC	Vitamins
DMJ2AH4	DT	Small molecular drug
DMJ2AH4	PC	445354
DMJ2AH4	MW	286.5
DMJ2AH4	FM	C20H30O
DMJ2AH4	IC	InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+
DMJ2AH4	CS	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C
DMJ2AH4	IK	FPIPGXGPPPQFEQ-OVSJKPMPSA-N
DMJ2AH4	IU	(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
DMJ2AH4	CA	CAS 11103-57-4
DMJ2AH4	CB	CHEBI:17336
DMJ2AH4	DE	Night blindness; Kinetoplastids

DMZ1WXJ	ID	DMZ1WXJ
DMZ1WXJ	DN	Vitamin B1
DMZ1WXJ	HS	Approved
DMZ1WXJ	SN	59-43-8; Thiamine monochloride; Aneurine; 3-((4-Amino-2-methylpyrimidin-5-yl)methyl)-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride; Tiamina; Oryzanin; Thiaminum; Oryzanine; Bethiamin; Vitaneurin; Beivon; Apatate drape; Thiamine, chloride; B-Amin; Thiamine [INN:BAN]; Tiamina [INN-Spanish]; Thiaminum [INN-Latin]; UNII-X66NSO3N35; CCRIS 5823; HSDB 220; thiamine(1+) chloride; EINECS 200-425-3; X66NSO3N35; CHEBI:33283; AK109288; Thiamine (Vit B1); Thiazolium,
DMZ1WXJ	TC	Vitamins
DMZ1WXJ	DT	Small molecular drug
DMZ1WXJ	PC	6042
DMZ1WXJ	MW	300.81
DMZ1WXJ	FM	C12H17ClN4OS
DMZ1WXJ	IC	InChI=1S/C12H17N4OS.ClH/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);1H/q+1;/p-1
DMZ1WXJ	CS	CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.[Cl-]
DMZ1WXJ	IK	MYVIATVLJGTBFV-UHFFFAOYSA-M
DMZ1WXJ	IU	2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol;chloride
DMZ1WXJ	CA	CAS 59-43-8
DMZ1WXJ	CB	CHEBI:33283
DMZ1WXJ	DE	Vitamin B1 deficiency

DMQVRZH	ID	DMQVRZH
DMQVRZH	DN	Vitamin B3
DMQVRZH	HS	Approved
DMQVRZH	SN	Niacin (TN); Niacinamide (TN); Nicotinamide (TN)
DMQVRZH	CP	Anmar
DMQVRZH	DT	Small molecular drug
DMQVRZH	PC	938
DMQVRZH	MW	123.11
DMQVRZH	FM	C6H5NO2
DMQVRZH	IC	InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
DMQVRZH	CS	C1=CC(=CN=C1)C(=O)O
DMQVRZH	IK	PVNIIMVLHYAWGP-UHFFFAOYSA-N
DMQVRZH	IU	pyridine-3-carboxylic acid
DMQVRZH	CA	CAS 59-67-6
DMQVRZH	CB	CHEBI:15940
DMQVRZH	DE	Lipid metabolism disorder

DMDBZMV	ID	DMDBZMV
DMDBZMV	DN	Vitamin B6
DMDBZMV	HS	Approved
DMDBZMV	SN	Aderoxin; Alestrol; Becilan; Beesix; Benadon; Bonasanit; Godabion; Hexavibex; Hexermin; Hexermine; Hexobion; Nestrex; Paxadon; Pydox; Pyridipca; Pyridox; Spondylonal; Vitaped; Adermin hydrochloride; Adermine hydrochloride; Aderomine hydrochloride; Component of Alestrol; Hexabione hydrochloride; PN HCl; PYRIDOXINE HYDROCHLORIDE; Pyridoxin hydrochloride; Pyridoxine HCl; Pyridoxine chloride; Pyridoxine hydrogen chloride; Pyridoxine monohydrochloride; Pyridoxinium chloride; Pyridoxinum hydrochloricum; Pyridoxol hydrochloride; Rodex TD; AIDS006784; Campoviton 6; Vitamin V6; AIDS-006784; Cernevit-12; Pyridoxine (INN); Pyridoxine Hydrochloride (B6); Pyridoxine hydrochloride[USAN:JAN]; Pyridoxine, hydrochloride; Pyridoxine-HCl Microencapsulated; Pyridoxinum hydrochloricum (Hungarian); Pyridoxol, hydrochloride; Rodex (R); Vitamin B6-hydrochloride; Vitamin V6 (TN); Vitamin-B6 hydrochloride; Hexa-Betalin (R); Hexa-betalin (TN); Pyridoxine hydrochloride (JP15/USP); Tex Six T.R.; PYRIDOXINE HYDROCHLORIDE, U.S.P.; (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate; 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]; 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine; 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine; 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; 2-methyl-4,5-dimethylol-pyridin-3-ol; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride; 3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride; 3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride; 3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol; 4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride; 4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride; 4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol; 4-Deoxypyridoxine 5'-phosphate; 5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride
DMDBZMV	TC	Vitamins
DMDBZMV	DT	Small molecular drug
DMDBZMV	PC	1054
DMDBZMV	MW	169.18
DMDBZMV	FM	C8H11NO3
DMDBZMV	IC	InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3
DMDBZMV	CS	CC1=NC=C(C(=C1O)CO)CO
DMDBZMV	IK	LXNHXLLTXMVWPM-UHFFFAOYSA-N
DMDBZMV	IU	4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
DMDBZMV	CA	CAS 65-23-6
DMDBZMV	CB	CHEBI:16709
DMDBZMV	DE	Vitamin B6 deficiency

DMXJ7O8	ID	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	HS	Approved
DMXJ7O8	SN	l-ascorbic acid; vitamin C; 50-81-7; L(+)-Ascorbic acid; Ascorbicap; Cevitamic acid; Ascoltin; Hybrin; Secorbate; Proscorbin; Lemascorb; Ascorteal; Ascorbajen; Vitascorbol; Vitamisin; Natrascorb; Citriscorb; Cescorbat; Ascorbutina; Testascorbic; Cevitamin; Cetemican; Allercorb; Vitacimin; Roscorbic; Laroscorbine; Viscorin; Redoxon; Cenetone; Cegiolan; Cebicure; Ascorvit; Viforcit; Concemin; Cevital; Cergona; Cemagyl; Cebione; Cantaxin; Ascorin; Vitacee; Vicelat; Cevimin; Cetamid; Cenolate; Celaskon; Vitacin; Adenex; Ascorb; Ascorbicab; Ascorbicin; Ascorbinsaeure; Cantan; Cebid; Cebion; Cecon; Ceglion; Celin; Cemill; Cereon; Cetebe; Cevalin; Cevatine; Cevex; Cevibid; Cevitan; Cevitex; Cewin; Ciamin; Cipca; Colascor; Cortalex; Duoscorb; Ferancee; Hicee; Magnorbin; Ribena; Scorbacid; Semidehydroascorbate; Sodascorbate; Stuartinic; Sunkist; Tolfrinic; Vitace; Xitix; Acid Ascorbic; Acide ascorbique; Acido ascorbico; Acidum ascorbicum; Acidum ascorbinicum; Antiscorbic vita min; Antiscorbic vitamin; Antiscorbutic factor; Antiscorbutic vitamin; Ascorbyl radical; Catavin C; Ce lent; Component of Cortalex; Component of Endoglobin Forte; Component of Ferancee; Davitamon C; Ferrous ascorbate; Kyselina askorbova; Kyselina askorbova [Czech]; Magnesium Ascorbicum; Monodehydroascorbic acid; Natrascorb injectable; Oral Vitamin C; Planavit C; Roscorbi c; Vicomin C; Acide ascorbique [INN-French]; Acido ascorbico [INN-Spanish]; Acidum ascorbicum [INN-Latin]; Arco-cee; Ascoltin (TN); Ascorbic Acid, Monosodium Salt; Ascorbicap (TN); C-Level; C-Long; C-Quin; C-Span; C-Vimin; Cee-Caps TD; Cee-Vite; Cee-caps td; Cetane-Caps TC; Cetane-Caps TD; Cevi-Bid; Component of E and C-Level; IDO-C; Iron(II) ascorbate; Iron-ascorbic acid complexes; L-Ascorbic acid; L-Lyxoascorbic acid; L-Xyloascorbic acid; L-ascorbic acid; Liqui-Cee; Meri-C; Sodium Ascorbate (Ascorbic Acid); Vitamin-C; Ascorbic acid [BAN:INN:JAN]; Ascorbic acid [INN:BAN:JAN]; CE-VI-Sol; Ce-Mi-Lin; Dora-C-500; L-3-Ketothreohexuronic acid lactone; L-3-ketothreohexuronic acid; L-Ascorbic acid, free radical form; Ascor-bid; Ascorbic acid (JP15/USP/INN); Ascor-BID; L-(+)-Ascorbic Acid; L-threo-Hex-2-enonic acid, gamma-lactone; L-threo-hex-1-eofuranos-3-ulose; L-threo-hex-2-enono-1,4-lactone; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; 3-Keto-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone (enol form); [14C]ascorbic acid
DMXJ7O8	TC	Vitamins
DMXJ7O8	DT	Small molecular drug
DMXJ7O8	PC	54670067
DMXJ7O8	MW	176.12
DMXJ7O8	FM	C6H8O6
DMXJ7O8	IC	InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1
DMXJ7O8	CS	C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O
DMXJ7O8	IK	CIWBSHSKHKDKBQ-JLAZNSOCSA-N
DMXJ7O8	IU	(2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one
DMXJ7O8	CA	CAS 50-81-7
DMXJ7O8	CB	CHEBI:29073
DMXJ7O8	DE	Vitamin C deficiency; Urinary tract infection

DMWQUC9	ID	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	HS	Approved
DMWQUC9	SN	Vigantol; Vigorsan; Vitamin D3; Vitinc Dan-Dee-3; cholecalciferol; vitamin d-3; (+)-Vitamin D3; Activated 7-dehydrocholesterol; Arachitol; Calciol; Cholecalciferol, D3; Cholecalciferolum; Colecalciferol; Colecalciferolo [DCIT]; Colecalciferolum; Colecalciferolum [INN-Latin]; Colecalcipherol; D3-Vicotrat; D3-Vigantol; Delsterol; Deparal; Duphafral D3 1000; Ebivit; FeraCol; NEO Dohyfral D3; Oleovitamin D3; Quintox; Rampage; Ricketon; Trivitan; VITAMIN D; Vi-De3; Vi-de-3-hydrosol; 1406-16-2; 67-97-0; 7-Dehydrocholestrol, activated;; MFCD00078131
DMWQUC9	PC	5280795
DMWQUC9	MW	384.6
DMWQUC9	FM	C27H44O
DMWQUC9	IC	QYSXJUFSXHHAJI-YRZJJWOYSA-N
DMWQUC9	CS	CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C
DMWQUC9	IK	1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
DMWQUC9	IU	(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMWQUC9	CA	CAS 67-97-0
DMWQUC9	CB	CHEBI:28940
DMWQUC9	DE	Hyperparathyroidism

DMZC90K	ID	DMZC90K
DMZC90K	DN	Vitamin E
DMZC90K	HS	Approved
DMZC90K	SN	Covi-ox; VITAMIN E; E-Vimin; Syntopherol; Profecundin; Evitaminum; Viprimol; Vascuals; Etamican; Viteolin; Tokopharm; Vitayonon; Epsilan; Emipherol; Denamone; Almefrol; Verrol; Ilitia; Etavit; 77171-98-3; Evion; Esorb; alpha-Tokoferol; alpha Tocopherol; Vitaplex E; Vitamin E alpha; Eprolin S; Viterra E; E Prolin; Spavit E; Vita E; Endo E; Med-E; Lan-E; Antisterility vitamin; alpha-Tocopherol acid; Tenox GT 1; (R)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-ol; Rhenogran Ronotec 50; Vi-E; Covitol F 1000; E 307 (tocopherol)
DMZC90K	DT	Small molecular drug
DMZC90K	PC	14985
DMZC90K	MW	430.7
DMZC90K	FM	C29H50O2
DMZC90K	IC	InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1
DMZC90K	CS	CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C
DMZC90K	IK	GVJHHUAWPYXKBD-IEOSBIPESA-N
DMZC90K	IU	(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol
DMZC90K	CA	CAS 59-02-9
DMZC90K	CB	CHEBI:18145
DMZC90K	DE	Cardiovascular disease

DMWIJTN	ID	DMWIJTN
DMWIJTN	DN	Voclosporin
DMWIJTN	HS	Approved
DMWIJTN	SN	Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3;  Luveniq; Voclosporin [USAN]; R 1524; Trans-ISA 247; Trans-ISA-247; TrkA-IgG
DMWIJTN	CP	Isotechnika
DMWIJTN	DT	Small molecular drug
DMWIJTN	PC	6918486
DMWIJTN	MW	1214.6
DMWIJTN	FM	C63H111N11O12
DMWIJTN	IC	InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1
DMWIJTN	CS	CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMWIJTN	IK	BICRTLVBTLFLRD-PTWUADNWSA-N
DMWIJTN	IU	(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMWIJTN	CA	CAS 515814-00-3
DMWIJTN	CB	CHEBI:135957
DMWIJTN	DE	Kidney disease; Psoriasis vulgaris; Lupus nephritis

DMUBP9O	ID	DMUBP9O
DMUBP9O	DN	Voglibose
DMUBP9O	HS	Approved
DMUBP9O	SN	Basen; Glustat; Vocarb; Basen OD; A-71100; AO-128; Basen (TN); Basen (Takeda Chemical Industries); Volix (Ranbaxy labs);Voglibose (JP15/USAN/INN); N-(1,3-Dihydroxyprop-2-yl)valiolamine; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol
DMUBP9O	CP	Takeda
DMUBP9O	TC	Hypoglycemic Agents
DMUBP9O	DT	Small molecular drug
DMUBP9O	PC	444020
DMUBP9O	MW	267.28
DMUBP9O	FM	C10H21NO7
DMUBP9O	IC	InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
DMUBP9O	CS	C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
DMUBP9O	IK	FZNCGRZWXLXZSZ-CIQUZCHMSA-N
DMUBP9O	IU	(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
DMUBP9O	CA	CAS 83480-29-9
DMUBP9O	CB	CHEBI:32300
DMUBP9O	DE	Diabetic complication

DM1YEPS	ID	DM1YEPS
DM1YEPS	DN	Volanesorsen
DM1YEPS	HS	Approved
DM1YEPS	CP	Akcea Therapeutics Cambridge, MA, Ionis Pharmaceuticals Carlsbad, CA
DM1YEPS	DT	Antisense oligonucleotide
DM1YEPS	PC	121494123
DM1YEPS	MW	7165
DM1YEPS	FM	C230H320N63O125P19S19
DM1YEPS	IC	InChI=1S/C230H320N63O125P19S19/c1-98-55-274(217(308)254-178(98)231)142-45-112(400-419(322,438)361-70-124-113(46-143(381-124)275-56-99(2)179(232)255-218(275)309)401-423(326,442)367-76-130-119(52-149(387-130)288-92-248-152-183(236)242-89-245-186(152)288)407-427(330,446)369-78-132-121(54-151(389-132)290-94-252-156-190(290)260-215(240)263-202(156)306)408-425(328,444)365-72-125-114(47-144(382-125)276-57-100(3)180(233)256-219(276)310)406-428(331,447)372-81-134-160(171(354-38-28-344-18)206(393-134)283-64-107(10)196(300)269-226(283)317)412-432(335,451)375-84-137-163(173(356-40-30-346-20)208(395-137)285-66-109(12)198(302)271-228(285)319)415-435(338,454)377-86-139-165(175(358-42-32-348-22)210(397-139)287-68-111(14)200(304)273-230(287)321)416-436(339,455)379-87-140-166(176(359-43-33-349-23)212(398-140)292-96-250-154-185(238)244-91-247-188(154)292)417-430(333,449)371-80-133-158(295)168(351-35-25-341-15)204(391-133)282-63-106(9)195(299)268-225(282)316)123(380-142)71-362-421(324,440)403-117-50-147(279-61-104(7)193(297)266-223(279)314)386-128(117)75-366-426(329,445)409-120-53-150(289-93-251-155-189(289)259-214(239)262-201(155)305)388-131(120)77-368-424(327,443)405-118-51-148(280-62-105(8)194(298)267-224(280)315)385-127(118)74-364-422(325,441)404-116-49-146(278-60-103(6)192(296)265-222(278)313)384-126(116)73-363-420(323,439)402-115-48-145(277-58-101(4)181(234)257-220(277)311)383-129(115)79-370-429(332,448)411-162-136(394-207(172(162)355-39-29-345-19)284-65-108(11)197(301)270-227(284)318)83-374-434(337,453)414-164-138(396-209(174(164)357-41-31-347-21)286-67-110(13)199(303)272-229(286)320)85-376-433(336,452)413-161-135(392-205(170(161)353-37-27-343-17)281-59-102(5)182(235)258-221(281)312)82-378-437(340,456)418-167-141(399-213(177(167)360-44-34-350-24)293-97-253-157-191(293)261-216(241)264-203(157)307)88-373-431(334,450)410-159-122(69-294)390-211(169(159)352-36-26-342-16)291-95-249-153-184(237)243-90-246-187(153)291/h55-68,89-97,112-151,158-177,204-213,294-295H,25-54,69-88H2,1-24H3,(H,322,438)(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H2,231,254,308)(H2,232,255,309)(H2,233,256,310)(H2,234,257,311)(H2,235,258,312)(H2,236,242,245)(H2,237,243,246)(H2,238,244,247)(H,265,296,313)(H,266,297,314)(H,267,298,315)(H,268,299,316)(H,269,300,317)(H,270,301,318)(H,271,302,319)(H,272,303,320)(H,273,304,321)(H3,239,259,262,305)(H3,240,260,263,306)(H3,241,261,264,307)/t112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,204+,205+,206+,207+,208+,209+,210+,211+,212+,213+,419?,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?/m0/s1
DM1YEPS	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OCCOC)N6C=C(C(=O)NC6=O)C)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OCCOC)N8C=C(C(=O)NC8=O)C)COP(=S)(O)O[C@@H]9[C@H](O[C@H]([C@@H]9OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C(N=CN=C21)N)CO)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O
DM1YEPS	IK	IJUQCWMZCMFFJP-GQSLRNSLSA-N
DM1YEPS	IU	1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-[hydroxy-[[(2R,3R,4R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM1YEPS	DE	Familial chylomicronemia syndrome; Hyperlipoproteinemia; Hypertriglyceridemia

DMO6315	ID	DMO6315
DMO6315	DN	Vonoprazan
DMO6315	HS	Approved
DMO6315	SN	TAK-438
DMO6315	CP	Takeda
DMO6315	DT	Small molecular drug
DMO6315	PC	45375887
DMO6315	MW	461.5
DMO6315	FM	C21H20FN3O6S
DMO6315	IC	InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMO6315	CS	CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3.C(=C/C(=O)O)\\C(=O)O
DMO6315	IK	ROGSHYHKHPCCJW-WLHGVMLRSA-N
DMO6315	IU	(E)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
DMO6315	CA	CAS 881681-01-2
DMO6315	DE	Gastroesophageal reflux disease; Helicobacter infection

DMI783H	ID	DMI783H
DMI783H	DN	Vonvendi
DMI783H	HS	Approved
DMI783H	SN	Vonicog alfa
DMI783H	CP	Vonvendi
DMI783H	DT	Recombinant protein
DMI783H	DE	Von willebrand disease

DMA16BR	ID	DMA16BR
DMA16BR	DN	Vorapaxar
DMA16BR	HS	Approved
DMA16BR	SN	Vorapaxar; 618385-01-6; Zontivity; SCH-530348; SCH530348; UNII-ZCE93644N2; CHEMBL493982; CHEBI:82702; ZCE93644N2; MK-5348; ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate; Ethyl [(1r,3ar,4ar,6r,8ar,9s,9as)-9-{(E)-2-[5-(3-Fluorophenyl)pyridin-2-Yl]ethenyl}-1-Methyl-3-Oxododecahydronaphtho[2,3-C]furan-6-Yl]carbamate; Vorapaxar [USAN:INN]; Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]etheny
DMA16BR	CP	Schering-Plough
DMA16BR	DT	Small molecular drug
DMA16BR	PC	10077130
DMA16BR	MW	492.6
DMA16BR	FM	C29H33FN2O4
DMA16BR	IC	InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1
DMA16BR	CS	CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/C4=NC=C(C=C4)C5=CC(=CC=C5)F)[C@H](OC3=O)C
DMA16BR	IK	ZBGXUVOIWDMMJE-QHNZEKIYSA-N
DMA16BR	IU	ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
DMA16BR	CA	CAS 618385-01-6
DMA16BR	CB	CHEBI:82702
DMA16BR	DE	Myocardial infarction

DMAOL2S	ID	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	HS	Approved
DMAOL2S	SN	VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC
DMAOL2S	CP	Pfizer
DMAOL2S	TC	Antifungal Agents
DMAOL2S	DT	Small molecular drug
DMAOL2S	PC	71616
DMAOL2S	MW	349.31
DMAOL2S	FM	C16H14F3N5O
DMAOL2S	IC	InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
DMAOL2S	CS	C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
DMAOL2S	IK	BCEHBSKCWLPMDN-MGPLVRAMSA-N
DMAOL2S	IU	(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
DMAOL2S	CA	CAS 188416-29-7
DMAOL2S	CB	CHEBI:10023
DMAOL2S	DE	Invasive aspergillosis

DMWMPD4	ID	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	HS	Approved
DMWMPD4	SN	NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)
DMWMPD4	CP	Merck
DMWMPD4	TC	Anticancer Agents
DMWMPD4	DT	Small molecular drug
DMWMPD4	PC	5311
DMWMPD4	MW	264.32
DMWMPD4	FM	C14H20N2O3
DMWMPD4	IC	InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
DMWMPD4	CS	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
DMWMPD4	IK	WAEXFXRVDQXREF-UHFFFAOYSA-N
DMWMPD4	IU	N'-hydroxy-N-phenyloctanediamide
DMWMPD4	CA	CAS 149647-78-9
DMWMPD4	CB	CHEBI:45716
DMWMPD4	DE	Cutaneous T-cell lymphoma

DM6F1PU	ID	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	HS	Approved
DM6F1PU	SN	VORTIOXETINE; 508233-74-7; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine; Lu AA21004; UNII-3O2K1S3WQV; 3O2K1S3WQV; CHEBI:76016; Trintellix; 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine; Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; Brintellix (TN); 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine; 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine; 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine; CHEMBL2204360; 1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine; Lu-AA21004
DM6F1PU	CP	Lundbeck; Takeda Pharmaceuticals
DM6F1PU	DT	Small molecular drug
DM6F1PU	PC	9966051
DM6F1PU	MW	298.4
DM6F1PU	FM	C18H22N2S
DM6F1PU	IC	InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
DM6F1PU	CS	CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C
DM6F1PU	IK	YQNWZWMKLDQSAC-UHFFFAOYSA-N
DM6F1PU	IU	1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine
DM6F1PU	CA	CAS 508233-74-7
DM6F1PU	CB	CHEBI:76016
DM6F1PU	DE	Major depressive disorder; Mood disorder

DMCS6M5	ID	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	HS	Approved
DMCS6M5	SN	Hemoglobin Modulators-1; 1446321-46-5; UNII-3ZO554A4Q8; GBT 440; 3ZO554A4Q8; 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-(propan-2-yl)-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; Voxelotor [USAN]; SCHEMBL15065529; Voxelotor(GBT440, GTx011); GTX-011; GBT-440; MolPort-044-830-677; FWCVZAQENIZVMY-UHFFFAOYSA-N; AKOS030526545; ZINC145969085; CS-5317; HY-18681; DA-44587; S
DMCS6M5	CP	Global Blood Therapeutics South San Francisco, CA
DMCS6M5	PC	71602803
DMCS6M5	MW	337.4
DMCS6M5	FM	C19H19N3O3
DMCS6M5	IC	InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
DMCS6M5	CS	CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O
DMCS6M5	IK	FWCVZAQENIZVMY-UHFFFAOYSA-N
DMCS6M5	IU	2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde
DMCS6M5	CA	CAS 1446321-46-5
DMCS6M5	DE	Sickle-cell disorder

DMAI83D	ID	DMAI83D
DMAI83D	DN	Voxilaprevir
DMAI83D	HS	Approved
DMAI83D	SN	Voxilaprevir; Voxilaprevir (USAN/INN); Voxilaprevir [USAN:INN]; 0570F37359;J3.665.048F;  1535212-07-7; CS-0017027; D10899; DB12026; GS-9857; HY-19840; L9P; SCHEMBL15412621; UNII-0570F37359
DMAI83D	PC	89921642
DMAI83D	MW	868.9
DMAI83D	FM	C40H52F4N6O9S
DMAI83D	IC	MZBLZLWXUBZHSL-FZNJKFJKSA-N
DMAI83D	CS	CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C
DMAI83D	IK	1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
DMAI83D	IU	(1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DMAI83D	CA	CAS 1535212-07-7
DMAI83D	DE	Viral hepatitis

DMIO4V5	ID	DMIO4V5
DMIO4V5	DN	VRX496
DMIO4V5	HS	Approved
DMIO4V5	SN	Nelfinavir; nelfinavir; 159989-64-7; Viracept; Nelfinavir [INN:BAN]; AG1343; UNII-HO3OGH5D7I; AG-1343; C32H45N3O4S; NELFINAVIR MESYLATE AG1343; Viracept (TN); HO3OGH5D7I; CHEBI:7496; AG 1343; NLF; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; NFV;  NFV; Nelfinavir Monomethane Sulfonate; AG1346; Nelfinavir (INN); Nelfinavir [BAN:INN]; AG1343 (*Mesylate salt*); Viracept (TM)(*Mesylate salt*); Met-SDF-1beta & Nelfinavir; Met-Stromal Cell-derived Factor-1beta (Human) & Nelfinavir; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
DMIO4V5	CP	VIRxSYS Corporation
DMIO4V5	TC	Antisense
DMIO4V5	DT	Antisense drug
DMIO4V5	DE	Acquired immune deficiency syndrome; Coronavirus infection

DMJYCVW	ID	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	HS	Approved
DMJYCVW	SN	Brumolin; Choice; Coumadin; Coumafen; Coumafene; Coumaphen; Coumaphene; Coumarins; Coumefene; Dethmor; Dethnel; Kumader; Kumadu; Kumatox; Kypfarin; Maveran; Panwarfin; Prothromadin; RAX; Ratorex; Ratoxin; Ratron; Rattentraenke; Rattunal; Rodafarin; Rosex; Sofarin; Solfarin; Warfarat; Warfarina; Warfarine; Warfarinum; Warficide; Zoocoumarin; Arab Rat Death; Arab rat deth; Coumafene [French]; Dicusat E; Eastern states duocide; Fasco fascrat powder; Maag Rattentod Cum; Mouse pak; Ratron G; Rattenstreupulver Neu Schacht; Rattenstreupulver new schacht; Rodafarin C; Rodex blox; Sorexa plus; Temus W; Twin light rat away; Vampirinip II; Vampirinip iii; Warfarin Q; Warfarin plus; Warfarin plus [discontinued]; Zoocoumarin [Netherlands and USSR]; Zoocoumarin [Russian]; CBKinase1_000192; CBKinase1_012592; Latka 42; Latka 42 [Czech]; PS104_SUPELCO; WARF compound 42; Warf 10; Warf 42; Athrombine-K; CO-Rax; Choice (TN); Coumadin (TN); D-Con; Frass-Ratron; Jantoven (TN); Liqua-tox; Mar-Frin; Marevan (TN); Place-pax; Rac-Warfarin; Rat & mice bait; Rat-Gard; Rat-Kill; Rat-Mix; Rat-Ola; Rat-Trol; Ratten-Koederrohr; Ro-Deth; Rough & ready mouse mix; Tox-hid; Waran (TN); Warfarin (INN); Warfarin (and salts of); Warfarin [BSI:ISO]; Warfarin [INN:BAN]; Warfarin(R); Warfarina [INN-Spanish]; Warfarine [INN-French]; Warfarine [ISO-French]; Warfarinum [INN-Latin]; Cov-R-Tox; Martin's mar-frin; Rat-B-gon; Rat-a-way; Rats-no-more; Spray-trol brand roden-trol; Rat-o-cide #2; Warfarin titrated to an INR of 2.5-3.0; W.A.R.F. 42; (-)-Warfarin; (S)-Warfarin; 200 coumarin
DMJYCVW	CP	Pharmaceutical Research Assoc Inc
DMJYCVW	TC	Anticoagulants
DMJYCVW	DT	Small molecular drug
DMJYCVW	PC	54678486
DMJYCVW	MW	308.3
DMJYCVW	FM	C19H16O4
DMJYCVW	IC	InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
DMJYCVW	CS	CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
DMJYCVW	IK	PJVWKTKQMONHTI-UHFFFAOYSA-N
DMJYCVW	IU	4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
DMJYCVW	CA	CAS 81-81-2
DMJYCVW	CB	CHEBI:87732
DMJYCVW	DE	Atrial fibrillation; Thrombosis

DMLHOA0	ID	DMLHOA0
DMLHOA0	DN	Xatral
DMLHOA0	HS	Approved
DMLHOA0	SN	Alfetim; Alfoten; Urion; Uroxatral; Alfuzosin HCl; Alfuzosin Hydrochloride; Alfuzosin hydrochloride [USAN]; Xatral OD; Xatral Retard; Xatral SR; Xatral XL; SL 77 499-10; SL 77499-10; SL-7749910; Uroxatral, Alfuzosin hydrochloride; Alfuzosin hydrochloride (JAN/USAN); SL-77499-10; SL-77.0499-10; N-[3-[4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride; N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide hydrochloride; N-{3-[(4-amino-6,7-dimethoxychinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamidhydrochlorid; (+-)-N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide monohydrochloride
DMLHOA0	CP	Sanofi-Aventis
DMLHOA0	DT	Small molecular drug
DMLHOA0	PC	71764
DMLHOA0	MW	425.9
DMLHOA0	FM	C19H28ClN5O4
DMLHOA0	IC	InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
DMLHOA0	CS	CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl
DMLHOA0	IK	YTNKWDJILNVLGX-UHFFFAOYSA-N
DMLHOA0	IU	N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride
DMLHOA0	CA	CAS 81403-68-1
DMLHOA0	CB	CHEBI:32286
DMLHOA0	DE	Benign prostatic hyperplasia

DMU8ANS	ID	DMU8ANS
DMU8ANS	DN	Ximelegatran
DMU8ANS	HS	Approved
DMU8ANS	SN	Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; y-27632; 146986-50-7; Y-27632 dihydrochloride; Y27632; UNII-0X370ROP6H; Y 27632; cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; 0X370ROP6H; CHEBI:75393; 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamide; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4-[(1R)-1-aminoethyl]-N-(4-pyridyl)cyclohexanecarboxamide; 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide; Y-27632
DMU8ANS	CP	AstraZeneca
DMU8ANS	DT	Small molecular drug
DMU8ANS	PC	448042
DMU8ANS	MW	247.34
DMU8ANS	FM	C14H21N3O
DMU8ANS	IC	InChI=1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11?,12?/m1/s1
DMU8ANS	CS	C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N
DMU8ANS	IK	IYOZTVGMEWJPKR-VOMCLLRMSA-N
DMU8ANS	IU	4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide
DMU8ANS	CA	CAS 146986-50-7
DMU8ANS	CB	CHEBI:75393
DMU8ANS	DE	Myocardial infarction; Asthma

DMAR467	ID	DMAR467
DMAR467	DN	Xylose
DMAR467	HS	Approved
DMAR467	SN	D-Xylose; D-Xylopyranose; Xyloside; D-xylopentose; (3R,4S,5R)-oxane-2,3,4,5-tetrol; 7261-26-9; CHEBI:53455; Xylopyranoside; D-Xylopyranoside; Xylomed; D-Xyl; 10257-31-5; (3R,4S,5R)-tetrahydro-2H-pyran-2,3,4,5-tetrol; (3R,4S,5R)-Tetrahydro-2H-pyran-2,3,4,5-tetraol; D-(+)-Xylose, &gt; Xyl; Xylose (USP); Xylo-Pfan (TN); DSSTox_CID_3745; Epitope ID:114701; AC1L35YW; DSSTox_RID_77180; SCHEMBL39891; DSSTox_GSID_23745; MLS001361339; cid_135191; CHEMBL502135; DTXSID0023745; CTK0H1735; BDBM16234; MolPort-003-934-029; D-xylose
DMAR467	DT	Small molecular drug
DMAR467	PC	135191
DMAR467	MW	150.13
DMAR467	FM	C5H10O5
DMAR467	IC	InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3+,4-,5?/m1/s1
DMAR467	CS	C1[C@H]([C@@H]([C@H](C(O1)O)O)O)O
DMAR467	IK	SRBFZHDQGSBBOR-IOVATXLUSA-N
DMAR467	IU	(3R,4S,5R)-oxane-2,3,4,5-tetrol
DMAR467	CA	CAS 10257-31-5
DMAR467	CB	CHEBI:53455
DMAR467	DE	Gastrointestinal disease

DMDPM7R	ID	DMDPM7R
DMDPM7R	DN	Y-25130
DMDPM7R	HS	Approved
DMDPM7R	SN	Azasetron; Nazasetron; Azasetron [INN]; C17H20ClN3O3; 123039-99-6; WUKZPHOXUVCQOR-UHFFFAOYSA-N; Azasetron (INN); 6-Chloro-4-methyl-3-oxo-N-(quinuclidin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide; NCGC00024563-02; DSSTox_RID_81029; DSSTox_CID_25651; DSSTox_GSID_45651; (- )-6-Chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-carboxamide; N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide
DMDPM7R	DT	Small molecular drug
DMDPM7R	PC	2264
DMDPM7R	MW	349.8
DMDPM7R	FM	C17H20ClN3O3
DMDPM7R	IC	InChI=1S/C17H20ClN3O3/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23)
DMDPM7R	CS	CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4
DMDPM7R	IK	WUKZPHOXUVCQOR-UHFFFAOYSA-N
DMDPM7R	IU	N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide
DMDPM7R	CA	CAS 123040-69-7
DMDPM7R	CB	CHEBI:91712
DMDPM7R	DE	Nausea and vomiting

DMNZCI1	ID	DMNZCI1
DMNZCI1	DN	YM443
DMNZCI1	HS	Approved
DMNZCI1	SN	Acofide; Acotiamide
DMNZCI1	CP	Astellas
DMNZCI1	DT	Small molecular drug
DMNZCI1	PC	6918406
DMNZCI1	MW	541.1
DMNZCI1	FM	C21H37ClN4O8S
DMNZCI1	IC	InChI=1S/C21H30N4O5S.ClH.3H2O/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26;;;;/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27);1H;3*1H2
DMNZCI1	CS	CC(C)N(CCNC(=O)C1=CSC(=N1)NC(=O)C2=CC(=C(C=C2O)OC)OC)C(C)C.O.O.O.Cl
DMNZCI1	IK	NPTDXIXCQCFGKC-UHFFFAOYSA-N
DMNZCI1	IU	N-[2-[di(propan-2-yl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;trihydrate;hydrochloride
DMNZCI1	CA	CAS 773092-05-0
DMNZCI1	DE	Functional dyspepsia

DMMP3Y2	ID	DMMP3Y2
DMMP3Y2	DN	Yn-968D1
DMMP3Y2	HS	Approved
DMMP3Y2	SN	Apatinib; Apatinib mesylate; VEGF receptor inhibitor (cancer), Advenchen; VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/ Bukwang
DMMP3Y2	CP	Advenchen Laboratories LLC
DMMP3Y2	DT	Small molecular drug
DMMP3Y2	PC	45139106
DMMP3Y2	MW	493.6
DMMP3Y2	FM	C25H27N5O4S
DMMP3Y2	IC	InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)
DMMP3Y2	CS	CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4
DMMP3Y2	IK	FYJROXRIVQPKRY-UHFFFAOYSA-N
DMMP3Y2	IU	N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid
DMMP3Y2	CA	CAS 1218779-75-9
DMMP3Y2	DE	Breast cancer

DMJCP1Y	ID	DMJCP1Y
DMJCP1Y	DN	Yohimbine
DMJCP1Y	HS	Approved
DMJCP1Y	SN	APHRODINE; Actibine; Aphrodyne; Aphrosol; Corynine; Johimbin; Quebrachin; Quebrachine; Thybine; Yocon; Yohimar; Yohimbin; Yohimex; Yoman; Yovital; Dayto himbin; Yohimbic acid methyl ester; Baron-X; Trans-Quinolizidine yohimbine; Yohimbine (DCF); Methyl 17alpha-hydroxyyohimban-16alpha-carboxylate; Yohimbol-16alpha-carboxylic acid, methyl ester (6CI); Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.; Methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate; Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI); Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)-(9CI); Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester; (+)-Yohimbin; (+)-Yohimbine; (16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester; (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester; 17-Hydroxy-yohimbane-16-carboxylic acid methyl ester; 17-Hydroxyyohimban-16-carboxylic acid methyl ester; 17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester; 2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester
DMJCP1Y	CP	Palisades Pharmaceuticals Inc
DMJCP1Y	TC	Mydriatics
DMJCP1Y	DT	Small molecular drug
DMJCP1Y	PC	8969
DMJCP1Y	MW	354.4
DMJCP1Y	FM	C21H26N2O3
DMJCP1Y	IC	InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1
DMJCP1Y	CS	COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O
DMJCP1Y	IK	BLGXFZZNTVWLAY-SCYLSFHTSA-N
DMJCP1Y	IU	methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMJCP1Y	CA	CAS 146-48-5
DMJCP1Y	CB	CHEBI:10093
DMJCP1Y	DE	Erectile dysfunction

DMHNQOG	ID	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	HS	Approved
DMHNQOG	SN	Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide
DMHNQOG	CP	AstraZeneca plc
DMHNQOG	TC	Antiasthmatic Agents
DMHNQOG	DT	Small molecular drug
DMHNQOG	PC	5717
DMHNQOG	MW	575.7
DMHNQOG	FM	C31H33N3O6S
DMHNQOG	IC	InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
DMHNQOG	CS	CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
DMHNQOG	IK	YEEZWCHGZNKEEK-UHFFFAOYSA-N
DMHNQOG	IU	cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate
DMHNQOG	CA	CAS 107753-78-6
DMHNQOG	CB	CHEBI:10100
DMHNQOG	DE	Asthma

DMH7MUV	ID	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	HS	Approved
DMH7MUV	SN	zalcitabine; Dideoxycytidine; 7481-89-2; 2',3'-DIDEOXYCYTIDINE; ddCyd; HIVID; ddC; Cytidine, 2',3'-dideoxy-; Zalcitibine; 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 2,3-dideoxycytidine; NSC 606170; UNII-6L3XT8CB3I; CCRIS 692; HSDB 7156; C9H13N3O3; Ro-24-2027/000; Ro 24-2027/000; CHEMBL853; BRN 0654956; 6L3XT8CB3I; CHEBI:10101; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; WREGKURFCTUGRC-POYBYMJQSA-N; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; MFCD00012188;  DdC; DdCyd; D 5782; DDC (DDC); DdC & Interferon alpha; DdC & sCD4; DdC (Antiviral); Hivid (TN); Hivid(TM); Interferon AD + ddC; KS-1130; SRI-7707; Beta-D-DDC; DS-4152 & ddC; DdC & GM-CSF; DdC & IFN-alpha; DdC & NP (from PHCA or HSA); PC-SOD & ddC; Zalcitabine [USAN:INN:BAN]; Hivid, Dideoxycytidine, NSC 606170, Zalcitabine; Zalcitabine (JAN/USP/INN); Beta-D-2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy & Interferon alpha; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy-& Colony-stimulating factor; Beta-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor; Lecithinized superoxide dismutase & beta-D-2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine & Interferon-alpha; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; DdC
DMH7MUV	CP	Hoffmann-La Roche pharmaceutical company
DMH7MUV	TC	Anti-HIV Agents
DMH7MUV	DT	Small molecular drug
DMH7MUV	PC	24066
DMH7MUV	MW	211.22
DMH7MUV	FM	C9H13N3O3
DMH7MUV	IC	InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
DMH7MUV	CS	C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N
DMH7MUV	IK	WREGKURFCTUGRC-POYBYMJQSA-N
DMH7MUV	IU	4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMH7MUV	CA	CAS 7481-89-2
DMH7MUV	CB	CHEBI:10101
DMH7MUV	DE	Human immunodeficiency virus infection

DMGFWSM	ID	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	HS	Approved
DMGFWSM	SN	Sonata; Zalaplon; Zerene; CL 284846; L 846; L846; LJC 10846; ZAL 846; AZ-007; CL 284,846; CL-284846; CL284,846; L-846; LJC-10846; SKP-1041; Sonata (TN); Staccato-zaleplon; Starnoc (TN); ZAL-846; Zaleplon [USAN:INN]; Zaleplon (JAN/USAN/INN); N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide; N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide; 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide; 3'-(3-Cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide
DMGFWSM	CP	King Pharm
DMGFWSM	TC	Hypnotics and Sedatives
DMGFWSM	DT	Small molecular drug
DMGFWSM	PC	5719
DMGFWSM	MW	305.33
DMGFWSM	FM	C17H15N5O
DMGFWSM	IC	InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
DMGFWSM	CS	CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
DMGFWSM	IK	HUNXMJYCHXQEGX-UHFFFAOYSA-N
DMGFWSM	IU	N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
DMGFWSM	CA	CAS 151319-34-5
DMGFWSM	CB	CHEBI:10102
DMGFWSM	DE	Insomnia

DMFMBZ4	ID	DMFMBZ4
DMFMBZ4	DN	Zanamivir
DMFMBZ4	HS	Approved
DMFMBZ4	SN	zanamivir; 139110-80-8; Relenza; 4-Guanidino-Neu5Ac2en; GANA; Zanamavir; MODIFIED SIALIC ACID; GG167; UNII-L6O3XI777I; GG 167; GR-121167X; Zanamivir (Relenza); Relenza (TN); 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; GR 121167X; CHEMBL222813; L6O3XI777I; ZMR; CHEBI:50663; GANA (inhibitor); 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; GNA; AK163166; GG-167; DSSTox_CID_3749; DSSTox_RID_77184; DSSTox_GSID_23749; Zanamivir [USAN:INN:BAN]; HSDB 7437; C12H20N4O7;  GANA; Zanamivir hydrate; GR121167X; Zanamivir (USAN/INN); (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 4-Guanidino-NeueAc2en; 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; ZNV; 4-guanidino-Neu5Ac2en; BAC-zanamivir
DMFMBZ4	CP	GlaxoSmithKline
DMFMBZ4	TC	Antiviral Agents
DMFMBZ4	DT	Small molecular drug
DMFMBZ4	PC	60855
DMFMBZ4	MW	332.31
DMFMBZ4	FM	C12H20N4O7
DMFMBZ4	IC	InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
DMFMBZ4	CS	CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)N=C(N)N
DMFMBZ4	IK	ARAIBEBZBOPLMB-UFGQHTETSA-N
DMFMBZ4	IU	(2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DMFMBZ4	CA	CAS 139110-80-8
DMFMBZ4	CB	CHEBI:50663
DMFMBZ4	DE	Influenza virus infection

DMJWRQP	ID	DMJWRQP
DMJWRQP	DN	Zanubrutinib
DMJWRQP	HS	Approved
DMJWRQP	SN	RNOAOAWBMHREKO-UHFFFAOYSA-N; 1633350-06-7; ( inverted exclamation markA)-Zanubrutinib; CHEMBL3973435; SCHEMBL19742851; SCHEMBL16208602; BGB3111; BDBM249900; BCP29110; BCP25045; BCP25838; AKOS032946689; SB18877; CS-6366; ( inverted exclamation markA)-BGB-3111; HY-101474; US9447106, 27
DMJWRQP	CP	BeiGene Cambridge, MA
DMJWRQP	PC	135905454
DMJWRQP	MW	471.5
DMJWRQP	FM	C27H29N5O3
DMJWRQP	IC	InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)
DMJWRQP	CS	C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
DMJWRQP	IK	RNOAOAWBMHREKO-UHFFFAOYSA-N
DMJWRQP	IU	2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
DMJWRQP	DE	B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma; Waldenstrom macroglobulinemia; Mantle cell lymphoma

DMUR5NG	ID	DMUR5NG
DMUR5NG	DN	Zanubrutinib
DMUR5NG	HS	Approved
DMUR5NG	SN	Zanubrutinib; Zanubrutinib (USAN/INN); Zanubrutinib [INN]; Zanubrutinib [USAN]; compound 27b [US9447106]; (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; 1691249-45-2; BDBM250082; BGB3111; CHEMBL3936761; CS-0021869; D11422; GTPL9861; HY-101474A; Pyrazolo(1,5-a)pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-, (7S)-; SCHEMBL17842597; AG9MHG098Z; US9447106, 27b (peak 2); ZINC584641430; UNII-AG9MHG098Z
DMUR5NG	PC	135565884
DMUR5NG	MW	471.5
DMUR5NG	FM	C27H29N5O3
DMUR5NG	IC	RNOAOAWBMHREKO-QFIPXVFZSA-N
DMUR5NG	CS	C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
DMUR5NG	IK	1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
DMUR5NG	IU	(7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
DMUR5NG	CA	CAS 1691249-45-2
DMUR5NG	DE	Mantle cell lymphoma

DMA5QPM	ID	DMA5QPM
DMA5QPM	DN	Zemaira
DMA5QPM	HS	Approved
DMA5QPM	SN	Alpha-1-antitrypsin
DMA5QPM	CP	CSL Behring
DMA5QPM	DT	Recombinant protein
DMA5QPM	DE	Emphysema

DMSLJP4	ID	DMSLJP4
DMSLJP4	DN	Ziconotide
DMSLJP4	HS	Approved
DMSLJP4	SN	Prialt; Ziconotide [USAN]; SNX 111; DRG-0250; Omega-Conotoxin M VIIA; Omega-conotoxin MVIIA; Prialt (TN); SNX-111; Omega-ConopeptideMVIIA (Conus); Omega-Conotoxin mviia, conus magus; Omega-Conotoxin M VIIA (reduced), cyclic (1-16),(8-20),(15-25)-tris(disulfide)
DMSLJP4	CP	Neurox/Parke Davis
DMSLJP4	TC	Analgesics
DMSLJP4	DT	Small molecular drug
DMSLJP4	PC	16135415
DMSLJP4	MW	2639.2
DMSLJP4	FM	C102H172N36O32S7
DMSLJP4	IC	InChI=1S/C102H172N36O32S7/c1-50(2)34-63-91(161)127-62(26-33-171-5)90(160)129-64(35-53-22-24-54(143)25-23-53)92(162)130-65(36-78(148)149)93(163)135-72-48-175-173-45-69(80(108)150)133-86(156)58(18-8-12-29-105)121-76(146)39-117-85(155)66(41-139)131-88(158)61(21-15-32-114-102(111)112)126-96(166)70-46-176-177-47-71(97(167)132-68(43-141)95(165)125-60(87(157)128-63)20-14-31-113-101(109)110)134-89(159)59(19-9-13-30-106)123-81(151)51(3)119-74(144)37-115-83(153)56(16-6-10-27-103)120-75(145)38-116-84(154)57(17-7-11-28-104)124-82(152)55(107)44-172-174-49-73(137-98(72)168)99(169)138-79(52(4)142)100(170)118-40-77(147)122-67(42-140)94(164)136-70/h22-25,50-52,55-73,79,139-143H,6-21,26-49,103-107H2,1-5H3,(H2,108,150)(H,115,153)(H,116,154)(H,117,155)(H,118,170)(H,119,144)(H,120,145)(H,121,146)(H,122,147)(H,123,151)(H,124,152)(H,125,165)(H,126,166)(H,127,161)(H,128,157)(H,129,160)(H,130,162)(H,131,158)(H,132,167)(H,133,156)(H,134,159)(H,135,163)(H,136,164)(H,137,168)(H,138,169)(H,148,149)(H4,109,110,113)(H4,111,112,114)/t51-,52+,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,79-/m0/s1
DMSLJP4	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N3)CO)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN
DMSLJP4	IK	BPKIMPVREBSLAJ-QTBYCLKRSA-N
DMSLJP4	IU	2-[(1R,4S,7S,13S,16R,21R,24S,27S,30S,33S,36S,39S,42R,45S,48S,54S,60S,63R,68R,71S,77S)-63-amino-13,45,54,60-tetrakis(4-aminobutyl)-4,36-bis(3-carbamimidamidopropyl)-16-carbamoyl-71-[(1R)-1-hydroxyethyl]-7,39,77-tris(hydroxymethyl)-27-[(4-hydroxyphenyl)methyl]-48-methyl-33-(2-methylpropyl)-30-(2-methylsulfanylethyl)-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,62,69,72,75,78,85-tetracosaoxo-18,19,65,66,81,82-hexathia-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosazatricyclo[40.37.4.221,68]pentaoctacontan-24-yl]acetic acid
DMSLJP4	CA	CAS 107452-89-1
DMSLJP4	CB	CHEBI:135912
DMSLJP4	DE	Pain; Traumatic brain injury

DM4KI7O	ID	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	HS	Approved
DM4KI7O	SN	zidovudine; Azidothymidine; 30516-87-1; 3'-Azido-3'-deoxythymidine; Retrovir; AZT; Zidovudinum; Compound S; Thymidine, 3'-azido-3'-deoxy-; ZIDOVUDINE [AZT]; zidovudin; BW A509U; Zidovudinum [Latin]; Zidovudina [Spanish]; BWA509U; DRG-0004; 3'-Azido-2',3'-Dideoxythymidine; ZDV; UNII-4B9XT59T7S; 3'-Deoxy-3'-azidothymidine; CCRIS 105; Aztec; BW-A509U; BW-A-509U; HSDB 6515; 3'-Azido-3'-deoxythymidine (AIDS); CHEMBL129; NSC 602670; BW-A 509U; MLS000028548; 4B9XT59T7S;  AZT; Antiviral; Azidodeoxythymidine; ZVD; Zidovudin; Zidovudina; AZT Antiviral; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; Antiviral AZT; Cpd S; Racemic Liposomal AZT; Zidovudine EP III; BWA 509U; K7 [P Ti2 W10 O40]; AZT & EPO; AZT & HPA; AZT & Lymphoblastoid Interferon; AZT & SST; AZT & rsT4; AZT & sCD4; AZT & srCD4; AZT (Antiviral); AZT+PRO 140; AZT, Antiviral; Apo-Zidovudine; BWA-509U; Intron A & AZT; Novo-Azt; Propolis+AZT; Retrovir (TN); Retrovir(TM); Retrovis (TN); Zidovudine+PRO 140; AZT & Colony-stimulating factor 2; AZT & Concanavalin A (ConA); AZT & GM-CSF; AZT & IFN-alpha; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Li & EPO; AZT & NP (from PHCA or HSA); AZT & PM-19; DS-4152 & AZT; Liposomal AZT-SN-1; Liposomal AZT-SN-3; PC-SOD+AZT;RIFN-beta seron & AZT; AZT & CD4(178)-PE 40; AZT & Li & GM-CSF; AZT & Li & IL-1; AZT & Li & IL-6; AZT & rIFNalpha2; Racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); Zidovudine (JAN/USP/INN); Zidovudine [USAN:INN:BAN:JAN]; AZT & rsCD4 & rIFNalphaA; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); AZT & Interferon-alpha-2; Met-SDF-1beta & AZT; Met-SDF-1beta & Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; 3&prime;-Azido-3&prime;-deoxythymidine; 3' Azido 2',3' Dideoxythymidine; 3' Azido 3' deoxythymidine; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; 3'-Azido-3'deoxythymidine & Interferon-alpha; 3'-Azidothymidine; 3'-azido-3'-deoxythymidine, AZT; 3-Azido-3-deoxythymidine; Dendrigen; CTCE-0422
DM4KI7O	CP	GlaxoSmithKline
DM4KI7O	TC	Anti-HIV Agents
DM4KI7O	DT	Small molecular drug
DM4KI7O	PC	35370
DM4KI7O	MW	267.24
DM4KI7O	FM	C10H13N5O4
DM4KI7O	IC	InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
DM4KI7O	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-]
DM4KI7O	IK	HBOMLICNUCNMMY-XLPZGREQSA-N
DM4KI7O	IU	1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM4KI7O	CA	CAS 30516-87-1
DM4KI7O	CB	CHEBI:10110
DM4KI7O	DE	Human immunodeficiency virus infection; Virus infection

DMVRIC2	ID	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	HS	Approved
DMVRIC2	SN	Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zyflo (TN); Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
DMVRIC2	CP	Cornerstone Therapeutics Inc
DMVRIC2	TC	Antiinflammatory Agents
DMVRIC2	DT	Small molecular drug
DMVRIC2	PC	60490
DMVRIC2	MW	236.29
DMVRIC2	FM	C11H12N2O2S
DMVRIC2	IC	InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)
DMVRIC2	CS	CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
DMVRIC2	IK	MWLSOWXNZPKENC-UHFFFAOYSA-N
DMVRIC2	IU	1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
DMVRIC2	CA	CAS 111406-87-2
DMVRIC2	CB	CHEBI:10112
DMVRIC2	DE	Asthma

DMZ4R3Q	ID	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	HS	Approved
DMZ4R3Q	DE	Arthritis

DMK4OL7	ID	DMK4OL7
DMK4OL7	DN	Zinostatin stimalamer
DMK4OL7	HS	Approved
DMK4OL7	SN	Smancs (TN)
DMK4OL7	DT	Small molecular drug
DMK4OL7	PC	70682998
DMK4OL7	MW	657.7
DMK4OL7	FM	C36H35NO11
DMK4OL7	IC	InChI=1S/C36H35NO11/c1-17-9-10-22-18(2)13-21(42-5)15-24(22)28(17)33(40)45-25-14-20-11-12-36(27-16-43-35(41)46-27)26(48-36)8-6-7-23(20)32(25)47-34-29(37-4)31(39)30(38)19(3)44-34/h7,9-10,13-15,19,25-27,29-32,34,37-39H,16H2,1-5H3/b23-7+/t19-,25-,26-,27+,29-,30+,31-,32?,34-,36+/m1/s1
DMK4OL7	CS	C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC\\2[C@@H](C=C3/C2=C\\C#C[C@@H]4[C@@](O4)(C#C3)[C@@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)C)NC)O)O
DMK4OL7	IK	FYQZGCBXYVWXSP-STTFAQHVSA-N
DMK4OL7	IU	[(4S,6R,9E,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4S)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-2,5-dimethylnaphthalene-1-carboxylate
DMK4OL7	DE	Brain cancer

DMM58JY	ID	DMM58JY
DMM58JY	DN	Ziprasidone
DMM58JY	HS	Approved
DMM58JY	SN	146939-27-7; Geodon; Zeldox; Ziprasidone hydrochloride; Ziprasidone [INN:BAN]; UNII-6UKA5VEJ6X; CP 88059; Ziprasidone mesylate trihydrate; 6UKA5VEJ6X; CHEMBL708; C21H21ClN4OS; CHEBI:10119; CP-88,059-1; ziprazidone; DSSTox_CID_3753; DSSTox_RID_77186; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DSSTox_GSID_23753; ziprasidonum; ziprasidona; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one;  Geodon; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); CP-88,059; CP-88059-1; CP-88,059-01; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; TC-5280
DMM58JY	CP	Pfizer
DMM58JY	TC	Antipsychotic Agents
DMM58JY	DT	Small molecular drug
DMM58JY	PC	60854
DMM58JY	MW	412.9
DMM58JY	FM	C21H21ClN4OS
DMM58JY	IC	InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
DMM58JY	CS	C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
DMM58JY	IK	MVWVFYHBGMAFLY-UHFFFAOYSA-N
DMM58JY	IU	5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
DMM58JY	CA	CAS 146939-27-7
DMM58JY	CB	CHEBI:10119
DMM58JY	DE	Schizophrenia

DMN4H2O	ID	DMN4H2O
DMN4H2O	DN	Zithromax
DMN4H2O	HS	Approved
DMN4H2O	SN	azithromycin; Zithromax; 83905-01-5; Azithromycinum; Azithromycine; Sumamed; Zitromax; Zmax; Hemomycin; Azitrocin; Azasite; Azenil; Aritromicina; Zitrotek; Zithrax; Mixoterin; Setron; Aziwok; Zitrim; Aztrin; Zifin; Tobil; Zmas; Zeto; Azithromycinum [Latin]; Azithromycine [French]; Zithromax IV; AZITHROMYCIN DIHYDRATE; Misultina; Azitromax; Z-Pak; Tromix; Aritromicina [Spanish]; Azitromicina; CP-62993; UNII-J2KLZ20U1M; DRG-0104; CCRIS 1961; HSDB 7205; Azithromycin (anhydrous); C38H72N2O12; BRN 5387583; J2KLZ20U1M; Azythromycin; CHEBI:2955
DMN4H2O	DT	Small molecular drug
DMN4H2O	PC	447043
DMN4H2O	MW	749
DMN4H2O	FM	C38H72N2O12
DMN4H2O	IC	InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
DMN4H2O	CS	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O
DMN4H2O	IK	MQTOSJVFKKJCRP-BICOPXKESA-N
DMN4H2O	IU	(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
DMN4H2O	CA	CAS 83905-01-5
DMN4H2O	CB	CHEBI:2955
DMN4H2O	DE	Syphilis infection

DMIXC7G	ID	DMIXC7G
DMIXC7G	DN	Zoledronate
DMIXC7G	HS	Approved
DMIXC7G	SN	Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
DMIXC7G	CP	Norvatis Phamaceuticals Corporation
DMIXC7G	TC	Bone Density Conservation Agents
DMIXC7G	DT	Small molecular drug
DMIXC7G	PC	68740
DMIXC7G	MW	272.09
DMIXC7G	FM	C5H10N2O7P2
DMIXC7G	IC	InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
DMIXC7G	CS	C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
DMIXC7G	IK	XRASPMIURGNCCH-UHFFFAOYSA-N
DMIXC7G	IU	(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
DMIXC7G	CA	CAS 118072-93-8
DMIXC7G	CB	CHEBI:46557
DMIXC7G	DE	Hypercalcaemia

DM57O90	ID	DM57O90
DM57O90	DN	Zolgensma
DM57O90	HS	Approved
DM57O90	SN	Onasemnogene abeparvovec-xioi
DM57O90	CP	AveXis
DM57O90	DT	Gene therapy
DM57O90	DE	Spinal muscular atrophy

DM1IB4Q	ID	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	HS	Approved
DM1IB4Q	SN	AscoTop; Flezol; Zolmitriptane; Zolmitriptanum; Zomig; Zomigon; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zomig Nasal Spray; Zomig ZMT; AscoTop (TN); BW-311C90; KS-5072; Zomig (TN); Zomig-ZMT; Zomigon (TN); Zomigoro (TN); Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
DM1IB4Q	CP	AstraZeneca
DM1IB4Q	TC	Antimigraine Agents
DM1IB4Q	DT	Small molecular drug
DM1IB4Q	PC	60857
DM1IB4Q	MW	287.36
DM1IB4Q	FM	C16H21N3O2
DM1IB4Q	IC	InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
DM1IB4Q	CS	CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@H]3COC(=O)N3
DM1IB4Q	IK	ULSDMUVEXKOYBU-ZDUSSCGKSA-N
DM1IB4Q	IU	(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
DM1IB4Q	CA	CAS 139264-17-8
DM1IB4Q	CB	CHEBI:10124
DM1IB4Q	DE	Migraine

DMWOSKJ	ID	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	HS	Approved
DMWOSKJ	SN	zolpidem; 82626-48-0; Ambien; Zolpidemum; Lorex; Zolpidemum [Latin]; Zolpidem [INN:BAN]; UNII-7K383OQI23; N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide; CHEMBL911; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; DEA No 2783; CHEBI:10125; ZAFYATHCZYHLPB-UHFFFAOYSA-N; 7K383OQI23; NCGC00095179-01; N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide; SL-800750; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide;  ZolpiMist; Zolpidem tartrate; Zolpidem (low-dose oral spray, middle-of-the-night awakenings); Zolpidem (low-dose oral spray, middle-of-the-night awakenings), NovaDel; [3H]zolpidem
DMWOSKJ	CP	NovaDel Pharma Inc
DMWOSKJ	DT	Small molecular drug
DMWOSKJ	PC	5732
DMWOSKJ	MW	307.4
DMWOSKJ	FM	C19H21N3O
DMWOSKJ	IC	InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
DMWOSKJ	CS	CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C
DMWOSKJ	IK	ZAFYATHCZYHLPB-UHFFFAOYSA-N
DMWOSKJ	IU	N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
DMWOSKJ	CA	CAS 82626-48-0
DMWOSKJ	CB	CHEBI:10125
DMWOSKJ	DE	Insomnia

DM0DTF7	ID	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	HS	Approved
DM0DTF7	SN	Exceglan; Excegram; Excegran; Tremode; Trerief; Zonegran; Zonisamida; Zonisamidum; Elan brand of zonisamide; Zonisamida [Spanish]; Zonisamide monosodium; Zonisamidum [Latin]; AD 810; PD 110843; SPR_2; AD-810; AD-810N; E-2090; Excegran (TN); PD-110843; Zonegran (TN); Zonegran, Zonisamide; Zonisamide (ZNS); Zonisamide (JAN/USAN/INN); Zonisamide [USAN:BAN:INN:JAN]; 1,2-Benzisoxazole-3-methanesulfonamide; 1,2-benzoxazol-3-ylmethanesulfonamide; 1-(1,2-Benzoxazol-3-Yl)methanesulfonamide; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; 3-sulfamoylmethyl-1,2-benzisoxazole
DM0DTF7	CP	Eisai
DM0DTF7	TC	Analgesics
DM0DTF7	DT	Small molecular drug
DM0DTF7	PC	5734
DM0DTF7	MW	212.23
DM0DTF7	FM	C8H8N2O3S
DM0DTF7	IC	InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
DM0DTF7	CS	C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N
DM0DTF7	IK	UBQNRHZMVUUOMG-UHFFFAOYSA-N
DM0DTF7	IU	1,2-benzoxazol-3-ylmethanesulfonamide
DM0DTF7	CA	CAS 68291-97-4
DM0DTF7	DE	Epilepsy

DMPI6Z0	ID	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	HS	Approved
DMPI6Z0	SN	Amoban; Amovane; Imovance; Imovane; Limovan; Optidorm; Rhovane; Siaten; Sopivan; Ximovan; Zileze; Zimoclone; Zimovane; Zopicalm; Zopicalma; Zopiclodura; Zopiclona; Zopiclonum; Zopitan; Zorclone; AbZ brand of zopiclone; Aliud brand of zopiclone; Alpharma brand of zopiclone; Aventis Pharma brand of zopiclone; Aventis brand of zopiclone; Azupharma brand of zopiclone; Betapharm brand of zopiclone; Ciclum brand of zopiclone; Clonmel brand of zopiclone; Dolorgeit brand of zopiclone; Gerard brand of zopiclone; Hexal brand of zopiclone; Hormosan brand of zopiclone; Italfarmaco brand of zopiclone; Merck dura brand of zopiclone; Neuraxpharm brand of zopiclone; Norton brand of zopiclone; Opus brand of zopiclone; Pinewood brand of zopiclone; Ratiopharm brand of zopiclone; Rhodiapharm brand of zopiclone; Stadapharm brand of zopiclone; TAD brand of zopiclone; Temmler brand of zopiclone; Teva brand of zopiclone; Zopiclon AL; Zopiclon AZU; Zopiclon AbZ; Zopiclon Stada; Zopiclon TAD; Zopiclon beta; Zopiclon von ct; RP 27 267; RP 27267; Z 4900; Z4900_SIGMA; Amoban (TN); Ct-Arzneimittel brand of zopiclone; Imovane (TN); Novo-zopiclone; Nu-Pharm brand of zopiclone; Nu-Zopiclone; RP-27267; Ran-zopiclone; Ratio-Zopiclone; Rhone-Poulenc Rorer brand of zopiclone; Zimovane (TN); Zopi-Puren; Zopiclon-TEVA; Zopiclon-neuraxpharm; Zopiclon-ratiopharm; Zopiclona [INN-Spanish]; Zopiclone (TN); Zopiclonum [INN-Latin]; Zopinox (TN); Zopiclone (JAN/INN); Zopiclone [BAN:INN:JAN]; Zopiclone, Imovane, Zimovane, Lunesta; [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; 4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; 4-Methyl-1-piperazinecarboxylic acid ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo(3,4-b)pyrazin-5-one; 6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; 6-(5-chloropyrid-2-yl)-5-(4-methylpiperazin-1-yl)carbonyloxy-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine; 6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate
DMPI6Z0	CP	Sanofi-Aventis
DMPI6Z0	TC	Hypnotics and Sedatives
DMPI6Z0	DT	Small molecular drug
DMPI6Z0	PC	5735
DMPI6Z0	MW	388.8
DMPI6Z0	FM	C17H17ClN6O3
DMPI6Z0	IC	InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3
DMPI6Z0	CS	CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
DMPI6Z0	IK	GBBSUAFBMRNDJC-UHFFFAOYSA-N
DMPI6Z0	IU	[6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
DMPI6Z0	CA	CAS 43200-80-2
DMPI6Z0	CB	CHEBI:32315
DMPI6Z0	DE	Insomnia

DMRMCXW	ID	DMRMCXW
DMRMCXW	DN	Zotarolimus
DMRMCXW	HS	Approved
DMRMCXW	SN	Abt-578; Zotarolimus (TN)
DMRMCXW	CP	Medtronic
DMRMCXW	DT	Small molecular drug
DMRMCXW	PC	9876378
DMRMCXW	MW	966.2
DMRMCXW	FM	C52H79N5O12
DMRMCXW	IC	InChI=1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1
DMRMCXW	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@@H]([C@@H](C4)OC)N5C=NN=N5)C)/C)O)OC)C)C)/C)OC
DMRMCXW	IK	CGTADGCBEXYWNE-JUKNQOCSSA-N
DMRMCXW	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-12-[(2R)-1-[(1S,3R,4S)-3-methoxy-4-(tetrazol-1-yl)cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMRMCXW	CA	CAS 221877-54-9
DMRMCXW	CB	CHEBI:135897
DMRMCXW	DE	Solid tumour/cancer

DMF3VXA	ID	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	HS	Approved
DMF3VXA	SN	zotepine; 26615-21-4; Nipolept; Lodopin; Zoleptil; Zotepina; Zotepinum; Compound-4; Zotepina [Spanish]; Zotepinum [INN-Latin]; Zotepina [INN-Spanish]; UNII-U29O83JAZW; 2-Chloro-11-(2-(dimethylamino)ethoxy)dibenzo(b,f)thiepin; 2-Chlor-11-(2-dimethylaminoaethoxy)-dibenzo(b,f)-thiepin; C18H18ClNOS; BRN 1435710; U29O83JAZW; CHEMBL285802; CHEBI:32316; HDOZVRUNCMBHFH-UHFFFAOYSA-N; 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethylethanamine; 2-Chloro-11-(2-dimethylaminoethoxy)-dibenzo(b,f)thiepine; NCGC00182081-02
DMF3VXA	DT	Small molecular drug
DMF3VXA	PC	5736
DMF3VXA	MW	331.9
DMF3VXA	FM	C18H18ClNOS
DMF3VXA	IC	InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3
DMF3VXA	CS	CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMF3VXA	IK	HDOZVRUNCMBHFH-UHFFFAOYSA-N
DMF3VXA	IU	2-(3-chlorobenzo[b][1]benzothiepin-5-yl)oxy-N,N-dimethylethanamine
DMF3VXA	CA	CAS 26615-21-4
DMF3VXA	CB	CHEBI:32316
DMF3VXA	DE	Anxiety disorder

DMKYD5N	ID	DMKYD5N
DMKYD5N	DN	Zuclopenthixol
DMKYD5N	HS	Approved
DMKYD5N	SN	Acuphase; CLOPENTHIXOL; Cisordinol; Clopenthixolum; Clopentixol; Clopixol; Zuclopenthixolum; Zuclopentixol; Alpha Clopenthixol; Zuclopenthixolum [Latin]; Zuclopentixol [Spanish]; Acuphase (TN); Alpha-Clopenthixol; Cisordinol (TN); Clopenthixol (USAN); Clopixol (TN); Zuclopenthixol (INN); Zuclopenthixol [BAN:INN]; (Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol; 2-{4-[(3Z)-3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 2-{4-[3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol
DMKYD5N	CP	Lundbeck pharmaceutical company
DMKYD5N	TC	Antipsychotic Agents
DMKYD5N	DT	Small molecular drug
DMKYD5N	PC	5311507
DMKYD5N	MW	401
DMKYD5N	FM	C22H25ClN2OS
DMKYD5N	IC	InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-
DMKYD5N	CS	C1CN(CCN1CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
DMKYD5N	IK	WFPIAZLQTJBIFN-DVZOWYKESA-N
DMKYD5N	IU	2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol
DMKYD5N	CA	CAS 53772-83-1
DMKYD5N	CB	CHEBI:51364
DMKYD5N	DE	Schizophrenia

DMRCOU5	ID	DMRCOU5
DMRCOU5	DN	Dicycloplatin
DMRCOU5	HS	Registered
DMRCOU5	CP	Peking University
DMRCOU5	PC	44475103
DMRCOU5	MW	515.38
DMRCOU5	FM	C12H20N2O8Pt
DMRCOU5	IC	InChI=1S/2C6H8O4.2H3N.Pt/c2*7-4(8)6(5(9)10)2-1-3-6;;;/h2*1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;;+2/p-2
DMRCOU5	CS	C1CC(C1)(C(=O)O)C(=O)O.C1CC(C1)(C(=O)[O-])C(=O)[O-].N.N.[Pt+2]
DMRCOU5	IK	IIJQICKYWPGJDT-UHFFFAOYSA-L
DMRCOU5	IU	azane;cyclobutane-1,1-dicarboxylate;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
DMRCOU5	CA	CAS 287402-09-9
DMRCOU5	DE	Prostate cancer

DMBZ27L	ID	DMBZ27L
DMBZ27L	DN	Favipiravir
DMBZ27L	HS	Registered
DMBZ27L	SN	AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705
DMBZ27L	CP	Toyama Chemical
DMBZ27L	DT	Small molecular drug
DMBZ27L	PC	492405
DMBZ27L	MW	157.1
DMBZ27L	FM	C5H4FN3O2
DMBZ27L	IC	InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
DMBZ27L	CS	C1=C(N=C(C(=O)N1)C(=O)N)F
DMBZ27L	IK	ZCGNOVWYSGBHAU-UHFFFAOYSA-N
DMBZ27L	IU	5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
DMBZ27L	CA	CAS 259793-96-9
DMBZ27L	CB	CHEBI:134722
DMBZ27L	DE	Influenza virus infection

DMDWYUN	ID	DMDWYUN
DMDWYUN	DN	HBI-8000
DMDWYUN	HS	Registered
DMDWYUN	SN	CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide
DMDWYUN	CP	HUYA Bioscience International; Quintiles
DMDWYUN	DT	Small molecular drug
DMDWYUN	PC	12136798
DMDWYUN	MW	390.4
DMDWYUN	FM	C22H19FN4O2
DMDWYUN	IC	InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+
DMDWYUN	CS	C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N
DMDWYUN	IK	SZMJVTADHFNAIS-BJMVGYQFSA-N
DMDWYUN	IU	N-(2-amino-4-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide
DMDWYUN	CA	CAS 1616493-44-7
DMDWYUN	CB	CHEBI:135918
DMDWYUN	DE	Solid tumour/cancer; Melanoma; Merkel cell carcinoma; Renal cell carcinoma; Non-small-cell lung cancer

DM5GFIK	ID	DM5GFIK
DM5GFIK	DN	Icotinib hydrochloride
DM5GFIK	HS	Registered
DM5GFIK	SN	Conmana; Conmanna; Icotinib; BPI-2009-H
DM5GFIK	CP	Beta Pharma Inc
DM5GFIK	DT	Small molecular drug
DM5GFIK	PC	44609731
DM5GFIK	MW	427.9
DM5GFIK	FM	C22H22ClN3O4
DM5GFIK	IC	InChI=1S/C22H21N3O4.ClH/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20;/h1,3-5,12-15H,6-11H2,(H,23,24,25);1H
DM5GFIK	CS	C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4.Cl
DM5GFIK	IK	PNNGXMJMUUJHAV-UHFFFAOYSA-N
DM5GFIK	IU	N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.014,19]icosa-1(12),13,15,17,19-pentaen-18-amine;hydrochloride
DM5GFIK	CA	CAS 1204313-51-8
DM5GFIK	DE	Non-small-cell lung cancer

DM5GIWZ	ID	DM5GIWZ
DM5GIWZ	DN	Mirogabalin
DM5GIWZ	HS	Registered
DM5GIWZ	SN	Mirogabalin; 1138245-13-2; UNII-S7LK2KDM5U; DS-5565; S7LK2KDM5U; Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; Bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid; ((1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid; Mirogabalin [INN]; Mirogabalin [USAN:INN]; [(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid; DS5565; DS 5565; GTPL8303
DM5GIWZ	DT	Small molecular drug
DM5GIWZ	PC	59509752
DM5GIWZ	MW	209.28
DM5GIWZ	FM	C12H19NO2
DM5GIWZ	IC	InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1
DM5GIWZ	CS	CCC1=C[C@@H]2[C@H](C1)C[C@@]2(CC(=O)O)CN
DM5GIWZ	IK	FTBQORVNHOIASH-CKYFFXLPSA-N
DM5GIWZ	IU	2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid
DM5GIWZ	CA	CAS 1138245-13-2
DM5GIWZ	DE	Fibromyalgia; Cancer related pain; Cardiovascular disease; Peripheral neuropathy

DMY67U8	ID	DMY67U8
DMY67U8	DN	Trapidil
DMY67U8	HS	Phase 4
DMY67U8	SN	trapidil; Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991
DMY67U8	DT	Small molecular drug
DMY67U8	PC	5531
DMY67U8	MW	205.26
DMY67U8	FM	C10H15N5
DMY67U8	IC	InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
DMY67U8	CS	CCN(CC)C1=CC(=NC2=NC=NN12)C
DMY67U8	IK	GSNOZLZNQMLSKJ-UHFFFAOYSA-N
DMY67U8	IU	N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
DMY67U8	CA	CAS 15421-84-8
DMY67U8	CB	CHEBI:32254
DMY67U8	DE	Multiple myeloma; Coronary artery disease; Acute coronary syndrome

DMVZL26	ID	DMVZL26
DMVZL26	DN	3,4-Dihydroxycinnamic Acid
DMVZL26	HS	Phase 4
DMVZL26	SN	Caffeic acid; caffeic acid; 3,4-Dihydroxycinnamic acid; 331-39-5; 3-(3,4-dihydroxyphenyl)acrylic acid; 501-16-6; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; 3,4-Dihydroxybenzeneacrylic acid; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; trans-caffeic acid; trans-Caffeate; 3,4-Dihydroxy-trans-cinnamate; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; Cinnamic acid, 3,4-dihydroxy-; 3-(3,4-Dihydroxyphenyl)propenoic acid; UNII-U2S3A33KVM; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene
DMVZL26	DT	Small molecular drug
DMVZL26	PC	689043
DMVZL26	MW	180.16
DMVZL26	FM	C9H8O4
DMVZL26	IC	InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+
DMVZL26	CS	C1=CC(=C(C=C1/C=C/C(=O)O)O)O
DMVZL26	IK	QAIPRVGONGVQAS-DUXPYHPUSA-N
DMVZL26	IU	(E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid
DMVZL26	CA	CAS 331-39-5
DMVZL26	CB	CHEBI:16433
DMVZL26	DE	Thrombocytopenia

DML6CN4	ID	DML6CN4
DML6CN4	DN	Acemetacin
DML6CN4	HS	Phase 4
DML6CN4	SN	Acemetacina; Acemetacina [INN-Spanish]; Acemetacine; Acemetacine [INN-French]; Acemetacinum; Acemetacinum [INN-Latin]; Acemix; Aximeixin; Emflex; Rantudil; Rheumibis; TVX 3322; indometacin carboxymethyl ester; indometacin glycolic ester; indomethacin carboxymethyl ester; indomethacin glycolic ester; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester; 53164-05-9; BRN 0501672; Bay f 4975; C21H18ClNO6; CHEBI:31162; CHEMBL189171; EINECS 258-403-4; K 708; K-708; UNII-5V141XK28X; acemetacin
DML6CN4	PC	1981
DML6CN4	MW	415.8
DML6CN4	FM	C21H18ClNO6
DML6CN4	IC	FSQKKOOTNAMONP-UHFFFAOYSA-N
DML6CN4	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O
DML6CN4	IK	1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)
DML6CN4	IU	2-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyacetic acid
DML6CN4	CA	CAS 53164-05-9
DML6CN4	CB	CHEBI:31162
DML6CN4	DE	Osteoarthritis

DM4UE3K	ID	DM4UE3K
DM4UE3K	DN	Acetylcarnitine
DM4UE3K	HS	Phase 4
DM4UE3K	SN	(-)-Acetylcarnitine; (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate; (R)-Acetylcarnitine; 3040-38-8; 6DH1W9VH8Q; ALCAR; Acetyl-L-(-)-carnitine; Acetyl-L-carnitine; Acetylcarnitine, L-; CAR(2:0); CHEBI:57589; Carnitine, acetyl-, L-; HSDB 7587; L-ACETYLCARNITINE; L-Acetyl carnitine; L-Carnitine acetyl ester; L-O-Acetylcarnitine; Levocarnitine acetyl; Nicetile; O-Acetyl-L-carnitine; R-Acetylcarnitine; RDHQFKQIGNGIED-MRVPVSSYSA-N; UNII-6DH1W9VH8Q; acetyl l-carnitine; acetyl-carnitine; acetylcarnitine
DM4UE3K	DT	Small molecular drug
DM4UE3K	PC	7045767
DM4UE3K	MW	203.238
DM4UE3K	FM	C9H17NO4
DM4UE3K	IC	InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1
DM4UE3K	CS	CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C
DM4UE3K	IK	RDHQFKQIGNGIED-MRVPVSSYSA-N
DM4UE3K	IU	(3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate
DM4UE3K	CA	CAS 3040-38-8
DM4UE3K	CB	CHEBI:57589
DM4UE3K	DE	Migraine

DM1237M	ID	DM1237M
DM1237M	DN	Alfacalcidol
DM1237M	HS	Phase 4
DM1237M	SN	Alfacalcidol [INN:BAN:JAN]; Alfacalcidolum; Alfacalcidolum [INN-Latin]; Alfarol; Alpha D 3; Alphacalcidol; Alsiodol; Bondiol; EinsAlpha; One-Alpha; Oxydevit; Sinovul; URQ2517572; Un-Alpha; Vitamin D3, 1alpha-Hydroxy-; alfacalcidol; alpha-Calcidol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol; 1-Hydroxycholecalciferol; 1-Hydroxyvitamin D3; 1alpha-Hydroxy-vitamin D3; 1alpha-Hydroxycholecalciferol; 1alpha-Hydroxyvitamin D3; 1alpha-OH-D3; 41294-56-8; CCRIS 3341; CHEBI:31186; UNII-URQ2517572
DM1237M	PC	5282181
DM1237M	MW	400.6
DM1237M	FM	C27H44O2
DM1237M	IC	OFHCOWSQAMBJIW-AVJTYSNKSA-N
DM1237M	CS	CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
DM1237M	IK	1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1
DM1237M	IU	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM1237M	CA	CAS 41294-56-8
DM1237M	CB	CHEBI:31186
DM1237M	DE	Diabetes mellitus

DMY2AH1	ID	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	HS	Phase 4
DMY2AH1	SN	AMINOPYRINE; Amidazofen; Amidazophen; Amidazophene; Amidofebrin; Amidofen; Amidophen; Amidophenazone; Amidopyrazoline; Amidopyrin; Amidopyrine; Aminofenazone; Aminophenazon; Aminopyrin; Anafebrina; Brufaneuxol; Dereuma; Dimapyrin; Dimethylaminoantipyrine; Dimethylaminoazophene; Dimethylaminophenazone; Dipirin; Dipyrin; Dipyrine; Eufibron; Febrinina; Febron; Hyparon; Itamidone; Mamallet-A; Novamidon; Piramidon; Pirazon; Piridol; Piromidina; Polinalin; Pyradone; Pyramidon; Pyramidone; aminophenazone; 4-Dimethylaminoantipyrine; 58-15-1
DMY2AH1	PC	6009
DMY2AH1	MW	231.29
DMY2AH1	FM	C13H17N3O
DMY2AH1	IC	RMMXTBMQSGEXHJ-UHFFFAOYSA-N
DMY2AH1	CS	CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C
DMY2AH1	IK	1S/C13H17N3O/c1-10-12(14(2)3)13(17)16(15(10)4)11-8-6-5-7-9-11/h5-9H,1-4H3
DMY2AH1	IU	4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one
DMY2AH1	CA	CAS 58-15-1
DMY2AH1	CB	CHEBI:160246
DMY2AH1	DE	Anaesthesia

DMWDEN0	ID	DMWDEN0
DMWDEN0	DN	Amylin
DMWDEN0	HS	Phase 4
DMWDEN0	SN	Amlintide; Pancreatic amylin; IAPP; Islet amyloid polypeptide; Insulinoma amyloid peptide; Diabetes-associated peptide; Insulinoma amyloid polypeptide; Amylin (human); Amlintide [USAN:INN]; 122384-88-7; Human islet amyloid peptide; AC001; AC 001; SCHEMBL374892; C8H16N2O4.C4H10; LS-172011; FT-0688968
DMWDEN0	DT	Small molecular drug
DMWDEN0	PC	16132430
DMWDEN0	MW	3903.3
DMWDEN0	FM	C165H261N51O55S2
DMWDEN0	IC	InChI=1S/C165H261N51O55S2/c1-22-75(12)124(159(266)200-95(47-71(4)5)140(247)203-108(64-219)153(260)206-110(66-221)154(261)216-129(84(21)226)163(270)202-105(58-119(174)234)147(254)209-122(73(8)9)157(264)181-61-121(236)187-106(62-217)150(257)198-103(56-117(172)232)148(255)215-128(83(20)225)162(269)190-93(130(175)237)49-87-38-40-89(227)41-39-87)211-132(239)76(13)183-120(235)60-180-136(243)97(50-85-32-25-23-26-33-85)194-144(251)101(54-115(170)230)196-145(252)102(55-116(171)231)197-151(258)107(63-218)205-152(259)109(65-220)204-142(249)99(52-88-59-178-69-182-88)201-158(265)123(74(10)11)210-146(253)96(48-72(6)7)193-141(248)98(51-86-34-27-24-28-35-86)195-143(250)100(53-114(169)229)191-131(238)77(14)184-139(246)94(46-70(2)3)192-137(244)91(37-31-45-179-165(176)177)188-138(245)92(42-43-113(168)228)189-161(268)126(81(18)223)212-133(240)78(15)185-155(262)111-67-272-273-68-112(207-135(242)90(167)36-29-30-44-166)156(263)199-104(57-118(173)233)149(256)214-125(80(17)222)160(267)186-79(16)134(241)213-127(82(19)224)164(271)208-111/h23-28,32-35,38-41,59,69-84,90-112,122-129,217-227H,22,29-31,36-37,42-58,60-68,166-167H2,1-21H3,(H2,168,228)(H2,169,229)(H2,170,230)(H2,171,231)(H2,172,232)(H2,173,233)(H2,174,234)(H2,175,237)(H,178,182)(H,180,243)(H,181,264)(H,183,235)(H,184,246)(H,185,262)(H,186,267)(H,187,236)(H,188,245)(H,189,268)(H,190,269)(H,191,238)(H,192,244)(H,193,248)(H,194,251)(H,195,250)(H,196,252)(H,197,258)(H,198,257)(H,199,263)(H,200,266)(H,201,265)(H,202,270)(H,203,247)(H,204,249)(H,205,259)(H,206,260)(H,207,242)(H,208,271)(H,209,254)(H,210,253)(H,211,239)(H,212,240)(H,213,241)(H,214,256)(H,215,255)(H,216,261)(H4,176,177,179)/t75-,76-,77-,78-,79-,80+,81+,82+,83+,84+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,122-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMWDEN0	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N
DMWDEN0	IK	PLOPBXQQPZYQFA-AXPWDRQUSA-N
DMWDEN0	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]pentanediamide
DMWDEN0	CA	CAS 106602-62-4

DM8EKSV	ID	DM8EKSV
DM8EKSV	DN	Anti-MIF antibodies
DM8EKSV	HS	Phase 4
DM8EKSV	SN	Antimacrophage inhibitory factor, Baxter; Anti-MIF antibodies (inflammation); Anti-MIF antibodies (inflammation), Baxter; Anti-MIF technology, Cytokine/IDEC; Anti-inflammatories, Cytokine/IDEC; Anti-macrophage inhibitory factor, Cytokine/IDEC
DM8EKSV	CP	Baxter healthcare
DM8EKSV	DE	Autoimmune diabetes

DML1VXW	ID	DML1VXW
DML1VXW	DN	Arotinolol
DML1VXW	HS	Phase 4
DML1VXW	SN	Arotinolol; Arotinolol (INN); Arotinolol [INN]; Arotinololum; Arotinololum [Latin]; (+-)-5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)-4-thiazolyl)-2-thiophenecarboxamide; 2-(3-tert-Butylamino-2-hydroxypropylthio)-4-(5-carbamoyl-2-thienyl)thiazole; 5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)thiazol-4-yl)thiophene-2-carboxamide; 5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide; 68377-92-4; AK129719; C15H21N3O2S3; S-596
DML1VXW	PC	2239
DML1VXW	MW	371.5
DML1VXW	FM	C15H21N3O2S3
DML1VXW	IC	BHIAIPWSVYSKJS-UHFFFAOYSA-N
DML1VXW	CS	CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O
DML1VXW	IK	1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)
DML1VXW	IU	5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide
DML1VXW	CA	CAS 68377-92-4
DML1VXW	CB	CHEBI:135569
DML1VXW	DE	Essential tremor

DMB7WYM	ID	DMB7WYM
DMB7WYM	DN	ATOSIBAN
DMB7WYM	HS	Phase 4
DMB7WYM	SN	Atosiban; Tractocile; 90779-69-4; Atosiban acetate; Antocin; UNII-081D12SI0Z; Rwj 22164; Orf-22164; RWJ-22164; CHEMBL382301; 1-Deamino-2D-tyr-(OEt)-4-thr-8-orn-oxytocin; dTVT; 081D12SI0Z; 1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin; 1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin; NCGC00165718-01; Atosibanum [INN-Latin]; ORF 22164; deTVT; Atosibanum; Antocin II; Atosiban [USAN:INN:BAN]; RWJ22164; 1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineox
DMB7WYM	DT	Small molecular drug
DMB7WYM	PC	5311010
DMB7WYM	MW	994.2
DMB7WYM	FM	C43H67N11O12S2
DMB7WYM	IC	InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1
DMB7WYM	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O
DMB7WYM	IK	VWXRQYYUEIYXCZ-OBIMUBPZSA-N
DMB7WYM	IU	(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMB7WYM	CA	CAS 90779-69-4
DMB7WYM	CB	CHEBI:135899

DMA12HL	ID	DMA12HL
DMA12HL	DN	Azelnidipine
DMA12HL	HS	Phase 4
DMA12HL	SN	Azelnidipine; Azelnidipine [INN]; Calblock; RS-9054; 123524-52-7; 3,5-PYRIDINEDICARBOXYLIC ACID, 2-AMINO-1,4-DIHYDRO-6-METHYL-4-(3-NITROPHENYL)-, 3-[1-(DIPHENYLMETHYL)-3-AZETIDINYL] 5-(1-METHYLETHYL) ESTER; 3-(1-Benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; C33H34N4O6; CS 905; CS-905; DSSTox_CID_120; DSSTox_GSID_20120; DSSTox_RID_75382; MFCD00865803; NCGC00167436-01; NCGC00167436-02
DMA12HL	PC	65948
DMA12HL	MW	582.6
DMA12HL	FM	C33H34N4O6
DMA12HL	IC	ZKFQEACEUNWPMT-UHFFFAOYSA-N
DMA12HL	CS	CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C
DMA12HL	IK	1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3
DMA12HL	IU	3-O-(1-benzhydrylazetidin-3-yl) 5-O-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMA12HL	CA	CAS 123524-52-7
DMA12HL	CB	CHEBI:31247
DMA12HL	DE	Essential hypertension

DMJSDBE	ID	DMJSDBE
DMJSDBE	DN	Barnidipine
DMJSDBE	HS	Phase 4
DMJSDBE	SN	Barnidipine [INN]; Barnidipine HCl; Barnidipino; Barnidipino [INN-Spanish]; Barnidipinum; Barnidipinum [INN-Latin]; Libradin; Mepirodipine; VXMOONUMYLCFJD-DHLKQENFSA-N; Vasexten (TN); YM 09730; barnidipine; (S)-3-((S)-1-Benzylpyrrolidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 104713-75-9; 2VBY96ASWJ; AC1L9FD3; BCP07244; C27H29N3O6; CHEBI:135793; CHEMBL2103761; CHEMBL2110040; CTK8B6661; SCHEMBL49302; UNII-2VBY96ASWJ
DMJSDBE	PC	443869
DMJSDBE	MW	491.5
DMJSDBE	FM	C27H29N3O6
DMJSDBE	IC	VXMOONUMYLCFJD-DHLKQENFSA-N
DMJSDBE	CS	CC1=C(C(C(=C(N1)C)C(=O)OC2CCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMJSDBE	IK	1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1
DMJSDBE	IU	5-O-[(3S)-1-benzylpyrrolidin-3-yl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMJSDBE	CA	CAS 104713-75-9
DMJSDBE	CB	CHEBI:135793
DMJSDBE	DE	Essential hypertension

DMLKUG7	ID	DMLKUG7
DMLKUG7	DN	Beclabuvir
DMLKUG7	HS	Phase 4
DMLKUG7	SN	Beclabuvir; Beclabuvir (USAN/INN); Beclabuvir(BMS-791325); SB16521; 958002-33-0; BDBM50448498; BMS-791325; CHEMBL3126842; CS-6041; HY-12429; SCHEMBL11951525; cyclohexyl-N-(dimethylsulfamoyl)-methoxy-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)[?]carboxamide
DMLKUG7	PC	49773361
DMLKUG7	MW	659.8
DMLKUG7	FM	C36H45N5O5S
DMLKUG7	IC	ZTTKEBYSXUCBSE-VSBZUFFNSA-N
DMLKUG7	CS	CN1CC2CCC(C1)N2C(=O)C34CC3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8
DMLKUG7	IK	1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24?,25?,30-,36-/m0/s1
DMLKUG7	IU	(8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide
DMLKUG7	CA	CAS 958002-33-0
DMLKUG7	DE	Viral hepatitis

DM5NW1E	ID	DM5NW1E
DM5NW1E	DN	Beclomethasone dipropionate
DM5NW1E	HS	Phase 4
DM5NW1E	SN	BECLOMETHASONE DIPROPIONATE; Beclometasone dipropionate; Beconase; Beclovent; Vancenase; Beclorhinol; Becloforte; Sanasthmyl; Beclazone; Sanasthmax; Propaderm; Beclomet; Vanceril; Aerobec; Becloturmant; Beclacin; Respocort; Entyderma; Korbutone; Viarox; Rino-clenil; Clenil-A; Beclometasone 17,21-dipropionate; Becotide; Aldecin; Turbinal; Aldecina; Rhinosol; Beclate; Atomase; Alanase; Benconase; Aldecine; Clenil; Spir; Beclocort Nasel; Beclomet Nasal; Propaderm Forte; Rhino Clenil; Inalone O; Inalone R; Qvar; QNASL; Beconase AQ; Qvar 80
DM5NW1E	PC	21700
DM5NW1E	MW	521
DM5NW1E	FM	C28H37ClO7
DM5NW1E	IC	InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
DM5NW1E	CS	CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)Cl)O)C)C)OC(=O)CC
DM5NW1E	IK	KUVIULQEHSCUHY-XYWKZLDCSA-N
DM5NW1E	IU	[2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
DM5NW1E	CA	CAS 5534-09-8
DM5NW1E	CB	CHEBI:3002
DM5NW1E	DE	Allergic rhinitis

DMWNP6B	ID	DMWNP6B
DMWNP6B	DN	Benidipine
DMWNP6B	HS	Phase 4
DMWNP6B	SN	Benidipene; Benidipine; Benidipine (INN); Benidipine [INN]; Benidipino; Benidipino [Spanish]; Benidipinum; Benidipinum [Latin]; ZINC100014880; ZINC21992076; (+-)-(R*)-3-((R*)-1-Benzyl-3-piperidyl) methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 105979-17-7; 5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; AC1LCVDP; AKOS015895389; C28H31N3O6; CHEMBL2105555; CHEMBL3303980; CTK8E8626; DTXSID0022648; NCGC00185768-01; SCHEMBL24516
DMWNP6B	PC	656668
DMWNP6B	MW	505.6
DMWNP6B	FM	C28H31N3O6
DMWNP6B	IC	QZVNQOLPLYWLHQ-ZEQKJWHPSA-N
DMWNP6B	CS	CC1=C(C(C(=C(N1)C)C(=O)OC2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMWNP6B	IK	1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1
DMWNP6B	IU	5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMWNP6B	CA	CAS 105979-17-7
DMWNP6B	DE	Diabetic nephropathy

DMHKZX1	ID	DMHKZX1
DMHKZX1	DN	Benzethonium
DMHKZX1	HS	Phase 4
DMHKZX1	SN	Benzethonii chloridum [INN-Latin]; Benzetonio cloruro [DCIT]; Formula 144; Inactisol; Phemerol; Phemersol chloride; Sanizol; Antiseptol (quarternary compound); Solamin; benzethonium; 10172-60-8; 1VU15B70BP; 498-77-1; BZT (VAN); CCRIS 4748; CHEMBL221753; Caswell No. 614B; Chlorure de benzethonium [INN-French]; Cloruro de benzetonio [INN-Spanish]; EINECS 204-479-9; HSDB 567; NCI-C61494; NSC 20200; NSC20200; UNII-1VU15B70BP; benzyl-dimethyl-[2-[2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethoxy]ethyl]ammonium
DMHKZX1	PC	2335
DMHKZX1	MW	412.6
DMHKZX1	FM	C27H42NO2+
DMHKZX1	IC	SIYLLGKDQZGJHK-UHFFFAOYSA-N
DMHKZX1	CS	CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2
DMHKZX1	IK	1S/C27H42NO2/c1-26(2,3)22-27(4,5)24-13-15-25(16-14-24)30-20-19-29-18-17-28(6,7)21-23-11-9-8-10-12-23/h8-16H,17-22H2,1-7H3/q+1
DMHKZX1	IU	benzyl-dimethyl-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]azanium
DMHKZX1	CA	CAS 10172-60-8
DMHKZX1	CB	CHEBI:94725
DMHKZX1	DE	Methicillin-resistant staphylococcus infection

DML634R	ID	DML634R
DML634R	DN	Beraprost
DML634R	HS	Phase 4
DML634R	SN	Beraprost [USAN:INN]; Beraprostum; Beraprostum [INN-Latin]; MDL-201229; ML-1229; beraprost; (+-)-(1R,2R,3aS,8bS)-2,3,3a,8b-Tetrahydro-2-hydroxy-1-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-5-butyric acid; 2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-5-butanoic acid; 88430-50-6; AC1OCEUA; CHEBI:135633; CHEMBL1207745; CTPOHARTNNSRSR-APJZLKAGSA-N; DTXSID7049136; SCHEMBL16904620; SCHEMBL34593
DML634R	PC	6917951
DML634R	MW	398.5
DML634R	FM	C24H30O5
DML634R	IC	CTPOHARTNNSRSR-APJZLKAGSA-N
DML634R	CS	CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
DML634R	IK	1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1
DML634R	IU	4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
DML634R	CA	CAS 88430-50-6
DML634R	CB	CHEBI:135633
DML634R	DE	Influenza virus infection

DMWL182	ID	DMWL182
DMWL182	DN	Beraprost
DMWL182	HS	Phase 4
DMWL182	SN	beraprost; 88430-50-6; 88430-50-6 (free acid); 1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-; Beraprost (USAN); GTPL1967; SCHEMBL1554142; SCHEMBL1554145; BDBM85181; CAS_2352; NSC_2352; 4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid; K578; D02720; L024061; Q5977854; (E)-4-(2-hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-ynyl)-2,3,3a,8b-tetrahydro-1H-benzo[d]cyclopenta[b]furan-5-yl)butanoic acid; 4-(2-Hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-5-yl)butanoic acid; 4-{4-hydroxy-3-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(12),8,10-trien-9-yl}butanoic acid
DMWL182	DT	Small molecular drug
DMWL182	PC	5282428
DMWL182	MW	398.5
DMWL182	FM	C24H30O5
DMWL182	IC	InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+
DMWL182	CS	CC#CCC(C)C(/C=C/C1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
DMWL182	IK	CTPOHARTNNSRSR-OUKQBFOZSA-N
DMWL182	IU	4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
DMWL182	CA	CAS 88430-50-6
DMWL182	DE	Pulmonary hypertension

DMC5Q8X	ID	DMC5Q8X
DMC5Q8X	DN	Berberine
DMC5Q8X	HS	Phase 4
DMC5Q8X	SN	berberine; 2086-83-1; Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE
DMC5Q8X	DT	Small molecular drug
DMC5Q8X	PC	2353
DMC5Q8X	MW	336.4
DMC5Q8X	FM	C20H18NO4+
DMC5Q8X	IC	InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1
DMC5Q8X	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC
DMC5Q8X	IK	YBHILYKTIRIUTE-UHFFFAOYSA-N
DMC5Q8X	IU	16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMC5Q8X	CA	CAS 2086-83-1
DMC5Q8X	CB	CHEBI:16118

DMGXD5T	ID	DMGXD5T
DMGXD5T	DN	Brotizolam
DMGXD5T	HS	Phase 4
DMGXD5T	SN	Brotizolamum; Brotizolamum [INN-Latin]; Lendorm; Lendormin; Mederantil; Sintonal; UMSGKTJDUHERQW-UHFFFAOYSA-N; WE 941; WE-941; brotizolam; 2-Bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 2-Bromo-4-(o-chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine; 2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 57801-81-7; 5XZM1R3DKF; BRN 0839277; C15H10BrClN4S; CHEMBL32479; EINECS 260-964-5; NCGC00183872-01; UNII-5XZM1R3DKF
DMGXD5T	PC	2451
DMGXD5T	MW	393.7
DMGXD5T	FM	C15H10BrClN4S
DMGXD5T	IC	UMSGKTJDUHERQW-UHFFFAOYSA-N
DMGXD5T	CS	CC1=NN=C2N1C3=C(C=C(S3)Br)C(=NC2)C4=CC=CC=C4Cl
DMGXD5T	IK	1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3
DMGXD5T	IU	4-bromo-7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
DMGXD5T	CA	CAS 57801-81-7
DMGXD5T	CB	CHEBI:31308
DMGXD5T	DE	Insomnia

DMXZU73	ID	DMXZU73
DMXZU73	DN	Carbapenem
DMXZU73	HS	Phase 4
DMXZU73	SN	Carbapenem; Cis-carbapenem; (5R)-1-azabicyclo[3.2.0]hept-2-en-7-one; 2,3-didehydro-1-carbapenam; 67836-EP2275424A1; 67836-EP2295402A2; 67836-EP2305219A1; 67836-EP2308874A1; CHEBI:46765; SCHEMBL37243
DMXZU73	PC	13293131
DMXZU73	MW	109.13
DMXZU73	FM	C6H7NO
DMXZU73	IC	YZBQHRLRFGPBSL-RXMQYKEDSA-N
DMXZU73	CS	C1C=CN2C1CC2=O
DMXZU73	IK	1S/C6H7NO/c8-6-4-5-2-1-3-7(5)6/h1,3,5H,2,4H2/t5-/m1/s1
DMXZU73	IU	(5R)-1-azabicyclo[3.2.0]hept-2-en-7-one
DMXZU73	CB	CHEBI:46765
DMXZU73	DE	Infectious cystitis

DMJKWPZ	ID	DMJKWPZ
DMJKWPZ	DN	Cefpirome
DMJKWPZ	HS	Phase 4
DMJKWPZ	SN	Cefpiroma; Cefpiroma [Spanish]; Cefpirome (INN); Cefpirome [INN:BAN]; Cefpiromum; Cefpiromum [Latin]; Cefrom; Cerfpirome; Keiten; Broact; CEFPIROME; S72Q2F09HY; cefpirome sulfate; cefpirome sulphate; (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 84957-29-9; C22H22N6O5S2; CHEBI:3503; HR 810; HR-810; NCGC00181339-01; UNII-S72Q2F09HY
DMJKWPZ	PC	5479539
DMJKWPZ	MW	514.6
DMJKWPZ	FM	C22H22N6O5S2
DMJKWPZ	IC	DKOQGJHPHLTOJR-WHRDSVKCSA-N
DMJKWPZ	CS	CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-]
DMJKWPZ	IK	1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1
DMJKWPZ	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMJKWPZ	CA	CAS 84957-29-9
DMJKWPZ	CB	CHEBI:3503
DMJKWPZ	DE	Pseudomonas infection

DMPZTRC	ID	DMPZTRC
DMPZTRC	DN	Ceftazidine
DMPZTRC	HS	Phase 4
DMPZTRC	SN	Ceftazidine [INN]; Ceftazidine [USAN]; Ceftazidine [IBAN]; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydroxide
DMPZTRC	PC	13505813
DMPZTRC	MW	564.6
DMPZTRC	FM	C22H24N6O8S2
DMPZTRC	IC	GCZOCVAKBHTGOL-ROMZVAKDSA-N
DMPZTRC	CS	CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)O.[OH-]
DMPZTRC	IK	1S/C22H22N6O7S2.H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);1H2/b26-13-;/t14-,18-;/m1./s1
DMPZTRC	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydroxide
DMPZTRC	DE	Meningitis

DMYGEH7	ID	DMYGEH7
DMYGEH7	DN	Ceftolozane sulfate
DMYGEH7	HS	Phase 4
DMYGEH7	SN	Ceftolozane; CXA-101; CXA-301; CXA-301); Cephalosporin derivatives, Astellas; Cephalosporinderivatives, Calixa Therapeutics; FR-193879; FR-264205; FR-295389; CXA-101 (inhaled), Calixa; CXA-101 (inhaled), Cubist; Cephalosporin derivative (H pylori/P aeruginosa infection), Astellas; CXA-101 (inhaled, bacterial lung infection), Cubist
DMYGEH7	CP	Fujisawa Pharmaceutical Co Ltd; Calixa Therapeutics Inc
DMYGEH7	DT	Small molecular drug
DMYGEH7	PC	11592969
DMYGEH7	MW	764.8
DMYGEH7	FM	C23H32N12O12S3
DMYGEH7	IC	InChI=1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11+;/t12-,18-;/m1./s1
DMYGEH7	CS	CC(C)(C(=O)O)O/N=C(\\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)O.OS(=O)(=O)[O-]
DMYGEH7	IK	UJDQGRLTPBVSFN-GZGOMJRCSA-N
DMYGEH7	IU	(6R,7R)-3-[[3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl]-7-[[(2E)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate
DMYGEH7	DE	Respiratory tract infection

DMYTGW0	ID	DMYTGW0
DMYTGW0	DN	Celiprolol
DMYTGW0	HS	Phase 4
DMYTGW0	SN	Celectol; Celiprolol [INN:BAN]; Celiprololum; Celiprololum [INN-Latin]; RHC 5320 A; RHC-5320A; ST-1396; Selectol; UL/1677; celiprolol; 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea; 56980-93-9; BRN 2776298; CCRIS 3400; EINECS 260-497-7; N'-(3-Acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethylurea; Urea, N'-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethyl-
DMYTGW0	PC	2663
DMYTGW0	MW	379.5
DMYTGW0	FM	C20H33N3O4
DMYTGW0	IC	JOATXPAWOHTVSZ-UHFFFAOYSA-N
DMYTGW0	CS	CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C
DMYTGW0	IK	1S/C20H33N3O4/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26)
DMYTGW0	IU	3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea
DMYTGW0	CA	CAS 56980-93-9
DMYTGW0	CB	CHEBI:94461
DMYTGW0	DE	Essential hypertension

DM6C4YJ	ID	DM6C4YJ
DM6C4YJ	DN	Chlorphenamine
DM6C4YJ	HS	Phase 4
DM6C4YJ	SN	Chloropheniramine; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamin; Chlorphenamine; Chlorphenaminum; Chlorpheniramine maleate; Chlorpheniramine polistirex; Chlorpheniraminum; Chlorprophenpyridamine; Clorfenamina; Clorfeniramina; Clorfeniramina [Italian]; Cloropiril; Aller-Chlor; Allergican; Allergisan; Antagonate; Chlor-trimeton; Haynon; Histadur; Kloromin; Phenetron; Polaramine; Polaronil; Telachlor; Teldrin; chlorpheniramine; 132-22-9; 4-Chloropheniramine
DM6C4YJ	PC	2725
DM6C4YJ	MW	274.79
DM6C4YJ	FM	C16H19ClN2
DM6C4YJ	IC	SOYKEARSMXGVTM-UHFFFAOYSA-N
DM6C4YJ	CS	CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DM6C4YJ	IK	1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m1/s1
DM6C4YJ	IU	3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DM6C4YJ	CA	CAS 132-22-9
DM6C4YJ	CB	CHEBI:52010
DM6C4YJ	DE	Allergy

DM0N19Y	ID	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	HS	Phase 4
DM0N19Y	SN	Chondritinsulfate; Chondritinsulphate; Chondroitin 4 and 6 sulfate; Chondroitin 4-sulfate; Chondroitin 6-sulfate; Chondroitin polysulfate; Chondroitin sulfate; Chondroitin sulfuric acid; Chondroitin sulfuric acids; Chondroitin sulphate; Chondroitin, CHONDROITIN SULFATES; hydrogen sulfate; Chondroitine sulfate; Chondroitinsulfate C; Chondroitinsulfuric acids; Chondron; Chonsurid; Condrosan; Condrosulf; Sodium chondroitin sulfate; Structum; Uropol S; chondroitin sulfate C; 9007-28-7; EINECS 232-696-9; Gepan; UNII-6IC1M3OG5Z
DM0N19Y	PC	24766
DM0N19Y	MW	463.37
DM0N19Y	FM	C13H21NO15S
DM0N19Y	IC	KXKPYJOVDUMHGS-OSRGNVMNSA-N
DM0N19Y	CS	CC(=O)NC1C(C(C(OC1O)OS(=O)(=O)O)O)OC2C(C(C(C(O2)C(=O)O)O)O)O
DM0N19Y	IK	1S/C13H21NO15S/c1-2(15)14-3-8(7(19)13(28-11(3)22)29-30(23,24)25)26-12-6(18)4(16)5(17)9(27-12)10(20)21/h3-9,11-13,16-19,22H,1H3,(H,14,15)(H,20,21)(H,23,24,25)/t3-,4+,5+,6-,7-,8-,9+,11-,12-,13-/m1/s1
DM0N19Y	IU	(2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DM0N19Y	CA	CAS 9007-28-7
DM0N19Y	DE	Osteoarthritis

DMBG0N4	ID	DMBG0N4
DMBG0N4	DN	Cibenzoline
DMBG0N4	HS	Phase 4
DMBG0N4	SN	Cibenzolina; Cibenzolina [INN-Spanish]; Cibenzoline; Cibenzoline (INN); Cibenzoline [INN]; Cibenzolinum; Cibenzolinum [INN-Latin]; Cifenline; Cifenline (USAN); Cifenline [USAN]; Ro 22-7796; Ro 227796; UP 33901; (+-)-2-(2,2-Diphenylcyclopropyl)-2-imidazoline; 1H-Imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-, (+-)-; 2-(2,2-Diphenyl-cyclopropyl)-4,5-dihydro-1H-imidazole; 2-(2,2-diphenylcyclopropyl)-2-imidazoline; 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole; 53267-01-9; C18H18N2; CHEMBL87045; EINECS 258-453-7
DMBG0N4	PC	2747
DMBG0N4	MW	262.3
DMBG0N4	FM	C18H18N2
DMBG0N4	IC	IPOBOOXFSRWSHL-UHFFFAOYSA-N
DMBG0N4	CS	C1CN=C(N1)C2CC2(C3=CC=CC=C3)C4=CC=CC=C4
DMBG0N4	IK	1S/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20)
DMBG0N4	IU	2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole
DMBG0N4	CA	CAS 53267-01-9
DMBG0N4	CB	CHEBI:135083
DMBG0N4	DE	Atrial fibrillation

DMSW5QP	ID	DMSW5QP
DMSW5QP	DN	Cotrimoxazole
DMSW5QP	HS	Phase 4
DMSW5QP	SN	Centran; Centrin; Cotrim.L.U.T; Eslectin; Insozalin; Biseptol-480; LS-2191; Metomide; Trimedin; Trimethoprim/Sulfamethoxazol; Trimezole; CHEMBL195591; Sulfamethoxazole-Trimethoprim Combination
DMSW5QP	PC	24719
DMSW5QP	MW	542.6
DMSW5QP	FM	C25H30N6O6S
DMSW5QP	IC	CTNTUFQBOKZSPI-UHFFFAOYSA-N
DMSW5QP	CS	CC1=CC(=NO1)CS(=O)(=O)C2=CC=C(C=C2)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N
DMSW5QP	IK	1S/C14H18N4O3.C11H12N2O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-8-6-10(13-16-8)7-17(14,15)11-4-2-9(12)3-5-11/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,7,12H2,1H3
DMSW5QP	IU	4-[(5-methyl-1,2-oxazol-3-yl)methylsulfonyl]aniline;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
DMSW5QP	DE	Human immunodeficiency virus infection

DMLMOIJ	ID	DMLMOIJ
DMLMOIJ	DN	Cyproterone acetate
DMLMOIJ	HS	Phase 4
DMLMOIJ	SN	Cyprosterone acetate; Cyproteron acetate; Cyproteron-R acetate; Cyproterone 17-O-acetate; Cyproterone 17.alpha.-acetate; Cyproterone 17alpha-acetate; Cyproterone acetate [USAN:JAN]; Androcur; CYPROTERONE ACETATE; Cyproteroneacetate; SH 714; SH 80714; SH-714; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-; 427-51-0; 4KM2BN5JHF; C24H29ClO4; CCRIS 4385; CHEBI:50743; CHEMBL139835; EINECS 207-048-3; HSDB 3592; MLS000859908; NSC 81430; NSC-81430; UNII-4KM2BN5JHF
DMLMOIJ	PC	9880
DMLMOIJ	MW	416.9
DMLMOIJ	FM	C24H29ClO4
DMLMOIJ	IC	UWFYSQMTEOIJJG-FDTZYFLXSA-N
DMLMOIJ	CS	CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)C5CC5C34C)Cl)C)OC(=O)C
DMLMOIJ	IK	1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1
DMLMOIJ	IU	[(1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxo-15-pentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dienyl] acetate
DMLMOIJ	CA	CAS 427-51-0
DMLMOIJ	CB	CHEBI:50743
DMLMOIJ	DE	Polycystic ovary syndrome

DMV6KFY	ID	DMV6KFY
DMV6KFY	DN	Dapoxetine
DMV6KFY	HS	Phase 4
DMV6KFY	SN	Priligy (TN)
DMV6KFY	CP	Furiex pharmaceuticals
DMV6KFY	DT	Small molecular drug
DMV6KFY	PC	71353
DMV6KFY	MW	305.4
DMV6KFY	FM	C21H23NO
DMV6KFY	IC	InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1
DMV6KFY	CS	CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3
DMV6KFY	IK	USRHYDPUVLEVMC-FQEVSTJZSA-N
DMV6KFY	IU	(1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine
DMV6KFY	CA	CAS 119356-77-3
DMV6KFY	CB	CHEBI:135962
DMV6KFY	DE	Premature ejaculation

DMV5KTJ	ID	DMV5KTJ
DMV5KTJ	DN	Demegestone
DMV5KTJ	HS	Phase 4
DMV5KTJ	SN	Demegestona; Demegestona [INN-Spanish]; Demegestone; Demegestone (INN); Demegestone [INN:DCF]; Demegestonum; Demegestonum [INN-Latin]; Lutionex; R 2453; R-2453; RU 2453; SCHEMBL146550; ZINC4215548; 10116-22-0; 17-Methyl-19-norpregna-4,9-diene-3,20-dione; 17alpha-Methyl-19-demethylpregna-4,9-diene-3,20-dione; 19-Norpregna-4,9-diene-3,20-dione, 17-methyl- (8CI)(9CI); 6E89AM91SZ; AC1L3PEV; CHEBI:135339; CHEMBL2104231; D07223; DTXSID20878581; EINECS 233-320-6; NSC 118189; UNII-6E89AM91SZ
DMV5KTJ	PC	93057
DMV5KTJ	MW	312.4
DMV5KTJ	FM	C21H28O2
DMV5KTJ	IC	JWAHBTQSSMYISL-MHTWAQMVSA-N
DMV5KTJ	CS	CC(=O)C1(CCC2C1(CCC3=C4CCC(=O)C=C4CCC23)C)C
DMV5KTJ	IK	1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1
DMV5KTJ	IU	(8S,13S,14S,17S)-17-acetyl-13,17-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMV5KTJ	CA	CAS 10116-22-0
DMV5KTJ	CB	CHEBI:135339
DMV5KTJ	DE	Corpus luteum cyst

DMN2Q5I	ID	DMN2Q5I
DMN2Q5I	DN	Diacerein
DMN2Q5I	HS	Phase 4
DMN2Q5I	SN	Diacerein; 13739-02-1; Diacetylrhein; Diacerhein; Fisiodar; Artrodar; 1,8-DIACETOXY-3-CARBOXYANTHRAQUINONE; DIACERIN; 4,5-Diacetylrhein; Diacereinum [Latin]; Diacereine [French]; Diacereina [Spanish]; UNII-4HU6J11EL5; Diacerein [INN]; SF-277; C19H12O8; EINECS 237-310-2; BRN 2184909; 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid; MLS000028577; 4HU6J11EL5; 1,8-Diacetoxyanthraquinone-3-carboxylic acid; Diacerein (INN); 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid; NCGC00018274-04; SMR000058958; AK468692
DMN2Q5I	DT	Small molecular drug
DMN2Q5I	PC	26248
DMN2Q5I	MW	368.3
DMN2Q5I	FM	C19H12O8
DMN2Q5I	IC	InChI=1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)
DMN2Q5I	CS	CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3OC(=O)C)C(=O)O
DMN2Q5I	IK	TYNLGDBUJLVSMA-UHFFFAOYSA-N
DMN2Q5I	IU	4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid
DMN2Q5I	CA	CAS 13739-02-1
DMN2Q5I	CB	CHEBI:94708

DMTX0PZ	ID	DMTX0PZ
DMTX0PZ	DN	Dibekacin
DMTX0PZ	HS	Phase 4
DMTX0PZ	SN	Debecacin; Dibekacin sulfate; Dibekacina; Dibekacina [INN-Spanish]; Dibekacine; Dibekacine [INN-French]; Dibekacinum; Dibekacinum [INN-Latin]; Dideoxykanamycin B; Kappati; Panamicin; dibekacin; 3',4'-Dideoxykanamycin B; 34493-98-6; 45ZFO9E525; BRN 1441606; CHEBI:37945; DKB; DKM; EINECS 252-064-6; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl-(1-6))-2-deoxy-L-streptamine; UNII-45ZFO9E525
DMTX0PZ	PC	470999
DMTX0PZ	MW	451.5
DMTX0PZ	FM	C18H37N5O8
DMTX0PZ	IC	JJCQSGDBDPYCEO-XVZSLQNASA-N
DMTX0PZ	CS	C1CC(C(OC1CN)OC2C(CC(C(C2O)OC3C(C(C(C(O3)CO)O)N)O)N)N)N
DMTX0PZ	IK	1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
DMTX0PZ	IU	(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
DMTX0PZ	CA	CAS 34493-98-6
DMTX0PZ	CB	CHEBI:37945
DMTX0PZ	DE	Acute lower respiratory infection

DMZ5Y1P	ID	DMZ5Y1P
DMZ5Y1P	DN	Dichloroacetate
DMZ5Y1P	HS	Phase 4
DMZ5Y1P	SN	2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050
DMZ5Y1P	DT	Small molecular drug
DMZ5Y1P	PC	25975
DMZ5Y1P	MW	127.93
DMZ5Y1P	FM	C2HCl2O2-
DMZ5Y1P	IC	InChI=1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1
DMZ5Y1P	CS	C(C(=O)[O-])(Cl)Cl
DMZ5Y1P	IK	JXTHNDFMNIQAHM-UHFFFAOYSA-M
DMZ5Y1P	IU	2,2-dichloroacetate
DMZ5Y1P	CA	CAS 13425-80-4
DMZ5Y1P	CB	CHEBI:28240
DMZ5Y1P	DE	Pulmonary fibrosis; Pyruvate dehydrogenase complex deficiency; Insulin-resistant disorder

DMB0FWL	ID	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	HS	Phase 4
DMB0FWL	SN	Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine
DMB0FWL	CP	Mundipharma AG
DMB0FWL	DT	Small molecular drug
DMB0FWL	PC	5284543
DMB0FWL	MW	301.4
DMB0FWL	FM	C18H23NO3
DMB0FWL	IC	InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
DMB0FWL	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O
DMB0FWL	IK	RBOXVHNMENFORY-DNJOTXNNSA-N
DMB0FWL	IU	(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
DMB0FWL	CA	CAS 125-28-0
DMB0FWL	CB	CHEBI:135276
DMB0FWL	DE	Cancer related pain

DM3S8XC	ID	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	HS	Phase 4
DM3S8XC	SN	Androstanolone; STANOLONE; dihydrotestosterone; 521-18-6; Andractim; Androlone; Proteina; Anaboleen; Stanaprol; Anabolex; Protona; Neodrol; Cristerona MB; 4-Dihydrotestosterone; 17beta-Hydroxy-5alpha-androstan-3-one; 5alpha-Dihydrotestosterone; Androstanolonum; Androstanolona; DHT; 5-alpha-Dihydrotestosterone; Dihydrotestosteron; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; 5alpha-Androstan-17beta-ol-3-one; Stanorone; Stanolon; 17beta-Hydroxyandrostan-3-one; 5alpha-DHT; LG 152; 17beta-Hydroxy-3-androstanone; [3H]dihydrotestosterone
DM3S8XC	DT	Small molecular drug
DM3S8XC	PC	10635
DM3S8XC	MW	290.4
DM3S8XC	FM	C19H30O2
DM3S8XC	IC	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
DM3S8XC	CS	C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C
DM3S8XC	IK	NVKAWKQGWWIWPM-ABEVXSGRSA-N
DM3S8XC	IU	(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
DM3S8XC	CA	CAS 521-18-6
DM3S8XC	CB	CHEBI:16330
DM3S8XC	DE	Prostate hyperplasia

DM3YH4I	ID	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	HS	Phase 4
DM3YH4I	SN	D-serine; 312-84-5; (R)-2-amino-3-hydroxypropanoic acid; (2R)-2-amino-3-hydroxypropanoic acid; Serine D-form; (R)-Serine; Serine, D-; d-(+)-serine; D-2-Amino-3-hydroxypropionic Acid; D-Serin; D-Ser; UNII-1K77H2Z9B1; EINECS 206-229-4; MFCD00004269; NSC 77689; (2R)-2-amino-3-hydroxy-propanoic acid; AI3-18476; CHEMBL285123; CHEBI:16523; MTCFGRXMJLQNBG-UWTATZPHSA-N; 1K77H2Z9B1; (R)-2-Amino-3-hydroxypropionic acid; DSN; NCGC00094363-03; D-Serine, 98%; D-2-Amino-3-hydroxypropanoic acid; NSC77689; serine d-; [3h]-d-serine; (2R)-serine
DM3YH4I	DT	Small molecular drug
DM3YH4I	PC	71077
DM3YH4I	MW	105.09
DM3YH4I	FM	C3H7NO3
DM3YH4I	IC	InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1
DM3YH4I	CS	C([C@H](C(=O)O)N)O
DM3YH4I	IK	MTCFGRXMJLQNBG-UWTATZPHSA-N
DM3YH4I	IU	(2R)-2-amino-3-hydroxypropanoic acid
DM3YH4I	CA	CAS 312-84-5
DM3YH4I	CB	CHEBI:16523

DMH21D9	ID	DMH21D9
DMH21D9	DN	Ebastine
DMH21D9	HS	Phase 4
DMH21D9	SN	ebastine; Kestine; Ebastel; Ebastin; Evastel; Kestin; Bactil; Ebastinum [Latin]; LAS W-090; Ebastina [Spanish]; Estivan; UNII-TQD7Q784P1; RP 64305; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; TQD7Q784P1; CHEMBL305660; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; C32H39NO2; MFCD00865661; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; NCGC00164603-01; RP-64305; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone
DMH21D9	PC	3191
DMH21D9	MW	469.7
DMH21D9	FM	C32H39NO2
DMH21D9	IC	InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3
DMH21D9	CS	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMH21D9	IK	MJJALKDDGIKVBE-UHFFFAOYSA-N
DMH21D9	IU	4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
DMH21D9	CA	CAS 90729-43-4
DMH21D9	CB	CHEBI:31528
DMH21D9	DE	Irritable bowel syndrome

DMQRX24	ID	DMQRX24
DMQRX24	DN	Ebastine
DMQRX24	HS	Phase 4
DMQRX24	SN	Ebastel; Ebastin; Ebastina [Spanish]; Ebastinum [Latin]; Estivan; Evastel; Kestin; Kestine; LAS W-090; RP 64305; Bactil; RP-64305; TQD7Q784P1; ebastine; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; 90729-43-4; C32H39NO2; CHEMBL305660; MFCD00865661; NCGC00164603-01; UNII-TQD7Q784P1
DMQRX24	PC	3191
DMQRX24	MW	469.7
DMQRX24	FM	C32H39NO2
DMQRX24	IC	MJJALKDDGIKVBE-UHFFFAOYSA-N
DMQRX24	CS	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMQRX24	IK	1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3
DMQRX24	IU	4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
DMQRX24	CA	CAS 90729-43-4
DMQRX24	CB	CHEBI:31528
DMQRX24	DE	Irritable bowel syndrome

DM9WPIH	ID	DM9WPIH
DM9WPIH	DN	Ergonovine maleate
DM9WPIH	HS	Phase 4
DM9WPIH	SN	Ergomet; Ergometrin maleate; Ergometrine acid maleate; Ergometrine hydrogen maleate; Ergometrine maleate (1:1); Ergonovine hydrogen maleate; Ergonovine maleate; Ergonovine maleate (USP); Ergonovine maleate [USP]; Ergonovine maleate salt; Ergonovine, maleate (1:1); Ergonovine, maleate (1:1) (salt); Ergotocin maleate; Ermetrin; Metriclavin; Oxytocic; Cornocentin; Crude ergot; D-Ergonovine maleate; YMH3D0ZJWV; ergometrine maleate; 129-51-1; CHEBI:31554; EINECS 204-953-5; NSC 93752; UNII-YMH3D0ZJWV
DM9WPIH	PC	6437065
DM9WPIH	MW	441.5
DM9WPIH	FM	C23H27N3O6
DM9WPIH	IC	YREISLCRUMOYAY-IIPCNOPRSA-N
DM9WPIH	CS	CC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=CC(=O)O)C(=O)O
DM9WPIH	IK	1S/C19H23N3O2.C4H4O4/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13;5-3(6)1-2-4(7)8/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24);1-2H,(H,5,6)(H,7,8)/b;2-1-/t11-,13+,17+;/m0./s1
DM9WPIH	IU	(6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(Z)-but-2-enedioic acid
DM9WPIH	CA	CAS 129-51-1
DM9WPIH	CB	CHEBI:31554
DM9WPIH	DE	Abnormal vaginal bleeding

DMKEGI3	ID	DMKEGI3
DMKEGI3	DN	Esmirtazapine
DMKEGI3	HS	Phase 4
DMKEGI3	SN	Esmirtazapine; Esmirtazapine [INN]; Org 44-20; Org-44-20; ZINC968310; (+)-Mirtazapine; (S)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; 4685R51V7M; 61337-87-9; AC1MJ43F; BIDD:PXR0200; CHEMBL1366933; DB06678; EINECS 262-714-0; PDSP1_001530; PDSP2_001514; SCHEMBL49330; UNII-4685R51V7M
DMKEGI3	PC	3085218
DMKEGI3	MW	265.35
DMKEGI3	FM	C17H19N3
DMKEGI3	IC	RONZAEMNMFQXRA-MRXNPFEDSA-N
DMKEGI3	CS	CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
DMKEGI3	IK	1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3/t16-/m1/s1
DMKEGI3	IU	(7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
DMKEGI3	CA	CAS 61337-87-9
DMKEGI3	DE	Depression

DM7ITZK	ID	DM7ITZK
DM7ITZK	DN	Ethinylestradiol propanesulfonate
DM7ITZK	HS	Phase 4
DM7ITZK	SN	Ethinylestradiol propanesulfonate; Ethinyl estradiol isopropylsulfonate; SCHEMBL457480; Turisteron; Turisteron (TN); XF48685MYR; ethinylestradiol sulfonate; (17; 17-Hydroxy-19-norpregna-1(10),2,4-trien-20-yn-3-yl propane-2-sulfonate; 17alpha-Ethinyl-3-isopropylsulfonyloxyestradiol; 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-propanesulfonate), (17alpha)-; 28913-23-7; A)-17-ethynyl-17-hydroxyestra-1,3,5(10)-trien-3-yl propane-2-sulfonate; AC1L2A1G; AC1Q6XYI; CHEBI:135643; D07928; DTXSID20951545; J-96; UNII-XF48685MYR
DM7ITZK	PC	68582
DM7ITZK	MW	402.5
DM7ITZK	FM	C23H30O4S
DM7ITZK	IC	KPEUDULLQDHKAZ-VROINQGHSA-N
DM7ITZK	CS	CC(C)S(=O)(=O)OC1=CC2=C(C=C1)C3CCC4(C(C3CC2)CCC4(C#C)O)C
DM7ITZK	IK	1S/C23H30O4S/c1-5-23(24)13-11-21-20-8-6-16-14-17(27-28(25,26)15(2)3)7-9-18(16)19(20)10-12-22(21,23)4/h1,7,9,14-15,19-21,24H,6,8,10-13H2,2-4H3/t19-,20-,21+,22+,23+/m1/s1
DM7ITZK	IU	[(8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] propane-2-sulfonate
DM7ITZK	CA	CAS 28913-23-7
DM7ITZK	CB	CHEBI:135643
DM7ITZK	DE	Prostate cancer

DM8TNX3	ID	DM8TNX3
DM8TNX3	DN	Etizolam
DM8TNX3	HS	Phase 4
DM8TNX3	SN	Etizolam [INN:JAN]; Etizolamum [INN-Latin]; VMZUTJCNQWMAGF-UHFFFAOYSA-N; Y 7131; Y-7131; etizolam; 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 40054-69-1; 6-(o-Chlorophenyl)-8-ethyl-1-methyl-4H-s-triazolo(3,4-c)thieno(2,3-e)(1,4)-diazepine; 8-Ethyl-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine; A76XI0HL37; AHR 3219; BRN 0572740; C17H15ClN4S; Depas; NCGC00182031-01; UNII-A76XI0HL37
DM8TNX3	PC	3307
DM8TNX3	MW	342.8
DM8TNX3	FM	C17H15ClN4S
DM8TNX3	IC	VMZUTJCNQWMAGF-UHFFFAOYSA-N
DM8TNX3	CS	CCC1=CC2=C(S1)N3C(=NN=C3CN=C2C4=CC=CC=C4Cl)C
DM8TNX3	IK	1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3
DM8TNX3	IU	7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
DM8TNX3	CA	CAS 40054-69-1
DM8TNX3	CB	CHEBI:31583
DM8TNX3	DE	Insomnia

DMR7U8F	ID	DMR7U8F
DMR7U8F	DN	Etoperidone
DMR7U8F	HS	Phase 4
DMR7U8F	SN	Etoperidona; Etoperidona [INN-Spanish]; Etoperidona [Spanish]; Etoperidone [INN]; Etoperidonum; Etoperidonum [INN-Latin]; ETOPERIDONE; IZBNNCFOBMGTQX-UHFFFAOYSA-N; KAI6MVO39Z; L001188; ZINC3830815; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one; 52942-31-1; AC1L242J; AC1Q3SR1; ACM52942311; BDBM82438; CAS_52942-31-1; CHEBI:135589; CHEMBL1743259; DB09194; DTXSID0023034; NSC_40589; PDSP1_000523; PDSP2_000521; SCHEMBL49314; UNII-KAI6MVO39Z
DMR7U8F	PC	40589
DMR7U8F	MW	377.9
DMR7U8F	FM	C19H28ClN5O
DMR7U8F	IC	IZBNNCFOBMGTQX-UHFFFAOYSA-N
DMR7U8F	CS	CCC1=NN(C(=O)N1CC)CCCN2CCN(CC2)C3=CC(=CC=C3)Cl
DMR7U8F	IK	1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3
DMR7U8F	IU	2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one
DMR7U8F	CA	CAS 52942-31-1
DMR7U8F	CB	CHEBI:135589
DMR7U8F	DE	Depression

DM9R1YU	ID	DM9R1YU
DM9R1YU	DN	Gestodene
DM9R1YU	HS	Phase 4
DM9R1YU	SN	Gestinol; Gestoden; Gestodene [USAN:INN:BAN]; Gestodeno; Gestodeno [INN-Spanish]; Gestodenum; Gestodenum [INN-Latin]; SH B 331; GESTODENE; 13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregna-4,15-dien-20-yn-3-one; 1664P6E6MI; 17-alpha-Ethinyl-13-ethyl-17-beta-hydroxy-4,15-gonadien-3-one; 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-; 60282-87-3; BRN 4237181; CCRIS 9189; DSSTox_CID_26478; DSSTox_GSID_46478; DSSTox_RID_81649; EINECS 262-145-8; HSDB 3594; UNII-1664P6E6MI
DM9R1YU	PC	3033968
DM9R1YU	MW	310.4
DM9R1YU	FM	C21H26O2
DM9R1YU	IC	SIGSPDASOTUPFS-XUDSTZEESA-N
DM9R1YU	CS	CCC12CCC3C(C1C=CC2(C#C)O)CCC4=CC(=O)CCC34
DM9R1YU	IK	1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
DM9R1YU	IU	(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one
DM9R1YU	CA	CAS 60282-87-3
DM9R1YU	CB	CHEBI:135323
DM9R1YU	DE	Contraception

DMDN4A1	ID	DMDN4A1
DMDN4A1	DN	Glitazone
DMDN4A1	HS	Phase 4
DMDN4A1	SN	74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; Glitazone; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087
DMDN4A1	DT	Small molecular drug
DMDN4A1	PC	10198397
DMDN4A1	MW	223.25
DMDN4A1	FM	C10H9NO3S
DMDN4A1	IC	InChI=1S/C10H9NO3S/c12-7-3-1-6(2-4-7)5-8-9(13)11-10(14)15-8/h1-4,8,12H,5H2,(H,11,13,14)
DMDN4A1	CS	C1=CC(=CC=C1CC2C(=O)NC(=O)S2)O
DMDN4A1	IK	NKOHRVBBQISBSB-UHFFFAOYSA-N
DMDN4A1	IU	5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione
DMDN4A1	CA	CAS 74772-78-4

DMF72W3	ID	DMF72W3
DMF72W3	DN	Glyceryl trinitrate
DMF72W3	HS	Phase 4
DMF72W3	SN	Gilustenon; Glycerol trinitrate; Glyceryl trinitrate; Lenitral; Minitran; Natispray; Nitro-Bid; Nitro-dur; Nitrocine; Nitroderm; Cordipatch; Corditrine; Epinitril; Nitroderm TTS; Nitroglicerina; Nitroglycerine; Nitroglycerol; Nitroglyn; Nitrolan; Nitrolingual; Nitronet; Nitrong; Nitroplast; Nitrorectal; Nitroretard; Nitrospan; Nitrostat; Perglottal; Perlinganit; Rectogesic; Susadrin; Sustonit; Transderm Nitro; Transderm-nitro; Tridil; Trinitrin; Trinitroglycerin; Trinitroglycerol; Trinitrolong; Trinitrosan; nitroglycerin; 55-63-0; Niong
DMF72W3	PC	4510
DMF72W3	MW	227.09
DMF72W3	FM	C3H5N3O9
DMF72W3	IC	SNIOPGDIGTZGOP-UHFFFAOYSA-N
DMF72W3	CS	C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
DMF72W3	IK	1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
DMF72W3	IU	1,3-dinitrooxypropan-2-yl nitrate
DMF72W3	CA	CAS 55-63-0
DMF72W3	CB	CHEBI:28787
DMF72W3	DE	Acute coronary syndrome

DM0OX31	ID	DM0OX31
DM0OX31	DN	Glypromate
DM0OX31	HS	Phase 4
DM0OX31	SN	Glypromate; Glycyl-prolyl-glutamic acid; Gly-Pro-Glu, &gt;=98% (HPLC); Gly-pro-glu; SCHEMBL1170125; ZINC3776571; ZYK4RVV5LS; glycyl-l-prolyl-l-glutamic acid; 32302-76-4; CHEMBL371315; DB05633; DTXSID80186038; UNII-ZYK4RVV5LS
DM0OX31	PC	3080768
DM0OX31	MW	301.3
DM0OX31	FM	C12H19N3O6
DM0OX31	IC	JJGBXTYGTKWGAT-YUMQZZPRSA-N
DM0OX31	CS	C1CC(N(C1)C(=O)CN)C(=O)NC(CCC(=O)O)C(=O)O
DM0OX31	IK	1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)/t7-,8-/m0/s1
DM0OX31	IU	(2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]pentanedioic acid
DM0OX31	CA	CAS 32302-76-4
DM0OX31	DE	Epilepsy

DM9BPLW	ID	DM9BPLW
DM9BPLW	DN	Grazoprevir
DM9BPLW	HS	Phase 4
DM9BPLW	SN	Grazoprevir; Grazoprevir [INN]; Grazoprevir anhydrous; MK 5172; MK-5172; MK5172; OBMNJSNZOWALQB-NCQNOWPTSA-N; SCHEMBL2175313; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; 1350514-68-9; 8YE81R1X1J; CHEBI:132975; CHEMBL2063090; DTXSID50159234; EX-A2253; UNII-8YE81R1X1J
DM9BPLW	PC	44603531
DM9BPLW	MW	766.9
DM9BPLW	FM	C38H50N6O9S
DM9BPLW	IC	OBMNJSNZOWALQB-NCQNOWPTSA-N
DM9BPLW	CS	CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1
DM9BPLW	IK	1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1
DM9BPLW	IU	(1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DM9BPLW	CA	CAS 1350514-68-9
DM9BPLW	CB	CHEBI:132975
DM9BPLW	DE	Viral hepatitis

DMPN5IH	ID	DMPN5IH
DMPN5IH	DN	Guanfacine
DMPN5IH	HS	Phase 4
DMPN5IH	SN	GUANFACINE; Tenex; Guanfacinum [INN-Latin]; Guanfacina [INN-Spanish]; Estulic; Intuniv; N-amidino-2-(2,6-dichlorophenyl)acetamide; CHEBI:5558; INJOMKTZOLKMBF-UHFFFAOYSA-N; SPD 503; C9H9Cl2N3O; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; Guanfacine Monohydrochloride; NCGC00015469-05; Lon798; Guanfacine (INN); Estulic (TN); Tenex (Salt/Mix); Estulic (Salt/Mix); Tocris-1030; Prestwick1_000339; Prestwick3_000339; Prestwick2_000339; Prestwick0_000339; Lopac-G-1043
DMPN5IH	PC	3519
DMPN5IH	MW	246.09
DMPN5IH	FM	C9H9Cl2N3O
DMPN5IH	IC	InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)
DMPN5IH	CS	C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl
DMPN5IH	IK	INJOMKTZOLKMBF-UHFFFAOYSA-N
DMPN5IH	IU	N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
DMPN5IH	CA	CAS 29110-47-2
DMPN5IH	CB	CHEBI:5558
DMPN5IH	DE	Primary liver cancer

DMLYXBF	ID	DMLYXBF
DMLYXBF	DN	Guanoxan
DMLYXBF	HS	Phase 4
DMLYXBF	SN	Guanoxan; Guanoxan [INN:BAN]; Guanoxane; Guanoxano; Guanoxano [INN-Spanish]; Guanoxanum; Guanoxanum [INN-Latin]; Guanoxon; ((2,3-Dihydro-1,4-benzodioxin-2-yl)methyl)guanidine; (1,4-Benzodioxan-2-ylmethyl)guanidine; 2165-19-7; Envacar (Salt/Mix); BRN 1251616; DSSTox_CID_26166; DSSTox_RID_81397; GUANIDINE, (1,4-BENZODIOXAN-2-YLMETHYL)-; Guanidine, ((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-; N-((2,3-Dihydro-1,4-benzodioxin-2-yl)methyl)guanidine; N-[(2,3-Dihydro-1,4-benzodioxin-2-yl)methyl]guanidine; NCGC00160462-01
DMLYXBF	PC	16564
DMLYXBF	MW	207.23
DMLYXBF	FM	C10H13N3O2
DMLYXBF	IC	HIUVKVDQFXDZHU-UHFFFAOYSA-N
DMLYXBF	CS	C1C(OC2=CC=CC=C2O1)CN=C(N)N
DMLYXBF	IK	1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13)
DMLYXBF	IU	2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)guanidine
DMLYXBF	CA	CAS 2165-19-7
DMLYXBF	CB	CHEBI:134871
DMLYXBF	DE	Essential hypertension

DM4OQRD	ID	DM4OQRD
DM4OQRD	DN	HIF-1alpha
DM4OQRD	HS	Phase 4
DM4OQRD	SN	Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; UNII-NA856793UT; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060
DM4OQRD	CP	Enzon
DM4OQRD	TC	Anticancer Agents
DM4OQRD	DT	Small molecular drug
DM4OQRD	PC	5328127
DM4OQRD	MW	396.4
DM4OQRD	FM	C20H24N6O3
DM4OQRD	IC	InChI=1S/C20H24N6O3/c1-20(2,3)26-19(27)25-17-15(8-12-10-22-18(21)24-16(12)23-17)11-6-13(28-4)9-14(7-11)29-5/h6-10H,1-5H3,(H4,21,22,23,24,25,26,27)
DM4OQRD	CS	CC(C)(C)NC(=O)NC1=C(C=C2C=NC(=NC2=N1)N)C3=CC(=CC(=C3)OC)OC
DM4OQRD	IK	NHJSWORVNIOXIT-UHFFFAOYSA-N
DM4OQRD	IU	1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea
DM4OQRD	CA	CAS 192705-79-6
DM4OQRD	CB	CHEBI:156259
DM4OQRD	DE	Lymphoma

DMYOC29	ID	DMYOC29
DMYOC29	DN	Hirudin
DMYOC29	HS	Phase 4
DMYOC29	SN	Hirudin (53-64); 135546-61-1; Hirudin 53-64; DTXSID20159463; L-Alanine, L-asparaginylglycyl-L-alpha-aspartyl-L-pheylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-
DMYOC29	DT	Small molecular drug
DMYOC29	PC	72941487
DMYOC29	MW	7044
DMYOC29	FM	C287H440N80O113S7
DMYOC29	IC	InChI=1S/C287H440N80O113S7/c1-25-133(19)226-281(469)345-161(87-125(3)4)235(423)306-111-208(394)320-180(116-370)266(454)344-175(101-219(414)415)237(425)307-105-202(388)316-151(62-75-212(400)401)242(430)321-145(41-30-33-81-288)240(428)339-170(96-197(297)383)258(446)326-152(57-70-193(293)379)249(437)351-185(121-484-481-118-182-239(427)310-107-201(387)313-147(55-68-191(291)377)232(420)303-108-205(391)317-169(95-196(296)382)257(445)322-146(42-31-34-82-289)241(429)350-186(271(459)360-226)122-485-482-119-183(268(456)323-149(61-74-211(398)399)234(422)304-110-207(393)319-179(115-369)265(453)342-173(99-200(300)386)264(452)357-223(130(13)14)279(467)355-182)352-253(441)164(90-128(9)10)335-269(457)184-120-483-486-123-187(354-262(450)177(103-221(418)419)347-283(471)230(137(23)374)362-263(451)167(92-140-47-51-143(376)52-48-140)346-278(466)224(131(15)16)359-276(464)222(301)129(11)12)272(460)363-229(136(22)373)282(470)330-157(66-79-216(408)409)248(436)348-178(114-368)238(426)309-106-203(389)315-150(56-69-192(292)378)243(431)340-171(97-198(298)384)259(447)334-163(89-127(7)8)252(440)353-184)270(458)358-225(132(17)18)280(468)364-228(135(21)372)277(465)311-112-204(390)314-148(60-73-210(396)397)233(421)305-113-209(395)356-231(138(24)375)286(474)367-86-38-46-190(367)275(463)331-159(43-32-35-83-290)284(472)365-84-36-44-188(365)273(461)328-153(58-71-194(294)380)247(435)349-181(117-371)267(455)338-168(94-142-104-302-124-312-142)256(444)341-172(98-199(299)385)260(448)343-174(100-218(412)413)236(424)308-109-206(392)318-176(102-220(416)417)261(449)337-165(91-139-39-28-27-29-40-139)254(442)327-154(63-76-213(402)403)244(432)325-158(67-80-217(410)411)250(438)361-227(134(20)26-2)285(473)366-85-37-45-189(366)274(462)329-156(65-78-215(406)407)245(433)324-155(64-77-214(404)405)246(434)336-166(93-141-49-53-144(54-50-141)480-487(477,478)479)255(443)333-162(88-126(5)6)251(439)332-160(287(475)476)59-72-195(295)381/h27-29,39-40,47-54,104,124-138,145-190,222-231,368-376H,25-26,30-38,41-46,55-103,105-123,288-290,301H2,1-24H3,(H2,291,377)(H2,292,378)(H2,293,379)(H2,294,380)(H2,295,381)(H2,296,382)(H2,297,383)(H2,298,384)(H2,299,385)(H2,300,386)(H,302,312)(H,303,420)(H,304,422)(H,305,421)(H,306,423)(H,307,425)(H,308,424)(H,309,426)(H,310,427)(H,311,465)(H,313,387)(H,314,390)(H,315,389)(H,316,388)(H,317,391)(H,318,392)(H,319,393)(H,320,394)(H,321,430)(H,322,445)(H,323,456)(H,324,433)(H,325,432)(H,326,446)(H,327,442)(H,328,461)(H,329,462)(H,330,470)(H,331,463)(H,332,439)(H,333,443)(H,334,447)(H,335,457)(H,336,434)(H,337,449)(H,338,455)(H,339,428)(H,340,431)(H,341,444)(H,342,453)(H,343,448)(H,344,454)(H,345,469)(H,346,466)(H,347,471)(H,348,436)(H,349,435)(H,350,429)(H,351,437)(H,352,441)(H,353,440)(H,354,450)(H,355,467)(H,356,395)(H,357,452)(H,358,458)(H,359,464)(H,360,459)(H,361,438)(H,362,451)(H,363,460)(H,364,468)(H,396,397)(H,398,399)(H,400,401)(H,402,403)(H,404,405)(H,406,407)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,475,476)(H,477,478,479)/t133-,134-,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,222-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1
DMYOC29	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)OS(=O)(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C
DMYOC29	IK	WQPDUTSPKFMPDP-OUMQNGNKSA-N
DMYOC29	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-15,76-bis(4-aminobutyl)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9,67-bis(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-18,47-bis(2-carboxyethyl)-24-(carboxymethyl)-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMYOC29	CA	CAS 8001-27-2

DM0WD1V	ID	DM0WD1V
DM0WD1V	DN	Human calcitonin
DM0WD1V	HS	Phase 4
DM0WD1V	SN	Calcitonin (human synthetic); Calcitonin (human); Calcitonin human; Calcitonin, human; Calcitonin, human synthetic
DM0WD1V	PC	16220016
DM0WD1V	IU	(4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM0WD1V	DE	Hyperparathyroidism

DMABXOZ	ID	DMABXOZ
DMABXOZ	DN	Hyaluronic acid
DMABXOZ	HS	Phase 4
DMABXOZ	SN	Hyaluronic Acid [BAN]; Hylan G-F 20; Hyvisc; Luronit; Mucoitin; Amo Vitrax; Amvisc; Biolon; Etamucine; Sepracoat; Sofast; Synvisc; C33H54N2O23; EINECS 232-678-0; HSDB 7240; Hyaluronate Sodium (hyaluronic acid)
DMABXOZ	PC	24847767
DMABXOZ	MW	846.8
DMABXOZ	FM	C33H54N2O23
DMABXOZ	IC	BVOZFCOTOYGLGD-VPQOAABJSA-N
DMABXOZ	CS	CC(=O)NC1C(C(C(OC1COCC2C(OC(C(C2O)(C)O)OCC3C(C(OC(C3O)CO)O)NC(=O)C)C(=O)O)CO)O)COC4C(C(C(C(O4)C(=O)O)O)O)O
DMABXOZ	IK	1S/C33H54N2O23/c1-10(38)34-18-12(7-53-31-24(44)22(42)23(43)26(57-31)29(48)49)20(40)15(4-36)55-17(18)9-52-6-14-25(28(46)47)58-32(33(3,51)27(14)45)54-8-13-19(35-11(2)39)30(50)56-16(5-37)21(13)41/h12-27,30-32,36-37,40-45,50-51H,4-9H2,1-3H3,(H,34,38)(H,35,39)(H,46,47)(H,48,49)/t12-,13-,14+,15?,16?,17-,18?,19?,20-,21-,22+,23-,24?,25?,26?,27+,30+,31+,32+,33?/m0/s1
DMABXOZ	IU	(3S,4R,6R)-3-[[(2R,4R,5S)-3-acetamido-4-[[(2R,4R,5S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxymethyl]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]methoxymethyl]-6-[[(2R,4R,5S)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]methoxy]-4,5-dihydroxy-5-methyloxane-2-carboxylic acid
DMABXOZ	DE	Osteoarthritis

DM8NWFD	ID	DM8NWFD
DM8NWFD	DN	Hypericum
DM8NWFD	HS	Phase 4
DM8NWFD	SN	6-formamidopenicillanic acid; UNII-2TC14ZH3A5; CHEBI:59004; CTK2F8101; 6-formamido-2,2-dimethylpenam-3alpha-carboxylic acid; 2TC14ZH3A5; 64527-04-4; (2S,5R,6R)-6-formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-Formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; PAB 141; 141a/2A; HIS-1201; Epitope ID:119700; SCHEMBL11176911; DTXSID90429524; 6beta-formylaminopenicillanic acid; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid, 6-(formylamino)-3,3-d
DM8NWFD	DT	Small molecular drug
DM8NWFD	PC	9548591
DM8NWFD	MW	244.27
DM8NWFD	FM	C9H12N2O4S
DM8NWFD	IC	InChI=1S/C9H12N2O4S/c1-9(2)5(8(14)15)11-6(13)4(10-3-12)7(11)16-9/h3-5,7H,1-2H3,(H,10,12)(H,14,15)/t4-,5+,7-/m1/s1
DM8NWFD	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC=O)C(=O)O)C
DM8NWFD	IK	MDQGTDMBVJCTBN-JCGDXUMPSA-N
DM8NWFD	IU	(2S,5R,6R)-6-formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM8NWFD	CA	CAS 64527-04-4
DM8NWFD	CB	CHEBI:59004

DMVXLOD	ID	DMVXLOD
DMVXLOD	DN	Imrecoxib
DMVXLOD	HS	Phase 4
DMVXLOD	SN	Imrecoxib; UNII-SGW6W5758V; SGW6W5758V; CHEMBL504535; 395683-14-4; Imricoxib; BAP-909; SCHEMBL3034253; BDBM50293282; AKOS032954049; DB12354; LS-194053; 2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-1-propyl-; BAP-909; ; 
DMVXLOD	DT	Small molecular drug
DMVXLOD	PC	11682175
DMVXLOD	MW	369.5
DMVXLOD	FM	C21H23NO3S
DMVXLOD	IC	InChI=1S/C21H23NO3S/c1-4-13-22-14-19(16-9-11-18(12-10-16)26(3,24)25)20(21(22)23)17-7-5-15(2)6-8-17/h5-12H,4,13-14H2,1-3H3
DMVXLOD	CS	CCCN1CC(=C(C1=O)C2=CC=C(C=C2)C)C3=CC=C(C=C3)S(=O)(=O)C
DMVXLOD	IK	AXMZZGKKZDJGAZ-UHFFFAOYSA-N
DMVXLOD	IU	4-(4-methylphenyl)-3-(4-methylsulfonylphenyl)-1-propyl-2H-pyrrol-5-one
DMVXLOD	CA	CAS 395683-14-4

DM2R496	ID	DM2R496
DM2R496	DN	Indenolol
DM2R496	HS	Phase 4
DM2R496	SN	Indenolol; Indenolol [INN]; Indenolol [BAN:INN]; Indenolol [INN:BAN]; Indenololum; Indenololum [INN-Latin]; Sch 28316 Z; Sch 28316Z; Securpres; 1-(4-Indenyloxy)-3-isopropylamino-2-propanol; 1-(Inden-4(or 7)-yloxy)-3-(isopropylamino)-2-propanol; 106656-86-4; 2-Propanol, 1-(1H-inden-4-yloxy)-3-((1-methylethyl)amino)-; 2-Propanol, 1-(1H-inden-4-yloxy)-3-[(1-methylethyl)amino]-; 4-(2-Hydroxy-3-isopropylaminopropoxy)indene; 60607-68-3; AC1L2H51; AC1Q77JA; ACMC-20macf; C15H27NO2; CHEMBL153585; EINECS 262-323-5; SCHEMBL79021; YB-2
DM2R496	PC	71955
DM2R496	MW	247.33
DM2R496	FM	C15H21NO2
DM2R496	IC	MPGBPFMOOXKQRX-UHFFFAOYSA-N
DM2R496	CS	CC(C)NCC(COC1=CC=CC2=C1C=CC2)O
DM2R496	IK	1S/C15H21NO2/c1-11(2)16-9-13(17)10-18-15-8-4-6-12-5-3-7-14(12)15/h3-4,6-8,11,13,16-17H,5,9-10H2,1-2H3
DM2R496	IU	1-(1H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
DM2R496	CA	CAS 60607-68-3
DM2R496	DE	Cardiac arrhythmia

DMVPLNC	ID	DMVPLNC
DMVPLNC	DN	Ingrezza
DMVPLNC	HS	Phase 4
DMVPLNC	SN	Valbenazine; 1025504-45-3; UNII-54K37P50KH; Valbenazine free base; NBI 98854; 54K37P50KH; 1025504-45-3 (free base); (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester; Valbenazine [USAN:INN]; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester; ValbenazineNBI-98854; Valbenazine (USAN/INN); GTPL8694; CHEMBL2364639; SCHEMBL15932979; EX-A2002; MFCD28963976; ZINC43195697; CS-5908; DB11915; SB17456; NCGC00522306-02; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate; AC-30929; AS-35294; HY-16771; D10675; NBI-98854;NBI98854;NBI 98854; Q27089118; (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate; (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate; Valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester
DMVPLNC	CP	Neurocrine Biosciences
DMVPLNC	DT	Small molecular drug
DMVPLNC	PC	24795069
DMVPLNC	MW	418.6
DMVPLNC	FM	C24H38N2O4
DMVPLNC	IC	InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1
DMVPLNC	CS	CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC
DMVPLNC	IK	GEJDGVNQKABXKG-CFKGEZKQSA-N
DMVPLNC	IU	[(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate
DMVPLNC	CA	CAS 1025504-45-3
DMVPLNC	DE	Tourette syndrome; Tardive dyskinesia

DM7U58J	ID	DM7U58J
DM7U58J	DN	Isoflavone
DM7U58J	HS	Phase 4
DM7U58J	SN	Isoflavone; Isoflavone (8CI); Isoflavone skeleton; LS-191186; MCULE-2586547916; OVO2KUW8H8; SBB068618; SCHEMBL8028; ST098957; VN10014; ZINC895390; isoflavon; 3-Phenylchromone; 3-phenyl-4H-1-benzopyran-4-one; 3-phenyl-4H-chromen-4-one; 3-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 3-phenyl-; 574-12-9; AC-12802; AK114020; AKOS015918505; AX8135136; BCP22856; BCP9000133; CCG-214095; CHEBI:18220; CHEMBL366460; CS-W006405; DB12007; DS-6374; DTXSID90205986; KS-00000GFW; NSC 135405; NSC-135405; NSC135405; GOMNOOKGLZYEJT-UHFFFAOYSA-N; UNII-OVO2KUW8H8
DM7U58J	PC	72304
DM7U58J	MW	222.24
DM7U58J	FM	C15H10O2
DM7U58J	IC	GOMNOOKGLZYEJT-UHFFFAOYSA-N
DM7U58J	CS	C1=CC=C(C=C1)C2=COC3=CC=CC=C3C2=O
DM7U58J	IK	1S/C15H10O2/c16-15-12-8-4-5-9-14(12)17-10-13(15)11-6-2-1-3-7-11/h1-10H
DM7U58J	IU	3-phenylchromen-4-one
DM7U58J	CA	CAS 574-12-9
DM7U58J	CB	CHEBI:18220
DM7U58J	DE	Asthma

DM170OH	ID	DM170OH
DM170OH	DN	Ketazolam
DM170OH	HS	Phase 4
DM170OH	SN	Ketazolamum; Ketazolamum [INN-Latin]; Loftran; U 28774; U-28,774; Unakalm; Anseren; Ansieten; KETAZOLAM; 11-Chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-(1,3)-oxazino(3,2-d)(1,4)benzodiazepine-4,7(6H)dione; 27223-35-4; 4H-(1,3)Oxazino(3,2-d)(1,4)benzodiazepine-4,7(6H)-dione, 8,12b-dihydro-11-chloro-2,8-dimethyl-12b-phenyl-; 4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-; Anxon; EINECS 248-346-3; NSC 338158
DM170OH	PC	33746
DM170OH	MW	368.8
DM170OH	FM	C20H17ClN2O3
DM170OH	IC	PWAJCNITSBZRBL-UHFFFAOYSA-N
DM170OH	CS	CC1=CC(=O)N2CC(=O)N(C3=C(C2(O1)C4=CC=CC=C4)C=C(C=C3)Cl)C
DM170OH	IK	1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
DM170OH	IU	11-chloro-2,8-dimethyl-12b-phenyl-6H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-dione
DM170OH	CA	CAS 27223-35-4
DM170OH	CB	CHEBI:135556
DM170OH	DE	Anxiety disorder

DMQP5I3	ID	DMQP5I3
DMQP5I3	DN	Lacidipine
DMQP5I3	HS	Phase 4
DMQP5I3	SN	Lacidipine; Lacidipine (Lacipil, Motens); Lacidipino; Lacidipino [Spanish]; Lacidipinum [Latin]; Lacimen; Lacipil; Motens; trans Lacidipine; 103890-78-4; 260080034N; 4-(o-((E)-2-Carboxyvinyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 4-tert-butyl diethyl ester; C26H33NO6; DSSTox_CID_26429; DSSTox_GSID_46429; DSSTox_RID_81607; GR 43659 X; GR 43659X; GR-43659X; GX-1048; UNII-260080034N; diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMQP5I3	PC	5311217
DMQP5I3	MW	455.5
DMQP5I3	FM	C26H33NO6
DMQP5I3	IC	GKQPCPXONLDCMU-CCEZHUSRSA-N
DMQP5I3	CS	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)C)C
DMQP5I3	IK	1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
DMQP5I3	IU	diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMQP5I3	CA	CAS 103890-78-4
DMQP5I3	CB	CHEBI:94480
DMQP5I3	DE	Essential hypertension

DM5FABJ	ID	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	HS	Phase 4
DM5FABJ	SN	Laropiprant; 571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B
DM5FABJ	DT	Small molecular drug
DM5FABJ	PC	9867642
DM5FABJ	MW	435.9
DM5FABJ	FM	C21H19ClFNO4S
DM5FABJ	IC	InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
DM5FABJ	CS	CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F
DM5FABJ	IK	NXFFJDQHYLNEJK-CYBMUJFWSA-N
DM5FABJ	IU	2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid
DM5FABJ	CA	CAS 571170-77-9
DM5FABJ	CB	CHEBI:135942
DM5FABJ	DE	Arteriosclerosis; Coronary heart disease

DM92S6N	ID	DM92S6N
DM92S6N	DN	Levamlodipine
DM92S6N	HS	Phase 4
DM92S6N	SN	Levamlodipine (hypertension); S-amlodipine gentisate; Levamlodipine (hypertension), SK Chemicals; S-amlodipine (hypertension), SK Chemicals
DM92S6N	CP	SK Chemicals Co Ltd
DM92S6N	DT	Small molecular drug
DM92S6N	PC	9822750
DM92S6N	MW	408.9
DM92S6N	FM	C20H25ClN2O5
DM92S6N	IC	InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1
DM92S6N	CS	CCOC(=O)C1=C(NC(=C([C@@H]1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
DM92S6N	IK	HTIQEAQVCYTUBX-KRWDZBQOSA-N
DM92S6N	IU	3-O-ethyl 5-O-methyl (4S)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DM92S6N	CA	CAS 103129-82-4
DM92S6N	CB	CHEBI:53796
DM92S6N	DE	Hypertension

DM82JP0	ID	DM82JP0
DM82JP0	DN	Lynestrenol
DM82JP0	HS	Phase 4
DM82JP0	SN	Linestrenol; Linestrenol [INN-Spanish]; Linestrenolo [DCIT]; Lynenol; Lynestrenolum [INN-Latin]; Lynoestrenol; Lynoestrenol [Progestins]; Lynstranol; Endometril; Ethinyl oestrenol; Ethinylestrenol; Ethinyloestranol; Ethynloestrenol; Ethynylestrenol; Exluten; Exlution; Exluton; Exlutona; IND 1006; LYNESTRENOL; Org 485-50; Orgametil; Orgametril; Orgametrol; 17-alpha-Ethynylestrenol; 17-alpha-Ethynyloestrenol; 17alpha-Ethynylestrenol; 3-Desoxynorlutin; 52-76-6; CCRIS 9093; EINECS 200-151-4; NSC 37725; NSC-37725; UNII-N2Z8ALG4U5
DM82JP0	PC	5857
DM82JP0	MW	284.4
DM82JP0	FM	C20H28O
DM82JP0	IC	YNVGQYHLRCDXFQ-XGXHKTLJSA-N
DM82JP0	CS	CC12CCC3C(C1CCC2(C#C)O)CCC4=CCCCC34
DM82JP0	IK	1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
DM82JP0	IU	(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
DM82JP0	CA	CAS 52-76-6
DM82JP0	CB	CHEBI:31790
DM82JP0	DE	Transsexualism

DM0UGYX	ID	DM0UGYX
DM0UGYX	DN	Medifoxamine
DM0UGYX	HS	Phase 4
DM0UGYX	SN	Medifoxamina; Medifoxamina [INN-Spanish]; Medifoxamine; Medifoxamine (INN); Medifoxamine [INN:DCF]; Medifoxaminum; Medifoxaminum [INN-Latin]; KWU7C2A1NT; ZX-AT022754; (Dimethylamino)acetaldehyde diphenyl acetal; 32359-34-5; AC1L1V3V; Acetaldehyde, (dimethylamino)-, diphenyl acetal; BRN 2054310; C16H19NO2; CHEBI:135061; CHEMBL85231; CTK4G8876; DTXSID80186078; EINECS 251-011-4; Ethanamine, N,N-dimethyl-2,2-diphenoxy-; N,N-Dimethyl-2,2-diphenoxyethanamine; N,N-Dimethyl-2,2-diphenoxyethylamine; SCHEMBL49319; UNII-KWU7C2A1NT
DM0UGYX	PC	36109
DM0UGYX	MW	257.329
DM0UGYX	FM	C16H19NO2
DM0UGYX	IC	QNMGHBMGNRQPNL-UHFFFAOYSA-N
DM0UGYX	CS	CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2
DM0UGYX	IK	1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3
DM0UGYX	IU	N,N-dimethyl-2,2-diphenoxyethanamine
DM0UGYX	CA	CAS 32359-34-5
DM0UGYX	CB	CHEBI:135061
DM0UGYX	DE	Depression

DME1X96	ID	DME1X96
DME1X96	DN	Mexazolam
DME1X96	HS	Phase 4
DME1X96	SN	Melex (TN); Mexazolam (JAN/INN); Mexazolam [INN:JAN]; Mexazolamum; Mexazolamum [INN-Latin]; Sedoxil; mexazolam; 10-Chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one; 10-Chloro-11b-(o-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one; 31868-18-5; AC1L1HL4; BRN 1091849; C18H16Cl2N2O2; CHEBI:31842; CS 386; CS-386; DSSTox_CID_31504; Melex; Oxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyl-
DME1X96	PC	4177
DME1X96	MW	363.2
DME1X96	FM	C18H16Cl2N2O2
DME1X96	IC	ANUCDXCTICZJRH-UHFFFAOYSA-N
DME1X96	CS	CC1COC2(N1CC(=O)NC3=C2C=C(C=C3)Cl)C4=CC=CC=C4Cl
DME1X96	IK	1S/C18H16Cl2N2O2/c1-11-10-24-18(13-4-2-3-5-15(13)20)14-8-12(19)6-7-16(14)21-17(23)9-22(11)18/h2-8,11H,9-10H2,1H3,(H,21,23)
DME1X96	IU	10-chloro-11b-(2-chlorophenyl)-3-methyl-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one
DME1X96	CA	CAS 31868-18-5
DME1X96	CB	CHEBI:31842
DME1X96	DE	Anxiety disorder

DM2VOQ3	ID	DM2VOQ3
DM2VOQ3	DN	Mosapride
DM2VOQ3	HS	Phase 4
DM2VOQ3	SN	Mosapride; 112885-41-3; 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide; Mosapride [INN]; CHEMBL60889; Mosapride (INN); 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]benzamide; AK-41276; 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; Q-201413; 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide
DM2VOQ3	DT	Small molecular drug
DM2VOQ3	PC	119584
DM2VOQ3	MW	421.9
DM2VOQ3	FM	C21H25ClFN3O3
DM2VOQ3	IC	InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)
DM2VOQ3	CS	CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N
DM2VOQ3	IK	YPELFRMCRYSPKZ-UHFFFAOYSA-N
DM2VOQ3	IU	4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide
DM2VOQ3	CA	CAS 112885-41-3
DM2VOQ3	CB	CHEBI:94373

DMVILAD	ID	DMVILAD
DMVILAD	DN	MOTILIN
DMVILAD	HS	Phase 4
DMVILAD	SN	Motilin (human, porcine); UNII-D85V250YSI; D85V250YSI; 9072-41-7; Human motilin; 52906-92-0; Motilin (swine); Motilin (human); Motilin (porcine); Motilin [MI]; Human motilin [MI]; Motilin porcine; h-Motilin; Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln; GTPL1458; CHEMBL525634; Motilin porcine, &gt
DMVILAD	DT	Small molecular drug
DMVILAD	PC	16136567
DMVILAD	MW	2699.1
DMVILAD	FM	C120H188N34O35S
DMVILAD	IC	InChI=1S/C120H188N34O35S/c1-9-64(6)97(152-114(184)86-31-22-53-154(86)117(187)96(63(4)5)151-99(169)70(123)56-66-23-12-10-13-24-66)115(185)150-84(57-67-25-14-11-15-26-67)113(183)153-98(65(7)155)116(186)149-83(58-68-32-34-69(156)35-33-68)101(171)135-60-91(161)136-75(39-45-93(163)164)105(175)147-82(55-62(2)3)111(181)145-77(37-43-88(125)158)106(176)140-73(29-20-51-132-119(128)129)103(173)146-80(48-54-190-8)110(180)142-76(36-42-87(124)157)107(177)144-79(41-47-95(167)168)108(178)139-72(28-17-19-50-122)102(172)143-78(40-46-94(165)166)109(179)141-74(30-21-52-133-120(130)131)104(174)148-85(59-90(127)160)112(182)138-71(27-16-18-49-121)100(170)134-61-92(162)137-81(118(188)189)38-44-89(126)159/h10-15,23-26,32-35,62-65,70-86,96-98,155-156H,9,16-22,27-31,36-61,121-123H2,1-8H3,(H2,124,157)(H2,125,158)(H2,126,159)(H2,127,160)(H,134,170)(H,135,171)(H,136,161)(H,137,162)(H,138,182)(H,139,178)(H,140,176)(H,141,179)(H,142,180)(H,143,172)(H,144,177)(H,145,181)(H,146,173)(H,147,175)(H,148,174)(H,149,186)(H,150,185)(H,151,169)(H,152,184)(H,153,183)(H,163,164)(H,165,166)(H,167,168)(H,188,189)(H4,128,129,132)(H4,130,131,133)/t64-,65+,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,96-,97-,98-/m0/s1
DMVILAD	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N
DMVILAD	IK	LVRVABPNVHYXRT-BQWXUCBYSA-N
DMVILAD	IU	(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMVILAD	CA	CAS 9072-41-7

DMHEAB1	ID	DMHEAB1
DMHEAB1	DN	Neupro
DMHEAB1	HS	Phase 4
DMHEAB1	SN	Rotigotine; 99755-59-6; Leganto; SPM 962; (S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; (6S)-rotigotine; UNII-87T4T8BO2E; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-962; N 0923; CHEMBL1303; 87T4T8BO2E; 99755-59-6 (free base); (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; NCGC00168748-01; Rotigotine CDS Patch; (6s)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol; DSSTox_CID_26772; DSSTox_RID_81893; DSSTox_GSID_46772; C19H25NOS; Rotigotine CDS; (S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; (S)-6-[Propyl-(2-thiophen-2-yl-ethyl)-amino]-5,6,7,8-tetrahydro-naphthalen-1-ol; CAS-99755-59-6; Neupro (TN); N-0923; Rotigotine [USAN:INN:BAN]; (S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol; (S)-6-[Propyl[2-(thiophen-2-yl)ethyl]amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-936; SPM-937; PubChem16423; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; GTPL941; cc-129; Rotigotine (JAN/USAN/INN); (-)-N-0437; SCHEMBL1088585; ZINC4028; DTXSID5046772; HSDB 8254; (2S)-2-[propyl-[2-(2-thienyl)ethyl]amino]tetralin-5-ol; CHEBI:135351; HMS3885D17; EX-A1164; Tox21_112627; 2696AH; BDBM50123626; MFCD00870193; s4274; AKOS016340728; Tox21_112627_1; AC-3547; CCG-267650; CS-0376; DB05271; SB19528; SS-4572; 1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl (2-(2-thienyl)ethyl)amino-(6S)-; NCGC00168748-02; HY-75502; AB0088886; SW220014-1; D05768; W-5179; 572R932; A846076; Q411985; J-502471; UNII-5QTR54Z0E1 component KFQYTPMOWPVWEJ-INIZCTEOSA-N; (6S)-6-(propyl-(2-thiophen-2-ylethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-, (6S)-
DMHEAB1	CP	UCB
DMHEAB1	DT	Small molecular drug
DMHEAB1	PC	59227
DMHEAB1	MW	315.5
DMHEAB1	FM	C19H25NOS
DMHEAB1	IC	InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
DMHEAB1	CS	CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O
DMHEAB1	IK	KFQYTPMOWPVWEJ-INIZCTEOSA-N
DMHEAB1	IU	(6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMHEAB1	CA	CAS 99755-59-6
DMHEAB1	CB	CHEBI:135351
DMHEAB1	DE	Parkinson disease; Restless legs syndrome

DMRP8XB	ID	DMRP8XB
DMRP8XB	DN	Nomegestrol
DMRP8XB	HS	Phase 4
DMRP8XB	SN	Nomegestrol; Nomegestrol (USAN/INN); Nomegestrol [USAN:INN:BAN]; Nomegestrolum; Nomegestrolum [Latin]; SCHEMBL139763; Thermex; nomegestrol[inn]; Monaco; (8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,13-dimethyl-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 10F89177CO; 17-Hydroxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione; 17-Hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dione; 58691-88-6; AC1L2AFS; AC1Q6OH0; CHEBI:135993; CHEMBL2105722; UNII-10F89177CO
DMRP8XB	PC	68783
DMRP8XB	MW	328.4
DMRP8XB	FM	C21H28O3
DMRP8XB	IC	KZUIYQJTUIACIG-YBZCJVABSA-N
DMRP8XB	CS	CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4C1=CC(=O)CC4
DMRP8XB	IK	1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1
DMRP8XB	IU	(8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,13-dimethyl-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMRP8XB	CA	CAS 58691-88-6
DMRP8XB	CB	CHEBI:135993
DMRP8XB	DE	Hypercoagulability

DMVAOME	ID	DMVAOME
DMVAOME	DN	Oleandomycin
DMVAOME	HS	Phase 4
DMVAOME	SN	Oleandomycin A; Amimycin; Landomycin; Matromycin; Antibiotic PA 105; LMPK04000007; P8ZQ646136; PA 105; Prestwick3_000152; RZPAKFUAFGMUPI-QESOVKLGSA-N; Romicil; SCHEMBL3717; ZINC85432018; oleandomycin; 3922-90-5; AB00513809; AC1L2I65; BDBM234401; BPBio1_000314; BSPBio_000284; C01946; CHEBI:16869; CHEMBL606258; CS-0063452; E704; HY-116010; NCGC00179617-01; UNII-P8ZQ646136
DMVAOME	PC	72493
DMVAOME	MW	687.9
DMVAOME	FM	C35H61NO12
DMVAOME	IC	RZPAKFUAFGMUPI-QESOVKLGSA-N
DMVAOME	CS	CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)O)OC)C)C)C)O)C)C)O)N(C)C
DMVAOME	IK	1S/C35H61NO12/c1-16-14-35(15-43-35)32(40)19(4)27(37)18(3)22(7)46-33(41)21(6)31(47-26-13-25(42-11)28(38)23(8)45-26)20(5)30(16)48-34-29(39)24(36(9)10)12-17(2)44-34/h16-31,34,37-39H,12-15H2,1-11H3/t16-,17+,18-,19+,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,34-,35+/m0/s1
DMVAOME	IU	(3R,5S,6S,7R,8S,9R,12R,13R,14S,15R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-8-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-1,11-dioxaspiro[2.13]hexadecane-10,16-dione
DMVAOME	CA	CAS 3922-90-5
DMVAOME	CB	CHEBI:16869
DMVAOME	DE	Acute upper respiratory infection

DMQIMTK	ID	DMQIMTK
DMQIMTK	DN	Ombitasvir
DMQIMTK	HS	Phase 4
DMQIMTK	SN	2302768XJ8; ABT 267; ABT-267; ABT-267;ABT267;ABT 267; ABT267; CHEBI:85183; CHEMBL3127326; CS-5330; DB09296; Ombitasvir; Ombitasvir (USAN); Ombitasvir [USAN:INN]; Ombitasvir pound&gt;&gt;ABT-267; Ombitasvir(ABT-267); SB16895; SCHEMBL8542284; UNII-2302768XJ8; ZINC150601177; dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate
DMQIMTK	TC	Antiviral Agent
DMQIMTK	DT	Small molecular drug
DMQIMTK	PC	54767916
DMQIMTK	MW	894.127
DMQIMTK	FM	C50H67N7O8
DMQIMTK	IC	InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
DMQIMTK	CS	CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
DMQIMTK	IK	PIDFDZJZLOTZTM-KHVQSSSXSA-N
DMQIMTK	IU	methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMQIMTK	CA	CAS 1258226-87-7
DMQIMTK	CB	CHEBI:85183
DMQIMTK	DE	Hepatitis C virus infection

DMPSKA5	ID	DMPSKA5
DMPSKA5	DN	Ortho-phosphate
DMPSKA5	HS	Phase 4
DMPSKA5	SN	Acide phosphorique; Acide phosphorique [French]; Acido fosforico; Acido fosforico [Italian]; Acidum phosphoricum; Fosforzuuroplossingen; Fosforzuuroplossingen [Dutch]; ORTHOPHOSPHORIC ACID; POLYPHOSPHORIC ACID; Phosphoric acid; Phosphoric acid 75%; Phosphoric acid, ortho-; Phosphorsaeure; Phosphorsaeureloesungen; Phosphorsaeureloesungen [German]; Superphosphoric acid; Wc-reiniger; White phosphoric acid; o-Phosphoric acid; ortho-phosphoric acid; 7664-38-2; Caswell No. 662; Evits; FEMA No. 2900; Sonac; UNII-E4GA8884NN
DMPSKA5	PC	1004
DMPSKA5	MW	97.995
DMPSKA5	FM	H3O4P
DMPSKA5	IC	NBIIXXVUZAFLBC-UHFFFAOYSA-N
DMPSKA5	CS	OP(=O)(O)O
DMPSKA5	IK	1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)
DMPSKA5	IU	phosphoric acid
DMPSKA5	CA	CAS 7664-38-2
DMPSKA5	CB	CHEBI:26078.
DMPSKA5	DE	Thyroid cancer

DMU1JVW	ID	DMU1JVW
DMU1JVW	DN	Otilonium
DMU1JVW	HS	Phase 4
DMU1JVW	SN	LS-187100; OTILONIUM; ZINC8214636; 105360-89-2; 6330179ARU; AB01566869_01; AC1L2HEM; AC1Q65RN; CHEBI:135780; CHEMBL1433361; CTK8G5037; DTXSID0048391; Diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium; Ethanaminium, N,N-diethyl-N-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-; N,N-Diethyl-N-methyl-2-(4-(2-(octyloxy)benzamido)benzoyloxy)ethanaminium; NCGC00163507-01; NCGC00163507-02; SCHEMBL20352274; UNII-6330179ARU
DMU1JVW	PC	72093
DMU1JVW	MW	483.7
DMU1JVW	FM	C29H43N2O4+
DMU1JVW	IC	NQHNLNLJPDMBFN-UHFFFAOYSA-O
DMU1JVW	CS	CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC
DMU1JVW	IK	1S/C29H42N2O4/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3/h12-13,15-20H,5-11,14,21-23H2,1-4H3/p+1
DMU1JVW	IU	diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium
DMU1JVW	CA	CAS 105360-89-2
DMU1JVW	CB	CHEBI:135780
DMU1JVW	DE	Irritable bowel syndrome

DMIGKA1	ID	DMIGKA1
DMIGKA1	DN	Ozagrel
DMIGKA1	HS	Phase 4
DMIGKA1	SN	Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika
DMIGKA1	CP	Kissei Pharmaceutical Co Ltd
DMIGKA1	DT	Small molecular drug
DMIGKA1	PC	5282440
DMIGKA1	MW	228.25
DMIGKA1	FM	C13H12N2O2
DMIGKA1	IC	InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+
DMIGKA1	CS	C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O
DMIGKA1	IK	SHZKQBHERIJWAO-AATRIKPKSA-N
DMIGKA1	IU	(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
DMIGKA1	CA	CAS 82571-53-7
DMIGKA1	CB	CHEBI:92359
DMIGKA1	DE	Chronic obstructive pulmonary disease; Xerophthalmia

DMY2AEF	ID	DMY2AEF
DMY2AEF	DN	PAI-1
DMY2AEF	HS	Phase 4
DMY2AEF	SN	PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-
DMY2AEF	DT	Small molecular drug
DMY2AEF	PC	3246941
DMY2AEF	MW	297.39
DMY2AEF	FM	C16H27NO4
DMY2AEF	IC	InChI=1S/C16H27NO4/c1-2-3-4-5-6-7-8-9-13(18)12-15(19)17-14-10-11-21-16(14)20/h14H,2-12H2,1H3,(H,17,19)/t14-/m0/s1
DMY2AEF	CS	CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O
DMY2AEF	IK	PHSRRHGYXQCRPU-AWEZNQCLSA-N
DMY2AEF	IU	3-oxo-N-[(3S)-2-oxooxolan-3-yl]dodecanamide
DMY2AEF	CA	CAS 168982-69-2
DMY2AEF	CB	CHEBI:44534

DMIV8CT	ID	DMIV8CT
DMIV8CT	DN	Parecoxib
DMIV8CT	HS	Phase 4
DMIV8CT	SN	Parecoxib; SC-69124; Dynastat; Valus-P; Vorth-P; SC 69124; UNII-9TUW81Y3CE; 9TUW81Y3CE; Parecoxib [USAN:INN:BAN]; CHEBI:73038; N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide; Parocoxib; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide; Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide; N-{[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide; parecoxibum; Valdecoxib Impurity J; Parecoxib (
DMIV8CT	DT	Small molecular drug
DMIV8CT	PC	119828
DMIV8CT	MW	370.4
DMIV8CT	FM	C19H18N2O4S
DMIV8CT	IC	InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)
DMIV8CT	CS	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C
DMIV8CT	IK	TZRHLKRLEZJVIJ-UHFFFAOYSA-N
DMIV8CT	IU	N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide
DMIV8CT	CA	CAS 198470-84-7
DMIV8CT	CB	CHEBI:73038

DMQY873	ID	DMQY873
DMQY873	DN	Pentifylline
DMQY873	HS	Phase 4
DMQY873	SN	Pentifilina [INN-Spanish]; Pentifyllin; Pentifylline; Pentifylline [INN:BAN:DCF]; Pentifyllinum [INN-Latin]; Cosadon; Cosaldon; Hexyltheobromine; MBM1C4K26S; SK 7 (Pharmaceutical); Theobromine, 1-hexyl-; 1-Hexyl-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1-Hexyl-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione; 1-Hexyl-3,7-dimethylxanthine; 1-Hexyltheobromine; 1-n-hexyltheobromine; 1028-33-7; 3,7-Dimethyl-1-hexyl-1H,3H-purin-2,6-dione; BRN 0270632; C13H20N4O2; EINECS 213-842-0; MFCD00041424; SK 7; UNII-MBM1C4K26S
DMQY873	PC	70569
DMQY873	MW	264.32
DMQY873	FM	C13H20N4O2
DMQY873	IC	MRWQRJMESRRJJB-UHFFFAOYSA-N
DMQY873	CS	CCCCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
DMQY873	IK	1S/C13H20N4O2/c1-4-5-6-7-8-17-12(18)10-11(14-9-15(10)2)16(3)13(17)19/h9H,4-8H2,1-3H3
DMQY873	IU	1-hexyl-3,7-dimethylpurine-2,6-dione
DMQY873	CA	CAS 1028-33-7
DMQY873	CB	CHEBI:135091
DMQY873	DE	Cerebrovascular dementia

DM4OIMZ	ID	DM4OIMZ
DM4OIMZ	DN	Pinaverium
DM4OIMZ	HS	Phase 4
DM4OIMZ	SN	Pinaverium; LS-176056; SCHEMBL312166; U2368VVE7O; 59995-65-2; AC1L24AP; BDBM50101975; C26H41BrNO4; CHEBI:135811; CHEMBL1909324; DB09090; Morpholinium, 4-((2-bromo-4,5-dimethoxyphenyl)methyl)-4-(2-(2-(6,6-dimethylbicyclo(3.1.1)hept-2-yl)ethoxy)ethyl)-; NCGC00181763-01; UNII-U2368VVE7O
DM4OIMZ	PC	40704
DM4OIMZ	MW	511.5
DM4OIMZ	FM	C26H41BrNO4+
DM4OIMZ	IC	DDHUTBKXLWCZCO-UHFFFAOYSA-N
DM4OIMZ	CS	CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C
DM4OIMZ	IK	1S/C26H41BrNO4/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27/h15,17,19,21-22H,5-14,16,18H2,1-4H3/q+1
DM4OIMZ	IU	4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium
DM4OIMZ	CA	CAS 59995-65-2
DM4OIMZ	CB	CHEBI:135811
DM4OIMZ	DE	Irritable bowel syndrome

DMWRYUH	ID	DMWRYUH
DMWRYUH	DN	Prasterone sulfate
DMWRYUH	HS	Phase 4
DMWRYUH	SN	Prasterone sulfate; Prasterone sulphate; 17-Ketoandrost-5-en-3beta-yl sulfate; 3-O-Sulfodehydroepiandrosterone; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; 651-48-9; DEHYDROEPIANDROSTERONE SULFATE; DHEA sulfate; DHEA sulphate; DHEA-S; Dehydroandrosterone sulfate; Dehydroepiandrosterone 3-sulfate; Dehydroepiandrosterone monosulfate; Dehydroepiandrosterone sulphate; Dehydroisoandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; Androst-5-en-17-on-3beta-yl sulfuric acid; CCRIS 6746; DHEAS; UNII-57B09Q7FJR
DMWRYUH	PC	12594
DMWRYUH	MW	368.5
DMWRYUH	FM	C19H28O5S
DMWRYUH	IC	CZWCKYRVOZZJNM-USOAJAOKSA-N
DMWRYUH	CS	CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C
DMWRYUH	IK	1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1
DMWRYUH	IU	[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMWRYUH	CA	CAS 651-48-9
DMWRYUH	CB	CHEBI:16814
DMWRYUH	DE	Adrenocortical deficiency

DM6VFO1	ID	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	HS	Phase 4
DM6VFO1	SN	Pregnenolone (schizophrenia); Neurosteroid (schizophrenia), Neuroscience; Pregnenolone (schizophrenia), Neuroscience
DM6VFO1	CP	Duke University
DM6VFO1	DT	Small molecular drug
DM6VFO1	PC	8955
DM6VFO1	MW	316.5
DM6VFO1	FM	C21H32O2
DM6VFO1	IC	InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1
DM6VFO1	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DM6VFO1	IK	ORNBQBCIOKFOEO-QGVNFLHTSA-N
DM6VFO1	IU	1-[(3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DM6VFO1	CA	CAS 145-13-1
DM6VFO1	CB	CHEBI:16581
DM6VFO1	DE	Schizophrenia

DM8PTSY	ID	DM8PTSY
DM8PTSY	DN	Prenylamine
DM8PTSY	HS	Phase 4
DM8PTSY	SN	Prenilamina; Prenilamina [INN-Spanish]; Prenylamine (vasodilator); Prenylamine [USAN:INN:BAN]; Prenylaminum; Prenylaminum [INN-Latin]; Bismethin; Carditin; Corontin; Corpax; DL-Prenylamine; Difril; Elecor; Falliocor; Hostaginan; PRENYLAMINE; SAN 13-194; Sandoz 13-194; Segontin; Synadrin; Valecor; 1-Phenyl-2-(1',1'-diphenylpropyl-3'-amino)propane; 390-64-7; B-436; BRN 2060323; CHEMBL24072; EINECS 206-869-4; N-(1-Methyl-2-phenylethyl)-gamma-phenylbenzenepropanamine; N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine
DM8PTSY	PC	9801
DM8PTSY	MW	329.5
DM8PTSY	FM	C24H27N
DM8PTSY	IC	IFFPICMESYHZPQ-UHFFFAOYSA-N
DM8PTSY	CS	CC(CC1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
DM8PTSY	IK	1S/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3
DM8PTSY	IU	3,3-diphenyl-N-(1-phenylpropan-2-yl)propan-1-amine
DM8PTSY	CA	CAS 390-64-7
DM8PTSY	CB	CHEBI:8397
DM8PTSY	DE	Angina pectoris

DM37FKA	ID	DM37FKA
DM37FKA	DN	Primovist
DM37FKA	HS	Phase 4
DM37FKA	SN	Eovist; Primovist; gadoxate disodium; AC1L9OPS; gadolinium ethoxybenzyl-DTPA; MOLI000482; 2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid; gadolinium(3+)
DM37FKA	PC	450096
DM37FKA	MW	684.8
DM37FKA	FM	C23H33GdN3O11+3
DM37FKA	IC	InChI=1S/C23H33N3O11.Gd/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);/q;+3
DM37FKA	CS	CCOC1=CC=C(C=C1)CC(CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O.[Gd+3]
DM37FKA	IK	PCZHWPSNPWAQNF-UHFFFAOYSA-N
DM37FKA	IU	2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid;gadolinium(3+)
DM37FKA	DE	Lung cancer

DMXL43T	ID	DMXL43T
DMXL43T	DN	Prulifloxacin
DMXL43T	HS	Phase 4
DMXL43T	SN	Prulifloxacin; Prulifloxacin [INN]; Pruvel; Q-101929; Quisnon; NM 441; NM-441; 123447-62-1; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; AK144730; CCRIS 7686; DSSTox_CID_26480; DSSTox_GSID_46480; DSSTox_RID_81651; NCGC00164615-01; NM441; Sword
DMXL43T	PC	65947
DMXL43T	MW	461.5
DMXL43T	FM	C21H20FN3O6S
DMXL43T	IC	PWNMXPDKBYZCOO-UHFFFAOYSA-N
DMXL43T	CS	CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C
DMXL43T	IK	1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)
DMXL43T	IU	6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
DMXL43T	CA	CAS 123447-62-1
DMXL43T	CB	CHEBI:32071
DMXL43T	DE	Chronic obstructive pulmonary disease

DMF8CJ9	ID	DMF8CJ9
DMF8CJ9	DN	Pyridine
DMF8CJ9	HS	Phase 4
DMF8CJ9	SN	Azabenzene; 110-86-1; Azine; Pyridin; Pirydyna; Piridina; Pyridin [German]; Pirydyna [Polish]; Piridina [Italian]; RCRA waste number U196; NCI-C55301; Caswell No. 717; CCRIS 2926; HSDB 118; pyridine-ring; CHEBI:16227; FEMA Number 2966; CP 32; UNII-NH9L3PP67S; EINECS 203-809-9; UN1282; NSC 406123; FEMA No. 2966; RCRA waste no. U196; EPA Pesticide Chemical Code 069202; NH9L3PP67S; AI3-01240; pyridine fraction; JUJWROOIHBZHMG-UHFFFAOYSA-N; MFCD00011732; Pentadeuteropyridine; Pyridine [UN1282]  [Flammable liquid]; 7291-22-7
DMF8CJ9	DT	Small molecular drug
DMF8CJ9	PC	1049
DMF8CJ9	MW	79.1
DMF8CJ9	FM	C5H5N
DMF8CJ9	IC	InChI=1S/C5H5N/c1-2-4-6-5-3-1/h1-5H
DMF8CJ9	CS	C1=CC=NC=C1
DMF8CJ9	IK	JUJWROOIHBZHMG-UHFFFAOYSA-N
DMF8CJ9	IU	pyridine
DMF8CJ9	CA	CAS 110-86-1
DMF8CJ9	CB	CHEBI:16227

DMBPN7T	ID	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	HS	Phase 4
DMBPN7T	SN	Rupatadine trihydrochloride; UNII-G61C8NZY2T; G61C8NZY2T; 156611-76-6; Rupatadine HCl; Rupatadine hydrochloride; UR 12592; AC1L320L; DTXSID90166109; BQFOTHHRVVHLEW-UHFFFAOYSA-N; 8-Chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine trihydrochloride; 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-, trihydrochloride
DMBPN7T	DT	Small molecular drug
DMBPN7T	PC	133017
DMBPN7T	MW	416
DMBPN7T	FM	C26H26ClN3
DMBPN7T	IC	InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3
DMBPN7T	CS	CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2
DMBPN7T	IK	WUZYKBABMWJHDL-UHFFFAOYSA-N
DMBPN7T	IU	13-chloro-2-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene]-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
DMBPN7T	CA	CAS 158876-82-5
DMBPN7T	CB	CHEBI:135673

DMXBYQR	ID	DMXBYQR
DMXBYQR	DN	Silymarin
DMXBYQR	HS	Phase 4
DMXBYQR	SN	Milk thistle extract; Sabal serrulata extract; 84604-20-6; AN-35849; FT-0656490; A835184; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxy-phenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chroman-4-one
DMXBYQR	DT	Small molecular drug
DMXBYQR	PC	5213
DMXBYQR	MW	482.4
DMXBYQR	FM	C25H22O10
DMXBYQR	IC	InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3
DMXBYQR	CS	COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
DMXBYQR	IK	SEBFKMXJBCUCAI-UHFFFAOYSA-N
DMXBYQR	IU	3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
DMXBYQR	CA	CAS 65666-07-1
DMXBYQR	CB	CHEBI:125451

DMOSJD0	ID	DMOSJD0
DMOSJD0	DN	Sivelestat sodium hydrate
DMOSJD0	HS	Phase 4
DMOSJD0	SN	sivelestat sodium hydrate; Sivelestat sodium tetrahydrate; 201677-61-4; Elaspol; Sodium sivelestat; EI546 sodium; UNII-737RR8Y409; Sivelestat (sodium tetrahydrate); LY544349 sodium; Sivelestat sodium [USAN]; Sivelestat sodium (USAN); 737RR8Y409; DSSTox_CID_26727; DSSTox_RID_81857; DSSTox_GSID_46727; sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; LY544349 Sodium Hydrate; Elaspol (TN); CAS-201677-61-4; NCGC00167577-01; AC1L4KMF; Sivelestat sodium hydrate (JAN); Sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; Sodium ((2-(((4-((2,2-dimethylpropanoyl)oxy)phenyl)sulfonyl)amino)benzoyl)amino)acetate tetrahydrate; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-, monosodium salt, tetrahydrate
DMOSJD0	CP	ONO Pharmaceuticals
DMOSJD0	DT	Small molecular drug
DMOSJD0	PC	23663985
DMOSJD0	MW	528.5
DMOSJD0	FM	C20H29N2NaO11S
DMOSJD0	IC	InChI=1S/C20H22N2O7S.Na.4H2O/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24;;;;;/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24);;4*1H2/q;+1;;;;/p-1
DMOSJD0	CS	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)[O-].O.O.O.O.[Na+]
DMOSJD0	IK	PLHREJBSQUSUCW-UHFFFAOYSA-M
DMOSJD0	IU	sodium;2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate;tetrahydrate
DMOSJD0	CA	CAS 201677-61-4
DMOSJD0	CB	CHEBI:32133
DMOSJD0	DE	Community-acquired pneumonia; Acute lung injury

DMTV7XH	ID	DMTV7XH
DMTV7XH	DN	SPN-812
DMTV7XH	HS	Phase 4
DMTV7XH	SN	Viloxazine hydrochloride; 35604-67-2; 2-((2-Ethoxyphenoxy)methyl)morpholine hydrochloride; Emovit; 2-[(2-ethoxyphenoxy)methyl]morpholine hydrochloride; ICI 58,834; Viloxazine hydrochloride [USAN]; 2-((2-ethoxyphenoxy)methyl)morpholinehydrochloride; 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride; Morpholine, 2-[(2-ethoxyphenoxy)methyl]-, hydrochloride; Vicilan; Vivalan; 2-[(2-ethoxy phenoxy)methyl]morpholine hydrochloride; Morpholine, 2-((2-ethoxyphenoxy)methyl)-, hydrochloride; Viloxazine hydrochloride (USAN); Viloxazine HCl; CCRIS 1915; Viloxacina clorhidrato; ICI-58834; Viloxacina clorhidrato [Spanish]; EINECS 252-638-6; Prestwick_734; 2-((o-Ethoxyphenoxy)methyl)morpholine hydrochloride; Vivalan (TN); 2-(2-Ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride; 2-(2-Ethoxyphenoxymethyl)-2,3,5,6-tetrahydro-1,4-oxazine hydrochloride; rac Viloxazine Hydrochloride; DSSTox_CID_31511; DSSTox_RID_97396; DSSTox_GSID_57722; SCHEMBL300741; CHEMBL2106483; DTXSID8057722; Tox21_113955; 1478AE; AKOS015847050; CCG-220828; NCGC00262964-01; CAS-35604-67-2; A6217; FT-0675815; FT-0675816; FT-0675817; FT-0675818; FT-0675819; D02572; Z-1958; 2-(o-ethoxyphenoxymethyl)morpholine hydrochloride; 604E672; SR-01000872636; SR-01000872636-1; W-110863; 2-(2-Ethoxy-phenoxymethyl)-morpholine; hydrochloride; 2-[(2-Ethoxyphenoxy)-methyl]morpholine hydrochloride; Q27285797; 2-(2-ethoxy-phenoxymethyl)-tetra-hydro-1,4-oxazine hydrochloride
DMTV7XH	CP	Supernus Pharmaceuticals
DMTV7XH	DT	Small molecular drug
DMTV7XH	PC	71424
DMTV7XH	MW	273.75
DMTV7XH	FM	C13H20ClNO3
DMTV7XH	IC	InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H
DMTV7XH	CS	CCOC1=CC=CC=C1OCC2CNCCO2.Cl
DMTV7XH	IK	HJOCKFVCMLCPTP-UHFFFAOYSA-N
DMTV7XH	IU	2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride
DMTV7XH	CA	CAS 35604-67-2
DMTV7XH	DE	Attention deficit hyperactivity disorder

DM4TX7J	ID	DM4TX7J
DM4TX7J	DN	Talipexole
DM4TX7J	HS	Phase 4
DM4TX7J	SN	Talipexole; 101626-70-4; Talipexole [INN]; Talipexolum [Latin]; Talipexol [Spanish]; UNII-7AM2J46Z1Y; Domin; 7AM2J46Z1Y; CHEMBL279085; Talipexole (INN); NCGC00163160-01; DSSTox_CID_26321; DSSTox_RID_81537; DSSTox_GSID_46321; Talipexolum; Talipexol; 6-Allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo(4,5-d)azepine; 6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-amine; 6-prop-2-enyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-2-amine; 4H-Thiazolo[4,5-d]azepin-2-amine,5,6,7,8-tetrahydro-6-(2-propen-1-yl)-; BHT920
DM4TX7J	DT	Small molecular drug
DM4TX7J	PC	5374
DM4TX7J	MW	209.31
DM4TX7J	FM	C10H15N3S
DM4TX7J	IC	InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)
DM4TX7J	CS	C=CCN1CCC2=C(CC1)SC(=N2)N
DM4TX7J	IK	DHSSDEDRBUKTQY-UHFFFAOYSA-N
DM4TX7J	IU	6-prop-2-enyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-2-amine
DM4TX7J	CA	CAS 101626-70-4
DM4TX7J	CB	CHEBI:93327

DM62IPN	ID	DM62IPN
DM62IPN	DN	Tenofovir disoproxil
DM62IPN	HS	Phase 4
DM62IPN	SN	Tenofovir (Disoproxil); Tenofovir disoproxil; 201341-05-1; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; Bis(POC)PMPA; PMPA prodrug; CHEBI:63717; F4YU4LON7I; UNII-F4YU4LON7I; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate; tenofovir bis(isopropyloxycarbonyloxymethyl) ester
DM62IPN	PC	5481350
DM62IPN	MW	519.4
DM62IPN	FM	C19H30N5O10P
DM62IPN	IC	JFVZFKDSXNQEJW-CQSZACIVSA-N
DM62IPN	CS	CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C
DM62IPN	IK	1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1
DM62IPN	IU	[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate
DM62IPN	CA	CAS 201341-05-1
DM62IPN	CB	CHEBI:63717
DM62IPN	DE	Human immunodeficiency virus infection

DMC40UY	ID	DMC40UY
DMC40UY	DN	Tenofovir disoproxil
DMC40UY	HS	Phase 4
DMC40UY	SN	Tenofovir disoproxil; PMPA prodrug; Bis(POC)PMPA; Tenofovir (Disoproxil); UNII-F4YU4LON7I; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; F4YU4LON7I; CHEBI:63717; tenofovir bis(isopropyloxycarbonyloxymethyl) ester; Tenofovir Disoproxil Fumarate; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate
DMC40UY	PC	5481350
DMC40UY	MW	519.4
DMC40UY	FM	C19H30N5O10P
DMC40UY	IC	InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1
DMC40UY	CS	CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C
DMC40UY	IK	JFVZFKDSXNQEJW-CQSZACIVSA-N
DMC40UY	IU	[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate
DMC40UY	CA	CAS 201341-05-1
DMC40UY	CB	CHEBI:63717
DMC40UY	DE	Chronic hepatitis B infection

DM2M47Y	ID	DM2M47Y
DM2M47Y	DN	TKM-ApoB
DM2M47Y	HS	Phase 4
DM2M47Y	CP	Tekmira Pharmaceuticals
DM2M47Y	DT	siRNA drug
DM2M47Y	DE	Hypercholesterolaemia

DM7NSI0	ID	DM7NSI0
DM7NSI0	DN	Urethane
DM7NSI0	HS	Phase 4
DM7NSI0	SN	Uretan; Uretan etylowy; Uretano [DCIT]; Urethan; Urethanum; Urethanum [INN-Latin]; Aethylcarbamat; Aethylcarbamat [German]; Aethylurethan; Aethylurethan [German]; Carbamic acid ethyl ester; Carbamic acid, ethyl ester; Carbamidsaeure-aethylester; ETHYL CARBAMATE; Estane 5703; Ethyl urethan; Ethyl urethane; Ethylcarbamate; Ethylester kyseliny karbaminove; Ethylurethan; Ethylurethane; Leucethane; Leucothane; O-Ethyl urethane; O-Ethylurethane; Pracarbamin; Pracarbamine; U-Compound; ethyl aminoformate; urethane; 51-79-6; NSC 746
DM7NSI0	PC	5641
DM7NSI0	MW	89.09
DM7NSI0	FM	C3H7NO2
DM7NSI0	IC	JOYRKODLDBILNP-UHFFFAOYSA-N
DM7NSI0	CS	CCOC(=O)N
DM7NSI0	IK	1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)
DM7NSI0	IU	ethyl carbamate
DM7NSI0	CA	CAS 51-79-6
DM7NSI0	CB	CHEBI:17967
DM7NSI0	DE	Lung cancer

DMCOJPS	ID	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	HS	Phase 4
DMCOJPS	SN	Vonoprazan; Vonoprazan [INN]; TAK-438 (free base); TAK-438 free base; SCHEMBL194487; 1-(5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine; 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine; 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonyl-pyrrol-3-yl]-~{N}-methyl-methanamine; 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine; 1R5L3J156G; 881681-00-1; BCP13240; CHEBI:136048; CHEMBL2079130; DTXSID20236869; KS-00000TU1; UNII-1R5L3J156G
DMCOJPS	PC	15981397
DMCOJPS	MW	345.4
DMCOJPS	FM	C17H16FN3O2S
DMCOJPS	IC	BFDBKMOZYNOTPK-UHFFFAOYSA-N
DMCOJPS	CS	CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3
DMCOJPS	IK	1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
DMCOJPS	IU	1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
DMCOJPS	CA	CAS 881681-00-1
DMCOJPS	CB	CHEBI:136048
DMCOJPS	DE	Gastro-oesophageal reflux disease

DMKV32D	ID	DMKV32D
DMKV32D	DN	Xylometazoline
DMKV32D	HS	Phase 4
DMKV32D	SN	Xylometazoline (nasal mucoadhesive/MucoAd, congestion); Decongestant (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences; Xylometazoline (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences
DMKV32D	CP	Fortune Apex Development Ltd
DMKV32D	DT	Small molecular drug
DMKV32D	PC	5709
DMKV32D	MW	244.37
DMKV32D	FM	C16H24N2
DMKV32D	IC	InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)
DMKV32D	CS	CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C
DMKV32D	IK	HUCJFAOMUPXHDK-UHFFFAOYSA-N
DMKV32D	IU	2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
DMKV32D	CA	CAS 526-36-3
DMKV32D	CB	CHEBI:10082
DMKV32D	DE	Allergic rhinitis

DM9RJH7	ID	DM9RJH7
DM9RJH7	DN	Zaltoprofen
DM9RJH7	HS	Phase 4
DM9RJH7	SN	Zaltoprofen (unspecified); Zaltoprofene; Zaltoprofeno; Zaltoprofenum; CN 100; CN-100; Soleton; zaltoprofen; (+-)-2-(10,11-Dihydro-10-oxodibenzo(b,f)thiepin-2-yl)propionic acid; 10,11-Dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid; 2-(10,11-Dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic Acid; 2-(10-oxo-10,11-dihydrodibenzo[b,f]thiepin-2-yl)propanoic acid; 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid; 74711-43-6; 89482-00-8; AK-77321; C17H14O3S; EINECS 277-973-5; NCGC00183878-01; Peon
DM9RJH7	PC	5720
DM9RJH7	MW	298.4
DM9RJH7	FM	C17H14O3S
DM9RJH7	IC	MUXFZBHBYYYLTH-UHFFFAOYSA-N
DM9RJH7	CS	CC(C1=CC2=C(C=C1)SC3=CC=CC=C3C(=O)C2)C(=O)O
DM9RJH7	IK	1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)
DM9RJH7	IU	2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid
DM9RJH7	CA	CAS 74711-43-6
DM9RJH7	CB	CHEBI:32306
DM9RJH7	DE	Anaesthesia

DMXIRA0	ID	DMXIRA0
DMXIRA0	DN	RLX030
DMXIRA0	HS	Approval submitted
DMXIRA0	SN	Serelaxin
DMXIRA0	CP	Novartis
DMXIRA0	DT	Small molecular drug
DMXIRA0	PC	71300755
DMXIRA0	MW	5963
DMXIRA0	FM	C256H408N74O74S8
DMXIRA0	IC	InChI=1S/C256H408N74O74S8/c1-32-128(20)198-246(396)286-135(27)207(357)326-199(129(21)33-2)248(398)321-180(210(360)279-106-189(343)289-161(79-88-405-30)221(371)315-177(111-334)239(389)329-202(137(29)337)250(400)312-171(232(382)317-178(112-335)251(401)402)98-141-103-277-148-57-41-39-55-145(141)148)114-408-412-118-184(252(403)404)322-230(380)168(95-138-52-36-35-37-53-138)308-215(365)154(63-50-86-274-255(267)268)291-203(353)132(24)283-226(376)164(91-121(6)7)307-238(388)176(110-333)314-216(366)155(64-51-87-275-256(269)270)293-213(363)151(59-43-46-82-258)301-249(399)201(136(28)336)330-242(392)181-115-409-411-117-183(319-217(367)150(58-42-45-81-257)294-233(383)173(101-186(262)340)303-206(356)133(25)284-225(375)163(90-120(4)5)302-205(355)134(26)285-236(386)174(108-331)316-229(379)169(96-139-65-67-143(338)68-66-139)309-227(377)165(92-122(8)9)305-218(368)156-70-75-187(341)287-156)241(391)320-182(240(390)311-172(99-142-104-271-119-281-142)235(385)323-195(125(14)15)243(393)280-107-190(344)290-181)116-410-407-113-179(209(359)278-105-188(342)288-149(61-48-84-272-253(263)264)212(362)295-159(72-77-192(347)348)220(370)306-167(94-124(12)13)234(384)325-196(126(16)17)244(394)299-153(62-49-85-273-254(265)266)211(361)282-131(23)204(354)292-157(224(374)327-198)69-74-185(261)339)318-228(378)166(93-123(10)11)304-214(364)152(60-44-47-83-259)300-247(397)200(130(22)34-3)328-245(395)197(127(18)19)324-223(373)160(73-78-193(349)350)297-219(369)158(71-76-191(345)346)296-222(372)162(80-89-406-31)298-231(381)170(97-140-102-276-147-56-40-38-54-144(140)147)310-237(387)175(109-332)313-208(358)146(260)100-194(351)352/h35-41,52-57,65-68,102-104,119-137,146,149-184,195-202,276-277,331-338H,32-34,42-51,58-64,69-101,105-118,257-260H2,1-31H3,(H2,261,339)(H2,262,340)(H,271,281)(H,278,359)(H,279,360)(H,280,393)(H,282,361)(H,283,376)(H,284,375)(H,285,386)(H,286,396)(H,287,341)(H,288,342)(H,289,343)(H,290,344)(H,291,353)(H,292,354)(H,293,363)(H,294,383)(H,295,362)(H,296,372)(H,297,369)(H,298,381)(H,299,394)(H,300,397)(H,301,399)(H,302,355)(H,303,356)(H,304,364)(H,305,368)(H,306,370)(H,307,388)(H,308,365)(H,309,377)(H,310,387)(H,311,390)(H,312,400)(H,313,358)(H,314,366)(H,315,371)(H,316,379)(H,317,382)(H,318,378)(H,319,367)(H,320,391)(H,321,398)(H,322,380)(H,323,385)(H,324,373)(H,325,384)(H,326,357)(H,327,374)(H,328,395)(H,329,389)(H,330,392)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,401,402)(H,403,404)(H4,263,264,272)(H4,265,266,273)(H4,267,268,274)(H4,269,270,275)/t128-,129-,130-,131-,132-,133-,134-,135-,136+,137+,146-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,195-,196-,197-,198-,199-,200-,201-,202-/m0/s1
DMXIRA0	CS	CC[C@H](C)[C@H]1C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C)[C@@H](C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]7CCC(=O)N7)[C@@H](C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC9=CNC1=CC=CC=C19)C(=O)N[C@@H](CO)C(=O)O
DMXIRA0	IK	DTLOVISJEFBXLX-REAFJZEQSA-N
DMXIRA0	IU	(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,80S,83S,88R)-6-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-88-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-4-methyl-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-68-(4-aminobutyl)-30-(3-amino-3-oxopropyl)-50-benzyl-33,39-bis[(2S)-butan-2-yl]-12,24,53,65-tetrakis(3-carbamimidamidopropyl)-15-(2-carboxyethyl)-42-[[2-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-2-oxoethyl]carbamoyl]-71-[(1R)-1-hydroxyethyl]-62-(hydroxymethyl)-83-(1H-imidazol-5-ylmethyl)-27,36,56-trimethyl-18,59-bis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,80-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-47-carboxylic acid
DMXIRA0	CA	CAS 99489-94-8
DMXIRA0	DE	Acute heart failure

DMOML9Q	ID	DMOML9Q
DMOML9Q	DN	Pancrecarb
DMOML9Q	HS	NDA filed
DMOML9Q	SN	Pancrelipase (Digestive Care)
DMOML9Q	CP	Digestive Care Inc
DMOML9Q	SQ	Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPPNENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGNAVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGLLDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAGSKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWGFVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWPRQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQPFTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGIKIYVSDDGKAHFSISNSAEDPFIAIHAESKL</sequence>    <sequence format="FASTA">&gt;Chymotrypsin BGVPAIHPVLSGLSRIVNGEDAVPGSWPWQVSLQDKTGFHFCGGSLISEDWVVTAAHCGVRTSDVVVAGEFDQGSDEENIQVLKIAKVFKNPKFSILTVNNDITLLKLATPARFSQTVSAVCLPSADDDFPAGTLCATTGWGKTKYNANKTPDKLQQAALPLLSNAECKKSWGRRITDVMICAGASGVSSCMGDSGGPLVCQKDGAWTLVGIVSWGSDTCSTSSPGVYARVTKLIPWVQKILAAN</sequence>    <sequence format="FASTA">&gt;pancreatic triacylglycerol lipaseMLPLWTLSLLLGAVAGKEVCYERLGCFSDDSPWSGITERPLHILPWSPKDVNTRFLLYTNENPNNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGEENWLANVCKNLFKVESVNCICVDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGRRTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGHLDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDGFAGFPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKVSVTLSGKKVTGHILVSLFGNKGNSKQYEIFKGTLKPDSTHSNEFDSDVDVGDLQMVKFIWYNNVINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC
DMOML9Q	DE	Pancreatic malfunction

DMF2O4T	ID	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	HS	Preregistration
DMF2O4T	SN	51543-39-6; esflurbiprofen; (S)-(+)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; UNII-J5ZZK9P7MX; (S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (S)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid; (2S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; J5ZZK9P7MX; CHEMBL435298; CHEBI:42446; SYTBZMRGLBWNTM-JTQLQIEISA-N; (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid; BTS-24332; (S)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (S)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic ac
DMF2O4T	CP	Taisho Pharmaceutical; TOKUHON
DMF2O4T	DT	Small molecular drug
DMF2O4T	PC	72099
DMF2O4T	MW	244.26
DMF2O4T	FM	C15H13FO2
DMF2O4T	IC	InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m0/s1
DMF2O4T	CS	C[C@@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
DMF2O4T	IK	SYTBZMRGLBWNTM-JTQLQIEISA-N
DMF2O4T	IU	(2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid
DMF2O4T	CA	CAS 51543-39-6
DMF2O4T	CB	CHEBI:42446
DMF2O4T	DE	Myalgia; Scapulohumeral periarthritis; Osteoarthritis

DMBRFUQ	ID	DMBRFUQ
DMBRFUQ	DN	B-cell lymphoma vaccine
DMBRFUQ	HS	Preregistration
DMBRFUQ	SN	BiovaxID (TN)
DMBRFUQ	CP	BioVest International
DMBRFUQ	DT	Vaccine
DMBRFUQ	DE	Follicular lymphoma

DMP5O1U	ID	DMP5O1U
DMP5O1U	DN	GSK2696273
DMP5O1U	HS	Preregistration
DMP5O1U	CP	Glaxosmithkline; molmed
DMP5O1U	DE	Chronic pain; Immunodeficiency

DMXSDJU	ID	DMXSDJU
DMXSDJU	DN	MPL-containing Pollinex allergy desensitization vaccine
DMXSDJU	HS	Preregistration
DMXSDJU	SN	Pollinex Quattro (ragweed allergy vaccine); Quattro MPL (ragweed allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (ragweed); Ragweed SC vaccine, Allergy Therapeutics/AllerPharma; MPL-containing Pollinex allergy desensitization vaccine (ragweed), AllergyTherapeutics/AllerPharma
DMXSDJU	CP	Allergy therapeutics
DMXSDJU	DT	Vaccine
DMXSDJU	DE	Allergy

DMLRKJX	ID	DMLRKJX
DMLRKJX	DN	Neugranin
DMLRKJX	HS	Preregistration
DMLRKJX	SN	Albugranin; CG-10639; Granulocyte colony stimulating factor (long-acting), CoGenesys; Granulocyte colony stimulating factor (long-acting), Teva Pharmaceutical; Long-acting G-CSF, HGS; Long-acting G-CSF, Teva Pharmaceutical; G-SCF (long-acting), CoGenesys
DMLRKJX	CP	Aventis Behring LLC
DMLRKJX	DE	Neutropenia

DMUY09W	ID	DMUY09W
DMUY09W	DN	SK-NBP601
DMUY09W	HS	Preregistration
DMUY09W	SN	NBP-601
DMUY09W	CP	SK Chemicals Co Ltd
DMUY09W	DE	Hemophilia

DM26I8H	ID	DM26I8H
DM26I8H	DN	TK-DLI
DM26I8H	HS	Preregistration
DM26I8H	SN	TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara
DM26I8H	CP	Molmed
DM26I8H	DE	Graft-versus-host disease

DMYA6TR	ID	DMYA6TR
DMYA6TR	DN	Human coagulation factor X
DMYA6TR	HS	BLA submitted
DMYA6TR	CP	Bio products laboratory
DMYA6TR	DE	Renal cell carcinoma

DMNCY1I	ID	DMNCY1I
DMNCY1I	DN	(-)-Phenserine
DMNCY1I	HS	Phase 3
DMNCY1I	SN	(-)-Phenserine; CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate
DMNCY1I	DT	Small molecular drug
DMNCY1I	PC	192706
DMNCY1I	MW	337.4
DMNCY1I	FM	C20H23N3O2
DMNCY1I	IC	InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m1/s1
DMNCY1I	CS	C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C
DMNCY1I	IK	PBHFNBQPZCRWQP-QUCCMNQESA-N
DMNCY1I	IU	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate
DMNCY1I	CA	CAS 101246-66-6
DMNCY1I	DE	Alzheimer disease

DMLRHM5	ID	DMLRHM5
DMLRHM5	DN	[3H](R)-(-)-baclofen
DMLRHM5	HS	Phase 3
DMLRHM5	SN	AC1OCG0F; ZB000014
DMLRHM5	DT	Small molecular drug
DMLRHM5	PC	44602
DMLRHM5	MW	213.66
DMLRHM5	FM	C10H12ClNO2
DMLRHM5	IC	InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/t8-/m0/s1
DMLRHM5	CS	C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl
DMLRHM5	IK	KPYSYYIEGFHWSV-QMMMGPOBSA-N
DMLRHM5	IU	(3R)-4-amino-3-(4-chlorophenyl)butanoic acid
DMLRHM5	CA	CAS 69308-37-8
DMLRHM5	DE	Multiple sclerosis

DM3YEV0	ID	DM3YEV0
DM3YEV0	DN	131I-labelled aCD45
DM3YEV0	HS	Phase 3
DM3YEV0	CP	Actinium Pharmaceuticals
DM3YEV0	DT	Radiopharmaceutical therapy agent
DM3YEV0	DE	Acute myeloid leukaemia

DMTZ1A5	ID	DMTZ1A5
DMTZ1A5	DN	13-cis-retinoic acid
DMTZ1A5	HS	Phase 3
DMTZ1A5	SN	CRA, UCSD
DMTZ1A5	CP	University of California San Diego
DMTZ1A5	DE	Glioma; Infertility; Azoospermia

DMP5L8S	ID	DMP5L8S
DMP5L8S	DN	177Lu-DOTA-octreotate
DMP5L8S	HS	Phase 3
DMP5L8S	SN	Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate
DMP5L8S	CP	Advanced accelerator applications
DMP5L8S	DE	Melanoma; Neuroendocrine cancer

DMQ0IZ6	ID	DMQ0IZ6
DMQ0IZ6	DN	177Lu-labelled PSMA-617
DMQ0IZ6	HS	Phase 3
DMQ0IZ6	CP	Novartis/Endocyte
DMQ0IZ6	DT	Radiopharmaceutical therapy agent
DMQ0IZ6	DE	Prostate cancer

DMMZS2T	ID	DMMZS2T
DMMZS2T	DN	177-Lu-oxodotreotide
DMMZS2T	HS	Phase 3
DMMZS2T	CP	Millburn
DMMZS2T	DT	Small molecular drug
DMMZS2T	DE	Neuroendocrine cancer

DMX178V	ID	DMX178V
DMX178V	DN	177-Lu-PSMA-617
DMX178V	HS	Phase 3
DMX178V	CP	Advanced Accelerator Applications
DMX178V	DT	Small molecular drug
DMX178V	DE	Prostate cancer

DME2A8X	ID	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	HS	Phase 3
DME2A8X	SN	5-MOP
DME2A8X	CP	Oclassen Pharmaceuticals Inc
DME2A8X	DT	Small molecular drug
DME2A8X	PC	2355
DME2A8X	MW	216.19
DME2A8X	FM	C12H8O4
DME2A8X	IC	InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3
DME2A8X	CS	COC1=C2C=CC(=O)OC2=CC3=C1C=CO3
DME2A8X	IK	BGEBZHIAGXMEMV-UHFFFAOYSA-N
DME2A8X	IU	4-methoxyfuro[3,2-g]chromen-7-one
DME2A8X	CA	CAS 484-20-8
DME2A8X	CB	CHEBI:18293
DME2A8X	DE	Psoriasis vulgaris

DM4OHMP	ID	DM4OHMP
DM4OHMP	DN	A-3309
DM4OHMP	HS	Phase 3
DM4OHMP	SN	Elobixibat; ALBI-3309; Ileal bile acid transporter inhibitors, AstraZeneca; ASBT inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitor (oral, chronic idiopathic constipation), Albireo; Apical sodium-dependent bile acid transporter inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitors (1,5-benzothiazepine derivatives), AstraZeneca
DM4OHMP	CP	AstraZeneca plc
DM4OHMP	DE	Lipid metabolism disorder

DMJNSLU	ID	DMJNSLU
DMJNSLU	DN	AAV2-hRPE65v2
DMJNSLU	HS	Phase 3
DMJNSLU	SN	RPE65 AAV gene therapy (Leber's congenital amaurosis), Children's Hospital of Philadelphia/Second University of Naples; RPE65 adeno-associated viral vector gene therapy (Leber's congenital amaurosis), Children's Hospital of Philadelphia/Second Univerity of Naples
DMJNSLU	CP	Childrens Hospital of Philadelphia
DMJNSLU	DE	Ocular disease

DMPDQ8T	ID	DMPDQ8T
DMPDQ8T	DN	AB-103
DMPDQ8T	HS	Phase 3
DMPDQ8T	SN	Superantigen toxin antagonist (iv/infusion, septic shock/toxic shock), Atox Bio/Hebrew University of Jerusalem
DMPDQ8T	CP	Atoxbio; fast-track drugs & biologics
DMPDQ8T	DT	Small molecular drug
DMPDQ8T	PC	16111
DMPDQ8T	MW	281.25
DMPDQ8T	FM	C12H16N3O3P
DMPDQ8T	IC	InChI=1S/C12H16N3O3P/c16-12(18-10-11-4-2-1-3-5-11)13-19(17,14-6-7-14)15-8-9-15/h1-5H,6-10H2,(H,13,16,17)
DMPDQ8T	CS	C1CN1P(=O)(NC(=O)OCC2=CC=CC=C2)N3CC3
DMPDQ8T	IK	VFIUCBTYGKMLCM-UHFFFAOYSA-N
DMPDQ8T	IU	benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate
DMPDQ8T	CA	CAS 1980-45-6
DMPDQ8T	DE	Necrotizing soft tissue infection

DMUES7Y	ID	DMUES7Y
DMUES7Y	DN	AB154
DMUES7Y	HS	Phase 3
DMUES7Y	SN	Domvanalimab
DMUES7Y	CP	Arcus Biosciences; Gilead Sciences
DMUES7Y	DT	Antibody
DMUES7Y	DE	Solid tumour/cancer; Non-small cell lung cancer

DMMWO7V	ID	DMMWO7V
DMMWO7V	DN	ABBV-951
DMMWO7V	HS	Phase 3
DMMWO7V	SN	Foslevodopa; UNII-37NQZ0J76I; 37NQZ0J76I; 3-hydroxy-O-phosphono-L-tyrosine; 101141-95-1; 97321-87-4; Dopa 4-phosphate; Levodopa-4'-monophosphate; 3-Hydroxy-O-phosphonotyrosine; Foslevodopa (JAN/USAN/INN); CHEMBL4594379; SCHEMBL17685899; DTXSID70905957; HY-109132; CS-0086774; D11839; (S)-2-amino-3-(3-hydroxy-4-(phosphonooxy)phenyl)propanoic acid
DMMWO7V	CP	AbbVie
DMMWO7V	DT	Small molecular drug
DMMWO7V	PC	127766
DMMWO7V	MW	277.17
DMMWO7V	FM	C9H12NO7P
DMMWO7V	IC	InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1
DMMWO7V	CS	C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O
DMMWO7V	IK	YNDMEEULGSTYJT-LURJTMIESA-N
DMMWO7V	IU	(2S)-2-amino-3-(3-hydroxy-4-phosphonooxyphenyl)propanoic acid
DMMWO7V	CA	CAS 97321-87-4
DMMWO7V	DE	Parkinson disease

DMCKPG4	ID	DMCKPG4
DMCKPG4	DN	ABC294640
DMCKPG4	HS	Phase 3
DMCKPG4	SN	ABC294640; 915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8; ABC294640; 915385-81-8; ABC-294640
DMCKPG4	CP	Apogee Biotechnology
DMCKPG4	DT	Small molecular drug
DMCKPG4	PC	15604015
DMCKPG4	MW	380.9
DMCKPG4	FM	C23H25ClN2O
DMCKPG4	IC	InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)
DMCKPG4	CS	C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl
DMCKPG4	IK	CAOTVXGYTWCKQE-UHFFFAOYSA-N
DMCKPG4	IU	3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
DMCKPG4	CA	CAS 915385-81-8
DMCKPG4	CB	CHEBI:124965
DMCKPG4	DE	Advanced solid tumour; Hepatocellular carcinoma; Cholangiocarcinoma; Multiple myeloma

DM91LGU	ID	DM91LGU
DM91LGU	DN	Abexinostat
DM91LGU	HS	Phase 3
DM91LGU	SN	PCI-24781; 783355-60-2; ABEXINOSTAT; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide
DM91LGU	CP	Pharmacyclics
DM91LGU	DT	Small molecular drug
DM91LGU	PC	11749858
DM91LGU	MW	397.4
DM91LGU	FM	C21H23N3O5
DM91LGU	IC	InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)
DM91LGU	CS	CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO
DM91LGU	IK	MAUCONCHVWBMHK-UHFFFAOYSA-N
DM91LGU	IU	3-[(dimethylamino)methyl]-N-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide
DM91LGU	CA	CAS 783355-60-2
DM91LGU	CB	CHEBI:92223
DM91LGU	DE	Acute myeloid leukaemia; Breast cancer; Diffuse large B-cell lymphoma; Follicular lymphoma; Gynecologic cancer; Peripheral T-cell lymphoma; Solid tumour/cancer; Renal cell carcinoma

DMMF5K4	ID	DMMF5K4
DMMF5K4	DN	ABL 001
DMMF5K4	HS	Phase 3
DMMF5K4	CP	Novartis pharmaceuticals
DMMF5K4	DE	leukaemia; Chronic myeloid leukaemia; Promyelocytic leukaemia

DM7EVUF	ID	DM7EVUF
DM7EVUF	DN	ABL001
DM7EVUF	HS	Phase 3
DM7EVUF	SN	asciminib; ABL-001; 1492952-76-7; Asciminib free base; ABL001-NX; UNII-L1F3R18W77; L1F3R18W77; NVP-ABL001; (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; 1492952-76-7 (free base); N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide; Asciminib [USAN]; Asciminib (ABL001); Asciminib (USAN/INN); GTPL8962; CHEMBL4208229; SCHEMBL15388306; TQP0925; EX-A3030; BDBM50459091; NSC789925; s8555; ZINC150275965; CCG-269232; CS-7655; DB12597; NSC-789925; SB18878; BS-15538; HY-104010; D11403; Q27074535; (R)-N-(4-(Chloro difluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; AY7
DM7EVUF	CP	Novartis
DM7EVUF	DT	Small molecular drug
DM7EVUF	PC	72165228
DM7EVUF	MW	449.8
DM7EVUF	FM	C20H18ClF2N5O3
DM7EVUF	IC	InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1
DM7EVUF	CS	C1CN(C[C@@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4
DM7EVUF	IK	VOVZXURTCKPRDQ-CQSZACIVSA-N
DM7EVUF	IU	N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
DM7EVUF	CA	CAS 1492952-76-7
DM7EVUF	DE	Chronic myeloid leukaemia

DM2J4YB	ID	DM2J4YB
DM2J4YB	DN	ABP 501
DM2J4YB	HS	Phase 3
DM2J4YB	CP	Amgen
DM2J4YB	DT	Antibody
DM2J4YB	DE	Rheumatoid arthritis; Plaque psoriasis

DMDXE4I	ID	DMDXE4I
DMDXE4I	DN	ABP959
DMDXE4I	HS	Phase 3
DMDXE4I	CP	Amgen
DMDXE4I	DT	Small molecular drug
DMDXE4I	DE	Paroxysmal nocturnal haemoglobinuria

DMNE56X	ID	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	HS	Phase 3
DMNE56X	SN	Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide
DMNE56X	CP	Roche; Genentech
DMNE56X	DT	Small molecular drug
DMNE56X	PC	24978538
DMNE56X	MW	974.6
DMNE56X	FM	C47H55ClF3N5O6S3
DMNE56X	IC	InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1
DMNE56X	CS	CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
DMNE56X	IK	JLYAXFNOILIKPP-KXQOOQHDSA-N
DMNE56X	IU	4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
DMNE56X	CA	CAS 923564-51-6
DMNE56X	CB	CHEBI:94128
DMNE56X	DE	Relapsed or refractory chronic lymphocytic leukaemia; Solid tumour/cancer; Myelofibrosis

DMNQ869	ID	DMNQ869
DMNQ869	DN	ABT-267
DMNQ869	HS	Phase 3
DMNQ869	SN	HCV therapeutic, Abbott
DMNQ869	CP	Abbott Laboratories
DMNQ869	DT	Small molecular drug
DMNQ869	PC	54767916
DMNQ869	MW	894.1
DMNQ869	FM	C50H67N7O8
DMNQ869	IC	InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
DMNQ869	CS	CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMNQ869	IK	PIDFDZJZLOTZTM-KHVQSSSXSA-N
DMNQ869	IU	methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMNQ869	CA	CAS 1258226-87-7
DMNQ869	CB	CHEBI:85183
DMNQ869	DE	Hepatitis C virus infection

DMJFD2I	ID	DMJFD2I
DMJFD2I	DN	ABT-492
DMJFD2I	HS	Phase 3
DMJFD2I	SN	Delafloxacin; 189279-58-1; ABT-492; WQ-3034; Abt 492; 1-(6-AMINO-3,5-DIFLUOROPYRIDIN-2-YL)-8-CHLORO-6-FLUORO-7-(3-HYDROXYAZETIDIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; ABT492; RX-3341; UNII-6315412YVF; 6315412YVF; 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-quinoline-3-carboxylic acid; 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid; Delafloxacin [USAN:INN]; Delafloxacinum; Delafloxacin (USAN)
DMJFD2I	DT	Small molecular drug
DMJFD2I	PC	487101
DMJFD2I	MW	440.8
DMJFD2I	FM	C18H12ClF3N4O4
DMJFD2I	IC	InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)
DMJFD2I	CS	C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O
DMJFD2I	IK	DYDCPNMLZGFQTM-UHFFFAOYSA-N
DMJFD2I	IU	1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMJFD2I	CA	CAS 189279-58-1
DMJFD2I	DE	Bacterial infection

DM3FIC2	ID	DM3FIC2
DM3FIC2	DN	ABT-761
DM3FIC2	HS	Phase 3
DM3FIC2	SN	Atreleuton; Atreleuton [USAN]; ABT 761; A-85761; Atreleuton (USAN/INN); 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DM3FIC2	CP	Abbott Laboratories
DM3FIC2	DT	Small molecular drug
DM3FIC2	PC	3086671
DM3FIC2	MW	318.4
DM3FIC2	FM	C16H15FN2O2S
DM3FIC2	IC	InChI=1S/C16H15FN2O2S/c1-11(19(21)16(18)20)2-7-14-8-9-15(22-14)10-12-3-5-13(17)6-4-12/h3-6,8-9,11,21H,10H2,1H3,(H2,18,20)/t11-/m1/s1
DM3FIC2	CS	C[C@H](C#CC1=CC=C(S1)CC2=CC=C(C=C2)F)N(C(=O)N)O
DM3FIC2	IK	MMSNEKOTSJRTRI-LLVKDONJSA-N
DM3FIC2	IU	1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DM3FIC2	CA	CAS 154355-76-7
DM3FIC2	DE	Asthma

DMREDYP	ID	DMREDYP
DMREDYP	DN	ABT-869
DMREDYP	HS	Phase 3
DMREDYP	SN	Linifanib; ABT 869; S1003_Selleck; AL-39324; RG-3635; ABT869, Linifanib, AL-39324, RG3635; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea
DMREDYP	CP	Abbott Laboratories
DMREDYP	TC	Anticancer Agents
DMREDYP	DT	Small molecular drug
DMREDYP	PC	11485656
DMREDYP	MW	375.4
DMREDYP	FM	C21H18FN5O
DMREDYP	IC	InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
DMREDYP	CS	CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N
DMREDYP	IK	MPVGZUGXCQEXTM-UHFFFAOYSA-N
DMREDYP	IU	1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea
DMREDYP	CA	CAS 796967-16-3
DMREDYP	CB	CHEBI:91435
DMREDYP	DE	Solid tumour/cancer

DMYHSO2	ID	DMYHSO2
DMYHSO2	DN	ABT-874
DMYHSO2	HS	Phase 3
DMYHSO2	CP	Abbott; Astra Zeneca
DMYHSO2	DE	Crohn disease; Rheumatoid arthritis; Plaque psoriasis

DM4HYMS	ID	DM4HYMS
DM4HYMS	DN	ABT-888
DM4HYMS	HS	Phase 3
DM4HYMS	SN	Veliparib; 912444-00-9; ABT-888; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride
DM4HYMS	DT	Small molecular drug
DM4HYMS	PC	45480520
DM4HYMS	MW	317.21
DM4HYMS	FM	C13H18Cl2N4O
DM4HYMS	IC	InChI=1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1
DM4HYMS	CS	C[C@@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl
DM4HYMS	IK	DSBSVDCHFMEYBX-FFXKMJQXSA-N
DM4HYMS	IU	2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide;dihydrochloride
DM4HYMS	CA	CAS 912445-05-7
DM4HYMS	DE	Breast cancer; Epithelial ovarian cancer; Melanoma; Ovarian cancer; Non-small-cell lung cancer

DMQRL2Y	ID	DMQRL2Y
DMQRL2Y	DN	AC0010
DMQRL2Y	HS	Phase 3
DMQRL2Y	SN	Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-
DMQRL2Y	CP	ACEA BiosciencesSan Diego, CA
DMQRL2Y	PC	72734520
DMQRL2Y	MW	487.5
DMQRL2Y	FM	C26H26FN7O2
DMQRL2Y	IC	InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
DMQRL2Y	CS	CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F
DMQRL2Y	IK	UOFYSRZSLXWIQB-UHFFFAOYSA-N
DMQRL2Y	IU	N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide
DMQRL2Y	CA	CAS 1557267-42-1
DMQRL2Y	DE	Non-small-cell lung cancer

DMXZ9T3	ID	DMXZ9T3
DMXZ9T3	DN	AC-170
DMXZ9T3	HS	Phase 3
DMXZ9T3	SN	88139-91-7; 5-Bromo-2-hydroxymethylpyridine; (5-Bromopyridin-2-yl)methanol; 2-hydroxymethyl-5-bromopyridine; 5-Bromo-2-(hydroxymethyl)pyridine; (5-bromopyrid-2-yl)methanol; 5-Bromo-2-pyridinemethanol; (5-Bromo-pyridin-2-yl)-methanol; 2-PYRIDINEMETHANOL, 5-BROMO-; 5-BROMOPYRIDINE-2-METHANOL; (5-bromo-2-pyridyl)methanol; (5-bromo-2-pyridyl)methan-1-ol; AC-170; (5-Bromo-pyridin-2-yl)methanol (5-Bromo-2-hydroxymethylpyridine); zlchem 391; PubChem7710; PubChem12387; ACMC-209qrb; AC1NP90H; 5-bromo-2-pyridine methanol; KSC494K9D
DMXZ9T3	CP	Aciex Therapeutics Inc
DMXZ9T3	DT	Small molecular drug
DMXZ9T3	PC	5200169
DMXZ9T3	MW	188.02
DMXZ9T3	FM	C6H6BrNO
DMXZ9T3	IC	InChI=1S/C6H6BrNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2
DMXZ9T3	CS	C1=CC(=NC=C1Br)CO
DMXZ9T3	IK	RUCZFWMEACWFER-UHFFFAOYSA-N
DMXZ9T3	IU	(5-bromopyridin-2-yl)methanol
DMXZ9T3	CA	CAS 88139-91-7
DMXZ9T3	DE	Allergic conjunctivitis

DM8Y4JS	ID	DM8Y4JS
DM8Y4JS	DN	AC220
DM8Y4JS	HS	Phase 3
DM8Y4JS	SN	Quizartinib
DM8Y4JS	CP	Ambit Biosciences; Astellas Pharma US
DM8Y4JS	DT	Small molecular drug
DM8Y4JS	PC	24889392
DM8Y4JS	MW	560.7
DM8Y4JS	FM	C29H32N6O4S
DM8Y4JS	IC	InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
DM8Y4JS	CS	CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3
DM8Y4JS	IK	CVWXJKQAOSCOAB-UHFFFAOYSA-N
DM8Y4JS	IU	1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
DM8Y4JS	CA	CAS 950769-58-1
DM8Y4JS	CB	CHEBI:90217
DM8Y4JS	DE	leukaemia; Acute myeloid leukaemia

DM1RMF5	ID	DM1RMF5
DM1RMF5	DN	Acadesine
DM1RMF5	HS	Phase 3
DM1RMF5	SN	AICAR; Acadra; ADV-P1; ATH-001; Acadesine (intravenous formulation, leukemia); Acadesine (intravenous formulation, leukemia), Advanced In Vitro Cell Technologies
DM1RMF5	CP	Schering-Plough
DM1RMF5	DT	Small molecular drug
DM1RMF5	PC	17513
DM1RMF5	MW	258.23
DM1RMF5	FM	C9H14N4O5
DM1RMF5	IC	InChI=1S/C9H14N4O5/c10-7-4(8(11)17)12-2-13(7)9-6(16)5(15)3(1-14)18-9/h2-3,5-6,9,14-16H,1,10H2,(H2,11,17)/t3-,5-,6-,9-/m1/s1
DM1RMF5	CS	C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N
DM1RMF5	IK	RTRQQBHATOEIAF-UUOKFMHZSA-N
DM1RMF5	IU	5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide
DM1RMF5	CA	CAS 2627-69-2
DM1RMF5	CB	CHEBI:28498
DM1RMF5	DE	Diabetic complication

DMY96O3	ID	DMY96O3
DMY96O3	DN	acelarin
DMY96O3	HS	Phase 3
DMY96O3	SN	NUC-1031
DMY96O3	DT	Small molecular drug
DMY96O3	PC	11169170
DMY96O3	MW	580.5
DMY96O3	FM	C25H27F2N4O8P
DMY96O3	IC	InChI=1S/C25H27F2N4O8P/c1-16(22(33)36-14-17-8-4-2-5-9-17)30-40(35,39-18-10-6-3-7-11-18)37-15-19-21(32)25(26,27)23(38-19)31-13-12-20(28)29-24(31)34/h2-13,16,19,21,23,32H,14-15H2,1H3,(H,30,35)(H2,28,29,34)/t16-,19+,21+,23+,40?/m0/s1
DMY96O3	CS	C[C@@H](C(=O)OCC1=CC=CC=C1)NP(=O)(OC[C@@H]2[C@H](C([C@@H](O2)N3C=CC(=NC3=O)N)(F)F)O)OC4=CC=CC=C4
DMY96O3	IK	NHTKGYOMICWFQZ-KKQYNPQSSA-N
DMY96O3	IU	benzyl (2S)-2-[[[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMY96O3	CA	CAS 840506-29-8
DMY96O3	DE	Alzheimer disease; Ovarian cancer; Biliary tract cancer

DM3UQ9K	ID	DM3UQ9K
DM3UQ9K	DN	Acolbifene
DM3UQ9K	HS	Phase 3
DM3UQ9K	SN	Acolbifene; EM-652; 182167-02-8; UNII-815LJ9X0D1; 815LJ9X0D1; EM 652; Acolbifene [INN:BAN]; SCH 57068; AC1L4EAA; SCHEMBL406183; CHEMBL68055; CTK4F5320; SCH-57068; HY-16023A; ( )-(2S)-3-(4-Hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-1-benzopyran-7-ol; CS-0007143; (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol; (S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-chromen-7-ol
DM3UQ9K	CP	EndoCeutics
DM3UQ9K	DT	Small molecular drug
DM3UQ9K	PC	155435
DM3UQ9K	MW	457.6
DM3UQ9K	FM	C29H31NO4
DM3UQ9K	IC	InChI=1S/C29H31NO4/c1-20-26-14-11-24(32)19-27(26)34-29(28(20)21-5-9-23(31)10-6-21)22-7-12-25(13-8-22)33-18-17-30-15-3-2-4-16-30/h5-14,19,29,31-32H,2-4,15-18H2,1H3/t29-/m0/s1
DM3UQ9K	CS	CC1=C([C@@H](OC2=C1C=CC(=C2)O)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
DM3UQ9K	IK	DUYNJNWVGIWJRI-LJAQVGFWSA-N
DM3UQ9K	IU	(2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol
DM3UQ9K	CA	CAS 182167-02-8
DM3UQ9K	DE	Breast cancer

DMXYRPO	ID	DMXYRPO
DMXYRPO	DN	Act1
DMXYRPO	HS	Phase 3
DMXYRPO	SN	51-34-3; UNII-DL48G20X8X; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; DL48G20X8X; CHEBI:16794
DMXYRPO	DT	Small molecular drug
DMXYRPO	DE	Wound healing

DMVLWG7	ID	DMVLWG7
DMVLWG7	DN	Ad5FGF-4
DMVLWG7	HS	Phase 3
DMVLWG7	DE	Angina pectoris

DMFIP35	ID	DMFIP35
DMFIP35	DN	Adhexil
DMFIP35	HS	Phase 3
DMFIP35	CP	OMRIX Biopharmaceuticals SA
DMFIP35	DE	Injury

DMLBYRA	ID	DMLBYRA
DMLBYRA	DN	ADX N05
DMLBYRA	HS	Phase 3
DMLBYRA	CP	Aerial BioPharma
DMLBYRA	DE	Excessive daytime sleepiness; Mood disorder

DMAYO46	ID	DMAYO46
DMAYO46	DN	AEZS-108
DMAYO46	HS	Phase 3
DMAYO46	SN	Zoptarelin doxorubicin; AEZS-108; AN-152; UNII-27844X2J29; ZEN-008; 27844X2J29; Zoptrex; Zoptarelin doxorubicin [INN]; Zoptarelin doxorubicin [USAN]; AEZS 108; CHEMBL3544954; AN 152; Luteinizing hormone-releasing factor (pig), 6-(N6-(5-(2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethoxy)-1,5-dioxopentyl)-D-lysine)-, (2S-cis)-
DMAYO46	CP	AEterna Zentaris
DMAYO46	DT	Small molecular drug
DMAYO46	PC	16134409
DMAYO46	MW	1893
DMAYO46	FM	C91H117N19O26
DMAYO46	IC	InChI=1S/C91H117N19O26/c1-44(2)31-58(83(125)104-57(17-11-29-98-90(94)95)89(131)110-30-12-18-63(110)88(130)100-40-67(93)114)105-81(123)55(16-7-8-28-97-68(115)20-10-21-70(117)134-42-66(113)91(132)36-52-73(65(37-91)136-71-35-53(92)76(118)45(3)135-71)80(122)75-74(78(52)120)77(119)51-14-9-19-64(133-4)72(51)79(75)121)103-84(126)59(32-46-22-24-49(112)25-23-46)106-87(129)62(41-111)109-85(127)60(33-47-38-99-54-15-6-5-13-50(47)54)107-86(128)61(34-48-39-96-43-101-48)108-82(124)56-26-27-69(116)102-56/h5-6,9,13-15,19,22-25,38-39,43-45,53,55-63,65,71,76,99,111-112,118,120,122,132H,7-8,10-12,16-18,20-21,26-37,40-42,92H2,1-4H3,(H2,93,114)(H,96,101)(H,97,115)(H,100,130)(H,102,116)(H,103,126)(H,104,125)(H,105,123)(H,106,129)(H,107,128)(H,108,124)(H,109,127)(H4,94,95,98)/t45-,53-,55+,56-,57-,58-,59-,60-,61-,62-,63-,65-,71-,76+,91-/m0/s1
DMAYO46	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)NCC(=O)N)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)O)N)O
DMAYO46	IK	OOUACICUAVTCEC-LZHWUUGESA-N
DMAYO46	IU	[2-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 5-[[(5R)-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]amino]-5-oxopentanoate
DMAYO46	CA	CAS 139570-93-7
DMAYO46	DE	Acute lymphoblastic leukaemia

DMS0ZBI	ID	DMS0ZBI
DMS0ZBI	DN	Ag-221
DMS0ZBI	HS	Phase 3
DMS0ZBI	SN	AG-221 (IDH2 inhibitor)
DMS0ZBI	CP	Agios pharmaceuticals; celgene
DMS0ZBI	PC	89683805
DMS0ZBI	MW	473.4
DMS0ZBI	FM	C19H17F6N7O
DMS0ZBI	IC	InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)
DMS0ZBI	CS	CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O
DMS0ZBI	IK	DYLUUSLLRIQKOE-UHFFFAOYSA-N
DMS0ZBI	IU	2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DMS0ZBI	CA	CAS 1446502-11-9
DMS0ZBI	CB	CHEBI:145374
DMS0ZBI	DE	Acute myeloid leukaemia; Acute myelogenous leukaemia

DMIE1WY	ID	DMIE1WY
DMIE1WY	DN	AG-881
DMIE1WY	HS	Phase 3
DMIE1WY	SN	Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop
DMIE1WY	CP	Agios Pharmaceuticals Cambridge, MA Celgene Summit, NJ
DMIE1WY	PC	117817422
DMIE1WY	MW	414.74
DMIE1WY	FM	C14H13ClF6N6
DMIE1WY	IC	InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1
DMIE1WY	CS	C[C@H](C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)N[C@H](C)C(F)(F)F
DMIE1WY	IK	QCZAWDGAVJMPTA-RNFRBKRXSA-N
DMIE1WY	IU	6-(6-chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine
DMIE1WY	CA	CAS 1644545-52-7
DMIE1WY	DE	Acute myeloid leukaemia; Glioma

DMYN3IH	ID	DMYN3IH
DMYN3IH	DN	AGI-1067
DMYN3IH	HS	Phase 3
DMYN3IH	SN	AGZ-1067; Succinic acid 2,6-di-tert-butyl-4-[1-(3,5-di-tert-butyl-4-hydroxyphenylsulfanyl)-1-methylethylsulfanyl]phenyl monoester
DMYN3IH	CP	AtheroGenics
DMYN3IH	DT	Small molecular drug
DMYN3IH	PC	216325
DMYN3IH	MW	616.9
DMYN3IH	FM	C35H52O5S2
DMYN3IH	IC	InChI=1S/C35H52O5S2/c1-31(2,3)23-17-21(18-24(29(23)39)32(4,5)6)41-35(13,14)42-22-19-25(33(7,8)9)30(26(20-22)34(10,11)12)40-28(38)16-15-27(36)37/h17-20,39H,15-16H2,1-14H3,(H,36,37)
DMYN3IH	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)OC(=O)CCC(=O)O)C(C)(C)C
DMYN3IH	IK	RKSMVPNZHBRNNS-UHFFFAOYSA-N
DMYN3IH	IU	4-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]-4-oxobutanoic acid
DMYN3IH	CA	CAS 216167-82-7
DMYN3IH	DE	Artery stenosis

DMJRQDG	ID	DMJRQDG
DMJRQDG	DN	AG-SPT201
DMJRQDG	HS	Phase 3
DMJRQDG	SN	SPT201; S-pantoprazole sodium trihydrate (ulcer), Ahn-Gook; (S)-pantoprazole sodium trihydrate
DMJRQDG	CP	Ahn-Gook Pharmaceuticals Co Ltd
DMJRQDG	DE	Ulcerative colitis

DMS2WV3	ID	DMS2WV3
DMS2WV3	DN	AIDSVAX
DMS2WV3	HS	Phase 3
DMS2WV3	SN	AIDSVAX B/B; AIDSVAX B/E; Bivalent gp120 HIV vaccines, GSID; Bivalent gp120 HIV vaccines, Global Solutions for Infectious Diseases; Bivalent gp120 HIV vaccines, VaxGen
DMS2WV3	CP	DiaDexus Inc
DMS2WV3	DT	Vaccine
DMS2WV3	DE	Human immunodeficiency virus infection

DM8SYTE	ID	DM8SYTE
DM8SYTE	DN	AIR-insulin
DM8SYTE	HS	Phase 3
DM8SYTE	SN	HIIP
DM8SYTE	CP	Alkermes
DM8SYTE	DE	Diabetic complication

DM5K6J4	ID	DM5K6J4
DM5K6J4	DN	AJM-300
DM5K6J4	HS	Phase 3
DM5K6J4	SN	Alpha-4 integrin antagonist (inflammatory bowel disease), Ajinomoto
DM5K6J4	CP	Ajinomoto Co Inc
DM5K6J4	DE	Crohn disease; Ulcerative colitis

DM2EJM3	ID	DM2EJM3
DM2EJM3	DN	AKB-6548
DM2EJM3	HS	Phase 3
DM2EJM3	CP	Akebia therapeutics
DM2EJM3	PC	23634441
DM2EJM3	MW	306.7
DM2EJM3	FM	C14H11ClN2O4
DM2EJM3	IC	InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
DM2EJM3	CS	C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
DM2EJM3	IK	JGRXMPYUTJLTKT-UHFFFAOYSA-N
DM2EJM3	IU	2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
DM2EJM3	CA	CAS 1000025-07-9
DM2EJM3	DE	Anaemia

DM3WP0N	ID	DM3WP0N
DM3WP0N	DN	Al3818
DM3WP0N	HS	Phase 3
DM3WP0N	SN	Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-
DM3WP0N	CP	Advenchen Laboratories Moorpark, CA
DM3WP0N	PC	25017411
DM3WP0N	MW	407.4
DM3WP0N	FM	C23H22FN3O3
DM3WP0N	IC	InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
DM3WP0N	CS	CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
DM3WP0N	IK	KSMZEXLVHXZPEF-UHFFFAOYSA-N
DM3WP0N	IU	1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine
DM3WP0N	CA	CAS 1058156-90-3
DM3WP0N	DE	Alveolar soft part sarcoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cavity cancer; Synovial sarcoma

DMK0QW6	ID	DMK0QW6
DMK0QW6	DN	Albinterferon alfa-2b
DMK0QW6	HS	Phase 3
DMK0QW6	SN	Albuferon; Joulferon; Zalbin; ABF-656; Albuferon-alpha; Interferon alpha-albumin fusion protein, HGS; Albumin-based fusion protein (viral disease), Principia; Interferon alpha-albumin fusion protein, HGS/Novartis
DMK0QW6	CP	Human Genome Sciences
DMK0QW6	DE	Hepatitis C virus infection

DMWAL73	ID	DMWAL73
DMWAL73	DN	Albutropin
DMWAL73	HS	Phase 3
DMWAL73	SN	Albumin-based fusion protein (growth deficiency), Teva Pharmaceutical; Recombinant human growth hormone (HGH, long acting),Human Genome Sciences; Albumin-based fusion protein (growth deficiency), Principia (HGS); Recombinant human growth hormone (HGH, long-acting), Teva Pharmaceutical
DMWAL73	CP	Aventis Behring LLC
DMWAL73	DE	Growth failure

DMHKCIS	ID	DMHKCIS
DMHKCIS	DN	Aldoxorubicin
DMHKCIS	HS	Phase 3
DMHKCIS	SN	1361644-26-9; ALDOXORUBICIN; Doxorubicin-EMCH; 151038-96-9; Aldoxorubicin (USAN); CHEMBL2107818; SCHEMBL15221892; OBMJQRLIQQTJLR-LBMCFUDOSA-N; ZINC163337436; AKOS030526452; CS-1186; HY-16261; D10383; W-5595; (8S)-1-Methoxy-6,8alpha,11-trihydroxy-8-[1-[2-[6-(2,5-dioxo-3-pyrroline-1-yl)hexanoyl]hydrazono]-2-hydroxyethyl]-10alpha-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydronaphthacene-5,12-dione
DMHKCIS	CP	CytRx, Los Angeles, CA
DMHKCIS	PC	9810709
DMHKCIS	MW	750.7
DMHKCIS	FM	C37H42N4O13
DMHKCIS	IC	InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/b39-23+/t17-,20-,22-,27-,32+,37-/m0/s1
DMHKCIS	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O
DMHKCIS	IK	OBMJQRLIQQTJLR-USGQOSEYSA-N
DMHKCIS	IU	N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
DMHKCIS	CA	CAS 1361644-26-9
DMHKCIS	DE	Soft tissue sarcoma; Pancreatic ductal carcinoma; Glioblastoma multiforme; Small-cell lung cancer; Solid tumour/cancer

DMPH1RK	ID	DMPH1RK
DMPH1RK	DN	Alferminogene tadenovec
DMPH1RK	HS	Phase 3
DMPH1RK	SN	Generx (TN)
DMPH1RK	CP	Cardium Therapeutics
DMPH1RK	DE	Heart disease; Angina pectoris

DMVHRL8	ID	DMVHRL8
DMVHRL8	DN	Alfimeprase
DMVHRL8	HS	Phase 3
DMVHRL8	SN	Thrombolytic fibrolase derivative (cardiovascular diseases), Nuvelo; Thrombolytic fibrolase derivative (cerebrovascular ischemia), Nuvelo; Thrombolytic fibrolase derivative (peripheral arterial occlusive diseases), Nuvelo
DMVHRL8	CP	Nuvelo
DMVHRL8	SQ	Alfimeprase Sequence: SFPQRYVQLVIVADHRMNTKYNGDSDKIRQWVHQIVNTINEIYRPLNIQFTLVGLEIWSNQDLITVTSVSHDTLASFGNWRETDLLRRQRHDNAQLLTAIDFDGDTVGLAYVGGMCQLKHSTGVIQDHSAINLLVALTMAHELGHNLGMNHDGNQCHCGANSCVMAAMLSDQPSKLFSDCSKKDYQTFLTVNNPQCILNKP
DMVHRL8	DE	Peripheral vascular disease

DMBQK0X	ID	DMBQK0X
DMBQK0X	DN	Algenpantucel-L
DMBQK0X	HS	Phase 3
DMBQK0X	SN	HyperAcute pancreas (TN)
DMBQK0X	CP	NewLink Genetics
DMBQK0X	DT	Vaccine
DMBQK0X	DE	Pancreatic cancer

DMQ509J	ID	DMQ509J
DMQ509J	DN	Alicaforsen
DMQ509J	HS	Phase 3
DMQ509J	SN	Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)
DMQ509J	CP	ISIS & Atlantic Healthcare
DMQ509J	TC	Antisense
DMQ509J	DT	Antisense drug
DMQ509J	PC	16197725
DMQ509J	MW	6349
DMQ509J	FM	C192H225N75O98P19S19-19
DMQ509J	IC	InChI=1S/C192H244N75O98P19S19/c1-76-40-256(190(286)245-169(76)270)136-30-89(357-376(299,395)314-50-106-84(25-131(334-106)251-15-7-122(196)230-185(251)281)351-370(293,389)312-49-105-87(28-134(333-105)254-18-10-125(199)233-188(254)284)355-374(297,393)323-59-115-97(38-145(343-115)266-74-225-154-167(266)238-180(208)243-175(154)276)364-381(304,400)319-55-111-90(31-137(339-111)257-41-77(2)170(271)246-191(257)287)356-375(298,394)313-46-102-81(22-128(330-102)248-12-4-119(193)227-182(248)278)348-366(289,385)308-44-100-79(269)20-127(328-100)259-67-218-147-156(201)210-63-214-160(147)259)110(338-136)54-318-380(303,399)359-92-33-139(260-68-219-148-157(202)211-64-215-161(148)260)340-112(92)56-320-373(296,392)354-88-29-135(255-19-11-126(200)234-189(255)285)336-108(88)52-316-379(302,398)363-96-37-144(265-73-224-153-166(265)237-179(207)242-174(153)275)346-118(96)62-326-384(307,403)365-98-39-146(267-75-226-155-168(267)239-181(209)244-176(155)277)344-116(98)60-324-377(300,396)358-91-32-138(258-42-78(3)171(272)247-192(258)288)337-109(91)53-317-371(294,390)352-85-26-132(252-16-8-123(197)231-186(252)282)335-107(85)51-315-378(301,397)362-95-36-143(264-72-223-152-165(264)236-178(206)241-173(152)274)345-117(95)61-325-383(306,402)361-94-35-141(262-70-221-150-159(204)213-66-217-163(150)262)342-114(94)58-322-382(305,401)360-93-34-140(261-69-220-149-158(203)212-65-216-162(149)261)341-113(93)57-321-372(295,391)353-86-27-133(253-17-9-124(198)232-187(253)283)332-104(86)48-311-369(292,388)350-83-24-130(250-14-6-121(195)229-184(250)280)331-103(83)47-310-368(291,387)349-82-23-129(249-13-5-120(194)228-183(249)279)329-101(82)45-309-367(290,386)347-80-21-142(327-99(80)43-268)263-71-222-151-164(263)235-177(205)240-172(151)273/h4-19,40-42,63-75,79-118,127-146,268-269H,20-39,43-62H2,1-3H3,(H,289,385)(H,290,386)(H,291,387)(H,292,388)(H,293,389)(H,294,390)(H,295,391)(H,296,392)(H,297,393)(H,298,394)(H,299,395)(H,300,396)(H,301,397)(H,302,398)(H,303,399)(H,304,400)(H,305,401)(H,306,402)(H,307,403)(H2,193,227,278)(H2,194,228,279)(H2,195,229,280)(H2,196,230,281)(H2,197,231,282)(H2,198,232,283)(H2,199,233,284)(H2,200,234,285)(H2,201,210,214)(H2,202,211,215)(H2,203,212,216)(H2,204,213,217)(H,245,270,286)(H,246,271,287)(H,247,272,288)(H3,205,235,240,273)(H3,206,236,241,274)(H3,207,237,242,275)(H3,208,238,243,276)(H3,209,239,244,277)/p-19/t79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,366?,367?,368?,369?,370?,371?,372?,373?,374?,375?,376?,377?,378?,379?,380?,381?,382?,383?,384?/m0/s1
DMQ509J	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=S)([O-])O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)O
DMQ509J	IK	ZMJWRJKGPUDEOX-LMXUULCNSA-A
DMQ509J	IU	1-[(2R,4S,5R)-4-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMQ509J	CA	CAS 185229-68-9
DMQ509J	DE	Ulcerative colitis; Crohn disease; Lleum inflammation

DM9R2SD	ID	DM9R2SD
DM9R2SD	DN	Alilusem
DM9R2SD	HS	Phase 3
DM9R2SD	SN	M-12285; M-17000; M-17055; MD-31
DM9R2SD	CP	Mochida Pharmaceutical Co Ltd
DM9R2SD	DT	Small molecular drug
DM9R2SD	PC	6338015
DM9R2SD	MW	394.8
DM9R2SD	FM	C17H15ClN2O5S
DM9R2SD	IC	InChI=1S/C17H15ClN2O5S/c1-11-4-2-3-5-13(11)17(21)20-9-8-15(19-25-26(22,23)24)14-7-6-12(18)10-16(14)20/h2-7,10H,8-9H2,1H3,(H,22,23,24)/b19-15+
DM9R2SD	CS	CC1=CC=CC=C1C(=O)N2CC/C(=N\\OS(=O)(=O)O)/C3=C2C=C(C=C3)Cl
DM9R2SD	IK	QQCSUWGQBREWRO-XDJHFCHBSA-N
DM9R2SD	IU	[(E)-[7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4-ylidene]amino] hydrogen sulfate
DM9R2SD	CA	CAS 791024-52-7
DM9R2SD	DE	Diuretic vasodilator

DM83EBP	ID	DM83EBP
DM83EBP	DN	Alisporivir
DM83EBP	HS	Phase 3
DM83EBP	SN	DEB-025; Debio-025; HCV infection therapy, Debiopharm/Novartis; HIV infection therapy, Debiopharm
DM83EBP	CP	Novartis pharmaceuticals
DM83EBP	DT	Protein/peptide drug
DM83EBP	PC	11513676
DM83EBP	MW	1216.6
DM83EBP	FM	C63H113N11O12
DM83EBP	IC	InChI=1S/C63H113N11O12/c1-26-29-30-40(16)52(75)51-56(79)66-44(27-2)59(82)68(20)43(19)58(81)74(28-3)49(38(12)13)55(78)67-48(37(10)11)62(85)69(21)45(31-34(4)5)54(77)64-41(17)53(76)65-42(18)57(80)70(22)46(32-35(6)7)60(83)71(23)47(33-36(8)9)61(84)72(24)50(39(14)15)63(86)73(51)25/h26,29,34-52,75H,27-28,30-33H2,1-25H3,(H,64,77)(H,65,76)(H,66,79)(H,67,78)/b29-26+/t40-,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-/m1/s1
DM83EBP	CS	CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C
DM83EBP	IK	OLROWHGDTNFZBH-XEMWPYQTSA-N
DM83EBP	IU	(3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DM83EBP	CA	CAS 254435-95-5
DM83EBP	DE	Duchenne dystrophy

DMCHA27	ID	DMCHA27
DMCHA27	DN	Almonertinib
DMCHA27	HS	Phase 3
DMCHA27	SN	HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
DMCHA27	CP	EQRx
DMCHA27	DT	Small molecular drug
DMCHA27	PC	121280087
DMCHA27	MW	525.6
DMCHA27	FM	C30H35N7O2
DMCHA27	IC	InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)
DMCHA27	CS	CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC
DMCHA27	IK	DOEOECWDNSEFDN-UHFFFAOYSA-N
DMCHA27	IU	N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
DMCHA27	CA	CAS 1899921-05-1
DMCHA27	DE	Non-small-cell lung cancer

DMFUOM7	ID	DMFUOM7
DMFUOM7	DN	ALN-TTRsc
DMFUOM7	HS	Phase 3
DMFUOM7	SN	SAR438714
DMFUOM7	CP	Alnylam pharmaceuticals
DMFUOM7	DE	Cardiomyopathy

DMKLBHX	ID	DMKLBHX
DMKLBHX	DN	ALO-02
DMKLBHX	HS	Phase 3
DMKLBHX	SN	ALO-02 Oxycodone-naltrexone core
DMKLBHX	CP	Elite Pharmaceuticals; pfizer
DMKLBHX	DE	Pain

DM2RTGP	ID	DM2RTGP
DM2RTGP	DN	Alpha-glucosidase
DM2RTGP	HS	Phase 3
DM2RTGP	SN	Pompes disease therapy, Pharming; Alpha-glucosidase (transgenic); Alpha-glucosidase, Pharming; GD-halpha-GLU; Alpha-glucosidase (transgenic), Pharming/Genzyme
DM2RTGP	CP	Pharming Group NV
DM2RTGP	DE	Muscle disease

DM7EBH9	ID	DM7EBH9
DM7EBH9	DN	ALX-0081
DM7EBH9	HS	Phase 3
DM7EBH9	CP	Ablynx
DM7EBH9	DE	Thrombocytopenia; Thrombotic thrombocytopenic purpura

DMG5BTD	ID	DMG5BTD
DMG5BTD	DN	ALZT-OP1
DMG5BTD	HS	Phase 3
DMG5BTD	SN	ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen
DMG5BTD	CP	AZTherapies Boston, MA
DMG5BTD	DE	Alzheimer disease

DMGMNUE	ID	DMGMNUE
DMGMNUE	DN	AM0010
DMGMNUE	HS	Phase 3
DMGMNUE	CP	Armo biosciences
DMGMNUE	DE	Solid tumour/cancer; Pancreatic ductal carcinoma; Renal cell carcinoma; Non-small-cell lung cancer; Pancreatic cancer

DM4E9PK	ID	DM4E9PK
DM4E9PK	DN	AM-111
DM4E9PK	HS	Phase 3
DM4E9PK	SN	UNII-FU288768DP; FU288768DP; XG102 peptide; AM111 peptide; D-JNKI-1; D-JNKI 1 peptide; XG 102; AM 111; D-JNKI 1; TAT-IB1 fusion peptide XG-102 (synthetic); HIV TAT-JIP-1 fusion peptide XG-102 (synthetic); 1198367-70-2; 1148126-36-6; Glycine, D-alpha-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl-D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl-D-asparaginyl-D-leucyl-D-threonyl-D-threonyl-D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-
DM4E9PK	CP	Auris Medical
DM4E9PK	PC	72941992
DM4E9PK	MW	3823.4
DM4E9PK	FM	C164H285N65O41
DM4E9PK	IC	InChI=1S/C164H285N65O41/c1-84(2)77-106(216-139(254)108(79-89-33-10-9-11-34-89)219-146(261)112-48-28-72-225(112)153(268)105(55-58-119(171)235)215-148(263)123(86(5)6)221-147(262)115-51-29-73-226(115)151(266)103(45-25-69-198-163(187)188)213-142(257)110(83-230)220-137(252)100(53-56-117(169)233)201-126(241)90(168)80-121(237)238)138(253)218-109(81-120(172)236)140(255)217-107(78-85(3)4)141(256)222-124(87(7)231)149(264)223-125(88(8)232)155(270)228-75-31-50-114(228)144(259)211-99(44-24-68-197-162(185)186)135(250)212-102(37-14-17-61-167)150(265)224-71-27-47-111(224)145(260)214-104(46-26-70-199-164(189)190)152(267)229-76-32-52-116(229)154(269)227-74-30-49-113(227)143(258)210-98(43-23-67-196-161(183)184)134(249)207-95(40-20-64-193-158(177)178)131(246)206-97(42-22-66-195-160(181)182)133(248)209-101(54-57-118(170)234)136(251)208-96(41-21-65-194-159(179)180)132(247)205-94(39-19-63-192-157(175)176)130(245)204-93(36-13-16-60-166)129(244)203-92(35-12-15-59-165)128(243)202-91(38-18-62-191-156(173)174)127(242)200-82-122(239)240/h9-11,33-34,84-88,90-116,123-125,230-232H,12-32,35-83,165-168H2,1-8H3,(H2,169,233)(H2,170,234)(H2,171,235)(H2,172,236)(H,200,242)(H,201,241)(H,202,243)(H,203,244)(H,204,245)(H,205,247)(H,206,246)(H,207,249)(H,208,251)(H,209,248)(H,210,258)(H,211,259)(H,212,250)(H,213,257)(H,214,260)(H,215,263)(H,216,254)(H,217,255)(H,218,253)(H,219,261)(H,220,252)(H,221,262)(H,222,256)(H,223,264)(H,237,238)(H,239,240)(H4,173,174,191)(H4,175,176,192)(H4,177,178,193)(H4,179,180,194)(H4,181,182,195)(H4,183,184,196)(H4,185,186,197)(H4,187,188,198)(H4,189,190,199)/t87-,88-,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,123+,124+,125+/m0/s1
DM4E9PK	CS	C[C@@H]([C@H](C(=O)N[C@H]([C@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N3CCC[C@@H]3C(=O)N4CCC[C@@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)[C@H]6CCCN6C(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](C(C)C)NC(=O)[C@H]7CCCN7C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC(=O)O)N)O
DM4E9PK	IK	HRMVIAFZYCCHGF-BMCUWHFPSA-N
DM4E9PK	IU	(3R)-3-amino-4-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[(2R)-2-[[(2R)-1-[[(2R)-5-amino-1-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2R)-4-amino-1-[[(2R)-1-[[(2R,3S)-1-[[(2R,3S)-1-[(2R)-2-[[(2R)-1-[[(2R)-6-amino-1-[(2R)-2-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[[(2R)-6-amino-1-[[(2R)-6-amino-1-[[(2R)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid
DM4E9PK	CA	CAS 1198367-70-2
DM4E9PK	DE	Neurological disorder

DMVOY6B	ID	DMVOY6B
DMVOY6B	DN	AMD-070
DMVOY6B	HS	Phase 3
DMVOY6B	SN	AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate
DMVOY6B	CP	Genzyme
DMVOY6B	DT	Small molecular drug
DMVOY6B	PC	11256587
DMVOY6B	MW	349.5
DMVOY6B	FM	C21H27N5
DMVOY6B	IC	InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1
DMVOY6B	CS	C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3
DMVOY6B	IK	WVLHHLRVNDMIAR-IBGZPJMESA-N
DMVOY6B	IU	N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine
DMVOY6B	CA	CAS 558447-26-0
DMVOY6B	CB	CHEBI:138865
DMVOY6B	DE	Human immunodeficiency virus infection; Renal cell carcinoma; Melanoma; Merkel cell carcinoma; Solid tumour/cancer; Whim syndrome

DM4FPM3	ID	DM4FPM3
DM4FPM3	DN	Amediplase
DM4FPM3	HS	Phase 3
DM4FPM3	SN	Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
DM4FPM3	CP	Menarini
DM4FPM3	DT	Small molecular drug
DM4FPM3	PC	154656
DM4FPM3	MW	346.4
DM4FPM3	FM	C22H18O4
DM4FPM3	IC	InChI=1S/C22H18O4/c23-19-8-7-13-15(20(19)24)6-5-11-9-17-12-3-1-2-4-14(12)21(25)22(26)18(17)10-16(11)13/h1-10,19-26H/t19-,20-,21-,22-/m0/s1
DM4FPM3	CS	C1=CC=C2C(=C1)[C@@H]([C@H](C3=C2C=C4C=CC5=C(C4=C3)C=C[C@@H]([C@H]5O)O)O)O
DM4FPM3	IK	YQINXCSNGCDFCQ-CMOCDZPBSA-N
DM4FPM3	IU	(3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
DM4FPM3	CA	CAS 151910-75-7
DM4FPM3	DE	Thrombosis; Myocardial infarction

DMG324Y	ID	DMG324Y
DMG324Y	DN	AMG 145
DMG324Y	HS	Phase 3
DMG324Y	CP	Amgen Thousand
DMG324Y	DE	Hypercholesterolaemia

DMQJXL4	ID	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	HS	Phase 3
DMQJXL4	SN	7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930
DMQJXL4	CP	Amgen
DMQJXL4	DT	Small molecular drug
DMQJXL4	PC	5360545
DMQJXL4	MW	22.989
DMQJXL4	FM	Na
DMQJXL4	IC	InChI=1S/Na
DMQJXL4	CS	[Na]
DMQJXL4	IK	KEAYESYHFKHZAL-UHFFFAOYSA-N
DMQJXL4	IU	sodium
DMQJXL4	CA	CAS 7440-23-5
DMQJXL4	CB	CHEBI:26708
DMQJXL4	DE	Alzheimer disease; Neuropathic pain; Sexual dysfunction; Breast cancer; Asthma

DMS1X67	ID	DMS1X67
DMS1X67	DN	Amitifadine
DMS1X67	HS	Phase 3
DMS1X67	SN	EB-1010
DMS1X67	CP	Euthymics Bioscience
DMS1X67	DT	Small molecular drug
DMS1X67	PC	11658655
DMS1X67	MW	228.11
DMS1X67	FM	C11H11Cl2N
DMS1X67	IC	InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2/t8-,11+/m1/s1
DMS1X67	CS	C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl
DMS1X67	IK	BSMNRYCSBFHEMQ-KCJUWKMLSA-N
DMS1X67	IU	(1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
DMS1X67	CA	CAS 410074-73-6
DMS1X67	DE	Obesity; Alcohol dependence; Mood disorder

DMF50XJ	ID	DMF50XJ
DMF50XJ	DN	Amitriptyline+ketamine
DMF50XJ	HS	Phase 3
DMF50XJ	SN	AmiKet
DMF50XJ	CP	EpiCept Pharmaceuticals
DMF50XJ	TC	Analgesics
DMF50XJ	DT	Small molecular drug
DMF50XJ	PC	24784105
DMF50XJ	MW	412.9
DMF50XJ	FM	C20H17ClN4O2S
DMF50XJ	IC	InChI=1S/C20H16N4O2S.ClH/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18;/h3-12H,1-2H3;1H
DMF50XJ	CS	CC(=O)N(C)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4.Cl
DMF50XJ	IK	HPYLZBPCIBFRAI-UHFFFAOYSA-N
DMF50XJ	IU	N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide;hydrochloride
DMF50XJ	DE	Neuropathic pain; Diabetic neuropathy; Postherpetic neuralgia

DMZ7AMY	ID	DMZ7AMY
DMZ7AMY	DN	Amivantamab
DMZ7AMY	HS	Phase 3
DMZ7AMY	CP	Janssen
DMZ7AMY	DT	Antibody
DMZ7AMY	DE	Non-small-cell lung cancer

DMB9587	ID	DMB9587
DMB9587	DN	Amocarzine
DMB9587	HS	Phase 3
DMB9587	SN	Phenthiourezine; Thiocarbamazine; CGP-6140; S-80016
DMB9587	CP	Novartis AG
DMB9587	DT	Small molecular drug
DMB9587	PC	5464102
DMB9587	MW	371.5
DMB9587	FM	C18H21N5O2S
DMB9587	IC	InChI=1S/C18H21N5O2S/c1-21-10-12-22(13-11-21)18(26)20-16-4-2-14(3-5-16)19-15-6-8-17(9-7-15)23(24)25/h2-9,19H,10-13H2,1H3,(H,20,26)
DMB9587	CS	CN1CCN(CC1)C(=S)NC2=CC=C(C=C2)NC3=CC=C(C=C3)[N+](=O)[O-]
DMB9587	IK	UFLRJROFPAGRPN-UHFFFAOYSA-N
DMB9587	IU	4-methyl-N-[4-(4-nitroanilino)phenyl]piperazine-1-carbothioamide
DMB9587	CA	CAS 36590-19-9
DMB9587	CB	CHEBI:38946
DMB9587	DE	Helminth infection

DM6SGUB	ID	DM6SGUB
DM6SGUB	DN	Amrubicin
DM6SGUB	HS	Phase 3
DM6SGUB	SN	110267-81-7; Amrubicin [INN]; SCHEMBL119022; AC1L4374; (+-)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; BC677604; AN-16624; LS-183761; FT-0662134; ( -)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; (7S,9S)-9-acetyl-9-amino-7-(4,5-dihydroxytetrahydropyran-2-yl)oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
DM6SGUB	CP	Celgene
DM6SGUB	DT	Small molecular drug
DM6SGUB	PC	3035016
DM6SGUB	MW	483.5
DM6SGUB	FM	C25H25NO9
DM6SGUB	IC	InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1
DM6SGUB	CS	CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O[C@H]5C[C@@H]([C@@H](CO5)O)O)N
DM6SGUB	IK	VJZITPJGSQKZMX-XDPRQOKASA-N
DM6SGUB	IU	(7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
DM6SGUB	CA	CAS 110267-81-7
DM6SGUB	CB	CHEBI:135779
DM6SGUB	DE	Small-cell lung cancer

DM8QIRN	ID	DM8QIRN
DM8QIRN	DN	AMT-011
DM8QIRN	HS	Phase 3
DM8QIRN	SN	Alipogene tiparvovec
DM8QIRN	CP	Amsterdam Molecular Therapeutics
DM8QIRN	DE	Blood forming organ disorder

DMSO02K	ID	DMSO02K
DMSO02K	DN	AMT-061
DMSO02K	HS	Phase 3
DMSO02K	SN	etranacogene dezaparvovec
DMSO02K	CP	uniQure
DMSO02K	DT	Gene therapy
DMSO02K	DE	Haemophilia B

DMP2BFG	ID	DMP2BFG
DMP2BFG	DN	Anacetrapib
DMP2BFG	HS	Phase 3
DMP2BFG	SN	MK0859; Anacetrapib (USAN); MK-0859
DMP2BFG	CP	Merck
DMP2BFG	DT	Small molecular drug
DMP2BFG	PC	11556427
DMP2BFG	MW	637.5
DMP2BFG	FM	C30H25F10NO3
DMP2BFG	IC	InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1
DMP2BFG	CS	C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMP2BFG	IK	MZZLGJHLQGUVPN-HAWMADMCSA-N
DMP2BFG	IU	(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one
DMP2BFG	CA	CAS 875446-37-0
DMP2BFG	DE	Hyperlipidaemia; Arteriosclerosis

DM2F9YO	ID	DM2F9YO
DM2F9YO	DN	Anakinra
DM2F9YO	HS	Phase 3
DM2F9YO	SN	Antril
DM2F9YO	TC	Antiviral Agents
DM2F9YO	DT	Protein/peptide drug
DM2F9YO	DE	Coronavirus Disease 2019 (COVID-19)

DM6HXTS	ID	DM6HXTS
DM6HXTS	DN	Anamorelin
DM6HXTS	HS	Phase 3
DM6HXTS	SN	249921-19-5; UNII-DD5RBA1NKF; DD5RBA1NKF; RC 1291; Anamorelin [INN]; ONO-7643; SCHEMBL935751; CHEMBL2110579; EX-A154; DTXSID20179702; C31H42N6O3; BCP06108; 3444AH; ZINC43130908; AKOS030526752; SB16911; API0008642; RC-1291; NCGC00378854-01; KB-80338; HY-14734; BC600755; (3R)-1-(2-Methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide; AB0165721; FT-0773543; W-5500; 921A195; CS 1036
DM6HXTS	CP	Sapphire Therape.
DM6HXTS	DT	Small molecular drug
DM6HXTS	PC	9828911
DM6HXTS	MW	546.7
DM6HXTS	FM	C31H42N6O3
DM6HXTS	IC	InChI=1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1
DM6HXTS	CS	CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@](C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N
DM6HXTS	IK	VQPFSIRUEPQQPP-MXBOTTGLSA-N
DM6HXTS	IU	2-amino-N-[(2R)-1-[(3R)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
DM6HXTS	CA	CAS 249921-19-5
DM6HXTS	DE	Carbohydrate metabolism disorder

DMK2Y4V	ID	DMK2Y4V
DMK2Y4V	DN	Ancrod
DMK2Y4V	HS	Phase 3
DMK2Y4V	SN	Arvin; Arwin; Venacil; Viprinex; Agkistrodon rhodostoma venom proteinase; Agkistrodon serine proteinase; Snake venom, Knoll
DMK2Y4V	CP	Knoll GmbH; Neurobiological Technologies
DMK2Y4V	DE	Blood forming organ disorder

DMLDB1X	ID	DMLDB1X
DMLDB1X	DN	Andecaliximab
DMLDB1X	HS	Phase 3
DMLDB1X	CP	Gilead Sciences Foster City, CA
DMLDB1X	DE	Solid tumour/cancer; Gastric adenocarcinoma

DMX36BH	ID	DMX36BH
DMX36BH	DN	Andolast
DMX36BH	HS	Phase 3
DMX36BH	SN	Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm
DMX36BH	CP	Rottapharm Madaus
DMX36BH	DT	Small molecular drug
DMX36BH	PC	65970
DMX36BH	MW	333.31
DMX36BH	FM	C15H11N9O
DMX36BH	IC	InChI=1S/C15H11N9O/c25-15(11-3-1-9(2-4-11)13-17-21-22-18-13)16-12-7-5-10(6-8-12)14-19-23-24-20-14/h1-8H,(H,16,25)(H,17,18,21,22)(H,19,20,23,24)
DMX36BH	CS	C1=CC(=CC=C1C2=NNN=N2)C(=O)NC3=CC=C(C=C3)C4=NNN=N4
DMX36BH	IK	VXEBMQZDPONDFB-UHFFFAOYSA-N
DMX36BH	IU	4-(2H-tetrazol-5-yl)-N-[4-(2H-tetrazol-5-yl)phenyl]benzamide
DMX36BH	CA	CAS 132640-22-3
DMX36BH	DE	Rhinitis

DMITJAK	ID	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	HS	Phase 3
DMITJAK	SN	androsterone; 53-41-8; Androkinine; Androtine; 5alpha-Androsterone; Atromide ICI; 3alpha-Hydroxy-5alpha-androstan-17-one; 3-Epihydroxyetioallocholan-17-one; cis-Androsterone; 3alpha-Hydroxyetioallocholan-17-one; 5alpha-Androstane-3alpha-ol-17-one; 3alpha-Hydroxy-17-androstanone; Androstanon-3-alpha-ol-17-one; 3-alpha-Hydroxy-17-androstanone; 3-alpha-Hydroxyetioallocholan-17-one; 3-alpha-Hydroxy-5-alpha-androstan-17-one; 5-alpha-Androstan-3-alpha-ol-17-one; Caswell No. 051G; Androstan-17-one, 3-hydroxy-, (3alpha,5alpha)-
DMITJAK	DT	Small molecular drug
DMITJAK	PC	5879
DMITJAK	MW	290.4
DMITJAK	FM	C19H30O2
DMITJAK	IC	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13+,14-,15-,16-,18-,19-/m0/s1
DMITJAK	CS	C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DMITJAK	IK	QGXBDMJGAMFCBF-HLUDHZFRSA-N
DMITJAK	IU	(3R,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMITJAK	CA	CAS 53-41-8
DMITJAK	CB	CHEBI:16032

DM76GZ0	ID	DM76GZ0
DM76GZ0	DN	Angiotensin-(1-7)
DM76GZ0	HS	Phase 3
DM76GZ0	SN	Ang (1-7); Angiotensin (1-7); Angiotensin-(1-7) (cancer); Angiotensin-(1-7) (cancer), Wake Forest University
DM76GZ0	CP	Tarix pharmaceuticals
DM76GZ0	DT	Small molecular drug
DM76GZ0	PC	123805
DM76GZ0	MW	899
DM76GZ0	FM	C41H62N12O11
DM76GZ0	IC	InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1
DM76GZ0	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DM76GZ0	IK	PVHLMTREZMEJCG-GDTLVBQBSA-N
DM76GZ0	IU	(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
DM76GZ0	CA	CAS 39386-80-6
DM76GZ0	CB	CHEBI:55438
DM76GZ0	DE	Lymphoma; Chemotherapy-induced nausea; Sarcoma; Duchenne dystrophy; Muscular dystrophy

DM3FPAQ	ID	DM3FPAQ
DM3FPAQ	DN	Anifrolumab
DM3FPAQ	HS	Phase 3
DM3FPAQ	CP	MedImmune Gaithersburg, MD
DM3FPAQ	DE	Systemic lupus erythematosus

DMX0PWV	ID	DMX0PWV
DMX0PWV	DN	Anti-IL-23
DMX0PWV	HS	Phase 3
DMX0PWV	SN	Anti-IL-23 (chronic inflammation); Anti-IL-23 (chronic inflammation), Merck & Co; Anti-IL-23 (chronic inflammation), Schering-Plough; Anti-interleukin-23 antibody (chronic inflammation), Merck & Co
DMX0PWV	CP	Schering-Plough Corp
DMX0PWV	DT	Antibody
DMX0PWV	DE	Inflammation

DMUYOC8	ID	DMUYOC8
DMUYOC8	DN	AP12009
DMUYOC8	HS	Phase 3
DMUYOC8	CP	Antisense therapeutics
DMUYOC8	TC	Antisense
DMUYOC8	DT	Antisense drug
DMUYOC8	DE	Colorectal cancer

DMD8QTC	ID	DMD8QTC
DMD8QTC	DN	Apadenoson
DMD8QTC	HS	Phase 3
DMD8QTC	SN	Stedivaze (TN)
DMD8QTC	CP	PGx Health
DMD8QTC	DT	Small molecular drug
DMD8QTC	PC	9805430
DMD8QTC	MW	486.5
DMD8QTC	FM	C23H30N6O6
DMD8QTC	IC	InChI=1S/C23H30N6O6/c1-3-25-21(32)18-16(30)17(31)22(35-18)29-11-26-15-19(24)27-14(28-20(15)29)6-4-5-12-7-9-13(10-8-12)23(33)34-2/h11-13,16-18,22,30-31H,3,5,7-10H2,1-2H3,(H,25,32)(H2,24,27,28)/t12?,13?,16-,17+,18-,22+/m0/s1
DMD8QTC	CS	CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)C#CCC4CCC(CC4)C(=O)OC)N)O)O
DMD8QTC	IK	FLEVIENZILQUKB-DMJMAAGCSA-N
DMD8QTC	IU	methyl 4-[3-[6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]prop-2-ynyl]cyclohexane-1-carboxylate
DMD8QTC	CA	CAS 250386-15-3
DMD8QTC	DE	Coronary artery disease

DMVY0BU	ID	DMVY0BU
DMVY0BU	DN	Apaziquone
DMVY0BU	HS	Phase 3
DMVY0BU	SN	EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola;  Apaziquonum; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin
DMVY0BU	CP	Spectrum
DMVY0BU	DT	Small molecular drug
DMVY0BU	PC	5813717
DMVY0BU	MW	288.3
DMVY0BU	FM	C15H16N2O4
DMVY0BU	IC	InChI=1S/C15H16N2O4/c1-16-10(3-2-6-18)9(8-19)13-14(16)12(20)7-11(15(13)21)17-4-5-17/h2-3,7,18-19H,4-6,8H2,1H3/b3-2+
DMVY0BU	CS	CN1C(=C(C2=C1C(=O)C=C(C2=O)N3CC3)CO)/C=C/CO
DMVY0BU	IK	MXPOCMVWFLDDLZ-NSCUHMNNSA-N
DMVY0BU	IU	5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione
DMVY0BU	CA	CAS 114560-48-4
DMVY0BU	DE	Non-muscle invasive bladder cancer; Bladder cancer

DMT0A3Y	ID	DMT0A3Y
DMT0A3Y	DN	APD-334
DMT0A3Y	HS	Phase 3
DMT0A3Y	SN	S1P1 receptor agonists (autoimmune diseases), Arena Pharmaceuticals
DMT0A3Y	CP	Arena Pharmaceuticals Inc
DMT0A3Y	PC	44623998
DMT0A3Y	MW	457.5
DMT0A3Y	FM	C26H26F3NO3
DMT0A3Y	IC	InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1
DMT0A3Y	CS	C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CC[C@@H]5CC(=O)O)C(F)(F)F
DMT0A3Y	IK	MVGWUTBTXDYMND-QGZVFWFLSA-N
DMT0A3Y	IU	2-[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
DMT0A3Y	CA	CAS 1206123-37-6
DMT0A3Y	DE	Autoimmune diabetes; Pyoderma gangrenosum; Ulcerative colitis

DM4HQ52	ID	DM4HQ52
DM4HQ52	DN	APL-2
DM4HQ52	HS	Phase 3
DM4HQ52	CP	Apellis Pharmaceuticals
DM4HQ52	DE	Paroxysmal nocturnal haemoglobinuria

DMBRQF5	ID	DMBRQF5
DMBRQF5	DN	ApoC-III
DMBRQF5	HS	Phase 3

DM1K78U	ID	DM1K78U
DM1K78U	DN	Apricitabine
DM1K78U	HS	Phase 3
DM1K78U	SN	Apricitabine; 160707-69-7; AVX754; AVX 754; UNII-K1YX059ML1; BCH 10618; (-)-dOTC; (-)-BCH 10652; K1YX059ML1; AVX-754; SPD-754; BCH-10618; 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one; 4-Amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]-2(1H)-pyrimidinone; BCH-10652; 2(1H)-Pyrimidinone, 4-amino-1-((2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl)-; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl)-, (2R-cis)-; Apricitabine [INN]; SPD754; BCH-10619; SPD 754; AC1L9S1I; (+/-)dOTC
DM1K78U	DT	Small molecular drug
DM1K78U	PC	455041
DM1K78U	MW	229.26
DM1K78U	FM	C8H11N3O3S
DM1K78U	IC	InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m1/s1
DM1K78U	CS	C1[C@@H](S[C@@H](O1)CO)N2C=CC(=NC2=O)N
DM1K78U	IK	RYMCFYKJDVMSIR-RNFRBKRXSA-N
DM1K78U	IU	4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one
DM1K78U	CA	CAS 160707-69-7
DM1K78U	DE	Human immunodeficiency virus infection

DM2YQK8	ID	DM2YQK8
DM2YQK8	DN	AR-301
DM2YQK8	HS	Phase 3
DM2YQK8	CP	Aridis Pharmaceuticals
DM2YQK8	DT	Antibody
DM2YQK8	DE	Ventilator-associated pneumonia; Hospital-acquired pneumonia; Pneumonia

DMZB9RI	ID	DMZB9RI
DMZB9RI	DN	Arabaclofen
DMZB9RI	HS	Phase 3
DMZB9RI	DT	Small molecular drug
DMZB9RI	DE	Fragile X syndrome

DMO628K	ID	DMO628K
DMO628K	DN	Arbaclofen placarbil
DMO628K	HS	Phase 3
DMO628K	SN	AP; R-baclofen - XenoPort; XP-19986
DMO628K	CP	Genentech
DMO628K	DT	Small molecular drug
DMO628K	PC	11281011
DMO628K	MW	399.9
DMO628K	FM	C19H26ClNO6
DMO628K	IC	InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1
DMO628K	CS	CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl
DMO628K	IK	JXTAALBWJQJLGN-KSSFIOAISA-N
DMO628K	IU	(3R)-3-(4-chlorophenyl)-4-[[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino]butanoic acid
DMO628K	CA	CAS 847353-30-4
DMO628K	DE	Fragile X syndrome; Alcohol dependence

DMYNJHI	ID	DMYNJHI
DMYNJHI	DN	Arc029
DMYNJHI	HS	Phase 3
DMYNJHI	SN	Nilvadipine; nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino; NILVADIPINE
DMYNJHI	CP	Archer Pharmaceuticals
DMYNJHI	DT	Small molecular drug
DMYNJHI	PC	4494
DMYNJHI	MW	385.4
DMYNJHI	FM	C19H19N3O6
DMYNJHI	IC	InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
DMYNJHI	CS	CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
DMYNJHI	IK	FAIIFDPAEUKBEP-UHFFFAOYSA-N
DMYNJHI	IU	3-O-methyl 5-O-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMYNJHI	CA	CAS 75530-68-6
DMYNJHI	CB	CHEBI:31911
DMYNJHI	DE	Alzheimer disease

DM180DM	ID	DM180DM
DM180DM	DN	ARGX-113
DM180DM	HS	Phase 3
DM180DM	CP	Argenx
DM180DM	DT	Small molecular drug
DM180DM	DE	Myasthenia gravis

DM84AD1	ID	DM84AD1
DM84AD1	DN	Arofylline
DM84AD1	HS	Phase 3
DM84AD1	SN	Arofyllin; KM09088; Arofylline (USAN/INN); 3-(4-chlorophenyl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione
DM84AD1	CP	Almiral Prodesfarma
DM84AD1	DT	Small molecular drug
DM84AD1	PC	166553
DM84AD1	MW	304.73
DM84AD1	FM	C14H13ClN4O2
DM84AD1	IC	InChI=1S/C14H13ClN4O2/c1-2-7-18-13(20)11-12(17-8-16-11)19(14(18)21)10-5-3-9(15)4-6-10/h3-6,8H,2,7H2,1H3,(H,16,17)
DM84AD1	CS	CCCN1C(=O)C2=C(N=CN2)N(C1=O)C3=CC=C(C=C3)Cl
DM84AD1	IK	GVTLDPJNRVMCAL-UHFFFAOYSA-N
DM84AD1	IU	3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione
DM84AD1	CA	CAS 136145-07-8
DM84AD1	DE	Chronic obstructive pulmonary disease

DM02BVQ	ID	DM02BVQ
DM02BVQ	DN	ARQ-087
DM02BVQ	HS	Phase 3
DM02BVQ	CP	ArQule Inc
DM02BVQ	PC	46834118
DM02BVQ	MW	468.6
DM02BVQ	FM	C29H29FN4O
DM02BVQ	IC	InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
DM02BVQ	CS	COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
DM02BVQ	IK	KPJDVVCDVBFRMU-AREMUKBSSA-N
DM02BVQ	IU	(6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine
DM02BVQ	CA	CAS 1234356-69-4
DM02BVQ	DE	Solid tumour/cancer; Cholangiocarcinoma; Intrahepatic cholangiocarcinoma

DML61S4	ID	DML61S4
DML61S4	DN	ARQ-151
DML61S4	HS	Phase 3
DML61S4	CP	Arcutis Biotherapeutics
DML61S4	DT	Small molecular drug
DML61S4	DE	Plaque psoriasis; Psoriasis vulgaris; Atopic dermatitis

DMD7XWS	ID	DMD7XWS
DMD7XWS	DN	AS-013
DMD7XWS	HS	Phase 3
DMD7XWS	SN	Circulase; Ecraprost; Prostaglandin E1 (liposomal), Mitsubishi Pharma/Asahi Glass
DMD7XWS	CP	Taisho Pharmaceutical Co Ltd
DMD7XWS	DT	Small molecular drug
DMD7XWS	PC	6917049
DMD7XWS	MW	480.7
DMD7XWS	FM	C28H48O6
DMD7XWS	IC	InChI=1S/C28H48O6/c1-4-7-11-15-22(29)18-19-23-24(26(21-25(23)30)34-28(32)14-6-3)16-12-9-10-13-17-27(31)33-20-8-5-2/h18-19,22-23,25,29-30H,4-17,20-21H2,1-3H3/b19-18+/t22-,23+,25+/m0/s1
DMD7XWS	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=C1CCCCCCC(=O)OCCCC)OC(=O)CCC)O)O
DMD7XWS	IK	HITYEEHTEOQBAC-OSIGYOHNSA-N
DMD7XWS	IU	butyl 7-[(4R,5R)-2-butanoyloxy-4-hydroxy-5-[(E,3S)-3-hydroxyoct-1-enyl]cyclopenten-1-yl]heptanoate
DMD7XWS	CA	CAS 136892-64-3
DMD7XWS	DE	Thrombosis

DMIV1WR	ID	DMIV1WR
DMIV1WR	DN	AS-12141
DMIV1WR	HS	Phase 3
DMIV1WR	SN	D-GalNAc; GalNAc; N-Acetyl-D-Galactosamine; N-acetyl-galactosamine; N-Acetyl-Galactosamine; 14215-68-0; 2-Acetamido-2-Deoxy-D-Galactopyranose; 2-Acetamido-2-Deoxy-D-Galactopyranoside; 2-Acetamido-2-Deoxy-D-Galactose; 2-Acetamido-2-Deoxy-Galactopyranose; 2-Acetamido-2-Deoxy-Galactopyranoside; 2-Acetamido-2-Deoxy-Galactose; 2-Deoxy-2-Acetamido-D-Galactopyranose; 2-Deoxy-2-Acetamido-D-Galactopyranoside; 2-Deoxy-2-Acetamido-D-Galactose; 2-Deoxy-2-Acetamido-Galactopyranose; 2-Deoxy-2-Acetamido-Galactopyranoside; 2-Deoxy-2-Acetamido-Galactose
DMIV1WR	PC	35717
DMIV1WR	MW	221.21
DMIV1WR	FM	C8H15NO6
DMIV1WR	IC	OVRNDRQMDRJTHS-KEWYIRBNSA-N
DMIV1WR	CS	CC(=O)NC1C(C(C(OC1O)CO)O)O
DMIV1WR	IK	1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6+,7-,8?/m1/s1
DMIV1WR	IU	N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DMIV1WR	CA	CAS 1136-42-1
DMIV1WR	CB	CHEBI:28037
DMIV1WR	DE	Gaucher disease

DMK09D4	ID	DMK09D4
DMK09D4	DN	ASC09 + ritonavir
DMK09D4	HS	Phase 3
DMK09D4	SN	TMC-310911 + norvir; ASC09F
DMK09D4	TC	Antiviral Agents
DMK09D4	DT	Combination drug
DMK09D4	DE	Coronavirus Disease 2019 (COVID-19)

DMWE3SC	ID	DMWE3SC
DMWE3SC	DN	ASC09 + ritonavir + oseltamivir
DMWE3SC	HS	Phase 3
DMWE3SC	SN	TMC-310911 + norvir + tamiflu
DMWE3SC	TC	Antiviral Agents
DMWE3SC	DT	Combination drug
DMWE3SC	DE	Coronavirus Disease 2019 (COVID-19)

DMND3AB	ID	DMND3AB
DMND3AB	DN	Asimadoline
DMND3AB	HS	Phase 3
DMND3AB	SN	Asimadoline [INN]; EMD 61753; N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide
DMND3AB	CP	Merck
DMND3AB	DT	Small molecular drug
DMND3AB	PC	179340
DMND3AB	MW	414.5
DMND3AB	FM	C27H30N2O2
DMND3AB	IC	InChI=1S/C27H30N2O2/c1-28(25(21-11-5-2-6-12-21)20-29-18-17-24(30)19-29)27(31)26(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,24-26,30H,17-20H2,1H3/t24-,25+/m0/s1
DMND3AB	CS	CN([C@H](CN1CC[C@@H](C1)O)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMND3AB	IK	JHLHNYVMZCADTC-LOSJGSFVSA-N
DMND3AB	IU	N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide
DMND3AB	CA	CAS 153205-46-0
DMND3AB	DE	Diarrhea-predominant irritable bowel syndrome; Pruritus

DMVA8KU	ID	DMVA8KU
DMVA8KU	DN	ASP0113
DMVA8KU	HS	Phase 3
DMVA8KU	SN	VCL-CB01
DMVA8KU	CP	Astellas
DMVA8KU	DT	Vaccine
DMVA8KU	DE	Cytomegalovirus infection

DMZ1UOI	ID	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	HS	Phase 3
DMZ1UOI	SN	Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; ASP-015K; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; ASP015K; JNJ-54781532; D10653; Peficitinib pound A
DMZ1UOI	CP	Astellas Pharma Inc
DMZ1UOI	DT	Small molecular drug
DMZ1UOI	PC	57928403
DMZ1UOI	MW	326.4
DMZ1UOI	FM	C18H22N4O2
DMZ1UOI	IC	InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,14?,18?
DMZ1UOI	CS	C1[C@@H]2CC3(C[C@@H](C2NC4=C5C=CNC5=NC=C4C(=O)N)CC1C3)O
DMZ1UOI	IK	DREIJXJRTLTGJC-JQCLMNFQSA-N
DMZ1UOI	IU	4-[[(1S,3R)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
DMZ1UOI	CA	CAS 944118-01-8
DMZ1UOI	DE	Psoriasis vulgaris; Rheumatoid arthritis

DMR71ST	ID	DMR71ST
DMR71ST	DN	ASP1929
DMR71ST	HS	Phase 3
DMR71ST	SN	Cetuximab sarotalocan
DMR71ST	CP	Rakuten Medical
DMR71ST	DT	Antibody
DMR71ST	DE	Solid tumour/cancer; Head and neck cancer

DMGQ1TV	ID	DMGQ1TV
DMGQ1TV	DN	ASP1941
DMGQ1TV	HS	Phase 3
DMGQ1TV	SN	Ipragliflozin L-proline; 951382-34-6; UNII-M6N3GK48A4; Suglat (TN); Ipragliflozin (L-Proline); M6N3GK48A4; Ipragliflozin L-proline [JAN]; Ipragliflozin L-proline (JAN); Ipragliflozin mixture with proline; DTXSID20241771; EX-A2771; L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1); HY-14894A; AKOS027321043; L-Proline, compd. with (1S)-1,5-anhydro-1-C-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-D-glucitol (1:1); AK310367; DS-11639; AC-29892; CS-0019749; D10200
DMGQ1TV	CP	Astellas Pharma US
DMGQ1TV	DT	Small molecular drug
DMGQ1TV	PC	10453870
DMGQ1TV	MW	404.5
DMGQ1TV	FM	C21H21FO5S
DMGQ1TV	IC	InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
DMGQ1TV	CS	C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)F
DMGQ1TV	IK	AHFWIQIYAXSLBA-RQXATKFSSA-N
DMGQ1TV	IU	(2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMGQ1TV	CA	CAS 761423-87-4
DMGQ1TV	CB	CHEBI:134724
DMGQ1TV	DE	Liver disease

DM5N1OB	ID	DM5N1OB
DM5N1OB	DN	Asp-2151
DM5N1OB	HS	Phase 3
DM5N1OB	SN	Helicase-primase inhibitor (herpes infection), Astellas
DM5N1OB	CP	Astellas Pharma Inc
DM5N1OB	DT	Small molecular drug
DM5N1OB	PC	11397521
DM5N1OB	MW	482.6
DM5N1OB	FM	C24H26N4O5S
DM5N1OB	IC	InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)
DM5N1OB	CS	CC1=C(C(=CC=C1)C)N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4
DM5N1OB	IK	MNHNIVNAFBSLLX-UHFFFAOYSA-N
DM5N1OB	IU	N-(2,6-dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide
DM5N1OB	CA	CAS 841301-32-4
DM5N1OB	DE	Herpes simplex virus infection

DMLY0H5	ID	DMLY0H5
DMLY0H5	DN	Astuprotimut-R
DMLY0H5	HS	Phase 3
DMLY0H5	CP	GlaxoSmithKline
DMLY0H5	DE	Non-small-cell lung cancer

DM4HK8Z	ID	DM4HK8Z
DM4HK8Z	DN	ASTX727
DM4HK8Z	HS	Phase 3
DM4HK8Z	CP	Astex Pharmaceuticals Pleasanton, CA
DM4HK8Z	DE	Chronic myelogenous leukaemia; Myelodysplastic syndrome

DMRV4DT	ID	DMRV4DT
DMRV4DT	DN	AT1001
DMRV4DT	HS	Phase 3
DMRV4DT	SN	Larazotide acetate; Larazotide acetate [USAN]; AT-1001; 881851-50-9; Larazotide acetate (USAN); UNII-FO8S2IW40N; AT 1001; FO8S2IW40N; CHEMBL2103815; NYGCNONRVCGHAT-UFIKZEAMSA-N; HY-106268A; CS-8047; D09352; Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine acetate; Glycine, glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl-, monoacetate
DMRV4DT	DT	Small molecular drug
DMRV4DT	PC	44146842
DMRV4DT	MW	785.9
DMRV4DT	FM	C34H59N9O12
DMRV4DT	IC	InChI=1S/C32H55N9O10.C2H4O2/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46;1-2(3)4/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46);1H3,(H,3,4)/t19-,20-,21-,26-,27-;/m0./s1
DMRV4DT	CS	CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN.CC(=O)O
DMRV4DT	IK	NYGCNONRVCGHAT-UFIKZEAMSA-N
DMRV4DT	IU	acetic acid;2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid
DMRV4DT	CA	CAS 881851-50-9
DMRV4DT	DE	Autoimmune diabetes

DMVJW0S	ID	DMVJW0S
DMVJW0S	DN	AT-406
DMVJW0S	HS	Phase 3
DMVJW0S	SN	1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143
DMVJW0S	CP	Ascenta Therapeutics; Debiopharm
DMVJW0S	DT	Small molecular drug
DMVJW0S	PC	25022340
DMVJW0S	MW	561.7
DMVJW0S	FM	C32H43N5O4
DMVJW0S	IC	InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1
DMVJW0S	CS	C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C)NC
DMVJW0S	IK	LSXUTRRVVSPWDZ-MKKUMYSQSA-N
DMVJW0S	IU	(5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-3-(3-methylbutanoyl)-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
DMVJW0S	CA	CAS 1071992-99-8
DMVJW0S	DE	Acute myeloid leukaemia; Lymphoma; Solid tumour/cancer; Squamous head and neck cell carcinom

DMQ94CT	ID	DMQ94CT
DMQ94CT	DN	AT9283
DMQ94CT	HS	Phase 3
DMQ94CT	CP	Astex Therape.
DMQ94CT	TC	Anticancer Agents
DMQ94CT	DT	Small molecular drug
DMQ94CT	PC	135398495
DMQ94CT	MW	381.4
DMQ94CT	FM	C19H23N7O2
DMQ94CT	IC	InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)
DMQ94CT	CS	C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5
DMQ94CT	IK	LOLPPWBBNUVNQZ-UHFFFAOYSA-N
DMQ94CT	IU	1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea
DMQ94CT	CA	CAS 896466-04-9
DMQ94CT	CB	CHEBI:125514
DMQ94CT	DE	Solid tumour/cancer

DM8GFEV	ID	DM8GFEV
DM8GFEV	DN	Atacicept
DM8GFEV	HS	Phase 3
DM8GFEV	CP	ZymoGenetics; Serono
DM8GFEV	DE	Multiple sclerosis; Rheumatoid arthritis; Lymphoma; Systemic lupus erythematosus; Lupus

DM4GXW3	ID	DM4GXW3
DM4GXW3	DN	Ataluren
DM4GXW3	HS	Phase 3
DM4GXW3	SN	Ataluren; 775304-57-9; PTC124; 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid; PTC-124; 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid; PTC124 (Ataluren); PTC 124; UNII-K16AME9I3V; Ataluren (PTC124); K16AME9I3V; NCGC00168759-02; Translarna; AK-31904; Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-; DSSTox_CID_26776; DSSTox_RID_81895; DSSTox_GSID_46776; Benzoic acid, 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-; CAS-775304-57-9; Ataluren [USAN:INN]; Translarna (TN); PTC124,Ataluren; Ataluren(ptc124)
DM4GXW3	CP	Genzyme; PTC Therapeutics
DM4GXW3	DT	Small molecular drug
DM4GXW3	PC	11219835
DM4GXW3	MW	284.24
DM4GXW3	FM	C15H9FN2O3
DM4GXW3	IC	InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20)
DM4GXW3	CS	C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F
DM4GXW3	IK	OOUGLTULBSNHNF-UHFFFAOYSA-N
DM4GXW3	IU	3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
DM4GXW3	CA	CAS 775304-57-9
DM4GXW3	CB	CHEBI:94805
DM4GXW3	DE	Aniridia; Cystic fibrosis; Mucopolysaccharidosis; Dravet syndrome; Duchenne dystrophy; Muscular dystrophy

DM3QLK2	ID	DM3QLK2
DM3QLK2	DN	Atamestane + Toremifene
DM3QLK2	HS	Phase 3
DM3QLK2	SN	Atamestane-plus-toremifene
DM3QLK2	CP	Intarcia Therapeutics
DM3QLK2	DE	Breast cancer

DM4VJ5Q	ID	DM4VJ5Q
DM4VJ5Q	DN	ATG-Fresenius S
DM4VJ5Q	HS	Phase 3
DM4VJ5Q	CP	Enzon
DM4VJ5Q	DT	Antibody
DM4VJ5Q	DE	Transplant rejection

DMBR0QK	ID	DMBR0QK
DMBR0QK	DN	Atorvastatin
DMBR0QK	HS	Phase 3
DMBR0QK	SN	atorvastatin; 134523-00-5; Cardyl; Xavator; Tozalip; Lipitor; Torvast; Sotis; ATORVASTATIN CALCIUM; Atorvastatin [INN:BAN]; 110862-48-1; UNII-A0JWA85V8F; CCRIS 7159; C33H35FN2O5; HSDB 7039; CI 981; Lipitor (TN); CHEMBL1487; A0JWA85V8F; CHEBI:39548; (betaR,deltaR)-2-(p-Fluorophenyl)-b; Atorvastatin
DMBR0QK	TC	Antiviral Agents
DMBR0QK	DT	Small molecular drug
DMBR0QK	PC	60823
DMBR0QK	MW	558.6
DMBR0QK	FM	C33H35FN2O5
DMBR0QK	IC	InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
DMBR0QK	CS	CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMBR0QK	IK	XUKUURHRXDUEBC-KAYWLYCHSA-N
DMBR0QK	IU	(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
DMBR0QK	CA	CAS 134523-00-5
DMBR0QK	CB	CHEBI:39548
DMBR0QK	DE	Coronavirus Disease 2019 (COVID-19)

DMM74PK	ID	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	HS	Phase 3
DMM74PK	SN	Xinlay; Atrasentan [INN]; A 127722; A 147627; ABT 627; A-127722; A-147627; ABT-627; Xinlay (TN); A-127722.5; (+)-A 127722; (+)-A-127722; (11C)ABT-627; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid; 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid; 2R-(4-methoxyphenyl)-4S(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid
DMM74PK	CP	Abbott
DMM74PK	DT	Small molecular drug
DMM74PK	PC	159594
DMM74PK	MW	510.6
DMM74PK	FM	C29H38N2O6
DMM74PK	IC	InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1
DMM74PK	CS	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
DMM74PK	IK	MOTJMGVDPWRKOC-QPVYNBJUSA-N
DMM74PK	IU	(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
DMM74PK	CA	CAS 173937-91-2
DMM74PK	CB	CHEBI:135810
DMM74PK	DE	Prostate cancer; Diabetic nephropathy

DM64WYC	ID	DM64WYC
DM64WYC	DN	Atx-101
DM64WYC	HS	Phase 3
DM64WYC	SN	ATX-101, APIM Therapeutics; Proliferating cell nuclear antigen (peptide, cancer), APIM
DM64WYC	CP	Bayer HealthCare Pharmaceuticals
DM64WYC	PC	222528
DM64WYC	MW	392.6
DM64WYC	FM	C24H40O4
DM64WYC	IC	InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
DM64WYC	CS	C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DM64WYC	IK	KXGVEGMKQFWNSR-LLQZFEROSA-N
DM64WYC	IU	(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM64WYC	CA	CAS 83-44-3
DM64WYC	CB	CHEBI:28834
DM64WYC	DE	Obesity

DM0EQ9X	ID	DM0EQ9X
DM0EQ9X	DN	Av 133
DM0EQ9X	HS	Phase 3
DM0EQ9X	CP	Avid Radiopharmaceuticals
DM0EQ9X	DE	Alzheimer disease

DMPW5UF	ID	DMPW5UF
DMPW5UF	DN	Avalglucosidase alfa
DMPW5UF	HS	Phase 3
DMPW5UF	CP	Sanofi
DMPW5UF	DT	Recombinant protein
DMPW5UF	DE	Pompe disease

DMA86FL	ID	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	HS	Phase 3
DMA86FL	SN	Juglone; juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS; JUGLONE
DMA86FL	CP	Genentech
DMA86FL	DT	Small molecular drug
DMA86FL	PC	3806
DMA86FL	MW	174.15
DMA86FL	FM	C10H6O3
DMA86FL	IC	InChI=1S/C10H6O3/c11-7-4-5-9(13)10-6(7)2-1-3-8(10)12/h1-5,12H
DMA86FL	CS	C1=CC2=C(C(=O)C=CC2=O)C(=C1)O
DMA86FL	IK	KQPYUDDGWXQXHS-UHFFFAOYSA-N
DMA86FL	IU	5-hydroxynaphthalene-1,4-dione
DMA86FL	CA	CAS 481-39-0
DMA86FL	CB	CHEBI:15794
DMA86FL	DE	Non-small-cell lung cancer; Nasopharyngeal carcinoma

DMRJK3U	ID	DMRJK3U
DMRJK3U	DN	Avotermin
DMRJK3U	HS	Phase 3
DMRJK3U	SN	Juvista; RN-1001; SPD-538; TGF3, Renovo; RN-1, Renovo
DMRJK3U	CP	Renovo, UK (Shire, UK)
DMRJK3U	DE	Sarcoidosis

DMV1SOR	ID	DMV1SOR
DMV1SOR	DN	AVP-786
DMV1SOR	HS	Phase 3
DMV1SOR	CP	Avanir pharmaceuticals
DMV1SOR	PC	25052519
DMV1SOR	MW	277.4
DMV1SOR	FM	C18H25NO
DMV1SOR	IC	InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1/i1D3,2D3
DMV1SOR	CS	[2H]C([2H])([2H])N1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC([2H])([2H])[2H]
DMV1SOR	IK	MKXZASYAUGDDCJ-QNNIAVNKSA-N
DMV1SOR	IU	(1S,9S,10S)-4-(trideuteriomethoxy)-17-(trideuteriomethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DMV1SOR	CA	CAS 1079043-55-2
DMV1SOR	DE	Pain; Alzheimer disease; Neurobehavioral disorder; Schizophrenia

DM6WZG8	ID	DM6WZG8
DM6WZG8	DN	AXS-05
DM6WZG8	HS	Phase 3
DM6WZG8	CP	Axsome Therapeutics
DM6WZG8	DT	Small molecular drug
DM6WZG8	DE	Alzheimer disease; Depression

DMM6G5D	ID	DMM6G5D
DMM6G5D	DN	AZD0914
DMM6G5D	HS	Phase 3
DMM6G5D	SN	Zoliflodacin
DMM6G5D	CP	Astrazeneca
DMM6G5D	PC	76685216
DMM6G5D	MW	487.4
DMM6G5D	FM	C22H22FN5O7
DMM6G5D	IC	InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1
DMM6G5D	CS	C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O
DMM6G5D	IK	ZSWMIFNWDQEXDT-ZESJGQACSA-N
DMM6G5D	IU	(4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione
DMM6G5D	CA	CAS 1620458-09-4
DMM6G5D	DE	Bacterial infection; Neisseria gonorrhoeae infection

DM9SKW8	ID	DM9SKW8
DM9SKW8	DN	AZD5363
DM9SKW8	HS	Phase 3
DM9SKW8	SN	AZD5363; 1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1
DM9SKW8	CP	Astex Pharmaceuticals
DM9SKW8	DT	Small molecular drug
DM9SKW8	PC	25227436
DM9SKW8	MW	428.9
DM9SKW8	FM	C21H25ClN6O2
DM9SKW8	IC	InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1
DM9SKW8	CS	C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4
DM9SKW8	IK	JDUBGYFRJFOXQC-KRWDZBQOSA-N
DM9SKW8	IU	4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
DM9SKW8	CA	CAS 1143532-39-1
DM9SKW8	DE	Solid tumour/cancer; Triple negative breast cancer

DMLY9F1	ID	DMLY9F1
DMLY9F1	DN	Azetirelin
DMLY9F1	HS	Phase 3
DMLY9F1	SN	Azetirelin; YM-14673 (dihydrate); Nalpha-[(S)-2-Azetidinone-4-carbonyl]-L-histidyl-L-prolinamide
DMLY9F1	DT	Small molecular drug
DMLY9F1	PC	65841
DMLY9F1	MW	348.36
DMLY9F1	FM	C15H20N6O4
DMLY9F1	IC	InChI=1S/C15H20N6O4/c16-13(23)11-2-1-3-21(11)15(25)10(4-8-6-17-7-18-8)20-14(24)9-5-12(22)19-9/h6-7,9-11H,1-5H2,(H2,16,23)(H,17,18)(H,19,22)(H,20,24)/t9-,10-,11-/m0/s1
DMLY9F1	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CC(=O)N3)C(=O)N
DMLY9F1	IK	WBGUMUGCONUXFK-DCAQKATOSA-N
DMLY9F1	IU	(2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-4-oxoazetidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carboxamide
DMLY9F1	CA	CAS 95729-65-0
DMLY9F1	DE	Pain

DMUIBV8	ID	DMUIBV8
DMUIBV8	DN	Azimilide
DMUIBV8	HS	Phase 3
DMUIBV8	SN	Azimilide [INN:BAN]; 1-({[5-(4-chlorophenyl)furan-2-yl]methylidene}amino)-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione
DMUIBV8	CP	Procter & Gamble
DMUIBV8	DT	Small molecular drug
DMUIBV8	PC	9571004
DMUIBV8	MW	458
DMUIBV8	FM	C23H28ClN5O3
DMUIBV8	IC	InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+
DMUIBV8	CS	CN1CCN(CC1)CCCCN2C(=O)CN(C2=O)/N=C/C3=CC=C(O3)C4=CC=C(C=C4)Cl
DMUIBV8	IK	MREBEPTUUMTTIA-PCLIKHOPSA-N
DMUIBV8	IU	1-[(E)-[5-(4-chlorophenyl)furan-2-yl]methylideneamino]-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione
DMUIBV8	CA	CAS 149908-53-2
DMUIBV8	CB	CHEBI:34545
DMUIBV8	DE	Atrial fibrillation

DM5Y4Q2	ID	DM5Y4Q2
DM5Y4Q2	DN	Azithromycin + hydroxychloroquine
DM5Y4Q2	HS	Phase 3
DM5Y4Q2	SN	Zithromax + oxichloroquine
DM5Y4Q2	TC	Antiviral Agents
DM5Y4Q2	DT	Combination drug
DM5Y4Q2	DE	Coronavirus Disease 2019 (COVID-19)

DMPV6B2	ID	DMPV6B2
DMPV6B2	DN	BA-058
DMPV6B2	HS	Phase 3
DMPV6B2	SN	BA-058 Microneedle Patch; BA-058 (transdermal microneedle patch, osteoporosis); BA-058 (transdermal microneedle patch, osteoporosis), Radius Health
DMPV6B2	CP	Radius Health Inc
DMPV6B2	DE	Osteoporosis

DMXBHR6	ID	DMXBHR6
DMXBHR6	DN	Balaglitazone
DMXBHR6	HS	Phase 3
DMXBHR6	SN	DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645
DMXBHR6	CP	Dr Reddy's Research Foundation
DMXBHR6	DT	Small molecular drug
DMXBHR6	PC	9889200
DMXBHR6	MW	395.4
DMXBHR6	FM	C20H17N3O4S
DMXBHR6	IC	InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26)
DMXBHR6	CS	CN1C(=NC2=CC=CC=C2C1=O)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DMXBHR6	IK	IETKPTYAGKZLKY-UHFFFAOYSA-N
DMXBHR6	IU	5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMXBHR6	CA	CAS 199113-98-9
DMXBHR6	DE	Type-1 diabetes

DMUOFAC	ID	DMUOFAC
DMUOFAC	DN	Balixafortide
DMUOFAC	HS	Phase 3
DMUOFAC	SN	1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide
DMUOFAC	CP	Polyphor
DMUOFAC	DT	Peptide
DMUOFAC	PC	91864511
DMUOFAC	MW	1782
DMUOFAC	FM	C80H112N22O21S2
DMUOFAC	IC	InChI=1S/C80H112N22O21S2/c1-42(82)65(108)98-59-39-124-125-40-60(99-70(113)55(34-45-16-22-49(105)23-17-45)93-66(109)51(10-5-29-87-80(84)85)91-74(117)61-11-6-30-100(61)76(119)43(2)89-71(114)58(38-103)97-73(59)116)72(115)94-54(33-44-14-20-48(104)21-15-44)68(111)90-52(26-27-64(83)107)67(110)92-53(9-3-4-28-81)77(120)102-32-8-13-63(102)78(121)101-31-7-12-62(101)75(118)95-56(35-46-18-24-50(106)25-19-46)69(112)96-57(79(122)123)36-47-37-86-41-88-47/h14-25,37,41-43,51-63,103-106H,3-13,26-36,38-40,81-82H2,1-2H3,(H2,83,107)(H,86,88)(H,89,114)(H,90,111)(H,91,117)(H,92,110)(H,93,109)(H,94,115)(H,95,118)(H,96,112)(H,97,116)(H,98,108)(H,99,113)(H,122,123)(H4,84,85,87)/t42-,43-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-/m0/s1
DMUOFAC	CS	C[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC=N7)C(=O)O)CC8=CC=C(C=C8)O)CCCNC(=N)N
DMUOFAC	IK	UUTLJGUXRVWOSI-YYXAXUJHSA-N
DMUOFAC	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(3S,6S,9R,14R,17S,20S,23S)-9-[[(2S)-2-aminopropanoyl]amino]-20-(3-carbamimidamidopropyl)-6-(hydroxymethyl)-17-[(4-hydroxyphenyl)methyl]-3-methyl-2,5,8,16,19,22-hexaoxo-11,12-dithia-1,4,7,15,18,21-hexazabicyclo[21.3.0]hexacosane-14-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid
DMUOFAC	DE	Metastatic breast cancer

DMKMTDG	ID	DMKMTDG
DMKMTDG	DN	Balovaptan
DMKMTDG	HS	Phase 3
DMKMTDG	SN	1228088-30-9; UNII-RAX5D5AGV6; RG7314; RAX5D5AGV6; RO5285119; 8-chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-5-methyl-1-{trans-4-[(pyridin-2-yl)oxy]cyclohexyl}-5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; Balovaptan [INN]; Balovaptan [USAN]; Balovaptan (USAN/INN); Balovaptan [USAN:INN]; SCHEMBL2471320; SCHEMBL3329710; SCHEMBL3332136; CHEMBL4297183; GTPL10615; compound 1 [PMID: 31951127]; DB14823; RG-7314; SB19643; Ro-5285119; BS-14780; HY-109024; CS-0030526; D11476; 12-chloro-8-methyl-3-[(1r,4r)-4-(pyridin-2-yloxy)cyclohexyl]-2,4,5,8-tetraazatricyclo[8.4.0.0,tetradeca-1(10),3,5,11,13-pentaene; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-; 8-Chloro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-5,6-dihydro-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine
DMKMTDG	CP	Genentech
DMKMTDG	DT	Small molecular drug
DMKMTDG	PC	46200932
DMKMTDG	MW	409.9
DMKMTDG	FM	C22H24ClN5O
DMKMTDG	IC	InChI=1S/C22H24ClN5O/c1-27-13-16-12-17(23)7-10-19(16)28-20(14-27)25-26-22(28)15-5-8-18(9-6-15)29-21-4-2-3-11-24-21/h2-4,7,10-12,15,18H,5-6,8-9,13-14H2,1H3
DMKMTDG	CS	CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCC(CC4)OC5=CC=CC=N5)C1
DMKMTDG	IK	GMPZPHGHNDMRKL-UHFFFAOYSA-N
DMKMTDG	IU	8-chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMKMTDG	CA	CAS 1228088-30-9
DMKMTDG	DE	Autism spectrum disorder

DMHQ5GK	ID	DMHQ5GK
DMHQ5GK	DN	Bapineuzumab
DMHQ5GK	HS	Phase 3
DMHQ5GK	SN	AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan
DMHQ5GK	CP	Elan Corp plc
DMHQ5GK	DT	Antibody
DMHQ5GK	DE	Alzheimer disease

DMODA2X	ID	DMODA2X
DMODA2X	DN	Bardoxolone methyl
DMODA2X	HS	Phase 3
DMODA2X	SN	BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4
DMODA2X	CP	Reata Pharmaceuticals Irving, TX
DMODA2X	DT	Small molecular drug
DMODA2X	PC	400769
DMODA2X	MW	505.7
DMODA2X	FM	C32H43NO4
DMODA2X	IC	InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1
DMODA2X	CS	C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC
DMODA2X	IK	WPTTVJLTNAWYAO-KPOXMGGZSA-N
DMODA2X	IU	methyl (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate
DMODA2X	CA	CAS 218600-53-4
DMODA2X	DE	Mixed connective tissue disease; Pulmonary arterial hypertension; Pulmonary hypertension

DMPRI14	ID	DMPRI14
DMPRI14	DN	Baricitinib
DMPRI14	HS	Phase 3
DMPRI14	SN	Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
DMPRI14	CP	Incyte/Eli Lilly
DMPRI14	TC	Antiviral Agents
DMPRI14	DT	Small molecular drug
DMPRI14	PC	44205240
DMPRI14	MW	371.4
DMPRI14	FM	C16H17N7O2S
DMPRI14	IC	InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
DMPRI14	CS	CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DMPRI14	IK	XUZMWHLSFXCVMG-UHFFFAOYSA-N
DMPRI14	IU	2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DMPRI14	CA	CAS 1187594-09-7
DMPRI14	CB	CHEBI:95341
DMPRI14	DE	Asthma; Atopic dermatitis; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus; Coronavirus Disease 2019 (COVID-19)

DMB147A	ID	DMB147A
DMB147A	DN	BAX-817
DMB147A	HS	Phase 3
DMB147A	CP	Baxter International Inc
DMB147A	DE	Hemophilia

DM407I6	ID	DM407I6
DM407I6	DN	BAY 853934
DM407I6	HS	Phase 3
DM407I6	SN	Molidustat; 1154028-82-6; BAY 85-3934; Molidustat (BAY85-3934); BAY85-3934; UNII-9JH486CZ13; Molidustat(BAY 85-3934); 9JH486CZ13; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one; 3H-Pyrazol-3-one, 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-; 2-(6-Morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-3(2H)-one; 2-[6-(4-Morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(1,2,3-triazol-1-yl)pyrazol-3-ol; 2-(6-Morpholin-4-Ylpyrimidin-4-Yl)-4-(1,2,3-Triazol-1-Yl)-1~{h}-Pyrazol-3-One; Molidustat [INN]; Molidustat(BAY85-3934); Molidustat (BAY 85-3934); QEQ; GTPL8456; SCHEMBL2569970; SCHEMBL6114312; CHEMBL3646118; CHEMBL3991036; DTXSID80151089; EX-A562; BDBM118339; AOB87194; BCP14477; MFCD28411428; AKOS026750584; ZINC167006010; BAY-853934; CCG-267626; SB17156; NCGC00388364-04; AK323698; AS-74456; HY-12654; QC-11791; DB-092822; B5861; S8138; A14404; BAY 85-3934;BAY-85-3934; US8653111, 72; Q27087553; OC1=C(N2N=NC=C2)C=NN1C(N=CN=1)=CC=1N1CCOCC1; 1-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol; Molidustat;BAY 85-3934;BAY-85-3934; BAY 853934; BAY-853934; BAY853934; 2-(6-(Morpholin-4-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-2,3-dihydro-1H-pyrazol-3-one; A1H
DM407I6	CP	Bayer
DM407I6	DT	Small molecular drug
DM407I6	PC	59603622
DM407I6	MW	314.3
DM407I6	FM	C13H14N8O2
DM407I6	IC	InChI=1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2
DM407I6	CS	C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4
DM407I6	IK	IJMBOKOTALXLKS-UHFFFAOYSA-N
DM407I6	IU	2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one
DM407I6	CA	CAS 1154028-82-6
DM407I6	DE	Anaemia

DMPW5SB	ID	DMPW5SB
DMPW5SB	DN	Bay 86-9766
DMPW5SB	HS	Phase 3
DMPW5SB	SN	923032-37-5; RDEA119; BAY 869766; RDEA 119; UNII-JPX07AFM0N; RDEA-119; Refametinib (RDEA119, Bay 86-9766); JPX07AFM0N; (S)-N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide; Refametinib [INN]; 923032-38-6; BAY-869766; BAY 8697661; 3e8n; Refametinib R enantiomer; Refametinib (RDEA119); SCHEMBL345333
DMPW5SB	CP	Ardea Biosciences
DMPW5SB	DT	Small molecular drug
DMPW5SB	PC	44182295
DMPW5SB	MW	572.3
DMPW5SB	FM	C19H20F3IN2O5S
DMPW5SB	IC	InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1
DMPW5SB	CS	COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F
DMPW5SB	IK	RDSACQWTXKSHJT-NSHDSACASA-N
DMPW5SB	IU	N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
DMPW5SB	CA	CAS 923032-37-5
DMPW5SB	DE	Solid tumour/cancer

DM09M3H	ID	DM09M3H
DM09M3H	DN	BAY 94-9027
DM09M3H	HS	Phase 3
DM09M3H	SN	Peg rFVIII
DM09M3H	CP	Bayer HealthCare Pharmaceuticals
DM09M3H	DE	Stroke; Hemophilia

DMWYPZF	ID	DMWYPZF
DMWYPZF	DN	BAY-35-3377
DMWYPZF	HS	Phase 3
DMWYPZF	SN	BY-377; Gastroquinolone antibacterial, Altana; Gastroquinolone antibacterial, Bayer; Quinolone antibacterials, Bayer
DMWYPZF	CP	Bayer AG
DMWYPZF	DT	Small molecular drug
DMWYPZF	PC	11662028
DMWYPZF	MW	434.8
DMWYPZF	FM	C20H20ClFN4O4
DMWYPZF	IC	InChI=1S/C20H19FN4O4.ClH/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15;/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28);1H/t15-,16-;/m0./s1
DMWYPZF	CS	C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O.Cl
DMWYPZF	IK	CQMSQUOHWYYEKM-MOGJOVFKSA-N
DMWYPZF	IU	7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydrochloride
DMWYPZF	CA	CAS 209342-41-6
DMWYPZF	DE	Otitis media

DMQG7ZM	ID	DMQG7ZM
DMQG7ZM	DN	Belagenpumatucel-L
DMQG7ZM	HS	Phase 3
DMQG7ZM	SN	Lucanix (TN)
DMQG7ZM	CP	NovaRx
DMQG7ZM	DT	Vaccine
DMQG7ZM	DE	Small-cell lung cancer; Non-small-cell lung cancer

DM71CK8	ID	DM71CK8
DM71CK8	DN	Beloranib
DM71CK8	HS	Phase 3
DM71CK8	SN	251111-30-5; CKD-732; UNII-FI471K8BU6; ZGN-433; FI471K8BU6; O-(4-(2-Dimethylaminoethoxy)-trans-cinnamoyl)fumagillol; Beloranib [INN]; ZGN 433; AC1OCFID; ZGN-440(Beloranib); US9682965, Compound A; GTPL8445; SCHEMBL14648763; DTXSID40179800; BDBM148430; ZINC3982162; AKOS027326543; DB12671; (3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(25)octan-6-yl (2E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)prop-2-enoate; O-(4-Dimethylaminoethoxycinnamoyl)fumagillol; CKD-731; Fumagillin analogs, Chong Kun Dang; HRK-429; HRK-512
DM71CK8	CP	Zafgen
DM71CK8	DT	Small molecular drug
DM71CK8	PC	6918502
DM71CK8	MW	499.6
DM71CK8	FM	C29H41NO6
DM71CK8	IC	InChI=1S/C29H41NO6/c1-20(2)7-13-24-28(3,36-24)27-26(32-6)23(15-16-29(27)19-34-29)35-25(31)14-10-21-8-11-22(12-9-21)33-18-17-30(4)5/h7-12,14,23-24,26-27H,13,15-19H2,1-6H3/b14-10+/t23-,24-,26-,27-,28+,29+/m1/s1
DM71CK8	CS	CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)/C=C/C4=CC=C(C=C4)OCCN(C)C)OC)C
DM71CK8	IK	ZEZFKUBILQRZCK-MJSCXXSSSA-N
DM71CK8	IU	[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (E)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate
DM71CK8	CA	CAS 251111-30-5
DM71CK8	DE	Obesity; Solid tumour/cancer

DMLU8NX	ID	DMLU8NX
DMLU8NX	DN	Benserazide
DMLU8NX	HS	Phase 3
DMLU8NX	SN	benserazide; Serazide; 322-35-0; Benseraszide; Benserazida; Benserazidum; Ro 4-4602; Ro 44602; DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide; Benserazidum [INN-Latin]; Benserazida [INN-Spanish]; Benserazide [USAN:INN:BAN]; DL-Seryltrihydroxybenzylhydrazine; C10H15N3O5; BRN 3984490; DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; CHEBI:64187; DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; Serine, 2-(2,3,4-trihydroxybenzyl)hyrazide, DL-; DL-serine 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide
DMLU8NX	DT	Small molecular drug
DMLU8NX	PC	2327
DMLU8NX	MW	257.24
DMLU8NX	FM	C10H15N3O5
DMLU8NX	IC	InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)
DMLU8NX	CS	C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O
DMLU8NX	IK	BNQDCRGUHNALGH-UHFFFAOYSA-N
DMLU8NX	IU	2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide
DMLU8NX	CA	CAS 322-35-0
DMLU8NX	CB	CHEBI:64187

DMS9503	ID	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	HS	Phase 3
DMS9503	SN	penicillin g; Benzylpenicillinic acid; Free penicillin II; Pencillin G; 61-33-6; Benzylpenicillin G; Bencilpenicilina; Benzylpenicillinum; Benzyl penicillin; Free penicillin G; Dropcillin; Pharmacillin; Gelacillin; Liquacillin; Benzopenicillin; Cilopen; Pradupen; Benzylpenicilline; Specilline G; Cilloral; Cosmopen; Ursopen; Galofak; Free benzylpenicillin; Compocillin G; Phenylacetamidopenicillanic acid; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen; Benzyl-6-aminopenicillinic acid
DMS9503	DT	Small molecular drug
DMS9503	PC	5904
DMS9503	MW	334.4
DMS9503	FM	C16H18N2O4S
DMS9503	IC	InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1
DMS9503	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
DMS9503	IK	JGSARLDLIJGVTE-MBNYWOFBSA-N
DMS9503	IU	(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMS9503	CA	CAS 61-33-6
DMS9503	CB	CHEBI:18208

DM6RWBN	ID	DM6RWBN
DM6RWBN	DN	Beperminogene perplasmid
DM6RWBN	HS	Phase 3
DM6RWBN	CP	AnGes; Daiichi
DM6RWBN	DE	Heart disease; Critical limb ischemia

DMLVNTA	ID	DMLVNTA
DMLVNTA	DN	Besipirdine
DMLVNTA	HS	Phase 3
DMLVNTA	SN	Besipirdine hydrochloride; HP-749; P86-7480
DMLVNTA	CP	Hoechst Marion Roussel Inc
DMLVNTA	DT	Small molecular drug
DMLVNTA	PC	60691
DMLVNTA	MW	251.33
DMLVNTA	FM	C16H17N3
DMLVNTA	IC	InChI=1S/C16H17N3/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19/h3-11,13H,2,12H2,1H3
DMLVNTA	CS	CCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DMLVNTA	IK	OTPPJICEBWOCKD-UHFFFAOYSA-N
DMLVNTA	IU	N-propyl-N-pyridin-4-ylindol-1-amine
DMLVNTA	CA	CAS 119257-34-0
DMLVNTA	DE	Cognitive impairment

DM0MI81	ID	DM0MI81
DM0MI81	DN	Bevacizumab + Erlotinib
DM0MI81	HS	Phase 3
DM0MI81	CP	Roche
DM0MI81	DE	Metastatic colorectal cancer; Non-small-cell lung cancer; Hypopharyngeal squamous cell carcinoma; Hepatocellular carcinoma

DM9EXGI	ID	DM9EXGI
DM9EXGI	DN	Bevacizumab + Rituximab
DM9EXGI	HS	Phase 3
DM9EXGI	CP	Roche
DM9EXGI	DT	Combination drug (Antibody)
DM9EXGI	PC	24801580
DM9EXGI	MW	396.2
DM9EXGI	FM	C14H18ILiN2O3
DM9EXGI	IC	InChI=1S/C14H19IN2O3.Li/c1-3-17(4-2)8-7-16-13(18)10-5-6-11(14(19)20)12(15)9-10;/h5-6,9H,3-4,7-8H2,1-2H3,(H,16,18)(H,19,20);/q;+1/p-1
DM9EXGI	CS	[Li+].CCN(CC)CCNC(=O)C1=CC(=C(C=C1)C(=O)[O-])I
DM9EXGI	IK	CNMYRBKJCDLCHB-UHFFFAOYSA-M
DM9EXGI	IU	lithium;4-[2-(diethylamino)ethylcarbamoyl]-2-iodobenzoate
DM9EXGI	DE	Non-hodgkin lymphoma; Lymphoma

DM9CEI5	ID	DM9CEI5
DM9CEI5	DN	Bevacizumab + Trastuzumab
DM9CEI5	HS	Phase 3
DM9CEI5	SN	Lithocholic acid; LITHOCHOLIC ACID; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-,
DM9CEI5	CP	Roche
DM9CEI5	DT	Combination drug (Antibody)
DM9CEI5	PC	9903
DM9CEI5	MW	376.6
DM9CEI5	FM	C24H40O3
DM9CEI5	IC	InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1
DM9CEI5	CS	C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C
DM9CEI5	IK	SMEROWZSTRWXGI-HVATVPOCSA-N
DM9CEI5	IU	(4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM9CEI5	CA	CAS 434-13-9
DM9CEI5	DE	Breast cancer

DMK56G0	ID	DMK56G0
DMK56G0	DN	Bexagliflozin
DMK56G0	HS	Phase 3
DMK56G0	SN	UNII-EY00JF42FV; EGT-1442; Bexagliflozin [USAN]; THR-1442; EY00JF42FV; CHEMBL1808388; 1118567-05-7; Bexagliflozin (USAN); D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol; EGT1442; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropylo
DMK56G0	CP	Theracos Marlborough, MA
DMK56G0	PC	25195624
DMK56G0	MW	464.9
DMK56G0	FM	C24H29ClO7
DMK56G0	IC	InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1
DMK56G0	CS	C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
DMK56G0	IK	BTCRKOKVYTVOLU-SJSRKZJXSA-N
DMK56G0	IU	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMK56G0	CA	CAS 1118567-05-7
DMK56G0	DE	Type-2 diabetes

DM7NJYC	ID	DM7NJYC
DM7NJYC	DN	BGB-A317
DM7NJYC	HS	Phase 3
DM7NJYC	CP	BeiGene Cambridge, MA
DM7NJYC	DE	Hepatocellular carcinoma; Solid tumour/cancer; Squamous cell carcinoma

DMNKBEC	ID	DMNKBEC
DMNKBEC	DN	BGJ398
DMNKBEC	HS	Phase 3
DMNKBEC	SN	Infigratinib
DMNKBEC	DT	Small molecular drug
DMNKBEC	PC	53235510
DMNKBEC	MW	560.5
DMNKBEC	FM	C26H31Cl2N7O3
DMNKBEC	IC	InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
DMNKBEC	CS	CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
DMNKBEC	IK	QADPYRIHXKWUSV-UHFFFAOYSA-N
DMNKBEC	IU	3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea
DMNKBEC	CA	CAS 872511-34-7
DMNKBEC	CB	CHEBI:63451
DMNKBEC	DE	Solid tumour/cancer; Cholangiocarcinoma

DM3MXT8	ID	DM3MXT8
DM3MXT8	DN	BI 201335
DM3MXT8	HS	Phase 3
DM3MXT8	SN	Faldaprevir; BI-201335; UNII-958X4J301A; CHEMBL1241348; 958X4J301A; N-[(Cyclopentyloxy)carbonyl]-3-Methyl-L-Valyl-(4r)-4-[(8-Bromo-7-Methoxy-2-{2-[(2-Methylpropanoyl)amino]-1,3-Thiazol-4-Yl}quinolin-4-Yl)oxy]-N-[(1r,2s)-1-Carboxy-2-Ethenylcyclopropyl]-L-Prolinamide; BI 201335; 801283-95-4; BI201335; Faldaprevir [USAN:INN]; SCHEMBL222429; BDBM50336545; SB16712; DB11808
DM3MXT8	CP	Boehringer Ingelheim Pharma
DM3MXT8	DT	Small molecular drug
DM3MXT8	PC	42601552
DM3MXT8	MW	869.8
DM3MXT8	FM	C40H49BrN6O9S
DM3MXT8	IC	InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
DM3MXT8	CS	CC(C)C(=O)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Br)OC)C(=C2)O[C@@H]4C[C@H](N(C4)C(=O)[C@H](C(C)(C)C)NC(=O)OC5CCCC5)C(=O)N[C@@]6(C[C@H]6C=C)C(=O)O
DM3MXT8	IK	LLGDPTDZOVKFDU-XUHJSTDZSA-N
DM3MXT8	IU	(1R,2S)-1-[[(2S,4R)-4-[8-bromo-7-methoxy-2-[2-(2-methylpropanoylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-1-[(2S)-2-(cyclopentyloxycarbonylamino)-3,3-dimethylbutanoyl]pyrrolidine-2-carbonyl]amino]-2-ethenylcyclopropane-1-carboxylic acid
DM3MXT8	CA	CAS 801283-95-4
DM3MXT8	DE	Hepatitis C virus infection

DMH3XDR	ID	DMH3XDR
DMH3XDR	DN	BI 425809
DMH3XDR	HS	Phase 3
DMH3XDR	CP	Boehringer Ingelheim
DMH3XDR	DT	Small molecular drug
DMH3XDR	DE	Schizophrenia

DMBH4FL	ID	DMBH4FL
DMBH4FL	DN	BI 655066
DMBH4FL	HS	Phase 3
DMBH4FL	CP	Boehringer ingelheim pharmaceuticals
DMBH4FL	DT	Antibody
DMBH4FL	DE	Ankylosing spondylitis; Chronic plaque psoriasis; Crohn disease; Psoriatic arthritis

DM42GP9	ID	DM42GP9
DM42GP9	DN	Bicifadine
DM42GP9	HS	Phase 3
DM42GP9	SN	BICIFADINE; 71195-57-8; 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane; 1-p-tolyl-3-azabicyclo[3.1.0]hexane; 5-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-; CL-220075; PubChem18323; AC1L2J2O; SCHEMBL38793; AZA001; CHEMBL511099; OFYVIGTWSQPCLF-UHFFFAOYSA-N; NIH-9542; MCV-4147; BDBM50417944; AKOS006271730; DOV-220075; AN-3206; DB04889; KB-13207; 5-(p-tolyl)-3-azabicyclo[3.1.0]hexane; AM20041063; FT-0718156; 1-(p-tolyl)-3-azabicyclo[3.1.0]-hexane
DM42GP9	CP	Dov Pharmaceutical
DM42GP9	TC	Analgesics
DM42GP9	DT	Small molecular drug
DM42GP9	PC	47953
DM42GP9	MW	173.25
DM42GP9	FM	C12H15N
DM42GP9	IC	InChI=1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3
DM42GP9	CS	CC1=CC=C(C=C1)C23CC2CNC3
DM42GP9	IK	OFYVIGTWSQPCLF-UHFFFAOYSA-N
DM42GP9	IU	1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane
DM42GP9	CA	CAS 71195-57-8
DM42GP9	DE	Neuropathic pain; Chronic low back pain

DM57B9J	ID	DM57B9J
DM57B9J	DN	Biferonex
DM57B9J	HS	Phase 3
DM57B9J	SN	Beneferon; Beneserin; Interferon beta 1a, BioPartners; Interferon beta 1a, Rentschler/Berlex/Schering; Beta-interferon (1a), Schering/Dr Rentschler
DM57B9J	CP	Dr Rentschler Biotechnologie GmbH
DM57B9J	DE	Multiple sclerosis

DM51JW4	ID	DM51JW4
DM51JW4	DN	BIIB037
DM51JW4	HS	Phase 3
DM51JW4	CP	Biogen Idec
DM51JW4	DE	Alzheimer disease

DM0AEDT	ID	DM0AEDT
DM0AEDT	DN	BIIB067
DM0AEDT	HS	Phase 3
DM0AEDT	SN	IONIS-SOD1RX; Tofersen
DM0AEDT	CP	Ionis Pharmaceuticals
DM0AEDT	DT	Antisense oligonucleotide
DM0AEDT	DE	Amyotrophic lateral sclerosis

DMR9TF1	ID	DMR9TF1
DMR9TF1	DN	Bimekizumab
DMR9TF1	HS	Phase 3
DMR9TF1	CP	UCB Atlanta, GA
DMR9TF1	DE	Psoriatic arthritis; Plaque psoriasis

DMS2GA1	ID	DMS2GA1
DMS2GA1	DN	Bindarit
DMS2GA1	HS	Phase 3
DMS2GA1	SN	Bindarit, Angelini Pharmaceuticals; CCL2 inhibitor (inflammatory disorders/kidney disease), Angelini Pharmaceuticals; MCP-1 inhibitor (inflammatory disorder/kidney disease), Angelini Pharmaceuticals
DMS2GA1	CP	Angelini Pharmaceuticals SpA
DMS2GA1	DT	Small molecular drug
DMS2GA1	PC	71354
DMS2GA1	MW	324.4
DMS2GA1	FM	C19H20N2O3
DMS2GA1	IC	InChI=1S/C19H20N2O3/c1-19(2,18(22)23)24-13-16-15-10-6-7-11-17(15)21(20-16)12-14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3,(H,22,23)
DMS2GA1	CS	CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3
DMS2GA1	IK	MTHORRSSURHQPZ-UHFFFAOYSA-N
DMS2GA1	IU	2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid
DMS2GA1	CA	CAS 130641-38-2
DMS2GA1	DE	Nephritis

DMVHF8G	ID	DMVHF8G
DMVHF8G	DN	Binodenoson
DMVHF8G	HS	Phase 3
DMVHF8G	SN	CorVue; MRE-0470; MRE-0479; MRE-470; SHA-174; WRC-0470
DMVHF8G	CP	Aderis Pharmaceuticals Inc
DMVHF8G	DT	Small molecular drug
DMVHF8G	PC	9576912
DMVHF8G	MW	391.4
DMVHF8G	FM	C17H25N7O4
DMVHF8G	IC	InChI=1S/C17H25N7O4/c18-14-11-15(22-17(21-14)23-20-6-9-4-2-1-3-5-9)24(8-19-11)16-13(27)12(26)10(7-25)28-16/h6,8-10,12-13,16,25-27H,1-5,7H2,(H3,18,21,22,23)/b20-6+/t10-,12-,13-,16-/m1/s1
DMVHF8G	CS	C1CCC(CC1)/C=N/NC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DMVHF8G	IK	XJFMHMFFBSOEPR-DNZQAUTHSA-N
DMVHF8G	IU	(2R,3R,4S,5R)-2-[6-amino-2-[(2E)-2-(cyclohexylmethylidene)hydrazinyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMVHF8G	CA	CAS 144348-08-3
DMVHF8G	DE	Hypertension

DME76AP	ID	DME76AP
DME76AP	DN	Bis(olanzapine) pamoate monohydrate
DME76AP	HS	Phase 3
DME76AP	SN	Bis[2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine] 4,4'-methylenebis(3-hydroxynaphthalen-2-carboxylic acid) salt monohydrate
DME76AP	DE	Psychotic disorder

DMW34B1	ID	DMW34B1
DMW34B1	DN	BL-8040
DMW34B1	HS	Phase 3
DMW34B1	CP	BioLineRx
DMW34B1	DT	Peptide
DMW34B1	PC	91865076
DMW34B1	MW	2159.5
DMW34B1	FM	C97H144FN33O19S2
DMW34B1	IC	InChI=1S/C97H144FN33O19S2/c98-60-33-31-58(32-34-60)78(135)119-65(19-8-42-113-93(104)105)79(136)121-68(21-10-44-115-95(108)109)83(140)126-73(51-56-25-30-57-14-1-2-15-59(57)48-56)87(144)130-75-53-152-151-52-74(88(145)118-63(77(101)134)18-7-41-112-92(102)103)129-84(141)69(23-12-46-117-97(111)150)122-81(138)66(20-9-43-114-94(106)107)124-86(143)72(50-55-28-37-62(133)38-29-55)128-90(147)76-24-13-47-131(76)91(148)70(17-4-6-40-100)125-82(139)64(16-3-5-39-99)120-80(137)67(22-11-45-116-96(110)149)123-85(142)71(127-89(75)146)49-54-26-35-61(132)36-27-54/h1-2,14-15,25-38,48,63-76,132-133H,3-13,16-24,39-47,49-53,99-100H2,(H2,101,134)(H,118,145)(H,119,135)(H,120,137)(H,121,136)(H,122,138)(H,123,142)(H,124,143)(H,125,139)(H,126,140)(H,127,146)(H,128,147)(H,129,141)(H,130,144)(H4,102,103,112)(H4,104,105,113)(H4,106,107,114)(H4,108,109,115)(H3,110,116,149)(H3,111,117,150)/t63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-/m0/s1
DMW34B1	CS	C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC5=CC=CC=C5C=C4)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O
DMW34B1	IK	JJVZSYKFCOBILL-MKMRYRNGSA-N
DMW34B1	IU	(3S,6S,9S,12S,15R,20R,23S,26S,29S,32S)-3,6-bis(4-aminobutyl)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-15-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-5-carbamimidamido-2-[(4-fluorobenzoyl)amino]pentanoyl]amino]pentanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-26-(3-carbamimidamidopropyl)-9,23-bis[3-(carbamoylamino)propyl]-12,29-bis[(4-hydroxyphenyl)methyl]-2,5,8,11,14,22,25,28,31-nonaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-20-carboxamide
DMW34B1	CA	CAS 664334-36-5
DMW34B1	CB	CHEBI:145536
DMW34B1	DE	Acute myeloid leukaemia; Pancreatic cancer; Myelodysplastic syndrome; Multiple myeloma

DM7V9LH	ID	DM7V9LH
DM7V9LH	DN	Blisibimod
DM7V9LH	HS	Phase 3
DM7V9LH	CP	Anthera Pharmaceuticals Hayward, CA
DM7V9LH	DE	Systemic lupus erythematosus

DM36C17	ID	DM36C17
DM36C17	DN	Blonanserin
DM36C17	HS	Phase 3
DM36C17	SN	Lonasen; Blonanserin [INN]; AD 5423; AD-5423; Blonanserin (JAN/INN); 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
DM36C17	CP	Dainippon
DM36C17	DT	Small molecular drug
DM36C17	PC	125564
DM36C17	MW	367.5
DM36C17	FM	C23H30FN3
DM36C17	IC	InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3
DM36C17	CS	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F
DM36C17	IK	XVGOZDAJGBALKS-UHFFFAOYSA-N
DM36C17	IU	2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
DM36C17	CA	CAS 132810-10-7
DM36C17	CB	CHEBI:31296
DM36C17	DE	Schizophrenia

DMBXR23	ID	DMBXR23
DMBXR23	DN	BMN-110
DMBXR23	HS	Phase 3
DMBXR23	SN	Enzyme replacement therapy (iv infusion, MPS IVA), BioMarin; Enzyme replacement therapy (iv infusion, Morquio A syndrome), BioMarin; Enzyme replacement therapy (iv infusion, mucopolysaccharidosis IVA), BioMarin; N-acetylgalactosamine-6-sulfatase (GALNS) (Morquio A syndrome), BioMarin
DMBXR23	CP	Biomarin pharmaceutical
DMBXR23	DE	Morquio syndrome

DMM9XL2	ID	DMM9XL2
DMM9XL2	DN	BMN-111
DMM9XL2	HS	Phase 3
DMM9XL2	SN	C-type natriuretic peptide analog (achondroplasia), BioMarin
DMM9XL2	CP	Biomarin pharmaceutical
DMM9XL2	PC	119058036
DMM9XL2	MW	4103
DMM9XL2	FM	C176H290N56O51S3
DMM9XL2	IC	InChI=1S/C176H290N56O51S3/c1-14-95(10)143-172(280)201-84-138(245)209-125(86-234)168(276)221-113(54-65-284-13)159(267)229-124(85-233)152(260)200-81-135(242)206-114(66-91(2)3)150(258)198-83-140(247)211-128(174(282)283)89-286-285-88-127(170(278)224-118(70-98-34-16-15-17-35-98)151(259)199-80-137(244)207-115(67-92(4)5)162(270)217-108(41-23-29-60-182)155(263)223-117(69-94(8)9)164(272)226-122(75-142(250)251)167(275)219-110(160(268)231-143)44-32-63-193-176(188)189)210-139(246)82-197-149(257)105(38-20-26-57-179)215-169(277)126(87-235)230-163(271)116(68-93(6)7)208-136(243)79-196-147(255)103(36-18-24-55-177)213-153(261)106(39-21-27-58-180)218-166(274)121(74-132(185)239)222-144(252)96(11)203-133(240)77-195-148(256)104(37-19-25-56-178)214-165(273)119(71-99-46-48-101(236)49-47-99)225-156(264)107(40-22-28-59-181)216-154(262)109(43-31-62-192-175(186)187)212-145(253)97(12)204-161(269)120(73-131(184)238)227-171(279)129-45-33-64-232(129)173(281)123(72-100-76-190-90-202-100)228-158(266)112(51-53-141(248)249)220-157(265)111(50-52-130(183)237)205-134(241)78-194-146(254)102-42-30-61-191-102/h15-17,34-35,46-49,76,90-97,102-129,143,191,233-236H,14,18-33,36-45,50-75,77-89,177-182H2,1-13H3,(H2,183,237)(H2,184,238)(H2,185,239)(H,190,202)(H,194,254)(H,195,256)(H,196,255)(H,197,257)(H,198,258)(H,199,259)(H,200,260)(H,201,280)(H,203,240)(H,204,269)(H,205,241)(H,206,242)(H,207,244)(H,208,243)(H,209,245)(H,210,246)(H,211,247)(H,212,253)(H,213,261)(H,214,273)(H,215,277)(H,216,262)(H,217,270)(H,218,274)(H,219,275)(H,220,265)(H,221,276)(H,222,252)(H,223,263)(H,224,278)(H,225,264)(H,226,272)(H,227,279)(H,228,266)(H,229,267)(H,230,271)(H,231,268)(H,248,249)(H,250,251)(H,282,283)(H4,186,187,192)(H4,188,189,193)/t95-,96-,97-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,143-/m0/s1
DMM9XL2	CS	CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO
DMM9XL2	IK	IGYWDDBBJPSOTG-WBAGYEQSSA-N
DMM9XL2	IU	(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-5-amino-5-oxo-2-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]hexanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-[(2S)-butan-2-yl]-31-(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,22-bis(hydroxymethyl)-10,37,43-tris(2-methylpropyl)-19-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carboxylic acid
DMM9XL2	CA	CAS 1480724-61-5
DMM9XL2	DE	Achondroplasia

DM94Y6O	ID	DM94Y6O
DM94Y6O	DN	BMN-701
DM94Y6O	HS	Phase 3
DM94Y6O	SN	IGF2-GAA; XC-701; ZC-701; Enzyme replacement therapy (GILT, Pompe disease), BioMarin/ZyStor
DM94Y6O	CP	Biomarin pharmaceutical
DM94Y6O	DE	Pompe disease; Type 2 glycogen storage disease

DMDAN8H	ID	DMDAN8H
DMDAN8H	DN	BMS-582664
DMDAN8H	HS	Phase 3
DMDAN8H	SN	Brivanib alaninate; BMS 582664; BMS582664; BMS-582664, Brivanib alaninate; Brivanib alaninate (INN/USAN); L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester
DMDAN8H	CP	Bristol Myers Squibb
DMDAN8H	TC	Anticancer Agents
DMDAN8H	DT	Small molecular drug
DMDAN8H	PC	11154925
DMDAN8H	MW	441.5
DMDAN8H	FM	C22H24FN5O4
DMDAN8H	IC	InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1
DMDAN8H	CS	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@H](C)N)C
DMDAN8H	IK	LTEJRLHKIYCEOX-OCCSQVGLSA-N
DMDAN8H	IU	[(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] (2S)-2-aminopropanoate
DMDAN8H	CA	CAS 649735-63-7
DMDAN8H	DE	Hepatocellular carcinoma

DMAR1YS	ID	DMAR1YS
DMAR1YS	DN	BMS-986165
DMAR1YS	HS	Phase 3
DMAR1YS	CP	Bristol-Myers Squibb Princeton, NJ
DMAR1YS	PC	134821691
DMAR1YS	MW	425.5
DMAR1YS	FM	C20H22N8O3
DMAR1YS	IC	InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
DMAR1YS	CS	[2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
DMAR1YS	IK	BZZKEPGENYLQSC-FIBGUPNXSA-N
DMAR1YS	IU	6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
DMAR1YS	CA	CAS 1609392-27-9
DMAR1YS	DE	Plaque psoriasis; Psoriasis vulgaris

DM3MAYQ	ID	DM3MAYQ
DM3MAYQ	DN	BMS-986205
DM3MAYQ	HS	Phase 3
DM3MAYQ	SN	KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
DM3MAYQ	CP	Bristol-Myers Squibb Princeton, NJ
DM3MAYQ	PC	121328278
DM3MAYQ	MW	410.9
DM3MAYQ	FM	C24H24ClFN2O
DM3MAYQ	IC	InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16?,17?/m1/s1
DM3MAYQ	CS	C[C@H](C1CCC(CC1)C2=C3C=C(C=CC3=NC=C2)F)C(=O)NC4=CC=C(C=C4)Cl
DM3MAYQ	IK	KRTIYQIPSAGSBP-KLAILNCOSA-N
DM3MAYQ	IU	(2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide
DM3MAYQ	CA	CAS 1923833-60-6
DM3MAYQ	DE	Advanced cancer; Gastric adenocarcinoma; Melanoma; Renal cell carcinoma; Solid tumour/cancer

DM2OBNW	ID	DM2OBNW
DM2OBNW	DN	Bococizumab
DM2OBNW	HS	Phase 3
DM2OBNW	CP	Pfizer
DM2OBNW	DT	Antibody
DM2OBNW	DE	Chronic obstructive pulmonary disease

DM6KRLW	ID	DM6KRLW
DM6KRLW	DN	BQ788
DM6KRLW	HS	Phase 3
DM6KRLW	SN	(2R)-2-[[(2R)-2-amino-3-(1-methoxycarbonylindol-3-yl)propanoyl]-[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]hexanoic acid; BQ 788; AC1MIWQ3; GTPL1010; SCHEMBL18429752
DM6KRLW	DT	Small molecular drug
DM6KRLW	PC	16759603
DM6KRLW	MW	663.8
DM6KRLW	FM	C34H50N5NaO7
DM6KRLW	IC	InChI=1S/C34H51N5O7.Na/c1-8-9-16-25(31(42)43)35-29(40)26(18-23-20-38(33(45)46-7)28-17-11-10-15-24(23)28)36-30(41)27(19-34(4,5)6)37-32(44)39-21(2)13-12-14-22(39)3;/h10-11,15,17,20-22,25-27H,8-9,12-14,16,18-19H2,1-7H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43);/q;+1/p-1/t21-,22+,25-,26-,27+;/m1./s1
DM6KRLW	CS	CCCC[C@H](C(=O)[O-])NC(=O)[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)OC)NC(=O)[C@H](CC(C)(C)C)NC(=O)N3[C@@H](CCC[C@@H]3C)C.[Na+]
DM6KRLW	IK	QCVIFBRTTLMEOV-FUKQNADPSA-M
DM6KRLW	IU	sodium;(2R)-2-[[(2R)-2-[[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]-3-(1-methoxycarbonylindol-3-yl)propanoyl]amino]hexanoate
DM6KRLW	CA	CAS 156161-89-6
DM6KRLW	DE	Hypertension; Acute kidney injury; Encephalopathy; Myasthenia gravis; Neuromyelitis optica

DM942HP	ID	DM942HP
DM942HP	DN	Brivanib
DM942HP	HS	Phase 3
DM942HP	SN	Brivanib; 649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol
DM942HP	CP	Bristol-Myers Squibb
DM942HP	DT	Small molecular drug
DM942HP	PC	11234052
DM942HP	MW	370.4
DM942HP	FM	C19H19FN4O3
DM942HP	IC	InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
DM942HP	CS	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C
DM942HP	IK	WCWUXEGQKLTGDX-LLVKDONJSA-N
DM942HP	IU	(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol
DM942HP	CA	CAS 649735-46-6
DM942HP	CB	CHEBI:94562
DM942HP	DE	Liver cancer; Breast cancer

DMM0VO3	ID	DMM0VO3
DMM0VO3	DN	BSI-201
DMM0VO3	HS	Phase 3
DMM0VO3	SN	Iniparib; NIBA; INO2BA; IND-71677; SAR-240550; Iniparib, NSC-746045, IND-71677, BSI201, BSI-201; 4-Iodo-3-nitrobenzamide; 4-iodo-3-nitro-benzamide
DMM0VO3	CP	Sanofi-Aventis
DMM0VO3	DT	Small molecular drug
DMM0VO3	PC	9796068
DMM0VO3	MW	292.03
DMM0VO3	FM	C7H5IN2O3
DMM0VO3	IC	InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)
DMM0VO3	CS	C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I
DMM0VO3	IK	MDOJTZQKHMAPBK-UHFFFAOYSA-N
DMM0VO3	IU	4-iodo-3-nitrobenzamide
DMM0VO3	CA	CAS 160003-66-7
DMM0VO3	CB	CHEBI:95067
DMM0VO3	DE	Solid tumour/cancer

DM50SNX	ID	DM50SNX
DM50SNX	DN	Bucelipase alfa
DM50SNX	HS	Phase 3
DM50SNX	SN	Exinalda; Kiobrina; BSSL, Biovitrum; Bile salt stimulated lipase, Arexis; Bile salt stimulated lipase, Biovitrum; Bile salt stimulated lipase, PPL Therapeutics; HrBSSL, Biovitrum; Human recombinant bile salt stimulated lipase, Biovitrum; TgBSSL, PPL Therapeutics
DM50SNX	CP	Astra Hassle AB
DM50SNX	DE	Exocrine pancreatic insufficiency

DM1WEHC	ID	DM1WEHC
DM1WEHC	DN	Buparlisib
DM1WEHC	HS	Phase 3
DM1WEHC	SN	BKM120
DM1WEHC	CP	Novartis
DM1WEHC	DT	Small molecular drug
DM1WEHC	PC	16654980
DM1WEHC	MW	410.4
DM1WEHC	FM	C18H21F3N6O2
DM1WEHC	IC	InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)
DM1WEHC	CS	C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
DM1WEHC	IK	CWHUFRVAEUJCEF-UHFFFAOYSA-N
DM1WEHC	IU	5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
DM1WEHC	CA	CAS 944396-07-0
DM1WEHC	CB	CHEBI:71954
DM1WEHC	DE	Breast cancer

DMAR9ND	ID	DMAR9ND
DMAR9ND	DN	Bupropion+Naltrexone
DMAR9ND	HS	Phase 3
DMAR9ND	SN	Mysimba; Contrave; Naltrexone/bupropion; Naltrexone / bupropion; Bupropion / naltrexone; Bupropion mixture with naltrexone; SCHEMBL15633271; 1201668-08-7
DMAR9ND	CP	Orexigen Therapeutics
DMAR9ND	DT	Small molecular drug
DMAR9ND	PC	11556075
DMAR9ND	MW	581.1
DMAR9ND	FM	C33H41ClN2O5
DMAR9ND	IC	InChI=1S/C20H23NO4.C13H18ClNO/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h3-4,11,15,18,22,24H,1-2,5-10H2;5-9,15H,1-4H3/t15-,18+,19+,20-;/m1./s1
DMAR9ND	CS	CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
DMAR9ND	IK	KVNBDVQGENTICK-ITLPAZOVSA-N
DMAR9ND	IU	(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
DMAR9ND	CA	CAS 1201668-08-7
DMAR9ND	DE	Obesity

DM6RUKX	ID	DM6RUKX
DM6RUKX	DN	BVT.2733
DM6RUKX	HS	Phase 3
DM6RUKX	SN	CHEMBL553071; AC1OCFOV; 376641-65-5; SCHEMBL5692696; MolPort-042-665-756; 3-chloro-2-methyl-N-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide hydrochloride
DM6RUKX	DT	Small molecular drug
DM6RUKX	PC	6918651
DM6RUKX	MW	429
DM6RUKX	FM	C17H21ClN4O3S2
DM6RUKX	IC	InChI=1S/C17H21ClN4O3S2/c1-12-14(18)4-3-5-15(12)27(24,25)20-17-19-13(11-26-17)10-16(23)22-8-6-21(2)7-9-22/h3-5,11H,6-10H2,1-2H3,(H,19,20)
DM6RUKX	CS	CC1=C(C=CC=C1Cl)S(=O)(=O)NC2=NC(=CS2)CC(=O)N3CCN(CC3)C
DM6RUKX	IK	YDPRNGAPPNPYQQ-UHFFFAOYSA-N
DM6RUKX	IU	3-chloro-2-methyl-N-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide
DM6RUKX	CA	CAS 376640-41-4
DM6RUKX	DE	Non-insulin dependent diabetes; Lupus; Myasthenia gravis; Systemic lupus erythematosus

DM1ARHT	ID	DM1ARHT
DM1ARHT	DN	BYM338
DM1ARHT	HS	Phase 3
DM1ARHT	CP	Novartis
DM1ARHT	DE	Acute myeloid leukaemia; Inclusion body myositis; Muscle atrophy

DMPTCYB	ID	DMPTCYB
DMPTCYB	DN	Cadi-05
DMPTCYB	HS	Phase 3
DMPTCYB	SN	Mycobacterium w; Poly-TLR agonist polyantigenic vaccine (cancer), Cadila; Poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila
DMPTCYB	CP	Cadila Pharmaceuticals Ltd
DMPTCYB	DT	Vaccine
DMPTCYB	DE	Prostate cancer

DM6CHNJ	ID	DM6CHNJ
DM6CHNJ	DN	Camptothecin
DM6CHNJ	HS	Phase 3
DM6CHNJ	SN	camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; d-Camptothecin; (+)-Camptothecine; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; (S)-Camptothecin; Camptothecine (8CI); 20(S)-Camptothecin; Camptothecine (S,+); CHEMBL65; UNII-XT3Z54Z28A; MLS000766223; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; XT3Z54Z28A; CHEBI:27656; VSJKWCGYPAHWDS-FQEVSTJZSA-N; Camptothecin, Camptotheca acuminata; NSC-94600; Camptothecin derivat
DM6CHNJ	DT	Small molecular drug
DM6CHNJ	PC	24360
DM6CHNJ	MW	348.4
DM6CHNJ	FM	C20H16N2O4
DM6CHNJ	IC	InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1
DM6CHNJ	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
DM6CHNJ	IK	VSJKWCGYPAHWDS-FQEVSTJZSA-N
DM6CHNJ	IU	(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DM6CHNJ	CA	CAS 7689-03-4
DM6CHNJ	CB	CHEBI:27656
DM6CHNJ	DE	Solid tumour/cancer

DMHJCGV	ID	DMHJCGV
DMHJCGV	DN	Candoxatril
DMHJCGV	HS	Phase 3
DMHJCGV	SN	UK 79300; Candoxatril [USAN:INN:BAN]; UK-79,300; Candoxatril (JAN/USAN/INN); Cyclohexanecarboxylic acid, 4-(((1-(2-carboxy-3-(2-methoxyethoxy)propyl)cyclopentyl)carbonyl)-amino)-, (4(S)-cis); [4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; Cis-4-{[(1-{(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl}cyclopentyl)carbonyl]amino}cyclohexanecarboxylic acid; (alphaS)-1-((cis-4-Carboxycyclohexyl)carbamoyl)-alpha-((2-methoxyethoxy)methyl)cyclopentanepropionic acid; 3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester; 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid; 4-[[1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
DMHJCGV	TC	Antihypertensive Agents
DMHJCGV	DT	Small molecular drug
DMHJCGV	PC	5362417
DMHJCGV	MW	515.6
DMHJCGV	FM	C29H41NO7
DMHJCGV	IC	InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21?,23-,24?/m0/s1
DMHJCGV	CS	COCCOC[C@H](CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3
DMHJCGV	IK	ZTWZVMIYIIVABD-RZMWZJFBSA-N
DMHJCGV	IU	4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
DMHJCGV	CA	CAS 123122-55-4
DMHJCGV	CB	CHEBI:3353
DMHJCGV	DE	Hypertension

DM4FHQR	ID	DM4FHQR
DM4FHQR	DN	Canfosfamide
DM4FHQR	HS	Phase 3
DM4FHQR	SN	Telcyta (TN)
DM4FHQR	CP	Telik
DM4FHQR	DT	Small molecular drug
DM4FHQR	PC	5312109
DM4FHQR	MW	787.5
DM4FHQR	FM	C26H40Cl4N5O10PS
DM4FHQR	IC	InChI=1S/C26H40Cl4N5O10PS/c27-8-12-34(13-9-28)46(42,35(14-10-29)15-11-30)45-16-17-47(43,44)18-21(32-22(36)7-6-20(31)25(38)39)24(37)33-23(26(40)41)19-4-2-1-3-5-19/h1-5,20-21,23H,6-18,31H2,(H,32,36)(H,33,37)(H,38,39)(H,40,41)/t20-,21-,23+/m0/s1
DM4FHQR	CS	C1=CC=C(C=C1)[C@H](C(=O)O)NC(=O)[C@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)NC(=O)CC[C@@H](C(=O)O)N
DM4FHQR	IK	OJLHWPALWODJPQ-QNWVGRARSA-N
DM4FHQR	IU	(2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM4FHQR	CA	CAS 158382-37-7
DM4FHQR	CB	CHEBI:135883
DM4FHQR	DE	Solid tumour/cancer

DMMZDJ6	ID	DMMZDJ6
DMMZDJ6	DN	Captopril
DMMZDJ6	HS	Phase 3
DMMZDJ6	SN	captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Cesplon; Captolane; Tensoprel; Dilabar; Acepress; Captoril; Tenosbon; Hypertil; Garranil; Alopresin; Lopril; Acepril; Captoprilum; Aceplus; Acediur; Tensobon; Isopresol;Apopril; Asisten; Captoprilum [INN-Latin]; SQ 14225; SQ-14225; SQ 14,225; SA 333; Captopril
DMMZDJ6	TC	Antiviral Agents
DMMZDJ6	DT	Small molecular drug
DMMZDJ6	PC	44093
DMMZDJ6	MW	217.29
DMMZDJ6	FM	C9H15NO3S
DMMZDJ6	IC	InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
DMMZDJ6	CS	C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
DMMZDJ6	IK	FAKRSMQSSFJEIM-RQJHMYQMSA-N
DMMZDJ6	IU	(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
DMMZDJ6	CA	CAS 62571-86-2
DMMZDJ6	CB	CHEBI:3380
DMMZDJ6	DE	Coronavirus Disease 2019 (COVID-19)

DMUVMWZ	ID	DMUVMWZ
DMUVMWZ	DN	Carebastine
DMUVMWZ	HS	Phase 3
DMUVMWZ	SN	Carebastina; Carebastinum; Carebastina [Spanish]; Carebastine [INN]; Carebastinum [Latin]; E00013; P-(4-(4-(Diphenylmethoxy)piperidino)butyryl)-alpha-methylhydratropic acid; 2-(4-(4-(4-Benzhydryloxypiperidino)butyryl)phenyl)-2-methylpropionsaeure; 2-[4-[4-(4-benzhydryloxypiperidin-1-yl)butanoyl]phenyl]-2-methylpropanoic acid
DMUVMWZ	CP	Almirall Prodesfarma
DMUVMWZ	DT	Small molecular drug
DMUVMWZ	PC	65820
DMUVMWZ	MW	499.6
DMUVMWZ	FM	C32H37NO4
DMUVMWZ	IC	InChI=1S/C32H37NO4/c1-32(2,31(35)36)27-17-15-24(16-18-27)29(34)14-9-21-33-22-19-28(20-23-33)37-30(25-10-5-3-6-11-25)26-12-7-4-8-13-26/h3-8,10-13,15-18,28,30H,9,14,19-23H2,1-2H3,(H,35,36)
DMUVMWZ	CS	CC(C)(C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)O
DMUVMWZ	IK	XGHOVGYJHWQGCC-UHFFFAOYSA-N
DMUVMWZ	IU	2-[4-[4-(4-benzhydryloxypiperidin-1-yl)butanoyl]phenyl]-2-methylpropanoic acid
DMUVMWZ	CA	CAS 90729-42-3
DMUVMWZ	DE	Ocular allergy

DM4Y1SP	ID	DM4Y1SP
DM4Y1SP	DN	Carisbamate
DM4Y1SP	HS	Phase 3
DM4Y1SP	SN	Comfyde; JNJ 10234094; RWJ 333369; YKP 509; Carisbamate (USAN); JNJ-10234094; RWJ-333369; YKP-509; S-2-O-Carbamoyl-1-o-chlorophenyl-ethanol; [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate
DM4Y1SP	CP	Johnson & Johnson
DM4Y1SP	DT	Small molecular drug
DM4Y1SP	PC	6918474
DM4Y1SP	MW	215.63
DM4Y1SP	FM	C9H10ClNO3
DM4Y1SP	IC	InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1
DM4Y1SP	CS	C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl
DM4Y1SP	IK	OLBWFRRUHYQABZ-MRVPVSSYSA-N
DM4Y1SP	IU	[(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate
DM4Y1SP	CA	CAS 194085-75-1
DM4Y1SP	CB	CHEBI:135966
DM4Y1SP	DE	Seizure disorder; Focal dystonia; Epilepsy

DMPG4OM	ID	DMPG4OM
DMPG4OM	DN	CAZ AVI
DMPG4OM	HS	Phase 3
DMPG4OM	SN	CAZ104
DMPG4OM	CP	AstraZeneca
DMPG4OM	DE	Serious infection

DM097UP	ID	DM097UP
DM097UP	DN	CBT-1
DM097UP	HS	Phase 3
DM097UP	CP	National Institutes of Health Clinical Center (CC)
DM097UP	DE	Non-small-cell lung cancer; Solid tumour/cancer

DMV7WSN	ID	DMV7WSN
DMV7WSN	DN	CC-25430
DMV7WSN	HS	Phase 3
DMV7WSN	SN	Caroverin; Caroverina; Caroverina [INN-Spanish]; Caroverine; Caroverine (INN); Caroverine [INN]; Caroverinum; Caroverinum [INN-Latin]; P 201-1; Spasmium; Spasmium (TN); Tox21_113512; XJ73B0K6KB; ZINC4212360; 1-Diethylaminoethyl-3-(p-methoxybenzyl)quinoxalone-2; 23465-76-1; AC1L23SW; BRD-K70161083-003-01-4; C-23692; CAS-23465-76-1; CC-25430; CHEBI:135541; CHEMBL1729803; D07098; DSSTox_CID_28936; DSSTox_GSID_49010; DSSTox_RID_83202; DTXSID6049010; FT-0716182; MFCD00865257; NCGC00186046-01; NCGC00186046-02; SCHEMBL25946; UNII-XJ73B0K6KB; P-201
DMV7WSN	PC	65709
DMV7WSN	MW	365.5
DMV7WSN	FM	C22H27N3O2
DMV7WSN	IC	MSPRUJDUTKRMLM-UHFFFAOYSA-N
DMV7WSN	CS	CCN(CC)CCN1C2=CC=CC=C2N=C(C1=O)CC3=CC=C(C=C3)OC
DMV7WSN	IK	1S/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3
DMV7WSN	IU	1-[2-(diethylamino)ethyl]-3-[(4-methoxyphenyl)methyl]quinoxalin-2-one
DMV7WSN	CA	CAS 23465-76-1
DMV7WSN	CB	CHEBI:135541
DMV7WSN	DE	Tinnitus

DMTNQB0	ID	DMTNQB0
DMTNQB0	DN	CC-486
DMTNQB0	HS	Phase 3
DMTNQB0	SN	AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917;  Nucleoside analogue
DMTNQB0	CP	Celgene
DMTNQB0	DT	Small molecular drug
DMTNQB0	PC	9840076
DMTNQB0	MW	320.4
DMTNQB0	FM	C19H20N4O
DMTNQB0	IC	InChI=1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24)
DMTNQB0	CS	CN(C)CC1=CC=C(C=C1)C2=NC3=CC=CC4=C3N2CCNC4=O
DMTNQB0	IK	SEKJSSBJKFLZIT-UHFFFAOYSA-N
DMTNQB0	IU	2-[4-[(dimethylamino)methyl]phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one
DMTNQB0	CA	CAS 328543-09-5
DMTNQB0	CB	CHEBI:92015
DMTNQB0	DE	Myelodysplastic syndrome; Acute myeloid leukaemia; Diffuse large B-cell lymphoma

DM5LQHB	ID	DM5LQHB
DM5LQHB	DN	CCX-168
DM5LQHB	HS	Phase 3
DM5LQHB	SN	Avacopan
DM5LQHB	CP	ChemoCentryx
DM5LQHB	PC	49841217
DM5LQHB	MW	581.6
DM5LQHB	FM	C33H35F4N3O2
DM5LQHB	IC	InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1
DM5LQHB	CS	CC1=C(C(=CC=C1)F)C(=O)N2CCC[C@@H]([C@@H]2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F
DM5LQHB	IK	PUKBOVABABRILL-YZNIXAGQSA-N
DM5LQHB	IU	(2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide
DM5LQHB	CA	CAS 1346623-17-3
DM5LQHB	DE	Eosinophilic granulomatosis with polyangiitis; Hereditary haemolytic anemia; Anca-associated vasculitis

DMWO5ZR	ID	DMWO5ZR
DMWO5ZR	DN	Cediranib
DMWO5ZR	HS	Phase 3
DMWO5ZR	SN	Recentin; AZD 2171; AZD2171; M6294; AZD-2171; ZD-2171; AZD2171, Recentin, Cediranib; Cediranib (USAN/INN); 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
DMWO5ZR	CP	AstraZeneca
DMWO5ZR	TC	Anticancer Agents
DMWO5ZR	DT	Small molecular drug
DMWO5ZR	PC	9933475
DMWO5ZR	MW	450.5
DMWO5ZR	FM	C25H27FN4O3
DMWO5ZR	IC	InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
DMWO5ZR	CS	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
DMWO5ZR	IK	XXJWYDDUDKYVKI-UHFFFAOYSA-N
DMWO5ZR	IU	4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
DMWO5ZR	CA	CAS 288383-20-0
DMWO5ZR	CB	CHEBI:94782
DMWO5ZR	DE	Peritoneal cavity cancer

DMLWIU4	ID	DMLWIU4
DMLWIU4	DN	Cefluprenam
DMLWIU4	HS	Phase 3
DMLWIU4	SN	E-1077
DMLWIU4	CP	Eisai Co Ltd
DMLWIU4	DT	Small molecular drug
DMLWIU4	PC	6536774
DMLWIU4	MW	556.6
DMLWIU4	FM	C20H25FN8O6S2
DMLWIU4	IC	InChI=1S/C20H25FN8O6S2/c1-3-29(2,7-11(22)30)6-4-5-10-8-36-18-13(17(32)28(18)14(10)19(33)34)24-16(31)12(26-35-9-21)15-25-20(23)37-27-15/h4-5,13,18H,3,6-9H2,1-2H3,(H5-,22,23,24,25,27,30,31,33,34)/b5-4+,26-12-/t13-,18-,29?/m1/s1
DMLWIU4	CS	CC[N+](C)(C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCF)/C3=NSC(=N3)N)SC1)C(=O)[O-])CC(=O)N
DMLWIU4	IK	XAKKNLNAJBNLPC-MAYKBZFQSA-N
DMLWIU4	IU	(6R,7R)-3-[(E)-3-[(2-amino-2-oxoethyl)-ethyl-methylazaniumyl]prop-1-enyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMLWIU4	CA	CAS 116853-25-9
DMLWIU4	CB	CHEBI:3488
DMLWIU4	DE	Bacterial infection

DMM76GL	ID	DMM76GL
DMM76GL	DN	Ceftobiprole
DMM76GL	HS	Phase 3
DMM76GL	SN	BAL 9141; BAL 9141-000; BAL-9141; Ro 63-9141; Ro-63-9141; Ro-63-9141/000; (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMM76GL	CP	Johnson & Johnson
DMM76GL	DT	Small molecular drug
DMM76GL	PC	135413542
DMM76GL	MW	534.6
DMM76GL	FM	C20H22N8O6S2
DMM76GL	IC	InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1
DMM76GL	CS	C1CNC[C@@H]1N2CC/C(=C\\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\\O)/C5=NSC(=N5)N)SC3)C(=O)O)/C2=O
DMM76GL	IK	VOAZJEPQLGBXGO-SDAWRPRTSA-N
DMM76GL	IU	(6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMM76GL	CA	CAS 209467-52-7
DMM76GL	CB	CHEBI:140407
DMM76GL	DE	Community-acquired pneumonia; Skin and skin-structure infection

DMWLF2X	ID	DMWLF2X
DMWLF2X	DN	Ceftobiprole medocaril
DMWLF2X	HS	Phase 3
DMWLF2X	SN	UNII-YXV28V1B07; YXV28V1B07; BAL5788; 376653-43-9; ceftobiprolemedocaril; Ceftobiprole Medocaril [INN]; SCHEMBL2671859; SCHEMBL19236293; CHEBI:135968; DB14733; 653C439; (6R,7R)-7-((2Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetamido)-3-((E)((3'R)-1'-((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl)-2-oxo-(1,3'-bipyrrolidin)-3-ylidene)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
DMWLF2X	CP	Basilea Pharmaceutica
DMWLF2X	DT	Small molecular drug
DMWLF2X	PC	135413544
DMWLF2X	MW	690.7
DMWLF2X	FM	C26H26N8O11S2
DMWLF2X	IC	InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31)/b11-6+,30-15-/t13-,16-,22-/m1/s1
DMWLF2X	CS	CC1=C(OC(=O)O1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\\O)/C6=NSC(=N6)N)SC4)C(=O)O)/C3=O
DMWLF2X	IK	HFTSMHTWUFCYMJ-YIOMYIDASA-N
DMWLF2X	IU	(6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-3-[(E)-[1-[(3R)-1-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl]pyrrolidin-3-yl]-2-oxopyrrolidin-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMWLF2X	CA	CAS 376653-43-9
DMWLF2X	CB	CHEBI:135968
DMWLF2X	DE	Skin and skin-structure infection

DMIGX84	ID	DMIGX84
DMIGX84	DN	Cethromycin
DMIGX84	HS	Phase 3
DMIGX84	SN	Restanza; Cethromycin [USAN]; ABT 773; A-195773; ABT-773; Abbott-195773; A-195773.0; Cethromycin (USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1S,2R,5R,7R,8R,9R,11R,13R,14R)-2-Ethyl-1,5,7,9,11,13-Hexamethyl-9-[3-(3-quinolyl)-2(E)-propenyloxy]-8-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-glucopyranosyloxy]-3,17-dioxa-15-azabicyclo[12.3.0]hepta; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15 hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15-hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone
DMIGX84	CP	Advanced life sciences
DMIGX84	DT	Small molecular drug
DMIGX84	PC	447451
DMIGX84	MW	765.9
DMIGX84	FM	C42H59N3O10
DMIGX84	IC	InChI=1S/C42H59N3O10/c1-11-32-42(8)36(44-40(50)55-42)25(4)33(46)23(2)21-41(7,51-18-14-15-28-20-29-16-12-13-17-30(29)43-22-28)37(26(5)34(47)27(6)38(49)53-32)54-39-35(48)31(45(9)10)19-24(3)52-39/h12-17,20,22-27,31-32,35-37,39,48H,11,18-19,21H2,1-10H3,(H,44,50)/b15-14+/t23-,24-,25+,26+,27-,31+,32-,35-,36-,37-,39+,41-,42-/m1/s1
DMIGX84	CS	CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC/C=C/C4=CC5=CC=CC=C5N=C4)C)C)NC(=O)O2)C
DMIGX84	IK	PENDGIOBPJLVBT-ONLVEXIXSA-N
DMIGX84	IU	(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMIGX84	CA	CAS 205110-48-1
DMIGX84	CB	CHEBI:29506
DMIGX84	DE	Bacterial infection; Pneumonia

DMWAHTN	ID	DMWAHTN
DMWAHTN	DN	Cetilistat
DMWAHTN	HS	Phase 3
DMWAHTN	SN	Cametor; Cetilistat [INN]; ATL 962; ATL962; ATL-962; Cetilistat (JAN/USAN/INN); 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one
DMWAHTN	CP	Alizyme; Takeda; Norgine B.V.
DMWAHTN	DT	Small molecular drug
DMWAHTN	PC	9952916
DMWAHTN	MW	401.6
DMWAHTN	FM	C25H39NO3
DMWAHTN	IC	InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3
DMWAHTN	CS	CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C=C2)C)C(=O)O1
DMWAHTN	IK	MVCQKIKWYUURMU-UHFFFAOYSA-N
DMWAHTN	IU	2-hexadecoxy-6-methyl-3,1-benzoxazin-4-one
DMWAHTN	CA	CAS 282526-98-1
DMWAHTN	CB	CHEBI:134721
DMWAHTN	DE	Obesity; Diabetic complication

DMX9K3W	ID	DMX9K3W
DMX9K3W	DN	Cetraxal Otic
DMX9K3W	HS	Phase 3
DMX9K3W	SN	Ciprofloxacin otic
DMX9K3W	CP	Salvat Laboratories
DMX9K3W	DE	Otitis externa

DMIKMA9	ID	DMIKMA9
DMIKMA9	DN	CG-100649
DMIKMA9	HS	Phase 3
DMIKMA9	SN	Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; CG-100649; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399
DMIKMA9	CP	CG Pharmaceuticals
DMIKMA9	DT	Small molecular drug
DMIKMA9	PC	9841854
DMIKMA9	MW	361.4
DMIKMA9	FM	C18H16FNO4S
DMIKMA9	IC	InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23)
DMIKMA9	CS	CC1(C(=O)C(=C(O1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC(=CC=C3)F)C
DMIKMA9	IK	IJWPAFMIFNSIGD-UHFFFAOYSA-N
DMIKMA9	IU	4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide
DMIKMA9	CA	CAS 301692-76-2
DMIKMA9	DE	Arthritis

DM1TJXA	ID	DM1TJXA
DM1TJXA	DN	Chloride
DM1TJXA	HS	Phase 3
DM1TJXA	SN	chloride ion; 16887-00-6; Chloride(1-); Chloride anion; Chlorine, ion; UNII-Q32ZN48698; Hydrochloric acid, ion(1-); Chlorid; CHEMBL19429; Cl-; CHEBI:17996; Q32ZN48698; Chlorides; Chloride ions; Chloride (ion); Perchloride; Chlorine anion; Chlorine ion; Chloride (Cl-); Chlorine(1-); Chlorine ion(1-); Chloride ion (1-); Chlorine, ion (Cl1-); AC1L18YJ; Cl(-); CTK0H5734; BDBM26979; VEXZGXHMUGYJMC-UHFFFAOYSA-M; c0884; AKOS015903642; FT-0755769; 3-Carbamoyl-1-ethoxymethylpyridinium chloride; 1-Butoxymethyl-3-carbamoyl-pyridinium
DM1TJXA	DT	Small molecular drug
DM1TJXA	PC	312
DM1TJXA	MW	35.45
DM1TJXA	FM	Cl-
DM1TJXA	IC	InChI=1S/ClH/h1H/p-1
DM1TJXA	CS	[Cl-]
DM1TJXA	IK	VEXZGXHMUGYJMC-UHFFFAOYSA-M
DM1TJXA	IU	chloride
DM1TJXA	CA	CAS 16887-00-6
DM1TJXA	CB	CHEBI:17996
DM1TJXA	DE	Solid tumour/cancer

DMORSFB	ID	DMORSFB
DMORSFB	DN	Chloroquine
DMORSFB	HS	Phase 3
DMORSFB	SN	Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244
DMORSFB	CP	Medreich Sterilab Ltd
DMORSFB	TC	Antiviral Agents
DMORSFB	DT	Small molecular drug
DMORSFB	PC	2719
DMORSFB	MW	319.9
DMORSFB	FM	C18H26ClN3
DMORSFB	IC	InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
DMORSFB	CS	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
DMORSFB	IK	WHTVZRBIWZFKQO-UHFFFAOYSA-N
DMORSFB	IU	4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
DMORSFB	CA	CAS 54-05-7
DMORSFB	CB	CHEBI:3638
DMORSFB	DE	Malaria; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM5X7DJ	ID	DM5X7DJ
DM5X7DJ	DN	Chlorpromazine
DM5X7DJ	HS	Phase 3
DM5X7DJ	SN	Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
DM5X7DJ	CP	GlaxoSmithKline
DM5X7DJ	TC	Antiviral Agents
DM5X7DJ	DT	Small molecular drug
DM5X7DJ	PC	2726
DM5X7DJ	MW	318.9
DM5X7DJ	FM	C17H19ClN2S
DM5X7DJ	IC	InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
DM5X7DJ	CS	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DM5X7DJ	IK	ZPEIMTDSQAKGNT-UHFFFAOYSA-N
DM5X7DJ	IU	3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
DM5X7DJ	CA	CAS 34468-21-8
DM5X7DJ	CB	CHEBI:3647
DM5X7DJ	DE	Schizophrenia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM0Q6CM	ID	DM0Q6CM
DM0Q6CM	DN	CIGB-300
DM0Q6CM	HS	Phase 3
DM0Q6CM	SN	P15; IGBC-300; P15-Tat
DM0Q6CM	CP	Center for Genetic Engineering and Biotechnology
DM0Q6CM	PC	86290205
DM0Q6CM	MW	3060.6
DM0Q6CM	FM	C127H215N53O30S3
DM0Q6CM	IC	InChI=1S/C127H215N53O30S3/c1-66(2)55-84-100(189)157-61-97(187)177-98(67(3)182)116(205)176-89(120(209)210)64-213-212-63-88(113(202)173-85(56-68-59-156-71-22-6-5-21-70(68)71)111(200)168-82(40-54-211-4)110(199)175-87(62-181)118(207)178-51-18-32-90(178)114(203)169-79(30-16-48-154-126(143)144)108(197)174-86(112(201)172-84)57-69-60-147-65-158-69)160-95(185)39-50-148-99(188)80(35-37-93(131)183)170-115(204)91-33-19-52-179(91)119(208)92-34-20-53-180(92)117(206)83(31-17-49-155-127(145)146)171-107(196)78(29-15-47-153-125(141)142)165-105(194)76(27-13-45-151-123(137)138)166-109(198)81(36-38-94(132)184)167-106(195)77(28-14-46-152-124(139)140)164-104(193)75(26-12-44-150-122(135)136)163-103(192)74(24-8-10-42-129)162-102(191)73(23-7-9-41-128)161-101(190)72(159-96(186)58-130)25-11-43-149-121(133)134/h5-6,21-22,59-60,65-67,72-92,98,156,181-182H,7-20,23-58,61-64,128-130H2,1-4H3,(H2,131,183)(H2,132,184)(H,147,158)(H,148,188)(H,157,189)(H,159,186)(H,160,185)(H,161,190)(H,162,191)(H,163,192)(H,164,193)(H,165,194)(H,166,198)(H,167,195)(H,168,200)(H,169,203)(H,170,204)(H,171,196)(H,172,201)(H,173,202)(H,174,197)(H,175,199)(H,176,205)(H,177,187)(H,209,210)(H4,133,134,149)(H4,135,136,150)(H4,137,138,151)(H4,139,140,152)(H4,141,142,153)(H4,143,144,154)(H4,145,146,155)/t67-,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,98+/m1/s1
DM0Q6CM	CS	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CC(C)C)CC3=CNC=N3)CCCNC(=N)N)CO)CCSC)CC4=CNC5=CC=CC=C54)NC(=O)CCNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]6CCCN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)O)O
DM0Q6CM	IK	RNELHWXSRSKXRD-QNKYCTLBSA-N
DM0Q6CM	IU	(3S,6S,9S,12R,17R,20S,26S,29S,32S,35S)-12-[3-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]propanoylamino]-32-(3-carbamimidamidopropyl)-20-[(1R)-1-hydroxyethyl]-3-(hydroxymethyl)-29-(1H-imidazol-4-ylmethyl)-9-(1H-indol-3-ylmethyl)-26-(2-methylpropyl)-6-(2-methylsulfanylethyl)-2,5,8,11,19,22,25,28,31,34-decaoxo-14,15-dithia-1,4,7,10,18,21,24,27,30,33-decazabicyclo[33.3.0]octatriacontane-17-carboxylic acid
DM0Q6CM	CB	CHEBI:83696
DM0Q6CM	DE	Cervical cancer

DMP0NGX	ID	DMP0NGX
DMP0NGX	DN	Cilansetron
DMP0NGX	HS	Phase 3
DMP0NGX	SN	Calmactin; DU-123265; KC-9946; Cilansetron (USAN/INN)
DMP0NGX	CP	Solvay Pharma
DMP0NGX	DT	Small molecular drug
DMP0NGX	PC	6918107
DMP0NGX	MW	319.4
DMP0NGX	FM	C20H21N3O
DMP0NGX	IC	InChI=1S/C20H21N3O/c1-13-21-9-11-22(13)12-15-7-8-17-18(20(15)24)16-6-2-4-14-5-3-10-23(17)19(14)16/h2,4,6,9,11,15H,3,5,7-8,10,12H2,1H3/t15-/m1/s1
DMP0NGX	CS	CC1=NC=CN1C[C@H]2CCC3=C(C2=O)C4=CC=CC5=C4N3CCC5
DMP0NGX	IK	NCNFDKWULDWJDS-OAHLLOKOSA-N
DMP0NGX	IU	(12R)-12-[(2-methylimidazol-1-yl)methyl]-1-azatetracyclo[7.6.1.05,16.010,15]hexadeca-5(16),6,8,10(15)-tetraen-11-one
DMP0NGX	CA	CAS 120635-74-7
DMP0NGX	DE	Irritable bowel syndrome

DMEAOZ0	ID	DMEAOZ0
DMEAOZ0	DN	Cilengitide
DMEAOZ0	HS	Phase 3
DMEAOZ0	SN	Cilengitide; 188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt)
DMEAOZ0	DT	Small molecular drug
DMEAOZ0	PC	176873
DMEAOZ0	MW	588.7
DMEAOZ0	FM	C27H40N8O7
DMEAOZ0	IC	InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1
DMEAOZ0	CS	CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DMEAOZ0	IK	AMLYAMJWYAIXIA-VWNVYAMZSA-N
DMEAOZ0	IU	2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMEAOZ0	CA	CAS 188968-51-6
DMEAOZ0	DE	Rheumatoid arthritis

DM1975O	ID	DM1975O
DM1975O	DN	Cilnidipine
DM1975O	HS	Phase 3
DM1975O	SN	Atelec; Cinaldipine; Cinalong; Siscard; Cilnidipine [INN]; FRC 8653; Atelec (TN); FRC-8653; Cilnidipine (JAN/INN); (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; 2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM1975O	CP	Fuji Viscera Pharmaceutical
DM1975O	DT	Small molecular drug
DM1975O	PC	5282138
DM1975O	MW	492.5
DM1975O	FM	C27H28N2O7
DM1975O	IC	InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+
DM1975O	CS	CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCOC
DM1975O	IK	KJEBULYHNRNJTE-DHZHZOJOSA-N
DM1975O	IU	3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM1975O	CA	CAS 132203-70-4
DM1975O	CB	CHEBI:31399
DM1975O	DE	High blood pressure

DMU2J7Y	ID	DMU2J7Y
DMU2J7Y	DN	Ciltacabtagene autoleucel
DMU2J7Y	HS	Phase 3
DMU2J7Y	SN	JNJ-68284528
DMU2J7Y	CP	Janssen
DMU2J7Y	DT	CAR T Cell Therapy
DMU2J7Y	DE	Multiple myeloma

DMEGFYD	ID	DMEGFYD
DMEGFYD	DN	Cinitapride
DMEGFYD	HS	Phase 3
DMEGFYD	SN	Cinitapride; 66564-14-5; Cidine; cinitapride tartrate; Blaston; Cinitapride [INN]; C21H30N4O4; Cinitapride hydrogen tartrate; Cinitapride (INN); 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide; Cinitapridum; Cinitaprida; Paxapride; Cinitapridum [INN-Latin]; Cinitaprida [INN-Spanish]; cidin; Cintapro; Cinmove; UNII-R8I97I2L24; Paxapride (TN); AC1Q1YMD; AC1L2AM4; (non-labelled)Cinitapride-d5; SCHEMBL476454; SCHEMBL19235643; CHEMBL2104523; CHEBI:135642; R8I97I2L24; BCP04096; AKOS015909742; DB08810
DMEGFYD	CP	Eisai
DMEGFYD	DT	Small molecular drug
DMEGFYD	PC	68867
DMEGFYD	MW	402.5
DMEGFYD	FM	C21H30N4O4
DMEGFYD	IC	InChI=1S/C21H30N4O4/c1-2-29-20-13-18(22)19(25(27)28)12-17(20)21(26)23-16-8-10-24(11-9-16)14-15-6-4-3-5-7-15/h3-4,12-13,15-16H,2,5-11,14,22H2,1H3,(H,23,26)
DMEGFYD	CS	CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N
DMEGFYD	IK	ZDLBNXXKDMLZMF-UHFFFAOYSA-N
DMEGFYD	IU	4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
DMEGFYD	CA	CAS 66564-14-5
DMEGFYD	CB	CHEBI:135642
DMEGFYD	DE	Functional dyspepsia

DM803GL	ID	DM803GL
DM803GL	DN	CIPEMASTAT
DM803GL	HS	Phase 3
DM803GL	SN	Cipemastat; Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306
DM803GL	DT	Small molecular drug
DM803GL	PC	9824350
DM803GL	MW	436.5
DM803GL	FM	C22H36N4O5
DM803GL	IC	InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1
DM803GL	CS	CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C
DM803GL	IK	GFUITADOEPNRML-SJORKVTESA-N
DM803GL	IU	(2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-piperidin-1-yl-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide
DM803GL	CA	CAS 190648-49-8
DM803GL	DE	Rheumatoid arthritis

DMJ9ZIY	ID	DMJ9ZIY
DMJ9ZIY	DN	CK-2017357
DMJ9ZIY	HS	Phase 3
DMJ9ZIY	SN	Tirasemtiv; 1005491-05-3; Tirasemtiv(CK-2017357); CK-2017357; UNII-G8WSM7R635; G8WSM7R635; 5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one; CK 2017357; 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2-ol; 2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-;2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-; Tirasemtiv [USAN:INN]; Tirasemtiv (USAN/INN); SCHEMBL976988; GTPL8280; tiraseMtiv (CK-2017357); CHEMBL3039529; EX-A367; DTXSID90143379; RSQGZEAXODVTOL-UHFFFAOYSA-N
DMJ9ZIY	CP	Cytokinetics
DMJ9ZIY	DT	Small molecular drug
DMJ9ZIY	PC	23729157
DMJ9ZIY	MW	230.27
DMJ9ZIY	FM	C12H14N4O
DMJ9ZIY	IC	InChI=1S/C12H14N4O/c1-4-8-7-13-10-11(14-8)16(12(17)15-10)9(5-2)6-3/h1,7,9H,5-6H2,2-3H3,(H,13,15,17)
DMJ9ZIY	CS	CCC(CC)N1C2=NC(=CN=C2NC1=O)C#C
DMJ9ZIY	IK	RSQGZEAXODVTOL-UHFFFAOYSA-N
DMJ9ZIY	IU	5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one
DMJ9ZIY	CA	CAS 1005491-05-3
DMJ9ZIY	DE	Muscle fatigue; Amyotrophic lateral sclerosis

DMTSONL	ID	DMTSONL
DMTSONL	DN	Claritin/Singulair
DMTSONL	HS	Phase 3
DMTSONL	SN	Loratadine/montelukast sodium
DMTSONL	CP	Schering-Plough
DMTSONL	DE	Allergic rhinitis

DMPQR1D	ID	DMPQR1D
DMPQR1D	DN	Claudiximab
DMPQR1D	HS	Phase 3
DMPQR1D	SN	IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
DMPQR1D	CP	Ganymed Pharmaceuticals AG
DMPQR1D	DT	Antibody
DMPQR1D	DE	Esophageal cancer; Gastric adenocarcinoma

DMQSBX4	ID	DMQSBX4
DMQSBX4	DN	Clazosentan
DMQSBX4	HS	Phase 3
DMQSBX4	SN	Clazosentan; 180384-56-9; Ro-61-1790; VML-588; UNII-3DRR0X4728; AXV-343434; CHEMBL109648; 3DRR0X4728; Clazosentan [INN]; VML 588; AXV 034; AXV-034343; Ro 61-1790; AXV-034; AXV 034343; AC1O5FK3; SCHEMBL1652657; CTK4D7597; DTXSID60170955; ZINC3939238; BDBM50066370; AKOS032946377; SB18855; N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-[2-(2H-TETRAZOL-5-YL)-4-PYRIDINYL]-4-PYRIMIDINYL]-5-METHYL-2-PYRIDINESULFONAMIDE; DB-065318; FT-0765561
DMQSBX4	CP	Actelion Pharmaceuticals
DMQSBX4	DT	Small molecular drug
DMQSBX4	PC	6433095
DMQSBX4	MW	577.6
DMQSBX4	FM	C25H23N9O6S
DMQSBX4	IC	InChI=1S/C25H23N9O6S/c1-15-7-8-20(27-14-15)41(36,37)32-24-21(40-19-6-4-3-5-18(19)38-2)25(39-12-11-35)29-22(28-24)16-9-10-26-17(13-16)23-30-33-34-31-23/h3-10,13-14,35H,11-12H2,1-2H3,(H,28,29,32)(H,30,31,33,34)
DMQSBX4	CS	CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC
DMQSBX4	IK	LFWCJABOXHSRGC-UHFFFAOYSA-N
DMQSBX4	IU	N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
DMQSBX4	CA	CAS 180384-56-9
DMQSBX4	DE	Vasospasm; Cerebral vasospasm

DMR21Q3	ID	DMR21Q3
DMR21Q3	DN	Clevudine
DMR21Q3	HS	Phase 3
DMR21Q3	SN	Clevudine; 163252-36-6; Levovir; L-FMAU; UNII-IN51MVP5F1; Clevudine (Levovir); IN51MVP5F1; 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)thymine; 1-((2S,3R,4S,5S)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; AK106264; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; Clevudine [USAN:INN]; Revovir; Clevudine (USAN)
DMR21Q3	CP	Bukwang; Eisai
DMR21Q3	DT	Small molecular drug
DMR21Q3	PC	73115
DMR21Q3	MW	260.22
DMR21Q3	FM	C10H13FN2O5
DMR21Q3	IC	InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1
DMR21Q3	CS	CC1=CN(C(=O)NC1=O)[C@@H]2[C@@H]([C@H]([C@@H](O2)CO)O)F
DMR21Q3	IK	GBBJCSTXCAQSSJ-XQXXSGGOSA-N
DMR21Q3	IU	1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR21Q3	CA	CAS 163252-36-6
DMR21Q3	CB	CHEBI:135964
DMR21Q3	DE	Hepatitis B virus infection

DMSPN58	ID	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	HS	Phase 3
DMSPN58	SN	Clomethiazole; 533-45-9; Chlormethiazole; 5-(2-CHLOROETHYL)-4-METHYLTHIAZOLE; Distraneurin; Emineurina; Clomethiazolum; Chlormethiazol; Chlorethiazol; Chlorethiazole; Somnevrin; Clometiazole; Clomethiazol; 5-(2-Chloroethyl)-4-methyl-1,3-thiazole; Thiazole, 5-(2-chloroethyl)-4-methyl-; Clometiazolo [DCIT]; Chloro-S.C.T.Z.; C6H8ClNS; UNII-0C5DBZ19HV; Clometiazol [INN-Spanish]; Clomethiazolum [INN-Latin]; WY 1485; Clomethiazole [INN]; SCTZ [as edisylate]; EINECS 208-565-7; 4-Methyl-5-(beta-chloroethyl)thiazole; BRN 0114244; 0C5DBZ19HV
DMSPN58	DT	Small molecular drug
DMSPN58	PC	10783
DMSPN58	MW	161.65
DMSPN58	FM	C6H8ClNS
DMSPN58	IC	InChI=1S/C6H8ClNS/c1-5-6(2-3-7)9-4-8-5/h4H,2-3H2,1H3
DMSPN58	CS	CC1=C(SC=N1)CCCl
DMSPN58	IK	PCLITLDOTJTVDJ-UHFFFAOYSA-N
DMSPN58	IU	5-(2-chloroethyl)-4-methyl-1,3-thiazole
DMSPN58	CA	CAS 533-45-9
DMSPN58	CB	CHEBI:92875
DMSPN58	DE	Stroke

DMFQ1WX	ID	DMFQ1WX
DMFQ1WX	DN	CLS006
DMFQ1WX	HS	Phase 3
DMFQ1WX	CP	Cutanea Wayne, PA
DMFQ1WX	DE	Verruca vulgaris

DMASPWR	ID	DMASPWR
DMASPWR	DN	CM-2395
DMASPWR	HS	Phase 3
DMASPWR	CP	Cenomed BioSciences
DMASPWR	DE	Schizophrenia

DMLMN2F	ID	DMLMN2F
DMLMN2F	DN	CM-AT
DMLMN2F	HS	Phase 3
DMLMN2F	DE	Autism spectrum disorder; Attention deficit hyperactivity disorder

DMC4X7L	ID	DMC4X7L
DMC4X7L	DN	CMS-024-02
DMC4X7L	HS	Phase 3
DMC4X7L	SN	Tyroserleutide; Tyroservatide; CMS-024; CMS-024); Tyroserleutide (iv, cancer), China Medical System; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals; Tyroservatide (cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System Holdings; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System; Tyrosyl-seryl-leucine (cancer), Tianjin Medical University/Shenzhen Kangzhe Pharmaceutical
DMC4X7L	CP	Shenzhen Kangzhe Pharmaceutical Co Ltd
DMC4X7L	PC	11303106
DMC4X7L	MW	367.4
DMC4X7L	FM	C17H25N3O6
DMC4X7L	IC	InChI=1S/C17H25N3O6/c1-9(2)14(17(25)26)20-16(24)13(8-21)19-15(23)12(18)7-10-3-5-11(22)6-4-10/h3-6,9,12-14,21-22H,7-8,18H2,1-2H3,(H,19,23)(H,20,24)(H,25,26)/t12-,13-,14-/m0/s1
DMC4X7L	CS	CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
DMC4X7L	IK	TYFLVOUZHQUBGM-IHRRRGAJSA-N
DMC4X7L	IU	(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid
DMC4X7L	CA	CAS 154039-16-4
DMC4X7L	CB	CHEBI:165974
DMC4X7L	DE	Solid tumour/cancer

DM9Y3B5	ID	DM9Y3B5
DM9Y3B5	DN	CMX-001
DM9Y3B5	HS	Phase 3
DM9Y3B5	SN	Brincidofovir; CMX001; 444805-28-1; Hexadecyloxypropyl-cidofovir; CMX 001; Hexadecyloxypropyl cidofovir; UNII-6794O900AX; 6794O900AX; HDP-Cidofovir; Cidofovir-HDP; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid; Brincidofovir [USAN:INN]; Hexadecyloxypropyl - cidofovir; Cidofovir prodrug; HDP-HPMPC; Brincidofovir (USAN); AC1LA8GF; 3-(hexadecyloxy)propyl hydrogen ((((S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)
DM9Y3B5	CP	Chimerix
DM9Y3B5	DT	Small molecular drug
DM9Y3B5	PC	483477
DM9Y3B5	MW	561.7
DM9Y3B5	FM	C27H52N3O7P
DM9Y3B5	IC	InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
DM9Y3B5	CS	CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](CN1C=CC(=NC1=O)N)CO)O
DM9Y3B5	IK	WXJFKKQWPMNTIM-VWLOTQADSA-N
DM9Y3B5	IU	[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
DM9Y3B5	CA	CAS 444805-28-1
DM9Y3B5	DE	Solid tumour/cancer

DMB4JPG	ID	DMB4JPG
DMB4JPG	DN	CNTX-4975
DMB4JPG	HS	Phase 3
DMB4JPG	CP	Centrexion Therapeutics Boston, MA
DMB4JPG	DE	Pain; Morton neuroma; Knee osteoarthritis

DMWZ2TU	ID	DMWZ2TU
DMWZ2TU	DN	CO-1686
DMWZ2TU	HS	Phase 3
DMWZ2TU	SN	1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284
DMWZ2TU	CP	Clovis Oncology
DMWZ2TU	DT	Small molecular drug
DMWZ2TU	PC	57335384
DMWZ2TU	MW	555.6
DMWZ2TU	FM	C27H28F3N7O3
DMWZ2TU	IC	InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)
DMWZ2TU	CS	CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC
DMWZ2TU	IK	HUFOZJXAKZVRNJ-UHFFFAOYSA-N
DMWZ2TU	IU	N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide
DMWZ2TU	CA	CAS 1374640-70-6
DMWZ2TU	DE	Lung cancer; Non-small-cell lung cancer

DMN9ETB	ID	DMN9ETB
DMN9ETB	DN	Contusugene ladenovec
DMN9ETB	HS	Phase 3
DMN9ETB	SN	Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
DMN9ETB	CP	Introgen Therapeutics
DMN9ETB	DE	Oral cancer; Liver metastasis

DMA0WEK	ID	DMA0WEK
DMA0WEK	DN	Coprexa
DMA0WEK	HS	Phase 3
DMA0WEK	SN	Tetrathiomolybdate
DMA0WEK	CP	Pipex Pharmaceuticals
DMA0WEK	DT	Small molecular drug
DMA0WEK	PC	5245480
DMA0WEK	MW	226.2
DMA0WEK	FM	H2MoS4-2
DMA0WEK	IC	InChI=1S/Mo.2H2S.2S/h;2*1H2;;/p-2
DMA0WEK	CS	[SH-].[SH-].S=[Mo]=S
DMA0WEK	IK	VVRHUOPINLMZBL-UHFFFAOYSA-L
DMA0WEK	IU	bis(sulfanylidene)molybdenum;sulfanide
DMA0WEK	CA	CAS 16330-92-0
DMA0WEK	CB	CHEBI:30703
DMA0WEK	DE	Neurological disorder

DMBS3UG	ID	DMBS3UG
DMBS3UG	DN	CORT-125134
DMBS3UG	HS	Phase 3
DMBS3UG	SN	relacorilant; Relacorilant; UNII-2158753C7E; 2158753C7E; 1496510-51-0; Relacorilant [INN]; Relacorilant [WHO-DD]; Relacorilant [USAN:INN]; SCHEMBL15454999; WANIDIGFXJFFEL-SANMLTNESA-N; CORT125134; ZINC141949519; AKOS032945759; J3.651.009I; ((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoqui
DMBS3UG	CP	Corcept TherapeuticsMenlo Park, CA
DMBS3UG	PC	73051463
DMBS3UG	MW	586.6
DMBS3UG	FM	C27H22F4N6O3S
DMBS3UG	IC	InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1
DMBS3UG	CS	CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
DMBS3UG	IK	WANIDIGFXJFFEL-SANMLTNESA-N
DMBS3UG	IU	[(4aR)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
DMBS3UG	CA	CAS 1496510-51-0
DMBS3UG	DE	Alcohol dependence; Solid tumour/cancer; Cushing disease

DMMEAOL	ID	DMMEAOL
DMMEAOL	DN	Coversin
DMMEAOL	HS	Phase 3
DMMEAOL	CP	Akari Therapeutics
DMMEAOL	DT	Recombinant?protein
DMMEAOL	DE	Paroxysmal nocturnal haemoglobinuria

DMZIM37	ID	DMZIM37
DMZIM37	DN	CP-868596
DMZIM37	HS	Phase 3
DMZIM37	SN	Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DMZIM37	CP	Pfizer
DMZIM37	TC	Anticancer Agents
DMZIM37	DT	Small molecular drug
DMZIM37	PC	10366136
DMZIM37	MW	443.5
DMZIM37	FM	C26H29N5O2
DMZIM37	IC	InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3
DMZIM37	CS	CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4
DMZIM37	IK	DYNHJHQFHQTFTP-UHFFFAOYSA-N
DMZIM37	IU	1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DMZIM37	CA	CAS 670220-88-9
DMZIM37	CB	CHEBI:145365
DMZIM37	DE	Gastrointestinal cancer; Acute myelogenous leukaemia; Malignant glioma; Acute myeloid leukaemia; Gastrointestinal stromal tumour

DM2EO5M	ID	DM2EO5M
DM2EO5M	DN	CPC-211
DM2EO5M	HS	Phase 3
DM2EO5M	SN	Dichloracetate; Dichloroacetate; Dichloroacetate ion; Dichloroacetic acid ion(1-); LS-11597; STL483470; 13425-80-4; 2,2-bis(chloranyl)ethanoate; 2,2-dichloroacetate; 2q8h; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; ACETIC ACID, DICHLORO-, ION(1-); Acetic acid,2,2-dichloro-, ion(1-); BRN 3903873; CHEBI:28240; CTK4B9070; DCA; DTXSID40158610; GTPL4518; NCGC00241105-01
DM2EO5M	PC	25975
DM2EO5M	MW	127.93
DM2EO5M	FM	C2HCl2O2-
DM2EO5M	IC	JXTHNDFMNIQAHM-UHFFFAOYSA-M
DM2EO5M	CS	C(C(=O)[O-])(Cl)Cl
DM2EO5M	IK	1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1
DM2EO5M	IU	2,2-dichloroacetate
DM2EO5M	CA	CAS 13425-80-4
DM2EO5M	CB	CHEBI:28240
DM2EO5M	DE	Dehydrogenase PDC deficiency

DMPXOYJ	ID	DMPXOYJ
DMPXOYJ	DN	CPI-0610
DMPXOYJ	HS	Phase 3
DMPXOYJ	CP	Constellation pharmaceuticals
DMPXOYJ	PC	57389999
DMPXOYJ	MW	365.8
DMPXOYJ	FM	C20H16ClN3O2
DMPXOYJ	IC	InChI=1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)/t16-/m0/s1
DMPXOYJ	CS	CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(=O)N)C4=CC=C(C=C4)Cl
DMPXOYJ	IK	GCWIQUVXWZWCLE-INIZCTEOSA-N
DMPXOYJ	IU	2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide
DMPXOYJ	CA	CAS 1380087-89-7
DMPXOYJ	DE	Acute myeloid leukaemia; Myelodysplastic neoplasm; Myeloproliferative neoplasm; Myelofibrosis

DM5XUQL	ID	DM5XUQL
DM5XUQL	DN	CPI-613
DM5XUQL	HS	Phase 3
DM5XUQL	SN	CPI-613; 95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
DM5XUQL	CP	Cornerstone Pharmaceuticals
DM5XUQL	DT	Small molecular drug
DM5XUQL	PC	24770514
DM5XUQL	MW	388.6
DM5XUQL	FM	C22H28O2S2
DM5XUQL	IC	InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)
DM5XUQL	CS	C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2
DM5XUQL	IK	ZYRLHJIMTROTBO-UHFFFAOYSA-N
DM5XUQL	IU	6,8-bis(benzylsulfanyl)octanoic acid
DM5XUQL	CA	CAS 95809-78-2
DM5XUQL	DE	Acute myeloid leukaemia; Myelodysplastic syndrome; B-cell lymphoma; Metastatic colorectal cancer; Recurrent adult burkitt lymphoma; T-cell lymphoma; Pancreatic cancer

DM62E7C	ID	DM62E7C
DM62E7C	DN	CPL-7075
DM62E7C	HS	Phase 3
DM62E7C	SN	Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751;  Mixed CB agonist/sodim channel blocker (pain), Cervelo
DM62E7C	CP	Cervelo Pharmaceuticals Ltd
DM62E7C	DT	Small molecular drug
DM62E7C	PC	3083542
DM62E7C	MW	400.5
DM62E7C	FM	C25H36O4
DM62E7C	IC	InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1
DM62E7C	CS	CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)C(=O)O)O
DM62E7C	IK	YCHYFHOSGQABSW-RTBURBONSA-N
DM62E7C	IU	(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid
DM62E7C	CA	CAS 137945-48-3
DM62E7C	DE	Cystic fibrosis; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic sclerosis; Diffuse systemic sclerosis

DM60TVK	ID	DM60TVK
DM60TVK	DN	CQA 206-291
DM60TVK	HS	Phase 3
DM60TVK	SN	Cqa 206-291; Cqa-206-291; 93822-42-5; UNII-9I4I0M95U7; 9I4I0M95U7; N,N-Diethyl-N-(1-ethyl-6-methylergoline-8-yl)sulfamide; AC1L3TWB; SCHEMBL8195741; Sulfamide, N,N-diethyl-N'-((8alpha)-1-ethyl-6-methylergolin-8-yl)-
DM60TVK	DT	Small molecular drug
DM60TVK	PC	9953076
DM60TVK	MW	404.6
DM60TVK	FM	C21H32N4O2S
DM60TVK	IC	InChI=1S/C21H32N4O2S/c1-5-24-13-15-11-20-18(17-9-8-10-19(24)21(15)17)12-16(14-23(20)4)22-28(26,27)25(6-2)7-3/h8-10,13,16,18,20,22H,5-7,11-12,14H2,1-4H3/t16-,18+,20+/m0/s1
DM60TVK	CS	CCN1C=C2C[C@@H]3[C@H](C[C@@H](CN3C)NS(=O)(=O)N(CC)CC)C4=C2C1=CC=C4
DM60TVK	IK	ARTRTLXKTHJPRW-ILZDJORESA-N
DM60TVK	IU	(6aR,9S,10aR)-9-(diethylsulfamoylamino)-4-ethyl-7-methyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline
DM60TVK	CA	CAS 93822-42-5
DM60TVK	DE	Parkinson disease

DMKD2BQ	ID	DMKD2BQ
DMKD2BQ	DN	Creatine ALS-08
DMKD2BQ	HS	Phase 3
DMKD2BQ	SN	Creatine; ALS-02; ALS-05; ALS-08; HD-02; PD-02; PD-04; PD-06; Creatine (ALS), Avicena; Creatine (amyotrophic lateral sclerosis), Avicena; PD-01, Avicena; AL-02 (ALS), Avicena; AL-08 (ALS), Avicena; Creatine (Huntington's disease), Avicena; Creatine (Parkinson's disease), Avicena
DMKD2BQ	CP	Avicena Group Inc; Avicena
DMKD2BQ	DT	Small molecular drug
DMKD2BQ	PC	586
DMKD2BQ	MW	131.13
DMKD2BQ	FM	C4H9N3O2
DMKD2BQ	IC	InChI=1S/C4H9N3O2/c1-7(4(5)6)2-3(8)9/h2H2,1H3,(H3,5,6)(H,8,9)
DMKD2BQ	CS	CN(CC(=O)O)C(=N)N
DMKD2BQ	IK	CVSVTCORWBXHQV-UHFFFAOYSA-N
DMKD2BQ	IU	2-[carbamimidoyl(methyl)amino]acetic acid
DMKD2BQ	CA	CAS 57-00-1
DMKD2BQ	CB	CHEBI:16919
DMKD2BQ	DE	Motor neurone disease

DM7QI29	ID	DM7QI29
DM7QI29	DN	Crenezumab
DM7QI29	HS	Phase 3
DM7QI29	SN	MABT5102A; RG7412
DM7QI29	CP	Genentech
DM7QI29	DT	Monoclonal antibody
DM7QI29	DE	Alzheimer disease

DM5F24X	ID	DM5F24X
DM5F24X	DN	Crocin
DM5F24X	HS	Phase 3
DM5F24X	DE	Knee osteoarthritis

DM67P0F	ID	DM67P0F
DM67P0F	DN	CS-038
DM67P0F	HS	Phase 3
DM67P0F	SN	Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences
DM67P0F	CP	Shenzhen Chipscreen Biosciences Ltd
DM67P0F	DT	Small molecular drug
DM67P0F	PC	71402018
DM67P0F	MW	572.6
DM67P0F	FM	C36H29FN2O4
DM67P0F	IC	InChI=1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1
DM67P0F	CS	C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C[C@@H](C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F
DM67P0F	IK	QNLWMPLUWMWDMQ-YTTGMZPUSA-N
DM67P0F	IU	(2S)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid
DM67P0F	CA	CAS 743438-45-1
DM67P0F	DE	Type-2 diabetes

DMSY0NE	ID	DMSY0NE
DMSY0NE	DN	CS1001
DMSY0NE	HS	Phase 3
DMSY0NE	CP	CStone Pharmaceuticals
DMSY0NE	DT	Antibody
DMSY0NE	DE	Non-small cell lung cancer

DM1PV4Y	ID	DM1PV4Y
DM1PV4Y	DN	CS-600G
DM1PV4Y	HS	Phase 3
DM1PV4Y	SN	Koloxo; Loxoprofen; Loxoprofen (INN); Loxoprofen [INN]; Loxoprofen sodium hydrate; Loxoprofene; Loxoprofene [French]; Loxoprofeno; Loxoprofeno [Spanish]; Loxoprofenum; Loxoprofenum [Latin]; YMBXTVYHTMGZDW-UHFFFAOYSA-N; sodium loxoprofen; yl]-propionic acid; 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid; 2-[4-(2-Oxo-cyclopentylmethyl)-phen; 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid; 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid; 68767-14-6; CHEBI:76172; CHEMBL19299; CS-600; MFCD00864331; Oxeno
DM1PV4Y	PC	3965
DM1PV4Y	MW	246.3
DM1PV4Y	FM	C15H18O3
DM1PV4Y	IC	YMBXTVYHTMGZDW-UHFFFAOYSA-N
DM1PV4Y	CS	CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
DM1PV4Y	IK	1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
DM1PV4Y	IU	2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid
DM1PV4Y	CA	CAS 68767-14-6
DM1PV4Y	CB	CHEBI:76172
DM1PV4Y	DE	Epilepsy

DM4CSDH	ID	DM4CSDH
DM4CSDH	DN	CS-8958
DM4CSDH	HS	Phase 3
DM4CSDH	SN	Inavir; Laninamivir octanoate; R-118958
DM4CSDH	CP	Biota
DM4CSDH	DT	Small molecular drug
DM4CSDH	PC	9847629
DM4CSDH	MW	472.5
DM4CSDH	FM	C21H36N4O8
DM4CSDH	IC	InChI=1S/C21H36N4O8/c1-4-5-6-7-8-9-16(28)32-11-14(27)18(31-3)19-17(24-12(2)26)13(25-21(22)23)10-15(33-19)20(29)30/h10,13-14,17-19,27H,4-9,11H2,1-3H3,(H,24,26)(H,29,30)(H4,22,23,25)/t13-,14+,17+,18+,19+/m0/s1
DM4CSDH	CS	CCCCCCCC(=O)OC[C@H]([C@H]([C@H]1[C@@H]([C@H](C=C(O1)C(=O)O)N=C(N)N)NC(=O)C)OC)O
DM4CSDH	IK	UKTIJASCFRNWCB-RMIBSVFLSA-N
DM4CSDH	IU	(2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2-hydroxy-1-methoxy-3-octanoyloxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DM4CSDH	CA	CAS 203120-46-1
DM4CSDH	CB	CHEBI:134741
DM4CSDH	DE	Influenza virus infection

DMV574J	ID	DMV574J
DMV574J	DN	CSL312
DMV574J	HS	Phase 3
DMV574J	SN	Garadacimab
DMV574J	CP	CSL Behring
DMV574J	DT	Antibody
DMV574J	DE	Hereditary angioedema

DMZJGVL	ID	DMZJGVL
DMZJGVL	DN	CSL-654
DMZJGVL	HS	Phase 3
DMZJGVL	SN	RIX-FP; Recombinant coagulation factor IX (iv, hemophilia B), CSL Behring; Recombinant coagulation factor IX (extended half-life, hemophilia B), CSL Behring
DMZJGVL	CP	Csl behring
DMZJGVL	SQ	DB00100 sequence: YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT
DMZJGVL	DE	Factor IX deficiency

DMU2ZFK	ID	DMU2ZFK
DMU2ZFK	DN	CT-2584
DMU2ZFK	HS	Phase 3
DMU2ZFK	SN	Apra (Cell Therapeutics, US, US); 1-[11-(Dodecylamino)-10-hydroxyundecyl]-3,7-dimethylxanthine
DMU2ZFK	CP	Cell Therapeutics
DMU2ZFK	DT	Small molecular drug
DMU2ZFK	PC	3081346
DMU2ZFK	MW	533.8
DMU2ZFK	FM	C30H55N5O3
DMU2ZFK	IC	InChI=1S/C30H55N5O3/c1-4-5-6-7-8-9-10-13-16-19-22-31-24-26(36)21-18-15-12-11-14-17-20-23-35-29(37)27-28(32-25-33(27)2)34(3)30(35)38/h25-26,31,36H,4-24H2,1-3H3
DMU2ZFK	CS	CCCCCCCCCCCCNCC(CCCCCCCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
DMU2ZFK	IK	MZNMZWZGUGFQJP-UHFFFAOYSA-N
DMU2ZFK	IU	1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethylpurine-2,6-dione
DMU2ZFK	CA	CAS 166981-13-1
DMU2ZFK	DE	Solid tumour/cancer

DMQPH29	ID	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	HS	Phase 3
DMQPH29	SN	curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil
DMQPH29	DT	Small molecular drug
DMQPH29	PC	969516
DMQPH29	MW	368.4
DMQPH29	FM	C21H20O6
DMQPH29	IC	InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+
DMQPH29	CS	COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O
DMQPH29	IK	VFLDPWHFBUODDF-FCXRPNKRSA-N
DMQPH29	IU	(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
DMQPH29	CA	CAS 458-37-7
DMQPH29	CB	CHEBI:3962
DMQPH29	DE	Solid tumour/cancer

DMIQ31Y	ID	DMIQ31Y
DMIQ31Y	DN	Custirsen
DMIQ31Y	HS	Phase 3
DMIQ31Y	SN	 OGX-001/TV-1011; OGX-011
DMIQ31Y	CP	OncoGenex Pharmaceuticals
DMIQ31Y	DT	Small molecular drug
DMIQ31Y	PC	72941942
DMIQ31Y	MW	7346
DMIQ31Y	FM	C231H312N78O119P20S20
DMIQ31Y	IC	InChI=1S/C231H312N78O119P20S20/c1-97-52-295(224(324)273-181(97)235)210-174(361-32-24-353-10)166(118(60-310)401-210)422-444(347,464)383-78-136-171(179(366-37-29-358-15)215(406-136)308-95-265-160-189(243)253-86-259-195(160)308)427-448(351,468)387-80-138-172(180(367-38-30-359-16)216(408-138)309-96-269-164-199(309)279-220(247)283-208(164)320)428-447(350,467)385-76-134-168(175(362-33-25-354-11)211(403-134)296-53-98(2)182(236)274-225(296)325)423-442(345,462)380-73-131-114(48-151(397-131)303-90-263-158-187(241)251-84-257-193(158)303)417-439(342,459)379-72-128-115(49-152(398-128)304-91-266-161-196(304)276-217(244)280-205(161)317)418-435(338,455)370-63-121-107(41-144(390-121)291-22-19-141(234)272-223(291)323)411-430(333,450)374-67-125-111(45-148(394-125)300-87-260-155-184(238)248-81-254-190(155)300)415-437(340,457)378-71-130-117(51-154(400-130)306-93-268-163-198(306)278-219(246)282-207(163)319)420-440(343,460)376-68-126-112(46-149(395-126)301-88-261-156-185(239)249-82-255-191(156)301)416-438(341,458)377-70-129-116(50-153(399-129)305-92-267-162-197(305)277-218(245)281-206(162)318)419-436(339,456)373-66-124-109(43-146(393-124)293-56-101(5)201(313)285-228(293)328)413-433(336,453)368-61-119-105(39-142(388-119)289-20-17-139(232)270-221(289)321)409-429(332,449)371-64-122-110(44-147(391-122)294-57-102(6)202(314)286-229(294)329)414-434(337,454)372-65-123-108(42-145(392-123)292-55-100(4)200(312)284-227(292)327)412-432(335,452)369-62-120-106(40-143(389-120)290-21-18-140(233)271-222(290)322)410-431(334,451)375-69-127-113(47-150(396-127)302-89-262-157-186(240)250-83-256-192(157)302)421-441(344,461)382-75-133-167(177(364-35-27-356-13)213(405-133)299-59-104(8)204(316)288-231(299)331)424-445(348,465)384-77-135-169(176(363-34-26-355-12)212(404-135)297-54-99(3)183(237)275-226(297)326)425-446(349,466)386-79-137-170(178(365-36-28-357-14)214(407-137)307-94-264-159-188(242)252-85-258-194(159)307)426-443(346,463)381-74-132-165(311)173(360-31-23-352-9)209(402-132)298-58-103(7)203(315)287-230(298)330/h17-22,52-59,81-96,105-138,142-154,165-180,209-216,310-311H,23-51,60-80H2,1-16H3,(H,332,449)(H,333,450)(H,334,451)(H,335,452)(H,336,453)(H,337,454)(H,338,455)(H,339,456)(H,340,457)(H,341,458)(H,342,459)(H,343,460)(H,344,461)(H,345,462)(H,346,463)(H,347,464)(H,348,465)(H,349,466)(H,350,467)(H,351,468)(H2,232,270,321)(H2,233,271,322)(H2,234,272,323)(H2,235,273,324)(H2,236,274,325)(H2,237,275,326)(H2,238,248,254)(H2,239,249,255)(H2,240,250,256)(H2,241,251,257)(H2,242,252,258)(H2,243,253,259)(H,284,312,327)(H,285,313,328)(H,286,314,329)(H,287,315,330)(H,288,316,331)(H3,244,276,280,317)(H3,245,277,281,318)(H3,246,278,282,319)(H3,247,279,283,320)/t105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,209+,210+,211+,212+,213+,214+,215+,216+,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?,440?,441?,442?,443?,444?,445?,446?,447?,448?/m0/s1
DMIQ31Y	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=S)(O)O[C@H]6C[C@@H](O[C@@H]6COP(=S)(O)O[C@H]7C[C@@H](O[C@@H]7COP(=S)(O)O[C@H]8C[C@@H](O[C@@H]8COP(=S)(O)O[C@H]9C[C@@H](O[C@@H]9COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O)S
DMIQ31Y	IK	RCFZILUHCNXXFY-DEDWCYLFSA-N
DMIQ31Y	IU	1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-[hydroxy-[[(2R,3R,4R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMIQ31Y	CA	CAS 890056-27-6
DMIQ31Y	DE	Lung cancer; Breast cancer; Prostate cancer

DM0JA9N	ID	DM0JA9N
DM0JA9N	DN	Cyrtominetin
DM0JA9N	HS	Phase 3
DM0JA9N	SN	IdB-1031; D,L-5,7,3',4'-Tetrahydroxy-6,8-dimethylflavanone; Rac-5,7-Dihydroxy-2-(3,4-dihydroxyphenyl)-6,8-dimethyl-2,3-dihydro-4H-1-benzopyran-4-one
DM0JA9N	DT	Small molecular drug
DM0JA9N	PC	125309
DM0JA9N	MW	316.3
DM0JA9N	FM	C17H16O6
DM0JA9N	IC	InChI=1S/C17H16O6/c1-7-15(21)8(2)17-14(16(7)22)12(20)6-13(23-17)9-3-4-10(18)11(19)5-9/h3-5,13,18-19,21-22H,6H2,1-2H3
DM0JA9N	CS	CC1=C(C(=C2C(=C1O)C(=O)CC(O2)C3=CC(=C(C=C3)O)O)C)O
DM0JA9N	IK	AESMRHCYHARBLU-UHFFFAOYSA-N
DM0JA9N	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6,8-dimethyl-2,3-dihydrochromen-4-one
DM0JA9N	CA	CAS 95272-99-4
DM0JA9N	DE	Phlegmy cough

DMUF0BJ	ID	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	HS	Phase 3
DMUF0BJ	SN	CYTISINE; 485-35-8; Sophorine; Baptitoxine; (-)-Cytisine; Laburnin; Baptitoxin; Tabex; Ulexin; Cytiton; Ulexine; Tsitizin; Cytitone; Cystisine; Cytizin; Citizin; Tabax; (1R,5S)-3,4,5,6-Tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one; Baphitoxine; UNII-53S5U404NU; Cytisine (-); HSDB 3560; EINECS 207-616-0; NSC 407282; BRN 0083882; Cytisin; (1r,5s)-1,2,3,4,5,6-Hexahydro-8h-1,5-Methanopyrido[1,2-A][1,5]diazocin-8-One; CHEBI:4055; CHEMBL497939; 53S5U404NU; Cytisine, 98%
DMUF0BJ	DT	Small molecular drug
DMUF0BJ	PC	10235
DMUF0BJ	MW	190.24
DMUF0BJ	FM	C11H14N2O
DMUF0BJ	IC	InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1
DMUF0BJ	CS	C1[C@H]2CNC[C@@H]1C3=CC=CC(=O)N3C2
DMUF0BJ	IK	ANJTVLIZGCUXLD-DTWKUNHWSA-N
DMUF0BJ	IU	(1R,9S)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
DMUF0BJ	CA	CAS 485-35-8
DMUF0BJ	CB	CHEBI:4055
DMUF0BJ	DE	Tobacco dependence

DMYJ2QB	ID	DMYJ2QB
DMYJ2QB	DN	D2A21
DMYJ2QB	HS	Phase 3
DMYJ2QB	SN	Demegel (Demegen, US, US); Alanyl-L-phenylalanyl-L-alanyl-L-phenylalanine
DMYJ2QB	PC	16199213
DMYJ2QB	MW	2775.4
DMYJ2QB	FM	C144H212N32O24
DMYJ2QB	IC	InChI=1S/C144H212N32O24/c1-91(155-128(183)105(154)83-97-49-15-7-16-50-97)122(177)161-106(65-31-40-74-145)129(184)165-111(70-36-45-79-150)134(189)172-117(86-100-55-21-10-22-56-100)139(194)156-93(3)124(179)163-108(67-33-42-76-147)131(186)167-114(73-39-48-82-153)137(192)175-120(89-103-61-27-13-28-62-103)143(198)169-110(69-35-44-78-149)132(187)168-113(72-38-47-81-152)136(191)174-119(88-102-59-25-12-26-60-102)140(195)157-92(2)123(178)162-107(66-32-41-75-146)130(185)166-112(71-37-46-80-151)135(190)173-118(87-101-57-23-11-24-58-101)141(196)158-94(4)125(180)164-109(68-34-43-77-148)133(188)171-116(85-99-53-19-9-20-54-99)142(197)159-95(5)126(181)170-115(84-98-51-17-8-18-52-98)138(193)160-96(6)127(182)176-121(144(199)200)90-104-63-29-14-30-64-104/h7-30,49-64,91-96,105-121H,31-48,65-90,145-154H2,1-6H3,(H,155,183)(H,156,194)(H,157,195)(H,158,196)(H,159,197)(H,160,193)(H,161,177)(H,162,178)(H,163,179)(H,164,180)(H,165,184)(H,166,185)(H,167,186)(H,168,187)(H,169,198)(H,170,181)(H,171,188)(H,172,189)(H,173,190)(H,174,191)(H,175,192)(H,176,182)(H,199,200)/t91-,92-,93-,94-,95-,96-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-/m0/s1
DMYJ2QB	CS	C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](C)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](C)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)O)NC(=O)[C@H](CC8=CC=CC=C8)N
DMYJ2QB	IK	WVRNJUBRGDUHNI-CPOCOYSOSA-N
DMYJ2QB	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoic acid
DMYJ2QB	DE	Burn and burn infection

DM9FAJM	ID	DM9FAJM
DM9FAJM	DN	D-5519
DM9FAJM	HS	Phase 3
DM9FAJM	DE	Asthma

DM6S4R2	ID	DM6S4R2
DM6S4R2	DN	DA-3031
DM6S4R2	HS	Phase 3
DM6S4R2	SN	Long-acting agent (neutropenia), Dong-A; PEG-GCSF (neutropenia), Dong-A; PEG-granulocyte colony stimulating factor (neutropenia),Dong-A
DM6S4R2	CP	Dong-A Pharmaceutical Co Ltd
DM6S4R2	DT	Small molecular drug
DM6S4R2	PC	168302
DM6S4R2	MW	185.26
DM6S4R2	FM	C10H19NO2
DM6S4R2	IC	InChI=1S/C8H15NO2.C2H4/c1-7(2)8(10)11-6-5-9(3)4;1-2/h1,5-6H2,2-4H3;1-2H2
DM6S4R2	CS	CC(=C)C(=O)OCCN(C)C.C=C
DM6S4R2	IK	PNMYDOBPCBCQIA-UHFFFAOYSA-N
DM6S4R2	IU	2-(dimethylamino)ethyl 2-methylprop-2-enoate;ethene
DM6S4R2	CA	CAS 25134-54-7
DM6S4R2	DE	Neutropenia

DMP2SGN	ID	DMP2SGN
DMP2SGN	DN	Dabelotine
DMP2SGN	HS	Phase 3
DMP2SGN	SN	Dabelotine mesilate; S-12024; S-12024-2
DMP2SGN	CP	Servier
DMP2SGN	DT	Small molecular drug
DMP2SGN	PC	177949
DMP2SGN	MW	262.35
DMP2SGN	FM	C15H22N2O2
DMP2SGN	IC	InChI=1S/C15H22N2O2/c1-17-8-3-5-12-4-2-6-14(15(12)17)19-11-13-10-16-7-9-18-13/h2,4,6,13,16H,3,5,7-11H2,1H3
DMP2SGN	CS	CN1CCCC2=C1C(=CC=C2)OCC3CNCCO3
DMP2SGN	IK	VXQWMLATWQSCBE-UHFFFAOYSA-N
DMP2SGN	IU	2-[(1-methyl-3,4-dihydro-2H-quinolin-8-yl)oxymethyl]morpholine
DMP2SGN	CA	CAS 118976-38-8
DMP2SGN	DE	Cognitive impairment

DMRDZ4X	ID	DMRDZ4X
DMRDZ4X	DN	Dabigatran etexilate
DMRDZ4X	HS	Phase 3
DMRDZ4X	SN	BIBR-1048; 211915-06-9; Dabigatran etexilate mesilate; ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate; Dabigatran etexilate methanesulfonate; BIBR-1048 (Dabigatran); UNII-2E18WX195X; BIBR1048; BIBR-1048-BS-RS1; CHEBI:70746; 2E18WX195X; cc-72; DSSTox_CID_31470; DSSTox_RID_97355; DSSTox_GSID_57681; SCHEMBL505829; DTXSID4057681; Dabigatran etexilate (USAN/INN); MolPort-016-633-287; EBD35035; Tox21_113924; BDBM504
DMRDZ4X	CP	Boehringer Ingelheim Ridgefield, CT
DMRDZ4X	PC	135565674
DMRDZ4X	MW	627.7
DMRDZ4X	FM	C34H41N7O5
DMRDZ4X	IC	InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
DMRDZ4X	CS	CCCCCCOC(=O)NC(=N)C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4
DMRDZ4X	IK	KSGXQBZTULBEEQ-UHFFFAOYSA-N
DMRDZ4X	IU	ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
DMRDZ4X	CA	CAS 211915-06-9
DMRDZ4X	DE	Venous thromboembolism

DMKNCVM	ID	DMKNCVM
DMKNCVM	DN	Dalcetrapib
DMKNCVM	HS	Phase 3
DMKNCVM	SN	JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate
DMKNCVM	CP	Roche
DMKNCVM	DT	Small molecular drug
DMKNCVM	PC	6918540
DMKNCVM	MW	389.6
DMKNCVM	FM	C23H35NO2S
DMKNCVM	IC	InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)
DMKNCVM	CS	CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
DMKNCVM	IK	YZQLWPMZQVHJED-UHFFFAOYSA-N
DMKNCVM	IU	S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate
DMKNCVM	CA	CAS 211513-37-0
DMKNCVM	CB	CHEBI:95001
DMKNCVM	DE	Hyperlipidaemia; Acute coronary syndrome

DM1C95G	ID	DM1C95G
DM1C95G	DN	DARE-BV1
DM1C95G	HS	Phase 3
DM1C95G	CP	Dare Bioscience
DM1C95G	DT	Small molecular drug
DM1C95G	DE	Bacterial vaginosis

DMR2JD4	ID	DMR2JD4
DMR2JD4	DN	Darotropium + 642444
DMR2JD4	HS	Phase 3
DMR2JD4	CP	GSK
DMR2JD4	DT	Combination drug
DMR2JD4	PC	25195533; 642444
DMR2JD4	DE	Chronic obstructive pulmonary disease

DM2FV5N	ID	DM2FV5N
DM2FV5N	DN	Darunavir + cobicistat
DM2FV5N	HS	Phase 3
DM2FV5N	SN	Prezcobix; Prezista + GS-9350
DM2FV5N	TC	Antiviral Agents
DM2FV5N	DT	Combination drug
DM2FV5N	DE	Coronavirus Disease 2019 (COVID-19)

DMF3V01	ID	DMF3V01
DMF3V01	DN	Darunavir + ritonavir + favipiravir + hydroxychloroquine
DMF3V01	HS	Phase 3
DMF3V01	SN	Prezista + norvir + T-705 + oxichloroquine
DMF3V01	TC	Antiviral Agents
DMF3V01	DT	Combination drug
DMF3V01	DE	Coronavirus Disease 2019 (COVID-19)

DMN9BO3	ID	DMN9BO3
DMN9BO3	DN	Darunavir + ritonavir + oseltamivir + hydroxychloroquine
DMN9BO3	HS	Phase 3
DMN9BO3	SN	Prezista + norvir + rseltamivir + oxichloroquine
DMN9BO3	TC	Antiviral Agents
DMN9BO3	DT	Combination drug
DMN9BO3	DE	Coronavirus Disease 2019 (COVID-19)

DMN8DQH	ID	DMN8DQH
DMN8DQH	DN	Darusentan
DMN8DQH	HS	Phase 3
DMN8DQH	SN	Endothelin antagonist, BASF; HMR-4005; LU-127043; LU-135252
DMN8DQH	CP	Gilead Sciences; Knoll GmbH
DMN8DQH	DT	Small molecular drug
DMN8DQH	PC	177236
DMN8DQH	MW	410.4
DMN8DQH	FM	C22H22N2O6
DMN8DQH	IC	InChI=1S/C22H22N2O6/c1-27-17-14-18(28-2)24-21(23-17)30-19(20(25)26)22(29-3,15-10-6-4-7-11-15)16-12-8-5-9-13-16/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
DMN8DQH	CS	COC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC
DMN8DQH	IK	FEJVSJIALLTFRP-LJQANCHMSA-N
DMN8DQH	IU	(2S)-2-(4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
DMN8DQH	CA	CAS 171714-84-4
DMN8DQH	DE	Hypotension

DMD7K9X	ID	DMD7K9X
DMD7K9X	DN	Davunetide
DMD7K9X	HS	Phase 3
DMD7K9X	SN	Davunetide; NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics
DMD7K9X	CP	Allon Therapeutics Inc
DMD7K9X	DE	Cognitive impairment; Alzheimer disease

DMUX7Z8	ID	DMUX7Z8
DMUX7Z8	DN	DE-117
DMUX7Z8	HS	Phase 3
DMUX7Z8	PC	44230999
DMUX7Z8	MW	520.6
DMUX7Z8	FM	C26H28N6O4S
DMUX7Z8	IC	InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30)
DMUX7Z8	CS	CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4
DMUX7Z8	IK	VIQCWEGEHRBLAC-UHFFFAOYSA-N
DMUX7Z8	IU	propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate
DMUX7Z8	CA	CAS 1187451-19-9
DMUX7Z8	DE	Glaucoma/ocular hypertension

DM0GUV2	ID	DM0GUV2
DM0GUV2	DN	DE-766
DM0GUV2	HS	Phase 3
DM0GUV2	CP	Daiichi Sankyo
DM0GUV2	DE	Non-small-cell lung cancer; Gastric adenocarcinoma; Nasopharyngeal carcinoma

DM2R15Q	ID	DM2R15Q
DM2R15Q	DN	DENBUFYLLINE
DM2R15Q	HS	Phase 3
DM2R15Q	SN	denbufylline; 57076-71-8; Denbufyllinum [Latin]; Denbufilina [Spanish]; BRL 30892; BRL-30892; UNII-04B949KO6F; 1,3-Di-n-butyl-7-(2-oxopropyl)xanthine; CHEMBL277465; 7-Acetonyl-1,3-dibutylxanthine; C16H24N4O3; 04B949KO6F; 3,7-Dihydro-1,3-dibutyl-7-(2-oxopropyl)-1H-purine-2,6-dione; 1,3-Di-n-butyl-7-(2&amp; -oxopropyl)xanthine; Denbufyllinum; Denbufilina; 1H-Purine-2,6-dione,1,3-dibutyl-3,7-dihydro-7-(2-oxopropyl)-; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-; Denbufylline [INN:BAN]; Denbufylline [BAN:INN
DM2R15Q	DT	Small molecular drug
DM2R15Q	PC	2984
DM2R15Q	MW	320.39
DM2R15Q	FM	C16H24N4O3
DM2R15Q	IC	InChI=1S/C16H24N4O3/c1-4-6-8-19-14-13(18(11-17-14)10-12(3)21)15(22)20(16(19)23)9-7-5-2/h11H,4-10H2,1-3H3
DM2R15Q	CS	CCCCN1C2=C(C(=O)N(C1=O)CCCC)N(C=N2)CC(=O)C
DM2R15Q	IK	HJPRDDKCXVCFOH-UHFFFAOYSA-N
DM2R15Q	IU	1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione
DM2R15Q	CA	CAS 57076-71-8
DM2R15Q	CB	CHEBI:92669
DM2R15Q	DE	Cognitive impairment

DM2ATZB	ID	DM2ATZB
DM2ATZB	DN	Deoxynojirimycin
DM2ATZB	HS	Phase 3
DM2ATZB	SN	1-DEOXYNOJIRIMYCIN; 19130-96-2; DUVOGLUSTAT; deoxynojirimycin; Moranoline; (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Deoxy-1,5-imino-D-mannitol; Moranolin; UNII-FZ56898FLE; D-1-deoxynojirimycin; 1,5-Dideoxy-1,5-imino-D-glucitol; CHEMBL307429; C6H13NO4; FZ56898FLE; CHEBI:44369; 1-Deoxy-Nojirimycin; 5-Amino-1,5-dideoxy-D-glucopyranose; DNJ; AK151410; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R,3R,4R,5S)-; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-
DM2ATZB	DT	Small molecular drug
DM2ATZB	PC	29435
DM2ATZB	MW	163.17
DM2ATZB	FM	C6H13NO4
DM2ATZB	IC	InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5-,6-/m1/s1
DM2ATZB	CS	C1[C@@H]([C@H]([C@@H]([C@H](N1)CO)O)O)O
DM2ATZB	IK	LXBIFEVIBLOUGU-JGWLITMVSA-N
DM2ATZB	IU	(2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
DM2ATZB	CA	CAS 19130-96-2
DM2ATZB	CB	CHEBI:44369
DM2ATZB	DE	Pompe disease

DMDLU4Z	ID	DMDLU4Z
DMDLU4Z	DN	Desmoteplase
DMDLU4Z	HS	Phase 3
DMDLU4Z	CP	Lundbeck Research
DMDLU4Z	SQ	P98119|URT1_DESRO Salivary plasminogen activator alpha 1 precursor - Desmodus rotundus: MVNTMKTKLLCVLLLCGAVFSLPRQETYRQLARGSRAYGVACKDEITQMTYRRQESWLRPEVRSKRVEHCQCDRGQARCHTVPVNSCSEPRCFNGGTCWQAVYFSDFVCQCPAGYTGKRCEVDTRATCYEGQGVTYRGTWSTAESRVECINWNSSLLTRRTYNGRMPDAFNLGLGNHNYCRNPNGAPKPWCYVIKAGKFTSESCSVPVCSKATCGLRKYKEPQLHSTGGLFTDITSHPWQAAIFAQNRRSSGERFLCGGILISSCWVLTAAHCFQESYLPDQLKVVLGRTYRVKPGEEEQTFKVKKYIVHKEFDDDTYNNDIALLQLKSDSPQCAQESDSVRAICLPEANLQLPDWTECELSGYGKHKSSSPFYSEQLKEGHVRLYPSSRCAPKFLFNKTVTNNMLCAGDTRSGEIYPNVHDACQGDSGGPLVCMNDNHMTLLGIISWGVGCGEKDVPGVYTKVTNYLGWIRDNMHL
DMDLU4Z	DE	Ischemic stroke

DMRH291	ID	DMRH291
DMRH291	DN	Dexanabinol
DMRH291	HS	Phase 3
DMRH291	SN	Sinnabidiol; HU 211; HU-211; PRS 211007-000; (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; 1,1-Dimethylheptyl-7-hydroxy-delta(6)-tetrahydrocannabinol; 11-Hydroxy-delta(8)-tetrahydrocannabinol-dimethylheptyl; 11-Hydroxy-delta-8-dmh-thc; 11-Hydroxymethyl-delta(8)-tetrahydrocannabinol-dimethylheptyl; 11-OH-delta(8)-Thc-dmh; 5'(1,1-Dimethylheptyl)-7-hydroxyhexahydrocannabinol; 7-Hydroxy-delta-6-tetrahydrocannabinoldimethylheptyl
DMRH291	CP	Pharmos
DMRH291	DT	Small molecular drug
DMRH291	PC	107778
DMRH291	MW	386.6
DMRH291	FM	C25H38O3
DMRH291	IC	InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1
DMRH291	CS	CCCCCCC(C)(C)C1=CC(=C2[C@H]3CC(=CC[C@@H]3C(OC2=C1)(C)C)CO)O
DMRH291	IK	SSQJFGMEZBFMNV-PMACEKPBSA-N
DMRH291	IU	(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DMRH291	CA	CAS 112924-45-5
DMRH291	DE	Traumatic brain injury

DM1WNGJ	ID	DM1WNGJ
DM1WNGJ	DN	DFP-10917
DM1WNGJ	HS	Phase 3
DM1WNGJ	CP	Delta-Fly Pharma
DM1WNGJ	DT	Small molecular drug
DM1WNGJ	PC	119184
DM1WNGJ	MW	252.23
DM1WNGJ	FM	C10H12N4O4
DM1WNGJ	IC	InChI=1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1
DM1WNGJ	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)C#N
DM1WNGJ	IK	DCYBPMFXJCWXNB-JWIUVKOKSA-N
DM1WNGJ	IU	(2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile
DM1WNGJ	CA	CAS 135598-68-4
DM1WNGJ	CB	CHEBI:145435
DM1WNGJ	DE	Acute lymphoblastic leukaemia; Solid tumour/cancer; Acute myeloid leukaemia

DMOUGX1	ID	DMOUGX1
DMOUGX1	DN	Diamyd
DMOUGX1	HS	Phase 3
DMOUGX1	SN	Oramyd; Human glutamate decarboxylase 65 kDa isoform; RhGAD-65; GAD65 (diabetes), Biosyn; GAD65 (diabetes), Diamyd; GAD65 (diabetes), OMJPI; GAD65 antigen-based therapy (diabetes), Johnson and Johnson; GAD65 (diabetes), Ortho-McNeil-Janssen Pharmaceuticals
DMOUGX1	CP	Diamyd medical
DMOUGX1	DE	Type-1 diabetes

DM4XBM7	ID	DM4XBM7
DM4XBM7	DN	DiaPep-277
DM4XBM7	HS	Phase 3
DM4XBM7	SN	Diaccine; AVE-0277; AVE-277; Antidiabetic, Peptor
DM4XBM7	CP	Andromeda biotech
DM4XBM7	DT	Small molecular drug
DM4XBM7	PC	16138701
DM4XBM7	MW	2390.7
DM4XBM7	FM	C106H180N28O34
DM4XBM7	IC	InChI=1S/C106H180N28O34/c1-23-55(18)83(131-102(164)82(54(16)17)130-90(152)60(27-24-32-111-106(109)110)118-91(153)65(38-50(8)9)123-92(154)63(36-48(4)5)121-87(149)58(21)117-101(163)81(53(14)15)129-76(140)45-113-74(138)43-112-75(139)44-114-88(150)62(35-47(2)3)126-100(162)80(108)52(12)13)103(165)133-33-25-28-71(133)98(160)115-56(19)85(147)120-64(37-49(6)7)93(155)125-68(41-78(143)144)95(157)128-70(46-135)97(159)124-66(39-51(10)11)96(158)132-84(59(22)136)104(166)134-34-26-29-72(134)99(161)116-57(20)86(148)122-67(40-73(107)137)94(156)119-61(30-31-77(141)142)89(151)127-69(105(167)168)42-79(145)146/h47-72,80-84,135-136H,23-46,108H2,1-22H3,(H2,107,137)(H,112,139)(H,113,138)(H,114,150)(H,115,160)(H,116,161)(H,117,163)(H,118,153)(H,119,156)(H,120,147)(H,121,149)(H,122,148)(H,123,154)(H,124,159)(H,125,155)(H,126,162)(H,127,151)(H,128,157)(H,129,140)(H,130,152)(H,131,164)(H,132,158)(H,141,142)(H,143,144)(H,145,146)(H,167,168)(H4,109,110,111)/t55-,56-,57-,58-,59+,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,80-,81-,82-,83-,84-/m0/s1
DM4XBM7	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N
DM4XBM7	IK	VGGRNGOEDNBLPH-YJHCMWSWSA-N
DM4XBM7	IU	(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]butanedioic acid
DM4XBM7	CA	CAS 179822-83-4
DM4XBM7	DE	Autoimmune diabetes

DMHZBEO	ID	DMHZBEO
DMHZBEO	DN	Difelikefalin
DMHZBEO	HS	Phase 3
DMHZBEO	SN	UNII-NA1U919MRO; NA1U919MRO; MR13A9; 1024828-77-0; FE202845; Difelikefalin [INN]; Difelikefalin [USAN:INN]; SEQ ID NO: 2; GTPL9044; CHEMBL3989915; SCHEMBL10316464; BDBM235785; DB11938; FE-202845; US9359399, 2; D-Phe-D-Phe-D-Leu-D-Lys-[gamma-(4-N-piperidinyl)amino carboxylic acid]; 4-Piperidinecarboylic acid, 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-; 4-Piperidinecarboxylic acid, N1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-4-amino-; 4-Piperidinecarboxylic acid, N1-(D
DMHZBEO	CP	Cara Therapeutics Stamford, CT
DMHZBEO	PC	24794466
DMHZBEO	MW	679.8
DMHZBEO	FM	C36H53N7O6
DMHZBEO	IC	InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1
DMHZBEO	CS	CC(C)C[C@H](C(=O)N[C@H](CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N
DMHZBEO	IK	FWMNVWWHGCHHJJ-SKKKGAJSSA-N
DMHZBEO	IU	4-amino-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid
DMHZBEO	CA	CAS 1024828-77-0
DMHZBEO	DE	Pruritus

DMU4T9Y	ID	DMU4T9Y
DMU4T9Y	DN	Dimesna
DMU4T9Y	HS	Phase 3
DMU4T9Y	SN	Tavocept (TN)
DMU4T9Y	CP	BioNumerik Pharmaceuticals
DMU4T9Y	DT	Small molecular drug
DMU4T9Y	PC	65625
DMU4T9Y	MW	326.4
DMU4T9Y	FM	C4H8Na2O6S4
DMU4T9Y	IC	InChI=1S/C4H10O6S4.2Na/c5-13(6,7)3-1-11-12-2-4-14(8,9)10;;/h1-4H2,(H,5,6,7)(H,8,9,10);;/q;2*+1/p-2
DMU4T9Y	CS	C(CS(=O)(=O)[O-])SSCCS(=O)(=O)[O-].[Na+].[Na+]
DMU4T9Y	IK	KQYGMURBTJPBPQ-UHFFFAOYSA-L
DMU4T9Y	IU	disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate
DMU4T9Y	CA	CAS 16208-51-8
DMU4T9Y	DE	Diabetic nephropathy; Lung cancer

DM19CFZ	ID	DM19CFZ
DM19CFZ	DN	DIMS-0150
DM19CFZ	HS	Phase 3
DM19CFZ	SN	Kappaproct; Antisense NF-kBp65 oligonucleotide (IBD), InDex Pharmaceuticals; Antisense NF-kBp65 oligonucleotide (IBD), Serono; Antisense NF-kBp65 oligonucleotide (inflammatory bowel disease), Serono
DM19CFZ	CP	Karolinska Institute
DM19CFZ	DT	Antisense drug
DM19CFZ	DE	Ulcerative colitis

DMG8U6M	ID	DMG8U6M
DMG8U6M	DN	DIPROTEVERINE HYDROCHLORIDE
DMG8U6M	HS	Phase 3
DMG8U6M	SN	UNII-T587ZFV6UM; T587ZFV6UM; Isoquinoline, 3,4-dihydro-6,7-bis(1-methylethoxy)-1-((3,4-diethoxyphenyl)methyl)-, hydrochloride; 69373-88-2; 1-(3',4'-Diethoxybenzyl)-6,7-diisoprooxy-3,4-dihydroisoquinoline hydrochloride; DIPROTEVERINE HYDROCHLORIDE; AC1MHK6D; SCHEMBL7313181; DTXSID30219461; AWQPJKUSDUHYIX-UHFFFAOYSA-N; 69373-95-1 (Parent); LS-85505; 1-(3'4'-diethoxybenzyl)-6,7-diisopropoxy-3,4-dihydroisoquinoline hydrochloride; 1-[(3,4-diethoxyphenyl)methyl]-6,7-di(propan-2-yloxy)-3,4-dihydroisoquinoline hydrochloride
DMG8U6M	DT	Small molecular drug
DMG8U6M	PC	3052867
DMG8U6M	MW	462
DMG8U6M	FM	C26H36ClNO4
DMG8U6M	IC	InChI=1S/C26H35NO4.ClH/c1-7-28-23-10-9-19(14-24(23)29-8-2)13-22-21-16-26(31-18(5)6)25(30-17(3)4)15-20(21)11-12-27-22;/h9-10,14-18H,7-8,11-13H2,1-6H3;1H
DMG8U6M	CS	CCOC1=C(C=C(C=C1)CC2=NCCC3=CC(=C(C=C32)OC(C)C)OC(C)C)OCC.Cl
DMG8U6M	IK	AWQPJKUSDUHYIX-UHFFFAOYSA-N
DMG8U6M	IU	1-[(3,4-diethoxyphenyl)methyl]-6,7-di(propan-2-yloxy)-3,4-dihydroisoquinoline;hydrochloride
DMG8U6M	CA	CAS 69373-88-2
DMG8U6M	DE	Angina pectoris

DM64QG9	ID	DM64QG9
DM64QG9	DN	Diquafosol
DM64QG9	HS	Phase 3
DM64QG9	SN	UppppU; Diquafosol [INN]; KPY 998; Diquafosol [INN:BAN]; INS-365; P1,P4-Bis(5'-uridyl) tetrahydrogen tetraphosphate; P1,P4-Bis(5'-uridyl) tetraphosphate; [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DM64QG9	CP	Santen Pharmaceutical
DM64QG9	DT	Small molecular drug
DM64QG9	PC	148197
DM64QG9	MW	790.3
DM64QG9	FM	C18H26N4O23P4
DM64QG9	IC	InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
DM64QG9	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O
DM64QG9	IK	NMLMACJWHPHKGR-NCOIDOBVSA-N
DM64QG9	IU	[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DM64QG9	CA	CAS 59985-21-6
DM64QG9	CB	CHEBI:27791
DM64QG9	DE	Dry eye disease

DMJS8V3	ID	DMJS8V3
DMJS8V3	DN	Disufenton sodium
DMJS8V3	HS	Phase 3
DMJS8V3	SN	Cerovive; ARL-16556; CPI-22; CXY-059; HPN-07; NXY-059; NXY-059G; OKN-007; S-PBN; Nitrones (cancer), Oklahoma Medical Research Foundation; Nitrones, Renovis/AstraZeneca; PBN derivatives, Renovis/AstraZeneca; Spin trap agents, Renovis/AstraZeneca
DMJS8V3	CP	AstraZeneca
DMJS8V3	DT	Small molecular drug
DMJS8V3	PC	6440181
DMJS8V3	MW	381.3
DMJS8V3	FM	C11H13NNa2O7S2
DMJS8V3	IC	InChI=1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2/b12-7-;;
DMJS8V3	CS	CC(C)(C)/[N+](=C/C1=C(C=C(C=C1)S(=O)(=O)[O-])S(=O)(=O)[O-])/[O-].[Na+].[Na+]
DMJS8V3	IK	XLZOVRYBVCMCGL-BPNVQINPSA-L
DMJS8V3	IU	disodium;4-[(Z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate
DMJS8V3	DE	Ischemia; Recurrent glioblastoma

DMMKGBP	ID	DMMKGBP
DMMKGBP	DN	D-Methionine
DMMKGBP	HS	Phase 3
DMMKGBP	SN	D-Methionine-(methyl-13C); D-Methionine-(methyl-13C), 99 atom % 13C
DMMKGBP	DT	Small molecular drug
DMMKGBP	PC	84815
DMMKGBP	MW	149.21
DMMKGBP	FM	C5H11NO2S
DMMKGBP	IC	InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1
DMMKGBP	CS	CSCC[C@H](C(=O)O)N
DMMKGBP	IK	FFEARJCKVFRZRR-SCSAIBSYSA-N
DMMKGBP	IU	(2R)-2-amino-4-methylsulfanylbutanoic acid
DMMKGBP	CA	CAS 348-67-4
DMMKGBP	CB	CHEBI:16867

DMO7BQS	ID	DMO7BQS
DMO7BQS	DN	DMP-444
DMO7BQS	HS	Phase 3
DMO7BQS	CP	Bristol-Myers Squibb Pharma Co
DMO7BQS	DE	Coronary artery disease

DMQLSMB	ID	DMQLSMB
DMQLSMB	DN	Dociparstat sodium
DMQLSMB	HS	Phase 3
DMQLSMB	SN	DSTAT
DMQLSMB	CP	Chimerix
DMQLSMB	DE	Acute myeloid leukaemia

DMH8IT5	ID	DMH8IT5
DMH8IT5	DN	Donaperminogene seltoplasmid
DMH8IT5	HS	Phase 3
DMH8IT5	SN	VM202
DMH8IT5	CP	ViroMed
DMH8IT5	DT	Gene therapy
DMH8IT5	DE	Amyotrophic lateral sclerosis; Diabetic foot ulcer; Diabetic neuropathy

DM97S10	ID	DM97S10
DM97S10	DN	DP-b99
DM97S10	HS	Phase 3
DM97S10	SN	DP-b99; 343340-21-6; 222315-88-0; SCHEMBL720046; DP-b 99; DTXSID20187908; DP-BAPTA-99, DP-b99; ZINC162948634; 2,2'-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis((2-(2-(octyloxy)ethoxy)-2-oxoethyl)azanediyl))diacetic acid
DM97S10	CP	D-Pharm
DM97S10	DT	Small molecular drug
DM97S10	PC	9810955
DM97S10	MW	789
DM97S10	FM	C42H64N2O12
DM97S10	IC	InChI=1S/C42H64N2O12/c1-3-5-7-9-11-17-23-51-25-27-55-41(49)33-43(31-39(45)46)35-19-13-15-21-37(35)53-29-30-54-38-22-16-14-20-36(38)44(32-40(47)48)34-42(50)56-28-26-52-24-18-12-10-8-6-4-2/h13-16,19-22H,3-12,17-18,23-34H2,1-2H3,(H,45,46)(H,47,48)
DM97S10	CS	CCCCCCCCOCCOC(=O)CN(CC(=O)O)C1=CC=CC=C1OCCOC2=CC=CC=C2N(CC(=O)O)CC(=O)OCCOCCCCCCCC
DM97S10	IK	FTGBVHPWUIHWRH-UHFFFAOYSA-N
DM97S10	IU	2-[2-[2-[2-[carboxymethyl-[2-(2-octoxyethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-N-[2-(2-octoxyethoxy)-2-oxoethyl]anilino]acetic acid
DM97S10	CA	CAS 343340-21-6
DM97S10	DE	Stroke

DMWUN1S	ID	DMWUN1S
DMWUN1S	DN	Drisapersen
DMWUN1S	HS	Phase 3
DMWUN1S	SN	2402968
DMWUN1S	CP	GlaxoSmithKline
DMWUN1S	DT	Antisense drug
DMWUN1S	PC	121494119
DMWUN1S	MW	6978
DMWUN1S	FM	C211H275N76O119P19S19
DMWUN1S	IC	InChI=1S/C211H275N76O119P19S19/c1-329-136-116(295)77(369-178(136)271-33-24-99(289)252-206(271)304)40-349-407(310,426)389-118-79(371-180(138(118)331-3)268-30-21-96(212)249-203(268)301)42-351-409(312,428)392-121-81(373-183(141(121)334-6)273-35-26-101(291)254-208(273)306)44-352-410(313,429)393-122-82(374-184(142(122)335-7)274-36-27-102(292)255-209(274)307)45-353-411(314,430)394-123-83(375-185(143(123)336-8)275-37-28-103(293)256-210(275)308)46-355-415(318,434)396-125-85(377-187(145(125)338-10)277-65-238-105-156(215)226-59-232-162(105)277)48-358-413(316,432)391-120-80(372-182(140(120)333-5)270-32-23-98(214)251-205(270)303)43-354-417(320,436)402-131-94(386-193(151(131)344-16)283-71-244-111-168(283)258-198(221)263-173(111)296)57-366-424(327,443)405-132-91(383-194(152(132)345-17)284-72-245-112-169(284)259-199(222)264-174(112)297)54-363-414(317,433)395-124-84(376-186(144(124)337-9)276-38-29-104(294)257-211(276)309)47-356-416(319,435)397-126-89(381-188(146(126)339-11)278-66-239-106-157(216)227-60-233-163(106)278)52-361-422(325,441)403-133-92(384-195(153(133)346-18)285-73-246-113-170(285)260-200(223)265-175(113)298)55-364-420(323,439)400-130-88(380-192(150(130)343-15)282-70-243-110-161(220)231-64-237-167(110)282)51-360-419(322,438)399-128-90(382-190(148(128)341-13)280-68-241-108-159(218)229-62-235-165(108)280)53-362-423(326,442)404-134-95(387-196(154(134)347-19)286-74-247-114-171(286)261-201(224)266-176(114)299)58-367-425(328,444)406-135-93(385-197(155(135)348-20)287-75-248-115-172(287)262-202(225)267-177(115)300)56-365-421(324,440)401-129-87(379-191(149(129)342-14)281-69-242-109-160(219)230-63-236-166(109)281)50-359-418(321,437)398-127-86(378-189(147(127)340-12)279-67-240-107-158(217)228-61-234-164(107)279)49-357-412(315,431)390-119-78(370-181(139(119)332-4)269-31-22-97(213)250-204(269)302)41-350-408(311,427)388-117-76(39-288)368-179(137(117)330-2)272-34-25-100(290)253-207(272)305/h21-38,59-95,116-155,178-197,288,295H,39-58H2,1-20H3,(H,310,426)(H,311,427)(H,312,428)(H,313,429)(H,314,430)(H,315,431)(H,316,432)(H,317,433)(H,318,434)(H,319,435)(H,320,436)(H,321,437)(H,322,438)(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H2,212,249,301)(H2,213,250,302)(H2,214,251,303)(H2,215,226,232)(H2,216,227,233)(H2,217,228,234)(H2,218,229,235)(H2,219,230,236)(H2,220,231,237)(H,252,289,304)(H,253,290,305)(H,254,291,306)(H,255,292,307)(H,256,293,308)(H,257,294,309)(H3,221,258,263,296)(H3,222,259,264,297)(H3,223,260,265,298)(H3,224,261,266,299)(H3,225,262,267,300)/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,407?,408?,409?,410?,411?,412?,413?,414?,415?,416?,417?,418?,419?,420?,421?,422?,423?,424?,425?/m1/s1
DMWUN1S	CS	CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=S)(O)O[C@@H]3[C@H](O[C@H]([C@@H]3OC)N4C=CC(=NC4=O)N)COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OC)N6C=CC(=O)NC6=O)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OC)N8C=CC(=O)NC8=O)COP(=S)(O)O[C@@H]9[C@H](O[C@H]([C@@H]9OC)N1C=CC(=O)NC1=O)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=NC1=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=O)NC1=O)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=O)(O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=NC1=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=O)NC1=O)CO)S)O
DMWUN1S	IK	HUGILZFVSVLCAO-XVKRXUDYSA-N
DMWUN1S	IU	1-[(2R,3R,4R,5R)-5-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-hydroxy-3-methoxyoxolan-2-yl]pyrimidine-2,4-dione
DMWUN1S	CA	CAS 1251830-50-8
DMWUN1S	DE	Duchenne dystrophy

DMM0HAE	ID	DMM0HAE
DMM0HAE	DN	DSC-127
DMM0HAE	HS	Phase 3
DMM0HAE	SN	aclerastide; UNII-YYD6UT8T47; YYD6UT8T47; Aclerastide [INN]; DSC-127; Norleu3-a(1-7); Asp-arg-nle-tyr-ile-his-pro; DSC127; USB-001; 227803-63-6; 1-7-Angiotensin II, 3-L-norleucine-5-L-isoleucine
DMM0HAE	CP	Derma Sciences
DMM0HAE	DT	Small molecular drug
DMM0HAE	PC	9811551
DMM0HAE	MW	913
DMM0HAE	FM	C42H64N12O11
DMM0HAE	IC	InChI=1S/C42H64N12O11/c1-4-6-9-28(50-36(59)29(10-7-16-47-42(44)45)49-35(58)27(43)20-33(56)57)37(60)51-30(18-24-12-14-26(55)15-13-24)38(61)53-34(23(3)5-2)39(62)52-31(19-25-21-46-22-48-25)40(63)54-17-8-11-32(54)41(64)65/h12-15,21-23,27-32,34,55H,4-11,16-20,43H2,1-3H3,(H,46,48)(H,49,58)(H,50,59)(H,51,60)(H,52,62)(H,53,61)(H,56,57)(H,64,65)(H4,44,45,47)/t23-,27-,28-,29-,30-,31-,32-,34-/m0/s1
DMM0HAE	CS	CCCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DMM0HAE	IK	RUBMHAHMIJSMHA-LBWFYSSPSA-N
DMM0HAE	IU	(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
DMM0HAE	CA	CAS 227803-63-6
DMM0HAE	DE	Diabetic foot ulcer

DM6P8HU	ID	DM6P8HU
DM6P8HU	DN	Dutasteride + tamsulosin
DM6P8HU	HS	Phase 3
DM6P8HU	SN	Jalyn; Dutasteride / tamsulosin; Tamsulosin / Dutasteride; Dutasteride mixture with tamsulosin
DM6P8HU	CP	GSK
DM6P8HU	DT	Combination drug (small molecular drug)
DM6P8HU	PC	11679580
DM6P8HU	MW	937
DM6P8HU	FM	C47H58F6N4O7S
DM6P8HU	IC	InChI=1S/C27H30F6N2O2.C20H28N2O5S/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33;1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36);5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-,16-,17-,19+,21+,24-,25+;15-/m01/s1
DM6P8HU	CS	CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
DM6P8HU	IK	SHHCJPKACHSWFP-NMXGMQNUSA-N
DM6P8HU	IU	(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
DM6P8HU	DE	Benign prostatic hyperplasia; Prostate cancer

DMM5VTA	ID	DMM5VTA
DMM5VTA	DN	Dutogliptin
DMM5VTA	HS	Phase 3
DMM5VTA	SN	Dutogliptin tartrate; PHX-1004; PHX-1149; PHX-1149T; DPP IV inhibitors (diabetes), Phenomix; DPP IV program (diabetes), Phenomix
DMM5VTA	CP	Phenomix Corp
DMM5VTA	PC	11253490
DMM5VTA	MW	241.1
DMM5VTA	FM	C10H20BN3O3
DMM5VTA	IC	InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1
DMM5VTA	CS	B([C@@H]1CCCN1C(=O)CN[C@@H]2CCNC2)(O)O
DMM5VTA	IK	DVJAMEIQRSHVKC-BDAKNGLRSA-N
DMM5VTA	IU	[(2R)-1-[2-[[(3R)-pyrrolidin-3-yl]amino]acetyl]pyrrolidin-2-yl]boronic acid
DMM5VTA	CA	CAS 852329-66-9
DMM5VTA	DE	Type-2 diabetes

DMAFUIR	ID	DMAFUIR
DMAFUIR	DN	DWP-431
DMAFUIR	HS	Phase 3
DMAFUIR	SN	Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong
DMAFUIR	CP	Daewoong Pharmaceutical Co Ltd
DMAFUIR	DE	Bone development disorder

DMM1YC4	ID	DMM1YC4
DMM1YC4	DN	E-101
DMM1YC4	HS	Phase 3
DMM1YC4	SN	Myeloperoxidase; Glucose oxidase; Human myeloperoxidase, dimer; E-101 (infections); Myeloperoxidase formulations (nosocomial infections), Exoxemis; E-101 (infections), Exoxemis; MPO enzyme system (hospital-acquiredl infections), Exoxemis; Myeloperoxidase + glucose oxidase (infections), Exoxemis
DMM1YC4	CP	Exoxemis
DMM1YC4	DT	Small molecular drug
DMM1YC4	PC	11973707
DMM1YC4	MW	377.3
DMM1YC4	FM	C17H26Cl2N2O3
DMM1YC4	IC	InChI=1S/C17H25ClN2O3.ClH/c1-4-12-8-13(18)16(23-3)14(15(12)21)17(22)19-9-11-6-7-20(5-2)10-11;/h8,11,21H,4-7,9-10H2,1-3H3,(H,19,22);1H/t11-;/m0./s1
DMM1YC4	CS	CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCN(C2)CC)OC)Cl.Cl
DMM1YC4	IK	RDZXYWICCLALQM-MERQFXBCSA-N
DMM1YC4	IU	5-chloro-3-ethyl-N-[[(3S)-1-ethylpyrrolidin-3-yl]methyl]-2-hydroxy-6-methoxybenzamide;hydrochloride
DMM1YC4	DE	Infectious disease

DMTNUJ8	ID	DMTNUJ8
DMTNUJ8	DN	E-2609
DMTNUJ8	HS	Phase 3
DMTNUJ8	SN	Beta secretase inhibitor (Alzheimer's disease), Eisai
DMTNUJ8	CP	Eisai Co Ltd
DMTNUJ8	PC	57827330
DMTNUJ8	MW	437.4
DMTNUJ8	FM	C19H18F3N5O2S
DMTNUJ8	IC	InChI=1S/C19H18F3N5O2S/c1-9-12-7-30-18(23)27-19(12,8-29-9)11-4-10(2-3-13(11)20)26-17(28)15-6-24-14(5-25-15)16(21)22/h2-6,9,12,16H,7-8H2,1H3,(H2,23,27)(H,26,28)/t9-,12-,19-/m1/s1
DMTNUJ8	CS	C[C@@H]1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(N=C4)C(F)F)F)N
DMTNUJ8	IK	AACUJFVOHGRMTR-DPXNYUHVSA-N
DMTNUJ8	IU	N-[3-[(4aS,5R,7aS)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide
DMTNUJ8	CA	CAS 1388651-30-6
DMTNUJ8	DE	Alzheimer disease

DM42PFT	ID	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	HS	Phase 3
DM42PFT	SN	Lucitanib; AL-3810; E-3810, EOS
DM42PFT	CP	Clovis oncology
DM42PFT	DT	Small molecular drug
DM42PFT	PC	25031915
DM42PFT	MW	443.5
DM42PFT	FM	C26H25N3O4
DM42PFT	IC	InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)
DM42PFT	CS	CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
DM42PFT	IK	CUDVHEFYRIWYQD-UHFFFAOYSA-N
DM42PFT	IU	6-[7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl]oxy-N-methylnaphthalene-1-carboxamide
DM42PFT	CA	CAS 1058137-23-7
DM42PFT	CB	CHEBI:65209
DM42PFT	DE	Solid tumour/cancer

DMUHS5Q	ID	DMUHS5Q
DMUHS5Q	DN	E-913
DMUHS5Q	HS	Phase 3
DMUHS5Q	SN	E913; E 913; 342394-93-8; 1,4,9-Triazaspiro(5.5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)-; 11-butyl-9-(cyclohexylmethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-3,8,11-triazaspiro[5.5]undecane-7,10-dione; 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-; AC1LANMM; E-913; SCHEMBL1649664; GTPL3500; CHEMBL1196395; e9-13; BDBM50190513; LS-184716
DMUHS5Q	DT	Small molecular drug
DMUHS5Q	PC	491774
DMUHS5Q	MW	483.6
DMUHS5Q	FM	C28H41N3O4
DMUHS5Q	IC	InChI=1S/C28H41N3O4/c1-2-3-13-31-26(32)23(18-21-7-5-4-6-8-21)29-27(33)28(31)11-14-30(15-12-28)20-22-9-10-24-25(19-22)35-17-16-34-24/h9-10,19,21,23H,2-8,11-18,20H2,1H3,(H,29,33)
DMUHS5Q	CS	CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC4=C(C=C3)OCCO4)CC5CCCCC5
DMUHS5Q	IK	VBONNDPACFTZMX-UHFFFAOYSA-N
DMUHS5Q	IU	1-butyl-3-(cyclohexylmethyl)-9-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane-2,5-dione
DMUHS5Q	CA	CAS 342394-93-8
DMUHS5Q	DE	Human immunodeficiency virus infection

DMLA1ER	ID	DMLA1ER
DMLA1ER	DN	EC20
DMLA1ER	HS	Phase 3
DMLA1ER	SN	Technetium Tc-99m etarfolatide
DMLA1ER	CP	Endocyte
DMLA1ER	DT	Small molecular drug
DMLA1ER	PC	135428923
DMLA1ER	MW	745.7
DMLA1ER	FM	C29H35N11O11S
DMLA1ER	IC	InChI=1S/C29H35N11O11S/c30-15(24(45)37-17(7-20(42)43)25(46)38-18(11-52)28(50)51)10-33-19(41)6-5-16(27(48)49)36-23(44)12-1-3-13(4-2-12)32-8-14-9-34-22-21(35-14)26(47)40-29(31)39-22/h1-4,9,15-18,32,52H,5-8,10-11,30H2,(H,33,41)(H,36,44)(H,37,45)(H,38,46)(H,42,43)(H,48,49)(H,50,51)(H3,31,34,39,40,47)/t15-,16+,17-,18-/m0/s1
DMLA1ER	CS	C1=CC(=CC=C1C(=O)N[C@H](CCC(=O)NC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
DMLA1ER	IK	RKGPQAGUQDVJHG-MHORFTMASA-N
DMLA1ER	IU	(2R)-5-[[(2S)-2-amino-3-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]amino]-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-oxopentanoic acid
DMLA1ER	CA	CAS 479578-27-3
DMLA1ER	DE	Ovarian cancer

DMS9R43	ID	DMS9R43
DMS9R43	DN	Ecopipam
DMS9R43	HS	Phase 3
DMS9R43	SN	Sch-39166; Sch 39166; 112108-01-7; Ecopipam [INN]; Sch39166; UNII-0X748O646K; CHEMBL298406; 0X748O646K; DSSTox_RID_80075; DSSTox_CID_23814; 6,7,7a,8,9,13b-Hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo(d)naphtho(2,1b)azepine; DSSTox_GSID_43814; 5H-Benzo(d)naphth(2,1-b)azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, trans-(-)-; (6aS,13bR)-11-chloro-7-methyl-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphtho[2,1-b]azepin-12-ol; 5H-Benzo[d]naphth[2,1-b]azepin-12-ol,; ecopipam (controlled-release, Lesch Nyhan syndrome/Tourette's syndrome/compulsive gambling). Psyadon Pharmaceuticals
DMS9R43	DT	Small molecular drug
DMS9R43	PC	107930
DMS9R43	MW	313.8
DMS9R43	FM	C19H20ClNO
DMS9R43	IC	InChI=1S/C19H20ClNO/c1-21-9-8-13-10-16(20)18(22)11-15(13)19-14-5-3-2-4-12(14)6-7-17(19)21/h2-5,10-11,17,19,22H,6-9H2,1H3/t17-,19+/m0/s1
DMS9R43	CS	CN1CCC2=CC(=C(C=C2[C@@H]3[C@@H]1CCC4=CC=CC=C34)O)Cl
DMS9R43	IK	DMJWENQHWZZWDF-PKOBYXMFSA-N
DMS9R43	IU	(6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol
DMS9R43	CA	CAS 112108-01-7
DMS9R43	CB	CHEBI:93645
DMS9R43	DE	Cocaine addiction; Tourette syndrome

DMRLXAI	ID	DMRLXAI
DMRLXAI	DN	ED-71
DMRLXAI	HS	Phase 3
DMRLXAI	SN	Edirol; Eldecalcitol; (5Z,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol; 104121-92-8; 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)cholecalciferol; 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3; 2-(3-Hydroxypropoxy)-1,25-dihydroxyvitamin D3; ED 71; ED-71; I2JP8UE90H; UNII-I2JP8UE90H
DMRLXAI	PC	6918141
DMRLXAI	MW	490.7
DMRLXAI	FM	C30H50O5
DMRLXAI	IC	FZEXGDDBXLBRTD-AYIMTCTASA-N
DMRLXAI	CS	CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(C(C(C3=C)O)OCCCO)O)C
DMRLXAI	IK	1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1
DMRLXAI	IU	(1R,2R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
DMRLXAI	CA	CAS 104121-92-8
DMRLXAI	CB	CHEBI:73927
DMRLXAI	DE	Osteoporosis

DMYVBF6	ID	DMYVBF6
DMYVBF6	DN	Edasalonexent
DMYVBF6	HS	Phase 3
DMYVBF6	SN	UNII-AF3Z6434KS; AF3Z6434KS; 1204317-86-1; Edasalonexent [INN]; SCHEMBL1823117; CHEMBL3786673; JQLBBYLGWHUHRW-KUBAVDMBSA-N; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide; Benzamide, 2-hydroxy-N-(2-(((4Z,7Z,10Z,13Z,16Z,19Z)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl)amino)ethyl)-; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16, 19-hexaenamidoethyl)-2-hydroxybenzamide
DMYVBF6	CP	Catabasis Pharmaceuticals Cambridge, MA
DMYVBF6	PC	44626120
DMYVBF6	MW	490.7
DMYVBF6	FM	C31H42N2O3
DMYVBF6	IC	InChI=1S/C31H42N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-30(35)32-26-27-33-31(36)28-23-21-22-24-29(28)34/h3-4,6-7,9-10,12-13,15-16,18-19,21-24,34H,2,5,8,11,14,17,20,25-27H2,1H3,(H,32,35)(H,33,36)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-
DMYVBF6	CS	CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)NCCNC(=O)C1=CC=CC=C1O
DMYVBF6	IK	JQLBBYLGWHUHRW-KUBAVDMBSA-N
DMYVBF6	IU	N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide
DMYVBF6	CA	CAS 1204317-86-1
DMYVBF6	DE	Duchenne dystrophy

DM3ZL7D	ID	DM3ZL7D
DM3ZL7D	DN	Edotecarin
DM3ZL7D	HS	Phase 3
DM3ZL7D	SN	ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
DM3ZL7D	CP	Pfizer
DM3ZL7D	DT	Small molecular drug
DM3ZL7D	PC	9808998
DM3ZL7D	MW	608.6
DM3ZL7D	FM	C29H28N4O11
DM3ZL7D	IC	InChI=1S/C29H28N4O11/c34-7-10(8-35)31-33-27(42)20-18-13-3-1-11(37)5-15(13)30-22(18)23-19(21(20)28(33)43)14-4-2-12(38)6-16(14)32(23)29-26(41)25(40)24(39)17(9-36)44-29/h1-6,10,17,24-26,29-31,34-41H,7-9H2/t17-,24-,25+,26-,29-/m1/s1
DM3ZL7D	CS	C1=CC2=C(C=C1O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC(CO)CO)C6=C(N4[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C=C(C=C6)O
DM3ZL7D	IK	QMVPQBFHUJZJCS-NTKFZFFISA-N
DM3ZL7D	IU	13-(1,3-dihydroxypropan-2-ylamino)-6,20-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
DM3ZL7D	CA	CAS 174402-32-5
DM3ZL7D	DE	Gastric adenocarcinoma

DMX7BM4	ID	DMX7BM4
DMX7BM4	DN	Efaproxyn
DMX7BM4	HS	Phase 3
DMX7BM4	SN	Efaproxiral; RSR13
DMX7BM4	CP	Allos Therapeutics
DMX7BM4	DT	Small molecular drug
DMX7BM4	PC	122335
DMX7BM4	MW	341.4
DMX7BM4	FM	C20H23NO4
DMX7BM4	IC	InChI=1S/C20H23NO4/c1-13-9-14(2)11-16(10-13)21-18(22)12-15-5-7-17(8-6-15)25-20(3,4)19(23)24/h5-11H,12H2,1-4H3,(H,21,22)(H,23,24)
DMX7BM4	CS	CC1=CC(=CC(=C1)NC(=O)CC2=CC=C(C=C2)OC(C)(C)C(=O)O)C
DMX7BM4	IK	BNFRJXLZYUTIII-UHFFFAOYSA-N
DMX7BM4	IU	2-[4-[2-(3,5-dimethylanilino)-2-oxoethyl]phenoxy]-2-methylpropanoic acid
DMX7BM4	CA	CAS 131179-95-8
DMX7BM4	DE	Lung cancer

DMKA2PI	ID	DMKA2PI
DMKA2PI	DN	Efpeglenatide
DMKA2PI	HS	Phase 3
DMKA2PI	SN	Langlenatide; Efpeglenatide [INN]; Langlenatide [WHO-DD]; UNII-3M1V5Z2270; SCHEMBL19712179; 3M1V5Z2270; 1296200-77-5
DMKA2PI	CP	Sanofi US Bridgewater, NJ
DMKA2PI	PC	86278345
DMKA2PI	MW	403.5
DMKA2PI	FM	C19H37N3O6
DMKA2PI	IC	InChI=1S/C19H37N3O6/c20-16(18(23)24)6-1-2-8-21-9-4-12-27-14-15-28-13-5-11-22-10-3-7-17(22)19(25)26/h16-17,21H,1-15,20H2,(H,23,24)(H,25,26)/t16-,17-/m0/s1
DMKA2PI	CS	C1C[C@H](N(C1)CCCOCCOCCCNCCCC[C@@H](C(=O)O)N)C(=O)O
DMKA2PI	IK	OJQLGILETRTDGQ-IRXDYDNUSA-N
DMKA2PI	IU	(2S)-1-[3-[2-[3-[[(5S)-5-amino-5-carboxypentyl]amino]propoxy]ethoxy]propyl]pyrrolidine-2-carboxylic acid
DMKA2PI	DE	Type-2 diabetes

DMCMJRA	ID	DMCMJRA
DMCMJRA	DN	EGF816
DMCMJRA	HS	Phase 3
DMCMJRA	CP	Novartis pharmaceuticals
DMCMJRA	PC	72703790
DMCMJRA	MW	495
DMCMJRA	FM	C26H31ClN6O2
DMCMJRA	IC	InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1
DMCMJRA	CS	CC1=NC=CC(=C1)C(=O)NC2=NC3=C(N2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)C(=CC=C3)Cl
DMCMJRA	IK	IOMMMLWIABWRKL-WUTDNEBXSA-N
DMCMJRA	IU	N-[7-chloro-1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]benzimidazol-2-yl]-2-methylpyridine-4-carboxamide
DMCMJRA	CA	CAS 1508250-71-2
DMCMJRA	DE	Non-small-cell lung cancer

DMB2C0E	ID	DMB2C0E
DMB2C0E	DN	Elagolix
DMB2C0E	HS	Phase 3
DMB2C0E	SN	Elagolix; 834153-87-6; UNII-5B2546MB5Z; NBI-56418; 5B2546MB5Z; NBI56418; NBI 56418; Elagolix [USAN:INN]; Orilissa; ELA gOLIX; Elagolix (USAN/INN); SCHEMBL1642523; GTPL8362; CHEMBL1208155; DTXSID40232348; ABT-620; 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid; EX-A1765; BCP08827; ZINC49888891; CS-5329; SB16700; DB11979; compound 10b [PMID 19006286]; HY-14789; AN-27202; D09335; Z-3253; 153E876; Butanoic acid, 4-(((1R)-2-(5-(2-flu
DMB2C0E	CP	Abbott Laboratories Abbott; Neurocrine Biosciences
DMB2C0E	DT	Small molecular drug
DMB2C0E	PC	11250647
DMB2C0E	MW	631.6
DMB2C0E	FM	C32H30F5N3O5
DMB2C0E	IC	InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1
DMB2C0E	CS	CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F
DMB2C0E	IK	HEAUOKZIVMZVQL-VWLOTQADSA-N
DMB2C0E	IU	4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid
DMB2C0E	CA	CAS 834153-87-6
DMB2C0E	DE	Uterine fibroids

DMW6C81	ID	DMW6C81
DMW6C81	DN	Eltoprazine
DMW6C81	HS	Phase 3
DMW6C81	SN	Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company
DMW6C81	CP	Amarantus bioscience; psychogenics
DMW6C81	DT	Small molecular drug
DMW6C81	PC	65853
DMW6C81	MW	220.27
DMW6C81	FM	C12H16N2O2
DMW6C81	IC	InChI=1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2
DMW6C81	CS	C1CN(CCN1)C2=C3C(=CC=C2)OCCO3
DMW6C81	IK	WVLHGCRWEHCIOT-UHFFFAOYSA-N
DMW6C81	IU	1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine
DMW6C81	CA	CAS 98224-03-4
DMW6C81	DE	Non-hodgkin lymphoma; Alzheimer disease; Attention deficit hyperactivity disorder; Dyskinesia; Parkinson disease

DMZKTYJ	ID	DMZKTYJ
DMZKTYJ	DN	Enmetazobactam
DMZKTYJ	HS	Phase 3
DMZKTYJ	SN	AAI-101; AAI101; 1001404-83-6; UNII-80VUN7L00C; 80VUN7L00C; (2S,3S,5R)-3-methyl-3-((3-methyl-1H-1,2,3-triazol-3-ium-1-yl)methyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide; CHEMBL4458276; SCHEMBL18110082; OCID-5090; CS-7557; HY-103095; J3.628.087E; (2S,3S,5R)-3-Methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4^6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate; (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1H-1,2,3-Triazolium, 3-(((2S,3S,5R)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, inner salt
DMZKTYJ	CP	Allecra Therapeutics
DMZKTYJ	DT	Small molecular drug
DMZKTYJ	PC	23653540
DMZKTYJ	MW	314.32
DMZKTYJ	FM	C11H14N4O5S
DMZKTYJ	IC	InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1
DMZKTYJ	CS	C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=C[N+](=N3)C
DMZKTYJ	IK	HFZITXBUTWITPT-YWVKMMECSA-N
DMZKTYJ	IU	(2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMZKTYJ	CA	CAS 1001404-83-6
DMZKTYJ	DE	Urinary tract infection

DMIKDCQ	ID	DMIKDCQ
DMIKDCQ	DN	Ensartinib
DMIKDCQ	HS	Phase 3
DMIKDCQ	CP	Xcovery Palm Beach Gardens, FL
DMIKDCQ	PC	56960363
DMIKDCQ	MW	561.4
DMIKDCQ	FM	C26H27Cl2FN6O3
DMIKDCQ	IC	InChI=1S/C26H27Cl2FN6O3/c1-13-11-35(12-14(2)31-13)26(37)16-4-6-17(7-5-16)32-25(36)20-10-21(24(30)34-33-20)38-15(3)22-18(27)8-9-19(29)23(22)28/h4-10,13-15,31H,11-12H2,1-3H3,(H2,30,34)(H,32,36)/t13-,14+,15-/m1/s1
DMIKDCQ	CS	C[C@@H]1CN(C[C@@H](N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)O[C@H](C)C4=C(C=CC(=C4Cl)F)Cl)N
DMIKDCQ	IK	GLYMPHUVMRFTFV-QLFBSQMISA-N
DMIKDCQ	IU	6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(3S,5R)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide
DMIKDCQ	CA	CAS 1370651-20-9
DMIKDCQ	DE	Non-small-cell lung cancer

DM7EOBQ	ID	DM7EOBQ
DM7EOBQ	DN	Entacapone+levodopa+carbidopa
DM7EOBQ	HS	Phase 3
DM7EOBQ	CP	Orion; Novartis
DM7EOBQ	DE	Restless legs syndrome; Parkinson disease

DMTWLXY	ID	DMTWLXY
DMTWLXY	DN	Entresto
DMTWLXY	HS	Phase 3
DMTWLXY	SN	Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi
DMTWLXY	CP	Novartis East Hanover, NJ
DMTWLXY	PC	71449007
DMTWLXY	MW	1916
DMTWLXY	FM	C96H120N12Na6O21
DMTWLXY	IC	InChI=1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O/c2*1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;/h2*6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;5*1H2/q;;;;6*+1;;;;;/p-6/t2*22-;2*17-,21+;;;;;;;;;;;/m0011.........../s1
DMTWLXY	CS	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMTWLXY	IK	ZASXKEGREHRXDL-CAWNUZPDSA-H
DMTWLXY	IU	hexasodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate
DMTWLXY	CA	CAS 936623-90-4
DMTWLXY	DE	Acute myocardial infarction; Heart failure

DM5H0R9	ID	DM5H0R9
DM5H0R9	DN	Enzastaurin
DM5H0R9	HS	Phase 3
DM5H0R9	SN	LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
DM5H0R9	CP	Eli Lilly
DM5H0R9	TC	Anticancer Agents
DM5H0R9	DT	Small molecular drug
DM5H0R9	PC	176167
DM5H0R9	MW	515.6
DM5H0R9	FM	C32H29N5O2
DM5H0R9	IC	InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
DM5H0R9	CS	CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7
DM5H0R9	IK	AXRCEOKUDYDWLF-UHFFFAOYSA-N
DM5H0R9	IU	3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
DM5H0R9	CA	CAS 170364-57-5
DM5H0R9	CB	CHEBI:91368
DM5H0R9	DE	Central nervous system disease; Glioblastoma multiforme; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma

DMEX86V	ID	DMEX86V
DMEX86V	DN	Epcoritamab
DMEX86V	HS	Phase 3
DMEX86V	CP	Genmab
DMEX86V	DT	Antibody
DMEX86V	DE	Diffuse large B-cell lymphoma

DM1SMAI	ID	DM1SMAI
DM1SMAI	DN	Eperisone
DM1SMAI	HS	Phase 3
DM1SMAI	SN	EMPP; Myonal; Myorelark; E-0646; E-2000; E-646; Eperisone (transdermal patch); Eperisone (oral), Eisai; Eperisone (transdermalpatch), Eisai; E-2000 (oral), Eisai; E-2000 (transdermal patch), Eisai
DM1SMAI	CP	Eisai Co Ltd
DM1SMAI	DT	Small molecular drug
DM1SMAI	PC	3236
DM1SMAI	MW	259.399
DM1SMAI	FM	C17H25NO
DM1SMAI	IC	InChI=1S/C17H25NO/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18/h7-10,14H,3-6,11-13H2,1-2H3
DM1SMAI	CS	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
DM1SMAI	IK	SQUNAWUMZGQQJD-UHFFFAOYSA-N
DM1SMAI	IU	1-(4-ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one
DM1SMAI	CA	CAS 64840-90-0
DM1SMAI	CB	CHEBI:77070
DM1SMAI	DE	Muscle spasm

DM08XIN	ID	DM08XIN
DM08XIN	DN	EPIANDROSTERONE
DM08XIN	HS	Phase 3
DM08XIN	SN	EPIANDROSTERONE; 481-29-8; trans-Androsterone; Isoandrosterone; 3Beta-hydroxy-5alpha-androstan-17-one; 3beta-Hydroxyetioallocholan-17-one; epi-andosterone; 5alpha-Androstan-3beta-ol-17-one; iso-Androsterone; d-Epiandrosterone; UNII-8TR252Z538; 3-Epiandrosterone; (3beta,5alpha)-3-hydroxyandrostan-17-one; CHEMBL272195; 3beta-Hydroxy-androstan-17-one; CHEBI:541975; QGXBDMJGAMFCBF-LUJOEAJASA-N; Androsterone, epi-; NSC 93996; MFCD00064134; 8TR252Z538; ST072176; Androstan-17-one, 3-hydroxy-, (3b,5a)-; epi-Androsterone; C19H30O2
DM08XIN	DT	Small molecular drug
DM08XIN	PC	441302
DM08XIN	MW	290.4
DM08XIN	FM	C19H30O2
DM08XIN	IC	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14-,15-,16-,18-,19-/m0/s1
DM08XIN	CS	C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DM08XIN	IK	QGXBDMJGAMFCBF-LUJOEAJASA-N
DM08XIN	IU	(3S,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DM08XIN	CA	CAS 481-29-8
DM08XIN	CB	CHEBI:541975

DMCGWBJ	ID	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	HS	Phase 3
DMCGWBJ	SN	(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl;  EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE
DMCGWBJ	CP	Anagen Therapeutics Inc; Enzo Life Sciences
DMCGWBJ	DT	Small molecular drug
DMCGWBJ	PC	65064
DMCGWBJ	MW	458.4
DMCGWBJ	FM	C22H18O11
DMCGWBJ	IC	InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
DMCGWBJ	CS	C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMCGWBJ	IK	WMBWREPUVVBILR-WIYYLYMNSA-N
DMCGWBJ	IU	[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMCGWBJ	CA	CAS 989-51-5
DMCGWBJ	CB	CHEBI:4806
DMCGWBJ	DE	Hepatic fibrosis

DM9QPOU	ID	DM9QPOU
DM9QPOU	DN	Epoetin zeta
DM9QPOU	HS	Phase 3
DM9QPOU	CP	Hospira
DM9QPOU	DE	Anemia

DMITJRU	ID	DMITJRU
DMITJRU	DN	Epothilon
DMITJRU	HS	Phase 3
DMITJRU	CP	Bayer AG
DMITJRU	DE	Ovarian cancer

DMI1ZXV	ID	DMI1ZXV
DMI1ZXV	DN	Epratuzumab
DMI1ZXV	HS	Phase 3
DMI1ZXV	SN	LymphoCide; Lymphocide (TN); Epratuzumab (USAN/INN)
DMI1ZXV	CP	Immunomedics
DMI1ZXV	DT	Antibody
DMI1ZXV	DE	Graft rejection in heart transplantation; Systemic lupus erythematosus; Acute lymphoblastic leukaemia

DM35T1O	ID	DM35T1O
DM35T1O	DN	Epristeride
DM35T1O	HS	Phase 3
DM35T1O	SN	Zariflo; ONO-9302; SKB-105657; SKF-105657
DM35T1O	CP	SmithKline Beecham plc
DM35T1O	DT	Small molecular drug
DM35T1O	PC	68741
DM35T1O	MW	399.6
DM35T1O	FM	C25H37NO3
DM35T1O	IC	InChI=1S/C25H37NO3/c1-23(2,3)26-21(27)20-9-8-18-17-7-6-16-14-15(22(28)29)10-12-24(16,4)19(17)11-13-25(18,20)5/h6,14,17-20H,7-13H2,1-5H3,(H,26,27)(H,28,29)/t17-,18-,19-,20+,24-,25-/m0/s1
DM35T1O	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC=C4[C@@]3(CCC(=C4)C(=O)O)C
DM35T1O	IK	VAPSMQAHNAZRKC-PQWRYPMOSA-N
DM35T1O	IU	(8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
DM35T1O	CA	CAS 119169-78-7
DM35T1O	CB	CHEBI:31552
DM35T1O	DE	Hirsutism

DMTV7ZM	ID	DMTV7ZM
DMTV7ZM	DN	Eptastigmine
DMTV7ZM	HS	Phase 3
DMTV7ZM	SN	heptastigmine; Heptylphysostigmine; Physostigmine heptyl; Eptastigmine [INN]; (-)-Heptylphysostigmine; Eptastigminum [INN-Latin]; Eptastigmina [INN-Spanish]; UNII-6PZZ52D76Q; N-Demethyl-N-heptylphysostigmine; 101246-68-8; BRN 4883778; CHEMBL433041; 6PZZ52D76Q; Heptylstigmine; heptyl-physostigmine; Eptastigminum; Eptastigmina; heptyl physostigmine; Carbamic acid, heptyl-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)-; AC1Q60XA; SCHEMBL195028; BDBM10972;  Epiastigmine; Eptastigmine tartrate; Heptylstigmine tartrate; Heptyl-physostigmine; L-693487; MF-201; HEPTYPHYSOSTIGMINE
DMTV7ZM	CP	Consiglio Nazionale delle Ricerche
DMTV7ZM	DT	Small molecular drug
DMTV7ZM	PC	65872
DMTV7ZM	MW	359.5
DMTV7ZM	FM	C21H33N3O2
DMTV7ZM	IC	InChI=1S/C21H33N3O2/c1-5-6-7-8-9-13-22-20(25)26-16-10-11-18-17(15-16)21(2)12-14-23(3)19(21)24(18)4/h10-11,15,19H,5-9,12-14H2,1-4H3,(H,22,25)/t19-,21+/m1/s1
DMTV7ZM	CS	CCCCCCCNC(=O)OC1=CC2=C(C=C1)N([C@@H]3[C@]2(CCN3C)C)C
DMTV7ZM	IK	RRGMXBQMCUKRLH-CTNGQTDRSA-N
DMTV7ZM	IU	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-heptylcarbamate
DMTV7ZM	CA	CAS 101246-68-8
DMTV7ZM	DE	Cognitive impairment

DM6BU57	ID	DM6BU57
DM6BU57	DN	Eraxis/Vfend
DM6BU57	HS	Phase 3
DM6BU57	CP	Pfizer
DM6BU57	DE	Fungal infection

DM9YI2C	ID	DM9YI2C
DM9YI2C	DN	ErepoXen
DM9YI2C	HS	Phase 3
DM9YI2C	CP	Lipoxen plc
DM9YI2C	DE	Anemia

DMKQZ0L	ID	DMKQZ0L
DMKQZ0L	DN	ERITORAN
DMKQZ0L	HS	Phase 3
DMKQZ0L	SN	ERITORAN; UNII-551541VI0Y; E5564; CHEMBL501259; CHEBI:68609; 185955-34-4; 551541VI0Y; Eritoran [INN]; 3-O-decyl-2-deoxy-6-O-{2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11E)-octadec-11-enoylamino]-4-O-phosphonato-beta-D-glucopyranosyl}-2-[(3-oxotetradecanoyl)amino]-1-O-phosphono-alpha-D-glucopyranose; 3-O-Decyl-2-Deoxy-6-O-{2-Deoxy-3-O-[(3r)-3-Methoxydecyl]-6-O-Methyl-2-[(11z)-Octadec-11-Enoylamino]-4-O-Phosphono-Beta-D-Glucopyranosyl}-2-[(3-Oxotetradecanoyl)amino]-1-O-Phosphono-Alpha-D-Glucopyranose; B1287
DMKQZ0L	DT	Small molecular drug
DMKQZ0L	PC	6912404
DMKQZ0L	MW	1313.7
DMKQZ0L	FM	C66H126N2O19P2
DMKQZ0L	IC	InChI=1S/C66H126N2O19P2/c1-7-11-15-19-22-25-26-27-28-29-30-32-34-38-42-46-57(70)67-60-64(82-49-47-54(80-6)45-41-36-18-14-10-4)62(86-88(73,74)75)56(51-79-5)85-65(60)83-52-55-61(72)63(81-48-43-39-35-24-21-17-13-9-3)59(66(84-55)87-89(76,77)78)68-58(71)50-53(69)44-40-37-33-31-23-20-16-12-8-2/h25-26,54-56,59-66,72H,7-24,27-52H2,1-6H3,(H,67,70)(H,68,71)(H2,73,74,75)(H2,76,77,78)/b26-25-/t54-,55-,56-,59-,60-,61-,62-,63-,64-,65-,66-/m1/s1
DMKQZ0L	CS	CCCCCCCCCCCC(=O)CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC)OP(=O)(O)O)OCC[C@@H](CCCCCCC)OC)NC(=O)CCCCCCCCC/C=C\\CCCCCC)O)OCCCCCCCCCC
DMKQZ0L	IK	BPSMYQFMCXXNPC-MFCPCZTFSA-N
DMKQZ0L	IU	[(2R,3R,4R,5S,6R)-4-decoxy-5-hydroxy-6-[[(2R,3R,4R,5S,6R)-4-[(3R)-3-methoxydecoxy]-6-(methoxymethyl)-3-[[(Z)-octadec-11-enoyl]amino]-5-phosphonooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] dihydrogen phosphate
DMKQZ0L	CA	CAS 185955-34-4
DMKQZ0L	CB	CHEBI:68609
DMKQZ0L	DE	Sepsis

DMVU687	ID	DMVU687
DMVU687	DN	Esketamine
DMVU687	HS	Phase 3
DMVU687	SN	(S)-Ketamine; l-Ketamine; (S)-(-)-Ketamine; 33643-46-8; S-Ketamine; UNII-50LFG02TXD; 50LFG02TXD; (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone; CHEBI:60799; esketamine HCl; (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2S)-; 6740-88-1 (Parent); Esketamine [USAN:INN:BAN]; S-Ketamin; S-(-)-Ketamine; Esketamine (USAN/INN); AC1L4AD8; DSSTox_CID_27787; DSSTox_RID_82562; DSSTox_GSID_47810; SCHEMBL5512024; GTPL9152; CHEMBL395091; DTXSID6047810; YQEZ
DMVU687	CP	Janssen Research & Development Raritan, NJ
DMVU687	PC	182137
DMVU687	MW	237.72
DMVU687	FM	C13H16ClNO
DMVU687	IC	InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3/t13-/m0/s1
DMVU687	CS	CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl
DMVU687	IK	YQEZLKZALYSWHR-ZDUSSCGKSA-N
DMVU687	IU	(2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
DMVU687	CA	CAS 33643-46-8
DMVU687	CB	CHEBI:60799
DMVU687	DE	Depression

DM8RBHJ	ID	DM8RBHJ
DM8RBHJ	DN	Esomeprazole magnesium + Aspirin
DM8RBHJ	HS	Phase 3
DM8RBHJ	CP	AstraZeneca
DM8RBHJ	DE	Peptic ulcer

DM4YGWA	ID	DM4YGWA
DM4YGWA	DN	Esonarimod
DM4YGWA	HS	Phase 3
DM4YGWA	SN	Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298
DM4YGWA	CP	Taisho Pharmaceutical Co Ltd
DM4YGWA	DT	Small molecular drug
DM4YGWA	PC	127998
DM4YGWA	MW	280.34
DM4YGWA	FM	C14H16O4S
DM4YGWA	IC	InChI=1S/C14H16O4S/c1-9-3-5-11(6-4-9)13(16)7-12(14(17)18)8-19-10(2)15/h3-6,12H,7-8H2,1-2H3,(H,17,18)
DM4YGWA	CS	CC1=CC=C(C=C1)C(=O)CC(CSC(=O)C)C(=O)O
DM4YGWA	IK	YRSSFEUQNAXQMX-UHFFFAOYSA-N
DM4YGWA	IU	2-(acetylsulfanylmethyl)-4-(4-methylphenyl)-4-oxobutanoic acid
DM4YGWA	CA	CAS 101973-77-7
DM4YGWA	CB	CHEBI:31559
DM4YGWA	DE	Arthritis

DMXLGED	ID	DMXLGED
DMXLGED	DN	esuberaprost
DMXLGED	HS	Phase 3
DMXLGED	SN	APS-314D free acid; BPS-314d
DMXLGED	DT	Small molecular drug
DMXLGED	PC	10501053
DMXLGED	MW	398.5
DMXLGED	FM	C24H30O5
DMXLGED	IC	InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15-,17-,19+,20+,21-,23-/m0/s1
DMXLGED	CS	CC#CC[C@H](C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
DMXLGED	IK	CTPOHARTNNSRSR-NOQAJONNSA-N
DMXLGED	IU	4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
DMXLGED	CA	CAS 94132-88-4
DMXLGED	DE	Gout; Pulmonary arterial hypertension

DMQHX1Y	ID	DMQHX1Y
DMQHX1Y	DN	Etirinotecan pegol
DMQHX1Y	HS	Phase 3
DMQHX1Y	SN	NKTR-102
DMQHX1Y	CP	Nektar Therapeutics
DMQHX1Y	DT	Small molecular drug
DMQHX1Y	PC	56935717
DMQHX1Y	MW	3047.4
DMQHX1Y	FM	C161H192N20O40
DMQHX1Y	IC	InChI=1S/C161H192N20O40/c1-9-105-109-69-101(214-153(198)174-53-37-97(38-54-174)170-45-21-17-22-46-170)29-33-125(109)166-141-113(105)81-178-129(141)73-121-117(145(178)190)85-210-149(194)158(121,13-5)218-137(186)77-162-133(182)89-202-61-65-206-93-157(94-207-66-62-203-90-134(183)163-78-138(187)219-159(14-6)122-74-130-142-114(82-179(130)146(191)118(122)86-211-150(159)195)106(10-2)110-70-102(30-34-126(110)167-142)215-154(199)175-55-39-98(40-56-175)171-47-23-18-24-48-171,95-208-67-63-204-91-135(184)164-79-139(188)220-160(15-7)123-75-131-143-115(83-180(131)147(192)119(123)87-212-151(160)196)107(11-3)111-71-103(31-35-127(111)168-143)216-155(200)176-57-41-99(42-58-176)172-49-25-19-26-50-172)96-209-68-64-205-92-136(185)165-80-140(189)221-161(16-8)124-76-132-144-116(84-181(132)148(193)120(124)88-213-152(161)197)108(12-4)112-72-104(32-36-128(112)169-144)217-156(201)177-59-43-100(44-60-177)173-51-27-20-28-52-173/h29-36,69-76,97-100H,9-28,37-68,77-96H2,1-8H3,(H,162,182)(H,163,183)(H,164,184)(H,165,185)/t158-,159-,160-,161-/m0/s1
DMQHX1Y	CS	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)CNC(=O)COCCOCC(COCCOCC(=O)NCC(=O)O[C@]5(C6=C(COC5=O)C(=O)N7CC8=C(C9=C(C=CC(=C9)OC(=O)N3CCC(CC3)N3CCCCC3)N=C8C7=C6)CC)CC)(COCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)OC(=O)N6CCC(CC6)N6CCCCC6)N=C5C3=C4)CC)CC)COCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)OC(=O)N6CCC(CC6)N6CCCCC6)N=C5C3=C4)CC)CC)C2=NC2=C1C=C(C=C2)OC(=O)N1CCC(CC1)N1CCCCC1
DMQHX1Y	IK	SELCJVNOEBVTAC-HLDPIHRNSA-N
DMQHX1Y	IU	[(19S)-19-[2-[[2-[2-[3-[2-[2-[[2-[[(19S)-10,19-diethyl-14,18-dioxo-7-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]-2,2-bis[2-[2-[[2-[[(19S)-10,19-diethyl-14,18-dioxo-7-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxymethyl]propoxy]ethoxy]acetyl]amino]acetyl]oxy-10,19-diethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
DMQHX1Y	DE	Breast cancer; Ovarian cancer

DMCDZ15	ID	DMCDZ15
DMCDZ15	DN	Evacetrapib
DMCDZ15	HS	Phase 3
DMCDZ15	SN	LY2484595
DMCDZ15	CP	Lilly
DMCDZ15	DT	Small molecular drug
DMCDZ15	PC	49836058
DMCDZ15	MW	638.6
DMCDZ15	FM	C31H36F6N6O2
DMCDZ15	IC	InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1
DMCDZ15	CS	CC1=CC(=C2C(=C1)[C@H](CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C
DMCDZ15	IK	IHIUGIVXARLYHP-UXNJHFGPSA-N
DMCDZ15	IU	4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexane-1-carboxylic acid
DMCDZ15	CA	CAS 1186486-62-3
DMCDZ15	DE	Cardiovascular disease

DMG4UJ6	ID	DMG4UJ6
DMG4UJ6	DN	EVK-001
DMG4UJ6	HS	Phase 3
DMG4UJ6	CP	Evoke Pharma
DMG4UJ6	DE	Diabetic gastroparesis

DMLQO7F	ID	DMLQO7F
DMLQO7F	DN	EVP-6124
DMLQO7F	HS	Phase 3
DMLQO7F	SN	Encenicline; EVP-6124; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626
DMLQO7F	CP	EnVivo Pharmaceuticals
DMLQO7F	DT	Small molecular drug
DMLQO7F	PC	46196517
DMLQO7F	MW	320.8
DMLQO7F	FM	C16H17ClN2OS
DMLQO7F	IC	InChI=1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)/t13-/m0/s1
DMLQO7F	CS	C1CN2CCC1[C@H](C2)NC(=O)C3=CC4=C(S3)C(=CC=C4)Cl
DMLQO7F	IK	SSRDSYXGYPJKRR-ZDUSSCGKSA-N
DMLQO7F	IU	N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide
DMLQO7F	CA	CAS 550999-75-2
DMLQO7F	DE	Schizophrenia; Alzheimer disease

DMCA7FN	ID	DMCA7FN
DMCA7FN	DN	Exatecan
DMCA7FN	HS	Phase 3
DMCA7FN	SN	Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2
DMCA7FN	CP	Daiichi Seiyaku Co Ltd
DMCA7FN	DT	Small molecular drug
DMCA7FN	PC	151115
DMCA7FN	MW	435.4
DMCA7FN	FM	C24H22FN3O4
DMCA7FN	IC	InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1
DMCA7FN	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O
DMCA7FN	IK	ZVYVPGLRVWUPMP-FYSMJZIKSA-N
DMCA7FN	IU	(10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione
DMCA7FN	CA	CAS 171335-80-1
DMCA7FN	CB	CHEBI:135709
DMCA7FN	DE	Solid tumour/cancer

DMBY56U	ID	DMBY56U
DMBY56U	DN	EXISULIND
DMBY56U	HS	Phase 3
DMBY56U	SN	Aposulind; Aptosyn; Sulindac sulfone; FGN-1; Prevatac (former Brand Name); Exisulind; (Z)-5-Fluoro-2-methyl-1-[4-(methylsulfonyl)benzylidene]-1H-indene-3-acetic acid
DMBY56U	CP	OSI Pharmaceuticals
DMBY56U	DT	Small molecular drug
DMBY56U	PC	5472495
DMBY56U	MW	372.4
DMBY56U	FM	C20H17FO4S
DMBY56U	IC	InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
DMBY56U	CS	CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O
DMBY56U	IK	MVGSNCBCUWPVDA-MFOYZWKCSA-N
DMBY56U	IU	2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfonylphenyl)methylidene]inden-1-yl]acetic acid
DMBY56U	CA	CAS 59973-80-7
DMBY56U	CB	CHEBI:64212
DMBY56U	DE	Colorectal cancer

DMOKT7Y	ID	DMOKT7Y
DMOKT7Y	DN	FARGLITAZAR
DMOKT7Y	HS	Phase 3
DMOKT7Y	SN	Farglitazar; GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-
DMOKT7Y	DT	Small molecular drug
DMOKT7Y	PC	170364
DMOKT7Y	MW	546.6
DMOKT7Y	FM	C34H30N2O5
DMOKT7Y	IC	InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1
DMOKT7Y	CS	CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H](C(=O)O)NC4=CC=CC=C4C(=O)C5=CC=CC=C5
DMOKT7Y	IK	ZZCHHVUQYRMYLW-HKBQPEDESA-N
DMOKT7Y	IU	(2S)-2-(2-benzoylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
DMOKT7Y	CA	CAS 196808-45-4
DMOKT7Y	DE	Type-1 diabetes

DM83SEB	ID	DM83SEB
DM83SEB	DN	Faricimab
DM83SEB	HS	Phase 3
DM83SEB	SN	RO6867461; RG7716
DM83SEB	DT	Antibody
DM83SEB	DE	Diabetic macular edema

DMFLWX1	ID	DMFLWX1
DMFLWX1	DN	Farletuzumab
DMFLWX1	HS	Phase 3
DMFLWX1	CP	Morphotek
DMFLWX1	DT	Monoclonal antibody
DMFLWX1	SQ	9067_H|farletuzumab|||H-GAMMA-1 (VH(1-119)+CH1(120-217)+HINGE-REGION(218-232)+CH2(233-342)+CH3(343-449))|||||||449||||MW 48946.2|MW 48946.2|: EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;9067_L|farletuzumab|||L-KAPPA (V-KAPPA(1-110)+C-KAPPA(111-217))|||||||217||||MW 23755.2|MW 23755.2|DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMFLWX1	DE	Ovarian cancer; Non-small-cell lung cancer

DMTGYSO	ID	DMTGYSO
DMTGYSO	DN	Fasiglifam hemihydrate
DMTGYSO	HS	Phase 3
DMTGYSO	SN	Fasiglifam hemihydrate; 1374598-80-7; UNII-8LDT91CH8A; 8LDT91CH8A; TAK-875 Hemihydrate; Fasiglifam hydrate (JAN); DTXSID80160191; MolPort-035-395-707; EX-A2165; s2637; AKOS025404925; 3-Benzofuranacetic acid, 6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)(1,1'-biphenyl)-3-yl)methoxy)-2,3-dihydro-, hydrate (2:1), (3S)-; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) biphenyl-3-yl)methoxy)-2,3-dihydro-l-benzofuran-3-yl)acetic acid hydrate; SC-95595; BC600332; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) 
DMTGYSO	CP	Apollo Scientific
DMTGYSO	DT	Small molecular drug
DMTGYSO	PC	57339446
DMTGYSO	MW	1067.3
DMTGYSO	FM	C58H66O15S2
DMTGYSO	IC	InChI=1S/2C29H32O7S.H2O/c2*1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24;/h2*4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31);1H2/t2*23-;/m11./s1
DMTGYSO	CS	CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C.CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C.O
DMTGYSO	IK	OJXYMYYDAVXPIK-IWKNALKQSA-N
DMTGYSO	IU	2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid;hydrate
DMTGYSO	CA	CAS 1374598-80-7
DMTGYSO	DE	Type-2 diabetes

DM5PRLA	ID	DM5PRLA
DM5PRLA	DN	Fasinumab
DM5PRLA	HS	Phase 3
DM5PRLA	CP	Regeneron Pharmaceuticals Tarrytown, NY Teva Pharmaceuticals USA North Wales, PA
DM5PRLA	DE	Neuropathic pain; Chronic low back pain; Pain; Osteoarthritis

DM8E51L	ID	DM8E51L
DM8E51L	DN	FASORACETAM
DM8E51L	HS	Phase 3
DM8E51L	SN	LAM-105; NS-105; Fasoracetam; (R)-1-[(5-Oxo-2-pyrrolidinyl)carbonyl]piperidine; (R)-5-(Piperidin-1-ylcarbonyl)pyrrolidin-2-one
DM8E51L	DT	Small molecular drug
DM8E51L	PC	198695
DM8E51L	MW	196.25
DM8E51L	FM	C10H16N2O2
DM8E51L	IC	InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
DM8E51L	CS	C1CCN(CC1)C(=O)[C@H]2CCC(=O)N2
DM8E51L	IK	GOWRRBABHQUJMX-MRVPVSSYSA-N
DM8E51L	IU	(5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one
DM8E51L	CA	CAS 110958-19-5
DM8E51L	CB	CHEBI:31592
DM8E51L	DE	Cognitive impairment

DM35GBS	ID	DM35GBS
DM35GBS	DN	Favipiravir
DM35GBS	HS	Phase 3
DM35GBS	SN	AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705
DM35GBS	CP	Toyama Chemical
DM35GBS	TC	Antiviral Agents
DM35GBS	DT	Small molecular drug
DM35GBS	PC	492405
DM35GBS	MW	157.1
DM35GBS	FM	C5H4FN3O2
DM35GBS	IC	InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
DM35GBS	CS	C1=C(N=C(C(=O)N1)C(=O)N)F
DM35GBS	IK	ZCGNOVWYSGBHAU-UHFFFAOYSA-N
DM35GBS	IU	5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
DM35GBS	CA	CAS 259793-96-9
DM35GBS	CB	CHEBI:134722
DM35GBS	DE	Influenza virus infection; Coronavirus Disease 2019 (COVID-19)

DM0762O	ID	DM0762O
DM0762O	DN	Fenfluramine
DM0762O	HS	Phase 3
DM0762O	SN	Acino; Adifax; Adipomin; Fenfluramina; Fenfluraminum; Isomeride; Obedrex; Pesos; Ponderex; Rotondin; Dexfenfluramina [Spanish]; Dexfenfluraminum [Latin]; Fenfluramina [DCIT]; Fenfluramine hydrochloride; Levofenfluramine [INN]; Ponderax PA; S 768; D-Fenfluramine; Dexfenfluramine [INN:BAN]; Fenfluramine (INN); Fenfluramine [INN:BAN]; Fenfluraminum [INN-Latin]; Ponderax (TN); Fenfluramine, (+-)-Isomer; N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine; D-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine; N-Ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine; N-Ethyl-alpha-methyl-m-(trifluoromethyl)phenethylamine; N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-(9CI); Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-(9CI);Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)-(9CI); (+)-Fenfluramine; (+-)-Fenfluramine; (+/-)-Fenfluramine hydrochloride; (S)-Fenfluramine; 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane; 1-(meta-Trifluoromethyl-phenyl)-2 ethylaminopropane; 2-Ethylamino-1-(3-trifluoromethylphenyl)propane; 3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine
DM0762O	CP	Zogenix Emeryville, CA
DM0762O	DT	Small molecular drug
DM0762O	PC	3337
DM0762O	MW	231.26
DM0762O	FM	C12H16F3N
DM0762O	IC	InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3
DM0762O	CS	CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
DM0762O	IK	DBGIVFWFUFKIQN-UHFFFAOYSA-N
DM0762O	IU	N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DM0762O	CA	CAS 458-24-2
DM0762O	CB	CHEBI:5000
DM0762O	DE	Dravet syndrome; LennoxGastaut syndrome; Obesity

DMRD5SP	ID	DMRD5SP
DMRD5SP	DN	Fenretinide
DMRD5SP	HS	Phase 3
DMRD5SP	SN	RT-101; ST-602; SYT-101; Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University; LXS/4-HPR; Fenretinide (Ewing's sarcoma), Cancer Research UK; Fenretinide (ILE formulation), Children's Hospital LA; Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles; Fenretinide (intravenous, cancer), SciTech Development; Fenretinide (iv), Children's Hospital LA; Fenretinide (oral, AMD), Sytera; Fenretinide (soft gel capsule, AMD), ReVision Therapeutics; Fenretinide (soft gel capsule, AMD), Sirion; Fenretinide (topical, actinic keratosis and cancer), SciTech Development; N-(4-hydroxyphenyl)retinamide; Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx; Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products; 4-HPR
DMRD5SP	CP	Sirion Therapeutics; cerrx; Sytera Inc
DMRD5SP	DT	Small molecular drug
DMRD5SP	PC	5288209
DMRD5SP	MW	391.5
DMRD5SP	FM	C26H33NO2
DMRD5SP	IC	InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+
DMRD5SP	CS	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)NC2=CC=C(C=C2)O)/C)/C
DMRD5SP	IK	AKJHMTWEGVYYSE-FXILSDISSA-N
DMRD5SP	IU	(2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
DMRD5SP	CA	CAS 65646-68-6
DMRD5SP	CB	CHEBI:42588
DMRD5SP	DE	Lymphoma; Peripheral T-cell lymphoma; Solid tumour/cancer; Tumour; Macular degeneration

DM4NX0C	ID	DM4NX0C
DM4NX0C	DN	Fevipiprant
DM4NX0C	HS	Phase 3
DM4NX0C	SN	872365-14-5; NVP-QAW039; QAW039; UNII-2PEX5N7DQ4; 2PEX5N7DQ4; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid; 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid; Fevipiprant [INN]; Fevipiprant [USAN:INN]; QAW 039; Fevipiprant (JAN/USAN/INN); GTPL8995; SCHEMBL1940595; CHEMBL3137332; QAW-039; HMS3743E19; BCP25015; EX-A2495; BDBM50233520; ZINC43101772; AB85348; CS-5956; DB12011; Fevipiprant; NVP-QAW039; QAW039; SB16897; (1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; 2-(1-((4-Methanesulfonyl-2-(trifluoromethyl)phenyl)methyl(-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; AC-31956; AS-74870; HY-16768; DS-022511; FT-0774596; D10631; Q27077292; 1-(4-methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; (2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid; [2-METHYL-1-[4-(METHYLSULFONYL)-2-(TRIFLUOROMETHYL)BENZYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID; 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[5,4-b]pyridin-3-yl]acetic acid; FSY
DM4NX0C	CP	Novartis
DM4NX0C	DT	Small molecular drug
DM4NX0C	PC	23582412
DM4NX0C	MW	426.4
DM4NX0C	FM	C19H17F3N2O4S
DM4NX0C	IC	InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
DM4NX0C	CS	CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O
DM4NX0C	IK	GFPPXZDRVCSVNR-UHFFFAOYSA-N
DM4NX0C	IU	2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid
DM4NX0C	CA	CAS 872365-14-5
DM4NX0C	DE	Asthma

DM4XSQ2	ID	DM4XSQ2
DM4XSQ2	DN	FG-4592
DM4XSQ2	HS	Phase 3
DM4XSQ2	SN	FG-4592; 808118-40-3; Roxadustat; Roxadustat (FG-4592); UNII-X3O30D9YMX; N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine; FG4592; ASP1517; Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-; X3O30D9YMX; CHEMBL2338329; 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid; FG 4592; AK198953; n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine; [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic Acid
DM4XSQ2	CP	FibroGen
DM4XSQ2	DT	Small molecular drug
DM4XSQ2	PC	11256664
DM4XSQ2	MW	352.3
DM4XSQ2	FM	C19H16N2O5
DM4XSQ2	IC	InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
DM4XSQ2	CS	CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3
DM4XSQ2	IK	YOZBGTLTNGAVFU-UHFFFAOYSA-N
DM4XSQ2	IU	2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
DM4XSQ2	CA	CAS 808118-40-3
DM4XSQ2	CB	CHEBI:132774
DM4XSQ2	DE	Kidney disease; Anaemia

DMFZ81T	ID	DMFZ81T
DMFZ81T	DN	Fidanacogene elaparvovec
DMFZ81T	HS	Phase 3
DMFZ81T	SN	AAV8-hFIX19
DMFZ81T	CP	Pfizer
DMFZ81T	DT	Gene therapy
DMFZ81T	DE	Haemophilia B

DMZL1I8	ID	DMZL1I8
DMZL1I8	DN	Fidarestat
DMZL1I8	HS	Phase 3
DMZL1I8	SN	Aldos; FID; Fidaresstat; SK 860; Snk 860; Aldos (TN); SNK-860; Fidarestat (JAN/INN); (+)-(2S,4S)-6-Fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; (+)-(2s,4s)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide; (2S,4S)-2-AMINOFORMYL-6-FLUORO-SPIRO[CHROMAN-4,4'-IMIDAZOLIDINE]-2',5'-DIONE; (2S,4S)-6-Fluoro-2',5'-dioxospiro(3,4-dihydro-2H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide; (2S,4S)-6-fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; (2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMZL1I8	CP	Sanwa Kagaku
DMZL1I8	DT	Small molecular drug
DMZL1I8	PC	160024
DMZL1I8	MW	279.22
DMZL1I8	FM	C12H10FN3O4
DMZL1I8	IC	InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12-/m0/s1
DMZL1I8	CS	C1[C@H](OC2=C([C@]13C(=O)NC(=O)N3)C=C(C=C2)F)C(=O)N
DMZL1I8	IK	WAAPEIZFCHNLKK-UFBFGSQYSA-N
DMZL1I8	IU	(2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMZL1I8	CA	CAS 136087-85-9
DMZL1I8	DE	Diabetic complication

DMM4FJ3	ID	DMM4FJ3
DMM4FJ3	DN	Finerenone
DMM4FJ3	HS	Phase 3
DMM4FJ3	SN	UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho
DMM4FJ3	CP	Bayer HealthCare Pharmaceuticals, Plainsboro, NJ
DMM4FJ3	PC	60150535
DMM4FJ3	MW	378.4
DMM4FJ3	FM	C21H22N4O3
DMM4FJ3	IC	InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
DMM4FJ3	CS	CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C
DMM4FJ3	IK	BTBHLEZXCOBLCY-QGZVFWFLSA-N
DMM4FJ3	IU	(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
DMM4FJ3	CA	CAS 1050477-31-0
DMM4FJ3	DE	Diabetic nephropathy

DMMQ7BY	ID	DMMQ7BY
DMMQ7BY	DN	Fitusiran
DMMQ7BY	HS	Phase 3
DMMQ7BY	SN	ALN-AT3SC
DMMQ7BY	CP	Sanofi
DMMQ7BY	DT	Small interfering RNA
DMMQ7BY	DE	Hemophilia

DM6R2XF	ID	DM6R2XF
DM6R2XF	DN	FKB238
DM6R2XF	HS	Phase 3
DM6R2XF	CP	Fujifilm; Centus Biotherapeutics
DM6R2XF	DT	Antibody
DM6R2XF	DE	Non-small-cell lung cancer

DMPSG4D	ID	DMPSG4D
DMPSG4D	DN	Flobufen
DMPSG4D	HS	Phase 3
DMPSG4D	SN	VUFB-16066; VUFB-17203
DMPSG4D	CP	VUFB
DMPSG4D	DT	Small molecular drug
DMPSG4D	PC	159476
DMPSG4D	MW	304.29
DMPSG4D	FM	C17H14F2O3
DMPSG4D	IC	InChI=1S/C17H14F2O3/c1-10(17(21)22)8-16(20)12-4-2-11(3-5-12)14-7-6-13(18)9-15(14)19/h2-7,9-10H,8H2,1H3,(H,21,22)
DMPSG4D	CS	CC(CC(=O)C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)C(=O)O
DMPSG4D	IK	FIKVYIRIUOFLLR-UHFFFAOYSA-N
DMPSG4D	IU	4-[4-(2,4-difluorophenyl)phenyl]-2-methyl-4-oxobutanoic acid
DMPSG4D	CA	CAS 112344-52-2
DMPSG4D	DE	Rheumatoid arthritis

DMKL5AT	ID	DMKL5AT
DMKL5AT	DN	Flurpiridaz F 18
DMKL5AT	HS	Phase 3
DMKL5AT	SN	Flurpiridaz (18F); PET myocardial perfusion imaging agents, Bristol-Myers Squibb Medical Imaging; RP-1003-18; RP-1004-18; RP-1005-18; [18F]-RP-1003; [18F]-RP-1004; [18F]-RP-1005; [18F]-labeled PET myocardial perfusion imaging agents, Lantheus Medical Imaging; BMS-747158-02-[18F]; Fluorine-18-BMS-747158; [18F]-labeled MC-1 inhibitors (MPIAs), Lantheus Medical Imaging; [18F]-labeled MC-1 inhibitors, Bristol-Myers Squibb Medical Imaging; [18fluorine]-labeled mitochondrial complex-1 inhibitors, Bristol-Myers Squibb Medical Imaging; 18F-BMS-747158-02
DMKL5AT	CP	Lantheus medical imaging
DMKL5AT	DT	Small molecular drug
DMKL5AT	PC	11405965
DMKL5AT	MW	367.8
DMKL5AT	FM	C18H22ClFN2O3
DMKL5AT	IC	InChI=1S/C18H22ClFN2O3/c1-18(2,3)22-17(23)16(19)15(10-21-22)25-12-14-6-4-13(5-7-14)11-24-9-8-20/h4-7,10H,8-9,11-12H2,1-3H3/i20-1
DMKL5AT	CS	CC(C)(C)N1C(=O)C(=C(C=N1)OCC2=CC=C(C=C2)COCC[18F])Cl
DMKL5AT	IK	RMXZKEPDYBTFOS-LRFGSCOBSA-N
DMKL5AT	IU	2-tert-butyl-4-chloro-5-[[4-(2-(18F)fluoranylethoxymethyl)phenyl]methoxy]pyridazin-3-one
DMKL5AT	CA	CAS 863887-89-2
DMKL5AT	DE	Myocardial disease

DM5S4DL	ID	DM5S4DL
DM5S4DL	DN	Forigerimod
DM5S4DL	HS	Phase 3
DM5S4DL	SN	CEP-33457
DM5S4DL	CP	Cephalon
DM5S4DL	DT	Small molecular drug
DM5S4DL	PC	56841982
DM5S4DL	MW	2638.9
DM5S4DL	FM	C117H181N34O32PS
DM5S4DL	IC	InChI=1S/C117H181N34O32PS/c1-9-64(5)94(148-99(163)75(120)24-18-47-128-115(121)122)112(176)144-85(56-71-57-127-62-132-71)106(170)139-80(44-51-185-8)103(167)147-93(63(3)4)110(174)143-83(54-69-32-38-73(154)39-33-69)105(169)146-87(60-152)108(172)138-78(25-14-16-45-118)101(165)137-76(27-19-48-129-116(123)124)96(160)97(161)88(150-184(180,181)182)61-183-133-59-91(157)135-81(26-15-17-46-119)113(177)151-50-21-29-89(151)109(173)140-77(28-20-49-130-117(125)126)100(164)131-58-90(156)136-82(53-68-30-36-72(153)37-31-68)104(168)134-66(7)98(162)142-84(52-67-22-12-11-13-23-67)107(171)149-95(65(6)10-2)111(175)141-79(42-43-92(158)159)102(166)145-86(114(178)179)55-70-34-40-74(155)41-35-70/h11-13,22-23,30-41,57,62-66,75-89,93-95,133,152-155H,9-10,14-21,24-29,42-56,58-61,118-120H2,1-8H3,(H,127,132)(H,131,164)(H,134,168)(H,135,157)(H,136,156)(H,137,165)(H,138,172)(H,139,170)(H,140,173)(H,141,175)(H,142,162)(H,143,174)(H,144,176)(H,145,166)(H,146,169)(H,147,167)(H,148,163)(H,149,171)(H,158,159)(H,178,179)(H4,121,122,128)(H4,123,124,129)(H4,125,126,130)(H3,150,180,181,182)/t64-,65-,66-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,93-,94-,95-/m0/s1
DM5S4DL	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)C(=O)[C@H](CONCC(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)O)NP(=O)(O)O)NC(=O)[C@H](CCCNC(=N)N)N
DM5S4DL	IK	LSLBZWAEEUGETG-GGVFYUGVSA-N
DM5S4DL	IU	(4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S,5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-8-carbamimidamido-3,4-dioxo-2-(phosphonoamino)octoxy]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-5-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-5-oxopentanoic acid
DM5S4DL	CA	CAS 497156-60-2
DM5S4DL	DE	Systemic lupus erythematosus

DM8L3JU	ID	DM8L3JU
DM8L3JU	DN	Fosclin
DM8L3JU	HS	Phase 3
DM8L3JU	SN	Fosmidomycin + clindamycin (oral, malaria), Jomaa; Fosmidomycin + clindamycin fixed-dose combination (oral, malaria), Jomaa
DM8L3JU	CP	Jomaa Pharma GmbH
DM8L3JU	DE	Malaria

DM3274D	ID	DM3274D
DM3274D	DN	Fostamatinib disodium
DM3274D	HS	Phase 3
DM3274D	SN	1025687-58-4; R788(prodrug of R406); R788 (Fostamatinib) Disodium; UNII-X9417132K8; R 788 sodium; R788(Fostamatinib disodium); R 935788 sodium; R935788 (Fostamatinib disodium, R788); R788 disodium; X9417132K8; R788 disodium hexahydrate; R788 SODIUM; R-788 disodium; R788, Fostamatinib; Tube731; sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl phosphate; Disodium (6-(5-fluoro-2-(3
DM3274D	CP	Rigel Pharmaceuticals South San Francisco, CA
DM3274D	PC	25008120
DM3274D	MW	624.4
DM3274D	FM	C23H24FN6Na2O9P
DM3274D	IC	InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2
DM3274D	CS	CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)([O-])[O-])C.[Na+].[Na+]
DM3274D	IK	HSYBQXDGYCYSGA-UHFFFAOYSA-L
DM3274D	IU	disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate
DM3274D	CA	CAS 1025687-58-4
DM3274D	DE	Thrombocytopenia

DM823WQ	ID	DM823WQ
DM823WQ	DN	FP-1201
DM823WQ	HS	Phase 3
DM823WQ	SN	Traumagen; Traumakine; MR-11-A-8; CD73 agonist (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/MaruishiPharmaceutical; Interferon beta-1a (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/Maruishi Pharmaceutical
DM823WQ	CP	Faron Pharmaceuticals Ltd
DM823WQ	DE	Acute lung injury

DMGF8MZ	ID	DMGF8MZ
DMGF8MZ	DN	FPL-62064
DMGF8MZ	HS	Phase 3
DMGF8MZ	SN	N-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine
DMGF8MZ	DT	Small molecular drug
DMGF8MZ	PC	128268
DMGF8MZ	MW	265.31
DMGF8MZ	FM	C16H15N3O
DMGF8MZ	IC	InChI=1S/C16H15N3O/c1-20-15-9-7-13(8-10-15)17-16-11-12-19(18-16)14-5-3-2-4-6-14/h2-12H,1H3,(H,17,18)
DMGF8MZ	CS	COC1=CC=C(C=C1)NC2=NN(C=C2)C3=CC=CC=C3
DMGF8MZ	IK	WKLGNFJHVJIZPK-UHFFFAOYSA-N
DMGF8MZ	IU	N-(4-methoxyphenyl)-1-phenylpyrazol-3-amine
DMGF8MZ	CA	CAS 103141-09-9
DMGF8MZ	DE	Inflammation

DMHOSCQ	ID	DMHOSCQ
DMHOSCQ	DN	Fruquintinib
DMHOSCQ	HS	Phase 3
DMHOSCQ	SN	HMPL-013
DMHOSCQ	CP	Hutchison Medipharma Enterprises Ltd
DMHOSCQ	PC	44480399
DMHOSCQ	MW	393.4
DMHOSCQ	FM	C21H19N3O5
DMHOSCQ	IC	InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)
DMHOSCQ	CS	CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC
DMHOSCQ	IK	BALLNEJQLSTPIO-UHFFFAOYSA-N
DMHOSCQ	IU	6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide
DMHOSCQ	CA	CAS 1194506-26-7
DMHOSCQ	DE	Solid tumour/cancer

DM1YVLM	ID	DM1YVLM
DM1YVLM	DN	FST-201
DM1YVLM	HS	Phase 3
DM1YVLM	SN	Dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics; Otic anti-infective (otitis), Foresight Biotherapeutics
DM1YVLM	CP	Foresight Biotherapeutics Inc
DM1YVLM	DE	Otitis externa

DMDKYVE	ID	DMDKYVE
DMDKYVE	DN	FT-0624878
DMDKYVE	HS	Phase 3
DMDKYVE	SN	Cellulosepulver; DEAE-CELLULOSE; DEAE-Sephacel(R); Diethylaminoethyl cellulose; Diethylaminoethyl-Sephacel(R); SBB058705; SC-21746; cellulose; 9004-34-6; AKOS015895024; Cellulose, 2-(diethylamino)ethyl ether; Diethylaminoethyl-Sephacel(R), aqueous ethanol suspension, 40-160 mum (wet), exclusion limit ~1,000,000 Da; Express-Ion(TM) exchanger?? D free base, 60-130 mum; FT-0624878; M158
DMDKYVE	PC	16211032
DMDKYVE	MW	342.3
DMDKYVE	FM	C12H22O11
DMDKYVE	IC	GUBGYTABKSRVRQ-WFVLMXAXSA-N
DMDKYVE	CS	C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)O)CO)O)O)O)O
DMDKYVE	IK	1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3?,4?,5?,6?,7?,8?,9?,10-,11?,12+/m1/s1
DMDKYVE	IU	(6S)-2-(hydroxymethyl)-6-[(3S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DMDKYVE	CA	CAS 9004-34-6
DMDKYVE	DE	Human immunodeficiency virus infection

DMF4I1V	ID	DMF4I1V
DMF4I1V	DN	FT-0710230
DMF4I1V	HS	Phase 3
DMF4I1V	SN	Meconic acid; Mekonsaure; NSC 805; NSC-805; NSC805; Opium acid; Poppy acid; Q421116; SCHEMBL546968; SCHEMBL600257; UNII-V502I79516; V502I79516; ZEGRKMXCOCRTCS-UHFFFAOYSA-N; ZINC1587602; Opio; Papaver somniferum exudate; Papaver somniferum resin; 3-HYDROXY-4-OXO-4H-PYRAN-2,6-DICARBOXYLIC ACID; 3-Hydroxy-4-oxo-1,4-pyran-2,6-dicarboxylic acid; 3-Hydroxy-4-oxopyran-2,6-dicarboxylic acid; 3-hydroxy-4-oxo-pyran-2,6-dicarboxylic acid; 3-hydroxy-4-pyrone-2,6-dicarboxylic acid; 497-59-6; 4H-Pyran-2, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylic acid, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylicacid, 3-hydroxy-4-oxo-; BDBM50147502; C20209; CHEMBL109516; CTK1D7773; DB-083476; DTXSID2060096; EINECS 207-848-2
DMF4I1V	PC	10347
DMF4I1V	IU	3-hydroxy-4-oxopyran-2,6-dicarboxylic acid
DMF4I1V	DE	Opiate dependence

DMK38MV	ID	DMK38MV
DMK38MV	DN	Fulranumab
DMK38MV	HS	Phase 3
DMK38MV	CP	Johnson & Johnson Pharmaceutical Research & Development
DMK38MV	DT	Monoclonal antibody
DMK38MV	DE	Cancer related pain; Back pain; Arthralgia

DMP83UZ	ID	DMP83UZ
DMP83UZ	DN	Fumaric acid
DMP83UZ	HS	Phase 3
DMP83UZ	SN	Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)
DMP83UZ	CP	Biogen Idec
DMP83UZ	DT	Small molecular drug
DMP83UZ	PC	444972
DMP83UZ	MW	116.07
DMP83UZ	FM	C4H4O4
DMP83UZ	IC	InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+
DMP83UZ	CS	C(=C/C(=O)O)\\C(=O)O
DMP83UZ	IK	VZCYOOQTPOCHFL-OWOJBTEDSA-N
DMP83UZ	IU	(E)-but-2-enedioic acid
DMP83UZ	CA	CAS 110-17-8
DMP83UZ	CB	CHEBI:18012
DMP83UZ	DE	Multiple sclerosis; Pustular palmoplantar psoriasis

DMZARP1	ID	DMZARP1
DMZARP1	DN	FV-100
DMZARP1	HS	Phase 3
DMZARP1	SN	CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy
DMZARP1	CP	Welsh School of Pharmacy
DMZARP1	DT	Small molecular drug
DMZARP1	PC	71587897
DMZARP1	MW	534
DMZARP1	FM	C27H36ClN3O6
DMZARP1	IC	InChI=1S/C27H35N3O6.ClH/c1-4-5-6-7-17-8-10-18(11-9-17)21-12-19-14-30(27(33)29-25(19)36-21)23-13-20(31)22(35-23)15-34-26(32)24(28)16(2)3;/h8-12,14,16,20,22-24,31H,4-7,13,15,28H2,1-3H3;1H/t20-,22+,23+,24-;/m0./s1
DMZARP1	CS	CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)COC(=O)[C@H](C(C)C)N)O.Cl
DMZARP1	IK	CAHTYTZOAVUCIU-ZMQZINMSSA-N
DMZARP1	IU	[(2R,3S,5R)-3-hydroxy-5-[2-oxo-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-3-yl]oxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DMZARP1	CA	CAS 956483-03-7
DMZARP1	DE	Varicella zoster virus infection

DMMNP2F	ID	DMMNP2F
DMMNP2F	DN	G17DT
DMMNP2F	HS	Phase 3
DMMNP2F	SN	Gastrimmune; Insegia
DMMNP2F	CP	Receptor Biologix
DMMNP2F	DT	Antibody
DMMNP2F	DE	Gastric adenocarcinoma

DMXJMKF	ID	DMXJMKF
DMXJMKF	DN	Ganaxolone
DMXJMKF	HS	Phase 3
DMXJMKF	SN	Ganaxolone [USAN]; CCD 1042; CCD-1042; Ganaxolone (USAN/INN); (3alpha,5alpha)-3-Hydroxy-3-methylpregnan-20-one; 1-[(3R,5S,10S,13S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 3alpha-Hydroxy-3-methyl-5alpha-pregnan-20-one; 3alpha-Hydroxy-3beta-methyl-5alpha-pregnan-20-one
DMXJMKF	CP	Marinus
DMXJMKF	DT	Small molecular drug
DMXJMKF	PC	6918305
DMXJMKF	MW	332.5
DMXJMKF	FM	C22H36O2
DMXJMKF	IC	InChI=1S/C22H36O2/c1-14(23)17-7-8-18-16-6-5-15-13-20(2,24)11-12-21(15,3)19(16)9-10-22(17,18)4/h15-19,24H,5-13H2,1-4H3/t15-,16-,17+,18-,19-,20+,21-,22+/m0/s1
DMXJMKF	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C
DMXJMKF	IK	PGTVWKLGGCQMBR-FLBATMFCSA-N
DMXJMKF	IU	1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
DMXJMKF	CA	CAS 38398-32-2
DMXJMKF	DE	Postpartum depression; Complex partial seizure

DMWX90U	ID	DMWX90U
DMWX90U	DN	Gantenerumab
DMWX90U	HS	Phase 3
DMWX90U	SN	RG1450
DMWX90U	CP	Roche
DMWX90U	DT	Monoclonal antibody
DMWX90U	DE	Alzheimer disease

DMO3ITF	ID	DMO3ITF
DMO3ITF	DN	GASTRAZOLE
DMO3ITF	HS	Phase 3
DMO3ITF	SN	JB-95008; 5-[N-[5-[N-(Cycloheptylmethyl)carbamoyl]-1H-benzimidazol-6-ylcarbonyl]-2-fluoro-L-phenylalanylamino]isophthalic acid
DMO3ITF	DT	Small molecular drug
DMO3ITF	PC	71587829
DMO3ITF	MW	687.6
DMO3ITF	FM	C34H32FN5Na2O7
DMO3ITF	IC	InChI=1S/C34H34FN5O7.2Na/c35-26-10-6-5-9-20(26)14-29(32(43)39-23-12-21(33(44)45)11-22(13-23)34(46)47)40-31(42)25-16-28-27(37-18-38-28)15-24(25)30(41)36-17-19-7-3-1-2-4-8-19;;/h5-6,9-13,15-16,18-19,29H,1-4,7-8,14,17H2,(H,36,41)(H,37,38)(H,39,43)(H,40,42)(H,44,45)(H,46,47);;/q;2*+1/p-2/t29-;;/m0../s1
DMO3ITF	CS	C1CCCC(CC1)CNC(=O)C2=CC3=C(C=C2C(=O)N[C@@H](CC4=CC=CC=C4F)C(=O)NC5=CC(=CC(=C5)C(=O)[O-])C(=O)[O-])N=CN3.[Na+].[Na+]
DMO3ITF	IK	VHAXHRARUCKASM-UJXPALLWSA-L
DMO3ITF	IU	disodium;5-[[(2S)-2-[[6-(cycloheptylmethylcarbamoyl)-1H-benzimidazole-5-carbonyl]amino]-3-(2-fluorophenyl)propanoyl]amino]benzene-1,3-dicarboxylate
DMO3ITF	CA	CAS 862583-15-1
DMO3ITF	DE	Duodenal ulcer

DMT4QHD	ID	DMT4QHD
DMT4QHD	DN	GDC-0032
DMT4QHD	HS	Phase 3
DMT4QHD	SN	Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N
DMT4QHD	CP	Genentech
DMT4QHD	DT	Small molecular drug
DMT4QHD	PC	51001932
DMT4QHD	MW	460.5
DMT4QHD	FM	C24H28N8O2
DMT4QHD	IC	InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)
DMT4QHD	CS	CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C
DMT4QHD	IK	BEUQXVWXFDOSAQ-UHFFFAOYSA-N
DMT4QHD	IU	2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide
DMT4QHD	CA	CAS 1282512-48-4
DMT4QHD	DE	Solid tumour/cancer; Breast cancer

DMWBZJD	ID	DMWBZJD
DMWBZJD	DN	GDC-0068
DMWBZJD	HS	Phase 3
DMWBZJD	SN	RG7440
DMWBZJD	CP	Genentech
DMWBZJD	DT	Small molecular drug
DMWBZJD	PC	24788740
DMWBZJD	MW	458
DMWBZJD	FM	C24H32ClN5O2
DMWBZJD	IC	InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1
DMWBZJD	CS	C[C@@H]1C[C@H](C2=C1C(=NC=N2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)C4=CC=C(C=C4)Cl)O
DMWBZJD	IK	GRZXWCHAXNAUHY-NSISKUIASA-N
DMWBZJD	IU	(2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one
DMWBZJD	CA	CAS 1001264-89-6
DMWBZJD	CB	CHEBI:95089
DMWBZJD	DE	Solid tumour/cancer; Breast cancer; Colorectal cancer; Gastric adenocarcinoma; Prostate cancer

DMBEL3Q	ID	DMBEL3Q
DMBEL3Q	DN	GDC-0853
DMBEL3Q	HS	Phase 3
DMBEL3Q	SN	Fenebrutinib
DMBEL3Q	CP	GenentechSouth San Francisco, CA
DMBEL3Q	PC	86567195
DMBEL3Q	MW	664.8
DMBEL3Q	FM	C37H44N8O4
DMBEL3Q	IC	InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1
DMBEL3Q	CS	C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8
DMBEL3Q	IK	WNEODWDFDXWOLU-QHCPKHFHSA-N
DMBEL3Q	IU	10-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-9-one
DMBEL3Q	CA	CAS 1434048-34-6
DMBEL3Q	DE	Solid tumour/cancer; Autoimmune disease; Chronic idiopathic urticaria; Multiple sclerosis

DMTUV7L	ID	DMTUV7L
DMTUV7L	DN	GED-0301
DMTUV7L	HS	Phase 3
DMTUV7L	SN	SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani
DMTUV7L	CP	Giuliani SpA
DMTUV7L	DE	Crohn disease; Ulcerative colitis

DM4GWL7	ID	DM4GWL7
DM4GWL7	DN	Gefapixant
DM4GWL7	HS	Phase 3
DM4GWL7	SN	UNII-6K6L7E3F1L; 6K6L7E3F1L; MK-7264; 1015787-98-0; Gefapixant [USAN]; GTPL9540; SCHEMBL1493905; CHEMBL3716057; HLWURFKMDLAKOD-UHFFFAOYSA-N; ZINC116342482; J3.556.891C; 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide; 2-Methoxy-4-isopropyl-5-(2,4-diamino-5-pyrimidinyloxy)benzenesulfonamide; 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide; 5-((2,4-Diaminopyrimidin-5-yl)oxy)-2-methoxy-4-(propan-2-yl)benzenesulfonamid
DM4GWL7	CP	Merck, Roche
DM4GWL7	PC	24764487
DM4GWL7	MW	353.4
DM4GWL7	FM	C14H19N5O4S
DM4GWL7	IC	InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
DM4GWL7	CS	CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
DM4GWL7	IK	HLWURFKMDLAKOD-UHFFFAOYSA-N
DM4GWL7	IU	5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
DM4GWL7	CA	CAS 1015787-98-0
DM4GWL7	DE	Overactive bladder; Cough

DMZKGPV	ID	DMZKGPV
DMZKGPV	DN	Gemigliptin
DMZKGPV	HS	Phase 3
DMZKGPV	SN	911637-19-9; UNII-5DHU18M5D6; 5DHU18M5D6; (S)-1-(2-Amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; (S)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; Gemigliptin [INN]; Gemigliptin (prop.INN); SCHEMBL1262740; CHEMBL3707235; CHEBI:134731; ZINC68245464; AKOS025290873; PB11419; DB12412; API0013914; AK170799; 2-Piperidinone, 1-((2S)-2-amino-4-(5,8-dihydro-2,4-
DMZKGPV	CP	LG Life Sciences Ltd
DMZKGPV	DT	Small molecular drug
DMZKGPV	PC	11953153
DMZKGPV	MW	489.4
DMZKGPV	FM	C18H19F8N5O2
DMZKGPV	IC	InChI=1S/C18H19F8N5O2/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23/h9H,1-8,27H2/t9-/m0/s1
DMZKGPV	CS	C1CC(CN(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F
DMZKGPV	IK	ZWPRRQZNBDYKLH-VIFPVBQESA-N
DMZKGPV	IU	1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one
DMZKGPV	CA	CAS 911637-19-9
DMZKGPV	CB	CHEBI:134731
DMZKGPV	DE	Diabetic complication; Type-2 diabetes

DM1WMOK	ID	DM1WMOK
DM1WMOK	DN	Generx
DM1WMOK	HS	Phase 3
DM1WMOK	SN	Alferminogene tadenovec
DM1WMOK	CP	Angionetics
DM1WMOK	DT	Gene therapy
DM1WMOK	DE	Angina pectoris

DM7ZOAE	ID	DM7ZOAE
DM7ZOAE	DN	GFT-505
DM7ZOAE	HS	Phase 3
DM7ZOAE	SN	GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit
DM7ZOAE	CP	Genfit SA
DM7ZOAE	PC	9864881
DM7ZOAE	MW	384.5
DM7ZOAE	FM	C22H24O4S
DM7ZOAE	IC	InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
DM7ZOAE	CS	CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC
DM7ZOAE	IK	AFLFKFHDSCQHOL-IZZDOVSWSA-N
DM7ZOAE	IU	2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid
DM7ZOAE	CA	CAS 923978-27-2
DM7ZOAE	DE	Type-2 diabetes; Non-alcoholic steatohepatitis

DMR6YH3	ID	DMR6YH3
DMR6YH3	DN	GLP-1
DMR6YH3	HS	Phase 3
DMR6YH3	SN	Glucagon-like peptide 1; Glucagon-like-peptide-1; Glucagon-like peptide-1; Proglucagon (72-108); Proglucagon (78-107)amide; Glucagon-related peptide I; 89750-14-1; GLP-1 (7-36) amide (human, bovine, guinea pig, mouse,;  Oral GLP (diabetes, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes); Glucagon-like peptides (oral, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes), Emisphere; NH2-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-CONH2
DMR6YH3	CP	Emisphere Technologies Inc
DMR6YH3	PC	16135499
DMR6YH3	MW	3297.6
DMR6YH3	FM	C149H226N40O45
DMR6YH3	IC	InChI=1S/C149H226N40O45/c1-17-76(10)119(146(232)167-80(14)126(212)175-104(60-86-63-159-91-36-25-24-35-89(86)91)136(222)177-100(56-73(4)5)137(223)186-117(74(6)7)144(230)174-93(37-26-28-52-150)128(214)160-65-110(197)168-92(122(154)208)39-30-54-158-149(155)156)188-138(224)102(57-83-31-20-18-21-32-83)178-133(219)98(47-51-115(204)205)173-132(218)94(38-27-29-53-151)170-124(210)78(12)164-123(209)77(11)166-131(217)97(44-48-109(153)196)169-111(198)66-161-130(216)96(46-50-114(202)203)172-134(220)99(55-72(2)3)176-135(221)101(59-85-40-42-88(195)43-41-85)179-141(227)106(68-190)182-143(229)108(70-192)183-145(231)118(75(8)9)187-140(226)105(62-116(206)207)180-142(228)107(69-191)184-148(234)121(82(16)194)189-139(225)103(58-84-33-22-19-23-34-84)181-147(233)120(81(15)193)185-112(199)67-162-129(215)95(45-49-113(200)201)171-125(211)79(13)165-127(213)90(152)61-87-64-157-71-163-87/h18-25,31-36,40-43,63-64,71-82,90,92-108,117-121,159,190-195H,17,26-30,37-39,44-62,65-70,150-152H2,1-16H3,(H2,153,196)(H2,154,208)(H,157,163)(H,160,214)(H,161,216)(H,162,215)(H,164,209)(H,165,213)(H,166,217)(H,167,232)(H,168,197)(H,169,198)(H,170,210)(H,171,211)(H,172,220)(H,173,218)(H,174,230)(H,175,212)(H,176,221)(H,177,222)(H,178,219)(H,179,227)(H,180,228)(H,181,233)(H,182,229)(H,183,231)(H,184,234)(H,185,199)(H,186,223)(H,187,226)(H,188,224)(H,189,225)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,155,156,158)/t76-,77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,117-,118-,119-,120-,121-/m0/s1
DMR6YH3	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
DMR6YH3	IK	DTHNMHAUYICORS-KTKZVXAJSA-N
DMR6YH3	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMR6YH3	CA	CAS 89750-14-1
DMR6YH3	DE	Diabetic complication

DMEFCTP	ID	DMEFCTP
DMEFCTP	DN	Glufosfamide
DMEFCTP	HS	Phase 3
DMEFCTP	SN	Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMEFCTP	CP	Threshold Pharmaceuticals
DMEFCTP	DT	Small molecular drug
DMEFCTP	PC	123628
DMEFCTP	MW	383.16
DMEFCTP	FM	C10H21Cl2N2O7P
DMEFCTP	IC	InChI=1S/C10H21Cl2N2O7P/c11-1-3-13-22(19,14-4-2-12)21-10-9(18)8(17)7(16)6(5-15)20-10/h6-10,15-18H,1-5H2,(H2,13,14,19)/t6-,7-,8+,9-,10+/m1/s1
DMEFCTP	CS	C(CCl)NP(=O)(NCCCl)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMEFCTP	IK	PSVUJBVBCOISSP-SPFKKGSWSA-N
DMEFCTP	IU	(2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMEFCTP	CA	CAS 132682-98-5
DMEFCTP	DE	Ovarian cancer; Pancreatic cancer

DMOUT89	ID	DMOUT89
DMOUT89	DN	Glutamic acid
DMOUT89	HS	Phase 3
DMOUT89	SN	D(-)-Glutamic acid; D-(-)-Glutamic acid; D-2-Aminoglutaric acid; D-2-Aminopentanedioic acid; D-Glutamicacid; D-Glutaminic acid; D-Glutaminsaeure; D-glutamate; D-glutamic acid; Gamma-D-Glutamic Acid; Glutamic acid D-form; Glutamic acid, D-; H-D-Glu-OH; L(+)-Glutamic acid; Lopac-G-2128; Q479989WEA; R-(-)-Glutamic acid; Tocris-0217; WHUUTDBJXJRKMK-GSVOUGTGSA-N; glutamate; (2R)-2-aminopentanedioic acid; (R)-2-aminopentanedioic acid; (r)-glutamic acid; 6893-26-1; CHEBI:15966; CHEMBL76232; D-Glu; DGL; MFCD00063112; UNII-Q479989WEA
DMOUT89	PC	23327
DMOUT89	MW	147.13
DMOUT89	FM	C5H9NO4
DMOUT89	IC	WHUUTDBJXJRKMK-GSVOUGTGSA-N
DMOUT89	CS	C(CC(=O)O)C(C(=O)O)N
DMOUT89	IK	1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m1/s1
DMOUT89	IU	(2R)-2-aminopentanedioic acid
DMOUT89	CA	CAS 6893-26-1
DMOUT89	CB	CHEBI:15966
DMOUT89	DE	Follicular lymphoma

DM8M2N3	ID	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	HS	Phase 3
DM8M2N3	SN	Glycyrrhizic acid; glycyrrhizin; Glycyrrhizinic acid; 1405-86-3; Glycyron; Glycyrrhetinic acid glycoside; glyzyrrhizin; 18-beta-Glycyrrhizic acid; Glycyrrizin; Liquorice; UNII-6FO62043WK; Rizinsan K2 A2 (free acid); HSDB 496; EINECS 215-785-7; C42H62O16; Glycyrrhizin [JAN]; NSC 167409; NSC 234419; BRN 0077922; CHEMBL441687; NSC 2800; beta-Glycyrrhizin; CHEBI:15939; 6FO62043WK; DSSTox_RID_82047; DSSTox_CID_27006; DSSTox_GSID_47006; Glycyram; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-
DM8M2N3	DT	Small molecular drug
DM8M2N3	PC	14982
DM8M2N3	MW	822.9
DM8M2N3	FM	C42H62O16
DM8M2N3	IC	InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1
DM8M2N3	CS	C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O
DM8M2N3	IK	LPLVUJXQOOQHMX-QWBHMCJMSA-N
DM8M2N3	IU	(2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DM8M2N3	CA	CAS 1405-86-3
DM8M2N3	CB	CHEBI:15939
DM8M2N3	DE	Influenza virus infection

DMQCZ4N	ID	DMQCZ4N
DMQCZ4N	DN	Glyminox
DMQCZ4N	HS	Phase 3
DMQCZ4N	SN	Savvy
DMQCZ4N	CP	Biosyn Inc
DMQCZ4N	DT	Small molecular drug
DMQCZ4N	PC	56842993
DMQCZ4N	MW	599
DMQCZ4N	FM	C36H74N2O4
DMQCZ4N	IC	InChI=1S/C20H39NO3.C16H35NO/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(22)21(2,3)18-20(23)24;1-4-5-6-7-8-9-10-11-12-13-14-15-16-17(2,3)18/h4-18H2,1-3H3;4-16H2,1-3H3
DMQCZ4N	CS	CCCCCCCCCCCCCCCC(=O)[N+](C)(C)CC(=O)[O-].CCCCCCCCCCCCCC[N+](C)(C)[O-]
DMQCZ4N	IK	KALYGJOYPFFBRF-UHFFFAOYSA-N
DMQCZ4N	IU	N,N-dimethyltetradecan-1-amine oxide;2-[hexadecanoyl(dimethyl)azaniumyl]acetate
DMQCZ4N	CA	CAS 664323-11-9
DMQCZ4N	DE	Sexually transmitted infection

DMOHUR2	ID	DMOHUR2
DMOHUR2	DN	GLYX-13
DMOHUR2	HS	Phase 3
DMOHUR2	SN	Rapastinel; 117928-94-6; GLYX-13; GLYX 13; GLYX13; UNII-6A1X56B95E; L-Threoninamide, L-threonyl-L-prolyl-L-prolyl-; 6A1X56B95E; (S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide; GLYX-13 trifluoroacetate; TPPT-amide trifluoroacetate; TPPT-amide; GLYX-13 peptide; Rapastinel [USAN:INN]; GLYX13;Rapastinel; Rapastinel(GLYX-13); L-Threonyl-L-prolyl-L-prolyl-L-threoninamide trifluoroacetate; Thr-Pro-Pro-Thr-NH2 trifluoroacetate
DMOHUR2	CP	Naurex
DMOHUR2	DT	Small molecular drug
DMOHUR2	PC	14539800
DMOHUR2	MW	413.5
DMOHUR2	FM	C18H31N5O6
DMOHUR2	IC	InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1
DMOHUR2	CS	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
DMOHUR2	IK	GIBQQARAXHVEGD-BSOLPCOYSA-N
DMOHUR2	IU	(2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide
DMOHUR2	CA	CAS 117928-94-6
DMOHUR2	DE	Major depressive disorder

DMQIE7U	ID	DMQIE7U
DMQIE7U	DN	GMA102
DMQIE7U	HS	Phase 3
DMQIE7U	CP	Gmax Biopharm
DMQIE7U	DT	Antibody
DMQIE7U	DE	Type-2 diabetes; Obesity

DM2XSG0	ID	DM2XSG0
DM2XSG0	DN	GMA105
DM2XSG0	HS	Phase 3
DM2XSG0	CP	Gmax Biopharm
DM2XSG0	DT	Antibody
DM2XSG0	DE	Type-2 diabetes; Obesity

DMJ432G	ID	DMJ432G
DMJ432G	DN	GMI-1070
DMJ432G	HS	Phase 3
DMJ432G	SN	GMI-1010; GMI-1011; GMI-1040 series; GMI-1077; Glyosin, GlycoMimetics; Heterobifunctional glycomimetic pan-selectin inhibitors (smallmolecule therapeutic), GlycoMimetics; Selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics
DMJ432G	CP	Glycomimetics; pfizer
DMJ432G	DT	Small molecular drug
DMJ432G	PC	44232546
DMJ432G	MW	1447.4
DMJ432G	FM	C58H74N6O31S3
DMJ432G	IC	InChI=1S/C58H74N6O31S3/c1-27-45(69)47(71)48(72)56(90-27)95-49-35(62-53(74)36-23-41(66)64-58(78)63-36)19-31(20-37(49)92-57-51(94-55(77)29-10-6-3-7-11-29)50(46(70)39(24-65)93-57)91-38(54(75)76)16-28-8-4-2-5-9-28)52(73)60-13-12-59-42(67)25-88-14-15-89-26-43(68)61-34-21-32(96(79,80)81)17-30-18-33(97(82,83)84)22-40(44(30)34)98(85,86)87/h3,6-7,10-11,17-18,21-23,27-28,31,35,37-39,45-51,56-57,65,69-72H,2,4-5,8-9,12-16,19-20,24-26H2,1H3,(H,59,67)(H,60,73)(H,61,68)(H,62,74)(H,75,76)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H2,63,64,66,78)/t27-,31+,35-,37+,38-,39+,45+,46-,47+,48-,49+,50-,51+,56-,57+/m0/s1
DMJ432G	CS	C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H](C[C@H](C[C@H]2O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H](CC4CCCCC4)C(=O)O)OC(=O)C5=CC=CC=C5)C(=O)NCCNC(=O)COCCOCC(=O)NC6=C7C(=CC(=C6)S(=O)(=O)O)C=C(C=C7S(=O)(=O)O)S(=O)(=O)O)NC(=O)C8=CC(=O)NC(=O)N8)O)O)O
DMJ432G	IK	VXBNTHRZPJLRSS-PTCSXESPSA-N
DMJ432G	IU	(2S)-2-[(2R,3R,4S,5S,6R)-3-benzoyloxy-2-[(1R,2R,3S,5R)-3-[(2,4-dioxo-1H-pyrimidine-6-carbonyl)amino]-5-[2-[[2-[2-[2-oxo-2-[(3,6,8-trisulfonaphthalen-1-yl)amino]ethoxy]ethoxy]acetyl]amino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoic acid
DMJ432G	CA	CAS 927881-99-0
DMJ432G	DE	Asthma; Vaso-occlusive crisis

DMDTGWQ	ID	DMDTGWQ
DMDTGWQ	DN	GMI-1271
DMDTGWQ	HS	Phase 3
DMDTGWQ	SN	Uproleselan
DMDTGWQ	CP	Glycomimetics
DMDTGWQ	DT	?
DMDTGWQ	PC	71600085
DMDTGWQ	MW	1304.5
DMDTGWQ	FM	C60H109N3O27
DMDTGWQ	IC	InChI=1S/C60H109N3O27/c1-5-44-38-45(39-46(55(44)90-60-54(70)53(69)51(67)41(2)86-60)88-59-50(63-42(3)65)56(52(68)48(40-64)89-59)87-47(58(72)73)37-43-9-7-6-8-10-43)57(71)62-13-12-61-49(66)11-14-75-17-18-77-21-22-79-25-26-81-29-30-83-33-34-85-36-35-84-32-31-82-28-27-80-24-23-78-20-19-76-16-15-74-4/h41,43-48,50-56,59-60,64,67-70H,5-40H2,1-4H3,(H,61,66)(H,62,71)(H,63,65)(H,72,73)/t41-,44-,45+,46+,47-,48+,50+,51+,52-,53+,54-,55+,56+,59+,60-/m0/s1
DMDTGWQ	CS	CC[C@H]1C[C@H](C[C@H]([C@@H]1O[C@H]2[C@H]([C@@H]([C@@H]([C@@H](O2)C)O)O)O)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H](CC4CCCCC4)C(=O)O)NC(=O)C)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC
DMDTGWQ	IK	LYSYOXNOOPBOSC-NGSKMYNLSA-N
DMDTGWQ	IU	(2S)-2-[(2R,3R,4R,5R,6R)-3-acetamido-2-[(1R,2R,3S,5R)-3-ethyl-5-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoic acid
DMDTGWQ	CA	CAS 1983970-12-2
DMDTGWQ	DE	Multiple myeloma; Acute myeloid leukaemia

DM0LQ94	ID	DM0LQ94
DM0LQ94	DN	GnRH
DM0LQ94	HS	Phase 3
DM0LQ94	SN	Lutrepatch; GnRH (Lutrepatch, female fertility); GnRH (Lutrepatch, female fertility), Ferring; GnRH (Lutrepatch, female infertility), Ferring/Vyteris; GnRH (Smart Patch, female infertility), Ferring/Vyteris; GnRH (Smart Patch, female infertility), Vyteris/Ferring; Iontophoretic anti-infertility peptide (Smart Patch), Ferring/Vyteris; Iontophoretic anti-infertility peptide (Smart Patch), Vyteris/Ferring; Anti-infertility peptide (iontophoretic/Smart Patch), Ferring/Vyteris; Anti-infertility peptide (iontophoretic/Smart Patch), Vyteris/Ferring; Gonadotropin-releasing hormone (Smart Patch, female infertility), Ferring/Vyteris; Gonadotropin-releasing hormone (Smart Patch, female infertility), Vyteris/Ferring
DM0LQ94	CP	Ferring Pharmaceuticals Inc
DM0LQ94	PC	16132914
DM0LQ94	MW	1212.3
DM0LQ94	FM	C60H73N15O13
DM0LQ94	IC	InChI=1S/C60H73N15O13/c1-32(2)20-47(60(88)75-19-7-12-49(75)59(87)65-28-50(61)78)73-55(83)44(22-34-25-63-40-10-5-3-8-38(34)40)69-52(80)29-66-53(81)43(21-33-13-15-37(77)16-14-33)70-58(86)48(30-76)74-56(84)45(23-35-26-64-41-11-6-4-9-39(35)41)71-57(85)46(24-36-27-62-31-67-36)72-54(82)42-17-18-51(79)68-42/h3-6,8-11,13-16,25-27,31-32,42-49,63-64,76-77H,7,12,17-24,28-30H2,1-2H3,(H2,61,78)(H,62,67)(H,65,87)(H,66,81)(H,68,79)(H,69,80)(H,70,86)(H,71,85)(H,72,82)(H,73,83)(H,74,84)
DM0LQ94	CS	CC(C)CC(C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8
DM0LQ94	IK	NMJREATYWWNIKX-UHFFFAOYSA-N
DM0LQ94	IU	N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM0LQ94	DE	Female infertility

DMKWV4B	ID	DMKWV4B
DMKWV4B	DN	Golnerminogene pradenovac
DMKWV4B	HS	Phase 3
DMKWV4B	SN	TNFerade (TN)
DMKWV4B	CP	GenVec
DMKWV4B	DE	Esophageal cancer

DMZS2R7	ID	DMZS2R7
DMZS2R7	DN	Granexin gel
DMZS2R7	HS	Phase 3
DMZS2R7	SN	alphaCT1
DMZS2R7	CP	FirstString Research
DMZS2R7	DE	Diabetic foot ulcer; Keloidal surgical scar; Radiation syndrome

DM4Y7WV	ID	DM4Y7WV
DM4Y7WV	DN	GRASPA
DM4Y7WV	HS	Phase 3
DM4Y7WV	SN	L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech
DM4Y7WV	CP	Erytech Pharma
DM4Y7WV	DT	Protein
DM4Y7WV	SQ	Elspar Sequence: QMSLQQELRYIEALSAIVETGQKMLEAGESALDVVTEAVRLLEECPLFNAGIGAVFTRDETHELDACVMDGNTLKAGAVAGVSHLRNPVLAARLVMEQSPHVMMIGEGAENFAFARGMERVSPEIFSTSLRYEQLLAARKEGATVLDHSGAPLDEKQKMGTVGAVALDLDGNLAAATSTGGMTNKLPGRVGDSPLVGAGCYANNASVAVSCTGTGEVFIRALAAYDIAALMDYGGLSLAEACERVVMEKLPTLGGSGGLIAIDHEGNVALPFNTEGMYRAWGYAGDTPTTGIYREKGDTVATQ</sequence>    <sequence format="FASTA">&gt;sp|P00805|ASPG2_ECOLI L-asparaginase 2 OS=Escherichia coli (strain K12) GN=ansB PE=1 SV=2MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY
DM4Y7WV	DE	Pancreatic cancer; Acute lymphoblastic leukaemia

DM71GPM	ID	DM71GPM
DM71GPM	DN	Grippol Plus
DM71GPM	HS	Phase 3
DM71GPM	SN	Egg-based adjuvanted seasonal influenza vaccine, Solvay
DM71GPM	CP	Solvay SA
DM71GPM	DT	Vaccine
DM71GPM	DE	Influenza virus infection

DMB34TZ	ID	DMB34TZ
DMB34TZ	DN	Grippol TC
DMB34TZ	HS	Phase 3
DMB34TZ	SN	Grippol; Grippol Neo; Cell-based adjuvanted seasonal influenza vaccine, Solvay/Petrovax; Seasonal influenza vaccine (tissue culture), Solvay/Petrovax
DMB34TZ	CP	Solvay SA
DMB34TZ	DT	Vaccine
DMB34TZ	DE	Influenza virus infection

DMHN3PG	ID	DMHN3PG
DMHN3PG	DN	GRT-6005
DMHN3PG	HS	Phase 3
DMHN3PG	SN	Cebranopadol; 863513-91-1; GRT6005; UNII-7GDW9S3GN3; GRT 6005; 7GDW9S3GN3; Cebranopadol [USAN:INN]; Cebranopadol (USAN/INN); Cebranopadol(GRT-6005); SCHEMBL566256; SCHEMBL154336; GTPL8866; CHEMBL3545616; CHEMBL2364605; SCHEMBL10035739; CHEMBL3962932; SCHEMBL19336241; SCHEMBL14183935; MolPort-039-063-422; BDBM177926; ZINC3950145; EX-A1095; BCP09612; BDBM50101095; BDBM50101112; AKOS032953927; AKOS025402576; AKOS025290738; DB12830; CS-1323; SB16531; NCGC00378895-01; AK170452; HY-15536; AS-35183;  Centrally-acting nociceptin agonist analgesic (oral liquid, pain/diabetic neuropathy), Grunenthal; GRT 6005/06
DMHN3PG	CP	Forest laboratories
DMHN3PG	DT	Small molecular drug
DMHN3PG	PC	11848225
DMHN3PG	MW	378.5
DMHN3PG	FM	C24H27FN2O
DMHN3PG	IC	InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3
DMHN3PG	CS	CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5
DMHN3PG	IK	CSMVOZKEWSOFER-UHFFFAOYSA-N
DMHN3PG	IU	6-fluoro-N,N-dimethyl-1'-phenylspiro[4,9-dihydro-3H-pyrano[3,4-b]indole-1,4'-cyclohexane]-1'-amine
DMHN3PG	CA	CAS 863513-91-1
DMHN3PG	DE	Diabetic neuropathy

DMNZO7M	ID	DMNZO7M
DMNZO7M	DN	GS-441524
DMNZO7M	HS	Phase 3
DMNZO7M	SN	EVO984; EVO-984; EVO 984; GS 441524; GS441524
DMNZO7M	TC	Antiviral Agents
DMNZO7M	DT	Small molecular drug
DMNZO7M	PC	44468216
DMNZO7M	MW	291.26
DMNZO7M	FM	C12H13N5O4
DMNZO7M	IC	InChI=1S/C12H13N5O4/c13-4-12(10(20)9(19)7(3-18)21-12)8-2-1-6-11(14)15-5-16-17(6)8/h1-2,5,7,9-10,18-20H,3H2,(H2,14,15,16)/t7-,9-,10-,12+/m1/s1
DMNZO7M	CS	C1=C2C(=NC=NN2C(=C1)[C@]3([C@@H]([C@@H]([C@H](O3)CO)O)O)C#N)N
DMNZO7M	IK	BRDWIEOJOWJCLU-LTGWCKQJSA-N
DMNZO7M	IU	(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile
DMNZO7M	CA	CAS 1191237-69-0
DMNZO7M	CB	CHEBI:147281
DMNZO7M	DE	Coronavirus Disease 2019 (COVID-19)

DMP8MDW	ID	DMP8MDW
DMP8MDW	DN	GS-5745
DMP8MDW	HS	Phase 3
DMP8MDW	CP	GILEAD
DMP8MDW	PC	56776542
DMP8MDW	MW	250.02
DMP8MDW	FM	C7H5BrFNO3
DMP8MDW	IC	InChI=1S/C7H5BrFNO3/c1-13-5-3-2-4(8)6(9)7(5)10(11)12/h2-3H,1H3
DMP8MDW	CS	COC1=C(C(=C(C=C1)Br)F)[N+](=O)[O-]
DMP8MDW	IK	LJJAOMRFFXQENV-UHFFFAOYSA-N
DMP8MDW	IU	1-bromo-2-fluoro-4-methoxy-3-nitrobenzene
DMP8MDW	CA	CAS 1352317-80-6
DMP8MDW	DE	Ulcerative colitis; Solid tumour/cancer; Crohn disease; Gastric adenocarcinoma; Rheumatoid arthritis

DMGJQVI	ID	DMGJQVI
DMGJQVI	DN	GS-6615
DMGJQVI	HS	Phase 3
DMGJQVI	SN	Eleclazine; 1443211-72-0; GS-6615; UNII-PUY08529FK; PUY08529FK; 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one; Eleclazine [INN]; Eleclazine [USAN:INN]; Eleclazine (USAN/INN); Eleclazine(GS-6615); GTPL8413; CHEMBL3707392; SCHEMBL14480722; MolPort-044-723-855; YNUAEEJQYHYLMS-UHFFFAOYSA-N; GS6615; ZINC206191652; AKOS030627706; DB12394; SB19622; KS-000006B4; 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-(4-(trifluoromethoxy)phenyl)-; AS-35245; J3.563.176C
DMGJQVI	CP	GILEAD
DMGJQVI	DT	Small molecular drug
DMGJQVI	PC	71183216
DMGJQVI	MW	415.4
DMGJQVI	FM	C21H16F3N3O3
DMGJQVI	IC	InChI=1S/C21H16F3N3O3/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19/h1-9,12H,10-11,13H2
DMGJQVI	CS	C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4
DMGJQVI	IK	YNUAEEJQYHYLMS-UHFFFAOYSA-N
DMGJQVI	IU	4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one
DMGJQVI	CA	CAS 1443211-72-0
DMGJQVI	DE	Ischemic heart disease; Long QT syndrome

DM936V7	ID	DM936V7
DM936V7	DN	GS-9674
DM936V7	HS	Phase 3
DM936V7	SN	Cilofexor; 1418274-28-8; UNII-YUN2306954; PX104; 1418274-28-8 (free acid); YUN2306954; 2-(3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)-3-hydroxyazetidin-1-yl)isonicotinic acid; GS 9674; 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid; Cilofexor [INN]; Cilofexor (GS(c)\\9674); CHEMBL4297613; SCHEMBL14641986; GTPL10644; BCP29283; BDBM50511109; GS9674; s6547; DB15168; example 13/9 [US10485795B2]; HY-109083; CS-0039260; 2-(3-(2-Chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)-3-hydroxy-1-azetidinyl)-4-pyridinecarboxylic acid; 4-Pyridinecarboxylic acid, 2-(3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)-3-hydroxy-1-azetidinyl)-
DM936V7	DT	Small molecular drug
DM936V7	PC	71228883
DM936V7	MW	586.8
DM936V7	FM	C28H22Cl3N3O5
DM936V7	IC	InChI=1S/C28H22Cl3N3O5/c29-20-2-1-3-21(30)24(20)25-18(26(39-33-25)15-4-5-15)12-38-17-6-7-19(22(31)11-17)28(37)13-34(14-28)23-10-16(27(35)36)8-9-32-23/h1-3,6-11,15,37H,4-5,12-14H2,(H,35,36)
DM936V7	CS	C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5(CN(C5)C6=NC=CC(=C6)C(=O)O)O)Cl
DM936V7	IK	KZSKGLFYQAYZCO-UHFFFAOYSA-N
DM936V7	IU	2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid
DM936V7	CA	CAS 1418274-28-8
DM936V7	DE	Non-alcoholic steatohepatitis; Primary sclerosing cholangitis

DMT8J0I	ID	DMT8J0I
DMT8J0I	DN	GSK1265744
DMT8J0I	HS	Phase 3
DMT8J0I	SN	Cabotegravir; 1051375-10-0; GSK1265744; UNII-HMH0132Z1Q; GSK744; GSK1265744A; GSK-1265744; HMH0132Z1Q; Cabotegravir (GSK744, GSK1265744); CAB; Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-;Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-; Cabotegravir [USAN:INN]; GSK744 LAP; GSK744 LA; S/GSK1265744; GSK 744; 744 LA; GSK 1265
DMT8J0I	CP	GSK
DMT8J0I	DT	Small molecular drug
DMT8J0I	PC	54713659
DMT8J0I	MW	405.4
DMT8J0I	FM	C19H17F2N3O5
DMT8J0I	IC	InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1
DMT8J0I	CS	C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
DMT8J0I	IK	WCWSTNLSLKSJPK-LKFCYVNXSA-N
DMT8J0I	IU	(3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide
DMT8J0I	CA	CAS 1051375-10-0
DMT8J0I	DE	Human immunodeficiency virus infection

DMRNGD2	ID	DMRNGD2
DMRNGD2	DN	GSK1278863
DMRNGD2	HS	Phase 3
DMRNGD2	SN	Daprodustat; 960539-70-2; GSK1278863; UNII-JVR38ZM64B; GSK-1278863; JVR38ZM64B; N-((1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl)glycine; Daprodustat [USAN:INN]; GSK 1278863; Daprodustat(GSK1278863); Daprodustat; GSK1278863; Daprodustat (JAN/USAN/INN); GTPL8455; Daprodustat (GSK1278863); CHEMBL3544988; KS-00000M8Z; EX-A1121; BCP16766; s8171; AKOS027439964; Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-; ZINC231226004; CS-5453; SB19761; DB11682; HY-17608; J3.560.573H; D10874
DMRNGD2	CP	GSK
DMRNGD2	DT	Small molecular drug
DMRNGD2	PC	91617630
DMRNGD2	MW	393.4
DMRNGD2	FM	C19H27N3O6
DMRNGD2	IC	InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,15H,1-11H2,(H,20,25)(H,23,24)
DMRNGD2	CS	C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O
DMRNGD2	IK	RUEYEZADQJCKGV-UHFFFAOYSA-N
DMRNGD2	IU	2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinane-5-carbonyl)amino]acetic acid
DMRNGD2	CA	CAS 960539-70-2
DMRNGD2	DE	Autism spectrum disorder; Diabetic foot ulcer; Anaemia

DMSMFN2	ID	DMSMFN2
DMSMFN2	DN	GSK2140944
DMSMFN2	HS	Phase 3
DMSMFN2	SN	Gepotidacin
DMSMFN2	CP	Glaxosmithkline
DMSMFN2	PC	25101874
DMSMFN2	MW	448.5
DMSMFN2	FM	C24H28N6O3
DMSMFN2	IC	InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1
DMSMFN2	CS	C1CC2=CC(=NC=C2OC1)CNC3CCN(CC3)C[C@@H]4CN5C(=O)C=CC6=C5N4C(=O)C=N6
DMSMFN2	IK	PZFAZQUREQIODZ-LJQANCHMSA-N
DMSMFN2	IU	(3R)-3-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione
DMSMFN2	CA	CAS 1075236-89-3
DMSMFN2	DE	Acute bacterial skin infection; Urinary tract infection; Neisseria gonorrhoeae infection

DMWL2XD	ID	DMWL2XD
DMWL2XD	DN	GSK2402968
DMWL2XD	HS	Phase 3
DMWL2XD	CP	GlaxoSmithKline; Prosensa
DMWL2XD	DE	Duchenne dystrophy

DMUVZAO	ID	DMUVZAO
DMUVZAO	DN	GSK642444
DMUVZAO	HS	Phase 3
DMUVZAO	SN	threo isoleucyl thiazolidide, 1; BDBM17299
DMUVZAO	CP	Theravance; GlaxoSmithKline
DMUVZAO	DT	Small molecular drug
DMUVZAO	PC	23647689
DMUVZAO	MW	203.33
DMUVZAO	FM	C9H19N2OS+
DMUVZAO	IC	InChI=1S/C9H18N2OS/c1-3-7(2)8(10)9(12)11-4-5-13-6-11/h7-8H,3-6,10H2,1-2H3/p+1/t7-,8-/m0/s1
DMUVZAO	CS	CC[C@H](C)[C@@H](C(=O)N1CCSC1)[NH3+]
DMUVZAO	IK	WCRLBFHWFPELKW-YUMQZZPRSA-O
DMUVZAO	IU	[(2S,3S)-3-methyl-1-oxo-1-(1,3-thiazolidin-3-yl)pentan-2-yl]azanium
DMUVZAO	DE	Chronic obstructive pulmonary disease

DMPS7U2	ID	DMPS7U2
DMPS7U2	DN	GTPL-9088
DMPS7U2	HS	Phase 3
DMPS7U2	SN	Clobetasona; Clobetasona [INN-Spanish]; Clobetasone; Clobetasone (INN); Clobetasone [INN:BAN]; Clobetasonum; Clobetasonum [INN-Latin]; LT69WY1J6D; SCHEMBL3581; XXIFVOHLGBURIG-OZCCCYNHSA-N; ZINC5752185; (8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3,11-dione; 21-Chlor-9-fluor-17-hydroxy-16beta-methyl-1,4-pregnadien-3,11,20-trion; 54063-32-0; AC1L2G2H; API0002061; D07717; DB13158; EINECS 258-953-5; GTPL9088; UNII-LT69WY1J6D
DMPS7U2	PC	71387
DMPS7U2	MW	408.9
DMPS7U2	FM	C22H26ClFO4
DMPS7U2	IC	XXIFVOHLGBURIG-OZCCCYNHSA-N
DMPS7U2	CS	CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(=O)CC2(C1(C(=O)CCl)O)C)F)C
DMPS7U2	IK	1S/C22H26ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-16,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19-,20-,21-,22-/m0/s1
DMPS7U2	IU	(8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3,11-dione
DMPS7U2	CA	CAS 54063-32-0
DMPS7U2	DE	Atopic dermatitis

DM9Y3EG	ID	DM9Y3EG
DM9Y3EG	DN	Guadecitabine
DM9Y3EG	HS	Phase 3
DM9Y3EG	SN	UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine
DM9Y3EG	CP	Astex Pharmaceuticals Pleasanton, CA
DM9Y3EG	PC	135564655
DM9Y3EG	MW	557.4
DM9Y3EG	FM	C18H24N9O10P
DM9Y3EG	IC	InChI=1S/C18H24N9O10P/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30)/t7-,8-,9+,10+,11+,12+/m0/s1
DM9Y3EG	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=NC(=NC5=O)N)O
DM9Y3EG	IK	GUWXKKAWLCENJA-WGWHJZDNSA-N
DM9Y3EG	IU	[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
DM9Y3EG	CA	CAS 929901-49-5
DM9Y3EG	DE	Myelodysplastic syndrome

DMN4E7T	ID	DMN4E7T
DMN4E7T	DN	Guaiacol
DMN4E7T	HS	Phase 3
DMN4E7T	SN	guaiacol; 2-Methoxyphenol; 90-05-1; o-Methoxyphenol; 2-Hydroxyanisole; Phenol, 2-methoxy-; Pyrocatechol monomethyl ether; Methylcatechol; Guaiastil; Guaicol; 1-Hydroxy-2-methoxybenzene; Pyroguaiac acid; o-Guaiacol; o-Hydroxyanisole; Guaicolina; Guajol; Guasol; Anastil; Phenol, o-methoxy-; Catechol monomethyl ether; O-Methyl catechol; CREOSOTE, WOOD; Methoxyphenol; Guajakol; Wood creosote; 2-Methoxy-Phenol; Creosote, beechwood; Guajacol; Methyl Catechol; Phenol, methoxy-; Guajakol [Czech]; Guaiacol (natural); 8021-39-4; Methylcatachol
DMN4E7T	DT	Small molecular drug
DMN4E7T	PC	460
DMN4E7T	MW	124.14
DMN4E7T	FM	C7H8O2
DMN4E7T	IC	InChI=1S/C7H8O2/c1-9-7-5-3-2-4-6(7)8/h2-5,8H,1H3
DMN4E7T	CS	COC1=CC=CC=C1O
DMN4E7T	IK	LHGVFZTZFXWLCP-UHFFFAOYSA-N
DMN4E7T	IU	2-methoxyphenol
DMN4E7T	CA	CAS 8021-39-4
DMN4E7T	CB	CHEBI:28591

DMIWLJE	ID	DMIWLJE
DMIWLJE	DN	Guanine
DMIWLJE	HS	Phase 3
DMIWLJE	DT	Small molecular drug
DMIWLJE	PC	135398634
DMIWLJE	MW	151.13
DMIWLJE	FM	C5H5N5O
DMIWLJE	IC	InChI=1S/C5H5N5O/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
DMIWLJE	CS	C1=NC2=C(N1)C(=O)NC(=N2)N
DMIWLJE	IK	UYTPUPDQBNUYGX-UHFFFAOYSA-N
DMIWLJE	IU	2-amino-1,7-dihydropurin-6-one
DMIWLJE	CA	CAS 73-40-5
DMIWLJE	CB	CHEBI:16235

DMHULRK	ID	DMHULRK
DMHULRK	DN	GV1001
DMHULRK	HS	Phase 3
DMHULRK	SN	GV1001
DMHULRK	CP	KAEL-GemVax
DMHULRK	DT	Vaccine
DMHULRK	DE	Pancreatic cancer

DMAXTFO	ID	DMAXTFO
DMAXTFO	DN	H1N1 influenza vaccine
DMAXTFO	HS	Phase 3
DMAXTFO	SN	Humenza; H1N1 influenza vaccine (AF-03-adjuvanted, EU market); H1N1 influenza vaccine (AF-03-adjuvanted, EU market), Sanofi Pasteur
DMAXTFO	CP	Sanofi Pasteur
DMAXTFO	DT	Vaccine
DMAXTFO	DE	Influenza virus infection

DM9CMI3	ID	DM9CMI3
DM9CMI3	DN	H5N1 influenza vaccine
DM9CMI3	HS	Phase 3
DM9CMI3	SN	KIB-PIA; H5N1 influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted); Avian influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted), Kitasato; H5N1 influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted), Kitasato
DM9CMI3	CP	Kitasato Institute
DM9CMI3	DT	Vaccine
DM9CMI3	DE	Influenza virus infection

DMQ38JZ	ID	DMQ38JZ
DMQ38JZ	DN	HB-AS02V
DMQ38JZ	HS	Phase 3
DMQ38JZ	SN	HBV vaccine (adjuvanted), Henogen; Hepatitis B virus vaccine (adjuvanted), Henogen
DMQ38JZ	CP	Henogen SA
DMQ38JZ	DT	Vaccine
DMQ38JZ	DE	Hepatitis B virus infection

DMB06MU	ID	DMB06MU
DMB06MU	DN	HC-1119
DMB06MU	HS	Phase 3
DMB06MU	SN	Enzalutamide D3; UNII-3OKI556HC2; 3OKI556HC2; HC 1119; 1443331-82-5; CHEMBL4594421; SCHEMBL18789402; HY-70002S; CS-0019855; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide; Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)-
DMB06MU	CP	Hinova Pharmaceuticals
DMB06MU	DT	Small molecular drug
DMB06MU	PC	71580408
DMB06MU	MW	467.5
DMB06MU	FM	C21H16F4N4O2S
DMB06MU	IC	InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)/i3D3
DMB06MU	CS	[2H]C([2H])([2H])NC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F)F
DMB06MU	IK	WXCXUHSOUPDCQV-HPRDVNIFSA-N
DMB06MU	IU	4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-(trideuteriomethyl)benzamide
DMB06MU	CA	CAS 1443331-82-5
DMB06MU	DE	Prostate cancer

DMB9U5E	ID	DMB9U5E
DMB9U5E	DN	HE3286
DMB9U5E	HS	Phase 3
DMB9U5E	SN	Triolex; HE3286; UNII-PH8858757I; PH8858757I; 1004264-32-7; HE 3286; HE-3286; 1001100-69-1; SCHEMBL512549; 3beta,7beta,17beta-Trihydroxy-17alpha-ethynylandrost-5-ene; DB05212; Pregn-5-en-20-yne-3,7,17-triol, (3beta,7beta,17alpha)-
DMB9U5E	CP	Hollis-Eden Pharmaceuticals
DMB9U5E	DT	Small molecular drug
DMB9U5E	PC	16739648
DMB9U5E	MW	330.5
DMB9U5E	FM	C21H30O3
DMB9U5E	IC	InChI=1S/C21H30O3/c1-4-21(24)10-7-16-18-15(6-9-20(16,21)3)19(2)8-5-14(22)11-13(19)12-17(18)23/h1,12,14-18,22-24H,5-11H2,2-3H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1
DMB9U5E	CS	C[C@]12CC[C@@H](CC1=C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O)O
DMB9U5E	IK	JJKOQZHWYLMASZ-FJWDNACWSA-N
DMB9U5E	IU	(3S,7R,8R,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,7,17-triol
DMB9U5E	CA	CAS 1001100-69-1
DMB9U5E	DE	Type-2 diabetes

DMQTLVB	ID	DMQTLVB
DMQTLVB	DN	Hebergel
DMQTLVB	HS	Phase 3
DMQTLVB	SN	Interferon alpha 2b gel (viral infection), CIGB
DMQTLVB	CP	Center for Genetic Engineering and Biotechnology
DMQTLVB	DE	Virus infection

DMUE843	ID	DMUE843
DMUE843	DN	Hematide
DMUE843	HS	Phase 3
DMUE843	CP	Affymax Inc; Takeda Pharmaceutical Co Ltd.
DMUE843	DE	Anemia

DMGFULM	ID	DMGFULM
DMGFULM	DN	Heparin low molecular weight
DMGFULM	HS	Phase 3
DMGFULM	SN	Heparin low molecular weight, Watson Laboratories; Heparin transmucosal, TheraTech
DMGFULM	CP	Watson Laboratories Inc
DMGFULM	DE	Thrombosis

DMXAZ47	ID	DMXAZ47
DMXAZ47	DN	HGH-CTP
DMXAZ47	HS	Phase 3
DMXAZ47	SN	MOD-401; MOD-4023; Human growth hormone (injectable, CTP, growth disorder), Modigene; Long-acting hGH (injectable, CTP, growth disorder), Modigene
DMXAZ47	CP	Prolor biotech; chiasma
DMXAZ47	DE	Growth hormone deficiency

DM6QOVN	ID	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	HS	Phase 3
DM6QOVN	SN	Neratinib (ERBB2 inhibitor)
DM6QOVN	CP	Wyeth Research
DM6QOVN	TC	Anticancer Agents
DM6QOVN	DT	Small molecular drug
DM6QOVN	PC	9915743
DM6QOVN	MW	557
DM6QOVN	FM	C30H29ClN6O3
DM6QOVN	IC	InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+
DM6QOVN	CS	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C
DM6QOVN	IK	JWNPDZNEKVCWMY-VQHVLOKHSA-N
DM6QOVN	IU	(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
DM6QOVN	CA	CAS 698387-09-6
DM6QOVN	CB	CHEBI:61397
DM6QOVN	DE	Breast cancer

DM29XGY	ID	DM29XGY
DM29XGY	DN	HMPL-004
DM29XGY	HS	Phase 3
DM29XGY	SN	Nuclear factor kappa B inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; TNF alpha ligand inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-1 beta modulator (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-6 antagonist (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma
DM29XGY	CP	Hutchison Medipharma Enterprises Ltd
DM29XGY	DE	Inflammatory bowel disease

DMAVIPZ	ID	DMAVIPZ
DMAVIPZ	DN	HSR-803
DMAVIPZ	HS	Phase 3
DMAVIPZ	SN	Ganaton; ITOPRIDE HCl; Itopride (hydrochloride); Q-201260; itopride hydrochloride; 122892-31-3; 2H9NV66W0I; C20H27ClN2O4; DSSTox_CID_26693; DSSTox_GSID_46693; DSSTox_RID_81827; HSR-803; HSR803; Hsr 803; Itax; MFCD00881710; N-((4-(2-(Dimethylamino)ethoxy)phenyl)methyl)-3,4-dimethoxybenzamide monohydrochloride; N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4-dimethoxidebenzamide hydrochloride; N-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide; UNII-2H9NV66W0I; n-[4-(2-dimethylaminoethoxy)benzyl]-3,4-dimethoxybenzamide hcl
DMAVIPZ	PC	129791
DMAVIPZ	MW	394.9
DMAVIPZ	FM	C20H27ClN2O4
DMAVIPZ	IC	ZTOUXLLIPWWHSR-UHFFFAOYSA-N
DMAVIPZ	CS	CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC.Cl
DMAVIPZ	IK	1S/C20H26N2O4.ClH/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4;/h5-10,13H,11-12,14H2,1-4H3,(H,21,23);1H
DMAVIPZ	IU	N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide;hydrochloride
DMAVIPZ	CA	CAS 122892-31-3
DMAVIPZ	DE	Functional nausea/vomiting

DMBER0Q	ID	DMBER0Q
DMBER0Q	DN	Hu5F9-G4
DMBER0Q	HS	Phase 3
DMBER0Q	CP	Forty Seven Menlo Park, CA
DMBER0Q	DE	Solid tumour/cancer; Acute myeloid leukaemia; Colorectal cancer; B-cell non-hodgkin lymphoma; Myelodysplastic syndrome

DMXZAL2	ID	DMXZAL2
DMXZAL2	DN	Hydroxychloroquine
DMXZAL2	HS	Phase 3
DMXZAL2	SN	Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258
DMXZAL2	CP	Concordia Pharmaceuticals Inc
DMXZAL2	TC	Antiviral Agents
DMXZAL2	DT	Small molecular drug
DMXZAL2	PC	3652
DMXZAL2	MW	335.9
DMXZAL2	FM	C18H26ClN3O
DMXZAL2	IC	InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
DMXZAL2	CS	CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
DMXZAL2	IK	XXSMGPRMXLTPCZ-UHFFFAOYSA-N
DMXZAL2	IU	2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
DMXZAL2	CA	CAS 118-42-3
DMXZAL2	CB	CHEBI:5801
DMXZAL2	DE	Malaria; Coronavirus Disease 2019 (COVID-19)

DMIGFOR	ID	DMIGFOR
DMIGFOR	DN	I3C
DMIGFOR	HS	Phase 3
DMIGFOR	SN	Indole-3-carbinol; 700-06-1; 3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 3-Hydroxymethylindole; 1H-Indole-3-methanol; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; MFCD00005632; UNII-C11E72455F; CHEBI:24814; C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); indole-3-carbinole; zlchem 356; PubChem7265; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); 3-Phenoxybenzylaminehydrochloride; DTXSID7031458; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL  (I3C); Tox21_400055; 9344AF; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS20980; MCULE-6344603304; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; CAS-700-06-1; SY015976; AB0008317; DB-011567; A9256; FT-0615875; ST50308202; SW219849-1; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165
DMIGFOR	DT	Small molecular drug
DMIGFOR	PC	3712
DMIGFOR	MW	147.17
DMIGFOR	FM	C9H9NO
DMIGFOR	IC	InChI=1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2
DMIGFOR	CS	C1=CC=C2C(=C1)C(=CN2)CO
DMIGFOR	IK	IVYPNXXAYMYVSP-UHFFFAOYSA-N
DMIGFOR	IU	1H-indol-3-ylmethanol
DMIGFOR	CA	CAS 700-06-1
DMIGFOR	CB	CHEBI:24814
DMIGFOR	DE	Breast cancer

DM5KL8E	ID	DM5KL8E
DM5KL8E	DN	IBI-308
DM5KL8E	HS	Phase 3
DM5KL8E	CP	Innovent Biologics
DM5KL8E	DT	Monoclonal antibody
DM5KL8E	DE	Bronchioalveolar carcinoma

DM9G5XD	ID	DM9G5XD
DM9G5XD	DN	IB-MECA
DM9G5XD	HS	Phase 3
DM9G5XD	SN	IB-Meca; 152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide; 3-IB-MECA
DM9G5XD	DT	Small molecular drug
DM9G5XD	PC	123683
DM9G5XD	MW	510.3
DM9G5XD	FM	C18H19IN6O4
DM9G5XD	IC	InChI=1S/C18H19IN6O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)/t12-,13+,14-,18+/m0/s1
DM9G5XD	CS	CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O
DM9G5XD	IK	HUJXGQILHAUCCV-MOROJQBDSA-N
DM9G5XD	IU	(2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide
DM9G5XD	CA	CAS 152918-18-8
DM9G5XD	CB	CHEBI:73286
DM9G5XD	DE	Solid tumour/cancer; Plaque psoriasis; Psoriasis vulgaris; Rheumatoid arthritis

DMT67EH	ID	DMT67EH
DMT67EH	DN	Ibodutant
DMT67EH	HS	Phase 3
DMT67EH	SN	MEN-15596; Tachykinin NK2 receptor antagonist (irritable bowel syndrome), Menarini
DMT67EH	CP	The Menarini Group
DMT67EH	DT	Small molecular drug
DMT67EH	PC	11527495
DMT67EH	MW	644.9
DMT67EH	FM	C37H48N4O4S
DMT67EH	IC	InChI=1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1
DMT67EH	CS	CC1=CC2=C(C=C1)C=C(S2)C(=O)NC3(CCCC3)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)NCC5CCN(CC5)CC6CCOCC6
DMT67EH	IK	YQYSVMKCMIUCHY-WJOKGBTCSA-N
DMT67EH	IU	6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4-yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide
DMT67EH	CA	CAS 522664-63-7
DMT67EH	DE	Irritable bowel syndrome

DMOJQGT	ID	DMOJQGT
DMOJQGT	DN	ICARIIN
DMOJQGT	HS	Phase 3
DMOJQGT	SN	Icariin; 489-32-7; Ieariline; UNII-VNM47R2QSQ; CHEBI:78420; VNM47R2QSQ; Icariine; 3-((6-Deoxymannopyranosyl)oxy)-7-(glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one; Icarin; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-7-(be
DMOJQGT	DT	Small molecular drug
DMOJQGT	PC	5318997
DMOJQGT	MW	676.7
DMOJQGT	FM	C33H40O15
DMOJQGT	IC	InChI=1S/C33H40O15/c1-13(2)5-10-17-19(45-33-28(42)26(40)23(37)20(12-34)46-33)11-18(35)21-24(38)31(48-32-27(41)25(39)22(36)14(3)44-32)29(47-30(17)21)15-6-8-16(43-4)9-7-15/h5-9,11,14,20,22-23,25-28,32-37,39-42H,10,12H2,1-4H3/t14-,20+,22-,23+,25+,26-,27+,28+,32-,33+/m0/s1
DMOJQGT	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)O)O
DMOJQGT	IK	TZJALUIVHRYQQB-XLRXWWTNSA-N
DMOJQGT	IU	5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DMOJQGT	CA	CAS 489-32-7
DMOJQGT	CB	CHEBI:78420

DM3OU54	ID	DM3OU54
DM3OU54	DN	ICI 118,551
DM3OU54	HS	Phase 3
DM3OU54	SN	Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO
DM3OU54	DT	Small molecular drug
DM3OU54	PC	3682
DM3OU54	MW	277.4
DM3OU54	FM	C17H27NO2
DM3OU54	IC	InChI=1S/C17H27NO2/c1-11(2)18-13(4)16(19)10-20-17-9-8-12(3)14-6-5-7-15(14)17/h8-9,11,13,16,18-19H,5-7,10H2,1-4H3
DM3OU54	CS	CC1=C2CCCC2=C(C=C1)OCC(C(C)NC(C)C)O
DM3OU54	IK	VFIDUCMKNJIJTO-UHFFFAOYSA-N
DM3OU54	IU	1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol
DM3OU54	CB	CHEBI:91879
DM3OU54	DE	Gastric adenocarcinoma; HER2-positive breast cancer

DM7YNV9	ID	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	HS	Phase 3
DM7YNV9	SN	192314-93-5; AR-100; 5-[(2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-yl)methyl]pyrimidine-2,4-diamine; RO-48-2622; Mersarex; 5-((2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl)pyrimidine-2,4-diamine; Iclaprim [USAN:INN]; Iclaprim (USAN/INN); 2,4-Pyrimidinediamine, 5-((2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl)-; 2,4-Pyrimidinediamine, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-; AR 100; AC1Q4WM5; SCHEMBL379386; CHEMBL134561; AC1L4U54; SCHEMBL12899446; CTK4E0971; BDBM18070; Iclaprim [INN]; AR-102; AR-100001; 5-((2RS)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl)pyrimidine-2,4-diamine
DM7YNV9	CP	Arpida
DM7YNV9	DT	Small molecular drug
DM7YNV9	PC	213043
DM7YNV9	MW	354.4
DM7YNV9	FM	C19H22N4O3
DM7YNV9	IC	InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)
DM7YNV9	CS	COC1=C(C2=C(C=CC(O2)C3CC3)C(=C1)CC4=CN=C(N=C4N)N)OC
DM7YNV9	IK	HWJPWWYTGBZDEG-UHFFFAOYSA-N
DM7YNV9	IU	5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine
DM7YNV9	CA	CAS 192314-93-5
DM7YNV9	CB	CHEBI:131751
DM7YNV9	DE	Pneumonia; Bacterial infection; Acute bacterial skin infection

DMU72KL	ID	DMU72KL
DMU72KL	DN	ICP-022
DMU72KL	HS	Phase 3
DMU72KL	SN	Orelabrutinib; 1655504-04-3; UNII-WJA5UO9E10; WJA5UO9E10; 4-yl]pyridine-3-carboxamide; ICP022; 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-; 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide; Orelabrutinib [INN]; orelabrutinib (proposed INN); SCHEMBL16597834; US9951056, Example 3; GTPL10629; BDBM389631; EX-A3442; NSC826039; s9600; NSC-826039; example 3 [WO2015048662A2]; DB-091042; HY-129390; CS-0105163; 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-; 6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide
DMU72KL	CP	InnoCare Pharma
DMU72KL	DT	Small molecular drug
DMU72KL	PC	91667513
DMU72KL	MW	427.5
DMU72KL	FM	C26H25N3O3
DMU72KL	IC	InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)
DMU72KL	CS	C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4
DMU72KL	IK	MZPVEMOYADUARK-UHFFFAOYSA-N
DMU72KL	IU	2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide
DMU72KL	CA	CAS 1655504-04-3
DMU72KL	DE	Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma

DMBIZ7H	ID	DMBIZ7H
DMBIZ7H	DN	ICT-107
DMBIZ7H	HS	Phase 3
DMBIZ7H	CP	ImmunoCellular Therapeutics
DMBIZ7H	DT	Vaccine
DMBIZ7H	DE	Glioblastoma multiforme; Brain cancer; Recurrent glioblastoma

DMSP0X8	ID	DMSP0X8
DMSP0X8	DN	IDAZOXAN HYDROCHLORIDE
DMSP0X8	HS	Phase 3
DMSP0X8	SN	IDAZOXAN HYDROCHLORIDE; 79944-56-2; Idazoxan HCl; RX 781094; MLS000069708; SMR000058458; SR-01000000206; Opera_ID_847; Idazoxan (hydrochloride); AC1L4CEL; MLS001148081; SCHEMBL707367; CHEMBL543467; CTK8G0263; MolPort-003-941-824; MYUBYOVCLMEAOH-UHFFFAOYSA-N; (+/-)-Idazoxan Monohydrochloride; Pharmakon1600-01506073; HMS1570J14; Tox21_500652; NSC759867; MFCD00069293; BN0267; AKOS024458652; NSC-759867; RX 781094A; LP00652; CCG-214002; 1H-Imidazole, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-,monohydrochloride; 1H-Imidazole, 2-(2,3-d
DMSP0X8	DT	Small molecular drug
DMSP0X8	PC	154494
DMSP0X8	MW	240.68
DMSP0X8	FM	C11H13ClN2O2
DMSP0X8	IC	InChI=1S/C11H12N2O2.ClH/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11;/h1-4,10H,5-7H2,(H,12,13);1H
DMSP0X8	CS	C1CN=C(N1)C2COC3=CC=CC=C3O2.Cl
DMSP0X8	IK	MYUBYOVCLMEAOH-UHFFFAOYSA-N
DMSP0X8	IU	2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole;hydrochloride
DMSP0X8	CA	CAS 79944-56-2
DMSP0X8	DE	Neurological disorder

DMV3DHQ	ID	DMV3DHQ
DMV3DHQ	DN	IDDBCP161883
DMV3DHQ	HS	Phase 3
DMV3DHQ	CP	Mitsubishi Tanabe
DMV3DHQ	DE	Type-2 diabetes

DM3A701	ID	DM3A701
DM3A701	DN	IDP-122
DM3A701	HS	Phase 3
DM3A701	CP	Valeant Pharmaceuticals Bridgewater, NJ
DM3A701	DE	Plaque psoriasis

DMRLVUD	ID	DMRLVUD
DMRLVUD	DN	Imagabalin
DMRLVUD	HS	Phase 3
DMRLVUD	SN	Imagabalin hydrochloride; PD-0332334; PD-332334; PF-00195889
DMRLVUD	CP	Pfizer Inc
DMRLVUD	DT	Small molecular drug
DMRLVUD	PC	10236037
DMRLVUD	MW	173.25
DMRLVUD	FM	C9H19NO2
DMRLVUD	IC	InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1
DMRLVUD	CS	CCC[C@@H](C)C[C@@H](CC(=O)O)N
DMRLVUD	IK	JXEHXYFSIOYTAH-SFYZADRCSA-N
DMRLVUD	IU	(3S,5R)-3-amino-5-methyloctanoic acid
DMRLVUD	CA	CAS 610300-07-7
DMRLVUD	DE	Generalized anxiety disorder

DMM9JEF	ID	DMM9JEF
DMM9JEF	DN	Imatinib
DMM9JEF	HS	Phase 3
DMM9JEF	SN	Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
DMM9JEF	CP	Novartis AG
DMM9JEF	TC	Antiviral Agents
DMM9JEF	DT	Small molecular drug
DMM9JEF	PC	5291
DMM9JEF	MW	493.6
DMM9JEF	FM	C29H31N7O
DMM9JEF	IC	InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
DMM9JEF	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DMM9JEF	IK	KTUFNOKKBVMGRW-UHFFFAOYSA-N
DMM9JEF	IU	4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMM9JEF	CA	CAS 152459-95-5
DMM9JEF	CB	CHEBI:45783
DMM9JEF	DE	Chronic myelogenous leukaemia; Intestinal cancer; Lung cancer; Systemic mastocytosis; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM7BCWT	ID	DM7BCWT
DM7BCWT	DN	Imiglitazar
DM7BCWT	HS	Phase 3
DM7BCWT	SN	TAK-559
DM7BCWT	CP	Takeda Pharmaceutical Co Ltd
DM7BCWT	DT	Small molecular drug
DM7BCWT	PC	9890879
DM7BCWT	MW	470.5
DM7BCWT	FM	C28H26N2O5
DM7BCWT	IC	InChI=1S/C28H26N2O5/c1-20-26(29-28(35-20)23-10-6-3-7-11-23)19-33-24-14-12-21(13-15-24)18-34-30-25(16-17-27(31)32)22-8-4-2-5-9-22/h2-15H,16-19H2,1H3,(H,31,32)/b30-25+
DM7BCWT	CS	CC1=C(N=C(O1)C2=CC=CC=C2)COC3=CC=C(C=C3)CO/N=C(\\CCC(=O)O)/C4=CC=CC=C4
DM7BCWT	IK	ULVDFHLHKNJICZ-QCWLDUFUSA-N
DM7BCWT	IU	(4E)-4-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methoxyimino]-4-phenylbutanoic acid
DM7BCWT	CA	CAS 250601-04-8
DM7BCWT	DE	Type-2 diabetes

DM735FA	ID	DM735FA
DM735FA	DN	IMO-2125
DM735FA	HS	Phase 3
DM735FA	CP	Idera Pharmaceuticals
DM735FA	DE	Hepatitis C virus infection; Melanoma; Solid tumour/cancer

DMIJGT9	ID	DMIJGT9
DMIJGT9	DN	INCB24360
DMIJGT9	HS	Phase 3
DMIJGT9	SN	Epacadostat
DMIJGT9	CP	Incyte
DMIJGT9	DT	Small molecular drug
DMIJGT9	PC	135564890
DMIJGT9	MW	438.24
DMIJGT9	FM	C11H13BrFN7O4S
DMIJGT9	IC	InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)
DMIJGT9	CS	C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F
DMIJGT9	IK	FBKMWOJEPMPVTQ-UHFFFAOYSA-N
DMIJGT9	IU	N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide
DMIJGT9	CA	CAS 1204669-58-8
DMIJGT9	DE	Recurrent glioblastoma; Melanoma; B-cell lymphoma; Colorectal cancer; Head and neck cancer; Lung cancer; Lymphoma; Merkel cell carcinoma; Ovarian cancer; Solid tumour/cancer; Urothelial carcinoma

DMZA2K0	ID	DMZA2K0
DMZA2K0	DN	INCSHR1210
DMZA2K0	HS	Phase 3
DMZA2K0	SN	Camrelizumab
DMZA2K0	CP	Incyte Wilmington, DE
DMZA2K0	DT	Monoclonal antibody
DMZA2K0	DE	Solid tumour/cancer; Bronchioalveolar carcinoma; Esophageal squamous cell carcinoma

DMLG96Z	ID	DMLG96Z
DMLG96Z	DN	INM-176
DMLG96Z	HS	Phase 3
DMLG96Z	SN	WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn
DMLG96Z	CP	Scigenic & Scigen Harvest Co Ltd
DMLG96Z	DE	Alzheimer disease

DM5L8QT	ID	DM5L8QT
DM5L8QT	DN	INO-1001
DM5L8QT	HS	Phase 3
DM5L8QT	SN	Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
DM5L8QT	CP	Inotek Pharma.
DM5L8QT	TC	Anticancer Agents
DM5L8QT	DT	Small molecular drug
DM5L8QT	PC	6708742
DM5L8QT	DE	Brain cancer

DMUS1F8	ID	DMUS1F8
DMUS1F8	DN	Inolimomab
DMUS1F8	HS	Phase 3
DMUS1F8	CP	EUSA Pharma
DMUS1F8	DT	Monoclonal antibody
DMUS1F8	DE	Heart transplant rejection

DMOTH6V	ID	DMOTH6V
DMOTH6V	DN	Interferon alpha 2a
DMOTH6V	HS	Phase 3
DMOTH6V	SN	LBSI-5535; Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV); Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV), LG Life Sciences; Sr-IFN alpha (Biohydrix sustained release/weekly dosing, HCV), LGLS
DMOTH6V	CP	LG Life Sciences Ltd
DMOTH6V	DE	Hepatitis C virus infection

DMZA47Y	ID	DMZA47Y
DMZA47Y	DN	Iomab-B
DMZA47Y	HS	Phase 3
DMZA47Y	SN	Iomab-B (TN)
DMZA47Y	CP	Actinium Pharmaceuticals
DMZA47Y	DT	Antibody
DMZA47Y	DE	Acute myeloid leukaemia; Bone marrow transplantation

DMSV12M	ID	DMSV12M
DMSV12M	DN	Isavuconazole
DMSV12M	HS	Phase 3
DMSV12M	SN	Isavuconazole; 241479-67-4; isavuconazol; BAL 4815; BAL-4815; UNII-60UTO373KE; Isavuconazole [INN]; 60UTO373KE; Isavuconazole(BAL-4815; RO-0094815); RO 0094815; CHEBI:85979; Isavuconazole (INN); RO-0094815; 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile; 1286730-05-9; 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
DMSV12M	CP	Astellas
DMSV12M	DT	Small molecular drug
DMSV12M	PC	6918485
DMSV12M	MW	437.5
DMSV12M	FM	C22H17F2N5OS
DMSV12M	IC	InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1
DMSV12M	CS	C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=CC(=C4)F)F)O
DMSV12M	IK	DDFOUSQFMYRUQK-RCDICMHDSA-N
DMSV12M	IU	4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
DMSV12M	CA	CAS 241479-67-4
DMSV12M	CB	CHEBI:85979
DMSV12M	DE	Invasive aspergillosis; Invasive candidiasis; Candidemia

DMQZI7K	ID	DMQZI7K
DMQZI7K	DN	ISIS 23722
DMQZI7K	HS	Phase 3
DMQZI7K	CP	Isis Pharmaceuticals
DMQZI7K	SQ	TGTGCTATTCTGTGAATT
DMQZI7K	DE	Solid tumour/cancer

DMKWBJR	ID	DMKWBJR
DMKWBJR	DN	ISIS-PKK
DMKWBJR	HS	Phase 3
DMKWBJR	SN	ISIS-PKKRx
DMKWBJR	DT	Antisense drug
DMKWBJR	DE	Amyloid cardiomyopathy

DM4U5NF	ID	DM4U5NF
DM4U5NF	DN	ISIS-TTR
DM4U5NF	HS	Phase 3
DM4U5NF	CP	ISIS Pharm
DM4U5NF	DT	Antisense drug
DM4U5NF	DE	Amyloidosis

DMBJTVL	ID	DMBJTVL
DMBJTVL	DN	Isotretinoin
DMBJTVL	HS	Phase 3
DMBJTVL	SN	Accutane; 13-cis-Retinoic acid; Roaccutane; Neovitamin A acid; 13-cis-Vitamin A acid; 13-cis retinoic acid; Claravis; Amnesteem; Isotrex; Teriosal; Sotret; isotretinoino; Isotretinoinum; Isotretinoine; Roaccutan; 13-RA; Roacutan; Absorica; ISOTRETINON; Isotretinoine [INN-French]; Isotretinoinum [INN-Latin]; Isotretinoino [INN-Spanish]; CIP-Isotretinoin; Accutane (TN); Isotretinoin (USP); Ro-4-3780; UNII-EH28UP18IF; CCRIS 4286; HSDB 3929
DMBJTVL	TC	Antiviral Agents
DMBJTVL	DT	Small molecular drug
DMBJTVL	PC	5282379
DMBJTVL	MW	300.4
DMBJTVL	FM	C20H28O2
DMBJTVL	IC	InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-
DMBJTVL	CS	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\\C(=O)O)/C)/C
DMBJTVL	IK	SHGAZHPCJJPHSC-XFYACQKRSA-N
DMBJTVL	IU	(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DMBJTVL	CA	CAS 4759-48-2
DMBJTVL	CB	CHEBI:6067
DMBJTVL	DE	Coronavirus Disease 2019 (COVID-19)

DMP61YB	ID	DMP61YB
DMP61YB	DN	ISRAPAFANT
DMP61YB	HS	Phase 3
DMP61YB	SN	Y-24180; Israpafant; Pafnol (Mitsubishi Pharma, JP); Rac-4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
DMP61YB	DT	Small molecular drug
DMP61YB	PC	119175
DMP61YB	MW	489.1
DMP61YB	FM	C28H29ClN4S
DMP61YB	IC	InChI=1S/C28H29ClN4S/c1-17(2)15-21-11-9-20(10-12-21)13-14-22-16-24-26(23-7-5-6-8-25(23)29)30-18(3)27-32-31-19(4)33(27)28(24)34-22/h5-12,16-18H,13-15H2,1-4H3
DMP61YB	CS	CC1C2=NN=C(N2C3=C(C=C(S3)CCC4=CC=C(C=C4)CC(C)C)C(=N1)C5=CC=CC=C5Cl)C
DMP61YB	IK	RMSWMRJVUJSDGN-UHFFFAOYSA-N
DMP61YB	IU	7-(2-chlorophenyl)-9,13-dimethyl-4-[2-[4-(2-methylpropyl)phenyl]ethyl]-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
DMP61YB	CA	CAS 117279-73-9
DMP61YB	DE	Asthma

DMNDGWE	ID	DMNDGWE
DMNDGWE	DN	IT-101
DMNDGWE	HS	Phase 3
DMNDGWE	CP	Insert Therapeutics
DMNDGWE	DE	Solid tumour/cancer

DMFZBNE	ID	DMFZBNE
DMFZBNE	DN	ITF2357
DMFZBNE	HS	Phase 3
DMFZBNE	SN	Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)
DMFZBNE	CP	Italfarmaco
DMFZBNE	DT	Small molecular drug
DMFZBNE	PC	9804992
DMFZBNE	MW	421.5
DMFZBNE	FM	C24H27N3O4
DMFZBNE	IC	InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
DMFZBNE	CS	CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO
DMFZBNE	IK	YALNUENQHAQXEA-UHFFFAOYSA-N
DMFZBNE	IU	[6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate
DMFZBNE	CA	CAS 497833-27-9
DMFZBNE	CB	CHEBI:94187
DMFZBNE	DE	Polycythemia vera; Essential thrombocythemia; Myelofibrosis; Duchenne dystrophy

DMUQ1DO	ID	DMUQ1DO
DMUQ1DO	DN	ITI-007
DMUQ1DO	HS	Phase 3
DMUQ1DO	CP	Intra-Cellular Therapies
DMUQ1DO	DT	Small molecular drug
DMUQ1DO	PC	21302490
DMUQ1DO	MW	393.5
DMUQ1DO	FM	C24H28FN3O
DMUQ1DO	IC	InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1
DMUQ1DO	CS	CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
DMUQ1DO	IK	HOIIHACBCFLJET-SFTDATJTSA-N
DMUQ1DO	IU	1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one
DMUQ1DO	CA	CAS 313369-37-8
DMUQ1DO	DE	Insomnia; Schizophrenia; Depression; Major depressive disorder

DMGWVLX	ID	DMGWVLX
DMGWVLX	DN	Itolizumab
DMGWVLX	HS	Phase 3
DMGWVLX	SN	T-1h-mAb; T-1h-mAb); Anti-CD6 humanized monoclonal antibody, Center of Molecular Immunology/Biocon Biopharmaceuticals; Anti-CD6 humanized monoclonal antibody (rheumatoid arthritis/ psoriasis/ T-cell lymphoma), CIM/Biocon Biopharmaceuticals
DMGWVLX	CP	Dermatology; The Center of Molecular Immunology
DMGWVLX	DT	Antibody
DMGWVLX	DE	Type-1 diabetes

DM7MLTR	ID	DM7MLTR
DM7MLTR	DN	Itopride
DM7MLTR	HS	Phase 3
DM7MLTR	SN	Itopride; Itopride (INN); Itopride [INN]; QQQIECGTIMUVDS-UHFFFAOYSA-N; SCHEMBL311309; SR-01000763470; 122898-67-3; 81BMQ80QRL; AC1L1GQ2; AC1Q5DLT; DTXSID7048320; N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzamide; N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzamide; N-[4-[2-(Dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide; N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide; NCGC00167529-01; UNII-81BMQ80QRL; n-{4-[2-(dimethylamino)ethoxy]benzyl}-3,4-dimethoxybenzamide
DM7MLTR	PC	3792
DM7MLTR	MW	358.4
DM7MLTR	FM	C20H26N2O4
DM7MLTR	IC	QQQIECGTIMUVDS-UHFFFAOYSA-N
DM7MLTR	CS	CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC
DM7MLTR	IK	1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23)
DM7MLTR	IU	N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide
DM7MLTR	CA	CAS 122898-67-3
DM7MLTR	CB	CHEBI:94809
DM7MLTR	DE	Functional nausea/vomiting

DMNORK8	ID	DMNORK8
DMNORK8	DN	Jakafi
DMNORK8	HS	Phase 3
DMNORK8	SN	Ruxolitinib phosphate; 1092939-17-7; Ruxolitinib (phosphate); Jakavi; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; UNII-436LRU32H5; Ruxolitinib phosphate salt; Ruxolitinib phosphate(INCB018424); CHEBI:66917; 436LRU32H5; J-501793; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate; Ruxolitinib phosphate [USAN]; Jaka
DMNORK8	CP	Incyte, Wilmington, DE
DMNORK8	PC	25127112
DMNORK8	MW	404.4
DMNORK8	FM	C17H21N6O4P
DMNORK8	IC	InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
DMNORK8	CS	C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
DMNORK8	IK	JFMWPOCYMYGEDM-XFULWGLBSA-N
DMNORK8	IU	(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid
DMNORK8	CA	CAS 1092939-17-7
DMNORK8	CB	CHEBI:66917
DMNORK8	DE	Essential thrombocythemia

DM8FSPV	ID	DM8FSPV
DM8FSPV	DN	JTZ-951
DM8FSPV	HS	Phase 3
DM8FSPV	PC	50899324
DM8FSPV	MW	340.33
DM8FSPV	FM	C17H16N4O4
DM8FSPV	IC	InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24)
DM8FSPV	CS	C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
DM8FSPV	IK	FJYRBJKWDXVHHO-UHFFFAOYSA-N
DM8FSPV	IU	2-[[7-oxo-5-(2-phenylethyl)-3H-[1,2,4]triazolo[1,5-a]pyridine-8-carbonyl]amino]acetic acid
DM8FSPV	CA	CAS 1262132-81-9
DM8FSPV	DE	Anaemia

DM5WCV4	ID	DM5WCV4
DM5WCV4	DN	JX-594
DM5WCV4	HS	Phase 3
DM5WCV4	SN	Pexastimogene devacirepvec
DM5WCV4	CP	Jennerex Biotherapeutics
DM5WCV4	DE	Liver cancer; Colorectal cancer; Hepatocellular carcinoma

DM9J0KD	ID	DM9J0KD
DM9J0KD	DN	K-103-IP
DM9J0KD	HS	Phase 3
DM9J0KD	DE	Pain

DMCRGY4	ID	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	HS	Phase 3
DMCRGY4	SN	Karenitecin (TN)
DMCRGY4	CP	BioNumerik Pharmaceuticals
DMCRGY4	DT	Small molecular drug
DMCRGY4	PC	148202
DMCRGY4	MW	448.6
DMCRGY4	FM	C25H28N2O4Si
DMCRGY4	IC	InChI=1S/C25H28N2O4Si/c1-5-25(30)19-12-21-22-17(13-27(21)23(28)18(19)14-31-24(25)29)15(10-11-32(2,3)4)16-8-6-7-9-20(16)26-22/h6-9,12,30H,5,10-11,13-14H2,1-4H3/t25-/m0/s1
DMCRGY4	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CC[Si](C)(C)C)O
DMCRGY4	IK	POADTFBBIXOWFJ-VWLOTQADSA-N
DMCRGY4	IU	(19S)-19-ethyl-19-hydroxy-10-(2-trimethylsilylethyl)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMCRGY4	CA	CAS 203923-89-1
DMCRGY4	DE	Lung cancer; Ovarian cancer

DM8VO16	ID	DM8VO16
DM8VO16	DN	KH-902
DM8VO16	HS	Phase 3
DM8VO16	SN	Fumintide; KH-902 (intravitreal, AMD/DME), Kanghong Biotechnologies
DM8VO16	CP	Chengdu Kanghong Biotechnologies Co Ltd
DM8VO16	DE	Diabetic macular edema

DMSDBPG	ID	DMSDBPG
DMSDBPG	DN	KN046
DMSDBPG	HS	Phase 3
DMSDBPG	CP	Alphamab Oncology
DMSDBPG	DT	Antibody
DMSDBPG	DE	Non-small-cell lung cancer

DMP5G1K	ID	DMP5G1K
DMP5G1K	DN	KPS-0373
DMP5G1K	HS	Phase 3
DMP5G1K	SN	S-0373; TSH release modulator (spinocerebellar ataxia), Kissei; Thyrotropin-releasing hormone derivative (spinocerebellarataxia), Shionogi; Thyrotropin-releasing hormone derivative (Parkinson's disease), Shionogi
DMP5G1K	CP	Shionogi & Co Ltd
DMP5G1K	DE	Parkinson disease

DMM2LTC	ID	DMM2LTC
DMM2LTC	DN	KSI-301
DMM2LTC	HS	Phase 3
DMM2LTC	CP	Kodiak Sciences
DMM2LTC	DT	Antibody biopolymer conjugate
DMM2LTC	DE	Diabetic macular edema

DMP3GI2	ID	DMP3GI2
DMP3GI2	DN	KW-3357
DMP3GI2	HS	Phase 3
DMP3GI2	SN	Coagulation factor inhibitor (iv, blood clotting disorder), Kyowa; Recombinant antithrombin (iv, blooding clottingdisorder), Kyowa Hakko Kirin
DMP3GI2	CP	Kyowa Hakko Kogyo Co Ltd
DMP3GI2	DE	Coagulation defect

DMF0NA9	ID	DMF0NA9
DMF0NA9	DN	KX-01
DMF0NA9	HS	Phase 3
DMF0NA9	CP	Athenex Buffalo, NY
DMF0NA9	DE	Actinic keratosis

DMWTPCA	ID	DMWTPCA
DMWTPCA	DN	L-651582
DMWTPCA	HS	Phase 3
DMWTPCA	SN	Carboxyamidotriazole (CAI)
DMWTPCA	CP	National Cancer Institute
DMWTPCA	DT	Small molecular drug
DMWTPCA	PC	108144
DMWTPCA	MW	424.7
DMWTPCA	FM	C17H12Cl3N5O2
DMWTPCA	IC	InChI=1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)
DMWTPCA	CS	C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)CN3C(=C(N=N3)C(=O)N)N)Cl)Cl
DMWTPCA	IK	WNRZHQBJSXRYJK-UHFFFAOYSA-N
DMWTPCA	IU	5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]triazole-4-carboxamide
DMWTPCA	CA	CAS 99519-84-3
DMWTPCA	DE	Solid tumour/cancer

DMI3YLK	ID	DMI3YLK
DMI3YLK	DN	LA-EP2006
DMI3YLK	HS	Phase 3
DMI3YLK	CP	Sandoz
DMI3YLK	DE	Neutropenia

DMA2NYS	ID	DMA2NYS
DMA2NYS	DN	Lampalizumab
DMA2NYS	HS	Phase 3
DMA2NYS	CP	Genentech
DMA2NYS	DT	Antibody
DMA2NYS	DE	Geographic retinal atrophy

DMFJLB6	ID	DMFJLB6
DMFJLB6	DN	Lanabecestat
DMFJLB6	HS	Phase 3
DMFJLB6	SN	1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane
DMFJLB6	CP	AstraZeneca Wilmington, DE; Eli Lilly Indianapolis, IN
DMFJLB6	PC	67979346
DMFJLB6	MW	412.5
DMFJLB6	FM	C26H28N4O
DMFJLB6	IC	InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22?,25?,26-/m0/s1
DMFJLB6	CS	CC#CC1=CC(=CN=C1)C2=CC3=C(CC4([C@]35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2
DMFJLB6	IK	WKDNQONLGXOZRG-BOPKNSRXSA-N
DMFJLB6	CA	CAS 1383982-64-6
DMFJLB6	DE	Alzheimer disease

DM4EGPN	ID	DM4EGPN
DM4EGPN	DN	Lanperisone
DM4EGPN	HS	Phase 3
DM4EGPN	SN	NK-433
DM4EGPN	CP	Nippon Kayaku Co Ltd
DM4EGPN	DT	Small molecular drug
DM4EGPN	PC	198707
DM4EGPN	MW	285.3
DM4EGPN	FM	C15H18F3NO
DM4EGPN	IC	InChI=1S/C15H18F3NO/c1-11(10-19-8-2-3-9-19)14(20)12-4-6-13(7-5-12)15(16,17)18/h4-7,11H,2-3,8-10H2,1H3/t11-/m1/s1
DM4EGPN	CS	C[C@H](CN1CCCC1)C(=O)C2=CC=C(C=C2)C(F)(F)F
DM4EGPN	IK	RYZCWZZJFAKYHX-LLVKDONJSA-N
DM4EGPN	IU	(2R)-2-methyl-3-pyrrolidin-1-yl-1-[4-(trifluoromethyl)phenyl]propan-1-one
DM4EGPN	CA	CAS 116287-14-0
DM4EGPN	DE	Musculoskeletal disorder

DMMA0C7	ID	DMMA0C7
DMMA0C7	DN	Laquinamod
DMMA0C7	HS	Phase 3
DMMA0C7	SN	Laquinimod sodium; Laquinimod Sodium Salt; 248282-07-7; UNII-4H914M0CSP; Laquinimod sodium [USAN]; TV-5600; 4H914M0CSP; ABR-215062 SODIUM; Laquinimod sodium (USAN); sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate; SAIK-MS compound; ABR 215062 Sodium; SCHEMBL1991182; CHEMBL2103814; DTXSID50179538; QCR-166; JWHPPWBIIQMBQC-UHFFFAOYSA-M; AKOS027326368; TV 5600; FT-0670730; D08938; Sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin- 4-olate; 3-Quinolinecarboxamide, 5-chlo
DMMA0C7	CP	Active Biotech; Teva
DMMA0C7	DT	Small molecular drug
DMMA0C7	PC	23697158
DMMA0C7	MW	378.8
DMMA0C7	FM	C19H16ClN2NaO3
DMMA0C7	IC	InChI=1S/C19H17ClN2O3.Na/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24;/h4-11,23H,3H2,1-2H3;/q;+1/p-1
DMMA0C7	CS	CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)[O-].[Na+]
DMMA0C7	IK	JWHPPWBIIQMBQC-UHFFFAOYSA-M
DMMA0C7	IU	sodium;5-chloro-3-[ethyl(phenyl)carbamoyl]-1-methyl-2-oxoquinolin-4-olate
DMMA0C7	CA	CAS 248282-07-7
DMMA0C7	DE	Multiple sclerosis

DM3IWS8	ID	DM3IWS8
DM3IWS8	DN	Laquinimod
DM3IWS8	HS	Phase 3
DM3IWS8	SN	Laquinimod; 248281-84-7; 5-CHLORO-N-ETHYL-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE; ABR-215062; ABR 215062; 5-Chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid ethyl-phenyl-amide; UNII-908SY76S4G; CIVENTICHEM CV-4057; Laquinimod (ABR-215062); 908SY76S4G; N-Ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide; 5-chloro-n-ethyl-2-hydroxy-1-methyl-4-oxo-n-phenyl-1,4-dihydroquinoline-3-carboxamide; C19H17ClN2O3
DM3IWS8	CP	Teva Neuroscience
DM3IWS8	DT	Small molecular drug
DM3IWS8	PC	54677946
DM3IWS8	MW	356.8
DM3IWS8	FM	C19H17ClN2O3
DM3IWS8	IC	InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3
DM3IWS8	CS	CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O
DM3IWS8	IK	GKWPCEFFIHSJOE-UHFFFAOYSA-N
DM3IWS8	IU	5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
DM3IWS8	CA	CAS 248281-84-7
DM3IWS8	CB	CHEBI:134738
DM3IWS8	DE	Lupus; Multiple sclerosis; Huntington disease; Primary progressive multiple sclerosis

DMH2EA1	ID	DMH2EA1
DMH2EA1	DN	Laromustine
DMH2EA1	HS	Phase 3
DMH2EA1	SN	Cloretazine; Onrigin; Alkylating agents, Vion; SHP, Vion; Sulfonyl hydrazine prodrugs, Vion; VN-40101M; VNP-40101M; VNP-4090-CE; 90CE
DMH2EA1	CP	Vion Pharmaceuticals Inc
DMH2EA1	DT	Small molecular drug
DMH2EA1	PC	3081349
DMH2EA1	MW	307.8
DMH2EA1	FM	C6H14ClN3O5S2
DMH2EA1	IC	InChI=1S/C6H14ClN3O5S2/c1-8-6(11)10(17(3,14)15)9(5-4-7)16(2,12)13/h4-5H2,1-3H3,(H,8,11)
DMH2EA1	CS	CNC(=O)N(N(CCCl)S(=O)(=O)C)S(=O)(=O)C
DMH2EA1	IK	PVCULFYROUOVGJ-UHFFFAOYSA-N
DMH2EA1	IU	1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea
DMH2EA1	CA	CAS 173424-77-6
DMH2EA1	DE	Solid tumour/cancer

DMAJM12	ID	DMAJM12
DMAJM12	DN	LATIN T1D
DMAJM12	HS	Phase 3
DMAJM12	SN	NN9211
DMAJM12	CP	Novo Nordisk
DMAJM12	DE	Type-1 diabetes

DM09RKB	ID	DM09RKB
DM09RKB	DN	LC-150444
DM09RKB	HS	Phase 3
DM09RKB	SN	LCD15-0444; Dipeptidyl peptidase IV inhibitors (oral, type 2 diabetes), LG Life Sciences
DM09RKB	CP	LG Life Sciences Ltd
DM09RKB	DE	Type-2 diabetes

DMT4K0Z	ID	DMT4K0Z
DMT4K0Z	DN	L-citrulline
DMT4K0Z	HS	Phase 3
DMT4K0Z	SN	L-citrulline; citrulline; 372-75-8; H-cit-oh; delta-Ureidonorvaline; Sitrulline; N5-Carbamoyl-L-ornithine; L-Cytrulline; L(+)-citrulline; N5-(Aminocarbonyl)ornithine; N(delta)-Carbamylornithine; Citrulline, L-; alpha-Amino-delta-ureidovaleric acid; (S)-2-Amino-5-ureidopentanoic acid; N5-carbamoylornithine; d-ureidonorvaline; Ornithine, N5-(aminocarbonyl)-; L-2-Amino-5-ureidovaleric acid; L-Ornithine, N5-(aminocarbonyl)-; L-(+)-Citrulline; 2-Amino-5-ureidovaleric acid; L-citrullin; (2S)-2-amino-5-(carbamoylamino)pentanoic acid
DMT4K0Z	DT	Small molecular drug
DMT4K0Z	PC	9750
DMT4K0Z	MW	175.19
DMT4K0Z	FM	C6H13N3O3
DMT4K0Z	IC	InChI=1S/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1
DMT4K0Z	CS	C(C[C@@H](C(=O)O)N)CNC(=O)N
DMT4K0Z	IK	RHGKLRLOHDJJDR-BYPYZUCNSA-N
DMT4K0Z	IU	(2S)-2-amino-5-(carbamoylamino)pentanoic acid
DMT4K0Z	CA	CAS 372-75-8
DMT4K0Z	CB	CHEBI:16349
DMT4K0Z	DE	Acute lung injury

DMFLJHQ	ID	DMFLJHQ
DMFLJHQ	DN	LCQ908
DMFLJHQ	HS	Phase 3
DMFLJHQ	SN	Pradigastat; LCQ-908; 956136-95-1; UNII-2U23G6VNUZ; LCQ908; 2U23G6VNUZ; LCQ 908; Pradigastat [USAN:INN]; LCQ 908NXA; 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid; 2-{4-[4-(5-{[6-(trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl)phenyl]cyclohexyl}acetic acid; Pradigastat (USAN); LCQ908-NXA; SCHEMBL180536; GTPL7830; SCHEMBL1289309; CHEMBL2364624; SCHEMBL18286769; SCHEMBL16104874; GXALXAKNHIROPE-UHFFFAOYSA-N; BCP21089; ZINC253387875; AKOS027338695; DB12866; SB16971; CS-1222
DMFLJHQ	CP	Novartis
DMFLJHQ	DT	Small molecular drug
DMFLJHQ	PC	53387035
DMFLJHQ	MW	455.5
DMFLJHQ	FM	C25H24F3N3O2
DMFLJHQ	IC	InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33)
DMFLJHQ	CS	C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)NC4=CN=C(C=C4)C(F)(F)F
DMFLJHQ	IK	GXALXAKNHIROPE-UHFFFAOYSA-N
DMFLJHQ	IU	2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid
DMFLJHQ	CA	CAS 956136-95-1
DMFLJHQ	DE	Hepatitis C virus infection; Familial chylomicronemia syndrome; Hypertriglyceridemia

DMQP0X5	ID	DMQP0X5
DMQP0X5	DN	Lebrikizumab
DMQP0X5	HS	Phase 3
DMQP0X5	SN	RG3637
DMQP0X5	CP	Aerovance
DMQP0X5	DT	Monoclonal antibody
DMQP0X5	DE	Chronic obstructive pulmonary disease; Severe asthma; Atopic dermatitis; Idiopathic pulmonary fibrosis

DMMX75K	ID	DMMX75K
DMMX75K	DN	LEE011
DMMX75K	HS	Phase 3
DMMX75K	SN	Ribociclib; LEE011; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013
DMMX75K	CP	Novartis AG
DMMX75K	DT	Small molecular drug
DMMX75K	PC	44631912
DMMX75K	MW	434.5
DMMX75K	FM	C23H30N8O
DMMX75K	IC	InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)
DMMX75K	CS	CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5
DMMX75K	IK	RHXHGRAEPCAFML-UHFFFAOYSA-N
DMMX75K	IU	7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
DMMX75K	CA	CAS 1211441-98-3
DMMX75K	DE	Solid tumour/cancer; Breast cancer

DMSCGM8	ID	DMSCGM8
DMSCGM8	DN	LentiGlobin
DMSCGM8	HS	Phase 3
DMSCGM8	SN	Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), Genetix; Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), bluebird
DMSCGM8	CP	Bluebird bio
DMSCGM8	DE	Sickle-cell disorder; Beta thalassemia

DMSRIT4	ID	DMSRIT4
DMSRIT4	DN	Lenzilumab
DMSRIT4	HS	Phase 3
DMSRIT4	SN	lenzilumab; GTPL8935; KB003; KB-003
DMSRIT4	TC	Antiviral Agents
DMSRIT4	DT	Monoclonal antibody
DMSRIT4	DE	Coronavirus Disease 2019 (COVID-19)

DMOTCIU	ID	DMOTCIU
DMOTCIU	DN	Lerisetron
DMOTCIU	HS	Phase 3
DMOTCIU	SN	Lerisetron[inn]; 1-benzyl-2-piperazin-1-ylbenzimidazole
DMOTCIU	CP	FAES Farma
DMOTCIU	DT	Small molecular drug
DMOTCIU	PC	65997
DMOTCIU	MW	292.4
DMOTCIU	FM	C18H20N4
DMOTCIU	IC	InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2
DMOTCIU	CS	C1CN(CCN1)C2=NC3=CC=CC=C3N2CC4=CC=CC=C4
DMOTCIU	IK	PWWDCRQZITYKDV-UHFFFAOYSA-N
DMOTCIU	IU	1-benzyl-2-piperazin-1-ylbenzimidazole
DMOTCIU	CA	CAS 143257-98-1
DMOTCIU	DE	Vomiting; Testicular germ cell tumour; Nausea

DMAYC76	ID	DMAYC76
DMAYC76	DN	Levomequitazine
DMAYC76	HS	Phase 3
DMAYC76	SN	V-0114; V-0114CP
DMAYC76	CP	Pierre Fabre SA
DMAYC76	DT	Small molecular drug
DMAYC76	PC	6992284
DMAYC76	MW	322.5
DMAYC76	FM	C20H22N2S
DMAYC76	IC	InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2/t16-/m0/s1
DMAYC76	CS	C1CN2CCC1[C@@H](C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
DMAYC76	IK	HOKDBMAJZXIPGC-INIZCTEOSA-N
DMAYC76	IU	10-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine
DMAYC76	CA	CAS 88598-74-7
DMAYC76	DE	Seasonal allergic rhinitis

DM103O8	ID	DM103O8
DM103O8	DN	Ligelizumab
DM103O8	HS	Phase 3
DM103O8	SN	QGE031
DM103O8	CP	Novartis
DM103O8	DT	Antibody
DM103O8	DE	Chronic idiopathic urticaria

DMNM93X	ID	DMNM93X
DMNM93X	DN	Linagliptin
DMNM93X	HS	Phase 3
DMNM93X	SN	Linagliptin; BI 1356; Ondero; 668270-12-0; Tradjenta; BI-1356; Linagliptin (BI-1356); UNII-3X29ZEJ4R2; BI-1356-BS; CHEMBL237500; 3X29ZEJ4R2; CHEBI:68610; C25H28N8O2; Linagliptin
DMNM93X	TC	Antiviral Agents
DMNM93X	DT	Small molecular drug
DMNM93X	PC	10096344
DMNM93X	MW	472.5
DMNM93X	FM	C25H28N8O2
DMNM93X	IC	InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
DMNM93X	CS	CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
DMNM93X	IK	LTXREWYXXSTFRX-QGZVFWFLSA-N
DMNM93X	IU	8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
DMNM93X	CA	CAS 668270-12-0
DMNM93X	CB	CHEBI:68610
DMNM93X	DE	Coronavirus Disease 2019 (COVID-19)

DM0ZOGX	ID	DM0ZOGX
DM0ZOGX	DN	Linopirdine
DM0ZOGX	HS	Phase 3
DM0ZOGX	SN	AVIVA; Linopirine; DuP-996
DM0ZOGX	CP	Bristol-Myers Squibb Pharma Co
DM0ZOGX	DT	Small molecular drug
DM0ZOGX	PC	3932
DM0ZOGX	MW	391.5
DM0ZOGX	FM	C26H21N3O
DM0ZOGX	IC	InChI=1S/C26H21N3O/c30-25-26(18-20-10-14-27-15-11-20,19-21-12-16-28-17-13-21)23-8-4-5-9-24(23)29(25)22-6-2-1-3-7-22/h1-17H,18-19H2
DM0ZOGX	CS	C1=CC=C(C=C1)N2C3=CC=CC=C3C(C2=O)(CC4=CC=NC=C4)CC5=CC=NC=C5
DM0ZOGX	IK	YEJCDKJIEMIWRQ-UHFFFAOYSA-N
DM0ZOGX	IU	1-phenyl-3,3-bis(pyridin-4-ylmethyl)indol-2-one
DM0ZOGX	CA	CAS 105431-72-9
DM0ZOGX	CB	CHEBI:34823
DM0ZOGX	DE	Cognitive impairment

DMNF4UH	ID	DMNF4UH
DMNF4UH	DN	Liprotamase
DMNF4UH	HS	Phase 3
DMNF4UH	SN	LY3031642
DMNF4UH	CP	Lilly
DMNF4UH	DE	Cystic fibrosis

DMKZRBP	ID	DMKZRBP
DMKZRBP	DN	Litoxetine
DMKZRBP	HS	Phase 3
DMKZRBP	SN	Litoxetine; 86811-09-8; 4-(2-Naphthylmethoxy)piperidine; UNII-9980ST005G; CHEMBL471036; 9980ST005G; Litoxetinum; Litoxetina; Litoxetine [INN]; Litoxetinum [INN-Latin]; Litoxetina [INN-Spanish]; AC1L23OW; SCHEMBL119884; ZINC3647; CTK3E8854; DTXSID30235828; BDBM50278564; 4-(naphthalen-2-ylmethoxy)piperidine
DMKZRBP	DT	Small molecular drug
DMKZRBP	PC	65650
DMKZRBP	MW	241.33
DMKZRBP	FM	C16H19NO
DMKZRBP	IC	InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2
DMKZRBP	CS	C1CNCCC1OCC2=CC3=CC=CC=C3C=C2
DMKZRBP	IK	MJJDYOLPMGIWND-UHFFFAOYSA-N
DMKZRBP	IU	4-(naphthalen-2-ylmethoxy)piperidine
DMKZRBP	CA	CAS 86811-09-8
DMKZRBP	DE	Mood disorder

DMDN4ZP	ID	DMDN4ZP
DMDN4ZP	DN	Lixivaptan
DMDN4ZP	HS	Phase 3
DMDN4ZP	SN	168079-32-1; VPA-985; WAY-VPA-985; UNII-8F5X4B082E; VPA985; CHEMBL49429; CRTX-080; VPA 985; 8F5X4B082E; N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide; Lixar; Lixivaptan [USAN:INN]; Lixivaptan (USAN/INN); WAY VPA-985; Lixivaptan (VPA-985); AC1L59LM; WAY-VPA 985; GTPL2238; SCHEMBL1649340; DTXSID00168472; PPHTXRNHTVLQED-UHFFFAOYSA-N; ZINC600399; EX-A1129; BCP09167; BDBM50065115; AKOS022181388; AN-1842; CS-7512; API0009250; NCGC00485402-01;  VPA985; BF-Derm1
DMDN4ZP	CP	Wyeth-Ayerst; Cardiokine
DMDN4ZP	DT	Small molecular drug
DMDN4ZP	PC	172997
DMDN4ZP	MW	473.9
DMDN4ZP	FM	C27H21ClFN3O2
DMDN4ZP	IC	InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
DMDN4ZP	CS	CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
DMDN4ZP	IK	PPHTXRNHTVLQED-UHFFFAOYSA-N
DMDN4ZP	IU	N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
DMDN4ZP	CA	CAS 168079-32-1
DMDN4ZP	DE	Skin infection; Congestive heart failure; Hyponatraemia

DM4OAIU	ID	DM4OAIU
DM4OAIU	DN	LMI070
DM4OAIU	HS	Phase 3
DM4OAIU	SN	branaplam; Branaplam; 1562338-42-4; NVS-SM1; UNII-P12R69543A; LMI-070; P12R69543A; 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol; Branaplam [INN]; SCHEMBL15475826; LMI070 (NVS-SM1); STWTUEAWRAIWJG-UHFFFAOYSA-N; BCP19909; ZINC146605125; AKOS030526592; CS-5319; HY-19620; Phenol, 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethyl-4-piperidinyl)oxy)-3-pyridazinyl)-
DM4OAIU	CP	Novartis Pharmaceuticals East Hanover, NJ
DM4OAIU	PC	135565042
DM4OAIU	MW	393.5
DM4OAIU	FM	C22H27N5O2
DM4OAIU	IC	InChI=1S/C22H27N5O2/c1-21(2)10-16(11-22(3,4)27-21)29-20-8-7-18(25-26-20)17-6-5-14(9-19(17)28)15-12-23-24-13-15/h5-9,12-13,16,27-28H,10-11H2,1-4H3,(H,23,24)
DM4OAIU	CS	CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=C3)C4=CNN=C4)O)C
DM4OAIU	IK	STWTUEAWRAIWJG-UHFFFAOYSA-N
DM4OAIU	IU	5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]phenol
DM4OAIU	CA	CAS 1562338-42-4
DM4OAIU	DE	Spinal muscular atrophy

DMOFIBM	ID	DMOFIBM
DMOFIBM	DN	LMT-X
DMOFIBM	HS	Phase 3
DMOFIBM	SN	Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx
DMOFIBM	CP	TauRx Therapeutics Pte Ltd
DMOFIBM	DE	Acute myeloid leukaemia; Alzheimer disease

DM9EZM0	ID	DM9EZM0
DM9EZM0	DN	LNP023
DM9EZM0	HS	Phase 3
DM9EZM0	SN	Iptacopan; LNP-023; UNII-8E05T07Z6W; 8E05T07Z6W; 1644670-37-0; 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid; 4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; Iptacopan [INN]; CHEMBL4594448; SCHEMBL16400416; GTPL10710; US9682968, Example-26a; BDBM160475; ZINC223246892; compound 41 [PMID: 32073845]; HY-127105; CS-0093107; 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid; Benzoic acid, 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-2-piperidinyl)-; JGQ
DM9EZM0	CP	Novartis
DM9EZM0	DT	Small molecular drug
DM9EZM0	PC	90467622
DM9EZM0	MW	422.5
DM9EZM0	FM	C25H30N2O4
DM9EZM0	IC	InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1
DM9EZM0	CS	CCO[C@H]1CCN([C@@H](C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC
DM9EZM0	IK	RENRQMCACQEWFC-UGKGYDQZSA-N
DM9EZM0	IU	4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid
DM9EZM0	CA	CAS 1644670-37-0
DM9EZM0	DE	IgA nephropathy; Paroxysmal nocturnal haemoglobinuria

DMQNVR8	ID	DMQNVR8
DMQNVR8	DN	Lopinavir + ritonavir
DMQNVR8	HS	Phase 3
DMQNVR8	SN	Aluviran + norvir; Kaletra
DMQNVR8	TC	Antiviral Agents
DMQNVR8	DT	Combination drug
DMQNVR8	PC	11979606
DMQNVR8	MW	1349.7
DMQNVR8	FM	C74H96N10O10S2
DMQNVR8	IC	InChI=1S/C37H48N6O5S2.C37H48N4O5/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30;1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46);5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t28-,31-,32-,33-;30-,31-,32-,34-/m00/s1
DMQNVR8	CS	CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
DMQNVR8	IK	OFFWOVJBSQMVPI-RMLGOCCBSA-N
DMQNVR8	IU	(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide;1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMQNVR8	CA	CAS 369372-47-4
DMQNVR8	DE	Coronavirus Disease 2019 (COVID-19)

DMX0O9U	ID	DMX0O9U
DMX0O9U	DN	Lopinavir + ritonavir + favipiravir
DMX0O9U	HS	Phase 3
DMX0O9U	SN	Aluviran + norvir + T-705
DMX0O9U	TC	Antiviral Agents
DMX0O9U	DT	Combination drug
DMX0O9U	DE	Coronavirus Disease 2019 (COVID-19)

DMNY05F	ID	DMNY05F
DMNY05F	DN	Lopinavir + ritonavir + oseltamivir
DMNY05F	HS	Phase 3
DMNY05F	SN	Aluviran + norvir + tamiflu
DMNY05F	TC	Antiviral Agents
DMNY05F	DT	Combination drug
DMNY05F	DE	Coronavirus Disease 2019 (COVID-19)

DMTL5Q0	ID	DMTL5Q0
DMTL5Q0	DN	Losartan
DMTL5Q0	HS	Phase 3
DMTL5Q0	SN	Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan
DMTL5Q0	CP	Merck & Co
DMTL5Q0	TC	Antiviral Agents
DMTL5Q0	DT	Small molecular drug
DMTL5Q0	PC	3961
DMTL5Q0	MW	422.9
DMTL5Q0	FM	C22H23ClN6O
DMTL5Q0	IC	InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
DMTL5Q0	CS	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
DMTL5Q0	IK	PSIFNNKUMBGKDQ-UHFFFAOYSA-N
DMTL5Q0	IU	[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
DMTL5Q0	CA	CAS 114798-26-4
DMTL5Q0	CB	CHEBI:6541
DMTL5Q0	DE	Discovery agent; Hypertension; Coronavirus Disease 2019 (COVID-19)

DMIL37Z	ID	DMIL37Z
DMIL37Z	DN	Losmapimod
DMIL37Z	HS	Phase 3
DMIL37Z	SN	585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587
DMIL37Z	CP	GSK
DMIL37Z	DT	Small molecular drug
DMIL37Z	PC	11552706
DMIL37Z	MW	383.5
DMIL37Z	FM	C22H26FN3O2
DMIL37Z	IC	InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)
DMIL37Z	CS	CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C
DMIL37Z	IK	KKYABQBFGDZVNQ-UHFFFAOYSA-N
DMIL37Z	IU	6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
DMIL37Z	CA	CAS 585543-15-3
DMIL37Z	CB	CHEBI:131167
DMIL37Z	DE	Acute coronary syndrome

DMWGRQD	ID	DMWGRQD
DMWGRQD	DN	LU AE58054
DMWGRQD	HS	Phase 3
DMWGRQD	SN	Idalopirdine; Lu AE58054; 467459-31-0; LU-AE58054; UNII-59WCJ0YNWM; LU AE 58054; 59WCJ0YNWM; 2-(6-fluoro-1H-indol-3-yl)-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine; 1H-Indole-3-ethanamine,6-fluoro-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-; 1H-Indole-3-ethanamine, 6-fluoro-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-; Idalopirdine [USAN:INN]; Idlopirdine; Idalopirdine (USAN/INN); Lu AE58054;Idalopirdine; SCHEMBL762762; Idalopirdine(Lu-AE-58054); GTPL8689; CHEMBL3286580; C20H19F5N2O; EX-A844
DMWGRQD	CP	Lundbeck
DMWGRQD	DT	Small molecular drug
DMWGRQD	PC	21071390
DMWGRQD	MW	398.4
DMWGRQD	FM	C20H19F5N2O
DMWGRQD	IC	InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2
DMWGRQD	CS	C1=CC(=CC(=C1)OCC(C(F)F)(F)F)CNCCC2=CNC3=C2C=CC(=C3)F
DMWGRQD	IK	YBAWYTYNMZWMMJ-UHFFFAOYSA-N
DMWGRQD	IU	2-(6-fluoro-1H-indol-3-yl)-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine
DMWGRQD	CA	CAS 467459-31-0
DMWGRQD	DE	Schizophrenia

DMNAYUJ	ID	DMNAYUJ
DMNAYUJ	DN	Lu AF35700
DMNAYUJ	HS	Phase 3
DMNAYUJ	CP	Lundbeck Deerfield, IL
DMNAYUJ	DE	Schizophrenia

DMMLXA9	ID	DMMLXA9
DMMLXA9	DN	LX-4211
DMMLXA9	HS	Phase 3
DMMLXA9	SN	Sotagliflozin; 1018899-04-1; LX-4211; LX4211; UNII-6B4ZBS263Y; 6B4ZBS263Y; AK170751; (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol; b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-;b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-; Sotagliflozin [USAN:INN]; beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)-; LX 4211; Tube103; LP 802034
DMMLXA9	CP	Lexicon Pharmaceuticals
DMMLXA9	DT	Small molecular drug
DMMLXA9	PC	24831714
DMMLXA9	MW	424.9
DMMLXA9	FM	C21H25ClO5S
DMMLXA9	IC	InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
DMMLXA9	CS	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl
DMMLXA9	IK	QKDRXGFQVGOQKS-CRSSMBPESA-N
DMMLXA9	IU	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol
DMMLXA9	CA	CAS 1018899-04-1
DMMLXA9	DE	Type-2 diabetes; Cardiovascular disease; Type-1 diabetes

DM1BXMY	ID	DM1BXMY
DM1BXMY	DN	LY2605541
DM1BXMY	HS	Phase 3
DM1BXMY	SN	UNII-6Y83I5F10I; Insulin peglispro [USAN:INN]; INSULIN PEGLISPRO; LY2605541; 6Y83I5F10I; 1200440-65-8; LY 2605541; Polyethylene glycol 20,000 pegylated insulin lispro:(28B-(6-N-((omega-methoxypoly(oxyethylene))carbonyl)-L-lysine),29B-L-proline)human insulin; Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy-, 28B-ester with 28B-(N6-carboxy-L- lysine)-29B-L-prolineinsulin (human)
DM1BXMY	CP	Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DM1BXMY	DT	Small molecular drug
DM1BXMY	PC	71301236
DM1BXMY	MW	5892
DM1BXMY	FM	C261H387N65O79S6
DM1BXMY	IC	InChI=1S/C261H387N65O79S6/c1-30-134(23)208(317-196(343)107-262)255(397)321-207(133(21)22)251(393)290-160(76-83-203(353)354)219(361)285-157(72-79-192(265)339)223(365)312-186-119-409-410-120-187-246(388)309-181(114-328)243(385)297-164(91-126(7)8)226(368)298-170(98-143-54-62-149(333)63-55-143)229(371)286-155(70-77-190(263)337)220(362)293-163(90-125(5)6)224(366)288-159(75-82-202(351)352)222(364)306-177(104-193(266)340)236(378)301-172(100-145-58-66-151(335)67-59-145)232(374)313-185-118-408-407-117-184(216(358)276-110-197(344)281-154(73-80-200(347)348)218(360)284-153(52-43-85-273-260(269)270)214(356)275-111-198(345)282-168(95-140-45-35-32-36-46-140)228(370)300-169(96-141-47-37-33-38-48-141)231(373)302-174(101-146-60-68-152(336)69-61-146)241(383)323-210(137(26)330)256(398)291-161(51-41-42-84-274-261(403)405-88-87-404-29)258(400)326-86-44-53-189(326)249(391)325-212(139(28)332)259(401)402)315-253(395)206(132(19)20)319-238(380)166(93-128(11)12)295-230(372)171(99-144-56-64-150(334)65-57-144)299-225(367)162(89-124(3)4)292-213(355)136(25)280-217(359)158(74-81-201(349)350)289-250(392)204(130(15)16)318-239(381)167(94-129(13)14)296-234(376)176(103-148-109-272-123-279-148)305-242(384)180(113-327)283-199(346)112-277-215(357)183(116-406-411-121-188(314-247(186)389)248(390)324-211(138(27)331)257(399)310-182(115-329)244(386)322-209(135(24)31-2)254(396)316-187)311-227(369)165(92-127(9)10)294-233(375)175(102-147-108-271-122-278-147)304-221(363)156(71-78-191(264)338)287-235(377)179(106-195(268)342)308-252(394)205(131(17)18)320-240(382)173(97-142-49-39-34-40-50-142)303-237(379)178(105-194(267)341)307-245(185)387/h32-40,45-50,54-69,108-109,122-139,153-189,204-212,327-336H,30-31,41-44,51-53,70-107,110-121,262H2,1-29H3,(H2,263,337)(H2,264,338)(H2,265,339)(H2,266,340)(H2,267,341)(H2,268,342)(H,271,278)(H,272,279)(H,274,403)(H,275,356)(H,276,358)(H,277,357)(H,280,359)(H,281,344)(H,282,345)(H,283,346)(H,284,360)(H,285,361)(H,286,371)(H,287,377)(H,288,366)(H,289,392)(H,290,393)(H,291,398)(H,292,355)(H,293,362)(H,294,375)(H,295,372)(H,296,376)(H,297,385)(H,298,368)(H,299,367)(H,300,370)(H,301,378)(H,302,373)(H,303,379)(H,304,363)(H,305,384)(H,306,364)(H,307,387)(H,308,394)(H,309,388)(H,310,399)(H,311,369)(H,312,365)(H,313,374)(H,314,389)(H,315,395)(H,316,396)(H,317,343)(H,318,381)(H,319,380)(H,320,382)(H,321,397)(H,322,386)(H,323,383)(H,324,390)(H,325,391)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,401,402)(H4,269,270,273)/t134-,135-,136-,137+,138+,139+,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,204-,205-,206-,207-,208-,209-,210-,211-,212-/m0/s1
DM1BXMY	CS	CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@H]3C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC4=CN=CN4)CCC(=O)N)CC(=O)N)C(C)C)CC5=CC=CC=C5)CC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC6=CC=C(C=C6)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC7=CC=C(C=C7)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CC9=CC=CC=C9)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCNC(=O)OCCOC)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC2=CC=C(C=C2)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DM1BXMY	IK	UFIPGFMPJACHTH-HXDLXPBZSA-N
DM1BXMY	IU	(4S)-4-[[2-[[(aS,1R,3aS,6R,6aS,9S,12S,13aR,15S,18R,21S,24S,27S,30S,33S,36S,39S,42S,45R,50R,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S,88S,91S,94S,97S)-13a-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6a,39,97-tris(2-amino-2-oxoethyl)-30,94-bis(3-amino-3-oxopropyl)-3a-benzyl-15-[(2S)-butan-2-yl]-36,68-bis(2-carboxyethyl)-9-[(1R)-1-hydroxyethyl]-12,21,80-tris(hydroxymethyl)-27,42,59-tris[(4-hydroxyphenyl)methyl]-77,91-bis(1H-imidazol-5-ylmethyl)-65-methyl-24,33,56,62,74,88-hexakis(2-methylpropyl)-2a,5a,7,8a,10,13,14a,16,19,22,25,28,31,34,37,40,43,52,55,58,61,64,67,70,73,76,79,82,85,87,90,93,96,99-tetratriacontaoxo-a,53,71-tri(propan-2-yl)-3,4,10a,11a,47,48-hexathia-1a,4a,7a,8,11,14,15a,17,20,23,26,29,32,35,38,41,44,51,54,57,60,63,66,69,72,75,78,81,84,86,89,92,95,98-tetratriacontazatricyclo[43.40.23.76,18]pentadecahectane-50-carbonyl]amino]acetyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-6-(2-methoxyethoxycarbonylamino)-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM1BXMY	DE	Type-1/2 diabetes

DMEZ0H5	ID	DMEZ0H5
DMEZ0H5	DN	LY2963016
DMEZ0H5	HS	Phase 3
DMEZ0H5	CP	Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DMEZ0H5	DE	Type-1/2 diabetes

DMWZIRJ	ID	DMWZIRJ
DMWZIRJ	DN	LY404039
DMWZIRJ	HS	Phase 3
DMWZIRJ	SN	LY 404039; LY-404039; (1R,2S,5R,6R)-2-amino-4,4-dioxo-4$l^{6}-thiabicyclo[3.1.0]hexane-2,6-dicarboxylic Acid; 4-amino-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid
DMWZIRJ	CP	Eli Lilly
DMWZIRJ	DT	Small molecular drug
DMWZIRJ	PC	9834591
DMWZIRJ	MW	235.22
DMWZIRJ	FM	C7H9NO6S
DMWZIRJ	IC	InChI=1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1
DMWZIRJ	CS	C1[C@]([C@@H]2[C@H]([C@@H]2S1(=O)=O)C(=O)O)(C(=O)O)N
DMWZIRJ	IK	AVDUGNCTZRCAHH-MDASVERJSA-N
DMWZIRJ	IU	(1R,4S,5S,6S)-4-amino-2,2-dioxo-2lambda6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
DMWZIRJ	CA	CAS 635318-11-5
DMWZIRJ	CB	CHEBI:94640
DMWZIRJ	DE	Schizophrenia

DM7WORZ	ID	DM7WORZ
DM7WORZ	DN	LY-686017
DM7WORZ	HS	Phase 3
DM7WORZ	SN	NK1 antagonist (anxiety/alcoholism), Eli Lilly
DM7WORZ	CP	Eli Lilly & Co
DM7WORZ	DT	Small molecular drug
DM7WORZ	PC	9916461
DM7WORZ	MW	587.9
DM7WORZ	FM	C28H16ClF6N5O
DM7WORZ	IC	InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2
DM7WORZ	CS	C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl
DM7WORZ	IK	CAVRKWRKTNINFF-UHFFFAOYSA-N
DM7WORZ	IU	[2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone
DM7WORZ	CA	CAS 622370-35-8
DM7WORZ	DE	Alcohol dependence; Atopic dermatitis

DM6LVCQ	ID	DM6LVCQ
DM6LVCQ	DN	LY-CoV555
DM6LVCQ	HS	Phase 3
DM6LVCQ	SN	LY3819253
DM6LVCQ	CP	Lilly; AbCellera
DM6LVCQ	DT	Antibody
DM6LVCQ	DE	Coronavirus Disease 2019 (COVID-19)

DMGNC6T	ID	DMGNC6T
DMGNC6T	DN	M-0011
DMGNC6T	HS	Phase 3
DMGNC6T	SN	N-0011; RhLAMAN, Zymenex; Recombinant human alpha-mannosidase (alpha mannosidosis), Zymenex
DMGNC6T	CP	Zymenex A/S
DMGNC6T	DE	Alpha-mannosidosis

DM7ZFBA	ID	DM7ZFBA
DM7ZFBA	DN	M100907
DM7ZFBA	HS	Phase 3
DM7ZFBA	SN	Volinanserin; 139290-65-6; UNII-EW71EE171J; (R)-(2,3-Dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol; CHEMBL74355; EW71EE171J; (R)-(+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUORO-PHENYL)ETHYL]-4-PIPERIDINE METHANOL; M-100907; (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol; Volinanserin [INN]; Serotonin 5-HT2 Receptor Antagonists; VOLINANSERIN
DM7ZFBA	DT	Small molecular drug
DM7ZFBA	PC	5311271
DM7ZFBA	MW	373.5
DM7ZFBA	FM	C22H28FNO3
DM7ZFBA	IC	InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1
DM7ZFBA	CS	COC1=CC=CC(=C1OC)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O
DM7ZFBA	IK	HXTGXYRHXAGCFP-OAQYLSRUSA-N
DM7ZFBA	IU	(R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol
DM7ZFBA	CA	CAS 139290-65-6
DM7ZFBA	DE	Sleep-wake disorder

DMZ6VD5	ID	DMZ6VD5
DMZ6VD5	DN	M-518101
DMZ6VD5	HS	Phase 3
DMZ6VD5	CP	Maruho Co Ltd
DMZ6VD5	DE	Psoriasis vulgaris; Plaque psoriasis

DM1PRT6	ID	DM1PRT6
DM1PRT6	DN	M710
DM1PRT6	HS	Phase 3
DM1PRT6	SN	637-01-4; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-tetramethylbenzene-1,4-diamine dihydrochloride; N,N,N',N'-Tetramethyl-1,4-phenylenediamine Dihydrochloride; UNII-66W8HKA51X; MFCD00012482; 66W8HKA51X; tetramethyl-p-phenylenediamine dihydrochloride; 1,4-Benzenediamine, N,N,N',N'-tetramethyl-, dihydrochloride; NSC36730; 1,4-Benzenediamine, N1,N1,N4,N4-tetramethyl-, hydrochloride (1:2); 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride; Wursters Reagent; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, 99%; EINECS 211-274-8; NSC 36730; TMPPD; ACMC-1B8O0; SCHEMBL379125; DTXSID2060915; N,N,N',N'-Tetramethyl-para-phenylenediamine dihydrochloride; ANW-34710; AKOS005254702; MCULE-3840175847; VZ32824; AS-14819; SY061584; 3-(4-Bromo-1H-pyrazol-1-yl)propanoicacid; DB-054526; FT-0629355; ST50308398; Tetramethyl-p-phenylene diamine hydrochloride; 1,4-Bis(dimethylamino)benzene dihydrochloride; X-4255; N,N,N',N'-Tetramethyl-p-phenylenediamine 2HCl; N,N,N',N'-Tetramethyl-p-phenylenediamine DiHCl; W-104885; Q27264036; [4-(dimethylamino)phenyl]dimethylamine, chloride, chloride; N,N,N\\',N\\'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-Tetramethyl-1,4-benzenediamine Dihydrochloride; p-Phenylenediamine, N,N,N',N'-tetramethyl-, dihydrochloride (8CI); N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=95%, powder; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=97.0% (AT)
DM1PRT6	CP	Momenta Pharmaceuticals; Mylan
DM1PRT6	DT	Small molecular drug
DM1PRT6	PC	71561
DM1PRT6	MW	237.17
DM1PRT6	FM	C10H18Cl2N2
DM1PRT6	IC	InChI=1S/C10H16N2.2ClH/c1-11(2)9-5-7-10(8-6-9)12(3)4;;/h5-8H,1-4H3;2*1H
DM1PRT6	CS	CN(C)C1=CC=C(C=C1)N(C)C.Cl.Cl
DM1PRT6	IK	FBHKTSXMTASXFJ-UHFFFAOYSA-N
DM1PRT6	IU	1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride
DM1PRT6	CA	CAS 637-01-4
DM1PRT6	DE	Diabetic macular edema

DM8D13S	ID	DM8D13S
DM8D13S	DN	MABp1
DM8D13S	HS	Phase 3
DM8D13S	CP	Xbiotech Austin, TX
DM8D13S	DE	Type-2 diabetes; Acne vulgaris; Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Pyoderma gangrenosum; Colorectal cancer; Peripheral vascular disease

DMVXUR0	ID	DMVXUR0
DMVXUR0	DN	Magrolimab
DMVXUR0	HS	Phase 3
DMVXUR0	SN	GS-4721
DMVXUR0	CP	Gilead Sciences
DMVXUR0	DT	Antibody
DMVXUR0	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DMJPGUA	ID	DMJPGUA
DMJPGUA	DN	Manidipine
DMJPGUA	HS	Phase 3
DMJPGUA	SN	manidipine; 89226-50-6; Franidipine; 120092-68-4; Manidipine 6300; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Iperten; Artedil; Manidipine [INN]; Manidipine (Manyper); C35H38N4O6; CHEMBL312176; Manidipine (INN); 2-(4-Diphenylmethyl-1-piperazinyl)ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; 2-[4-(diphenylmethyl)piperazin-1-yl]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin
DMJPGUA	DT	Small molecular drug
DMJPGUA	PC	4008
DMJPGUA	MW	610.7
DMJPGUA	FM	C35H38N4O6
DMJPGUA	IC	InChI=1S/C35H38N4O6/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-16,23,32-33,36H,17-22H2,1-3H3
DMJPGUA	CS	CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC
DMJPGUA	IK	ANEBWFXPVPTEET-UHFFFAOYSA-N
DMJPGUA	IU	5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMJPGUA	CA	CAS 89226-50-6
DMJPGUA	CB	CHEBI:135849

DMR23M1	ID	DMR23M1
DMR23M1	DN	Mapracorat
DMR23M1	HS	Phase 3
DMR23M1	SN	BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb
DMR23M1	CP	Bayer Schering Pharma AG
DMR23M1	DT	Small molecular drug
DMR23M1	PC	24795088
DMR23M1	MW	462.5
DMR23M1	FM	C25H26F4N2O2
DMR23M1	IC	InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1
DMR23M1	CS	CC1=NC2=C(C=C1)C(=CC=C2)NC[C@](CC(C)(C)C3=CC(=CC4=C3OCC4)F)(C(F)(F)F)O
DMR23M1	IK	VJGFOYBQOIPQFY-XMMPIXPASA-N
DMR23M1	IU	(2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol
DMR23M1	CA	CAS 887375-26-0
DMR23M1	DE	Ocular disease

DMJCF1O	ID	DMJCF1O
DMJCF1O	DN	Maralixibat
DMJCF1O	HS	Phase 3
DMJCF1O	SN	Lopixibat; UNII-UYB6UOF69L; Maralixibat [USAN]; 716313-53-0; UYB6UOF69L; CHEMBL363392; Maralixibat (USAN); Lopixibat cation; CHEMBL17879; 1-(4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium; LUM001 CATION; LUM-001 CATION; SCHEMBL10013954; BDBM50140282; 4-Aza-1-azoniabicyclo(2.2.2)octane, 1-((4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)methyl)phenyl)methyl)-; D10951; Q27291331; (4R,5R)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1$l^{6}-benzothiepin-4-ol; 1-{4-[4-((4R,5R)-3,3-Dibutyl-7-dimethylamino-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-1lambda*6*-benzo[b]thiepin-5-yl)-phenoxymethyl]-benzyl}-4-aza-1-azonia-bicyclo[2.2.2]octane; chloride
DMJCF1O	CP	Mirum Pharmaceuticals
DMJCF1O	DT	Small molecular drug
DMJCF1O	PC	9831643
DMJCF1O	MW	675
DMJCF1O	FM	C40H56N3O4S+
DMJCF1O	IC	InChI=1S/C40H56N3O4S/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3/q+1/t38-,39-/m1/s1
DMJCF1O	CS	CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC
DMJCF1O	IK	STPKWKPURVSAJF-LJEWAXOPSA-N
DMJCF1O	IU	(4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol
DMJCF1O	CA	CAS 716313-53-0
DMJCF1O	DE	Alagille syndrome; Progressive familial intrahepatic cholestasis

DM3GTAL	ID	DM3GTAL
DM3GTAL	DN	Maribavir
DM3GTAL	HS	Phase 3
DM3GTAL	SN	176161-24-3; Benzimidavir; (2S,3S,4R,5S)-2-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 1263W94; UNII-PTB4X93HE1; PTB4X93HE1; 5,6-Dichloro-2-(isopropylamino)-1-(beta-L-ribofuranosyl)-1H-benzimidazole; 5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine; (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol; Maribavir [USAN:INN:BAN]; Camvia; C15H19Cl2N3O4; Camvia(TM); Camvia (TN); Bzurea
DM3GTAL	DT	Small molecular drug
DM3GTAL	PC	471161
DM3GTAL	MW	376.2
DM3GTAL	FM	C15H19Cl2N3O4
DM3GTAL	IC	InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1
DM3GTAL	CS	CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl
DM3GTAL	IK	KJFBVJALEQWJBS-XUXIUFHCSA-N
DM3GTAL	IU	(2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM3GTAL	CA	CAS 176161-24-3
DM3GTAL	DE	Cytomegalovirus infection

DM6V34C	ID	DM6V34C
DM6V34C	DN	Marimastat
DM6V34C	HS	Phase 3
DM6V34C	SN	Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
DM6V34C	CP	British Biotech plc; Schering-Plough
DM6V34C	TC	Anticancer Agents
DM6V34C	DT	Small molecular drug
DM6V34C	PC	119031
DM6V34C	MW	331.41
DM6V34C	FM	C15H29N3O5
DM6V34C	IC	InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
DM6V34C	CS	CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@H](C(=O)NC)C(C)(C)C
DM6V34C	IK	OCSMOTCMPXTDND-OUAUKWLOSA-N
DM6V34C	IU	(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide
DM6V34C	CA	CAS 154039-60-8
DM6V34C	CB	CHEBI:50662
DM6V34C	DE	Lung cancer; Pancreatic cancer

DME9QGW	ID	DME9QGW
DME9QGW	DN	Marizomib
DME9QGW	HS	Phase 3
DME9QGW	SN	MARIZOMIB; salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1
DME9QGW	CP	Nereus Pharmaceuticals
DME9QGW	DT	Small molecular drug
DME9QGW	PC	11347535
DME9QGW	MW	313.77
DME9QGW	FM	C15H20ClNO4
DME9QGW	IC	InChI=1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
DME9QGW	CS	C[C@]12[C@H](C(=O)N[C@]1(C(=O)O2)[C@H]([C@H]3CCCC=C3)O)CCCl
DME9QGW	IK	NGWSFRIPKNWYAO-SHTIJGAHSA-N
DME9QGW	IU	(1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
DME9QGW	CA	CAS 437742-34-2
DME9QGW	CB	CHEBI:48045
DME9QGW	DE	Solid tumour/cancer; Malignant glioma; Multiple myeloma; Glioblastoma of brain

DMRSNEU	ID	DMRSNEU
DMRSNEU	DN	Masitinib
DMRSNEU	HS	Phase 3
DMRSNEU	SN	Masitinib; 790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
DMRSNEU	CP	AB Science
DMRSNEU	DT	Small molecular drug
DMRSNEU	PC	10074640
DMRSNEU	MW	498.6
DMRSNEU	FM	C28H30N6OS
DMRSNEU	IC	InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
DMRSNEU	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5
DMRSNEU	IK	WJEOLQLKVOPQFV-UHFFFAOYSA-N
DMRSNEU	IU	4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
DMRSNEU	CA	CAS 790299-79-5
DMRSNEU	CB	CHEBI:63450
DMRSNEU	DE	Amyotrophic lateral sclerosis; Metastatic gastric or gastroesophageal junction cancer; Multiple sclerosis; Gastrointestinal stromal tumour; Ovarian cancer; Pancreatic cancer

DMK9BP2	ID	DMK9BP2
DMK9BP2	DN	Mavacamten
DMK9BP2	HS	Phase 3
DMK9BP2	SN	SAR-439152; SAR 439152; SAR439152; MYK-461; MYK 461; MYK461
DMK9BP2	CP	MyoKardia South San Francisco, CA Sanofi Bridgewater, NJ
DMK9BP2	PC	117761397
DMK9BP2	MW	273.33
DMK9BP2	FM	C15H19N3O2
DMK9BP2	IC	InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
DMK9BP2	CS	C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C
DMK9BP2	IK	RLCLASQCAPXVLM-NSHDSACASA-N
DMK9BP2	IU	6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
DMK9BP2	CA	CAS 1642288-47-8
DMK9BP2	DE	Obstructive hypertrophic cardiomyopathy

DMBPY9Z	ID	DMBPY9Z
DMBPY9Z	DN	MBG453
DMBPY9Z	HS	Phase 3
DMBPY9Z	CP	Novartis Oncology East Hanover, NJ
DMBPY9Z	DE	Solid tumour/cancer; Myelodysplastic syndrome

DMVZ57G	ID	DMVZ57G
DMVZ57G	DN	MD1003
DMVZ57G	HS	Phase 3
DMVZ57G	CP	MedDay Pharmaceuticals Paris, France
DMVZ57G	DE	Multiple sclerosis

DM5X849	ID	DM5X849
DM5X849	DN	MEDI4736
DM5X849	HS	Phase 3
DM5X849	CP	AstraZeneca
DM5X849	DT	Monoclonal antibody
DM5X849	DE	Solid tumour/cancer

DM4W8RE	ID	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	HS	Phase 3
DM4W8RE	SN	Melagatran; 159776-70-2; UNII-2A9QP32MD4; Melagatran [INN]; 2A9QP32MD4; CHEBI:43966; MELAGATRAN (ASTRA-ZENECA); C22H31N5O4; Melagatran (INN); N-((R)-(((2S)-2-((-p-Amidobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; [((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID; MEL; H-319/68; N-((R)-(((2S)-2-((p-Amidinobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine
DM4W8RE	DT	Small molecular drug
DM4W8RE	PC	183797
DM4W8RE	MW	429.5
DM4W8RE	FM	C22H31N5O4
DM4W8RE	IC	InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
DM4W8RE	CS	C1CCC(CC1)[C@H](C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)C(=N)N)NCC(=O)O
DM4W8RE	IK	DKWNMCUOEDMMIN-PKOBYXMFSA-N
DM4W8RE	IU	2-[[(1R)-2-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]azetidin-1-yl]-1-cyclohexyl-2-oxoethyl]amino]acetic acid
DM4W8RE	CA	CAS 159776-70-2
DM4W8RE	CB	CHEBI:43966

DMQEC6Z	ID	DMQEC6Z
DMQEC6Z	DN	Melanoma vaccine
DMQEC6Z	HS	Phase 3
DMQEC6Z	SN	NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie
DMQEC6Z	CP	Institut Curie
DMQEC6Z	DT	Vaccine
DMQEC6Z	DE	Melanoma

DM8Z0I3	ID	DM8Z0I3
DM8Z0I3	DN	MF-101
DM8Z0I3	HS	Phase 3
DM8Z0I3	SN	DW-700; DW-700); Menopause Formula-101; Estrogen receptor beta agonist (menopausal symptoms), Bionovo; Liquiritigenin (menopausal symptoms), Bionovo
DM8Z0I3	CP	Bionovo Inc; Daewon Pharm Co Ltd
DM8Z0I3	DE	Hepatitis virus infection

DMRKTCP	ID	DMRKTCP
DMRKTCP	DN	MGA012
DMRKTCP	HS	Phase 3
DMRKTCP	SN	INCMGA0012; Retifanlimab
DMRKTCP	CP	MacroGenics
DMRKTCP	DT	Antibody
DMRKTCP	DE	Solid tumour/cancer; Metastatic colorectal cancer; Non-small-cell lung cancer; Merkel cell carcinoma; Penile squamous cancer

DMCJRL1	ID	DMCJRL1
DMCJRL1	DN	MGN-1703
DMCJRL1	HS	Phase 3
DMCJRL1	SN	TLR-9 agonist (cancer), Mologen
DMCJRL1	CP	Mologen Holding AG
DMCJRL1	DE	Colorectal cancer; Solid tumour/cancer

DMZHN5B	ID	DMZHN5B
DMZHN5B	DN	MIM-D3
DMZHN5B	HS	Phase 3
DMZHN5B	SN	TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen
DMZHN5B	CP	Mimetogen Pharmaceuticals Inc
DMZHN5B	DT	Small molecular drug
DMZHN5B	PC	9808372
DMZHN5B	MW	580.5
DMZHN5B	FM	C24H32N6O11
DMZHN5B	IC	InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1
DMZHN5B	CS	C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]1C(=O)NCC(=O)O)CCCCN)CCC(=O)O
DMZHN5B	IK	DVJXNXPFYJIACK-ULQDDVLXSA-N
DMZHN5B	IU	3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
DMZHN5B	CA	CAS 263251-78-1
DMZHN5B	DE	Alzheimer disease

DMCJY35	ID	DMCJY35
DMCJY35	DN	MIN-101
DMCJY35	HS	Phase 3
DMCJY35	SN	Roluperidone
DMCJY35	CP	Minerva neurosciences
DMCJY35	PC	9799284
DMCJY35	MW	366.4
DMCJY35	FM	C22H23FN2O2
DMCJY35	IC	InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2
DMCJY35	CS	C1CN(CCC1CN2CC3=CC=CC=C3C2=O)CC(=O)C4=CC=C(C=C4)F
DMCJY35	IK	RNRYULFRLCBRQS-UHFFFAOYSA-N
DMCJY35	IU	2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3H-isoindol-1-one
DMCJY35	CA	CAS 359625-79-9
DMCJY35	DE	Schizophrenia

DM7R3N5	ID	DM7R3N5
DM7R3N5	DN	Mirikizumab
DM7R3N5	HS	Phase 3
DM7R3N5	CP	Eli Lilly Indianapolis, IN
DM7R3N5	DE	Psoriasis vulgaris

DM5S4LX	ID	DM5S4LX
DM5S4LX	DN	Mirvetuximab soravtansine
DM5S4LX	HS	Phase 3
DM5S4LX	SN	ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489
DM5S4LX	CP	ImmunoGen Waltham, MA
DM5S4LX	PC	91810695
DM5S4LX	MW	977.6
DM5S4LX	FM	C42H61ClN4O14S3
DM5S4LX	IC	InChI=1S/C42H61ClN4O14S3/c1-23-12-11-13-31(58-10)42(53)22-29(59-39(52)45-42)24(2)36-41(6,61-36)32(21-34(49)47(8)27-19-26(18-23)20-28(57-9)35(27)43)60-38(51)25(3)46(7)33(48)14-16-40(4,5)63-62-17-15-30(37(44)50)64(54,55)56/h11-13,19-20,24-25,29-32,36,53H,14-18,21-22H2,1-10H3,(H2,44,50)(H,45,52)(H,54,55,56)/b13-11+,23-12+/t24-,25+,29+,30?,31-,32+,36+,41+,42+/m1/s1
DM5S4LX	CS	C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)\\C)OC)(NC(=O)O2)O
DM5S4LX	IK	ZOHXWSHGANNQGO-DSIKUUPMSA-N
DM5S4LX	IU	1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid
DM5S4LX	DE	Endometrial cancer; Ovarian cancer

DM3PSUF	ID	DM3PSUF
DM3PSUF	DN	MK-3102
DM3PSUF	HS	Phase 3
DM3PSUF	SN	Omarigliptin
DM3PSUF	CP	Merck
DM3PSUF	DT	Small molecular drug
DM3PSUF	PC	46209133
DM3PSUF	MW	398.4
DM3PSUF	FM	C17H20F2N4O3S
DM3PSUF	IC	InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1
DM3PSUF	CS	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@@H]3C[C@@H]([C@H](OC3)C4=C(C=CC(=C4)F)F)N
DM3PSUF	IK	MKMPWKUAHLTIBJ-ISTRZQFTSA-N
DM3PSUF	IU	(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine
DM3PSUF	CA	CAS 1226781-44-7
DM3PSUF	CB	CHEBI:134735
DM3PSUF	DE	Type-2 diabetes

DMQBF7O	ID	DMQBF7O
DMQBF7O	DN	MK-3222
DMQBF7O	HS	Phase 3
DMQBF7O	CP	Merck
DMQBF7O	DT	Antibody
DMQBF7O	DE	Psoriasis vulgaris; Hairy cell leukaemia; Plaque psoriasis

DMGNHC2	ID	DMGNHC2
DMGNHC2	DN	MK-3415A
DMGNHC2	HS	Phase 3
DMGNHC2	SN	Actoxumab/bezlotoxumab
DMGNHC2	CP	Merck
DMGNHC2	DT	Antibody
DMGNHC2	DE	Malaria; Clostridium infection

DMA25NO	ID	DMA25NO
DMA25NO	DN	MK-4214
DMA25NO	HS	Phase 3
DMA25NO	SN	INS-19; Recombinant human GCSF (biosimilar), Insmed
DMA25NO	CP	Insmed Inc
DMA25NO	DE	Neutropenia

DMLYGH4	ID	DMLYGH4
DMLYGH4	DN	MK-4827
DMLYGH4	HS	Phase 3
DMLYGH4	SN	1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226
DMLYGH4	CP	Merck
DMLYGH4	DT	Small molecular drug
DMLYGH4	PC	24958200
DMLYGH4	MW	320.4
DMLYGH4	FM	C19H20N4O
DMLYGH4	IC	InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
DMLYGH4	CS	C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
DMLYGH4	IK	PCHKPVIQAHNQLW-CQSZACIVSA-N
DMLYGH4	IU	2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
DMLYGH4	CA	CAS 1038915-60-4
DMLYGH4	DE	Ewing sarcoma; Ovarian cancer; Breast cancer

DM84LO5	ID	DM84LO5
DM84LO5	DN	MK-8109
DM84LO5	HS	Phase 3
DM84LO5	CP	Merck
DM84LO5	DE	Ovarian cancer

DMK301H	ID	DMK301H
DMK301H	DN	MK-8742
DMK301H	HS	Phase 3
DMK301H	CP	Merck
DMK301H	DE	Hepatitis C virus infection

DMT8IAJ	ID	DMT8IAJ
DMT8IAJ	DN	MK-8808
DMT8IAJ	HS	Phase 3
DMT8IAJ	CP	Merck
DMT8IAJ	DE	Rheumatoid arthritis; Follicular lymphoma

DMP36KD	ID	DMP36KD
DMP36KD	DN	MLN4924
DMP36KD	HS	Phase 3
DMP36KD	SN	Pevonedistat; 905579-51-3; MLN4924; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn
DMP36KD	CP	Takeda
DMP36KD	DT	Small molecular drug
DMP36KD	PC	16720766
DMP36KD	MW	443.5
DMP36KD	FM	C21H25N5O4S
DMP36KD	IC	InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1
DMP36KD	CS	C1CC2=CC=CC=C2[C@H]1NC3=C4C=CN(C4=NC=N3)[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N
DMP36KD	IK	MPUQHZXIXSTTDU-QXGSTGNESA-N
DMP36KD	IU	[(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate
DMP36KD	CA	CAS 905579-51-3
DMP36KD	CB	CHEBI:95028
DMP36KD	DE	Advanced malignancy; Myelodysplastic syndrome; Acute myelogenous leukaemia; Nasopharyngeal carcinoma

DMO8PT9	ID	DMO8PT9
DMO8PT9	DN	MLN8237
DMO8PT9	HS	Phase 3
DMO8PT9	SN	Alisertib
DMO8PT9	TC	Anticancer Agents
DMO8PT9	DT	Small molecular drug
DMO8PT9	PC	24771867
DMO8PT9	MW	518.9
DMO8PT9	FM	C27H20ClFN4O4
DMO8PT9	IC	InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
DMO8PT9	CS	COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC
DMO8PT9	IK	ZLHFILGSQDJULK-UHFFFAOYSA-N
DMO8PT9	IU	4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
DMO8PT9	CA	CAS 1028486-01-2
DMO8PT9	CB	CHEBI:125628
DMO8PT9	DE	Solid tumour/cancer; Small-cell lung cancer

DMFWE9S	ID	DMFWE9S
DMFWE9S	DN	Mobocertinib
DMFWE9S	HS	Phase 3
DMFWE9S	SN	1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; TAK788; AP32788; AP-32788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate
DMFWE9S	CP	Takeda
DMFWE9S	DT	Small molecular drug
DMFWE9S	PC	118607832
DMFWE9S	MW	585.7
DMFWE9S	FM	C32H39N7O4
DMFWE9S	IC	InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)
DMFWE9S	CS	CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
DMFWE9S	IK	AZSRSNUQCUDCGG-UHFFFAOYSA-N
DMFWE9S	IU	propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate
DMFWE9S	CA	CAS 1847461-43-1
DMFWE9S	DE	Non-small cell lung cancer

DM2TNJ1	ID	DM2TNJ1
DM2TNJ1	DN	Molgramostim
DM2TNJ1	HS	Phase 3
DM2TNJ1	SN	Genfulin; Molgramostim (topical, wound healing); Molgramostim (topical, wound healing), GeneScience; GM-CSF (topical, woundhealing), GeneScience; Granulocyte-macrophage colony stimulating factor (topical, wound healing), GeneScience
DM2TNJ1	CP	GeneScience Pharmaceuticals Co Ltd
DM2TNJ1	DE	Wound healing; Autoimmune pulmonary alveolar proteinosis

DMF98Q0	ID	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	HS	Phase 3
DMF98Q0	SN	Cyt387; 1056634-68-4; MOMELOTINIB; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide
DMF98Q0	CP	Gilead Sciences
DMF98Q0	DT	Small molecular drug
DMF98Q0	PC	25062766
DMF98Q0	MW	414.5
DMF98Q0	FM	C23H22N6O2
DMF98Q0	IC	InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
DMF98Q0	CS	C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N
DMF98Q0	IK	ZVHNDZWQTBEVRY-UHFFFAOYSA-N
DMF98Q0	IU	N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
DMF98Q0	CA	CAS 1056634-68-4
DMF98Q0	CB	CHEBI:91407
DMF98Q0	DE	Myelofibrosis; Polycythemia vera; Thrombocythemia

DMQ1FU8	ID	DMQ1FU8
DMQ1FU8	DN	Montelukast
DMQ1FU8	HS	Phase 3
DMQ1FU8	SN	Singulair; Montelukast [INN:BAN]; UNII-MHM278SD3E; MK 0476; CHEMBL787; MHM278SD3E; CHEBI:50730; 142522-28-9; Aerokast; Brondilat (TN)
DMQ1FU8	TC	Antiviral Agents
DMQ1FU8	DT	Small molecular drug
DMQ1FU8	PC	5281040
DMQ1FU8	MW	586.2
DMQ1FU8	FM	C35H36ClNO3S
DMQ1FU8	IC	InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
DMQ1FU8	CS	CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
DMQ1FU8	IK	UCHDWCPVSPXUMX-TZIWLTJVSA-N
DMQ1FU8	IU	2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
DMQ1FU8	CA	CAS 158966-92-8
DMQ1FU8	CB	CHEBI:50730
DMQ1FU8	DE	Coronavirus Disease 2019 (COVID-19)

DMPVW6H	ID	DMPVW6H
DMPVW6H	DN	Morphine-6-glucuronide
DMPVW6H	HS	Phase 3
DMPVW6H	SN	Morphine-6-glucuronide; Morphine 6-glucuronide; 20290-10-2; UNII-64Y9KYM60R; Morphine 6-beta-D-glucopyranosiduronide; 64Y9KYM60R; CHEBI:80581; MORPHINE GLUCURONIDE; MORPHINE 6-GLUCURONIDE(MINOR); beta-D-Glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl; Morphine 6-beta-D-Glucuronide; Glucopyranosiduronic acid, 7,8-didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-alpha-yl-, beta-D-; Morphine glucuronide [INN]; morphine-glucuronide
DMPVW6H	TC	Analgesics
DMPVW6H	DT	Small molecular drug
DMPVW6H	PC	5360621
DMPVW6H	MW	461.5
DMPVW6H	FM	C23H27NO9
DMPVW6H	IC	InChI=1S/C23H27NO9/c1-24-7-6-23-10-3-5-13(31-22-17(28)15(26)16(27)19(33-22)21(29)30)20(23)32-18-12(25)4-2-9(14(18)23)8-11(10)24/h2-5,10-11,13,15-17,19-20,22,25-28H,6-8H2,1H3,(H,29,30)/t10-,11+,13-,15-,16-,17+,19-,20-,22+,23-/m0/s1
DMPVW6H	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O
DMPVW6H	IK	GNJCUHZOSOYIEC-GAROZEBRSA-N
DMPVW6H	IU	(2S,3S,4S,5R,6R)-6-[[(4R,4aR,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DMPVW6H	CA	CAS 20290-10-2
DMPVW6H	CB	CHEBI:80581
DMPVW6H	DE	Pain

DM15ZIB	ID	DM15ZIB
DM15ZIB	DN	Mosunetuzumab
DM15ZIB	HS	Phase 3
DM15ZIB	SN	RG7828; RO7030816; BTCT4465A
DM15ZIB	DT	Antibody
DM15ZIB	DE	Follicular lymphoma

DMB24H7	ID	DMB24H7
DMB24H7	DN	Motavizumab
DMB24H7	HS	Phase 3
DMB24H7	SN	MEDI-524; Motavizumab (USAN/INN)
DMB24H7	CP	AstraZeneca
DMB24H7	DT	Monoclonal antibody
DMB24H7	DE	Respiratory syncytial virus infection

DM8K5Z6	ID	DM8K5Z6
DM8K5Z6	DN	Motexafin lutetium
DM8K5Z6	HS	Phase 3
DM8K5Z6	SN	Lutetium texaphyrin; Lu-Tex; Motexafin lutetium < USAN; Optrin (Pharmacyclics); PCI-0123; Antrin (Pharmacyclics, US, US); Lutrin (National Cancer Institute (US), US; Pharmacyclics, , , JP); (PB-7-11-233'2'4)-Bis(acetato-O)[9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-N1,N18,N23,N24
DM8K5Z6	CP	Pharmacyclics
DM8K5Z6	DT	Small molecular drug
DM8K5Z6	PC	3081907
DM8K5Z6	MW	1184.1
DM8K5Z6	FM	C52H74LuN5O15
DM8K5Z6	IC	InChI=1S/C48H66N5O10.2C2H4O2.Lu.H2O/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);;1H2/q-1;;;+3;/p-2
DM8K5Z6	CS	CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].O.[Lu+3]
DM8K5Z6	IK	WIQKYZYFTAEWBF-UHFFFAOYSA-L
DM8K5Z6	IU	3-[4,5-diethyl-24-(3-hydroxypropyl)-16,17-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-10,23-dimethyl-13,20,25,26-tetraza-27-azanidapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1(25),2,4,6,8(26),9,11,13,15,17,19,21,23-tridecaen-9-yl]propan-1-ol;lutetium(3+);diacetate;hydrate
DM8K5Z6	CA	CAS 156436-90-7
DM8K5Z6	DE	Artery stenosis

DM9K3LM	ID	DM9K3LM
DM9K3LM	DN	MPDL-3280A
DM9K3LM	HS	Phase 3
DM9K3LM	CP	Genentech
DM9K3LM	DT	Monoclonal antibody
DM9K3LM	DE	Melanoma

DMNDCFY	ID	DMNDCFY
DMNDCFY	DN	MPL-S
DMNDCFY	HS	Phase 3
DMNDCFY	CP	Ribi ImmunoChem Research Inc
DMNDCFY	DE	Endotoxic shock

DMDV4EP	ID	DMDV4EP
DMDV4EP	DN	MRTX849
DMDV4EP	HS	Phase 3
DMDV4EP	SN	2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX-849; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-
DMDV4EP	CP	Mirati Therapeutics
DMDV4EP	DT	Small molecular drug
DMDV4EP	PC	138611145
DMDV4EP	MW	604.1
DMDV4EP	FM	C32H35ClFN7O2
DMDV4EP	IC	InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1
DMDV4EP	CS	CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F
DMDV4EP	IK	PEMUGDMSUDYLHU-ZEQRLZLVSA-N
DMDV4EP	IU	2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
DMDV4EP	CA	CAS 2326521-71-3
DMDV4EP	DE	Non-small-cell lung cancer

DMUNBMA	ID	DMUNBMA
DMUNBMA	DN	MT-1621
DMUNBMA	HS	Phase 3
DMUNBMA	CP	Modis Therapeutics
DMUNBMA	DT	Deoxynucleoside
DMUNBMA	DE	Thymidine kinase 2 deficiency

DMZPEHY	ID	DMZPEHY
DMZPEHY	DN	Multi-epitope peptide melanoma vaccine
DMZPEHY	HS	Phase 3
DMZPEHY	SN	Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b
DMZPEHY	CP	University of Pittsburgh
DMZPEHY	DT	Vaccine
DMZPEHY	DE	Melanoma

DMG3NFZ	ID	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	HS	Phase 3
DMG3NFZ	SN	Muraglitazar; 331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N
DMG3NFZ	DT	Small molecular drug
DMG3NFZ	PC	206044
DMG3NFZ	MW	516.5
DMG3NFZ	FM	C29H28N2O7
DMG3NFZ	IC	InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)
DMG3NFZ	CS	CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC
DMG3NFZ	IK	IRLWJILLXJGJTD-UHFFFAOYSA-N
DMG3NFZ	IU	2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid
DMG3NFZ	CA	CAS 331741-94-7

DMUQ390	ID	DMUQ390
DMUQ390	DN	Murepavadin
DMUQ390	HS	Phase 3
DMUQ390	SN	UNII-0D02GRY87Z; 0D02GRY87Z; 944252-63-5; Murepavadin [INN]; Murepavadin [USAN:INN]; Murepavadin (USAN/INN); CHEMBL3946483; Cyclo(L-alanyl-L-seryl-D-prolyl-L-prolyl-L-threonyl-L-tryptophyl-L-isoleucyl-(2S)-2,4-diaminobutanoyl-L-ornithyl-(2R)-2,4-diaminobutanoyl-(2S)-2,4-diaminobutanoyl-L-tryptophyl-(2S)-2,4-diaminobutanoyl-(2S)-2,4-diaminobutanoyl); RO7033877; D10957
DMUQ390	CP	Polyphor
DMUQ390	PC	91824766
DMUQ390	MW	1553.8
DMUQ390	FM	C73H112N22O16
DMUQ390	IC	InChI=1S/C73H112N22O16/c1-5-38(2)58-70(108)88-52(24-30-79)65(103)83-47(17-10-25-74)62(100)85-49(21-27-76)63(101)86-51(23-29-78)66(104)89-53(33-41-35-80-45-15-8-6-13-43(41)45)67(105)87-50(22-28-77)64(102)84-48(20-26-75)61(99)82-39(3)60(98)91-55(37-96)72(110)95-32-12-19-57(95)73(111)94-31-11-18-56(94)69(107)93-59(40(4)97)71(109)90-54(68(106)92-58)34-42-36-81-46-16-9-7-14-44(42)46/h6-9,13-16,35-36,38-40,47-59,80-81,96-97H,5,10-12,17-34,37,74-79H2,1-4H3,(H,82,99)(H,83,103)(H,84,102)(H,85,100)(H,86,101)(H,87,105)(H,88,108)(H,89,104)(H,90,109)(H,91,98)(H,92,106)(H,93,107)/t38-,39-,40+,47-,48-,49+,50-,51-,52-,53-,54-,55-,56-,57+,58-,59-/m0/s1
DMUQ390	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CNC5=CC=CC=C54)[C@@H](C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN
DMUQ390	IK	RIDRXGOBXZLKHZ-NZUANIILSA-N
DMUQ390	IU	(3R,9S,12S,15S,18S,21S,24S,27R,30S,33S,36S,39S,42S,45S)-15,18,24,27,33-pentakis(2-aminoethyl)-30-(3-aminopropyl)-36-[(2S)-butan-2-yl]-42-[(1R)-1-hydroxyethyl]-9-(hydroxymethyl)-21,39-bis(1H-indol-3-ylmethyl)-12-methyl-1,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazatricyclo[43.3.0.03,7]octatetracontane-2,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecone
DMUQ390	CA	CAS 944252-63-5
DMUQ390	DE	Ventilator-associated pneumonia

DMS9GE1	ID	DMS9GE1
DMS9GE1	DN	MyoCell SDF-1
DMS9GE1	HS	Phase 3
DMS9GE1	SN	Autologous skeletal myoblast therapy (SDF-1, cardiovascular disease), Bioheart
DMS9GE1	CP	Bioheart
DMS9GE1	DE	Heart failure

DMY60DT	ID	DMY60DT
DMY60DT	DN	N8-GP
DMY60DT	HS	Phase 3
DMY60DT	SN	NN7088
DMY60DT	CP	Novo Nordisk
DMY60DT	DE	Factor VIII deficiency

DMHKJ5I	ID	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	HS	Phase 3
DMHKJ5I	SN	Nabiximols; Sativex; GW-1000; Cannador; Nabiximols [USAN]; GW1000; GW 1000; Tetrahydrocannabinol-cannabidiol combination; Cannabidiol mixture with Tetrahydrocannabinol; delta-9-Tetrahydrocannabinol and cannabidiol; Cannabidiol and delta-9-tetrahydrocarnabinol; GW-1000-02
DMHKJ5I	CP	Otsuka America Pharmaceutical
DMHKJ5I	DT	Small molecular drug
DMHKJ5I	PC	44148067
DMHKJ5I	MW	628.9
DMHKJ5I	FM	C42H60O4
DMHKJ5I	IC	InChI=1S/2C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,16-17,22H,5-10H2,1-4H3;11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t16-,17-;17-,18?/m10/s1
DMHKJ5I	CS	CCCCCC1=CC(=C(C(=C1)O)C2C=C(CC[C@H]2C(=C)C)C)O.CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
DMHKJ5I	IK	SSNHGLKFJISNTR-FWUPRJFYSA-N
DMHKJ5I	IU	(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
DMHKJ5I	CA	CAS 56575-23-6
DMHKJ5I	DE	Cancer related pain; Muscle spasm

DMDZ6Q3	ID	DMDZ6Q3
DMDZ6Q3	DN	Napabucasin
DMDZ6Q3	HS	Phase 3
DMDZ6Q3	SN	83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919
DMDZ6Q3	CP	Boston Biomedical Cambridge, MA
DMDZ6Q3	PC	10331844
DMDZ6Q3	MW	240.21
DMDZ6Q3	FM	C14H8O4
DMDZ6Q3	IC	InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3
DMDZ6Q3	CS	CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O
DMDZ6Q3	IK	DPHUWDIXHNQOSY-UHFFFAOYSA-N
DMDZ6Q3	IU	2-acetylbenzo[f][1]benzofuran-4,9-dione
DMDZ6Q3	CA	CAS 83280-65-3
DMDZ6Q3	DE	Pancreatic cancer; Colorectal cancer; Advanced malignancy; Solid tumour/cancer; Gastrointestinal cancer; Haematological malignancy; Hepatocellular carcinoma; Recurring respiratory infection; Recurrent glioblastoma

DMKP45D	ID	DMKP45D
DMKP45D	DN	Naproxcinod
DMKP45D	HS	Phase 3
DMKP45D	SN	Beprana; Nitronaproxen; AR-P900758XX; AZD-3582; HCT-3012; Nitronaproxen, NicOx; NO-naproxen, AstraZeneca; NO-naproxen, NicOx; NO-NSAID, NicOx/AstraZeneca; Nitric oxide-donating derivative of naproxen (oral, osteoarthritis), NicOx
DMKP45D	CP	NicOx SA
DMKP45D	DT	Small molecular drug
DMKP45D	PC	9884642
DMKP45D	MW	347.4
DMKP45D	FM	C18H21NO6
DMKP45D	IC	InChI=1S/C18H21NO6/c1-13(18(20)24-9-3-4-10-25-19(21)22)14-5-6-16-12-17(23-2)8-7-15(16)11-14/h5-8,11-13H,3-4,9-10H2,1-2H3/t13-/m0/s1
DMKP45D	CS	C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OCCCCO[N+](=O)[O-]
DMKP45D	IK	AKFJWRDCWYYTIG-ZDUSSCGKSA-N
DMKP45D	IU	4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DMKP45D	CA	CAS 163133-43-5
DMKP45D	CB	CHEBI:76254
DMKP45D	DE	Inflammation

DMIC56X	ID	DMIC56X
DMIC56X	DN	NASVAC
DMIC56X	HS	Phase 3
DMIC56X	SN	NASTERAP; HBV vaccine (intranasal), CIGB
DMIC56X	CP	Center for Genetic Engineering and Biotechnology
DMIC56X	DT	Vaccine
DMIC56X	DE	Hepatitis B virus infection

DMRSI1M	ID	DMRSI1M
DMRSI1M	DN	NAV5001
DMRSI1M	HS	Phase 3
DMRSI1M	CP	Navidea biopharmaceuticals
DMRSI1M	DE	Dementia

DMVO1C0	ID	DMVO1C0
DMVO1C0	DN	NBI-98854
DMVO1C0	HS	Phase 3
DMVO1C0	SN	NBI-98782; Vesicular monoamine transporter 2 inhibitor (CNS indications), Neurocrine; VMAT-2 inhibitor (CNS disease), Neurocrine
DMVO1C0	CP	Neurocrine biosciences
DMVO1C0	DT	Small molecular drug
DMVO1C0	PC	123836
DMVO1C0	MW	319.4
DMVO1C0	FM	C19H29NO3
DMVO1C0	IC	InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3
DMVO1C0	CS	CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1O)OC)OC
DMVO1C0	IK	WEQLWGNDNRARGE-UHFFFAOYSA-N
DMVO1C0	IU	9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol
DMVO1C0	CA	CAS 3466-75-9
DMVO1C0	DE	Movement disorder; Tourette syndrome

DMFD249	ID	DMFD249
DMFD249	DN	Nebracetam
DMFD249	HS	Phase 3
DMFD249	SN	Memolog; WEB-1881; WEB-1881-FU
DMFD249	CP	Boehringer Ingelheim Corp
DMFD249	DT	Small molecular drug
DMFD249	PC	65926
DMFD249	MW	204.27
DMFD249	FM	C12H16N2O
DMFD249	IC	InChI=1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2
DMFD249	CS	C1C(CN(C1=O)CC2=CC=CC=C2)CN
DMFD249	IK	LCAFGJGYCUMTGS-UHFFFAOYSA-N
DMFD249	IU	4-(aminomethyl)-1-benzylpyrrolidin-2-one
DMFD249	CA	CAS 97205-34-0
DMFD249	DE	Parkinson disease

DMDBY30	ID	DMDBY30
DMDBY30	DN	Nelipepimut S
DMDBY30	HS	Phase 3
DMDBY30	SN	E75
DMDBY30	CP	Galena biopharma
DMDBY30	DT	Small molecular drug
DMDBY30	PC	9941306
DMDBY30	MW	995.2
DMDBY30	FM	C50H78N10O11
DMDBY30	IC	InChI=1S/C50H78N10O11/c1-8-31(6)42(60-44(64)35(52)21-15-16-22-51)49(69)58-37(25-33-17-11-9-12-18-33)45(65)53-27-41(62)55-40(28-61)48(68)57-36(23-29(2)3)46(66)54-32(7)43(63)56-38(26-34-19-13-10-14-20-34)47(67)59-39(50(70)71)24-30(4)5/h9-14,17-20,29-32,35-40,42,61H,8,15-16,21-28,51-52H2,1-7H3,(H,53,65)(H,54,66)(H,55,62)(H,56,63)(H,57,68)(H,58,69)(H,59,67)(H,60,64)(H,70,71)/t31-,32-,35-,36-,37-,38-,39-,40-,42-/m0/s1
DMDBY30	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N
DMDBY30	IK	AHOKKYCUWBLDST-QYULHYBRSA-N
DMDBY30	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMDBY30	CA	CAS 160212-35-1
DMDBY30	DE	Non-hodgkin lymphoma; Breast cancer; Gastric adenocarcinoma

DMH9EUA	ID	DMH9EUA
DMH9EUA	DN	Nemolizumab
DMH9EUA	HS	Phase 3
DMH9EUA	CP	Galderma Fort Worth, TX
DMH9EUA	DE	Atopic dermatitis

DMIPNBG	ID	DMIPNBG
DMIPNBG	DN	Nemonaxacin
DMIPNBG	HS	Phase 3
DMIPNBG	CP	Warner Chilcott plc
DMIPNBG	DE	Methicillin-resistant staphylococci infection

DMVP7HI	ID	DMVP7HI
DMVP7HI	DN	Nestorone
DMVP7HI	HS	Phase 3
DMVP7HI	SN	Nestorone; Nestorone MDTS; Nestorone metered dose transdermal system; Nestorone transdermal spray, Acrux; ST-1435; Nestorone transdermal spray, Population Council/Acrux
DMVP7HI	CP	Population Council; Population Council Center for Biomedical Research
DMVP7HI	DT	Small molecular drug
DMVP7HI	PC	108059
DMVP7HI	MW	370.5
DMVP7HI	FM	C23H30O4
DMVP7HI	IC	InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1
DMVP7HI	CS	CC(=O)[C@]1(C(=C)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)OC(=O)C
DMVP7HI	IK	CKFBRGLGTWAVLG-GOMYTPFNSA-N
DMVP7HI	IU	[(8R,9S,10R,13S,14S,17R)-17-acetyl-13-methyl-16-methylidene-3-oxo-2,6,7,8,9,10,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMVP7HI	CA	7759-35-5
DMVP7HI	DE	Endometriosis

DMTKRY1	ID	DMTKRY1
DMTKRY1	DN	Netivudine
DMTKRY1	HS	Phase 3
DMTKRY1	SN	Zonavir; BW-882; BW-882C; 882-C-87; 882C
DMTKRY1	CP	Burroughs Wellcome Inc
DMTKRY1	DT	Small molecular drug
DMTKRY1	PC	55281
DMTKRY1	MW	282.25
DMTKRY1	FM	C12H14N2O6
DMTKRY1	IC	InChI=1S/C12H14N2O6/c1-2-3-6-4-14(12(19)13-10(6)18)11-9(17)8(16)7(5-15)20-11/h4,7-9,11,15-17H,5H2,1H3,(H,13,18,19)/t7-,8-,9+,11-/m1/s1
DMTKRY1	CS	CC#CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
DMTKRY1	IK	QLOCVMVCRJOTTM-SDNRWEOFSA-N
DMTKRY1	IU	1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione
DMTKRY1	CA	CAS 84558-93-0
DMTKRY1	DE	Virus infection

DMEKAYI	ID	DMEKAYI
DMEKAYI	DN	Netupitant
DMEKAYI	HS	Phase 3
DMEKAYI	SN	R-1124; NK1 antagonist (emesis), Roche; Ro-67-3189
DMEKAYI	CP	Helsinn Therapeutics
DMEKAYI	DT	Small molecular drug
DMEKAYI	PC	6451149
DMEKAYI	MW	578.6
DMEKAYI	FM	C30H32F6N4O
DMEKAYI	IC	InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3
DMEKAYI	CS	CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C
DMEKAYI	IK	WAXQNWCZJDTGBU-UHFFFAOYSA-N
DMEKAYI	IU	2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide
DMEKAYI	CA	CAS 290297-26-6
DMEKAYI	CB	CHEBI:85155
DMEKAYI	DE	Chemotherapy-induced nausea

DME617W	ID	DME617W
DME617W	DN	Neucardin
DME617W	HS	Phase 3
DME617W	SN	Human neuregulin-1 recombinant peptide fragment (injectable, heart failure/cardiomyopathy), Zensun; RhNRG-1 (injectable, heartfailure/cardiomyopathy), Zensun
DME617W	CP	Zensun (Shanghai) Sci-Tech Co Ltd
DME617W	DE	Heart failure; Chronic heart failure

DMYTC4I	ID	DMYTC4I
DMYTC4I	DN	NeuVax
DMYTC4I	HS	Phase 3
DMYTC4I	SN	NeuVax (TN)
DMYTC4I	CP	Galena Biopharma
DMYTC4I	DT	Vaccine
DMYTC4I	DE	Breast cancer

DMJ2KIE	ID	DMJ2KIE
DMJ2KIE	DN	NI-101
DMJ2KIE	HS	Phase 3
DMJ2KIE	SN	BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec
DMJ2KIE	CP	Neurimmune Therapeutics AG
DMJ2KIE	DT	Antibody
DMJ2KIE	DE	Alzheimer disease

DMFBNA3	ID	DMFBNA3
DMFBNA3	DN	Nicaraven
DMFBNA3	HS	Phase 3
DMFBNA3	SN	AVS; Antevan; Antevas
DMFBNA3	CP	Chugai Pharmaceutical
DMFBNA3	DT	Small molecular drug
DMFBNA3	PC	71234
DMFBNA3	MW	284.31
DMFBNA3	FM	C15H16N4O2
DMFBNA3	IC	InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)
DMFBNA3	CS	CC(CNC(=O)C1=CN=CC=C1)NC(=O)C2=CN=CC=C2
DMFBNA3	IK	KTXBOOWDLPUROC-UHFFFAOYSA-N
DMFBNA3	IU	N-[2-(pyridine-3-carbonylamino)propyl]pyridine-3-carboxamide
DMFBNA3	CA	CAS 79455-30-4
DMFBNA3	DE	Cerebrovascular disease

DM376WT	ID	DM376WT
DM376WT	DN	NKTR 214
DM376WT	HS	Phase 3
DM376WT	CP	Nektar Therapeutics San Francisco, CA
DM376WT	DE	Bladder cancer; Colorectal cancer; Melanoma; Renal cell carcinoma; Solid tumour/cancer; Sarcoma

DM45DS8	ID	DM45DS8
DM45DS8	DN	NKTR-181
DM45DS8	HS	Phase 3
DM45DS8	CP	Nektar therapeutics
DM45DS8	PC	73673720
DM45DS8	MW	595.7
DM45DS8	FM	C31H49NO10
DM45DS8	IC	InChI=1S/C31H49NO10/c1-32-9-8-30-27-23-4-5-24(35-3)28(27)42-29(30)25(6-7-31(30,33)26(32)22-23)41-21-20-40-19-18-39-17-16-38-15-14-37-13-12-36-11-10-34-2/h4-5,25-26,29,33H,6-22H2,1-3H3/t25-,26+,29-,30-,31+/m0/s1
DM45DS8	CS	CN1CC[C@]23[C@@H]4[C@H](CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O)OCCOCCOCCOCCOCCOCCOC
DM45DS8	IK	RQHILGKAOIGUHU-XPLSERNMSA-N
DM45DS8	IU	(4R,4aS,7S,7aR,12bS)-9-methoxy-7-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol
DM45DS8	CA	CAS 1211231-76-3
DM45DS8	DE	Neuropathic pain; Chronic low back pain; Pain

DMACYW6	ID	DMACYW6
DMACYW6	DN	NKTR-214
DMACYW6	HS	Phase 3
DMACYW6	SN	bempegaldesleukin 
DMACYW6	CP	Nektar Therapeutics
DMACYW6	DT	Recombinant protein
DMACYW6	DE	Melanoma

DMDJLY9	ID	DMDJLY9
DMDJLY9	DN	NM-702
DMDJLY9	HS	Phase 3
DMDJLY9	SN	NM-702; Parogrelil hydrochloride; UNII-65O9DMS368; 65O9DMS368; NM702; NM 702; 878796-94-2; SCHEMBL1739368; QWGUGDYWUADMGB-UHFFFAOYSA-N; 3(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1); 139145-84-9; 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride
DMDJLY9	CP	Nissan Chemical America
DMDJLY9	DT	Small molecular drug
DMDJLY9	PC	9848253
DMDJLY9	MW	486.2
DMDJLY9	FM	C19H19BrCl2N4O2
DMDJLY9	IC	InChI=1S/C19H18BrClN4O2.ClH/c20-16-17(23-12-14-3-1-9-22-11-14)19(25-24-18(16)26)27-10-2-4-13-5-7-15(21)8-6-13;/h1,3,5-9,11H,2,4,10,12H2,(H2,23,24,26);1H
DMDJLY9	CS	C1=CC(=CN=C1)CNC2=C(C(=O)NN=C2OCCCC3=CC=C(C=C3)Cl)Br.Cl
DMDJLY9	IK	QWGUGDYWUADMGB-UHFFFAOYSA-N
DMDJLY9	IU	5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochloride
DMDJLY9	CA	CAS 878796-94-2
DMDJLY9	DE	Angina pectoris

DMDGK83	ID	DMDGK83
DMDGK83	DN	NN1841
DMDGK83	HS	Phase 3
DMDGK83	SN	NovoThirteen (TN)
DMDGK83	CP	Novo Nordisk
DMDGK83	DE	Hemophilia

DM0QV27	ID	DM0QV27
DM0QV27	DN	NN5401
DM0QV27	HS	Phase 3
DM0QV27	SN	Insulin degludec and insulin aspart; Ryzodeg (TN)
DM0QV27	CP	Novo Nordisk
DM0QV27	DE	Diabetic complication

DM1PI9G	ID	DM1PI9G
DM1PI9G	DN	NN8717
DM1PI9G	HS	Phase 3
DM1PI9G	CP	Novo Nordisk
DM1PI9G	DE	Graft-versus-host disease

DMOF0CA	ID	DMOF0CA
DMOF0CA	DN	Nolatrexed
DMOF0CA	HS	Phase 3
DMOF0CA	SN	Thymitaq; AG-337; ZX-337; Nolatrexed (intravenous), EXIMIAS
DMOF0CA	CP	Agouron Pharmaceuticals Inc
DMOF0CA	DT	Small molecular drug
DMOF0CA	PC	135400184
DMOF0CA	MW	284.34
DMOF0CA	FM	C14H12N4OS
DMOF0CA	IC	InChI=1S/C14H12N4OS/c1-8-2-3-10-11(13(19)18-14(15)17-10)12(8)20-9-4-6-16-7-5-9/h2-7H,1H3,(H3,15,17,18,19)
DMOF0CA	CS	CC1=C(C2=C(C=C1)N=C(NC2=O)N)SC3=CC=NC=C3
DMOF0CA	IK	XHWRWCSCBDLOLM-UHFFFAOYSA-N
DMOF0CA	IU	2-amino-6-methyl-5-pyridin-4-ylsulfanyl-3H-quinazolin-4-one
DMOF0CA	CA	CAS 147149-76-6
DMOF0CA	DE	Solid tumour/cancer

DMMC3Y8	ID	DMMC3Y8
DMMC3Y8	DN	NPC-01
DMMC3Y8	HS	Phase 3
DMMC3Y8	SN	LEP pill; Low dose estrogen progestin pill (dysmenorrhea), Nobelpharma
DMMC3Y8	CP	Nobelpharma Co Ltd
DMMC3Y8	DE	Dysmenorrhea

DMCMIJ1	ID	DMCMIJ1
DMCMIJ1	DN	NT0202
DMCMIJ1	HS	Phase 3
DMCMIJ1	SN	Amphetamine polistirex
DMCMIJ1	CP	Neos therapeutics
DMCMIJ1	DE	Attention deficit hyperactivity disorder

DMA16IL	ID	DMA16IL
DMA16IL	DN	NU-100
DMA16IL	HS	Phase 3
DMA16IL	SN	BaroFeron; Interferon beta-1b (PreEMT, multiple sclerosis), BaroFold; Interferon beta-1b (PreEMT, multiple sclerosis), NuronBiotech
DMA16IL	CP	Nuron biotech
DMA16IL	PC	21987656
DMA16IL	MW	378.5
DMA16IL	FM	C24H30N2O2
DMA16IL	IC	InChI=1S/C24H30N2O2/c27-23(25-21-7-3-1-4-8-21)19-13-11-18-16-20(14-12-17(18)15-19)24(28)26-22-9-5-2-6-10-22/h11-16,21-22H,1-10H2,(H,25,27)(H,26,28)
DMA16IL	CS	C1CCC(CC1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=O)NC4CCCCC4
DMA16IL	IK	MBSRTKPGZKQXQR-UHFFFAOYSA-N
DMA16IL	IU	2-N,6-N-dicyclohexylnaphthalene-2,6-dicarboxamide
DMA16IL	CA	CAS 153250-52-3
DMA16IL	DE	Multiple sclerosis

DM8JWNA	ID	DM8JWNA
DM8JWNA	DN	NVP-LAQ824
DM8JWNA	HS	Phase 3
DM8JWNA	SN	Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide;  Dacinostat; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539
DM8JWNA	CP	Corcept Therapeutics
DM8JWNA	DT	Small molecular drug
DM8JWNA	PC	6445533
DM8JWNA	MW	379.5
DM8JWNA	FM	C22H25N3O3
DM8JWNA	IC	InChI=1S/C22H25N3O3/c26-14-13-25(12-11-19-15-23-21-4-2-1-3-20(19)21)16-18-7-5-17(6-8-18)9-10-22(27)24-28/h1-10,15,23,26,28H,11-14,16H2,(H,24,27)/b10-9+
DM8JWNA	CS	C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)/C=C/C(=O)NO
DM8JWNA	IK	BWDQBBCUWLSASG-MDZDMXLPSA-N
DM8JWNA	IU	(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
DM8JWNA	CA	CAS 404951-53-7
DM8JWNA	CB	CHEBI:94063
DM8JWNA	DE	leukaemia; Multiple myeloma; Mood disorder

DM3L2GT	ID	DM3L2GT
DM3L2GT	DN	O6-Benzylguanine alkylade
DM3L2GT	HS	Phase 3
DM3L2GT	SN	KRX-0402; O6-Benzylguanine (BG)
DM3L2GT	CP	Wiley-Liss; Keryx Biopharmaceuticals
DM3L2GT	DE	Sarcoma

DMENDP6	ID	DMENDP6
DMENDP6	DN	OBI-1
DMENDP6	HS	Phase 3
DMENDP6	SN	Porcine rFVIII, Ipsen/Inspiration; Porcine rFVIII, Octagen/Ipsen; Porcine rFactor VIII, Ipsen/Inspiration; Porcine rFactor VIII, Octagen/Ipsen; Recombinant porcine Factor VIII, Ipsen/Inspiration; Recombinant porcine Factor VIII, Octagen/Ipsen
DMENDP6	CP	Baxter international; inspiration biopharmaceuticals
DMENDP6	DE	Factor VIII deficiency

DM7KI4E	ID	DM7KI4E
DM7KI4E	DN	Oblimersen
DM7KI4E	HS	Phase 3
DM7KI4E	CP	Genta Incorp
DM7KI4E	PC	118984457
DM7KI4E	MW	6058
DM7KI4E	FM	C172H204N62Na17O91P17S17
DM7KI4E	IC	InChI=1S/C172H221N62O91P17S17.17Na/c1-69-39-225(169(253)213-149(69)237)117-21-73(236)92(292-117)44-274-326(257,343)320-85-33-129(229-63-191-135-141(181)187-61-189-143(135)229)303-103(85)55-285-332(263,349)314-79-27-122(221-17-9-113(177)201-165(221)249)295-95(79)47-278-330(261,347)312-78-26-121(220-16-8-112(176)200-164(220)248)298-98(78)50-280-338(269,355)322-87-35-131(231-65-193-137-145(231)205-157(183)209-153(137)241)305-105(87)57-287-334(265,351)316-81-29-124(223-19-11-115(179)203-167(223)251)299-99(81)51-281-339(270,356)323-88-36-132(232-66-194-138-146(232)206-158(184)210-154(138)242)307-107(88)59-289-337(268,354)319-84-32-128(228-42-72(4)152(240)216-172(228)256)302-102(84)54-284-341(272,358)325-90-38-134(234-68-196-140-148(234)208-160(186)212-156(140)244)306-106(90)58-288-335(266,352)317-82-30-125(224-20-12-116(180)204-168(224)252)300-100(82)52-282-340(271,357)324-89-37-133(233-67-195-139-147(233)207-159(185)211-155(139)243)308-108(89)60-290-342(273,359)321-86-34-130(230-64-192-136-142(182)188-62-190-144(136)230)304-104(86)56-286-333(264,350)315-80-28-123(222-18-10-114(178)202-166(222)250)296-96(80)48-277-328(259,345)310-76-24-119(218-14-6-110(174)198-162(218)246)294-94(76)46-276-329(260,346)311-77-25-120(219-15-7-111(175)199-163(219)247)297-97(77)49-279-336(267,353)318-83-31-127(227-41-71(3)151(239)215-171(227)255)301-101(83)53-283-331(262,348)313-75-23-118(217-13-5-109(173)197-161(217)245)293-93(75)45-275-327(258,344)309-74-22-126(291-91(74)43-235)226-40-70(2)150(238)214-170(226)254;;;;;;;;;;;;;;;;;/h5-20,39-42,61-68,73-108,117-134,235-236H,21-38,43-60H2,1-4H3,(H,257,343)(H,258,344)(H,259,345)(H,260,346)(H,261,347)(H,262,348)(H,263,349)(H,264,350)(H,265,351)(H,266,352)(H,267,353)(H,268,354)(H,269,355)(H,270,356)(H,271,357)(H,272,358)(H,273,359)(H2,173,197,245)(H2,174,198,246)(H2,175,199,247)(H2,176,200,248)(H2,177,201,249)(H2,178,202,250)(H2,179,203,251)(H2,180,204,252)(H2,181,187,189)(H2,182,188,190)(H,213,237,253)(H,214,238,254)(H,215,239,255)(H,216,240,256)(H3,183,205,209,241)(H3,184,206,210,242)(H3,185,207,211,243)(H3,186,208,212,244);;;;;;;;;;;;;;;;;/q;17*+1/p-17/t73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,326?,327?,328?,329?,330?,331?,332?,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?;;;;;;;;;;;;;;;;;/m0................./s1
DM7KI4E	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)[S-])N1C=NC2=C(N=CN=C21)N)O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM7KI4E	IK	IBXPAFBDJCXCDW-MHFPCNPESA-A
DM7KI4E	IU	heptadecasodium;1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-sulfidophosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM7KI4E	CA	CAS 190977-41-4
DM7KI4E	DE	Multiple myeloma; Melanoma

DMEDSVJ	ID	DMEDSVJ
DMEDSVJ	DN	Ociperlimab
DMEDSVJ	HS	Phase 3
DMEDSVJ	SN	BGB-A1217
DMEDSVJ	CP	BeiGene
DMEDSVJ	DT	Antibody
DMEDSVJ	DE	Cervical cancer; Non-small-cell lung cancer

DM1EO3G	ID	DM1EO3G
DM1EO3G	DN	Odanacatib
DM1EO3G	HS	Phase 3
DM1EO3G	SN	MK 0822; MK0822; MK-0822A; Odanacatib (USAN)
DM1EO3G	CP	Merck
DM1EO3G	DT	Small molecular drug
DM1EO3G	PC	10152654
DM1EO3G	MW	525.6
DM1EO3G	FM	C25H27F4N3O3S
DM1EO3G	IC	InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1
DM1EO3G	CS	CC(C)(C[C@@H](C(=O)NC1(CC1)C#N)N[C@@H](C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
DM1EO3G	IK	FWIVDMJALNEADT-SFTDATJTSA-N
DM1EO3G	IU	(2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide
DM1EO3G	CA	CAS 603139-19-1
DM1EO3G	DE	Osteoporosis

DMYN391	ID	DMYN391
DMYN391	DN	Odevixibat
DMYN391	HS	Phase 3
DMYN391	SN	501692-44-0; UNII-2W150K0UUC; 2W150K0UUC; A4250; AZD8294; 501692-44-0 (free base); Odevixibat (USAN); Odevixibat [USAN]; AR-H064974; A-4250; (S)-2-((R)-2-(2-((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)acetamido)-2-(4-hydroxyphenyl)acetamido)butanoic acid; SCHEMBL946468; CHEMBL4297588; BDBM77040; GTPL11194; AZD-8294; example 5 [US9694018B1]; WHO 10706; HY-109120; Unk-D-nTyr-Abu-OH (IUPAC condensed name); CS-0078340; D11716; US9694018, 5; (2S)-2-(((2R)-2-((((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)butanoic acid; (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid; Butanoic acid, 2-(((2R)-((((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)(4-hydroxyphenyl)acetyl)amino)-, (2S)-; Butanoic acid, 2-(((2R)-2-((2-((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)-, (2S)-
DMYN391	CP	Albireo Pharma
DMYN391	DT	Small molecular drug
DMYN391	PC	10153627
DMYN391	MW	740.9
DMYN391	FM	C37H48N4O8S2
DMYN391	IC	InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1
DMYN391	CS	CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)N[C@H](C3=CC=C(C=C3)O)C(=O)N[C@@H](CC)C(=O)O)SC)C4=CC=CC=C4)CCCC
DMYN391	IK	XULSCZPZVQIMFM-IPZQJPLYSA-N
DMYN391	IU	(2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid
DMYN391	CA	CAS 501692-44-0
DMYN391	DE	Alagille syndrome

DMBWO5T	ID	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	HS	Phase 3
DMBWO5T	SN	H-c(Cys3-Phe6-Phe7-DTrp8-Lys9-Thr10-Phe11-Cys14)-OH; CHEMBL266477; BDBM50136824; (4R,7S,10S,13S,16R,19S,22S,25R)-16-((1H-indol-3-yl)methyl)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-((R)-1-hydroxyethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptaazacyclohexacosane-4-carboxylic acid
DMBWO5T	PC	11251755
DMBWO5T	MW	1079.3
DMBWO5T	FM	C54H66N10O10S2
DMBWO5T	IC	InChI=1S/C54H66N10O10S2/c1-32(65)46-53(72)62-43(27-35-19-9-4-10-20-35)51(70)63-45(54(73)74)31-76-75-30-38(56)47(66)59-41(25-33-15-5-2-6-16-33)49(68)60-42(26-34-17-7-3-8-18-34)50(69)61-44(28-36-29-57-39-22-12-11-21-37(36)39)52(71)58-40(48(67)64-46)23-13-14-24-55/h2-12,15-22,29,32,38,40-46,57,65H,13-14,23-28,30-31,55-56H2,1H3,(H,58,71)(H,59,66)(H,60,68)(H,61,69)(H,62,72)(H,63,70)(H,64,67)(H,73,74)/t32-,38+,40+,41+,42+,43+,44-,45+,46+/m1/s1
DMBWO5T	CS	C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)CC6=CC=CC=C6)O
DMBWO5T	IK	PJRZZHKHLDKTKL-OCZUONHDSA-N
DMBWO5T	IU	(4R,7S,10S,13S,16R,19S,22S,25R)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carboxylic acid

DM1FBZ7	ID	DM1FBZ7
DM1FBZ7	DN	Olodaterol/tiotropium bromide
DM1FBZ7	HS	Phase 3
DM1FBZ7	SN	136310-93-5; UNII-XX112XZP0J; XX112XZP0J; (1R,2R,4S,5S,7s)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide; AK-72842; (1R,2R,4S,5S,7S)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0
DM1FBZ7	CP	Boehringer Ingelheim Pharmaceuticals
DM1FBZ7	DT	Small molecular drug
DM1FBZ7	PC	5487426
DM1FBZ7	MW	472.4
DM1FBZ7	FM	C19H22BrNO4S2
DM1FBZ7	IC	InChI=1S/C19H22NO4S2.BrH/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15;/h3-8,11-13,16-17,22H,9-10H2,1-2H3;1H/q+1;/p-1/t11?,12-,13+,16-,17+;
DM1FBZ7	CS	C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-]
DM1FBZ7	IK	DQHNAVOVODVIMG-RGECMCKFSA-M
DM1FBZ7	IU	[(1R,2R,4S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide
DM1FBZ7	CA	CAS 136310-93-5
DM1FBZ7	CB	CHEBI:90959
DM1FBZ7	DE	Chronic obstructive pulmonary disease

DM4Z9QI	ID	DM4Z9QI
DM4Z9QI	DN	Olokizumab
DM4Z9QI	HS	Phase 3
DM4Z9QI	CP	UCB
DM4Z9QI	DT	Monoclonal antibody
DM4Z9QI	DE	Rheumatoid arthritis

DM624TW	ID	DM624TW
DM624TW	DN	Omecamtiv mecarbil
DM624TW	HS	Phase 3
DM624TW	SN	Omecamtiv mecarbil; 873697-71-3; Omecamtiv mecarbil (CK-1827452); CK-1827452; CK1827452; UNII-2M19539ERK; CK 1827452; methyl 4-(2-fluoro-3-(3-(6-Methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate; CHEMBL1800955; AMG-423; 2M19539ERK; Methyl 4-(2-Fluoro-3-{[(6-Methylpyridin-3-Yl)carbamoyl]amino}benzyl)piperazine-1-Carboxylate; Methyl 4-[[2-fluoro-3-[n'-(6-methylpyridin-3-yl)ureido]phenyl]methyl]piperazine-1-carboxylate; Omecamtiv mecarbil [USAN:INN]; omecamtiv mercarbil; MLS006011266; SCHEMBL400544; Omecamtiv Mecarbil;
DM624TW	CP	Amgen
DM624TW	DT	Small molecular drug
DM624TW	PC	11689883
DM624TW	MW	401.4
DM624TW	FM	C20H24FN5O3
DM624TW	IC	InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)
DM624TW	CS	CC1=NC=C(C=C1)NC(=O)NC2=CC=CC(=C2F)CN3CCN(CC3)C(=O)OC
DM624TW	IK	RFUBTTPMWSKEIW-UHFFFAOYSA-N
DM624TW	IU	methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate
DM624TW	CA	CAS 873697-71-3
DM624TW	DE	Heart failure

DMBWY8V	ID	DMBWY8V
DMBWY8V	DN	Omega-6-FA
DMBWY8V	HS	Phase 3
DMBWY8V	SN	Fatty Acids, Omega-6; Omega-6 Fatty Acids; Omega-6 Polyunsaturates; N-6 Fatty Acids; SCHEMBL17080398
DMBWY8V	PC	56842208
DMBWY8V	MW	584.9
DMBWY8V	FM	C38H64O4
DMBWY8V	IC	ZCDMRPMKAQLWAO-PZLFCYFRSA-N
DMBWY8V	CS	CCCCCC=CCC=CCCCCCCCC(=O)O.CCCCCC=CCC=CCC=CCC=CCCCC(=O)O
DMBWY8V	IK	1S/C20H32O2.C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22);6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-,16-15-;7-6-,10-9-
DMBWY8V	IU	(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid;(9Z,12Z)-octadeca-9,12-dienoic acid
DMBWY8V	DE	Attention deficit hyperactivity disorder

DMK6QBZ	ID	DMK6QBZ
DMK6QBZ	DN	OMS721
DMK6QBZ	HS	Phase 3
DMK6QBZ	CP	Omeros, Seattle, WA
DMK6QBZ	DE	Thrombotic microangiopathy; Glomerulonephritis; Lupus; Atypical hemolytic uremic syndrome

DMU86DM	ID	DMU86DM
DMU86DM	DN	ONO-1101
DMU86DM	HS	Phase 3
DMU86DM	SN	Landiolol; Landiolol [INN]; ONO-1101; Ono 1101; (S-(R*,R*))-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl 4-(2-hydroxy-3-((2-((4-morpholinylcarbonyl)amino)ethyl)amino)propoxy)benzenepropanoate; 133242-30-5; 62NWQ924LH; Benzenepropanoic acid, 4-((2S)-2-hydroxy-3-((2-((4-morpholinylcarbonyl)amino)ethyl)amino)propoxy)-, ((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester; UNII-62NWQ924LH; [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate
DMU86DM	PC	114905
DMU86DM	MW	509.6
DMU86DM	FM	C25H39N3O8
DMU86DM	IC	WMDSZGFJQKSLLH-RBBKRZOGSA-N
DMU86DM	CS	CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C
DMU86DM	IK	1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)/t20-,22+/m0/s1
DMU86DM	IU	[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate
DMU86DM	CA	CAS 133242-30-5
DMU86DM	CB	CHEBI:135809
DMU86DM	DE	Atrial fibrillation

DM06KRC	ID	DM06KRC
DM06KRC	DN	Oregovomab
DM06KRC	HS	Phase 3
DM06KRC	CP	Quest PharmaTech
DM06KRC	DT	Monoclonal antibody
DM06KRC	DE	Ovarian cancer; Epithelial ovarian cancer

DMWD3IV	ID	DMWD3IV
DMWD3IV	DN	Oseltamivir + hydroxychloroquine
DMWD3IV	HS	Phase 3
DMWD3IV	SN	Tamiflu  + oxichloroquine
DMWD3IV	TC	Antiviral Agents
DMWD3IV	DT	Combination drug
DMWD3IV	DE	Coronavirus Disease 2019 (COVID-19)

DMHKZLF	ID	DMHKZLF
DMHKZLF	DN	OSI-906
DMHKZLF	HS	Phase 3
DMHKZLF	SN	Linsitinib; 867160-71-2; OSI-906; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906AA; OSI-906 (Linsitinib); UNII-15A52GPT8T; Kinome_3532; ASP-7487; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; Linsitinib [USAN:INN]; OSI906/Linsitinib/; Linsitinib; OSI-906
DMHKZLF	DT	Small molecular drug
DMHKZLF	PC	11640390
DMHKZLF	MW	421.5
DMHKZLF	FM	C26H23N5O
DMHKZLF	IC	InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)
DMHKZLF	CS	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O
DMHKZLF	IK	PKCDDUHJAFVJJB-UHFFFAOYSA-N
DMHKZLF	IU	3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
DMHKZLF	CA	CAS 867160-71-2
DMHKZLF	CB	CHEBI:91402
DMHKZLF	DE	Solid tumour/cancer

DM7R145	ID	DM7R145
DM7R145	DN	Otesaconazole
DM7R145	HS	Phase 3
DM7R145	SN	Oteseconazole; 1340593-59-0; VT-1161; UNII-VHH774W97N; VHH774W97N; CHEMBL3311228; (R)-2-(2,4-Difluorophenyl)-1,1-Difluoro-3-(1h-Tetrazol-1-Yl)-1-(5-(4-(2,2,2-Trifluoroethoxy)phenyl)pyridin-2-Yl)propan-2-Ol; Oteseconazole [USAN]; Oteseconazole (USAN/INN); SCHEMBL17113021; BDBM50046187; WHO 10138; DB13055; SB17420; HY-17643; CS-0016914; D11785; Q27291837; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol; 2-Pyridineethanol, alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1H-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-, (alphaR)-
DM7R145	CP	Mycovia Pharmaceuticals
DM7R145	DT	Small molecular drug
DM7R145	PC	77050711
DM7R145	MW	527.4
DM7R145	FM	C23H16F7N5O2
DM7R145	IC	InChI=1S/C23H16F7N5O2/c24-16-4-7-18(19(25)9-16)21(36,11-35-13-32-33-34-35)23(29,30)20-8-3-15(10-31-20)14-1-5-17(6-2-14)37-12-22(26,27)28/h1-10,13,36H,11-12H2/t21-/m0/s1
DM7R145	CS	C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
DM7R145	IK	IDUYJRXRDSPPRC-NRFANRHFSA-N
DM7R145	IU	(2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol
DM7R145	CA	CAS 1340593-59-0
DM7R145	DE	Onychomycosis; Vulvovaginal Candidiasis

DMLMS6J	ID	DMLMS6J
DMLMS6J	DN	OTL-101
DMLMS6J	HS	Phase 3
DMLMS6J	CP	Orchard Therapeutics
DMLMS6J	DT	Gene therapy
DMLMS6J	DE	Severe combined immunodeficiency

DM3BK2Y	ID	DM3BK2Y
DM3BK2Y	DN	OTL-103
DM3BK2Y	HS	Phase 3
DM3BK2Y	CP	Orchard Therapeutics
DM3BK2Y	DT	Gene therapy
DM3BK2Y	DE	Wiskott-Aldrich syndrome

DM5DRMY	ID	DM5DRMY
DM5DRMY	DN	P1101
DM5DRMY	HS	Phase 3
DM5DRMY	SN	N-Phenylethylenediamine; 1664-40-0; N1-Phenylethane-1,2-diamine; N-(2-Aminoethyl)aniline; 1,2-Ethanediamine, N-phenyl-; Ethylenediamine, N-phenyl-; N-Phenyl-1,2-ethanediamine; 1,2-Ethanediamine, N1-phenyl-; Benzenamine, N-(2-aminoethyl)-; N'-phenylethane-1,2-diamine; N-phenylethane-1,2-diamine; n1-phenyl-1,2-ethanediamine; MFCD00008162; (2-aminoethyl)phenylamine; N-Phenylethylenediamine, 99%; NSC84247; phenylethylenediamine; EINECS 216-773-4; NSC 84247; 2-phenylaminoethylamine; phenyl ethylene diamine; ACMC-209duf; N -phenylethylenediamine; N-phenyl ethylenediamine; N-phenyl ethylene diamine; N-phenyl-ethylene-diamine; N-(2-aminoethyl)-aniline; N-phenyl ethyl-ene diamine; n2-phenyl-1,2-ethanediamine; N-phenyl-ethane-1,2-diamine; SCHEMBL307775; N-Phenylethylenediamine, 98%; N'-phenyl-ethane-1,2-diamine; N1-phenyl-ethane-1,2-diamine; DTXSID1061861; OCIDXARMXNJACB-UHFFFAOYSA-; Ethylenediamine, N-phenyl- (8CI); STR05027; ZINC1736738; 8473AA; ANW-22213; NSC-84247; SBB004200; STL257388; AKOS005135725; LS10740; MCULE-5870561171; NE53436; AC-25457; AK122216; SY009366; DB-043652; CS-0045385; FT-0629102; ST45237853; EN300-81504; J-010281
DM5DRMY	CP	PharmaEssentia
DM5DRMY	DT	Small molecular drug
DM5DRMY	PC	74270
DM5DRMY	MW	136.19
DM5DRMY	FM	C8H12N2
DM5DRMY	IC	InChI=1S/C8H12N2/c9-6-7-10-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
DM5DRMY	CS	C1=CC=C(C=C1)NCCN
DM5DRMY	IK	OCIDXARMXNJACB-UHFFFAOYSA-N
DM5DRMY	IU	N'-phenylethane-1,2-diamine
DM5DRMY	CA	CAS 1664-40-0
DM5DRMY	DE	Polycythemia vera

DM7WYXJ	ID	DM7WYXJ
DM7WYXJ	DN	P-1101
DM7WYXJ	HS	Phase 3
DM7WYXJ	SN	Pegylated interferon alpha (hepatitis B and C virus infection), PharmaEssentia; Pegylated interferon alpha-2b (polycythemia vera), AOP Orphan; PEG-INF-alpha (hepatitis B and C virus infection), PharmaEssentia; PEG-P-IFN-alpha-2b
DM7WYXJ	CP	Hanall biopharma; medtronic
DM7WYXJ	DE	Hepatitis B virus infection; Essential thrombocythemia; Myelofibrosis

DM9PVHX	ID	DM9PVHX
DM9PVHX	DN	P2B-001
DM9PVHX	HS	Phase 3
DM9PVHX	SN	Fixed-dose combination therapy (Parkinsons diease), Pharma Two B
DM9PVHX	CP	Pharma Two B Ltd
DM9PVHX	DE	Parkinson disease

DM1T6ZN	ID	DM1T6ZN
DM1T6ZN	DN	Pacritinib
DM1T6ZN	HS	Phase 3
DM1T6ZN	SN	JAK inhibitor (alone or in combination)s
DM1T6ZN	CP	Cell Therapeutics
DM1T6ZN	DT	Small molecular drug
DM1T6ZN	PC	46216796
DM1T6ZN	MW	472.6
DM1T6ZN	FM	C28H32N4O3
DM1T6ZN	IC	InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
DM1T6ZN	CS	C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2
DM1T6ZN	IK	HWXVIOGONBBTBY-ONEGZZNKSA-N
DM1T6ZN	IU	(16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene
DM1T6ZN	CA	CAS 937272-79-2
DM1T6ZN	DE	Myelofibrosis

DMFKOR9	ID	DMFKOR9
DMFKOR9	DN	Pafuramidine
DMFKOR9	HS	Phase 3
DMFKOR9	SN	Pafuramidine maleate; DB-289; DB-290; DB-75 prodrug, Immtech; Pafuramidine maleate (oral formulation), Strativa
DMFKOR9	CP	Immtech International; University of North Carolina
DMFKOR9	DT	Small molecular drug
DMFKOR9	PC	5480200
DMFKOR9	MW	364.4
DMFKOR9	FM	C20H20N4O3
DMFKOR9	IC	InChI=1S/C20H20N4O3/c1-25-23-19(21)15-7-3-13(4-8-15)17-11-12-18(27-17)14-5-9-16(10-6-14)20(22)24-26-2/h3-12H,1-2H3,(H2,21,23)(H2,22,24)
DMFKOR9	CS	CO/N=C(\\N)/C1=CC=C(C=C1)C2=CC=C(O2)C3=CC=C(C=C3)/C(=N/OC)/N
DMFKOR9	IK	UKOQVLAXCBRRGH-UHFFFAOYSA-N
DMFKOR9	IU	N'-methoxy-4-[5-[4-[(Z)-N'-methoxycarbamimidoyl]phenyl]furan-2-yl]benzenecarboximidamide
DMFKOR9	CA	CAS 186953-56-0
DMFKOR9	DE	Malaria

DMAD2OZ	ID	DMAD2OZ
DMAD2OZ	DN	Palovarotene
DMAD2OZ	HS	Phase 3
DMAD2OZ	SN	R-667; RG-667; Retinoid receptor agonist, Roche; Ro-3300074; Ro-330074
DMAD2OZ	CP	Roche
DMAD2OZ	DT	Small molecular drug
DMAD2OZ	PC	10295295
DMAD2OZ	MW	414.5
DMAD2OZ	FM	C27H30N2O2
DMAD2OZ	IC	InChI=1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)/b11-8+
DMAD2OZ	CS	CC1(CCC(C2=C1C=C(C(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C
DMAD2OZ	IK	YTFHCXIPDIHOIA-DHZHZOJOSA-N
DMAD2OZ	IU	4-[(E)-2-[5,5,8,8-tetramethyl-3-(pyrazol-1-ylmethyl)-6,7-dihydronaphthalen-2-yl]ethenyl]benzoic acid
DMAD2OZ	CA	CAS 410528-02-8
DMAD2OZ	DE	Emphysema; Fibrodysplasia ossificans progressiva

DM4SKYI	ID	DM4SKYI
DM4SKYI	DN	PAMAQUESIDE
DM4SKYI	HS	Phase 3
DM4SKYI	SN	CP-148623; Pamaqueside < Prop INN; 11-Ketotigogenyl beta-O-cellobioside
DM4SKYI	DT	Small molecular drug
DM4SKYI	PC	9918516
DM4SKYI	MW	754.9
DM4SKYI	FM	C39H62O14
DM4SKYI	IC	InChI=1S/C39H62O14/c1-17-7-10-39(48-16-17)18(2)27-24(53-39)12-22-21-6-5-19-11-20(8-9-37(19,3)28(21)23(42)13-38(22,27)4)49-35-33(47)31(45)34(26(15-41)51-35)52-36-32(46)30(44)29(43)25(14-40)50-36/h17-22,24-36,40-41,43-47H,5-16H2,1-4H3/t17-,18+,19+,20+,21+,22+,24+,25-,26-,27+,28-,29-,30+,31-,32-,33-,34-,35-,36+,37+,38+,39-/m1/s1
DM4SKYI	CS	C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC(=O)[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)C)C)C)OC1
DM4SKYI	IK	VWMZIGBYZQUQOA-QEEMJVPDSA-N
DM4SKYI	IU	(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13S,16S,18S)-16-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-11-one
DM4SKYI	CA	CAS 150332-35-7
DM4SKYI	DE	Hyperlipidaemia

DMIRYU9	ID	DMIRYU9
DMIRYU9	DN	Pancopride
DMIRYU9	HS	Phase 3
DMIRYU9	SN	LAS-30451
DMIRYU9	CP	Almirall Prodesfarma SA
DMIRYU9	DT	Small molecular drug
DMIRYU9	PC	71342
DMIRYU9	MW	349.9
DMIRYU9	FM	C18H24ClN3O2
DMIRYU9	IC	InChI=1S/C18H24ClN3O2/c19-14-7-13(17(8-15(14)20)24-10-11-1-2-11)18(23)21-16-9-22-5-3-12(16)4-6-22/h7-8,11-12,16H,1-6,9-10,20H2,(H,21,23)
DMIRYU9	CS	C1CC1COC2=CC(=C(C=C2C(=O)NC3CN4CCC3CC4)Cl)N
DMIRYU9	IK	DBQMQBCSKXTCIJ-UHFFFAOYSA-N
DMIRYU9	IU	4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-(cyclopropylmethoxy)benzamide
DMIRYU9	DE	Nausea

DMEW5Z8	ID	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	HS	Phase 3

DM3H2U4	ID	DM3H2U4
DM3H2U4	DN	Patrome
DM3H2U4	HS	Phase 3
DM3H2U4	CP	GlaxoSmithKline
DM3H2U4	DE	Parkinson disease

DMHXTAQ	ID	DMHXTAQ
DMHXTAQ	DN	Pazufloxacin
DMHXTAQ	HS	Phase 3
DMHXTAQ	SN	127045-41-4; T-3761; UNII-4CZ1R38NDI; 4CZ1R38NDI; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; Pazufloxacin [INN]; SMR000466380; CCRIS 7312; CAS-127045-41-4; T 3761; 127046-18-8; PZFX; Pazufloxacin (JAN/INN); SCHEMBL34460; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; MLS000759513; MLS001424116; CHEMBL240163; DTXSID5046697; CHEBI:94700; HY-B0724B; HMS2051B05; HMS2090H07; BCP12954; LSM-5745; RKL10069; ZINC3779726; Tox21_112531; BDBM50248017; MFCD00865012; AKOS015900451; Tox21_112531_1; AC-3506; CCG-100919; DB11774; GM-1171; KS-5008; NC00169; NCGC00167534-02; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (S)-; AB0012715; D01153; AB00639918-07; AB00639918-09; AB00639918_10; Pazufloxacin, VETRANAL(TM), analytical standard; SR-01000759348; J-005457; Q3898423; SR-01000759348-4; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)-; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-
DMHXTAQ	DT	Small molecular drug
DMHXTAQ	PC	65957
DMHXTAQ	MW	318.3
DMHXTAQ	FM	C16H15FN2O4
DMHXTAQ	IC	InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
DMHXTAQ	CS	C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O
DMHXTAQ	IK	XAGMUUZPGZWTRP-ZETCQYMHSA-N
DMHXTAQ	IU	(2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMHXTAQ	CA	CAS 127045-41-4
DMHXTAQ	CB	CHEBI:94700
DMHXTAQ	DE	Conjunctivitis

DMP3G0W	ID	DMP3G0W
DMP3G0W	DN	Pazufloxacin
DMP3G0W	HS	Phase 3
DMP3G0W	SN	Pazufloxacin; T-3761; Pazufloxacin [INN]; UNII-4CZ1R38NDI; CCRIS 7312; T 3761; 4CZ1R38NDI; C16H15FN2O4; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; SMR000466380; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
DMP3G0W	PC	65957
DMP3G0W	MW	318.3
DMP3G0W	FM	C16H15FN2O4
DMP3G0W	IC	InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
DMP3G0W	CS	CC1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O
DMP3G0W	IK	XAGMUUZPGZWTRP-ZETCQYMHSA-N
DMP3G0W	IU	(2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMP3G0W	CA	CAS 127045-41-4
DMP3G0W	CB	CHEBI:94700
DMP3G0W	DE	Bacterial conjunctivitis

DMJBHO0	ID	DMJBHO0
DMJBHO0	DN	PC-DAC:Insulin
DMJBHO0	HS	Phase 3
DMJBHO0	SN	Capsulin; Intesulin; Macrulin; Nodlin; SuliXen; AERx Diabetes Management System; AERx iDMS; Capsulin IR; Capsulin OAD; Capsulin insulin replacement; Insulin tregopil; Ultrafast Insulin program; HIM2; AERx (insulin); AT-1391; AT-2391; Analog-PH20; CADDYS (insulin); CJC-1530; CJC-1531; CJC-1575; CJC-1576; Capsulin oral anti-diabetic; DTY-001; GW-843362; GW-843362M; Hexyl insulin monoconjugate, Nobex; IN-105; Inhaled insulin, Andaris; Insulin-PH20; Intesulin-1; Intesulin-IVE; NB-058; NIN-058; NN-1998; ORMD-0801; Oral insulin, Emisphere; Oral insulin, Nobex; PC-Insulin; Inhaled insulin, QDose/BMS; Inhaled insulin, Quadrant/MicroDose; Insulin (inhaled), Aradigm; Insulin (inhaled), QDose; Insulin (inhaled),Translational Research; Insulin (oral), Biocon; Insulin (oral), Coremed; Insulin (oral), Protein Delivery Inc; Insulin (pulmonary), Translational Research; MicroPor (insulin), Altea
DMJBHO0	CP	Lipoxen plc; Aradigm; Translational Research Ltd; Diabetology Ltd; Coremed Inc; Nobex Corp; Altea Therapeutics; ConjuChem Biotechnologies Inc; Bioglan Pharmaceuticals Co; Epic Therapeutics Inc; NOD Pharmaceuticals Inc; Andaris Group Ltd; Emisphere Technologies Inc; halozyme therapeutics
DMJBHO0	DE	Type-1 diabetes; Type-2 diabetes

DMMBC5W	ID	DMMBC5W
DMMBC5W	DN	PDGF-BB
DMMBC5W	HS	Phase 3
DMMBC5W	SN	PDGF-BB (BioChaperone technology, diabetic foot ulcer/venous ulcers/burns)
DMMBC5W	CP	Adocia SAS
DMMBC5W	DE	Diabetic foot ulcer

DM53J6B	ID	DM53J6B
DM53J6B	DN	PDR001
DM53J6B	HS	Phase 3
DM53J6B	CP	Novartis Oncology East Hanover, NJ
DM53J6B	DT	Antibody
DM53J6B	DE	Lymphoma; Neuroendocrine cancer; Solid tumour/cancer; Melanoma; Esophageal squamous cell carcinoma

DMBKWAF	ID	DMBKWAF
DMBKWAF	DN	Peg-G-CSF
DMBKWAF	HS	Phase 3
DMBKWAF	SN	Peg-G-CSF (chemotherapy induced side effects)
DMBKWAF	CP	Phage Biotechnology Corp
DMBKWAF	DE	Solid tumour/cancer

DMK6OFY	ID	DMK6OFY
DMK6OFY	DN	Peginterferon lambda-1a
DMK6OFY	HS	Phase 3
DMK6OFY	SN	BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb
DMK6OFY	CP	Bristol-myers squibb
DMK6OFY	DE	Acute myeloid leukaemia

DMESAZK	ID	DMESAZK
DMESAZK	DN	Peretinoin
DMESAZK	HS	Phase 3
DMESAZK	SN	Polyprenoic acid; E-5166; NIK-333; Peretinoin (oral); Peretinoin (oral), Kowa; Peretinoin (oral formulation, hepatocellular carcinoma), Kowa Pharmaceutical
DMESAZK	CP	Kowa Pharmaceutical Co Ltd; Eisai Co Ltd
DMESAZK	DT	Small molecular drug
DMESAZK	PC	6437836
DMESAZK	MW	302.5
DMESAZK	FM	C20H30O2
DMESAZK	IC	InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+
DMESAZK	CS	CC(=CCC/C(=C/CC/C(=C/C=C/C(=C/C(=O)O)/C)/C)/C)C
DMESAZK	IK	UUBHZHZSIKRVIV-KCXSXWJSSA-N
DMESAZK	IU	(2E,4E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid
DMESAZK	CA	CAS 81485-25-8
DMESAZK	DE	Hepatocellular carcinoma

DMUP5Z0	ID	DMUP5Z0
DMUP5Z0	DN	PF-03084014
DMUP5Z0	HS	Phase 3
DMUP5Z0	SN	Nirogacestat; 1290543-63-3; PF-03084014; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01
DMUP5Z0	CP	Pfizer
DMUP5Z0	DT	Small molecular drug
DMUP5Z0	PC	46224413
DMUP5Z0	MW	489.6
DMUP5Z0	FM	C27H41F2N5O
DMUP5Z0	IC	InChI=1S/C27H41F2N5O/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35)/t20-,23-/m0/s1
DMUP5Z0	CS	CCC[C@@H](C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)N[C@H]2CCC3=C(C2)C(=CC(=C3)F)F
DMUP5Z0	IK	VFCRKLWBYMDAED-REWPJTCUSA-N
DMUP5Z0	IU	(2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide
DMUP5Z0	CA	CAS 1290543-63-3
DMUP5Z0	DE	Alzheimer disease; Solid tumour/cancer; Desmoid tumour

DM0TWCY	ID	DM0TWCY
DM0TWCY	DN	PF-04950615
DM0TWCY	HS	Phase 3
DM0TWCY	CP	Pfizer New York, NY
DM0TWCY	DT	Antibody
DM0TWCY	DE	Hypercholesterolaemia

DM8J29L	ID	DM8J29L
DM8J29L	DN	PF-04965842
DM8J29L	HS	Phase 3
DM8J29L	PC	78323835
DM8J29L	MW	323.42
DM8J29L	FM	C14H21N5O2S
DM8J29L	IC	InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)
DM8J29L	CS	CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3
DM8J29L	IK	IUEWXNHSKRWHDY-UHFFFAOYSA-N
DM8J29L	IU	N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
DM8J29L	CA	CAS 1622902-68-4
DM8J29L	DE	Lupus; Atopic dermatitis

DM23BUP	ID	DM23BUP
DM23BUP	DN	PF-05280014
DM23BUP	HS	Phase 3
DM23BUP	CP	Pfizer
DM23BUP	DE	Breast cancer

DMNZOCK	ID	DMNZOCK
DMNZOCK	DN	PF-05280586
DMNZOCK	HS	Phase 3
DMNZOCK	CP	Pfizer
DMNZOCK	DE	Cluster headache; Follicular lymphoma

DM2GF14	ID	DM2GF14
DM2GF14	DN	PF-06410293
DM2GF14	HS	Phase 3
DM2GF14	CP	Pfizer
DM2GF14	DT	Antibody
DM2GF14	DE	Rheumatoid arthritis

DMM4C95	ID	DMM4C95
DMM4C95	DN	PF-06438179
DMM4C95	HS	Phase 3
DMM4C95	CP	Pfizer
DMM4C95	DE	Rheumatoid arthritis

DMVHZDP	ID	DMVHZDP
DMVHZDP	DN	PF-06439535
DMVHZDP	HS	Phase 3
DMVHZDP	CP	Pfizer
DMVHZDP	DT	Antibody
DMVHZDP	DE	Solid tumour/cancer; Non-small-cell lung cancer

DMW63TQ	ID	DMW63TQ
DMW63TQ	DN	PF-06741086
DMW63TQ	HS	Phase 3
DMW63TQ	SN	marstacimab 
DMW63TQ	CP	Pfizer
DMW63TQ	DT	Antibody
DMW63TQ	DE	Hemophilia

DMWPA4L	ID	DMWPA4L
DMWPA4L	DN	PF-07055480
DMWPA4L	HS	Phase 3
DMWPA4L	SN	giroctocogene fitelparvovec
DMWPA4L	CP	Pfizer
DMWPA4L	DT	Gene therapy
DMWPA4L	DE	Haemophilia A

DMS1EQ7	ID	DMS1EQ7
DMS1EQ7	DN	PF-1228305
DMS1EQ7	HS	Phase 3
DMS1EQ7	SN	Sitaxentan sodium; Sitaxsentan sodium
DMS1EQ7	CP	Pfizer
DMS1EQ7	DT	Small molecular drug
DMS1EQ7	PC	11477084
DMS1EQ7	MW	476.9
DMS1EQ7	FM	C18H14ClN2NaO6S2
DMS1EQ7	IC	InChI=1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1
DMS1EQ7	CS	CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)[N-]C4=C(C(=NO4)C)Cl)OCO2.[Na+]
DMS1EQ7	IK	MDTNUYUCUYPIHE-UHFFFAOYSA-N
DMS1EQ7	IU	sodium;(4-chloro-3-methyl-1,2-oxazol-5-yl)-[2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophen-3-yl]sulfonylazanide
DMS1EQ7	CA	CAS 210421-74-2
DMS1EQ7	DE	Pulmonary hypertension

DMJ7IKW	ID	DMJ7IKW
DMJ7IKW	DN	PF-4494700
DMJ7IKW	HS	Phase 3
DMJ7IKW	SN	PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer
DMJ7IKW	CP	Transtech pharma
DMJ7IKW	DT	Small molecular drug
DMJ7IKW	PC	11180124
DMJ7IKW	MW	532.1
DMJ7IKW	FM	C32H38ClN3O2
DMJ7IKW	IC	InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3
DMJ7IKW	CS	CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC
DMJ7IKW	IK	KJNNWYBAOPXVJY-UHFFFAOYSA-N
DMJ7IKW	IU	3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine
DMJ7IKW	CA	CAS 603148-36-3
DMJ7IKW	DE	Dementia; Alzheimer disease

DM5DAP3	ID	DM5DAP3
DM5DAP3	DN	PGF2ALPHA-IE
DM5DAP3	HS	Phase 3
DM5DAP3	SN	Prostaglandin F2alpha isopropyl ester; (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid isopropyl ester
DM5DAP3	DT	Small molecular drug
DM5DAP3	PC	5283077
DM5DAP3	MW	396.6
DM5DAP3	FM	C23H40O5
DM5DAP3	IC	InChI=1S/C23H40O5/c1-4-5-8-11-18(24)14-15-20-19(21(25)16-22(20)26)12-9-6-7-10-13-23(27)28-17(2)3/h6,9,14-15,17-22,24-26H,4-5,7-8,10-13,16H2,1-3H3/b9-6-,15-14+/t18-,19+,20+,21-,22+/m0/s1
DM5DAP3	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)OC(C)C)O)O)O
DM5DAP3	IK	FPABVZYYTCHNMK-YNRDDPJXSA-N
DM5DAP3	IU	propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoate
DM5DAP3	CA	CAS 53764-90-2
DM5DAP3	CB	CHEBI:165336
DM5DAP3	DE	Glaucoma/ocular hypertension

DM8Y12A	ID	DM8Y12A
DM8Y12A	DN	PH-80
DM8Y12A	HS	Phase 3
DM8Y12A	SN	Vomeropherin (premenstrual syndrome), Pherin; Vomeropherin (premenstrual syndrome), Pherin/ Organon
DM8Y12A	CP	Pherin Corp
DM8Y12A	DE	Premenstrual syndrome

DMDC7OH	ID	DMDC7OH
DMDC7OH	DN	PH94B NS
DMDC7OH	HS	Phase 3
DMDC7OH	SN	Aloradine IN; Aloradine NS
DMDC7OH	CP	Pherin Pharmaceuticals Los Altos, CA
DMDC7OH	DE	Social anxiety disorder

DMVEHM4	ID	DMVEHM4
DMVEHM4	DN	Phentermine+topiramate
DMVEHM4	HS	Phase 3
DMVEHM4	SN	Qnexa (TN)
DMVEHM4	CP	Vivus
DMVEHM4	DT	Small molecular drug
DMVEHM4	PC	56842108
DMVEHM4	MW	488.6
DMVEHM4	FM	C22H36N2O8S
DMVEHM4	IC	InChI=1S/C12H21NO8S.C10H15N/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12;1-10(2,11)8-9-6-4-3-5-7-9/h7-9H,5-6H2,1-4H3,(H2,13,14,15);3-7H,8,11H2,1-2H3/t7-,8-,9?,12+;/m1./s1
DMVEHM4	CS	CC1(O[C@@H]2CO[C@@]3(C([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C.CC(C)(CC1=CC=CC=C1)N
DMVEHM4	IK	PWDLDBWXTVILPC-QGGVPXFVSA-N
DMVEHM4	IU	2-methyl-1-phenylpropan-2-amine;[(1R,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate
DMVEHM4	CA	CAS 960078-81-3
DMVEHM4	DE	Obesity

DMGZPX6	ID	DMGZPX6
DMGZPX6	DN	PI-88
DMGZPX6	HS	Phase 3
DMGZPX6	SN	CHEMBL603733
DMGZPX6	CP	Progen Industries
DMGZPX6	TC	Anticancer Agents
DMGZPX6	DT	Small molecular drug
DMGZPX6	PC	46233427
DMGZPX6	MW	2516.5
DMGZPX6	FM	C30H35Na15O77PS16-3
DMGZPX6	IC	InChI=1S/C30H53O77PS16.15Na/c31-108(32,33)82-1-6-14(99-116(55,56)57)20(102-119(64,65)66)25(106-123(76,77)78)29(87-6)94-17-12(97-114(49,50)51)8(3-84-110(37,38)39)89-27(23(17)104-121(70,71)72)92-16-11(96-113(46,47)48)7(2-83-109(34,35)36)88-26(22(16)103-120(67,68)69)93-18-13(98-115(52,53)54)9(4-85-111(40,41)42)90-28(24(18)105-122(73,74)75)95-21-19(101-118(61,62)63)15(100-117(58,59)60)10(5-86-112(43,44)45)91-30(21)107-124(79,80)81;;;;;;;;;;;;;;;/h6-30H,1-5H2,(H2,31,32,33)(H,34,35,36)(H,37,38,39)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81);;;;;;;;;;;;;;;/q;15*+1/p-18/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-;;;;;;;;;;;;;;;/m1.............../s1
DMGZPX6	CS	C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O[C@H]2[C@@H]([C@H](O[C@@H]([C@H]2OS(=O)(=O)[O-])O[C@H]3[C@@H]([C@H](O[C@@H]([C@H]3OS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H](O[C@@H]([C@H]4OS(=O)(=O)[O-])O[C@H]5[C@H]([C@@H]([C@H](O[C@@H]5OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMGZPX6	IK	FIYNUMVQYZZZCH-JSZMYKOGSA-A
DMGZPX6	IU	pentadecasodium;[(2R,3R,4S,5S,6R)-6-[(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5R,6R)-2-[(2R,3R,4S,5S,6R)-3,5-disulfonatooxy-2-(sulfonatooxymethyl)-6-[(2R,3S,4R,5R,6R)-2,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,4,5-trisulfonatooxyoxan-2-yl]methyl phosphate
DMGZPX6	DE	Prostate cancer; Hepatocellular carcinoma

DM7OSHC	ID	DM7OSHC
DM7OSHC	DN	Pinaverium bromide
DM7OSHC	HS	Phase 3
DM7OSHC	SN	Dicetel; Bromure de pinaverium; Bromuro de pinaverio; Pinaverii bromidum; Pinaverium bromide [INN]; LAT 1717; Bromure de pinaverium [INN-French]; Bromuro de pinaverio [INN-Spanish]; Dicetel (TN); Pinaverii bromidum [INN-Latin]; Pinaverium bromide (INN); Morpholinium, 4-(2-bromo-4,5-dimethoxy)benzyl-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)-, bromide; 4-(6-Bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium bromide; 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium bromide
DM7OSHC	CP	Solvay
DM7OSHC	DT	Small molecular drug
DM7OSHC	PC	40703
DM7OSHC	MW	591.4
DM7OSHC	FM	C26H41Br2NO4
DM7OSHC	IC	InChI=1S/C26H41BrNO4.BrH/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27;/h15,17,19,21-22H,5-14,16,18H2,1-4H3;1H/q+1;/p-1
DM7OSHC	CS	CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C.[Br-]
DM7OSHC	IK	IKGXLCMLVINENI-UHFFFAOYSA-M
DM7OSHC	IU	4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium;bromide
DM7OSHC	CA	CAS 53251-94-8
DM7OSHC	DE	Irritable bowel syndrome

DMRG1X3	ID	DMRG1X3
DMRG1X3	DN	Pirtobrutinib
DMRG1X3	HS	Phase 3
DMRG1X3	SN	BTK inhibitor 16; 2101700-15-4; Pirtobrutinib [USAN]; UNII-JNA39I7ZVB; JNA39I7ZVB; LOXO-305; SCHEMBL19014257; WHO 11681; HY-131328; LY3527727; CS-0133286; (S)-5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide; 1H-Pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1S)-2,2,2-trifluoro-1-methylethyl)-
DMRG1X3	CP	LOXO Oncology
DMRG1X3	DT	Small molecular drug
DMRG1X3	PC	129269915
DMRG1X3	MW	479.4
DMRG1X3	FM	C22H21F4N5O3
DMRG1X3	IC	InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1
DMRG1X3	CS	C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N
DMRG1X3	IK	FWZAWAUZXYCBKZ-NSHDSACASA-N
DMRG1X3	IU	5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide
DMRG1X3	CA	CAS 2101700-15-4
DMRG1X3	DE	Chronic lymphocytic leukaemia; Small lymphocytic lymphoma

DMQGR45	ID	DMQGR45
DMQGR45	DN	Pixantrone
DMQGR45	HS	Phase 3
DMQGR45	SN	Pixuvri (TN)
DMQGR45	CP	Cell Therapeutics
DMQGR45	DT	Small molecular drug
DMQGR45	PC	134019
DMQGR45	MW	325.4
DMQGR45	FM	C17H19N5O2
DMQGR45	IC	InChI=1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2
DMQGR45	CS	C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN
DMQGR45	IK	PEZPMAYDXJQYRV-UHFFFAOYSA-N
DMQGR45	IU	6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione
DMQGR45	CA	CAS 144510-96-3
DMQGR45	CB	CHEBI:135945
DMQGR45	DE	Multiple sclerosis; Follicular lymphoma; Diffuse large B-cell lymphoma; Pediatric cancer

DMCA6BW	ID	DMCA6BW
DMCA6BW	DN	Pixykine
DMCA6BW	HS	Phase 3
DMCA6BW	SN	Milodistim; Plasmid Immunex yeast 321; PIXY-321
DMCA6BW	CP	Immunex Corp
DMCA6BW	DE	Human immunodeficiency virus infection

DM1RWMY	ID	DM1RWMY
DM1RWMY	DN	Plasma derived factor VIII PEGylated liposomal
DM1RWMY	HS	Phase 3
DM1RWMY	SN	LongAte; NecLip-pdFVIII; Plasma derived factor VIII (PEGylated liposomal (NecLip), hemophilia A), Recoly
DM1RWMY	CP	Recoly NV
DM1RWMY	DE	Factor VIII deficiency

DMD7L48	ID	DMD7L48
DMD7L48	DN	Plinabulin
DMD7L48	HS	Phase 3
DMD7L48	SN	NPI-2358
DMD7L48	CP	Nereus Pharmaceuticals
DMD7L48	DT	Small molecular drug
DMD7L48	PC	9949641
DMD7L48	MW	336.4
DMD7L48	FM	C19H20N4O2
DMD7L48	IC	InChI=1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9-,15-10-
DMD7L48	CS	CC(C)(C)C1=C(N=CN1)/C=C\\2/C(=O)N/C(=C\\C3=CC=CC=C3)/C(=O)N2
DMD7L48	IK	UNRCMCRRFYFGFX-TYPNBTCFSA-N
DMD7L48	IU	(3Z,6Z)-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]piperazine-2,5-dione
DMD7L48	CA	CAS 714272-27-2
DMD7L48	DE	Non-small-cell lung cancer

DMJ8AUE	ID	DMJ8AUE
DMJ8AUE	DN	Plitidepsin
DMJ8AUE	HS	Phase 3
DMJ8AUE	SN	Aplidin (TN)
DMJ8AUE	CP	PharmaMar
DMJ8AUE	DT	Small molecular drug
DMJ8AUE	PC	9812534
DMJ8AUE	MW	1110.3
DMJ8AUE	FM	C57H87N7O15
DMJ8AUE	IC	InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1
DMJ8AUE	CS	CC[C@H](C)[C@@H]1[C@H](CC(=O)O[C@H](C(=O)[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O
DMJ8AUE	IK	UUSZLLQJYRSZIS-LXNNNBEUSA-N
DMJ8AUE	IU	(2S)-N-[(2R)-1-[[(3S,6S,8S,12S,13R,16S,17R,20S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
DMJ8AUE	CA	CAS 137219-37-5
DMJ8AUE	CB	CHEBI:90205
DMJ8AUE	DE	Multiple myeloma; Angioimmunoblastic T-cell Lymphoma

DMV8EXG	ID	DMV8EXG
DMV8EXG	DN	PolyHeme
DMV8EXG	HS	Phase 3
DMV8EXG	SN	Oxygen-carrying blood substitute, Northfield Laboratories
DMV8EXG	CP	Northfield Laboratories
DMV8EXG	PC	72941846
DMV8EXG	MW	347.26
DMV8EXG	FM	C13H18NO8P
DMV8EXG	IC	InChI=1S/C8H10NO6P.C5H8O2/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14;6-4-2-1-3-5-7/h2-3,11H,4H2,1H3,(H2,12,13,14);4-5H,1-3H2
DMV8EXG	CS	CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O.C(CC=O)CC=O
DMV8EXG	IK	SKKYPUWZZNPUMG-UHFFFAOYSA-N
DMV8EXG	IU	(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate;pentanedial
DMV8EXG	DE	Blood forming organ disorder

DMTD7AB	ID	DMTD7AB
DMTD7AB	DN	Pracinostat
DMTD7AB	HS	Phase 3
DMTD7AB	SN	Pracinostat; 929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-
DMTD7AB	CP	MEI Pharma
DMTD7AB	DT	Small molecular drug
DMTD7AB	PC	49855250
DMTD7AB	MW	358.5
DMTD7AB	FM	C20H30N4O2
DMTD7AB	IC	InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+
DMTD7AB	CS	CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)/C=C/C(=O)NO
DMTD7AB	IK	JHDKZFFAIZKUCU-ZRDIBKRKSA-N
DMTD7AB	IU	(E)-3-[2-butyl-1-[2-(diethylamino)ethyl]benzimidazol-5-yl]-N-hydroxyprop-2-enamide
DMTD7AB	CA	CAS 929016-96-6
DMTD7AB	CB	CHEBI:95071
DMTD7AB	DE	Myelofibrosis; Myelodysplastic syndrome; Acute myeloid leukaemia

DM2ZYX9	ID	DM2ZYX9
DM2ZYX9	DN	Pradaxa
DM2ZYX9	HS	Phase 3
DM2ZYX9	SN	Dabigatran etexilate mesylate; 872728-81-9; XETBXHPXHHOLOE-UHFFFAOYSA-N; CP0128; FT-0660872; ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate methanesulphonate; 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-amino-methyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide mesylate
DM2ZYX9	CP	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DM2ZYX9	PC	11434065
DM2ZYX9	MW	723.8
DM2ZYX9	FM	C35H45N7O8S
DM2ZYX9	IC	InChI=1S/C34H41N7O5.CH4O3S/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29;1-5(2,3)4/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44);1H3,(H,2,3,4)
DM2ZYX9	CS	CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)\\N.CS(=O)(=O)O
DM2ZYX9	IK	XETBXHPXHHOLOE-UHFFFAOYSA-N
DM2ZYX9	IU	ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid
DM2ZYX9	CA	CAS 872728-81-9
DM2ZYX9	DE	Stroke

DMOMDXI	ID	DMOMDXI
DMOMDXI	DN	Pratosartan
DMOMDXI	HS	Phase 3
DMOMDXI	SN	KD3-671; KT3-671
DMOMDXI	CP	Kotobuki Pharmaceutical Co Ltd
DMOMDXI	DT	Small molecular drug
DMOMDXI	PC	9802561
DMOMDXI	MW	426.5
DMOMDXI	FM	C25H26N6O
DMOMDXI	IC	InChI=1S/C25H26N6O/c1-2-7-23-26-21-10-5-6-11-22(32)24(21)31(23)16-17-12-14-18(15-13-17)19-8-3-4-9-20(19)25-27-29-30-28-25/h3-4,8-9,12-15H,2,5-7,10-11,16H2,1H3,(H,27,28,29,30)
DMOMDXI	CS	CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)CCCC2
DMOMDXI	IK	KCTFTBCZZUBAKN-UHFFFAOYSA-N
DMOMDXI	IU	2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6,7,8-tetrahydrocyclohepta[d]imidazol-4-one
DMOMDXI	CA	CAS 153804-05-8
DMOMDXI	CB	CHEBI:32041
DMOMDXI	DE	Hypertension

DMLSOB7	ID	DMLSOB7
DMLSOB7	DN	Premarin/Pravachol
DMLSOB7	HS	Phase 3
DMLSOB7	SN	Estrogen/Eptastatin
DMLSOB7	CP	Bristol-Myers Squibb
DMLSOB7	DE	Hyperlipidaemia

DMX9YLR	ID	DMX9YLR
DMX9YLR	DN	Pridopidine
DMX9YLR	HS	Phase 3
DMX9YLR	SN	PRIDOPIDINE; 346688-38-8; 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine; 4-(3-(Methylsulfonyl)phenyl)-1-propylpiperidine; ACR-16; UNII-HD4TW8S2VK; ACR16; ACR 16; HD4TW8S2VK; CHEMBL596802; FR310826; Pridopidine [USAN:INN]; Pridopidine (USAN/INN); 4-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine; SCHEMBL166748; CTK4H2809; DTXSID90188225; ASP 2314; ZINC22063703; BDBM50308028; AKOS015891431; DB11947; NCGC00386586-01; HY-10684; AS-50146; AJ-80925; FR 310826; DB-014417; AX8258340; CS-0002733; FT-0672149;  Huntexil; Pridopidine hydrochloride; ASP-2314; Dopamine modulator (Huntingtons disease), Carlsson Research; Dopamine modulator (Huntingtons disease), NeuroSearch; Dopamine modulator (schizophrenia), Astellas; Dopamine modulator (schizophrenia), Fujisawa; Dopamine modulator (neurological disorders), Merck & Co
DMX9YLR	CP	Teva pharmaceutical
DMX9YLR	DT	Small molecular drug
DMX9YLR	PC	9795739
DMX9YLR	MW	281.4
DMX9YLR	FM	C15H23NO2S
DMX9YLR	IC	InChI=1S/C15H23NO2S/c1-3-9-16-10-7-13(8-11-16)14-5-4-6-15(12-14)19(2,17)18/h4-6,12-13H,3,7-11H2,1-2H3
DMX9YLR	CS	CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C
DMX9YLR	IK	YGKUEOZJFIXDGI-UHFFFAOYSA-N
DMX9YLR	IU	4-(3-methylsulfonylphenyl)-1-propylpiperidine
DMX9YLR	CA	CAS 346688-38-8
DMX9YLR	DE	Huntington disease

DMD1FTP	ID	DMD1FTP
DMD1FTP	DN	PRO-140
DMD1FTP	HS	Phase 3
DMD1FTP	SN	PRO-140 (sc); Humanized monoclonal anibody (subcutaneous, HIV infection), Progenics; PRO-140 (subcutaneous, HIV); CCR5 antagonist (subcutaneous, humanized mAb, HIV infection), Progenics; PRO-140 (subcutaneous, HIV), Progenics Pharmaceuticals
DMD1FTP	CP	Progenics Pharmaceuticals Inc
DMD1FTP	DE	Human immunodeficiency virus infection

DM5FZH4	ID	DM5FZH4
DM5FZH4	DN	ProstaVac
DM5FZH4	HS	Phase 3
DM5FZH4	SN	Pox virus vector prostate specific antigen vaccine (benign prostatic hyperplasia/prostatitis); Pox virus vector prostate specific antigen vaccine (benign prostatic hyperplasia/prostatitis), AmVac
DM5FZH4	CP	AmVac AG
DM5FZH4	DT	Vaccine
DM5FZH4	DE	Prostate hyperplasia

DMVU8RW	ID	DMVU8RW
DMVU8RW	DN	PRT4445
DMVU8RW	HS	Phase 3
DMVU8RW	CP	Portola pharmaceuticals
DMVU8RW	DE	Bleeding disorder

DMEH641	ID	DMEH641
DMEH641	DN	PRX-302
DMEH641	HS	Phase 3
DMEH641	CP	Sophiris
DMEH641	DE	Prostate cancer

DMIZJ8M	ID	DMIZJ8M
DMIZJ8M	DN	Psoralen
DMIZJ8M	HS	Phase 3
DMIZJ8M	SN	Psoralen; 66-97-7; 7H-Furo[3,2-g]chromen-7-one; Ficusin; Furocoumarin; Psoralene; 7H-Furo[3,2-g][1]benzopyran-7-one; Psorline-P; 6,7-Furanocoumarin; furo[3,2-g]chromen-7-one; Furo[3,2-g]coumarin; Furo(4',5',6,7)coumarin; Furo(2',3',7,6)coumarin; Furo(3,2-g)-coumarin; Furo[4',5':6,7]coumarin; Furo[2',3':7,6]coumarin; NSC 404562; UNII-KTZ7ZCN2EX; 7H-Furo(3,2-g)(1)benzopyran-7-one; 7H-Furo[3,2-g]benzopyran-7-one; CCRIS 4343; Furo[2'.3':7.6]coumarin; HSDB 3528; KTZ7ZCN2EX; EINECS 200-639-7; 6-Hydroxy-5-benzofuranacrylic acid beta-lacto
DMIZJ8M	DT	Small molecular drug
DMIZJ8M	PC	6199
DMIZJ8M	MW	186.16
DMIZJ8M	FM	C11H6O3
DMIZJ8M	IC	InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H
DMIZJ8M	CS	C1=CC(=O)OC2=CC3=C(C=CO3)C=C21
DMIZJ8M	IK	ZCCUUQDIBDJBTK-UHFFFAOYSA-N
DMIZJ8M	IU	furo[3,2-g]chromen-7-one
DMIZJ8M	CA	CAS 66-97-7
DMIZJ8M	CB	CHEBI:27616

DMTSN8L	ID	DMTSN8L
DMTSN8L	DN	PT005
DMTSN8L	HS	Phase 3
DMTSN8L	SN	Perforomist; Atock; Foradil Aerolizer; Foradil Certihaler; YM-08316; Broncoral; Eolus; Oxis Turbuhaler; BD-40A; Eformoterol fumarate; Formoterol Easyhaler; CGP-25827A; AC1OCEVQ; PT-005
DMTSN8L	CP	Pearl Therapeutics
DMTSN8L	DT	Small molecular drug
DMTSN8L	PC	6917983
DMTSN8L	MW	822.9
DMTSN8L	FM	C42H54N4O13
DMTSN8L	IC	InChI=1S/2C19H24N2O4.C4H4O4.H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);1H2/b;;2-1+;/t2*13-,19+;;/m11../s1
DMTSN8L	CS	C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O.C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O.C(=C/C(=O)O)\\C(=O)O.O
DMTSN8L	IK	BPXZSHHCUKRDHD-HTLUESNNSA-N
DMTSN8L	IU	(E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;hydrate
DMTSN8L	DE	Chronic obstructive pulmonary disease

DML1KTO	ID	DML1KTO
DML1KTO	DN	PT2977
DML1KTO	HS	Phase 3
DML1KTO	SN	MK-6482
DML1KTO	CP	Peloton Therapeutics Dallas, TX
DML1KTO	PC	117947097
DML1KTO	MW	383.3
DML1KTO	FM	C17H12F3NO4S
DML1KTO	IC	InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1
DML1KTO	CS	CS(=O)(=O)C1=C2[C@@H]([C@@H]([C@@H](C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O
DML1KTO	IK	LOMMPXLFBTZENJ-ZACQAIPSSA-N
DML1KTO	IU	3-[[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]oxy]-5-fluorobenzonitrile
DML1KTO	CA	CAS 1672668-24-4
DML1KTO	DE	Solid tumour/cancer; Von hippel-lindau disease; Renal cell carcinoma

DMMJ63A	ID	DMMJ63A
DMMJ63A	DN	PT-304
DMMJ63A	HS	Phase 3
DMMJ63A	SN	149486-04-4; Thiourea, N-(2-(3-fluorophenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(3-fluorophenyl)ethyl]-N'-2-thiazolyl-; PETT Analog 3; AC1MHDMA; SCHEMBL6964163; CHEMBL253995; BDBM1896; DTXSID20164299; 1-[2-(3-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; AKOS030030941; 1-(2-Thiazolyl)-3-[3-fluorophenethyl]thiourea; N-(2-(3-Fluorophenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(3-fluorophenyl)ethyl]-3-thiazol-2-yl-thiourea
DMMJ63A	DT	Small molecular drug
DMMJ63A	PC	3001163
DMMJ63A	MW	281.4
DMMJ63A	FM	C12H12FN3S2
DMMJ63A	IC	InChI=1S/C12H12FN3S2/c13-10-3-1-2-9(8-10)4-5-14-11(17)16-12-15-6-7-18-12/h1-3,6-8H,4-5H2,(H2,14,15,16,17)
DMMJ63A	CS	C1=CC(=CC(=C1)F)CCNC(=S)NC2=NC=CS2
DMMJ63A	IK	NDHSDDFIIZKISX-UHFFFAOYSA-N
DMMJ63A	IU	1-[2-(3-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMMJ63A	CA	CAS 149486-04-4

DMVDCGZ	ID	DMVDCGZ
DMVDCGZ	DN	Pyridoxamine
DMVDCGZ	HS	Phase 3
DMVDCGZ	SN	Pyridorin (TN)
DMVDCGZ	CP	Nephrogenex
DMVDCGZ	DT	Small molecular drug
DMVDCGZ	PC	1052
DMVDCGZ	MW	168.19
DMVDCGZ	FM	C8H12N2O2
DMVDCGZ	IC	InChI=1S/C8H12N2O2/c1-5-8(12)7(2-9)6(4-11)3-10-5/h3,11-12H,2,4,9H2,1H3
DMVDCGZ	CS	CC1=NC=C(C(=C1O)CN)CO
DMVDCGZ	IK	NHZMQXZHNVQTQA-UHFFFAOYSA-N
DMVDCGZ	IU	4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol
DMVDCGZ	CA	CAS 85-87-0
DMVDCGZ	CB	CHEBI:16410
DMVDCGZ	DE	Diabetic nephropathy; Diabetic kidney disease

DMPCFXN	ID	DMPCFXN
DMPCFXN	DN	QAW-039
DMPCFXN	HS	Phase 3
DMPCFXN	DE	Asthma

DMDU5Y2	ID	DMDU5Y2
DMDU5Y2	DN	QPI-1002
DMDU5Y2	HS	Phase 3
DMDU5Y2	CP	Quark Pharmaceuticals
DMDU5Y2	TC	siRNA
DMDU5Y2	DT	siRNA drug
DMDU5Y2	DE	Renal artery disease; Renal transplantation

DMUWXEB	ID	DMUWXEB
DMUWXEB	DN	QPI-1007
DMUWXEB	HS	Phase 3
DMUWXEB	SN	SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals
DMUWXEB	CP	Quark pharmaceuticals
DMUWXEB	DT	siRNA drug
DMUWXEB	DE	Glaucoma/ocular hypertension; Ischemic optic neuropathy; Non-arteritic anterior ischemic optic neuropathy

DMDCQW0	ID	DMDCQW0
DMDCQW0	DN	Quinotolast
DMDCQW0	HS	Phase 3
DMDCQW0	SN	Aslock; Quinotalast; FK-021; FR-71021
DMDCQW0	CP	Fujisawa Pharmaceutical Co Ltd
DMDCQW0	DT	Small molecular drug
DMDCQW0	PC	65871
DMDCQW0	MW	348.32
DMDCQW0	FM	C17H12N6O3
DMDCQW0	IC	InChI=1S/C17H12N6O3/c24-15(18-17-19-21-22-20-17)12-10-14(26-11-6-2-1-3-7-11)13-8-4-5-9-23(13)16(12)25/h1-10H,(H2,18,19,20,21,22,24)
DMDCQW0	CS	C1=CC=C(C=C1)OC2=C3C=CC=CN3C(=O)C(=C2)C(=O)NC4=NNN=N4
DMDCQW0	IK	ZUPLNRDTYQWUHP-UHFFFAOYSA-N
DMDCQW0	IU	4-oxo-1-phenoxy-N-(2H-tetrazol-5-yl)quinolizine-3-carboxamide
DMDCQW0	CA	CAS 101193-40-2
DMDCQW0	DE	Asthma

DMSFX75	ID	DMSFX75
DMSFX75	DN	QVA-149
DMSFX75	HS	Phase 3
DMSFX75	SN	Glycopyrrolate mixture with indacaterol; 1262431-94-6; Utibron; Utibron Neohaler; Ultibro Breezhaler; Glycopyrrolate / indacaterol; Indacaterol / glycopyrronium; Indacaterol / glycopyrrolate; QVA149; QVA 149; Glycopyrronium bromide / indacaterol
DMSFX75	CP	Sosei; Vectura; Novartis
DMSFX75	DT	Small molecular drug
DMSFX75	PC	11564052
DMSFX75	MW	790.8
DMSFX75	FM	C43H56BrN3O6
DMSFX75	IC	InChI=1S/C24H28N2O3.C19H28NO3.BrH/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q;+1;/p-1/t22-;;/m0../s1
DMSFX75	CS	CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC.C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
DMSFX75	IK	GCUZFFAPBPDIFM-IKXQUJFKSA-M
DMSFX75	IU	5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one;(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
DMSFX75	CA	CAS 1262431-94-6
DMSFX75	DE	Chronic obstructive pulmonary disease

DM4K9WH	ID	DM4K9WH
DM4K9WH	DN	R1678
DM4K9WH	HS	Phase 3
DM4K9WH	SN	R-1678; RG-1678
DM4K9WH	CP	Roche
DM4K9WH	DT	Small molecular drug
DM4K9WH	PC	137905
DM4K9WH	MW	342.3
DM4K9WH	FM	C22H14O4
DM4K9WH	IC	InChI=1S/C22H14O4/c23-19(15-7-3-1-4-8-15)21(25)17-11-13-18(14-12-17)22(26)20(24)16-9-5-2-6-10-16/h1-14H
DM4K9WH	CS	C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)C(=O)C(=O)C3=CC=CC=C3
DM4K9WH	IK	FUEGWHHUYNHBNI-UHFFFAOYSA-N
DM4K9WH	IU	1-[4-(2-oxo-2-phenylacetyl)phenyl]-2-phenylethane-1,2-dione
DM4K9WH	CA	CAS 3363-97-1
DM4K9WH	DE	Schizophrenia

DM9Z4N5	ID	DM9Z4N5
DM9Z4N5	DN	RA101495
DM9Z4N5	HS	Phase 3
DM9Z4N5	SN	Zilucoplan
DM9Z4N5	CP	Ra Pharmaceuticals Cambridge, MA
DM9Z4N5	PC	133083018
DM9Z4N5	MW	3562
DM9Z4N5	FM	C172H278N24O55
DM9Z4N5	IC	InChI=1S/C172H278N24O55/c1-9-10-11-12-13-14-15-16-17-18-19-20-27-44-146(202)182-136(170(226)227)53-56-144(200)177-64-67-229-69-71-231-73-75-233-77-79-235-81-83-237-85-87-239-89-91-241-93-95-243-97-99-245-101-103-247-105-107-249-109-111-251-113-112-250-110-108-248-106-104-246-102-100-244-98-96-242-94-92-240-90-88-238-86-84-236-82-80-234-78-76-232-74-72-230-70-68-228-66-59-145(201)175-60-31-29-41-135(169(224)225)186-165(220)152(126-37-25-22-26-38-126)193-162(217)142-43-34-65-196(142)168(223)140(116-125-47-51-129(199)52-48-125)190-157(212)133(54-57-148(204)205)184-161(216)139(117-127-120-180-154-130(127)39-32-62-178-154)188-159(214)138(115-124-45-49-128(198)50-46-124)189-166(221)153(172(5,6)7)194-163(218)143(119-150(208)209)195(8)167(222)141-118-147(203)176-61-30-28-40-131(181-122(4)197)158(213)192-151(121(2)3)164(219)185-134(55-58-149(206)207)156(211)183-132(42-33-63-179-171(173)174)155(210)187-137(160(215)191-141)114-123-35-23-21-24-36-123/h21,23-24,32,35-36,39,45-52,62,120-121,126,131-143,151-153,198-199H,9-20,22,25-31,33-34,37-38,40-44,53-61,63-119H2,1-8H3,(H,175,201)(H,176,203)(H,177,200)(H,178,180)(H,181,197)(H,182,202)(H,183,211)(H,184,216)(H,185,219)(H,186,220)(H,187,210)(H,188,214)(H,189,221)(H,190,212)(H,191,215)(H,192,213)(H,193,217)(H,194,218)(H,204,205)(H,206,207)(H,208,209)(H,224,225)(H,226,227)(H4,173,174,179)/t131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,151-,152-,153+/m0/s1
DM9Z4N5	CS	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](C1CCCCC1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CNC5=C4C=CC=N5)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(=O)O)N(C)C(=O)[C@@H]7CC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O
DM9Z4N5	IK	JDXCOXKBIGBZSK-PSNKNOTQSA-N
DM9Z4N5	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,5S,8S,11S,14S,22S)-22-acetamido-11-benzyl-8-(3-carbamimidamidopropyl)-5-(2-carboxyethyl)-3,6,9,12,16,23-hexaoxo-2-propan-2-yl-1,4,7,10,13,17-hexazacyclotricosane-14-carbonyl]-methylamino]-3-carboxypropanoyl]amino]-3,3-dimethylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-2-cyclohexylacetyl]amino]-6-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(4S)-4-carboxy-4-(hexadecanoylamino)butanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]hexanoic acid
DM9Z4N5	CA	CAS 1841136-73-9
DM9Z4N5	DE	Paroxysmal nocturnal haemoglobinuria; Myasthenia gravis

DM8RLJ5	ID	DM8RLJ5
DM8RLJ5	DN	RAD-1901
DM8RLJ5	HS	Phase 3
DM8RLJ5	SN	ER-306323; ER-308698; SERMs, Eisai/Radius; Selective estrogen receptor modulators, Eisai/Radius
DM8RLJ5	CP	Eisai Co Ltd
DM8RLJ5	PC	23642301
DM8RLJ5	MW	458.6
DM8RLJ5	FM	C30H38N2O2
DM8RLJ5	IC	InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1
DM8RLJ5	CS	CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)[C@@H]3CCC4=C(C3)C=CC(=C4)O
DM8RLJ5	IK	SIFNOOUKXBRGGB-AREMUKBSSA-N
DM8RLJ5	IU	(6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
DM8RLJ5	CA	CAS 722533-56-4
DM8RLJ5	DE	Breast cancer

DMN1ZEU	ID	DMN1ZEU
DMN1ZEU	DN	Radiosensitizer gene therapy
DMN1ZEU	HS	Phase 3
DMN1ZEU	SN	Radiosensitizer gene therapy (prostate cancer)
DMN1ZEU	CP	Advantagene
DMN1ZEU	DE	Pancreatic cancer

DMWA74Y	ID	DMWA74Y
DMWA74Y	DN	Radotinib
DMWA74Y	HS	Phase 3
DMWA74Y	SN	IY-5511; IY-GV50205; Anticancer, Il-yang
DMWA74Y	CP	Il-Yang Pharmaceutical Co
DMWA74Y	DT	Small molecular drug
DMWA74Y	PC	16063245
DMWA74Y	MW	530.5
DMWA74Y	FM	C27H21F3N8O
DMWA74Y	IC	InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
DMWA74Y	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=NC=CN=C5
DMWA74Y	IK	DUPWHXBITIZIKZ-UHFFFAOYSA-N
DMWA74Y	IU	4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide
DMWA74Y	CA	CAS 926037-48-1
DMWA74Y	DE	leukaemia

DMFSHEM	ID	DMFSHEM
DMFSHEM	DN	Ragaglitazar
DMFSHEM	HS	Phase 3
DMFSHEM	SN	Ragaglitazar; DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid
DMFSHEM	DT	Small molecular drug
DMFSHEM	PC	447458
DMFSHEM	MW	419.5
DMFSHEM	FM	C25H25NO5
DMFSHEM	IC	InChI=1S/C25H25NO5/c1-2-29-24(25(27)28)17-18-11-13-19(14-12-18)30-16-15-26-20-7-3-5-9-22(20)31-23-10-6-4-8-21(23)26/h3-14,24H,2,15-17H2,1H3,(H,27,28)/t24-/m0/s1
DMFSHEM	CS	CCO[C@@H](CC1=CC=C(C=C1)OCCN2C3=CC=CC=C3OC4=CC=CC=C42)C(=O)O
DMFSHEM	IK	WMUIIGVAWPWQAW-DEOSSOPVSA-N
DMFSHEM	IU	(2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid
DMFSHEM	CA	CAS 222834-30-2
DMFSHEM	DE	Type-1 diabetes

DMUNMY0	ID	DMUNMY0
DMUNMY0	DN	Ralfinamide
DMUNMY0	HS	Phase 3
DMUNMY0	SN	Ralfinamida; Ralfinamide [INN]; NW 1029; NW-1029; Ralfinamida [INN-Spanish]; (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide; (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DMUNMY0	CP	Newron
DMUNMY0	TC	Analgesics
DMUNMY0	DT	Small molecular drug
DMUNMY0	PC	5745207
DMUNMY0	MW	302.34
DMUNMY0	FM	C17H19FN2O2
DMUNMY0	IC	InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DMUNMY0	CS	C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2F
DMUNMY0	IK	BHJIBOFHEFDSAU-LBPRGKRZSA-N
DMUNMY0	IU	(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DMUNMY0	CA	CAS 133865-88-0
DMUNMY0	DE	Neuropathic pain

DMD5QRS	ID	DMD5QRS
DMD5QRS	DN	Ranirestat
DMD5QRS	HS	Phase 3
DMD5QRS	SN	AS-3201
DMD5QRS	CP	Eisai
DMD5QRS	DT	Small molecular drug
DMD5QRS	PC	153948
DMD5QRS	MW	420.2
DMD5QRS	FM	C17H11BrFN3O4
DMD5QRS	IC	InChI=1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1
DMD5QRS	CS	C1C(=O)NC(=O)[C@@]12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
DMD5QRS	IK	QCVNMNYRNIMDKV-QGZVFWFLSA-N
DMD5QRS	IU	(3R)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone
DMD5QRS	CA	CAS 147254-64-6
DMD5QRS	DE	Diabetic neuropathy

DMVKL3B	ID	DMVKL3B
DMVKL3B	DN	Ravulizumab
DMVKL3B	HS	Phase 3
DMVKL3B	SN	Ultomiris (TN); Ravulizumab (USAN); Ravulizumab (genetical recombination) (JAN); D11054; 1803171-55-2
DMVKL3B	TC	Antiviral Agents
DMVKL3B	DT	Monoclonal antibody
DMVKL3B	DE	Coronavirus Disease 2019 (COVID-19)

DMPJTZ1	ID	DMPJTZ1
DMPJTZ1	DN	RBP-7000
DMPJTZ1	HS	Phase 3
DMPJTZ1	CP	Reckitt benckiser pharmaceutical
DMPJTZ1	DE	Non-small-cell lung cancer; Schizophrenia

DMDZW8K	ID	DMDZW8K
DMDZW8K	DN	RBT-101
DMDZW8K	HS	Phase 3
DMDZW8K	SN	RBT-102; RBT-103; RBT-104; Seasonal/pandemic influenza vaccines (VLPs); Seasonal/pandemic influenza vaccines (VLPs), Redbiotec; Seasonal/pandemic influenza vaccines (virus-like-particles), Redbiotec
DMDZW8K	CP	Redbiotec AG
DMDZW8K	DE	Influenza virus infection; Heart failure; Respiratory tract infection

DM2GHCR	ID	DM2GHCR
DM2GHCR	DN	Rebamipide
DM2GHCR	HS	Phase 3
DM2GHCR	SN	rebamipide; 90098-04-7; Mucosta; Proamipide; 111911-87-6; OPC-12759; Rebamipidum; Pramipide; Rebamipide [INN:JAN]; Rebamipidum [INN-Latin]; Rebamipida [INN-Spanish]; OPC 12759; CCRIS 3585; Rebamipide hydrate; 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid; 139344-42-6; 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid; Mucosta hydrate; NCGC00095161-01; Proamipide hydrate; 2-(4-Chlorobenzamido)-3-[2(1H)-quinolinon-4-yl]propionic Acid
DM2GHCR	DT	Small molecular drug
DM2GHCR	PC	5042
DM2GHCR	MW	370.8
DM2GHCR	FM	C19H15ClN2O4
DM2GHCR	IC	InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)
DM2GHCR	CS	C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl
DM2GHCR	IK	ALLWOAVDORUJLA-UHFFFAOYSA-N
DM2GHCR	IU	2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
DM2GHCR	CA	CAS 90098-04-7
DM2GHCR	CB	CHEBI:93814
DM2GHCR	DE	Peptic ulcer

DM8HVNR	ID	DM8HVNR
DM8HVNR	DN	Recombinant acidic fibroblast growth factor
DM8HVNR	HS	Phase 3
DM8HVNR	SN	AFGF; Rh-aFGF; Recombinant acidic fibroblast growth factor (ulcer/burns); Recombinant acidic fibroblast growth factor (ulcer/burns), SinoBiomed; Recombinant acidic fibroplast growth factor (ulcer/burns), SinoBiomed
DM8HVNR	CP	SinoBiomed Inc
DM8HVNR	DE	Skin burns

DMOWQAF	ID	DMOWQAF
DMOWQAF	DN	Recombinant human iduronate-2-sulfatase
DMOWQAF	HS	Phase 3
DMOWQAF	SN	GC-1111; Recombinant human iduronate-2-sulfatase (Hunter syndrome); Recombinant human iduronate-2-sulfatase (Hunter syndrome), Green Cross
DMOWQAF	CP	Green Cross Corp
DMOWQAF	DE	Hunter syndrome

DM7JFDO	ID	DM7JFDO
DM7JFDO	DN	Recombinant von Willebrand factor/recombinant Factor VIII complex
DM7JFDO	HS	Phase 3
DM7JFDO	SN	Willebrand factor/recombinant Factor VIII complex; Recombinant von Willebrand factor/recombinant Factor VIII complex (von Willebrand disease)
DM7JFDO	CP	Csl behring
DM7JFDO	DE	Von willebrand disease

DM34GOF	ID	DM34GOF
DM34GOF	DN	REL-1017
DM34GOF	HS	Phase 3
DM34GOF	SN	Dextromethadone; d-Methadone; S-Methadone; (S)-methadone; (+)-Methadone; S-(+)-Methadone; 6S-Methadone; 5653-80-5; L-(+)-Methadone; (6S)-Methadone; l-Methadone; (S)-(+)-Methadone; UNII-S95RZH8AMH; d-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; S95RZH8AMH; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; CHEMBL350719; (S)-6-(dimethylamino)-4,4-diphenylheptan-3-one; 3-14-00-00279 (Beilstein Handbook Reference); Methadone, (+)-; BRN 3213667; (+)-(S)-Methadone; (+)-(6S)-Methadone; SCHEMBL24294; (6S)-6-(dimethylamino)-4,4-diphenylheptan-3-one; CHEBI:167308; 3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, (S)-; ZINC1530707; BDBM50223640; DB15198; SB18896; (S)-6-Dimethylamino4,4-diphenylheptan-3-on; Q15634047; (+)-(S)-6-(dimethylamino)-4,4-diphenyl-3-heptanone; 3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6S)-; UNII-UC6VBE7V1Z component USSIQXCVUWKGNF-KRWDZBQOSA-N; UNII-UC6VBE7V1Z component USSIQXCVUWKGNF-QGZVFWFLSA-N; 3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6S)- (9CI); 3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, (S)- (8CI)
DM34GOF	CP	Relmada Therapeutics
DM34GOF	DT	Small molecular drug
DM34GOF	PC	643985
DM34GOF	MW	309.4
DM34GOF	FM	C21H27NO
DM34GOF	IC	InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3/t17-/m0/s1
DM34GOF	CS	CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
DM34GOF	IK	USSIQXCVUWKGNF-KRWDZBQOSA-N
DM34GOF	IU	(6S)-6-(dimethylamino)-4,4-diphenylheptan-3-one
DM34GOF	CA	CAS 5653-80-5
DM34GOF	CB	CHEBI:167308
DM34GOF	DE	Neuropathic pain; Major depressive disorder

DMOWINT	ID	DMOWINT
DMOWINT	DN	Reloxaliase
DMOWINT	HS	Phase 3
DMOWINT	SN	ALLN-177
DMOWINT	CP	Allena Pharmaceuticals
DMOWINT	DT	Protein
DMOWINT	DE	Hyperoxaluria

DM3YXP8	ID	DM3YXP8
DM3YXP8	DN	Remacemide
DM3YXP8	HS	Phase 3
DM3YXP8	SN	Remacemida; Remacemidum; Remacemide [INN]; FPL 12924; FPL 12924AA; FPL 14144; FPL 14145; FPL-12944AA; PR 1032-644; PR 934-423; PR1032-646; Remacemida [INN-Spanish]; Remacemidum [INN-Latin]; PR-934-423; Remacemide monohydrochloride, (+-)-isomer; (+)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; (+-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; (-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide; 2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide
DM3YXP8	CP	Astra Zeneca
DM3YXP8	DT	Small molecular drug
DM3YXP8	PC	60511
DM3YXP8	MW	268.35
DM3YXP8	FM	C17H20N2O
DM3YXP8	IC	InChI=1S/C17H20N2O/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14/h2-11H,12-13,18H2,1H3,(H,19,20)
DM3YXP8	CS	CC(CC1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)CN
DM3YXP8	IK	YSGASDXSLKIKOD-UHFFFAOYSA-N
DM3YXP8	IU	2-amino-N-(1,2-diphenylpropan-2-yl)acetamide
DM3YXP8	CA	CAS 128298-28-2
DM3YXP8	CB	CHEBI:91654
DM3YXP8	DE	Pain

DM49IGE	ID	DM49IGE
DM49IGE	DN	Remdesivir
DM49IGE	HS	Phase 3
DM49IGE	SN	L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
DM49IGE	CP	Gilead Sciences, Foster City, CA
DM49IGE	TC	Antiviral Agents
DM49IGE	DT	Small molecular drug
DM49IGE	PC	121304016
DM49IGE	MW	602.6
DM49IGE	FM	C27H35N6O8P
DM49IGE	IC	InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
DM49IGE	CS	CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
DM49IGE	IK	RWWYLEGWBNMMLJ-YSOARWBDSA-N
DM49IGE	IU	2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DM49IGE	CA	CAS 1809249-37-3
DM49IGE	CB	CHEBI:145994
DM49IGE	DE	Ebola virus infection; Coronavirus Disease 2019 (COVID-19); Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM7HQNX	ID	DM7HQNX
DM7HQNX	DN	Renzapride
DM7HQNX	HS	Phase 3
DM7HQNX	SN	Renzaprida; Renzapridum; Renzaprida [INN-Spanish]; Renzapridum [INN-Latin]; 4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
DM7HQNX	CP	Alizyme
DM7HQNX	DT	Small molecular drug
DM7HQNX	PC	119574
DM7HQNX	MW	323.82
DM7HQNX	FM	C16H22ClN3O2
DM7HQNX	IC	InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14+/m0/s1
DM7HQNX	CS	COC1=CC(=C(C=C1C(=O)N[C@@H]2CCN3CCC[C@H]2C3)Cl)N
DM7HQNX	IK	GZSKEXSLDPEFPT-IINYFYTJSA-N
DM7HQNX	IU	4-amino-N-[(4R,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
DM7HQNX	CA	CAS 112727-80-7
DM7HQNX	DE	Irritable bowel syndrome

DMVBA7I	ID	DMVBA7I
DMVBA7I	DN	Reparixin
DMVBA7I	HS	Phase 3
DMVBA7I	SN	reparixin; repertaxin; 266359-83-5; UNII-U604E1NB3K; CHEMBL191413; U604E1NB3K; DF 1681Y; (R)-2-(4-isobutylphenyl)-N-(methylsulfonyl)propanamide; Reparixin [USAN:INN]; (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide; (2R)-2-(4-(2-Methylpropyl)phenyl)-N-methylsulfonylpropanamide; 2-(4-isobutylphenyl)propionylmethanesulfonamide; Reparixin (USAN/INN); DSSTox_RID_81678; DSSTox_CID_26509; DSSTox_GSID_46509; ZINC8717; SCHEMBL1884299; GTPL8498; DTXSID6046509; EX-A2461; DF-1681Y; BCP10635; Tox21_112272; BDBM50169045;  Repertaxin; Reparixin [INN]; Reparixin (INN/USAN); (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide; RAPARIXIN
DMVBA7I	CP	Dompe s.p.a.
DMVBA7I	DT	Small molecular drug
DMVBA7I	PC	9838712
DMVBA7I	MW	283.39
DMVBA7I	FM	C14H21NO3S
DMVBA7I	IC	InChI=1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
DMVBA7I	CS	C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NS(=O)(=O)C
DMVBA7I	IK	KQDRVXQXKZXMHP-LLVKDONJSA-N
DMVBA7I	IU	(2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide
DMVBA7I	CA	CAS 266359-83-5
DMVBA7I	DE	Graft rejection in heart transplantation; lung transplantation; Ischemia-reperfusion injury; Pancreatic islet transplantation failure

DMDEJX9	ID	DMDEJX9
DMDEJX9	DN	Reproxalap
DMDEJX9	HS	Phase 3
DMDEJX9	SN	2-(3-Amino-6-chloroquinolin-2-yl)propan-2-ol; 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol; Reproxalap [USAN]; UNII-F0GIZ22IJH; F0GIZ22IJH; SCHEMBL12228833; ALD-102; ADX-102; 2-Quinolinemethanol, 3-amino-6-chloro-alpha,alpha-dimethyl-; NS2
DMDEJX9	CP	Aldeyra Therapeutics Lexington, MA
DMDEJX9	PC	16088030
DMDEJX9	MW	236.7
DMDEJX9	FM	C12H13ClN2O
DMDEJX9	IC	InChI=1S/C12H13ClN2O/c1-12(2,16)11-9(14)6-7-5-8(13)3-4-10(7)15-11/h3-6,16H,14H2,1-2H3
DMDEJX9	CS	CC(C)(C1=C(C=C2C=C(C=CC2=N1)Cl)N)O
DMDEJX9	IK	GUHFUVLKYSQIOQ-UHFFFAOYSA-N
DMDEJX9	IU	2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol
DMDEJX9	CA	CAS 916056-79-6
DMDEJX9	DE	Sjogren-Larsson syndrome

DMFMWYC	ID	DMFMWYC
DMFMWYC	DN	Resatorvid
DMFMWYC	HS	Phase 3
DMFMWYC	SN	Resatorvid; TAK-242; 243984-11-4; UNII-H2MZ648C31; CHEMBL225157; H2MZ648C31; TAK242; Resatorvid [INN]; TAK-242 (Resatorvid); C15H17ClFNO4S; SCHEMBL872197; GTPL9036; MolPort-035-773-739; BDBM50155929; ZINC13982410; 4003AH; AKOS027250774; CS-0408; KB-80786; AN-16512; HY-11109; A3850; W-5468; P111021; ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate; ethyl (6r)-6-[n-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate; ethyl (6R)-6-[(2-chloro-4-fluoro-phenyl)sulfamoyl]cyclohexene-1-carboxylate
DMFMWYC	CP	Takeda
DMFMWYC	DT	Small molecular drug
DMFMWYC	PC	11703255
DMFMWYC	MW	361.8
DMFMWYC	FM	C15H17ClFNO4S
DMFMWYC	IC	InChI=1S/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-7-10(17)9-12(13)16/h5,7-9,14,18H,2-4,6H2,1H3/t14-/m1/s1
DMFMWYC	CS	CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC2=C(C=C(C=C2)F)Cl
DMFMWYC	IK	LEEIJTHMHDMWLJ-CQSZACIVSA-N
DMFMWYC	IU	ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate
DMFMWYC	CA	CAS 243984-11-4
DMFMWYC	DE	Sepsis

DM3RWXL	ID	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	HS	Phase 3
DM3RWXL	SN	Resveratrol; Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4&prime;,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
DM3RWXL	CP	Sirtris Pharma
DM3RWXL	DT	Small molecular drug
DM3RWXL	PC	445154
DM3RWXL	MW	228.24
DM3RWXL	FM	C14H12O3
DM3RWXL	IC	InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
DM3RWXL	CS	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O
DM3RWXL	IK	LUKBXSAWLPMMSZ-OWOJBTEDSA-N
DM3RWXL	IU	5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
DM3RWXL	CA	CAS 501-36-0
DM3RWXL	CB	CHEBI:45713
DM3RWXL	DE	Colorectal cancer; Giant cell arteritis; Rheumatoid arthritis; Systemic sclerosis

DMOYGZF	ID	DMOYGZF
DMOYGZF	DN	Retosiban
DMOYGZF	HS	Phase 3
DMOYGZF	SN	820957-38-8; UNII-GIE06H28OX; GSK221149A; GSK-221149A; GIE06H28OX; CHEMBL429736; Retosiban [USAN:INN]; Retosiban (USAN); GSK 221149A; SCHEMBL230301; GTPL8403; DTXSID00231559; PLVGDGRBPMVYPB-FDUHJNRSSA-N; ZINC6718496; BDBM50372608; GSK-221,149-A; SB16762; DB11818; HY-14778; CS-0003555; J3.542.064I; D08986; 2,5-Piperazinedione, 3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-, (3R,6R)-
DMOYGZF	CP	GlaxoSmithKline
DMOYGZF	DT	Small molecular drug
DMOYGZF	PC	11340891
DMOYGZF	MW	494.6
DMOYGZF	FM	C27H34N4O5
DMOYGZF	IC	InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1
DMOYGZF	CS	CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=COC(=N2)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4
DMOYGZF	IK	PLVGDGRBPMVYPB-FDUHJNRSSA-N
DMOYGZF	IU	(3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
DMOYGZF	CA	CAS 820957-38-8
DMOYGZF	DE	Preterm labour

DM5E73H	ID	DM5E73H
DM5E73H	DN	Revusiran
DM5E73H	HS	Phase 3
DM5E73H	DT	siRNA drug
DM5E73H	DE	Amyloidosis

DMQ4CSX	ID	DMQ4CSX
DMQ4CSX	DN	Rezafungin
DMQ4CSX	HS	Phase 3
DMQ4CSX	SN	CD-101; CD101; SP-3025; CHEMBL3989945; HY-108009; CS-0027142; J3.555.717B; J3.599.425D; (4R,5R)-N2-[4-(4'-Pentoxy-1,1'-biphenyl-4-yl)benzoyl]-5-[2-(trimethylaminio)ethoxy]-4-hydroxy-cyclo[L-Orn*-[(3R)-3-methyl-L-Ser-]-[(4R)-4-hydroxy-L-Pro-]-2-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-L-Gly-[(3R)-3-methyl-L-Ser-]-[(3S,4S)-3-hydroxy-4-methyl-L-Pro-]-]
DMQ4CSX	CP	Cidara Therapeutics
DMQ4CSX	DT	Small molecular drug
DMQ4CSX	PC	78318119
DMQ4CSX	MW	1226.4
DMQ4CSX	FM	C63H85N8O17+
DMQ4CSX	IC	InChI=1S/C63H84N8O17/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84)/p+1/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+/m0/s1
DMQ4CSX	CS	CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)OCC[N+](C)(C)C)O
DMQ4CSX	IK	LNFCWEXGZIEGJW-TXSVMFMRSA-O
DMQ4CSX	IU	2-[[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[4-(4-pentoxyphenyl)phenyl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-21-yl]oxy]ethyl-trimethylazanium
DMQ4CSX	DE	Candidiasis

DMTQJE0	ID	DMTQJE0
DMTQJE0	DN	RG3638
DMTQJE0	HS	Phase 3
DMTQJE0	SN	Onartuzumab
DMTQJE0	CP	Roche
DMTQJE0	DE	Non-small-cell lung cancer; Gastric adenocarcinoma

DMER75Y	ID	DMER75Y
DMER75Y	DN	RG6013
DMER75Y	HS	Phase 3
DMER75Y	DT	Antibody
DMER75Y	DE	Haemophilia A

DMJRFYB	ID	DMJRFYB
DMJRFYB	DN	RG7201
DMJRFYB	HS	Phase 3
DMJRFYB	CP	Roche
DMJRFYB	DE	Type-2 diabetes

DMF5GZI	ID	DMF5GZI
DMF5GZI	DN	RG7388
DMF5GZI	HS	Phase 3
DMF5GZI	SN	Idasanutlin; RG7388; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856
DMF5GZI	CP	Roche
DMF5GZI	DT	Small molecular drug
DMF5GZI	PC	53358942
DMF5GZI	MW	616.5
DMF5GZI	FM	C31H29Cl2F2N3O4
DMF5GZI	IC	InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)/t24-,25-,27+,31-/m0/s1
DMF5GZI	CS	CC(C)(C)C[C@H]1[C@]([C@H]([C@@H](N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F
DMF5GZI	IK	TVTXCJFHQKSQQM-LJQIRTBHSA-N
DMF5GZI	IU	4-[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid
DMF5GZI	CA	CAS 1229705-06-9
DMF5GZI	DE	Haematological malignancy; Solid tumour/cancer; Polycythemia vera; Acute myeloid leukaemia

DMDVAFP	ID	DMDVAFP
DMDVAFP	DN	RG7601
DMDVAFP	HS	Phase 3
DMDVAFP	CP	Abbott; Roche
DMDVAFP	DE	Chronic lymphocytic leukaemia

DMGOTK4	ID	DMGOTK4
DMGOTK4	DN	Rhumab Beta7
DMGOTK4	HS	Phase 3
DMGOTK4	CP	Roche; Genentech
DMGOTK4	DT	Antibody
DMGOTK4	DE	Ulcerative colitis

DMLHEU7	ID	DMLHEU7
DMLHEU7	DN	Ridaforolimus
DMLHEU7	HS	Phase 3
DMLHEU7	SN	Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus
DMLHEU7	CP	Merck
DMLHEU7	DT	Small molecular drug
DMLHEU7	PC	11520894
DMLHEU7	MW	990.2
DMLHEU7	FM	C53H84NO14P
DMLHEU7	IC	InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
DMLHEU7	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OP(=O)(C)C)C)/C)O)OC)C)C)/C)OC
DMLHEU7	IK	BUROJSBIWGDYCN-GAUTUEMISA-N
DMLHEU7	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-12-[(2R)-1-[(1S,3R,4R)-4-dimethylphosphoryloxy-3-methoxycyclohexyl]propan-2-yl]-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMLHEU7	CA	CAS 572924-54-0
DMLHEU7	CB	CHEBI:79700
DMLHEU7	DE	Sarcoma

DMYXOHV	ID	DMYXOHV
DMYXOHV	DN	Rifalazil
DMYXOHV	HS	Phase 3
DMYXOHV	DT	Small molecular drug
DMYXOHV	PC	135431094
DMYXOHV	MW	941.1
DMYXOHV	FM	C51H64N4O13
DMYXOHV	IC	InChI=1S/C51H64N4O13/c1-24(2)23-54-16-18-55(19-17-54)32-21-33(57)39-35(22-32)67-48-40(52-39)36-37-44(60)30(8)47-38(36)49(62)51(10,68-47)65-20-15-34(64-11)27(5)46(66-31(9)56)29(7)43(59)28(6)42(58)25(3)13-12-14-26(4)50(63)53-41(48)45(37)61/h12-15,20-22,24-25,27-29,34,42-43,46,58-60,62H,16-19,23H2,1-11H3,(H,53,63)/b13-12+,20-15+,26-14-/t25-,27+,28+,29+,34-,42-,43+,46+,51-/m0/s1
DMYXOHV	CS	C[C@H]1/C=C/C=C(\\C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C([C@](O5)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCN(CC7)CC(C)C)O3)/C
DMYXOHV	IK	IXSVOCGZBUJEPI-HTQYORAHSA-N
DMYXOHV	IU	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,6,15,17-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-30-[4-(2-methylpropyl)piperazin-1-yl]-23,32,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.14,7.05,36.026,35.028,33]octatriaconta-1,3,5,9,19,21,25,28,30,33,35-undecaen-13-yl] acetate
DMYXOHV	CA	CAS 129791-92-0
DMYXOHV	DE	Bacterial infection

DMKTS2M	ID	DMKTS2M
DMKTS2M	DN	Rifaximin DR
DMKTS2M	HS	Phase 3
DMKTS2M	CP	Salix Pharmaceuticals Raleigh, NC
DMKTS2M	DE	Crohn disease

DMOSTXF	ID	DMOSTXF
DMOSTXF	DN	Rigosertib
DMOSTXF	HS	Phase 3
DMOSTXF	SN	Rigosertib; 592542-59-1; UNII-67DOW7F9GL; 67DOW7F9GL; N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; ON-01910.Na; Rigosertib [USAN:INN]; 6FS; Rigosertib (USAN); AC1OCFT5; SCHEMBL498624; Estybon (proposed trade name); SCHEMBL498623; GTPL7833; CHEMBL1241855; ON01910.Na; DTXSID30207984; CHEBI:124939; OWBFCJROIKNMGD-BQYQJAHWSA-N; 1910 Na; ZINC3942646; BCP08296; BDBM50060917; 4006AH; AKOS015966442; DB12146; SB16468; (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic a
DMOSTXF	CP	Onconova Therapeutics
DMOSTXF	DT	Small molecular drug
DMOSTXF	PC	6918736
DMOSTXF	MW	451.5
DMOSTXF	FM	C21H25NO8S
DMOSTXF	IC	InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+
DMOSTXF	CS	COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O
DMOSTXF	IK	OWBFCJROIKNMGD-BQYQJAHWSA-N
DMOSTXF	IU	2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic acid
DMOSTXF	CA	CAS 592542-59-1
DMOSTXF	CB	CHEBI:124939
DMOSTXF	DE	Solid tumour/cancer; Myelodysplastic syndrome

DMGTCI0	ID	DMGTCI0
DMGTCI0	DN	Rilimogene galvacirepvec
DMGTCI0	HS	Phase 3
DMGTCI0	SN	Prostvac (TN)
DMGTCI0	CP	BM ImmunoTherapeutics
DMGTCI0	DE	Prostate cancer

DMP6IMQ	ID	DMP6IMQ
DMP6IMQ	DN	Rindopepimut
DMP6IMQ	HS	Phase 3
DMP6IMQ	CP	Celldex Therapeutics
DMP6IMQ	DE	Glioblastoma multiforme; Brain cancer

DMYX7VI	ID	DMYX7VI
DMYX7VI	DN	Rintatolimod
DMYX7VI	HS	Phase 3
DMYX7VI	CP	Hemispherx Biopharma
DMYX7VI	DT	siRNA drug
DMYX7VI	DE	Human immunodeficiency virus infection

DM13V0P	ID	DM13V0P
DM13V0P	DN	Rivoceranib
DM13V0P	HS	Phase 3
DM13V0P	CP	Elevar Therapeutics
DM13V0P	DT	Small molecular drug
DM13V0P	DE	Gastric adenocarcinoma; Solid tumour/cancer; Sarcoma

DMBY31K	ID	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	HS	Phase 3
DMBY31K	SN	CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen
DMBY31K	CP	Sankyo Co Ltd
DMBY31K	DT	Small molecular drug
DMBY31K	PC	3055168
DMBY31K	MW	397.4
DMBY31K	FM	C20H19N3O4S
DMBY31K	IC	InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25)
DMBY31K	CS	CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DMBY31K	IK	XMSXOLDPMGMWTH-UHFFFAOYSA-N
DMBY31K	IU	5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMBY31K	CA	CAS 185428-18-6
DMBY31K	DE	Ocular inflammation

DMVQ5X1	ID	DMVQ5X1
DMVQ5X1	DN	Roclatan
DMVQ5X1	HS	Phase 3
DMVQ5X1	SN	PG324
DMVQ5X1	CP	Aerie pharmaceuticals
DMVQ5X1	PC	118984471
DMVQ5X1	MW	886.1
DMVQ5X1	FM	C54H67N3O8
DMVQ5X1	IC	InChI=1S/C28H27N3O3.C26H40O5/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24;1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32);3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b;8-3-/t26-;21-,22+,23+,24-,25+/m10/s1
DMVQ5X1	CS	CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C.CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O
DMVQ5X1	IK	QILUCPOIAVKEBG-GCBPXYGZSA-N
DMVQ5X1	IU	[4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DMVQ5X1	DE	Glaucoma/ocular hypertension

DMSZPR3	ID	DMSZPR3
DMSZPR3	DN	Rolofylline
DMSZPR3	HS	Phase 3
DMSZPR3	SN	KW 3902; HMR-4902; KW-3902; MK-7418; Rolofylline (USAN); 1,3-Dipropyl-8-(3-noradamantyl)xanthine; 1,3-Dnax; 8-(3-Noradamantyl)-1,3-dipropylxanthine; 8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione; 8-(Noradamantan-3-yl)-1,3-dipropylxanthine; 8-(hexahydro-2,5-methanopentalen-3a(1h)-yl)-1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione
DMSZPR3	CP	Merck
DMSZPR3	DT	Small molecular drug
DMSZPR3	PC	64627
DMSZPR3	MW	356.5
DMSZPR3	FM	C20H28N4O2
DMSZPR3	IC	InChI=1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22)
DMSZPR3	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CC5CC(C3)CC4C5
DMSZPR3	IK	PJBFVWGQFLYWCB-UHFFFAOYSA-N
DMSZPR3	IU	1,3-dipropyl-8-(3-tricyclo[3.3.1.03,7]nonanyl)-7H-purine-2,6-dione
DMSZPR3	CA	CAS 136199-02-5
DMSZPR3	DE	Heart failure

DMPIDXT	ID	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	HS	Phase 3
DMPIDXT	SN	Orantinib; TSU-68; 252916-29-3; SU-6668; SU6668; SU 6668; 210644-62-5; UNII-9RL37ZZ665; Orantinib (TSU-68); NSC 702827; TSU68; CHEMBL274654; 9RL37ZZ665; TSU 68; PDGFR Tyrosine Kinase Inhibitor VI, SU6668; 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid; J-502593; Orantinibum; 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; Orantinib [INN]
DMPIDXT	CP	GSK
DMPIDXT	DT	Combination drug (small molecular drug)
DMPIDXT	PC	5329099
DMPIDXT	MW	310.3
DMPIDXT	FM	C18H18N2O3
DMPIDXT	IC	InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-
DMPIDXT	CS	CC1=C(NC(=C1CCC(=O)O)C)/C=C\\2/C3=CC=CC=C3NC2=O
DMPIDXT	IK	NHFDRBXTEDBWCZ-ZROIWOOFSA-N
DMPIDXT	IU	3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
DMPIDXT	CA	CAS 210644-62-5
DMPIDXT	DE	Advanced solid tumour; Diabetic complication

DM18B72	ID	DM18B72
DM18B72	DN	Rosiglitazone + simvastatin
DM18B72	HS	Phase 3
DM18B72	CP	GSK
DM18B72	DT	Combination drug (small molecular drug)
DM18B72	PC	23644561
DM18B72	MW	241.24
DM18B72	FM	C13H11N3O2
DM18B72	IC	InChI=1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-8H,1H3,(H,16,17)/b11-4-
DM18B72	CS	COC1=CC\\2=C(C=C1)NC(=O)/C2=C\\C3C=NC=N3
DM18B72	IK	KKGJVFQBVRACGR-WCIBSUBMSA-N
DM18B72	IU	(3Z)-3-(4H-imidazol-4-ylmethylidene)-5-methoxy-1H-indol-2-one
DM18B72	DE	Type-2 diabetes

DMNGCAD	ID	DMNGCAD
DMNGCAD	DN	Rova-T
DMNGCAD	HS	Phase 3
DMNGCAD	SN	rovalpituzumab tesirine; Rovalpituzumab Tesirine; Rova-t; Rovalpituzumab-Tesirin; UNII-P256HB60FF; Rovalpituzumab tesirine [INN]; P256HB60FF; Rovalpituzumab tesirine [WHO-DD]; Rovalpituzumab tesirine [USAN:INN]; SC0002; 1613313-09-9
DMNGCAD	CP	StemcentRx South San Francisco, CA
DMNGCAD	PC	131954443
DMNGCAD	MW	1617.8
DMNGCAD	FM	C78H108N10O25S
DMNGCAD	IC	InChI=1S/C78H108N10O25S/c1-49(2)70(84-68(90)16-21-103-23-25-105-27-29-107-31-33-109-35-36-110-34-32-108-30-28-106-26-24-104-22-17-80-67(89)15-18-85-69(91)43-66(76(85)97)114-48-58(79)77(98)99)72(93)82-52(5)71(92)83-54-13-11-53(12-14-54)47-113-78(100)88-60-42-65(63(102-7)40-57(60)74(95)87-46-51(4)38-61(87)75(88)96)112-20-10-8-9-19-111-64-41-59-56(39-62(64)101-6)73(94)86-45-50(3)37-55(86)44-81-59/h11-14,39-42,44-46,49,52,55,58,61,66,70,75,96H,8-10,15-38,43,47-48,79H2,1-7H3,(H,80,89)(H,82,93)(H,83,92)(H,84,90)(H,98,99)/t52-,55-,58-,61-,66+,70-,75-/m0/s1
DMNGCAD	CS	CC1=CN2[C@@H](C1)C=NC3=CC(=C(C=C3C2=O)OC)OCCCCCOC4=C(C=C5C(=C4)N([C@H]([C@@H]6CC(=CN6C5=O)C)O)C(=O)OCC7=CC=C(C=C7)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN8C(=O)C[C@H](C8=O)SC[C@@H](C(=O)O)N)OC
DMNGCAD	IK	NQUUPTGRJYIXSL-YPDXTJLXSA-N
DMNGCAD	IU	(2R)-3-[(3R)-1-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[(2S)-1-[[(2S)-1-[4-[[(6S,6aS)-3-[5-[[(6aS)-2-methoxy-8-methyl-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]pentoxy]-6-hydroxy-2-methoxy-8-methyl-11-oxo-6a,7-dihydro-6H-pyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl]oxymethyl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-2-aminopropanoic acid
DMNGCAD	CA	CAS 1613313-09-9
DMNGCAD	DE	Small-cell lung cancer; Neuroendocrine cancer

DM9T8OF	ID	DM9T8OF
DM9T8OF	DN	RQ-00000004
DM9T8OF	HS	Phase 3
DM9T8OF	SN	PF-03716556; RQ-00000774; RQ-4; Acid pump inhibitor (GERD), Pfizer; Acid pump inhibitor (GERD), RaQualia;Acid pump inhibitor (gastroesophageal reflux), Pfizer; Acid pump inhibitor (gastroesophageal reflux), RaQualia
DM9T8OF	CP	Pfizer Inc
DM9T8OF	DE	Gastroesophageal reflux disease

DMQM2FH	ID	DMQM2FH
DMQM2FH	DN	RRx-001
DMQM2FH	HS	Phase 3
DMQM2FH	SN	RRX-001; 925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015
DMQM2FH	CP	RadioRx
DMQM2FH	DT	Small molecular drug
DMQM2FH	PC	15950826
DMQM2FH	MW	268.02
DMQM2FH	FM	C5H6BrN3O5
DMQM2FH	IC	InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2
DMQM2FH	CS	C1C(CN1C(=O)CBr)([N+](=O)[O-])[N+](=O)[O-]
DMQM2FH	IK	JODKFOVZURLVTG-UHFFFAOYSA-N
DMQM2FH	IU	2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
DMQM2FH	CA	CAS 925206-65-1
DMQM2FH	DE	Lymphoma; Anaplastic glioma; Neuroendocrine cancer; Ovarian epithelial cancer; Solid tumour/cancer; Non-small-cell lung cancer; Small-cell lung cancer

DM62QTW	ID	DM62QTW
DM62QTW	DN	RTB101
DM62QTW	HS	Phase 3
DM62QTW	CP	ResTORbio
DM62QTW	DT	Small molecular drug
DM62QTW	DE	Coronavirus Disease 2019 (COVID-19); Respiratory tract infection

DMDWU1S	ID	DMDWU1S
DMDWU1S	DN	Rubitecan
DMDWU1S	HS	Phase 3
DMDWU1S	SN	9-Nitrocamptothecin; 91421-42-0; Orathecin; 9-nitro-20(S)-camptothecin; Camptogen; 9-NC; RFS 2000; RFS-2000; UNII-H19C446XXB; Nitrocamptothecin; H19C446XXB; CHEBI:90225; C20H15N3O6; (S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NCGC00167969-01; (s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; 9NC; Q-100889; (4s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione;  Inhaled Orathecin; L9NC; Rubitecan (inhaled); Aerosolized liposomal 9 nitro-20 (S) camptothecin; Rubitecan (inhaled), SuperGen; 9-Nitro-20(S)-camptothecin; 9-Nitrocamptothecin (9-NC)
DMDWU1S	CP	SuperGen; Clayton Foundation For Research; MD Anderson Cancer Center
DMDWU1S	DT	Small molecular drug
DMDWU1S	PC	472335
DMDWU1S	MW	393.3
DMDWU1S	FM	C20H15N3O6
DMDWU1S	IC	InChI=1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1
DMDWU1S	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O
DMDWU1S	IK	VHXNKPBCCMUMSW-FQEVSTJZSA-N
DMDWU1S	IU	(19S)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DMDWU1S	CA	CAS 91421-42-0
DMDWU1S	CB	CHEBI:90225
DMDWU1S	DE	Human immunodeficiency virus infection

DMQOCD8	ID	DMQOCD8
DMQOCD8	DN	RUBOXISTAURIN HYDROCHLORIDE
DMQOCD8	HS	Phase 3
DMQOCD8	SN	LY-333531.HCl; Ruboxistaurin hydrochloride; 9(S)-(Dimethylaminomethyl)-5,6,7,9,10,11,12,17,18,19,20,21-dodecahydro-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione hydrochloride
DMQOCD8	PC	9870785
DMQOCD8	MW	505
DMQOCD8	FM	C28H29ClN4O3
DMQOCD8	IC	InChI=1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H/t18-;/m0./s1
DMQOCD8	CS	CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O.Cl
DMQOCD8	IK	NYQIEYDJYFVLPO-FERBBOLQSA-N
DMQOCD8	IU	(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione;hydrochloride
DMQOCD8	CA	CAS 169939-93-9
DMQOCD8	DE	Lymphoma

DM25TMP	ID	DM25TMP
DM25TMP	DN	Rubraca rucaparib
DM25TMP	HS	Phase 3
DM25TMP	CP	Clovis Oncology Boulder, CO
DM25TMP	DE	Prostate cancer; Ovarian cancer

DM20KYR	ID	DM20KYR
DM20KYR	DN	Ruxolitinib
DM20KYR	HS	Phase 3
DM20KYR	SN	Ruxolitinib (JAK inhibitor)
DM20KYR	CP	Incyte
DM20KYR	TC	Antiviral Agents
DM20KYR	DT	Small molecular drug
DM20KYR	PC	25126798
DM20KYR	MW	306.4
DM20KYR	FM	C17H18N6
DM20KYR	IC	InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
DM20KYR	CS	C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM20KYR	IK	HFNKQEVNSGCOJV-OAHLLOKOSA-N
DM20KYR	IU	(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
DM20KYR	CA	CAS 941678-49-5
DM20KYR	CB	CHEBI:66919
DM20KYR	DE	Essential thrombocythemia; High-risk myelofibrosis; Nasopharyngeal carcinoma; Pancreatic cancer; Coronavirus Disease 2019 (COVID-19)

DMAYTIH	ID	DMAYTIH
DMAYTIH	DN	S-06911
DMAYTIH	HS	Phase 3
DMAYTIH	SN	Strontium ranelate + vitamin D3 (osteoporosis), Servier; Strontium ranelate + vitamin D3 (fixed-dose combination, osteoporosis), Servier
DMAYTIH	CP	Servier
DMAYTIH	DE	Osteoporosis

DMXY34J	ID	DMXY34J
DMXY34J	DN	S-110
DMXY34J	HS	Phase 3
DMXY34J	SN	DNA demethylating agent (myelodysplastic syndrome), Supergen
DMXY34J	CP	SuperGen Inc
DMXY34J	DE	Acute myeloid leukaemia; Chronic myelogenous leukaemia; Solid tumour/cancer

DM408GM	ID	DM408GM
DM408GM	DN	S-474474
DM408GM	HS	Phase 3
DM408GM	CP	Shionogi
DM408GM	DE	Metabolic syndrome x

DM7F2VG	ID	DM7F2VG
DM7F2VG	DN	SA-237
DM7F2VG	HS	Phase 3
DM7F2VG	SN	Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai
DM7F2VG	CP	Chugai Pharmaceutical Co Ltd
DM7F2VG	DE	Rheumatoid arthritis; Encephalopathy; Neuromyelitis optica

DMGR98T	ID	DMGR98T
DMGR98T	DN	SAGE-217
DMGR98T	HS	Phase 3
DMGR98T	SN	HARRKNSQXBRBGZ-GVKWWOCJSA-N; SCHEMBL16189866; HY-103040; CS-0023489; 1632051-40-1
DMGR98T	CP	Sage Therapeutics Cambridge, MA
DMGR98T	PC	86294073
DMGR98T	MW	409.6
DMGR98T	FM	C25H35N3O2
DMGR98T	IC	InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1
DMGR98T	CS	C[C@]1(CC[C@H]2[C@@H](C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C(=O)CN5C=C(C=N5)C#N)C)O
DMGR98T	IK	HARRKNSQXBRBGZ-GVKWWOCJSA-N
DMGR98T	IU	1-[2-[(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile
DMGR98T	CA	CAS 1632051-40-1
DMGR98T	DE	Essential tremor or related tremors; Major depressive disorder; Parkinson disease; Postpartum depression

DMI1R5S	ID	DMI1R5S
DMI1R5S	DN	SAIT101
DMI1R5S	HS	Phase 3
DMI1R5S	CP	Archigen Biotech
DMI1R5S	DT	Antibody
DMI1R5S	DE	Follicular lymphoma

DMKHLRT	ID	DMKHLRT
DMKHLRT	DN	SAND-26
DMKHLRT	HS	Phase 3
DMKHLRT	SN	Begedina; CD26-targeting antibody (autoimmunity), ADIENNE
DMKHLRT	CP	ADIENNE Pharma & Biotech
DMKHLRT	DT	Antibody
DMKHLRT	DE	Autoimmune diabetes

DMXAO4J	ID	DMXAO4J
DMXAO4J	DN	SAR153191
DMXAO4J	HS	Phase 3
DMXAO4J	CP	Sanofi-Aventis
DMXAO4J	DE	Ankylosing spondylitis

DMHFBOG	ID	DMHFBOG
DMHFBOG	DN	SAR231893
DMHFBOG	HS	Phase 3
DMHFBOG	CP	Sanofi
DMHFBOG	DE	Atopic dermatitis; Asthma

DMR0EWV	ID	DMR0EWV
DMR0EWV	DN	SAR342434
DMR0EWV	HS	Phase 3
DMR0EWV	DE	Diabetic complication; Type-1 diabetes; Type-2 diabetes

DMXGE3O	ID	DMXGE3O
DMXGE3O	DN	SAR408701
DMXGE3O	HS	Phase 3
DMXGE3O	CP	Sanofi
DMXGE3O	DT	Antibody drug conjugate
DMXGE3O	DE	Solid tumour/cancer; Non-small-cell lung cancer

DMDMAE4	ID	DMDMAE4
DMDMAE4	DN	SAR438584
DMDMAE4	HS	Phase 3
DMDMAE4	SN	REGN2222
DMDMAE4	DT	Antibody
DMDMAE4	DE	Respiratory syncytial virus infection

DM8HCFD	ID	DM8HCFD
DM8HCFD	DN	Sarilumab
DM8HCFD	HS	Phase 3
DM8HCFD	SN	Kevzara
DM8HCFD	CP	Sanofi/Regeneron
DM8HCFD	TC	Antiviral Agents
DM8HCFD	DT	Monoclonal antibody
DM8HCFD	SQ	Heavy chain: EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt;Light chainDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM8HCFD	DE	Rheumatoid arthritis; Severely active rheumatoid arthritis; Coronavirus Disease 2019 (COVID-19)

DMUVSG4	ID	DMUVSG4
DMUVSG4	DN	Sasanlimab
DMUVSG4	HS	Phase 3
DMUVSG4	SN	PF-06801591
DMUVSG4	CP	Pfizer
DMUVSG4	DT	Antibody
DMUVSG4	DE	Non-muscle invasive bladder cancer

DME5PN3	ID	DME5PN3
DME5PN3	DN	Satavaptan
DME5PN3	HS	Phase 3
DME5PN3	CP	Sanofi-Aventis
DME5PN3	DT	Small molecular drug
DME5PN3	PC	158348
DME5PN3	MW	643.8
DME5PN3	FM	C33H45N3O8S
DME5PN3	IC	InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)
DME5PN3	CS	CCOC1=CC2=C(C=C1)N(C(=O)C23CCC(CC3)OCCN4CCOCC4)S(=O)(=O)C5=C(C=C(C=C5)C(=O)NC(C)(C)C)OC
DME5PN3	IK	QKXJWFOKVQWEDZ-UHFFFAOYSA-N
DME5PN3	IU	N-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide
DME5PN3	CA	CAS 185913-78-4
DME5PN3	DE	Acute and chronic heart failure

DMALFKX	ID	DMALFKX
DMALFKX	DN	Savolitinib
DMALFKX	HS	Phase 3
DMALFKX	SN	1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri
DMALFKX	CP	AstraZeneca Wilmington, DE
DMALFKX	PC	68289010
DMALFKX	MW	345.4
DMALFKX	FM	C17H15N9
DMALFKX	IC	InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
DMALFKX	CS	C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
DMALFKX	IK	XYDNMOZJKOGZLS-NSHDSACASA-N
DMALFKX	IU	3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
DMALFKX	CA	CAS 1313725-88-0
DMALFKX	DE	Solid tumour/cancer; Renal cell carcinoma

DMAPRWV	ID	DMAPRWV
DMAPRWV	DN	SaxaDapa FDC
DMAPRWV	HS	Phase 3
DMAPRWV	CP	AstraZeneca
DMAPRWV	DE	Diabetic complication

DMME6GJ	ID	DMME6GJ
DMME6GJ	DN	SB12
DMME6GJ	HS	Phase 3
DMME6GJ	CP	Samsung Bioepis
DMME6GJ	DT	Antibody
DMME6GJ	DE	Paroxysmal nocturnal haemoglobinuria

DM6L4ZT	ID	DM6L4ZT
DM6L4ZT	DN	SB-742457
DM6L4ZT	HS	Phase 3
DM6L4ZT	SN	GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline
DM6L4ZT	CP	GlaxoSmithKline
DM6L4ZT	DT	Small molecular drug
DM6L4ZT	PC	11256720
DM6L4ZT	MW	353.4
DM6L4ZT	FM	C19H19N3O2S
DM6L4ZT	IC	InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2
DM6L4ZT	CS	C1CN(CCN1)C2=CC=CC3=CC(=CN=C32)S(=O)(=O)C4=CC=CC=C4
DM6L4ZT	IK	JJZFWROHYSMCMU-UHFFFAOYSA-N
DM6L4ZT	IU	3-(benzenesulfonyl)-8-piperazin-1-ylquinoline
DM6L4ZT	CA	CAS 607742-69-8
DM6L4ZT	DE	Alzheimer disease

DM6XNJR	ID	DM6XNJR
DM6XNJR	DN	SC-46553
DM6XNJR	HS	Phase 3
DM6XNJR	SN	Ginsenoside 20-Glc-Rf; PubChem13034; SC-46553; ZINC238808898; ginsenoside-Rd; 705G938; CHEMBL525935; S597; Ginsenoside Rd
DM6XNJR	PC	24721561
DM6XNJR	MW	963.2
DM6XNJR	FM	C48H82O19
DM6XNJR	IC	FBFMBWCLBGQEBU-RXMALORBSA-N
DM6XNJR	CS	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)O)C)OC7C(C(C(C(O7)CO)O)O)O)C
DM6XNJR	IK	1S/C48H82O19/c1-21(2)10-9-13-48(8,67-42-38(61)35(58)32(55)26(19-50)64-42)22-11-15-46(6)30(22)23(52)16-28-45(5)14-12-29(53)44(3,4)40(45)24(17-47(28,46)7)62-43-39(36(59)33(56)27(20-51)65-43)66-41-37(60)34(57)31(54)25(18-49)63-41/h10,22-43,49-61H,9,11-20H2,1-8H3/t22-,23+,24-,25+,26+,27+,28+,29-,30-,31+,32+,33+,34-,35-,36-,37+,38+,39+,40-,41-,42-,43+,45+,46+,47+,48-/m0/s1
DM6XNJR	IU	(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM6XNJR	DE	Cerebral stroke

DMK1IPV	ID	DMK1IPV
DMK1IPV	DN	SCY-078
DMK1IPV	HS	Phase 3
DMK1IPV	SN	Ibrexafungerp
DMK1IPV	CP	Scynexis
DMK1IPV	DT	Small molecular drug
DMK1IPV	PC	46871657
DMK1IPV	MW	730
DMK1IPV	FM	C44H67N5O4
DMK1IPV	IC	InChI=1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1
DMK1IPV	CS	C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
DMK1IPV	IK	BODYFEUFKHPRCK-ZCZMVWJSSA-N
DMK1IPV	IU	(1R,5S,6R,7R,10R,11R,14R,15S,20R,21R)-21-[(2R)-2-amino-2,3,3-trimethylbutoxy]-5,7,10,15-tetramethyl-7-[(2R)-3-methylbutan-2-yl]-20-(5-pyridin-4-yl-1,2,4-triazol-1-yl)-17-oxapentacyclo[13.3.3.01,14.02,11.05,10]henicos-2-ene-6-carboxylic acid
DMK1IPV	CA	CAS 1207753-03-4
DMK1IPV	DE	Fungal infection; Invasive candidiasis

DMAMTGI	ID	DMAMTGI
DMAMTGI	DN	SD-101
DMAMTGI	HS	Phase 3
DMAMTGI	SN	HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo
DMAMTGI	CP	Scioderm
DMAMTGI	DT	Oligonucleotide
DMAMTGI	DE	Hepatitis C virus infection; Melanoma; Skin disease; Squamous cell carcinoma; Squamous head and neck cell carcinom

DM9DEYL	ID	DM9DEYL
DM9DEYL	DN	SD-6010
DM9DEYL	HS	Phase 3
DM9DEYL	CP	Pfizer New York, NY
DM9DEYL	DE	Osteoarthritis

DMBD4K3	ID	DMBD4K3
DMBD4K3	DN	Selinexor
DMBD4K3	HS	Phase 3
DMBD4K3	SN	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F
DMBD4K3	CP	Karyopharm therapeutics
DMBD4K3	DT	Small molecular drug
DMBD4K3	PC	71481097
DMBD4K3	MW	443.3
DMBD4K3	FM	C17H11F6N7O
DMBD4K3	IC	InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-
DMBD4K3	CS	C1=CN=C(C=N1)NNC(=O)/C=C\\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMBD4K3	IK	DEVSOMFAQLZNKR-RJRFIUFISA-N
DMBD4K3	IU	(Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide
DMBD4K3	CA	CAS 1393477-72-9
DMBD4K3	DE	Solid tumour/cancer; Diffuse large B-cell lymphoma; Acute myeloid leukaemia; Multiple myeloma; Liposarcoma; Neuroendocrine cancer; Recurrent glioblastoma

DMC7W6R	ID	DMC7W6R
DMC7W6R	DN	Selumetinib
DMC7W6R	HS	Phase 3
DMC7W6R	SN	Selumetinib; AZD-6244; ARRY142886; AZD6244; ARRY142886; AZD 6244; AZD-6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
DMC7W6R	CP	AstraZeneca
DMC7W6R	DT	Small molecular drug
DMC7W6R	PC	10127622
DMC7W6R	MW	457.7
DMC7W6R	FM	C17H15BrClFN4O3
DMC7W6R	IC	InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
DMC7W6R	CS	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
DMC7W6R	IK	CYOHGALHFOKKQC-UHFFFAOYSA-N
DMC7W6R	IU	6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
DMC7W6R	CA	CAS 606143-52-6
DMC7W6R	CB	CHEBI:90227
DMC7W6R	DE	Non-small-cell lung cancer; Melanoma; Thyroid cancer; Solid tumour/cancer

DML83IW	ID	DML83IW
DML83IW	DN	Semagacestat
DML83IW	HS	Phase 3
DML83IW	SN	DAPT; AN-37124; AN-44989; LY-374973; LY-411575; LY-424354; LY-450139; LY-4501395; Gamma-secretase inhibitors (Alzheimer's disease), Elan Pharmaceuticals/Eli Lilly
DML83IW	CP	Eli Lilly & Co
DML83IW	DT	Small molecular drug
DML83IW	PC	9843750
DML83IW	MW	361.4
DML83IW	FM	C19H27N3O4
DML83IW	IC	InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1
DML83IW	CS	C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2CCN(C1=O)C)NC(=O)[C@H](C(C)C)O
DML83IW	IK	PKXWXXPNHIWQHW-RCBQFDQVSA-N
DML83IW	IU	(2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide
DML83IW	CA	CAS 425386-60-3
DML83IW	CB	CHEBI:131158
DML83IW	DE	Parkinson disease

DMKL9QO	ID	DMKL9QO
DMKL9QO	DN	Seocalcitol
DMKL9QO	HS	Phase 3
DMKL9QO	SN	Seocalcitol; 134404-52-7; UNII-Q0OZ0D9223; EB-1089; Q0OZ0D9223; EB1089; EB 1089; Seocalcitol [INN:BAN]; CB-1089; (22E,24E)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homovitamin D3 / (22E,24E)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homocholecalciferol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMKL9QO	DT	Small molecular drug
DMKL9QO	PC	5288149
DMKL9QO	MW	454.7
DMKL9QO	FM	C30H46O3
DMKL9QO	IC	InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1
DMKL9QO	CS	CCC(CC)(/C=C/C=C/[C@@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C)O
DMKL9QO	IK	LVLLALCJVJNGQQ-SEODYNFXSA-N
DMKL9QO	IU	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMKL9QO	CA	CAS 134404-52-7
DMKL9QO	DE	Rickets

DMG2QP4	ID	DMG2QP4
DMG2QP4	DN	SEP-363856
DMG2QP4	HS	Phase 3
DMG2QP4	CP	Sunovion
DMG2QP4	PC	89532783
DMG2QP4	MW	183.27
DMG2QP4	FM	C9H13NOS
DMG2QP4	IC	InChI=1S/C9H13NOS/c1-10-6-8-9-7(2-4-11-8)3-5-12-9/h3,5,8,10H,2,4,6H2,1H3/t8-/m0/s1
DMG2QP4	CS	CNC[C@H]1C2=C(CCO1)C=CS2
DMG2QP4	IK	ABDDQTDRAHXHOC-QMMMGPOBSA-N
DMG2QP4	IU	1-[(7S)-5,7-dihydro-4H-thieno[2,3-c]pyran-7-yl]-N-methylmethanamine
DMG2QP4	CA	CAS 1310426-33-5
DMG2QP4	DE	Major depressive disorder; Parkinson disease; Schizophrenia

DM5VH6U	ID	DM5VH6U
DM5VH6U	DN	Serlopitant
DM5VH6U	HS	Phase 3
DM5VH6U	SN	VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one
DM5VH6U	CP	Menlo Therapeutics Redwood City, CA
DM5VH6U	PC	23653789
DM5VH6U	MW	555.5
DM5VH6U	FM	C29H28F7NO2
DM5VH6U	IC	InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1
DM5VH6U	CS	C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5
DM5VH6U	IK	FLNYCRJBCNNHRH-OIYLJQICSA-N
DM5VH6U	IU	3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one
DM5VH6U	CA	CAS 860642-69-9
DM5VH6U	DE	Prurigo nodularis; Psoriasis vulgaris

DMZ61IA	ID	DMZ61IA
DMZ61IA	DN	Setipiprant
DMZ61IA	HS	Phase 3
DMZ61IA	SN	ACT-129968
DMZ61IA	CP	Actelion Pharmaceuticals
DMZ61IA	DT	Small molecular drug
DMZ61IA	PC	49843471
DMZ61IA	MW	402.4
DMZ61IA	FM	C24H19FN2O3
DMZ61IA	IC	InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29)
DMZ61IA	CS	C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54
DMZ61IA	IK	IHAXLPDVOWLUOS-UHFFFAOYSA-N
DMZ61IA	IU	2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid
DMZ61IA	CA	CAS 866460-33-5
DMZ61IA	DE	Asthma

DM1NQDW	ID	DM1NQDW
DM1NQDW	DN	SGI110
DM1NQDW	HS	Phase 3
DM1NQDW	CP	Astex Pharmaceuticals
DM1NQDW	PC	137295284
DM1NQDW	MW	581.4
DM1NQDW	FM	C18H25N9NaO10P
DM1NQDW	IC	InChI=1S/C18H24N9O10P.Na.H/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30;;/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30);;/q;+1;-1/t7?,8-,9+,10+,11?,12+;;/m0../s1
DM1NQDW	CS	[H-].C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)OP(=O)(O)OC[C@@H]3C(CC(O3)N4C=NC5=C4N=C(NC5=O)N)O.[Na+]
DM1NQDW	IK	AYXRQJHOBFJIHP-ZWBDGAAVSA-N
DM1NQDW	IU	sodium;[(2R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate;hydride
DM1NQDW	DE	Acute myeloid leukaemia

DM4N1SP	ID	DM4N1SP
DM4N1SP	DN	Shigamabs
DM4N1SP	HS	Phase 3
DM4N1SP	SN	C-Stx1; C-Stx2; Ca-Stx1; Ca-Stx2; Anti-Shiga toxin monoclonal antibodies, Thallion; Anti-Shiga toxin monoclonals, Sunol;Monoclonal antibodies (HUS), Sunol; Monoclonal antibodies (HUS), Thallion
DM4N1SP	CP	Bellus Health
DM4N1SP	DT	Monoclonal antibody
DM4N1SP	DE	Haemolytic uraemic syndrome; Bacterial infection

DMEWRXA	ID	DMEWRXA
DMEWRXA	DN	SHP647
DMEWRXA	HS	Phase 3
DMEWRXA	CP	inhibitor, Lexington, MA
DMEWRXA	DE	Crohn disease; Ulcerative colitis

DMMIWCE	ID	DMMIWCE
DMMIWCE	DN	Sifuvirtide
DMMIWCE	HS	Phase 3
DMMIWCE	SN	FS-0101; HIV fusion inhibitor (oral), FusoGen; HIV gp41 protein inhibitor (oral), FusoGen; Sifuvirtide (oral, HIV); Sifuvirtide (oral, HIV), FusoGen
DMMIWCE	CP	FusoGen Pharmaceuticals Inc
DMMIWCE	PC	49769437
DMMIWCE	MW	4686
DMMIWCE	FM	C201H307N59O71
DMMIWCE	IC	InChI=1S/C201H307N59O71/c1-15-93(10)156(257-177(311)124(54-67-151(285)286)235-162(296)109(31-22-70-219-197(209)210)226-168(302)119(49-62-146(275)276)237-184(318)133(81-101-87-225-108-30-21-19-28-105(101)108)254-195(329)160(97(14)264)259-178(312)125(55-68-152(287)288)239-183(317)132(244-161(295)106(202)88-261)80-100-86-224-107-29-20-18-27-104(100)107)191(325)242-123(53-66-150(283)284)173(307)249-135(83-144(208)272)186(320)247-131(79-99-38-42-103(266)43-39-99)189(323)260-159(96(13)263)194(328)241-112(34-25-73-222-200(215)216)163(297)232-117(47-60-142(206)270)176(310)258-158(95(12)17-3)193(327)253-130(78-98-36-40-102(265)41-37-98)182(316)229-113(35-26-74-223-201(217)218)175(309)256-157(94(11)16-2)192(326)252-129(77-92(8)9)179(313)236-121(51-64-148(279)280)171(305)234-122(52-65-149(281)282)174(308)255-138(89-262)190(324)240-115(45-58-140(204)268)167(301)233-118(48-61-145(273)274)170(304)230-114(44-57-139(203)267)166(300)231-116(46-59-141(205)269)172(306)251-136(84-154(291)292)187(321)228-111(33-24-72-221-199(213)214)164(298)248-134(82-143(207)271)185(319)238-120(50-63-147(277)278)169(303)227-110(32-23-71-220-198(211)212)165(299)250-137(85-155(293)294)188(322)246-128(76-91(6)7)181(315)245-127(75-90(4)5)180(314)243-126(196(330)331)56-69-153(289)290/h18-21,27-30,36-43,86-87,90-97,106,109-138,156-160,224-225,261-266H,15-17,22-26,31-35,44-85,88-89,202H2,1-14H3,(H2,203,267)(H2,204,268)(H2,205,269)(H2,206,270)(H2,207,271)(H2,208,272)(H,226,302)(H,227,303)(H,228,321)(H,229,316)(H,230,304)(H,231,300)(H,232,297)(H,233,301)(H,234,305)(H,235,296)(H,236,313)(H,237,318)(H,238,319)(H,239,317)(H,240,324)(H,241,328)(H,242,325)(H,243,314)(H,244,295)(H,245,315)(H,246,322)(H,247,320)(H,248,298)(H,249,307)(H,250,299)(H,251,306)(H,252,326)(H,253,327)(H,254,329)(H,255,308)(H,256,309)(H,257,311)(H,258,310)(H,259,312)(H,260,323)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,330,331)(H4,209,210,219)(H4,211,212,220)(H4,213,214,221)(H4,215,216,222)(H4,217,218,223)/t93-,94-,95-,96+,97+,106-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,156-,157-,158-,159-,160-/m0/s1
DMMIWCE	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CO)N
DMMIWCE	IK	WIOOVJJJJQAZGJ-ISHQQBGZSA-N
DMMIWCE	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]pentanedioic acid
DMMIWCE	DE	Human immunodeficiency virus infection

DM4YDAJ	ID	DM4YDAJ
DM4YDAJ	DN	Sildenafil
DM4YDAJ	HS	Phase 3
DM4YDAJ	SN	sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; BNRNXUUZRGQAQC-UHFFFAOYSA-N; Sildenafil
DM4YDAJ	TC	Antiviral Agents
DM4YDAJ	DT	Small molecular drug
DM4YDAJ	PC	135398744
DM4YDAJ	MW	474.6
DM4YDAJ	FM	C22H30N6O4S
DM4YDAJ	IC	InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
DM4YDAJ	CS	CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
DM4YDAJ	IK	BNRNXUUZRGQAQC-UHFFFAOYSA-N
DM4YDAJ	IU	5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DM4YDAJ	CA	CAS 139755-83-2
DM4YDAJ	CB	CHEBI:9139
DM4YDAJ	DE	Coronavirus Disease 2019 (COVID-19)

DMVO7UW	ID	DMVO7UW
DMVO7UW	DN	Siltuximab
DMVO7UW	HS	Phase 3
DMVO7UW	SN	Sylvant (TN); Siltuximab (USAN/INN); D09669; 541502-14-1
DMVO7UW	TC	Antiviral Agents
DMVO7UW	DT	Monoclonal antibody
DMVO7UW	DE	Coronavirus Disease 2019 (COVID-19)

DM18QHT	ID	DM18QHT
DM18QHT	DN	Simvastatin acid
DM18QHT	HS	Phase 3
DM18QHT	SN	Simvastatin acid; Tenivastatin; UNII-9L6M5TH46B; DIMETHYL-COMPACTIN; 9L6M5TH46B; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; Tenivastatin [INN]; (3R,5R)-7-{(1S,2S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoic acid
DM18QHT	PC	64718
DM18QHT	MW	436.6
DM18QHT	FM	C25H40O6
DM18QHT	IC	InChI=1S/C25H40O6/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29/h7-8,11,15-16,18-21,23,26-27H,6,9-10,12-14H2,1-5H3,(H,28,29)/t15-,16-,18+,19+,20-,21-,23-/m0/s1
DM18QHT	CS	CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)C
DM18QHT	IK	XWLXKKNPFMNSFA-HGQWONQESA-N
DM18QHT	IU	(3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DM18QHT	CA	CAS 121009-77-6
DM18QHT	DE	Chronic obstructive pulmonary disease

DMK8AQP	ID	DMK8AQP
DMK8AQP	DN	Sirukumab
DMK8AQP	HS	Phase 3
DMK8AQP	CP	GlaxoSmithKline
DMK8AQP	DT	Monoclonal antibody
DMK8AQP	DE	Rheumatoid arthritis; Cutaneous lupus erythematosus; Giant cell arteritis; Major depressive disorder

DM6BZCV	ID	DM6BZCV
DM6BZCV	DN	Sivelestat
DM6BZCV	HS	Phase 3
DM6BZCV	SN	127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine
DM6BZCV	DT	Small molecular drug
DM6BZCV	PC	107706
DM6BZCV	MW	434.5
DM6BZCV	FM	C20H22N2O7S
DM6BZCV	IC	InChI=1S/C20H22N2O7S/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24)
DM6BZCV	CS	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O
DM6BZCV	IK	BTGNGJJLZOIYID-UHFFFAOYSA-N
DM6BZCV	IU	2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid
DM6BZCV	CA	CAS 127373-66-4
DM6BZCV	CB	CHEBI:135704
DM6BZCV	DE	Anterior uveitis; Pyoderma gangrenosum; Axial spondyloarthritis; Crohn disease; Multiple sclerosis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

DMWOF1E	ID	DMWOF1E
DMWOF1E	DN	SKY59
DMWOF1E	HS	Phase 3
DMWOF1E	SN	Crovalimab; RO7112689
DMWOF1E	CP	Roche
DMWOF1E	DT	Antibody
DMWOF1E	DE	Haemolytic uraemic syndrome

DMH7W9X	ID	DMH7W9X
DMH7W9X	DN	SNDX-275
DMH7W9X	HS	Phase 3
DMH7W9X	SN	Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate
DMH7W9X	CP	Bayer Schering
DMH7W9X	DT	Small molecular drug
DMH7W9X	PC	4261
DMH7W9X	MW	376.4
DMH7W9X	FM	C21H20N4O3
DMH7W9X	IC	InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)
DMH7W9X	CS	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
DMH7W9X	IK	INVTYAOGFAGBOE-UHFFFAOYSA-N
DMH7W9X	IU	pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate
DMH7W9X	CA	CAS 209783-80-2
DMH7W9X	CB	CHEBI:132082
DMH7W9X	DE	Colorectal cancer; Melanoma; Ovarian cancer; Non-small-cell lung cancer; Breast cancer

DMOQKAD	ID	DMOQKAD
DMOQKAD	DN	SNF472
DMOQKAD	HS	Phase 3
DMOQKAD	SN	Hexasodium phytate; UNII-ZBX50UG81V; 34367-89-0(Hexasodium phytate); ZBX50UG81V; 34367-89-0; sodium cyclohexane-1,2,3,4,5,6-hexayl hexakis(hydrogen phosphate); Inositol, hexakis(dihydrogen phosphate) hexasodium salt, myo-; Myo-inositol, hexakis(dihydrogen phosphate), hexasodium salt; Q27295268; scyllo-inositol,1,2,3,4,5,6-hexakis(dihydrogenphosphate),hexasodiumsalt; (1R,2R,3S,4S,5S,6S)-cyclohexane-(1,2,3,4,5,6)-hexaylhexakis(hydrogenphosphate),hexasodiumsalt
DMOQKAD	CP	Sanifit
DMOQKAD	DT	Small molecular drug
DMOQKAD	PC	91667962
DMOQKAD	MW	791.93
DMOQKAD	FM	C6H12Na6O24P6
DMOQKAD	IC	InChI=1S/C6H18O24P6.6Na/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15;;;;;;/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24);;;;;;/q;6*+1/p-6
DMOQKAD	CS	C1(C(C(C(C(C1OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMOQKAD	IK	DHZIAGCFFSRULK-UHFFFAOYSA-H
DMOQKAD	IU	hexasodium;[2,3,4,5,6-pentakis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate
DMOQKAD	CA	CAS 34367-89-0
DMOQKAD	DE	Calciphylaxis; Calcific uremic arteriolopathy

DMZE2JO	ID	DMZE2JO
DMZE2JO	DN	SNS-595
DMZE2JO	HS	Phase 3
DMZE2JO	SN	Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DMZE2JO	CP	Sunesis Pharmaceuticals Inc
DMZE2JO	DT	Small molecular drug
DMZE2JO	PC	9952884
DMZE2JO	MW	401.4
DMZE2JO	FM	C18H19N5O4S
DMZE2JO	IC	InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m0/s1
DMZE2JO	CS	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O
DMZE2JO	IK	XZAFZXJXZHRNAQ-STQMWFEESA-N
DMZE2JO	IU	7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,8-naphthyridine-3-carboxylic acid
DMZE2JO	CA	CAS 175414-77-4
DMZE2JO	DE	Ovarian cancer; Acute myeloid leukaemia

DMPBA0D	ID	DMPBA0D
DMPBA0D	DN	Sofpironium bromide
DMPBA0D	HS	Phase 3
DMPBA0D	SN	BBI-4000; 1628106-94-4; Sofpironium bromide [USAN]; CHEMBL3707223; Sofpironium bromide (JAN/USAN/INN); D10989; Pyrrolidinium, 3-(((2R)-2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy)-1-(2-ethoxy-2-oxoethyl)-1-methyl-, bromide (1:1), (3R)-
DMPBA0D	CP	Brickell Biotech Boulder, CO
DMPBA0D	PC	86301316
DMPBA0D	MW	470.4
DMPBA0D	FM	C22H32BrNO5
DMPBA0D	IC	InChI=1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1
DMPBA0D	CS	CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
DMPBA0D	IK	FIAFMTCUJCWADZ-JOFREBOKSA-M
DMPBA0D	IU	[(3R)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
DMPBA0D	CA	CAS 1628106-94-4
DMPBA0D	DE	Primary axillary hyperhidrosis

DM0HIU5	ID	DM0HIU5
DM0HIU5	DN	Solanezumab
DM0HIU5	HS	Phase 3
DM0HIU5	CP	Eli Lilly
DM0HIU5	DT	Monoclonal antibody
DM0HIU5	DE	Alzheimer disease

DM6QZIA	ID	DM6QZIA
DM6QZIA	DN	Solithromycin
DM6QZIA	HS	Phase 3
DM6QZIA	SN	Solithromycin; CEM-101; OP-1068; OPT-1068; Solithromycin (iv, bacterial pneumonia), Cempra; Solithromycin (malaria), Cempra/Medicines for Malaria Venture; Solithromycin (oral, bacterial pneumonia), Cempra; CEM-101 (iv, bacterial pneumonia), Cempra; CEM-101 (malaria), Cempra/Medicines for Malaria Venture; CEM-101 (oral, bacterial pneumonia), Cempra
DM6QZIA	CP	Cempra pharmaceuticals
DM6QZIA	DT	Small molecular drug
DM6QZIA	PC	25242512
DM6QZIA	MW	845
DM6QZIA	FM	C43H65FN6O10
DM6QZIA	IC	InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3/t24-,25-,26+,27+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1
DM6QZIA	CS	CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@](C(=O)O1)(C)F)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=N4)C5=CC(=CC=C5)N)C
DM6QZIA	IK	IXXFZUPTQVDPPK-ZAWHAJPISA-N
DM6QZIA	IU	(1S,2R,5S,7R,8R,9R,11R,13R,14R)-15-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-5-fluoro-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DM6QZIA	CA	760981-83-7
DM6QZIA	DE	Bacillus anthracis infection

DMLAYTP	ID	DMLAYTP
DMLAYTP	DN	Soluble ferric pyrophosphate
DMLAYTP	HS	Phase 3
DMLAYTP	SN	Ferric pyrophosphate; Soluble ferric pyrophosphate (anemia)
DMLAYTP	CP	Rockwell Medical Inc
DMLAYTP	DT	Small molecular drug
DMLAYTP	PC	24877
DMLAYTP	MW	745.21
DMLAYTP	FM	Fe4O21P6
DMLAYTP	IC	InChI=1S/4Fe.3H4O7P2/c;;;;3*1-8(2,3)7-9(4,5)6/h;;;;3*(H2,1,2,3)(H2,4,5,6)/q4*+3;;;/p-12
DMLAYTP	CS	[O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[Fe+3].[Fe+3].[Fe+3].[Fe+3]
DMLAYTP	IK	CADNYOZXMIKYPR-UHFFFAOYSA-B
DMLAYTP	IU	iron(3+);phosphonato phosphate
DMLAYTP	CA	CAS 10058-44-3
DMLAYTP	CB	CHEBI:132767
DMLAYTP	DE	Iron-deficiency anemia

DMIG4OX	ID	DMIG4OX
DMIG4OX	DN	SOTB07
DMIG4OX	HS	Phase 3
DMIG4OX	DE	Asthma

DMLSV74	ID	DMLSV74
DMLSV74	DN	Sotorasib
DMLSV74	HS	Phase 3
DMLSV74	SN	AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; AMG510 ; AMG 510; AMG-510; AMG510; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-
DMLSV74	CP	Amgen
DMLSV74	DT	Small molecular drug
DMLSV74	PC	137278711
DMLSV74	MW	560.6
DMLSV74	FM	C30H30F2N6O3
DMLSV74	IC	InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1
DMLSV74	CS	C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C
DMLSV74	IK	NXQKSXLFSAEQCZ-SFHVURJKSA-N
DMLSV74	IU	6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
DMLSV74	CA	CAS 2252403-56-6
DMLSV74	DE	Non-small-cell lung cancer

DMMP51W	ID	DMMP51W
DMMP51W	DN	sparsentan
DMMP51W	HS	Phase 3
DMMP51W	SN	Sparsentan; RE-021; 254740-64-2; UNII-9242RO5URM; PS433540; PS-433540; CHEMBL539423; 9242RO5URM; BMS-346567; retrophin; Sparsentan [USAN]; compound 7 [PMID 15634011]; PS 33540; Sparsentan (RE-021); Sparsentan(PS433540); SCHEMBL535109; GTPL8448; BCP23969; BDBM50175523; SB16876; DB12548; CS-7947; DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors); HY-17621; L023324; 4'-((2-butyl-4-oxo-1,3-diazaspiro[44]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide;  RE-021
DMMP51W	DT	Small molecular drug
DMMP51W	PC	10257882
DMMP51W	MW	592.8
DMMP51W	FM	C32H40N4O5S
DMMP51W	IC	InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
DMMP51W	CS	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC
DMMP51W	IK	WRFHGDPIDHPWIQ-UHFFFAOYSA-N
DMMP51W	IU	2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
DMMP51W	CA	CAS 254740-64-2
DMMP51W	DE	Myocardial infarction; Hypertension; Focal segmental glomerulosclerosis

DM4TOEQ	ID	DM4TOEQ
DM4TOEQ	DN	Spartalizumab
DM4TOEQ	HS	Phase 3
DM4TOEQ	CP	Novartis
DM4TOEQ	DT	Monoclonal antibody
DM4TOEQ	DE	Melanoma

DM7NV1I	ID	DM7NV1I
DM7NV1I	DN	SPD-465
DM7NV1I	HS	Phase 3
DM7NV1I	SN	Triple-bead MAS, Shire; Triple-bead mixed amphetamine salts (oral, attention deficit hyperactivity disorder ADHD), Shire
DM7NV1I	CP	Shire plc
DM7NV1I	DE	Attention deficit hyperactivity disorder

DMVJNFI	ID	DMVJNFI
DMVJNFI	DN	Spermidine
DMVJNFI	HS	Phase 3
DMVJNFI	SN	Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, &gt; =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0
DMVJNFI	DT	Small molecular drug
DMVJNFI	PC	1102
DMVJNFI	MW	145.25
DMVJNFI	FM	C7H19N3
DMVJNFI	IC	InChI=1S/C7H19N3/c8-4-1-2-6-10-7-3-5-9/h10H,1-9H2
DMVJNFI	CS	C(CCNCCCN)CN
DMVJNFI	IK	ATHGHQPFGPMSJY-UHFFFAOYSA-N
DMVJNFI	IU	N'-(3-aminopropyl)butane-1,4-diamine
DMVJNFI	CA	CAS 124-20-9
DMVJNFI	CB	CHEBI:16610
DMVJNFI	DE	Plaque psoriasis; Rheumatoid arthritis

DMACVEI	ID	DMACVEI
DMACVEI	DN	SPI-2012
DMACVEI	HS	Phase 3
DMACVEI	CP	SPECTRUM pharmaceuticals
DMACVEI	DE	Breast cancer

DM3PS2E	ID	DM3PS2E
DM3PS2E	DN	Squalamine
DM3PS2E	HS	Phase 3
DM3PS2E	SN	Squalamine; 148717-90-2; Squalamine [INN]; UNII-F8PO54Z4V7; F8PO54Z4V7; CHEBI:80765; 3beta-N-1-(N-(3-(4-Aminobutyl))-1,3-diaminopropane)-7alpha,24-dihydroxy-5alpha-cholestane 24-sulfate; (3beta,5alpha,7alpha,24R)-3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate); 3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)-; Cholestane-7,24-diol, 3-((3-(4-(aminobutyl)amino)propyl)amio)-, 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)-
DM3PS2E	CP	OHR Pharmaceutical
DM3PS2E	DT	Small molecular drug
DM3PS2E	PC	72495
DM3PS2E	MW	628
DM3PS2E	FM	C34H65N3O5S
DM3PS2E	IC	InChI=1S/C34H65N3O5S/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41)/t24-,25-,26+,27-,28+,29+,30-,31-,32+,33+,34-/m1/s1
DM3PS2E	CS	C[C@H](CC[C@H](C(C)C)OS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@@H]4[C@@]3(CC[C@@H](C4)NCCCNCCCCN)C)O)C
DM3PS2E	IK	UIRKNQLZZXALBI-MSVGPLKSSA-N
DM3PS2E	IU	[(3R,6R)-6-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-3-[3-(4-aminobutylamino)propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate
DM3PS2E	CA	CAS 148717-90-2
DM3PS2E	CB	CHEBI:80765
DM3PS2E	DE	Solid tumour/cancer; Diabetic macular edema

DM1ODMR	ID	DM1ODMR
DM1ODMR	DN	SR46349B
DM1ODMR	HS	Phase 3
DM1ODMR	SN	Eplivanserin fumarate; SR 46349; SR 46349B; SR-46349B; 2-Propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z,E)-, (E)-2-butenedioate (2:1) (salt); 4-((3Z)-3-(2-Dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate; 4-[(E)-3-(2-dimethylaminoethyloxyamino)-3-(2-fluorophenyl)prop-2-enylidene]cyclohexa-2,5-dien-1-one
DM1ODMR	CP	Sanofi-Aventis
DM1ODMR	DT	Small molecular drug
DM1ODMR	PC	135456189
DM1ODMR	MW	772.8
DM1ODMR	FM	C42H46F2N4O8
DM1ODMR	IC	InChI=1S/2C19H21FN2O2.C4H4O4/c2*1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15;5-3(6)1-2-4(7)8/h2*3-12,23H,13-14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b2*12-9+,21-19-;2-1+
DM1ODMR	CS	CN(CCO/N=C(\\C1=CC=CC=C1F)/C=C/C2=CC=C(C=C2)O)C.CN(CCO/N=C(\\C1=CC=CC=C1F)/C=C/C2=CC=C(C=C2)O)C.C(=C/C(=O)O)\\C(=O)O
DM1ODMR	IK	RNLKLYQQDLHHBH-ABDBJYMXSA-N
DM1ODMR	IU	(E)-but-2-enedioic acid;4-[(E,3Z)-3-[2-(dimethylamino)ethoxyimino]-3-(2-fluorophenyl)prop-1-enyl]phenol
DM1ODMR	CA	CAS 130580-02-8
DM1ODMR	DE	Schizophrenia; Primary insomnia; Sleep-wake disorder

DMT71EX	ID	DMT71EX
DMT71EX	DN	SSR-126517E
DMT71EX	HS	Phase 3
DMT71EX	CP	Sanofi-aventis
DMT71EX	DE	Thrombosis

DMVLKDX	ID	DMVLKDX
DMVLKDX	DN	Streptokinase rectal suppository
DMVLKDX	HS	Phase 3
DMVLKDX	SN	Proctokinase; Streptokinase rectal suppository (hemorrhoids); Streptokinase rectal suppository (hemorrhoids), CIGB
DMVLKDX	CP	Center for Genetic Engineering and Biotechnology
DMVLKDX	DE	Hemorrhoids

DMPOTM4	ID	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	HS	Phase 3
DMPOTM4	SN	Anticancer agents, Hutchison; HMPL-012; Kinase inhibitors (cancer), Hutchison; VEGFR-1, 2, 3 and FGFR 1 inhibitor (oral, cancer), Hutchison
DMPOTM4	CP	Hutchison Medipharma Enterprises Ltd
DMPOTM4	PC	52920501
DMPOTM4	MW	480.6
DMPOTM4	FM	C24H28N6O3S
DMPOTM4	IC	InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
DMPOTM4	CS	CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C
DMPOTM4	IK	TTZSNFLLYPYKIL-UHFFFAOYSA-N
DMPOTM4	IU	N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
DMPOTM4	CA	CAS 1308672-74-3
DMPOTM4	DE	Solid tumour/cancer; Neuroendocrine cancer

DMMD856	ID	DMMD856
DMMD856	DN	Sulopenem
DMMD856	HS	Phase 3
DMMD856	SN	CP-70,429; PF-03709270; PF-3,709,270
DMMD856	TC	Antiinfective Agents
DMMD856	DT	Small molecular drug
DMMD856	PC	9950244
DMMD856	MW	349.5
DMMD856	FM	C12H15NO5S3
DMMD856	IC	InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1
DMMD856	CS	C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3CC[S@@](=O)C3)C(=O)O)O
DMMD856	IK	FLSUCZWOEMTFAQ-PRBGKLEPSA-N
DMMD856	IU	(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMMD856	CA	CAS 120788-07-0
DMMD856	DE	Urinary tract infection

DM07653	ID	DM07653
DM07653	DN	SULTHIAME
DM07653	HS	Phase 3
DM07653	SN	sultiame; SULTHIAME; Ospolot; sultiam; Sulphenyltame; Sulthiamine; Contravul; Trolone; 61-56-3; Sultiamum; Elisal; Conadil; Riker 594; Bayer A-168; Sultiamum [INN-Latin]; Sultiamo [INN-Spanish]; Sulthiame [USAN]; 4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide; UNII-I00Q766CZ2; RP-10284; R-594; EINECS 200-511-0; p-(Tetrahydro-2H-1,2-thiazin-2-yl)benzenesulfonamide, S,S-dioxide; BRN 1222219; Benzenesulfonamide, 4-(tetrahydro-2H-1,2-thiazin-2-yl)-, S,S-dioxide; RP 10284; 4-(1,1-Dioxido-1,2-thiazinan-2-yl)benzenesulfonamide; CHEMBL328560
DM07653	DT	Small molecular drug
DM07653	PC	5356
DM07653	MW	290.4
DM07653	FM	C10H14N2O4S2
DM07653	IC	InChI=1S/C10H14N2O4S2/c11-18(15,16)10-5-3-9(4-6-10)12-7-1-2-8-17(12,13)14/h3-6H,1-2,7-8H2,(H2,11,15,16)
DM07653	CS	C1CCS(=O)(=O)N(C1)C2=CC=C(C=C2)S(=O)(=O)N
DM07653	IK	HMHVCUVYZFYAJI-UHFFFAOYSA-N
DM07653	IU	4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide
DM07653	CA	CAS 61-56-3
DM07653	CB	CHEBI:32171

DMYHV17	ID	DMYHV17
DMYHV17	DN	Sumanirole
DMYHV17	HS	Phase 3
DMYHV17	SN	PNU 95666; U 95666E; PNU-95666; [2-[(1R)-1-(methylamino)ethyl]phenyl]methanol; Benzenemethanol, alpha-((1R)-1-(methylamino)ethyl)-, (alphaS)-rel-, 2-naphthalenesulfonate (salt); 2-Naphthalenesulfonic acid, compd with (R*,S*)-alpha-(1-(methylamino)ethyl)benzenemethanol (1:1); 2-Naphthalenesulfonic acid, compd with rel-(alphaS)-alpha-((1R)-1-(methylamino)ethyl)benzenemethanol (1:1)
DMYHV17	CP	Pfizer
DMYHV17	DT	Small molecular drug
DMYHV17	PC	9818479
DMYHV17	MW	203.24
DMYHV17	FM	C11H13N3O
DMYHV17	IC	InChI=1S/C11H13N3O/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9/h2-4,8,12H,5-6H2,1H3,(H,13,15)/t8-/m1/s1
DMYHV17	CS	CN[C@@H]1CC2=C3C(=CC=C2)NC(=O)N3C1
DMYHV17	IK	RKZSNTNMEFVBDT-MRVPVSSYSA-N
DMYHV17	IU	(10R)-10-(methylamino)-1,3-diazatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-2-one
DMYHV17	CA	CAS 179386-43-7
DMYHV17	DE	Parkinson disease

DMXNZQK	ID	DMXNZQK
DMXNZQK	DN	SUN-101
DMXNZQK	HS	Phase 3
DMXNZQK	CP	Sunovion
DMXNZQK	DE	Chronic obstructive pulmonary disease

DMH2FN1	ID	DMH2FN1
DMH2FN1	DN	Suronacrine maleate
DMH2FN1	HS	Phase 3
DMH2FN1	SN	HP-128; Suronacrine maleate < Rec INNM; Rac-9-(Benzylamino)-1,2,3,4-tetrahydroacridin-1-ol maleate
DMH2FN1	DT	Small molecular drug
DMH2FN1	PC	9953907
DMH2FN1	MW	420.5
DMH2FN1	FM	C24H24N2O5
DMH2FN1	IC	InChI=1S/C20H20N2O.C4H4O4/c23-18-12-6-11-17-19(18)20(15-9-4-5-10-16(15)22-17)21-13-14-7-2-1-3-8-14;5-3(6)1-2-4(7)8/h1-5,7-10,18,23H,6,11-13H2,(H,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1-
DMH2FN1	CS	C1CC(C2=C(C3=CC=CC=C3N=C2C1)NCC4=CC=CC=C4)O.C(=C\\C(=O)O)\\C(=O)O
DMH2FN1	IK	JRQSVNSUJOFXHC-BTJKTKAUSA-N
DMH2FN1	IU	9-(benzylamino)-1,2,3,4-tetrahydroacridin-1-ol;(Z)-but-2-enedioic acid
DMH2FN1	CA	CAS 113108-86-4
DMH2FN1	DE	Cognitive impairment

DMY7WH1	ID	DMY7WH1
DMY7WH1	DN	Sutimlimab
DMY7WH1	HS	Phase 3
DMY7WH1	CP	Sanofi
DMY7WH1	DT	Antibody
DMY7WH1	DE	Cold type autoimmune haemolytic anemia

DM3BO8G	ID	DM3BO8G
DM3BO8G	DN	SUVN-G3031
DM3BO8G	HS	Phase 3
DM3BO8G	SN	LNXDUSQEXVQFGP-UHFFFAOYSA-N; UNII-65V47O9NOP; 65V47O9NOP; SCHEMBL12484542; N-[4-(1-Cyclobutyl piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; 1394808-82-2
DM3BO8G	CP	Suven Life Sciences Hyderabad, India
DM3BO8G	PC	60151477
DM3BO8G	MW	373.5
DM3BO8G	FM	C21H31N3O3
DM3BO8G	IC	InChI=1S/C21H31N3O3/c25-21(16-23-12-14-26-15-13-23)22-17-4-6-19(7-5-17)27-20-8-10-24(11-9-20)18-2-1-3-18/h4-7,18,20H,1-3,8-16H2,(H,22,25)
DM3BO8G	CS	C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)NC(=O)CN4CCOCC4
DM3BO8G	IK	LNXDUSQEXVQFGP-UHFFFAOYSA-N
DM3BO8G	IU	N-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide
DM3BO8G	CA	CAS 1394808-82-2
DM3BO8G	DE	Cognitive impairment

DMOVEDH	ID	DMOVEDH
DMOVEDH	DN	SYM-004
DMOVEDH	HS	Phase 3
DMOVEDH	SN	Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
DMOVEDH	CP	Symphogen A/S
DMOVEDH	DT	Antibody
DMOVEDH	DE	Head and neck cancer; Colorectal cancer; Metastatic colorectal cancer; Recurrent glioblastoma; Non-small-cell lung cancer

DMRUEKC	ID	DMRUEKC
DMRUEKC	DN	Synthetic conjugated estrogen
DMRUEKC	HS	Phase 3
DMRUEKC	SN	Bijuva; Bithena; DR-2041; SCE-A Vaginal Cream; Synthetic conjugated estrogen (cream, vulvovaginal atrophy); Synthetic conjugated estrogen (cream, vulvovaginal atrophy), Teva
DMRUEKC	CP	Duramed Pharmaceuticals Inc
DMRUEKC	DE	Vaginal disease

DMXU4ON	ID	DMXU4ON
DMXU4ON	DN	Synthetic hypericin
DMXU4ON	HS	Phase 3
DMXU4ON	SN	Hypericin; VIMRxyn; Synthetic hypericin, Nexell
DMXU4ON	CP	Nexell Therapeutics Inc
DMXU4ON	DE	Virus infection

DM9L1AC	ID	DM9L1AC
DM9L1AC	DN	SYR-472
DM9L1AC	HS	Phase 3
DM9L1AC	SN	Trelagliptin succinate; TRELAGLIPTIN SUCCINATE; 1029877-94-8; Trelagliptin (succinate); UNII-4118932Z90; AK198895; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile; 4118932Z90; SYR-472 succinate; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile succinate; SYR 111472 succinate; Trelagliptin succinate [USAN]; SYR111472 SUCCINATE; SYR 472; SYR472; Zafatek (TN); Trelagliptin succinat; SYR472 succinate; syr; Trelagliptin Succinate
DM9L1AC	CP	Takeda
DM9L1AC	DT	Small molecular drug
DM9L1AC	PC	15983988
DM9L1AC	MW	357.4
DM9L1AC	FM	C18H20FN5O2
DM9L1AC	IC	InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1
DM9L1AC	CS	CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCC[C@H](C3)N
DM9L1AC	IK	IWYJYHUNXVAVAA-OAHLLOKOSA-N
DM9L1AC	IU	2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile
DM9L1AC	CA	CAS 865759-25-7
DM9L1AC	CB	CHEBI:134715
DM9L1AC	DE	Non-insulin dependent diabetes; Metabolic disorder

DMR32KN	ID	DMR32KN
DMR32KN	DN	TA-6366
DMR32KN	HS	Phase 3
DMR32KN	SN	Hipertene (TN); Imidapril (INN); Imidapril HCl; Imidapril [BAN:INN]; Imidapril [INN:BAN]; Imidaprilum; Imidaprilum [INN-Latin]; Novaloc; Tanatril; imidapril; lmidaprfil; (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid; (S)-3-(N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl)-1-methyl-2-oxoimidazoline-4-carboxylic acid; 89371-37-9; BW7H1TJS22; C20H27N3O6; CHEMBL317094; MFCD00923828; NCGC00181342-01; UNII-BW7H1TJS22
DMR32KN	PC	5464343
DMR32KN	MW	405.4
DMR32KN	FM	C20H27N3O6
DMR32KN	IC	KLZWOWYOHUKJIG-BPUTZDHNSA-N
DMR32KN	CS	CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C(CN(C2=O)C)C(=O)O
DMR32KN	IK	1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
DMR32KN	IU	(4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
DMR32KN	CA	CAS 89371-37-9
DMR32KN	CB	CHEBI:135654
DMR32KN	DE	Essential hypertension

DMKSAG1	ID	DMKSAG1
DMKSAG1	DN	Tabalumab
DMKSAG1	HS	Phase 3
DMKSAG1	SN	LY2127399
DMKSAG1	CP	Lilly
DMKSAG1	DT	Monoclonal antibody
DMKSAG1	DE	Multiple myeloma

DMW5PHL	ID	DMW5PHL
DMW5PHL	DN	Taberminogene vadenovec
DMW5PHL	HS	Phase 3
DMW5PHL	SN	Trinam (TN)
DMW5PHL	CP	Ark Therapeutics
DMW5PHL	DE	Vascular restinosis

DM1NTVQ	ID	DM1NTVQ
DM1NTVQ	DN	Tadekinig alfa
DM1NTVQ	HS	Phase 3
DM1NTVQ	CP	AB2 Bio
DM1NTVQ	DT	Recombinant protein
DM1NTVQ	DE	XIAP deficiency

DMCF6SX	ID	DMCF6SX
DMCF6SX	DN	TAK-491
DMCF6SX	HS	Phase 3
DMCF6SX	SN	TAK 491
DMCF6SX	CP	Takeda
DMCF6SX	DT	Small molecular drug
DMCF6SX	PC	135409642
DMCF6SX	MW	568.5
DMCF6SX	FM	C30H24N4O8
DMCF6SX	IC	InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
DMCF6SX	CS	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C
DMCF6SX	IK	QJFSABGVXDWMIW-UHFFFAOYSA-N
DMCF6SX	IU	(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
DMCF6SX	CA	CAS 863031-21-4
DMCF6SX	CB	CHEBI:68845
DMCF6SX	DE	Hypertension

DM2H8FZ	ID	DM2H8FZ
DM2H8FZ	DN	TAK-700
DM2H8FZ	HS	Phase 3
DM2H8FZ	SN	Orteronel
DM2H8FZ	CP	Millennium Pharmaceuticals
DM2H8FZ	DT	Small molecular drug
DM2H8FZ	PC	9883029
DM2H8FZ	MW	307.3
DM2H8FZ	FM	C18H17N3O2
DM2H8FZ	IC	InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)
DM2H8FZ	CS	CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O
DM2H8FZ	IK	OZPFIJIOIVJZMN-UHFFFAOYSA-N
DM2H8FZ	IU	6-(7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide
DM2H8FZ	CB	CHEBI:94965
DM2H8FZ	DE	Prostate cancer

DMIM5AP	ID	DMIM5AP
DMIM5AP	DN	TAK-875
DMIM5AP	HS	Phase 3
DMIM5AP	SN	TAK-875; Fasiglifam; 1000413-72-8; TAK875; TAK 875; UNII-GLP1W4JXAH; GLP1W4JXAH; (S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid; CHEMBL1829174; [(3s)-6-({2',6'-Dimethyl-4'-[3-(Methylsulfonyl)propoxy]biphenyl-3-Yl}methoxy)-2,3-Dihydro-1-Benzofuran-3-Yl]acetic Acid; 3-Benzofuranacetic acid, 6-[[2',6'-diMethyl-4'-[3-(Methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-; J-501277
DMIM5AP	CP	Takeda Pharmaceuticals U.S.A.
DMIM5AP	DT	Small molecular drug
DMIM5AP	PC	24857286
DMIM5AP	MW	524.6
DMIM5AP	FM	C29H32O7S
DMIM5AP	IC	InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1
DMIM5AP	CS	CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C
DMIM5AP	IK	BZCALJIHZVNMGJ-HSZRJFAPSA-N
DMIM5AP	IU	2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid
DMIM5AP	CA	CAS 1000413-72-8
DMIM5AP	DE	Type-2 diabetes

DM1IZ5D	ID	DM1IZ5D
DM1IZ5D	DN	Talabostat
DM1IZ5D	HS	Phase 3
DM1IZ5D	SN	Talabostat mesylate; Boroproline compounds, DARA BioSciences; Boroproline compounds, Point Therapeutics; PT-100; Val-boro-Pro
DM1IZ5D	CP	Point Therapeutics; Tufts University School of Medicine
DM1IZ5D	DT	Small molecular drug
DM1IZ5D	PC	6918572
DM1IZ5D	MW	214.07
DM1IZ5D	FM	C9H19BN2O3
DM1IZ5D	IC	InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/t7-,8-/m0/s1
DM1IZ5D	CS	B([C@@H]1CCCN1C(=O)[C@H](C(C)C)N)(O)O
DM1IZ5D	IK	FKCMADOPPWWGNZ-YUMQZZPRSA-N
DM1IZ5D	IU	[(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid
DM1IZ5D	CA	CAS 149682-77-9
DM1IZ5D	DE	Constitutional neutropenia; Solid tumour/cancer

DMV7T64	ID	DMV7T64
DMV7T64	DN	Talactoferrin
DMV7T64	HS	Phase 3
DMV7T64	SN	Talactoferrin (topical)
DMV7T64	CP	Agennix AG
DMV7T64	DE	Diabetic foot ulcer

DM3G74J	ID	DM3G74J
DM3G74J	DN	Tamibarotene
DM3G74J	HS	Phase 3
DM3G74J	SN	Tamibarotene (oral, Alzheimer's disease)
DM3G74J	CP	Research Foundation Itsuu Laboratory
DM3G74J	DT	Small molecular drug
DM3G74J	PC	108143
DM3G74J	MW	351.4
DM3G74J	FM	C22H25NO3
DM3G74J	IC	InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)
DM3G74J	CS	CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C
DM3G74J	IK	MUTNCGKQJGXKEM-UHFFFAOYSA-N
DM3G74J	IU	4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid
DM3G74J	CA	CAS 94497-51-5
DM3G74J	CB	CHEBI:32181
DM3G74J	DE	Alzheimer disease; T-cell leukaemia

DMJKWMA	ID	DMJKWMA
DMJKWMA	DN	Tanezumab
DMJKWMA	HS	Phase 3
DMJKWMA	CP	Pfizer New York, NY
DMJKWMA	DT	Monoclonal antibody
DMJKWMA	DE	Neuropathic pain; Chronic low back pain; Pain; Osteoarthritis; Cancer related pain

DMWM4D0	ID	DMWM4D0
DMWM4D0	DN	TAS-120
DMWM4D0	HS	Phase 3
DMWM4D0	CP	Taiho oncology
DMWM4D0	PC	71621331
DMWM4D0	MW	418.4
DMWM4D0	FM	C22H22N6O3
DMWM4D0	IC	InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1
DMWM4D0	CS	COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)[C@H]4CCN(C4)C(=O)C=C)OC
DMWM4D0	IK	KEIPNCCJPRMIAX-HNNXBMFYSA-N
DMWM4D0	IU	1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
DMWM4D0	CA	CAS 1448169-71-8
DMWM4D0	DE	Multiple myeloma; Solid tumour/cancer; Cholangiocarcinoma

DMPYET9	ID	DMPYET9
DMPYET9	DN	Taspoglutide
DMPYET9	HS	Phase 3
DMPYET9	SN	BIM-51077; BIM-51079; BIM-51182; Glucagon agonists, Ipsen; ITM-077; R-1583; RG-1583; RO-5073031; Glucagon agonists, Beaufour-Ipsen
DMPYET9	CP	Ipsen
DMPYET9	PC	56842233
DMPYET9	MW	3339.7
DMPYET9	FM	C152H232N40O45
DMPYET9	IC	InChI=1S/C152H232N40O45/c1-20-78(10)119(145(233)168-81(13)125(213)174-105(63-87-66-162-92-39-28-27-38-90(87)92)134(222)176-101(59-75(4)5)135(223)187-117(76(6)7)143(231)173-95(41-30-32-56-154)142(230)192-152(18,19)148(236)184-93(122(157)210)42-33-57-161-150(158)159)189-136(224)103(60-84-34-23-21-24-35-84)177-131(219)99(50-54-115(206)207)172-130(218)94(40-29-31-55-153)170-124(212)80(12)166-123(211)79(11)167-129(217)98(47-51-110(156)199)169-111(200)68-163-127(215)96(48-52-113(202)203)171-132(220)100(58-74(2)3)175-133(221)102(62-86-43-45-89(198)46-44-86)178-139(227)107(70-193)181-141(229)109(72-195)182-144(232)118(77(8)9)188-138(226)106(65-116(208)209)179-140(228)108(71-194)183-147(235)121(83(15)197)190-137(225)104(61-85-36-25-22-26-37-85)180-146(234)120(82(14)196)186-112(201)69-164-128(216)97(49-53-114(204)205)185-149(237)151(16,17)191-126(214)91(155)64-88-67-160-73-165-88/h21-28,34-39,43-46,66-67,73-83,91,93-109,117-121,162,193-198H,20,29-33,40-42,47-65,68-72,153-155H2,1-19H3,(H2,156,199)(H2,157,210)(H,160,165)(H,163,215)(H,164,216)(H,166,211)(H,167,217)(H,168,233)(H,169,200)(H,170,212)(H,171,220)(H,172,218)(H,173,231)(H,174,213)(H,175,221)(H,176,222)(H,177,219)(H,178,227)(H,179,228)(H,180,234)(H,181,229)(H,182,232)(H,183,235)(H,184,236)(H,185,237)(H,186,201)(H,187,223)(H,188,226)(H,189,224)(H,190,225)(H,191,214)(H,192,230)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,117-,118-,119-,120-,121-/m0/s1
DMPYET9	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
DMPYET9	IK	WRGVLTAWMNZWGT-VQSPYGJZSA-N
DMPYET9	IU	(4S)-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid
DMPYET9	CA	CAS 275371-94-3
DMPYET9	DE	Type-1 diabetes

DM9GSVQ	ID	DM9GSVQ
DM9GSVQ	DN	Tasquinimod
DM9GSVQ	HS	Phase 3
DM9GSVQ	SN	TASQ
DM9GSVQ	CP	Active Biotech
DM9GSVQ	DT	Small molecular drug
DM9GSVQ	PC	54682876
DM9GSVQ	MW	406.4
DM9GSVQ	FM	C20H17F3N2O4
DM9GSVQ	IC	InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
DM9GSVQ	CS	CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O
DM9GSVQ	IK	ONDYALNGTUAJDX-UHFFFAOYSA-N
DM9GSVQ	IU	4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]quinoline-3-carboxamide
DM9GSVQ	CA	CAS 254964-60-8
DM9GSVQ	DE	Prostate cancer

DMD6AUX	ID	DMD6AUX
DMD6AUX	DN	Tat-NR2B9c
DMD6AUX	HS	Phase 3
DMD6AUX	SN	NA-1; NA-1); PSD-95 inhibitor (stroke), NoNO/Arbor Vita; NMDAR NR2 domain-binding protein + HIV-1 Tat protein (Stroke), NoNO/Arbor Vita
DMD6AUX	CP	Nono inc
DMD6AUX	DT	Peptide
DMD6AUX	PC	44568939
DMD6AUX	MW	2518.9
DMD6AUX	FM	C105H188N42O30
DMD6AUX	IC	InChI=1S/C105H188N42O30/c1-7-55(6)80(98(175)140-69(34-36-77(154)155)92(169)143-72(50-148)95(172)142-71(48-78(156)157)94(171)146-79(54(4)5)99(176)177)147-97(174)74(52-150)145-96(173)73(51-149)144-93(170)70(46-53(2)3)141-90(167)62(22-10-13-39-108)133-85(162)63(24-15-41-124-101(113)114)135-87(164)65(26-17-43-126-103(117)118)136-88(165)66(27-18-44-127-104(119)120)138-91(168)68(33-35-75(110)152)139-89(166)67(28-19-45-128-105(121)122)137-86(163)64(25-16-42-125-102(115)116)134-84(161)61(21-9-12-38-107)132-83(160)60(20-8-11-37-106)131-82(159)59(23-14-40-123-100(111)112)130-76(153)49-129-81(158)58(109)47-56-29-31-57(151)32-30-56/h29-32,53-55,58-74,79-80,148-151H,7-28,33-52,106-109H2,1-6H3,(H2,110,152)(H,129,158)(H,130,153)(H,131,159)(H,132,160)(H,133,162)(H,134,161)(H,135,164)(H,136,165)(H,137,163)(H,138,168)(H,139,166)(H,140,175)(H,141,167)(H,142,172)(H,143,169)(H,144,170)(H,145,173)(H,146,171)(H,147,174)(H,154,155)(H,156,157)(H,176,177)(H4,111,112,123)(H4,113,114,124)(H4,115,116,125)(H4,117,118,126)(H4,119,120,127)(H4,121,122,128)/t55-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,79-,80-/m0/s1
DMD6AUX	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N
DMD6AUX	IK	XWQVQFBTSBCKLI-FKXNDIMNSA-N
DMD6AUX	IU	(4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMD6AUX	CA	CAS 500992-11-0
DMD6AUX	DE	Cerebrovascular ischaemia; Stroke

DML6GAN	ID	DML6GAN
DML6GAN	DN	Taxol/Paraplatin/Herceptin
DML6GAN	HS	Phase 3
DML6GAN	SN	Paclitaxel/carboplatin/trastuzumab
DML6GAN	CP	Bristol-Myers Squibb
DML6GAN	DE	Breast cancer

DMGKBZH	ID	DMGKBZH
DMGKBZH	DN	TD-1792
DMGKBZH	HS	Phase 3
DMGKBZH	CP	Theravance
DMGKBZH	DT	Small molecular drug
DMGKBZH	PC	76960417
DMGKBZH	MW	1983.3
DMGKBZH	FM	C87H95Cl3N16O28S2
DMGKBZH	IC	InChI=1S/C87H95Cl3N16O28S2/c1-33(2)20-45(94-5)74(117)100-62-66(112)36-11-14-49(43(88)22-36)130-51-24-38-25-52(70(51)134-85-71(69(115)68(114)53(31-107)132-85)133-55-29-87(4,93)72(116)34(3)129-55)131-50-15-12-37(23-44(50)89)67(113)63-81(124)99-59(42-26-40(108)27-48(110)56(42)41-21-35(10-13-47(41)109)57(77(120)101-63)98-78(121)58(38)97-75(118)46(28-54(91)111)96-80(62)123)76(119)95-16-9-19-128-104-61(60-73(90)136-86(92)103-60)79(122)102-64-82(125)106-65(84(126)127)39(32-135-83(64)106)30-105-17-7-6-8-18-105/h6-8,10-15,17-18,21-27,33-34,45-46,53,55,57-59,62-64,66-69,71-72,83,85,94,107,112-116H,9,16,19-20,28-32,93H2,1-5H3,(H15-,91,92,95,96,97,98,99,100,101,102,103,104,108,109,110,111,117,118,119,120,121,122,123,124,126,127)/t34-,45+,46-,53+,55-,57+,58+,59-,62+,63-,64+,66+,67+,68+,69-,71+,72+,83+,85-,87-/m0/s1
DMGKBZH	CS	C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)NCCCO/N=C(/C1=C(SC(=N1)N)Cl)\\C(=O)N[C@H]1[C@@H]2N(C1=O)C(=C(CS2)C[N+]1=CC=CC=C1)C(=O)[O-])CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
DMGKBZH	IK	OGUAFUAJSPORAH-KHCCTVBNSA-N
DMGKBZH	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-[3-[[(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carbonyl]amino]propoxyimino]acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMGKBZH	CA	CAS 722454-12-8
DMGKBZH	DE	Gram-positive bacterial infection; Skin infection

DMVSX6O	ID	DMVSX6O
DMVSX6O	DN	Tebipenem
DMVSX6O	HS	Phase 3
DMVSX6O	SN	Tebipenem [INN]
DMVSX6O	CP	Sanofi-Aventis
DMVSX6O	DT	Small molecular drug
DMVSX6O	PC	9800194
DMVSX6O	MW	383.5
DMVSX6O	FM	C16H21N3O4S2
DMVSX6O	IC	InChI=1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1
DMVSX6O	CS	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O)[C@@H](C)O
DMVSX6O	IK	GXXLUDOKHXEFBQ-YJFSRANCSA-N
DMVSX6O	IU	(4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMVSX6O	CA	CAS 161715-21-5
DMVSX6O	DE	Obesity; Nicotine dependence; Urinary tract infection

DMTCR2O	ID	DMTCR2O
DMTCR2O	DN	Tecarfarin
DMTCR2O	HS	Phase 3
DMTCR2O	SN	ATI-5923
DMTCR2O	CP	ARYx Therapeutics
DMTCR2O	DT	Small molecular drug
DMTCR2O	PC	54718618
DMTCR2O	MW	460.3
DMTCR2O	FM	C21H14F6O5
DMTCR2O	IC	InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
DMTCR2O	CS	CC(C(F)(F)F)(C(F)(F)F)OC(=O)C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O
DMTCR2O	IK	QFLNTQDOVCLQKW-UHFFFAOYSA-N
DMTCR2O	IU	(1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate
DMTCR2O	CA	CAS 867257-26-9
DMTCR2O	DE	Cerebrovascular ischaemia; Thrombosis

DMKE187	ID	DMKE187
DMKE187	DN	Telmisartan
DMKE187	HS	Phase 3
DMKE187	SN	Telmisartan; 144701-48-4; Micardis; Pritor; BIBR 277; Kinzalmono; BIBR-277; BIBR 277SE; Telmisattan; Targit; Telmisartan [INN]; UNII-U5SYW473RQ; BIBR-277SE; BIBR-277-SE; U5SYW473RQ; CHEMBL1017; CHEBI:9434; Telmisartan
DMKE187	TC	Antiviral Agents
DMKE187	DT	Small molecular drug
DMKE187	PC	65999
DMKE187	MW	514.6
DMKE187	FM	C33H30N4O2
DMKE187	IC	InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
DMKE187	CS	CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C
DMKE187	IK	RMMXLENWKUUMAY-UHFFFAOYSA-N
DMKE187	IU	2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
DMKE187	CA	CAS 144701-48-4
DMKE187	CB	CHEBI:9434
DMKE187	DE	Coronavirus Disease 2019 (COVID-19)

DMHQRYE	ID	DMHQRYE
DMHQRYE	DN	Tenidap
DMHQRYE	HS	Phase 3
DMHQRYE	DT	Small molecular drug
DMHQRYE	PC	60712
DMHQRYE	MW	320.8
DMHQRYE	FM	C14H9ClN2O3S
DMHQRYE	IC	InChI=1S/C14H9ClN2O3S/c15-7-3-4-9-8(6-7)11(13(19)17(9)14(16)20)12(18)10-2-1-5-21-10/h1-6,19H,(H2,16,20)
DMHQRYE	CS	C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O
DMHQRYE	IK	IZSFDUMVCVVWKW-UHFFFAOYSA-N
DMHQRYE	IU	5-chloro-2-hydroxy-3-(thiophene-2-carbonyl)indole-1-carboxamide
DMHQRYE	CA	CAS 120210-48-2
DMHQRYE	CB	CHEBI:35847
DMHQRYE	DE	Rheumatoid arthritis

DMHOV7D	ID	DMHOV7D
DMHOV7D	DN	Tenofovir alafenamide
DMHOV7D	HS	Phase 3
DMHOV7D	SN	(S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE; Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy
DMHOV7D	TC	Antiviral Agent
DMHOV7D	DT	Small molecular drug
DMHOV7D	PC	9574768
DMHOV7D	MW	476.474
DMHOV7D	FM	C21H29N6O5P
DMHOV7D	IC	InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
DMHOV7D	CS	CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C1N=CN=C2N)OC3=CC=CC=C3
DMHOV7D	IK	LDEKQSIMHVQZJK-CAQYMETFSA-N
DMHOV7D	IU	propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMHOV7D	CA	CAS 379270-37-8
DMHOV7D	CB	CHEBI:90926
DMHOV7D	DE	Chronic hepatitis B infection; Human immunodeficiency virus infection

DMZ3P6C	ID	DMZ3P6C
DMZ3P6C	DN	Teplizumab
DMZ3P6C	HS	Phase 3
DMZ3P6C	CP	MacroGenics
DMZ3P6C	DT	Antibody
DMZ3P6C	DE	Type-1 diabetes; Melanoma

DM4MZXE	ID	DM4MZXE
DM4MZXE	DN	Terodiline
DM4MZXE	HS	Phase 3
DM4MZXE	SN	Bicor; Microl; Mictrol; Micturin; Micturol; Terolin; Terodiline hydrochloride; TD-758
DM4MZXE	CP	Pharmacia & Upjohn AB
DM4MZXE	DT	Small molecular drug
DM4MZXE	PC	23480
DM4MZXE	MW	281.4
DM4MZXE	FM	C20H27N
DM4MZXE	IC	InChI=1S/C20H27N/c1-16(21-20(2,3)4)15-19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,16,19,21H,15H2,1-4H3
DM4MZXE	CS	CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C
DM4MZXE	IK	UISARWKNNNHPGI-UHFFFAOYSA-N
DM4MZXE	IU	N-tert-butyl-4,4-diphenylbutan-2-amine
DM4MZXE	CA	CAS 15793-40-5
DM4MZXE	CB	CHEBI:135168
DM4MZXE	DE	Urinary incontinence

DMGRBN5	ID	DMGRBN5
DMGRBN5	DN	TESAGLITAZAR
DMGRBN5	HS	Phase 3
DMGRBN5	SN	Tesaglitazar; 251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
DMGRBN5	DT	Small molecular drug
DMGRBN5	PC	208901
DMGRBN5	MW	408.5
DMGRBN5	FM	C20H24O7S
DMGRBN5	IC	InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1
DMGRBN5	CS	CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O
DMGRBN5	IK	CXGTZJYQWSUFET-IBGZPJMESA-N
DMGRBN5	IU	(2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
DMGRBN5	CA	CAS 251565-85-2
DMGRBN5	DE	Type-1 diabetes

DMMTKC6	ID	DMMTKC6
DMMTKC6	DN	TEV-48125
DMMTKC6	HS	Phase 3
DMMTKC6	DT	Antibody
DMMTKC6	DE	Migraine

DM9R5J6	ID	DM9R5J6
DM9R5J6	DN	Tezepelumab
DM9R5J6	HS	Phase 3
DM9R5J6	CP	Amgen; AstraZeneca
DM9R5J6	DT	Antibody
DM9R5J6	DE	Severe asthma

DMLCXPD	ID	DMLCXPD
DMLCXPD	DN	TG-C
DMLCXPD	HS	Phase 3
DMLCXPD	SN	3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC
DMLCXPD	DT	Small molecular drug
DMLCXPD	PC	24768536
DMLCXPD	MW	899.7
DMLCXPD	FM	C25H40N7O19P3S2
DMLCXPD	IC	InChI=1S/C25H40N7O19P3S2/c1-25(2,20(38)23(39)28-4-3-14(33)27-5-6-56-16(36)9-55-8-15(34)35)10-48-54(45,46)51-53(43,44)47-7-13-19(50-52(40,41)42)18(37)24(49-13)32-12-31-17-21(26)29-11-30-22(17)32/h11-13,18-20,24,37-38H,3-10H2,1-2H3,(H,27,33)(H,28,39)(H,34,35)(H,43,44)(H,45,46)(H2,26,29,30)(H2,40,41,42)/t13-,18-,19-,20+,24-/m1/s1
DMLCXPD	CS	CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSC(=O)CSCC(=O)O)O
DMLCXPD	IK	GKSSRSUPHZUOQO-ITIYDSSPSA-N
DMLCXPD	IU	2-[2-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-2-oxoethyl]sulfanylacetic acid
DMLCXPD	DE	Arthritis

DMPGH7N	ID	DMPGH7N
DMPGH7N	DN	ThermoProfen
DMPGH7N	HS	Phase 3
DMPGH7N	CP	ZARS Pharma
DMPGH7N	DE	Pain

DM3PA8H	ID	DM3PA8H
DM3PA8H	DN	THVD-201
DM3PA8H	HS	Phase 3
DM3PA8H	SN	Tolterodine + pilocarpine (overactive bladder/urinary incontinence), TheraVida
DM3PA8H	CP	TheraVida Inc
DM3PA8H	DE	Overactive bladder

DM3DG5C	ID	DM3DG5C
DM3DG5C	DN	THX-TS01
DM3DG5C	HS	Phase 3
DM3DG5C	CP	Therapix Biosciences Givatayim, Israel
DM3DG5C	DE	Tourette syndrome

DMMO6P0	ID	DMMO6P0
DMMO6P0	DN	Tifacogin
DMMO6P0	HS	Phase 3
DMMO6P0	SN	LACI; SC-59735; TFP-561; LACI, Pharmacia/Chiron; LACI, Searle/Chiron; Lipoprotein associated coagulation inhibitor, Pharmacia/Chiron;Lipoprotein associated coagulation inhibitor, Searle/Chiron; RTFPI, Pharmacia/Chiron; RTFPI, Searle/Chiron; Tissue factor pathway inhibitor, Pharmacia/Chiron; Tissue factor pathway inhibitor, Searle/Chiron
DMMO6P0	CP	GD Searle & Co; Chiron
DMMO6P0	DT	Small molecular drug
DMMO6P0	PC	961320
DMMO6P0	MW	203.31
DMMO6P0	FM	C12H13NS
DMMO6P0	IC	InChI=1S/C12H13NS/c1-2-5-11(6-3-1)9-13-10-12-7-4-8-14-12/h1-8,13H,9-10H2
DMMO6P0	CS	C1=CC=C(C=C1)CNCC2=CC=CS2
DMMO6P0	IK	GEWKIDGKZRKUFB-UHFFFAOYSA-N
DMMO6P0	IU	1-phenyl-N-(thiophen-2-ylmethyl)methanamine
DMMO6P0	CA	CAS 73325-61-8
DMMO6P0	DE	Sepsis

DMZBGI8	ID	DMZBGI8
DMZBGI8	DN	Tilarginine acetate
DMZBGI8	HS	Phase 3
DMZBGI8	SN	53308-83-1; L-NMMA acetate; UNII-2FL3530AF2; 2FL3530AF2; DSSTox_RID_81122; DSSTox_CID_25780; DSSTox_GSID_45780; SMR000449329; CAS-53308-83-1; N-omega-Monomethyl-L-arginine monoacetate, 99%
DMZBGI8	CP	ArgiNOx
DMZBGI8	DT	Small molecular drug
DMZBGI8	PC	135242
DMZBGI8	MW	248.28
DMZBGI8	FM	C9H20N4O4
DMZBGI8	IC	InChI=1S/C7H16N4O2.C2H4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13;1-2(3)4/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11);1H3,(H,3,4)/t5-;/m0./s1
DMZBGI8	CS	CC(=O)O.CN=C(N)NCCC[C@@H](C(=O)O)N
DMZBGI8	IK	IKPNWIGTWUZCKM-JEDNCBNOSA-N
DMZBGI8	IU	acetic acid;(2S)-2-amino-5-[(N'-methylcarbamimidoyl)amino]pentanoic acid
DMZBGI8	CA	CAS 53308-83-1
DMZBGI8	DE	Angina pectoris; Myocardial infarction

DMGYK2N	ID	DMGYK2N
DMGYK2N	DN	Tilsotolimod
DMGYK2N	HS	Phase 3
DMGYK2N	SN	IMO-2125
DMGYK2N	CP	Idera Pharmaceuticals
DMGYK2N	DT	Oligonucleotide
DMGYK2N	DE	Melanoma

DMBFE4K	ID	DMBFE4K
DMBFE4K	DN	Tirapazamine
DMBFE4K	HS	Phase 3
DMBFE4K	SN	TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075
DMBFE4K	CP	Sri international
DMBFE4K	DT	Small molecular drug
DMBFE4K	PC	135413511
DMBFE4K	MW	178.15
DMBFE4K	FM	C7H6N4O2
DMBFE4K	IC	InChI=1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9)
DMBFE4K	CS	C1=CC=C2C(=C1)[N+](=C(N=[N+]2[O-])N)[O-]
DMBFE4K	IK	ORYDPOVDJJZGHQ-UHFFFAOYSA-N
DMBFE4K	IU	1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine
DMBFE4K	CA	CAS 27314-97-2
DMBFE4K	CB	CHEBI:78887
DMBFE4K	DE	Alzheimer disease; Hepatocellular carcinoma

DMQNMAT	ID	DMQNMAT
DMQNMAT	DN	Tirzepatide
DMQNMAT	HS	Phase 3
DMQNMAT	CP	Eli Lilly
DMQNMAT	DE	Type 2 diabetes

DM95IPS	ID	DM95IPS
DM95IPS	DN	Tivanisiran
DM95IPS	HS	Phase 3
DM95IPS	CP	Sylentis
DM95IPS	DT	Small interfering RNA
DM95IPS	DE	Dry eye disease

DMNVP8Q	ID	DMNVP8Q
DMNVP8Q	DN	Tivantinib
DMNVP8Q	HS	Phase 3
DMNVP8Q	SN	Tivantinib; 905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; Tivantinib; ARQ197; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102
DMNVP8Q	CP	ArQule; Daiichi Sankyo
DMNVP8Q	DT	Small molecular drug
DMNVP8Q	PC	11494412
DMNVP8Q	MW	369.4
DMNVP8Q	FM	C23H19N3O2
DMNVP8Q	IC	InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1
DMNVP8Q	CS	C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65
DMNVP8Q	IK	UCEQXRCJXIVODC-PMACEKPBSA-N
DMNVP8Q	IU	(3R,4R)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
DMNVP8Q	CA	CAS 905854-02-6
DMNVP8Q	CB	CHEBI:91398
DMNVP8Q	DE	Solid tumour/cancer; Hepatocellular carcinoma

DMYLT67	ID	DMYLT67
DMYLT67	DN	TKI258
DMYLT67	HS	Phase 3
DMYLT67	SN	Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
DMYLT67	CP	Novartis & Chiron Corp
DMYLT67	TC	Anticancer Agents
DMYLT67	DT	Small molecular drug
DMYLT67	PC	135611162
DMYLT67	MW	500.5
DMYLT67	FM	C24H29FN6O5
DMYLT67	IC	InChI=1S/C21H21FN6O.C3H6O3.H2O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29;1-2(4)3(5)6;/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29);2,4H,1H3,(H,5,6);1H2
DMYLT67	CS	CC(C(=O)O)O.CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N.O
DMYLT67	IK	QDPVYZNVVQQULH-UHFFFAOYSA-N
DMYLT67	IU	4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one;2-hydroxypropanoic acid;hydrate
DMYLT67	CA	CAS 915769-50-5
DMYLT67	DE	Endometrial cancer; Renal cell carcinoma; Triple negative breast cancer

DMO1234	ID	DMO1234
DMO1234	DN	TNX-102
DMO1234	HS	Phase 3
DMO1234	SN	Cyclobenzaprine very low dose
DMO1234	CP	TONIX Pharmaceuticals
DMO1234	DT	Small molecular drug
DMO1234	PC	22576
DMO1234	MW	311.8
DMO1234	FM	C20H22ClN
DMO1234	IC	InChI=1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H
DMO1234	CS	CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31.Cl
DMO1234	IK	VXEAYBOGHINOKW-UHFFFAOYSA-N
DMO1234	IU	N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine;hydrochloride
DMO1234	CA	CAS 6202-23-9
DMO1234	CB	CHEBI:3997
DMO1234	DE	Fibromyalgia; Post-traumatic stress disorder

DMYA41S	ID	DMYA41S
DMYA41S	DN	TNX-355
DMYA41S	HS	Phase 3
DMYA41S	CP	Tanox; Biogen
DMYA41S	DE	Human immunodeficiency virus infection

DMFDNT0	ID	DMFDNT0
DMFDNT0	DN	Tocilizumab
DMFDNT0	HS	Phase 3
DMFDNT0	SN	Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody
DMFDNT0	CP	Roche; Genentech
DMFDNT0	TC	Antiviral Agents
DMFDNT0	DT	Monoclonal antibody
DMFDNT0	DE	Juvenile idiopathic arthritis; Rheumatoid arthritis; Systemic sclerosis; Coronavirus Disease 2019 (COVID-19)

DMATC14	ID	DMATC14
DMATC14	DN	Tozadenant
DMATC14	HS	Phase 3
DMATC14	SN	Ro-2; SYN-115; A2a receptor antagonists (Parkinson's disease), Synosia/Roche; Adenosine A2a receptor antagonists (Parkinson's disease), Synosia/Roche
DMATC14	CP	Biotie therapies
DMATC14	DT	Small molecular drug
DMATC14	PC	11618368
DMATC14	MW	406.5
DMATC14	FM	C19H26N4O4S
DMATC14	IC	InChI=1S/C19H26N4O4S/c1-19(25)5-7-23(8-6-19)18(24)21-17-20-15-14(26-2)4-3-13(16(15)28-17)22-9-11-27-12-10-22/h3-4,25H,5-12H2,1-2H3,(H,20,21,24)
DMATC14	CS	CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O
DMATC14	IK	XNBRWUQWSKXMPW-UHFFFAOYSA-N
DMATC14	IU	4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide
DMATC14	CA	CAS 870070-55-6
DMATC14	DE	Parkinson disease

DMLKI2B	ID	DMLKI2B
DMLKI2B	DN	Trafermin
DMLKI2B	HS	Phase 3
DMLKI2B	SN	Fiblast; Fiblast (TN); Trafermin (genetical recombination); Trafermin (USAN/INN); Trafermin (genetical recombination) (JAN)
DMLKI2B	CP	Johnson & Johnson Licensee; Kaken Pharmaceutical
DMLKI2B	DE	Periodontitis

DM6ENSJ	ID	DM6ENSJ
DM6ENSJ	DN	Tralokinumab
DM6ENSJ	HS	Phase 3
DM6ENSJ	SN	CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca
DM6ENSJ	CP	Ception Therapeutics
DM6ENSJ	DT	Monoclonal antibody
DM6ENSJ	DE	Asthma; Ulcerative colitis; Atopic dermatitis

DM7BSRH	ID	DM7BSRH
DM7BSRH	DN	Tramiprosate
DM7BSRH	HS	Phase 3
DM7BSRH	SN	Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS
DM7BSRH	CP	Neurochem
DM7BSRH	DT	Small molecular drug
DM7BSRH	PC	1646
DM7BSRH	MW	139.18
DM7BSRH	FM	C3H9NO3S
DM7BSRH	IC	InChI=1S/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7)
DM7BSRH	CS	C(CN)CS(=O)(=O)O
DM7BSRH	IK	SNKZJIOFVMKAOJ-UHFFFAOYSA-N
DM7BSRH	IU	3-aminopropane-1-sulfonic acid
DM7BSRH	CA	CAS 3687-18-1
DM7BSRH	CB	CHEBI:1457
DM7BSRH	DE	Alzheimer disease

DMLB3I4	ID	DMLB3I4
DMLB3I4	DN	Trastuzumab-DM1
DMLB3I4	HS	Phase 3
DMLB3I4	CP	Genentech
DMLB3I4	DT	Antibody drug conjugate
DMLB3I4	DE	Breast cancer

DM1874J	ID	DM1874J
DM1874J	DN	TRC105
DM1874J	HS	Phase 3
DM1874J	DT	Monoclonal antibody
DM1874J	DE	Breast cancer; Lung cancer; Ovarian cancer; Macular degeneration; Peritoneal cancer; Fallopian tube cancer; Soft tissue sarcoma; Gestational trophoblastic neoplasia; Hemangiosarcoma; Hepatocellular carcinoma; Renal cell carcinoma; Recurrent glioblastoma; Angiosarcoma

DMOG2X1	ID	DMOG2X1
DMOG2X1	DN	Trebananib
DMOG2X1	HS	Phase 3
DMOG2X1	CP	Amgen
DMOG2X1	DT	Recombinant protein
DMOG2X1	DE	Solid tumour/cancer; Renal cell carcinoma; Ovarian cancer

DMOQ9H1	ID	DMOQ9H1
DMOQ9H1	DN	Tremelimumab
DMOQ9H1	HS	Phase 3
DMOQ9H1	CP	AstraZeneca
DMOQ9H1	DT	Monoclonal antibody
DMOQ9H1	DE	Solid tumour/cancer; Malignant mesothelioma

DMS57DJ	ID	DMS57DJ
DMS57DJ	DN	Trimegestone/ethinyl estradiol
DMS57DJ	HS	Phase 3
DMS57DJ	CP	Wyeth
DMS57DJ	DE	Contraception

DMCMDVR	ID	DMCMDVR
DMCMDVR	DN	Triptolide
DMCMDVR	HS	Phase 3
DMCMDVR	SN	triptolide; 38748-32-2; Triptolid; PG490; UNII-19ALD1S53J; NSC 163062; CHEMBL463763; CHEBI:9747; 19ALD1S53J; C20H24O6; PG-490; CPD000466307; Triptolide, Tripterygium wilfordii; (-)-Triptolide; PG 490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; SMR000466307; NSC163062; Triptolide, 1; Triptolide(PG490)/; AC1Q6AXN; BSPBio_001595; KBioGR_000315; KBioSS_000315
DMCMDVR	DT	Small molecular drug
DMCMDVR	PC	107985
DMCMDVR	MW	360.4
DMCMDVR	FM	C20H24O6
DMCMDVR	IC	InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1
DMCMDVR	CS	CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2O)O7)COC6=O)C
DMCMDVR	IK	DFBIRQPKNDILPW-CIVMWXNOSA-N
DMCMDVR	IU	(1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one
DMCMDVR	CA	CAS 38748-32-2
DMCMDVR	CB	CHEBI:9747
DMCMDVR	DE	Autoimmune diabetes

DMHDNK0	ID	DMHDNK0
DMHDNK0	DN	TroVax
DMHDNK0	HS	Phase 3
DMHDNK0	SN	TroVax (TN)
DMHDNK0	CP	Oxford BioMedica
DMHDNK0	DT	Vaccine
DMHDNK0	DE	Prostate cancer

DM0QNF4	ID	DM0QNF4
DM0QNF4	DN	TRx0237
DM0QNF4	HS	Phase 3
DM0QNF4	SN	951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide
DM0QNF4	CP	TauRx Therapeutics
DM0QNF4	DT	Small molecular drug
DM0QNF4	PC	23651551
DM0QNF4	MW	447.2
DM0QNF4	FM	C16H21Br2N3S
DM0QNF4	IC	InChI=1S/C16H19N3S.2BrH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;/h5-10,17H,1-4H3;2*1H
DM0QNF4	CS	CN(C)C1=CC2=C(C=C1)NC3=C(S2)C=C(C=C3)N(C)C.Br.Br
DM0QNF4	IK	JAUPSVVTGFBHTN-UHFFFAOYSA-N
DM0QNF4	IU	3-N,3-N,7-N,7-N-tetramethyl-10H-phenothiazine-3,7-diamine;dihydrobromide
DM0QNF4	CA	CAS 951131-15-0
DM0QNF4	DE	Alzheimer disease

DMAFPHB	ID	DMAFPHB
DMAFPHB	DN	TRYPTAMINE
DMAFPHB	HS	Phase 3
DMAFPHB	SN	tryptamine; 61-54-1; 2-(1H-Indol-3-yl)ethanamine; 3-(2-aminoethyl)indole; 1H-Indole-3-ethanamine; 2-(3-Indolyl)ethylamine; Indol-3-ethylamine; Indole, 3-(2-aminoethyl)-; 2-(Indol-3-yl)ethylamine; 2-(1H-Indol-3-Yl)Ethan-1-Amine; 3-Indoleethylamine; Tryptamin; 2-(1H-indol-3-yl)ethylamine; 2-Indol-3-ylethylamine; 2-(1H-INDOL-3-YL)-ETHYLAMINE; UNII-422ZU9N5TV; (Amino-2 ethyl)-3 indole; (Amino-2 ethyl)-3 indole [French]; Tryptamine, 98%; BRN 0125513; EINECS 200-510-5; CHEMBL6640; 422ZU9N5TV; CHEBI:16765; APJYDQYYACXCRM-UHFFFAOYSA-N
DMAFPHB	DT	Small molecular drug
DMAFPHB	PC	1150
DMAFPHB	MW	160.22
DMAFPHB	FM	C10H12N2
DMAFPHB	IC	InChI=1S/C10H12N2/c11-6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6,11H2
DMAFPHB	CS	C1=CC=C2C(=C1)C(=CN2)CCN
DMAFPHB	IK	APJYDQYYACXCRM-UHFFFAOYSA-N
DMAFPHB	IU	2-(1H-indol-3-yl)ethanamine
DMAFPHB	CA	CAS 61-54-1
DMAFPHB	CB	CHEBI:16765

DMPBJ8W	ID	DMPBJ8W
DMPBJ8W	DN	Turoctocog alfa
DMPBJ8W	HS	Phase 3
DMPBJ8W	SN	NN7008
DMPBJ8W	CP	Novo Nordisk
DMPBJ8W	DE	Haemophilia A

DM71ZL6	ID	DM71ZL6
DM71ZL6	DN	TZTX-001
DM71ZL6	HS	Phase 3
DM71ZL6	SN	Teverelix LA; TX 12-001-HR
DM71ZL6	CP	Ardana Bioscience
DM71ZL6	DE	Endometriosis

DMN72OM	ID	DMN72OM
DMN72OM	DN	U300
DMN72OM	HS	Phase 3
DMN72OM	SN	Methyl 3,5-dinitrobenzoate; 2702-58-1; Benzoic acid, 3,5-dinitro-, methyl ester; POGCCFLNFPIIGW-UHFFFAOYSA-N; 3,5-dinitro-benzoic acid methyl ester; Methyl 3,5-Dinitrobenzoate,99%; Methyl-3,5-dinitrobenzoate; U300; ACMC-1CR6Q; AC1L5B8W; AC1Q5AI0; KSC494Q3H; SCHEMBL418416; Jsp005266; CHEMBL2252127; CTK3J4833; KS-00000ZZJ; NSC7317; MolPort-001-012-121; Methyl 3,5-dinitrobenzoate, 99%; ALBB-024845; NSC-7317; ZINC1683476; METHYL-3,5-DINITRO BENZOATE; BBL000013; ANW-44565; SBB068882; MFCD00017016; STK386186; 3,5-Dinitrobenzoic acid methyl e
DMN72OM	CP	Sanofi us
DMN72OM	DT	Small molecular drug
DMN72OM	PC	222067
DMN72OM	MW	226.14
DMN72OM	FM	C8H6N2O6
DMN72OM	IC	InChI=1S/C8H6N2O6/c1-16-8(11)5-2-6(9(12)13)4-7(3-5)10(14)15/h2-4H,1H3
DMN72OM	CS	COC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-]
DMN72OM	IK	POGCCFLNFPIIGW-UHFFFAOYSA-N
DMN72OM	IU	methyl 3,5-dinitrobenzoate
DMN72OM	CA	CAS 2702-58-1
DMN72OM	DE	Type-2 diabetes

DMHTY9W	ID	DMHTY9W
DMHTY9W	DN	Ublituximab
DMHTY9W	HS	Phase 3
DMHTY9W	SN	TG-1101
DMHTY9W	CP	TG Therapeutics
DMHTY9W	DT	Antibody
DMHTY9W	DE	Chronic lymphocytic leukaemia; Lymphoma; Multiple sclerosis; Nodal marginal zone lymphoma

DMKUOVP	ID	DMKUOVP
DMKUOVP	DN	Ublituximab + umbralisib
DMKUOVP	HS	Phase 3
DMKUOVP	CP	TG Therapeutics New York, NY
DMKUOVP	DE	Chronic lymphocytic leukaemia; Non-hodgkin lymphoma

DM90AG2	ID	DM90AG2
DM90AG2	DN	Ularitide
DM90AG2	HS	Phase 3
DM90AG2	SN	Urodilatin; 115966-23-9; Atriopeptin (95-126); Human urodilatin; Urodilatin human; Ularitide [INN]; Urodilatin ularitide; Anf (95-126); Anp (95-126); ANP 95-126; Atrial natriuretic peptide (95-126); CHEMBL2103920; Urodilatin human, &gt; AKOS030213250; DB05034; CDD 95-126; LS-187531; LS-186876; Thr-Ala-Pro-Arg-Atrial Natriuretic Peptide; atrial natriuretic factor prohormone (95-126)
DM90AG2	CP	EKR Therapeutics
DM90AG2	DT	Small molecular drug
DM90AG2	PC	16132416
DM90AG2	MW	3505.9
DM90AG2	FM	C145H234N52O44S3
DM90AG2	IC	InChI=1S/C145H234N52O44S3/c1-11-72(6)112-137(238)171-60-106(208)172-73(7)113(214)177-86(40-41-103(146)205)122(223)190-95(63-198)116(217)170-61-108(210)175-88(51-70(2)3)114(215)169-62-109(211)176-100(133(234)187-92(56-104(147)206)127(228)193-97(65-200)130(231)186-91(54-77-27-16-13-17-28-77)126(227)180-82(31-20-45-163-142(153)154)119(220)189-94(139(240)241)55-78-36-38-79(204)39-37-78)68-243-244-69-101(134(235)185-90(53-76-25-14-12-15-26-76)115(216)168-58-105(207)167-59-107(209)174-80(29-18-43-161-140(149)150)117(218)182-87(42-50-242-10)123(224)188-93(57-110(212)213)128(229)181-85(124(225)196-112)34-23-48-166-145(159)160)195-132(233)99(67-202)194-131(232)98(66-201)192-120(221)83(32-21-46-164-143(155)156)178-118(219)81(30-19-44-162-141(151)152)179-125(226)89(52-71(4)5)184-129(230)96(64-199)191-121(222)84(33-22-47-165-144(157)158)183-135(236)102-35-24-49-197(102)138(239)74(8)173-136(237)111(148)75(9)203/h12-17,25-28,36-39,70-75,80-102,111-112,198-204H,11,18-24,29-35,40-69,148H2,1-10H3,(H2,146,205)(H2,147,206)(H,167,207)(H,168,216)(H,169,215)(H,170,217)(H,171,238)(H,172,208)(H,173,237)(H,174,209)(H,175,210)(H,176,211)(H,177,214)(H,178,219)(H,179,226)(H,180,227)(H,181,229)(H,182,218)(H,183,236)(H,184,230)(H,185,235)(H,186,231)(H,187,234)(H,188,224)(H,189,220)(H,190,223)(H,191,222)(H,192,221)(H,193,228)(H,194,232)(H,195,233)(H,196,225)(H,212,213)(H,240,241)(H4,149,150,161)(H4,151,152,162)(H4,153,154,163)(H4,155,156,164)(H4,157,158,165)(H4,159,160,166)/t72-,73-,74-,75+,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,111-,112-/m0/s1
DM90AG2	CS	CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C
DM90AG2	IK	IUCCYQIEZNQWRS-DWWHXVEHSA-N
DM90AG2	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,40-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM90AG2	CA	CAS 118812-69-4
DM90AG2	DE	Heart failure; Acute heart failure

DMIQCFG	ID	DMIQCFG
DMIQCFG	DN	Ulinastatin
DMIQCFG	HS	Phase 3
DMIQCFG	SN	Urinastatin; Urinary trypsin inhibitor; Trypsin inhibitor MR-20; MR-20 (Magnetic powder); Uti(68); Acid-stable protease inhibitor; Urinary trypsin inhibitor (68); 2,4-Dioxaspiro[5.5]undec-8-ene, 3-(2-furanyl)-; 80449-31-6; Urinary trypsin inhibitor-like inhibitor (43); Trypsin inhibitor (human urine urinastatin protein moiety); 80449-32-7; 2,4-Dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)-; Miraclid; AC1L2Y1N; UTI68; 3-(2-Furanyl)-2,4-dioxaspiro(5.5)undec-8-ene; AC1Q70L4; AKOS025401879; CS-7119; MR 20 (magnetic p
DMIQCFG	DT	Small molecular drug
DMIQCFG	PC	105102
DMIQCFG	MW	220.26
DMIQCFG	FM	C13H16O3
DMIQCFG	IC	InChI=1S/C13H16O3/c1-2-6-13(7-3-1)9-15-12(16-10-13)11-5-4-8-14-11/h1-2,4-5,8,12H,3,6-7,9-10H2
DMIQCFG	CS	C1CC2(CC=C1)COC(OC2)C3=CC=CO3
DMIQCFG	IK	ODVKSTFPQDVPJZ-UHFFFAOYSA-N
DMIQCFG	IU	3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-9-ene
DMIQCFG	CA	CAS 80449-32-7
DMIQCFG	DE	Premature labour

DM6PMNR	ID	DM6PMNR
DM6PMNR	DN	Ulocuplumab
DM6PMNR	HS	Phase 3
DM6PMNR	CP	Bristol-myers squibb
DM6PMNR	DT	Monoclonal antibody
DM6PMNR	DE	Haematological malignancy; Multiple myeloma

DMCWM03	ID	DMCWM03
DMCWM03	DN	Unfractionated heparin
DMCWM03	HS	Phase 3
DMCWM03	SN	Elaprin; UFH (solid oral), Emisphere; Unfractionated heparin (solid oral, eligen); SNAC/heparin capsule (solid oral), Emisphere; SNAD/heparin tablet (solid oral), Emisphere; Unfractionated heparin (solid oral, eligen), Emisphere
DMCWM03	CP	Emisphere Technologies Inc
DMCWM03	DE	Thrombosis

DM0DIEZ	ID	DM0DIEZ
DM0DIEZ	DN	UNI-rhIL-11
DM0DIEZ	HS	Phase 3
DM0DIEZ	SN	Recombinant human interleukin 11 (thrombocytopenia), Uni-Bio Science Group; RhIL-11 (thrombocytopenia), Uni-Bio Science Group
DM0DIEZ	CP	Uni-Bio Science Group Limited
DM0DIEZ	DE	Thrombocytopenia

DMM2OZH	ID	DMM2OZH
DMM2OZH	DN	Ushercell
DMM2OZH	HS	Phase 3
DMM2OZH	SN	Cellulose sulfate gel, Polydex
DMM2OZH	CP	Polydex Pharmaceuticals Ltd
DMM2OZH	DT	Small molecular drug
DMM2OZH	PC	154413
DMM2OZH	MW	457.6
DMM2OZH	FM	C30H35NO3
DMM2OZH	IC	InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m0/s1
DMM2OZH	CS	CC1([C@@H]([C@H](C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C
DMM2OZH	IK	XZEUAXYWNKYKPL-URLMMPGGSA-N
DMM2OZH	IU	1-[2-[4-[(3S,4S)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine
DMM2OZH	CA	CAS 31477-60-8
DMM2OZH	DE	Bacterial infection

DMD2O0L	ID	DMD2O0L
DMD2O0L	DN	UX-001
DMD2O0L	HS	Phase 3
DMD2O0L	CP	Ultragenyx Pharmaceutical
DMD2O0L	DT	Small molecular drug
DMD2O0L	PC	656387
DMD2O0L	MW	309.27
DMD2O0L	FM	C11H19NO9
DMD2O0L	IC	InChI=1S/C11H19NO9/c1-4(14)12-7-5(15)2-11(20,10(18)19)21-9(7)8(17)6(16)3-13/h5-9,13,15-17,20H,2-3H2,1H3,(H,12,14)(H,18,19)/t5-,6-,7+,8-,9+,11+/m0/s1
DMD2O0L	CS	CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@H]([C@H](CO)O)O)(C(=O)O)O)O
DMD2O0L	IK	SQVRNKJHWKZAKO-USOVHJGOSA-N
DMD2O0L	IU	(2R,4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(1S,2S)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMD2O0L	DE	Myopathy; Hereditary inclusion body myositis

DMDCFXJ	ID	DMDCFXJ
DMDCFXJ	DN	Vaborbactam
DMDCFXJ	HS	Phase 3
DMDCFXJ	SN	RPX-7009; 1360457-46-0; RPX7009; UNII-1C75676F8V; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; CHEMBL3317857; 1C75676F8V; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; Vaborbactam [INN]; RPX 7009; Vaborbactam. RPX7009; Vaborbactam (USAN/INN); Vaborbactam [USAN:INN]; SCHEMBL620289; GTPL10871; Vabomere (vaborbactam + meropenem); EX-A2589; BDBM50089084; MFCD28502176; AKOS032961376; CS-6445; DB12107; SB17184; 1,2-Oxaborinane-6-acetic acid, 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-, (3R,6S)-; compound 9f [PMID: 25782055]; NCGC00510003-01; HY-19930; 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-; D10998; Q27252228; {(3R,6S)-2-hydroxy-3-[(thiophen-2-ylacetyl)amino]-1,2-oxaborinan-6-yl}acetic acid; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; 1,2-Oxaborinane-6-acetic acid
DMDCFXJ	DT	Small molecular drug
DMDCFXJ	PC	56649692
DMDCFXJ	MW	297.14
DMDCFXJ	FM	C12H16BNO5S
DMDCFXJ	IC	InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1
DMDCFXJ	CS	B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O
DMDCFXJ	IK	IOOWNWLVCOUUEX-WPRPVWTQSA-N
DMDCFXJ	IU	2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid
DMDCFXJ	CA	CAS 1360457-46-0
DMDCFXJ	DE	Urinary tract infection

DM9LH10	ID	DM9LH10
DM9LH10	DN	Vadastuximab talirine
DM9LH10	HS	Phase 3
DM9LH10	SN	vadastuximab talirine; Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5
DM9LH10	CP	Seattle Genetics Bothell, WA
DM9LH10	PC	122706909
DM9LH10	MW	1210.4
DM9LH10	FM	C63H71N9O14S
DM9LH10	IC	InChI=1S/C63H71N9O14S/c1-35(2)57(69-55(73)11-8-7-9-20-70-56(74)29-54(62(70)79)87-34-47(64)63(80)81)59(76)67-36(3)58(75)68-41-16-12-37(13-17-41)39-23-42-30-65-48-27-52(50(83-5)25-45(48)60(77)71(42)32-39)85-21-10-22-86-53-28-49-46(26-51(53)84-6)61(78)72-33-40(24-43(72)31-66-49)38-14-18-44(82-4)19-15-38/h12-19,25-28,30-33,35-36,42-43,47,54,57H,7-11,20-24,29,34,64H2,1-6H3,(H,67,76)(H,68,75)(H,69,73)(H,80,81)/t36-,42-,43-,47-,54+,57-/m0/s1
DM9LH10	CS	C[C@@H](C(=O)NC1=CC=C(C=C1)C2=CN3[C@@H](C2)C=NC4=CC(=C(C=C4C3=O)OC)OCCCOC5=C(C=C6C(=C5)N=C[C@@H]7CC(=CN7C6=O)C8=CC=C(C=C8)OC)OC)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN9C(=O)C[C@H](C9=O)SC[C@@H](C(=O)O)N
DM9LH10	IK	BNJNAEJASPUJTO-DUOHOMBCSA-N
DM9LH10	IU	(2R)-3-[(3R)-1-[6-[[(2S)-1-[[(2S)-1-[4-[(6aS)-3-[3-[[(6aS)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-6-oxohexyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-2-aminopropanoic acid
DM9LH10	CA	CAS 1436390-64-5
DM9LH10	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DM9J5Q4	ID	DM9J5Q4
DM9J5Q4	DN	VAL-083
DM9J5Q4	HS	Phase 3
DM9J5Q4	SN	VAL-083; Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6
DM9J5Q4	CP	Del Mar Pharmaceuticals
DM9J5Q4	DT	Small molecular drug
DM9J5Q4	PC	15942827
DM9J5Q4	MW	146.14
DM9J5Q4	FM	C6H10O4
DM9J5Q4	IC	InChI=1S/C6H10O4/c7-5(3-1-9-3)6(8)4-2-10-4/h3-8H,1-2H2/t3-,4+,5+,6-
DM9J5Q4	CS	C1[C@@H](O1)[C@@H]([C@@H]([C@@H]2CO2)O)O
DM9J5Q4	IK	AAFJXZWCNVJTMK-GUCUJZIJSA-N
DM9J5Q4	IU	(1S,2R)-1-[(2S)-oxiran-2-yl]-2-[(2R)-oxiran-2-yl]ethane-1,2-diol
DM9J5Q4	CA	CAS 23261-20-3
DM9J5Q4	DE	Grade IV malignant glioma; Acute myeloid leukaemia; Recurrent glioblastoma; Recurring respiratory infection

DMMKE2H	ID	DMMKE2H
DMMKE2H	DN	Valoctocogene roxaparvovec
DMMKE2H	HS	Phase 3
DMMKE2H	SN	BMN 270
DMMKE2H	CP	BioMarin Pharmaceutical
DMMKE2H	DT	Gene therapy
DMMKE2H	DE	Haemophilia A

DMQL0KF	ID	DMQL0KF
DMQL0KF	DN	Vanadate
DMQL0KF	HS	Phase 3
DMQL0KF	SN	Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3
DMQL0KF	DT	Small molecular drug
DMQL0KF	PC	516859
DMQL0KF	MW	116.978
DMQL0KF	FM	H4NO3V
DMQL0KF	IC	InChI=1S/H3N.3O.V/h1H3;;;;/q;;;-1;/p+1
DMQL0KF	CS	[NH4+].[O-][V](=O)=O
DMQL0KF	IK	UNTBPXHCXVWYOI-UHFFFAOYSA-O
DMQL0KF	IU	azanium;oxido(dioxo)vanadium
DMQL0KF	CA	CAS 7803-55-6
DMQL0KF	DE	Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis

DMLIMEA	ID	DMLIMEA
DMLIMEA	DN	Varespladib methyl
DMLIMEA	HS	Phase 3
DMLIMEA	SN	A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera
DMLIMEA	CP	Shionogi & Co Ltd
DMLIMEA	DT	Small molecular drug
DMLIMEA	PC	9886917
DMLIMEA	MW	394.4
DMLIMEA	FM	C22H22N2O5
DMLIMEA	IC	InChI=1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27)
DMLIMEA	CS	CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)OC)C(=O)C(=O)N
DMLIMEA	IK	VJYDOJXJUCJUHL-UHFFFAOYSA-N
DMLIMEA	IU	methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate
DMLIMEA	CA	CAS 172733-08-3
DMLIMEA	DE	Rheumatoid arthritis

DMANKTO	ID	DMANKTO
DMANKTO	DN	Vatreptacog alfa (activated)
DMANKTO	HS	Phase 3
DMANKTO	SN	NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk
DMANKTO	CP	Novo Nordisk A/S
DMANKTO	DE	Bleeding disorder

DMX04CA	ID	DMX04CA
DMX04CA	DN	VB-111
DMX04CA	HS	Phase 3
DMX04CA	CP	VBL Therapeutics
DMX04CA	DE	Glioblastoma multiforme; Malignant glioma; Ovarian cancer; Recurrent glioblastoma

DMXHI89	ID	DMXHI89
DMXHI89	DN	Velac Gel
DMXHI89	HS	Phase 3
DMXHI89	SN	Clindamycin/tretinoin
DMXHI89	CP	Stiefel Laboratories
DMXHI89	DE	Acne vulgaris

DMJBU9V	ID	DMJBU9V
DMJBU9V	DN	Velimogene aliplasmid
DMJBU9V	HS	Phase 3
DMJBU9V	SN	Allovectin (TN)
DMJBU9V	CP	Vical
DMJBU9V	DE	Melanoma

DM6L5ZQ	ID	DM6L5ZQ
DM6L5ZQ	DN	Vercirnon
DM6L5ZQ	HS	Phase 3
DM6L5ZQ	SN	1605786
DM6L5ZQ	CP	GlaxoSmithKline
DM6L5ZQ	DT	Small molecular drug
DM6L5ZQ	PC	10343454
DM6L5ZQ	MW	444.9
DM6L5ZQ	FM	C22H21ClN2O4S
DM6L5ZQ	IC	InChI=1S/C22H21ClN2O4S/c1-22(2,3)16-4-7-18(8-5-16)30(28,29)24-20-9-6-17(23)14-19(20)21(26)15-10-12-25(27)13-11-15/h4-14,24H,1-3H3
DM6L5ZQ	CS	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(C=C2)Cl)C(=O)C3=CC=[N+](C=C3)[O-]
DM6L5ZQ	IK	JRWROCIMSDXGOZ-UHFFFAOYSA-N
DM6L5ZQ	IU	4-tert-butyl-N-[4-chloro-2-(1-oxidopyridin-1-ium-4-carbonyl)phenyl]benzenesulfonamide
DM6L5ZQ	CA	CAS 698394-73-9
DM6L5ZQ	DE	Crohn disease

DMOQ81Y	ID	DMOQ81Y
DMOQ81Y	DN	Vernakalant
DMOQ81Y	HS	Phase 3
DMOQ81Y	SN	Vernakalant; 794466-70-9; UNII-9G468C8B13; Vemakalant; RSD1235; 9G468C8B13; (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol; 3-Pyrrolidinol,1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-; RSD-1235; Vernakalant [INN:BAN]; SCHEMBL410062; CHEMBL2111112; DTXSID60229659; VBHQKCBVWWUUKN-KZNAEPCWSA-N; CHEBI:135956; EX-A2465; ZINC22010910; 4151AH; AKOS027326205; DB06217; SB16873; CS-0276; API0014187; RL05068; 3-Pyrrolidinol, 1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)-, (3R)-
DMOQ81Y	CP	Cardiome Pharma; Merck
DMOQ81Y	DT	Small molecular drug
DMOQ81Y	PC	9930049
DMOQ81Y	MW	349.5
DMOQ81Y	FM	C20H31NO4
DMOQ81Y	IC	InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1
DMOQ81Y	CS	COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC
DMOQ81Y	IK	VBHQKCBVWWUUKN-KZNAEPCWSA-N
DMOQ81Y	IU	(3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
DMOQ81Y	CA	CAS 794466-70-9
DMOQ81Y	CB	CHEBI:135956
DMOQ81Y	DE	Atrial fibrillation

DM4CGH5	ID	DM4CGH5
DM4CGH5	DN	verubecestat
DM4CGH5	HS	Phase 3
DM4CGH5	SN	example 25 (US8940748)
DM4CGH5	DT	Small molecular drug
DM4CGH5	PC	51352361
DM4CGH5	MW	409.4
DM4CGH5	FM	C17H17F2N5O3S
DM4CGH5	IC	InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1
DM4CGH5	CS	C[C@]1(CS(=O)(=O)N(C(=N1)N)C)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)F)F
DM4CGH5	IK	YHYKUSGACIYRML-KRWDZBQOSA-N
DM4CGH5	IU	N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide
DM4CGH5	CA	CAS 1286770-55-5
DM4CGH5	DE	Alzheimer disease

DMMQ2U9	ID	DMMQ2U9
DMMQ2U9	DN	VGX-3100
DMMQ2U9	HS	Phase 3
DMMQ2U9	CP	Inovio Pharmaceuticals
DMMQ2U9	DE	Human papillomavirus infection; Cervical Intraepithelial neoplasia; Vulvar squamous intraepithelial lesion; Dysplasia; Vulvar intraepithelial neoplasia

DMCWNZG	ID	DMCWNZG
DMCWNZG	DN	Vibegron
DMCWNZG	HS	Phase 3
DMCWNZG	SN	Beova; Beova (TN); VIBEGRON; Vibegron (JAN/USAN); Vibegron [USAN:INN]; compound 7 [PMID: 26709102]; vibegronum
DMCWNZG	DT	Small molecular drug
DMCWNZG	PC	44472635
DMCWNZG	MW	444.535
DMCWNZG	FM	C26H28N4O3
DMCWNZG	IC	InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
DMCWNZG	CS	C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O
DMCWNZG	IK	DJXRIQMCROIRCZ-XOEOCAAJSA-N
DMCWNZG	IU	(6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
DMCWNZG	CA	CAS 1190389-15-1
DMCWNZG	CB	ChEBI:142418
DMCWNZG	DE	Overactive bladder disorder

DMLO0KD	ID	DMLO0KD
DMLO0KD	DN	Vicineum
DMLO0KD	HS	Phase 3
DMLO0KD	SN	Oportuzumab monatox
DMLO0KD	CP	Sesen Bio
DMLO0KD	DT	Recombinant protein
DMLO0KD	DE	Bladder cancer

DMMTW9K	ID	DMMTW9K
DMMTW9K	DN	Vicriviroc
DMMTW9K	HS	Phase 3
DMMTW9K	SN	SchD; Sch 417690; PRO 140 & Vicrivirac; SCH-417690; SCH-D; SCH-D690; Sch-D compound; PRO 140 (Anti-CCR5 monoclonal antibody) & 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine; (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone; 1-((4,6-Dimethyl-5-pyrimidinyl)carbonyl)-4-(4-(2-methoxy-4-(trifluoromethyl)phenyl)ethyl-3-methyl-1-piperazinyl)-4-methylpiperidine; 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine
DMMTW9K	CP	Schering-Plough
DMMTW9K	DT	Small molecular drug
DMMTW9K	PC	3009355
DMMTW9K	MW	533.6
DMMTW9K	FM	C28H38F3N5O2
DMMTW9K	IC	InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1
DMMTW9K	CS	C[C@H]1CN(CCN1[C@@H](COC)C2=CC=C(C=C2)C(F)(F)F)C3(CCN(CC3)C(=O)C4=C(N=CN=C4C)C)C
DMMTW9K	IK	CNPVJJQCETWNEU-CYFREDJKSA-N
DMMTW9K	IU	(4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone
DMMTW9K	CA	CAS 306296-47-9
DMMTW9K	CB	CHEBI:94843
DMMTW9K	DE	Human immunodeficiency virus infection

DMJFNR9	ID	DMJFNR9
DMJFNR9	DN	Viramidine
DMJFNR9	HS	Phase 3
DMJFNR9	SN	Ribamidine; Prodrug of Ribavirin; Ribavirin amidine; Taribavirin hydrochloride; ICN 3142; AVS-000206; AVS-206;ICN-3142; Taribavirin hydrochloride (USAN); Viramidine (TN); 1-.Beta.-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine hydrochloride; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide hydrochloride; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine
DMJFNR9	CP	Valeant Pharmaceuticals International
DMJFNR9	DT	Small molecular drug
DMJFNR9	PC	451448
DMJFNR9	MW	243.22
DMJFNR9	FM	C8H13N5O4
DMJFNR9	IC	InChI=1S/C8H13N5O4/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)/t3-,4-,5-,8-/m1/s1
DMJFNR9	CS	C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=N)N
DMJFNR9	IK	NHKZSTHOYNWEEZ-AFCXAGJDSA-N
DMJFNR9	IU	1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide
DMJFNR9	CA	CAS 119567-79-2
DMJFNR9	CB	CHEBI:134989
DMJFNR9	DE	Hepatitis C virus infection

DMXYM1H	ID	DMXYM1H
DMXYM1H	DN	Visilizumab
DMXYM1H	HS	Phase 3
DMXYM1H	SN	Nuvion; Visiluzumab; HuM291; SMART anti-CD3 MAb, PDL; SMART anti-CD3 MAb, Protein Design Labs; Anti-CD3 MAb (humanized), PDL
DMXYM1H	CP	PDL BioPharma Inc; PDL BioPharma
DMXYM1H	DT	Antibody
DMXYM1H	DE	Graft-versus-host disease

DMQGV5P	ID	DMQGV5P
DMQGV5P	DN	VLB-01
DMQGV5P	HS	Phase 3
DMQGV5P	CP	Marco Polo Pharmaceuticals SA
DMQGV5P	DE	Epilepsy

DMSW80U	ID	DMSW80U
DMSW80U	DN	VM-202
DMSW80U	HS	Phase 3
DMSW80U	CP	ViroMed
DMSW80U	DE	Angina pectoris; Amyotrophic lateral sclerosis; Peripheral neuropathy; Diabetic foot ulcer; Peripheral arterial disease

DM4P5UJ	ID	DM4P5UJ
DM4P5UJ	DN	VM-501
DM4P5UJ	HS	Phase 3
DM4P5UJ	SN	IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed
DM4P5UJ	CP	ViroMed Co Ltd
DM4P5UJ	DE	Thrombocytopenia

DMOFH1M	ID	DMOFH1M
DMOFH1M	DN	Volasertib
DMOFH1M	HS	Phase 3
DMOFH1M	SN	Volasertib; 755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947
DMOFH1M	CP	Boehringer Ingelheim
DMOFH1M	DT	Small molecular drug
DMOFH1M	PC	10461508
DMOFH1M	MW	618.8
DMOFH1M	FM	C34H50N8O3
DMOFH1M	IC	InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1
DMOFH1M	CS	CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C
DMOFH1M	IK	SXNJFOWDRLKDSF-XKHVUIRMSA-N
DMOFH1M	IU	N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide
DMOFH1M	CA	CAS 755038-65-4
DMOFH1M	DE	Acute myeloid leukaemia

DM5T4IS	ID	DM5T4IS
DM5T4IS	DN	VP-102
DM5T4IS	HS	Phase 3
DM5T4IS	CP	Verrica Pharmaceuticals West Chester, PA
DM5T4IS	DE	Common wart; Molluscum contagiosum infection

DMWMT5N	ID	DMWMT5N
DMWMT5N	DN	VRS-317
DMWMT5N	HS	Phase 3
DMWMT5N	SN	HGH-XTEN; Human growth hormone-XTEN; RPEG HGH (injectable, growth deficiency), Versartis; Recombinant PEGylated human growth hormone (injectable, growth deficiency), Versartis
DMWMT5N	CP	Versartis
DMWMT5N	DE	Growth hormone deficiency

DMM1Z9G	ID	DMM1Z9G
DMM1Z9G	DN	Vutrisiran
DMM1Z9G	HS	Phase 3
DMM1Z9G	SN	ALN-TTRsc02
DMM1Z9G	CP	Alnylam Pharmaceuticals
DMM1Z9G	DT	Small interfering RNA
DMM1Z9G	DE	Transthyretin familial amyloid cardiomyopathy

DMJBXO3	ID	DMJBXO3
DMJBXO3	DN	VX-661
DMJBXO3	HS	Phase 3
DMJBXO3	CP	Vertex Pharmaceuticals Inc
DMJBXO3	DT	Small molecular drug
DMJBXO3	PC	46199646
DMJBXO3	MW	520.5
DMJBXO3	FM	C26H27F3N2O6
DMJBXO3	IC	InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1
DMJBXO3	CS	CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
DMJBXO3	IK	MJUVRTYWUMPBTR-MRXNPFEDSA-N
DMJBXO3	IU	1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
DMJBXO3	CA	CAS 1152311-62-0
DMJBXO3	DE	Cystic fibrosis

DMM2JXP	ID	DMM2JXP
DMM2JXP	DN	VX-787
DMM2JXP	HS	Phase 3
DMM2JXP	SN	Pimodivir
DMM2JXP	CP	Vertex pharmaceuticals
DMM2JXP	DT	Small molecular drug
DMM2JXP	PC	67286591
DMM2JXP	MW	399.4
DMM2JXP	FM	C20H19F2N5O2
DMM2JXP	IC	InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1
DMM2JXP	CS	C1CC2CCC1[C@@H]([C@H]2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O
DMM2JXP	IK	JGPXDNKSIXAZEQ-SBBZOCNPSA-N
DMM2JXP	IU	(2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid
DMM2JXP	CA	CAS 1629869-44-8
DMM2JXP	DE	Influenza A virus infection

DM1JCW8	ID	DM1JCW8
DM1JCW8	DN	Xaliproden
DM1JCW8	HS	Phase 3
DM1JCW8	SN	Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine
DM1JCW8	CP	Sanofi-Aventis
DM1JCW8	DT	Small molecular drug
DM1JCW8	PC	128919
DM1JCW8	MW	381.4
DM1JCW8	FM	C24H22F3N
DM1JCW8	IC	InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2
DM1JCW8	CS	C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3
DM1JCW8	IK	WJJYZXPHLSLMGE-UHFFFAOYSA-N
DM1JCW8	IU	1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine
DM1JCW8	CA	CAS 135354-02-8
DM1JCW8	CB	CHEBI:48520
DM1JCW8	DE	Lateral sclerosis; Peripheral sensory neuropathies; Alzheimer disease; Juvenile idiopathic arthritis; Plaque psoriasis

DMK34MZ	ID	DMK34MZ
DMK34MZ	DN	Xilonix
DMK34MZ	HS	Phase 3
DMK34MZ	CP	Xbiotech
DMK34MZ	DE	Non-small-cell lung cancer; Influenza virus infection; Colorectal cancer

DMJ6F5C	ID	DMJ6F5C
DMJ6F5C	DN	XL019
DMJ6F5C	HS	Phase 3
DMJ6F5C	SN	XL019; 945755-56-6; UNII-4L1AM42NVA; (S)-N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide; 4L1AM42NVA; (2S)-N-[4-[2-[[4-(4-Morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide; 945750-13-0; (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide; (2S)-N-[4-(2-{[4-(MORPHOLIN-4-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)PHENYL]PYRROLIDINE-2-CARBOXAMIDE; C25H28N6O2; 2-Pyrrolidinecarboxamide, N-(4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)phe
DMJ6F5C	DT	Small molecular drug
DMJ6F5C	PC	57990869
DMJ6F5C	MW	444.5
DMJ6F5C	FM	C25H28N6O2
DMJ6F5C	IC	InChI=1S/C25H28N6O2/c32-24(23-2-1-12-26-23)28-19-5-3-18(4-6-19)22-11-13-27-25(30-22)29-20-7-9-21(10-8-20)31-14-16-33-17-15-31/h3-11,13,23,26H,1-2,12,14-17H2,(H,28,32)(H,27,29,30)/t23-/m0/s1
DMJ6F5C	CS	C1C[C@H](NC1)C(=O)NC2=CC=C(C=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCOCC5
DMJ6F5C	IK	ISOCDPQFIXDIMS-QHCPKHFHSA-N
DMJ6F5C	IU	(2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide
DMJ6F5C	CA	CAS 945755-56-6
DMJ6F5C	DE	Polycythemia vera; Solid tumour/cancer

DMOKQV7	ID	DMOKQV7
DMOKQV7	DN	XOMA 052
DMOKQV7	HS	Phase 3
DMOKQV7	SN	Gevokizumab
DMOKQV7	CP	XOMA
DMOKQV7	DT	Antibody
DMOKQV7	DE	Type-2 diabetes

DMOLR5W	ID	DMOLR5W
DMOLR5W	DN	Yttrium (90Y) clivatuzumab tetraxetan
DMOLR5W	HS	Phase 3
DMOLR5W	SN	PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4
DMOLR5W	CP	Immunomedics; Garden State Cancer Center; Immunomedics
DMOLR5W	DT	Antibody
DMOLR5W	DE	Pancreatic cancer

DMEY1F3	ID	DMEY1F3
DMEY1F3	DN	Zabofloxacin
DMEY1F3	HS	Phase 3
DMEY1F3	SN	DW-224a; DW-224aa; PB-101; Zabofloxacin (oral), IASO Pharma/DHP
DMEY1F3	CP	Dong Wha Pharmaceutical Co Ltd
DMEY1F3	DT	Small molecular drug
DMEY1F3	PC	10388396
DMEY1F3	MW	401.4
DMEY1F3	FM	C19H20FN5O4
DMEY1F3	IC	InChI=1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14+
DMEY1F3	CS	CO/N=C/1\\CN(CC12CNC2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F
DMEY1F3	IK	ZNPOCLHDJCAZAH-OEAKJJBVSA-N
DMEY1F3	IU	1-cyclopropyl-6-fluoro-7-[(8Z)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMEY1F3	DE	Pneumonia

DM52QEZ	ID	DM52QEZ
DM52QEZ	DN	Zalutumumab
DM52QEZ	HS	Phase 3
DM52QEZ	CP	Genmab
DM52QEZ	DT	Antibody
DM52QEZ	SQ	Zalutumumab (A chain): QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>    <sequence format="FASTA">&gt; Zalutumumab (B chain)AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM52QEZ	DE	Head and neck cancer

DMKB4ZY	ID	DMKB4ZY
DMKB4ZY	DN	Zanolimumab
DMKB4ZY	HS	Phase 3
DMKB4ZY	CP	Emergent BioSolutions
DMKB4ZY	DT	Antibody
DMKB4ZY	DE	Lymphoma

DM9HUYP	ID	DM9HUYP
DM9HUYP	DN	ZANOTERONE
DM9HUYP	HS	Phase 3
DM9HUYP	SN	ZANOTERONE; 107000-34-0; UNII-XQ5V1W49JG; XQ5V1W49JG; WIN-49596; Zanoterone [USAN:INN]; Win 49,596; Zanoterone (USAN/INN); win49596; SCHEMBL60980; CHEMBL1908363; DTXSID50147873; BDBM50368314; 1'-(Methylsulfonyl)-1'H-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol; D06357; 34004-EP2305642A2; 34004-EP2298765A1; 34004-EP2275420A1; 34004-EP2311453A1; 34004-EP2298764A1; 34004-EP2298748A2; 34004-EP2295416A2; 34004-EP2295055A2; 1'H-Pregn-20-yno(3,2-c)pyrazol-17-ol, 1'-(methylsulfonyl)-, (5alpha,17alpha)-
DM9HUYP	DT	Small molecular drug
DM9HUYP	PC	9844827
DM9HUYP	MW	416.6
DM9HUYP	FM	C23H32N2O3S
DM9HUYP	IC	InChI=1S/C23H32N2O3S/c1-5-23(26)11-9-19-17-7-6-16-12-20-15(14-25(24-20)29(4,27)28)13-21(16,2)18(17)8-10-22(19,23)3/h1,14,16-19,26H,6-13H2,2-4H3/t16-,17+,18-,19-,21-,22-,23-/m0/s1
DM9HUYP	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CC[C@@H]4[C@@]3(CC5=CN(N=C5C4)S(=O)(=O)C)C
DM9HUYP	IK	MHDDZDPNIDVLNK-ZGIWMXSJSA-N
DM9HUYP	IU	(1S,2S,10S,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-6-methylsulfonyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4,7-dien-17-ol
DM9HUYP	CA	CAS 107000-34-0
DM9HUYP	DE	Prostate hyperplasia

DMF30HL	ID	DMF30HL
DMF30HL	DN	Zarnestra
DMF30HL	HS	Phase 3
DMF30HL	SN	JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
DMF30HL	CP	Johnson & Johnson
DMF30HL	TC	Anticancer Agents
DMF30HL	DT	Small molecular drug
DMF30HL	PC	159324
DMF30HL	MW	489.4
DMF30HL	FM	C27H22Cl2N4O
DMF30HL	IC	InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1
DMF30HL	CS	CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N
DMF30HL	IK	PLHJCIYEEKOWNM-HHHXNRCGSA-N
DMF30HL	IU	6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one
DMF30HL	CA	CAS 192185-72-1
DMF30HL	CB	CHEBI:141969
DMF30HL	DE	Colorectal cancer; Pancreatic cancer; Chronic myelogenous leukaemia; Myelodysplastic syndrome; Human papillomavirus infection; Peripheral T-cell lymphoma; Acute myeloid leukaemia

DMWDEFC	ID	DMWDEFC
DMWDEFC	DN	Zatosetron maleate
DMWDEFC	HS	Phase 3
DMWDEFC	SN	LY-277359 maleate; Zatosetron maleate < Rec INNM; Endo-5-Chloro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydrobenzofuran-7-carboxamide maleate
DMWDEFC	DT	Small molecular drug
DMWDEFC	PC	6918153
DMWDEFC	MW	464.9
DMWDEFC	FM	C23H29ClN2O6
DMWDEFC	IC	InChI=1S/C19H25ClN2O2.C4H4O4/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3;5-3(6)1-2-4(7)8/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23);1-2H,(H,5,6)(H,7,8)/b;2-1-/t13?,14-,15+;
DMWDEFC	CS	CC1(CC2=C(O1)C(=CC(=C2)Cl)C(=O)NC3C[C@H]4CC[C@@H](C3)N4C)C.C(=C\\C(=O)O)\\C(=O)O
DMWDEFC	IK	HAFQATMFFHYNPN-BSLJCGBVSA-N
DMWDEFC	IU	(Z)-but-2-enedioic acid;5-chloro-2,2-dimethyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-3H-1-benzofuran-7-carboxamide
DMWDEFC	CA	CAS 123482-23-5
DMWDEFC	DE	Anxiety disorder

DMP8ESD	ID	DMP8ESD
DMP8ESD	DN	Zicronapine
DMP8ESD	HS	Phase 3
DMP8ESD	SN	Zicronapine; 170381-16-5; UNII-QZV11V7G6A; QZV11V7G6A; Zicronapine [USAN:INN]; Zicronapine (USAN/INN); SCHEMBL904402; CHEMBL3039528; DTXSID30168849; Lu31-130; AKOS032946690; DB12188; 4-((1R,3S)-6-Chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine; LU-31130; D10329; Piperazine, 4-((1R,3S)-6-chloro-2,3-dihydro-3-phenyl-1H-inden-1-yl)-1,2,2-trimethyl-
DMP8ESD	CP	Lundbeck
DMP8ESD	DT	Small molecular drug
DMP8ESD	PC	11465618
DMP8ESD	MW	354.9
DMP8ESD	FM	C22H27ClN2
DMP8ESD	IC	InChI=1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1
DMP8ESD	CS	CC1(CN(CCN1C)[C@@H]2C[C@H](C3=C2C=C(C=C3)Cl)C4=CC=CC=C4)C
DMP8ESD	IK	BYPMJBXPNZMNQD-PZJWPPBQSA-N
DMP8ESD	IU	4-[(1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine
DMP8ESD	CA	CAS 170381-16-5
DMP8ESD	DE	Schizophrenia

DM09TVB	ID	DM09TVB
DM09TVB	DN	Zimura
DM09TVB	HS	Phase 3
DM09TVB	SN	ARC-1905
DM09TVB	CP	Ophthotech Corp
DM09TVB	DT	Oligonucleotide
DM09TVB	DE	Macular degeneration

DMFWMKZ	ID	DMFWMKZ
DMFWMKZ	DN	ZK-93423
DMFWMKZ	HS	Phase 3
DMFWMKZ	SN	ZK 93423; 83910-44-5; ZK93423; ZK 93 423; 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-6-(phenylmethoxy)-, ethyl ester; ALBKMJDFBZVHAK-UHFFFAOYSA-N; PDSP1_001754; AC1L3TNV; AC1Q64YI; CHEMBL10947; GTPL4346; SCHEMBL7117282; CHEMBL1518572; BDBM85039; CHEBI:92593; ZINC5857871; PDSP2_001737; PDSP1_001771; ethyl 6-(benzyloxy)-4-(methoxymethyl)-9h-; BDBM50007553; PDSP2_001754; CAS_121926; NSC_121926
DMFWMKZ	DT	Small molecular drug
DMFWMKZ	PC	121926
DMFWMKZ	MW	390.4
DMFWMKZ	FM	C23H22N2O4
DMFWMKZ	IC	InChI=1S/C23H22N2O4/c1-3-28-23(26)22-18(14-27-2)21-17-11-16(29-13-15-7-5-4-6-8-15)9-10-19(17)25-20(21)12-24-22/h4-12,25H,3,13-14H2,1-2H3
DMFWMKZ	CS	CCOC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC(=C3)OCC4=CC=CC=C4
DMFWMKZ	IK	ALBKMJDFBZVHAK-UHFFFAOYSA-N
DMFWMKZ	IU	ethyl 4-(methoxymethyl)-6-phenylmethoxy-9H-pyrido[3,4-b]indole-3-carboxylate
DMFWMKZ	CA	CAS 83910-44-5
DMFWMKZ	CB	CHEBI:92593
DMFWMKZ	DE	Epileptic seizures

DM5ST9Z	ID	DM5ST9Z
DM5ST9Z	DN	Zolbetuximab
DM5ST9Z	HS	Phase 3
DM5ST9Z	SN	IMAB362
DM5ST9Z	CP	Astellas Pharma
DM5ST9Z	DT	Antibody
DM5ST9Z	DE	Pancreatic cancer; Gastric adenocarcinoma; Esophagogastric junction neoplasm

DM8L7JD	ID	DM8L7JD
DM8L7JD	DN	Zoniporide hydrochloride
DM8L7JD	HS	Phase 3
DM8L7JD	SN	CP-597396; EMD-392426; Zoniporide hydrochloride < Prop INNM; N''-[5-Cyclopropyl-1-(5-quinolyl)-1H-pyrazol-4-ylcarbonyl]guanidine hydrochloride monohydrate
DM8L7JD	DT	Small molecular drug
DM8L7JD	PC	11962997
DM8L7JD	MW	356.8
DM8L7JD	FM	C17H17ClN6O
DM8L7JD	IC	InChI=1S/C17H16N6O.ClH/c18-17(19)22-16(24)12-9-21-23(15(12)10-6-7-10)14-5-1-4-13-11(14)3-2-8-20-13;/h1-5,8-10H,6-7H2,(H4,18,19,22,24);1H
DM8L7JD	CS	C1CC1C2=C(C=NN2C3=CC=CC4=C3C=CC=N4)C(=O)N=C(N)N.Cl
DM8L7JD	IK	JTEXNYIOROVPIR-UHFFFAOYSA-N
DM8L7JD	IU	5-cyclopropyl-N-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide;hydrochloride
DM8L7JD	CA	CAS 241800-97-5
DM8L7JD	DE	Angina pectoris

DMMBJYC	ID	DMMBJYC
DMMBJYC	DN	ZYH-1
DMMBJYC	HS	Phase 3
DMMBJYC	SN	Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila
DMMBJYC	CP	Zydus-Cadila Group
DMMBJYC	DE	Lipid metabolism disorder

DM12UX6	ID	DM12UX6
DM12UX6	DN	131 I-omburtamab
DM12UX6	HS	Phase 2/3
DM12UX6	CP	Y-mAbs Therapeutics
DM12UX6	DT	Antibody
DM12UX6	DE	Neuroblastoma; Brain and central nervous system tumour

DMZ0T24	ID	DMZ0T24
DMZ0T24	DN	Abagovomab
DMZ0T24	HS	Phase 2/3
DMZ0T24	CP	Menarini
DMZ0T24	DT	Monoclonal antibody
DMZ0T24	DE	Ovarian cancer

DMKY9GI	ID	DMKY9GI
DMKY9GI	DN	Activated recombinant FVII-albumin fusion protein
DMKY9GI	HS	Phase 2/3
DMKY9GI	SN	CSL-689; Activated recombinant FVII-albumin fusion protein (hemophilia); Activated recombinant FVII-albumin fusion protein (hemophilia), CSL Behring; RVIIa-FP (hemophilia), CSL Behring; Recombinant factor VIIa/human albumin fusion protein (hemophilia), CSL Behring
DMKY9GI	CP	Csl behring
DMKY9GI	DE	Hemophilia

DM6GTMD	ID	DM6GTMD
DM6GTMD	DN	ADX-48621
DM6GTMD	HS	Phase 2/3
DM6GTMD	SN	Dipraglurant; 872363-17-2; UNII-CV8JZR21A1; ADX48621; CV8JZR21A1; CHEMBL2346738; 6-fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]-Imidazo[1,2-a]pyridine; Dipraglurant [INN]; ADX-48621; SCHEMBL103033; GTPL6452; C16H12FN3; DTXSID90236230; BCP23706; BDBM50431705; ZINC72266314; 3590AH; 6-Fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine; AKOS030526956; SB16993; DB12733; CS-0690; NCGC00351745-02; HY-14859; DB-076892; FT-0705373; J3.560.334D; W-5761; ADX 48621;ADX48621;ADX-48621
DM6GTMD	CP	Addex Pharma.
DM6GTMD	DT	Small molecular drug
DM6GTMD	PC	44557636
DM6GTMD	MW	265.28
DM6GTMD	FM	C16H12FN3
DM6GTMD	IC	InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2
DM6GTMD	CS	C1=CC=NC(=C1)C#CCCC2=CN3C=C(C=CC3=N2)F
DM6GTMD	IK	LZXMUJCJAWVHPZ-UHFFFAOYSA-N
DM6GTMD	IU	6-fluoro-2-(4-pyridin-2-ylbut-3-ynyl)imidazo[1,2-a]pyridine
DM6GTMD	CA	CAS 872363-17-2
DM6GTMD	DE	Mood disorder; Dyskinesia; Parkinson disease

DMMHSLC	ID	DMMHSLC
DMMHSLC	DN	Afq056
DMMHSLC	HS	Phase 2/3
DMMHSLC	SN	Mavoglurant
DMMHSLC	CP	Novartis
DMMHSLC	DT	Small molecular drug
DMMHSLC	PC	9926832
DMMHSLC	MW	313.4
DMMHSLC	FM	C19H23NO3
DMMHSLC	IC	InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1
DMMHSLC	CS	CC1=CC(=CC=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O
DMMHSLC	IK	ZFPZEYHRWGMJCV-ZHALLVOQSA-N
DMMHSLC	IU	methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate
DMMHSLC	CA	CAS 543906-09-8
DMMHSLC	DE	Fragile X syndrome

DMGC970	ID	DMGC970
DMGC970	DN	AG-013
DMGC970	HS	Phase 2/3
DMGC970	SN	ActoBiotic (oral mucositis), ActoGenix; TFF-producing Lactococci lactis (mucositis), ActoGenix/VIB/University of Ghent; Trefoil factor producing micro-organisms (TopAct, oral, mucositis), ActoGenix
DMGC970	CP	Flanders Interuniversity Institute for Biotechnology (VIB)
DMGC970	DE	Oral mucositis

DMD741P	ID	DMD741P
DMD741P	DN	Alagebrium chloride
DMD741P	HS	Phase 2/3
DMD741P	SN	PTB; Tetrazolium chloride; ALT-711; ALT-766; N-phenacylthiazolium bromide; Advanced glycosylation end product (AGE)breakers, Alteon; Advanced glycosylation end product (AGE) breakers, Synvista
DMD741P	CP	Synvista Therapeutics Inc
DMD741P	DT	Small molecular drug
DMD741P	PC	216306
DMD741P	MW	267.77
DMD741P	FM	C13H14ClNOS
DMD741P	IC	InChI=1S/C13H14NOS.ClH/c1-10-11(2)16-9-14(10)8-13(15)12-6-4-3-5-7-12;/h3-7,9H,8H2,1-2H3;1H/q+1;/p-1
DMD741P	CS	CC1=C(SC=[N+]1CC(=O)C2=CC=CC=C2)C.[Cl-]
DMD741P	IK	MKOMESMZHZNBIZ-UHFFFAOYSA-M
DMD741P	IU	2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;chloride
DMD741P	CA	CAS 341028-37-3
DMD741P	DE	Hypotension

DM36HBS	ID	DM36HBS
DM36HBS	DN	ALXN1101
DM36HBS	HS	Phase 2/3
DM36HBS	CP	Alexion pharmaceuticals
DM36HBS	DE	Molybdenum cofactor deficiency

DMBFOAZ	ID	DMBFOAZ
DMBFOAZ	DN	AMG520
DMBFOAZ	HS	Phase 2/3
DMBFOAZ	SN	CNP520
DMBFOAZ	CP	Amgen Thousand Oaks, CA Novartis East Hanover, NJ
DMBFOAZ	DE	Alzheimer disease

DMN6F1W	ID	DMN6F1W
DMN6F1W	DN	Amiodarone
DMN6F1W	HS	Phase 2/3
DMN6F1W	SN	amiodarone; 1951-25-3; Cordarone; Amiodarona; Amiodaronum; Amjodaronum; Amiodaronum [INN-Latin]; Amiodarona [INN-Spanish]; Pacerone; L 3428; L-3428; UNII-N3RQ532IUT; C25H29I2NO3; SKF 33134-A; EINECS 217-772-1; CHEMBL633; BRN 1271711; N3RQ532; Amiodarone
DMN6F1W	TC	Antiviral Agents
DMN6F1W	DT	Small molecular drug
DMN6F1W	PC	2157
DMN6F1W	MW	645.3
DMN6F1W	FM	C25H29I2NO3
DMN6F1W	IC	InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
DMN6F1W	CS	CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMN6F1W	IK	IYIKLHRQXLHMJQ-UHFFFAOYSA-N
DMN6F1W	IU	(2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone
DMN6F1W	CA	CAS 1951-25-3
DMN6F1W	CB	CHEBI:2663
DMN6F1W	DE	Coronavirus Disease 2019 (COVID-19)

DMJRU3A	ID	DMJRU3A
DMJRU3A	DN	AMO-02
DMJRU3A	HS	Phase 2/3
DMJRU3A	CP	AMO Pharma Berwyn, PA
DMJRU3A	DE	Myotonic dystrophy

DMDLGRO	ID	DMDLGRO
DMDLGRO	DN	Aramchol
DMDLGRO	HS	Phase 2/3
DMDLGRO	SN	Stearoyl CoA desaturase-1 inhibitor (oral, liver/lipid metabolism diseases), Galmed
DMDLGRO	CP	Galmed Medical Research Ltd
DMDLGRO	DT	Small molecular drug
DMDLGRO	PC	18738120
DMDLGRO	MW	702.1
DMDLGRO	FM	C44H79NO5
DMDLGRO	IC	InChI=1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)/t32-,33+,34+,35-,36+,37+,38-,39+,42+,43+,44-/m1/s1
DMDLGRO	CS	CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@]2([C@@H](C1)C[C@H]([C@@H]3[C@@H]2C[C@@H]([C@]4([C@H]3CC[C@@H]4[C@H](C)CCC(=O)O)C)O)O)C
DMDLGRO	IK	SHKXZIQNFMOPBS-OOMQYRRCSA-N
DMDLGRO	IU	(4R)-4-[(3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMDLGRO	CA	CAS 246529-22-6
DMDLGRO	DE	Lipid metabolism disorder

DMS8QF9	ID	DMS8QF9
DMS8QF9	DN	Arimoclomol
DMS8QF9	HS	Phase 2/3
DMS8QF9	SN	BRX-345
DMS8QF9	CP	Biorex Research and Development Co
DMS8QF9	DT	Small molecular drug
DMS8QF9	PC	9568077
DMS8QF9	MW	313.78
DMS8QF9	FM	C14H20ClN3O3
DMS8QF9	IC	InChI=1S/C14H20ClN3O3/c15-14(12-5-4-8-18(20)9-12)16-21-11-13(19)10-17-6-2-1-3-7-17/h4-5,8-9,13,19H,1-3,6-7,10-11H2/b16-14-/t13-/m1/s1
DMS8QF9	CS	C1CCN(CC1)C[C@H](CO/N=C(/C2=C[N+](=CC=C2)[O-])\\Cl)O
DMS8QF9	IK	SGEIEGAXKLMUIZ-XUVDNFPMSA-N
DMS8QF9	IU	(3Z)-N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride
DMS8QF9	CA	CAS 289893-25-0
DMS8QF9	DE	Cerebrovascular ischaemia; Inclusion body myositis

DM15VBJ	ID	DM15VBJ
DM15VBJ	DN	Artemisone
DM15VBJ	HS	Phase 2/3
DM15VBJ	SN	Artemifone; Artemisone, Medicines For Malaria Venture; MMV-00/1007; Artemisinin derviative, Bayer/WHO/Hong Kong University; Artemisone, Bayer/WHO/Hong Kong University; Semi-synthetic endoperoxide, Bayer/WHO/Hong Kong University
DM15VBJ	CP	Hong Kong University of Science & Technology
DM15VBJ	DT	Small molecular drug
DM15VBJ	PC	11531457
DM15VBJ	MW	401.5
DM15VBJ	FM	C19H31NO6S
DM15VBJ	IC	InChI=1S/C19H31NO6S/c1-12-4-5-15-13(2)16(20-8-10-27(21,22)11-9-20)23-17-19(15)14(12)6-7-18(3,24-17)25-26-19/h12-17H,4-11H2,1-3H3/t12-,13-,14+,15+,16-,17-,18-,19-/m1/s1
DM15VBJ	CS	C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)N5CCS(=O)(=O)CC5)C
DM15VBJ	IK	FDMUNKXWYMSZIR-NQWKWHCYSA-N
DM15VBJ	IU	4-[(1R,4S,5R,8S,9R,10R,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]-1,4-thiazinane 1,1-dioxide
DM15VBJ	CA	CAS 255730-18-8
DM15VBJ	DE	Malaria

DMZGKXW	ID	DMZGKXW
DMZGKXW	DN	Atogepant
DMZGKXW	HS	Phase 2/3
DMZGKXW	SN	UNII-7CRV8RR151; 7CRV8RR151; AGN-241689; MK-8031; 1374248-81-3; Atogepant [INN]; Atogepant [WHO-DD]; Atogepant [USAN:INN]; SCHEMBL4570348; GTPL9730; CHEMBL3991065; example 4 [US20120122911]; Spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide, 1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl)-2'-oxo-, (3'S)-; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1
DMZGKXW	CP	Allergan Parsippany, NJ
DMZGKXW	PC	72163100
DMZGKXW	MW	603.5
DMZGKXW	FM	C29H23F6N5O3
DMZGKXW	IC	InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1
DMZGKXW	CS	C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F
DMZGKXW	IK	QIVUCLWGARAQIO-OLIXTKCUSA-N
DMZGKXW	IU	(3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DMZGKXW	CA	CAS 1374248-81-3
DMZGKXW	DE	Migraine

DMVB4OS	ID	DMVB4OS
DMVB4OS	DN	AVN 211
DMVB4OS	HS	Phase 2/3
DMVB4OS	CP	Avineuro Pharmaceuticals
DMVB4OS	DE	Schizophrenia

DM5YHU2	ID	DM5YHU2
DM5YHU2	DN	Avoralstat
DM5YHU2	HS	Phase 2/3
DM5YHU2	SN	TUWMKPVJGGWGNL-UHFFFAOYSA-N; UNII-UX17773O15; UX17773O15; 918407-35-9; Avoralstat [INN]; 3-(2-((4-Carbamimidoylphenyl)carbamoyl)-4-ethenyl-5-methoxyphenyl)-6-((cyclopropylmethyl)carbamoyl)pyridine-2-carboxylic acid; 3-{2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl}-6-[(cyclopropylmethyl)carbamoyl]pyridine-2-carboxylic acid; SCHEMBL17513082; AKOS030629101; DB12120; CS-7551; 2-Pyridinecarboxylic acid, 3-(2-(((4-(aminoiminomethyl)phenyl)amino)carbonyl)-4-ethenyl-5-met
DM5YHU2	CP	BioCryst Pharmaceuticals Durham, NC
DM5YHU2	PC	86566678
DM5YHU2	MW	513.5
DM5YHU2	FM	C28H27N5O5
DM5YHU2	IC	InChI=1S/C28H27N5O5/c1-3-16-12-21(26(34)32-18-8-6-17(7-9-18)25(29)30)20(13-23(16)38-2)19-10-11-22(33-24(19)28(36)37)27(35)31-14-15-4-5-15/h3,6-13,15H,1,4-5,14H2,2H3,(H3,29,30)(H,31,35)(H,32,34)(H,36,37)
DM5YHU2	CS	COC1=CC(=C(C=C1C=C)C(=O)NC2=CC=C(C=C2)C(=N)N)C3=C(N=C(C=C3)C(=O)NCC4CC4)C(=O)O
DM5YHU2	IK	TUWMKPVJGGWGNL-UHFFFAOYSA-N
DM5YHU2	IU	3-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl]-6-(cyclopropylmethylcarbamoyl)pyridine-2-carboxylic acid
DM5YHU2	CA	CAS 918407-35-9
DM5YHU2	DE	Hereditary angioedema

DMJQHXD	ID	DMJQHXD
DMJQHXD	DN	AZD3293
DMJQHXD	HS	Phase 2/3
DMJQHXD	SN	CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099
DMJQHXD	CP	AstraZeneca
DMJQHXD	DT	Small molecular drug
DMJQHXD	PC	57404290
DMJQHXD	MW	412.5
DMJQHXD	FM	C26H28N4O
DMJQHXD	IC	InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)
DMJQHXD	CS	CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2
DMJQHXD	IK	WKDNQONLGXOZRG-UHFFFAOYSA-N
DMJQHXD	DE	Alzheimer disease

DM3827C	ID	DM3827C
DM3827C	DN	AZD4547
DM3827C	HS	Phase 2/3
DM3827C	SN	AZD4547; 1035270-39-3; AZD-4547; AZD 4547; UNII-2167OG1EKJ; 2167OG1EKJ; CHEBI:63453; KB-74810; N-(5-(3,5-Dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3R,5S)-rel-3,5-dimethylpiperazin-1-yl)benzamide; N-{5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-(cis-3,5-dimethylpiperazin-1-yl)benzamide; rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide; N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide
DM3827C	CP	AstraZeneca
DM3827C	DT	Small molecular drug
DM3827C	PC	51039095
DM3827C	MW	463.6
DM3827C	FM	C26H33N5O3
DM3827C	IC	InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+
DM3827C	CS	C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC
DM3827C	IK	VRQMAABPASPXMW-HDICACEKSA-N
DM3827C	IU	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]benzamide
DM3827C	CA	CAS 1035270-39-3
DM3827C	CB	CHEBI:63453
DM3827C	DE	Solid tumour/cancer

DMHWE5R	ID	DMHWE5R
DMHWE5R	DN	Batabulin
DMHWE5R	HS	Phase 2/3
DMHWE5R	SN	T-138067; T-138068; T-67
DMHWE5R	CP	Tularik Inc
DMHWE5R	DT	Small molecular drug
DMHWE5R	PC	216324
DMHWE5R	MW	371.26
DMHWE5R	FM	C13H7F6NO3S
DMHWE5R	IC	InChI=1S/C13H7F6NO3S/c1-23-7-3-2-5(4-6(7)14)20-24(21,22)13-11(18)9(16)8(15)10(17)12(13)19/h2-4,20H,1H3
DMHWE5R	CS	COC1=C(C=C(C=C1)NS(=O)(=O)C2=C(C(=C(C(=C2F)F)F)F)F)F
DMHWE5R	IK	ROZCIVXTLACYNY-UHFFFAOYSA-N
DMHWE5R	IU	2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide
DMHWE5R	CA	CAS 195533-53-0
DMHWE5R	DE	Solid tumour/cancer

DMKT16N	ID	DMKT16N
DMKT16N	DN	Bevacizumab
DMKT16N	HS	Phase 2/3
DMKT16N	SN	Bevacizumab (ophthalmic slow-release tissue tablet); Avastin
DMKT16N	TC	Antiviral Agents
DMKT16N	DT	Monoclonal antibody
DMKT16N	DE	Metastatic colorectal cancer; Coronavirus Disease 2019 (COVID-19)

DMUSJ3D	ID	DMUSJ3D
DMUSJ3D	DN	BIIB-088
DMUSJ3D	HS	Phase 2/3
DMUSJ3D	SN	AGTC 501
DMUSJ3D	CP	Applied Genetic Technologies
DMUSJ3D	DT	Gene therapy
DMUSJ3D	DE	Retinitis pigmentosa

DMYFQJL	ID	DMYFQJL
DMYFQJL	DN	BNV-222
DMYFQJL	HS	Phase 2/3
DMYFQJL	SN	Diepalrestat choline; UNII-16AHE7410O; 16AHE7410O; CHEMBL4297277; Q27251797; 1665300-21-9; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate (1:1:1)
DMYFQJL	CP	BioNevia Pharmaceuticals
DMYFQJL	DT	Small molecular drug
DMYFQJL	PC	117587644
DMYFQJL	MW	742
DMYFQJL	FM	C35H39N3O7S4
DMYFQJL	IC	InChI=1S/2C15H13NO3S2.C5H14NO/c2*1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12;1-6(2,3)4-5-7/h2*2-8H,9H2,1H3,(H,17,18);7H,4-5H2,1-3H3/q;;+1/p-1/b2*10-7+,12-8-;
DMYFQJL	CS	C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)O.C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)[O-].C[N+](C)(C)CCO
DMYFQJL	IK	WKSNHZZSMLFYFI-UROVXFGGSA-M
DMYFQJL	IU	2-hydroxyethyl(trimethyl)azanium;2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetate;2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
DMYFQJL	CA	CAS 1665300-21-9
DMYFQJL	DE	Diabetic neuropathy

DMV52CP	ID	DMV52CP
DMV52CP	DN	Bucindolol
DMV52CP	HS	Phase 2/3
DMV52CP	SN	Bucindolol; 71119-11-4; Bucindolol [INN:BAN]; Bucindololum [INN-Latin]; CHEMBL321582; C22H25N3O2; NCGC00167817-01; 2-(2-Hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile; DSSTox_RID_81872; DSSTox_CID_26744; DSSTox_GSID_46744; Bucindololum; 2-[2-Hydroxy-3-[2-(indol-3-yl)-1,1-dimethylethylamino]propoxy]benzonitrile; Benzonitrile, 2-(2-hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-; 2-[2-Hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile
DMV52CP	DT	Small molecular drug
DMV52CP	PC	51045
DMV52CP	MW	363.5
DMV52CP	FM	C22H25N3O2
DMV52CP	IC	InChI=1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3
DMV52CP	CS	CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O
DMV52CP	IK	FBMYKMYQHCBIGU-UHFFFAOYSA-N
DMV52CP	IU	2-[2-hydroxy-3-[[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile
DMV52CP	CA	CAS 71119-11-4
DMV52CP	DE	Hypertension; Atrial fibrillation

DM31VZT	ID	DM31VZT
DM31VZT	DN	CAD-106
DM31VZT	HS	Phase 2/3
DM31VZT	SN	Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis
DM31VZT	CP	Cytos Biotechnology AG
DM31VZT	DT	Vaccine
DM31VZT	DE	Alzheimer disease

DMVLXMG	ID	DMVLXMG
DMVLXMG	DN	Camostat mesylate
DMVLXMG	HS	Phase 2/3
DMVLXMG	SN	Camostat (mesylate); Camostat Methanesulfonate; Camostat methanesulfate; DSSTox_CID_238; DSSTox_GSID_20238; DSSTox_RID_75452; FOY 305; FOY-305; FOY305; Foipan; Foipan (TN); Foipan mesylate; NCGC00167526-01; Q-200778; UNII-451M50A1EQ; camostat mesilate; 451M50A1EQ; C21H26N4O8S; CAS-59721-29-8; CHEMBL85164
DMVLXMG	TC	Antiviral Agents
DMVLXMG	DT	Small molecular drug
DMVLXMG	PC	5284360
DMVLXMG	MW	494.5
DMVLXMG	FM	C21H26N4O8S
DMVLXMG	IC	InChI=1S/C20H22N4O5.CH4O3S/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22;1-5(2,3)4/h3-10H,11-12H2,1-2H3,(H4,21,22,23);1H3,(H,2,3,4)
DMVLXMG	CS	CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O
DMVLXMG	IK	FSEKIHNIDBATFG-UHFFFAOYSA-N
DMVLXMG	IU	[4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate;methanesulfonic acid
DMVLXMG	CA	CAS 59721-29-8
DMVLXMG	CB	CHEBI:31347
DMVLXMG	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS); Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMST3FM	ID	DMST3FM
DMST3FM	DN	CART-19
DMST3FM	HS	Phase 2/3
DMST3FM	CP	Fujian Medical University
DMST3FM	DT	CAR T Cell Therapy
DMST3FM	DE	Acute lymphoblastic leukaemia

DM45Z3P	ID	DM45Z3P
DM45Z3P	DN	CD123/CLL1 CAR-T Cells
DM45Z3P	HS	Phase 2/3
DM45Z3P	CP	Fujian Medical University
DM45Z3P	DT	CAR T Cell Therapy (Dual specific)
DM45Z3P	DE	Acute myeloid leukaemia

DM32148	ID	DM32148
DM32148	DN	CD19 CAR T cells
DM32148	HS	Phase 2/3
DM32148	CP	Fujian Medical University
DM32148	DT	CAR T Cell Therapy
DM32148	DE	Acute lymphoblastic leukaemia; B-cell lymphoma

DMFCLT6	ID	DMFCLT6
DMFCLT6	DN	CE-224535
DMFCLT6	HS	Phase 2/3
DMFCLT6	SN	CP-23575
DMFCLT6	CP	Pfizer Inc
DMFCLT6	DT	Small molecular drug
DMFCLT6	PC	11547499
DMFCLT6	MW	480.9
DMFCLT6	FM	C22H29ClN4O6
DMFCLT6	IC	InChI=1S/C22H29ClN4O6/c1-33-13-16(28)12-26-19(29)11-25-27(21(26)31)15-6-7-18(23)17(10-15)20(30)24-14-22(32)8-4-2-3-5-9-22/h6-7,10-11,16,28,32H,2-5,8-9,12-14H2,1H3,(H,24,30)/t16-/m1/s1
DMFCLT6	CS	COC[C@@H](CN1C(=O)C=NN(C1=O)C2=CC(=C(C=C2)Cl)C(=O)NCC3(CCCCCC3)O)O
DMFCLT6	IK	FUCKCIVGBCBZNP-MRXNPFEDSA-N
DMFCLT6	IU	2-chloro-N-[(1-hydroxycycloheptyl)methyl]-5-[4-[(2R)-2-hydroxy-3-methoxypropyl]-3,5-dioxo-1,2,4-triazin-2-yl]benzamide
DMFCLT6	CA	CAS 724424-43-5
DMFCLT6	DE	Arthralgia

DMXCD69	ID	DMXCD69
DMXCD69	DN	CEP1347
DMXCD69	HS	Phase 2/3
DMXCD69	SN	AC1L31ZX; SCHEMBL1649555; ZINC103589452; DB05403
DMXCD69	DT	Small molecular drug
DMXCD69	PC	9917013
DMXCD69	MW	615.8
DMXCD69	FM	C33H33N3O5S2
DMXCD69	IC	InChI=1S/C33H33N3O5S2/c1-5-42-15-17-7-9-22-19(11-17)26-27-21(14-34-30(27)37)25-20-12-18(16-43-6-2)8-10-23(20)36-29(25)28(26)35(22)24-13-33(39,31(38)40-4)32(36,3)41-24/h7-12,24,39H,5-6,13-16H2,1-4H3,(H,34,37)/t24-,32+,33+/m1/s1
DMXCD69	CS	CCSCC1=CC2=C(C=C1)N3[C@H]4C[C@@]([C@](O4)(N5C6=C(C=C(C=C6)CSCC)C7=C8CNC(=O)C8=C2C3=C75)C)(C(=O)OC)O
DMXCD69	IK	SCMLRESZJCKCTC-KMYQRJGFSA-N
DMXCD69	IU	methyl (15S,16R,18R)-10,23-bis(ethylsulfanylmethyl)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8(13),9,11,20(25),21,23,26-nonaene-16-carboxylate
DMXCD69	CA	CAS 156177-65-0
DMXCD69	DE	Asthma

DMUOMBZ	ID	DMUOMBZ
DMUOMBZ	DN	CLL1 CAR-T Cell
DMUOMBZ	HS	Phase 2/3
DMUOMBZ	CP	Fujian Medical University
DMUOMBZ	DT	CAR T Cell Therapy (Dual specific)
DMUOMBZ	DE	Acute myeloid leukaemia

DMX9V8K	ID	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	HS	Phase 2/3
DMX9V8K	SN	Isoquercitrin; Isoquercetin; 482-35-9; Hirsutrin; 3-Glucosylquercetin; Glucosyl 3-quercetin; Quercetin 3-glucoside; Quercetol 3-glucoside; Quercetin 3-o-glucopyranoside; Quercetin 3-D-glucoside; Quercetol 3-monoglucoside; Quercetin 3-monoglucoside; Isotrifoliin; Quercetin 3-beta-glucoside; Quercetin 3-O-glucoside; quercetin-3-glucoside; Quercetin 3-beta-O-glucoside; Quercetin-3-O-glucopyranoside; UNII-6HN2PC637T; quercetin-3-O-glucoside; NSC 115918; BRN 0100989; CHEMBL250450; 6HN2PC637T; CHEBI:68352; quercetin 3-O-beta-D-glucopyran
DMX9V8K	DT	Small molecular drug
DMX9V8K	PC	5280804
DMX9V8K	MW	464.4
DMX9V8K	FM	C21H20O12
DMX9V8K	IC	InChI=1S/C21H20O12/c22-6-13-15(27)17(29)18(30)21(32-13)33-20-16(28)14-11(26)4-8(23)5-12(14)31-19(20)7-1-2-9(24)10(25)3-7/h1-5,13,15,17-18,21-27,29-30H,6H2/t13-,15-,17+,18-,21+/m1/s1
DMX9V8K	CS	C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O
DMX9V8K	IK	OVSQVDMCBVZWGM-QSOFNFLRSA-N
DMX9V8K	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMX9V8K	CA	CAS 482-35-9
DMX9V8K	CB	CHEBI:68352
DMX9V8K	DE	Thrombosis

DMJYTUQ	ID	DMJYTUQ
DMJYTUQ	DN	CR-845
DMJYTUQ	HS	Phase 2/3
DMJYTUQ	SN	Kappa opioid agonist (intravenous, pain), Cara/Ferring; Kappa opioid agonist (oral, pain), Cara/Ferring; Kappa opioid agonist (subcutaneous, pain), Cara/Ferring; CR-845 (iv infusion, pain), Cara/Ferring; CR-845 (oral capsule, pain), Cara/Ferring; CR-845 (subcutaneous, pain), Cara/Ferring; FE-202845 (iv, pain), Cara/Ferring; FE-202845 (oral, pain), Cara/Ferring; FE-202845 (sc, pain), Cara/Ferring
DMJYTUQ	CP	Cara Therapeutics Inc; cara therapeutics
DMJYTUQ	DE	Pain; Chronic pain

DMSR7D2	ID	DMSR7D2
DMSR7D2	DN	CX-516
DMSR7D2	HS	Phase 2/3
DMSR7D2	SN	Ampalex; BDP 12; CX 516; CX516; BDP-12; SPD-420; Piperidin-1-yl(quinoxalin-6-yl)methanone; 1-(6-Quinoxalinylcarbonyl)piperidine; 1-(6-quinoxalinylcarbonyl)-Piperidine; 1-(quinoxalin-6-ylcarbonyl)piperidine; 6-(piperidin-1-ylcarbonyl)quinoxaline
DMSR7D2	CP	Cortex
DMSR7D2	DT	Small molecular drug
DMSR7D2	PC	148184
DMSR7D2	MW	241.29
DMSR7D2	FM	C14H15N3O
DMSR7D2	IC	InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2
DMSR7D2	CS	C1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2
DMSR7D2	IK	ANDGGVOPIJEHOF-UHFFFAOYSA-N
DMSR7D2	IU	piperidin-1-yl(quinoxalin-6-yl)methanone
DMSR7D2	CA	CAS 154235-83-3
DMSR7D2	CB	CHEBI:34605
DMSR7D2	DE	Pervasive developmental disorder; Schizophrenia

DML906E	ID	DML906E
DML906E	DN	CY-1503
DML906E	HS	Phase 2/3
DML906E	SN	Cylexin
DML906E	CP	Epimmune Inc
DML906E	DE	Hypertension

DMYVKM5	ID	DMYVKM5
DMYVKM5	DN	Darbufelone
DMYVKM5	HS	Phase 2/3
DMYVKM5	SN	PD-136095
DMYVKM5	CP	Parke-Davis & Co
DMYVKM5	DT	Small molecular drug
DMYVKM5	PC	6444826
DMYVKM5	MW	332.5
DMYVKM5	FM	C18H24N2O2S
DMYVKM5	IC	InChI=1S/C18H24N2O2S/c1-17(2,3)11-7-10(8-12(14(11)21)18(4,5)6)9-13-15(22)20-16(19)23-13/h7-9,21H,1-6H3,(H2,19,20,22)/b13-9-
DMYVKM5	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)N=C(S2)N
DMYVKM5	IK	AKTXOQVMWSFEBQ-LCYFTJDESA-N
DMYVKM5	IU	(5Z)-2-amino-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazol-4-one
DMYVKM5	CA	CAS 139226-28-1
DMYVKM5	DE	Asthma

DMZV3SY	ID	DMZV3SY
DMZV3SY	DN	Denagliptin
DMZV3SY	HS	Phase 2/3
DMZV3SY	SN	GW 823093; GW823093; (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoro-pyrrolidine-2-carbonitrile
DMZV3SY	CP	Glaxo Smithkline
DMZV3SY	DT	Small molecular drug
DMZV3SY	PC	9887755
DMZV3SY	MW	373.4
DMZV3SY	FM	C20H18F3N3O
DMZV3SY	IC	InChI=1S/C20H18F3N3O/c21-14-5-1-12(2-6-14)18(13-3-7-15(22)8-4-13)19(25)20(27)26-11-16(23)9-17(26)10-24/h1-8,16-19H,9,11,25H2/t16-,17-,19-/m0/s1
DMZV3SY	CS	C1[C@@H](CN([C@@H]1C#N)C(=O)[C@H](C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)N)F
DMZV3SY	IK	URRAHSMDPCMOTH-LNLFQRSKSA-N
DMZV3SY	IU	(2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile
DMZV3SY	CA	CAS 483369-58-0
DMZV3SY	DE	Type-2 diabetes

DMVSIN2	ID	DMVSIN2
DMVSIN2	DN	Emapalumab
DMVSIN2	HS	Phase 2/3
DMVSIN2	SN	emapalumab; Gamifant; emapalumab-lzsg; GTPL9295; Ni-0501; NI0501
DMVSIN2	TC	Antiviral Agents
DMVSIN2	DT	Monoclonal antibody
DMVSIN2	DE	Coronavirus Disease 2019 (COVID-19)

DMH8VMP	ID	DMH8VMP
DMH8VMP	DN	Emixustat
DMH8VMP	HS	Phase 2/3
DMH8VMP	SN	EMIXUSTAT; UNII-02DZ1HBF0M; 1141777-14-1; 02DZ1HBF0M; Emixustat [USAN:INN]; (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol; Incemixustat; ACU 4229; A3V; Emixustat (USAN); SCHEMBL966515; CHEMBL2107821; DTXSID50150665; WJIGGYYSZBWCGC-MRXNPFEDSA-N; ZINC59126886; AKOS032945088; CS-6177; DB12608; HY-19720; D10348; (r)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol; 3-Amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1(R)-ol hydro -chloride
DMH8VMP	CP	Acucela Seattle, WA
DMH8VMP	DT	Small molecular drug
DMH8VMP	PC	25221720
DMH8VMP	MW	263.37
DMH8VMP	FM	C16H25NO2
DMH8VMP	IC	InChI=1S/C16H25NO2/c17-10-9-16(18)14-7-4-8-15(11-14)19-12-13-5-2-1-3-6-13/h4,7-8,11,13,16,18H,1-3,5-6,9-10,12,17H2/t16-/m1/s1
DMH8VMP	CS	C1CCC(CC1)COC2=CC=CC(=C2)[C@@H](CCN)O
DMH8VMP	IK	WJIGGYYSZBWCGC-MRXNPFEDSA-N
DMH8VMP	IU	(1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol
DMH8VMP	CA	CAS 1141777-14-1
DMH8VMP	DE	Age-related macular degeneration; Proliferative diabetic retinopathy

DMOYE70	ID	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	HS	Phase 2/3
DMOYE70	SN	Fexinidazole (human African trypanosomiasis); Fexinidazole (African sleeping sickness), Drugs for Neglected Diseases initiative; Fexinidazole (HAT), Drugs for Neglected Diseases initiative; Fexinidazole (human African trypanosomiasis), Drugs for Neglected Diseases initiative
DMOYE70	CP	Drugs for Neglected Diseases initiative
DMOYE70	DT	Small molecular drug
DMOYE70	PC	68792
DMOYE70	MW	279.32
DMOYE70	FM	C12H13N3O3S
DMOYE70	IC	InChI=1S/C12H13N3O3S/c1-14-11(13-7-12(14)15(16)17)8-18-9-3-5-10(19-2)6-4-9/h3-7H,8H2,1-2H3
DMOYE70	CS	CN1C(=CN=C1COC2=CC=C(C=C2)SC)[N+](=O)[O-]
DMOYE70	IK	MIWWSGDADVMLTG-UHFFFAOYSA-N
DMOYE70	IU	1-methyl-2-[(4-methylsulfanylphenoxy)methyl]-5-nitroimidazole
DMOYE70	CA	CAS 59729-37-2
DMOYE70	DE	Trypanosomiasis

DMH7CSQ	ID	DMH7CSQ
DMH7CSQ	DN	Gavilimomab
DMH7CSQ	HS	Phase 2/3
DMH7CSQ	SN	ABX-CBL; CBL-1
DMH7CSQ	CP	Abgenix Inc
DMH7CSQ	DT	Antibody
DMH7CSQ	DE	Graft-versus-host disease

DM0JETC	ID	DM0JETC
DM0JETC	DN	Genistein
DM0JETC	HS	Phase 2/3
DM0JETC	SN	Bonistein; GEN; Genestein; Genisteol; Genisterin; Prunetol; Sophoricol; Differenol A; G 6649; G10000; IN1327; NPI 031L; STO514; TNP00151; GENISTEIN (ENDOCRINE DISRUPTER); Lactoferrin-genistein; PTI G4660 (Genistein); PTI-G4660; SIPI 807-1; C.I. 75610; SIPI-9764-I; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; ,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
DM0JETC	CP	DSM Nutritional Products
DM0JETC	DT	Small molecular drug
DM0JETC	PC	5280961
DM0JETC	MW	270.24
DM0JETC	FM	C15H10O5
DM0JETC	IC	InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
DM0JETC	CS	C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
DM0JETC	IK	TZBJGXHYKVUXJN-UHFFFAOYSA-N
DM0JETC	IU	5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
DM0JETC	CA	CAS 446-72-0
DM0JETC	CB	CHEBI:28088
DM0JETC	DE	Prostate cancer; Menopause symptom

DMW7TZV	ID	DMW7TZV
DMW7TZV	DN	GS-6207
DMW7TZV	HS	Phase 2/3
DMW7TZV	SN	2189684-45-3; N-[(1R)-1-[3-[4-Chloro-3-(cyclopropylsulfonylamino)-1-(2,2-difluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2R,4S)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide
DMW7TZV	CP	Gilead Sciences
DMW7TZV	DT	Small molecular drug
DMW7TZV	PC	138059678
DMW7TZV	MW	958.3
DMW7TZV	FM	C41H36ClF8N7O5S2
DMW7TZV	IC	InChI=1S/C41H36ClF8N7O5S2/c1-40(2,63(3,59)60)11-10-22-4-7-24(25-8-9-28(42)33-36(25)56(17-30(45)46)54-39(33)55-64(61,62)23-5-6-23)34(51-22)29(14-19-12-20(43)15-21(44)13-19)52-31(58)18-57-37-32(35(53-57)38(47)48)26-16-27(26)41(37,49)50/h4,7-9,12-13,15,23,26-27,29-30,38H,5-6,14,16-18H2,1-3H3,(H,52,58)(H,54,55)/t26-,27+,29-/m1/s1
DMW7TZV	CS	CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)F)NS(=O)(=O)C4CC4)[C@@H](CC5=CC(=CC(=C5)F)F)NC(=O)CN6C7=C([C@@H]8C[C@@H]8C7(F)F)C(=N6)C(F)F)S(=O)(=O)C
DMW7TZV	IK	CPCUUUACFKQOHY-IUAQSZDVSA-N
DMW7TZV	IU	N-[(1R)-1-[3-[4-chloro-3-(cyclopropylsulfonylamino)-1-(2,2-difluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2R,4S)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide
DMW7TZV	DE	Human immunodeficiency virus infection

DMMTL7V	ID	DMMTL7V
DMMTL7V	DN	Hemoglobin raffimer
DMMTL7V	HS	Phase 2/3
DMMTL7V	SN	Hemolink; Cross-linked hemoglobin, Hemosol
DMMTL7V	CP	Ontario Inc
DMMTL7V	DE	Anemia

DMPLQ1V	ID	DMPLQ1V
DMPLQ1V	DN	IFX-1
DMPLQ1V	HS	Phase 2/3
DMPLQ1V	SN	IFX-1 mab
DMPLQ1V	TC	Antiviral Agents
DMPLQ1V	DT	Monoclonal antibody
DMPLQ1V	DE	Coronavirus Disease 2019 (COVID-19)

DMONWJ4	ID	DMONWJ4
DMONWJ4	DN	Imetelstat
DMONWJ4	HS	Phase 2/3
DMONWJ4	SN	Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448
DMONWJ4	CP	Geron
DMONWJ4	DT	Small molecular drug
DMONWJ4	PC	71587831
DMONWJ4	MW	4610
DMONWJ4	FM	C148H211N68O53P13S13
DMONWJ4	IC	InChI=1S/C148H211N68O53P13S13/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-97(218)160-34-69(217)38-255-282(242,295)256-51-95-74(25-102(261-95)207-37-68(4)136(221)191-148(207)229)195-274(234,287)249-45-89-78(29-106(264-89)212-61-175-115-124(155)165-56-170-129(115)212)199-277(237,290)252-48-92-81(32-109(267-92)215-64-178-118-132(215)183-143(158)187-139(118)224)202-280(240,293)254-50-94-82(33-110(269-94)216-65-179-119-133(216)184-144(159)188-140(119)225)203-281(241,294)253-49-93-79(30-107(268-93)213-62-176-116-130(213)181-141(156)185-137(116)222)200-278(238,291)246-42-86-72(23-100(260-86)205-35-66(2)134(219)189-146(205)227)193-272(232,285)245-41-85-73(24-101(259-85)206-36-67(3)135(220)190-147(206)228)194-273(233,286)248-44-88-77(28-105(263-88)211-60-174-114-123(154)164-55-169-128(114)211)198-276(236,289)251-47-91-80(31-108(266-91)214-63-177-117-131(214)182-142(157)186-138(117)223)201-279(239,292)250-46-90-76(27-104(265-90)210-59-173-113-122(153)163-54-168-127(113)210)197-275(235,288)244-40-84-71(22-99(258-84)204-20-19-96(150)180-145(204)226)192-271(231,284)247-43-87-75(26-103(262-87)209-58-172-112-121(152)162-53-167-126(112)209)196-270(230,283)243-39-83-70(149)21-98(257-83)208-57-171-111-120(151)161-52-166-125(111)208/h19-20,35-37,52-65,69-95,98-110,217H,5-18,21-34,38-51,149H2,1-4H3,(H,160,218)(H,242,295)(H2,150,180,226)(H2,151,161,166)(H2,152,162,167)(H2,153,163,168)(H2,154,164,169)(H2,155,165,170)(H,189,219,227)(H,190,220,228)(H,191,221,229)(H2,192,231,284)(H2,193,232,285)(H2,194,233,286)(H2,195,234,287)(H2,196,230,283)(H2,197,235,288)(H2,198,236,289)(H2,199,237,290)(H2,200,238,291)(H2,201,239,292)(H2,202,240,293)(H2,203,241,294)(H3,156,181,185,222)(H3,157,182,186,223)(H3,158,183,187,224)(H3,159,184,188,225)/t69?,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,270?,271?,272?,273?,274?,275?,276?,277?,278?,279?,280?,281?,282?/m0/s1
DMONWJ4	CS	CCCCCCCCCCCCCCCC(=O)NCC(COP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)NP(=S)(O)OC[C@@H]3[C@H](C[C@@H](O3)N4C=NC5=C(N=CN=C54)N)NP(=S)(O)OC[C@@H]6[C@H](C[C@@H](O6)N7C=NC8=C7N=C(NC8=O)N)NP(=S)(O)OC[C@@H]9[C@H](C[C@@H](O9)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)N)S)O
DMONWJ4	IK	LVZYXEALRXBLJZ-ISQYCPACSA-N
DMONWJ4	IU	N-[3-[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-amino-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-sulfanylphosphoryl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2-hydroxypropyl]hexadecanamide
DMONWJ4	CA	CAS 868169-64-6
DMONWJ4	DE	Multiple myeloma; Breast cancer; Non-small-cell lung cancer; Essential thrombocythemia; Myelodysplastic syndrome; Myelofibrosis

DMIUA3M	ID	DMIUA3M
DMIUA3M	DN	Imprime PGG
DMIUA3M	HS	Phase 2/3
DMIUA3M	SN	Imprime PGG (TN)
DMIUA3M	CP	Biothera
DMIUA3M	DE	Breast cancer; Colorectal cancer; Head and neck cancer; Melanoma; Non-hodgkin lymphoma

DM5UJ9P	ID	DM5UJ9P
DM5UJ9P	DN	IMU-838
DM5UJ9P	HS	Phase 2/3
DM5UJ9P	SN	Vidofludimus; 717824-30-1; 4SC-101; SC12267; UNII-8Y1PJ3VG81; SC 12267; CHEMBL197194; 8Y1PJ3VG81; Vidofludimus(4SC-101; SC12267); Vidofludimus [INN]; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; IMU-838; DTXSID50431325; HMS3740I15; AOB87354; BCP14555; ZINC14960644; s7262; AK; Vidofludimus
DM5UJ9P	TC	Antiviral Agents
DM5UJ9P	DT	Small molecular drug
DM5UJ9P	PC	9820008
DM5UJ9P	MW	355.4
DM5UJ9P	FM	C20H18FNO4
DM5UJ9P	IC	InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
DM5UJ9P	CS	COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
DM5UJ9P	IK	XPRDUGXOWVXZLL-UHFFFAOYSA-N
DM5UJ9P	IU	2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
DM5UJ9P	CA	CAS 717824-30-1
DM5UJ9P	DE	Coronavirus Disease 2019 (COVID-19)

DMC3794	ID	DMC3794
DMC3794	DN	Indium-111
DMC3794	HS	Phase 2/3
DMC3794	SN	ABT-806
DMC3794	CP	Abbott Laboratories Abbott
DMC3794	DT	Antibody
DMC3794	DE	Solid tumour/cancer

DMGPJ5U	ID	DMGPJ5U
DMGPJ5U	DN	JNJ-54861911
DMGPJ5U	HS	Phase 2/3
DMGPJ5U	CP	Janssen research & development
DMGPJ5U	PC	68254185
DMGPJ5U	MW	367.4
DMGPJ5U	FM	C18H14FN5OS
DMGPJ5U	IC	InChI=1S/C18H14FN5OS/c1-18(6-7-26-17(21)24-18)13-8-12(3-4-14(13)19)23-16(25)15-5-2-11(9-20)10-22-15/h2-8,10H,1H3,(H2,21,24)(H,23,25)/t18-/m0/s1
DMGPJ5U	CS	C[C@]1(C=CSC(=N1)N)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F
DMGPJ5U	IK	VLLFGVHGKLDDLW-SFHVURJKSA-N
DMGPJ5U	IU	N-[3-[(4S)-2-amino-4-methyl-1,3-thiazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
DMGPJ5U	CA	CAS 1200493-78-2
DMGPJ5U	DE	Alzheimer disease

DMBJ4IZ	ID	DMBJ4IZ
DMBJ4IZ	DN	LECOZOTAN HYDROCHLORIDE
DMBJ4IZ	HS	Phase 2/3
DMBJ4IZ	SN	Lecozotan hydrochloride < USAN; SRA-333; 4-Cyano-N-[2(R)-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-(2-pyridyl)benzamide hydrochloride
DMBJ4IZ	DT	Small molecular drug
DMBJ4IZ	PC	11156648
DMBJ4IZ	MW	520
DMBJ4IZ	FM	C28H30ClN5O3
DMBJ4IZ	IC	InChI=1S/C28H29N5O3.ClH/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23;/h2-12,21H,13-18,20H2,1H3;1H/t21-;/m1./s1
DMBJ4IZ	CS	C[C@H](CN(C1=CC=CC=N1)C(=O)C2=CC=C(C=C2)C#N)N3CCN(CC3)C4=C5C(=CC=C4)OCCO5.Cl
DMBJ4IZ	IK	GXYZREDEYDFJPT-ZMBIFBSDSA-N
DMBJ4IZ	IU	4-cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-pyridin-2-ylbenzamide;hydrochloride
DMBJ4IZ	CA	CAS 433282-68-9
DMBJ4IZ	DE	Cognitive impairment

DMEUGZL	ID	DMEUGZL
DMEUGZL	DN	Legumain-cleavable doxorubicin prodrugs
DMEUGZL	HS	Phase 2/3
DMEUGZL	SN	Legubicin; LEG-2; LEG-3; Legumain-cleavable doxorubicin prodrugs (cancer); Legumain-cleavabledoxorubicin prodrugs (cancer), Affinity Pharmaceuticals
DMEUGZL	CP	Scripps Research Institute
DMEUGZL	DE	Solid tumour/cancer

DM4OYXE	ID	DM4OYXE
DM4OYXE	DN	LIAROZOLE
DM4OYXE	HS	Phase 2/3
DM4OYXE	SN	Liarozole; Liazal; 115575-11-6; R-75251; LIAROZOLE FUMARATE; Liarozole [INN:BAN]; Liarozolum [INN-Latin]; Liarozol [INN-Spanish]; R 75251; R-61405; R085246; R 61405; R-085246; R 085246; 6-((3-chlorophenyl)(1H-imidazol-1-yl)methyl)-1H-benzo[d]imidazole; UNII-17NYD2210B; CHEMBL389433; UNII-090Y06W08H; 17NYD2210B; 090Y06W08H; Liarozolum; Liarozol; 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-; NCGC00181034-01; Liarozole, (-)-; Liarozole, (+)-; AC1L1TNN; AC1Q3M3B; SCHEMBL18597; GTPL5210; SCHEMBL15944205; DTXSID9048277
DM4OYXE	DT	Small molecular drug
DM4OYXE	PC	60652
DM4OYXE	MW	308.8
DM4OYXE	FM	C17H13ClN4
DM4OYXE	IC	InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)
DM4OYXE	CS	C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4
DM4OYXE	IK	UGFHIPBXIWJXNA-UHFFFAOYSA-N
DM4OYXE	IU	6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole
DM4OYXE	CA	CAS 115575-11-6
DM4OYXE	CB	CHEBI:135316
DM4OYXE	DE	Dermatological disease

DMI215P	ID	DMI215P
DMI215P	DN	Lopinavir + ritonavir + interferon beta-1b
DMI215P	HS	Phase 2/3
DMI215P	SN	Aluviran + norvir + betaseron
DMI215P	TC	Antiviral Agents
DMI215P	DT	Combination drug
DMI215P	DE	Middle East Respiratory Syndrome (MERS)

DMP8HW1	ID	DMP8HW1
DMP8HW1	DN	LY2157299
DMP8HW1	HS	Phase 2/3
DMP8HW1	SN	Galunisertib; 700874-72-2; LY2157299; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
DMP8HW1	CP	Eli Lilly
DMP8HW1	DT	Small molecular drug
DMP8HW1	PC	10090485
DMP8HW1	MW	369.4
DMP8HW1	FM	C22H19N5O
DMP8HW1	IC	InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)
DMP8HW1	CS	CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N
DMP8HW1	IK	IVRXNBXKWIJUQB-UHFFFAOYSA-N
DMP8HW1	IU	4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
DMP8HW1	CA	CAS 700874-72-2
DMP8HW1	CB	CHEBI:137064
DMP8HW1	DE	Arteriosclerosis; Glioma; Hepatocellular carcinoma; Pancreatic cancer; Solid tumour/cancer; Non-small-cell lung cancer

DMUQWRD	ID	DMUQWRD
DMUQWRD	DN	LYS-SAF302
DMUQWRD	HS	Phase 2/3
DMUQWRD	SN	SRP-9002
DMUQWRD	CP	Lysogene; Sarepta Therapeutics
DMUQWRD	DT	Gene therapy
DMUQWRD	DE	Mucopolysaccharidosis

DM948AP	ID	DM948AP
DM948AP	DN	MAb114
DM948AP	HS	Phase 2/3
DM948AP	CP	Ridgeback Biotherapeutics
DM948AP	DT	Antibody
DM948AP	DE	Ebola virus infection

DMONYS9	ID	DMONYS9
DMONYS9	DN	MBX-102
DMONYS9	HS	Phase 2/3
DMONYS9	SN	Arhalofenate; Mbx-102; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV
DMONYS9	CP	Metabolex
DMONYS9	DT	Small molecular drug
DMONYS9	PC	12082259
DMONYS9	MW	415.8
DMONYS9	FM	C19H17ClF3NO4
DMONYS9	IC	InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1
DMONYS9	CS	CC(=O)NCCOC(=O)[C@@H](C1=CC=C(C=C1)Cl)OC2=CC=CC(=C2)C(F)(F)F
DMONYS9	IK	BJBCSGQLZQGGIQ-QGZVFWFLSA-N
DMONYS9	IU	2-acetamidoethyl (2R)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate
DMONYS9	CA	CAS 24136-23-0
DMONYS9	DE	Gout

DMNTCV4	ID	DMNTCV4
DMNTCV4	DN	MBX-8025
DMNTCV4	HS	Phase 2/3
DMNTCV4	SN	Ppar; A agonist 2; SCHEMBL4950228; CHEMBL3545019; XJHXZGHPCAKRFK-UHFFFAOYSA-N; HY-100120; CS-0018099; {2-Methyl-4-[5-methyl-2-(4-trifluoromethyl-phenyl)-2H-[1,2,3]triazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid
DMNTCV4	CP	Metabolex
DMNTCV4	DT	Small molecular drug
DMNTCV4	PC	11236126
DMNTCV4	MW	444.5
DMNTCV4	FM	C21H23F3O5S
DMNTCV4	IC	InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1
DMNTCV4	CS	CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C
DMNTCV4	IK	JWHYSEDOYMYMNM-QGZVFWFLSA-N
DMNTCV4	IU	2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid
DMNTCV4	CA	CAS 851528-79-5
DMNTCV4	DE	Obesity; Familial hypercholesterolemia; Primary biliary cholangitis

DMBIO6E	ID	DMBIO6E
DMBIO6E	DN	Meclinertant
DMBIO6E	HS	Phase 2/3
DMBIO6E	SN	Reminertant; SR 48692; SR48692; SR-48692; 2-(((1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)tricyclo(3.3.1.1(sup 3,7))decane-2-carboxylic acid; 2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid;2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
DMBIO6E	CP	Sanofi-aventis
DMBIO6E	TC	Anticancer Agents
DMBIO6E	DT	Small molecular drug
DMBIO6E	PC	119192
DMBIO6E	MW	587.1
DMBIO6E	FM	C32H31ClN4O5
DMBIO6E	IC	InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)
DMBIO6E	CS	COC1=C(C(=CC=C1)OC)C2=CC(=NN2C3=C4C=CC(=CC4=NC=C3)Cl)C(=O)NC5(C6CC7CC(C6)CC5C7)C(=O)O
DMBIO6E	IK	DYLJVOXRWLXDIG-UHFFFAOYSA-N
DMBIO6E	IU	2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
DMBIO6E	CA	CAS 146362-70-1
DMBIO6E	CB	CHEBI:125516
DMBIO6E	DE	Inflammatory bowel disease

DMFE0P1	ID	DMFE0P1
DMFE0P1	DN	Metformin glycinate
DMFE0P1	HS	Phase 2/3
DMFE0P1	SN	DMMET-01; Metformin glycinate (diabetes); Type 2 diabetes therapy, Laboratorios Silanes; Metformin glycinate (diabetes), Laboratorios Silanes
DMFE0P1	CP	Laboratorios Silanes SA De CV
DMFE0P1	DT	Small molecular drug
DMFE0P1	PC	44520175
DMFE0P1	MW	204.23
DMFE0P1	FM	C6H16N6O2
DMFE0P1	IC	InChI=1S/C4H11N5.C2H5NO2/c1-9(2)4(7)8-3(5)6;3-1-2(4)5/h1-2H3,(H5,5,6,7,8);1,3H2,(H,4,5)
DMFE0P1	CS	CN(C)C(=N)N=C(N)N.C(C(=O)O)N
DMFE0P1	IK	KOFRCHIVYXPUNL-UHFFFAOYSA-N
DMFE0P1	IU	2-aminoacetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine
DMFE0P1	CA	CAS 121369-64-0
DMFE0P1	DE	Type-2 diabetes

DM752PU	ID	DM752PU
DM752PU	DN	MGCD516
DM752PU	HS	Phase 2/3
DM752PU	SN	Sitravatinib
DM752PU	CP	Mirati therapeutics
DM752PU	PC	25212148
DM752PU	MW	629.7
DM752PU	FM	C33H29F2N5O4S
DM752PU	IC	InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)
DM752PU	CS	COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
DM752PU	IK	WLAVZAAODLTUSW-UHFFFAOYSA-N
DM752PU	IU	1-N'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DM752PU	CA	CAS 1123837-84-2
DM752PU	DE	Non-small-cell lung cancer; Solid tumour/cancer; Breast cancer

DM2YNMI	ID	DM2YNMI
DM2YNMI	DN	MK-1654
DM2YNMI	HS	Phase 2/3
DM2YNMI	CP	Merck
DM2YNMI	DT	Antibody
DM2YNMI	DE	Respiratory syncytial virus infection

DMDQOWT	ID	DMDQOWT
DMDQOWT	DN	MOR-208
DMDQOWT	HS	Phase 2/3
DMDQOWT	SN	XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor
DMDQOWT	CP	Morphosys
DMDQOWT	DT	Antibody
DMDQOWT	DE	Autoimmune diabetes; Diffuse large B-cell lymphoma; B-cell chronic lymphocytic leukaemia; Chronic lymphocytic leukaemia; Non-hodgkin lymphoma

DMKMZW2	ID	DMKMZW2
DMKMZW2	DN	MTC-DOX
DMKMZW2	HS	Phase 2/3
DMKMZW2	SN	MTC-doxorubicin
DMKMZW2	CP	FeRx
DMKMZW2	DE	Liver cancer

DM16PWF	ID	DM16PWF
DM16PWF	DN	N1-methylnicotinamide
DM16PWF	HS	Phase 2/3
DM16PWF	SN	Trigonellinamide; 1-methylnicotinamide; N(1)-Methylnicotinamide; N1-Methylnicotinamide; 3-(Aminocarbonyl)-1-methylpyridinium; 1-Methyl nicotinamide; 3-carbamoyl-1-methylpyridinium; 3106-60-3; Pyridinium, 3-carbamoyl-1-methyl-; UNII-UM47085BXC; N(sup 1)-Methylnicotinamide; 3-carbamoyl-1-methylpyridin-1-ium; BRN 3540351; 1-methylpyridine-3-carboxamide; UM47085BXC; CHEBI:16797; 1-methylpyridin-1-ium-3-carboxamide; CHEMBL1209652; Trigonellamide; Pyridinium, 3-(aminocarbonyl)-1-methyl-; 1-methyl-3-carbamoylpyridinium; 8GC; I-methyl n
DM16PWF	DT	Small molecular drug
DM16PWF	PC	457
DM16PWF	MW	137.16
DM16PWF	FM	C7H9N2O+
DM16PWF	IC	InChI=1S/C7H8N2O/c1-9-4-2-3-6(5-9)7(8)10/h2-5H,1H3,(H-,8,10)/p+1
DM16PWF	CS	C[N+]1=CC=CC(=C1)C(=O)N
DM16PWF	IK	LDHMAVIPBRSVRG-UHFFFAOYSA-O
DM16PWF	IU	1-methylpyridin-1-ium-3-carboxamide
DM16PWF	CA	CAS 3106-60-3
DM16PWF	CB	CHEBI:16797
DM16PWF	DE	Hyperlipidemia

DM8D6O2	ID	DM8D6O2
DM8D6O2	DN	Nafamostat
DM8D6O2	HS	Phase 2/3
DM8D6O2	SN	FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum
DM8D6O2	TC	Antiviral Agents
DM8D6O2	DT	Small molecular drug
DM8D6O2	PC	4413
DM8D6O2	MW	347.4
DM8D6O2	FM	C19H17N5O2
DM8D6O2	IC	InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
DM8D6O2	CS	C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
DM8D6O2	IK	MQQNFDZXWVTQEH-UHFFFAOYSA-N
DM8D6O2	IU	(6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
DM8D6O2	CA	CAS 81525-10-2
DM8D6O2	CB	CHEBI:135466
DM8D6O2	DE	Pancreatitis; Sepsis; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS)

DMD5AEB	ID	DMD5AEB
DMD5AEB	DN	NAL-GLU
DMD5AEB	HS	Phase 2/3
DMD5AEB	SN	[Ac-D2Nal1,D4ClPhe2,D3Pal3,Arg5,DGlu5(anisole adduct),DAla10]-GnRH; Acetyl-D-2-naphthylalanyl-D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L-arginyl-[4-(4-methoxybenzoyl)-D-2-aminobutyryl]-L-leucyl-L-arginyl-L-prolyl-D-alanylamide; N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-arginyl-5-(4-methoxyphenyl)-5-oxo-D-norvalyl-L-leucyl-L-arginyl-L-prolyl-D-alanylamide
DMD5AEB	PC	44412112
DMD5AEB	MW	343.4
DMD5AEB	FM	C18H21N3O4
DMD5AEB	IC	InChI=1S/C18H21N3O4/c19-14(17(23)21-15(18(24)25)7-8-16(20)22)10-11-5-6-12-3-1-2-4-13(12)9-11/h1-6,9,14-15H,7-8,10,19H2,(H2,20,22)(H,21,23)(H,24,25)/t14-,15-/m0/s1
DMD5AEB	CS	C1=CC=C2C=C(C=CC2=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DMD5AEB	IK	VSZVSSYQFUFEQG-GJZGRUSLSA-N
DMD5AEB	IU	(2S)-5-amino-2-[[(2S)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-5-oxopentanoic acid
DMD5AEB	DE	Prostate cancer

DM901ZW	ID	DM901ZW
DM901ZW	DN	Naptumomab estafenatox
DM901ZW	HS	Phase 2/3
DM901ZW	CP	Active Biotech
DM901ZW	DE	Solid tumour/cancer

DM3MJUS	ID	DM3MJUS
DM3MJUS	DN	NBTX-001
DM3MJUS	HS	Phase 2/3
DM3MJUS	CP	Nobilis Therapeutics Portland, OR
DM3MJUS	DE	Panic disorder; Post-traumatic stress disorder

DM0798Z	ID	DM0798Z
DM0798Z	DN	NLG8189
DM0798Z	HS	Phase 2/3
DM0798Z	SN	1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
DM0798Z	CP	NewLink Genetics
DM0798Z	DT	Small molecular drug
DM0798Z	PC	405012
DM0798Z	MW	218.25
DM0798Z	FM	C12H14N2O2
DM0798Z	IC	InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m1/s1
DM0798Z	CS	CN1C=C(C2=CC=CC=C21)C[C@H](C(=O)O)N
DM0798Z	IK	ZADWXFSZEAPBJS-SNVBAGLBSA-N
DM0798Z	IU	(2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid
DM0798Z	CA	CAS 110117-83-4
DM0798Z	DE	Acute myeloid leukaemia; Melanoma; Brain cancer; Pancreatic cancer; Prostate cancer

DM4H78P	ID	DM4H78P
DM4H78P	DN	NT-501
DM4H78P	HS	Phase 2/3
DM4H78P	SN	NTC-201E; CNTF cell implant (ECT), Neurotech; CNTF ophthalmic cell implant (retinitis pigmentosa), Neurotech; Cell implant (ciliary neurotrophic factor), Neurotech; Cell implant (retinitis pigmentosa, ECT), Neurotech
DM4H78P	CP	Amgen Inc
DM4H78P	DE	Ocular inflammation; Macular telangiectasia type 2; Retinitis pigmentosa

DMT13UA	ID	DMT13UA
DMT13UA	DN	Olokizumab
DMT13UA	HS	Phase 2/3
DMT13UA	SN	OLOKIZUMAB; CHEMBL1743050; CDP-6038
DMT13UA	TC	Antiviral Agents
DMT13UA	DT	Monoclonal antibody
DMT13UA	DE	Coronavirus Disease 2019 (COVID-19)

DMTIESG	ID	DMTIESG
DMTIESG	DN	Omburtamab
DMTIESG	HS	Phase 2/3
DMTIESG	CP	Y-mAbs Therapeutics
DMTIESG	DT	Antibody
DMTIESG	DE	Neuroblastoma

DMPDA17	ID	DMPDA17
DMPDA17	DN	Omburtamab I-131
DMPDA17	HS	Phase 2/3
DMPDA17	CP	Y-mAbs Therapeutics New York, NY
DMPDA17	DE	Small round cell desmoplastic tumour; Neuroblastoma

DMCA2PJ	ID	DMCA2PJ
DMCA2PJ	DN	ONO-2506
DMCA2PJ	HS	Phase 2/3
DMCA2PJ	SN	(2R)-2-Propyloctanoic acid; Arundic acid; 185517-21-9; (R)-2-PROPYLOCTANOIC ACID; Proglia; Cereact; ONO 2506; R-(-)-Arundic Acid; UNII-F2628ZD0FO; MK-0724; (R)-(-)-2-Propyloctanoic Acid; F2628ZD0FO; NCGC00183861-01; Acide arundique; Acido arzndico; Acidum arundicum; Arundic acid [INN]; Arocyte; Acide arundique [INN-French]; Acidum arundicum [INN-Latin]; Arundic acid (JAN/INN); Acido arzndico [INN-Spanish]; ONO-2506PO; MK 0724; AC1L4LMD; AC1Q5QIF; SCHEMBL4365; DSSTox_RID_83036; DSSTox_CID_28767; DSSTox_GSID_48841; ONO 2506PO;  Arocyte; Ono2506; Acido arundico [INN-Spanish]; 2-Propyloctanoic acid; FR149175
DMCA2PJ	CP	Ono Pharmaceuticals
DMCA2PJ	DT	Small molecular drug
DMCA2PJ	PC	208925
DMCA2PJ	MW	186.29
DMCA2PJ	FM	C11H22O2
DMCA2PJ	IC	InChI=1S/C11H22O2/c1-3-5-6-7-9-10(8-4-2)11(12)13/h10H,3-9H2,1-2H3,(H,12,13)/t10-/m1/s1
DMCA2PJ	CS	CCCCCC[C@@H](CCC)C(=O)O
DMCA2PJ	IK	YCYMCMYLORLIJX-SNVBAGLBSA-N
DMCA2PJ	IU	(2R)-2-propyloctanoic acid
DMCA2PJ	CA	CAS 185517-21-9
DMCA2PJ	DE	Stroke; Type-2 diabetes

DMCTRLN	ID	DMCTRLN
DMCTRLN	DN	OT-101
DMCTRLN	HS	Phase 2/3
DMCTRLN	CP	Mateon/Oncotelic
DMCTRLN	DT	Antisense oligonucleotide
DMCTRLN	DE	Melanoma; Merkel cell carcinoma; Pancreatic cancer; Recurrent glioblastoma; Coronavirus Disease 2019 (COVID-19)

DMURH4X	ID	DMURH4X
DMURH4X	DN	Oxypurinol
DMURH4X	HS	Phase 2/3
DMURH4X	SN	Oxypurinol (intravenous)
DMURH4X	CP	Johns Hopkins University
DMURH4X	DT	Small molecular drug
DMURH4X	PC	135398752
DMURH4X	MW	152.11
DMURH4X	FM	C5H4N4O2
DMURH4X	IC	InChI=1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11)
DMURH4X	CS	C1=NNC2=C1C(=O)NC(=O)N2
DMURH4X	IK	HXNFUBHNUDHIGC-UHFFFAOYSA-N
DMURH4X	IU	1,7-dihydropyrazolo[3,4-d]pyrimidine-4,6-dione
DMURH4X	CA	CAS 2465-59-0
DMURH4X	CB	CHEBI:28315
DMURH4X	DE	Heart failure

DM0NZDT	ID	DM0NZDT
DM0NZDT	DN	Pactimibe
DM0NZDT	HS	Phase 2/3
DM0NZDT	SN	Pactimibe; 189198-30-9; UNII-D874R9PZ9T; D874R9PZ9T; CHEMBL478858; Pactimibe [INN:BAN]; [7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid; (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid; AC1MIXTD; SCHEMBL282098; CTK0H7032; DTXSID80172315; TXIIZHHIOHVWJD-UHFFFAOYSA-N; ZINC1545445; BDBM50263192; DB12971; 2-[7-(2,2-Dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo L-5-yl]acetic acid; AN-30445; 198P309
DM0NZDT	DT	Small molecular drug
DM0NZDT	PC	3081927
DM0NZDT	MW	416.6
DM0NZDT	FM	C25H40N2O3
DM0NZDT	IC	InChI=1S/C25H40N2O3/c1-7-8-9-10-11-12-14-27-15-13-19-17(2)20(16-21(28)29)18(3)22(23(19)27)26-24(30)25(4,5)6/h7-16H2,1-6H3,(H,26,30)(H,28,29)
DM0NZDT	CS	CCCCCCCCN1CCC2=C(C(=C(C(=C21)NC(=O)C(C)(C)C)C)CC(=O)O)C
DM0NZDT	IK	TXIIZHHIOHVWJD-UHFFFAOYSA-N
DM0NZDT	IU	2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid
DM0NZDT	CA	CAS 189198-30-9
DM0NZDT	DE	Arteriosclerosis

DMRZ1F2	ID	DMRZ1F2
DMRZ1F2	DN	Padsevonil
DMRZ1F2	HS	Phase 2/3
DMRZ1F2	SN	1294000-61-5; UNII-0R1HN52K0N; UCB0942; UCB1415943-000; (R)-4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one; Padsevonil [INN]; Padsevonil [USAN]; Padsevonil (JAN/USAN); SCHEMBL1672843; CHEMBL4297521; UCB-0942; WHO 10384; DB14977; SB18725; HY-109009; CS-0030507; D11842; Q27237119; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)-2-pyrrolidinone; 2-Pyrrolidinone, 4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)-1,3,4-thiadiazol-5-yl)methyl)-, (4R)-
DMRZ1F2	CP	UCB
DMRZ1F2	DT	Small molecular drug
DMRZ1F2	PC	52911611
DMRZ1F2	MW	432.8
DMRZ1F2	FM	C14H14ClF5N4O2S
DMRZ1F2	IC	InChI=1S/C14H14ClF5N4O2S/c1-26-6-9-22-24-8(11(14(18,19)20)21-12(24)27-9)5-23-4-7(2-10(23)25)3-13(15,16)17/h7H,2-6H2,1H3/t7-/m1/s1
DMRZ1F2	CS	COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3C[C@H](CC3=O)CC(F)(F)Cl
DMRZ1F2	IK	DCXFIOLWWRXEQH-SSDOTTSWSA-N
DMRZ1F2	IU	(4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one
DMRZ1F2	CA	CAS 1294000-61-5
DMRZ1F2	DE	Epilepsy

DMHWY2G	ID	DMHWY2G
DMHWY2G	DN	Pagoclone
DMHWY2G	HS	Phase 2/3
DMHWY2G	SN	IP-456; RP-59037; RP-62955
DMHWY2G	CP	Rhone-Poulenc SA
DMHWY2G	DT	Small molecular drug
DMHWY2G	PC	131664
DMHWY2G	MW	407.9
DMHWY2G	FM	C23H22ClN3O2
DMHWY2G	IC	InChI=1S/C23H22ClN3O2/c1-14(2)7-10-16(28)13-19-17-5-3-4-6-18(17)23(29)27(19)21-12-9-15-8-11-20(24)25-22(15)26-21/h3-6,8-9,11-12,14,19H,7,10,13H2,1-2H3
DMHWY2G	CS	CC(C)CCC(=O)CC1C2=CC=CC=C2C(=O)N1C3=NC4=C(C=C3)C=CC(=N4)Cl
DMHWY2G	IK	HIUPRQPBWVEQJJ-UHFFFAOYSA-N
DMHWY2G	IU	2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one
DMHWY2G	CA	CAS 133737-32-3
DMHWY2G	DE	Anxiety disorder

DMBJ15R	ID	DMBJ15R
DMBJ15R	DN	Pexacerfont
DMBJ15R	HS	Phase 2/3
DMBJ15R	SN	PEXACERFONT; 459856-18-9; UNII-LF1VBG4ZUK; CRF1 ANTAGONIST; LF1VBG4ZUK; BMS-562086; Pexacerfont [USAN:INN]; BMS 562086; Pexacerfont (USAN/INN); CHEMBL482950; SCHEMBL5235999; BDBM29490; DTXSID60196675; CS-6630; DB12572; HY-12127; D10022; Pyrazolo[1,5-a]-1,3,5-triazine, 13-15; BMS562086;BMS 562086;BMS-562086; Pyrazolo(1,5-a)-1,3,5-triazin-4-amine, 8-(6-methoxy-2-methyl-3-pyridinyl)-2,7-dimethyl-N-((1R)-1-methylpropyl)-
DMBJ15R	CP	Bristol-Myers Squibb
DMBJ15R	DT	Small molecular drug
DMBJ15R	PC	9884366
DMBJ15R	MW	340.4
DMBJ15R	FM	C18H24N6O
DMBJ15R	IC	InChI=1S/C18H24N6O/c1-7-10(2)19-18-22-13(5)21-17-16(12(4)23-24(17)18)14-8-9-15(25-6)20-11(14)3/h8-10H,7H2,1-6H3,(H,19,21,22)/t10-/m1/s1
DMBJ15R	CS	CC[C@@H](C)NC1=NC(=NC2=C(C(=NN21)C)C3=C(N=C(C=C3)OC)C)C
DMBJ15R	IK	LBWQSAZEYIZZCE-SNVBAGLBSA-N
DMBJ15R	IU	N-[(2R)-butan-2-yl]-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DMBJ15R	CA	CAS 459856-18-9
DMBJ15R	DE	Anxiety disorder

DMYKNME	ID	DMYKNME
DMYKNME	DN	PF-06651600
DMYKNME	HS	Phase 2/3
DMYKNME	SN	CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
DMYKNME	CP	Pfizer New York, NY
DMYKNME	PC	118115473
DMYKNME	MW	285.34
DMYKNME	FM	C15H19N5O
DMYKNME	IC	InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
DMYKNME	CS	C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
DMYKNME	IK	CBRJPFGIXUFMTM-WDEREUQCSA-N
DMYKNME	IU	1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
DMYKNME	CA	CAS 1792180-81-4
DMYKNME	DE	Asthma; Crohn disease; Alopecia

DM1QSM3	ID	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	HS	Phase 2/3
DM1QSM3	SN	carbolic acid; 108-95-2; Hydroxybenzene; Phenic acid; Oxybenzene; Phenylic acid; Benzenol; Phenyl hydrate; Monophenol; Phenyl hydroxide; Phenylic alcohol; PhOH; Monohydroxybenzene; Phenole; Paoscle; Phenyl alcohol; Phenol alcohol; Izal; Phenol, liquefied; Acide carbolique; Fenolo; Phenosmolin; Fenosmoline; Fenosmolin; Carbolsaure; Fenol; Liquid phenol; Carbolic oil; Phenol, pure; Phenol homopolymer; Phenole [German]; Fenolo [Italian]; Benzene, hydroxy-; Rcra waste number U188; Campho-Phenique Gel; Phenic; Carbolsaure [German]
DM1QSM3	DT	Small molecular drug
DM1QSM3	PC	996
DM1QSM3	MW	94.11
DM1QSM3	FM	C6H6O
DM1QSM3	IC	InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H
DM1QSM3	CS	C1=CC=C(C=C1)O
DM1QSM3	IK	ISWSIDIOOBJBQZ-UHFFFAOYSA-N
DM1QSM3	IU	phenol
DM1QSM3	CA	CAS 108-95-2
DM1QSM3	CB	CHEBI:15882

DM1SV8I	ID	DM1SV8I
DM1SV8I	DN	PHN-131
DM1SV8I	HS	Phase 2/3
DM1SV8I	SN	NALBUPHINE HYDROCHLORIDE; Nalbuphine HCL; Nubain; 23277-43-2; Nalbufina clorhidrato [Spanish]; Nalbuphine hydrochloride [USAN]; En 2234A; UNII-ZU4275277R; EN-2234A; EINECS 245-549-9; ZU4275277R; 17-(Cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol hydrochloride; Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, hydrochloride, (5-alpha,6-alpha)-; (5alpha,6alpha)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride; N-Cyclobutylmethyl-14-hydroxydihydronormorphine hydrochloride; Nalbuphine h
DM1SV8I	CP	PhytoHealth Corp
DM1SV8I	DT	Small molecular drug
DM1SV8I	PC	5360733
DM1SV8I	MW	393.9
DM1SV8I	FM	C21H28ClNO4
DM1SV8I	IC	InChI=1S/C21H27NO4.ClH/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12;/h4-5,12,15-16,19,23-25H,1-3,6-11H2;1H/t15-,16+,19-,20-,21+;/m0./s1
DM1SV8I	CS	C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O.Cl
DM1SV8I	IK	YZLZPSJXMWGIFH-BCXQGASESA-N
DM1SV8I	IU	(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol;hydrochloride
DM1SV8I	CA	CAS 23277-43-2
DM1SV8I	CB	CHEBI:7455
DM1SV8I	DE	Pain

DMPWH30	ID	DMPWH30
DMPWH30	DN	Pimagedine HCl
DMPWH30	HS	Phase 2/3
DMPWH30	CP	Synvista Therapeutics
DMPWH30	DT	Small molecular drug
DMPWH30	PC	85468708
DMPWH30	MW	110.55
DMPWH30	FM	CH7ClN4
DMPWH30	IC	InChI=1S/CH6N4.ClH/c2-1(3)5-4;/h4H2,(H4,2,3,5);1H
DMPWH30	CS	C(=[NH+]N)(N)N.[Cl-]
DMPWH30	IK	UBDZFAGVPPMTIT-UHFFFAOYSA-N
DMPWH30	IU	amino(diaminomethylidene)azanium;chloride
DMPWH30	CA	CAS 16139-18-7
DMPWH30	DE	Diabetic kidney disease

DM0EFQS	ID	DM0EFQS
DM0EFQS	DN	Plasminogen
DM0EFQS	HS	Phase 2/3
DM0EFQS	CP	Kedrion
DM0EFQS	DE	Alzheimer disease

DMCGK6X	ID	DMCGK6X
DMCGK6X	DN	PRO 140
DMCGK6X	HS	Phase 2/3
DMCGK6X	CP	CytoDyn
DMCGK6X	DT	Antibody
DMCGK6X	DE	Human immunodeficiency virus-1 infection

DMZI4OV	ID	DMZI4OV
DMZI4OV	DN	QLT-091001
DMZI4OV	HS	Phase 2/3
DMZI4OV	SN	Crystalets; Davitan A 650; Myvak (VAN); Myvax (VAN); O~15~-acetylretinol; RETINYL ACETATE; RO 1-5275; Retinol acetate; Retinol, acetate; Retinol, acetate, all-trans-; Retinyl acetate, all-trans-; Vitamin A acetate; Vitamin A acetate (VAN); Vitamin A alcohol acetate; Vitamin A ester; Vitamin A1 acetate; all-trans-Retinol acetate; all-trans-Retinyl acetate; all-trans-Retinylacetate; all-trans-Vitamin A acetate; trans-Retinol Acetate; 127-47-9; Acetic acid, retinyl ester; CCRIS 1907; NSC 122045; UNII-3LE3D9D6OY
DMZI4OV	PC	638034
DMZI4OV	MW	328.5
DMZI4OV	FM	C22H32O2
DMZI4OV	IC	QGNJRVVDBSJHIZ-QHLGVNSISA-N
DMZI4OV	CS	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCOC(=O)C)C)C
DMZI4OV	IK	1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9+,18-14+
DMZI4OV	IU	[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] acetate
DMZI4OV	CA	CAS 127-47-9
DMZI4OV	CB	CHEBI:32095
DMZI4OV	DE	Barrett esophagus

DMB8UQ3	ID	DMB8UQ3
DMB8UQ3	DN	Ramatroban
DMB8UQ3	HS	Phase 2/3
DMB8UQ3	SN	116649-85-5; Baynas; BAY u3405; Bay u-3405; Bay u 3406; Bay-u-3405; Bay u 3405; BAY-u 3405; UNII-P1ALI72U6C; C21H21FN2O4S; 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid; P1ALI72U6C; 3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid; CHEMBL361812; (+)-(3R)-3-(p-Fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic acid; NCGC00167519-01; EN-137774; DSSTox_RID_81819; Baynas (TN); Ramatroban (JAN/INN); [3H]ramatroban
DMB8UQ3	CP	Bayer Yakuhin
DMB8UQ3	DT	Small molecular drug
DMB8UQ3	PC	123879
DMB8UQ3	MW	416.5
DMB8UQ3	FM	C21H21FN2O4S
DMB8UQ3	IC	InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
DMB8UQ3	CS	C1CC2=C(C[C@@H]1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
DMB8UQ3	IK	LDXDSHIEDAPSSA-OAHLLOKOSA-N
DMB8UQ3	IU	3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid
DMB8UQ3	CA	CAS 116649-85-5
DMB8UQ3	CB	CHEBI:32087
DMB8UQ3	DE	Perennial allergic rhinitis

DM1LFUN	ID	DM1LFUN
DM1LFUN	DN	Ravidasvir
DM1LFUN	HS	Phase 2/3
DM1LFUN	SN	PPI-668 free base; UNII-AL3G001BI8; AL3G001BI8; 1242087-93-9; Methyl N-[(1S)-1-[[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-benzimidazol-6-yl]-2-naphthalenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]carbamate; Ravidasvir [USAN]; Ravidasvir free base; BL-238630; SCHEMBL7603463; CHEMBL3121849; SCHEMBL12075676; BDBM243443; methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; SB19743; Carbamic acid, N-((1S)-1-(((2S)-2-(5-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-pyrrolidinyl)-1H-benzimidazol-6-yl)-2-naphthalenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)-, methyl ester; Methyl N-((1S)-1-(((2S)-2-(5-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3- methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)naphthalen-2-yl)-1H-benzimidazol-2-yl)pyrrolidin-1-yl)carbonyl)-2-methylpropyl)carbamate; BI 238630; BI-238630; US9427428, 3; Q27273972; methyl ((1S)-1-(((2S)-2-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-benzimidazol-5-yl)-2-naphthyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate; methyl((1S)-1-(((2S)-2-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-benzimidazol-5-yl)-2-naphthyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate; methyl((s)-1-((s)-2-(5-(6-(2((s)-1-((methoxycarbonyl)-l-valyl)pyrrolidin-2-yl)-1h-imidazol-4-yl)naphthalen-2-yl)-1h-benzo[d]imidazol-2-yl) pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
DM1LFUN	CP	Presidio Pharmaceuticals
DM1LFUN	DT	Small molecular drug
DM1LFUN	PC	52918888
DM1LFUN	MW	762.9
DM1LFUN	FM	C42H50N8O6
DM1LFUN	IC	InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1
DM1LFUN	CS	CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DM1LFUN	IK	LCHMHYPWGWYXEL-ZYADHFCISA-N
DM1LFUN	IU	methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DM1LFUN	CA	CAS 1242087-93-9
DM1LFUN	DE	Hepatitis C

DML9FD4	ID	DML9FD4
DML9FD4	DN	Rinfabate
DML9FD4	HS	Phase 2/3
DML9FD4	SN	RhIGFBP-3; Rinfabate, Insmed; RhIGF-BP3, Insmed; Insulin-like growth factor binding protein-3, Insmed
DML9FD4	CP	Insmed Inc
DML9FD4	DE	Solid tumour/cancer

DMWZ6DK	ID	DMWZ6DK
DMWZ6DK	DN	Roledumab
DMWZ6DK	HS	Phase 2/3
DMWZ6DK	SN	DMATRIA; LFB-R593; R-297; R-593; Anti-D human monoclonal antibody, Laboratoire Francais du Fractionnement et des Biotechnologies; R297 antibody (hematological disease), LFB; R297 antibody (hematological disease), Laboratoire Francais du Fractionnement et des Biotechnologies; Anti-RhD antibody (hematological disease), LFB; Anti-rhesus D mAB (hematological disease), LFB
DMWZ6DK	CP	LFB Biotechnologies
DMWZ6DK	DT	Antibody
DMWZ6DK	DE	Anemia

DMNIYSZ	ID	DMNIYSZ
DMNIYSZ	DN	RP101
DMNIYSZ	HS	Phase 2/3
DMNIYSZ	SN	SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,
DMNIYSZ	CP	RESprotect
DMNIYSZ	DT	Small molecular drug
DMNIYSZ	PC	446727
DMNIYSZ	MW	333.13
DMNIYSZ	FM	C11H13BrN2O5
DMNIYSZ	IC	InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1
DMNIYSZ	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)/C=C/Br)CO)O
DMNIYSZ	IK	ODZBBRURCPAEIQ-PIXDULNESA-N
DMNIYSZ	IU	5-[(E)-2-bromoethenyl]-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMNIYSZ	CA	CAS 69304-47-8
DMNIYSZ	DE	Pancreatic cancer; Infectious disease

DMOJLCV	ID	DMOJLCV
DMOJLCV	DN	SAR164877
DMOJLCV	HS	Phase 2/3
DMOJLCV	CP	Sanofi-Aventis
DMOJLCV	TC	Analgesics
DMOJLCV	DE	Pain

DMH7IPW	ID	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	HS	Phase 2/3
DMH7IPW	SN	Sarizotan [INN]; EMD 128130; N-((3,4-Dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)-3-pyridinemethanamine; (-)-3-((((R)-2-Chromanylmethyl)amino)methyl)-5-(p-fluorophenyl)pyridine; 1-(3,4-dihydro-2H-chromen-2-yl)-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine
DMH7IPW	CP	EMD Serono
DMH7IPW	DT	Small molecular drug
DMH7IPW	PC	6918388
DMH7IPW	MW	348.4
DMH7IPW	FM	C22H21FN2O
DMH7IPW	IC	InChI=1S/C22H21FN2O/c23-20-8-5-17(6-9-20)19-11-16(12-24-14-19)13-25-15-21-10-7-18-3-1-2-4-22(18)26-21/h1-6,8-9,11-12,14,21,25H,7,10,13,15H2/t21-/m1/s1
DMH7IPW	CS	C1CC2=CC=CC=C2O[C@H]1CNCC3=CC(=CN=C3)C4=CC=C(C=C4)F
DMH7IPW	IK	HKFMQJUJWSFOLY-OAQYLSRUSA-N
DMH7IPW	IU	1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine
DMH7IPW	CA	CAS 351862-32-3
DMH7IPW	DE	Parkinson disease; Rett syndrome

DM31L9K	ID	DM31L9K
DM31L9K	DN	Sepofarsen
DM31L9K	HS	Phase 2/3
DM31L9K	SN	QR-110
DM31L9K	CP	ProQR Therapeutics
DM31L9K	DT	Oligonucleotide
DM31L9K	DE	Leber congenital amaurosis

DMTV5XC	ID	DMTV5XC
DMTV5XC	DN	Sitafloxacin
DMTV5XC	HS	Phase 2/3
DMTV5XC	SN	Sitafloxacin; Gracevit; Sitafloxacin Sesquihydrate; UNII-3GJC60U4Q8; Sitafloxacin isomer II; DU-6859a; C19H18ClF2N3O3; 3GJC60U4Q8; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid
DMTV5XC	PC	461399
DMTV5XC	MW	409.8
DMTV5XC	FM	C19H18ClF2N3O3
DMTV5XC	IC	InChI=1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)/t10-,12+,13+/m0/s1
DMTV5XC	CS	C1CC12CN(CC2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5CC5F)F
DMTV5XC	IK	PNUZDKCDAWUEGK-CYZMBNFOSA-N
DMTV5XC	IU	7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid
DMTV5XC	CA	CAS 127254-12-0
DMTV5XC	CB	CHEBI:4304
DMTV5XC	DE	Escherichia Coli Infections

DM30JWZ	ID	DM30JWZ
DM30JWZ	DN	SM04554
DM30JWZ	HS	Phase 2/3
DM30JWZ	CP	Samumed San Diego,CA
DM30JWZ	DT	Small molecular drug
DM30JWZ	DE	Alopecia

DMD9ISG	ID	DMD9ISG
DMD9ISG	DN	SM-88
DMD9ISG	HS	Phase 2/3
DMD9ISG	CP	Tyme Technologies New York, NY
DMD9ISG	PC	3125
DMD9ISG	MW	195.21
DMD9ISG	FM	C10H13NO3
DMD9ISG	IC	InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)
DMD9ISG	CS	CC(CC1=CC=C(C=C1)O)(C(=O)O)N
DMD9ISG	IK	NHTGHBARYWONDQ-UHFFFAOYSA-N
DMD9ISG	IU	2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
DMD9ISG	CA	CAS 658-48-0
DMD9ISG	DE	Prostate cancer; Pancreatic cancer

DM5WQ2U	ID	DM5WQ2U
DM5WQ2U	DN	SR-123781A
DM5WQ2U	HS	Phase 2/3
DM5WQ2U	CP	Sanofi-aventis
DM5WQ2U	PC	145996625
DM5WQ2U	MW	4854
DM5WQ2U	FM	C127H201Na19O134S17
DM5WQ2U	IC	InChI=1S/C127H220O134S17.19Na/c1-183-32-46-60(235-114-95(203-21)76(192-10)62(48(223-114)34-185-3)237-116-97(205-23)78(194-12)64(50(225-116)36-187-5)239-118-99(207-25)80(196-14)66(52(227-118)38-189-7)241-120-101(209-27)82(198-16)68(55(229-120)41-216-264(138,139)140)244-124-106(258-275(171,172)173)89(254-271(159,160)161)71(57(231-124)43-218-266(144,145)146)246-125-107(259-276(174,175)176)90(255-272(162,163)164)72(58(232-125)44-219-267(147,148)149)247-126-109(261-278(180,181)182)91(256-273(165,166)167)73(252-269(153,154)155)59(234-126)45-220-268(150,151)152)74(190-8)94(202-20)113(222-46)236-61-47(33-184-2)224-115(96(204-22)75(61)191-9)238-63-49(35-186-4)226-117(98(206-24)77(63)193-11)240-65-51(37-188-6)228-119(100(208-26)79(65)195-13)242-67-54(40-215-263(135,136)137)230-121(102(210-28)81(67)197-15)248-86-84(200-18)104(212-30)123(251-92(86)110(128)129)245-70-56(42-217-265(141,142)143)233-127(108(260-277(177,178)179)88(70)253-270(156,157)158)249-87-85(201-19)103(211-29)122(250-93(87)111(130)131)243-69-53(39-214-262(132,133)134)221-112(213-31)105(83(69)199-17)257-274(168,169)170;;;;;;;;;;;;;;;;;;;/h46-109,112-127H,32-45H2,1-31H3,(H,128,129)(H,130,131)(H,132,133,134)(H,135,136,137)(H,138,139,140)(H,141,142,143)(H,144,145,146)(H,147,148,149)(H,150,151,152)(H,153,154,155)(H,156,157,158)(H,159,160,161)(H,162,163,164)(H,165,166,167)(H,168,169,170)(H,171,172,173)(H,174,175,176)(H,177,178,179)(H,180,181,182);;;;;;;;;;;;;;;;;;;/q;19*+1/p-19/t46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67+,68-,69-,70-,71-,72-,73-,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103+,104-,105+,106-,107-,108-,109-,112+,113-,114+,115+,116+,117-,118+,119+,120-,121-,122-,123-,124+,125-,126-,127-;;;;;;;;;;;;;;;;;;;/m1.................../s1
DM5WQ2U	CS	COC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2OC)OC)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3OC)OC)O[C@H]4[C@H](O[C@@H]([C@@H]([C@H]4OC)OC)O[C@H]5[C@@H]([C@H]([C@@H](O[C@H]5C(=O)[O-])O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]7[C@@H]([C@@H]([C@@H](O[C@H]7C(=O)[O-])O[C@@H]8[C@H](O[C@@H]([C@H]([C@H]8OC)OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])COC)COC)OC)OC)O[C@@H]9[C@@H]([C@H]([C@@H]([C@H](O9)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)OC)OC)OC)OC)OC)OC)OC)OC)OC.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM5WQ2U	IK	RRHHPXJSGSYSHW-ZURHXDBDSA-A
DM5WQ2U	IU	nonadecasodium;(2R,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5S,6R)-2-carboxylato-6-[(2R,3R,4S,5S,6S)-4,6-dimethoxy-5-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5S,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-3,4-disulfonatooxy-6-(sulfonatooxymethyl)-5-[(2R,3R,4S,5R,6R)-3,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-disulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dimethoxyoxane-2-carboxylate
DM5WQ2U	CA	CAS 232602-93-6
DM5WQ2U	DE	Venous thrombosis

DMKGQF0	ID	DMKGQF0
DMKGQF0	DN	Suvodirsen
DMKGQF0	HS	Phase 2/3
DMKGQF0	SN	WVE-210201
DMKGQF0	CP	Wave Life Sciences
DMKGQF0	DT	Antisense oligonucleotide
DMKGQF0	DE	Duchenne dystrophy

DMWE3GB	ID	DMWE3GB
DMWE3GB	DN	TG-4010
DMWE3GB	HS	Phase 2/3
DMWE3GB	SN	MVA-Muc1-IL-2; MVA-TG-9931 (frozen suspension); MUC1/IL-2 antigen therapy (gene transfer system, cancer), Transgene
DMWE3GB	CP	Transgene
DMWE3GB	DE	Bipolar disorder; Non-small-cell lung cancer

DMVDTR2	ID	DMVDTR2
DMVDTR2	DN	Thymoquinone
DMVDTR2	HS	Phase 2/3
DMVDTR2	SN	490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; Thymoquinone; 2-isopropyl-5-methylbenzo-1,4-quinone; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
DMVDTR2	DT	Small molecular drug
DMVDTR2	PC	10281
DMVDTR2	MW	164.2
DMVDTR2	FM	C10H12O2
DMVDTR2	IC	InChI=1S/C10H12O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6H,1-3H3
DMVDTR2	CS	CC1=CC(=O)C(=CC1=O)C(C)C
DMVDTR2	IK	KEQHJBNSCLWCAE-UHFFFAOYSA-N
DMVDTR2	IU	2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione
DMVDTR2	CA	CAS 490-91-5
DMVDTR2	CB	CHEBI:113532
DMVDTR2	DE	Polycystic ovarian syndrome

DM23ARP	ID	DM23ARP
DM23ARP	DN	V-710
DM23ARP	HS	Phase 2/3
DM23ARP	SN	Vaccine (Staphylococcus aureus), Intercell; Vaccine (Staphylococcus aureus), Merck & Co; Iron surface determinant B-based vaccine (Staphylococcus aureus infection), Merck & Co; IsdB-based vaccine (Staphylococcus aureus infection), Merck & Co
DM23ARP	CP	Intercell AG
DM23ARP	DT	Vaccine
DM23ARP	DE	Staphylococcus infection

DMDG8Q3	ID	DMDG8Q3
DMDG8Q3	DN	Varlitinib
DMDG8Q3	HS	Phase 2/3
DMDG8Q3	SN	VARLITINIB; 845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
DMDG8Q3	CP	ASLAN Pharmaceuticals
DMDG8Q3	DT	Small molecular drug
DMDG8Q3	PC	42642648
DMDG8Q3	MW	466.9
DMDG8Q3	FM	C22H19ClN6O2S
DMDG8Q3	IC	InChI=1S/C22H19ClN6O2S/c1-13-10-31-22(27-13)29-14-2-4-18-16(8-14)21(26-12-25-18)28-15-3-5-19(17(23)9-15)30-11-20-24-6-7-32-20/h2-9,12-13H,10-11H2,1H3,(H,27,29)(H,25,26,28)/t13-/m1/s1
DMDG8Q3	CS	C[C@@H]1COC(=N1)NC2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=NC=CS5)Cl
DMDG8Q3	IK	UWXSAYUXVSFDBQ-CYBMUJFWSA-N
DMDG8Q3	IU	4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
DMDG8Q3	CA	CAS 845272-21-1
DMDG8Q3	DE	Breast cancer; Metastatic biliary tract neoplasms

DMTROUI	ID	DMTROUI
DMTROUI	DN	Vazegepant
DMTROUI	HS	Phase 2/3
DMTROUI	SN	UNII-ODU3ZAZ94J; ODU3ZAZ94J; BHV-3500; BDBM50436107
DMTROUI	TC	Antiviral Agents
DMTROUI	DT	Small molecular drug
DMTROUI	PC	53472683
DMTROUI	MW	638.8
DMTROUI	FM	C36H46N8O3
DMTROUI	IC	InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
DMTROUI	CS	CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
DMTROUI	IK	JJVAPHYEOZSKJZ-JGCGQSQUSA-N
DMTROUI	IU	N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1H-quinolin-3-yl)piperidine-1-carboxamide
DMTROUI	CA	CAS 1337918-83-8
DMTROUI	DE	Coronavirus Disease 2019 (COVID-19)

DMGKRAJ	ID	DMGKRAJ
DMGKRAJ	DN	VB4-845
DMGKRAJ	HS	Phase 2/3
DMGKRAJ	CP	Viventia Biotechnologies
DMGKRAJ	DT	Antibody
DMGKRAJ	SQ	9045_H|oportuzumab monatox|||SCFV-KAPPA-HEAVY-TOXIN (V-KAPPA(7-118)+LINKER(119-144)+VH(145-260)+TOX-DOMAIN(281-637))|||||||647||||MW 69566.3|MW 69566.3|: HHHHHHDIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELKRATPSHNSHQVPSAGGPTANSGTSGSEVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSSEFGGAPEFPKPSTPPGSSGLEGGSLAALTAHQACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPGSGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAASADVVSLTCPVAAGECAGPADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGFYRTGLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPHHHHHHKDEL
DMGKRAJ	DE	Head and neck cancer

DM0ASTP	ID	DM0ASTP
DM0ASTP	DN	Verapamil
DM0ASTP	HS	Phase 2/3
DM0ASTP	SN	VERAPAMIL; Iproveratril; 52-53-9; Vasolan; Dilacoran; Isoptin; Falicard; Isoptine; Isoptimo; Finoptin; Calan; Verapamilo; Verapamilum; Verapamilum [INN-Latin]; Lekoptin; Verapamilo [INN-Spanish]; Isotopin; Calcan; Tarka; D-365; Securon; Verelan; Izoptin; Verapamil [USAN:INN:BAN]; CP-16533-1; Covera-HS; Verpamil; CCRIS 6749; Verelan PM; Isoptin SR; C; Verapamil
DM0ASTP	TC	Antiviral Agents
DM0ASTP	DT	Small molecular drug
DM0ASTP	PC	2520
DM0ASTP	MW	454.6
DM0ASTP	FM	C27H38N2O4
DM0ASTP	IC	InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
DM0ASTP	CS	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DM0ASTP	IK	SGTNSNPWRIOYBX-UHFFFAOYSA-N
DM0ASTP	IU	2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DM0ASTP	CA	CAS 52-53-9
DM0ASTP	CB	CHEBI:77733
DM0ASTP	DE	Coronavirus Disease 2019 (COVID-19)

DM4WQBO	ID	DM4WQBO
DM4WQBO	DN	VM-1500
DM4WQBO	HS	Phase 2/3
DM4WQBO	SN	VM-1500 (topical gel formulation, HIV infection)
DM4WQBO	CP	Viriom Ltd
DM4WQBO	DE	Human immunodeficiency virus infection

DM5G1NT	ID	DM5G1NT
DM5G1NT	DN	VX-210
DM5G1NT	HS	Phase 2/3
DM5G1NT	SN	BA-210; VX210
DM5G1NT	CP	Vertex Pharmaceuticals Boston, MA
DM5G1NT	DE	Spinal cord injury

DM2U3MX	ID	DM2U3MX
DM2U3MX	DN	VX-509
DM2U3MX	HS	Phase 2/3
DM2U3MX	SN	Decernotinib; Adelatinib; 944842-54-0; VX-509; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK
DM2U3MX	CP	Vertex Pharmaceuticals
DM2U3MX	DT	Small molecular drug
DM2U3MX	PC	59422203
DM2U3MX	MW	392.4
DM2U3MX	FM	C18H19F3N6O
DM2U3MX	IC	InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1
DM2U3MX	CS	CC[C@](C)(C(=O)NCC(F)(F)F)NC1=NC(=NC=C1)C2=CNC3=C2C=CC=N3
DM2U3MX	IK	ASUGUQWIHMTFJL-QGZVFWFLSA-N
DM2U3MX	IU	(2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide
DM2U3MX	CA	CAS 944842-54-0
DM2U3MX	DE	Rheumatoid arthritis

DMHXJ68	ID	DMHXJ68
DMHXJ68	DN	WVE-210201
DMHXJ68	HS	Phase 2/3
DMHXJ68	CP	WaVe Life Sciences Cambridge, MA
DMHXJ68	DE	Duchenne dystrophy

DM78DOT	ID	DM78DOT
DM78DOT	DN	AllerB
DM78DOT	HS	Phase 2b
DM78DOT	CP	Anergis SA
DM78DOT	DE	Allergy

DMJM9LZ	ID	DMJM9LZ
DMJM9LZ	DN	LB80380
DMJM9LZ	HS	Phase 2b
DMJM9LZ	SN	LB80380; UNII-S9I9P4J8IU; LB 80380; S9I9P4J8IU; LB-80380; 441785-26-8; PMCDG dipivoxil; AC1O59EP; SCHEMBL4270816; CHEMBL1652128; ANA-380; DTXSID90196062; J3.616.617G; [[1-[(2-aminopurin-9-yl)methyl]cyclopropoxy]methyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; [({[(2-Aminopurin-9-yl)methyl]cyclopropoxy}methyl)[(2,2-dimethylpropanoyloxy)methoxy]carbonyloxy]methyl 2,2-dimethylpropanoate; 872968-04-2
DMJM9LZ	CP	LG Life Sciences
DMJM9LZ	DT	Small molecular drug
DMJM9LZ	PC	6480442
DMJM9LZ	MW	527.5
DMJM9LZ	FM	C22H34N5O8P
DMJM9LZ	IC	InChI=1S/C22H34N5O8P/c1-20(2,3)17(28)31-12-34-36(30,35-13-32-18(29)21(4,5)6)14-33-22(7-8-22)10-27-11-25-15-9-24-19(23)26-16(15)27/h9,11H,7-8,10,12-14H2,1-6H3,(H2,23,24,26)
DMJM9LZ	CS	CC(C)(C)C(=O)OCOP(=O)(COC1(CC1)CN2C=NC3=CN=C(N=C32)N)OCOC(=O)C(C)(C)C
DMJM9LZ	IK	JLKJXDOWBVVABZ-UHFFFAOYSA-N
DMJM9LZ	IU	[[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
DMJM9LZ	CA	CAS 441785-26-8
DMJM9LZ	DE	Hepatitis B virus infection

DMXB4NL	ID	DMXB4NL
DMXB4NL	DN	MEDI4893
DMXB4NL	HS	Phase 2b
DMXB4NL	CP	AstraZeneca
DMXB4NL	DT	Antibody
DMXB4NL	DE	Hospital-acquired pneumonia; Ventilator-associated pneumonia

DMEARCM	ID	DMEARCM
DMEARCM	DN	OrM3
DMEARCM	HS	Phase 2b
DMEARCM	CP	Merck Research Laboratories
DMEARCM	DE	Chronic obstructive pulmonary disease

DMOE582	ID	DMOE582
DMOE582	DN	TZP-101
DMOE582	HS	Phase 2b
DMOE582	SN	Ulimorelin; TZP-101; TZP 101; UNII-LGI67MCW2S; 842131-33-3; LGI67MCW2S; CHEMBL1923502; Ulimorelin [USAN:INN]; Ulimorelin (USAN/INN); SCHEMBL804500; TZP101; GTPL3535; CHEMBL1963249; DTXSID00233139; BDBM50359256; DB12128; D09981; (3R,6S,9R,12R)-6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione; D-Phenylalanine, (2S)-N-((2R)-2-(2-(3-aminopropyl)phenoxy)propyl)-2-     cyclopropylglycyl-N-methyl-D-alanyl-4-fluoro-, (3-1)-lactam
DMOE582	CP	Tranzyme
DMOE582	DT	Small molecular drug
DMOE582	PC	11526696
DMOE582	MW	538.7
DMOE582	FM	C30H39FN4O4
DMOE582	IC	InChI=1S/C30H39FN4O4/c1-19-18-33-27(23-12-13-23)30(38)35(3)20(2)28(36)34-25(17-21-10-14-24(31)15-11-21)29(37)32-16-6-8-22-7-4-5-9-26(22)39-19/h4-5,7,9-11,14-15,19-20,23,25,27,33H,6,8,12-13,16-18H2,1-3H3,(H,32,37)(H,34,36)/t19-,20-,25-,27+/m1/s1
DMOE582	CS	C[C@@H]1CN[C@H](C(=O)N([C@@H](C(=O)N[C@@H](C(=O)NCCCC2=CC=CC=C2O1)CC3=CC=C(C=C3)F)C)C)C4CC4
DMOE582	IK	WGYPAJVJMXQXTR-ABNZCKJZSA-N
DMOE582	IU	(3R,6S,9R,12R)-6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione
DMOE582	CA	CAS 842131-33-3
DMOE582	DE	Gastrointestinal disease; Gastroparesis; Ileus

DMUB8WN	ID	DMUB8WN
DMUB8WN	DN	Aerovant
DMUB8WN	HS	Phase 2a
DMUB8WN	CP	Aerovance
DMUB8WN	DE	Asthma

DMSC8YW	ID	DMSC8YW
DMSC8YW	DN	ANA773
DMSC8YW	HS	Phase 2a
DMSC8YW	CP	Anadys Pharmaceuticals
DMSC8YW	DE	Hepatitis C virus infection

DMJBDL0	ID	DMJBDL0
DMJBDL0	DN	BIIB104
DMJBDL0	HS	Phase 2a
DMJBDL0	CP	Biogen
DMJBDL0	DE	Cognitive impairment

DM0TH9A	ID	DM0TH9A
DM0TH9A	DN	Bimosiamose
DM0TH9A	HS	Phase 2a
DM0TH9A	SN	TBC 1269; TBC-1269
DM0TH9A	CP	Encysive Pharma
DM0TH9A	DT	Small molecular drug
DM0TH9A	PC	9811353
DM0TH9A	MW	862.9
DM0TH9A	FM	C46H54O16
DM0TH9A	IC	InChI=1S/C46H54O16/c47-23-35-39(53)41(55)43(57)45(61-35)59-33-15-13-25(19-31(33)29-11-5-9-27(17-29)21-37(49)50)7-3-1-2-4-8-26-14-16-34(60-46-44(58)42(56)40(54)36(24-48)62-46)32(20-26)30-12-6-10-28(18-30)22-38(51)52/h5-6,9-20,35-36,39-48,53-58H,1-4,7-8,21-24H2,(H,49,50)(H,51,52)/t35-,36-,39-,40-,41+,42+,43+,44+,45+,46+/m1/s1
DM0TH9A	CS	C1=CC(=CC(=C1)C2=C(C=CC(=C2)CCCCCCC3=CC(=C(C=C3)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=CC=CC(=C5)CC(=O)O)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)CC(=O)O
DM0TH9A	IK	RYWCQJDEHXJHRI-XJMXIVSISA-N
DM0TH9A	IU	2-[3-[5-[6-[3-[3-(carboxymethyl)phenyl]-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]hexyl]-2-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]phenyl]acetic acid
DM0TH9A	CA	CAS 187269-40-5
DM0TH9A	DE	Atopic dermatitis; Psoriatic disorder; Chronic obstructive pulmonary disease; Asthma

DMR6LXM	ID	DMR6LXM
DMR6LXM	DN	CAP-232
DMR6LXM	HS	Phase 2a
DMR6LXM	SN	TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP-232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01
DMR6LXM	TC	Anticancer Agents
DMR6LXM	DT	Small molecular drug
DMR6LXM	PC	6918265
DMR6LXM	MW	947.1
DMR6LXM	FM	C45H58N10O9S2
DMR6LXM	IC	InChI=1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38+/m1/s1
DMR6LXM	CS	C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)O
DMR6LXM	IK	SNAJPQVDGYDQSW-DYCFWDQMSA-N
DMR6LXM	IU	(4R,7S,10R,13S,16R)-7-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-16-[[(2R)-2-amino-3-phenylpropanoyl]amino]-13-[(4-hydroxyphenyl)methyl]-10-(1H-indol-3-ylmethyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide
DMR6LXM	CA	CAS 147159-51-1
DMR6LXM	DE	Pain; Renal cell carcinoma

DMLQ3PO	ID	DMLQ3PO
DMLQ3PO	DN	INCB13739
DMLQ3PO	HS	Phase 2a
DMLQ3PO	SN	Phenylarsine oxide; phenylarsine oxide; Oxophenylarsine; 637-03-6; Arzene; Phenylarsenoxide; Arsenosobenzene; ARSINE, OXOPHENYL-; Phenyl arsine oxide; Benzene, arsenoso-; arsorosobenzene; Fenylarsinoxid; Caswell No 060; Fenylarsinoxid [Czech]; C6H5AsO; Phenyl arsenoxide; UNII-0HUR2WY345; PAO; EINECS 211-275-3; NSC 42470; EPA Pesticide Chemical Code 007101; BRN 2935227; 0HUR2WY345; CHEBI:75253; MFCD00001990; Phenylarsine oxide, 97%; Phenylarsine Oxide Solution; oxo(phenyl)arsan; Phenylarsinoxyd; oxo(phenyl)arsine; oxo(phenyl)arsane; PhAsO; phenylarsenious
DMLQ3PO	CP	Incyte
DMLQ3PO	DT	Small molecular drug
DMLQ3PO	PC	11502183
DMLQ3PO	MW	398.9
DMLQ3PO	FM	C19H27ClN2O3S
DMLQ3PO	IC	InChI=1S/C19H27ClN2O3S/c1-14-17(20)10-5-11-18(14)26(24,25)22-12-6-7-15(13-22)19(23)21-16-8-3-2-4-9-16/h5,10-11,15-16H,2-4,6-9,12-13H2,1H3,(H,21,23)
DMLQ3PO	CS	CC1=C(C=CC=C1Cl)S(=O)(=O)N2CCCC(C2)C(=O)NC3CCCCC3
DMLQ3PO	IK	ODRPEKCTTLECBX-UHFFFAOYSA-N
DMLQ3PO	IU	1-(3-chloro-2-methylphenyl)sulfonyl-N-cyclohexylpiperidine-3-carboxamide
DMLQ3PO	DE	Diabetic complication; Type-2 diabetes

DMMWC6F	ID	DMMWC6F
DMMWC6F	DN	INCB9471
DMMWC6F	HS	Phase 2a
DMMWC6F	SN	INCB-9471; UNII-C5D4W25708; INCB9471; CHEMBL1688243; INCB009471; C5D4W25708; INCB-009471; INCB 9471; INCB0 09471; 869769-98-2; SCHEMBL3676335; ZINC43171152; BDBM50339033; DB12960; 925701-76-4; Piperidine, 1-((4,6-dimethyl-5-pyrimidinyl)carbonyl)-4-((3S)-4-((1R,2R)-2-ethoxy-2,3-dihydro-5-(trifluoromethyl)-1H-inden-1-yl)-3-methyl-1-piperazinyl)-4-methyl-; 5-((4-(4-(2-Ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl)-4-methylpiperidin-1-yl)carbonyl)-4,6-dimethylpyrimidine
DMMWC6F	CP	Incyte
DMMWC6F	DT	Small molecular drug
DMMWC6F	PC	49871007
DMMWC6F	MW	559.7
DMMWC6F	FM	C30H40F3N5O2
DMMWC6F	IC	InChI=1S/C30H40F3N5O2/c1-6-40-25-16-22-15-23(30(31,32)33)7-8-24(22)27(25)38-14-13-37(17-19(38)2)29(5)9-11-36(12-10-29)28(39)26-20(3)34-18-35-21(26)4/h7-8,15,18-19,25,27H,6,9-14,16-17H2,1-5H3/t19-,25+,27+/m0/s1
DMMWC6F	CS	CCO[C@@H]1CC2=C([C@H]1N3CCN(C[C@@H]3C)C4(CCN(CC4)C(=O)C5=C(N=CN=C5C)C)C)C=CC(=C2)C(F)(F)F
DMMWC6F	IK	ZMCJFJZOSKEMOM-DNKZPPIMSA-N
DMMWC6F	IU	(4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R,2R)-2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone
DMMWC6F	CA	CAS 869769-98-2
DMMWC6F	DE	Human immunodeficiency virus infection; Infectious disease

DMYZU6G	ID	DMYZU6G
DMYZU6G	DN	MEM-1003
DMYZU6G	HS	Phase 2a
DMYZU6G	SN	SCHEMBL1191960; SCHEMBL16332975
DMYZU6G	CP	Bayer
DMYZU6G	DT	Small molecular drug
DMYZU6G	PC	9802887
DMYZU6G	MW	432.9
DMYZU6G	FM	C22H25ClN2O5
DMYZU6G	IC	InChI=1S/C22H25ClN2O5/c1-12(2)30-22(27)18-14(4)25-13(3)17(21(26)29-10-9-28-5)19(18)16-8-6-7-15(11-24)20(16)23/h6-8,12,19,25H,9-10H2,1-5H3
DMYZU6G	CS	CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC(=C2Cl)C#N)C(=O)OCCOC
DMYZU6G	IK	GTIKSQYSAKETQA-UHFFFAOYSA-N
DMYZU6G	IU	3-O-(2-methoxyethyl) 5-O-propan-2-yl 4-(2-chloro-3-cyanophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMYZU6G	DE	Dementia; Bipolar disorder

DMGM1IR	ID	DMGM1IR
DMGM1IR	DN	RhuDex
DMGM1IR	HS	Phase 2a
DMGM1IR	CP	MediGene AG
DMGM1IR	DE	Rheumatoid arthritis

DMKJDR6	ID	DMKJDR6
DMKJDR6	DN	VX-702
DMKJDR6	HS	Phase 2a
DMKJDR6	SN	ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide
DMKJDR6	CP	Vertex Pharma
DMKJDR6	DT	Small molecular drug
DMKJDR6	PC	10341154
DMKJDR6	MW	404.3
DMKJDR6	FM	C19H12F4N4O2
DMKJDR6	IC	InChI=1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29)
DMKJDR6	CS	C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F
DMKJDR6	IK	FYSRKRZDBHOFAY-UHFFFAOYSA-N
DMKJDR6	IU	6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxamide
DMKJDR6	CA	CAS 745833-23-2
DMKJDR6	CB	CHEBI:94489
DMKJDR6	DE	Coronary artery disease; Rheumatoid arthritis; Inflammation

DMAV426	ID	DMAV426
DMAV426	DN	(S)-oxybutynin
DMAV426	HS	Phase 2
DMAV426	CP	Sepracor
DMAV426	PC	206530
DMAV426	MW	357.5
DMAV426	FM	C22H31NO3
DMAV426	IC	InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1
DMAV426	CS	CCN(CC)CC#CCOC(=O)[C@](C1CCCCC1)(C2=CC=CC=C2)O
DMAV426	IK	XIQVNETUBQGFHX-JOCHJYFZSA-N
DMAV426	IU	4-(diethylamino)but-2-ynyl (2S)-2-cyclohexyl-2-hydroxy-2-phenylacetate
DMAV426	CA	CAS 119618-22-3
DMAV426	CB	CHEBI:51329
DMAV426	DE	Urinary incontinence

DMGDOS2	ID	DMGDOS2
DMGDOS2	DN	(Z)-endoxifen
DMGDOS2	HS	Phase 2
DMGDOS2	SN	Endoxifen; Z-Endoxifen; 4-Hydroxy-N-desmethyltamoxifen; (E/Z)-Endoxifen; Endoxifen Z-Isomer; UNII-46AF8680RC; N-Desmethyl-4-hydroxytamoxifen; 110025-28-0; 4-Hydroxy-N-desmethyl-tamoxifen; CHEBI:80555; 46AF8680RC; 4OHNDtam; W-200834; N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture); (Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer); 4-hydroxy-N-desmethyltamoxifen, (Z)-isomer; (Z)-Endoxifen; Endoxifen(E/Z=1:1); 4-hydroxy-N-desmethyl tamoxifen; SCHEMBL10107920; CHEMBL1093458; GTPL10203; EX-A645
DMGDOS2	PC	10090750
DMGDOS2	MW	373.5
DMGDOS2	FM	C25H27NO2
DMGDOS2	IC	InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-
DMGDOS2	CS	CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCNC)C3=CC=CC=C3
DMGDOS2	IK	MHJBZVSGOZTKRH-IZHYLOQSSA-N
DMGDOS2	IU	4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMGDOS2	CA	CAS 112093-28-4
DMGDOS2	CB	CHEBI:80555
DMGDOS2	DE	Breast cancer

DMV86DY	ID	DMV86DY
DMV86DY	DN	[131I]-BC8
DMV86DY	HS	Phase 2
DMV86DY	DT	Antibody
DMV86DY	DE	leukaemia

DM4VWXI	ID	DM4VWXI
DM4VWXI	DN	[131I]-Metuximab
DM4VWXI	HS	Phase 2
DM4VWXI	CP	Elsevier
DM4VWXI	DT	Antibody
DM4VWXI	DE	Liver cancer

DMSLMY7	ID	DMSLMY7
DMSLMY7	DN	11C-PBR-28
DMSLMY7	HS	Phase 2
DMSLMY7	SN	Radiolabeled benzodiazepine receptor ligands, NIH; Carbon-11-PBR-101; Carbon-11-PBR-28; Fluorine-18-PBR-06; 11C-PBR-01; 18F-PBR-06
DMSLMY7	CP	National Institutes of Health
DMSLMY7	PC	11653141
DMSLMY7	MW	347.4
DMSLMY7	FM	C21H20N2O3
DMSLMY7	IC	InChI=1S/C21H20N2O3/c1-16(24)23(15-17-8-6-7-11-20(17)25-2)19-14-22-13-12-21(19)26-18-9-4-3-5-10-18/h3-14H,15H2,1-2H3/i2-1
DMSLMY7	CS	CC(=O)N(CC1=CC=CC=C1O[11CH3])C2=C(C=CN=C2)OC3=CC=CC=C3
DMSLMY7	IK	DHZBNHMEIOBPAE-JVVVGQRLSA-N
DMSLMY7	IU	N-[(2-(111C)methoxyphenyl)methyl]-N-(4-phenoxypyridin-3-yl)acetamide
DMSLMY7	CA	CAS 1005325-43-8
DMSLMY7	DE	Brain disease

DMTIED1	ID	DMTIED1
DMTIED1	DN	131I-TM-601
DMTIED1	HS	Phase 2
DMTIED1	SN	Glioma therapy, Transmolecular; Solid tumor imaging, TransMolecular; TM-602; TM-603; TM-803; Toxin-based anticancers, Transmolecular; Iodine-131-TM-601
DMTIED1	CP	TransMolecular Inc
DMTIED1	DE	Glioma

DM4EP6Y	ID	DM4EP6Y
DM4EP6Y	DN	13-DEOXYADRIAMYCIN HYDROCHLORIDE
DM4EP6Y	HS	Phase 2
DM4EP6Y	SN	GPX-100; (8R,10S)-10-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-1-methoxynaphthacene-5,12-dione hydrochloride; 13-Deoxydoxorubicin hydrochloride
DM4EP6Y	CP	Access Pharmaceuticals
DM4EP6Y	PC	9829418
DM4EP6Y	MW	566
DM4EP6Y	FM	C27H32ClNO10
DM4EP6Y	IC	InChI=1S/C27H31NO10.ClH/c1-11-22(30)14(28)8-17(37-11)38-16-10-27(35,6-7-29)9-13-19(16)26(34)21-20(24(13)32)23(31)12-4-3-5-15(36-2)18(12)25(21)33;/h3-5,11,14,16-17,22,29-30,32,34-35H,6-10,28H2,1-2H3;1H/t11-,14-,16-,17-,22+,27-;/m0./s1
DM4EP6Y	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(CCO)O)N)O.Cl
DM4EP6Y	IK	YZSQITAPLDJGKS-RYQLBYGJSA-N
DM4EP6Y	IU	(7S,9R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
DM4EP6Y	CA	CAS 65360-29-4
DM4EP6Y	DE	Solid tumour/cancer

DMNF38S	ID	DMNF38S
DMNF38S	DN	16,16-dimethyl-PGE2
DMNF38S	HS	Phase 2
DMNF38S	SN	16,16-dimethylprostaglandin E2
DMNF38S	DT	Small molecular drug
DMNF38S	PC	5283066
DMNF38S	MW	380.5
DMNF38S	FM	C22H36O5
DMNF38S	IC	InChI=1S/C22H36O5/c1-4-5-14-22(2,3)20(25)13-12-17-16(18(23)15-19(17)24)10-8-6-7-9-11-21(26)27/h6,8,12-13,16-17,19-20,24-25H,4-5,7,9-11,14-15H2,1-3H3,(H,26,27)/b8-6-,13-12+/t16-,17-,19-,20-/m1/s1
DMNF38S	CS	CCCCC(C)(C)[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O
DMNF38S	IK	QAOBBBBDJSWHMU-WMBBNPMCSA-N
DMNF38S	IU	(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMNF38S	CA	CAS 39746-25-3
DMNF38S	CB	CHEBI:141046
DMNF38S	DE	Stem cell engraftment

DMT8GVU	ID	DMT8GVU
DMT8GVU	DN	177Lu-DOTATATE
DMT8GVU	HS	Phase 2
DMT8GVU	CP	Advanced accelerator applications
DMT8GVU	PC	76966897
DMT8GVU	MW	1609.5
DMT8GVU	FM	C65H87LuN14O19S2
DMT8GVU	IC	InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2
DMT8GVU	CS	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[177Lu+3]
DMT8GVU	IK	MXDPZUIOZWKRAA-PRDSJKGBSA-K
DMT8GVU	IU	2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+)
DMT8GVU	CA	CAS 437608-50-9
DMT8GVU	DE	Hepatitis C virus infection

DM2TSMD	ID	DM2TSMD
DM2TSMD	DN	177Lu-labelled NeoBOMB1
DM2TSMD	HS	Phase 2
DM2TSMD	CP	Novartis/AAA
DM2TSMD	DT	Radiopharmaceutical therapy agent
DM2TSMD	DE	Solid tumour/cancer

DM8JVIB	ID	DM8JVIB
DM8JVIB	DN	18F-LMI-1195
DM8JVIB	HS	Phase 2
DM8JVIB	SN	Flourine-18-LMI-1195; Fluorine-18-based PET imaging agent (intravenous, heart failure), Lantheus; 18F-based PET imaging agent (intravenous, heart failure), Lantheus
DM8JVIB	CP	Lantheus medical imaging
DM8JVIB	DE	Heart failure

DMZWNQF	ID	DMZWNQF
DMZWNQF	DN	2'3'-Dideoxyinosine
DMZWNQF	HS	Phase 2
DMZWNQF	DT	Small molecular drug
DMZWNQF	PC	16219192

DMBOL4K	ID	DMBOL4K
DMBOL4K	DN	264W94
DMBOL4K	HS	Phase 2
DMBOL4K	SN	GW-264
DMBOL4K	CP	Glaxo Wellcome plc
DMBOL4K	DT	Small molecular drug
DMBOL4K	PC	9823277
DMBOL4K	MW	417.6
DMBOL4K	FM	C23H31NO4S
DMBOL4K	IC	InChI=1S/C23H31NO4S/c1-5-7-13-23(6-2)16-29(25,26)21-15-20(28-4)19(27-3)14-18(21)22(24-23)17-11-9-8-10-12-17/h8-12,14-15,22,24H,5-7,13,16H2,1-4H3/t22-,23-/m1/s1
DMBOL4K	CS	CCCC[C@@]1(CS(=O)(=O)C2=CC(=C(C=C2[C@H](N1)C3=CC=CC=C3)OC)OC)CC
DMBOL4K	IK	CKFWDLFFXXVSBJ-DHIUTWEWSA-N
DMBOL4K	IU	(3R,5R)-3-butyl-3-ethyl-7,8-dimethoxy-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepine 1,1-dioxide
DMBOL4K	CA	CAS 178259-25-1
DMBOL4K	DE	Hyperlipidaemia

DMGBPME	ID	DMGBPME
DMGBPME	DN	2-Methoxyestradiol
DMGBPME	HS	Phase 2
DMGBPME	SN	ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene
DMGBPME	CP	EntreMed
DMGBPME	DT	Small molecular drug
DMGBPME	PC	66414
DMGBPME	MW	302.4
DMGBPME	FM	C19H26O3
DMGBPME	IC	InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1
DMGBPME	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)OC)O
DMGBPME	IK	CQOQDQWUFQDJMK-SSTWWWIQSA-N
DMGBPME	IU	(8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMGBPME	CA	CAS 362-07-2
DMGBPME	CB	CHEBI:28955
DMGBPME	DE	Pulmonary arterial hypertension

DMX9MSL	ID	DMX9MSL
DMX9MSL	DN	2X-121
DMX9MSL	HS	Phase 2
DMX9MSL	CP	2X Oncology Cambridge, MA
DMX9MSL	DE	Breast cancer

DML8M5T	ID	DML8M5T
DML8M5T	DN	3,5-diiodothyropropionic acid
DML8M5T	HS	Phase 2
DML8M5T	SN	DITPA)
DML8M5T	CP	Titan Pharmaceuticals
DML8M5T	DT	Small molecular drug
DML8M5T	PC	160565
DML8M5T	MW	510.06
DML8M5T	FM	C15H12I2O4
DML8M5T	IC	InChI=1S/C15H12I2O4/c16-12-7-9(1-6-14(19)20)8-13(17)15(12)21-11-4-2-10(18)3-5-11/h2-5,7-8,18H,1,6H2,(H,19,20)
DML8M5T	CS	C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CCC(=O)O)I
DML8M5T	IK	WONYMNWUJVKVII-UHFFFAOYSA-N
DML8M5T	IU	3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
DML8M5T	CA	CAS 1158-10-7
DML8M5T	CB	CHEBI:134267
DML8M5T	DE	Cardiovascular disease; Congestive heart failure

DMTLR6Y	ID	DMTLR6Y
DMTLR6Y	DN	3K3A-APC
DMTLR6Y	HS	Phase 2
DMTLR6Y	CP	Zz biotech
DMTLR6Y	DE	Cerebrovascular ischaemia; Ischemic stroke

DMPFVJB	ID	DMPFVJB
DMPFVJB	DN	5-hydroxymethyl-2-furfural
DMPFVJB	HS	Phase 2
DMPFVJB	SN	Aes-103; 5-HMF; 5-hydroxymethylfurfural
DMPFVJB	CP	Aesrx
DMPFVJB	DT	Small molecular drug
DMPFVJB	PC	237332
DMPFVJB	MW	126.11
DMPFVJB	FM	C6H6O3
DMPFVJB	IC	InChI=1S/C6H6O3/c7-3-5-1-2-6(4-8)9-5/h1-3,8H,4H2
DMPFVJB	CS	C1=C(OC(=C1)C=O)CO
DMPFVJB	IK	NOEGNKMFWQHSLB-UHFFFAOYSA-N
DMPFVJB	IU	5-(hydroxymethyl)furan-2-carbaldehyde
DMPFVJB	CA	67-47-0
DMPFVJB	DE	Anemia

DMHBN8X	ID	DMHBN8X
DMHBN8X	DN	60P002
DMHBN8X	HS	Phase 2
DMHBN8X	CP	60 Degrees Pharmaceuticals
DMHBN8X	DT	Small molecular drug
DMHBN8X	DE	Dengue

DMOV0AP	ID	DMOV0AP
DMOV0AP	DN	842166X
DMOV0AP	HS	Phase 2
DMOV0AP	SN	GW842166X; 666260-75-9; GW 842166X; GW-842166X; UNII-VL1I6P2DZ8; VL1I6P2DZ8; GW842166; GW 842166; CHEMBL225411; 2-((2,4-dichlorophenyl)amino)-N-((tetrahydro-2H-pyran-4-yl)methyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide; TWQYWUXBZHPIIV-UHFFFAOYSA-N; 842166X; MLS006010287; C18H17Cl2F3N4O2; SCHEMBL3015040; DTXSID60216786; MolPort-009-019-316; HMS3656P06; BCP05306; ZINC3947932; BDBM50211843; s2778; 2455AH; AKOS032945128; DB11903; BCP9000755; CS-7768; SB19546; API0013938; GW-842,166X; NCGC00346697-05; NCGC00346697-01; KB-77649; HY-14167
DMOV0AP	DT	Small molecular drug
DMOV0AP	PC	10253143
DMOV0AP	MW	449.3
DMOV0AP	FM	C18H17Cl2F3N4O2
DMOV0AP	IC	InChI=1S/C18H17Cl2F3N4O2/c19-11-1-2-14(13(20)7-11)26-17-25-9-12(15(27-17)18(21,22)23)16(28)24-8-10-3-5-29-6-4-10/h1-2,7,9-10H,3-6,8H2,(H,24,28)(H,25,26,27)
DMOV0AP	CS	C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=C(C=C3)Cl)Cl
DMOV0AP	IK	TWQYWUXBZHPIIV-UHFFFAOYSA-N
DMOV0AP	IU	2-(2,4-dichloroanilino)-N-(oxan-4-ylmethyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide
DMOV0AP	CA	CAS 666260-75-9
DMOV0AP	DE	Pain

DML4GU1	ID	DML4GU1
DML4GU1	DN	99mTc-MIP-1404
DML4GU1	HS	Phase 2
DML4GU1	CP	Molecular Insight Pharmaceuticals Inc
DML4GU1	DT	?
DML4GU1	PC	71300957
DML4GU1	MW	1176.3
DML4GU1	FM	C40H53ClN10O23Tc
DML4GU1	IC	InChI=1S/C37H50N10O20.3CHO.ClH.Tc/c48-26(6-4-22(35(63)64)41-37(67)42-23(36(65)66)5-7-29(51)52)40-21(34(61)62)3-1-2-10-43(13-24-38-8-11-44(24)15-27(49)46(17-30(53)54)18-31(55)56)14-25-39-9-12-45(25)16-28(50)47(19-32(57)58)20-33(59)60;3*1-2;;/h8-9,11-12,21-23H,1-7,10,13-20H2,(H,40,48)(H,51,52)(H,53,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,41,42,67);3*1H;1H;/q;3*-1;;+4/p-1/t21-,22-,23-;;;;;/m0...../s1/i;;;;;1+1
DML4GU1	CS	[CH-]=O.[CH-]=O.[CH-]=O.C1=CN(C(=N1)CN(CCCC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CC2=NC=CN2CC(=O)N(CC(=O)O)CC(=O)O)CC(=O)N(CC(=O)O)CC(=O)O.[Cl-].[99Tc+4]
DML4GU1	IK	XOJYSFPEJAILJZ-LCERUKBVSA-M
DML4GU1	IU	(2S)-2-[[(1S)-4-[[(1S)-5-[bis[[1-[2-[bis(carboxymethyl)amino]-2-oxoethyl]imidazol-2-yl]methyl]amino]-1-carboxypentyl]amino]-1-carboxy-4-oxobutyl]carbamoylamino]pentanedioic acid;methanone;technetium-99(4+);chloride
DML4GU1	CA	CAS 1333117-95-5
DML4GU1	DE	Prostate cancer

DMX2LO3	ID	DMX2LO3
DMX2LO3	DN	99mTc-RP-128
DMX2LO3	HS	Phase 2
DMX2LO3	SN	(SP-5-25)-Hydrogen [N,N-dimethylglycyl-kappaN-L-seryl-kappaN-L-cysteinyl-kappaN,kappaS-glycyl-L-threonyl-L-lysyl-L-prolyl-L-prolyl-L-argininato(4-)]oxotechnetate(1-)-99Tc; 186037-48-9
DMX2LO3	DE	Diagnostic imaging

DMQXYRG	ID	DMQXYRG
DMQXYRG	DN	9-AMINOCAMPTOTHECIN
DMQXYRG	HS	Phase 2
DMQXYRG	SN	IDEC-132; (S)-10-Amino-4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione; 9-Amino-20(S)-camptothecin
DMQXYRG	DT	Small molecular drug
DMQXYRG	PC	72402
DMQXYRG	MW	363.4
DMQXYRG	FM	C20H17N3O4
DMQXYRG	IC	InChI=1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1
DMQXYRG	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)N)O
DMQXYRG	IK	FUXVKZWTXQUGMW-FQEVSTJZSA-N
DMQXYRG	IU	(19S)-8-amino-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMQXYRG	CA	CAS 91421-43-1
DMQXYRG	CB	CHEBI:80755
DMQXYRG	DE	Acquired immune deficiency syndrome

DM57TY3	ID	DM57TY3
DM57TY3	DN	9-ING-41
DM57TY3	HS	Phase 2
DM57TY3	SN	1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione
DM57TY3	CP	Actuate Therapeutics
DM57TY3	DT	Small molecular drug
DM57TY3	PC	44582816
DM57TY3	MW	404.3
DM57TY3	FM	C22H13FN2O5
DM57TY3	IC	InChI=1S/C22H13FN2O5/c1-25-7-13(11-5-17-18(6-15(11)25)30-9-29-17)19-20(22(27)24-21(19)26)14-8-28-16-3-2-10(23)4-12(14)16/h2-8H,9H2,1H3,(H,24,26,27)
DM57TY3	CS	CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F
DM57TY3	IK	FARXPFGGGGLENU-UHFFFAOYSA-N
DM57TY3	IU	3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
DM57TY3	CA	CAS 1034895-42-5
DM57TY3	DE	Solid tumour/cancer; Myelofibrosis

DM6ZIES	ID	DM6ZIES
DM6ZIES	DN	A-6
DM6ZIES	HS	Phase 2
DM6ZIES	SN	Angstrom-6; CD44 binding peptide (cancer), Angstrom
DM6ZIES	CP	Angstrom pharmaceuticals
DM6ZIES	DE	Macular degeneration

DMHOLB7	ID	DMHOLB7
DMHOLB7	DN	A-85380
DMHOLB7	HS	Phase 2
DMHOLB7	SN	A-85380; A 85380; 161416-98-4; CHEMBL59986; (S)-3-(AZETIDIN-2-YLMETHOXY)PYRIDINE; AC1NSJQT; Pyridine, 3-[(2S)-2-azetidinylmethoxy]-; SCHEMBL676026; A-159470; GTPL5460; ZINC3805142; 3-(2(s)-azetidinylmethoxy)pyridine; BDBM50049750; AKOS030230435; NCGC00387223-01; 3-[(2S)-azetidin-2-ylmethoxy]pyridine; 3-[[(2S)-azetidin-2-yl]methoxy]pyridine; 3-((S)-1-Azetidin-2-ylmethoxy)-pyridine; Pyridine, 3-(2-azetidinylmethoxy)-, (S)-
DMHOLB7	DT	Small molecular drug
DMHOLB7	PC	5310969
DMHOLB7	MW	164.2
DMHOLB7	FM	C9H12N2O
DMHOLB7	IC	InChI=1S/C9H12N2O/c1-2-9(6-10-4-1)12-7-8-3-5-11-8/h1-2,4,6,8,11H,3,5,7H2/t8-/m0/s1
DMHOLB7	CS	C1CN[C@@H]1COC2=CN=CC=C2
DMHOLB7	IK	XKFMBGWHHBCWCD-QMMMGPOBSA-N
DMHOLB7	IU	3-[[(2S)-azetidin-2-yl]methoxy]pyridine
DMHOLB7	CA	CAS 161416-98-4

DMOGDCQ	ID	DMOGDCQ
DMOGDCQ	DN	Ab-01
DMOGDCQ	HS	Phase 2
DMOGDCQ	SN	Ab-02; IL-21 receptor-targeted human monoclonal antibodies (inflammation); Anti-IL-21R mAb (inflammation), Pfizer; IL-21 receptor-targeted human monoclonal antibodies (inflammation), Pfizer
DMOGDCQ	CP	Pfizer Inc
DMOGDCQ	DT	Antibody
DMOGDCQ	DE	Inflammation

DMEW62S	ID	DMEW62S
DMEW62S	DN	AB-106
DMEW62S	HS	Phase 2
DMEW62S	SN	DS6051b; GTPL11198; AB106
DMEW62S	CP	AnHeart Therapeutics
DMEW62S	DT	Small molecular drug
DMEW62S	PC	154699459
DMEW62S	MW	405.5
DMEW62S	FM	C23H24FN5O
DMEW62S	IC	InChI=1S/C23H24FN5O/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18/h3-13,15-16H,14,25H2,1-2H3,(H,27,28)
DMEW62S	CS	CC(COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)NC(C)C4=CC(=CC=C4)F)N
DMEW62S	IK	HEVHTYMYEMEBPX-UHFFFAOYSA-N
DMEW62S	IU	3-[4-(2-aminopropoxy)phenyl]-N-[1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine
DMEW62S	DE	Non-small cell lung cancer

DM48DPS	ID	DM48DPS
DM48DPS	DN	AB-729
DM48DPS	HS	Phase 2
DM48DPS	CP	Arbutus Biopharma
DM48DPS	DT	Small interfering RNA
DM48DPS	DE	Hepatitis B virus infection

DM4ZLTY	ID	DM4ZLTY
DM4ZLTY	DN	ABBV-2222
DM4ZLTY	HS	Phase 2
DM4ZLTY	SN	QVDYQHXNAQHIKH-YMBRHYMPSA-N; ABBV 2222; 1918143-53-9; BCP25130
DM4ZLTY	CP	AbbVie
DM4ZLTY	PC	121301049
DM4ZLTY	MW	559.5
DM4ZLTY	FM	C28H21F4NO7
DM4ZLTY	IC	InChI=1S/C28H21F4NO7/c29-26(30)37-17-6-7-18-19(13-21(38-22(18)12-17)14-1-3-15(4-2-14)24(34)35)33-25(36)27(9-10-27)16-5-8-20-23(11-16)40-28(31,32)39-20/h1-8,11-12,19,21,26H,9-10,13H2,(H,33,36)(H,34,35)/t19-,21-/m1/s1
DM4ZLTY	CS	C1CC1(C2=CC3=C(C=C2)OC(O3)(F)F)C(=O)N[C@@H]4C[C@@H](OC5=C4C=CC(=C5)OC(F)F)C6=CC=C(C=C6)C(=O)O
DM4ZLTY	IK	QVDYQHXNAQHIKH-TZIWHRDSSA-N
DM4ZLTY	IU	4-[(2R,4R)-4-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid
DM4ZLTY	CA	CAS 1918143-53-9
DM4ZLTY	DE	Cystic fibrosis

DMT6H3J	ID	DMT6H3J
DMT6H3J	DN	AbGn-168
DMT6H3J	HS	Phase 2
DMT6H3J	SN	AbGn-168H; Antibody 168 (autoimmune diseases), Boehringer Ingelheim/AbGenomics; Anti-CD162 mAb (psoriasis), Boehringer/AbGenomics
DMT6H3J	CP	Abgenomics international
DMT6H3J	DT	Antibody
DMT6H3J	DE	Allergy

DMQ6KZM	ID	DMQ6KZM
DMQ6KZM	DN	ABI-009
DMQ6KZM	HS	Phase 2
DMQ6KZM	CP	Celgene
DMQ6KZM	DE	Solid tumour/cancer; Malignant perivascular epithelioid cell tumour; Non-muscle invasive bladder cancer; Pulmonary arterial hypertension

DM59OJ2	ID	DM59OJ2
DM59OJ2	DN	Abicipar pegol
DM59OJ2	HS	Phase 2
DM59OJ2	CP	Allergan Parsippany, NJ Molecular Partners Zurich, Switzerland
DM59OJ2	DE	Diabetic macular edema

DMX1KDM	ID	DMX1KDM
DMX1KDM	DN	ABI-H0731
DMX1KDM	HS	Phase 2
DMX1KDM	SN	Vebicorvir; UNII-16F6055SMG; 16F6055SMG; 11-Oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide; 2090064-66-5; Vebicorvir [INN]; Vebicorvir [USAN]; SCHEMBL21250344; WHO 11201; Dibenzo(b,F)(1,4)thiazepine-8-carboxamide, 10,11-dihydro-11-oxo-N-((2-(trifluoromethyl)-5-thiazolyl)methyl)-, 5,5-dioxide
DMX1KDM	CP	Assembly Biosciences
DMX1KDM	DT	Small molecular drug
DMX1KDM	PC	139394142
DMX1KDM	MW	467.4
DMX1KDM	FM	C19H12F3N3O4S2
DMX1KDM	IC	InChI=1S/C19H12F3N3O4S2/c20-19(21,22)18-24-9-11(30-18)8-23-16(26)10-5-6-15-13(7-10)25-17(27)12-3-1-2-4-14(12)31(15,28)29/h1-7,9H,8H2,(H,23,26)(H,25,27)
DMX1KDM	CS	C1=CC=C2C(=C1)C(=O)NC3=C(S2(=O)=O)C=CC(=C3)C(=O)NCC4=CN=C(S4)C(F)(F)F
DMX1KDM	IK	LBJVBJYMZKEREY-UHFFFAOYSA-N
DMX1KDM	IU	6,11,11-trioxo-N-[[2-(trifluoromethyl)-1,3-thiazol-5-yl]methyl]-5H-benzo[b][1,4]benzothiazepine-3-carboxamide
DMX1KDM	CA	CAS 2090064-66-5
DMX1KDM	DE	Hepatitis B

DM6X70G	ID	DM6X70G
DM6X70G	DN	ABI-H2158
DM6X70G	HS	Phase 2
DM6X70G	CP	Assembly Biosciences
DM6X70G	DT	Small molecular drug
DM6X70G	DE	Hepatitis B

DMTCXSG	ID	DMTCXSG
DMTCXSG	DN	Abituzumab
DMTCXSG	HS	Phase 2
DMTCXSG	CP	Emd serono
DMTCXSG	DT	Antibody
DMTCXSG	DE	Colorectal cancer

DM23UQ9	ID	DM23UQ9
DM23UQ9	DN	ABT-122
DM23UQ9	HS	Phase 2
DM23UQ9	CP	AbbVie
DM23UQ9	DT	Monoclonal antibody
DM23UQ9	DE	Rheumatoid arthritis; Psoriatic arthritis

DM2OS51	ID	DM2OS51
DM2OS51	DN	ABT-126
DM2OS51	HS	Phase 2
DM2OS51	CP	Abbott Laboratories
DM2OS51	PC	24987875
DM2OS51	MW	313.4
DM2OS51	FM	C17H19N3OS
DM2OS51	IC	InChI=1S/C17H19N3OS/c1-2-4-12(5-3-1)16-18-19-17(22-16)21-15-13-6-11-7-14(15)10-20(8-11)9-13/h1-5,11,13-15H,6-10H2
DM2OS51	CS	C1C2CC3CN(C2)CC1C3OC4=NN=C(S4)C5=CC=CC=C5
DM2OS51	IK	QZDCYUCETTWCMO-UHFFFAOYSA-N
DM2OS51	IU	2-(1-azatricyclo[3.3.1.13,7]decan-4-yloxy)-5-phenyl-1,3,4-thiadiazole
DM2OS51	CA	CAS 1026687-03-5
DM2OS51	DE	Schizophrenia; Alzheimer disease

DMN3S1B	ID	DMN3S1B
DMN3S1B	DN	ABT-229
DMN3S1B	HS	Phase 2
DMN3S1B	SN	Alemcinal; ABT-229; UNII-5DS173ODI4; 5DS173ODI4; ABBOTT-81229.0; 150785-53-8; A-81229; Alemcinal (USAN/INN); CHEMBL300049; ABT229; GTPL1444; BDBM86685; ABT 229; D02801; 8,9-didehydro-N-demethyl-9-deoxo-4', 6, 12-trideoxy-6,9-epoxy-N-ethylerythromycin
DMN3S1B	DT	Small molecular drug
DMN3S1B	PC	9918079
DMN3S1B	MW	697.9
DMN3S1B	FM	C38H67NO10
DMN3S1B	IC	InChI=1S/C38H67NO10/c1-14-28-23(6)30(40)24(7)32-20(3)17-38(11,49-32)34(48-36-31(41)27(39(12)15-2)16-21(4)45-36)25(8)33(26(9)35(42)46-28)47-29-19-37(10,43-13)18-22(5)44-29/h21-31,33-34,36,40-41H,14-19H2,1-13H3/t21-,22+,23+,24-,25+,26-,27+,28-,29+,30+,31-,33+,34-,36+,37+,38-/m1/s1
DMN3S1B	CS	CC[C@@H]1[C@@H]([C@@H]([C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@](C[C@@H](O3)C)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)CC)O)C)C)C)O)C
DMN3S1B	IK	IWTSXJNGTTXMFK-KTQUSEMZSA-N
DMN3S1B	IU	(2R,3S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-11-[(2S,3R,4S,6R)-4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-3-hydroxy-9-[(2S,4S,6S)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DMN3S1B	CA	CAS 150785-53-8
DMN3S1B	DE	Pain

DM7X54F	ID	DM7X54F
DM7X54F	DN	ABT-288
DM7X54F	HS	Phase 2
DM7X54F	SN	ABT-288; UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4
DM7X54F	CP	Abbott Laboratories
DM7X54F	DT	Small molecular drug
DM7X54F	PC	24743471
DM7X54F	MW	372.5
DM7X54F	FM	C23H24N4O
DM7X54F	IC	InChI=1S/C23H24N4O/c1-25-15-19-12-14-26(22(19)16-25)20-8-4-17(5-9-20)18-6-10-21(11-7-18)27-23(28)3-2-13-24-27/h2-11,13,19,22H,12,14-16H2,1H3/t19-,22+/m1/s1
DM7X54F	CS	CN1C[C@H]2CCN([C@H]2C1)C3=CC=C(C=C3)C4=CC=C(C=C4)N5C(=O)C=CC=N5
DM7X54F	IK	GNIRITULTPTAQW-KNQAVFIVSA-N
DM7X54F	IU	2-[4-[4-[(3aR,6aR)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]phenyl]phenyl]pyridazin-3-one
DM7X54F	CA	CAS 948845-91-8
DM7X54F	DE	Alzheimer disease

DM6WN2D	ID	DM6WN2D
DM6WN2D	DN	ABT-308
DM6WN2D	HS	Phase 2
DM6WN2D	DE	Asthma; Eosinophilic esophagitis

DMMZOYN	ID	DMMZOYN
DMMZOYN	DN	ABT-348
DMMZOYN	HS	Phase 2
DMMZOYN	SN	ILORASERTIB; ABT-348; 1227939-82-3; UNII-6L5D03D975; ABT 348; ABT348; 6L5D03D975; A-968660; Abbott-969660; Ilorasertib [USAN:INN]; Ilorasertib (USAN); Kinome_405; GTPL9914; A-968660.0; SCHEMBL3381224; CHEMBL1980297; DTXSID10153718; WPHKIQPVPYJNAX-UHFFFAOYSA-N; BCP07256; ZINC63298074; BDBM50381716; SB16853; CS-6804; DB11694; KB-74395; HY-16018; US8722890, 1; Z-3287; US8722890, 2; D10423; N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea
DMMZOYN	CP	Abbott Laboratories Abbott
DMMZOYN	DT	Small molecular drug
DMMZOYN	PC	46207586
DMMZOYN	MW	488.5
DMMZOYN	FM	C25H21FN6O2S
DMMZOYN	IC	InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)
DMMZOYN	CS	C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CCO)N
DMMZOYN	IK	WPHKIQPVPYJNAX-UHFFFAOYSA-N
DMMZOYN	IU	1-[4-[4-amino-7-[1-(2-hydroxyethyl)pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-3-(3-fluorophenyl)urea
DMMZOYN	CA	CAS 1227939-82-3
DMMZOYN	DE	Haematological malignancy

DM7XW5Y	ID	DM7XW5Y
DM7XW5Y	DN	ABT-384
DM7XW5Y	HS	Phase 2
DM7XW5Y	SN	ABT-384; UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide
DM7XW5Y	CP	Abbott Laboratories
DM7XW5Y	DT	Small molecular drug
DM7XW5Y	PC	11670435
DM7XW5Y	MW	493.6
DM7XW5Y	FM	C25H34F3N5O2
DM7XW5Y	IC	InChI=1S/C25H34F3N5O2/c1-23(2,33-7-5-32(6-8-33)19-4-3-18(14-30-19)25(26,27)28)22(35)31-20-16-9-15-10-17(20)13-24(11-15,12-16)21(29)34/h3-4,14-17,20H,5-13H2,1-2H3,(H2,29,34)(H,31,35)
DM7XW5Y	CS	CC(C)(C(=O)NC1C2CC3CC1CC(C3)(C2)C(=O)N)N4CCN(CC4)C5=NC=C(C=C5)C(F)(F)F
DM7XW5Y	IK	CLHMYBJIOZXCEX-UHFFFAOYSA-N
DM7XW5Y	IU	4-[[2-methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide
DM7XW5Y	CA	CAS 868623-40-9
DM7XW5Y	DE	Alzheimer disease; Hepatitis C virus infection

DMGUTPN	ID	DMGUTPN
DMGUTPN	DN	ABT-414
DMGUTPN	HS	Phase 2
DMGUTPN	CP	Abbvie
DMGUTPN	DT	Antibody
DMGUTPN	DE	Glioblastoma multiforme; Brain cancer; Recurrent glioblastoma

DMNAU1V	ID	DMNAU1V
DMNAU1V	DN	ABT-436
DMNAU1V	HS	Phase 2
DMNAU1V	CP	Abbott Laboratories
DMNAU1V	DE	Anxiety disorder

DMFW860	ID	DMFW860
DMFW860	DN	ABT-450
DMFW860	HS	Phase 2
DMFW860	CP	Abbott; Enanta
DMFW860	PC	45110509
DMFW860	MW	765.9
DMFW860	FM	C40H43N7O7S
DMFW860	IC	InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
DMFW860	CS	CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC/C=C\\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8
DMFW860	IK	UAUIUKWPKRJZJV-QPLHLKROSA-N
DMFW860	IU	(1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
DMFW860	CA	CAS 1216941-48-8
DMFW860	DE	Hepatitis C virus infection

DMPDVM8	ID	DMPDVM8
DMPDVM8	DN	ABT-510
DMPDVM8	HS	Phase 2
DMPDVM8	SN	N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide
DMPDVM8	CP	Abbott Laboratories
DMPDVM8	DT	Small molecular drug
DMPDVM8	PC	6918562
DMPDVM8	MW	994.2
DMPDVM8	FM	C46H83N13O11
DMPDVM8	IC	InChI=1S/C46H83N13O11/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-/m0/s1
DMPDVM8	CS	CCC[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN(C)C(=O)C
DMPDVM8	IK	RIWLPSIAFBLILR-WVNGMBSFSA-N
DMPDVM8	IU	(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R,3S)-2-[[(2S)-2-[[2-[[2-[acetyl(methyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-ethylpyrrolidine-2-carboxamide
DMPDVM8	CA	CAS 251579-55-2
DMPDVM8	DE	Solid tumour/cancer

DMEWQ4X	ID	DMEWQ4X
DMEWQ4X	DN	ABT-639
DMEWQ4X	HS	Phase 2
DMEWQ4X	SN	ABT-639; 1235560-28-7; ABT 639; UNII-0G7D0CQ88I; ABT639; 0G7D0CQ88I; CHEMBL3589557; ABT-639 free base; SCHEMBL400073; GTPL7721; CHEMBL3590674; AGPIHNZOZNKRGT-CYBMUJFWSA-N; MolPort-046-033-584; EX-A1021; BCP17732; BDBM50095309; ZINC113741875; AKOS030526344; SB19105; CS-5515; HY-19721; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylcarbonyl]benzenesulfonamide
DMEWQ4X	DT	Small molecular drug
DMEWQ4X	PC	46851313
DMEWQ4X	MW	455.9
DMEWQ4X	FM	C20H20ClF2N3O3S
DMEWQ4X	IC	InChI=1S/C20H20ClF2N3O3S/c21-15-11-17(23)19(30(28,29)24-18-6-2-1-5-16(18)22)10-14(15)20(27)26-9-8-25-7-3-4-13(25)12-26/h1-2,5-6,10-11,13,24H,3-4,7-9,12H2/t13-/m1/s1
DMEWQ4X	CS	C1C[C@@H]2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F
DMEWQ4X	IK	AGPIHNZOZNKRGT-CYBMUJFWSA-N
DMEWQ4X	IU	5-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine-2-carbonyl]-4-chloro-2-fluoro-N-(2-fluorophenyl)benzenesulfonamide
DMEWQ4X	CA	CAS 1235560-28-7
DMEWQ4X	DE	Pain

DMLEO2Z	ID	DMLEO2Z
DMLEO2Z	DN	ABT-652
DMLEO2Z	HS	Phase 2
DMLEO2Z	CP	Abbott Laboratories
DMLEO2Z	DE	Musculoskeletal pain; Diabetic neuropathy

DMNG35S	ID	DMNG35S
DMNG35S	DN	ABT-751
DMNG35S	HS	Phase 2
DMNG35S	SN	ABT-751; 141430-65-1; ABT 751; E-7010; ABT751; ABT-751 (E7010); UNII-WDT5V5OB9F; E 7010; WDT5V5OB9F; N-[2-[(4-HYDROXYPHENYL)AMINO]-3-PYRIDYL]-4-METHOXYBENZENESULFONAMIDE; CHEMBL20684; N-(2-((4-Hydroxyphenyl)amino)-3-pyridinyl)-4-methoxybenzenesulfonamide; N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide; Benzenesulfonamide,N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy-; N-(2-(4-hydroxyphenylamino)pyridin-3-yl)-4-methoxybenzenesulfonamide
DMNG35S	DT	Small molecular drug
DMNG35S	PC	3035714
DMNG35S	MW	371.4
DMNG35S	FM	C18H17N3O4S
DMNG35S	IC	InChI=1S/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20)
DMNG35S	CS	COC1=CC=C(C=C1)S(=O)(=O)NC2=C(N=CC=C2)NC3=CC=C(C=C3)O
DMNG35S	IK	URCVCIZFVQDVPM-UHFFFAOYSA-N
DMNG35S	IU	N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide
DMNG35S	CA	CAS 141430-65-1
DMNG35S	CB	CHEBI:95043
DMNG35S	DE	Solid tumour/cancer

DM6PTIX	ID	DM6PTIX
DM6PTIX	DN	ABT-981
DM6PTIX	HS	Phase 2
DM6PTIX	CP	AbbVie
DM6PTIX	DT	Monoclonal antibody
DM6PTIX	DE	Osteoarthritis

DM9Y1XB	ID	DM9Y1XB
DM9Y1XB	DN	ABT-RTA-408
DM9Y1XB	HS	Phase 2
DM9Y1XB	CP	Abbvie; reata pharmaceuticals
DM9Y1XB	DE	Non-small-cell lung cancer

DM91U0R	ID	DM91U0R
DM91U0R	DN	ABX-EGF
DM91U0R	HS	Phase 2
DM91U0R	DT	Antibody

DMCZFMS	ID	DMCZFMS
DMCZFMS	DN	ABX-IL8
DMCZFMS	HS	Phase 2
DMCZFMS	DT	Antibody
DMCZFMS	DE	Melanoma

DMNVFZA	ID	DMNVFZA
DMNVFZA	DN	AC-1202
DMNVFZA	HS	Phase 2
DMNVFZA	SN	Ketasyn
DMNVFZA	CP	Accera
DMNVFZA	DT	Small molecular drug
DMNVFZA	PC	10850
DMNVFZA	MW	470.7
DMNVFZA	FM	C27H50O6
DMNVFZA	IC	InChI=1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3
DMNVFZA	CS	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC
DMNVFZA	IK	VLPFTAMPNXLGLX-UHFFFAOYSA-N
DMNVFZA	IU	2,3-di(octanoyloxy)propyl octanoate
DMNVFZA	CA	CAS 538-23-8
DMNVFZA	CB	CHEBI:76978
DMNVFZA	DE	Memory loss

DMB0TNL	ID	DMB0TNL
DMB0TNL	DN	AC-201
DMB0TNL	HS	Phase 2
DMB0TNL	CP	TWi Biotechnology Taipei, Taiwan
DMB0TNL	DE	Type-2 diabetes

DM3TUBR	ID	DM3TUBR
DM3TUBR	DN	Acalabrutinib
DM3TUBR	HS	Phase 2 
DM3TUBR	SN	Acalabrutinib; 1420477-60-6; ACP-196; Calquence; UNII-I42748ELQW; I42748ELQW; Benzamide; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Acalabrutinib (ACP-196); Calquence (TN); Benzamide, ACP-196; Acalabrutinib; Acalabrutinib(ACP196); GTPL8912; CHEMBL3707348; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; ACP 196; WDENQI; Acalabrutinib
DM3TUBR	TC	Antiviral Agents
DM3TUBR	DT	Small molecular drug
DM3TUBR	PC	71226662
DM3TUBR	MW	465.5
DM3TUBR	FM	C26H23N7O2
DM3TUBR	IC	InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
DM3TUBR	CS	CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
DM3TUBR	IK	WDENQIQQYWYTPO-IBGZPJMESA-N
DM3TUBR	IU	4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
DM3TUBR	CA	CAS 1420477-60-6
DM3TUBR	DE	Coronavirus Disease 2019 (COVID-19)

DM0FGDO	ID	DM0FGDO
DM0FGDO	DN	ACCLAIM
DM0FGDO	HS	Phase 2
DM0FGDO	SN	Depon; Excel; Furore; PUMA; Whip; Fenoxaprop ethyl; Fenoxaprop ethyl ester; Fenoxaprop ethyl ester [ANSI]; Tiller Herbicide; HOE 33171; FENOXAPROP-ETHYL; HOE-A 25-01; Ethyl 2-(4-((6-chlorobenzoxazol-2-yl)oxy)phenoxy)propionate; Ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate [French]; Ethyl 2-(4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy)propanoate; Ethyl 2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate; Ethyl-2-((4-(6-chloro-2-benzoxazolyloxy))-phenoxy)propionate; Ethyl (+-)-2-(4-(6-chloro-2-benzoxazolyloxy)phenoxy)propanoate; Propanoic acid, 2-(4-((6-chloro-2-benzoxazolyl)oxy)phenoxy)-, ethyl ester; (+/-)-2-(4-((6-Chloro-2-benzoxazolyl)oxy)phenoxy)propanoic acid ethyl ester; 2-(4-((6-Chloro-2-benzoxazolylen)oxy)phenoxy)propanoic acid, ethyl ester
DM0FGDO	CP	Angiogenix
DM0FGDO	DT	Small molecular drug
DM0FGDO	PC	47938
DM0FGDO	MW	361.8
DM0FGDO	FM	C18H16ClNO5
DM0FGDO	IC	InChI=1S/C18H16ClNO5/c1-3-22-17(21)11(2)23-13-5-7-14(8-6-13)24-18-20-15-9-4-12(19)10-16(15)25-18/h4-11H,3H2,1-2H3
DM0FGDO	CS	CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl
DM0FGDO	IK	PQKBPHSEKWERTG-UHFFFAOYSA-N
DM0FGDO	IU	ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate
DM0FGDO	CA	CAS 66441-23-4
DM0FGDO	CB	CHEBI:5008
DM0FGDO	DE	Coronary artery disease; Angina pectoris

DMZ8PY0	ID	DMZ8PY0
DMZ8PY0	DN	ACE-031
DMZ8PY0	HS	Phase 2
DMZ8PY0	CP	Acceleron Pharma
DMZ8PY0	DE	Duchenne dystrophy

DMIVUFL	ID	DMIVUFL
DMIVUFL	DN	ACH-1625
DMIVUFL	HS	Phase 2
DMIVUFL	SN	SOVAPREVIR; 1001667-23-7; UNII-2ND9V3MN6O; ACH-0141625; 2ND9V3MN6O; Sovaprevir [USAN:INN]; Sovaprevir (USAN); Prodrug of ACH-1095; SCHEMBL1462843; CHEMBL2105750; DTXSID00142994; DB12069; SB16836; D10166; 2-Pyrrolidinecarboxamide, N-((1R,2S)-1-(((cyclopropylsulfonyl)amino)carbonyl)-2- ethenylcyclopropyl)-1-((2S)-3,3-dimethyl-1-oxo-2-(2-oxo-2-(1-piperidinyl)ethyl)butyl)-4-
DMIVUFL	CP	Achillion
DMIVUFL	DT	Small molecular drug
DMIVUFL	PC	53362096
DMIVUFL	MW	800
DMIVUFL	FM	C43H53N5O8S
DMIVUFL	IC	InChI=1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1
DMIVUFL	CS	CC(C)(C)[C@H](CC(=O)N1CCCCC1)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7
DMIVUFL	IK	MHFMTUBUVQZIRE-WINRQGAFSA-N
DMIVUFL	IU	(2S,4R)-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-3,3-dimethyl-2-(2-oxo-2-piperidin-1-ylethyl)butanoyl]-4-(7-methoxy-2-phenylquinolin-4-yl)oxypyrrolidine-2-carboxamide
DMIVUFL	CA	CAS 1001667-23-7
DMIVUFL	DE	Hepatitis C virus infection

DM0RPY5	ID	DM0RPY5
DM0RPY5	DN	ACH-3102
DM0RPY5	HS	Phase 2
DM0RPY5	CP	Achillion pharmaceuticals
DM0RPY5	PC	71474517
DM0RPY5	MW	1001.3
DM0RPY5	FM	C60H72N8O6
DM0RPY5	IC	InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1
DM0RPY5	CS	CC(C)[C@@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DM0RPY5	IK	LSYBRGMTRKJATA-IVEWBXRVSA-N
DM0RPY5	IU	methyl N-[(2S)-1-[(2S,3aS,7aS)-2-[6-[11-[2-[(2S,3aS,7aS)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2,3,3a,4,5,6,7,7a-octahydroindol-2-yl]-3H-benzimidazol-5-yl]-5-tricyclo[8.2.2.24,7]hexadeca-1(12),4,6,10,13,15-hexaenyl]-1H-benzimidazol-2-yl]-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DM0RPY5	CA	CAS 1415119-52-6
DM0RPY5	DE	Hepatitis C virus infection

DMLVCZR	ID	DMLVCZR
DMLVCZR	DN	ACH-4471
DMLVCZR	HS	Phase 2
DMLVCZR	SN	PIBARDGJJAGJAJ-NQIIRXRSSA-N; UNII-JM8C1SFX0U; JM8C1SFX0U; SCHEMBL17024981; 1903768-17-1; (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide
DMLVCZR	CP	Achillion Pharmaceuticals New Haven, CT
DMLVCZR	PC	118323590
DMLVCZR	MW	580.4
DMLVCZR	FM	C26H23BrFN7O3
DMLVCZR	IC	InChI=1S/C26H23BrFN7O3/c1-14(36)25-19-8-16(17-10-29-15(2)30-11-17)6-7-20(19)35(33-25)13-24(37)34-12-18(28)9-21(34)26(38)32-23-5-3-4-22(27)31-23/h3-8,10-11,18,21H,9,12-13H2,1-2H3,(H,31,32,38)/t18-,21+/m1/s1
DMLVCZR	CS	CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4C[C@@H](C[C@H]4C(=O)NC5=NC(=CC=C5)Br)F
DMLVCZR	IK	PIBARDGJJAGJAJ-NQIIRXRSSA-N
DMLVCZR	IU	(2S,4R)-1-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide
DMLVCZR	CA	CAS 1903768-17-1
DMLVCZR	DE	Glomerulonephritis; Anaemia

DMPR8E9	ID	DMPR8E9
DMPR8E9	DN	ACP-001
DMPR8E9	HS	Phase 2
DMPR8E9	SN	TransCon-PEG Growth Hormone; TransCon-PEG-hGH; Growth hormone (TransCon, subcutaneous sustained-release), Ascendis Pharma
DMPR8E9	CP	Ascendis Pharma A/S
DMPR8E9	DE	Growth hormone deficiency

DMMG61B	ID	DMMG61B
DMMG61B	DN	ACT-GRO-777
DMMG61B	HS	Phase 2
DMMG61B	SN	AGRO-100; AS-1411; Anticancer aptamers, Aptamera; GRO-26B; AGRO-100 derivatives, Aptamera; Nucleolin inhibitors (cancer), Aptamera; Nucleolin inhibitors (iv, acute myeloid leukemia), Advanced Cancer Therapeutics
DMMG61B	CP	Aptamera Inc
DMMG61B	DT	Aptamer
DMMG61B	DE	Solid tumour/cancer

DMKBIPR	ID	DMKBIPR
DMKBIPR	DN	Actimab-A
DMKBIPR	HS	Phase 2
DMKBIPR	CP	Actinium Pharmaceuticals New York, NY
DMKBIPR	DE	Acute myeloid leukaemia

DM9GRTK	ID	DM9GRTK
DM9GRTK	DN	ACYLINE
DM9GRTK	HS	Phase 2
DM9GRTK	SN	Acyline; UNII-S3439D3B35; CHEMBL262747; S3439D3B35; BDBM50102456; DB11906; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-(acetylamino)-L-phenylalanyl-4-(acetylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-; Z-3146; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(Ac)]-D-[Aph(Ac)]-Leu-ILys-Pro-DAla-NH2
DM9GRTK	PC	16137348
DM9GRTK	MW	1533.2
DM9GRTK	FM	C80H102ClN15O14
DM9GRTK	IC	InChI=1S/C80H102ClN15O14/c1-46(2)37-63(72(102)89-62(18-11-12-35-84-47(3)4)80(110)96-36-14-19-70(96)79(109)85-48(5)71(82)101)90-74(104)66(40-53-23-30-60(31-24-53)86-49(6)98)92-76(106)67(41-54-25-32-61(33-26-54)87-50(7)99)94-78(108)69(45-97)95-77(107)68(43-56-15-13-34-83-44-56)93-75(105)65(39-52-21-28-59(81)29-22-52)91-73(103)64(88-51(8)100)42-55-20-27-57-16-9-10-17-58(57)38-55/h9-10,13,15-17,20-34,38,44,46-48,62-70,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,109)(H,86,98)(H,87,99)(H,88,100)(H,89,102)(H,90,104)(H,91,103)(H,92,106)(H,93,105)(H,94,108)(H,95,107)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,70+/m1/s1
DM9GRTK	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM9GRTK	IK	ZWNUQDJANZGVFO-YHSALVGYSA-N
DM9GRTK	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM9GRTK	CA	CAS 170157-13-8
DM9GRTK	DE	Prostate cancer

DMLV9GS	ID	DMLV9GS
DMLV9GS	DN	AD04
DMLV9GS	HS	Phase 2
DMLV9GS	CP	ADial Pharmaceuticals Charlottesville, VA
DMLV9GS	DE	Alcohol dependence; Opioid dependence

DMMFLXN	ID	DMMFLXN
DMMFLXN	DN	AD-452
DMMFLXN	HS	Phase 2
DMMFLXN	SN	RS(+)-mefloquine; (+)-erythro-mefloquine
DMMFLXN	CP	Sosei R&D Ltd
DMMFLXN	DE	Rheumatoid arthritis

DM8GHIX	ID	DM8GHIX
DM8GHIX	DN	ADC-3680
DM8GHIX	HS	Phase 2
DM8GHIX	SN	ADC-3680B; CRTh2 antagonists (oral, allergic asthma/allergic rhinitis/COPD), Argenta Discovery; CRTh2 antagonists (oral, allergic asthma/allergic rhinitis/COPD), Pulmagen; Prostaglandin D2 receptor antagonists (oral, COPD/allergic asthma/allergic rhinitis), Argenta Discovery
DM8GHIX	CP	Argenta Discovery Ltd
DM8GHIX	DE	Allergic rhinitis

DM821BS	ID	DM821BS
DM821BS	DN	Adipiplon
DM821BS	HS	Phase 2
DM821BS	SN	GABA modulator (insomnia), Neurogen; NG-2-73
DM821BS	CP	Neurogen Corporation
DM821BS	DT	Small molecular drug
DM821BS	PC	11198924
DM821BS	MW	351.4
DM821BS	FM	C18H18FN7
DM821BS	IC	InChI=1S/C18H18FN7/c1-3-5-13-15(22-11-26-17(13)23-12(2)24-26)10-25-9-8-21-18(25)16-14(19)6-4-7-20-16/h4,6-9,11H,3,5,10H2,1-2H3
DM821BS	CS	CCCC1=C(N=CN2C1=NC(=N2)C)CN3C=CN=C3C4=C(C=CC=N4)F
DM821BS	IK	UAMAIHOEGLEXSV-UHFFFAOYSA-N
DM821BS	IU	7-[[2-(3-fluoropyridin-2-yl)imidazol-1-yl]methyl]-2-methyl-8-propyl-[1,2,4]triazolo[1,5-c]pyrimidine
DM821BS	CA	CAS 840486-93-3
DM821BS	DE	Sleep-wake disorder

DMMUPTN	ID	DMMUPTN
DMMUPTN	DN	ADL-5747
DMMUPTN	HS	Phase 2
DMMUPTN	CP	Pfizer
DMMUPTN	DT	Small molecular drug
DMMUPTN	PC	76967747
DMMUPTN	MW	428.9
DMMUPTN	FM	C24H29ClN2O3
DMMUPTN	IC	InChI=1S/C24H28N2O3.ClH/c1-3-26(4-2)23(28)17-9-10-18(21(27)15-17)20-16-24(11-13-25-14-12-24)29-22-8-6-5-7-19(20)22;/h5-10,15-16,25,27H,3-4,11-14H2,1-2H3;1H
DMMUPTN	CS	CCN(CC)C(=O)C1=CC(=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC=C42)O.Cl
DMMUPTN	IK	XROFSGVHHSJMMG-UHFFFAOYSA-N
DMMUPTN	IU	N,N-diethyl-3-hydroxy-4-spiro[chromene-2,4'-piperidine]-4-ylbenzamide;hydrochloride
DMMUPTN	CA	CAS 1187653-56-0
DMMUPTN	DE	Pain

DMDQH9A	ID	DMDQH9A
DMDQH9A	DN	ADL-5859
DMDQH9A	HS	Phase 2
DMDQH9A	SN	PF-04856880
DMDQH9A	CP	Pfizer
DMDQH9A	DT	Small molecular drug
DMDQH9A	PC	46931003
DMDQH9A	MW	428.9
DMDQH9A	FM	C24H29ClN2O3
DMDQH9A	IC	InChI=1S/C24H28N2O3.ClH/c1-3-26(4-2)23(28)18-10-8-17(9-11-18)19-16-24(12-14-25-15-13-24)29-21-7-5-6-20(27)22(19)21;/h5-11,16,25,27H,3-4,12-15H2,1-2H3;1H
DMDQH9A	CS	CCN(CC)C(=O)C1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC(=C42)O.Cl
DMDQH9A	IK	ZFNLSWREIULTDO-UHFFFAOYSA-N
DMDQH9A	IU	N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide;hydrochloride
DMDQH9A	CA	CAS 850173-95-4
DMDQH9A	DE	Rheumatoid arthritis

DM819CO	ID	DM819CO
DM819CO	DN	ADMVA
DM819CO	HS	Phase 2
DM819CO	SN	RMVA vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankara vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankaravaccine (HIV-1), Aaron Diamond AIDS Research Center; DNA vaccine (gag, pol, env, tat, nef), ADARC; DNA vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center; HIV-1 vaccine (gag, pol, env, tat, nef), ADARC; HIV-1 vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center
DM819CO	CP	Aaron Diamond AIDS Research Center
DM819CO	DT	Vaccine
DM819CO	DE	Diabetic complication

DMJSWXL	ID	DMJSWXL
DMJSWXL	DN	Ad-p53
DMJSWXL	HS	Phase 2
DMJSWXL	SN	P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough
DMJSWXL	CP	Transgene SA
DMJSWXL	DE	Colorectal cancer; Solid tumour/cancer

DMRYH3M	ID	DMRYH3M
DMRYH3M	DN	ADP-A2M4
DMRYH3M	HS	Phase 2
DMRYH3M	CP	Adaptimmune
DMRYH3M	DE	Solid tumour/cancer; Synovial sarcoma

DME384W	ID	DME384W
DME384W	DN	AdPEDR
DME384W	HS	Phase 2
DME384W	CP	GenVec
DME384W	DT	Small molecular drug
DME384W	PC	11557063
DME384W	MW	964.7
DME384W	FM	C38H41IN14O9
DME384W	IC	InChI=1S/C20H22N8O5.C18H19IN6O4/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)/t13-;12-,13+,14-,18+/m00/s1
DME384W	CS	CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O.CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DME384W	IK	BDNQEWFVMDIRTE-VXJTWHGRSA-N
DME384W	IU	(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;(2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide
DME384W	DE	Exudative age-related macular degeneration

DMCNTFW	ID	DMCNTFW
DMCNTFW	DN	Ad-RTS-hIL-12
DMCNTFW	HS	Phase 2
DMCNTFW	CP	Ziopharm Oncology
DMCNTFW	DT	Gene therapy
DMCNTFW	DE	Melanoma; Malignant glioma; Recurrent glioblastoma; Glioblastoma of brain

DMM6B2Y	ID	DMM6B2Y
DMM6B2Y	DN	ADU- S100
DMM6B2Y	HS	Phase 2
DMM6B2Y	DT	Small molecular drug
DMM6B2Y	DE	Head and neck cancer

DM8HBUI	ID	DM8HBUI
DM8HBUI	DN	ADU-S100
DM8HBUI	HS	Phase 2
DM8HBUI	SN	MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885
DM8HBUI	CP	Aduro Biotech Berkeley, CANovartis Oncology East Hanover, NJ
DM8HBUI	PC	135390762
DM8HBUI	MW	734.5
DM8HBUI	FM	C20H22N10Na2O10P2S2
DM8HBUI	IC	InChI=1S/C20H24N10O10P2S2.2Na/c21-15-9-17(25-3-23-15)29(5-27-9)19-12(32)13-8(38-19)2-36-42(34,44)40-14-11(31)7(1-35-41(33,43)39-13)37-20(14)30-6-28-10-16(22)24-4-26-18(10)30;;/h3-8,11-14,19-20,31-32H,1-2H2,(H,33,43)(H,34,44)(H2,21,23,25)(H2,22,24,26);;/q;2*+1/p-2/t7-,8-,11-,12-,13-,14-,19-,20-,41?,42?;;/m1../s1
DM8HBUI	CS	C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)OP(=S)(OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)O)OP(=O)(O1)[S-])[O-])O.[Na+].[Na+]
DM8HBUI	IK	GDWOOOCBNOMMTL-QYUKNOIISA-L
DM8HBUI	IU	disodium;(1R,6R,8R,9R,10S,15R,17R,18R)-8,17-bis(6-aminopurin-9-yl)-3-oxido-12-oxo-3-sulfanylidene-12-sulfido-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecane-9,18-diol
DM8HBUI	CA	CAS 1638750-95-4
DM8HBUI	DE	Solid tumour/cancer; Head and neck cancer

DMGVKHQ	ID	DMGVKHQ
DMGVKHQ	DN	ADX10059
DMGVKHQ	HS	Phase 2
DMGVKHQ	CP	Addex Pharma.
DMGVKHQ	DE	Anxiety disorder

DMC8NAO	ID	DMC8NAO
DMC8NAO	DN	ADXS-HPV
DMC8NAO	HS	Phase 2
DMC8NAO	CP	Advaxis
DMC8NAO	DT	Vaccine
DMC8NAO	DE	Cervical Intraepithelial neoplasia; Cervical cancer

DMJVN89	ID	DMJVN89
DMJVN89	DN	AEB07
DMJVN89	HS	Phase 2
DMJVN89	CP	Novartis
DMJVN89	DT	Small molecular drug
DMJVN89	PC	9963383
DMJVN89	MW	1078.3
DMJVN89	FM	C52H71N9O12S2
DMJVN89	IC	InChI=1S/C27H36N4O5S.C24H31N5O4.CH4O3S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27;1-3-16-6-8-19(27-23(16)25-2)9-7-17-10-12-29(24(17)33)15-21(30)28-20(13-22(31)32)18-5-4-11-26-14-18;1-5(2,3)4/h4-12,22H,13-19,28H2,1-3H3,(H,29,33);4-6,8,11,14,17,20H,3,7,9-10,12-13,15H2,1-2H3,(H,25,27)(H,28,30)(H,31,32);1H3,(H,2,3,4)/t22-;17-,20-;/m10./s1
DMJVN89	CS	CCC1=C(N=C(C=C1)CC[C@H]2CCN(C2=O)CC(=O)N[C@@H](CC(=O)O)C3=CN=CC=C3)NC.CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N.CS(=O)(=O)O
DMJVN89	IK	XAOWMNBAVQDQSR-WQDYQDSXSA-N
DMJVN89	IU	2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;(3S)-3-[[2-[(3S)-3-[2-[5-ethyl-6-(methylamino)pyridin-2-yl]ethyl]-2-oxopyrrolidin-1-yl]acetyl]amino]-3-pyridin-3-ylpropanoic acid;methanesulfonic acid
DMJVN89	DE	Transplant rejection

DMQ1GH4	ID	DMQ1GH4
DMQ1GH4	DN	AEF0117
DMQ1GH4	HS	Phase 2
DMQ1GH4	CP	Aelis Farma
DMQ1GH4	DT	Small molecular drug
DMQ1GH4	DE	Marijuana use disorder

DMSBLOU	ID	DMSBLOU
DMSBLOU	DN	AEG-33773
DMSBLOU	HS	Phase 2
DMSBLOU	CP	Aegera Therapeutics Inc
DMSBLOU	DE	Diabetic neuropathy

DMI5TXZ	ID	DMI5TXZ
DMI5TXZ	DN	AEM-28
DMI5TXZ	HS	Phase 2
DMI5TXZ	SN	Apo-E peptide mimetic (acute coronary syndrome), University of Alabama at Birmingham/LipimetiX
DMI5TXZ	CP	Lipimetix development
DMI5TXZ	DE	Hyperlipidaemia; Familial hypercholesterolemia

DMNO7BC	ID	DMNO7BC
DMNO7BC	DN	AeroLEF
DMNO7BC	HS	Phase 2
DMNO7BC	DE	Pain

DMFO2G5	ID	DMFO2G5
DMFO2G5	DN	Afabicin
DMFO2G5	HS	Phase 2
DMFO2G5	SN	UNII-DMM8663H2R; DMM8663H2R; 1518800-35-5; Afabicin [INN]; SCHEMBL15479062; SCHEMBL16262317; (6-((1E)-3-(Methyl((3-methyl-1-benzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate; 2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-8-((phosphonooxy)methyl)-1,8-naphthyridin-3-yl)-, (2E)-
DMFO2G5	CP	Debiopharm Lausanne, Switzerland
DMFO2G5	PC	72696796
DMFO2G5	MW	485.4
DMFO2G5	FM	C23H24N3O7P
DMFO2G5	IC	InChI=1S/C23H24N3O7P/c1-15-18-5-3-4-6-19(18)33-20(15)13-25(2)21(27)9-7-16-11-17-8-10-22(28)26(23(17)24-12-16)14-32-34(29,30)31/h3-7,9,11-12H,8,10,13-14H2,1-2H3,(H2,29,30,31)/b9-7+
DMFO2G5	CS	CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(N=C3)N(C(=O)CC4)COP(=O)(O)O
DMFO2G5	IK	HFYMDQMXVPJNTH-VQHVLOKHSA-N
DMFO2G5	IU	[6-[(E)-3-[methyl-[(3-methyl-1-benzofuran-2-yl)methyl]amino]-3-oxoprop-1-enyl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1-yl]methyl dihydrogen phosphate
DMFO2G5	CA	CAS 1518800-35-5
DMFO2G5	DE	Acute bacterial skin infection

DMFORDT	ID	DMFORDT
DMFORDT	DN	Afimoxifene
DMFORDT	HS	Phase 2
DMFORDT	SN	4-Hydroxytamoxifen; Afimoxifene; (Z)-4-Hydroxytamoxifen; Hydroxytamoxifen; 4-Monohydroxytamoxifen; Tamogel; 68047-06-3; trans-4-Hydroxytamoxifen; Ici 79280; 68392-35-8; 65213-48-1; 4-OH-TAM; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; Z-4-hydroxytamoxifen; UNII-95K54647BZ; CHEMBL489; ICI 79,280; TAMOXIFEN, 4-HYDROXY-, (Z)-; BRN 4910749; (E/Z)-4-Hydroxy Tamoxifen; MLS000069742; C26H29NO2; CHEBI:44616; 95K54647BZ; SMR000058939; 4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
DMFORDT	CP	ASCEND Therapeutics
DMFORDT	DT	Small molecular drug
DMFORDT	PC	449459
DMFORDT	MW	387.5
DMFORDT	FM	C26H29NO2
DMFORDT	IC	InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-
DMFORDT	CS	CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
DMFORDT	IK	TXUZVZSFRXZGTL-QPLCGJKRSA-N
DMFORDT	IU	4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMFORDT	CA	CAS 68047-06-3
DMFORDT	CB	CHEBI:44616
DMFORDT	DE	Breast cancer; Ductal carcinoma

DMN45IC	ID	DMN45IC
DMN45IC	DN	AFM13
DMN45IC	HS	Phase 2
DMN45IC	CP	Affimed Therapeutics
DMN45IC	DT	Antibody
DMN45IC	DE	Hodgkin lymphoma; Lymphoma; Peripheral T-cell lymphoma; Mycosis fungoides

DMTFE9Y	ID	DMTFE9Y
DMTFE9Y	DN	AFN-1252
DMTFE9Y	HS	Phase 2
DMTFE9Y	SN	API-1252; API-1401; Antibacterial therapeutics, Affinium; Antibacterials, Affinium; Bacterial fatty acid biosynthesis inhibitors, Affinium; Galapagos program, Affinium; Antibacterial therapeutics, Affinium/GSK; Antibacterials, Affinium/GSK; FabI inhibitors (antibacterial), Affinium; AFN-1252 (oral, bacterial infection); AFN-1252 (oral, bacterial infection), Affinium
DMTFE9Y	CP	Affinium pharmaceuticals
DMTFE9Y	DT	Small molecular drug
DMTFE9Y	PC	10407120
DMTFE9Y	MW	375.4
DMTFE9Y	FM	C22H21N3O3
DMTFE9Y	IC	InChI=1S/C22H21N3O3/c1-14-17-5-3-4-6-18(17)28-19(14)13-25(2)21(27)10-7-15-11-16-8-9-20(26)24-22(16)23-12-15/h3-7,10-12H,8-9,13H2,1-2H3,(H,23,24,26)/b10-7+
DMTFE9Y	CS	CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(NC(=O)CC4)N=C3
DMTFE9Y	IK	QXTWSUQCXCWEHF-JXMROGBWSA-N
DMTFE9Y	IU	(E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-3-yl)prop-2-enamide
DMTFE9Y	CA	CAS 620175-39-5
DMTFE9Y	DE	Staphylococcus infection

DM6AJKC	ID	DM6AJKC
DM6AJKC	DN	AFN-1720
DM6AJKC	HS	Phase 2
DM6AJKC	CP	Affinium pharmaceuticals
DM6AJKC	DE	Bacterial infection

DM1FJ2B	ID	DM1FJ2B
DM1FJ2B	DN	AFP464
DM1FJ2B	HS	Phase 2
DM1FJ2B	SN	UNII-73JNH95XPX; AFP464; 73JNH95XPX; 468719-53-1; AFP 464; AFP-464; Hexanamide, 2,6-diamino-N-(4-(5-amino-6,8-difluoro-7-methyl-4-oxo-4H-1-benzopyran-2-yl)-2-fluorophenyl)-, (2S)-, dimethanesulfonate
DM1FJ2B	CP	Kirax
DM1FJ2B	DT	Small molecular drug
DM1FJ2B	PC	399587
DM1FJ2B	MW	544.5
DM1FJ2B	FM	C23H27F3N4O6S
DM1FJ2B	IC	InChI=1S/C22H23F3N4O3.CH4O3S/c1-10-18(24)20(28)17-15(30)9-16(32-21(17)19(10)25)11-5-6-14(12(23)8-11)29-22(31)13(27)4-2-3-7-26;1-5(2,3)4/h5-6,8-9,13H,2-4,7,26-28H2,1H3,(H,29,31);1H3,(H,2,3,4)/t13-;/m0./s1
DM1FJ2B	CS	CC1=C(C(=C2C(=O)C=C(OC2=C1F)C3=CC(=C(C=C3)NC(=O)[C@H](CCCCN)N)F)N)F.CS(=O)(=O)O
DM1FJ2B	IK	MJVICFBYAVBBOA-ZOWNYOTGSA-N
DM1FJ2B	IU	(2S)-2,6-diamino-N-[4-(5-amino-6,8-difluoro-7-methyl-4-oxochromen-2-yl)-2-fluorophenyl]hexanamide;methanesulfonic acid
DM1FJ2B	CA	CAS 468719-53-1
DM1FJ2B	DE	Breast cancer

DMD3XMG	ID	DMD3XMG
DMD3XMG	DN	AFTVac
DMD3XMG	HS	Phase 2
DMD3XMG	SN	Autologous fixed tumor vaccine (AFTVac) therapy; Autologous vaccine (cancer), Cell-Medicine; GM-CSF agonist/IL-2 agonist containing-vaccine; Fixed autologous tumor derivatives + microparticles encapsulating GM-CSF and IL-2, Cell-Medicine
DMD3XMG	CP	Cell-Medicine Inc
DMD3XMG	DT	Vaccine
DMD3XMG	DE	Glioblastoma multiforme

DMA9FKY	ID	DMA9FKY
DMA9FKY	DN	AG140699
DMA9FKY	HS	Phase 2
DMA9FKY	CP	Pfizer
DMA9FKY	TC	Anticancer Agents
DMA9FKY	DE	Melanoma

DMNQ5T2	ID	DMNQ5T2
DMNQ5T2	DN	AG-858
DMNQ5T2	HS	Phase 2
DMNQ5T2	SN	Chronic myeloid leukemia therapy, Antigenics; HSP-70 cancer vaccine, Antigenics; HSPPC-70 (cancer); HSPPC-70-C
DMNQ5T2	CP	Agenus Inc; Antigenics
DMNQ5T2	DT	Vaccine
DMNQ5T2	DE	leukaemia

DMPO7UG	ID	DMPO7UG
DMPO7UG	DN	AGEN2034
DMPO7UG	HS	Phase 2
DMPO7UG	CP	AgenusLexington, MA
DMPO7UG	DT	Monoclonal antibody
DMPO7UG	DE	Solid tumour/cancer; Cervical cancer

DMP5Y1A	ID	DMP5Y1A
DMP5Y1A	DN	AGN-199981
DMP5Y1A	HS	Phase 2
DMP5Y1A	CP	Allergan
DMP5Y1A	TC	Analgesics
DMP5Y1A	DE	Neuropathic pain

DM4KOAC	ID	DM4KOAC
DM4KOAC	DN	AGN-241751
DM4KOAC	HS	Phase 2
DM4KOAC	CP	Allergan
DM4KOAC	DT	Small molecular drug
DM4KOAC	DE	Major depressive disorder

DMLQRFO	ID	DMLQRFO
DMLQRFO	DN	AGN-2979
DMLQRFO	HS	Phase 2
DMLQRFO	SN	BTG-1501; SC-48274; AGN-2979 (free base); 3-[3-(Dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione; 3-[3-(Dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione monohydrochloride
DMLQRFO	DT	Small molecular drug
DMLQRFO	PC	40914
DMLQRFO	MW	332.4
DMLQRFO	FM	C19H28N2O3
DMLQRFO	IC	InChI=1S/C19H28N2O3/c1-18(2)13-16(22)20-17(23)19(18,10-7-11-21(3)4)14-8-6-9-15(12-14)24-5/h6,8-9,12H,7,10-11,13H2,1-5H3,(H,20,22,23)
DMLQRFO	CS	CC1(CC(=O)NC(=O)C1(CCCN(C)C)C2=CC(=CC=C2)OC)C
DMLQRFO	IK	UJFNSGBGJMRZKS-UHFFFAOYSA-N
DMLQRFO	IU	3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione
DMLQRFO	CA	CAS 53873-21-5
DMLQRFO	DE	Psychotic disorder

DMMGAUK	ID	DMMGAUK
DMMGAUK	DN	AGN-XX/YY
DMMGAUK	HS	Phase 2
DMMGAUK	SN	Rezatomidine
DMMGAUK	CP	ACADIA Pharmaceuticals
DMMGAUK	DT	Small molecular drug
DMMGAUK	PC	11287722
DMMGAUK	MW	232.35
DMMGAUK	FM	C13H16N2S
DMMGAUK	IC	InChI=1S/C13H16N2S/c1-8-5-4-6-11(9(8)2)10(3)12-7-14-13(16)15-12/h4-7,10H,1-3H3,(H2,14,15,16)/t10-/m0/s1
DMMGAUK	CS	CC1=C(C(=CC=C1)[C@H](C)C2=CNC(=S)N2)C
DMMGAUK	IK	WQXVKEDUCPMRRI-JTQLQIEISA-N
DMMGAUK	IU	4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydroimidazole-2-thione
DMMGAUK	CA	CAS 847829-38-3
DMMGAUK	DE	Fibromyalgia; Diabetic nephropathy

DM2POHA	ID	DM2POHA
DM2POHA	DN	AGS-16C3F
DM2POHA	HS	Phase 2
DM2POHA	CP	AgensysSanta Monica, CA
DM2POHA	DE	Renal cell carcinoma

DMMKASG	ID	DMMKASG
DMMKASG	DN	AGTC-0106
DMMKASG	HS	Phase 2
DMMKASG	SN	Alpha-1 antitrypsin deficiency gene therapy, AGTC; RAAV1-CB-hAAT; Gene therapy (alpha-1 antitrypsin deficiency), Applied Genetic Technologies
DMMKASG	CP	Agtc; applied genetic technologies
DMMKASG	DE	Alpha-1 antitrypsin deficiency

DMXJ8Z4	ID	DMXJ8Z4
DMXJ8Z4	DN	AK104
DMXJ8Z4	HS	Phase 2
DMXJ8Z4	CP	Akeso Biopharma
DMXJ8Z4	DT	Antibody
DMXJ8Z4	DE	Cervical cancer; Hepatocellular carcinoma

DMKNRYH	ID	DMKNRYH
DMKNRYH	DN	AKB-9778
DMKNRYH	HS	Phase 2
DMKNRYH	CP	Aerpio Therapeutics
DMKNRYH	PC	46700782
DMKNRYH	MW	586.7
DMKNRYH	FM	C26H26N4O6S3
DMKNRYH	IC	InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1
DMKNRYH	CS	COC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)NS(=O)(=O)O)C3=CSC(=N3)C4=CC=CS4
DMKNRYH	IK	KWJDHELCGJFUHW-SFTDATJTSA-N
DMKNRYH	IU	[4-[(2S)-2-[[(2S)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid
DMKNRYH	CA	CAS 1008510-37-9
DMKNRYH	DE	Peripheral arterial disease; Diabetic macular edema

DMR8W7Y	ID	DMR8W7Y
DMR8W7Y	DN	AKCEA-ANGPTL3-LRX
DMR8W7Y	HS	Phase 2
DMR8W7Y	CP	Akcea Therapeutics Cambridge, MA
DMR8W7Y	DE	Cardiovascular disease

DMCTWIB	ID	DMCTWIB
DMCTWIB	DN	AL102
DMCTWIB	HS	Phase 2
DMCTWIB	CP	Ayala Pharmaceuticals
DMCTWIB	DT	Small molecular drug
DMCTWIB	DE	Desmoid tumour

DM3P91Z	ID	DM3P91Z
DM3P91Z	DN	Alacizumab pegol
DM3P91Z	HS	Phase 2
DM3P91Z	SN	CDP-791
DM3P91Z	CP	UCB Celltech
DM3P91Z	DT	Antibody
DM3P91Z	DE	Non-small-cell lung cancer

DM2U530	ID	DM2U530
DM2U530	DN	ALD-401
DM2U530	HS	Phase 2
DM2U530	SN	ALD-401, Aldagen; ALDH-expressing stem cell therapy (ischemic stroke), Aldagen
DM2U530	CP	Cytomedix
DM2U530	DE	Cerebrovascular ischaemia

DM6RBYT	ID	DM6RBYT
DM6RBYT	DN	ALD-403
DM6RBYT	HS	Phase 2
DM6RBYT	SN	MAb (migraine), Alder
DM6RBYT	CP	Alder biopharmaceuticals
DM6RBYT	DE	Migraine

DMPWSBL	ID	DMPWSBL
DMPWSBL	DN	ALD-518
DMPWSBL	HS	Phase 2
DMPWSBL	DE	Rheumatoid arthritis; Psoriatic arthritis

DMUA0XC	ID	DMUA0XC
DMUA0XC	DN	ALF-5755
DMUA0XC	HS	Phase 2
DMUA0XC	SN	HIP/PAP; Hepatocarcinoma-intestine-pancreas/pancreatic-associated protein
DMUA0XC	CP	INSERM
DMUA0XC	DE	Liver failure

DMR2YPF	ID	DMR2YPF
DMR2YPF	DN	ALG-1001
DMR2YPF	HS	Phase 2
DMR2YPF	CP	Allegro Ophthalmics
DMR2YPF	PC	130476723
DMR2YPF	MW	637.7
DMR2YPF	FM	C22H39N9O11S
DMR2YPF	IC	InChI=1S/C22H39N9O11S/c1-11(32)17(20(37)31-7-3-5-14(31)21(38)39)30-19(36)13(10-43(40,41)42)29-16(34)9-27-18(35)12(28-15(33)8-23)4-2-6-26-22(24)25/h11-14,17,32H,2-10,23H2,1H3,(H,27,35)(H,28,33)(H,29,34)(H,30,36)(H,38,39)(H4,24,25,26)(H,40,41,42)/t11-,12+,13+,14+,17+/m1/s1
DMR2YPF	CS	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O
DMR2YPF	IK	MYZAXBZLEILEBR-RVFOSREFSA-N
DMR2YPF	IU	(2S)-1-[(2S,3R)-2-[[(2R)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid
DMR2YPF	CA	CAS 1307293-62-4
DMR2YPF	DE	Diabetic macular edema

DME3ZYC	ID	DME3ZYC
DME3ZYC	DN	ALKS 4230
DME3ZYC	HS	Phase 2
DME3ZYC	CP	Alkermes
DME3ZYC	DT	Protein
DME3ZYC	DE	Solid tumour/cancer

DMF3QN1	ID	DMF3QN1
DMF3QN1	DN	ALKS33
DMF3QN1	HS	Phase 2
DMF3QN1	SN	Samidorphan
DMF3QN1	CP	Alkermes
DMF3QN1	DT	Small molecular drug
DMF3QN1	PC	11667832
DMF3QN1	MW	370.4
DMF3QN1	FM	C21H26N2O4
DMF3QN1	IC	InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1
DMF3QN1	CS	C1CC1CN2CC[C@]34CC(=O)CC[C@]3([C@H]2CC5=C4C(=C(C=C5)C(=O)N)O)O
DMF3QN1	IK	RYIDHLJADOKWFM-MAODMQOUSA-N
DMF3QN1	IU	(1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dihydroxy-13-oxo-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4-carboxamide
DMF3QN1	CA	CAS 852626-89-2
DMF3QN1	DE	Alcohol dependence

DMWYMJN	ID	DMWYMJN
DMWYMJN	DN	ALN-CC5
DMWYMJN	HS	Phase 2
DMWYMJN	CP	Alnylam Pharmaceuticals: Cemdisiran
DMWYMJN	DT	Antisense oligonucleotide
DMWYMJN	DE	Haemolytic uraemic syndrome

DMEYNQA	ID	DMEYNQA
DMEYNQA	DN	ALN-RSV01
DMEYNQA	HS	Phase 2
DMEYNQA	DT	siRNA drug
DMEYNQA	DE	Respiratory infection; Respiratory syncytial virus infection

DMJPV5X	ID	DMJPV5X
DMJPV5X	DN	Alovudine
DMJPV5X	HS	Phase 2
DMJPV5X	SN	Alovudine; 25526-93-6; FddT; 3'-DEOXY-3'-FLUOROTHYMIDINE; FddThD; 3'-Fluoro-3'-deoxythymidine; Thymidine, 3'-deoxy-3'-fluoro-; 3'F-TdR; 3'-FddT; Alovudine [USAN:INN]; UNII-PG53R0DWDQ; 3'-Fluorothymidine; 3'-FLT; DRG-0097; PG53R0DWDQ; NSC 140025; BRN 0754299; 3'-Fluorodeoxythymidine; CL 184824; CHEMBL105318; FLT; 1-((2R,4S,5R)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; C10H13FN2O4; MIV-310; 1-(3'-Deoxy-3'-fluoro-beta-D-pentofuranosyl)thymine; CL-184824; DSSTox_RID_81738; DSSTox_CID_26579
DMJPV5X	DT	Small molecular drug
DMJPV5X	PC	33039
DMJPV5X	MW	244.22
DMJPV5X	FM	C10H13FN2O4
DMJPV5X	IC	InChI=1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1
DMJPV5X	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)F
DMJPV5X	IK	UXCAQJAQSWSNPQ-XLPZGREQSA-N
DMJPV5X	IU	1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMJPV5X	CA	CAS 25526-93-6
DMJPV5X	DE	Breast cancer

DM5EFXZ	ID	DM5EFXZ
DM5EFXZ	DN	Alpha-1 antitrypsin
DM5EFXZ	HS	Phase 2
DM5EFXZ	SN	AAT, Transgene; Alpha-1 antitrypsin, Transgene
DM5EFXZ	CP	Transgene SA
DM5EFXZ	DE	Bacillus anthracis infection; Coagulation defect

DMLBWT1	ID	DMLBWT1
DMLBWT1	DN	ALRN-6924
DMLBWT1	HS	Phase 2
DMLBWT1	CP	Aileron Therapeutics Cambridge, MA
DMLBWT1	DE	Acute myeloid leukaemia; Haematological malignancy; Myelodysplastic syndrome; Solid tumour/cancer

DM9KL7P	ID	DM9KL7P
DM9KL7P	DN	ALT-801
DM9KL7P	HS	Phase 2
DM9KL7P	SN	ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
DM9KL7P	CP	Altor bioscience
DM9KL7P	DE	Acute myeloid leukaemia; Bladder cancer; Non-muscle invasive bladder cancer

DMK3U1X	ID	DMK3U1X
DMK3U1X	DN	ALT-803
DMK3U1X	HS	Phase 2
DMK3U1X	SN	IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
DMK3U1X	CP	Altor bioscience
DMK3U1X	DE	Human immunodeficiency virus infection; Solid tumour/cancer; Non-hodgkin lymphoma; Pancreatic cancer; Non-small-cell lung cancer; Bladder cancer; Multiple myeloma; Acute myeloid leukaemia

DMGJ71F	ID	DMGJ71F
DMGJ71F	DN	ALT-836
DMGJ71F	HS	Phase 2
DMGJ71F	CP	Altor BioScience
DMGJ71F	DE	Adult respiratory distress syndrome

DMLSK01	ID	DMLSK01
DMLSK01	DN	Altrakincept
DMLSK01	HS	Phase 2
DMLSK01	CP	Novartis
DMLSK01	DT	Monoclonal antibody
DMLSK01	DE	Asthma

DMXSFA0	ID	DMXSFA0
DMXSFA0	DN	ALV-003
DMXSFA0	HS	Phase 2
DMXSFA0	SN	Gluten-detoxifying protease (celiac sprue), Alvine Pharmaceuticals; Glutamine-specific cysteine protease (EP-B2) + proline-specific prolyl endopeptidase (PEP) (celiac disease), Alvine
DMXSFA0	CP	Alvine Pharmaceuticals Inc
DMXSFA0	DE	Coeliac disease

DMO1VHC	ID	DMO1VHC
DMO1VHC	DN	ALX-0061
DMO1VHC	HS	Phase 2
DMO1VHC	SN	Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx
DMO1VHC	CP	Ablynx NV
DMO1VHC	DT	Antibody
DMO1VHC	DE	Autoimmune diabetes; Rheumatoid arthritis; Systemic lupus erythematosus

DMCAFXM	ID	DMCAFXM
DMCAFXM	DN	ALX-101
DMCAFXM	HS	Phase 2
DMCAFXM	SN	Rovazolac; UNII-W51K389XIL; W51K389XIL; Rovazolac [INN]; GTPL9625; SCHEMBL15242823; ZUMNJDGBYXHASJ-UHFFFAOYSA-N; example 36 [WO2013130892]; HY-109073; CS-0033536; A-110; ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate; ethyl 2-(5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; ethyl 2-(5-(3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; Ethyl 2-(5-(3'-(methylsulfonyl)-(1,1'-biphenyl)-4-yl)-3-(trifluoromethy
DMCAFXM	CP	Ralexar Therapeutics Malvern, PA
DMCAFXM	PC	89792952
DMCAFXM	MW	452.4
DMCAFXM	FM	C21H19F3N2O4S
DMCAFXM	IC	InChI=1S/C21H19F3N2O4S/c1-3-30-20(27)13-26-18(12-19(25-26)21(22,23)24)15-9-7-14(8-10-15)16-5-4-6-17(11-16)31(2,28)29/h4-12H,3,13H2,1-2H3
DMCAFXM	CS	CCOC(=O)CN1C(=CC(=N1)C(F)(F)F)C2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C
DMCAFXM	IK	ZUMNJDGBYXHASJ-UHFFFAOYSA-N
DMCAFXM	IU	ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate
DMCAFXM	CA	CAS 1454288-88-0
DMCAFXM	DE	Atopic dermatitis

DMV934L	ID	DMV934L
DMV934L	DN	ALX-40-4C
DMV934L	HS	Phase 2
DMV934L	SN	AV-9
DMV934L	CP	NPS Allelix Corp
DMV934L	DT	Small molecular drug
DMV934L	PC	25077385
DMV934L	MW	1464.7
DMV934L	FM	C56H113N37O10
DMV934L	IC	InChI=1S/C56H113N37O10/c1-29(94)85-31(12-3-21-77-49(60)61)40(96)87-33(14-5-23-79-51(64)65)42(98)89-35(16-7-25-81-53(68)69)44(100)91-37(18-9-27-83-55(72)73)46(102)93-38(19-10-28-84-56(74)75)47(103)92-36(17-8-26-82-54(70)71)45(101)90-34(15-6-24-80-52(66)67)43(99)88-32(13-4-22-78-50(62)63)41(97)86-30(39(57)95)11-2-20-76-48(58)59/h30-38H,2-28H2,1H3,(H2,57,95)(H,85,94)(H,86,97)(H,87,96)(H,88,99)(H,89,98)(H,90,101)(H,91,100)(H,92,103)(H,93,102)(H4,58,59,76)(H4,60,61,77)(H4,62,63,78)(H4,64,65,79)(H4,66,67,80)(H4,68,69,81)(H4,70,71,82)(H4,72,73,83)(H4,74,75,84)/t30-,31-,32-,33-,34-,35-,36-,37-,38-/m1/s1
DMV934L	CS	CC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N
DMV934L	IK	LGLVVVCSQBZONM-HCCLCSBVSA-N
DMV934L	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DMV934L	CA	CAS 153127-49-2
DMV934L	DE	Human immunodeficiency virus infection

DMH5LFR	ID	DMH5LFR
DMH5LFR	DN	ALXN6000
DMH5LFR	HS	Phase 2
DMH5LFR	SN	Samalizumab
DMH5LFR	CP	Alexion Pharmaceuticals
DMH5LFR	DT	Antibody
DMH5LFR	DE	Chronic lymphocytic leukaemia; Acute myeloid leukaemia; Solid tumour/cancer

DM7ZQAT	ID	DM7ZQAT
DM7ZQAT	DN	ALZ-801
DM7ZQAT	HS	Phase 2
DM7ZQAT	CP	Alzheon
DM7ZQAT	PC	25008296
DM7ZQAT	MW	238.31
DM7ZQAT	FM	C8H18N2O4S
DM7ZQAT	IC	InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1
DM7ZQAT	CS	CC(C)[C@@H](C(=O)NCCCS(=O)(=O)O)N
DM7ZQAT	IK	NRZRFNYKMSAZBI-ZETCQYMHSA-N
DM7ZQAT	IU	3-[[(2S)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid
DM7ZQAT	CA	CAS 1034190-08-3
DM7ZQAT	DE	Alzheimer disease

DM9UMSJ	ID	DM9UMSJ
DM9UMSJ	DN	AM001
DM9UMSJ	HS	Phase 2
DM9UMSJ	SN	MLS000562506; CHEMBL1407569; HMS2222P08; SMR000453693
DM9UMSJ	CP	AmDerma Pharmaceuticals
DM9UMSJ	DT	Small molecular drug
DM9UMSJ	PC	16745944
DM9UMSJ	MW	369.4
DM9UMSJ	FM	C19H19N3O5
DM9UMSJ	IC	InChI=1S/C19H19N3O5/c1-2-10-26-14-11-17(27-15(14)12-23)22-9-8-16(21-19(22)25)20-18(24)13-6-4-3-5-7-13/h1,3-9,14-15,17,23H,10-12H2,(H,20,21,24,25)/t14-,15-,17-/m1/s1
DM9UMSJ	CS	C#CCO[C@@H]1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)NC(=O)C3=CC=CC=C3
DM9UMSJ	IK	VUDFTOHJBXWAGS-BFYDXBDKSA-N
DM9UMSJ	IU	N-[1-[(2R,4R,5R)-5-(hydroxymethyl)-4-prop-2-ynoxyoxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide
DM9UMSJ	DE	Actinic keratosis

DMGVQI8	ID	DMGVQI8
DMGVQI8	DN	AM-001
DMGVQI8	HS	Phase 2
DMGVQI8	SN	AM-001 (topical); AM-001 (topical), DermAct
DMGVQI8	CP	DermAct Pharmaceutical Inc
DMGVQI8	DE	Dermatological disease; Actinic keratosis

DMBWNX5	ID	DMBWNX5
DMBWNX5	DN	AMA-76
DMBWNX5	HS	Phase 2
DMBWNX5	CP	Amakem
DMBWNX5	DE	Glaucoma/ocular hypertension

DMEB3T9	ID	DMEB3T9
DMEB3T9	DN	Amdoxovir
DMEB3T9	HS	Phase 2
DMEB3T9	SN	Amdoxovir; DAPD; 145514-04-1; DAPD cpd; UNII-54I81H0M9C; (-)-DAPD; beta-D-2,6-Diaminopurine-dioxolane; 54I81H0M9C; [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol; (2R-cis)-4-(2,6-Diamino-9H-purin-9-yl)-1,3-dioxolane-2-methanol; (2R,4R)-4-(2,6-Diamino-9H-purin-9-yl)-1,3-dioxolane-2-methanol; (-)-(2R,4R)-2-Amino-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)adenine; 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R,4R)-; 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R-cis)-; Amdoxovir [USAN]
DMEB3T9	DT	Small molecular drug
DMEB3T9	PC	124088
DMEB3T9	MW	252.23
DMEB3T9	FM	C9H12N6O3
DMEB3T9	IC	InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1
DMEB3T9	CS	C1[C@@H](O[C@@H](O1)CO)N2C=NC3=C(N=C(N=C32)N)N
DMEB3T9	IK	RLAHNGKRJJEIJL-RFZPGFLSSA-N
DMEB3T9	IU	[(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
DMEB3T9	CA	CAS 145514-04-1
DMEB3T9	DE	Hepatitis B virus infection

DMIVZ3M	ID	DMIVZ3M
DMIVZ3M	DN	AME-133v
DMIVZ3M	HS	Phase 2
DMIVZ3M	SN	Ocaratuzumab
DMIVZ3M	CP	MENTRIK Biotech
DMIVZ3M	DT	Antibody
DMIVZ3M	DE	Non-hodgkin lymphoma

DMUMCB9	ID	DMUMCB9
DMUMCB9	DN	Amelubant
DMUMCB9	HS	Phase 2
DMUMCB9	SN	Amelubant [INN]; BIIL 283 BS; BIIL 284; Ethyl ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)benzyl)oxy)phenyl)(imino)methyl)carbamate; Carbamic acid, ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)-, ethyl ester
DMUMCB9	CP	Boehringer Ingelheim
DMUMCB9	DT	Small molecular drug
DMUMCB9	PC	135564996
DMUMCB9	MW	538.6
DMUMCB9	FM	C33H34N2O5
DMUMCB9	IC	InChI=1S/C33H34N2O5/c1-4-38-32(37)35-31(34)25-8-16-29(17-9-25)39-21-23-6-5-7-24(20-23)22-40-30-18-12-27(13-19-30)33(2,3)26-10-14-28(36)15-11-26/h5-20,36H,4,21-22H2,1-3H3,(H2,34,35,37)
DMUMCB9	CS	CCOC(=O)NC(=N)C1=CC=C(C=C1)OCC2=CC(=CC=C2)COC3=CC=C(C=C3)C(C)(C)C4=CC=C(C=C4)O
DMUMCB9	IK	SBVYURPQULDJTI-UHFFFAOYSA-N
DMUMCB9	IU	ethyl N-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]benzenecarboximidoyl]carbamate
DMUMCB9	CA	CAS 346735-24-8
DMUMCB9	DE	Cystic fibrosis; Pulmonary disease

DMGOFL3	ID	DMGOFL3
DMGOFL3	DN	AMG 151
DMGOFL3	HS	Phase 2
DMGOFL3	CP	Amgen
DMGOFL3	DE	Type-2 diabetes

DMPQHOR	ID	DMPQHOR
DMPQHOR	DN	AMG 208
DMPQHOR	HS	Phase 2
DMPQHOR	SN	AMG-208; 1002304-34-8; AMG 208; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8
DMPQHOR	CP	Amgen Thousand
DMPQHOR	DT	Small molecular drug
DMPQHOR	PC	24864821
DMPQHOR	MW	383.4
DMPQHOR	FM	C22H17N5O2
DMPQHOR	IC	InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3
DMPQHOR	CS	COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5
DMPQHOR	IK	HEAIZQNMNCHNFD-UHFFFAOYSA-N
DMPQHOR	IU	7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline
DMPQHOR	CA	CAS 1002304-34-8
DMPQHOR	CB	CHEBI:90626
DMPQHOR	DE	Solid tumour/cancer

DM65PTO	ID	DM65PTO
DM65PTO	DN	AMG 232
DM65PTO	HS	Phase 2
DM65PTO	SN	KRT-232
DM65PTO	CP	Amgen
DM65PTO	PC	58573469
DM65PTO	MW	568.6
DM65PTO	FM	C28H35Cl2NO5S
DM65PTO	IC	InChI=1S/C28H35Cl2NO5S/c1-17(2)24(16-37(35,36)18(3)4)31-26(19-9-11-21(29)12-10-19)23(20-7-6-8-22(30)13-20)14-28(5,27(31)34)15-25(32)33/h6-13,17-18,23-24,26H,14-16H2,1-5H3,(H,32,33)/t23-,24-,26-,28-/m1/s1
DM65PTO	CS	CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC(=O)O)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl
DM65PTO	IK	DRLCSJFKKILATL-YWCVFVGNSA-N
DM65PTO	IU	2-[(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2S)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid
DM65PTO	CA	CAS 1352066-68-2
DM65PTO	DE	Solid tumour/cancer; Merkel cell carcinoma

DMO72IF	ID	DMO72IF
DMO72IF	DN	AMG 301
DMO72IF	HS	Phase 2
DMO72IF	CP	Amgen Thousand Oaks, CA Novartis Pharmaceuticals East Hanover, NJ
DMO72IF	DE	Migraine; Hyperprolactinaemia

DMI3WFG	ID	DMI3WFG
DMI3WFG	DN	AMG 334
DMI3WFG	HS	Phase 2
DMI3WFG	CP	Amgen
DMI3WFG	DE	Migraine

DMIOUEY	ID	DMIOUEY
DMIOUEY	DN	AMG 337
DMIOUEY	HS	Phase 2
DMIOUEY	PC	44181686
DMIOUEY	MW	463.5
DMIOUEY	FM	C23H22FN7O3
DMIOUEY	IC	InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1
DMIOUEY	CS	C[C@H](C1=NN=C2N1C=C(C=C2F)C3=CN(N=C3)C)N4C=CC5=C(C4=O)C=C(C=N5)OCCOC
DMIOUEY	IK	DWHXUGDWKAIASB-CQSZACIVSA-N
DMIOUEY	IU	6-[(1R)-1-[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one
DMIOUEY	CA	CAS 1173699-31-4
DMIOUEY	DE	Solid tumour/cancer; Clear cell sarcoma

DM0DRAZ	ID	DM0DRAZ
DM0DRAZ	DN	AMG 479
DM0DRAZ	HS	Phase 2
DM0DRAZ	CP	Amgen
DM0DRAZ	DE	Breast cancer

DME6QH1	ID	DME6QH1
DME6QH1	DN	AMG 557
DME6QH1	HS	Phase 2
DME6QH1	CP	Amgen Thousand
DME6QH1	DE	Systemic lupus erythematosus; Sjogren syndrome

DMY1XJH	ID	DMY1XJH
DMY1XJH	DN	AMG 570
DMY1XJH	HS	Phase 2
DMY1XJH	CP	Amgen
DMY1XJH	DT	Small molecular drug
DMY1XJH	DE	Systemic lupus erythematosus

DMFXN2T	ID	DMFXN2T
DMFXN2T	DN	AMG 745
DMFXN2T	HS	Phase 2
DMFXN2T	CP	Amgen
DMFXN2T	DE	Muscle atrophy

DMWPGB8	ID	DMWPGB8
DMWPGB8	DN	Amg 747
DMWPGB8	HS	Phase 2
DMWPGB8	CP	Amgen
DMWPGB8	DE	Schizophrenia

DM973N4	ID	DM973N4
DM973N4	DN	AMG 853
DM973N4	HS	Phase 2
DM973N4	SN	VIDUPIPRANT; 1169483-24-2; AMG 853; AMG-853; UNII-61OTZ32XNC; 61OTZ32XNC; 2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid; CHEMBL1951575; AMG 853(AMG853;Vidupiprant); Benzeneacetic acid, 5-chloro-4-[2-[[(2-chloro-4-cyclopropylphenyl)sulfonyl]amino]-4-[[(1,1-dimethylethyl)amino]carbonyl]phenoxy]-2-fluoro-; Vidupiprant [USAN:INN]; AMG853;Vidupiprant; Vidupiprant (USAN/INN); AMG853; SCHEMBL4344221; GTPL10169; DTXSID40151606; BCP28132; ZINC43206238
DM973N4	CP	Amgen Thousand
DM973N4	DT	Small molecular drug
DM973N4	PC	42641863
DM973N4	MW	609.5
DM973N4	FM	C28H27Cl2FN2O6S
DM973N4	IC	InChI=1S/C28H27Cl2FN2O6S/c1-28(2,3)32-27(36)17-6-8-23(39-24-14-21(31)18(11-19(24)29)13-26(34)35)22(12-17)33-40(37,38)25-9-7-16(10-20(25)30)15-4-5-15/h6-12,14-15,33H,4-5,13H2,1-3H3,(H,32,36)(H,34,35)
DM973N4	CS	CC(C)(C)NC(=O)C1=CC(=C(C=C1)OC2=C(C=C(C(=C2)F)CC(=O)O)Cl)NS(=O)(=O)C3=C(C=C(C=C3)C4CC4)Cl
DM973N4	IK	PFWVGKROPKKEDW-UHFFFAOYSA-N
DM973N4	IU	2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid
DM973N4	CA	CAS 1169483-24-2
DM973N4	DE	Asthma

DM3H0IX	ID	DM3H0IX
DM3H0IX	DN	AMG 890
DM3H0IX	HS	Phase 2
DM3H0IX	SN	Olpasiran
DM3H0IX	CP	Amgen
DM3H0IX	DT	Small interfering RNA
DM3H0IX	DE	Cardiac fibrosis

DMODJTX	ID	DMODJTX
DMODJTX	DN	AMG-181
DMODJTX	HS	Phase 2
DMODJTX	SN	Inflammatory bowel disease therapeutics, Amgen
DMODJTX	CP	Amgen; astrazeneca
DMODJTX	DT	Antibody
DMODJTX	DE	Crohn disease; Ulcerative colitis

DM1T3KQ	ID	DM1T3KQ
DM1T3KQ	DN	AMG-714
DM1T3KQ	HS	Phase 2
DM1T3KQ	CP	Genmab; Amgen
DM1T3KQ	DT	Antibody
DM1T3KQ	DE	Rheumatoid arthritis; Coeliac disease

DMJ4GPR	ID	DMJ4GPR
DMJ4GPR	DN	AMP-579
DMJ4GPR	HS	Phase 2
DMJ4GPR	SN	RPR-100579; (1S,2R,3S,4R)-4-[7-[1(R)-(3-Chloro-2-thienylmethyl)propylamino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
DMJ4GPR	DT	Small molecular drug
DMJ4GPR	PC	72941762
DMJ4GPR	MW	478
DMJ4GPR	FM	C22H28ClN5O3S
DMJ4GPR	IC	InChI=1S/C22H28ClN5O3S/c1-3-12(9-17-15(23)6-8-32-17)27-20-13-5-7-28(21(13)26-11-25-20)16-10-14(18(29)19(16)30)22(31)24-4-2/h5-8,11-12,14,16,18-19,29-30H,3-4,9-10H2,1-2H3,(H,24,31)(H,25,26,27)/t12-,14+,16-,18-,19+/m1/s1
DMJ4GPR	CS	CC[C@H](CC1=C(C=CS1)Cl)NC2=C3C=CN(C3=NC=N2)[C@@H]4C[C@@H]([C@H]([C@H]4O)O)C(=O)NCC
DMJ4GPR	IK	CKQOOYMMAAPDKH-QODLLSGVSA-N
DMJ4GPR	IU	(1S,2R,3S,4R)-4-[4-[[(2R)-1-(3-chlorothiophen-2-yl)butan-2-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
DMJ4GPR	CA	CAS 213453-89-5
DMJ4GPR	DE	Hyperlipidaemia

DMGE8FK	ID	DMGE8FK
DMGE8FK	DN	AMR-001
DMGE8FK	HS	Phase 2
DMGE8FK	CP	Amorcyte; Progenitor Cell Therapy
DMGE8FK	DE	Heart failure

DMOB01U	ID	DMOB01U
DMOB01U	DN	Amsilarotene
DMOB01U	HS	Phase 2
DMOB01U	SN	Am-555S; TAC-101; Anticancer retinoic acid receptor antagonist (oral), Taiho
DMOB01U	CP	Taiho Pharmaceutical Co Ltd
DMOB01U	DT	Small molecular drug
DMOB01U	PC	9800306
DMOB01U	MW	385.6
DMOB01U	FM	C20H27NO3Si2
DMOB01U	IC	InChI=1S/C20H27NO3Si2/c1-25(2,3)17-11-15(12-18(13-17)26(4,5)6)19(22)21-16-9-7-14(8-10-16)20(23)24/h7-13H,1-6H3,(H,21,22)(H,23,24)
DMOB01U	CS	C[Si](C)(C)C1=CC(=CC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)O)[Si](C)(C)C
DMOB01U	IK	VVTNSTLJOVCBDL-UHFFFAOYSA-N
DMOB01U	IU	4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
DMOB01U	CA	CAS 125973-56-0
DMOB01U	DE	Solid tumour/cancer

DMS0GA6	ID	DMS0GA6
DMS0GA6	DN	AMY-101
DMS0GA6	HS	Phase 2
DMS0GA6	SN	UNII-4Z4DFR9BX7; 4Z4DFR9BX7; 1427001-89-5 (free base); Compstatin 40; Compstatin analog peptide CP40; CHEMBL4297260; 1427001-89-5; L-Isoleucinamide, D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophyl-N-methylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N2-methyl-, cyclic (3->13)-disulfide; S3,S13-Cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)
DMS0GA6	CP	Amyndas
DMS0GA6	DT	Peptide
DMS0GA6	PC	131634231
DMS0GA6	MW	1789.1
DMS0GA6	FM	C83H117N23O18S2
DMS0GA6	IC	InChI=1S/C83H117N23O18S2/c1-11-43(5)68(103-72(114)53(84)30-46-23-25-50(107)26-24-46)80(122)100-61-39-125-126-40-62(82(124)106(10)69(70(86)112)44(6)12-2)101-73(115)55(21-17-29-90-83(87)88)94-76(118)58(33-49-36-89-41-92-49)96-71(113)45(7)93-65(109)38-105(9)81(123)60(31-47-35-91-54-20-15-13-18-51(47)54)99-77(119)59(34-66(110)111)97-74(116)56(27-28-64(85)108)95-75(117)57(98-79(121)67(42(3)4)102-78(61)120)32-48-37-104(8)63-22-16-14-19-52(48)63/h13-16,18-20,22-26,35-37,41-45,53,55-62,67-69,91,107H,11-12,17,21,27-34,38-40,84H2,1-10H3,(H2,85,108)(H2,86,112)(H,89,92)(H,93,109)(H,94,118)(H,95,117)(H,96,113)(H,97,116)(H,98,121)(H,99,119)(H,100,122)(H,101,115)(H,102,120)(H,103,114)(H,110,111)(H4,87,88,90)/t43-,44-,45-,53+,55-,56-,57-,58-,59-,60-,61-,62-,67-,68-,69-/m0/s1
DMS0GA6	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CN(C3=CC=CC=C32)C)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N(C)[C@@H]([C@@H](C)CC)C(=O)N)NC(=O)[C@@H](CC7=CC=C(C=C7)O)N
DMS0GA6	IK	MUSGYEMSJUFFHT-UWABRSFTSA-N
DMS0GA6	IU	2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMS0GA6	CA	CAS 1427001-89-5
DMS0GA6	DE	Gingivitis

DMT3S10	ID	DMT3S10
DMT3S10	DN	AN0128
DMT3S10	HS	Phase 2
DMT3S10	SN	Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane
DMT3S10	CP	Anacor Pharma.
DMT3S10	DT	Small molecular drug
DMT3S10	PC	11704019
DMT3S10	MW	400.1
DMT3S10	FM	C20H16BCl2NO3
DMT3S10	IC	InChI=1S/C20H16BCl2NO3/c1-12-5-7-14(10-16(12)22)21(15-8-6-13(2)17(23)11-15)27-20(26)19-18(25)4-3-9-24-19/h3-11,25H,1-2H3
DMT3S10	CS	B(C1=CC(=C(C=C1)C)Cl)(C2=CC(=C(C=C2)C)Cl)OC(=O)C3=C(C=CC=N3)O
DMT3S10	IK	ZTLSOLUCMQEGEA-UHFFFAOYSA-N
DMT3S10	IU	bis(3-chloro-4-methylphenyl)boranyl 3-hydroxypyridine-2-carboxylate
DMT3S10	CA	CAS 872044-70-7
DMT3S10	DE	Psoriatic disorder; Atopic dermatitis

DMJ7QP8	ID	DMJ7QP8
DMJ7QP8	DN	AN-019
DMJ7QP8	HS	Phase 2
DMJ7QP8	SN	NRC-19; NRC-24; NRC-AN-015; NRC-AN-019; Bcr-Abl inhibitors (CML), Natco
DMJ7QP8	CP	Natco Pharma Ltd
DMJ7QP8	DE	Chronic myelogenous leukaemia

DM3JNXS	ID	DM3JNXS
DM3JNXS	DN	AN-1792
DM3JNXS	HS	Phase 2
DM3JNXS	SN	Betabloc; AIP-001
DM3JNXS	CP	Elan Pharmaceutical Research
DM3JNXS	DT	Small molecular drug
DM3JNXS	PC	15176
DM3JNXS	MW	283.83
DM3JNXS	FM	C16H26ClNO
DM3JNXS	IC	InChI=1S/C16H25NO.ClH/c1-3-12(2)17-11-16(18)15-9-8-13-6-4-5-7-14(13)10-15;/h8-10,12,16-18H,3-7,11H2,1-2H3;1H
DM3JNXS	CS	CCC(C)[NH2+]CC(C1=CC2=C(CCCC2)C=C1)O.[Cl-]
DM3JNXS	IK	KHBXORBAOCQNMC-UHFFFAOYSA-N
DM3JNXS	IU	butan-2-yl-[2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]azanium;chloride
DM3JNXS	CA	CAS 1506-12-3
DM3JNXS	DE	Alzheimer disease

DMDK7CL	ID	DMDK7CL
DMDK7CL	DN	AN-2898
DMDK7CL	HS	Phase 2
DMDK7CL	SN	PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor
DMDK7CL	CP	Anacor Pharmaceuticals Inc
DMDK7CL	PC	24806574
DMDK7CL	MW	276.06
DMDK7CL	FM	C15H9BN2O3
DMDK7CL	IC	InChI=1S/C15H9BN2O3/c17-7-10-1-2-13(5-11(10)8-18)21-14-3-4-15-12(6-14)9-20-16(15)19/h1-6,19H,9H2
DMDK7CL	CS	B1(C2=C(CO1)C=C(C=C2)OC3=CC(=C(C=C3)C#N)C#N)O
DMDK7CL	IK	UBMGTTRDNUKZMT-UHFFFAOYSA-N
DMDK7CL	IU	4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzene-1,2-dicarbonitrile
DMDK7CL	CA	CAS 906673-33-4
DMDK7CL	DE	Atopic dermatitis

DMG7IEN	ID	DMG7IEN
DMG7IEN	DN	Anatibant
DMG7IEN	HS	Phase 2
DMG7IEN	SN	Anatibant [INN]; (2S)-N-(3-(4-Carbamimidoylbenzamido)propyl)-1-(2,4-dichloro-3-((2,4-dimethyl-8-quinolyloxy)methyl)phenylsulfonyl)pyrrolidine-2-carboxamide
DMG7IEN	CP	Fournier Pharma
DMG7IEN	DT	Small molecular drug
DMG7IEN	PC	9831652
DMG7IEN	MW	711.7
DMG7IEN	FM	C34H36Cl2N6O5S
DMG7IEN	IC	InChI=1S/C34H36Cl2N6O5S/c1-20-18-21(2)41-31-24(20)6-3-8-28(31)47-19-25-26(35)13-14-29(30(25)36)48(45,46)42-17-4-7-27(42)34(44)40-16-5-15-39-33(43)23-11-9-22(10-12-23)32(37)38/h3,6,8-14,18,27H,4-5,7,15-17,19H2,1-2H3,(H3,37,38)(H,39,43)(H,40,44)/t27-/m0/s1
DMG7IEN	CS	CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)N4CCC[C@H]4C(=O)NCCCNC(=O)C5=CC=C(C=C5)C(=N)N)Cl)C
DMG7IEN	IK	XUHBBTKJWIBQMY-MHZLTWQESA-N
DMG7IEN	IU	(2S)-N-[3-[(4-carbamimidoylbenzoyl)amino]propyl]-1-[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylpyrrolidine-2-carboxamide
DMG7IEN	CA	CAS 209733-45-9
DMG7IEN	CB	CHEBI:138828
DMG7IEN	DE	Traumatic brain injury

DMTG2O0	ID	DMTG2O0
DMTG2O0	DN	Anrukinzumab
DMTG2O0	HS	Phase 2
DMTG2O0	SN	Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer
DMTG2O0	CP	Genentech
DMTG2O0	DT	Monoclonal antibody
DMTG2O0	DE	Ulcerative colitis; Asthma

DMHVZ27	ID	DMHVZ27
DMHVZ27	DN	Anti-CD137
DMHVZ27	HS	Phase 2
DMHVZ27	SN	BMS-663513
DMHVZ27	CP	Bristol-Myers Squibb
DMHVZ27	DT	Antibody
DMHVZ27	DE	Solid tumour/cancer

DMPRIHK	ID	DMPRIHK
DMPRIHK	DN	Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells
DMPRIHK	HS	Phase 2
DMPRIHK	SN	Her2Bi-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute; Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer); Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute
DMPRIHK	CP	Transtarget; barbara ann karmanos cancer institute
DMPRIHK	DT	Antibody
DMPRIHK	DE	Breast cancer

DMVQHBK	ID	DMVQHBK
DMVQHBK	DN	Anti-GD2 CART
DMVQHBK	HS	Phase 2
DMVQHBK	CP	Zhujiang Hospital
DMVQHBK	DT	CAR T Cell Therapy
DMVQHBK	DE	Neuroblastoma

DMVRNAO	ID	DMVRNAO
DMVRNAO	DN	Anti-IP10
DMVRNAO	HS	Phase 2
DMVRNAO	CP	Bristol-myers squibb
DMVRNAO	DT	Antibody
DMVRNAO	DE	Ulcerative colitis; Crohn disease

DMJO402	ID	DMJO402
DMJO402	DN	Anti-LAG3
DMJO402	HS	Phase 2
DMJO402	CP	Bristol-Myers Squibb Princeton, NJ
DMJO402	DE	Gastric adenocarcinoma; Renal cell carcinoma; Non-small-cell lung cancer

DMQ58YH	ID	DMQ58YH
DMQ58YH	DN	Anti-LT alpha
DMQ58YH	HS	Phase 2
DMQ58YH	CP	Genentech
DMQ58YH	DT	Antibody
DMQ58YH	DE	Rheumatoid arthritis

DMQFU1R	ID	DMQFU1R
DMQFU1R	DN	Anti-M1 prime
DMQFU1R	HS	Phase 2
DMQFU1R	CP	Genentech
DMQFU1R	DT	Antibody
DMQFU1R	DE	Asthma

DMJPZDC	ID	DMJPZDC
DMJPZDC	DN	Anti-PSCA mab
DMJPZDC	HS	Phase 2
DMJPZDC	CP	Agensys
DMJPZDC	DT	Monoclonal antibody
DMJPZDC	DE	Pancreatic cancer

DMDKRS3	ID	DMDKRS3
DMDKRS3	DN	Antistasin
DMDKRS3	HS	Phase 2
DMDKRS3	DE	Attention deficit hyperactivity disorder

DMRGQVZ	ID	DMRGQVZ
DMRGQVZ	DN	Antroquinonol
DMRGQVZ	HS	Phase 2
DMRGQVZ	SN	Hocena; Fungal extract (cancer), Golden Biotechnology
DMRGQVZ	CP	Golden biotechnology
DMRGQVZ	PC	24875259
DMRGQVZ	MW	390.6
DMRGQVZ	FM	C24H38O4
DMRGQVZ	IC	InChI=1S/C24H38O4/c1-16(2)10-8-11-17(3)12-9-13-18(4)14-15-20-19(5)21(25)23(27-6)24(28-7)22(20)26/h10,12,14,19-20,22,26H,8-9,11,13,15H2,1-7H3/b17-12+,18-14+/t19-,20-,22-/m1/s1
DMRGQVZ	CS	C[C@@H]1[C@H]([C@H](C(=C(C1=O)OC)OC)O)C/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DMRGQVZ	IK	LJTSIMVOOOLKOL-FNRDIUJOSA-N
DMRGQVZ	IU	(4R,5R,6R)-4-hydroxy-2,3-dimethoxy-6-methyl-5-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]cyclohex-2-en-1-one
DMRGQVZ	CA	CAS 1010081-09-0
DMRGQVZ	CB	CHEBI:65415
DMRGQVZ	DE	Non-small-cell lung cancer; Pancreatic cancer

DMMJOZD	ID	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	HS	Phase 2
DMMJOZD	SN	Cholest-5-en-3-beta-ol; Cholesterol; Cholest-5-en-3-ol (3beta)-; Cholest-5-en-3beta-ol; Cholesterin; Cholesterine; Cholesterol base H; Cholesteryl alcohol; Cholestrin; Cholestrol; Cordulan; Dastar; Dusoline; Dusoran; Dythol; Hydrocerin; Kathro; Lidinit; Lidinite; Nimco cholesterol base H; Provitamin D; Super hartolan; Tegolan; Tegolan (VAN); Wool alcohols B. P.; cholesterol; (-)-Cholesterol; (3beta)-cholest-5-en-3-ol; 3-beta-Hydroxycholest-5-ene; 3beta-Hydroxycholest-5-ene; 5-Cholesten-3beta-ol; 57-88-5; 5:6-Cholesten-3beta-ol; CCRIS 2834; Lanol
DMMJOZD	PC	5997
DMMJOZD	MW	386.664
DMMJOZD	FM	C27H46O
DMMJOZD	IC	HVYWMOMLDIMFJA-DPAQBDIFSA-N
DMMJOZD	CS	CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C
DMMJOZD	IK	InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DMMJOZD	IU	(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMMJOZD	CA	CAS 17528-72-2
DMMJOZD	CB	ChEBI:15372
DMMJOZD	DE	Cone rod dystrophy

DMYBQEF	ID	DMYBQEF
DMYBQEF	DN	AP26113
DMYBQEF	HS	Phase 2
DMYBQEF	SN	1197958-12-5; ALK-IN-1; UNII-3DGD69C6PV; 3DGD69C6PV; CHEMBL3397300; (2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 5-Chloro-N~2~-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-N~4~-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine; 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine; AP26113-analog; Tube723; compound 11q [PMID: 27144831]
DMYBQEF	DT	Small molecular drug
DMYBQEF	PC	57390074
DMYBQEF	MW	529
DMYBQEF	FM	C26H34ClN6O2P
DMYBQEF	IC	InChI=1S/C26H34ClN6O2P/c1-32(2)18-12-14-33(15-13-18)19-10-11-21(23(16-19)35-3)30-26-28-17-20(27)25(31-26)29-22-8-6-7-9-24(22)36(4,5)34/h6-11,16-18H,12-15H2,1-5H3,(H2,28,29,30,31)
DMYBQEF	CS	CN(C)C1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4P(=O)(C)C)Cl)OC
DMYBQEF	IK	OVDSPTSBIQCAIN-UHFFFAOYSA-N
DMYBQEF	IU	5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine
DMYBQEF	CA	CAS 1197958-12-5
DMYBQEF	DE	Solid tumour/cancer

DM3ICYL	ID	DM3ICYL
DM3ICYL	DN	AP-301-IH
DM3ICYL	HS	Phase 2
DM3ICYL	SN	AP-301; AP-301-IRI; AP-301-PN; AP-301-PN); Peptide TNF alpha analog (pneumonia), Apeptico; Peptide TNF alpha modulator (edema in acute lung injury), Apeptico/Medical College of Georgia; Peptide TNF alpha modulator (ischemia/reperfusion injury), Apeptico
DM3ICYL	CP	Apeptico Forschung und Entwicklung GmbH
DM3ICYL	DE	Pneumonia

DMISQOZ	ID	DMISQOZ
DMISQOZ	DN	AP-761
DMISQOZ	HS	Phase 2
DMISQOZ	SN	BI-671800
DMISQOZ	CP	Actimis Pharmaceuticals Inc
DMISQOZ	DT	Small molecular drug
DMISQOZ	PC	45270144
DMISQOZ	MW	501.5
DMISQOZ	FM	C25H26F3N5O3
DMISQOZ	IC	InChI=1S/C25H26F3N5O3/c1-32(2)22-19(14-21(34)35)23(33(3)4)31-20(30-22)13-15-5-11-18(12-6-15)29-24(36)16-7-9-17(10-8-16)25(26,27)28/h5-12H,13-14H2,1-4H3,(H,29,36)(H,34,35)
DMISQOZ	CS	CN(C)C1=C(C(=NC(=N1)CC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(F)(F)F)N(C)C)CC(=O)O
DMISQOZ	IK	XEOSTBFUCNZKGS-UHFFFAOYSA-N
DMISQOZ	IU	2-[4,6-bis(dimethylamino)-2-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid
DMISQOZ	CA	CAS 1093108-50-9
DMISQOZ	DE	Asthma

DM1B8IT	ID	DM1B8IT
DM1B8IT	DN	Apadoline
DM1B8IT	HS	Phase 2
DM1B8IT	SN	ACMC-20mvlw; SCHEMBL7518667; CTK8G8521; 10H-Phenothiazine-2-carboxamide,10-[(1R)-1-methyl-2-(1-pyrrolidinyl)ethyl]-N-propyl-; KXMAIWXPZGQNCR-UHFFFAOYSA-N; L001386; N-propyl-10-[1-(pyrrolidinyl)-2-propyl]-2-phenothiazinecarboxamide; N-propyl-10-[1-(1-pyrrolidinyl)-2-propyl]-2-phenothiazinecarboxamide
DM1B8IT	CP	Rhone-Poulenc SA
DM1B8IT	DT	Small molecular drug
DM1B8IT	PC	179334
DM1B8IT	MW	395.6
DM1B8IT	FM	C23H29N3OS
DM1B8IT	IC	InChI=1S/C23H29N3OS/c1-3-12-24-23(27)18-10-11-22-20(15-18)26(17(2)16-25-13-6-7-14-25)19-8-4-5-9-21(19)28-22/h4-5,8-11,15,17H,3,6-7,12-14,16H2,1-2H3,(H,24,27)/t17-/m1/s1
DM1B8IT	CS	CCCNC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2[C@H](C)CN4CCCC4
DM1B8IT	IK	KXMAIWXPZGQNCR-QGZVFWFLSA-N
DM1B8IT	IU	N-propyl-10-[(2R)-1-pyrrolidin-1-ylpropan-2-yl]phenothiazine-2-carboxamide
DM1B8IT	CA	CAS 135003-30-4
DM1B8IT	DE	Pain

DMQMV9F	ID	DMQMV9F
DMQMV9F	DN	Apaxifylline
DMQMV9F	HS	Phase 2
DMQMV9F	SN	BIIP-20; U-98950; BIIP-20-XX
DMQMV9F	CP	Boehringer Ingelheim Corp
DMQMV9F	DT	Small molecular drug
DMQMV9F	PC	60949
DMQMV9F	MW	318.37
DMQMV9F	FM	C16H22N4O3
DMQMV9F	IC	InChI=1S/C16H22N4O3/c1-3-7-19-14-12(15(22)20(8-4-2)16(19)23)17-13(18-14)10-5-6-11(21)9-10/h10H,3-9H2,1-2H3,(H,17,18)/t10-/m0/s1
DMQMV9F	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)[C@H]3CCC(=O)C3
DMQMV9F	IK	RUHGOZFOVBMWOO-JTQLQIEISA-N
DMQMV9F	IU	8-[(1S)-3-oxocyclopentyl]-1,3-dipropyl-7H-purine-2,6-dione
DMQMV9F	CA	CAS 151581-23-6
DMQMV9F	DE	Cognitive impairment

DM3VP19	ID	DM3VP19
DM3VP19	DN	APC-8015F
DM3VP19	HS	Phase 2
DM3VP19	SN	CD54-postive autologous cell immunotherapy (hormone refractory prostate cancer), Dendreon
DM3VP19	CP	Dendreon Corp
DM3VP19	DE	Prostate cancer

DMNQ7DV	ID	DMNQ7DV
DMNQ7DV	DN	APD-209
DMNQ7DV	HS	Phase 2
DMNQ7DV	SN	Undisclosed cachexia therapy (oral fixed-dose combination), Acacia
DMNQ7DV	CP	Acacia Pharma Ltd
DMNQ7DV	PC	49837938
DMNQ7DV	MW	1042.3
DMNQ7DV	FM	C54H95N3O16
DMNQ7DV	IC	InChI=1S/C54H95N3O16/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-25-28-48(62)56-31-34-68-36-38-70-40-42-71-41-39-69-37-35-67-33-29-49(63)55-30-26-24-27-32-72-54(53(65)66)43-46(60)50(57-45(2)59)52(73-54)51(64)47(61)44-58/h46-47,50-52,58,60-61,64H,3-13,18-44H2,1-2H3,(H,55,63)(H,56,62)(H,57,59)(H,65,66)/t46-,47+,50+,51+,52+,54+/m0/s1
DMNQ7DV	CS	CCCCCCCCCCCCC#CC#CCCCCCCCCC(=O)NCCOCCOCCOCCOCCOCCC(=O)NCCCCCO[C@@]1(C[C@@H]([C@H]([C@@H](O1)[C@@H]([C@@H](CO)O)O)NC(=O)C)O)C(=O)O
DMNQ7DV	IK	VRJMVFQLUBTBKF-HBJHFNNESA-N
DMNQ7DV	IU	(2R,4S,5R,6R)-5-acetamido-4-hydroxy-2-[5-[3-[2-[2-[2-[2-[2-(pentacosa-10,12-diynoylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]pentoxy]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMNQ7DV	CA	CAS 1261156-82-4
DMNQ7DV	DE	Cachexia

DM3XT5V	ID	DM3XT5V
DM3XT5V	DN	APD371
DM3XT5V	HS	Phase 2
DM3XT5V	SN	Olorinab; UNII-581F7DFA9B; 581F7DFA9B; Olorinab [USAN]; SCHEMBL11995430; 1268881-20-4; (4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide; 1H-Cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide, 4,4a,5,5a-tetrahydro-N-((1S)-1-(hydroxymethyl)-2,2-dimethylpropyl)-1-(4-oxido-2-pyrazinyl)-, (4aS,5aS)-; (1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa(a)pentalene-4-carboxylic aci
DM3XT5V	CP	Arena Pharmaceuticals San Diego, CA
DM3XT5V	PC	60164925
DM3XT5V	MW	357.4
DM3XT5V	FM	C18H23N5O3
DM3XT5V	IC	InChI=1S/C18H23N5O3/c1-18(2,3)13(9-24)20-17(25)15-12-7-10-6-11(10)16(12)23(21-15)14-8-22(26)5-4-19-14/h4-5,8,10-11,13,24H,6-7,9H2,1-3H3,(H,20,25)/t10-,11-,13+/m0/s1
DM3XT5V	CS	CC(C)(C)[C@@H](CO)NC(=O)C1=NN(C2=C1C[C@H]3[C@@H]2C3)C4=NC=C[N+](=C4)[O-]
DM3XT5V	IK	ACSQLTBPYZSGBA-GMXVVIOVSA-N
DM3XT5V	IU	(2S,4S)-N-[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]-9-(4-oxidopyrazin-4-ium-2-yl)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxamide
DM3XT5V	CA	CAS 1268881-20-4
DM3XT5V	DE	Crohn disease

DM1VITS	ID	DM1VITS
DM1VITS	DN	APD-403
DM1VITS	HS	Phase 2
DM1VITS	CP	Acacia Pharma Ltd
DM1VITS	DE	Vomiting

DM9LZ0M	ID	DM9LZ0M
DM9LZ0M	DN	APD-515
DM9LZ0M	HS	Phase 2
DM9LZ0M	SN	ACA-1515
DM9LZ0M	CP	Acacia Pharma Ltd
DM9LZ0M	DE	Xerostomia

DM0FXMZ	ID	DM0FXMZ
DM0FXMZ	DN	APG-101
DM0FXMZ	HS	Phase 2
DM0FXMZ	SN	CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix
DM0FXMZ	CP	Apogenix GmbH
DM0FXMZ	DE	Cerebrovascular ischaemia

DMIFA0L	ID	DMIFA0L
DMIFA0L	DN	APG-115
DMIFA0L	HS	Phase 2
DMIFA0L	SN	15Qau0SI9J; 15QAU0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-
DMIFA0L	CP	Ascentage Pharma Rockville, MD
DMIFA0L	PC	91972012
DMIFA0L	MW	642.6
DMIFA0L	FM	C34H38Cl2FN3O4
DMIFA0L	IC	InChI=1S/C34H38Cl2FN3O4/c1-2-40-27(28(41)39-32-16-13-31(14-17-32,15-18-32)30(43)44)25(21-7-6-8-23(36)26(21)37)34(33(40)11-4-3-5-12-33)22-10-9-20(35)19-24(22)38-29(34)42/h6-10,19,25,27H,2-5,11-18H2,1H3,(H,38,42)(H,39,41)(H,43,44)/t25-,27+,31?,32?,34+/m0/s1
DMIFA0L	CS	CCN1[C@H]([C@@H]([C@]2(C13CCCCC3)C4=C(C=C(C=C4)Cl)NC2=O)C5=C(C(=CC=C5)Cl)F)C(=O)NC67CCC(CC6)(CC7)C(=O)O
DMIFA0L	IK	YJCZPJQGFSSFOL-MNZPCBJKSA-N
DMIFA0L	CA	CAS 1818393-16-6
DMIFA0L	DE	Solid tumour/cancer; Prolymphocytic leukaemia

DM756GE	ID	DM756GE
DM756GE	DN	APH-0812
DM756GE	HS	Phase 2
DM756GE	SN	Bryostatin-1 + HDAC inhibitor combination (HIV-1 infection), Aphios
DM756GE	CP	Aphios Corp
DM756GE	DE	Human immunodeficiency virus-1 infection; Human immunodeficiency virus infection

DMHIS6Z	ID	DMHIS6Z
DMHIS6Z	DN	Apilimod
DMHIS6Z	HS	Phase 2 
DMHIS6Z	SN	Apilimod; STA 5326; STA-5326; GFW2K84S4L; STA5326; Apilimod [INN]; EX-A908
DMHIS6Z	TC	Antiviral Agents
DMHIS6Z	DT	Small molecular drug
DMHIS6Z	PC	10173277
DMHIS6Z	MW	418.5
DMHIS6Z	FM	C23H26N6O2
DMHIS6Z	IC	InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+
DMHIS6Z	CS	CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4
DMHIS6Z	IK	HSKAZIJJKRAJAV-KOEQRZSOSA-N
DMHIS6Z	IU	N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DMHIS6Z	CA	CAS 541550-19-0
DMHIS6Z	DE	Coronavirus Disease 2019 (COVID-19)

DM4N2O0	ID	DM4N2O0
DM4N2O0	DN	Apilimod dimesylate
DM4N2O0	HS	Phase 2
DM4N2O0	CP	LAM Therapeutics Guilford, CT
DM4N2O0	PC	11527330
DM4N2O0	MW	610.7
DM4N2O0	FM	C25H34N6O8S2
DM4N2O0	IC	InChI=1S/C23H26N6O2.2CH4O3S/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20;2*1-5(2,3)4/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28);2*1H3,(H,2,3,4)/b25-17+;;
DM4N2O0	CS	CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4.CS(=O)(=O)O.CS(=O)(=O)O
DM4N2O0	IK	GAJWNIKZLYZYSY-OKUPSQOASA-N
DM4N2O0	IU	methanesulfonic acid;N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DM4N2O0	CA	CAS 870087-36-8
DM4N2O0	DE	Non-hodgkin lymphoma

DM7IGO9	ID	DM7IGO9
DM7IGO9	DN	Apimostinel
DM7IGO9	HS	Phase 2
DM7IGO9	SN	UNII-TTT1F11FZB; TTT1F11FZB; 1421866-48-9; Apimostinel [USAN]; SCHEMBL14682282; CHEMBL3989872; DB11784; Threonyl-prolyl-2R-(2-benzyl)-prolyl-threonine amide; L-Threoninamide, L-threonyl-L-prolyl-2-(phenylmethyl)-L-prolyl-
DM7IGO9	CP	Allergan Parsippany, NJ
DM7IGO9	PC	71249967
DM7IGO9	MW	503.6
DM7IGO9	FM	C25H37N5O6
DM7IGO9	IC	InChI=1S/C25H37N5O6/c1-15(31)19(26)23(35)29-12-6-10-18(29)22(34)30-13-7-11-25(30,14-17-8-4-3-5-9-17)24(36)28-20(16(2)32)21(27)33/h3-5,8-9,15-16,18-20,31-32H,6-7,10-14,26H2,1-2H3,(H2,27,33)(H,28,36)/t15-,16-,18+,19+,20+,25-/m1/s1
DM7IGO9	CS	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@@]2(CC3=CC=CC=C3)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
DM7IGO9	IK	DVBUEXCIEIAXPM-PJUQSVSOSA-N
DM7IGO9	IU	(2R)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-2-benzylpyrrolidine-2-carboxamide
DM7IGO9	CA	CAS 1421866-48-9
DM7IGO9	DE	Major depressive disorder

DMP0LST	ID	DMP0LST
DMP0LST	DN	APL-101
DMP0LST	HS	Phase 2
DMP0LST	SN	Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine
DMP0LST	CP	Apollomics
DMP0LST	DT	Small molecular drug
DMP0LST	PC	72202701
DMP0LST	MW	424.4
DMP0LST	FM	C20H15F3N8
DMP0LST	IC	InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3
DMP0LST	CS	CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F
DMP0LST	IK	QHXLXUIZUCJRKV-UHFFFAOYSA-N
DMP0LST	IU	6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
DMP0LST	CA	CAS 1440964-89-5
DMP0LST	DE	Non-small cell lung cancer

DMGJ1X2	ID	DMGJ1X2
DMGJ1X2	DN	Aplindore fumarate
DMGJ1X2	HS	Phase 2
DMGJ1X2	SN	Aplindore; Aplindore fumarate (USAN); WAY-DAB-452; (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one; 8H-1,4-Dioxino(2,3-e)indol-8-one,2,3,7,9-tetrahydro-2-(((phenylmethyl)amino)methyl)-,2(S)-, (2E)-2-butenediotate (1:1)
DMGJ1X2	CP	Wyeth
DMGJ1X2	DT	Small molecular drug
DMGJ1X2	PC	6440763
DMGJ1X2	MW	426.4
DMGJ1X2	FM	C22H22N2O7
DMGJ1X2	IC	InChI=1S/C18H18N2O3.C4H4O4/c21-17-8-14-15(20-17)6-7-16-18(14)23-13(11-22-16)10-19-9-12-4-2-1-3-5-12;5-3(6)1-2-4(7)8/h1-7,13,19H,8-11H2,(H,20,21);1-2H,(H,5,6)(H,7,8)/b;2-1+/t13-;/m0./s1
DMGJ1X2	CS	C1[C@@H](OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4.C(=C/C(=O)O)\\C(=O)O
DMGJ1X2	IK	GELJVTSEGKGLDF-QDSMGTAFSA-N
DMGJ1X2	IU	(2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one;(E)-but-2-enedioic acid
DMGJ1X2	CA	CAS 189681-71-8
DMGJ1X2	DE	Schizophrenia

DMGNFBC	ID	DMGNFBC
DMGNFBC	DN	APN301
DMGNFBC	HS	Phase 2
DMGNFBC	SN	MAb hu14.18 linked with IL-2
DMGNFBC	CP	Apeiron Biologics
DMGNFBC	DT	Antibody
DMGNFBC	DE	Neuroblastoma

DM32YTJ	ID	DM32YTJ
DM32YTJ	DN	APN-301
DM32YTJ	HS	Phase 2
DM32YTJ	SN	EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2
DM32YTJ	CP	Apeiron biologics
DM32YTJ	DE	Melanoma; Neuroblastoma

DMEXN7V	ID	DMEXN7V
DMEXN7V	DN	APN401
DMEXN7V	HS	Phase 2
DMEXN7V	SN	APN-411; E3 ubiquitin protein ligase Cbl-b silencing siRNA therapeutics (cancer); Cbl-b modulators (cancer), Apeiron Biologics; E3 ubiquitin ligase casitas B cell lymphoma-b silencing siRNA therapeutics (cancer), Apeiron Biologics; E3 ubiquitin protein ligase Cbl-b silencing siRNA therapeutics (cancer), Apeiron Biologics
DMEXN7V	CP	Apeiron Biologics
DMEXN7V	DT	Small interfering RNA
DMEXN7V	DE	Solid tumour/cancer

DMKVP7E	ID	DMKVP7E
DMKVP7E	DN	Apolizumab
DMKVP7E	HS	Phase 2
DMKVP7E	SN	Remitogen; Hu 1D10; Hu1D10, PDL; SMART 1D10 MAb, Protein Design Labs; SMART anti-B cell lymphoma
DMKVP7E	CP	PDL BioPharma
DMKVP7E	DT	Monoclonal antibody
DMKVP7E	DE	Solid tumour/cancer

DM6B9HP	ID	DM6B9HP
DM6B9HP	DN	Apomine
DM6B9HP	HS	Phase 2
DM6B9HP	SN	Apomine; SR-45023A; UNII-JQ95208805; JQ95208805; SR-9223i; SR 45023A; APB-231-A2; SKF 99085; F-99085; 126411-13-0; SCHEMBL1648488; AC1L423G; DB12276; 4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol; tetraisopropyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-biphosphonate; Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis-, tetrakis(1-methylethyl); SK&F-99085; 2-(3,5-Di-tert-butyl-4-hydroxyphenyl)ethylidene-1,1-diphosphonic acid tetraisopropyl ester; SR-45023A (Apomine)
DM6B9HP	CP	Genzyme
DM6B9HP	DT	Small molecular drug
DM6B9HP	PC	176405
DM6B9HP	MW	562.7
DM6B9HP	FM	C28H52O7P2
DM6B9HP	IC	InChI=1S/C28H52O7P2/c1-18(2)32-36(30,33-19(3)4)25(37(31,34-20(5)6)35-21(7)8)17-22-15-23(27(9,10)11)26(29)24(16-22)28(12,13)14/h15-16,18-21,25,29H,17H2,1-14H3
DM6B9HP	CS	CC(C)OP(=O)(C(CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OC(C)C)OC(C)C)OC(C)C
DM6B9HP	IK	YLJOVCWVJCDPLN-UHFFFAOYSA-N
DM6B9HP	IU	4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol
DM6B9HP	CA	CAS 126411-13-0
DM6B9HP	DE	Osteopetrosis

DMNFADH	ID	DMNFADH
DMNFADH	DN	APR-246
DMNFADH	HS	Phase 2
DMNFADH	SN	Eprenetapopt
DMNFADH	CP	Aprea Therapeutics
DMNFADH	DT	Small molecular drug
DMNFADH	PC	52918385
DMNFADH	MW	199.25
DMNFADH	FM	C10H17NO3
DMNFADH	IC	InChI=1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3
DMNFADH	CS	COCC1(C(=O)C2CCN1CC2)CO
DMNFADH	IK	BGBNULCRKBVAKL-UHFFFAOYSA-N
DMNFADH	IU	2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one
DMNFADH	CA	CAS 5291-32-7
DMNFADH	DE	Solid tumour/cancer; Ovarian cancer; Esophageal cancer; Myelodysplastic syndrome; Bladder cancer; Gastric adenocarcinoma

DM8W4N9	ID	DM8W4N9
DM8W4N9	DN	Apratastat
DM8W4N9	HS	Phase 2
DM8W4N9	SN	TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, &gt; MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst
DM8W4N9	CP	Wyeth Research
DM8W4N9	DT	Small molecular drug
DM8W4N9	PC	11452716
DM8W4N9	MW	414.5
DM8W4N9	FM	C17H22N2O6S2
DM8W4N9	IC	InChI=1S/C17H22N2O6S2/c1-17(2)15(16(21)18-22)19(9-12-26-17)27(23,24)14-7-5-13(6-8-14)25-11-4-3-10-20/h5-8,15,20,22H,9-12H2,1-2H3,(H,18,21)/t15-/m0/s1
DM8W4N9	CS	CC1([C@@H](N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OCC#CCO)C(=O)NO)C
DM8W4N9	IK	MAVDNGWEBZTACC-HNNXBMFYSA-N
DM8W4N9	IU	(3S)-N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide
DM8W4N9	CA	CAS 287405-51-0
DM8W4N9	DE	Rheumatoid arthritis

DMEJICQ	ID	DMEJICQ
DMEJICQ	DN	Aprocitentan
DMEJICQ	HS	Phase 2
DMEJICQ	SN	ACT-132577; UNII-MZI81HV01P; 1103522-45-7; Despropyl Macitentan; MZI81HV01P; CHEMBL2165326; CHEBI:76609; Macitentan metabolite; ACT 132577; SCHEMBL3646065; ZINC95553608; BDBM50395672; AKOS028114466; CS-2687; HY-15895; BC600808; 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfuric diamide
DMEJICQ	CP	Idorsia Pharmaceuticals Allschwil, Switzerland Janssen Biotech Horsham, PA
DMEJICQ	PC	25099191
DMEJICQ	MW	546.2
DMEJICQ	FM	C16H14Br2N6O4S
DMEJICQ	IC	InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24)
DMEJICQ	CS	C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br
DMEJICQ	IK	DKULOVKANLVDEA-UHFFFAOYSA-N
DMEJICQ	IU	5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine
DMEJICQ	CA	CAS 1103522-45-7
DMEJICQ	CB	CHEBI:76609
DMEJICQ	DE	Hypertension

DMX2P5G	ID	DMX2P5G
DMX2P5G	DN	APX005M
DMX2P5G	HS	Phase 2
DMX2P5G	CP	Apexigen San Carlos, CA
DMX2P5G	DT	Antibody
DMX2P5G	DE	Solid tumour/cancer; Brain cancer; Chronic lymphocytic leukaemia; Melanoma

DMU6NBO	ID	DMU6NBO
DMU6NBO	DN	APX3330
DMU6NBO	HS	Phase 2
DMU6NBO	SN	E3330; 136164-66-4; E-3330; E 3330; CHEMBL578390; UNII-11267UI968; 11267UI968; (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid; (E)-2-((4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylene)undecanoic acid; (2E)-3-(5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl))-2-nonyl-2-propenoic acid; SCHEMBL3758716; SCHEMBL3758719; HMS3886N15; APX 3330; EX-A2212; BDBM50303955; s7445; ZINC14252145; CCG-268389; HY-19357; B5875; CS-0015424; E3330, >=98% (HPLC); A14440; (E)-3-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dienyl)-2-nonylpropenoic acid; (E)-3-(5,6-Dimethoxy-3-methyl-14-dioxocyclohexa-25-dienyl)-2-nonylpropenoic Acid; Undecanoic acid, 2-((4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene)-, (E)-
DMU6NBO	CP	Apexian Pharmaceuticals
DMU6NBO	DT	Small molecular drug
DMU6NBO	PC	6439397
DMU6NBO	MW	378.5
DMU6NBO	FM	C21H30O6
DMU6NBO	IC	InChI=1S/C21H30O6/c1-5-6-7-8-9-10-11-12-15(21(24)25)13-16-14(2)17(22)19(26-3)20(27-4)18(16)23/h13H,5-12H2,1-4H3,(H,24,25)/b15-13+
DMU6NBO	CS	CCCCCCCCC/C(=C\\C1=C(C(=O)C(=C(C1=O)OC)OC)C)/C(=O)O
DMU6NBO	IK	AALSSIXXBDPENJ-FYWRMAATSA-N
DMU6NBO	IU	(2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid
DMU6NBO	CA	CAS 136164-66-4
DMU6NBO	DE	Solid tumour/cancer; Diabetic retinopathy

DM1USXR	ID	DM1USXR
DM1USXR	DN	AQ-13
DM1USXR	HS	Phase 2
DM1USXR	SN	AQ-13 Dihydrochloride; 169815-40-1; UNII-PKT9732S5K; AQ 13; PKT9732S5K; DTXSID10168761; (N1-(7-Chloroquinolin-4-yl)-3-(N3,N3-diethylamino)propylamine) dihydrochloride; HY-100358; CS-0018673; 1,3-Propanediamine, N'-(7-chloro-4-quinolinyl)-N,N-diethyl-,     dihydrochloride
DM1USXR	CP	Tulane University
DM1USXR	DT	Small molecular drug
DM1USXR	PC	9820475
DM1USXR	MW	364.7
DM1USXR	FM	C16H24Cl3N3
DM1USXR	IC	InChI=1S/C16H22ClN3.2ClH/c1-3-20(4-2)11-5-9-18-15-8-10-19-16-12-13(17)6-7-14(15)16;;/h6-8,10,12H,3-5,9,11H2,1-2H3,(H,18,19);2*1H
DM1USXR	CS	CCN(CC)CCCNC1=C2C=CC(=CC2=NC=C1)Cl.Cl.Cl
DM1USXR	IK	ZNHBPWZRWNFJPN-UHFFFAOYSA-N
DM1USXR	IU	N-(7-chloroquinolin-4-yl)-N',N'-diethylpropane-1,3-diamine;dihydrochloride
DM1USXR	CA	CAS 169815-40-1
DM1USXR	DE	Malaria

DMD2RFO	ID	DMD2RFO
DMD2RFO	DN	AQW-051
DMD2RFO	HS	Phase 2
DMD2RFO	SN	AQW-051; 669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane
DMD2RFO	CP	Novartis AG
DMD2RFO	DT	Small molecular drug
DMD2RFO	PC	50914822
DMD2RFO	MW	294.4
DMD2RFO	FM	C19H22N2O
DMD2RFO	IC	InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
DMD2RFO	CS	CC1=CC=C(C=C1)C2=NC=C(C=C2)O[C@H]3CN4CCC3CC4
DMD2RFO	IK	NPDLTEZXGWRMLQ-IBGZPJMESA-N
DMD2RFO	IU	(3R)-3-[6-(4-methylphenyl)pyridin-3-yl]oxy-1-azabicyclo[2.2.2]octane
DMD2RFO	DE	Alzheimer disease

DMCH3G5	ID	DMCH3G5
DMCH3G5	DN	AQX-1125
DMCH3G5	HS	Phase 2
DMCH3G5	SN	AQX-108; AQX-131; AQX-132; AQX-133; AQX-134; AQX-135; AQX-140; AQX-150; SHIP agonists (cancer/inflammation), Aquinox
DMCH3G5	CP	Aquinox Pharmaceuticals Inc
DMCH3G5	DT	Small molecular drug
DMCH3G5	PC	76965484
DMCH3G5	MW	321.5
DMCH3G5	FM	C20H35NO2
DMCH3G5	IC	InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1
DMCH3G5	CS	C[C@@]1(CC[C@@H](C[C@@H]1CO)O)[C@H]2CC[C@]3([C@H]([C@@H]2CN)CCC3=C)C
DMCH3G5	IK	MDEJTPWQNNMAQF-BVMLLJBZSA-N
DMCH3G5	IU	(1S,3S,4R)-4-[(3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylidene-3,3a,4,5,6,7-hexahydro-2H-inden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexan-1-ol
DMCH3G5	CA	CAS 782487-28-9
DMCH3G5	DE	Chronic obstructive pulmonary disease

DM93CTQ	ID	DM93CTQ
DM93CTQ	DN	AR08
DM93CTQ	HS	Phase 2
DM93CTQ	CP	Arbor pharmaceuticals
DM93CTQ	DE	Attention deficit hyperactivity disorder

DM5TC43	ID	DM5TC43
DM5TC43	DN	AR-12286
DM5TC43	HS	Phase 2
DM5TC43	SN	AR-11236; AR-12080; AR-12132; CF-286-03; CF-286-04
DM5TC43	CP	Aerie Pharmaceuticals Inc
DM5TC43	PC	66906051
DM5TC43	MW	327.4
DM5TC43	FM	C17H17N3O2S
DM5TC43	IC	InChI=1S/C17H17N3O2S/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21/h3-10,15H,1-2H3,(H,18,21)(H,19,22)
DM5TC43	CS	CN(C)C(C1=CSC=C1)C(=O)NC2=CC3=C(C=C2)C(=O)NC=C3
DM5TC43	IK	VDYRZXYYQMMFJW-UHFFFAOYSA-N
DM5TC43	IU	2-(dimethylamino)-N-(1-oxo-2H-isoquinolin-6-yl)-2-thiophen-3-ylacetamide
DM5TC43	CA	CAS 1414854-42-4
DM5TC43	DE	Glaucoma/ocular hypertension

DM8A71F	ID	DM8A71F
DM8A71F	DN	AR-67
DM8A71F	HS	Phase 2
DM8A71F	SN	AR-67; Silatecan; 220913-32-6; DB-67; UNII-3YEA04NV6H; 3YEA04NV6H; DB67; AR67; AR 67; (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin; NCI60_038363; C26H30N2O5Si; SCHEMBL1266162; CHEMBL412309; GTPL8919; DTXSID00176592; DB 67; BCP19768; 7555AD; NSC708298; ZINC170020689; AKOS030627314; DB12384; NSC-708298; compound 14 [PMID:11052802]; KB-74723; Z3398; Z-3160; 1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 11-((1,1-dimethylethyl)dimethylsilyl)-4-ethyl-4,9-dihydroxy-, (4S)-
DM8A71F	CP	Arno Therapeutics
DM8A71F	DT	Small molecular drug
DM8A71F	PC	6712744
DM8A71F	MW	478.6
DM8A71F	FM	C26H30N2O5Si
DM8A71F	IC	InChI=1S/C26H30N2O5Si/c1-7-26(32)18-11-20-21-16(12-28(20)23(30)17(18)13-33-24(26)31)22(34(5,6)25(2,3)4)15-10-14(29)8-9-19(15)27-21/h8-11,29,32H,7,12-13H2,1-6H3/t26-/m0/s1
DM8A71F	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=C(C=CC(=C5)O)N=C4C3=C2)[Si](C)(C)C(C)(C)C)O
DM8A71F	IK	XUSKJHCMMWAAHV-SANMLTNESA-N
DM8A71F	IU	(19S)-10-[tert-butyl(dimethyl)silyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DM8A71F	CA	CAS 220913-32-6
DM8A71F	DE	Myelodysplastic syndrome; Glioblastoma multiforme

DMJHA6Q	ID	DMJHA6Q
DMJHA6Q	DN	Ar9281
DMJHA6Q	HS	Phase 2
DMJHA6Q	SN	1-(Adamantane-1-yl)-3-(1-acetylpiperidine-4-yl)urea; UNII-4HA03Q8EZ9; 4HA03Q8EZ9; CHEMBL436774; 1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea; 913548-29-5; Ar9281; AR-9281; Apau (enzyme inhibitor); SCHEMBL654229; 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea; SCHEMBL18464997; MolPort-023-222-910; HUDQLWBKJOMXSZ-UHFFFAOYSA-N; BDBM100423; BDBM50191854; ZINC36330562; AKOS030231617; J3137087F; US8501783, 1153; 1-(adamant-1-yl)-3-(1-acetylpiperidin-4-yl) urea; N-(1-Acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea; N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea
DMJHA6Q	CP	Ar  te Therapeutics
DMJHA6Q	DT	Small molecular drug
DMJHA6Q	PC	12000797
DMJHA6Q	MW	319.4
DMJHA6Q	FM	C18H29N3O2
DMJHA6Q	IC	InChI=1S/C18H29N3O2/c1-12(22)21-4-2-16(3-5-21)19-17(23)20-18-9-13-6-14(10-18)8-15(7-13)11-18/h13-16H,2-11H2,1H3,(H2,19,20,23)
DMJHA6Q	CS	CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMJHA6Q	IK	HUDQLWBKJOMXSZ-UHFFFAOYSA-N
DMJHA6Q	IU	1-(1-acetylpiperidin-4-yl)-3-(1-adamantyl)urea
DMJHA6Q	CA	CAS 913548-29-5
DMJHA6Q	DE	Hypertension

DM7PCLY	ID	DM7PCLY
DM7PCLY	DN	ARC1779
DM7PCLY	HS	Phase 2
DM7PCLY	CP	Archemix
DM7PCLY	DT	Small molecular drug
DM7PCLY	DE	Intracranial embolism

DM9LNXS	ID	DM9LNXS
DM9LNXS	DN	ARI-3037MO
DM9LNXS	HS	Phase 2
DM9LNXS	CP	Arisaph Pharmaceuticals
DM9LNXS	DE	Dyslipidemia; Cardiovascular disease; Hypertriglyceridemia

DML3PJF	ID	DML3PJF
DML3PJF	DN	ARN-810
DML3PJF	HS	Phase 2
DML3PJF	CP	Seragon pharmaceuticals
DML3PJF	PC	56941241
DML3PJF	MW	446.9
DML3PJF	FM	C26H20ClFN2O2
DML3PJF	IC	InChI=1S/C26H20ClFN2O2/c1-2-21(22-10-9-20(28)14-23(22)27)26(18-8-11-24-19(13-18)15-29-30-24)17-6-3-16(4-7-17)5-12-25(31)32/h3-15H,2H2,1H3,(H,29,30)(H,31,32)/b12-5+,26-21+
DML3PJF	CS	CC/C(=C(/C1=CC=C(C=C1)/C=C/C(=O)O)\\C2=CC3=C(C=C2)NN=C3)/C4=C(C=C(C=C4)F)Cl
DML3PJF	IK	BURHGPHDEVGCEZ-KJGLQBJMSA-N
DML3PJF	IU	(E)-3-[4-[(E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-enyl]phenyl]prop-2-enoic acid
DML3PJF	CA	CAS 1365888-06-7
DML3PJF	DE	Breast cancer

DM2UP6Z	ID	DM2UP6Z
DM2UP6Z	DN	ARO-AAT
DM2UP6Z	HS	Phase 2
DM2UP6Z	CP	Arrowhead Pharmaceuticals
DM2UP6Z	DT	Small interfering RNA
DM2UP6Z	DE	Alpha-1 antitrypsin deficiency; Alopecia

DM5WK0J	ID	DM5WK0J
DM5WK0J	DN	ARQ 092
DM5WK0J	HS	Phase 2
DM5WK0J	SN	Miransertib
DM5WK0J	CP	ArQule; Daiichi
DM5WK0J	PC	53262401
DM5WK0J	MW	432.5
DM5WK0J	FM	C27H24N6
DM5WK0J	IC	InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)
DM5WK0J	CS	C1CC(C1)(C2=CC=C(C=C2)N3C4=C(C=CC(=N4)C5=CC=CC=C5)N=C3C6=C(N=CC=C6)N)N
DM5WK0J	IK	HNFMVVHMKGFCMB-UHFFFAOYSA-N
DM5WK0J	IU	3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine
DM5WK0J	CA	CAS 1313881-70-7
DM5WK0J	DE	Solid tumour/cancer; Proteus syndrome

DMRG0A3	ID	DMRG0A3
DMRG0A3	DN	ARQ 531
DMRG0A3	HS	Phase 2
DMRG0A3	SN	JSFCZQSJQXFJDS-QAPCUYQASA-N; UNII-JTZ51LIXN4; JTZ51LIXN4; 2095393-15-8; ARQ-531; ARQ531; SCHEMBL18770934; SCHEMBL18756744; EX-A2727; BCP29029; HY-112215; CS-0044154; HRA; (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)methanone; 1,5-anhydro-2-{[5-(2-chloro-4-phenoxybenzene-1-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-2,3,4-trideoxy-D-erythro-hexitol
DMRG0A3	CP	ArQule Burlington, MA
DMRG0A3	PC	129045720
DMRG0A3	MW	478.9
DMRG0A3	FM	C25H23ClN4O4
DMRG0A3	IC	InChI=1S/C25H23ClN4O4/c26-21-10-17(34-16-4-2-1-3-5-16)8-9-19(21)23(32)20-11-27-24-22(20)25(29-14-28-24)30-15-6-7-18(12-31)33-13-15/h1-5,8-11,14-15,18,31H,6-7,12-13H2,(H2,27,28,29,30)/t15-,18+/m1/s1
DMRG0A3	CS	C1C[C@H](OC[C@@H]1NC2=NC=NC3=C2C(=CN3)C(=O)C4=C(C=C(C=C4)OC5=CC=CC=C5)Cl)CO
DMRG0A3	IK	JSFCZQSJQXFJDS-QAPCUYQASA-N
DMRG0A3	IU	(2-chloro-4-phenoxyphenyl)-[4-[[(3R,6S)-6-(hydroxymethyl)oxan-3-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]methanone
DMRG0A3	CA	CAS 2095393-15-8
DMRG0A3	DE	Hematologic tumour

DMH5CAL	ID	DMH5CAL
DMH5CAL	DN	ARQ 761
DMH5CAL	HS	Phase 2
DMH5CAL	CP	ArQule
DMH5CAL	DE	Solid tumour/cancer; Pancreatic cancer

DMYEIOH	ID	DMYEIOH
DMYEIOH	DN	ARQ-154
DMYEIOH	HS	Phase 2
DMYEIOH	CP	Arcutis Biotherapeutics
DMYEIOH	DT	Small molecular drug
DMYEIOH	DE	Plaque psoriasis

DM0VGDC	ID	DM0VGDC
DM0VGDC	DN	ARRY-382
DM0VGDC	HS	Phase 2
DM0VGDC	CP	Array BioPharma; Celgene
DM0VGDC	DE	Solid tumour/cancer

DM17469	ID	DM17469
DM17469	DN	ARRY-502
DM17469	HS	Phase 2
DM17469	CP	Array BioPharma
DM17469	PC	131633366
DM17469	MW	516.4
DM17469	FM	C26H23Cl2NO6
DM17469	IC	InChI=1S/C26H23Cl2NO6/c1-33-22-12-17(27)5-2-15(22)8-10-29-25(30)16-3-6-18(7-4-16)35-24-14-23-20(13-21(24)28)19(26(31)32)9-11-34-23/h2-7,12-14,19H,8-11H2,1H3,(H,29,30)(H,31,32)/t19-/m0/s1
DM17469	CS	COC1=C(C=CC(=C1)Cl)CCNC(=O)C2=CC=C(C=C2)OC3=C(C=C4[C@H](CCOC4=C3)C(=O)O)Cl
DM17469	IK	QIDYUNXQPQEJEC-IBGZPJMESA-N
DM17469	IU	(4S)-6-chloro-7-[4-[2-(4-chloro-2-methoxyphenyl)ethylcarbamoyl]phenoxy]-3,4-dihydro-2H-chromene-4-carboxylic acid
DM17469	CA	CAS 1202891-16-4
DM17469	DE	Allergic asthma

DMTOI7S	ID	DMTOI7S
DMTOI7S	DN	ARRY-520
DMTOI7S	HS	Phase 2
DMTOI7S	SN	Filanesib; ARRY-520; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; ARRY-520; Filanesib; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04
DMTOI7S	CP	Array BioPharma.
DMTOI7S	TC	Anticancer Agents
DMTOI7S	DT	Small molecular drug
DMTOI7S	PC	44224257
DMTOI7S	MW	420.5
DMTOI7S	FM	C20H22F2N4O2S
DMTOI7S	IC	InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23,14-7-4-3-5-8-14)29-18(24-26)16-13-15(21)9-10-17(16)22/h3-5,7-10,13H,6,11-12,23H2,1-2H3/t20-/m0/s1
DMTOI7S	CS	CN(C(=O)N1[C@](SC(=N1)C2=C(C=CC(=C2)F)F)(CCCN)C3=CC=CC=C3)OC
DMTOI7S	IK	LLXISKGBWFTGEI-FQEVSTJZSA-N
DMTOI7S	IU	(2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3-carboxamide
DMTOI7S	CA	CAS 885060-09-3
DMTOI7S	DE	Solid tumour/cancer; Multiple myeloma

DMJ48AB	ID	DMJ48AB
DMJ48AB	DN	ARRY-797
DMJ48AB	HS	Phase 2
DMJ48AB	SN	CHEMBL1088750; ARRY-797; SCHEMBL222635; ARRY-371797; BDBM50314072
DMJ48AB	CP	Array BioPharma.
DMJ48AB	TC	Analgesics
DMJ48AB	DT	Small molecular drug
DMJ48AB	PC	46883775
DMJ48AB	MW	416.5
DMJ48AB	FM	C22H26F2N4O2
DMJ48AB	IC	InChI=1S/C22H26F2N4O2/c1-14(2)13-28-19-11-17(22(29)25-7-8-27(3)4)21(9-15(19)12-26-28)30-20-6-5-16(23)10-18(20)24/h5-6,9-12,14H,7-8,13H2,1-4H3,(H,25,29)
DMJ48AB	CS	CC(C)CN1C2=CC(=C(C=C2C=N1)OC3=C(C=C(C=C3)F)F)C(=O)NCCN(C)C
DMJ48AB	IK	IFGWYHGYNVGVRB-UHFFFAOYSA-N
DMJ48AB	IU	5-(2,4-difluorophenoxy)-N-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)indazole-6-carboxamide
DMJ48AB	DE	Pain; Osteoarthritis; Dilated cardiomyopathy

DML27AE	ID	DML27AE
DML27AE	DN	Arverapamil
DML27AE	HS	Phase 2
DML27AE	SN	Arverapamil; (R)-norverapamil; Agi-003; UNII-3J8P56R04P; (R)-(+)-Nor Verapamil Hydrochloride; 123932-43-4; 3J8P56R04P; Rezular; (+)-norverapamil; (R)-desmethylverapamil; (+)-desmethylverapamil; CHEBI:134082; ZINC13492624; AKOS030532539; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, (alphaR)-; UNII-957Z3K3R56 component UPKQNCPKPOLASS-AREMUKBSSA-N
DML27AE	CP	AGI Therapeutics
DML27AE	DT	Small molecular drug
DML27AE	PC	15593907
DML27AE	MW	440.6
DML27AE	FM	C26H36N2O4
DML27AE	IC	InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1
DML27AE	CS	CC(C)[C@@](CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DML27AE	IK	UPKQNCPKPOLASS-AREMUKBSSA-N
DML27AE	IU	(2R)-2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-propan-2-ylpentanenitrile
DML27AE	CA	CAS 123932-43-4
DML27AE	CB	CHEBI:134082
DML27AE	DE	Irritable bowel syndrome

DMMX1EJ	ID	DMMX1EJ
DMMX1EJ	DN	AS-1402
DMMX1EJ	HS	Phase 2
DMMX1EJ	SN	Therex; R-1550; HuHMFG1 derivative, ICRF/Antisoma/Roche; Anti-mucin MAb, ICRF/Antisoma/Roche
DMMX1EJ	CP	Antisoma
DMMX1EJ	DT	Antibody
DMMX1EJ	DE	Breast cancer

DMTUMYX	ID	DMTUMYX
DMTUMYX	DN	AS-902330
DMTUMYX	HS	Phase 2
DMTUMYX	SN	Sprifermin; Zfgf5; FGF-18, Merck Serono; FGF-18, ZymoGenetics
DMTUMYX	CP	Emd serono
DMTUMYX	DE	Arthropathy

DMNVU28	ID	DMNVU28
DMNVU28	DN	ASB17061
DMNVU28	HS	Phase 2
DMNVU28	CP	Daiichi Sankyo
DMNVU28	DE	Atopic dermatitis

DMMBVCJ	ID	DMMBVCJ
DMMBVCJ	DN	ASCJ-9
DMMBVCJ	HS	Phase 2
DMMBVCJ	SN	Dimethylcurcumin; ASC-JMX1; ASCJ-9; ASCJ-9 (systemic), AndroScience; ASCJ-9 (topical), AndroScience; Androgen antagonist (alopecia/acne), AndroScience; Androgen receptor degradation enhancers (oral, spinal bulbar muscular atrophy), AndroScience
DMMBVCJ	CP	AndroScience
DMMBVCJ	DE	Alopecia; Acne vulgaris

DMDQS4W	ID	DMDQS4W
DMDQS4W	DN	ASC-J9
DMDQS4W	HS	Phase 2
DMDQS4W	SN	Dimethylcurcumin; 52328-98-0; 917813-54-8; ASCJ-9; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; GO-Y-025; (1E,4E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; Dimethylcurcumin (ASC-J9); 1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; SCHEMBL3487103; CHC-004; DTXSID10200352; EX-A927; AMY15692; 3454AH; MFCD12912341; MFCD22123809; NSC734923; RSC004738; s6630; AKOS015891371; AKOS025311328; ZINC100007120; CS-0533; DB06133; LS40141; NSC-734923; SB18767; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (1E,4Z,6E)--; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (Z,E,E)-; AC-31058; DS-14720; HY-15194; ASC-J9,CAS:52328-98-0; W9512; J3.606.945G; A11300; W-5544; GO-Y025; Dimethylcurcumin; ASC J9; GO Y025; 1, 4-dimethoxyphenyl)-1, 6-heptadiene-3,5-dione; (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)- 5-hydroxy-hepta-1,4,6-trien-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one; (1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 115851-85-9
DMDQS4W	CP	AndroScience
DMDQS4W	DT	Small molecular drug
DMDQS4W	PC	6477182
DMDQS4W	MW	396.4
DMDQS4W	FM	C23H24O6
DMDQS4W	IC	InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-15,24H,1-4H3/b9-5+,10-6+,18-15-
DMDQS4W	CS	COC1=C(C=C(C=C1)/C=C/C(=C/C(=O)/C=C/C2=CC(=C(C=C2)OC)OC)/O)OC
DMDQS4W	IK	ZMGUKFHHNQMKJI-CIOHCNBKSA-N
DMDQS4W	IU	(1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one
DMDQS4W	CA	CAS 52328-98-0
DMDQS4W	DE	Thrombosis; End-stage renal disease

DMZF68E	ID	DMZF68E
DMZF68E	DN	Ascrolimus
DMZF68E	HS	Phase 2
DMZF68E	SN	A-86281; ABT-281; ZK-248258
DMZF68E	CP	Abbott Laboratories
DMZF68E	PC	9919023
DMZF68E	MW	844
DMZF68E	FM	C44H69N5O11
DMZF68E	IC	InChI=1S/C44H69N5O11/c1-10-31-18-25(2)17-26(3)19-37(57-8)40-38(58-9)21-28(5)44(55,60-40)41(52)42(53)48-16-12-11-13-33(48)43(54)59-39(29(6)34(50)23-35(31)51)27(4)20-30-14-15-32(36(22-30)56-7)49-24-45-46-47-49/h18,20,24,26,28-34,36-40,50,55H,10-17,19,21-23H2,1-9H3/b25-18+,27-20+/t26-,28+,29+,30-,31+,32-,33-,34-,36+,37-,38-,39+,40+,44+/m0/s1
DMZF68E	CS	CC[C@@H]1/C=C(/C[C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@@H]([C@@H](C4)OC)N5C=NN=N5)/C)O)C)OC)OC)C)\\C
DMZF68E	IK	HIEKJRVYXXINKH-ADVKXBNGSA-N
DMZF68E	IU	(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-12-[(E)-1-[(1R,3R,4S)-3-methoxy-4-(tetrazol-1-yl)cyclohexyl]prop-1-en-2-yl]-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMZF68E	CA	CAS 148147-65-3
DMZF68E	DE	Psoriasis vulgaris

DM1CLKO	ID	DM1CLKO
DM1CLKO	DN	ASKP-1240
DM1CLKO	HS	Phase 2
DM1CLKO	SN	Anti-CD40 mAb (organ transplant rejection/autoimmune disease), Kirin/Astellas; Anti-CD40 mAb (organ transplant rejection/autoimmune disease), Kyowa Hakko Kirin/Astellas; 4D11
DM1CLKO	CP	Astellas pharma us; kyowa hakko kirin pharma
DM1CLKO	DT	Antibody
DM1CLKO	DE	Transplant rejection

DM35S2I	ID	DM35S2I
DM35S2I	DN	ASM-024
DM35S2I	HS	Phase 2
DM35S2I	CP	Asmacure Lt |e
DM35S2I	PC	117587641
DM35S2I	MW	404.6
DM35S2I	FM	C22H32N2O3S
DM35S2I	IC	InChI=1S/C15H25N2.C7H8O3S/c1-3-17(4-2)13-8-11-16(12-14-17)15-9-6-5-7-10-15;1-6-2-4-7(5-3-6)11(8,9)10/h5-7,9-10H,3-4,8,11-14H2,1-2H3;2-5H,1H3,(H,8,9,10)/q+1;/p-1
DM35S2I	CS	CC[N+]1(CCCN(CC1)C2=CC=CC=C2)CC.CC1=CC=C(C=C1)S(=O)(=O)[O-]
DM35S2I	IK	PXRYYARWCNIUKT-UHFFFAOYSA-M
DM35S2I	IU	1,1-diethyl-4-phenyl-1,4-diazepan-1-ium;4-methylbenzenesulfonate
DM35S2I	CA	CAS 1609534-90-8
DM35S2I	DE	Asthma

DMTHR4U	ID	DMTHR4U
DMTHR4U	DN	ASM8
DMTHR4U	HS	Phase 2
DMTHR4U	CP	Pharmaxis
DMTHR4U	DT	Antisense drug
DMTHR4U	DE	Allergic asthma

DM92X7N	ID	DM92X7N
DM92X7N	DN	ASN002
DM92X7N	HS	Phase 2
DM92X7N	SN	POAZPIKWEFFCBP-UHFFFAOYSA-N; GTPL10000; 2-[1-(4-{[4-(4-hydroxypiperazin-1-yl)phenyl]amino}-5-oxo-5H,6H-pyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl]acetonitrile
DM92X7N	CP	Asana BioSciences Lawrenceville, NJ
DM92X7N	PC	71269142
DM92X7N	MW	460.5
DM92X7N	FM	C24H28N8O2
DM92X7N	IC	InChI=1S/C24H28N8O2/c25-10-5-16-6-11-32(12-7-16)24-28-20-15-26-30-23(34)21(20)22(29-24)27-17-1-3-18(4-2-17)31-13-8-19(33)9-14-31/h1-4,15-16,19,33H,5-9,11-14H2,(H,30,34)(H,27,28,29)
DM92X7N	CS	C1CN(CCC1CC#N)C2=NC3=C(C(=O)NN=C3)C(=N2)NC4=CC=C(C=C4)N5CCC(CC5)O
DM92X7N	IK	NLFLXLJXEIUQDL-UHFFFAOYSA-N
DM92X7N	IU	2-[1-[4-[4-(4-hydroxypiperidin-1-yl)anilino]-5-oxo-6H-pyrimido[4,5-d]pyridazin-2-yl]piperidin-4-yl]acetonitrile
DM92X7N	CA	CAS 1425381-60-7
DM92X7N	DE	Eczema; Lymphoma; Solid tumour/cancer

DMWPGLS	ID	DMWPGLS
DMWPGLS	DN	ASN100
DMWPGLS	HS	Phase 2
DMWPGLS	CP	Arsanis
DMWPGLS	DT	Monoclonal antibody
DMWPGLS	DE	Ventilator-associated pneumonia; Hospital-acquired pneumonia

DM6HJ3V	ID	DM6HJ3V
DM6HJ3V	DN	ASP0819
DM6HJ3V	HS	Phase 2
DM6HJ3V	CP	Astellas Pharma
DM6HJ3V	DT	Small molecular drug
DM6HJ3V	DE	Fibromyalgia

DME8XD7	ID	DME8XD7
DME8XD7	DN	ASP-1707
DME8XD7	HS	Phase 2
DME8XD7	CP	Astellas Pharma Inc
DME8XD7	DE	Endometriosis

DMBADQV	ID	DMBADQV
DMBADQV	DN	ASP-3291
DMBADQV	HS	Phase 2
DMBADQV	CP	Astellas Pharma Inc
DMBADQV	DE	Ulcerative colitis

DM4KTN6	ID	DM4KTN6
DM4KTN6	DN	ASP-3652
DM4KTN6	HS	Phase 2
DM4KTN6	SN	FK-175; Beta 3 adrenoceptor agonists (overactive bladder), Astellas
DM4KTN6	CP	Astellas Pharma Inc
DM4KTN6	DE	Overactive bladder

DMZUAH2	ID	DMZUAH2
DMZUAH2	DN	ASP-4901
DMZUAH2	HS	Phase 2
DMZUAH2	CP	Astellas Pharma
DMZUAH2	DE	Genitourinary disease

DMTF24A	ID	DMTF24A
DMTF24A	DN	ASP-7035
DMTF24A	HS	Phase 2
DMTF24A	CP	Astellas Pharma Inc
DMTF24A	PC	11478371
DMTF24A	MW	548.4
DMTF24A	FM	C25H23F7N2O4
DMTF24A	IC	InChI=1S/C25H23F7N2O4/c1-14(26)13-38-16-3-4-17(20(11-16)25(30,31)32)23(37)34-8-6-24(28,29)19(12-22(36)33-7-9-35)18-10-15(27)2-5-21(18)34/h2-5,10-12,14,35H,6-9,13H2,1H3,(H,33,36)/b19-12-/t14-/m1/s1
DMTF24A	CS	C[C@H](COC1=CC(=C(C=C1)C(=O)N2CCC(/C(=C\\C(=O)NCCO)/C3=C2C=CC(=C3)F)(F)F)C(F)(F)F)F
DMTF24A	IK	VSXSHTIGQAUGMW-VCRXTVNUSA-N
DMTF24A	IU	(2Z)-N-(2-hydroxyethyl)-2-[4,4,7-trifluoro-1-[4-[(2R)-2-fluoropropoxy]-2-(trifluoromethyl)benzoyl]-2,3-dihydro-1-benzazepin-5-ylidene]acetamide
DMTF24A	CA	CAS 790694-26-7
DMTF24A	DE	Nocturia

DMGDF2X	ID	DMGDF2X
DMGDF2X	DN	ASP-7147
DMGDF2X	HS	Phase 2
DMGDF2X	CP	Astellas Pharma Inc
DMGDF2X	DE	Irritable bowel syndrome

DM3TN1A	ID	DM3TN1A
DM3TN1A	DN	ASP7991
DM3TN1A	HS	Phase 2
DM3TN1A	CP	Astellas
DM3TN1A	DE	Hyperparathyroidism

DMR1MIV	ID	DMR1MIV
DMR1MIV	DN	ASP8062
DMR1MIV	HS	Phase 2
DMR1MIV	CP	Astellas Northbrook, IL
DMR1MIV	DE	Fibromyalgia

DMYK1JU	ID	DMYK1JU
DMYK1JU	DN	ASP8232
DMYK1JU	HS	Phase 2
DMYK1JU	CP	Astellas
DMYK1JU	DE	Diabetic nephropathy; Diabetic macular edema

DMHLXUY	ID	DMHLXUY
DMHLXUY	DN	ASP8273
DMHLXUY	HS	Phase 2
DMHLXUY	CP	Astellas pharma us
DMHLXUY	PC	71667668
DMHLXUY	MW	562.7
DMHLXUY	FM	C30H42N8O3
DMHLXUY	IC	InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1
DMHLXUY	CS	CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C
DMHLXUY	IK	QKDCLUARMDUUKN-XMMPIXPASA-N
DMHLXUY	IU	6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide
DMHLXUY	CA	CAS 1448232-80-1
DMHLXUY	DE	Non-small-cell lung cancer

DMBZQS7	ID	DMBZQS7
DMBZQS7	DN	ASP-8477
DMBZQS7	HS	Phase 2
DMBZQS7	CP	Astellas Pharma Inc
DMBZQS7	DE	Neuropathic pain

DM2MSGF	ID	DM2MSGF
DM2MSGF	DN	ASP9831
DM2MSGF	HS	Phase 2
DM2MSGF	CP	Astellas
DM2MSGF	DT	Small molecular drug
DM2MSGF	DE	Steatohepatitis; Non-alcoholic steatohepatitis

DMMKW8L	ID	DMMKW8L
DMMKW8L	DN	ASTX660
DMMKW8L	HS	Phase 2
DMMKW8L	SN	YCXOHEXZVKOGEV-DNRQZRRGSA-N; 1799328-86-1; SCHEMBL16830758; CS-8216; HY-109565; 1-(6-(4-fluorobenzyl)-5-(hydroxymethyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-((2R,5R)-5-methyl-2-(((R)-3-methylmorpholino)methyl)piperazin-1-yl)ethan-1-one
DMMKW8L	CP	Astex Pharmaceuticals Pleasanton, CA
DMMKW8L	PC	118169620
DMMKW8L	MW	539.7
DMMKW8L	FM	C30H42FN5O3
DMMKW8L	IC	InChI=1S/C30H42FN5O3/c1-20-14-35(25(13-32-20)15-34-9-10-39-18-21(34)2)16-28(38)36-19-30(3,4)29-27(36)12-23(26(17-37)33-29)11-22-5-7-24(31)8-6-22/h5-8,12,20-21,25,32,37H,9-11,13-19H2,1-4H3/t20-,21-,25-/m1/s1
DMMKW8L	CS	C[C@@H]1CN([C@H](CN1)CN2CCOC[C@H]2C)CC(=O)N3CC(C4=C3C=C(C(=N4)CO)CC5=CC=C(C=C5)F)(C)C
DMMKW8L	IK	YCXOHEXZVKOGEV-DNRQZRRGSA-N
DMMKW8L	IU	1-[6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-2H-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-[[(3R)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone
DMMKW8L	CA	CAS 1799328-86-1
DMMKW8L	DE	Solid tumour/cancer; Lymphoma

DMARIQK	ID	DMARIQK
DMARIQK	DN	AT-527
DMARIQK	HS	Phase 2
DMARIQK	SN	AT527; SCHEMBL18061556; GTPL11295; 2241337-84-6; propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMARIQK	CP	Atea Pharmaceuticals
DMARIQK	DT	Small molecular drug
DMARIQK	PC	122527270
DMARIQK	MW	581.5
DMARIQK	FM	C24H33FN7O7P
DMARIQK	IC	InChI=1S/C24H33FN7O7P/c1-13(2)37-21(34)14(3)31-40(35,39-15-9-7-6-8-10-15)36-11-16-18(33)24(4,25)22(38-16)32-12-28-17-19(27-5)29-23(26)30-20(17)32/h6-10,12-14,16,18,22,33H,11H2,1-5H3,(H,31,35)(H3,26,27,29,30)/t14-,16?,18+,22+,24+,40-/m0/s1
DMARIQK	CS	C[C@@H](C(=O)OC(C)C)N[P@](=O)(OCC1[C@H]([C@@]([C@@H](O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4
DMARIQK	IK	OISLSHLAXHALQZ-ZXWZJMKMSA-N
DMARIQK	IU	propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMARIQK	DE	Coronavirus Disease 2019 (COVID-19)

DM35KDA	ID	DM35KDA
DM35KDA	DN	Ataciguat
DM35KDA	HS	Phase 2
DM35KDA	SN	Ataciguat [INN]; HMR 1766; HMR-1766; 5-Chloro-2-((5-chloro-2-thienyl)sulfonylamino)-N-(4-(morpholin-4-ylsulfonyl)phenyl)benzamide; 5-Chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide; 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide
DM35KDA	CP	Sanofi-Aventis
DM35KDA	TC	Analgesics
DM35KDA	DT	Small molecular drug
DM35KDA	PC	213037
DM35KDA	MW	576.5
DM35KDA	FM	C21H19Cl2N3O6S3
DM35KDA	IC	InChI=1S/C21H19Cl2N3O6S3/c22-14-1-6-18(25-34(28,29)20-8-7-19(23)33-20)17(13-14)21(27)24-15-2-4-16(5-3-15)35(30,31)26-9-11-32-12-10-26/h1-8,13,25H,9-12H2,(H,24,27)
DM35KDA	CS	C1COCCN1S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3=C(C=CC(=C3)Cl)NS(=O)(=O)C4=CC=C(S4)Cl
DM35KDA	IK	PQHLRGARXNPFCF-UHFFFAOYSA-N
DM35KDA	IU	5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide
DM35KDA	CA	CAS 254877-67-3
DM35KDA	DE	Neuropathic pain

DM6ABD9	ID	DM6ABD9
DM6ABD9	DN	ATHX-105
DM6ABD9	HS	Phase 2
DM6ABD9	SN	ATH-88651; 5-HT2c receptor agonists (obesity), Athersys Inc
DM6ABD9	CP	Athersys
DM6ABD9	DE	Obesity

DMWP59B	ID	DMWP59B
DMWP59B	DN	ATI-2042
DMWP59B	HS	Phase 2
DMWP59B	SN	Budiodarone
DMWP59B	CP	ARYx Therapeutics
DMWP59B	DT	Small molecular drug
DMWP59B	PC	9833332
DMWP59B	MW	703.3
DMWP59B	FM	C27H31I2NO5
DMWP59B	IC	InChI=1S/C27H31I2NO5/c1-5-17(4)34-24(31)16-23-25(19-10-8-9-11-22(19)35-23)26(32)18-14-20(28)27(21(29)15-18)33-13-12-30(6-2)7-3/h8-11,14-15,17H,5-7,12-13,16H2,1-4H3/t17-/m0/s1
DMWP59B	CS	CC[C@H](C)OC(=O)CC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMWP59B	IK	ZXOSVKYCXLTVGS-KRWDZBQOSA-N
DMWP59B	IU	[(2S)-butan-2-yl] 2-[3-[4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl]-1-benzofuran-2-yl]acetate
DMWP59B	CA	CAS 335148-45-3
DMWP59B	DE	Atrial fibrillation

DMT5QYJ	ID	DMT5QYJ
DMT5QYJ	DN	ATI-2173
DMT5QYJ	HS	Phase 2
DMT5QYJ	CP	Antios Therapeutics
DMT5QYJ	DT	Small molecular drug
DMT5QYJ	DE	Hepatitis B

DMTY6OF	ID	DMTY6OF
DMTY6OF	DN	ATI-501
DMTY6OF	HS	Phase 2
DMTY6OF	CP	Aclaris Therapeutics
DMTY6OF	DT	Small molecular drug
DMTY6OF	DE	Alopecia

DM8NODR	ID	DM8NODR
DM8NODR	DN	ATI-502
DM8NODR	HS	Phase 2
DM8NODR	SN	ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one
DM8NODR	CP	Aclaris Therapeutics
DM8NODR	DT	Small molecular drug
DM8NODR	PC	46851625
DM8NODR	MW	395.4
DM8NODR	FM	C20H18FN5O3
DM8NODR	IC	InChI=1S/C20H18FN5O3/c1-10-6-13(8-16(28-3)17(10)21)24-19-22-9-11(2)18(26-19)23-12-4-5-15-14(7-12)25-20(27)29-15/h4-9H,1-3H3,(H,25,27)(H2,22,23,24,26)
DM8NODR	CS	CC1=CC(=CC(=C1F)OC)NC2=NC=C(C(=N2)NC3=CC4=C(C=C3)OC(=O)N4)C
DM8NODR	IK	OYFMQDVLFYKOPZ-UHFFFAOYSA-N
DM8NODR	IU	5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one
DM8NODR	CA	CAS 1236667-40-5
DM8NODR	DE	Atopic dermatitis; Alopecia

DMK3VYU	ID	DMK3VYU
DMK3VYU	DN	ATI-502
DMK3VYU	HS	Phase 2
DMK3VYU	CP	Aclaris Therapeutics Wayne, PA
DMK3VYU	DE	Atopic dermatitis; Vitiligo

DMYAQV2	ID	DMYAQV2
DMYAQV2	DN	ATL101
DMYAQV2	HS	Phase 2
DMYAQV2	CP	Atlab pharma; weill medical college
DMYAQV2	DE	Influenza virus infection

DMD0I29	ID	DMD0I29
DMD0I29	DN	ATL-104
DMD0I29	HS	Phase 2
DMD0I29	DE	Solid tumour/cancer

DM3POT6	ID	DM3POT6
DM3POT6	DN	ATL1102
DM3POT6	HS	Phase 2
DM3POT6	CP	ISIS Pharm; Antisense Therapeutics
DM3POT6	DE	Multiple sclerosis

DM7I56B	ID	DM7I56B
DM7I56B	DN	ATM AVI
DM7I56B	HS	Phase 2
DM7I56B	CP	AstraZeneca
DM7I56B	DE	Bacterial infection

DM4T9RS	ID	DM4T9RS
DM4T9RS	DN	ATN-161
DM4T9RS	HS	Phase 2
DM4T9RS	SN	PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan
DM4T9RS	CP	University of Michigan
DM4T9RS	DT	Small molecular drug
DM4T9RS	PC	9960285
DM4T9RS	MW	597.6
DM4T9RS	FM	C23H35N9O8S
DM4T9RS	IC	InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38)/t13-,14-,15-,16-,17-/m0/s1
DM4T9RS	CS	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N
DM4T9RS	IK	MMHDBUJXLOFTLC-WOYTXXSLSA-N
DM4T9RS	IU	(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]butanediamide
DM4T9RS	CA	CAS 262438-43-7
DM4T9RS	DE	Renal cell carcinoma

DMQJ5DV	ID	DMQJ5DV
DMQJ5DV	DN	ATN-224
DMQJ5DV	HS	Phase 2
DMQJ5DV	SN	Angiogenesis inhibitor, Attenuon; Superoxide dismutase 1 inhibitor, Attenuon
DMQJ5DV	CP	University of Michigan
DMQJ5DV	DT	Small molecular drug
DMQJ5DV	PC	18442052
DMQJ5DV	MW	434.6
DMQJ5DV	FM	C10H30MoN2O2S4
DMQJ5DV	IC	InChI=1S/2C5H14NO.Mo.2H2S.2S/c2*1-6(2,3)4-5-7;;;;;/h2*7H,4-5H2,1-3H3;;2*1H2;;/q2*+1;;;;;/p-2
DMQJ5DV	CS	C[N+](C)(C)CCO.C[N+](C)(C)CCO.[SH-].[SH-].S=[Mo]=S
DMQJ5DV	IK	FSWNJZRQQVVVJT-UHFFFAOYSA-L
DMQJ5DV	IU	bis(sulfanylidene)molybdenum;2-hydroxyethyl(trimethyl)azanium;sulfanide
DMQJ5DV	CA	CAS 649749-10-0
DMQJ5DV	DE	Solid tumour/cancer

DMUXO3Z	ID	DMUXO3Z
DMUXO3Z	DN	AUS-131
DMUXO3Z	HS	Phase 2
DMUXO3Z	SN	AUS-131; S-Equol; (-)-(S)-Equol; (-)-Equol; (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-7-ol; (3S)-3-(4-hydroxyphenyl)chroman-7-ol; (S)-(-)-4',7-Isoflavandiol; (S)-3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol; (S)-3-(4-Hydroxyphenyl)chroman-7-ol; (S)-Equol; 2H-1-Benzopyran-7-ol, 3,4-dihydro-3-(4-hydroxyphenyl)-, (3S)-; 2T6D2HPX7Q; 4',7-Dihydroxyisoflavan; 4',7-Isoflavandiol; 531-95-3; 7,4'-dihydroxyisoflavan; CCRIS 9222; CHEBI:34741; CHEMBL198877; EINECS 208-522-2; Equol; UNII-2T6D2HPX7Q
DMUXO3Z	PC	91469
DMUXO3Z	MW	242.27
DMUXO3Z	FM	C15H14O3
DMUXO3Z	IC	ADFCQWZHKCXPAJ-GFCCVEGCSA-N
DMUXO3Z	IU	(3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol
DMUXO3Z	DE	Prostatic hyperplasia

DMZMSQJ	ID	DMZMSQJ
DMZMSQJ	DN	AUS-131
DMZMSQJ	HS	Phase 2
DMZMSQJ	CP	Ausio Pharmaceuticals
DMZMSQJ	PC	91469
DMZMSQJ	MW	242.27
DMZMSQJ	FM	C15H14O3
DMZMSQJ	IC	InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1
DMZMSQJ	CS	C1[C@H](COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O
DMZMSQJ	IK	ADFCQWZHKCXPAJ-GFCCVEGCSA-N
DMZMSQJ	IU	(3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol
DMZMSQJ	CA	CAS 531-95-3
DMZMSQJ	CB	CHEBI:34741
DMZMSQJ	DE	Hot flushes; Alzheimer disease

DMN7VK1	ID	DMN7VK1
DMN7VK1	DN	AV-101
DMN7VK1	HS	Phase 2
DMN7VK1	SN	Anti-epileptic, VistaGen; L-4-chlorokynurenine; NMDA receptor antagonists, University of Maryland/VistaGen; 4-Cl-kynurenine, NIH/VistaGen; 7-Chlorokynurenic acid; 7-Cl-KYN; 7-Cl-KYNA, NIH
DMN7VK1	CP	Vistagen therapeutics
DMN7VK1	PC	9859632
DMN7VK1	MW	242.66
DMN7VK1	FM	C10H11ClN2O3
DMN7VK1	IC	InChI=1S/C10H11ClN2O3/c11-5-1-2-6(7(12)3-5)9(14)4-8(13)10(15)16/h1-3,8H,4,12-13H2,(H,15,16)/t8-/m0/s1
DMN7VK1	CS	C1=CC(=C(C=C1Cl)N)C(=O)C[C@@H](C(=O)O)N
DMN7VK1	IK	HQLHZNDJQSRKDT-QMMMGPOBSA-N
DMN7VK1	IU	(2S)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid
DMN7VK1	CA	CAS 153152-32-0
DMN7VK1	DE	Neuropathic pain; Major depressive disorder

DMDL9WU	ID	DMDL9WU
DMDL9WU	DN	AV-201
DMDL9WU	HS	Phase 2
DMDL9WU	SN	AAV (amino acid decarboxylase), Avigen; AAV (tyrosine hydroxylase), Avigen; AAV gene therapy (Parkinsons), Avigen; AAV vector (AADC), Avigen; AAV vector (TH), Avigen; AAV-hAADC-2; Gene therapy (PD), Avigen; Gene therapy (Parkinsons disease), Avigen; Gene therapy (L-aromatic amino acid decarboxylase), Avigen
DMDL9WU	CP	Avigen Inc
DMDL9WU	DE	Parkinson disease

DMASRP3	ID	DMASRP3
DMASRP3	DN	AVA-101
DMASRP3	HS	Phase 2
DMASRP3	CP	Avalanche biotechnologies
DMASRP3	DE	Age-related macular degeneration

DMORJD4	ID	DMORJD4
DMORJD4	DN	AVB-500
DMORJD4	HS	Phase 2
DMORJD4	CP	Aravive
DMORJD4	DT	Protein
DMORJD4	DE	IgA nephropathy

DMLAOHX	ID	DMLAOHX
DMLAOHX	DN	Avdoralimab
DMLAOHX	HS	Phase 2 
DMLAOHX	SN	IPH5401
DMLAOHX	TC	Antiviral Agents
DMLAOHX	DT	Monoclonal antibody
DMLAOHX	DE	Coronavirus Disease 2019 (COVID-19)

DMESMHU	ID	DMESMHU
DMESMHU	DN	AVE-0657
DMESMHU	HS	Phase 2
DMESMHU	SN	IDDBCP219683
DMESMHU	CP	Sanofi
DMESMHU	DE	Cheyne-stokes respiration

DMA42BV	ID	DMA42BV
DMA42BV	DN	AVE-2268
DMA42BV	HS	Phase 2
DMA42BV	CP	Aventis SA
DMA42BV	DE	Diabetic complication

DMQGI73	ID	DMQGI73
DMQGI73	DN	AVI-4557
DMQGI73	HS	Phase 2
DMQGI73	CP	AVI BioPharma
DMQGI73	DT	Antisense drug
DMQGI73	DE	Anxiety disorder

DMUOYQR	ID	DMUOYQR
DMUOYQR	DN	AVI-5126
DMUOYQR	HS	Phase 2
DMUOYQR	SN	Resten-CP; NeuGene (CABG), AVI
DMUOYQR	CP	AVI BioPharma
DMUOYQR	DT	Antisense drug
DMUOYQR	DE	Coronary artery disease

DMJFLBC	ID	DMJFLBC
DMJFLBC	DN	AVN 101
DMJFLBC	HS	Phase 2
DMJFLBC	CP	Avineuro Pharmaceuticals
DMJFLBC	DE	Anxiety disorder; Alzheimer disease; Cognitive impairment

DMK2LGM	ID	DMK2LGM
DMK2LGM	DN	AVN 322
DMK2LGM	HS	Phase 2
DMK2LGM	CP	Avineuro Pharmaceuticals
DMK2LGM	DE	Alzheimer disease; Cognitive impairment

DMOGFNI	ID	DMOGFNI
DMOGFNI	DN	AVN-101
DMOGFNI	HS	Phase 2
DMOGFNI	SN	1061354-48-0; UNII-XML910S5X8; XML910S5X8; 2,8-Dimethyl-5-phenethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride; AVN-101 hydrochloride; AVN-101 HCl; SB18759; 1H-Pyrido(4,3-b)indole, 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-phenylethyl)-, hydrochloride (1:1)
DMOGFNI	CP	Avineuro
DMOGFNI	DT	Small molecular drug
DMOGFNI	PC	126843189
DMOGFNI	MW	340.9
DMOGFNI	FM	C21H25ClN2
DMOGFNI	IC	InChI=1S/C21H24N2.ClH/c1-16-8-9-20-18(14-16)19-15-22(2)12-11-21(19)23(20)13-10-17-6-4-3-5-7-17;/h3-9,14H,10-13,15H2,1-2H3;1H
DMOGFNI	CS	CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=C4.Cl
DMOGFNI	IK	RKLJJDFIWWRTEJ-UHFFFAOYSA-N
DMOGFNI	IU	2,8-dimethyl-5-(2-phenylethyl)-3,4-dihydro-1H-pyrido[4,3-b]indole;hydrochloride
DMOGFNI	CA	CAS 1061354-48-0
DMOGFNI	DE	Cognitive impairment

DMVADGZ	ID	DMVADGZ
DMVADGZ	DN	AWD-12-281
DMVADGZ	HS	Phase 2
DMVADGZ	SN	GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline; 842470
DMVADGZ	CP	ASTA Medica AG
DMVADGZ	DT	Small molecular drug
DMVADGZ	PC	6918428
DMVADGZ	MW	458.3
DMVADGZ	FM	C22H14Cl2FN3O3
DMVADGZ	IC	InChI=1S/C22H14Cl2FN3O3/c23-17-8-26-9-18(24)20(17)27-22(31)21(30)16-11-28(10-12-1-3-13(25)4-2-12)19-6-5-14(29)7-15(16)19/h1-9,11,29H,10H2,(H,26,27,31)
DMVADGZ	CS	C1=CC(=CC=C1CN2C=C(C3=C2C=CC(=C3)O)C(=O)C(=O)NC4=C(C=NC=C4Cl)Cl)F
DMVADGZ	IK	DPHDSIQHVGSITN-UHFFFAOYSA-N
DMVADGZ	IU	N-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide
DMVADGZ	CA	CAS 257892-33-4
DMVADGZ	DE	Rhinitis

DMTAEMB	ID	DMTAEMB
DMTAEMB	DN	AX-200
DMTAEMB	HS	Phase 2
DMTAEMB	SN	Filgrastim (stroke, ALS), Sygnis; Granulocyte colony stimulating factor (stroke, ALS), Sygnis; Granulocyte colony stimulating factor (intravenous, peripheral arterial occlusive disease/spinal cord injury/stroke/Parkinsons disease), Axaron; G-CSF (protein recombinant/iv, stroke/ALS/PAO/PD/SCI), Sygnis
DMTAEMB	CP	SYGNIS Bioscience GmbH & Co KG
DMTAEMB	DE	Cardiovascular disease

DMTQ1Y3	ID	DMTQ1Y3
DMTQ1Y3	DN	AXL-1717
DMTQ1Y3	HS	Phase 2
DMTQ1Y3	SN	BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum
DMTQ1Y3	CP	Axelar AB
DMTQ1Y3	DT	Small molecular drug
DMTQ1Y3	PC	72435
DMTQ1Y3	MW	414.4
DMTQ1Y3	FM	C22H22O8
DMTQ1Y3	IC	InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19+,20-/m0/s1
DMTQ1Y3	CS	COC1=CC(=CC(=C1OC)OC)[C@H]2[C@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O
DMTQ1Y3	IK	YJGVMLPVUAXIQN-HAEOHBJNSA-N
DMTQ1Y3	IU	(5R,5aR,8aS,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMTQ1Y3	CA	CAS 477-47-4
DMTQ1Y3	CB	CHEBI:75251
DMTQ1Y3	DE	Solid tumour/cancer

DM4CJNE	ID	DM4CJNE
DM4CJNE	DN	AYX-1
DM4CJNE	HS	Phase 2
DM4CJNE	DE	Pain

DMHFUJT	ID	DMHFUJT
DMHFUJT	DN	AZ-01, PEGylated interferon-beta
DMHFUJT	HS	Phase 2
DMHFUJT	SN	PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne; AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis); AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne
DMHFUJT	CP	Allozyne Inc
DMHFUJT	DE	Multiple sclerosis

DM9LKYP	ID	DM9LKYP
DM9LKYP	DN	AZ-40140
DM9LKYP	HS	Phase 2
DM9LKYP	CP	Asahi Kasei
DM9LKYP	DE	Type-2 diabetes; Obesity

DMM0N1F	ID	DMM0N1F
DMM0N1F	DN	AZD-0865
DMM0N1F	HS	Phase 2
DMM0N1F	SN	AR-H044277
DMM0N1F	CP	AstraZeneca plc
DMM0N1F	DT	Small molecular drug
DMM0N1F	PC	9951066
DMM0N1F	MW	366.5
DMM0N1F	FM	C21H26N4O2
DMM0N1F	IC	InChI=1S/C21H26N4O2/c1-13-6-5-7-14(2)18(13)11-23-19-10-17(21(27)22-8-9-26)12-25-16(4)15(3)24-20(19)25/h5-7,10,12,23,26H,8-9,11H2,1-4H3,(H,22,27)
DMM0N1F	CS	CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO
DMM0N1F	IK	GHVIMBCFLRTFHI-UHFFFAOYSA-N
DMM0N1F	IU	8-[(2,6-dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide
DMM0N1F	CA	CAS 248919-64-4
DMM0N1F	DE	Gastrointestinal disease

DM7B1AR	ID	DM7B1AR
DM7B1AR	DN	AZD-1446
DM7B1AR	HS	Phase 2
DM7B1AR	SN	TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca
DM7B1AR	CP	Targacept Inc
DM7B1AR	DT	Small molecular drug
DM7B1AR	PC	96568204
DM7B1AR	MW	240.68
DM7B1AR	FM	C11H13ClN2O2
DM7B1AR	IC	InChI=1S/C11H13ClN2O2/c12-10-2-1-9(16-10)11(15)14-5-7-3-13-4-8(7)6-14/h1-2,7-8,13H,3-6H2/t7-,8+
DM7B1AR	CS	C1[C@@H]2CN(C[C@@H]2CN1)C(=O)C3=CC=C(O3)Cl
DM7B1AR	IK	GTUIQNHJSXQMKW-OCAPTIKFSA-N
DM7B1AR	IU	[(3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl]-(5-chlorofuran-2-yl)methanone
DM7B1AR	CA	CAS 1025007-04-8
DM7B1AR	DE	Alzheimer disease

DMLK59M	ID	DMLK59M
DMLK59M	DN	AZD1480
DMLK59M	HS	Phase 2
DMLK59M	SN	RET inhibitors
DMLK59M	CP	AstraZeneca
DMLK59M	DT	Small molecular drug
DMLK59M	PC	16659841
DMLK59M	MW	348.76
DMLK59M	FM	C14H14ClFN8
DMLK59M	IC	InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1
DMLK59M	CS	CC1=CC(=NN1)NC2=NC(=NC=C2Cl)N[C@@H](C)C3=NC=C(C=N3)F
DMLK59M	IK	PDOQBOJDRPLBQU-QMMMGPOBSA-N
DMLK59M	IU	5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
DMLK59M	CA	CAS 935666-88-9
DMLK59M	DE	Myeloproliferative syndrome

DMUE90I	ID	DMUE90I
DMUE90I	DN	AZD1656
DMUE90I	HS	Phase 2
DMUE90I	SN	AZD1656; AZD-1656; FJEJHJINOKKDCW-INIZCTEOSA-N; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide; SCHEMBL321593; GTPL7701; UNII-660M185X4D; CHEMBL3219124; AZD 1656; 660M185X4D; 89961-EP2305674A1; 89961-EP2301929A1; 89961-EP2301935A1; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1S)-2-methoxy-1-methylethoxy]-N-(5-methylpyrazin-2-yl)benzamide
DMUE90I	CP	AstraZeneca
DMUE90I	DT	Small molecular drug
DMUE90I	PC	16039797
DMUE90I	MW	478.5
DMUE90I	FM	C24H26N6O5
DMUE90I	IC	InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1
DMUE90I	CS	CC1=CN=C(C=N1)NC(=O)C2=CC(=CC(=C2)O[C@@H](C)COC)OC3=NC=C(N=C3)C(=O)N4CCC4
DMUE90I	IK	FJEJHJINOKKDCW-INIZCTEOSA-N
DMUE90I	IU	3-[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy-5-[(2S)-1-methoxypropan-2-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide
DMUE90I	CA	CAS 919783-22-5
DMUE90I	DE	Diabetic complication

DMX5SG7	ID	DMX5SG7
DMX5SG7	DN	AZD1772//RDX5791
DMX5SG7	HS	Phase 2
DMX5SG7	CP	Ardelyx; astrazeneca
DMX5SG7	DE	Chronic kidney disease

DMMCL9F	ID	DMMCL9F
DMMCL9F	DN	AZD1981
DMMCL9F	HS	Phase 2
DMMCL9F	SN	AZD1981; 802904-66-1; AZD-1981; UNII-2AD53WQ2CX; AZD 1981; 2AD53WQ2CX; CHEMBL1914489; 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-((4-chlorophenyl)thio)-2-methyl-; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-; JWYIGNODXSRKGP-UHFFFAOYSA-N; GTPL7680; SCHEMBL1053662; EX-A662; MolPort-035-395-811; HMS3653A06; BCP20957; ZINC73196066; s7263; BDBM50357102; AKOS027263775; SB16902; DB11946; CS-4189; NCGC00386290-04; HY-15950; SC-94603
DMMCL9F	DT	Small molecular drug
DMMCL9F	PC	11292191
DMMCL9F	MW	388.9
DMMCL9F	FM	C19H17ClN2O3S
DMMCL9F	IC	InChI=1S/C19H17ClN2O3S/c1-11-19(26-14-8-6-13(20)7-9-14)18-15(21-12(2)23)4-3-5-16(18)22(11)10-17(24)25/h3-9H,10H2,1-2H3,(H,21,23)(H,24,25)
DMMCL9F	CS	CC1=C(C2=C(C=CC=C2N1CC(=O)O)NC(=O)C)SC3=CC=C(C=C3)Cl
DMMCL9F	IK	JWYIGNODXSRKGP-UHFFFAOYSA-N
DMMCL9F	IU	2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid
DMMCL9F	CA	CAS 802904-66-1
DMMCL9F	DE	Chronic obstructive pulmonary disease

DMOEARH	ID	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	HS	Phase 2
DMOEARH	SN	AZD2014; 1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)
DMOEARH	CP	AstraZeneca
DMOEARH	DT	Small molecular drug
DMOEARH	PC	25262792
DMOEARH	MW	462.5
DMOEARH	FM	C25H30N6O3
DMOEARH	IC	InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1
DMOEARH	CS	C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOC[C@@H]5C
DMOEARH	IK	JUSFANSTBFGBAF-IRXDYDNUSA-N
DMOEARH	IU	3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide
DMOEARH	CA	CAS 1009298-59-2
DMOEARH	DE	Solid tumour/cancer

DMGQSVX	ID	DMGQSVX
DMGQSVX	DN	AZD-2115
DMGQSVX	HS	Phase 2
DMGQSVX	SN	Dual action MABA (COPD), AstraZeneca; Dual action muscarinic acetylcholine receptor antagonist/beta 2 adrenoceptor agonist (COPD), AstraZeneca
DMGQSVX	CP	AstraZeneca
DMGQSVX	DE	Chronic obstructive pulmonary disease

DM8FZOG	ID	DM8FZOG
DM8FZOG	DN	AZD-2327
DM8FZOG	HS	Phase 2
DM8FZOG	SN	Opioid receptor delta agonist (anxiety, depression), AstraZeneca
DM8FZOG	CP	AstraZeneca plc
DM8FZOG	DT	Small molecular drug
DM8FZOG	PC	11525765
DM8FZOG	MW	474.6
DM8FZOG	FM	C29H35FN4O
DM8FZOG	IC	InChI=1S/C29H35FN4O/c1-3-33(4-2)29(35)24-12-10-23(11-13-24)28(25-6-5-7-27(31)20-25)34-18-16-32(17-19-34)21-22-8-14-26(30)15-9-22/h5-15,20,28H,3-4,16-19,21,31H2,1-2H3/t28-/m1/s1
DM8FZOG	CS	CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)N)N3CCN(CC3)CC4=CC=C(C=C4)F
DM8FZOG	IK	XGFLMBBZEPJGHY-MUUNZHRXSA-N
DM8FZOG	IU	4-[(R)-(3-aminophenyl)-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]methyl]-N,N-diethylbenzamide
DM8FZOG	CA	CAS 875647-81-7
DM8FZOG	DE	Anxiety disorder

DMF34UY	ID	DMF34UY
DMF34UY	DN	AZD-2423
DMF34UY	HS	Phase 2
DMF34UY	SN	CCR2b antagonist (pain, COPD), AstraZeneca
DMF34UY	CP	AstraZeneca plc
DMF34UY	DT	Small molecular drug
DMF34UY	PC	46213922
DMF34UY	MW	425.9
DMF34UY	FM	C20H29ClFN5O2
DMF34UY	IC	InChI=1S/C20H29ClFN5O2/c1-20(2,3)27-7-6-23-17(13-27)18(28)25-8-10-26(11-9-25)19(29)24-14-4-5-15(21)16(22)12-14/h4-5,12,17,23H,6-11,13H2,1-3H3,(H,24,29)/t17-/m1/s1
DMF34UY	CS	CC(C)(C)N1CCN[C@H](C1)C(=O)N2CCN(CC2)C(=O)NC3=CC(=C(C=C3)Cl)F
DMF34UY	IK	SRWQVWAIVQXPJY-QGZVFWFLSA-N
DMF34UY	IU	4-[(2R)-4-tert-butylpiperazine-2-carbonyl]-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide
DMF34UY	CA	CAS 1229603-37-5
DMF34UY	DE	Chronic obstructive pulmonary disease

DMZLGQV	ID	DMZLGQV
DMZLGQV	DN	AZD2624
DMZLGQV	HS	Phase 2
DMZLGQV	SN	Pavinetant; AZD-2624; MLE4901; 941690-55-7; UNII-3U471ZVC5K; 3U471ZVC5K; AZ124752520; pavinetantum; Pavinetant [USAN]; SCHEMBL3587478; GTPL5775; CHEMBL3545233; CHEBI:140478; QYTBBBAHNIWFOD-NRFANRHFSA-N; BDBM50180193; AKOS032946112; DB11692; CS-7979; 4-Quinolinecarboxamide, 3-((methylsulfonyl)amino)-2-phenyl-N-((1S)-1-phenylpropyl)-; HY-14432; KB-74807; 3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; 3-[(methanesulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DMZLGQV	CP	AstraZeneca
DMZLGQV	DT	Small molecular drug
DMZLGQV	PC	23649245
DMZLGQV	MW	459.6
DMZLGQV	FM	C26H25N3O3S
DMZLGQV	IC	InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1
DMZLGQV	CS	CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)NS(=O)(=O)C
DMZLGQV	IK	QYTBBBAHNIWFOD-NRFANRHFSA-N
DMZLGQV	IU	3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DMZLGQV	CA	CAS 941690-55-7
DMZLGQV	CB	CHEBI:140478
DMZLGQV	DE	Schizophrenia; Multiple sclerosis; .

DMYUNXP	ID	DMYUNXP
DMYUNXP	DN	AZD2811
DMYUNXP	HS	Phase 2
DMYUNXP	CP	AstraZeneca
DMYUNXP	DT	Small molecular drug
DMYUNXP	DE	Small-cell lung cancer

DM6AI9N	ID	DM6AI9N
DM6AI9N	DN	AZD-2927
DM6AI9N	HS	Phase 2
DM6AI9N	SN	AZD2927
DM6AI9N	CP	AstraZenec, UK
DM6AI9N	DT	Small molecular drug
DM6AI9N	PC	57345449
DM6AI9N	MW	308.4
DM6AI9N	FM	C17H25FN2O2
DM6AI9N	IC	InChI=1S/C17H25FN2O2/c1-11(2)16(10-20-8-14(21)9-20)19(4)17(22)13-5-6-15(18)12(3)7-13/h5-7,11,14,16,21H,8-10H2,1-4H3/t16-/m1/s1
DM6AI9N	CS	CC1=C(C=CC(=C1)C(=O)N(C)[C@H](CN2CC(C2)O)C(C)C)F
DM6AI9N	IK	GAHPWXLXWUVMIV-MRXNPFEDSA-N
DM6AI9N	IU	4-fluoro-N-[(2S)-1-(3-hydroxyazetidin-1-yl)-3-methylbutan-2-yl]-N,3-dimethylbenzamide
DM6AI9N	DE	Atrial fibrillation

DME8Z5M	ID	DME8Z5M
DME8Z5M	DN	AZD-3199
DME8Z5M	HS	Phase 2
DME8Z5M	PC	16035068
DME8Z5M	MW	578.8
DME8Z5M	FM	C32H42N4O4S
DME8Z5M	IC	InChI=1S/C32H42N4O4S/c1-3-35(4-2)20-21-36(19-18-33-17-14-26-12-13-28(37)30-31(26)41-32(39)34-30)29(38)16-23-40-22-15-25-10-7-9-24-8-5-6-11-27(24)25/h5-13,33,37H,3-4,14-23H2,1-2H3,(H,34,39)
DME8Z5M	CS	CCN(CC)CCN(CCNCCC1=C2C(=C(C=C1)O)NC(=O)S2)C(=O)CCOCCC3=CC=CC4=CC=CC=C43
DME8Z5M	IK	ZVULMJYRVAVKCP-UHFFFAOYSA-N
DME8Z5M	IU	N-[2-(diethylamino)ethyl]-N-[2-[2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethylamino]ethyl]-3-(2-naphthalen-1-ylethoxy)propanamide
DME8Z5M	CA	CAS 925243-19-2
DME8Z5M	DE	Asthma

DMANC59	ID	DMANC59
DMANC59	DN	AZD-3241
DMANC59	HS	Phase 2
DMANC59	SN	Parkinson's disease therapeutic, AstraZeneca
DMANC59	CP	AstraZeneca plc
DMANC59	PC	11528958
DMANC59	MW	253.32
DMANC59	FM	C11H15N3O2S
DMANC59	IC	InChI=1S/C11H15N3O2S/c1-7(2)16-6-5-14-8-3-4-12-9(8)10(15)13-11(14)17/h3-4,7,12H,5-6H2,1-2H3,(H,13,15,17)
DMANC59	CS	CC(C)OCCN1C2=C(C(=O)NC1=S)NC=C2
DMANC59	IK	FVJCUZCRPIMVLB-UHFFFAOYSA-N
DMANC59	IU	1-(2-propan-2-yloxyethyl)-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one
DMANC59	CA	CAS 890655-80-8
DMANC59	DE	Parkinson disease

DML9M5S	ID	DML9M5S
DML9M5S	DN	AZD-4017
DML9M5S	HS	Phase 2
DML9M5S	SN	AZD-4017 (oral tablet, ocular hypertension)
DML9M5S	CP	AstraZeneca plc
DML9M5S	DT	Small molecular drug
DML9M5S	PC	24946280
DML9M5S	MW	419.6
DML9M5S	FM	C22H33N3O3S
DML9M5S	IC	InChI=1S/C22H33N3O3S/c1-2-13-29-22-18(21(28)23-17-8-4-3-5-9-17)10-11-19(24-22)25-12-6-7-16(15-25)14-20(26)27/h10-11,16-17H,2-9,12-15H2,1H3,(H,23,28)(H,26,27)/t16-/m0/s1
DML9M5S	CS	CCCSC1=C(C=CC(=N1)N2CCC[C@H](C2)CC(=O)O)C(=O)NC3CCCCC3
DML9M5S	IK	NCDZABJPWMBMIQ-INIZCTEOSA-N
DML9M5S	IU	2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid
DML9M5S	CA	CAS 1024033-43-9
DML9M5S	DE	Ocular hypertension

DM8SVIY	ID	DM8SVIY
DM8SVIY	DN	AZD4635
DM8SVIY	HS	Phase 2
DM8SVIY	SN	NCWQLHHDGDXIJN-UHFFFAOYSA-N; AZD-4635; 1321514-06-0; 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; SCHEMBL2320714; EX-A1681; AC-30333; HY-101980; CS-0022379; 5-(4-fluorophenyl)-6-(2-chloro-6-methyl-pyridin-4-yl)-1,2,4-triazin-3-amine
DM8SVIY	CP	AstraZeneca Wilmington, DE
DM8SVIY	PC	86676119
DM8SVIY	MW	315.73
DM8SVIY	FM	C15H11ClFN5
DM8SVIY	IC	InChI=1S/C15H11ClFN5/c1-8-6-10(7-12(16)19-8)14-13(20-15(18)22-21-14)9-2-4-11(17)5-3-9/h2-7H,1H3,(H2,18,20,22)
DM8SVIY	CS	CC1=CC(=CC(=N1)Cl)C2=C(N=C(N=N2)N)C3=CC=C(C=C3)F
DM8SVIY	IK	NCWQLHHDGDXIJN-UHFFFAOYSA-N
DM8SVIY	IU	6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine
DM8SVIY	CA	CAS 1321514-06-0
DM8SVIY	DE	Solid tumour/cancer; Prostate cancer

DMFVL5J	ID	DMFVL5J
DMFVL5J	DN	AZD-4877
DMFVL5J	HS	Phase 2
DMFVL5J	SN	Anticancer therapeutic (solid tumors), AstraZeneca
DMFVL5J	CP	AstraZeneca plc
DMFVL5J	DT	Small molecular drug
DMFVL5J	PC	10368812
DMFVL5J	MW	503.7
DMFVL5J	FM	C28H33N5O2S
DMFVL5J	IC	InChI=1S/C28H33N5O2S/c1-18(2)24(32(16-8-15-29)27(34)22-13-11-19(3)12-14-22)25-30-26-23(20(4)31-36-26)28(35)33(25)17-21-9-6-5-7-10-21/h5-7,9-14,18,24H,8,15-17,29H2,1-4H3
DMFVL5J	CS	CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=NC3=C(C(=NS3)C)C(=O)N2CC4=CC=CC=C4)C(C)C
DMFVL5J	IK	SMFXSYMLJDHGIE-UHFFFAOYSA-N
DMFVL5J	IU	N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide
DMFVL5J	CA	CAS 1176760-49-8
DMFVL5J	DE	Acute myeloid leukaemia

DM3JSFK	ID	DM3JSFK
DM3JSFK	DN	AZD-5069
DM3JSFK	HS	Phase 2
DM3JSFK	SN	CXCR2 inhibitor (COPD), Astrazeneca
DM3JSFK	CP	AstraZeneca plc
DM3JSFK	PC	56645576
DM3JSFK	MW	476.5
DM3JSFK	FM	C18H22F2N4O5S2
DM3JSFK	IC	InChI=1S/C18H22F2N4O5S2/c1-11(14(26)9-25)29-16-8-15(23-31(27,28)24-6-3-7-24)21-18(22-16)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,25-26H,3,6-7,9-10H2,1H3,(H,21,22,23)/t11-,14+/m1/s1
DM3JSFK	CS	C[C@H]([C@H](CO)O)OC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F
DM3JSFK	IK	QZECRCLSIGFCIO-RISCZKNCSA-N
DM3JSFK	IU	N-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[(2R,3S)-3,4-dihydroxybutan-2-yl]oxypyrimidin-4-yl]azetidine-1-sulfonamide
DM3JSFK	CA	CAS 878385-84-3
DM3JSFK	DE	Asthma

DMOZ04X	ID	DMOZ04X
DMOZ04X	DN	AZD-5213
DMOZ04X	HS	Phase 2
DMOZ04X	CP	AstraZeneca plc
DMOZ04X	PC	53342708
DMOZ04X	MW	327.4
DMOZ04X	FM	C19H25N3O2
DMOZ04X	IC	InChI=1S/C19H25N3O2/c20-18(23)14-6-4-13(5-7-14)16-12-17(16)19(24)22-10-8-21(9-11-22)15-2-1-3-15/h4-7,15-17H,1-3,8-12H2,(H2,20,23)/t16-,17+/m1/s1
DMOZ04X	CS	C1CC(C1)N2CCN(CC2)C(=O)[C@H]3C[C@@H]3C4=CC=C(C=C4)C(=O)N
DMOZ04X	IK	VCQZCDSEWSFTPO-SJORKVTESA-N
DMOZ04X	IU	4-[(1S,2S)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]benzamide
DMOZ04X	CA	CAS 1119807-02-1
DMOZ04X	DE	Alzheimer disease

DMJ8V3K	ID	DMJ8V3K
DMJ8V3K	DN	AZD5312
DMJ8V3K	HS	Phase 2
DMJ8V3K	CP	Astrazeneca; isis pharmaceuticals
DMJ8V3K	DE	Prostate cancer

DM0PFNC	ID	DM0PFNC
DM0PFNC	DN	AZD6738
DM0PFNC	HS	Phase 2
DM0PFNC	CP	Astrazeneca; eagle pharmaceuticals
DM0PFNC	DT	Small molecular drug
DM0PFNC	PC	54761306
DM0PFNC	MW	412.5
DM0PFNC	FM	C20H24N6O2S
DM0PFNC	IC	InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1
DM0PFNC	CS	C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@](=N)(=O)C)C4=C5C=CNC5=NC=C4
DM0PFNC	IK	OHUHVTCQTUDPIJ-JYCIKRDWSA-N
DM0PFNC	IU	imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane
DM0PFNC	DE	Chronic lymphocytic leukaemia; Solid tumour/cancer; Small-cell lung cancer

DMIBXK0	ID	DMIBXK0
DMIBXK0	DN	AZD-7009
DMIBXK0	HS	Phase 2
DMIBXK0	SN	AR-H065522XX; AZD-7009 (iv formulation, atrial fibrillation conversion)
DMIBXK0	CP	AstraZeneca plc
DMIBXK0	DT	Small molecular drug
DMIBXK0	PC	72440971
DMIBXK0	MW	496.9
DMIBXK0	FM	C22H23ClF2N4O5
DMIBXK0	IC	InChI=1S/C22H23ClF2N4O5/c1-33-28-19(26)13-4-2-12(3-5-13)11-27-20(31)17-6-7-29(17)21(32)18(30)14-8-15(23)10-16(9-14)34-22(24)25/h2-5,8-10,17-18,22,30H,6-7,11H2,1H3,(H2,26,28)(H,27,31)
DMIBXK0	CS	CON=C(C1=CC=C(C=C1)CNC(=O)C2CCN2C(=O)C(C3=CC(=CC(=C3)Cl)OC(F)F)O)N
DMIBXK0	IK	XSNMGLZVFNDDPW-UHFFFAOYSA-N
DMIBXK0	IU	1-[2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-(N'-methoxycarbamimidoyl)phenyl]methyl]azetidine-2-carboxamide
DMIBXK0	DE	Atrial fibrillation

DMC48SP	ID	DMC48SP
DMC48SP	DN	AZD-7268
DMC48SP	HS	Phase 2
DMC48SP	SN	Enkephalinergic receptor modulator (oral, depression, anxiety), AstraZeneca
DMC48SP	CP	AstraZeneca plc
DMC48SP	DT	Small molecular drug
DMC48SP	PC	24772484
DMC48SP	MW	498.6
DMC48SP	FM	C29H30N4O2S
DMC48SP	IC	InChI=1S/C29H30N4O2S/c1-32(16-17-34)29(35)24-9-7-21(8-10-24)27(26-6-2-4-23-5-3-13-30-28(23)26)22-11-14-33(15-12-22)18-25-19-36-20-31-25/h2-10,13,19-20,34H,11-12,14-18H2,1H3
DMC48SP	CS	CN(CCO)C(=O)C1=CC=C(C=C1)C(=C2CCN(CC2)CC3=CSC=N3)C4=CC=CC5=C4N=CC=C5
DMC48SP	IK	ZJKUETLEJYCOBO-UHFFFAOYSA-N
DMC48SP	IU	N-(2-hydroxyethyl)-N-methyl-4-[quinolin-8-yl-[1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl]benzamide
DMC48SP	CA	CAS 1018988-00-5
DMC48SP	DE	Anxiety disorder

DMXF26Y	ID	DMXF26Y
DMXF26Y	DN	AZD7325
DMXF26Y	HS	Phase 2
DMXF26Y	SN	AZD-7325; UNII-KNM216XOUH; KNM216XOUH; CHEMBL1783282; 942437-37-8; AZD7325; KYDURMHFWXCKMW-UHFFFAOYSA-N; SCHEMBL1962584; GTPL7712; AZD 7325; BDBM50418481; SB17497; 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide; 4-Amino-8-(2-fluoro-6-methoxy-phenyl)-N-propylcinnoline-3-carboxamide
DMXF26Y	CP	AstraZeneca
DMXF26Y	DT	Small molecular drug
DMXF26Y	PC	23581869
DMXF26Y	MW	354.4
DMXF26Y	FM	C19H19FN4O2
DMXF26Y	IC	InChI=1S/C19H19FN4O2/c1-3-10-22-19(25)18-16(21)12-7-4-6-11(17(12)23-24-18)15-13(20)8-5-9-14(15)26-2/h4-9H,3,10H2,1-2H3,(H2,21,23)(H,22,25)
DMXF26Y	CS	CCCNC(=O)C1=NN=C2C(=C1N)C=CC=C2C3=C(C=CC=C3F)OC
DMXF26Y	IK	KYDURMHFWXCKMW-UHFFFAOYSA-N
DMXF26Y	IU	4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide
DMXF26Y	CA	CAS 942437-37-8
DMXF26Y	DE	Anxiety disorder

DMEW3K9	ID	DMEW3K9
DMEW3K9	DN	AZD7624
DMEW3K9	HS	Phase 2
DMEW3K9	CP	Astrazeneca
DMEW3K9	PC	25143624
DMEW3K9	MW	491.6
DMEW3K9	FM	C27H30FN5O3
DMEW3K9	IC	InChI=1S/C27H30FN5O3/c1-17-21(28)15-18(25(34)31-19-7-8-19)16-22(17)33-13-11-30-24(26(33)35)32-27(9-10-27)20-5-3-4-6-23(20)36-14-12-29-2/h3-6,11,13,15-16,19,29H,7-10,12,14H2,1-2H3,(H,30,32)(H,31,34)
DMEW3K9	CS	CC1=C(C=C(C=C1F)C(=O)NC2CC2)N3C=CN=C(C3=O)NC4(CC4)C5=CC=CC=C5OCCNC
DMEW3K9	IK	NNKPHNTWNILINE-UHFFFAOYSA-N
DMEW3K9	IU	N-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide
DMEW3K9	CA	CAS 1095004-78-6
DMEW3K9	DE	Chronic obstructive pulmonary disease

DMLXFM6	ID	DMLXFM6
DMLXFM6	DN	AZD-8683
DMLXFM6	HS	Phase 2
DMLXFM6	CP	AstraZeneca plc
DMLXFM6	DE	Chronic obstructive pulmonary disease

DM0M7QW	ID	DM0M7QW
DM0M7QW	DN	AZD-8848
DM0M7QW	HS	Phase 2
DM0M7QW	SN	AZ-12441970; DSP-3025; SM-324405; TLR7 agonist (allergy), Dainippon/AstraZeneca
DM0M7QW	CP	Dainippon Sumitomo Pharma Co Ltd
DM0M7QW	PC	11592228
DM0M7QW	MW	569.7
DM0M7QW	FM	C29H43N7O5
DM0M7QW	IC	InChI=1S/C29H43N7O5/c1-3-4-16-41-28-32-26(30)25-27(33-28)36(29(38)31-25)13-7-12-35(11-6-10-34-14-17-40-18-15-34)21-23-9-5-8-22(19-23)20-24(37)39-2/h5,8-9,19H,3-4,6-7,10-18,20-21H2,1-2H3,(H,31,38)(H2,30,32,33)
DM0M7QW	CS	CCCCOC1=NC(=C2C(=N1)N(C(=O)N2)CCCN(CCCN3CCOCC3)CC4=CC=CC(=C4)CC(=O)OC)N
DM0M7QW	IK	FEFIBEHSXLKJGI-UHFFFAOYSA-N
DM0M7QW	IU	methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7H-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate
DM0M7QW	CA	CAS 866269-28-5
DM0M7QW	DE	Allergic rhinitis

DMFLCW4	ID	DMFLCW4
DMFLCW4	DN	AZD8931
DMFLCW4	HS	Phase 2
DMFLCW4	SN	Sapitinib; AZD8931; 848942-61-0; AZD8931 (Sapitinib); AZD-8931; Sapitinib(AZD8931); UNII-3499328002; CHEMBL2408045; 2-(4-((4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-n-methylacetamide; 2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]-N-methylacetamide; Sapitinib [INN]; 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-((1-(n-methylcarbamoylmethyl)piperidin-4-yl)oxy)quinazoline
DMFLCW4	CP	AstraZeneca
DMFLCW4	DT	Small molecular drug
DMFLCW4	PC	11488320
DMFLCW4	MW	473.9
DMFLCW4	FM	C23H25ClFN5O3
DMFLCW4	IC	InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)
DMFLCW4	CS	CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC
DMFLCW4	IK	DFJSJLGUIXFDJP-UHFFFAOYSA-N
DMFLCW4	IU	2-[4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-N-methylacetamide
DMFLCW4	CA	CAS 848942-61-0
DMFLCW4	CB	CHEBI:132986
DMFLCW4	DE	Breast cancer

DMJGYPK	ID	DMJGYPK
DMJGYPK	DN	AZD9056
DMJGYPK	HS	Phase 2
DMJGYPK	SN	AZD-9056; AZD9056; 345304-65-6; UNII-F13K378W4L; N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide; F13K378W4L; AZD 9056; GTPL7826; SCHEMBL4126642; CHEMBL3545108; HSQAARMBHJCUOK-UHFFFAOYSA-N; MolPort-044-723-510; KS-000000WO; BCP25185; ZINC34356159; AKOS030228502; DB12594; Benzamide, 2-chloro-5-(3-((3-hydroxypropyl)amino)propyl)-N-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-; 2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide
DMJGYPK	CP	AstraZeneca
DMJGYPK	DT	Small molecular drug
DMJGYPK	PC	10161381
DMJGYPK	MW	419
DMJGYPK	FM	C24H35ClN2O2
DMJGYPK	IC	InChI=1S/C24H35ClN2O2/c25-22-5-4-17(3-1-6-26-7-2-8-28)12-21(22)23(29)27-16-24-13-18-9-19(14-24)11-20(10-18)15-24/h4-5,12,18-20,26,28H,1-3,6-11,13-16H2,(H,27,29)
DMJGYPK	CS	C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=C(C=CC(=C4)CCCNCCCO)Cl
DMJGYPK	IK	HSQAARMBHJCUOK-UHFFFAOYSA-N
DMJGYPK	IU	N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide
DMJGYPK	CA	CAS 345304-65-6
DMJGYPK	DE	Chronic obstructive pulmonary disease

DMVKPEZ	ID	DMVKPEZ
DMVKPEZ	DN	AZD-9164
DMVKPEZ	HS	Phase 2
DMVKPEZ	SN	IDDBCP239717
DMVKPEZ	CP	AstraZeneca plc
DMVKPEZ	PC	44517831
DMVKPEZ	MW	465.6
DMVKPEZ	FM	C29H38FN2O2+
DMVKPEZ	IC	InChI=1S/C29H38FN2O2/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3/q+1/t24?,27-,29-,32?/m0/s1
DMVKPEZ	CS	C[C@](C1=CC=CC=C1)(C(=O)O[C@H]2C[N+]3(CCC2CC3)CCC4=CC=C(C=C4)F)N5CCCCC5
DMVKPEZ	IK	FNYFFCOCVNTJCD-NNMXADRKSA-N
DMVKPEZ	IU	[(3R)-1-[2-(4-fluorophenyl)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2S)-2-phenyl-2-piperidin-1-ylpropanoate
DMVKPEZ	CA	CAS 1034978-04-5
DMVKPEZ	DE	Chronic obstructive pulmonary disease

DMB87M3	ID	DMB87M3
DMB87M3	DN	AZD9668
DMB87M3	HS	Phase 2
DMB87M3	SN	Alvelestat; 848141-11-7; AZD9668; Alvelestat (AZD9668); AZD 9668; CHEMBL3617964; AZD-9668; KB-105160; Avelestat; 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide; 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide
DMB87M3	CP	AstraZeneca
DMB87M3	DT	Small molecular drug
DMB87M3	PC	46861623
DMB87M3	MW	545.5
DMB87M3	FM	C25H22F3N5O4S
DMB87M3	IC	InChI=1S/C25H22F3N5O4S/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28/h4-12,14H,13H2,1-3H3,(H,30,34)
DMB87M3	CS	CC1=C(C=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)NCC3=NC=C(C=C3)S(=O)(=O)C)C4=CC=NN4C
DMB87M3	IK	QNQZWEGMKJBHEM-UHFFFAOYSA-N
DMB87M3	IU	6-methyl-5-(2-methylpyrazol-3-yl)-N-[(5-methylsulfonylpyridin-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide
DMB87M3	CA	CAS 848141-11-7
DMB87M3	DE	Chronic obstructive pulmonary disease; Bronchiectasis

DMQOTHP	ID	DMQOTHP
DMQOTHP	DN	AZD9833
DMQOTHP	HS	Phase 2
DMQOTHP	SN	AZD-9833; UNII-JUP57A8EPZ; JUP57A8EPZ; 2222844-89-3; Camizestrant; Camizestrant [USAN]; SCHEMBL20089710; NSC828717; WHO 11592; NSC-828717; HY-136255; AZ14066724; CS-0121043; 3-Pyridinamine, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6S,8R)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3H-pyrazolo(4,3-F)isoquinolin-6-yl)-
DMQOTHP	CP	AstraZeneca
DMQOTHP	DT	Small molecular drug
DMQOTHP	PC	134453496
DMQOTHP	MW	476.5
DMQOTHP	FM	C24H28F4N6
DMQOTHP	IC	InChI=1S/C24H28F4N6/c1-15-9-19-18(4-6-21-20(19)11-30-32-21)23(34(15)14-24(26,27)28)22-5-3-16(10-29-22)31-17-12-33(13-17)8-2-7-25/h3-6,10-11,15,17,23,31H,2,7-9,12-14H2,1H3,(H,30,32)/t15-,23+/m1/s1
DMQOTHP	CS	C[C@@H]1CC2=C(C=CC3=C2C=NN3)[C@H](N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF
DMQOTHP	IK	WDHOIABIERMLGY-CMJOXMDJSA-N
DMQOTHP	IU	N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine
DMQOTHP	CA	CAS 2222844-89-3
DMQOTHP	DE	ER-positive breast cancer

DME0JMV	ID	DME0JMV
DME0JMV	DN	AZX-100
DME0JMV	HS	Phase 2
DME0JMV	CP	AzERx Inc
DME0JMV	DE	Asthma

DMOMDA4	ID	DMOMDA4
DMOMDA4	DN	B-701
DMOMDA4	HS	Phase 2
DMOMDA4	SN	VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester
DMOMDA4	CP	BioClin Therapeutics San Ramon, CA
DMOMDA4	PC	95987
DMOMDA4	MW	355.6
DMOMDA4	FM	C10H22Cl3N2O3P
DMOMDA4	IC	InChI=1S/C10H22Cl3N2O3P/c11-3-1-10-18-19(17,14-6-2-9-16)15(7-4-12)8-5-13/h16H,1-10H2,(H,14,17)
DMOMDA4	CS	C(CNP(=O)(N(CCCl)CCCl)OCCCCl)CO
DMOMDA4	IK	VKRFJPYJBOIVPD-UHFFFAOYSA-N
DMOMDA4	IU	3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol
DMOMDA4	CA	CAS 78218-88-9
DMOMDA4	DE	Bladder cancer; Urothelial carcinoma

DM7586F	ID	DM7586F
DM7586F	DN	Bafetinib
DM7586F	HS	Phase 2
DM7586F	SN	Bafetinib; 859212-16-1; INNO-406; NS-187; UNII-NVW4Z03I9B; CNS-9; NVW4Z03I9B; INNO406; CHEMBL206834; (S)-N-(3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide; 4-[[(3S)-3-DIMETHYLAMINOPYRROLIDIN-1-YL]METHYL]-N-[4-METHYL-3-[(4-PYRIMIDIN-5-YLPYRIMIDIN-2-YL)AMINO]PHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE; INNO 406; NS 187; N-[3-(4,5'-Bipyrimidin-2-Ylamino)-4-Methylphenyl]-4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]methyl}-3-(Trifluoromethyl)benzamide
DM7586F	CP	CytRx
DM7586F	DT	Small molecular drug
DM7586F	PC	11387605
DM7586F	MW	576.6
DM7586F	FM	C30H31F3N8O
DM7586F	IC	InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1
DM7586F	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CC[C@@H](C3)N(C)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CN=C5
DM7586F	IK	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
DM7586F	IU	4-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-N-[4-methyl-3-[(4-pyrimidin-5-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide
DM7586F	CA	CAS 859212-16-1
DM7586F	DE	Bone disease

DM4C7E6	ID	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	HS	Phase 2
DM4C7E6	SN	baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Noroxylin; Biacalein; BaiKalein; Baicelein; UNII-49QAH60606; NSC661431; NSC 661431; CHEMBL8260; 5,6,7-trihydroxy-2-phenylchromen-4-one; CHEBI:2979; FXNFHKRTJBSTCS-UHFFFAOYSA-N; MFCD00017459; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; 49QAH60606; 5,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; AC1NQYPP; Tocris-1761
DM4C7E6	DT	Small molecular drug
DM4C7E6	PC	5281605
DM4C7E6	MW	270.24
DM4C7E6	FM	C15H10O5
DM4C7E6	IC	InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H
DM4C7E6	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O
DM4C7E6	IK	FXNFHKRTJBSTCS-UHFFFAOYSA-N
DM4C7E6	IU	5,6,7-trihydroxy-2-phenylchromen-4-one
DM4C7E6	CA	CAS 491-67-8
DM4C7E6	CB	CHEBI:2979
DM4C7E6	DE	Influenza virus infection

DM3WCL4	ID	DM3WCL4
DM3WCL4	DN	Baltaleucel-T
DM3WCL4	HS	Phase 2
DM3WCL4	CP	Cell Medica Houston, TX
DM3WCL4	DE	Diffuse large B-cell lymphoma; Hodgkin lymphoma; Lymphoma; Post-transplant lymphoproliferative disorder

DMSZOXQ	ID	DMSZOXQ
DMSZOXQ	DN	Baminercept
DMSZOXQ	HS	Phase 2
DMSZOXQ	SN	BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec
DMSZOXQ	CP	Biogen Idec
DMSZOXQ	DE	Rheumatoid arthritis

DM0TZEP	ID	DM0TZEP
DM0TZEP	DN	Bamosiran
DM0TZEP	HS	Phase 2
DM0TZEP	SN	SYL040012
DM0TZEP	CP	Sylentis
DM0TZEP	DT	Small interfering RNA
DM0TZEP	DE	Glaucoma/ocular hypertension

DMW03YD	ID	DMW03YD
DMW03YD	DN	BAN2401
DMW03YD	HS	Phase 2
DMW03YD	CP	BioArtic Neuroscience
DMW03YD	DE	Alzheimer disease

DMWI0X3	ID	DMWI0X3
DMWI0X3	DN	Barusiban
DMWI0X3	HS	Phase 2
DMWI0X3	SN	FE-200440
DMWI0X3	CP	Ferring Pharmaceuticals Inc
DMWI0X3	DT	Small molecular drug
DMWI0X3	PC	9832431
DMWI0X3	MW	830.1
DMWI0X3	FM	C40H63N9O8S
DMWI0X3	IC	InChI=1S/C40H63N9O8S/c1-6-23(3)34-38(55)46-31(20-32(42)51)36(53)45-29(40(57)49(5)26(22-50)11-10-16-41)14-17-58-18-15-33(52)44-30(19-25-21-43-28-13-9-8-12-27(25)28)37(54)47-35(24(4)7-2)39(56)48-34/h8-9,12-13,21,23-24,26,29-31,34-35,43,50H,6-7,10-11,14-20,22,41H2,1-5H3,(H2,42,51)(H,44,52)(H,45,53)(H,46,55)(H,47,54)(H,48,56)/t23-,24+,26+,29+,30-,31+,34+,35+/m1/s1
DMWI0X3	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCSCCC(=O)N[C@@H](C(=O)N1)CC2=CNC3=CC=CC=C32)C(=O)N(C)[C@@H](CCCN)CO)CC(=O)N)[C@H](C)CC
DMWI0X3	IK	UGNGRKKDUVKQDF-IHOMMZCZSA-N
DMWI0X3	IU	(4S,7S,10S,13S,16R)-N-[(2S)-5-amino-1-hydroxypentan-2-yl]-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-10-[(2R)-butan-2-yl]-16-(1H-indol-3-ylmethyl)-N-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMWI0X3	CA	CAS 285571-64-4
DMWI0X3	DE	Androgen deficiency

DMQ8J0U	ID	DMQ8J0U
DMQ8J0U	DN	Basmisanil
DMQ8J0U	HS	Phase 2
DMQ8J0U	SN	1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha
DMQ8J0U	CP	Roche
DMQ8J0U	PC	57336276
DMQ8J0U	MW	445.5
DMQ8J0U	FM	C21H20FN3O5S
DMQ8J0U	IC	InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3
DMQ8J0U	CS	CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4
DMQ8J0U	IK	VCGRFBXVSFAGGA-UHFFFAOYSA-N
DMQ8J0U	IU	(1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone
DMQ8J0U	CA	CAS 1159600-41-5
DMQ8J0U	DE	Alzheimer disease; Cognitive impairment; Complete androgen insensitivity syndrome; Immune dysregulation

DM6CVZ5	ID	DM6CVZ5
DM6CVZ5	DN	Bavisant
DM6CVZ5	HS	Phase 2
DM6CVZ5	SN	JNJ-31001074
DM6CVZ5	CP	Johnson & Johnson Pharmaceutical Research & Development
DM6CVZ5	DT	Small molecular drug
DM6CVZ5	PC	16061509
DM6CVZ5	MW	329.4
DM6CVZ5	FM	C19H27N3O2
DM6CVZ5	IC	InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2
DM6CVZ5	CS	C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4
DM6CVZ5	IK	BGBVSGSIXIIREO-UHFFFAOYSA-N
DM6CVZ5	IU	(4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone
DM6CVZ5	CA	CAS 929622-08-2
DM6CVZ5	DE	Attention deficit hyperactivity disorder

DM4JGNH	ID	DM4JGNH
DM4JGNH	DN	BAY 1067197
DM4JGNH	HS	Phase 2
DM4JGNH	CP	Bayer HealthCare Pharmaceuticals
DM4JGNH	DE	Heart failure

DMHKTGX	ID	DMHKTGX
DMHKTGX	DN	BAY 1142524
DMHKTGX	HS	Phase 2
DMHKTGX	SN	Fulacimstat; UNII-VIR72PP4ZU; VIR72PP4ZU; BAY1142524; 1488354-15-9; 1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-; 2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-; Fulacimstat  [INN]; Fulacimstat; BAY1142524; Fulacimstat(BAY 1142524); CHEMBL4297596; SCHEMBL16701233; EX-A2732; DB15085; BAY-1142524; HY-109059; CS-0032987; (R)-1-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-2,4-dioxo-3-(4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 1-(2,3-Dihydro-3-methyl-2-oxo-6-benzoxazolyl)-3-((1R)-2,3-dihydro-4-(trifluoromethyl)-1H-inden-1-yl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxylic acid; 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]pyrimidine-5-carboxylic acid; 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-((1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylic acid; 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 5-Pyrimidinecarboxylic acid, 1-(2,3-dihydro-3-methyl-2-oxo-6-benzoxazolyl)-3-((1R)-2,3-dihydro-4-(trifluoromethyl)-1H-inden-1-yl)-1,2,3,4-tetrahydro-2,4-dioxo-
DMHKTGX	CP	Bayer
DMHKTGX	DT	Small molecular drug
DMHKTGX	PC	91758792
DMHKTGX	MW	487.4
DMHKTGX	FM	C23H16F3N3O6
DMHKTGX	IC	InChI=1S/C23H16F3N3O6/c1-27-17-7-5-11(9-18(17)35-22(27)34)28-10-14(20(31)32)19(30)29(21(28)33)16-8-6-12-13(16)3-2-4-15(12)23(24,25)26/h2-5,7,9-10,16H,6,8H2,1H3,(H,31,32)/t16-/m1/s1
DMHKTGX	CS	CN1C2=C(C=C(C=C2)N3C=C(C(=O)N(C3=O)[C@@H]4CCC5=C4C=CC=C5C(F)(F)F)C(=O)O)OC1=O
DMHKTGX	IK	JDARDSVOVYVQST-MRXNPFEDSA-N
DMHKTGX	IU	1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]pyrimidine-5-carboxylic acid
DMHKTGX	CA	CAS 1488354-15-9
DMHKTGX	DE	Myocardial infarction

DM8SNEM	ID	DM8SNEM
DM8SNEM	DN	BAY 11-42524
DM8SNEM	HS	Phase 2
DM8SNEM	CP	Bayer healthcare pharmaceuticals
DM8SNEM	DE	Heart failure; Left ventricular dysfunction

DM450XS	ID	DM450XS
DM450XS	DN	BAY 2253651
DM450XS	HS	Phase 2
DM450XS	CP	Bayer
DM450XS	DT	Small molecular drug
DM450XS	DE	Obstructive sleep apnea

DMSUB64	ID	DMSUB64
DMSUB64	DN	BAY 57-1293
DMSUB64	HS	Phase 2
DMSUB64	SN	Pritelivir; 348086-71-5; BAY-57-1293; UNII-07HQ1TJ4JE; AIC316; BAY57-1293; 07HQ1TJ4JE; Pritelivir (BAY 57-1293); N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide; N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide; Pritelivir [INN]; AIC-316; AIC 316; AC1LANY1; PritelivirBAY-57-1293; SCHEMBL1074614; Pritelivir(BAY 57-1293); DTXSID70188344; EX-A247; MolPort-029-887-140; IVZKZONQVYTCKC-UHFFFAOYSA-N; HMS3653B15; BCP08742
DMSUB64	DT	Small molecular drug
DMSUB64	PC	491941
DMSUB64	MW	402.5
DMSUB64	FM	C18H18N4O3S2
DMSUB64	IC	InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
DMSUB64	CS	CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N
DMSUB64	IK	IVZKZONQVYTCKC-UHFFFAOYSA-N
DMSUB64	IU	N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide
DMSUB64	CA	CAS 348086-71-5
DMSUB64	DE	Herpes simplex virus infection

DMA75FG	ID	DMA75FG
DMA75FG	DN	BAY 794980
DMA75FG	HS	Phase 2
DMA75FG	SN	BAY-794980; Kogenate FS liposome; Kogenate liposomal; NecLip-rFVIII; PEGLip-formulated exogenous FVIII - Bayer/Zilip-Pharma; PEGLip-FVIII FS - Bayer/Zilip-Pharma; PEGylated octocog alfa sucrose - Bayer/Zilip-Pharma
DMA75FG	DE	Discovery agent

DMCPUKG	ID	DMCPUKG
DMCPUKG	DN	BAY 85-8501
DMCPUKG	HS	Phase 2
DMCPUKG	CP	Bayer HealthCare Pharmaceuticals
DMCPUKG	PC	66601502
DMCPUKG	MW	474.5
DMCPUKG	FM	C22H17F3N4O3S
DMCPUKG	IC	InChI=1S/C22H17F3N4O3S/c1-13-18(12-27)20(17-8-7-14(11-26)9-19(17)33(3,31)32)28(2)21(30)29(13)16-6-4-5-15(10-16)22(23,24)25/h4-10,20H,1-3H3/t20-/m1/s1
DMCPUKG	CS	CC1=C([C@H](N(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C)C3=C(C=C(C=C3)C#N)S(=O)(=O)C)C#N
DMCPUKG	IK	YAJWYFPMASPAMM-HXUWFJFHSA-N
DMCPUKG	IU	(4S)-4-(4-cyano-2-methylsulfonylphenyl)-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4H-pyrimidine-5-carbonitrile
DMCPUKG	CA	CAS 1161921-82-9
DMCPUKG	DE	Bronchiectasis

DMRZLU4	ID	DMRZLU4
DMRZLU4	DN	BAY 86-5044
DMRZLU4	HS	Phase 2
DMRZLU4	SN	Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE;  Lonaprisan
DMRZLU4	CP	Bayer HealthCare Pharmaceuticals
DMRZLU4	DT	Small molecular drug
DMRZLU4	PC	6918548
DMRZLU4	MW	508.5
DMRZLU4	FM	C28H29F5O3
DMRZLU4	IC	InChI=1S/C28H29F5O3/c1-15(34)16-3-5-17(6-4-16)22-14-25(2)23(11-12-26(25,36)27(29,30)28(31,32)33)21-9-7-18-13-19(35)8-10-20(18)24(21)22/h3-6,13,21-23,36H,7-12,14H2,1-2H3/t21-,22+,23-,25-,26-/m0/s1
DMRZLU4	CS	CC(=O)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(C(C(F)(F)F)(F)F)O)[C@H]4C2=C5CCC(=O)C=C5CC4)C
DMRZLU4	IK	VHZPUDNSVGRVMB-RXDLHWJPSA-N
DMRZLU4	IU	(8S,11R,13S,14S,17S)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMRZLU4	CA	CAS 211254-73-8
DMRZLU4	DE	Breast cancer

DMCSGJ2	ID	DMCSGJ2
DMCSGJ2	DN	BAY1163877
DMCSGJ2	HS	Phase 2
DMCSGJ2	SN	Rogaratinib
DMCSGJ2	CP	Bayer healthcare pharmaceuticals
DMCSGJ2	PC	71611869
DMCSGJ2	MW	466.6
DMCSGJ2	FM	C23H26N6O3S
DMCSGJ2	IC	InChI=1S/C23H26N6O3S/c1-13-6-14-8-18(33-22(14)17(7-13)32-3)20-15(11-31-2)16(9-28-5-4-25-19(30)10-28)29-21(20)23(24)26-12-27-29/h6-8,12H,4-5,9-11H2,1-3H3,(H,25,30)(H2,24,26,27)
DMCSGJ2	CS	CC1=CC2=C(C(=C1)OC)SC(=C2)C3=C4C(=NC=NN4C(=C3COC)CN5CCNC(=O)C5)N
DMCSGJ2	IK	HNLRRJSKGXOYNO-UHFFFAOYSA-N
DMCSGJ2	IU	4-[[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one
DMCSGJ2	CA	CAS 1443530-05-9
DMCSGJ2	DE	Solid tumour/cancer; Bladder cancer

DM83IYE	ID	DM83IYE
DM83IYE	DN	BAY1193397
DM83IYE	HS	Phase 2
DM83IYE	CP	Bayer HealthCare Pharmaceuticals Whippany, NJ
DM83IYE	DE	Peripheral arterial disease

DMYSQMW	ID	DMYSQMW
DMYSQMW	DN	BAY-1902607
DMYSQMW	HS	Phase 2
DMYSQMW	CP	Bayer
DMYSQMW	DE	Cough

DMM7Q68	ID	DMM7Q68
DMM7Q68	DN	BAY-2253651
DMM7Q68	HS	Phase 2
DMM7Q68	CP	Bayer
DMM7Q68	DE	Obstructive sleep apnea

DMVA5NS	ID	DMVA5NS
DMVA5NS	DN	BAY-57-9352
DMVA5NS	HS	Phase 2
DMVA5NS	SN	Telatinib; Bay 57-9352
DMVA5NS	CP	Bayer AG
DMVA5NS	TC	Anticancer Agents
DMVA5NS	DT	Small molecular drug
DMVA5NS	PC	9808844
DMVA5NS	MW	409.8
DMVA5NS	FM	C20H16ClN5O3
DMVA5NS	IC	InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)
DMVA5NS	CS	CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl
DMVA5NS	IK	QFCXANHHBCGMAS-UHFFFAOYSA-N
DMVA5NS	IU	4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide
DMVA5NS	CA	CAS 332012-40-5
DMVA5NS	DE	Solid tumour/cancer; Gastric adenocarcinoma

DM7NHLC	ID	DM7NHLC
DM7NHLC	DN	BAY-85-3934
DM7NHLC	HS	Phase 2
DM7NHLC	SN	Hypoxia-inducible factor prolyl hydroxylase inhibitors (anemia); HIF-PH inhibitors (anemia), Bayer
DM7NHLC	CP	Bayer HealthCare Pharmaceuticals
DM7NHLC	DT	Small molecular drug
DM7NHLC	PC	69669724
DM7NHLC	MW	336.28
DM7NHLC	FM	C13H13N8NaO2
DM7NHLC	IC	InChI=1S/C13H14N8O2.Na/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19;/h1-2,7-9,22H,3-6H2;/q;+1/p-1
DM7NHLC	CS	C1COCCN1C2=NC=NC(=C2)N3C(=C(C=N3)N4C=CN=N4)[O-].[Na+]
DM7NHLC	IK	VYRQLKYGGSWDNH-UHFFFAOYSA-M
DM7NHLC	IU	sodium;2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)pyrazol-3-olate
DM7NHLC	DE	Anemia

DM2XE80	ID	DM2XE80
DM2XE80	DN	BAY-X-7195
DM2XE80	HS	Phase 2
DM2XE80	SN	BAY-X-7195; UGWPB2QIT9; UNII-UGWPB2QIT9; BAY X-7195; BAY X 7195; AC1O5X0Q; 143538-27-6; SCHEMBL156423; CHEMBL314115; 4-[(Z,4S)-7-hydroxy-7-oxo-1-[4-(4-phenoxybutoxy)phenyl]hept-2-en-4-yl]sulfanylbenzoic acid
DM2XE80	CP	Bayer AG
DM2XE80	DT	Small molecular drug
DM2XE80	PC	6442328
DM2XE80	MW	520.6
DM2XE80	FM	C30H32O6S
DM2XE80	IC	InChI=1S/C30H32O6S/c31-29(32)20-19-27(37-28-17-13-24(14-18-28)30(33)34)10-6-7-23-11-15-26(16-12-23)36-22-5-4-21-35-25-8-2-1-3-9-25/h1-3,6,8-18,27H,4-5,7,19-22H2,(H,31,32)(H,33,34)/b10-6-/t27-/m1/s1
DM2XE80	CS	C1=CC=C(C=C1)OCCCCOC2=CC=C(C=C2)C/C=C\\[C@H](CCC(=O)O)SC3=CC=C(C=C3)C(=O)O
DM2XE80	IK	MHKAEITVUICXRN-BPGQXAFDSA-N
DM2XE80	IU	4-[(Z,3S)-1-carboxy-6-[4-(4-phenoxybutoxy)phenyl]hex-4-en-3-yl]sulfanylbenzoic acid
DM2XE80	CA	CAS 143538-27-6
DM2XE80	DE	Asthma

DMLO18H	ID	DMLO18H
DMLO18H	DN	BAY-Y-5959
DMLO18H	HS	Phase 2
DMLO18H	CP	Bayer AG
DMLO18H	PC	9910240
DMLO18H	MW	424.5
DMLO18H	FM	C26H24N4O2
DMLO18H	IC	InChI=1S/C26H24N4O2/c1-15(2)32-26(31)24-23(21(13-27)16(3)30-25(24)28)19-10-7-11-22-20(19)12-18(14-29-22)17-8-5-4-6-9-17/h4-12,14-15,23,30H,28H2,1-3H3/t23-/m1/s1
DMLO18H	CS	CC1=C([C@H](C(=C(N1)N)C(=O)OC(C)C)C2=C3C=C(C=NC3=CC=C2)C4=CC=CC=C4)C#N
DMLO18H	IK	PHJVBZVDUNTGNR-HSZRJFAPSA-N
DMLO18H	IU	propan-2-yl (4R)-2-amino-5-cyano-6-methyl-4-(3-phenylquinolin-5-yl)-1,4-dihydropyridine-3-carboxylate
DMLO18H	CA	CAS 146136-94-9
DMLO18H	DE	Cardiovascular disease

DMB0UF9	ID	DMB0UF9
DMB0UF9	DN	Bb2121
DMB0UF9	HS	Phase 2
DMB0UF9	CP	bluebird bioCambridge, MACelgeneSummit, NJ
DMB0UF9	DT	CAR T Cell Therapy
DMB0UF9	DE	Multiple myeloma

DMR59I4	ID	DMR59I4
DMR59I4	DN	BBI-5000
DMR59I4	HS	Phase 2
DMR59I4	CP	Brickell Biotech
DMR59I4	DT	Small molecular drug
DMR59I4	DE	Alopecia

DMDSNIR	ID	DMDSNIR
DMDSNIR	DN	BBI503
DMDSNIR	HS	Phase 2
DMDSNIR	CP	Boston Biomedical
DMDSNIR	PC	25190990
DMDSNIR	MW	539.7
DMDSNIR	FM	C31H33N5O2S
DMDSNIR	IC	InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-
DMDSNIR	CS	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)C4=CSC(=N4)C5=CC=CC=C5)NC2=O)C
DMDSNIR	IK	QDWKGEFGLQMDAM-ULJHMMPZSA-N
DMDSNIR	IU	N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[(Z)-[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide
DMDSNIR	CA	CAS 1129403-56-0
DMDSNIR	DE	Ovarian cancer; Hepatocellular carcinoma; Cholangiocarcinoma; Solid tumour/cancer

DMY1UGV	ID	DMY1UGV
DMY1UGV	DN	Bc-3781 intravenous
DMY1UGV	HS	Phase 2
DMY1UGV	SN	BC-3781 (intravenous), Nabriva; BC-3781 (oral), Nabriva
DMY1UGV	CP	Nabriva therapeutics
DMY1UGV	DT	Small molecular drug
DMY1UGV	PC	52918381
DMY1UGV	MW	507.7
DMY1UGV	FM	C28H45NO5S
DMY1UGV	IC	InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18?,20?,21?,22-,24+,25+,26-,27+,28+/m1/s1
DMY1UGV	CS	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4CCC(CC4O)N)C
DMY1UGV	IK	KPVIXBKIJXZQJX-IJUBVZAWSA-N
DMY1UGV	IU	[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-(4-amino-2-hydroxycyclohexyl)sulfanylacetate
DMY1UGV	CA	CAS 1061872-97-6
DMY1UGV	DE	Bacterial infection

DMMKCJ6	ID	DMMKCJ6
DMMKCJ6	DN	BC-7013
DMMKCJ6	HS	Phase 2
DMMKCJ6	SN	Pleuromutilin (topical, dermatological infection), Nabriva
DMMKCJ6	CP	Nabriva Therapeutics AG
DMMKCJ6	DE	Skin infection

DM2BO9W	ID	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	HS	Phase 2
DM2BO9W	SN	Propacetamol; Pro-Dafalgan; Propacetamol (INN); Propacetamol [INN:BAN]; Propacetamol [INN]; Propacetamolum; Propacetamolum [Latin]; Tox21_113811; ZINC55161176; (4-acetamidophenyl) 2-(diethylamino)acetate; 5CHW4JMR82; 66532-85-2; AC1L2ALY; AC1Q6199; AKOS015890722; BCP13498; CHEBI:135089; CHEMBL1851805; DB09288; DSSTox_CID_31589; DSSTox_GSID_57800; DSSTox_RID_97473; DTXSID3057800; EINECS 266-390-1; Glycine, N,N-diethyl-, 4-(acetylamino)phenyl ester; N,N-Diethylglycine, ester with 4'-hydroxyacetanilide; SCHEMBL26155; UNII-5CHW4JMR82
DM2BO9W	PC	68865
DM2BO9W	MW	264.32
DM2BO9W	FM	C14H20N2O3
DM2BO9W	IC	QTGAJCQTLIRCFL-UHFFFAOYSA-N
DM2BO9W	CS	CCN(CC)CC(=O)OC1=CC=C(C=C1)NC(=O)C
DM2BO9W	IK	1S/C14H20N2O3/c1-4-16(5-2)10-14(18)19-13-8-6-12(7-9-13)15-11(3)17/h6-9H,4-5,10H2,1-3H3,(H,15,17)
DM2BO9W	IU	(4-acetamidophenyl) 2-(diethylamino)acetate
DM2BO9W	CA	CAS 66532-85-2
DM2BO9W	CB	CHEBI:135089
DM2BO9W	DE	Anaesthesia

DMUFY4K	ID	DMUFY4K
DMUFY4K	DN	BCT303
DMUFY4K	HS	Phase 2
DMUFY4K	SN	Liothyronine sustained release
DMUFY4K	CP	Intellectual property executives
DMUFY4K	DE	Hypothyroidism

DMRSG31	ID	DMRSG31
DMRSG31	DN	BCX-3408
DMRSG31	HS	Phase 2
DMRSG31	SN	ULODESINE; 548486-59-5; UNII-JNG8L9460Y; JNG8L9460Y; CHEMBL269864; DADMe-immucillin H; Ulodesine [USAN:INN]; Ulodesine (USAN); DADMe-ImmH,7; 1n3i; AC1L9KNW; 7-[[(3R,4R)-3-(hydroxymethyl)-4-oxidanyl-pyrrolidin-1-ium-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one; R-3421; SCHEMBL474735; SCHEMBL16320802; CTK5A2657; BDBM22109; DTXSID00203332; AKOS030554378; DB12353; SB17254; D10431; 4H-Pyrrolo[3,2-d]pyrimidin-4-one,1,5-dihydro-7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-pyrrolidinyl]methyl]-; BCX-4208; Ulodesine
DMRSG31	DT	Small molecular drug
DMRSG31	PC	135449518
DMRSG31	MW	264.28
DMRSG31	FM	C12H16N4O3
DMRSG31	IC	InChI=1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1
DMRSG31	CS	C1[C@@H]([C@H](CN1CC2=CNC3=C2N=CNC3=O)O)CO
DMRSG31	IK	AFNHHLILYQEHKK-BDAKNGLRSA-N
DMRSG31	IU	7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMRSG31	CA	CAS 548486-59-5
DMRSG31	DE	Plaque psoriasis; Gout; Autoimmune diabetes

DMKFJXP	ID	DMKFJXP
DMKFJXP	DN	BDB001
DMKFJXP	HS	Phase 2
DMKFJXP	CP	Birdie Biopharmaceuticals; Seven and Eight Biopharmaceuticals
DMKFJXP	DT	Antibody
DMKFJXP	DE	Solid tumour/cancer

DM2Q50G	ID	DM2Q50G
DM2Q50G	DN	Belnacasan
DM2Q50G	HS	Phase 2
DM2Q50G	SN	Second generation ICE inhibitors, Vertex; VRT-043198; VRT-43198; VX-765; VX-765)
DM2Q50G	CP	MedKoo Biosciences; vertex pharmaceuticals
DM2Q50G	DT	Small molecular drug
DM2Q50G	PC	11398092
DM2Q50G	MW	509
DM2Q50G	FM	C24H33ClN4O6
DM2Q50G	IC	InChI=1S/C24H33ClN4O6/c1-5-34-23-16(12-18(30)35-23)27-21(32)17-7-6-10-29(17)22(33)19(24(2,3)4)28-20(31)13-8-9-15(26)14(25)11-13/h8-9,11,16-17,19,23H,5-7,10,12,26H2,1-4H3,(H,27,32)(H,28,31)/t16-,17-,19+,23+/m0/s1
DM2Q50G	CS	CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)(C)C)NC(=O)C3=CC(=C(C=C3)N)Cl
DM2Q50G	IK	SJDDOCKBXFJEJB-MOKWFATOSA-N
DM2Q50G	IU	(2S)-1-[(2S)-2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide
DM2Q50G	CA	CAS 273404-37-8
DM2Q50G	DE	Epilepsy

DMWNYIE	ID	DMWNYIE
DMWNYIE	DN	Bemarituzumab
DMWNYIE	HS	Phase 2
DMWNYIE	CP	Five Prime Therapeutics South San Francisco, CA
DMWNYIE	DE	Gastric adenocarcinoma

DM0YCPL	ID	DM0YCPL
DM0YCPL	DN	Bemcentinib
DM0YCPL	HS	Phase 2
DM0YCPL	SN	R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; BGB324; BGB-324; BGB 324; R 428; R-428; Bemcentinib; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine
DM0YCPL	CP	Rigel Pharmaceuticals; BerGen BIO
DM0YCPL	DT	Small molecular drug
DM0YCPL	PC	46215462
DM0YCPL	MW	506.6
DM0YCPL	FM	C30H34N8
DM0YCPL	IC	InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1
DM0YCPL	CS	C1CCN(C1)[C@H]2CCC3=C(CC2)C=C(C=C3)NC4=NN(C(=N4)N)C5=NN=C6C(=C5)CCCC7=CC=CC=C76
DM0YCPL	IK	KXMZDGSRSGHMMK-VWLOTQADSA-N
DM0YCPL	IU	1-(3,4-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine
DM0YCPL	CA	CAS 1037624-75-1
DM0YCPL	DE	Non-small-cell lung cancer; Myelodysplastic syndrome; Triple negative breast cancer

DMUL6GY	ID	DMUL6GY
DMUL6GY	DN	BEMORADAN
DMUL6GY	HS	Phase 2
DMUL6GY	SN	Orf-22867; RWJ-22867; Bemoradan; Rac-7-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one; Rac-5-Methyl-6-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-2,3,4,5-tetrahydropyridazin-3-one
DMUL6GY	DT	Small molecular drug
DMUL6GY	PC	5362399
DMUL6GY	MW	259.26
DMUL6GY	FM	C13H13N3O3
DMUL6GY	IC	InChI=1S/C13H13N3O3/c1-7-4-11(17)15-16-13(7)8-2-3-9-10(5-8)19-6-12(18)14-9/h2-3,5,7H,4,6H2,1H3,(H,14,18)(H,15,17)
DMUL6GY	CS	CC1CC(=O)NN=C1C2=CC3=C(C=C2)NC(=O)CO3
DMUL6GY	IK	XZPGINPFWXLYNW-UHFFFAOYSA-N
DMUL6GY	IU	7-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-4H-1,4-benzoxazin-3-one
DMUL6GY	CA	CAS 112018-01-6
DMUL6GY	DE	Heart failure

DMRC0EQ	ID	DMRC0EQ
DMRC0EQ	DN	Bertilimumab
DMRC0EQ	HS	Phase 2
DMRC0EQ	SN	CAT-213; ICo-008
DMRC0EQ	CP	Cambridge Antibody Technology
DMRC0EQ	DT	Monoclonal antibody
DMRC0EQ	DE	Ocular allergy; Bullous pemphigoid; Psoriasis vulgaris; Ulcerative colitis

DMJ2REU	ID	DMJ2REU
DMJ2REU	DN	Berubicin
DMJ2REU	HS	Phase 2
DMJ2REU	SN	Berubicin hydrochloride; RTA-744; RTA-769; WP-744; WP-769; Anthracycline derivative topoisomerase II inhibitor (cancer), MD Anderson; Anthracycline derivative topoisomerase II inhibitor (cancer), Reata; Berubicin (intravenous), Reata Pharmaceuticals; Berubicin (oral, cancer); Anthracycline topoisomerase II inhibitor (oral, cancer), MD Anderson Cancer Center; Anthracycline topoisomerase II inhibitor (oral, cancer), Reata Pharmaceuticals; Berubicin (oral, cancer), Reata Pharmaceuticals
DMJ2REU	CP	MD Anderson Cancer Center
DMJ2REU	DT	Small molecular drug
DMJ2REU	PC	9874592
DMJ2REU	MW	633.6
DMJ2REU	FM	C34H35NO11
DMJ2REU	IC	InChI=1S/C34H35NO11/c1-16-33(44-15-17-7-4-3-5-8-17)20(35)11-24(45-16)46-22-13-34(42,23(37)14-36)12-19-26(22)32(41)28-27(30(19)39)29(38)18-9-6-10-21(43-2)25(18)31(28)40/h3-10,16,20,22,24,33,36,39,41-42H,11-15,35H2,1-2H3/t16-,20-,22-,24-,33+,34-/m0/s1
DMJ2REU	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OCC6=CC=CC=C6
DMJ2REU	IK	FIGNGSHKNAHTSH-JJMFXPFOSA-N
DMJ2REU	IU	(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-phenylmethoxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMJ2REU	CA	CAS 677017-23-1
DMJ2REU	DE	Solid tumour/cancer

DM7583A	ID	DM7583A
DM7583A	DN	Beta-caryophyllene
DM7583A	HS	Phase 2
DM7583A	SN	BETA-CARYOPHYLLENE; Caryophyllene; (-)-trans-Caryophyllene; 87-44-5; L-Caryophyllene; (-)-beta-caryophyllene; trans-Caryophyllene; (E)-Caryophyllene; (E)-beta-caryophyllene; b-caryophyllene; trans-beta-caryophyllene; Beta-Caryophylene; (-)-Caryophyllene; beta-Caryophyllen; beta-Caryophyllene; CHEBI:10357; (E)-beta-caryophylene; beta-(E)-Caryophyllene; beta-Caryophyllen; (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene; MFCD00075925; UNII-BHW853AU9H; g-Caryophyllene; (1R,9S,E)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; (1S,9R)-6,10,10-trimethyl-2-methylenebicyclo[7.2.0]undec-5-ene; NSC 11906; E-.beta.-caryophyllene; BHW853AU9H; beta-Caryophyllene, (-); Tincturoid; NSC11906; Caryophyllene B; beta-cariofillene; (1R,4E,9S)-4,11,11-trimethyl-8-methylene-bicyclo[7.2.0]undec-4-ene; beta-caryophillene; Bicyclo(7.2.0)undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R-(1R*,4E,9S*)]-; E-beta-caryophyllene; Caryophyllene, (E); beta-(e)-caryophyllene; beta-trans-caryophyllene; (-)-  -caryophyllene; (-)-(E)-Caryophyllene; DSSTox_CID_4739; beta-trans-Caryophyllene; trans-.beta.-Caryophyllene; (-)-I(2)-caryophyllene; DSSTox_RID_77517; DSSTox_GSID_24739; 8-Methylene-4,11,11-(trimethyl)bicyclo[7.2.0]undec-4-ene; CHEMBL445740; DTXSID8024739; HY-N1415; ZINC8234282; Tox21_301497; BDBM50529607; s6058; (1R,4E,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; AKOS024283988; trans-(1R,9S)-8-Methylene-4,11,11-trimethylbicyclo[7.2.0]undec-4-ene; LMPR0103120001; beta-Caryophyllene, >=80%, FCC, FG; CAS-87-44-5; NCGC00142620-01; NCGC00255159-01; ST072181; (-)-trans-Caryophyllene, analytical standard; CS-0016839; V0915; C09629; Q421614; W-109317; UNII-K4H93P747O component NPNUFJAVOOONJE-GFUGXAQUSA-N; (-)-trans-Caryophyllene, >=98.5% (sum of enantiomers, GC); trans-(1R,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; 8-Methylene-4,11,11-(trimethyl)bicyclo(7.2.0)undec-4-ene, (1R,4E,9S)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R- (1R*,4E,9S*)]-
DM7583A	DT	Small molecular drug
DM7583A	PC	5281515
DM7583A	MW	204.35
DM7583A	FM	C15H24
DM7583A	IC	InChI=1S/C15H24/c1-11-6-5-7-12(2)13-10-15(3,4)14(13)9-8-11/h6,13-14H,2,5,7-10H2,1,3-4H3/b11-6+/t13-,14-/m1/s1
DM7583A	CS	C/C/1=C\\CCC(=C)[C@H]2CC([C@@H]2CC1)(C)C
DM7583A	IK	NPNUFJAVOOONJE-GFUGXAQUSA-N
DM7583A	IU	(1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene
DM7583A	CA	CAS 87-44-5
DM7583A	CB	CHEBI:10357
DM7583A	DE	Pain

DMMI84K	ID	DMMI84K
DMMI84K	DN	Beta-lapachone
DMMI84K	HS	Phase 2
DMMI84K	SN	ARQ 501; SL 11001; A-lapachone; LAPACHONE, BETA; AK-693/21096016; 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-B]pyran-5,6-dione
DMMI84K	CP	Roche
DMMI84K	DT	Small molecular drug
DMMI84K	PC	3885
DMMI84K	MW	242.27
DMMI84K	FM	C15H14O3
DMMI84K	IC	InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3
DMMI84K	CS	CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C
DMMI84K	IK	QZPQTZZNNJUOLS-UHFFFAOYSA-N
DMMI84K	IU	2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione
DMMI84K	CA	CAS 4707-32-8
DMMI84K	CB	CHEBI:10429
DMMI84K	DE	Solid tumour/cancer

DML2D8Q	ID	DML2D8Q
DML2D8Q	DN	Bevirimat
DML2D8Q	HS	Phase 2
DML2D8Q	SN	DSB; Bevirimat dimeglumine; DSB 2NMG; MPC-4326; PA-457; PA-103001-01; PA-103001-04; PA-457 di-NMG; Viral maturation inhibitor (HIV), Myrexis; Viral maturation inhibitor (HIV), Myriad; Viral maturation inhibitor (HIV), Panacos; YK-FH-312; 3-O-(3' 3'-dimethylsuccinyl)-betulinic acid
DML2D8Q	CP	Panacos
DML2D8Q	DT	Small molecular drug
DML2D8Q	PC	457928
DML2D8Q	MW	584.8
DML2D8Q	FM	C36H56O6
DML2D8Q	IC	InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1
DML2D8Q	CS	CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C)C(=O)O
DML2D8Q	IK	YJEJKUQEXFSVCJ-WRFMNRASSA-N
DML2D8Q	IU	(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
DML2D8Q	CA	CAS 174022-42-5
DML2D8Q	CB	CHEBI:65484
DML2D8Q	DE	Human immunodeficiency virus infection

DMKBRDL	ID	DMKBRDL
DMKBRDL	DN	BEZ235
DMKBRDL	HS	Phase 2
DMKBRDL	SN	BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
DMKBRDL	CP	Novartis
DMKBRDL	DT	Small molecular drug
DMKBRDL	PC	11977753
DMKBRDL	MW	469.5
DMKBRDL	FM	C30H23N5O
DMKBRDL	IC	InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3
DMKBRDL	CS	CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5
DMKBRDL	IK	JOGKUKXHTYWRGZ-UHFFFAOYSA-N
DMKBRDL	IU	2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile
DMKBRDL	CA	CAS 915019-65-7
DMKBRDL	CB	CHEBI:71952
DMKBRDL	DE	Solid tumour/cancer

DMVUX1C	ID	DMVUX1C
DMVUX1C	DN	BFH-772
DMVUX1C	HS	Phase 2
DMVUX1C	SN	NVP-BFH-772
DMVUX1C	CP	Novartis AG
DMVUX1C	PC	24756034
DMVUX1C	MW	439.4
DMVUX1C	FM	C23H16F3N3O3
DMVUX1C	IC	InChI=1S/C23H16F3N3O3/c24-23(25,26)15-4-2-5-16(10-15)29-22(31)20-6-1-3-14-9-18(7-8-19(14)20)32-21-11-17(12-30)27-13-28-21/h1-11,13,30H,12H2,(H,29,31)
DMVUX1C	CS	C1=CC(=CC(=C1)NC(=O)C2=CC=CC3=C2C=CC(=C3)OC4=NC=NC(=C4)CO)C(F)(F)F
DMVUX1C	IK	JNLSTLQFDDAULK-UHFFFAOYSA-N
DMVUX1C	IU	6-[6-(hydroxymethyl)pyrimidin-4-yl]oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
DMVUX1C	CA	CAS 890128-81-1
DMVUX1C	DE	Psoriasis vulgaris

DMRO6XT	ID	DMRO6XT
DMRO6XT	DN	BGB-290
DMRO6XT	HS	Phase 2
DMRO6XT	SN	Pamiparib
DMRO6XT	PC	135565554
DMRO6XT	MW	298.31
DMRO6XT	FM	C16H15FN4O
DMRO6XT	IC	InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1
DMRO6XT	CS	C[C@]12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F
DMRO6XT	IK	DENYZIUJOTUUNY-MRXNPFEDSA-N
DMRO6XT	IU	(2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one
DMRO6XT	CA	CAS 1446261-44-4
DMRO6XT	DE	Recurrent glioblastoma; Solid tumour/cancer; Ovarian cancer

DMQCFSM	ID	DMQCFSM
DMQCFSM	DN	BGB-3112
DMQCFSM	HS	Phase 2
DMQCFSM	CP	BeiGene Cambridge, MA
DMQCFSM	DE	Follicular lymphoma

DMDI43Y	ID	DMDI43Y
DMDI43Y	DN	BGB-324
DMDI43Y	HS	Phase 2
DMDI43Y	SN	BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio
DMDI43Y	CP	BergenBio AS
DMDI43Y	DT	siRNA drug
DMDI43Y	DE	Metastatic malignant neoplasm; Acute myeloid leukaemia; Breast cancer; Myelodysplastic syndrome

DM1X3L0	ID	DM1X3L0
DM1X3L0	DN	BGB-3245
DM1X3L0	HS	Phase 2
DM1X3L0	CP	BeiGene
DM1X3L0	DT	Small molecular drug
DM1X3L0	DE	Solid tumour/cancer

DMS2MQ5	ID	DMS2MQ5
DMS2MQ5	DN	BGC-20-1531
DMS2MQ5	HS	Phase 2
DMS2MQ5	SN	AH-22921; EP4 antagonist, BTG; EP4 antagonist, Pharmagene; Migraine therapy, BTG; Migraine therapy, Pharmagene; PGN-1531; EP4 receptor antagonists (migraine), Asterand; R-4 (migraine), Pharmagene
DMS2MQ5	CP	Pharmagene plc
DMS2MQ5	DT	Small molecular drug
DMS2MQ5	PC	25209437
DMS2MQ5	MW	514.5
DMS2MQ5	FM	C26H23N2NaO6S
DMS2MQ5	IC	InChI=1S/C26H24N2O6S.Na/c1-17-6-4-5-7-25(17)35(30,31)28-26(29)24-14-20(18(2)34-24)16-33-21-10-8-19(9-11-21)23-13-12-22(32-3)15-27-23;/h4-15H,16H2,1-3H3,(H,28,29);/q;+1/p-1
DMS2MQ5	CS	CC1=CC=CC=C1S(=O)(=O)[N-]C(=O)C2=CC(=C(O2)C)COC3=CC=C(C=C3)C4=NC=C(C=C4)OC.[Na+]
DMS2MQ5	IK	TVDHMDXPKGMXRT-UHFFFAOYSA-M
DMS2MQ5	IU	sodium;[4-[[4-(5-methoxypyridin-2-yl)phenoxy]methyl]-5-methylfuran-2-carbonyl]-(2-methylphenyl)sulfonylazanide
DMS2MQ5	DE	Migraine

DMYDM68	ID	DMYDM68
DMYDM68	DN	BGP-15
DMYDM68	HS	Phase 2
DMYDM68	SN	66611-37-8; BGP-15 2HCl; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, hydrochloride (1:2); BGP 15; BGP15; SCHEMBL3067994; MolPort-039-099-291; MolPort-027-834-918; s8370; AKOS016007888; AKOS026745444; SB17119; CS-6045; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, dihydrochloride; BGP-15, &gt; AS-16983; TC-162219; AX8217132; KB-258115; HY-100828; (Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide dihydrochloride
DMYDM68	CP	N-Gene Research Laboratories
DMYDM68	DT	Small molecular drug
DMYDM68	PC	9884807
DMYDM68	MW	351.3
DMYDM68	FM	C14H24Cl2N4O2
DMYDM68	IC	InChI=1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H
DMYDM68	CS	C1CCN(CC1)CC(CO/N=C(/C2=CN=CC=C2)\\N)O.Cl.Cl
DMYDM68	IK	ISGGVCWFTPTHIX-UHFFFAOYSA-N
DMYDM68	IU	N'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride
DMYDM68	CA	CAS 66611-37-8
DMYDM68	DE	Type-2 diabetes

DMO4MNQ	ID	DMO4MNQ
DMO4MNQ	DN	BGS-649
DMO4MNQ	HS	Phase 2
DMO4MNQ	CP	Novartis AG
DMO4MNQ	DE	Endometriosis

DMSROM4	ID	DMSROM4
DMSROM4	DN	BHQ880
DMSROM4	HS	Phase 2
DMSROM4	SN	BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis
DMSROM4	CP	Novartis
DMSROM4	DT	Antibody
DMSROM4	DE	Multiple myeloma

DM7ZM1H	ID	DM7ZM1H
DM7ZM1H	DN	BHT-3009
DM7ZM1H	HS	Phase 2
DM7ZM1H	CP	Bayhill Therapeutics
DM7ZM1H	DT	Vaccine
DM7ZM1H	DE	Multiple sclerosis

DM740BS	ID	DM740BS
DM740BS	DN	BI 1358894
DM740BS	HS	Phase 2
DM740BS	CP	Boehringer Ingelheim
DM740BS	DT	Small molecular drug
DM740BS	DE	Depression

DMMSGAT	ID	DMMSGAT
DMMSGAT	DN	BI 207127
DMMSGAT	HS	Phase 2
DMMSGAT	SN	Deleobuvir; UNII-58BU988K90; 58BU988K90; 863884-77-9; Deleobuvir [USAN:INN]; SCHEMBL900174; SCHEMBL900176; CHEMBL2403318; DTXSID40235516; BMAIGAHXAJEULY-UKTHLTGXSA-N; SB16520; BI-207127; 1221574-24-8; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic;  Deleobuvir; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid; 2-Propenoic acid, 3-(2-(1-(((2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1H-benzimidazol-6-yl)-, (2E)-; (E)-3-(2-(1
DMMSGAT	CP	Boehringer Ingelheim Pharma
DMMSGAT	DT	Small molecular drug
DMMSGAT	PC	56948249
DMMSGAT	MW	653.6
DMMSGAT	FM	C34H33BrN6O3
DMMSGAT	IC	InChI=1S/C34H33BrN6O3/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43)/b13-9+
DMMSGAT	CS	CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C4=NC5=C(N4C)C=C(C=C5)/C=C/C(=O)O)C(=C1C6=NC=C(C=N6)Br)C7CCCC7
DMMSGAT	IK	BMAIGAHXAJEULY-UKTHLTGXSA-N
DMMSGAT	IU	(E)-3-[2-[1-[[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methylindole-6-carbonyl]amino]cyclobutyl]-3-methylbenzimidazol-5-yl]prop-2-enoic acid
DMMSGAT	CA	CAS 863884-77-9
DMMSGAT	DE	Hepatitis C virus infection

DMJSADP	ID	DMJSADP
DMJSADP	DN	BI 2536
DMJSADP	HS	Phase 2
DMJSADP	SN	BI2536, BI 2536
DMJSADP	CP	Boehringer Ingelheim
DMJSADP	TC	Anticancer Agents
DMJSADP	DT	Small molecular drug
DMJSADP	PC	11364421
DMJSADP	MW	521.7
DMJSADP	FM	C28H39N7O3
DMJSADP	IC	InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1
DMJSADP	CS	CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C
DMJSADP	IK	XQVVPGYIWAGRNI-JOCHJYFZSA-N
DMJSADP	IU	4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
DMJSADP	CA	CAS 755038-02-9
DMJSADP	DE	Acute myeloid leukaemia

DM1NMGJ	ID	DM1NMGJ
DM1NMGJ	DN	BI 456906
DM1NMGJ	HS	Phase 2
DM1NMGJ	CP	Boehringer Ingelheim; Zealand Pharma
DM1NMGJ	DT	Small molecular drug
DM1NMGJ	DE	Type 2 diabetes

DMF86P2	ID	DMF86P2
DMF86P2	DN	BI 655064
DMF86P2	HS	Phase 2
DMF86P2	CP	Boehringer ingelheim pharmaceuticals
DMF86P2	DT	Antibody
DMF86P2	DE	Rheumatoid arthritis; Lupus; Thrombocytopenia

DMJFDS0	ID	DMJFDS0
DMJFDS0	DN	BI-409306
DMJFDS0	HS	Phase 2
DMJFDS0	CP	Boehringer Ingelheim Pharmaceuticals
DMJFDS0	PC	135908617
DMJFDS0	MW	311.34
DMJFDS0	FM	C16H17N5O2
DMJFDS0	IC	InChI=1S/C16H17N5O2/c22-16-13-10-18-21(12-4-7-23-8-5-12)15(13)19-14(20-16)9-11-3-1-2-6-17-11/h1-3,6,10,12H,4-5,7-9H2,(H,19,20,22)
DMJFDS0	CS	C1COCCC1N2C3=C(C=N2)C(=O)NC(=N3)CC4=CC=CC=N4
DMJFDS0	IK	BZTIJCSHNVZMES-UHFFFAOYSA-N
DMJFDS0	IU	1-(oxan-4-yl)-6-(pyridin-2-ylmethyl)-5H-pyrazolo[3,4-d]pyrimidin-4-one
DMJFDS0	CA	CAS 1189767-28-9
DMJFDS0	DE	Psychiatric disorder; Alzheimer disease; Schizophrenia

DMZR9OU	ID	DMZR9OU
DMZR9OU	DN	BI-44370
DMZR9OU	HS	Phase 2
DMZR9OU	SN	BI-44370; Calcitonin gene-related peptide antagonist (migraine), Boehringer Ingelheim
DMZR9OU	CP	Boehringer Ingelheim Corp
DMZR9OU	DE	Migraine

DMSZQHX	ID	DMSZQHX
DMSZQHX	DN	BI-505
DMSZQHX	HS	Phase 2
DMSZQHX	CP	BioInvent International
DMSZQHX	DT	Antibody
DMSZQHX	DE	Multiple myeloma

DM9FZYT	ID	DM9FZYT
DM9FZYT	DN	BI-655130
DM9FZYT	HS	Phase 2
DM9FZYT	CP	Boehringer Ingelheim Ridgefield, CT
DM9FZYT	DE	Plaque psoriasis; Palmoplantar pustulosis

DMWH7Z5	ID	DMWH7Z5
DMWH7Z5	DN	BI-836826
DMWH7Z5	HS	Phase 2
DMWH7Z5	CP	Boehringer Ingelheim Pharmaceuticals
DMWH7Z5	DT	Antibody
DMWH7Z5	DE	Chronic lymphocytic leukaemia; Solid tumour/cancer; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma

DMUVMY9	ID	DMUVMY9
DMUVMY9	DN	BI-836858
DMUVMY9	HS	Phase 2
DMUVMY9	CP	Boehringer Ingelheim Pharmaceuticals
DMUVMY9	DT	Antibody
DMUVMY9	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DMG3ON2	ID	DMG3ON2
DMG3ON2	DN	BIA 3-202
DMG3ON2	HS	Phase 2
DMG3ON2	SN	Nebicapone; 274925-86-9; UNII-NM2KXJ990T; NM2KXJ990T; CHEMBL160038; Ethanone, 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-; BIA 3-202; Nebicapone [INN]; 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone; SCHEMBL132167; ZINC8750; 1-(3,4-dihydroxy-5-nitro-phenyl)-2-phenyl-ethanone; CTK8H9559; DTXSID30181912; BIA-3-202; BDBM50108878; AKOS028111881; ACM274925869; FT-0703128
DMG3ON2	DT	Small molecular drug
DMG3ON2	PC	9838389
DMG3ON2	MW	273.24
DMG3ON2	FM	C14H11NO5
DMG3ON2	IC	InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2
DMG3ON2	CS	C1=CC=C(C=C1)CC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
DMG3ON2	IK	MRFOLGFFTUGAEB-UHFFFAOYSA-N
DMG3ON2	IU	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone
DMG3ON2	CA	CAS 274925-86-9
DMG3ON2	DE	Parkinson disease

DMHYZEK	ID	DMHYZEK
DMHYZEK	DN	BIBH 1
DMHYZEK	HS	Phase 2
DMHYZEK	CP	Boehringer Ingelheim
DMHYZEK	DT	Antibody
DMHYZEK	DE	Solid tumour/cancer

DM9OXEJ	ID	DM9OXEJ
DM9OXEJ	DN	BIIB 023
DM9OXEJ	HS	Phase 2
DM9OXEJ	CP	Biogen Idec
DM9OXEJ	DE	Rheumatoid arthritis

DM293JT	ID	DM293JT
DM293JT	DN	BIIB 033
DM293JT	HS	Phase 2
DM293JT	DT	Antibody
DM293JT	DE	Multiple sclerosis

DMH7RJ1	ID	DMH7RJ1
DMH7RJ1	DN	BIIB014
DMH7RJ1	HS	Phase 2
DMH7RJ1	SN	V2006
DMH7RJ1	CP	Biogen Idec
DMH7RJ1	DT	Small molecular drug
DMH7RJ1	PC	21874557
DMH7RJ1	MW	321.34
DMH7RJ1	FM	C16H15N7O
DMH7RJ1	IC	InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20)
DMH7RJ1	CS	CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N
DMH7RJ1	IK	HQSBCDPYXDGTCL-UHFFFAOYSA-N
DMH7RJ1	IU	3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine
DMH7RJ1	CA	CAS 442908-10-3
DMH7RJ1	DE	Parkinson disease

DMPAJ41	ID	DMPAJ41
DMPAJ41	DN	BIIB-021
DMPAJ41	HS	Phase 2
DMPAJ41	SN	CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma
DMPAJ41	CP	Conforma Therapeutics Corp
DMPAJ41	DT	Small molecular drug
DMPAJ41	PC	16736529
DMPAJ41	MW	318.76
DMPAJ41	FM	C14H15ClN6O
DMPAJ41	IC	InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20)
DMPAJ41	CS	CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N
DMPAJ41	IK	QULDDKSCVCJTPV-UHFFFAOYSA-N
DMPAJ41	IU	6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine
DMPAJ41	CA	CAS 848695-25-0
DMPAJ41	CB	CHEBI:90687
DMPAJ41	DE	Breast cancer

DMZO2SY	ID	DMZO2SY
DMZO2SY	DN	BIIB054
DMZO2SY	HS	Phase 2
DMZO2SY	CP	Biogen Cambridge, MA
DMZO2SY	DE	Parkinson disease

DMLV1ET	ID	DMLV1ET
DMLV1ET	DN	BIIB074
DMLV1ET	HS	Phase 2
DMLV1ET	SN	CNV1014082; BC600719; HY-12796; B5927; (5R)-5-(4-[2-
DMLV1ET	CP	Biogen
DMLV1ET	PC	16046068
DMLV1ET	MW	314.4
DMLV1ET	FM	C18H19FN2O2
DMLV1ET	IC	InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1
DMLV1ET	CS	C1C[C@H](N[C@H]1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N
DMLV1ET	IK	JESCETIFNOFKEU-SJORKVTESA-N
DMLV1ET	IU	(2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide
DMLV1ET	CA	CAS 934240-30-9
DMLV1ET	DE	Lumbosacral radiculopathy; Trigeminal neuralgia; Bipolar disorder

DM263RP	ID	DM263RP
DM263RP	DN	BIIB092
DM263RP	HS	Phase 2
DM263RP	CP	Biogen Cambridge, MA
DM263RP	DE	Alzheimer disease; Progressive supranuclear palsy

DM2J36F	ID	DM2J36F
DM2J36F	DN	BILN-2061
DM2J36F	HS	Phase 2
DM2J36F	SN	Ciluprevir; BILN-2061; 300832-84-2; BILN 2061; UNII-75C8DU40T0; CHEMBL297884; 75C8DU40T0; Ciluprevir [USAN:INN]; Ciluprevir (BILN-2061); BILN 2061 ZW; BILN2061; SCHEMBL2524642; BILN-2061-ZW; C40H50N6O8S; (cyclopentoxycarbonylamino)-[[2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy]-dioxo-[ ]carboxylic acid; BDBM50142916; 3548AH; ZINC150339466; AKOS024627485; CS-0339; DB05868; BILN 2061; ; ; BILN 2061ZW; HY-10242; W-5515; F2145-0237
DM2J36F	TC	Antiviral Agents
DM2J36F	DT	Small molecular drug
DM2J36F	PC	9853710
DM2J36F	MW	774.9
DM2J36F	FM	C40H50N6O8S
DM2J36F	IC	InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24-,27-,29+,33+,40-/m1/s1
DM2J36F	CS	CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3)OC)C(=C2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6/C=C\\CCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)O
DM2J36F	IK	PJZPDFUUXKKDNB-KNINVFKUSA-N
DM2J36F	IU	(1S,4R,6S,7Z,14S,18R)-14-(cyclopentyloxycarbonylamino)-18-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
DM2J36F	CA	CAS 300832-84-2
DM2J36F	DE	Hepatitis virus infection

DMAG4SX	ID	DMAG4SX
DMAG4SX	DN	BILR-355
DMAG4SX	HS	Phase 2
DMAG4SX	SN	BILR-355-BS; 11-Ethyl-5-methyl-8-[2-(1-oxidoquinolin-4-yloxy)ethyl]-6,11-dihydro-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
DMAG4SX	DE	Human immunodeficiency virus infection

DM6EIZG	ID	DM6EIZG
DM6EIZG	DN	BIM23A760
DM6EIZG	HS	Phase 2
DM6EIZG	SN	Lonapalene; LONAPALENE; RS-43179; 91431-42-4; UNII-WIF31Q54NJ; WIF31Q54NJ; CHEMBL36648; Lonapalenum; Lonapaleno; Lonapalenum [Latin]; Lonapaleno [Spanish]; Lonapalene (USAN); Lonapalene [USAN:INN]; RS 43179; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; AC1L1KN9; SCHEMBL120134; ZINC1630; DTXSID00238563; IFWMVQUGSGWCRP-UHFFFAOYSA-N; HY-U00156; BDBM50004677; CS-7197; ZB000377; D04770; 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene
DM6EIZG	CP	Ipsen
DM6EIZG	DT	Small molecular drug
DM6EIZG	PC	56237
DM6EIZG	MW	338.74
DM6EIZG	FM	C16H15ClO6
DM6EIZG	IC	InChI=1S/C16H15ClO6/c1-8(18)22-13-11-6-5-10(17)7-12(11)14(23-9(2)19)16(21-4)15(13)20-3/h5-7H,1-4H3
DM6EIZG	CS	CC(=O)OC1=C(C(=C(C2=C1C=CC(=C2)Cl)OC(=O)C)OC)OC
DM6EIZG	IK	IFWMVQUGSGWCRP-UHFFFAOYSA-N
DM6EIZG	IU	(4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate
DM6EIZG	CA	CAS 91431-42-4
DM6EIZG	DE	Acromegaly; Carcinoid syndrome; Psoriasis vulgaris

DMH7Q4E	ID	DMH7Q4E
DMH7Q4E	DN	Bimagrumab
DMH7Q4E	HS	Phase 2
DMH7Q4E	CP	Novartis
DMH7Q4E	DT	Antibody
DMH7Q4E	DE	Type 2 diabetes

DMBRL19	ID	DMBRL19
DMBRL19	DN	Bimakalim
DMBRL19	HS	Phase 2
DMBRL19	SN	EMD-52692; SR-44866
DMBRL19	CP	Merck KGaA
DMBRL19	DT	Small molecular drug
DMBRL19	PC	60674
DMBRL19	MW	278.3
DMBRL19	FM	C17H14N2O2
DMBRL19	IC	InChI=1S/C17H14N2O2/c1-17(2)10-14(19-8-4-3-5-16(19)20)13-9-12(11-18)6-7-15(13)21-17/h3-10H,1-2H3
DMBRL19	CS	CC1(C=C(C2=C(O1)C=CC(=C2)C#N)N3C=CC=CC3=O)C
DMBRL19	IK	JTVSKASWNROQQF-UHFFFAOYSA-N
DMBRL19	IU	2,2-dimethyl-4-(2-oxopyridin-1-yl)chromene-6-carbonitrile
DMBRL19	CA	CAS 117545-11-6
DMBRL19	DE	Angina pectoris

DMB9LRJ	ID	DMB9LRJ
DMB9LRJ	DN	Bintrafusp alfa
DMB9LRJ	HS	Phase 2
DMB9LRJ	CP	EMD Serono; GlaxoSmithKline
DMB9LRJ	DT	Recombinant protein
DMB9LRJ	DE	Non-small cell lung cancer

DM6N05H	ID	DM6N05H
DM6N05H	DN	BIO-11006
DM6N05H	HS	Phase 2
DM6N05H	CP	BioMarck Pharmaceuticals
DM6N05H	DE	Chronic obstructive pulmonary disease; Non-small-cell lung cancer

DMPNYXQ	ID	DMPNYXQ
DMPNYXQ	DN	BIO-11006
DMPNYXQ	HS	Phase 2
DMPNYXQ	SN	UNII-609AWV0US2; 609AWV0US2; DB14886; (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid; 901117-03-1
DMPNYXQ	CP	BioMarck Pharmaceuticals
DMPNYXQ	DT	Small molecular drug
DMPNYXQ	PC	11622197
DMPNYXQ	MW	1050.2
DMPNYXQ	FM	C46H75N13O15
DMPNYXQ	IC	InChI=1S/C46H75N13O15/c1-24(51-36(64)22-50-28(5)62)39(66)54-31(17-18-35(49)63)41(68)57-33(21-29-13-7-6-8-14-29)43(70)58-34(23-60)44(71)55-30(15-9-11-19-47)42(69)59-37(27(4)61)45(72)53-25(2)38(65)52-26(3)40(67)56-32(46(73)74)16-10-12-20-48/h6-8,13-14,24-27,30-34,37,60-61H,9-12,15-23,47-48H2,1-5H3,(H2,49,63)(H,50,62)(H,51,64)(H,52,65)(H,53,72)(H,54,66)(H,55,71)(H,56,67)(H,57,68)(H,58,70)(H,59,69)(H,73,74)/t24-,25-,26-,27+,30-,31-,32-,33-,34-,37-/m0/s1
DMPNYXQ	CS	C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)C)O
DMPNYXQ	IK	KCSNGWMKFYVMKF-HGYIIGRXSA-N
DMPNYXQ	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid
DMPNYXQ	CA	CAS 901117-03-1
DMPNYXQ	DE	Non-small-cell lung cancer

DMKICA3	ID	DMKICA3
DMKICA3	DN	BIO-1211
DMKICA3	HS	Phase 2
DMKICA3	SN	BIO-1211; BIO 1211; 187735-94-0; UNII-61G4E2353I; CHEMBL88478; 61G4E2353I; BIO1211; GTPL6589; SCHEMBL1223367; MolPort-023-276-985; ZINC3930111; BDBM50074661; AKOS024457866; L-Proline, N-(2-(4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-; L-Proline, N-((4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-
DMKICA3	DT	Small molecular drug
DMKICA3	PC	9961766
DMKICA3	MW	708.8
DMKICA3	FM	C36H48N6O9
DMKICA3	IC	InChI=1S/C36H48N6O9/c1-20(2)17-26(38-29(43)18-23-12-14-24(15-13-23)37-36(51)40-25-10-7-6-9-22(25)5)32(46)39-27(19-30(44)45)33(47)41-31(21(3)4)34(48)42-16-8-11-28(42)35(49)50/h6-7,9-10,12-15,20-21,26-28,31H,8,11,16-19H2,1-5H3,(H,38,43)(H,39,46)(H,41,47)(H,44,45)(H,49,50)(H2,37,40,51)/t26-,27-,28-,31-/m0/s1
DMKICA3	CS	CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)O
DMKICA3	IK	NVVGCQABIHSJSQ-KFZSMJGVSA-N
DMKICA3	IU	(2S)-1-[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-4-methyl-2-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid
DMKICA3	CA	CAS 187735-94-0
DMKICA3	DE	Asthma

DM7PT8R	ID	DM7PT8R
DM7PT8R	DN	BioE-743
DM7PT8R	HS	Phase 2
DM7PT8R	CP	BioElectron Technology Mountain View, CA
DM7PT8R	DE	Leigh syndrome; Pontocerebellar hypoplasia type 6

DM6PBUM	ID	DM6PBUM
DM6PBUM	DN	Birinapant
DM6PBUM	HS	Phase 2
DM6PBUM	SN	Birinapant; 1260251-31-7; Birinapant (TL32711); TL-32711; UNII-6O4Z07B57R; TL 32711; 6O4Z07B57R; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide
DM6PBUM	CP	TetraLogic Pharmaceuticals
DM6PBUM	DT	Small molecular drug
DM6PBUM	PC	49836020
DM6PBUM	MW	806.9
DM6PBUM	FM	C42H56F2N8O6
DM6PBUM	IC	InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1
DM6PBUM	CS	CC[C@@H](C(=O)N1C[C@H](C[C@H]1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)C[C@@H]6C[C@@H](CN6C(=O)[C@H](CC)NC(=O)[C@H](C)NC)O)O)NC(=O)[C@H](C)NC
DM6PBUM	IK	PKWRMUKBEYJEIX-DXXQBUJASA-N
DM6PBUM	IU	(2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide
DM6PBUM	CA	CAS 1260251-31-7
DM6PBUM	DE	Lymphoma; Solid tumour/cancer

DMW76V0	ID	DMW76V0
DMW76V0	DN	Bisantrene
DMW76V0	HS	Phase 2
DMW76V0	SN	39C34M111K; 78186-34-2; 9,10-Anthracendicarbaldehyde bis(2-imidazolin-2-ylhydrazon); 9,10-Anthracenedicarboxaldehyde, bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-; BISANTRENE HYDROCHLORIDE; BRN 0966309; Bisantrene; Bisantrene [INN]; Bisantreno; Bisantreno [INN-Spanish]; Bisantrenum; Bisantrenum [INN-Latin]; CHEMBL25336; CL 216942; N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazono)methyl]-9-anthryl]methyleneamino]-4,5-dihydro-1H-imidazol-2-amine; NSC 337766; UNII-39C34M111K
DMW76V0	DT	Small molecular drug
DMW76V0	PC	5351322
DMW76V0	MW	398.474
DMW76V0	FM	C22H22N8
DMW76V0	IC	InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)/b27-13+,28-14+
DMW76V0	CS	C1CN=C(N1)NN=CC2=C3C=CC=CC3=C(C4=CC=CC=C42)C=NNC5=NCCN5
DMW76V0	IK	NJSMWLQOCQIOPE-OCHFTUDZSA-N
DMW76V0	IU	N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine
DMW76V0	CA	CAS 78186-34-2
DMW76V0	DE	Acute myelogenous leukemia

DMVDO93	ID	DMVDO93
DMVDO93	DN	BL-1020
DMVDO93	HS	Phase 2
DMVDO93	SN	BL 1020; Perphenazine 4-aminobutyrate; Butanoic acid, 4-amino-, 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
DMVDO93	CP	BioLineRx
DMVDO93	DT	Small molecular drug
DMVDO93	PC	11203271
DMVDO93	MW	489.1
DMVDO93	FM	C25H33ClN4O2S
DMVDO93	IC	InChI=1S/C25H33ClN4O2S/c26-20-8-9-24-22(19-20)30(21-5-1-2-6-23(21)33-24)12-4-11-28-13-15-29(16-14-28)17-18-32-25(31)7-3-10-27/h1-2,5-6,8-9,19H,3-4,7,10-18,27H2
DMVDO93	CS	C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCOC(=O)CCCN
DMVDO93	IK	BABFYCSPNDKXRI-UHFFFAOYSA-N
DMVDO93	IU	2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate
DMVDO93	CA	CAS 751477-01-7
DMVDO93	DE	Schizophrenia

DM8R71T	ID	DM8R71T
DM8R71T	DN	BL-22
DM8R71T	HS	Phase 2
DM8R71T	SN	CAT-3888; GCR-3888; RFB4(dsFv)-PE38; PE38-conjugated anti-CD22 immunotoxin, NCI/Cambridge Antibody Technology/AstraZeneca
DM8R71T	CP	National Cancer Institute
DM8R71T	DT	Antibody
DM8R71T	DE	Acute lymphoblastic leukaemia

DMSBPJI	ID	DMSBPJI
DMSBPJI	DN	BL-7040
DMSBPJI	HS	Phase 2
DMSBPJI	SN	Monarsen; EN-101; TLR-9 activator (oral, inflammatory bowel disease), BioLineRx; TLR-9 activator (oral, inflammatory bowel disease), Hebrew University of Jerusalem
DMSBPJI	CP	Yissum Research Development Co
DMSBPJI	DT	Small molecular drug
DMSBPJI	PC	56841946
DMSBPJI	MW	6375
DMSBPJI	FM	C194H253N64O106P19S19
DMSBPJI	IC	InChI=1S/C194H253N64O106P19S19/c1-78-45-248(189(279)233-165(78)261)137-35-91(108(333-137)58-307-365(285,384)346-84-28-130(326-101(84)51-259)239-19-10-121(195)218-180(239)270)357-375(295,394)321-66-116-98(42-144(341-116)255-74-215-149-162(255)227-177(206)230-171(149)267)360-378(298,397)312-56-106-85(29-131(331-106)240-20-11-122(196)219-181(240)271)347-366(286,385)308-52-102-88(32-134(327-102)243-23-14-125(199)222-184(243)274)350-369(289,388)319-64-114-97(41-143(339-114)254-73-213-147-158(204)209-71-211-160(147)254)359-377(297,396)311-55-105-89(33-135(330-105)244-24-15-126(200)223-185(244)275)351-370(290,389)320-65-115-100(44-146(340-115)257-76-217-151-164(257)229-179(208)232-173(151)269)362-380(300,399)318-63-113-95(39-141(338-113)252-49-82(5)169(265)237-193(252)283)356-374(294,393)316-61-111-93(37-139(336-111)250-47-80(3)167(263)235-191(250)281)354-372(292,391)310-54-104-86(30-132(329-104)241-21-12-123(197)220-182(241)272)348-367(287,386)314-59-109-92(36-138(334-109)249-46-79(2)166(262)234-190(249)280)353-371(291,390)309-53-103-87(31-133(328-103)242-22-13-124(198)221-183(242)273)349-368(288,387)315-60-110-94(38-140(335-110)251-48-81(4)168(264)236-192(251)282)355-373(293,392)317-62-112-96(40-142(337-112)253-50-83(6)170(266)238-194(253)284)358-376(296,395)322-67-117-99(43-145(342-117)256-75-216-150-163(256)228-178(207)231-172(150)268)361-379(299,398)313-57-107-90(34-136(332-107)245-25-16-127(201)224-186(245)276)352-381(301,400)324-69-120-154(157(306-9)176(345-120)258-77-214-148-159(205)210-72-212-161(148)258)364-383(303,402)325-70-119-153(156(305-8)175(344-119)247-27-18-129(203)226-188(247)278)363-382(302,401)323-68-118-152(260)155(304-7)174(343-118)246-26-17-128(202)225-187(246)277/h10-27,45-50,71-77,84-120,130-146,152-157,174-176,259-260H,28-44,51-70H2,1-9H3,(H,285,384)(H,286,385)(H,287,386)(H,288,387)(H,289,388)(H,290,389)(H,291,390)(H,292,391)(H,293,392)(H,294,393)(H,295,394)(H,296,395)(H,297,396)(H,298,397)(H,299,398)(H,300,399)(H,301,400)(H,302,401)(H,303,402)(H2,195,218,270)(H2,196,219,271)(H2,197,220,272)(H2,198,221,273)(H2,199,222,274)(H2,200,223,275)(H2,201,224,276)(H2,202,225,277)(H2,203,226,278)(H2,204,209,211)(H2,205,210,212)(H,233,261,279)(H,234,262,280)(H,235,263,281)(H,236,264,282)(H,237,265,283)(H,238,266,284)(H3,206,227,230,267)(H3,207,228,231,268)(H3,208,229,232,269)
DMSBPJI	CS	CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3CO)N4C=CC(=NC4=O)N)OP(=S)(O)OCC5C(CC(O5)N6C=NC7=C6N=C(NC7=O)N)OP(=S)(O)OCC8C(CC(O8)N9C=CC(=NC9=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)O
DMSBPJI	IK	QJYMZHMIZZYHBI-UHFFFAOYSA-N
DMSBPJI	IU	1-[4-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMSBPJI	DE	Inflammatory bowel disease

DMKO0BQ	ID	DMKO0BQ
DMKO0BQ	DN	BLD-2660
DMKO0BQ	HS	Phase 2 
DMKO0BQ	SN	BLD 2660
DMKO0BQ	TC	Antiviral Agents
DMKO0BQ	DT	Small molecular drug
DMKO0BQ	DE	Coronavirus Disease 2019 (COVID-19)

DMYK1DR	ID	DMYK1DR
DMYK1DR	DN	BLI-1005
DMYK1DR	HS	Phase 2
DMYK1DR	CP	BioLite Taipei, Taiwan
DMYK1DR	DE	Major depressive disorder

DMG1LVA	ID	DMG1LVA
DMG1LVA	DN	BLZ-945
DMG1LVA	HS	Phase 2
DMG1LVA	SN	CSF-1R inhibitor (bone cancer); CSF-1R inhibitor (bone cancer), Novartis
DMG1LVA	CP	Novartis Institutes for BioMedical Research Inc
DMG1LVA	DT	Small molecular drug
DMG1LVA	PC	46184986
DMG1LVA	MW	398.5
DMG1LVA	FM	C20H22N4O3S
DMG1LVA	IC	InChI=1S/C20H22N4O3S/c1-21-19(26)16-10-13(8-9-22-16)27-12-6-7-15-18(11-12)28-20(24-15)23-14-4-2-3-5-17(14)25/h6-11,14,17,25H,2-5H2,1H3,(H,21,26)(H,23,24)/t14-,17-/m1/s1
DMG1LVA	CS	CNC(=O)C1=NC=CC(=C1)OC2=CC3=C(C=C2)N=C(S3)N[C@@H]4CCCC[C@H]4O
DMG1LVA	IK	ADZBMFGQQWPHMJ-RHSMWYFYSA-N
DMG1LVA	IU	4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide
DMG1LVA	CA	CAS 953769-46-5
DMG1LVA	DE	Solid tumour/cancer; Amyotrophic lateral sclerosis

DMQI43G	ID	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	HS	Phase 2
DMQI43G	SN	Asunaprevir; 630420-16-5; BMS-650032; UNII-S9X0KRJ00S; BMS 650032; S9X0KRJ00S; Asunaprevir (BMS-650032); N-(Tert-Butoxycarbonyl)-3-Methyl-L-Valyl-(4r)-4-[(7-Chloro-4-Methoxyisoquinolin-1-Yl)oxy]-N-{(1r,2s)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-Ethenylcyclopropyl}-L-Prolinamide; Asunaprevir [USAN:INN]; Sunvepra (TN); tert-butyl N-[(1S)-1-[(2S,4R)-4-[(7-chloro-4-methoxy-1-isoquinolyl)oxy]-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]carbamate; 2R9
DMQI43G	CP	Bristol-Myers Squibb
DMQI43G	DT	Small molecular drug
DMQI43G	PC	16076883
DMQI43G	MW	748.3
DMQI43G	FM	C35H46ClN5O9S
DMQI43G	IC	InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1
DMQI43G	CS	CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
DMQI43G	IK	XRWSZZJLZRKHHD-WVWIJVSJSA-N
DMQI43G	IU	tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
DMQI43G	CA	CAS 630420-16-5
DMQI43G	CB	CHEBI:134723
DMQI43G	DE	Hepatitis C virus infection

DMKH4PI	ID	DMKH4PI
DMKH4PI	DN	BMS 791325
DMKH4PI	HS	Phase 2
DMKH4PI	SN	BMS-791325
DMKH4PI	CP	Bristol-Myers Squibb
DMKH4PI	DT	Small molecular drug
DMKH4PI	PC	56934415
DMKH4PI	MW	659.8
DMKH4PI	FM	C36H45N5O5S
DMKH4PI	IC	InChI=1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24-,25+,30-,36-/m0/s1
DMKH4PI	CS	CN1C[C@H]2CC[C@@H](C1)N2C(=O)[C@]34C[C@H]3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8
DMKH4PI	IK	ZTTKEBYSXUCBSE-QDFUAKMASA-N
DMKH4PI	IU	(8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-[(1S,5R)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl]-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide
DMKH4PI	CA	CAS 958002-33-0
DMKH4PI	DE	Hepatitis C virus infection

DMDPLEM	ID	DMDPLEM
DMDPLEM	DN	BMS-184476
DMDPLEM	HS	Phase 2
DMDPLEM	SN	10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; 7-O-(Methylsulfanylmethyl)paclitaxel
DMDPLEM	DT	Small molecular drug
DMDPLEM	PC	6918461
DMDPLEM	MW	914
DMDPLEM	FM	C49H55NO14S
DMDPLEM	IC	InChI=1S/C49H55NO14S/c1-27-33(62-45(57)38(53)37(30-17-11-8-12-18-30)50-43(55)31-19-13-9-14-20-31)24-49(58)42(63-44(56)32-21-15-10-16-22-32)40-47(6,41(54)39(61-28(2)51)36(27)46(49,4)5)34(60-26-65-7)23-35-48(40,25-59-35)64-29(3)52/h8-22,33-35,37-40,42,53,58H,23-26H2,1-7H3,(H,50,55)/t33-,34-,35+,37-,38+,39+,40-,42-,47+,48-,49+/m0/s1
DMDPLEM	CS	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)OCSC)C)OC(=O)C
DMDPLEM	IK	UBJAHGAUPNGZFF-XOVTVWCYSA-N
DMDPLEM	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-10,14,17,17-tetramethyl-9-(methylsulfanylmethoxy)-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMDPLEM	CA	CAS 160237-25-2
DMDPLEM	DE	Solid tumour/cancer

DML1CK2	ID	DML1CK2
DML1CK2	DN	BMS-188797
DML1CK2	HS	Phase 2
DML1CK2	SN	11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; 4-O-Deacetyl-4-O-(methoxycarbonyl)paclitaxel
DML1CK2	DT	Small molecular drug
DML1CK2	PC	6918494
DML1CK2	MW	869.9
DML1CK2	FM	C47H51NO15
DML1CK2	IC	InChI=1S/C47H51NO15/c1-25-30(61-42(55)35(51)34(27-16-10-7-11-17-27)48-40(53)28-18-12-8-13-19-28)23-47(57)39(62-41(54)29-20-14-9-15-21-29)37-45(5,38(52)36(60-26(2)49)33(25)44(47,3)4)31(50)22-32-46(37,24-59-32)63-43(56)58-6/h7-21,30-32,34-37,39,50-51,57H,22-24H2,1-6H3,(H,48,53)/t30-,31-,32+,34-,35+,36+,37-,39-,45+,46-,47+/m0/s1
DML1CK2	CS	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)OC)O)C)OC(=O)C
DML1CK2	IK	GMJWGJSDPOAZTP-MIDYMNAOSA-N
DML1CK2	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-12-acetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DML1CK2	CA	CAS 172481-83-3
DML1CK2	DE	Solid tumour/cancer

DMJUV6C	ID	DMJUV6C
DMJUV6C	DN	BMS-223131
DMJUV6C	HS	Phase 2
DMJUV6C	SN	4-(5-Chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)quinolin-2(1H)-one
DMJUV6C	PC	9951995
DMJUV6C	MW	383.7
DMJUV6C	FM	C18H13ClF3NO3
DMJUV6C	IC	InChI=1S/C18H13ClF3NO3/c19-10-2-4-15(25)13(8-10)16-11(5-6-24)17(26)23-14-3-1-9(7-12(14)16)18(20,21)22/h1-4,7-8,24-25H,5-6H2,(H,23,26)
DMJUV6C	CS	C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O
DMJUV6C	IK	QESHSZWKJULSAR-UHFFFAOYSA-N
DMJUV6C	IU	4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-1H-quinolin-2-one
DMJUV6C	CA	CAS 275375-69-4
DMJUV6C	DE	Erectile dysfunction

DMQL3VS	ID	DMQL3VS
DMQL3VS	DN	BMS-275183
DMQL3VS	HS	Phase 2
DMQL3VS	SN	BMS-198246; Oral taxane (cancer), BMS; Oral taxane (cancer), Bristol-Myers Squibb
DMQL3VS	CP	Bristol-Myers Squibb Co
DMQL3VS	DT	Small molecular drug
DMQL3VS	PC	6918594
DMQL3VS	MW	845.9
DMQL3VS	FM	C43H59NO16
DMQL3VS	IC	InChI=1S/C43H59NO16/c1-21-24(57-35(50)28(47)31(38(3,4)5)44-36(51)59-39(6,7)8)19-43(53)33(58-34(49)23-16-14-13-15-17-23)30-41(11,32(48)29(56-22(2)45)27(21)40(43,9)10)25(46)18-26-42(30,20-55-26)60-37(52)54-12/h13-17,24-26,28-31,33,46-47,53H,18-20H2,1-12H3,(H,44,51)/t24-,25-,26+,28+,29+,30-,31+,33-,41+,42-,43+/m0/s1
DMQL3VS	CS	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C(C)(C)C)NC(=O)OC(C)(C)C)O)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)OC)O)C)OC(=O)C
DMQL3VS	IK	AHXICHPPXIGCBN-GPWPDEGDSA-N
DMQL3VS	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-12-acetyloxy-1,9-dihydroxy-15-[(2R,3S)-2-hydroxy-4,4-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]oxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMQL3VS	CA	CAS 355113-98-3
DMQL3VS	DE	Solid tumour/cancer

DMGYXFP	ID	DMGYXFP
DMGYXFP	DN	BMS-582949
DMGYXFP	HS	Phase 2
DMGYXFP	SN	BMS-582949; 623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; PS540446; BMS582949 free base; PS 540446
DMGYXFP	CP	Bristol-Myers Squibb
DMGYXFP	DT	Small molecular drug
DMGYXFP	PC	10409068
DMGYXFP	MW	406.5
DMGYXFP	FM	C22H26N6O2
DMGYXFP	IC	InChI=1S/C22H26N6O2/c1-4-9-23-22(30)17-11-28-19(14(17)3)20(24-12-25-28)27-18-10-15(6-5-13(18)2)21(29)26-16-7-8-16/h5-6,10-12,16H,4,7-9H2,1-3H3,(H,23,30)(H,26,29)(H,24,25,27)
DMGYXFP	CS	CCCNC(=O)C1=CN2C(=C1C)C(=NC=N2)NC3=C(C=CC(=C3)C(=O)NC4CC4)C
DMGYXFP	IK	GDTQLZHHDRRBEB-UHFFFAOYSA-N
DMGYXFP	IU	4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
DMGYXFP	CA	CAS 623152-17-0
DMGYXFP	DE	Psoriasis vulgaris; Atherosclerosis

DMDPQV5	ID	DMDPQV5
DMDPQV5	DN	BMS-599626
DMDPQV5	HS	Phase 2
DMDPQV5	SN	BMS-599626; 714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703
DMDPQV5	CP	Bristol Myers Squibb
DMDPQV5	TC	Anticancer Agents
DMDPQV5	DT	Small molecular drug
DMDPQV5	PC	10437018
DMDPQV5	MW	530.6
DMDPQV5	FM	C27H27FN8O3
DMDPQV5	IC	InChI=1S/C27H27FN8O3/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33)/t22-/m0/s1
DMDPQV5	CS	CC1=C2C(=NC=NN2C=C1NC(=O)OC[C@@H]3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F
DMDPQV5	IK	LUJZZYWHBDHDQX-QFIPXVFZSA-N
DMDPQV5	IU	[(3S)-morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate
DMDPQV5	CA	CAS 714971-09-2
DMDPQV5	DE	Solid tumour/cancer

DMX302C	ID	DMX302C
DMX302C	DN	BMS-690514
DMX302C	HS	Phase 2
DMX302C	SN	BMS 690514; BMS690514
DMX302C	DT	Small molecular drug
DMX302C	PC	11349170
DMX302C	MW	368.4
DMX302C	FM	C19H24N6O2
DMX302C	IC	InChI=1S/C19H24N6O2/c1-27-15-4-2-3-14(9-15)23-19-18-13(5-8-25(18)22-12-21-19)10-24-7-6-16(20)17(26)11-24/h2-5,8-9,12,16-17,26H,6-7,10-11,20H2,1H3,(H,21,22,23)/t16-,17-/m1/s1
DMX302C	CS	COC1=CC=CC(=C1)NC2=NC=NN3C2=C(C=C3)CN4CC[C@H]([C@@H](C4)O)N
DMX302C	IK	CSGQVNMSRKWUSH-IAGOWNOFSA-N
DMX302C	IU	(3R,4R)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
DMX302C	CA	CAS 859853-30-8
DMX302C	DE	Chronic pain

DM51LTG	ID	DM51LTG
DM51LTG	DN	BMS-708163
DM51LTG	HS	Phase 2
DM51LTG	SN	Avagacestat
DM51LTG	CP	Bristol-Myers Squibb
DM51LTG	DT	Small molecular drug
DM51LTG	PC	46883536
DM51LTG	MW	520.9
DM51LTG	FM	C20H17ClF4N4O4S
DM51LTG	IC	InChI=1S/C20H17ClF4N4O4S/c21-14-3-5-15(6-4-14)34(31,32)29(17(18(26)30)7-8-20(23,24)25)10-13-2-1-12(9-16(13)22)19-27-11-33-28-19/h1-6,9,11,17H,7-8,10H2,(H2,26,30)/t17-/m1/s1
DM51LTG	CS	C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)[C@H](CCC(F)(F)F)C(=O)N)Cl
DM51LTG	IK	XEAOPVUAMONVLA-QGZVFWFLSA-N
DM51LTG	IU	(2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide
DM51LTG	CA	CAS 1146699-66-2
DM51LTG	DE	Alzheimer disease

DMTVGY7	ID	DMTVGY7
DMTVGY7	DN	BMS-770767
DMTVGY7	HS	Phase 2
DMTVGY7	CP	Bristol-Myers Squibb
DMTVGY7	DE	Hypercholesterolaemia

DMKY638	ID	DMKY638
DMKY638	DN	BMS-813160
DMKY638	HS	Phase 2
DMKY638	SN	BMS-585059; CCR2/CCR5 chemokine antagonist (immune disorders, cardiovascular disorders), BMS; CCR2/CCR5 dual antagonist (cardiovascular disease), Bristol-Myers Squibb; CCR2/CCR5 dual antagonist (immunology), Bristol-Myers Squibb
DMKY638	CP	Bristol-myers squibb
DMKY638	PC	51039119
DMKY638	MW	484.6
DMKY638	FM	C25H40N8O2
DMKY638	IC	InChI=1S/C25H40N8O2/c1-15(34)28-18-12-16(30-25(5,6)7)8-9-19(18)32-11-10-17(22(32)35)29-23-27-14-26-21-13-20(24(2,3)4)31-33(21)23/h13-14,16-19,30H,8-12H2,1-7H3,(H,28,34)(H,26,27,29)/t16-,17+,18-,19+/m1/s1
DMKY638	CS	CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N2CC[C@@H](C2=O)NC3=NC=NC4=CC(=NN43)C(C)(C)C)NC(C)(C)C
DMKY638	IK	CMVHFGNTABZQJU-HCXYKTFWSA-N
DMKY638	IU	N-[(1R,2S,5R)-5-(tert-butylamino)-2-[(3S)-3-[(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino]-2-oxopyrrolidin-1-yl]cyclohexyl]acetamide
DMKY638	CA	CAS 1286279-29-5
DMKY638	DE	Diabetic nephropathy; Solid tumour/cancer

DMT8L6P	ID	DMT8L6P
DMT8L6P	DN	BMS-817399
DMT8L6P	HS	Phase 2
DMT8L6P	CP	Bristol-Myers Squibb
DMT8L6P	PC	44537841
DMT8L6P	MW	454
DMT8L6P	FM	C23H36ClN3O4
DMT8L6P	IC	InChI=1S/C23H36ClN3O4/c1-15(2)18(26-20(29)25-13-22(5,6)30)19(28)27-12-11-23(31,21(3,4)14-27)16-7-9-17(24)10-8-16/h7-10,15,18,30-31H,11-14H2,1-6H3,(H2,25,26,29)/t18-,23+/m1/s1
DMT8L6P	CS	CC(C)[C@H](C(=O)N1CC[C@@](C(C1)(C)C)(C2=CC=C(C=C2)Cl)O)NC(=O)NCC(C)(C)O
DMT8L6P	IK	GTDPZONCGOCXOD-JPYJTQIMSA-N
DMT8L6P	IU	1-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-(2-hydroxy-2-methylpropyl)urea
DMT8L6P	CA	CAS 1202400-18-7
DMT8L6P	DE	Rheumatoid arthritis

DMF46PD	ID	DMF46PD
DMF46PD	DN	BMS-911543
DMF46PD	HS	Phase 2
DMF46PD	SN	BMS-911543; 1271022-90-2; BMS 911543; BMS911543; UNII-7N03P021J8; 7N03P021J8; N,N-Dicyclopropyl-4-[(1,5-Dimethyl-1h-Pyrazol-3-Yl)amino]-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-Carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide; JCINBYQJBYJGDM-UHFFFAOYSA-N
DMF46PD	CP	Bristol-Myers Squibb
DMF46PD	DT	Small molecular drug
DMF46PD	PC	50922691
DMF46PD	MW	432.5
DMF46PD	FM	C23H28N8O
DMF46PD	IC	InChI=1S/C23H28N8O/c1-5-30-17(23(32)31(14-6-7-14)15-8-9-15)11-16-20-19(24-12-28(20)3)21(26-22(16)30)25-18-10-13(2)29(4)27-18/h10-12,14-15H,5-9H2,1-4H3,(H,25,26,27)
DMF46PD	CS	CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6
DMF46PD	IK	JCINBYQJBYJGDM-UHFFFAOYSA-N
DMF46PD	IU	N,N-dicyclopropyl-7-[(1,5-dimethylpyrazol-3-yl)amino]-10-ethyl-3-methyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaene-11-carboxamide
DMF46PD	CA	CAS 1271022-90-2
DMF46PD	DE	Myelofibrosis

DMN28WK	ID	DMN28WK
DMN28WK	DN	BMS-919373
DMN28WK	HS	Phase 2
DMN28WK	CP	Bristol-myers squibb
DMN28WK	PC	51030730
DMN28WK	MW	468.5
DMN28WK	FM	C25H20N6O2S
DMN28WK	IC	InChI=1S/C25H20N6O2S/c26-34(32,33)20-13-18(14-27-16-20)24-30-22-11-6-10-21(17-7-2-1-3-8-17)23(22)25(31-24)29-15-19-9-4-5-12-28-19/h1-14,16H,15H2,(H2,26,32,33)(H,29,30,31)
DMN28WK	CS	C1=CC=C(C=C1)C2=C3C(=CC=C2)N=C(N=C3NCC4=CC=CC=N4)C5=CC(=CN=C5)S(=O)(=O)N
DMN28WK	IK	XGKULQQVQWCASY-UHFFFAOYSA-N
DMN28WK	IU	5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide
DMN28WK	CA	CAS 1272353-82-8
DMN28WK	DE	Atrial fibrillation

DMUTS1W	ID	DMUTS1W
DMUTS1W	DN	BMS-936557
DMUTS1W	HS	Phase 2
DMUTS1W	SN	Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex
DMUTS1W	CP	Medarex Inc
DMUTS1W	DT	Antibody
DMUTS1W	DE	Immune System disease

DM7XV4R	ID	DM7XV4R
DM7XV4R	DN	BMS-954561
DM7XV4R	HS	Phase 2
DM7XV4R	SN	AGN-001; AGN-209323; AGN-2XXXXX; AGN-323; EHT-001; EHT/AGN-0001; EHT/AGN-001; GABA/nicotinic modulator (neuroscience), BMS; Neuropathic pain therapy, ExonHit/Allergan/Bristol-Myers Squibb
DM7XV4R	CP	Exonhit
DM7XV4R	DE	Diabetic neuropathy

DMMEAGO	ID	DMMEAGO
DMMEAGO	DN	BMS-955176
DMMEAGO	HS	Phase 2
DMMEAGO	CP	Bristol-myers squibb
DMMEAGO	DE	Human immunodeficiency virus-1 infection

DMVJXOH	ID	DMVJXOH
DMVJXOH	DN	BMS-986012
DMVJXOH	HS	Phase 2
DMVJXOH	CP	Bristol-Myers Squibb
DMVJXOH	DT	Antibody
DMVJXOH	DE	Small-cell lung cancer; Solid tumour/cancer

DMHMV6E	ID	DMHMV6E
DMHMV6E	DN	BMS-986020
DMHMV6E	HS	Phase 2
DMHMV6E	SN	GQBRZBHEPUQRPL-LJQANCHMSA-N; 1257213-50-5; AP-3152 free acid; UNII-38CTP01B4L; 38CTP01B4L; SCHEMBL344742; GTPL9498; EX-A866; MolPort-044-616-249; ZINC113624125; AKOS030631907; CS-5844; AS-35060; HY-100619; FT-0700148; J-690107; Cyclopropanecarboxylic acid, 1-(4'-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1'-biphenyl)-4-yl)-; 1-{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonyl
DMHMV6E	CP	Bristol-Myers SquibbPrinceton, NJ
DMHMV6E	PC	49792850
DMHMV6E	MW	482.5
DMHMV6E	FM	C29H26N2O5
DMHMV6E	IC	InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1
DMHMV6E	CS	CC1=NOC(=C1NC(=O)O[C@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O
DMHMV6E	IK	GQBRZBHEPUQRPL-LJQANCHMSA-N
DMHMV6E	IU	1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid
DMHMV6E	CA	CAS 1257213-50-5
DMHMV6E	DE	Psoriasis vulgaris; Scleroderma

DMIZKEC	ID	DMIZKEC
DMIZKEC	DN	BMS-986036
DMIZKEC	HS	Phase 2
DMIZKEC	CP	Bristol-Myers Squibb Princeton, NJ
DMIZKEC	DE	Type-2 diabetes

DMTKDIP	ID	DMTKDIP
DMTKDIP	DN	BMS-986141
DMTKDIP	HS	Phase 2
DMTKDIP	SN	UNII-W530IRZ40G; W530IRZ40G; UDM-003183; 1478711-48-6; 4-(4-(((6-Methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)thiazol-2-yl)-N,N-dimethylbenzamide; CHEMBL3716552; SCHEMBL15348940; BDBM176003; DB14942; US9688695, 36; 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-1,3-thiazol-2-yl]-N,N-dimethylbenzamide; Benzamide, 4-(4-(((6-methoxy-2-(2-methoxyimidazo(2,1-b)-1,3,4-thiadiazol-6-yl)-4-benzofuranyl)oxy)methyl)-2-thiazolyl)-N,N-dimethyl-
DMTKDIP	CP	Bristol-Myers Squibb
DMTKDIP	DT	Small molecular drug
DMTKDIP	PC	72188743
DMTKDIP	MW	561.6
DMTKDIP	FM	C27H23N5O5S2
DMTKDIP	IC	InChI=1S/C27H23N5O5S2/c1-31(2)25(33)16-7-5-15(6-8-16)24-28-17(14-38-24)13-36-21-9-18(34-3)10-22-19(21)11-23(37-22)20-12-32-26(29-20)39-27(30-32)35-4/h5-12,14H,13H2,1-4H3
DMTKDIP	CS	CN(C)C(=O)C1=CC=C(C=C1)C2=NC(=CS2)COC3=CC(=CC4=C3C=C(O4)C5=CN6C(=N5)SC(=N6)OC)OC
DMTKDIP	IK	KEEBLYWBELVGPQ-UHFFFAOYSA-N
DMTKDIP	IU	4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-1,3-thiazol-2-yl]-N,N-dimethylbenzamide
DMTKDIP	CA	CAS 1478711-48-6
DMTKDIP	DE	Thrombosis

DMZB8AJ	ID	DMZB8AJ
DMZB8AJ	DN	BMS-986142
DMZB8AJ	HS	Phase 2
DMZB8AJ	SN	Unii-pjx9GH268R; UNII-PJX9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide
DMZB8AJ	CP	Bristol-Myers SquibbPrinceton, NJ
DMZB8AJ	PC	86582336
DMZB8AJ	MW	572.6
DMZB8AJ	FM	C32H30F2N4O4
DMZB8AJ	IC	InChI=1S/C32H30F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-10,14,16,36,42H,11-13H2,1-4H3,(H2,35,39)/t16-/m0/s1
DMZB8AJ	CS	CC1=C(C=CC=C1N2C(=O)C3=C(C(=CC=C3)F)N(C2=O)C)C4=C(C=C(C5=C4C6=C(N5)C[C@H](CC6)C(C)(C)O)C(=O)N)F
DMZB8AJ	IK	ZRYMMWAJAFUANM-INIZCTEOSA-N
DMZB8AJ	IU	(7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide
DMZB8AJ	CA	CAS 1643368-58-4
DMZB8AJ	DE	Rheumatoid arthritis

DM4QHZS	ID	DM4QHZS
DM4QHZS	DN	BMS-986177
DM4QHZS	HS	Phase 2
DM4QHZS	SN	Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2
DM4QHZS	CP	Bristol-Myers Squibb
DM4QHZS	DT	Small molecular drug
DM4QHZS	PC	118277544
DM4QHZS	MW	626.4
DM4QHZS	FM	C28H23Cl2F2N9O2
DM4QHZS	IC	InChI=1S/C28H23Cl2F2N9O2/c1-15-3-2-4-23(20-9-16(7-8-33-20)26-21(36-27(15)43)12-35-41(26)28(31)32)39-14-34-19(11-25(39)42)18-10-17(29)5-6-22(18)40-13-24(30)37-38-40/h5-15,23,28H,2-4H2,1H3,(H,36,43)/t15-,23+/m1/s1
DM4QHZS	CS	C[C@@H]1CCC[C@@H](C2=NC=CC(=C2)C3=C(C=NN3C(F)F)NC1=O)N4C=NC(=CC4=O)C5=C(C=CC(=C5)Cl)N6C=C(N=N6)Cl
DM4QHZS	IK	FSWFYCYPTDLKON-CMJOXMDJSA-N
DM4QHZS	IU	(9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
DM4QHZS	CA	CAS 1802425-99-5
DM4QHZS	DE	Thrombosis; Cerebral ischemia

DM42B0C	ID	DM42B0C
DM42B0C	DN	BMS-986253
DM42B0C	HS	Phase 2
DM42B0C	CP	Bristol-Myers Squibb
DM42B0C	DT	Antibody
DM42B0C	DE	Solid tumour/cancer; Coronavirus Disease 2019 (COVID-19)

DM5OU2W	ID	DM5OU2W
DM5OU2W	DN	BMS-986253
DM5OU2W	HS	Phase 2 
DM5OU2W	SN	Humax-inflam; HuMax-IL8; Humax-IL-8; UNII-N0YWS8X3S9; N0YWS8X3S9; MDX-018; BMS-986253; anti-Il-8 monoclonal antibody humax-IL8; 2231258-73-2
DM5OU2W	TC	Antiviral Agents
DM5OU2W	DT	Monoclonal antibody
DM5OU2W	DE	Coronavirus Disease 2019 (COVID-19)

DMSRVXO	ID	DMSRVXO
DMSRVXO	DN	BMS-986263
DMSRVXO	HS	Phase 2
DMSRVXO	SN	ND L02 s0201
DMSRVXO	CP	Bristol-Myers Squibb
DMSRVXO	DT	Small interfering RNA
DMSRVXO	DE	Hepatic fibrosis

DMUM2KA	ID	DMUM2KA
DMUM2KA	DN	BN82451
DMUM2KA	HS	Phase 2
DMUM2KA	SN	UNII-531B661QBY; 335242-75-6; BN-82451; 531B661QBY; 4-(2-(Aminomethyl)-1,3-thiazol-4-yl)-2,6-di(tert-butyl)phenol; Phenol,4-2-(aminomethyl)-4-thiazolyl-2,6-bis(1,1-dimethyl ethyl)-; 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di(tert-butyl)phenol; SCHEMBL197161; HAQOEWGSBVQDHB-UHFFFAOYSA-N; Phenol, 4-(2-(aminomethyl)-4-thiazolyl)-2,6-bis(1,1-dimethylethyl)-; SB17395; KB-59536
DMUM2KA	CP	Ipsen
DMUM2KA	DT	Small molecular drug
DMUM2KA	PC	72941952
DMUM2KA	MW	354.9
DMUM2KA	FM	C18H27ClN2OS
DMUM2KA	IC	InChI=1S/C18H26N2OS.ClH/c1-17(2,3)12-7-11(14-10-22-15(9-19)20-14)8-13(16(12)21)18(4,5)6;/h7-8,10,21H,9,19H2,1-6H3;1H
DMUM2KA	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C2=CSC(=N2)CN.Cl
DMUM2KA	IK	WPWBWGUPSJCKKF-UHFFFAOYSA-N
DMUM2KA	IU	4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-ditert-butylphenol;hydrochloride
DMUM2KA	CA	CAS 918656-59-4
DMUM2KA	DE	Parkinson disease

DMJC8DR	ID	DMJC8DR
DMJC8DR	DN	BNC-105
DMJC8DR	HS	Phase 2
DMJC8DR	SN	BNC-105P; IL-0035; IL-0049; Combretastatin A4 analogs (cancer), Bionomics; VDAs (cancer), Bionomics; Vascular disruption agents (cancer), Bionomics; Vascular targeting agents (cancer), Bionomics
DMJC8DR	CP	Iliad Chemicals Pty Ltd
DMJC8DR	DT	Small molecular drug
DMJC8DR	PC	24786555
DMJC8DR	MW	372.4
DMJC8DR	FM	C20H20O7
DMJC8DR	IC	InChI=1S/C20H20O7/c1-10-16(12-6-7-13(23-2)18(22)19(12)27-10)17(21)11-8-14(24-3)20(26-5)15(9-11)25-4/h6-9,22H,1-5H3
DMJC8DR	CS	CC1=C(C2=C(O1)C(=C(C=C2)OC)O)C(=O)C3=CC(=C(C(=C3)OC)OC)OC
DMJC8DR	IK	RADMJHVVIZTENA-UHFFFAOYSA-N
DMJC8DR	IU	(7-hydroxy-6-methoxy-2-methyl-1-benzofuran-3-yl)-(3,4,5-trimethoxyphenyl)methanone
DMJC8DR	CA	CAS 945771-74-4
DMJC8DR	DE	Mesothelioma

DMEGDWA	ID	DMEGDWA
DMEGDWA	DN	BNC-210
DMEGDWA	HS	Phase 2
DMEGDWA	SN	BNC-10002; GABA-A modulators (oral, anxiety), Bionomics
DMEGDWA	CP	Bionomics Ltd
DMEGDWA	DE	Anxiety disorder

DMRWG8B	ID	DMRWG8B
DMRWG8B	DN	BNT321
DMRWG8B	HS	Phase 2
DMRWG8B	SN	MVT-5873
DMRWG8B	CP	BioNTech
DMRWG8B	DT	Antibody
DMRWG8B	DE	Pancreatic cancer

DM8JQZC	ID	DM8JQZC
DM8JQZC	DN	BNZ-1
DM8JQZC	HS	Phase 2
DM8JQZC	CP	Bioniz Therapeutics
DM8JQZC	DT	Peptide
DM8JQZC	DE	Cutaneous T-cell lymphoma; T-cell leukaemia; Large granular lymphocytic leukemia

DMZ70GE	ID	DMZ70GE
DMZ70GE	DN	BOS-228
DMZ70GE	HS	Phase 2
DMZ70GE	CP	Boston Pharmaceuticals
DMZ70GE	DT	Small molecular drug
DMZ70GE	DE	Bacterial infection

DMKDGI8	ID	DMKDGI8
DMKDGI8	DN	BP-100-1-01
DMKDGI8	HS	Phase 2
DMKDGI8	CP	Bio-Path Ogden, Utah
DMKDGI8	DE	Myelodysplastic syndrome; Hematologic tumour; Chronic myelogenous leukaemia; Acute myeloid leukaemia; Acute lymphoblastic leukaemia

DMWVPO0	ID	DMWVPO0
DMWVPO0	DN	BPN14770
DMWVPO0	HS	Phase 2
DMWVPO0	SN	KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide
DMWVPO0	CP	Tetra Discovery Partners Grand Rapids, MI
DMWVPO0	PC	90111638
DMWVPO0	MW	405.8
DMWVPO0	FM	C21H15ClF3NO2
DMWVPO0	IC	InChI=1S/C21H15ClF3NO2/c22-17-3-1-2-16(12-17)18-9-15(10-19(26-18)21(23,24)25)8-13-4-6-14(7-5-13)11-20(27)28/h1-7,9-10,12H,8,11H2,(H,27,28)
DMWVPO0	CS	C1=CC(=CC(=C1)Cl)C2=NC(=CC(=C2)CC3=CC=C(C=C3)CC(=O)O)C(F)(F)F
DMWVPO0	IK	LTSUMTMGJHPGFX-UHFFFAOYSA-N
DMWVPO0	IU	2-[4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl]phenyl]acetic acid
DMWVPO0	CA	CAS 1606974-33-7
DMWVPO0	DE	Alzheimer disease

DMDYZRS	ID	DMDYZRS
DMDYZRS	DN	BPS-804
DMDYZRS	HS	Phase 2
DMDYZRS	SN	Anti-sclerostin antibody (osteoporosis/hypophophatasia), Novartis
DMDYZRS	CP	Novartis AG
DMDYZRS	DT	Antibody
DMDYZRS	DE	Metabolic bone disease

DM0MO8I	ID	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	HS	Phase 2
DM0MO8I	SN	BQ-123; 136553-81-6; BQ123; BQ 123; Cyclo(D-trp-D-asp-pro-D-val-leu); UNII-S2A8YZM151; CHEBI:2965; S2A8YZM151; CHEMBL314691; cyclo[D-Trp-D-Asp-Pro-D-Val-Leu]; cyclo(D-Asp-Pro-D-Val-Leu-D-Trp); cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu); cyclo-[D-Asp-Pro-d-Val-Leu-d-Trp]; cyclo-(D-Asp-Pro-D-Val-Leu-D-Trp); Cyclo(D-trp-D-asp-L-pro-D-val-L-leu); Cyclo[D-trp-D-asp-L-pro-D-val-L-leu]; cyclo[(D)Trp-(D)Asp-Pro-(D)Val-Leu]; cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp]; cyclo(D-Asp-L-Pro-D-Val-L-Leu-D-Trp)
DM0MO8I	DT	Small molecular drug
DM0MO8I	PC	443289
DM0MO8I	MW	610.7
DM0MO8I	FM	C31H42N6O7
DM0MO8I	IC	InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-,22+,23+,24-,26+/m0/s1
DM0MO8I	CS	CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N1)C(C)C)CC(=O)O)CC3=CNC4=CC=CC=C43
DM0MO8I	IK	VYCMAAOURFJIHD-PJNXIOHISA-N
DM0MO8I	IU	2-[(3R,6R,9S,12R,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-propan-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid
DM0MO8I	CA	CAS 136553-81-6
DM0MO8I	CB	CHEBI:2965
DM0MO8I	DE	Pulmonary arterial hypertension

DMNFKVW	ID	DMNFKVW
DMNFKVW	DN	BR-4628
DMNFKVW	HS	Phase 2
DMNFKVW	CP	Bayer HealthCare Pharmaceuticals
DMNFKVW	PC	60168629
DMNFKVW	MW	381.4
DMNFKVW	FM	C22H23NO5
DMNFKVW	IC	InChI=1S/C22H23NO5/c1-6-27-22(26)19-13(4)23-12(3)18(14(5)24)20(19)16-9-7-8-15-17(25)10-11(2)28-21(15)16/h7-10,20,23H,6H2,1-5H3/t20-/m1/s1
DMNFKVW	CS	CCOC(=O)C1=C(NC(=C([C@H]1C2=CC=CC3=C2OC(=CC3=O)C)C(=O)C)C)C
DMNFKVW	IK	DXCPBIXBBLLGOZ-HXUWFJFHSA-N
DMNFKVW	IU	ethyl (4R)-5-acetyl-2,6-dimethyl-4-(2-methyl-4-oxochromen-8-yl)-1,4-dihydropyridine-3-carboxylate
DMNFKVW	DE	Heart failure

DM3TRF7	ID	DM3TRF7
DM3TRF7	DN	Brasofensine
DM3TRF7	HS	Phase 2
DM3TRF7	SN	Brasofensine [INN]
DM3TRF7	CP	Lundbeck
DM3TRF7	DT	Small molecular drug
DM3TRF7	PC	9554198
DM3TRF7	MW	327.2
DM3TRF7	FM	C16H20Cl2N2O
DM3TRF7	IC	InChI=1S/C16H20Cl2N2O/c1-20-11-4-6-16(20)13(9-19-21-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,9,11-13,16H,4,6,8H2,1-2H3/b19-9+/t11?,12-,13-,16?/m1/s1
DM3TRF7	CS	CN1C2CCC1[C@@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)/C=N/OC
DM3TRF7	IK	NRLIFEGHTNUYFL-MTKJPOGLSA-N
DM3TRF7	IU	(E)-1-[(2R,3S)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-N-methoxymethanimine
DM3TRF7	CA	CAS 171655-91-7
DM3TRF7	DE	Parkinson disease

DMKGM42	ID	DMKGM42
DMKGM42	DN	BREQUINAR
DMKGM42	HS	Phase 2
DMKGM42	SN	Brequinar; 96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum
DMKGM42	DT	Small molecular drug
DMKGM42	PC	57030
DMKGM42	MW	375.4
DMKGM42	FM	C23H15F2NO2
DMKGM42	IC	InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)
DMKGM42	CS	CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)O
DMKGM42	IK	PHEZJEYUWHETKO-UHFFFAOYSA-N
DMKGM42	IU	6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid
DMKGM42	CA	CAS 96187-53-0
DMKGM42	DE	Acute myeloid leukaemia; Coronavirus Disease 2019 (COVID-19)

DMXI9BP	ID	DMXI9BP
DMXI9BP	DN	Brilacidin
DMXI9BP	HS	Phase 2
DMXI9BP	SN	UNII-I1679X069H; 1224095-98-0; I1679X069H; Brilacidin [USAN:INN]; Brilacidin (USAN); SCHEMBL2878543; CHEMBL2219413; DTXSID90153594; AKOS030238222; DB12997; CS-6677; HY-19892; D10414; N,N'-Bis(3-((5-(carbamimidoylamino)pentanoyl)amino)-2-((3R)-pyrrolidin-3-yloxy)-5-(trifluoromethyl)phenyl)pyrimidine-4,6-dicarboxamide; 4,6-Pyrimidinedicarboxamide, N4,N6-bis(3-((5-((aminoiminomethyl)amino)-1-oxopentyl)amino)-2-((3R)-3-pyrrolidinyloxy)-5-(trifluoromethyl)phenyl)-
DMXI9BP	CP	Cellceutix
DMXI9BP	DT	Small molecular drug
DMXI9BP	PC	25023695
DMXI9BP	MW	936.9
DMXI9BP	FM	C40H50F6N14O6
DMXI9BP	IC	InChI=1S/C40H50F6N14O6/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54)/t23-,24-/m1/s1
DMXI9BP	CS	C1CNC[C@@H]1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4O[C@@H]5CCNC5)NC(=O)CCCCN=C(N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCN=C(N)N
DMXI9BP	IK	QPDYBCZNGUJZDK-DNQXCXABSA-N
DMXI9BP	IU	4-N,6-N-bis[3-[5-(diaminomethylideneamino)pentanoylamino]-2-[(3R)-pyrrolidin-3-yl]oxy-5-(trifluoromethyl)phenyl]pyrimidine-4,6-dicarboxamide
DMXI9BP	CA	CAS 1224095-98-0
DMXI9BP	DE	Infectious disease; Acute bacterial skin infection

DMLD80M	ID	DMLD80M
DMLD80M	DN	Brivoligide
DMLD80M	HS	Phase 2
DMLD80M	SN	AYX1
DMLD80M	CP	Adynxx
DMLD80M	DT	Oligonucleotide
DMLD80M	DE	Postoperative pain

DMLFGHX	ID	DMLFGHX
DMLFGHX	DN	BRL 35135
DMLFGHX	HS	Phase 2
DMLFGHX	SN	Brl35135A; BRL 35135; Methyl 4-(2-(2-hydroxy-2-(3-chlorophenyl)ethylamino)propyl)phenoxyacetate; Brl-35135; 91097-81-3; C20H24ClNO4; Acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-, methyl ester; AC1Q3M3M; AC1L3U5A; CHEMBL49289; SCHEMBL4611391; CTK5G8940; ZFLBZHXQAMUEFS-UHFFFAOYSA-N; LS-178136; L003499; methyl 4-[2-[(3-chloro-beta-hydroxyphenethyl) amino]propyl]phenoxyacetate; [4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid methyl ester; methyl 2-[4-[2-[[2-(3-chloroph
DMLFGHX	DT	Small molecular drug
DMLFGHX	PC	122186
DMLFGHX	MW	377.9
DMLFGHX	FM	C20H24ClNO4
DMLFGHX	IC	InChI=1S/C20H24ClNO4/c1-14(22-12-19(23)16-4-3-5-17(21)11-16)10-15-6-8-18(9-7-15)26-13-20(24)25-2/h3-9,11,14,19,22-23H,10,12-13H2,1-2H3
DMLFGHX	CS	CC(CC1=CC=C(C=C1)OCC(=O)OC)NCC(C2=CC(=CC=C2)Cl)O
DMLFGHX	IK	ZFLBZHXQAMUEFS-UHFFFAOYSA-N
DMLFGHX	IU	methyl 2-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate
DMLFGHX	CA	CAS 91097-81-3
DMLFGHX	DE	Diabetic complication

DMUI5PA	ID	DMUI5PA
DMUI5PA	DN	Brostallicin
DMUI5PA	HS	Phase 2
DMUI5PA	SN	Brostallicin; UNII-RPC6R41K4I; 203258-60-0; RPC6R41K4I; PNU-166196A; Brostallicin [INN]; AC1OCFEA; SCHEMBL3678233; CHEMBL1189025; DTXSID70174222; ZINC3979512; Z-3228; 4-[[4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-N-[2-(diaminomethylideneamino)ethyl]-1-methylpyrrole-2-carboxamide
DMUI5PA	CP	Cell Therapeutics
DMUI5PA	DT	Small molecular drug
DMUI5PA	PC	6918408
DMUI5PA	MW	723.6
DMUI5PA	FM	C30H35BrN12O5
DMUI5PA	IC	InChI=1S/C30H35BrN12O5/c1-16(31)25(44)36-17-9-22(41(3)12-17)27(46)38-19-11-24(43(5)14-19)29(48)39-20-10-23(42(4)15-20)28(47)37-18-8-21(40(2)13-18)26(45)34-6-7-35-30(32)33/h8-15H,1,6-7H2,2-5H3,(H,34,45)(H,36,44)(H,37,47)(H,38,46)(H,39,48)(H4,32,33,35)
DMUI5PA	CS	CN1C=C(C=C1C(=O)NCCN=C(N)N)NC(=O)C2=CC(=CN2C)NC(=O)C3=CC(=CN3C)NC(=O)C4=CC(=CN4C)NC(=O)C(=C)Br
DMUI5PA	IK	RXOVOXFAAGIKDQ-UHFFFAOYSA-N
DMUI5PA	IU	4-[[4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-N-[2-(diaminomethylideneamino)ethyl]-1-methylpyrrole-2-carboxamide
DMUI5PA	CA	CAS 203258-60-0
DMUI5PA	DE	Breast cancer

DM1ZOCK	ID	DM1ZOCK
DM1ZOCK	DN	Bryostatin-1
DM1ZOCK	HS	Phase 2
DM1ZOCK	SN	Bryostatin 1; 83314-01-6
DM1ZOCK	DT	Small molecular drug
DM1ZOCK	PC	5280757
DM1ZOCK	MW	905
DM1ZOCK	FM	C47H68O17
DM1ZOCK	IC	InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1
DM1ZOCK	CS	CCC/C=C/C=C/C(=O)O[C@H]1/C(=C/C(=O)OC)/C[C@H]2C[C@@H](OC(=O)C[C@@H](C[C@@H]3C[C@@H](C([C@@](O3)(C[C@@H]4C/C(=C/C(=O)OC)/C[C@@H](O4)/C=C/C([C@@]1(O2)O)(C)C)O)(C)C)OC(=O)C)O)[C@@H](C)O
DM1ZOCK	IK	MJQUEDHRCUIRLF-TVIXENOKSA-N
DM1ZOCK	IU	[(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate
DM1ZOCK	CA	CAS 83314-01-6
DM1ZOCK	CB	CHEBI:88353
DM1ZOCK	DE	Alzheimer disease

DM2LZIY	ID	DM2LZIY
DM2LZIY	DN	BT-061
DM2LZIY	HS	Phase 2
DM2LZIY	CP	Biotest
DM2LZIY	DT	Antibody
DM2LZIY	DE	Asthma; Psoriasis vulgaris

DMYO185	ID	DMYO185
DMYO185	DN	BT-062
DMYO185	HS	Phase 2
DMYO185	CP	Biotest Pharmaceuticals; ImmunoGen
DMYO185	DT	Antibody
DMYO185	DE	Multiple myeloma

DMDWP0U	ID	DMDWP0U
DMDWP0U	DN	BTA-798
DMDWP0U	HS	Phase 2
DMDWP0U	SN	Capsid-binding inhibitors, Biota; Capsid-binding (anti-rhinovirus) agents, Biota
DMDWP0U	CP	Biota pharmaceuticals
DMDWP0U	DE	Rhinovirus infection

DMS6ZA0	ID	DMS6ZA0
DMS6ZA0	DN	BTD-001
DMS6ZA0	HS	Phase 2
DMS6ZA0	CP	Balance Therapeutics San Bruno, CA
DMS6ZA0	DE	Narcolepsy

DMY5IX4	ID	DMY5IX4
DMY5IX4	DN	BTL-TML-001
DMY5IX4	HS	Phase 2
DMY5IX4	SN	Influenza virus infection, Beech Tree Labs
DMY5IX4	CP	Beech Tree Labs Inc
DMY5IX4	DE	Influenza virus infection; Herpes simplex labialis

DMA9238	ID	DMA9238
DMA9238	DN	BTRX-246040
DMA9238	HS	Phase 2
DMA9238	CP	BlackThorn Therapeutics San Francisco, CA
DMA9238	DE	Major depressive disorder

DMWPDUZ	ID	DMWPDUZ
DMWPDUZ	DN	BTRX-335140
DMWPDUZ	HS	Phase 2
DMWPDUZ	SN	CYM-53093; UNII-XK5ILZ28KI; XK5ILZ28KI; 2244614-14-8; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4 amine; CHEMBL4592045; SCHEMBL20670520; GTPL10452; BTRX335140; BCP32121; CYM53093; BDBM50531908; compound 58 [PMID: 30707578]; HY-124754; CS-0087593; BTRX 335140; BTRX335140; CYM-53093; CYM 53093; CYM53093; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine; 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine; 4-Piperidinamine, 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolinyl)-N-(tetrahydro-2H-pyran-4-yl)-
DMWPDUZ	CP	BlackThorn Therapeutics
DMWPDUZ	DT	Small molecular drug
DMWPDUZ	PC	137434175
DMWPDUZ	MW	453.6
DMWPDUZ	FM	C25H32FN5O2
DMWPDUZ	IC	InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3
DMWPDUZ	CS	CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
DMWPDUZ	IK	CQOJHAJWCDJEAT-UHFFFAOYSA-N
DMWPDUZ	IU	1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
DMWPDUZ	CA	CAS 2244614-14-8
DMWPDUZ	DE	Major depressive disorder

DMIEPJG	ID	DMIEPJG
DMIEPJG	DN	BTT-1023
DMIEPJG	HS	Phase 2
DMIEPJG	SN	SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie
DMIEPJG	CP	BioTie Therapies Corp
DMIEPJG	DT	Antibody
DMIEPJG	DE	Psoriasis vulgaris

DMZC4V0	ID	DMZC4V0
DMZC4V0	DN	Buproprion+zonisamide
DMZC4V0	HS	Phase 2
DMZC4V0	SN	Empatic (TN)
DMZC4V0	CP	Orexigen Therapeutics
DMZC4V0	DE	Obesity

DMNB4XK	ID	DMNB4XK
DMNB4XK	DN	BVD-523
DMNB4XK	HS	Phase 2
DMNB4XK	CP	Biomed valley discoveries
DMNB4XK	PC	11719003
DMNB4XK	MW	433.3
DMNB4XK	FM	C21H22Cl2N4O2
DMNB4XK	IC	InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1
DMNB4XK	CS	CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl
DMNB4XK	IK	KSERXGMCDHOLSS-LJQANCHMSA-N
DMNB4XK	IU	N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide
DMNB4XK	CA	CAS 869886-67-9
DMNB4XK	DE	Solid tumour/cancer; Pancreatic cancer; Melanoma

DM8CWL0	ID	DM8CWL0
DM8CWL0	DN	BVT.28949
DM8CWL0	HS	Phase 2
DM8CWL0	CP	Biovitrum
DM8CWL0	DE	Glaucoma/ocular hypertension

DMD8GNB	ID	DMD8GNB
DMD8GNB	DN	BXT-51072
DMD8GNB	HS	Phase 2
DMD8GNB	SN	ALT-2074; SYI-2074
DMD8GNB	CP	Synvista Therapeutics
DMD8GNB	DT	Small molecular drug
DMD8GNB	PC	130165
DMD8GNB	MW	226.19
DMD8GNB	FM	C10H13NSe
DMD8GNB	IC	InChI=1S/C10H13NSe/c1-10(2)7-11-12-9-6-4-3-5-8(9)10/h3-6,11H,7H2,1-2H3
DMD8GNB	CS	CC1(CN[Se]C2=CC=CC=C21)C
DMD8GNB	IK	FXRYWOJYVGJZLE-UHFFFAOYSA-N
DMD8GNB	IU	4,4-dimethyl-2,3-dihydro-1,2-benzoselenazine
DMD8GNB	CA	CAS 173026-17-0
DMD8GNB	DE	Cardiovascular disease

DMTRONK	ID	DMTRONK
DMTRONK	DN	BZL-101
DMTRONK	HS	Phase 2
DMTRONK	CP	Bionovo
DMTRONK	DE	Breast cancer

DMGE058	ID	DMGE058
DMGE058	DN	Cabiralizumab
DMGE058	HS	Phase 2
DMGE058	CP	Bristol-Myers Squibb Princeton, NJFive Prime Therapeutics South San Francisco, CA
DMGE058	DE	Solid tumour/cancer; Pancreatic cancer

DMGXCY9	ID	DMGXCY9
DMGXCY9	DN	Calcium phosphate
DMGXCY9	HS	Phase 2
DMGXCY9	SN	Bonarka; Calcigenol simple; Calcium orthophosphate; Calcium phosphate; Calcium phosphate (3:2); Calcium phosphate (Ca3(PO4)2); Calcium phosphate tribasic; Calcium tertiary phosphate; Natural whitlockite; Phosphoric acid, calcium salt; Phosphoric acid, calcium salt (2:3); Synthos; TRICALCIUM PHOSPHATE; Tertiary calcium phosphate; Tribasic calcium phosphate; Tricalcium diphosphate; Tricalcium orthophosphate; beta-TCP; beta-Tricalcium phosphate
DMGXCY9	DT	Small molecular drug
DMGXCY9	PC	24456
DMGXCY9	MW	310.174
DMGXCY9	FM	Ca3O8P2
DMGXCY9	IC	InChI=1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6
DMGXCY9	CS	[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
DMGXCY9	IK	QORWJWZARLRLPR-UHFFFAOYSA-H
DMGXCY9	IU	tricalcium;diphosphate
DMGXCY9	CA	CAS 7758-87-410103-46-5
DMGXCY9	CB	ChEBI:9679
DMGXCY9	DE	Osteoporosis

DMDV8MK	ID	DMDV8MK
DMDV8MK	DN	CALDARET HYDRATE
DMDV8MK	HS	Phase 2
DMDV8MK	SN	MCC-135; Caldaret hydrate; 5-Methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate
DMDV8MK	CP	Mitsubishi Pharma
DMDV8MK	DT	Small molecular drug
DMDV8MK	PC	9816981
DMDV8MK	MW	274.34
DMDV8MK	FM	C11H18N2O4S
DMDV8MK	IC	InChI=1S/C11H16N2O3S.H2O/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13;/h2-3,8,12H,4-7H2,1H3,(H,14,15,16);1H2
DMDV8MK	CS	CC1=CC(=C(C=C1)N2CCNCC2)S(=O)(=O)O.O
DMDV8MK	IK	ZRQKZWAOIRVBFD-UHFFFAOYSA-N
DMDV8MK	IU	5-methyl-2-piperazin-1-ylbenzenesulfonic acid;hydrate
DMDV8MK	CA	CAS 192509-24-3
DMDV8MK	DE	Cardiovascular disease

DMAKSMX	ID	DMAKSMX
DMAKSMX	DN	Camicinal
DMAKSMX	HS	Phase 2
DMAKSMX	SN	962040
DMAKSMX	CP	GlaxoSmithKline
DMAKSMX	DT	Small molecular drug
DMAKSMX	PC	15984937
DMAKSMX	MW	424.6
DMAKSMX	FM	C25H33FN4O
DMAKSMX	IC	InChI=1S/C25H33FN4O/c1-19-17-29(14-11-27-19)18-21-7-5-20(6-8-21)15-25(31)30-12-9-23(10-13-30)28-24-4-2-3-22(26)16-24/h2-8,16,19,23,27-28H,9-15,17-18H2,1H3/t19-/m0/s1
DMAKSMX	CS	C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F
DMAKSMX	IK	RZKDEGZIFSJVNA-IBGZPJMESA-N
DMAKSMX	IU	1-[4-(3-fluoroanilino)piperidin-1-yl]-2-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]ethanone
DMAKSMX	CA	CAS 923565-21-3
DMAKSMX	DE	Delayed gastric emptying; Diabetic gastroparesis

DMQ7UL8	ID	DMQ7UL8
DMQ7UL8	DN	Camostat
DMQ7UL8	HS	Phase 2
DMQ7UL8	SN	Camostat; 59721-28-7; camostate; Camostat [INN]; Camostatum [INN-Latin]; UNII-0FD207WKDU; CCRIS 7219; 4-(2-(2-(Dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate; 0FD207WKDU; C20H22N4O5; Camostat (INN); Foipan; FOY 305; FOY-305; Dimethylcarbamoylmethyl 4-(4-guqnidinobenzoyloxy)phenylacetat; foypan; Camostatum; CHEMBL85164; camostate-mesilate; [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate; p-Guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with N
DMQ7UL8	DT	Small molecular drug
DMQ7UL8	PC	2536
DMQ7UL8	MW	398.4
DMQ7UL8	FM	C20H22N4O5
DMQ7UL8	IC	InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23)
DMQ7UL8	CS	CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
DMQ7UL8	IK	XASIMHXSUQUHLV-UHFFFAOYSA-N
DMQ7UL8	IU	[4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate
DMQ7UL8	CA	CAS 59721-28-7
DMQ7UL8	CB	CHEBI:135632
DMQ7UL8	DE	Cystic fibrosis

DMEZLFT	ID	DMEZLFT
DMEZLFT	DN	Camsirubicin
DMEZLFT	HS	Phase 2
DMEZLFT	SN	UNII-VI79RD8VNN; VI79RD8VNN; 236095-26-4; (8R,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,9,10,12-tetrahydrotetracen-5(8H)-one; 5(8H)-Naphthacenone, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-, (8R,10S)-
DMEZLFT	CP	Monopar Therapeutics
DMEZLFT	DT	Small molecular drug
DMEZLFT	PC	135446069
DMEZLFT	MW	528.5
DMEZLFT	FM	C27H32N2O9
DMEZLFT	IC	InChI=1S/C27H32N2O9/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3/t11-,14-,16-,17-,23+,27-/m0/s1
DMEZLFT	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=N)C(=CC=C5)OC)O)(CCO)O)N)O
DMEZLFT	IK	GNCWGPLZJLZZPI-KUIJCEFOSA-N
DMEZLFT	IU	(8R,10S)-10-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-9,10-dihydro-7H-tetracen-5-one
DMEZLFT	CA	CAS 236095-26-4
DMEZLFT	DE	Soft tissue sarcoma

DMEYIVW	ID	DMEYIVW
DMEYIVW	DN	CAP1-6D
DMEYIVW	HS	Phase 2
DMEYIVW	SN	Modified CEA peptide (pancreatic cancer), University of Chicago
DMEYIVW	CP	University of Chicago
DMEYIVW	DT	Small molecular drug
DMEYIVW	PC	396060
DMEYIVW	MW	965.1
DMEYIVW	FM	C43H68N10O15
DMEYIVW	IC	InChI=1S/C43H68N10O15/c1-20(2)12-27(49-37(61)26(44)15-24-8-10-25(55)11-9-24)40(64)53-32(19-54)38(62)46-18-34(57)47-23(7)36(60)48-30(17-35(58)59)42(66)50-28(13-21(3)4)39(63)51-29(16-33(45)56)41(65)52-31(43(67)68)14-22(5)6/h8-11,20-23,26-32,54-55H,12-19,44H2,1-7H3,(H2,45,56)(H,46,62)(H,47,57)(H,48,60)(H,49,61)(H,50,66)(H,51,63)(H,52,65)(H,53,64)(H,58,59)(H,67,68)
DMEYIVW	CS	CC(C)CC(C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)N
DMEYIVW	IK	SNKUSVNHTCUELQ-UHFFFAOYSA-N
DMEYIVW	IU	2-[[4-amino-2-[[2-[[2-[2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic acid
DMEYIVW	DE	Pancreatic cancer

DMJKLHU	ID	DMJKLHU
DMJKLHU	DN	CAP-7.1
DMJKLHU	HS	Phase 2
DMJKLHU	CP	CellAct Pharma GmbH
DMJKLHU	PC	154701729
DMJKLHU	DE	Solid tumour/cancer

DMYWO62	ID	DMYWO62
DMYWO62	DN	Capadenoson
DMYWO62	HS	Phase 2
DMYWO62	SN	Capadenoson; 544417-40-5; UNII-O519NVW73R; O519NVW73R; CHEMBL3235279; BAY 68-4986; 2-amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-3,5-Pyridinedicarbonitrile; C25H18ClN5O2S2; Capadenoson [INN]; 2-amino-6-({(2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl}sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)pyridine-3,5-dicarbonitrile; 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile; SCHEMBL174016; Capadenoson;BAY 68-4986
DMYWO62	CP	Bayer HealthCare Pharmaceuticals
DMYWO62	DT	Small molecular drug
DMYWO62	PC	9936489
DMYWO62	MW	520
DMYWO62	FM	C25H18ClN5O2S2
DMYWO62	IC	InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31)
DMYWO62	CS	C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N)C#N)OCCO
DMYWO62	IK	CITWCLNVRIKQAF-UHFFFAOYSA-N
DMYWO62	IU	2-amino-6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile
DMYWO62	CA	CAS 544417-40-5
DMYWO62	DE	Atrial fibrillation

DMY4OMS	ID	DMY4OMS
DMY4OMS	DN	Carabersat
DMY4OMS	HS	Phase 2
DMY4OMS	SN	SB-204268; SB-204269; SB-258339
DMY4OMS	CP	SmithKline Beecham plc
DMY4OMS	DT	Small molecular drug
DMY4OMS	PC	193943
DMY4OMS	MW	357.4
DMY4OMS	FM	C20H20FNO4
DMY4OMS	IC	InChI=1S/C20H20FNO4/c1-11(23)13-6-9-16-15(10-13)17(18(24)20(2,3)26-16)22-19(25)12-4-7-14(21)8-5-12/h4-10,17-18,24H,1-3H3,(H,22,25)/t17-,18+/m0/s1
DMY4OMS	CS	CC(=O)C1=CC2=C(C=C1)OC([C@@H]([C@H]2NC(=O)C3=CC=C(C=C3)F)O)(C)C
DMY4OMS	IK	RCLXAPJEFHPYEG-ZWKOTPCHSA-N
DMY4OMS	IU	N-[(3R,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide
DMY4OMS	CA	CAS 184653-84-7
DMY4OMS	DE	Epileptic seizures

DMN5JCX	ID	DMN5JCX
DMN5JCX	DN	Carboxyamidotriazole orotate
DMN5JCX	HS	Phase 2
DMN5JCX	CP	Tactical Therapeutics
DMN5JCX	PC	154732136
DMN5JCX	DE	Glioblastoma multiforme

DM7ADGX	ID	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	HS	Phase 2
DM7ADGX	SN	CARFENTANIL; Carfentanyl; Carfentanila; Carfentanilum; Wildnil; 59708-52-0; Carfentanil [INN]; Carfentanila [Spanish]; UNII-LA9DTA2L8F; Carfentanilum [INN-Latin]; Carfentanila [INN-Spanish]; Methyl 1-phenylethyl-4-(N-phenylpropionamido)isonipecotate; CHEBI:61084; Methyl 4-(N-propionyl-N-phenylamino)-1-(2-phenylethyl)-4-piperidine-carboxylate; Methyl 4-(N-(1-oxopropyl)-N-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylate; 4-((1-Oxopropyl)phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester
DM7ADGX	DT	Small molecular drug
DM7ADGX	PC	62156
DM7ADGX	MW	394.5
DM7ADGX	FM	C24H30N2O3
DM7ADGX	IC	InChI=1S/C24H30N2O3/c1-3-22(27)26(21-12-8-5-9-13-21)24(23(28)29-2)15-18-25(19-16-24)17-14-20-10-6-4-7-11-20/h4-13H,3,14-19H2,1-2H3
DM7ADGX	CS	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CC=C3)C(=O)OC
DM7ADGX	IK	YDSDEBIZUNNPOB-UHFFFAOYSA-N
DM7ADGX	IU	methyl 1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
DM7ADGX	CA	CAS 59708-52-0
DM7ADGX	CB	CHEBI:61084

DMAUN15	ID	DMAUN15
DMAUN15	DN	Carlumab
DMAUN15	HS	Phase 2
DMAUN15	SN	CCL-2; CNTO-888; Anti-MCP1 monoclonal antibodies, Centocor; CCL2 monoclonal antibody (infusion, cancer), Centocor
DMAUN15	CP	Janssen biotech
DMAUN15	DT	Antibody
DMAUN15	DE	Pulmonary fibrosis

DMN6TKI	ID	DMN6TKI
DMN6TKI	DN	Carmoterol
DMN6TKI	HS	Phase 2
DMN6TKI	SN	147568-66-9; 8-Hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)quinolin-2(1H)-one; UNII-9810NUL4D1; CHEMBL1094785; 9810NUL4D1; 2(1h)-quinolinone, 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-; 8-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]-1,2-dihydroquinolin-2-one; Carmoterol [INN]; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one; AC1Q6MT1
DMN6TKI	CP	Chiesi
DMN6TKI	DT	Small molecular drug
DMN6TKI	PC	63952
DMN6TKI	MW	368.4
DMN6TKI	FM	C21H24N2O4
DMN6TKI	IC	InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1
DMN6TKI	CS	C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O
DMN6TKI	IK	IHOXNOQMRZISPV-YJYMSZOUSA-N
DMN6TKI	IU	8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one
DMN6TKI	CA	CAS 147568-66-9
DMN6TKI	DE	Chronic obstructive pulmonary disease

DMTBFXW	ID	DMTBFXW
DMTBFXW	DN	CART 19
DMTBFXW	HS	Phase 2
DMTBFXW	CP	University of Pennsylvania
DMTBFXW	DT	CAR T Cell Therapy
DMTBFXW	DE	Acute lymphoblastic leukaemia; Pancreatic cancer

DM28A5D	ID	DM28A5D
DM28A5D	DN	CAR-T cells targeting CD19
DM28A5D	HS	Phase 2
DM28A5D	CP	The First Affiliated Hospital of Soochow University
DM28A5D	DT	CAR T Cell Therapy
DM28A5D	DE	Non-hodgkin lymphoma

DM3RU0A	ID	DM3RU0A
DM3RU0A	DN	CAR-T cells targeting CD20
DM3RU0A	HS	Phase 2
DM3RU0A	CP	The First Affiliated Hospital of Soochow University
DM3RU0A	DT	CAR T Cell Therapy
DM3RU0A	DE	Non-hodgkin lymphoma

DM6XN4C	ID	DM6XN4C
DM6XN4C	DN	CAR-T cells targeting CD22
DM6XN4C	HS	Phase 2
DM6XN4C	CP	The First Affiliated Hospital of Soochow University
DM6XN4C	DT	CAR T Cell Therapy
DM6XN4C	DE	Non-hodgkin lymphoma

DML0KWM	ID	DML0KWM
DML0KWM	DN	CAR-T cells targeting CD30
DML0KWM	HS	Phase 2
DML0KWM	CP	The First Affiliated Hospital of Soochow University
DML0KWM	DT	CAR T Cell Therapy
DML0KWM	DE	Non-hodgkin lymphoma

DMHQKN6	ID	DMHQKN6
DMHQKN6	DN	CART-19
DMHQKN6	HS	Phase 2
DMHQKN6	CP	University of Pennsylvania
DMHQKN6	DT	CAR T Cell Therapy
DMHQKN6	DE	Non-hodgkin lymphoma; B-cell lymphoma; leukaemia; Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Haematopoietic/lymphoid cancer; Mantle cell lymphoma; Prolymphocytic leukaemia

DMZUV7T	ID	DMZUV7T
DMZUV7T	DN	CART-19 cells
DMZUV7T	HS	Phase 2
DMZUV7T	CP	University of Pennsylvania
DMZUV7T	DT	CAR T Cell Therapy
DMZUV7T	DE	Acute lymphocytic leukaemia; Multiple myeloma

DMQBP7R	ID	DMQBP7R
DMQBP7R	DN	CAT 1004
DMQBP7R	HS	Phase 2
DMQBP7R	CP	Catabasis Pharmaceuticals
DMQBP7R	DE	Type-2 diabetes; Duchenne dystrophy

DM2IFYZ	ID	DM2IFYZ
DM2IFYZ	DN	CB-10-01
DM2IFYZ	HS	Phase 2
DM2IFYZ	CP	Cosmo Pharmaceuticals
DM2IFYZ	DT	Vaccine
DM2IFYZ	DE	Melanoma

DM094UH	ID	DM094UH
DM094UH	DN	CB-839
DM094UH	HS	Phase 2
DM094UH	PC	71577426
DM094UH	MW	571.6
DM094UH	FM	C26H24F3N7O3S
DM094UH	IC	InChI=1S/C26H24F3N7O3S/c27-26(28,29)39-20-9-5-6-17(14-20)15-22(37)31-21-12-11-18(33-34-21)7-1-2-10-24-35-36-25(40-24)32-23(38)16-19-8-3-4-13-30-19/h3-6,8-9,11-14H,1-2,7,10,15-16H2,(H,31,34,37)(H,32,36,38)
DM094UH	CS	C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F
DM094UH	IK	PRAAPINBUWJLGA-UHFFFAOYSA-N
DM094UH	IU	N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide
DM094UH	CA	CAS 1439399-58-2
DM094UH	DE	leukaemia; Breast cancer; Renal cell carcinoma; Solid tumour/cancer

DMK4FRU	ID	DMK4FRU
DMK4FRU	DN	CBLB-502
DMK4FRU	HS	Phase 2
DMK4FRU	SN	CBLB-501; Mini-flagellin, Cleveland BioLabs; Recombinant flagellin proteins (injury protection), Cleveland BioLabs
DMK4FRU	CP	Cleveland BioLabs Inc
DMK4FRU	DE	Acute radiation syndrome

DMSBNTZ	ID	DMSBNTZ
DMSBNTZ	DN	CBX-129801
DMSBNTZ	HS	Phase 2
DMSBNTZ	SN	Ersatta; C-peptide (depot formulation), Cebix; Long-acting synthetic C-peptide, Cebix; PEGylated C-peptide (diabetic complications), Cebix
DMSBNTZ	CP	Cebix
DMSBNTZ	DE	Diabetic complication

DMQ874W	ID	DMQ874W
DMQ874W	DN	CC-1088
DMQ874W	HS	Phase 2
DMQ874W	SN	CDC801; CC-1088; CHEMBL88153; SCHEMBL185853; CDC-801; DDYUBCCTNHWSQM-UHFFFAOYSA-N; BDBM50216298; HY-U00179; CS-7247; 192819-27-5
DMQ874W	DT	Small molecular drug
DMQ874W	PC	9844338
DMQ874W	MW	408.4
DMQ874W	FM	C23H24N2O5
DMQ874W	IC	InChI=1S/C23H24N2O5/c1-29-19-11-10-14(12-20(19)30-15-6-2-3-7-15)18(13-21(24)26)25-22(27)16-8-4-5-9-17(16)23(25)28/h4-5,8-12,15,18H,2-3,6-7,13H2,1H3,(H2,24,26)
DMQ874W	CS	COC1=C(C=C(C=C1)C(CC(=O)N)N2C(=O)C3=CC=CC=C3C2=O)OC4CCCC4
DMQ874W	IK	DDYUBCCTNHWSQM-UHFFFAOYSA-N
DMQ874W	IU	3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide
DMQ874W	CA	CAS 192819-27-5
DMQ874W	DE	Crohn disease

DMNE7L3	ID	DMNE7L3
DMNE7L3	DN	CC-220
DMNE7L3	HS	Phase 2
DMNE7L3	SN	AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266
DMNE7L3	DT	Small molecular drug
DMNE7L3	PC	67335295
DMNE7L3	MW	449.5
DMNE7L3	FM	C25H27N3O5
DMNE7L3	IC	InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1
DMNE7L3	CS	C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
DMNE7L3	IK	IXZOHGPZAQLIBH-NRFANRHFSA-N
DMNE7L3	IU	(3S)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
DMNE7L3	CA	CAS 1323403-33-3
DMNE7L3	DE	Sarcoidosis; Multiple myeloma; Systemic lupus erythematosus

DMJR9H0	ID	DMJR9H0
DMJR9H0	DN	CC-292
DMJR9H0	HS	Phase 2
DMJR9H0	SN	AVL-292; 1202757-89-8; spebrutinib; cc-292; UNII-DRU6NG543J; CC-292 (AVL-292); DRU6NG543J; AVL292; N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide; AK198940; N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide; N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide; Btk inhibitor CC-292; Spebrutinib [USAN:INN]; Spebrutinib (USAN/INN); SCHEMBL626216; GTPL7837; CHEMBL3301625; EX-A255; AVL 292
DMJR9H0	CP	Celgene
DMJR9H0	DT	Small molecular drug
DMJR9H0	PC	59174488
DMJR9H0	MW	423.4
DMJR9H0	FM	C22H22FN5O3
DMJR9H0	IC	InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)
DMJR9H0	CS	COCCOC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)NC(=O)C=C)F
DMJR9H0	IK	KXBDTLQSDKGAEB-UHFFFAOYSA-N
DMJR9H0	IU	N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide
DMJR9H0	CA	CAS 1202757-89-8
DMJR9H0	DE	Chronic lymphocytic leukaemia

DMPMO6G	ID	DMPMO6G
DMPMO6G	DN	CC-401
DMPMO6G	HS	Phase 2
DMPMO6G	SN	CC-401; 395104-30-0; UNII-NOE38VQA1W; NOE38VQA1W; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-5-yl)-1H-indazole; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-3-yl)-1H-indazole; 3-[3-[2-(1-PIPERIDINYL)ETHOXY]PHENYL]-5-(1H-1,2,4-TRIAZOL-5-YL)-1H-INDAZOLE; CC 401; C22H24N6O; PubChem22434; SCHEMBL4604749; CHEMBL1614713; CHEBI:91437; DTXSID40192650; MolPort-044-561-531; MolPort-021-804-942; BCPP000298; BCP01960; ZINC38836256; RS0046; HY-13022A; AKOS027251057; AKOS027336636; DB12432; BCP9000495; CS-1955
DMPMO6G	TC	Anticancer Agents
DMPMO6G	DT	Small molecular drug
DMPMO6G	PC	10430360
DMPMO6G	MW	388.5
DMPMO6G	FM	C22H24N6O
DMPMO6G	IC	InChI=1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27)
DMPMO6G	CS	C1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5
DMPMO6G	IK	XDJCLCLBSGGNKS-UHFFFAOYSA-N
DMPMO6G	IU	3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole
DMPMO6G	CA	CAS 395104-30-0
DMPMO6G	CB	CHEBI:91437
DMPMO6G	DE	Solid tumour/cancer

DM0EDHJ	ID	DM0EDHJ
DM0EDHJ	DN	CC-90011
DM0EDHJ	HS	Phase 2
DM0EDHJ	SN	UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y
DM0EDHJ	CP	Bristol-Myers Squibb
DM0EDHJ	DT	Small molecular drug
DM0EDHJ	PC	118483201
DM0EDHJ	MW	451.5
DM0EDHJ	FM	C24H23F2N5O2
DM0EDHJ	IC	InChI=1S/C24H23F2N5O2/c1-30-23(32)21(14-5-6-20(33-2)19(26)11-14)22(15-3-4-16(13-27)18(25)12-15)29-24(30)31-9-7-17(28)8-10-31/h3-6,11-12,17H,7-10,28H2,1-2H3
DM0EDHJ	CS	CN1C(=O)C(=C(N=C1N2CCC(CC2)N)C3=CC(=C(C=C3)C#N)F)C4=CC(=C(C=C4)OC)F
DM0EDHJ	IK	NBAIXBAUHIQQGF-UHFFFAOYSA-N
DM0EDHJ	IU	4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile
DM0EDHJ	CA	CAS 1821307-10-1
DM0EDHJ	DE	Lymphoma; Non-hodgkin lymphoma

DMHVEGJ	ID	DMHVEGJ
DMHVEGJ	DN	CC-930
DMHVEGJ	HS	Phase 2
DMHVEGJ	SN	TANZISERTIB; CC-930; 899805-25-5; CC 930; UNII-M5O06306UO; CHEMBL1950289; M5O06306UO; CC930; Trans-4-({9-[(3s)-Tetrahydrofuran-3-Yl]-8-[(2,4,6-Trifluorophenyl)amino]-9h-Purin-2-Yl}amino)cyclohexanol; Tanzisertib [USAN:INN]; 3tti; trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol; Tanzisertib (USAN); CC-930(Tanzisertib); SCHEMBL2133061; SCHEMBL4760419; SCHEMBL2133055; GTPL9836; SCHEMBL8082102; SCHEMBL15589918; CHEMBL1950305; SCHEMBL10179476; JNK-930; MolPort-044-562-358
DMHVEGJ	CP	Celgene
DMHVEGJ	DT	Small molecular drug
DMHVEGJ	PC	11597537
DMHVEGJ	MW	448.4
DMHVEGJ	FM	C21H23F3N6O2
DMHVEGJ	IC	InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1
DMHVEGJ	CS	C1COC[C@H]1N2C3=NC(=NC=C3N=C2NC4=C(C=C(C=C4F)F)F)NC5CCC(CC5)O
DMHVEGJ	IK	IBGLGMOPHJQDJB-MOKVOYLWSA-N
DMHVEGJ	IU	4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol
DMHVEGJ	CA	CAS 899805-25-5
DMHVEGJ	DE	Discoid lupus erythematosus; Idiopathic pulmonary fibrosis

DMJ9XCO	ID	DMJ9XCO
DMJ9XCO	DN	CCX-140
DMJ9XCO	HS	Phase 2
DMJ9XCO	SN	CCX-140-B; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease), ChemoCentryx; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease/chronic kidney disease), ChemoCentryx
DMJ9XCO	CP	Chemocentryx
DMJ9XCO	PC	25134303
DMJ9XCO	MW	495.9
DMJ9XCO	FM	C20H13ClF3N5O3S
DMJ9XCO	IC	InChI=1S/C20H13ClF3N5O3S/c1-10-6-15(29-33(31,32)11-2-3-14(21)13(7-11)20(22,23)24)17(26-8-10)18(30)16-12-4-5-25-19(12)28-9-27-16/h2-9,29H,1H3,(H,25,27,28)
DMJ9XCO	CS	CC1=CC(=C(N=C1)C(=O)C2=C3C=CNC3=NC=N2)NS(=O)(=O)C4=CC(=C(C=C4)Cl)C(F)(F)F
DMJ9XCO	IK	LUUMLYXKTPBTQR-UHFFFAOYSA-N
DMJ9XCO	IU	4-chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide
DMJ9XCO	CA	CAS 1100318-47-5
DMJ9XCO	DE	Diabetic nephropathy

DMSHV9C	ID	DMSHV9C
DMSHV9C	DN	CCX-354
DMSHV9C	HS	Phase 2
DMSHV9C	SN	CCX-354-C; GSK2941266
DMSHV9C	CP	ChemoCentryx Inc
DMSHV9C	PC	135565361
DMSHV9C	MW	451.9
DMSHV9C	FM	C22H22ClN7O2
DMSHV9C	IC	InChI=1S/C22H22ClN7O2/c1-32-18-13-15(4-5-17(18)23)28-9-11-29(12-10-28)19(31)14-30-22-16(3-2-6-26-22)20(27-30)21-24-7-8-25-21/h2-8,13H,9-12,14H2,1H3,(H,24,25)
DMSHV9C	CS	COC1=C(C=CC(=C1)N2CCN(CC2)C(=O)CN3C4=C(C=CC=N4)C(=N3)C5=NC=CN5)Cl
DMSHV9C	IK	ZIMLRKWQDLVPEK-UHFFFAOYSA-N
DMSHV9C	IU	1-[4-(4-chloro-3-methoxyphenyl)piperazin-1-yl]-2-[3-(1H-imidazol-2-yl)pyrazolo[3,4-b]pyridin-1-yl]ethanone
DMSHV9C	CA	CAS 1010073-75-2
DMSHV9C	DE	Autoimmune diabetes; Rheumatoid arthritis

DMPVAUT	ID	DMPVAUT
DMPVAUT	DN	CCX872
DMPVAUT	HS	Phase 2
DMPVAUT	CP	Chemocentryx
DMPVAUT	DE	Diabetic nephropathy; Pancreatic tumour

DMEK580	ID	DMEK580
DMEK580	DN	CD19 CAR T cells
DMEK580	HS	Phase 2
DMEK580	CP	Southwest Hospital, China
DMEK580	DT	CAR T Cell Therapy
DMEK580	DE	B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma

DMQJBUK	ID	DMQJBUK
DMQJBUK	DN	CD19-targeting CAR T cells
DMQJBUK	HS	Phase 2
DMQJBUK	CP	Uppsala University
DMQJBUK	DT	CAR T Cell Therapy
DMQJBUK	DE	B-cell lymphoma; leukaemia

DMQGI8R	ID	DMQGI8R
DMQGI8R	DN	CD20 CAR T cells
DMQGI8R	HS	Phase 2
DMQGI8R	CP	Southwest Hospital, China
DMQGI8R	DT	CAR T Cell Therapy
DMQGI8R	DE	B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma

DMXYLTI	ID	DMXYLTI
DMXYLTI	DN	CDP323
DMXYLTI	HS	Phase 2
DMXYLTI	SN	Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01
DMXYLTI	CP	UCB; Biogen Idec
DMXYLTI	DT	Small molecular drug
DMXYLTI	PC	23394557
DMXYLTI	MW	549.5
DMXYLTI	FM	C28H29BrN4O3
DMXYLTI	IC	InChI=1S/C28H29BrN4O3/c1-2-36-27(35)22(33-24-23(29)25(34)28(24)12-4-3-5-13-28)16-18-6-8-20(9-7-18)32-26-21-17-30-14-10-19(21)11-15-31-26/h6-11,14-15,17,22,33H,2-5,12-13,16H2,1H3,(H,31,32)/t22-/m0/s1
DMXYLTI	CS	CCOC(=O)[C@H](CC1=CC=C(C=C1)NC2=NC=CC3=C2C=NC=C3)NC4=C(C(=O)C45CCCCC5)Br
DMXYLTI	IK	QCYAXXZCQKMTMO-QFIPXVFZSA-N
DMXYLTI	IU	ethyl (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoate
DMXYLTI	CA	CAS 455264-30-9
DMXYLTI	DE	Rheumatoid arthritis; Multiple sclerosis

DM3YB2C	ID	DM3YB2C
DM3YB2C	DN	CDP-6038
DM3YB2C	HS	Phase 2
DM3YB2C	DE	Rheumatoid arthritis

DM8UQJG	ID	DM8UQJG
DM8UQJG	DN	CDX-1307
DM8UQJG	HS	Phase 2
DM8UQJG	SN	BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics
DM8UQJG	CP	Medarex Inc
DM8UQJG	DT	Vaccine
DM8UQJG	DE	Bladder cancer

DMCGNJ6	ID	DMCGNJ6
DMCGNJ6	DN	CDX-1401
DMCGNJ6	HS	Phase 2
DMCGNJ6	CP	Celldex Therapeutics
DMCGNJ6	DE	Solid tumour/cancer; Ovarian cancer

DMKRFCO	ID	DMKRFCO
DMKRFCO	DN	CDX-301
DMKRFCO	HS	Phase 2
DMKRFCO	DE	Hematopoietic stem cell transplantation; Solid tumour/cancer; Multiple myeloma

DM5GKYD	ID	DM5GKYD
DM5GKYD	DN	CDX-3379
DM5GKYD	HS	Phase 2
DM5GKYD	CP	Celldex Therapeutics Hampton, NJ
DM5GKYD	DE	Solid tumour/cancer; Squamous cell carcinoma

DM6Z9BV	ID	DM6Z9BV
DM6Z9BV	DN	CeaVac
DM6Z9BV	HS	Phase 2
DM6Z9BV	SN	Idiotypic vaccine (CEA), Titan; Monoclonal antibody (cancer), Titan
DM6Z9BV	CP	Titan Pharmaceuticals
DM6Z9BV	DT	Vaccine
DM6Z9BV	DE	Colorectal cancer

DM1S2FZ	ID	DM1S2FZ
DM1S2FZ	DN	Cemdisiran
DM1S2FZ	HS	Phase 2
DM1S2FZ	CP	Alnylam Pharmaceuticals
DM1S2FZ	DT	Small interfering RNA
DM1S2FZ	DE	Paroxysmal nocturnal haemoglobinuria; Haemolytic uraemic syndrome

DMCT8EY	ID	DMCT8EY
DMCT8EY	DN	Cenderitide
DMCT8EY	HS	Phase 2
DMCT8EY	CP	Nile Therapeutics
DMCT8EY	DE	Heart failure; Heart disease

DMU3P1K	ID	DMU3P1K
DMU3P1K	DN	Cenerimod
DMU3P1K	HS	Phase 2
DMU3P1K	SN	1262414-04-9; UNII-Y333RS1786; ACT-334441; Y333RS1786; Cenerimod [INN]; Cenerimod [USAN]; SCHEMBL2671193; GTPL9824; MolPort-044-723-844; KS-000006AE; ZINC167253016; AKOS030630068; CS-6364; DB12705; 1,2-Propanediol, 3-(4-(5-(2-cyclopentyl-6-methoxy-4-pyridinyl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-, (2S)-; (S)-3-((4-(5-(2-Cyclopentyl-6-methoxypyridin-4-yl)(1,2,4)oxadiazol-3-yl)-2-ethyl-6-methylphenyl)oxy)propane-1,2-diol; HY-17606; AS-35045; (S)-3-(4-(5-(2-Cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol
DMU3P1K	CP	Actelion Pharmaceuticals South San Francisco, CA
DMU3P1K	PC	49871973
DMU3P1K	MW	453.5
DMU3P1K	FM	C25H31N3O5
DMU3P1K	IC	InChI=1S/C25H31N3O5/c1-4-16-10-18(9-15(2)23(16)32-14-20(30)13-29)24-27-25(33-28-24)19-11-21(17-7-5-6-8-17)26-22(12-19)31-3/h9-12,17,20,29-30H,4-8,13-14H2,1-3H3/t20-/m0/s1
DMU3P1K	CS	CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)OC)C4CCCC4)C)OC[C@H](CO)O
DMU3P1K	IK	KJKKMMMRWISKRF-FQEVSTJZSA-N
DMU3P1K	IU	(2S)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propane-1,2-diol
DMU3P1K	CA	CAS 1262414-04-9
DMU3P1K	DE	Systemic lupus erythematosus

DMMN21R	ID	DMMN21R
DMMN21R	DN	Cenersen
DMMN21R	HS	Phase 2
DMMN21R	CP	Eleos
DMMN21R	DT	Antisense drug
DMMN21R	PC	56841947
DMMN21R	MW	6415
DMMN21R	FM	C195H253N66O106P19S19
DMMN21R	IC	InChI=1S/C195H253N66O106P19S19/c1-77-43-250(190(282)236-165(77)264)134-32-89(107(336-134)56-317-370(290,389)351-85-28-130(244-20-12-122(198)222-184(244)276)332-103(85)52-313-375(295,394)357-91-34-136(252-45-79(3)167(266)238-192(252)284)340-111(91)60-321-382(302,401)364-99-42-144(260-75-219-150-164(260)231-181(209)235-174(150)273)344-115(99)64-324-378(298,397)360-94-37-139(255-48-82(6)170(269)241-195(255)287)339-110(94)59-320-381(301,400)361-95-38-140(256-71-214-145-157(204)210-69-212-159(145)256)341-112(95)61-322-372(292,391)353-87-30-132(246-22-14-124(200)224-186(246)278)333-104(87)53-314-379(299,398)363-98-41-143(259-74-218-149-163(259)230-180(208)234-173(149)272)345-116(98)65-325-383(303,402)365-96-39-141(257-72-216-147-161(257)228-178(206)232-171(147)270)342-113(96)62-310-368(288,387)349-83-26-128(329-100(83)49-262)242-18-10-120(196)220-182(242)274)355-373(293,392)311-50-101-84(27-129(330-101)243-19-11-121(197)221-183(243)275)350-369(289,388)316-55-106-90(33-135(335-106)251-44-78(2)166(265)237-191(251)283)356-374(294,393)312-51-102-86(29-131(331-102)245-21-13-123(199)223-185(245)277)352-371(291,390)318-57-108-92(35-137(337-108)253-46-80(4)168(267)239-193(253)285)358-376(296,395)319-58-109-93(36-138(338-109)254-47-81(5)169(268)240-194(254)286)359-377(297,396)323-63-114-97(40-142(343-114)258-73-217-148-162(258)229-179(207)233-172(148)271)362-380(300,399)315-54-105-88(31-133(334-105)247-23-15-125(201)225-187(247)279)354-384(304,403)327-67-119-153(156(309-9)177(348-119)261-76-215-146-158(205)211-70-213-160(146)261)367-386(306,405)328-68-118-152(155(308-8)176(347-118)249-25-17-127(203)227-189(249)281)366-385(305,404)326-66-117-151(263)154(307-7)175(346-117)248-24-16-126(202)226-188(248)280/h10-25,43-48,69-76,83-119,128-144,151-156,175-177,262-263H,26-42,49-68H2,1-9H3,(H,288,387)(H,289,388)(H,290,389)(H,291,390)(H,292,391)(H,293,392)(H,294,393)(H,295,394)(H,296,395)(H,297,396)(H,298,397)(H,299,398)(H,300,399)(H,301,400)(H,302,401)(H,303,402)(H,304,403)(H,305,404)(H,306,405)(H2,196,220,274)(H2,197,221,275)(H2,198,222,276)(H2,199,223,277)(H2,200,224,278)(H2,201,225,279)(H2,202,226,280)(H2,203,227,281)(H2,204,210,212)(H2,205,211,213)(H,236,264,282)(H,237,265,283)(H,238,266,284)(H,239,267,285)(H,240,268,286)(H,241,269,287)(H3,206,228,232,270)(H3,207,229,233,271)(H3,208,230,234,272)(H3,209,231,235,273)
DMMN21R	CS	CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)O
DMMN21R	IK	UTNSIDJKCKLZLN-UHFFFAOYSA-N
DMMN21R	IU	1-[5-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMMN21R	DE	Acute myeloid leukaemia

DM4V8WF	ID	DM4V8WF
DM4V8WF	DN	Cenicriviroc
DM4V8WF	HS	Phase 2
DM4V8WF	SN	Cenicriviroc; 497223-25-3; TBR-652; TAK-652; Cenicriviroc mesylate; UNII-15C116UA4Y; TAK652; 15C116UA4Y; TBR652; Cenicriviroc (USAN/INN); SCHEMBL3157768; SCHEMBL3157748; CHEMBL2110727; MolPort-044-723-655; MolPort-044-649-359; EX-A1608; BDBM50422828; AKOS027250788; CS-6148; DB11758; SB16976; HY-14882; AS-35184; D09878; UNII-15C116UA4Y component PNDKCRDVVKJPKG-WHERJAGFSA-N; 1-Benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (5E)-
DM4V8WF	CP	Tobira Therapeutics
DM4V8WF	DT	Small molecular drug
DM4V8WF	PC	11285792
DM4V8WF	MW	696.9
DM4V8WF	FM	C41H52N4O4S
DM4V8WF	IC	InChI=1S/C41H52N4O4S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46)/b34-26+/t50-/m0/s1
DM4V8WF	CS	CCCCOCCOC1=CC=C(C=C1)C2=CC/3=C(C=C2)N(CCC/C(=C3)/C(=O)NC4=CC=C(C=C4)[S@@](=O)CC5=CN=CN5CCC)CC(C)C
DM4V8WF	IK	PNDKCRDVVKJPKG-WHERJAGFSA-N
DM4V8WF	IU	(5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide
DM4V8WF	CA	CAS 497223-25-3
DM4V8WF	CB	CHEBI:149636
DM4V8WF	DE	Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection

DMWUQI9	ID	DMWUQI9
DMWUQI9	DN	CER-001
DMWUQI9	HS	Phase 2
DMWUQI9	CP	Cerenis Therapeutics
DMWUQI9	DE	Acute coronary syndrome; Cardiovascular disease

DMSABRI	ID	DMSABRI
DMSABRI	DN	CERC-301
DMSABRI	HS	Phase 2
DMSABRI	CP	Cerecor
DMSABRI	PC	11394238
DMSABRI	MW	358.4
DMSABRI	FM	C19H23FN4O2
DMSABRI	IC	InChI=1S/C19H23FN4O2/c1-14-3-5-15(6-4-14)13-26-19(25)24-10-7-16(17(20)12-24)11-23-18-21-8-2-9-22-18/h2-6,8-9,16-17H,7,10-13H2,1H3,(H,21,22,23)/t16-,17-/m1/s1
DMSABRI	CS	CC1=CC=C(C=C1)COC(=O)N2CC[C@@H]([C@@H](C2)F)CNC3=NC=CC=N3
DMSABRI	IK	RECBFDWSXWAXHY-IAGOWNOFSA-N
DMSABRI	IU	(4-methylphenyl)methyl (3S,4R)-3-fluoro-4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate
DMSABRI	CA	CAS 808733-05-3
DMSABRI	DE	Major depressive disorder

DM3SZ7P	ID	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	HS	Phase 2
DM3SZ7P	SN	D-(+)-Galactose Anhydrous; D-Galactopyranose; D-Galactopyranoside; D-Galactose; D-Galactose (9CI); D-Glucose-2-13C; Echocon; Echovist; Galactopyranose; Galactopyranoside; Galactose; Galactose, D- (8CI); Galactose, pure; Shu 450; Shu 454; Shu-454; brain sugar; cerebrose; dl-Galactose; 10257-28-0; AC1L1LNU; AC1Q28DZ; AI3-18440; CHEBI:4139; D-Gal; DSSTox_CID_3088; DSSTox_GSID_23088; DSSTox_RID_76869; EINECS 233-595-2; Epitope ID:141794; Gal; MLS001335983; MLS001335984; NCGC00159442-02; SCHEMBL38935; SMR000857326
DM3SZ7P	PC	6036
DM3SZ7P	MW	180.16
DM3SZ7P	FM	C6H12O6
DM3SZ7P	IC	WQZGKKKJIJFFOK-SVZMEOIVSA-N
DM3SZ7P	CS	C(C1C(C(C(C(O1)O)O)O)O)O
DM3SZ7P	IK	1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1
DM3SZ7P	IU	(3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM3SZ7P	CA	CAS 10257-28-0
DM3SZ7P	CB	CHEBI:4139
DM3SZ7P	DE	Glycosylation disorder

DMSCR2H	ID	DMSCR2H
DMSCR2H	DN	Cerdulatinib
DMSCR2H	HS	Phase 2
DMSCR2H	SN	PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals
DMSCR2H	CP	Portola Pharmaceuticals Inc; portola pharmaceuticals
DMSCR2H	PC	44595079
DMSCR2H	MW	445.5
DMSCR2H	FM	C20H27N7O3S
DMSCR2H	IC	InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)
DMSCR2H	CS	CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
DMSCR2H	IK	BGLPECHZZQDNCD-UHFFFAOYSA-N
DMSCR2H	IU	4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
DMSCR2H	CA	CAS 1198300-79-6
DMSCR2H	DE	Non-hodgkin lymphoma; Atopic dermatitis; B-cell lymphoma; Vitiligo

DMNW5I9	ID	DMNW5I9
DMNW5I9	DN	CERE-110
DMNW5I9	HS	Phase 2
DMNW5I9	CP	Ceregene
DMNW5I9	DE	Alzheimer disease

DMS01AX	ID	DMS01AX
DMS01AX	DN	CERE-120
DMS01AX	HS	Phase 2
DMS01AX	SN	Neurturin; NeuroRescue PD; AAV-NTN; AAV2-NRTN; AAV2-Neurturin; NTN gene therapy, Ceregene; Neurological gene therapy, Ceregene; Neurturin gene therapy, Ceregene; Neurturin, Genentech; Parkinsons disease gene therapy, Ceregene; GDNF agonist, StemCells/Genentech; NTN gene-expressing AAV vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme; Neurturin gene-expressing adeno-associated virus vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme
DMS01AX	CP	Ceregene
DMS01AX	DE	Parkinson disease

DMAWKSM	ID	DMAWKSM
DMAWKSM	DN	CetuGEX
DMAWKSM	HS	Phase 2
DMAWKSM	CP	Glycotope GmbH
DMAWKSM	DT	Antibody
DMAWKSM	DE	Solid tumour/cancer

DMP56WJ	ID	DMP56WJ
DMP56WJ	DN	CF102
DMP56WJ	HS	Phase 2
DMP56WJ	SN	2-Cl-IB-Meca; 163042-96-4; Cl-IB-MECA; Namodenoson; C-Ibza-MU; CF-102; CI-IB-MECA; (2S,3S,4R,5R)-5-(2-Chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide; UNII-Z07JR07J6C; 2Cl-IB-MECA; 1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE; CHEMBL431733; Z07JR07J6C; CF102; 2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
DMP56WJ	CP	Can-Fite BioPharm
DMP56WJ	DT	Small molecular drug
DMP56WJ	PC	3035850
DMP56WJ	MW	544.7
DMP56WJ	FM	C18H18ClIN6O4
DMP56WJ	IC	InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1
DMP56WJ	CS	CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O
DMP56WJ	IK	IPSYPUKKXMNCNQ-PFHKOEEOSA-N
DMP56WJ	IU	(2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
DMP56WJ	CA	CAS 163042-96-4
DMP56WJ	DE	Hepatitis C virus infection; Hepatocellular carcinoma

DM3BN4W	ID	DM3BN4W
DM3BN4W	DN	CFI-400945
DM3BN4W	HS	Phase 2
DM3BN4W	SN	CFI 400945; CFI400945
DM3BN4W	DT	Small molecular drug
DM3BN4W	PC	58486178
DM3BN4W	MW	534.6
DM3BN4W	FM	C33H34N4O3
DM3BN4W	IC	InChI=1S/C33H34N4O3/c1-20-17-37(18-21(2)40-20)19-23-6-4-22(5-7-23)8-12-29-26-11-9-24(14-31(26)36-35-29)28-16-33(28)27-15-25(39-3)10-13-30(27)34-32(33)38/h4-15,20-21,28H,16-19H2,1-3H3,(H,34,38)(H,35,36)/b12-8+/t20-,21+,28-,33-/m0/s1
DM3BN4W	CS	C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O
DM3BN4W	IK	DADASRPKWOGKCU-FVTQAUBDSA-N
DM3BN4W	IU	(2'S,3R)-2'-[3-[(E)-2-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5-methoxyspiro[1H-indole-3,1'-cyclopropane]-2-one
DM3BN4W	CA	CAS 1338806-73-7
DM3BN4W	DE	Breast cancer

DM1TWIE	ID	DM1TWIE
DM1TWIE	DN	CFZ533
DM1TWIE	HS	Phase 2
DM1TWIE	CP	Novartis pharmaceuticals
DM1TWIE	DE	Rheumatoid arthritis; Graves disease; Myasthenia gravis; Sjogren syndrome

DMWY609	ID	DMWY609
DMWY609	DN	CG201
DMWY609	HS	Phase 2
DMWY609	SN	Bevonium methyl sulfate; BEVONIUM METILSULFATE; Bevonium methylsulfate; 5205-82-3; Bevonium methylsulphate; Piribenzil methyl sulfate; Bevonii metilsulfas [INN-Latin]; EINECS 226-001-8; CG 201; Metilsulfato de bevonio [INN-Spanish]; Metilsulfate de bevonium [INN-French]; Bevonium metilsulfate [INN]; L-99; 2-(Hydroxymethyl)-1,1-dimethylpiperidinium methyl sulfate benzilate; Piperidinium, 2-(hydroxymethyl)-1,1-dimethyl-, methyl sulfate, benzilate; alpha-Phenylmandelic acid N,N-dimethylpiperidinium-2-methyl ester methylsulfa
DMWY609	CP	CG Therapeutics
DMWY609	DT	Small molecular drug
DMWY609	PC	31799
DMWY609	MW	465.6
DMWY609	FM	C23H31NO7S
DMWY609	IC	InChI=1S/C22H28NO3.CH4O4S/c1-23(2)16-10-9-15-20(23)17-26-21(24)22(25,18-11-5-3-6-12-18)19-13-7-4-8-14-19;1-5-6(2,3)4/h3-8,11-14,20,25H,9-10,15-17H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
DMWY609	CS	C[N+]1(CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C.COS(=O)(=O)[O-]
DMWY609	IK	AXKJGGRSAVLXTE-UHFFFAOYSA-M
DMWY609	IU	(1,1-dimethylpiperidin-1-ium-2-yl)methyl 2-hydroxy-2,2-diphenylacetate;methyl sulfate
DMWY609	CA	CAS 5205-82-3
DMWY609	CB	CHEBI:31283
DMWY609	DE	Solid tumour/cancer

DMFAKGR	ID	DMFAKGR
DMFAKGR	DN	CG-400549
DMFAKGR	HS	Phase 2
DMFAKGR	SN	CG-400329; CG-400462; CG-400587; Bacterial enoyl-ACP reductase inhibitors, CrystalGenomics; FabI inhibitors (antibacterial), CrystalGenomics; FabK inhibitors (bacterial infections, oral), CrystalGenomics
DMFAKGR	CP	Cg pharmaceuticals
DMFAKGR	DT	Small molecular drug
DMFAKGR	PC	11844916
DMFAKGR	MW	340.4
DMFAKGR	FM	C19H20N2O2S
DMFAKGR	IC	InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3
DMFAKGR	CS	CC1=C(C=CC=C1N)CN2C=CC(=CC2=O)OCCC3=CC=CS3
DMFAKGR	IK	YCLREGRRHGLOAK-UHFFFAOYSA-N
DMFAKGR	IU	1-[(3-amino-2-methylphenyl)methyl]-4-(2-thiophen-2-ylethoxy)pyridin-2-one
DMFAKGR	CA	CAS 934628-27-0
DMFAKGR	DE	Bacterial infection

DM17JSI	ID	DM17JSI
DM17JSI	DN	CGC-11047
DM17JSI	HS	Phase 2
DM17JSI	SN	UNII-2C4Y86R2AX; 2C4Y86R2AX; (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine; 206991-64-2; CHEMBL3104344; CGC-11047 free base; Pg-11047(free base); AC1O51NW; CHEMBL142464; SCHEMBL2360444; BDBM50445365; 308145-19-9; (Z)-N,N'-Bis[3-(ethylamino)propyl]-2-butene-1,4-diamine; 2-Butene-1,4-diamine, N1,N4-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis[3-(ethylamino)propyl]-, tetrahydrochloride, (2Z)-
DM17JSI	CP	Progen Pharmaceuticals
DM17JSI	DT	Small molecular drug
DM17JSI	PC	6475492
DM17JSI	MW	256.43
DM17JSI	FM	C14H32N4
DM17JSI	IC	InChI=1S/C14H32N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h5-6,15-18H,3-4,7-14H2,1-2H3/b6-5-
DM17JSI	CS	CCNCCCNC/C=C\\CNCCCNCC
DM17JSI	IK	XFWLTFZLLXVKDY-WAYWQWQTSA-N
DM17JSI	IU	(Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine
DM17JSI	CA	CAS 308145-19-9
DM17JSI	DE	Prostate cancer

DMYNTQV	ID	DMYNTQV
DMYNTQV	DN	CGP-28014
DMYNTQV	HS	Phase 2
DMYNTQV	SN	Cgp 28014; 111757-17-6; Methanimidamide, N'-(1,6-dihydro-6-oxo-2-pyridinyl)-N,N-dipropyl-; N-(2-Oxopyridin-6-yl)-N',N'-di-n-propylformamidine; N'-(1,6-Dihydro-6-oxo-2-pyridinyl)-N,N-dipropylmethanimidamide; CGP-28014; N-(2-pyridone-6-yl)-N',N'-di-n-propylformamidine; cgp28014; CHEBI:79969; LS-90457
DMYNTQV	CP	Novartis AG
DMYNTQV	DT	Small molecular drug
DMYNTQV	PC	159470
DMYNTQV	MW	221.3
DMYNTQV	FM	C12H19N3O
DMYNTQV	IC	InChI=1S/C12H19N3O/c1-3-8-15(9-4-2)10-13-11-6-5-7-12(16)14-11/h5-7,10H,3-4,8-9H2,1-2H3,(H,14,16)
DMYNTQV	CS	CCCN(CCC)C=NC1=CC=CC(=O)N1
DMYNTQV	IK	MEYPAYJYAZKERR-UHFFFAOYSA-N
DMYNTQV	IU	N'-(6-oxo-1H-pyridin-2-yl)-N,N-dipropylmethanimidamide
DMYNTQV	CA	CAS 111757-17-6
DMYNTQV	DE	Major depressive disorder

DMKS7RJ	ID	DMKS7RJ
DMKS7RJ	DN	CGS-15873A
DMKS7RJ	HS	Phase 2
DMKS7RJ	SN	Rac-trans-7-Hydroxy-4-propyl-1,2,3,4a,5,10b-hexahydro-4H-[1]benzopyrano[3,4-b]pyridine monohydrochloride
DMKS7RJ	DT	Small molecular drug
DMKS7RJ	PC	195284
DMKS7RJ	MW	283.79
DMKS7RJ	FM	C15H22ClNO2
DMKS7RJ	IC	InChI=1S/C15H21NO2.ClH/c1-2-8-16-9-4-6-11-12-5-3-7-14(17)15(12)18-10-13(11)16;/h3,5,7,11,13,17H,2,4,6,8-10H2,1H3;1H/t11-,13-;/m0./s1
DMKS7RJ	CS	CCCN1CCC[C@@H]2[C@@H]1COC3=C2C=CC=C3O.Cl
DMKS7RJ	IK	CEVXGMUELSDOPY-JZKFLRDJSA-N
DMKS7RJ	IU	(4aR,10bS)-4-propyl-1,2,3,4a,5,10b-hexahydrochromeno[3,4-b]pyridin-7-ol;hydrochloride
DMKS7RJ	CA	CAS 118929-49-0
DMKS7RJ	DE	Psychotic disorder

DMLQRYH	ID	DMLQRYH
DMLQRYH	DN	CH-4051
DMLQRYH	HS	Phase 2
DMLQRYH	CP	Chelsea Therapeutics
DMLQRYH	PC	11532464
DMLQRYH	MW	449.5
DMLQRYH	FM	C23H23N5O5
DMLQRYH	IC	InChI=1S/C23H23N5O5/c1-12(21(30)31)10-18(22(32)33)26-20(29)15-7-4-13(5-8-15)2-3-14-6-9-17-16(11-14)19(24)28-23(25)27-17/h4-9,11,18H,1-3,10H2,(H,26,29)(H,30,31)(H,32,33)(H4,24,25,27,28)/t18-/m0/s1
DMLQRYH	CS	C=C(C[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)CCC2=CC3=C(C=C2)N=C(N=C3N)N)C(=O)O
DMLQRYH	IK	NAWXUBYGYWOOIX-SFHVURJKSA-N
DMLQRYH	IU	(2S)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid
DMLQRYH	DE	Rheumatoid arthritis

DMQ2O8V	ID	DMQ2O8V
DMQ2O8V	DN	CHF-3381
DMQ2O8V	HS	Phase 2
DMQ2O8V	SN	Indantadol; UNII-Z3867B9SQP; Z3867B9SQP; Indantadol [INN]; CHF 3381; N-(2-Indanyl)glycinamide hydrochloride; 2-(2-indanylamino)acetamide; SCHEMBL399565; ZINC9005; MolPort-015-094-768; MNLULKBKWKTZPE-UHFFFAOYSA-N; AKOS009549166
DMQ2O8V	CP	Chiesi
DMQ2O8V	TC	Analgesics
DMQ2O8V	DT	Small molecular drug
DMQ2O8V	PC	10198454
DMQ2O8V	MW	226.7
DMQ2O8V	FM	C11H15ClN2O
DMQ2O8V	IC	InChI=1S/C11H14N2O.ClH/c12-11(14)7-13-10-5-8-3-1-2-4-9(8)6-10;/h1-4,10,13H,5-7H2,(H2,12,14);1H
DMQ2O8V	CS	C1C(CC2=CC=CC=C21)NCC(=O)N.Cl
DMQ2O8V	IK	JPNNIRXUJSPGRM-UHFFFAOYSA-N
DMQ2O8V	IU	2-(2,3-dihydro-1H-inden-2-ylamino)acetamide;hydrochloride
DMQ2O8V	CA	CAS 202914-18-9
DMQ2O8V	DE	Neuropathic pain

DMTE071	ID	DMTE071
DMTE071	DN	CHF-5074
DMTE071	HS	Phase 2
DMTE071	SN	CHF 5074; CHF5074; 749269-83-8; CHF-5074; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261
DMTE071	CP	Chiesi Pharmaceuticals
DMTE071	DT	Small molecular drug
DMTE071	PC	9996409
DMTE071	MW	325.2
DMTE071	FM	C16H11Cl2FO2
DMTE071	IC	InChI=1S/C16H11Cl2FO2/c17-12-4-1-9(7-13(12)18)11-3-2-10(8-14(11)19)16(5-6-16)15(20)21/h1-4,7-8H,5-6H2,(H,20,21)
DMTE071	CS	C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)Cl)Cl)F)C(=O)O
DMTE071	IK	LIYLTQQDABRNRX-UHFFFAOYSA-N
DMTE071	IU	1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid
DMTE071	CA	CAS 749269-83-8
DMTE071	DE	Alzheimer disease; Cognitive impairment

DMALN2M	ID	DMALN2M
DMALN2M	DN	Cholyl lysyl fluorescein
DMALN2M	HS	Phase 2
DMALN2M	PC	44470395
DMALN2M	FM	C51H63N3O11S
DMALN2M	IC	InChI=1S/C51H63N3O11S/c1-26(36-14-15-37-46-38(25-43(59)51(36,37)3)50(2)18-17-31(57)20-27(50)21-40(46)58)7-16-44(60)54-39(48(63)64)6-4-5-19-52-49(66)53-28-8-11-32(35(22-28)47(61)62)45-33-12-9-29(55)23-41(33)65-42-24-30(56)10-13-34(42)45/h8-13,22-24,26-27,31,36-40,43,46,55,57-59H,4-7,14-21,25H2,1-3H3,(H,54,60)(H,61,62)(H,63,64)(H2,52,53,66)/t26-,27+,31-,36-,37+,38+,39+,40-,43+,46+,50+,51-/m1/s1
DMALN2M	CS	CC(CCC(=O)NC(CCCCNC(=S)NC1=CC(=C(C=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O)C(=O)O)C5CCC6C5(C(CC7C6C(CC8C7(CCC(C8)O)C)O)O)C
DMALN2M	IK	ZUJFMZPBQQCXQR-TZCNZRNCSA-N
DMALN2M	IU	5-[[(5S)-5-carboxy-5-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]pentyl]carbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid
DMALN2M	DE	Hepatitis virus infection

DMULZ4W	ID	DMULZ4W
DMULZ4W	DN	CHR-2797
DMULZ4W	HS	Phase 2
DMULZ4W	SN	Tosedostat; Tosedostat, CHR2797, CHR-2797
DMULZ4W	CP	Chroma Therape.
DMULZ4W	TC	Anticancer Agents
DMULZ4W	DT	Small molecular drug
DMULZ4W	PC	15547703
DMULZ4W	MW	406.5
DMULZ4W	FM	C21H30N2O6
DMULZ4W	IC	InChI=1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1
DMULZ4W	CS	CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@@H](C1=CC=CC=C1)C(=O)OC2CCCC2
DMULZ4W	IK	FWFGIHPGRQZWIW-SQNIBIBYSA-N
DMULZ4W	IU	cyclopentyl (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-2-phenylacetate
DMULZ4W	CA	CAS 238750-77-1
DMULZ4W	CB	CHEBI:95044
DMULZ4W	DE	Acute myeloid leukaemia; Myelodysplastic syndrome; Inflammation

DMMRKPF	ID	DMMRKPF
DMMRKPF	DN	CHS-131
DMMRKPF	HS	Phase 2
DMMRKPF	CP	Coherus Biosciences Redwood City, CA
DMMRKPF	DE	Multiple sclerosis

DMLRTN1	ID	DMLRTN1
DMLRTN1	DN	CI-1012
DMLRTN1	HS	Phase 2
DMLRTN1	SN	NCS-675753; PD-161374; HIV replication inhibitor, Parke-Davis/NIAID
DMLRTN1	CP	Parke-Davis & Co Ltd
DMLRTN1	DT	Small molecular drug
DMLRTN1	PC	72552
DMLRTN1	MW	304.4
DMLRTN1	FM	C14H12N2O2S2
DMLRTN1	IC	InChI=1S/C14H12N2O2S2/c15-13(17)9-5-1-3-7-11(9)19-20-12-8-4-2-6-10(12)14(16)18/h1-8H,(H2,15,17)(H2,16,18)
DMLRTN1	CS	C1=CC=C(C(=C1)C(=O)N)SSC2=CC=CC=C2C(=O)N
DMLRTN1	IK	OEEHSSKRJOGQMP-UHFFFAOYSA-N
DMLRTN1	IU	2-[(2-carbamoylphenyl)disulfanyl]benzamide
DMLRTN1	CA	CAS 2527-57-3
DMLRTN1	DE	Acquired immune deficiency syndrome

DMSI8N3	ID	DMSI8N3
DMSI8N3	DN	CI-1033
DMSI8N3	HS	Phase 2
DMSI8N3	SN	Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride
DMSI8N3	CP	Pfizer
DMSI8N3	TC	Anticancer Agents
DMSI8N3	DT	Small molecular drug
DMSI8N3	PC	156414
DMSI8N3	MW	485.9
DMSI8N3	FM	C24H25ClFN5O3
DMSI8N3	IC	InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)
DMSI8N3	CS	C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
DMSI8N3	IK	OMZCMEYTWSXEPZ-UHFFFAOYSA-N
DMSI8N3	IU	N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide
DMSI8N3	CA	CAS 267243-28-7
DMSI8N3	CB	CHEBI:61399
DMSI8N3	DE	Lymphoma

DMCFLRH	ID	DMCFLRH
DMCFLRH	DN	Cibinetide
DMCFLRH	HS	Phase 2
DMCFLRH	SN	UNII-9W5677JKDA; 9W5677JKDA; 1208243-50-8; Cibinetide [USAN]; Pglu-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser; Pyr-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser-OH; GTPL9677; CHEMBL3545305; DB13006; L-Serine, 5-oxo-L-prolyl-L-alpha-glutamyl-L-glutaminyl-L-leucyl-L-alpha-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-; L-Pyroglutamyl-L-glutamyl-L-glutaminyl-L-leucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine; L-Pyroglutamyl-L-glutamyl-L-glutam
DMCFLRH	CP	Araim Pharmaceuticals Tarrytown, NY
DMCFLRH	PC	91810664
DMCFLRH	MW	1257.3
DMCFLRH	FM	C51H84N16O21
DMCFLRH	IC	InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DMCFLRH	CS	C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1
DMCFLRH	IK	WZTIQQBMSJTRBR-WYKNNRPVSA-N
DMCFLRH	IU	(4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
DMCFLRH	CA	CAS 1208243-50-8
DMCFLRH	DE	Depression; Diabetic macular edema; Neuropathic pain; Sarcoidosis; Peripheral neuropathy

DMGTZLW	ID	DMGTZLW
DMGTZLW	DN	Cicletanine
DMGTZLW	HS	Phase 2
DMGTZLW	SN	Cicletanine; Cycletanide; Tenstaten; 89943-82-8; Justar; BN-1270; Win-90000; cicletanide; BN 1270; Cicletaninum; Cicletanina; Cicletaninum [Latin]; Cicletanina [Spanish]; Cicletanine [USAN:INN:BAN]; Win 90,000; ACMC-20mckj; ACMC-20mcin; AC1Q3NNY; Cicletanine (USAN/INN); (+-)-BN-1270; AC1L1HZ3; SCHEMBL49794; CHEMBL191886; (R)-(-)-CICLETANINE; CHEBI:135078; Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (S)-; Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (R)-; CVKNDPRBJVBDSS-UHFFFAOYSA-N
DMGTZLW	CP	Gilead Sciences
DMGTZLW	DT	Small molecular drug
DMGTZLW	PC	54910
DMGTZLW	MW	261.7
DMGTZLW	FM	C14H12ClNO2
DMGTZLW	IC	InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3
DMGTZLW	CS	CC1=NC=C2C(OCC2=C1O)C3=CC=C(C=C3)Cl
DMGTZLW	IK	CVKNDPRBJVBDSS-UHFFFAOYSA-N
DMGTZLW	IU	3-(4-chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
DMGTZLW	CA	CAS 89943-82-8
DMGTZLW	CB	CHEBI:135078
DMGTZLW	DE	Pulmonary arterial hypertension

DMTKSVA	ID	DMTKSVA
DMTKSVA	DN	CIMICOXIB
DMTKSVA	HS	Phase 2
DMTKSVA	SN	Cimicoxib; 265114-23-6; UNII-W7FHJ107MC; UR-8880; W7FHJ107MC; CHEMBL435381; CHEBI:76127; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide; 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide; Cimicoxib [INN]; 4-(4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl)benzenesulfonamide; AC1Q6UZ8; AC1L4U5V; SCHEMBL3123310; CTK4F8038; DTXSID30181093; KYXDNECMRLFQMZ-UHFFFAOYSA-N; BCP24933; ZINC1494105
DMTKSVA	DT	Small molecular drug
DMTKSVA	PC	213053
DMTKSVA	MW	381.8
DMTKSVA	FM	C16H13ClFN3O3S
DMTKSVA	IC	InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)
DMTKSVA	CS	COC1=C(C=C(C=C1)C2=C(N=CN2C3=CC=C(C=C3)S(=O)(=O)N)Cl)F
DMTKSVA	IK	KYXDNECMRLFQMZ-UHFFFAOYSA-N
DMTKSVA	IU	4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide
DMTKSVA	CA	CAS 265114-23-6
DMTKSVA	CB	CHEBI:76127
DMTKSVA	DE	Pain

DMGEAM6	ID	DMGEAM6
DMGEAM6	DN	Cinaciguat
DMGEAM6	HS	Phase 2
DMGEAM6	SN	Cinaciguat; 329773-35-5; BAY 58-2667; BAY582667; UNII-59K0Y58UAD; BAY-58-2667; 59K0Y58UAD; 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid; Cinaciguat [INN:JAN]; cinaciguatum; Z90; Cinaciguat (JAN/INN); SCHEMBL249267; GTPL5168; CHEMBL1236936; QCR-279; Cinaciguat (BAY 58-2667); MolPort-039-139-611; CHEBI:142433; ZINC3934935; BCP07942; 3550AH; AKOS026750293; AN-1845; CS-1169; HY-14181; KB-40005; AB0095741; D07577; W-5794
DMGEAM6	DT	Small molecular drug
DMGEAM6	PC	9808022
DMGEAM6	MW	565.7
DMGEAM6	FM	C36H39NO5
DMGEAM6	IC	InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41)
DMGEAM6	CS	C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O
DMGEAM6	IK	WPYWMXNXEZFMAK-UHFFFAOYSA-N
DMGEAM6	IU	4-[[4-carboxybutyl-[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid
DMGEAM6	CA	CAS 329773-35-5
DMGEAM6	CB	CHEBI:142433
DMGEAM6	DE	Acute decompensated heart failure

DM98RW0	ID	DM98RW0
DM98RW0	DN	Cirmtuzumab
DM98RW0	HS	Phase 2
DM98RW0	SN	UC-961
DM98RW0	CP	Oncternal Therapeutics San Diego, CA
DM98RW0	DE	Mantle cell lymphoma; Chronic lymphocytic leukaemia

DMNRYPF	ID	DMNRYPF
DMNRYPF	DN	Cixutumumab
DMNRYPF	HS	Phase 2
DMNRYPF	SN	LY3012217
DMNRYPF	CP	Lilly
DMNRYPF	DT	Monoclonal antibody
DMNRYPF	DE	Non-small-cell lung cancer; Liver cancer

DMOFTRE	ID	DMOFTRE
DMOFTRE	DN	Cizolirtine
DMOFTRE	HS	Phase 2
DMOFTRE	SN	Cizolirtine [INN]; N,N-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine; N,N-dimethyl-2-[(R)-(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine
DMOFTRE	CP	Esteve Laboratories
DMOFTRE	TC	Analgesics
DMOFTRE	DT	Small molecular drug
DMOFTRE	PC	132412
DMOFTRE	MW	259.35
DMOFTRE	FM	C15H21N3O
DMOFTRE	IC	InChI=1S/C15H21N3O/c1-17(2)11-12-19-15(13-7-5-4-6-8-13)14-9-10-16-18(14)3/h4-10,15H,11-12H2,1-3H3
DMOFTRE	CS	CN1C(=CC=N1)C(C2=CC=CC=C2)OCCN(C)C
DMOFTRE	IK	DCMJBKFKXGPPMT-UHFFFAOYSA-N
DMOFTRE	IU	N,N-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine
DMOFTRE	CA	CAS 142155-43-9
DMOFTRE	DE	Neuropathic pain

DMTSVJM	ID	DMTSVJM
DMTSVJM	DN	CJM112
DMTSVJM	HS	Phase 2
DMTSVJM	CP	Novartis Pharmaceuticals East Hanover, NJ
DMTSVJM	DE	Chronic plaque psoriasis; Multiple myeloma; Plaque psoriasis; Solid tumour/cancer; Acne vulgaris

DM9FHV8	ID	DM9FHV8
DM9FHV8	DN	CK-2127107
DM9FHV8	HS	Phase 2
DM9FHV8	CP	Cytokinetics
DM9FHV8	PC	67454400
DM9FHV8	MW	384.4
DM9FHV8	FM	C19H18F2N6O
DM9FHV8	IC	InChI=1S/C19H18F2N6O/c20-13-6-19(7-13,16-15(21)2-1-4-23-16)11-26-18-24-8-14(9-25-18)27-5-3-12(10-27)17(22)28/h1-5,8-10,13H,6-7,11H2,(H2,22,28)(H,24,25,26)
DM9FHV8	CS	C1C(CC1(CNC2=NC=C(C=N2)N3C=CC(=C3)C(=O)N)C4=C(C=CC=N4)F)F
DM9FHV8	IK	MQXWPWOCXGARRK-UHFFFAOYSA-N
DM9FHV8	IU	1-[2-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyrimidin-5-yl]pyrrole-3-carboxamide
DM9FHV8	CA	CAS 1345410-31-2
DM9FHV8	DE	Muscle atrophy; Amyotrophic lateral sclerosis; Spinal muscular atrophy

DMW9F1G	ID	DMW9F1G
DMW9F1G	DN	CKD602
DMW9F1G	HS	Phase 2
DMW9F1G	SN	Belotecan hydrochloride; 213819-48-8; Belotecan; CKD-602; Belotecan HCl; Camtobell hydrochloride; Belotecan (hydrochloride); CKD 602; UNII-01DZ4127G7; 01DZ4127G7; Belotecan hydrochloride (USAN); Belotecan Hydrochloride [USAN]; CHEMBL2107315; DTXSID60175647; BCP28717; HY-13566A; AKOS027420465; API0009359; CS-6955; (S)-4-ethyl-4-hydroxy-11-(2-(isopropylamino)ethyl)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride; AN-29684; ACM213819488; FT-0662513; D03225; 819C488; J-014022
DMW9F1G	DT	Small molecular drug
DMW9F1G	PC	6456014
DMW9F1G	MW	433.5
DMW9F1G	FM	C25H27N3O4
DMW9F1G	IC	InChI=1S/C25H27N3O4/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3/t25-/m0/s1
DMW9F1G	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CCNC(C)C)O
DMW9F1G	IK	LNHWXBUNXOXMRL-VWLOTQADSA-N
DMW9F1G	IU	(19S)-19-ethyl-19-hydroxy-10-[2-(propan-2-ylamino)ethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMW9F1G	CA	CAS 256411-32-2
DMW9F1G	CB	CHEBI:135702
DMW9F1G	DE	Solid tumour/cancer

DMXH1KC	ID	DMXH1KC
DMXH1KC	DN	CL-316,243
DMXH1KC	HS	Phase 2
DMXH1KC	SN	UNII-52H8DB0TKX; 52H8DB0TKX; 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid; CL-316243; 5-((2R)-2-(((2R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)-1,3-benzodioxole-2,2-dicarboxylic acid; CL 316243; CL316,243; Cl-316243 Free diacid; AC1NUOLQ; Lopac0_000295; SCHEMBL2345491; GTPL3462; CHEMBL1204876; BDBM25763; ZINC1493298; 183720-02-7; 1,3-Benzodioxole-2,2-dicarboxylic acid, 5-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-; LS-187111
DMXH1KC	DT	Small molecular drug
DMXH1KC	PC	5312115
DMXH1KC	MW	465.8
DMXH1KC	FM	C20H18ClNNa2O7
DMXH1KC	IC	InChI=1S/C20H20ClNO7.2Na/c1-11(22-10-15(23)13-3-2-4-14(21)9-13)7-12-5-6-16-17(8-12)29-20(28-16,18(24)25)19(26)27;;/h2-6,8-9,11,15,22-23H,7,10H2,1H3,(H,24,25)(H,26,27);;/q;2*+1/p-2/t11-,15+;;/m1../s1
DMXH1KC	CS	C[C@H](CC1=CC2=C(C=C1)OC(O2)(C(=O)[O-])C(=O)[O-])NC[C@@H](C3=CC(=CC=C3)Cl)O.[Na+].[Na+]
DMXH1KC	IK	FUZBPOHHSBDTJQ-CFOQQKEYSA-L
DMXH1KC	IU	disodium;5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate
DMXH1KC	CA	CAS 138908-40-4
DMXH1KC	DE	Obesity

DMSF7WJ	ID	DMSF7WJ
DMSF7WJ	DN	CL-329167
DMSF7WJ	HS	Phase 2
DMSF7WJ	SN	2-Butyl-6-(1-methoxy-1-methylethyl)-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]quinazolin-4(3H)-one
DMSF7WJ	DT	Small molecular drug
DMSF7WJ	PC	6918269
DMSF7WJ	MW	508.6
DMSF7WJ	FM	C30H32N6O2
DMSF7WJ	IC	InChI=1S/C30H32N6O2/c1-5-6-11-27-31-26-17-16-22(30(2,3)38-4)18-25(26)29(37)36(27)19-20-12-14-21(15-13-20)23-9-7-8-10-24(23)28-32-34-35-33-28/h7-10,12-18H,5-6,11,19H2,1-4H3,(H,32,33,34,35)
DMSF7WJ	CS	CCCCC1=NC2=C(C=C(C=C2)C(C)(C)OC)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMSF7WJ	IK	XZCUIMYYMKTCBA-UHFFFAOYSA-N
DMSF7WJ	IU	2-butyl-6-(2-methoxypropan-2-yl)-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-4-one
DMSF7WJ	DE	Hypertension

DM6ZOUV	ID	DM6ZOUV
DM6ZOUV	DN	Clazakizumab
DM6ZOUV	HS	Phase 2 
DM6ZOUV	SN	Clazakizumab; ALD518; CHEMBL2108589; BMS-945429
DM6ZOUV	TC	Antiviral Agents
DM6ZOUV	DT	Monoclonal antibody
DM6ZOUV	DE	Coronavirus Disease 2019 (COVID-19)

DMAIW6C	ID	DMAIW6C
DMAIW6C	DN	Clazakizumab
DMAIW6C	HS	Phase 2
DMAIW6C	CP	Bristol-myers squibb; alder biopharmaceuticals
DMAIW6C	DT	Monoclonal antibody
DMAIW6C	DE	Crohn disease; Rheumatoid arthritis

DMU6R3O	ID	DMU6R3O
DMU6R3O	DN	CLG561
DMU6R3O	HS	Phase 2
DMU6R3O	CP	Alcon
DMU6R3O	DT	Antibody
DMU6R3O	DE	Geographic retinal atrophy

DMH2VS0	ID	DMH2VS0
DMH2VS0	DN	CLP-1001
DMH2VS0	HS	Phase 2
DMH2VS0	SN	Cross-linked polyelectrolyte polymer (renal disease), Sorbent Therapeutics
DMH2VS0	CP	Sorbent therapeutics
DMH2VS0	DE	Chronic heart failure

DMAW4EL	ID	DMAW4EL
DMAW4EL	DN	CLR-1404
DMAW4EL	HS	Phase 2
DMAW4EL	SN	CLR-1501; CLR-1502
DMAW4EL	CP	Cellectar LLC
DMAW4EL	DE	Solid tumour/cancer

DM3Z6IQ	ID	DM3Z6IQ
DM3Z6IQ	DN	CLR-3001
DM3Z6IQ	HS	Phase 2
DM3Z6IQ	CP	Clera Inc
DM3Z6IQ	DE	Major depressive disorder

DMQSIY1	ID	DMQSIY1
DMQSIY1	DN	CLS003
DMQSIY1	HS	Phase 2
DMQSIY1	SN	Furosemide/digoxin; ICVT; Ionic contra viral therapy
DMQSIY1	CP	Cutanea Wayne, PA
DMQSIY1	DE	Plantar wart

DM1NCUY	ID	DM1NCUY
DM1NCUY	DN	CMI-392
DM1NCUY	HS	Phase 2
DM1NCUY	SN	LDP-392; 3-[2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[trans-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzyl]-1-hydroxy-1-methylurea
DM1NCUY	CP	Millennium Pharmaceuticals
DM1NCUY	DT	Small molecular drug
DM1NCUY	PC	6918268
DM1NCUY	MW	633.2
DM1NCUY	FM	C31H37ClN2O8S
DM1NCUY	IC	InChI=1S/C31H37ClN2O8S/c1-34(36)31(35)33-18-21-14-19(15-26(37-2)29(21)41-12-13-43-23-8-6-22(32)7-9-23)24-10-11-25(42-24)20-16-27(38-3)30(40-5)28(17-20)39-4/h6-9,14-17,24-25,36H,10-13,18H2,1-5H3,(H,33,35)/t24-,25-/m0/s1
DM1NCUY	CS	CN(C(=O)NCC1=C(C(=CC(=C1)[C@@H]2CC[C@H](O2)C3=CC(=C(C(=C3)OC)OC)OC)OC)OCCSC4=CC=C(C=C4)Cl)O
DM1NCUY	IK	LZVBMKDVEPGGFK-DQEYMECFSA-N
DM1NCUY	IU	3-[[2-[2-(4-chlorophenyl)sulfanylethoxy]-3-methoxy-5-[(2S,5S)-5-(3,4,5-trimethoxyphenyl)oxolan-2-yl]phenyl]methyl]-1-hydroxy-1-methylurea
DM1NCUY	DE	Psoriasis vulgaris

DM7GELO	ID	DM7GELO
DM7GELO	DN	CMVpp65-A0201
DM7GELO	HS	Phase 2
DM7GELO	SN	CMV vaccine (pp65 antigen), City of Hope
DM7GELO	CP	City of Hope
DM7GELO	DT	Vaccine
DM7GELO	DE	Cytomegalovirus infection

DMPSCVY	ID	DMPSCVY
DMPSCVY	DN	CMX-2043
DMPSCVY	HS	Phase 2
DMPSCVY	CP	Ischemix
DMPSCVY	PC	49802864
DMPSCVY	MW	406.5
DMPSCVY	FM	C16H26N2O6S2
DMPSCVY	IC	InChI=1S/C16H26N2O6S2/c1-10(16(23)24)17-15(22)12(6-7-14(20)21)18-13(19)5-3-2-4-11-8-9-25-26-11/h10-12H,2-9H2,1H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)/t10-,11+,12-/m0/s1
DMPSCVY	CS	C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1
DMPSCVY	IK	MQXRTCVZPIHBLD-TUAOUCFPSA-N
DMPSCVY	IU	(4S)-5-[[(1S)-1-carboxyethyl]amino]-4-[5-[(3R)-dithiolan-3-yl]pentanoylamino]-5-oxopentanoic acid
DMPSCVY	CA	CAS 910627-26-8
DMPSCVY	DE	Myocardial reperfusion injury; Cardiac disease

DM0MTP8	ID	DM0MTP8
DM0MTP8	DN	CN-105
DM0MTP8	HS	Phase 2
DM0MTP8	SN	5-Nitroisoquinoline; 607-32-9; Isoquinoline, 5-nitro-; 5-Nitro-isoquinoline; MLS002637661; PYGMPFQCCWBTJQ-UHFFFAOYSA-N; 5-nitroisochinolin; EINECS 210-133-8; 5-nitro isoquinoline; PubChem6272; AI3-61887; Maybridge1_001820; ACMC-1AV1Q; AC1Q1X2S; 5-Nitroisoquinoline, 98%; Oprea1_032003; SCHEMBL1010663; AC1Q201M; AC1L2B31; CHEMBL353253; PYGMPFQCCWBTJQ-UHFFFAOYSA-; KS-00000DJC; CTK2F2846; ZINC93213; HMS546K16; DTXSID00209511; NSC3017; MolPort-001-761-771; HMS3078A13; ACT09900; ALBB-021274; NSC-3017; ANW-33564; SBB066313; MFCD00006905
DM0MTP8	CP	AegisCN Raleigh, NC
DM0MTP8	PC	69085
DM0MTP8	MW	174.16
DM0MTP8	FM	C9H6N2O2
DM0MTP8	IC	InChI=1S/C9H6N2O2/c12-11(13)9-3-1-2-7-6-10-5-4-8(7)9/h1-6H
DM0MTP8	CS	C1=CC2=C(C=CN=C2)C(=C1)[N+](=O)[O-]
DM0MTP8	IK	PYGMPFQCCWBTJQ-UHFFFAOYSA-N
DM0MTP8	IU	5-nitroisoquinoline
DM0MTP8	CA	CAS 607-32-9
DM0MTP8	DE	Nontraumatic intracerebral hemorrhage

DM16KJ3	ID	DM16KJ3
DM16KJ3	DN	CNS-5161
DM16KJ3	HS	Phase 2
DM16KJ3	SN	CNS5161; 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine; 2-[2-chloro-5-(methylsulfanyl)phenyl]-1-methyl-1-[3-(methylsulfanyl)phenyl]guanidine
DM16KJ3	CP	CeNeS
DM16KJ3	TC	Analgesics
DM16KJ3	DT	Small molecular drug
DM16KJ3	PC	192711
DM16KJ3	MW	351.9
DM16KJ3	FM	C16H18ClN3S2
DM16KJ3	IC	InChI=1S/C16H18ClN3S2/c1-20(11-5-4-6-12(9-11)21-2)16(18)19-15-10-13(22-3)7-8-14(15)17/h4-10H,1-3H3,(H2,18,19)
DM16KJ3	CS	CN(C1=CC(=CC=C1)SC)C(=NC2=C(C=CC(=C2)SC)Cl)N
DM16KJ3	IK	JHVHEDNLONERHY-UHFFFAOYSA-N
DM16KJ3	IU	2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine
DM16KJ3	CA	CAS 160754-76-7
DM16KJ3	DE	Neuropathic pain

DM2PEU5	ID	DM2PEU5
DM2PEU5	DN	CNSB-001
DM2PEU5	HS	Phase 2
DM2PEU5	SN	Flupirtine + opioid (fixed dose, diabetic neuropathic pain), CNSBio; Flupirtine + opioid (fixed dose, diabetic neuropathic pain), Relevare
DM2PEU5	CP	Relevare Pharmaceuticals Ltd
DM2PEU5	DE	Neuropathic pain

DMOR8SY	ID	DMOR8SY
DMOR8SY	DN	CNT0-1959
DMOR8SY	HS	Phase 2
DMOR8SY	CP	Janssen biotech
DMOR8SY	DT	Antibody
DMOR8SY	DE	Rheumatoid arthritis

DM6RQXB	ID	DM6RQXB
DM6RQXB	DN	CNTO-6785
DM6RQXB	HS	Phase 2
DM6RQXB	CP	Janssen research & development
DM6RQXB	DT	Antibody
DM6RQXB	DE	Rheumatoid arthritis

DMLT7JV	ID	DMLT7JV
DMLT7JV	DN	CNV-2197944
DMLT7JV	HS	Phase 2
DMLT7JV	SN	GSK-2197944; Cav2.2 channel blocker (chronic pain), GlaxoSmithKline/Convergence Pharmaceuticals
DMLT7JV	CP	GlaxoSmithKline plc
DMLT7JV	PC	44595848
DMLT7JV	MW	427.4
DMLT7JV	FM	C19H20F3N3O3S
DMLT7JV	IC	InChI=1S/C19H20F3N3O3S/c1-13-12-24(10-11-25(13)18(26)17-4-3-9-23-14(17)2)29(27,28)16-7-5-15(6-8-16)19(20,21)22/h3-9,13H,10-12H2,1-2H3/t13-/m0/s1
DMLT7JV	CS	C[C@H]1CN(CCN1C(=O)C2=C(N=CC=C2)C)S(=O)(=O)C3=CC=C(C=C3)C(F)(F)F
DMLT7JV	IK	BLFJGFDZMABYMY-ZDUSSCGKSA-N
DMLT7JV	IU	(2-methylpyridin-3-yl)-[(2S)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone
DMLT7JV	CA	CAS 1204535-44-3
DMLT7JV	DE	Pain

DMH5GQU	ID	DMH5GQU
DMH5GQU	DN	CO-101
DMH5GQU	HS	Phase 2
DMH5GQU	SN	methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester
DMH5GQU	CP	Clovis Oncology
DMH5GQU	DT	Small molecular drug
DMH5GQU	PC	9828310
DMH5GQU	MW	527.6
DMH5GQU	FM	C27H43F2N3O5
DMH5GQU	IC	InChI=1S/C27H43F2N3O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(33)36-20-21-24(34)27(28,29)25(37-21)32-19-18-22(30)31-26(32)35/h9-10,18-19,21,24-25,34H,2-8,11-17,20H2,1H3,(H2,30,31,35)/b10-9+/t21-,24-,25-/m1/s1
DMH5GQU	CS	CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O
DMH5GQU	IK	HESSNRGIEVBPRB-QDDPNBLJSA-N
DMH5GQU	IU	[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate
DMH5GQU	CA	CAS 210829-30-4
DMH5GQU	DE	Pancreatic cancer

DMF4MX9	ID	DMF4MX9
DMF4MX9	DN	Cobomarsen
DMF4MX9	HS	Phase 2
DMF4MX9	SN	MRG-106
DMF4MX9	CP	miRagen Therapeutics Boulder, CO
DMF4MX9	DE	Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Cutaneous T-cell lymphoma

DMDWG36	ID	DMDWG36
DMDWG36	DN	Codrituzumab
DMDWG36	HS	Phase 2
DMDWG36	CP	GenentechSouth San Francisco, CA
DMDWG36	DE	Hepatic metastasis

DMO0VGH	ID	DMO0VGH
DMO0VGH	DN	Coenzyme Q10 analog
DMO0VGH	HS	Phase 2
DMO0VGH	SN	Coenzyme Q10 analog (mitochondrial disease); Coenzyme Q10 analog (mitochondrial disease), Edison Pharmaceuticals
DMO0VGH	CP	Edison Pharmaceuticals Inc
DMO0VGH	DE	Huntington disease; Leigh syndrome; Mitochondrial respiratory chain disease; Rett syndrome

DMNC76I	ID	DMNC76I
DMNC76I	DN	COL-1077
DMNC76I	HS	Phase 2
DMNC76I	CP	Columbia Laboratories Inc
DMNC76I	DE	Pain

DMSGFOY	ID	DMSGFOY
DMSGFOY	DN	Coltuximab ravtansine
DMSGFOY	HS	Phase 2
DMSGFOY	CP	ImmunoGen Waltham, MA
DMSGFOY	DE	Diffuse large B-cell lymphoma; Non-hodgkin lymphoma

DMI2GSK	ID	DMI2GSK
DMI2GSK	DN	Coluracetam
DMI2GSK	HS	Phase 2
DMI2GSK	SN	BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells
DMI2GSK	CP	Mitsubishi Pharma Corp
DMI2GSK	DT	Small molecular drug
DMI2GSK	PC	214346
DMI2GSK	MW	341.4
DMI2GSK	FM	C19H23N3O3
DMI2GSK	IC	InChI=1S/C19H23N3O3/c1-11-12(2)25-19-17(11)18(13-6-3-4-7-14(13)20-19)21-15(23)10-22-9-5-8-16(22)24/h3-10H2,1-2H3,(H,20,21,23)
DMI2GSK	CS	CC1=C(OC2=NC3=C(CCCC3)C(=C12)NC(=O)CN4CCCC4=O)C
DMI2GSK	IK	PSPGQHXMUKWNDI-UHFFFAOYSA-N
DMI2GSK	IU	N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide
DMI2GSK	CA	CAS 135463-81-9
DMI2GSK	DE	Alzheimer disease

DMGCTX5	ID	DMGCTX5
DMGCTX5	DN	Combined PR1/WT1 vaccine
DMGCTX5	HS	Phase 2
DMGCTX5	SN	Combined PR1/WT1 vaccine (leukemia); Combined PR1/WT1 vaccine (leukemia), NIH; Proteinase 1/Wilms tumor 1 vaccine (leukemia), NIH
DMGCTX5	CP	National Institutes of Health
DMGCTX5	DT	Vaccine
DMGCTX5	DE	Myeloid leukaemia

DM2UOSN	ID	DM2UOSN
DM2UOSN	DN	Conatumumab
DM2UOSN	HS	Phase 2
DM2UOSN	CP	Amgen; Takeda
DM2UOSN	DT	Monoclonal antibody
DM2UOSN	DE	Pain; Colorectal cancer

DMZ0F65	ID	DMZ0F65
DMZ0F65	DN	Contezolid
DMZ0F65	HS	Phase 2
DMZ0F65	SN	MRX-I; UNII-B669M62ELP; B669M62ELP; CHEMBL3287379; 1112968-42-9; 4(1H)-Pyridinone, 2,3-dihydro-1-(2,3,6-trifluoro-4-((5S)-5-((3-isoxazolylamino)methyl)-2-oxo-3-oxazolidinyl)phenyl)-; 4(1H)-Pyridinone, 2,3-dihydro-1-[2,3,6-trifluoro-4-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-; Contezolid [USAN]; SCHEMBL5945221; BDBM50017203; DB12796
DMZ0F65	CP	MicuRx Pharmaceuticals Hayward, CA
DMZ0F65	PC	25184541
DMZ0F65	MW	408.3
DMZ0F65	FM	C18H15F3N4O4
DMZ0F65	IC	InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1
DMZ0F65	CS	C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3C[C@@H](OC3=O)CNC4=NOC=C4)F
DMZ0F65	IK	SULYVXZZUMRQAX-NSHDSACASA-N
DMZ0F65	IU	(5S)-5-[(1,2-oxazol-3-ylamino)methyl]-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-2-one
DMZ0F65	CA	CAS 1112968-42-9
DMZ0F65	DE	MRSA infection; Skin infection

DMMOHUA	ID	DMMOHUA
DMMOHUA	DN	Contezolid acefosamil
DMMOHUA	HS	Phase 2
DMMOHUA	SN	JANNTEAGZXJITO-BTQNPOSSSA-M; UNII-T79C086548; T79C086548; Contezolid acefosamil [USAN]; CHEMBL3989966; Acetic acid, anhydride with N-(((5R)-3-(4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-2,3,5-trifluorophenyl)-2-oxo-5-oxazolidinyl)methyl)-N-3-isoxazolylphosphoramidic acid, sodium salt (1:1:1); Acetic (5R)-isoxazol-3yl((2-oxo-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-5-yl)methyl)phosphoramidic anhydride, sodium salt (1:1); 1807365-35-0
DMMOHUA	CP	MicuRx Pharmaceuticals Hayward, CA
DMMOHUA	PC	131750213
DMMOHUA	MW	552.3
DMMOHUA	FM	C20H17F3N4NaO8P
DMMOHUA	IC	InChI=1S/C20H18F3N4O8P.Na/c1-11(28)35-36(31,32)27(16-4-7-33-24-16)10-13-9-26(20(30)34-13)15-8-14(21)19(18(23)17(15)22)25-5-2-12(29)3-6-25;/h2,4-5,7-8,13H,3,6,9-10H2,1H3,(H,31,32);/q;+1/p-1/t13-;/m1./s1
DMMOHUA	CS	CC(=O)OP(=O)(N(C[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2F)F)N3CCC(=O)C=C3)F)C4=NOC=C4)[O-].[Na+]
DMMOHUA	IK	JANNTEAGZXJITO-BTQNPOSSSA-M
DMMOHUA	IU	sodium;acetyloxy-[1,2-oxazol-3-yl-[[(5R)-2-oxo-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]amino]phosphinate
DMMOHUA	CA	CAS 1807365-35-0
DMMOHUA	DE	Acute bacterial skin infection

DMER82Z	ID	DMER82Z
DMER82Z	DN	COR-1
DMER82Z	HS	Phase 2
DMER82Z	CP	Corimmun GmbH
DMER82Z	DE	Heart failure

DMHBOUX	ID	DMHBOUX
DMHBOUX	DN	CORT125281
DMHBOUX	HS	Phase 2
DMHBOUX	SN	Exicorilant; UNII-GTB859B7K8; GTB859B7K8; Exicorilant [INN]; SCHEMBL16737057; CORT-125281; 1781244-77-6; Methanone, ((4aR,8aS)-1-(4-fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-
DMHBOUX	CP	Corcept Therapeutics Menlo Park, CA
DMHBOUX	PC	118092367
DMHBOUX	MW	589.6
DMHBOUX	FM	C26H23F4N7O3S
DMHBOUX	IC	InChI=1S/C26H23F4N7O3S/c1-35-32-14-23(34-35)41(39,40)36-9-7-17-11-22-16(13-33-37(22)20-4-2-19(27)3-5-20)12-25(17,15-36)24(38)21-10-18(6-8-31-21)26(28,29)30/h2-6,8,10,13-14,17H,7,9,11-12,15H2,1H3/t17-,25-/m0/s1
DMHBOUX	CS	CN1N=CC(=N1)S(=O)(=O)N2CC[C@H]3CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
DMHBOUX	IK	HWJYJKAURRIWJM-GKVSMKOHSA-N
DMHBOUX	IU	[(4aR,8aS)-1-(4-fluorophenyl)-6-(2-methyltriazol-4-yl)sulfonyl-4,5,7,8,8a,9-hexahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
DMHBOUX	CA	CAS 1781244-77-6
DMHBOUX	DE	Prostate cancer

DMVKW0N	ID	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	HS	Phase 2
DMVKW0N	DT	Small molecular drug
DMVKW0N	PC	9859866
DMVKW0N	MW	255.25
DMVKW0N	FM	C10H9NO5S
DMVKW0N	IC	InChI=1S/C10H9NO5S/c1-6-4-10(12)15-9-5-7(2-3-8(6)9)16-17(11,13)14/h2-5H,1H3,(H2,11,13,14)
DMVKW0N	CS	CC1=CC(=O)OC2=C1C=CC(=C2)OS(=O)(=O)N
DMVKW0N	IK	UFGBGFMPBMEVMI-UHFFFAOYSA-N
DMVKW0N	IU	(4-methyl-2-oxochromen-7-yl) sulfamate
DMVKW0N	CA	CAS 136167-05-0
DMVKW0N	DE	Breast cancer

DM2K5VP	ID	DM2K5VP
DM2K5VP	DN	Coxsackievirus A21
DM2K5VP	HS	Phase 2
DM2K5VP	SN	Cavatak (TN)
DM2K5VP	CP	Viralytics
DM2K5VP	DE	Bladder cancer; Lung cancer; Melanoma; Prostate cancer; Glioblastoma multiforme

DM8X5Q1	ID	DM8X5Q1
DM8X5Q1	DN	CP101
DM8X5Q1	HS	Phase 2
DM8X5Q1	CP	Finch Therapeutics
DM8X5Q1	DT	Small molecular drug
DM8X5Q1	DE	Autism spectrum disorder; Clostridium infection

DMIU19E	ID	DMIU19E
DMIU19E	DN	CP-101,606
DMIU19E	HS	Phase 2
DMIU19E	SN	SCHEMBL5888841; CHEMBL321758; AKOS030627610; CP-101581; (1R,2R)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 1-((1R,2R)-Rel-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)-4-phenylpiperidin-4-ol
DMIU19E	TC	Analgesics
DMIU19E	DT	Small molecular drug
DMIU19E	PC	219101
DMIU19E	MW	327.4
DMIU19E	FM	C20H25NO3
DMIU19E	IC	InChI=1S/C20H25NO3/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17/h2-10,15,19,22-24H,11-14H2,1H3/t15-,19+/m0/s1
DMIU19E	CS	C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O
DMIU19E	IK	QEMSVZNTSXPFJA-HNAYVOBHSA-N
DMIU19E	IU	1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol
DMIU19E	CA	CAS 134234-12-1
DMIU19E	DE	Ischemic stroke; Parkinson disease

DMSWLM5	ID	DMSWLM5
DMSWLM5	DN	CP-122721
DMSWLM5	HS	Phase 2
DMSWLM5	SN	CP-122721; UNII-R7OYP6N58F; R7OYP6N58F; CHEMBL319118; CHEMBL1917847; DSSTox_CID_27251; DSSTox_RID_82210; DSSTox_GSID_47251; SCHEMBL156646; DTXSID9047251; Tox21_300205; BDBM50067935; ZINC22441997; AKOS030542331; DB05421; NCGC00254228-01; NCGC00247927-01; CAS-145742-28-5; (2S,3S)-N-(2-methoxy-5-(trifluoromethoxy)benzyl)-2-phenylpiperidin-3-amine
DMSWLM5	DT	Small molecular drug
DMSWLM5	PC	9821217
DMSWLM5	MW	380.4
DMSWLM5	FM	C20H23F3N2O2
DMSWLM5	IC	InChI=1S/C20H23F3N2O2/c1-26-18-10-9-16(27-20(21,22)23)12-15(18)13-25-17-8-5-11-24-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,24-25H,5,8,11,13H2,1H3/t17-,19-/m0/s1
DMSWLM5	CS	COC1=C(C=C(C=C1)OC(F)(F)F)CN[C@H]2CCCN[C@H]2C3=CC=CC=C3
DMSWLM5	IK	ZIWFCOIGUNPHPM-HKUYNNGSSA-N
DMSWLM5	IU	(2S,3S)-N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine
DMSWLM5	CA	CAS 145742-28-5
DMSWLM5	DE	Major depressive disorder

DMVO5DR	ID	DMVO5DR
DMVO5DR	DN	CP-331684
DMVO5DR	HS	Phase 2
DMVO5DR	SN	2-[4-[2-[2(R)-(6-Amino-3-pyridinyl)-2-hydroxyethylamino]ethoxy]phenyl]acetic acid
DMVO5DR	DT	Small molecular drug
DMVO5DR	PC	9840517
DMVO5DR	MW	331.4
DMVO5DR	FM	C17H21N3O4
DMVO5DR	IC	InChI=1S/C17H21N3O4/c18-16-6-3-13(10-20-16)15(21)11-19-7-8-24-14-4-1-12(2-5-14)9-17(22)23/h1-6,10,15,19,21H,7-9,11H2,(H2,18,20)(H,22,23)/t15-/m0/s1
DMVO5DR	CS	C1=CC(=CC=C1CC(=O)O)OCCNC[C@@H](C2=CN=C(C=C2)N)O
DMVO5DR	IK	GZJZZQHTBTUBEL-HNNXBMFYSA-N
DMVO5DR	IU	2-[4-[2-[[(2R)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]amino]ethoxy]phenyl]acetic acid
DMVO5DR	CA	CAS 207922-70-1
DMVO5DR	DE	Diabetic complication

DMEYMTX	ID	DMEYMTX
DMEYMTX	DN	CP-461
DMEYMTX	HS	Phase 2
DMEYMTX	SN	CP-461; OSI 461; UNII-68OJX9I7DT; CP 461; 68OJX9I7DT; 1H-Indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-(4-pyridinylmethylene)-, monohydrochloride, (1Z)-; 227619-96-7; N-benzyl-2-[(3Z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide hydrochloride; AC1O6379; 279238-68-5
DMEYMTX	DT	Small molecular drug
DMEYMTX	PC	6445781
DMEYMTX	MW	420.9
DMEYMTX	FM	C25H22ClFN2O
DMEYMTX	IC	InChI=1S/C25H21FN2O.ClH/c1-17-22(13-18-9-11-27-12-10-18)21-8-7-20(26)14-24(21)23(17)15-25(29)28-16-19-5-3-2-4-6-19;/h2-14H,15-16H2,1H3,(H,28,29);1H/b22-13-;
DMEYMTX	CS	CC\\1=C(C2=C(/C1=C\\C3=CC=NC=C3)C=CC(=C2)F)CC(=O)NCC4=CC=CC=C4.Cl
DMEYMTX	IK	KGXPDNOBLLACKL-BWLGBDCWSA-N
DMEYMTX	IU	N-benzyl-2-[(3Z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide;hydrochloride
DMEYMTX	CA	CAS 227619-96-7
DMEYMTX	DE	Inflammatory bowel disease

DMZEJLB	ID	DMZEJLB
DMZEJLB	DN	CP-533536
DMZEJLB	HS	Phase 2
DMZEJLB	SN	Evatanepag; CP-533,536; 2-(3-((((4-(1,1-dimethylethyl)phenyl)methyl)(pyridin-3-ylsulfonyl)amino)methyl)phenoxy)acetic acid; 2-[3-[[pyridin-3-ylsulfonyl-[(4-tert-butylphenyl)methyl]amino]methyl]phenoxy]acetic Acid
DMZEJLB	CP	Pfizer
DMZEJLB	DT	Small molecular drug
DMZEJLB	PC	9890801
DMZEJLB	MW	468.6
DMZEJLB	FM	C25H28N2O5S
DMZEJLB	IC	InChI=1S/C25H28N2O5S/c1-25(2,3)21-11-9-19(10-12-21)16-27(33(30,31)23-8-5-13-26-15-23)17-20-6-4-7-22(14-20)32-18-24(28)29/h4-15H,16-18H2,1-3H3,(H,28,29)
DMZEJLB	CS	CC(C)(C)C1=CC=C(C=C1)CN(CC2=CC(=CC=C2)OCC(=O)O)S(=O)(=O)C3=CN=CC=C3
DMZEJLB	IK	WOHRHWDYFNWPNG-UHFFFAOYSA-N
DMZEJLB	IU	2-[3-[[(4-tert-butylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid
DMZEJLB	CA	CAS 223488-57-1
DMZEJLB	DE	Osteoporosis

DMX054A	ID	DMX054A
DMX054A	DN	CP-547632
DMX054A	HS	Phase 2
DMX054A	SN	BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide
DMX054A	CP	OSI Pharmaceuticals
DMX054A	TC	Anticancer Agents
DMX054A	DT	Small molecular drug
DMX054A	PC	9811611
DMX054A	MW	532.4
DMX054A	FM	C20H24BrF2N5O3S
DMX054A	IC	InChI=1S/C20H24BrF2N5O3S/c21-12-9-14(22)13(15(23)10-12)11-31-18-16(17(24)29)19(32-27-18)26-20(30)25-5-1-2-6-28-7-3-4-8-28/h9-10H,1-8,11H2,(H2,24,29)(H2,25,26,30)
DMX054A	CS	C1CCN(C1)CCCCNC(=O)NC2=C(C(=NS2)OCC3=C(C=C(C=C3F)Br)F)C(=O)N
DMX054A	IK	HXHAJRMTJXHJJZ-UHFFFAOYSA-N
DMX054A	IU	3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide
DMX054A	CA	CAS 252003-65-9
DMX054A	DE	Solid tumour/cancer; Ovarian cancer; Non-small-cell lung cancer

DMKJFDM	ID	DMKJFDM
DMKJFDM	DN	CP-601927
DMKJFDM	HS	Phase 2
DMKJFDM	SN	CP-601932; Alpha4beta2 nAchR partial agonists (depression), Pfizer
DMKJFDM	CP	Pfizer Inc
DMKJFDM	DT	Small molecular drug
DMKJFDM	PC	11498153
DMKJFDM	MW	227.22
DMKJFDM	FM	C12H12F3N
DMKJFDM	IC	InChI=1S/C12H12F3N/c13-12(14,15)9-1-2-10-7-3-8(6-16-5-7)11(10)4-9/h1-2,4,7-8,16H,3,5-6H2/t7-,8+/m0/s1
DMKJFDM	CS	C1[C@H]2CNC[C@@H]1C3=C2C=CC(=C3)C(F)(F)F
DMKJFDM	IK	RNOBTWYQAWEZHH-JGVFFNPUSA-N
DMKJFDM	IU	(1S,8R)-4-(trifluoromethyl)-10-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene
DMKJFDM	CA	CAS 357425-02-6
DMKJFDM	DE	Gastrointestinal disease

DMUJ0W7	ID	DMUJ0W7
DMUJ0W7	DN	CP-724714
DMUJ0W7	HS	Phase 2
DMUJ0W7	SN	CP 724714; CP-724,714; CP724,714, CP-724,714; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide
DMUJ0W7	CP	Pfizer
DMUJ0W7	TC	Anticancer Agents
DMUJ0W7	DT	Small molecular drug
DMUJ0W7	PC	9874913
DMUJ0W7	MW	469.5
DMUJ0W7	FM	C27H27N5O3
DMUJ0W7	IC	InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+
DMUJ0W7	CS	CC1=NC=C(C=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)/C=C/CNC(=O)COC)C
DMUJ0W7	IK	LLVZBTWPGQVVLW-SNAWJCMRSA-N
DMUJ0W7	IU	2-methoxy-N-[(E)-3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-enyl]acetamide
DMUJ0W7	CA	CAS 845680-17-3
DMUJ0W7	CB	CHEBI:91331
DMUJ0W7	DE	Lymphoma

DMT3ORQ	ID	DMT3ORQ
DMT3ORQ	DN	CP-80794
DMT3ORQ	HS	Phase 2
DMT3ORQ	DT	Small molecular drug
DMT3ORQ	PC	64922
DMT3ORQ	MW	620.8
DMT3ORQ	FM	C31H48N4O7S
DMT3ORQ	IC	InChI=1S/C31H48N4O7S/c1-21(2)42-30(39)27(36)24(18-22-10-6-4-7-11-22)32-29(38)26(20-43-3)33-28(37)25(19-23-12-8-5-9-13-23)34-31(40)35-14-16-41-17-15-35/h5,8-9,12-13,21-22,24-27,36H,4,6-7,10-11,14-20H2,1-3H3,(H,32,38)(H,33,37)(H,34,40)/t24-,25-,26-,27+/m0/s1
DMT3ORQ	CS	CC(C)OC(=O)[C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CSC)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)N3CCOCC3)O
DMT3ORQ	IK	UZQBKCWYZBHBOW-YIPNQBBMSA-N
DMT3ORQ	IU	propan-2-yl (2R,3S)-4-cyclohexyl-2-hydroxy-3-[[(2R)-3-methylsulfanyl-2-[[(2S)-2-(morpholine-4-carbonylamino)-3-phenylpropanoyl]amino]propanoyl]amino]butanoate
DMT3ORQ	CA	CAS 119625-78-4
DMT3ORQ	DE	Hypertension

DM6MUCX	ID	DM6MUCX
DM6MUCX	DN	CpG-10101
DM6MUCX	HS	Phase 2
DM6MUCX	SN	Actilon; Anti-HCV therapy, Coley
DM6MUCX	CP	Coley Pharmaceutical Group Inc; Coley Pharmaceutical
DM6MUCX	DE	Hepatitis C virus infection

DMK9NQI	ID	DMK9NQI
DMK9NQI	DN	CPP-115
DMK9NQI	HS	Phase 2
DMK9NQI	SN	GABA aminotransferase inhibitors (oral), Northwestern University/Catalyst Pharmaceutical Partners; Vigabatrin derivatives (oral, neurological diseases), Northwestern University; Vigabatrin derivatives (oral, drug addiction/epilepsy/neuropathic pain), Catalyst Pharmaceutical Partners
DMK9NQI	CP	Catalyst pharmaceutical partners
DMK9NQI	DT	Small molecular drug
DMK9NQI	PC	9794014
DMK9NQI	MW	177.15
DMK9NQI	FM	C7H9F2NO2
DMK9NQI	IC	InChI=1S/C7H9F2NO2/c8-6(9)4-1-3(7(11)12)2-5(4)10/h3,5H,1-2,10H2,(H,11,12)/t3-,5-/m0/s1
DMK9NQI	CS	C1[C@H](CC(=C(F)F)[C@H]1N)C(=O)O
DMK9NQI	IK	CBSRETZPFOBWNG-UCORVYFPSA-N
DMK9NQI	IU	(1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid
DMK9NQI	CA	CAS 640897-20-7
DMK9NQI	DE	Substance use disorder; Infantile spasm; Tourette syndrome

DMK7DFM	ID	DMK7DFM
DMK7DFM	DN	CPX-POM
DMK7DFM	HS	Phase 2
DMK7DFM	CP	CicloMed
DMK7DFM	DT	Small molecular drug
DMK7DFM	DE	Solid tumour/cancer; Bladder cancer

DMHJEZS	ID	DMHJEZS
DMHJEZS	DN	CR-3294
DMHJEZS	HS	Phase 2
DMHJEZS	CP	Rottapharm Madaus
DMHJEZS	DE	Diarrhea

DMNC1AF	ID	DMNC1AF
DMNC1AF	DN	CR-665
DMNC1AF	HS	Phase 2
DMNC1AF	SN	CR665; UNII-3BX9UG06GG; 3BX9UG06GG; 228546-92-7; CR-665; CR 665; FE 200665; FE-200665; SCHEMBL4451321; DTXSID30177395; jnj-38488502; DB05155; D-Argininamide, D-phenylalanyl-D-phenylalanyl-D-norleucyl-N-(4-pyridinylmethyl)-
DMNC1AF	CP	Ferring Pharmaceuticals Inc
DMNC1AF	DT	Small molecular drug
DMNC1AF	PC	25030387
DMNC1AF	MW	671.8
DMNC1AF	FM	C36H49N9O4
DMNC1AF	IC	InChI=1S/C36H49N9O4/c1-2-3-15-30(34(48)43-29(16-10-19-41-36(38)39)33(47)42-24-27-17-20-40-21-18-27)44-35(49)31(23-26-13-8-5-9-14-26)45-32(46)28(37)22-25-11-6-4-7-12-25/h4-9,11-14,17-18,20-21,28-31H,2-3,10,15-16,19,22-24,37H2,1H3,(H,42,47)(H,43,48)(H,44,49)(H,45,46)(H4,38,39,41)/t28-,29-,30-,31-/m1/s1
DMNC1AF	CS	CCCC[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC1=CC=NC=C1)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N
DMNC1AF	IK	DBOGGOVKHSCMNB-OMRVPHBLSA-N
DMNC1AF	IU	(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-N-[(2R)-5-(diaminomethylideneamino)-1-oxo-1-(pyridin-4-ylmethylamino)pentan-2-yl]hexanamide
DMNC1AF	CA	CAS 228546-92-7
DMNC1AF	DE	Pain

DMQ47U6	ID	DMQ47U6
DMQ47U6	DN	CR8020
DMQ47U6	HS	Phase 2
DMQ47U6	SN	H3N2 and H7N7 influenza monoclonal antibody therapy, Crucell
DMQ47U6	CP	Crucell
DMQ47U6	DT	Antibody
DMQ47U6	DE	Influenza A virus infection; Influenza virus infection

DMO1ZGX	ID	DMO1ZGX
DMO1ZGX	DN	CRILVASTATIN
DMO1ZGX	HS	Phase 2
DMO1ZGX	SN	Crilvastatin < Rec INN; PMD-387; L-Pyroglutamic acid rac-cis-3,3,5-trimethylcyclohexyl ester; 5-Oxo-L-proline rac-cis-3,3,5-trimethylcyclohexyl ester
DMO1ZGX	DT	Small molecular drug
DMO1ZGX	PC	22845140
DMO1ZGX	MW	253.34
DMO1ZGX	FM	C14H23NO3
DMO1ZGX	IC	InChI=1S/C14H23NO3/c1-9-6-10(8-14(2,3)7-9)18-13(17)11-4-5-12(16)15-11/h9-11H,4-8H2,1-3H3,(H,15,16)/t9?,10?,11-/m0/s1
DMO1ZGX	CS	CC1CC(CC(C1)(C)C)OC(=O)[C@@H]2CCC(=O)N2
DMO1ZGX	IK	FXAAOALUHHXBSO-ILDUYXDCSA-N
DMO1ZGX	IU	(3,3,5-trimethylcyclohexyl) (2S)-5-oxopyrrolidine-2-carboxylate
DMO1ZGX	CA	CAS 120551-59-9
DMO1ZGX	DE	Hyperlipidaemia

DMQUWXY	ID	DMQUWXY
DMQUWXY	DN	CRLX101
DMQUWXY	HS	Phase 2
DMQUWXY	CP	Cerulean Pharma
DMQUWXY	PC	184196
DMQUWXY	MW	348.4
DMQUWXY	FM	C20H16N2O4
DMQUWXY	IC	InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m1/s1
DMQUWXY	CS	CC[C@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
DMQUWXY	IK	VSJKWCGYPAHWDS-HXUWFJFHSA-N
DMQUWXY	IU	(19R)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMQUWXY	CA	CAS 110351-92-3
DMQUWXY	DE	Solid tumour/cancer; Renal cell carcinoma; Ovarian cancer; Non-small-cell lung cancer

DM85WID	ID	DM85WID
DM85WID	DN	Crobenetine
DM85WID	HS	Phase 2
DM85WID	SN	CROBENETINE; CROBENETINE); BIII-890-CL; Crobenetine; Crobenetine hydrochloride; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol hydrochloride
DM85WID	DT	Small molecular drug
DM85WID	PC	9886143
DM85WID	MW	379.5
DM85WID	FM	C25H33NO2
DM85WID	IC	InChI=1S/C25H33NO2/c1-18(28-17-19-9-6-5-7-10-19)16-26-14-13-25(4)21-11-8-12-22(27)20(21)15-23(26)24(25,2)3/h5-12,18,23,27H,13-17H2,1-4H3/t18-,23+,25-/m0/s1
DM85WID	CS	C[C@@H](CN1CC[C@]2(C3=C(C[C@@H]1C2(C)C)C(=CC=C3)O)C)OCC4=CC=CC=C4
DM85WID	IK	VCCBCXVFGHTDQN-UODBTFMRSA-N
DM85WID	IU	(1S,9R)-1,13,13-trimethyl-10-[(2S)-2-phenylmethoxypropyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-6-ol
DM85WID	CA	221019-25-6
DM85WID	DE	Pain

DM129T7	ID	DM129T7
DM129T7	DN	CROMOGLYCATE LISETIL HYDROCHLORIDE
DM129T7	HS	Phase 2
DM129T7	SN	Diethyl L-lysylcromoglycate dihydrochloride; KY-556; N-556; Cromoglycate lisetil hydrochloride
DM129T7	DT	Small molecular drug
DM129T7	PC	196639
DM129T7	MW	652.6
DM129T7	FM	C33H36N2O12
DM129T7	IC	InChI=1S/C33H36N2O12/c1-3-41-32(39)27-15-21(36)29-23(10-7-12-25(29)46-27)43-17-19(45-31(38)20(35)9-5-6-14-34)18-44-24-11-8-13-26-30(24)22(37)16-28(47-26)33(40)42-4-2/h7-8,10-13,15-16,19-20H,3-6,9,14,17-18,34-35H2,1-2H3/t20-/m0/s1
DM129T7	CS	CCOC(=O)C1=CC(=O)C2=C(O1)C=CC=C2OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)OCC)OC(=O)[C@H](CCCCN)N
DM129T7	IK	NGJJDHCBOKNREV-FQEVSTJZSA-N
DM129T7	IU	ethyl 5-[2-[(2S)-2,6-diaminohexanoyl]oxy-3-(2-ethoxycarbonyl-4-oxochromen-5-yl)oxypropoxy]-4-oxochromene-2-carboxylate
DM129T7	CA	CAS 110816-79-0
DM129T7	CB	CHEBI:31438
DM129T7	DE	Asthma

DMXU5LZ	ID	DMXU5LZ
DMXU5LZ	DN	CRS-207
DMXU5LZ	HS	Phase 2
DMXU5LZ	CP	Aduro BioTech
DMXU5LZ	DT	Vaccine
DMXU5LZ	DE	Pancreatic cancer; Ovarian cancer; Gastric adenocarcinoma; Mesothelioma

DM16IMT	ID	DM16IMT
DM16IMT	DN	CRYPTOPHYCIN 52
DM16IMT	HS	Phase 2
DM16IMT	SN	LY-355703; [3S-(3alpha,10beta,13E,16beta)]-10-(3-Chloro-4-methoxybenzyl)-16-[2(R*),3(R*)-epoxy-1(R)-methyl-3-phenylpropyl]-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone
DM16IMT	DT	Small molecular drug
DM16IMT	PC	9939639
DM16IMT	MW	669.2
DM16IMT	FM	C36H45ClN2O8
DM16IMT	IC	InChI=1S/C36H45ClN2O8/c1-21(2)17-29-34(42)45-27(22(3)31-32(47-31)24-11-8-7-9-12-24)13-10-14-30(40)39-26(19-23-15-16-28(44-6)25(37)18-23)33(41)38-20-36(4,5)35(43)46-29/h7-12,14-16,18,21-22,26-27,29,31-32H,13,17,19-20H2,1-6H3,(H,38,41)(H,39,40)/b14-10+/t22-,26+,27-,29-,31+,32+/m0/s1
DM16IMT	CS	C[C@@H]([C@@H]1C/C=C/C(=O)N[C@@H](C(=O)NCC(C(=O)O[C@H](C(=O)O1)CC(C)C)(C)C)CC2=CC(=C(C=C2)OC)Cl)[C@@H]3[C@H](O3)C4=CC=CC=C4
DM16IMT	IK	LSXOBYNBRKOTIQ-RQUBOUMQSA-N
DM16IMT	IU	(3S,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
DM16IMT	CA	CAS 186256-67-7
DM16IMT	DE	Solid tumour/cancer

DMZCG91	ID	DMZCG91
DMZCG91	DN	CSL-112
DMZCG91	HS	Phase 2
DMZCG91	SN	Reconstituted HDL (acute coronary syndrome), CSL
DMZCG91	CP	Csl
DMZCG91	DE	Arteriosclerosis; Cardiovascular disease

DMQXL1T	ID	DMQXL1T
DMQXL1T	DN	CT 327
DMQXL1T	HS	Phase 2
DMQXL1T	CP	Creabilis Therapeutics
DMQXL1T	DE	Psoriasis vulgaris; Plaque psoriasis

DMBRKZ7	ID	DMBRKZ7
DMBRKZ7	DN	CT1812
DMBRKZ7	HS	Phase 2
DMBRKZ7	SN	Elayta
DMBRKZ7	CP	Cognition Therapeutics Pittsburgh, PA
DMBRKZ7	PC	118278088
DMBRKZ7	MW	431.6
DMBRKZ7	FM	C24H33NO4S
DMBRKZ7	IC	InChI=1S/C24H33NO4S/c1-23(2,3)29-22-13-17(7-10-21(22)26)11-12-24(4,5)25-15-18-8-9-20(30(6,27)28)14-19(18)16-25/h7-10,13-14,26H,11-12,15-16H2,1-6H3
DMBRKZ7	CS	CC(C)(C)OC1=C(C=CC(=C1)CCC(C)(C)N2CC3=C(C2)C=C(C=C3)S(=O)(=O)C)O
DMBRKZ7	IK	ISQAPFMBJFZOLG-UHFFFAOYSA-N
DMBRKZ7	IU	4-[3-methyl-3-(5-methylsulfonyl-1,3-dihydroisoindol-2-yl)butyl]-2-[(2-methylpropan-2-yl)oxy]phenol
DMBRKZ7	CA	CAS 1802632-22-9
DMBRKZ7	DE	Alzheimer disease

DMSGYNP	ID	DMSGYNP
DMSGYNP	DN	CTK0H-9987
DMSGYNP	HS	Phase 2
DMSGYNP	SN	Neoprontosil; Neoprontosil, disodium salt; Neoprontsil; PRONTOCIL; ZINC261161909; ZINC28863804; AZOSULFAMIDE; 132-38-7; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-((4-(aminosulfonyl)phenyl)azo)-4-hydroxy-; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-[[4-(aminosulfonyl)phenyl]azo]-4-hydroxy-; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-[[4-(aminosulfonyl)phenyl]azo]-4-hydroxy-, disodium salt; AABSSN; BDBM50221406; CHEMBL237251; CTK0H9987; DTXSID0074500
DMSGYNP	PC	8625
DMSGYNP	MW	544.5
DMSGYNP	FM	C18H16N4O10S3
DMSGYNP	IC	RALNLQYPLYWQRT-UHFFFAOYSA-N
DMSGYNP	CS	CC(=O)NC1=C(C=C2C=C(C(=C(C2=C1)O)N=NC3=CC=C(C=C3)S(=O)(=O)N)S(=O)(=O)O)S(=O)(=O)O
DMSGYNP	IK	1S/C18H16N4O10S3/c1-9(23)20-14-8-13-10(6-15(14)34(27,28)29)7-16(35(30,31)32)17(18(13)24)22-21-11-2-4-12(5-3-11)33(19,25)26/h2-8,24H,1H3,(H,20,23)(H2,19,25,26)(H,27,28,29)(H,30,31,32)
DMSGYNP	IU	6-acetamido-4-hydroxy-3-[(4-sulfamoylphenyl)diazenyl]naphthalene-2,7-disulfonic acid
DMSGYNP	DE	Trachoma

DMMPC6W	ID	DMMPC6W
DMMPC6W	DN	CTL019
DMMPC6W	HS	Phase 2
DMMPC6W	CP	Novartis Pharmaceuticals
DMMPC6W	DT	CAR T Cell Therapy
DMMPC6W	DE	Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia

DM3SYOK	ID	DM3SYOK
DM3SYOK	DN	CTP-543
DM3SYOK	HS	Phase 2
DM3SYOK	CP	Concert Pharmaceuticals Lexington, MA
DM3SYOK	DE	Asthma

DMBT46Y	ID	DMBT46Y
DMBT46Y	DN	CTP-543
DMBT46Y	HS	Phase 2
DMBT46Y	SN	Deuruxolitinib; D8-ruxolitinib; UNII-0CA0VSF91Y; Deuruxolitinib (USAN); Deuruxolitinib [USAN]; C-21543; (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1513883-39-0; CTP543; CHEMBL4594381; SCHEMBL19555526; GTPL11410; WHO 11622; D11866; (3R)-3-(2,2,3,3,4,4,5,5-D8)cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1Hpyrazol-1-yl)propanenitrile; H-Pyrazole-1-propanenitrile, beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (betaR)-
DMBT46Y	CP	Concert Pharmaceuticals
DMBT46Y	DT	Small molecular drug
DMBT46Y	PC	72704611
DMBT46Y	MW	314.41
DMBT46Y	FM	C17H18N6
DMBT46Y	IC	InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1/i1D2,2D2,3D2,4D2
DMBT46Y	CS	[2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H]
DMBT46Y	IK	HFNKQEVNSGCOJV-FBXGHSCESA-N
DMBT46Y	IU	(3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
DMBT46Y	CA	CAS 1513883-39-0
DMBT46Y	DE	Alopecia

DMYPXQ2	ID	DMYPXQ2
DMYPXQ2	DN	CVBT-141H
DMYPXQ2	HS	Phase 2
DMYPXQ2	SN	CVBT-141A; CVBT-141C; CVBT-141C); Cardio Vascu-Grow; FGF-1-141; Recombinant FGF-1 (coronary heart disease), CardioVascular Therapeutics; Recombinant FGF-1 (peripheral vascular disease), CardioVascular biotherapeutics
DMYPXQ2	CP	CardioVascular BioTherapeutics Inc; CardioVascular Biotherapeutics
DMYPXQ2	DE	Coronary artery disease; Peripheral arterial disease; Coronary heart disease

DMCN9GX	ID	DMCN9GX
DMCN9GX	DN	CVX-045
DMCN9GX	HS	Phase 2
DMCN9GX	SN	CVX-22; CovX-045; PF-4856882; TSP-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), Pfizer
DMCN9GX	CP	CovX Pharmaceuticals Inc
DMCN9GX	DE	Solid tumour/cancer

DMVZT2I	ID	DMVZT2I
DMVZT2I	DN	CX-072
DMVZT2I	HS	Phase 2
DMVZT2I	CP	CytomX Therapeutics South San Francisco, CA
DMVZT2I	DT	Antibody
DMVZT2I	DE	Solid tumour/cancer; Advanced malignancy; Lymphoma; Medulloblastoma

DMS2WB5	ID	DMS2WB5
DMS2WB5	DN	CX157
DMS2WB5	HS	Phase 2
DMS2WB5	SN	CX157; O6L62LZJ0Q; CX-157; CX 157; 205187-53-7; UNII-O6L62LZJ0Q; SCHEMBL235650; DTXSID40174517; PDIMOTRDGUQMNY-UHFFFAOYSA-N; HY-100178; CS-0018174; 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide; Phenoxathiin, 3-fluoro-7-(2,2,2-trifluoroethoxy)-, 10,10-dioxide
DMS2WB5	CP	CeNeRx Pharma
DMS2WB5	DT	Small molecular drug
DMS2WB5	PC	18687754
DMS2WB5	MW	348.27
DMS2WB5	FM	C14H8F4O4S
DMS2WB5	IC	InChI=1S/C14H8F4O4S/c15-8-1-3-12-10(5-8)22-11-6-9(21-7-14(16,17)18)2-4-13(11)23(12,19)20/h1-6H,7H2
DMS2WB5	CS	C1=CC2=C(C=C1OCC(F)(F)F)OC3=C(S2(=O)=O)C=CC(=C3)F
DMS2WB5	IK	PDIMOTRDGUQMNY-UHFFFAOYSA-N
DMS2WB5	IU	3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide
DMS2WB5	CA	CAS 205187-53-7
DMS2WB5	DE	Mood disorder

DMJD7H4	ID	DMJD7H4
DMJD7H4	DN	CX-1739
DMJD7H4	HS	Phase 2
DMJD7H4	SN	CX-1739 (injectable/AMPAKINE, respiratory depression); CX-717 follow-on compound (AMPAKINE), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Biovail Laboratories; CX-1739 (injectable/AMPAKINE, respiratory depression), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Valeant
DMJD7H4	CP	Cortex Pharmaceuticals Inc
DMJD7H4	DE	Attention deficit hyperactivity disorder

DMA5D6T	ID	DMA5D6T
DMA5D6T	DN	CX1789
DMA5D6T	HS	Phase 2
DMA5D6T	CP	RespireRx Pharmaceuticals Glen Rock, NJ
DMA5D6T	DE	Obstructive sleep apnea

DMU62I8	ID	DMU62I8
DMU62I8	DN	CX2009
DMU62I8	HS	Phase 2
DMU62I8	CP	CytomX Therapeutics
DMU62I8	DT	Probody drug conjugate
DMU62I8	DE	Solid tumour/cancer; Neoplasm

DMWE7B9	ID	DMWE7B9
DMWE7B9	DN	CX-4945
DMWE7B9	HS	Phase 2
DMWE7B9	SN	1009820-21-6; Silmitasertib; CX-4945; 5-((3-Chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid; CX4945; CX-4945 (Silmitasertib); CX 4945; UNII-C6RWP0N0L2; 5-[(3-chlorophenyl)amino]-Benzo[c]-2,6-naphthyridine-8-carboxylic acid; 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid; C6RWP0N0L2; CHEMBL1230165; AK-82006; 5-[(3-Chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-Carboxylic Acid; 5-((3-Chlorophenyl)amino)benzo-[c][2,6]naphthyridine-8-carboxylic acid; C19H12ClN3O2; W-204393
DMWE7B9	CP	Cylene Pharmaceuticals
DMWE7B9	DT	Small molecular drug
DMWE7B9	PC	24748573
DMWE7B9	MW	349.8
DMWE7B9	FM	C19H12ClN3O2
DMWE7B9	IC	InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)
DMWE7B9	CS	C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4
DMWE7B9	IK	MUOKSQABCJCOPU-UHFFFAOYSA-N
DMWE7B9	IU	5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid
DMWE7B9	CA	CAS 1009820-21-6
DMWE7B9	DE	Solid tumour/cancer; Cholangiocarcinoma; Coronavirus infection

DMM65W1	ID	DMM65W1
DMM65W1	DN	CX-717
DMM65W1	HS	Phase 2
DMM65W1	SN	CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex
DMM65W1	CP	University of California
DMM65W1	DT	Small molecular drug
DMM65W1	PC	3323368
DMM65W1	MW	233.22
DMM65W1	FM	C11H11N3O3
DMM65W1	IC	InChI=1S/C11H11N3O3/c15-11(14-3-5-16-6-4-14)8-1-2-9-10(7-8)13-17-12-9/h1-2,7H,3-6H2
DMM65W1	CS	C1COCCN1C(=O)C2=CC3=NON=C3C=C2
DMM65W1	IK	KFRQROSRKSVROW-UHFFFAOYSA-N
DMM65W1	IU	2,1,3-benzoxadiazol-5-yl(morpholin-4-yl)methanone
DMM65W1	CA	CAS 211735-82-9
DMM65W1	DE	Alzheimer disease; Spinal cord injury

DM3GEHC	ID	DM3GEHC
DM3GEHC	DN	CX-8998
DM3GEHC	HS	Phase 2
DM3GEHC	CP	Cavion Charlottesville, VA
DM3GEHC	DE	Epilepsy; Essential tremor or related tremors; Parkinson disease

DMM7Z6K	ID	DMM7Z6K
DMM7Z6K	DN	CXA10
DMM7Z6K	HS	Phase 2
DMM7Z6K	CP	Complexa
DMM7Z6K	DT	Small molecular drug
DMM7Z6K	DE	Pulmonary arterial hypertension; Focal segmental glomerulosclerosis

DM3JFZ2	ID	DM3JFZ2
DM3JFZ2	DN	CXL
DM3JFZ2	HS	Phase 2
DM3JFZ2	SN	CYCLOHEXANOL; 108-93-0; Cyclohexyl alcohol; Hexahydrophenol; Hydrophenol; Hydroxycyclohexane; Hexalin; 1-Cyclohexanol; Hydralin; Adronal; Naxol; Adronol; Anol; Cykloheksanol; Cicloesanolo; Phenol, hexahydro-; Cicloesanolo [Italian]; Cykloheksanol [Polish]; Cyclohexanone cyclohexanol mixture; Cyclohexan-1-ol; HSDB 61; NSC 403656; UNII-8E7S519M3P; CCRIS 5896; EINECS 203-630-6; BRN 0906744; AI3-00040; CHEBI:18099; HPXRVTGHNJAIIH-UHFFFAOYSA-N; 8E7S519M3P; MFCD00003855; Cyclohexanol, 98%; CXL; Cyclohexanols; DSSTox_CID_1894; DSSTox_RID_76390
DM3JFZ2	CP	AstraZeneca
DM3JFZ2	DT	Small molecular drug
DM3JFZ2	PC	7966
DM3JFZ2	MW	100.16
DM3JFZ2	FM	C6H12O
DM3JFZ2	IC	InChI=1S/C6H12O/c7-6-4-2-1-3-5-6/h6-7H,1-5H2
DM3JFZ2	CS	C1CCC(CC1)O
DM3JFZ2	IK	HPXRVTGHNJAIIH-UHFFFAOYSA-N
DM3JFZ2	IU	cyclohexanol
DM3JFZ2	CA	CAS 108-93-0
DM3JFZ2	CB	CHEBI:18099
DM3JFZ2	DE	Methicillin-resistant staphylococci infection

DMXR8WN	ID	DMXR8WN
DMXR8WN	DN	CYCLOPLATAM
DMXR8WN	HS	Phase 2
DMXR8WN	SN	Ammine(cyclopentanamine)[(S)-hydroxybutanedioato(2-)-O1,O4]platinum; (S)-(-)-Malatoammine(cyclopentylamine)platinum (II)
DMXR8WN	DT	Small molecular drug
DMXR8WN	PC	3035239
DMXR8WN	MW	429.33
DMXR8WN	FM	C9H18N2O5Pt
DMXR8WN	IC	InChI=1S/C5H11N.C4H6O5.H3N.Pt/c6-5-3-1-2-4-5;5-2(4(8)9)1-3(6)7;;/h5H,1-4,6H2;2,5H,1H2,(H,6,7)(H,8,9);1H3;/q;;;+2/p-2
DMXR8WN	CS	C1CCC(C1)N.C(C(C(=O)[O-])O)C(=O)[O-].N.[Pt+2]
DMXR8WN	IK	OPWOOOGFNULJAQ-UHFFFAOYSA-L
DMXR8WN	IU	azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+)
DMXR8WN	CA	CAS 109837-67-4
DMXR8WN	DE	Solid tumour/cancer

DM0DT45	ID	DM0DT45
DM0DT45	DN	CYSTEMUSTINE
DM0DT45	HS	Phase 2
DM0DT45	SN	CMSO2EN2; N-(2-Chloroethyl)-N'-[2-(methylsulfonyl)ethyl]-N-nitrosourea
DM0DT45	DT	Small molecular drug
DM0DT45	PC	119545
DM0DT45	MW	257.7
DM0DT45	FM	C6H12ClN3O4S
DM0DT45	IC	InChI=1S/C6H12ClN3O4S/c1-15(13,14)5-3-8-6(11)10(9-12)4-2-7/h2-5H2,1H3,(H,8,11)
DM0DT45	CS	CS(=O)(=O)CCNC(=O)N(CCCl)N=O
DM0DT45	IK	IUOVOJHLRFQQNS-UHFFFAOYSA-N
DM0DT45	IU	1-(2-chloroethyl)-3-(2-methylsulfonylethyl)-1-nitrosourea
DM0DT45	CA	CAS 79955-36-5
DM0DT45	DE	Solid tumour/cancer

DMMWIHC	ID	DMMWIHC
DMMWIHC	DN	CYT 99007
DMMWIHC	HS	Phase 2
DMMWIHC	CP	Cytheris
DMMWIHC	TC	Anticancer Agents
DMMWIHC	DE	Acquired immune deficiency syndrome

DM4LJH8	ID	DM4LJH8
DM4LJH8	DN	CYT003
DM4LJH8	HS	Phase 2
DM4LJH8	DE	Asthma

DMIRSWE	ID	DMIRSWE
DMIRSWE	DN	CYT-006-AngQb
DMIRSWE	HS	Phase 2
DMIRSWE	SN	AngQb; Immunodrug vaccines (hypertension), Cytos
DMIRSWE	CP	Cytos Biotechnology AG
DMIRSWE	DT	Vaccine
DMIRSWE	DE	Hypertension

DMUDMHA	ID	DMUDMHA
DMUDMHA	DN	CZEN-002
DMUDMHA	HS	Phase 2
DMUDMHA	SN	Bis(N-acetyl-L-cysteinyl-L-lysyl-L-prolyl-L-valinamide) disulfide
DMUDMHA	DT	Small molecular drug
DMUDMHA	PC	16133793
DMUDMHA	MW	1664.9
DMUDMHA	FM	C77H109N21O19S
DMUDMHA	IC	InChI=1S/C77H109N21O19S/c1-42(2)64(65(79)106)97-75(116)61-20-13-30-98(61)76(117)54(18-10-11-28-78)88-62(103)38-85-66(107)57(34-46-36-84-50-17-9-8-16-49(46)50)94-67(108)51(19-12-29-83-77(80)81)89-70(111)55(32-44-14-6-5-7-15-44)92-72(113)58(35-47-37-82-41-86-47)95-68(109)52(25-26-63(104)105)90-69(110)53(27-31-118-4)91-74(115)60(40-100)96-71(112)56(33-45-21-23-48(102)24-22-45)93-73(114)59(39-99)87-43(3)101/h5-9,14-17,21-24,36-37,41-42,51-61,64,84,99-100,102H,10-13,18-20,25-35,38-40,78H2,1-4H3,(H2,79,106)(H,82,86)(H,85,107)(H,87,101)(H,88,103)(H,89,111)(H,90,110)(H,91,115)(H,92,113)(H,93,114)(H,94,108)(H,95,109)(H,96,112)(H,97,116)(H,104,105)(H4,80,81,83)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,64-/m0/s1
DMUDMHA	CS	CC(C)[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
DMUDMHA	IK	WHNFPRLDDSXQCL-UAZQEYIDSA-N
DMUDMHA	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMUDMHA	CA	CAS 581-05-5
DMUDMHA	DE	Fungal infection

DMP6MH9	ID	DMP6MH9
DMP6MH9	DN	DA-8031
DMP6MH9	HS	Phase 2
DMP6MH9	SN	Serotonin transporter inhibitor (premature ejaculation), Dong A
DMP6MH9	CP	Dong-A Pharmaceutical Co Ltd
DMP6MH9	DE	Premature ejaculation

DMACTBM	ID	DMACTBM
DMACTBM	DN	DAC-060
DMACTBM	HS	Phase 2
DMACTBM	SN	DAC-0060; DAC-60; HDAC inhibitor (topical, skin cancer/actinic keratosis), DAC
DMACTBM	CP	DAC Srl
DMACTBM	DE	Keratosis

DM2U45Q	ID	DM2U45Q
DM2U45Q	DN	Danegaptide
DM2U45Q	HS	Phase 2
DM2U45Q	SN	SCHEMBL2399760; BCP17534; ZP 1609
DM2U45Q	CP	Pfizer; Zealand Pharma
DM2U45Q	DT	Small molecular drug
DM2U45Q	PC	16656685
DM2U45Q	MW	291.3
DM2U45Q	FM	C14H17N3O4
DM2U45Q	IC	InChI=1S/C14H17N3O4/c15-7-12(18)17-8-10(6-11(17)14(20)21)16-13(19)9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,19)(H,20,21)/t10-,11+/m1/s1
DM2U45Q	CS	C1[C@H](CN([C@@H]1C(=O)O)C(=O)CN)NC(=O)C2=CC=CC=C2
DM2U45Q	IK	BIZKIHUJGMSVFD-MNOVXSKESA-N
DM2U45Q	IU	(2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid
DM2U45Q	CA	CAS 943134-39-2
DM2U45Q	DE	Atrial fibrillation

DM20MDU	ID	DM20MDU
DM20MDU	DN	Danoprevir
DM20MDU	HS	Phase 2
DM20MDU	SN	850876-88-9; Danoprevir (USAN/INN)
DM20MDU	CP	InterMune; Genentech
DM20MDU	DT	Small molecular drug
DM20MDU	PC	11285588
DM20MDU	MW	731.8
DM20MDU	FM	C35H46FN5O9S
DM20MDU	IC	InChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)/b11-7-/t22-,23-,27+,28+,35-/m1/s1
DM20MDU	CS	CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\\[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6
DM20MDU	IK	ZVTDLPBHTSMEJZ-JSZLBQEHSA-N
DM20MDU	IU	[(1S,4R,6S,7Z,14S,18R)-4-(cyclopropylsulfonylcarbamoyl)-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-18-yl] 4-fluoro-1,3-dihydroisoindole-2-carboxylate
DM20MDU	CA	CAS 850876-88-9
DM20MDU	DE	Hepatitis C virus infection

DM7IH48	ID	DM7IH48
DM7IH48	DN	Dapansutrile
DM7IH48	HS	Phase 2
DM7IH48	SN	54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073
DM7IH48	CP	Olatec Therapeutics New York, NY
DM7IH48	PC	12714644
DM7IH48	MW	133.17
DM7IH48	FM	C4H7NO2S
DM7IH48	IC	InChI=1S/C4H7NO2S/c1-8(6,7)4-2-3-5/h2,4H2,1H3
DM7IH48	CS	CS(=O)(=O)CCC#N
DM7IH48	IK	LQFRYKBDZNPJSW-UHFFFAOYSA-N
DM7IH48	IU	3-methylsulfonylpropanenitrile
DM7IH48	CA	CAS 54863-37-5
DM7IH48	DE	Acute gout flare; Musculoskeletal pain

DMIYFWA	ID	DMIYFWA
DMIYFWA	DN	Dapirolizumab pegol
DMIYFWA	HS	Phase 2
DMIYFWA	CP	Biogen Cambridge, MAUCBSmyrna, GA
DMIYFWA	DE	Systemic lupus erythematosus

DMR5J6K	ID	DMR5J6K
DMR5J6K	DN	DAPITANT
DMR5J6K	HS	Phase 2
DMR5J6K	SN	CHEMBL2103951
DMR5J6K	DT	Small molecular drug
DMR5J6K	PC	132961
DMR5J6K	MW	561.7
DMR5J6K	FM	C37H39NO4
DMR5J6K	IC	InChI=1S/C37H39NO4/c1-26(29-18-10-12-20-33(29)41-2)35(39)38-24-31-32(25-38)37(40,30-19-11-13-21-34(30)42-3)23-22-36(31,27-14-6-4-7-15-27)28-16-8-5-9-17-28/h4-21,26,31-32,40H,22-25H2,1-3H3/t26-,31-,32+,37+/m0/s1
DMR5J6K	CS	C[C@@H](C1=CC=CC=C1OC)C(=O)N2C[C@@H]3[C@H](C2)C(CC[C@]3(C4=CC=CC=C4OC)O)(C5=CC=CC=C5)C6=CC=CC=C6
DMR5J6K	IK	CCIWVEMVBWEMCY-RCFOMQFPSA-N
DMR5J6K	IU	(2S)-1-[(3aS,4S,7aS)-4-hydroxy-4-(2-methoxyphenyl)-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-2-yl]-2-(2-methoxyphenyl)propan-1-one
DMR5J6K	CA	CAS 153438-49-4
DMR5J6K	DE	Pain

DMCU74R	ID	DMCU74R
DMCU74R	DN	Daporinad
DMCU74R	HS	Phase 2
DMCU74R	SN	APO-866; FK-866; WK-175
DMCU74R	CP	Astellas Pharma GmbH
DMCU74R	DT	Small molecular drug
DMCU74R	PC	6914657
DMCU74R	MW	391.5
DMCU74R	FM	C24H29N3O2
DMCU74R	IC	InChI=1S/C24H29N3O2/c28-23(12-11-21-8-6-15-25-19-21)26-16-5-4-7-20-13-17-27(18-14-20)24(29)22-9-2-1-3-10-22/h1-3,6,8-12,15,19-20H,4-5,7,13-14,16-18H2,(H,26,28)/b12-11+
DMCU74R	CS	C1CN(CCC1CCCCNC(=O)/C=C/C2=CN=CC=C2)C(=O)C3=CC=CC=C3
DMCU74R	IK	KPBNHDGDUADAGP-VAWYXSNFSA-N
DMCU74R	IU	(E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide
DMCU74R	CA	CAS 658084-64-1
DMCU74R	CB	CHEBI:94671
DMCU74R	DE	leukaemia

DM0Y8JP	ID	DM0Y8JP
DM0Y8JP	DN	DAS-181
DM0Y8JP	HS	Phase 2
DM0Y8JP	SN	Fludase; NEX-DAS-181; Enzyme-based therapy (Tosap, influenza), NexBio
DM0Y8JP	CP	Nexbio
DM0Y8JP	DE	Influenza virus infection

DMM3BPL	ID	DMM3BPL
DMM3BPL	DN	DAS-431
DMM3BPL	HS	Phase 2
DMM3BPL	CP	DrugAbuse Sciences
DMM3BPL	DE	Dementia

DM7JV4O	ID	DM7JV4O
DM7JV4O	DN	DB-041901
DM7JV4O	HS	Phase 2
DM7JV4O	SN	Pursennid; Senekot; Senna-lax; Sennaglucosides; Sennosides; Sennoside A&amp;B; Sennoside [JAN]; Sennosides A and B; sennoside; (9,9'-Bianthracene)-2,2'-dicarboxylic acid, 5,5'-bis(beta-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo-; 5,5'-Bis(beta-D-glucopyranosyloxy)-4,4'-dihydroxy(9,9'-bianthrachinon)-2,2'-dicarbonsaeure; 5,5'-Bis(beta-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo(9,9'-bianthracene)-2,2'-dicarboxylic acid; 517-43-1; C42H38O20; EINECS 208-238-9; SENNA
DM7JV4O	PC	5199
DM7JV4O	MW	862.7
DM7JV4O	FM	C42H38O20
DM7JV4O	IC	IPQVTOJGNYVQEO-UHFFFAOYSA-N
DM7JV4O	CS	C1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C4=C(C2C5C6=C(C(=CC=C6)OC7C(C(C(C(O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O
DM7JV4O	IK	1S/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-26,31-32,35-38,41-48,51-54H,11-12H2,(H,55,56)(H,57,58)
DM7JV4O	IU	9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
DM7JV4O	CA	CAS 517-43-1
DM7JV4O	DE	Opioid-induced constipation

DMQRCX5	ID	DMQRCX5
DMQRCX5	DN	DCDS-4501A
DMQRCX5	HS	Phase 2
DMQRCX5	CP	Genentech
DMQRCX5	DT	Antibody
DMQRCX5	DE	Diffuse large B-cell lymphoma; Non-hodgkin lymphoma

DMCHWX1	ID	DMCHWX1
DMCHWX1	DN	DCR-PHXC
DMCHWX1	HS	Phase 2
DMCHWX1	SN	nedosiran
DMCHWX1	CP	Dicerna Pharmaceuticals
DMCHWX1	DT	Small interfering RNA
DMCHWX1	DE	Hyperoxaluria

DM9REBL	ID	DM9REBL
DM9REBL	DN	DDP-225
DM9REBL	HS	Phase 2
DM9REBL	SN	AA-10021; AA-10025; AA-10026; 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine hydrate hydrochloride
DM9REBL	CP	Dynogen
DM9REBL	DT	Small molecular drug
DM9REBL	PC	6918194
DM9REBL	MW	382.9
DM9REBL	FM	C17H20ClFN4OS
DM9REBL	IC	InChI=1S/C17H17FN4S.ClH.H2O/c1-11-10-13-15(12-4-2-3-5-14(12)18)20-17(21-16(13)23-11)22-8-6-19-7-9-22;;/h2-5,10,19H,6-9H2,1H3;1H;1H2
DM9REBL	CS	CC1=CC2=C(N=C(N=C2S1)N3CCNCC3)C4=CC=CC=C4F.O.Cl
DM9REBL	IK	SAURKKOJWIFYSR-UHFFFAOYSA-N
DM9REBL	IU	4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine;hydrate;hydrochloride
DM9REBL	CA	CAS 476148-82-0
DM9REBL	DE	Chronic functional vomiting; Irritable bowel syndrome

DM5XT3G	ID	DM5XT3G
DM5XT3G	DN	DE-098
DM5XT3G	HS	Phase 2
DM5XT3G	SN	ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen
DM5XT3G	CP	Centocor Ortho Biotech Inc
DM5XT3G	DT	Antibody
DM5XT3G	DE	Rheumatoid arthritis

DMCQL5I	ID	DMCQL5I
DMCQL5I	DN	DE-110
DMCQL5I	HS	Phase 2
DMCQL5I	SN	Selective glucocorticoid receptor agonist (allergy), Santen
DMCQL5I	CP	Santen Pharmaceutical Co Ltd
DMCQL5I	DE	Xerophthalmia

DMZW50O	ID	DMZW50O
DMZW50O	DN	Debio 1347
DMZW50O	HS	Phase 2
DMZW50O	CP	Debiopharm
DMZW50O	PC	66555680
DMZW50O	MW	356.4
DMZW50O	FM	C20H16N6O
DMZW50O	IC	InChI=1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,25H,21H2,1H3,(H,23,24)
DMZW50O	CS	CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N
DMZW50O	IK	BEMNJULZEQTDJY-UHFFFAOYSA-N
DMZW50O	IU	[5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone
DMZW50O	CA	CAS 1265229-25-1
DMZW50O	DE	Breast cancer; Solid tumour/cancer

DM1H7UK	ID	DM1H7UK
DM1H7UK	DN	Dectrekumab
DM1H7UK	HS	Phase 2
DM1H7UK	SN	QAX-576
DM1H7UK	DT	Antibody
DM1H7UK	DE	Idiopathic pulmonary fibrosis

DMX4DQH	ID	DMX4DQH
DMX4DQH	DN	Delanzomib
DMX4DQH	HS	Phase 2
DMX4DQH	SN	((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-
DMX4DQH	CP	Cephalon
DMX4DQH	DT	Small molecular drug
DMX4DQH	PC	24800541
DMX4DQH	MW	413.3
DMX4DQH	FM	C21H28BN3O5
DMX4DQH	IC	InChI=1S/C21H28BN3O5/c1-13(2)12-18(22(29)30)24-21(28)19(14(3)26)25-20(27)17-11-7-10-16(23-17)15-8-5-4-6-9-15/h4-11,13-14,18-19,26,29-30H,12H2,1-3H3,(H,24,28)(H,25,27)/t14-,18+,19+/m1/s1
DMX4DQH	CS	B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O
DMX4DQH	IK	SJFBTAPEPRWNKH-CCKFTAQKSA-N
DMX4DQH	IU	[(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
DMX4DQH	CA	CAS 847499-27-8
DMX4DQH	CB	CHEBI:141530
DMX4DQH	DE	Multiple myeloma

DMS2WIN	ID	DMS2WIN
DMS2WIN	DN	Delphinidin
DMS2WIN	HS	Phase 2
DMS2WIN	SN	IdB-1056; 3,3',4',5,5',7-Hexahydroxy-2-phenylbenzopyrylium chloride; 3,3',4',5,5',7-Hexahydroxyflavylium chloride;3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrilium chloride
DMS2WIN	DT	Small molecular drug
DMS2WIN	PC	68245
DMS2WIN	MW	338.69
DMS2WIN	FM	C15H11ClO7
DMS2WIN	IC	InChI=1S/C15H10O7.ClH/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6;/h1-5H,(H5-,16,17,18,19,20,21);1H
DMS2WIN	CS	C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-]
DMS2WIN	IK	FFNDMZIBVDSQFI-UHFFFAOYSA-N
DMS2WIN	IU	2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol;chloride
DMS2WIN	CA	CAS 8012-95-1
DMS2WIN	CB	CHEBI:38701
DMS2WIN	DE	Cardiovascular disease

DM5CB8U	ID	DM5CB8U
DM5CB8U	DN	DELTIBANT
DM5CB8U	HS	Phase 2
DM5CB8U	SN	CP-0127; Deltibant < Prop INN; SB-238592; Bradycor (Cortech, US); S,S'-(Hexane-1,6-diyl)bis(succinimide-1,3-diyl)bis[D-arginyl-L-arginyl-L-prolyl-(4-hydroxy)-L-prolyl-glycyl-L-phenylalanyl-L-cysteinyl-D-phenylalanyl-L-leucyl-L-arginine]
DM5CB8U	PC	70697628
DM5CB8U	MW	2805.3
DM5CB8U	FM	C128H194N40O28S2
DM5CB8U	IC	InChI=1S/C128H194N40O28S2/c1-71(2)55-85(105(177)155-83(121(193)194)41-25-49-147-127(139)140)157-109(181)89(59-75-33-15-9-16-34-75)159-111(183)91(161-107(179)87(57-73-29-11-7-12-30-73)151-99(171)65-149-113(185)95-61-77(169)67-167(95)117(189)93-43-27-53-163(93)115(187)81(39-23-47-145-125(135)136)153-103(175)79(129)37-21-45-143-123(131)132)69-197-97-63-101(173)165(119(97)191)51-19-5-6-20-52-166-102(174)64-98(120(166)192)198-70-92(112(184)160-90(60-76-35-17-10-18-36-76)110(182)158-86(56-72(3)4)106(178)156-84(122(195)196)42-26-50-148-128(141)142)162-108(180)88(58-74-31-13-8-14-32-74)152-100(172)66-150-114(186)96-62-78(170)68-168(96)118(190)94-44-28-54-164(94)116(188)82(40-24-48-146-126(137)138)154-104(176)80(130)38-22-46-144-124(133)134/h7-18,29-36,71-72,77-98,169-170H,5-6,19-28,37-70,129-130H2,1-4H3,(H,149,185)(H,150,186)(H,151,171)(H,152,172)(H,153,175)(H,154,176)(H,155,177)(H,156,178)(H,157,181)(H,158,182)(H,159,183)(H,160,184)(H,161,179)(H,162,180)(H,193,194)(H,195,196)(H4,131,132,143)(H4,133,134,144)(H4,135,136,145)(H4,137,138,146)(H4,139,140,147)(H4,141,142,148)/t77-,78-,79-,80-,81+,82+,83+,84+,85+,86+,87+,88+,89-,90-,91+,92+,93+,94+,95+,96+,97-,98+/m1/s1
DM5CB8U	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CS[C@@H]2CC(=O)N(C2=O)CCCCCCN3C(=O)C[C@@H](C3=O)SC[C@@H](C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)CNC(=O)[C@@H]9C[C@H](CN9C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O
DM5CB8U	IK	JKUYFMHGTOPVMR-WQVVEKGHSA-N
DM5CB8U	IU	(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[(3S)-1-[6-[(3R)-3-[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxopropyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoic acid
DM5CB8U	CA	CAS 140661-97-8
DM5CB8U	DE	Sepsis

DML4PMG	ID	DML4PMG
DML4PMG	DN	Dendritic cell vaccine
DML4PMG	HS	Phase 2
DML4PMG	SN	Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn
DML4PMG	CP	University of Bonn
DML4PMG	DT	Vaccine
DML4PMG	DE	Ovarian cancer

DM7GPMB	ID	DM7GPMB
DM7GPMB	DN	Depatuxizumab
DM7GPMB	HS	Phase 2
DM7GPMB	CP	AbbVieNorth Chicago, IL
DM7GPMB	DE	Solid tumour/cancer; Glioblastoma of brain

DMH96JW	ID	DMH96JW
DMH96JW	DN	Dersalazine
DMH96JW	HS	Phase 2
DMH96JW	SN	UR-12715; UR-12746
DMH96JW	CP	Grupo Uriach
DMH96JW	DT	Small molecular drug
DMH96JW	PC	135484128
DMH96JW	MW	600.7
DMH96JW	FM	C35H32N6O4
DMH96JW	IC	InChI=1S/C35H32N6O4/c1-23-37-31-21-36-16-13-32(31)41(23)22-24-14-17-40(18-15-24)34(43)20-29(25-5-3-2-4-6-25)26-7-9-27(10-8-26)38-39-28-11-12-33(42)30(19-28)35(44)45/h2-13,16,19-21,24,42H,14-15,17-18,22H2,1H3,(H,44,45)/b29-20-,39-38?
DMH96JW	CS	CC1=NC2=C(N1CC3CCN(CC3)C(=O)/C=C(/C4=CC=CC=C4)\\C5=CC=C(C=C5)N=NC6=CC(=C(C=C6)O)C(=O)O)C=CN=C2
DMH96JW	IK	AYEAMZDTWLXZIJ-JEFTWCRZSA-N
DMH96JW	IU	2-hydroxy-5-[[4-[(Z)-3-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]-3-oxo-1-phenylprop-1-enyl]phenyl]diazenyl]benzoic acid
DMH96JW	CA	CAS 188913-58-8
DMH96JW	DE	Inflammatory bowel disease

DM63P1W	ID	DM63P1W
DM63P1W	DN	Descartes-08
DM63P1W	HS	Phase 2
DM63P1W	CP	Cartesian Therapeutics
DM63P1W	DT	CAR T Cell Therapy
DM63P1W	DE	Multiple myeloma

DM1UO4S	ID	DM1UO4S
DM1UO4S	DN	Descartes-11
DM1UO4S	HS	Phase 2
DM1UO4S	CP	Cartesian Therapeutics
DM1UO4S	DT	CAR T Cell Therapy
DM1UO4S	DE	Multiple myeloma

DMTY4KN	ID	DMTY4KN
DMTY4KN	DN	Dexefaroxan
DMTY4KN	HS	Phase 2
DMTY4KN	SN	Dexefaroxan [INN]; (+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline; 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole
DMTY4KN	CP	Pierre Fabre
DMTY4KN	DT	Small molecular drug
DMTY4KN	PC	208820
DMTY4KN	MW	216.28
DMTY4KN	FM	C13H16N2O
DMTY4KN	IC	InChI=1S/C13H16N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-6H,2,7-9H2,1H3,(H,14,15)/t13-/m1/s1
DMTY4KN	CS	CC[C@@]1(CC2=CC=CC=C2O1)C3=NCCN3
DMTY4KN	IK	RATZLMXRALDSJW-CYBMUJFWSA-N
DMTY4KN	IU	2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole
DMTY4KN	CA	CAS 143249-88-1
DMTY4KN	DE	Schizophrenia; Parkinson disease

DM52HUD	ID	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	HS	Phase 2
DM52HUD	SN	Dexloxiglumide; 119817-90-2; (R)-4-(3,4-Dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; UNII-69DY40RH9B; CR-2017; 69DY40RH9B; Dexloxiglumidum; Dexloxiglumida; Dexloxiglumide [INN]; Dexloxiglumidum [INN-Latin]; Dexloxiglumida [INN-Spanish]; PubChem16049; AC1Q3MXI; GTPL889; SCHEMBL366142; CHEMBL550781; AC1L24A8; DTXSID50152604; MolPort-006-170-001; CHEBI:135747; ZINC3801027; KS-000007QQ; AKOS000279054; PB12713; DB04856; CC-26372; AJ-45649; AK129760; AS-35102; KB-210163; AX8123879; CS-0054881; FT-0603098; Q-4119
DM52HUD	DT	Small molecular drug
DM52HUD	PC	65937
DM52HUD	MW	461.4
DM52HUD	FM	C21H30Cl2N2O5
DM52HUD	IC	InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1
DM52HUD	CS	CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
DM52HUD	IK	QNQZBKQEIFTHFZ-GOSISDBHSA-N
DM52HUD	IU	(4R)-4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid
DM52HUD	CA	CAS 119817-90-2
DM52HUD	CB	CHEBI:135747
DM52HUD	DE	Pancreatic malfunction

DM9L15R	ID	DM9L15R
DM9L15R	DN	Dextofisopam
DM9L15R	HS	Phase 2
DM9L15R	SN	R-Tofisopam; Dextofisopam (USAN/INN); (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DM9L15R	CP	Vela Pharmaceuticals
DM9L15R	DT	Small molecular drug
DM9L15R	PC	204105
DM9L15R	MW	382.5
DM9L15R	FM	C22H26N2O4
DM9L15R	IC	InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3/t15-/m0/s1
DM9L15R	CS	CC[C@H]1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C
DM9L15R	IK	RUJBDQSFYCKFAA-HNNXBMFYSA-N
DM9L15R	IU	(5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DM9L15R	CA	CAS 82059-50-5
DM9L15R	DE	Irritable bowel syndrome

DMFI5J4	ID	DMFI5J4
DMFI5J4	DN	Dextromethorphan+quinidine
DMFI5J4	HS	Phase 2
DMFI5J4	SN	Dextromethorphan hydrobromide monohydrate; 6700-34-1; Dextromethorphan hydrobromide; Methorate; Drixoral Cough; PediaCare 1; Dextromethorphan hydrobromide hydrate; Dextromethorphan (hydrobromide hydrate); Hold; St. Joseph Cough Syrup; Chloraseptic DM; UNII-9D2RTI9KYH; Romilar; Tylenol Cough Liquid; Endotussin-NN Pediatric; Robitussin Cough Calmers; Robitussin Pediatric Cough; 9D2RTI9KYH; Dextromethorphan hydrobromide OROS Tablets; Drixoral Cough &amp; Sore Throat; Robitussin Maximum Strength Cough
DMFI5J4	CP	Avanir
DMFI5J4	DT	Small molecular drug
DMFI5J4	PC	5462351
DMFI5J4	MW	370.3
DMFI5J4	FM	C18H28BrNO2
DMFI5J4	IC	InChI=1S/C18H25NO.BrH.H2O/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H;1H2/t15-,17+,18+;;/m1../s1
DMFI5J4	CS	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC.O.Br
DMFI5J4	IK	STTADZBLEUMJRG-IKNOHUQMSA-N
DMFI5J4	IU	(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrate;hydrobromide
DMFI5J4	CA	CAS 6700-34-1
DMFI5J4	CB	CHEBI:4471
DMFI5J4	DE	Diabetic neuropathy

DMS9Y1T	ID	DMS9Y1T
DMS9Y1T	DN	DG-17
DMS9Y1T	HS	Phase 2
DMS9Y1T	SN	DG-35; Nar DG-35 Prodrug; DG-35-VIII
DMS9Y1T	CP	Narhex Life Sciences Ltd
DMS9Y1T	DE	Human immunodeficiency virus infection

DMK6FYR	ID	DMK6FYR
DMK6FYR	DN	DiabeCell
DMK6FYR	HS	Phase 2
DMK6FYR	SN	Porcine pancreatic islet cell therapy (Immupel encapsulated, type 1 diabetes), LCT; Porcine pancreatic islet celltherapy (alginate encapsulated, type 1 diabetes), LCT
DMK6FYR	CP	Living Cell Technologies Ltd
DMK6FYR	DE	Insulin-dependent diabetes

DMTJOEL	ID	DMTJOEL
DMTJOEL	DN	DIADENOSINE TETRAPHOSPHATE
DMTJOEL	HS	Phase 2
DMTJOEL	SN	Ap4A; F-1500 (tetraNa salt); Diadenosine 5',5''-P1,P4-tetraphosphate
DMTJOEL	DT	Small molecular drug
DMTJOEL	PC	21706
DMTJOEL	MW	836.4
DMTJOEL	FM	C20H28N10O19P4
DMTJOEL	IC	InChI=1S/C20H28N10O19P4/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(45-19)1-43-50(35,36)47-52(39,40)49-53(41,42)48-51(37,38)44-2-8-12(32)14(34)20(46-8)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H,39,40)(H,41,42)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1
DMTJOEL	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N
DMTJOEL	IK	YOAHKNVSNCMZGQ-XPWFQUROSA-N
DMTJOEL	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DMTJOEL	CA	CAS 5542-28-9
DMTJOEL	CB	CHEBI:17422
DMTJOEL	DE	Cardiac arrhythmias

DM7AFJ8	ID	DM7AFJ8
DM7AFJ8	DN	Diannexin
DM7AFJ8	HS	Phase 2
DM7AFJ8	CP	Altavita Pharmaceuticals; Astellas Pharma
DM7AFJ8	DE	Myocardial reperfusion injury

DM20ATW	ID	DM20ATW
DM20ATW	DN	Diflomotecan
DM20ATW	HS	Phase 2
DM20ATW	SN	BN-80915; R-1536; Diflomotecan; (+)-5(R)-Ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione
DM20ATW	DT	Small molecular drug
DM20ATW	PC	219023
DM20ATW	MW	398.4
DM20ATW	FM	C21H16F2N2O4
DM20ATW	IC	InChI=1S/C21H16F2N2O4/c1-2-21(28)7-18(26)29-9-12-13(21)5-17-19-11(8-25(17)20(12)27)3-10-4-14(22)15(23)6-16(10)24-19/h3-6,28H,2,7-9H2,1H3/t21-/m1/s1
DM20ATW	CS	CC[C@]1(CC(=O)OCC2=C1C=C3C4=C(CN3C2=O)C=C5C=C(C(=CC5=N4)F)F)O
DM20ATW	IK	LFQCJSBXBZRMTN-OAQYLSRUSA-N
DM20ATW	IU	(20R)-20-ethyl-6,7-difluoro-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2(11),3,5,7,9,15(21)-heptaene-14,18-dione
DM20ATW	CA	CAS 220997-97-7
DM20ATW	CB	CHEBI:144046
DM20ATW	DE	Solid tumour/cancer

DMTLB92	ID	DMTLB92
DMTLB92	DN	DI-Leu16-IL2
DMTLB92	HS	Phase 2
DMTLB92	CP	Alopexx Oncology
DMTLB92	DT	Recombinant protein
DMTLB92	DE	B-cell lymphoma; Non-hodgkin lymphoma

DMBYJ92	ID	DMBYJ92
DMBYJ92	DN	Dilmapimod
DMBYJ92	HS	Phase 2
DMBYJ92	SN	Dilmapimod; SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602; SB-681323; GW-681323
DMBYJ92	CP	GSK
DMBYJ92	TC	Analgesics
DMBYJ92	DT	Small molecular drug
DMBYJ92	PC	10297982
DMBYJ92	MW	456.4
DMBYJ92	FM	C23H19F3N4O3
DMBYJ92	IC	InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)
DMBYJ92	CS	CC1=C(C=CC(=C1)F)C2=C3C=CC(=O)N(C3=NC(=N2)NC(CO)CO)C4=C(C=CC=C4F)F
DMBYJ92	IK	ORVNHOYNEHYKJG-UHFFFAOYSA-N
DMBYJ92	IU	8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one
DMBYJ92	CA	CAS 444606-18-2
DMBYJ92	DE	Acute lung injury

DMCATH2	ID	DMCATH2
DMCATH2	DN	Dilpacimab
DMCATH2	HS	Phase 2
DMCATH2	SN	ABT-165
DMCATH2	DT	Antibody
DMCATH2	DE	Solid tumour/cancer

DM96NHM	ID	DM96NHM
DM96NHM	DN	Dimiracetam
DM96NHM	HS	Phase 2
DM96NHM	SN	BND-11624; Dimiracetam, Neurotune; NT-11624; NMDA receptor antagonist (oral, neuropathic pain/osteoarthritic pain), Neurotune
DM96NHM	CP	Brane Discovery Srl
DM96NHM	DT	Small molecular drug
DM96NHM	PC	65955
DM96NHM	MW	140.14
DM96NHM	FM	C6H8N2O2
DM96NHM	IC	InChI=1S/C6H8N2O2/c9-5-3-8-4(7-5)1-2-6(8)10/h4H,1-3H2,(H,7,9)
DM96NHM	CS	C1CC(=O)N2C1NC(=O)C2
DM96NHM	IK	XTXXOHPHLNROBN-UHFFFAOYSA-N
DM96NHM	IU	3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione
DM96NHM	CA	CAS 126100-97-8
DM96NHM	DE	Neuropathic pain

DM2QBDS	ID	DM2QBDS
DM2QBDS	DN	Disitertide
DM2QBDS	HS	Phase 2
DM2QBDS	SN	NAFB-001; Disitertide cream (skin disorders), Digna
DM2QBDS	CP	University of Navarra
DM2QBDS	PC	9833838
DM2QBDS	MW	1580.8
DM2QBDS	FM	C68H109N17O22S2
DM2QBDS	IC	InChI=1S/C68H109N17O22S2/c1-12-32(5)53(85-67(105)54(33(6)13-2)84-64(102)48(30-87)82-56(94)35(8)74-61(99)45(27-51(91)92)79-62(100)43(24-31(3)4)78-63(101)47(29-86)83-65(103)52(71)36(9)88)66(104)80-44(25-37-28-72-39-17-15-14-16-38(37)39)60(98)73-34(7)55(93)75-41(20-22-108-10)58(96)77-42(21-23-109-11)59(97)76-40(18-19-49(69)89)57(95)81-46(68(106)107)26-50(70)90/h14-17,28,31-36,40-48,52-54,72,86-88H,12-13,18-27,29-30,71H2,1-11H3,(H2,69,89)(H2,70,90)(H,73,98)(H,74,99)(H,75,93)(H,76,97)(H,77,96)(H,78,101)(H,79,100)(H,80,104)(H,81,95)(H,82,94)(H,83,103)(H,84,102)(H,85,105)(H,91,92)(H,106,107)/t32-,33-,34-,35-,36+,40-,41-,42-,43-,44-,45-,46-,47-,48-,52-,53-,54-/m0/s1
DM2QBDS	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)N
DM2QBDS	IK	IUYPEUHIWDMJLM-SWHDLQTQSA-N
DM2QBDS	IU	(2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DM2QBDS	CA	CAS 272105-42-7
DM2QBDS	DE	Macular degeneration

DMYC2LE	ID	DMYC2LE
DMYC2LE	DN	Disufenton
DMYC2LE	HS	Phase 2
DMYC2LE	SN	168021-77-0; UNII-797K01YF1M; 797K01YF1M; N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide; SCHEMBL727315; CHEMBL2111090; 2,4-disulfophenyl-N-t-butylnitrone; alpha-(2,4-disulfophenyl)-N-tert-butylnitrone; Q27266726
DMYC2LE	CP	Oblato
DMYC2LE	DT	Small molecular drug
DMYC2LE	PC	151179
DMYC2LE	MW	337.4
DMYC2LE	FM	C11H15NO7S2
DMYC2LE	IC	InChI=1S/C11H15NO7S2/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19)
DMYC2LE	CS	CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)O)S(=O)(=O)O)[O-]
DMYC2LE	IK	OVTCHWSLKGENKP-UHFFFAOYSA-N
DMYC2LE	IU	N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide
DMYC2LE	CA	CAS 168021-77-0
DMYC2LE	DE	Recurrent glioblastoma

DMBMKV8	ID	DMBMKV8
DMBMKV8	DN	Disulfiram
DMBMKV8	HS	Phase 2 
DMBMKV8	SN	Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
DMBMKV8	CP	Odyssey Pharmaceuticals
DMBMKV8	TC	Antiviral Agents
DMBMKV8	DT	Small molecular drug
DMBMKV8	PC	3117
DMBMKV8	MW	296.5
DMBMKV8	FM	C10H20N2S4
DMBMKV8	IC	InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
DMBMKV8	CS	CCN(CC)C(=S)SSC(=S)N(CC)CC
DMBMKV8	IK	AUZONCFQVSMFAP-UHFFFAOYSA-N
DMBMKV8	IU	diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate
DMBMKV8	CA	CAS 97-77-8
DMBMKV8	CB	CHEBI:4659
DMBMKV8	DE	Alcoholism; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMOHT5V	ID	DMOHT5V
DMOHT5V	DN	DKN-01
DMOHT5V	HS	Phase 2
DMOHT5V	CP	Leap Therapeutics
DMOHT5V	DT	Antibody
DMOHT5V	DE	Multiple myeloma; Cholangiocarcinoma; Esophageal cancer; Biliary tract cancer; Endometrial cancer; Oesophagogastric junction cancer; Ovarian cancer; Prostate cancer

DMDJUWG	ID	DMDJUWG
DMDJUWG	DN	DLX-105
DMDJUWG	HS	Phase 2
DMDJUWG	SN	DLX-106; ESBA-105 (intra-articular formulation), ESBATech; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), Delenex; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), ESBATech
DMDJUWG	CP	ESBATech AG
DMDJUWG	DT	Antibody
DMDJUWG	DE	Osteoarthritis

DM0157T	ID	DM0157T
DM0157T	DN	DM199
DM0157T	HS	Phase 2
DM0157T	CP	DiaMedica Therapeutics
DM0157T	DT	Recombinant?protein
DM0157T	DE	Autoimmune diabetes; Ischemic stroke; Diabetic nephropathy; Cerebral ischemia

DMMSIG7	ID	DMMSIG7
DMMSIG7	DN	DM-71
DMMSIG7	HS	Phase 2
DMMSIG7	SN	Insulin sensitizer (type 2 diabetes), DiaMedica; Bethanechol + n-acetyl cysteine (type 2 diabetes), DiaMedica
DMMSIG7	CP	DiaMedica Inc
DMMSIG7	DE	Type-2 diabetes

DM1HG3U	ID	DM1HG3U
DM1HG3U	DN	DM-99
DM1HG3U	HS	Phase 2
DM1HG3U	CP	DiaMedica Inc
DM1HG3U	DE	Alzheimer disease

DMBC7HZ	ID	DMBC7HZ
DMBC7HZ	DN	DM-CHOC-PEN
DMBC7HZ	HS	Phase 2
DMBC7HZ	CP	Dekk-Tec
DMBC7HZ	PC	16126905
DMBC7HZ	MW	724
DMBC7HZ	FM	C35H48Cl5NO4
DMBC7HZ	IC	InChI=1S/C35H48Cl5NO4/c1-19(2)8-7-9-20(3)24-12-13-25-23-11-10-21-18-22(14-16-33(21,4)26(23)15-17-34(24,25)5)44-32(42)45-29-27(36)30(35(38,39)40)41-31(43-6)28(29)37/h10,19-20,22-26H,7-9,11-18H2,1-6H3/t20-,22+,23+,24-,25+,26+,33+,34-/m1/s1
DMBC7HZ	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)OC5=C(C(=NC(=C5Cl)OC)C(Cl)(Cl)Cl)Cl)C)C
DMBC7HZ	IK	ZJUUIXYKTPSIOH-LEZJFEBPSA-N
DMBC7HZ	IU	[3,5-dichloro-2-methoxy-6-(trichloromethyl)pyridin-4-yl] [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] carbonate
DMBC7HZ	CA	CAS 942149-56-6
DMBC7HZ	DE	Brain cancer; Brain metastases

DM725UG	ID	DM725UG
DM725UG	DN	DN24-02
DM725UG	HS	Phase 2
DM725UG	SN	Lapuleucel-T
DM725UG	CP	Dendreon
DM725UG	DE	Urogenital cancer; Colorectal cancer

DMDTVYC	ID	DMDTVYC
DMDTVYC	DN	DNCB
DMDTVYC	HS	Phase 2
DMDTVYC	SN	1-Chloro-2,4-dinitrobenzene
DMDTVYC	DT	Small molecular drug
DMDTVYC	PC	6
DMDTVYC	MW	202.55
DMDTVYC	FM	C6H3ClN2O4
DMDTVYC	IC	InChI=1S/C6H3ClN2O4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3H
DMDTVYC	CS	C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])Cl
DMDTVYC	IK	VYZAHLCBVHPDDF-UHFFFAOYSA-N
DMDTVYC	IU	1-chloro-2,4-dinitrobenzene
DMDTVYC	CA	CAS 97-00-7
DMDTVYC	CB	CHEBI:34718
DMDTVYC	DE	Immune System disease

DM89D6C	ID	DM89D6C
DM89D6C	DN	DNL758
DM89D6C	HS	Phase 2
DM89D6C	SN	SAR443122
DM89D6C	CP	Denali Therapeutics
DM89D6C	DT	Small molecular drug
DM89D6C	DE	Cutaneous lupus erythematosus

DM0QDC9	ID	DM0QDC9
DM0QDC9	DN	Dolastatin 10
DM0QDC9	HS	Phase 2
DM0QDC9	SN	Dolastatin 10; Dolastatin-10; Dolostatin 10; UNII-EI946JT51X; CCRIS 7310; CHEBI:67357; NSC 376128; EI946JT51X; L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-
DM0QDC9	PC	9810929
DM0QDC9	MW	785.1
DM0QDC9	FM	C42H68N6O6S
DM0QDC9	IC	InChI=1S/C42H68N6O6S/c1-13-28(6)37(47(10)42(52)35(26(2)3)45-40(51)36(27(4)5)46(8)9)33(53-11)25-34(49)48-22-17-20-32(48)38(54-12)29(7)39(50)44-31(41-43-21-23-55-41)24-30-18-15-14-16-19-30/h14-16,18-19,21,23,26-29,31-33,35-38H,13,17,20,22,24-25H2,1-12H3,(H,44,50)(H,45,51)/t28-,29+,31-,32-,33+,35-,36-,37-,38+/m0/s1
DM0QDC9	CS	CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C
DM0QDC9	IK	OFDNQWIFNXBECV-VFSYNPLYSA-N
DM0QDC9	IU	(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
DM0QDC9	CA	CAS 110417-88-4
DM0QDC9	CB	CHEBI:67357
DM0QDC9	DE	Leukemia

DMDUV1S	ID	DMDUV1S
DMDUV1S	DN	DOLASTATIN-10
DMDUV1S	HS	Phase 2
DMDUV1S	DT	Small molecular drug
DMDUV1S	PC	9810929
DMDUV1S	MW	785.1
DMDUV1S	FM	C42H68N6O6S
DMDUV1S	IC	InChI=1S/C42H68N6O6S/c1-13-28(6)37(47(10)42(52)35(26(2)3)45-40(51)36(27(4)5)46(8)9)33(53-11)25-34(49)48-22-17-20-32(48)38(54-12)29(7)39(50)44-31(41-43-21-23-55-41)24-30-18-15-14-16-19-30/h14-16,18-19,21,23,26-29,31-33,35-38H,13,17,20,22,24-25H2,1-12H3,(H,44,50)(H,45,51)/t28-,29+,31-,32-,33+,35-,36-,37-,38+/m0/s1
DMDUV1S	CS	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C
DMDUV1S	IK	OFDNQWIFNXBECV-VFSYNPLYSA-N
DMDUV1S	IU	(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
DMDUV1S	CA	CAS 110417-88-4
DMDUV1S	CB	CHEBI:67357
DMDUV1S	DE	Solid tumour/cancer

DMCT08V	ID	DMCT08V
DMCT08V	DN	Domagrozumab
DMCT08V	HS	Phase 2
DMCT08V	CP	Pfizer New York, NY
DMCT08V	DE	Duchenne dystrophy

DM8VWPH	ID	DM8VWPH
DM8VWPH	DN	Doxorubicin-eluting beads
DM8VWPH	HS	Phase 2
DM8VWPH	SN	DC Bead (TN)
DM8VWPH	CP	Bayer HealthCare Pharmaceuticals; Biocompatibles
DM8VWPH	DE	Liver cancer

DM059CZ	ID	DM059CZ
DM059CZ	DN	DPK-060
DM059CZ	HS	Phase 2
DM059CZ	SN	DP-9011; DP-9012; DP-9013; DP-9011-DP-9013 series (atopic dermatitis/impetigo), DermaGen
DM059CZ	CP	DermaGen AB
DM059CZ	DE	Atopic dermatitis

DMMC3XR	ID	DMMC3XR
DMMC3XR	DN	DPV-001
DMMC3XR	HS	Phase 2
DMMC3XR	CP	Ubivac
DMMC3XR	DE	Non-small-cell lung cancer; Prostate cancer

DMGD3XT	ID	DMGD3XT
DMGD3XT	DN	DRL-17822
DMGD3XT	HS	Phase 2
DMGD3XT	SN	CETP inhibitor (dyslipidemia/atherosclerosis/cardiovascular diseases), Dr Reddy's
DMGD3XT	CP	Dr Reddy's Laboratories Ltd
DMGD3XT	PC	58689743
DMGD3XT	MW	603.6
DMGD3XT	FM	C30H31F6N7
DMGD3XT	IC	InChI=1S/C30H31F6N7/c1-18-4-3-5-22-12-23(27(37-26(18)22)42(14-19-6-7-19)15-20-8-9-20)17-43(28-38-40-41(2)39-28)16-21-10-24(29(31,32)33)13-25(11-21)30(34,35)36/h3-5,10-13,19-20H,6-9,14-17H2,1-2H3
DMGD3XT	CS	CC1=C2C(=CC=C1)C=C(C(=N2)N(CC3CC3)CC4CC4)CN(CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)C6=NN(N=N6)C
DMGD3XT	IK	OCNBSSLDAIWTKS-UHFFFAOYSA-N
DMGD3XT	IU	3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-N,N-bis(cyclopropylmethyl)-8-methylquinolin-2-amine
DMGD3XT	CA	CAS 898911-09-6
DMGD3XT	DE	Arteriosclerosis

DM8WU3O	ID	DM8WU3O
DM8WU3O	DN	Drug 2862277
DM8WU3O	HS	Phase 2
DM8WU3O	SN	2862277
DM8WU3O	DT	Antibody
DM8WU3O	DE	Acute lung injury

DMI69E5	ID	DMI69E5
DMI69E5	DN	DS-3201b
DMI69E5	HS	Phase 2
DMI69E5	SN	Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551
DMI69E5	CP	Daiichi Sankyo
DMI69E5	DT	Small molecular drug
DMI69E5	PC	126481870
DMI69E5	MW	488
DMI69E5	FM	C26H34ClN3O4
DMI69E5	IC	InChI=1S/C26H34ClN3O4/c1-14-11-15(2)29-25(32)20(14)13-28-24(31)19-12-21(27)23-22(16(19)3)33-26(4,34-23)17-7-9-18(10-8-17)30(5)6/h11-12,17-18H,7-10,13H2,1-6H3,(H,28,31)(H,29,32)/t17?,18?,26-/m1/s1
DMI69E5	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC(=C3C(=C2C)O[C@@](O3)(C)C4CCC(CC4)N(C)C)Cl)C
DMI69E5	IK	SSDRNUPMYCFXGM-ZZHSESOFSA-N
DMI69E5	IU	(2R)-7-chloro-2-[4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide
DMI69E5	CA	CAS 1809336-39-7
DMI69E5	DE	Acute myeloid leukaemia; Acute lymphoblastic leukaemia; Urothelial carcinoma; Renal cell carcinoma; Small-cell lung cancer; T-cell leukaemia

DMUXIRM	ID	DMUXIRM
DMUXIRM	DN	DS-8500
DMUXIRM	HS	Phase 2
DMUXIRM	CP	Daiichi Sankyo
DMUXIRM	PC	74889211
DMUXIRM	MW	153.18
DMUXIRM	FM	C8H11NO2
DMUXIRM	IC	InChI=1S/C8H11NO2/c1-3-7-6(4-5-9-7)8(10)11-2/h4-5,9H,3H2,1-2H3
DMUXIRM	CS	CCC1=C(C=CN1)C(=O)OC
DMUXIRM	IK	FWZOVQKKSCXOHE-UHFFFAOYSA-N
DMUXIRM	IU	methyl 2-ethyl-1H-pyrrole-3-carboxylate
DMUXIRM	DE	Diabetic complication; Type-2 diabetes

DM6UGHA	ID	DM6UGHA
DM6UGHA	DN	DSP-6952
DM6UGHA	HS	Phase 2
DM6UGHA	SN	Serotonin 4 receptor partial agonist (constipation), Dainippon Sumitomo
DM6UGHA	CP	Dainippon Sumitomo Pharma Co Ltd
DM6UGHA	DE	Constipation

DMU2GP4	ID	DMU2GP4
DMU2GP4	DN	DT-1687
DMU2GP4	HS	Phase 2
DMU2GP4	SN	DT-1386; MGluR4 PAM (neurological disease/psychiatric disorder), Domain Therapeutics; MGluR4 PAM (neurological disease/psychiatric disorder), Merck Serono
DMU2GP4	CP	Domain Therapeutics SA
DMU2GP4	PC	135565465
DMU2GP4	MW	421.5
DMU2GP4	FM	C23H23N3O3S
DMU2GP4	IC	InChI=1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,27H,1-2,6-10H2/b25-19+
DMU2GP4	CS	C1COCCN1CCCC2=CC\\3=C(C=C2)OC(=C/C3=N\\O)C4=NC=C5C=CSC5=C4
DMU2GP4	IK	ZTEDNASHAWNBKQ-NCELDCMTSA-N
DMU2GP4	IU	(NE)-N-[6-(3-morpholin-4-ylpropyl)-2-thieno[3,2-c]pyridin-6-ylchromen-4-ylidene]hydroxylamine
DMU2GP4	CA	CAS 1883329-53-0
DMU2GP4	DE	Neurological disorder; Parkinson disease

DMV84OK	ID	DMV84OK
DMV84OK	DN	DTI-0009
DMV84OK	HS	Phase 2
DMV84OK	SN	Selodenosan
DMV84OK	CP	Aderis Pharmaceuticals
DMV84OK	DE	Atrial fibrillation

DMX27IT	ID	DMX27IT
DMX27IT	DN	DTRM-555
DMX27IT	HS	Phase 2
DMX27IT	CP	Zhejiang DTRM Biopharma
DMX27IT	DT	Small molecular drug
DMX27IT	DE	Chronic lymphocytic leukaemia

DM1ZJYS	ID	DM1ZJYS
DM1ZJYS	DN	Dusigitumab
DM1ZJYS	HS	Phase 2
DM1ZJYS	CP	MedImmune Gaithersburg, MD
DM1ZJYS	DE	Breast cancer

DM7USVA	ID	DM7USVA
DM7USVA	DN	Duvelisib
DM7USVA	HS	Phase 2 
DM7USVA	SN	Duvelisib; 1201438-56-3; IPI-145; INK-1197; UNII-610V23S0JI; IPI 145; 610V23S0JI; INK-1147; Copiktra; IPI-145 (INK1197); Duvelisib [USAN:INN]; IPI145; INK1197; Copiktra (TN); AK145604; Duvelisib (IPI-145, INK1197); Duvel; Duvelisib
DM7USVA	TC	Antiviral Agents
DM7USVA	DT	Small molecular drug
DM7USVA	PC	50905713
DM7USVA	MW	416.9
DM7USVA	FM	C22H17ClN6O
DM7USVA	IC	InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
DM7USVA	CS	C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DM7USVA	IK	SJVQHLPISAIATJ-ZDUSSCGKSA-N
DM7USVA	IU	8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
DM7USVA	CA	CAS 1201438-56-3
DM7USVA	CB	CHEBI:131169
DM7USVA	DE	Coronavirus Disease 2019 (COVID-19)

DMUGBQK	ID	DMUGBQK
DMUGBQK	DN	DVC1-0101
DMUGBQK	HS	Phase 2
DMUGBQK	SN	Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University
DMUGBQK	CP	DNAVEC Corp
DMUGBQK	DE	Arteriosclerosis

DMQKU2F	ID	DMQKU2F
DMQKU2F	DN	DWP-05195
DMQKU2F	HS	Phase 2
DMQKU2F	SN	DWJ-204; DWP-0519
DMQKU2F	CP	Daewoong Pharmaceutical Co Ltd
DMQKU2F	DE	Neuropathic pain

DMBFZET	ID	DMBFZET
DMBFZET	DN	DX-890
DMBFZET	HS	Phase 2
DMBFZET	CP	Dyax Corp.
DMBFZET	PC	56841753
DMBFZET	MW	6231
DMBFZET	FM	C282H412N74O75S6
DMBFZET	IC	InChI=1S/C282H412N74O75S6/c1-21-150(15)229-273(424)312-154(19)232(383)328-185(117-157-58-30-24-31-59-157)255(406)339-196(123-160-64-36-27-37-65-160)277(428)353-110-52-76-205(353)267(418)324-177(74-50-108-300-282(296)297)246(397)332-189(124-164-129-301-170-67-39-38-66-168(164)170)250(401)310-153(18)231(382)327-184(116-156-56-28-23-29-57-156)253(404)334-193(128-224(380)381)251(402)311-155(20)234(385)347-225(146(7)8)270(421)325-171(68-40-44-102-283)236(387)304-132-215(367)313-173(69-41-45-103-284)242(393)344-202-142-436-435-141-201-262(413)319-176(73-49-107-299-281(294)295)244(395)321-180(95-100-222(376)377)248(399)330-188(121-163-84-90-167(360)91-85-163)257(408)342-198(241(392)307-135-218(370)346-228(149(13)14)278(429)356-113-55-79-208(356)279(430)431)138-432-434-140-200(341-233(384)152(17)309-235(386)169(287)92-98-220(372)373)263(414)333-192(127-212(291)364)259(410)337-194(115-145(5)6)275(426)355-112-54-78-207(355)269(420)351-230(151(16)22-2)274(425)349-227(148(11)12)271(422)326-172(72-48-106-298-280(292)293)237(388)308-136-219(371)352-109-51-75-204(352)266(417)345-203(265(416)350-229)143-437-433-139-199(316-214(366)131-302-213(365)130-303-239(390)183(119-161-80-86-165(358)87-81-161)335-268(419)206-77-53-111-354(206)276(427)195(122-159-62-34-26-35-63-159)338-252(403)182(114-144(3)4)336-272(423)226(147(9)10)348-264(202)415)261(412)320-178(93-97-209(288)361)238(389)305-133-216(368)314-190(125-210(289)362)240(391)306-134-217(369)315-191(126-211(290)363)258(409)318-175(71-43-47-105-286)245(396)329-186(118-158-60-32-25-33-61-158)254(405)331-187(120-162-82-88-166(359)89-83-162)256(407)340-197(137-357)260(411)323-179(94-99-221(374)375)247(398)317-174(70-42-46-104-285)243(394)322-181(249(400)343-201)96-101-223(378)379/h23-39,56-67,80-91,129,144-155,169,171-208,225-230,301,357-360H,21-22,40-55,68-79,92-128,130-143,283-287H2,1-20H3,(H2,288,361)(H2,289,362)(H2,290,363)(H2,291,364)(H,302,365)(H,303,390)(H,304,387)(H,305,389)(H,306,391)(H,307,392)(H,308,388)(H,309,386)(H,310,401)(H,311,402)(H,312,424)(H,313,367)(H,314,368)(H,315,369)(H,316,366)(H,317,398)(H,318,409)(H,319,413)(H,320,412)(H,321,395)(H,322,394)(H,323,411)(H,324,418)(H,325,421)(H,326,422)(H,327,382)(H,328,383)(H,329,396)(H,330,399)(H,331,405)(H,332,397)(H,333,414)(H,334,404)(H,335,419)(H,336,423)(H,337,410)(H,338,403)(H,339,406)(H,340,407)(H,341,384)(H,342,408)(H,343,400)(H,344,393)(H,345,417)(H,346,370)(H,347,385)(H,348,415)(H,349,425)(H,350,416)(H,351,420)(H,372,373)(H,374,375)(H,376,377)(H,378,379)(H,380,381)(H,430,431)(H4,292,293,298)(H4,294,295,299)(H4,296,297,300)/t150-,151-,152-,153-,154-,155-,169-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,225-,226-,227-,228-,229-,230-/m0/s1
DMBFZET	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H]3CSSC[C@H]4C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N4)CC6=CC=C(C=C6)O)CC7=CC=CC=C7)CC(C)C)C(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC3=O)[C@@H](C)CC)C)CC9=CC=CC=C9)CC2=CC=CC=C2)CCCNC(=N)N)CC2=CNC3=CC=CC=C32)C)CC2=CC=CC=C2)CC(=O)O)C)C(C)C)CCCCN)CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N1)CC(C)C)CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)O)CC1=CC=C(C=C1)O)CCC(=O)O)CCCNC(=N)N)CCC(=O)O)CCCCN)CCC(=O)O)CO)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CCCCN)CC(=O)N)CC(=O)N)CCC(=O)N)CCCNC(=N)N)C(C)C
DMBFZET	IK	CARVNSROHCBVAO-BUGJESOBSA-N
DMBFZET	IU	(2S)-1-[(2S)-2-[[2-[[(1R,2aS,4S,8aS,11aS,13S,14aS,16S,17aR,19S,20aS,22S,26aS,28S,29aS,31S,32aS,34R,35aS,38aS,39R,41aS,42S,44aS,45S,47aS,48S,50aS,51R,54S,56aS,57S,59aS,60S,62aS,63S,65aS,66S,69S,72S,75S,81S,87S,90R,99S)-20a,26a,57,72-tetrakis(4-aminobutyl)-34-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-31,75,81-tris(2-amino-2-oxoethyl)-87-(3-amino-3-oxopropyl)-8a,38a,56a,59a,69-pentabenzyl-19,65a-bis[(2S)-butan-2-yl]-13,47a,48-tris(3-carbamimidamidopropyl)-45,54,60-tris(2-carboxyethyl)-35a-(carboxymethyl)-63-(hydroxymethyl)-42,66,99-tris[(4-hydroxyphenyl)methyl]-44a-(1H-indol-3-ylmethyl)-32a,41a,62a-trimethyl-11a,28-bis(2-methylpropyl)-1a,3,7a,9,10a,12,13a,15,16a,18,19a,21,22a,25a,27,28a,30,31a,33,34a,37a,40a,41,43a,44,46a,47,49a,50,53,55a,56,58a,59,61a,62,64a,65,67a,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-14a,16,29a-tri(propan-2-yl)-36,37,69a,70a,73a,74a-hexathia-a,2,6a,8,9a,11,12a,14,15a,17,18a,20,21a,24a,26,27a,29,30a,32,33a,36a,39a,40,42a,43,45a,46,48a,49,52,54a,55,57a,58,60a,61,63a,64,66a,67,70,73,76,79,82,85,88,91,94,97-pentacontazaheptacyclo[88.77.4.451,117.04,8.022,26.0102,106.0150,154]pentaheptacontahectane-39-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid
DMBFZET	CA	CAS 506433-25-6
DMBFZET	DE	Acute lung injury

DMDYWM8	ID	DMDYWM8
DMDYWM8	DN	E-10030
DMDYWM8	HS	Phase 2
DMDYWM8	SN	PDGF-B antagonist (AMD), Eyetech/Archemix; PDGF-B antagonist (AMD), (OSI) Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), (OSI) Eyetech/Archemix
DMDYWM8	CP	Archemix Corp
DMDYWM8	DE	Macular degeneration

DMLS269	ID	DMLS269
DMLS269	DN	E-1224
DMLS269	HS	Phase 2
DMLS269	SN	BMS-292655; BMS-315801; BMS-379224; Ravuconazole prodrugs, BMS; Ravuconazole back-up compounds, Eisai; Ravuconazole prodrug (fungal infection), Brain Factory; Ravuconazole prodrugs, Bristol-Myers Squibb
DMLS269	CP	Bristol-Myers Squibb Co
DMLS269	DT	Small molecular drug
DMLS269	PC	57416740
DMLS269	MW	273.14
DMLS269	FM	C15H20BNO3
DMLS269	IC	InChI=1S/C15H20BNO3/c1-11(18)13-12(7-6-10-17-13)8-9-16-19-14(2,3)15(4,5)20-16/h6-10H,1-5H3/b9-8+
DMLS269	CS	B1(OC(C(O1)(C)C)(C)C)/C=C/C2=C(N=CC=C2)C(=O)C
DMLS269	IK	DAQLKAUMCVWOCH-CMDGGOBGSA-N
DMLS269	IU	1-[3-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridin-2-yl]ethanone
DMLS269	DE	Fungal infection

DMK8SY6	ID	DMK8SY6
DMK8SY6	DN	E2027
DMK8SY6	HS	Phase 2
DMK8SY6	CP	Eisai
DMK8SY6	DT	Small molecular drug
DMK8SY6	DE	Alzheimer disease; Parkinson disease; Lewy body dementia

DMC5PB2	ID	DMC5PB2
DMC5PB2	DN	E-4716
DMC5PB2	HS	Phase 2
DMC5PB2	SN	Mapinastine
DMC5PB2	CP	Laboratorios Dr Esteve SA
DMC5PB2	DE	Respiratory disease

DMQERC6	ID	DMQERC6
DMQERC6	DN	E5555
DMQERC6	HS	Phase 2
DMQERC6	SN	Atopaxar
DMQERC6	CP	Eisai
DMQERC6	DT	Small molecular drug
DMQERC6	PC	10459564
DMQERC6	MW	527.6
DMQERC6	FM	C29H38FN3O5
DMQERC6	IC	InChI=1S/C29H38FN3O5/c1-7-37-23-15-19-16-33(28(31)24(19)25(30)27(23)38-8-2)17-22(34)18-13-20(29(3,4)5)26(35-6)21(14-18)32-9-11-36-12-10-32/h13-15,31H,7-12,16-17H2,1-6H3
DMQERC6	CS	CCOC1=C(C(=C2C(=C1)CN(C2=N)CC(=O)C3=CC(=C(C(=C3)N4CCOCC4)OC)C(C)(C)C)F)OCC
DMQERC6	IK	QWKAUGRRIXBIPO-UHFFFAOYSA-N
DMQERC6	IU	1-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2-(5,6-diethoxy-4-fluoro-3-imino-1H-isoindol-2-yl)ethanone
DMQERC6	CA	CAS 751475-53-3
DMQERC6	DE	Acute coronary syndrome

DM1S489	ID	DM1S489
DM1S489	DN	E6005
DM1S489	HS	Phase 2
DM1S489	SN	Lotamilast; 947620-48-6; E6005; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7
DM1S489	CP	Eisai
DM1S489	DT	Small molecular drug
DM1S489	PC	24864553
DM1S489	MW	472.5
DM1S489	FM	C26H24N4O5
DM1S489	IC	InChI=1S/C26H24N4O5/c1-27-26-29-20-14-22(34-3)21(33-2)13-19(20)23(30-26)17-6-5-7-18(12-17)28-24(31)15-8-10-16(11-9-15)25(32)35-4/h5-14H,1-4H3,(H,28,31)(H,27,29,30)
DM1S489	CS	CNC1=NC2=CC(=C(C=C2C(=N1)C3=CC(=CC=C3)NC(=O)C4=CC=C(C=C4)C(=O)OC)OC)OC
DM1S489	IK	BBTFKAOFCSOZMB-UHFFFAOYSA-N
DM1S489	IU	methyl 4-[[3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl]carbamoyl]benzoate
DM1S489	CA	CAS 947620-48-6
DM1S489	DE	Atopic dermatitis

DMOSL9P	ID	DMOSL9P
DMOSL9P	DN	E6201
DMOSL9P	HS	Phase 2
DMOSL9P	SN	novel MEK inhibitors
DMOSL9P	CP	Eisai Ltd.
DMOSL9P	DT	Small molecular drug
DMOSL9P	PC	10172827
DMOSL9P	MW	389.4
DMOSL9P	FM	C21H27NO6
DMOSL9P	IC	InChI=1S/C21H27NO6/c1-4-22-15-10-14-6-5-7-16(23)20(26)17(24)9-8-12(2)13(3)28-21(27)19(14)18(25)11-15/h5-6,8-13,16,20,22-23,25-26H,4,7H2,1-3H3/b6-5+,9-8-/t12-,13+,16+,20+/m1/s1
DMOSL9P	CS	CCNC1=CC\\2=C(C(=C1)O)C(=O)O[C@H]([C@@H](/C=C\\C(=O)[C@H]([C@H](C/C=C2)O)O)C)C
DMOSL9P	IK	MWUFVYLAWAXDHQ-HMNLTAHHSA-N
DMOSL9P	IU	(4S,5R,6Z,9S,10S,12E)-16-(ethylamino)-9,10,18-trihydroxy-4,5-dimethyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione
DMOSL9P	CA	CAS 603987-35-5
DMOSL9P	DE	Psoriasis vulgaris

DMUWJI4	ID	DMUWJI4
DMUWJI4	DN	E-6700
DMUWJI4	HS	Phase 2
DMUWJI4	PC	9843006
DMUWJI4	MW	383.4
DMUWJI4	FM	C22H25NO5
DMUWJI4	IC	InChI=1S/C22H25NO5/c1-14-18(19(24)15(2)21(28-3)20(14)25)12-17(22(26)27)10-6-4-5-8-16-9-7-11-23-13-16/h7,9,11-13H,4-6,8,10H2,1-3H3,(H,26,27)/b17-12+
DMUWJI4	CS	CC1=C(C(=O)C(=C(C1=O)OC)C)/C=C(\\CCCCCC2=CN=CC=C2)/C(=O)O
DMUWJI4	IK	WWYFKRSBSWBEGV-SFQUDFHCSA-N
DMUWJI4	IU	(2E)-2-[(4-methoxy-2,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]-7-pyridin-3-ylheptanoic acid
DMUWJI4	DE	Asthma

DMAHGKE	ID	DMAHGKE
DMAHGKE	DN	E7016
DMAHGKE	HS	Phase 2
DMAHGKE	SN	UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; E7016; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016
DMAHGKE	CP	Eisai
DMAHGKE	DT	Small molecular drug
DMAHGKE	PC	11660296
DMAHGKE	MW	349.4
DMAHGKE	FM	C20H19N3O3
DMAHGKE	IC	InChI=1S/C20H19N3O3/c24-13-6-8-23(9-7-13)11-12-4-5-16-15(10-12)19-18-14(20(25)22-21-19)2-1-3-17(18)26-16/h1-5,10,13,24H,6-9,11H2,(H,22,25)
DMAHGKE	CS	C1CN(CCC1O)CC2=CC3=C(C=C2)OC4=CC=CC5=C4C3=NNC5=O
DMAHGKE	IK	HAVFFEMDLROBGI-UHFFFAOYSA-N
DMAHGKE	IU	4-[(4-hydroxypiperidin-1-yl)methyl]-8-oxa-15,16-diazatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17)-heptaen-14-one
DMAHGKE	CA	CAS 902128-92-1
DMAHGKE	DE	Melanoma

DMZRXTL	ID	DMZRXTL
DMZRXTL	DN	E7820
DMZRXTL	HS	Phase 2
DMZRXTL	SN	E7820; 289483-69-8; E-7820; E 7820; UNII-TVH5K7949N; TVH5K7949N; 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; NSC-719239; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-; LWGUASZLXHYWIV-UHFFFAOYSA-N; AC1L52N5; ZINC8704; SCHEMBL1581157; DTXSID20183142; BCP25835; EX-A1818; 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide; NSC719239; AKOS032944953; CS-6075
DMZRXTL	CP	Eisai
DMZRXTL	DT	Small molecular drug
DMZRXTL	PC	196970
DMZRXTL	MW	336.4
DMZRXTL	FM	C17H12N4O2S
DMZRXTL	IC	InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3
DMZRXTL	CS	CC1=C2C(=CNC2=C(C=C1)NS(=O)(=O)C3=CC=CC(=C3)C#N)C#N
DMZRXTL	IK	LWGUASZLXHYWIV-UHFFFAOYSA-N
DMZRXTL	IU	3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide
DMZRXTL	CA	CAS 289483-69-8
DMZRXTL	DE	Solid tumour/cancer; Colorectal cancer

DM8K5IF	ID	DM8K5IF
DM8K5IF	DN	E7850
DM8K5IF	HS	Phase 2
DM8K5IF	SN	Irofulven
DM8K5IF	CP	Eisai
DM8K5IF	DT	Small molecular drug
DM8K5IF	PC	148189
DM8K5IF	MW	246.3
DM8K5IF	FM	C15H18O3
DM8K5IF	IC	InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1
DM8K5IF	CS	CC1=C(C2=C(C3(CC3)[C@@](C(=O)C2=C1)(C)O)C)CO
DM8K5IF	IK	NICJCIQSJJKZAH-AWEZNQCLSA-N
DM8K5IF	IU	(5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one
DM8K5IF	CA	CAS 158440-71-2
DM8K5IF	CB	CHEBI:135002
DM8K5IF	DE	Solid tumour/cancer

DM753H8	ID	DM753H8
DM753H8	DN	EB8018
DM753H8	HS	Phase 2
DM753H8	SN	Sibofimloc; 1616113-45-1; Antibiotic-202; VRT-1353385; UNII-00OF00QZC4; 1-[2,7-Bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; 1-[2,7-bis({2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl})spiro[fluorene-9,4'-piperidine]-1'-yl]ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; Sibofimloc [INN]; Sibofimloc [USAN]; Sibofimloc (USAN/INN); CHEMBL4594305; SCHEMBL15836795; EX-A750; Antibiotic-202;VRT-1353385; MFCD28144726; WHO 10950; ZINC209678340; ACN-052475; CS-5487; DA-43714; HY-12820; B5896; D11825; J-690221; 1-(2,7-Bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol-8-yl)spiro(fluorene-9,4'-piperidin)-1'-yl)ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4a?piperidine]-1a?yl]ethanone; 8,8'-(1'-Acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol); D-Glycero-D-manno-oct-7-ynitol, 8,8'-(1'-acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy-
DM753H8	CP	Enterome Biosciences
DM753H8	DT	Small molecular drug
DM753H8	PC	76684239
DM753H8	MW	649.7
DM753H8	FM	C35H39NO11
DM753H8	IC	InChI=1S/C35H39NO11/c1-18(39)36-12-10-35(11-13-36)23-14-19(4-8-25-29(40)33(44)31(42)27(16-37)46-25)2-6-21(23)22-7-3-20(15-24(22)35)5-9-26-30(41)34(45)32(43)28(17-38)47-26/h2-3,6-7,14-15,25-34,37-38,40-45H,10-13,16-17H2,1H3/t25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m1/s1
DM753H8	CS	CC(=O)N1CCC2(CC1)C3=C(C=CC(=C3)C#C[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=C2C=C(C=C5)C#C[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O
DM753H8	IK	SFHMWDMKUYVSQJ-VECBPBMLSA-N
DM753H8	IU	1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone
DM753H8	CA	CAS 1616113-45-1
DM753H8	DE	Crohn disease

DM0KVJC	ID	DM0KVJC
DM0KVJC	DN	EC-145
DM0KVJC	HS	Phase 2
DM0KVJC	SN	EC-0255; EC-0260
DM0KVJC	CP	Endocyte; Merck
DM0KVJC	PC	25014653
DM0KVJC	MW	1917
DM0KVJC	FM	C86H109N21O26S2
DM0KVJC	IC	InChI=1S/C86H109N21O26S2/c1-6-82(129)35-42-36-85(78(127)132-5,64-47(21-26-106(39-42)41-82)46-12-8-9-13-50(46)95-64)49-30-48-57(34-58(49)131-4)105(3)75-84(48)23-27-107-25-11-22-83(7-2,74(84)107)76(125)86(75,130)77(126)103-104-81(128)133-28-29-134-135-40-56(73(123)124)100-70(119)55(33-62(113)114)99-69(118)54(32-61(111)112)98-67(116)51(14-10-24-90-79(87)88)96-68(117)53(31-60(109)110)94-59(108)20-19-52(72(121)122)97-66(115)43-15-17-44(18-16-43)91-37-45-38-92-65-63(93-45)71(120)102-80(89)101-65/h8-9,11-13,15-18,22,30,34,38,42,51-56,74-76,91,95,125,129-130H,6-7,10,14,19-21,23-29,31-33,35-37,39-41H2,1-5H3,(H,94,108)(H,96,117)(H,97,115)(H,98,116)(H,99,118)(H,100,119)(H,103,126)(H,104,128)(H,109,110)(H,111,112)(H,113,114)(H,121,122)(H,123,124)(H4,87,88,90)(H3,89,92,101,102,120)/t42-,51-,52-,53-,54-,55-,56-,74-,75+,76+,82-,83+,84+,85-,86-/m0/s1
DM0KVJC	CS	CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)NNC(=O)OCCSSC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)NCC1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O)CC)OC)C(=O)OC)O
DM0KVJC	IK	KUZYSQSABONDME-QRLOMCMNSA-N
DM0KVJC	IU	(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-[2-[[[(1R,9R,10S,11R,12R,19R)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carbonyl]amino]carbamoyloxy]ethyldisulfanyl]ethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM0KVJC	CA	CAS 742092-03-1
DM0KVJC	DE	Solid tumour/cancer

DM1LDIP	ID	DM1LDIP
DM1LDIP	DN	Econail
DM1LDIP	HS	Phase 2
DM1LDIP	SN	Econazole/SEPA
DM1LDIP	CP	MacroChem Corporation
DM1LDIP	DT	Small molecular drug
DM1LDIP	PC	68589
DM1LDIP	MW	444.7
DM1LDIP	FM	C18H16Cl3N3O4
DM1LDIP	IC	InChI=1S/C18H15Cl3N2O.HNO3/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21;2-1(3)4/h1-9,12,18H,10-11H2;(H,2,3,4)
DM1LDIP	CS	C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl.[N+](=O)(O)[O-]
DM1LDIP	IK	DDXORDQKGIZAME-UHFFFAOYSA-N
DM1LDIP	IU	1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid
DM1LDIP	CA	CAS 24169-02-6
DM1LDIP	DE	Fungal infection

DMKAUM9	ID	DMKAUM9
DMKAUM9	DN	Eculizumab
DMKAUM9	HS	Phase 2 
DMKAUM9	SN	Eculizumab (intravitreal, AMD); Eculizumab (intravitreal, AMD), Alexion; Eculizumab (intravitreal, age-related macular degeneration), Alexion
DMKAUM9	CP	Alexion Pharmaceuticals Inc
DMKAUM9	TC	Antiviral Agents
DMKAUM9	DT	Monoclonal antibody
DMKAUM9	DE	Age-related macular degeneration; Coronavirus Disease 2019 (COVID-19)

DMQ08AJ	ID	DMQ08AJ
DMQ08AJ	DN	Edotreotide
DMQ08AJ	HS	Phase 2
DMQ08AJ	SN	Edotreotide; SMT-487; UNII-U194AS08HZ; 204318-14-9; U194AS08HZ; CHEMBL408350; DOTATOC; DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7); SMT 487; Edotreotide [USAN:INN]; DOTA-TOC acetate; AC1L4KLV; SCHEMBL1649285; SCHEMBL19712197; RZHKDBRREKOZEW-AAXZNHDCSA-N; BDBM50165171; N-((4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacycoldodec-1-yl)acetyl-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryprophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
DMQ08AJ	PC	158782
DMQ08AJ	MW	1421.6
DMQ08AJ	FM	C65H92N14O18S2
DMQ08AJ	IC	InChI=1S/C65H92N14O18S2/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90)/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+/m1/s1
DMQ08AJ	CS	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@H](CO)[C@@H](C)O)O
DMQ08AJ	IK	RZHKDBRREKOZEW-AAXZNHDCSA-N
DMQ08AJ	IU	2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
DMQ08AJ	CA	CAS 204318-14-9
DMQ08AJ	DE	Acromegaly

DMGJYZ8	ID	DMGJYZ8
DMGJYZ8	DN	EDP-305
DMGJYZ8	HS	Phase 2
DMGJYZ8	DT	Small molecular drug
DMGJYZ8	DE	Non-alcoholic steatohepatitis; Primary biliary cholangitis

DM5WZ0O	ID	DM5WZ0O
DM5WZ0O	DN	EDP-420
DM5WZ0O	HS	Phase 2
DM5WZ0O	SN	EP-013420
DM5WZ0O	CP	Enanta
DM5WZ0O	DT	Small molecular drug
DM5WZ0O	PC	9875927
DM5WZ0O	MW	841
DM5WZ0O	FM	C43H64N6O11
DM5WZ0O	IC	InChI=1S/C43H64N6O11/c1-12-33-43(9,54)39-26(4)35(46-29(7)50)24(2)19-42(8,56-23-31(22-55-39)47-57-21-30-14-15-34(44-20-30)49-17-13-16-45-49)38(27(5)36(51)28(6)40(53)59-33)60-41-37(52)32(48(10)11)18-25(3)58-41/h13-17,20,24-28,32-33,37-39,41,52,54H,12,18-19,21-23H2,1-11H3/b46-35?,47-31+/t24-,25-,26+,27+,28-,32+,33-,37-,38-,39-,41+,42-,43-/m1/s1
DM5WZ0O	CS	CC[C@@H]1[C@@]([C@H]2[C@H](C(=NC(=O)C)[C@@H](C[C@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(OC/C(=N/OCC4=CN=C(C=C4)N5C=CC=N5)/CO2)C)C)C)(C)O
DM5WZ0O	IK	WLGSYOKBEDVHQB-ZIJNRMRWSA-N
DM5WZ0O	IU	N-[(1R,2R,3R,6R,8R,9R,10R,13E,16S,18R)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2-hydroxy-2,6,8,10,16,18-hexamethyl-5,7-dioxo-13-[(6-pyrazol-1-ylpyridin-3-yl)methoxyimino]-4,11,15-trioxabicyclo[8.5.4]nonadecan-17-ylidene]acetamide
DM5WZ0O	CA	CAS 736992-12-4
DM5WZ0O	DE	Bacterial infection

DM32UOC	ID	DM32UOC
DM32UOC	DN	EDP-938
DM32UOC	HS	Phase 2
DM32UOC	CP	Enanta Pharmaceuticals
DM32UOC	DT	Small molecular drug
DM32UOC	DE	Respiratory syncytial virus infection

DMX4RSD	ID	DMX4RSD
DMX4RSD	DN	EFEGATRAN SULFATE HYDRATE
DMX4RSD	HS	Phase 2
DMX4RSD	SN	Efegatran sulfate hydrate < Rec INNM; N-Methyl-D-phenylalanyl-L-prolyl-L-arginal sulfate hydrate; N-Methyl-D-phenylalanyl-N-[4-guanidino-1(S)-formylbutyl]-L-prolinamide sulfate hydrate
DMX4RSD	DT	Small molecular drug
DMX4RSD	PC	6918161
DMX4RSD	MW	532.6
DMX4RSD	FM	C21H36N6O8S
DMX4RSD	IC	InChI=1S/C21H32N6O3.H2O4S.H2O/c1-24-17(13-15-7-3-2-4-8-15)20(30)27-12-6-10-18(27)19(29)26-16(14-28)9-5-11-25-21(22)23;1-5(2,3)4;/h2-4,7-8,14,16-18,24H,5-6,9-13H2,1H3,(H,26,29)(H4,22,23,25);(H2,1,2,3,4);1H2/t16-,17+,18-;;/m0../s1
DMX4RSD	CS	CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O.O.OS(=O)(=O)O
DMX4RSD	IK	JJJFZLGPEFEADH-VWRRVXQQSA-N
DMX4RSD	IU	(2S)-N-[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;sulfuric acid;hydrate
DMX4RSD	DE	Myocardial infarction

DMX6RZG	ID	DMX6RZG
DMX6RZG	DN	EFT508
DMX6RZG	HS	Phase 2
DMX6RZG	SN	Tomivosertib; eFT508; 1849590-01-7; EFT-508; UNII-U2H19X4WBV; U2H19X4WBV; Tomivosertib [INN]; Tomivosertib [USAN]; SCHEMBL17362622; GTPL10167; eFT-508 (eFT508); EFT 508; MolPort-044-560-418; BCP18993; EX-A2494; ZINC575623807; AKOS030627405; CS-5841; compound 23 [PMID: 29526098]; HY-100022; S8275; 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione; 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
DMX6RZG	CP	eFFECTOR Therapeutics San Diego, CA
DMX6RZG	PC	118598754
DMX6RZG	MW	340.4
DMX6RZG	FM	C17H20N6O2
DMX6RZG	IC	InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)
DMX6RZG	CS	CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3
DMX6RZG	IK	HKTBYUWLRDZAJK-UHFFFAOYSA-N
DMX6RZG	IU	6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
DMX6RZG	CA	CAS 1849590-01-7
DMX6RZG	DE	Solid tumour/cancer; Colorectal cancer; Hepatocellular carcinoma; Lymphoma; Triple negative breast cancer

DMBHP56	ID	DMBHP56
DMBHP56	DN	Efungumab
DMBHP56	HS	Phase 2
DMBHP56	SN	Mycograb; Hsp90 mAb; Myc-123C28Y; Hsp90 mAb (cancer), NeuTec; Hsp90 mAb (Candida albicans infection/Cryptococcus neoformans meningitis), NeuTec
DMBHP56	CP	University of Manchester
DMBHP56	DT	Antibody
DMBHP56	DE	Breast cancer

DM6L5TR	ID	DM6L5TR
DM6L5TR	DN	EGEN-001
DM6L5TR	HS	Phase 2
DM6L5TR	CP	EGEN
DM6L5TR	DE	Ovarian cancer; Peritoneal cancer; Fallopian tube cancer

DMN1SWB	ID	DMN1SWB
DMN1SWB	DN	EGS-21
DMN1SWB	HS	Phase 2
DMN1SWB	SN	Glucocerebroside, Enzo; Glucosylceramide, Enzo Biochem
DMN1SWB	CP	Enzo Biochem Inc
DMN1SWB	DT	Small molecular drug
DMN1SWB	PC	6475228
DMN1SWB	MW	812.3
DMN1SWB	FM	C48H93NO8
DMN1SWB	IC	InChI=1S/C48H93NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(40-56-48-47(55)46(54)45(53)43(39-50)57-48)42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h35,37,41-43,45-48,50-51,53-55H,3-34,36,38-40H2,1-2H3,(H,49,52)/b37-35+/t41-,42+,43+,45+,46-,47+,48+/m0/s1
DMN1SWB	CS	CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)[C@@H](/C=C/CCCCCCCCCCCCC)O
DMN1SWB	IK	POQRWMRXUOPCLD-GZXCKHLVSA-N
DMN1SWB	IU	N-[(E,2S,3R)-3-hydroxy-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide
DMN1SWB	CB	CHEBI:84744
DMN1SWB	DE	Crohn disease

DML7WP0	ID	DML7WP0
DML7WP0	DN	Eldacimibe
DML7WP0	HS	Phase 2
DML7WP0	SN	ACA-147; WAY-ACA-147
DML7WP0	CP	Wyeth
DML7WP0	DT	Small molecular drug
DML7WP0	PC	170321
DML7WP0	MW	634.9
DML7WP0	FM	C39H58N2O5
DML7WP0	IC	InChI=1S/C39H58N2O5/c1-13-14-15-16-21-41(25-27-19-17-26(18-20-27)24-36(2,3)4)33(31-34(43)45-39(11,12)46-35(31)44)40-28-22-29(37(5,6)7)32(42)30(23-28)38(8,9)10/h17-20,22-23,40,42H,13-16,21,24-25H2,1-12H3
DML7WP0	CS	CCCCCCN(CC1=CC=C(C=C1)CC(C)(C)C)C(=C2C(=O)OC(OC2=O)(C)C)NC3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C
DML7WP0	IK	HGLFNRGXRCKGSW-UHFFFAOYSA-N
DML7WP0	IU	5-[(3,5-ditert-butyl-4-hydroxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-hexylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione
DML7WP0	CA	CAS 141993-70-6
DML7WP0	DE	Hyperlipidaemia

DMCSXI4	ID	DMCSXI4
DMCSXI4	DN	Elezanumab
DMCSXI4	HS	Phase 2
DMCSXI4	CP	AbbVie
DMCSXI4	DT	Antibody
DMCSXI4	DE	Multiple sclerosis; Spinal cord injury

DMIOGZM	ID	DMIOGZM
DMIOGZM	DN	ELIPRODIL
DMIOGZM	HS	Phase 2
DMIOGZM	SN	Eliprodil; 119431-25-3; Eliprodil [INN]; C20H23ClFNO; SL 820715; SL 82-0715; CHEMBL28564; alpha-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol; NCGC00092329-02; 1-Piperidineethanol, alpha-(4-chlorophenyl)-4-(4-fluorophenyl)-, (+-)-; DSSTox_RID_81089; DSSTox_CID_25744; DSSTox_GSID_45744; 1-(4-Chlorophenyl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethanol; (+-)-alpha-(p-Chlorophenyl)-4-(p-fluorobenzyl)-1-piperidineethanol; 1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol
DMIOGZM	DT	Small molecular drug
DMIOGZM	PC	60703
DMIOGZM	MW	347.9
DMIOGZM	FM	C20H23ClFNO
DMIOGZM	IC	InChI=1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2
DMIOGZM	CS	C1CN(CCC1CC2=CC=C(C=C2)F)CC(C3=CC=C(C=C3)Cl)O
DMIOGZM	IK	GGUSQTSTQSHJAH-UHFFFAOYSA-N
DMIOGZM	IU	1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol
DMIOGZM	CA	CAS 119431-25-3
DMIOGZM	CB	CHEBI:91784
DMIOGZM	DE	Multiple sclerosis

DMB38KH	ID	DMB38KH
DMB38KH	DN	Elisidepsin
DMB38KH	HS	Phase 2
DMB38KH	SN	Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar
DMB38KH	CP	PharmaMar SA
DMB38KH	PC	9855343
DMB38KH	MW	1477.9
DMB38KH	FM	C75H124N14O16
DMB38KH	IC	InChI=1S/C75H124N14O16/c1-20-43(15)33-34-53(91)80-54(38(5)6)68(97)87-61(46(18)90)72(101)82-56(40(9)10)69(98)83-57(41(11)12)74(103)89-36-28-32-52(89)66(95)78-50(31-27-35-76)64(93)85-59(44(16)21-2)71(100)88-62-47(19)105-75(104)58(42(13)14)84-63(92)49(23-4)77-65(94)51(37-48-29-25-24-26-30-48)79-67(96)55(39(7)8)81-70(99)60(45(17)22-3)86-73(62)102/h23-26,29-30,38-47,50-52,54-62,90H,20-22,27-28,31-37,76H2,1-19H3,(H,77,94)(H,78,95)(H,79,96)(H,80,91)(H,81,99)(H,82,101)(H,83,98)(H,84,92)(H,85,93)(H,86,102)(H,87,97)(H,88,100)/b49-23-/t43-,44-,45-,46+,47+,50-,51-,52+,54+,55+,56-,57+,58-,59+,60+,61-,62+/m0/s1
DMB38KH	CS	CC[C@H](C)CCC(=O)N[C@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]2[C@H](OC(=O)[C@@H](NC(=O)/C(=C/C)/NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)[C@@H](C)CC)C(C)C)CC3=CC=CC=C3)C(C)C)C
DMB38KH	IK	ZNVCPJPCKSJWDH-UCTDCHLSSA-N
DMB38KH	IU	(2R)-N-[(2S)-5-amino-1-[[(2R,3S)-1-[[(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]-1-[(2R)-2-[[(2S)-2-[[(2S,3R)-3-hydroxy-2-[[(2R)-3-methyl-2-[[(4S)-4-methylhexanoyl]amino]butanoyl]amino]butanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxamide
DMB38KH	CB	CHEBI:83152
DMB38KH	DE	Psoriasis vulgaris

DMR50I7	ID	DMR50I7
DMR50I7	DN	Elsamitrucin
DMR50I7	HS	Phase 2
DMR50I7	SN	Elsamicin; Elsamitrucina; Elsamitrucine; Elsamitrucinum; Chartreusin analog; Elsamicin A; Antibiotic BBM 2478A; BBM 2478A; BMY 28090; SPI 28090; BBM-2478A; BMS-181171; BMY-28090; BU-2478A; Elsamitrucin [USAN:INN]; Elsamitrucina [INN-Spanish]; Elsamitrucine [INN-French]; Elsamitrucinum [INN-Latin]; E-87/025; 10-O-Elsaminosylelsarosylchartarin; 2-Amino-2,6-dideoxy-3-O-methyl-D-galactose
DMR50I7	CP	Spectrum
DMR50I7	DT	Small molecular drug
DMR50I7	PC	5362259
DMR50I7	MW	653.6
DMR50I7	FM	C33H35NO13
DMR50I7	IC	InChI=1S/C33H35NO13/c1-11-9-10-16-19-17(11)29(38)46-25-18-14(24(36)21(20(19)25)30(39)44-16)7-6-8-15(18)45-32-28(33(4,40)27(37)13(3)43-32)47-31-22(34)26(41-5)23(35)12(2)42-31/h6-10,12-13,22-23,26-28,31-32,35-37,40H,34H2,1-5H3/t12-,13-,22-,23+,26-,27+,28+,31-,32+,33+/m1/s1
DMR50I7	CS	C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H](O[C@@H]([C@@H]([C@]2(C)O)O)C)OC3=CC=CC4=C3C5=C6C7=C(C=CC(=C7C(=O)O5)C)OC(=O)C6=C4O)N)OC)O
DMR50I7	IK	MGQRRMONVLMKJL-KWJIQSIXSA-N
DMR50I7	IU	3-[(2S,3R,4S,5S,6R)-3-[(2R,3R,4R,5S,6R)-3-amino-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-8-hydroxy-15-methyl-11,18-dioxapentacyclo[10.6.2.02,7.09,19.016,20]icosa-1(19),2(7),3,5,8,12(20),13,15-octaene-10,17-dione
DMR50I7	CA	CAS 97068-30-9
DMR50I7	DE	Solid tumour/cancer

DMB7CPG	ID	DMB7CPG
DMB7CPG	DN	Elsiglutide
DMB7CPG	HS	Phase 2
DMB7CPG	SN	Tide ZP-1846; ZP-1846; GLP-2 analog (chemotherapy-induced diarrhoea), Zealand Pharma
DMB7CPG	CP	Zealand Pharma A/S
DMB7CPG	DE	Diarrhea

DMYOUB6	ID	DMYOUB6
DMYOUB6	DN	EMA-401
DMYOUB6	HS	Phase 2
DMYOUB6	SN	Neuropathic pain targeting small molecules (postherpetic neuralgia), Spinifex
DMYOUB6	CP	Spinifex pharmaceuticals
DMYOUB6	DT	Small molecular drug
DMYOUB6	PC	9937291
DMYOUB6	MW	507.6
DMYOUB6	FM	C32H29NO5
DMYOUB6	IC	InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
DMYOUB6	CS	COC1=C(C2=C(CN([C@@H](C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5
DMYOUB6	IK	GHBCIXGRCZIPNQ-MHZLTWQESA-N
DMYOUB6	IU	(3S)-2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMYOUB6	CA	CAS 1316755-16-4
DMYOUB6	DE	Postherpetic neuralgia; Peripheral neuropathy

DMCLT2F	ID	DMCLT2F
DMCLT2F	DN	Emepepimut-S
DMCLT2F	HS	Phase 2
DMCLT2F	CP	EMD Serono; Oncothyreon
DMCLT2F	DT	Vaccine
DMCLT2F	DE	Non-small-cell lung cancer

DMT4MKF	ID	DMT4MKF
DMT4MKF	DN	Emibetuzumab
DMT4MKF	HS	Phase 2
DMT4MKF	CP	Eli Lilly Indianapolis, IN
DMT4MKF	DE	Solid tumour/cancer

DMQH1NV	ID	DMQH1NV
DMQH1NV	DN	Emivirine
DMQH1NV	HS	Phase 2
DMQH1NV	SN	Emivirine; Coactinon; MKC-442; 149950-60-7; I-EBU; 6-Benzyl-1-(ethoxymethyl)-5-isopropyluracil; 1EtOMe6Bz5i-Pr-U; Emivirine [USAN:INN]; Mkc 442; UNII-X87G8IX72O; 6-BENZYL-1-ETHOXYMETHYL-5-ISOPROPYL URACIL; DRG-0302; CHEMBL35033; X87G8IX72O; CHEBI:44143; 6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil; 6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione; 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)
DMQH1NV	DT	Small molecular drug
DMQH1NV	PC	65013
DMQH1NV	MW	302.37
DMQH1NV	FM	C17H22N2O3
DMQH1NV	IC	InChI=1S/C17H22N2O3/c1-4-22-11-19-14(10-13-8-6-5-7-9-13)15(12(2)3)16(20)18-17(19)21/h5-9,12H,4,10-11H2,1-3H3,(H,18,20,21)
DMQH1NV	CS	CCOCN1C(=C(C(=O)NC1=O)C(C)C)CC2=CC=CC=C2
DMQH1NV	IK	MLILORUFDVLTSP-UHFFFAOYSA-N
DMQH1NV	IU	6-benzyl-1-(ethoxymethyl)-5-propan-2-ylpyrimidine-2,4-dione
DMQH1NV	CA	CAS 149950-60-7
DMQH1NV	CB	CHEBI:44143
DMQH1NV	DE	Human immunodeficiency virus infection

DMDEL3F	ID	DMDEL3F
DMDEL3F	DN	EMZ701
DMDEL3F	HS	Phase 2
DMDEL3F	SN	Interferon enhancing therapy
DMDEL3F	CP	Transition Therapeutics
DMDEL3F	DE	Hepatitis B virus infection

DMGFZOL	ID	DMGFZOL
DMGFZOL	DN	Enadoline
DMGFZOL	HS	Phase 2
DMGFZOL	SN	ENADOLINE; 124378-77-4; UNII-KJL283326C; CI-977; 2-(Benzofuran-4-yl)-N-methyl-N-((5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[45]decan-8-yl)acetamide; CHEMBL318859; KJL283326C; CI 977; 4-Benzofuranacetamide, N-methyl-N-((5R,7S,8S)-7-(1-pyrrolidinyl)-1-oxaspiro(45)dec-8-yl)-; [3H]enadoline; Enadoline [INN]; [3H]-enadoline; C24H32N2O3; 2-(1-benzofuran-4-yl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[45]decan-8-yl]acetamide; [3H]CI977; [3H]CI-977; [3H]-CI977; AC1L1TVT; AC1Q5HUV; DSSTox_CID_27258; DSSTox_RID_82216;  Enadoline hydrochloride; PD-129290
DMGFZOL	CP	Parke-Davis & Co
DMGFZOL	DT	Small molecular drug
DMGFZOL	PC	60768
DMGFZOL	MW	396.5
DMGFZOL	FM	C24H32N2O3
DMGFZOL	IC	InChI=1S/C24H32N2O3/c1-25(23(27)16-18-6-4-7-22-19(18)9-15-28-22)20-8-11-24(10-5-14-29-24)17-21(20)26-12-2-3-13-26/h4,6-7,9,15,20-21H,2-3,5,8,10-14,16-17H2,1H3/t20-,21-,24-/m0/s1
DMGFZOL	CS	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=C5C=COC5=CC=C4
DMGFZOL	IK	JMBYBVLCYODBJQ-HFMPRLQTSA-N
DMGFZOL	IU	2-(1-benzofuran-4-yl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
DMGFZOL	CA	CAS 124378-77-4
DMGFZOL	DE	Pain

DMM8Z3Q	ID	DMM8Z3Q
DMM8Z3Q	DN	Encequidar
DMM8Z3Q	HS	Phase 2
DMM8Z3Q	SN	849675-66-7; HM-30181-A; HM-30181; HM30181; UNII-K4I4I996O4; K4I4I996O4; 849675-66-7 (free base); HM 30181A; N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide; HM30181A; Encequidar [USAN]; HM-30181A; Encequidar (USAN/INN); HM-30181 free base; CHEMBL4594298; SCHEMBL13822558; EX-A3429A; BCP25240; MFCD25976625; WHO 10861; ZINC68014383; CS-6194; DB14070; SB18921; 4-Oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide; AS-35283; HY-13646; D11782; Q27281950; 4-oxo-4H-chromen-2-carboxylic acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide; 4H-1-Benzopyran-2-carboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-2H-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-; N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide; N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
DMM8Z3Q	CP	Athenex Oncology
DMM8Z3Q	DT	Small molecular drug
DMM8Z3Q	PC	11399764
DMM8Z3Q	MW	688.7
DMM8Z3Q	FM	C38H36N6O7
DMM8Z3Q	IC	InChI=1S/C38H36N6O7/c1-47-32-17-24-14-16-43(22-25(24)18-33(32)48-2)15-13-23-9-11-26(12-10-23)44-41-37(40-42-44)28-19-34(49-3)35(50-4)20-29(28)39-38(46)36-21-30(45)27-7-5-6-8-31(27)51-36/h5-12,17-21H,13-16,22H2,1-4H3,(H,39,46)
DMM8Z3Q	CS	COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)N4N=C(N=N4)C5=CC(=C(C=C5NC(=O)C6=CC(=O)C7=CC=CC=C7O6)OC)OC)OC
DMM8Z3Q	IK	AHJUHHDDCJQACA-UHFFFAOYSA-N
DMM8Z3Q	IU	N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
DMM8Z3Q	CA	CAS 849675-66-7
DMM8Z3Q	DE	Metastatic breast cancer

DM8NLDI	ID	DM8NLDI
DM8NLDI	DN	Endostatin
DM8NLDI	HS	Phase 2
DM8NLDI	CP	EntreMed
DM8NLDI	PC	187888
DM8NLDI	MW	178.19
DM8NLDI	FM	C9H10N2O2
DM8NLDI	IC	InChI=1S/C9H10N2O2/c1-11(10-13)7-9(12)8-5-3-2-4-6-8/h2-6H,7H2,1H3
DM8NLDI	CS	CN(CC(=O)C1=CC=CC=C1)N=O
DM8NLDI	IK	AAFYOVPTFNNVDN-UHFFFAOYSA-N
DM8NLDI	IU	N-methyl-N-phenacylnitrous amide
DM8NLDI	CA	CAS 55984-52-6
DM8NLDI	DE	Solid tumour/cancer

DMTX8IZ	ID	DMTX8IZ
DMTX8IZ	DN	Endoxifen
DMTX8IZ	HS	Phase 2
DMTX8IZ	SN	Endoxifen (topical formulation, cancer); Endoxifen (topical formulation, cancer), Jina Pharmaceuticals; Tamoxifen metabolite (topical formulation, cancer), Jina Pharmaceuticals
DMTX8IZ	CP	Jina Pharmaceuticals Inc
DMTX8IZ	DT	Small molecular drug
DMTX8IZ	PC	10090750
DMTX8IZ	MW	373.5
DMTX8IZ	FM	C25H27NO2
DMTX8IZ	IC	InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-
DMTX8IZ	CS	CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3
DMTX8IZ	IK	MHJBZVSGOZTKRH-IZHYLOQSSA-N
DMTX8IZ	IU	4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMTX8IZ	CA	CAS 112093-28-4
DMTX8IZ	CB	CHEBI:80555
DMTX8IZ	DE	Breast cancer

DMMIHSO	ID	DMMIHSO
DMMIHSO	DN	ENERGI-F701
DMMIHSO	HS	Phase 2
DMMIHSO	CP	Energenesis Biomedical
DMMIHSO	DT	Small molecular drug
DMMIHSO	DE	Alopecia

DM96NCR	ID	DM96NCR
DM96NCR	DN	Eniluracil
DM96NCR	HS	Phase 2
DM96NCR	SN	Eniluracil; 5-ETHYNYLURACIL; 59989-18-3; 5-ethynylpyrimidine-2,4(1H,3H)-dione; Compound 776C; GW776C85; 5-Ethynylpyrimidine-2,4-diol; 776C85; UNII-2E2W0W5XIU; 5-ethynyl-1H-pyrimidine-2,4-dione; 5-Ethynyl-2,4(1H,3H)-pyrimidinedione; 5-Ethynyl-4-hydroxypyrimidin-2(1H)-one; 5-Ethynyl-6-hydroxypyrimidin-2(1H)-one; 5-Ethynyl-2-hydroxypyrimidin-4(3H)-one; 5-Ethynyl-2-hydroxypyrimidin-4(1H)-one; 5-Ethynyl-2,4(1H,3H)pyrimidinedione; 2E2W0W5XIU; 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl-; CHEMBL355200; C6H4N2O2; Eniluracil [USAN]
DM96NCR	CP	Adherex Technologies
DM96NCR	DT	Small molecular drug
DM96NCR	PC	43157
DM96NCR	MW	136.11
DM96NCR	FM	C6H4N2O2
DM96NCR	IC	InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10)
DM96NCR	CS	C#CC1=CNC(=O)NC1=O
DM96NCR	IK	JOZGNYDSEBIJDH-UHFFFAOYSA-N
DM96NCR	IU	5-ethynyl-1H-pyrimidine-2,4-dione
DM96NCR	CA	CAS 59989-18-3
DM96NCR	DE	Hyperlipidaemia

DMJZVPB	ID	DMJZVPB
DMJZVPB	DN	ENMD-2076
DMJZVPB	HS	Phase 2
DMJZVPB	SN	ENMD-2076; 934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159
DMJZVPB	CP	Entremed
DMJZVPB	DT	Small molecular drug
DMJZVPB	PC	16041424
DMJZVPB	MW	375.5
DMJZVPB	FM	C21H25N7
DMJZVPB	IC	InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+
DMJZVPB	CS	CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C
DMJZVPB	IK	BLQYVHBZHAISJM-CMDGGOBGSA-N
DMJZVPB	IU	6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine
DMJZVPB	CA	CAS 934353-76-1
DMJZVPB	DE	Acute myeloid leukaemia; Fibrolamellar liver cancer; Hepatocellular carcinoma; Triple negative breast cancer

DMDS20X	ID	DMDS20X
DMDS20X	DN	Enoblituzumab
DMDS20X	HS	Phase 2
DMDS20X	CP	MacroGenics Rockville, MD
DMDS20X	DE	Solid tumour/cancer; Prostate cancer

DMLPRZJ	ID	DMLPRZJ
DMLPRZJ	DN	Ensaculin hydrochloride
DMLPRZJ	HS	Phase 2
DMLPRZJ	SN	Anseculin hydrochloride; Ensaculin hydrochloride; KA-672.HCl; 7-Methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethyl-2H-1-benzopyran-2-one hydrochloride
DMLPRZJ	DT	Small molecular drug
DMLPRZJ	PC	6918282
DMLPRZJ	MW	489
DMLPRZJ	FM	C26H33ClN2O5
DMLPRZJ	IC	InChI=1S/C26H32N2O5.ClH/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3;/h5-6,8-9,16-17H,7,10-15H2,1-4H3;1H
DMLPRZJ	CS	CC1=C(C(=O)OC2=CC(=C(C=C12)OCCCN3CCN(CC3)C4=CC=CC=C4OC)OC)C.Cl
DMLPRZJ	IK	XMONKHCPLIYQCY-UHFFFAOYSA-N
DMLPRZJ	IU	7-methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one;hydrochloride
DMLPRZJ	DE	Parkinson disease

DM69NF1	ID	DM69NF1
DM69NF1	DN	EP-101
DM69NF1	HS	Phase 2
DM69NF1	SN	106-86-5; 1,2-Epoxy-4-vinylcyclohexane; 3-Vinyl-7-oxabicyclo[4.1.0]heptane; Epoxide 101; 4-Vinylcyclohexene oxide; Unoxat epoxide 101; Vinylcyclohexane monoxide; 4-Vinyl-1,2-epoxycyclohexane; 1-Vinyl-3,4-epoxycyclohexane; 4-Vinylcyclohexene monoxide; 3,4-Epoxycyclohexylethylene; 7-Oxabicyclo[4.1.0]heptane, 3-ethenyl-; 4-Vinylcyclohexane monoepoxide; EP-101; Vinylcyclohexene monoxide; 4-Vinylcyclohexene-1,2-epoxide; 4-Vinylcyclohexane, 1,2-epoxide; EINECS 203-436-1; 4-Vinyl-1-Cyclohexene 1,2-Epoxide; NSC 35409
DM69NF1	CP	Elevation Pharmaceuticals
DM69NF1	DT	Small molecular drug
DM69NF1	PC	7832
DM69NF1	MW	124.18
DM69NF1	FM	C8H12O
DM69NF1	IC	InChI=1S/C8H12O/c1-2-6-3-4-7-8(5-6)9-7/h2,6-8H,1,3-5H2
DM69NF1	CS	C=CC1CCC2C(C1)O2
DM69NF1	IK	SLJFKNONPLNAPF-UHFFFAOYSA-N
DM69NF1	IU	3-ethenyl-7-oxabicyclo[4.1.0]heptane
DM69NF1	CA	CAS 106-86-5
DM69NF1	DE	Chronic obstructive pulmonary disease; Breast cancer

DMPC4EK	ID	DMPC4EK
DMPC4EK	DN	EP-217609
DMPC4EK	HS	Phase 2
DMPC4EK	SN	Neutralizable NAPAP analog (thrombosis), Endotis; Neutralizable NAPAP analog (thrombosis), Organon; Fondaparinux analog + thrombin inhibitor (thrombosis), Endotis; Neutralizable Factor IIa/Factor X dual inhibitor (thrombosis), Endotis; Neutralizable Factor IIa/Factor X dual inhibitor (thrombosis), Organon
DMPC4EK	CP	Organon BioSciences
DMPC4EK	PC	11686894
DMPC4EK	MW	2647.8
DMPC4EK	FM	C95H151N11O59S8
DMPC4EK	IC	InChI=1S/C95H151N11O59S8/c1-48-41-57(138-4)49(2)50(3)83(48)167(118,119)105-54(86(111)102-55(87(112)106-32-18-13-19-33-106)42-51-25-27-52(28-26-51)84(96)97)43-64(109)99-30-20-24-63(108)101-53(21-16-17-29-98-62(107)23-15-14-22-61-65-56(47-166-61)103-95(117)104-65)85(110)100-31-34-147-35-36-148-37-38-149-39-40-150-66-58(44-151-168(120,121)122)155-91(78(143-9)69(66)139-5)159-73-71(141-7)80(145-11)93(162-76(73)88(113)114)158-68-60(46-153-170(126,127)128)156-94(82(165-173(135,136)137)75(68)163-171(129,130)131)160-74-72(142-8)79(144-10)92(161-77(74)89(115)116)157-67-59(45-152-169(123,124)125)154-90(146-12)81(70(67)140-6)164-172(132,133)134/h25-28,41,53-56,58-61,65-82,90-94,105H,13-24,29-40,42-47H2,1-12H3,(H3,96,97)(H,98,107)(H,99,109)(H,100,110)(H,101,108)(H,102,111)(H,113,114)(H,115,116)(H2,103,104,117)(H,120,121,122)(H,123,124,125)(H,126,127,128)(H,129,130,131)(H,132,133,134)(H,135,136,137)/t53-,54-,55+,56-,58+,59+,60+,61-,65-,66+,67+,68+,69-,70-,71-,72-,73-,74-,75-,76-,77+,78+,79+,80+,81+,82+,90-,91+,92+,93+,94+/m0/s1
DMPC4EK	CS	CC1=CC(=C(C(=C1S(=O)(=O)N[C@@H](CC(=O)NCCCC(=O)N[C@@H](CCCCNC(=O)CCCC[C@H]2[C@@H]3[C@H](CS2)NC(=O)N3)C(=O)NCCOCCOCCOCCO[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4OC)OC)O[C@H]5[C@@H]([C@H]([C@@H](O[C@@H]5C(=O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]7[C@@H]([C@H]([C@@H](O[C@H]7C(=O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8OC)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)C(=O)N[C@H](CC9=CC=C(C=C9)C(=N)N)C(=O)N1CCCCC1)C)C)OC
DMPC4EK	IK	QIBHGITUGYXJDF-UDLCEBFESA-N
DMPC4EK	IU	(2S,3S,4S,5R,6R)-3-[(2R,3R,4S,5R,6R)-5-[2-[2-[2-[2-[[(2S)-6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-2-[4-[[(3S)-4-[[(2R)-3-(4-carbamimidoylphenyl)-1-oxo-1-piperidin-1-ylpropan-2-yl]amino]-3-[(4-methoxy-2,3,6-trimethylphenyl)sulfonylamino]-4-oxobutanoyl]amino]butanoylamino]hexanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]-3,4-dimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-6-[(2R,3R,4S,5R,6S)-4,6-dimethoxy-5-sulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxane-2-carboxylic acid
DMPC4EK	CA	CAS 894494-99-6
DMPC4EK	DE	Thrombosis

DMZT7EP	ID	DMZT7EP
DMZT7EP	DN	EPI 589
DMZT7EP	HS	Phase 2
DMZT7EP	SN	(R)-troloxamide quinone; EPI-589
DMZT7EP	CP	BioElectron Technology Mountain View, CA Sumitomo Dainippon Pharma Osaka, Japan
DMZT7EP	DE	Amyotrophic lateral sclerosis; Parkinson disease

DMWK26Q	ID	DMWK26Q
DMWK26Q	DN	EPX-200
DMWK26Q	HS	Phase 2
DMWK26Q	CP	Epygenix Therapeutics Paramus, NJ
DMWK26Q	DE	Dravet syndrome

DMUXDGZ	ID	DMUXDGZ
DMUXDGZ	DN	EPX-300
DMUXDGZ	HS	Phase 2
DMUXDGZ	CP	Epygenix Therapeutics Paramus, NJ

DMD4YRG	ID	DMD4YRG
DMD4YRG	DN	EQ-917
DMD4YRG	HS	Phase 2
DMD4YRG	CP	Equispharm Co Ltd
DMD4YRG	DE	Solid tumour/cancer

DMCEPUA	ID	DMCEPUA
DMCEPUA	DN	ERB-041
DMCEPUA	HS	Phase 2
DMCEPUA	SN	2-(3-Fluoro-4-hydroxyphenyl)-7-vinylbenzoxazol-5-ol
DMCEPUA	DT	Small molecular drug
DMCEPUA	PC	656954
DMCEPUA	MW	271.24
DMCEPUA	FM	C15H10FNO3
DMCEPUA	IC	InChI=1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,18-19H,1H2
DMCEPUA	CS	C=CC1=C2C(=CC(=C1)O)N=C(O2)C3=CC(=C(C=C3)O)F
DMCEPUA	IK	MQIMZDXIAHJKQP-UHFFFAOYSA-N
DMCEPUA	IU	7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMCEPUA	CA	CAS 524684-52-4
DMCEPUA	DE	Inflammatory bowel disease

DMU1XZD	ID	DMU1XZD
DMU1XZD	DN	Erteberel
DMU1XZD	HS	Phase 2
DMU1XZD	SN	LY-500307; SERBA-1; ER beta agonist (BPH), Lilly; Lead estrogen receptor beta agonists (benign prostatic hyperplasia),Eli Lilly
DMU1XZD	CP	Eli Lilly & Co
DMU1XZD	DT	Small molecular drug
DMU1XZD	PC	10286159
DMU1XZD	MW	282.3
DMU1XZD	FM	C18H18O3
DMU1XZD	IC	InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2/t14-,15+,18+/m1/s1
DMU1XZD	CS	C1C[C@H]2[C@@H](C1)C3=C(C=CC(=C3)O)O[C@H]2C4=CC=C(C=C4)O
DMU1XZD	IK	XIESSJVMWNJCGZ-VKJFTORMSA-N
DMU1XZD	IU	(3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
DMU1XZD	CA	CAS 533884-09-2
DMU1XZD	DE	Prostate hyperplasia

DM5Z3VP	ID	DM5Z3VP
DM5Z3VP	DN	Ertumaxomab
DM5Z3VP	HS	Phase 2
DM5Z3VP	SN	Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius
DM5Z3VP	CP	Trion
DM5Z3VP	DT	Antibody
DM5Z3VP	DE	Breast cancer

DMYZWDC	ID	DMYZWDC
DMYZWDC	DN	ESBA-105
DMYZWDC	HS	Phase 2
DMYZWDC	SN	ESBA-105 (ophthalmic liquid formulation); ESBA-105 (ophthalmic liquid formulation), ESBATech; Anti-cytokine single-chain antibody (inflammation), ESBATech
DMYZWDC	CP	ESBATech AG
DMYZWDC	DT	Antibody
DMYZWDC	DE	Ocular disease

DMTB63Q	ID	DMTB63Q
DMTB63Q	DN	Estetrol
DMTB63Q	HS	Phase 2
DMTB63Q	SN	Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer); Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer), Pantarhei; Estrogen receptor modulator (oral, contraception/hormone deficiency/autoimmune disease/breast cancer/prostate cancer/osteoporosis/cardiovascular disease), Pantarhei
DMTB63Q	CP	Pantarhei Bioscience BV
DMTB63Q	DT	Small molecular drug
DMTB63Q	PC	27125
DMTB63Q	MW	304.4
DMTB63Q	FM	C18H24O4
DMTB63Q	IC	InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1
DMTB63Q	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1[C@H]([C@H]([C@@H]2O)O)O)CCC4=C3C=CC(=C4)O
DMTB63Q	IK	AJIPIJNNOJSSQC-NYLIRDPKSA-N
DMTB63Q	IU	(8R,9S,13S,14S,15R,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,15,16,17-tetrol
DMTB63Q	CA	CAS 15183-37-6
DMTB63Q	CB	CHEBI:142773
DMTB63Q	DE	Autoimmune diabetes

DM71BZV	ID	DM71BZV
DM71BZV	DN	Etamicastat
DM71BZV	HS	Phase 2
DM71BZV	SN	BIA-5453; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), BIAL; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), Portela
DM71BZV	CP	Portela & Ca SA
DM71BZV	DT	Small molecular drug
DM71BZV	PC	10450387
DM71BZV	MW	311.35
DM71BZV	FM	C14H15F2N3OS
DM71BZV	IC	InChI=1S/C14H15F2N3OS/c15-9-3-8-4-11(7-20-13(8)12(16)5-9)19-10(1-2-17)6-18-14(19)21/h3,5-6,11H,1-2,4,7,17H2,(H,18,21)/t11-/m1/s1
DM71BZV	CS	C1[C@H](COC2=C1C=C(C=C2F)F)N3C(=CNC3=S)CCN
DM71BZV	IK	CWWWTTYMUOYSQA-LLVKDONJSA-N
DM71BZV	IU	4-(2-aminoethyl)-3-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-1H-imidazole-2-thione
DM71BZV	CA	CAS 760173-05-5
DM71BZV	DE	Heart failure

DMOCID7	ID	DMOCID7
DMOCID7	DN	Etazolate
DMOCID7	HS	Phase 2
DMOCID7	SN	Etazolate hydrochloride; EHT-0202; SQ-20009
DMOCID7	CP	Exonhit
DMOCID7	DT	Small molecular drug
DMOCID7	PC	3277
DMOCID7	MW	289.33
DMOCID7	FM	C14H19N5O2
DMOCID7	IC	InChI=1S/C14H19N5O2/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2/h7-8H,5-6H2,1-4H3,(H,15,18)
DMOCID7	CS	CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC
DMOCID7	IK	OPQRBXUBWHDHPQ-UHFFFAOYSA-N
DMOCID7	IU	ethyl 1-ethyl-4-(2-propan-2-ylidenehydrazinyl)pyrazolo[3,4-b]pyridine-5-carboxylate
DMOCID7	CA	CAS 51022-77-6
DMOCID7	CB	CHEBI:93135
DMOCID7	DE	Neurodegenerative disorder

DM68K39	ID	DM68K39
DM68K39	DN	ETIPREDNOL DICLOACETATE
DM68K39	HS	Phase 2
DM68K39	SN	BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester
DM68K39	CP	Teva Pharmaceutical USA
DM68K39	DT	Small molecular drug
DM68K39	PC	9935073
DM68K39	MW	485.4
DM68K39	FM	C24H30Cl2O6
DM68K39	IC	InChI=1S/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24-/m0/s1
DM68K39	CS	CCOC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)C(Cl)Cl
DM68K39	IK	QAIOVDNCIZSSSF-RFAJLIJZSA-N
DM68K39	IU	ethyl (8S,9S,10R,11S,13S,14S,17R)-17-(2,2-dichloroacetyl)oxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
DM68K39	CA	CAS 199331-40-3
DM68K39	CB	CHEBI:135783
DM68K39	DE	Rhinitis

DMV96BY	ID	DMV96BY
DMV96BY	DN	ETS-6218
DMV96BY	HS	Phase 2
DMV96BY	SN	Antihistamine+antiviral (fibromyalgia), e-Therapeutics
DMV96BY	CP	E-Therapeutics Ltd
DMV96BY	DE	Fibromyalgia

DMZOA2L	ID	DMZOA2L
DMZOA2L	DN	ETX-9101
DMZOA2L	HS	Phase 2
DMZOA2L	CP	E-Therapeutics Ltd
DMZOA2L	DE	Asthma

DM1FCDH	ID	DM1FCDH
DM1FCDH	DN	EV-077
DM1FCDH	HS	Phase 2
DM1FCDH	SN	EV-077-3201; EV-077 series (diabetes), Evolva Biotech; EV-077-3201-2; EV-077-3201-2TBS; Thromboxane antagonist (cardiovascular/proteinuric renal disease), Evolva Holding; Thromboxane synthesis inhibitor (cardiovascular/ proteinuric renal disease), Evolva Holding; EV-0400 series (metabolic disease/diabetes), Evolva Biotech; PPAR-gamma agonists (metabolic disease/diabetes/proteinuric renal disease/cardiovascular), Evolva Biotech
DM1FCDH	CP	Evolva SA
DM1FCDH	DE	Type-2 diabetes

DMWB94K	ID	DMWB94K
DMWB94K	DN	Evenamide
DMWB94K	HS	Phase 2
DMWB94K	SN	1092977-61-1; 2-((3-Butoxyphenethyl)amino)-N,N-dimethylacetamide; UNII-ON5S6N53JS; ON5S6N53JS; MFCD28502433; 2-[(3-Butoxyphenethyl)amino]-N,N-dimethylacetamide; Evenamide [INN]; SCHEMBL3025285; CHEMBL3678076; 2-((2-(3-Butoxyphenyl)ethyl)amino)-N,N-dimethylacetamide; Acetamide, 2-((2-(3-butoxyphenyl)ethyl)amino)-N,N-dimethyl-; BDBM161090; NW-3509; SB18910; AS-48527; HY-17612; SY244487; CS-0014697; Q21098995; 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide; US9051240, 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylacetamide
DMWB94K	CP	Newron Pharmaceuticals
DMWB94K	DT	Small molecular drug
DMWB94K	PC	25105689
DMWB94K	MW	278.39
DMWB94K	FM	C16H26N2O2
DMWB94K	IC	InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
DMWB94K	CS	CCCCOC1=CC=CC(=C1)CCNCC(=O)N(C)C
DMWB94K	IK	GRHBODILPPXVKN-UHFFFAOYSA-N
DMWB94K	IU	2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
DMWB94K	CA	CAS 1092977-61-1
DMWB94K	DE	Schizophrenia

DM8QXEY	ID	DM8QXEY
DM8QXEY	DN	Evt201
DM8QXEY	HS	Phase 2
DM8QXEY	CP	Evotec
DM8QXEY	DT	Small molecular drug
DM8QXEY	DE	Sleep-wake disorder

DMQGBM1	ID	DMQGBM1
DMQGBM1	DN	EVT-201
DMQGBM1	HS	Phase 2
DMQGBM1	SN	IDDBCP221837
DMQGBM1	CP	Roche Holding AG
DMQGBM1	PC	9885841
DMQGBM1	MW	372.8
DMQGBM1	FM	C17H17ClN6O2
DMQGBM1	IC	InChI=1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3
DMQGBM1	CS	CN1CC2=C(N=CN2C3=C(C1=O)C(=CC=C3)Cl)C4=NOC(=N4)CN(C)C
DMQGBM1	IK	JCYLWUVDHLVGER-UHFFFAOYSA-N
DMQGBM1	IU	7-chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMQGBM1	CA	CAS 308239-86-3
DMQGBM1	DE	Insomnia

DM73XNG	ID	DM73XNG
DM73XNG	DN	EVT302
DM73XNG	HS	Phase 2
DM73XNG	CP	Evotec Princeton, NJ
DM73XNG	DE	Alzheimer disease

DM4FBUH	ID	DM4FBUH
DM4FBUH	DN	EXC 001
DM4FBUH	HS	Phase 2
DM4FBUH	CP	ISIS Pharm; Excaliard
DM4FBUH	DT	Antisense drug
DM4FBUH	DE	Fibrosis

DMC1I56	ID	DMC1I56
DMC1I56	DN	Exherin
DMC1I56	HS	Phase 2
DMC1I56	SN	Exherin; 229971-81-7; UNII-B058ME29VU; ADH-1; ADH1; B058ME29VU; ADH 1; ADH-1 pepide; Exherin (ADH-1); ADH-1;ADH1;ADH 1; SCHEMBL13857500; CHEMBL3818130; ZINC3939935; ADH-10001; AKOS030526741; CS-3450; L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-l-alanyl-L-valyl-, cyclic (1-5)-disulfide; HY-13541
DMC1I56	CP	Adherex Technol.
DMC1I56	TC	Anticancer Agents
DMC1I56	DT	Small molecular drug
DMC1I56	PC	9916058
DMC1I56	MW	570.7
DMC1I56	FM	C22H34N8O6S2
DMC1I56	IC	InChI=1S/C22H34N8O6S2/c1-10(2)17-22(36)29-15(18(23)32)7-37-38-8-16(27-12(4)31)21(35)28-14(5-13-6-24-9-25-13)20(34)26-11(3)19(33)30-17/h6,9-11,14-17H,5,7-8H2,1-4H3,(H2,23,32)(H,24,25)(H,26,34)(H,27,31)(H,28,35)(H,29,36)(H,30,33)/t11-,14-,15-,16-,17-/m0/s1
DMC1I56	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CN=CN2)NC(=O)C)C(=O)N)C(C)C
DMC1I56	IK	FQVLRGLGWNWPSS-BXBUPLCLSA-N
DMC1I56	IU	(4R,7S,10S,13S,16R)-16-acetamido-13-(1H-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide
DMC1I56	CA	CAS 229971-81-7
DMC1I56	DE	Solid tumour/cancer

DM5PBLM	ID	DM5PBLM
DM5PBLM	DN	EYP001
DM5PBLM	HS	Phase 2
DM5PBLM	SN	Vonafexor; 1192171-69-9; UNII-XG6DG6A1UN; XG6DG6A1UN; 4-chloro-5-[4-(2,6-dichlorobenzene-1-; sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid; Vonafexor [INN]; SCHEMBL1893285; Vonafexor(PLX007,EYP-001); BCP33693; EX-A4037; EYP001;EYP 001;EYP-001; HY-109197; CS-0119143; 2-Benzofurancarboxylic acid, 4-chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)-1-piperazinyl)-; 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid
DM5PBLM	CP	ENYO Pharma
DM5PBLM	DT	Small molecular drug
DM5PBLM	PC	67202717
DM5PBLM	MW	489.8
DM5PBLM	FM	C19H15Cl3N2O5S
DM5PBLM	IC	InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26)
DM5PBLM	CS	C1CN(CCN1C2=C(C3=C(C=C2)OC(=C3)C(=O)O)Cl)S(=O)(=O)C4=C(C=CC=C4Cl)Cl
DM5PBLM	IK	XLGQSYUNOIJBNR-UHFFFAOYSA-N
DM5PBLM	IU	4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid
DM5PBLM	CA	CAS 1192171-69-9
DM5PBLM	DE	Non-alcoholic steatohepatitis

DM2L9CO	ID	DM2L9CO
DM2L9CO	DN	Ezatiostat
DM2L9CO	HS	Phase 2
DM2L9CO	SN	Telintra (TN)
DM2L9CO	CP	Telik
DM2L9CO	DT	Small molecular drug
DM2L9CO	PC	5310939
DM2L9CO	MW	529.6
DM2L9CO	FM	C27H35N3O6S
DM2L9CO	IC	InChI=1S/C27H35N3O6S/c1-3-35-26(33)21(28)15-16-23(31)29-22(18-37-17-19-11-7-5-8-12-19)25(32)30-24(27(34)36-4-2)20-13-9-6-10-14-20/h5-14,21-22,24H,3-4,15-18,28H2,1-2H3,(H,29,31)(H,30,32)/t21-,22-,24+/m0/s1
DM2L9CO	CS	CCOC(=O)[C@H](CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@H](C2=CC=CC=C2)C(=O)OCC)N
DM2L9CO	IK	GWEJFLVSOGNLSS-WPFOTENUSA-N
DM2L9CO	IU	ethyl (2S)-2-amino-5-[[(2R)-3-benzylsulfanyl-1-[[(1R)-2-ethoxy-2-oxo-1-phenylethyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoate
DM2L9CO	CA	CAS 168682-53-9
DM2L9CO	DE	Myelodysplastic syndrome

DMJ4BKT	ID	DMJ4BKT
DMJ4BKT	DN	F-16-IL-2 fusion protein
DMJ4BKT	HS	Phase 2
DMJ4BKT	SN	Teleukin; F-16-IL-2; F-16-IL-2 fusion protein (cancer); F-16-IL-2 fusion protein (cancer), Philogen
DMJ4BKT	CP	Philogen SpA
DMJ4BKT	DE	Solid tumour/cancer

DMKP3SJ	ID	DMKP3SJ
DMKP3SJ	DN	F-351
DMKP3SJ	HS	Phase 2
DMKP3SJ	SN	Liver cirrhosis, Gene Networks International; Liver cirrhosis, Shanghai; Liver fibrosis therapy, Shanghai Genomics; Liver fibrosis, Gene Networks International; Liver fibrosis, Shanghai
DMKP3SJ	CP	GNI Ltd
DMKP3SJ	DT	Small molecular drug
DMKP3SJ	PC	11217901
DMKP3SJ	MW	201.22
DMKP3SJ	FM	C12H11NO2
DMKP3SJ	IC	InChI=1S/C12H11NO2/c1-9-2-7-12(15)13(8-9)10-3-5-11(14)6-4-10/h2-8,14H,1H3
DMKP3SJ	CS	CC1=CN(C(=O)C=C1)C2=CC=C(C=C2)O
DMKP3SJ	IK	NETTXQJYJRFTFS-UHFFFAOYSA-N
DMKP3SJ	IU	1-(4-hydroxyphenyl)-5-methylpyridin-2-one
DMKP3SJ	CA	CAS 851518-71-3
DMKP3SJ	DE	Liver disease

DM6UQNW	ID	DM6UQNW
DM6UQNW	DN	F4co vaccine
DM6UQNW	HS	Phase 2
DM6UQNW	SN	F4co vaccine (AIDS/HIV infection)
DM6UQNW	CP	GlaxoSmithKline plc
DM6UQNW	DT	Vaccine
DM6UQNW	DE	Human immunodeficiency virus infection

DMDNJ18	ID	DMDNJ18
DMDNJ18	DN	F-627
DMDNJ18	HS	Phase 2
DMDNJ18	SN	Recombinant human G-CSF dimer (neutropenia), Generon (Shanghai) Corporation Ltd
DMDNJ18	CP	Generon
DMDNJ18	DE	Neutropenia

DMBFPO1	ID	DMBFPO1
DMBFPO1	DN	F-8-IL-10 fusion protein
DMBFPO1	HS	Phase 2
DMBFPO1	SN	Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen
DMBFPO1	CP	Pfizer
DMBFPO1	DE	Endometriosis; Inflammatory bowel disease; Rheumatoid arthritis

DM2CUS0	ID	DM2CUS0
DM2CUS0	DN	F901318
DM2CUS0	HS	Phase 2
DM2CUS0	SN	Olorofim; F-901318; UNII-T34SH2H9HI; T34SH2H9HI; 1928707-56-5; 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide; CHEMBL4297609; SCHEMBL17767345; BCP25872; BDBM50526857; DB15245; SB19827; F901318; F 901318; Olorofim; HY-104029; CS-0025660; Q27896127; CN1C(=C(C=C1C)C1=CC=CC=C1)C(C(=O)NC1=CC=C(C=C1)N1CCN(CC1)C1=NC=C(C=N1)F)=O; 1H-Pyrrole-2-acetamide, N-(4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)phenyl)-1,5-dimethyl-alpha-oxo-3-phenyl-; 2-(1,5-Dimethyl-3-phenyl-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxo-acetamide
DM2CUS0	CP	F2G
DM2CUS0	DT	Small molecular drug
DM2CUS0	PC	91885568
DM2CUS0	MW	498.6
DM2CUS0	FM	C28H27FN6O2
DM2CUS0	IC	InChI=1S/C28H27FN6O2/c1-19-16-24(20-6-4-3-5-7-20)25(33(19)2)26(36)27(37)32-22-8-10-23(11-9-22)34-12-14-35(15-13-34)28-30-17-21(29)18-31-28/h3-11,16-18H,12-15H2,1-2H3,(H,32,37)
DM2CUS0	CS	CC1=CC(=C(N1C)C(=O)C(=O)NC2=CC=C(C=C2)N3CCN(CC3)C4=NC=C(C=N4)F)C5=CC=CC=C5
DM2CUS0	IK	SUFPWYYDCOKDLL-UHFFFAOYSA-N
DM2CUS0	IU	2-(1,5-dimethyl-3-phenylpyrrol-2-yl)-N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl]-2-oxoacetamide
DM2CUS0	CA	CAS 1928707-56-5
DM2CUS0	DE	Fungal infection

DMXB6KG	ID	DMXB6KG
DMXB6KG	DN	FAD-104
DMXB6KG	HS	Phase 2
DMXB6KG	SN	ME-2303; (8S,10S)-8-(6-Carboxyhexanoyloxyacetyl)-10-[(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)adriamycinone-14-O-hemipimelate; 7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)pimelyladryamycinone
DMXB6KG	DT	Small molecular drug
DMXB6KG	PC	115362
DMXB6KG	MW	704.6
DMXB6KG	FM	C34H37FO15
DMXB6KG	IC	InChI=1S/C34H37FO15/c1-14-27(40)32(45)26(35)33(49-14)50-18-12-34(46,19(36)13-48-21(39)10-5-3-4-9-20(37)38)11-16-23(18)31(44)25-24(29(16)42)28(41)15-7-6-8-17(47-2)22(15)30(25)43/h6-8,14,18,26-27,32-33,40,42,44-46H,3-5,9-13H2,1-2H3,(H,37,38)/t14-,18-,26+,27+,32-,33-,34-/m0/s1
DMXB6KG	CS	C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCCCC(=O)O)O)F)O)O
DMXB6KG	IK	PQMIPLRIRFVQJZ-QBYYVRQOSA-N
DMXB6KG	IU	7-[2-[(2S,4S)-4-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethoxy]-7-oxoheptanoic acid
DMXB6KG	CA	CAS 116521-53-0
DMXB6KG	DE	Solid tumour/cancer

DM6RKG3	ID	DM6RKG3
DM6RKG3	DN	Fadolmidine
DM6RKG3	HS	Phase 2
DM6RKG3	SN	Fadolmidine hydrochloride; MPV-2426
DM6RKG3	CP	Orion Corp
DM6RKG3	DT	Small molecular drug
DM6RKG3	PC	6433098
DM6RKG3	MW	214.26
DM6RKG3	FM	C13H14N2O
DM6RKG3	IC	InChI=1S/C13H14N2O/c16-12-4-3-9-1-2-10(13(9)6-12)5-11-7-14-8-15-11/h3-4,6-8,10,16H,1-2,5H2,(H,14,15)
DM6RKG3	CS	C1CC2=C(C1CC3=CN=CN3)C=C(C=C2)O
DM6RKG3	IK	VTZPAJGVRWKMAG-UHFFFAOYSA-N
DM6RKG3	IU	3-(1H-imidazol-5-ylmethyl)-2,3-dihydro-1H-inden-5-ol
DM6RKG3	CA	CAS 189353-31-9
DM6RKG3	DE	Pain; Neuropathic pain

DMSFWT7	ID	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	HS	Phase 2
DMSFWT7	SN	Receptor tyrosine kinase inhibitors (cancer); SHR-1020; Receptor tyrosine kinase inhibitors (cancer), Shanghai Hengrui; Tyrosine-kinase inhibitor (oral, cancer), Jiangsu Hengrui; C-Kit/VEGFR2/PDGFR/VEGFR3/Flt1/Flt3 inhibitor (oral, cancer), Jiangsu Hengrui
DMSFWT7	CP	Shanghai Hengrui Pharmaceutical Co Ltd; Jiangsu Hengrui Medicine Co Ltd
DMSFWT7	DT	Small molecular drug
DMSFWT7	PC	16662431
DMSFWT7	MW	410.5
DMSFWT7	FM	C23H27FN4O2
DMSFWT7	IC	InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-
DMSFWT7	CS	CCN(CC)CCN1CCC2=C(C1=O)C(=C(N2)/C=C\\3/C4=C(C=CC(=C4)F)NC3=O)C
DMSFWT7	IK	GKEYKDOLBLYGRB-LGMDPLHJSA-N
DMSFWT7	IU	5-[2-(diethylamino)ethyl]-2-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4-one
DMSFWT7	CA	CAS 945380-27-8
DMSFWT7	DE	Solid tumour/cancer

DM563NC	ID	DM563NC
DM563NC	DN	Fasitibant chloride
DM563NC	HS	Phase 2
DM563NC	SN	MEN-16132; Bradykinin B2 antagonist (inflammation), Menarini; MEN-11270 analogs, Menarini
DM563NC	CP	The Menarini Group
DM563NC	DT	Small molecular drug
DM563NC	PC	11535140
DM563NC	MW	800.2
DM563NC	FM	C36H49Cl3N6O6S
DM563NC	IC	InChI=1S/C36H49Cl2N6O6S.ClH/c1-24-22-25(2)40-33-26(24)8-6-10-30(33)50-23-27-28(37)11-12-31(32(27)38)51(47,48)41-36(13-20-49-21-14-36)35(46)43-17-15-42(16-18-43)34(45)29(39)9-7-19-44(3,4)5;/h6,8,10-12,22,29,41H,7,9,13-21,23,39H2,1-5H3;1H/q+1;/p-1/t29-;/m0./s1
DM563NC	CS	CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)NC4(CCOCC4)C(=O)N5CCN(CC5)C(=O)[C@H](CCC[N+](C)(C)C)N)Cl)C.[Cl-]
DM563NC	IK	ZNHJDJYKDVGQSH-JMAPEOGHSA-M
DM563NC	IU	[(4S)-4-amino-5-[4-[4-[[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylamino]oxane-4-carbonyl]piperazin-1-yl]-5-oxopentyl]-trimethylazanium;chloride
DM563NC	DE	Osteoarthritis

DMR3952	ID	DMR3952
DMR3952	DN	FBS-0701
DMR3952	HS	Phase 2
DMR3952	SN	Desferrithiocin analog (oral, iron overload), FerroKin Biosciences; Iron chelator (oral, iron overload), FerroKin Biosciences
DMR3952	CP	FerroKin BioSciences Inc
DMR3952	DT	Small molecular drug
DMR3952	PC	135565672
DMR3952	MW	399.5
DMR3952	FM	C18H25NO7S
DMR3952	IC	InChI=1S/C18H25NO7S/c1-18(17(21)22)12-27-16(19-18)13-4-3-5-14(15(13)20)26-11-10-25-9-8-24-7-6-23-2/h3-5,20H,6-12H2,1-2H3,(H,21,22)/t18-/m1/s1
DMR3952	CS	C[C@@]1(CSC(=N1)C2=C(C(=CC=C2)OCCOCCOCCOC)O)C(=O)O
DMR3952	IK	AWHIMFSHNAAMBM-GOSISDBHSA-N
DMR3952	IU	(4S)-2-[2-hydroxy-3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]-4-methyl-5H-1,3-thiazole-4-carboxylic acid
DMR3952	CA	CAS 945635-15-4
DMR3952	DE	Iron overload disease

DM3CVHQ	ID	DM3CVHQ
DM3CVHQ	DN	FE-202158
DM3CVHQ	HS	Phase 2
DM3CVHQ	SN	V1a agonist (septic shock), Ferring; Vasopressin 1a agonist (septic shock), Ferring
DM3CVHQ	CP	Ferring Pharmaceuticals Inc
DM3CVHQ	PC	53330936
DM3CVHQ	MW	1048.3
DM3CVHQ	FM	C46H73N13O11S2
DM3CVHQ	IC	InChI=1S/C46H73N13O11S2/c1-5-26(4)38-45(69)54-30(14-9-17-35(48)60)41(65)56-32(21-36(49)61)42(66)57-33(24-72-71-23-28(47)39(63)55-31(43(67)58-38)20-27-12-7-6-8-13-27)46(70)59-19-11-16-34(59)44(68)53-29(15-10-18-51-25(2)3)40(64)52-22-37(50)62/h6-8,12-13,25-26,28-34,38,51H,5,9-11,14-24,47H2,1-4H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,52,64)(H,53,68)(H,54,69)(H,55,63)(H,56,65)(H,57,66)(H,58,67)/t26-,28-,29-,30-,31-,32-,33-,34-,38-/m0/s1
DM3CVHQ	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCCC(=O)N
DM3CVHQ	IK	JCVQBJTWWDYUFQ-MRUTUVJXSA-N
DM3CVHQ	IU	(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-10-(4-amino-4-oxobutyl)-7-(2-amino-2-oxoethyl)-16-benzyl-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-5-(propan-2-ylamino)pentan-2-yl]pyrrolidine-2-carboxamide
DM3CVHQ	CA	CAS 876296-47-8
DM3CVHQ	DE	Sepsis

DMDGZ1C	ID	DMDGZ1C
DMDGZ1C	DN	FE-202767
DMDGZ1C	HS	Phase 2
DMDGZ1C	SN	Oxytocin agonists (erectile dysfunction), Ferring
DMDGZ1C	CP	Ferring Pharmaceuticals Inc
DMDGZ1C	PC	102341060
DMDGZ1C	MW	1042.2
DMDGZ1C	FM	C48H68FN11O12S
DMDGZ1C	IC	InChI=1S/C48H68FN11O12S/c1-5-27(4)42-47(71)56-32(16-17-37(50)62)44(68)57-35(21-38(51)63)45(69)58-36(25-73-18-6-7-40(65)54-34(46(70)59-42)20-28-10-14-31(61)15-11-28)48(72)60(23-29-8-12-30(49)13-9-29)24-41(66)55-33(19-26(2)3)43(67)53-22-39(52)64/h8-15,26-27,32-36,42,61H,5-7,16-25H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,67)(H,54,65)(H,55,66)(H,56,71)(H,57,68)(H,58,69)(H,59,70)/t27?,32-,33-,34-,35-,36-,42-/m0/s1
DMDGZ1C	CS	CCC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N(CC3=CC=C(C=C3)F)CC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMDGZ1C	IK	PVVHQWISMVJHFK-JWKDVPIGSA-N
DMDGZ1C	IU	(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-N-[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-9-(3-amino-3-oxopropyl)-12-butan-2-yl-N-[(4-fluorophenyl)methyl]-15-[(4-hydroxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carboxamide
DMDGZ1C	DE	Erectile dysfunction

DMICMXE	ID	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	HS	Phase 2
DMICMXE	SN	Ferroquine; UNII-8D81JS19ET; 8D81JS19ET; SSR97193; Ferroquine [INN]; 185055-67-8
DMICMXE	CP	Sanofi
DMICMXE	DT	Small molecular drug
DMICMXE	PC	56841801
DMICMXE	MW	433.8
DMICMXE	FM	C23H24ClFeN3
DMICMXE	IC	InChI=1S/C18H19ClN3.C5H5.Fe/c1-22(2)12-14-5-3-4-13(14)11-21-17-8-9-20-18-10-15(19)6-7-16(17)18;1-2-4-5-3-1;/h4,6-10H,5,11-12H2,1-2H3,(H,20,21);1-3H,4H2;/q2*-1;+2
DMICMXE	CS	CN(C)CC1=C(C=[C-]C1)CNC2=C3C=CC(=CC3=NC=C2)Cl.C1C=CC=[C-]1.[Fe+2]
DMICMXE	IK	DLYPREQTTOHKSM-UHFFFAOYSA-N
DMICMXE	IU	7-chloro-N-[[2-[(dimethylamino)methyl]cyclopenta-1,4-dien-1-yl]methyl]quinolin-4-amine;cyclopenta-1,3-diene;iron(2+)
DMICMXE	CA	CAS 185055-67-8
DMICMXE	DE	Malaria

DMJX2P4	ID	DMJX2P4
DMJX2P4	DN	Fezakinumab
DMJX2P4	HS	Phase 2
DMJX2P4	SN	Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC)
DMJX2P4	CP	Wyeth; pfizer
DMJX2P4	DT	Antibody
DMJX2P4	DE	Psoriasis vulgaris

DM7RYL4	ID	DM7RYL4
DM7RYL4	DN	FG-2216
DM7RYL4	HS	Phase 2
DM7RYL4	PC	6914666
DM7RYL4	MW	280.66
DM7RYL4	FM	C12H9ClN2O4
DM7RYL4	IC	InChI=1S/C12H9ClN2O4/c13-11-7-4-2-1-3-6(7)10(18)9(15-11)12(19)14-5-8(16)17/h1-4,18H,5H2,(H,14,19)(H,16,17)
DM7RYL4	CS	C1=CC=C2C(=C1)C(=C(N=C2Cl)C(=O)NCC(=O)O)O
DM7RYL4	IK	OUQVKRKGTAUJQA-UHFFFAOYSA-N
DM7RYL4	IU	2-[(1-chloro-4-hydroxyisoquinoline-3-carbonyl)amino]acetic acid
DM7RYL4	CA	CAS 223387-75-5
DM7RYL4	DE	Kidney disease

DMXMC8I	ID	DMXMC8I
DMXMC8I	DN	FGF-1
DMXMC8I	HS	Phase 2
DMXMC8I	CP	CardioVascular BioTherape.
DMXMC8I	DE	Coronary heart disease

DMCIGRB	ID	DMCIGRB
DMCIGRB	DN	Fialuridine
DMCIGRB	HS	Phase 2
DMCIGRB	SN	FIAU
DMCIGRB	CP	Oclassen Pharmaceuticals Inc
DMCIGRB	DT	Small molecular drug
DMCIGRB	PC	50313
DMCIGRB	MW	372.09
DMCIGRB	FM	C9H10FIN2O5
DMCIGRB	IC	InChI=1S/C9H10FIN2O5/c10-5-6(15)4(2-14)18-8(5)13-1-3(11)7(16)12-9(13)17/h1,4-6,8,14-15H,2H2,(H,12,16,17)/t4-,5+,6-,8-/m1/s1
DMCIGRB	CS	C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F)I
DMCIGRB	IK	IPVFGAYTKQKGBM-BYPJNBLXSA-N
DMCIGRB	IU	1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
DMCIGRB	CA	CAS 69123-98-4
DMCIGRB	DE	Hepatitis B virus infection

DMG65WH	ID	DMG65WH
DMG65WH	DN	Ficlatuzumab
DMG65WH	HS	Phase 2
DMG65WH	SN	AV-299
DMG65WH	CP	AVEO Pharmaceuticals
DMG65WH	DT	Monoclonal antibody
DMG65WH	DE	Non-small-cell lung cancer; Multiple myeloma; Acute myeloid leukaemia; Pancreatic cancer; Squamous cell carcinoma

DMNSYXB	ID	DMNSYXB
DMNSYXB	DN	Filibuvir
DMNSYXB	HS	Phase 2
DMNSYXB	SN	Filibuvir; 877130-28-4; PF-00868554; UNII-198J479Y2L; 198J479Y2L; (6R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl(1,2,4)triazolo(1,5-a)pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydro-2H-pyran-2-one; (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; Filibuvir [USAN:INN]; 3frz
DMNSYXB	CP	Pfizer
DMNSYXB	DT	Small molecular drug
DMNSYXB	PC	54708673
DMNSYXB	MW	503.6
DMNSYXB	FM	C29H37N5O3
DMNSYXB	IC	InChI=1S/C29H37N5O3/c1-5-22-14-20(15-23(6-2)31-22)11-12-29(21-9-7-8-10-21)17-25(35)24(27(36)37-29)16-26-32-28-30-18(3)13-19(4)34(28)33-26/h13-15,21,35H,5-12,16-17H2,1-4H3/t29-/m1/s1
DMNSYXB	CS	CCC1=CC(=CC(=N1)CC)CC[C@@]2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5
DMNSYXB	IK	SLVAPEZTBDBAPI-GDLZYMKVSA-N
DMNSYXB	IU	(2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one
DMNSYXB	CA	CAS 877130-28-4
DMNSYXB	DE	Hepatitis C virus infection

DMG439E	ID	DMG439E
DMG439E	DN	Fipamezole
DMG439E	HS	Phase 2
DMG439E	SN	Fipamezole; 150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole
DMG439E	DT	Small molecular drug
DMG439E	PC	213041
DMG439E	MW	230.28
DMG439E	FM	C14H15FN2
DMG439E	IC	InChI=1S/C14H15FN2/c1-2-14(13-8-16-9-17-13)6-10-3-4-12(15)5-11(10)7-14/h3-5,8-9H,2,6-7H2,1H3,(H,16,17)
DMG439E	CS	CCC1(CC2=C(C1)C=C(C=C2)F)C3=CN=CN3
DMG439E	IK	KXSUAWAUCNFBQJ-UHFFFAOYSA-N
DMG439E	IU	5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole
DMG439E	CA	CAS 150586-58-6
DMG439E	DE	Acute myeloid leukaemia

DMW2QYT	ID	DMW2QYT
DMW2QYT	DN	Firategrast
DMW2QYT	HS	Phase 2
DMW2QYT	SN	SB 683699; Firategrast (USAN); SB-683699; 2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxy-phenyl]phenyl]propanoic Acid
DMW2QYT	CP	GSK
DMW2QYT	DT	Small molecular drug
DMW2QYT	PC	9935681
DMW2QYT	MW	499.5
DMW2QYT	FM	C27H27F2NO6
DMW2QYT	IC	InChI=1S/C27H27F2NO6/c1-4-36-15-17-13-22(34-2)24(23(14-17)35-3)18-10-8-16(9-11-18)12-21(27(32)33)30-26(31)25-19(28)6-5-7-20(25)29/h5-11,13-14,21H,4,12,15H2,1-3H3,(H,30,31)(H,32,33)/t21-/m0/s1
DMW2QYT	CS	CCOCC1=CC(=C(C(=C1)OC)C2=CC=C(C=C2)C[C@@H](C(=O)O)NC(=O)C3=C(C=CC=C3F)F)OC
DMW2QYT	IK	YLFZHHDVRSYTKT-NRFANRHFSA-N
DMW2QYT	IU	(2S)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid
DMW2QYT	CA	CAS 402567-16-2
DMW2QYT	DE	Multiple sclerosis

DMJSD5W	ID	DMJSD5W
DMJSD5W	DN	FK-070
DMJSD5W	HS	Phase 2
DMJSD5W	SN	KDI-792; Kdi 792; FK 070; FK-070; AC1O5X7F; SCHEMBL8657761; JGCFJVFIRFTRKJ-YOLZMAEBSA-N; 130047-30-2; FR-121070; 167678-84-4; (2S,4R)-2-[(Z)-5-carboxy-1-pentenyl]-4-(4-chlorophenylsulfonylamino)-1-(3-pyridylmethyl)pyrrolidine hydrochloride; 5-Hexenoic acid, 6-((2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1-(3-     pyridinylmethyl)-2-pyrrolidinyl)-, monohydrochloride, (5Z)-; 178895-18-6; (Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid hydrochloride
DMJSD5W	DT	Small molecular drug
DMJSD5W	PC	6442424
DMJSD5W	MW	500.4
DMJSD5W	FM	C22H27Cl2N3O4S
DMJSD5W	IC	InChI=1S/C22H26ClN3O4S.ClH/c23-18-8-10-21(11-9-18)31(29,30)25-19-13-20(6-2-1-3-7-22(27)28)26(16-19)15-17-5-4-12-24-14-17;/h2,4-6,8-12,14,19-20,25H,1,3,7,13,15-16H2,(H,27,28);1H/b6-2-;/t19-,20-;/m1./s1
DMJSD5W	CS	C1[C@H](CN([C@@H]1/C=C\\CCCC(=O)O)CC2=CN=CC=C2)NS(=O)(=O)C3=CC=C(C=C3)Cl.Cl
DMJSD5W	IK	JGCFJVFIRFTRKJ-YOLZMAEBSA-N
DMJSD5W	IU	(Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid;hydrochloride
DMJSD5W	CA	CAS 130047-30-2
DMJSD5W	DE	Angina pectoris

DMEL15U	ID	DMEL15U
DMEL15U	DN	FK-143
DMEL15U	HS	Phase 2
DMEL15U	SN	FK-143; Fk 143; CHEMBL25083; 163136-03-6; 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; 4-[3-[3-(bis[4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; SCHEMBL3504489; AC1L435G; CTK0H5706; DTXSID80167524; LACIBZRFAYFTOV-UHFFFAOYSA-N; BDBM50057477; 1H-Indole-1-butanoicacid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-; 4-[3-[3-[bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid
DMEL15U	DT	Small molecular drug
DMEL15U	PC	178077
DMEL15U	MW	600.8
DMEL15U	FM	C40H44N2O3
DMEL15U	IC	InChI=1S/C40H44N2O3/c1-27(2)23-29-14-18-31(19-15-29)39(32-20-16-30(17-21-32)24-28(3)4)41-34-10-7-9-33(25-34)40(45)36-26-42(22-8-13-38(43)44)37-12-6-5-11-35(36)37/h5-7,9-12,14-21,25-28,39,41H,8,13,22-24H2,1-4H3,(H,43,44)
DMEL15U	CS	CC(C)CC1=CC=C(C=C1)C(C2=CC=C(C=C2)CC(C)C)NC3=CC=CC(=C3)C(=O)C4=CN(C5=CC=CC=C54)CCCC(=O)O
DMEL15U	IK	LACIBZRFAYFTOV-UHFFFAOYSA-N
DMEL15U	IU	4-[3-[3-[bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid
DMEL15U	CA	CAS 163136-03-6
DMEL15U	DE	Prostate disease

DML5AE4	ID	DML5AE4
DML5AE4	DN	FK-3311
DML5AE4	HS	Phase 2
DML5AE4	SN	116686-15-8; FK 3311; FK-3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474
DML5AE4	CP	Fujisawa Pharmaceutical Co Ltd
DML5AE4	DT	Small molecular drug
DML5AE4	PC	164009
DML5AE4	MW	341.3
DML5AE4	FM	C15H13F2NO4S
DML5AE4	IC	InChI=1S/C15H13F2NO4S/c1-9(19)10-3-5-13(18-23(2,20)21)15(7-10)22-14-6-4-11(16)8-12(14)17/h3-8,18H,1-2H3
DML5AE4	CS	CC(=O)C1=CC(=C(C=C1)NS(=O)(=O)C)OC2=C(C=C(C=C2)F)F
DML5AE4	IK	DIIYLGZNZGPXRR-UHFFFAOYSA-N
DML5AE4	IU	N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide
DML5AE4	CA	CAS 116686-15-8
DML5AE4	DE	Rheumatoid arthritis

DMKVXYS	ID	DMKVXYS
DMKVXYS	DN	FK-409
DMKVXYS	HS	Phase 2
DMKVXYS	SN	nor-3; 3-Hexenamide, 4-ethyl-2-(hydroxyimino)-5-nitro-; 92454-83-6; 163180-49-2; ACMC-20eif3; AC1OAT8P; 4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide; CTK3H0114; CTK4D1460
DMKVXYS	CP	Fujisawa Pharmaceutical Co Ltd
DMKVXYS	DT	Small molecular drug
DMKVXYS	PC	6413529
DMKVXYS	MW	215.21
DMKVXYS	FM	C8H13N3O4
DMKVXYS	IC	InChI=1S/C8H13N3O4/c1-3-6(5(2)11(14)15)4-7(10-13)8(9)12/h4-5,13H,3H2,1-2H3,(H2,9,12)/b6-4+,10-7-
DMKVXYS	CS	CC/C(=C\\C(=N\\O)\\C(=O)N)/C(C)[N+](=O)[O-]
DMKVXYS	IK	MZAGXDHQGXUDDX-JSRXJHBZSA-N
DMKVXYS	IU	(E,2Z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide
DMKVXYS	CA	CAS 92454-60-9
DMKVXYS	DE	Angina pectoris

DMGROQP	ID	DMGROQP
DMGROQP	DN	FK-505
DMGROQP	HS	Phase 2
DMGROQP	SN	FR-76505; 2-[3-(4-Bromo-2-fluorobenzyl)-7-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl]acetic acid
DMGROQP	DT	Small molecular drug
DMGROQP	PC	3086955
DMGROQP	MW	425.2
DMGROQP	FM	C17H11BrF2N2O4
DMGROQP	IC	InChI=1S/C17H11BrF2N2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24)
DMGROQP	CS	C1=CC2=C(C=C1F)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
DMGROQP	IK	XLOHSVVOWVIPFC-UHFFFAOYSA-N
DMGROQP	IU	2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-fluoro-2,4-dioxoquinazolin-1-yl]acetic acid
DMGROQP	CA	CAS 112733-08-1
DMGROQP	DE	Hyperuricaemia

DMY61TJ	ID	DMY61TJ
DMY61TJ	DN	FK-614
DMY61TJ	HS	Phase 2
DMY61TJ	SN	ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus
DMY61TJ	CP	Fujisawa Pharmaceutical Co Ltd; aestus therapeutics
DMY61TJ	DT	Small molecular drug
DMY61TJ	PC	9869229
DMY61TJ	MW	468.4
DMY61TJ	FM	C21H23Cl2N3O3S
DMY61TJ	IC	InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)15-7-9-19-20(11-15)26(14(2)24-19)13-16-6-8-17(22)12-18(16)23/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27)
DMY61TJ	CS	CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(N2CC3=C(C=C(C=C3)Cl)Cl)C
DMY61TJ	IK	UYGZODVVDUIDDQ-UHFFFAOYSA-N
DMY61TJ	IU	3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide
DMY61TJ	CA	CAS 193012-35-0
DMY61TJ	DE	Type-2 diabetes

DMV0MZ3	ID	DMV0MZ3
DMV0MZ3	DN	FK-962
DMV0MZ3	HS	Phase 2
DMV0MZ3	SN	FK-960 analog, Fujisawa
DMV0MZ3	CP	Fujisawa Pharmaceutical Co Ltd
DMV0MZ3	DT	Small molecular drug
DMV0MZ3	PC	56842107
DMV0MZ3	MW	263.31
DMV0MZ3	FM	C15H18FNO2
DMV0MZ3	IC	InChI=1S/C15H18FNO2/c1-10(18)11-4-8-14(9-5-11)17-15(19)12-2-6-13(16)7-3-12/h2-3,6-7,11,14H,4-5,8-9H2,1H3,(H,17,19)
DMV0MZ3	CS	CC(=O)C1CCC(CC1)NC(=O)C2=CC=C(C=C2)F
DMV0MZ3	IK	PYMCWQVGVQEZNO-UHFFFAOYSA-N
DMV0MZ3	IU	N-(4-acetylcyclohexyl)-4-fluorobenzamide
DMV0MZ3	CA	CAS 283167-06-6
DMV0MZ3	DE	Alzheimer disease

DM2O7NM	ID	DM2O7NM
DM2O7NM	DN	FKB01MD
DM2O7NM	HS	Phase 2
DM2O7NM	CP	Fabre-Kramer Pharmaceuticals Houston, TX

DMPXH7N	ID	DMPXH7N
DMPXH7N	DN	FKW00GA
DMPXH7N	HS	Phase 2
DMPXH7N	CP	Fabre-Kramer Pharmaceuticals Houston, TX
DMPXH7N	DE	Social phobia

DMKSUOI	ID	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	HS	Phase 2
DMKSUOI	SN	FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
DMKSUOI	CP	Sanofi-Aventis
DMKSUOI	DT	Small molecular drug
DMKSUOI	PC	5287969
DMKSUOI	MW	401.8
DMKSUOI	FM	C21H20ClNO5
DMKSUOI	IC	InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1
DMKSUOI	CS	CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
DMKSUOI	IK	BIIVYFLTOXDAOV-YVEFUNNKSA-N
DMKSUOI	IU	2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
DMKSUOI	CA	CAS 146426-40-6
DMKSUOI	CB	CHEBI:47344
DMKSUOI	DE	Chronic lymphocytic leukaemia; Acute myeloid leukaemia

DMCN4H6	ID	DMCN4H6
DMCN4H6	DN	Flezelastine
DMCN4H6	HS	Phase 2
DMCN4H6	SN	D-18024
DMCN4H6	CP	ASTA Medica AG
DMCN4H6	DT	Small molecular drug
DMCN4H6	PC	60432
DMCN4H6	MW	455.6
DMCN4H6	FM	C29H30FN3O
DMCN4H6	IC	InChI=1S/C29H30FN3O/c30-24-14-12-23(13-15-24)21-28-26-10-4-5-11-27(26)29(34)33(31-28)25-9-6-18-32(20-17-25)19-16-22-7-2-1-3-8-22/h1-5,7-8,10-15,25H,6,9,16-21H2
DMCN4H6	CS	C1CC(CCN(C1)CCC2=CC=CC=C2)N3C(=O)C4=CC=CC=C4C(=N3)CC5=CC=C(C=C5)F
DMCN4H6	IK	HQFSNUYUXXPVKL-UHFFFAOYSA-N
DMCN4H6	IU	4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one
DMCN4H6	CA	CAS 135381-77-0
DMCN4H6	DE	Asthma

DMVR6OM	ID	DMVR6OM
DMVR6OM	DN	Flotetuzumab
DMVR6OM	HS	Phase 2
DMVR6OM	CP	MacroGenics Rockville, MD
DMVR6OM	DE	Myelodysplastic syndrome; Acute myeloid leukaemia; Acute biphenotypic leukaemia

DMMQ1YU	ID	DMMQ1YU
DMMQ1YU	DN	FLUASTERONE
DMMQ1YU	HS	Phase 2
DMMQ1YU	SN	HE-2500; 16alpha-Fluoroandrost-5-en-17-one; 8354
DMMQ1YU	CP	Aeson Therapeutics
DMMQ1YU	DT	Small molecular drug
DMMQ1YU	PC	133967
DMMQ1YU	MW	290.4
DMMQ1YU	FM	C19H27FO
DMMQ1YU	IC	InChI=1S/C19H27FO/c1-18-9-4-3-5-12(18)6-7-13-14(18)8-10-19(2)15(13)11-16(20)17(19)21/h6,13-16H,3-5,7-11H2,1-2H3/t13-,14+,15+,16-,18+,19+/m1/s1
DMMQ1YU	CS	C[C@]12CCCCC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3C[C@H](C4=O)F)C
DMMQ1YU	IK	VHZXNQKVFDBFIK-NBBHSKLNSA-N
DMMQ1YU	IU	(8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
DMMQ1YU	CA	CAS 112859-71-9
DMMQ1YU	DE	Arthritis

DME01HT	ID	DME01HT
DME01HT	DN	Fluciclatide F-18
DME01HT	HS	Phase 2
DME01HT	CP	GE Healthcare; National Cancer Institute
DME01HT	DT	Small molecular drug
DME01HT	PC	139033064
DME01HT	MW	1815
DME01HT	FM	C75H115FN18O27S3
DME01HT	IC	InChI=1S/C75H115FN18O27S3/c76-52-13-11-51(12-14-52)39-87-121-45-65(100)83-19-23-113-27-31-117-34-36-118-35-33-116-30-26-112-22-18-82-64(99)44-120-43-62(97)80-15-5-4-9-54-70(106)93-58-47-123-124-48-59(94-72(108)56(38-67(102)103)89-61(96)40-86-68(104)53(90-73(58)109)10-6-16-85-75(78)79)74(110)91-55(37-50-7-2-1-3-8-50)71(107)92-57(46-122-49-66(101)88-54)69(105)84-20-24-114-28-32-115-29-25-111-21-17-81-63(98)42-119-41-60(77)95/h1-3,7-8,11-14,39,53-59H,4-6,9-10,15-38,40-49H2,(H2,77,95)(H,80,97)(H,81,98)(H,82,99)(H,83,100)(H,84,105)(H,86,104)(H,88,101)(H,89,96)(H,90,109)(H,91,110)(H,92,107)(H,93,106)(H,94,108)(H,102,103)(H4,78,79,85)/b87-39-/t53-,54-,55-,56-,57-,58-,59-/m0/s1/i76-1
DME01HT	CS	C1[C@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N[C@H](C(=O)N[C@@H](CSCC(=O)N[C@H](C(=O)N2)CCCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CO/N=C\\C3=CC=C(C=C3)[18F])C(=O)NCCOCCOCCOCCNC(=O)COCC(=O)N)CC4=CC=CC=C4)CC(=O)O)CCCN=C(N)N
DME01HT	IK	VXFFXZSNVKXXIB-SOFHUQNMSA-N
DME01HT	IU	2-[(1R,4S,10R,13S,16R,19S,25S)-10-[2-[2-[2-[2-[[2-(2-amino-2-oxoethoxy)acetyl]amino]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]-13-benzyl-25-[3-(diaminomethylideneamino)propyl]-4-[4-[[2-[2-[2-[2-[2-[2-[2-[2-[[2-[(Z)-(4-(18F)fluoranylphenyl)methylideneamino]oxyacetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetyl]amino]butyl]-3,6,12,15,18,21,24,27-octaoxo-8,29,30-trithia-2,5,11,14,17,20,23,26-octazabicyclo[14.11.4]hentriacontan-19-yl]acetic acid
DME01HT	DE	Solid tumour/cancer

DM0G5O6	ID	DM0G5O6
DM0G5O6	DN	Flumatinib
DM0G5O6	HS	Phase 2
DM0G5O6	SN	HH-GV-678
DM0G5O6	CP	Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
DM0G5O6	DT	Small molecular drug
DM0G5O6	PC	46848036
DM0G5O6	MW	562.6
DM0G5O6	FM	C29H29F3N8O
DM0G5O6	IC	InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)
DM0G5O6	CS	CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5
DM0G5O6	IK	BJCJYEYYYGBROF-UHFFFAOYSA-N
DM0G5O6	IU	4-[(4-methylpiperazin-1-yl)methyl]-N-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide
DM0G5O6	CA	CAS 895519-90-1
DM0G5O6	DE	Chronic myelogenous leukaemia

DMCEUOH	ID	DMCEUOH
DMCEUOH	DN	Fluoropeptide vaccine
DMCEUOH	HS	Phase 2
DMCEUOH	SN	FP-01; Fluoropeptide vaccine (influenza); Fluoropeptide vaccine (influenza), Immune Targeting Systems
DMCEUOH	CP	Immune Targeting Systems Ltd
DMCEUOH	DT	Vaccine
DMCEUOH	DE	Influenza virus infection

DMPBV9D	ID	DMPBV9D
DMPBV9D	DN	Flupirtine
DMPBV9D	HS	Phase 2
DMPBV9D	SN	Flupirtine; 56995-20-1; Flupirtine [INN:BAN]; Flupirtinum [INN-Latin]; Flupirtino [INN-Spanish]; UNII-MOH3ET196H; C15H17FN4O2; EINECS 260-503-8; MOH3ET196H; JUUFBMODXQKSTD-UHFFFAOYSA-N; ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; D 9998; flupirtin maleate; ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate; Flupirtinum; Flupirtino; MLS002153180; Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester; NCGC00015451-03; SMR001230672; Flupirtin; Carbamic acid, [2-ami
DMPBV9D	CP	Adeona Pharmaceuticals; MI Meda Pharmaceuticals
DMPBV9D	DT	Small molecular drug
DMPBV9D	PC	53276
DMPBV9D	MW	304.32
DMPBV9D	FM	C15H17FN4O2
DMPBV9D	IC	InChI=1S/C15H17FN4O2/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20)
DMPBV9D	CS	CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N
DMPBV9D	IK	JUUFBMODXQKSTD-UHFFFAOYSA-N
DMPBV9D	IU	ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate
DMPBV9D	CA	CAS 56995-20-1
DMPBV9D	CB	CHEBI:94646
DMPBV9D	DE	Fibromyalgia; Cancer related pain

DMQX5UA	ID	DMQX5UA
DMQX5UA	DN	FLX-787
DMQX5UA	HS	Phase 2
DMQX5UA	CP	Flex Pharma, Boston, MA
DMQX5UA	DE	Amyotrophic lateral sclerosis; Multiple sclerosis; Muscle spasm

DMB9ADM	ID	DMB9ADM
DMB9ADM	DN	FolateImmune
DMB9ADM	HS	Phase 2
DMB9ADM	SN	Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5
DMB9ADM	CP	Endocyte Inc
DMB9ADM	DT	Small molecular drug
DMB9ADM	PC	135564966
DMB9ADM	MW	872.9
DMB9ADM	FM	C42H36N10O10S
DMB9ADM	IC	InChI=1S/C42H36N10O10S/c43-33(55)12-11-30(38(58)59)52(37(57)20-1-3-21(4-2-20)46-18-23-19-47-35-34(48-23)36(56)51-40(44)50-35)14-13-45-41(63)49-22-5-8-27-26(15-22)39(60)62-42(27)28-9-6-24(53)16-31(28)61-32-17-25(54)7-10-29(32)42/h1-10,15-17,19,30,46,53-54H,11-14,18H2,(H2,43,55)(H,58,59)(H2,45,49,63)(H3,44,47,50,51,56)/t30-/m0/s1
DMB9ADM	CS	C1=CC(=CC=C1C(=O)N(CCNC(=S)NC2=CC3=C(C=C2)C4(C5=C(C=C(C=C5)O)OC6=C4C=CC(=C6)O)OC3=O)[C@@H](CCC(=O)N)C(=O)O)NCC7=CN=C8C(=N7)C(=O)NC(=N8)N
DMB9ADM	IK	ZMTAPBHUSYTHBY-PMERELPUSA-N
DMB9ADM	IU	(2S)-5-amino-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]-[2-[(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)carbamothioylamino]ethyl]amino]-5-oxopentanoic acid
DMB9ADM	CA	CAS 583037-91-6
DMB9ADM	DE	Renal cell carcinoma; Solid tumour/cancer

DMJNO3D	ID	DMJNO3D
DMJNO3D	DN	Follicle stimulating hormone
DMJNO3D	HS	Phase 2
DMJNO3D	SN	FSH-GEX; Follicle stimulating hormone (GEX, inferticlity); GT-GP 2.4 GEX; Follicle stimulating hormone (GEX, inferticlity), Glycotope
DMJNO3D	CP	Glycotope GmbH
DMJNO3D	DE	Infertility

DMUAXS5	ID	DMUAXS5
DMUAXS5	DN	FP-1039
DMUAXS5	HS	Phase 2
DMUAXS5	SN	FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences
DMUAXS5	CP	FivePrime Therapeutics Inc
DMUAXS5	DE	Solid tumour/cancer; Endometrial cancer

DMC1F2T	ID	DMC1F2T
DMC1F2T	DN	FP-1097
DMC1F2T	HS	Phase 2
DMC1F2T	SN	Urinary incontinence therapy, FemmePharma
DMC1F2T	CP	FemmePharma Inc
DMC1F2T	DE	Urinary incontinence

DMXOTMP	ID	DMXOTMP
DMXOTMP	DN	FPI-01
DMXOTMP	HS	Phase 2
DMXOTMP	SN	WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals
DMXOTMP	CP	Formula pharmaceuticals
DMXOTMP	DT	Vaccine
DMXOTMP	DE	Acute myeloid leukaemia

DMEL5SV	ID	DMEL5SV
DMEL5SV	DN	FR139317
DMEL5SV	HS	Phase 2
DMEL5SV	SN	D-Alanine, N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl-1-methyl-D-tryptophyl-3-(2-pyridinyl)-; FR 139317; 142375-60-8; CHEMBL352396; 2-((1-(Hexahydro-1H-azepinyl)carbonyl)amino-4-methylpentanoyl)-3-(-(1-methyl-1H-indolyl)propionyl)amino-3-(2-pyridyl)propionic acid; D-Alanine, N-(N-(N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-1-methyl-D-tryptophyl)-3-(2-pyridinyl)-; GSK424887
DMEL5SV	DT	Small molecular drug
DMEL5SV	PC	107810
DMEL5SV	MW	604.7
DMEL5SV	FM	C33H44N6O5
DMEL5SV	IC	InChI=1S/C33H44N6O5/c1-22(2)18-26(37-33(44)39-16-10-4-5-11-17-39)30(40)35-27(19-23-21-38(3)29-14-7-6-13-25(23)29)31(41)36-28(32(42)43)20-24-12-8-9-15-34-24/h6-9,12-15,21-22,26-28H,4-5,10-11,16-20H2,1-3H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43)/t26-,27+,28+/m0/s1
DMEL5SV	CS	CC(C)C[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C)C(=O)N[C@H](CC3=CC=CC=N3)C(=O)O)NC(=O)N4CCCCCC4
DMEL5SV	IK	LIOKMIQQPDDTNO-UPRLRBBYSA-N
DMEL5SV	IU	(2R)-2-[[(2R)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-methylindol-3-yl)propanoyl]amino]-3-pyridin-2-ylpropanoic acid
DMEL5SV	CA	CAS 142375-60-8
DMEL5SV	DE	Anxiety disorder; Depression; Hypertension

DMGO45I	ID	DMGO45I
DMGO45I	DN	FR-146687
DMGO45I	HS	Phase 2
DMGO45I	SN	FK-687; TF-505; 4-[1-[4-[1(S)-(4-Isobutylphenyl)butoxy]benzoyl]indolizin-3-yl]butyric acid
DMGO45I	DE	Prostate disease

DMFZ084	ID	DMFZ084
DMFZ084	DN	Fresolimumab
DMFZ084	HS	Phase 2
DMFZ084	SN	GC-1008
DMFZ084	DT	Antibody
DMFZ084	DE	Brain cancer

DM9ORUW	ID	DM9ORUW
DM9ORUW	DN	FRM-0962
DM9ORUW	HS	Phase 2
DM9ORUW	CP	Forum pharmaceuticals
DM9ORUW	DE	Alzheimer disease

DMPQFTA	ID	DMPQFTA
DMPQFTA	DN	Fucoxanthin
DMPQFTA	HS	Phase 2
DMPQFTA	SN	Fucoxanthin; UNII-06O0TC0VSM; CCRIS 4055; all-trans-Fucoxanthin; BRN 0073179; 06O0TC0VSM; beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one
DMPQFTA	PC	5281239
DMPQFTA	MW	658.9
DMPQFTA	FM	C42H58O6
DMPQFTA	IC	InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1
DMPQFTA	CS	CC(=CC=CC=C(C)C=CC=C(C)C(=O)CC12C(CC(CC1(O2)C)O)(C)C)C=CC=C(C)C=C=C3C(CC(CC3(C)O)OC(=O)C)(C)C
DMPQFTA	IK	SJWWTRQNNRNTPU-ABBNZJFMSA-N
DMPQFTA	IU	nan
DMPQFTA	CA	CAS 3351-86-8
DMPQFTA	CB	CHEBI:5186
DMPQFTA	DE	Metabolic syndrome

DMZLBAW	ID	DMZLBAW
DMZLBAW	DN	Fucoxanthin
DMZLBAW	HS	Phase 2
DMZLBAW	SN	3351-86-8; UNII-06O0TC0VSM; all-trans-Fucoxanthin; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-beta,beta-carotene; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; CCRIS 4055; BRN 0073179; Fucoxanthol; cis-Fucoxanthin; yl acetate; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-yl acetate; C42H58O6; Beta-sitosterol 45%; SCHEMBL37284; 5-18-04-00673 (Beilstein Handbook Reference); beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; MLS000728353; Fucoxanthin, analytical standard; CHEMBL1575074; SJWWTRQNNRNTPU-ABBNZJFMSA-; Fucoxanthin carotenoid antioxidant; Fucoxanthin, carotenoid antioxidant; HMS2219K22; Fucoxanthin (from Wakame) (Brown Seaweed) (Undaria Pinnatifida); HY-N2302; ZINC8221218; 1772AH; LMPR01070300; MFCD01745140; AKOS037514648; CS-8167; NCGC00247434-01; AS-56344; SMR000453597; C08596; Q96385; 351F868; Fucoxanthin solution, 1 mg/L in ethanol, analytical standard; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaenylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S)-3'-Acetoxy-5alpha,6alpha-epoxy-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6,7,8-tetrahydro-beta,beta-carotene; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-
DMZLBAW	DT	Small molecular drug
DMZLBAW	PC	5281239
DMZLBAW	MW	658.9
DMZLBAW	FM	C42H58O6
DMZLBAW	IC	InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1
DMZLBAW	CS	C/C(=C\\C=C\\C=C(/C)\\C=C\\C=C(/C)\\C(=O)C[C@]12[C@](O1)(C[C@H](CC2(C)C)O)C)/C=C/C=C(\\C)/C=C=C3[C@](C[C@H](CC3(C)C)OC(=O)C)(C)O
DMZLBAW	IK	SJWWTRQNNRNTPU-ABBNZJFMSA-N
DMZLBAW	CA	CAS 3351-86-8
DMZLBAW	DE	Metabolic syndrome x

DMKHNXA	ID	DMKHNXA
DMKHNXA	DN	G100
DMKHNXA	HS	Phase 2
DMKHNXA	SN	Caffeine, 8-((3-methoxypropyl)amino)-; 8-((3-Methoxypropyl)amino)caffeine; CAFFEINE, 8-((3-METHOXYPROPYL)AMINO)-; BRN 1086127; 95982-26-6; 8-(gamma-Methoxypropyl)-aminocoffein [German]; 8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione; 8-[(3-methoxypropyl)amino]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-(gamma-Methoxypropyl)-aminocoffein; AC1L1M3J; CTK5H8490; DTXSID70242056; MolPort-002-837-706; CCG-22657; ZINC17172964; AKOS001669223; MCULE-8333260193; LS-48594; EU-0014431; G-100; AO-343/41780992
DMKHNXA	CP	Immune Design Seattle, WA
DMKHNXA	PC	56998
DMKHNXA	MW	281.31
DMKHNXA	FM	C12H19N5O3
DMKHNXA	IC	InChI=1S/C12H19N5O3/c1-15-8-9(14-11(15)13-6-5-7-20-4)16(2)12(19)17(3)10(8)18/h5-7H2,1-4H3,(H,13,14)
DMKHNXA	CS	CN1C2=C(N=C1NCCCOC)N(C(=O)N(C2=O)C)C
DMKHNXA	IK	ZZQHGKMTMAORFI-UHFFFAOYSA-N
DMKHNXA	IU	8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione
DMKHNXA	CA	CAS 95982-26-6
DMKHNXA	DE	Non-hodgkin lymphoma

DMQO2IT	ID	DMQO2IT
DMQO2IT	DN	G1T38
DMQO2IT	HS	Phase 2
DMQO2IT	SN	YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4
DMQO2IT	CP	G1 Therapeutics Research Tringle Park, NC
DMQO2IT	PC	86269224
DMQO2IT	MW	474.6
DMQO2IT	FM	C26H34N8O
DMQO2IT	IC	InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31)
DMQO2IT	CS	CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
DMQO2IT	IK	YPJRHEKCFKOVRT-UHFFFAOYSA-N
DMQO2IT	IU	4-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
DMQO2IT	CA	CAS 1628256-23-4
DMQO2IT	DE	Breast cancer; Non-small-cell lung cancer

DMQR9I8	ID	DMQR9I8
DMQR9I8	DN	G-202
DMQR9I8	HS	Phase 2
DMQR9I8	SN	UNII-Q032I35QMX; Q032I35QMX; 1245732-48-2; Mipsagargin [USAN:INN]; Mipsagargin (USAN/INN); CHEMBL3989865; DB11813; D10715
DMQR9I8	CP	GenSpera
DMQR9I8	PC	24772106
DMQR9I8	MW	1409.5
DMQR9I8	FM	C66H100N6O27
DMQR9I8	IC	InChI=1S/C66H100N6O27/c1-8-10-11-17-20-24-51(81)96-55-53-52(37(4)54(55)97-62(91)36(3)9-2)56-66(94,65(7,93)63(92)98-56)44(35-64(53,6)99-38(5)73)95-50(80)23-21-18-15-13-12-14-16-19-22-33-68-48(77)34-39(67)57(82)72-43(61(89)90)27-31-47(76)70-41(59(85)86)25-29-45(74)69-40(58(83)84)26-30-46(75)71-42(60(87)88)28-32-49(78)79/h9,39-44,53-56,93-94H,8,10-35,67H2,1-7H3,(H,68,77)(H,69,74)(H,70,76)(H,71,75)(H,72,82)(H,78,79)(H,83,84)(H,85,86)(H,87,88)(H,89,90)/b36-9-/t39-,40-,41-,42-,43-,44-,53+,54-,55-,56-,64-,65+,66+/m0/s1
DMQR9I8	CS	CCCCCCCC(=O)O[C@H]1[C@H]2C(=C([C@@H]1OC(=O)/C(=C\\C)/C)C)[C@H]3[C@]([C@H](C[C@]2(C)OC(=O)C)OC(=O)CCCCCCCCCCCNC(=O)C[C@@H](C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)N)([C@](C(=O)O3)(C)O)O
DMQR9I8	IK	UPYNTAIBQVNPIH-ODMLWHIESA-N
DMQR9I8	IU	(2S)-2-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[(2S)-4-[[12-[[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-acetyloxy-3,3a-dihydroxy-3,6,9-trimethyl-8-[(Z)-2-methylbut-2-enoyl]oxy-7-octanoyloxy-2-oxo-4,5,6a,7,8,9b-hexahydroazuleno[4,5-b]furan-4-yl]oxy]-12-oxododecyl]amino]-2-amino-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid
DMQR9I8	CA	CAS 1245732-48-2
DMQR9I8	DE	Solid tumour/cancer; Adenocarcinoma

DMJY2TM	ID	DMJY2TM
DMJY2TM	DN	Gabapentin enacarbil
DMJY2TM	HS	Phase 2
DMJY2TM	SN	1838262; ASP8825; Gabapentin-XP; GSK 1838262; Horizant; Regnite; Solzira; XP13512
DMJY2TM	TC	Neurology Agents
DMJY2TM	DT	Small molecular drug
DMJY2TM	PC	9883933
DMJY2TM	MW	329.39
DMJY2TM	FM	C16H27NO6
DMJY2TM	IC	InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19)
DMJY2TM	CS	CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O
DMJY2TM	IK	TZDUHAJSIBHXDL-UHFFFAOYSA-N
DMJY2TM	IU	2-[1-[[1-(2-methylpropanoyloxy)ethoxycarbonylamino]methyl]cyclohexyl]acetic acid
DMJY2TM	CA	CAS 478296-72-9
DMJY2TM	CB	CHEBI:68840
DMJY2TM	DE	Alcohol dependence

DMTXCUS	ID	DMTXCUS
DMTXCUS	DN	Galiximab
DMTXCUS	HS	Phase 2
DMTXCUS	CP	Biogen Idec
DMTXCUS	DT	Antibody
DMTXCUS	DE	Lymphoma

DMXBR27	ID	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	HS	Phase 2
DMXBR27	SN	16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; Methoxyverapamil; GSK 796406
DMXBR27	DT	Small molecular drug
DMXBR27	PC	1234
DMXBR27	MW	484.6
DMXBR27	FM	C28H40N2O5
DMXBR27	IC	InChI=1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3
DMXBR27	CS	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC
DMXBR27	IK	XQLWNAFCTODIRK-UHFFFAOYSA-N
DMXBR27	IU	5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile
DMXBR27	CA	CAS 16662-47-8
DMXBR27	CB	CHEBI:34772
DMXBR27	DE	Hypertension; Asthma

DMAEWS1	ID	DMAEWS1
DMAEWS1	DN	GAM-501
DMAEWS1	HS	Phase 2
DMAEWS1	SN	Excellarate; Diabetic ulcer product, Selective Genetics; AdPDGF-B/GAM; Adenoviral gene therapy (PDGF-B), Selective Genetics; PDGF-B adenoviral gene therapy (collagen gel, diabetic foot ulcer), Tissue Repair Company
DMAEWS1	CP	Selective Genetics Inc
DMAEWS1	DE	Diabetic foot ulcer

DM2IFJQ	ID	DM2IFJQ
DM2IFJQ	DN	GBL-310
DM2IFJQ	HS	Phase 2
DM2IFJQ	SN	Anti-hyperproliferative (topical, actinic keratosis), Grannus
DM2IFJQ	CP	Grannus BioSciences Ltd
DM2IFJQ	DE	Keratosis

DM2VO9T	ID	DM2VO9T
DM2VO9T	DN	GBR 830
DM2VO9T	HS	Phase 2
DM2VO9T	CP	Glenmark Pharmaceuticals Mumbai, India
DM2VO9T	DE	Atopic dermatitis

DMYS6MW	ID	DMYS6MW
DMYS6MW	DN	GCS-100
DMYS6MW	HS	Phase 2
DMYS6MW	CP	La jolla pharmaceutical
DMYS6MW	DE	Chronic kidney disease

DMY6WUV	ID	DMY6WUV
DMY6WUV	DN	GDC-0077
DMY6WUV	HS	Phase 2
DMY6WUV	SN	RG6114; SGEUNORSOZVTOL-CABZTGNLSA-N; UNII-L4C1UY2NYH; L4C1UY2NYH; 2060571-02-8; GDC0077; GTPL9636; SCHEMBL18360780; EX-A2685; ZINC669678973; Ro7113755; CS-6459; HY-101562; Propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)-, (2S)-; (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide; (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxa
DMY6WUV	CP	GenentechSouth San Francisco, CA
DMY6WUV	PC	124173720
DMY6WUV	MW	407.4
DMY6WUV	FM	C18H19F2N5O4
DMY6WUV	IC	InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1
DMY6WUV	CS	C[C@@H](C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4[C@@H](COC4=O)C(F)F
DMY6WUV	IK	SGEUNORSOZVTOL-CABZTGNLSA-N
DMY6WUV	IU	(2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
DMY6WUV	CA	CAS 2060571-02-8
DMY6WUV	DE	Breast cancer; Solid tumour/cancer

DMA9SEY	ID	DMA9SEY
DMA9SEY	DN	GDC-0084
DMA9SEY	HS	Phase 2
DMA9SEY	SN	GDC-0084/RG7666
DMA9SEY	CP	Genentech
DMA9SEY	PC	57384863
DMA9SEY	MW	382.4
DMA9SEY	FM	C18H22N8O2
DMA9SEY	IC	InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)
DMA9SEY	CS	CC1(C2=NC3=C(N2CCO1)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N)C
DMA9SEY	IK	LGWACEZVCMBSKW-UHFFFAOYSA-N
DMA9SEY	IU	5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine
DMA9SEY	CA	CAS 1382979-44-3
DMA9SEY	DE	Glioblastoma of brain

DM1YAK6	ID	DM1YAK6
DM1YAK6	DN	GDC0941
DM1YAK6	HS	Phase 2
DM1YAK6	SN	Pictilisib; GDC-0941; 957054-30-7; PICTILISIB; Pictrelisib; GDC 0941; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; 2-(1H-Indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine; UNII-ICY00EMP8P; ICY00EMP8P; Pictilisib (GDC-0941); CHEBI:65326; AK-40872; Thieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-;  GD9; GDC-0941, GDC0941; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
DM1YAK6	CP	Genentech
DM1YAK6	DT	Small molecular drug
DM1YAK6	PC	17755052
DM1YAK6	MW	513.6
DM1YAK6	FM	C23H27N7O3S2
DM1YAK6	IC	InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)
DM1YAK6	CS	CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6
DM1YAK6	IK	LHNIIDJUOCFXAP-UHFFFAOYSA-N
DM1YAK6	IU	4-[2-(1H-indazol-4-yl)-6-[(4-methylsulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine
DM1YAK6	CA	CAS 957054-30-7
DM1YAK6	CB	CHEBI:65326
DM1YAK6	DE	Non-hodgkin lymphoma; Solid tumour/cancer; Breast cancer

DMF3MV1	ID	DMF3MV1
DMF3MV1	DN	GDC-0980/RG7422
DMF3MV1	HS	Phase 2
DMF3MV1	SN	Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S
DMF3MV1	CP	Genentech; Roche
DMF3MV1	DT	Small molecular drug
DMF3MV1	PC	25254071
DMF3MV1	MW	498.6
DMF3MV1	FM	C23H30N8O3S
DMF3MV1	IC	InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1
DMF3MV1	CS	CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)[C@H](C)O
DMF3MV1	IK	YOVVNQKCSKSHKT-HNNXBMFYSA-N
DMF3MV1	IU	(2S)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one
DMF3MV1	CA	CAS 1032754-93-0
DMF3MV1	DE	Non-hodgkin lymphoma; Solid tumour/cancer

DMMQY0O	ID	DMMQY0O
DMMQY0O	DN	GED-0507-34-Levo
DMMQY0O	HS	Phase 2
DMMQY0O	SN	GED-0507; GED-0507-34; GED-0507-34E2
DMMQY0O	CP	Giuliani SpA
DMMQY0O	PC	67008033
DMMQY0O	MW	195.21
DMMQY0O	FM	C10H13NO3
DMMQY0O	IC	InChI=1S/C10H13NO3/c1-14-9(10(12)13)6-7-2-4-8(11)5-3-7/h2-5,9H,6,11H2,1H3,(H,12,13)/t9-/m0/s1
DMMQY0O	CS	CO[C@@H](CC1=CC=C(C=C1)N)C(=O)O
DMMQY0O	IK	QLJYLJGYIDIJPT-VIFPVBQESA-N
DMMQY0O	IU	(2S)-3-(4-aminophenyl)-2-methoxypropanoic acid
DMMQY0O	CA	CAS 921195-93-9
DMMQY0O	DE	Inflammatory bowel disease

DMJN09S	ID	DMJN09S
DMJN09S	DN	GEN-1
DMJN09S	HS	Phase 2
DMJN09S	CP	Celsion
DMJN09S	DT	Gene therapy
DMJN09S	DE	Ovarian cancer

DMO9WU8	ID	DMO9WU8
DMO9WU8	DN	Gepirone
DMO9WU8	HS	Phase 2
DMO9WU8	SN	Gepirone; 4,4-Dimethyl-1-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)piperidine-2,6-dione; Gepirone ER; Gepironum [Latin]; Gepirone [INN]; Gepirona [Spanish]; UNII-JW5Y7B8Z18; BMY-13805; JW5Y7B8Z18; CHEMBL284092; MJ-13805; Variza; Ariza; Gepironum; AK115965; Gepirona; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione; Travivo; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; BMY 13805; MJ 13805; gepiron ER; MJ 13805-1; ORG-13011(Gepirone); AC1L1IK6; AC1Q6F8Q
DMO9WU8	PC	55191
DMO9WU8	MW	359.5
DMO9WU8	FM	C19H29N5O2
DMO9WU8	IC	InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3
DMO9WU8	CS	CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C
DMO9WU8	IK	QOIGKGMMAGJZNZ-UHFFFAOYSA-N
DMO9WU8	IU	4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
DMO9WU8	CA	CAS 83928-76-1
DMO9WU8	CB	CHEBI:135990
DMO9WU8	DE	Cocaine related disorders

DMD3RU8	ID	DMD3RU8
DMD3RU8	DN	GFT14
DMD3RU8	HS	Phase 2
DMD3RU8	CP	Genfit
DMD3RU8	DE	Hyperlipidaemia

DMTY4PG	ID	DMTY4PG
DMTY4PG	DN	GI-4000
DMTY4PG	HS	Phase 2
DMTY4PG	CP	GlobeImmune
DMTY4PG	DT	Vaccine
DMTY4PG	DE	Colorectal cancer; Pancreatic cancer

DMQ0XZE	ID	DMQ0XZE
DMQ0XZE	DN	GI-4000 + gemcitabine
DMQ0XZE	HS	Phase 2
DMQ0XZE	CP	GlobeImmune
DMQ0XZE	DE	Pancreatic cancer

DM72O6F	ID	DM72O6F
DM72O6F	DN	GI-6207
DM72O6F	HS	Phase 2
DM72O6F	CP	GlobeImmune
DM72O6F	DE	Thyroid cancer

DMOMS7R	ID	DMOMS7R
DMOMS7R	DN	GI-6301
DMOMS7R	HS	Phase 2
DMOMS7R	CP	GlobeImmune
DMOMS7R	DT	Vaccine
DMOMS7R	DE	Solid tumour/cancer; Advanced cancer; Chordoma

DMSKMET	ID	DMSKMET
DMSKMET	DN	Gimatecan
DMSKMET	HS	Phase 2
DMSKMET	SN	LBQ-707; ST-1480; ST-1481; Camptothecin analogs, Sigma-Tau; 7-cyano-camptothecin
DMSKMET	CP	Sigma-Tau Ind Farm Riunite SpA
DMSKMET	DT	Small molecular drug
DMSKMET	PC	9577124
DMSKMET	MW	447.5
DMSKMET	FM	C25H25N3O5
DMSKMET	IC	InChI=1S/C25H25N3O5/c1-5-25(31)18-10-20-21-16(12-28(20)22(29)17(18)13-32-23(25)30)15(11-26-33-24(2,3)4)14-8-6-7-9-19(14)27-21/h6-11,31H,5,12-13H2,1-4H3/b26-11+/t25-/m0/s1
DMSKMET	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)/C=N/OC(C)(C)C)O
DMSKMET	IK	UIVFUQKYVFCEKJ-OPTOVBNMSA-N
DMSKMET	IU	(19S)-19-ethyl-19-hydroxy-10-[(E)-(2-methylpropan-2-yl)oxyiminomethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMSKMET	CA	CAS 292618-32-7
DMSKMET	DE	Breast cancer

DMG3O2Z	ID	DMG3O2Z
DMG3O2Z	DN	Girentuximab I-124
DMG3O2Z	HS	Phase 2
DMG3O2Z	SN	Redectane (TN)
DMG3O2Z	CP	Wilex
DMG3O2Z	DT	Monoclonal antibody
DMG3O2Z	DE	Renal cell carcinoma

DMLFSMX	ID	DMLFSMX
DMLFSMX	DN	GK1-399
DMLFSMX	HS	Phase 2
DMLFSMX	SN	TTP-399
DMLFSMX	CP	Forest Laboratories
DMLFSMX	DE	Diabetic complication; Type-2 diabetes

DMOVB3Y	ID	DMOVB3Y
DMOVB3Y	DN	GKT-137831
DMOVB3Y	HS	Phase 2
DMOVB3Y	SN	GKT-01; NADPH oxidase inhibitor (oral, renal cancer/ idiopathic pulmonary fibrosis), GenKyoTex
DMOVB3Y	CP	Genkyotex innovation
DMOVB3Y	DT	Small molecular drug
DMOVB3Y	PC	58496428
DMOVB3Y	MW	394.9
DMOVB3Y	FM	C21H19ClN4O2
DMOVB3Y	IC	InChI=1S/C21H19ClN4O2/c1-24(2)14-8-6-7-13(11-14)20-19-16(12-18(27)25(20)3)23-26(21(19)28)17-10-5-4-9-15(17)22/h4-12,23H,1-3H3
DMOVB3Y	CS	CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl
DMOVB3Y	IK	RGYQPQARIQKJKH-UHFFFAOYSA-N
DMOVB3Y	IU	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6-dione
DMOVB3Y	CA	CAS 1218942-37-0
DMOVB3Y	DE	Fibrosis

DM17OZM	ID	DM17OZM
DM17OZM	DN	GL-0817
DM17OZM	HS	Phase 2
DM17OZM	SN	912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
DM17OZM	CP	Gliknik 
DM17OZM	DT	Small molecular drug
DM17OZM	PC	122706930
DM17OZM	MW	5758
DM17OZM	FM	C261H449N91O56
DM17OZM	IC	InChI=1S/C261H449N91O56/c1-30-147(26)204(249(406)339-186(124-153-70-38-33-39-71-153)234(391)342-190(131-354)238(395)322-159(75-43-49-99-263)210(367)309-149(28)207(364)341-189(130-353)240(397)344-192(133-356)241(398)343-191(132-355)239(396)335-180(118-137(6)7)230(387)324-175(93-96-195(270)358)223(380)331-178(116-135(2)3)228(385)320-168(84-58-108-298-255(279)280)218(375)313-160(76-44-50-100-264)212(369)312-161(77-45-51-101-265)213(370)314-165(81-55-105-295-252(273)274)216(373)315-167(83-57-107-297-254(277)278)219(376)323-174(92-95-194(269)357)222(379)318-166(82-56-106-296-253(275)276)217(374)316-169(85-59-109-299-256(281)282)220(377)329-177(250(407)408)90-64-114-304-261(291)292)351-248(405)203(146(24)25)348-225(382)171(87-61-111-301-258(285)286)319-215(372)163(79-47-53-103-267)327-245(402)200(143(18)19)347-227(384)173(89-63-113-303-260(289)290)328-246(403)201(144(20)21)349-236(393)182(120-139(10)11)330-206(363)148(27)308-211(368)164(80-54-104-294-251(271)272)325-242(399)193-91-65-115-352(193)196(359)129-306-209(366)187(125-154-127-305-158-74-41-40-72-156(154)158)338-231(388)181(119-138(8)9)334-232(389)184(122-151-66-34-31-35-67-151)336-221(378)170(86-60-110-300-257(283)284)317-214(371)162(78-46-52-102-266)326-244(401)199(142(16)17)346-226(383)172(88-62-112-302-259(287)288)321-229(386)179(117-136(4)5)333-233(390)185(123-152-68-36-32-37-69-152)337-235(392)188(126-155-128-293-134-307-155)340-247(404)202(145(22)23)350-237(394)183(121-140(12)13)332-224(381)176(94-97-197(360)361)311-205(362)150(29)310-243(400)198(141(14)15)345-208(365)157(268)73-42-48-98-262/h31-41,66-72,74,127-128,134-150,157,159-193,198-204,305,353-356H,30,42-65,73,75-126,129-133,262-268H2,1-29H3,(H2,269,357)(H2,270,358)(H,293,307)(H,306,366)(H,308,368)(H,309,367)(H,310,400)(H,311,362)(H,312,369)(H,313,375)(H,314,370)(H,315,373)(H,316,374)(H,317,371)(H,318,379)(H,319,372)(H,320,385)(H,321,386)(H,322,395)(H,323,376)(H,324,387)(H,325,399)(H,326,401)(H,327,402)(H,328,403)(H,329,377)(H,330,363)(H,331,380)(H,332,381)(H,333,390)(H,334,389)(H,335,396)(H,336,378)(H,337,392)(H,338,388)(H,339,406)(H,340,404)(H,341,364)(H,342,391)(H,343,398)(H,344,397)(H,345,365)(H,346,383)(H,347,384)(H,348,382)(H,349,393)(H,350,394)(H,351,405)(H,360,361)(H,407,408)(H4,271,272,294)(H4,273,274,295)(H4,275,276,296)(H4,277,278,297)(H4,279,280,298)(H4,281,282,299)(H4,283,284,300)(H4,285,286,301)(H4,287,288,302)(H4,289,290,303)(H4,291,292,304)/t147-,148-,149-,150-,157-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,198-,199-,200-,201-,202-,203-,204-/m0/s1
DM17OZM	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N
DM17OZM	IK	SSOORFWOBGFTHL-OTEJMHTDSA-N
DM17OZM	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DM17OZM	CA	CAS 911338-45-9
DM17OZM	DE	Head and neck cancer; Squamous cell carcinoma; Multiple myeloma; Oral cavity squamous cell carcinoma

DMSVBND	ID	DMSVBND
DMSVBND	DN	Glecaprevir
DMSVBND	HS	Phase 2
DMSVBND	SN	A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CS-8098; D10814; DB13879; EX-A1940; Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; HY-17634; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; UNII-K6BUU8J72P; glecaprevirum
DMSVBND	TC	Antiviral Agent
DMSVBND	DT	Small molecular drug
DMSVBND	PC	66828839
DMSVBND	MW	838.873
DMSVBND	FM	C38H46F4N6O9S
DMSVBND	IC	InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
DMSVBND	CS	CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
DMSVBND	IK	CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
DMSVBND	IU	(1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide
DMSVBND	CA	CAS 1365970-03-1
DMSVBND	DE	Chronic hepatitis C infection

DMPHCDL	ID	DMPHCDL
DMPHCDL	DN	GLPG-0634
DMPHCDL	HS	Phase 2
DMPHCDL	SN	Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK
DMPHCDL	CP	Abbvie; galapagos
DMPHCDL	DT	Small molecular drug
DMPHCDL	PC	49831257
DMPHCDL	MW	425.5
DMPHCDL	FM	C21H23N5O3S
DMPHCDL	IC	InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)
DMPHCDL	CS	C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
DMPHCDL	IK	RIJLVEAXPNLDTC-UHFFFAOYSA-N
DMPHCDL	IU	N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
DMPHCDL	CA	CAS 1206161-97-8
DMPHCDL	DE	Rheumatoid arthritis; Crohn disease; Cutaneous lupus erythematosus

DMXO4T8	ID	DMXO4T8
DMXO4T8	DN	GLPG0974
DMXO4T8	HS	Phase 2
DMXO4T8	SN	compound 99 [PMID 25380412]
DMXO4T8	DT	Small molecular drug
DMXO4T8	PC	57520598
DMXO4T8	MW	485
DMXO4T8	FM	C25H25ClN2O4S
DMXO4T8	IC	InChI=1S/C25H25ClN2O4S/c1-25(11-13-28(25)23(31)20-16-33-21-9-3-2-8-19(20)21)24(32)27(12-5-10-22(29)30)15-17-6-4-7-18(26)14-17/h2-4,6-9,14,16H,5,10-13,15H2,1H3,(H,29,30)/t25-/m1/s1
DMXO4T8	CS	C[C@@]1(CCN1C(=O)C2=CSC3=CC=CC=C32)C(=O)N(CCCC(=O)O)CC4=CC(=CC=C4)Cl
DMXO4T8	IK	MPMKMQHJHDHPBE-RUZDIDTESA-N
DMXO4T8	IU	4-[[(2R)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid
DMXO4T8	CA	CAS 1391076-61-1
DMXO4T8	DE	Abortion

DMOCRYB	ID	DMOCRYB
DMOCRYB	DN	GLPG-1837
DMOCRYB	HS	Phase 2
DMOCRYB	SN	GHTGYZMBQPXTCQ-UHFFFAOYSA-N; GLPG1837; 1654725-02-6; SCHEMBL16444982; GLPG 1837; EX-A1819; BCP23611; GLPG-1837(ABBV-974); HY-111099; CS-0034220; N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-3-carboxamide
DMOCRYB	CP	Galapagos, AbbVie
DMOCRYB	PC	117857370
DMOCRYB	MW	348.4
DMOCRYB	FM	C16H20N4O3S
DMOCRYB	IC	InChI=1S/C16H20N4O3S/c1-15(2)7-8-10(12(17)21)14(24-11(8)16(3,4)23-15)19-13(22)9-5-6-18-20-9/h5-6H,7H2,1-4H3,(H2,17,21)(H,18,20)(H,19,22)
DMOCRYB	CS	CC1(CC2=C(C(O1)(C)C)SC(=C2C(=O)N)NC(=O)C3=CC=NN3)C
DMOCRYB	IK	GHTGYZMBQPXTCQ-UHFFFAOYSA-N
DMOCRYB	IU	N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide
DMOCRYB	DE	Cystic fibrosis

DMJ85FS	ID	DMJ85FS
DMJ85FS	DN	Glutathione-S-S-glutathione
DMJ85FS	HS	Phase 2
DMJ85FS	SN	oxiglutatione; glutathione disulfide; GSSG; oxidized glutathione; Glutathione disulphide; L-Glutathione oxidized; Glutathione-ssg; Glutathione, oxidized; Oxigluthione; glutathione oxidized; Glutathone disulfide; Bi(glutathion-S-yl); Oxidized L-glutathione; L-Oxidized glutathione; L(-)-Glutathione; Oxiglutatione [INN]; S,S'-Ethylenebis(glutathione); Oxiglutationum [INN-Latin]; Oxiglutationa [INN-Spanish]; CCRIS 780; OXIDIZED GLUTATHIONE DISULFIDE; Glutathiol; UNII-ULW86O013H
DMJ85FS	PC	65359
DMJ85FS	MW	612.6
DMJ85FS	FM	C20H32N6O12S2
DMJ85FS	IC	InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1
DMJ85FS	CS	C(CC(=O)NC(CSSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)C(=O)NCC(=O)O)C(C(=O)O)N
DMJ85FS	IK	YPZRWBKMTBYPTK-BJDJZHNGSA-N
DMJ85FS	IU	(2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMJ85FS	CA	CAS 27025-41-8
DMJ85FS	CB	CHEBI:17858
DMJ85FS	DE	Ovarian cancer

DML6PO5	ID	DML6PO5
DML6PO5	DN	GM-CSF cancer vaccine
DML6PO5	HS	Phase 2
DML6PO5	CP	Thomas Jefferson University
DML6PO5	DT	Vaccine
DML6PO5	DE	Solid tumour/cancer

DMLWKZ7	ID	DMLWKZ7
DMLWKZ7	DN	GO-203-2c
DMLWKZ7	HS	Phase 2
DMLWKZ7	CP	Genus Oncology
DMLWKZ7	DE	Solid tumour/cancer; Acute myeloid leukaemia

DMKZN3A	ID	DMKZN3A
DMKZN3A	DN	Golotimod
DMKZN3A	HS	Phase 2
DMKZN3A	SN	229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812;  Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta
DMKZN3A	CP	Verta Ltd; SciClone Pharmaceuticals
DMKZN3A	DT	Small molecular drug
DMKZN3A	PC	6992140
DMKZN3A	MW	333.34
DMKZN3A	FM	C16H19N3O5
DMKZN3A	IC	InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13+/m1/s1
DMKZN3A	CS	C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CC[C@H](C(=O)O)N
DMKZN3A	IK	CATMPQFFVNKDEY-YPMHNXCESA-N
DMKZN3A	IU	(2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid
DMKZN3A	CA	CAS 229305-39-9
DMKZN3A	DE	Inflammation; Immune System disease

DMYWA0Z	ID	DMYWA0Z
DMYWA0Z	DN	GORALATIDE
DMYWA0Z	HS	Phase 2
DMYWA0Z	SN	AcSDKP; Seraspenide; BIM-32001; Goralatide; Acetyl-seryl-aspartyl-lysyl-proline
DMYWA0Z	DT	Small molecular drug
DMYWA0Z	PC	65938
DMYWA0Z	MW	487.5
DMYWA0Z	FM	C20H33N5O9
DMYWA0Z	IC	InChI=1S/C20H33N5O9/c1-11(27)22-14(10-26)18(31)24-13(9-16(28)29)17(30)23-12(5-2-3-7-21)19(32)25-8-4-6-15(25)20(33)34/h12-15,26H,2-10,21H2,1H3,(H,22,27)(H,23,30)(H,24,31)(H,28,29)(H,33,34)/t12-,13-,14-,15-/m0/s1
DMYWA0Z	CS	CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O
DMYWA0Z	IK	HJDRXEQUFWLOGJ-AJNGGQMLSA-N
DMYWA0Z	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carboxylic acid
DMYWA0Z	CA	CAS 120081-14-3
DMYWA0Z	DE	Constitutional neutropenia

DMJWE3I	ID	DMJWE3I
DMJWE3I	DN	Gossypol
DMJWE3I	HS	Phase 2
DMJWE3I	SN	gossypol; 303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate
DMJWE3I	DT	Small molecular drug
DMJWE3I	PC	3503
DMJWE3I	MW	518.6
DMJWE3I	FM	C30H30O8
DMJWE3I	IC	InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3
DMJWE3I	CS	CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O
DMJWE3I	IK	QBKSWRVVCFFDOT-UHFFFAOYSA-N
DMJWE3I	IU	7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde
DMJWE3I	CA	CAS 20300-26-9
DMJWE3I	DE	Prostate cancer

DM38ARE	ID	DM38ARE
DM38ARE	DN	Gp100:209-217(210M) peptide vaccine
DM38ARE	HS	Phase 2
DM38ARE	SN	Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI
DM38ARE	CP	National Cancer Institute
DM38ARE	DT	Vaccine
DM38ARE	DE	Melanoma

DMOHAS2	ID	DMOHAS2
DMOHAS2	DN	GPC-3298306
DMOHAS2	HS	Phase 2
DMOHAS2	SN	GPC3 peptide vaccine (hepatocellular carcinoma), Japanese National Cancer Center
DMOHAS2	CP	Japanese National Cancer Center
DMOHAS2	DT	Vaccine
DMOHAS2	DE	Hepatocellular carcinoma

DMOQ7YI	ID	DMOQ7YI
DMOQ7YI	DN	GPD-1116
DMOQ7YI	HS	Phase 2
DMOQ7YI	PC	9841417
DMOQ7YI	MW	352.4
DMOQ7YI	FM	C22H16N4O
DMOQ7YI	IC	InChI=1S/C22H16N4O/c27-22-19-18(14-15-8-3-1-4-9-15)24-25-20(19)17-12-7-13-23-21(17)26(22)16-10-5-2-6-11-16/h1-13H,14H2,(H,24,25)
DMOQ7YI	CS	C1=CC=C(C=C1)CC2=C3C(=NN2)C4=C(N=CC=C4)N(C3=O)C5=CC=CC=C5
DMOQ7YI	IK	NOZMPLJNURLIAQ-UHFFFAOYSA-N
DMOQ7YI	IU	3-benzyl-5-phenyl-2H-pyrazolo[4,3-c][1,8]naphthyridin-4-one
DMOQ7YI	DE	Asthma

DM64ZYM	ID	DM64ZYM
DM64ZYM	DN	GPI-1485
DM64ZYM	HS	Phase 2
DM64ZYM	SN	186268-78-0; GPI-1485; UNII-0709BVY57W; (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid; (2S)-1-(1,2-DIOXO-3,3-DIMETHYLPENTYL)-2-PYRROLIDINECARBOXYLIC ACID; 0709BVY57W; (S)-1-(3,3-Dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid; L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-; GPI 1485; SCHEMBL2006950; CTK6C7007; FOPALECPEUVCTL-QMMMGPOBSA-N; MolPort-023-219-569; ZX-RL003437; 1-(1,2-Dioxo-3,3-dimethylpentyl)-2-pyrrolidine carboxylic acid, 2S; ZINC33979157; 6256AD; AKOS015991368; DB05814; EG-0058
DM64ZYM	CP	Eisai
DM64ZYM	DT	Small molecular drug
DM64ZYM	PC	9837656
DM64ZYM	MW	241.28
DM64ZYM	FM	C12H19NO4
DM64ZYM	IC	InChI=1S/C12H19NO4/c1-4-12(2,3)9(14)10(15)13-7-5-6-8(13)11(16)17/h8H,4-7H2,1-3H3,(H,16,17)/t8-/m0/s1
DM64ZYM	CS	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)O
DM64ZYM	IK	FOPALECPEUVCTL-QMMMGPOBSA-N
DM64ZYM	IU	(2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid
DM64ZYM	CA	CAS 186268-78-0
DM64ZYM	DE	Parkinson disease

DMHNIGB	ID	DMHNIGB
DMHNIGB	DN	GPX-150D
DMHNIGB	HS	Phase 2
DMHNIGB	SN	CNDO-101; CNDO-101); GPX-150; Doxorubicin analog (cancer), Coronado; 5-imino-13-deoxy-doxorubicin
DMHNIGB	CP	Gem Pharmaceuticals LLC
DMHNIGB	DE	Breast cancer; Soft tissue sarcoma

DMMZQ7V	ID	DMMZQ7V
DMMZQ7V	DN	Granotapide
DMMZQ7V	HS	Phase 2
DMMZQ7V	SN	JTT-130
DMMZQ7V	CP	Japan Tobacco Inc
DMMZQ7V	DT	Small molecular drug
DMMZQ7V	PC	11607299
DMMZQ7V	MW	718.7
DMMZQ7V	FM	C39H37F3N2O8
DMMZQ7V	IC	InChI=1S/C39H37F3N2O8/c1-5-50-36(48)38(37(49)51-6-2,27-12-8-7-9-13-27)24-52-33(45)23-25-16-21-32(31(22-25)35(47)44(3)4)43-34(46)30-15-11-10-14-29(30)26-17-19-28(20-18-26)39(40,41)42/h7-22H,5-6,23-24H2,1-4H3,(H,43,46)
DMMZQ7V	CS	CCOC(=O)C(COC(=O)CC1=CC(=C(C=C1)NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)C(=O)N(C)C)(C4=CC=CC=C4)C(=O)OCC
DMMZQ7V	IK	FPUQGCOBYOXAED-UHFFFAOYSA-N
DMMZQ7V	IU	diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate
DMMZQ7V	CA	CAS 594842-13-4
DMMZQ7V	DE	Hyperlipidaemia

DMWXJSZ	ID	DMWXJSZ
DMWXJSZ	DN	GRC-15300
DMWXJSZ	HS	Phase 2
DMWXJSZ	CP	Glenmark Pharmaceuticals Ltd
DMWXJSZ	DE	Pain

DM9QF65	ID	DM9QF65
DM9QF65	DN	GR-MD-02
DM9QF65	HS	Phase 2
DM9QF65	SN	Belapectin
DM9QF65	CP	Galectin therapeutics
DM9QF65	DT	Protein
DM9QF65	DE	Melanoma; Plaque psoriasis; Non-alcoholic steatohepatitis; Hypertension

DMAHOEP	ID	DMAHOEP
DMAHOEP	DN	GRNVAC1
DMAHOEP	HS	Phase 2
DMAHOEP	CP	Argos Therapeutics
DMAHOEP	DT	Vaccine
DMAHOEP	DE	Acute myeloid leukaemia

DMHQV6R	ID	DMHQV6R
DMHQV6R	DN	GS-4059
DMHQV6R	HS	Phase 2
DMHQV6R	SN	tirabrutinib; Tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno
DMHQV6R	CP	Gilead Sciences Foster City, CA
DMHQV6R	PC	54755438
DMHQV6R	MW	454.5
DMHQV6R	FM	C25H22N6O3
DMHQV6R	IC	InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)/t18-/m1/s1
DMHQV6R	CS	CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
DMHQV6R	IK	SEJLPXCPMNSRAM-GOSISDBHSA-N
DMHQV6R	IU	6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one
DMHQV6R	CA	CAS 1351636-18-4
DMHQV6R	DE	B-cell lymphoma; Rheumatoid arthritis

DMBDFN7	ID	DMBDFN7
DMBDFN7	DN	GS-4977
DMBDFN7	HS	Phase 2
DMBDFN7	CP	Gilead sciences
DMBDFN7	DE	Diabetic nephropathy

DMNABMU	ID	DMNABMU
DMNABMU	DN	GS-4997
DMNABMU	HS	Phase 2
DMNABMU	PC	71245288
DMNABMU	MW	445.5
DMNABMU	FM	C24H24FN7O
DMNABMU	IC	InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)
DMNABMU	CS	CC1=CC(=C(C=C1N2C=C(N=C2)C3CC3)C(=O)NC4=CC=CC(=N4)C5=NN=CN5C(C)C)F
DMNABMU	IK	YIDDLAAKOYYGJG-UHFFFAOYSA-N
DMNABMU	IU	5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-N-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide
DMNABMU	CA	CAS 1448428-04-3
DMNABMU	DE	Diabetic nephropathy; Pulmonary arterial hypertension

DMDAHL6	ID	DMDAHL6
DMDAHL6	DN	GS-5806
DMDAHL6	HS	Phase 2
DMDAHL6	CP	GILEAD
DMDAHL6	DT	Small molecular drug
DMDAHL6	PC	58029842
DMDAHL6	MW	532.1
DMDAHL6	FM	C24H30ClN7O3S
DMDAHL6	IC	InChI=1S/C24H30ClN7O3S/c1-15-13-32-22(27-23(15)30-10-8-17(26)14-30)12-20(28-32)21-5-3-4-9-31(21)24(33)18-11-16(25)6-7-19(18)29-36(2,34)35/h6-7,11-13,17,21,29H,3-5,8-10,14,26H2,1-2H3/t17-,21-/m0/s1
DMDAHL6	CS	CC1=CN2C(=CC(=N2)[C@@H]3CCCCN3C(=O)C4=C(C=CC(=C4)Cl)NS(=O)(=O)C)N=C1N5CC[C@@H](C5)N
DMDAHL6	IK	GOFXWTVKPWJNGD-UWJYYQICSA-N
DMDAHL6	IU	N-[2-[(2S)-2-[5-[(3S)-3-aminopyrrolidin-1-yl]-6-methylpyrazolo[1,5-a]pyrimidin-2-yl]piperidine-1-carbonyl]-4-chlorophenyl]methanesulfonamide
DMDAHL6	CA	CAS 1353625-73-6
DMDAHL6	DE	Respiratory syncytial virus infection

DMSL3DX	ID	DMSL3DX
DMSL3DX	DN	GS-5885
DMSL3DX	HS	Phase 2
DMSL3DX	SN	Ledipasvir; 1256388-51-8; GS-5885; UNII-013TE6E4WV; GS5885; GS 5885; WHO 9796; Ledipasvir (GS5885); 013TE6E4WV; CHEBI:85089; methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Ledipasvir [USAN:INN]; Ledipasvir (USAN); SCHEMBL2706494; SCHEMBL15116943; CHEMBL2374220; EX-A411; DTXSID90154829; MolPort-039-138-665
DMSL3DX	CP	Gilead Sciences Inc
DMSL3DX	DT	Small molecular drug
DMSL3DX	PC	67505836
DMSL3DX	MW	889
DMSL3DX	FM	C49H54F2N8O6
DMSL3DX	IC	InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1
DMSL3DX	CS	CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMSL3DX	IK	VRTWBAAJJOHBQU-KMWAZVGDSA-N
DMSL3DX	IU	methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMSL3DX	CA	CAS 1256388-51-8
DMSL3DX	CB	CHEBI:85089
DMSL3DX	DE	Hepatitis C virus infection

DMV7ZU0	ID	DMV7ZU0
DMV7ZU0	DN	GS-6624
DMV7ZU0	HS	Phase 2
DMV7ZU0	CP	Gilead Sciences
DMV7ZU0	DT	Antibody
DMV7ZU0	DE	Colorectal cancer

DMCZH5B	ID	DMCZH5B
DMCZH5B	DN	GS-9256
DMCZH5B	HS	Phase 2
DMCZH5B	SN	GS-9256; UNII-8V42Y78HRU; 1001094-46-7; GS 9256; 8V42Y78HRU; [[8-chloro-2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy-(cyclopentoxycarbonylamino)-dioxo-[ ]yl]-[(2,6-difluorophenyl)methyl]phosphinic acid; GS9256; SCHEMBL9987287; CHEMBL1956820; DTXSID70142946; DB12876
DMCZH5B	CP	Gilead
DMCZH5B	DT	Small molecular drug
DMCZH5B	PC	24823649
DMCZH5B	MW	957.5
DMCZH5B	FM	C46H56ClF2N6O8PS
DMCZH5B	IC	InChI=1S/C46H56ClF2N6O8PS/c1-26(2)50-44-52-36(25-65-44)35-21-39(30-18-19-38(61-3)40(47)41(30)51-35)62-29-20-37-42(56)54-46(64(59,60)24-31-32(48)15-11-16-33(31)49)22-27(46)12-7-5-4-6-8-17-34(43(57)55(37)23-29)53-45(58)63-28-13-9-10-14-28/h11,15-16,18-19,21,25-29,34,37H,4-10,12-14,17,20,22-24H2,1-3H3,(H,50,52)(H,53,58)(H,54,56)(H,59,60)/t27-,29-,34+,37+,46+/m1/s1
DMCZH5B	CS	CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Cl)OC)C(=C2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6CCCCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)P(=O)(CC8=C(C=CC=C8F)F)O
DMCZH5B	IK	RFGUWOCFYCYEDM-ZOMNBDOOSA-N
DMCZH5B	IU	[(1S,4S,6R,14S,18R)-18-[8-chloro-7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-14-(cyclopentyloxycarbonylamino)-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadecan-4-yl]-[(2,6-difluorophenyl)methyl]phosphinic acid
DMCZH5B	CA	CAS 1001094-46-7
DMCZH5B	DE	Hepatitis C virus infection

DMF910Q	ID	DMF910Q
DMF910Q	DN	GS-9451
DMF910Q	HS	Phase 2
DMF910Q	SN	Vedroprevir; GS-9451; 1098189-15-1; UNII-KGD958X2B9; KGD958X2B9; CHEMBL2013174; Cyclopropanecarboxylic acid, N-[[(1a,3b,5a)-bicyclo[3.1.0]hex-3-yloxy]carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-chloro-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-7-[2-(4-morpholinyl)ethoxy]-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethyl-, (1R,2R)-; 1310824-24-8; Vedroprevir [USAN:INN]; GS 9451; GS9451; Vedroprevir (USAN); SCHEMBL10082460; SCHEMBL16241357; BDBM50379653; SB16765; DB12037; D10408
DMF910Q	CP	GILEAD
DMF910Q	DT	Small molecular drug
DMF910Q	PC	25167947
DMF910Q	MW	910.5
DMF910Q	FM	C45H60ClN7O9S
DMF910Q	IC	InChI=1S/C45H60ClN7O9S/c1-7-27-21-45(27,41(56)57)51-39(54)33-19-29(22-53(33)40(55)38(44(4,5)6)50-43(58)62-28-17-25-16-26(25)18-28)61-35-20-31(32-23-63-42(49-32)47-24(2)3)48-37-30(35)8-9-34(36(37)46)60-15-12-52-10-13-59-14-11-52/h8-9,20,23-29,33,38H,7,10-19,21-22H2,1-6H3,(H,47,49)(H,50,58)(H,51,54)(H,56,57)/t25-,26+,27-,28?,29-,33+,38-,45-/m1/s1
DMF910Q	CS	CC[C@@H]1C[C@@]1(C(=O)O)NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](C(C)(C)C)NC(=O)OC3C[C@H]4C[C@H]4C3)OC5=CC(=NC6=C5C=CC(=C6Cl)OCCN7CCOCC7)C8=CSC(=N8)NC(C)C
DMF910Q	IK	OTXAMWFYPMNDME-OPUYQWCOSA-N
DMF910Q	IU	(1R,2R)-1-[[(2S,4R)-1-[(2S)-2-[[(1S,5R)-3-bicyclo[3.1.0]hexanyl]oxycarbonylamino]-3,3-dimethylbutanoyl]-4-[8-chloro-7-(2-morpholin-4-ylethoxy)-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxypyrrolidine-2-carbonyl]amino]-2-ethylcyclopropane-1-carboxylic acid
DMF910Q	CA	CAS 1098189-15-1
DMF910Q	DE	Chronic HCV-1 infection

DMG5C8D	ID	DMG5C8D
DMG5C8D	DN	GS-9620
DMG5C8D	HS	Phase 2
DMG5C8D	SN	GS-9620; 1228585-88-3; Vesatolimod; GS9620; UNII-O8M467C50G; GS 9620; CHEMBL2424780; O8M467C50G; 8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one; 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; 4-Amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one; 4-azanyl-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; Vesatolimod [INN]; Vesatolimod [USAN:INN]; Vesatolimod (USAN/INN); SCHEMBL10083191
DMG5C8D	CP	GILEAD
DMG5C8D	DT	Small molecular drug
DMG5C8D	PC	46241268
DMG5C8D	MW	410.5
DMG5C8D	FM	C22H30N6O2
DMG5C8D	IC	InChI=1S/C22H30N6O2/c1-2-3-11-30-22-25-20(23)19-21(26-22)28(15-18(29)24-19)14-17-8-6-7-16(12-17)13-27-9-4-5-10-27/h6-8,12H,2-5,9-11,13-15H2,1H3,(H,24,29)(H2,23,25,26)
DMG5C8D	CS	CCCCOC1=NC(=C2C(=N1)N(CC(=O)N2)CC3=CC=CC(=C3)CN4CCCC4)N
DMG5C8D	IK	VFOKSTCIRGDTBR-UHFFFAOYSA-N
DMG5C8D	IU	4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one
DMG5C8D	CA	CAS 1228585-88-3
DMG5C8D	DE	Hepatitis B virus infection; Human immunodeficiency virus infection

DMYU6P5	ID	DMYU6P5
DMYU6P5	DN	GS-9857
DMYU6P5	HS	Phase 2
DMYU6P5	DT	Small molecular drug
DMYU6P5	PC	89921642
DMYU6P5	MW	868.9
DMYU6P5	FM	C40H52F4N6O9S
DMYU6P5	IC	InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
DMYU6P5	CS	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C
DMYU6P5	IK	MZBLZLWXUBZHSL-FZNJKFJKSA-N
DMYU6P5	IU	(1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DMYU6P5	CA	CAS 1535212-07-7
DMYU6P5	DE	Hepatitis C virus infection

DM9Q2B6	ID	DM9Q2B6
DM9Q2B6	DN	GS-9876
DM9Q2B6	HS	Phase 2
DM9Q2B6	SN	XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr
DM9Q2B6	CP	Gilead Sciences Foster City, CA
DM9Q2B6	PC	118161062
DM9Q2B6	MW	443.5
DM9Q2B6	FM	C23H25N9O
DM9Q2B6	IC	InChI=1S/C23H25N9O/c24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18/h1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29)
DM9Q2B6	CS	C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N
DM9Q2B6	IK	XCIGZBVOUQVIPI-UHFFFAOYSA-N
DM9Q2B6	IU	6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine
DM9Q2B6	CA	CAS 1800046-95-0
DM9Q2B6	DE	Cutaneous lupus erythematosus; Rheumatoid arthritis

DMKWCTR	ID	DMKWCTR
DMKWCTR	DN	GS-9973
DMKWCTR	HS	Phase 2
DMKWCTR	SN	Entospletinib; 1229208-44-9; GS-9973; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; GS-9973; Entospletinib; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385
DMKWCTR	CP	Gilead Sciences
DMKWCTR	DT	Small molecular drug
DMKWCTR	PC	59473233
DMKWCTR	MW	411.5
DMKWCTR	FM	C23H21N7O
DMKWCTR	IC	InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
DMKWCTR	CS	C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6
DMKWCTR	IK	XSMSNFMDVXXHGJ-UHFFFAOYSA-N
DMKWCTR	IU	6-(1H-indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
DMKWCTR	CA	CAS 1229208-44-9
DMKWCTR	DE	B-cell lymphoma; Acute myeloid leukaemia; Haematological malignancy

DMQGPLO	ID	DMQGPLO
DMQGPLO	DN	GSK-1070806
DMQGPLO	HS	Phase 2
DMQGPLO	SN	Anti-IL-18 monoclonal antibody (intravenous, inflammatory bowel disease), GSK
DMQGPLO	CP	GlaxoSmithKline
DMQGPLO	DT	Antibody
DMQGPLO	DE	Type-2 diabetes

DMDMXKQ	ID	DMDMXKQ
DMDMXKQ	DN	GSK1292263
DMDMXKQ	HS	Phase 2
DMDMXKQ	CP	GSK
DMDMXKQ	DT	Small molecular drug
DMDMXKQ	PC	24996872
DMDMXKQ	MW	456.6
DMDMXKQ	FM	C23H28N4O4S
DMDMXKQ	IC	InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3
DMDMXKQ	CS	CC(C)C1=NOC(=N1)N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(=O)(=O)C
DMDMXKQ	IK	AYJRTVVIBJSSKN-UHFFFAOYSA-N
DMDMXKQ	IU	5-[4-[[6-(4-methylsulfonylphenyl)pyridin-3-yl]oxymethyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole
DMDMXKQ	CA	CAS 1032823-75-8
DMDMXKQ	DE	Type-2 diabetes; Gastric adenocarcinoma

DM1EPMF	ID	DM1EPMF
DM1EPMF	DN	GSK1322322
DM1EPMF	HS	Phase 2
DM1EPMF	SN	GSK-1322322
DM1EPMF	CP	GlaxoSmithKline
DM1EPMF	PC	52918384
DM1EPMF	MW	479.5
DM1EPMF	FM	C22H34FN7O4
DM1EPMF	IC	InChI=1S/C22H34FN7O4/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26)/t17-,18+/m1/s1
DM1EPMF	CS	CC1=NC(=C(C(=N1)N2CCN3CCOC[C@@H]3C2)F)NNC(=O)[C@H](CC4CCCC4)CN(C=O)O
DM1EPMF	IK	SWHNZGMQMGFQGW-MSOLQXFVSA-N
DM1EPMF	IU	N-[(2R)-3-[2-[6-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-5-fluoro-2-methylpyrimidin-4-yl]hydrazinyl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
DM1EPMF	CA	CAS 1152107-25-9
DM1EPMF	DE	Bacterial infection

DMA6RBF	ID	DMA6RBF
DMA6RBF	DN	GSK1325756
DMA6RBF	HS	Phase 2
DMA6RBF	SN	Danirixin; 954126-98-8; GSK1325756; UNII-R318PGH5VP; GSK-1325756B; R318PGH5VP; GSK1325756B; Danirixin [USAN:INN]; GSK-1325756; GSK 1325756; Danirixin (USAN/INN); Danirixin(GSK1325756); GTPL8500; SCHEMBL1198688; CHEMBL3039531; MolPort-044-561-791; EX-A1178; ZINC95627831; AKOS030527036; DB11922; CS-5465; 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea; HY-19768; D10387; (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea
DMA6RBF	CP	GlaxoSmithKline
DMA6RBF	DT	Small molecular drug
DMA6RBF	PC	24780598
DMA6RBF	MW	441.9
DMA6RBF	FM	C19H21ClFN3O4S
DMA6RBF	IC	InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1
DMA6RBF	CS	CC1=C(C=CC=C1F)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)[C@H]3CCCNC3)O
DMA6RBF	IK	NGYNBSHYFOFVLS-LBPRGKRZSA-N
DMA6RBF	IU	1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea
DMA6RBF	CA	CAS 954126-98-8
DMA6RBF	DE	Chronic obstructive pulmonary disease

DM6HBGN	ID	DM6HBGN
DM6HBGN	DN	GSK-1399686
DM6HBGN	HS	Phase 2
DM6HBGN	SN	1399686
DM6HBGN	CP	GlaxoSmithKline plc
DM6HBGN	DE	Inflammatory bowel disease

DMZHB37	ID	DMZHB37
DMZHB37	DN	GSK2110183
DMZHB37	HS	Phase 2
DMZHB37	CP	GlaxoSmithKline
DMZHB37	DT	Small molecular drug
DMZHB37	PC	46843057
DMZHB37	MW	427.3
DMZHB37	FM	C18H17Cl2FN4OS
DMZHB37	IC	InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1
DMZHB37	CS	CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl
DMZHB37	IK	AFJRDFWMXUECEW-LBPRGKRZSA-N
DMZHB37	IU	N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide
DMZHB37	CA	CAS 1047644-62-1
DMZHB37	CB	CHEBI:131168
DMZHB37	DE	Multiple myeloma; leukaemia; Solid tumour/cancer

DMSHE70	ID	DMSHE70
DMSHE70	DN	GSK2141795
DMSHE70	HS	Phase 2
DMSHE70	SN	Uprosertib; 1047634-65-0; GSK2141795; UNII-ZXM835LQ5E; Uprosertib (GSK2141795); GSK2141795C; ZXM835LQ5E; GSK795; GSK-2141795; 2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-;2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; Uprosertib [USAN:INN]; Uprosertib (USAN/INN); Uprosertib, GSK2141795; SCHEMBL168584; GTPL7902; CHEMBL3137336; MolPort-044-560-307; AXTAPYRUEKNRBA-JTQLQIEISA-N
DMSHE70	CP	GlaxoSmithKline
DMSHE70	DT	Small molecular drug
DMSHE70	PC	51042438
DMSHE70	MW	429.2
DMSHE70	FM	C18H16Cl2F2N4O2
DMSHE70	IC	InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1
DMSHE70	CS	CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)N[C@@H](CC3=CC(=C(C=C3)F)F)CN)Cl
DMSHE70	IK	AXTAPYRUEKNRBA-JTQLQIEISA-N
DMSHE70	IU	N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide
DMSHE70	CA	CAS 1047634-65-0
DMSHE70	DE	Lymphoma; Colorectal cancer

DMBWPZJ	ID	DMBWPZJ
DMBWPZJ	DN	GSK2245035
DMBWPZJ	HS	Phase 2
DMBWPZJ	SN	GSK-2245035
DMBWPZJ	CP	GlaxoSmithKline
DMBWPZJ	DT	Small molecular drug
DMBWPZJ	PC	44623937
DMBWPZJ	MW	390.5
DMBWPZJ	FM	C20H34N6O2
DMBWPZJ	IC	InChI=1S/C20H34N6O2/c1-3-10-15(2)28-19-23-17(21)16-18(24-19)26(20(27)22-16)14-9-5-8-13-25-11-6-4-7-12-25/h15H,3-14H2,1-2H3,(H,22,27)(H2,21,23,24)/t15-/m0/s1
DMBWPZJ	CS	CCC[C@H](C)OC1=NC(=C2C(=N1)N(C(=O)N2)CCCCCN3CCCCC3)N
DMBWPZJ	IK	LFMPVTVPXHNXOT-HNNXBMFYSA-N
DMBWPZJ	IU	6-amino-2-[(2S)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7H-purin-8-one
DMBWPZJ	CA	CAS 1207629-49-9
DMBWPZJ	DE	Asthma

DMG7YQL	ID	DMG7YQL
DMG7YQL	DN	GSK2245840
DMG7YQL	HS	Phase 2
DMG7YQL	SN	Gepirone hydrochloride; GEPIRONE HYDROCHLORIDE; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,
DMG7YQL	CP	GSK
DMG7YQL	DT	Small molecular drug
DMG7YQL	PC	25108829
DMG7YQL	MW	516.6
DMG7YQL	FM	C26H24N6O2S2
DMG7YQL	IC	InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
DMG7YQL	CS	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6
DMG7YQL	IK	LAMQVIQMVKWXOC-UHFFFAOYSA-N
DMG7YQL	IU	4-methyl-N-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide
DMG7YQL	CA	CAS 1093403-33-8
DMG7YQL	DE	Chronic obstructive pulmonary disease

DMLFI7Q	ID	DMLFI7Q
DMLFI7Q	DN	GSK-2251052
DMLFI7Q	HS	Phase 2
DMLFI7Q	SN	ABX; AN-3365; GSK '052; Boron-based LeuRS inhibitors (Gram-negative bacterial infection), Anacor/GSK; Boron-based leucyl-tRNA synthetase inhibitors (bacterial infection), Anacor/GSK
DMLFI7Q	CP	Anacor Pharmaceuticals Inc
DMLFI7Q	DT	Small molecular drug
DMLFI7Q	PC	46836890
DMLFI7Q	MW	237.06
DMLFI7Q	FM	C11H16BNO4
DMLFI7Q	IC	InChI=1S/C11H16BNO4/c13-7-10-8-3-1-4-9(16-6-2-5-14)11(8)12(15)17-10/h1,3-4,10,14-15H,2,5-7,13H2/t10-/m1/s1
DMLFI7Q	CS	B1(C2=C(C=CC=C2OCCCO)[C@H](O1)CN)O
DMLFI7Q	IK	FXQIIDINBDJDKL-SNVBAGLBSA-N
DMLFI7Q	IU	3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol
DMLFI7Q	CA	CAS 1093643-37-8
DMLFI7Q	DE	Urinary tract infection

DMIN0SV	ID	DMIN0SV
DMIN0SV	DN	GSK2269557
DMIN0SV	HS	Phase 2
DMIN0SV	CP	Glaxosmithkline
DMIN0SV	PC	49784002
DMIN0SV	MW	440.5
DMIN0SV	FM	C26H28N6O
DMIN0SV	IC	InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)
DMIN0SV	CS	CC(C)N1CCN(CC1)CC2=CN=C(O2)C3=C4C=NNC4=CC(=C3)C5=C6C=CNC6=CC=C5
DMIN0SV	IK	MCIDWGZGWVSZMK-UHFFFAOYSA-N
DMIN0SV	IU	2-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole
DMIN0SV	CA	CAS 1254036-71-9
DMIN0SV	DE	Asthma

DM4BTH8	ID	DM4BTH8
DM4BTH8	DN	GSK2330672
DM4BTH8	HS	Phase 2
DM4BTH8	CP	GlaxoSmithKline
DM4BTH8	PC	53492727
DM4BTH8	MW	546.7
DM4BTH8	FM	C28H38N2O7S
DM4BTH8	IC	InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1
DM4BTH8	CS	CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC
DM4BTH8	IK	CZGVOBIGEBDYTP-VSGBNLITSA-N
DM4BTH8	IU	3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-yl]methylamino]pentanedioic acid
DM4BTH8	CA	CAS 1345982-69-5
DM4BTH8	DE	Type-2 diabetes; Pruritus

DMB0CXT	ID	DMB0CXT
DMB0CXT	DN	GSK2330811
DMB0CXT	HS	Phase 2
DMB0CXT	CP	GlaxoSmithKline Research Triangle Park, NC
DMB0CXT	DE	Systemic sclerosis; Crohn disease

DMXUCG3	ID	DMXUCG3
DMXUCG3	DN	GSK233705
DMXUCG3	HS	Phase 2
DMXUCG3	CP	GlaxoSmithKline
DMXUCG3	DE	Chronic obstructive pulmonary disease

DMRA3T2	ID	DMRA3T2
DMRA3T2	DN	GSK2339345
DMRA3T2	HS	Phase 2
DMRA3T2	SN	GSK-2339345
DMRA3T2	CP	GlaxoSmithKline
DMRA3T2	DE	Cough

DMBJMZC	ID	DMBJMZC
DMBJMZC	DN	GSK239512
DMBJMZC	HS	Phase 2
DMBJMZC	SN	720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; GSK239512; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K
DMBJMZC	CP	GSK
DMBJMZC	DT	Small molecular drug
DMBJMZC	PC	9976892
DMBJMZC	MW	377.5
DMBJMZC	FM	C23H27N3O2
DMBJMZC	IC	InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2
DMBJMZC	CS	C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O
DMBJMZC	IK	YFRBKEVUUCQYOW-UHFFFAOYSA-N
DMBJMZC	IU	1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one
DMBJMZC	CA	CAS 720691-69-0
DMBJMZC	DE	Dementia; Alzheimer disease

DMFAU3Z	ID	DMFAU3Z
DMFAU3Z	DN	GSK249320
DMFAU3Z	HS	Phase 2
DMFAU3Z	CP	GlaxoSmithKline
DMFAU3Z	DT	Antibody
DMFAU3Z	DE	Stroke

DMMAIY2	ID	DMMAIY2
DMMAIY2	DN	GSK-256073
DMMAIY2	HS	Phase 2
DMMAIY2	SN	GPCR agonists (hyperlipidemia), GSK; GSK-256073-A; HM74A receptor agonists (hyperlipidemia), GSK; G protein-coupled receptor agonists (hyperlipidemia), GSK
DMMAIY2	CP	GlaxoSmithKline plc
DMMAIY2	DT	Small molecular drug
DMMAIY2	PC	46215799
DMMAIY2	MW	256.69
DMMAIY2	FM	C10H13ClN4O2
DMMAIY2	IC	InChI=1S/C10H13ClN4O2/c1-2-3-4-5-15-7-6(12-9(11)13-7)8(16)14-10(15)17/h2-5H2,1H3,(H,12,13)(H,14,16,17)
DMMAIY2	CS	CCCCCN1C2=C(C(=O)NC1=O)NC(=N2)Cl
DMMAIY2	IK	CGAMDQCXAAOFSR-UHFFFAOYSA-N
DMMAIY2	IU	8-chloro-3-pentyl-7H-purine-2,6-dione
DMMAIY2	CA	CAS 862892-90-8
DMMAIY2	DE	Hyperlipidaemia

DMA2IXQ	ID	DMA2IXQ
DMA2IXQ	DN	GSK2586184
DMA2IXQ	HS	Phase 2
DMA2IXQ	SN	GSK-2586184
DMA2IXQ	CP	GlaxoSmithKline
DMA2IXQ	PC	44603362
DMA2IXQ	MW	389.4
DMA2IXQ	FM	C22H23N5O2
DMA2IXQ	IC	InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)
DMA2IXQ	CS	CC1(CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(=NN43)NC(=O)C5CC5)C
DMA2IXQ	IK	MPYACSQFXVMWNO-UHFFFAOYSA-N
DMA2IXQ	IU	N-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
DMA2IXQ	CA	CAS 1206163-45-2
DMA2IXQ	DE	Arthritis; Systemic lupus erythematosus

DMU5EVR	ID	DMU5EVR
DMU5EVR	DN	GSK2586881
DMU5EVR	HS	Phase 2
DMU5EVR	SN	GSK-2586881
DMU5EVR	CP	GlaxoSmithKline
DMU5EVR	DE	Acute lung injury; Pulmonary arterial hypertension

DM7V96W	ID	DM7V96W
DM7V96W	DN	GSK2798745
DM7V96W	HS	Phase 2
DM7V96W	CP	GlaxoSmithKline Research Triangle Park, NC
DM7V96W	DE	Heart failure

DMCIGRW	ID	DMCIGRW
DMCIGRW	DN	GSK2838232
DMCIGRW	HS	Phase 2
DMCIGRW	CP	GlaxoSmithKline
DMCIGRW	DT	Small molecular drug
DMCIGRW	DE	Human immunodeficiency virus-1 infection

DMT5YK7	ID	DMT5YK7
DMT5YK7	DN	GSK2890457
DMT5YK7	HS	Phase 2
DMT5YK7	SN	GSK-2890457
DMT5YK7	CP	GlaxoSmithKline
DMT5YK7	DE	Obesity

DM25YLM	ID	DM25YLM
DM25YLM	DN	GSK2981278
DM25YLM	HS	Phase 2
DM25YLM	SN	ROR gama modulator 1; 1474110-21-8; UNII-L49V5G013I; L49V5G013I; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide; GTPL9661; SCHEMBL15352875; LZLBRISQTJVZNP-UHFFFAOYSA-N; MolPort-044-561-790; EX-A1179; ZINC142250256; AKOS030526564; CS-5449; GSK-2981278; HY-19770; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide; Benzenesulfonamide, N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-((tetrahydro-2H-pyran-4-yl)
DM25YLM	CP	GlaxoSmithKline Research Triangle Park, NC
DM25YLM	PC	89875987
DM25YLM	MW	461.6
DM25YLM	FM	C25H35NO5S
DM25YLM	IC	InChI=1S/C25H35NO5S/c1-4-20-5-7-23(8-6-20)26(16-19(2)3)32(28,29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10,15,19,21,27H,4,11-14,16-18H2,1-3H3
DM25YLM	CS	CCC1=CC=C(C=C1)N(CC(C)C)S(=O)(=O)C2=CC(=C(C=C2)OCC3CCOCC3)CO
DM25YLM	IK	LZLBRISQTJVZNP-UHFFFAOYSA-N
DM25YLM	IU	N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide
DM25YLM	CA	CAS 1474110-21-8
DM25YLM	DE	Plaque psoriasis

DM7HNFV	ID	DM7HNFV
DM7HNFV	DN	GSK2982772
DM7HNFV	HS	Phase 2
DM7HNFV	SN	LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr
DM7HNFV	CP	GlaxoSmithKline Research Triangle Park, NC
DM7HNFV	PC	77108121
DM7HNFV	MW	377.4
DM7HNFV	FM	C20H19N5O3
DM7HNFV	IC	InChI=1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(23-24-18)11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24)/t14-/m0/s1
DM7HNFV	CS	CN1C2=CC=CC=C2OC[C@@H](C1=O)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4
DM7HNFV	IK	LYPAFUINURXJSG-AWEZNQCLSA-N
DM7HNFV	IU	5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide
DM7HNFV	CA	CAS 1622848-92-3
DM7HNFV	DE	Plaque psoriasis; Psoriasis vulgaris; Rheumatoid arthritis; Ulcerative colitis

DMCDAVK	ID	DMCDAVK
DMCDAVK	DN	GSK3036656
DMCDAVK	HS	Phase 2
DMCDAVK	SN	GSK656 HCl; GSK656; 2131798-13-3; UNII-P83HS633ZK; P83HS633ZK; CHEMBL4082159; 2131798-13-3 (HCl); GSK-656; GSK-070; BCP29367; EX-A3128; BDBM50241779; GSK-3036656; GSK3036656; GSK070 hydrochloride; HY-107775; CS-0030140; (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride; (S)3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)ol hydrochloride; (S)a?-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)a'ol hydrochloride; Ethanol, 2-(((3S)-3-(aminomethyl)-4-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl)oxy)-, hydrochloride (1:1)
DMCDAVK	CP	GlaxoSmithKline
DMCDAVK	DT	Small molecular drug
DMCDAVK	PC	134691736
DMCDAVK	MW	293.94
DMCDAVK	FM	C10H14BCl2NO4
DMCDAVK	IC	InChI=1S/C10H13BClNO4.ClH/c12-6-1-2-7(16-4-3-14)10-9(6)8(5-13)17-11(10)15;/h1-2,8,14-15H,3-5,13H2;1H/t8-;/m1./s1
DMCDAVK	CS	B1(C2=C(C=CC(=C2[C@H](O1)CN)Cl)OCCO)O.Cl
DMCDAVK	IK	FUOKBESTQMGROA-DDWIOCJRSA-N
DMCDAVK	IU	2-[[(3S)-3-(aminomethyl)-4-chloro-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]ethanol;hydrochloride
DMCDAVK	CA	CAS 2131798-13-3
DMCDAVK	DE	Tuberculosis

DMEXKF4	ID	DMEXKF4
DMEXKF4	DN	GSK3196165
DMEXKF4	HS	Phase 2
DMEXKF4	CP	GlaxoSmithKline Research Triangle Park, NC
DMEXKF4	DE	Rheumatoid arthritis

DMPBK8N	ID	DMPBK8N
DMPBK8N	DN	GSK3228836
DMPBK8N	HS	Phase 2
DMPBK8N	SN	IONIS-HBVRX; GSK'836
DMPBK8N	CP	GlaxoSmithKline
DMPBK8N	DT	Antisense oligonucleotide
DMPBK8N	DE	Hepatitis B

DMJRD7A	ID	DMJRD7A
DMJRD7A	DN	GSK3326595
DMJRD7A	HS	Phase 2
DMJRD7A	SN	JLCCNYVTIWRPIZ-NRFANRHFSA-N; 1616392-22-3; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide; SCHEMBL15825290; MolPort-044-813-754; BDBM178166; AKOS030528008; ZINC220119494; CS-6451; AS-53150; HY-101563; GSK3326595(EPZ015938); US9675614, 208; (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
DMJRD7A	CP	GlaxoSmithKline Research Triangle Park, NC
DMJRD7A	PC	90241742
DMJRD7A	MW	452.5
DMJRD7A	FM	C24H32N6O3
DMJRD7A	IC	InChI=1S/C24H32N6O3/c1-17(31)30-10-7-20(8-11-30)28-23-12-22(26-16-27-23)24(33)25-13-21(32)15-29-9-6-18-4-2-3-5-19(18)14-29/h2-5,12,16,20-21,32H,6-11,13-15H2,1H3,(H,25,33)(H,26,27,28)/t21-/m0/s1
DMJRD7A	CS	CC(=O)N1CCC(CC1)NC2=NC=NC(=C2)C(=O)NC[C@@H](CN3CCC4=CC=CC=C4C3)O
DMJRD7A	IK	JLCCNYVTIWRPIZ-NRFANRHFSA-N
DMJRD7A	IU	6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide
DMJRD7A	CA	CAS 1616392-22-3
DMJRD7A	DE	Non-hodgkin lymphoma; Solid tumour/cancer; Breast cancer

DMO5JS3	ID	DMO5JS3
DMO5JS3	DN	GSK3389404
DMO5JS3	HS	Phase 2
DMO5JS3	SN	IONIS-HBV-LRX
DMO5JS3	CP	GlaxoSmithKline
DMO5JS3	DT	Antisense oligonucleotide
DMO5JS3	DE	Hepatitis B

DMMOWT9	ID	DMMOWT9
DMMOWT9	DN	GSK3640254
DMMOWT9	HS	Phase 2
DMMOWT9	SN	GSK'254
DMMOWT9	CP	ViiV Healthcare
DMMOWT9	DE	Human immunodeficiency virus infection

DMV3TO4	ID	DMV3TO4
DMV3TO4	DN	GSK3810109
DMV3TO4	HS	Phase 2
DMV3TO4	CP	ViiV Healthcare
DMV3TO4	DT	Antibody
DMV3TO4	DE	Human immunodeficiency virus-1 infection

DMV6SNU	ID	DMV6SNU
DMV6SNU	DN	GSK4069889
DMV6SNU	HS	Phase 2
DMV6SNU	SN	TSR-022
DMV6SNU	CP	AnaptysBio
DMV6SNU	DT	Antibody
DMV6SNU	DE	Non-small cell lung cancer

DM3ZL2O	ID	DM3ZL2O
DM3ZL2O	DN	GSK-557296
DM3ZL2O	HS	Phase 2
DM3ZL2O	SN	Epelsiban; Epelsiban besylate; Premature ejaculation therapeutic (oral), GlaxoSmithKline
DM3ZL2O	CP	GlaxoSmithKline plc
DM3ZL2O	DT	Small molecular drug
DM3ZL2O	PC	11634973
DM3ZL2O	MW	518.6
DM3ZL2O	FM	C30H38N4O4
DM3ZL2O	IC	InChI=1S/C30H38N4O4/c1-5-18(2)26-28(35)32-25(23-16-21-8-6-7-9-22(21)17-23)29(36)34(26)27(24-11-10-19(3)31-20(24)4)30(37)33-12-14-38-15-13-33/h6-11,18,23,25-27H,5,12-17H2,1-4H3,(H,32,35)/t18-,25+,26+,27+/m0/s1
DM3ZL2O	CS	CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(N=C(C=C2)C)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4
DM3ZL2O	IK	UWHCWRQFNKUYCG-QUZACWSFSA-N
DM3ZL2O	IU	(3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethylpyridin-3-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
DM3ZL2O	CA	CAS 872599-83-2
DM3ZL2O	DE	Premature ejaculation

DMEVARK	ID	DMEVARK
DMEVARK	DN	GSK561679
DMEVARK	HS	Phase 2
DMEVARK	SN	VERUCERFONT; 885220-61-1; GSK561679; GSK561679A; UNII-X60608B091; GSK 561679A; NBI-77860; X60608B091; GSK561679;3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine; NBI 77860; Verucerfont [USAN:INN]; GSK 561679; GSK-561679; Verucerfont (USAN/INN); Verucerfont,GSK561679; SCHEMBL205309; CHEMBL1287935; EX-A1718; BDBM50417503; ZINC34661169; SB17107; CS-8099; DB12512; KB-77609; HY-14875; AC-30339; D09695
DMEVARK	CP	GSK
DMEVARK	DT	Small molecular drug
DMEVARK	PC	11596613
DMEVARK	MW	406.5
DMEVARK	FM	C22H26N6O2
DMEVARK	IC	InChI=1S/C22H26N6O2/c1-7-18(22-24-15(5)27-30-22)25-19-11-13(3)23-21-20(14(4)26-28(19)21)17-9-8-16(29-6)10-12(17)2/h8-11,18,25H,7H2,1-6H3/t18-/m0/s1
DMEVARK	CS	CC[C@@H](C1=NC(=NO1)C)NC2=CC(=NC3=C(C(=NN23)C)C4=C(C=C(C=C4)OC)C)C
DMEVARK	IK	VKHVAUKFLBBZFJ-SFHVURJKSA-N
DMEVARK	IU	3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine
DMEVARK	CA	CAS 885220-61-1
DMEVARK	DE	Major depressive disorder; Alcohol dependence

DMGU05N	ID	DMGU05N
DMGU05N	DN	GSK598809
DMGU05N	HS	Phase 2
DMGU05N	CP	GSK
DMGU05N	PC	24743758
DMGU05N	MW	481.5
DMGU05N	FM	C22H23F4N5OS
DMGU05N	IC	InChI=1S/C22H23F4N5OS/c1-13-18(32-12-27-13)19-28-29-20(30(19)2)33-7-3-6-31-10-15-9-21(15,11-31)16-5-4-14(8-17(16)23)22(24,25)26/h4-5,8,12,15H,3,6-7,9-11H2,1-2H3
DMGU05N	CS	CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=C(C=C(C=C5)C(F)(F)F)F
DMGU05N	IK	ZKRWPAYTJMRKLJ-UHFFFAOYSA-N
DMGU05N	IU	5-[5-[3-[1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexan-3-yl]propylsulfanyl]-4-methyl-1,2,4-triazol-3-yl]-4-methyl-1,3-oxazole
DMGU05N	DE	Drug abuse

DMTW79H	ID	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	HS	Phase 2
DMTW79H	SN	4-Aminobutanoic acid; 4-aminobutyric acid; GABA; gamma-aminobutyric acid; 1956/12/2; Piperidic acid; Piperidinic acid; Aminalon; Mielogen; Gammalon; Gaballon; butanoic acid, 4-amino-; Mielomade; Gammalone; Gamarex; Gammasol; Gammar; Reanal; Immu-G; gamma-amino-n-butyric acid; gamma-Aminobutanoic acid; Butyric acid, 4-amino-; Gamastan; Gammagee; Gamulin; 4-aminobutyrate; omega-Aminobutyric acid; gamma-Aminobutyric acid; 3-Carboxypropylamine; gamma-Aminobuttersaeure; 4-amino-butanoic acid; gamma-Amino butyric acid; GAMMA-AMINO-BUTANOIC ACID
DMTW79H	CP	GSK; Tanabe
DMTW79H	DT	Small molecular drug
DMTW79H	PC	119
DMTW79H	MW	103.12
DMTW79H	FM	C4H9NO2
DMTW79H	IC	InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)
DMTW79H	CS	C(CC(=O)O)CN
DMTW79H	IK	BTCSSZJGUNDROE-UHFFFAOYSA-N
DMTW79H	IU	4-aminobutanoic acid
DMTW79H	CA	CAS 56-12-2
DMTW79H	CB	CHEBI:16865
DMTW79H	DE	Inflammatory bowel disease

DMPLKAH	ID	DMPLKAH
DMPLKAH	DN	GSK-706769
DMPLKAH	HS	Phase 2
DMPLKAH	SN	GSK-163929; GSK-929; CCR5 antagonist (HIV), GSK; CCR5 antagonist (HIV), ViiV; CCR5 chemokine antagonists (HIV-1 infection),GlaxoSmithKline
DMPLKAH	CP	GlaxoSmithKline plc
DMPLKAH	DE	Human immunodeficiency virus infection

DMIEXUM	ID	DMIEXUM
DMIEXUM	DN	GSK768974
DMIEXUM	HS	Phase 2
DMIEXUM	SN	PTH analog, GlaxoSmithKline/Unigene; Parathyroid hormone analog (oral, Enteripep), Unigene/GlaxoSmithKline
DMIEXUM	CP	Unigene Laboratories Inc
DMIEXUM	DE	Osteoporosis

DMX27Q1	ID	DMX27Q1
DMX27Q1	DN	GSK933776A
DMX27Q1	HS	Phase 2
DMX27Q1	CP	GlaxoSmithKline
DMX27Q1	DE	Macular degeneration; Alzheimer disease

DM6DKF9	ID	DM6DKF9
DM6DKF9	DN	GSK961081
DM6DKF9	HS	Phase 2
DM6DKF9	SN	CHEMBL1683934; SCHEMBL524583; NVEMUJANQDPDSC-DHUJRADRSA-N; BDBM50337878; Biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester; (R)-1-(9-(2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)piperidin-4-yl biphenyl-2-ylcarbamate
DM6DKF9	CP	GSK
DM6DKF9	DT	Small molecular drug
DM6DKF9	PC	10372836
DM6DKF9	MW	740.2
DM6DKF9	FM	C40H42ClN5O7
DM6DKF9	IC	InChI=1S/C40H42ClN5O7/c1-52-36-22-33(31(41)21-26(36)23-42-24-35(48)29-11-13-34(47)39-30(29)12-14-37(49)45-39)43-38(50)17-20-46-18-15-27(16-19-46)53-40(51)44-32-10-6-5-9-28(32)25-7-3-2-4-8-25/h2-14,21-22,27,35,42,47-48H,15-20,23-24H2,1H3,(H,43,50)(H,44,51)(H,45,49)/t35-/m0/s1
DM6DKF9	CS	COC1=CC(=C(C=C1CNC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O)Cl)NC(=O)CCN4CCC(CC4)OC(=O)NC5=CC=CC=C5C6=CC=CC=C6
DM6DKF9	IK	URWYQGVSPQJGGB-DHUJRADRSA-N
DM6DKF9	IU	[1-[3-[2-chloro-4-[[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-5-methoxyanilino]-3-oxopropyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate
DM6DKF9	CA	CAS 743461-65-6
DM6DKF9	DE	Chronic obstructive pulmonary disease

DM8N3OQ	ID	DM8N3OQ
DM8N3OQ	DN	GT-AADC
DM8N3OQ	HS	Phase 2
DM8N3OQ	CP	PTC Therapeutics
DM8N3OQ	DT	Gene therapy
DM8N3OQ	DE	Aromatic L-amino acid decarboxylase deficiency

DMN6IDO	ID	DMN6IDO
DMN6IDO	DN	GTP-010
DMN6IDO	HS	Phase 2
DMN6IDO	CP	Gastrotech Pharma
DMN6IDO	DE	Dyspepsia; Irritable bowel syndrome

DM03NQS	ID	DM03NQS
DM03NQS	DN	GTP-200
DM03NQS	HS	Phase 2
DM03NQS	DE	Solid tumour/cancer

DMEN5KA	ID	DMEN5KA
DMEN5KA	DN	GTS-21
DMEN5KA	HS	Phase 2
DMEN5KA	SN	Gts-21; DMXBA; Gts 21; DMXB-Anabaseine; GTS-21 (dihydrochloride); DMXB-A; (E)-3-((2,4-Dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-2,3'-bipyridine dihydrochloride; 2,3'-Bipyridine, 3-((2,4-dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-, dihydrochloride, (E)-; DMBX-anabaseine; DMBX-A; AC1O5PJQ; SCHEMBL2561893; SCHEMBL12274790; HY-14564A; CS-5486; SB16826; BC654014; AN-16572; GTS-21, &gt; LS-173500; 3-(2,4-Dimethoxybenzylidene)anabaseine dihydrochloride
DMEN5KA	DT	Small molecular drug
DMEN5KA	PC	5310985
DMEN5KA	MW	308.4
DMEN5KA	FM	C19H20N2O2
DMEN5KA	IC	InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+
DMEN5KA	CS	COC1=CC(=C(C=C1)/C=C/2\\CCCN=C2C3=CN=CC=C3)OC
DMEN5KA	IK	RPYWXZCFYPVCNQ-RVDMUPIBSA-N
DMEN5KA	IU	3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine
DMEN5KA	CA	CAS 148372-04-7
DMEN5KA	DE	Parkinson disease

DMDWYZS	ID	DMDWYZS
DMDWYZS	DN	GTx-758
DMDWYZS	HS	Phase 2
DMDWYZS	CP	GTx
DMDWYZS	PC	46861578
DMDWYZS	MW	341.3
DMDWYZS	FM	C19H13F2NO3
DMDWYZS	IC	InChI=1S/C19H13F2NO3/c20-13-2-4-14(5-3-13)22(15-6-8-16(23)9-7-15)19(25)12-1-10-18(24)17(21)11-12/h1-11,23-24H
DMDWYZS	CS	C1=CC(=CC=C1N(C2=CC=C(C=C2)F)C(=O)C3=CC(=C(C=C3)O)F)O
DMDWYZS	IK	FBCQEUMZZNVQKD-UHFFFAOYSA-N
DMDWYZS	IU	3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl)benzamide
DMDWYZS	CA	CAS 938067-78-8
DMDWYZS	DE	Prostate cancer

DMY53PL	ID	DMY53PL
DMY53PL	DN	GW 597599
DMY53PL	HS	Phase 2
DMY53PL	SN	Vestipitant mesylate < USAN; N-[1(R)-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-2(S)-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide methanesulfonate
DMY53PL	CP	GlaxoSmithKline
DMY53PL	DT	Small molecular drug
DMY53PL	PC	24969622
DMY53PL	MW	587.6
DMY53PL	FM	C24H28F7N3O4S
DMY53PL	IC	InChI=1S/C23H24F7N3O.CH4O3S/c1-13-8-18(24)4-5-19(13)20-12-31-6-7-33(20)21(34)32(3)14(2)15-9-16(22(25,26)27)11-17(10-15)23(28,29)30;1-5(2,3)4/h4-5,8-11,14,20,31H,6-7,12H2,1-3H3;1H3,(H,2,3,4)/t14-,20-;/m1./s1
DMY53PL	CS	CC1=C(C=CC(=C1)F)[C@H]2CNCCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F.CS(=O)(=O)O
DMY53PL	IK	BHECXGHXWKHZOY-DXPOFMJKSA-N
DMY53PL	IU	(2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide;methanesulfonic acid
DMY53PL	CA	CAS 334476-64-1
DMY53PL	DE	Mood disorder; Major depressive disorder

DMZMCB1	ID	DMZMCB1
DMZMCB1	DN	GW274150
DMZMCB1	HS	Phase 2
DMZMCB1	SN	GW274150; GW-274150; UNII-0ZZF1V8G63; 0ZZF1V8G63; CHEMBL114551; SCHEMBL120693; L-Homocysteine, S-(2-((1-iminoethyl)amino)ethyl)-; GTPL9849; ZINC2004483; BDBM50086467; AKOS030526714; DB12237; CS-5419; HY-12119; GW-274150;GW 274150; [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine; (S)-4-(2-Acetimidoylamino-ethylsulfanyl)-2-amino-butyric acid; (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid
DMZMCB1	DT	Small molecular drug
DMZMCB1	PC	9797017
DMZMCB1	MW	219.31
DMZMCB1	FM	C8H17N3O2S
DMZMCB1	IC	InChI=1S/C8H17N3O2S/c1-6(9)11-3-5-14-4-2-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1
DMZMCB1	CS	CC(=NCCSCC[C@@H](C(=O)O)N)N
DMZMCB1	IK	MOLOJNHYNHBPCW-ZETCQYMHSA-N
DMZMCB1	IU	(2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid
DMZMCB1	CA	CAS 210354-22-6
DMZMCB1	DE	Asthma

DMY3KSU	ID	DMY3KSU
DMY3KSU	DN	GW-42004
DMY3KSU	HS	Phase 2
DMY3KSU	SN	CB1/CB2 receptor antagonist (oral/capsule, obesity/type 2 diabetes/dyslipidemia), GW Pharmaceuticals
DMY3KSU	CP	GW Pharmaceuticals plc
DMY3KSU	DE	Lipid metabolism disorder

DMBX9C0	ID	DMBX9C0
DMBX9C0	DN	GW-427353
DMBX9C0	HS	Phase 2
DMBX9C0	SN	UNII-GU14FR8D4A; GU14FR8D4A; GW427353B; Solabegron hydrochloride [USAN]; Solabegron hydrochloride (USAN); GW 427353B; Solabegron Hydrochloride; Solabegron HCl; SCHEMBL565177; CHEMBL2107299; PMXCGBVBIRYFPR-FTBISJDPSA-N; BCP28076; 3'-[(2-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]biphenyl-3-carboxylic acid hydrochloride; D05879; (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-, hydrochloride
DMBX9C0	CP	GSK
DMBX9C0	DT	Small molecular drug
DMBX9C0	PC	9887812
DMBX9C0	MW	410.9
DMBX9C0	FM	C23H23ClN2O3
DMBX9C0	IC	InChI=1S/C23H23ClN2O3/c24-20-8-2-6-18(13-20)22(27)15-25-10-11-26-21-9-3-5-17(14-21)16-4-1-7-19(12-16)23(28)29/h1-9,12-14,22,25-27H,10-11,15H2,(H,28,29)/t22-/m0/s1
DMBX9C0	CS	C1=CC(=CC(=C1)C(=O)O)C2=CC(=CC=C2)NCCNC[C@@H](C3=CC(=CC=C3)Cl)O
DMBX9C0	IK	LLDXOPKUNJTIRF-QFIPXVFZSA-N
DMBX9C0	IU	3-[3-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethylamino]phenyl]benzoic acid
DMBX9C0	CA	CAS 252920-94-8
DMBX9C0	CB	CHEBI:141346
DMBX9C0	DE	Urinary incontinence

DMH0C8J	ID	DMH0C8J
DMH0C8J	DN	GW-813893
DMH0C8J	HS	Phase 2
DMH0C8J	SN	Factor Xa inhibitors, GSK; Factor Xa inhibitors, GlaxoSmithKline; 813893
DMH0C8J	CP	GlaxoSmithKline plc
DMH0C8J	PC	9911502
DMH0C8J	MW	448
DMH0C8J	FM	C17H22ClN3O5S2
DMH0C8J	IC	InChI=1S/C17H22ClN3O5S2/c1-12(16(22)20-7-9-26-10-8-20)21-6-4-14(17(21)23)19-28(24,25)11-5-13-2-3-15(18)27-13/h2-3,5,11-12,14,19H,4,6-10H2,1H3/b11-5+/t12-,14-/m0/s1
DMH0C8J	CS	C[C@@H](C(=O)N1CCOCC1)N2CC[C@@H](C2=O)NS(=O)(=O)/C=C/C3=CC=C(S3)Cl
DMH0C8J	IK	ACEFOQMQINFMRW-DYCFVMESSA-N
DMH0C8J	IU	(E)-2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(2S)-1-morpholin-4-yl-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide
DMH0C8J	CA	CAS 478644-12-1
DMH0C8J	DE	Thrombosis

DM489FT	ID	DM489FT
DM489FT	DN	GW-870086-X
DM489FT	HS	Phase 2
DM489FT	SN	GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline
DM489FT	CP	GlaxoSmithKline plc
DM489FT	DE	Atopic dermatitis

DMQEC9P	ID	DMQEC9P
DMQEC9P	DN	GW-870086-X
DMQEC9P	HS	Phase 2
DMQEC9P	SN	Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline
DMQEC9P	CP	GlaxoSmithKline plc
DMQEC9P	DE	Asthma

DM8XH3S	ID	DM8XH3S
DM8XH3S	DN	H-1152
DM8XH3S	HS	Phase 2
DM8XH3S	SN	451462-58-1; (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE; CHEBI:88220; H-1152P; (S)-H-1152 (hydrochloride); H52; dimethyl fasudil; 4-methyl-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline; 4-methyl-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline; 2gnh; 2gnl; 1q8u; AC1L9LJA; H 1152; SCHEMBL124161; CHEMBL406821; ZINC22706; BDBM14028; BCP16935; 3714AH; AKOS027263830; DB07876; CS-1536; HY-15720; LS-193100; W-5343; 4-methyl-5-[(2S)-2-methyl-1,4-diazepane-1-sulfonyl]isoquinoline
DM8XH3S	CP	CoTherix
DM8XH3S	DT	Small molecular drug
DM8XH3S	PC	448043
DM8XH3S	MW	319.4
DM8XH3S	FM	C16H21N3O2S
DM8XH3S	IC	InChI=1S/C16H21N3O2S/c1-12-9-18-11-14-5-3-6-15(16(12)14)22(20,21)19-8-4-7-17-10-13(19)2/h3,5-6,9,11,13,17H,4,7-8,10H2,1-2H3/t13-/m0/s1
DM8XH3S	CS	C[C@H]1CNCCCN1S(=O)(=O)C2=CC=CC3=C2C(=CN=C3)C
DM8XH3S	IK	AWDORCFLUJZUQS-ZDUSSCGKSA-N
DM8XH3S	IU	4-methyl-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline
DM8XH3S	CA	CAS 451462-58-1
DM8XH3S	CB	CHEBI:88220
DM8XH3S	DE	Pulmonary arterial hypertension

DMO4I61	ID	DMO4I61
DMO4I61	DN	H5N1 influenza vaccine
DMO4I61	HS	Phase 2
DMO4I61	SN	Daronrix; GSK-1119711A; H5N1 influenza vaccine (inactivated whole virus adjuvanted); Avian influenzavaccine (inactivated whole virus adjuvanted), GlaxoSmithKline; H5N1 influenza vaccine (inactivated whole virus adjuvanted), GlaxoSmithKline
DMO4I61	CP	GlaxoSmithKline plc
DMO4I61	DT	Vaccine
DMO4I61	DE	Influenza virus infection

DM74ZKN	ID	DM74ZKN
DM74ZKN	DN	HBI-3000
DM74ZKN	HS	Phase 2
DM74ZKN	SN	Sulcardine; Multi-ion channel blocker (oral, arrhythmia), SIMM; Multi-ion channel blocker (oral/iv, arrhythmia), HUYA
DM74ZKN	CP	Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
DM74ZKN	DE	Heart arrhythmia; Atrial fibrillation

DMSMCXN	ID	DMSMCXN
DMSMCXN	DN	HBV vaccine
DMSMCXN	HS	Phase 2
DMSMCXN	SN	HBV vaccine (adjuvanted); HBV vaccine (adjuvanted), GlaxoSmithKline Biologicals
DMSMCXN	CP	GlaxoSmithKline Biologicals
DMSMCXN	DT	Vaccine
DMSMCXN	DE	Hepatitis B virus infection

DMX8C6J	ID	DMX8C6J
DMX8C6J	DN	HCB1019
DMX8C6J	HS	Phase 2
DMX8C6J	CP	OcuNexus Therapeutics
DMX8C6J	DT	Small molecular drug
DMX8C6J	DE	Diabetic macular edema

DMRQGMZ	ID	DMRQGMZ
DMRQGMZ	DN	HD-003
DMRQGMZ	HS	Phase 2
DMRQGMZ	SN	NZ-419; Selective hydroxy radical modulator (chronic kidney disease), Hyundai/ Nippon Zoki
DMRQGMZ	CP	Nippon Zoki Pharmaceutical Co Ltd
DMRQGMZ	DE	Kidney disease

DMAX632	ID	DMAX632
DMAX632	DN	HDV-interferon
DMAX632	HS	Phase 2
DMAX632	SN	HDV-interferon (sc, HCV infection); HDV-IFN (sc, HCV infection), Hepasome Pharmaceuticals; HDV-interferon (sc, HCV infection), Hepasome Pharmaceuticals
DMAX632	CP	Hepasome Pharmaceuticals
DMAX632	DE	Hepatitis C virus infection

DMV50R1	ID	DMV50R1
DMV50R1	DN	HE3235
DMV50R1	HS	Phase 2
DMV50R1	SN	Apoptone; HE3235; UNII-891O182ZP5; 183387-50-0; HE 3235; 891O182ZP5; SCHEMBL3402872; Pregn-20-yne-3,17-diol, (3alpha,5alpha,17alpha)-; DTXSID70171418; MolPort-044-561-946; ZINC5921098
DMV50R1	CP	Harbor Therapeutics
DMV50R1	DT	Small molecular drug
DMV50R1	PC	42611099
DMV50R1	MW	316.5
DMV50R1	FM	C21H32O2
DMV50R1	IC	InChI=1S/C21H32O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,14-18,22-23H,5-13H2,2-3H3/t14-,15+,16+,17-,18-,19-,20-,21-/m0/s1
DMV50R1	CS	C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O
DMV50R1	IK	CKAXZOYFIHQCBN-JRRMKBMNSA-N
DMV50R1	IU	(3R,5S,8R,9S,10S,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol
DMV50R1	CA	CAS 183387-50-0
DMV50R1	DE	Breast cancer

DM9OZU5	ID	DM9OZU5
DM9OZU5	DN	Heat shock protein vaccine
DM9OZU5	HS	Phase 2
DM9OZU5	CP	Agenus
DM9OZU5	DT	Vaccine
DM9OZU5	DE	Meningococcal infection

DM8QGPE	ID	DM8QGPE
DM8QGPE	DN	HepaStem
DM8QGPE	HS	Phase 2
DM8QGPE	CP	Promethera Biosciences SA/NV
DM8QGPE	DE	Liver failure

DMX6B95	ID	DMX6B95
DMX6B95	DN	HER1-VSSP vaccine
DMX6B95	HS	Phase 2
DMX6B95	SN	HER1-VSSP vaccine (cancer)
DMX6B95	CP	The Center of Molecular Immunology
DMX6B95	DT	Vaccine
DMX6B95	DE	Solid tumour/cancer

DM8TOS0	ID	DM8TOS0
DM8TOS0	DN	HER-2 Protein AutoVac
DM8TOS0	HS	Phase 2
DM8TOS0	CP	Pharmexa
DM8TOS0	DE	Breast cancer

DMISETH	ID	DMISETH
DMISETH	DN	HER2/neu peptide vaccine
DMISETH	HS	Phase 2
DMISETH	SN	HER2/neu peptide vaccine (intradermal, breast cancer)
DMISETH	CP	Fred Hutchinson Cancer Research Center
DMISETH	DT	Vaccine
DMISETH	DE	Breast cancer

DMQTREC	ID	DMQTREC
DMQTREC	DN	Her2-targeted autologous T-cell therapy
DMQTREC	HS	Phase 2
DMQTREC	SN	Her2-targeted autologous T-cell therapy (cancer)
DMQTREC	CP	Baylor College of Medicine
DMQTREC	DE	Glioblastoma multiforme

DMI4C90	ID	DMI4C90
DMI4C90	DN	HF-0220
DMI4C90	HS	Phase 2
DMI4C90	SN	Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming
DMI4C90	CP	Hunter-Fleming Ltd
DMI4C90	PC	9836181
DMI4C90	MW	306.4
DMI4C90	FM	C19H30O3
DMI4C90	IC	InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h11-15,17,20-21H,3-10H2,1-2H3/t11-,12+,13+,14+,15+,17+,18+,19+/m1/s1
DMI4C90	CS	C[C@]12CC[C@@H](C[C@@H]1C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O)O
DMI4C90	IK	VFPMCLQMAUVEHD-UCPSWNCLSA-N
DMI4C90	IU	(3S,5R,7S,8R,9S,10S,13S,14S)-3,7-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMI4C90	CA	CAS 25848-69-5
DMI4C90	DE	Alzheimer disease

DMDZE3B	ID	DMDZE3B
DMDZE3B	DN	HGT-1111
DMDZE3B	HS	Phase 2
DMDZE3B	SN	Metazym; M-0001; Recombinant arylsulfatase A (lysosomal storage disease), Shire; Recombinant arylsulfatase A (lysosomal storage disease), Zymenex; Recombinant arylsulfatase A (metachromatic leukodystrophy), Shire; Lysosomal arylsulfatase A replacement therapy (FGE, metachromatic leukodystrophy), Shire; Lysosomal asa replacement therapy (FGE, metachromatic leukodystrophy), Shire
DMDZE3B	CP	Zymenex A/S
DMDZE3B	DE	Metachromatic leukodystrophy

DMHZ4JI	ID	DMHZ4JI
DMHZ4JI	DN	HGT-1410
DMHZ4JI	HS	Phase 2
DMHZ4JI	SN	Intrathecal sulfamidase replacement therapy (FGE, Sanfilippo syndrome), Shire; Intrathecal heparin n-sulfamidase (FGE, Sanfilippo syndrome), Shire
DMHZ4JI	CP	Shire Human Genetic Therapies Inc
DMHZ4JI	DE	Sanfilippo syndrome

DM0LA6E	ID	DM0LA6E
DM0LA6E	DN	HGTV43
DM0LA6E	HS	Phase 2
DM0LA6E	CP	Enzo Biochem
DM0LA6E	TC	Antisense
DM0LA6E	DT	Antisense drug
DM0LA6E	DE	Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection

DMO10JI	ID	DMO10JI
DMO10JI	DN	HibTITER
DMO10JI	HS	Phase 2
DMO10JI	SN	Haemophilus vaccine II, Praxis; Conjugate vaccine (Haemophilus influenzae type B/ meningitis), Nuron Biotech
DMO10JI	CP	Nuron biotech
DMO10JI	DT	Vaccine
DMO10JI	DE	Pneumococcal infection

DMLQDBH	ID	DMLQDBH
DMLQDBH	DN	HM-5016504
DMLQDBH	HS	Phase 2
DMLQDBH	SN	C-Met inhibitor (cancer), Hutchison
DMLQDBH	CP	Hutchison Medipharma Enterprises Ltd
DMLQDBH	DE	Solid tumour/cancer

DMZ3BER	ID	DMZ3BER
DMZ3BER	DN	HM-78136B
DMZ3BER	HS	Phase 2
DMZ3BER	SN	Pan-Her/EGFR inhibitors (cancer), Hanmi
DMZ3BER	CP	Hanmi Pharmaceutical Co Ltd
DMZ3BER	DT	Small molecular drug
DMZ3BER	PC	25127713
DMZ3BER	MW	491.3
DMZ3BER	FM	C23H21Cl2FN4O3
DMZ3BER	IC	InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)
DMZ3BER	CS	COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C
DMZ3BER	IK	LPFWVDIFUFFKJU-UHFFFAOYSA-N
DMZ3BER	IU	1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one
DMZ3BER	CA	CAS 1092364-38-9
DMZ3BER	DE	Solid tumour/cancer; HER2-positive breast cancer; Non-small-cell lung cancer

DMMQZ3I	ID	DMMQZ3I
DMMQZ3I	DN	HMR59
DMMQZ3I	HS	Phase 2
DMMQZ3I	SN	AAVCAGsCD59
DMMQZ3I	CP	Hemera Biosciences
DMMQZ3I	DT	Gene therapy
DMMQZ3I	DE	Wet age-related macular degeneration; Dry age-related macular degeneration; Geographic retinal atrophy

DMA6HQJ	ID	DMA6HQJ
DMA6HQJ	DN	HO/03/03
DMA6HQJ	HS	Phase 2
DMA6HQJ	SN	PKC modulator (topical peptide, DU/VU/PU), HealOr
DMA6HQJ	CP	HealOr Ltd
DMA6HQJ	DE	Diabetic foot ulcer

DMNOMV2	ID	DMNOMV2
DMNOMV2	DN	HP-184
DMNOMV2	HS	Phase 2
DMNOMV2	SN	Nerispirdine; Nerispirdine hydrochloride; HP 184; N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine; N-(n-Propyl)-3-fluoro-4-pyridinyl-1H-3-methylindol-1-amine hydrochloride; N-(3-Fluoro-4-pyridinyl)-3-methyl-N-propyl-1H-indol-1-amine; 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride
DMNOMV2	CP	Sanofi-Aventis
DMNOMV2	DT	Small molecular drug
DMNOMV2	PC	3081185
DMNOMV2	MW	283.34
DMNOMV2	FM	C17H18FN3
DMNOMV2	IC	InChI=1S/C17H18FN3/c1-3-10-20(17-8-9-19-11-15(17)18)21-12-13(2)14-6-4-5-7-16(14)21/h4-9,11-12H,3,10H2,1-2H3
DMNOMV2	CS	CCCN(C1=C(C=NC=C1)F)N2C=C(C3=CC=CC=C32)C
DMNOMV2	IK	BTDHTARYCBHHPJ-UHFFFAOYSA-N
DMNOMV2	IU	N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine
DMNOMV2	CA	CAS 119229-65-1
DMNOMV2	DE	Multiple sclerosis

DMNZ35F	ID	DMNZ35F
DMNZ35F	DN	HP-228
DMNZ35F	HS	Phase 2
DMNZ35F	SN	HP 228; Ac-Nle-gln-his-D-phe-arg-D-trp-gly-NH2; AC1L2XO7; 109022-88-0; Acetyl-norleucyl-glutaminyl-histidyl-phenylalanyl-arginyl-tryptophyl-glycinamide; L-Norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycinamide; Glycinamide, L-norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-
DMNZ35F	CP	LION bioscience Inc
DMNZ35F	DT	Small molecular drug
DMNZ35F	PC	9876430
DMNZ35F	MW	984.1
DMNZ35F	FM	C47H65N15O9
DMNZ35F	IC	InChI=1S/C47H65N15O9/c1-3-4-14-33(57-27(2)63)42(67)59-35(17-18-39(48)64)44(69)62-38(22-30-24-52-26-56-30)46(71)60-36(20-28-11-6-5-7-12-28)45(70)58-34(16-10-19-53-47(50)51)43(68)61-37(41(66)55-25-40(49)65)21-29-23-54-32-15-9-8-13-31(29)32/h5-9,11-13,15,23-24,26,33-38,54H,3-4,10,14,16-22,25H2,1-2H3,(H2,48,64)(H2,49,65)(H,52,56)(H,55,66)(H,57,63)(H,58,70)(H,59,67)(H,60,71)(H,61,68)(H,62,69)(H4,50,51,53)/t33-,34-,35-,36+,37+,38-/m0/s1
DMNZ35F	CS	CCCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N)NC(=O)C
DMNZ35F	IK	UHKZNDVUBSEJJO-XAYNKGEHSA-N
DMNZ35F	IU	(2S)-2-[[(2S)-2-acetamidohexanoyl]amino]-N-[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[(2-amino-2-oxoethyl)amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]pentanediamide
DMNZ35F	DE	Postoperative pain

DM3WSL2	ID	DM3WSL2
DM3WSL2	DN	HPH-116
DM3WSL2	HS	Phase 2
DM3WSL2	SN	Azocarbonamide; Azodicarbonamide; ADA, Hubriphar; Azodicarbonamide, H-Phar
DM3WSL2	CP	H-Phar Co
DM3WSL2	DE	Human immunodeficiency virus infection

DM25PQB	ID	DM25PQB
DM25PQB	DN	HPPH
DM25PQB	HS	Phase 2
DM25PQB	SN	CHEMBL500853; SCHEMBL12722713; EX-A2655; 14-Ethyl-9-(1-(hexyloxy)ethyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoic acid; HY-13722; 3-Phorbinepropanoic acid, 14-ethyl-9-[1-(hexyloxy)ethyl]-4,8,13,18-tetramethyl-20-oxo-, (3S,4S)-; CS-0007752
DM25PQB	PC	148160
DM25PQB	MW	636.8
DM25PQB	FM	C39H48N4O4
DM25PQB	IC	InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,42,44H,8-16H2,1-7H3,(H,45,46)/t21-,24?,26-/m0/s1
DM25PQB	CS	CCCCCCOC(C)C1=C(C2=NC1=CC3=NC(=CC4=C(C5=C(CC(=C6C(C(C(=C2)N6)C)CCC(=O)O)C5=N4)O)C)C(=C3C)CC)C
DM25PQB	IK	PUUBADHCONCMPA-USOGPTGWSA-N
DM25PQB	IU	3-[(21S,22S)-11-ethyl-16-(1-hexoxyethyl)-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
DM25PQB	CA	CAS 149402-51-7
DM25PQB	DE	Lung cancer

DM7QUN0	ID	DM7QUN0
DM7QUN0	DN	HQK-1001
DM7QUN0	HS	Phase 2
DM7QUN0	SN	Sodium ST-20; Hematological disease therapeutic (oral), HemaQuest
DM7QUN0	CP	Hemaquest pharmaceuticals
DM7QUN0	DT	Small molecular drug
DM7QUN0	PC	53247304
DM7QUN0	MW	138.14
DM7QUN0	FM	C6H11NaO2
DM7QUN0	IC	InChI=1S/C6H12O2.Na/c1-4-6(2,3)5(7)8;/h4H2,1-3H3,(H,7,8);/q;+1/p-1
DM7QUN0	CS	CCC(C)(C)C(=O)[O-].[Na+]
DM7QUN0	IK	OOPXYEYPPHJHSE-UHFFFAOYSA-M
DM7QUN0	IU	sodium;2,2-dimethylbutanoate
DM7QUN0	CA	CAS 3934-02-9
DM7QUN0	DE	Beta thalassemia

DM3WX0K	ID	DM3WX0K
DM3WX0K	DN	HQK-1004
DM3WX0K	HS	Phase 2
DM3WX0K	SN	Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest
DM3WX0K	CP	HemaQuest Pharmaceuticals Inc; Vertex Pharmaceuticals Inc
DM3WX0K	PC	23622962
DM3WX0K	MW	875
DM3WX0K	FM	C34H74N12O14
DM3WX0K	IC	InChI=1S/3C6H14N4O2.4C4H8O2/c3*7-4(5(11)12)2-1-3-10-6(8)9;4*1-2-3-4(5)6/h3*4H,1-3,7H2,(H,11,12)(H4,8,9,10);4*2-3H2,1H3,(H,5,6)/t3*4-;;;;/m000..../s1
DM3WX0K	CS	CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.C(C[C@@H](C(=O)O)N)CN=C(N)N.C(C[C@@H](C(=O)O)N)CN=C(N)N.C(C[C@@H](C(=O)O)N)CN=C(N)N
DM3WX0K	IK	ZVEMACCDKBQNGX-KALODSIISA-N
DM3WX0K	IU	(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid
DM3WX0K	CA	CAS 80407-72-3
DM3WX0K	DE	Solid tumour/cancer

DMQ30X2	ID	DMQ30X2
DMQ30X2	DN	HQP1351
DMQ30X2	HS	Phase 2
DMQ30X2	SN	GZD824; 1257628-77-5; GZD-824; 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; UNII-KV1M7Q3CBP; KV1M7Q3CBP; 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide; CHEMBL2316582; Benzamide, 4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-; HQP-1351; olverembatinib; 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide; Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-; HQP1351 free base; HQP-1351 free base; SCHEMBL3424528; GTPL10630; EX-A829; AOB87323; BCP07502; BDBM50425780; ZINC95594040; AKOS026750647; CS-1444; SB16617; compound 10a [PMID: 23301703]; NCGC00351607-06; AK547162; AS-75170; HY-15666; D-824; FT-0700150; A16264; W-6136; J-690110; 4-Methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide
DMQ30X2	CP	Ascentage Pharma
DMQ30X2	DT	Small molecular drug
DMQ30X2	PC	51038269
DMQ30X2	MW	532.6
DMQ30X2	FM	C29H27F3N6O
DMQ30X2	IC	InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)
DMQ30X2	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4
DMQ30X2	IK	TZKBVRDEOITLRB-UHFFFAOYSA-N
DMQ30X2	IU	4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
DMQ30X2	CA	CAS 1257628-77-5
DMQ30X2	DE	Chronic myeloid leukaemia

DML4RCG	ID	DML4RCG
DML4RCG	DN	HS-110
DML4RCG	HS	Phase 2
DML4RCG	CP	Heat Biologics
DML4RCG	DT	Vaccine
DML4RCG	DE	Non-small-cell lung cancer

DM2WP8F	ID	DM2WP8F
DM2WP8F	DN	HT-0712
DM2WP8F	HS	Phase 2
DM2WP8F	SN	IPL-455903; Small-molecule PDE4 inhibitors (memory disorders), Inflazyme/Helicon
DM2WP8F	CP	Dart neuroscience
DM2WP8F	DT	Small molecular drug
DM2WP8F	PC	9865375
DM2WP8F	MW	393.5
DM2WP8F	FM	C25H31NO3
DM2WP8F	IC	InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1
DM2WP8F	CS	CC1=CC(=CC=C1)C[C@@H]2C[C@H](CNC2=O)C3=CC(=C(C=C3)OC)OC4CCCC4
DM2WP8F	IK	ABEJDMOBAFLQNJ-NHCUHLMSSA-N
DM2WP8F	IU	(3S,5S)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3-[(3-methylphenyl)methyl]piperidin-2-one
DM2WP8F	CA	CAS 617720-02-2
DM2WP8F	DE	Cognitive impairment

DM2QIN1	ID	DM2QIN1
DM2QIN1	DN	HT-100
DM2QIN1	HS	Phase 2
DM2QIN1	SN	Halofunginone
DM2QIN1	CP	Halo therapeutics
DM2QIN1	DT	Small molecular drug
DM2QIN1	PC	62894
DM2QIN1	MW	414.7
DM2QIN1	FM	C16H17BrClN3O3
DM2QIN1	IC	InChI=1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2
DM2QIN1	CS	C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O
DM2QIN1	IK	LVASCWIMLIKXLA-UHFFFAOYSA-N
DM2QIN1	IU	7-bromo-6-chloro-3-[3-(3-hydroxypiperidin-2-yl)-2-oxopropyl]quinazolin-4-one
DM2QIN1	CA	CAS 55837-20-2
DM2QIN1	DE	Duchenne dystrophy

DMURXMJ	ID	DMURXMJ
DMURXMJ	DN	HTI-101
DMURXMJ	HS	Phase 2
DMURXMJ	CP	Hemodynamic Therapeutics
DMURXMJ	DE	Obesity

DM9MKQ5	ID	DM9MKQ5
DM9MKQ5	DN	Hu3F8 mAb
DM9MKQ5	HS	Phase 2
DM9MKQ5	CP	Y-mAbs Therapeutics New York, NY
DM9MKQ5	DE	Neuroblastoma; Osteosarcoma

DMKQ3MC	ID	DMKQ3MC
DMKQ3MC	DN	Human interferon alpha oral
DMKQ3MC	HS	Phase 2
DMKQ3MC	CP	Amarillo biosciences
DMKQ3MC	DE	Hepatitis C virus infection

DM0NJWG	ID	DM0NJWG
DM0NJWG	DN	Human interleukin-2
DM0NJWG	HS	Phase 2
DM0NJWG	SN	Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice
DM0NJWG	CP	Immunservice GmbH
DM0NJWG	DE	Renal cell carcinoma

DMOPWSX	ID	DMOPWSX
DMOPWSX	DN	Ibrolipim
DMOPWSX	HS	Phase 2
DMOPWSX	SN	Ibrolipim < Prop INN; NO-1886; OPF-009; 4-[N-(4-Bromo-2-cyanophenyl)carbamoyl]benzylphosphonic acid diethyl ester
DMOPWSX	CP	TAP Pharmaceuticals
DMOPWSX	DT	Small molecular drug
DMOPWSX	PC	131601
DMOPWSX	MW	451.2
DMOPWSX	FM	C19H20BrN2O4P
DMOPWSX	IC	InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)
DMOPWSX	CS	CCOP(=O)(CC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)Br)C#N)OCC
DMOPWSX	IK	KPRTURMJVWXURQ-UHFFFAOYSA-N
DMOPWSX	IU	N-(4-bromo-2-cyanophenyl)-4-(diethoxyphosphorylmethyl)benzamide
DMOPWSX	CA	CAS 133208-93-2
DMOPWSX	DE	Hyperlipidaemia

DM37CX4	ID	DM37CX4
DM37CX4	DN	IC14
DM37CX4	HS	Phase 2 
DM37CX4	SN	CD14 antibody
DM37CX4	TC	Antiviral Agents
DM37CX4	DT	Monoclonal antibody
DM37CX4	DE	Coronavirus Disease 2019 (COVID-19)

DMUFCQG	ID	DMUFCQG
DMUFCQG	DN	IC14
DMUFCQG	HS	Phase 2
DMUFCQG	DT	Antibody
DMUFCQG	DE	Sepsis

DMB1UYV	ID	DMB1UYV
DMB1UYV	DN	IC-485
DMB1UYV	HS	Phase 2
DMB1UYV	CP	ICOS
DMB1UYV	DT	Small molecular drug
DMB1UYV	PC	23724885
DMB1UYV	DE	Chronic obstructive pulmonary disease

DMP925B	ID	DMP925B
DMP925B	DN	ICA-105665
DMP925B	HS	Phase 2
DMP925B	CP	Icagen
DMP925B	DE	Epilepsy

DMRFY7I	ID	DMRFY7I
DMRFY7I	DN	ICA-17043
DMRFY7I	HS	Phase 2
DMRFY7I	SN	Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215;  Senicapoc
DMRFY7I	CP	Icagen
DMRFY7I	DT	Small molecular drug
DMRFY7I	PC	216327
DMRFY7I	MW	323.3
DMRFY7I	FM	C20H15F2NO
DMRFY7I	IC	InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
DMRFY7I	CS	C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
DMRFY7I	IK	SCTZUZTYRMOMKT-UHFFFAOYSA-N
DMRFY7I	IU	2,2-bis(4-fluorophenyl)-2-phenylacetamide
DMRFY7I	CA	CAS 289656-45-7
DMRFY7I	DE	Constitutional neutropenia; Alzheimer disease

DMGHQ37	ID	DMGHQ37
DMGHQ37	DN	Icaritin
DMGHQ37	HS	Phase 2
DMGHQ37	SN	Icaritin; 118525-40-9; UNII-UFE666UELY; UFE666UELY; CHEMBL498485; 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one; Icartin; Anhydroicaritin; AC1NSXIV; Icaritin(Anhydroicaritin); MLS006010055; BIDD:ER0021; SCHEMBL4223542; Icaritin, &gt; DTXSID00152154; MolPort-020-006-012; TUUXBSASAQJECY-UHFFFAOYSA-N; HY-N0678; ZINC14762797; BDBM50272527; AKOS015896858; CS-3679; DB12672; NCGC00345813-01; AK168251; SMR004701218
DMGHQ37	DT	Small molecular drug
DMGHQ37	PC	5318980
DMGHQ37	MW	368.4
DMGHQ37	FM	C21H20O6
DMGHQ37	IC	InChI=1S/C21H20O6/c1-11(2)4-9-14-15(22)10-16(23)17-18(24)19(25)20(27-21(14)17)12-5-7-13(26-3)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3
DMGHQ37	CS	CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)O)C
DMGHQ37	IK	TUUXBSASAQJECY-UHFFFAOYSA-N
DMGHQ37	IU	3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
DMGHQ37	CA	CAS 118525-40-9
DMGHQ37	DE	Breast cancer

DMC13BQ	ID	DMC13BQ
DMC13BQ	DN	ICO-25
DMC13BQ	HS	Phase 2
DMC13BQ	SN	Imuteran; Anti-MUC1 monoclonal antibodies, P Hertzen Moscow Cancer Research Institute; Anti-AG-4 antibodies, P Hertzen Moscow Cancer Research Institute
DMC13BQ	CP	Russian National Cancer Research Center
DMC13BQ	DT	Antibody
DMC13BQ	DE	Breast cancer

DMTXNZK	ID	DMTXNZK
DMTXNZK	DN	Icofungipen
DMTXNZK	HS	Phase 2
DMTXNZK	SN	PLD-118; 198022-65-0; UNII-I20202Q8M8; BAY-10-8888; I20202Q8M8; Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)-; Icofungipen [INN]; (1R,2S)-2-Amino-4-methylene-cyclopentanecarboxylic acid; PLD118; PLD 118; 156292-16-9; BAY 10-8888; (1r,2s)-2-amino-4-methylidenecyclopentanecarboxylic acid; AC1Q5QVF; AC1L50CI; 2-amino-4-methylenecyclopentane-1-carboxylic acid; SCHEMBL117349; CHEMBL343803; CTK0H0639; DTXSID90173515; RKOUGZGFAYMUIO-RITPCOANSA-N; (1R,2S)-2-amino-4-methylidenecyclopentane-1-carboxylic acid;  Icofungipen [INN]; (1R,2S)-2-Amino-4-methylenecyclopentane-1-carboxylic acid; AHMA
DMTXNZK	TC	Antifungal Agents
DMTXNZK	DT	Small molecular drug
DMTXNZK	PC	216240
DMTXNZK	MW	141.17
DMTXNZK	FM	C7H11NO2
DMTXNZK	IC	InChI=1S/C7H11NO2/c1-4-2-5(7(9)10)6(8)3-4/h5-6H,1-3,8H2,(H,9,10)/t5-,6+/m1/s1
DMTXNZK	CS	C=C1C[C@H]([C@H](C1)N)C(=O)O
DMTXNZK	IK	RKOUGZGFAYMUIO-RITPCOANSA-N
DMTXNZK	IU	(1R,2S)-2-amino-4-methylidenecyclopentane-1-carboxylic acid
DMTXNZK	CA	CAS 198022-65-0
DMTXNZK	DE	Fungal infection

DM524GR	ID	DM524GR
DM524GR	DN	ICP-192
DM524GR	HS	Phase 2
DM524GR	CP	InnoCare Pharma
DM524GR	DE	Bladder cancer

DM7XIAJ	ID	DM7XIAJ
DM7XIAJ	DN	ID-93/GLA-SE
DM7XIAJ	HS	Phase 2
DM7XIAJ	CP	Infectious disease research institute; aeras global tb vaccine foundation
DM7XIAJ	DE	Tuberculosis

DMABRXY	ID	DMABRXY
DMABRXY	DN	IDM-2101
DMABRXY	HS	Phase 2
DMABRXY	CP	Biotech Synergy
DMABRXY	DT	Vaccine
DMABRXY	DE	Colorectal cancer

DMSRC5D	ID	DMSRC5D
DMSRC5D	DN	IDX899
DMSRC5D	HS	Phase 2
DMSRC5D	SN	Fosdevirine; IDX-899; IDX899; GSK2248761; GSK-2248761; 1018450-26-4; UNII-Z4I0C281BJ; Z4I0C281BJ; Fosdevirine [USAN:INN]; GSK2248761A; GSK 2248761A; Fosdevirine (USAN/INN); SCHEMBL1035677; CHEMBL2104968; IDX 899; 1097733-15-7; IDX-12899; GSK 2248761; D09906
DMSRC5D	CP	GSK
DMSRC5D	DT	Small molecular drug
DMSRC5D	PC	23583058
DMSRC5D	MW	413.8
DMSRC5D	FM	C20H17ClN3O3P
DMSRC5D	IC	InChI=1S/C20H17ClN3O3P/c1-12-8-13(4-3-7-22)10-15(9-12)28(26,27-2)19-16-11-14(21)5-6-17(16)24-18(19)20(23)25/h3-6,8-11,24H,1-2H3,(H2,23,25)/b4-3+
DMSRC5D	CS	CC1=CC(=CC(=C1)P(=O)(C2=C(NC3=C2C=C(C=C3)Cl)C(=O)N)OC)/C=C/C#N
DMSRC5D	IK	CGBYTKOSZYQOPV-ONEGZZNKSA-N
DMSRC5D	IU	5-chloro-3-[[3-[(E)-2-cyanoethenyl]-5-methylphenyl]-methoxyphosphoryl]-1H-indole-2-carboxamide
DMSRC5D	DE	Human immunodeficiency virus infection

DMGWNCJ	ID	DMGWNCJ
DMGWNCJ	DN	Ifabotuzumab
DMGWNCJ	HS	Phase 2
DMGWNCJ	CP	Humanigen Brisbane, CA Olivia Newton-John Cancer Research Institute Heidelberg, Australia
DMGWNCJ	DE	Acute myeloid leukaemia; Myelodysplastic syndrome; Recurrent glioblastoma

DMZP84Y	ID	DMZP84Y
DMZP84Y	DN	Ifetroban sodium
DMZP84Y	HS	Phase 2
DMZP84Y	SN	BMS-180291 sodium salt; BMS-180291-02
DMZP84Y	CP	Bristol-Myers Squibb
DMZP84Y	DT	Small molecular drug
DMZP84Y	PC	23663994
DMZP84Y	MW	462.5
DMZP84Y	FM	C25H31N2NaO5
DMZP84Y	IC	InChI=1S/C25H32N2O5.Na/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29;/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29);/q;+1/p-1/t18-,20-,21+,23-;/m0./s1
DMZP84Y	CS	CCCCCNC(=O)C1=COC(=N1)[C@@H]2[C@H]3CC[C@@H]([C@@H]2CC4=CC=CC=C4CCC(=O)[O-])O3.[Na+]
DMZP84Y	IK	WOHSQDNIXPEQAE-QBKVZTCDSA-M
DMZP84Y	IU	sodium;3-[2-[[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate
DMZP84Y	DE	Thrombosis

DM4H8EZ	ID	DM4H8EZ
DM4H8EZ	DN	IFN-alpha
DM4H8EZ	HS	Phase 2
DM4H8EZ	SN	Hanferon; HL-143; IFN-alpha (sc injection, HCV infection); Belerofon (subcutaneous, HCV infection), Nautilus/HanAll; IFN-alpha (sc injection, HCV infection), HanAll; IFN-alpha (subcutaneous, HCV infection), Nautilus/HanAll; Interferon-alpha (subcutaneous, HCV infection), Nautilus/HanAll
DM4H8EZ	CP	Hanall biopharma
DM4H8EZ	DE	Hepatitis C virus infection; Hepatocellular carcinoma

DMHI36A	ID	DMHI36A
DMHI36A	DN	IFX-1
DMHI36A	HS	Phase 2
DMHI36A	SN	XZAPEHKCHWMSPW-MTALQEDYSA-N; Ifx-1; J3.560.481B
DMHI36A	CP	InflaRx Planegg, Germany
DMHI36A	PC	137254326
DMHI36A	MW	672.9
DMHI36A	FM	C43H60O6
DMHI36A	IC	InChI=1S/C43H60O6/c1-30(17-14-18-31(2)19-21-39-42(9,10)27-37(49-33(4)45)28-43(39,11)48)15-12-13-16-32(3)23-35(46)24-34(29-44)20-22-38-40(5,6)25-36(47)26-41(38,7)8/h12-24,29,36-38,47-48H,25-28H2,1-11H3/b15-12?,16-13?,18-14?,22-20+,30-17?,31-19?,32-23?,34-24-,39-21?/t36?,37-,38?,43-/m1/s1
DMHI36A	CS	CC(=CC=CC(=CC=C1[C@](C[C@@H](CC1(C)C)OC(=O)C)(C)O)C)C=CC=CC(=CC(=O)/C=C(/C=C/C2C(CC(CC2(C)C)O)(C)C)\\C=O)C
DMHI36A	IK	XZAPEHKCHWMSPW-MTALQEDYSA-N
DMHI36A	IU	[(1R,3R)-4-[(15Z,17E)-16-formyl-18-(4-hydroxy-2,2,6,6-tetramethylcyclohexyl)-3,7,12-trimethyl-14-oxooctadeca-2,4,6,8,10,12,15,17-octaenylidene]-3-hydroxy-3,5,5-trimethylcyclohexyl] acetate
DMHI36A	DE	Hidradenitis suppurativa

DMH97XA	ID	DMH97XA
DMH97XA	DN	Igmesine
DMH97XA	HS	Phase 2
DMH97XA	SN	Igmesine hydrochloride; JO-1784; UNII-JV6M14TY35; Igmesine Hydrochloride [USAN]; 130152-35-1; Cinnamyl-1-phenyl-1-N-methyl-N-cyclopropylene; JO 1784; CI 1019; CI-1019; JV6M14TY35; (+)-alpha-(E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; (+)-Igmesine hydrochloride; (+)-(E)-N-(Cyclopropylmethyl)-alpha-ethyl-N-methyl-alpha-(3-phenyl-2-propenyl)benzenemethanamine hydrochloride; Igmesine hydrochloride (USAN); (+)-alpha-((E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; Alphagen
DMH97XA	DT	Small molecular drug
DMH97XA	PC	6438340
DMH97XA	MW	319.5
DMH97XA	FM	C23H29N
DMH97XA	IC	InChI=1S/C23H29N/c1-3-23(22-14-8-5-9-15-22,24(2)19-21-16-17-21)18-10-13-20-11-6-4-7-12-20/h4-15,21H,3,16-19H2,1-2H3/b13-10+
DMH97XA	CS	CCC(C/C=C/C1=CC=CC=C1)(C2=CC=CC=C2)N(C)CC3CC3
DMH97XA	IK	VCZSWYIFCKGTJI-JLHYYAGUSA-N
DMH97XA	IU	(E)-N-(cyclopropylmethyl)-N-methyl-3,6-diphenylhex-5-en-3-amine
DMH97XA	CA	CAS 140850-73-3
DMH97XA	DE	Cystic fibrosis; Chronic obstructive pulmonary disease; Major depressive disorder

DMIHQ5G	ID	DMIHQ5G
DMIHQ5G	DN	IL-2/CD40L-expressing leukemia vaccine
DMIHQ5G	HS	Phase 2
DMIHQ5G	SN	Autologous vaccine (leukemia), Baylor College of Medicine; Autologous vaccine (leukemia), MaxCyte; Autologous vaccine (leukemia), Baylor College of Medicine/MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine; IL-2/CD40L-expressing leukemia vaccine, MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine/MaxCyte
DMIHQ5G	CP	Baylor College of Medicine
DMIHQ5G	DT	Vaccine
DMIHQ5G	DE	Chronic lymphocytic leukaemia

DM1E4VP	ID	DM1E4VP
DM1E4VP	DN	IL-21
DM1E4VP	HS	Phase 2
DM1E4VP	SN	BMS-982470
DM1E4VP	CP	Bristol-Myers Squibb
DM1E4VP	DE	Colorectal cancer

DMYEGRH	ID	DMYEGRH
DMYEGRH	DN	IL-4R
DMYEGRH	HS	Phase 2

DMDNHRA	ID	DMDNHRA
DMDNHRA	DN	Ilodecakin
DMDNHRA	HS	Phase 2
DMDNHRA	SN	Prevascar; Ilodecakin, Renovo; Recombinant IL-10 (scarring), Renovo
DMDNHRA	CP	Renovo Group plc
DMDNHRA	DE	Sarcoidosis

DMUJ1WV	ID	DMUJ1WV
DMUJ1WV	DN	IMCgp100
DMUJ1WV	HS	Phase 2
DMUJ1WV	CP	Immunocore
DMUJ1WV	DT	Monoclonal antibody
DMUJ1WV	DE	Melanoma; Cutaneous melanoma

DMU1MR9	ID	DMU1MR9
DMU1MR9	DN	IMD-1041
DMU1MR9	HS	Phase 2
DMU1MR9	SN	IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD
DMU1MR9	CP	Institute of Medicinal Molecular Design Inc
DMU1MR9	DE	Alzheimer disease

DMMQFG2	ID	DMMQFG2
DMMQFG2	DN	Imeglimin
DMMQFG2	HS	Phase 2
DMMQFG2	SN	775351-65-0; UNII-UU226QGU97; UU226QGU97; Imeglimin [INN]; Emd 387008 (R-imeglimin) HCl; SCHEMBL2158106; SCHEMBL14868241; C6H13N5; DTXSID50228237; BCP11085; ZINC34380900; 3733AH; AKOS027338676; DB12509; CS-1751; HY-14771
DMMQFG2	CP	Merck KGaA
DMMQFG2	DT	Small molecular drug
DMMQFG2	PC	24812808
DMMQFG2	MW	155.2
DMMQFG2	FM	C6H13N5
DMMQFG2	IC	InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
DMMQFG2	CS	C[C@@H]1N=C(NC(=N1)N(C)C)N
DMMQFG2	IK	GFICWFZTBXUVIG-SCSAIBSYSA-N
DMMQFG2	IU	(4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine
DMMQFG2	CA	CAS 775351-65-0
DMMQFG2	DE	Type-2 diabetes; Diabetic complication

DML9AVG	ID	DML9AVG
DML9AVG	DN	IMG-7289
DML9AVG	HS	Phase 2
DML9AVG	SN	KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide
DML9AVG	CP	Imago BioSciences San Carlos, CA
DML9AVG	PC	122460381
DML9AVG	MW	519.6
DML9AVG	FM	C28H34FN7O2
DML9AVG	IC	InChI=1S/C28H34FN7O2/c1-34-15-17-35(18-16-34)28(38)25(3-2-12-30-26-19-24(26)20-4-8-22(29)9-5-20)32-27(37)21-6-10-23(11-7-21)36-14-13-31-33-36/h4-11,13-14,24-26,30H,2-3,12,15-19H2,1H3,(H,32,37)/t24-,25-,26+/m0/s1
DML9AVG	CS	CN1CCN(CC1)C(=O)[C@H](CCCN[C@@H]2C[C@H]2C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)N5C=CN=N5
DML9AVG	IK	KQKBMHGOHXOHTD-KKUQBAQOSA-N
DML9AVG	IU	N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide
DML9AVG	CA	CAS 1990504-34-1
DML9AVG	DE	Acute myeloid leukaemia; Myelodysplastic syndrome; Myelofibrosis

DMNJ491	ID	DMNJ491
DMNJ491	DN	IMGN529
DMNJ491	HS	Phase 2
DMNJ491	CP	ImmunoGen
DMNJ491	DT	Antibody
DMNJ491	DE	Metastatic non-hodgkin's lymphoma; Non-hodgkin lymphoma

DMIUC3M	ID	DMIUC3M
DMIUC3M	DN	IMGN901
DMIUC3M	HS	Phase 2
DMIUC3M	SN	Lorvotuzumab mertansine
DMIUC3M	CP	ImmunoGen
DMIUC3M	DE	Solid tumour/cancer

DME3POC	ID	DME3POC
DME3POC	DN	Imisopasem manganese
DME3POC	HS	Phase 2
DME3POC	SN	KM-4403; M-40403; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis); Imisopasem manganese (dermatological,psoriasis/atopic dermatitis), ActivBiotics; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis), Metaphore; M-40403 (dermatological, psoriasis/atopic dermatitis), Metaphore
DME3POC	CP	MetaPhore Pharmaceuticals
DME3POC	DT	Small molecular drug
DME3POC	PC	6918487
DME3POC	MW	483.4
DME3POC	FM	C21H35Cl2MnN5
DME3POC	IC	InChI=1S/C21H35N5.2ClH.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;;;/h5-7,18-25H,1-4,8-15H2;2*1H;/q;;;+2/p-2/t18-,19-,20-,21-;;;/m1.../s1
DME3POC	CS	C1CC[C@@H]2[C@@H](C1)NCCN[C@@H]3CCCC[C@H]3NCC4=CC=CC(=N4)CN2.Cl[Mn]Cl
DME3POC	IK	WXEMWBBXVXHEPU-XNPJUPKFSA-L
DME3POC	IU	dichloromanganese;(4R,9R,14R,19R)-3,10,13,20,26-pentazatetracyclo[20.3.1.04,9.014,19]hexacosa-1(26),22,24-triene
DME3POC	DE	Pain

DM6IQ3V	ID	DM6IQ3V
DM6IQ3V	DN	IMO-2055
DM6IQ3V	HS	Phase 2
DM6IQ3V	CP	Idera Pharmaceuticals
DM6IQ3V	DE	Solid tumour/cancer; Renal cell carcinoma

DMM549D	ID	DMM549D
DMM549D	DN	IMO-3100
DMM549D	HS	Phase 2
DMM549D	CP	Idera Pharmaceuticals
DMM549D	DE	Autoimmune diabetes; Psoriasis vulgaris

DMDPNCJ	ID	DMDPNCJ
DMDPNCJ	DN	IMO-8400
DMDPNCJ	HS	Phase 2
DMDPNCJ	SN	Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M
DMDPNCJ	CP	Idera Pharmaceuticals Cambridge, MA
DMDPNCJ	SQ	CTATCTNNNNTTCTCTNN
DMDPNCJ	PC	119058029
DMDPNCJ	MW	5801
DMDPNCJ	FM	C179H233N52O101P17S17
DMDPNCJ	IC	InChI=1S/C179H233N52O101P17S17/c1-71-41-221(172(252)200-143(71)184)123-32-85(106(303-123)62-293-347(274,364)330-136-109(313-160(140(136)278-10)220-26-19-117(234)199-171(220)251)66-297-349(276,366)332-138-111(315-162(142(138)280-12)231-70-193-134-148(231)203-165(188)206-158(134)245)65-296-346(273,363)328-92-39-130(228-48-78(8)155(242)213-179(228)259)310-105(92)60-289-337(264,354)320-84-31-122(218-24-17-115(183)197-169(218)249)302-98(84)53-285-341(268,358)324-89-36-127(225-45-75(5)152(239)210-176(225)256)308-103(89)58-291-344(271,361)329-93-40-131(229-68-191-132-144(185)189-67-190-146(132)229)311-107(93)61-292-343(270,360)326-86-33-124(222-42-72(2)149(236)207-173(222)253)304-99(86)54-281-333(260,350)316-80-27-119(298-94(80)49-232)215-21-14-112(180)194-166(215)246)321-338(265,355)282-50-95-81(28-118(299-95)214-20-13-79-145(214)201-163(186)204-156(79)243)317-334(261,351)286-55-100-90(37-128(305-100)226-46-76(6)153(240)211-177(226)257)325-342(269,359)290-57-102-88(35-126(307-102)224-44-74(4)151(238)209-175(224)255)323-340(267,357)284-51-96-82(29-120(300-96)216-22-15-113(181)195-167(216)247)318-335(262,352)287-56-101-87(34-125(306-101)223-43-73(3)150(237)208-174(223)254)322-339(266,356)283-52-97-83(30-121(301-97)217-23-16-114(182)196-168(217)248)319-336(263,353)288-59-104-91(38-129(309-104)227-47-77(7)154(241)212-178(227)258)327-345(272,362)295-64-110-137(141(279-11)161(314-110)230-69-192-133-147(230)202-164(187)205-157(133)244)331-348(275,365)294-63-108-135(235)139(277-9)159(312-108)219-25-18-116(233)198-170(219)250/h13-26,41-48,67-70,80-111,118-131,135-142,159-162,232,235H,27-40,49-66H2,1-12H3,(H,260,350)(H,261,351)(H,262,352)(H,263,353)(H,264,354)(H,265,355)(H,266,356)(H,267,357)(H,268,358)(H,269,359)(H,270,360)(H,271,361)(H,272,362)(H,273,363)(H,274,364)(H,275,365)(H,276,366)(H2,180,194,246)(H2,181,195,247)(H2,182,196,248)(H2,183,197,249)(H2,184,200,252)(H2,185,189,190)(H,198,233,250)(H,199,234,251)(H,207,236,253)(H,208,237,254)(H,209,238,255)(H,210,239,256)(H,211,240,257)(H,212,241,258)(H,213,242,259)(H3,186,201,204,243)(H3,187,202,205,244)(H3,188,203,206,245)/t80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,135+,136+,137+,138+,139+,140+,141+,142+,159+,160+,161+,162+,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?,343?,344?,345?,346?,347?,348?,349?/m0/s1
DMDPNCJ	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OC)N6C=CC(=O)NC6=O)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OC)N8C=NC9=C8N=C(NC9=O)N)COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=O)(O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1CO)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)S)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=CC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=O)NC1=O)OC)O
DMDPNCJ	IK	HDRGJRSISASRAJ-WKPMUQCKSA-N
DMDPNCJ	IU	1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMDPNCJ	CA	CAS 1378549-07-5
DMDPNCJ	DE	Diffuse large B-cell lymphoma; Rheumatoid arthritis; Waldenstrom macroglobulinemia

DMTN16K	ID	DMTN16K
DMTN16K	DN	Implitapide
DMTN16K	HS	Phase 2
DMTN16K	SN	Implitapide [INN]; (2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide
DMTN16K	CP	MRL international
DMTN16K	DT	Small molecular drug
DMTN16K	PC	5745206
DMTN16K	MW	531.7
DMTN16K	FM	C35H37N3O2
DMTN16K	IC	InChI=1S/C35H37N3O2/c1-23-19-24(2)36-34-32(23)29-17-8-9-18-31(29)38(34)21-25-11-10-16-28(20-25)33(27-14-6-7-15-27)35(40)37-30(22-39)26-12-4-3-5-13-26/h3-5,8-13,16-20,27,30,33,39H,6-7,14-15,21-22H2,1-2H3,(H,37,40)/t30-,33-/m0/s1
DMTN16K	CS	CC1=CC(=NC2=C1C3=CC=CC=C3N2CC4=CC(=CC=C4)[C@H](C5CCCC5)C(=O)N[C@@H](CO)C6=CC=CC=C6)C
DMTN16K	IK	AMNXBQPRODZJQR-DITALETJSA-N
DMTN16K	IU	(2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide
DMTN16K	CA	CAS 177469-96-4
DMTN16K	DE	Hyperlipidaemia

DMB1N6P	ID	DMB1N6P
DMB1N6P	DN	Impoyz
DMB1N6P	HS	Phase 2
DMB1N6P	SN	Clobetasol propionate; CLOBETASOL PROPIONATE; 25122-46-7; Clobetasol 17-propionate; Clobex; Temovate; Dermovate; Embeline; Embeline E; Clobesol; Cormax; Olux; Temovate E; Olux-E; clobetasol 17-propanoate; GR 2/925; C25H32ClFO5; MLS000028708; Clobestasol propionate; Clobetasol propionate [USAN:JAN]; CGP 9555; CCI 4725; EINECS 246-634-3; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; UNII-779619577M; [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12
DMB1N6P	CP	Promius Pharma Princeton, NJ
DMB1N6P	PC	32798
DMB1N6P	MW	467
DMB1N6P	FM	C25H32ClFO5
DMB1N6P	IC	InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1
DMB1N6P	CS	CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl
DMB1N6P	IK	CBGUOGMQLZIXBE-XGQKBEPLSA-N
DMB1N6P	IU	[(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
DMB1N6P	CA	CAS 25122-46-7
DMB1N6P	CB	CHEBI:31414
DMB1N6P	DE	Plaque psoriasis

DM15MRZ	ID	DM15MRZ
DM15MRZ	DN	IMR-687
DM15MRZ	HS	Phase 2
DM15MRZ	SN	Tovinontrine; UNII-W248Y1AKOR; W248Y1AKOR; 2062661-53-2; a]pyrazin-8(7H)-one; CHEMBL4297290; SCHEMBL20358493; BDBM426313; US10513524, Compound (P3; 6-{(3S,4S)-4-methyl-1-[(pyrimidin-2-; yl)methyl]pyrrolidin-3-yl}-3-(oxan-4-yl)imidazo[1,5-; 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7himidazo(1,5-a)pyrazin-8-one; Imidazo(1,5-a)pyrazin-8(7H)-one, 6-((3S,4S)-4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl)-3-(tetrahydro-2H-pyran-4-yl)-
DM15MRZ	CP	Imara
DM15MRZ	DT	Small molecular drug
DM15MRZ	PC	124220601
DM15MRZ	MW	394.5
DM15MRZ	FM	C21H26N6O2
DM15MRZ	IC	InChI=1S/C21H26N6O2/c1-14-10-26(13-19-22-5-2-6-23-19)11-16(14)17-12-27-18(21(28)25-17)9-24-20(27)15-3-7-29-8-4-15/h2,5-6,9,12,14-16H,3-4,7-8,10-11,13H2,1H3,(H,25,28)/t14-,16-/m1/s1
DM15MRZ	CS	C[C@@H]1CN(C[C@H]1C2=CN3C(=CN=C3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5
DM15MRZ	IK	GWGNPYYVGANHRJ-GDBMZVCRSA-N
DM15MRZ	IU	6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-(oxan-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one
DM15MRZ	CA	CAS 2062661-53-2
DM15MRZ	DE	Sickle-cell disorder

DMNUXKA	ID	DMNUXKA
DMNUXKA	DN	INCAGN01876
DMNUXKA	HS	Phase 2
DMNUXKA	CP	Agenis; Incyte
DMNUXKA	DT	Antibody
DMNUXKA	DE	Solid tumour/cancer

DMK7OHI	ID	DMK7OHI
DMK7OHI	DN	INCAGN01949
DMK7OHI	HS	Phase 2
DMK7OHI	CP	Agenis; Incyte
DMK7OHI	DT	Antibody
DMK7OHI	DE	Advanced malignancy; Metastatic malignant neoplasm

DMFG8TI	ID	DMFG8TI
DMFG8TI	DN	INCB00928
DMFG8TI	HS	Phase 2
DMFG8TI	CP	Incyte
DMFG8TI	DT	Small molecular drug
DMFG8TI	DE	Multiple myeloma; Myelodysplastic syndrome; Anemia

DMD9RV3	ID	DMD9RV3
DMD9RV3	DN	INCB039110
DMD9RV3	HS	Phase 2
DMD9RV3	SN	Examlpe 294 [WO2011112662]
DMD9RV3	DT	Small molecular drug
DMD9RV3	PC	53380437
DMD9RV3	MW	553.5
DMD9RV3	FM	C26H23F4N9O
DMD9RV3	IC	InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)
DMD9RV3	CS	C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F
DMD9RV3	IK	KTBSXLIQKWEBRB-UHFFFAOYSA-N
DMD9RV3	IU	2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DMD9RV3	CA	CAS 1334298-90-6
DMD9RV3	DE	Malignant neoplasm; Non-small-cell lung cancer

DMZJP2T	ID	DMZJP2T
DMZJP2T	DN	INCB50465
DMZJP2T	HS	Phase 2
DMZJP2T	CP	Incyte Wilmington, DE
DMZJP2T	DE	Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Marginal zone lymphoma

DMDK0HX	ID	DMDK0HX
DMDK0HX	DN	INCB54707
DMDK0HX	HS	Phase 2
DMDK0HX	CP	Incyte Wilmington, DE
DMDK0HX	DE	Hidradenitis suppurativa

DMJN9PU	ID	DMJN9PU
DMJN9PU	DN	INCB86550
DMJN9PU	HS	Phase 2
DMJN9PU	CP	Incyte
DMJN9PU	DT	Small molecular drug
DMJN9PU	DE	Solid tumour/cancer

DM6OFJ8	ID	DM6OFJ8
DM6OFJ8	DN	Indibulin
DM6OFJ8	HS	Phase 2
DM6OFJ8	SN	Indibulin; 204205-90-3; 2-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-oxo-N-(pyridin-4-yl)acetamide; d-24851; UNII-80K4H2RB8P; 80K4H2RB8P; ZIO-301; D 24851; 2-[1-(4-chlorobenzyl)-1h-indol-3-yl]-2-oxo-n-(pyridin-4-yl)acetamide; N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]-glyoxyl Amide; Indibulin [USAN:INN]; 2-{1-[(4-chlorophenyl)methyl]indol-3-yl}-2-oxo-N-(4-pyridyl)acetamide; 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-(4-pyridyl)acetamide; Indibulin (USAN/INN); AC1L1ESK; AC1Q5NS8; MLS006011745; CHEMBL49642
DM6OFJ8	CP	ZioPharm
DM6OFJ8	DT	Small molecular drug
DM6OFJ8	PC	2929
DM6OFJ8	MW	389.8
DM6OFJ8	FM	C22H16ClN3O2
DM6OFJ8	IC	InChI=1S/C22H16ClN3O2/c23-16-7-5-15(6-8-16)13-26-14-19(18-3-1-2-4-20(18)26)21(27)22(28)25-17-9-11-24-12-10-17/h1-12,14H,13H2,(H,24,25,28)
DM6OFJ8	CS	C1=CC=C2C(=C1)C(=CN2CC3=CC=C(C=C3)Cl)C(=O)C(=O)NC4=CC=NC=C4
DM6OFJ8	IK	SOLIIYNRSAWTSQ-UHFFFAOYSA-N
DM6OFJ8	IU	2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-pyridin-4-ylacetamide
DM6OFJ8	CA	CAS 204205-90-3
DM6OFJ8	DE	Advanced sarcoma

DM9SX6Y	ID	DM9SX6Y
DM9SX6Y	DN	Indisulam
DM9SX6Y	HS	Phase 2
DM9SX6Y	SN	Indisulam; 165668-41-7; E7070; N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; UNII-WJ98J3NM90; E-7070; E 7070; N-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide; CHEMBL77517; WJ98J3NM90; N1-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-; ER-35744; N-(3-Chloro-1H-indol-7-yl)benzene-1,4disulfonamide; Indisulam (IND); indisulam (e7070); Indisulam (USAN/INN); AC1Q6VCX; AC1L50QL; SCHEMBL91389; N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; Indisulam [USAN:INN:BAN]
DM9SX6Y	DT	Small molecular drug
DM9SX6Y	PC	216468
DM9SX6Y	MW	385.8
DM9SX6Y	FM	C14H12ClN3O4S2
DM9SX6Y	IC	InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)
DM9SX6Y	CS	C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)N)NC=C2Cl
DM9SX6Y	IK	SETFNECMODOHTO-UHFFFAOYSA-N
DM9SX6Y	IU	4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide
DM9SX6Y	CA	CAS 165668-41-7
DM9SX6Y	CB	CHEBI:145431
DM9SX6Y	DE	Lymphoma

DMU5SZP	ID	DMU5SZP
DMU5SZP	DN	Inecalcitol oral
DMU5SZP	HS	Phase 2
DMU5SZP	SN	Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796;  Inecalcitol; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics; 19-nor-14-epi-23-yne-1,25 dihydroxyvitamin D3
DMU5SZP	CP	Catholic University of Leuven; Hybrigenics
DMU5SZP	DT	Small molecular drug
DMU5SZP	PC	6915835
DMU5SZP	MW	400.6
DMU5SZP	FM	C26H40O3
DMU5SZP	IC	InChI=1S/C26H40O3/c1-18(7-5-13-25(2,3)29)23-11-12-24-20(8-6-14-26(23,24)4)10-9-19-15-21(27)17-22(28)16-19/h9-10,18,21-24,27-29H,6-8,11-12,14-17H2,1-4H3/b20-10+/t18-,21-,22-,23-,24-,26-/m1/s1
DMU5SZP	CS	C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C[C@@H](C3)O)O)C
DMU5SZP	IK	HHGRMHMXKPQNGF-WNSNRMDMSA-N
DMU5SZP	IU	(1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
DMU5SZP	CA	CAS 163217-09-2
DMU5SZP	DE	Prostate cancer; Acute myeloid leukaemia

DMEO9Y7	ID	DMEO9Y7
DMEO9Y7	DN	INGAP peptide
DMEO9Y7	HS	Phase 2
DMEO9Y7	CP	Exsulin
DMEO9Y7	DE	Type-1/2 diabetes

DMF7J6D	ID	DMF7J6D
DMF7J6D	DN	INGN-225
DMF7J6D	HS	Phase 2
DMF7J6D	SN	Cancer vaccine (p53), Introgen
DMF7J6D	CP	Introgen Therapeutics
DMF7J6D	DT	Vaccine
DMF7J6D	DE	Head and neck cancer

DM6P91T	ID	DM6P91T
DM6P91T	DN	INGN-241
DM6P91T	HS	Phase 2
DM6P91T	SN	AD-IL-24, Introgen; AD-mda-7, Introgen; Adenovirus-IL-24, Introgen; Adenovirus-mda-7, Introgen
DM6P91T	CP	Multivir; Introgen Therapeutics
DM6P91T	DE	Solid tumour/cancer

DMGO7QT	ID	DMGO7QT
DMGO7QT	DN	INK128
DMGO7QT	HS	Phase 2
DMGO7QT	SN	1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)
DMGO7QT	CP	Intellikine; MMRC
DMGO7QT	DT	Small molecular drug
DMGO7QT	PC	45375953
DMGO7QT	MW	309.33
DMGO7QT	FM	C15H15N7O
DMGO7QT	IC	InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)
DMGO7QT	CS	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N
DMGO7QT	IK	GYLDXIAOMVERTK-UHFFFAOYSA-N
DMGO7QT	IU	5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
DMGO7QT	CA	CAS 1224844-38-5
DMGO7QT	CB	CHEBI:91450
DMGO7QT	DE	Multiple myeloma; Breast cancer

DMKRGVJ	ID	DMKRGVJ
DMKRGVJ	DN	INS-1
DMKRGVJ	HS	Phase 2
DMKRGVJ	SN	Diabetes therapeutics, Insmed; Inositol phosphoglycans, Insmed; D-chiro-inositol, Insmed
DMKRGVJ	CP	Insmed Inc
DMKRGVJ	DE	Metabolic disorder

DMF93RQ	ID	DMF93RQ
DMF93RQ	DN	INS-37217
DMF93RQ	HS	Phase 2
DMF93RQ	SN	Denufosol tetrasodium; DCp4U; INS 37217; INS37217; Up4dC; Denufosol tetrasodium (USAN); Uridine 5'-(pentahydrogen tetraphosphate), P'''-5'-ester with 2'-deoxycytidine, tetrasodium salt; Tetrasodium [[(3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DMF93RQ	CP	Inspire Pharmaceuticals
DMF93RQ	DT	Small molecular drug
DMF93RQ	PC	10219163
DMF93RQ	MW	861.3
DMF93RQ	FM	C18H23N5Na4O21P4
DMF93RQ	IC	InChI=1S/C18H27N5O21P4.4Na/c19-11-1-3-22(17(28)20-11)13-5-8(24)9(40-13)6-38-45(30,31)42-47(34,35)44-48(36,37)43-46(32,33)39-7-10-14(26)15(27)16(41-10)23-4-2-12(25)21-18(23)29;;;;/h1-4,8-10,13-16,24,26-27H,5-7H2,(H,30,31)(H,32,33)(H,34,35)(H,36,37)(H2,19,20,28)(H,21,25,29);;;;/q;4*+1/p-4/t8-,9+,10+,13+,14+,15+,16+;;;;/m0..../s1
DMF93RQ	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O.[Na+].[Na+].[Na+].[Na+]
DMF93RQ	IK	PASYJVRFGUDDEW-WMUGRWSXSA-J
DMF93RQ	IU	tetrasodium;[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate
DMF93RQ	CA	CAS 318250-11-2
DMF93RQ	DE	Cystic fibrosis

DMKZUVC	ID	DMKZUVC
DMKZUVC	DN	INS-50589
DMKZUVC	HS	Phase 2
DMKZUVC	SN	Regrelor; UNII-Q6C8TY6SW1; Q6C8TY6SW1; CHEMBL1162175; INS-50589; 787548-03-2; Regrelor [INN]; GTPL1770; DTXSID80229272; INS 50589; BDBM50371580; [(2S,3aR,4R,6R,6aR)-6-[6-(ethylcarbamoylamino)purin-9-yl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[4,3-d][1,3]dioxol-4-yl]methyl dihydrogen phosphate
DMKZUVC	CP	Inspire Pharmaceuticals
DMKZUVC	DT	Small molecular drug
DMKZUVC	PC	11273179
DMKZUVC	MW	532.4
DMKZUVC	FM	C22H25N6O8P
DMKZUVC	IC	InChI=1S/C22H25N6O8P/c1-2-23-22(29)27-19-16-20(25-11-24-19)28(12-26-16)21-18-17(14(34-21)10-33-37(30,31)32)35-15(36-18)9-8-13-6-4-3-5-7-13/h3-9,11-12,14-15,17-18,21H,2,10H2,1H3,(H2,30,31,32)(H2,23,24,25,27,29)/b9-8+/t14-,15+,17-,18-,21-/m1/s1
DMKZUVC	CS	CCNC(=O)NC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@H]4[C@@H]([C@H](O3)COP(=O)(O)O)O[C@@H](O4)/C=C/C5=CC=CC=C5
DMKZUVC	IK	NXHAXEBZOXCDKD-XIXRRVGJSA-N
DMKZUVC	IU	[(2S,3aR,4R,6R,6aR)-4-[6-(ethylcarbamoylamino)purin-9-yl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl dihydrogen phosphate
DMKZUVC	CA	CAS 787548-03-2
DMKZUVC	DE	Cardiovascular disease

DMNKAFQ	ID	DMNKAFQ
DMNKAFQ	DN	Instiladrin
DMNKAFQ	HS	Phase 2
DMNKAFQ	CP	Fkd therapies
DMNKAFQ	DE	Bladder cancer

DMYTKF5	ID	DMYTKF5
DMYTKF5	DN	Interferon
DMYTKF5	HS	Phase 2
DMYTKF5	CP	Amarillo biosciences
DMYTKF5	DE	Human papillomavirus infection; Hepatitis C virus infection

DMVACTU	ID	DMVACTU
DMVACTU	DN	Interferon alpha-2b
DMVACTU	HS	Phase 2
DMVACTU	SN	IFN-alpha-XL; IFN-alpha (Medusa), Flamel; Interferon alpha-2b (subcutaneous/controlled release, Medusa); Interferon alpha-2b (subcutaneous/controlled release, Medusa), Flamel
DMVACTU	CP	Hanall biopharma; medtronic
DMVACTU	DE	Hepatitis C virus infection

DMQSA7H	ID	DMQSA7H
DMQSA7H	DN	Interferon beta 1a
DMQSA7H	HS	Phase 2
DMQSA7H	SN	Aerosolised interferon beta 1a; AZD-9412; Inhaled interferon beta 1a; SNG-001
DMQSA7H	TC	Respiratory Agents
DMQSA7H	DE	Discovery agent

DM8YF01	ID	DM8YF01
DM8YF01	DN	Interferon-alpha lozenge
DM8YF01	HS	Phase 2
DM8YF01	SN	Veldona (TN)
DM8YF01	CP	Amarillo Biosciences
DM8YF01	DE	Fibromyalgia; Chronic obstructive pulmonary disease; Behcet disease

DMBXEG9	ID	DMBXEG9
DMBXEG9	DN	Intetumumab
DMBXEG9	HS	Phase 2
DMBXEG9	CP	Janssen Biotech
DMBXEG9	DT	Monoclonal antibody
DMBXEG9	DE	Prostate cancer

DMSTJ6Q	ID	DMSTJ6Q
DMSTJ6Q	DN	INX-189
DMSTJ6Q	HS	Phase 2
DMSTJ6Q	SN	INX-08032; INX-08189; INX-108; Nucleoside polymerase inhibitors (HCV infection), Cardiff University/Rega Institute; Nucleoside polymerase inhibitors (oral, HCV infection), Inhibitex
DMSTJ6Q	CP	Cardiff University
DMSTJ6Q	DT	Small molecular drug
DMSTJ6Q	PC	46700744
DMSTJ6Q	MW	658.6
DMSTJ6Q	FM	C30H39N6O9P
DMSTJ6Q	IC	InChI=1S/C30H39N6O9P/c1-17(26(38)42-15-29(2,3)4)35-46(40,45-20-13-9-11-18-10-7-8-12-19(18)20)43-14-21-23(37)30(5,39)27(44-21)36-16-32-22-24(36)33-28(31)34-25(22)41-6/h7-13,16-17,21,23,27,37,39H,14-15H2,1-6H3,(H,35,40)(H2,31,33,34)/t17-,21+,23+,27+,30+,46?/m0/s1
DMSTJ6Q	CS	C[C@@H](C(=O)OCC(C)(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=NC3=C2N=C(N=C3OC)N)(C)O)O)OC4=CC=CC5=CC=CC=C54
DMSTJ6Q	IK	YFXGICNMLCGLHJ-RSKRLRQZSA-N
DMSTJ6Q	IU	2,2-dimethylpropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate
DMSTJ6Q	CA	CAS 1234490-83-5
DMSTJ6Q	DE	Hepatitis C virus infection

DMNW0DG	ID	DMNW0DG
DMNW0DG	DN	Iodine-131-tositumomab
DMNW0DG	HS	Phase 2
DMNW0DG	DT	Antibody

DM5F0QY	ID	DM5F0QY
DM5F0QY	DN	IONIS-416858
DM5F0QY	HS	Phase 2
DM5F0QY	SN	IONIS-FXI-LRx
DM5F0QY	CP	Ionis Pharmaceuticals
DM5F0QY	DT	Antisense oligonucleotide
DM5F0QY	DE	Thrombosis

DM6PDX2	ID	DM6PDX2
DM6PDX2	DN	IONIS-C9Rx
DM6PDX2	HS	Phase 2
DM6PDX2	SN	BIIB078
DM6PDX2	CP	Ionis Pharmaceuticals
DM6PDX2	DT	Antisense oligonucleotide
DM6PDX2	DE	Amyotrophic lateral sclerosis

DM5LM3O	ID	DM5LM3O
DM5LM3O	DN	IONIS-DNM2-2.5Rx
DM5LM3O	HS	Phase 2
DM5LM3O	CP	Ionis Pharmaceuticals
DM5LM3O	DT	Antisense oligonucleotide
DM5LM3O	DE	Centronuclear myopathy

DMJ2763	ID	DMJ2763
DMJ2763	DN	IONIS-FB-LRx
DMJ2763	HS	Phase 2
DMJ2763	CP	Ionis Pharmaceuticals
DMJ2763	DT	Antisense oligonucleotide
DMJ2763	DE	IgA nephropathy

DMWV2N1	ID	DMWV2N1
DMWV2N1	DN	IONIS-GCCRRX
DMWV2N1	HS	Phase 2
DMWV2N1	CP	onis Pharmaceuticals Carlsbad, CA
DMWV2N1	DE	Type-2 diabetes

DMB4GD9	ID	DMB4GD9
DMB4GD9	DN	IONIS-GCGR-Rx
DMB4GD9	HS	Phase 2
DMB4GD9	CP	Ionis Pharmaceuticals
DMB4GD9	DT	Antisense oligonucleotide
DMB4GD9	DE	Type-2 diabetes; Type 2 diabetes

DMGTJUP	ID	DMGTJUP
DMGTJUP	DN	IONIS-PTP1BRX
DMGTJUP	HS	Phase 2
DMGTJUP	CP	onis Pharmaceuticals Carlsbad, CA
DMGTJUP	DE	Type-2 diabetes

DM7VJE1	ID	DM7VJE1
DM7VJE1	DN	IONIS-TMPRSS6-LRx
DM7VJE1	HS	Phase 2
DM7VJE1	CP	Ionis Pharmaceuticals
DM7VJE1	DT	Antisense oligonucleotide
DM7VJE1	DE	Beta thalassemia

DM5TMYC	ID	DM5TMYC
DM5TMYC	DN	iOWH032
DM5TMYC	HS	Phase 2
DM5TMYC	SN	IOWH-032; CFTR inhibitors (diarrhea), BioFocus
DM5TMYC	CP	The Institute for OneWorld Health
DM5TMYC	PC	135565181
DM5TMYC	MW	545.2
DM5TMYC	FM	C22H15Br2N3O4
DM5TMYC	IC	InChI=1S/C22H15Br2N3O4/c23-17-10-14(11-18(24)19(17)28)20-26-22(31-27-20)21(29)25-12-13-6-8-16(9-7-13)30-15-4-2-1-3-5-15/h1-11,28H,12H2,(H,25,29)
DM5TMYC	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)CNC(=O)C3=NC(=NO3)C4=CC(=C(C(=C4)Br)O)Br
DM5TMYC	IK	DSFNLJXHXBIKDS-UHFFFAOYSA-N
DM5TMYC	IU	3-(3,5-dibromo-4-hydroxyphenyl)-N-[(4-phenoxyphenyl)methyl]-1,2,4-oxadiazole-5-carboxamide
DM5TMYC	CA	CAS 1191252-49-9
DM5TMYC	DE	Diarrhea

DMANRGW	ID	DMANRGW
DMANRGW	DN	IP10 C8
DMANRGW	HS	Phase 2
DMANRGW	SN	IP10C8
DMANRGW	DE	Psoriasis vulgaris

DMDUVCZ	ID	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	HS	Phase 2
DMDUVCZ	CP	Innate Pharma
DMDUVCZ	DE	Multiple myeloma

DMPBR0D	ID	DMPBR0D
DMPBR0D	DN	IPH-2102
DMPBR0D	HS	Phase 2
DMPBR0D	CP	Innate Pharma SA
DMPBR0D	DE	Acute myeloid leukaemia

DMQH2SF	ID	DMQH2SF
DMQH2SF	DN	IPH4102
DMQH2SF	HS	Phase 2
DMQH2SF	CP	Innate Pharma Marseille, France
DMQH2SF	DE	T-cell lymphoma

DMG5Q7F	ID	DMG5Q7F
DMG5Q7F	DN	IPI-549
DMG5Q7F	HS	Phase 2
DMG5Q7F	SN	XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((
DMG5Q7F	CP	Infinity Pharmaceuticals Cambridge, MA
DMG5Q7F	PC	91933883
DMG5Q7F	MW	528.6
DMG5Q7F	FM	C30H24N8O2
DMG5Q7F	IC	InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1
DMG5Q7F	CS	C[C@@H](C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N
DMG5Q7F	IK	XUMALORDVCFWKV-IBGZPJMESA-N
DMG5Q7F	IU	2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
DMG5Q7F	CA	CAS 1693758-51-8
DMG5Q7F	DE	Adrenocortical carcinoma; Breast cancer; Head and neck cancer; Melanoma; Mesothelioma; Solid tumour/cancer; Bladder cancer

DMW2IF9	ID	DMW2IF9
DMW2IF9	DN	IR502
DMW2IF9	HS	Phase 2
DMW2IF9	SN	Zorcell
DMW2IF9	CP	Orchestra Therapeutics
DMW2IF9	DE	Psoriatic disorder; Plaque psoriasis; Psoriasis vulgaris

DMQ3RWN	ID	DMQ3RWN
DMQ3RWN	DN	Iralukast
DMQ3RWN	HS	Phase 2
DMQ3RWN	SN	CGP-45715A
DMQ3RWN	CP	Novartis AG
DMQ3RWN	DT	Small molecular drug
DMQ3RWN	PC	6913104
DMQ3RWN	MW	710.8
DMQ3RWN	FM	C38H37F3O8S
DMQ3RWN	IC	InChI=1S/C38H37F3O8S/c1-3-11-29-31(18-17-27(23(2)42)36(29)45)48-19-9-7-5-4-6-8-14-34(35(44)24-12-10-13-25(20-24)38(39,40)41)50-26-15-16-28-30(43)22-33(37(46)47)49-32(28)21-26/h4,6,8,10,12-18,20-22,34-35,44-45H,3,5,7,9,11,19H2,1-2H3,(H,46,47)/b6-4-,14-8+/t34-,35+/m0/s1
DMQ3RWN	CS	CCCC1=C(C=CC(=C1O)C(=O)C)OCCCC/C=C\\C=C\\[C@@H]([C@@H](C2=CC(=CC=C2)C(F)(F)F)O)SC3=CC4=C(C=C3)C(=O)C=C(O4)C(=O)O
DMQ3RWN	IK	IXJCHVMUTFCRBH-SDUHDBOFSA-N
DMQ3RWN	IU	7-[(1R,2S,3E,5Z)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-[3-(trifluoromethyl)phenyl]deca-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid
DMQ3RWN	CA	CAS 151581-24-7
DMQ3RWN	DE	Asthma

DMI874B	ID	DMI874B
DMI874B	DN	Iratumumab
DMI874B	HS	Phase 2
DMI874B	SN	MDX-060; Anti-CD30 antibody, Medarex; 5F11
DMI874B	CP	Medarex
DMI874B	DT	Antibody
DMI874B	DE	Lymphoma

DMCAFVN	ID	DMCAFVN
DMCAFVN	DN	IRT-102
DMCAFVN	HS	Phase 2
DMCAFVN	CP	Tni biotech
DMCAFVN	DT	Small molecular drug
DMCAFVN	PC	42785
DMCAFVN	MW	573.7
DMCAFVN	FM	C27H35N5O7S
DMCAFVN	IC	InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)
DMCAFVN	CS	CSCCC(C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)N
DMCAFVN	IK	YFGBQHOOROIVKG-UHFFFAOYSA-N
DMCAFVN	IU	2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DMCAFVN	CA	CAS 58569-55-4
DMCAFVN	DE	Pancreatic cancer

DMODLN7	ID	DMODLN7
DMODLN7	DN	IRX-2
DMODLN7	HS	Phase 2
DMODLN7	CP	IRX Therapeutics
DMODLN7	DE	Head and neck cancer; Acute myeloid leukaemia; Breast cancer; Squamous cell carcinoma; leukaemia

DMHOJ8W	ID	DMHOJ8W
DMHOJ8W	DN	Isatoribine
DMHOJ8W	HS	Phase 2
DMHOJ8W	SN	7-Thia-8-oxoguanosine; ANA245; 122970-40-5; UNII-2DNT962H92; ANA-245; 2DNT962H92; Immusine; Isatoribine [USAN:INN]; 7-TOG; Immunosine; Satoribine; N10146; 7-Deaza-7-thia-8-oxoguanosine; AC1L2HO7; SCHEMBL127980; AC1Q6N18; SCHEMBL12592999; CHEMBL2105116; ANA 245; TZYVRXZQAWPIAB-FCLHUMLKSA-N; ZINC8214713; 5-Amino-3-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3H,6H)-dione; DB04860; 5-amino-3-(; A-d-ribofuranosyl)[1,3]thiazolo[4,5-d]pyrimidine-2,7(3h,4h)-dione; BRD-K87535339-001-01-6
DMHOJ8W	CP	Anadys Pharmaceuticals
DMHOJ8W	DT	Small molecular drug
DMHOJ8W	PC	135409474
DMHOJ8W	MW	316.29
DMHOJ8W	FM	C10H12N4O6S
DMHOJ8W	IC	InChI=1S/C10H12N4O6S/c11-9-12-6-5(7(18)13-9)21-10(19)14(6)8-4(17)3(16)2(1-15)20-8/h2-4,8,15-17H,1H2,(H3,11,12,13,18)/t2-,3-,4-,8-/m1/s1
DMHOJ8W	CS	C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=C(C(=O)NC(=N3)N)SC2=O)O)O)O
DMHOJ8W	IK	TZYVRXZQAWPIAB-FCLHUMLKSA-N
DMHOJ8W	IU	5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione
DMHOJ8W	CA	CAS 122970-40-5
DMHOJ8W	DE	Hepatitis C virus infection

DMBZK3P	ID	DMBZK3P
DMBZK3P	DN	ISF35
DMBZK3P	HS	Phase 2
DMBZK3P	CP	Memgen
DMBZK3P	DE	Small lymphocytic lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukaemia

DMUPD4G	ID	DMUPD4G
DMUPD4G	DN	ISIS 113715
DMUPD4G	HS	Phase 2
DMUPD4G	CP	ISIS
DMUPD4G	TC	Antisense
DMUPD4G	DT	Antisense drug
DMUPD4G	SQ	GCTCCTTCCACTGATCCTGC
DMUPD4G	DE	Type-2 diabetes

DMQ3C05	ID	DMQ3C05
DMQ3C05	DN	ISIS-APO(a)
DMQ3C05	HS	Phase 2
DMQ3C05	DT	Antisense drug
DMQ3C05	DE	Coronary artery disease

DML84CN	ID	DML84CN
DML84CN	DN	ISIS-CRPRx
DML84CN	HS	Phase 2
DML84CN	CP	ISIS pharmaceuticals
DML84CN	DE	Coronary artery disease

DMRN543	ID	DMRN543
DMRN543	DN	ISIS-EIF4E
DMRN543	HS	Phase 2
DMRN543	CP	ISIS Pharm
DMRN543	DT	Antisense drug
DMRN543	DE	Prostate cancer; Non-small-cell lung cancer; Solid tumour/cancer

DMNVZDT	ID	DMNVZDT
DMNVZDT	DN	ISIS-FGFR4
DMNVZDT	HS	Phase 2
DMNVZDT	CP	ISIS Pharm
DMNVZDT	DT	Antisense drug
DMNVZDT	DE	Obesity

DMHETPI	ID	DMHETPI
DMHETPI	DN	ISIS-FXI
DMHETPI	HS	Phase 2
DMHETPI	CP	ISIS Pharm
DMHETPI	DT	Antisense drug
DMHETPI	DE	Coagulation defect

DMICMNU	ID	DMICMNU
DMICMNU	DN	ISIS-GCCR
DMICMNU	HS	Phase 2
DMICMNU	CP	ISIS Pharm
DMICMNU	DT	Antisense drug
DMICMNU	DE	Diabetic complication; Type-2 diabetes

DMHNYWP	ID	DMHNYWP
DMHNYWP	DN	ISIS-GCGR
DMHNYWP	HS	Phase 2
DMHNYWP	CP	ISIS Pharm
DMHNYWP	DT	Antisense drug
DMHNYWP	DE	Diabetic complication; Type-2 diabetes

DM4RXDQ	ID	DM4RXDQ
DM4RXDQ	DN	ISIS-HBV
DM4RXDQ	HS	Phase 2
DM4RXDQ	DT	Antisense drug
DM4RXDQ	DE	Hepatitis B virus infection

DMJGVXT	ID	DMJGVXT
DMJGVXT	DN	ISIS-PTP1Brx
DMJGVXT	HS	Phase 2
DMJGVXT	CP	Isis Pharmaceuticals
DMJGVXT	DT	Antisense drug
DMJGVXT	DE	Type-2 diabetes

DM2RS0V	ID	DM2RS0V
DM2RS0V	DN	Isofagomine tartrate
DM2RS0V	HS	Phase 2
DM2RS0V	SN	Plicera; Afegostat tartrate; AT-2101; HGT-3410; Plicera (TN); NN-42-1007
DM2RS0V	CP	Amicus Therape.
DM2RS0V	DT	Small molecular drug
DM2RS0V	PC	23581846
DM2RS0V	MW	297.26
DM2RS0V	FM	C10H19NO9
DM2RS0V	IC	InChI=1S/C6H13NO3.C4H6O6/c8-3-4-1-7-2-5(9)6(4)10;5-1(3(7)8)2(6)4(9)10/h4-10H,1-3H2;1-2,5-6H,(H,7,8)(H,9,10)/t4-,5-,6-;1-,2-/m11/s1
DM2RS0V	CS	C1[C@@H]([C@H]([C@@H](CN1)O)O)CO.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DM2RS0V	IK	ULBPPCHRAVUQMC-MUMXBIPUSA-N
DM2RS0V	IU	(2R,3R)-2,3-dihydroxybutanedioic acid;(3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol
DM2RS0V	CA	CAS 919364-56-0
DM2RS0V	DE	Metabolic disorder

DMP2BWX	ID	DMP2BWX
DMP2BWX	DN	Ispinesib
DMP2BWX	HS	Phase 2
DMP2BWX	SN	SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
DMP2BWX	CP	Cytokinetics
DMP2BWX	TC	Anticancer Agents
DMP2BWX	DT	Small molecular drug
DMP2BWX	PC	6851740
DMP2BWX	MW	517.1
DMP2BWX	FM	C30H33ClN4O2
DMP2BWX	IC	InChI=1S/C30H33ClN4O2/c1-20(2)27(34(17-7-16-32)29(36)23-12-10-21(3)11-13-23)28-33-26-18-24(31)14-15-25(26)30(37)35(28)19-22-8-5-4-6-9-22/h4-6,8-15,18,20,27H,7,16-17,19,32H2,1-3H3/t27-/m1/s1
DMP2BWX	CS	CC1=CC=C(C=C1)C(=O)N(CCCN)[C@@H](C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4)C(C)C
DMP2BWX	IK	QJZRFPJCWMNVAV-HHHXNRCGSA-N
DMP2BWX	IU	N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
DMP2BWX	CA	CAS 336113-53-2
DMP2BWX	CB	CHEBI:94692
DMP2BWX	DE	Solid tumour/cancer; Ovarian cancer; Renal cell carcinoma; Head and neck cancer

DMCY9PO	ID	DMCY9PO
DMCY9PO	DN	Itarnafloxin
DMCY9PO	HS	Phase 2
DMCY9PO	SN	Quarfloxin; CX-3385; CX-3543; Quadruplex DNA oncogene inhibitor (cancer), Cylene; C-Myc/VEGF oncogene inhibitor (cancer), Cylene
DMCY9PO	CP	Cylene Pharmaceuticals Inc
DMCY9PO	DT	Small molecular drug
DMCY9PO	PC	11635763
DMCY9PO	MW	604.7
DMCY9PO	FM	C35H33FN6O3
DMCY9PO	IC	InChI=1S/C35H33FN6O3/c1-40-13-4-7-24(40)8-10-39-35(44)26-20-42-29-15-21-5-2-3-6-22(21)16-30(29)45-34-31(42)25(33(26)43)17-27(36)32(34)41-14-9-23(19-41)28-18-37-11-12-38-28/h2-3,5-6,11-12,15-18,20,23-24H,4,7-10,13-14,19H2,1H3,(H,39,44)/t23?,24-/m0/s1
DMCY9PO	CS	CN1CCC[C@H]1CCNC(=O)C2=CN3C4=CC5=CC=CC=C5C=C4OC6=C3C(=CC(=C6N7CCC(C7)C8=NC=CN=C8)F)C2=O
DMCY9PO	IK	WOQIDNWTQOYDLF-CGAIIQECSA-N
DMCY9PO	IU	15-fluoro-N-[2-[(2S)-1-methylpyrrolidin-2-yl]ethyl]-18-oxo-14-(3-pyrazin-2-ylpyrrolidin-1-yl)-12-oxa-1-azapentacyclo[11.7.1.02,11.04,9.017,21]henicosa-2,4,6,8,10,13(21),14,16,19-nonaene-19-carboxamide
DMCY9PO	CA	CAS 865311-47-3
DMCY9PO	DE	leukaemia

DMDZWPL	ID	DMDZWPL
DMDZWPL	DN	ITCA-638
DMDZWPL	HS	Phase 2
DMDZWPL	SN	Omega DUROS, BioMedicines/ ALZA; Omega DUROS, Intarcia/ALZA; Omega IFN (sustained release), BioMedicines/ ALZA; Omega IFN (sustained release, hepatitis C), Intarcia/ALZA; Omega interferon (sustained release/subcutaneous/DUROS, hepatitis C), BioMedicines/ ALZA; Omega interferon (sustained release/subcutaneous/DUROS, hepatitis C), Intarcia/ALZA
DMDZWPL	CP	Intarcia Therapeutics Inc
DMDZWPL	DE	Hepatitis C virus infection

DM5UFRO	ID	DM5UFRO
DM5UFRO	DN	Itriglumide
DM5UFRO	HS	Phase 2
DM5UFRO	SN	CR-2945
DM5UFRO	CP	Rottapharm Madaus
DM5UFRO	DT	Small molecular drug
DM5UFRO	PC	6604121
DM5UFRO	MW	526.7
DM5UFRO	FM	C33H38N2O4
DM5UFRO	IC	InChI=1S/C33H38N2O4/c1-22-18-23(2)31(28(19-22)32(39)35-16-14-33(15-17-35)12-5-6-13-33)34-29(36)20-25(21-30(37)38)27-11-7-9-24-8-3-4-10-26(24)27/h3-4,7-11,18-19,25H,5-6,12-17,20-21H2,1-2H3,(H,34,36)(H,37,38)/t25-/m1/s1
DM5UFRO	CS	CC1=CC(=C(C(=C1)C(=O)N2CCC3(CCCC3)CC2)NC(=O)C[C@H](CC(=O)O)C4=CC=CC5=CC=CC=C54)C
DM5UFRO	IK	MFOOVZCXWVAWOV-RUZDIDTESA-N
DM5UFRO	IU	(3R)-5-[2-(8-azaspiro[4.5]decane-8-carbonyl)-4,6-dimethylanilino]-3-naphthalen-1-yl-5-oxopentanoic acid
DM5UFRO	CA	CAS 201605-51-8
DM5UFRO	DE	Anxiety disorder

DMCJX79	ID	DMCJX79
DMCJX79	DN	ITV-1
DMCJX79	HS	Phase 2
DMCJX79	CP	Immunotech Laboratories
DMCJX79	DT	Vaccine
DMCJX79	DE	Human immunodeficiency virus infection

DMJV3AX	ID	DMJV3AX
DMJV3AX	DN	IVA337
DMJV3AX	HS	Phase 2
DMJV3AX	SN	Lanifibranor; 927961-18-0; IVA-337; UNII-28Q8AG0PYL; 28Q8AG0PYL; CHEMBL4091374; CPD1537; 4-(1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic acid; 1H-Indole-2-butanoic acid, 1-(6-benzothiazolylsulfonyl)-5-chloro-; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic acid; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid; Lanifbranor; Libfranor; Lanifbranor [INN]; Lanifibranor(IVA-337); SCHEMBL3528615; AMY16813; EX-A1511; BDBM50244350; s8770; DB14801; SB18746; AC-31451; AK689102; BS-17993; HY-104049; CS-0027586; Q27896056; 1-(6-Benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic Acid; 5-Chloro-1-((6-benzothiazolyl)sulfonyl)-1H-indole-2-butanoic acid; 4-(1-(benzo[d]thiazol-6-ylsulfonyl)-5-chloro-1H-indol-2-yl)butanoic acid; BJB
DMJV3AX	DT	Small molecular drug
DMJV3AX	PC	68677842
DMJV3AX	MW	434.9
DMJV3AX	FM	C19H15ClN2O4S2
DMJV3AX	IC	InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)
DMJV3AX	CS	C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2
DMJV3AX	IK	OQDQIFQRNZIEEJ-UHFFFAOYSA-N
DMJV3AX	IU	4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid
DMJV3AX	CA	CAS 927961-18-0
DMJV3AX	DE	Non-alcoholic steatohepatitis

DM0OYLQ	ID	DM0OYLQ
DM0OYLQ	DN	I-vation
DM0OYLQ	HS	Phase 2
DM0OYLQ	SN	Triamcinolone implant
DM0OYLQ	CP	SurModics
DM0OYLQ	DE	Diabetic retinopathy

DM457XO	ID	DM457XO
DM457XO	DN	IW-1701
DM457XO	HS	Phase 2
DM457XO	SN	Olinciguat; 1628732-62-6; UNII-PD5F4ZXD21; PD5F4ZXD21; IW1701; 5-(1,2-oxazol-3-yl)-1H-pyrazol-; 3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-; Olinciguat [INN]; Olinciguat [USAN]; Olinciguat (USAN/INN); Olinciguat [USAN:INN]; CHEMBL4297616; SCHEMBL16081945; GTPL10213; BDBM321744; DB15238; US10183021, Compound I-531; AC-31551; HY-109066; CS-0033431; D11475; (2~{R})-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide
DM457XO	CP	Cyclerion Therapeutics
DM457XO	DT	Small molecular drug
DM457XO	PC	90445883
DM457XO	MW	509.4
DM457XO	FM	C21H16F5N7O3
DM457XO	IC	InChI=1S/C21H16F5N7O3/c22-12-4-2-1-3-11(12)9-33-16(14-5-6-36-32-14)7-15(31-33)18-28-8-13(23)17(30-18)29-10-20(35,19(27)34)21(24,25)26/h1-8,35H,9-10H2,(H2,27,34)(H,28,29,30)/t20-/m1/s1
DM457XO	CS	C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NC[C@@](C(=O)N)(C(F)(F)F)O)F)C4=NOC=C4)F
DM457XO	IK	YWQFJNWMWZMXRW-HXUWFJFHSA-N
DM457XO	IU	(2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide
DM457XO	CA	CAS 1628732-62-6
DM457XO	DE	Sickle-cell disorder

DMK2T7J	ID	DMK2T7J
DMK2T7J	DN	IW-1973
DMK2T7J	HS	Phase 2
DMK2T7J	SN	Praliciguat; UNII-R1S0H458SA; R1S0H458SA; 1628730-49-3; Praliciguat [INN]; GTPL9900; SCHEMBL16082414; IW1973; 1,1,1-trifluoro-3-[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)-1H-pyrazol-3-yl}pyrimidin-4-yl)amino]-2-(trifluoromethyl)propan-2-ol; 2-Propanol, 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-((2-fluorophenyl)methyl)-5-(3-isoxazolyl)-1H-pyrazol-3-yl)-4-pyrimidinyl)amino)methyl)-
DMK2T7J	CP	Ironwood Pharmaceuticals Cambridge, MA
DMK2T7J	PC	86269973
DMK2T7J	MW	534.4
DMK2T7J	FM	C21H14F8N6O2
DMK2T7J	IC	InChI=1S/C21H14F8N6O2/c22-12-4-2-1-3-11(12)9-35-16(14-5-6-37-34-14)7-15(33-35)18-30-8-13(23)17(32-18)31-10-19(36,20(24,25)26)21(27,28)29/h1-8,36H,9-10H2,(H,30,31,32)
DMK2T7J	CS	C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NCC(C(F)(F)F)(C(F)(F)F)O)F)C4=NOC=C4)F
DMK2T7J	IK	CYSJNTQNMDWAJV-UHFFFAOYSA-N
DMK2T7J	IU	1,1,1,3,3,3-hexafluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]propan-2-ol
DMK2T7J	CA	CAS 1628730-49-3
DMK2T7J	CB	CHEBI:142431
DMK2T7J	DE	Heart failure

DMP42W1	ID	DMP42W1
DMP42W1	DN	IW-6118
DMP42W1	HS	Phase 2
DMP42W1	CP	Ironwood Pharmaceuticals Inc
DMP42W1	DE	Inflammation

DM3WSDR	ID	DM3WSDR
DM3WSDR	DN	IXT-m200
DM3WSDR	HS	Phase 2
DM3WSDR	CP	InterveXion Therapeutics
DM3WSDR	DT	Antibody
DM3WSDR	DE	Methamphetamine use disorder

DM9XKJU	ID	DM9XKJU
DM9XKJU	DN	J 591 Lu-177
DM9XKJU	HS	Phase 2
DM9XKJU	CP	BZL Biologics
DM9XKJU	DE	Prostate cancer

DMKU6MW	ID	DMKU6MW
DMKU6MW	DN	JB991
DMKU6MW	HS	Phase 2
DMKU6MW	CP	Synphora
DMKU6MW	DE	Sarcoidosis; Skin infection

DM89ASO	ID	DM89ASO
DM89ASO	DN	JCAR015
DM89ASO	HS	Phase 2
DM89ASO	CP	Juno Therapeutics, Inc.
DM89ASO	DT	CAR T Cell Therapy
DM89ASO	DE	B-cell lymphoma; Acute lymphoblastic leukaemia

DMM02VJ	ID	DMM02VJ
DMM02VJ	DN	JI-101
DMM02VJ	HS	Phase 2
DMM02VJ	SN	JI-101; 900573-88-8; CGI-1842; UNII-980M4N37DH; 980M4N37DH; 1-(1-((2-AMINOPYRIDIN-4-YL)METHYL)-1H-INDOL-4-YL)-3-(5-BROMO-2-METHOXYPHENYL)UREA; SCHEMBL5585996; CHEMBL3545155; MolPort-044-567-620; BCP16892; EX-A2371; JI 101; ZINC38255464; AKOS030526978; SB16904; DB12744; CS-5636; Urea, N-(1-((2-amino-4-pyridinyl)methyl)-1H-indol-4-yl)-N'-(5-bromo-2-methoxyphenyl)-; KB-77988; HY-16265
DMM02VJ	CP	Jubilant Biosys
DMM02VJ	DT	Small molecular drug
DMM02VJ	PC	11691242
DMM02VJ	MW	466.3
DMM02VJ	FM	C22H20BrN5O2
DMM02VJ	IC	InChI=1S/C22H20BrN5O2/c1-30-20-6-5-15(23)12-18(20)27-22(29)26-17-3-2-4-19-16(17)8-10-28(19)13-14-7-9-25-21(24)11-14/h2-12H,13H2,1H3,(H2,24,25)(H2,26,27,29)
DMM02VJ	CS	COC1=C(C=C(C=C1)Br)NC(=O)NC2=C3C=CN(C3=CC=C2)CC4=CC(=NC=C4)N
DMM02VJ	IK	ZXBFYBLSJMEBEP-UHFFFAOYSA-N
DMM02VJ	IU	1-[1-[(2-aminopyridin-4-yl)methyl]indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea
DMM02VJ	CA	CAS 900573-88-8
DMM02VJ	DE	Solid tumour/cancer

DMARQ0H	ID	DMARQ0H
DMARQ0H	DN	JKB-122
DMARQ0H	HS	Phase 2
DMARQ0H	SN	Opioid receptor modulator (liver disease), Jenken Bioscience
DMARQ0H	CP	Jenken Biosciences
DMARQ0H	DE	Hepatitis virus infection

DMJSVRL	ID	DMJSVRL
DMJSVRL	DN	JM216
DMJSVRL	HS	Phase 2
DMJSVRL	SN	129580-63-8; JM 216; satraplatin(jm216); Satraplatin (USAN/INN); C081294; YHI-601; C6H13N.C4H6Cl2O4Pt.H3N; Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)-; 4023AH; AKOS015914237; BMS-182751; BC679462; FT-0601550; D05807; Bis(acetato-O)amminedichloro(cyclohexanamine)-pt; 580S638; I14-43013; Platinum (lV) cis-dichloro-trans-bis(acetato-O)ammine(cyclohexanamine)
DMJSVRL	DT	Small molecular drug
DMJSVRL	PC	6918220
DMJSVRL	MW	502.3
DMJSVRL	FM	C10H24Cl2N2O4Pt
DMJSVRL	IC	InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+2/p-2
DMJSVRL	CS	CC(=O)O.CC(=O)O.C1CCC(CC1)N.N.Cl[Pt]Cl
DMJSVRL	IK	TWEQNPPRXJRHHM-UHFFFAOYSA-L
DMJSVRL	IU	acetic acid;azane;cyclohexanamine;dichloroplatinum
DMJSVRL	DE	Solid tumour/cancer

DMBXWJ5	ID	DMBXWJ5
DMBXWJ5	DN	JNJ 63723283
DMBXWJ5	HS	Phase 2
DMBXWJ5	CP	Janssen Research & Development Raritan, NJ
DMBXWJ5	DT	Monoclonal antibody
DMBXWJ5	DE	Solid tumour/cancer; Multiple myeloma; Prostate cancer; Ulcerative colitis

DMY7Q3I	ID	DMY7Q3I
DMY7Q3I	DN	JNJ-10229570
DMY7Q3I	HS	Phase 2
DMY7Q3I	SN	JNJ-10229570-AAA; MC5R antagonist (topical, acne), Johnson & Johnson; Melanocortin-5 receptor antagonist (topical, acne), Johnson & Johnson
DMY7Q3I	CP	Johnson & Johnson
DMY7Q3I	PC	10110895
DMY7Q3I	MW	389.5
DMY7Q3I	FM	C22H19N3O2S
DMY7Q3I	IC	InChI=1S/C22H19N3O2S/c1-26-19-14-8-6-12-17(19)21-24-22(23-16-10-4-3-5-11-16)28-25(21)18-13-7-9-15-20(18)27-2/h3-15H,1-2H3
DMY7Q3I	CS	COC1=CC=CC=C1C2=NC(=NC3=CC=CC=C3)SN2C4=CC=CC=C4OC
DMY7Q3I	IK	XTHRTBCPBWJYRO-UHFFFAOYSA-N
DMY7Q3I	IU	2,3-bis(2-methoxyphenyl)-N-phenyl-1,2,4-thiadiazol-5-imine
DMY7Q3I	CA	CAS 524923-88-4
DMY7Q3I	DE	Acne vulgaris

DM7OTQS	ID	DM7OTQS
DM7OTQS	DN	JNJ-10311795
DM7OTQS	HS	Phase 2
DM7OTQS	SN	JNJ-10311795; CHEMBL374027; 518062-14-1; SCHEMBL1260969; GTPL6563; BDBM50208224; Phosphonic acid, (2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; Phosphonic acid, P-(2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid
DM7OTQS	DT	Small molecular drug
DM7OTQS	PC	10146470
DM7OTQS	MW	670.7
DM7OTQS	FM	C40H35N2O6P
DM7OTQS	IC	InChI=1S/C40H35N2O6P/c1-41(32-19-21-42(22-20-32)39(44)31-18-17-26-9-2-3-11-28(26)23-31)40(45)36-25-30-13-5-4-12-29(30)24-35(36)37(43)38(49(46,47)48)34-16-8-14-27-10-6-7-15-33(27)34/h2-18,23-25,32,38H,19-22H2,1H3,(H2,46,47,48)
DM7OTQS	CS	CN(C1CCN(CC1)C(=O)C2=CC3=CC=CC=C3C=C2)C(=O)C4=CC5=CC=CC=C5C=C4C(=O)C(C6=CC=CC7=CC=CC=C76)P(=O)(O)O
DM7OTQS	IK	XUJQPDQURBZEGJ-UHFFFAOYSA-N
DM7OTQS	IU	[2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid
DM7OTQS	CA	CAS 518062-14-1
DM7OTQS	DE	Chronic obstructive pulmonary disease

DMPFG7H	ID	DMPFG7H
DMPFG7H	DN	JNJ-16269110
DMPFG7H	HS	Phase 2
DMPFG7H	SN	SCHEMBL803531; CHEMBL2103860
DMPFG7H	CP	Janssen Research & Development
DMPFG7H	DT	Small molecular drug
DMPFG7H	PC	56842069
DMPFG7H	MW	572.6
DMPFG7H	FM	C34H31F3N2O3
DMPFG7H	IC	InChI=1S/C34H31F3N2O3/c1-42-33(41)31(26-7-3-2-4-8-26)39-21-19-24(20-22-39)23-13-17-28(18-14-23)38-32(40)30-10-6-5-9-29(30)25-11-15-27(16-12-25)34(35,36)37/h2-18,24,31H,19-22H2,1H3,(H,38,40)/t31-/m1/s1
DMPFG7H	CS	COC(=O)[C@@H](C1=CC=CC=C1)N2CCC(CC2)C3=CC=C(C=C3)NC(=O)C4=CC=CC=C4C5=CC=C(C=C5)C(F)(F)F
DMPFG7H	IK	WSYALRNYQFNNGP-WJOKGBTCSA-N
DMPFG7H	IU	methyl (2R)-2-phenyl-2-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]piperidin-1-yl]acetate
DMPFG7H	CA	CAS 403989-79-7
DMPFG7H	DE	Type-2 diabetes

DM1GRCU	ID	DM1GRCU
DM1GRCU	DN	JNJ-17216498
DM1GRCU	HS	Phase 2
DM1GRCU	SN	Histamine H3 antagonist (oral, narcolepsy) J&J
DM1GRCU	CP	Johnson & Johnson
DM1GRCU	DE	Narcolepsy

DMV1T59	ID	DMV1T59
DMV1T59	DN	JNJ-18038683
DMV1T59	HS	Phase 2
DMV1T59	SN	Serotonin 7 antagonist (depression), Johnson & Johnson; 5-HT 7 antagonist (depression), Johnson & Johnson
DMV1T59	CP	Johnson & Johnson
DMV1T59	DT	Small molecular drug
DMV1T59	PC	11151899
DMV1T59	MW	337.8
DMV1T59	FM	C20H20ClN3
DMV1T59	IC	InChI=1S/C20H20ClN3/c21-17-8-6-16(7-9-17)20-18-10-12-22-13-11-19(18)24(23-20)14-15-4-2-1-3-5-15/h1-9,22H,10-14H2
DMV1T59	CS	C1CNCCC2=C1C(=NN2CC3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMV1T59	IK	UKJPMZGILXATGT-UHFFFAOYSA-N
DMV1T59	IU	1-benzyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[3,4-d]azepine
DMV1T59	CA	CAS 851373-91-6
DMV1T59	DE	Major depressive disorder

DMKIE9C	ID	DMKIE9C
DMKIE9C	DN	JNJ-26481585
DMKIE9C	HS	Phase 2
DMKIE9C	SN	875320-29-9; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; UNII-9BJ85K1J8S; Quisinostat (JNJ-26481585); JNJ26481585; 9BJ85K1J8S; N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide; 2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]-~{N}-oxidanyl-pyrimidine-5-carboxamide; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)-methyl)piperidin-1-yl)pyrimidine-5-carboxamide
DMKIE9C	CP	Janssen Research & Development
DMKIE9C	DT	Small molecular drug
DMKIE9C	PC	11538455
DMKIE9C	MW	394.5
DMKIE9C	FM	C21H26N6O2
DMKIE9C	IC	InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)
DMKIE9C	CS	CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO
DMKIE9C	IK	PAWIYAYFNXQGAP-UHFFFAOYSA-N
DMKIE9C	IU	N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide
DMKIE9C	CA	CAS 875320-29-9
DMKIE9C	CB	CHEBI:94771
DMKIE9C	DE	Advanced stage follicular lymphoma; Solid tumour/cancer

DMQD1GN	ID	DMQD1GN
DMQD1GN	DN	JNJ-32729463
DMQD1GN	HS	Phase 2
DMQD1GN	SN	Acorafloxacin HCl; Avarofloxacin hydrochloride; Acorafloxacin hydrochloride; UNII-1NWW5SKQ0N; JNJ-32729463-AAC; 1NWW5SKQ0N; Acorafloxacin hydrochloride [USAN]; 1001162-01-1 (HCl); Acorafloxacin hydrochloride (USAN); Avarofloxacin HCl; 1001162-01-1; (E)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride; JNJ-Q2 hydrochloride; SCHEMBL2190495; CHEMBL2364603; DTXSID70142966; JNJ-32729463AAC; Jnj-32729463; 7-((3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride; D10544; Q27252661
DMQD1GN	DT	Small molecular drug
DMQD1GN	PC	67311433
DMQD1GN	MW	455.9
DMQD1GN	FM	C21H24ClF2N3O4
DMQD1GN	IC	InChI=1S/C21H23F2N3O4.ClH/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24;/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29);1H/b16-11+;
DMQD1GN	CS	COC1=C2C(=CC(=C1N3CCC/C(=C(/CN)\\F)/C3)F)C(=O)C(=CN2C4CC4)C(=O)O.Cl
DMQD1GN	IK	RDXCNSOGHLLWDV-YFMOEUEHSA-N
DMQD1GN	IU	7-[(3E)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride
DMQD1GN	CA	CAS 1001162-01-1
DMQD1GN	DE	Community-acquired pneumonia

DMV41P5	ID	DMV41P5
DMV41P5	DN	JNJ-37822681
DMV41P5	HS	Phase 2
DMV41P5	SN	UNII-GJB2URS7NJ; JNJ-37822681; GJB2URS7NJ; CHEMBL3234237; 935776-74-2; SCHEMBL1022639; MolPort-039-267-898; BDBM50003063; ZINC34951380; DB12579; 3-Pyridazinamine, N-(1-((3,4-difluorophenyl)methyl)-4-piperidinyl)-6-(trifluoromethyl)-; NCGC00386644-01; Z1558691527
DMV41P5	CP	Johnson & Johnson Pharmaceutical Research & Development
DMV41P5	DT	Small molecular drug
DMV41P5	PC	16058752
DMV41P5	MW	372.34
DMV41P5	FM	C17H17F5N4
DMV41P5	IC	InChI=1S/C17H17F5N4/c18-13-2-1-11(9-14(13)19)10-26-7-5-12(6-8-26)23-16-4-3-15(24-25-16)17(20,21)22/h1-4,9,12H,5-8,10H2,(H,23,25)
DMV41P5	CS	C1CN(CCC1NC2=NN=C(C=C2)C(F)(F)F)CC3=CC(=C(C=C3)F)F
DMV41P5	IK	UVUYWJWYRLJHEN-UHFFFAOYSA-N
DMV41P5	IU	N-[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine
DMV41P5	CA	CAS 935776-74-2
DMV41P5	DE	Schizophrenia

DM9UMIO	ID	DM9UMIO
DM9UMIO	DN	JNJ-38518168
DM9UMIO	HS	Phase 2
DM9UMIO	CP	Janssen research & development
DM9UMIO	PC	23650961
DM9UMIO	MW	392.5
DM9UMIO	FM	C23H32N6
DM9UMIO	IC	InChI=1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26)
DM9UMIO	CS	CC1=CC(=C2C(=C1)NC(=N2)C3=CN=C(N=C3C)NCCCC4CCN(CC4)C)C
DM9UMIO	IK	FCRFVPZAXGJLPW-UHFFFAOYSA-N
DM9UMIO	IU	5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine
DM9UMIO	CA	CAS 952494-46-1
DM9UMIO	DE	Rheumatoid arthritis; Plaque psoriasis

DM0WY3H	ID	DM0WY3H
DM0WY3H	DN	JNJ-39220675
DM0WY3H	HS	Phase 2
DM0WY3H	SN	Histamine H3 receptor antagonist (allergic rhinitis/alcoholism), Johnson & Johnson
DM0WY3H	CP	Johnson & Johnson Pharmaceutical Research & Development LLC
DM0WY3H	DT	Small molecular drug
DM0WY3H	PC	24771368
DM0WY3H	MW	369.4
DM0WY3H	FM	C21H24FN3O2
DM0WY3H	IC	InChI=1S/C21H24FN3O2/c22-17-6-8-19(9-7-17)27-20-10-5-16(15-23-20)21(26)25-12-2-11-24(13-14-25)18-3-1-4-18/h5-10,15,18H,1-4,11-14H2
DM0WY3H	CS	C1CC(C1)N2CCCN(CC2)C(=O)C3=CN=C(C=C3)OC4=CC=C(C=C4)F
DM0WY3H	IK	IQOWHZHNGJXGHG-UHFFFAOYSA-N
DM0WY3H	IU	(4-cyclobutyl-1,4-diazepan-1-yl)-[6-(4-fluorophenoxy)pyridin-3-yl]methanone
DM0WY3H	CA	CAS 959740-39-7
DM0WY3H	DE	Alcohol dependence

DMUOEKM	ID	DMUOEKM
DMUOEKM	DN	JNJ-39393406
DMUOEKM	HS	Phase 2
DMUOEKM	SN	JNJ-39393406; UNII-T930SOU82P; T930SOU82P; JNJ 39393406; 953428-73-4; SCHEMBL827762; CHEMBL3545291; DB11867; 1H-1,2,4-Triazole-1-propanamide, 3-((2,2-difluoro-1,3-benzodioxol-5-yl)amino)-N,N-dimethyl-5-(4-pyridinyl)-
DMUOEKM	CP	Janssen Pharmaceutica NV
DMUOEKM	DT	Small molecular drug
DMUOEKM	PC	16755766
DMUOEKM	MW	416.4
DMUOEKM	FM	C19H18F2N6O3
DMUOEKM	IC	InChI=1S/C19H18F2N6O3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11H,7,10H2,1-2H3,(H,23,25)
DMUOEKM	CS	CN(C)C(=O)CCN1C(=NC(=N1)NC2=CC3=C(C=C2)OC(O3)(F)F)C4=CC=NC=C4
DMUOEKM	IK	IURMHZBQEYNQOH-UHFFFAOYSA-N
DMUOEKM	IU	3-[3-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-5-pyridin-4-yl-1,2,4-triazol-1-yl]-N,N-dimethylpropanamide
DMUOEKM	CA	CAS 953428-73-4
DMUOEKM	DE	Cognitive impairment; Depression; Tobacco dependence

DM219SF	ID	DM219SF
DM219SF	DN	JNJ-40346527
DM219SF	HS	Phase 2
DM219SF	CP	Janssen Research & Development
DM219SF	PC	25230468
DM219SF	MW	461.6
DM219SF	FM	C27H35N5O2
DM219SF	IC	InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)
DM219SF	CS	CC1(CCC(=CC1)C2=C(C=CC(=N2)C3CC(OC(C3)(C)C)(C)C)NC(=O)C4=NC=C(N4)C#N)C
DM219SF	IK	BNVPFDRNGHMRJS-UHFFFAOYSA-N
DM219SF	IU	5-cyano-N-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1H-imidazole-2-carboxamide
DM219SF	CA	CAS 1142363-52-7
DM219SF	DE	Hodgkin lymphoma

DM72GZO	ID	DM72GZO
DM72GZO	DN	JNJ-42165279
DM72GZO	HS	Phase 2
DM72GZO	CP	Janssen research & development
DM72GZO	PC	54576693
DM72GZO	MW	410.8
DM72GZO	FM	C18H17ClF2N4O3
DM72GZO	IC	InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)
DM72GZO	CS	C1CN(CCN1CC2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=CN=C4)Cl
DM72GZO	IK	YWGYNGCRVZLMCS-UHFFFAOYSA-N
DM72GZO	IU	N-(4-chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide
DM72GZO	CA	CAS 1346528-50-4
DM72GZO	DE	Anxiety disorder; Social anxiety disorder

DMJ1FXL	ID	DMJ1FXL
DMJ1FXL	DN	JNJ-53718678
DMJ1FXL	HS	Phase 2
DMJ1FXL	SN	Rilematovir; JNJ-678; UNII-NQ99E8OH3P; NQ99E8OH3P; 1383450-81-4; 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one; 3-[[5-Chloranyl-1-(3-Methylsulfonylpropyl)indol-2-Yl]methyl]-1-[2,2,2-Tris(Fluoranyl)ethyl]imidazo[4,5-C]pyridin-2-One; Rilematovir [INN]; CHEMBL4437054; SCHEMBL17529353; HY-112180; CS-0043622; C(CCN1C(=CC2=CC(=CC=C12)Cl)CN1C2=C(N(C1=O)CC(F)(F)F)C=CN=C2)S(=O)(=O)C; 2H-Imidazo(4,5-C)pyridin-2-one, 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-; 3-((5-Chloro-1-(3-methylsulfonylpropyl)indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)imidazo(4,5-C)pyridin-2-one; 6YA
DMJ1FXL	CP	Janssen
DMJ1FXL	DT	Small molecular drug
DMJ1FXL	PC	118892432
DMJ1FXL	MW	500.9
DMJ1FXL	FM	C21H20ClF3N4O3S
DMJ1FXL	IC	InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3
DMJ1FXL	CS	CS(=O)(=O)CCCN1C2=C(C=C(C=C2)Cl)C=C1CN3C4=C(C=CN=C4)N(C3=O)CC(F)(F)F
DMJ1FXL	IK	GTQTUABHRCWVLL-UHFFFAOYSA-N
DMJ1FXL	IU	3-[[5-chloro-1-(3-methylsulfonylpropyl)indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)imidazo[4,5-c]pyridin-2-one
DMJ1FXL	CA	CAS 1383450-81-4
DMJ1FXL	DE	Respiratory syncytial virus infection

DM9RW6H	ID	DM9RW6H
DM9RW6H	DN	JNJ-56136379
DM9RW6H	HS	Phase 2
DM9RW6H	SN	JNJ-6379
DM9RW6H	CP	Janssen
DM9RW6H	DT	Antibody
DM9RW6H	DE	Hepatitis B

DME2S4D	ID	DME2S4D
DME2S4D	DN	JNJ-61393215
DME2S4D	HS	Phase 2
DME2S4D	SN	Q66977422
DME2S4D	CP	Janssen
DME2S4D	DT	Small molecular drug
DME2S4D	PC	139030979
DME2S4D	MW	460.4
DME2S4D	FM	C23H18F4N4O2
DME2S4D	IC	InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2
DME2S4D	CS	[2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H]
DME2S4D	IK	HUKWIAXQBOHZIX-USKNZQBOSA-N
DME2S4D	IU	[(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone
DME2S4D	DE	Major depressive disorder

DMVSUH1	ID	DMVSUH1
DMVSUH1	DN	JNJ-64565111
DMVSUH1	HS	Phase 2
DMVSUH1	CP	Janssen Research & Development Raritan, NJ
DMVSUH1	DE	Type-2 diabetes; Obesity

DM3ICO6	ID	DM3ICO6
DM3ICO6	DN	JNJ-74494550
DM3ICO6	HS	Phase 2
DM3ICO6	SN	Cusatuzumab
DM3ICO6	CP	Argen Boston; Janssen
DM3ICO6	DT	Antibody
DM3ICO6	DE	Myelodysplastic syndrome

DMXTKCR	ID	DMXTKCR
DMXTKCR	DN	JT02
DMXTKCR	HS	Phase 2
DMXTKCR	CP	JYANT Technologies Marietta, GA
DMXTKCR	DE	Inflammatory bowel disease

DM2LBHN	ID	DM2LBHN
DM2LBHN	DN	JTE-051
DM2LBHN	HS	Phase 2
DM2LBHN	DE	Allergy; Plaque psoriasis

DM1945H	ID	DM1945H
DM1945H	DN	JTT-251
DM1945H	HS	Phase 2
DM1945H	CP	Akros pharma
DM1945H	DE	Type-2 diabetes; Pulmonary arterial hypertension

DMGLVBI	ID	DMGLVBI
DMGLVBI	DN	JTT-302
DMGLVBI	HS	Phase 2
DMGLVBI	SN	CETP inhibitor (oral, dyslipidemia), Japan Tobacco
DMGLVBI	CP	Japan Tobacco Inc
DMGLVBI	DE	Lipid metabolism disorder

DM50M2R	ID	DM50M2R
DM50M2R	DN	JTT-654
DM50M2R	HS	Phase 2
DM50M2R	SN	11-beta HSD1 inhibitor (oral, type 2 diabetes), Japan Tobacco; 11-beta hydroxysteroid dehydrogenase (oral, type 2 diabetes), Japan Tobacco
DM50M2R	CP	Japan Tobacco Inc
DM50M2R	DE	Type-2 diabetes

DMED5J6	ID	DMED5J6
DMED5J6	DN	JTT-851
DMED5J6	HS	Phase 2
DMED5J6	SN	GPCR 40 agonist (type 2 diabetes) Japan Tobacco
DMED5J6	CP	Akros pharma
DMED5J6	DE	Type-2 diabetes

DMGXTOP	ID	DMGXTOP
DMGXTOP	DN	JTX-2011
DMGXTOP	HS	Phase 2
DMGXTOP	CP	Jounce Therapeutics Cambridge, MA
DMGXTOP	DE	Solid tumour/cancer

DMOT0M7	ID	DMOT0M7
DMOT0M7	DN	JTX-4014
DMOT0M7	HS	Phase 2
DMOT0M7	SN	Pimivalimab
DMOT0M7	CP	Jounce Therapeutics
DMOT0M7	DT	Antibody
DMOT0M7	DE	Non-small-cell lung cancer

DMZKYNO	ID	DMZKYNO
DMZKYNO	DN	Juvidex
DMZKYNO	HS	Phase 2
DMZKYNO	SN	Adaprev; Mannose-6-phosphate (scarring), Renovo
DMZKYNO	CP	Renovo Group plc
DMZKYNO	PC	6101690
DMZKYNO	MW	260.14
DMZKYNO	FM	C6H13O9P
DMZKYNO	IC	InChI=1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h1,3-6,8-11H,2H2,(H2,12,13,14)/t3-,4-,5-,6-/m1/s1
DMZKYNO	CS	C([C@H]([C@H]([C@@H]([C@@H](C=O)O)O)O)O)OP(=O)(O)O
DMZKYNO	IK	VFRROHXSMXFLSN-KVTDHHQDSA-N
DMZKYNO	IU	[(2R,3R,4S,5S)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate
DMZKYNO	CA	CAS 3672-15-9
DMZKYNO	CB	CHEBI:48042
DMZKYNO	DE	Sarcoidosis

DMPMU38	ID	DMPMU38
DMPMU38	DN	JVRS-100
DMPMU38	HS	Phase 2
DMPMU38	CP	Colby Pharmaceutical
DMPMU38	DT	Vaccine
DMPMU38	DE	leukaemia

DMD4OK0	ID	DMD4OK0
DMD4OK0	DN	K-134
DMD4OK0	HS	Phase 2
DMD4OK0	SN	SULBACTAM; 68373-14-8; sulbactam acid; Sulbactamum; Betamaze; Penicillanic Acid Sulfone; (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; penicillanic acid 1,1-dioxide; UNII-S4TF6I2330; CP 45899; CHEMBL403; CHEBI:9321; S4TF6I2330; Sulbactam;Penicillanic acid sulfone; (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; Sulbactam [INN:BAN]; CP-45,899; Sulbactamum [INN-Latin]; DSSTox_CID_3605; DSSTox_RID_77104
DMD4OK0	CP	Kowa Pharmaceuticals America
DMD4OK0	DT	Small molecular drug
DMD4OK0	PC	9908900
DMD4OK0	MW	399.5
DMD4OK0	FM	C22H29N3O4
DMD4OK0	IC	InChI=1S/C22H29N3O4/c26-20-5-2-1-4-19(20)25(16-7-8-16)22(28)23-12-3-13-29-17-9-10-18-15(14-17)6-11-21(27)24-18/h6,9-11,14,16,19-20,26H,1-5,7-8,12-13H2,(H,23,28)(H,24,27)/t19-,20-/m1/s1
DMD4OK0	CS	C1CC[C@H]([C@@H](C1)N(C2CC2)C(=O)NCCCOC3=CC4=C(C=C3)NC(=O)C=C4)O
DMD4OK0	IK	ULGNGSQNNMKROG-WOJBJXKFSA-N
DMD4OK0	IU	1-cyclopropyl-1-[(1R,2R)-2-hydroxycyclohexyl]-3-[3-[(2-oxo-1H-quinolin-6-yl)oxy]propyl]urea
DMD4OK0	CA	CAS 189362-06-9
DMD4OK0	DE	Arteriosclerosis

DMZCVD7	ID	DMZCVD7
DMZCVD7	DN	K-201
DMZCVD7	HS	Phase 2
DMZCVD7	SN	DKKLXCRMAXNIJF-UHFFFAOYSA-N; UNII-0I621Y6R4Q; K201; 0I621Y6R4Q; 1038410-88-6; K 201; SCHEMBL194018; CHEMBL2440857; DTXSID90146108;  K-201, Moberg; Dermatological drug combination (kaprolac, atopic dermatitis), Moberg; Urea + PEG/propylene glycol formulation (atopic dermatitis), Moberg; JTV 519
DMZCVD7	CP	Moberg Derma AB
DMZCVD7	DT	Small molecular drug
DMZCVD7	PC	9868902
DMZCVD7	MW	461.1
DMZCVD7	FM	C25H33ClN2O2S
DMZCVD7	IC	InChI=1S/C25H32N2O2S.ClH/c1-29-23-7-8-24-22(18-23)19-27(15-16-30-24)25(28)11-14-26-12-9-21(10-13-26)17-20-5-3-2-4-6-20;/h2-8,18,21H,9-17,19H2,1H3;1H
DMZCVD7	CS	COC1=CC2=C(C=C1)SCCN(C2)C(=O)CCN3CCC(CC3)CC4=CC=CC=C4.Cl
DMZCVD7	IK	DKKLXCRMAXNIJF-UHFFFAOYSA-N
DMZCVD7	IU	3-(4-benzylpiperidin-1-yl)-1-(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)propan-1-one;hydrochloride
DMZCVD7	CA	CAS 1038410-88-6
DMZCVD7	DE	Atopic dermatitis

DMQVN6P	ID	DMQVN6P
DMQVN6P	DN	K-604
DMQVN6P	HS	Phase 2
DMQVN6P	SN	BDBM86691
DMQVN6P	CP	Kowa Pharmaceuticals America
DMQVN6P	DT	Small molecular drug
DMQVN6P	PC	9892288
DMQVN6P	MW	502.7
DMQVN6P	FM	C23H30N6OS3
DMQVN6P	IC	InChI=1S/C23H30N6OS3/c1-16-14-19(31-2)21(22(24-16)32-3)27-20(30)15-29-10-8-28(9-11-29)12-13-33-23-25-17-6-4-5-7-18(17)26-23/h4-7,14H,8-13,15H2,1-3H3,(H,25,26)(H,27,30)
DMQVN6P	CS	CC1=CC(=C(C(=N1)SC)NC(=O)CN2CCN(CC2)CCSC3=NC4=CC=CC=C4N3)SC
DMQVN6P	IK	VGGMTOYKEDKFLN-UHFFFAOYSA-N
DMQVN6P	IU	2-[4-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]piperazin-1-yl]-N-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]acetamide
DMQVN6P	CA	CAS 561023-90-3
DMQVN6P	DE	Arteriosclerosis

DMJLNZQ	ID	DMJLNZQ
DMJLNZQ	DN	K-828-AB
DMJLNZQ	HS	Phase 2
DMJLNZQ	SN	GABA transaminase inhibitor (oral, dementia), Kowa
DMJLNZQ	CP	Kowa Co Ltd
DMJLNZQ	DE	Dementia

DMMSTCF	ID	DMMSTCF
DMMSTCF	DN	K-832
DMMSTCF	HS	Phase 2
DMMSTCF	SN	10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9
DMMSTCF	CP	Kowa
DMMSTCF	DT	Small molecular drug
DMMSTCF	PC	9844960
DMMSTCF	MW	418.9
DMMSTCF	FM	C24H19ClN2OS
DMMSTCF	IC	InChI=1S/C24H19ClN2OS/c1-29-21-13-9-19(10-14-21)24-22(18-7-11-20(25)12-8-18)15-23(28)27(26-24)16-17-5-3-2-4-6-17/h2-15H,16H2,1H3
DMMSTCF	CS	CSC1=CC=C(C=C1)C2=NN(C(=O)C=C2C3=CC=C(C=C3)Cl)CC4=CC=CC=C4
DMMSTCF	IK	HEUAVAATAFEENP-UHFFFAOYSA-N
DMMSTCF	IU	2-benzyl-5-(4-chlorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one
DMMSTCF	DE	Rheumatoid arthritis

DMTMCPZ	ID	DMTMCPZ
DMTMCPZ	DN	KB001A
DMTMCPZ	HS	Phase 2
DMTMCPZ	CP	Sanofi
DMTMCPZ	DT	Antibody
DMTMCPZ	DE	Infectious disease; Cystic fibrosis

DM60G5O	ID	DM60G5O
DM60G5O	DN	KB002/003
DM60G5O	HS	Phase 2
DM60G5O	CP	KaloBios Pharmaceuticals
DM60G5O	DE	Rheumatoid arthritis

DM74KIM	ID	DM74KIM
DM74KIM	DN	KB-003
DM74KIM	HS	Phase 2
DM74KIM	SN	KB-002; Anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios; Anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios
DM74KIM	CP	Kalobios pharmaceuticals
DM74KIM	DT	Antibody
DM74KIM	DE	Severe asthma

DMZ4MCG	ID	DMZ4MCG
DMZ4MCG	DN	KB-6806
DMZ4MCG	HS	Phase 2
DMZ4MCG	SN	Prucalopride succinate; 179474-85-2; Prucalopride Succinat; Prucalopride (succinate); UNII-4V2G75E1CK; R-108512; BUTANEDIOIC ACID 4-AMINO-5-CHLORO-2,3-DIHYDRO-N-[1-(3-METHOXYPROPYL)-4-PIPERIDINYL]-7-BENZOFURANCARBOXAMIDE; Prucalopride succinate [USAN]; 4V2G75E1CK; R 108512; AK175654; Prucalopride succinate (USAN); resotran; Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidinyl)-7-benzofurancarboxamide (1:1); Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-[1-
DMZ4MCG	CP	Kanebo
DMZ4MCG	DT	Small molecular drug
DMZ4MCG	PC	3073291
DMZ4MCG	MW	307.82
DMZ4MCG	FM	C15H22ClN5
DMZ4MCG	IC	InChI=1S/C15H22ClN5/c1-10(2)21-14-9-12(17)11(16)8-13(14)18-15(21)20-6-4-19(3)5-7-20/h8-10H,4-7,17H2,1-3H3
DMZ4MCG	CS	CC(C)N1C2=C(C=C(C(=C2)N)Cl)N=C1N3CCN(CC3)C
DMZ4MCG	IK	QEANRFDFBNUCJR-UHFFFAOYSA-N
DMZ4MCG	IU	6-chloro-2-(4-methylpiperazin-1-yl)-3-propan-2-ylbenzimidazol-5-amine
DMZ4MCG	CA	CAS 148014-93-1
DMZ4MCG	DE	Chemotherapy-induced nausea

DMEFW3G	ID	DMEFW3G
DMEFW3G	DN	KD019
DMEFW3G	HS	Phase 2
DMEFW3G	SN	Tesevatinib; XL647; XL-647; 781613-23-8; EXEL-7647; UNII-F6XM2TN5A1; KD-019; XL 647; F6XM2TN5A1; 651031-01-5; 7-[[(3aS,6aR)-2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy]-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine; Tesevatinib [USAN:INN]; EXEL 7647; 874286-84-7; KD 019; 1000599-06-3; SCHEMBL721994; SCHEMBL721993; SCHEMBL721992; C24H25Cl2FN4O2; GTPL7944; CHEMBL3544983; EX-A172; QCR-153; MolPort-044-724-458; BCP23438; ZINC38912363; 2809AH; AKOS027255007
DMEFW3G	CP	Kadmon Pharmaceuticals
DMEFW3G	DT	Small molecular drug
DMEFW3G	PC	10458325
DMEFW3G	MW	491.4
DMEFW3G	FM	C24H25Cl2FN4O2
DMEFW3G	IC	InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13?,14-,15+
DMEFW3G	CS	CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC
DMEFW3G	IK	HVXKQKFEHMGHSL-GOOCMWNKSA-N
DMEFW3G	IU	7-[[(3aS,6aR)-2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy]-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine
DMEFW3G	CA	CAS 781613-23-8
DMEFW3G	DE	Non-small-cell lung cancer; Polycystic kidney disease; Brain metastases; Meningioma metastases; Recurrent glioblastoma

DM548TK	ID	DM548TK
DM548TK	DN	KD025
DM548TK	HS	Phase 2
DM548TK	CP	Kadmon
DM548TK	PC	11950170
DM548TK	MW	452.5
DM548TK	FM	C26H24N6O2
DM548TK	IC	InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31)
DM548TK	CS	CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5
DM548TK	IK	GKHIVNAUVKXIIY-UHFFFAOYSA-N
DM548TK	IU	2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide
DM548TK	CA	CAS 911417-87-3
DM548TK	DE	Rheumatoid arthritis; Psoriasis vulgaris; Psoriatic arthritis; Scleroderma; Systemic lupus erythematosus

DME1WV2	ID	DME1WV2
DME1WV2	DN	KD-7040
DME1WV2	HS	Phase 2
DME1WV2	CP	Kalypsys Inc
DME1WV2	DE	Pain

DMFO6MH	ID	DMFO6MH
DMFO6MH	DN	Kevetrin
DMFO6MH	HS	Phase 2
DMFO6MH	CP	Cellceutix Corp
DMFO6MH	DT	Small molecular drug
DMFO6MH	PC	437740
DMFO6MH	MW	143.21
DMFO6MH	FM	C5H9N3S
DMFO6MH	IC	InChI=1S/C5H9N3S/c6-3-1-2-4-9-5(7)8/h1-2,4H2,(H3,7,8)
DMFO6MH	CS	C(CC#N)CSC(=N)N
DMFO6MH	IK	PRDJGNVQBVXXEO-UHFFFAOYSA-N
DMFO6MH	IU	3-cyanopropyl carbamimidothioate
DMFO6MH	CA	CAS 500863-50-3
DMFO6MH	DE	Solid tumour/cancer; Ovarian cancer

DMF6CTI	ID	DMF6CTI
DMF6CTI	DN	KHK-6188
DMF6CTI	HS	Phase 2
DMF6CTI	CP	Kyowa Hakko Kirin Co Ltd
DMF6CTI	DE	Neuropathic pain

DM40HOY	ID	DM40HOY
DM40HOY	DN	KLH-2109
DM40HOY	HS	Phase 2
DM40HOY	CP	Kissei Pharmaceutical Co Ltd
DM40HOY	PC	16656889
DM40HOY	MW	508.4
DM40HOY	FM	C22H15F3N2O7S
DM40HOY	IC	InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30)
DM40HOY	CS	COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC
DM40HOY	IK	BMAAMIIYNNPHAB-UHFFFAOYSA-N
DM40HOY	IU	3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-2,4-dioxo-1H-thieno[3,4-d]pyrimidine-5-carboxylic acid
DM40HOY	CA	CAS 935283-04-8
DM40HOY	DE	Endometriosis

DM05TBE	ID	DM05TBE
DM05TBE	DN	KLS-0611
DM05TBE	HS	Phase 2
DM05TBE	SN	Mucin stimulator (dry eye), Kissei
DM05TBE	CP	Kissei Pharmaceutical Co Ltd
DM05TBE	DE	Xerophthalmia

DMNLH9W	ID	DMNLH9W
DMNLH9W	DN	KN026
DMNLH9W	HS	Phase 2
DMNLH9W	CP	Alphamab Oncology
DMNLH9W	DT	Antibody
DMNLH9W	DE	Breast cancer

DMKLMG6	ID	DMKLMG6
DMKLMG6	DN	KN035
DMKLMG6	HS	Phase 2
DMKLMG6	SN	Envafolimab
DMKLMG6	CP	TRACON Pharmaceuticals
DMKLMG6	DT	Antibody
DMKLMG6	DE	Advanced malignancy; Solid tumour/cancer; Pleomorphic sarcoma

DMQZ5HF	ID	DMQZ5HF
DMQZ5HF	DN	KNI-272
DMQZ5HF	HS	Phase 2
DMQZ5HF	SN	NSC651714; NSC-651714; AC1Q5L2H; (4r)-n-tert-butyl-3-[2-hydroxy-3-({n-[(isoquinolin-5-yloxy)acetyl]-s-methyl-l-cysteinyl}amino)-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide; AC1L88B1; KNI 272; 3-(3,4-Dimethoxyphenyl)propionamide; NCI60_018063; 4-Thiazolidinecarboxamide,1-dimethylethyl)-3- [2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3- (methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-,[4R-[3[2S*,3S*(R*)],4R*]]
DMQZ5HF	DT	Small molecular drug
DMQZ5HF	PC	60927
DMQZ5HF	MW	667.8
DMQZ5HF	FM	C33H41N5O6S2
DMQZ5HF	IC	InChI=1S/C33H41N5O6S2/c1-33(2,3)37-31(42)26-19-46-20-38(26)32(43)29(40)24(15-21-9-6-5-7-10-21)36-30(41)25(18-45-4)35-28(39)17-44-27-12-8-11-22-16-34-14-13-23(22)27/h5-14,16,24-26,29,40H,15,17-20H2,1-4H3,(H,35,39)(H,36,41)(H,37,42)/t24-,25-,26-,29-/m0/s1
DMQZ5HF	CS	CC(C)(C)NC(=O)[C@@H]1CSCN1C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC4=C3C=CN=C4)O
DMQZ5HF	IK	NJBBLOIWMSYVCQ-VZTVMPNDSA-N
DMQZ5HF	IU	(4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[(2-isoquinolin-5-yloxyacetyl)amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide
DMQZ5HF	CA	CAS 147318-81-8
DMQZ5HF	CB	CHEBI:80006
DMQZ5HF	DE	Human immunodeficiency virus infection

DMCO8UZ	ID	DMCO8UZ
DMCO8UZ	DN	KP-496
DMCO8UZ	HS	Phase 2
DMCO8UZ	DE	Asthma

DM4WHOS	ID	DM4WHOS
DM4WHOS	DN	KPP203
DM4WHOS	HS	Phase 2
DM4WHOS	CP	Novartis PharmaceuticalsEast Hanover, NJ
DM4WHOS	DE	Subacute cutaneous lupus erythematosus

DMQDLVW	ID	DMQDLVW
DMQDLVW	DN	KRP-104
DMQDLVW	HS	Phase 2
DMQDLVW	SN	Antigen inhibitor
DMQDLVW	CP	ActivX Biosciences
DMQDLVW	DE	Type-2 diabetes

DMOW9X2	ID	DMOW9X2
DMOW9X2	DN	KRP-203
DMOW9X2	HS	Phase 2
DMOW9X2	SN	KNF-299; KRP-203-P prodrug, Kyorin
DMOW9X2	CP	Kyorin Pharmaceutical Co Ltd
DMOW9X2	DT	Small molecular drug
DMOW9X2	PC	11155873
DMOW9X2	MW	480.4
DMOW9X2	FM	C24H27Cl2NO3S
DMOW9X2	IC	InChI=1S/C24H26ClNO3S.ClH/c25-23-14-22(10-9-19(23)11-12-24(26,16-27)17-28)30-21-8-4-7-20(13-21)29-15-18-5-2-1-3-6-18;/h1-10,13-14,27-28H,11-12,15-17,26H2;1H
DMOW9X2	CS	C1=CC=C(C=C1)COC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(CO)N)Cl.Cl
DMOW9X2	IK	MYIFLDFUXIHOCJ-UHFFFAOYSA-N
DMOW9X2	IU	2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride
DMOW9X2	CA	CAS 509088-69-1
DMOW9X2	DE	Cutaneous lupus erythematosus

DM08F12	ID	DM08F12
DM08F12	DN	KT6-971
DM08F12	HS	Phase 2
DM08F12	SN	Cholesterol absorption inhibitor, Kotobuki
DM08F12	CP	Kotobuki Pharmaceutical Co Ltd
DM08F12	DE	Hypercholesterolaemia

DMZL48U	ID	DMZL48U
DMZL48U	DN	KUR-111
DMZL48U	HS	Phase 2
DMZL48U	SN	I-0401; I-040302; TGplPTH1-34; Fibrin-PTH (bone cysts), Kuros; Human parathyroid hormone (PTH) + TISSEEL fibrin sealant + hydroxyapatite/tri-calcium phosphate granules (bone fracture), Kuros/Baxter
DMZL48U	CP	Kuros Biosurgery AG
DMZL48U	DE	Bone disease

DM2N0Z3	ID	DM2N0Z3
DM2N0Z3	DN	KUR-211
DM2N0Z3	HS	Phase 2
DM2N0Z3	CP	Baxter international; kuros biosurgery
DM2N0Z3	DE	Ulcer

DMB4HCY	ID	DMB4HCY
DMB4HCY	DN	KUR-212
DMB4HCY	HS	Phase 2
DMB4HCY	SN	I-020502; Fibrin-PDGF (wound healing), Baxter/Kuros; Fibrin-recombinant human platelet-derived growth factor (wound healing), Baxter/Kuros
DMB4HCY	CP	Baxter International Inc
DMB4HCY	DE	Wound healing

DMK4VOU	ID	DMK4VOU
DMK4VOU	DN	KVD001
DMK4VOU	HS	Phase 2
DMK4VOU	CP	KalVista Pharmaceuticals Cambridge, MA
DMK4VOU	DE	Diabetic macular edema

DM5N4OA	ID	DM5N4OA
DM5N4OA	DN	KVD824
DM5N4OA	HS	Phase 2
DM5N4OA	CP	KalVista Pharmaceuticals
DM5N4OA	DE	Diabetic macular edema

DMJGL72	ID	DMJGL72
DMJGL72	DN	KW-2478
DMJGL72	HS	Phase 2
DMJGL72	SN	KW-2478; 819812-04-9; KW-2478 free base; 2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide; UNII-QY50S617NM; KW 2478; KW2478; QY50S617NM; 2-ethyl-3,5-dihydroxy-n,n-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)benzeneacetamide; 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide
DMJGL72	CP	Kyowa Hakko Kirin
DMJGL72	DT	Small molecular drug
DMJGL72	PC	23116322
DMJGL72	MW	574.7
DMJGL72	FM	C30H42N2O9
DMJGL72	IC	InChI=1S/C30H42N2O9/c1-5-22-23(19-28(35)32(11-13-37-2)12-14-38-3)29(25(34)20-24(22)33)30(36)21-6-7-26(27(18-21)39-4)41-17-10-31-8-15-40-16-9-31/h6-7,18,20,33-34H,5,8-17,19H2,1-4H3
DMJGL72	CS	CCC1=C(C(=C(C=C1O)O)C(=O)C2=CC(=C(C=C2)OCCN3CCOCC3)OC)CC(=O)N(CCOC)CCOC
DMJGL72	IK	VFUXSYAXEKYYMB-UHFFFAOYSA-N
DMJGL72	IU	2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide
DMJGL72	CA	CAS 819812-04-9
DMJGL72	DE	Solid tumour/cancer

DM15RZO	ID	DM15RZO
DM15RZO	DN	KYMRIAH
DM15RZO	HS	Phase 2
DM15RZO	CP	Masonic Cancer Center, University of Minnesota
DM15RZO	DT	CAR T Cell Therapy
DM15RZO	DE	Acute lymphoblastic leukaemia

DMLHPVW	ID	DMLHPVW
DMLHPVW	DN	L1-79
DMLHPVW	HS	Phase 2
DMLHPVW	SN	alpha-methylparatyrosine
DMLHPVW	CP	Yamo Pharmaceuticals
DMLHPVW	DE	Autism spectrum disorder

DMI2XP1	ID	DMI2XP1
DMI2XP1	DN	L19-IL-2 fusion protein
DMI2XP1	HS	Phase 2
DMI2XP1	SN	Darleukin; Immunocytokine fusion protein, Bayer Schering; Immunocytokine fusion protein, Philogen; L19-IL-2 fusion protein, Bayer Schering; L19-IL-2 fusion protein, Philogen
DMI2XP1	CP	Philogen SpA
DMI2XP1	DT	Antibody
DMI2XP1	DE	Lymphoma

DMW6NMP	ID	DMW6NMP
DMW6NMP	DN	L19-TNF-alpha
DMW6NMP	HS	Phase 2
DMW6NMP	SN	Fibromun
DMW6NMP	CP	Philogen SpA
DMW6NMP	DT	Antibody
DMW6NMP	DE	Colorectal cancer

DMA0DSJ	ID	DMA0DSJ
DMA0DSJ	DN	L-694,458
DMA0DSJ	HS	Phase 2
DMA0DSJ	SN	DMP 777; 157341-41-8; DMP-777; UNII-3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4-methylpiperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide; DMP777; CHEMBL310871; L-694458; 3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4methyl-piperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide (3.5%  w/w solution); L-694,458; L 694458; SCHEMBL6538142; AC1L433D; CTK4C9348; DTXSID00166251; MolPort-023-332-820; C31H40N4O6; ZINC3936307; KS-00001E6Q; BCP02269
DMA0DSJ	DT	Small molecular drug
DMA0DSJ	PC	177992
DMA0DSJ	MW	564.7
DMA0DSJ	FM	C31H40N4O6
DMA0DSJ	IC	InChI=1S/C31H40N4O6/c1-5-8-24(22-11-14-25-26(19-22)40-20-39-25)32-30(38)35-28(37)31(6-2,7-3)29(35)41-23-12-9-21(10-13-23)27(36)34-17-15-33(4)16-18-34/h9-14,19,24,29H,5-8,15-18,20H2,1-4H3,(H,32,38)/t24-,29+/m1/s1
DMA0DSJ	CS	CCC[C@H](C1=CC2=C(C=C1)OCO2)NC(=O)N3[C@H](C(C3=O)(CC)CC)OC4=CC=C(C=C4)C(=O)N5CCN(CC5)C
DMA0DSJ	IK	ZSDCIRYNTCVTMF-GIGWZHCTSA-N
DMA0DSJ	IU	(2S)-N-[(1R)-1-(1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2-[4-(4-methylpiperazine-1-carbonyl)phenoxy]-4-oxoazetidine-1-carboxamide
DMA0DSJ	CA	CAS 157341-41-8
DMA0DSJ	DE	Cystic fibrosis

DMB7WT1	ID	DMB7WT1
DMB7WT1	DN	L-697,661
DMB7WT1	HS	Phase 2
DMB7WT1	SN	L-697661; L-697,661; 135525-78-9; L 697661; 3-(((4,7-Dichloro-1,3-benzoxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one; CHEMBL268871; UNII-4660N666EZ; 4660N666EZ; 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one; 2(1H)-Pyridinone, 3-(((4,7-dichloro-2-benzoxazolyl)methyl)amino)-5-ethyl-6-methyl-; ACMC-20mvsm; SCHEMBL599639; BDBM1317; AC1Q69B2; AC1L22E2; CTK0H5173; DTXSID10159457; AKOS030539285; LS-186956; LS-187602; L697,661; L 697,661
DMB7WT1	DT	Small molecular drug
DMB7WT1	PC	65002
DMB7WT1	MW	352.2
DMB7WT1	FM	C16H15Cl2N3O2
DMB7WT1	IC	InChI=1S/C16H15Cl2N3O2/c1-3-9-6-12(16(22)20-8(9)2)19-7-13-21-14-10(17)4-5-11(18)15(14)23-13/h4-6,19H,3,7H2,1-2H3,(H,20,22)
DMB7WT1	CS	CCC1=C(NC(=O)C(=C1)NCC2=NC3=C(C=CC(=C3O2)Cl)Cl)C
DMB7WT1	IK	WHFRDXVXYMGAJD-UHFFFAOYSA-N
DMB7WT1	IU	3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one
DMB7WT1	CA	CAS 135525-78-9
DMB7WT1	DE	Human immunodeficiency virus infection

DMTGR25	ID	DMTGR25
DMTGR25	DN	L-745,870
DMTGR25	HS	Phase 2
DMTGR25	SN	158985-00-3; L-745870; UNII-J3OLN3XSX7; J3OLN3XSX7; L-745,870; CHEMBL267014; L 745,870; 3-((4-(4-Chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine; 3-(4-[4-Chlorophenyl]piperazin-1-yl)-methyl-1H-pyrrolo[2,3-b]pyridine trihydrochloride; 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine; 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine; CPMPP-3; Tocris-1002; Lopac-L-131; Biomol-NT_000049; AC1NSK75; L745870; Lopac0_000791; GTPL3303; BPBio1_001299; SCHEMBL1059886; CHEBI:92099
DMTGR25	DT	Small molecular drug
DMTGR25	PC	5311200
DMTGR25	MW	326.8
DMTGR25	FM	C18H19ClN4
DMTGR25	IC	InChI=1S/C18H19ClN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)
DMTGR25	CS	C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)Cl
DMTGR25	IK	OGJGQVFWEPNYSB-UHFFFAOYSA-N
DMTGR25	IU	3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine
DMTGR25	CA	CAS 158985-00-3
DMTGR25	CB	CHEBI:92099
DMTGR25	DE	Psychotic disorder

DMNO5UE	ID	DMNO5UE
DMNO5UE	DN	Labetuzumab I-131
DMNO5UE	HS	Phase 2
DMNO5UE	SN	IMMU-111
DMNO5UE	CP	Immunomedics
DMNO5UE	DT	Antibody
DMNO5UE	DE	Colorectal cancer

DM7063I	ID	DM7063I
DM7063I	DN	LADIRUBICIN
DM7063I	HS	Phase 2
DM7063I	SN	FCE-28729; PNU-159548; Ladirubicin; 3'-(1-Aziridinyl)-3'-deamino-4-demethoxy-4'-O-(methanesulfonyl)daunomycin
DM7063I	DT	Small molecular drug
DM7063I	PC	216232
DM7063I	MW	601.6
DM7063I	FM	C29H31NO11S
DM7063I	IC	InChI=1S/C29H31NO11S/c1-13-28(41-42(3,37)38)18(30-8-9-30)10-20(39-13)40-19-12-29(36,14(2)31)11-17-21(19)27(35)23-22(26(17)34)24(32)15-6-4-5-7-16(15)25(23)33/h4-7,13,18-20,28,34-36H,8-12H2,1-3H3/t13-,18-,19-,20-,28+,29-/m0/s1
DM7063I	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N6CC6)OS(=O)(=O)C
DM7063I	IK	VMDWTZZCNDEKIO-CBNJBKGYSA-N
DM7063I	IU	[(2S,3S,4S,6R)-6-[[(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]-4-(aziridin-1-yl)-2-methyloxan-3-yl] methanesulfonate
DM7063I	CA	CAS 171047-47-5
DM7063I	DE	Breast cancer

DMJSY3Q	ID	DMJSY3Q
DMJSY3Q	DN	Ladostigil
DMJSY3Q	HS	Phase 2
DMJSY3Q	SN	Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326
DMJSY3Q	CP	Hebrew University of Jerusalem
DMJSY3Q	DT	Small molecular drug
DMJSY3Q	PC	208907
DMJSY3Q	MW	272.34
DMJSY3Q	FM	C16H20N2O2
DMJSY3Q	IC	InChI=1S/C16H20N2O2/c1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2/h1,6,8,11,15,17H,5,7,9-10H2,2-3H3/t15-/m1/s1
DMJSY3Q	CS	CCN(C)C(=O)OC1=CC2=C(CC[C@H]2NCC#C)C=C1
DMJSY3Q	IK	LHXOCOHMBFOVJS-OAHLLOKOSA-N
DMJSY3Q	IU	[(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate
DMJSY3Q	CA	CAS 209394-27-4
DMJSY3Q	DE	Alzheimer disease

DMSIGAB	ID	DMSIGAB
DMSIGAB	DN	L-alanosine
DMSIGAB	HS	Phase 2
DMSIGAB	SN	SDX-102
DMSIGAB	CP	Salmedix
DMSIGAB	DT	Small molecular drug
DMSIGAB	PC	135409347
DMSIGAB	MW	149.11
DMSIGAB	FM	C3H7N3O4
DMSIGAB	IC	InChI=1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,9H,1,4H2,(H,7,8)/b6-5-/t2-/m0/s1
DMSIGAB	CS	C([C@@H](C(=O)O)N)/[N+](=N/O)/[O-]
DMSIGAB	IK	ZGNLFUXWZJGETL-YUSKDDKASA-N
DMSIGAB	IU	(Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium
DMSIGAB	CA	CAS 5854-93-3
DMSIGAB	DE	Brain cancer

DMR0N74	ID	DMR0N74
DMR0N74	DN	LAM-002
DMR0N74	HS	Phase 2
DMR0N74	CP	LAM Therapeutics Guilford, CT
DMR0N74	DE	B-cell non-hodgkin lymphoma; Non-hodgkin lymphoma; Chronic lymphocytic leukaemia

DM7MBV6	ID	DM7MBV6
DM7MBV6	DN	Lancovutide
DM7MBV6	HS	Phase 2
DM7MBV6	SN	Duramycin; Lancovutide; Cystic fibrosis treatment, Molichem; Moli-1901; Moli-901; Duramycin(ophthalmic, dry eye), Lantibio; Lancovutide (ophthalmic, dry eye), Lantibio; Duramycin (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Duramycin (inhaled, cystic fibrosis), Molichem/AOP Orphan; Lancovutide (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Moli-1901 (ophthalmic, dry eye), Lantibio
DM7MBV6	CP	Lantibio Inc
DM7MBV6	PC	86289378
DM7MBV6	MW	2013.3
DM7MBV6	FM	C89H125N23O25S3
DM7MBV6	IC	InChI=1S/C89H125N23O25S3/c1-44(2)67-85(131)107-60-42-138-41-59-80(126)106-61-43-140-46(4)69(87(133)103-56(76(122)108-67)35-49-23-12-7-13-24-49)109-77(123)55(34-48-21-10-6-11-22-48)102-83(129)62-27-18-32-112(62)66(116)39-96-73(119)54(33-47-19-8-5-9-20-47)101-79(125)58(104-81(61)127)37-94-31-17-15-26-53(88(134)135)100-86(132)68(110-78(124)57(36-64(93)114)97-65(115)38-95-84(130)70(111-82(60)128)71(117)89(136)137)45(3)139-40-50(91)72(118)98-51(25-14-16-30-90)74(120)99-52(75(121)105-59)28-29-63(92)113/h5-13,19-24,44-46,50-62,67-71,94,117H,14-18,25-43,90-91H2,1-4H3,(H2,92,113)(H2,93,114)(H,95,130)(H,96,119)(H,97,115)(H,98,118)(H,99,120)(H,100,132)(H,101,125)(H,102,129)(H,103,133)(H,104,127)(H,105,121)(H,106,126)(H,107,131)(H,108,122)(H,109,123)(H,110,124)(H,111,128)(H,134,135)(H,136,137)/t45?,46-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59+,60-,61-,62-,67-,68+,69+,70-,71+/m0/s1
DM7MBV6	CS	C[C@H]1[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]3CSC[C@@H]4C(=O)N[C@@H](CS1)C(=O)N[C@@H](CNCCCC[C@H](NC(=O)[C@@H](C(SC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCC(=O)N)CCCCN)N)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC3=O)[C@H](C(=O)O)O)CC(=O)N)C(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N2)CC6=CC=CC=C6)CC7=CC=CC=C7)C(C)C)CC8=CC=CC=C8
DM7MBV6	IK	SFWLDKQAUHFCBS-WWXQEMPQSA-N
DM7MBV6	IU	(1S,4S,13S,16S,19S,22S,25S,28R,31S,37S,40S,44R,47S,50S,53S,56R,65S,70S)-44-amino-47-(4-aminobutyl)-37-(2-amino-2-oxoethyl)-50-(3-amino-3-oxopropyl)-4,16,22-tribenzyl-31-[(R)-carboxy(hydroxy)methyl]-41,70-dimethyl-2,5,8,14,17,20,23,26,29,32,35,38,45,48,51,54,57,67-octadecaoxo-25-propan-2-yl-42,69,72-trithia-3,6,9,15,18,21,24,27,30,33,36,39,46,49,52,55,58,60,66-nonadecazapentacyclo[38.18.9.319,56.328,53.09,13]triheptacontane-65-carboxylic acid
DM7MBV6	DE	Chronic obstructive pulmonary disease

DM1VK96	ID	DM1VK96
DM1VK96	DN	LANEPITANT
DM1VK96	HS	Phase 2
DM1VK96	SN	LY-303870; LY-302654 (racemate); Lanepitant; N-[1(R)-(1H-Indol-3-ylmethyl)-2-[N-(2-methoxybenzyl)acetamido]ethyl]-2-[4-(1-piperidinyl)piperidin-1-yl]acetamide
DM1VK96	DT	Small molecular drug
DM1VK96	PC	3086681
DM1VK96	MW	559.7
DM1VK96	FM	C33H45N5O3
DM1VK96	IC	InChI=1S/C33H45N5O3/c1-25(39)38(22-26-10-4-7-13-32(26)41-2)23-28(20-27-21-34-31-12-6-5-11-30(27)31)35-33(40)24-36-18-14-29(15-19-36)37-16-8-3-9-17-37/h4-7,10-13,21,28-29,34H,3,8-9,14-20,22-24H2,1-2H3,(H,35,40)/t28-/m1/s1
DM1VK96	CS	CC(=O)N(CC1=CC=CC=C1OC)C[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)CN4CCC(CC4)N5CCCCC5
DM1VK96	IK	CVXJAPZTZWLRBP-MUUNZHRXSA-N
DM1VK96	IU	N-[(2R)-1-[acetyl-[(2-methoxyphenyl)methyl]amino]-3-(1H-indol-3-yl)propan-2-yl]-2-(4-piperidin-1-ylpiperidin-1-yl)acetamide
DM1VK96	CA	CAS 170566-84-4
DM1VK96	DE	Pain

DMPRZX4	ID	DMPRZX4
DMPRZX4	DN	LAS 100977
DMPRZX4	HS	Phase 2
DMPRZX4	SN	LABA
DMPRZX4	CP	Almirall; Forest Laboratories
DMPRZX4	DT	Small molecular drug
DMPRZX4	PC	11962616
DMPRZX4	MW	460.5
DMPRZX4	FM	C25H30F2N2O4
DMPRZX4	IC	InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1
DMPRZX4	CS	C1=CC=C(C=C1)C(COCCCCCCNC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O)(F)F
DMPRZX4	IK	SFYAXIFVXBKRPK-QFIPXVFZSA-N
DMPRZX4	IU	5-[(1R)-2-[6-(2,2-difluoro-2-phenylethoxy)hexylamino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
DMPRZX4	CA	CAS 915133-65-2
DMPRZX4	CB	CHEBI:142077
DMPRZX4	DE	Chronic obstructive pulmonary disease

DM3WY0B	ID	DM3WY0B
DM3WY0B	DN	LAS-41002
DM3WY0B	HS	Phase 2
DM3WY0B	SN	Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall
DM3WY0B	CP	Almirall Prodesfarma SA
DM3WY0B	DE	Eczema

DMC04SR	ID	DMC04SR
DMC04SR	DN	LB-100
DMC04SR	HS	Phase 2
DMC04SR	DT	Small molecular drug
DMC04SR	PC	3578572
DMC04SR	MW	268.31
DMC04SR	FM	C13H20N2O4
DMC04SR	IC	InChI=1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18)
DMC04SR	CS	CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3
DMC04SR	IK	JUQMLSGOTNKJKI-UHFFFAOYSA-N
DMC04SR	IU	3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
DMC04SR	DE	Solid tumour/cancer; Astrocytoma

DM0OHX3	ID	DM0OHX3
DM0OHX3	DN	LB-30870
DM0OHX3	HS	Phase 2
DM0OHX3	SN	N-(Carboxymethyl)-D-diphenylalanyl-L-proline 5-amidinothien-2-ylmethyl amide bis(trifluoroacetate)
DM0OHX3	PC	9871765
DM0OHX3	MW	533.6
DM0OHX3	FM	C28H31N5O4S
DM0OHX3	IC	InChI=1S/C28H31N5O4S/c29-26(30)22-14-13-20(38-22)16-32-27(36)21-12-7-15-33(21)28(37)25(31-17-23(34)35)24(18-8-3-1-4-9-18)19-10-5-2-6-11-19/h1-6,8-11,13-14,21,24-25,31H,7,12,15-17H2,(H3,29,30)(H,32,36)(H,34,35)/t21-,25+/m0/s1
DM0OHX3	CS	C1C[C@H](N(C1)C(=O)[C@@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NCC(=O)O)C(=O)NCC4=CC=C(S4)C(=N)N
DM0OHX3	IK	BIHPYGVYKSQDLA-SQJMNOBHSA-N
DM0OHX3	IU	2-[[(2R)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]pyrrolidin-1-yl]-1-oxo-3,3-diphenylpropan-2-yl]amino]acetic acid
DM0OHX3	CA	CAS 280780-95-2
DM0OHX3	DE	Myocardial infarction

DMQZJNA	ID	DMQZJNA
DMQZJNA	DN	LCAR-B38M CAR-T Cell
DMQZJNA	HS	Phase 2
DMQZJNA	CP	Nanjing Legend Biotech Co.
DMQZJNA	DT	CAR T Cell Therapy
DMQZJNA	DE	Multiple myeloma

DMY4IWC	ID	DMY4IWC
DMY4IWC	DN	LCB-2183
DMY4IWC	HS	Phase 2
DMY4IWC	PC	135418284
DMY4IWC	MW	206.2
DMY4IWC	FM	C9H10N4O2
DMY4IWC	IC	InChI=1S/C9H10N4O2/c1-2-15-5-6-12-8-7(9(14)13-6)10-3-4-11-8/h3-4H,2,5H2,1H3,(H,11,12,13,14)
DMY4IWC	CS	CCOCC1=NC2=NC=CN=C2C(=O)N1
DMY4IWC	IK	SFWVULIFVPNTOF-UHFFFAOYSA-N
DMY4IWC	IU	2-(ethoxymethyl)-3H-pteridin-4-one
DMY4IWC	CA	CAS 133914-85-9
DMY4IWC	DE	Asthma

DMTM4QA	ID	DMTM4QA
DMTM4QA	DN	LCL161
DMTM4QA	HS	Phase 2
DMTM4QA	CP	Novartis
DMTM4QA	PC	24737642
DMTM4QA	MW	500.6
DMTM4QA	FM	C26H33FN4O3S
DMTM4QA	IC	InChI=1S/C26H33FN4O3S/c1-16(28-2)24(33)30-22(17-7-4-3-5-8-17)26(34)31-14-6-9-21(31)25-29-20(15-35-25)23(32)18-10-12-19(27)13-11-18/h10-13,15-17,21-22,28H,3-9,14H2,1-2H3,(H,30,33)/t16-,21-,22-/m0/s1
DMTM4QA	CS	C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC
DMTM4QA	IK	UFPFGVNKHCLJJO-SSKFGXFMSA-N
DMTM4QA	IU	(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide
DMTM4QA	CA	CAS 1005342-46-0
DMTM4QA	DE	Solid tumour/cancer; Breast cancer; Multiple myeloma; Myelofibrosis

DMM9F25	ID	DMM9F25
DMM9F25	DN	LDE225
DMM9F25	HS	Phase 2
DMM9F25	SN	Erismodegib
DMM9F25	CP	Novartis Pharmaceuticals
DMM9F25	DT	Small molecular drug
DMM9F25	PC	24775005
DMM9F25	MW	485.5
DMM9F25	FM	C26H26F3N3O3
DMM9F25	IC	InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+
DMM9F25	CS	C[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F
DMM9F25	IK	VZZJRYRQSPEMTK-CALCHBBNSA-N
DMM9F25	IU	N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide
DMM9F25	CA	CAS 956697-53-3
DMM9F25	CB	CHEBI:90863
DMM9F25	DE	Skin cancer; Medulloblastoma

DMIEZUB	ID	DMIEZUB
DMIEZUB	DN	L-DOS47
DMIEZUB	HS	Phase 2
DMIEZUB	CP	Helix BioPharma
DMIEZUB	DE	Lung cancer; Non-small-cell lung cancer; Non-small cell lung cancer

DMS6E9J	ID	DMS6E9J
DMS6E9J	DN	Lefitolimod
DMS6E9J	HS	Phase 2
DMS6E9J	SN	MGN1703
DMS6E9J	CP	Mologen
DMS6E9J	DE	Human immunodeficiency virus-1 infection

DMV2YDK	ID	DMV2YDK
DMV2YDK	DN	LEISH-F1
DMV2YDK	HS	Phase 2
DMV2YDK	SN	LeIF adjuvant, Corixa; Leish-111f; Leishmanial eukaryotic initiation factor, Corixa; Leishmaniasis vaccine (LeIF), Corixa; Leishmaniasis vaccine, Corixa/ Infectious Disease Research Institute; Vaccine (leishmania), Corixa; LeIF enhanced T-cell vaccine, Corixa, Infectious Disease Research Institute
DMV2YDK	CP	Infectious Disease Research Institute
DMV2YDK	DT	Vaccine
DMV2YDK	DE	Leishmania infection

DMZKBMG	ID	DMZKBMG
DMZKBMG	DN	Lenapenem hydrochloride hydrate
DMZKBMG	HS	Phase 2
DMZKBMG	SN	BO-2727; L-739428
DMZKBMG	CP	MSD Japan
DMZKBMG	DT	Small molecular drug
DMZKBMG	PC	443100
DMZKBMG	MW	454
DMZKBMG	FM	C18H32ClN3O6S
DMZKBMG	IC	InChI=1S/C18H29N3O5S.ClH.H2O/c1-8-14-13(9(2)22)17(24)21(14)15(18(25)26)16(8)27-10-6-11(20-7-10)12(23)4-5-19-3;;/h8-14,19-20,22-23H,4-7H2,1-3H3,(H,25,26);1H;1H2/t8-,9-,10+,11+,12-,13-,14-;;/m1../s1
DMZKBMG	CS	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)[C@@H](CCNC)O)C(=O)O)[C@@H](C)O.O.Cl
DMZKBMG	IK	FNSICOGCVDQJPU-HCRFUVGVSA-N
DMZKBMG	IU	(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrate;hydrochloride
DMZKBMG	CA	CAS 149882-71-3
DMZKBMG	DE	Bacterial infection

DMWAD93	ID	DMWAD93
DMWAD93	DN	Leniolisib
DMWAD93	HS	Phase 2
DMWAD93	SN	1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib;  CDZ173; Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ
DMWAD93	CP	Novartis
DMWAD93	DT	Small molecular drug
DMWAD93	PC	57495353
DMWAD93	MW	450.5
DMWAD93	FM	C21H25F3N6O2
DMWAD93	IC	InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1
DMWAD93	CS	CCC(=O)N1CC[C@@H](C1)NC2=NC=NC3=C2CN(CC3)C4=CC(=C(N=C4)OC)C(F)(F)F
DMWAD93	IK	MWKYMZXCGYXLPL-ZDUSSCGKSA-N
DMWAD93	IU	1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one
DMWAD93	CA	CAS 1354690-24-6
DMWAD93	DE	Sjogren syndrome

DMR1MQW	ID	DMR1MQW
DMR1MQW	DN	Lenzilumab
DMR1MQW	HS	Phase 2
DMR1MQW	CP	Humanigen Brisbane, CA
DMR1MQW	DE	Chronic myelogenous leukaemia; Coronavirus Disease 2019 (COVID-19)

DM7W0JE	ID	DM7W0JE
DM7W0JE	DN	LEO 124249
DM7W0JE	HS	Phase 2
DM7W0JE	SN	delgocitinib; Delgocitinib; UNII-9L0Q8KK220; JTE-052; 9L0Q8KK220; 1263774-59-9; Delgocitinib [USAN]; Delgocitinib (JAN/USAN); JTE052; JTE-052A; GTPL9619; SCHEMBL12547007; LEO 124249A; HY-109053; CS-0031558; D11046; 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)-; 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile
DM7W0JE	CP	LEO Pharma Madison, NJ
DM7W0JE	PC	50914062
DM7W0JE	MW	310.35
DM7W0JE	FM	C16H18N6O
DM7W0JE	IC	InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
DM7W0JE	CS	C[C@H]1CN([C@]12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N
DM7W0JE	IK	LOWWYYZBZNSPDT-ZBEGNZNMSA-N
DM7W0JE	IU	3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
DM7W0JE	CA	CAS 1263774-59-9
DM7W0JE	DE	Asthma; Eczema

DMZ6Y0T	ID	DMZ6Y0T
DMZ6Y0T	DN	LEO-32731
DMZ6Y0T	HS	Phase 2
DMZ6Y0T	SN	LP0058
DMZ6Y0T	CP	LEO Pharma A/S
DMZ6Y0T	PC	54765967
DMZ6Y0T	MW	510.3
DMZ6Y0T	FM	C19H15Cl2F2NO7S
DMZ6Y0T	IC	InChI=1S/C19H15Cl2F2NO7S/c20-12-8-24(26)9-13(21)11(12)7-14(25)10-1-2-15(29-18(22)23)17-16(10)30-19(31-17)3-5-32(27,28)6-4-19/h1-2,8-9,18H,3-7H2
DMZ6Y0T	CS	C1CS(=O)(=O)CCC12OC3=C(C=CC(=C3O2)OC(F)F)C(=O)CC4=C(C=[N+](C=C4Cl)[O-])Cl
DMZ6Y0T	IK	ZININGNRPUGNSL-UHFFFAOYSA-N
DMZ6Y0T	IU	2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-[7-(difluoromethoxy)-1',1'-dioxospiro[1,3-benzodioxole-2,4'-thiane]-4-yl]ethanone
DMZ6Y0T	CA	CAS 1353546-86-7
DMZ6Y0T	DE	Psoriasis vulgaris; Plaque psoriasis

DM6DL5K	ID	DM6DL5K
DM6DL5K	DN	Leridistim
DM6DL5K	HS	Phase 2
DM6DL5K	SN	MPO, Searle; MPO-1; SC-70935; Myelopoietin (1), Searle
DM6DL5K	CP	GD Searle & Co
DM6DL5K	DE	Immune System disease

DMMQ6VT	ID	DMMQ6VT
DMMQ6VT	DN	Leronlimab
DMMQ6VT	HS	Phase 2 
DMMQ6VT	SN	PRO 140
DMMQ6VT	TC	Antiviral Agents
DMMQ6VT	DT	Monoclonal antibody
DMMQ6VT	DE	Coronavirus Disease 2019 (COVID-19)

DMSEVBH	ID	DMSEVBH
DMSEVBH	DN	Lersivirine
DMSEVBH	HS	Phase 2
DMSEVBH	SN	cc-718; Lersivirine (UK-453061)
DMSEVBH	CP	ViiV Healthcare
DMSEVBH	DT	Small molecular drug
DMSEVBH	PC	16739244
DMSEVBH	MW	310.35
DMSEVBH	FM	C17H18N4O2
DMSEVBH	IC	InChI=1S/C17H18N4O2/c1-3-15-17(16(4-2)21(20-15)5-6-22)23-14-8-12(10-18)7-13(9-14)11-19/h7-9,22H,3-6H2,1-2H3
DMSEVBH	CS	CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)C#N)C#N
DMSEVBH	IK	MCPUZZJBAHRIPO-UHFFFAOYSA-N
DMSEVBH	IU	5-[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxybenzene-1,3-dicarbonitrile
DMSEVBH	CA	CAS 473921-12-9
DMSEVBH	DE	Human immunodeficiency virus infection

DMW50NF	ID	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	HS	Phase 2
DMW50NF	SN	7-Ethyl-10-hydroxycamptothecin; 86639-52-3; SN-38; SN 38 lactone; 7-Ethyl-10-hydroxy-camptothecin; SN 38; 10-Hydroxy-7-ethylcamptothecin; 7-Ethyl-10-hydroxycamptothecine; SN38; 7-Ethyl-10-hydroxy-20(S)-camptothecin; UNII-0H43101T0J; Captothecin, 7-ethyl-10-hydroxy-; CHEBI:8988; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 7-Ethyl-10-hydroxy camptothecin; NSC673596; 0H43101T0J; (+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; 113015-38-6
DMW50NF	CP	NeoPharm
DMW50NF	DT	Small molecular drug
DMW50NF	PC	104842
DMW50NF	MW	392.4
DMW50NF	FM	C22H20N2O5
DMW50NF	IC	InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1
DMW50NF	CS	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)O
DMW50NF	IK	FJHBVJOVLFPMQE-QFIPXVFZSA-N
DMW50NF	IU	(19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DMW50NF	CA	CAS 86639-52-3
DMW50NF	CB	CHEBI:8988
DMW50NF	DE	Solid tumour/cancer; Colorectal cancer

DMIFGLY	ID	DMIFGLY
DMIFGLY	DN	Leukemia cancer vaccine
DMIFGLY	HS	Phase 2
DMIFGLY	CP	BioSante Pharmaceuticals
DMIFGLY	DT	Vaccine
DMIFGLY	DE	Acute myeloid leukaemia

DM5LQEI	ID	DM5LQEI
DM5LQEI	DN	Leuvectin
DM5LQEI	HS	Phase 2
DM5LQEI	SN	IL-2 gene therapy, Vical; Cytofectin (IL-2), Vical; Gene therapy (interleukin-2), Vical
DM5LQEI	CP	Vical Inc
DM5LQEI	DE	Melanoma

DMOS5JZ	ID	DMOS5JZ
DMOS5JZ	DN	Lexatumumab
DMOS5JZ	HS	Phase 2
DMOS5JZ	SN	HGS-ETR2; TRAIL receptor-2 monoclonal antibodies (cancer), HGS/CAT; TRAIL-R2 mAbs (cancer), Human Genome Sciences/Cambridge Antibody Technology; TNF-related apoptosis-inducing ligand receptor-2 mAbs (cancer), HGS/CAT
DMOS5JZ	CP	Cambridge Antibody Technology Group plc
DMOS5JZ	DT	Antibody
DMOS5JZ	DE	Solid tumour/cancer

DMLEX1D	ID	DMLEX1D
DMLEX1D	DN	Lexibulin
DMLEX1D	HS	Phase 2
DMLEX1D	SN	Lexibulin; CYT-997; Microtubule inhibitor (oral, solid tumors) Cytopia; VDA anticancer program (iv), Cytopia; Lexibulin (iv infusion, cancer), YM BioSciences; Lexibulin (oral capsule, cancer), YM Biosciences; CYT-997 (iv infusion, cancer), Cytopia; CYT-997 (iv infusion, cancer), YM BioSciences; CYT-997 (oral capsule, cancer), Cytopia; CYT-997 (oral capsule, cancer), YM Biosciences; Vascular disrupting agent/ tubulin inhibitor (iv, cancer), Cytopia; Vascular disrupting agent/tubulin inhibitor (oral, cancer), Cytopia; Vascular targeting agent/ tubulin inhibitor (iv, cancer), Cytopia
DMLEX1D	CP	Cytopia Ltd; Cytopia
DMLEX1D	DE	Glioblastoma multiforme

DMZ2YBE	ID	DMZ2YBE
DMZ2YBE	DN	Lexipafant
DMZ2YBE	HS	Phase 2
DMZ2YBE	SN	LEXIPAFANT; 139133-26-9; UNII-H14917M9YW; BB-882; CHEMBL322832; H14917M9YW; DO6; Lexipafant [USAN:INN:BAN]; BB 882; Lexipafant (USAN/INN); SCHEMBL194598; ZINC1851122; BDBM50048485; N-Methyl-N-((alpha-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)-p-tolyl)sulfonyl)-L-leucine, ethyl ester; D04724; L-Leucine, N-methyl-N-((4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)ethyl)phenyl)sulfonyl)-, ethyl ester; ETHYL4-METHYL-2-[METHYL-[4-[(2-METHYLIMIDAZO[4,5-C]PYRIDIN-1-YL)METHYL]PHENYL]SULFONYLAMINO]PENTANOATE; Benzothiadiazines
DMZ2YBE	DT	Small molecular drug
DMZ2YBE	PC	9804204
DMZ2YBE	MW	458.6
DMZ2YBE	FM	C23H30N4O4S
DMZ2YBE	IC	InChI=1S/C23H30N4O4S/c1-6-31-23(28)22(13-16(2)3)26(5)32(29,30)19-9-7-18(8-10-19)15-27-17(4)25-20-14-24-12-11-21(20)27/h7-12,14,16,22H,6,13,15H2,1-5H3/t22-/m0/s1
DMZ2YBE	CS	CCOC(=O)[C@H](CC(C)C)N(C)S(=O)(=O)C1=CC=C(C=C1)CN2C(=NC3=C2C=CN=C3)C
DMZ2YBE	IK	AQRXDPFOYJSPMP-QFIPXVFZSA-N
DMZ2YBE	IU	ethyl (2S)-4-methyl-2-[methyl-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonylamino]pentanoate
DMZ2YBE	CA	CAS 139133-26-9
DMZ2YBE	DE	Hepatovirus infection; Nerve injury

DMCT1RQ	ID	DMCT1RQ
DMCT1RQ	DN	LFG-316
DMCT1RQ	HS	Phase 2
DMCT1RQ	CP	Novartis AG
DMCT1RQ	DT	Antibody
DMCT1RQ	DE	Macular degeneration

DM9T8A2	ID	DM9T8A2
DM9T8A2	DN	LGD-4665
DM9T8A2	HS	Phase 2
DM9T8A2	CP	Ligand
DM9T8A2	DE	Immune thrombocytopenic purpura

DMPL9KG	ID	DMPL9KG
DMPL9KG	DN	LGD-6972
DMPL9KG	HS	Phase 2
DMPL9KG	SN	MB-11262
DMPL9KG	CP	Ligand pharmaceuticals
DMPL9KG	PC	44625560
DMPL9KG	MW	702.9
DMPL9KG	FM	C43H46N2O5S
DMPL9KG	IC	InChI=1S/C43H46N2O5S/c1-28-25-29(2)40(30(3)26-28)35-17-21-38(22-18-35)45-42(47)39(27-31-7-9-36(10-8-31)41(46)44-23-24-51(48,49)50)34-13-11-32(12-14-34)33-15-19-37(20-16-33)43(4,5)6/h7-22,25-26,39H,23-24,27H2,1-6H3,(H,44,46)(H,45,47)(H,48,49,50)/t39-/m1/s1
DMPL9KG	CS	CC1=CC(=C(C(=C1)C)C2=CC=C(C=C2)NC(=O)[C@H](CC3=CC=C(C=C3)C(=O)NCCS(=O)(=O)O)C4=CC=C(C=C4)C5=CC=C(C=C5)C(C)(C)C)C
DMPL9KG	IK	HKJMCBYPVCGZFB-LDLOPFEMSA-N
DMPL9KG	IU	2-[[4-[(2R)-2-[4-(4-tert-butylphenyl)phenyl]-3-oxo-3-[4-(2,4,6-trimethylphenyl)anilino]propyl]benzoyl]amino]ethanesulfonic acid
DMPL9KG	CA	CAS 1207989-09-0
DMPL9KG	DE	Type-2 diabetes; Non-insulin dependent diabetes

DMA0RI9	ID	DMA0RI9
DMA0RI9	DN	LIDORESTAT
DMA0RI9	HS	Phase 2
DMA0RI9	SN	Lidorestat; 245116-90-9; IDD-676; UNII-R3734K0M7L; IDD-000676-01; {3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID; CHEMBL363387; R3734K0M7L; 1H-Indole-1-aceticacid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 3-[(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL]INDOLE-N-ACETIC ACID; 3NA; Lidorestat [USAN:INN]; 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 1H-Indole-1-acetic acid, 3-((4,5,7-trifluor
DMA0RI9	DT	Small molecular drug
DMA0RI9	PC	157839
DMA0RI9	MW	376.4
DMA0RI9	FM	C18H11F3N2O2S
DMA0RI9	IC	InChI=1S/C18H11F3N2O2S/c19-11-6-12(20)18-17(16(11)21)22-14(26-18)5-9-7-23(8-15(24)25)13-4-2-1-3-10(9)13/h1-4,6-7H,5,8H2,(H,24,25)
DMA0RI9	CS	C1=CC=C2C(=C1)C(=CN2CC(=O)O)CC3=NC4=C(C(=CC(=C4S3)F)F)F
DMA0RI9	IK	KYHVTMFADJNSGS-UHFFFAOYSA-N
DMA0RI9	IU	2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid
DMA0RI9	CA	CAS 245116-90-9
DMA0RI9	DE	Diabetic complication

DM32NWD	ID	DM32NWD
DM32NWD	DN	LIK-066
DM32NWD	HS	Phase 2
DM32NWD	CP	Novartis AG
DM32NWD	PC	52913524
DM32NWD	MW	416.5
DM32NWD	FM	C23H28O7
DM32NWD	IC	InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1
DM32NWD	CS	CCC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4
DM32NWD	IK	XFJAMQQAAMJFGB-ZQGJOIPISA-N
DM32NWD	IU	(2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DM32NWD	CA	CAS 1291094-73-9
DM32NWD	DE	Type-2 diabetes; Heart failure

DM9ZHRS	ID	DM9ZHRS
DM9ZHRS	DN	LIM-0705
DM9ZHRS	HS	Phase 2
DM9ZHRS	CP	Limerick Biopharma
DM9ZHRS	PC	20833257
DM9ZHRS	MW	382.21
DM9ZHRS	FM	C15H11O10P
DM9ZHRS	IC	InChI=1S/C15H11O10P/c16-7-4-9(18)12-11(5-7)24-15(14(20)13(12)19)6-1-2-8(17)10(3-6)25-26(21,22)23/h1-5,16-18,20H,(H2,21,22,23)
DM9ZHRS	CS	C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)OP(=O)(O)O)O
DM9ZHRS	IK	UWJBYNLLMAPJMM-UHFFFAOYSA-N
DM9ZHRS	IU	[2-hydroxy-5-(3,5,7-trihydroxy-4-oxochromen-2-yl)phenyl] dihydrogen phosphate
DM9ZHRS	CA	CAS 1111616-69-3
DM9ZHRS	DE	Insulin-resistant disorder

DMSHGWN	ID	DMSHGWN
DMSHGWN	DN	Lintopride
DMSHGWN	HS	Phase 2
DMSHGWN	SN	SL-920075
DMSHGWN	CP	Synthelabo
DMSHGWN	DT	Small molecular drug
DMSHGWN	PC	65900
DMSHGWN	MW	310.78
DMSHGWN	FM	C14H19ClN4O2
DMSHGWN	IC	InChI=1S/C14H19ClN4O2/c1-3-19-5-4-17-13(19)8-18-14(20)9-6-10(15)11(16)7-12(9)21-2/h6-7H,3-5,8,16H2,1-2H3,(H,18,20)
DMSHGWN	CS	CCN1CCN=C1CNC(=O)C2=CC(=C(C=C2OC)N)Cl
DMSHGWN	IK	MJCKISCWHDATBN-UHFFFAOYSA-N
DMSHGWN	IU	4-amino-5-chloro-N-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide
DMSHGWN	CA	CAS 107429-63-0
DMSHGWN	DE	Nausea

DMWY0V1	ID	DMWY0V1
DMWY0V1	DN	LIPO-5
DMWY0V1	HS	Phase 2
DMWY0V1	SN	HIV vaccine (lipoprotein), ANRS/Aventis Pasteur
DMWY0V1	CP	Sanofi Pasteur
DMWY0V1	DT	Vaccine
DMWY0V1	DE	Human immunodeficiency virus infection

DMNGT89	ID	DMNGT89
DMNGT89	DN	Lirilumab
DMNGT89	HS	Phase 2
DMNGT89	CP	Bristol-Myers Squibb
DMNGT89	DT	Monoclonal antibody
DMNGT89	DE	Acute myeloid leukaemia; Solid tumour/cancer; Chronic lymphocytic leukaemia; Myelodysplastic syndrome

DMD4KAU	ID	DMD4KAU
DMD4KAU	DN	LIRIMILAST
DMD4KAU	HS	Phase 2
DMD4KAU	SN	Lirimilast; Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzofuran-6-ylester
DMD4KAU	DT	Small molecular drug
DMD4KAU	PC	6433118
DMD4KAU	MW	443.3
DMD4KAU	FM	C17H12Cl2N2O6S
DMD4KAU	IC	InChI=1S/C17H12Cl2N2O6S/c1-28(24,25)27-9-3-5-11-13(7-9)26-16(14(11)21-17(20)23)15(22)10-4-2-8(18)6-12(10)19/h2-7H,1H3,(H3,20,21,23)
DMD4KAU	CS	CS(=O)(=O)OC1=CC2=C(C=C1)C(=C(O2)C(=O)C3=C(C=C(C=C3)Cl)Cl)NC(=O)N
DMD4KAU	IK	YPFLFUJKZDAXRA-UHFFFAOYSA-N
DMD4KAU	IU	[3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate
DMD4KAU	CA	CAS 329306-27-6
DMD4KAU	DE	Chronic obstructive pulmonary disease

DMVU9X1	ID	DMVU9X1
DMVU9X1	DN	Lisofylline
DMVU9X1	HS	Phase 2
DMVU9X1	SN	LISOFYLLINE; (R)-Lisofylline; 100324-81-0; CT-1501R; ProTec; Lisophylline; NSMXQKNUPPXBRG-SECBINFHSA-N; (R)-Lisophylline; 3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; UNII-L1F2Q2X956; 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione; L1F2Q2X956; ProTec (TN); AC1L9UOZ; Lisofylline (USAN/INN); CHEMBL1411; SCHEMBL39131; GTPL9225; DTXSID7058709; CTK8E6838; CT1501R; MolPort-005-943-169; ZINC1887263; LSF; 1836AH; AKOS025394050; SB18959; DB12406; NCGC00186630-01; FT-0670822
DMVU9X1	CP	DiaKine Therapeutics
DMVU9X1	DT	Small molecular drug
DMVU9X1	PC	501254
DMVU9X1	MW	280.32
DMVU9X1	FM	C13H20N4O3
DMVU9X1	IC	InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1
DMVU9X1	CS	C[C@H](CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
DMVU9X1	IK	NSMXQKNUPPXBRG-SECBINFHSA-N
DMVU9X1	IU	1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
DMVU9X1	CA	CAS 100324-81-0
DMVU9X1	CB	CHEBI:143527
DMVU9X1	DE	Type-1 diabetes

DMZ3OU6	ID	DMZ3OU6
DMZ3OU6	DN	Lithium
DMZ3OU6	HS	Phase 2
DMZ3OU6	SN	7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis
DMZ3OU6	DT	Small molecular drug
DMZ3OU6	PC	3028194
DMZ3OU6	MW	7
DMZ3OU6	FM	Li
DMZ3OU6	IC	InChI=1S/Li
DMZ3OU6	CS	[Li]
DMZ3OU6	IK	WHXSMMKQMYFTQS-UHFFFAOYSA-N
DMZ3OU6	IU	lithium
DMZ3OU6	CA	CAS 7439-93-2
DMZ3OU6	CB	CHEBI:30145
DMZ3OU6	DE	Fragile X syndrome

DM3XRUH	ID	DM3XRUH
DM3XRUH	DN	LJN452
DM3XRUH	HS	Phase 2
DM3XRUH	SN	Tropifexor; 1383816-29-2; UNII-NMZ08KM76Z; NMZ08KM76Z; CPD1549; Tropifexor [INN]; GTPL9725; SCHEMBL19178329; SCHEMBL17848159; LJN-452; EX-A1934; CS-8153; compound 1 [PMID: 29148806]; ACN-053193; AC-30341; 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid; HY-107418; 2-((1R,5S)-3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorob
DM3XRUH	CP	Novartis Pharmaceuticals East Hanover, NJ
DM3XRUH	PC	121418176
DM3XRUH	MW	603.6
DM3XRUH	FM	C29H25F4N3O5S
DM3XRUH	IC	InChI=1S/C29H25F4N3O5S/c30-21-9-15(27(37)38)10-23-25(21)34-28(42-23)36-16-7-8-17(36)12-18(11-16)39-13-20-24(35-41-26(20)14-5-6-14)19-3-1-2-4-22(19)40-29(31,32)33/h1-4,9-10,14,16-18H,5-8,11-13H2,(H,37,38)/t16-,17+,18?
DM3XRUH	CS	C1C[C@H]2CC(C[C@@H]1N2C3=NC4=C(C=C(C=C4S3)C(=O)O)F)OCC5=C(ON=C5C6=CC=CC=C6OC(F)(F)F)C7CC7
DM3XRUH	IK	VYLOOGHLKSNNEK-JWTNVVGKSA-N
DM3XRUH	IU	2-[(1R,5S)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid
DM3XRUH	CA	CAS 1383816-29-2
DM3XRUH	DE	Primary biliary cholangitis

DMVM13R	ID	DMVM13R
DMVM13R	DN	LJPC-401
DMVM13R	HS	Phase 2
DMVM13R	CP	La Jolla Pharmaceutical
DMVM13R	DT	Peptide
DMVM13R	DE	Hemochromatosis; Beta thalassemia

DMCFGP3	ID	DMCFGP3
DMCFGP3	DN	LKA651
DMCFGP3	HS	Phase 2
DMCFGP3	SN	9-Nov
DMCFGP3	CP	Novartis
DMCFGP3	DT	Antibody
DMCFGP3	DE	Diabetic macular edema

DMSJOE3	ID	DMSJOE3
DMSJOE3	DN	LM-030
DMSJOE3	HS	Phase 2
DMSJOE3	CP	LifeMax Laboratories Palo Alto, CA
DMSJOE3	DE	Congenital ichthyosiform erythroderma

DMW6VA0	ID	DMW6VA0
DMW6VA0	DN	LM-1507.NA
DMW6VA0	HS	Phase 2
DMW6VA0	SN	MEN-91507; (E)-8-[2-[4-[4-(4-Fluorophenyl)butoxy]phenyl]vinyl]-2-(1H-tetrazol-5-yl)-4H-benzopyran-4-one sodium salt
DMW6VA0	DE	Asthma

DMG7RAV	ID	DMG7RAV
DMG7RAV	DN	LMB-2
DMG7RAV	HS	Phase 2
DMG7RAV	SN	LMB-2a; AntiTac(Fv)-PE38; Immunotoxin (cancer), National Cancer Institute
DMG7RAV	CP	National Cancer Institute
DMG7RAV	DE	Chronic lymphocytic leukaemia

DMQOXNL	ID	DMQOXNL
DMQOXNL	DN	LMB763
DMQOXNL	HS	Phase 2
DMQOXNL	SN	Nidufexor; 1773489-72-7; LMB-763; UNII-CJ1PL0TE6J; CJ1PL0TE6J; 4-[(N-benzyl-8-chloro-1-methyl-1,4-dihydro[1]benzopyrano[4,3-c]pyrazole-3-carboxamido)methyl]benzoic acid; Nidufexor [INN]; CHEMBL4297626; SCHEMBL16702097; GTPL10655; BCP28929; EX-A1854; Nidufexor pound LMB-763 pound(c); BDBM50527021; MFCD31657267; ZINC584641402; compound 1 [PMID: 31940200]; 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid; BS-15605; HY-109096; CS-0039398; Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2)C(O)=O)c2COc3ccc(Cl)cc3-c12; 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid; Benzoic acid, 4-((((8-chloro-1,4-dihydro-1-methyl(1)benzopyrano(4,3-C)pyrazol-3-yl)carbonyl)(phenylmethyl)amino)methyl)-
DMQOXNL	CP	Novartis
DMQOXNL	DT	Small molecular drug
DMQOXNL	PC	118063735
DMQOXNL	MW	487.9
DMQOXNL	FM	C27H22ClN3O4
DMQOXNL	IC	InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)
DMQOXNL	CS	CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O
DMQOXNL	IK	JYTIXGYXBIBOMN-UHFFFAOYSA-N
DMQOXNL	IU	4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid
DMQOXNL	CA	CAS 1773489-72-7
DMQOXNL	DE	Non-alcoholic steatohepatitis; Diabetic nephropathy

DM01SR6	ID	DM01SR6
DM01SR6	DN	L-NAME
DM01SR6	HS	Phase 2
DM01SR6	SN	N-Nitroarginine methyl ester; NG-NITROARGININE METHYL ESTER; N(G)-Nitroarginine methyl ester; N-Nitro-L-arginine methylester; Ngamma-Nitro-L-arginine methyl ester; N(G)-Nitro-L-arginine methyl ester; N(sup G)-Nitro-L-arginine methyl ester; N-omega-Nitro-O-arginine methyl ester; Methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate; Methyl N5-(N'-nitrocarbamimidoyl)-L-ornithinate; N(5)-(Imino(nitroamino)methyl)-L-ornithine methyl ester; N-.omega.-Nitro-O-arginine methyl ester; L-Ornithine, N(5)-(imino(nitroamino)methyl)-, methyl ester; Methyl (2S)-2-amino-5-[(amino-nitramido-methylidene)amino]pentanoate
DM01SR6	CP	Registry Operator
DM01SR6	DT	Small molecular drug
DM01SR6	PC	39836
DM01SR6	MW	233.23
DM01SR6	FM	C7H15N5O4
DM01SR6	IC	InChI=1S/C7H15N5O4/c1-16-6(13)5(8)3-2-4-10-7(9)11-12(14)15/h5H,2-4,8H2,1H3,(H3,9,10,11)/t5-/m0/s1
DM01SR6	CS	COC(=O)[C@H](CCCN=C(N)N[N+](=O)[O-])N
DM01SR6	IK	KCWZGJVSDFYRIX-YFKPBYRVSA-N
DM01SR6	IU	methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate
DM01SR6	CA	CAS 50903-99-6
DM01SR6	CB	CHEBI:7549
DM01SR6	DE	Hypertension

DMT3KB4	ID	DMT3KB4
DMT3KB4	DN	Lobeline
DMT3KB4	HS	Phase 2
DMT3KB4	SN	lobeline; Lobelin; Inflatine; Lobeline [INN]; Lobelinum [INN-Latin]; Lobelina [INN-Spanish]; EINECS 202-012-3; BRN 0091533; AC1LEL62; ZINC56446; Ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, (2R-(2alpha,6alpha(S*)))-; LS-88107
DMT3KB4	DT	Small molecular drug
DMT3KB4	PC	101616
DMT3KB4	MW	337.5
DMT3KB4	FM	C22H27NO2
DMT3KB4	IC	InChI=1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1
DMT3KB4	CS	CN1[C@@H](CCC[C@@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O
DMT3KB4	IK	MXYUKLILVYORSK-HBMCJLEFSA-N
DMT3KB4	IU	2-[(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone
DMT3KB4	CA	CAS 90-69-7
DMT3KB4	CB	CHEBI:48723
DMT3KB4	DE	Substance use disorder

DMN0VS2	ID	DMN0VS2
DMN0VS2	DN	Lopinavir + ritonavir + ribavirin + interferon beta-1b
DMN0VS2	HS	Phase 2 
DMN0VS2	SN	Aluviran + norvir + rebetol + betaseron
DMN0VS2	TC	Antiviral Agents
DMN0VS2	DT	Combination drug
DMN0VS2	DE	Coronavirus Disease 2019 (COVID-19)

DM0GZTD	ID	DM0GZTD
DM0GZTD	DN	L-ornithine phenylacetate
DM0GZTD	HS	Phase 2
DM0GZTD	SN	L-ornthine phenylacetate; OCR-002; UCL-L1V; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy); Nitrogen metabolism modulator (injectable, AHE), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), UCL; Nitrogen metabolism modulator (injectable, hyperammonemia), Ocera; L-ornithine phenylacetate (injectable, AHE), Ocera; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy), Ocera; L-ornithine phenylacetate (injectable, hyperammonemia), Ocera
DM0GZTD	CP	Ocera therapeutics
DM0GZTD	DT	Small molecular drug
DM0GZTD	PC	44247677
DM0GZTD	MW	268.31
DM0GZTD	FM	C13H20N2O4
DM0GZTD	IC	InChI=1S/C8H8O2.C5H12N2O2/c9-8(10)6-7-4-2-1-3-5-7;6-3-1-2-4(7)5(8)9/h1-5H,6H2,(H,9,10);4H,1-3,6-7H2,(H,8,9)/t;4-/m.0/s1
DM0GZTD	CS	C1=CC=C(C=C1)CC(=O)O.C(C[C@@H](C(=O)O)N)CN
DM0GZTD	IK	LRSYFEZBIMVWRY-VWMHFEHESA-N
DM0GZTD	IU	(2S)-2,5-diaminopentanoic acid;2-phenylacetic acid
DM0GZTD	CA	CAS 952154-79-9
DM0GZTD	DE	Acute liver failure

DME8O5K	ID	DME8O5K
DME8O5K	DN	LOU064
DME8O5K	HS	Phase 2
DME8O5K	CP	Novartis Pharmaceuticals East Hanover, NJ
DME8O5K	DE	Chronic idiopathic urticaria

DMIV9ZE	ID	DMIV9ZE
DMIV9ZE	DN	LOXORIBINE
DMIV9ZE	HS	Phase 2
DMIV9ZE	SN	AOG; Loxoribine < Rec INN; RWJ-21757; 7-(2-Propenyl)-8-oxo-7,8-dihydroguanosine; 7-Allyl-2-amino-9-beta-D-ribofuranosylpurine-6,8(1H,9H)-dione; 7-Allyl-8-oxo-7,8-dihydroguanosine; 7A8OGua
DMIV9ZE	DT	Small molecular drug
DMIV9ZE	PC	135410906
DMIV9ZE	MW	339.3
DMIV9ZE	FM	C13H17N5O6
DMIV9ZE	IC	InChI=1S/C13H17N5O6/c1-2-3-17-6-9(15-12(14)16-10(6)22)18(13(17)23)11-8(21)7(20)5(4-19)24-11/h2,5,7-8,11,19-21H,1,3-4H2,(H3,14,15,16,22)/t5-,7-,8-,11-/m1/s1
DMIV9ZE	CS	C=CCN1C2=C(N=C(NC2=O)N)N(C1=O)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMIV9ZE	IK	VDCRFBBZFHHYGT-IOSLPCCCSA-N
DMIV9ZE	IU	2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-1H-purine-6,8-dione
DMIV9ZE	CA	CAS 121288-39-9
DMIV9ZE	DE	Immune System disease

DM7BN5W	ID	DM7BN5W
DM7BN5W	DN	LPN023
DM7BN5W	HS	Phase 2
DM7BN5W	CP	Novartis
DM7BN5W	DT	Small molecular drug
DM7BN5W	DE	IgA nephropathy

DMZQBCL	ID	DMZQBCL
DMZQBCL	DN	LR3001
DMZQBCL	HS	Phase 2
DMZQBCL	CP	Genta
DMZQBCL	TC	Anticancer Agents
DMZQBCL	DT	Antisense drug
DMZQBCL	DE	Myeloid leukaemia

DM0TZPL	ID	DM0TZPL
DM0TZPL	DN	LS-71719
DM0TZPL	HS	Phase 2
DM0TZPL	SN	Galactooligosaccharide; LS-71719; NOCAS_276547; 4'-Galactooligosaccharide; D-Glucose, O-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-; DTXSID60276547; SCHEMBL12362685
DM0TZPL	PC	165512
DM0TZPL	MW	504.4
DM0TZPL	FM	C18H32O16
DM0TZPL	IC	RXVWSYJTUUKTEA-DSOVBJLESA-N
DM0TZPL	CS	C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC(C(CO)O)C(C(C=O)O)O)CO)O)O)O)O
DM0TZPL	IK	1S/C18H32O16/c19-1-5(23)9(25)15(6(24)2-20)33-18-14(30)12(28)16(8(4-22)32-18)34-17-13(29)11(27)10(26)7(3-21)31-17/h1,5-18,20-30H,2-4H2/t5-,6+,7+,8+,9+,10-,11-,12+,13+,14+,15+,16-,17-,18-/m0/s1
DM0TZPL	IU	(2R,3R,4R,5R)-4-[(2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal
DM0TZPL	CA	CAS 6587-31-1
DM0TZPL	DE	Anxiety disorder

DME26RS	ID	DME26RS
DME26RS	DN	LTB4
DME26RS	HS	Phase 2
DME26RS	SN	Leukotriene B4; LEUKOTRIENE B4; 5,12-Dihete; 71160-24-2; 5,12-Hete; UNII-1HGW4DR56D; (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid; 1HGW4DR56D; CHEMBL65061; 5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid; CHEBI:15647; VNYSSYRCGWBHLG-AMOLWHMGSA-N; [5S,12R]-Dihydroxy-[6Z,8E,10E,14Z]-eicosatetraenoic acid; Leukotriene B; 5(S),12(R)-Dihydroxy-6-cis-8-trans-10-trans-14-cis-eicosatetraenoic Acid; (S-(R*,S*-(E,Z,E,Z)))-5,12-Dihydroxy-6,8,10,14-eicosatetraenoic acid; 6,8,10,14-Eicosatetraenoic acid,;  Leukotriene B4 agonist (HIV infection), LTB4 Sweden AB; LEUKOTRIENE_B4
DME26RS	CP	LTB4 Sweden AB
DME26RS	DT	Small molecular drug
DME26RS	PC	5280492
DME26RS	MW	336.5
DME26RS	FM	C20H32O4
DME26RS	IC	InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11-/t18-,19-/m1/s1
DME26RS	CS	CCCCC/C=C\\C[C@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O
DME26RS	IK	VNYSSYRCGWBHLG-AMOLWHMGSA-N
DME26RS	IU	(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid
DME26RS	CA	CAS 71160-24-2
DME26RS	CB	CHEBI:15647
DME26RS	DE	Human immunodeficiency virus infection

DMXEQ0R	ID	DMXEQ0R
DMXEQ0R	DN	LTX-109
DMXEQ0R	HS	Phase 2
DMXEQ0R	SN	Lytixar
DMXEQ0R	CP	Lytix Biopharma AS
DMXEQ0R	DT	Small molecular drug
DMXEQ0R	PC	25242323
DMXEQ0R	MW	788.1
DMXEQ0R	FM	C43H69N11O3
DMXEQ0R	IC	InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1
DMXEQ0R	CS	CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)[C@H](CCCN=C(N)N)N)C(C)(C)C
DMXEQ0R	IK	ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
DMXEQ0R	IU	(2S)-2-amino-5-(diaminomethylideneamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-(2,5,7-tritert-butyl-1H-indol-3-yl)propan-2-yl]pentanamide
DMXEQ0R	CA	CAS 1166254-80-3
DMXEQ0R	CB	CHEBI:77752
DMXEQ0R	DE	Bacterial infection

DMJOYNZ	ID	DMJOYNZ
DMJOYNZ	DN	Lu AF11167
DMJOYNZ	HS	Phase 2
DMJOYNZ	CP	Lundbeck
DMJOYNZ	DT	Small molecular drug
DMJOYNZ	DE	Schizophrenia

DM2ZUXK	ID	DM2ZUXK
DM2ZUXK	DN	Lu-AA34893
DM2ZUXK	HS	Phase 2
DM2ZUXK	CP	H Lundbeck A/S
DM2ZUXK	DE	Anxiety disorder

DM34FWR	ID	DM34FWR
DM34FWR	DN	Lu-AA39959
DM34FWR	HS	Phase 2
DM34FWR	CP	H Lundbeck A/S
DM34FWR	DE	Bipolar disorder

DMY2L7V	ID	DMY2L7V
DMY2L7V	DN	Lucatumumab
DMY2L7V	HS	Phase 2
DMY2L7V	SN	HDC122
DMY2L7V	CP	Novartis Pharmaceuticals
DMY2L7V	DT	Monoclonal antibody
DMY2L7V	DE	Lymphoma

DMCKNBA	ID	DMCKNBA
DMCKNBA	DN	Lufironil
DMCKNBA	HS	Phase 2
DMCKNBA	SN	Hoe-077
DMCKNBA	CP	Hoechst AG
DMCKNBA	DT	Small molecular drug
DMCKNBA	PC	60788
DMCKNBA	MW	281.31
DMCKNBA	FM	C13H19N3O4
DMCKNBA	IC	InChI=1S/C13H19N3O4/c1-19-7-5-15-12(17)10-3-4-14-11(9-10)13(18)16-6-8-20-2/h3-4,9H,5-8H2,1-2H3,(H,15,17)(H,16,18)
DMCKNBA	CS	COCCNC(=O)C1=CC(=NC=C1)C(=O)NCCOC
DMCKNBA	IK	JUCNGMPTCXPMNB-UHFFFAOYSA-N
DMCKNBA	IU	2-N,4-N-bis(2-methoxyethyl)pyridine-2,4-dicarboxamide
DMCKNBA	CA	CAS 128075-79-6
DMCKNBA	DE	Liver cirrhosis

DMGWZ93	ID	DMGWZ93
DMGWZ93	DN	Lulizumab pegol
DMGWZ93	HS	Phase 2
DMGWZ93	CP	Bristol-Myers SquibbPrinceton, NJ
DMGWZ93	DE	Systemic lupus erythematosus

DMQZXDW	ID	DMQZXDW
DMQZXDW	DN	Lum001
DMQZXDW	HS	Phase 2
DMQZXDW	SN	SHP625
DMQZXDW	CP	Lumena pharmaceuticals
DMQZXDW	PC	9831642
DMQZXDW	MW	710.4
DMQZXDW	FM	C40H56ClN3O4S
DMQZXDW	IC	InChI=1S/C40H56N3O4S.ClH/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43;/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3;1H/q+1;/p-1/t38-,39-;/m1./s1
DMQZXDW	CS	CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC.[Cl-]
DMQZXDW	IK	POMVPJBWDDJCMP-RUKDTIIFSA-M
DMQZXDW	IU	(4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol;chloride
DMQZXDW	CA	CAS 228113-66-4
DMQZXDW	DE	Primary biliary cirrhosis; Primary biliary cholangitis; Primary sclerosing cholangitis; Progressive familial intrahepatic cholestasis; Structural developmental anomalies of liver

DMCLWDJ	ID	DMCLWDJ
DMCLWDJ	DN	Lumacaftor
DMCLWDJ	HS	Phase 2
DMCLWDJ	SN	VRT-325; VRT-422; VRT-532; VX-809
DMCLWDJ	CP	Vertex Pharmaceuticals Inc
DMCLWDJ	DT	Small molecular drug
DMCLWDJ	PC	16678941
DMCLWDJ	MW	452.4
DMCLWDJ	FM	C24H18F2N2O5
DMCLWDJ	IC	InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
DMCLWDJ	CS	CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O
DMCLWDJ	IK	UFSKUSARDNFIRC-UHFFFAOYSA-N
DMCLWDJ	IU	3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid
DMCLWDJ	CA	CAS 936727-05-8
DMCLWDJ	CB	CHEBI:90951
DMCLWDJ	DE	Cystic fibrosis

DMLTI39	ID	DMLTI39
DMLTI39	DN	Lumiliximab
DMLTI39	HS	Phase 2
DMLTI39	SN	Gomiliximab; IDEC-152; SI-3401; ST-152; PRIMATIZED anti-CD23 antibody, IDEC
DMLTI39	CP	IDEC Pharmaceuticals Corp; Biogen Idec
DMLTI39	DT	Antibody
DMLTI39	DE	leukaemia

DMLRU9I	ID	DMLRU9I
DMLRU9I	DN	Lunacalcipol
DMLRU9I	HS	Phase 2
DMLRU9I	SN	CTA-018; MT-2832; Lunacalcipol (intravenous, secondary hyperparathyroidism); Lunacalcipol (intravenous, secondary hyperparathyroidism), Cytochroma; Vitamin D analogs (secondary hyperparathyroidism), Johns Hopkins/Cytochroma; CTA-018 (intravenous, secondary hyperparathyroidism), Cytochroma; CYP24 inhibitors (intravenous, secondary hyperparathyroidism), Johns Hopkins/Cytochroma
DMLRU9I	CP	Johns Hopkins University
DMLRU9I	DT	Small molecular drug
DMLRU9I	PC	10672195
DMLRU9I	MW	474.7
DMLRU9I	FM	C28H42O4S
DMLRU9I	IC	InChI=1S/C28H42O4S/c1-19(9-8-16-33(31,32)27(3,4)5)24-13-14-25-21(10-7-15-28(24,25)6)11-12-22-17-23(29)18-26(30)20(22)2/h8,11-13,16,19,23,25-26,29-30H,2,7,9-10,14-15,17-18H2,1,3-6H3/b16-8+,21-11+,22-12-/t19-,23-,25+,26+,28-/m1/s1
DMLRU9I	CS	C[C@H](C/C=C/S(=O)(=O)C(C)(C)C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DMLRU9I	IK	RFQHCLMGLJGZNV-UXXOMSPDSA-N
DMLRU9I	IU	(1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(E,2R)-5-tert-butylsulfonylpent-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMLRU9I	CA	CAS 250384-82-8
DMLRU9I	DE	Psoriasis vulgaris

DMZ2XAP	ID	DMZ2XAP
DMZ2XAP	DN	LX-1031
DMZ2XAP	HS	Phase 2
DMZ2XAP	SN	LG-103; LP-389924; LP-507518; LP-533401; LP-615819; TPH inhibitor (IBS), Lexicon; Tryptophan 5-hydroxylase inhibitor(IBS), Lexicon
DMZ2XAP	CP	Lexicon Pharmaceuticals Inc
DMZ2XAP	DT	Small molecular drug
DMZ2XAP	PC	23633604
DMZ2XAP	MW	538.5
DMZ2XAP	FM	C28H25F3N4O4
DMZ2XAP	IC	InChI=1S/C28H25F3N4O4/c1-38-21-4-2-3-20(14-21)17-9-11-19(12-10-17)25(28(29,30)31)39-24-15-23(34-27(33)35-24)18-7-5-16(6-8-18)13-22(32)26(36)37/h2-12,14-15,22,25H,13,32H2,1H3,(H,36,37)(H2,33,34,35)/t22-,25+/m0/s1
DMZ2XAP	CS	COC1=CC=CC(=C1)C2=CC=C(C=C2)[C@H](C(F)(F)F)OC3=NC(=NC(=C3)C4=CC=C(C=C4)C[C@@H](C(=O)O)N)N
DMZ2XAP	IK	XNMUICFMGGQSMZ-WIOPSUGQSA-N
DMZ2XAP	IU	(2S)-2-amino-3-[4-[2-amino-6-[(1R)-2,2,2-trifluoro-1-[4-(3-methoxyphenyl)phenyl]ethoxy]pyrimidin-4-yl]phenyl]propanoic acid
DMZ2XAP	CA	CAS 945976-76-1
DMZ2XAP	DE	Irritable bowel syndrome

DMLA8H3	ID	DMLA8H3
DMLA8H3	DN	LX2931
DMLA8H3	HS	Phase 2
DMLA8H3	CP	Lexicon Pharmaceuticals
DMLA8H3	DT	Small molecular drug
DMLA8H3	PC	135564845
DMLA8H3	MW	245.23
DMLA8H3	FM	C9H15N3O5
DMLA8H3	IC	InChI=1S/C9H15N3O5/c1-4(12-17)9-10-2-5(11-9)7(15)8(16)6(14)3-13/h2,6-8,13-17H,3H2,1H3,(H,10,11)/b12-4+/t6-,7-,8-/m1/s1
DMLA8H3	CS	C/C(=N\\O)/C1=NC=C(N1)[C@H]([C@@H]([C@@H](CO)O)O)O
DMLA8H3	IK	AMXVYJYMZLDINS-RSWLNLDNSA-N
DMLA8H3	IU	(1R,2S,3R)-1-[2-[(E)-N-hydroxy-C-methylcarbonimidoyl]-1H-imidazol-5-yl]butane-1,2,3,4-tetrol
DMLA8H3	CA	CAS 948840-25-3
DMLA8H3	DE	Rheumatoid arthritis; Hereditary acantholytic dermatoses

DMLBD5I	ID	DMLBD5I
DMLBD5I	DN	LXE408
DMLBD5I	HS	Phase 2
DMLBD5I	SN	SCHEMBL16822697; HY-131350; CS-0133456; FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2C)=N1; 1799330-15-6; N-(4-Fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide
DMLBD5I	CP	Novartis
DMLBD5I	DT	Small molecular drug
DMLBD5I	PC	118162630
DMLBD5I	MW	443.4
DMLBD5I	FM	C23H18FN7O2
DMLBD5I	IC	InChI=1S/C23H18FN7O2/c1-12-5-4-8-25-19(12)15-10-26-23-29-21(30-31(23)11-15)17-9-16(6-7-18(17)24)28-22(32)20-13(2)27-14(3)33-20/h4-11H,1-3H3,(H,28,32)
DMLBD5I	CS	CC1=C(N=CC=C1)C2=CN3C(=NC(=N3)C4=C(C=CC(=C4)NC(=O)C5=C(N=C(O5)C)C)F)N=C2
DMLBD5I	IK	GNVVPYCWVLCWKV-UHFFFAOYSA-N
DMLBD5I	IU	N-[4-fluoro-3-[6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide
DMLBD5I	DE	Visceral leishmaniasis

DM5IX9M	ID	DM5IX9M
DM5IX9M	DN	LY-156735
DM5IX9M	HS	Phase 2
DM5IX9M	SN	LY 156735; N-[(2r)-2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl]acetamide
DM5IX9M	CP	Phase 2 Discovery
DM5IX9M	DT	Small molecular drug
DM5IX9M	PC	219018
DM5IX9M	MW	280.75
DM5IX9M	FM	C14H17ClN2O2
DM5IX9M	IC	InChI=1S/C14H17ClN2O2/c1-8(6-16-9(2)18)11-7-17-13-5-12(15)14(19-3)4-10(11)13/h4-5,7-8,17H,6H2,1-3H3,(H,16,18)/t8-/m0/s1
DM5IX9M	CS	C[C@@H](CNC(=O)C)C1=CNC2=CC(=C(C=C21)OC)Cl
DM5IX9M	IK	RKHCTAKUYDTFHE-QMMMGPOBSA-N
DM5IX9M	IU	N-[(2R)-2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide
DM5IX9M	CA	CAS 118702-11-7
DM5IX9M	DE	Anxiety disorder

DMTBFE4	ID	DMTBFE4
DMTBFE4	DN	LY2090314
DMTBFE4	HS	Phase 2
DMTBFE4	SN	603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt
DMTBFE4	CP	Eli Lilly
DMTBFE4	DT	Small molecular drug
DMTBFE4	PC	10029385
DMTBFE4	MW	512.5
DMTBFE4	FM	C28H25FN6O3
DMTBFE4	IC	InChI=1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)
DMTBFE4	CS	C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7
DMTBFE4	IK	HRJWTAWVFDCTGO-UHFFFAOYSA-N
DMTBFE4	IU	3-[6-fluoro-10-(piperidine-1-carbonyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-3-yl]-4-imidazo[1,2-a]pyridin-3-ylpyrrole-2,5-dione
DMTBFE4	CA	CAS 603288-22-8
DMTBFE4	DE	Acute myeloid leukaemia

DMU81BH	ID	DMU81BH
DMU81BH	DN	LY-2189102
DMU81BH	HS	Phase 2
DMU81BH	SN	Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly
DMU81BH	CP	Eli lilly
DMU81BH	DT	Antibody
DMU81BH	DE	Cardiovascular disease

DMH3YKJ	ID	DMH3YKJ
DMH3YKJ	DN	LY2382770
DMH3YKJ	HS	Phase 2
DMH3YKJ	CP	Eli Lilly & Co
DMH3YKJ	DT	Antibody
DMH3YKJ	DE	Diabetic nephropathy; Diabetic kidney disease

DMZOIP4	ID	DMZOIP4
DMZOIP4	DN	LY-2409021
DMZOIP4	HS	Phase 2
DMZOIP4	SN	Oral glucagon receptor antagonist (type 2 diabetes), Eli Lilly
DMZOIP4	CP	Eli Lilly & Co
DMZOIP4	PC	91933867
DMZOIP4	MW	555.6
DMZOIP4	FM	C32H36F3NO4
DMZOIP4	IC	InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)/t27-/m0/s1
DMZOIP4	CS	CC1=CC(=CC(=C1C2=CC=C(C=C2)C(C)(C)C)C)O[C@@H](CCC(F)(F)F)C3=CC=C(C=C3)C(=O)NCCC(=O)O
DMZOIP4	IK	FASLTMSUPQDLIB-MHZLTWQESA-N
DMZOIP4	IU	3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid
DMZOIP4	CA	CAS 1488363-78-5
DMZOIP4	DE	Type-2 diabetes

DMKYMS2	ID	DMKYMS2
DMKYMS2	DN	LY-2428757
DMKYMS2	HS	Phase 2
DMKYMS2	SN	GLP-PEG, Eli Lilly; GLP1-PEG, Eli Lilly
DMKYMS2	CP	Eli Lilly & Co
DMKYMS2	DE	Type-2 diabetes

DMLTSDC	ID	DMLTSDC
DMLTSDC	DN	LY-2456302
DMLTSDC	HS	Phase 2
DMLTSDC	SN	Opioid receptor kappa (KOR) antagonist (alcohol dependence), Eli Lilly
DMLTSDC	CP	Eli Lilly & Co
DMLTSDC	DT	Small molecular drug
DMLTSDC	PC	44129648
DMLTSDC	MW	418.5
DMLTSDC	FM	C26H27FN2O2
DMLTSDC	IC	InChI=1S/C26H27FN2O2/c1-17-12-18(2)14-21(13-17)24-4-3-11-29(24)16-19-5-8-22(9-6-19)31-25-10-7-20(26(28)30)15-23(25)27/h5-10,12-15,24H,3-4,11,16H2,1-2H3,(H2,28,30)/t24-/m0/s1
DMLTSDC	CS	CC1=CC(=CC(=C1)[C@@H]2CCCN2CC3=CC=C(C=C3)OC4=C(C=C(C=C4)C(=O)N)F)C
DMLTSDC	IK	ZHPMYDSXGRRERG-DEOSSOPVSA-N
DMLTSDC	IU	4-[4-[[(2S)-2-(3,5-dimethylphenyl)pyrrolidin-1-yl]methyl]phenoxy]-3-fluorobenzamide
DMLTSDC	CA	CAS 1174130-61-0
DMLTSDC	DE	Alcohol dependence; Major depressive disorder

DMM5JAN	ID	DMM5JAN
DMM5JAN	DN	LY2495655
DMM5JAN	HS	Phase 2
DMM5JAN	CP	Eli Lilly
DMM5JAN	DE	Disuse muscle atrophy

DMCV602	ID	DMCV602
DMCV602	DN	LY2523355
DMCV602	HS	Phase 2
DMCV602	SN	Litronesib
DMCV602	CP	Lilly
DMCV602	DT	Small molecular drug
DMCV602	PC	25167017
DMCV602	MW	511.7
DMCV602	FM	C23H37N5O4S2
DMCV602	IC	InChI=1S/C23H37N5O4S2/c1-8-24-14-15-34(31,32)25-16-23(17-12-10-9-11-13-17)28(19(30)22(5,6)7)27-20(33-23)26-18(29)21(2,3)4/h9-13,24-25H,8,14-16H2,1-7H3,(H,26,27,29)/t23-/m0/s1
DMCV602	CS	CCNCCS(=O)(=O)NC[C@@]1(N(N=C(S1)NC(=O)C(C)(C)C)C(=O)C(C)(C)C)C2=CC=CC=C2
DMCV602	IK	YVAFBXLHPINSIK-QHCPKHFHSA-N
DMCV602	IU	N-[(5R)-4-(2,2-dimethylpropanoyl)-5-[[2-(ethylamino)ethylsulfonylamino]methyl]-5-phenyl-1,3,4-thiadiazol-2-yl]-2,2-dimethylpropanamide
DMCV602	CA	CAS 910634-41-2
DMCV602	DE	Acute myeloid leukaemia

DMTVU2Q	ID	DMTVU2Q
DMTVU2Q	DN	LY2541546
DMTVU2Q	HS	Phase 2
DMTVU2Q	CP	Eli Lilly
DMTVU2Q	DT	Antibody
DMTVU2Q	DE	Osteoporosis

DM81UJW	ID	DM81UJW
DM81UJW	DN	LY-2590443
DM81UJW	HS	Phase 2
DM81UJW	CP	Eli Lilly & Co
DM81UJW	DE	Migraine

DMMI0RH	ID	DMMI0RH
DMMI0RH	DN	LY-2599506
DMMI0RH	HS	Phase 2
DMMI0RH	SN	PSN-010
DMMI0RH	CP	Prosidion Ltd
DMMI0RH	PC	11517248
DMMI0RH	MW	415.5
DMMI0RH	FM	C21H25N3O4S
DMMI0RH	IC	InChI=1S/C21H25N3O4S/c25-21(24-20-14-22-9-10-23-20)19(13-15-7-11-28-12-8-15)16-1-3-17(4-2-16)29(26,27)18-5-6-18/h1-4,9-10,14-15,18-19H,5-8,11-13H2,(H,23,24,25)/t19-/m1/s1
DMMI0RH	CS	C1CC1S(=O)(=O)C2=CC=C(C=C2)[C@@H](CC3CCOCC3)C(=O)NC4=NC=CN=C4
DMMI0RH	IK	DQIITKNITDKAJZ-LJQANCHMSA-N
DMMI0RH	IU	(2R)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)-N-pyrazin-2-ylpropanamide
DMMI0RH	CA	CAS 745051-65-4
DMMI0RH	DE	Diabetic complication

DMCXRZF	ID	DMCXRZF
DMCXRZF	DN	LY2603618
DMCXRZF	HS	Phase 2
DMCXRZF	SN	LY2603618; Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618  IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea
DMCXRZF	CP	Eli Lilly
DMCXRZF	DT	Small molecular drug
DMCXRZF	PC	11955855
DMCXRZF	MW	436.3
DMCXRZF	FM	C18H22BrN5O3
DMCXRZF	IC	InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1
DMCXRZF	CS	CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OC[C@@H]3CNCCO3
DMCXRZF	IK	SYYBDNPGDKKJDU-ZDUSSCGKSA-N
DMCXRZF	IU	1-[5-bromo-4-methyl-2-[[(2S)-morpholin-2-yl]methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea
DMCXRZF	CA	CAS 911222-45-2
DMCXRZF	CB	CHEBI:124917
DMCXRZF	DE	Pancreatic cancer

DM4XMF7	ID	DM4XMF7
DM4XMF7	DN	LY2606368
DM4XMF7	HS	Phase 2
DM4XMF7	SN	prexasertib; Prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013
DM4XMF7	CP	Eli Lilly, Indianapolis, IN
DM4XMF7	PC	46700756
DM4XMF7	MW	365.4
DM4XMF7	FM	C18H19N7O2
DM4XMF7	IC	InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25)
DM4XMF7	CS	COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N
DM4XMF7	IK	DOTGPNHGTYJDEP-UHFFFAOYSA-N
DM4XMF7	IU	5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile
DM4XMF7	CA	CAS 1234015-52-1
DM4XMF7	DE	Head and neck cancer; Ovarian cancer; Small-cell lung cancer; Squamous cell anal carcinoma; Solid tumour/cancer

DM4EF9Y	ID	DM4EF9Y
DM4EF9Y	DN	LY-2608204
DM4EF9Y	HS	Phase 2
DM4EF9Y	SN	Glucokinase activator (type 2 diabetes), Eli Lilly
DM4EF9Y	CP	Eli Lilly & Co
DM4EF9Y	DT	Small molecular drug
DM4EF9Y	PC	46832368
DM4EF9Y	MW	559.8
DM4EF9Y	FM	C28H37N3O3S3
DM4EF9Y	IC	InChI=1S/C28H37N3O3S3/c32-26(30-27-29-19-25(36-27)35-17-16-31-14-4-5-15-31)28(18-24(28)20-6-2-1-3-7-20)21-8-10-22(11-9-21)37(33,34)23-12-13-23/h8-11,19-20,23-24H,1-7,12-18H2,(H,29,30,32)/t24-,28-/m0/s1
DM4EF9Y	CS	C1CCC(CC1)[C@@H]2C[C@@]2(C3=CC=C(C=C3)S(=O)(=O)C4CC4)C(=O)NC5=NC=C(S5)SCCN6CCCC6
DM4EF9Y	IK	QIIVJLHCZUTGSD-CUBQBAPOSA-N
DM4EF9Y	IU	(1R,2S)-2-cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N-[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide
DM4EF9Y	CA	CAS 1234703-40-2
DM4EF9Y	DE	Type-2 diabetes

DMFGNB4	ID	DMFGNB4
DMFGNB4	DN	LY-2623091
DMFGNB4	HS	Phase 2
DMFGNB4	SN	Chronic renal disease therapy, Eli Lilly
DMFGNB4	CP	Eli Lilly & Co
DMFGNB4	PC	42636651
DMFGNB4	MW	527.6
DMFGNB4	FM	C30H30FN5O3
DMFGNB4	IC	InChI=1S/C30H30FN5O3/c1-19(17-35-10-12-38-13-11-35)36-27-9-6-20(15-26(27)33-30(36)34-29(32)37)14-25-23-5-3-2-4-21(23)18-39-28-16-22(31)7-8-24(25)28/h2-9,14-16,19H,10-13,17-18H2,1H3,(H3,32,33,34,37)/b25-14+/t19-/m1/s1
DMFGNB4	CS	C[C@H](CN1CCOCC1)N2C3=C(C=C(C=C3)/C=C\\4/C5=C(C=C(C=C5)F)OCC6=CC=CC=C64)N=C2NC(=O)N
DMFGNB4	IK	YPCLDHGBEKZGEB-RUDKWAFVSA-N
DMFGNB4	IU	[5-[(E)-(3-fluoro-6H-benzo[c][1]benzoxepin-11-ylidene)methyl]-1-[(2R)-1-morpholin-4-ylpropan-2-yl]benzimidazol-2-yl]urea
DMFGNB4	CA	CAS 1162264-07-4
DMFGNB4	DE	Chronic kidney disease

DMTPQUA	ID	DMTPQUA
DMTPQUA	DN	LY-2624803
DMTPQUA	HS	Phase 2
DMTPQUA	SN	HY-10275; Insomnia therapy, Hypnion; Insomnia therapy, Lilly; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Hypnion; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Lilly
DMTPQUA	CP	Hypnion
DMTPQUA	PC	11567064
DMTPQUA	MW	379.5
DMTPQUA	FM	C22H25N3O3
DMTPQUA	IC	InChI=1S/C22H25N3O3/c1-22(2,21(26)27)15-24-11-13-25(14-12-24)20-16-7-3-5-9-18(16)28-19-10-6-4-8-17(19)23-20/h3-10H,11-15H2,1-2H3,(H,26,27)
DMTPQUA	CS	CC(C)(CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=CC=CC=C42)C(=O)O
DMTPQUA	IK	UEFWDVMEDFCHGW-UHFFFAOYSA-N
DMTPQUA	IU	3-(4-benzo[b][1,4]benzoxazepin-6-ylpiperazin-1-yl)-2,2-dimethylpropanoic acid
DMTPQUA	CA	CAS 879409-35-5
DMTPQUA	DE	Insomnia

DMZASMP	ID	DMZASMP
DMZASMP	DN	LY2784544
DMZASMP	HS	Phase 2
DMZASMP	SN	LY2784544; 1229236-86-5; GANDOTINIB; LY 2784544; LY-2784544; Gandotinib (LY2784544); UNII-ANC71R916O; LY2784544(Gandotinib); ANC71R916O; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; C23H25ClFN7O; 3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine
DMZASMP	CP	Eli Lilly
DMZASMP	DT	Small molecular drug
DMZASMP	PC	46213929
DMZASMP	MW	469.9
DMZASMP	FM	C23H25ClFN7O
DMZASMP	IC	InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
DMZASMP	CS	CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F
DMZASMP	IK	SQSZANZGUXWJEA-UHFFFAOYSA-N
DMZASMP	IU	3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine
DMZASMP	CA	CAS 1229236-86-5
DMZASMP	DE	Breast cancer; Myeloproliferative neoplasm

DM0KJDY	ID	DM0KJDY
DM0KJDY	DN	LY2801653
DM0KJDY	HS	Phase 2
DM0KJDY	SN	Merestinib; LY2801653; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N
DM0KJDY	CP	Lilly
DM0KJDY	DT	Small molecular drug
DM0KJDY	PC	44603533
DM0KJDY	MW	552.5
DM0KJDY	FM	C30H22F2N6O3
DM0KJDY	IC	InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)
DM0KJDY	CS	CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F
DM0KJDY	IK	QHADVLVFMKEIIP-UHFFFAOYSA-N
DM0KJDY	IU	N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide
DM0KJDY	CA	CAS 1206799-15-6
DM0KJDY	DE	Solid tumour/cancer; Biliary tract cancer

DMO8IEZ	ID	DMO8IEZ
DMO8IEZ	DN	LY-2828360
DMO8IEZ	HS	Phase 2
DMO8IEZ	CP	Eli Lilly & Co
DMO8IEZ	DE	Pain

DMZ0DMY	ID	DMZ0DMY
DMZ0DMY	DN	LY2874455
DMZ0DMY	HS	Phase 2
DMZ0DMY	SN	LY2874455; 1254473-64-7; LY-2874455; UNII-E9M363811V; CHEMBL3828009; E9M363811V; AK186860; LY 2874455; (R,E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)-ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; C21H19Cl2N5O2; (R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; GKJCVYLDJWTWQU-CXLRFSCWSA-N; SCHEMBL298446; SCHEMBL298445; QCR-90; GTPL8104; DTXSID20154776; MolPort-044-724-281; MolPort-023-219-117; EX-A1340; BCP04756; ZINC73069242; BDBM50189781; 2529AH; s7057; AKOS027251051
DMZ0DMY	CP	Lilly
DMZ0DMY	DT	Small molecular drug
DMZ0DMY	PC	46944259
DMZ0DMY	MW	444.3
DMZ0DMY	FM	C21H19Cl2N5O2
DMZ0DMY	IC	InChI=1S/C21H19Cl2N5O2/c1-13(21-17(22)10-24-11-18(21)23)30-15-3-5-20-16(8-15)19(26-27-20)4-2-14-9-25-28(12-14)6-7-29/h2-5,8-13,29H,6-7H2,1H3,(H,26,27)/b4-2+/t13-/m1/s1
DMZ0DMY	CS	C[C@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO
DMZ0DMY	IK	GKJCVYLDJWTWQU-CXLRFSCWSA-N
DMZ0DMY	IU	2-[4-[(E)-2-[5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1H-indazol-3-yl]ethenyl]pyrazol-1-yl]ethanol
DMZ0DMY	CA	CAS 1254473-64-7
DMZ0DMY	DE	Solid tumour/cancer

DMQV1OU	ID	DMQV1OU
DMQV1OU	DN	LY-2875358
DMQV1OU	HS	Phase 2
DMQV1OU	SN	C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly
DMQV1OU	CP	Eli lilly
DMQV1OU	DT	Antibody
DMQV1OU	DE	Solid tumour/cancer

DMV14LM	ID	DMV14LM
DMV14LM	DN	LY2886721
DMV14LM	HS	Phase 2
DMV14LM	SN	LY2886721; 1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475
DMV14LM	CP	Lilly
DMV14LM	DT	Small molecular drug
DMV14LM	PC	49837968
DMV14LM	MW	390.4
DMV14LM	FM	C18H16F2N4O2S
DMV14LM	IC	InChI=1S/C18H16F2N4O2S/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18/h1-6,10H,7-9H2,(H2,21,24)(H,23,25)/t10-,18-/m0/s1
DMV14LM	CS	C1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N
DMV14LM	IK	NIDRNVHMMDAAIK-YPMLDQLKSA-N
DMV14LM	IU	N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide
DMV14LM	CA	CAS 1262036-50-9
DMV14LM	DE	Alzheimer disease

DMRDEKZ	ID	DMRDEKZ
DMRDEKZ	DN	LY2928057
DMRDEKZ	HS	Phase 2
DMRDEKZ	CP	Lilly
DMRDEKZ	DE	Anaemia

DM4N6EK	ID	DM4N6EK
DM4N6EK	DN	LY293558
DM4N6EK	HS	Phase 2
DM4N6EK	SN	Tezampanel; 154652-83-2; LY-293558; LY293558; Ted-isoquinoline-3-cooh; LY 293558; UNII-GA36S2O9C2; CHEMBL14935; GA36S2O9C2; 150131-78-5; Decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-3-isoquinolinecarboxylic acid; 6-(2-(1H-Tetrazol-5-yl)ethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S,4aR,6R,8aR)-; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-; Tezampanel [INN]
DM4N6EK	CP	Eli Lilly
DM4N6EK	TC	Analgesics
DM4N6EK	DT	Small molecular drug
DM4N6EK	PC	127894
DM4N6EK	MW	279.34
DM4N6EK	FM	C13H21N5O2
DM4N6EK	IC	InChI=1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)/t8-,9+,10-,11+/m1/s1
DM4N6EK	CS	C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CCC3=NNN=N3)C(=O)O
DM4N6EK	IK	ZXFRFPSZAKNPQQ-YTWAJWBKSA-N
DM4N6EK	IU	(3S,4aR,6R,8aR)-6-[2-(2H-tetrazol-5-yl)ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
DM4N6EK	CA	CAS 154652-83-2
DM4N6EK	DE	Pain

DMB5L6Q	ID	DMB5L6Q
DMB5L6Q	DN	LY-2940094
DMB5L6Q	HS	Phase 2
DMB5L6Q	CP	Eli Lilly & Co
DMB5L6Q	PC	52914971
DMB5L6Q	MW	481
DMB5L6Q	FM	C22H23ClF2N4O2S
DMB5L6Q	IC	InChI=1S/C22H23ClF2N4O2S/c1-14-16(11-29(27-14)20-15(12-30)3-2-6-26-20)10-28-7-4-21(5-8-28)19-17(9-18(23)32-19)22(24,25)13-31-21/h2-3,6,9,11,30H,4-5,7-8,10,12-13H2,1H3
DMB5L6Q	CS	CC1=NN(C=C1CN2CCC3(CC2)C4=C(C=C(S4)Cl)C(CO3)(F)F)C5=C(C=CC=N5)CO
DMB5L6Q	IK	NKQHBJNRBKHUQR-UHFFFAOYSA-N
DMB5L6Q	IU	[2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]pyridin-3-yl]methanol
DMB5L6Q	CA	CAS 1307245-86-8
DMB5L6Q	DE	Major depressive disorder

DML6XWR	ID	DML6XWR
DML6XWR	DN	LY2944876
DML6XWR	HS	Phase 2
DML6XWR	PC	121494121
DML6XWR	MW	405.5
DML6XWR	FM	C16H27N3O7S
DML6XWR	IC	InChI=1S/C16H27N3O7S/c1-25-7-8-26-6-2-4-18-13(20)3-5-19-14(21)9-12(15(19)22)27-10-11(17)16(23)24/h11-12H,2-10,17H2,1H3,(H,18,20)(H,23,24)/t11-,12?/m0/s1
DML6XWR	CS	COCCOCCCNC(=O)CCN1C(=O)CC(C1=O)SC[C@@H](C(=O)O)N
DML6XWR	IK	DLVAZTPQKCTPLB-PXYINDEMSA-N
DML6XWR	IU	(2R)-2-amino-3-[1-[3-[3-(2-methoxyethoxy)propylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid
DML6XWR	CA	CAS 1492924-65-8
DML6XWR	DE	Diabetic complication

DMRVEHY	ID	DMRVEHY
DMRVEHY	DN	LY3012212
DMRVEHY	HS	Phase 2
DMRVEHY	SN	Icrucumab
DMRVEHY	CP	Lilly
DMRVEHY	DE	Bladder cancer; Arteriosclerosis

DMFMKQ3	ID	DMFMKQ3
DMFMKQ3	DN	LY3015014
DMFMKQ3	HS	Phase 2
DMFMKQ3	CP	Eli lilly
DMFMKQ3	DT	Antibody
DMFMKQ3	DE	Cardiovascular disease

DMD9KYF	ID	DMD9KYF
DMD9KYF	DN	LY3023414
DMD9KYF	HS	Phase 2
DMD9KYF	CP	Lilly
DMD9KYF	PC	57519748
DMD9KYF	MW	406.5
DMD9KYF	FM	C23H26N4O3
DMD9KYF	IC	InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1
DMD9KYF	CS	C[C@@H](CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC
DMD9KYF	IK	ACCFLVVUVBJNGT-AWEZNQCLSA-N
DMD9KYF	IU	8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one
DMD9KYF	CA	CAS 1386874-06-1
DMD9KYF	DE	Solid tumour/cancer; Prostate cancer

DMDFZK8	ID	DMDFZK8
DMDFZK8	DN	LY3113593
DMDFZK8	HS	Phase 2
DMDFZK8	CP	Eli Lilly
DMDFZK8	DT	Antibody
DMDFZK8	DE	Anaemia

DMAC457	ID	DMAC457
DMAC457	DN	LY3127804
DMAC457	HS	Phase 2 
DMAC457	TC	Antiviral Agents
DMAC457	DT	Monoclonal antibody
DMAC457	DE	Coronavirus Disease 2019 (COVID-19)

DM7IFNB	ID	DM7IFNB
DM7IFNB	DN	LY3202626
DM7IFNB	HS	Phase 2
DM7IFNB	CP	Eli Lilly Indianapolis, IN
DM7IFNB	DE	Alzheimer disease

DMGMC8H	ID	DMGMC8H
DMGMC8H	DN	LY333531
DMGMC8H	HS	Phase 2
DMGMC8H	SN	Ruboxistaurin; 169939-94-0; LY-333531; Ruboxistaurin [INN]; LY 333531; UNII-721809WQCP; 721809WQCP; K00587a; 13-((Dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione; CHEMBL432130; (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione; Br-WR99210
DMGMC8H	DT	Small molecular drug
DMGMC8H	PC	153999
DMGMC8H	MW	468.5
DMGMC8H	FM	C28H28N4O3
DMGMC8H	IC	InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
DMGMC8H	CS	CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O
DMGMC8H	IK	ZCBUQCWBWNUWSU-SFHVURJKSA-N
DMGMC8H	IU	(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione
DMGMC8H	CA	CAS 169939-94-0
DMGMC8H	DE	Solid tumour/cancer

DM43O9N	ID	DM43O9N
DM43O9N	DN	LY-334370
DM43O9N	HS	Phase 2
DM43O9N	SN	LY334370; LY-334370; 182563-08-2; UNII-5Q7I1WL2UY; 5Q7I1WL2UY; LY 334370; CHEMBL101690; LY-334,370; 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide; 4-Fluoro-N-[3-(1-methyl-piperidin-4-yl)-1H-indol-5-yl]-benzamide; 4-Fluoro-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzamide; AC1NSKBH; GTPL20; GTPL151; SCHEMBL6911508; DTXSID40415518; ZINC1488294; BCP29131; BDBM50130461; NCGC00378776-02; [3H]LY334370; HY-103107; CS-0025021; L000364; 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1h-indol-5-yl]-benzamide
DM43O9N	DT	Small molecular drug
DM43O9N	PC	5311258
DM43O9N	MW	351.4
DM43O9N	FM	C21H22FN3O
DM43O9N	IC	InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26)
DM43O9N	CS	CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)NC(=O)C4=CC=C(C=C4)F
DM43O9N	IK	MDMJLMDBRQXOOI-UHFFFAOYSA-N
DM43O9N	IU	4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide
DM43O9N	CA	CAS 182563-08-2
DM43O9N	DE	Migraine

DMD09CT	ID	DMD09CT
DMD09CT	DN	LY-362884
DMD09CT	HS	Phase 2
DMD09CT	CP	Eli Lilly
DMD09CT	PC	9870239
DMD09CT	MW	491.5
DMD09CT	FM	C26H29N5O5
DMD09CT	IC	InChI=1S/C26H29N5O5/c1-26(2,29-14-18(32)15-35-21-5-3-4-20-23(21)31-25(34)30-20)12-16-6-9-19(10-7-16)36-22-11-8-17(13-28-22)24(27)33/h3-11,13,18,29,32H,12,14-15H2,1-2H3,(H2,27,33)(H2,30,31,34)
DMD09CT	CS	CC(C)(CC1=CC=C(C=C1)OC2=NC=C(C=C2)C(=O)N)NCC(COC3=CC=CC4=C3NC(=O)N4)O
DMD09CT	IK	RLYDBONATWKYQX-UHFFFAOYSA-N
DMD09CT	IU	6-[4-[2-[[2-hydroxy-3-[(2-oxo-1,3-dihydrobenzimidazol-4-yl)oxy]propyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide
DMD09CT	DE	Type-2 diabetes; Obesity

DMZCU7I	ID	DMZCU7I
DMZCU7I	DN	LY-377604
DMZCU7I	HS	Phase 2
DMZCU7I	SN	Ethanolamine analogs, Lilly; Obesity therapeutics, Lilly; Beta-3 adrenoceptor agonists, Lilly
DMZCU7I	CP	Eli Lilly & Co
DMZCU7I	DT	Small molecular drug
DMZCU7I	PC	9849699
DMZCU7I	MW	524.6
DMZCU7I	FM	C31H32N4O4
DMZCU7I	IC	InChI=1S/C31H32N4O4/c1-31(2,16-20-10-13-23(14-11-20)39-28-15-12-21(17-33-28)30(32)37)34-18-22(36)19-38-27-9-5-8-26-29(27)24-6-3-4-7-25(24)35-26/h3-15,17,22,34-36H,16,18-19H2,1-2H3,(H2,32,37)/t22-/m0/s1
DMZCU7I	CS	CC(C)(CC1=CC=C(C=C1)OC2=NC=C(C=C2)C(=O)N)NC[C@@H](COC3=CC=CC4=C3C5=CC=CC=C5N4)O
DMZCU7I	IK	RBSGUQYXRDKPAE-QFIPXVFZSA-N
DMZCU7I	IU	6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide
DMZCU7I	CA	CAS 204592-94-9
DMZCU7I	DE	Obesity

DM8OG0J	ID	DM8OG0J
DM8OG0J	DN	LY-517717
DM8OG0J	HS	Phase 2
DM8OG0J	SN	SCHEMBL676862
DM8OG0J	CP	Eli Lilly
DM8OG0J	DT	Small molecular drug
DM8OG0J	PC	9939865
DM8OG0J	MW	459.6
DM8OG0J	FM	C27H33N5O2
DM8OG0J	IC	InChI=1S/C27H33N5O2/c1-30-13-10-23(11-14-30)31-15-17-32(18-16-31)27(34)25(21-5-3-2-4-6-21)29-26(33)22-8-7-20-9-12-28-24(20)19-22/h2-9,12,19,23,25,28H,10-11,13-18H2,1H3,(H,29,33)/t25-/m1/s1
DM8OG0J	CS	CN1CCC(CC1)N2CCN(CC2)C(=O)[C@@H](C3=CC=CC=C3)NC(=O)C4=CC5=C(C=C4)C=CN5
DM8OG0J	IK	VYNKVNDKAOGAAQ-RUZDIDTESA-N
DM8OG0J	IU	N-[(1R)-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]-1H-indole-6-carboxamide
DM8OG0J	CA	CAS 313489-71-3
DM8OG0J	DE	Thrombosis

DMBM2I9	ID	DMBM2I9
DMBM2I9	DN	LY-518674
DMBM2I9	HS	Phase 2
DMBM2I9	SN	LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid
DMBM2I9	CP	Eli Lilly
DMBM2I9	DT	Small molecular drug
DMBM2I9	PC	135449333
DMBM2I9	MW	409.5
DMBM2I9	FM	C23H27N3O4
DMBM2I9	IC	InChI=1S/C23H27N3O4/c1-16-7-9-18(10-8-16)15-26-22(29)24-20(25-26)6-4-5-17-11-13-19(14-12-17)30-23(2,3)21(27)28/h7-14H,4-6,15H2,1-3H3,(H,27,28)(H,24,25,29)
DMBM2I9	CS	CC1=CC=C(C=C1)CN2C(=O)NC(=N2)CCCC3=CC=C(C=C3)OC(C)(C)C(=O)O
DMBM2I9	IK	PNHFDVSKDSLUFH-UHFFFAOYSA-N
DMBM2I9	IU	2-methyl-2-[4-[3-[1-[(4-methylphenyl)methyl]-5-oxo-4H-1,2,4-triazol-3-yl]propyl]phenoxy]propanoic acid
DMBM2I9	CA	CAS 425671-29-0
DMBM2I9	DE	Diabetic complication

DMMSBW5	ID	DMMSBW5
DMMSBW5	DN	LY-545694
DMMSBW5	HS	Phase 2
DMMSBW5	SN	Lead iGluR5 antagonist (pain), Eli Lilly
DMMSBW5	CP	Eli Lilly & Co
DMMSBW5	DE	Neuropathic pain

DMP05GL	ID	DMP05GL
DMP05GL	DN	LYC-30937
DMP05GL	HS	Phase 2
DMP05GL	CP	Lycera Ann Arbor, MI
DMP05GL	DE	Plaque psoriasis; Ulcerative colitis

DMV8WU9	ID	DMV8WU9
DMV8WU9	DN	LYC-55716
DMV8WU9	HS	Phase 2
DMV8WU9	SN	Cintirorgon; UNII-LPN433P0EA; LPN433P0EA; 2055536-64-4; Cintirorgon [INN]; cintirorgon (proposed INN); SCHEMBL18302870; GTPL10045; LYC55716; BCP28882; EX-A2635; LYC 55716; CS-7496; compound 32J [WO2016201225A1]; HY-104037; 3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid
DMV8WU9	CP	Lycera Ann Arbor, MI
DMV8WU9	PC	124126348
DMV8WU9	MW	603.5
DMV8WU9	FM	C27H23F6NO6S
DMV8WU9	IC	InChI=1S/C27H23F6NO6S/c1-26(2,24(35)36)13-20-14-34(41(37,38)21-5-3-4-17(11-21)27(31,32)33)22-10-15(6-7-23(22)39-20)16-8-18(28)12-19(9-16)40-25(29)30/h3-12,20,25H,13-14H2,1-2H3,(H,35,36)/t20-/m0/s1
DMV8WU9	CS	CC(C)(C[C@H]1CN(C2=C(O1)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F)C(=O)O
DMV8WU9	IK	GULSIMHVQYBADX-FQEVSTJZSA-N
DMV8WU9	IU	3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid
DMV8WU9	CA	CAS 2055536-64-4
DMV8WU9	DE	Solid tumour/cancer; Non-small-cell lung cancer

DM23Y6K	ID	DM23Y6K
DM23Y6K	DN	LYS228
DM23Y6K	HS	Phase 2
DM23Y6K	SN	1810051-96-7 (free acid); 1-((((Z)-1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropane-1-carboxylic acid; SCHEMBL17094584; 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid; l-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid
DM23Y6K	DT	Small molecular drug
DM23Y6K	PC	118380292
DM23Y6K	MW	518.5
DM23Y6K	FM	C16H18N6O10S2
DM23Y6K	IC	InChI=1S/C16H18N6O10S2/c17-14-18-7(6-33-14)9(20-32-16(1-2-16)13(25)26)11(23)19-10-8(5-21-3-4-31-15(21)27)22(12(10)24)34(28,29)30/h6,8,10H,1-5H2,(H2,17,18)(H,19,23)(H,25,26)(H,28,29,30)/b20-9+/t8-,10+/m1/s1
DM23Y6K	CS	C1CC1(C(=O)O)O/N=C(\\C2=CSC(=N2)N)/C(=O)N[C@H]3[C@H](N(C3=O)S(=O)(=O)O)CN4CCOC4=O
DM23Y6K	IK	FWTGYTRQUBRVDW-UWGJAOEXSA-N
DM23Y6K	IU	1-[(E)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-[[(3S,4R)-2-oxo-4-[(2-oxo-1,3-oxazolidin-3-yl)methyl]-1-sulfoazetidin-3-yl]amino]ethylidene]amino]oxycyclopropane-1-carboxylic acid
DM23Y6K	DE	Urinary tract infection

DML0I2Z	ID	DML0I2Z
DML0I2Z	DN	M118
DML0I2Z	HS	Phase 2
DML0I2Z	SN	Adomiparin
DML0I2Z	CP	Momenta Pharmaceuticals
DML0I2Z	DT	Small molecular drug
DML0I2Z	PC	21156139
DML0I2Z	MW	801.9
DML0I2Z	FM	C34H42Cl4N8O2Zn
DML0I2Z	IC	InChI=1S/2C17H20N4O.4ClH.Zn/c2*1-4-21(5-2)11-6-7-14-15(8-11)22-17-10(3)12(18)9-13(19)16(17)20-14;;;;;/h2*6-9H,4-5H2,1-3H3,(H3,18,19);4*1H;/q;;;;;;+2/p-2
DML0I2Z	CS	CC[N+](=C1C=CC2=NC3=C(C=C(C(=C3OC2=C1)C)N)N)CC.CC[N+](=C1C=CC2=NC3=C(C=C(C(=C3OC2=C1)C)N)N)CC.Cl[Zn-2](Cl)(Cl)Cl
DML0I2Z	IK	JJKNZNYHIUJGIC-UHFFFAOYSA-L
DML0I2Z	IU	(7,9-diamino-6-methylphenoxazin-3-ylidene)-diethylazanium;tetrachlorozinc(2-)
DML0I2Z	DE	Acute coronary syndrome

DMZ7YX3	ID	DMZ7YX3
DMZ7YX3	DN	M-16209
DMZ7YX3	HS	Phase 2
DMZ7YX3	SN	1-(3-Bromo-benzo[b]furan-2-ylsulfonyl)imidazolidine-2,4-dione; 1-(3-Bromobenzo[b]furan-2-ylsulfonyl)hydantoin
DMZ7YX3	DT	Small molecular drug
DMZ7YX3	PC	164260
DMZ7YX3	MW	359.15
DMZ7YX3	FM	C11H7BrN2O5S
DMZ7YX3	IC	InChI=1S/C11H7BrN2O5S/c12-9-6-3-1-2-4-7(6)19-10(9)20(17,18)14-5-8(15)13-11(14)16/h1-4H,5H2,(H,13,15,16)
DMZ7YX3	CS	C1C(=O)NC(=O)N1S(=O)(=O)C2=C(C3=CC=CC=C3O2)Br
DMZ7YX3	IK	ZJSUDHQFSBHLDV-UHFFFAOYSA-N
DMZ7YX3	IU	1-[(3-bromo-1-benzofuran-2-yl)sulfonyl]imidazolidine-2,4-dione
DMZ7YX3	CA	CAS 128851-36-5
DMZ7YX3	DE	Diabetic complication

DMC5MQD	ID	DMC5MQD
DMC5MQD	DN	M2951
DMC5MQD	HS	Phase 2
DMC5MQD	SN	evobrutinib; Evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin
DMC5MQD	CP	EMD Serono Rockland, MA
DMC5MQD	PC	71479709
DMC5MQD	MW	429.5
DMC5MQD	FM	C25H27N5O2
DMC5MQD	IC	InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
DMC5MQD	CS	C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
DMC5MQD	IK	QUIWHXQETADMGN-UHFFFAOYSA-N
DMC5MQD	IU	1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
DMC5MQD	CA	CAS 1415823-73-2
DMC5MQD	DE	Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

DMJCULI	ID	DMJCULI
DMJCULI	DN	M7824
DMJCULI	HS	Phase 2
DMJCULI	CP	EMD SeronoRockland, MA
DMJCULI	DT	Antibody
DMJCULI	DE	Solid tumour/cancer

DMQOBH4	ID	DMQOBH4
DMQOBH4	DN	mab 1-7F9
DMQOBH4	HS	Phase 2
DMQOBH4	CP	CeMines
DMQOBH4	DT	Antibody
DMQOBH4	DE	Multiple myeloma

DMBYDNE	ID	DMBYDNE
DMBYDNE	DN	Managlinat dialanetil
DMBYDNE	HS	Phase 2
DMBYDNE	SN	CS-917; GP-3034; MB-05032; MB-06322; MB-06633; MB-6322; R-132917; Type 2 diabetes therapeutic, Gensia/Sankyo; Type 2 diabetes therapeutic, SICOR/Sankyo; Diabetes therapeutics, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, Gensia/Sankyo/Daiichi Sankyo; Purine nucleotide analogs, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, SICOR/Sankyo/Daiichi Sankyo
DMBYDNE	CP	Metabasis Therapeutics Inc
DMBYDNE	PC	73014123
DMBYDNE	MW	484.6
DMBYDNE	FM	C21H33N4O5PS
DMBYDNE	IC	InChI=1S/C21H33N4O5PS/c1-7-28-19(26)13(5)24-31(25-14(6)20(27)29-8-2)17-10-9-15(30-17)18-16(11-12(3)4)32-21(22)23-18/h9-10,12-14,24-25H,7-8,11H2,1-6H3,(H2,22,23)/t13-,14-/m0/s1
DMBYDNE	CS	CCOC(=O)[C@H](C)NP(C1=CC=C(O1)C2=C(SC(=N2)N)CC(C)C)N[C@@H](C)C(=O)OCC
DMBYDNE	IK	JGCMEVUWRCNKKE-KBPBESRZSA-N
DMBYDNE	IU	ethyl (2S)-2-[[[5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-yl]-[[(2S)-1-ethoxy-1-oxopropan-2-yl]amino]phosphanyl]amino]propanoate
DMBYDNE	DE	Type-2 diabetes

DMB4A8I	ID	DMB4A8I
DMB4A8I	DN	MANOALIDE
DMB4A8I	HS	Phase 2
DMB4A8I	SN	manoalide; UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975
DMB4A8I	DT	Small molecular drug
DMB4A8I	PC	6437368
DMB4A8I	MW	416.5
DMB4A8I	FM	C25H36O5
DMB4A8I	IC	InChI=1S/C25H36O5/c1-16(10-12-20-17(2)8-6-14-25(20,3)4)7-5-9-18-11-13-21(29-23(18)27)19-15-22(26)30-24(19)28/h7,11,15,21,23-24,27-28H,5-6,8-10,12-14H2,1-4H3/b16-7+/t21-,23-,24-/m1/s1
DMB4A8I	CS	CC1=C(C(CCC1)(C)C)CC/C(=C/CCC2=CC[C@@H](O[C@H]2O)C3=CC(=O)O[C@H]3O)/C
DMB4A8I	IK	FGJIDQWRRLDGDB-CPIXEKRISA-N
DMB4A8I	IU	(2R)-2-hydroxy-3-[(2R,6R)-6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one
DMB4A8I	CA	CAS 75088-80-1
DMB4A8I	CB	CHEBI:66666
DMB4A8I	DE	Arthritis

DMGQ175	ID	DMGQ175
DMGQ175	DN	Mapatumumab
DMGQ175	HS	Phase 2
DMGQ175	CP	Human Genome Sciences
DMGQ175	DT	Monoclonal antibody
DMGQ175	DE	Non-small-cell lung cancer

DMDTI0L	ID	DMDTI0L
DMDTI0L	DN	Masilukast
DMDTI0L	HS	Phase 2
DMDTI0L	SN	D-3523; MCC-847; ZD-3523
DMDTI0L	CP	Zeneca Group plc
DMDTI0L	DT	Small molecular drug
DMDTI0L	PC	204056
DMDTI0L	MW	615.7
DMDTI0L	FM	C31H32F3N3O5S
DMDTI0L	IC	InChI=1S/C31H32F3N3O5S/c1-19(16-31(32,33)34)17-35-29(38)22-11-12-26-25(14-22)24(18-37(26)3)13-21-9-10-23(15-27(21)42-4)30(39)36-43(40,41)28-8-6-5-7-20(28)2/h5-12,14-15,18-19H,13,16-17H2,1-4H3,(H,35,38)(H,36,39)/t19-/m1/s1
DMDTI0L	CS	CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)C(=O)NC[C@H](C)CC(F)(F)F)C)OC
DMDTI0L	IK	ULMFXAMQUGLVGA-LJQANCHMSA-N
DMDTI0L	IU	3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-N-[(2R)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide
DMDTI0L	CA	CAS 136564-68-6
DMDTI0L	DE	Asthma

DM2458E	ID	DM2458E
DM2458E	DN	Matuzumab
DM2458E	HS	Phase 2
DM2458E	SN	EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals
DM2458E	CP	Merck KgaA; Merck KGaA
DM2458E	DT	Antibody
DM2458E	SQ	3c08_H|Fab72000|Humanized||VH-CH1 (VH(1-115)+CH1(116-213))|||||||223||||MW 24063.8|MW 24063.8|: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS</sequence>    <sequence format="FASTA">&gt;3c08_L|Fab72000|Humanized||L-KAPPA (V-KAPPA(1-101)+C-KAPPA(102-206))|||||||212||||MW 23214.7|MW 23214.7|DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE</sequence>    <sequence format="FASTA">&gt;3c09_B|Fab72000|Humanized||L-KAPPA (V-KAPPA(1-106)+C-KAPPA(107-175))|||||||212||||MW 23214.7|MW 23214.7|DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE</sequence>    <sequence format="FASTA">&gt;3c09_C|Fab72000|Humanized||VH-CH1 (VH(1-121)+CH1(122-191))|||||||223||||MW 24019.8|MW 24019.8|QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYAGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
DM2458E	DE	Gastric adenocarcinoma

DMMVFRC	ID	DMMVFRC
DMMVFRC	DN	Mavrilimumab
DMMVFRC	HS	Phase 2
DMMVFRC	CP	MedImmune
DMMVFRC	DT	Antibody
DMMVFRC	DE	Rheumatoid arthritis

DMWLIPJ	ID	DMWLIPJ
DMWLIPJ	DN	MAXY-G34
DMWLIPJ	HS	Phase 2
DMWLIPJ	SN	Maxy-G21; MAXY-G-CSF; G-CSF agonist (neutropenia, leukopenia), Maxygen
DMWLIPJ	CP	Maxygen
DMWLIPJ	DE	Neutropenia

DMJKHVX	ID	DMJKHVX
DMJKHVX	DN	Mazapertine succinate
DMJKHVX	HS	Phase 2
DMJKHVX	SN	RWJ-37796
DMJKHVX	CP	RW Johnson Pharmaceutical Research Institute
DMJKHVX	DT	Small molecular drug
DMJKHVX	PC	60819
DMJKHVX	MW	539.7
DMJKHVX	FM	C30H41N3O6
DMJKHVX	IC	InChI=1S/C26H35N3O2.C4H6O4/c1-21(2)31-25-12-5-4-11-24(25)28-17-15-27(16-18-28)20-22-9-8-10-23(19-22)26(30)29-13-6-3-7-14-29;5-3(6)1-2-4(7)8/h4-5,8-12,19,21H,3,6-7,13-18,20H2,1-2H3;1-2H2,(H,5,6)(H,7,8)
DMJKHVX	CS	CC(C)OC1=CC=CC=C1N2CCN(CC2)CC3=CC(=CC=C3)C(=O)N4CCCCC4.C(CC(=O)O)C(=O)O
DMJKHVX	IK	WAHFGTZTVZRLEY-UHFFFAOYSA-N
DMJKHVX	IU	butanedioic acid;piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
DMJKHVX	CA	CAS 134208-18-7
DMJKHVX	DE	Psychotic disorder

DMHU8SJ	ID	DMHU8SJ
DMHU8SJ	DN	MB07803
DMHU8SJ	HS	Phase 2
DMHU8SJ	SN	MB-07803; 882757-24-6; UNII-GG81XF45C2; MB 07803; GG81XF45C2; SCHEMBL14255484; DTXSID90236932; ACT04837; SB17400; DB05053; HY-16309; CS-0006389; Alanine, N,N'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methyl-, diethyl ester; n,n'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methylalanine) diethyl ester
DMHU8SJ	CP	Metabasis Therape
DMHU8SJ	DT	Small molecular drug
DMHU8SJ	PC	24770445
DMHU8SJ	MW	556.6
DMHU8SJ	FM	C24H37N4O7PS
DMHU8SJ	IC	InChI=1S/C24H37N4O7PS/c1-10-33-19(30)23(6,7)27-36(32,28-24(8,9)20(31)34-11-2)15-13-12-14(35-15)16-17(37-21(25)26-16)18(29)22(3,4)5/h12-13H,10-11H2,1-9H3,(H2,25,26)(H2,27,28,32)
DMHU8SJ	CS	CCOC(=O)C(C)(C)NP(=O)(C1=CC=C(O1)C2=C(SC(=N2)N)C(=O)C(C)(C)C)NC(C)(C)C(=O)OCC
DMHU8SJ	IK	CTKZZUXRWBCFEI-UHFFFAOYSA-N
DMHU8SJ	IU	ethyl 2-[[[5-[2-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-4-yl]furan-2-yl]-[(1-ethoxy-2-methyl-1-oxopropan-2-yl)amino]phosphoryl]amino]-2-methylpropanoate
DMHU8SJ	CA	CAS 882757-24-6
DMHU8SJ	DE	Type-2 diabetes

DM6JTSZ	ID	DM6JTSZ
DM6JTSZ	DN	MB-07811
DM6JTSZ	HS	Phase 2
DM6JTSZ	SN	CHEMBL471897; MB-07811; SCHEMBL3147495; BDBM50242404
DM6JTSZ	CP	Ligand Pharmaceuticals
DM6JTSZ	DT	Small molecular drug
DM6JTSZ	PC	15942005
DM6JTSZ	MW	515
DM6JTSZ	FM	C28H32ClO5P
DM6JTSZ	IC	InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1
DM6JTSZ	CS	CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OC[P@@]3(=O)OCC[C@H](O3)C4=CC(=CC=C4)Cl
DM6JTSZ	IK	LGGPZDRLTDGYSQ-JADSYQMUSA-N
DM6JTSZ	IU	4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol
DM6JTSZ	CA	CAS 852948-13-1
DM6JTSZ	DE	Hyperlipidaemia

DMLPNVS	ID	DMLPNVS
DMLPNVS	DN	MB-102
DMLPNVS	HS	Phase 2
DMLPNVS	SN	Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0
DMLPNVS	CP	Mustang Bio New York, NY
DMLPNVS	PC	53389120
DMLPNVS	MW	372.29
DMLPNVS	FM	C12H16N6O8
DMLPNVS	IC	InChI=1S/C12H16N6O8/c13-7-5(9(21)15-3(1-19)11(23)24)17-8(14)6(18-7)10(22)16-4(2-20)12(25)26/h3-4,19-20H,1-2H2,(H2,14,17)(H2,13,18)(H,15,21)(H,16,22)(H,23,24)(H,25,26)/t3-,4-/m1/s1
DMLPNVS	CS	C([C@H](C(=O)O)NC(=O)C1=C(N=C(C(=N1)N)C(=O)N[C@H](CO)C(=O)O)N)O
DMLPNVS	IK	XHNJXRDGTITISI-QWWZWVQMSA-N
DMLPNVS	IU	(2R)-2-[[3,6-diamino-5-[[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl]pyrazine-2-carbonyl]amino]-3-hydroxypropanoic acid
DMLPNVS	CA	CAS 1313706-17-0
DMLPNVS	DE	Acute myeloid leukaemia; Acute kidney injury

DM3RBJW	ID	DM3RBJW
DM3RBJW	DN	MB-11055
DM3RBJW	HS	Phase 2
DM3RBJW	SN	Cryptotanshinone, MD BioAlpha; Cryptotanshinone, Mazence; AMP activated protein kinase stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; AMPK stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; Lipid metabolism stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence
DM3RBJW	CP	Mazence Inc
DM3RBJW	DE	Fatty liver disease

DMRSN2C	ID	DMRSN2C
DMRSN2C	DN	MB-12066
DMRSN2C	HS	Phase 2
DMRSN2C	SN	B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence
DMRSN2C	CP	Mazence Inc
DMRSN2C	DE	Obesity

DM0AOID	ID	DM0AOID
DM0AOID	DN	MB-CART19.1
DM0AOID	HS	Phase 2
DM0AOID	CP	Shanghai Children's Medical Center
DM0AOID	DT	CAR T Cell Therapy
DM0AOID	DE	Precursor B-lymphoblastic neoplasm

DMJVU7Y	ID	DMJVU7Y
DMJVU7Y	DN	MBL-HCV1
DMJVU7Y	HS	Phase 2
DMJVU7Y	SN	Anti-HCV antibody, MassBiologics
DMJVU7Y	CP	Massbiologics
DMJVU7Y	DE	Hepatitis C virus infection

DMQMTO1	ID	DMQMTO1
DMQMTO1	DN	MBX-2044
DMQMTO1	HS	Phase 2
DMQMTO1	SN	MBX-102 analogs, Metabolex
DMQMTO1	CP	Metabolex Inc
DMQMTO1	DE	Type-2 diabetes

DM0W3R7	ID	DM0W3R7
DM0W3R7	DN	MCLA-128
DM0W3R7	HS	Phase 2
DM0W3R7	CP	MerusUtrecht, Netherlands
DM0W3R7	DE	Breast cancer

DM0CL4I	ID	DM0CL4I
DM0CL4I	DN	MCS-110
DM0CL4I	HS	Phase 2
DM0CL4I	SN	Colony stimulating factor-1 inhibiting antibody (cancer), Novartis; Anti-CSF-1 antibody (cancer), Novartis
DM0CL4I	CP	Novartis pharmaceuticals
DM0CL4I	DE	Bone metastases; Advanced malignancy; Breast cancer; Tenosynovial giant cell tumour; Triple negative breast cancer

DMX4U0B	ID	DMX4U0B
DMX4U0B	DN	MCS-18
DMX4U0B	HS	Phase 2
DMX4U0B	SN	Helleborus purpurascens-derived anti-inflammatory analgesic (injection, autoimmune disease), DoNatur
DMX4U0B	CP	DoNatur GmbH
DMX4U0B	DE	Autoimmune diabetes

DMDR2SZ	ID	DMDR2SZ
DMDR2SZ	DN	MCT-125
DMDR2SZ	HS	Phase 2
DMDR2SZ	CP	Laxdale Ltd
DMDR2SZ	DE	Fatigue

DM5DSGJ	ID	DM5DSGJ
DM5DSGJ	DN	MD-0727
DM5DSGJ	HS	Phase 2
DM5DSGJ	CP	Ironwood Pharmaceuticals
DM5DSGJ	PC	11586434
DM5DSGJ	MW	193.2
DM5DSGJ	FM	C10H11NO3
DM5DSGJ	IC	InChI=1S/C10H11NO3/c1-3-14-10(13)9-6-4-5-8(11-9)7(2)12/h4-6H,3H2,1-2H3
DM5DSGJ	CS	CCOC(=O)C1=CC=CC(=N1)C(=O)C
DM5DSGJ	IK	COYXIUHSZNHMAS-UHFFFAOYSA-N
DM5DSGJ	IU	ethyl 6-acetylpyridine-2-carboxylate
DM5DSGJ	CA	CAS 114578-70-0
DM5DSGJ	DE	Hypercholesterolaemia

DM9FXU7	ID	DM9FXU7
DM9FXU7	DN	MDL-27192
DM9FXU7	HS	Phase 2
DM9FXU7	SN	3-(4-Chlorophenyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one; 5-(4-Chlorophenyl)-4-ethyl-3,4-dihydro-2H-1,2,4-triazol-3-one
DM9FXU7	PC	35793
DM9FXU7	MW	223.66
DM9FXU7	FM	C10H10ClN3O
DM9FXU7	IC	InChI=1S/C10H10ClN3O/c1-2-14-9(12-13-10(14)15)7-3-5-8(11)6-4-7/h3-6H,2H2,1H3,(H,13,15)
DM9FXU7	CS	CCN1C(=NNC1=O)C2=CC=C(C=C2)Cl
DM9FXU7	IK	PXINDYJACXPZIN-UHFFFAOYSA-N
DM9FXU7	IU	3-(4-chlorophenyl)-4-ethyl-1H-1,2,4-triazol-5-one
DM9FXU7	CA	CAS 31409-32-2
DM9FXU7	DE	Epileptic seizures

DMCK8SX	ID	DMCK8SX
DMCK8SX	DN	MDX-1097
DMCK8SX	HS	Phase 2
DMCK8SX	SN	CKap; MKap; K-1-21; Mab therapy, Immune System therapeutics/Medarex; Monoclonal antibody (multiple myeloma, humanized/murine/chimeric), PacMab/Medarex
DMCK8SX	CP	Immune System Therapeutics Ltd
DMCK8SX	DT	Antibody
DMCK8SX	DE	Haematological malignancy

DM0EZWI	ID	DM0EZWI
DM0EZWI	DN	MDX-1100
DM0EZWI	HS	Phase 2
DM0EZWI	CP	Medarex
DM0EZWI	DT	Antibody
DM0EZWI	DE	Crohn disease

DMKMSC4	ID	DMKMSC4
DMKMSC4	DN	MDX-1342
DMKMSC4	HS	Phase 2
DMKMSC4	SN	Anti-CD19 (cancer), MDX/BMS; Anti-CD19 antibody (cancer), Medarex/BMS
DMKMSC4	CP	Medarex
DMKMSC4	DT	Antibody
DMKMSC4	DE	leukaemia

DMO84TL	ID	DMO84TL
DMO84TL	DN	ME-3407
DMO84TL	HS	Phase 2
DMO84TL	SN	EF-4040; 2-(Butoxycarbonylmethylsulfinyl)thiazolo[5,4-b]pyridine; 2-(Thiazolo[5,4-b]pyridin-2-ylsulfinyl)acetic acid butyl ester
DMO84TL	DT	Small molecular drug
DMO84TL	PC	6918179
DMO84TL	MW	298.4
DMO84TL	FM	C12H14N2O3S2
DMO84TL	IC	InChI=1S/C12H14N2O3S2/c1-2-3-7-17-10(15)8-19(16)12-14-9-5-4-6-13-11(9)18-12/h4-6H,2-3,7-8H2,1H3
DMO84TL	CS	CCCCOC(=O)CS(=O)C1=NC2=C(S1)N=CC=C2
DMO84TL	IK	BUXNKFNNJJTLOS-UHFFFAOYSA-N
DMO84TL	IU	butyl 2-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfinyl)acetate
DMO84TL	DE	Duodenal ulcer

DMX9Y7V	ID	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	HS	Phase 2
DMX9Y7V	DT	Small molecular drug
DMX9Y7V	PC	68602
DMX9Y7V	MW	200.28
DMX9Y7V	FM	C13H16N2
DMX9Y7V	IC	InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)
DMX9Y7V	CS	CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C
DMX9Y7V	IK	CUHVIMMYOGQXCV-UHFFFAOYSA-N
DMX9Y7V	IU	5-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DMX9Y7V	CA	CAS 86347-14-0
DMX9Y7V	CB	CHEBI:48552
DMX9Y7V	DE	Pain

DMSV60C	ID	DMSV60C
DMSV60C	DN	MEDI0382
DMSV60C	HS	Phase 2
DMSV60C	SN	Cotadutide; UNII-QL6A9B13HW; QL6A9B13HW; Cotadutide [INN]; Cotadutide [USAN]; MEDI-0382; MEDI 0382 [WHO-DD]; 1686108-82-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys-(gamma-glupalmitoyl)-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp- Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly; Glycine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-N6-(N-(1-oxotetradecyl)-L-gamma-glutamyl)-L-lysyl-L-seryl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-L-seryl-L-alpha-glutamyl
DMSV60C	CP	MedImmune Gaithersburg, MD
DMSV60C	PC	134694273
DMSV60C	MW	3728
DMSV60C	FM	C167H252N42O55
DMSV60C	IC	InChI=1S/C167H252N42O55/c1-13-14-15-16-17-18-19-20-21-22-23-24-31-47-125(219)186-109(165(263)264)53-58-124(218)175-62-35-34-44-102(189-153(251)116(72-131(228)229)201-161(259)122(83-213)206-164(262)137(92(12)215)209-157(255)114(68-94-40-29-26-30-41-94)202-163(261)136(91(11)214)207-127(221)78-181-142(240)105(52-57-123(169)217)190-158(256)119(80-210)203-141(239)100(168)71-97-76-174-84-182-97)146(244)204-120(81-211)159(257)193-108(56-61-130(226)227)148(246)197-112(69-95-48-50-98(216)51-49-95)151(249)195-111(66-86(4)5)150(248)200-118(74-133(232)233)155(253)205-121(82-212)160(258)192-107(55-60-129(224)225)147(245)188-103(45-36-63-176-166(170)171)143(241)184-89(9)139(237)187-104(46-37-64-177-167(172)173)145(243)199-117(73-132(230)231)154(252)198-113(67-93-38-27-25-28-39-93)156(254)208-135(87(6)7)162(260)185-90(10)140(238)194-115(70-96-75-178-101-43-33-32-42-99(96)101)152(250)196-110(65-85(2)3)149(247)191-106(54-59-128(222)223)144(242)183-88(8)138(236)180-77-126(220)179-79-134(234)235/h25-30,32-33,38-43,48-51,75-76,84-92,100,102-122,135-137,178,210-216H,13-24,31,34-37,44-47,52-74,77-83,168H2,1-12H3,(H2,169,217)(H,174,182)(H,175,218)(H,179,220)(H,180,236)(H,181,240)(H,183,242)(H,184,241)(H,185,260)(H,186,219)(H,187,237)(H,188,245)(H,189,251)(H,190,256)(H,191,247)(H,192,258)(H,193,257)(H,194,238)(H,195,249)(H,196,250)(H,197,246)(H,198,252)(H,199,243)(H,200,248)(H,201,259)(H,202,261)(H,203,239)(H,204,244)(H,205,253)(H,206,262)(H,207,221)(H,208,254)(H,209,255)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,263,264)(H4,170,171,176)(H4,172,173,177)/t88-,89-,90-,91+,92+,100-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,135-,136-,137-/m0/s1
DMSV60C	CS	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)N)C(=O)O
DMSV60C	IK	YEKUUBPJRPXMBM-PTCFZACGSA-N
DMSV60C	IU	(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[2-(carboxymethylamino)-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
DMSV60C	CA	CAS 1686108-82-6
DMSV60C	DE	Type-2 diabetes

DMOXKIC	ID	DMOXKIC
DMOXKIC	DN	MEDI3902
DMOXKIC	HS	Phase 2
DMOXKIC	CP	AstraZeneca
DMOXKIC	DT	Antibody
DMOXKIC	DE	Pseudomonas infection; Ventilator-associated pneumonia

DMDYVN8	ID	DMDYVN8
DMDYVN8	DN	MEDI-528
DMDYVN8	HS	Phase 2
DMDYVN8	CP	MedImmune
DMDYVN8	DT	Monoclonal antibody
DMDYVN8	DE	Asthma

DMPKWR3	ID	DMPKWR3
DMPKWR3	DN	MEDI-546
DMPKWR3	HS	Phase 2
DMPKWR3	CP	AstraZeneca
DMPKWR3	DE	Ovarian cancer

DMBTVFE	ID	DMBTVFE
DMBTVFE	DN	MEDI-551
DMBTVFE	HS	Phase 2
DMBTVFE	CP	MedImmune
DMBTVFE	DT	Antibody
DMBTVFE	DE	Chronic lymphocytic leukaemia; Encephalopathy; Neuromyelitis optica

DMI9WVM	ID	DMI9WVM
DMI9WVM	DN	MEDI-575
DMI9WVM	HS	Phase 2
DMI9WVM	CP	MedImmune
DMI9WVM	DT	Antibody
DMI9WVM	DE	Glioblastoma multiforme

DMU4CS8	ID	DMU4CS8
DMU4CS8	DN	MEDI6012
DMU4CS8	HS	Phase 2
DMU4CS8	SN	RhLCAT; ACP-501
DMU4CS8	DE	Acute coronary syndrome; Coronary artery disease

DMGD1YP	ID	DMGD1YP
DMGD1YP	DN	MEDI9929
DMGD1YP	HS	Phase 2
DMGD1YP	CP	AstraZeneca
DMGD1YP	DE	Asthma

DM2C1YN	ID	DM2C1YN
DM2C1YN	DN	MEGF0444A
DM2C1YN	HS	Phase 2
DM2C1YN	CP	Genentech
DM2C1YN	DE	Non-small-cell lung cancer; Metastatic colorectal cancer

DMHOF7T	ID	DMHOF7T
DMHOF7T	DN	MEHD-7945A
DMHOF7T	HS	Phase 2
DMHOF7T	SN	RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech
DMHOF7T	CP	Genentech Inc
DMHOF7T	DE	Colorectal cancer; Solid tumour/cancer

DMVJ6WS	ID	DMVJ6WS
DMVJ6WS	DN	Melogliptin
DMVJ6WS	HS	Phase 2
DMVJ6WS	CP	Glenmark pharma
DMVJ6WS	PC	11623906
DMVJ6WS	MW	320.37
DMVJ6WS	FM	C15H21FN6O
DMVJ6WS	IC	InChI=1S/C15H21FN6O/c16-12-4-14(5-17)22(8-12)15(23)6-19-13-2-1-11(3-13)7-21-10-18-9-20-21/h9-14,19H,1-4,6-8H2/t11-,12-,13+,14-/m0/s1
DMVJ6WS	CS	C1C[C@H](C[C@H]1CN2C=NC=N2)NCC(=O)N3C[C@H](C[C@H]3C#N)F
DMVJ6WS	IK	JSYGLDMGERSRPC-FQUUOJAGSA-N
DMVJ6WS	IU	(2S,4S)-4-fluoro-1-[2-[[(1R,3S)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile
DMVJ6WS	CA	CAS 868771-57-7
DMVJ6WS	DE	Type-2 diabetes

DMPNDYU	ID	DMPNDYU
DMPNDYU	DN	MEM-3454
DMPNDYU	HS	Phase 2
DMPNDYU	CP	Memory Pharmaceuticals
DMPNDYU	DT	Small molecular drug
DMPNDYU	PC	10380472
DMPNDYU	MW	306.79
DMPNDYU	FM	C15H19ClN4O
DMPNDYU	IC	InChI=1S/C15H18N4O.ClH/c20-15(14-11-3-1-2-4-12(11)17-18-14)16-13-9-19-7-5-10(13)6-8-19;/h1-4,10,13H,5-9H2,(H,16,20)(H,17,18);1H/t13-;/m1./s1
DMPNDYU	CS	C1CN2CCC1[C@@H](C2)NC(=O)C3=NNC4=CC=CC=C43.Cl
DMPNDYU	IK	CMRLNEYJEPELSM-BTQNPOSSSA-N
DMPNDYU	IU	N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-1H-indazole-3-carboxamide;hydrochloride
DMPNDYU	CA	CAS 677305-02-1
DMPNDYU	DE	Schizophrenia

DMUMCWS	ID	DMUMCWS
DMUMCWS	DN	MEMP1972A
DMUMCWS	HS	Phase 2
DMUMCWS	SN	RG7449
DMUMCWS	CP	Genentech
DMUMCWS	DE	Allergic rhinitis; Asthma

DMIVR9K	ID	DMIVR9K
DMIVR9K	DN	MER-3001
DMIVR9K	HS	Phase 2
DMIVR9K	SN	Insulin B chain therapeutics (type 1 diabetes), Mercia Pharma/Joslin Diabetes Center
DMIVR9K	CP	Mercia Pharma Inc
DMIVR9K	DE	Type-1 diabetes; Type-2 diabetes

DM89QXT	ID	DM89QXT
DM89QXT	DN	MET409
DM89QXT	HS	Phase 2
DM89QXT	CP	Metacrine
DM89QXT	DT	Small molecular drug
DM89QXT	DE	Non-alcoholic steatohepatitis

DMNST69	ID	DMNST69
DMNST69	DN	Metaiodobenzylguanidine I-131
DMNST69	HS	Phase 2
DMNST69	SN	Azedra (TN)
DMNST69	CP	Molecular Insights Pharmaceuticals
DMNST69	DT	Small molecular drug
DMNST69	PC	71184
DMNST69	MW	279.09
DMNST69	FM	C8H10IN3
DMNST69	IC	InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9+4
DMNST69	CS	C1=CC(=CC(=C1)[131I])CN=C(N)N
DMNST69	IK	PDWUPXJEEYOOTR-JRGAVVOBSA-N
DMNST69	IU	2-[(3-(131I)iodanylphenyl)methyl]guanidine
DMNST69	CA	CAS 77679-27-7
DMNST69	CB	CHEBI:135997
DMNST69	DE	Neuroblastoma; Neuroendocrine cancer; Pheochromocytoma

DMSZFTP	ID	DMSZFTP
DMSZFTP	DN	Met-enkephalin
DMSZFTP	HS	Phase 2
DMSZFTP	SN	MET-enkephalin; H-Tyr-Gly-Gly-Phe-Met-OH; 58569-55-4; Tyr-Gly-Gly-Phe-Met-OH; METENKEFALIN; [Met]enkephalin; [5-Methionine]Enkephalin; TYR-GLY-GLY-PHE-MET; Enkephalin M; UNII-9JEZ9OD3AS; (Met5)-enkephalin; Lupex; 9JEZ9OD3AS; CHEMBL13786; CHEBI:6618; ENKEPHALIN, METHIONINE; Opioid growth factor; [Met5]-ENKEPHALIN; [Met5]Enkephalin acetate salt hydrate; Porcine beta-endorphin 1-5; (2S,5S,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-(2-(methylthio)ethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic
DMSZFTP	DT	Small molecular drug
DMSZFTP	PC	443363
DMSZFTP	MW	573.7
DMSZFTP	FM	C27H35N5O7S
DMSZFTP	IC	InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1
DMSZFTP	CS	CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMSZFTP	IK	YFGBQHOOROIVKG-FKBYEOEOSA-N
DMSZFTP	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DMSZFTP	CA	CAS 58569-55-4
DMSZFTP	CB	CHEBI:6618
DMSZFTP	DE	Pain

DMS7FRI	ID	DMS7FRI
DMS7FRI	DN	Methanesulfonyl fluoride
DMS7FRI	HS	Phase 2
DMS7FRI	SN	Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder)
DMS7FRI	CP	University of Texas
DMS7FRI	DT	Small molecular drug
DMS7FRI	PC	11207
DMS7FRI	MW	98.1
DMS7FRI	FM	CH3FO2S
DMS7FRI	IC	InChI=1S/CH3FO2S/c1-5(2,3)4/h1H3
DMS7FRI	CS	CS(=O)(=O)F
DMS7FRI	IK	KNWQLFOXPQZGPX-UHFFFAOYSA-N
DMS7FRI	IU	methanesulfonyl fluoride
DMS7FRI	CA	CAS 558-25-8
DMS7FRI	DE	Alzheimer disease

DMHSL87	ID	DMHSL87
DMHSL87	DN	Methoxyestradiol
DMHSL87	HS	Phase 2
DMHSL87	SN	SCHEMBL18733359; CHEMBL1473145; HMS3229K11
DMHSL87	DT	Small molecular drug
DMHSL87	PC	129631909
DMHSL87	MW	302.4
DMHSL87	FM	C19H26O3
DMHSL87	IC	InChI=1S/C19H26O3/c1-19-8-7-14-13(15(19)5-6-17(19)21)4-3-11-9-12(20)10-16(22-2)18(11)14/h9-10,13-15,17,20-21H,3-8H2,1-2H3/t13-,14-,15-,17-,19-/m0/s1
DMHSL87	CS	C[C@]12CC[C@H]3[C@@H]([C@@H]1CC[C@@H]2O)CCC4=C3C(=CC(=C4)O)OC
DMHSL87	IK	PJCUYTOXKIUJSL-SARNLOFESA-N
DMHSL87	IU	(8R,9S,13S,14S,17S)-1-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol

DM5GQD7	ID	DM5GQD7
DM5GQD7	DN	Metoprine
DM5GQD7	HS	Phase 2
DM5GQD7	SN	METOPRINE; Methodichlorophen; DDMP; 7761-45-7; Metoprine [USAN]; BW-197U; TCMDC-123931; NSC-19494; SK 5265; 5-(3,4-DICHLOROPHENYL)-6-METHYLPYRIMIDINE-2,4-DIAMINE; U 197; NSC7364; U-197; UNII-2L9RKX796Q; Metoprine (USAN); BW 50-197; METOPRINE, METHODICHLOROPHEN; 5-(3,4-Dichlorophenyl)-6-methyl-2,4-pyrimidinediamine; NSC 7364; 2,4-Pyrimidinediamine, 5-(3,4-dichlorophenyl)-6-methyl-; NSC 19494; BW50197; BRN 0223622; 5-(3,4-Dichlorphenyl)-6-methyl-2,4-pyrimidindiamin; 2,4-Diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine; MLS002701892;  DDMP; BW 197 U; BW 1970; BW 197U; BW 50197; BW 50,197; 2,4-Diamino-5-(3',4'-dichlorophenyl)-6-methyl pyrimidine; Chloroaniline 1
DM5GQD7	CP	Werkheiser
DM5GQD7	DT	Small molecular drug
DM5GQD7	PC	24466
DM5GQD7	MW	269.13
DM5GQD7	FM	C11H10Cl2N4
DM5GQD7	IC	InChI=1S/C11H10Cl2N4/c1-5-9(10(14)17-11(15)16-5)6-2-3-7(12)8(13)4-6/h2-4H,1H3,(H4,14,15,16,17)
DM5GQD7	CS	CC1=C(C(=NC(=N1)N)N)C2=CC(=C(C=C2)Cl)Cl
DM5GQD7	IK	VQJHOPSWBGJHQS-UHFFFAOYSA-N
DM5GQD7	IU	5-(3,4-dichlorophenyl)-6-methylpyrimidine-2,4-diamine
DM5GQD7	CA	CAS 7761-45-7
DM5GQD7	DE	Advanced cancer

DMIXT2Y	ID	DMIXT2Y
DMIXT2Y	DN	MGAH22
DMIXT2Y	HS	Phase 2
DMIXT2Y	CP	MacroGenics
DMIXT2Y	DE	Solid tumour/cancer

DMPBTVK	ID	DMPBTVK
DMPBTVK	DN	MGB-BP-3
DMPBTVK	HS	Phase 2
DMPBTVK	SN	1000277-08-6; MGB-BP3; UNII-532PWU9738; 532PWU9738; J2.725.402K; (E)-1-methyl-4-(1-methyl-4-(4-(2-(quinolin-3-yl)vinyl)benzamido)-1H-pyrrole-2-carboxamido)-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide; 4-((4-(4-((E)-2-(3-Quinolyl)vinyl)benzoylamino)-1-methyl-1H-pyrrole-2-yl)carbonylamino)-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 4-[[4-[4-[(E)-2-(3-Quinolyl)vinyl]benzoylamino]-1-methyl-1H-pyrrole-2-yl]carbonylamino]-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; CHEMBL236345; SCHEMBL2398755; GTPL10996; HY-U00035; ZINC28864451; CS-6785; DB12892; SB19161; compound 50 [PMID: 17960927]; Q27261055; 1H-Pyrrole-2-carboxamide, 1-methyl-N-(1-methyl-5-(((2-(4-morpholinyl)ethyl)amino)carbonyl)-1H-pyrrol-3-yl)-4-((4-((1E)-2-(3-quinolinyl)ethenyl)benzoyl)amino)-
DMPBTVK	CP	MGB Biopharma
DMPBTVK	DT	Small molecular drug
DMPBTVK	PC	23730143
DMPBTVK	MW	631.7
DMPBTVK	FM	C36H37N7O4
DMPBTVK	IC	InChI=1S/C36H37N7O4/c1-41-24-30(20-32(41)35(45)37-13-14-43-15-17-47-18-16-43)40-36(46)33-21-29(23-42(33)2)39-34(44)27-11-9-25(10-12-27)7-8-26-19-28-5-3-4-6-31(28)38-22-26/h3-12,19-24H,13-18H2,1-2H3,(H,37,45)(H,39,44)(H,40,46)/b8-7+
DMPBTVK	CS	CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCN3CCOCC3)C)NC(=O)C4=CC=C(C=C4)/C=C/C5=CC6=CC=CC=C6N=C5
DMPBTVK	IK	OEKXCVYZBVOWBR-BQYQJAHWSA-N
DMPBTVK	IU	1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide
DMPBTVK	CA	CAS 1000277-08-6
DMPBTVK	DE	Clostridium infection

DM726HX	ID	DM726HX
DM726HX	DN	MGCD-0103
DM726HX	HS	Phase 2
DM726HX	SN	Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
DM726HX	CP	MethylGene Inc
DM726HX	TC	Anticancer Agents
DM726HX	DT	Small molecular drug
DM726HX	PC	9865515
DM726HX	MW	396.4
DM726HX	FM	C23H20N6O
DM726HX	IC	InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
DM726HX	CS	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4
DM726HX	IK	HRNLUBSXIHFDHP-UHFFFAOYSA-N
DM726HX	IU	N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide
DM726HX	CA	CAS 726169-73-9
DM726HX	CB	CHEBI:94525
DM726HX	DE	Solid tumour/cancer; Diffuse large B-cell lymphoma; Melanoma; Non-small-cell lung cancer

DMRPCF2	ID	DMRPCF2
DMRPCF2	DN	MGCD265
DMRPCF2	HS	Phase 2
DMRPCF2	SN	MGCD-265; 875337-44-3; MGCD265; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide
DMRPCF2	CP	MethylGene
DMRPCF2	DT	Small molecular drug
DMRPCF2	PC	24901704
DMRPCF2	MW	517.6
DMRPCF2	FM	C26H20FN5O2S2
DMRPCF2	IC	InChI=1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35)
DMRPCF2	CS	CN1C=C(N=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=CC=C5)F
DMRPCF2	IK	UFICVEHDQUKCEA-UHFFFAOYSA-N
DMRPCF2	IU	N-[[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide
DMRPCF2	CA	CAS 875337-44-3
DMRPCF2	CB	CHEBI:91393
DMRPCF2	DE	Non-small-cell lung cancer; Solid tumour/cancer

DMRSK2I	ID	DMRSK2I
DMRSK2I	DN	MGCD290
DMRSK2I	HS	Phase 2
DMRSK2I	CP	Mirati Therapeutics
DMRSK2I	DT	Small molecular drug
DMRSK2I	DE	Vulvovaginal Candidiasis

DMNYPW7	ID	DMNYPW7
DMNYPW7	DN	MGI-114
DMNYPW7	HS	Phase 2
DMNYPW7	SN	Irofulven; Irofulven [USAN:INN]; MGI 114; MGI-114; (R)-6'-Hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'-(5H)inden)-7'(6'H)-one; (R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-inden]-7'(6'H)-one; 158440-71-2; 6-(Hydroxymethyl)acylfulvene; 6-Hydroxymethylacylfulvene; 6B799IH05A; Acylfulvene, 6-(hydroxymethyl)-; HMAF; NSC 683863; NSC-683863; Spiro(cyclopropane-1,5'(5H)-inden)-7'(6'H)-one, 6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-, (R)-; UNII-6B799IH05A
DMNYPW7	PC	148189
DMNYPW7	MW	246.3
DMNYPW7	FM	C15H18O3
DMNYPW7	IC	NICJCIQSJJKZAH-AWEZNQCLSA-N
DMNYPW7	CS	CC1=C(C2=C(C3(CC3)C(C(=O)C2=C1)(C)O)C)CO
DMNYPW7	IK	1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1
DMNYPW7	IU	(5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one
DMNYPW7	CA	CAS 158440-71-2
DMNYPW7	CB	CHEBI:135002
DMNYPW7	DE	Lung cancer

DM1HC9R	ID	DM1HC9R
DM1HC9R	DN	MGL-3196
DM1HC9R	HS	Phase 2
DM1HC9R	CP	Madrigal pharmaceuticals
DM1HC9R	PC	15981237
DM1HC9R	MW	435.2
DM1HC9R	FM	C17H12Cl2N6O4
DM1HC9R	IC	InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)
DM1HC9R	CS	CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl
DM1HC9R	IK	FDBYIYFVSAHJLY-UHFFFAOYSA-N
DM1HC9R	IU	2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile
DM1HC9R	CA	CAS 920509-32-6
DM1HC9R	DE	Hyperlipidaemia; Familial hypercholesterolemia; Hypercholesterolaemia

DME5CSV	ID	DME5CSV
DME5CSV	DN	Mibampator
DME5CSV	HS	Phase 2
DME5CSV	SN	LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly
DME5CSV	CP	Eli Lilly & Co
DME5CSV	DT	Small molecular drug
DME5CSV	PC	9889366
DME5CSV	MW	438.6
DME5CSV	FM	C21H30N2O4S2
DME5CSV	IC	InChI=1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3/t17-/m0/s1
DME5CSV	CS	C[C@@H](CNS(=O)(=O)C(C)C)C1=CC=C(C=C1)C2=CC=C(C=C2)CCNS(=O)(=O)C
DME5CSV	IK	ULRDYYKSPCRXAJ-KRWDZBQOSA-N
DME5CSV	IU	N-[(2R)-2-[4-[4-[2-(methanesulfonamido)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide
DME5CSV	CA	CAS 375345-95-2
DME5CSV	DE	Alzheimer disease

DMGCRKY	ID	DMGCRKY
DMGCRKY	DN	Midismase
DMGCRKY	HS	Phase 2
DMGCRKY	SN	PC-01; SI-3501; PC-SOD (intravenous), LTT; Lecithin-bound superoxide dismutase (ulcerative colitis), LTT Bio-Pharma
DMGCRKY	CP	Asahi Glass Co Ltd
DMGCRKY	DE	Cerebral infarction

DMN45RI	ID	DMN45RI
DMN45RI	DN	MIJ821
DMN45RI	HS	Phase 2
DMN45RI	SN	CAD 9271
DMN45RI	CP	Novartis; Cadent Therapeutics
DMN45RI	DE	Major depressive disorder

DM50Z4U	ID	DM50Z4U
DM50Z4U	DN	Milataxel
DM50Z4U	HS	Phase 2
DM50Z4U	SN	M-10; MAC-321; Milataxel (oral); TL-00139; TL-139; Milataxel (oral), Taxolog; MAC-321 (injectable), Taxolog/Wyeth; MAC-321 (oral), Taxolog/Wyeth; TL-00139 (injectable), Taxolog/Wyeth; TL-00139 (oral), Taxolog/Wyeth; TL-139 (injectable), Taxolog/Wyeth; TL-139 (oral), Taxolog/Wyeth
DM50Z4U	CP	Taxolog Inc
DM50Z4U	DT	Small molecular drug
DM50Z4U	PC	6918589
DM50Z4U	MW	853.9
DM50Z4U	FM	C44H55NO16
DM50Z4U	IC	InChI=1S/C44H55NO16/c1-10-29(47)58-27-19-28-43(21-56-28,60-23(3)46)34-36(59-37(51)24-15-12-11-13-16-24)44(54)20-26(22(2)30(41(44,7)8)32(48)35(50)42(27,34)9)57-38(52)33(49)31(25-17-14-18-55-25)45-39(53)61-40(4,5)6/h11-18,26-28,31-34,36,48-49,54H,10,19-21H2,1-9H3,(H,45,53)/t26-,27-,28+,31-,32+,33+,34-,36-,42+,43-,44+/m0/s1
DM50Z4U	CS	CCC(=O)O[C@H]1C[C@@H]2[C@@](CO2)([C@@H]3[C@@]1(C(=O)[C@@H](C4=C([C@H](C[C@@]([C@H]3OC(=O)C5=CC=CC=C5)(C4(C)C)O)OC(=O)[C@@H]([C@H](C6=CC=CO6)NC(=O)OC(C)(C)C)O)C)O)C)OC(=O)C
DM50Z4U	IK	XIVMHSNIQAICTR-UQYHODNASA-N
DM50Z4U	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-15-[(2R,3R)-3-(furan-2-yl)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]oxy-1,12-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-propanoyloxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DM50Z4U	CA	CAS 352425-37-7
DM50Z4U	DE	Solid tumour/cancer

DMSLIW6	ID	DMSLIW6
DMSLIW6	DN	MIN-117
DMSLIW6	HS	Phase 2
DMSLIW6	CP	Minerva neurosciences
DMSLIW6	PC	74424169
DMSLIW6	MW	538.8
DMSLIW6	FM	C25H26Cl3N3O4
DMSLIW6	IC	InChI=1S/C25H25Cl2N3O4.ClH/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17;/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3;1H
DMSLIW6	CS	CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OCC(CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O.Cl
DMSLIW6	IK	HRNDUKHBCUTNAL-UHFFFAOYSA-N
DMSLIW6	IU	1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-benzofuran-4-yl]oxy]propan-2-ol;hydrochloride
DMSLIW6	DE	Major depressive disorder

DMZFW8V	ID	DMZFW8V
DMZFW8V	DN	MIN-202
DMZFW8V	HS	Phase 2
DMZFW8V	SN	Seltorexant; 1293281-49-8; Seltorexant [USAN]; SCHEMBL1671257; GTPL9308; CHEMBL3597971; JNJ-922; SQOCEMCKYDVLMM-UHFFFAOYSA-N; BDBM118454; Methanone, (5-(4,6-dimethyl-2-pyrimidinyl)hexahydropyrrolo(3,4-C)pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)-; AKOS032954213; US8653263, 107; [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone; ((3aR,6aS)-5-(4,6-dimethylpyrimidin- 2-yl)hexahydropyrrolo(3,4-c)pyrrol-2(1H)-yl)(2
DMZFW8V	CP	Minerva Neurosciences Waltham, MA
DMZFW8V	PC	67116280
DMZFW8V	MW	407.4
DMZFW8V	FM	C21H22FN7O
DMZFW8V	IC	InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3
DMZFW8V	CS	CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C
DMZFW8V	IK	SQOCEMCKYDVLMM-UHFFFAOYSA-N
DMZFW8V	IU	[2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone
DMZFW8V	CA	CAS 1293281-49-8
DMZFW8V	DE	Major depressive disorder

DMWJMFZ	ID	DMWJMFZ
DMWJMFZ	DN	Miravirsen
DMWJMFZ	HS	Phase 2
DMWJMFZ	SN	Miravirsen; Miravirsen [INN]; SPC3649 Parent Acid; UNII-Q083AJW7VS; Q083AJW7VS; 1072874-90-8; RNA, (P-thio)((2'-O,4'-C-methylene)m5C-dC-(2'-O,4'-C-methylene)A-dT-dT-(2'-O,4'-C-methylene)G-(2'-O,4'-C-methylene)m5U-dC-dA-(2'-O,4'-C-methylene)m5C-dA-(2'-O,4'-C-methylene)m5C-dT-(2'-O,4'-C-methylene)m5C-(2'-O,4'-C-methylene)m5C)
DMWJMFZ	CP	Santaris Pharma A/S
DMWJMFZ	DT	Small molecular drug
DMWJMFZ	PC	56843415
DMWJMFZ	MW	4897
DMWJMFZ	FM	C151H185N49O83P14S14
DMWJMFZ	IC	InChI=1S/C151H185N49O83P14S14/c1-60-26-193(140(215)182-119(60)203)87-21-66(74(258-87)34-245-290(225,304)281-110-102-130(199-58-171-94-114(161)165-55-168-117(94)199)268-150(110,44-239-102)50-252-291(226,305)272-65-20-86(187-13-6-79(153)174-134(187)209)256-72(65)33-243-286(221,300)277-105-97-125(262-144(105,37-201)38-234-97)189-15-8-81(155)176-136(189)211)271-285(220,299)241-30-73-67(22-88(257-73)194-27-61(2)120(204)183-141(194)216)273-293(228,307)253-51-151-45-240-103(131(269-151)200-59-172-95-118(200)180-132(162)181-123(95)207)111(151)283-297(232,311)254-52-149-43-238-101(129(267-149)196-29-63(4)122(206)185-143(196)218)109(149)280-289(224,303)244-32-71-64(19-85(255-71)186-12-5-78(152)173-133(186)208)270-284(219,298)242-31-76-69(24-90(260-76)197-56-169-92-112(159)163-53-166-115(92)197)275-294(229,308)249-47-147-41-236-99(127(265-147)191-17-10-83(157)178-138(191)213)107(147)279-288(223,302)247-36-77-70(25-91(261-77)198-57-170-93-113(160)164-54-167-116(93)198)276-295(230,309)250-48-146-40-235-98(126(264-146)190-16-9-82(156)177-137(190)212)106(146)278-287(222,301)246-35-75-68(23-89(259-75)195-28-62(3)121(205)184-142(195)217)274-292(227,306)251-49-148-42-237-100(128(266-148)192-18-11-84(158)179-139(192)214)108(148)282-296(231,310)248-46-145-39-233-96(104(145)202)124(263-145)188-14-7-80(154)175-135(188)210/h5-18,26-29,53-59,64-77,85-91,96-111,124-131,201-202H,19-25,30-52H2,1-4H3,(H,219,298)(H,220,299)(H,221,300)(H,222,301)(H,223,302)(H,224,303)(H,225,304)(H,226,305)(H,227,306)(H,228,307)(H,229,308)(H,230,309)(H,231,310)(H,232,311)(H2,152,173,208)(H2,153,174,209)(H2,154,175,210)(H2,155,176,211)(H2,156,177,212)(H2,157,178,213)(H2,158,179,214)(H2,159,163,166)(H2,160,164,167)(H2,161,165,168)(H,182,203,215)(H,183,204,216)(H,184,205,217)(H,185,206,218)(H3,162,180,181,207)
DMWJMFZ	CS	CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3C4C(OC3(CO4)COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6C7C(OC6(CO7)CO)N8C=CC(=NC8=O)N)N9C=CC(=NC9=O)N)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC12COC(C1OP(=S)(O)OCC13COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC4=C(N=CN=C41)N)OP(=S)(O)OCC14COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=NC5=C(N=CN=C51)N)OP(=S)(O)OCC15COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC16COC(C1OP(=S)(O)OCC17COC(C1O)C(O7)N1C=CC(=NC1=O)N)C(O6)N1C=CC(=NC1=O)N)C(O5)N1C=CC(=NC1=O)N)C(O4)N1C=CC(=NC1=O)N)C(O3)N1C=C(C(=O)NC1=O)C)C(O2)N1C=NC2=C1N=C(NC2=O)N
DMWJMFZ	IK	OSOOBMBDIGGTCP-UHFFFAOYSA-N
DMWJMFZ	IU	1-[4-[[3-[[3-(2-amino-6-oxo-1H-purin-9-yl)-7-[[7-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-3-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[1-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[3-(4-amino-2-oxopyrimidin-1-yl)-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-3-(6-aminopurin-9-yl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMWJMFZ	CA	CAS 1072874-90-8
DMWJMFZ	DE	Hepatitis C virus infection

DM7K4YR	ID	DM7K4YR
DM7K4YR	DN	MIS-416
DM7K4YR	HS	Phase 2
DM7K4YR	SN	Microparticle adjuvant (anthrax), Virionyx; Microparticle adjuvant (iv, autoimmune disease/cancer/anthrax), Innate Therapeutics
DM7K4YR	CP	Innate Therapeutics Ltd
DM7K4YR	DE	Bacillus anthracis infection; Autoimmune diabetes

DMOJ7QA	ID	DMOJ7QA
DMOJ7QA	DN	Mitemcinal fumarate
DMOJ7QA	HS	Phase 2
DMOJ7QA	SN	(2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione
DMOJ7QA	CP	Roche
DMOJ7QA	DT	Small molecular drug
DMOJ7QA	PC	11513721
DMOJ7QA	MW	1628
DMOJ7QA	FM	C84H142N2O28
DMOJ7QA	IC	InChI=1S/2C40H69NO12.C4H4O4/c2*1-16-28-40(12,47-15)33(43)23(6)31-21(4)18-39(11,53-31)35(52-37-30(42)27(17-22(5)48-37)41(13)20(2)3)24(7)32(25(8)36(45)50-28)51-29-19-38(10,46-14)34(44)26(9)49-29;5-3(6)1-2-4(7)8/h2*20,22-30,32,34-35,37,42,44H,16-19H2,1-15H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*22-,23+,24+,25-,26+,27+,28-,29+,30-,32+,34+,35-,37+,38-,39-,40-;/m11./s1
DMOJ7QA	CS	CC[C@@H]1[C@@](C(=O)[C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C(C)C)O)C)C)C)(C)OC.CC[C@@H]1[C@@](C(=O)[C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C(C)C)O)C)C)C)(C)OC.C(=C/C(=O)O)\\C(=O)O
DMOJ7QA	IK	KQRXEQGYUDDPNW-QXRSSOOUSA-N
DMOJ7QA	IU	(E)-but-2-enedioic acid;(2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione
DMOJ7QA	CA	CAS 154802-96-7
DMOJ7QA	DE	Pain

DMIRPSA	ID	DMIRPSA
DMIRPSA	DN	Mitoglitazone
DMIRPSA	HS	Phase 2
DMIRPSA	SN	MSDC-0160; Mitoglitazone (TN)
DMIRPSA	CP	Metabolic Solutions Development
DMIRPSA	DT	Small molecular drug
DMIRPSA	PC	10429242
DMIRPSA	MW	370.4
DMIRPSA	FM	C19H18N2O4S
DMIRPSA	IC	InChI=1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24)
DMIRPSA	CS	CCC1=CN=C(C=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMIRPSA	IK	IRNJSRAGRIZIHD-UHFFFAOYSA-N
DMIRPSA	IU	5-[[4-[2-(5-ethylpyridin-2-yl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMIRPSA	CA	CAS 146062-49-9
DMIRPSA	CB	CHEBI:94409
DMIRPSA	DE	Type-2 diabetes; Alzheimer disease

DMKPZ0Q	ID	DMKPZ0Q
DMKPZ0Q	DN	Mitoquinone
DMKPZ0Q	HS	Phase 2
DMKPZ0Q	SN	mitoquinone; Mitoquinone cation; 444890-41-9; UNII-47BYS17IY0; 47BYS17IY0; MitoQ; 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium; Mito-Q; Mitoquinone ion; MitoQ; MitoQ10; CHEMBL1229093; SCHEMBL12135674; EX-A926; BCP19134; HY-100116; CS-0018095; A17092; Q27259044; (10-(2,5-Dihydroxy-3,4-dimethoxy-6-methylphenyl)decyl)triphenyl phosphonium
DMKPZ0Q	DT	Small molecular drug
DMKPZ0Q	PC	11388332
DMKPZ0Q	MW	583.7
DMKPZ0Q	FM	C37H44O4P+
DMKPZ0Q	IC	InChI=1S/C37H44O4P/c1-29-33(35(39)37(41-3)36(40-2)34(29)38)27-19-8-6-4-5-7-9-20-28-42(30-21-13-10-14-22-30,31-23-15-11-16-24-31)32-25-17-12-18-26-32/h10-18,21-26H,4-9,19-20,27-28H2,1-3H3/q+1
DMKPZ0Q	CS	CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMKPZ0Q	IK	OIIMUKXVVLRCAF-UHFFFAOYSA-N
DMKPZ0Q	IU	10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium
DMKPZ0Q	CA	CAS 444890-41-9
DMKPZ0Q	DE	Hepatitis C virus infection

DM2NF6X	ID	DM2NF6X
DM2NF6X	DN	MIV-210
DM2NF6X	HS	Phase 2
DM2NF6X	CP	Medivir; Daewoong
DM2NF6X	DT	Small molecular drug
DM2NF6X	PC	135431817
DM2NF6X	MW	269.23
DM2NF6X	FM	C10H12FN5O3
DM2NF6X	IC	InChI=1S/C10H12FN5O3/c11-4-1-6(19-5(4)2-17)16-3-13-7-8(16)14-10(12)15-9(7)18/h3-6,17H,1-2H2,(H3,12,14,15,18)/t4-,5+,6+/m0/s1
DM2NF6X	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)CO)F
DM2NF6X	IK	RTJUXLYUUDBAJN-KVQBGUIXSA-N
DM2NF6X	IU	2-amino-9-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DM2NF6X	CA	CAS 92562-88-4
DM2NF6X	DE	Hepatitis B virus infection

DMWFTRJ	ID	DMWFTRJ
DMWFTRJ	DN	MK-0354
DMWFTRJ	HS	Phase 2
DMWFTRJ	SN	MK-0354; 851776-28-8; UNII-4U62D8JYIQ; 4U62D8JYIQ; CHEMBL456145; 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole; 1,4,5,6-Tetrahydro-3-(1H-tetrazol-5-yl)cyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; LTQYSJKGRPGMPO-UHFFFAOYSA-N; SCHEMBL1875705; GTPL5784; MolPort-009-683-033; 1,4,5,6-tetrahydro-3-(2H-tetrazol-5-yl)Cyclopentapyrazole; BCP18112; ZINC38312374; BDBM50273099; AKOS030526928; MK 0354; CS-4589
DMWFTRJ	DT	Small molecular drug
DMWFTRJ	PC	11159621
DMWFTRJ	MW	176.18
DMWFTRJ	FM	C7H8N6
DMWFTRJ	IC	InChI=1S/C7H8N6/c1-2-4-5(3-1)8-9-6(4)7-10-12-13-11-7/h1-3H2,(H,8,9)(H,10,11,12,13)
DMWFTRJ	CS	C1CC2=C(C1)NN=C2C3=NNN=N3
DMWFTRJ	IK	LTQYSJKGRPGMPO-UHFFFAOYSA-N
DMWFTRJ	IU	3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole
DMWFTRJ	CA	CAS 851776-28-8

DMLTAES	ID	DMLTAES
DMLTAES	DN	MK-0752
DMLTAES	HS	Phase 2
DMLTAES	SN	MK-0752; 471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635
DMLTAES	CP	Merck
DMLTAES	DT	Small molecular drug
DMLTAES	PC	9803433
DMLTAES	MW	442.9
DMLTAES	FM	C21H21ClF2O4S
DMLTAES	IC	InChI=1S/C21H21ClF2O4S/c22-15-2-5-17(6-3-15)29(27,28)21(18-13-16(23)4-7-19(18)24)11-9-14(10-12-21)1-8-20(25)26/h2-7,13-14H,1,8-12H2,(H,25,26)
DMLTAES	CS	C1CC(CCC1CCC(=O)O)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl
DMLTAES	IK	XCGJIFAKUZNNOR-UHFFFAOYSA-N
DMLTAES	IU	3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid
DMLTAES	CA	CAS 471905-41-6
DMLTAES	DE	Alzheimer disease

DM2CJB4	ID	DM2CJB4
DM2CJB4	DN	MK-0773
DM2CJB4	HS	Phase 2
DM2CJB4	SN	C-8500; MK-773
DM2CJB4	CP	Merck & Co Inc
DM2CJB4	DT	Small molecular drug
DM2CJB4	PC	11950726
DM2CJB4	MW	479.6
DM2CJB4	FM	C27H34FN5O2
DM2CJB4	IC	InChI=1S/C27H34FN5O2/c1-26-11-10-17-15(6-9-21-27(17,2)13-19(28)25(35)33(21)3)16(26)7-8-18(26)24(34)30-14-22-31-20-5-4-12-29-23(20)32-22/h4-5,12-13,15-18,21H,6-11,14H2,1-3H3,(H,30,34)(H,29,31,32)/t15-,16-,17-,18+,21+,26-,27+/m0/s1
DM2CJB4	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NCC4=NC5=C(N4)C=CC=N5)CC[C@@H]6[C@@]3(C=C(C(=O)N6C)F)C
DM2CJB4	IK	GBEUKTWTUSPHEE-JWJWXJQQSA-N
DM2CJB4	IU	(1S,3aS,3bS,5aR,9aS,9bS,11aS)-8-fluoro-N-(1H-imidazo[4,5-b]pyridin-2-ylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,9b,10,11-decahydro-1H-indeno[5,4-f]quinoline-1-carboxamide
DM2CJB4	CA	CAS 606101-58-0
DM2CJB4	DE	Osteoporosis

DMRT8K4	ID	DMRT8K4
DMRT8K4	DN	MK-0812
DMRT8K4	HS	Phase 2
DMRT8K4	SN	C-6448; MK-812; CCR2 antagonist (rheumatoid arthritis/multiple sclerosis), Merck
DMRT8K4	CP	Merck & Co Inc
DMRT8K4	DT	Small molecular drug
DMRT8K4	PC	11180808
DMRT8K4	MW	469.5
DMRT8K4	FM	C24H34F3N3O3
DMRT8K4	IC	InChI=1S/C24H34F3N3O3/c1-15(2)23(7-4-18(11-23)29-20-6-9-33-14-21(20)32-3)22(31)30-8-5-19-16(13-30)10-17(12-28-19)24(25,26)27/h10,12,15,18,20-21,29H,4-9,11,13-14H2,1-3H3/t18-,20+,21-,23+/m1/s1
DMRT8K4	CS	CC(C)[C@@]1(CC[C@H](C1)N[C@H]2CCOC[C@H]2OC)C(=O)N3CCC4=C(C3)C=C(C=N4)C(F)(F)F
DMRT8K4	IK	MTMDXAIUENDNDL-RJSMDTJLSA-N
DMRT8K4	IU	[(1S,3R)-3-[[(3S,4S)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[3-(trifluoromethyl)-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone
DMRT8K4	CA	CAS 624733-88-6
DMRT8K4	DE	Multiple sclerosis

DM0568C	ID	DM0568C
DM0568C	DN	MK-0873
DM0568C	HS	Phase 2
DM0568C	SN	MK-0873 (dermatological, psoriasis); MK-0873 (dermatological, psoriasis), Merck & Co
DM0568C	CP	Merck & Co Inc
DM0568C	DT	Small molecular drug
DM0568C	PC	9919680
DM0568C	MW	422.4
DM0568C	FM	C25H18N4O3
DM0568C	IC	InChI=1S/C25H18N4O3/c30-23-21-7-2-12-26-24(21)29(16-22(23)25(31)27-19-10-11-19)20-6-1-4-17(14-20)8-9-18-5-3-13-28(32)15-18/h1-7,12-16,19H,10-11H2,(H,27,31)
DM0568C	CS	C1CC1NC(=O)C2=CN(C3=C(C2=O)C=CC=N3)C4=CC=CC(=C4)C#CC5=C[N+](=CC=C5)[O-]
DM0568C	IK	JJWKQXNHYDJXKF-UHFFFAOYSA-N
DM0568C	IU	N-cyclopropyl-1-[3-[2-(1-oxidopyridin-1-ium-3-yl)ethynyl]phenyl]-4-oxo-1,8-naphthyridine-3-carboxamide
DM0568C	CA	CAS 500355-52-2
DM0568C	DE	Psoriasis vulgaris

DM8ZTW7	ID	DM8ZTW7
DM8ZTW7	DN	MK-1029
DM8ZTW7	HS	Phase 2
DM8ZTW7	DE	Asthma

DMEDITW	ID	DMEDITW
DMEDITW	DN	MK-1454
DMEDITW	HS	Phase 2
DMEDITW	CP	Merck
DMEDITW	DE	Lymphoma; Solid tumour/cancer; Squamous head and neck cell carcinom

DM3WDZ5	ID	DM3WDZ5
DM3WDZ5	DN	MK-1775
DM3WDZ5	HS	Phase 2
DM3WDZ5	SN	MK-1775; 955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219
DM3WDZ5	CP	Merck
DM3WDZ5	DT	Small molecular drug
DM3WDZ5	PC	24856436
DM3WDZ5	MW	500.6
DM3WDZ5	FM	C27H32N8O2
DM3WDZ5	IC	InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)
DM3WDZ5	CS	CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O
DM3WDZ5	IK	BKWJAKQVGHWELA-UHFFFAOYSA-N
DM3WDZ5	IU	1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one
DM3WDZ5	CA	CAS 955365-80-7
DM3WDZ5	CB	CHEBI:91414
DM3WDZ5	DE	Ovarian cancer; Solid tumour/cancer

DMVJB09	ID	DMVJB09
DMVJB09	DN	MK-1903
DMVJB09	HS	Phase 2
DMVJB09	SN	Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co
DMVJB09	CP	Arena Pharmaceuticals Inc
DMVJB09	DT	Small molecular drug
DMVJB09	PC	49763030
DMVJB09	MW	164.16
DMVJB09	FM	C8H8N2O2
DMVJB09	IC	InChI=1S/C8H8N2O2/c11-8(12)7-5-2-3-1-4(3)6(5)9-10-7/h3-4H,1-2H2,(H,9,10)(H,11,12)/t3-,4-/m1/s1
DMVJB09	CS	C1[C@H]2[C@@H]1C3=C(C2)C(=NN3)C(=O)O
DMVJB09	IK	CUTZNERBKDMLAP-QWWZWVQMSA-N
DMVJB09	IU	(2R,4R)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxylic acid
DMVJB09	CA	CAS 1268882-43-4
DMVJB09	DE	Arteriosclerosis

DMT1OZ6	ID	DMT1OZ6
DMT1OZ6	DN	MK-2206
DMT1OZ6	HS	Phase 2
DMT1OZ6	SN	MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;
DMT1OZ6	CP	Merck
DMT1OZ6	DT	Small molecular drug
DMT1OZ6	PC	24964624
DMT1OZ6	MW	407.5
DMT1OZ6	FM	C25H21N5O
DMT1OZ6	IC	InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)
DMT1OZ6	CS	C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N
DMT1OZ6	IK	ULDXWLCXEDXJGE-UHFFFAOYSA-N
DMT1OZ6	IU	8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one
DMT1OZ6	CA	CAS 1032349-93-1
DMT1OZ6	CB	CHEBI:67271
DMT1OZ6	DE	Rectal adenocarcinoma; Nasopharyngeal carcinoma

DM1M57I	ID	DM1M57I
DM1M57I	DN	MK-2578
DM1M57I	HS	Phase 2
DM1M57I	CP	Merck Bioventures
DM1M57I	DE	Anemia

DM6OLGC	ID	DM6OLGC
DM6OLGC	DN	MK-3207
DM6OLGC	HS	Phase 2
DM6OLGC	SN	957116-20-0; MK-3207 Hydrochloride; MK-3207 (Hydrochloride); MK-3207 HCl; MK-3207 HCl salt; 2-((R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl)-N-((R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-Pyrrolo[2,3-b]pyridin]-5-yl)acetamide hydrochloride; MK3207; (8R)-8-(3,5-Difluorophenyl)-10-oxo-n-[(2r)-1,1',2',3-tetrahydro-2'-oxospiro[2h-indene-2,3'-[3h]pyrrolo[2,3-b]pyridin]-5-yl]-6,9-diazaspiro[4.5]decane-9-acetamide hydrochloride; MK 3207 hydrochloride; MK-3207(Hydrochloride); MK3207 HCl
DM6OLGC	CP	Merck & Co Inc
DM6OLGC	DT	Small molecular drug
DM6OLGC	PC	25019940
DM6OLGC	MW	557.6
DM6OLGC	FM	C31H29F2N5O3
DM6OLGC	IC	InChI=1S/C31H29F2N5O3/c32-21-10-19(11-22(33)13-21)25-16-35-31(7-1-2-8-31)29(41)38(25)17-26(39)36-23-6-5-18-14-30(15-20(18)12-23)24-4-3-9-34-27(24)37-28(30)40/h3-6,9-13,25,35H,1-2,7-8,14-17H2,(H,36,39)(H,34,37,40)/t25-,30+/m0/s1
DM6OLGC	CS	C1CCC2(C1)C(=O)N([C@@H](CN2)C3=CC(=CC(=C3)F)F)CC(=O)NC4=CC5=C(C[C@@]6(C5)C7=C(NC6=O)N=CC=C7)C=C4
DM6OLGC	IK	AZAANWYREOQRFB-SETSBSEESA-N
DM6OLGC	IU	2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide
DM6OLGC	CA	CAS 957118-49-9
DM6OLGC	DE	Migraine

DM347TQ	ID	DM347TQ
DM347TQ	DN	MK-3697
DM347TQ	HS	Phase 2
DM347TQ	CP	Merck
DM347TQ	PC	46190695
DM347TQ	MW	447.5
DM347TQ	FM	C23H21N5O3S
DM347TQ	IC	InChI=1S/C23H21N5O3S/c1-14-8-15(11-24-10-14)19-9-17(18(13-26-19)23-25-6-7-32-23)21(29)27-12-16-4-5-20(30-2)22(28-16)31-3/h4-11,13H,12H2,1-3H3,(H,27,29)
DM347TQ	CS	CC1=CC(=CN=C1)C2=NC=C(C(=C2)C(=O)NCC3=NC(=C(C=C3)OC)OC)C4=NC=CS4
DM347TQ	IK	VSOUDUXMPUHJEU-UHFFFAOYSA-N
DM347TQ	IU	N-[(5,6-dimethoxypyridin-2-yl)methyl]-2-(5-methylpyridin-3-yl)-5-(1,3-thiazol-2-yl)pyridine-4-carboxamide
DM347TQ	CA	CAS 1224846-01-8
DM347TQ	DE	Insomnia

DMSPWX6	ID	DMSPWX6
DMSPWX6	DN	MK-5172
DMSPWX6	HS	Phase 2
DMSPWX6	SN	UNII-RU4QU6O6X6; 1206524-85-7; RU4QU6O6X6; (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid; 8H-7,10-Methanocyclopropa(18,19)(1,10,3,6)dioxadiazacyclononadecino(11,12-b)quinoxaline-8-carboxylic acid, 5-(1,1-dimethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-methoxy-3,6-dioxo-, (1aR,5S,8S,10R,22aR)-
DMSPWX6	CP	Merck
DMSPWX6	DT	Small molecular drug
DMSPWX6	PC	46930991
DMSPWX6	MW	554.6
DMSPWX6	FM	C29H38N4O7
DMSPWX6	IC	InChI=1S/C29H38N4O7/c1-29(2,3)24-26(34)33-15-18(14-22(33)27(35)36)39-25-20(30-19-11-10-17(38-4)13-21(19)31-25)9-7-5-6-8-16-12-23(16)40-28(37)32-24/h10-11,13,16,18,22-24H,5-9,12,14-15H2,1-4H3,(H,32,37)(H,35,36)/t16-,18-,22+,23-,24-/m1/s1
DMSPWX6	CS	CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)O)OC3=NC4=C(C=CC(=C4)OC)N=C3CCCCC[C@@H]5C[C@H]5OC(=O)N1
DMSPWX6	IK	IVROMYPOGKZNLP-FDOFPDFBSA-N
DMSPWX6	IU	(1R,18R,20R,24S,27S)-24-tert-butyl-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxylic acid
DMSPWX6	CA	CAS 1206524-85-7
DMSPWX6	DE	Hepatitis C virus infection

DMHTIGU	ID	DMHTIGU
DMHTIGU	DN	MK-5442
DMHTIGU	HS	Phase 2
DMHTIGU	CP	Merck
DMHTIGU	PC	46917559
DMHTIGU	MW	514
DMHTIGU	FM	C29H33ClFNO4
DMHTIGU	IC	InChI=1S/C29H33ClFNO4/c1-18-13-21(10-11-23(18)28(34)35)25-8-6-5-7-24(25)19(2)36-17-22(33)16-32-29(3,4)15-20-9-12-26(30)27(31)14-20/h5-14,19,22,32-33H,15-17H2,1-4H3,(H,34,35)/t19-,22-/m1/s1
DMHTIGU	CS	CC1=C(C=CC(=C1)C2=CC=CC=C2[C@@H](C)OC[C@@H](CNC(C)(C)CC3=CC(=C(C=C3)Cl)F)O)C(=O)O
DMHTIGU	IK	UNFHDRVFEQPUEL-DENIHFKCSA-N
DMHTIGU	IU	4-[2-[(1R)-1-[(2R)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid
DMHTIGU	CA	CAS 787583-71-5
DMHTIGU	DE	Osteoporosis

DMLMV0O	ID	DMLMV0O
DMLMV0O	DN	MK-7655
DMLMV0O	HS	Phase 2
DMLMV0O	SN	Relebactam; 1174018-99-5; Relebactam anhydrous; MK-7655; UNII-1OQF7TT3PF; 1OQF7TT3PF; CHEMBL3112741; Sulfuric acid, mono[(1R,2S,5R)-7-oxo-2-[(4-piperidinylamino)carbonyl]-1,6-diazabicyclo[3.2.1]oct-6-yl] ester; Relebactam [INN]; MK7655; MK 7655; (-)-Relebactam anhydrous; BDBM1858; SCHEMBL3721178; EX-A864; SMOBCLHAZXOKDQ-ZJUUUORDSA-N; MolPort-044-723-879; MK-7655A; ZINC43206319; BDBM50447651; AKOS027338697; SB16968; DB12377; CS-5391; Sulfuric acid mono-((2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo(3.2.1)oct-6-yl) est
DMLMV0O	CP	Merck
DMLMV0O	DT	Small molecular drug
DMLMV0O	PC	44129647
DMLMV0O	MW	348.38
DMLMV0O	FM	C12H20N4O6S
DMLMV0O	IC	InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1
DMLMV0O	CS	C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
DMLMV0O	IK	SMOBCLHAZXOKDQ-ZJUUUORDSA-N
DMLMV0O	IU	[(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
DMLMV0O	CA	CAS 1174018-99-5
DMLMV0O	DE	Bacterial infection

DMG6KXB	ID	DMG6KXB
DMG6KXB	DN	MK-8245
DMG6KXB	HS	Phase 2
DMG6KXB	SN	MK-8245; 1030612-90-8; MK8245; MK 8245; UNII-537E7QE8LX; 537E7QE8LX; CHEMBL1938870; 5-[3-[4-(2-Bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-2H-tetrazole-2-acetic acid; 2H-Tetrazole-2-acetic acid, 5-[3-[4-(2-bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-;2H-Tetrazole-2-acetic acid, 5-[3-[4-(2-bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-; 2-(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid; UJEAABFSXKCSGI-UHFFFAOYSA-N; C17H16BrFN6O4; MLS006011144
DMG6KXB	DT	Small molecular drug
DMG6KXB	PC	24988881
DMG6KXB	MW	467.2
DMG6KXB	FM	C17H16BrFN6O4
DMG6KXB	IC	InChI=1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27)
DMG6KXB	CS	C1CN(CCC1OC2=C(C=CC(=C2)F)Br)C3=NOC(=C3)C4=NN(N=N4)CC(=O)O
DMG6KXB	IK	UJEAABFSXKCSGI-UHFFFAOYSA-N
DMG6KXB	IU	2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid
DMG6KXB	CA	CAS 1030612-90-8
DMG6KXB	DE	Type-2 diabetes

DMD6E5W	ID	DMD6E5W
DMD6E5W	DN	MK-8342
DMD6E5W	HS	Phase 2
DMD6E5W	CP	Merck
DMD6E5W	DE	Contraception

DMVNAYE	ID	DMVNAYE
DMVNAYE	DN	MK-8521
DMVNAYE	HS	Phase 2
DMVNAYE	CP	Merck
DMVNAYE	DE	Type-2 diabetes

DMQHS6B	ID	DMQHS6B
DMQHS6B	DN	MK-866
DMQHS6B	HS	Phase 2
DMQHS6B	TC	Anticancer Agents
DMQHS6B	DE	Discovery agent

DMXKOW6	ID	DMXKOW6
DMXKOW6	DN	MKC-1106-MT
DMXKOW6	HS	Phase 2
DMXKOW6	SN	Melanoma vaccine (MART-1/tyrosinase), Mannkind
DMXKOW6	CP	Colby pharmaceuticals
DMXKOW6	DE	Melanoma

DM3I71U	ID	DM3I71U
DM3I71U	DN	MKT-077
DM3I71U	HS	Phase 2
DM3I71U	SN	FJ-776 (formerly); SDZ-MKT-077; 1-Ethyl-2-[3-ethyl-5-(3-methyl-2,3-dihydrobenzothiazolin-2-ylidene)-4-oxothiazolidin-2-ylidenemethyl]pyridinium chloride
DM3I71U	DT	Small molecular drug
DM3I71U	PC	6444403
DM3I71U	MW	432
DM3I71U	FM	C21H22ClN3OS2
DM3I71U	IC	InChI=1S/C21H22N3OS2.ClH/c1-4-23-13-9-8-10-15(23)14-18-24(5-2)20(25)19(27-18)21-22(3)16-11-6-7-12-17(16)26-21;/h6-14H,4-5H2,1-3H3;1H/q+1;/p-1/b21-19+;
DM3I71U	CS	CCN1/C(=C/C2=CC=CC=[N+]2CC)/S/C(=C/3\\N(C4=CC=CC=C4S3)C)/C1=O.[Cl-]
DM3I71U	IK	VSKYOTRJSLYFHX-UXJRWBAGSA-M
DM3I71U	IU	(2Z,5E)-3-ethyl-2-[(1-ethylpyridin-1-ium-2-yl)methylidene]-5-(3-methyl-1,3-benzothiazol-2-ylidene)-1,3-thiazolidin-4-one;chloride
DM3I71U	CA	CAS 147366-41-4
DM3I71U	DE	Solid tumour/cancer

DMQSO4L	ID	DMQSO4L
DMQSO4L	DN	ML-04
DMQSO4L	HS	Phase 2
DMQSO4L	SN	BTL-cg; HP-4; ML-04A; Urological therapeutics, Milkhaus; Human chorionic gonadotropin (benign prostate hyperplasia/prostatitis/cancer), Beech Tree Labs
DMQSO4L	CP	Milkhaus Laboratory Inc
DMQSO4L	DE	Myelodysplastic syndrome

DMI4E9K	ID	DMI4E9K
DMI4E9K	DN	MLN0264
DMI4E9K	HS	Phase 2
DMI4E9K	CP	Millenium; The Takeda oncology company
DMI4E9K	DE	Gastrointestinal cancer

DM24SOL	ID	DM24SOL
DM24SOL	DN	MLN1202
DM24SOL	HS	Phase 2
DM24SOL	SN	UNNCHYARSNZOPF-UHFFFAOYSA-L; RFI-641; UNII-FR2W015BG1; FR2W015BG1; WAY-154641; CHEMBL425633; SCHEMBL20741446; RF-1461
DM24SOL	CP	Novartis & Millenium
DM24SOL	DT	Small molecular drug
DM24SOL	PC	16156223
DM24SOL	MW	1683.6
DM24SOL	FM	C58H60N24Na2O22S6
DM24SOL	IC	InChI=1S/C58H62N24O22S6.2Na/c59-45(83)23-79(24-46(60)84)105(91,92)37-9-1-5-31(17-37)67-53-73-54(68-32-6-2-10-38(18-32)106(93,94)80(25-47(61)85)26-48(62)86)76-57(75-53)71-35-13-15-41(43(21-35)109(99,100)101)42-16-14-36(22-44(42)110(102,103)104)72-58-77-55(69-33-7-3-11-39(19-33)107(95,96)81(27-49(63)87)28-50(64)88)74-56(78-58)70-34-8-4-12-40(20-34)108(97,98)82(29-51(65)89)30-52(66)90;;/h1-22H,23-30H2,(H2,59,83)(H2,60,84)(H2,61,85)(H2,62,86)(H2,63,87)(H2,64,88)(H2,65,89)(H2,66,90)(H,99,100,101)(H,102,103,104)(H3,67,68,71,73,75,76)(H3,69,70,72,74,77,78);;/q;2*+1/p-2
DM24SOL	CS	C1=CC(=CC(=C1)S(=O)(=O)N(CC(=O)N)CC(=O)N)NC2=NC(=NC(=N2)NC3=CC(=C(C=C3)C4=C(C=C(C=C4)NC5=NC(=NC(=N5)NC6=CC(=CC=C6)S(=O)(=O)N(CC(=O)N)CC(=O)N)NC7=CC(=CC=C7)S(=O)(=O)N(CC(=O)N)CC(=O)N)S(=O)(=O)[O-])S(=O)(=O)[O-])NC8=CC(=CC=C8)S(=O)(=O)N(CC(=O)N)CC(=O)N.[Na+].[Na+]
DM24SOL	IK	UNNCHYARSNZOPF-UHFFFAOYSA-L
DM24SOL	IU	disodium;5-[[4,6-bis[3-[bis(2-amino-2-oxoethyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-[4-[[4,6-bis[3-[bis(2-amino-2-oxoethyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]benzenesulfonate
DM24SOL	CA	CAS 197366-24-8
DM24SOL	DE	Multiple sclerosis; Metastatic cancer; Respiratory syncytial virus infection

DMBR8NF	ID	DMBR8NF
DMBR8NF	DN	MLN2480
DMBR8NF	HS	Phase 2
DMBR8NF	SN	VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819
DMBR8NF	CP	Millennium Pharmaceuticals
DMBR8NF	DT	Small molecular drug
DMBR8NF	PC	25161177
DMBR8NF	MW	506.3
DMBR8NF	FM	C17H12Cl2F3N7O2S
DMBR8NF	IC	InChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)/t6-/m1/s1
DMBR8NF	CS	C[C@H](C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl
DMBR8NF	IK	VWMJHAFYPMOMGF-ZCFIWIBFSA-N
DMBR8NF	IU	2-[(1R)-1-[(6-amino-5-chloropyrimidine-4-carbonyl)amino]ethyl]-N-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide
DMBR8NF	CA	CAS 1096708-71-2
DMBR8NF	DE	Solid tumour/cancer; Melanoma

DMJHVZC	ID	DMJHVZC
DMJHVZC	DN	MLN-591RL
DMJHVZC	HS	Phase 2
DMJHVZC	SN	HuJ591; J591; MLN-5591RL; MLN-591; ATG-J591:RC; Anti-PSMA, Millennium; Lutetium-177-J591; Yttrium-90-J591; Anti-PSMA, Millennium/BZL Biologics; Lutetium-177-MLN-591; Yttrium-90-MLN-591; 111In-J591; 177Lu-J591; 177Lu-MLN-591; 90Y-J591; 90Y-MLN-591
DMJHVZC	CP	Millennium Pharmaceuticals
DMJHVZC	DT	Antibody
DMJHVZC	DE	Prostate cancer

DMXJWNS	ID	DMXJWNS
DMXJWNS	DN	MM-093
DMXJWNS	HS	Phase 2
DMXJWNS	SN	ABI-001; Recombinant human alpha fetoprotein (autoimmune diseases), Merrimack; RhAFP (autoimmune diseases), Merrimack; Recombinant human alpha-fetoprotein (autoimmune disease), GTC Biotherapeutics
DMXJWNS	CP	Merrimack Pharmaceuticals
DMXJWNS	SQ	&gt;Q4QR90|Q4QR90_RAT Alpha-fetoprotein - Rattus norvegicus (Rat).: MKQPATMKWSASISFLLLLNFAEPRVLHTNEFGIESTLDSSQCPTEKNMFNVATIVVAQFVQDATKAEVNKMSSDALAAMKENTGDGCLENQLSVFLDEICHETELFNKYGFSGCCNQSGVERHQCLLARKKTAPDSVPPFHFPETAESCPAYEENRAMSINTFIYDVSKRNPFLYAPTILYLAAQYDKAVPACCKADNMEECFQTKRASMAKELREGSMLNEHVCAVIRKFGSRNLQAVLIIKLSQKFPKANITEIRKLALDVAHIHEQCCHGNAMECLQDGESVMTHICSQQEILSSKTAECCKLPTIELGYCIIHAENGDKPEGLTLNPSEFLGDRNFAQFSSEEKLLFMASFLHEYSRNHPNLPVSVILKTAKSYQEILEKCSQSETPSKCQDNMEEELQKHIQESQALAKQSCDLYQKLGPYYLQNLFLIGYTRKAPQLTSAELIDLTGKMVSIASMCCQLSEEKRSACGEGLADIYIGHLCLRHEANPVNSGINHCCSSSYSNRRLCITSFLRDETYVPPPFSEDKFIFHKDLCQAQGRALQTMKQELLINLVKQKPEMTEEQHAAVTADFSGLLEKCCKDQDQEACFAKEGPKLISKTREALGV
DMXJWNS	DE	Autoimmune diabetes

DMO7MBS	ID	DMO7MBS
DMO7MBS	DN	MM-111
DMO7MBS	HS	Phase 2
DMO7MBS	CP	Merrimack
DMO7MBS	DT	Monoclonal antibody
DMO7MBS	DE	Gastric adenocarcinoma; Breast cancer

DMDJRU1	ID	DMDJRU1
DMDJRU1	DN	MM-121
DMDJRU1	HS	Phase 2
DMDJRU1	SN	SAR-256212; EGFR antibodies (cancer), Merrimack; ErbB antibodies (cancer), Merrimack; MM-1x1 program (cancer), Merrimack; EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis; ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis
DMDJRU1	CP	Merrimack pharmaceuticals; sanofi us
DMDJRU1	DE	Breast cancer; Non-small-cell lung cancer

DM2RJ4D	ID	DM2RJ4D
DM2RJ4D	DN	MM-141
DM2RJ4D	HS	Phase 2
DM2RJ4D	DE	Solid tumour/cancer; Pancreatic cancer

DM6VPIO	ID	DM6VPIO
DM6VPIO	DN	MM36
DM6VPIO	HS	Phase 2
DM6VPIO	SN	CHEMBL225555
DM6VPIO	CP	Medimetriks Pharmaceuticals Fairfield, NJ
DM6VPIO	DT	Small molecular drug
DM6VPIO	PC	57855696
DM6VPIO	MW	446.4
DM6VPIO	FM	C23H24F2N2O5
DM6VPIO	IC	InChI=1S/C23H24F2N2O5/c1-4-29-18-8-6-5-7-17(18)21(28)26-12-16-13-30-22(27-16)15-9-10-19(32-23(24)25)20(11-15)31-14(2)3/h5-11,13-14,23H,4,12H2,1-3H3,(H,26,28)
DM6VPIO	CS	CCOC1=CC=CC=C1C(=O)NCC2=COC(=N2)C3=CC(=C(C=C3)OC(F)F)OC(C)C
DM6VPIO	IK	VFBILHPIHUPBPZ-UHFFFAOYSA-N
DM6VPIO	IU	N-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide
DM6VPIO	CA	CAS 937782-05-3
DM6VPIO	DE	Atopic dermatitis

DMBX2RE	ID	DMBX2RE
DMBX2RE	DN	MN-221
DMBX2RE	HS	Phase 2
DMBX2RE	SN	Bedoradrine
DMBX2RE	CP	MediciNova
DMBX2RE	DT	Small molecular drug
DMBX2RE	PC	9963056
DMBX2RE	MW	955.1
DMBX2RE	FM	C48H66N4O14S
DMBX2RE	IC	InChI=1S/2C24H32N2O5.H2O4S/c2*1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27;1-5(2,3)4/h2*4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3;(H2,1,2,3,4)/t2*20-,23-;/m00./s1
DMBX2RE	CS	CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=C(C=C3)O)CCO)O)C=C1.CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=C(C=C3)O)CCO)O)C=C1.OS(=O)(=O)O
DMBX2RE	IK	VPCOODFYDJWLHD-YMZXMBPUSA-N
DMBX2RE	IU	2-[[(7S)-7-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-N,N-dimethylacetamide;sulfuric acid
DMBX2RE	CA	CAS 194785-31-4
DMBX2RE	DE	Exacerbation of acute asthma; Aging skin

DMUGN4B	ID	DMUGN4B
DMUGN4B	DN	MN-305
DMUGN4B	HS	Phase 2
DMUGN4B	SN	Osemozotan hydrochloride; Mkc 242; MCI-242; MKC-242; 3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine hydrochloride; 5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride
DMUGN4B	CP	MediciNova
DMUGN4B	DT	Small molecular drug
DMUGN4B	PC	198746
DMUGN4B	MW	379.8
DMUGN4B	FM	C19H22ClNO5
DMUGN4B	IC	InChI=1S/C19H21NO5.ClH/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17;/h1-2,4-7,10,15,20H,3,8-9,11-13H2;1H/t15-;/m0./s1
DMUGN4B	CS	C1[C@@H](OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl
DMUGN4B	IK	GGNCUSDIUUCNKE-RSAXXLAASA-N
DMUGN4B	IU	3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride
DMUGN4B	CA	CAS 137275-80-0
DMUGN4B	DE	Mood disorder

DMQA3MV	ID	DMQA3MV
DMQA3MV	DN	MNX-100
DMQA3MV	HS	Phase 2
DMQA3MV	CP	MetronomX
DMQA3MV	DE	Solid tumour/cancer; Medulloblastoma

DMGK1JE	ID	DMGK1JE
DMGK1JE	DN	MORAb-004
DMGK1JE	HS	Phase 2
DMGK1JE	CP	Eisai
DMGK1JE	DE	Sarcoma; Melanoma; Colorectal cancer; Merkel cell carcinoma

DMCXNIP	ID	DMCXNIP
DMCXNIP	DN	MORAb-009
DMCXNIP	HS	Phase 2
DMCXNIP	SN	Amatuximab
DMCXNIP	CP	Eisai
DMCXNIP	DT	Antibody
DMCXNIP	DE	Mesothelioma

DMYCITZ	ID	DMYCITZ
DMYCITZ	DN	MP-101
DMYCITZ	HS	Phase 2
DMYCITZ	CP	Mediti Pharma
DMYCITZ	DE	Alzheimer disease

DMELUAK	ID	DMELUAK
DMELUAK	DN	MP470
DMELUAK	HS	Phase 2
DMELUAK	SN	Amuvatinib; 850879-09-3; MP-470; MP470; MP 470; Amuvatinib (MP-470); HPK56; UNII-SO9S6QZB4R; Amuvatinib(MP470); N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; SO9S6QZB4R; HPK-56; HPK 56; N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro-[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; Amuvatinib [USAN:INN]; Amuvatinib (MP-470, HPK 56); PubChem22479; Amuvatinib (USAN/INN)
DMELUAK	CP	SuperGen
DMELUAK	TC	Anticancer Agents
DMELUAK	DT	Small molecular drug
DMELUAK	PC	11282283
DMELUAK	MW	447.5
DMELUAK	FM	C23H21N5O3S
DMELUAK	IC	InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)
DMELUAK	CS	C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6
DMELUAK	IK	FOFDIMHVKGYHRU-UHFFFAOYSA-N
DMELUAK	IU	N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide
DMELUAK	CA	CAS 850879-09-3
DMELUAK	CB	CHEBI:91389
DMELUAK	DE	Solid tumour/cancer

DMMRYEK	ID	DMMRYEK
DMMRYEK	DN	MPSK3169A
DMMRYEK	HS	Phase 2
DMMRYEK	SN	RG7652
DMMRYEK	CP	Genentech
DMMRYEK	DE	Metabolic disorder; Cardiovascular disease

DMQR23W	ID	DMQR23W
DMQR23W	DN	MRE-0094
DMQR23W	HS	Phase 2
DMQR23W	SN	SCHEMBL13010610; MRE 0094
DMQR23W	CP	Aderis Pharmaceuticals Licensee; King Pharmaceuticals
DMQR23W	DT	Small molecular drug
DMQR23W	PC	9910098
DMQR23W	MW	421.8
DMQR23W	FM	C18H20ClN5O5
DMQR23W	IC	InChI=1S/C18H20ClN5O5/c19-10-3-1-9(2-4-10)5-6-28-18-22-15(20)12-16(23-18)24(8-21-12)17-14(27)13(26)11(7-25)29-17/h1-4,8,11,13-14,17,25-27H,5-7H2,(H2,20,22,23)/t11-,13-,14-,17-/m1/s1
DMQR23W	CS	C1=CC(=CC=C1CCOC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N)Cl
DMQR23W	IK	WUCQGGOGHZRELS-LSCFUAHRSA-N
DMQR23W	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(4-chlorophenyl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMQR23W	CA	CAS 131865-88-8
DMQR23W	DE	Diabetic foot ulcer

DMJK8L1	ID	DMJK8L1
DMJK8L1	DN	MRG002
DMJK8L1	HS	Phase 2
DMJK8L1	CP	Miracogen
DMJK8L1	DT	Antibody drug conjugate
DMJK8L1	DE	Urothelial carcinoma

DM9M5WV	ID	DM9M5WV
DM9M5WV	DN	MRG-201
DM9M5WV	HS	Phase 2
DM9M5WV	CP	miRagen Therapeutics Boulder, CO
DM9M5WV	DE	Scleroderma; Keloid

DMQZWYE	ID	DMQZWYE
DMQZWYE	DN	MRX-4
DMQZWYE	HS	Phase 2
DMQZWYE	SN	Non-steroidal multifunctional anti-inflammatory drug (MFAID) (nasal spray, allergic rhinitis), Morria
DMQZWYE	CP	Morria Biopharmaceuticals plc
DMQZWYE	PC	91864617
DMQZWYE	MW	530.3
DMQZWYE	FM	C20H18F3N4O8P
DMQZWYE	IC	InChI=1S/C20H18F3N4O8P/c1-11(28)35-36(31,32)27(16-4-7-33-24-16)10-13-9-26(20(30)34-13)15-8-14(21)19(18(23)17(15)22)25-5-2-12(29)3-6-25/h2,4-5,7-8,13H,3,6,9-10H2,1H3,(H,31,32)/t13-/m1/s1
DMQZWYE	CS	CC(=O)OP(=O)(N(C[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2F)F)N3CCC(=O)C=C3)F)C4=NOC=C4)O
DMQZWYE	IK	YCRAGJLWFBGKFE-CYBMUJFWSA-N
DMQZWYE	IU	acetyloxy-N-(1,2-oxazol-3-yl)-N-[[(5R)-2-oxo-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]phosphonamidic acid
DMQZWYE	CA	CAS 1807497-11-5
DMQZWYE	DE	Allergic rhinitis

DMLVQKF	ID	DMLVQKF
DMLVQKF	DN	MRX-6
DMLVQKF	HS	Phase 2
DMLVQKF	SN	CXCL10 gene inhibitor/phospholipase A2/ MIP 1 ligand inhibitor (contact dermatitis), Morria Biopharmaceuticals; IL 1 beta/IL-6/PGE 2 modulator (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Monocyte chemotactic protein 1/GM-CSF/TNF alpha ligand inhibitor (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Non-steroidal multifunctional anti-inflammatory drug (MFAID) (topical formulation, contact dermatitis), Morria
DMLVQKF	CP	Morria Biopharmaceuticals plc
DMLVQKF	DE	Contact dermatitis

DMH1DYU	ID	DMH1DYU
DMH1DYU	DN	MSC1936369B
DMH1DYU	HS	Phase 2
DMH1DYU	SN	Pimasertib; 1236699-92-5; AS703026; AS-703026; Pimasertib (AS-703026); MSC1936369B; UNII-6ON9RK82AL; AS 703026; (S)-N-(2,3-dihydroxypropyl)-3-(2-fluoro-4-iodophenylamino)isonicotinamide; 6ON9RK82AL; N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide; 1204531-26-9; C15H15FIN3O3; N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodo-anilino)pyridine-4-carboxamide; N-((2S)-2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)pyridine-4-carboxamide; Pimasertib [USAN:INN]
DMH1DYU	CP	EMD Serono
DMH1DYU	DT	Small molecular drug
DMH1DYU	PC	44187362
DMH1DYU	MW	431.2
DMH1DYU	FM	C15H15FIN3O3
DMH1DYU	IC	InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1
DMH1DYU	CS	C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NC[C@@H](CO)O
DMH1DYU	IK	VIUAUNHCRHHYNE-JTQLQIEISA-N
DMH1DYU	IU	N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide
DMH1DYU	CA	CAS 1204531-26-9
DMH1DYU	CB	CHEBI:94793
DMH1DYU	DE	Colorectal cancer

DMGUI51	ID	DMGUI51
DMGUI51	DN	MSDC-0602
DMGUI51	HS	Phase 2
DMGUI51	SN	MSDC-0602; 1133819-87-0; MSDC 0602; 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione; 2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-; YAUMOGALQJYOJQ-UHFFFAOYSA-N; SCHEMBL623654; AKOS027382993
DMGUI51	CP	Metabolic Solutions Development
DMGUI51	DT	Small molecular drug
DMGUI51	PC	25230266
DMGUI51	MW	371.4
DMGUI51	FM	C19H17NO5S
DMGUI51	IC	InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23)
DMGUI51	CS	COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMGUI51	IK	YAUMOGALQJYOJQ-UHFFFAOYSA-N
DMGUI51	IU	5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMGUI51	CA	CAS 1133819-87-0
DMGUI51	DE	Type-2 diabetes

DMUM370	ID	DMUM370
DMUM370	DN	MSH-1001
DMUM370	HS	Phase 2
DMUM370	SN	DNB-001; KR-31378; KR-31378); K+ channel activating compounds, Dongbu/KRICT
DMUM370	CP	Danube Pharmaceuticals Inc; Korea Research Institute of Chemical Technology
DMUM370	PC	9823724
DMUM370	MW	425.5
DMUM370	FM	C22H27N5O4
DMUM370	IC	InChI=1S/C22H27N5O4/c1-22(20(29-2)30-3)19(28)18(16-11-15(24)9-10-17(16)31-22)27-21(26-13-23)25-12-14-7-5-4-6-8-14/h4-11,18-20,28H,12,24H2,1-3H3,(H2,25,26,27)/t18-,19+,22+/m1/s1
DMUM370	CS	C[C@]1([C@H]([C@@H](C2=C(O1)C=CC(=C2)N)NC(=NCC3=CC=CC=C3)NC#N)O)C(OC)OC
DMUM370	IK	OZHUPJHJQIEDFA-DXIQSLLYSA-N
DMUM370	IU	1-[(2S,3S,4R)-6-amino-2-(dimethoxymethyl)-3-hydroxy-2-methyl-3,4-dihydrochromen-4-yl]-2-benzyl-3-cyanoguanidine
DMUM370	DE	Ocular hypertension

DMSE9TH	ID	DMSE9TH
DMSE9TH	DN	MT-1303
DMSE9TH	HS	Phase 2
DMSE9TH	CP	Mitsubishi Tanabe Pharma Corp
DMSE9TH	DT	Small molecular drug
DMSE9TH	PC	67418070
DMSE9TH	MW	413.9
DMSE9TH	FM	C19H31ClF3NO3
DMSE9TH	IC	InChI=1S/C19H30F3NO3.ClH/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25;/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3;1H
DMSE9TH	CS	CCCCCCCOC1=C(C=C(C=C1)CCC(CO)(CO)N)C(F)(F)F.Cl
DMSE9TH	IK	GEDVJGOVRLHFQG-UHFFFAOYSA-N
DMSE9TH	IU	2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol;hydrochloride
DMSE9TH	CA	CAS 942398-84-7
DMSE9TH	DE	Multiple sclerosis; Crohn disease

DM7I0MT	ID	DM7I0MT
DM7I0MT	DN	MT203
DM7I0MT	HS	Phase 2
DM7I0MT	SN	Namilumab
DM7I0MT	CP	National Institute of Allergy and Infectious Diseases (NIAID)
DM7I0MT	DT	Monoclonal antibody
DM7I0MT	DE	Plaque psoriasis

DMCNL7Z	ID	DMCNL7Z
DMCNL7Z	DN	MT-3724
DMCNL7Z	HS	Phase 2
DMCNL7Z	CP	Molecular Templates
DMCNL7Z	DT	Recombinant?protein
DMCNL7Z	DE	B-cell chronic lymphocytic leukaemia; B-cell lymphoma; B-cell non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma

DMXSZA4	ID	DMXSZA4
DMXSZA4	DN	MT-3995
DMXSZA4	HS	Phase 2
DMXSZA4	CP	Mitsubishi tanabe pharma
DMXSZA4	DE	Diabetic nephropathy

DM7VG8L	ID	DM7VG8L
DM7VG8L	DN	MTC-896
DM7VG8L	HS	Phase 2
DM7VG8L	SN	MC-5 antagonists (dermatological disease), Mimetica
DM7VG8L	CP	Mimetica Pty Ltd
DM7VG8L	DE	Seborrhea

DMT0K4F	ID	DMT0K4F
DMT0K4F	DN	MTR105
DMT0K4F	HS	Phase 2
DMT0K4F	SN	UNII-CTD25O6OBI; CTD25O6OBI; MTR 105; S-Ethylisothiuronium diethyl phosphate; 21704-46-1; Carbamimidothioic acid, ethyl ester, mono(diethyl phospate); Phosphoric acid, diethyl ester, compd. with 2-ethyl-2-thiopseudourea (1:1); Difetur; AC1Q6SNE; AC1L4PKY; CTK4E7529; nitric oxide synthase inhibi-tors; ethyl carbamimidothioate- diethyl hydrogen phosphate(1:1); MTR-105; DTXSID60176093; AKOS030611139; LS-107705; diethyl hydrogen phosphate; Carbamimidothioic acid, ethyl ester, diethyl phosphate (1
DMT0K4F	CP	Meditor Pharmaceuticals
DMT0K4F	DT	Small molecular drug
DMT0K4F	PC	210823
DMT0K4F	MW	258.279
DMT0K4F	FM	C7H19N2O4PS
DMT0K4F	IC	InChI=1S/C4H11O4P.C3H8N2S/c1-3-7-9(5,6)8-4-2;1-2-6-3(4)5/h3-4H2,1-2H3,(H,5,6);2H2,1H3,(H3,4,5)
DMT0K4F	CS	CCOP(=O)(O)OCC.CCSC(=N)N
DMT0K4F	IK	CSYSULGPHGCBQD-UHFFFAOYSA-N
DMT0K4F	IU	diethyl hydrogen phosphate;ethyl carbamimidothioate
DMT0K4F	CA	CAS 21704-46-1
DMT0K4F	DE	Hypotension

DML7N4B	ID	DML7N4B
DML7N4B	DN	MUC1-Poly-ICLC
DML7N4B	HS	Phase 2
DML7N4B	SN	Mucin1 peptide vaccine (cancer), University of Pittsburgh
DML7N4B	CP	University of Pittsburgh
DML7N4B	DT	Vaccine
DML7N4B	DE	Colorectal cancer

DMN68ZL	ID	DMN68ZL
DMN68ZL	DN	Multi-epitope tyrosinase/gp100 vaccine
DMN68ZL	HS	Phase 2
DMN68ZL	SN	Melanoma vaccine, Memorial Sloan-Kettering; Multi-epitope tyrosinase/gp100 vaccine (melanoma); Multi-epitope tyrosinase/gp100 vaccine (melanoma), Memorial Sloan-Kettering
DMN68ZL	CP	Memorial Sloan-Kettering Cancer Center
DMN68ZL	DT	Vaccine
DMN68ZL	DE	Melanoma

DMM6KZR	ID	DMM6KZR
DMM6KZR	DN	Mutant ras vaccine
DMM6KZR	HS	Phase 2
DMM6KZR	SN	Mutant ras vaccine, NCI; Ras peptide vaccine, NCI; 13 mer ras peptide, NCI
DMM6KZR	CP	National Cancer Institute
DMM6KZR	DT	Vaccine
DMM6KZR	DE	Solid tumour/cancer

DMKDN1C	ID	DMKDN1C
DMKDN1C	DN	MVA-85A
DMKDN1C	HS	Phase 2
DMKDN1C	SN	AERAS-485; MVA-AG85A; MVA-85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC; MVA-Ag85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC
DMKDN1C	CP	University of Oxford
DMKDN1C	DT	Vaccine
DMKDN1C	DE	Mycobacterium infection

DMDN6FO	ID	DMDN6FO
DMDN6FO	DN	MVI-816
DMDN6FO	HS	Phase 2
DMDN6FO	CP	Madison vaccines
DMDN6FO	DE	Prostate cancer

DM25VY8	ID	DM25VY8
DM25VY8	DN	Mydicar
DM25VY8	HS	Phase 2
DM25VY8	SN	Mydicar (TN)
DM25VY8	CP	Celladon; Targeted Genetics
DM25VY8	DE	Heart failure

DMO1XUK	ID	DMO1XUK
DMO1XUK	DN	Myeloma cancer vaccine
DMO1XUK	HS	Phase 2
DMO1XUK	CP	BioSante Pharmaceuticals
DMO1XUK	DT	Vaccine
DMO1XUK	DE	Multiple myeloma

DM9BREJ	ID	DM9BREJ
DM9BREJ	DN	MYK-491
DM9BREJ	HS	Phase 2
DM9BREJ	SN	Danicamtiv; UNII-7B2CS922HI; 7B2CS922HI; SAR440181; 1970972-74-7; Danicamtiv [INN]; Danicamtiv [USAN]; Danicamtiv (USAN/INN); MYK491; CHEMBL4594304; SCHEMBL17942536; WHO 10942; SAR-440181; HY-109128; CS-0086762; D11824; (R)-4-(1-((3-(Difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide; 1-Piperidinecarboxamide, 4-((1R)-1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-3-isoxazolyl-
DM9BREJ	CP	MyoKardia; Sanofi
DM9BREJ	DT	Small molecular drug
DM9BREJ	PC	122424426
DM9BREJ	MW	435.4
DM9BREJ	FM	C16H20F3N5O4S
DM9BREJ	IC	InChI=1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1
DM9BREJ	CS	C[C@@](C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C
DM9BREJ	IK	NREKKBAMVWQRES-MRXNPFEDSA-N
DM9BREJ	IU	4-[(1R)-1-[3-(difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-N-(1,2-oxazol-3-yl)piperidine-1-carboxamide
DM9BREJ	CA	CAS 1970972-74-7
DM9BREJ	DE	Dilated cardiomyopathy

DMQKSGI	ID	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	HS	Phase 2
DMQKSGI	SN	Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite
DMQKSGI	DT	Small molecular drug
DMQKSGI	PC	892
DMQKSGI	MW	180.16
DMQKSGI	FM	C6H12O6
DMQKSGI	IC	InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H
DMQKSGI	CS	C1(C(C(C(C(C1O)O)O)O)O)O
DMQKSGI	IK	CDAISMWEOUEBRE-UHFFFAOYSA-N
DMQKSGI	IU	cyclohexane-1,2,3,4,5,6-hexol
DMQKSGI	CA	CAS 551-72-4
DMQKSGI	CB	CHEBI:17268
DMQKSGI	DE	Alzheimer disease

DMUK6HC	ID	DMUK6HC
DMUK6HC	DN	N-5984
DMUK6HC	HS	Phase 2
DMUK6HC	SN	N-5984; SCHEMBL364457; XSOXUIXLUNBLJA-RNRVQEDPSA-N; 6-(2-(R)-((2-(R)-(3-chlorophenyl)-2-hydroxyethyl)amino)-propyl)-2,3-dihydro-1,4-benzodioxin-2-(R)-carboxylic acid; 6-(2-(R)-((2-(R)-(3-chlorophenyl)-2-hydroxyethyl)amino )-propyl)-2,3-dihydro-1,4-benzodioxin-2-(R)-carboxylic acid
DMUK6HC	CP	Nisshin Kyorin
DMUK6HC	DT	Small molecular drug
DMUK6HC	PC	9865284
DMUK6HC	MW	391.8
DMUK6HC	FM	C20H22ClNO5
DMUK6HC	IC	InChI=1S/C20H22ClNO5/c1-12(22-10-16(23)14-3-2-4-15(21)9-14)7-13-5-6-17-18(8-13)26-11-19(27-17)20(24)25/h2-6,8-9,12,16,19,22-23H,7,10-11H2,1H3,(H,24,25)/t12-,16+,19-/m1/s1
DMUK6HC	CS	C[C@H](CC1=CC2=C(C=C1)O[C@H](CO2)C(=O)O)NC[C@@H](C3=CC(=CC=C3)Cl)O
DMUK6HC	IK	XSOXUIXLUNBLJA-RNRVQEDPSA-N
DMUK6HC	IU	(2R)-6-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-2,3-dihydro-1,4-benzodioxine-2-carboxylic acid
DMUK6HC	DE	Type-2 diabetes; Obesity

DMN7EUO	ID	DMN7EUO
DMN7EUO	DN	N6022
DMN7EUO	HS	Phase 2
DMN7EUO	SN	N6022; 1208315-24-5; N-6022; UNII-80LIU5P95D; 80LIU5P95D; CHEMBL1738699; 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid; 3-{1-(4-Carbamoyl-2-Methylphenyl)-5-[4-(1h-Imidazol-1-Yl)phenyl]-1h-Pyrrol-2-Yl}propanoic Acid; N 6022; YVPGZQLRPAGKLA-UHFFFAOYSA-N; 3-[1-(4-carbamoyl-2-methylphenyl)-5-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrol-2-yl]propanoic acid; SCHEMBL244480; EX-A343; MolPort-035-789-691; HMS3653J15; BCP09367; s7589; ZINC66156654; BDBM50354475; 2573AH; AKOS030526322; DB12206
DMN7EUO	DT	Small molecular drug
DMN7EUO	PC	44623946
DMN7EUO	MW	414.5
DMN7EUO	FM	C24H22N4O3
DMN7EUO	IC	InChI=1S/C24H22N4O3/c1-16-14-18(24(25)31)4-9-21(16)28-20(8-11-23(29)30)7-10-22(28)17-2-5-19(6-3-17)27-13-12-26-15-27/h2-7,9-10,12-15H,8,11H2,1H3,(H2,25,31)(H,29,30)
DMN7EUO	CS	CC1=C(C=CC(=C1)C(=O)N)N2C(=CC=C2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O
DMN7EUO	IK	YVPGZQLRPAGKLA-UHFFFAOYSA-N
DMN7EUO	IU	3-[1-(4-carbamoyl-2-methylphenyl)-5-(4-imidazol-1-ylphenyl)pyrrol-2-yl]propanoic acid
DMN7EUO	CA	CAS 1208315-24-5
DMN7EUO	DE	Asthma

DM7P0WR	ID	DM7P0WR
DM7P0WR	DN	NAI-acne
DM7P0WR	HS	Phase 2
DM7P0WR	CP	Vicuron Pharmaceuticals Inc
DM7P0WR	DE	Acne vulgaris

DMSWUNX	ID	DMSWUNX
DMSWUNX	DN	Naratuximab emtansine
DMSWUNX	HS	Phase 2
DMSWUNX	SN	DEBIO 1562
DMSWUNX	CP	Debiopharm
DMSWUNX	DT	Antibody
DMSWUNX	DE	Diffuse large B-cell lymphoma; Non-hodgkin lymphoma

DMD0E8U	ID	DMD0E8U
DMD0E8U	DN	Naveglitazar
DMD0E8U	HS	Phase 2
DMD0E8U	SN	LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand
DMD0E8U	CP	Ligand Pharmaceuticals
DMD0E8U	DT	Small molecular drug
DMD0E8U	PC	9888484
DMD0E8U	MW	422.5
DMD0E8U	FM	C25H26O6
DMD0E8U	IC	InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1
DMD0E8U	CS	CO[C@@H](CC1=CC=C(C=C1)OCCCOC2=CC=C(C=C2)OC3=CC=CC=C3)C(=O)O
DMD0E8U	IK	OKJHGOPITGTTIM-DEOSSOPVSA-N
DMD0E8U	IU	(2S)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoic acid
DMD0E8U	CA	CAS 476436-68-7
DMD0E8U	DE	Diabetic complication

DMH9JFZ	ID	DMH9JFZ
DMH9JFZ	DN	NBI-5788
DMH9JFZ	HS	Phase 2
DMH9JFZ	SN	Tiplimotide; CGP-77116; MSP-771; MSP-771A; APL (multiple sclerosis), Neurocrine/Novartis; Altered peptide ligand (MS), Neurocrine/Novartis
DMH9JFZ	CP	Neurocrine Biosciences Inc
DMH9JFZ	PC	25084501
DMH9JFZ	MW	1860.2
DMH9JFZ	FM	C87H142N24O21
DMH9JFZ	IC	InChI=1S/C87H142N24O21/c1-15-47(10)67(82(127)105-66(46(8)9)81(126)108-69(51(14)113)84(129)110-35-23-29-60(110)77(122)97-54(28-21-33-94-87(91)92)72(117)107-68(50(13)112)85(130)111-36-24-31-62(111)86(131)132)106-76(121)59(40-63(90)114)99-71(116)49(12)96-73(118)57(38-52-25-17-16-18-26-52)101-74(119)56(37-43(2)3)100-75(120)58(39-53-41-93-42-95-53)102-79(124)64(44(4)5)104-80(125)65(45(6)7)103-78(123)61-30-22-34-109(61)83(128)55(27-19-20-32-88)98-70(115)48(11)89/h16-18,25-26,41-51,54-62,64-69,112-113H,15,19-24,27-40,88-89H2,1-14H3,(H2,90,114)(H,93,95)(H,96,118)(H,97,122)(H,98,115)(H,99,116)(H,100,120)(H,101,119)(H,102,124)(H,103,123)(H,104,125)(H,105,127)(H,106,121)(H,107,117)(H,108,126)(H,131,132)(H4,91,92,94)/t47?,48-,49+,50?,51?,54+,55+,56+,57+,58+,59+,60+,61+,62+,64+,65+,66+,67+,68+,69+/m1/s1
DMH9JFZ	CS	CCC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)O)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCCN)NC(=O)[C@@H](C)N
DMH9JFZ	IK	NITUEMISTORFON-OOMTWUQISA-N
DMH9JFZ	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-aminopropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid
DMH9JFZ	DE	Multiple sclerosis

DMT6O2E	ID	DMT6O2E
DMT6O2E	DN	NC318
DMT6O2E	HS	Phase 2
DMT6O2E	CP	NextCure
DMT6O2E	DT	Antibody
DMT6O2E	DE	Non-small cell lung cancer

DMVQKB3	ID	DMVQKB3
DMVQKB3	DN	NCI-C50000
DMVQKB3	HS	Phase 2
DMVQKB3	SN	Levomenthol; D-(-)-Menthol; Headache crystals; Hexahydrothymol; I-menthol; Levomentholum; Menthacamphor; Menthol (VAN); Menthol natural; Menthol racemic; Menthomenthol; Peppermint camphor; Racementhol; U.S.P. Menthol; d,l-Menthol; l-(-)-Menthol; l-Menthol; l-Menthol (natural); p-Menthan-3-ol; (+-)-Menthol; (-)-(1R,3R,4S)-Menthol; (-)-Menthyl alcohol; (-)-menthol; (-)-trans-p-Menthan-cis-ol; (1R)-(-)-Menthol; (1R,2S,5R)-2-Isopropyl-5-methylcyclohexanol; (1r,2s,5r)-(-)-menthol; (R)-(-)-Menthol; 1-Menthol; 2216-51-5; 89-78-1
DMVQKB3	PC	16666
DMVQKB3	MW	156.26
DMVQKB3	FM	C10H20O
DMVQKB3	IC	NOOLISFMXDJSKH-KXUCPTDWSA-N
DMVQKB3	CS	CC1CCC(C(C1)O)C(C)C
DMVQKB3	IK	1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1
DMVQKB3	IU	(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-ol
DMVQKB3	CA	CAS 89-78-1
DMVQKB3	CB	CHEBI:15409
DMVQKB3	DE	Pruritus

DM4W28K	ID	DM4W28K
DM4W28K	DN	NCX 1022
DM4W28K	HS	Phase 2
DM4W28K	CP	NicOx SA
DM4W28K	DE	Atopic dermatitis

DM2YIZH	ID	DM2YIZH
DM2YIZH	DN	NCX-1000
DM2YIZH	HS	Phase 2
DM2YIZH	SN	Nitric oxide ursodiol derivative, NicOx/Axcan; UDCA derivative, NicOx/Axcan; Ursodeoxycholic acid derivative, NicOx/Axcan
DM2YIZH	CP	NicOx SA
DM2YIZH	DT	Small molecular drug
DM2YIZH	PC	129628949
DM2YIZH	MW	685.8
DM2YIZH	FM	C38H55NO10
DM2YIZH	IC	InChI=1S/C38H55NO10/c1-24(28-10-11-29-36-30(16-18-38(28,29)3)37(2)17-15-27(40)22-26(37)23-31(36)41)7-13-35(43)49-32-12-8-25(21-33(32)46-4)9-14-34(42)47-19-5-6-20-48-39(44)45/h8-9,12,14,21,24,26-31,36,40-41H,5-7,10-11,13,15-20,22-23H2,1-4H3/b14-9+/t24-,26+,27-,28-,29+,30+,31+,36+,37+,38-/m1/s1
DM2YIZH	CS	C[C@H](CCC(=O)OC1=C(C=C(C=C1)/C=C/C(=O)OCCCCO[N+](=O)[O-])OC)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3[C@H](C[C@H]5[C@@]4(CC[C@H](C5)O)C)O)C
DM2YIZH	IK	WTAVOESJEWSDJC-OBOLPPCUSA-N
DM2YIZH	IU	[2-methoxy-4-[(E)-3-(4-nitrooxybutoxy)-3-oxoprop-1-enyl]phenyl] (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
DM2YIZH	CA	CAS 401519-96-8
DM2YIZH	DE	Cardiovascular disease

DMOX1CU	ID	DMOX1CU
DMOX1CU	DN	NCX-4016
DMOX1CU	HS	Phase 2
DMOX1CU	SN	Nitroaspirin; Ncx 4016; NO-ASA; Nitric oxide-releasing aspirin; M-NO-ASA; M-NO-aspirin; [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate; Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester; Benzoic acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl ester; 2-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 2-Acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-(nitrooxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-nitrooxymethylphenyl ester; 3-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 3-(Nitroxymethyl)phenyl 2-acetoxybenzoate
DMOX1CU	CP	NiCox SA
DMOX1CU	TC	Analgesics
DMOX1CU	DT	Small molecular drug
DMOX1CU	PC	119032
DMOX1CU	MW	331.28
DMOX1CU	FM	C16H13NO7
DMOX1CU	IC	InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3
DMOX1CU	CS	CC(=O)OC1=CC=CC=C1C(=O)OC2=CC=CC(=C2)CO[N+](=O)[O-]
DMOX1CU	IK	IOJUJUOXKXMJNF-UHFFFAOYSA-N
DMOX1CU	IU	[3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate
DMOX1CU	CA	CAS 175033-36-0
DMOX1CU	CB	CHEBI:125482
DMOX1CU	DE	Claudication; Nephropathy; Type-2 diabetes; Inflammation

DM6S83X	ID	DM6S83X
DM6S83X	DN	NDDP
DM6S83X	HS	Phase 2
DM6S83X	SN	Cis-Bis(2,2-dimethyloctanoato)[trans-1(R),2(R)-diaminocyclohexane]platinum (II)
DM6S83X	DT	Small molecular drug
DM6S83X	PC	56841091
DM6S83X	MW	649.8
DM6S83X	FM	C26H50N2O4Pt
DM6S83X	IC	InChI=1S/2C10H20O2.C6H12N2.Pt/c2*1-10(2,3)8-6-4-5-7-9(11)12;7-5-3-1-2-4-6(5)8;/h2*4-8H2,1-3H3,(H,11,12);5-8H,1-4H2;/q;;-2;+4/p-2
DM6S83X	CS	CC(C)(C)CCCCCC(=O)[O-].CC(C)(C)CCCCCC(=O)[O-].C1CCC(C(C1)[NH-])[NH-].[Pt+4]
DM6S83X	IK	ALPHSAWEOKVWID-UHFFFAOYSA-L
DM6S83X	IU	(2-azanidylcyclohexyl)azanide;7,7-dimethyloctanoate;platinum(4+)
DM6S83X	CA	CAS 113427-19-3
DM6S83X	DE	Solid tumour/cancer

DMVIRN3	ID	DMVIRN3
DMVIRN3	DN	N-DESMETHYLCLOZAPINE
DMVIRN3	HS	Phase 2
DMVIRN3	DT	Small molecular drug
DMVIRN3	PC	135409468
DMVIRN3	MW	312.8
DMVIRN3	FM	C17H17ClN4
DMVIRN3	IC	InChI=1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2
DMVIRN3	CS	C1CN(CCN1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
DMVIRN3	IK	JNNOSTQEZICQQP-UHFFFAOYSA-N
DMVIRN3	IU	3-chloro-6-piperazin-1-yl-11H-benzo[b][1,4]benzodiazepine
DMVIRN3	CA	CAS 6104-71-8
DMVIRN3	CB	CHEBI:64050
DMVIRN3	DE	Schizoaffective disorder; Schizophrenia

DMUPZFO	ID	DMUPZFO
DMUPZFO	DN	Neihulizumab
DMUPZFO	HS	Phase 2
DMUPZFO	CP	AbGenomics International Los Altos, CA
DMUPZFO	DE	Psoriatic arthritis

DMSVWI7	ID	DMSVWI7
DMSVWI7	DN	Neladenoson bialanate
DMSVWI7	HS	Phase 2
DMSVWI7	SN	UNII-IV690462VZ; IV690462VZ; 1239309-58-0; Neladenoson dalanate; Neladenoson dalanate [INN]; Neladenoson bialanate [INN]; SCHEMBL7904070; AKOS032946515; DB13138; L-Alanine, L-alanyl-, 2-(4-(2-(((2-(4-chlorophenyl)-4-thiazolyl)methyl)thio)-3,5-dicyano-6-(1-pyrrolidinyl)-4-pyridinyl)phenoxy)ethyl ester; 2-(4-(2-(((2-(4-Chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl L-alanyl-L-alaninate
DMSVWI7	CP	Bayer HealthCare Pharmaceuticals Whippany, NJ
DMSVWI7	PC	56848985
DMSVWI7	MW	716.3
DMSVWI7	FM	C35H34ClN7O4S2
DMSVWI7	IC	InChI=1S/C35H34ClN7O4S2/c1-21(39)32(44)40-22(2)35(45)47-16-15-46-27-11-7-23(8-12-27)30-28(17-37)31(43-13-3-4-14-43)42-34(29(30)18-38)49-20-26-19-48-33(41-26)24-5-9-25(36)10-6-24/h5-12,19,21-22H,3-4,13-16,20,39H2,1-2H3,(H,40,44)/t21-,22-/m0/s1
DMSVWI7	CS	C[C@@H](C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N5CCCC5)C#N)N
DMSVWI7	IK	WESNEIGKOAXSGX-VXKWHMMOSA-N
DMSVWI7	IU	2-[4-[2-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-3,5-dicyano-6-pyrrolidin-1-ylpyridin-4-yl]phenoxy]ethyl (2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoate
DMSVWI7	CA	CAS 1239309-58-0
DMSVWI7	DE	Chronic heart failure

DM4LKFO	ID	DM4LKFO
DM4LKFO	DN	NELOTANSERIN
DM4LKFO	HS	Phase 2
DM4LKFO	SN	NELOTANSERIN; 839713-36-9; UNII-4ZA73QEW2P; 4ZA73QEW2P; CHEMBL598172; APD125; APD-125; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea; 1-[3-(4-BROMO-1-METHYL-1H-PYRAZOL-5-YL)-4-METHOXYPHENYL]-3-(2,4-DIFLUOROPHENYL)UREA; N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-N'-(2,4-difluorophenyl)-Urea; Nelotanserin [USAN:INN]; Nelotanserin (USAN/INN); SCHEMBL2345325; APD 125; DTXSID40232868; COSPVUFTLGQDQL-UHFFFAOYSA-N; BCP24992; ZINC38239930; BDBM50324541; AKOS027255058; DB12555
DM4LKFO	DT	Small molecular drug
DM4LKFO	PC	11683556
DM4LKFO	MW	437.2
DM4LKFO	FM	C18H15BrF2N4O2
DM4LKFO	IC	InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)
DM4LKFO	CS	CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)F)F)OC
DM4LKFO	IK	COSPVUFTLGQDQL-UHFFFAOYSA-N
DM4LKFO	IU	1-[3-(4-bromo-2-methylpyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
DM4LKFO	CA	CAS 839713-36-9
DM4LKFO	DE	Sleep-wake disorder; Lewy body dementia

DMNM9DZ	ID	DMNM9DZ
DMNM9DZ	DN	Nepicastat oral
DMNM9DZ	HS	Phase 2
DMNM9DZ	SN	SYN117
DMNM9DZ	CP	Biotie Therapies
DMNM9DZ	DT	Small molecular drug
DMNM9DZ	PC	9840545
DMNM9DZ	MW	331.8
DMNM9DZ	FM	C14H16ClF2N3S
DMNM9DZ	IC	InChI=1S/C14H15F2N3S.ClH/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20;/h3,5,7,10H,1-2,4,6,17H2,(H,18,20);1H/t10-;/m0./s1
DMNM9DZ	CS	C1CC2=C(C[C@H]1N3C(=CNC3=S)CN)C=C(C=C2F)F.Cl
DMNM9DZ	IK	DIPDUAJWNBEVOY-PPHPATTJSA-N
DMNM9DZ	IU	4-(aminomethyl)-3-[(2S)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1H-imidazole-2-thione;hydrochloride
DMNM9DZ	CA	CAS 170151-24-3
DMNM9DZ	DE	Post-traumatic stress disorder

DM3ORVD	ID	DM3ORVD
DM3ORVD	DN	Neramexane
DM3ORVD	HS	Phase 2
DM3ORVD	SN	Neramexane [INN]; Mrz 2579; MRZ 2-579; 1,3,3,5,5-Pentamethylcyclohexanamine; 1,3,3,5,5-pentamethylcyclohexan-1-amine
DM3ORVD	CP	Merz Pharmaceuticals GmbH
DM3ORVD	TC	Analgesics
DM3ORVD	DT	Small molecular drug
DM3ORVD	PC	6433106
DM3ORVD	MW	169.31
DM3ORVD	FM	C11H23N
DM3ORVD	IC	InChI=1S/C11H23N/c1-9(2)6-10(3,4)8-11(5,12)7-9/h6-8,12H2,1-5H3
DM3ORVD	CS	CC1(CC(CC(C1)(C)N)(C)C)C
DM3ORVD	IK	OGZQTTHDGQBLBT-UHFFFAOYSA-N
DM3ORVD	IU	1,3,3,5,5-pentamethylcyclohexan-1-amine
DM3ORVD	CA	CAS 219810-59-0
DM3ORVD	DE	Cancer related pain

DMBJ3GL	ID	DMBJ3GL
DMBJ3GL	DN	Nerenone
DMBJ3GL	HS	Phase 2
DMBJ3GL	CP	Bayer healthcare pharmaceuticals
DMBJ3GL	DE	Diabetic nephropathy

DM8H7OA	ID	DM8H7OA
DM8H7OA	DN	Netoglitazone
DM8H7OA	HS	Phase 2
DM8H7OA	SN	Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione
DM8H7OA	CP	Mitsubishi Pharma
DM8H7OA	DT	Small molecular drug
DM8H7OA	PC	204109
DM8H7OA	MW	381.4
DM8H7OA	FM	C21H16FNO3S
DM8H7OA	IC	InChI=1S/C21H16FNO3S/c22-18-4-2-1-3-16(18)12-26-17-8-7-14-9-13(5-6-15(14)11-17)10-19-20(24)23-21(25)27-19/h1-9,11,19H,10,12H2,(H,23,24,25)
DM8H7OA	CS	C1=CC=C(C(=C1)COC2=CC3=C(C=C2)C=C(C=C3)CC4C(=O)NC(=O)S4)F
DM8H7OA	IK	PKWDZWYVIHVNKS-UHFFFAOYSA-N
DM8H7OA	IU	5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione
DM8H7OA	CA	CAS 161600-01-7
DM8H7OA	DE	Non-alcoholic fatty liver disease

DMOZW4C	ID	DMOZW4C
DMOZW4C	DN	Neublastin
DMOZW4C	HS	Phase 2
DMOZW4C	CP	Biogen Idec
DMOZW4C	DE	Pain

DMIQDFW	ID	DMIQDFW
DMIQDFW	DN	Neu-P11
DMIQDFW	HS	Phase 2
DMIQDFW	SN	Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; NEU-P11; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819
DMIQDFW	CP	Neurim Pharmaceuticals
DMIQDFW	DT	Small molecular drug
DMIQDFW	PC	24815904
DMIQDFW	MW	312.32
DMIQDFW	FM	C17H16N2O4
DMIQDFW	IC	InChI=1S/C17H16N2O4/c1-22-13-2-3-15-14(9-13)11(10-19-15)4-6-18-17(21)16-8-12(20)5-7-23-16/h2-3,5,7-10,19H,4,6H2,1H3,(H,18,21)
DMIQDFW	CS	COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3
DMIQDFW	IK	PNTNBIHOAPJYDB-UHFFFAOYSA-N
DMIQDFW	IU	N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-4-oxopyran-2-carboxamide
DMIQDFW	CA	CAS 946846-83-9
DMIQDFW	DE	Insomnia; Alzheimer disease; Dementia

DMINQP1	ID	DMINQP1
DMINQP1	DN	NEUROPEPTIDE-Y
DMINQP1	HS	Phase 2
DMINQP1	SN	XKWCTHKJQNUFOQ-HRPSIEBRSA-N; Neuropeptide Y
DMINQP1	DT	Small molecular drug
DMINQP1	PC	91928728
DMINQP1	MW	4254
DMINQP1	FM	C190H287N55O57
DMINQP1	IC	InChI=1S/C190H287N55O57/c1-16-94(9)149(180(296)235-129(81-141(194)255)169(285)227-124(74-93(7)8)172(288)240-150(95(10)17-2)181(297)241-151(100(15)248)182(298)222-116(32-23-67-209-190(203)204)156(272)221-118(57-60-140(193)254)161(277)219-114(30-21-65-207-188(199)200)157(273)224-121(152(196)268)76-102-39-49-108(250)50-40-102)239-173(289)127(79-105-45-55-111(253)56-46-105)230-168(284)128(80-106-86-205-90-211-106)231-159(275)115(31-22-66-208-189(201)202)220-165(281)123(73-92(5)6)225-155(271)97(12)213-174(290)134(88-246)237-167(283)126(78-104-43-53-110(252)54-44-104)229-166(282)125(77-103-41-51-109(251)52-42-103)228-158(274)113(29-20-64-206-187(197)198)217-153(269)96(11)212-163(279)122(72-91(3)4)226-170(286)131(84-147(264)265)233-162(278)119(59-62-145(260)261)218-154(270)98(13)214-177(293)137-34-25-68-242(137)183(299)99(14)215-164(280)130(83-146(262)263)232-160(276)117(58-61-144(258)259)216-143(257)87-210-176(292)136-33-24-70-244(136)186(302)133(82-142(195)256)236-171(287)132(85-148(266)267)234-178(294)139-36-27-71-245(139)185(301)120(28-18-19-63-191)223-175(291)135(89-247)238-179(295)138-35-26-69-243(138)184(300)112(192)75-101-37-47-107(249)48-38-101/h37-56,86,90-100,112-139,149-151,246-253H,16-36,57-85,87-89,191-192H2,1-15H3,(H2,193,254)(H2,194,255)(H2,195,256)(H2,196,268)(H,205,211)(H,210,292)(H,212,279)(H,213,290)(H,214,293)(H,215,280)(H,216,257)(H,217,269)(H,218,270)(H,219,277)(H,220,281)(H,221,272)(H,222,298)(H,223,291)(H,224,273)(H,225,271)(H,226,286)(H,227,285)(H,228,274)(H,229,282)(H,230,284)(H,231,275)(H,232,276)(H,233,278)(H,234,294)(H,235,296)(H,236,287)(H,237,283)(H,238,295)(H,239,289)(H,240,288)(H,241,297)(H,258,259)(H,260,261)(H,262,263)(H,264,265)(H,266,267)(H4,197,198,206)(H4,199,200,207)(H4,201,202,208)(H4,203,204,209)/t94-,95-,96-,97-,98-,99-,100+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,149-,150-,151-/m0/s1
DMINQP1	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]7CCCN7C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]8CCCN8C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]9CCCN9C(=O)[C@H](CC1=CC=C(C=C1)O)N
DMINQP1	IK	URPYMXQQVHTUDU-OFGSCBOVSA-N
DMINQP1	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-[[2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoic acid

DML5S71	ID	DML5S71
DML5S71	DN	Nexopamil
DML5S71	HS	Phase 2
DML5S71	SN	LU-49938
DML5S71	CP	BASF AG
DML5S71	DT	Small molecular drug
DML5S71	PC	65984
DML5S71	MW	404.6
DML5S71	FM	C24H40N2O3
DML5S71	IC	InChI=1S/C24H40N2O3/c1-8-9-10-11-14-26(4)15-12-13-24(18-25,19(2)3)20-16-21(27-5)23(29-7)22(17-20)28-6/h16-17,19H,8-15H2,1-7H3/t24-/m0/s1
DML5S71	CS	CCCCCCN(C)CCC[C@@](C#N)(C1=CC(=C(C(=C1)OC)OC)OC)C(C)C
DML5S71	IK	SKDZEFVVFACNLS-DEOSSOPVSA-N
DML5S71	IU	(2S)-5-[hexyl(methyl)amino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile
DML5S71	CA	CAS 136033-49-3
DML5S71	DE	Hypertension

DMJKBAY	ID	DMJKBAY
DMJKBAY	DN	NGX-267
DMJKBAY	HS	Phase 2
DMJKBAY	SN	503431-81-0; AF267B; (2S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4,5]DECAN-3-ONE; UNII-8D3PZX7G73; AF 267B; 8D3PZX7G73; (S)-2-Ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one; NGX-267; NGX267; NGX 267; SCHEMBL3651146; CTK1G8674; DTXSID40198399; AF-267B; PHOZOHFUXHPOCK-QMMMGPOBSA-N; ZINC13816318; AKOS025295388; NCGC00162382-01; RT-005412; FT-0668336; (S)-2-Ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one; 1-Thia-4,8-diazaspiro(4.5)decan-3-one, 2-ethyl-8-methyl-, (2S)-
DMJKBAY	DT	Small molecular drug
DMJKBAY	PC	10013505
DMJKBAY	MW	214.33
DMJKBAY	FM	C10H18N2OS
DMJKBAY	IC	InChI=1S/C10H18N2OS/c1-3-8-9(13)11-10(14-8)4-6-12(2)7-5-10/h8H,3-7H2,1-2H3,(H,11,13)/t8-/m0/s1
DMJKBAY	CS	CC[C@H]1C(=O)NC2(S1)CCN(CC2)C
DMJKBAY	IK	PHOZOHFUXHPOCK-QMMMGPOBSA-N
DMJKBAY	IU	(2S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one
DMJKBAY	CA	CAS 503431-81-0
DMJKBAY	DE	Schizophrenia

DMDY01J	ID	DMDY01J
DMDY01J	DN	NHS-IL2-LT
DMDY01J	HS	Phase 2
DMDY01J	SN	Selectikine; EMD-521873; Immunocytokine (solid tumors), Merck Serono
DMDY01J	CP	Merck Serono SA
DMDY01J	DE	Solid tumour/cancer

DMRQUH4	ID	DMRQUH4
DMRQUH4	DN	NI-0801
DMRQUH4	HS	Phase 2
DMRQUH4	SN	Anti-interferon inducible protein 10, NovImmune
DMRQUH4	CP	NovImmune SA
DMRQUH4	DT	Antibody
DMRQUH4	DE	Autoimmune diabetes

DMKLJMI	ID	DMKLJMI
DMKLJMI	DN	NIC-002
DMKLJMI	HS	Phase 2
DMKLJMI	SN	NicQb; Nicotine-Qbeta; CYT-002-NicQb; Nicotine vaccine, Cytos/Novartis; Immunodrug (nicotine addiction), Cytos/Novartis
DMKLJMI	CP	Cytos Biotechnology AG
DMKLJMI	DT	Vaccine
DMKLJMI	DE	Nicotine dependence

DMG7XOC	ID	DMG7XOC
DMG7XOC	DN	NIC5-15
DMG7XOC	HS	Phase 2
DMG7XOC	SN	D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336
DMG7XOC	CP	Humanetics Minneapolis, MN
DMG7XOC	DT	Small molecular drug
DMG7XOC	PC	164619
DMG7XOC	MW	194.18
DMG7XOC	FM	C7H14O6
DMG7XOC	IC	InChI=1S/C7H14O6/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h2-12H,1H3/t2?,3-,4-,5-,6+,7?/m0/s1
DMG7XOC	CS	COC1[C@@H]([C@H](C([C@@H]([C@@H]1O)O)O)O)O
DMG7XOC	IK	DSCFFEYYQKSRSV-FEPQRWDDSA-N
DMG7XOC	IU	(1S,2S,4S,5R)-6-methoxycyclohexane-1,2,3,4,5-pentol
DMG7XOC	CA	CAS 484-68-4
DMG7XOC	CB	CHEBI:28548
DMG7XOC	DE	Alzheimer disease

DM21Z68	ID	DM21Z68
DM21Z68	DN	Nimacimab
DM21Z68	HS	Phase 2
DM21Z68	SN	Namacizumab
DM21Z68	CP	Bird Rock Bio
DM21Z68	DT	Antibody
DM21Z68	DE	Diabetic nephropathy

DMPER4A	ID	DMPER4A
DMPER4A	DN	NIR178
DMPER4A	HS	Phase 2
DMPER4A	CP	Novartis Oncology East Hanover, 
DMPER4A	DE	Non-hodgkin lymphoma; Solid tumour/cancer

DM81SDB	ID	DM81SDB
DM81SDB	DN	Niravoline
DM81SDB	HS	Phase 2
DM81SDB	SN	AC1L24CB; AC1Q1ZY1; N-methyl-2-(3-nitrophenyl)-N-[(2S)-2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-1-yl]acetamide
DM81SDB	DT	Small molecular drug
DM81SDB	PC	9821174
DM81SDB	MW	379.5
DM81SDB	FM	C22H25N3O3
DM81SDB	IC	InChI=1S/C22H25N3O3/c1-23(21(26)14-16-7-6-9-18(13-16)25(27)28)22-19-10-3-2-8-17(19)15-20(22)24-11-4-5-12-24/h2-3,6-10,13,20,22H,4-5,11-12,14-15H2,1H3/t20-,22-/m0/s1
DM81SDB	CS	CN([C@@H]1[C@H](CC2=CC=CC=C12)N3CCCC3)C(=O)CC4=CC(=CC=C4)[N+](=O)[O-]
DM81SDB	IK	ZSDAQBWGAOKTSI-UNMCSNQZSA-N
DM81SDB	IU	N-methyl-2-(3-nitrophenyl)-N-[(1S,2S)-2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-1-yl]acetamide
DM81SDB	CA	CAS 130610-93-4
DM81SDB	DE	Pain

DM8LBYT	ID	DM8LBYT
DM8LBYT	DN	NIS793
DM8LBYT	HS	Phase 2
DM8LBYT	CP	Novartis Oncology East Hanover, 
DM8LBYT	DE	Solid tumour/cancer; Pancreatic ductal carcinoma

DMQHBSX	ID	DMQHBSX
DMQHBSX	DN	NITD609
DMQHBSX	HS	Phase 2
DMQHBSX	SN	Cipargamin; 1193314-23-6; NITD-609; NITD 609; UNII-Z7Q4FWA04P; (1'R,3'S)-5,7'-Dichloro-6'-fluoro-3'-methyl-2',3',4',9'-tetrahydrospiro[indoline-3,1'-pyrido[3,4-b]indol]-2-one; Z7Q4FWA04P; CHEMBL1082723; Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one, 5,7'-dichloro-6'-fluoro-2',3',4',9'-tetrahydro-3'-methyl-, (1'R,3'S)-; Cipargamin [INN]; 1252008-89-1; GTPL9721; SCHEMBL1306342; DTXSID70152424; MolPort-039-337-269; ZINC49037032; BDBM50318666; AKOS027253851; SB16518; DB12306; CS-7486; NCGC00263785-01
DMQHBSX	DT	Small molecular drug
DMQHBSX	PC	44469321
DMQHBSX	MW	390.2
DMQHBSX	FM	C19H14Cl2FN3O
DMQHBSX	IC	InChI=1S/C19H14Cl2FN3O/c1-8-4-11-10-6-14(22)13(21)7-16(10)23-17(11)19(25-8)12-5-9(20)2-3-15(12)24-18(19)26/h2-3,5-8,23,25H,4H2,1H3,(H,24,26)/t8-,19+/m0/s1
DMQHBSX	CS	C[C@H]1CC2=C([C@]3(N1)C4=C(C=CC(=C4)Cl)NC3=O)NC5=CC(=C(C=C25)F)Cl
DMQHBSX	IK	CKLPLPZSUQEDRT-WPCRTTGESA-N
DMQHBSX	IU	(3R,3'S)-5,7'-dichloro-6'-fluoro-3'-methylspiro[1H-indole-3,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-2-one
DMQHBSX	CA	CAS 1193314-23-6
DMQHBSX	DE	Malaria

DMAOUZV	ID	DMAOUZV
DMAOUZV	DN	Nivatrotamab
DMAOUZV	HS	Phase 2
DMAOUZV	CP	Memorial Sloan Kettering; Y-mAbs Therapeutics
DMAOUZV	DT	Antibody
DMAOUZV	DE	Solid tumour/cancer; Small-cell lung cancer

DMUX8JZ	ID	DMUX8JZ
DMUX8JZ	DN	Nivocasan
DMUX8JZ	HS	Phase 2
DMUX8JZ	SN	GS-9450; LB-84451
DMUX8JZ	CP	LG Life Sciences Ltd
DMUX8JZ	PC	11633038
DMUX8JZ	MW	415.4
DMUX8JZ	FM	C21H22FN3O5
DMUX8JZ	IC	InChI=1S/C21H22FN3O5/c1-12(2)20(19(27)24-16-9-17(26)29-21(16,28)11-22)10-15(25-30-20)18-14-6-4-3-5-13(14)7-8-23-18/h3-8,12,16,28H,9-11H2,1-2H3,(H,24,27)/t16-,20+,21+/m0/s1
DMUX8JZ	CS	CC(C)[C@]1(CC(=NO1)C2=NC=CC3=CC=CC=C32)C(=O)N[C@H]4CC(=O)O[C@@]4(CF)O
DMUX8JZ	IK	VYFGDLGHHBUDTQ-ZLGUVYLKSA-N
DMUX8JZ	IU	(5R)-N-[(2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxooxolan-3-yl]-3-isoquinolin-1-yl-5-propan-2-yl-4H-1,2-oxazole-5-carboxamide
DMUX8JZ	CA	CAS 908253-63-4
DMUX8JZ	DE	Fibrosis

DMTVGMZ	ID	DMTVGMZ
DMTVGMZ	DN	NKP 608
DMTVGMZ	HS	Phase 2
DMTVGMZ	SN	AV608)
DMTVGMZ	CP	Novartis; Avera Pharmaceuticals
DMTVGMZ	PC	9917079
DMTVGMZ	MW	620
DMTVGMZ	FM	C31H24ClF6N3O2
DMTVGMZ	IC	InChI=1S/C31H24ClF6N3O2/c32-22-7-5-18(6-8-22)13-24-17-23(40-28(42)26-9-11-39-27-4-2-1-3-25(26)27)10-12-41(24)29(43)19-14-20(30(33,34)35)16-21(15-19)31(36,37)38/h1-9,11,14-16,23-24H,10,12-13,17H2,(H,40,42)/t23-,24+/m0/s1
DMTVGMZ	CS	C1CN([C@@H](C[C@H]1NC(=O)C2=CC=NC3=CC=CC=C23)CC4=CC=C(C=C4)Cl)C(=O)C5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F
DMTVGMZ	IK	NXLUTEDAEFXMQR-BJKOFHAPSA-N
DMTVGMZ	IU	N-[(2R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide
DMTVGMZ	CA	CAS 177707-12-9
DMTVGMZ	DE	Mood disorder

DMKD5ZO	ID	DMKD5ZO
DMKD5ZO	DN	NN-8226
DMKD5ZO	HS	Phase 2
DMKD5ZO	SN	NNC-109-0012; IL-20 monoclonal antibody (inflammation), Novo Nordisk; Anti-IL20 (inflammation), ZymoGenetics/Novo Nordisk; Anti-IL20mAb (RA), ZymoGenetics/Novo Nordisk; Anti-interleukin-20 (rheumatoid arthritis), ZymoGenetics/Novo Nordisk
DMKD5ZO	CP	ZymoGenetics Inc
DMKD5ZO	DT	Antibody
DMKD5ZO	DE	Psoriasis vulgaris

DM3IEHP	ID	DM3IEHP
DM3IEHP	DN	NN8555
DM3IEHP	HS	Phase 2
DM3IEHP	CP	Novo Nordisk
DM3IEHP	DE	Rheumatoid arthritis; Crohn disease

DMCFPBE	ID	DMCFPBE
DMCFPBE	DN	NN8765
DMCFPBE	HS	Phase 2
DMCFPBE	CP	Novo Nordisk
DMCFPBE	DE	Rheumatoid arthritis

DMDTNOS	ID	DMDTNOS
DMDTNOS	DN	NNC-0123-0000-0338
DMDTNOS	HS	Phase 2
DMDTNOS	CP	Novo Nordisk A/S
DMDTNOS	DE	Diabetic complication

DMU3KOH	ID	DMU3KOH
DMU3KOH	DN	NNC-0151-0000-0000
DMU3KOH	HS	Phase 2
DMU3KOH	SN	Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk
DMU3KOH	CP	G2 Therapies Ltd
DMU3KOH	DT	Antibody
DMU3KOH	DE	Rheumatoid arthritis

DMPZ97S	ID	DMPZ97S
DMPZ97S	DN	NNZ-2566
DMPZ97S	HS	Phase 2
DMPZ97S	SN	Glypromate analogs (oral, neuroprotection), Neuren; NNZ-2566 (oral, neurodegeneration/injury); NNZ-2566 (oral, neurodegeneration/injury), Neuren
DMPZ97S	CP	Neuren pharmaceuticals
DMPZ97S	DT	Small molecular drug
DMPZ97S	PC	11318905
DMPZ97S	MW	315.32
DMPZ97S	FM	C13H21N3O6
DMPZ97S	IC	InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1
DMPZ97S	CS	C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMPZ97S	IK	BUSXWGRAOZQTEY-SDBXPKJASA-N
DMPZ97S	IU	(2S)-2-[[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino]pentanedioic acid
DMPZ97S	CA	CAS 853400-76-7
DMPZ97S	DE	Fragile X syndrome; Rett syndrome; Traumatic brain injury; Type-1 diabetes

DME8IFQ	ID	DME8IFQ
DME8IFQ	DN	Noberastine
DME8IFQ	HS	Phase 2
DME8IFQ	SN	Flamizole; R-64947; R-72075
DME8IFQ	CP	Janssen Pharmaceutica NV
DME8IFQ	DT	Small molecular drug
DME8IFQ	PC	60531
DME8IFQ	MW	311.4
DME8IFQ	FM	C17H21N5O
DME8IFQ	IC	InChI=1S/C17H21N5O/c1-12-4-5-14(23-12)11-22-16-15(3-2-8-19-16)21-17(22)20-13-6-9-18-10-7-13/h2-5,8,13,18H,6-7,9-11H2,1H3,(H,20,21)
DME8IFQ	CS	CC1=CC=C(O1)CN2C3=C(C=CC=N3)N=C2NC4CCNCC4
DME8IFQ	IK	VNIOQSAWKLOGLY-UHFFFAOYSA-N
DME8IFQ	IU	3-[(5-methylfuran-2-yl)methyl]-N-piperidin-4-ylimidazo[4,5-b]pyridin-2-amine
DME8IFQ	CA	CAS 110588-56-2
DME8IFQ	DE	Asthma

DMEHOI1	ID	DMEHOI1
DMEHOI1	DN	Novaferon
DMEHOI1	HS	Phase 2
DMEHOI1	SN	Recombinant interferon-like protein, Genova/Novagenetics/Novagen; Recombinant huIFN-alpha-like protein (cancer, viral infection), Genova/Novagenetics/Novagen
DMEHOI1	CP	Novagenetics Inc
DMEHOI1	DE	Colorectal cancer

DMHG3UR	ID	DMHG3UR
DMHG3UR	DN	NOX-E36
DMHG3UR	HS	Phase 2
DMHG3UR	SN	Monocyte chemoattractant protein-1 ligand inhibitor(spiegelmer, diabetic complications), NOXXON; MCP-1 inhibitor (spiegelmer/injectable, diabetic complications/diabetic nephropathy), NOXXON
DMHG3UR	CP	NOXXON Pharma AG
DMHG3UR	DE	Diabetic complication

DM5HPZU	ID	DM5HPZU
DM5HPZU	DN	NOX-H94
DM5HPZU	HS	Phase 2
DM5HPZU	CP	NOXXON Pharma AG; Avant Immunotherapeutics
DM5HPZU	DE	Anemia

DMP1W9Z	ID	DMP1W9Z
DMP1W9Z	DN	NP-01
DMP1W9Z	HS	Phase 2
DMP1W9Z	SN	Vanadium (buccal, nanodroplet emulsion (Aonys), type 2 diabetes/metabolic syndrome), Medesis
DMP1W9Z	CP	Medesis Pharma SA
DMP1W9Z	DE	Type-2 diabetes

DMLMZ6Q	ID	DMLMZ6Q
DMLMZ6Q	DN	NP-2
DMLMZ6Q	HS	Phase 2
DMLMZ6Q	SN	NP2 Enkephalin; NPE-1; NPE-2; Enkephalin-expressing gene therapy (HSV carrier, pain), Diamyd; Enkephalin-expressinggene therapy (HSV carrier/NTDDS, pain), Nurel
DMLMZ6Q	CP	Periphagen holdings
DMLMZ6Q	DT	Small molecular drug
DMLMZ6Q	PC	16130887
DMLMZ6Q	MW	3855
DMLMZ6Q	FM	C161H282N62O36S6
DMLMZ6Q	IC	InChI=1S/C161H282N62O36S6/c1-20-84(15)120(148(254)206-91(38-25-51-182-153(163)164)125(231)192-70-115(224)197-92(39-26-52-183-154(165)166)132(238)220-121(85(16)21-2)149(255)212-106(67-90-68-181-77-193-90)151(257)223-61-35-48-114(223)145(251)210-103(64-80(7)8)136(242)215-112(76-265)143(249)217-110(74-263)141(247)203-97(44-31-57-188-159(175)176)130(236)207-100(152(258)259)46-33-59-190-161(179)180)221-133(239)98(45-32-58-189-160(177)178)204-140(246)109(73-262)216-137(243)104(66-89-36-23-22-24-37-89)198-116(225)69-191-122(228)86(17)194-126(232)93(40-27-53-184-155(167)168)199-128(234)95(42-29-55-186-157(171)172)201-131(237)99(49-50-117(226)227)205-134(240)102(63-79(5)6)209-144(250)113-47-34-60-222(113)150(256)105(65-81(9)10)211-142(248)111(75-264)214-135(241)101(62-78(3)4)208-123(229)87(18)195-127(233)94(41-28-54-185-156(169)170)200-129(235)96(43-30-56-187-158(173)174)202-139(245)108(72-261)213-124(230)88(19)196-138(244)107(71-260)218-147(253)119(83(13)14)219-146(252)118(162)82(11)12/h22-24,36-37,68,77-88,91-114,118-121,260-265H,20-21,25-35,38-67,69-76,162H2,1-19H3,(H,181,193)(H,191,228)(H,192,231)(H,194,232)(H,195,233)(H,196,244)(H,197,224)(H,198,225)(H,199,234)(H,200,235)(H,201,237)(H,202,245)(H,203,247)(H,204,246)(H,205,240)(H,206,254)(H,207,236)(H,208,229)(H,209,250)(H,210,251)(H,211,248)(H,212,255)(H,213,230)(H,214,241)(H,215,242)(H,216,243)(H,217,249)(H,218,253)(H,219,252)(H,220,238)(H,221,239)(H,226,227)(H,258,259)(H4,163,164,182)(H4,165,166,183)(H4,167,168,184)(H4,169,170,185)(H4,171,172,186)(H4,173,174,187)(H4,175,176,188)(H4,177,178,189)(H4,179,180,190)/t84-,85-,86-,87-,88-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,118-,119-,120-,121-/m0/s1
DMLMZ6Q	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N
DMLMZ6Q	IK	AEUKDPKXTPNBNY-XEYRWQBLSA-N
DMLMZ6Q	IU	(4S)-4-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-[[(2S)-5-carbamimidamido-1-[[(2S,3S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMLMZ6Q	CA	CAS 88086-40-2
DMLMZ6Q	DE	Influenza A virus infection

DME6KAF	ID	DME6KAF
DME6KAF	DN	NPC-15199
DME6KAF	HS	Phase 2
DME6KAF	SN	2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; F-L-Leu; CHEMBL294989; PPARgamma Activator, Fmoc-Leu; 2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; Fmoc-DL-leucine; N-alpha-Fmoc-L-leucine; NSC334290; ACMC-209iik; AC1L1HVH; n-[(9h-fluoren-9-ylmethoxy)carbonyl]leucin; ACMC-2099ky; AC1Q5SK7; 126727-03-5; 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid; (2S)-2-[(fluoren-9-ylmethoxy)carbonylamino]-4-methylpentanoic acid; GTPL2705; SCHEMBL1002861; CHEBI:91726; CTK8G6077; MolPort-003-700-319; HMS3266H19; SBB056939; IN1334; BDBM50034787; AKOS017268980
DME6KAF	CP	Scios Inc
DME6KAF	DT	Small molecular drug
DME6KAF	PC	1549133
DME6KAF	MW	353.4
DME6KAF	FM	C21H23NO4
DME6KAF	IC	InChI=1S/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)/t19-/m0/s1
DME6KAF	CS	CC(C)C[C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
DME6KAF	IK	CBPJQFCAFFNICX-IBGZPJMESA-N
DME6KAF	IU	(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid
DME6KAF	CA	CAS 35661-60-0
DME6KAF	DE	Inflammation

DM9VEAL	ID	DM9VEAL
DM9VEAL	DN	NPC-1C
DM9VEAL	HS	Phase 2
DM9VEAL	SN	Ensituximab
DM9VEAL	CP	Neogenix Oncology
DM9VEAL	DT	Antibody
DM9VEAL	DE	Colorectal cancer; Pancreatic tumour; Pancreatic cancer

DM3DQXG	ID	DM3DQXG
DM3DQXG	DN	NPSP-795
DM3DQXG	HS	Phase 2
DM3DQXG	SN	NPSP-790; SB-423557; SB-423557A; SB-423562; SB-423562A
DM3DQXG	CP	GlaxoSmithKline plc
DM3DQXG	PC	9910902
DM3DQXG	MW	436.5
DM3DQXG	FM	C26H32N2O4
DM3DQXG	IC	InChI=1S/C26H32N2O4/c1-26(2,14-19-11-20-5-3-4-6-21(20)12-19)28-16-23(29)17-32-24-13-18(8-10-25(30)31)7-9-22(24)15-27/h3-7,9,13,19,23,28-29H,8,10-12,14,16-17H2,1-2H3,(H,30,31)/t23-/m1/s1
DM3DQXG	CS	CC(C)(CC1CC2=CC=CC=C2C1)NC[C@H](COC3=C(C=CC(=C3)CCC(=O)O)C#N)O
DM3DQXG	IK	NJBFJCJKWWIKRD-HSZRJFAPSA-N
DM3DQXG	IU	3-[4-cyano-3-[(2R)-3-[[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]phenyl]propanoic acid
DM3DQXG	CA	CAS 351490-27-2
DM3DQXG	DE	Osteoporosis

DMYXOU2	ID	DMYXOU2
DMYXOU2	DN	NRX-4204
DMYXOU2	HS	Phase 2
DMYXOU2	SN	AGN-190205; AGN-191659; AGN-191701; AGN-192326; AGN-192327; AGN-192509; AGN-192599; AGN-192870; AGN-194277; AGN-195393; AGN-4202; ALRT-326; ALRT-4204; LGD-4204; LGD-4326; NRX-194202; RXR ligands, ALRT; RXR ligands, Allergan; Retinoid X receptor agonists, ALRT; Retinoid X receptor agonists, Allergan; VTP-4204; RXR agonists, Allergan/Pfizer; Rexinoid receptor agonist (cancer), NuRx; RXR agonists (cancer/ diabetes), Vitae Pharmaceuticals; RXR agonists, Allergan/Parke-Davis
DMYXOU2	CP	Allergan Ligand Retinoid Therapeutics Inc
DMYXOU2	DT	Small molecular drug
DMYXOU2	PC	9863342
DMYXOU2	MW	352.5
DMYXOU2	FM	C24H32O2
DMYXOU2	IC	InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+
DMYXOU2	CS	C/C(=C\\C(=O)O)/C=C/C1CC1(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C
DMYXOU2	IK	BOOOLEGQBVUTKC-YWRSBGDESA-N
DMYXOU2	IU	(2E,4E)-3-methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid
DMYXOU2	DE	Diabetic complication

DM9EFH0	ID	DM9EFH0
DM9EFH0	DN	NS 1209
DM9EFH0	HS	Phase 2
DM9EFH0	CP	NeuroSearch
DM9EFH0	TC	Analgesics
DM9EFH0	DT	Small molecular drug
DM9EFH0	PC	135456058
DM9EFH0	MW	516.6
DM9EFH0	FM	C24H28N4O7S
DM9EFH0	IC	InChI=1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30)
DM9EFH0	CS	CN1CCC2=C(C1)C3=C(C=C2C4=CC=C(C=C4)S(=O)(=O)N(C)C)/C(=N/OC(CCO)C(=O)O)/C(=O)N3
DM9EFH0	IK	CFJRSKULEDUDKL-UHFFFAOYSA-N
DM9EFH0	IU	2-[(Z)-[5-[4-(dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-1,6,7,9-tetrahydropyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy-4-hydroxybutanoic acid
DM9EFH0	CA	CAS 245063-59-6
DM9EFH0	DE	Neuropathic pain; Epilepsy

DMI5HFU	ID	DMI5HFU
DMI5HFU	DN	NS 2359
DMI5HFU	HS	Phase 2
DMI5HFU	SN	FPTPUYCHSWIWIB-FUTJPDQTSA-N; SCHEMBL2640060; (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo-[321]octane; GSK372475
DMI5HFU	CP	GlaxoSmithKline
DMI5HFU	DT	Small molecular drug
DMI5HFU	PC	68470595
DMI5HFU	MW	314.2
DMI5HFU	FM	C16H21Cl2NO
DMI5HFU	IC	InChI=1S/C16H21Cl2NO/c1-19-11-4-6-16(19)13(9-20-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,11-13,16H,4,6,8-9H2,1-2H3/t11-,12+,13+,16+/m0/s1
DMI5HFU	CS	CN1[C@H]2CC[C@@H]1[C@@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)COC
DMI5HFU	IK	PGYDXVBZYKQYCS-VPWBDBDCSA-N
DMI5HFU	IU	(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
DMI5HFU	CA	CAS 195875-68-4
DMI5HFU	DE	Cocaine addiction; Attention deficit hyperactivity disorder; Mood disorder

DMMUR6V	ID	DMMUR6V
DMMUR6V	DN	NS-2710
DMMUR6V	HS	Phase 2
DMMUR6V	SN	ME-3127
DMMUR6V	CP	NeuroSearch A/S
DMMUR6V	DT	Small molecular drug
DMMUR6V	PC	9863520
DMMUR6V	MW	356.4
DMMUR6V	FM	C22H20N4O
DMMUR6V	IC	InChI=1S/C22H20N4O/c1-3-27-25-16(2)17-9-10-22-21(13-17)24-15-26(22)20-8-4-6-18(12-20)19-7-5-11-23-14-19/h4-15H,3H2,1-2H3/b25-16+
DMMUR6V	CS	CCO/N=C(\\C)/C1=CC2=C(C=C1)N(C=N2)C3=CC=CC(=C3)C4=CN=CC=C4
DMMUR6V	IK	NHJFEXZXSCFYRX-PCLIKHOPSA-N
DMMUR6V	IU	(E)-N-ethoxy-1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]ethanimine
DMMUR6V	CA	CAS 184220-36-8
DMMUR6V	DE	Anxiety disorder

DM3H82Q	ID	DM3H82Q
DM3H82Q	DN	NS-7
DM3H82Q	HS	Phase 2
DM3H82Q	SN	(3r)-3-Cyclopentyl-6-Methyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide; DB08305; NS7
DM3H82Q	TC	Analgesics
DM3H82Q	DT	Small molecular drug
DM3H82Q	PC	9800750
DM3H82Q	MW	393.9
DM3H82Q	FM	C21H29ClFN3O
DM3H82Q	IC	InChI=1S/C21H28FN3O.ClH/c1-17-23-20(18-8-10-19(22)11-9-18)16-21(24-17)26-15-7-3-6-14-25-12-4-2-5-13-25;/h8-11,16H,2-7,12-15H2,1H3;1H
DM3H82Q	CS	CC1=NC(=CC(=N1)OCCCCCN2CCCCC2)C3=CC=C(C=C3)F.Cl
DM3H82Q	IK	VLYZLIWXMLUPLD-UHFFFAOYSA-N
DM3H82Q	IU	4-(4-fluorophenyl)-2-methyl-6-(5-piperidin-1-ylpentoxy)pyrimidine;hydrochloride
DM3H82Q	CA	CAS 178429-67-9
DM3H82Q	DE	Nerve injury

DMPJQZG	ID	DMPJQZG
DMPJQZG	DN	NSC-645809
DMPJQZG	HS	Phase 2
DMPJQZG	SN	XF-02; NSC-645809; C-1311; Imidacrine; Symadex; CHEMBL3545337; XJYNBZQTAZDMHZ-UHFFFAOYSA-N; Imidazoacridone dihydrocheloride hydrate; 138154-55-9; 5-((2-(diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one dihydrochloride hydrate
DMPJQZG	DT	Small molecular drug
DMPJQZG	PC	132127
DMPJQZG	MW	350.4
DMPJQZG	FM	C20H22N4O2
DMPJQZG	IC	InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3
DMPJQZG	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C2=O)C=C(C=C4)O
DMPJQZG	IK	CUNDRHORZHFPLY-UHFFFAOYSA-N
DMPJQZG	IU	10-[2-(diethylamino)ethylamino]-5-hydroxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DMPJQZG	CA	CAS 138154-39-9
DMPJQZG	DE	Breast cancer

DMRYLBW	ID	DMRYLBW
DMRYLBW	DN	NTO-1151
DMRYLBW	HS	Phase 2
DMRYLBW	CP	Nanotherapeutics; national cancer institute
DMRYLBW	DE	Cervical cancer

DMORNVB	ID	DMORNVB
DMORNVB	DN	NU-172
DMORNVB	HS	Phase 2
DMORNVB	CP	ARCA biopharma
DMORNVB	DE	Thrombosis

DMO0C5R	ID	DMO0C5R
DMO0C5R	DN	NU300
DMO0C5R	HS	Phase 2
DMO0C5R	CP	Nuron biotech
DMO0C5R	DE	Influenza virus infection

DMOJA5G	ID	DMOJA5G
DMOJA5G	DN	Nuplazid
DMOJA5G	HS	Phase 2
DMOJA5G	SN	Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,  ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate
DMOJA5G	CP	ACADIA Pharmaceuticals
DMOJA5G	DT	Small molecular drug
DMOJA5G	PC	11672491
DMOJA5G	MW	1005.2
DMOJA5G	FM	C54H74F2N6O10
DMOJA5G	IC	InChI=1S/2C25H34FN3O2.C4H6O6/c2*1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21;5-1(3(7)8)2(6)4(9)10/h2*4-11,19,23H,12-18H2,1-3H3,(H,27,30);1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1
DMOJA5G	CS	CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMOJA5G	IK	RGSULKHNAKTFIZ-CEAXSRTFSA-N
DMOJA5G	IU	(2R,3R)-2,3-dihydroxybutanedioic acid;1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
DMOJA5G	CA	CAS 706782-28-7
DMOJA5G	CB	CHEBI:133014
DMOJA5G	DE	Alzheimer disease

DMTYXQF	ID	DMTYXQF
DMTYXQF	DN	NVP-AUY922
DMTYXQF	HS	Phase 2
DMTYXQF	SN	Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide
DMTYXQF	CP	Vernalis; Novartis
DMTYXQF	TC	Anticancer Agents
DMTYXQF	DT	Small molecular drug
DMTYXQF	PC	135539077
DMTYXQF	MW	465.5
DMTYXQF	FM	C26H31N3O5
DMTYXQF	IC	InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)
DMTYXQF	CS	CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C
DMTYXQF	IK	NDAZATDQFDPQBD-UHFFFAOYSA-N
DMTYXQF	IU	5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide
DMTYXQF	CA	CAS 747412-49-3
DMTYXQF	CB	CHEBI:83656
DMTYXQF	DE	Multiple myeloma; Solid tumour/cancer

DM2UJ1H	ID	DM2UJ1H
DM2UJ1H	DN	NW-3509
DM2UJ1H	HS	Phase 2
DM2UJ1H	SN	NW-3381; Sodium channel blockers (epilepsy/pain/mania), Newron
DM2UJ1H	CP	Newron pharmaceuticals
DM2UJ1H	DE	Schizophrenia

DMMBAIH	ID	DMMBAIH
DMMBAIH	DN	NXN-188
DMMBAIH	HS	Phase 2
DMMBAIH	SN	6634-56-6; 4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid; NSC51920; AC1Q5VTF; AC1L6AFP; CTK5C4317; ZINC4721635; NSC-51920; AKOS030583716; KB-274877
DMMBAIH	CP	Neuraxon
DMMBAIH	DT	Small molecular drug
DMMBAIH	PC	242911
DMMBAIH	MW	484.6
DMMBAIH	FM	C27H36N2O6
DMMBAIH	IC	InChI=1S/C27H36N2O6/c1-27(7-6-26(32)33,22-2-4-24(30)20(16-22)18-28-8-12-34-13-9-28)23-3-5-25(31)21(17-23)19-29-10-14-35-15-11-29/h2-5,16-17,30-31H,6-15,18-19H2,1H3,(H,32,33)
DMMBAIH	CS	CC(CCC(=O)O)(C1=CC(=C(C=C1)O)CN2CCOCC2)C3=CC(=C(C=C3)O)CN4CCOCC4
DMMBAIH	IK	JWNUBAIGCVTLMJ-UHFFFAOYSA-N
DMMBAIH	IU	4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid
DMMBAIH	CA	CAS 6634-56-6
DMMBAIH	DE	Migraine

DMWVBS2	ID	DMWVBS2
DMWVBS2	DN	NXN-462
DMWVBS2	HS	Phase 2
DMWVBS2	SN	NNOS inhibitor (chronic headache), Neuraxon; NNOS inhibitor (neuropathic pain), NeurAxon
DMWVBS2	CP	Neuraxon
DMWVBS2	DE	Headache

DM1P60V	ID	DM1P60V
DM1P60V	DN	NYX-2925
DM1P60V	HS	Phase 2
DM1P60V	CP	Aptinyx  Evanston, IL
DM1P60V	DE	Peripheral neuropathy; Fibromyalgia

DMX04O8	ID	DMX04O8
DMX04O8	DN	NYX-2925
DMX04O8	HS	Phase 2
DMX04O8	SN	2012536-16-0
DMX04O8	CP	Aptinyx
DMX04O8	DT	Small molecular drug
DMX04O8	PC	134820579
DMX04O8	MW	297.35
DMX04O8	FM	C14H23N3O4
DMX04O8	IC	InChI=1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m0/s1
DMX04O8	CS	C[C@@H]([C@H](C(=O)N)N1C[C@]2(C1=O)CCCN2C(=O)C(C)C)O
DMX04O8	IK	NFXPEHLDVKVVKA-RBZYPMLTSA-N
DMX04O8	IU	(2R,3S)-3-hydroxy-2-[(4S)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide
DMX04O8	DE	Diabetic neuropathy; Fibromyalgia

DMAVM2E	ID	DMAVM2E
DMAVM2E	DN	NYX-783
DMAVM2E	HS	Phase 2
DMAVM2E	CP	Aptinyx
DMAVM2E	DT	Small molecular drug
DMAVM2E	DE	Post-traumatic stress disorder

DMXM34I	ID	DMXM34I
DMXM34I	DN	O-304
DMXM34I	HS	Phase 2
DMXM34I	SN	1261289-04-6; O304; 4-chloro-N-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-2,3-dihydro-3-oxo-1,2,4-thiadiazol-5-yl]-benzamide; SCHEMBL1050337; BCP29039; EX-A1990; MFCD31657425; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide; BS-14854; HY-112233; CS-0044210; O 304; S0795
DMXM34I	CP	Betagenon
DMXM34I	DT	Small molecular drug
DMXM34I	PC	50923806
DMXM34I	MW	380.2
DMXM34I	FM	C16H11Cl2N3O2S
DMXM34I	IC	InChI=1S/C16H11Cl2N3O2S/c17-12-5-1-10(2-6-12)9-21-16(23)20-15(24-21)19-14(22)11-3-7-13(18)8-4-11/h1-8H,9H2,(H,19,20,22,23)
DMXM34I	CS	C1=CC(=CC=C1CN2C(=O)N=C(S2)NC(=O)C3=CC=C(C=C3)Cl)Cl
DMXM34I	IK	WEDWLYRQKUTOAX-UHFFFAOYSA-N
DMXM34I	IU	4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide
DMXM34I	DE	Type 2 diabetes

DMPF9ZM	ID	DMPF9ZM
DMPF9ZM	DN	Obatoclax
DMPF9ZM	HS	Phase 2
DMPF9ZM	SN	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7
DMPF9ZM	CP	Cephalon
DMPF9ZM	DT	Small molecular drug
DMPF9ZM	PC	11404337
DMPF9ZM	MW	317.4
DMPF9ZM	FM	C20H19N3O
DMPF9ZM	IC	InChI=1S/C20H19N3O/c1-12-8-13(2)21-16(12)10-19-20(24-3)11-18(23-19)17-9-14-6-4-5-7-15(14)22-17/h4-11,21,23H,1-3H3/b18-17-,19-10-
DMPF9ZM	CS	CC1=CC(=C(N1)/C=C\\2/C(=C/C(=C/3\\C=C4C=CC=CC4=N3)/N2)OC)C
DMPF9ZM	IK	CVCLJVVBHYOXDC-IAZSKANUSA-N
DMPF9ZM	IU	(2Z)-2-[(5Z)-5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole
DMPF9ZM	CA	CAS 803712-67-6
DMPF9ZM	DE	Solid tumour/cancer

DMJIBSG	ID	DMJIBSG
DMJIBSG	DN	OBE-101
DMJIBSG	HS	Phase 2
DMJIBSG	CP	OBEcure
DMJIBSG	DE	Obesity

DM5D6Y7	ID	DM5D6Y7
DM5D6Y7	DN	OBI-3424
DM5D6Y7	HS	Phase 2
DM5D6Y7	SN	UNII-X6SH5T8H76; X6SH5T8H76; CHEMBL4297474; SCHEMBL20870529; 2097713-68-1; 3-(5-((1R)-1-(Bis(aziridin-1-yl(phosphoryloxy)ethyl)-2-nitrophenoxy)-N,N-dimethylbenzamide; Phosphinic acid, P,P-bis(1-aziridinyl)-, (1R)-1-(3-(3-((dimethylamino)carbonyl)phenoxy)-4-nitrophenyl)ethyl ester
DM5D6Y7	CP	OBI Pharma
DM5D6Y7	DT	Small molecular drug
DM5D6Y7	PC	126961329
DM5D6Y7	MW	460.4
DM5D6Y7	FM	C21H25N4O6P
DM5D6Y7	IC	InChI=1S/C21H25N4O6P/c1-15(31-32(29,23-9-10-23)24-11-12-24)16-7-8-19(25(27)28)20(14-16)30-18-6-4-5-17(13-18)21(26)22(2)3/h4-8,13-15H,9-12H2,1-3H3/t15-/m1/s1
DM5D6Y7	CS	C[C@H](C1=CC(=C(C=C1)[N+](=O)[O-])OC2=CC=CC(=C2)C(=O)N(C)C)OP(=O)(N3CC3)N4CC4
DM5D6Y7	IK	NWGZZGNICQFUHV-OAHLLOKOSA-N
DM5D6Y7	IU	3-[5-[(1R)-1-[bis(aziridin-1-yl)phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide
DM5D6Y7	CA	CAS 2097713-68-1
DM5D6Y7	DE	Hepatocellular carcinoma; Prostate cancer; Solid tumour/cancer; Acute lymphoblastic leukaemia

DMVXZC4	ID	DMVXZC4
DMVXZC4	DN	OBP-601
DMVXZC4	HS	Phase 2
DMVXZC4	SN	Festinavir; Ed4T; Nucleoside reverse transcriptase inhibitor (HIV infection), Oncolys; Nucleoside reverse transcriptase inhibitor (HIV infection), Yale; 4'-Ed4T; 4'-ethynylstavudine
DMVXZC4	CP	Bristol-myers squibb
DMVXZC4	DT	Small molecular drug
DMVXZC4	PC	3008897
DMVXZC4	MW	248.23
DMVXZC4	FM	C12H12N2O4
DMVXZC4	IC	InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1
DMVXZC4	CS	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C
DMVXZC4	IK	OSYWBJSVKUFFSU-SKDRFNHKSA-N
DMVXZC4	IU	1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
DMVXZC4	CA	CAS 634907-30-5
DMVXZC4	DE	Human immunodeficiency virus-1 infection

DM1JBD8	ID	DM1JBD8
DM1JBD8	DN	OC-000459
DM1JBD8	HS	Phase 2
DM1JBD8	SN	OC-1768; OC-2125; OC-2184; OC-459; OC-499; ODC-9101; CRTH2 antagonists (asthma/allergy), Oxagen
DM1JBD8	CP	Oxagen Ltd
DM1JBD8	DT	Small molecular drug
DM1JBD8	PC	11462174
DM1JBD8	MW	348.4
DM1JBD8	FM	C21H17FN2O2
DM1JBD8	IC	InChI=1S/C21H17FN2O2/c1-13-17(11-16-8-6-14-4-2-3-5-19(14)23-16)18-10-15(22)7-9-20(18)24(13)12-21(25)26/h2-10H,11-12H2,1H3,(H,25,26)
DM1JBD8	CS	CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NC4=CC=CC=C4C=C3
DM1JBD8	IK	FATGTHLOZSXOBC-UHFFFAOYSA-N
DM1JBD8	IU	2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid
DM1JBD8	CA	CAS 851723-84-7
DM1JBD8	DE	Allergy

DMP6B59	ID	DMP6B59
DMP6B59	DN	Ocaperidone
DMP6B59	HS	Phase 2
DMP6B59	SN	Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one;  Ocaperidona; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019
DMP6B59	CP	Johnson & Johnson
DMP6B59	DT	Small molecular drug
DMP6B59	PC	71351
DMP6B59	MW	420.5
DMP6B59	FM	C24H25FN4O2
DMP6B59	IC	InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3
DMP6B59	CS	CC1=CC=CN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C
DMP6B59	IK	ZZQNEJILGNNOEP-UHFFFAOYSA-N
DMP6B59	IU	3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one
DMP6B59	CA	CAS 129029-23-8
DMP6B59	DE	Schizoaffective disorder; Schizophrenia; Idiopathic pulmonary fibrosis; Type-2 diabetes; Diabetic nephropathy; Pancreatic cancer

DM8TDBY	ID	DM8TDBY
DM8TDBY	DN	OCFENTANIL
DM8TDBY	HS	Phase 2
DM8TDBY	SN	Ocfentanil < Rec INN; A-3217 (hydrochloride); N-(2-Fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide; 1-(2-Phenylethyl)-4-[N-(2-fluorophenyl)methoxyacetamido]piperidine; 2'-Fluoro-2-methoxy-N-(1-phenethyl-4-piperidinyl)acetanilide
DM8TDBY	DT	Small molecular drug
DM8TDBY	PC	60575
DM8TDBY	MW	370.5
DM8TDBY	FM	C22H27FN2O2
DM8TDBY	IC	InChI=1S/C22H27FN2O2/c1-27-17-22(26)25(21-10-6-5-9-20(21)23)19-12-15-24(16-13-19)14-11-18-7-3-2-4-8-18/h2-10,19H,11-17H2,1H3
DM8TDBY	CS	COCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3F
DM8TDBY	IK	NYISTOZKVCMVEL-UHFFFAOYSA-N
DM8TDBY	IU	N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide
DM8TDBY	CA	CAS 101343-69-5
DM8TDBY	DE	Pain

DMT9QI2	ID	DMT9QI2
DMT9QI2	DN	OCV-101
DMT9QI2	HS	Phase 2
DMT9QI2	SN	OTS-11101
DMT9QI2	CP	OncoTherapy Science Inc
DMT9QI2	DE	Pancreatic cancer

DMK0MJP	ID	DMK0MJP
DMK0MJP	DN	Odelepran
DMK0MJP	HS	Phase 2
DMK0MJP	SN	Odelepran hydrochloride; LY2196044 HCl; LY-2196044; OpRA (alcohol dependence), Eli Lilly; OpRA II (alcoholism), Eli Lilly; Opioid receptor antagonist (alcoholism), Eli Lilly
DMK0MJP	CP	Eli Lilly & Co
DMK0MJP	DT	Small molecular drug
DMK0MJP	PC	10457387
DMK0MJP	MW	373.4
DMK0MJP	FM	C20H24FN3O3
DMK0MJP	IC	InChI=1S/C20H24FN3O3/c21-17-11-15(12-23-8-5-14-6-9-26-10-7-14)1-3-18(17)27-19-4-2-16(13-24-19)20(22)25/h1-4,11,13-14,23H,5-10,12H2,(H2,22,25)
DMK0MJP	CS	C1COCCC1CCNCC2=CC(=C(C=C2)OC3=NC=C(C=C3)C(=O)N)F
DMK0MJP	IK	QWNDOCKIKKQJNN-UHFFFAOYSA-N
DMK0MJP	IU	6-[2-fluoro-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyridine-3-carboxamide
DMK0MJP	CA	CAS 676501-25-0
DMK0MJP	DE	Alcohol dependence

DMJL4A7	ID	DMJL4A7
DMJL4A7	DN	O-desulfated heparin
DMJL4A7	HS	Phase 2
DMJL4A7	SN	Intravenous
DMJL4A7	CP	ParinGenix
DMJL4A7	DE	Chronic obstructive pulmonary disease

DMWCBY7	ID	DMWCBY7
DMWCBY7	DN	Odiparcil
DMWCBY7	HS	Phase 2
DMWCBY7	SN	SB-424323
DMWCBY7	CP	GlaxoSmithKline
DMWCBY7	DT	Small molecular drug
DMWCBY7	PC	216385
DMWCBY7	MW	324.4
DMWCBY7	FM	C15H16O6S
DMWCBY7	IC	InChI=1S/C15H16O6S/c1-7-4-12(17)21-11-5-8(2-3-9(7)11)20-15-14(19)13(18)10(16)6-22-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13+,14-,15-/m1/s1
DMWCBY7	CS	CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H](CS3)O)O)O
DMWCBY7	IK	JRHNIQQUVJOPQC-AQNFWKISSA-N
DMWCBY7	IU	4-methyl-7-[(2R,3R,4S,5S)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one
DMWCBY7	CA	CAS 137215-12-4
DMWCBY7	DE	Cardiovascular disease

DMVC90W	ID	DMVC90W
DMVC90W	DN	Oglemilast
DMVC90W	HS	Phase 2
DMVC90W	SN	GRC-3886; Oglemilast (oral, COPD/asthma), Glenmark
DMVC90W	CP	Glenmark Pharmaceuticals Ltd
DMVC90W	DT	Small molecular drug
DMVC90W	PC	11387409
DMVC90W	MW	516.299
DMVC90W	FM	C20H13Cl2F2N3O5S
DMVC90W	IC	InChI=1S/C20H13Cl2F2N3O5S/c1-33(29,30)27-9-2-4-14-11(6-9)16-10(3-5-15(18(16)31-14)32-20(23)24)19(28)26-17-12(21)7-25-8-13(17)22/h2-8,20,27H,1H3,(H,25,26,28)
DMVC90W	CS	CS(=O)(=O)NC1=CC2=C(C=C1)OC3=C(C=CC(=C23)C(=O)NC4=C(C=NC=C4Cl)Cl)OC(F)F
DMVC90W	IK	OKFDRAHPFKMAJH-UHFFFAOYSA-N
DMVC90W	IU	N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide
DMVC90W	CA	CAS 778576-62-8
DMVC90W	DE	Asthma

DMJTU8D	ID	DMJTU8D
DMJTU8D	DN	OGX-427
DMJTU8D	HS	Phase 2
DMJTU8D	CP	Isis Pharmaceuticals & OncoGenex
DMJTU8D	TC	Antisense
DMJTU8D	DT	Antisense drug
DMJTU8D	PC	71710946
DMJTU8D	MW	7157
DMJTU8D	FM	C224H304N79O116P19S19
DMJTU8D	IC	InChI=1S/C224H304N79O116P19S19/c1-88-46-284(216(318)257-168(88)225)129-34-97(401-420(327,439)363-60-114-102(39-134(386-114)289-52-94(7)187(306)281-222(289)324)406-421(328,440)362-56-110-98(35-130(381-110)285-47-89(2)169(226)258-217(285)319)402-422(329,441)368-63-119-107(44-139(390-119)297-81-252-147-182(297)267-211(237)276-194(147)313)411-430(337,449)372-66-121-108(45-140(392-121)298-82-253-148-183(298)268-212(238)277-195(148)314)412-431(338,450)375-69-123-154(163(357-29-21-349-13)201(396-123)292-54-96(9)189(308)283-224(292)326)414-435(342,454)377-70-124-155(162(356-28-20-348-12)200(395-124)290-51-93(6)173(230)262-221(290)323)415-436(343,455)378-72-126-157(165(359-31-23-351-15)203(398-126)300-84-247-142-175(232)243-76-245-177(142)300)417-433(340,452)374-68-122-152(305)160(354-26-18-346-10)199(394-122)291-53-95(8)188(307)282-223(291)325)111(382-129)57-364-426(333,445)407-103-40-135(293-77-248-143-178(293)263-207(233)272-190(143)309)387-116(103)61-367-423(330,442)403-99-36-131(286-48-90(3)170(227)259-218(286)320)384-113(99)59-366-428(335,447)409-105-42-137(295-79-250-145-180(295)265-209(235)274-192(145)311)391-120(105)65-371-429(336,448)410-106-43-138(296-80-251-146-181(296)266-210(236)275-193(146)312)389-118(106)62-369-424(331,443)404-100-37-132(287-49-91(4)171(228)260-219(287)321)383-112(100)58-365-427(334,446)408-104-41-136(294-78-249-144-179(294)264-208(234)273-191(144)310)388-117(104)64-370-425(332,444)405-101-38-133(288-50-92(5)172(229)261-220(288)322)385-115(101)67-373-432(339,451)416-156-125(397-202(164(156)358-30-22-350-14)299-83-246-141-174(231)242-75-244-176(141)299)71-379-437(344,456)419-159-128(400-206(167(159)361-33-25-353-17)303-87-256-151-186(303)271-215(241)280-198(151)317)74-380-438(345,457)418-158-127(399-205(166(158)360-32-24-352-16)302-86-255-150-185(302)270-214(240)279-197(150)316)73-376-434(341,453)413-153-109(55-304)393-204(161(153)355-27-19-347-11)301-85-254-149-184(301)269-213(239)278-196(149)315/h46-54,75-87,97-140,152-167,199-206,304-305H,18-45,55-74H2,1-17H3,(H,327,439)(H,328,440)(H,329,441)(H,330,442)(H,331,443)(H,332,444)(H,333,445)(H,334,446)(H,335,447)(H,336,448)(H,337,449)(H,338,450)(H,339,451)(H,340,452)(H,341,453)(H,342,454)(H,343,455)(H,344,456)(H,345,457)(H2,225,257,318)(H2,226,258,319)(H2,227,259,320)(H2,228,260,321)(H2,229,261,322)(H2,230,262,323)(H2,231,242,244)(H2,232,243,245)(H,281,306,324)(H,282,307,325)(H,283,308,326)(H3,233,263,272,309)(H3,234,264,273,310)(H3,235,265,274,311)(H3,236,266,275,312)(H3,237,267,276,313)(H3,238,268,277,314)(H3,239,269,278,315)(H3,240,270,279,316)(H3,241,271,280,317)/t97?,98?,99?,100?,101?,102?,103?,104?,105?,106?,107?,108?,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,152?,153?,154?,155?,156?,157?,158?,159?,160?,161?,162?,163?,164?,165?,166?,167?,199-,200-,201-,202-,203-,204-,205-,206-,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?/m1/s1
DMJTU8D	CS	CC1=CN(C(=O)NC1=O)[C@H]2CC([C@H](O2)COP(=S)(O)OC3C[C@@H](O[C@@H]3COP(=S)(O)OC4C[C@@H](O[C@@H]4COP(=S)(O)OC5C[C@@H](O[C@@H]5COP(=S)(O)OC6C[C@@H](O[C@@H]6COP(=S)(O)OC7C[C@@H](O[C@@H]7COP(=S)(O)OC8C[C@@H](O[C@@H]8COP(=O)(OC9C[C@@H](O[C@@H]9COP(=S)(O)OC1C[C@@H](O[C@@H]1COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)S)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=NC2=C1N=CNC2=N)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O
DMJTU8D	IK	RMTMMKNSPRRFHW-SVAVBUBPSA-N
DMJTU8D	IU	1-[(2R,5R)-5-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,5R)-3-[[(2R,5R)-3-[[(2R,5R)-3-[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[hydroxy-[[(2R,5R)-3-[hydroxy-[[(2R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(6-imino-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMJTU8D	CA	CAS 1002331-21-6
DMJTU8D	DE	Lung cancer; Prostate cancer; Bladder cancer; Ovarian cancer; Breast cancer

DMNEHY1	ID	DMNEHY1
DMNEHY1	DN	OI338GT
DMNEHY1	HS	Phase 2
DMNEHY1	CP	Novo Nordisk
DMNEHY1	DE	Type-1/2 diabetes; Type-1 diabetes; Type-2 diabetes

DMVW5KR	ID	DMVW5KR
DMVW5KR	DN	Olcegepant
DMVW5KR	HS	Phase 2
DMVW5KR	SN	Olcegepant [INN]; BIBN 4096; BIBN 4096 BS; BIBN-4096; BIBN-4096BS; N-((1R)-2-(((1S)-5-Amino-1-((4-(pyridin-4-yl)piperazin-1-yl)carbonyl)pentyl)amino)-1-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl)-4-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)piperidine-1-carboxamide; N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide
DMVW5KR	CP	Boehringer Ingelheim
DMVW5KR	DT	Small molecular drug
DMVW5KR	PC	6918509
DMVW5KR	MW	869.6
DMVW5KR	FM	C38H47Br2N9O5
DMVW5KR	IC	InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)/t32-,33+/m0/s1
DMVW5KR	CS	C1CN(CCC1N2CC3=CC=CC=C3NC2=O)C(=O)N[C@H](CC4=CC(=C(C(=C4)Br)O)Br)C(=O)N[C@@H](CCCCN)C(=O)N5CCN(CC5)C6=CC=NC=C6
DMVW5KR	IK	ITIXDWVDFFXNEG-JHOUSYSJSA-N
DMVW5KR	IU	N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide
DMVW5KR	CA	CAS 204697-65-4
DMVW5KR	DE	Migraine

DM0RA8F	ID	DM0RA8F
DM0RA8F	DN	Oleoyl-estrone
DM0RA8F	HS	Phase 2
DM0RA8F	SN	Anti-obesity hormone-based therapy, Manhattan
DM0RA8F	CP	Oleoyl-Estrone Developments
DM0RA8F	DT	Small molecular drug
DM0RA8F	PC	6918373
DM0RA8F	MW	534.8
DM0RA8F	FM	C36H54O3
DM0RA8F	IC	InChI=1S/C36H54O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-35(38)39-29-20-22-30-28(27-29)19-21-32-31(30)25-26-36(2)33(32)23-24-34(36)37/h10-11,20,22,27,31-33H,3-9,12-19,21,23-26H2,1-2H3/b11-10-/t31-,32-,33+,36+/m1/s1
DM0RA8F	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CCC4=O)C
DM0RA8F	IK	IMIPDPVHGGHVNH-YWVHRCQQSA-N
DM0RA8F	IU	[(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] (Z)-octadec-9-enoate
DM0RA8F	CA	CAS 180003-17-2
DM0RA8F	DE	Obesity; Alzheimer disease; Psychotic disorder

DMXL7HO	ID	DMXL7HO
DMXL7HO	DN	OLX10010
DMXL7HO	HS	Phase 2
DMXL7HO	SN	OLX 101A
DMXL7HO	CP	Olix Pharmaceuticals
DMXL7HO	DT	Small interfering RNA
DMXL7HO	DE	Hypertrophic scars

DMLMNFX	ID	DMLMNFX
DMLMNFX	DN	Omaveloxolone
DMLMNFX	HS	Phase 2
DMLMNFX	SN	RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563
DMLMNFX	CP	Reata Pharmaceuticals Irving, TX
DMLMNFX	DT	Small molecular drug
DMLMNFX	PC	71811910
DMLMNFX	MW	554.7
DMLMNFX	FM	C33H44F2N2O3
DMLMNFX	IC	InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1
DMLMNFX	CS	C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F
DMLMNFX	IK	RJCWBNBKOKFWNY-IDPLTSGASA-N
DMLMNFX	IU	N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
DMLMNFX	CA	CAS 1474034-05-3
DMLMNFX	DE	Friedreich's ataxia; Melanoma; Psychiatric disorder

DMH9RTV	ID	DMH9RTV
DMH9RTV	DN	Omigapil
DMH9RTV	HS	Phase 2
DMH9RTV	SN	Omigapil); CGP-3466; CGP-3499B; Neuroprotectant, Novartis; Neuroprotectant, Santhera; Nootropic agent, Novartis; Nootropicagent, Santhera; SNT-317; TCH-346; TCH-346B
DMH9RTV	CP	Novartis AG
DMH9RTV	DT	Small molecular drug
DMH9RTV	PC	6419718
DMH9RTV	MW	275.3
DMH9RTV	FM	C19H17NO
DMH9RTV	IC	InChI=1S/C19H17NO/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19/h1,4-11,13H,12,14H2,2H3
DMH9RTV	CS	CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C31
DMH9RTV	IK	QLMMOGWZCFQAPU-UHFFFAOYSA-N
DMH9RTV	IU	N-(benzo[b][1]benzoxepin-5-ylmethyl)-N-methylprop-2-yn-1-amine
DMH9RTV	CA	CAS 181296-84-4
DMH9RTV	CB	CHEBI:41778
DMH9RTV	DE	Lateral sclerosis; Muscular dystrophy

DMWC36Y	ID	DMWC36Y
DMWC36Y	DN	OMS405
DMWC36Y	HS	Phase 2
DMWC36Y	CP	Omeros
DMWC36Y	DE	Nicotine dependence; Opioid dependence

DMA4OGL	ID	DMA4OGL
DMA4OGL	DN	OMS824
DMA4OGL	HS	Phase 2
DMA4OGL	SN	OMS-824
DMA4OGL	CP	Omeros
DMA4OGL	DE	Huntington disease

DMT6E5N	ID	DMT6E5N
DMT6E5N	DN	Onapristone
DMT6E5N	HS	Phase 2
DMT6E5N	SN	Onapristone; 96346-61-1; Onapristone [INN]; ZK-98299; Onapristonum [Latin]; Onapristona [Spanish]; UNII-H6H7G23O3N; ZK 299; CCRIS 6530; ZK 98299; ZK-299; H6H7G23O3N; C29H39NO3; Onapristone (INN); Onapristonum; Onapristona; (8S,11R,13R,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-, (11-beta,13-alpha,17-alpha)-
DMT6E5N	CP	Context Therapeutics
DMT6E5N	DT	Small molecular drug
DMT6E5N	PC	5311505
DMT6E5N	MW	449.6
DMT6E5N	FM	C29H39NO3
DMT6E5N	IC	InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1
DMT6E5N	CS	C[C@@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(CCCO)O)C5=CC=C(C=C5)N(C)C
DMT6E5N	IK	IEXUMDBQLIVNHZ-YOUGDJEHSA-N
DMT6E5N	IU	(8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMT6E5N	CA	CAS 96346-61-1
DMT6E5N	DE	Breast cancer

DMM5SCF	ID	DMM5SCF
DMM5SCF	DN	ONC201
DMM5SCF	HS	Phase 2
DMM5SCF	SN	Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid
DMM5SCF	CP	Oncoceutics Philadelphia, PA
DMM5SCF	PC	73777259
DMM5SCF	MW	386.5
DMM5SCF	FM	C24H26N4O
DMM5SCF	IC	InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3
DMM5SCF	CS	CC1=CC=CC=C1CN2C(=O)C3=C(CCN(C3)CC4=CC=CC=C4)N5C2=NCC5
DMM5SCF	IK	VLULRUCCHYVXOH-UHFFFAOYSA-N
DMM5SCF	IU	11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one
DMM5SCF	CA	CAS 1616632-77-9
DMM5SCF	DE	Glioma; Endometrial cancer; leukaemia; Lymphoma; Multiple myeloma; Neuroendocrine cancer; Recurring respiratory infection; Solid tumour/cancer

DMKIZAL	ID	DMKIZAL
DMKIZAL	DN	ONO-1603
DMKIZAL	HS	Phase 2
DMKIZAL	SN	N-(4-Chlorobenzyl)-4-[2(S)-formylpyrrolidin-1-yl]-4-oxobutyramide
DMKIZAL	DT	Small molecular drug
DMKIZAL	PC	9797271
DMKIZAL	MW	322.78
DMKIZAL	FM	C16H19ClN2O3
DMKIZAL	IC	InChI=1S/C16H19ClN2O3/c17-13-5-3-12(4-6-13)10-18-15(21)7-8-16(22)19-9-1-2-14(19)11-20/h3-6,11,14H,1-2,7-10H2,(H,18,21)/t14-/m0/s1
DMKIZAL	CS	C1C[C@H](N(C1)C(=O)CCC(=O)NCC2=CC=C(C=C2)Cl)C=O
DMKIZAL	IK	KGDFDVHLEYUZLN-AWEZNQCLSA-N
DMKIZAL	IU	N-[(4-chlorophenyl)methyl]-4-[(2S)-2-formylpyrrolidin-1-yl]-4-oxobutanamide
DMKIZAL	DE	Cognitive impairment

DMOT0WR	ID	DMOT0WR
DMOT0WR	DN	ONO-2333Ms
DMOT0WR	HS	Phase 2
DMOT0WR	SN	Corticotropin-releasing factor-1 antagonist (oral, anxiety/depression), Ono
DMOT0WR	CP	Ono Pharmaceutical Co Ltd
DMOT0WR	PC	9801039
DMOT0WR	MW	398.9
DMOT0WR	FM	C22H27ClN4O
DMOT0WR	IC	InChI=1S/C22H27ClN4O/c1-5-14(6-2)24-21-17-8-7-9-19(17)25-22-20(13(3)26-27(21)22)16-11-10-15(28-4)12-18(16)23/h10-12,14,24H,5-9H2,1-4H3
DMOT0WR	CS	CCC(CC)NC1=C2CCCC2=NC3=C(C(=NN31)C)C4=C(C=C(C=C4)OC)Cl
DMOT0WR	IK	LDIOUQIXNSSOGU-UHFFFAOYSA-N
DMOT0WR	IU	10-(2-chloro-4-methoxyphenyl)-11-methyl-N-pentan-3-yl-1,8,12-triazatricyclo[7.3.0.03,7]dodeca-2,7,9,11-tetraen-2-amine
DMOT0WR	CA	CAS 441060-02-2
DMOT0WR	DE	Anxiety disorder

DMOGYQ0	ID	DMOGYQ0
DMOGYQ0	DN	ONO-2952
DMOGYQ0	HS	Phase 2
DMOGYQ0	SN	Translocator protein 18kDr (TSPO) antagonist (irritable bowel syndrome), Ono Pharmaceutical
DMOGYQ0	CP	Ono Pharmaceutical Co Ltd
DMOGYQ0	PC	11524127
DMOGYQ0	MW	398.9
DMOGYQ0	FM	C22H20ClFN2O2
DMOGYQ0	IC	InChI=1S/C22H20ClFN2O2/c1-12(27)26-11-22(8-9-22)19-18-15(24)4-3-5-16(18)25-20(19)21(26)14-7-6-13(23)10-17(14)28-2/h3-7,10,21,25H,8-9,11H2,1-2H3/t21-/m0/s1
DMOGYQ0	CS	CC(=O)N1CC2(CC2)C3=C([C@@H]1C4=C(C=C(C=C4)Cl)OC)NC5=C3C(=CC=C5)F
DMOGYQ0	IK	ZBQMTQGDBFZUBG-NRFANRHFSA-N
DMOGYQ0	IU	1-[(1S)-1-(4-chloro-2-methoxyphenyl)-5-fluorospiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,1'-cyclopropane]-2-yl]ethanone
DMOGYQ0	CA	CAS 895169-20-7
DMOGYQ0	DE	Irritable bowel syndrome

DMQGO74	ID	DMQGO74
DMQGO74	DN	ONO-3307
DMQGO74	HS	Phase 2
DMQGO74	SN	4-Guanidinobenzoic acid 4-sulfamoylphenyl ester methanesulfonate
DMQGO74	DT	Small molecular drug
DMQGO74	PC	127139
DMQGO74	MW	334.35
DMQGO74	FM	C14H14N4O4S
DMQGO74	IC	InChI=1S/C14H14N4O4S/c15-14(16)18-10-3-1-9(2-4-10)13(19)22-11-5-7-12(8-6-11)23(17,20)21/h1-8H,(H4,15,16,18)(H2,17,20,21)
DMQGO74	CS	C1=CC(=CC=C1C(=O)OC2=CC=C(C=C2)S(=O)(=O)N)N=C(N)N
DMQGO74	IK	YFUQTMNUQVFBBS-UHFFFAOYSA-N
DMQGO74	IU	(4-sulfamoylphenyl) 4-(diaminomethylideneamino)benzoate
DMQGO74	CA	CAS 76472-28-1
DMQGO74	DE	Coagulation defect

DMX4MVP	ID	DMX4MVP
DMX4MVP	DN	ONO-4053
DMX4MVP	HS	Phase 2
DMX4MVP	SN	PGD2 receptor antagonist (allergic rhinitis), Ono Pharmaceutical; Prostaglandin D2 receptor antagonists (allergy/inflammation), Ono Pharmaceutical
DMX4MVP	CP	Ono Pharmaceutical Co Ltd
DMX4MVP	DE	Allergic rhinitis

DMLUM3Y	ID	DMLUM3Y
DMLUM3Y	DN	ONO-4641
DMLUM3Y	HS	Phase 2
DMLUM3Y	SN	Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono
DMLUM3Y	CP	Emd serono
DMLUM3Y	PC	11502996
DMLUM3Y	MW	435.6
DMLUM3Y	FM	C27H33NO4
DMLUM3Y	IC	InChI=1S/C27H33NO4/c1-4-5-19-6-7-22(26(12-19)31-3)17-32-24-10-11-25-18(2)21(9-8-20(25)13-24)14-28-15-23(16-28)27(29)30/h6-7,10-13,23H,4-5,8-9,14-17H2,1-3H3,(H,29,30)
DMLUM3Y	CS	CCCC1=CC(=C(C=C1)COC2=CC3=C(C=C2)C(=C(CC3)CN4CC(C4)C(=O)O)C)OC
DMLUM3Y	IK	QDDQIPUKAXBMBX-UHFFFAOYSA-N
DMLUM3Y	IU	1-[[6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid
DMLUM3Y	CA	CAS 891859-12-4
DMLUM3Y	DE	Rheumatoid arthritis

DMFX3P1	ID	DMFX3P1
DMFX3P1	DN	ONO-5129
DMFX3P1	HS	Phase 2
DMFX3P1	SN	Dual PPAR alpha/gamma agonist (metabolic disorder), Ono
DMFX3P1	CP	Ono Pharmaceutical Co Ltd
DMFX3P1	DE	Diabetic complication

DMRT28X	ID	DMRT28X
DMRT28X	DN	ONO-6126
DMRT28X	HS	Phase 2
DMRT28X	SN	21-Cyanosaframycin-B; NSC 325663; 66082-27-7; C29H30N4O8; 21-cyanosaframycin B; AC1L2P2O; SCHEMBL637953; CHEMBL452709
DMRT28X	CP	Ono Pharmaceuticals
DMRT28X	DT	Small molecular drug
DMRT28X	PC	9864321
DMRT28X	MW	373.4
DMRT28X	FM	C20H27N3O4
DMRT28X	IC	InChI=1S/C20H27N3O4/c1-26-17-7-6-15(12-18(17)27-16-4-2-3-5-16)20(14-21)8-10-23(11-9-20)13-19(24)22-25/h6-7,12,16,25H,2-5,8-11,13H2,1H3,(H,22,24)
DMRT28X	CS	COC1=C(C=C(C=C1)C2(CCN(CC2)CC(=O)NO)C#N)OC3CCCC3
DMRT28X	IK	VXYDHPDQMSVQCU-UHFFFAOYSA-N
DMRT28X	IU	2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-N-hydroxyacetamide
DMRT28X	CA	CAS 401519-28-6
DMRT28X	DE	Chronic obstructive pulmonary disease

DM5O6GC	ID	DM5O6GC
DM5O6GC	DN	ONO-9054
DM5O6GC	HS	Phase 2
DM5O6GC	CP	Ono pharmaceutical
DM5O6GC	DE	Glaucoma/ocular hypertension

DMCUGI8	ID	DMCUGI8
DMCUGI8	DN	ONO-AE1-437
DMCUGI8	HS	Phase 2
DMCUGI8	SN	16-[3-(Methoxymethyl)phenyl]-5-thia-17,18,19,20-tetranorprostaglandin E1
DMCUGI8	DT	Small molecular drug
DMCUGI8	PC	9824353
DMCUGI8	MW	436.6
DMCUGI8	FM	C23H32O6S
DMCUGI8	IC	InChI=1S/C23H32O6S/c1-29-15-17-5-2-4-16(12-17)13-18(24)7-8-19-20(22(26)14-21(19)25)9-11-30-10-3-6-23(27)28/h2,4-5,7-8,12,18-21,24-25H,3,6,9-11,13-15H2,1H3,(H,27,28)/b8-7+/t18-,19-,20-,21-/m1/s1
DMCUGI8	CS	COCC1=CC=CC(=C1)C[C@@H](/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCSCCCC(=O)O)O)O
DMCUGI8	IK	ORSJUPRAHPZYRL-XHTUOEPPSA-N
DMCUGI8	IU	4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-5-oxocyclopentyl]ethylsulfanyl]butanoic acid
DMCUGI8	CA	CAS 256382-23-7
DMCUGI8	DE	Asthma

DMS8Q7A	ID	DMS8Q7A
DMS8Q7A	DN	Ontazolast
DMS8Q7A	HS	Phase 2
DMS8Q7A	SN	Ontazolast; UNII-8P8TW6B25I; BIRM-270; 147432-77-7; 8P8TW6B25I; N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine; Ontazolast [USAN:INN]; AC1Q4WID; Ontazolast (USAN/INN); SCHEMBL75875; AC1L2G78; CHEMBL2104845; 2-(((S)-2-Cyclohexyl-1-(2-pyridyl)ethyl)amino)-5-methylbenzoxazole; n-[(1s)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine; D02847; 32254-EP2311827A1; 32254-EP2301933A1; 32254-EP2281815A1; 32254-EP2305640A2; 2-Benzoxazolamine, N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (S)-
DMS8Q7A	CP	Boehringer Ingelheim Corp
DMS8Q7A	DT	Small molecular drug
DMS8Q7A	PC	71458
DMS8Q7A	MW	335.4
DMS8Q7A	FM	C21H25N3O
DMS8Q7A	IC	InChI=1S/C21H25N3O/c1-15-10-11-20-19(13-15)24-21(25-20)23-18(17-9-5-6-12-22-17)14-16-7-3-2-4-8-16/h5-6,9-13,16,18H,2-4,7-8,14H2,1H3,(H,23,24)/t18-/m0/s1
DMS8Q7A	CS	CC1=CC2=C(C=C1)OC(=N2)N[C@@H](CC3CCCCC3)C4=CC=CC=N4
DMS8Q7A	IK	RVXKHAITGKBBAC-SFHVURJKSA-N
DMS8Q7A	IU	N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine
DMS8Q7A	CA	CAS 147432-77-7
DMS8Q7A	DE	Asthma

DM0FJIE	ID	DM0FJIE
DM0FJIE	DN	Ontuxizumab
DM0FJIE	HS	Phase 2
DM0FJIE	SN	Amatuximab
DM0FJIE	CP	EisaiWoodcliff Lake, NJ MorphotekExton, PA
DM0FJIE	DT	Antibody
DM0FJIE	DE	Melanoma; Merkel cell carcinoma; Soft tissue sarcoma; Colorectal cancer

DMB1WF3	ID	DMB1WF3
DMB1WF3	DN	OPC-14523
DMB1WF3	HS	Phase 2
DMB1WF3	SN	OPC-14523; UNII-1981OTB4DS; 1981OTB4DS; CHEMBL294144; 145969-30-8; OPC-14523 free base; SCHEMBL5022801; ZINC598353; BDBM50005656; 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-methoxy-3,4-dihydro-2-quinolinone; L001554; 2(1H)-Quinolinone, 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-3,4-dihydro-5-methoxy-
DMB1WF3	CP	Otsuka Pharmaceutical and Vela Pharmaceuticals; Pharmos and Otsaku
DMB1WF3	DT	Small molecular drug
DMB1WF3	PC	9892540
DMB1WF3	MW	413.9
DMB1WF3	FM	C23H28ClN3O2
DMB1WF3	IC	InChI=1S/C23H28ClN3O2/c1-29-22-8-3-7-21-20(22)9-10-23(28)27(21)12-4-11-25-13-15-26(16-14-25)19-6-2-5-18(24)17-19/h2-3,5-8,17H,4,9-16H2,1H3
DMB1WF3	CS	COC1=CC=CC2=C1CCC(=O)N2CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
DMB1WF3	IK	TZZGTNZBLPCBIS-UHFFFAOYSA-N
DMB1WF3	IU	1-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-methoxy-3,4-dihydroquinolin-2-one
DMB1WF3	CA	CAS 145969-30-8
DMB1WF3	DE	Mood disorder; Bulimia nervosa; Female sexual arousal dysfunction

DMIK2AD	ID	DMIK2AD
DMIK2AD	DN	OPC-64005
DMIK2AD	HS	Phase 2
DMIK2AD	CP	Otsuka Pharmaceutical
DMIK2AD	DE	Attention deficit hyperactivity disorder

DML6TAS	ID	DML6TAS
DML6TAS	DN	OPI-1002
DML6TAS	HS	Phase 2
DML6TAS	CP	Quark Pharm; Pfizer
DML6TAS	DT	siRNA drug
DML6TAS	DE	Acute kidney injury

DM1IBRT	ID	DM1IBRT
DM1IBRT	DN	OPN-305
DM1IBRT	HS	Phase 2
DM1IBRT	SN	OPN-301; TLR-specific mAbs (inflammatory diseases), Opsona; Toll-like receptor specific monoclonal antibodies (inflammatory diseases), Opsona
DM1IBRT	CP	Opsona therapeutics
DM1IBRT	DT	Antibody
DM1IBRT	DE	Myelodysplastic syndrome

DMYG1ZQ	ID	DMYG1ZQ
DMYG1ZQ	DN	OPNT001
DMYG1ZQ	HS	Phase 2
DMYG1ZQ	CP	Opiant Pharmaceuticals Santa Monica, CA
DMYG1ZQ	DE	Eating disorder

DM16RIC	ID	DM16RIC
DM16RIC	DN	Oprozomib
DM16RIC	HS	Phase 2
DM16RIC	CP	Onyx Pharmaceuticals
DM16RIC	DT	Small molecular drug
DM16RIC	PC	25067547
DM16RIC	MW	532.6
DM16RIC	FM	C25H32N4O7S
DM16RIC	IC	InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1
DM16RIC	CS	CC1=NC=C(S1)C(=O)N[C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@]3(CO3)C
DM16RIC	IK	SWZXEVABPLUDIO-WSZYKNRRSA-N
DM16RIC	IU	N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
DM16RIC	CA	CAS 935888-69-0
DM16RIC	DE	Solid tumour/cancer; Hodgkin lymphoma; Multiple myeloma; Haematological malignancy

DMS4XFI	ID	DMS4XFI
DMS4XFI	DN	OPT-302
DMS4XFI	HS	Phase 2
DMS4XFI	CP	Opthea
DMS4XFI	DE	Diabetic macular edema

DMR3P98	ID	DMR3P98
DMR3P98	DN	ORG 34517/34850
DMR3P98	HS	Phase 2
DMR3P98	SN	Sardomozide; 4-Aiah; SAM 486A; Cgp 48664; UNII-CEB05S0B9I; SAM486A; 149400-88-4; CEB05S0B9I; 4-amidinoindan-1-one 2'-amidinohydrazone; (E)-2-(4-carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide; Urea azine with 1-oxo-4-indancarboxamidine; Sardomozide chloride; Hydrazinecarboximidamide, 2-(4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene)-; 4-AMIDINOINDAN-1-ONE-2'-AMIDINOHYDRAZONE; 1443105-76-7; C11H14N6; Cgp 48664A; CHEMBL1202793; Sardomozide [INN]
DMR3P98	CP	Organon
DMR3P98	DT	Small molecular drug
DMR3P98	PC	9576789
DMR3P98	MW	230.27
DMR3P98	FM	C11H14N6
DMR3P98	IC	InChI=1S/C11H14N6/c12-10(13)8-3-1-2-7-6(8)4-5-9(7)16-17-11(14)15/h1-3H,4-5H2,(H3,12,13)(H4,14,15,17)/b16-9+
DMR3P98	CS	C1C/C(=N\\N=C(N)N)/C2=C1C(=CC=C2)C(=N)N
DMR3P98	IK	CYPGNVSXMAUSJY-CXUHLZMHSA-N
DMR3P98	IU	(1E)-1-(diaminomethylidenehydrazinylidene)-2,3-dihydroindene-4-carboximidamide
DMR3P98	CA	CAS 149400-88-4
DMR3P98	DE	Solid tumour/cancer; Mood disorder

DMAWXJT	ID	DMAWXJT
DMAWXJT	DN	ORG-13011
DMAWXJT	HS	Phase 2
DMAWXJT	SN	FIBOFLAPON; 936350-00-4; UNII-Y1NA96IX3T; Y1NA96IX3T; CHEMBL1922660; Fiboflapon [USAN:INN]; AM803; Fiboflapon (USAN); AM-803; AM 803; SCHEMBL11820; DTXSID20239496; DFQGDHBGRSTTHX-UHFFFAOYSA-N; GSK2190915B; ZINC68247071; BDBM50359080; AKOS030527019; SB16524; CS-3604; Fiboflapon; NCGC00485966-01; HY-15874; 1H-Indole-2-propanoic acid, 3-((1,1-dimethylethyl)thio)-1-((4-(6-ethoxy-3-pyridinyl)phenyl)methyl)-alpha,alpha-Dimethyl-5-((5-methyl-2-pyridinyl)methoxy)-; D10069
DMAWXJT	DT	Small molecular drug
DMAWXJT	PC	9907401
DMAWXJT	MW	370.4
DMAWXJT	FM	C18H25F3N4O
DMAWXJT	IC	InChI=1S/C18H25F3N4O/c19-18(20,21)15-5-6-22-16(14-15)24-12-10-23(11-13-24)7-1-2-8-25-9-3-4-17(25)26/h5-6,14H,1-4,7-13H2
DMAWXJT	CS	C1CC(=O)N(C1)CCCCN2CCN(CC2)C3=NC=CC(=C3)C(F)(F)F
DMAWXJT	IK	YKJJCYZZWWSBEW-UHFFFAOYSA-N
DMAWXJT	IU	1-[4-[4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]butyl]pyrrolidin-2-one
DMAWXJT	CA	CAS 142494-12-0
DMAWXJT	DE	Psychotic disorder; Anxiety disorder; Major depressive disorder

DMWN2EC	ID	DMWN2EC
DMWN2EC	DN	ORG-25935
DMWN2EC	HS	Phase 2
DMWN2EC	SN	Cis-N-(6-Methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-N-methylglycine hydrochloride
DMWN2EC	DT	Small molecular drug
DMWN2EC	PC	11717074
DMWN2EC	MW	339.4
DMWN2EC	FM	C21H25NO3
DMWN2EC	IC	InChI=1S/C21H25NO3/c1-22(14-20(23)24)13-17-9-8-16-12-18(25-2)10-11-19(16)21(17)15-6-4-3-5-7-15/h3-7,10-12,17,21H,8-9,13-14H2,1-2H3,(H,23,24)/t17-,21+/m1/s1
DMWN2EC	CS	CN(C[C@H]1CCC2=C([C@H]1C3=CC=CC=C3)C=CC(=C2)OC)CC(=O)O
DMWN2EC	IK	UEBBYLJZCHTLEG-UTKZUKDTSA-N
DMWN2EC	IU	2-[[(1R,2S)-6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl]methyl-methylamino]acetic acid
DMWN2EC	CA	CAS 1147011-84-4
DMWN2EC	DE	Psychotic disorder

DMDZ4R2	ID	DMDZ4R2
DMDZ4R2	DN	Org-30029
DMDZ4R2	HS	Phase 2
DMDZ4R2	SN	Org-30029; Org 30029; 101041-95-6; N'-Hydroxy-5,6-dimethoxybenzo[b]thiophene-2-carboximidamide hydrochloride; DTXSID50143698; AKOS015848621; Benzo(b)thiophene-2-carboximidamide, N-hydroxy-5,6-dimethoxy-, monohydrochloride; (Z)-N'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide hydrochloride
DMDZ4R2	CP	Organon BioSciences
DMDZ4R2	DT	Small molecular drug
DMDZ4R2	PC	9576838
DMDZ4R2	MW	288.75
DMDZ4R2	FM	C11H13ClN2O3S
DMDZ4R2	IC	InChI=1S/C11H12N2O3S.ClH/c1-15-7-3-6-4-10(11(12)13-14)17-9(6)5-8(7)16-2;/h3-5,14H,1-2H3,(H2,12,13);1H
DMDZ4R2	CS	COC1=C(C=C2C(=C1)C=C(S2)/C(=N/O)/N)OC.Cl
DMDZ4R2	IK	DVWBMWJOYIFITF-UHFFFAOYSA-N
DMDZ4R2	IU	N'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide;hydrochloride
DMDZ4R2	CA	CAS 101041-95-6
DMDZ4R2	DE	Heart failure

DMIO59F	ID	DMIO59F
DMIO59F	DN	ORG-34517
DMIO59F	HS	Phase 2
DMIO59F	SN	11beta-(1,3-Benzodioxol-5-yl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
DMIO59F	CP	Organon
DMIO59F	DT	Small molecular drug
DMIO59F	PC	9867361
DMIO59F	MW	430.5
DMIO59F	FM	C28H30O4
DMIO59F	IC	InChI=1S/C28H30O4/c1-3-11-28(30)12-10-23-21-7-4-17-13-19(29)6-8-20(17)26(21)22(15-27(23,28)2)18-5-9-24-25(14-18)32-16-31-24/h5,9,13-14,21-23,30H,4,6-8,10,12,15-16H2,1-2H3/t21-,22+,23-,27-,28-/m0/s1
DMIO59F	CS	CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC6=C(C=C5)OCO6)C)O
DMIO59F	IK	DFELGYQKEOCHOA-BZAFBGKRSA-N
DMIO59F	IU	(8S,11R,13S,14S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMIO59F	CA	CAS 189035-07-2
DMIO59F	DE	Depression

DM8ARQW	ID	DM8ARQW
DM8ARQW	DN	ORM-12741
DM8ARQW	HS	Phase 2
DM8ARQW	SN	Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion
DM8ARQW	CP	Orion Corp
DM8ARQW	DT	Small molecular drug
DM8ARQW	PC	71301276
DM8ARQW	MW	285.4
DM8ARQW	FM	C18H23NO2
DM8ARQW	IC	InChI=1S/C18H23NO2/c1-18(12-20-2)9-5-10-19-11-8-14-13-6-3-4-7-15(13)21-16(14)17(18)19/h3-4,6-7,17H,5,8-12H2,1-2H3/t17-,18-/m1/s1
DM8ARQW	CS	C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC
DM8ARQW	IK	OCUKPFWNSAAHRP-QZTJIDSGSA-N
DM8ARQW	IU	(1S,12bS)-1-(methoxymethyl)-1-methyl-2,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine
DM8ARQW	CA	CAS 610782-82-6
DM8ARQW	DE	Alzheimer disease

DMRIO6D	ID	DMRIO6D
DMRIO6D	DN	ORMD-0901
DMRIO6D	HS	Phase 2
DMRIO6D	SN	Exenatide-4 (oral, diabetes), Oramed; GLP1-analog (oral, non-insulin dependent diabetes), Oramed Pharmaceuticals
DMRIO6D	CP	Oramed Pharmaceuticals Inc
DMRIO6D	DE	Type-2 diabetes

DM1EK5D	ID	DM1EK5D
DM1EK5D	DN	Ortataxel
DM1EK5D	HS	Phase 2
DM1EK5D	SN	UNII-8H61Y4E29N; 186348-23-2; 8H61Y4E29N; IDN-5109; IDN 5109; Ortataxel [INN]; Bay-59-8862; SB-T-101131; SB-T 101131; idn5109; SCHEMBL9932772; CHEMBL382300; BAY-59; IND-5109; DB11669; Z-3102; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-,;  Hexanoic acid; IND5109; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate; Genz29155
DM1EK5D	CP	Spectrum
DM1EK5D	DT	Small molecular drug
DM1EK5D	PC	6918412
DM1EK5D	MW	871.9
DM1EK5D	FM	C44H57NO17
DM1EK5D	IC	InChI=1S/C44H57NO17/c1-20(2)17-25(45-38(53)61-40(6,7)8)29(49)37(52)57-30-21(3)28-31(56-22(4)46)33(50)42(11)26(48)18-27-43(19-55-27,60-23(5)47)32(42)35(58-36(51)24-15-13-12-14-16-24)44(41(28,9)10)34(30)59-39(54)62-44/h12-16,20,25-27,29-32,34-35,48-49H,17-19H2,1-11H3,(H,45,53)/t25-,26-,27+,29+,30+,31+,32-,34-,35-,42+,43-,44+/m0/s1
DM1EK5D	CS	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@]5(C2(C)C)[C@H]([C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)OC(=O)O5)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C
DM1EK5D	IK	BWKDAMBGCPRVPI-ZQRPHVBESA-N
DM1EK5D	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15R,16S)-4,12-diacetyloxy-9-hydroxy-15-[(2R,3S)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-10,14,20,20-tetramethyl-11,18-dioxo-6,17,19-trioxapentacyclo[11.6.1.01,16.03,10.04,7]icos-13-en-2-yl] benzoate
DM1EK5D	CA	CAS 186348-23-2
DM1EK5D	DE	Solid tumour/cancer; Heart transplant rejection

DMSO846	ID	DMSO846
DMSO846	DN	Orvepitant
DMSO846	HS	Phase 2
DMSO846	SN	Orvepitant; UNII-IIU6V0W3JD; 579475-18-6; GW823296X; IIU6V0W3JD; GW823296; Orvepitant [USAN:INN]; Orvepitant (USAN/INN); SCHEMBL1421784; CHEMBL2105667; XWNBGDJPEXZSQM-VZOBGQTKSA-N; BDBM50442585; ZINC56898864; AKOS030231272; SB17117; DB12427; NCGC00386593-01; (2R,4S)-N-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-4-((S)-6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)piperidine-1-c; D09650
DMSO846	CP	GSK
DMSO846	DT	Small molecular drug
DMSO846	PC	9852175
DMSO846	MW	628.6
DMSO846	FM	C31H35F7N4O2
DMSO846	IC	InChI=1S/C31H35F7N4O2/c1-18-12-23(32)4-6-26(18)27-16-24(40-10-11-41-25(17-40)5-7-28(41)43)8-9-42(27)29(44)39(3)19(2)20-13-21(30(33,34)35)15-22(14-20)31(36,37)38/h4,6,12-15,19,24-25,27H,5,7-11,16-17H2,1-3H3/t19-,24+,25+,27-/m1/s1
DMSO846	CS	CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN5[C@H](C4)CCC5=O
DMSO846	IK	XWNBGDJPEXZSQM-VZOBGQTKSA-N
DMSO846	IU	(2R,4S)-4-[(8aS)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide
DMSO846	CA	CAS 579475-18-6
DMSO846	DE	Anxiety disorder; Depression

DMJX3O8	ID	DMJX3O8
DMJX3O8	DN	OSI-027
DMJX3O8	HS	Phase 2
DMJX3O8	CP	OSI
DMJX3O8	DT	Small molecular drug
DMJX3O8	PC	135398516
DMJX3O8	MW	406.4
DMJX3O8	FM	C21H22N6O3
DMJX3O8	IC	InChI=1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24)
DMJX3O8	CS	COC1=CC=CC2=C1NC(=C2)C3=C4C(=NC=NN4C(=N3)C5CCC(CC5)C(=O)O)N
DMJX3O8	IK	JROFGZPOBKIAEW-UHFFFAOYSA-N
DMJX3O8	IU	4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid
DMJX3O8	CA	CAS 936890-98-1
DMJX3O8	CB	CHEBI:91363
DMJX3O8	DE	Renal cell carcinoma

DMBVI6E	ID	DMBVI6E
DMBVI6E	DN	Ostabolin-C
DMBVI6E	HS	Phase 2
DMBVI6E	CP	Zelos Therape.
DMBVI6E	DE	Osteoporosis

DMHKIOF	ID	DMHKIOF
DMHKIOF	DN	OT551
DMHKIOF	HS	Phase 2
DMHKIOF	CP	Colby Pharmaceuticals
DMHKIOF	DT	Small interfering RNA
DMHKIOF	DE	Age-related macular degeneration

DMTNOXQ	ID	DMTNOXQ
DMTNOXQ	DN	OT-551
DMTNOXQ	HS	Phase 2
DMTNOXQ	SN	Tempol-H prodrug, Othera
DMTNOXQ	CP	Othera Pharmaceuticals Inc
DMTNOXQ	DT	Small molecular drug
DMTNOXQ	PC	10131000
DMTNOXQ	MW	241.33
DMTNOXQ	FM	C13H23NO3
DMTNOXQ	IC	InChI=1S/C13H23NO3/c1-12(2)7-10(8-13(3,4)14(12)16)17-11(15)9-5-6-9/h9-10,16H,5-8H2,1-4H3
DMTNOXQ	CS	CC1(CC(CC(N1O)(C)C)OC(=O)C2CC2)C
DMTNOXQ	IK	ZWEXEKJLDHNLLA-UHFFFAOYSA-N
DMTNOXQ	IU	(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) cyclopropanecarboxylate
DMTNOXQ	CA	CAS 627085-11-4
DMTNOXQ	DE	Ocular inflammation

DMFNDBC	ID	DMFNDBC
DMFNDBC	DN	Otelixizumab
DMFNDBC	HS	Phase 2
DMFNDBC	CP	GSK
DMFNDBC	DT	Monoclonal antibody
DMFNDBC	DE	Type-1 diabetes

DM1AQLW	ID	DM1AQLW
DM1AQLW	DN	Otilimab
DM1AQLW	HS	Phase 2 
DM1AQLW	SN	Otilimab [USAN]; UNII-Y8127R3VCH; Y8127R3VCH; MOR103; GSK3196165; 1638332-55-4; human monoclonal antibody
DM1AQLW	TC	Antiviral Agents
DM1AQLW	DT	Monoclonal antibody
DM1AQLW	DE	Coronavirus Disease 2019 (COVID-19)

DMAZIND	ID	DMAZIND
DMAZIND	DN	Otlertuzumab
DMAZIND	HS	Phase 2
DMAZIND	CP	Aptevo Therapeutics Seattle, WA
DMAZIND	DE	Chronic lymphocytic leukaemia; Peripheral T-cell lymphoma

DM5Q9RY	ID	DM5Q9RY
DM5Q9RY	DN	OX-914
DM5Q9RY	HS	Phase 2
DM5Q9RY	CP	Inflazyme Pharmaceuticals
DM5Q9RY	DE	Asthma

DMBM47Z	ID	DMBM47Z
DMBM47Z	DN	Oxazolidinones
DMBM47Z	HS	Phase 2
DMBM47Z	SN	2-Oxazolidone; Oxazolidin-2-one; 2-Oxazolidinone; 497-25-6; 1,3-Oxazolidin-2-one; Oxazolidinone; Oxazolidone; UNII-Z4D49W92PP; EINECS 207-840-9; NSC 35382; BRN 0106251; AI3-38980; CHEBI:1237; Z4D49W92PP; IZXIZTKNFFYFOF-UHFFFAOYSA-N; Carbamic acid, (2-hydroxyethyl)-, gamma-lactone; MFCD00005268; 2-Oxazolidone, 98%; WLN: T5MVOTJ; 51667-26-6; Carbamic acid, .gamma.-lactone; Oxazolidinones; SMR000857362; oxazolodinone; hydroxyoxazoline; 2-oxazolidinon; hydroxy-oxazoline; 2-Oxazolidine; oxazolidine-2-one; PubChem8624; ACMC-209upq; AC1Q6HSI
DMBM47Z	DT	Small molecular drug
DMBM47Z	PC	73949
DMBM47Z	MW	87.08
DMBM47Z	FM	C3H5NO2
DMBM47Z	IC	InChI=1S/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5)
DMBM47Z	CS	C1COC(=O)N1
DMBM47Z	IK	IZXIZTKNFFYFOF-UHFFFAOYSA-N
DMBM47Z	IU	1,3-oxazolidin-2-one
DMBM47Z	CA	CAS 497-25-6
DMBM47Z	CB	CHEBI:1237
DMBM47Z	DE	Gram-positive bacterial infection

DMSNL51	ID	DMSNL51
DMSNL51	DN	Oxfendazole
DMSNL51	HS	Phase 2
DMSNL51	SN	Oxfendazole; Fenbendazole sulfoxide; Synanthic; Systamex; OFDZ; Systemax; Repidose; Oxfendazolum; Oxfendazol; Synanthic (Veterinary); RS-8858; fenbendazole S-oxide; RS 8858; 5-Phenylsulfinyl-2-carbomethoxyaminobenzimidazole; Oxfendazol [INN-Spanish]; Oxfendazolum [INN-Latin]; UNII-OMP2H17F9E; HOE 8105; methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate; Oxfendazole [USAN:BAN:INN]; Methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate; Oxfendazole (USP/INN)
DMSNL51	PC	40854
DMSNL51	MW	315.3
DMSNL51	FM	C15H13N3O3S
DMSNL51	IC	InChI=1S/C15H13N3O3S/c1-21-15(19)18-14-16-12-8-7-11(9-13(12)17-14)22(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)
DMSNL51	CS	COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3
DMSNL51	IK	BEZZFPOZAYTVHN-UHFFFAOYSA-N
DMSNL51	IU	methyl N-[6-(benzenesulfinyl)-1H-benzimidazol-2-yl]carbamate
DMSNL51	CA	CAS 53716-50-0
DMSNL51	CB	CHEBI:35812
DMSNL51	DE	Trichuris infection

DMC3PJS	ID	DMC3PJS
DMC3PJS	DN	Oxytrex
DMC3PJS	HS	Phase 2
DMC3PJS	DE	Pain

DMEGTH1	ID	DMEGTH1
DMEGTH1	DN	Ozarelix
DMEGTH1	HS	Phase 2
DMEGTH1	CP	Spectrum
DMEGTH1	PC	25080293
DMEGTH1	MW	1459.1
DMEGTH1	FM	C72H96ClN17O14
DMEGTH1	IC	InChI=1S/C72H96ClN17O14/c1-5-6-17-52(63(96)85-54(19-12-33-79-71(75)76)70(103)90-34-13-20-59(90)67(100)81-42(2)61(74)94)83-62(95)53(18-9-10-32-80-72(77)104)84-68(101)60(39-45-24-29-51(93)30-25-45)89(4)69(102)58(41-91)88-66(99)57(38-47-14-11-31-78-40-47)87-65(98)56(36-44-22-27-50(73)28-23-44)86-64(97)55(82-43(3)92)37-46-21-26-48-15-7-8-16-49(48)35-46/h7-8,11,14-16,21-31,35,40,42,52-60,91,93H,5-6,9-10,12-13,17-20,32-34,36-39,41H2,1-4H3,(H2,74,94)(H,81,100)(H,82,92)(H,83,95)(H,84,101)(H,85,96)(H,86,97)(H,87,98)(H,88,99)(H4,75,76,79)(H3,77,80,104)/t42-,52+,53-,54+,55-,56-,57-,58+,59+,60+/m1/s1
DMEGTH1	CS	CCCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DMEGTH1	IK	KATZUZNTRINHDT-HALMFYTRSA-N
DMEGTH1	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(carbamoylamino)hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMEGTH1	CA	CAS 295350-45-7
DMEGTH1	DE	Prostate disease

DMEYQPN	ID	DMEYQPN
DMEYQPN	DN	P-1736
DMEYQPN	HS	Phase 2
DMEYQPN	SN	Pyyy; GPR40 modulators (diabetes), Nicholas Piramal; GPR40 modulators (diabetes), Piramal Life Sciences; P-1736-05; GPR40 modulators (diabetes), NPIL Research & Development
DMEYQPN	CP	Piramal Healthcare Ltd
DMEYQPN	DE	Diabetic complication

DMMJUHD	ID	DMMJUHD
DMMJUHD	DN	P-276
DMMJUHD	HS	Phase 2
DMMJUHD	SN	CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development
DMMJUHD	CP	Piramal Healthcare Ltd
DMMJUHD	DT	Small molecular drug
DMMJUHD	PC	23643976
DMMJUHD	MW	401.8
DMMJUHD	FM	C21H20ClNO5
DMMJUHD	IC	InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1
DMMJUHD	CS	CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
DMMJUHD	IK	QLUYMIVVAYRECT-OCCSQVGLSA-N
DMMJUHD	IU	2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one
DMMJUHD	DE	Breast cancer

DM9DJL2	ID	DM9DJL2
DM9DJL2	DN	P276-00
DM9DJL2	HS	Phase 2
DM9DJL2	SN	CHEMBL2312181; SCHEMBL1180418
DM9DJL2	CP	Nicholas Piramal
DM9DJL2	DT	Small molecular drug
DM9DJL2	PC	23643975
DM9DJL2	MW	438.3
DM9DJL2	FM	C21H21Cl2NO5
DM9DJL2	IC	InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3;1H/t12-,14+;/m1./s1
DM9DJL2	CS	CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl
DM9DJL2	IK	OOVTUOCTLAERQD-OJMBIDBESA-N
DM9DJL2	IU	2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride
DM9DJL2	CA	CAS 920113-03-7
DM9DJL2	DE	Mantle cell lymphoma

DMW1OI6	ID	DMW1OI6
DMW1OI6	DN	P32/98
DMW1OI6	HS	Phase 2
DMW1OI6	SN	Isoleucine-thiazolidide; AC1OCFGS; MolPort-044-561-375
DMW1OI6	DT	Small molecular drug
DMW1OI6	PC	6918464
DMW1OI6	MW	318.39
DMW1OI6	FM	C13H22N2O5S
DMW1OI6	IC	InChI=1S/C9H18N2OS.C4H4O4/c1-3-7(2)8(10)9(12)11-4-5-13-6-11;5-3(6)1-2-4(7)8/h7-8H,3-6,10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t7-,8-;/m0./s1
DMW1OI6	CS	CC[C@H](C)[C@@H](C(=O)N1CCSC1)N.C(=C/C(=O)O)\\C(=O)O
DMW1OI6	IK	ZSOPWZQRZHWYFY-NUXPJIRBSA-N
DMW1OI6	IU	(2S,3S)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(E)-but-2-enedioic acid
DMW1OI6	DE	Autism spectrum disorder

DMCBEYH	ID	DMCBEYH
DMCBEYH	DN	P54
DMCBEYH	HS	Phase 2
DMCBEYH	DE	Solid tumour/cancer

DMG8NLI	ID	DMG8NLI
DMG8NLI	DN	P-9808
DMG8NLI	HS	Phase 2
DMG8NLI	SN	Porphogen; Porphozym; PBGD, HemeBiotech; PBGD, Zymenex; Recombinant porphobilinogen deaminase, HemeBiotech; Recombinant porphobilinogen deaminase, Zymenex
DMG8NLI	CP	Zymenex A/S
DMG8NLI	DE	Porphyria

DM3816P	ID	DM3816P
DM3816P	DN	PAC-14028
DM3816P	HS	Phase 2
DM3816P	CP	Pacific Pharmaceuticals Co Ltd
DM3816P	PC	56649347
DM3816P	MW	491.5
DM3816P	FM	C21H22F5N3O3S
DM3816P	IC	InChI=1S/C21H22F5N3O3S/c1-4-5-17-13(6-8-18(28-17)21(24,25)26)7-9-19(30)27-12(2)14-10-15(22)20(16(23)11-14)29-33(3,31)32/h6-12,29H,4-5H2,1-3H3,(H,27,30)/b9-7+/t12-/m1/s1
DM3816P	CS	CCCC1=C(C=CC(=N1)C(F)(F)F)/C=C/C(=O)N[C@H](C)C2=CC(=C(C(=C2)F)NS(=O)(=O)C)F
DM3816P	IK	UKGJZDSUJSPAJL-YPUOHESYSA-N
DM3816P	IU	(E)-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide
DM3816P	CA	CAS 1005168-10-4
DM3816P	DE	Atopic dermatitis

DMMIYZ7	ID	DMMIYZ7
DMMIYZ7	DN	Palifosfamide
DMMIYZ7	HS	Phase 2
DMMIYZ7	SN	ZIO-201
DMMIYZ7	CP	ZIOPHARM Oncology
DMMIYZ7	DT	Small molecular drug
DMMIYZ7	PC	100427
DMMIYZ7	MW	221.02
DMMIYZ7	FM	C4H11Cl2N2O2P
DMMIYZ7	IC	InChI=1S/C4H11Cl2N2O2P/c5-1-3-7-11(9,10)8-4-2-6/h1-4H2,(H3,7,8,9,10)
DMMIYZ7	CS	C(CCl)NP(=O)(NCCCl)O
DMMIYZ7	IK	BKCJZNIZRWYHBN-UHFFFAOYSA-N
DMMIYZ7	IU	bis(2-chloroethylamino)phosphinic acid
DMMIYZ7	CA	CAS 31645-39-3
DMMIYZ7	CB	CHEBI:80566
DMMIYZ7	DE	Soft tissue sarcoma

DMX8ZAQ	ID	DMX8ZAQ
DMX8ZAQ	DN	Paliroden
DMX8ZAQ	HS	Phase 2
DMX8ZAQ	SN	SR-57667; SR-57667B
DMX8ZAQ	CP	Sanofi-aventis
DMX8ZAQ	DT	Small molecular drug
DMX8ZAQ	PC	11567682
DMX8ZAQ	MW	407.5
DMX8ZAQ	FM	C26H24F3N
DMX8ZAQ	IC	InChI=1S/C26H24F3N/c27-26(28,29)25-8-4-7-24(19-25)23-14-17-30(18-15-23)16-13-20-9-11-22(12-10-20)21-5-2-1-3-6-21/h1-12,14,19H,13,15-18H2
DMX8ZAQ	CS	C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC=C(C=C3)C4=CC=CC=C4
DMX8ZAQ	IK	CNEWKIDCGDXBDE-UHFFFAOYSA-N
DMX8ZAQ	IU	1-[2-(4-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine
DMX8ZAQ	CA	CAS 188396-77-2
DMX8ZAQ	DE	Parkinson disease

DMAZ460	ID	DMAZ460
DMAZ460	DN	Pankomab-GEX
DMAZ460	HS	Phase 2
DMAZ460	SN	GT-MAB 2.5 GEX; PankoMab (GlycoExpress, cancer), Glycotope
DMAZ460	CP	Glycotope GmbH
DMAZ460	DT	Antibody
DMAZ460	DE	Solid tumour/cancer

DMV27SP	ID	DMV27SP
DMV27SP	DN	Panobacumab
DMV27SP	HS	Phase 2
DMV27SP	SN	KBPA-101; Human monoclonal antibody (Pseudomonas aeruginosa), Berna; MAb (Pseudomonas aeruginosa), Berna
DMV27SP	CP	Aridis Pharmaceuticals
DMV27SP	DT	Monoclonal antibody
DMV27SP	DE	Ventilator-associated pneumonia; Hospital-acquired pneumonia; Pseudomonas infection

DMPO4M1	ID	DMPO4M1
DMPO4M1	DN	Paquinimod
DMPO4M1	HS	Phase 2
DMPO4M1	SN	ABR-215757; ABR-25757; Project 57-57, Active Biotech
DMPO4M1	CP	Active Biotech AB
DMPO4M1	DT	Small molecular drug
DMPO4M1	PC	54684617
DMPO4M1	MW	350.4
DMPO4M1	FM	C21H22N2O3
DMPO4M1	IC	InChI=1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3
DMPO4M1	CS	CCC1=C2C(=CC=C1)N(C(=O)C(=C2O)C(=O)N(CC)C3=CC=CC=C3)C
DMPO4M1	IK	DIKSYHCCYVYKRO-UHFFFAOYSA-N
DMPO4M1	IU	N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
DMPO4M1	CA	CAS 248282-01-1
DMPO4M1	DE	Lupus

DMD275X	ID	DMD275X
DMD275X	DN	Pardoprunox
DMD275X	HS	Phase 2
DMD275X	SN	Pardoprunox (USAN/INN); 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one; 7-(4-methylpiperazin-1-yl)-3H-benzooxazol-2-one
DMD275X	CP	Solvay
DMD275X	DT	Small molecular drug
DMD275X	PC	6918525
DMD275X	MW	233.27
DMD275X	FM	C12H15N3O2
DMD275X	IC	InChI=1S/C12H15N3O2/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9/h2-4H,5-8H2,1H3,(H,13,16)
DMD275X	CS	CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3
DMD275X	IK	YVPUUUDAZYFFQT-UHFFFAOYSA-N
DMD275X	IU	7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one
DMD275X	CA	CAS 269718-84-5
DMD275X	DE	Parkinson disease

DM4N7BT	ID	DM4N7BT
DM4N7BT	DN	Paritaprevir
DM4N7BT	HS	Phase 2
DM4N7BT	SN	(2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous
DM4N7BT	TC	Antiviral Agent
DM4N7BT	DT	Small molecular drug
DM4N7BT	PC	45110509
DM4N7BT	MW	765.886
DM4N7BT	FM	C40H43N7O7S
DM4N7BT	IC	InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
DM4N7BT	CS	CC1=NC=C(N=C1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8
DM4N7BT	IK	UAUIUKWPKRJZJV-QPLHLKROSA-N
DM4N7BT	IU	(1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
DM4N7BT	CA	CAS 1216941-48-8
DM4N7BT	DE	Hepatitis C virus infection

DMYBIFS	ID	DMYBIFS
DMYBIFS	DN	Parsaclisib
DMYBIFS	HS	Phase 2
DMYBIFS	SN	INCB050465; Parsaclisib free base; UNII-OS7097575K; 1426698-88-5 (free base); OS7097575K; 1426698-88-5; (4R)-4-{3-[(1S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one; INCB-050465; (4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; Parsaclisib [INN]; Parsaclisib [USAN]; Parsaclisib (USAN/INN); Parsaclisib [USAN:INN]; INCB050465 free base; INCB-050465 free base; CHEMBL4297615; SCHEMBL14736228; BDBM272573; EX-A2638; WHO 10589; DB14867; US10065963, 32c; HY-109068; CS-0033435; D11437; (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; 2-Pyrrolidinone, 4-(3-((1S)-1-(4-amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4R)-
DMYBIFS	CP	Incyte
DMYBIFS	DT	Small molecular drug
DMYBIFS	PC	86677874
DMYBIFS	MW	432.9
DMYBIFS	FM	C20H22ClFN6O2
DMYBIFS	IC	InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1
DMYBIFS	CS	CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4
DMYBIFS	IK	ZQPDJCIXJHUERQ-QWRGUYRKSA-N
DMYBIFS	IU	(4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one
DMYBIFS	CA	CAS 1426698-88-5
DMYBIFS	DE	Follicular lymphoma

DMCQBFT	ID	DMCQBFT
DMCQBFT	DN	Parthenolide
DMCQBFT	HS	Phase 2
DMCQBFT	SN	parthenolide; 20554-84-1; (-)-Parthenolide; CHEBI:7939; Parthenolide, Tanacetum parthenium; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; partenolide; C15H20O3; 29552-41-8; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_001308; BSPBio_000599; MLS002153872; CHEMBL465158; BPBio1_000659; SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, &gt; MolPort-008-268-168; MolPort-003-959-089; HMS1361B10; HMS3402B10; HMS1989B10; HMS1791B10; HMS1569N21; HMS2096N21
DMCQBFT	DT	Small molecular drug
DMCQBFT	PC	7251185
DMCQBFT	MW	248.32
DMCQBFT	FM	C15H20O3
DMCQBFT	IC	InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1
DMCQBFT	CS	C/C/1=C\\CC[C@@]2([C@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C
DMCQBFT	IK	KTEXNACQROZXEV-PVLRGYAZSA-N
DMCQBFT	IU	(1S,2R,4R,7E,11S)-4,8-dimethyl-12-methylidene-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-13-one
DMCQBFT	CA	CAS 20554-84-1
DMCQBFT	CB	CHEBI:7939

DMU3XJP	ID	DMU3XJP
DMU3XJP	DN	Pascolizumab
DMU3XJP	HS	Phase 2
DMU3XJP	SN	SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs
DMU3XJP	CP	Novartis
DMU3XJP	DT	Monoclonal antibody
DMU3XJP	DE	Asthma

DM2NJYC	ID	DM2NJYC
DM2NJYC	DN	Patidegib
DM2NJYC	HS	Phase 2
DM2NJYC	SN	Patidegib hydrochloride; UNII-ZL14FCA5PK; 1169829-40-6; ZL14FCA5PK; IPI-926 Hydrochloride; Saridegib HCl; Patidegib [USAN:INN]; Saridegib [Rescinded USAN]; Saridegib hydrochloride (USAN); CHEMBL2105764; D10325; Methanesulfonamide, N-((2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)-   2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3H),9'(1'H)-naphth(2,1-a)azulen)-3'-yl)-
DM2NJYC	CP	PellePharm San Francisco, CA
DM2NJYC	PC	25027363
DM2NJYC	MW	504.8
DM2NJYC	FM	C29H48N2O3S
DM2NJYC	IC	InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1
DM2NJYC	CS	C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC[C@@H]6C[C@@H](CC[C@@]6([C@H]5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1
DM2NJYC	IK	HZLFFNCLTRVYJG-WWGOJCOQSA-N
DM2NJYC	IU	N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]methanesulfonamide
DM2NJYC	CA	CAS 1037210-93-7
DM2NJYC	DE	Basal cell carcinoma; Basal cell nevus syndrome; Chondrosarcoma

DMU0812	ID	DMU0812
DMU0812	DN	PAZ-320
DMU0812	HS	Phase 2
DMU0812	CP	Boston Therapeutics
DMU0812	DE	Type-2 diabetes

DMVJD2W	ID	DMVJD2W
DMVJD2W	DN	Pazopanib + Tyverb/Tykerb
DMVJD2W	HS	Phase 2
DMVJD2W	CP	GSK
DMVJD2W	DT	Combination drug
DMVJD2W	PC	10113978; 9941095
DMVJD2W	DE	Inflammatory breast cancer

DMZCI04	ID	DMZCI04
DMZCI04	DN	PB-1023
DMZCI04	HS	Phase 2
DMZCI04	CP	PhaseBio Pharmaceuticals
DMZCI04	DE	Type-2 diabetes

DM8MJ3F	ID	DM8MJ3F
DM8MJ3F	DN	PB1046
DM8MJ3F	HS	Phase 2
DM8MJ3F	SN	Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera
DM8MJ3F	CP	Phasebio pharmaceuticals
DM8MJ3F	DT	Recombinant protein
DM8MJ3F	DE	Hypertension; Cardiomyopathy; Duchenne dystrophy; Heart failure; Pulmonary arterial hypertension

DM05WIU	ID	DM05WIU
DM05WIU	DN	PBI-05204
DM05WIU	HS	Phase 2
DM05WIU	CP	Phoenix Biotechnology
DM05WIU	PC	11541511
DM05WIU	MW	576.7
DM05WIU	FM	C32H48O9
DM05WIU	IC	InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1
DM05WIU	CS	C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)OC(=O)C)O)C)C)OC)O
DM05WIU	IK	JLPDBLFIVFSOCC-XYXFTTADSA-N
DM05WIU	IU	[(3S,5R,8R,9S,10S,13R,14S,16S,17R)-14-hydroxy-3-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate
DM05WIU	CA	CAS 465-16-7
DM05WIU	CB	CHEBI:59030
DM05WIU	DE	Solid tumour/cancer; Pancreatic cancer

DMPXK27	ID	DMPXK27
DMPXK27	DN	PBI-4050
DMPXK27	HS	Phase 2
DMPXK27	SN	setogepram; (3-pentylphenyl)acetic acid; 2-(3-Pentylphenyl)acetic acid; 1002101-19-0; 3-Pentylbenzeneacetic acid; UNII-879OVM0Y1S; Benzeneacetic acid, 3-pentyl-; 879OVM0Y1S; 1002101-19-0 (free acid); Fezagepras; SCHEMBL289216; CHEMBL4297635; GTPL10043; PBI4050; ZINC113492390; DB15447; HY-100775A; AS-59875; CS-0062694; A1-19258; Q27895887
DMPXK27	CP	Liminal BioSciences
DMPXK27	DT	Small molecular drug
DMPXK27	PC	24749700
DMPXK27	MW	206.28
DMPXK27	FM	C13H18O2
DMPXK27	IC	InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15)
DMPXK27	CS	CCCCCC1=CC(=CC=C1)CC(=O)O
DMPXK27	IK	PEGQOIGYZLJMIB-UHFFFAOYSA-N
DMPXK27	IU	2-(3-pentylphenyl)acetic acid
DMPXK27	CA	CAS 1002101-19-0
DMPXK27	DE	Idiopathic pulmonary fibrosis

DMKWGS1	ID	DMKWGS1
DMKWGS1	DN	PBT-2
DMKWGS1	HS	Phase 2
DMKWGS1	SN	AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana
DMKWGS1	CP	Prana biotechnology
DMKWGS1	DT	Small molecular drug
DMKWGS1	PC	10016012
DMKWGS1	MW	271.14
DMKWGS1	FM	C12H12Cl2N2O
DMKWGS1	IC	InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3
DMKWGS1	CS	CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl
DMKWGS1	IK	YZPOQCQXOSEMAZ-UHFFFAOYSA-N
DMKWGS1	IU	5,7-dichloro-2-[(dimethylamino)methyl]quinolin-8-ol
DMKWGS1	CA	CAS 747408-78-2
DMKWGS1	DE	Alzheimer disease; Huntington disease

DMYRIHZ	ID	DMYRIHZ
DMYRIHZ	DN	PCL-016
DMYRIHZ	HS	Phase 2
DMYRIHZ	CP	Novactyl
DMYRIHZ	DE	Acne vulgaris

DMYFRTB	ID	DMYFRTB
DMYFRTB	DN	PCM-075
DMYFRTB	HS	Phase 2
DMYFRTB	SN	Onvansertib
DMYFRTB	CP	TrovaGene San Diego, CA
DMYFRTB	PC	49792852
DMYFRTB	MW	532.5
DMYFRTB	FM	C24H27F3N8O3
DMYFRTB	IC	InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)
DMYFRTB	CS	CN1CCN(CC1)C2=CC(=C(C=C2)OC(F)(F)F)NC3=NC=C4CCC5=C(C4=N3)N(N=C5C(=O)N)CCO
DMYFRTB	IK	QHLVBNKYJGBCQJ-UHFFFAOYSA-N
DMYFRTB	IU	1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide
DMYFRTB	CA	CAS 1034616-18-6
DMYFRTB	DE	Acute myeloid leukaemia; Solid tumour/cancer; Prostate cancer

DMUHDX3	ID	DMUHDX3
DMUHDX3	DN	PC-SOD
DMUHDX3	HS	Phase 2
DMUHDX3	SN	PC-SOD (inhaled)
DMUHDX3	CP	LTT Bio-Pharma Co Ltd
DMUHDX3	DE	Interstitial lung disease

DM27D4J	ID	DM27D4J
DM27D4J	DN	PD-0325901
DM27D4J	HS	Phase 2
DM27D4J	SN	PD 0325901; PD 325901; PD0325901; PD325901; PD-325901; S06-0029; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
DM27D4J	CP	Pfizer
DM27D4J	TC	Anticancer Agents
DM27D4J	DT	Small molecular drug
DM27D4J	PC	9826528
DM27D4J	MW	482.19
DM27D4J	FM	C16H14F3IN2O4
DM27D4J	IC	InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1
DM27D4J	CS	C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O
DM27D4J	IK	SUDAHWBOROXANE-SECBINFHSA-N
DM27D4J	IU	N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
DM27D4J	CA	CAS 391210-10-9
DM27D4J	CB	CHEBI:88249
DM27D4J	DE	Breast cancer

DMXAH4G	ID	DMXAH4G
DMXAH4G	DN	PD-143188
DMXAH4G	HS	Phase 2
DMXAH4G	SN	PD-147693; PD-149394; PD-155144; PD-163637; PD-163639
DMXAH4G	CP	Parke-Davis & Co
DMXAH4G	DT	Small molecular drug
DMXAH4G	PC	101650979
DMXAH4G	MW	329.5
DMXAH4G	FM	C24H27N
DMXAH4G	IC	InChI=1S/C24H27N/c1-3-9-21(10-4-1)23-14-16-25(17-15-23)19-20-8-7-13-24(18-20)22-11-5-2-6-12-22/h1-7,9-14,20,24H,8,15-19H2/t20-,24?/m1/s1
DMXAH4G	CS	C1CN(CC=C1C2=CC=CC=C2)C[C@@H]3CC=CC(C3)C4=CC=CC=C4
DMXAH4G	IK	SDOHTVBFDDPWNE-CGHJUBPDSA-N
DMXAH4G	IU	4-phenyl-1-[[(1R)-5-phenylcyclohex-3-en-1-yl]methyl]-3,6-dihydro-2H-pyridine
DMXAH4G	DE	Psychotic disorder

DMWVBTQ	ID	DMWVBTQ
DMWVBTQ	DN	PD-145065
DMWVBTQ	HS	Phase 2
DMWVBTQ	SN	N-Acetyl-2-D-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl-L-leucyl-L-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan
DMWVBTQ	DT	Small molecular drug
DMWVBTQ	PC	123959
DMWVBTQ	MW	950.1
DMWVBTQ	FM	C52H67N7O10
DMWVBTQ	IC	InChI=1S/C52H67N7O10/c1-8-29(5)44(49(65)57-41(52(68)69)25-34-27-53-38-21-15-14-18-35(34)38)59-50(66)45(30(6)9-2)58-48(64)40(26-42(61)62)55-47(63)39(24-28(3)4)56-51(67)46(54-31(7)60)43-36-19-12-10-16-32(36)22-23-33-17-11-13-20-37(33)43/h10-21,27-30,39-41,43-46,53H,8-9,22-26H2,1-7H3,(H,54,60)(H,55,63)(H,56,67)(H,57,65)(H,58,64)(H,59,66)(H,61,62)(H,68,69)/t29-,30-,39-,40-,41-,44-,45-,46+/m0/s1
DMWVBTQ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C3C4=CC=CC=C4CCC5=CC=CC=C35)NC(=O)C
DMWVBTQ	IK	HRAQSWKGRRUBDJ-OMUAVVNCSA-N
DMWVBTQ	IU	(3S)-3-[[(2S)-2-[[(2R)-2-acetamido-2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)acetyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMWVBTQ	CA	CAS 153049-49-1
DMWVBTQ	DE	Hypertension

DMPW28M	ID	DMPW28M
DMPW28M	DN	PD-200390
DMPW28M	HS	Phase 2
DMPW28M	SN	AC1L4NQF; SCHEMBL9494809; YPPRSIHNTQEZCJ-UHFFFAOYSA-N; 3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide; 3-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-[2-(2-pyridyl)ethyl]-N-methylpropanamide; 3-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-methyl-N-[2-(2-pyridinyl)ethyl]propanamide
DMPW28M	CP	Pfizer
DMPW28M	DT	Small molecular drug
DMPW28M	PC	188931
DMPW28M	MW	428.6
DMPW28M	FM	C25H36N2O2S
DMPW28M	IC	InChI=1S/C25H36N2O2S/c1-24(2,3)20-16-19(17-21(23(20)29)25(4,5)6)30-15-12-22(28)27(7)14-11-18-10-8-9-13-26-18/h8-10,13,16-17,29H,11-12,14-15H2,1-7H3
DMPW28M	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SCCC(=O)N(C)CCC2=CC=CC=N2
DMPW28M	IK	YPPRSIHNTQEZCJ-UHFFFAOYSA-N
DMPW28M	IU	3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide
DMPW28M	DE	Insomnia

DM6F5EV	ID	DM6F5EV
DM6F5EV	DN	PD-360324
DM6F5EV	HS	Phase 2
DM6F5EV	SN	PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer
DM6F5EV	CP	Pfizer
DM6F5EV	DE	Rheumatoid arthritis

DMGP9VN	ID	DMGP9VN
DMGP9VN	DN	PDC-1421
DMGP9VN	HS	Phase 2
DMGP9VN	CP	BioLite
DMGP9VN	DE	Attention deficit hyperactivity disorder

DM6OC53	ID	DM6OC53
DM6OC53	DN	PDX-101
DM6OC53	HS	Phase 2
DM6OC53	SN	Belinostat; 414864-00-9; PXD101; PXD-101; Belinostat (PXD101); Beleodaq; 866323-14-0; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; PXD 101; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; UNII-F4H96P17NZ; Belinostat(Random Configuration); NSC726630; PX105684; PX 105684; F4H96P17NZ; CHEBI:61076; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PX-105684
DM6OC53	CP	National Cancer Institute (NCI)
DM6OC53	TC	Anticancer Agents
DM6OC53	DT	Small molecular drug
DM6OC53	PC	6918638
DM6OC53	MW	318.3
DM6OC53	FM	C15H14N2O4S
DM6OC53	IC	InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
DM6OC53	CS	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO
DM6OC53	IK	NCNRHFGMJRPRSK-MDZDMXLPSA-N
DM6OC53	IU	(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
DM6OC53	CA	CAS 866323-14-0
DM6OC53	CB	CHEBI:61076
DM6OC53	DE	Solid tumour/cancer; Haematological malignancy; Peripheral T-cell lymphoma

DMFL96Z	ID	DMFL96Z
DMFL96Z	DN	Pegamotecan
DMFL96Z	HS	Phase 2
DMFL96Z	SN	Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon
DMFL96Z	CP	Enzon Pharmaceuticals Inc
DMFL96Z	DT	Small molecular drug
DMFL96Z	PC	11297617
DMFL96Z	MW	981
DMFL96Z	FM	C52H48N6O14
DMFL96Z	IC	InChI=1S/C52H48N6O14/c1-5-51(35-19-39-43-31(17-29-11-7-9-13-37(29)55-43)21-57(39)45(61)33(35)23-69-49(51)65)71-47(63)27(3)53-41(59)25-67-15-16-68-26-42(60)54-28(4)48(64)72-52(6-2)36-20-40-44-32(18-30-12-8-10-14-38(30)56-44)22-58(40)46(62)34(36)24-70-50(52)66/h7-14,17-20,27-28H,5-6,15-16,21-26H2,1-4H3,(H,53,59)(H,54,60)/t27-,28-,51-,52-/m0/s1
DMFL96Z	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)OC(=O)[C@H](C)NC(=O)COCCOCC(=O)N[C@@H](C)C(=O)O[C@]6(C7=C(COC6=O)C(=O)N8CC9=CC1=CC=CC=C1N=C9C8=C7)CC
DMFL96Z	IK	DZNNFZGDBUXWMV-ZUWDIFAMSA-N
DMFL96Z	IU	[(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] (2S)-2-[[2-[2-[2-[[(2S)-1-[[(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxy]-1-oxopropan-2-yl]amino]-2-oxoethoxy]ethoxy]acetyl]amino]propanoate
DMFL96Z	CA	CAS 581079-18-7
DMFL96Z	DE	Esophageal cancer

DMPD3X6	ID	DMPD3X6
DMPD3X6	DN	Pegmusirudin
DMPD3X6	HS	Phase 2
DMPD3X6	SN	BSF-87981; LU-57291; LU-87981; Polyethylene glycol hirudin, Knoll; SPP-200; PEG-hirudin, Knoll
DMPD3X6	CP	Knoll GmbH
DMPD3X6	PC	56841834
DMPD3X6	MW	7266
DMPD3X6	FM	C299H462N84O115S6
DMPD3X6	IC	InChI=1S/C299H462N84O115S6/c1-27-142(21)234-289(485)361-171(97-134(5)6)244(440)323-120-216(410)335-188(124-385)273(469)337-154(45-34-36-86-317-298(493)497-95-93-495-29-3)240(436)319-114-210(404)332-161(67-80-221(418)419)250(446)338-156(47-38-88-315-296(310)311)248(444)356-180(106-205(305)399)266(462)343-162(61-74-201(301)395)257(453)367-194(130-502-499-127-191-247(443)326-116-209(403)329-157(64-77-218(412)413)241(437)320-117-213(407)333-179(105-204(304)398)265(461)339-155(46-35-37-87-318-299(494)498-96-94-496-30-4)249(445)366-195(279(475)376-234)131-503-500-128-192(276(472)340-159(66-79-220(416)417)243(439)321-119-215(409)336-189(125-386)274(470)359-183(109-208(308)402)272(468)373-231(139(15)16)287(483)371-191)368-261(457)174(100-137(11)12)352-277(473)193-129-501-504-132-196(370-270(466)186(112-229(434)435)363-291(487)238(146(25)390)378-271(467)177(103-150-54-58-153(393)59-55-150)362-286(482)232(140(17)18)375-284(480)230(309)138(13)14)280(476)379-237(145(24)389)290(486)347-167(71-84-225(426)427)256(452)364-187(123-384)246(442)325-115-211(405)331-160(60-73-200(300)394)251(447)357-181(107-206(306)400)267(463)351-173(99-136(9)10)260(456)369-193)278(474)374-233(141(19)20)288(484)380-236(144(23)388)285(481)327-121-212(406)330-158(65-78-219(414)415)242(438)322-122-217(411)372-239(147(26)391)294(490)383-92-42-51-199(383)283(479)348-169(48-39-89-316-297(312)313)292(488)381-90-40-49-197(381)281(477)345-163(62-75-202(302)396)255(451)365-190(126-387)275(471)355-178(104-151-113-314-133-328-151)264(460)358-182(108-207(307)401)268(464)360-184(110-227(430)431)245(441)324-118-214(408)334-185(111-228(432)433)269(465)354-175(101-148-43-32-31-33-44-148)262(458)344-164(68-81-222(420)421)252(448)342-168(72-85-226(428)429)258(454)377-235(143(22)28-2)293(489)382-91-41-50-198(382)282(478)346-166(70-83-224(424)425)253(449)341-165(69-82-223(422)423)254(450)353-176(102-149-52-56-152(392)57-53-149)263(459)350-172(98-135(7)8)259(455)349-170(295(491)492)63-76-203(303)397/h31-33,43-44,52-59,113,133-147,154-199,230-239,384-393H,27-30,34-42,45-51,60-112,114-132,309H2,1-26H3,(H2,300,394)(H2,301,395)(H2,302,396)(H2,303,397)(H2,304,398)(H2,305,399)(H2,306,400)(H2,307,401)(H2,308,402)(H,314,328)(H,317,493)(H,318,494)(H,319,436)(H,320,437)(H,321,439)(H,322,438)(H,323,440)(H,324,441)(H,325,442)(H,326,443)(H,327,481)(H,329,403)(H,330,406)(H,331,405)(H,332,404)(H,333,407)(H,334,408)(H,335,410)(H,336,409)(H,337,469)(H,338,446)(H,339,461)(H,340,472)(H,341,449)(H,342,448)(H,343,462)(H,344,458)(H,345,477)(H,346,478)(H,347,486)(H,348,479)(H,349,455)(H,350,459)(H,351,463)(H,352,473)(H,353,450)(H,354,465)(H,355,471)(H,356,444)(H,357,447)(H,358,460)(H,359,470)(H,360,464)(H,361,485)(H,362,482)(H,363,487)(H,364,452)(H,365,451)(H,366,445)(H,367,453)(H,368,457)(H,369,456)(H,370,466)(H,371,483)(H,372,411)(H,373,468)(H,374,474)(H,375,480)(H,376,475)(H,377,454)(H,378,467)(H,379,476)(H,380,484)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,428,429)(H,430,431)(H,432,433)(H,434,435)(H,491,492)(H4,310,311,315)(H4,312,313,316)/t142-,143-,144+,145+,146+,147+,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,230-,231-,232-,233-,234-,235-,236-,237-,238-,239-/m0/s1
DMPD3X6	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)C(=O)N1)CCCCNC(=O)OCCOCC)CC(=O)N)CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CCC(=O)O)CCCCNC(=O)OCCOCC)CO)CC(C)C
DMPD3X6	IK	MFPRYDMAZLLTGM-IJDGSQHYSA-N
DMPD3X6	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-15-(3-carbamimidamidopropyl)-18,47,67-tris(2-carboxyethyl)-24,76-bis[4-(2-ethoxyethoxycarbonylamino)butyl]-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMPD3X6	DE	Angina pectoris

DM26YJ1	ID	DM26YJ1
DM26YJ1	DN	PEGPH20
DM26YJ1	HS	Phase 2
DM26YJ1	CP	Halozyme Therapeutics San Diego, CA
DM26YJ1	DE	Pancreatic cancer; Gallbladder disease; Gastric adenocarcinoma; Non-small-cell lung cancer

DMX9ZM4	ID	DMX9ZM4
DMX9ZM4	DN	PEG-SN38
DMX9ZM4	HS	Phase 2
DMX9ZM4	SN	EZN-2208
DMX9ZM4	CP	Enzon pharmaceuticals
DMX9ZM4	DT	Small molecular drug
DMX9ZM4	PC	59443782
DMX9ZM4	MW	2300.3
DMX9ZM4	FM	C118H122N12O37
DMX9ZM4	IC	InChI=1S/C118H122N12O37/c1-9-67-71-33-61(131)17-21-87(71)123-103-75(67)45-127-91(103)37-83-79(107(127)143)53-160-111(147)115(83,13-5)164-99(139)41-119-95(135)57-153-27-25-151-49-65(158-31-29-155-59-97(137)121-43-101(141)166-117(15-7)85-39-93-105-77(47-129(93)109(145)81(85)55-162-113(117)149)69(11-3)73-35-63(133)19-23-89(73)125-105)51-157-52-66(159-32-30-156-60-98(138)122-44-102(142)167-118(16-8)86-40-94-106-78(48-130(94)110(146)82(86)56-163-114(118)150)70(12-4)74-36-64(134)20-24-90(74)126-106)50-152-26-28-154-58-96(136)120-42-100(140)165-116(14-6)84-38-92-104-76(46-128(92)108(144)80(84)54-161-112(116)148)68(10-2)72-34-62(132)18-22-88(72)124-104/h17-24,33-40,65-66,131-134H,9-16,25-32,41-60H2,1-8H3,(H,119,135)(H,120,136)(H,121,137)(H,122,138)/t65?,66?,115-,116-,117-,118-/m0/s1
DMX9ZM4	CS	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)CNC(=O)COCCOCC(COCC(COCCOCC(=O)NCC(=O)O[C@]5(C6=C(COC5=O)C(=O)N7CC8=C(C9=C(C=CC(=C9)O)N=C8C7=C6)CC)CC)OCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)O)N=C5C3=C4)CC)CC)OCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)O)N=C5C3=C4)CC)CC)C2=NC2=C1C=C(C=C2)O
DMX9ZM4	IK	CXWRXYDTWCBSJF-DPTNTHPESA-N
DMX9ZM4	IU	[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] 2-[[2-[2-[3-[2,3-bis[2-[2-[[2-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]propoxy]-2-[2-[2-[[2-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]propoxy]ethoxy]acetyl]amino]acetate
DMX9ZM4	CA	CAS 946062-05-1
DMX9ZM4	DE	Metastatic colorectal cancer; Breast cancer

DMTDANB	ID	DMTDANB
DMTDANB	DN	Pegsunercept
DMTDANB	HS	Phase 2
DMTDANB	SN	STNF-R1
DMTDANB	CP	Amgen
DMTDANB	DE	Rheumatoid arthritis

DMBPJ9U	ID	DMBPJ9U
DMBPJ9U	DN	PEGylated pitrakinra
DMBPJ9U	HS	Phase 2
DMBPJ9U	SN	Aeroderm; Dermalast; AER-003; PEGylated pitrakinra (subcutaneous, eczema/allergy), Aerovance; PEGylated AER-001 (subcutaneous, eczema/allergy), Aerovance; PEGylated IL-4 variant (subcutaneous, eczema/allergy), Aerovance
DMBPJ9U	CP	Aerovance
DMBPJ9U	DT	Monoclonal antibody
DMBPJ9U	DE	Allergy; Asthma

DMOMN31	ID	DMOMN31
DMOMN31	DN	PEITC
DMOMN31	HS	Phase 2
DMOMN31	SN	Phenethyl-isothiocyanate
DMOMN31	CP	New York University
DMOMN31	DT	Small molecular drug
DMOMN31	PC	16741
DMOMN31	MW	163.24
DMOMN31	FM	C9H9NS
DMOMN31	IC	InChI=1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2
DMOMN31	CS	C1=CC=C(C=C1)CCN=C=S
DMOMN31	IK	IZJDOKYDEWTZSO-UHFFFAOYSA-N
DMOMN31	IU	2-isothiocyanatoethylbenzene
DMOMN31	CA	CAS 2257-09-2
DMOMN31	CB	CHEBI:351346
DMOMN31	DE	Prostate cancer

DMIW453	ID	DMIW453
DMIW453	DN	Pelitinib
DMIW453	HS	Phase 2
DMIW453	SN	EKB-569; EKI-569; WAY-EKB-569
DMIW453	CP	Wyeth
DMIW453	DT	Small molecular drug
DMIW453	PC	6445562
DMIW453	MW	467.9
DMIW453	FM	C24H23ClFN5O2
DMIW453	IC	InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+
DMIW453	CS	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)F)Cl)C#N)NC(=O)/C=C/CN(C)C
DMIW453	IK	WVUNYSQLFKLYNI-AATRIKPKSA-N
DMIW453	IU	(E)-N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
DMIW453	CA	CAS 257933-82-7
DMIW453	CB	CHEBI:38927
DMIW453	DE	Lymphoma

DMR6USG	ID	DMR6USG
DMR6USG	DN	PELITREXOL
DMR6USG	HS	Phase 2
DMR6USG	SN	AG-2037; Pelitrexol < USAN; AG-2032 (racemate); AG-2038 ((6R)-isomer); N-[5-[2-[2-Amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6(S)-yl]ethyl]-4-methylthien-2-ylcarbonyl]-L-glutamic acid
DMR6USG	DT	Small molecular drug
DMR6USG	PC	135431074
DMR6USG	MW	463.5
DMR6USG	FM	C20H25N5O6S
DMR6USG	IC	InChI=1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1
DMR6USG	CS	CC1=C(SC(=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC[C@H]2CC3=C(NC2)N=C(NC3=O)N
DMR6USG	IK	QXOPTIPQEVJERB-JQWIXIFHSA-N
DMR6USG	IU	(2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid
DMR6USG	CA	CAS 446022-33-9
DMR6USG	DE	Solid tumour/cancer

DMGY5JC	ID	DMGY5JC
DMGY5JC	DN	Pentacea
DMGY5JC	HS	Phase 2
DMGY5JC	SN	HMN14-734; Bispecific CEA antibody (radiotherapeutic pretargeting), IBC; Anti-CEA/anti-In-DTPA antibody, IBC
DMGY5JC	CP	IBC Pharmaceuticals Inc
DMGY5JC	DT	Antibody
DMGY5JC	DE	Small-cell lung cancer

DMNU48O	ID	DMNU48O
DMNU48O	DN	Peptide YY 3-36
DMNU48O	HS	Phase 2
DMNU48O	SN	YY 3-36; Peptide YY 3-36 (oral, eligen)
DMNU48O	CP	Emisphere Technologies Inc
DMNU48O	DE	Obesity

DMFM6OU	ID	DMFM6OU
DMFM6OU	DN	PerioPatch
DMFM6OU	HS	Phase 2
DMFM6OU	CP	Izun Pharmaceuticals Corp
DMFM6OU	DE	Periodontal disease

DMNM4CK	ID	DMNM4CK
DMNM4CK	DN	PF-00734200
DMNM4CK	HS	Phase 2
DMNM4CK	SN	GOSOGLIPTIN; 869490-23-3; UNII-GI718UO477; PF-00734200; PF-734200; CHEMBL515387; GI718UO477; 2-(4-{(3s,5s)-5-[(3,3-Difluoropyrrolidin-1-Yl)carbonyl]pyrrolidin-3-Yl}piperazin-1-Yl)pyrimidine; 869490-47-1; (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone; (3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone; (3,3-DIFLUOROPYRROLIDIN-1-YL)[(2S,4S)-4-[4-(PYRIMIDIN-2-YL)PIPERAZIN-1-YL]PYRROLIDIN-2-YL]METHANONE; Gosogliptin [USAN:
DMNM4CK	DT	Small molecular drug
DMNM4CK	PC	11516136
DMNM4CK	MW	366.4
DMNM4CK	FM	C17H24F2N6O
DMNM4CK	IC	InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1
DMNM4CK	CS	C1CN(CC1(F)F)C(=O)[C@@H]2C[C@@H](CN2)N3CCN(CC3)C4=NC=CC=N4
DMNM4CK	IK	QWEWGXUTRTXFRF-KBPBESRZSA-N
DMNM4CK	IU	(3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone
DMNM4CK	CA	CAS 869490-23-3
DMNM4CK	DE	Type-2 diabetes

DMJPE61	ID	DMJPE61
DMJPE61	DN	PF-02545920
DMJPE61	HS	Phase 2
DMJPE61	SN	1037309-45-7; 2-((4-(1-Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline succinate; UNII-TJ5KAZ8T5G; TJ5KAZ8T5G; PF-2545920 succinate; SCHEMBL439127; CTK8C0559; DTXSID90647726; ANW-64894; AKOS016005150; KB-80291; Quinoline, 2-((4-(1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl)phenoxy)methyl)-, butanedioate (1:1); AX8234870; TC-153639; Quinoline,2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-,succinate salt; 2-[[4-[1-Methyl-4-(4-pyridyl)pyrazol-3-yl]phenoxy]methyl]quinoline
DMJPE61	CP	Pfizer
DMJPE61	DT	Small molecular drug
DMJPE61	PC	11581936
DMJPE61	MW	392.5
DMJPE61	FM	C25H20N4O
DMJPE61	IC	InChI=1S/C25H20N4O/c1-29-16-23(18-12-14-26-15-13-18)25(28-29)20-7-10-22(11-8-20)30-17-21-9-6-19-4-2-3-5-24(19)27-21/h2-16H,17H2,1H3
DMJPE61	CS	CN1C=C(C(=N1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C5=CC=NC=C5
DMJPE61	IK	AZEXWHKOMMASPA-UHFFFAOYSA-N
DMJPE61	IU	2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline
DMJPE61	CA	CAS 898562-94-2
DMJPE61	DE	Schizophrenia; Huntington disease

DMTJWNE	ID	DMTJWNE
DMTJWNE	DN	PF-03446962
DMTJWNE	HS	Phase 2
DMTJWNE	CP	Pfizer New York, NY
DMTJWNE	DE	Solid tumour/cancer

DM826SW	ID	DM826SW
DM826SW	DN	PF-04236921
DM826SW	HS	Phase 2
DM826SW	CP	Pfizer New York, NY
DM826SW	DE	Systemic lupus erythematosus; Crohn disease

DMPRYU1	ID	DMPRYU1
DMPRYU1	DN	PF-04457845
DMPRYU1	HS	Phase 2
DMPRYU1	SN	PF-04457845; 1020315-31-4; UNII-H4C81M8YYW; H4C81M8YYW; CHEMBL1651534; PF 04457845; PF04457845; C23H20F3N5O2; N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; N-Pyridazin-3-yl-4-((3-(5-(trifluoromethyl)pyridin-2-yl)oxyphenyl)methylidene)piperidine-1-carboxamide; 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-;1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-
DMPRYU1	DT	Small molecular drug
DMPRYU1	PC	24771824
DMPRYU1	MW	455.4
DMPRYU1	FM	C23H20F3N5O2
DMPRYU1	IC	InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32)
DMPRYU1	CS	C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4
DMPRYU1	IK	BATCTBJIJJEPHM-UHFFFAOYSA-N
DMPRYU1	IU	N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide
DMPRYU1	CA	CAS 1020315-31-4
DMPRYU1	DE	Liver disease

DMZMUIL	ID	DMZMUIL
DMZMUIL	DN	PF-04518600
DMZMUIL	HS	Phase 2
DMZMUIL	CP	Pfizer New York, NY
DMZMUIL	DE	Solid tumour/cancer

DMA9MBR	ID	DMA9MBR
DMA9MBR	DN	PF-04523655
DMA9MBR	HS	Phase 2
DMA9MBR	CP	Pfizer; Quark Pharmaceuticals
DMA9MBR	TC	siRNA
DMA9MBR	DT	siRNA drug
DMA9MBR	DE	Diabetic macular edema

DMS610L	ID	DMS610L
DMS610L	DN	PF-04691502
DMS610L	HS	Phase 2
DMS610L	SN	PF-04691502; 1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
DMS610L	CP	Pfizer New York, NY
DMS610L	DT	Small molecular drug
DMS610L	PC	25033539
DMS610L	MW	425.5
DMS610L	FM	C22H27N5O4
DMS610L	IC	InChI=1S/C22H27N5O4/c1-13-17-11-18(14-3-8-19(30-2)24-12-14)21(29)27(20(17)26-22(23)25-13)15-4-6-16(7-5-15)31-10-9-28/h3,8,11-12,15-16,28H,4-7,9-10H2,1-2H3,(H2,23,25,26)
DMS610L	CS	CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC
DMS610L	IK	XDLYKKIQACFMJG-UHFFFAOYSA-N
DMS610L	IU	2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
DMS610L	CA	CAS 1013101-36-4
DMS610L	DE	Endometrial cancer

DMQMF4O	ID	DMQMF4O
DMQMF4O	DN	PF-04937319
DMQMF4O	HS	Phase 2
DMQMF4O	CP	Pfizer
DMQMF4O	PC	46916694
DMQMF4O	MW	432.4
DMQMF4O	FM	C22H20N6O4
DMQMF4O	IC	InChI=1S/C22H20N6O4/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4/h5-11H,1-4H3,(H,24,27,29)
DMQMF4O	CS	CC1=CC2=C(O1)C=C(C=C2OC3=CN=C(N=C3)C(=O)N(C)C)C(=O)NC4=NC=C(N=C4)C
DMQMF4O	IK	MASKQITXHVYVFL-UHFFFAOYSA-N
DMQMF4O	IU	N,N-dimethyl-5-[[2-methyl-6-[(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yl]oxy]pyrimidine-2-carboxamide
DMQMF4O	CA	CAS 1245603-92-2
DMQMF4O	DE	Type-2 diabetes

DMRAFBK	ID	DMRAFBK
DMRAFBK	DN	PF-04958242
DMRAFBK	HS	Phase 2
DMRAFBK	CP	Pfizer
DMRAFBK	PC	49853967
DMRAFBK	MW	392.5
DMRAFBK	FM	C18H20N2O4S2
DMRAFBK	IC	InChI=1S/C18H20N2O4S2/c1-12(2)26(21,22)20-16-10-23-11-17(16)24-14-5-3-13(4-6-14)18-8-7-15(9-19)25-18/h3-8,12,16-17,20H,10-11H2,1-2H3/t16-,17+/m0/s1
DMRAFBK	CS	CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC2=CC=C(C=C2)C3=CC=C(S3)C#N
DMRAFBK	IK	TTYKUKSFWHEBLI-DLBZAZTESA-N
DMRAFBK	IU	N-[(3S,4S)-4-[4-(5-cyanothiophen-2-yl)phenoxy]oxolan-3-yl]propane-2-sulfonamide
DMRAFBK	CA	CAS 1258963-59-5
DMRAFBK	DE	Schizophrenia

DM94NBE	ID	DM94NBE
DM94NBE	DN	PF-04991532
DM94NBE	HS	Phase 2
DM94NBE	CP	Pfizer
DM94NBE	PC	46181428
DM94NBE	MW	396.4
DM94NBE	FM	C18H19F3N4O3
DM94NBE	IC	InChI=1S/C18H19F3N4O3/c19-18(20,21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6,8-11,13H,1-4,7H2,(H,27,28)(H,22,24,26)/t13-/m0/s1
DM94NBE	CS	C1CCC(C1)C[C@@H](C(=O)NC2=NC=C(C=C2)C(=O)O)N3C=C(N=C3)C(F)(F)F
DM94NBE	IK	GKMLFBRLRVQVJO-ZDUSSCGKSA-N
DM94NBE	IU	6-[[(2S)-3-cyclopentyl-2-[4-(trifluoromethyl)imidazol-1-yl]propanoyl]amino]pyridine-3-carboxylic acid
DM94NBE	CA	CAS 1215197-37-7
DM94NBE	DE	Diabetic complication

DMD74BJ	ID	DMD74BJ
DMD74BJ	DN	PF-05089771
DMD74BJ	HS	Phase 2
DMD74BJ	SN	Nav1.7 blockers (pain), Pfizer; SCN9A blockers (pain), Pfizer/Icagen/Birkbeck; Voltage-gated sodium channel 1.7 blockers (pain), Pfizer
DMD74BJ	CP	Pfizer
DMD74BJ	PC	46840946
DMD74BJ	MW	500.4
DMD74BJ	FM	C18H12Cl2FN5O3S2
DMD74BJ	IC	InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25)
DMD74BJ	CS	C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F
DMD74BJ	IK	ZYSCOUXLBXGGIM-UHFFFAOYSA-N
DMD74BJ	IU	4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide
DMD74BJ	CA	CAS 1235403-62-9
DMD74BJ	DE	Chronic pain

DMLQ3OK	ID	DMLQ3OK
DMLQ3OK	DN	PF-05175157
DMLQ3OK	HS	Phase 2
DMLQ3OK	CP	Pfizer
DMLQ3OK	PC	52934180
DMLQ3OK	MW	405.5
DMLQ3OK	FM	C23H27N5O2
DMLQ3OK	IC	InChI=1S/C23H27N5O2/c1-14(2)28-21-17(13-24-28)11-23(12-20(21)29)6-8-27(9-7-23)22(30)16-4-5-18-19(10-16)26-15(3)25-18/h4-5,10,13-14H,6-9,11-12H2,1-3H3,(H,25,26)
DMLQ3OK	CS	CC1=NC2=C(N1)C=C(C=C2)C(=O)N3CCC4(CC3)CC5=C(C(=O)C4)N(N=C5)C(C)C
DMLQ3OK	IK	BDXXSFOJPYSYOC-UHFFFAOYSA-N
DMLQ3OK	IU	1'-(2-methyl-3H-benzimidazole-5-carbonyl)-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-7-one
DMLQ3OK	CA	CAS 1301214-47-0
DMLQ3OK	DE	Type-2 diabetes

DMPVQYR	ID	DMPVQYR
DMPVQYR	DN	PF-05212377
DMPVQYR	HS	Phase 2
DMPVQYR	SN	SAM-760
DMPVQYR	CP	Pfizer New York, NY
DMPVQYR	DE	Alzheimer disease

DMBL3VD	ID	DMBL3VD
DMBL3VD	DN	PF-05212384
DMBL3VD	HS	Phase 2
DMBL3VD	SN	PKI-587; 1197160-78-3; Gedatolisib; PF-05212384; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-
DMBL3VD	CP	Pfizer New York, NY
DMBL3VD	DT	Small molecular drug
DMBL3VD	PC	44516953
DMBL3VD	MW	615.7
DMBL3VD	FM	C32H41N9O4
DMBL3VD	IC	InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)
DMBL3VD	CS	CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6
DMBL3VD	IK	DWZAEMINVBZMHQ-UHFFFAOYSA-N
DMBL3VD	IU	1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
DMBL3VD	CA	CAS 1197160-78-3
DMBL3VD	DE	Solid tumour/cancer

DMQLZOF	ID	DMQLZOF
DMQLZOF	DN	PF-06252616
DMQLZOF	HS	Phase 2
DMQLZOF	CP	Pfizer
DMQLZOF	DT	Antibody
DMQLZOF	DE	Muscular dystrophy; Duchenne dystrophy

DMUAOFM	ID	DMUAOFM
DMUAOFM	DN	PF-06290510
DMUAOFM	HS	Phase 2
DMUAOFM	CP	Pfizer
DMUAOFM	DT	Vaccine
DMUAOFM	DE	Staphylococcus infection; Major depressive disorder

DMN94QM	ID	DMN94QM
DMN94QM	DN	PF-06291874
DMN94QM	HS	Phase 2
DMN94QM	CP	Pfizer
DMN94QM	PC	60151939
DMN94QM	MW	503.5
DMN94QM	FM	C26H28F3N3O4
DMN94QM	IC	InChI=1S/C26H28F3N3O4/c1-4-5-22(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-21-12-16(2)24(17(3)13-21)32-15-20(14-31-32)26(27,28)29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)/t22-/m0/s1
DMN94QM	CS	CCC[C@@H](C1=CC=C(C=C1)C(=O)NCCC(=O)O)OC2=CC(=C(C(=C2)C)N3C=C(C=N3)C(F)(F)F)C
DMN94QM	IK	IBDYYOQKQCCSDP-QFIPXVFZSA-N
DMN94QM	IU	3-[[4-[(1S)-1-[3,5-dimethyl-4-[4-(trifluoromethyl)pyrazol-1-yl]phenoxy]butyl]benzoyl]amino]propanoic acid
DMN94QM	CA	CAS 1393124-08-7
DMN94QM	DE	Type-2 diabetes

DMKM7EW	ID	DMKM7EW
DMKM7EW	DN	PF-06463922
DMKM7EW	HS	Phase 2
DMKM7EW	SN	SCHEMBL15274056
DMKM7EW	CP	Pfizer
DMKM7EW	DT	Small molecular drug
DMKM7EW	PC	71731823
DMKM7EW	MW	406.4
DMKM7EW	FM	C21H19FN6O2
DMKM7EW	IC	InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
DMKM7EW	CS	C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
DMKM7EW	IK	IIXWYSCJSQVBQM-LLVKDONJSA-N
DMKM7EW	IU	(16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
DMKM7EW	CA	CAS 1454846-35-5
DMKM7EW	CB	CHEBI:143117
DMKM7EW	DE	Solid tumour/cancer; Non-small-cell lung cancer

DM9S3P7	ID	DM9S3P7
DM9S3P7	DN	PF-06473871
DM9S3P7	HS	Phase 2
DM9S3P7	CP	Pfizer
DM9S3P7	DT	Antisense oligonucleotide
DM9S3P7	DE	Hypertrophic scars

DMMGSFV	ID	DMMGSFV
DMMGSFV	DN	PF-06700841
DMMGSFV	HS	Phase 2
DMMGSFV	SN	BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone
DMMGSFV	CP	Pfizer New York, NY
DMMGSFV	PC	118878093
DMMGSFV	MW	389.4
DMMGSFV	FM	C18H21F2N7O
DMMGSFV	IC	InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1
DMMGSFV	CS	CN1C=C(C=N1)NC2=NC=CC(=N2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F
DMMGSFV	IK	BUWBRTXGQRBBHG-MJBXVCDLSA-N
DMMGSFV	IU	[(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone
DMMGSFV	CA	CAS 1883299-62-4
DMMGSFV	DE	Asthma; Plaque psoriasis; Psoriasis vulgaris

DM8C1H4	ID	DM8C1H4
DM8C1H4	DN	PF-06823859
DM8C1H4	HS	Phase 2
DM8C1H4	CP	Pfizer, New York, NY
DM8C1H4	DE	Lupus; Rheumatoid arthritis; Dermatomycosis

DM5H8V1	ID	DM5H8V1
DM5H8V1	DN	PF-06826647
DM5H8V1	HS	Phase 2
DM5H8V1	SN	Tyk2-IN-8; 2127109-84-4; Tyk2-IN-9; (1r,3r)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Ropsacitinib; Ropsacitinib [USAN]; UNII-HY5SOV7O0Q; HY5SOV7O0Q; CHEMBL4459585; SCHEMBL19253418; SCHEMBL19253420; SCHEMBL19271747; SCHEMBL19276506; BDBM305820; BDBM305821; BCP33615; EX-A4020; US10144738, Example 19; US10144738, Example 20; MFCD32197240; s9676; WHO 11834; HY-126290A; HY-126290; CS-0101462; CS-0114967; (1s,3s)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Cyclobutaneacetonitrile, 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4- yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)-, trans-; trans-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutanecarbonitrile; trans-3-Cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)- 1H-pyrazol-1-yl)-cyclobutaneacetonitrile
DM5H8V1	CP	Pfizer
DM5H8V1	DT	Small molecular drug
DM5H8V1	PC	130339268
DM5H8V1	MW	383.4
DM5H8V1	FM	C20H17N9
DM5H8V1	IC	InChI=1S/C20H17N9/c1-27-11-15(9-24-27)17-13-28-18(2-5-23-28)19(26-17)16-10-25-29(12-16)20(3-4-21)6-14(7-20)8-22/h2,5,9-14H,3,6-7H2,1H3
DM5H8V1	CS	CN1C=C(C=N1)C2=CN3C(=CC=N3)C(=N2)C4=CN(N=C4)C5(CC(C5)C#N)CC#N
DM5H8V1	IK	XPLZTJWZDBFWDE-UHFFFAOYSA-N
DM5H8V1	IU	3-(cyanomethyl)-3-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclobutane-1-carbonitrile
DM5H8V1	CA	CAS 2127109-84-4
DM5H8V1	DE	Plaque psoriasis

DM7EJ8S	ID	DM7EJ8S
DM7EJ8S	DN	PF-06882961
DM7EJ8S	HS	Phase 2
DM7EJ8S	SN	2230198-02-2; UNII-DN9IUI24GP; DN9IUI24GP; 2230198-02-2 (free acid); (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid; 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[(2S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid; Danuglipron; UK4; Danuglipron [USAN]; CHEMBL4518483; SCHEMBL20266351; BDBM349662; EX-A3607; WHO 11630; US10208019, Example 1A-09; US10208019, Example 4A-01; 2-[[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridyl]-1-piperidyl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid; AC-31472; PF6882961; Q63141738; 1H-Benzimidazole-6-carboxylic acid, 2-((4-(6-((4-cyano-2-fluorophenyl)methoxy)-2-pyridinyl)-1-piperidinyl)methyl)-1-((2S)-2-oxetanylmethyl)-; 2-{[4-(6-{[(4-cyano-2-fluorophenyl)(methyl-d2)]oxy}pyridin-2-yl)piperidin-1-yl]methyl}-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F
DM7EJ8S	CP	Pfizer
DM7EJ8S	DT	Small molecular drug
DM7EJ8S	PC	134611040
DM7EJ8S	MW	555.6
DM7EJ8S	FM	C31H30FN5O4
DM7EJ8S	IC	InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1
DM7EJ8S	CS	C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F
DM7EJ8S	IK	HYBAKUMPISVZQP-DEOSSOPVSA-N
DM7EJ8S	IU	2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
DM7EJ8S	CA	CAS 2230198-02-2
DM7EJ8S	DE	Type 2 diabetes

DM8T6KQ	ID	DM8T6KQ
DM8T6KQ	DN	PF-232798
DM8T6KQ	HS	Phase 2
DM8T6KQ	SN	PF-00232798
DM8T6KQ	CP	Pfizer Inc
DM8T6KQ	DT	Small molecular drug
DM8T6KQ	PC	53316710
DM8T6KQ	MW	509.7
DM8T6KQ	FM	C29H40FN5O2
DM8T6KQ	IC	InChI=1S/C29H40FN5O2/c1-18(2)29(37)33-12-11-28-27(17-33)31-19(3)35(28)25-15-23-8-9-24(16-25)34(23)13-10-26(32-20(4)36)21-6-5-7-22(30)14-21/h5-7,14,18,23-26H,8-13,15-17H2,1-4H3,(H,32,36)/t23-,24+,25?,26-/m0/s1
DM8T6KQ	CS	CC1=NC2=C(N1C3C[C@H]4CC[C@@H](C3)N4CC[C@@H](C5=CC(=CC=C5)F)NC(=O)C)CCN(C2)C(=O)C(C)C
DM8T6KQ	IK	QETUKYDWZIRTEI-HLMSNRGBSA-N
DM8T6KQ	IU	N-[(1S)-1-(3-fluorophenyl)-3-[(1R,5S)-3-[2-methyl-5-(2-methylpropanoyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridin-1-yl]-8-azabicyclo[3.2.1]octan-8-yl]propyl]acetamide
DM8T6KQ	CA	CAS 849753-15-7
DM8T6KQ	DE	Human immunodeficiency virus infection

DMO02LU	ID	DMO02LU
DMO02LU	DN	PF-3463275
DMO02LU	HS	Phase 2
DMO02LU	SN	PF-03463275
DMO02LU	CP	Pfizer Inc
DMO02LU	PC	44156901
DMO02LU	MW	376.9
DMO02LU	FM	C19H22ClFN4O
DMO02LU	IC	InChI=1S/C19H22ClFN4O/c1-23-7-13-14(8-23)15(13)9-25(19(26)18-10-24(2)11-22-18)6-12-3-4-17(21)16(20)5-12/h3-5,10-11,13-15H,6-9H2,1-2H3/t13-,14+,15?
DMO02LU	CS	CN1C[C@@H]2[C@H](C1)C2CN(CC3=CC(=C(C=C3)F)Cl)C(=O)C4=CN(C=N4)C
DMO02LU	IK	KYLOBHXXQOZRKK-YIONKMFJSA-N
DMO02LU	IU	N-[(3-chloro-4-fluorophenyl)methyl]-1-methyl-N-[[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide
DMO02LU	CA	CAS 1173239-39-8
DMO02LU	DE	Schizophrenia

DMC2FAL	ID	DMC2FAL
DMC2FAL	DN	PF-3893787
DMC2FAL	HS	Phase 2
DMC2FAL	SN	PF-03893787; PF-3826719
DMC2FAL	CP	Pfizer Inc
DMC2FAL	DT	Small molecular drug
DMC2FAL	PC	24745335
DMC2FAL	MW	262.35
DMC2FAL	FM	C13H22N6
DMC2FAL	IC	InChI=1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1
DMC2FAL	CS	CN[C@@H]1CCN(C1)C2=NC(=NC(=C2)NCC3CC3)N
DMC2FAL	IK	ISBHYKVAFKTATD-SNVBAGLBSA-N
DMC2FAL	IU	4-N-(cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
DMC2FAL	CA	CAS 943057-12-3
DMC2FAL	DE	Asthma; Atopic dermatitis; Plaque psoriasis

DM3DWKN	ID	DM3DWKN
DM3DWKN	DN	PF-4191834
DM3DWKN	HS	Phase 2
DM3DWKN	SN	PF-04191834
DM3DWKN	CP	Pfizer Inc
DM3DWKN	DT	Small molecular drug
DM3DWKN	PC	24986635
DM3DWKN	MW	393.5
DM3DWKN	FM	C22H23N3O2S
DM3DWKN	IC	InChI=1S/C22H23N3O2S/c1-25-20(9-12-24-25)16-5-7-18(8-6-16)28-19-4-2-3-17(15-19)22(21(23)26)10-13-27-14-11-22/h2-9,12,15H,10-11,13-14H2,1H3,(H2,23,26)
DM3DWKN	CS	CN1C(=CC=N1)C2=CC=C(C=C2)SC3=CC=CC(=C3)C4(CCOCC4)C(=O)N
DM3DWKN	IK	DVNQWYLVSNPCJZ-UHFFFAOYSA-N
DM3DWKN	IU	4-[3-[4-(2-methylpyrazol-3-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide
DM3DWKN	CA	CAS 1029317-21-2
DM3DWKN	DE	Asthma

DM81D4I	ID	DM81D4I
DM81D4I	DN	PF-4447943
DM81D4I	HS	Phase 2
DM81D4I	SN	BCP16255
DM81D4I	CP	Pfizer Inc
DM81D4I	DT	Small molecular drug
DM81D4I	PC	135564558
DM81D4I	MW	395.5
DM81D4I	FM	C20H25N7O2
DM81D4I	IC	InChI=1S/C20H25N7O2/c1-13-10-26(12-17-21-5-2-6-22-17)11-16(13)18-24-19-15(20(28)25-18)9-23-27(19)14-3-7-29-8-4-14/h2,5-6,9,13-14,16H,3-4,7-8,10-12H2,1H3,(H,24,25,28)/t13-,16-/m1/s1
DM81D4I	CS	C[C@@H]1CN(C[C@H]1C2=NC3=C(C=NN3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5
DM81D4I	IK	IWXUVYOOUMLUTQ-CZUORRHYSA-N
DM81D4I	IU	6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(oxan-4-yl)-5H-pyrazolo[3,4-d]pyrimidin-4-one
DM81D4I	CA	CAS 1082744-20-4
DM81D4I	DE	Alzheimer disease; Sickle-cell disorder

DML38VU	ID	DML38VU
DML38VU	DN	PF-446687
DML38VU	HS	Phase 2
DML38VU	SN	PF-00446687; PF-2336652
DML38VU	CP	Pfizer Inc
DML38VU	DE	Female sexual arousal dysfunction

DM3YIKR	ID	DM3YIKR
DM3YIKR	DN	PF-4523655
DM3YIKR	HS	Phase 2
DM3YIKR	CP	Quark Pharm; Pfizer
DM3YIKR	DT	siRNA drug
DM3YIKR	DE	Age-related macular degeneration; Diabetic macular degeneration

DM24I0N	ID	DM24I0N
DM24I0N	DN	PF-4878691
DM24I0N	HS	Phase 2
DM24I0N	SN	PF-04878691; PF-4171455
DM24I0N	CP	Pfizer Inc
DM24I0N	PC	10309114
DM24I0N	MW	361.5
DM24I0N	FM	C17H23N5O2S
DM24I0N	IC	InChI=1S/C17H23N5O2S/c1-3-14-21-15-16(12-8-4-5-9-13(12)20-17(15)18)22(14)11-7-6-10-19-25(2,23)24/h4-5,8-9,19H,3,6-7,10-11H2,1-2H3,(H2,18,20)
DM24I0N	CS	CCC1=NC2=C(N1CCCCNS(=O)(=O)C)C3=CC=CC=C3N=C2N
DM24I0N	IK	YZOQZEXYFLXNKA-UHFFFAOYSA-N
DM24I0N	IU	N-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide
DM24I0N	CA	CAS 532959-63-0
DM24I0N	DE	Hepatitis C virus infection; Melanoma

DM3C8GQ	ID	DM3C8GQ
DM3C8GQ	DN	PF-489791
DM3C8GQ	HS	Phase 2
DM3C8GQ	SN	UNII-2S27T3DSZ3; PF-489791; PF-00489791; 853003-48-2; 2S27T3DSZ3; PF-489,791; ZUHZNKJIJDAJFD-UHFFFAOYSA-N; UK-489,791; SCHEMBL331279; SCHEMBL8042129; GTPL8377; DB11736; SB16722; 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl); n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
DM3C8GQ	CP	Pfizer New York, NY
DM3C8GQ	DT	Small molecular drug
DM3C8GQ	PC	11465695
DM3C8GQ	MW	476.6
DM3C8GQ	FM	C20H28N8O4S
DM3C8GQ	IC	InChI=1S/C20H28N8O4S/c1-6-27(4)20-23-15-16(19(29)26-33(5,30)31)25-28(10-11-32-7-2)17(15)18(24-20)22-14-12-13(3)8-9-21-14/h8-9,12H,6-7,10-11H2,1-5H3,(H,26,29)(H,21,22,23,24)
DM3C8GQ	CS	CCN(C)C1=NC2=C(C(=N1)NC3=NC=CC(=C3)C)N(N=C2C(=O)NS(=O)(=O)C)CCOCC
DM3C8GQ	IK	ZUHZNKJIJDAJFD-UHFFFAOYSA-N
DM3C8GQ	IU	1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-N-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide
DM3C8GQ	CA	CAS 853003-48-2
DM3C8GQ	DE	Raynaud disease; Chronic obstructive pulmonary disease

DM0KRLJ	ID	DM0KRLJ
DM0KRLJ	DN	PF-885706
DM0KRLJ	HS	Phase 2
DM0KRLJ	SN	PF-00885706
DM0KRLJ	CP	Pfizer Inc
DM0KRLJ	DE	Gastroesophageal reflux disease

DMF5YEN	ID	DMF5YEN
DMF5YEN	DN	PG-102
DMF5YEN	HS	Phase 2
DMF5YEN	SN	TNX-100; 5-D12
DMF5YEN	CP	PanGenetics BV
DMF5YEN	DE	Autoimmune diabetes

DMJTYO4	ID	DMJTYO4
DMJTYO4	DN	PGL-2
DMJTYO4	HS	Phase 2
DMJTYO4	CP	ProSci
DMJTYO4	DE	Endometriosis

DMKA705	ID	DMKA705
DMKA705	DN	PGL-2001
DMKA705	HS	Phase 2
DMKA705	SN	Steroid sulfatase inhibitor (endometriosis), PregLem
DMKA705	CP	Ipsen
DMKA705	PC	6918339
DMKA705	MW	351.5
DMKA705	FM	C18H25NO4S
DMKA705	IC	InChI=1S/C18H25NO4S/c1-18-9-8-14-13-5-3-12(23-24(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,20H,2,4,6-9H2,1H3,(H2,19,21,22)/t14-,15-,16+,17+,18+/m1/s1
DMKA705	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OS(=O)(=O)N
DMKA705	IK	YXYXCSOJKUAPJI-ZBRFXRBCSA-N
DMKA705	IU	[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate
DMKA705	CA	CAS 172377-52-5
DMKA705	DE	Endometriosis

DM9JGTQ	ID	DM9JGTQ
DM9JGTQ	DN	PH10 nasal spray
DM9JGTQ	HS	Phase 2
DM9JGTQ	CP	Pherin Pharmaceuticals Los Altos, CA
DM9JGTQ	DE	Major depressive disorder

DM71HVW	ID	DM71HVW
DM71HVW	DN	PH-794428
DM71HVW	HS	Phase 2
DM71HVW	SN	PHA-794428
DM71HVW	CP	Pfizer
DM71HVW	DE	Growth hormone deficiency

DMGYBZI	ID	DMGYBZI
DMGYBZI	DN	PHA-739358
DMGYBZI	HS	Phase 2
DMGYBZI	SN	Danusertib; PHA 739358; Danusertib, PHA-739358; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; 5-Amido-pyrrolopyrazole 9d
DMGYBZI	CP	Pfizer; Nerviano
DMGYBZI	DT	Small molecular drug
DMGYBZI	PC	11442891
DMGYBZI	MW	474.6
DMGYBZI	FM	C26H30N6O3
DMGYBZI	IC	InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1
DMGYBZI	CS	CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC4=C3CN(C4)C(=O)[C@@H](C5=CC=CC=C5)OC
DMGYBZI	IK	XKFTZKGMDDZMJI-HSZRJFAPSA-N
DMGYBZI	IU	N-[5-[(2R)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
DMGYBZI	CA	CAS 827318-97-8
DMGYBZI	CB	CHEBI:94490
DMGYBZI	DE	Prostate cancer

DMS2Q9G	ID	DMS2Q9G
DMS2Q9G	DN	PHA848125
DMS2Q9G	HS	Phase 2
DMS2Q9G	SN	Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; PHA848125; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide
DMS2Q9G	CP	Nerviano Medical Services
DMS2Q9G	DT	Small molecular drug
DMS2Q9G	PC	16718576
DMS2Q9G	MW	460.6
DMS2Q9G	FM	C25H32N8O
DMS2Q9G	IC	InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)
DMS2Q9G	CS	CC1(CC2=CN=C(N=C2C3=C1C(=NN3C)C(=O)NC)NC4=CC=C(C=C4)N5CCN(CC5)C)C
DMS2Q9G	IK	RXZMYLDMFYNEIM-UHFFFAOYSA-N
DMS2Q9G	IU	N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,3-h]quinazoline-3-carboxamide
DMS2Q9G	CA	CAS 802539-81-7
DMS2Q9G	DE	Thymic cancer

DMRP3CV	ID	DMRP3CV
DMRP3CV	DN	Phenylalanine hydroxylase
DMRP3CV	HS	Phase 2
DMRP3CV	SN	Oralase; Phenylase; AvPAL-PEG; Phenylalanine hydroxylase, BioMarin; Phenylalanine hydroxylase, IBEX; Poly ethylene glycol-phenylalanine ammonia lyase; Phenylketonuria therapy (enzyme), BioMarin
DMRP3CV	CP	Biomarin pharmaceutical
DMRP3CV	DE	Autoimmune diabetes

DMBHPDW	ID	DMBHPDW
DMBHPDW	DN	Phenylbutyrate
DMBHPDW	HS	Phase 2
DMBHPDW	SN	Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate
DMBHPDW	CP	Scandinavian
DMBHPDW	DT	Small molecular drug
DMBHPDW	PC	4775
DMBHPDW	MW	164.2
DMBHPDW	FM	C10H12O2
DMBHPDW	IC	InChI=1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)
DMBHPDW	CS	C1=CC=C(C=C1)CCCC(=O)O
DMBHPDW	IK	OBKXEAXTFZPCHS-UHFFFAOYSA-N
DMBHPDW	IU	4-phenylbutanoic acid
DMBHPDW	CA	CAS 1821-12-1
DMBHPDW	CB	CHEBI:41500
DMBHPDW	DE	Urea cycle disorder

DMJWD62	ID	DMJWD62
DMJWD62	DN	phorbol 12-myristate 13-acetate
DMJWD62	HS	Phase 2
DMJWD62	SN	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate
DMJWD62	DT	Small molecular drug
DMJWD62	PC	27924
DMJWD62	MW	616.8
DMJWD62	FM	C36H56O8
DMJWD62	IC	InChI=1S/C36H56O8/c1-7-8-9-10-11-12-13-14-15-16-17-18-29(39)43-32-24(3)35(42)27(30-33(5,6)36(30,32)44-25(4)38)20-26(22-37)21-34(41)28(35)19-23(2)31(34)40/h19-20,24,27-28,30,32,37,41-42H,7-18,21-22H2,1-6H3/t24-,27+,28-,30-,32-,34-,35-,36-/m1/s1
DMJWD62	CS	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)C)O)C
DMJWD62	IK	PHEDXBVPIONUQT-RGYGYFBISA-N
DMJWD62	IU	[(1S,2S,6R,10S,11R,13S,14R,15R)-13-acetyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate
DMJWD62	CA	CAS 16561-29-8
DMJWD62	CB	CHEBI:37537
DMJWD62	DE	Acute myeloid leukaemia; Hodgkin lymphoma

DM4FIWC	ID	DM4FIWC
DM4FIWC	DN	PI-88/Taxotere
DM4FIWC	HS	Phase 2
DM4FIWC	SN	PI-88/docetaxel
DM4FIWC	CP	Progen Industries
DM4FIWC	DE	Solid tumour/cancer

DM3ZEYL	ID	DM3ZEYL
DM3ZEYL	DN	Piboserod
DM3ZEYL	HS	Phase 2
DM3ZEYL	SN	Piboserod; 152811-62-6; UNII-4UQ3S81B25; SB-207266; SB207256; 4UQ3S81B25; N-((1-butylpiperidin-4-yl)methyl)-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide; SB 207266; N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]-oxazino[3,2-a]indole-10-carboxamide; N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide; Piboserod [INN:BAN]; Serotonin 5-HT4 Receptor Antagonists; SB207266(Piboserod); AC1L42OO; GTPL225; SCHEMBL467339; CHEMBL356359; BDBM85026; DTXSID60165129
DM3ZEYL	DT	Small molecular drug
DM3ZEYL	PC	177336
DM3ZEYL	MW	369.5
DM3ZEYL	FM	C22H31N3O2
DM3ZEYL	IC	InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26)
DM3ZEYL	CS	CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42
DM3ZEYL	IK	KVCSJPATKXABRQ-UHFFFAOYSA-N
DM3ZEYL	IU	N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide
DM3ZEYL	CA	CAS 152811-62-6
DM3ZEYL	DE	Atrial fibrillation

DMYL7VR	ID	DMYL7VR
DMYL7VR	DN	Piclamilast
DMYL7VR	HS	Phase 2
DMYL7VR	SN	Piclamilast; 144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL
DMYL7VR	DT	Small molecular drug
DMYL7VR	PC	154575
DMYL7VR	MW	381.2
DMYL7VR	FM	C18H18Cl2N2O3
DMYL7VR	IC	InChI=1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23)
DMYL7VR	CS	COC1=C(C=C(C=C1)C(=O)NC2=C(C=NC=C2Cl)Cl)OC3CCCC3
DMYL7VR	IK	RRRUXBQSQLKHEL-UHFFFAOYSA-N
DMYL7VR	IU	3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide
DMYL7VR	CA	CAS 144035-83-6
DMYL7VR	CB	CHEBI:47619
DMYL7VR	DE	Rheumatoid arthritis

DMMO46E	ID	DMMO46E
DMMO46E	DN	Pidilizumab
DMMO46E	HS	Phase 2
DMMO46E	SN	CT-011
DMMO46E	CP	CureTech
DMMO46E	DT	Monoclonal antibody
DMMO46E	DE	Diffuse large B-cell lymphoma

DMAFZ84	ID	DMAFZ84
DMAFZ84	DN	PIKAMILONE
DMAFZ84	HS	Phase 2
DMAFZ84	SN	N-Nicotinoyl-gamma-aminobutyric acid sodium salt; N-(3-Pyridylcarbonyl)-4-aminobutyric acid sodium salt
DMAFZ84	DT	Small molecular drug
DMAFZ84	PC	60608
DMAFZ84	MW	208.21
DMAFZ84	FM	C10H12N2O3
DMAFZ84	IC	InChI=1S/C10H12N2O3/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14)
DMAFZ84	CS	C1=CC(=CN=C1)C(=O)NCCCC(=O)O
DMAFZ84	IK	NAJVRARAUNYNDX-UHFFFAOYSA-N
DMAFZ84	IU	4-(pyridine-3-carbonylamino)butanoic acid
DMAFZ84	CA	CAS 34562-97-5
DMAFZ84	DE	Anxiety disorder

DM96VWD	ID	DM96VWD
DM96VWD	DN	PINOCEMBRIN
DM96VWD	HS	Phase 2
DM96VWD	SN	Pinocembrin; 480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-
DM96VWD	DT	Small molecular drug
DM96VWD	PC	68071
DM96VWD	MW	256.25
DM96VWD	FM	C15H12O4
DM96VWD	IC	InChI=1S/C15H12O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-7,13,16-17H,8H2/t13-/m0/s1
DM96VWD	CS	C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=CC=C3
DM96VWD	IK	URFCJEUYXNAHFI-ZDUSSCGKSA-N
DM96VWD	IU	(2S)-5,7-dihydroxy-2-phenyl-2,3-dihydrochromen-4-one
DM96VWD	CA	CAS 480-39-7
DM96VWD	CB	CHEBI:28157

DM276N1	ID	DM276N1
DM276N1	DN	Piritrexim
DM276N1	HS	Phase 2
DM276N1	SN	Piritrexim; 72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine
DM276N1	DT	Small molecular drug
DM276N1	PC	54369
DM276N1	MW	325.4
DM276N1	FM	C17H19N5O2
DM276N1	IC	InChI=1S/C17H19N5O2/c1-9-11(6-10-7-12(23-2)4-5-13(10)24-3)8-20-16-14(9)15(18)21-17(19)22-16/h4-5,7-8H,6H2,1-3H3,(H4,18,19,20,21,22)
DM276N1	CS	CC1=C2C(=NC(=NC2=NC=C1CC3=C(C=CC(=C3)OC)OC)N)N
DM276N1	IK	VJXSSYDSOJBUAV-UHFFFAOYSA-N
DM276N1	IU	6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
DM276N1	CA	CAS 72732-56-0
DM276N1	DE	Bladder cancer

DMC3T2S	ID	DMC3T2S
DMC3T2S	DN	PIRODOMAST
DMC3T2S	HS	Phase 2
DMC3T2S	SN	Sch-37224; Pirodomast; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidine; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide inner salt; 4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one
DMC3T2S	DT	Small molecular drug
DMC3T2S	PC	54680204
DMC3T2S	MW	307.3
DMC3T2S	FM	C18H17N3O2
DMC3T2S	IC	InChI=1S/C18H17N3O2/c22-16-14-9-6-10-19-17(14)21(13-7-2-1-3-8-13)18(23)15(16)20-11-4-5-12-20/h1-3,6-10,22H,4-5,11-12H2
DMC3T2S	CS	C1CCN(C1)C2=C(C3=C(N=CC=C3)N(C2=O)C4=CC=CC=C4)O
DMC3T2S	IK	ULGABHCZIJXUFO-UHFFFAOYSA-N
DMC3T2S	IU	4-hydroxy-1-phenyl-3-pyrrolidin-1-yl-1,8-naphthyridin-2-one
DMC3T2S	CA	CAS 108310-20-9
DMC3T2S	DE	Asthma

DMHI6GE	ID	DMHI6GE
DMHI6GE	DN	Pirsidomine
DMHI6GE	HS	Phase 2
DMHI6GE	SN	C87-3754; CAS-936
DMHI6GE	CP	Hoechst Marion Roussel Inc
DMHI6GE	DT	Small molecular drug
DMHI6GE	PC	9571076
DMHI6GE	MW	330.4
DMHI6GE	FM	C17H22N4O3
DMHI6GE	IC	InChI=1S/C17H22N4O3/c1-12-5-4-6-13(2)21(12)20-11-16(24-19-20)18-17(22)14-7-9-15(23-3)10-8-14/h7-13H,4-6H2,1-3H3/t12-,13+
DMHI6GE	CS	C[C@@H]1CCC[C@@H](N1[N+]2=NOC(=C2)/N=C(/C3=CC=C(C=C3)OC)\\[O-])C
DMHI6GE	IK	TXPUBJSOHAMNEI-BETUJISGSA-N
DMHI6GE	IU	(1Z)-N-[3-[(2S,6R)-2,6-dimethylpiperidin-1-yl]oxadiazol-3-ium-5-yl]-4-methoxybenzenecarboximidate
DMHI6GE	CA	CAS 132722-74-8
DMHI6GE	DE	Angina pectoris

DMKEV7N	ID	DMKEV7N
DMKEV7N	DN	PK1
DMKEV7N	HS	Phase 2
DMKEV7N	SN	FCE-28068; N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer linked to Gly-Phe-Leu-Gly-doxorubicin
DMKEV7N	DT	Small molecular drug
DMKEV7N	PC	59235249
DMKEV7N	MW	381.3
DMKEV7N	FM	C17H14Cl2N2O2S
DMKEV7N	IC	InChI=1S/C17H14Cl2N2O2S/c1-17(10-3-6-12(22)7-4-10)15(23)21(16(24)20(17)2)11-5-8-13(18)14(19)9-11/h3-9,22H,1-2H3/t17-/m1/s1
DMKEV7N	CS	C[C@]1(C(=O)N(C(=S)N1C)C2=CC(=C(C=C2)Cl)Cl)C3=CC=C(C=C3)O
DMKEV7N	IK	YPONBLYNQFHCLA-QGZVFWFLSA-N
DMKEV7N	IU	(5R)-3-(3,4-dichlorophenyl)-5-(4-hydroxyphenyl)-1,5-dimethyl-2-sulfanylideneimidazolidin-4-one
DMKEV7N	DE	Solid tumour/cancer

DMHUCQS	ID	DMHUCQS
DMHUCQS	DN	PL-3994
DMHUCQS	HS	Phase 2
DMHUCQS	PC	121488161
DMHUCQS	MW	1875.2
DMHUCQS	FM	C82H127N27O20S2
DMHUCQS	IC	InChI=1S/C82H127N27O20S2/c1-6-9-11-15-25-62(112)98-59-41-130-131-42-60(76(126)104-56(34-47-26-28-49(111)29-27-47)79(129)109-39-57(66(83)116)105-77(127)61(109)24-18-32-93-82(88)89)107-74(124)58(40-110)106-78(128)65(44(4)8-3)108-70(120)52(23-17-31-92-81(86)87)100-73(123)55(36-64(114)115)103-69(119)51(21-10-7-2)99-68(118)50(22-16-30-91-80(84)85)97-63(113)38-94-67(117)45(5)96-71(121)53(33-46-19-13-12-14-20-46)101-72(122)54(102-75(59)125)35-48-37-90-43-95-48/h12-14,19-20,26-29,37,43-45,50-61,65,110-111H,6-11,15-18,21-25,30-36,38-42H2,1-5H3,(H2,83,116)(H,90,95)(H,94,117)(H,96,121)(H,97,113)(H,98,112)(H,99,118)(H,100,123)(H,101,122)(H,102,125)(H,103,119)(H,104,126)(H,105,127)(H,106,128)(H,107,124)(H,108,120)(H,114,115)(H4,84,85,91)(H4,86,87,92)(H4,88,89,93)/t44-,45+,50-,51+,52-,53-,54-,55-,56-,57+,58-,59+,60-,61-,65-/m0/s1
DMHUCQS	CS	CCCCCCC(=O)N[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CNC=N2)CC3=CC=CC=C3)C)CCCNC(=N)N)CCCC)CC(=O)O)CCCNC(=N)N)[C@@H](C)CC)CO)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N5C[C@@H](NC(=O)[C@@H]5CCCNC(=N)N)C(=O)N
DMHUCQS	IK	HSHVZRILAMZYHY-WXSGKXQHSA-N
DMHUCQS	IU	2-[(4R,7S,10S,13S,16S,19R,22S,28R,31S,34S,37S)-31-benzyl-10-[(2S)-butan-2-yl]-19-butyl-13,22-bis(3-carbamimidamidopropyl)-4-[[(2S)-1-[(2S,5R)-2-(3-carbamimidamidopropyl)-5-carbamoyl-3-oxopiperazin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-37-(heptanoylamino)-7-(hydroxymethyl)-34-(1H-imidazol-4-ylmethyl)-28-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacont-16-yl]acetic acid
DMHUCQS	CA	CAS 952295-80-6
DMHUCQS	DE	Hypertension; Congestive heart failure; Asthma

DMYUO6B	ID	DMYUO6B
DMYUO6B	DN	PlaMavax
DMYUO6B	HS	Phase 2
DMYUO6B	SN	AdCh63-ME-TRAP; MVA-ME-TRAP; ME-TRAP fusion antigen adenoviral vector vaccine (Malaria), Okairos
DMYUO6B	CP	University of Oxford
DMYUO6B	DT	Vaccine
DMYUO6B	DE	Malaria

DMOB1EM	ID	DMOB1EM
DMOB1EM	DN	Plasmin
DMOB1EM	HS	Phase 2
DMOB1EM	SN	Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke); Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke), Talecris Biotherapeutics
DMOB1EM	CP	Grifols therapeutics
DMOB1EM	DE	Occlusive disease; Peripheral arterial disease

DMK10ZC	ID	DMK10ZC
DMK10ZC	DN	PLECONARIL
DMK10ZC	HS	Phase 2
DMK10ZC	SN	Picovir; Pleconaril < Prop INN; SR-263843; SR-63843; VP-63843; Win-63843; 3-[3,5-Dimethyl-4-[3-(3-methylisoxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole
DMK10ZC	CP	ViroPharma
DMK10ZC	DT	Small molecular drug
DMK10ZC	PC	1684
DMK10ZC	MW	381.3
DMK10ZC	FM	C18H18F3N3O3
DMK10ZC	IC	InChI=1S/C18H18F3N3O3/c1-10-7-13(16-22-17(27-24-16)18(19,20)21)8-11(2)15(10)25-6-4-5-14-9-12(3)23-26-14/h7-9H,4-6H2,1-3H3
DMK10ZC	CS	CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F
DMK10ZC	IK	KQOXLKOJHVFTRN-UHFFFAOYSA-N
DMK10ZC	IU	3-[3,5-dimethyl-4-[3-(3-methyl-1,2-oxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole
DMK10ZC	CA	CAS 153168-05-9
DMK10ZC	DE	Virus infection

DM7Y60I	ID	DM7Y60I
DM7Y60I	DN	Plevitrexed
DM7Y60I	HS	Phase 2
DM7Y60I	SN	ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,
DM7Y60I	CP	BTG
DM7Y60I	DT	Small molecular drug
DM7Y60I	PC	135430970
DM7Y60I	MW	532.5
DM7Y60I	FM	C26H25FN8O4
DM7Y60I	IC	InChI=1S/C26H25FN8O4/c1-4-9-35(13-16-11-19-22(10-14(16)2)28-15(3)29-25(19)37)17-5-6-18(20(27)12-17)24(36)30-21(26(38)39)7-8-23-31-33-34-32-23/h1,5-6,10-12,21H,7-9,13H2,2-3H3,(H,30,36)(H,38,39)(H,28,29,37)(H,31,32,33,34)/t21-/m0/s1
DM7Y60I	CS	CC1=CC2=C(C=C1CN(CC#C)C3=CC(=C(C=C3)C(=O)N[C@@H](CCC4=NNN=N4)C(=O)O)F)C(=O)NC(=N2)C
DM7Y60I	IK	IEJSCSAMMLUINT-NRFANRHFSA-N
DM7Y60I	IU	(2S)-2-[[4-[(2,7-dimethyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid
DM7Y60I	CA	CAS 153537-73-6
DM7Y60I	DE	Gastric adenocarcinoma

DMTL39C	ID	DMTL39C
DMTL39C	DN	Plevitrexed (R)-isomer
DMTL39C	HS	Phase 2
DMTL39C	SN	YW3548
DMTL39C	CP	BTG
DMTL39C	DT	Small molecular drug
DMTL39C	PC	213022
DMTL39C	DE	Gastric adenocarcinoma

DMRTD7I	ID	DMRTD7I
DMRTD7I	DN	PLX8394
DMRTD7I	HS	Phase 2
DMRTD7I	CP	Daiichi sankyo parsippany
DMRTD7I	PC	90116675
DMRTD7I	MW	542.5
DMRTD7I	FM	C25H21F3N6O3S
DMRTD7I	IC	InChI=1S/C25H21F3N6O3S/c26-16-5-6-34(12-16)38(36,37)33-20-4-3-19(27)21(22(20)28)23(35)18-11-32-25-17(18)7-14(8-31-25)15-9-29-24(30-10-15)13-1-2-13/h3-4,7-11,13,16,33H,1-2,5-6,12H2,(H,31,32)/t16-/m1/s1
DMRTD7I	CS	C1CN(C[C@@H]1F)S(=O)(=O)NC2=C(C(=C(C=C2)F)C(=O)C3=CNC4=C3C=C(C=N4)C5=CN=C(N=C5)C6CC6)F
DMRTD7I	IK	YYACLQUDUDXAPA-MRXNPFEDSA-N
DMRTD7I	IU	(3R)-N-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide
DMRTD7I	CA	CAS 1393466-87-9
DMRTD7I	DE	Melanoma; Solid tumour/cancer

DMMKOPX	ID	DMMKOPX
DMMKOPX	DN	PM-00104
DMMKOPX	HS	Phase 2
DMMKOPX	SN	Zalypsis; PM00104; UNII-C21EZR41AY; C21EZR41AY; PM-00104; 308359-57-1; (6aS,7R,13S,14S,16R)-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-16-[({(2E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl}amino)methyl]-6,7,12,13,14,16-hexahydro-6aH-7,13-epimino[1,3]dioxolo[7,8]isoquino[3,2-b][3]benzazocin-5-yl acetate; SCHEMBL7975282; DTXSID0044026; NOCAS_44026; DB12454; CS-1940; HY-16401; 2-Propenamide, N-(((6aS,7R,13S,14S,16R)-5-(acetyloxy)-6,6a,7,13,14,16-hexahydro-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-7,13-imino-12H-1,3-dioxolo
DMMKOPX	CP	PharmaMar
DMMKOPX	DT	Small molecular drug
DMMKOPX	PC	16061448
DMMKOPX	MW	709.7
DMMKOPX	FM	C37H38F3N3O8
DMMKOPX	IC	InChI=1S/C37H38F3N3O8/c1-17-11-21-13-25-36(47)43-24(30(42(25)4)28(21)31(46)32(17)48-5)14-23-29(35-34(49-16-50-35)18(2)33(23)51-19(3)44)26(43)15-41-27(45)10-9-20-7-6-8-22(12-20)37(38,39)40/h6-12,24-26,30,36,46-47H,13-16H2,1-5H3,(H,41,45)/b10-9+/t24-,25-,26-,30-,36-/m0/s1
DMMKOPX	CS	CC1=CC2=C([C@@H]3[C@@H]4CC5=C(C(=C6C(=C5[C@@H](N4[C@H]([C@H](C2)N3C)O)CNC(=O)/C=C/C7=CC(=CC=C7)C(F)(F)F)OCO6)C)OC(=O)C)C(=C1OC)O
DMMKOPX	IK	VPAHZSUNBOYNQY-DLVGLDQCSA-N
DMMKOPX	IU	[(1R,2S,13R,15S,16S)-15,22-dihydroxy-21-methoxy-6,20,24-trimethyl-13-[[[(E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl]amino]methyl]-8,10-dioxa-14,24-diazahexacyclo[14.7.1.02,14.04,12.07,11.018,23]tetracosa-4,6,11,18(23),19,21-hexaen-5-yl] acetate
DMMKOPX	CA	CAS 308359-57-1
DMMKOPX	DE	Solid tumour/cancer

DMS34YO	ID	DMS34YO
DMS34YO	DN	PM184
DMS34YO	HS	Phase 2
DMS34YO	CP	PharmaMar Madrid, Spain
DMS34YO	DE	Colorectal cancer

DM0OVZ2	ID	DM0OVZ2
DM0OVZ2	DN	PMID27841036-Compound-37
DM0OVZ2	HS	Phase 2
DM0OVZ2	SN	2X-121
DM0OVZ2	CP	EISAI INC. XU, Weizheng DELAHANTY, Greg WEI, Ling ZHANG, Jie
DM0OVZ2	DT	Small molecular drug
DM0OVZ2	PC	135565981
DM0OVZ2	MW	317.3
DM0OVZ2	FM	C18H15N5O
DM0OVZ2	IC	InChI=1S/C18H15N5O/c24-18-13-6-3-7-14-16(13)17(21-22-18)20-15(19-14)10-23-8-11-4-1-2-5-12(11)9-23/h1-7H,8-10H2,(H,22,24)(H,19,20,21)
DM0OVZ2	CS	C1C2=CC=CC=C2CN1CC3=NC4=NNC(=O)C5=C4C(=CC=C5)N3
DM0OVZ2	IK	JLFSBHQQXIAQEC-UHFFFAOYSA-N
DM0OVZ2	IU	11-(1,3-dihydroisoindol-2-ylmethyl)-2,3,10,12-tetrazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8,11-pentaen-4-one
DM0OVZ2	CA	CAS 1140964-99-3
DM0OVZ2	DE	Ovarian cancer

DMZUAJ4	ID	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	HS	Phase 2
DMZUAJ4	SN	YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445;  AcF-[OP(D-Cha)WR]; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam
DMZUAJ4	DT	Small molecular drug
DMZUAJ4	PC	6918468
DMZUAJ4	MW	896.1
DMZUAJ4	FM	C47H65N11O7
DMZUAJ4	IC	InChI=1S/C47H65N11O7/c1-29(59)53-37(25-30-13-4-2-5-14-30)42(61)55-36-20-11-22-50-41(60)35(19-10-23-51-47(48)49)54-44(63)39(27-32-28-52-34-18-9-8-17-33(32)34)56-43(62)38(26-31-15-6-3-7-16-31)57-45(64)40-21-12-24-58(40)46(36)65/h2,4-5,8-9,13-14,17-18,28,31,35-40,52H,3,6-7,10-12,15-16,19-27H2,1H3,(H,50,60)(H,53,59)(H,54,63)(H,55,61)(H,56,62)(H,57,64)(H4,48,49,51)/t35-,36-,37-,38+,39-,40-/m0/s1
DMZUAJ4	CS	CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]2CCCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H]3CCCN3C2=O)CC4CCCCC4)CC5=CNC6=CC=CC=C65)CCCN=C(N)N
DMZUAJ4	IK	YOKBGCTZYPOSQM-HPSWDUTRSA-N
DMZUAJ4	IU	(2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide
DMZUAJ4	DE	Atopic dermatitis

DMWT73D	ID	DMWT73D
DMWT73D	DN	PMX-60056
DMWT73D	HS	Phase 2
DMWT73D	SN	PMX-150; PMX-60054; PMX-60065; PMX-60077; PMX-60079; PMX-60087; PMX-640; PMX-686; PMX-747; PMX-801; Heparin andlow molecular weight heparin (LMWH) reversing agents, PolyMedix
DMWT73D	CP	PolyMedix Inc
DMWT73D	DT	Small molecular drug
DMWT73D	PC	51349239
DMWT73D	MW	1126.3
DMWT73D	FM	C56H79N13O12
DMWT73D	IC	InChI=1S/C56H79N13O12/c1-78-45-21-17-33(29-37(45)49(62)70)64-54(75)42(14-6-10-26-58)67-51(72)39-31-35(19-23-47(39)80-3)66-56(77)44(16-8-12-28-60)69-52(73)40-32-36(20-24-48(40)81-4)65-55(76)43(15-7-11-27-59)68-50(71)38-30-34(18-22-46(38)79-2)63-53(74)41(61)13-5-9-25-57/h17-24,29-32,41-44H,5-16,25-28,57-61H2,1-4H3,(H2,62,70)(H,63,74)(H,64,75)(H,65,76)(H,66,77)(H,67,72)(H,68,71)(H,69,73)/t41-,42-,43-,44-/m0/s1
DMWT73D	CS	COC1=C(C=C(C=C1)NC(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CCCCN)C(=O)NC2=CC(=C(C=C2)OC)C(=O)N[C@@H](CCCCN)C(=O)NC3=CC(=C(C=C3)OC)C(=O)N[C@@H](CCCCN)C(=O)NC4=CC(=C(C=C4)OC)C(=O)N
DMWT73D	IK	PWFIFNGOPQUNIT-ITMZJIMRSA-N
DMWT73D	IU	N-[(2S)-6-amino-1-[3-[[(2S)-6-amino-1-[3-[[(2S)-6-amino-1-(3-carbamoyl-4-methoxyanilino)-1-oxohexan-2-yl]carbamoyl]-4-methoxyanilino]-1-oxohexan-2-yl]carbamoyl]-4-methoxyanilino]-1-oxohexan-2-yl]-5-[[(2S)-2,6-diaminohexanoyl]amino]-2-methoxybenzamide
DMWT73D	CA	CAS 872454-31-4
DMWT73D	DE	Coagulation defect

DMUVON0	ID	DMUVON0
DMUVON0	DN	PNT-2258
DMUVON0	HS	Phase 2
DMUVON0	CP	ProNAi Therapeutics Inc
DMUVON0	DT	Antisense drug
DMUVON0	DE	Solid tumour/cancer; Diffuse large B-cell lymphoma

DMM8IAQ	ID	DMM8IAQ
DMM8IAQ	DN	PNU-142731A
DMM8IAQ	HS	Phase 2
DMM8IAQ	SN	9-[2-Oxo-2-(pyrrolidin-1-yl)ethyl]-2,4-bis(pyrrolidin-1-yl)-9H-pyrimido[4,5-b]indole hydrochloride
DMM8IAQ	PC	9846800
DMM8IAQ	MW	455
DMM8IAQ	FM	C24H31ClN6O
DMM8IAQ	IC	InChI=1S/C24H30N6O.ClH/c31-20(27-11-3-4-12-27)17-30-19-10-2-1-9-18(19)21-22(28-13-5-6-14-28)25-24(26-23(21)30)29-15-7-8-16-29;/h1-2,9-10H,3-8,11-17H2;1H
DMM8IAQ	CS	C1CCN(C1)C2=NC(=NC3=C2C4=CC=CC=C4N3CC(=O)N5CCCC5)N6CCCC6.Cl
DMM8IAQ	IK	RLFYAIUQWFELJD-UHFFFAOYSA-N
DMM8IAQ	IU	2-(2,4-dipyrrolidin-1-ylpyrimido[4,5-b]indol-9-yl)-1-pyrrolidin-1-ylethanone;hydrochloride
DMM8IAQ	CA	CAS 214212-38-1
DMM8IAQ	DE	Asthma

DM4OT29	ID	DM4OT29
DM4OT29	DN	POL-6326
DM4OT29	HS	Phase 2
DM4OT29	SN	CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor
DM4OT29	CP	Polyphor Ltd
DM4OT29	DE	Human immunodeficiency virus infection; Breast cancer

DMFCIKN	ID	DMFCIKN
DMFCIKN	DN	Polivy
DMFCIKN	HS	Phase 2
DMFCIKN	SN	Polatuzumab vedotin-piiq
DMFCIKN	CP	Roche/Genentech
DMFCIKN	DT	Antibody
DMFCIKN	DE	Mantle cell lymphoma

DMUXEBQ	ID	DMUXEBQ
DMUXEBQ	DN	Polyamine
DMUXEBQ	HS	Phase 2
DMUXEBQ	DE	Subjective cognitive decline

DMXROM7	ID	DMXROM7
DMXROM7	DN	Polyglutamate camptothecin
DMXROM7	HS	Phase 2
DMXROM7	SN	CT-2106; PG-interferon; Polyglutamate camptothecin, Cell Therapeutics; Polyglutamate-camptothecin; CPT-Gly-PG; Camptothecin-glycine-polyglutamate; PG-CPT, Cell Therapeutics; PG-camptothecin, CT; Polyglutamate-linked anticancer agents, Cell Therapeutics; PG-G-CSF, Cell Therapeutics
DMXROM7	CP	Cell Therapeutics Inc
DMXROM7	DE	Solid tumour/cancer

DM2570B	ID	DM2570B
DM2570B	DN	Poly-ICLC
DM2570B	HS	Phase 2
DM2570B	CP	Oncovir 
DM2570B	DT	Small molecular drug
DM2570B	PC	136033680
DM2570B	MW	879.6
DM2570B	FM	C26H43N9O21P2
DM2570B	IC	InChI=1S/C10H13N4O8P.C9H14N3O8P.C5H12N2O2.C2H4O3/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;6-3-1-2-4-7-5(8)9;3-1-2(4)5/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18);7H,1-4,6H2,(H,8,9);3H,1H2,(H,4,5)
DM2570B	CS	C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O.C(CCNC(=O)O)CN.C(C(=O)O)O
DM2570B	IK	MRYYMYCQXMFJNE-UHFFFAOYSA-N
DM2570B	IU	4-aminobutylcarbamic acid;[5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;[3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate;2-hydroxyacetic acid
DM2570B	DE	Glioblastoma multiforme; Recurrent glioblastoma; Solid tumour/cancer

DM3QDA6	ID	DM3QDA6
DM3QDA6	DN	Polynoma-1
DM3QDA6	HS	Phase 2
DM3QDA6	SN	Polyvalent melanoma vaccine, Vaccinoma
DM3QDA6	CP	Vaccinoma Inc
DM3QDA6	DT	Vaccine
DM3QDA6	DE	Melanoma

DMIAZ13	ID	DMIAZ13
DMIAZ13	DN	Ponezumab
DMIAZ13	HS	Phase 2
DMIAZ13	SN	Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219
DMIAZ13	CP	Rinat Neuroscience Corp
DMIAZ13	DT	Antibody
DMIAZ13	DE	Alzheimer disease

DM5HMTB	ID	DM5HMTB
DM5HMTB	DN	Porphobilinogen
DM5HMTB	HS	Phase 2
DM5HMTB	SN	porphobilinogen; 487-90-1; 3-[5-(AMINOMETHYL)-4-(CARBOXYMETHYL)-1H-PYRROL-3-YL]PROPANOIC ACID; UNII-74KHC72QXK; 1H-Pyrrole-3-propanoic acid, 5-(aminomethyl)-4-(carboxymethyl)-; 2-aminomethylpyrrol-3-acetic acid 4-propionic acid; 74KHC72QXK; PBG; CHEBI:17381; 5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propanoic acid; 5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propionic acid; 3-(5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrol-3-yl)propanoic acid; 5-(aminomethyl)-4-(carboxymethyl)-pyrrole-3-propionic acid
DM5HMTB	DT	Small molecular drug
DM5HMTB	PC	1021
DM5HMTB	MW	226.23
DM5HMTB	FM	C10H14N2O4
DM5HMTB	IC	InChI=1S/C10H14N2O4/c11-4-8-7(3-10(15)16)6(5-12-8)1-2-9(13)14/h5,12H,1-4,11H2,(H,13,14)(H,15,16)
DM5HMTB	CS	C1=C(C(=C(N1)CN)CC(=O)O)CCC(=O)O
DM5HMTB	IK	QSHWIQZFGQKFMA-UHFFFAOYSA-N
DM5HMTB	IU	3-[5-(aminomethyl)-4-(carboxymethyl)-1H-pyrrol-3-yl]propanoic acid
DM5HMTB	CA	CAS 487-90-1
DM5HMTB	CB	CHEBI:17381

DMH0LM2	ID	DMH0LM2
DMH0LM2	DN	POT-4
DMH0LM2	HS	Phase 2
DMH0LM2	SN	AL-78898A; POT-4 EOS Insert; Compstatin complement-inhibiting peptides, Pennsylvania/Potentia; 4(1MeW)7W
DMH0LM2	CP	University of Pennsylvania
DMH0LM2	DE	Macular degeneration

DMTE8DC	ID	DMTE8DC
DMTE8DC	DN	Pozelimab
DMTE8DC	HS	Phase 2
DMTE8DC	SN	REGN3918
DMTE8DC	CP	Regeneron Pharmaceuticals
DMTE8DC	DT	Antibody
DMTE8DC	DE	Paroxysmal nocturnal haemoglobinuria

DM4EHVB	ID	DM4EHVB
DM4EHVB	DN	PPI-668
DM4EHVB	HS	Phase 2
DM4EHVB	CP	Presidio pharmaceuticals
DM4EHVB	PC	71665718
DM4EHVB	MW	835.8
DM4EHVB	FM	C42H52Cl2N8O6
DM4EHVB	IC	InChI=1S/C42H50N8O6.2ClH/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6;;/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54);2*1H/t33-,34-,35-,36-;;/m0../s1
DM4EHVB	CS	CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC.Cl.Cl
DM4EHVB	IK	JYLMWUZJMRNMDA-SPRBZRACSA-N
DM4EHVB	IU	methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride
DM4EHVB	CA	CAS 1303533-81-4
DM4EHVB	DE	Hepatitis C virus infection

DMM6J5Z	ID	DMM6J5Z
DMM6J5Z	DN	PQ-912
DMM6J5Z	HS	Phase 2
DMM6J5Z	PC	51030870
DMM6J5Z	MW	336.4
DMM6J5Z	FM	C19H20N4O2
DMM6J5Z	IC	InChI=1S/C19H20N4O2/c1-2-9-25-15-6-3-13(4-7-15)18-11-20-19(24)23(18)14-5-8-16-17(10-14)22-12-21-16/h3-8,10,12,18H,2,9,11H2,1H3,(H,20,24)(H,21,22)/t18-/m1/s1
DMM6J5Z	CS	CCCOC1=CC=C(C=C1)[C@H]2CNC(=O)N2C3=CC4=C(C=C3)N=CN4
DMM6J5Z	IK	XHIKZWOEFZENIX-GOSISDBHSA-N
DMM6J5Z	IU	(5S)-1-(3H-benzimidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one
DMM6J5Z	CA	CAS 1276021-65-8
DMM6J5Z	DE	Dementia

DMMCYZ8	ID	DMMCYZ8
DMMCYZ8	DN	PQR309
DMMCYZ8	HS	Phase 2
DMMCYZ8	SN	Bimiralisib; PQR309; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; PQR309; Bimiralisib; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; PQR309; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)
DMMCYZ8	DT	Small molecular drug
DMMCYZ8	PC	58507717
DMMCYZ8	MW	411.4
DMMCYZ8	FM	C17H20F3N7O2
DMMCYZ8	IC	InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)
DMMCYZ8	CS	C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
DMMCYZ8	IK	ADGGYDAFIHSYFI-UHFFFAOYSA-N
DMMCYZ8	IU	5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
DMMCYZ8	CA	CAS 1225037-39-7
DMMCYZ8	DE	Pain; Squamous head and neck cell carcinom

DM1O0DV	ID	DM1O0DV
DM1O0DV	DN	Pradefovir
DM1O0DV	HS	Phase 2
DM1O0DV	SN	Remofovir; Pradefovir mesylate; Remofovir mesylate; Hepavir-B; ICN 2001-3; MB-06866; MB-6866; Pradefovir (oral, hepatitis B), Ligand/Chiva
DM1O0DV	CP	Metabasis Therapeutics Inc
DM1O0DV	DT	Small molecular drug
DM1O0DV	PC	9604654
DM1O0DV	MW	423.8
DM1O0DV	FM	C17H19ClN5O4P
DM1O0DV	IC	InChI=1S/C17H19ClN5O4P/c18-13-3-1-2-12(8-13)14-4-6-26-28(24,27-14)11-25-7-5-23-10-22-15-16(19)20-9-21-17(15)23/h1-3,8-10,14H,4-7,11H2,(H2,19,20,21)/t14-,28+/m0/s1
DM1O0DV	CS	C1CO[P@@](=O)(O[C@@H]1C2=CC(=CC=C2)Cl)COCCN3C=NC4=C(N=CN=C43)N
DM1O0DV	IK	GWNHAOBXDGOXRR-HJFSHJIFSA-N
DM1O0DV	IU	9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine
DM1O0DV	CA	CAS 625095-60-5
DM1O0DV	DE	Hepatitis virus infection

DMIVMR3	ID	DMIVMR3
DMIVMR3	DN	Prajmaline
DMIVMR3	HS	Phase 2
DMIVMR3	SN	N(sup 4)-Propylajmalinium; N-Propylajmaline; N-Propylajmalinium; Prajmaline; Prajmalium; Prajmalum; (17R,21-alpha)-17,21-Dihydroxy-4-propylajmalanium; 35080-11-6; 75934UD4GJ; Ajmalanium, 17,21-dihydroxy-4-propyl-, (17R,21-alpha)-; CHEBI:135560; UNII-75934UD4GJ
DMIVMR3	PC	76959818
DMIVMR3	MW	369.5
DMIVMR3	FM	C23H33N2O2+
DMIVMR3	IC	UAUHEPXILIZYCU-ALHOSYKFSA-N
DMIVMR3	CS	CCC[N+]12C3CC(C(C1O)CC)C4C2CC5(C3N(C6=CC=CC=C65)C)C4O
DMIVMR3	IK	1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17-,18-,19-,20-,21+,22+,23+,25-/m0/s1
DMIVMR3	IU	(1R,9R,10S,12R,13S,14R,15R,16S,17S,18R)-13-ethyl-8-methyl-15-propyl-8-aza-15-azoniahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol
DMIVMR3	CA	CAS 35080-11-6
DMIVMR3	CB	CHEBI:135560
DMIVMR3	DE	Atherosclerosis

DM73UTG	ID	DM73UTG
DM73UTG	DN	PRALNACASAN
DM73UTG	HS	Phase 2
DM73UTG	SN	Pralnacasan; VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide
DM73UTG	DT	Small molecular drug
DM73UTG	PC	153270
DM73UTG	MW	523.5
DM73UTG	FM	C26H29N5O7
DM73UTG	IC	InChI=1S/C26H29N5O7/c1-2-37-26-18(14-21(33)38-26)29-23(34)19-8-5-13-30-20(32)10-9-17(25(36)31(19)30)28-24(35)22-16-7-4-3-6-15(16)11-12-27-22/h3-4,6-7,11-12,17-19,26H,2,5,8-10,13-14H2,1H3,(H,28,35)(H,29,34)/t17-,18-,19-,26+/m0/s1
DM73UTG	CS	CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN3N2C(=O)[C@H](CCC3=O)NC(=O)C4=NC=CC5=CC=CC=C54
DM73UTG	IK	CXAGHAZMQSCAKJ-WAHHBDPQSA-N
DM73UTG	IU	(4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide
DM73UTG	CA	CAS 192755-52-5
DM73UTG	DE	Rheumatoid arthritis

DMBH7XI	ID	DMBH7XI
DMBH7XI	DN	Pramiconazole
DMBH7XI	HS	Phase 2
DMBH7XI	SN	Azoline; Antifungals, Janssen Research Foundation; R-126638
DMBH7XI	CP	Barrier Therapeutics
DMBH7XI	DT	Small molecular drug
DMBH7XI	PC	3013050
DMBH7XI	MW	659.7
DMBH7XI	FM	C35H39F2N7O4
DMBH7XI	IC	InChI=1S/C35H39F2N7O4/c1-25(2)43-17-18-44(34(43)45)29-6-4-27(5-7-29)40-13-15-41(16-14-40)28-8-10-30(11-9-28)46-20-33-47-22-35(48-33,21-42-24-38-23-39-42)31-12-3-26(36)19-32(31)37/h3-12,19,23-25,33H,13-18,20-22H2,1-2H3/t33-,35+/m0/s1
DMBH7XI	CS	CC(C)N1CCN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5OC[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
DMBH7XI	IK	AEKNYBWUEYNWMJ-QWOOXDRHSA-N
DMBH7XI	IU	1-[4-[4-[4-[[(2S,4R)-4-(2,4-difluorophenyl)-4-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-3-propan-2-ylimidazolidin-2-one
DMBH7XI	CA	CAS 219923-85-0
DMBH7XI	DE	Dermatological disease

DMZT8FS	ID	DMZT8FS
DMZT8FS	DN	Preverex
DMZT8FS	HS	Phase 2
DMZT8FS	SN	Biostent; Phomin; Cytochalasin B; Cytochalasin B containing stent
DMZT8FS	CP	Poniard Pharmaceuticals Inc
DMZT8FS	DT	Small molecular drug
DMZT8FS	PC	5311281
DMZT8FS	MW	479.6
DMZT8FS	FM	C29H37NO5
DMZT8FS	IC	InChI=1S/C29H37NO5/c1-18-9-7-13-22(31)15-16-25(32)35-29-23(14-8-10-18)27(33)20(3)19(2)26(29)24(30-28(29)34)17-21-11-5-4-6-12-21/h4-6,8,11-12,14-16,18-19,22-24,26-27,31,33H,3,7,9-10,13,17H2,1-2H3,(H,30,34)/b14-8+,16-15+/t18-,19-,22-,23+,24+,26+,27-,29-/m1/s1
DMZT8FS	CS	C[C@@H]1CCC[C@H](/C=C/C(=O)O[C@]23[C@@H](/C=C/C1)[C@@H](C(=C)[C@H]([C@H]2[C@@H](NC3=O)CC4=CC=CC=C4)C)O)O
DMZT8FS	IK	GBOGMAARMMDZGR-TYHYBEHESA-N
DMZT8FS	IU	(1S,4E,6R,10R,12E,14S,15S,17S,18S,19S)-19-benzyl-6,15-dihydroxy-10,17-dimethyl-16-methylidene-2-oxa-20-azatricyclo[12.7.0.01,18]henicosa-4,12-diene-3,21-dione
DMZT8FS	CA	CAS 14930-96-2
DMZT8FS	CB	CHEBI:23527
DMZT8FS	DE	Artery stenosis

DMK8PTH	ID	DMK8PTH
DMK8PTH	DN	PRM-151
DMK8PTH	HS	Phase 2
DMK8PTH	CP	Promedior
DMK8PTH	DE	Macular degeneration; Idiopathic pulmonary fibrosis; Myelofibrosis; Polycythemia vera; Thrombocythemia

DMBZ6CP	ID	DMBZ6CP
DMBZ6CP	DN	PRN1008
DMBZ6CP	HS	Phase 2
DMBZ6CP	SN	LCFFREMLXLZNHE-GBOLQPHISA-N; SCHEMBL15506003; BDBM143212; US8940744, 31; (R,E)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile
DMBZ6CP	CP	Principia Biopharma South San Francisco, CA
DMBZ6CP	PC	73388818
DMBZ6CP	MW	665.8
DMBZ6CP	FM	C36H40FN9O3
DMBZ6CP	IC	InChI=1S/C36H40FN9O3/c1-36(2,45-15-13-43(14-16-45)26-21-48-22-26)18-24(19-38)35(47)44-12-6-7-25(20-44)46-34-31(33(39)40-23-41-34)32(42-46)29-11-10-28(17-30(29)37)49-27-8-4-3-5-9-27/h3-5,8-11,17-18,23,25-26H,6-7,12-16,20-22H2,1-2H3,(H2,39,40,41)/b24-18+/t25-/m1/s1
DMBZ6CP	CS	CC(C)(/C=C(\\C#N)/C(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C(C=C(C=C4)OC5=CC=CC=C5)F)N)N6CCN(CC6)C7COC7
DMBZ6CP	IK	LCFFREMLXLZNHE-GBOLQPHISA-N
DMBZ6CP	IU	(E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
DMBZ6CP	CA	CAS 1575596-29-0
DMBZ6CP	DE	Pemphigus vulgaris

DM5ZTE4	ID	DM5ZTE4
DM5ZTE4	DN	PRO-001
DM5ZTE4	HS	Phase 2
DM5ZTE4	SN	PRO-001, ProRetina; Proinsulin (recombinant human protein, retinitis pigmentosa), ProRetina
DM5ZTE4	CP	ProRetina Therapeutics SL
DM5ZTE4	DE	Retinitis pigmentosa

DMFYABR	ID	DMFYABR
DMFYABR	DN	PRO-044
DMFYABR	HS	Phase 2
DMFYABR	SN	Exon-44 skipping antisense oligonucleotide (Duchenne muscular dystrophy), Prosensa
DMFYABR	CP	Leiden University Medical Center
DMFYABR	DT	Antisense drug
DMFYABR	DE	Duchenne dystrophy

DMMEL6B	ID	DMMEL6B
DMMEL6B	DN	PRO22
DMMEL6B	HS	Phase 2
DMMEL6B	CP	Realm Therapeutics Malvern, PA
DMMEL6B	DE	Atopic dermatitis

DMF9RB4	ID	DMF9RB4
DMF9RB4	DN	Procysteine
DMF9RB4	HS	Phase 2
DMF9RB4	SN	Procysteine; 19771-63-2; (R)-2-Oxothiazolidine-4-carboxylic acid; (4R)-2-oxo-1,3-thiazolidine-4-carboxylic acid; L-2-Oxothiazolidine-4-carboxylic acid; L-2-Oxothiazolidine-4-carboxylate; 4-Thiazolidinecarboxylic acid, 2-oxo-, (4R)-; CCRIS 7672; Oxothiazolidine carboxylate, L-; UNII-X7063P804E; 2-Oxothiazolidine-4-carboxylate, L-; L-2-Oxo-4-thiazolidinecarboxylic acid; BRN 4179169; (R)-2-Oxo-4-thiazolidinecarboxylic acid; (4R)-2-oxo-4-thiazolidinecarboxylic acid; CHEMBL442218; 4-Thiazolidinecarboxylic acid, 2-oxo-, L-
DMF9RB4	CP	Cornell University
DMF9RB4	DT	Small molecular drug
DMF9RB4	PC	72390
DMF9RB4	MW	147.15
DMF9RB4	FM	C4H5NO3S
DMF9RB4	IC	InChI=1S/C4H5NO3S/c6-3(7)2-1-9-4(8)5-2/h2H,1H2,(H,5,8)(H,6,7)/t2-/m0/s1
DMF9RB4	CS	C1[C@H](NC(=O)S1)C(=O)O
DMF9RB4	IK	BMLMGCPTLHPWPY-REOHCLBHSA-N
DMF9RB4	IU	(4R)-2-oxo-1,3-thiazolidine-4-carboxylic acid
DMF9RB4	CA	CAS 19771-63-2
DMF9RB4	CB	CHEBI:125673
DMF9RB4	DE	Amyotrophic lateral sclerosis

DM4MF9V	ID	DM4MF9V
DM4MF9V	DN	proglumide
DM4MF9V	HS	Phase 2
DM4MF9V	SN	Milid; Nulsa; W-5219
DM4MF9V	DT	Small molecular drug
DM4MF9V	PC	4922
DM4MF9V	MW	334.4
DM4MF9V	FM	C18H26N2O4
DM4MF9V	IC	InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)
DM4MF9V	CS	CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1
DM4MF9V	IK	DGMKFQYCZXERLX-UHFFFAOYSA-N
DM4MF9V	IU	4-benzamido-5-(dipropylamino)-5-oxopentanoic acid
DM4MF9V	CA	CAS 6620-60-6
DM4MF9V	CB	CHEBI:32058
DM4MF9V	DE	Influenza virus infection

DMZIQ8G	ID	DMZIQ8G
DMZIQ8G	DN	Prolarix
DMZIQ8G	HS	Phase 2
DMZIQ8G	SN	Prolarix (TN)
DMZIQ8G	CP	Protherics
DMZIQ8G	TC	Anticancer Agents
DMZIQ8G	DT	Small molecular drug
DMZIQ8G	PC	403128
DMZIQ8G	MW	181.19
DMZIQ8G	FM	C8H11N3O2
DMZIQ8G	IC	InChI=1S/C8H11N3O2/c9-7(12)5-11-3-1-2-6(4-11)8(10)13/h1,3-4H,2,5H2,(H2,9,12)(H2,10,13)
DMZIQ8G	CS	C1C=CN(C=C1C(=O)N)CC(=O)N
DMZIQ8G	IK	WEJRSYKFMCUCRQ-UHFFFAOYSA-N
DMZIQ8G	IU	1-(2-amino-2-oxoethyl)-4H-pyridine-3-carboxamide
DMZIQ8G	CA	CAS 64881-21-6
DMZIQ8G	DE	Solid tumour/cancer

DME25TI	ID	DME25TI
DME25TI	DN	Prosaptide TX14(A)
DME25TI	HS	Phase 2
DME25TI	SN	Prosaptide; TX-14(A)
DME25TI	CP	Myelos Corp
DME25TI	PC	16197909
DME25TI	MW	1579.7
DME25TI	FM	C69H110N16O26
DME25TI	IC	InChI=1S/C69H110N16O26/c1-13-31(7)53(66(107)80-41(23-29(3)4)61(102)82-46(69(110)111)25-37-15-17-38(88)18-16-37)83-59(100)40(20-22-50(93)94)75-58(99)39(19-21-49(91)92)76-68(109)55(36(12)87)85-57(98)34(10)73-60(101)43(26-47(70)89)78-62(103)44(27-48(71)90)79-63(104)45(28-51(95)96)81-67(108)54(32(8)14-2)84-64(105)42(24-30(5)6)77-56(97)33(9)74-65(106)52(72)35(11)86/h15-18,29-36,39-46,52-55,86-88H,13-14,19-28,72H2,1-12H3,(H2,70,89)(H2,71,90)(H,73,101)(H,74,106)(H,75,99)(H,76,109)(H,77,97)(H,78,103)(H,79,104)(H,80,107)(H,81,108)(H,82,102)(H,83,100)(H,84,105)(H,85,98)(H,91,92)(H,93,94)(H,95,96)(H,110,111)/t31-,32-,33+,34-,35+,36+,39-,40-,41-,42-,43-,44-,45-,46-,52-,53-,54-,55-/m0/s1
DME25TI	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H]([C@@H](C)O)N
DME25TI	IK	SMUKRAODILXPSW-SRWCCNGVSA-N
DME25TI	IU	(4S)-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DME25TI	DE	Neuropathic pain

DMM7F1E	ID	DMM7F1E
DMM7F1E	DN	PRUVANSERIN
DMM7F1E	HS	Phase 2
DMM7F1E	SN	Pruvanserin; UNII-UL09X1D9EM; 443144-26-1; UL09X1D9EM; CHEMBL1215661; Pruvanserin [USAN:INN]; 7-{4-(2-(4-Fluorophenyl)ethyl)piperazine-1-carbonyl}-1H-indole-3-carbonitrile; 7-[4-[2-(4-fluorophenyl)ethyl]piperazine-1-carbonyl]-1H-indole-3-carbonitrile; AC1O5FMC; Pruvanserin (USAN/INN); SCHEMBL678751; DTXSID40196133; AQRLDDAFYYAIJP-UHFFFAOYSA-N; ZINC56898757; BDBM50324540; LSN2422347; SB16534; EMD 390920; DB13094; EMD-390920; LSN-2422347; NCGC00370956-01; LY2420586; LY-2422347; D06632; L001679
DMM7F1E	DT	Small molecular drug
DMM7F1E	PC	6433122
DMM7F1E	MW	376.4
DMM7F1E	FM	C22H21FN4O
DMM7F1E	IC	InChI=1S/C22H21FN4O/c23-18-6-4-16(5-7-18)8-9-26-10-12-27(13-11-26)22(28)20-3-1-2-19-17(14-24)15-25-21(19)20/h1-7,15,25H,8-13H2
DMM7F1E	CS	C1CN(CCN1CCC2=CC=C(C=C2)F)C(=O)C3=CC=CC4=C3NC=C4C#N
DMM7F1E	IK	AQRLDDAFYYAIJP-UHFFFAOYSA-N
DMM7F1E	IU	7-[4-[2-(4-fluorophenyl)ethyl]piperazine-1-carbonyl]-1H-indole-3-carbonitrile
DMM7F1E	CA	CAS 443144-26-1
DMM7F1E	DE	Sleep-wake disorder

DMKTP8E	ID	DMKTP8E
DMKTP8E	DN	PRX002
DMKTP8E	HS	Phase 2
DMKTP8E	SN	Prasinezumab
DMKTP8E	CP	ProThena; Roche
DMKTP8E	DT	Antibody
DMKTP8E	DE	Parkinson disease

DM1JNDV	ID	DM1JNDV
DM1JNDV	DN	PRX00933
DM1JNDV	HS	Phase 2
DM1JNDV	CP	Proximagen Group plc
DM1JNDV	DE	Diabetic complication; Obesity

DMR7H2V	ID	DMR7H2V
DMR7H2V	DN	PRX-08066
DMR7H2V	HS	Phase 2
DMR7H2V	SN	PRX-08066; 866206-54-4; PRX-08066 free base; UNII-82SK298EBU; PRX 08066; CHEMBL513994; 82SK298EBU; 5-((4-(6-chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile; SCHEMBL1604039; DTXSID60235710; IENZFHBNCRQMNP-UHFFFAOYSA-N; BCP14768; BDBM50249180; ZINC40403513; AKOS030526950; QC-5875; CS-0991; SB16508; 5-((4-(6-Chlorothieno(2,3-d)pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile; PRX 08066;PRX08066; NCGC00386238-02; AK548029; HY-15472; Benzonitrile, 5-((4-((6-chlorothieno(2,3-d)pyrimidi
DMR7H2V	CP	Predix Pharmaceuticals
DMR7H2V	DT	Small molecular drug
DMR7H2V	PC	11502243
DMR7H2V	MW	401.9
DMR7H2V	FM	C19H17ClFN5S
DMR7H2V	IC	InChI=1S/C19H17ClFN5S/c20-17-8-15-18(23-11-24-19(15)27-17)25-14-3-5-26(6-4-14)10-12-1-2-16(21)13(7-12)9-22/h1-2,7-8,11,14H,3-6,10H2,(H,23,24,25)
DMR7H2V	CS	C1CN(CCC1NC2=C3C=C(SC3=NC=N2)Cl)CC4=CC(=C(C=C4)F)C#N
DMR7H2V	IK	IENZFHBNCRQMNP-UHFFFAOYSA-N
DMR7H2V	IU	5-[[4-[(6-chlorothieno[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]-2-fluorobenzonitrile
DMR7H2V	CA	CAS 866206-54-4
DMR7H2V	DE	Pulmonary arterial hypertension

DMEVXS1	ID	DMEVXS1
DMEVXS1	DN	PRX-3140
DMEVXS1	HS	Phase 2
DMEVXS1	CP	Nanotherapeutics
DMEVXS1	DE	Post-traumatic stress disorder; Alzheimer disease

DM7YWVT	ID	DM7YWVT
DM7YWVT	DN	PRX-321
DM7YWVT	HS	Phase 2
DM7YWVT	SN	Silybin B; Milk thistle; 142797-34-0; UNII-853OHH1429; Flavobion; Legalon 70; 853OHH1429; CCRIS 7096; Wild Artichoke; Silybum marianum; Silybin A and B; Milk thistle [NF]; Silymarin + Melatonin; AC1LU7MH; UNII-U946SH95EE; Milk Thistle (Silybum marianum) Extract or Powder; SCHEMBL751461; Silybin B, analytical standard; U946SH95EE; CHEMBL592675; Milk Thistle (Silybum marianum) Extract or Powder [seed]; DTXSID30858697; SEBFKMXJBCUCAI-WAABAYLZSA-N; MolPort-039-139-345; ZINC1530850; BDBM50088491; 2717AH; AKOS015912848
DM7YWVT	TC	Anticancer Agents
DM7YWVT	DT	Small molecular drug
DM7YWVT	PC	1548994
DM7YWVT	MW	482.4
DM7YWVT	FM	C25H22O10
DM7YWVT	IC	InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23-,24-,25+/m0/s1
DM7YWVT	CS	COC1=C(C=CC(=C1)[C@H]2[C@@H](OC3=C(O2)C=C(C=C3)[C@@H]4[C@H](C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
DM7YWVT	IK	SEBFKMXJBCUCAI-WAABAYLZSA-N
DM7YWVT	IU	(2R,3R)-3,5,7-trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
DM7YWVT	CA	CAS 65666-07-1
DM7YWVT	DE	Solid tumour/cancer

DMHZIFJ	ID	DMHZIFJ
DMHZIFJ	DN	PS-938285
DMHZIFJ	HS	Phase 2
DMHZIFJ	CP	Schering-Plough
DMHZIFJ	DE	Chronic obstructive pulmonary disease

DMCSN69	ID	DMCSN69
DMCSN69	DN	PT2385
DMCSN69	HS	Phase 2
DMCSN69	SN	ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A
DMCSN69	CP	Peloton Therapeutics Dallas, TX
DMCSN69	PC	91754484
DMCSN69	MW	383.3
DMCSN69	FM	C17H12F3NO4S
DMCSN69	IC	InChI=1S/C17H12F3NO4S/c1-26(23,24)14-3-2-13(12-7-17(19,20)16(22)15(12)14)25-11-5-9(8-21)4-10(18)6-11/h2-6,16,22H,7H2,1H3/t16-/m0/s1
DMCSN69	CS	CS(=O)(=O)C1=C2[C@@H](C(CC2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)(F)F)O
DMCSN69	IK	ONBSHRSJOPSEGS-INIZCTEOSA-N
DMCSN69	IU	3-[[(1S)-2,2-difluoro-1-hydroxy-7-methylsulfonyl-1,3-dihydroinden-4-yl]oxy]-5-fluorobenzonitrile
DMCSN69	CA	CAS 1672665-49-4
DMCSN69	DE	Recurrent glioblastoma; Von hippel-lindau disease; Brain cancer

DMP9TKE	ID	DMP9TKE
DMP9TKE	DN	PTC299
DMP9TKE	HS	Phase 2
DMP9TKE	SN	6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002
DMP9TKE	CP	PTC Therape
DMP9TKE	TC	Anticancer Agents
DMP9TKE	DT	Small molecular drug
DMP9TKE	PC	49787172
DMP9TKE	MW	467.3
DMP9TKE	FM	C25H20Cl2N2O3
DMP9TKE	IC	InChI=1S/C25H20Cl2N2O3/c1-31-18-7-2-15(3-8-18)24-23-20(21-14-17(27)6-11-22(21)28-23)12-13-29(24)25(30)32-19-9-4-16(26)5-10-19/h2-11,14,24,28H,12-13H2,1H3/t24-/m0/s1
DMP9TKE	CS	COC1=CC=C(C=C1)[C@H]2C3=C(CCN2C(=O)OC4=CC=C(C=C4)Cl)C5=C(N3)C=CC(=C5)Cl
DMP9TKE	IK	SRSHBZRURUNOSM-DEOSSOPVSA-N
DMP9TKE	IU	(4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate
DMP9TKE	DE	Rheumatoid arthritis; Solid tumour/cancer

DMOYS8A	ID	DMOYS8A
DMOYS8A	DN	PTG-300
DMOYS8A	HS	Phase 2
DMOYS8A	SN	Rusfertide; Rusfertide [USAN]; UNII-XM71MYX0IQ; XM71MYX0IQ; PTG-300FB; WHO 11456; 1628323-80-7; Isovaleryl-Asp-Thr-His-Phe-Pro-cyclo(Cys-Ile-Lys(palm-gamma-Glu)- Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys)-Lys-NH2
DMOYS8A	CP	Protagonist Therapeutics
DMOYS8A	DT	Peptide
DMOYS8A	PC	155884410
DMOYS8A	MW	2442
DMOYS8A	FM	C114H181N27O28S2
DMOYS8A	IC	InChI=1S/C114H181N27O28S2/c1-7-9-10-11-12-13-14-15-16-17-18-19-26-46-90(145)125-79(113(168)169)47-49-89(144)121-53-32-29-42-76-99(154)133-80(58-71-36-22-20-23-37-71)101(156)132-78(48-50-93(148)149)111(166)140-55-34-44-87(140)107(162)130-77(43-33-54-122-114(118)119)100(155)136-84(64-142)104(159)129-75(41-28-31-52-116)98(153)123-63-92(147)127-85(105(160)128-74(97(117)152)40-27-30-51-115)65-170-171-66-86(106(161)138-95(69(5)8-2)109(164)131-76)137-108(163)88-45-35-56-141(88)112(167)83(59-72-38-24-21-25-39-72)135-102(157)81(60-73-62-120-67-124-73)134-110(165)96(70(6)143)139-103(158)82(61-94(150)151)126-91(146)57-68(3)4/h20-25,36-39,62,67-70,74-88,95-96,142-143H,7-19,26-35,40-61,63-66,115-116H2,1-6H3,(H2,117,152)(H,120,124)(H,121,144)(H,123,153)(H,125,145)(H,126,146)(H,127,147)(H,128,160)(H,129,159)(H,130,162)(H,131,164)(H,132,156)(H,133,154)(H,134,165)(H,135,157)(H,136,155)(H,137,163)(H,138,161)(H,139,158)(H,148,149)(H,150,151)(H,168,169)(H4,118,119,122)/t69-,70+,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,95-,96-/m0/s1
DMOYS8A	CS	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)[C@@H](C)CC)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCC(=O)O)CC6=CC=CC=C6)C(=O)O
DMOYS8A	IK	JRVOBXXOZFTSRF-GVIPULMVSA-N
DMOYS8A	IU	(2S)-5-[4-[(3S,6S,9S,12S,15R,20R,26S,29S,32S,35S)-26-(4-aminobutyl)-6-benzyl-12-[(2S)-butan-2-yl]-32-(3-carbamimidamidopropyl)-3-(2-carboxyethyl)-15-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-3-carboxy-2-(3-methylbutanoylamino)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-20-[[(2S)-1,6-diamino-1-oxohexan-2-yl]carbamoyl]-29-(hydroxymethyl)-2,5,8,11,14,22,25,28,31,34-decaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30,33-decazabicyclo[33.3.0]octatriacontan-9-yl]butylamino]-2-(hexadecanoylamino)-5-oxopentanoic acid
DMOYS8A	CA	CAS 1628323-80-7
DMOYS8A	DE	Hemochromatosis; Polycythemia vera

DMV17HK	ID	DMV17HK
DMV17HK	DN	PTI-125
DMV17HK	HS	Phase 2
DMV17HK	SN	UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6
DMV17HK	CP	Pain Therapeutics
DMV17HK	DT	Small molecular drug
DMV17HK	PC	46195331
DMV17HK	MW	259.35
DMV17HK	FM	C15H21N3O
DMV17HK	IC	InChI=1S/C15H21N3O/c1-17-9-7-15(8-10-17)16-11-14(19)18(15)12-13-5-3-2-4-6-13/h2-6,16H,7-12H2,1H3
DMV17HK	CS	CN1CCC2(CC1)NCC(=O)N2CC3=CC=CC=C3
DMV17HK	IK	BSQPTZYKCAULBH-UHFFFAOYSA-N
DMV17HK	IU	4-benzyl-8-methyl-1,4,8-triazaspiro[4.5]decan-3-one
DMV17HK	CA	CAS 1224591-33-6
DMV17HK	DE	Alzheimer disease

DM0ZIT2	ID	DM0ZIT2
DM0ZIT2	DN	PTX-200
DM0ZIT2	HS	Phase 2
DM0ZIT2	SN	Plant-derived antiparkinsonian, Phytrix
DM0ZIT2	CP	Phytrix AG
DM0ZIT2	DE	Parkinson disease; Breast cancer; Acute myeloid leukaemia; Ovarian cancer

DMJIMXH	ID	DMJIMXH
DMJIMXH	DN	Puerarin
DMJIMXH	HS	Phase 2
DMJIMXH	SN	NPI-031-G; Puerarin (oral formulation, alcoholism); Puerarin (oral formulation, alcoholism), Natural Pharmacia; 5-HT2creceptor antagonists/GABA receptor antagonists (oral formulation, alcoholism), Natural Pharmacia
DMJIMXH	CP	Natural Pharmacia International Inc
DMJIMXH	DT	Small molecular drug
DMJIMXH	PC	5281807
DMJIMXH	MW	416.4
DMJIMXH	FM	C21H20O9
DMJIMXH	IC	InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2/t14-,17-,18+,19-,21+/m1/s1
DMJIMXH	CS	C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O
DMJIMXH	IK	HKEAFJYKMMKDOR-VPRICQMDSA-N
DMJIMXH	IU	7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
DMJIMXH	CA	CAS 3681-99-0
DMJIMXH	CB	CHEBI:8633
DMJIMXH	DE	Alcohol dependence

DMW7L0Y	ID	DMW7L0Y
DMW7L0Y	DN	PUL-042
DMW7L0Y	HS	Phase 2 
DMW7L0Y	SN	ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042
DMW7L0Y	TC	Antiviral Agents
DMW7L0Y	DT	Protein/peptide drug
DMW7L0Y	DE	Coronavirus Disease 2019 (COVID-19)

DMBUSNL	ID	DMBUSNL
DMBUSNL	DN	Pumosetrag
DMBUSNL	HS	Phase 2
DMBUSNL	SN	DDP-733; MKC-733; N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-oxo-4H-thieno[3,2-b]pyridine-6-carboxamide; N-((3R)-1-Azabicyclo(2.2.2)oct-3-yl)-7-oxo-4,7-dihydrothieno(3,2-b)pyridine-6-carboxamide; N-(1-azabicyclo[2.2.2]oct-8-yl)-2-oxo-9-thia-5-azabicyclo[4.3.0]nona-3,7,10-triene-3-carboxamide
DMBUSNL	CP	Dynogen
DMBUSNL	DT	Small molecular drug
DMBUSNL	PC	154104
DMBUSNL	MW	303.4
DMBUSNL	FM	C15H17N3O2S
DMBUSNL	IC	InChI=1S/C15H17N3O2S/c19-13-10(7-16-11-3-6-21-14(11)13)15(20)17-12-8-18-4-1-9(12)2-5-18/h3,6-7,9,12H,1-2,4-5,8H2,(H,16,19)(H,17,20)/t12-/m0/s1
DMBUSNL	CS	C1CN2CCC1[C@H](C2)NC(=O)C3=CNC4=C(C3=O)SC=C4
DMBUSNL	IK	AFUWQWYPPZFWCO-LBPRGKRZSA-N
DMBUSNL	IU	N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-oxo-4H-thieno[3,2-b]pyridine-6-carboxamide
DMBUSNL	CA	CAS 153062-94-3
DMBUSNL	DE	Gastro-oesophageal reflux; Irritable bowel syndrome

DMVUGF7	ID	DMVUGF7
DMVUGF7	DN	PUR-0110
DMVUGF7	HS	Phase 2
DMVUGF7	SN	PCT-233; Purecell complex, inflammation; Thylakoid extract (inflammation), PureCell
DMVUGF7	CP	PurGenesis Technologies Inc
DMVUGF7	DE	Inflammation

DM6DK9A	ID	DM6DK9A
DM6DK9A	DN	PVX-410
DM6DK9A	HS	Phase 2
DM6DK9A	DE	Solid tumour/cancer; Multiple myeloma; Triple negative breast cancer

DMLVHAJ	ID	DMLVHAJ
DMLVHAJ	DN	PX-12
DMLVHAJ	HS	Phase 2
DMLVHAJ	SN	PX12, PX 12, IV-2
DMLVHAJ	CP	Biomira
DMLVHAJ	TC	Anticancer Agents
DMLVHAJ	DT	Small molecular drug
DMLVHAJ	PC	219104
DMLVHAJ	MW	188.3
DMLVHAJ	FM	C7H12N2S2
DMLVHAJ	IC	InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)
DMLVHAJ	CS	CCC(C)SSC1=NC=CN1
DMLVHAJ	IK	BPBPYQWMFCTCNG-UHFFFAOYSA-N
DMLVHAJ	IU	2-(butan-2-yldisulfanyl)-1H-imidazole
DMLVHAJ	CA	CAS 141400-58-0
DMLVHAJ	CB	CHEBI:94291
DMLVHAJ	DE	Solid tumour/cancer

DMYISJK	ID	DMYISJK
DMYISJK	DN	PX-866
DMYISJK	HS	Phase 2
DMYISJK	SN	Sonolisib; PX-866; CHEBI:65345; 502632-66-8; PX866; UNII-987796874T; PX 866; 987796874T; (4S,4aR,5R,6aS,9aR,E)-1-((diallylamino)methylene)-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-2,7,10-trioxo-1,2,4,4a,5,6,6a,7,8,9,9a,10-dodecahydroindeno[4,5-h]isochromen-5-yl acetate; (1E,4S,4aR,5R,6aS,9aR)-1-{[di(prop-2-en-1-yl)amino]methylidene}-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-2,7,10-trioxo-1,2,4,4a,5,6,6a,7,8,9,9a,10-dodecahydroindeno[4,5-h]isochromen-5-yl acetate; Sonolisib [INN]; GTPL7941; CHEMBL411907
DMYISJK	CP	Oncothyreon
DMYISJK	DT	Small molecular drug
DMYISJK	PC	9849735
DMYISJK	MW	525.6
DMYISJK	FM	C29H35NO8
DMYISJK	IC	InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1
DMYISJK	CS	CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C
DMYISJK	IK	QIUASFSNWYMDFS-NILGECQDSA-N
DMYISJK	IU	[(3aR,6E,9S,9aR,10R,11aS)-6-[[bis(prop-2-enyl)amino]methylidene]-5-hydroxy-9-(methoxymethyl)-9a,11a-dimethyl-1,4,7-trioxo-2,3,3a,9,10,11-hexahydroindeno[4,5-h]isochromen-10-yl] acetate
DMYISJK	CA	CAS 502632-66-8
DMYISJK	CB	CHEBI:65345
DMYISJK	DE	Solid tumour/cancer

DMNSRY7	ID	DMNSRY7
DMNSRY7	DN	PXL-770
DMNSRY7	HS	Phase 2
DMNSRY7	CP	Poxel SA
DMNSRY7	DT	Small molecular drug
DMNSRY7	DE	Non-alcoholic fatty liver disease

DMLQK6E	ID	DMLQK6E
DMLQK6E	DN	PYM-50028
DMLQK6E	HS	Phase 2
DMLQK6E	SN	Cogane; Smilagenin; P-58; P-63
DMLQK6E	CP	Phytopharm
DMLQK6E	DE	Neurological disorder

DMSOPAU	ID	DMSOPAU
DMSOPAU	DN	Pyrazoloacridine
DMSOPAU	HS	Phase 2
DMSOPAU	SN	PD-115934; 2-[3-(Dimethylamino)propyl]-9-methoxy-5-nitro-2,6-dihydropyrazolo[3,4,5-kl]acridine; 9-Methoxy-N,N-dimethyl-5-nitro-2,6-dihydropyrazolo[3,4,5-kl]acridine-2-propanamine
DMSOPAU	DT	Small molecular drug
DMSOPAU	PC	339455
DMSOPAU	MW	367.4
DMSOPAU	FM	C19H21N5O3
DMSOPAU	IC	InChI=1S/C19H21N5O3/c1-22(2)9-4-10-23-15-7-8-16(24(25)26)19-17(15)18(21-23)13-11-12(27-3)5-6-14(13)20-19/h5-8,11,20H,4,9-10H2,1-3H3
DMSOPAU	CS	CN(C)CCCN1C2=C3C(=C(C=C2)[N+](=O)[O-])NC4=C(C3=N1)C=C(C=C4)OC
DMSOPAU	IK	HZCWPKGYTCJSEB-UHFFFAOYSA-N
DMSOPAU	IU	3-(4-methoxy-10-nitro-8,14,15-triazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-14-yl)-N,N-dimethylpropan-1-amine
DMSOPAU	CA	CAS 99009-20-8
DMSOPAU	DE	Colorectal cancer

DM1794O	ID	DM1794O
DM1794O	DN	Pyrethroids
DM1794O	HS	Phase 2
DM1794O	SN	resmethrin; 10453-86-8; Benzofuroline; For-syn; Penncapthrin; Resmethrine; Benzyfuroline; Isathrine; Enforcer; Chryson; Synthrin; Pyresthrin; Premgard; Crossfire; Chrysron; Resmethrin [ANSI]; Resbuthrin; Caswell No. 083E; Bioresmethrine; SB Pennick 1382; Penick 1382; Resmetrina [Portuguese]; ARI-B; Resmethrine [ISO-French]; S.B. Penick 1382; d-trans-Resmethrin; 5-Benzylfurfuryl chrysanthemate; NRDC 104; Bioresmethrin (d trans isomer); CCRIS 2501; HSDB 1516; SBP-1382; OMS-1206; EINECS 233-940-7; FMC 17370; ENT 27474; NIA 17370
DM1794O	DT	Small molecular drug
DM1794O	PC	5053
DM1794O	MW	338.4
DM1794O	FM	C22H26O3
DM1794O	IC	InChI=1S/C22H26O3/c1-15(2)10-19-20(22(19,3)4)21(23)25-14-17-12-18(24-13-17)11-16-8-6-5-7-9-16/h5-10,12-13,19-20H,11,14H2,1-4H3
DM1794O	CS	CC(=CC1C(C1(C)C)C(=O)OCC2=COC(=C2)CC3=CC=CC=C3)C
DM1794O	IK	VEMKTZHHVJILDY-UHFFFAOYSA-N
DM1794O	IU	(5-benzylfuran-3-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate
DM1794O	CA	CAS 10453-86-8
DM1794O	CB	CHEBI:8811
DM1794O	DE	Pest attack

DMU5H3A	ID	DMU5H3A
DMU5H3A	DN	PZ-128
DMU5H3A	HS	Phase 2
DMU5H3A	SN	UNII-IYT6MP4NS9; IYT6MP4NS9; 371131-16-7; N-((2S,5S,8S,11S,14S,17S,20S)-1,24-diamino-17-(4-aminobutyl)-2-benzyl-11-(3-guanidinopropyl)-14-(hydroxymethyl)-5-isobutyl-8-methyl-1,4,7,10,13,16,19-heptaoxo-3,6,9,12,15,18-hexaazatetracosan-20-yl)palmitamide; Palmitate-kksralf-NH2; PZ128; PZ 128; CHEMBL4297323; DB11839; L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl-; Q27280961; N-[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]
DMU5H3A	CP	Tufts Medical Center
DMU5H3A	DT	Small molecular drug
DMU5H3A	PC	72187679
DMU5H3A	MW	1086.5
DMU5H3A	FM	C55H99N13O9
DMU5H3A	IC	InChI=1S/C55H99N13O9/c1-5-6-7-8-9-10-11-12-13-14-15-16-20-31-47(70)63-41(28-21-23-32-56)51(74)64-42(29-22-24-33-57)52(75)68-46(37-69)54(77)65-43(30-25-34-61-55(59)60)50(73)62-39(4)49(72)67-45(35-38(2)3)53(76)66-44(48(58)71)36-40-26-18-17-19-27-40/h17-19,26-27,38-39,41-46,69H,5-16,20-25,28-37,56-57H2,1-4H3,(H2,58,71)(H,62,73)(H,63,70)(H,64,74)(H,65,77)(H,66,76)(H,67,72)(H,68,75)(H4,59,60,61)/t39-,41-,42-,43-,44-,45-,46-/m0/s1
DMU5H3A	CS	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N
DMU5H3A	IK	VZRIKWNVDCTBTF-BKGFHLQYSA-N
DMU5H3A	IU	N-[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]hexadecanamide
DMU5H3A	CA	CAS 371131-16-7
DMU5H3A	DE	Peripheral arterial occlusive disorder

DME71WA	ID	DME71WA
DME71WA	DN	Q301
DME71WA	HS	Phase 2
DME71WA	SN	Boc-N-Me-Val-OH; 45170-31-8; Boc-N-methyl-L-valine; N-Boc-N-methyl-L-valine; Boc-MeVal-OH; (S)-2-((tert-Butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid; Boc-N-a-methyl-L-valine; L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; MFCD00038760; n-(tert-butoxycarbonyl)-n-methyl-l-valine; N-Boc-N-methylvaline; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid; PubChem12254; Boc-N-Me-L-Val-OH; Boc-Nalpha-methyl-L-valine; Boc-N-; A-Methyl-L-valine; N-Boc-N-Methyl-L-Val-OH; SCHEMBL59435; DTXSID10426676; ZINC2391126; ANW-41482; AKOS015836686; AKOS015905243; AC-8571; AM82390; AT-5684; CS-W008976; AS-15695; BP-21374; AB0017502; Boc-N-Me-Val-OH, >=99.0% (TLC); DB-038153; 170B318; J-300310; N-alpha-t-Butyloxycarbonyl-N-alpha-methyl-L-valine; Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; (2S)-(tert-Butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (s)-2-(t-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (s)-2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (S)-2-(tert-butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]-3-methyl butanoic acid; (2S)-2-[[(tert-Butoxy)carbonyl](methyl)amino]-3-methylbutanoic acid; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoicacid
DME71WA	CP	Qurient
DME71WA	DT	Small molecular drug
DME71WA	PC	7010608
DME71WA	MW	231.29
DME71WA	FM	C11H21NO4
DME71WA	IC	InChI=1S/C11H21NO4/c1-7(2)8(9(13)14)12(6)10(15)16-11(3,4)5/h7-8H,1-6H3,(H,13,14)/t8-/m0/s1
DME71WA	CS	CC(C)[C@@H](C(=O)O)N(C)C(=O)OC(C)(C)C
DME71WA	IK	XPUAXAVJMJDPDH-QMMMGPOBSA-N
DME71WA	IU	(2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid
DME71WA	CA	CAS 45170-31-8
DME71WA	DE	Atopic dermatitis

DMIZYV1	ID	DMIZYV1
DMIZYV1	DN	QAV-680
DMIZYV1	HS	Phase 2
DMIZYV1	CP	Novartis AG
DMIZYV1	PC	11508736
DMIZYV1	MW	358.4
DMIZYV1	FM	C18H18N2O4S
DMIZYV1	IC	InChI=1S/C18H18N2O4S/c1-12-16(10-17(21)22)15-4-3-9-19-18(15)20(12)11-13-5-7-14(8-6-13)25(2,23)24/h3-9H,10-11H2,1-2H3,(H,21,22)
DMIZYV1	CS	CC1=C(C2=C(N1CC3=CC=C(C=C3)S(=O)(=O)C)N=CC=C2)CC(=O)O
DMIZYV1	IK	YOPFAMROKXHVCQ-UHFFFAOYSA-N
DMIZYV1	IU	2-[2-methyl-1-[(4-methylsulfonylphenyl)methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid
DMIZYV1	CA	CAS 872365-16-7
DMIZYV1	DE	Allergic rhinitis

DMXY0H2	ID	DMXY0H2
DMXY0H2	DN	QAX-028
DMXY0H2	HS	Phase 2
DMXY0H2	SN	Bronchodilatory agent (inhaled, COPD), Novartis
DMXY0H2	CP	Novartis AG
DMXY0H2	DE	Chronic obstructive pulmonary disease

DMUWFI7	ID	DMUWFI7
DMUWFI7	DN	QAX-576
DMUWFI7	HS	Phase 2
DMUWFI7	SN	IL-13 modulator (intravenous), Novartis
DMUWFI7	CP	Novartis AG
DMUWFI7	DE	Allergic rhinitis

DMAFUHK	ID	DMAFUHK
DMAFUHK	DN	QGC-001
DMAFUHK	HS	Phase 2
DMAFUHK	SN	QGC001
DMAFUHK	CP	Pfizer
DMAFUHK	PC	24851355
DMAFUHK	MW	368.5
DMAFUHK	FM	C8H20N2O6S4
DMAFUHK	IC	InChI=1S/C8H20N2O6S4/c9-7(1-3-19(11,12)13)5-17-18-6-8(10)2-4-20(14,15)16/h7-8H,1-6,9-10H2,(H,11,12,13)(H,14,15,16)/t7-,8-/m0/s1
DMAFUHK	CS	C(CS(=O)(=O)O)[C@@H](CSSC[C@H](CCS(=O)(=O)O)N)N
DMAFUHK	IK	HJPXZXVKLGEMGP-YUMQZZPRSA-N
DMAFUHK	IU	(3S)-3-amino-4-[[(2S)-2-amino-4-sulfobutyl]disulfanyl]butane-1-sulfonic acid
DMAFUHK	CA	CAS 648927-86-0
DMAFUHK	DE	Hypertension

DMKVIWM	ID	DMKVIWM
DMKVIWM	DN	QR-333
DMKVIWM	HS	Phase 2
DMKVIWM	CP	Quigley Pharma Inc
DMKVIWM	DE	Diabetic neuropathy

DMIUS5X	ID	DMIUS5X
DMIUS5X	DN	R1507
DMIUS5X	HS	Phase 2
DMIUS5X	CP	Roche
DMIUS5X	PC	5376617
DMIUS5X	MW	276.29
DMIUS5X	FM	C17H12N2O2
DMIUS5X	IC	InChI=1S/C17H12N2O2/c20-19(21)16-6-3-4-13(12-16)8-10-15-11-9-14-5-1-2-7-17(14)18-15/h1-12H/b10-8+
DMIUS5X	CS	C1=CC=C2C(=C1)C=CC(=N2)/C=C/C3=CC(=CC=C3)[N+](=O)[O-]
DMIUS5X	IK	URIXDBULDXTIHZ-CSKARUKUSA-N
DMIUS5X	IU	2-[(E)-2-(3-nitrophenyl)ethenyl]quinoline
DMIUS5X	CA	CAS 7251-91-4
DMIUS5X	DE	Graves ophthalmopathy

DMP7J0S	ID	DMP7J0S
DMP7J0S	DN	R411
DMP7J0S	HS	Phase 2
DMP7J0S	CP	Roche
DMP7J0S	DT	Small molecular drug
DMP7J0S	PC	61516
DMP7J0S	MW	178.27
DMP7J0S	FM	C12H18O
DMP7J0S	IC	InChI=1S/C12H18O/c1-3-12(2,13)10-9-11-7-5-4-6-8-11/h4-8,13H,3,9-10H2,1-2H3
DMP7J0S	CS	CCC(C)(CCC1=CC=CC=C1)O
DMP7J0S	IK	AEJRTNBCFUOSEM-UHFFFAOYSA-N
DMP7J0S	IU	3-methyl-1-phenylpentan-3-ol
DMP7J0S	CA	CAS 10415-87-9
DMP7J0S	DE	Asthma

DM79YAS	ID	DM79YAS
DM79YAS	DN	Racotumomab
DM79YAS	HS	Phase 2
DM79YAS	SN	P3 MAb, CIM; 1E10 anti-idiotypic MAb, Center of Molecular Immunology
DM79YAS	CP	The Center of Molecular Immunology
DM79YAS	DT	Monoclonal antibody
DM79YAS	DE	Breast cancer

DMOI9EL	ID	DMOI9EL
DMOI9EL	DN	Radezolid
DMOI9EL	HS	Phase 2
DMOI9EL	SN	Radezolid; Radezolid hydrochloride; RX-103; RX-1741; RX-01-667; Oxazolidinone antibiotic (bacterial infection), Rib-X Pharmaceuticals; Oxazolidinone antibiotic (CAP/uSSSI), Rib-X Pharamceuticals; Radezolid (iv, gram positive bacterial infection), Rib-X Pharmaceuticals; RX-1741 (iv, gram positive bacterial infection), Rib-X Pharmaceuticals; Radezolid (oral, CAP/uSSSI), Rib-X Pharmaceuticals; RX-1741 (oral, CAP/uSSSI), Rib-X Pharmaceuticals
DMOI9EL	CP	Melinta therapeutics
DMOI9EL	DE	Pneumonia; Acne vulgaris

DMC56T4	ID	DMC56T4
DMC56T4	DN	RAF265
DMC56T4	HS	Phase 2
DMC56T4	SN	RAF265; 927880-90-8; CHIR-265; RAF 265; RAF-265; CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; CHIR265; RAF265(CHIR-265); UNII-8O434L3768; 8O434L3768; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; PubChem22594
DMC56T4	CP	Novartis Pharmaceuticals
DMC56T4	DT	Small molecular drug
DMC56T4	PC	11656518
DMC56T4	MW	518.4
DMC56T4	FM	C24H16F6N6O
DMC56T4	IC	InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)
DMC56T4	CS	CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F
DMC56T4	IK	YABJJWZLRMPFSI-UHFFFAOYSA-N
DMC56T4	IU	1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine
DMC56T4	CA	CAS 927880-90-8
DMC56T4	CB	CHEBI:91451
DMC56T4	DE	Melanoma

DM7G4Y9	ID	DM7G4Y9
DM7G4Y9	DN	Ralinepag
DM7G4Y9	HS	Phase 2
DM7G4Y9	SN	UNII-CQY12ZJN6E; CQY12ZJN6E; 1187856-49-0; Ralinepag [USAN:INN]; Ralinepag (USAN/INN); SCHEMBL1118504; SCHEMBL1118506; SCHEMBL12786473; CHEMBL3919269; CHEMBL3301604; AKOS027337124; DB12462; 2-((trans-4-((((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetic acid; Acetic acid, 2-((trans-4-(((((4-chlorophenyl)phenylamino)carbonyl)oxy)methyl)cyclohexyl)methoxy)-; HY-16751; CS-0012350; J3.614.088G; D10725
DM7G4Y9	CP	Arena Pharmaceuticals San Diego, CA
DM7G4Y9	PC	44219292
DM7G4Y9	MW	431.9
DM7G4Y9	FM	C23H26ClNO5
DM7G4Y9	IC	InChI=1S/C23H26ClNO5/c24-19-10-12-21(13-11-19)25(20-4-2-1-3-5-20)23(28)30-15-18-8-6-17(7-9-18)14-29-16-22(26)27/h1-5,10-13,17-18H,6-9,14-16H2,(H,26,27)
DM7G4Y9	CS	C1CC(CCC1COCC(=O)O)COC(=O)N(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DM7G4Y9	IK	NPDKXVKJRHPDQT-UHFFFAOYSA-N
DM7G4Y9	IU	2-[[4-[[(4-chlorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid
DM7G4Y9	CA	CAS 1187856-49-0
DM7G4Y9	DE	Pulmonary hypertension; Pulmonary arterial hypertension

DMBFZSX	ID	DMBFZSX
DMBFZSX	DN	RALURIDINE
DMBFZSX	HS	Phase 2
DMBFZSX	SN	FCU; FddClUrd; BW-935U83; Raluridine; 5-Chloro-2',3'-dideoxy-3'-fluorouridine
DMBFZSX	DT	Small molecular drug
DMBFZSX	PC	451480
DMBFZSX	MW	264.64
DMBFZSX	FM	C9H10ClFN2O4
DMBFZSX	IC	InChI=1S/C9H10ClFN2O4/c10-4-2-13(9(16)12-8(4)15)7-1-5(11)6(3-14)17-7/h2,5-7,14H,1,3H2,(H,12,15,16)/t5-,6+,7+/m0/s1
DMBFZSX	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Cl)CO)F
DMBFZSX	IK	WKVDSZYIGHLONN-RRKCRQDMSA-N
DMBFZSX	IU	5-chloro-1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMBFZSX	CA	CAS 119644-22-3
DMBFZSX	DE	Human immunodeficiency virus infection

DMP2DNS	ID	DMP2DNS
DMP2DNS	DN	Rambazole
DMP2DNS	HS	Phase 2
DMP2DNS	SN	Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole  pound&gt; SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510
DMP2DNS	CP	Barrier
DMP2DNS	DT	Small molecular drug
DMP2DNS	PC	9799888
DMP2DNS	MW	377.5
DMP2DNS	FM	C21H23N5S
DMP2DNS	IC	InChI=1S/C21H23N5S/c1-3-15(4-2)20(26-14-22-13-23-26)16-9-11-17(12-10-16)24-21-25-18-7-5-6-8-19(18)27-21/h5-15,20H,3-4H2,1-2H3,(H,24,25)
DMP2DNS	CS	CCC(CC)C(C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=NC=N4
DMP2DNS	IK	SNFYYXUGUBUECJ-UHFFFAOYSA-N
DMP2DNS	IU	N-[4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl]-1,3-benzothiazol-2-amine
DMP2DNS	CA	CAS 201410-53-9
DMP2DNS	CB	CHEBI:102167
DMP2DNS	DE	Asthma; Psoriasis vulgaris

DMO2TYL	ID	DMO2TYL
DMO2TYL	DN	Ramipril
DMO2TYL	HS	Phase 2 
DMO2TYL	SN	ramipril; 87333-19-5; Tritace; Altace; Carasel; Triatec; Ramace; Delix; Vesdil; Acovil; Cardace; Lostapres; Quark; Hytren; Ramiprilum [Latin]; Hoe-498; Ramiprilum; Pramace; HOE 498; Altace (TN); UNII-L35JN3I7SJ; CHEMBL1168; L35JN3I7SJ; CHEBI:8774; C23H32N2O5; Ramipril
DMO2TYL	TC	Antiviral Agents
DMO2TYL	DT	Small molecular drug
DMO2TYL	PC	5362129
DMO2TYL	MW	416.5
DMO2TYL	FM	C23H32N2O5
DMO2TYL	IC	InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
DMO2TYL	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
DMO2TYL	IK	HDACQVRGBOVJII-JBDAPHQKSA-N
DMO2TYL	IU	(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
DMO2TYL	CA	CAS 87333-19-5
DMO2TYL	CB	CHEBI:8774
DMO2TYL	DE	Coronavirus Disease 2019 (COVID-19)

DMM15RI	ID	DMM15RI
DMM15RI	DN	Ranpirnase
DMM15RI	HS	Phase 2
DMM15RI	CP	Tamir Biotechnology
DMM15RI	DE	Lung cancer

DMK2E0N	ID	DMK2E0N
DMK2E0N	DN	RAXOFELAST
DMK2E0N	HS	Phase 2
DMK2E0N	SN	IRFI-016; Raxofelast; Rac-2-(5-Acetoxy-4,6,7-trimethyl-2,3-dihydrobenzofuran-2-yl)acetic acid
DMK2E0N	DT	Small molecular drug
DMK2E0N	PC	65961
DMK2E0N	MW	278.3
DMK2E0N	FM	C15H18O5
DMK2E0N	IC	InChI=1S/C15H18O5/c1-7-8(2)15-12(5-11(20-15)6-13(17)18)9(3)14(7)19-10(4)16/h11H,5-6H2,1-4H3,(H,17,18)
DMK2E0N	CS	CC1=C(C(=C(C2=C1OC(C2)CC(=O)O)C)OC(=O)C)C
DMK2E0N	IK	QLWBKUUORSULMI-UHFFFAOYSA-N
DMK2E0N	IU	2-(5-acetyloxy-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-2-yl)acetic acid
DMK2E0N	CA	CAS 128232-14-4
DMK2E0N	DE	Ischemia

DMIG98L	ID	DMIG98L
DMIG98L	DN	RC-3095
DMIG98L	HS	Phase 2
DMIG98L	SN	Rc-3095; D-Tpi-Gln-Trp-Ala-Val-Gly-His-Leu-Y(CH2-NH)-Leu-NH2 trifluoroacetate salt; GTPL6183; [D-Tpi6, Leu13 psi(CH2NH)-Leu14]bombesin-(6-14); (D-Tpi6, Leu13psi(CH2-NH)-Leu14)bombesin (6-14)
DMIG98L	DT	Small molecular drug
DMIG98L	PC	11948463
DMIG98L	MW	1106.3
DMIG98L	FM	C56H79N15O9
DMIG98L	IC	InChI=1S/C56H79N15O9/c1-29(2)18-35(25-61-42(50(58)74)19-30(3)4)66-55(79)45(21-34-24-59-28-64-34)68-48(73)27-63-56(80)49(31(5)6)71-51(75)32(7)65-54(78)44(20-33-23-60-39-14-10-8-12-36(33)39)70-52(76)41(16-17-47(57)72)69-53(77)43-22-38-37-13-9-11-15-40(37)67-46(38)26-62-43/h8-15,23-24,28-32,35,41-45,49,60-62,67H,16-22,25-27H2,1-7H3,(H2,57,72)(H2,58,74)(H,59,64)(H,63,80)(H,65,78)(H,66,79)(H,68,73)(H,69,77)(H,70,76)(H,71,75)/t32-,35-,41-,42-,43+,44-,45-,49-/m0/s1
DMIG98L	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)CN[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]4CC5=C(CN4)NC6=CC=CC=C56
DMIG98L	IK	IUYCRRDHLJIJBB-QAGBKCHLSA-N
DMIG98L	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methylpentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(3R)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl]amino]pentanediamide
DMIG98L	DE	Solid tumour/cancer

DM1TKG4	ID	DM1TKG4
DM1TKG4	DN	RDEA3170
DM1TKG4	HS	Phase 2
DM1TKG4	CP	AstraZeneca
DM1TKG4	PC	54767229
DM1TKG4	MW	348.4
DM1TKG4	FM	C20H16N2O2S
DM1TKG4	IC	InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)
DM1TKG4	CS	CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N
DM1TKG4	IK	YYBOLPLTQDKXPM-UHFFFAOYSA-N
DM1TKG4	IU	2-[3-(4-cyanonaphthalen-1-yl)pyridin-4-yl]sulfanyl-2-methylpropanoic acid
DM1TKG4	CA	CAS 1352792-74-5
DM1TKG4	DE	Hyperuricaemia

DMNWYHD	ID	DMNWYHD
DMNWYHD	DN	RDEA-684
DMNWYHD	HS	Phase 2
DMNWYHD	CP	Ardea Biosciences Inc
DMNWYHD	DE	Gout

DM4CIKA	ID	DM4CIKA
DM4CIKA	DN	RDP58
DM4CIKA	HS	Phase 2
DM4CIKA	SN	Delmitide; RDP58; RDP-58; UNII-5759XTJ706; 5759XTJ706; Delmitide [INN]; Allotrap-1258; Allotrap 1258; 287096-87-1; AC1L55WS; AC1Q5JM9; (2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-5-guanidino-pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-n-[(1r)-1-[[(1r)-1-[[(1r)-1-[[(1r)-1-[[2-[[(1r)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]-4-guanidino-butyl]hexanamide; RDP 58; RSP-58; SCHEMBL18758870; D-Tyrosinamide, D-arginyl-D-norleucyl-D-norleucyl-D-n
DM4CIKA	CP	Genzyme
DM4CIKA	DT	Small molecular drug
DM4CIKA	PC	219021
DM4CIKA	MW	1228.6
DM4CIKA	FM	C59H105N17O11
DM4CIKA	IC	InChI=1S/C59H105N17O11/c1-7-13-22-40(51(81)68-36-48(78)69-47(49(61)79)35-37-29-31-38(77)32-30-37)71-53(83)42(24-15-9-3)73-55(85)44(26-17-11-5)75-57(87)46(28-20-34-67-59(64)65)76-56(86)45(27-18-12-6)74-54(84)43(25-16-10-4)72-52(82)41(23-14-8-2)70-50(80)39(60)21-19-33-66-58(62)63/h29-32,39-47,77H,7-28,33-36,60H2,1-6H3,(H2,61,79)(H,68,81)(H,69,78)(H,70,80)(H,71,83)(H,72,82)(H,73,85)(H,74,84)(H,75,87)(H,76,86)(H4,62,63,66)(H4,64,65,67)/t39-,40-,41-,42-,43-,44-,45-,46-,47-/m1/s1
DM4CIKA	CS	CCCC[C@H](C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)NCC(=O)N[C@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)N
DM4CIKA	IK	SFGFYNXPJMOUHK-PKAFTLKUSA-N
DM4CIKA	IU	(2R)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[2-[[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]hexanamide
DM4CIKA	CA	CAS 287096-87-1
DM4CIKA	DE	Diarrhea

DM2CJ4O	ID	DM2CJ4O
DM2CJ4O	DN	Rebmab-100
DM2CJ4O	HS	Phase 2
DM2CJ4O	CP	Genesis Biopharma
DM2CJ4O	DT	Antibody
DM2CJ4O	DE	Fallopian tube cancer

DML8N3Y	ID	DML8N3Y
DML8N3Y	DN	Recifercept
DML8N3Y	HS	Phase 2
DML8N3Y	SN	TA-46
DML8N3Y	CP	Pfizer
DML8N3Y	DT	Antibody
DML8N3Y	DE	Achondroplasia

DMCSR8I	ID	DMCSR8I
DMCSR8I	DN	Recoflavone
DMCSR8I	HS	Phase 2
DMCSR8I	SN	Recoflavone; DA-6034; Recoflavone (gastritis), Dong-A; DA-6034 (gastritis), Dong-A; Recoflavone (eyedrops, xerophthalmia), Dong-A; DA-6034 (eye drops, xerophthalmia), Dong-A; DA-6034 (ophthalmic, dry eye), Dong-A
DMCSR8I	CP	Dong-A Pharmaceutical Co Ltd
DMCSR8I	DT	Small molecular drug
DMCSR8I	PC	9952125
DMCSR8I	MW	386.4
DMCSR8I	FM	C20H18O8
DMCSR8I	IC	InChI=1S/C20H18O8/c1-24-14-5-4-11(6-16(14)25-2)15-9-13(21)20-17(26-3)7-12(8-18(20)28-15)27-10-19(22)23/h4-9H,10H2,1-3H3,(H,22,23)
DMCSR8I	CS	COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3OC)OCC(=O)O)OC
DMCSR8I	IK	BCPQOBQIVJZOFL-UHFFFAOYSA-N
DMCSR8I	IU	2-[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxochromen-7-yl]oxyacetic acid
DMCSR8I	CA	203191-10-0
DMCSR8I	DE	Inflammatory bowel disease

DMURX4B	ID	DMURX4B
DMURX4B	DN	Recombinant batroxobin
DMURX4B	HS	Phase 2
DMURX4B	CP	SinoBiomed
DMURX4B	DE	Blood forming organ disorder

DMV0A28	ID	DMV0A28
DMV0A28	DN	Recombinant RGD-hirudin
DMV0A28	HS	Phase 2
DMV0A28	SN	Rh-RGD-hirudin; Recombinant RGD-hirudin (injectable, thrombosis); Recombinant RGD-hirudin (injectable, thrombosis),Simcere
DMV0A28	CP	Simcere Pharmaceutical Group
DMV0A28	DE	Thrombosis

DMSJ3Z5	ID	DMSJ3Z5
DMSJ3Z5	DN	REGN1979
DMSJ3Z5	HS	Phase 2
DMSJ3Z5	CP	Regeneron Pharmaceuticals Tarrytown, NY
DMSJ3Z5	DE	Solid tumour/cancer; Chronic lymphocytic leukaemia; B-cell non-hodgkin lymphoma

DMTBRPO	ID	DMTBRPO
DMTBRPO	DN	REGN910-3
DMTBRPO	HS	Phase 2
DMTBRPO	DT	Antibody
DMTBRPO	DE	Neovascular age-related macular degeneration

DM0KBML	ID	DM0KBML
DM0KBML	DN	REGN-COV2
DM0KBML	HS	Phase 2
DM0KBML	CP	Regeneron Pharmaceuticals
DM0KBML	DT	Antibody
DM0KBML	DE	Coronavirus Disease 2019 (COVID-19)

DM13OVF	ID	DM13OVF
DM13OVF	DN	REMD 477
DM13OVF	HS	Phase 2
DM13OVF	SN	Volagidemab
DM13OVF	CP	REMD Biotherapeutics
DM13OVF	DT	Antibody
DM13OVF	DE	Type-2 diabetes; Type-1 diabetes; Type 2 diabetes

DMJIB89	ID	DMJIB89
DMJIB89	DN	Remetinostat
DMJIB89	HS	Phase 2
DMJIB89	SN	UNII-37NT056AT4; 946150-57-8; Methylparaben suberohydroxamic acid phenyl ester; 37NT056AT4; Remetinostat [USAN]; Remetinostat (USAN/INN); CHEMBL3707219; SCHEMBL12682510; DTXSID20647779; NSC748492; Benzoic acid, 4-((8-(hydroxyamino)-1,8-dioxooctyl)oxy)-, methyl ester; NSC-748492; D10977; methyl 4-[8-(hydroxyamino)-8-oxooctanoyl]oxybenzoate; Methyl 4-{[8-(hydroxyamino)-8-oxooctanoyl]oxy}benzoate; Benzoic acid,8-dioxooctyl]oxy]-, methyl ester (MP-shape)
DMJIB89	CP	Medivir Huddinge, Sweden
DMJIB89	PC	24875489
DMJIB89	MW	323.34
DMJIB89	FM	C16H21NO6
DMJIB89	IC	InChI=1S/C16H21NO6/c1-22-16(20)12-8-10-13(11-9-12)23-15(19)7-5-3-2-4-6-14(18)17-21/h8-11,21H,2-7H2,1H3,(H,17,18)
DMJIB89	CS	COC(=O)C1=CC=C(C=C1)OC(=O)CCCCCCC(=O)NO
DMJIB89	IK	XDZAHHULFQIBFE-UHFFFAOYSA-N
DMJIB89	IU	methyl 4-[8-(hydroxyamino)-8-oxooctanoyl]oxybenzoate
DMJIB89	CA	CAS 946150-57-8
DMJIB89	DE	Basal cell carcinoma; Cutaneous T-cell lymphoma

DM2USXP	ID	DM2USXP
DM2USXP	DN	Remlarsen
DM2USXP	HS	Phase 2
DM2USXP	CP	miRagen Therapeutics
DM2USXP	DE	Keloid

DMZFV3E	ID	DMZFV3E
DMZFV3E	DN	Remogli ozin-etabonate
DMZFV3E	HS	Phase 2
DMZFV3E	CP	Bhv pharma
DMZFV3E	DE	Type-2 diabetes

DMW4YK1	ID	DMW4YK1
DMW4YK1	DN	Remogliflozin etabonate
DMW4YK1	HS	Phase 2
DMW4YK1	SN	GSK-189075; GSK-189075A; KGT-1681
DMW4YK1	CP	GSK
DMW4YK1	DT	Small molecular drug
DMW4YK1	PC	9871420
DMW4YK1	MW	522.6
DMW4YK1	FM	C26H38N2O9
DMW4YK1	IC	InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
DMW4YK1	CS	CCOC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O
DMW4YK1	IK	UAOCLDQAQNNEAX-ABMICEGHSA-N
DMW4YK1	IU	ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate
DMW4YK1	CA	CAS 442201-24-3
DMW4YK1	DE	Type-1/2 diabetes; Type-2 diabetes

DMTGU6K	ID	DMTGU6K
DMTGU6K	DN	REN-1654
DMTGU6K	HS	Phase 2
DMTGU6K	SN	Antineurodegeneratives, Centaur; CPI-1160; CPI-1189; Parkinsons therapy, Centaur; REN-1189
DMTGU6K	CP	Centaur Pharmaceuticals Inc
DMTGU6K	DT	Small molecular drug
DMTGU6K	PC	151118
DMTGU6K	MW	234.29
DMTGU6K	FM	C13H18N2O2
DMTGU6K	IC	InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)
DMTGU6K	CS	CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C
DMTGU6K	IK	DJKNRCWSXSZACF-UHFFFAOYSA-N
DMTGU6K	IU	4-acetamido-N-tert-butylbenzamide
DMTGU6K	CA	CAS 183619-38-7
DMTGU6K	DE	Cognitive impairment

DMQ73AY	ID	DMQ73AY
DMQ73AY	DN	Reovirus
DMQ73AY	HS	Phase 2
DMQ73AY	SN	Reolysin (TN)
DMQ73AY	CP	Oncolytics Biotech
DMQ73AY	DE	Head and neck cancer

DMT5QSD	ID	DMT5QSD
DMT5QSD	DN	Resimmune
DMT5QSD	HS	Phase 2
DMT5QSD	SN	A-dmDT390-bisFv immunotoxin
DMT5QSD	CP	Angimmune
DMT5QSD	DE	Melanoma; Cutaneous T-cell lymphoma

DMP62L5	ID	DMP62L5
DMP62L5	DN	Resiniferatoxin
DMP62L5	HS	Phase 2
DMP62L5	SN	Reciniferatoxin; UNII-A5O6P1UL4I; A5O6P1UL4I; 57444-62-9; RTX; [3H]resiniferatoxin; 6,7-Deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)daphnetoxin 20-(3-hydroxy-5-methoxybenzeneacetate); CHEMBL448382; resinferatoxin; Benzeneacetic acid, 4-hydroxy-3-methoxy-, ((2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7H-2,9b-epoxyazuleno(5,4-e)-1,3-benzodioxol-5-yl)methyl ester; Resiniferatoxin(RTX); CHEMBL17976;  RTX
DMP62L5	CP	Afferon
DMP62L5	TC	Analgesics
DMP62L5	DT	Small molecular drug
DMP62L5	PC	5702546
DMP62L5	MW	628.7
DMP62L5	FM	C37H40O9
DMP62L5	IC	InChI=1S/C37H40O9/c1-21(2)35-17-23(4)37-27(33(35)44-36(45-35,46-37)19-24-9-7-6-8-10-24)14-26(18-34(41)30(37)13-22(3)32(34)40)20-43-31(39)16-25-11-12-28(38)29(15-25)42-5/h6-15,23,27,30,33,38,41H,1,16-20H2,2-5H3/t23-,27+,30-,33-,34-,35-,36-,37-/m1/s1
DMP62L5	CS	C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5(CC(=C4)COC(=O)CC6=CC(=C(C=C6)O)OC)O)C)O[C@](O3)(O2)CC7=CC=CC=C7)C(=C)C
DMP62L5	IK	DSDNAKHZNJAGHN-MXTYGGKSSA-N
DMP62L5	IU	[(1R,2R,6R,10S,11R,13S,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-methoxyphenyl)acetate
DMP62L5	CA	CAS 57444-62-9
DMP62L5	CB	CHEBI:8809
DMP62L5	DE	Pain; Osteoarthritis; Neuropathic pain; Cancer related pain

DML6XSP	ID	DML6XSP
DML6XSP	DN	Resiquimod
DML6XSP	HS	Phase 2
DML6XSP	SN	Resiquimod [INN]; R 848; S 28463; R-848; S-28463; VML-600; 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol; 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 4-amino-2-(ethoxymethyl)-a,a-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol; 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol
DML6XSP	CP	3M Pharma.
DML6XSP	DT	Small molecular drug
DML6XSP	PC	159603
DML6XSP	MW	314.4
DML6XSP	FM	C17H22N4O2
DML6XSP	IC	InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
DML6XSP	CS	CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
DML6XSP	IK	BXNMTOQRYBFHNZ-UHFFFAOYSA-N
DML6XSP	IU	1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
DML6XSP	CA	CAS 144875-48-9
DML6XSP	CB	CHEBI:36706
DML6XSP	DE	Herpes simplex virus infection; Actinic keratosis; Cutaneous T-cell lymphoma

DMNE1FR	ID	DMNE1FR
DMNE1FR	DN	Resminostat
DMNE1FR	HS	Phase 2
DMNE1FR	SN	Resminostat; 864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895
DMNE1FR	CP	4SC AG
DMNE1FR	DT	Small molecular drug
DMNE1FR	PC	11609955
DMNE1FR	MW	349.4
DMNE1FR	FM	C16H19N3O4S
DMNE1FR	IC	InChI=1S/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)/b8-5+
DMNE1FR	CS	CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)/C=C/C(=O)NO
DMNE1FR	IK	FECGNJPYVFEKOD-VMPITWQZSA-N
DMNE1FR	IU	(E)-3-[1-[4-[(dimethylamino)methyl]phenyl]sulfonylpyrrol-3-yl]-N-hydroxyprop-2-enamide
DMNE1FR	CA	CAS 864814-88-0
DMNE1FR	DE	Hepatocellular carcinoma

DMM4EJI	ID	DMM4EJI
DMM4EJI	DN	Resten-NG
DMM4EJI	HS	Phase 2
DMM4EJI	SN	Resten-NG (TN)
DMM4EJI	CP	Cook Pharmica
DMM4EJI	DT	Antisense drug
DMM4EJI	DE	Coronary artery disease; Solid tumour/cancer

DMVXZJ4	ID	DMVXZJ4
DMVXZJ4	DN	RetinoStat
DMVXZJ4	HS	Phase 2
DMVXZJ4	SN	AngiStat; XiaGen; Cardiovascular disease therapy, Oxford Biomedica; Gene therapy (HRE), Oxford Biomedica; Angiostatin/endostatin gene therapy (LentiVector, AMD), Oxford Biomedica
DMVXZJ4	CP	Oxford BioMedica plc
DMVXZJ4	DE	Macular degeneration

DMJ37UX	ID	DMJ37UX
DMJ37UX	DN	Revacept
DMJ37UX	HS	Phase 2
DMJ37UX	SN	Arterial thrombosis treatment, Trigen; PR-15; Antiplatelet protein therapy (arterial thrombosis/atherosclerosis), Trigen
DMJ37UX	CP	ProCorde GmbH
DMJ37UX	DE	Arteriosclerosis

DM1FS2W	ID	DM1FS2W
DM1FS2W	DN	Revamilast
DM1FS2W	HS	Phase 2
DM1FS2W	SN	GRC-4039; PDE 4 inhibitor (inflammation), Glenmark; Phosphodiesterase 4 inhibitor (inflammation), Glenmark; Revamilast (inflammation), Glenmark
DM1FS2W	CP	Glenmark Pharmaceuticals Ltd
DM1FS2W	DT	Small molecular drug
DM1FS2W	PC	11546664
DM1FS2W	MW	440.2
DM1FS2W	FM	C18H9Cl2F2N3O4
DM1FS2W	IC	InChI=1S/C18H9Cl2F2N3O4/c19-10-6-25(27)7-11(20)15(10)24-17(26)8-1-2-13(29-18(21)22)16-14(8)9-5-23-4-3-12(9)28-16/h1-7,18,27H
DM1FS2W	CS	C1=CC(=C2C(=C1C(=O)N=C3C(=CN(C=C3Cl)O)Cl)C4=C(O2)C=CN=C4)OC(F)F
DM1FS2W	IK	CFRXVFRHMZLQBS-UHFFFAOYSA-N
DM1FS2W	IU	N-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-6-(difluoromethoxy)-[1]benzofuro[3,2-c]pyridine-9-carboxamide
DM1FS2W	CA	CAS 893555-90-3
DM1FS2W	DE	Asthma

DMFIVSR	ID	DMFIVSR
DMFIVSR	DN	R-flurbiprofen
DMFIVSR	HS	Phase 2
DMFIVSR	SN	Tarenflurbil; (R)-Flurbiprofen; 51543-40-9; Flurizan; R-Flurbiprofen; (R)-2-Flurbiprofen; (R)-2-Flubiprofen; MPC-7869; UNII-501W00OOWA; R-(-)-Flurbiprofen; (2r)-2-(3-Fluoro-4-Phenyl-Phenyl)propanoic Acid; (-)-(2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (R)-(-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (R)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; (2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid; CHEMBL190083; 501W00OOWA; CHEBI:38666; E-7869
DMFIVSR	DT	Small molecular drug
DMFIVSR	PC	92337
DMFIVSR	MW	244.26
DMFIVSR	FM	C15H13FO2
DMFIVSR	IC	InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1
DMFIVSR	CS	C[C@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
DMFIVSR	IK	SYTBZMRGLBWNTM-SNVBAGLBSA-N
DMFIVSR	IU	(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
DMFIVSR	CA	CAS 51543-40-9
DMFIVSR	CB	CHEBI:38666

DMQ8K93	ID	DMQ8K93
DMQ8K93	DN	RFT-5.dgA
DMQ8K93	HS	Phase 2
DMQ8K93	SN	IMTOX-25; Anti-CD25 antibody, University of Texas Southwestern Medical Center; Immunotoxin (cancer), University of Texas Southwestern Medical Center/ Cologne University
DMQ8K93	CP	University of Texas Southwestern Medical Center
DMQ8K93	DE	Human immunodeficiency virus infection

DM2UGT7	ID	DM2UGT7
DM2UGT7	DN	RG-101
DM2UGT7	HS	Phase 2
DM2UGT7	DE	Hepatitis C virus infection

DMT1ZX0	ID	DMT1ZX0
DMT1ZX0	DN	RG1577
DMT1ZX0	HS	Phase 2
DMT1ZX0	CP	Roche
DMT1ZX0	DE	Alzheimer disease

DMT4QRD	ID	DMT4QRD
DMT4QRD	DN	RG-4929
DMT4QRD	HS	Phase 2
DMT4QRD	SN	R-4929; RO-5093151; 11-beta HSD inhibitor (type 2 diabetes), Roche; 11-beta hydroxysteroid dehydrogenase inhibitor (type 2 diabetes), Roche
DMT4QRD	CP	F Hoffmann-La Roche Ltd
DMT4QRD	DT	Small molecular drug
DMT4QRD	PC	21846
DMT4QRD	MW	398.9
DMT4QRD	FM	C23H27ClN2O2
DMT4QRD	IC	InChI=1S/C23H26N2O2.ClH/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18;/h1-10,20H,11-17H2,(H,24,26,27);1H
DMT4QRD	CS	C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4.Cl
DMT4QRD	IK	XSOOSXRNMDUWEM-UHFFFAOYSA-N
DMT4QRD	IU	3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione;hydrochloride
DMT4QRD	CA	CAS 5633-14-7
DMT4QRD	DE	Metabolic disorder

DMEFD0B	ID	DMEFD0B
DMEFD0B	DN	RG6100
DMEFD0B	HS	Phase 2
DMEFD0B	CP	AC Immune Lausanne, Switzerland Genentech South San Francisco, CA
DMEFD0B	DE	Alzheimer disease

DMX8JYN	ID	DMX8JYN
DMX8JYN	DN	RG-7090
DMX8JYN	HS	Phase 2
DMX8JYN	SN	RO-4917523; Antidepressant (oral), Hoffmann-La Roche; MGluR5 antagonist (depression/fragile X syndrome, oral), Roche
DMX8JYN	CP	F Hoffmann-La Roche Ltd
DMX8JYN	DT	Small molecular drug
DMX8JYN	PC	11438771
DMX8JYN	MW	325.8
DMX8JYN	FM	C18H13ClFN3
DMX8JYN	IC	InChI=1S/C18H13ClFN3/c1-12-17(8-3-14-9-10-21-18(19)11-14)22-13(2)23(12)16-6-4-15(20)5-7-16/h4-7,9-11H,1-2H3
DMX8JYN	CS	CC1=C(N=C(N1C2=CC=C(C=C2)F)C)C#CC3=CC(=NC=C3)Cl
DMX8JYN	IK	UPZWINBEAHDTLA-UHFFFAOYSA-N
DMX8JYN	IU	2-chloro-4-[2-[1-(4-fluorophenyl)-2,5-dimethylimidazol-4-yl]ethynyl]pyridine
DMX8JYN	CA	CAS 802906-73-6
DMX8JYN	DE	Fragile X syndrome

DM8JMNL	ID	DM8JMNL
DM8JMNL	DN	RG7155
DM8JMNL	HS	Phase 2
DM8JMNL	CP	Roche
DM8JMNL	DE	Solid tumour/cancer

DM8J9DC	ID	DM8J9DC
DM8J9DC	DN	RG7221
DM8J9DC	HS	Phase 2
DM8J9DC	CP	Roche
DM8J9DC	DE	Colorectal cancer; Metastatic colorectal cancer

DM5RAB9	ID	DM5RAB9
DM5RAB9	DN	RG-7234
DM5RAB9	HS	Phase 2
DM5RAB9	SN	R-7234; RO-5027838; 11-beta HSD 2 (type 2 diabetes), Roche; 11-beta hydroxysteroid dehydrogenase inhibitor 2 (type 2 diabetes), Roche
DM5RAB9	CP	F Hoffmann-La Roche Ltd
DM5RAB9	DE	Type-2 diabetes

DMB4M6O	ID	DMB4M6O
DMB4M6O	DN	RG7314
DMB4M6O	HS	Phase 2
DMB4M6O	DE	Autism spectrum disorder

DMVXGU0	ID	DMVXGU0
DMVXGU0	DN	RG7596
DMVXGU0	HS	Phase 2
DMVXGU0	CP	Genentech
DMVXGU0	DE	Haematological malignancy

DMDGPKS	ID	DMDGPKS
DMDGPKS	DN	RG7625
DMDGPKS	HS	Phase 2
DMDGPKS	SN	Petesicatib; UNII-A26QO95U37; A26QO95U37; RG-7625; RO-5459072; Petesicatib [INN]; SCHEMBL700776; GTPL9855; KXAAIORSMACJSI-AEFFLSMTSA-N; RO5459072; 2-Pyrrolidinecarboxamide, N-(1-cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)sulfonyl)-1-((1-(trifluoromethyl)cyclopropyl)carbonyl)-, (2S,4R)-; 1252637-35-6; (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide; (2s,4r)-4-[4-(1-me
DMDGPKS	CP	RocheBasel, Switzerland
DMDGPKS	PC	59543597
DMDGPKS	MW	603.5
DMDGPKS	FM	C25H23F6N5O4S
DMDGPKS	IC	InChI=1S/C25H23F6N5O4S/c1-35-11-15(10-33-35)14-2-3-19(17(8-14)24(26,27)28)41(39,40)16-9-18(20(37)34-22(13-32)4-5-22)36(12-16)21(38)23(6-7-23)25(29,30)31/h2-3,8,10-11,16,18H,4-7,9,12H2,1H3,(H,34,37)/t16-,18+/m1/s1
DMDGPKS	CS	CN1C=C(C=N1)C2=CC(=C(C=C2)S(=O)(=O)[C@@H]3C[C@H](N(C3)C(=O)C4(CC4)C(F)(F)F)C(=O)NC5(CC5)C#N)C(F)(F)F
DMDGPKS	IK	KXAAIORSMACJSI-AEFFLSMTSA-N
DMDGPKS	IU	(2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide
DMDGPKS	CA	CAS 1252637-35-6
DMDGPKS	DE	Autoimmune disease; Coeliac disease; Sjogren syndrome

DM6CNFW	ID	DM6CNFW
DM6CNFW	DN	RG7686
DM6CNFW	HS	Phase 2
DM6CNFW	CP	Roche
DM6CNFW	DT	Antibody
DM6CNFW	DE	Hepatocellular carcinoma

DMK5PYS	ID	DMK5PYS
DMK5PYS	DN	RG7745
DMK5PYS	HS	Phase 2
DMK5PYS	CP	Genentech
DMK5PYS	DT	Antibody
DMK5PYS	DE	Infectious disease

DM452RF	ID	DM452RF
DM452RF	DN	RG7880
DM452RF	HS	Phase 2
DM452RF	CP	Genentech South San Francisco, CA
DM452RF	DE	Ulcerative colitis; Diabetic foot ulcer

DM2SWI8	ID	DM2SWI8
DM2SWI8	DN	RG7888
DM2SWI8	HS	Phase 2
DM2SWI8	SN	MOXR0916
DM2SWI8	DT	Antibody
DM2SWI8	DE	Solid tumour/cancer; Urothelial carcinoma

DME1YMX	ID	DME1YMX
DME1YMX	DN	RG7935
DME1YMX	HS	Phase 2
DME1YMX	DT	Antibody
DME1YMX	DE	Parkinson disease

DMCHZAN	ID	DMCHZAN
DMCHZAN	DN	RGH-896
DMCHZAN	HS	Phase 2
DMCHZAN	SN	AC1L338E; 1-[2-[[[[[5beta-[(Octadecylaminocarbonyloxy)methyl]tetrahydrofuran]-2beta-yl]methoxy]oxylatophosphinyl]oxy]ethyl]quinolinium; [[[(2R)-5beta-[[(Octadecylcarbamoyl)oxy]methyl]tetrahydrofuran]-2beta-yl]methyl][2-(quinolinium-1-yl)ethyl] phosphate; [(2S,5R)-5-[[hydroxy(2-quinolin-1-ium-1-ylethoxy)phosphoryl]oxymethyl]oxolan-2-yl]methyl N-octadecylcarbamate
DMCHZAN	CP	Gedeon Richter
DMCHZAN	TC	Analgesics
DMCHZAN	DT	Small molecular drug
DMCHZAN	PC	10200813
DMCHZAN	MW	397.4
DMCHZAN	FM	C21H20FN3O4
DMCHZAN	IC	InChI=1S/C21H20FN3O4/c22-15-3-1-13(2-4-15)11-14-7-9-25(10-8-14)20(27)19(26)23-16-5-6-17-18(12-16)29-21(28)24-17/h1-6,12,14H,7-11H2,(H,23,26)(H,24,28)
DMCHZAN	CS	C1CN(CCC1CC2=CC=C(C=C2)F)C(=O)C(=O)NC3=CC4=C(C=C3)NC(=O)O4
DMCHZAN	IK	GKGRZLGAQZPEHO-UHFFFAOYSA-N
DMCHZAN	IU	2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide
DMCHZAN	CA	CAS 496054-87-6
DMCHZAN	DE	Peripheral neuropathy; Epilepsy

DM4AC2F	ID	DM4AC2F
DM4AC2F	DN	RGI-2001
DM4AC2F	HS	Phase 2
DM4AC2F	CP	REGiMMUNE
DM4AC2F	PC	2826713
DM4AC2F	MW	858.3
DM4AC2F	FM	C50H99NO9
DM4AC2F	IC	InChI=1S/C50H99NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-45(54)51-42(41-59-50-49(58)48(57)47(56)44(40-52)60-50)46(55)43(53)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h42-44,46-50,52-53,55-58H,3-41H2,1-2H3,(H,51,54)/t42-,43+,44+,46-,47-,48-,49+,50-/m0/s1
DM4AC2F	CS	CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)[C@@H]([C@@H](CCCCCCCCCCCCCC)O)O
DM4AC2F	IK	VQFKFAKEUMHBLV-BYSUZVQFSA-N
DM4AC2F	IU	N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]hexacosanamide
DM4AC2F	CA	CAS 158021-47-7
DM4AC2F	CB	CHEBI:466659
DM4AC2F	DE	Graft-versus-host disease

DMSF10P	ID	DMSF10P
DMSF10P	DN	RGN-259
DMSF10P	HS	Phase 2
DMSF10P	CP	Regenerx biopharmaceuticals
DMSF10P	DE	Vaginal infection

DMBSXR9	ID	DMBSXR9
DMBSXR9	DN	rhACE2
DMBSXR9	HS	Phase 2 
DMBSXR9	SN	recombinant human ACE2; APN01
DMBSXR9	TC	Antiviral Agents
DMBSXR9	DT	Protein/peptide drug
DMBSXR9	SQ	MSSSSWLLLSLVAVTAAQSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHDETYCDPASLFHVSNDYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPWTLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYADQSIKVRISLKSALGDKAYEWNDNEMYLFRSSVAYAMRQYFLKVKNQMILFGEEDVRVANLKPRISFNFFVTAPKNVSDIIPRTEVEKAIRMSRSRINDAFRLNDNSLEFLGIQPTLGPPNQPPVSIWLIVFGVVMGVIVVGIVILIFTGIRDRKKKNKARSGENPYASIDISKGENNPGFQNTDDVQTSF
DMBSXR9	DE	Coronavirus Disease 2019 (COVID-19)

DMN1EFR	ID	DMN1EFR
DMN1EFR	DN	RhGDF-5
DMN1EFR	HS	Phase 2
DMN1EFR	SN	MD-05; MD-06; MD-07; MD-08; RhGDF-5 (bone regeneration); MP52 (BCP carrier, bone regeneration), BioPharm/Scil; RhGDF-5 (bone regeneration), Scil/Medtronic; RhGDF-5 (implantable bone substitute), BioPharm/Scil; MP52 (beta-tricalciumphosphate carrier, bone regeneration), BioPharm/Scil
DMN1EFR	CP	Biopharm GmbH
DMN1EFR	DE	Periodontal disease

DMO9QB8	ID	DMO9QB8
DMO9QB8	DN	R-IFN-1a
DMO9QB8	HS	Phase 2
DMO9QB8	CP	Merck-Serono Laboratories
DMO9QB8	DE	Hepatitis C virus infection

DM3L51O	ID	DM3L51O
DM3L51O	DN	Rilopirox
DM3L51O	HS	Phase 2
DM3L51O	SN	Riloprox; Hoe-351
DM3L51O	CP	Hoechst AG
DM3L51O	DT	Small molecular drug
DM3L51O	PC	71778
DM3L51O	MW	357.8
DM3L51O	FM	C19H16ClNO4
DM3L51O	IC	InChI=1S/C19H16ClNO4/c1-13-10-15(21(23)19(22)11-13)12-24-16-6-8-18(9-7-16)25-17-4-2-14(20)3-5-17/h2-11,23H,12H2,1H3
DM3L51O	CS	CC1=CC(=O)N(C(=C1)COC2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)O
DM3L51O	IK	UDYUIWXQUBNDHC-UHFFFAOYSA-N
DM3L51O	IU	6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one
DM3L51O	CA	CAS 104153-37-9
DM3L51O	DE	Fungal infection

DMSC7TN	ID	DMSC7TN
DMSC7TN	DN	Rimacalib
DMSC7TN	HS	Phase 2
DMSC7TN	SN	SMP-114
DMSC7TN	CP	Sumitomo Pharmaceuticals Co Ltd
DMSC7TN	DT	Small molecular drug
DMSC7TN	PC	9800765
DMSC7TN	MW	394.4
DMSC7TN	FM	C22H23FN4O2
DMSC7TN	IC	InChI=1S/C22H23FN4O2/c1-15(17-7-8-18(19(23)13-17)16-5-3-2-4-6-16)20-14-21(29-26-20)25-22(24)27-9-11-28-12-10-27/h2-8,13-15H,9-12H2,1H3,(H2,24,25)/t15-/m0/s1
DMSC7TN	CS	C[C@@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C3=NOC(=C3)/N=C(\\N)/N4CCOCC4
DMSC7TN	IK	MYTIJGWONQOOLC-HNNXBMFYSA-N
DMSC7TN	IU	N'-[3-[(1S)-1-(3-fluoro-4-phenylphenyl)ethyl]-1,2-oxazol-5-yl]morpholine-4-carboximidamide
DMSC7TN	CA	CAS 215174-50-8
DMSC7TN	DE	Rheumatoid arthritis

DM2VO97	ID	DM2VO97
DM2VO97	DN	RK-023
DM2VO97	HS	Phase 2
DM2VO97	DE	Alopecia

DMVU1R9	ID	DMVU1R9
DMVU1R9	DN	RM-1929
DMVU1R9	HS	Phase 2
DMVU1R9	CP	Aspyrian Therapeutics San Diego, CA
DMVU1R9	DE	Head and neck cancer

DM20CIM	ID	DM20CIM
DM20CIM	DN	RNF43-721
DM20CIM	HS	Phase 2
DM20CIM	SN	RNF43-721/Montanide ISA51; Peptide vaccine (subcutaneous, colorectal cancer), Tokyo Women's Medical College
DM20CIM	CP	Vaccinogen
DM20CIM	DE	Colorectal cancer

DMDNRU1	ID	DMDNRU1
DMDNRU1	DN	RNS-60
DMDNRU1	HS	Phase 2
DMDNRU1	CP	Revalesio Corp
DMDNRU1	DE	Asthma; Amyotrophic lateral sclerosis; Multiple sclerosis

DM83QCL	ID	DM83QCL
DM83QCL	DN	Ro 31-7453
DM83QCL	HS	Phase 2
DM83QCL	SN	Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione
DM83QCL	CP	Hoffmann La Roche
DM83QCL	TC	Anticancer Agents
DM83QCL	DT	Small molecular drug
DM83QCL	PC	5327686
DM83QCL	MW	400.4
DM83QCL	FM	C22H16N4O4
DM83QCL	IC	InChI=1S/C22H16N4O4/c1-24-10-15(13-5-3-4-6-17(13)24)19-20(22(28)23-21(19)27)16-11-25(2)18-9-12(26(29)30)7-8-14(16)18/h3-11H,1-2H3,(H,23,27,28)
DM83QCL	CS	CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=C4C=CC(=C5)[N+](=O)[O-])C
DM83QCL	IK	OVSKGTONMLKNPZ-UHFFFAOYSA-N
DM83QCL	IU	3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione
DM83QCL	CA	CAS 125313-92-0
DM83QCL	DE	Solid tumour/cancer

DMA2UYE	ID	DMA2UYE
DMA2UYE	DN	Ro-24-7429
DMA2UYE	HS	Phase 2
DMA2UYE	CP	Roche Holding AG
DMA2UYE	DT	Small molecular drug
DMA2UYE	PC	135422895
DMA2UYE	MW	272.73
DMA2UYE	FM	C14H13ClN4
DMA2UYE	IC	InChI=1S/C14H13ClN4/c1-16-13-8-18-14(12-3-2-6-17-12)10-7-9(15)4-5-11(10)19-13/h2-7,17H,8H2,1H3,(H,16,19)
DMA2UYE	CS	CN=C1CN=C(C2=C(N1)C=CC(=C2)Cl)C3=CC=CN3
DMA2UYE	IK	LEAKQIXYSHIHCW-UHFFFAOYSA-N
DMA2UYE	IU	7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-1,3-dihydro-1,4-benzodiazepin-2-imine
DMA2UYE	CA	CAS 139339-45-0
DMA2UYE	CB	CHEBI:93522
DMA2UYE	DE	Human immunodeficiency virus infection

DMV319J	ID	DMV319J
DMV319J	DN	RO-4905417
DMV319J	HS	Phase 2
DMV319J	CP	Roche
DMV319J	DT	Antibody
DMV319J	DE	Acute coronary syndrome

DMXA6B3	ID	DMXA6B3
DMXA6B3	DN	RO-4929097
DMXA6B3	HS	Phase 2
DMXA6B3	SN	RO4929097; 847925-91-1; Ro 4929097; UNII-KK8645V7LE; KK8645V7LE; RG-4733; N1-[(7S)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropropyl)propanediamide; n1-((7s)-6,7-dihydro-6-oxo-5h-dibenz(b,d)azepin-7-yl)-2,2-dimethyl-n3-(2,2,3,3,3-pentafluoropropyl)propanediamide; OJPLJFIFUQPSJR-INIZCTEOSA-N; cc-19; MLS006011071; SCHEMBL1376366; GTPL7338; CHEBI:86474; DTXSID20233833; C22H20F5N3O3; MolPort-016-633-243; BCPP000088; EX-A1750; ZINC43208642; ABP000966; s1575; AKOS027250816
DMXA6B3	CP	Roche
DMXA6B3	DT	Small molecular drug
DMXA6B3	PC	49867930
DMXA6B3	MW	469.4
DMXA6B3	FM	C22H20F5N3O3
DMXA6B3	IC	InChI=1S/C22H20F5N3O3/c1-20(2,18(32)28-11-21(23,24)22(25,26)27)19(33)30-16-14-9-4-3-7-12(14)13-8-5-6-10-15(13)29-17(16)31/h3-10,16H,11H2,1-2H3,(H,28,32)(H,29,31)(H,30,33)/t16-/m0/s1
DMXA6B3	CS	CC(C)(C(=O)NCC(C(F)(F)F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C3=CC=CC=C3NC1=O
DMXA6B3	IK	OJPLJFIFUQPSJR-INIZCTEOSA-N
DMXA6B3	IU	2,2-dimethyl-N-[(7S)-6-oxo-5,7-dihydrobenzo[d][1]benzazepin-7-yl]-N'-(2,2,3,3,3-pentafluoropropyl)propanediamide
DMXA6B3	CA	CAS 847925-91-1
DMXA6B3	CB	CHEBI:86474
DMXA6B3	DE	Breast cancer

DMNTC7O	ID	DMNTC7O
DMNTC7O	DN	RO-4995819
DMNTC7O	HS	Phase 2
DMNTC7O	CP	F Hoffmann-La Roche Ltd
DMNTC7O	PC	71533696
DMNTC7O	MW	447.3
DMNTC7O	FM	C21H11F6N5
DMNTC7O	IC	InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)
DMNTC7O	CS	C1=CC(=CC=C1C2=NC3=C(C=NN3C(=C2)C(F)(F)F)C#CC4=CN=C(C=C4)N)C(F)(F)F
DMNTC7O	IK	DMJHZVARRXJSEG-UHFFFAOYSA-N
DMNTC7O	IU	5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]pyridin-2-amine
DMNTC7O	CA	CAS 911115-16-7
DMNTC7O	DE	Major depressive disorder

DMZJREM	ID	DMZJREM
DMZJREM	DN	RO-4998452
DMZJREM	HS	Phase 2
DMZJREM	SN	Type 2 diabetes therapeutic (oral), Roche
DMZJREM	CP	F Hoffmann-La Roche Ltd
DMZJREM	DE	Type-2 diabetes

DM3U9BY	ID	DM3U9BY
DM3U9BY	DN	RO-5126766
DM3U9BY	HS	Phase 2
DM3U9BY	SN	VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche
DM3U9BY	CP	Roche; Verastem Oncology
DM3U9BY	DT	Small molecular drug
DM3U9BY	PC	16719221
DM3U9BY	MW	471.5
DM3U9BY	FM	C21H18FN5O5S
DM3U9BY	IC	InChI=1S/C21H18FN5O5S/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23H,10H2,1-2H3,(H,24,27)
DM3U9BY	CS	CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=NC=C4)NS(=O)(=O)NC)F
DM3U9BY	IK	LMMJFBMMJUMSJS-UHFFFAOYSA-N
DM3U9BY	IU	3-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one
DM3U9BY	CA	CAS 946128-88-7
DM3U9BY	CB	CHEBI:78825
DM3U9BY	DE	Solid tumour/cancer; Ovarian cancer; Non-small cell lung cancer

DMUB3OY	ID	DMUB3OY
DMUB3OY	DN	RO-5323441
DMUB3OY	HS	Phase 2
DMUB3OY	SN	Placental growth factor inhibitors (humanized mAb, cancer), BioInvent/Thrombogenics/Roche; 89Zr-RO-5323441
DMUB3OY	CP	F Hoffmann-La Roche Ltd
DMUB3OY	DE	Solid tumour/cancer

DMD3WNP	ID	DMD3WNP
DMD3WNP	DN	RO5520985
DMD3WNP	HS	Phase 2
DMD3WNP	CP	Roche
DMD3WNP	DT	Monoclonal antibody
DMD3WNP	DE	Colorectal cancer

DM8A120	ID	DM8A120
DM8A120	DN	RO7121661
DM8A120	HS	Phase 2
DM8A120	SN	RG7769
DM8A120	CP	Roche
DM8A120	DT	Antibody
DM8A120	DE	Esophageal squamous cell carcinoma

DMSTH01	ID	DMSTH01
DMSTH01	DN	Rocilinostat
DMSTH01	HS	Phase 2
DMSTH01	SN	1316214-52-4; Rocilinostat (ACY-1215); 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-WKT909C62B; ACY-63; WKT909C62B; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; AK151416; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide; 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; Ricolinostat [USAN:INN]; AH4; Ricolinostat (USAN/INN); MLS006011181; SCHEMBL574580; GTPL7010
DMSTH01	CP	Acetylon pharmaceuticals
DMSTH01	DT	Small molecular drug
DMSTH01	PC	53340666
DMSTH01	MW	433.5
DMSTH01	FM	C24H27N5O3
DMSTH01	IC	InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)
DMSTH01	CS	C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO
DMSTH01	IK	QGZYDVAGYRLSKP-UHFFFAOYSA-N
DMSTH01	IU	N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide
DMSTH01	CA	CAS 1316214-52-4
DMSTH01	CB	CHEBI:95073
DMSTH01	DE	Autoimmune diabetes; Multiple myeloma

DMYEZ5J	ID	DMYEZ5J
DMYEZ5J	DN	Romilkimab
DMYEZ5J	HS	Phase 2
DMYEZ5J	SN	SAR156597
DMYEZ5J	DT	Antibody
DMYEZ5J	DE	Idiopathic pulmonary fibrosis

DMBJN19	ID	DMBJN19
DMBJN19	DN	Rontalizumab
DMBJN19	HS	Phase 2
DMBJN19	CP	Genentech
DMBJN19	DT	Antibody
DMBJN19	DE	Systemic lupus erythematosus

DMKQXDB	ID	DMKQXDB
DMKQXDB	DN	Rostafuroxin
DMKQXDB	HS	Phase 2
DMKQXDB	SN	PST-2238; Na+ K+ ATPase (oral, hypertension), Sigma-Tau
DMKQXDB	CP	Sigma-Tau Ind Farm Riunite SpA
DMKQXDB	DT	Small molecular drug
DMKQXDB	PC	153976
DMKQXDB	MW	374.5
DMKQXDB	FM	C23H34O4
DMKQXDB	IC	InChI=1S/C23H34O4/c1-20-8-5-17(24)13-15(20)3-4-19-18(20)6-9-21(2)22(25,10-11-23(19,21)26)16-7-12-27-14-16/h7,12,14-15,17-19,24-26H,3-6,8-11,13H2,1-2H3/t15-,17+,18+,19-,20+,21-,22+,23+/m1/s1
DMKQXDB	CS	C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@]4(C5=COC=C5)O)O)C)O
DMKQXDB	IK	AEAPORIZZWBIEX-DTBDINHYSA-N
DMKQXDB	IU	(3S,5R,8R,9S,10S,13S,14S,17S)-17-(furan-3-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol
DMKQXDB	CA	CAS 156722-18-8
DMKQXDB	DE	Hypertension

DMXB9RS	ID	DMXB9RS
DMXB9RS	DN	ROTIGAPTIDE
DMXB9RS	HS	Phase 2
DMXB9RS	SN	GAP-486; Rotigaptide < USAN; ZP-123; N-Acetyl-D-tyrosyl-D-prolyl-4(S)-hydroxy-D-prolyl-glycyl-D-alanyl-glycinamide
DMXB9RS	DT	Small molecular drug
DMXB9RS	PC	9938933
DMXB9RS	MW	617.7
DMXB9RS	FM	C28H39N7O9
DMXB9RS	IC	InChI=1S/C28H39N7O9/c1-15(25(41)30-12-23(29)39)32-24(40)13-31-26(42)22-11-19(38)14-35(22)28(44)21-4-3-9-34(21)27(43)20(33-16(2)36)10-17-5-7-18(37)8-6-17/h5-8,15,19-22,37-38H,3-4,9-14H2,1-2H3,(H2,29,39)(H,30,41)(H,31,42)(H,32,40)(H,33,36)/t15-,19+,20-,21-,22-/m1/s1
DMXB9RS	CS	C[C@H](C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H]1C[C@@H](CN1C(=O)[C@H]2CCCN2C(=O)[C@@H](CC3=CC=C(C=C3)O)NC(=O)C)O
DMXB9RS	IK	GFJRASPBQLDRRY-TWTQBQJDSA-N
DMXB9RS	IU	(2R,4S)-1-[(2R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]-N-[2-[[(2R)-1-[(2-amino-2-oxoethyl)amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]-4-hydroxypyrrolidine-2-carboxamide
DMXB9RS	CA	CAS 355151-12-1
DMXB9RS	DE	Cardiac arrhythmias

DMIZMYQ	ID	DMIZMYQ
DMIZMYQ	DN	Roxatidine
DMIZMYQ	HS	Phase 2
DMIZMYQ	SN	Desacetyl-tzu-0460; IV9VHT3YUM; ROXATIDINE; Roxatidine (INN); Roxatidine [INN:BAN]; 2-hydroxy-N-(3-(3-(piperidin-1-ylmethyl)phenoxy)propyl)acetamide; 2-hydroxy-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide; 2-hydroxy-n-{3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}acetamide; 78273-80-0; 97900-88-4; Acetamide, 2-hydroxy-N-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-; C17H26N2O3; N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]hydroxyacetamide; N-{3-[3-(1-Piperidinylmethyl)phenoxy]propyl}hydroxyacetamide; UNII-IV9VHT3YUM
DMIZMYQ	PC	91276
DMIZMYQ	MW	306.4
DMIZMYQ	FM	C17H26N2O3
DMIZMYQ	IC	BCCREUFCSIMJFS-UHFFFAOYSA-N
DMIZMYQ	CS	C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC(=O)CO
DMIZMYQ	IK	1S/C17H26N2O3/c20-14-17(21)18-8-5-11-22-16-7-4-6-15(12-16)13-19-9-2-1-3-10-19/h4,6-7,12,20H,1-3,5,8-11,13-14H2,(H,18,21)
DMIZMYQ	IU	2-hydroxy-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide
DMIZMYQ	CA	CAS 78273-80-0
DMIZMYQ	DE	Gastro-oesophageal reflux disease

DM15QL9	ID	DM15QL9
DM15QL9	DN	ROXINDOLE
DM15QL9	HS	Phase 2
DM15QL9	SN	Roxindole; 112192-04-8; UNII-43227SMS0O; 3-(4-(3,6-Dihydro-4-phenyl-1(2H)-pyridinyl)butyl)-1H-indol-5-ol; 3-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1H-indol-5-ol; CHEMBL431367; CHEBI:48558; 43227SMS0O; NCGC00025216-01; 3-[4-(4-phenyl-3,6-dihydropyridin-1(2H)-yl)butyl]-1H-indol-5-ol; DSSTox_RID_80082; DSSTox_CID_23895; DSSTox_GSID_43895; roxindol; roxindole[inn]; Roxindole [INN]; CAS-112192-04-8; roxindolum; Tocris-1559; AC1Q7AGH; GTPL52; AC1L55YV; SCHEMBL49673; DTXSID5043895; 119742-13-1 (mesylate); ZINC1548439
DM15QL9	DT	Small molecular drug
DM15QL9	PC	219050
DM15QL9	MW	346.5
DM15QL9	FM	C23H26N2O
DM15QL9	IC	InChI=1S/C23H26N2O/c26-21-9-10-23-22(16-21)20(17-24-23)8-4-5-13-25-14-11-19(12-15-25)18-6-2-1-3-7-18/h1-3,6-7,9-11,16-17,24,26H,4-5,8,12-15H2
DM15QL9	CS	C1CN(CC=C1C2=CC=CC=C2)CCCCC3=CNC4=C3C=C(C=C4)O
DM15QL9	IK	HGEYJZMMUGWEOT-UHFFFAOYSA-N
DM15QL9	IU	3-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1H-indol-5-ol
DM15QL9	CA	CAS 112192-04-8
DM15QL9	CB	CHEBI:48558
DM15QL9	DE	Psychotic disorder

DMK0NGB	ID	DMK0NGB
DMK0NGB	DN	Rozanolixizumab
DMK0NGB	HS	Phase 2
DMK0NGB	CP	UCB Smyrna, GA
DMK0NGB	DE	Myasthenia gravis

DM4N6PF	ID	DM4N6PF
DM4N6PF	DN	RP-49356
DM4N6PF	HS	Phase 2
DM4N6PF	SN	Aprikalim; Aprim; Aprikalim); RP-52891
DM4N6PF	CP	Rhone-Poulenc SA
DM4N6PF	DT	Small molecular drug
DM4N6PF	PC	3034038
DM4N6PF	MW	268.4
DM4N6PF	FM	C12H16N2OS2
DM4N6PF	IC	InChI=1S/C12H16N2OS2/c1-13-11(16)12(6-2-3-8-17(12)15)10-5-4-7-14-9-10/h4-5,7,9H,2-3,6,8H2,1H3,(H,13,16)/t12-,17?/m1/s1
DM4N6PF	CS	CNC(=S)[C@@]1(CCCCS1=O)C2=CN=CC=C2
DM4N6PF	IK	GKEMHVLBZNVZOI-MTATWXBHSA-N
DM4N6PF	IU	(2R)-N-methyl-1-oxo-2-pyridin-3-ylthiane-2-carbothioamide
DM4N6PF	CA	CAS 89544-10-5
DM4N6PF	DE	Hypertension

DMKUE8O	ID	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	HS	Phase 2
DMKUE8O	CP	Reviva Pharmaceuticals
DMKUE8O	DE	Schizophrenia; Alzheimer disease; Attention deficit hyperactivity disorder; Bipolar disorder; Major depressive disorder; Parkinson disease

DMYILGK	ID	DMYILGK
DMYILGK	DN	RP6530
DMYILGK	HS	Phase 2
DMYILGK	SN	tenalisib; HDXDQPRPFRKGKZ-INIZCTEOSA-N; Tenalisib; 1639417-53-0; UNII-2261HH611H; 2261HH611H; Tenalisib [INN]; GTPL9907; SCHEMBL16279460; AKOS027325582; RP-6530; RP 6530; CS-6375; HY-17645; 4H-1-Benzopyran-4-one, 3-(3-fluorophenyl)-2-((1S)-1-(9H-purin-6-ylamino)propyl)-; (S)-2-(1-((7H-purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one; 3-(3-fluorophenyl)-2-[(1S)-1-[(9H-purin-6-yl)amino]propyl]-4H-chromen-4-one; 3-(3-Fluorophenyl)-2-((1S)-1-((7H-purin-6-yl)amino)propyl)-4H-1-benzopyran-4-one; 1693773-94-2
DMYILGK	CP	Rhizen PharmaceuticalsLa Chaux-de-Fonds, Switzerland
DMYILGK	PC	86291103
DMYILGK	MW	415.4
DMYILGK	FM	C23H18FN5O2
DMYILGK	IC	InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)/t16-/m0/s1
DMYILGK	CS	CC[C@@H](C1=C(C(=O)C2=CC=CC=C2O1)C3=CC(=CC=C3)F)NC4=NC=NC5=C4NC=N5
DMYILGK	IK	HDXDQPRPFRKGKZ-INIZCTEOSA-N
DMYILGK	IU	3-(3-fluorophenyl)-2-[(1S)-1-(7H-purin-6-ylamino)propyl]chromen-4-one
DMYILGK	CA	CAS 1639417-53-0
DMYILGK	DE	Cutaneous T-cell lymphoma; Chronic lymphocytic leukaemia

DM4L5VJ	ID	DM4L5VJ
DM4L5VJ	DN	R-phenserine
DM4L5VJ	HS	Phase 2
DM4L5VJ	SN	Posiphen (TN)
DM4L5VJ	CP	QR Pharma
DM4L5VJ	PC	11249342
DM4L5VJ	MW	337.4
DM4L5VJ	FM	C20H23N3O2
DM4L5VJ	IC	InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m0/s1
DM4L5VJ	CS	C[C@]12CCN([C@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C
DM4L5VJ	IK	PBHFNBQPZCRWQP-AZUAARDMSA-N
DM4L5VJ	IU	[(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate
DM4L5VJ	CA	CAS 159652-53-6
DM4L5VJ	DE	Cognitive impairment; Alzheimer disease; Dementia

DMSJU5B	ID	DMSJU5B
DMSJU5B	DN	RP-L102
DMSJU5B	HS	Phase 2
DMSJU5B	CP	Rocket Pharmaceuticals
DMSJU5B	DT	Gene therapy
DMSJU5B	DE	Fanconi's anemia

DMLD4VQ	ID	DMLD4VQ
DMLD4VQ	DN	RPL-554
DMLD4VQ	HS	Phase 2
DMLD4VQ	SN	RPL-565; VMX-554; VMX-565; PDE 3/PDE 4 inhibitors, Kings College; PDE3/4 inhibitors (respiratory therapeutics), Rhinopharma; PDE3/4 inhibitors (nasal, respiratory disease), Verona Pharma; Trequinsin analogs (respiratory therapeutics), Kings College/Vernalis/Rhinopharma
DMLD4VQ	CP	King's College London
DMLD4VQ	DT	Small molecular drug
DMLD4VQ	PC	9934746
DMLD4VQ	MW	477.6
DMLD4VQ	FM	C26H31N5O4
DMLD4VQ	IC	InChI=1S/C26H31N5O4/c1-15-10-16(2)24(17(3)11-15)29-23-14-20-19-13-22(35-5)21(34-4)12-18(19)6-8-30(20)26(33)31(23)9-7-28-25(27)32/h10-14H,6-9H2,1-5H3,(H3,27,28,32)
DMLD4VQ	CS	CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2CCNC(=O)N)OC)OC)C
DMLD4VQ	IK	CSOBIBXVIYAXFM-UHFFFAOYSA-N
DMLD4VQ	IU	2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]ethylurea
DMLD4VQ	CA	CAS 298680-25-8
DMLD4VQ	DE	Allergic rhinitis

DM0BFJ5	ID	DM0BFJ5
DM0BFJ5	DN	RPSGL-Ig
DM0BFJ5	HS	Phase 2
DM0BFJ5	CP	Thios Pharmaceuticals
DM0BFJ5	DE	Delayed graft function

DMBHN4K	ID	DMBHN4K
DMBHN4K	DN	RQ-00000005
DMBHN4K	HS	Phase 2
DMBHN4K	SN	Capromorelin
DMBHN4K	CP	RaQualia Pharma
DMBHN4K	DT	Small molecular drug
DMBHN4K	PC	216208
DMBHN4K	MW	505.6
DMBHN4K	FM	C28H35N5O4
DMBHN4K	IC	InChI=1S/C28H35N5O4/c1-27(2,29)25(35)30-22(18-37-17-21-12-8-5-9-13-21)24(34)33-15-14-23-28(19-33,26(36)32(3)31-23)16-20-10-6-4-7-11-20/h4-13,22H,14-19,29H2,1-3H3,(H,30,35)/t22-,28-/m1/s1
DMBHN4K	CS	CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3=NN(C(=O)[C@@]3(C2)CC4=CC=CC=C4)C)N
DMBHN4K	IK	KVLLHLWBPNCVNR-SKCUWOTOSA-N
DMBHN4K	IU	N-[(2R)-1-[(3aR)-3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-oxo-3-phenylmethoxypropan-2-yl]-2-amino-2-methylpropanamide
DMBHN4K	CA	CAS 193273-66-4
DMBHN4K	DE	Frailty

DMMYTRU	ID	DMMYTRU
DMMYTRU	DN	RQ-00000007 (oral)
DMMYTRU	HS	Phase 2
DMMYTRU	SN	CJ-023423; RQ-00000007 (iv); MR-10-A-7
DMMYTRU	CP	Pfizer Inc; RaQualia Pharma Inc
DMMYTRU	DT	Small molecular drug
DMMYTRU	PC	11677589
DMMYTRU	MW	491.6
DMMYTRU	FM	C26H29N5O3S
DMMYTRU	IC	InChI=1S/C26H29N5O3S/c1-5-24-29-25-19(4)28-18(3)16-23(25)31(24)21-10-8-20(9-11-21)14-15-27-26(32)30-35(33,34)22-12-6-17(2)7-13-22/h6-13,16H,5,14-15H2,1-4H3,(H2,27,30,32)
DMMYTRU	CS	CCC1=NC2=C(N1C3=CC=C(C=C3)CCNC(=O)NS(=O)(=O)C4=CC=C(C=C4)C)C=C(N=C2C)C
DMMYTRU	IK	HZVLFTCYCLXTGV-UHFFFAOYSA-N
DMMYTRU	IU	1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea
DMMYTRU	CA	CAS 415903-37-6
DMMYTRU	DE	Pain

DMSH108	ID	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	HS	Phase 2
DMSH108	SN	Seliciclib; roscovitine; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; Roscovitine; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine
DMSH108	CP	Cyclacel
DMSH108	DT	Small molecular drug
DMSH108	PC	160355
DMSH108	MW	354.4
DMSH108	FM	C19H26N6O
DMSH108	IC	InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
DMSH108	CS	CC[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3
DMSH108	IK	BTIHMVBBUGXLCJ-OAHLLOKOSA-N
DMSH108	IU	(2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol
DMSH108	CA	CAS 186692-46-6
DMSH108	CB	CHEBI:45307
DMSH108	DE	Non-small-cell lung cancer; Solid tumour/cancer; Nasopharyngeal carcinoma

DMGLCVU	ID	DMGLCVU
DMGLCVU	DN	R-salbutamol sulphate
DMGLCVU	HS	Phase 2
DMGLCVU	SN	ASF-1096
DMGLCVU	CP	Astion Pharma A/S
DMGLCVU	DE	Skin infection

DMAJH75	ID	DMAJH75
DMAJH75	DN	RSV-604
DMAJH75	HS	Phase 2
DMAJH75	SN	A-60444; A-60445; RSV therapeutics, Arrow; RSV therapeutics, Novartis; Respiratory syncytial virus therapeutics, Novartis; Respiratory syncytial virus therapeutics, Arrow/Virogen; Antivirals (RSV), Arrow/ Virogen
DMAJH75	CP	Novavax
DMAJH75	DT	Small molecular drug
DMAJH75	PC	5279172
DMAJH75	MW	388.4
DMAJH75	FM	C22H17FN4O2
DMAJH75	IC	InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)/t20-/m1/s1
DMAJH75	CS	C1=CC=C(C=C1)C2=N[C@@H](C(=O)NC3=CC=CC=C32)NC(=O)NC4=CC=CC=C4F
DMAJH75	IK	MTPVBMVUENFFLL-HXUWFJFHSA-N
DMAJH75	IU	1-(2-fluorophenyl)-3-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea
DMAJH75	CA	CAS 676128-63-5
DMAJH75	DE	Virus infection

DM3FS1G	ID	DM3FS1G
DM3FS1G	DN	RT-001
DM3FS1G	HS	Phase 2
DM3FS1G	SN	RT-001, Revance therapeutics; BoNTA protein (topical gel, hyperhidrosis), Revance
DM3FS1G	CP	Revance Therapeutics Inc
DM3FS1G	DT	Small molecular drug
DM3FS1G	PC	124037379
DM3FS1G	MW	310.5
DM3FS1G	FM	C20H36O2
DM3FS1G	IC	InChI=1S/C20H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22-4-2/h8-9,11-12H,3-7,10,13-19H2,1-2H3/b9-8-,12-11-/i10D2
DM3FS1G	CS	[2H]C([2H])(/C=C\\CCCCC)/C=C\\CCCCCCCC(=O)OCC
DM3FS1G	IK	FMMOOAYVCKXGMF-XMCVDNGOSA-N
DM3FS1G	IU	ethyl (9Z,12Z)-11,11-dideuteriooctadeca-9,12-dienoate
DM3FS1G	CA	CAS 1404475-07-5
DM3FS1G	DE	Acne vulgaris; Friedreich's ataxia

DM8DVC9	ID	DM8DVC9
DM8DVC9	DN	RT-400
DM8DVC9	HS	Phase 2
DM8DVC9	SN	JNJ-39588146
DM8DVC9	CP	Renova Therapeutics
DM8DVC9	DT	Peptide
DM8DVC9	DE	Acute decompensated heart failure

DM45NHF	ID	DM45NHF
DM45NHF	DN	RTR-003632
DM45NHF	HS	Phase 2
DM45NHF	SN	Acetates; Acetic acid,phenyl ester; Phenyl acetate; Acetoxybenzene; Acetyl phenol; Acetylphenol; Fenylester kyseliny octove; IPBVNPXQWQGGJP-UHFFFAOYSA-N; PHENYL ACETATE; Phenol acetate; Phenyl acetate, 97%; Phenyl acetate, 99%; Phenyl ester of acetic acid; phenoxy ethan-1-one; (Acetyloxy)benzene; 122-79-2; 355G9R500Y; AI3-01972; Acetic acid phenyl ester; Acetic acid, phenyl ester; BRN 0636458; CHEBI:8082; EINECS 204-575-0; Fenylester kyseliny octove [Czech]; HSDB 2667; MFCD00008699; NSC 27795; PhOAc; UNII-355G9R500Y; acetic acid phenyl
DM45NHF	PC	31229
DM45NHF	MW	136.15
DM45NHF	FM	C8H8O2
DM45NHF	IC	IPBVNPXQWQGGJP-UHFFFAOYSA-N
DM45NHF	CS	CC(=O)OC1=CC=CC=C1
DM45NHF	IK	1S/C8H8O2/c1-7(9)10-8-5-3-2-4-6-8/h2-6H,1H3
DM45NHF	IU	phenyl acetate
DM45NHF	CA	CAS 122-79-2
DM45NHF	CB	CHEBI:8082
DM45NHF	DE	Brain cancer

DMVCXZK	ID	DMVCXZK
DMVCXZK	DN	Rupintrivir
DMVCXZK	HS	Phase 2
DMVCXZK	SN	AG-7088; AG-7185
DMVCXZK	CP	Pfizer
DMVCXZK	DT	Small molecular drug
DMVCXZK	PC	6440352
DMVCXZK	MW	598.7
DMVCXZK	FM	C31H39FN4O7
DMVCXZK	IC	InChI=1S/C31H39FN4O7/c1-5-42-27(38)11-10-24(16-21-12-13-33-29(21)39)34-30(40)22(15-20-6-8-23(32)9-7-20)17-26(37)28(18(2)3)35-31(41)25-14-19(4)43-36-25/h6-11,14,18,21-22,24,28H,5,12-13,15-17H2,1-4H3,(H,33,39)(H,34,40)(H,35,41)/b11-10+/t21-,22+,24+,28-/m0/s1
DMVCXZK	CS	CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC2=CC=C(C=C2)F)CC(=O)[C@H](C(C)C)NC(=O)C3=NOC(=C3)C
DMVCXZK	IK	CAYJBRBGZBCZKO-BHGBQCOSSA-N
DMVCXZK	IU	ethyl (E,4S)-4-[[(2R,5S)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-4-oxoheptanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
DMVCXZK	CA	CAS 223537-30-2
DMVCXZK	DE	Virus infection

DMSW5XJ	ID	DMSW5XJ
DMSW5XJ	DN	RV521
DMSW5XJ	HS	Phase 2
DMSW5XJ	SN	RV521 free base; UNII-KE63TTO7WK; KE63TTO7WK; RV-521; 1903763-82-5 (free base); 1'-((5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzo[d]imidazol-2-yl)methyl)-6'-fluorospiro[cyclopropane-1,3'-indolin]-2'-one; 1903763-82-5; Sisunatovir; CHEMBL4297497; SCHEMBL19470916; EX-A4653; RV 521; NCC1=CC2=C(N(C(=N2)CN2C(C3(C4=CC=C(C=C24)F)CC3)=O)CCCC(F)(F)F)C=C1; 1'-{[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzimidazol-2-yl]methyl}-6'-fluorospiro[cyclopropane-1,3'-indol]-2'(1'H)-one; Spiro(cyclopropane-1,3'-(3H)indol)-2'(1'H)-one, 1'-((5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzimidazol-2-yl)methyl)-6'-fluoro-; WVA
DMSW5XJ	CP	ReViral
DMSW5XJ	DT	Small molecular drug
DMSW5XJ	PC	132016492
DMSW5XJ	MW	446.4
DMSW5XJ	FM	C23H22F4N4O
DMSW5XJ	IC	InChI=1S/C23H22F4N4O/c24-15-3-4-16-19(11-15)31(21(32)22(16)7-8-22)13-20-29-17-10-14(12-28)2-5-18(17)30(20)9-1-6-23(25,26)27/h2-5,10-11H,1,6-9,12-13,28H2
DMSW5XJ	CS	C1CC12C3=C(C=C(C=C3)F)N(C2=O)CC4=NC5=C(N4CCCC(F)(F)F)C=CC(=C5)CN
DMSW5XJ	IK	JOPCJJSYRPUEDS-UHFFFAOYSA-N
DMSW5XJ	IU	1'-[[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)benzimidazol-2-yl]methyl]-6'-fluorospiro[cyclopropane-1,3'-indole]-2'-one
DMSW5XJ	CA	CAS 1903763-82-5
DMSW5XJ	DE	Respiratory syncytial virus infection

DM652CM	ID	DM652CM
DM652CM	DN	RV-568
DM652CM	HS	Phase 2
DM652CM	PC	45109868
DM652CM	MW	592.7
DM652CM	FM	C34H36N6O4
DM652CM	IC	InChI=1S/C34H36N6O4/c1-22-10-12-24(13-11-22)40-31(19-29(39-40)34(2,3)4)38-33(42)36-27-14-15-28(26-9-7-6-8-25(26)27)44-20-23-16-17-35-30(18-23)37-32(41)21-43-5/h6-19H,20-21H2,1-5H3,(H,35,37,41)(H2,36,38,42)
DM652CM	CS	CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCC5=CC(=NC=C5)NC(=O)COC
DM652CM	IK	RTDCVLCTBQDLBW-UHFFFAOYSA-N
DM652CM	IU	N-[4-[[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxymethyl]pyridin-2-yl]-2-methoxyacetamide
DM652CM	CA	CAS 1220626-82-3
DM652CM	DE	Asthma

DM3C9F8	ID	DM3C9F8
DM3C9F8	DN	RVT-505
DM3C9F8	HS	Phase 2
DM3C9F8	CP	Dermavant Sciences Phoenix, AZ
DM3C9F8	DE	Atopic dermatitis; Psoriasis vulgaris

DMTBAV3	ID	DMTBAV3
DMTBAV3	DN	RX-0201
DMTBAV3	HS	Phase 2
DMTBAV3	CP	Rexahn
DMTBAV3	TC	Anticancer Agents
DMTBAV3	DE	Solid tumour/cancer; Renal cell carcinoma; Pancreatic cancer

DME8ARP	ID	DME8ARP
DME8ARP	DN	RX-3117
DME8ARP	HS	Phase 2
DME8ARP	SN	Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva
DME8ARP	CP	Rexahn
DME8ARP	PC	11242315
DME8ARP	MW	257.22
DME8ARP	FM	C10H12FN3O4
DME8ARP	IC	InChI=1S/C10H12FN3O4/c11-6-4(3-15)8(16)9(17)7(6)14-2-1-5(12)13-10(14)18/h1-2,7-9,15-17H,3H2,(H2,12,13,18)/t7-,8-,9+/m1/s1
DME8ARP	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H](C(=C2F)CO)O)O
DME8ARP	IK	QLLGKCJUPWYJON-HLTSFMKQSA-N
DME8ARP	IU	4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one
DME8ARP	CA	CAS 865838-26-2
DME8ARP	CB	CHEBI:147412
DME8ARP	DE	Solid tumour/cancer; Bladder cancer; Pancreatic cancer

DMBOZPH	ID	DMBOZPH
DMBOZPH	DN	RX-5902
DMBOZPH	HS	Phase 2
DMBOZPH	SN	Microtubule-cell cycle inhibitor (oral, cancer), Rexahn; Piperazine G2/M-specific cell cycle and Bcl inhibitors (oral,cancer), Rexahn
DMBOZPH	CP	Rexahn
DMBOZPH	PC	11619093
DMBOZPH	MW	441.5
DMBOZPH	FM	C22H24FN5O4
DMBOZPH	IC	InChI=1S/C22H24FN5O4/c1-30-16-11-15(12-17(13-16)31-2)27-6-8-28(9-7-27)22(29)26-20-21(32-3)25-18-5-4-14(23)10-19(18)24-20/h4-5,10-13H,6-9H2,1-3H3,(H,24,26,29)
DMBOZPH	CS	COC1=CC(=CC(=C1)N2CCN(CC2)C(=O)NC3=NC4=C(C=CC(=C4)F)N=C3OC)OC
DMBOZPH	IK	KAKPGJJRYRYSTP-UHFFFAOYSA-N
DMBOZPH	IU	4-(3,5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide
DMBOZPH	CA	CAS 888478-45-3
DMBOZPH	DE	Solid tumour/cancer; Triple negative breast cancer

DMXG9ES	ID	DMXG9ES
DMXG9ES	DN	RXI-109
DMXG9ES	HS	Phase 2
DMXG9ES	SN	A45sd-RxNA
DMXG9ES	CP	Phio Pharmaceuticals
DMXG9ES	DT	Small interfering RNA
DMXG9ES	DE	Fibrosis; Hypertrophic scars

DM4KWEF	ID	DM4KWEF
DM4KWEF	DN	S-0509
DM4KWEF	HS	Phase 2
DM4KWEF	SN	3-[3-[N-(2-Benzoylphenyl)-N-(tert-butoxycarbonylmethyl)carbamoylmethyl]ureido]benzoic acid
DM4KWEF	PC	9893240
DM4KWEF	MW	531.6
DM4KWEF	FM	C29H29N3O7
DM4KWEF	IC	InChI=1S/C29H29N3O7/c1-29(2,3)39-25(34)18-32(23-15-8-7-14-22(23)26(35)19-10-5-4-6-11-19)24(33)17-30-28(38)31-21-13-9-12-20(16-21)27(36)37/h4-16H,17-18H2,1-3H3,(H,36,37)(H2,30,31,38)
DM4KWEF	CS	CC(C)(C)OC(=O)CN(C1=CC=CC=C1C(=O)C2=CC=CC=C2)C(=O)CNC(=O)NC3=CC=CC(=C3)C(=O)O
DM4KWEF	IK	LROWLFSPDIVWSD-UHFFFAOYSA-N
DM4KWEF	IU	3-[[2-(2-benzoyl-N-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]anilino)-2-oxoethyl]carbamoylamino]benzoic acid
DM4KWEF	DE	Ulcerative colitis

DM9KTSG	ID	DM9KTSG
DM9KTSG	DN	S-1360
DM9KTSG	HS	Phase 2
DM9KTSG	SN	GW-810781; 810781
DM9KTSG	CP	Shionogi & Co Ltd
DM9KTSG	DT	Small molecular drug
DM9KTSG	PC	6451047
DM9KTSG	MW	313.28
DM9KTSG	FM	C16H12FN3O3
DM9KTSG	IC	InChI=1S/C16H12FN3O3/c17-11-3-1-10(2-4-11)7-12-5-6-15(23-12)13(21)8-14(22)16-18-9-19-20-16/h1-6,8-9,22H,7H2,(H,18,19,20)/b14-8-
DM9KTSG	CS	C1=CC(=CC=C1CC2=CC=C(O2)C(=O)/C=C(/C3=NC=NN3)\\O)F
DM9KTSG	IK	HFHDGHOGHWXXDT-ZSOIEALJSA-N
DM9KTSG	IU	(Z)-1-[5-[(4-fluorophenyl)methyl]furan-2-yl]-3-hydroxy-3-(1H-1,2,4-triazol-5-yl)prop-2-en-1-one
DM9KTSG	CA	CAS 280571-30-4
DM9KTSG	DE	Human immunodeficiency virus infection

DMKTLSD	ID	DMKTLSD
DMKTLSD	DN	S-15535
DMKTLSD	HS	Phase 2
DMKTLSD	SN	4-(Benzodioxan-5-yl)-1-(indan-2-yl)piperazine; S15535; 146998-34-7; S 15535; 1-(2,3-Dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1h-inden-2-yl)-piperazine; 1-(2,3-dihydro-1H-inden-2-yl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperazine; Piperazine,1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)-; 1-(2,3-dihydro-1,4-benzodioxin-8-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine; PDSP1_000559; ACMC-20ehn1; [3H]S-15535; GTPL26; GTPL32; AC1L31KI; CHEMBL49247; SCHEMBL1650175; CTK4C5212; BDBM82564; ZINC16050;  1-(1,4-Benzodioxan-5-yl)-4-(indan-2-yl)piperazine
DMKTLSD	DT	Small molecular drug
DMKTLSD	PC	132787
DMKTLSD	MW	336.4
DMKTLSD	FM	C21H24N2O2
DMKTLSD	IC	InChI=1S/C21H24N2O2/c1-2-5-17-15-18(14-16(17)4-1)22-8-10-23(11-9-22)19-6-3-7-20-21(19)25-13-12-24-20/h1-7,18H,8-15H2
DMKTLSD	CS	C1CN(CCN1C2CC3=CC=CC=C3C2)C4=C5C(=CC=C4)OCCO5
DMKTLSD	IK	QJPPEMXOOWNICQ-UHFFFAOYSA-N
DMKTLSD	IU	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine
DMKTLSD	CA	CAS 146998-34-7
DMKTLSD	DE	Anxiety disorder

DML2D30	ID	DML2D30
DML2D30	DN	S-16924
DML2D30	HS	Phase 2
DML2D30	SN	S-16924; GTPL167; SCHEMBL8109895; s16924; S 16924
DML2D30	CP	Servier
DML2D30	DT	Small molecular drug
DML2D30	PC	9821498
DML2D30	MW	385.4
DML2D30	FM	C22H24FNO4
DML2D30	IC	InChI=1S/C22H24FNO4/c23-18-6-4-17(5-7-18)19(25)14-16-8-9-24(15-16)10-11-26-20-2-1-3-21-22(20)28-13-12-27-21/h1-7,16H,8-15H2
DML2D30	CS	C1CN(CC1CC(=O)C2=CC=C(C=C2)F)CCOC3=CC=CC4=C3OCCO4
DML2D30	IK	DXBFVLGYPFUTEZ-UHFFFAOYSA-N
DML2D30	IU	2-[1-[2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)ethyl]pyrrolidin-3-yl]-1-(4-fluorophenyl)ethanone
DML2D30	DE	Anxiety disorder

DMTAX8B	ID	DMTAX8B
DMTAX8B	DN	S-2150
DMTAX8B	HS	Phase 2
DMTAX8B	PC	234610
DMTAX8B	MW	98.11
DMTAX8B	FM	C3H6N4
DMTAX8B	IC	InChI=1S/C3H6N4/c1-2-5-3(4)7-6-2/h1H3,(H3,4,5,6,7)
DMTAX8B	CS	CC1=NC(=NN1)N
DMTAX8B	IK	FJRZOOICEHBAED-UHFFFAOYSA-N
DMTAX8B	IU	5-methyl-1H-1,2,4-triazol-3-amine
DMTAX8B	CA	CAS 4923-01-7
DMTAX8B	DE	Angina pectoris

DM26IH8	ID	DM26IH8
DM26IH8	DN	S-297995
DM26IH8	HS	Phase 2
DM26IH8	SN	NALDEMEDINE; UNII-03KSI6WLXH; 03KSI6WLXH; S-297,995; 916072-89-4; Naldemedine [USAN:INN]; Naldemedine (USAN/INN); S 297995; SCHEMBL9880572; GTPL9150; CHEMBL2105755; AKOS032945757; DB11691; Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14- trihydroxy-N-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-; J3.573.009E; D10188
DM26IH8	CP	Shionogi
DM26IH8	DT	Small molecular drug
DM26IH8	PC	54732242
DM26IH8	MW	570.6
DM26IH8	FM	C32H34N4O6
DM26IH8	IC	InChI=1S/C32H34N4O6/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39)/t22-,26+,31+,32-/m1/s1
DM26IH8	CS	CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O
DM26IH8	IK	AXQACEQYCPKDMV-RZAWKFBISA-N
DM26IH8	IU	(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide
DM26IH8	CA	CAS 916072-89-4
DM26IH8	DE	Opioid dependence

DMU7ZMH	ID	DMU7ZMH
DMU7ZMH	DN	S-364735
DMU7ZMH	HS	Phase 2
DMU7ZMH	SN	GSK-364735; HIV integrase inhibitors (2), Shionogi/GlaxoSmithKline
DMU7ZMH	CP	Shionogi
DMU7ZMH	DE	Human immunodeficiency virus infection

DMD8XOY	ID	DMD8XOY
DMD8XOY	DN	S-38093
DMD8XOY	HS	Phase 2
DMD8XOY	SN	S-41150; S-38471-1; S-750-1; Histamine H3 antagonists (sleep/cognitive disorders), Servier
DMD8XOY	CP	Servier
DMD8XOY	PC	11380684
DMD8XOY	MW	288.4
DMD8XOY	FM	C17H24N2O2
DMD8XOY	IC	InChI=1S/C17H24N2O2/c18-17(20)13-5-7-16(8-6-13)21-10-2-9-19-11-14-3-1-4-15(14)12-19/h5-8,14-15H,1-4,9-12H2,(H2,18,20)
DMD8XOY	CS	C1CC2CN(CC2C1)CCCOC3=CC=C(C=C3)C(=O)N
DMD8XOY	IK	MRNMYWNBLVJWKG-UHFFFAOYSA-N
DMD8XOY	IU	4-[3-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)propoxy]benzamide
DMD8XOY	DE	Alzheimer disease

DMXDVNZ	ID	DMXDVNZ
DMXDVNZ	DN	S-555739
DMXDVNZ	HS	Phase 2
DMXDVNZ	CP	Shionogi
DMXDVNZ	PC	59232326
DMXDVNZ	MW	501.6
DMXDVNZ	FM	C24H27N3O7S
DMXDVNZ	IC	InChI=1S/C24H27N3O7S/c1-17(2)34-19-4-6-20(7-5-19)35(30,31)27-12-10-26(11-13-27)18-3-8-21(24-25-9-14-32-24)22(15-18)33-16-23(28)29/h3-9,14-15,17H,10-13,16H2,1-2H3,(H,28,29)
DMXDVNZ	CS	CC(C)OC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=CC(=C(C=C3)C4=NC=CO4)OCC(=O)O
DMXDVNZ	IK	ZMZNWNTZRWXTJU-UHFFFAOYSA-N
DMXDVNZ	IU	2-[2-(1,3-oxazol-2-yl)-5-[4-(4-propan-2-yloxyphenyl)sulfonylpiperazin-1-yl]phenoxy]acetic acid
DMXDVNZ	CA	CAS 932372-01-5
DMXDVNZ	DE	Allergy

DM3GRKY	ID	DM3GRKY
DM3GRKY	DN	S-707106
DM3GRKY	HS	Phase 2
DM3GRKY	CP	Shionogi
DM3GRKY	DE	Type-2 diabetes

DMZGNOJ	ID	DMZGNOJ
DMZGNOJ	DN	S-777469
DMZGNOJ	HS	Phase 2
DMZGNOJ	CP	Shionogi USA Inc
DMZGNOJ	PC	57331749
DMZGNOJ	MW	414.5
DMZGNOJ	FM	C23H27FN2O4
DMZGNOJ	IC	InChI=1S/C23H27FN2O4/c1-3-19-15(2)13-18(20(27)25-23(22(29)30)11-5-4-6-12-23)21(28)26(19)14-16-7-9-17(24)10-8-16/h7-10,13H,3-6,11-12,14H2,1-2H3,(H,25,27)(H,29,30)
DMZGNOJ	CS	CCC1=C(C=C(C(=O)N1CC2=CC=C(C=C2)F)C(=O)NC3(CCCCC3)C(=O)O)C
DMZGNOJ	IK	JIYXOJFSPOFZPY-UHFFFAOYSA-N
DMZGNOJ	IU	1-[[6-ethyl-1-[(4-fluorophenyl)methyl]-5-methyl-2-oxopyridine-3-carbonyl]amino]cyclohexane-1-carboxylic acid
DMZGNOJ	CA	CAS 885496-53-7
DMZGNOJ	DE	Atopic dermatitis

DMRZA6G	ID	DMRZA6G
DMRZA6G	DN	S-8921
DMRZA6G	HS	Phase 2
DMRZA6G	SN	S-8921; 151165-96-7; S 8921; CHEMBL18380; Methyl-1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate; AC1L4BG3; SCHEMBL1650817; DTXSID70164724; BDBM50085476; Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-2-naphthalenecarboxylate; HY-19298; LS-193177; CS-0015040; methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylpentanoyl)-4-hydroxy-6,7,8-trimethoxynaphthalene-2-carboxylate; 2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7
DMRZA6G	CP	Shionogi & Co Ltd
DMRZA6G	DT	Small molecular drug
DMRZA6G	PC	153965
DMRZA6G	MW	540.6
DMRZA6G	FM	C30H36O9
DMRZA6G	IC	InChI=1S/C30H36O9/c1-9-16(10-2)13-19(31)25-26(30(33)39-8)23(17-11-12-20(34-3)21(14-17)35-4)24-18(27(25)32)15-22(36-5)28(37-6)29(24)38-7/h11-12,14-16,32H,9-10,13H2,1-8H3
DMRZA6G	CS	CCC(CC)CC(=O)C1=C(C2=CC(=C(C(=C2C(=C1C(=O)OC)C3=CC(=C(C=C3)OC)OC)OC)OC)OC)O
DMRZA6G	IK	QEJQEIIPZKQCNP-UHFFFAOYSA-N
DMRZA6G	IU	methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylpentanoyl)-4-hydroxy-6,7,8-trimethoxynaphthalene-2-carboxylate
DMRZA6G	CA	CAS 151165-96-7
DMRZA6G	DE	Hyperlipidaemia

DMBZO8N	ID	DMBZO8N
DMBZO8N	DN	Sabarubicin
DMBZO8N	HS	Phase 2
DMBZO8N	SN	BMS-195615; MEN-10755
DMBZO8N	CP	The Menarini Group
DMBZO8N	DT	Small molecular drug
DMBZO8N	PC	151897
DMBZO8N	MW	643.6
DMBZO8N	FM	C32H37NO13
DMBZO8N	IC	InChI=1S/C32H37NO13/c1-12-26(37)17(33)7-21(43-12)46-31-13(2)44-22(8-18(31)35)45-19-10-32(42,20(36)11-34)9-16-23(19)30(41)25-24(29(16)40)27(38)14-5-3-4-6-15(14)28(25)39/h3-6,12-13,17-19,21-22,26,31,34-35,37,40-42H,7-11,33H2,1-2H3/t12-,13-,17-,18-,19-,21-,22-,26+,31+,32-/m0/s1
DMBZO8N	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@@H](O[C@H](C[C@@H]2O)O[C@H]3C[C@@](CC4=C3C(=C5C(=C4O)C(=O)C6=CC=CC=C6C5=O)O)(C(=O)CO)O)C)N)O
DMBZO8N	IK	VQHRZZISQVWPLK-UIRGBLDSSA-N
DMBZO8N	IU	(7S,9S)-7-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione
DMBZO8N	CA	CAS 211100-13-9
DMBZO8N	DE	Solid tumour/cancer

DMKDP57	ID	DMKDP57
DMKDP57	DN	Safotibant
DMKDP57	HS	Phase 2
DMKDP57	SN	UNII-02HU8HWP7U; 02HU8HWP7U; 633698-99-4; CHEMBL1254771; LF22-0542; LF-22-0542; Safotibant [INN]; Lf 22-0542; SCHEMBL1723565; DTXSID20212769; BDBM50326708; N-((4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl)methyl)-2-(2-(((4-methoxy-2,6-dimethylphenyl)sulfonyl)methylamino)ethoxy)-N-methylacetamide; N-((4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl]methyl)-2-(2-((4-methoxy-2,6-dimethylbenzenesulfonyl)(methyl)amino]ethoxy)-N-methylacetamide; Acetamide, N-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)methyl)-2-(2-(((4-meth
DMKDP57	CP	Sanofi
DMKDP57	DT	Small molecular drug
DMKDP57	PC	11953367
DMKDP57	MW	502.6
DMKDP57	FM	C25H34N4O5S
DMKDP57	IC	InChI=1S/C25H34N4O5S/c1-18-14-22(33-5)15-19(2)24(18)35(31,32)29(4)12-13-34-17-23(30)28(3)16-20-6-8-21(9-7-20)25-26-10-11-27-25/h6-9,14-15H,10-13,16-17H2,1-5H3,(H,26,27)
DMKDP57	CS	CC1=CC(=CC(=C1S(=O)(=O)N(C)CCOCC(=O)N(C)CC2=CC=C(C=C2)C3=NCCN3)C)OC
DMKDP57	IK	AMTQCENHQIDBHQ-UHFFFAOYSA-N
DMKDP57	IU	N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide
DMKDP57	CA	CAS 633698-99-4
DMKDP57	DE	Diabetic macular edema

DMRFK0B	ID	DMRFK0B
DMRFK0B	DN	SAGE-217b
DMRFK0B	HS	Phase 2
DMRFK0B	CP	Sage Therapeutics
DMRFK0B	DE	Major depressive disorder

DM5NC39	ID	DM5NC39
DM5NC39	DN	SAGE-324
DM5NC39	HS	Phase 2
DM5NC39	CP	Sage Therapeutics
DM5NC39	DT	Small molecular drug
DM5NC39	DE	Parkinson disease; Essential tremor or related tremors

DM9RC7D	ID	DM9RC7D
DM9RC7D	DN	SAGE-718
DM9RC7D	HS	Phase 2
DM9RC7D	CP	Sage Therapeutics
DM9RC7D	DT	Small molecular drug
DM9RC7D	DE	Schizophrenia; Parkinson disease

DMRSU4X	ID	DMRSU4X
DMRSU4X	DN	Salirasib
DMRSU4X	HS	Phase 2
DMRSU4X	SN	162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-;  FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032
DMRSU4X	CP	Kadmon
DMRSU4X	DT	Small molecular drug
DMRSU4X	PC	5469318
DMRSU4X	MW	358.5
DMRSU4X	FM	C22H30O2S
DMRSU4X	IC	InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+
DMRSU4X	CS	CC(=CCC/C(=C/CC/C(=C/CSC1=CC=CC=C1C(=O)O)/C)/C)C
DMRSU4X	IK	WUILNKCFCLNXOK-CFBAGHHKSA-N
DMRSU4X	IU	2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid
DMRSU4X	CA	CAS 162520-00-5
DMRSU4X	DE	Pancreatic cancer; Non-small-cell lung cancer; Lung cancer

DMQVC3E	ID	DMQVC3E
DMQVC3E	DN	Salvianolic acid B
DMQVC3E	HS	Phase 2
DMQVC3E	SN	115939-25-8; 121521-90-2; Salvianolic-acid-B; Lithospermic acid B; MFCD07779133; (2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid; (R)-2-(((2R,3R)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid; Danshensuan B; Salcianolic acid B; C36H30O16; PubChem13035; CHEMBL3747259; ZINC49538629; AKOS015920258; AS-56980; S609; 939S258; (R)-2-((2R,3R)-4-((E)-3-((R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-enyl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyloxy)-3-(3,4-dihydroxyphenyl)propanoic acid; 1607436-77-0
DMQVC3E	DT	Small molecular drug
DMQVC3E	PC	11629084
DMQVC3E	MW	718.6
DMQVC3E	FM	C36H30O16
DMQVC3E	IC	InChI=1S/C36H30O16/c37-20-6-1-16(11-24(20)41)13-27(34(45)46)50-29(44)10-5-18-3-9-23(40)33-30(18)31(32(52-33)19-4-8-22(39)26(43)15-19)36(49)51-28(35(47)48)14-17-2-7-21(38)25(42)12-17/h1-12,15,27-28,31-32,37-43H,13-14H2,(H,45,46)(H,47,48)/b10-5+/t27-,28-,31-,32+/m1/s1
DMQVC3E	CS	C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3[C@H]([C@@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@H](CC5=CC(=C(C=C5)O)O)C(=O)O)O)O
DMQVC3E	IK	SNKFFCBZYFGCQN-PDVBOLEISA-N
DMQVC3E	IU	(2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid
DMQVC3E	DE	Vascular dementia

DM0298B	ID	DM0298B
DM0298B	DN	Salvicine
DM0298B	HS	Phase 2
DM0298B	SN	Salvicine; 240423-23-8; 8-(3,4-dihydroxy-4-methylpentyl)-3-isopropyl-7-methylnaphthalene-1,2-dione; CHEMBL90715; DTXSID50438718; MolPort-028-744-855; AKOS025401738; ( inverted exclamation markA)Salvicine; QC-1122
DM0298B	CP	Shanghai Institute of Materia Medica (SIMM)
DM0298B	DT	Small molecular drug
DM0298B	PC	10359290
DM0298B	MW	330.4
DM0298B	FM	C20H26O4
DM0298B	IC	InChI=1S/C20H26O4/c1-11(2)15-10-13-7-6-12(3)14(17(13)19(23)18(15)22)8-9-16(21)20(4,5)24/h6-7,10-11,16,21,24H,8-9H2,1-5H3
DM0298B	CS	CC1=C(C2=C(C=C1)C=C(C(=O)C2=O)C(C)C)CCC(C(C)(C)O)O
DM0298B	IK	NZIUPDOWWMGNCV-UHFFFAOYSA-N
DM0298B	IU	8-(3,4-dihydroxy-4-methylpentyl)-7-methyl-3-propan-2-ylnaphthalene-1,2-dione
DM0298B	CA	CAS 240423-23-8
DM0298B	DE	Solid tumour/cancer

DMHVJZ6	ID	DMHVJZ6
DMHVJZ6	DN	SAM-531
DMHVJZ6	HS	Phase 2
DMHVJZ6	SN	PF-05212365; PF-5212365; WAY-262531; 5-HT6 receptor antagonist (Alzheimer's disease, schizophrenia), Pfizer
DMHVJZ6	CP	Wyeth
DMHVJZ6	DT	Small molecular drug
DMHVJZ6	PC	16071605
DMHVJZ6	MW	409.5
DMHVJZ6	FM	C22H23N3O3S
DMHVJZ6	IC	InChI=1S/C22H23N3O3S/c1-25(2)13-6-14-28-17-11-12-20-19(15-17)22(24-23-20)29(26,27)21-10-5-8-16-7-3-4-9-18(16)21/h3-5,7-12,15H,6,13-14H2,1-2H3,(H,23,24)
DMHVJZ6	CS	CN(C)CCCOC1=CC2=C(NN=C2C=C1)S(=O)(=O)C3=CC=CC4=CC=CC=C43
DMHVJZ6	IK	NXQGEDVQXVTCDA-UHFFFAOYSA-N
DMHVJZ6	IU	N,N-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]propan-1-amine
DMHVJZ6	CA	CAS 925448-93-7
DMHVJZ6	DE	Alzheimer disease

DMXTOVE	ID	DMXTOVE
DMXTOVE	DN	Sampatrilat
DMXTOVE	HS	Phase 2
DMXTOVE	SN	AC1L2YMI; SCHEMBL49065; C26H40N4O9S; UK 81252; LS-172743; (3R)-3-[[(2S)-6-amino-2-(methanesulfonamido)hexanoyl]amino]-4-[1-[[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]cyclopentyl]butanoic acid
DMXTOVE	DT	Small molecular drug
DMXTOVE	PC	6324648
DMXTOVE	MW	584.7
DMXTOVE	FM	C26H40N4O9S
DMXTOVE	IC	InChI=1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)22(32)28-16-18(23(33)34)15-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,32)(H,29,37)(H,33,34)(H,35,36)/t18-,20-,21-/m0/s1
DMXTOVE	CS	CS(=O)(=O)N[C@@H](CCCCN)C(=O)NC[C@H](CC1(CCCC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)C(=O)O
DMXTOVE	IK	LPUDGHQMOAHMMF-JBACZVJFSA-N
DMXTOVE	IU	(2S)-2-[[[(2S)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid
DMXTOVE	CA	CAS 129981-36-8
DMXTOVE	DE	Hypotension

DMP5Z9N	ID	DMP5Z9N
DMP5Z9N	DN	SAN-300
DMP5Z9N	HS	Phase 2
DMP5Z9N	CP	Santarus
DMP5Z9N	DE	Rheumatoid arthritis

DMDMQW0	ID	DMDMQW0
DMDMQW0	DN	SAR-100842
DMDMQW0	HS	Phase 2
DMDMQW0	SN	LPA1/LPA3 antagonist (renal fibrosis), sanofi-aventis
DMDMQW0	CP	Sanofi us
DMDMQW0	PC	44481866
DMDMQW0	MW	445.5
DMDMQW0	FM	C27H27NO5
DMDMQW0	IC	InChI=1S/C27H27NO5/c1-18-6-5-7-19(14-18)12-13-33-24-15-20(10-11-23(24)32-2)25(29)28-27(26(30)31)16-21-8-3-4-9-22(21)17-27/h3-11,14-15H,12-13,16-17H2,1-2H3,(H,28,29)(H,30,31)
DMDMQW0	CS	CC1=CC(=CC=C1)CCOC2=C(C=CC(=C2)C(=O)NC3(CC4=CC=CC=C4C3)C(=O)O)OC
DMDMQW0	IK	SOJDTNUCCXWTMG-UHFFFAOYSA-N
DMDMQW0	IU	2-[[4-methoxy-3-[2-(3-methylphenyl)ethoxy]benzoyl]amino]-1,3-dihydroindene-2-carboxylic acid
DMDMQW0	CA	CAS 1195941-38-8
DMDMQW0	DE	Fibrosis; Systemic sclerosis

DMCLEXM	ID	DMCLEXM
DMCLEXM	DN	SAR-110894
DMCLEXM	HS	Phase 2
DMCLEXM	SN	SAR-110894D
DMCLEXM	CP	Sanofi
DMCLEXM	DE	Alzheimer disease

DMMCA9V	ID	DMMCA9V
DMMCA9V	DN	SAR-113945
DMMCA9V	HS	Phase 2
DMMCA9V	SN	S-0100229; S-0100658
DMMCA9V	CP	Sanofi
DMMCA9V	DE	Osteoarthritis

DMJ34G6	ID	DMJ34G6
DMJ34G6	DN	SAR-125844
DMJ34G6	HS	Phase 2
DMJ34G6	SN	Met inhibitor (iv, cancer), sanofi-aventis
DMJ34G6	CP	Sanofi
DMJ34G6	PC	25182860
DMJ34G6	MW	550.6
DMJ34G6	FM	C25H23FN8O2S2
DMJ34G6	IC	InChI=1S/C25H23FN8O2S2/c26-17-3-1-16(2-4-17)19-7-8-22-30-31-25(34(22)32-19)37-18-5-6-20-21(15-18)38-24(28-20)29-23(35)27-9-10-33-11-13-36-14-12-33/h1-8,15H,9-14H2,(H2,27,28,29,35)
DMJ34G6	CS	C1COCCN1CCNC(=O)NC2=NC3=C(S2)C=C(C=C3)SC4=NN=C5N4N=C(C=C5)C6=CC=C(C=C6)F
DMJ34G6	IK	ODIUNTQOXRXOIV-UHFFFAOYSA-N
DMJ34G6	IU	1-[6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea
DMJ34G6	CA	CAS 1116743-46-4
DMJ34G6	DE	Solid tumour/cancer

DMUICJD	ID	DMUICJD
DMUICJD	DN	SAR-156597
DMUICJD	HS	Phase 2
DMUICJD	SN	IL-4/IL-13-targeting bispecific mAb (idiopathic pulmonary fibrosis), sanofi-aventis
DMUICJD	CP	Sanofi
DMUICJD	DT	Antibody
DMUICJD	DE	Pulmonary fibrosis; Idiopathic pulmonary fibrosis; Systemic sclerosis

DMQM7IL	ID	DMQM7IL
DMQM7IL	DN	SAR245409
DMQM7IL	HS	Phase 2
DMQM7IL	CP	Sanofi; Exelixis
DMQM7IL	DT	Small molecular drug
DMQM7IL	PC	16123056
DMQM7IL	MW	270.29
DMQM7IL	FM	C13H14N6O
DMQM7IL	IC	InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)
DMQM7IL	CS	CCN1C2=NC(=NC(=C2C=C(C1=O)C3=CC=NN3)C)N
DMQM7IL	IK	RGHYDLZMTYDBDT-UHFFFAOYSA-N
DMQM7IL	IU	2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one
DMQM7IL	CA	CAS 934493-76-2
DMQM7IL	CB	CHEBI:124914
DMQM7IL	DE	Solid tumour/cancer

DMBJU2G	ID	DMBJU2G
DMBJU2G	DN	SAR-260093
DMBJU2G	HS	Phase 2
DMBJU2G	CP	Pharmaceuticals
DMBJU2G	PC	25025505
DMBJU2G	MW	448.5
DMBJU2G	FM	C22H24N8OS
DMBJU2G	IC	InChI=1S/C22H24N8OS/c1-2-16-11-23-22(24-12-16)29-9-7-17(8-10-29)21-26-18(14-32-21)13-31-20-5-3-19(4-6-20)30-15-25-27-28-30/h3-6,11-12,14-15,17H,2,7-10,13H2,1H3
DMBJU2G	CS	CCC1=CN=C(N=C1)N2CCC(CC2)C3=NC(=CS3)COC4=CC=C(C=C4)N5C=NN=N5
DMBJU2G	IK	NFTMKHWBOINJGM-UHFFFAOYSA-N
DMBJU2G	IU	2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]-4-[[4-(tetrazol-1-yl)phenoxy]methyl]-1,3-thiazole
DMBJU2G	CA	CAS 1037792-44-1
DMBJU2G	DE	Type-2 diabetes

DMEGNHZ	ID	DMEGNHZ
DMEGNHZ	DN	SAR279356
DMEGNHZ	HS	Phase 2
DMEGNHZ	SN	F598
DMEGNHZ	CP	Sanofi
DMEGNHZ	DE	Serious infection

DM63QY0	ID	DM63QY0
DM63QY0	DN	SAR292833
DM63QY0	HS	Phase 2
DM63QY0	CP	Sanofi-aventis; Glenmark Pharmaceuticals
DM63QY0	DE	Insulin-dependent diabetes; Pain

DMJ9RN8	ID	DMJ9RN8
DMJ9RN8	DN	SAR-339658
DMJ9RN8	HS	Phase 2
DMJ9RN8	SN	CHR-1103; GBR-500; TMC-2003; Integrin antibody (inflammation), Chromos; Integrin antibody (inflammation), Targeted Molecules Corp; Integrin antibody (multiple sclerosis), Chromos; Integrin antibody (multiple sclerosis), Glenmark; CD49b antagonist (inflammation/multiple sclerosis), Glenmark
DMJ9RN8	CP	Targeted Molecules Corp
DMJ9RN8	DT	Antibody
DMJ9RN8	DE	Inflammatory bowel disease

DMOSCBF	ID	DMOSCBF
DMOSCBF	DN	SAR-3419
DMOSCBF	HS	Phase 2
DMOSCBF	SN	HuB4-DM4; DM4-conjugated anti-CD19 monoclonal (cancer), sanofi-aventis/ImmunoGen
DMOSCBF	CP	ImmunoGen Inc
DMOSCBF	DT	Antibody
DMOSCBF	DE	Non-hodgkin lymphoma

DMS1YPZ	ID	DMS1YPZ
DMS1YPZ	DN	SAR391786
DMS1YPZ	HS	Phase 2
DMS1YPZ	CP	Sanofi
DMS1YPZ	DT	Antibody
DMS1YPZ	DE	Muscle atrophy

DMF95KD	ID	DMF95KD
DMF95KD	DN	SAR-407899
DMF95KD	HS	Phase 2
DMF95KD	SN	ROCK inhibitors, sanofi-aventis; Rho kinase inhibitors, sanofi-aventis
DMF95KD	CP	Sanofi
DMF95KD	PC	15604510
DMF95KD	MW	244.29
DMF95KD	FM	C14H16N2O2
DMF95KD	IC	InChI=1S/C14H16N2O2/c17-14-13-2-1-12(9-10(13)3-8-16-14)18-11-4-6-15-7-5-11/h1-3,8-9,11,15H,4-7H2,(H,16,17)
DMF95KD	CS	C1CNCCC1OC2=CC3=C(C=C2)C(=O)NC=C3
DMF95KD	IK	IPEXHQGMTHOKQV-UHFFFAOYSA-N
DMF95KD	IU	6-piperidin-4-yloxy-2H-isoquinolin-1-one
DMF95KD	CA	CAS 923359-38-0
DMF95KD	DE	Diabetic nephropathy; Microvascular angina

DM6Q295	ID	DM6Q295
DM6Q295	DN	SAR566658
DM6Q295	HS	Phase 2
DM6Q295	CP	Sanofi
DM6Q295	DT	Antibody
DM6Q295	DE	Solid tumour/cancer

DMT4FI5	ID	DMT4FI5
DMT4FI5	DN	SAR-566658
DMT4FI5	HS	Phase 2
DMT4FI5	SN	CA6-targeted DM4 immunotoxin (cancer), sanofi-aventis; DM4-conjugated DS6 MAb (cancer), sanofi-aventis; DM4-conjugated anti-Muc1 monoclonal antibody (cancer), sanofi-aventis
DMT4FI5	CP	ImmunoGen Inc
DMT4FI5	DT	Antibody
DMT4FI5	DE	Solid tumour/cancer; Triple negative breast cancer

DMG9MN2	ID	DMG9MN2
DMG9MN2	DN	SAR97276
DMG9MN2	HS	Phase 2
DMG9MN2	SN	Albitiazolium bromide; UNII-3AC0AJ4ILP; 3AC0AJ4ILP; 321915-72-4; SAR 97276; Albitiazolium bromide [INN]; SCHEMBL2017697; CHEMBL520613; DTXSID60185968; 3,3'-(Dodecan-1,12-diyl)bis(5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium) dibromide; AN-28886; 2-[3-[12-[5-(2-hydroxyethyl)-4-methyl-thiazol-3-ium-3-yl]dodecyl]-4-methyl-thiazol-3-ium-5-yl]ethanol dibromide
DMG9MN2	CP	Sanofi
DMG9MN2	DT	Small molecular drug
DMG9MN2	PC	11377023
DMG9MN2	MW	454.7
DMG9MN2	FM	C24H42N2O2S2+2
DMG9MN2	IC	InChI=1S/C24H42N2O2S2/c1-21-23(13-17-27)29-19-25(21)15-11-9-7-5-3-4-6-8-10-12-16-26-20-30-24(14-18-28)22(26)2/h19-20,27-28H,3-18H2,1-2H3/q+2
DMG9MN2	CS	CC1=C(SC=[N+]1CCCCCCCCCCCC[N+]2=CSC(=C2C)CCO)CCO
DMG9MN2	IK	UZPXHZIQHWKNPF-UHFFFAOYSA-N
DMG9MN2	IU	2-[3-[12-[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]dodecyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol
DMG9MN2	CA	CAS 753439-46-2
DMG9MN2	DE	Malaria

DMBLHGP	ID	DMBLHGP
DMBLHGP	DN	Saracatinib
DMBLHGP	HS	Phase 2
DMBLHGP	SN	H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
DMBLHGP	CP	AstraZeneca
DMBLHGP	TC	Anticancer Agents
DMBLHGP	DT	Small molecular drug
DMBLHGP	PC	10302451
DMBLHGP	MW	542
DMBLHGP	FM	C27H32ClN5O5
DMBLHGP	IC	InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)
DMBLHGP	CS	CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl
DMBLHGP	IK	OUKYUETWWIPKQR-UHFFFAOYSA-N
DMBLHGP	IU	N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine
DMBLHGP	CA	CAS 379231-04-6
DMBLHGP	DE	Solid tumour/cancer; Hematologic tumour; Osteosarcoma

DMUE0AK	ID	DMUE0AK
DMUE0AK	DN	Saratin
DMUE0AK	HS	Phase 2
DMUE0AK	CP	BioVascular
DMUE0AK	DE	Inflammation

DM5R89X	ID	DM5R89X
DM5R89X	DN	SARIPIDEM
DM5R89X	HS	Phase 2
DM5R89X	SN	SL-85.0274; Saripidem; N-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-ylmethyl]-N-methylbutanamide
DM5R89X	DT	Small molecular drug
DM5R89X	PC	3058746
DM5R89X	MW	341.8
DM5R89X	FM	C19H20ClN3O
DM5R89X	IC	InChI=1S/C19H20ClN3O/c1-3-6-18(24)22(2)13-16-19(14-8-10-15(20)11-9-14)21-17-7-4-5-12-23(16)17/h4-5,7-12H,3,6,13H2,1-2H3
DM5R89X	CS	CCCC(=O)N(C)CC1=C(N=C2N1C=CC=C2)C3=CC=C(C=C3)Cl
DM5R89X	IK	LIFDPEORUVTOCP-UHFFFAOYSA-N
DM5R89X	IU	N-[[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-N-methylbutanamide
DM5R89X	CA	CAS 103844-86-6
DM5R89X	DE	Anxiety disorder

DM1M0PR	ID	DM1M0PR
DM1M0PR	DN	Saruplase
DM1M0PR	HS	Phase 2
DM1M0PR	SN	Rescupase; CG-4509; PUK, Grunenthal; Pro-urokinase, Grunenthal; Rscu-PA, Grunenthal
DM1M0PR	CP	Grunenthal GmbH
DM1M0PR	DE	Thrombosis

DM27KFY	ID	DM27KFY
DM27KFY	DN	SB-207266A
DM27KFY	HS	Phase 2
DM27KFY	SN	Piboserod hydrochloride; Piboserod HCl; Piboserod (hydrochloride); 178273-87-5; UNII-61Z0VMM0AJ; SB 207266A; 61Z0VMM0AJ; Piboserod hydrochloride [USAN]; SB-207266-A; Piboserod hydrochloride (USAN); N-[(1-Butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide monohydrochloride; SB 207266 hydrochloride; SB-207266A; AC1L42ON; MLS006010278; SCHEMBL2228911; CHEMBL2106927; DTXSID40170453; UABVCZHWRUGYSR-UHFFFAOYSA-N; MolPort-042-665-633; HY-15574A; AKOS030526663; API0004730; SMR004701348; FT-0724495; D05471
DM27KFY	DT	Small molecular drug
DM27KFY	PC	177335
DM27KFY	MW	406
DM27KFY	FM	C22H32ClN3O2
DM27KFY	IC	InChI=1S/C22H31N3O2.ClH/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25;/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26);1H
DM27KFY	CS	CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42.Cl
DM27KFY	IK	UABVCZHWRUGYSR-UHFFFAOYSA-N
DM27KFY	IU	N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide;hydrochloride
DM27KFY	CA	CAS 178273-87-5
DM27KFY	DE	Irritable bowel syndrome

DM8TKG5	ID	DM8TKG5
DM8TKG5	DN	SB-265610
DM8TKG5	HS	Phase 2
DM8TKG5	SN	SB 265610; 211096-49-0; CHEMBL38182; UNII-9P785F0579; N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA; 9P785F0579; 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea; sb265610; SCHEMBL1535925; CTK8E9340; DTXSID10175339; MolPort-019-939-274; MolPort-044-561-465; ZINC603064; BCP28242; BDBM50102222; AKOS024457259; NCGC00242491-01; NCGC00242491-02; KB-80496; RT-015648; SB265610, &gt; J-013849; 1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea; Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be
DM8TKG5	CP	GlaxoSmithKline
DM8TKG5	DT	Small molecular drug
DM8TKG5	PC	9841667
DM8TKG5	MW	357.16
DM8TKG5	FM	C14H9BrN6O
DM8TKG5	IC	InChI=1S/C14H9BrN6O/c15-9-3-1-2-4-10(9)17-14(22)18-11-6-5-8(7-16)12-13(11)20-21-19-12/h1-6H,(H2,17,18,22)(H,19,20,21)
DM8TKG5	CS	C1=CC=C(C(=C1)NC(=O)NC2=CC=C(C3=NNN=C23)C#N)Br
DM8TKG5	IK	SEDUMQWZEOMXSO-UHFFFAOYSA-N
DM8TKG5	IU	1-(2-bromophenyl)-3-(7-cyano-2H-benzotriazol-4-yl)urea
DM8TKG5	CA	CAS 211096-49-0
DM8TKG5	DE	Chronic obstructive pulmonary disease; Asthma

DM4NY58	ID	DM4NY58
DM4NY58	DN	SB-623
DM4NY58	HS	Phase 2
DM4NY58	SN	(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide
DM4NY58	CP	GlaxoSmithKline
DM4NY58	TC	Anticancer Agents
DM4NY58	DT	Small molecular drug
DM4NY58	PC	6918876
DM4NY58	MW	406.5
DM4NY58	FM	C24H30N4O2
DM4NY58	IC	InChI=1S/C24H30N4O2/c1-3-27(4-2)16-17-28-22-13-10-20(12-15-24(29)26-30)18-21(22)25-23(28)14-11-19-8-6-5-7-9-19/h5-10,12-13,15,18,30H,3-4,11,14,16-17H2,1-2H3,(H,26,29)/b15-12+
DM4NY58	CS	CCN(CC)CCN1C2=C(C=C(C=C2)/C=C/C(=O)NO)N=C1CCC3=CC=CC=C3
DM4NY58	IK	FFXUDLUXUIJFSS-NTCAYCPXSA-N
DM4NY58	IU	(E)-3-[1-[2-(diethylamino)ethyl]-2-(2-phenylethyl)benzimidazol-5-yl]-N-hydroxyprop-2-enamide
DM4NY58	DE	Cerebrovascular ischaemia; Ischemic stroke; Stroke; Traumatic brain injury

DMYLBOU	ID	DMYLBOU
DMYLBOU	DN	SB-649868
DMYLBOU	HS	Phase 2
DMYLBOU	SN	380899-24-1; UNII-1L1V1K2M4V; SB 649868; 1L1V1K2M4V; SB649868; GTPL4461; N-[[(2S)-1-[5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]piperidin-2-yl]methyl]-1-benzofuran-4-carboxamide; SCHEMBL8045969; CHEMBL1272307; DTXSID90191491; EX-A2570; BDBM50417257; AKOS027323765; CS-7584; SB19110; HY-10806; SB-649,868; N-((1-((5-(4-Fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide; 4-Benzofurancarboxamide, N-(((2S)-1-((5-(4-fluorophenyl)-2-m
DMYLBOU	CP	GlaxoSmithKline
DMYLBOU	DT	Small molecular drug
DMYLBOU	PC	25195495
DMYLBOU	MW	477.6
DMYLBOU	FM	C26H24FN3O3S
DMYLBOU	IC	InChI=1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)/t19-/m0/s1
DMYLBOU	CS	CC1=NC(=C(S1)C2=CC=C(C=C2)F)C(=O)N3CCCC[C@H]3CNC(=O)C4=C5C=COC5=CC=C4
DMYLBOU	IK	ZJXIUGNEAIHSBI-IBGZPJMESA-N
DMYLBOU	IU	N-[[(2S)-1-[5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]piperidin-2-yl]methyl]-1-benzofuran-4-carboxamide
DMYLBOU	CA	CAS 380899-24-1
DMYLBOU	DE	Insomnia

DMCY785	ID	DMCY785
DMCY785	DN	SB-656933
DMCY785	HS	Phase 2
DMCY785	SN	Elubrixin; UNII-MW2AIJ8USP; MW2AIJ8USP; SB-656933-AAF; SB-656933; 688763-64-6; CHEMBL2178579; Elubrixin [USAN:INN]; SB656933; elubirixin; Elubrixin (USAN); SCHEMBL1562280; GTPL8499; DTXSID60218962; BDBM50398333; DB12135; SB 656933; D10332
DMCY785	CP	GlaxoSmithKline
DMCY785	DT	Small molecular drug
DMCY785	PC	10479502
DMCY785	MW	463.3
DMCY785	FM	C17H17Cl2FN4O4S
DMCY785	IC	InChI=1S/C17H17Cl2FN4O4S/c18-10-4-5-13(23-17(26)22-12-3-1-2-11(20)14(12)19)15(25)16(10)29(27,28)24-8-6-21-7-9-24/h1-5,21,25H,6-9H2,(H2,22,23,26)
DMCY785	CS	C1CN(CCN1)S(=O)(=O)C2=C(C=CC(=C2O)NC(=O)NC3=C(C(=CC=C3)F)Cl)Cl
DMCY785	IK	YQYFEGTYCUQBEI-UHFFFAOYSA-N
DMCY785	IU	1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea
DMCY785	CA	CAS 688763-64-6
DMCY785	DE	Chronic obstructive pulmonary disease; Cystic fibrosis

DMRYHWI	ID	DMRYHWI
DMRYHWI	DN	SB-705498
DMRYHWI	HS	Phase 2
DMRYHWI	SN	SB-705498; 501951-42-4; SB705498; SB 705498; UNII-T74V9O0Y2W; (R)-1-(2-bromophenyl)-3-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)urea; T74V9O0Y2W; 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea; N-(2-Bromophenyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]urea; 1-(2-Bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)-2-pyridyl]pyrrolidin-3-yl]urea; JYILLRHXRVTRSH-GFCCVEGCSA-N; MLS006011113; SCHEMBL1350298; GTPL4311; CHEMBL207433; BMCL163287 Compound 15; BDBM20504
DMRYHWI	CP	GlaxoSmithKline
DMRYHWI	DT	Small molecular drug
DMRYHWI	PC	9910486
DMRYHWI	MW	429.2
DMRYHWI	FM	C17H16BrF3N4O
DMRYHWI	IC	InChI=1S/C17H16BrF3N4O/c18-13-3-1-2-4-14(13)24-16(26)23-12-7-8-25(10-12)15-6-5-11(9-22-15)17(19,20)21/h1-6,9,12H,7-8,10H2,(H2,23,24,26)/t12-/m1/s1
DMRYHWI	CS	C1CN(C[C@@H]1NC(=O)NC2=CC=CC=C2Br)C3=NC=C(C=C3)C(F)(F)F
DMRYHWI	IK	JYILLRHXRVTRSH-GFCCVEGCSA-N
DMRYHWI	IU	1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea
DMRYHWI	CA	CAS 501951-42-4
DMRYHWI	DE	Migraine; Rhinitis

DMRWE5D	ID	DMRWE5D
DMRWE5D	DN	SB-728-T
DMRWE5D	HS	Phase 2
DMRWE5D	CP	Sangamo BioSciences
DMRWE5D	DE	Human immunodeficiency virus infection

DM6XJ9S	ID	DM6XJ9S
DM6XJ9S	DN	SB-743921
DM6XJ9S	HS	Phase 2
DM6XJ9S	SN	N-[1-(3-benzyl-7-chloro-4-oxo-quinazolin-2-yl)propyl]-4-bromo-N-(3-dimethylaminopropyl)benzamide
DM6XJ9S	CP	GlaxoSmithKline
DM6XJ9S	TC	Anticancer Agents
DM6XJ9S	DT	Small molecular drug
DM6XJ9S	PC	49867937
DM6XJ9S	MW	553.5
DM6XJ9S	FM	C31H34Cl2N2O3
DM6XJ9S	IC	InChI=1S/C31H33ClN2O3.ClH/c1-20(2)28(34(17-7-16-33)31(36)23-12-10-21(3)11-13-23)30-26(18-22-8-5-4-6-9-22)29(35)25-15-14-24(32)19-27(25)37-30;/h4-6,8-15,19-20,28H,7,16-18,33H2,1-3H3;1H/t28-;/m1./s1
DM6XJ9S	CS	CC1=CC=C(C=C1)C(=O)N(CCCN)[C@@H](C2=C(C(=O)C3=C(O2)C=C(C=C3)Cl)CC4=CC=CC=C4)C(C)C.Cl
DM6XJ9S	IK	MLMZVWABFOLFGV-LNLSOMNWSA-N
DM6XJ9S	IU	N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxochromen-2-yl)-2-methylpropyl]-4-methylbenzamide;hydrochloride
DM6XJ9S	CA	CAS 940929-33-9
DM6XJ9S	DE	Solid tumour/cancer

DMJRK6D	ID	DMJRK6D
DMJRK6D	DN	SB-9200
DMJRK6D	HS	Phase 2
DMJRK6D	SN	SB 9200
DMJRK6D	CP	Spring bank pharmaceuticals
DMJRK6D	PC	24737742
DMJRK6D	MW	703.6
DMJRK6D	FM	C25H34N7O13PS
DMJRK6D	IC	InChI=1S/C25H34N7O13PS/c1-12(2)42-25(37)40-11-47-46(38,45-19-14(7-33)44-23(20(19)39-3)31-5-4-16(35)30-24(31)36)41-8-15-13(34)6-17(43-15)32-10-29-18-21(26)27-9-28-22(18)32/h4-5,9-10,12-15,17,19-20,23,33-34H,6-8,11H2,1-3H3,(H2,26,27,28)(H,30,35,36)/t13-,14+,15+,17+,19+,20+,23+,46?/m0/s1
DMJRK6D	CS	CC(C)OC(=O)OCSP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O[C@@H]4[C@H](O[C@H]([C@@H]4OC)N5C=CC(=O)NC5=O)CO
DMJRK6D	IK	CJCYTUJOSMYXLE-JDLSZIHUSA-N
DMJRK6D	IU	[[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxyphosphoryl]sulfanylmethyl propan-2-yl carbonate
DMJRK6D	CA	CAS 942123-43-5
DMJRK6D	DE	Hepatitis B virus infection

DMG1VXR	ID	DMG1VXR
DMG1VXR	DN	SBC-014
DMG1VXR	HS	Phase 2
DMG1VXR	SN	AVI-014; Glycosylated recombinant G-CSF (neutropenia), AviGenics; Glycosylated recombinant G-CSF (neutropenia), Synageva
DMG1VXR	CP	Synageva BioPharma Corp
DMG1VXR	DE	Neutropenia

DMSUQFJ	ID	DMSUQFJ
DMSUQFJ	DN	SBI-087
DMSUQFJ	HS	Phase 2
DMSUQFJ	SN	PF-05230895
DMSUQFJ	CP	Emergent BioSolutions; Pfizer
DMSUQFJ	DE	Rheumatoid arthritis; Multiple sclerosis

DMGH4Q0	ID	DMGH4Q0
DMGH4Q0	DN	SC-47085
DMGH4Q0	HS	Phase 2
DMGH4Q0	SN	Olsalazine; Azodisal; Dipentium; Mirtazanine; Olsalazina; Olsalazina [Spanish]; Olsalazine (INN); Olsalazine [INN:BAN]; Olsalazinum; Olsalazinum [Latin]; Salicylic acid, 5,5'-azodi-; ULS5I8J03O; mordant yellow 5; (E)-5,5'-(diazene-1,2-diyl)bis(2-hydroxybenzoic acid); 15722-48-2; 3,3'-Azobis(6-hydroxybenzoic acid); 3,3'-diazene-1,2-diylbis(6-hydroxybenzoic acid); 5,5'-Azobis(salicylic acid); 5,5'-azodisalicylic acid; Benzoic acid, 3,3'-azobis(6-hydroxy-; C.I. Mordant Yellow 5; C14H10N2O6; CHEBI:7770; Rasal; UNII-ULS5I8J03O
DMGH4Q0	PC	22419
DMGH4Q0	MW	302.24
DMGH4Q0	FM	C14H10N2O6
DMGH4Q0	IC	QQBDLJCYGRGAKP-UHFFFAOYSA-N
DMGH4Q0	CS	C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
DMGH4Q0	IK	1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)
DMGH4Q0	IU	5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid
DMGH4Q0	CA	CAS 15722-48-2
DMGH4Q0	CB	CHEBI:7770
DMGH4Q0	DE	Ankylosing spondylitis

DM180VX	ID	DM180VX
DM180VX	DN	SC-49483
DM180VX	HS	Phase 2
DM180VX	SN	Glycovir; 131262-82-3; UNII-QXJ91425UL; DRG-0193; NSC 670880; Perbutylated-N-butyl-1-deoxynojiromycin; SC 49483; QXJ91425UL; N-Butyl DNJ Prodrug; Butanoic acid, 1-butyl-2-((1-oxobutoxy)methyl)-3,4,5-piperidinetriyl ester, (2R-(2alpha,3beta,4alpha,5beta))-; SC-48334 Prodrug; NSC670880; SC49483; AC1L1TYK; 1,5-(Butylimino)-1-5-dideoxy-D-glucitol tetrabutanoate; AC1Q60AI; SCHEMBL5967912; DTXSID10156986; NSC-670880; DB13106; LS-46130; 1-Butyl-2R,4.alpha.,5.beta.-piperidinetriyl butanoate
DM180VX	CP	GD Searle & Co
DM180VX	DT	Small molecular drug
DM180VX	PC	60807
DM180VX	MW	499.6
DM180VX	FM	C26H45NO8
DM180VX	IC	InChI=1S/C26H45NO8/c1-6-11-16-27-17-20(33-22(29)13-8-3)26(35-24(31)15-10-5)25(34-23(30)14-9-4)19(27)18-32-21(28)12-7-2/h19-20,25-26H,6-18H2,1-5H3/t19-,20+,25-,26-/m1/s1
DM180VX	CS	CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1COC(=O)CCC)OC(=O)CCC)OC(=O)CCC)OC(=O)CCC
DM180VX	IK	MKGDNVHZSCXBKR-KYVQNOJUSA-N
DM180VX	IU	[(2R,3R,4R,5S)-3,4,5-tri(butanoyloxy)-1-butylpiperidin-2-yl]methyl butanoate
DM180VX	CA	CAS 131262-82-3
DM180VX	DE	Acquired immune deficiency syndrome

DM58HR7	ID	DM58HR7
DM58HR7	DN	SC-75416
DM58HR7	HS	Phase 2
DM58HR7	PC	9858913
DM58HR7	MW	334.72
DM58HR7	FM	C15H14ClF3O3
DM58HR7	IC	InChI=1S/C15H14ClF3O3/c1-14(2,3)9-6-11-7(5-10(9)16)4-8(13(20)21)12(22-11)15(17,18)19/h4-6,12H,1-3H3,(H,20,21)/t12-/m0/s1
DM58HR7	CS	CC(C)(C)C1=C(C=C2C=C([C@H](OC2=C1)C(F)(F)F)C(=O)O)Cl
DM58HR7	IK	QGCKNIAMHUUUDI-LBPRGKRZSA-N
DM58HR7	IU	(2S)-7-tert-butyl-6-chloro-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid
DM58HR7	CA	CAS 215122-74-0
DM58HR7	DE	Pain

DMMWCZS	ID	DMMWCZS
DMMWCZS	DN	SCH 420814
DMMWCZS	HS	Phase 2
DMMWCZS	SN	Preladenant; SCH-420814
DMMWCZS	CP	Schering-Plough
DMMWCZS	DT	Small molecular drug
DMMWCZS	PC	10117987
DMMWCZS	MW	503.6
DMMWCZS	FM	C25H29N9O3
DMMWCZS	IC	InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17H,8-13,15-16H2,1H3,(H2,26,29)
DMMWCZS	CS	COCCOC1=CC=C(C=C1)N2CCN(CC2)CCN3C4=C(C=N3)C5=NC(=NN5C(=N4)N)C6=CC=CO6
DMMWCZS	IK	DTYWJKSSUANMHD-UHFFFAOYSA-N
DMMWCZS	IU	4-(furan-2-yl)-10-[2-[4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl]ethyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
DMMWCZS	CA	CAS 377727-87-2
DMMWCZS	DE	Parkinson disease

DMPUAOE	ID	DMPUAOE
DMPUAOE	DN	SCH-527123
DMPUAOE	HS	Phase 2
DMPUAOE	SN	Navarixin; 473727-83-2; Sch527123; SCH 527123; (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide; MK-7123; CHEMBL216981; (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide; SCHEMBL184744; GTPL8497; KS-00001CQK; CTK8B8735; MolPort-023-331-228; BDBM50200880; MK7123; ANW-61143; ZINC100033051; AKOS016003539; CS-0609; NCGC00390675-01; HY-10198; AX8217127; TC-149888; W-5650; SCH 527123,CAS:473727-83-2; PF-00547659
DMPUAOE	CP	Pharmacopeia; Schering-Plough
DMPUAOE	DT	Small molecular drug
DMPUAOE	PC	9865554
DMPUAOE	MW	397.4
DMPUAOE	FM	C21H23N3O5
DMPUAOE	IC	InChI=1S/C21H23N3O5/c1-5-13(15-10-9-11(2)29-15)22-16-17(20(27)19(16)26)23-14-8-6-7-12(18(14)25)21(28)24(3)4/h6-10,13,22-23,25H,5H2,1-4H3/t13-/m1/s1
DMPUAOE	CS	CC[C@H](C1=CC=C(O1)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C
DMPUAOE	IK	RXIUEIPPLAFSDF-CYBMUJFWSA-N
DMPUAOE	IU	2-hydroxy-N,N-dimethyl-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide
DMPUAOE	DE	Inflammatory bowel disease; Ulcerative colitis; Chronic obstructive pulmonary disease; Solid tumour/cancer

DMBJY1Z	ID	DMBJY1Z
DMBJY1Z	DN	SCH-900271
DMBJY1Z	HS	Phase 2
DMBJY1Z	SN	SCH-900271; UNII-G2283XQ6VJ; SCH 900271; G2283XQ6VJ; 915210-50-3; CHEMBL2036958; GTPL8469; SCHEMBL12602910; DTXSID00238609; BDBM50384612; SCH900271; SB17408; DB12433; 2H-Pyrano(2,3-d)pyrimidine-2,4,7(1H,3h)-trione, 5-(3-(1-methylcyclopropyl)propyl)-; 5-(3-(1-Methylcyclopropyl)propyl)-1H-pyrano(2,3-d)pyrimidine-2,4,7(3H)-trione
DMBJY1Z	CP	Merck
DMBJY1Z	DT	Small molecular drug
DMBJY1Z	PC	56950369
DMBJY1Z	MW	276.29
DMBJY1Z	FM	C14H16N2O4
DMBJY1Z	IC	InChI=1S/C14H16N2O4/c1-14(5-6-14)4-2-3-8-7-9(17)20-12-10(8)11(18)15-13(19)16-12/h7H,2-6H2,1H3,(H2,15,16,18,19)
DMBJY1Z	CS	CC1(CC1)CCCC2=CC(=O)OC3=C2C(=O)NC(=O)N3
DMBJY1Z	IK	ARJKMWXLIHZLQZ-UHFFFAOYSA-N
DMBJY1Z	IU	5-[3-(1-methylcyclopropyl)propyl]-1H-pyrano[2,3-d]pyrimidine-2,4,7-trione
DMBJY1Z	CA	CAS 915210-50-3
DMBJY1Z	DE	Ischemic stroke

DM67EMK	ID	DM67EMK
DM67EMK	DN	SCH-900776
DM67EMK	HS	Phase 2
DM67EMK	SN	CHEMBL1643208; MK-8776; 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine; GTPL7943; SCHEMBL10380123; CHEBI:131165; HMS3656J19; BCP02883; BDBM50334854; AKOS026750519; MK 8776; NCGC00387868-02; DA-40779; 4CA-1150; BCP0726000317; J3.517.083I; 891494-63-6 pound not SCH900776 pound not SCH-900776; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[5,1-b]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3S)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine
DM67EMK	CP	Merck
DM67EMK	DT	Small molecular drug
DM67EMK	PC	46239015
DM67EMK	MW	376.25
DM67EMK	FM	C15H18BrN7
DM67EMK	IC	InChI=1S/C15H18BrN7/c1-22-8-10(6-19-22)11-7-20-23-14(17)12(16)13(21-15(11)23)9-3-2-4-18-5-9/h6-9,18H,2-5,17H2,1H3/t9-/m1/s1
DM67EMK	CS	CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)[C@@H]4CCCNC4
DM67EMK	IK	GMIZZEXBPRLVIV-SECBINFHSA-N
DM67EMK	IU	6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3R)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine
DM67EMK	CA	CAS 891494-63-6
DM67EMK	DE	Solid tumour/cancer

DMPBKUZ	ID	DMPBKUZ
DMPBKUZ	DN	SCH-900978
DMPBKUZ	HS	Phase 2
DMPBKUZ	SN	Neurokinin 1 receptor antagonist (emesis), OPKO Health
DMPBKUZ	CP	OPKO Health Inc
DMPBKUZ	PC	11671080
DMPBKUZ	MW	539.5
DMPBKUZ	FM	C25H23F6N5O2
DMPBKUZ	IC	InChI=1S/C25H23F6N5O2/c1-16(17-9-19(24(26,27)28)11-20(10-17)25(29,30)31)38-14-23(18-5-3-2-4-6-18)8-7-22(12-32,13-33-23)36-15-34-35-21(36)37/h2-6,9-11,15-16,33H,7-8,13-14H2,1H3,(H,35,37)/t16-,22-,23-/m1/s1
DMPBKUZ	CS	C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@](CN2)(C#N)N3C=NNC3=O)C4=CC=CC=C4
DMPBKUZ	IK	ACZWFJDLNLZWDP-ZGNKEGEESA-N
DMPBKUZ	IU	(3S,6S)-6-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-3-(5-oxo-1H-1,2,4-triazol-4-yl)-6-phenylpiperidine-3-carbonitrile
DMPBKUZ	CA	CAS 873947-10-5
DMPBKUZ	DE	Cough

DM1C9NQ	ID	DM1C9NQ
DM1C9NQ	DN	SCY-635
DM1C9NQ	HS	Phase 2
DM1C9NQ	SN	SCY-635; CHEMBL1269597; UNII-WSU5343074; WSU5343074; SCY 635; CID6479267; AC1O57KA; 210759-10-7; BDBM50136473; DB12451; (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-(2-dimethylaminoethylsulfanyl)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DM1C9NQ	CP	SCYNEXIS
DM1C9NQ	DT	Small molecular drug
DM1C9NQ	PC	6479267
DM1C9NQ	MW	1321.8
DM1C9NQ	FM	C66H120N12O13S
DM1C9NQ	IC	InChI=1S/C66H120N12O13S/c1-27-29-30-42(13)53(79)52-57(83)69-45(28-2)59(85)78(26)65(92-32-31-71(18)19)64(90)75(23)49(36-66(16,17)91)56(82)70-50(40(9)10)62(88)72(20)46(33-37(3)4)55(81)67-43(14)54(80)68-44(15)58(84)73(21)47(34-38(5)6)60(86)74(22)48(35-39(7)8)61(87)76(24)51(41(11)12)63(89)77(52)25/h27,29,37-53,65,79,91H,28,30-36H2,1-26H3,(H,67,81)(H,68,80)(H,69,83)(H,70,82)/b29-27+/t42-,43+,44-,45+,46+,47+,48+,49+,50+,51+,52+,53-,65-/m1/s1
DM1C9NQ	CS	CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)(C)O)C)SCCN(C)C)C
DM1C9NQ	IK	AQHMBDAHQGYLIU-XNFHFXFQSA-N
DM1C9NQ	IU	(3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DM1C9NQ	CA	CAS 210759-10-7
DM1C9NQ	DE	Hepatitis C virus infection

DM80HOV	ID	DM80HOV
DM80HOV	DN	SDF-1
DM80HOV	HS	Phase 2
DM80HOV	SN	JVS-100
DM80HOV	CP	Juventas Therapeutics
DM80HOV	DE	Heart failure; Peripheral arterial disease

DMPZ67G	ID	DMPZ67G
DMPZ67G	DN	SDZ-281-240
DMPZ67G	HS	Phase 2
DMPZ67G	SN	[1R,9S,12S(1'R,3'S),13R,14S,17R,21S,23S,24R,25S,27R]-17-Ethyl-1,14-dihydroxy-12-[2-[3-(hydroxymethyl)cyclopentyl]-1(E)-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22
DMPZ67G	DE	Pruritus

DM2YIOE	ID	DM2YIOE
DM2YIOE	DN	SDZ-MAR-327
DM2YIOE	HS	Phase 2
DM2YIOE	CP	Novartis
DM2YIOE	DT	Small molecular drug
DM2YIOE	PC	56603721
DM2YIOE	MW	367.5
DM2YIOE	FM	C23H33N3O
DM2YIOE	IC	InChI=1S/C23H33N3O/c1-6-23(4,7-2)22(27)25-15-11-18-16-9-8-10-19-21(16)17(14(3)24-19)12-20(18)26(5)13-15/h8-10,15,18,20,24H,6-7,11-13H2,1-5H3,(H,25,27)/t15-,18?,20+/m0/s1
DM2YIOE	CS	CCC(C)(CC)C(=O)N[C@H]1CC2[C@@H](CC3=C(NC4=CC=CC2=C34)C)N(C1)C
DM2YIOE	IK	UXRWQKITDPCICD-BEHPGTHXSA-N
DM2YIOE	IU	N-[(6aR,9S)-5,7-dimethyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-2-ethyl-2-methylbutanamide
DM2YIOE	DE	Psychotic disorder; Schizophrenia

DMTQ2K0	ID	DMTQ2K0
DMTQ2K0	DN	SelG1
DMTQ2K0	HS	Phase 2
DMTQ2K0	CP	Selexys Pharmaceuticals
DMTQ2K0	DT	Antibody
DMTQ2K0	DE	Vaso-occlusive crisis

DMST4OR	ID	DMST4OR
DMST4OR	DN	Selgantolimod
DMST4OR	HS	Phase 2
DMST4OR	SN	2004677-13-6; 4-yl)amino]-2-methylhexan-1-ol; GS-9688; (2R)-2-[(2-amino-7-fluoropyrido[3,2-d]pyrimidin-; (2R)-2-[(2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino]-2-methylhexan-1-ol; (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol; Selgantolimod (USAN/INN); CHEMBL4594258; SCHEMBL18109405; GTPL10889; EX-A4247; GS9688; HY-109137; compound (R)-7 [PMID: 32407112]; CS-0086927; D11871; U57
DMST4OR	CP	Gilead Sciences
DMST4OR	DT	Small molecular drug
DMST4OR	PC	122585078
DMST4OR	MW	293.34
DMST4OR	FM	C14H20FN5O
DMST4OR	IC	InChI=1S/C14H20FN5O/c1-3-4-5-14(2,8-21)20-12-11-10(18-13(16)19-12)6-9(15)7-17-11/h6-7,21H,3-5,8H2,1-2H3,(H3,16,18,19,20)/t14-/m1/s1
DMST4OR	CS	CCCC[C@](C)(CO)NC1=NC(=NC2=C1N=CC(=C2)F)N
DMST4OR	IK	HTCJUBZBSJQWBW-CQSZACIVSA-N
DMST4OR	IU	(2R)-2-[(2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino]-2-methylhexan-1-ol
DMST4OR	DE	Hepatitis B

DMDLOBZ	ID	DMDLOBZ
DMDLOBZ	DN	Selinexor oral
DMDLOBZ	HS	Phase 2
DMDLOBZ	CP	Karyopharm Therapeutics Newton, MA
DMDLOBZ	DE	Recurrent glioblastoma

DMQM3IX	ID	DMQM3IX
DMQM3IX	DN	SELODENOSON
DMQM3IX	HS	Phase 2
DMQM3IX	SN	DT-009; DTI-0009; RG-14202; Selodenoson; N6-Cyclopentyl-N5'-ethyladenosine-5'-uronamide
DMQM3IX	DT	Small molecular drug
DMQM3IX	PC	3082555
DMQM3IX	MW	376.4
DMQM3IX	FM	C17H24N6O4
DMQM3IX	IC	InChI=1S/C17H24N6O4/c1-2-18-16(26)13-11(24)12(25)17(27-13)23-8-21-10-14(19-7-20-15(10)23)22-9-5-3-4-6-9/h7-9,11-13,17,24-25H,2-6H2,1H3,(H,18,26)(H,19,20,22)/t11-,12+,13-,17+/m0/s1
DMQM3IX	CS	CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NC4CCCC4)O)O
DMQM3IX	IK	GWVQGVCXFNYGFP-PFHKOEEOSA-N
DMQM3IX	IU	(2S,3S,4R,5R)-5-[6-(cyclopentylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
DMQM3IX	CA	CAS 110299-05-3
DMQM3IX	DE	Cardiac arrhythmias

DMJH6EL	ID	DMJH6EL
DMJH6EL	DN	Selurampanel
DMJH6EL	HS	Phase 2
DMJH6EL	SN	BGG-492; BGG-492A; AMPA antagonist (oral, epilepsy), Novartis
DMJH6EL	CP	Novartis pharmaceuticals
DMJH6EL	DT	Small molecular drug
DMJH6EL	PC	45381907
DMJH6EL	MW	377.4
DMJH6EL	FM	C16H19N5O4S
DMJH6EL	IC	InChI=1S/C16H19N5O4S/c1-9(2)10-8-13-12(7-11(10)14-5-6-17-20(14)3)15(22)21(16(23)18-13)19-26(4,24)25/h5-9,19H,1-4H3,(H,18,23)
DMJH6EL	CS	CC(C)C1=C(C=C2C(=C1)NC(=O)N(C2=O)NS(=O)(=O)C)C3=CC=NN3C
DMJH6EL	IK	MCECSFFXUPEPDB-UHFFFAOYSA-N
DMJH6EL	IU	N-[6-(2-methylpyrazol-3-yl)-2,4-dioxo-7-propan-2-yl-1H-quinazolin-3-yl]methanesulfonamide
DMJH6EL	CA	CAS 912574-69-7
DMJH6EL	DE	Epilepsy

DMIJNLG	ID	DMIJNLG
DMIJNLG	DN	Semapimod
DMIJNLG	HS	Phase 2
DMIJNLG	SN	CPSI-2364; Semapimod (oral); Semapimod (oral), Cytokine PharmaSciences
DMIJNLG	CP	Cytokine PharmaSciences Inc
DMIJNLG	DT	Small molecular drug
DMIJNLG	PC	5745214
DMIJNLG	MW	744.9
DMIJNLG	FM	C34H52N18O2
DMIJNLG	IC	InChI=1S/C34H52N18O2/c1-19(45-49-31(35)36)23-13-24(20(2)46-50-32(37)38)16-27(15-23)43-29(53)11-9-7-5-6-8-10-12-30(54)44-28-17-25(21(3)47-51-33(39)40)14-26(18-28)22(4)48-52-34(41)42/h13-18H,5-12H2,1-4H3,(H,43,53)(H,44,54)(H4,35,36,49)(H4,37,38,50)(H4,39,40,51)(H4,41,42,52)/b45-19+,46-20+,47-21+,48-22+
DMIJNLG	CS	C/C(=N\\N=C(N)N)/C1=CC(=CC(=C1)NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C
DMIJNLG	IK	PWDYHMBTPGXCSN-VCBMUGGBSA-N
DMIJNLG	IU	N,N'-bis[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanediamide
DMIJNLG	CA	CAS 352513-83-8
DMIJNLG	DE	Inflammatory bowel disease; Autoimmune diabetes

DMLDBQ5	ID	DMLDBQ5
DMLDBQ5	DN	SEN-196
DMLDBQ5	HS	Phase 2
DMLDBQ5	SN	EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena
DMLDBQ5	CP	Elixir Pharmaceuticals Inc
DMLDBQ5	DT	Small molecular drug
DMLDBQ5	PC	5113032
DMLDBQ5	MW	248.71
DMLDBQ5	FM	C13H13ClN2O
DMLDBQ5	IC	InChI=1S/C13H13ClN2O/c14-7-4-5-11-10(6-7)8-2-1-3-9(13(15)17)12(8)16-11/h4-6,9,16H,1-3H2,(H2,15,17)
DMLDBQ5	CS	C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N
DMLDBQ5	IK	FUZYTVDVLBBXDL-UHFFFAOYSA-N
DMLDBQ5	IU	6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
DMLDBQ5	CA	CAS 49843-98-3
DMLDBQ5	CB	CHEBI:90369
DMLDBQ5	DE	Huntington disease

DMOH8LD	ID	DMOH8LD
DMOH8LD	DN	Senktide
DMOH8LD	HS	Phase 2
DMOH8LD	SN	Senktide; CHEMBL106124; Succinyl-6-asp-8-Me-phe-substance P (6-11); Substance P (6-11), succinyl-asp(6)-Me-phe(8)-; Substance P (6-11), succinyl-aspartyl(6)-methylphenylalanine(8)-; L-Methioninamide, N-(3-carboxy-1-oxopropyl)-L-alpha-aspartyl-L-phenylalanyl-N-methyl-L-phenylalanylglycyl-L-leucyl-
DMOH8LD	DT	Small molecular drug
DMOH8LD	PC	108147
DMOH8LD	MW	842
DMOH8LD	FM	C40H55N7O11S
DMOH8LD	IC	InChI=1S/C40H55N7O11S/c1-24(2)19-28(37(55)45-27(36(41)54)17-18-59-4)44-33(49)23-42-39(57)31(21-26-13-9-6-10-14-26)47(3)40(58)30(20-25-11-7-5-8-12-25)46-38(56)29(22-35(52)53)43-32(48)15-16-34(50)51/h5-14,24,27-31H,15-23H2,1-4H3,(H2,41,54)(H,42,57)(H,43,48)(H,44,49)(H,45,55)(H,46,56)(H,50,51)(H,52,53)/t27-,28-,29-,30-,31-/m0/s1
DMOH8LD	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)N(C)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
DMOH8LD	IK	HMHYXLVEFVGOPM-QKUYTOGTSA-N
DMOH8LD	IU	(3S)-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutanoic acid
DMOH8LD	CA	CAS 106128-89-6
DMOH8LD	DE	Ischemic stroke; Epilepsy

DMA12HB	ID	DMA12HB
DMA12HB	DN	SEP--4199
DMA12HB	HS	Phase 2
DMA12HB	CP	Sunovion Pharmaceuticals
DMA12HB	DT	Small molecular drug
DMA12HB	DE	Bipolar disorder

DMD8RU0	ID	DMD8RU0
DMD8RU0	DN	SEphB4-HSA
DMD8RU0	HS	Phase 2
DMD8RU0	CP	VasGene Therapeutics
DMD8RU0	DT	Recombinant protein
DMD8RU0	DE	Solid tumour/cancer; Kaposi sarcoma

DMDW5ZC	ID	DMDW5ZC
DMDW5ZC	DN	SER-100
DMDW5ZC	HS	Phase 2
DMDW5ZC	SN	ORL1 receptor agonists, Zealand Pharma; ZP-120; ZP-120C
DMDW5ZC	CP	Zealand Pharma A/S
DMDW5ZC	PC	25086585
DMDW5ZC	MW	1781.2
DMDW5ZC	FM	C85H141N27O15
DMDW5ZC	IC	InChI=1S/C85H141N27O15/c1-52(113)101-61(29-18-46-98-84(94)95)73(117)110-70(49-54-33-37-57(115)38-34-54)82(126)111-69(48-53-31-35-56(114)36-32-53)81(125)109-68(30-19-47-99-85(96)97)80(124)112-71(50-55-51-100-59-21-3-2-20-58(55)59)83(127)108-67(28-10-17-45-92)79(123)107-66(27-9-16-44-91)78(122)106-65(26-8-15-43-90)77(121)105-64(25-7-14-42-89)76(120)104-63(24-6-13-41-88)75(119)103-62(23-5-12-40-87)74(118)102-60(72(93)116)22-4-11-39-86/h2-3,20-21,31-38,51,60-71,100,114-115H,4-19,22-30,39-50,86-92H2,1H3,(H2,93,116)(H,101,113)(H,102,118)(H,103,119)(H,104,120)(H,105,121)(H,106,122)(H,107,123)(H,108,127)(H,109,125)(H,110,117)(H,111,126)(H,112,124)(H4,94,95,98)(H4,96,97,99)/t60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-/m0/s1
DMDW5ZC	CS	CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N
DMDW5ZC	IK	GJLXVWOMRRWCIB-MERZOTPQSA-N
DMDW5ZC	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide
DMDW5ZC	CA	CAS 383123-18-0
DMDW5ZC	DE	Heart failure

DMYT470	ID	DMYT470
DMYT470	DN	Seribantumab
DMYT470	HS	Phase 2
DMYT470	CP	Merrimack Pharmaceuticals Cambridge, MA
DMYT470	DE	Colorectal cancer; Head and neck cancer; Non-small-cell lung cancer

DMTNDM2	ID	DMTNDM2
DMTNDM2	DN	Setrobuvir
DMTNDM2	HS	Phase 2
DMTNDM2	CP	Anadys Pharmaceuticals
DMTNDM2	DT	Small molecular drug
DMTNDM2	PC	135565932
DMTNDM2	MW	560.6
DMTNDM2	FM	C25H25FN4O6S2
DMTNDM2	IC	InChI=1S/C25H25FN4O6S2/c1-37(33,34)28-17-8-9-18-19(11-17)38(35,36)29-24(27-18)21-23(31)20-14-4-5-15(10-14)22(20)30(25(21)32)12-13-2-6-16(26)7-3-13/h2-3,6-9,11,14-15,20,22,28,31H,4-5,10,12H2,1H3,(H,27,29)/t14-,15+,20+,22-/m0/s1
DMTNDM2	CS	CS(=O)(=O)NC1=CC2=C(C=C1)NC(=NS2(=O)=O)C3=C([C@@H]4[C@H]5CC[C@H](C5)[C@@H]4N(C3=O)CC6=CC=C(C=C6)F)O
DMTNDM2	IK	DEKOYVOWOVJMPM-RLHIPHHXSA-N
DMTNDM2	IU	N-[3-[(1R,2S,7R,8S)-3-[(4-fluorophenyl)methyl]-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazin-7-yl]methanesulfonamide
DMTNDM2	CA	CAS 1071517-39-9
DMTNDM2	DE	Hepatitis C virus infection

DM9IMEZ	ID	DM9IMEZ
DM9IMEZ	DN	Seviteronel
DM9IMEZ	HS	Phase 2
DM9IMEZ	SN	INO-464; 1610537-15-9; CHEMBL3264610; ZINC139920592; AKOS030526607; DB12275; CS-3139; HY-15996; 1H-1,2,3-Triazole-5-methanol, alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (alphaS)-; UNII-8S5OIN36X4 component ZBRAJOQFSNYJMF-SFHVURJKSA-N
DM9IMEZ	CP	Innocrin Pharmaceuticals Durham, NC
DM9IMEZ	PC	78357816
DM9IMEZ	MW	399.3
DM9IMEZ	FM	C18H17F4N3O3
DM9IMEZ	IC	InChI=1S/C18H17F4N3O3/c1-9(2)18(26,15-8-23-25-24-15)12-4-3-10-6-13(27-16(19)20)14(28-17(21)22)7-11(10)5-12/h3-9,16-17,26H,1-2H3,(H,23,24,25)/t18-/m0/s1
DM9IMEZ	CS	CC(C)[C@](C1=CC2=CC(=C(C=C2C=C1)OC(F)F)OC(F)F)(C3=NNN=C3)O
DM9IMEZ	IK	ZBRAJOQFSNYJMF-SFHVURJKSA-N
DM9IMEZ	IU	(1S)-1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol
DM9IMEZ	CA	CAS 1610537-15-9
DM9IMEZ	DE	Breast cancer; Prostate cancer

DML10K3	ID	DML10K3
DML10K3	DN	SF1126
DML10K3	HS	Phase 2
DML10K3	SN	CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt
DML10K3	CP	Semafore Pharma
DML10K3	TC	Anticancer Agents
DML10K3	DT	Small molecular drug
DML10K3	PC	66577114
DML10K3	MW	852.8
DML10K3	FM	C39H48N8O14
DML10K3	IC	InChI=1S/C39H48N8O14/c40-39(41)42-13-5-10-26(36(55)43-20-31(51)45-27(18-33(52)53)37(56)46-28(21-48)38(57)58)44-30(50)11-12-34(54)60-22-47(14-16-59-17-15-47)32-19-29(49)25-9-4-8-24(35(25)61-32)23-6-2-1-3-7-23/h1-4,6-9,19,26-28,48H,5,10-18,20-22H2,(H9-,40,41,42,43,44,45,46,50,51,52,53,55,56,57,58)/t26-,27-,28-/m0/s1
DML10K3	CS	C1COCC[N+]1(COC(=O)CCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)[O-])C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DML10K3	IK	SVNJBEMPMKWDCO-KCHLEUMXSA-N
DML10K3	IU	(2S)-2-[[(2S)-3-carboxy-2-[[2-[[(2S)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate
DML10K3	DE	Solid tumour/cancer; Head and neck cancer; Hepatocellular carcinoma

DMVIWNK	ID	DMVIWNK
DMVIWNK	DN	SFV IL-12 gene therapy
DMVIWNK	HS	Phase 2
DMVIWNK	SN	LipoVIL12; SFV IL-12 gene therapy (liposomal); SFV IL-12 gene therapy (liposomal), Regulon
DMVIWNK	CP	Regulon Inc
DMVIWNK	DE	Breast cancer

DMAQW9M	ID	DMAQW9M
DMAQW9M	DN	SFX-01
DMAQW9M	HS	Phase 2
DMAQW9M	CP	Evgen Pharma
DMAQW9M	DE	Breast cancer; Subarachnoid hemorrhage

DMJ9M5D	ID	DMJ9M5D
DMJ9M5D	DN	SGN-30
DMJ9M5D	HS	Phase 2
DMJ9M5D	DT	Antibody
DMJ9M5D	DE	Solid tumour/cancer

DMA4LNE	ID	DMA4LNE
DMA4LNE	DN	SGN-LIV1A
DMA4LNE	HS	Phase 2
DMA4LNE	SN	Ladiratuzumab Vedotin
DMA4LNE	CP	Seattle Genetics
DMA4LNE	DT	Antibody drug conjugate
DMA4LNE	DE	Small-cell lung cancer; Non-small cell lung cancer

DM5XYFH	ID	DM5XYFH
DM5XYFH	DN	SGS742
DM5XYFH	HS	Phase 2
DM5XYFH	SN	CGP-36742; CGP36742
DM5XYFH	CP	Saegis Pharmaceuticals
DM5XYFH	DT	Small molecular drug
DM5XYFH	PC	130021
DM5XYFH	MW	179.2
DM5XYFH	FM	C7H18NO2P
DM5XYFH	IC	InChI=1S/C7H18NO2P/c1-2-3-6-11(9,10)7-4-5-8/h2-8H2,1H3,(H,9,10)
DM5XYFH	CS	CCCCP(=O)(CCCN)O
DM5XYFH	IK	ONNMDRQRSGKZCN-UHFFFAOYSA-N
DM5XYFH	IU	3-aminopropyl(butyl)phosphinic acid
DM5XYFH	CA	CAS 123690-78-8
DM5XYFH	DE	Schizophrenia

DMLYIPA	ID	DMLYIPA
DMLYIPA	DN	SGT-53
DMLYIPA	HS	Phase 2
DMLYIPA	SN	P53 gene stimulator (solid tumor), Synergene Therapeutics
DMLYIPA	CP	Synergene Therapeutics Inc
DMLYIPA	DT	Gene therapy
DMLYIPA	DE	Solid tumour/cancer; Pancreatic cancer; Recurrent glioblastoma

DMGIRM1	ID	DMGIRM1
DMGIRM1	DN	SH-529
DMGIRM1	HS	Phase 2
DMGIRM1	SN	Glucoprime; GLYC-101; GLYC-101); Iloprost beta-cyclodextrin clathrate; Z-101; ZK-96944; (1-3)-(1-6)-beta-D-glucan,Glycotex
DMGIRM1	CP	Bayer Schering Pharma AG; Novogen Ltd
DMGIRM1	DE	Peripheral vascular disease

DMIQB13	ID	DMIQB13
DMIQB13	DN	SHAPE
DMIQB13	HS	Phase 2
DMIQB13	DE	Lymphoma; Cutaneous T-cell lymphoma

DMT4UC1	ID	DMT4UC1
DMT4UC1	DN	Sibrotuzumab
DMT4UC1	HS	Phase 2
DMT4UC1	DT	Antibody
DMT4UC1	DE	Metastatic colorectal cancer

DM39RXO	ID	DM39RXO
DM39RXO	DN	SiG12D-LODER
DM39RXO	HS	Phase 2
DM39RXO	CP	Silenseed
DM39RXO	DT	Small interfering RNA
DM39RXO	DE	Pancreatic cancer

DM75RFJ	ID	DM75RFJ
DM75RFJ	DN	Siplizumab
DM75RFJ	HS	Phase 2
DM75RFJ	SN	Siplizumab (USAN/INN)
DM75RFJ	CP	Medlmmune; AstraZeneca
DM75RFJ	DT	Antibody
DM75RFJ	DE	Psoriasis vulgaris; Lymphoma

DMTXHJ9	ID	DMTXHJ9
DMTXHJ9	DN	Sirolimus
DMTXHJ9	HS	Phase 2 
DMTXHJ9	SN	Rapammune; Sirolimus; Rapamycin; I2190A; 53123-88-9; (-)-Rapamycin; Wy 090217; SIIA 9268A; Rapamune; I-2190A; AY-22989; RAPA; NSC 226080; I 2190A; AY 22989; Rapamycin (Sirolimus); WY-090217; Antibiotic AY 22989; UNII-W36ZG6FT64; SILA 9268A; CHEBI:9168; CCRIS 9024; W36ZG6FT64; HSDB 7284; C51H79NO13; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Supralimus; Sirolimus
DMTXHJ9	TC	Antiviral Agents
DMTXHJ9	DT	Small molecular drug
DMTXHJ9	PC	5284616
DMTXHJ9	MW	914.2
DMTXHJ9	FM	C51H79NO13
DMTXHJ9	IC	InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
DMTXHJ9	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
DMTXHJ9	IK	QFJCIRLUMZQUOT-HPLJOQBZSA-N
DMTXHJ9	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMTXHJ9	CA	CAS 53123-88-9
DMTXHJ9	CB	CHEBI:9168
DMTXHJ9	DE	Coronavirus Disease 2019 (COVID-19)

DM90DTM	ID	DM90DTM
DM90DTM	DN	Sirukumab
DM90DTM	HS	Phase 2 
DM90DTM	SN	Sirukumab (USAN); Sirukumab (genetical recombination) (JAN); D10080; 1194585-53-9
DM90DTM	TC	Antiviral Agents
DM90DTM	DT	Monoclonal antibody
DM90DTM	DE	Coronavirus Disease 2019 (COVID-19)

DMA9VGW	ID	DMA9VGW
DMA9VGW	DN	Sitafloxacin
DMA9VGW	HS	Phase 2
DMA9VGW	SN	127254-12-0; Gracevit; Sitafloxacin Sesquihydrate; DU 6859; 163253-35-8; UNII-3GJC60U4Q8; DU-6859a; Sitafloxacin isomer II; DU 6859A; C19H18ClF2N3O3; 3GJC60U4Q8; CHEBI:4304; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid; Sitafloxacin [INN]; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; DU-6859; 127254-10-8; Sitafloxacin isomer III (RRS); 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-3-quinolinecarboxylic acid; 7-[(7S)-7-azanyl-5-azaspiro[2.4]heptan-5-yl]-8-chloranyl-6-fluoranyl-1-[(1R,2S)-2-fluoranylcyclopropyl]-4-oxidanylidene-quinoline-3-carboxylic acid; SITAFLOXACIN ISOMER III(RRS); SITAFLOXACINISOMER; SCHEMBL74553; 7-((7S)-Amino-5-azaspiro(2,4)heptan-5-yl)-8-chloro-6-fluoro-1-((1R,2R)-cis-2-fluoro-1-cyclopropyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid; 7-(7-Amino-5-azaspiro(2.4)heptan-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid sesquihydrate; SITAFLOXACINISOMER(RRS); SITAFLOXACINISOMER(RSR); DU6859a; CHEMBL108821; AMSP00027; GTPL11040; HY-B0395; ZINC3795983; AKOS015962212; AC-1388; ACN-048224; AM85541; compound 33 [PMID: 7932562]; YF10030; (-)-7-((7S)-Amino-5-azaspiro(2,4)hept-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-1,4-dihydro-4-oxoq-3-uinolonecarboxylic acid; 3-Quinolinecarboxylic acid, 7-(7-amino-5-azaspiro(2.4)hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, (1R-(1alpha(S*),2alpha))-; 3-Quinolinecarboxylic acid, 7-[(7S)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid; AT-21032; AB01568244_01; 253S358; A805671; A805673; J-519022; (-)-7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluoro-1-cyclopropyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 273401-03-9; 3-Quinolinecarboxylic acid, 7-((7S)-7-amino-5-azaspiro(24)hept-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-1,4-dihydro-4-oxo-; 7-((7S)-7-Amino-5-azaspiro[2.4]hept-5-yl)-1-((1S,2S)-2-fluorocyclopropyl)-8-chloro-6-fluoro-4-oxohydroquinoline-3-carboxylic acid; 7-((S)-7-Amino-5-azaspiro[2.4]Heptan-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic  acid; 7-[(7S)-7-Amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1 R,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydro-3-quinolinecarboxyli c acid; rel-7-((R)-7-Amino-5-azaspiro[2.4]heptan-5-yl)-8-chloro-6-fluoro-1-((1S,2R)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
DMA9VGW	DT	Small molecular drug
DMA9VGW	PC	461399
DMA9VGW	MW	409.8
DMA9VGW	FM	C19H18ClF2N3O3
DMA9VGW	IC	InChI=1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)/t10-,12+,13+/m0/s1
DMA9VGW	CS	C1CC12CN(C[C@H]2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)[C@@H]5C[C@@H]5F)F
DMA9VGW	IK	PNUZDKCDAWUEGK-CYZMBNFOSA-N
DMA9VGW	IU	7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid
DMA9VGW	CA	CAS 127254-12-0
DMA9VGW	CB	CHEBI:4304
DMA9VGW	DE	Escherichia coli infection

DMY3JWO	ID	DMY3JWO
DMY3JWO	DN	Sitamaquine
DMY3JWO	HS	Phase 2
DMY3JWO	SN	WR-006026; WR-6026
DMY3JWO	CP	GlaxoSmithKline; Walter Reed Army Institute of Research
DMY3JWO	DT	Small molecular drug
DMY3JWO	PC	42548
DMY3JWO	MW	343.5
DMY3JWO	FM	C21H33N3O
DMY3JWO	IC	InChI=1S/C21H33N3O/c1-5-24(6-2)14-10-8-7-9-12-22-20-16-18(25-4)15-19-17(3)11-13-23-21(19)20/h11,13,15-16,22H,5-10,12,14H2,1-4H3
DMY3JWO	CS	CCN(CC)CCCCCCNC1=CC(=CC2=C(C=CN=C12)C)OC
DMY3JWO	IK	RVAKDGYPIVSYEU-UHFFFAOYSA-N
DMY3JWO	IU	N',N'-diethyl-N-(6-methoxy-4-methylquinolin-8-yl)hexane-1,6-diamine
DMY3JWO	CA	CAS 57695-04-2
DMY3JWO	DE	Infectious disease

DMNRHMX	ID	DMNRHMX
DMNRHMX	DN	SKF-110679
DMNRHMX	HS	Phase 2
DMNRHMX	SN	U-75799E
DMNRHMX	CP	SmithKline Beecham plc
DMNRHMX	DT	Small molecular drug
DMNRHMX	PC	4345065
DMNRHMX	MW	873
DMNRHMX	FM	C46H56N12O6
DMNRHMX	IC	InChI=1S/C46H56N12O6/c1-27(54-44(62)39(20-29-23-51-35-15-7-5-13-32(29)35)57-43(61)34(48)22-31-25-50-26-53-31)42(60)56-40(21-30-24-52-36-16-8-6-14-33(30)36)46(64)58-38(19-28-11-3-2-4-12-28)45(63)55-37(41(49)59)17-9-10-18-47/h2-8,11-16,23-27,34,37-40,51-52H,9-10,17-22,47-48H2,1H3,(H2,49,59)(H,50,53)(H,54,62)(H,55,63)(H,56,60)(H,57,61)(H,58,64)
DMNRHMX	CS	CC(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)C(CC6=CN=CN6)N
DMNRHMX	IK	WZHKXNSOCOQYQX-UHFFFAOYSA-N
DMNRHMX	IU	6-amino-2-[[2-[[2-[2-[[2-[[2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoylamino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
DMNRHMX	DE	Growth hormone deficiency

DMRHD6B	ID	DMRHD6B
DMRHD6B	DN	SKL-NP
DMRHD6B	HS	Phase 2
DMRHD6B	DE	Pain

DMCDON3	ID	DMCDON3
DMCDON3	DN	SLV 306
DMCDON3	HS	Phase 2
DMCDON3	SN	Daglutril; SLV 306; SLV-306; SLV306; UNII-KKV299446X; 182821-27-8; KKV299446X; ((3S)-3-{1-((2R)-2-Ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetic acid; Daglutril [INN]; 2-[(3S)-3-[[1-[(2R)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid; 1H-1-Benzazepine-1-acetic acid, 3-(((1-(2-(ethoxycarbonyl)-4-phenylbutyl)cyclopentyl)carbonyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,S*))-
DMCDON3	CP	Solvay Pharma
DMCDON3	DT	Small molecular drug
DMCDON3	PC	3038505
DMCDON3	MW	534.6
DMCDON3	FM	C31H38N2O6
DMCDON3	IC	InChI=1S/C31H38N2O6/c1-2-39-29(37)24(15-14-22-10-4-3-5-11-22)20-31(18-8-9-19-31)30(38)32-25-17-16-23-12-6-7-13-26(23)33(28(25)36)21-27(34)35/h3-7,10-13,24-25H,2,8-9,14-21H2,1H3,(H,32,38)(H,34,35)/t24-,25+/m1/s1
DMCDON3	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)CC2(CCCC2)C(=O)N[C@H]3CCC4=CC=CC=C4N(C3=O)CC(=O)O
DMCDON3	IK	XMQODGUTLZXUGZ-RPBOFIJWSA-N
DMCDON3	IU	2-[(3S)-3-[[1-[(2R)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMCDON3	CA	CAS 182821-27-8
DMCDON3	DE	Acute decompensated heart failure

DM867BJ	ID	DM867BJ
DM867BJ	DN	SLV320
DM867BJ	HS	Phase 2
DM867BJ	SN	SLV-320; 4-[(4-phenyl-3,5,7-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-2-yl)amino]cyclohexan-1-ol
DM867BJ	CP	Solvay
DM867BJ	DT	Small molecular drug
DM867BJ	PC	9953065
DM867BJ	MW	308.4
DM867BJ	FM	C18H20N4O
DM867BJ	IC	InChI=1S/C18H20N4O/c23-14-8-6-13(7-9-14)20-18-15-10-11-19-17(15)21-16(22-18)12-4-2-1-3-5-12/h1-5,10-11,13-14,23H,6-9H2,(H2,19,20,21,22)
DM867BJ	CS	C1CC(CCC1NC2=NC(=NC3=C2C=CN3)C4=CC=CC=C4)O
DM867BJ	IK	RBZNJGHIKXAKQE-UHFFFAOYSA-N
DM867BJ	IU	4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexan-1-ol
DM867BJ	CA	CAS 251945-92-3
DM867BJ	DE	Heart failure

DMXCJKY	ID	DMXCJKY
DMXCJKY	DN	SLV-334
DMXCJKY	HS	Phase 2
DMXCJKY	CP	Solvay SA
DMXCJKY	PC	11215055
DMXCJKY	MW	556.6
DMXCJKY	FM	C33H36N2O6
DMXCJKY	IC	InChI=1S/C33H36N2O6/c36-29(37)21-35-28-13-4-2-9-24(28)16-17-27(30(35)38)34-32(41)33(18-5-6-19-33)20-25(31(39)40)15-14-23-11-7-10-22-8-1-3-12-26(22)23/h1-4,7-13,25,27H,5-6,14-21H2,(H,34,41)(H,36,37)(H,39,40)/t25-,27+/m1/s1
DMXCJKY	CS	C1CCC(C1)(C[C@@H](CCC2=CC=CC3=CC=CC=C32)C(=O)O)C(=O)N[C@H]4CCC5=CC=CC=C5N(C4=O)CC(=O)O
DMXCJKY	IK	LOFDNSDPZTVIIO-VPUSJEBWSA-N
DMXCJKY	IU	(2R)-2-[[1-[[(3S)-1-(carboxymethyl)-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]carbamoyl]cyclopentyl]methyl]-4-naphthalen-1-ylbutanoic acid
DMXCJKY	CA	CAS 182821-33-6
DMXCJKY	DE	Brain injury

DMM3AI8	ID	DMM3AI8
DMM3AI8	DN	SLx-4090
DMM3AI8	HS	Phase 2
DMM3AI8	SN	SLx 4090; SCHEMBL1484252
DMM3AI8	CP	Surface
DMM3AI8	DT	Small molecular drug
DMM3AI8	PC	53497429
DMM3AI8	MW	546.5
DMM3AI8	FM	C31H25F3N2O4
DMM3AI8	IC	InChI=1S/C31H25F3N2O4/c1-39-27-9-5-8-26(28(27)20-10-13-23(14-11-20)31(32,33)34)29(37)35-24-15-12-22-19-36(17-16-21(22)18-24)30(38)40-25-6-3-2-4-7-25/h2-15,18H,16-17,19H2,1H3,(H,35,37)
DMM3AI8	CS	COC1=CC=CC(=C1C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=CC4=C(CN(CC4)C(=O)OC5=CC=CC=C5)C=C3
DMM3AI8	IK	AZUIUVJESCFSLJ-UHFFFAOYSA-N
DMM3AI8	IU	phenyl 6-[[3-methoxy-2-[4-(trifluoromethyl)phenyl]benzoyl]amino]-3,4-dihydro-1H-isoquinoline-2-carboxylate
DMM3AI8	CA	CAS 913541-47-6
DMM3AI8	DE	Hyperlipidaemia; Dyslipidemia; Diabetic complication

DMOLTAD	ID	DMOLTAD
DMOLTAD	DN	SM-04690
DMOLTAD	HS	Phase 2
DMOLTAD	CP	Samumed
DMOLTAD	PC	135565709
DMOLTAD	MW	505.5
DMOLTAD	FM	C29H24FN7O
DMOLTAD	IC	InChI=1S/C29H24FN7O/c1-16(2)8-26(38)33-21-10-19(12-31-13-21)17-6-7-24-22(11-17)28(37-36-24)29-34-25-15-32-14-23(27(25)35-29)18-4-3-5-20(30)9-18/h3-7,9-16H,8H2,1-2H3,(H,33,38)(H,34,35)(H,36,37)
DMOLTAD	CS	CC(C)CC(=O)NC1=CN=CC(=C1)C2=CC3=C(C=C2)NN=C3C4=NC5=C(N4)C=NC=C5C6=CC(=CC=C6)F
DMOLTAD	IK	AQDWDWAYVBQMAM-UHFFFAOYSA-N
DMOLTAD	IU	N-[5-[3-[7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl]pyridin-3-yl]-3-methylbutanamide
DMOLTAD	CA	CAS 1467093-03-3
DMOLTAD	DE	Osteoarthritis

DMTJOQX	ID	DMTJOQX
DMTJOQX	DN	SMP-986
DMTJOQX	HS	Phase 2
DMTJOQX	SN	Afacifenacin
DMTJOQX	CP	Sumitomo Pharmaceuticals Co Ltd
DMTJOQX	DT	Small molecular drug
DMTJOQX	PC	10188853
DMTJOQX	MW	481.5
DMTJOQX	FM	C27H26F3N3O2
DMTJOQX	IC	InChI=1S/C27H26F3N3O2/c28-27(29,30)35-22-10-6-7-19(17-22)18-32-15-13-21(14-16-32)33-25(20-8-2-1-3-9-20)23-11-4-5-12-24(23)31-26(33)34/h1-12,17,21,25H,13-16,18H2,(H,31,34)
DMTJOQX	CS	C1CN(CCC1N2C(C3=CC=CC=C3NC2=O)C4=CC=CC=C4)CC5=CC(=CC=C5)OC(F)(F)F
DMTJOQX	IK	IJUMFEAYOMCXAQ-UHFFFAOYSA-N
DMTJOQX	IU	4-phenyl-3-[1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]-1,4-dihydroquinazolin-2-one
DMTJOQX	DE	Overactive bladder

DMCD6G1	ID	DMCD6G1
DMCD6G1	DN	SMT-C1100
DMCD6G1	HS	Phase 2
DMCD6G1	SN	BMN-195; Utrophin modulators (Duchenne muscular dystrophy); VOXC-1100; Utrophin modulators (Duchennemuscular dystrophy), VASTox; Utorphin upregulators (Duchenne muscular dystrophy), VASTox/University of Oxford; Utrophin modulators (Duchenne muscular dystrophy), Summit/BioMarin; Utropine inducer (Duchenne muscular dystrophy), Summit/BioMarin
DMCD6G1	CP	Summit Corp plc
DMCD6G1	DT	Small molecular drug
DMCD6G1	PC	25109292
DMCD6G1	MW	337.4
DMCD6G1	FM	C19H15NO3S
DMCD6G1	IC	InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3
DMCD6G1	CS	CCS(=O)(=O)C1=CC2=C(C=C1)OC(=N2)C3=CC4=CC=CC=C4C=C3
DMCD6G1	IK	KSGCNXAZROJSNW-UHFFFAOYSA-N
DMCD6G1	IU	5-ethylsulfonyl-2-naphthalen-2-yl-1,3-benzoxazole
DMCD6G1	CA	CAS 945531-77-1
DMCD6G1	DE	Duchenne dystrophy

DMPN314	ID	DMPN314
DMPN314	DN	SNA-120
DMPN314	HS	Phase 2
DMPN314	SN	Pegcantratinib; Pegcantratinib [INN]; Pegcantratinib [USAN]; Pegcantratinib [WHO-DD]; UNII-VG44NU1168; VG44NU1168; 1233363-33-1
DMPN314	CP	Creabilis Therapeutics Canterbury, United Kingdom
DMPN314	PC	132494168
DMPN314	MW	580.6
DMPN314	FM	C32H28N4O7
DMPN314	IC	InChI=1S/C32H28N4O7/c1-31-32(29(38)34(30(39)43-32)11-12-41-14-13-40-2)15-22(42-31)35-20-9-5-3-7-17(20)24-25-19(16-33-28(25)37)23-18-8-4-6-10-21(18)36(31)27(23)26(24)35/h3-10,22H,11-16H2,1-2H3,(H,33,37)
DMPN314	CS	CC12C3(CC(O1)N4C5=CC=CC=C5C6=C7C(=C8C9=CC=CC=C9N2C8=C64)CNC7=O)C(=O)N(C(=O)O3)CCOCCOC
DMPN314	IK	MTDVEOMKVDOULD-UHFFFAOYSA-N
DMPN314	IU	3-[2-(2-methoxyethoxy)ethyl]-15'-methylspiro[1,3-oxazolidine-5,16'-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene]-2,3',4-trione
DMPN314	DE	Plaque psoriasis; Pruritus

DMO4EYX	ID	DMO4EYX
DMO4EYX	DN	Soblidotin
DMO4EYX	HS	Phase 2
DMO4EYX	SN	Auristatin PE; Dolastatin derivative; TZT-1027; YHI-501; ZT-1027
DMO4EYX	CP	Teikoku Hormone Manufacturing Co Ltd
DMO4EYX	DT	Small molecular drug
DMO4EYX	PC	6918315
DMO4EYX	MW	702
DMO4EYX	FM	C39H67N5O6
DMO4EYX	IC	InChI=1S/C39H67N5O6/c1-13-27(6)35(43(10)39(48)33(25(2)3)41-38(47)34(26(4)5)42(8)9)31(49-11)24-32(45)44-23-17-20-30(44)36(50-12)28(7)37(46)40-22-21-29-18-15-14-16-19-29/h14-16,18-19,25-28,30-31,33-36H,13,17,20-24H2,1-12H3,(H,40,46)(H,41,47)/t27-,28+,30-,31+,33-,34-,35-,36+/m0/s1
DMO4EYX	CS	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)NCCC2=CC=CC=C2)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C
DMO4EYX	IK	DZMVCVHATYROOS-ZBFGKEHZSA-N
DMO4EYX	IU	(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-(2-phenylethylamino)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
DMO4EYX	CA	CAS 149606-27-9
DMO4EYX	CB	CHEBI:32135
DMO4EYX	DE	Solid tumour/cancer

DMKNIVG	ID	DMKNIVG
DMKNIVG	DN	Sodium butyrate
DMKNIVG	HS	Phase 2
DMKNIVG	SN	Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)
DMKNIVG	CP	Allerderm
DMKNIVG	DT	Small molecular drug
DMKNIVG	PC	5222465
DMKNIVG	MW	110.09
DMKNIVG	FM	C4H7NaO2
DMKNIVG	IC	InChI=1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1
DMKNIVG	CS	CCCC(=O)[O-].[Na+]
DMKNIVG	IK	MFBOGIVSZKQAPD-UHFFFAOYSA-M
DMKNIVG	IU	sodium;butanoate
DMKNIVG	CA	CAS 156-54-7
DMKNIVG	CB	CHEBI:64103
DMKNIVG	DE	Refractory sickle cell ulcers; Acute myeloid leukaemia

DMH5MVE	ID	DMH5MVE
DMH5MVE	DN	Sodium stibogluconate
DMH5MVE	HS	Phase 2
DMH5MVE	SN	Lenocta; Sodium stibogluconate (cancer); VQD-001; Sodium stibogluconate (cancer), Greenwich; Sodium stibogluconate (cancer), VioQuest
DMH5MVE	CP	VioQuest
DMH5MVE	DE	Solid tumour/cancer

DM157U0	ID	DM157U0
DM157U0	DN	Sofinicline
DM157U0	HS	Phase 2
DM157U0	SN	Sofinicline; ABT 894; Sofiniclin; ABT-894; UNII-SQC232V4YY; 799279-80-4; SQC232V4YY; CHEMBL238465; A-422894.0; Sofinicline [USAN:INN]; Sofinicline (USAN); SCHEMBL650488; A 422894.0;Sofiniclin; A 422894.0; MBQYQLWSBRANKQ-IMTBSYHQSA-N; BDBM50224483; ZINC28866069; CS-6792; DB12527; HY-14824; KB-74391; D09382; (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane; (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]-heptane; (1S,5S)-3-(5,6-Dichloro-pyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane; (1S, 5S)-3-(5,6-d
DM157U0	CP	Abbott Laboratories; NeuroSearch
DM157U0	DT	Small molecular drug
DM157U0	PC	10131048
DM157U0	MW	244.12
DM157U0	FM	C10H11Cl2N3
DM157U0	IC	InChI=1S/C10H11Cl2N3/c11-8-1-7(3-14-10(8)12)15-4-6-2-13-9(6)5-15/h1,3,6,9,13H,2,4-5H2/t6-,9+/m0/s1
DM157U0	CS	C1[C@H]2CN(C[C@H]2N1)C3=CC(=C(N=C3)Cl)Cl
DM157U0	IK	MBQYQLWSBRANKQ-IMTBSYHQSA-N
DM157U0	IU	(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane
DM157U0	CA	CAS 799279-80-4
DM157U0	DE	Attention deficit hyperactivity disorder

DML2ZWR	ID	DML2ZWR
DML2ZWR	DN	Solubilized type 1 native bovine collagen
DML2ZWR	HS	Phase 2
DML2ZWR	SN	Solubilized type 1 native bovine collagen (oral, scleroderma); Solubilized type 1 native bovine collagen (oral, scleroderma), arGentis/University of Tennessee
DML2ZWR	CP	University of Tennessee
DML2ZWR	DE	Scleroderma

DMKCBSM	ID	DMKCBSM
DMKCBSM	DN	SOM3355
DMKCBSM	HS	Phase 2
DMKCBSM	CP	SOM Biotech Cambridge, MA
DMKCBSM	DE	Tardive dyskinesia; Huntington disease

DMTVS3A	ID	DMTVS3A
DMTVS3A	DN	Somatoprim
DMTVS3A	HS	Phase 2
DMTVS3A	SN	SCHEMBL10652839
DMTVS3A	CP	DeveloGen
DMTVS3A	DT	Small molecular drug
DMTVS3A	PC	9919857
DMTVS3A	MW	1123.3
DMTVS3A	FM	C60H74N12O10
DMTVS3A	IC	InChI=1S/C60H74N12O10/c1-37(73)54-59(81)70-50(31-39-18-6-3-7-19-39)60(82)72(36-51(62)74)29-15-26-52(75)63-28-14-25-53(76)66-47(30-38-16-4-2-5-17-38)56(78)68-49(33-41-35-65-45-23-11-9-21-43(41)45)58(80)69-48(32-40-34-64-44-22-10-8-20-42(40)44)57(79)67-46(55(77)71-54)24-12-13-27-61/h2-11,16-23,34-35,37,46-50,54,64-65,73H,12-15,24-33,36,61H2,1H3,(H2,62,74)(H,63,75)(H,66,76)(H,67,79)(H,68,78)(H,69,80)(H,70,81)(H,71,77)/t37-,46+,47+,48-,49+,50+,54+/m1/s1
DMTVS3A	CS	C[C@H]([C@H]1C(=O)N[C@H](C(=O)N(CCCC(=O)NCCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC(=O)N)CC7=CC=CC=C7)O
DMTVS3A	IK	ABFNTRQPWNXUHA-VEVJRHMJSA-N
DMTVS3A	IU	2-[(3S,6S,9S,12R,15S,18S)-9-(4-aminobutyl)-3,18-dibenzyl-6-[(1R)-1-hydroxyethyl]-12,15-bis(1H-indol-3-ylmethyl)-2,5,8,11,14,17,20,25-octaoxo-1,4,7,10,13,16,19,24-octazacyclooctacos-1-yl]acetamide
DMTVS3A	CA	CAS 252845-37-7
DMTVS3A	DE	Acromegaly

DMK3RL8	ID	DMK3RL8
DMK3RL8	DN	Somatropin intranasal rhGH
DMK3RL8	HS	Phase 2
DMK3RL8	SN	ALTU-238; CP-024; HGH-191; Somatropin (intranasal); Human growth hormone (crystalline), Altus/Genentech; RhGH (oral, eligen), Novartis; Somatropin (crystalline), Altus/Genentech; Somatropin (sustained release, subcutaneous), Althea; Humatrope (oral, CADDYS), Lilly/Emisphere; Recombinant human growth hormone (oral, CADDYS), Lilly/Emisphere; RhGH (oral, CADDYS), Lilly/Emisphere; RhGH (oral, eligen), Emisphere/Novartis; Somatropin (nasal spray, CriticalSorb, growth hormone deficiency), Critical Pharmaceuticals; Somatropin (oral, CADDYS), Lilly/Emisphere; Somatropin (sustained release, subcutaneous), Altus/Genentech; Human growth hormone, (sustained release, subcutaneous), Altus/Genentech
DMK3RL8	CP	Nastech Pharmaceutical; Emisphere Technologies Inc; Critical Pharmaceuticals Ltd; Altus Pharmaceuticals Inc
DMK3RL8	DE	Growth hormone deficiency

DME53YS	ID	DME53YS
DME53YS	DN	Sotrastaurin acetate
DME53YS	HS	Phase 2
DME53YS	SN	Sotrastaurin acetate; UNII-R1SIA15KZ1; 908351-31-5; R1SIA15KZ1; Sotrastaurin acetate [USAN]; AEB 071; Sotrastaurin acetate (USAN); SCHEMBL3846239; CHEMBL2105655; KB-74525; D09718; 3-(1H-Indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4-yl)-1H-pyrrole-2,5-dione acetate; 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(2-(4-methyl-1-piperazinyl)-4-quinazolinyl)-, acetate
DME53YS	CP	Novartis
DME53YS	DT	Small molecular drug
DME53YS	PC	24779745
DME53YS	MW	498.5
DME53YS	FM	C27H26N6O4
DME53YS	IC	InChI=1S/C25H22N6O2.C2H4O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18;1-2(3)4/h2-9,14,26H,10-13H2,1H3,(H,29,32,33);1H3,(H,3,4)
DME53YS	CS	CC(=O)O.CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65
DME53YS	IK	RVEUYBMXVVDLFO-UHFFFAOYSA-N
DME53YS	IU	acetic acid;3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione
DME53YS	CA	CAS 908351-31-5
DME53YS	DE	Renal transplantation

DM2UKJV	ID	DM2UKJV
DM2UKJV	DN	SP-333
DM2UKJV	HS	Phase 2
DM2UKJV	SN	Guanylate cyclase-C receptor agonist (peptide, UC), Synergy Pharmaceuticals; Guanylate cyclase-C receptor analog (peptide, UC), Synergy Pharmaceuticals
DM2UKJV	CP	Synergy Pharmaceuticals Inc
DM2UKJV	DE	Ulcerative colitis

DM9OPK3	ID	DM9OPK3
DM9OPK3	DN	SPD-556
DM9OPK3	HS	Phase 2
DM9OPK3	SN	M-0002
DM9OPK3	CP	Movetis
DM9OPK3	DT	Small molecular drug
DM9OPK3	PC	73030
DM9OPK3	MW	382.4
DM9OPK3	FM	C21H18O5S
DM9OPK3	IC	InChI=1S/C21H18O5S/c1-13-11-15(22)7-9-17(13)21(18-10-8-16(23)12-14(18)2)19-5-3-4-6-20(19)27(24,25)26-21/h3-12,22-23H,1-2H3
DM9OPK3	CS	CC1=C(C=CC(=C1)O)C2(C3=CC=CC=C3S(=O)(=O)O2)C4=C(C=C(C=C4)O)C
DM9OPK3	IK	OLQIKGSZDTXODA-UHFFFAOYSA-N
DM9OPK3	IU	4-[3-(4-hydroxy-2-methylphenyl)-1,1-dioxo-2,1lambda6-benzoxathiol-3-yl]-3-methylphenol
DM9OPK3	CA	CAS 2303-01-7
DM9OPK3	DE	Heart failure

DMJH2AC	ID	DMJH2AC
DMJH2AC	DN	SPD-557
DMJH2AC	HS	Phase 2
DMJH2AC	SN	M-0003; Gastroprokinetic compound (gastroparesis), Janssen; Gastroprokinetic compound (gastroparesis), Movetis
DMJH2AC	CP	Janssen Pharmaceutica NV
DMJH2AC	PC	9823762
DMJH2AC	MW	425.9
DMJH2AC	FM	C21H32ClN3O4
DMJH2AC	IC	InChI=1S/C21H32ClN3O4/c1-21(2)10-15-18(23)16(22)9-14(19(15)29-21)20(27)24-11-13-5-7-25(12-17(13)26)6-4-8-28-3/h9,13,17,26H,4-8,10-12,23H2,1-3H3,(H,24,27)/t13-,17+/m0/s1
DMJH2AC	CS	CC1(CC2=C(O1)C(=CC(=C2N)Cl)C(=O)NC[C@@H]3CCN(C[C@H]3O)CCCOC)C
DMJH2AC	IK	FOUUNSGQVBGYQM-SUMWQHHRSA-N
DMJH2AC	IU	4-amino-5-chloro-N-[[(3S,4S)-3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl]methyl]-2,2-dimethyl-3H-1-benzofuran-7-carboxamide
DMJH2AC	CA	CAS 219984-49-3
DMJH2AC	DE	Diabetic gastroparesis

DMKJ9LU	ID	DMKJ9LU
DMKJ9LU	DN	SPD602
DMKJ9LU	HS	Phase 2
DMKJ9LU	CP	Shire
DMKJ9LU	DE	Anemia

DM26AHR	ID	DM26AHR
DM26AHR	DN	SPI-1005
DM26AHR	HS	Phase 2 
DM26AHR	SN	Ebselen [INN]; Ebselene; Ebselene [French]; Ebseleno; Ebseleno [Spanish]; Ebselenum; Ebselenum [Latin]; Harmokisane; PZ 51; PZ-51; PZ51; RP 60931; SPI-1005; SPI-3005; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-Phenyl-1,2-benzisoselenazolin-3-one; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; 2-phenyl-1,2-benzoselenazol-3-one; DR 3305; DR-3305; E 3520
DM26AHR	TC	Antiviral Agents
DM26AHR	DT	Small molecular drug
DM26AHR	PC	3194
DM26AHR	MW	274.19
DM26AHR	FM	C13H9NOSe
DM26AHR	IC	InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
DM26AHR	CS	C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
DM26AHR	IK	DYEFUKCXAQOFHX-UHFFFAOYSA-N
DM26AHR	IU	2-phenyl-1,2-benzoselenazol-3-one
DM26AHR	CA	CAS 60940-34-3
DM26AHR	CB	CHEBI:77543
DM26AHR	DE	Reperfusion injury and stroke; Coronavirus Disease 2019 (COVID-19)

DMNPRMC	ID	DMNPRMC
DMNPRMC	DN	SPI-1620
DMNPRMC	HS	Phase 2
DMNPRMC	SN	142569-99-1; SPI-1620; Suc[Glu9,Ala11,15]ET-110-21; GTPL3886; IRL1620; IRL2620; AKOS024456459
DMNPRMC	CP	Spectrum
DMNPRMC	DT	Small molecular drug
DMNPRMC	PC	16133819
DMNPRMC	MW	1820.9
DMNPRMC	FM	C86H117N17O27
DMNPRMC	IC	InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1
DMNPRMC	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
DMNPRMC	IK	DXPHNGAMYPPTBJ-TZMIJSMNSA-N
DMNPRMC	IU	(4S)-4-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-(3-carboxypropanoylamino)propanoyl]amino]butanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMNPRMC	CA	CAS 142569-99-1
DMNPRMC	DE	Solid tumour/cancer

DMHC2AW	ID	DMHC2AW
DMHC2AW	DN	SPI-205
DMHC2AW	HS	Phase 2
DMHC2AW	CP	SPECTRUM pharmaceuticals
DMHC2AW	DE	Parkinson disease

DM7NJWY	ID	DM7NJWY
DM7NJWY	DN	Spiroglumide
DM7NJWY	HS	Phase 2
DM7NJWY	SN	UNII-EZS5V8UN4Y; 137795-35-8; EZS5V8UN4Y; CHEMBL283820; CR-2194; (4R)-5-(8-azaspiro[45]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid; (R)-gamma-(3,5-Dichlorobenzamido)-delta-oxo-8-azaspiro(45)decane-8-valeric acid; Spiroglumide [INN]; AC1Q3LYL; AC1L24DH; SCHEMBL7920324; CTK0H9697; DTXSID60160311; FJCZHMXAGBYXHJ-QGZVFWFLSA-N; BDBM50048772; (R)-5-(8-Aza-spiro[45]dec-8-yl)-4-(3,5-dichloro-benzoylamino)-5-oxo-pentanoic acid; Radaxafine HCl
DM7NJWY	DT	Small molecular drug
DM7NJWY	PC	65987
DM7NJWY	MW	441.3
DM7NJWY	FM	C21H26Cl2N2O4
DM7NJWY	IC	InChI=1S/C21H26Cl2N2O4/c22-15-11-14(12-16(23)13-15)19(28)24-17(3-4-18(26)27)20(29)25-9-7-21(8-10-25)5-1-2-6-21/h11-13,17H,1-10H2,(H,24,28)(H,26,27)/t17-/m1/s1
DM7NJWY	CS	C1CCC2(C1)CCN(CC2)C(=O)[C@@H](CCC(=O)O)NC(=O)C3=CC(=CC(=C3)Cl)Cl
DM7NJWY	IK	FJCZHMXAGBYXHJ-QGZVFWFLSA-N
DM7NJWY	IU	(4R)-5-(8-azaspiro[4.5]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid
DM7NJWY	CA	CAS 137795-35-8
DM7NJWY	DE	Neuropathic pain; Stomach disease

DMRXCUQ	ID	DMRXCUQ
DMRXCUQ	DN	SPL-108
DMRXCUQ	HS	Phase 2
DMRXCUQ	CP	Splash Pharmaceuticals
DMRXCUQ	DT	Peptide
DMRXCUQ	DE	Ovarian epithelial cancer; Ovarian cancer

DMZIC4Q	ID	DMZIC4Q
DMZIC4Q	DN	SPN-812
DMZIC4Q	HS	Phase 2
DMZIC4Q	CP	Supernus Pharmaceuticals
DMZIC4Q	DE	Attention deficit hyperactivity disorder

DMOVQP8	ID	DMOVQP8
DMOVQP8	DN	SPP-600
DMOVQP8	HS	Phase 2
DMOVQP8	SN	SPP-630; SPP-635
DMOVQP8	CP	Speedel Pharma
DMOVQP8	DE	Hypertension

DMFAO5G	ID	DMFAO5G
DMFAO5G	DN	S-PRAnt
DMFAO5G	HS	Phase 2
DMFAO5G	SN	S-PRAnt (symptoms of uterine fibroids)
DMFAO5G	CP	Bayer AG
DMFAO5G	DE	Uterine fibroids

DMWK9BX	ID	DMWK9BX
DMWK9BX	DN	SQ-109
DMWK9BX	HS	Phase 2
DMWK9BX	SN	SQ-37; SQ-59; Antibiotics (tuberculosis), Sequella; Second-generation EMB, Sequella; Second-generation ethambutol, Sequella
DMWK9BX	CP	Sequella
DMWK9BX	DT	Small molecular drug
DMWK9BX	PC	5274428
DMWK9BX	MW	330.5
DMWK9BX	FM	C22H38N2
DMWK9BX	IC	InChI=1S/C22H38N2/c1-16(2)5-4-6-17(3)7-8-23-9-10-24-22-20-12-18-11-19(14-20)15-21(22)13-18/h5,7,18-24H,4,6,8-15H2,1-3H3/b17-7+
DMWK9BX	CS	CC(=CCC/C(=C/CNCCNC1C2CC3CC(C2)CC1C3)/C)C
DMWK9BX	IK	JFIBVDBTCDTBRH-REZTVBANSA-N
DMWK9BX	IU	N'-(2-adamantyl)-N-[(2E)-3,7-dimethylocta-2,6-dienyl]ethane-1,2-diamine
DMWK9BX	CA	CAS 502487-67-4
DMWK9BX	DE	Bacterial infection; Tuberculosis

DMRFO34	ID	DMRFO34
DMRFO34	DN	SR 16234
DMRFO34	HS	Phase 2
DMRFO34	SN	229634-98-4; TS 108; TAS-108; SR 16234; SR16234; UNII-9B29N23K7E; 9B29N23K7E; SCHEMBL2836841; DTXSID30177512; C33H47NO3.C6H8O7; (7alpha)-21-(4-((Diethylamino)methyl)-2-methoxyphenoxy)-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate; Y1847; 354808-47-2; (7R,8S,9S,13R,14S,17R)-17-(2-(4-((Diethylamino)methyl)-2-methoxyphenoxy)ethyl)-7,13-dimethyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol 2-hydroxypropane-1,2,3-tricarboxylate
DMRFO34	CP	SRI International
DMRFO34	DT	Small molecular drug
DMRFO34	PC	9874874
DMRFO34	MW	697.9
DMRFO34	FM	C39H55NO10
DMRFO34	IC	InChI=1S/C33H47NO3.C6H8O7/c1-6-34(7-2)21-23-8-13-30(31(19-23)36-5)37-17-15-25-9-12-29-32-22(3)18-24-20-26(35)10-11-27(24)28(32)14-16-33(25,29)4;7-3(8)1-6(13,5(11)12)2-4(9)10/h8,10-11,13,19-20,22,25,28-29,32,35H,6-7,9,12,14-18,21H2,1-5H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t22-,25-,28-,29+,32-,33-;/m1./s1
DMRFO34	CS	CCN(CC)CC1=CC(=C(C=C1)OCC[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3[C@@H](CC5=C4C=CC(=C5)O)C)C)OC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMRFO34	IK	VOHOCSJONOJOSD-SCIDSJFVSA-N
DMRFO34	IU	(7R,8S,9S,13R,14S,17R)-17-[2-[4-(diethylaminomethyl)-2-methoxyphenoxy]ethyl]-7,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol;2-hydroxypropane-1,2,3-tricarboxylic acid
DMRFO34	CA	CAS 229634-98-4
DMRFO34	DE	Breast cancer

DMNAECP	ID	DMNAECP
DMNAECP	DN	SR-147778
DMNAECP	HS	Phase 2
DMNAECP	SN	Surinabant; SR-147778; UNII-SF8R9VCB0X; 288104-79-0; SR147778; SR 147778; SF8R9VCB0X; CHEMBL189676; Surinabant [INN]; DSSTox_CID_27357; DSSTox_RID_82293; DSSTox_GSID_47357; SCHEMBL675894; GTPL9233; DTXSID2047357; CHEBI:125484; ZINC1549068; Tox21_300239; BDBM50171290; DB13070; NCGC00254070-01; NCGC00247959-01; 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide; LS-193786; FT-0766481; CAS-288104-79-0; BRD-K09557221-001-01-6
DMNAECP	DT	Small molecular drug
DMNAECP	PC	9849616
DMNAECP	MW	522.299
DMNAECP	FM	C23H23BrCl2N4O
DMNAECP	IC	InChI=1S/C23H23BrCl2N4O/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14H,2-5,12-13H2,1H3,(H,28,31)
DMNAECP	CS	CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Br
DMNAECP	IK	HMXDWDSNPRNUKI-UHFFFAOYSA-N
DMNAECP	IU	5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMNAECP	CA	CAS 288104-79-0
DMNAECP	CB	CHEBI:125484
DMNAECP	DE	Obesity

DMFDA4Y	ID	DMFDA4Y
DMFDA4Y	DN	SR-2640
DMFDA4Y	HS	Phase 2
DMFDA4Y	SN	SR 2640; SR-2640; SR 2640 Hydrochloride; 105350-26-3; CHEMBL18132; SR2640; Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]amino]-; QMPB; Benzoic acid, 2-((3-(2-quinolinylmethoxy)phenyl)amino)-; SR-01000076219; Tocris-1804; Lopac-S-7690; AC1L2TN9; Lopac0_001079; 2-(3-(2-Quinolylmethoxy)phenylamino)benzoic acid; MLS002153402; cid_128355; GTPL3329; SCHEMBL9119607; CTK8F0698; CHEBI:104023; HMS3263G20; HMS2236C03; ZINC596951; HMS3373N15; Tox21_501079; BDBM50006798; AKOS030239522; LP01079; CCG-205156; NCGC00015965-02; NCGC00015965-04
DMFDA4Y	DT	Small molecular drug
DMFDA4Y	PC	128355
DMFDA4Y	MW	370.4
DMFDA4Y	FM	C23H18N2O3
DMFDA4Y	IC	InChI=1S/C23H18N2O3/c26-23(27)20-9-2-4-11-22(20)24-17-7-5-8-19(14-17)28-15-18-13-12-16-6-1-3-10-21(16)25-18/h1-14,24H,15H2,(H,26,27)
DMFDA4Y	CS	C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=CC(=C3)NC4=CC=CC=C4C(=O)O
DMFDA4Y	IK	LMPZHLXYBWGGNT-UHFFFAOYSA-N
DMFDA4Y	IU	2-[3-(quinolin-2-ylmethoxy)anilino]benzoic acid
DMFDA4Y	CA	CAS 105350-26-3
DMFDA4Y	CB	CHEBI:104023
DMFDA4Y	DE	Asthma

DMQSN7B	ID	DMQSN7B
DMQSN7B	DN	SR-31747
DMQSN7B	HS	Phase 2
DMQSN7B	SN	SR-317417A
DMQSN7B	CP	Sanofi-aventis; Sanofi-Synthelabo
DMQSN7B	DT	Small molecular drug
DMQSN7B	PC	6439330
DMQSN7B	MW	396.4
DMQSN7B	FM	C23H35Cl2N
DMQSN7B	IC	InChI=1S/C23H34ClN.ClH/c1-2-25(21-13-7-4-8-14-21)17-9-10-19-15-16-22(23(24)18-19)20-11-5-3-6-12-20;/h9-10,15-16,18,20-21H,2-8,11-14,17H2,1H3;1H/b10-9-;
DMQSN7B	CS	CCN(C/C=C\\C1=CC(=C(C=C1)C2CCCCC2)Cl)C3CCCCC3.Cl
DMQSN7B	IK	HKHPCMBPASXYGP-KVVVOXFISA-N
DMQSN7B	IU	N-[(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]-N-ethylcyclohexanamine;hydrochloride
DMQSN7B	CA	CAS 132173-07-0
DMQSN7B	DE	Rheumatoid arthritis

DMTOCIV	ID	DMTOCIV
DMTOCIV	DN	SR-43845
DMTOCIV	HS	Phase 2
DMTOCIV	SN	N-[3-(3-Pyridyl)propionyl]-L-phenylalanyl-L-histidyl-cyclostatinyl-L-isoleucyl-1,1-di(hydroxymethyl)ethylamide; N-[3-(3-Pyridyl)propionyl]-L-phenylalanyl-L-histidyl-(3S,4S)-4-amino-3-hydroxy-5-cyclohexylpentanoyl-L-isoleucyl-1,1-di(hydroxymethyl)ethylamide; [S-(R*,R*)]-5-Cyclohexyl-2,4,5-trideoxy-N-[1-[[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]carbonyl]-2-methylbutyl]-4-[[N-[N-[1-oxo-3-(3-pyridinyl)propyl]-L-phenylalanyl]-L-histidyl]amino-L-threo
DMTOCIV	DT	Small molecular drug
DMTOCIV	PC	163918
DMTOCIV	MW	833
DMTOCIV	FM	C44H64N8O8
DMTOCIV	IC	InChI=1S/C44H64N8O8/c1-4-29(2)40(43(60)52-44(3,26-53)27-54)51-39(57)23-37(55)34(20-30-12-7-5-8-13-30)49-42(59)36(22-33-25-46-28-47-33)50-41(58)35(21-31-14-9-6-10-15-31)48-38(56)18-17-32-16-11-19-45-24-32/h6,9-11,14-16,19,24-25,28-30,34-37,40,53-55H,4-5,7-8,12-13,17-18,20-23,26-27H2,1-3H3,(H,46,47)(H,48,56)(H,49,59)(H,50,58)(H,51,57)(H,52,60)
DMTOCIV	CS	CCC(C)C(C(=O)NC(C)(CO)CO)NC(=O)CC(C(CC1CCCCC1)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC3=CC=CC=C3)NC(=O)CCC4=CN=CC=C4)O
DMTOCIV	IK	NZGWKVVFXREROW-UHFFFAOYSA-N
DMTOCIV	IU	2-[[5-cyclohexyl-3-hydroxy-4-[[3-(1H-imidazol-5-yl)-2-[[3-phenyl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]propanoyl]amino]pentanoyl]amino]-N-(1,3-dihydroxy-2-methylpropan-2-yl)-3-methylpentanamide
DMTOCIV	CA	CAS 114037-60-4
DMTOCIV	DE	Glaucoma/ocular hypertension

DMW6UA3	ID	DMW6UA3
DMW6UA3	DN	SR-46559A
DMW6UA3	HS	Phase 2
DMW6UA3	SN	6-[2-(Diethylamino)-2-methylpropylamino]-3-phenyl-4-propylpyridazine sesquifumarate
DMW6UA3	DT	Small molecular drug
DMW6UA3	PC	57348184
DMW6UA3	MW	1029.2
DMW6UA3	FM	C54H76N8O12
DMW6UA3	IC	InChI=1S/2C21H32N4.3C4H4O4/c2*1-6-12-18-15-19(22-16-21(4,5)25(7-2)8-3)23-24-20(18)17-13-10-9-11-14-17;3*5-3(6)1-2-4(7)8/h2*9-11,13-15H,6-8,12,16H2,1-5H3,(H,22,23);3*1-2H,(H,5,6)(H,7,8)
DMW6UA3	CS	CCCC1=CC(=NN=C1C2=CC=CC=C2)NCC(C)(C)N(CC)CC.CCCC1=CC(=NN=C1C2=CC=CC=C2)NCC(C)(C)N(CC)CC.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O
DMW6UA3	IK	AEOGOPZZLSQJKM-UHFFFAOYSA-N
DMW6UA3	IU	but-2-enedioic acid;2-N,2-N-diethyl-2-methyl-1-N-(6-phenyl-5-propylpyridazin-3-yl)propane-1,2-diamine
DMW6UA3	CA	CAS 137733-33-6
DMW6UA3	DE	Cognitive impairment

DM5GAC4	ID	DM5GAC4
DM5GAC4	DN	SRD-441
DM5GAC4	HS	Phase 2
DM5GAC4	SN	Aureostat; ST-441; STP-01a; Protease inhibitor (atopic dermatitis), Surface Therapeutics
DM5GAC4	CP	Surface Therapeutics Ltd
DM5GAC4	DE	Atopic dermatitis

DMYAXNM	ID	DMYAXNM
DMYAXNM	DN	SRK-015
DMYAXNM	HS	Phase 2
DMYAXNM	SN	Apitegromab
DMYAXNM	CP	Scholar Rock
DMYAXNM	DT	Antibody
DMYAXNM	DE	Spinal muscular atrophy

DMR09IH	ID	DMR09IH
DMR09IH	DN	SRP-9001
DMR09IH	HS	Phase 2
DMR09IH	CP	Sarepta Therapeutics
DMR09IH	DT	Gene therapy
DMR09IH	DE	Duchenne dystrophy

DMKOTUJ	ID	DMKOTUJ
DMKOTUJ	DN	SRX246
DMKOTUJ	HS	Phase 2
DMKOTUJ	CP	Azevan Pharmaceuticals
DMKOTUJ	DT	Small molecular drug
DMKOTUJ	DE	Fear-related disorder; Anxiety disorder; Intermittent explosive disorder; Huntington disease; Post-traumatic stress disorder

DMMU41F	ID	DMMU41F
DMMU41F	DN	SRX-246
DMMU41F	HS	Phase 2
DMMU41F	SN	AVN-518; SRX-246-HCI; Vasopressin V1a antagonist (capsule/oral, stress-related affective illness/anxiety), Azevan Pharmaceutoicals
DMMU41F	CP	Azevan Pharmaceuticals Inc
DMMU41F	DT	Small molecular drug
DMMU41F	PC	44428550
DMMU41F	MW	703.9
DMMU41F	FM	C42H49N5O5
DMMU41F	IC	InChI=1S/C42H49N5O5/c1-30(32-16-8-3-9-17-32)43-40(49)36(28-38(48)45-26-22-34(23-27-45)44-24-12-5-13-25-44)46-35(21-20-31-14-6-2-7-15-31)39(41(46)50)47-37(29-52-42(47)51)33-18-10-4-11-19-33/h2-4,6-11,14-21,30,34-37,39H,5,12-13,22-29H2,1H3,(H,43,49)/b21-20+/t30-,35-,36-,37-,39+/m1/s1
DMMU41F	CS	C[C@H](C1=CC=CC=C1)NC(=O)[C@@H](CC(=O)N2CCC(CC2)N3CCCCC3)N4[C@@H]([C@@H](C4=O)N5[C@H](COC5=O)C6=CC=CC=C6)/C=C/C7=CC=CC=C7
DMMU41F	IK	FJUKOXWSIGULLE-JVOQCOEYSA-N
DMMU41F	IU	(2R)-4-oxo-2-[(3S,4R)-2-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]-4-[(E)-2-phenylethenyl]azetidin-1-yl]-N-[(1R)-1-phenylethyl]-4-(4-piperidin-1-ylpiperidin-1-yl)butanamide
DMMU41F	CA	CAS 512784-93-9
DMMU41F	DE	Anxiety disorder; Post-traumatic stress disorder

DMGJEB8	ID	DMGJEB8
DMGJEB8	DN	SSR125543
DMGJEB8	HS	Phase 2
DMGJEB8	SN	SSR 125543; 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine
DMGJEB8	CP	Sanofi-Aventis
DMGJEB8	DT	Small molecular drug
DMGJEB8	PC	5282340
DMGJEB8	MW	483
DMGJEB8	FM	C27H28ClFN2OS
DMGJEB8	IC	InChI=1S/C27H28ClFN2OS/c1-6-11-31(24(13-19-8-9-19)20-10-7-16(2)23(29)14-20)27-30-26(18(4)33-27)21-12-17(3)25(32-5)15-22(21)28/h1,7,10,12,14-15,19,24H,8-9,11,13H2,2-5H3/t24-/m0/s1
DMGJEB8	CS	CC1=C(C=C(C=C1)[C@H](CC2CC2)N(CC#C)C3=NC(=C(S3)C)C4=C(C=C(C(=C4)C)OC)Cl)F
DMGJEB8	IK	IEAKXXNRGSLYTQ-DEOSSOPVSA-N
DMGJEB8	IU	4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine
DMGJEB8	CA	CAS 752253-39-7
DMGJEB8	CB	CHEBI:34969
DMGJEB8	DE	Anxiety disorder; Congenital adrenal hyperplasia

DMCMD93	ID	DMCMD93
DMCMD93	DN	SSR149415
DMCMD93	HS	Phase 2
DMCMD93	SN	Nelivaptan; SSR 149415; 439687-69-1; UNII-3TY57MQ4OA; SR-149415; SSR-149415; 3TY57MQ4OA; CHEMBL582857; Nelivaptan [INN]; DSSTox_CID_27358; DSSTox_RID_82294; DSSTox_GSID_47358; GTPL2202; DTXSID7047358; SCHEMBL14517029; MolPort-042-665-640; Tox21_300240; BDBM50299343; ZINC42833251; DB12643; SSR-149,415; NCGC00254222-01; NCGC00247960-01; CAS-439687-69-1; (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide;  Nelivaptan; 1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide
DMCMD93	CP	Sanofi-Aventis
DMCMD93	DT	Small molecular drug
DMCMD93	PC	9895468
DMCMD93	MW	630.1
DMCMD93	FM	C30H32ClN3O8S
DMCMD93	IC	InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1
DMCMD93	CS	CN(C)C(=O)[C@@H]1C[C@H](CN1[C@]2(C3=C(C=CC(=C3)Cl)N(C2=O)S(=O)(=O)C4=C(C=C(C=C4)OC)OC)C5=CC=CC=C5OC)O
DMCMD93	IK	NJXZWIIMWNEOGJ-WEWKHQNJSA-N
DMCMD93	IU	(2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide
DMCMD93	CA	CAS 439687-69-1
DMCMD93	DE	Anxiety disorder; Major depressive disorder

DMA0QZH	ID	DMA0QZH
DMA0QZH	DN	SSR-180575
DMA0QZH	HS	Phase 2
DMA0QZH	SN	2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide
DMA0QZH	DT	Small molecular drug
DMA0QZH	PC	9930560
DMA0QZH	MW	394.9
DMA0QZH	FM	C21H19ClN4O2
DMA0QZH	IC	InChI=1S/C21H19ClN4O2/c1-24(2)18(27)12-16-19-15-10-9-13(22)11-17(15)25(3)20(19)21(28)26(23-16)14-7-5-4-6-8-14/h4-11H,12H2,1-3H3
DMA0QZH	CS	CN1C2=C(C=CC(=C2)Cl)C3=C1C(=O)N(N=C3CC(=O)N(C)C)C4=CC=CC=C4
DMA0QZH	IK	HJSQVJOROCIILI-UHFFFAOYSA-N
DMA0QZH	IU	2-(7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide
DMA0QZH	CA	CAS 220448-02-2
DMA0QZH	DE	Rheumatoid arthritis

DMVZ01T	ID	DMVZ01T
DMVZ01T	DN	SSR240600
DMVZ01T	HS	Phase 2
DMVZ01T	SN	Burapitant; SSR-240600; SCHEMBL1281822; CHEMBL3544947; BDBM86055; SSR-240600C; AN-27922; L001672
DMVZ01T	DT	Small molecular drug
DMVZ01T	PC	9917944
DMVZ01T	MW	682.5
DMVZ01T	FM	C31H35Cl2F6N3O3
DMVZ01T	IC	InChI=1S/C31H35Cl2F6N3O3/c1-28(2,27(40)44)20-5-8-41(9-6-20)10-7-29(21-3-4-24(32)25(33)17-21)18-42(11-12-45-29)26(43)15-19-13-22(30(34,35)36)16-23(14-19)31(37,38)39/h3-4,13-14,16-17,20H,5-12,15,18H2,1-2H3,(H2,40,44)
DMVZ01T	CS	CC(C)(C1CCN(CC1)CCC2(CN(CCO2)C(=O)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=CC(=C(C=C4)Cl)Cl)C(=O)N
DMVZ01T	IK	ZLNYUCXXSDDIFU-UHFFFAOYSA-N
DMVZ01T	IU	2-[1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]piperidin-4-yl]-2-methylpropanamide
DMVZ01T	DE	Urinary incontinence

DMFNZPY	ID	DMFNZPY
DMFNZPY	DN	SSR-240612
DMFNZPY	HS	Phase 2
DMFNZPY	SN	N2-[3(R)-(1,3-Benzodioxol-5-yl)-3-(6-methoxynaphthalen-2-ylsulfonamido)propionyl]-4-[2(R),6(S)-dimethylpiperidin-1-ylmethyl]-N1-isopropyl-N1-methyl-D-phenylalaninamide hydrochloride
DMFNZPY	DT	Small molecular drug
DMFNZPY	PC	44235958
DMFNZPY	MW	793.4
DMFNZPY	FM	C42H53ClN4O7S
DMFNZPY	IC	InChI=1S/C42H52N4O7S.ClH/c1-27(2)45(5)42(48)38(20-30-10-12-31(13-11-30)25-46-28(3)8-7-9-29(46)4)43-41(47)24-37(34-16-19-39-40(23-34)53-26-52-39)44-54(49,50)36-18-15-32-21-35(51-6)17-14-33(32)22-36;/h10-19,21-23,27-29,37-38,44H,7-9,20,24-26H2,1-6H3,(H,43,47);1H/t28-,29+,37-,38-;/m1./s1
DMFNZPY	CS	C[C@@H]1CCC[C@@H](N1CC2=CC=C(C=C2)C[C@H](C(=O)N(C)C(C)C)NC(=O)C[C@H](C3=CC4=C(C=C3)OCO4)NS(=O)(=O)C5=CC6=C(C=C5)C=C(C=C6)OC)C.Cl
DMFNZPY	IK	GLHHFOSVBQQNAW-GDYXXZBVSA-N
DMFNZPY	IU	(2R)-2-[[(3R)-3-(1,3-benzodioxol-5-yl)-3-[(6-methoxynaphthalen-2-yl)sulfonylamino]propanoyl]amino]-3-[4-[[(2S,6R)-2,6-dimethylpiperidin-1-yl]methyl]phenyl]-N-methyl-N-propan-2-ylpropanamide;hydrochloride
DMFNZPY	CA	CAS 464930-42-5
DMFNZPY	DE	Rheumatoid arthritis

DMGTB2Q	ID	DMGTB2Q
DMGTB2Q	DN	SSR411298
DMGTB2Q	HS	Phase 2
DMGTB2Q	CP	Sanofi-Aventis
DMGTB2Q	DE	Major depressive disorder

DMRGTZ2	ID	DMRGTZ2
DMRGTZ2	DN	SSTarbaclofen
DMRGTZ2	HS	Phase 2
DMRGTZ2	CP	Seaside Therapeutics; Roche
DMRGTZ2	DE	Fragile X syndrome; Autism spectrum disorder

DMH4C3M	ID	DMH4C3M
DMH4C3M	DN	STA-5326
DMH4C3M	HS	Phase 2
DMH4C3M	SN	Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DMH4C3M	CP	Synta Pharma
DMH4C3M	DT	Small molecular drug
DMH4C3M	PC	10173277
DMH4C3M	MW	418.5
DMH4C3M	FM	C23H26N6O2
DMH4C3M	IC	InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+
DMH4C3M	CS	CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4
DMH4C3M	IK	HSKAZIJJKRAJAV-KOEQRZSOSA-N
DMH4C3M	IU	N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DMH4C3M	CA	CAS 541550-19-0
DMH4C3M	DE	Rheumatoid arthritis; Crohn disease

DMEG4TC	ID	DMEG4TC
DMEG4TC	DN	Stannsoporfin
DMEG4TC	HS	Phase 2
DMEG4TC	SN	SNMPP; Stanate; Sn Mesoporphyrin; Tin mesoporphyrin; Stanate (TN); Stannsoporfin (USAN/INN)
DMEG4TC	CP	InfaCare Pharma.
DMEG4TC	DT	Small molecular drug
DMEG4TC	PC	23725028
DMEG4TC	MW	754.3
DMEG4TC	FM	C34H36Cl2N4O4Sn
DMEG4TC	IC	InChI=1S/C34H38N4O4.2ClH.Sn/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;;;/h13-16H,7-12H2,1-6H3,(H4,35,36,37,38,39,40,41,42);2*1H;/q;;;+4/p-4
DMEG4TC	CS	[H+].[H+].CCC1=C(C2=NC1=CC3=C(C(=C([N-]3)C=C4C(=C(C(=CC5=NC(=C2)C(=C5C)CC)[N-]4)C)CCC(=O)[O-])CCC(=O)[O-])C)C.[Cl-].[Cl-].[Sn+4]
DMEG4TC	IK	LLDZJTIZVZFNCM-UHFFFAOYSA-J
DMEG4TC	IU	3-[18-(2-carboxylatoethyl)-8,13-diethyl-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate;hydron;tin(4+);dichloride
DMEG4TC	DE	Neonatal hyperbilirubinemia

DMJ1DIB	ID	DMJ1DIB
DMJ1DIB	DN	S-tenatoprazole
DMJ1DIB	HS	Phase 2
DMJ1DIB	SN	Benatoprazole; Protop; Tenatoprazole; Ulsacare; STU-199; STU-Na; TU-199; S-tenatoprazole-Na
DMJ1DIB	CP	Mitsubishi-Tokyo Pharmaceuticals Inc
DMJ1DIB	DE	Peptic ulcer

DMKVBL8	ID	DMKVBL8
DMKVBL8	DN	Stenoparib
DMKVBL8	HS	Phase 2
DMKVBL8	CP	Allarity Therapeutics
DMKVBL8	DT	Small molecular drug
DMKVBL8	DE	Ovarian cancer

DMR9COG	ID	DMR9COG
DMR9COG	DN	STX-100
DMR9COG	HS	Phase 2
DMR9COG	CP	Biogen Idec
DMR9COG	DE	Idiopathic pulmonary fibrosis

DMLNKX7	ID	DMLNKX7
DMLNKX7	DN	STX-107
DMLNKX7	HS	Phase 2
DMLNKX7	SN	2-Methyl-4-(pyridin-3-ylethynyl)thiazole; MTEP; mGluR5 Antagonist, MTEP; 329205-68-7; 2-methyl-4-(pyridin-3-ylethynyl)thiazole; CHEMBL292065; 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine; 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; 3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; 3-(2-(2-methylthiazol-4-yl)ethynyl)pyridine; 3-[2-(2-Methylthiazol-4-yl)ethynyl]pyridine; 3-(2-Methyl-thiazol-4-ylethynyl)-pyridine; SCHEMBL187254; GTPL3336; CTK1B8867; DTXSID30430775; ZINC1489321; IN1238; BDBM50122758; FCH3417361; API0006876; ACN-027361; KB-274670
DMLNKX7	CP	Merck Research Laboratories
DMLNKX7	DT	Small molecular drug
DMLNKX7	PC	16662948
DMLNKX7	MW	319.4
DMLNKX7	FM	C18H10FN3S
DMLNKX7	IC	InChI=1S/C18H10FN3S/c1-12-22-17(11-23-12)4-2-13-3-5-18(21-10-13)15-6-14(9-20)7-16(19)8-15/h3,5-8,10-11H,1H3
DMLNKX7	CS	CC1=NC(=CS1)C#CC2=CN=C(C=C2)C3=CC(=CC(=C3)C#N)F
DMLNKX7	IK	SYOSUEIMOYEGKU-UHFFFAOYSA-N
DMLNKX7	IU	3-fluoro-5-[5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridin-2-yl]benzonitrile
DMLNKX7	CA	CAS 935685-90-8
DMLNKX7	DE	Autism spectrum disorder

DMJK5CT	ID	DMJK5CT
DMJK5CT	DN	STX-140
DMJK5CT	HS	Phase 2
DMJK5CT	SN	(9beta,13alpha,14beta,17alpha)-2-Methoxyestra-1,3,5(10)-Triene-3,17-Diyl Disulfamate; STX140; CHEMBL218382; 2-MeOE2bisMATE; 2-methoxyestradiol-3,17-O,O-bis-sulfamate; STX 140; 2-MeOEbisMATE; 2gd8; 2-methoxyestradiol 3,17-O,O-bis-sulfamate; 2-MbM; 2-methoxyestradiol-3,17-O,O-bis(sulfamate); SCHEMBL446846; BDBM50200936; DB08416; (9beta,17beta)-2-methoxyestra-1,3,5(10)-triene-3,17-diyl disulfamate; Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, disulfamate, (17beta)-; 401600-86-0; Angiomates; Estrone sulphatase inhibitors, Ipsen; STX-213; STX-641; Steroid sulfatase inhibitors, Sterix Ltd; 2-MeOE2-bis MATE; 2-MeSEMATE; 2-ethyl-estradiol bis-sulfamate; 2-methoxyestradiol, Sterix; 2-methoxyestradiol-bis-sulfamate; 2-methoxyestradiol-bis-sulfamate, Sterix
DMJK5CT	CP	EntreMed
DMJK5CT	DT	Small molecular drug
DMJK5CT	PC	9804302
DMJK5CT	MW	460.6
DMJK5CT	FM	C19H28N2O7S2
DMJK5CT	IC	InChI=1S/C19H28N2O7S2/c1-19-8-7-12-13(15(19)5-6-18(19)28-30(21,24)25)4-3-11-9-17(27-29(20,22)23)16(26-2)10-14(11)12/h9-10,12-13,15,18H,3-8H2,1-2H3,(H2,20,22,23)(H2,21,24,25)/t12-,13+,15-,18-,19-/m0/s1
DMJK5CT	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=CC(=C(C=C34)OC)OS(=O)(=O)N
DMJK5CT	IK	AQSNIXKAKUZPSI-SSTWWWIQSA-N
DMJK5CT	IU	[(8R,9S,13S,14S,17S)-2-methoxy-13-methyl-3-sulfamoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMJK5CT	CA	CAS 401600-86-0
DMJK5CT	DE	Osteoporosis

DMO9LBE	ID	DMO9LBE
DMO9LBE	DN	SUN N4057
DMO9LBE	HS	Phase 2
DMO9LBE	SN	Piclozotan; UNII-FQE44HS7AH; FQE44HS7AH; CHEMBL345237; 182415-09-4; SUN N4057; Piclozotan [INN]; 3-Chloro-4-(4-(4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl)butyl)-1,4-benzoxazepin-5(4H)-one; SCHEMBL562627; URMTUEWUIGOJBW-UHFFFAOYSA-N; SUN N-4057; BDBM50097342; DB12361; L001621; 3-Chloro-4-[4-(3'',6''-dihydro-2''H-[2,4'']bipyridinyl-1''-yl)-butyl]-4H-benzo[f][1,4]oxazepin-5-one; 3-chloro-4,5-dihydro-4-(4-(4-(2-pyridyl)-1,2,5,6-tetrahydropyridin-1-yl)butyl)-1,4-benzoxazepin-5-one
DMO9LBE	DT	Small molecular drug
DMO9LBE	PC	9801640
DMO9LBE	MW	409.9
DMO9LBE	FM	C23H24ClN3O2
DMO9LBE	IC	InChI=1S/C23H24ClN3O2/c24-22-17-29-21-9-2-1-7-19(21)23(28)27(22)14-6-5-13-26-15-10-18(11-16-26)20-8-3-4-12-25-20/h1-4,7-10,12,17H,5-6,11,13-16H2
DMO9LBE	CS	C1CN(CC=C1C2=CC=CC=N2)CCCCN3C(=COC4=CC=CC=C4C3=O)Cl
DMO9LBE	IK	URMTUEWUIGOJBW-UHFFFAOYSA-N
DMO9LBE	IU	3-chloro-4-[4-(4-pyridin-2-yl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1,4-benzoxazepin-5-one
DMO9LBE	CA	CAS 182415-09-4
DMO9LBE	DE	Coronary artery disease

DMPK34E	ID	DMPK34E
DMPK34E	DN	Sun13834
DMPK34E	HS	Phase 2
DMPK34E	SN	Trifluperidol; Trisedil; Triperidol; Psychoperidol; Flumoperone; Psicoperidol; Trisedyl; Psicoperidol-R; McN-JR-2498; 749-13-3; Trifluperidolo; Trifluperidolo [DCIT]; R-2498; Trifluperidolo [Italian]; Trifluperidolum [INN-Latin]; NSC 170978; UNII-R8869Q7R8I; Trifluperidol [USAN:INN:BAN]; P 459; BRN 1556208; CHEMBL15023; 1-Butanone, 1-(4-fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)-1-piperidinyl)-; GPMXUUPHFNMNDH-UHFFFAOYSA-N; R8869Q7R8I; NSC170978; Triperidol (TN)
DMPK34E	CP	Wyeth
DMPK34E	DT	Small molecular drug
DMPK34E	PC	5567
DMPK34E	MW	409.4
DMPK34E	FM	C22H23F4NO2
DMPK34E	IC	InChI=1S/C22H23F4NO2/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26/h1,3-4,6-9,15,29H,2,5,10-14H2
DMPK34E	CS	C1CN(CCC1(C2=CC(=CC=C2)C(F)(F)F)O)CCCC(=O)C3=CC=C(C=C3)F
DMPK34E	IK	GPMXUUPHFNMNDH-UHFFFAOYSA-N
DMPK34E	IU	1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one
DMPK34E	CA	CAS 749-13-3
DMPK34E	CB	CHEBI:135662
DMPK34E	DE	Gram-positive bacterial infection

DMSWPA6	ID	DMSWPA6
DMSWPA6	DN	Superoxide dismutase
DMSWPA6	HS	Phase 2
DMSWPA6	SN	Orgotein; HSOD, Yeda; Manganese SOD, Boehringer Ingelheim; NK-341; Orgotein, Yeda; SOD, Yeda; Superoxide dismutase, Boehringer Ingelheim; Superoxide dismutase, Nippon; Superoxide dismutase, Yeda; HSOD, Bio-Technology General; Orgotein, Bio-Technology General; SOD, Bio-Technology General; Superoxide dismutase, Bio-Technology
DMSWPA6	CP	Weizmann Institute of Science; Nippon Kayaku Co Ltd; Boehringer Ingelheim Corp
DMSWPA6	DE	Myocardial infarction

DMAIGTE	ID	DMAIGTE
DMAIGTE	DN	SurVaxM
DMAIGTE	HS	Phase 2
DMAIGTE	CP	MimiVax Rochester, NY
DMAIGTE	DE	Multiple myeloma; Glioblastoma of brain

DM2KQ71	ID	DM2KQ71
DM2KQ71	DN	Sutezolid
DM2KQ71	HS	Phase 2
DM2KQ71	SN	PF-02341272; PF-2341272; PNU-100480; PNU-101244; PNU-101603; U-100480; U-101244; U-101603; U-94901
DM2KQ71	CP	Sequella
DM2KQ71	DT	Small molecular drug
DM2KQ71	PC	465951
DM2KQ71	MW	353.4
DM2KQ71	FM	C16H20FN3O3S
DM2KQ71	IC	InChI=1S/C16H20FN3O3S/c1-11(21)18-9-13-10-20(16(22)23-13)12-2-3-15(14(17)8-12)19-4-6-24-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
DM2KQ71	CS	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCSCC3)F
DM2KQ71	IK	FNDDDNOJWPQCBZ-ZDUSSCGKSA-N
DM2KQ71	IU	N-[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
DM2KQ71	CA	CAS 168828-58-8
DM2KQ71	DE	Tuberculosis

DMQD753	ID	DMQD753
DMQD753	DN	SUVN-502
DMQD753	HS	Phase 2
DMQD753	SN	SVN-502; 5-HT 6 receptor antagonist (Alzheimer's disease), Suven; 5-HT 6 receptor antagonist (cognitive/memory disorder), Suven
DMQD753	CP	Suven Life Sciences
DMQD753	DT	Small molecular drug
DMQD753	PC	10073773
DMQD753	MW	478.4
DMQD753	FM	C21H24BrN3O3S
DMQD753	IC	InChI=1S/C21H24BrN3O3S/c1-23-9-11-24(12-10-23)14-16-15-25(20-8-7-17(28-2)13-18(16)20)29(26,27)21-6-4-3-5-19(21)22/h3-8,13,15H,9-12,14H2,1-2H3
DMQD753	CS	CN1CCN(CC1)CC2=CN(C3=C2C=C(C=C3)OC)S(=O)(=O)C4=CC=CC=C4Br
DMQD753	IK	GWCYPEHWIZXYFZ-UHFFFAOYSA-N
DMQD753	IU	1-(2-bromophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole
DMQD753	CA	CAS 701205-60-9
DMQD753	DE	Neurological disorder; Alzheimer disease

DMZV27P	ID	DMZV27P
DMZV27P	DN	SXC-2023
DMZV27P	HS	Phase 2
DMZV27P	CP	Promentis Pharmaceuticals
DMZV27P	DT	Small molecular drug
DMZV27P	DE	Trichotillomania

DMXLE71	ID	DMXLE71
DMXLE71	DN	SYL-040012
DMXLE71	HS	Phase 2
DMXLE71	SN	SYL-0012; Beta 2 adrenoceptor-targeting siRNA (ocular hypertension), Sylentis
DMXLE71	CP	Sylentis Sau
DMXLE71	DT	siRNA drug
DMXLE71	DE	Ocular hypertension

DMDF7XB	ID	DMDF7XB
DMDF7XB	DN	SYN120
DMDF7XB	HS	Phase 2
DMDF7XB	SN	Landipirdine; 1000308-25-7; UNII-J0NX985GDI; J0NX985GDI; CHEMBL1082508; RO5025181; RO5025181-000; N-(((1R)-6-(3-fluorobenzenesulfonyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)urea; Landipirdine [USAN]; Landipirdine (USAN/INN); SCHEMBL315956; SYN-120; BDBM50416003; SB18761; D11157; Q27896229; R05025181; R0-5025181; R0-5025181-000; R05025181-000; (R)-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea; [(1R)-6-(3-fluorophenyl)sulfonyl-1,2,3,4-tetrahydronaphthalen-1-yl]methylurea; Urea, N-(((1R)-6-((3-fluorophenyl)sulfonyl)-1,2,3,4-tetrahydro-1-naphthalenyl)methyl)-
DMDF7XB	CP	Acorda Therapeutics
DMDF7XB	DT	Small molecular drug
DMDF7XB	PC	46220503
DMDF7XB	MW	362.4
DMDF7XB	FM	C18H19FN2O3S
DMDF7XB	IC	InChI=1S/C18H19FN2O3S/c19-14-5-2-6-15(10-14)25(23,24)16-7-8-17-12(9-16)3-1-4-13(17)11-21-18(20)22/h2,5-10,13H,1,3-4,11H2,(H3,20,21,22)/t13-/m0/s1
DMDF7XB	CS	C1C[C@H](C2=C(C1)C=C(C=C2)S(=O)(=O)C3=CC=CC(=C3)F)CNC(=O)N
DMDF7XB	IK	MTTHRRVVGMPYQG-ZDUSSCGKSA-N
DMDF7XB	IU	[(1R)-6-(3-fluorophenyl)sulfonyl-1,2,3,4-tetrahydronaphthalen-1-yl]methylurea
DMDF7XB	CA	CAS 1000308-25-7
DMDF7XB	DE	Parkinson disease

DMPW0UL	ID	DMPW0UL
DMPW0UL	DN	SYN-120
DMPW0UL	HS	Phase 2
DMPW0UL	CP	Biotie Therapies
DMPW0UL	DE	Alzheimer disease; Parkinson disease

DMF9Z2T	ID	DMF9Z2T
DMF9Z2T	DN	T-2007
DMF9Z2T	HS	Phase 2
DMF9Z2T	SN	DPB sodium; Diphenylbarbituric sodium; Diphenylbarbituric acid (epilepsy), Taro; 5,5-diphenylbarbituric sodium
DMF9Z2T	CP	Taro Pharmaceutical Industries Ltd
DMF9Z2T	DE	Epilepsy

DM06GDC	ID	DM06GDC
DM06GDC	DN	T2c-001
DM06GDC	HS	Phase 2
DM06GDC	SN	T2c-001-AMI; T2c-001-CHD; T2c-001-DCM; T2c-001-SW; Autologous bone marrow-derived endothelial progenitor cell therapy, Goethe University/t2cure; Autologous endothelial progenitor cells (myocardial infarction), Goethe University/t2cure; Endothelial progenitor cell therapy (ischemia), Goethe University/t2cure
DM06GDC	CP	Johann Wolfgang Goethe-Universitat Frankfurt am Main
DM06GDC	DE	Congestive heart failure

DM5C70M	ID	DM5C70M
DM5C70M	DN	T-607
DM5C70M	HS	Phase 2
DM5C70M	SN	T-607; AC1LA5AL; 2-[(Ethyl)disulfanyl]-2-methylthioacetamide; 2-(ethyldisulfanyl)-2-methylsulfanylacetamide; 2-(ethyldisulfanyl)-2-methylsulfanyl-acetamide; 92504-EP2298748A2; 92504-EP2295416A2
DM5C70M	CP	Tularik Inc
DM5C70M	DT	Small molecular drug
DM5C70M	PC	462014
DM5C70M	MW	197.3
DM5C70M	FM	C5H11NOS3
DM5C70M	IC	InChI=1S/C5H11NOS3/c1-3-9-10-5(8-2)4(6)7/h5H,3H2,1-2H3,(H2,6,7)
DM5C70M	CS	CCSSC(C(=O)N)SC
DM5C70M	IK	OKTRVIBXCNRKHI-UHFFFAOYSA-N
DM5C70M	IU	2-(ethyldisulfanyl)-2-methylsulfanylacetamide
DM5C70M	DE	Solid tumour/cancer

DMD72F4	ID	DMD72F4
DMD72F4	DN	T-817MA
DMD72F4	HS	Phase 2
DMD72F4	SN	Edonerpic maleate; T-817MA; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:
DMD72F4	CP	Toyama Chemical
DMD72F4	DT	Small molecular drug
DMD72F4	PC	11338749
DMD72F4	MW	407.5
DMD72F4	FM	C20H25NO6S
DMD72F4	IC	InChI=1S/C16H21NO2S.C4H4O4/c18-15-11-17(12-15)6-1-7-19-8-4-13-2-3-16-14(10-13)5-9-20-16;5-3(6)1-2-4(7)8/h2-3,5,9-10,15,18H,1,4,6-8,11-12H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMD72F4	CS	C1C(CN1CCCOCCC2=CC3=C(C=C2)SC=C3)O.C(=C\\C(=O)O)\\C(=O)O
DMD72F4	IK	RLUCYBFCLXANSO-BTJKTKAUSA-N
DMD72F4	IU	1-[3-[2-(1-benzothiophen-5-yl)ethoxy]propyl]azetidin-3-ol;(Z)-but-2-enedioic acid
DMD72F4	CA	CAS 519187-97-4
DMD72F4	DE	Alzheimer disease

DM4JFMZ	ID	DM4JFMZ
DM4JFMZ	DN	T-82
DM4JFMZ	HS	Phase 2
DM4JFMZ	SN	2-[2-(1-Benzylpiperidin-4-yl)ethyl]-9-methoxy-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-one hemifumarate
DM4JFMZ	DT	Small molecular drug
DM4JFMZ	PC	193285
DM4JFMZ	MW	598.2
DM4JFMZ	FM	C31H36ClN3O5S
DM4JFMZ	IC	InChI=1S/C31H36ClN3O5S/c1-37-26-19-22(20-27(38-2)30(26)39-3)31(36)40-18-17-34-15-13-33(14-16-34)11-6-12-35-24-7-4-5-8-28(24)41-29-21-23(32)9-10-25(29)35/h4-5,7-10,19-21H,6,11-18H2,1-3H3
DM4JFMZ	CS	COC1=CC(=CC(=C1OC)OC)C(=O)OCCN2CCN(CC2)CCCN3C4=C(C=C(C=C4)Cl)SC5=CC=CC=C53
DM4JFMZ	IK	KZAJTVRKNKAXAG-UHFFFAOYSA-N
DM4JFMZ	IU	2-[4-[3-(3-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 3,4,5-trimethoxybenzoate
DM4JFMZ	CA	CAS 38455-99-1
DM4JFMZ	DE	Cognitive impairment

DMMWPSQ	ID	DMMWPSQ
DMMWPSQ	DN	TA-2005
DMMWPSQ	HS	Phase 2
DMMWPSQ	SN	Carmoterol hydrochloride; CHF 4226.01; 8-Hydroxy-5-((1R)-1-hydroxy-2-(N-(1R)-2-(p-methoxyphenyl)isopropylamino)ethyl)carbostyril HCl; 8-Hydroxy-5-(1-hydroxy-2-(N-(2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)carbostyril hydrochloride; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one hydrochloride; 8-hydroxy-5-[(1r)-1-hydroxy-2-{[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]quinolin-2(1h)-one hydrochloride(1:1)
DMMWPSQ	CP	Chiesi
DMMWPSQ	DT	Small molecular drug
DMMWPSQ	PC	63951
DMMWPSQ	MW	404.9
DMMWPSQ	FM	C21H25ClN2O4
DMMWPSQ	IC	InChI=1S/C21H24N2O4.ClH/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21;/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26);1H/t13-,19+;/m1./s1
DMMWPSQ	CS	C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O.Cl
DMMWPSQ	IK	SYCWERNQGSKYAG-QVRIGTRMSA-N
DMMWPSQ	IU	8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one;hydrochloride
DMMWPSQ	CA	CAS 100429-08-1
DMMWPSQ	DE	Chronic obstructive pulmonary disease

DMZ7I51	ID	DMZ7I51
DMZ7I51	DN	TA-270
DMZ7I51	HS	Phase 2
DMZ7I51	CP	DIC Corporation
DMZ7I51	PC	54710630
DMZ7I51	MW	524.6
DMZ7I51	FM	C29H36N2O7
DMZ7I51	IC	InChI=1S/C29H36N2O7/c1-5-6-7-8-9-10-15-38-28-26(33)21-13-12-20(18-22(21)31(2)29(28)35)30-25(32)14-11-19-16-23(36-3)27(34)24(17-19)37-4/h11-14,16-18,33-34H,5-10,15H2,1-4H3,(H,30,32)/b14-11+
DMZ7I51	CS	CCCCCCCCOC1=C(C2=C(C=C(C=C2)NC(=O)/C=C/C3=CC(=C(C(=C3)OC)O)OC)N(C1=O)C)O
DMZ7I51	IK	SZNJINHODJLULD-SDNWHVSQSA-N
DMZ7I51	IU	(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-N-(4-hydroxy-1-methyl-3-octoxy-2-oxoquinolin-7-yl)prop-2-enamide
DMZ7I51	DE	Asthma

DMZTAJL	ID	DMZTAJL
DMZTAJL	DN	TA-7906
DMZTAJL	HS	Phase 2
DMZTAJL	SN	T-2585; PDE4 inhibitor (skin disease), Maruho; PDE4 inhibitors (inflammation), Tanabe Seiyaku; T-2585.HCl
DMZTAJL	CP	Tanabe Seiyaku Co Ltd
DMZTAJL	DE	Atopic dermatitis

DMAZHT0	ID	DMAZHT0
DMAZHT0	DN	TA-8995
DMAZHT0	HS	Phase 2
DMAZHT0	SN	Obicetrapib; UNII-8O74K609HN; 8O74K609HN; 866399-87-3; Obicetrapib [INN]; CHEMBL3785197; SCHEMBL17002081; AMG-899; DEZ-001; Obicetrapib (AMG-899 TA-8995); AKOS032954130; HY-18778; 4-((2-(((3,5-Bis(trifluoromethyl)phenyl)methyl)((2R,4S)-1- (ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4- tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic acid; 1(2H)-Quinolinecarboxylic acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl)(5-(3-carboxypropoxy)-2-pyrimidinyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-,
DMAZHT0	CP	Mitsubishi Tanabe Pharma Corp
DMAZHT0	PC	11498596
DMAZHT0	MW	722.6
DMAZHT0	FM	C32H31F9N4O5
DMAZHT0	IC	InChI=1S/C32H31F9N4O5/c1-3-22-14-26(24-13-19(30(33,34)35)7-8-25(24)45(22)29(48)49-4-2)44(28-42-15-23(16-43-28)50-9-5-6-27(46)47)17-18-10-20(31(36,37)38)12-21(11-18)32(39,40)41/h7-8,10-13,15-16,22,26H,3-6,9,14,17H2,1-2H3,(H,46,47)/t22-,26+/m1/s1
DMAZHT0	CS	CC[C@@H]1C[C@@H](C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O
DMAZHT0	IK	NRWORBQAOQVYBJ-GJZUVCINSA-N
DMAZHT0	IU	4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2R,4S)-1-ethoxycarbonyl-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinolin-4-yl]amino]pyrimidin-5-yl]oxybutanoic acid
DMAZHT0	CA	CAS 866399-87-3
DMAZHT0	DE	Hyperlipidaemia; Cardiovascular disease

DMNL9HO	ID	DMNL9HO
DMNL9HO	DN	Tabimorelin
DMNL9HO	HS	Phase 2
DMNL9HO	SN	NN-703; NNC-26-0703; Tabimorelin; N-[5-Amino-5-methyl-2(E)-hexenoyl]-N-methyl-3-(2-naphthyl)-D-alanyl-N-methyl-D-phenylalanine methylamide
DMNL9HO	DT	Small molecular drug
DMNL9HO	PC	9810101
DMNL9HO	MW	528.7
DMNL9HO	FM	C32H40N4O3
DMNL9HO	IC	InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
DMNL9HO	CS	CC(C)(C/C=C/C(=O)N(C)[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N(C)[C@H](CC3=CC=CC=C3)C(=O)NC)N
DMNL9HO	IK	WURGZWOTGMLDJP-ZCYANPAGSA-N
DMNL9HO	IU	(E)-5-amino-N,5-dimethyl-N-[(2R)-1-[methyl-[(2R)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide
DMNL9HO	CA	CAS 193079-69-5
DMNL9HO	DE	Growth hormone deficiency

DMP1873	ID	DMP1873
DMP1873	DN	TAK-063
DMP1873	HS	Phase 2
DMP1873	CP	Takeda
DMP1873	PC	46848915
DMP1873	MW	428.4
DMP1873	FM	C23H17FN6O2
DMP1873	IC	InChI=1S/C23H17FN6O2/c1-32-21-15-29(19-9-8-17(14-18(19)24)28-13-5-11-25-28)27-22(23(21)31)20-10-12-26-30(20)16-6-3-2-4-7-16/h2-15H,1H3
DMP1873	CS	COC1=CN(N=C(C1=O)C2=CC=NN2C3=CC=CC=C3)C4=C(C=C(C=C4)N5C=CC=N5)F
DMP1873	IK	KVHRYLNQDWXAGI-UHFFFAOYSA-N
DMP1873	IU	1-(2-fluoro-4-pyrazol-1-ylphenyl)-5-methoxy-3-(2-phenylpyrazol-3-yl)pyridazin-4-one
DMP1873	CA	CAS 1238697-26-1
DMP1873	DE	Schizophrenia

DMHPEFS	ID	DMHPEFS
DMHPEFS	DN	TAK-128
DMHPEFS	HS	Phase 2
DMHPEFS	SN	Y-128
DMHPEFS	CP	Mitsubishi Pharma Corp
DMHPEFS	DE	Diabetic neuropathy

DM81UAZ	ID	DM81UAZ
DM81UAZ	DN	TAK-272
DM81UAZ	HS	Phase 2
DM81UAZ	CP	Takeda
DM81UAZ	DT	Small molecular drug
DM81UAZ	PC	56591871
DM81UAZ	MW	536.1
DM81UAZ	FM	C27H42ClN5O4
DM81UAZ	IC	InChI=1S/C27H41N5O4.ClH/c1-20(2)19-32(22-16-21(17-28-18-22)26(33)30-11-14-36-15-12-30)27(34)25-29-23-8-4-5-9-24(23)31(25)10-6-7-13-35-3;/h4-5,8-9,20-22,28H,6-7,10-19H2,1-3H3;1H/t21-,22+;/m1./s1
DM81UAZ	CS	CC(C)CN([C@H]1C[C@H](CNC1)C(=O)N2CCOCC2)C(=O)C3=NC4=CC=CC=C4N3CCCCOC.Cl
DM81UAZ	IK	PUXOYQIZZIWCHH-NSLUPJTDSA-N
DM81UAZ	IU	1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholine-4-carbonyl)piperidin-3-yl]benzimidazole-2-carboxamide;hydrochloride
DM81UAZ	CA	CAS 1202269-24-6
DM81UAZ	DE	Type-2 diabetes

DMEYKRN	ID	DMEYKRN
DMEYKRN	DN	TAK-379
DMEYKRN	HS	Phase 2
DMEYKRN	SN	Insulin sensitizer (oral, diabetes mellitus), Takeda
DMEYKRN	CP	Takeda Pharmaceutical Co Ltd
DMEYKRN	DE	Type-2 diabetes

DMD51RN	ID	DMD51RN
DMD51RN	DN	TAK-448
DMD51RN	HS	Phase 2
DMD51RN	CP	Takeda
DMD51RN	PC	46700761
DMD51RN	MW	1225.4
DMD51RN	FM	C58H80N16O14
DMD51RN	IC	InChI=1S/C58H80N16O14/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+/m1/s1
DMD51RN	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=NC)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H](CC5=CC=C(C=C5)O)NC(=O)C)O)O
DMD51RN	IK	MWXWMWSUUYXMRA-GRKBUMBKSA-N
DMD51RN	IU	(2S)-2-[[(2S,4R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide
DMD51RN	CA	CAS 1234319-68-6
DMD51RN	DE	Prostate cancer

DMNB4P1	ID	DMNB4P1
DMNB4P1	DN	TAK-653
DMNB4P1	HS	Phase 2
DMNB4P1	CP	Takeda
DMNB4P1	PC	56655833
DMNB4P1	MW	373.5
DMNB4P1	FM	C19H23N3O3S
DMNB4P1	IC	InChI=1S/C19H23N3O3S/c1-14-13-22-11-12-26(23,24)21-19(22)18(20-14)15-7-9-17(10-8-15)25-16-5-3-2-4-6-16/h7-10,13,16H,2-6,11-12H2,1H3
DMNB4P1	CS	CC1=CN2CCS(=O)(=O)N=C2C(=N1)C3=CC=C(C=C3)OC4CCCCC4
DMNB4P1	IK	PXJBHEHFVQVDDS-UHFFFAOYSA-N
DMNB4P1	IU	9-(4-cyclohexyloxyphenyl)-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide
DMNB4P1	CA	CAS 1358751-06-0
DMNB4P1	DE	Depression

DMJH3U0	ID	DMJH3U0
DMJH3U0	DN	TAK-659
DMJH3U0	HS	Phase 2
DMJH3U0	CP	Millennium pharmaceuticals
DMJH3U0	PC	53252276
DMJH3U0	MW	344.4
DMJH3U0	FM	C17H21FN6O
DMJH3U0	IC	InChI=1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23)/t11-,12+/m0/s1
DMJH3U0	CS	CN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)N[C@@H]4CCCC[C@@H]4N
DMJH3U0	IK	MJHOMTRKVMKCNE-NWDGAFQWSA-N
DMJH3U0	IU	6-[[(1R,2S)-2-aminocyclohexyl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one
DMJH3U0	CA	CAS 1312691-33-0
DMJH3U0	DE	Haematological malignancy; Diffuse large B-cell lymphoma

DMZKPI8	ID	DMZKPI8
DMZKPI8	DN	TAK-715
DMZKPI8	HS	Phase 2
DMZKPI8	SN	P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda
DMZKPI8	CP	Takeda Pharmaceutical Co Ltd
DMZKPI8	DT	Small molecular drug
DMZKPI8	PC	9952773
DMZKPI8	MW	399.5
DMZKPI8	FM	C24H21N3OS
DMZKPI8	IC	InChI=1S/C24H21N3OS/c1-3-21-27-22(18-11-7-8-16(2)14-18)23(29-21)19-12-13-25-20(15-19)26-24(28)17-9-5-4-6-10-17/h4-15H,3H2,1-2H3,(H,25,26,28)
DMZKPI8	CS	CCC1=NC(=C(S1)C2=CC(=NC=C2)NC(=O)C3=CC=CC=C3)C4=CC=CC(=C4)C
DMZKPI8	IK	HEKAIDKUDLCBRU-UHFFFAOYSA-N
DMZKPI8	IU	N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]pyridin-2-yl]benzamide
DMZKPI8	CA	CAS 303162-79-0
DMZKPI8	CB	CHEBI:91360
DMZKPI8	DE	Rheumatoid arthritis

DMWPSJR	ID	DMWPSJR
DMWPSJR	DN	TAK-831
DMWPSJR	HS	Phase 2
DMWPSJR	CP	Takeda Deerfield, IL
DMWPSJR	DE	Friedreich's ataxia; Schizophrenia

DMZEU6M	ID	DMZEU6M
DMZEU6M	DN	TAK-831
DMZEU6M	HS	Phase 2
DMZEU6M	SN	Luvadaxistat; 3(2H)-one; UNII-76IC00YRVR; 76IC00YRVR; CHEMBL2338801; 1425511-32-5; 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-; 4-Hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one; 4-Hydroxy-6-(2-(4-(trifluoromethyl)phenyl)ethyl)pyridazin-3(2H)-one; Luvadaxistat [USAN]; SCHEMBL14719667; BDBM50431085; WHO 11254; ZINC95592350; 3(2H)-Pyridazinone, 4-hydroxy-6-(2-(4-(trifluoromethyl)phenyl)ethyl)-; 6-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione
DMZEU6M	CP	Takeda
DMZEU6M	DT	Small molecular drug
DMZEU6M	PC	71270546
DMZEU6M	MW	284.23
DMZEU6M	FM	C13H11F3N2O2
DMZEU6M	IC	InChI=1S/C13H11F3N2O2/c14-13(15,16)9-4-1-8(2-5-9)3-6-10-7-11(19)12(20)18-17-10/h1-2,4-5,7H,3,6H2,(H,17,19)(H,18,20)
DMZEU6M	CS	C1=CC(=CC=C1CCC2=CC(=O)C(=O)NN2)C(F)(F)F
DMZEU6M	IK	QBQMUMMSYHUDFM-UHFFFAOYSA-N
DMZEU6M	IU	6-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione
DMZEU6M	CA	CAS 1425511-32-5
DMZEU6M	DE	Friedreich's ataxia

DMBQD9H	ID	DMBQD9H
DMBQD9H	DN	TAK-906
DMBQD9H	HS	Phase 2
DMBQD9H	SN	Trazpiroben; UNII-FH87H57Q4Y; FH87H57Q4Y; triazaspiro[4.5]decan-3-yl]methyl}benzoic acid; 1352993-39-5; 3-{[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-; Trazpiroben [INN]; Trazpiroben [USAN]; SCHEMBL318454; WHO 11123; (3-((1-Cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8 triazaspiro(4.5) decan-3-yl)methyl)benzoic acid; 3-[[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoic acid; Benzoic acid, 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro(4.5)dec-3-yl)methyl)-
DMBQD9H	CP	Takeda
DMBQD9H	DT	Small molecular drug
DMBQD9H	PC	54768846
DMBQD9H	MW	517.7
DMBQD9H	FM	C31H39N3O4
DMBQD9H	IC	InChI=1S/C31H39N3O4/c35-28(25-10-3-1-4-11-25)15-8-18-32-19-16-31(17-20-32)30(38)33(23-34(31)27-13-5-2-6-14-27)22-24-9-7-12-26(21-24)29(36)37/h1,3-4,7,9-12,21,27H,2,5-6,8,13-20,22-23H2,(H,36,37)
DMBQD9H	CS	C1CCC(CC1)N2CN(C(=O)C23CCN(CC3)CCCC(=O)C4=CC=CC=C4)CC5=CC(=CC=C5)C(=O)O
DMBQD9H	IK	BDXJYAAYLZTLEK-UHFFFAOYSA-N
DMBQD9H	IU	3-[[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoic acid
DMBQD9H	CA	CAS 1352993-39-5
DMBQD9H	DE	Diabetic gastroparesis

DMOZAMN	ID	DMOZAMN
DMOZAMN	DN	TAK-935
DMOZAMN	HS	Phase 2
DMOZAMN	PC	73437845
DMOZAMN	MW	373.4
DMOZAMN	FM	C23H23N3O2
DMOZAMN	IC	InChI=1S/C23H23N3O2/c27-22(20-7-4-12-25-21(20)19-8-13-24-14-9-19)26-15-10-23(28,11-16-26)17-18-5-2-1-3-6-18/h1-9,12-14,28H,10-11,15-17H2
DMOZAMN	CS	C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4
DMOZAMN	IK	XKUZMIUSBMCVPP-UHFFFAOYSA-N
DMOZAMN	IU	(4-benzyl-4-hydroxypiperidin-1-yl)-(2-pyridin-4-ylpyridin-3-yl)methanone
DMOZAMN	CA	CAS 1429505-03-2
DMOZAMN	DE	Glutamate excitotoxity; Dravet syndrome; LennoxGastaut syndrome; Tuberous sclerosis

DMARVFG	ID	DMARVFG
DMARVFG	DN	Talacotuzumab
DMARVFG	HS	Phase 2
DMARVFG	SN	JNJ 473; JNJ 56022473; TAL
DMARVFG	CP	Janssen Research & Development Raritan, NJ
DMARVFG	DE	Acute myeloid leukaemia

DMJOM5L	ID	DMJOM5L
DMJOM5L	DN	Talampanel
DMJOM5L	HS	Phase 2
DMJOM5L	SN	Ampanel; Kinampa; GYKI 53773; LY 300164; GYKI-53773; IDR-53773; LY-300164; Talampanel (INN); (8R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-(-)-1-(4-Aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine; (R)-7-Acetyl-5-(p-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo(4,5-h)(2,3)benzodiazepine; (R)-7-acetyl-5-(p-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine
DMJOM5L	CP	Teva Pharmaceutical Industries
DMJOM5L	DT	Small molecular drug
DMJOM5L	PC	164509
DMJOM5L	MW	337.4
DMJOM5L	FM	C19H19N3O3
DMJOM5L	IC	InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3/t11-/m1/s1
DMJOM5L	CS	C[C@@H]1CC2=CC3=C(C=C2C(=NN1C(=O)C)C4=CC=C(C=C4)N)OCO3
DMJOM5L	IK	JACAAXNEHGBPOQ-LLVKDONJSA-N
DMJOM5L	IU	1-[(8R)-5-(4-aminophenyl)-8-methyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone
DMJOM5L	CA	CAS 161832-65-1
DMJOM5L	CB	CHEBI:34992
DMJOM5L	DE	Parkinson disease

DMQKZDT	ID	DMQKZDT
DMQKZDT	DN	Talnetant
DMQKZDT	HS	Phase 2
DMQKZDT	SN	Talnetant [INN]; SB 223412; SB-223412; N-((S)-alpha-Ethylbenzyl)-3-hydroxy-2-phenylcinchoninamide;N-(alpha-Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide; 3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
DMQKZDT	CP	GlaxoSmithKline
DMQKZDT	DT	Small molecular drug
DMQKZDT	PC	5311424
DMQKZDT	MW	382.5
DMQKZDT	FM	C25H22N2O2
DMQKZDT	IC	InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29)/t20-/m0/s1
DMQKZDT	CS	CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)O
DMQKZDT	IK	BIAVGWDGIJKWRM-FQEVSTJZSA-N
DMQKZDT	IU	3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DMQKZDT	CA	CAS 174636-32-9
DMQKZDT	DE	Schizoaffective disorder; Schizophrenia; Irritable bowel syndrome

DMNLQHK	ID	DMNLQHK
DMNLQHK	DN	Tanespimycin
DMNLQHK	HS	Phase 2
DMNLQHK	SN	CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374
DMNLQHK	CP	Bristol-Myers Squibb; Infinity Pharmaceuticals
DMNLQHK	TC	Anticancer Agents
DMNLQHK	DT	Small molecular drug
DMNLQHK	PC	6505803
DMNLQHK	MW	585.7
DMNLQHK	FM	C31H43N3O8
DMNLQHK	IC	InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1
DMNLQHK	CS	C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)/C)OC)OC(=O)N)\\C)C)O)OC
DMNLQHK	IK	AYUNIORJHRXIBJ-TXHRRWQRSA-N
DMNLQHK	IU	[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DMNLQHK	CA	CAS 75747-14-7
DMNLQHK	CB	CHEBI:64153
DMNLQHK	DE	Multiple myeloma; Breast cancer

DM1TSHL	ID	DM1TSHL
DM1TSHL	DN	Taprenepag
DM1TSHL	HS	Phase 2
DM1TSHL	SN	Taprenepag isopropyl; CP-544326; PF-04217329; PF-4217329
DM1TSHL	CP	Pfizer Inc
DM1TSHL	DT	Small molecular drug
DM1TSHL	PC	18376177
DM1TSHL	MW	478.5
DM1TSHL	FM	C24H22N4O5S
DM1TSHL	IC	InChI=1S/C24H22N4O5S/c29-24(30)18-33-22-5-1-4-20(14-22)17-27(34(31,32)23-6-2-11-25-15-23)16-19-7-9-21(10-8-19)28-13-3-12-26-28/h1-15H,16-18H2,(H,29,30)
DM1TSHL	CS	C1=CC(=CC(=C1)OCC(=O)O)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4
DM1TSHL	IK	MFFBXYNKZHTCEY-UHFFFAOYSA-N
DM1TSHL	IU	2-[3-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid
DM1TSHL	CA	CAS 752187-80-7
DM1TSHL	DE	Glaucoma/ocular hypertension

DMDB4EJ	ID	DMDB4EJ
DMDB4EJ	DN	Tarafenacin
DMDB4EJ	HS	Phase 2
DMDB4EJ	SN	SVT-40776; Muscarinic M3 receptor antagonist (overactive bladder), SALVAT
DMDB4EJ	CP	Laboratorios SALVAT SA
DMDB4EJ	DT	Small molecular drug
DMDB4EJ	PC	25147683
DMDB4EJ	MW	408.4
DMDB4EJ	FM	C21H20F4N2O2
DMDB4EJ	IC	InChI=1S/C21H20F4N2O2/c22-15-2-1-3-16(10-15)27(11-13-8-17(23)20(25)18(24)9-13)21(28)29-19-12-26-6-4-14(19)5-7-26/h1-3,8-10,14,19H,4-7,11-12H2/t19-/m0/s1
DMDB4EJ	CS	C1CN2CCC1[C@H](C2)OC(=O)N(CC3=CC(=C(C(=C3)F)F)F)C4=CC(=CC=C4)F
DMDB4EJ	IK	UXZDMXYRRQJIBJ-IBGZPJMESA-N
DMDB4EJ	IU	[(3R)-1-azabicyclo[2.2.2]octan-3-yl] N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]carbamate
DMDB4EJ	CA	CAS 385367-47-5
DMDB4EJ	DE	Overactive bladder

DM95FR3	ID	DM95FR3
DM95FR3	DN	Tarextumab
DM95FR3	HS	Phase 2
DM95FR3	CP	Oncomed pharmaceuticals
DM95FR3	DT	Monoclonal antibody
DM95FR3	DE	Pancreatic cancer; Small-cell lung cancer

DMA7ISF	ID	DMA7ISF
DMA7ISF	DN	Tarloxotinib
DMA7ISF	HS	Phase 2
DMA7ISF	SN	Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0
DMA7ISF	CP	Rain Therapeutics
DMA7ISF	DT	Small molecular drug
DMA7ISF	PC	51038316
DMA7ISF	MW	601.9
DMA7ISF	FM	C24H24BrClN9O3+
DMA7ISF	IC	InChI=1S/C24H23BrClN9O3/c1-33-14-30-24(34(37)38)20(33)12-35(2,3)8-4-5-22(36)32-21-10-16-19(11-27-21)28-13-29-23(16)31-15-6-7-18(26)17(25)9-15/h4-7,9-11,13-14H,8,12H2,1-3H3,(H-,27,28,29,31,32,36)/p+1/b5-4+
DMA7ISF	CS	CN1C=NC(=C1C[N+](C)(C)C/C=C/C(=O)NC2=NC=C3C(=C2)C(=NC=N3)NC4=CC(=C(C=C4)Cl)Br)[N+](=O)[O-]
DMA7ISF	IK	MUJMYVFVAWFUJL-SNAWJCMRSA-O
DMA7ISF	IU	[(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium
DMA7ISF	CA	CAS 1636938-13-0
DMA7ISF	DE	Non-small-cell lung cancer

DML97KB	ID	DML97KB
DML97KB	DN	TAS-106
DML97KB	HS	Phase 2
DML97KB	CP	Taiho Pharma U.S.A.
DML97KB	DT	Small molecular drug
DML97KB	PC	176885
DML97KB	MW	267.24
DML97KB	FM	C11H13N3O5
DML97KB	IC	InChI=1S/C11H13N3O5/c1-2-11(18)6(5-15)19-9(8(11)16)14-4-3-7(12)13-10(14)17/h1,3-4,6,8-9,15-16,18H,5H2,(H2,12,13,17)/t6-,8+,9-,11-/m1/s1
DML97KB	CS	C#C[C@]1([C@H](O[C@H]([C@@H]1O)N2C=CC(=NC2=O)N)CO)O
DML97KB	IK	JFIWEPHGRUDAJN-DYUFWOLASA-N
DML97KB	IU	4-amino-1-[(2R,3R,4S,5R)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DML97KB	CA	CAS 180300-43-0
DML97KB	DE	Head and neck cancer

DM3D52L	ID	DM3D52L
DM3D52L	DN	TAS-114
DM3D52L	HS	Phase 2
DM3D52L	PC	53630253
DM3D52L	MW	451.5
DM3D52L	FM	C21H29N3O6S
DM3D52L	IC	InChI=1S/C21H29N3O6S/c1-16(17-6-4-9-19(14-17)30-18-7-2-3-8-18)23-31(27,28)13-5-12-29-15-24-11-10-20(25)22-21(24)26/h4,6,9-11,14,16,18,23H,2-3,5,7-8,12-13,15H2,1H3,(H,22,25,26)/t16-/m1/s1
DM3D52L	CS	C[C@H](C1=CC(=CC=C1)OC2CCCC2)NS(=O)(=O)CCCOCN3C=CC(=O)NC3=O
DM3D52L	IK	AMCGLRWKUQPNKD-MRXNPFEDSA-N
DM3D52L	IU	N-[(1R)-1-(3-cyclopentyloxyphenyl)ethyl]-3-[(2,4-dioxopyrimidin-1-yl)methoxy]propane-1-sulfonamide
DM3D52L	DE	Solid tumour/cancer; Non-small-cell lung cancer

DM9QFW2	ID	DM9QFW2
DM9QFW2	DN	Tau-binding PET tracer
DM9QFW2	HS	Phase 2
DM9QFW2	SN	T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens
DM9QFW2	CP	Siemens Medical Solutions Molecular Imaging
DM9QFW2	DT	Small molecular drug
DM9QFW2	PC	71059746
DM9QFW2	MW	263.27
DM9QFW2	FM	C16H10FN3
DM9QFW2	IC	InChI=1S/C16H10FN3/c17-16-4-2-11(8-19-16)10-1-3-12-13-9-18-6-5-14(13)20-15(12)7-10/h1-9,20H
DM9QFW2	CS	C1=CC2=C(C=C1C3=CN=C(C=C3)F)NC4=C2C=NC=C4
DM9QFW2	IK	GETAAWDSFUCLBS-UHFFFAOYSA-N
DM9QFW2	IU	7-(6-fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole
DM9QFW2	CA	CAS 1415379-56-4
DM9QFW2	DE	Alzheimer disease

DMZX0VF	ID	DMZX0VF
DMZX0VF	DN	Tavokinogene telseplasmid
DMZX0VF	HS	Phase 2
DMZX0VF	SN	TAVO
DMZX0VF	CP	OncoSec Medical
DMZX0VF	DT	Gene therapy
DMZX0VF	DE	Melanoma; Triple negative breast cancer

DM4I6XK	ID	DM4I6XK
DM4I6XK	DN	TB-402
DM4I6XK	HS	Phase 2
DM4I6XK	SN	Anti-FVIII MAb 2E9; MAb-LE2E9; TGX-LE2E9
DM4I6XK	CP	ThromboGenics
DM4I6XK	DT	Antibody
DM4I6XK	DE	Atrial fibrillation; Venous thromboembolism

DMDPBMH	ID	DMDPBMH
DMDPBMH	DN	TB-403
DMDPBMH	HS	Phase 2
DMDPBMH	CP	BioInvent International Lund, Sweden Oncurious Leuven, Belgium
DMDPBMH	DE	Glioblastoma of brain

DMZTOJ6	ID	DMZTOJ6
DMZTOJ6	DN	TBA-7371
DMZTOJ6	HS	Phase 2
DMZTOJ6	SN	1494675-86-3; DprE1-IN-1; AZ7371; N-(2-hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide; UNII-R3T98GBE3C; AZ-7371; R3T98GBE3C; CHEMBL3109802; 1H-Pyrrolo(3,2-b)pyridine-3-carboxamide, N-(2-hydroxyethyl)-1-((6-methoxy-5-methyl-4-pyrimidinyl)methyl)-6-methyl-; 1H-Pyrrolo[3,2-b]pyridine-3-carboxamide, N-(2-hydroxyethyl)-1-[(6-methoxy-5-methyl-4-pyrimidinyl)methyl]-6-methyl-; ZA7371; AZ-7371DprE1-IN-1; AZ7371;DprE1-IN-1; SCHEMBL16395186; EX-A777; BCP16818; BDBM50019654; MFCD29477419; ZINC103248024; CS-5414; ZA-7371; HY-19750; FT-0700212; J-690193; N-(2-Hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6- methyl-1H-pyrrolo(3,2-b)pyridine-3-carboxamide; N-(2-hydroxyethyl)-1-[(6-methoxy-5-methyl-pyrimidin-4-yl)methyl]-6-methyl-pyrrolo[3,2-b]pyridine-3-carboxamide; N-(2-hydroxyethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methylpyrrolo[3,2-b]pyridine-3-carboxamide
DMZTOJ6	CP	TB Alliance
DMZTOJ6	DT	Small molecular drug
DMZTOJ6	PC	72792692
DMZTOJ6	MW	355.4
DMZTOJ6	FM	C18H21N5O3
DMZTOJ6	IC	InChI=1S/C18H21N5O3/c1-11-6-15-16(20-7-11)13(17(25)19-4-5-24)8-23(15)9-14-12(2)18(26-3)22-10-21-14/h6-8,10,24H,4-5,9H2,1-3H3,(H,19,25)
DMZTOJ6	CS	CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCO)N=C1
DMZTOJ6	IK	VDRYGTNDKXIPSK-UHFFFAOYSA-N
DMZTOJ6	IU	N-(2-hydroxyethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methylpyrrolo[3,2-b]pyridine-3-carboxamide
DMZTOJ6	CA	CAS 1494675-86-3
DMZTOJ6	DE	Tuberculosis

DMZCA0K	ID	DMZCA0K
DMZCA0K	DN	TBC-3711
DMZCA0K	HS	Phase 2
DMZCA0K	SN	N-(2-Acetyl-4,6-dimethylphenyl)-3-[N-(3,4-dimethylisoxazol-5-yl)sulfamoyl]thiophene-2-carboxamide
DMZCA0K	CP	Encysive Pharmaceuticals
DMZCA0K	DT	Small molecular drug
DMZCA0K	PC	9911482
DMZCA0K	MW	447.5
DMZCA0K	FM	C20H21N3O5S2
DMZCA0K	IC	InChI=1S/C20H21N3O5S2/c1-10-8-11(2)17(15(9-10)14(5)24)21-19(25)18-16(6-7-29-18)30(26,27)23-20-12(3)13(4)22-28-20/h6-9,23H,1-5H3,(H,21,25)
DMZCA0K	CS	CC1=CC(=C(C(=C1)C(=O)C)NC(=O)C2=C(C=CS2)S(=O)(=O)NC3=C(C(=NO3)C)C)C
DMZCA0K	IK	IAYNHDZSSDUYHY-UHFFFAOYSA-N
DMZCA0K	IU	N-(2-acetyl-4,6-dimethylphenyl)-3-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxamide
DMZCA0K	CA	CAS 349453-49-2
DMZCA0K	DE	Hypotension

DMM5BVG	ID	DMM5BVG
DMM5BVG	DN	TBR-760
DMM5BVG	HS	Phase 2
DMM5BVG	SN	CHEMBL4594435; BIM-23A760
DMM5BVG	CP	Tiburio Therapeutics
DMM5BVG	DT	Small molecular drug
DMM5BVG	PC	139593389
DMM5BVG	DE	Pituitary adenoma

DM8AM60	ID	DM8AM60
DM8AM60	DN	TC-5214
DM8AM60	HS	Phase 2
DM8AM60	SN	Dexmecamylamine; DEXMECAMYLAMINE; UNII-5Y1141YI4U; 107538-05-6; 5Y1141YI4U; TC 5214; (1R,2S,4S)-N,2,3,3-Tetramethylbicyclo(2.2.1)heptan-2-amine; Dexmecamylamine [USAN:INN]; Dexmecamylamine (USAN); CHEMBL2103881; BDBM50045047; ZINC43763856; DB11807; D10111; UNII-6EE945D3OK component IMYZQPCYWPFTAG-NGZCFLSTSA-N; Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl-, (1R,2S,4S)-
DM8AM60	CP	Atacama Therapeutics Wellesley, MA
DM8AM60	PC	12358971
DM8AM60	MW	203.75
DM8AM60	FM	C11H22ClN
DM8AM60	IC	InChI=1S/C11H21N.ClH/c1-10(2)8-5-6-9(7-8)11(10,3)12-4;/h8-9,12H,5-7H2,1-4H3;1H/t8-,9+,11-;/m0./s1
DM8AM60	CS	C[C@@]1([C@@H]2CC[C@@H](C2)C1(C)C)NC.Cl
DM8AM60	IK	PKVZBNCYEICAQP-GSTSRXQZSA-N
DM8AM60	IU	(1R,2S,4S)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine;hydrochloride
DM8AM60	CA	CAS 107596-30-5
DM8AM60	DE	Palmar hyperhidrosis

DMWPI2U	ID	DMWPI2U
DMWPI2U	DN	TC-6499-12
DMWPI2U	HS	Phase 2
DMWPI2U	SN	TC-6499; Alpha 4 beta 2 neuronal nicotinic modulator (pain/IBS), Targacept
DMWPI2U	CP	Targacept Inc
DMWPI2U	DE	Irritable bowel syndrome

DMNFP21	ID	DMNFP21
DMNFP21	DN	TC-6987
DMNFP21	HS	Phase 2
DMNFP21	PC	44511587
DMNFP21	MW	357.4
DMNFP21	FM	C20H21F2N3O
DMNFP21	IC	InChI=1S/C20H21F2N3O/c21-16-9-15(10-17(22)11-16)20(26)24-19-14-3-6-25(7-4-14)18(19)8-13-2-1-5-23-12-13/h1-2,5,9-12,14,18-19H,3-4,6-8H2,(H,24,26)/t18-,19+/m0/s1
DMNFP21	CS	C1CN2CCC1[C@H]([C@@H]2CC3=CN=CC=C3)NC(=O)C4=CC(=CC(=C4)F)F
DMNFP21	IK	UAKZGMMGIMKFMV-RBUKOAKNSA-N
DMNFP21	IU	3,5-difluoro-N-[(2S,3R)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide
DMNFP21	CA	CAS 1196701-27-5
DMNFP21	DE	Asthma

DM9PVNJ	ID	DM9PVNJ
DM9PVNJ	DN	TCN-032
DM9PVNJ	HS	Phase 2
DM9PVNJ	CP	Theraclone Sciences
DM9PVNJ	DT	Antibody
DM9PVNJ	DE	Influenza virus infection

DMJ3KPO	ID	DMJ3KPO
DMJ3KPO	DN	TD-101
DMJ3KPO	HS	Phase 2
DMJ3KPO	CP	Transderm
DMJ3KPO	DT	siRNA drug
DMJ3KPO	DE	Pachyonychia; Flavivirus infection

DMTJMK5	ID	DMTJMK5
DMTJMK5	DN	TD-1211
DMTJMK5	HS	Phase 2
DMTJMK5	SN	Axelopran; UNII-85U7ROB149; TD-1211; 85U7ROB149; 949904-48-7; Axelopran [USAN:INN]; TD 1211; SCHEMBL1773803; SCHEMBL1773801; CHEMBL3137313; AKOS027337117; SB16947; DB12013; Benzamide, 3-((3-endo)-8-(2-((cyclohexylmethyl)((2S)-2,3-dihydroxy-1-oxopropyl)amino)ethyl)-8-azabicyclo(3.2.1)oct-3-yl)-
DMTJMK5	CP	Theravance
DMTJMK5	DT	Small molecular drug
DMTJMK5	PC	67156338
DMTJMK5	MW	457.6
DMTJMK5	FM	C26H39N3O4
DMTJMK5	IC	InChI=1S/C26H39N3O4/c27-25(32)20-8-4-7-19(13-20)21-14-22-9-10-23(15-21)29(22)12-11-28(26(33)24(31)17-30)16-18-5-2-1-3-6-18/h4,7-8,13,18,21-24,30-31H,1-3,5-6,9-12,14-17H2,(H2,27,32)/t21?,22-,23+,24-/m0/s1
DMTJMK5	CS	C1CCC(CC1)CN(CCN2[C@@H]3CC[C@H]2CC(C3)C4=CC(=CC=C4)C(=O)N)C(=O)[C@H](CO)O
DMTJMK5	IK	ATLYLVPZNWDJBW-NHYNNZIHSA-N
DMTJMK5	IU	3-[(1S,5R)-8-[2-[cyclohexylmethyl-[(2S)-2,3-dihydroxypropanoyl]amino]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzamide
DMTJMK5	CA	CAS 949904-48-7
DMTJMK5	DE	Opioid-induced constipation

DM6SANW	ID	DM6SANW
DM6SANW	DN	TD-5108
DM6SANW	HS	Phase 2
DM6SANW	SN	Velusetrag; TD-5108; UNII-J4VNV64ARB; J4VNV64ARB; Velusetrag [USAN:INN]; SCHEMBL2917361; GTPL8425; CHEMBL2087337; Serotonin 5-HT4 Receptor Agonists; BDBM50391069; ZINC15821733; TD 5108; DB12702; compound 15 [PMID 22959244]; N-((1R,3R,5S)-8-((2R)-2-hydroxy-3-(methyl(methylsulfonyl)amino)propyl)-8-azabicyclo(3.2.1)oct-3-yl)-1-(1-methylethyl)-2-oxo-1,2-dihydroquinoline-3-carboxamide; 3-Quinolinecarboxamide, 1,2-dihydro-N-((3-endo)-8-((2R)-2-hydroxy-3-(methyl(methylsulfonyl)amino)propyl)-8-azabicyclo(3.2.1)oct-3-yl)-1-(1-meth
DM6SANW	DT	Small molecular drug
DM6SANW	PC	11842633
DM6SANW	MW	504.6
DM6SANW	FM	C25H36N4O5S
DM6SANW	IC	InChI=1S/C25H36N4O5S/c1-16(2)29-23-8-6-5-7-17(23)11-22(25(29)32)24(31)26-18-12-19-9-10-20(13-18)28(19)15-21(30)14-27(3)35(4,33)34/h5-8,11,16,18-21,30H,9-10,12-15H2,1-4H3,(H,26,31)/t18?,19-,20+,21-/m0/s1
DM6SANW	CS	CC(C)N1C2=CC=CC=C2C=C(C1=O)C(=O)NC3C[C@H]4CC[C@@H](C3)N4C[C@H](CN(C)S(=O)(=O)C)O
DM6SANW	IK	HXLOHDZQBKCUCR-VTHDOGFWSA-N
DM6SANW	IU	N-[(1S,5R)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-1-propan-2-ylquinoline-3-carboxamide
DM6SANW	CA	CAS 866933-46-2
DM6SANW	DE	Gastroparesis

DM3C9NV	ID	DM3C9NV
DM3C9NV	DN	TD-8954
DM3C9NV	HS	Phase 2
DM3C9NV	SN	TD-8954; UNII-35F0Y2W16Q; CHEMBL2402904; 35F0Y2W16Q; 916075-84-8; compound 18 [PMID 23756062]; SCHEMBL390795; GTPL8426; BDBM50436989; SB17471; DB12725; 1-Piperidinecarboxylic acid, 4-((4-((((2-(1-methylethyl)-1H-benzimidazol-7-yl)carbonyl)amino)methyl)-1-piperidinyl)methyl)-, methyl ester; methyl 4-[[4-[[(2-propan-2-yl1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate
DM3C9NV	CP	Theravance
DM3C9NV	DT	Small molecular drug
DM3C9NV	PC	11961293
DM3C9NV	MW	455.6
DM3C9NV	FM	C25H37N5O3
DM3C9NV	IC	InChI=1S/C25H37N5O3/c1-17(2)23-27-21-6-4-5-20(22(21)28-23)24(31)26-15-18-7-11-29(12-8-18)16-19-9-13-30(14-10-19)25(32)33-3/h4-6,17-19H,7-16H2,1-3H3,(H,26,31)(H,27,28)
DM3C9NV	CS	CC(C)C1=NC2=C(C=CC=C2N1)C(=O)NCC3CCN(CC3)CC4CCN(CC4)C(=O)OC
DM3C9NV	IK	MZOITCJKGUIQEI-UHFFFAOYSA-N
DM3C9NV	IU	methyl 4-[[4-[[(2-propan-2-yl-1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate
DM3C9NV	CA	CAS 916075-84-8
DM3C9NV	DE	Alzheimer disease; Gastrointestinal disease

DMQD5NA	ID	DMQD5NA
DMQD5NA	DN	TD-9855
DMQD5NA	HS	Phase 2
DMQD5NA	PC	46189893
DMQD5NA	MW	321.3
DMQD5NA	FM	C18H18F3NO
DMQD5NA	IC	InChI=1S/C18H18F3NO/c19-14-9-16(20)18(17(21)10-14)23-11-13-3-1-2-4-15(13)12-5-7-22-8-6-12/h1-4,9-10,12,22H,5-8,11H2
DMQD5NA	CS	C1CNCCC1C2=CC=CC=C2COC3=C(C=C(C=C3F)F)F
DMQD5NA	IK	TZIALEBTHQWNAO-UHFFFAOYSA-N
DMQD5NA	IU	4-[2-[(2,4,6-trifluorophenoxy)methyl]phenyl]piperidine
DMQD5NA	CA	CAS 1227056-84-9
DMQD5NA	DE	Pain; Orthostatic hypotension

DM6YI5T	ID	DM6YI5T
DM6YI5T	DN	Tegobuvir
DM6YI5T	HS	Phase 2
DM6YI5T	SN	Tegobuvir; 1000787-75-6; UNII-5NOK5X389M; 5-((6-(2,4-bis(Trifluoromethyl)phenyl)pyridazin-3-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; 5NOK5X389M; GS-9190; GS-333126; W-204340; 5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-;5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-; Tegobuvir [USAN:INN]; GS 9190; Tegobuvir (USAN/INN); GS 333126; SCHEMBL496778; CHEMBL1957287; DTXSID80142917
DM6YI5T	CP	Gilead
DM6YI5T	DT	Small molecular drug
DM6YI5T	PC	23649154
DM6YI5T	MW	517.4
DM6YI5T	FM	C25H14F7N5
DM6YI5T	IC	InChI=1S/C25H14F7N5/c26-19-4-2-1-3-17(19)23-33-21-9-10-37(13-22(21)34-23)12-15-6-8-20(36-35-15)16-7-5-14(24(27,28)29)11-18(16)25(30,31)32/h1-11,13H,12H2
DM6YI5T	CS	C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F
DM6YI5T	IK	XBEQSQDCBSKCHJ-UHFFFAOYSA-N
DM6YI5T	IU	5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine
DM6YI5T	CA	CAS 1000787-75-6
DM6YI5T	DE	Hepatitis C virus infection

DM9AWSO	ID	DM9AWSO
DM9AWSO	DN	Telapristone
DM9AWSO	HS	Phase 2
DM9AWSO	SN	Telapristone acetate; Proellex; 198414-31-2; UNII-1K9EYK92PQ; CDB-4124; 1K9EYK92PQ; Telapristone acetate [USAN]; Telapristone acetate (USAN); CCRIS 9331; CDB 4124; SCHEMBL374762; CHEMBL2105694; DTXSID60173587; RU-44675; 17alpha-Acetoxy-11beta-(4-(dimethylamino)phenyl)-21-methoxy-19-norpregna-4,9-dien-3,20-dione; D09972; 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-21-methoxy-, (11beta)-; A-Acetoxy-21-methoxy-11
DM9AWSO	CP	Repros Therapeutics
DM9AWSO	DT	Small molecular drug
DM9AWSO	PC	20761503
DM9AWSO	MW	463.6
DM9AWSO	FM	C29H37NO4
DM9AWSO	IC	InChI=1S/C29H37NO4/c1-28-16-24(18-5-8-20(9-6-18)30(2)3)27-22-12-10-21(31)15-19(22)7-11-23(27)25(28)13-14-29(28,33)26(32)17-34-4/h5-6,8-9,15,23-25,33H,7,10-14,16-17H2,1-4H3/t23-,24+,25-,28-,29-/m0/s1
DM9AWSO	CS	C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(C(=O)COC)O)C5=CC=C(C=C5)N(C)C
DM9AWSO	IK	BHERMCLNVOVDPU-DQFOBABISA-N
DM9AWSO	IU	(8S,11R,13S,14S,17R)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(2-methoxyacetyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DM9AWSO	CA	CAS 198414-30-1
DM9AWSO	DE	Endometriosis

DMFT5D6	ID	DMFT5D6
DMFT5D6	DN	Telcagepant
DMFT5D6	HS	Phase 2
DMFT5D6	SN	MK 0974; MK0974; N7R; MK-0974; Telcagepant (USAN); N-(6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide
DMFT5D6	CP	Merck
DMFT5D6	DT	Small molecular drug
DMFT5D6	PC	11319053
DMFT5D6	MW	566.5
DMFT5D6	FM	C26H27F5N6O3
DMFT5D6	IC	InChI=1S/C26H27F5N6O3/c27-18-4-1-3-17(21(18)28)15-6-7-19(23(38)36(13-15)14-26(29,30)31)33-24(39)35-11-8-16(9-12-35)37-20-5-2-10-32-22(20)34-25(37)40/h1-5,10,15-16,19H,6-9,11-14H2,(H,33,39)(H,32,34,40)/t15-,19-/m1/s1
DMFT5D6	CS	C1C[C@H](C(=O)N(C[C@@H]1C2=C(C(=CC=C2)F)F)CC(F)(F)F)NC(=O)N3CCC(CC3)N4C5=C(NC4=O)N=CC=C5
DMFT5D6	IK	CGDZXLJGHVKVIE-DNVCBOLYSA-N
DMFT5D6	IU	N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
DMFT5D6	CA	CAS 781649-09-0
DMFT5D6	DE	Cluster headache; Migraine

DM8UCNK	ID	DM8UCNK
DM8UCNK	DN	Telisotuzumab vedotin
DM8UCNK	HS	Phase 2
DM8UCNK	SN	ABBV-399
DM8UCNK	CP	AbbVie
DM8UCNK	DT	Antibody
DM8UCNK	DE	Non-small-cell lung cancer

DMUQH78	ID	DMUQH78
DMUQH78	DN	Tempol
DMUQH78	HS	Phase 2
DMUQH78	SN	MTS-01; Tempol (hypertension); Tempol (hypertension), Cary; Tempol (gel formulation, hair loss), Mitos
DMUQH78	CP	Georgetown University; Mitos Pharmaceuticals Inc
DMUQH78	DT	Small molecular drug
DMUQH78	PC	137994
DMUQH78	MW	172.24
DMUQH78	FM	C9H18NO2
DMUQH78	IC	InChI=1S/C9H18NO2/c1-8(2)5-7(11)6-9(3,4)10(8)12/h7,11H,5-6H2,1-4H3
DMUQH78	CS	CC1(CC(CC(N1[O])(C)C)O)C
DMUQH78	IK	UZFMOKQJFYMBGY-UHFFFAOYSA-N
DMUQH78	CA	CAS 2226-96-2
DMUQH78	DE	Spinal cord injury

DMVS61L	ID	DMVS61L
DMVS61L	DN	Tepoxalin
DMVS61L	HS	Phase 2
DMVS61L	SN	TEPOXALIN; 103475-41-8; Orf-20485; ORF 20485; Tepoxaline; Tepoxalina; Tepoxalinum [Latin]; Tepoxaline [French]; Tepoxalina [Spanish]; RWJ 20485; Tepoxalin [USAN:INN]; 5-(4-Chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide; UNII-TZ4OX61974; C20H20ClN3O3; 1H-Pyrazole-3-propanamide, 5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-; CHEMBL316040; CHEBI:76277; TZ4OX61974; 5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-N-methylpyrazole-3-propionohydroxamic acid; RWJ-20485; SIL-4R
DMVS61L	DT	Small molecular drug
DMVS61L	PC	59757
DMVS61L	MW	385.8
DMVS61L	FM	C20H20ClN3O3
DMVS61L	IC	InChI=1S/C20H20ClN3O3/c1-23(26)20(25)12-7-16-13-19(14-3-5-15(21)6-4-14)24(22-16)17-8-10-18(27-2)11-9-17/h3-6,8-11,13,26H,7,12H2,1-2H3
DMVS61L	CS	CN(C(=O)CCC1=NN(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)OC)O
DMVS61L	IK	XYKWNRUXCOIMFZ-UHFFFAOYSA-N
DMVS61L	IU	3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-N-hydroxy-N-methylpropanamide
DMVS61L	CA	CAS 103475-41-8
DMVS61L	CB	CHEBI:76277
DMVS61L	DE	Asthma

DMC3P45	ID	DMC3P45
DMC3P45	DN	Terameprocol
DMC3P45	HS	Phase 2
DMC3P45	SN	EM-1421; Terameprocol (INN/USAN); Meso-Tetra-O-methylnordihydroguaiaretic acid; Meso-Tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol; Meso-1,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane; 4-[(2S,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene
DMC3P45	CP	Erimos
DMC3P45	DT	Small molecular drug
DMC3P45	PC	476861
DMC3P45	MW	358.5
DMC3P45	FM	C22H30O4
DMC3P45	IC	InChI=1S/C22H30O4/c1-15(11-17-7-9-19(23-3)21(13-17)25-5)16(2)12-18-8-10-20(24-4)22(14-18)26-6/h7-10,13-16H,11-12H2,1-6H3/t15-,16+
DMC3P45	CS	C[C@H](CC1=CC(=C(C=C1)OC)OC)[C@@H](C)CC2=CC(=C(C=C2)OC)OC
DMC3P45	IK	ORQFDHFZSMXRLM-IYBDPMFKSA-N
DMC3P45	IU	4-[(2S,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene
DMC3P45	CA	CAS 24150-24-1
DMC3P45	DE	Solid tumour/cancer

DMZNFPG	ID	DMZNFPG
DMZNFPG	DN	Terguride
DMZNFPG	HS	Phase 2
DMZNFPG	SN	terguride; Dironyl; 37686-84-3; trans-Dihydrolisuride; (+)-Terguride; (5R,8S,10R)-Terguride; S(+)-Terguride; UNII-21OJT43Q88; TDHL; Transdihydrolisuride; (+)-(5R,8S,10R)-Terguride; CHEMBL73151; MLS000069833; Terguride [INN]; 21OJT43Q88; Terguridum [Latin]; Tergurida [Spanish]; SMR000058934; 9,10-alpha-Dihydrolisuride; 1,1-diethyl-3-(6-methyl-8alpha-ergolinyl)urea; Terguridum; Tergurida; Tergurid; EINECS 253-624-2; BRN 0766582; ZK 31224; trans-Dihydro Lisuride; 6-Methyl-8alpha-(diethylcarbamoylamino)ergoline
DMZNFPG	CP	ErgoNex Pharma; Pfizer
DMZNFPG	DT	Small molecular drug
DMZNFPG	PC	443951
DMZNFPG	MW	340.5
DMZNFPG	FM	C20H28N4O
DMZNFPG	IC	InChI=1S/C20H28N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,11,14,16,18,21H,4-5,9-10,12H2,1-3H3,(H,22,25)/t14-,16+,18+/m0/s1
DMZNFPG	CS	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
DMZNFPG	IK	JOAHPSVPXZTVEP-YXJHDRRASA-N
DMZNFPG	IU	3-[(6aR,9S,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
DMZNFPG	CA	CAS 37686-84-3
DMZNFPG	CB	CHEBI:32193
DMZNFPG	DE	Pulmonary arterial hypertension

DMR4YEG	ID	DMR4YEG
DMR4YEG	DN	Tesidolumab
DMR4YEG	HS	Phase 2
DMR4YEG	SN	LFG316
DMR4YEG	CP	Novartis
DMR4YEG	DT	Antibody
DMR4YEG	DE	Age-related macular degeneration

DM1KGS7	ID	DM1KGS7
DM1KGS7	DN	Tesofensine
DM1KGS7	HS	Phase 2
DM1KGS7	SN	NS-2330
DM1KGS7	CP	NeuroSearch A/S
DM1KGS7	DT	Small molecular drug
DM1KGS7	PC	11370864
DM1KGS7	MW	328.3
DM1KGS7	FM	C17H23Cl2NO
DM1KGS7	IC	InChI=1S/C17H23Cl2NO/c1-3-21-10-14-13(9-12-5-7-17(14)20(12)2)11-4-6-15(18)16(19)8-11/h4,6,8,12-14,17H,3,5,7,9-10H2,1-2H3/t12-,13+,14+,17+/m0/s1
DM1KGS7	CS	CCOC[C@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl
DM1KGS7	IK	VCVWXKKWDOJNIT-ZOMKSWQUSA-N
DM1KGS7	IU	(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
DM1KGS7	CA	CAS 195875-84-4
DM1KGS7	DE	Pain

DMMK6IT	ID	DMMK6IT
DMMK6IT	DN	Testogen TDS
DMMK6IT	HS	Phase 2
DMMK6IT	SN	OriTex; OriTex); TDS-testosterone; Testosterone (oral, testosterone deficiency), Clarus; Testosterone (transdermal, TDS), TransDermal Technologies
DMMK6IT	CP	TransDermal Technologies Inc; Clarus Therapeutics Inc
DMMK6IT	DE	Hypogonadism

DMR5GSB	ID	DMR5GSB
DMR5GSB	DN	Tetrahydrouridine
DMR5GSB	HS	Phase 2
DMR5GSB	SN	3,4,5,6-Tetrahydrouridine; NSC-112907; NSC 112907; CHEMBL2311128; 18771-50-1; U 23284; NSC-112907-D; BRN 0752319; 2(1H)-pyrimidinone, tetrahydro-4-hydroxy-1-beta-D-ribofuranosyl-; NSC112907; AC1L1H1G; SCHEMBL587704; 3,4,5, 6-Tetrahydrouridine; 2(1H)-Pyrimidinone, tetrahydro-4-hydroxy-1-.beta.-D-ribofuranosyl-; UCKYOOZPSJFJIZ-XVKVHKPRSA-N; MolPort-044-561-340; BDBM50421666; AKOS032953792; DB12484; LS-7719; CS-7633; HY-15345; 3,4,5,6-Tetrahydrouridine (&gt; 80% by HPLC); J-012078
DMR5GSB	CP	BioVision
DMR5GSB	DT	Small molecular drug
DMR5GSB	PC	29243
DMR5GSB	MW	248.23
DMR5GSB	FM	C9H16N2O6
DMR5GSB	IC	InChI=1S/C9H16N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h4-8,12-15H,1-3H2,(H,10,16)/t4-,5?,6-,7-,8-/m1/s1
DMR5GSB	CS	C1CN(C(=O)NC1O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
DMR5GSB	IK	UCKYOOZPSJFJIZ-XVKVHKPRSA-N
DMR5GSB	IU	1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one
DMR5GSB	CA	CAS 18771-50-1
DMR5GSB	DE	Solid tumour/cancer

DMGNK67	ID	DMGNK67
DMGNK67	DN	TETRAPLATIN TETRANITRATE
DMGNK67	HS	Phase 2
DMGNK67	SN	BBR-3464; Tetraplatin tetranitrate; Hexaamminedichlorobis[mu-(1,6-hexanediamine-kappaN:kappaN')]triplatinum(4+) tetranitrate
DMGNK67	DE	Solid tumour/cancer

DM2LBC3	ID	DM2LBC3
DM2LBC3	DN	TEW-7197
DM2LBC3	HS	Phase 2
DM2LBC3	SN	Vactosertib
DM2LBC3	CP	Medpacto
DM2LBC3	PC	54766013
DM2LBC3	MW	399.4
DM2LBC3	FM	C22H18FN7
DM2LBC3	IC	InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)
DM2LBC3	CS	CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4
DM2LBC3	IK	FJCDSQATIJKQKA-UHFFFAOYSA-N
DM2LBC3	IU	2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline
DM2LBC3	CA	CAS 1352608-82-2
DM2LBC3	DE	Solid tumour/cancer; Myelodysplastic syndrome; Myeloproliferative neoplasm; Urothelial carcinoma

DMF61ML	ID	DMF61ML
DMF61ML	DN	TF0023
DMF61ML	HS	Phase 2
DMF61ML	CP	Techfields Pharma Dover, DE
DMF61ML	DE	Heart attack; Ischemic stroke; Type-2 diabetes

DM2ZLWH	ID	DM2ZLWH
DM2ZLWH	DN	TG-0054
DM2ZLWH	HS	Phase 2
DM2ZLWH	SN	CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology
DM2ZLWH	CP	TaiGen Biotechnology Co Ltd
DM2ZLWH	PC	44479007
DM2ZLWH	MW	566.7
DM2ZLWH	FM	C27H51N8O3P
DM2ZLWH	IC	InChI=1S/C27H51N8O3P/c28-25-19-26(35-15-13-34(14-16-35)17-18-39(36,37)38)33-27(32-25)31-21-23-9-7-22(8-10-23)20-29-11-4-12-30-24-5-2-1-3-6-24/h19,22-24,29-30H,1-18,20-21H2,(H2,36,37,38)(H3,28,31,32,33)
DM2ZLWH	CS	C1CCC(CC1)NCCCNCC2CCC(CC2)CNC3=NC(=CC(=N3)N4CCN(CC4)CCP(=O)(O)O)N
DM2ZLWH	IK	QLVSJMZJSABWRX-UHFFFAOYSA-N
DM2ZLWH	IU	2-[4-[6-amino-2-[[4-[[3-(cyclohexylamino)propylamino]methyl]cyclohexyl]methylamino]pyrimidin-4-yl]piperazin-1-yl]ethylphosphonic acid
DM2ZLWH	CA	CAS 1191448-17-5
DM2ZLWH	DE	Macular degeneration

DMPH1AG	ID	DMPH1AG
DMPH1AG	DN	TG100801
DMPH1AG	HS	Phase 2
DMPH1AG	SN	867331-82-6; TG 100801; TG100801; UNII-1VZO7A0J9S; TG-100801; 1VZO7A0J9S; 4-Chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)benzo[e][1,2,4]triazin-7-yl)phenyl benzoate; 4-Chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-amino)benzo[e][1,2,4]triazin-7-yl)phenyl benzoate; C33H30ClN5O3; CHEMBL403989; SCHEMBL12198196; KS-00001CQP; BDBM97971; DTXSID20235791; MolPort-027-835-464; BCP02570; 3641AC; ABP000364; ZINC29136020; AKOS016008711; CS-0785; DB05075; NCGC00378840-01; KB-81090; HY-10186; TG100-801; W-5618
DMPH1AG	CP	TargeGen
DMPH1AG	DT	Small molecular drug
DMPH1AG	PC	11973736
DMPH1AG	MW	580.1
DMPH1AG	FM	C33H30ClN5O3
DMPH1AG	IC	InChI=1S/C33H30ClN5O3/c1-22-19-24(28-21-27(13-14-29(28)34)42-32(40)23-7-3-2-4-8-23)20-30-31(22)36-33(38-37-30)35-25-9-11-26(12-10-25)41-18-17-39-15-5-6-16-39/h2-4,7-14,19-21H,5-6,15-18H2,1H3,(H,35,36,38)
DMPH1AG	CS	CC1=CC(=CC2=C1N=C(N=N2)NC3=CC=C(C=C3)OCCN4CCCC4)C5=C(C=CC(=C5)OC(=O)C6=CC=CC=C6)Cl
DMPH1AG	IK	JMGXJHWTVBGOKG-UHFFFAOYSA-N
DMPH1AG	IU	[4-chloro-3-[5-methyl-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-benzotriazin-7-yl]phenyl] benzoate
DMPH1AG	CA	CAS 867331-82-6
DMPH1AG	DE	Macular degeneration

DMZ571Y	ID	DMZ571Y
DMZ571Y	DN	TG-2349
DMZ571Y	HS	Phase 2
DMZ571Y	SN	HCV NS3-4A protease inhibitor, TaiGen Biotechnology
DMZ571Y	CP	Taigen biotechnology
DMZ571Y	PC	51037069
DMZ571Y	MW	897
DMZ571Y	FM	C47H56N6O10S
DMZ571Y	IC	InChI=1S/C47H56N6O10S/c1-28(2)60-32-21-19-29(20-22-32)40-49-38-34-16-11-12-18-37(34)63-39(38)42(50-40)61-33-25-36-41(54)51-47(44(56)52-64(58,59)46(3)23-24-46)26-30(47)13-7-5-4-6-8-17-35(43(55)53(36)27-33)48-45(57)62-31-14-9-10-15-31/h7,11-13,16,18-22,28,30-31,33,35-36H,4-6,8-10,14-15,17,23-27H2,1-3H3,(H,48,57)(H,51,54)(H,52,56)/b13-7-/t30-,33-,35+,36+,47-/m1/s1
DMZ571Y	CS	CC(C)OC1=CC=C(C=C1)C2=NC3=C(C(=N2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6/C=C\\CCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)NS(=O)(=O)C8(CC8)C)OC9=CC=CC=C93
DMZ571Y	IK	GZRNOYTVBWWFLJ-NTPALUMKSA-N
DMZ571Y	IU	cyclopentyl N-[(1S,4R,6S,7Z,14S,18R)-4-[(1-methylcyclopropyl)sulfonylcarbamoyl]-2,15-dioxo-18-[[2-(4-propan-2-yloxyphenyl)-[1]benzofuro[3,2-d]pyrimidin-4-yl]oxy]-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-14-yl]carbamate
DMZ571Y	CA	CAS 1435923-88-8
DMZ571Y	DE	Hepatitis C virus infection

DMJ2FTU	ID	DMJ2FTU
DMJ2FTU	DN	TGBA01AD
DMJ2FTU	HS	Phase 2
DMJ2FTU	SN	ARABINOFURANOSYLURACIL; Spongouridin; 1-pentofuranosylpyrimidine-2,4(1H,3H)-dione; Uracil arabinoside; 3083-77-0; 1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; Uridine-5-d; AK-47314; AC1L1AWE; ACMC-209m8u; 1-.beta.-D-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione; NCIOpen2_003486; Oprea1_327785; MLS006011814; CHEMBL68846; SCHEMBL2056758; ARONIS003790; AC1Q69D3; KS-00003WPG; CTK8J4890
DMJ2FTU	CP	Fabre-Kramer
DMJ2FTU	DT	Small molecular drug
DMJ2FTU	PC	1177
DMJ2FTU	MW	244.2
DMJ2FTU	FM	C9H12N2O6
DMJ2FTU	IC	InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)
DMJ2FTU	CS	C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O
DMJ2FTU	IK	DRTQHJPVMGBUCF-UHFFFAOYSA-N
DMJ2FTU	IU	1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMJ2FTU	CA	CAS 40436-51-9
DMJ2FTU	CB	CHEBI:143353
DMJ2FTU	DE	Mood disorder

DMNXJ5B	ID	DMNXJ5B
DMNXJ5B	DN	TGFK08AA
DMNXJ5B	HS	Phase 2
DMNXJ5B	CP	Fabre Kramer Pharmaceuticals Inc
DMNXJ5B	DE	Generalized anxiety disorder

DMGWE4H	ID	DMGWE4H
DMGWE4H	DN	TGFK09SD
DMGWE4H	HS	Phase 2
DMGWE4H	CP	Fabre Kramer Pharmaceuticals Inc
DMGWE4H	DE	Hypoactive sexual desire dysfunction

DMQ6ANE	ID	DMQ6ANE
DMQ6ANE	DN	TGOF02N
DMQ6ANE	HS	Phase 2
DMQ6ANE	CP	Fabre-Kramer Pharmaceuticals
DMQ6ANE	DE	Schizophrenia

DMI57ZA	ID	DMI57ZA
DMI57ZA	DN	TGWOOAA
DMI57ZA	HS	Phase 2
DMI57ZA	CP	Fabre-Kramer Pharmaceuticals
DMI57ZA	DE	Social phobia; Generalized anxiety disorder

DMFU0JY	ID	DMFU0JY
DMFU0JY	DN	TH-302
DMFU0JY	HS	Phase 2
DMFU0JY	SN	TH-302; evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; TH-302; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174
DMFU0JY	CP	Threshold Pharmaceuticals
DMFU0JY	DT	Small molecular drug
DMFU0JY	PC	11984561
DMFU0JY	MW	449.04
DMFU0JY	FM	C9H16Br2N5O4P
DMFU0JY	IC	InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)
DMFU0JY	CS	CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr
DMFU0JY	IK	UGJWRPJDTDGERK-UHFFFAOYSA-N
DMFU0JY	IU	2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine
DMFU0JY	CA	CAS 918633-87-1
DMFU0JY	DE	Soft tissue sarcoma; Melanoma; Prostate cancer; Squamous cell carcinoma; Pancreatic cancer

DMW8X05	ID	DMW8X05
DMW8X05	DN	THR-149
DMW8X05	HS	Phase 2
DMW8X05	CP	Oxurion
DMW8X05	DT	Small molecular drug
DMW8X05	DE	Diabetic macular edema

DMBO021	ID	DMBO021
DMBO021	DN	THR-18
DMBO021	HS	Phase 2
DMBO021	CP	Thrombotech Technologies Ltd
DMBO021	PC	86291591
DMBO021	MW	2390.8
DMBO021	FM	C105H167F3N28O28S2
DMBO021	IC	InChI=1S/C103H166N28O26S2.C2HF3O2/c1-15-56(9)81(129-98(155)82(57(10)16-2)128-88(145)66(37-39-77(136)137)117-86(143)65(36-38-76(134)135)119-93(150)74-30-23-45-130(74)99(156)58(11)114-84(141)67(40-47-158-13)118-85(142)64(115-59(12)132)28-21-43-112-102(107)108)97(154)120-68(41-48-159-14)87(144)124-73(52-78(138)139)91(148)121-69(29-22-44-113-103(109)110)100(157)131-46-24-31-75(131)94(151)125-71(50-60-25-18-17-19-26-60)90(147)122-70(49-53(3)4)89(146)123-72(51-61-32-34-62(133)35-33-61)92(149)126-80(55(7)8)96(153)127-79(54(5)6)95(152)116-63(83(104)140)27-20-42-111-101(105)106;3-2(4,5)1(6)7/h17-19,25-26,32-35,53-58,63-75,79-82,133H,15-16,20-24,27-31,36-52H2,1-14H3,(H2,104,140)(H,114,141)(H,115,132)(H,116,152)(H,117,143)(H,118,142)(H,119,150)(H,120,154)(H,121,148)(H,122,147)(H,123,146)(H,124,144)(H,125,151)(H,126,149)(H,127,153)(H,128,145)(H,129,155)(H,134,135)(H,136,137)(H,138,139)(H4,105,106,111)(H4,107,108,112)(H4,109,110,113);(H,6,7)/t56-,57-,58-,63-,64-,65-,66-,67-,68-,69-,70-,71?,72-,73-,74-,75-,79?,80-,81-,82-;/m0./s1
DMBO021	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NC(CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](C(C)C)C(=O)NC(C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C.C(=O)(C(F)(F)F)O
DMBO021	IK	UNDAPMUKULIMSY-HGKXDEPLSA-N
DMBO021	IU	(4S)-4-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid;2,2,2-trifluoroacetic acid
DMBO021	CA	CAS 1383452-03-6
DMBO021	DE	Asthma

DMAVQR1	ID	DMAVQR1
DMAVQR1	DN	THR-184
DMAVQR1	HS	Phase 2
DMAVQR1	CP	Oxurion
DMAVQR1	DT	Small molecular drug
DMAVQR1	DE	Renal fibrosis

DM1BYNF	ID	DM1BYNF
DM1BYNF	DN	THRX-198321
DM1BYNF	HS	Phase 2
DM1BYNF	SN	Beta 2 adrenoreceptor agonist/muscarinic receptor antagonist (asthma), Theravance
DM1BYNF	CP	GlaxoSmithKline; Theravance
DM1BYNF	DE	Chronic obstructive pulmonary disease

DM4BLJM	ID	DM4BLJM
DM4BLJM	DN	Thymoctonan
DM4BLJM	HS	Phase 2
DM4BLJM	SN	FCE-25388; Thymic humoral factor gamma-2; Thymus humoral factor gamma-2; THF-gamma-2
DM4BLJM	CP	Weizmann Institute of Science
DM4BLJM	DT	Small molecular drug
DM4BLJM	PC	9897695
DM4BLJM	MW	918
DM4BLJM	FM	C43H67N9O13
DM4BLJM	IC	InChI=1S/C43H67N9O13/c1-24(2)19-27(45)37(58)47-29(15-16-35(54)55)40(61)50-31(22-36(56)57)38(59)46-23-34(53)52-18-10-14-33(52)42(63)48-28(13-8-9-17-44)39(60)49-30(21-26-11-6-5-7-12-26)41(62)51-32(43(64)65)20-25(3)4/h5-7,11-12,24-25,27-33H,8-10,13-23,44-45H2,1-4H3,(H,46,59)(H,47,58)(H,48,63)(H,49,60)(H,50,61)(H,51,62)(H,54,55)(H,56,57)(H,64,65)/t27-,28-,29-,30-,31-,32-,33-/m0/s1
DM4BLJM	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)N
DM4BLJM	IK	NYJVPTKMDYSZDU-MRNVWEPHSA-N
DM4BLJM	IU	(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM4BLJM	CA	CAS 107489-37-2
DM4BLJM	DE	Immune System disease

DME4LA1	ID	DME4LA1
DME4LA1	DN	Tideglusib
DME4LA1	HS	Phase 2
DME4LA1	SN	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)
DME4LA1	DT	Small molecular drug
DME4LA1	PC	11313622
DME4LA1	MW	334.4
DME4LA1	FM	C19H14N2O2S
DME4LA1	IC	InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2
DME4LA1	CS	C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43
DME4LA1	IK	PMJIHLSCWIDGMD-UHFFFAOYSA-N
DME4LA1	IU	4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
DME4LA1	CA	CAS 865854-05-3
DME4LA1	CB	CHEBI:147398
DME4LA1	DE	Osteosarcoma

DM5XRMA	ID	DM5XRMA
DM5XRMA	DN	Tipapkinogene sovacivec
DM5XRMA	HS	Phase 2
DM5XRMA	CP	Transgene
DM5XRMA	DE	Cervical Intraepithelial neoplasia

DMS9BDQ	ID	DMS9BDQ
DMS9BDQ	DN	Tipelukast
DMS9BDQ	HS	Phase 2
DMS9BDQ	SN	Asthma therapy, MediciNova; KCA-757; MN-001
DMS9BDQ	CP	Kyorin Pharmaceutical Co Ltd
DMS9BDQ	DT	Small molecular drug
DMS9BDQ	PC	9893228
DMS9BDQ	MW	530.7
DMS9BDQ	FM	C29H38O7S
DMS9BDQ	IC	InChI=1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33)
DMS9BDQ	CS	CCCC1=C(C=CC(=C1OCCCC(=O)O)C(=O)C)OCCCSC2=C(C(=C(C=C2)C(=O)C)O)CCC
DMS9BDQ	IK	KPWYNAGOBXLMSE-UHFFFAOYSA-N
DMS9BDQ	IU	4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenyl)sulfanylpropoxy]-2-propylphenoxy]butanoic acid
DMS9BDQ	CA	CAS 125961-82-2
DMS9BDQ	DE	Asthma; Idiopathic pulmonary fibrosis

DM1SB94	ID	DM1SB94
DM1SB94	DN	Tiprelestat
DM1SB94	HS	Phase 2
DM1SB94	SN	Elafin; Recombinant leukocyte elastase/proteinase-3 inhibitor (iv, inflammation), Proteo Biotech
DM1SB94	CP	Proteo Biotech AG
DM1SB94	PC	44201346
DM1SB94	MW	5999
DM1SB94	FM	C254H416N72O75S10
DM1SB94	IC	InChI=1S/C254H416N72O75S10/c1-28-129(17)195-239(387)288-142(60-38-43-85-258)208(356)283-141(59-37-42-84-257)210(358)306-168-120-407-406-119-167-228(376)294-152(99-123(5)6)215(363)284-140(58-36-41-83-256)209(357)296-158(106-191(347)348)221(369)317-200(137(25)331)244(392)299-157(105-190(345)346)218(366)308-169(248(396)321-91-49-65-172(321)231(379)274-110-186(339)310-195)121-410-408-117-165(227(375)295-155(102-138-55-33-32-34-56-138)220(368)313-194(128(15)16)251(399)325-95-53-68-175(325)232(380)292-151(252(400)401)73-77-180(262)333)302-203(351)135(23)276-207(355)147(80-97-402-26)278-183(336)107-272-206(354)163-115-404-405-116-164(225(373)277-134(22)202(350)282-148(81-98-403-27)214(362)293-153(100-124(7)8)216(364)300-159(104-182(264)335)247(395)326-96-54-71-178(326)250(398)324-94-52-67-174(324)233(381)297-156(103-181(263)334)217(365)285-143(211(359)305-167)62-45-87-269-253(265)266)304-212(360)144(63-46-88-270-254(267)268)289-240(388)196(130(18)29-2)314-219(367)154(101-125(9)10)298-241(389)197(131(19)30-3)316-242(390)198(132(20)31-4)315-236(384)177-70-51-93-323(177)249(397)170(122-411-409-118-166(307-229(168)377)226(374)286-145(74-78-188(341)342)205(353)271-108-184(337)279-160(112-327)222(370)303-163)309-223(371)161(113-328)280-185(338)109-273-230(378)171-64-48-90-320(171)245(393)149(61-39-44-86-259)291-243(391)199(136(24)330)318-224(372)162(114-329)301-238(386)193(127(13)14)311-234(382)173-66-47-89-319(173)187(340)111-275-204(352)139(57-35-40-82-255)287-237(385)192(126(11)12)312-235(383)176-69-50-92-322(176)246(394)150(75-79-189(343)344)290-213(361)146(72-76-179(261)332)281-201(349)133(21)260/h32-34,55-56,123-137,139-178,192-200,327-331H,28-31,35-54,57-122,255-260H2,1-27H3,(H2,261,332)(H2,262,333)(H2,263,334)(H2,264,335)(H,271,353)(H,272,354)(H,273,378)(H,274,379)(H,275,352)(H,276,355)(H,277,373)(H,278,336)(H,279,337)(H,280,338)(H,281,349)(H,282,350)(H,283,356)(H,284,363)(H,285,365)(H,286,374)(H,287,385)(H,288,387)(H,289,388)(H,290,361)(H,291,391)(H,292,380)(H,293,362)(H,294,376)(H,295,375)(H,296,357)(H,297,381)(H,298,389)(H,299,392)(H,300,364)(H,301,386)(H,302,351)(H,303,370)(H,304,360)(H,305,359)(H,306,358)(H,307,377)(H,308,366)(H,309,371)(H,310,339)(H,311,382)(H,312,383)(H,313,368)(H,314,367)(H,315,384)(H,316,390)(H,317,369)(H,318,372)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,400,401)(H4,265,266,269)(H4,267,268,270)/t129-,130-,131-,132-,133-,134-,135-,136+,137+,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,192-,193-,194-,195-,196-,197-,198-,199-,200-/m0/s1
DM1SB94	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCNC(=N)N)CC(=O)N)CC(=O)N)CC(C)C)CCSC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]7CCCN7C(=O)[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N4)CO)CCC(=O)O)NC2=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H]8CCCN8C(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]9CCCN9C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)N)[C@@H](C)CC)[C@@H](C)CC)CC(C)C)[C@@H](C)CC)CCCNC(=N)N)CCSC)C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)O)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N1)CC(=O)O)[C@@H](C)O)CC(=O)O)CCCCN)CC(C)C)CCCCN)CCCCN
DM1SB94	IK	MDCUNMLZLNGCQA-HWOAGHQOSA-N
DM1SB94	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(1R,4S,4aS,7S,7aS,10S,10aS,13aR,16S,20aS,22S,23aS,25S,26aS,28S,29aS,31S,32aS,34R,37S,40S,43S,46S,49S,52S,58R,63R,66S,72S,75R,81S,84S,87R,92R,98S)-58-[[(2S)-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-7a,10a,23a-tris(4-aminobutyl)-7,22-bis(2-amino-2-oxoethyl)-4a,40,46,49-tetrakis[(2S)-butan-2-yl]-4,37-bis(3-carbamimidamidopropyl)-66-(2-carboxyethyl)-26a,32a-bis(carboxymethyl)-29a-[(1R)-1-hydroxyethyl]-72-(hydroxymethyl)-31,84-dimethyl-20a,25,43-tris(2-methylpropyl)-28,81-bis(2-methylsulfanylethyl)-2a,3,5a,6,8a,9,11a,15,18a,21,21a,24,24a,27,27a,30,30a,33,33a,35a,36,39,42,45,48,51,57,64,67,70,73,76,79,82,85,93,99-heptatriacontaoxo-15a,16a,38a,39a,60,61,89,90-octathia-a,2,3a,5,6a,8,9a,12a,14,19a,20,22a,23,25a,26,28a,29,31a,32,34a,35,36a,38,41,44,47,50,56,65,68,71,74,77,80,83,86,94-heptatriacontazaoctacyclo[90.25.17.434,75.263,113.010,14.016,20.052,56.094,98]tetracontahectane-87-carbonyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid
DM1SB94	CA	CAS 820211-82-3
DM1SB94	DE	Myocardial infarction

DMT8SMO	ID	DMT8SMO
DMT8SMO	DN	TKA-731
DMT8SMO	HS	Phase 2
DMT8SMO	DE	Pain

DMGWP8L	ID	DMGWP8L
DMGWP8L	DN	TLC-388
DMGWP8L	HS	Phase 2
DMGWP8L	CP	TLC Biopharmaceuticals
DMGWP8L	PC	46871946
DMGWP8L	MW	850.7
DMGWP8L	FM	C39H30N8O15
DMGWP8L	IC	InChI=1S/C39H30N8O15/c1-5-39(26-13-30-34-18(14-43(30)36(49)25(26)16-60-38(39)51)8-21-24(15-42(3)4)31(48)7-6-27(21)40-34)61-37(50)17(2)62-41-35-22-9-19(44(52)53)11-28(46(56)57)32(22)33-23(35)10-20(45(54)55)12-29(33)47(58)59/h6-13,17,48H,5,14-16H2,1-4H3/t17?,39-/m0/s1
DMGWP8L	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)OC(=O)C(C)ON=C6C7=C(C(=CC(=C7)[N+](=O)[O-])[N+](=O)[O-])C8=C6C=C(C=C8[N+](=O)[O-])[N+](=O)[O-]
DMGWP8L	IK	JCCCLGDYMMTBPM-HXDHBHDHSA-N
DMGWP8L	IU	[(19S)-8-[(dimethylamino)methyl]-19-ethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] 2-[(2,4,5,7-tetranitrofluoren-9-ylidene)amino]oxypropanoate
DMGWP8L	CA	CAS 1432468-79-5
DMGWP8L	DE	Solid tumour/cancer

DMVXLQ7	ID	DMVXLQ7
DMVXLQ7	DN	TLN-4601
DMVXLQ7	HS	Phase 2
DMVXLQ7	SN	Diazepinomicin; TLN-4601; BU-4664L; 733035-26-2; UNII-YPH994Y0RF; ECO-4601; YPH994Y0RF; 11H-Dibenzo(b,E)(1,4)diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl)-; TLN 4601; ECO 4601; CHEMBL550961; DTXSID40223539; SALVHVNECODMJP-GNUCVDFRSA-N; ZINC3938687; ECO-04601; DB12420; KB-81170
DMVXLQ7	DT	Small molecular drug
DMVXLQ7	PC	9868980
DMVXLQ7	MW	462.6
DMVXLQ7	FM	C28H34N2O4
DMVXLQ7	IC	InChI=1S/C28H34N2O4/c1-18(2)8-5-9-19(3)10-6-11-20(4)14-15-30-23-16-21(31)17-25(33)27(23)29-26-22(28(30)34)12-7-13-24(26)32/h7-8,10,12-14,16-17,29,31-33H,5-6,9,11,15H2,1-4H3/b19-10+,20-14+
DMVXLQ7	CS	CC(=CCC/C(=C/CC/C(=C/CN1C2=C(C(=CC(=C2)O)O)NC3=C(C1=O)C=CC=C3O)/C)/C)C
DMVXLQ7	IK	SALVHVNECODMJP-GNUCVDFRSA-N
DMVXLQ7	IU	1,3,10-trihydroxy-5-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]-11H-benzo[b][1,4]benzodiazepin-6-one
DMVXLQ7	CA	CAS 733035-26-2
DMVXLQ7	CB	CHEBI:156321
DMVXLQ7	DE	Solid tumour/cancer

DMKV5UM	ID	DMKV5UM
DMKV5UM	DN	TM-601
DMKV5UM	HS	Phase 2
DMKV5UM	CP	TransMolecular Inc
DMKV5UM	PC	86278273
DMKV5UM	MW	3996
DMKV5UM	FM	C158H249N53O47S11
DMKV5UM	IC	InChI=1S/C158H249N53O47S11/c1-77(2)55-96-138(241)205-105(144(247)186-86(125(165)228)28-18-47-173-156(166)167)70-264-262-68-103-131(234)177-63-115(217)176-64-116(218)183-87(25-12-15-44-159)128(231)178-65-117(219)184-88(29-19-48-174-157(168)169)129(232)179-66-118(220)185-89(26-13-16-45-160)133(236)202-107-72-267-269-75-110-149(252)195-98(56-81-23-10-9-11-24-81)143(246)208-124(80(5)213)154(257)209-123(79(4)212)153(256)199-102(61-122(226)227)141(244)196-99(58-83-62-172-76-181-83)139(242)189-92(37-39-113(163)215)136(239)190-94(42-53-260-7)132(235)182-78(3)126(229)187-91(30-20-49-175-158(170)171)134(237)188-90(27-14-17-46-161)135(238)203-108(73-266-265-71-106(146(249)193-96)204-137(240)93(38-40-114(164)216)191-151(254)111-31-21-50-210(111)119(221)67-180-130(233)97(194-147(107)250)57-82-33-35-84(214)36-34-82)148(251)198-100(59-120(222)223)140(243)197-101(60-121(224)225)142(245)206-109(150(253)201-103)74-268-263-69-104(200-127(230)85(162)41-52-259-6)145(248)192-95(43-54-261-8)155(258)211-51-22-32-112(211)152(255)207-110/h9-11,23-24,33-36,62,76-80,85-112,123-124,212-214H,12-22,25-32,37-61,63-75,159-162H2,1-8H3,(H2,163,215)(H2,164,216)(H2,165,228)(H,172,181)(H,176,217)(H,177,234)(H,178,231)(H,179,232)(H,180,233)(H,182,235)(H,183,218)(H,184,219)(H,185,220)(H,186,247)(H,187,229)(H,188,237)(H,189,242)(H,190,239)(H,191,254)(H,192,248)(H,193,249)(H,194,250)(H,195,252)(H,196,244)(H,197,243)(H,198,251)(H,199,256)(H,200,230)(H,201,253)(H,202,236)(H,203,238)(H,204,240)(H,205,241)(H,206,245)(H,207,255)(H,208,246)(H,209,257)(H,222,223)(H,224,225)(H,226,227)(H4,166,167,173)(H4,168,169,174)(H4,170,171,175)/t78-,79+,80+,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,123-,124-/m0/s1
DMKV5UM	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]4C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCSC)CCC(=O)N)CC5=CNC=N5)CC(=O)O)[C@@H](C)O)[C@@H](C)O)CC6=CC=CC=C6)NC(=O)[C@@H]7CCCN7C(=O)[C@@H](NC(=O)[C@H](CSSC[C@@H](C(=O)N4)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC(=O)O)CC(=O)O)NC(=O)[C@H](CCSC)N)CCSC)C(=O)N[C@H](C(=O)NCC(=O)N8CCC[C@H]8C(=O)N[C@H](C(=O)N3)CCC(=O)N)CC9=CC=C(C=C9)O)CCCCN)CCCNC(=N)N)CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CC(C)C)CCCCN)CCCNC(=N)N
DMKV5UM	IK	QPAKKWCQMHUHNI-GQIQPHNSSA-N
DMKV5UM	IU	2-[(1R,4R,5aR,8aS,9R,12S,17aS,18S,20aS,21R,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54R,59R,62S,65S,74S,77R,80S,86S,92S)-51,80,92-tris(4-aminobutyl)-5a-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]-9-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-39,62-bis(3-amino-3-oxopropyl)-24-benzyl-48,86-bis(3-carbamimidamidopropyl)-20a,33-bis(carboxymethyl)-27,30-bis[(1R)-1-hydroxyethyl]-74-[(4-hydroxyphenyl)methyl]-36-(1H-imidazol-4-ylmethyl)-45-methyl-8a-(2-methylpropyl)-12,42-bis(2-methylsulfanylethyl)-a,3,7a,10,10a,13,15a,18a,19,21a,22,25,28,31,34,37,40,43,46,49,52,61,64,70,73,76,79,82,85,88,91,94,97-tritriacontaoxo-2a,3a,6,7,12a,13a,56,57-octathia-2,6a,9a,11,14,16a,19a,20,22a,23,26,29,32,35,38,41,44,47,50,53,60,63,69,72,75,78,81,84,87,90,93,96,99-tritriacontazahexacyclo[57.41.10.84,54.421,77.014,18.065,69]docosahectan-17a-yl]acetic acid
DMKV5UM	CA	CAS 163515-35-3
DMKV5UM	DE	Solid tumour/cancer

DMW145U	ID	DMW145U
DMW145U	DN	TMC-310911
DMW145U	HS	Phase 2
DMW145U	CP	Janssen research & development
DMW145U	PC	53361968
DMW145U	MW	756
DMW145U	FM	C38H53N5O7S2
DMW145U	IC	InChI=1S/C38H53N5O7S2/c1-25(2)22-43(23-33(44)32(20-26-8-4-3-5-9-26)41-38(45)50-34-24-49-36-30(34)16-19-48-36)52(46,47)29-12-13-31-35(21-29)51-37(40-31)39-27-14-17-42(18-15-27)28-10-6-7-11-28/h3-5,8-9,12-13,21,25,27-28,30,32-34,36,44H,6-7,10-11,14-20,22-24H2,1-2H3,(H,39,40)(H,41,45)/t30-,32-,33+,34-,36+/m0/s1
DMW145U	CS	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC5=C(C=C4)N=C(S5)NC6CCN(CC6)C7CCCC7
DMW145U	IK	JQUNFHFWXCXPRK-AMMMHQJVSA-N
DMW145U	IU	[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[[2-[(1-cyclopentylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl]sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMW145U	CA	CAS 1000287-05-7
DMW145U	DE	Human immunodeficiency virus infection

DME8PFQ	ID	DME8PFQ
DME8PFQ	DN	TMX-049
DME8PFQ	HS	Phase 2
DME8PFQ	CP	Teijin Pharma
DME8PFQ	DE	Diabetic nephropathy

DMH4BFD	ID	DMH4BFD
DMH4BFD	DN	TN-871
DMH4BFD	HS	Phase 2
DMH4BFD	SN	1-[6-Butyl-5H-indeno[5,6-d]-1,3-dioxol-5-yl]-4-methylpiperazine dihydrochloride; 2-n-Butyl-5,6-methylenedioxy-1-(4-methylpiperazinyl)indene dihydrochloride
DMH4BFD	DE	Cognitive impairment

DM3AIF7	ID	DM3AIF7
DM3AIF7	DN	TNF alpha kinoid
DM3AIF7	HS	Phase 2
DM3AIF7	SN	TNFa Kinoid; Debio-0512; TNF-K; TNF-kinoid; Anti-TNF alpha vaccine, Neovacs
DM3AIF7	CP	Neovacs SA
DM3AIF7	DT	Vaccine
DM3AIF7	DE	Autoimmune diabetes

DM8DZKI	ID	DM8DZKI
DM8DZKI	DN	TNP-2092
DM8DZKI	HS	Phase 2
DM8DZKI	SN	UNII-W2P7EF7O6O; W2P7EF7O6O; CBR-2092; CHEMBL4594404; 3-((E)-((4-((1-((3R)-1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl)cyclopropyl)methylamino)-1-piperidinyl)imino)methyl)rifamycin; Rifamycin, 3-((E)-((4-((1-((3R)-1-(3-carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl)cyclopropyl)methylamino)-1-piperidinyl)imino)methyl)-
DM8DZKI	CP	TenNor Therapeutics
DM8DZKI	DT	Small molecular drug
DM8DZKI	PC	145722022
DM8DZKI	MW	1205.4
DM8DZKI	FM	C65H81FN6O15
DM8DZKI	IC	InChI=1S/C65H81FN6O15/c1-31-13-12-14-32(2)61(80)68-50-44(56(77)47-48(57(50)78)55(76)37(7)59-49(47)60(79)64(9,87-59)85-26-20-46(84-11)33(3)58(86-38(8)73)36(6)54(75)35(5)53(31)74)28-67-71-24-18-41(19-25-71)69(10)65(21-22-65)40-17-23-70(29-40)52-34(4)51-42(39-15-16-39)27-43(63(82)83)62(81)72(51)30-45(52)66/h12-14,20,26-28,30-31,33,35-36,39-41,46,53-54,58,74-78H,15-19,21-25,29H2,1-11H3,(H,68,80)(H,82,83)/b13-12+,26-20+,32-14-,67-28+/t31-,33-,35+,36-,40+,46-,53-,54+,58+,64-/m0/s1
DM8DZKI	CS	C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCC(CC5)N(C)C6(CC6)[C@@H]7CCN(C7)C8=C(C9=C(C=C(C(=O)N9C=C8F)C(=O)O)C1CC1)C)/C
DM8DZKI	IK	OPZFMLLAJBIKAN-YSBZUPOXSA-N
DM8DZKI	IU	8-[(3R)-3-[1-[[1-[(E)-[(7S,9E,11S,12S,13S,14S,15R,16R,17S,18S,19E,21Z)-13-acetyloxy-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-26-yl]methylideneamino]piperidin-4-yl]-methylamino]cyclopropyl]pyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid
DM8DZKI	CA	CAS 922717-97-3
DM8DZKI	DE	Joint infection; Skin and skin-structure infection

DMAJ6YL	ID	DMAJ6YL
DMAJ6YL	DN	TNX-1300
DMAJ6YL	HS	Phase 2
DMAJ6YL	SN	RBP-8000
DMAJ6YL	CP	Tonix Pharmaceuticals
DMAJ6YL	DT	Recombinant protein
DMAJ6YL	DE	Cocaine addiction

DMBIJZ6	ID	DMBIJZ6
DMBIJZ6	DN	Tocopherol
DMBIJZ6	HS	Phase 2
DMBIJZ6	SN	Methyltocols; tocoferol; tocoferoles; tocophrol; Tocopherols
DMBIJZ6	PC	14985
DMBIJZ6	IU	(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol
DMBIJZ6	DE	Phenylketonuria

DMLCUAS	ID	DMLCUAS
DMLCUAS	DN	TOFIMILAST
DMLCUAS	HS	Phase 2
DMLCUAS	SN	CP-325366; Tofimilast < Prop INN; 9-Cyclopentyl-7-ethyl-3-(2-thienyl)-5,6-dihydro-9H-pyrazolo[3,4-c][1,2,4]triazolo[4,3-a]pyridine
DMLCUAS	DT	Small molecular drug
DMLCUAS	PC	9896267
DMLCUAS	MW	339.5
DMLCUAS	FM	C18H21N5S
DMLCUAS	IC	InChI=1S/C18H21N5S/c1-2-14-13-9-10-22-17(15-8-5-11-24-15)19-20-18(22)16(13)23(21-14)12-6-3-4-7-12/h5,8,11-12H,2-4,6-7,9-10H2,1H3
DMLCUAS	CS	CCC1=NN(C2=C1CCN3C2=NN=C3C4=CC=CS4)C5CCCC5
DMLCUAS	IK	DHCOPPHTVOXDKU-UHFFFAOYSA-N
DMLCUAS	IU	12-cyclopentyl-10-ethyl-5-thiophen-2-yl-3,4,6,11,12-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,10-tetraene
DMLCUAS	CA	CAS 185954-27-2
DMLCUAS	DE	Chronic obstructive pulmonary disease

DMTGNWU	ID	DMTGNWU
DMTGNWU	DN	Tofisopam
DMTGNWU	HS	Phase 2
DMTGNWU	SN	tofisopam; 22345-47-7; Grandaxin; Seriel; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; Egyt 341; Tofisopamum; 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-; tofizopam; NCGC00165912-02; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine; benzodiazepine; EGYT 341; Grandaxin; Nodeprine; Seriel; Tofisopamum [INN-Latin]; 7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine; Tofisopam [INN:DCF:JAN]; EINECS 244-922-3; CCRIS 8738; Emandaxin (TN); DSSTox_CID_3681; Tofisopam (JP17/INN); DSSTox_RID_77145; DSSTox_GSID_23681; SCHEMBL43522; Tofisopam (patented in japan); CHEMBL404216; SCHEMBL8086894; DTXSID3023681; CHEBI:32241; BCP09600; Tox21_112269; MFCD00823171; Tofisopam, >=98% (HPLC), solid; AKOS025401672; DB08811; QC-1212; NCGC00165912-01; NCGC00165912-03; AC-24288; LS-14948; CAS-22345-47-7; DB-045872; FT-0638212; X6663; D01254; 345T477; Q945537; Q-201839; BRD-A69095630-001-01-1; 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine; 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine; (1Z,3Z)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine
DMTGNWU	DT	Small molecular drug
DMTGNWU	PC	5502
DMTGNWU	MW	382.5
DMTGNWU	FM	C22H26N2O4
DMTGNWU	IC	InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3
DMTGNWU	CS	CCC1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C
DMTGNWU	IK	RUJBDQSFYCKFAA-UHFFFAOYSA-N
DMTGNWU	IU	1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DMTGNWU	CA	CAS 22345-47-7
DMTGNWU	CB	CHEBI:32241
DMTGNWU	DE	Irritable bowel syndrome; Hyperuricaemia

DMVJWPR	ID	DMVJWPR
DMVJWPR	DN	TOK-001
DMVJWPR	HS	Phase 2
DMVJWPR	SN	Galeterone; 851983-85-2; Galaterone; VN/124-1; UNII-WA33E149SW; TOK 001; VN/124; WA33E149SW; (3beta)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol; (3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol; Galeterone [USAN:INN]; Galeterone (USAN); TOK-001(Galeterone); SCHEMBL939234; GTPL8638; 17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3beta-ol; CHEMBL2105738; Galeterone, &gt
DMVJWPR	CP	Tokai Pharmaceuticals
DMVJWPR	DT	Small molecular drug
DMVJWPR	PC	11188409
DMVJWPR	MW	388.5
DMVJWPR	FM	C26H32N2O
DMVJWPR	IC	InChI=1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3/t18-,19-,20-,21-,25-,26-/m0/s1
DMVJWPR	CS	C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4N5C=NC6=CC=CC=C65)C)O
DMVJWPR	IK	PAFKTGFSEFKSQG-PAASFTFBSA-N
DMVJWPR	IU	(3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DMVJWPR	CA	CAS 851983-85-2
DMVJWPR	DE	Prostate cancer

DMW17KS	ID	DMW17KS
DMW17KS	DN	TOL-3021
DMW17KS	HS	Phase 2
DMW17KS	CP	Tolerion
DMW17KS	DE	leukaemia

DMORFZD	ID	DMORFZD
DMORFZD	DN	Tolamba
DMORFZD	HS	Phase 2
DMORFZD	SN	AIC, Dynavax; AIC, UCB Pharma; AIC-0003; Allergy therapeutic, Dynavax; Amb a 1 ISS conjugate, Dynavax; Ragweed allergy vaccine, Dynavax; Ragweed allergy vaccine, UCB Pharma; ISS-1018 (allergy), Dynavax
DMORFZD	CP	Dynavax Technologies
DMORFZD	DT	Vaccine
DMORFZD	DE	Allergic rhinitis

DMT4OPL	ID	DMT4OPL
DMT4OPL	DN	Tonabersat
DMT4OPL	HS	Phase 2
DMT4OPL	SN	SB-220453; USL-260; 5-HT1d agonist (migraine), Minster; 5-HT1d agonist (migraine), SB
DMT4OPL	CP	Upsher-smith laboratories
DMT4OPL	DT	Small molecular drug
DMT4OPL	PC	6918324
DMT4OPL	MW	391.8
DMT4OPL	FM	C20H19ClFNO4
DMT4OPL	IC	InChI=1S/C20H19ClFNO4/c1-10(24)11-5-7-16-13(8-11)17(18(25)20(2,3)27-16)23-19(26)12-4-6-15(22)14(21)9-12/h4-9,17-18,25H,1-3H3,(H,23,26)/t17-,18-/m0/s1
DMT4OPL	CS	CC(=O)C1=CC2=C(C=C1)OC([C@H]([C@H]2NC(=O)C3=CC(=C(C=C3)F)Cl)O)(C)C
DMT4OPL	IK	XLIIRNOPGJTBJD-ROUUACIJSA-N
DMT4OPL	IU	N-[(3S,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-chloro-4-fluorobenzamide
DMT4OPL	CA	CAS 175013-84-0
DMT4OPL	DE	Epilepsy

DMBH316	ID	DMBH316
DMBH316	DN	Tonapofylline
DMBH316	HS	Phase 2
DMBH316	SN	Bg 9928; 340021-17-2; BG-9928; UNII-83VNU4U44T; BG9928; CHEMBL386974; CHEMBL414157; 83VNU4U44T; 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[222]octanyl]propanoic acid; bicyclo[222]octane-1-propanoic acid, 4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1h-purin-8-yl)-; 3-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[222]oct-1-yl]-propionic acid; Bicyclo(222)octane-1-propanoic acid, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-; Tonapofylline [USAN:INN]
DMBH316	DT	Small molecular drug
DMBH316	PC	216466
DMBH316	MW	416.5
DMBH316	FM	C22H32N4O4
DMBH316	IC	InChI=1S/C22H32N4O4/c1-3-13-25-17-16(18(29)26(14-4-2)20(25)30)23-19(24-17)22-10-7-21(8-11-22,9-12-22)6-5-15(27)28/h3-14H2,1-2H3,(H,23,24)(H,27,28)
DMBH316	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CCC(CC3)(CC4)CCC(=O)O
DMBH316	IK	ZWTVVWUOTJRXKM-UHFFFAOYSA-N
DMBH316	IU	3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[2.2.2]octanyl]propanoic acid
DMBH316	CA	CAS 340021-17-2
DMBH316	DE	Acute and chronic heart failure

DMA04DE	ID	DMA04DE
DMA04DE	DN	Topiroxostat
DMA04DE	HS	Phase 2
DMA04DE	SN	FYX-051; Xanthine oxidoreductase inhibitor (oral, gout), Fuji Yakuhin
DMA04DE	CP	Fuji Yakuhin Kogyo Co Ltd
DMA04DE	DT	Small molecular drug
DMA04DE	PC	5288320
DMA04DE	MW	248.24
DMA04DE	FM	C13H8N6
DMA04DE	IC	InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
DMA04DE	CS	C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
DMA04DE	IK	UBVZQGOVTLIHLH-UHFFFAOYSA-N
DMA04DE	IU	4-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile
DMA04DE	CA	CAS 577778-58-6
DMA04DE	DE	Gout

DM2HDTM	ID	DM2HDTM
DM2HDTM	DN	Tosagestin
DM2HDTM	HS	Phase 2
DM2HDTM	SN	Org-30659; Org-30659/estradiol
DM2HDTM	CP	Organon BioSciences
DM2HDTM	DT	Small molecular drug
DM2HDTM	PC	159355
DM2HDTM	MW	308.4
DM2HDTM	FM	C21H24O2
DM2HDTM	IC	InChI=1S/C21H24O2/c1-4-21(23)10-9-18-17-7-5-14-11-15(22)6-8-16(14)19(17)13(2)12-20(18,21)3/h1,9-11,16-19,23H,2,5-8,12H2,3H3/t16-,17-,18-,19+,20-,21-/m0/s1
DM2HDTM	CS	C[C@]12CC(=C)[C@H]3[C@H]([C@@H]1C=C[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DM2HDTM	IK	YJSTYQGZKJHXLN-OLGWUGKESA-N
DM2HDTM	IU	(8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-11-methylidene-2,6,7,8,9,10,12,14-octahydro-1H-cyclopenta[a]phenanthren-3-one
DM2HDTM	CA	CAS 110072-15-6
DM2HDTM	DE	Contraception

DMAWLVB	ID	DMAWLVB
DMAWLVB	DN	TPI ASM8
DMAWLVB	HS	Phase 2
DMAWLVB	CP	Topigen Pharmaceuticals
DMAWLVB	TC	Antisense
DMAWLVB	DT	Antisense drug
DMAWLVB	DE	Asthma

DMSA2LZ	ID	DMSA2LZ
DMSA2LZ	DN	TPI-1020
DMSA2LZ	HS	Phase 2
DMSA2LZ	SN	Nitrobudesonide; NCX-1020; NO-budesonide; Budesonide-21-nitrooxymethylbenzoate
DMSA2LZ	CP	NicOx SA
DMSA2LZ	DE	Chronic obstructive pulmonary disease

DMC5TV6	ID	DMC5TV6
DMC5TV6	DN	TPI-287
DMC5TV6	HS	Phase 2
DMC5TV6	SN	849213-15-6; (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate; TPI 287; SCHEMBL10000720; DTXSID50233967; Q27273546
DMC5TV6	CP	Cortice Biosciences
DMC5TV6	DT	Small molecular drug
DMC5TV6	PC	11564168
DMC5TV6	MW	870
DMC5TV6	FM	C46H63NO15
DMC5TV6	IC	InChI=1S/C46H63NO15/c1-13-32-58-30-20-31-45(22-55-31,61-26(6)49)36-38(60-39(51)27-17-15-14-16-18-27)46(54)21-29(57-40(52)34(50)28(19-23(2)3)47-41(53)62-42(7,8)9)24(4)33(43(46,10)11)35(56-25(5)48)37(59-32)44(30,36)12/h13-18,23,28-32,34-38,50,54H,1,19-22H2,2-12H3,(H,47,53)/t28-,29-,30-,31+,32?,34+,35-,36-,37-,38-,44+,45-,46+/m0/s1
DMC5TV6	CS	CC1=C2[C@@H]([C@H]3[C@@]4([C@H](C[C@@H]5[C@]([C@H]4[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO5)OC(=O)C)OC(O3)C=C)C)OC(=O)C
DMC5TV6	IK	FDTAUJJRHBRHIJ-FDJAAIFISA-N
DMC5TV6	IU	[(1R,2S,5R,7S,11R,12S,15S,17S,18S,19S)-2,12-diacetyloxy-9-ethenyl-17-hydroxy-15-[(2R,3S)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-14,19,20,20-tetramethyl-4,8,10-trioxapentacyclo[9.7.1.113,17.02,5.07,19]icos-13-en-18-yl] benzoate
DMC5TV6	CA	CAS 849213-15-6
DMC5TV6	DE	Progressive supranuclear palsy; Alzheimer disease; Glioblastoma multiforme; Breast cancer

DM4R23C	ID	DM4R23C
DM4R23C	DN	TPM-1/Morphine
DM4R23C	HS	Phase 2
DM4R23C	CP	Phosphagenics
DM4R23C	DE	Pain

DMYP7TO	ID	DMYP7TO
DMYP7TO	DN	Trametinib + 2141795
DMYP7TO	HS	Phase 2
DMYP7TO	CP	GlaxoSmithKline
DMYP7TO	DT	Combination drug
DMYP7TO	PC	11707110; 2141795
DMYP7TO	DE	Solid tumour/cancer

DMU1LXS	ID	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	HS	Phase 2
DMU1LXS	CP	GenentechSouth San Francisco, CA
DMU1LXS	DT	Antibody drug conjugate
DMU1LXS	DE	Breast cancer; HER2-positive breast cancer

DM1ZQEN	ID	DM1ZQEN
DM1ZQEN	DN	TRAXOPRODIL MESYLATE
DM1ZQEN	HS	Phase 2
DM1ZQEN	SN	(S,S)-1-(4-Hydroxyphenyl)-2-[4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate
DM1ZQEN	DT	Small molecular drug
DM1ZQEN	PC	9802399
DM1ZQEN	MW	423.5
DM1ZQEN	FM	C21H29NO6S
DM1ZQEN	IC	InChI=1S/C20H25NO3.CH4O3S/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17;1-5(2,3)4/h2-10,15,19,22-24H,11-14H2,1H3;1H3,(H,2,3,4)/t15-,19+;/m0./s1
DM1ZQEN	CS	C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O.CS(=O)(=O)O
DM1ZQEN	IK	OZBWUANKVIMZIA-WRRDZZDISA-N
DM1ZQEN	IU	1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol;methanesulfonic acid
DM1ZQEN	CA	CAS 188591-67-5
DM1ZQEN	DE	Neurological disorder

DM7XZY5	ID	DM7XZY5
DM7XZY5	DN	Triapine
DM7XZY5	HS	Phase 2
DM7XZY5	SN	Triapine; 236392-56-6; 143621-35-6; 3-Apct; Pan 811; 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP; UNII-U4XIL4091C; NSC 663249; 200933-27-3; OCX 191; 2-((3-Aminopyridin-2-yl)methylene)hydrazinecarbothioamide; C7H9N5S; PAN-811; U4XIL4091C; 3-aminopyridine-2-carbaldehyde-thiosemicarbazone; [(E)-(3-amino-2-pyridyl)methyleneamino]thiourea; 3-Aminopyridine-2-carboxaldehyde- thiosemicarbazone; Hydrazinecarbothioamide, 2-((3-amino-2-pyridinyl)methylene)-; (E)-2-((3-aminopyridin-2-yl)methylene)hydrazinecarbothioamide
DM7XZY5	DT	Small molecular drug
DM7XZY5	PC	9571836
DM7XZY5	MW	195.25
DM7XZY5	FM	C7H9N5S
DM7XZY5	IC	InChI=1S/C7H9N5S/c8-5-2-1-3-10-6(5)4-11-12-7(9)13/h1-4H,8H2,(H3,9,12,13)/b11-4+
DM7XZY5	CS	C1=CC(=C(N=C1)/C=N/NC(=S)N)N
DM7XZY5	IK	XMYKNCNAZKMVQN-NYYWCZLTSA-N
DM7XZY5	IU	[(E)-(3-aminopyridin-2-yl)methylideneamino]thiourea
DM7XZY5	CA	CAS 143621-35-6
DM7XZY5	DE	Nerve injury

DMWU41P	ID	DMWU41P
DMWU41P	DN	TRIDMAC
DMWU41P	HS	Phase 2
DMWU41P	SN	65-23-6; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-; 2-Picoline-4,5-dimethanol, 3-hydroxy-
DMWU41P	CP	Targacept
DMWU41P	DT	Small molecular drug
DMWU41P	DE	Mood disorder

DM13G5R	ID	DM13G5R
DM13G5R	DN	TRK-170
DM13G5R	HS	Phase 2
DM13G5R	CP	Toray Industries Inc
DM13G5R	DE	Inflammatory bowel disease

DM64NYP	ID	DM64NYP
DM64NYP	DN	TRN-157
DM64NYP	HS	Phase 2
DM64NYP	SN	LAMA antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals; Long acting muscarinic M3 antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals
DM64NYP	CP	Theron pharmaceuticals
DM64NYP	DE	Chronic obstructive pulmonary disease

DMMQYF6	ID	DMMQYF6
DMMQYF6	DN	TRO-19622
DMMQYF6	HS	Phase 2
DMMQYF6	SN	Olesoxime; UNII-I2QN18P645; TRO 19622; NSC 21311; 22033-87-0; Cholest-4-en-3-one oxime; I2QN18P645; TRO-19622; Olesoxime, Z-; cholest-4-en-3-one, oxime; Olesoxime [USAN:INN]; SCHEMBL1010552; C27H45NO; QNTASHOAVRSLMD-FCARAQADSA-; MolPort-023-276-596; 3948AH; AKOS005145744; ZINC100657483; API0009039; 66514-00-9; 033T870; UNII-A6778U5IFY component QNTASHOAVRSLMD-FCARAQADSA-N
DMMQYF6	CP	Trophos
DMMQYF6	DT	Small molecular drug
DMMQYF6	PC	9930827
DMMQYF6	MW	399.7
DMMQYF6	FM	C27H45NO
DMMQYF6	IC	InChI=1S/C27H45NO/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28-29)13-15-26(20,4)25(22)14-16-27(23,24)5/h17-19,22-25,29H,6-16H2,1-5H3/b28-21+/t19-,22+,23-,24+,25+,26+,27-/m1/s1
DMMQYF6	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C/C(=N/O)/CC[C@]34C)C
DMMQYF6	IK	QNTASHOAVRSLMD-SIWSWZRQSA-N
DMMQYF6	IU	(NE)-N-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ylidene]hydroxylamine
DMMQYF6	CA	CAS 66538-08-7
DMMQYF6	DE	Peripheral neuropathy

DMR8Y4F	ID	DMR8Y4F
DMR8Y4F	DN	Troplasminogen alfa
DMR8Y4F	HS	Phase 2
DMR8Y4F	SN	TAPgen; BB-10153; Thrombin activatable plasminogen, British Biotech; Thrombin activatable plasminogen, Vernalis
DMR8Y4F	CP	Vernalis
DMR8Y4F	DE	Myocardial infarction

DMAZ2L6	ID	DMAZ2L6
DMAZ2L6	DN	TROXACITABINE
DMAZ2L6	HS	Phase 2
DMAZ2L6	SN	Troxatyl; BCH-4556; SPD-758; Troxacitabine < Prop INN; Beta-L-OddC; (-)-beta-L-Dioxolanecytidine
DMAZ2L6	CP	Shire Pharmaceuticals
DMAZ2L6	DT	Small molecular drug
DMAZ2L6	PC	454194
DMAZ2L6	MW	213.19
DMAZ2L6	FM	C8H11N3O4
DMAZ2L6	IC	InChI=1S/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m0/s1
DMAZ2L6	CS	C1[C@H](O[C@H](O1)CO)N2C=CC(=NC2=O)N
DMAZ2L6	IK	RXRGZNYSEHTMHC-BQBZGAKWSA-N
DMAZ2L6	IU	4-amino-1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one
DMAZ2L6	CA	CAS 145918-75-8
DMAZ2L6	CB	CHEBI:134886
DMAZ2L6	DE	Solid tumour/cancer

DMHEWT7	ID	DMHEWT7
DMHEWT7	DN	TRU-015
DMHEWT7	HS	Phase 2
DMHEWT7	SN	CytoxB20G; XXX_CytoxB20G; CD20 antagonist, Trubion; PF-5212374
DMHEWT7	CP	Trubion Pharmaceuticals Inc; Trubion
DMHEWT7	DE	Lymphoma

DMVX6H0	ID	DMVX6H0
DMVX6H0	DN	TRV027
DMVX6H0	HS	Phase 2
DMVX6H0	CP	Forest laboratories; trevena
DMVX6H0	PC	3082475
DMVX6H0	MW	926.1
DMVX6H0	FM	C43H67N13O10
DMVX6H0	IC	InChI=1S/C43H67N13O10/c1-7-24(4)35(40(63)53-31(19-27-20-47-22-49-27)41(64)56-17-9-11-32(56)38(61)50-25(5)42(65)66)55-37(60)30(18-26-12-14-28(57)15-13-26)52-39(62)34(23(2)3)54-36(59)29(51-33(58)21-46-6)10-8-16-48-43(44)45/h12-15,20,22-25,29-32,34-35,46,57H,7-11,16-19,21H2,1-6H3,(H,47,49)(H,50,61)(H,51,58)(H,52,62)(H,53,63)(H,54,59)(H,55,60)(H,65,66)(H4,44,45,48)/t24-,25+,29-,30-,31-,32-,34-,35-/m0/s1
DMVX6H0	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMVX6H0	IK	XIEWFECSPPTVQN-KMIMAYJXSA-N
DMVX6H0	IU	(2R)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid
DMVX6H0	CA	CAS 1234510-46-3
DMVX6H0	DE	Heart failure

DMMNXIW	ID	DMMNXIW
DMMNXIW	DN	TS-022
DMMNXIW	HS	Phase 2
DMMNXIW	SN	Prostaglandin derivative (topical, dermatitis), Taisho
DMMNXIW	CP	Taisho Pharmaceutical Co Ltd
DMMNXIW	PC	16049813
DMMNXIW	MW	421
DMMNXIW	FM	C20H33ClO5S
DMMNXIW	IC	InChI=1S/C20H31ClO4S.H2O/c21-17-12-19(23)16(9-10-18(22)14-6-2-1-3-7-14)15(17)8-4-5-11-26-13-20(24)25;/h14-19,22-23H,1-8,11-13H2,(H,24,25);1H2/t15-,16-,17-,18-,19-;/m1./s1
DMMNXIW	CS	C1CCC(CC1)[C@@H](C#C[C@H]2[C@@H](C[C@H]([C@@H]2CCCCSCC(=O)O)Cl)O)O.O
DMMNXIW	IK	HBBRGHQOBDRHIE-HICYURJWSA-N
DMMNXIW	IU	2-[4-[(1R,2S,3R,5R)-5-chloro-2-[(3S)-3-cyclohexyl-3-hydroxyprop-1-ynyl]-3-hydroxycyclopentyl]butylsulfanyl]acetic acid;hydrate
DMMNXIW	DE	Atopic dermatitis

DMZE6Y9	ID	DMZE6Y9
DMZE6Y9	DN	TT-100
DMZE6Y9	HS	Phase 2
DMZE6Y9	SN	TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct
DMZE6Y9	CP	TriAct Therapeutics
DMZE6Y9	DE	Non-small-cell lung cancer

DMSIXG4	ID	DMSIXG4
DMSIXG4	DN	TT-173
DMSIXG4	HS	Phase 2
DMSIXG4	CP	Thrombotargets
DMSIXG4	DE	Bleeding disorder

DMCDMFP	ID	DMCDMFP
DMCDMFP	DN	TT-223
DMCDMFP	HS	Phase 2
DMCDMFP	SN	E1-INT; GLP1-INT; Islet cell neogenesis therapy, Transition Therapeutics; Islet neogenesis therapy, Transition; Diabetes therapy, Waratah/MGH; EGF-INT, Transition Therapeutics; Glucagon-like peptide + gastrin analog, Transition; INT (diabetes), Waratah/MGH; Epidermal growth factor analog + TT-223 (diabetes), Transition; Islet neogenesis therapy (GLP-1, gastrin), Transition; Glucagon-like peptide + TT-223, (diabetes) Transition
DMCDMFP	CP	Waratah Pharmaceuticals Inc
DMCDMFP	DE	Type-1 diabetes

DMRQ0SA	ID	DMRQ0SA
DMRQ0SA	DN	TT-401
DMRQ0SA	HS	Phase 2
DMRQ0SA	CP	Transition Therapeutics
DMRQ0SA	DE	Type-2 diabetes

DM6TAFE	ID	DM6TAFE
DM6TAFE	DN	TTAC-0001
DM6TAFE	HS	Phase 2
DM6TAFE	SN	VEGFR-2 antibody (cancer), PharmAbcine
DM6TAFE	CP	PharmAbcine
DM6TAFE	DT	Antibody
DM6TAFE	DE	Recurrent glioblastoma

DMBNU1W	ID	DMBNU1W
DMBNU1W	DN	TTP-054
DMBNU1W	HS	Phase 2
DMBNU1W	SN	Glucagon-like peptide 1 receptor modulator (oral, type 2 diabetes) TransTech Pharma
DMBNU1W	CP	TransTech Pharma Inc
DMBNU1W	DE	Type-2 diabetes

DMZ6RG2	ID	DMZ6RG2
DMZ6RG2	DN	TTP273
DMZ6RG2	HS	Phase 2
DMZ6RG2	CP	vTv Therapeutics High Point, NC
DMZ6RG2	DE	Type-2 diabetes

DMBKQSZ	ID	DMBKQSZ
DMBKQSZ	DN	TTP399
DMBKQSZ	HS	Phase 2
DMBKQSZ	CP	vTv Therapeutics
DMBKQSZ	DT	Small interfering RNA
DMBKQSZ	DE	Type-1 diabetes; Type 2 diabetes

DMMNTOW	ID	DMMNTOW
DMMNTOW	DN	TTP435
DMMNTOW	HS	Phase 2
DMMNTOW	DE	Obesity

DMR37X8	ID	DMR37X8
DMR37X8	DN	TTP-448
DMR37X8	HS	Phase 2
DMR37X8	CP	TransTech Pharma
DMR37X8	DE	Alzheimer disease

DMCQARM	ID	DMCQARM
DMCQARM	DN	TTP889
DMCQARM	HS	Phase 2
DMCQARM	SN	VP-14637; VP 14637; 235106-62-4; (E)-2,2'-((4-hydroxyphenyl)methylene)bis(4-((E)-(5-methyl-1H-tetrazol-1-ylimino)methyl)phenol); MDT-637; AC1O5AXS; CHEMBL3393516; SCHEMBL20741449; SCHEMBL16743389; CHEMBL3393661; (4E)-2-[(4-hydroxyphenyl)-[(3E)-3-[[(5-methyltetrazol-1-yl)amino]methylidene]-6-oxocyclohexa-1,4-dien-1-yl]methyl]-4-[[(5-methyltetrazol-1-yl)amino]methylidene]cyclohexa-2,5-dien-1-one; DB12195; ACM235106624; J-015135
DMCQARM	CP	TransTech Pharma
DMCQARM	DT	Small molecular drug
DMCQARM	PC	135484065
DMCQARM	MW	510.5
DMCQARM	FM	C25H22N10O3
DMCQARM	IC	InChI=1S/C25H22N10O3/c1-15-28-30-32-34(15)26-13-17-3-9-23(37)21(11-17)25(19-5-7-20(36)8-6-19)22-12-18(4-10-24(22)38)14-27-35-16(2)29-31-33-35/h3-14,25,36-38H,1-2H3/b26-13+,27-14+
DMCQARM	CS	CC1=NN=NN1/N=C/C2=CC(=C(C=C2)O)C(C3=C(C=CC(=C3)/C=N/N4N=NN=C4C)O)C5=CC=C(C=C5)O
DMCQARM	IK	BLUJRJMLDHEMRX-BMNRKXRESA-N
DMCQARM	IU	2-[[2-hydroxy-5-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenol
DMCQARM	CA	CAS 235106-62-4
DMCQARM	DE	Blood forming organ disorder; Respiratory syncytial virus infection

DMW7PFS	ID	DMW7PFS
DMW7PFS	DN	Turosteride
DMW7PFS	HS	Phase 2
DMW7PFS	SN	FCE-26073
DMW7PFS	CP	Pharmacia & Upjohn AB
DMW7PFS	DT	Small molecular drug
DMW7PFS	PC	65986
DMW7PFS	MW	459.7
DMW7PFS	FM	C27H45N3O3
DMW7PFS	IC	InChI=1S/C27H45N3O3/c1-16(2)28-25(33)30(17(3)4)24(32)21-10-9-19-18-8-11-22-27(6,15-13-23(31)29(22)7)20(18)12-14-26(19,21)5/h16-22H,8-15H2,1-7H3,(H,28,33)/t18-,19-,20-,21+,22+,26-,27+/m0/s1
DMW7PFS	CS	CC(C)NC(=O)N(C(C)C)C(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=O)N4C)C)C
DMW7PFS	IK	WMPQMBUXZHMEFZ-YJPJVVPASA-N
DMW7PFS	IU	(1S,3aS,3bS,5aR,9aR,9bS,11aS)-6,9a,11a-trimethyl-7-oxo-N-propan-2-yl-N-(propan-2-ylcarbamoyl)-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-1-carboxamide
DMW7PFS	CA	CAS 137099-09-3
DMW7PFS	DE	Prostate disease

DM28M6I	ID	DM28M6I
DM28M6I	DN	TV-1102
DM28M6I	HS	Phase 2
DM28M6I	CP	Teva Pharmaceutical & Antisense Therapeutics
DM28M6I	TC	Antisense
DM28M6I	DT	Antisense drug
DM28M6I	DE	Multiple sclerosis

DM19GUH	ID	DM19GUH
DM19GUH	DN	TVB-2640
DM19GUH	HS	Phase 2
DM19GUH	CP	3-v biosciences
DM19GUH	DE	Advanced solid tumour; Astrocytoma; Colon cancer

DMP30SA	ID	DMP30SA
DMP30SA	DN	TVB-2640
DMP30SA	HS	Phase 2
DMP30SA	SN	FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile
DMP30SA	CP	3-V Biosciences
DMP30SA	DT	Small molecular drug
DMP30SA	PC	66548316
DMP30SA	MW	439.6
DMP30SA	FM	C27H29N5O
DMP30SA	IC	InChI=1S/C27H29N5O/c1-17-14-24(22-4-3-5-22)25(26-29-18(2)30-31-26)15-23(17)27(33)32-12-10-21(11-13-32)20-8-6-19(16-28)7-9-20/h6-9,14-15,21-22H,3-5,10-13H2,1-2H3,(H,29,30,31)
DMP30SA	CS	CC1=CC(=C(C=C1C(=O)N2CCC(CC2)C3=CC=C(C=C3)C#N)C4=NNC(=N4)C)C5CCC5
DMP30SA	IK	BBGOSBDSLYHMRA-UHFFFAOYSA-N
DMP30SA	IU	4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile
DMP30SA	DE	Non-alcoholic fatty liver disease

DMGYSZ0	ID	DMGYSZ0
DMGYSZ0	DN	TVI-Kidney-1
DMGYSZ0	HS	Phase 2
DMGYSZ0	CP	TVAX Biomedical
DMGYSZ0	DT	Vaccine
DMGYSZ0	DE	Renal cell carcinoma

DMKJIDU	ID	DMKJIDU
DMKJIDU	DN	TZI-41078
DMKJIDU	HS	Phase 2
DMKJIDU	SN	3,5-Di-tert-butyl-4-hydroxybenzophenone oxime
DMKJIDU	DE	Arthritis

DM4NXWE	ID	DM4NXWE
DM4NXWE	DN	UB-311
DM4NXWE	HS	Phase 2
DM4NXWE	CP	United Biomedical
DM4NXWE	DE	Alzheimer disease

DMXLAPF	ID	DMXLAPF
DMXLAPF	DN	UCB-11056
DMXLAPF	HS	Phase 2
DMXLAPF	SN	127390-77-6; Ucb-11056; Ucb 11056; 2-(4-morpholino-6-propyl-1,3,5-triazin-2-yl)aminoethanol; UNII-MU6BC50P47; MU6BC50P47; 2-((4-Morpholino-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; 2-((4-(4-Morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; Ethanol,2-[[4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl]amino]-; Ethanol, 2-((4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)-; NERMEVBNTXXDNG-UHFFFAOYSA-N; ACMC-20msf9; AC1L2Y9Y; SCHEMBL3365592; CTK4B5589; DTXSID60155545; ZINC3803539
DMXLAPF	CP	UCB Pharma SA
DMXLAPF	DT	Small molecular drug
DMXLAPF	PC	130928
DMXLAPF	MW	267.33
DMXLAPF	FM	C12H21N5O2
DMXLAPF	IC	InChI=1S/C12H21N5O2/c1-2-3-10-14-11(13-4-7-18)16-12(15-10)17-5-8-19-9-6-17/h18H,2-9H2,1H3,(H,13,14,15,16)
DMXLAPF	CS	CCCC1=NC(=NC(=N1)N2CCOCC2)NCCO
DMXLAPF	IK	NERMEVBNTXXDNG-UHFFFAOYSA-N
DMXLAPF	IU	2-[(4-morpholin-4-yl-6-propyl-1,3,5-triazin-2-yl)amino]ethanol
DMXLAPF	CA	CAS 127390-77-6
DMXLAPF	DE	Cognitive impairment

DM5Z34K	ID	DM5Z34K
DM5Z34K	DN	UCB-35440
DM5Z34K	HS	Phase 2
DM5Z34K	SN	5-[4-(N-Carbamoyl-N-hydroxyamino)-1-butynyl]-2-[2-[4-[1(R)-(4-chlorophenyl)-1-phenylmethyl]piperazin-1-yl]ethoxy]benzamide
DM5Z34K	PC	9894415
DM5Z34K	MW	576.1
DM5Z34K	FM	C31H34ClN5O4
DM5Z34K	IC	InChI=1S/C31H34ClN5O4/c32-26-12-10-25(11-13-26)29(24-7-2-1-3-8-24)36-18-16-35(17-19-36)20-21-41-28-14-9-23(22-27(28)30(33)38)6-4-5-15-37(40)31(34)39/h1-3,7-14,22,29,40H,5,15-21H2,(H2,33,38)(H2,34,39)/t29-/m1/s1
DM5Z34K	CS	C1CN(CCN1CCOC2=C(C=C(C=C2)C#CCCN(C(=O)N)O)C(=O)N)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl
DM5Z34K	IK	KHVLZYHEWIBDOU-GDLZYMKVSA-N
DM5Z34K	IU	5-[4-[carbamoyl(hydroxy)amino]but-1-ynyl]-2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]benzamide
DM5Z34K	CA	CAS 299460-62-1
DM5Z34K	DE	Rhinitis

DMUNJZB	ID	DMUNJZB
DMUNJZB	DN	UCN-01
DMUNJZB	HS	Phase 2
DMUNJZB	SN	UCN; UCN01; Ucn 01; KRX-0601; KW-2401; UCN-02; (5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; 7-Hydroxystaurosporine; 7-hydroxystaurosporine (UCN-01)
DMUNJZB	CP	Keryx BioPharma.
DMUNJZB	TC	Anticancer Agents
DMUNJZB	DT	Small molecular drug
DMUNJZB	PC	72271
DMUNJZB	MW	482.5
DMUNJZB	FM	C28H26N4O4
DMUNJZB	IC	InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1
DMUNJZB	CS	C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC
DMUNJZB	IK	PBCZSGKMGDDXIJ-HQCWYSJUSA-N
DMUNJZB	IU	(2S,3R,4R,6R,18R)-18-hydroxy-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one
DMUNJZB	CA	CAS 112953-11-4
DMUNJZB	DE	Non-small-cell lung cancer

DMIERPK	ID	DMIERPK
DMIERPK	DN	UE-2343
DMIERPK	HS	Phase 2
DMIERPK	CP	Actinogen Medical Sydney, Australia
DMIERPK	DE	Alzheimer disease

DMWDJ15	ID	DMWDJ15
DMWDJ15	DN	UFT/leucovorin calcium
DMWDJ15	HS	Phase 2
DMWDJ15	CP	Taiho Pharmaceutical
DMWDJ15	DE	Colorectal cancer

DM2O4MI	ID	DM2O4MI
DM2O4MI	DN	UK-432097
DM2O4MI	HS	Phase 2
DM2O4MI	SN	Adenosine A2a agonist (asthma), Pfizer
DM2O4MI	CP	Pfizer Inc
DM2O4MI	DT	Small molecular drug
DM2O4MI	PC	9833519
DM2O4MI	MW	777.9
DM2O4MI	FM	C40H47N11O6
DM2O4MI	IC	InChI=1S/C40H47N11O6/c1-2-41-37(54)33-31(52)32(53)39(57-33)51-24-46-30-34(45-23-28(25-11-5-3-6-12-25)26-13-7-4-8-14-26)48-35(49-36(30)51)38(55)43-19-20-44-40(56)47-27-16-21-50(22-17-27)29-15-9-10-18-42-29/h3-15,18,24,27-28,31-33,39,52-53H,2,16-17,19-23H2,1H3,(H,41,54)(H,43,55)(H2,44,47,56)(H,45,48,49)/t31-,32+,33-,39+/m0/s1
DM2O4MI	CS	CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)C(=O)NCCNC(=O)NC4CCN(CC4)C5=CC=CC=N5)NCC(C6=CC=CC=C6)C7=CC=CC=C7)O)O
DM2O4MI	IK	ZOTHAEBAWXWVID-HXEFRTELSA-N
DM2O4MI	IU	6-(2,2-diphenylethylamino)-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]-N-[2-[(1-pyridin-2-ylpiperidin-4-yl)carbamoylamino]ethyl]purine-2-carboxamide
DM2O4MI	CA	CAS 380221-63-6
DM2O4MI	DE	Chronic obstructive pulmonary disease

DM8LBUK	ID	DM8LBUK
DM8LBUK	DN	UNI-PH (1-34)
DM8LBUK	HS	Phase 2
DM8LBUK	SN	Recombinant parathyroid hormone 1-34 (osteoporosis), Uni-Bio Science Group; RhPTH 1-34 (osteoporosis), Uni-Bio Science Group
DM8LBUK	CP	Uni-Bio Science Group Limited
DM8LBUK	DE	Osteoporosis

DMOMI97	ID	DMOMI97
DMOMI97	DN	UNI-rE-4
DMOMI97	HS	Phase 2
DMOMI97	SN	RE-4 (type 2 diabetes), Uni-Bio Science Group; Recombinant exendin-4 (type 2 diabetes), Uni-Bio Science Group
DMOMI97	CP	Uni-Bio Science Group Limited
DMOMI97	DE	Type-2 diabetes

DMFZULI	ID	DMFZULI
DMFZULI	DN	Upamostat
DMFZULI	HS	Phase 2
DMFZULI	SN	WX-671
DMFZULI	CP	Wilex
DMFZULI	DT	Small molecular drug
DMFZULI	PC	9830667
DMFZULI	MW	629.8
DMFZULI	FM	C32H47N5O6S
DMFZULI	IC	InChI=1S/C32H47N5O6S/c1-8-43-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34-40)35-44(41,42)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35,40H,8,12-15,17H2,1-7H3,(H2,33,34)/t28-/m0/s1
DMFZULI	CS	CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC2=CC(=CC=C2)/C(=N/O)/N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C
DMFZULI	IK	HUASEDVYRABWCV-NDEPHWFRSA-N
DMFZULI	IU	ethyl 4-[(2S)-3-[3-[(Z)-N'-hydroxycarbamimidoyl]phenyl]-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate
DMFZULI	DE	Breast cancer

DME6X27	ID	DME6X27
DME6X27	DN	UR-63325
DME6X27	HS	Phase 2
DME6X27	SN	DP-1; Histamine H4 antagonist (allergic rhinitis, asthma), Palau
DME6X27	CP	Palau Pharma SA
DME6X27	PC	42603186
DME6X27	MW	259.31
DME6X27	FM	C13H17N5O
DME6X27	IC	InChI=1S/C13H17N5O/c1-15-7-5-18(6-7)12-11-10(16-13(14)17-12)8-3-2-4-9(8)19-11/h7,15H,2-6H2,1H3,(H2,14,16,17)
DME6X27	CS	CNC1CN(C1)C2=NC(=NC3=C2OC4=C3CCC4)N
DME6X27	IK	WUSKTVHULHXVSO-UHFFFAOYSA-N
DME6X27	IU	9-[3-(methylamino)azetidin-1-yl]-7-oxa-10,12-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraen-11-amine
DME6X27	DE	Allergic rhinitis

DMY89BN	ID	DMY89BN
DMY89BN	DN	URC102
DMY89BN	HS	Phase 2
DMY89BN	DE	Gout

DM6RTVG	ID	DM6RTVG
DM6RTVG	DN	Urelumab
DM6RTVG	HS	Phase 2
DM6RTVG	CP	Bristol-Myers Squibb Princeton, NJ
DM6RTVG	DE	Solid tumour/cancer; B-cell non-hodgkin lymphoma; Melanoma

DM0YO4Q	ID	DM0YO4Q
DM0YO4Q	DN	Urocortin 2
DM0YO4Q	HS	Phase 2
DM0YO4Q	SN	Urocortin 2; Urocortin II; Urocortin-2; 351999-18-3
DM0YO4Q	CP	Neurocrine Biosci
DM0YO4Q	PC	56843276
DM0YO4Q	MW	4450
DM0YO4Q	FM	C194H339N63O54S
DM0YO4Q	IC	InChI=1S/C194H339N63O54S/c1-38-96(25)142(199)181(303)250-144(94(21)22)184(306)243-126(76-92(17)18)176(298)247-130(83-258)179(301)241-124(74-90(13)14)174(296)242-129(79-141(271)272)178(300)251-145(95(23)24)189(311)257-69-47-53-132(257)180(302)254-146(97(26)39-2)183(305)218-82-137(265)227-120(70-86(5)6)171(293)239-122(72-88(9)10)172(294)237-117(56-61-135(197)263)168(290)253-148(99(28)41-4)186(308)245-125(75-91(15)16)175(297)240-123(73-89(11)12)173(295)238-119(58-63-140(269)270)165(287)235-115(54-59-133(195)261)161(283)223-103(32)155(277)230-111(49-43-65-213-191(203)204)160(282)222-102(31)154(276)229-110(48-42-64-212-190(201)202)159(281)221-100(29)152(274)220-101(30)153(275)231-112(50-44-66-214-192(205)206)163(285)236-118(57-62-139(267)268)164(286)234-116(55-60-134(196)262)162(284)224-106(35)158(280)255-150(108(37)260)188(310)256-149(107(36)259)187(309)246-128(78-136(198)264)170(292)226-105(34)157(279)233-114(52-46-68-216-194(209)210)167(289)252-147(98(27)40-3)185(307)244-121(71-87(7)8)169(291)225-104(33)156(278)232-113(51-45-67-215-193(207)208)166(288)249-143(93(19)20)182(304)217-81-138(266)228-127(77-109-80-211-85-219-109)177(299)248-131(84-312)151(200)273/h80,85-108,110-132,142-150,258-260,312H,38-79,81-84,199H2,1-37H3,(H2,195,261)(H2,196,262)(H2,197,263)(H2,198,264)(H2,200,273)(H,211,219)(H,217,304)(H,218,305)(H,220,274)(H,221,281)(H,222,282)(H,223,283)(H,224,284)(H,225,291)(H,226,292)(H,227,265)(H,228,266)(H,229,276)(H,230,277)(H,231,275)(H,232,278)(H,233,279)(H,234,286)(H,235,287)(H,236,285)(H,237,294)(H,238,295)(H,239,293)(H,240,297)(H,241,301)(H,242,296)(H,243,306)(H,244,307)(H,245,308)(H,246,309)(H,247,298)(H,248,299)(H,249,288)(H,250,303)(H,251,300)(H,252,289)(H,253,290)(H,254,302)(H,255,280)(H,256,310)(H,267,268)(H,269,270)(H,271,272)(H4,201,202,212)(H4,203,204,213)(H4,205,206,214)(H4,207,208,215)(H4,209,210,216)/t96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107+,108+,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,142-,143-,144-,145-,146-,147-,148-,149-,150-/m0/s1
DM0YO4Q	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CS)C(=O)N)N
DM0YO4Q	IK	ZEBBPGHOLWPSGI-KPLDDXDLSA-N
DM0YO4Q	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3R)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxopentanoic acid
DM0YO4Q	CA	CAS 351999-18-3
DM0YO4Q	DE	Congestive heart failure

DM4SOAW	ID	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	HS	Phase 2
DM4SOAW	SN	Ursolic acid; Prunol; Malol; Urson; 77-52-1; 3beta-Hydroxyurs-12-en-28-oic acid; (3beta)-3-Hydroxyurs-12-en-28-oic acid; 3beta-Hydroxy-12-ursen-28-ic acid; UNII-P3M2575F3F; CHEBI:9908; CCRIS 7123; EINECS 201-034-0; CHEMBL169; Merotaine; AI3-03109; NSC4060; P3M2575F3F; NSC-4060; Urs-12-en-28-oic acid, 3-hydroxy-, (3beta)-; HNMR; .beta.-Ursolic acid; NSC 4060; NSC 167406
DM4SOAW	DT	Small molecular drug
DM4SOAW	PC	64945
DM4SOAW	MW	456.7
DM4SOAW	FM	C30H48O3
DM4SOAW	IC	InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1
DM4SOAW	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DM4SOAW	IK	WCGUUGGRBIKTOS-GPOJBZKASA-N
DM4SOAW	IU	(1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DM4SOAW	CA	CAS 77-52-1
DM4SOAW	CB	CHEBI:9908
DM4SOAW	DE	Metabolic syndrome x

DMDPFTB	ID	DMDPFTB
DMDPFTB	DN	V-101
DMDPFTB	HS	Phase 2
DMDPFTB	SN	TETRASUL; Tetradisul; Animert; 2227-13-6; Animert V-10; Animert V-10K; Animert V-101; Philips-duphar V-101; Caswell No. 213; Tetrasul [BSI:ISO]; UNII-BEO7JP5U0R; ENT 27,115; 2,4,4',5-Tetrachlorodiphenyl sulfide; 2,4,5,4'-Tetrachlorodiphenyl sulfide; 2,4,4',5-Tetrachlorodiphenyl sulphide; V-101; V 101; p-Chlorophenyl 2,4,5-trichlorophenyl sulfide; 4-Chlorophenyl 2,4,5-trichlorophenyl sulfide; Sulfide, p-chlorophenyl 2,4,5-trichlorophenyl; EINECS 218-761-4; BEO7JP5U0R; 3,4,6,4'-Tetrachlor-diphenylsulfid; EPA Pesticide Chemical Code
DMDPFTB	CP	Vicept Therapeutics Inc
DMDPFTB	DT	Small molecular drug
DMDPFTB	PC	16685
DMDPFTB	MW	324
DMDPFTB	FM	C12H6Cl4S
DMDPFTB	IC	InChI=1S/C12H6Cl4S/c13-7-1-3-8(4-2-7)17-12-6-10(15)9(14)5-11(12)16/h1-6H
DMDPFTB	CS	C1=CC(=CC=C1SC2=CC(=C(C=C2Cl)Cl)Cl)Cl
DMDPFTB	IK	QUWSDLYBOVGOCW-UHFFFAOYSA-N
DMDPFTB	IU	1,2,4-trichloro-5-(4-chlorophenyl)sulfanylbenzene
DMDPFTB	CA	CAS 2227-13-6
DMDPFTB	CB	CHEBI:82162
DMDPFTB	DE	Erythema

DM1ODP6	ID	DM1ODP6
DM1ODP6	DN	VA-106483
DM1ODP6	HS	Phase 2
DM1ODP6	SN	Fedovapagon; UNII-VX2GBO4I0V; 347887-36-9; VX2GBO4I0V; VA-106483; CHEMBL518043; Fedovapagon [INN]; SCHEMBL2547119; DTXSID40188331; MolPort-042-665-819; BDBM50246575; ZINC38471398; DB11734; NCGC00386702-01; 1,2-Pyrrolidinedicarboxamide, N2,N2-dimethyl-N1-((2-methyl-4-((2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)methyl)-, (2S)-; (2S)-N2,N2-dimethyl-N1-((2-Methyl-4-(2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)phenyl)methyl)pyrrolidine-1,2-dicarboxamide
DM1ODP6	DT	Small molecular drug
DM1ODP6	PC	10298385
DM1ODP6	MW	462.6
DM1ODP6	FM	C27H34N4O3
DM1ODP6	IC	InChI=1S/C27H34N4O3/c1-19-17-21(25(32)30-15-7-6-10-20-9-4-5-11-23(20)30)13-14-22(19)18-28-27(34)31-16-8-12-24(31)26(33)29(2)3/h4-5,9,11,13-14,17,24H,6-8,10,12,15-16,18H2,1-3H3,(H,28,34)/t24-/m0/s1
DM1ODP6	CS	CC1=C(C=CC(=C1)C(=O)N2CCCCC3=CC=CC=C32)CNC(=O)N4CCC[C@H]4C(=O)N(C)C
DM1ODP6	IK	RUOLFWZIFNQQGH-DEOSSOPVSA-N
DM1ODP6	IU	(2S)-2-N,2-N-dimethyl-1-N-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]pyrrolidine-1,2-dicarboxamide
DM1ODP6	CA	CAS 347887-36-9
DM1ODP6	DE	Nocturia

DMAYWXD	ID	DMAYWXD
DMAYWXD	DN	VA-111913
DMAYWXD	HS	Phase 2
DMAYWXD	SN	VA-111913 TS; VA-913; VT-913; V1a antagonists (dysmenorrhea), Vantia; Vasopressin 1a antagonists (dysmenorrhea), Vantia/Ferring
DMAYWXD	CP	Ferring Pharmaceuticals Inc
DMAYWXD	DT	Small molecular drug
DMAYWXD	PC	135564707
DMAYWXD	MW	453.9
DMAYWXD	FM	C23H21ClFN5O2
DMAYWXD	IC	InChI=1S/C23H21ClFN5O2/c1-29-21-16(11-27-29)12-30(20-7-6-17(24)9-19(20)28-21)23(32)14-4-5-15(18(25)8-14)10-26-22(31)13-2-3-13/h4-9,11,13,28H,2-3,10,12H2,1H3,(H,26,31)
DMAYWXD	CS	CN1C2=C(CN(C3=C(N2)C=C(C=C3)Cl)C(=O)C4=CC(=C(C=C4)CNC(=O)C5CC5)F)C=N1
DMAYWXD	IK	VOEZSPDOPDPGSY-UHFFFAOYSA-N
DMAYWXD	IU	N-[[4-(8-chloro-1-methyl-4,10-dihydropyrazolo[4,3-c][1,5]benzodiazepine-5-carbonyl)-2-fluorophenyl]methyl]cyclopropanecarboxamide
DMAYWXD	CA	CAS 877856-17-2
DMAYWXD	DE	Dysmenorrhea

DM9GZW6	ID	DM9GZW6
DM9GZW6	DN	Vabicaserin
DM9GZW6	HS	Phase 2
DM9GZW6	SN	Vabicaserin hydrochloride; PF-05208769; PF-5208769; SCA-136; WY-16629
DM9GZW6	CP	Wyeth
DM9GZW6	DT	Small molecular drug
DM9GZW6	PC	11521822
DM9GZW6	MW	228.33
DM9GZW6	FM	C15H20N2
DM9GZW6	IC	InChI=1S/C15H20N2/c1-3-11-9-16-7-8-17-10-12-4-2-5-13(12)14(6-1)15(11)17/h1,3,6,12-13,16H,2,4-5,7-10H2/t12-,13-/m0/s1
DM9GZW6	CS	C1C[C@H]2CN3CCNCC4=C3C(=CC=C4)[C@H]2C1
DM9GZW6	IK	NPTIPEQJIDTVKR-STQMWFEESA-N
DM9GZW6	IU	(12R,16S)-7,10-diazatetracyclo[8.6.1.05,17.012,16]heptadeca-1,3,5(17)-triene
DM9GZW6	CA	CAS 887258-95-9
DM9GZW6	DE	Psychotic disorder

DMDAKZW	ID	DMDAKZW
DMDAKZW	DN	Vacc-4x
DMDAKZW	HS	Phase 2
DMDAKZW	CP	Bionor Pharma
DMDAKZW	DT	Vaccine
DMDAKZW	DE	Human immunodeficiency virus-1 infection

DMK7CYX	ID	DMK7CYX
DMK7CYX	DN	Vadimezan
DMK7CYX	HS	Phase 2
DMK7CYX	SN	DMXAA; AS-1404; ASA-404; R-1564; 5,6-MeXAA; 5,6-dimethylxanthenone-4-acetic acid
DMK7CYX	CP	Antisoma; University of Auckland
DMK7CYX	DT	Small molecular drug
DMK7CYX	PC	123964
DMK7CYX	MW	282.29
DMK7CYX	FM	C17H14O4
DMK7CYX	IC	InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)
DMK7CYX	CS	CC1=C(C2=C(C=C1)C(=O)C3=CC=CC(=C3O2)CC(=O)O)C
DMK7CYX	IK	XGOYIMQSIKSOBS-UHFFFAOYSA-N
DMK7CYX	IU	2-(5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid
DMK7CYX	CA	CAS 117570-53-3
DMK7CYX	CB	CHEBI:75934
DMK7CYX	DE	Solid tumour/cancer

DMIKH67	ID	DMIKH67
DMIKH67	DN	Valetizumab
DMIKH67	HS	Phase 2
DMIKH67	DT	Antibody
DMIKH67	DE	Multiple sclerosis

DMAEB9O	ID	DMAEB9O
DMAEB9O	DN	Valomaciclovir stearate
DMAEB9O	HS	Phase 2
DMAEB9O	SN	Omaciclovir; Valomaciclovir; A 174606.0; A 182091.0; ABT-091; ABT-606; Anti-VZV drug; EPB-348; MIV-606; RP-606; A-174606.6; ABT-182091.0; 2HM-HBG
DMAEB9O	CP	Medivir AB
DMAEB9O	DT	Small molecular drug
DMAEB9O	PC	135399823
DMAEB9O	MW	618.9
DMAEB9O	FM	C33H58N6O5
DMAEB9O	IC	InChI=1S/C33H58N6O5/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(40)44-23-26(20-21-43-32(42)28(34)25(2)3)22-39-24-36-29-30(39)37-33(35)38-31(29)41/h24-26,28H,4-23,34H2,1-3H3,(H3,35,37,38,41)/t26-,28+/m1/s1
DMAEB9O	CS	CCCCCCCCCCCCCCCCCC(=O)OC[C@H](CCOC(=O)[C@H](C(C)C)N)CN1C=NC2=C1N=C(NC2=O)N
DMAEB9O	IK	ACBSZTQIFTYFGH-IAPPQJPRSA-N
DMAEB9O	IU	[(2R)-4-[(2S)-2-amino-3-methylbutanoyl]oxy-2-[(2-amino-6-oxo-1H-purin-9-yl)methyl]butyl] octadecanoate
DMAEB9O	CA	CAS 195156-77-5
DMAEB9O	DE	Varicella zoster virus infection

DMFWZ2U	ID	DMFWZ2U
DMFWZ2U	DN	Valopicitabine dihydrochloride
DMFWZ2U	HS	Phase 2
DMFWZ2U	SN	Valopicitabine; NM-106; NM-107; NM-283; NMC-283; Hepatitis C therapeutics, Novartis/Idenix; 2'-C-methylcytidine
DMFWZ2U	CP	Idenix Pharmaceuticals Inc
DMFWZ2U	DT	Small molecular drug
DMFWZ2U	PC	11293303
DMFWZ2U	MW	429.3
DMFWZ2U	FM	C15H26Cl2N4O6
DMFWZ2U	IC	InChI=1S/C15H24N4O6.2ClH/c1-7(2)10(17)12(21)25-11-8(6-20)24-13(15(11,3)23)19-5-4-9(16)18-14(19)22;;/h4-5,7-8,10-11,13,20,23H,6,17H2,1-3H3,(H2,16,18,22);2*1H/t8-,10+,11-,13-,15-;;/m1../s1
DMFWZ2U	CS	CC(C)[C@@H](C(=O)O[C@@H]1[C@H](O[C@H]([C@]1(C)O)N2C=CC(=NC2=O)N)CO)N.Cl.Cl
DMFWZ2U	IK	XENHXZMAOSTXGD-DSMKLBDQSA-N
DMFWZ2U	IU	[(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2S)-2-amino-3-methylbutanoate;dihydrochloride
DMFWZ2U	CA	CAS 640725-71-9
DMFWZ2U	DE	Virus infection

DMCF5E0	ID	DMCF5E0
DMCF5E0	DN	Vaniprevir
DMCF5E0	HS	Phase 2
DMCF5E0	SN	Vaniprevir; UNII-CV3X74AO1H; MK-7009; MK7009; 923590-37-8; CV3X74AO1H; Vaniprevir [USAN:INN]; vanihep; 3su6; SCHEMBL3264200; BDBM103836; BCP09841; ZINC95627836; AKOS030527003; SB16734; DB11929; CS-0340; NCGC00485973-01; HY-10243; Cyclopropanecarboxamide, N-(((6-(2-carboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethyl-, (1-2)-lactone, (1R,2R)-
DMCF5E0	CP	Merck
DMCF5E0	DT	Small molecular drug
DMCF5E0	PC	24765256
DMCF5E0	MW	757.9
DMCF5E0	FM	C38H55N5O9S
DMCF5E0	IC	InChI=1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26-,29+,30-,38-/m1/s1
DMCF5E0	CS	CC[C@@H]1C[C@@]1(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C
DMCF5E0	IK	KUQWGLQLLVFLSM-ONAXAZCASA-N
DMCF5E0	IU	(1R,21S,24S)-21-tert-butyl-N-[(1R,2R)-1-(cyclopropylsulfonylcarbamoyl)-2-ethylcyclopropyl]-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6(11),7,9-triene-24-carboxamide
DMCF5E0	CA	CAS 923590-37-8
DMCF5E0	DE	Hepatitis C virus infection

DMNFVKC	ID	DMNFVKC
DMNFVKC	DN	Vapitadine
DMNFVKC	HS	Phase 2
DMNFVKC	SN	Hivenyl; Vapitadine dihydrochloride; R-129160; Vapitadine (oral), Barrier Therapeutics
DMNFVKC	CP	Barrier Therapeutics Inc
DMNFVKC	DT	Small molecular drug
DMNFVKC	PC	9842252
DMNFVKC	MW	296.37
DMNFVKC	FM	C17H20N4O
DMNFVKC	IC	InChI=1S/C17H20N4O/c18-15(22)14-11-20-16-17(6-8-19-9-7-17)13-4-2-1-3-12(13)5-10-21(14)16/h1-4,11,19H,5-10H2,(H2,18,22)
DMNFVKC	CS	C1CN2C(=CN=C2C3(CCNCC3)C4=CC=CC=C41)C(=O)N
DMNFVKC	IK	VQWGYPVNVICKFC-UHFFFAOYSA-N
DMNFVKC	IU	spiro[5,6-dihydroimidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide
DMNFVKC	CA	CAS 793655-64-8
DMNFVKC	DE	Allergic skin disorder

DMQSC5O	ID	DMQSC5O
DMQSC5O	DN	Varlilumab
DMQSC5O	HS	Phase 2
DMQSC5O	CP	Celldex Therapeutics Hampton, NJ
DMQSC5O	DE	Colorectal cancer; Head and neck cancer; Ovarian cancer; Recurrent glioblastoma; Renal cell carcinoma

DMKU93J	ID	DMKU93J
DMKU93J	DN	VAS-203
DMKU93J	HS	Phase 2
DMKU93J	SN	NOS inhibitor, Vasopharm; Nitric oxide synthase inhibitor, Vasopharm
DMKU93J	CP	Vasopharm GmbH
DMKU93J	DE	Brain injury

DMRJ5LP	ID	DMRJ5LP
DMRJ5LP	DN	Vasoactive intestinal peptide
DMRJ5LP	HS	Phase 2
DMRJ5LP	SN	CCRIS 7231; Vasoactive intestinal polypeptide; Vasointestinal Peptide; Vasoactive intestinal peptide, synthetic porcine; SCHEMBL3041046; GTPL1152; VIP (Vasoactive Intestinal Peptide); LS-174653; VIP
DMRJ5LP	CP	Mondo Biotech
DMRJ5LP	DT	Small molecular drug
DMRJ5LP	PC	53314964
DMRJ5LP	MW	3326.8
DMRJ5LP	FM	C147H237N43O43S
DMRJ5LP	IC	InChI=1S/C147H237N43O43S/c1-18-75(12)115(142(229)180-96(56-72(6)7)131(218)183-104(145(232)233)63-110(155)200)188-139(226)106(68-192)185-134(221)101(62-109(154)199)177-130(217)95(55-71(4)5)174-132(219)97(58-81-37-41-84(195)42-38-81)175-125(212)88(33-23-26-49-149)167-123(210)89(34-24-27-50-150)171-140(227)113(73(8)9)186-118(205)76(13)164-121(208)93(47-53-234-17)170-127(214)92(45-46-107(152)197)169-122(209)87(32-22-25-48-148)166-124(211)90(35-28-51-161-146(156)157)168-129(216)94(54-70(2)3)173-126(213)91(36-29-52-162-147(158)159)172-143(230)116(78(15)193)189-136(223)98(59-82-39-43-85(196)44-40-82)176-133(220)100(61-108(153)198)178-135(222)103(65-112(203)204)182-144(231)117(79(16)194)190-137(224)99(57-80-30-20-19-21-31-80)181-141(228)114(74(10)11)187-119(206)77(14)165-128(215)102(64-111(201)202)179-138(225)105(67-191)184-120(207)86(151)60-83-66-160-69-163-83/h19-21,30-31,37-44,66,69-79,86-106,113-117,191-196H,18,22-29,32-36,45-65,67-68,148-151H2,1-17H3,(H2,152,197)(H2,153,198)(H2,154,199)(H2,155,200)(H,160,163)(H,164,208)(H,165,215)(H,166,211)(H,167,210)(H,168,216)(H,169,209)(H,170,214)(H,171,227)(H,172,230)(H,173,213)(H,174,219)(H,175,212)(H,176,220)(H,177,217)(H,178,222)(H,179,225)(H,180,229)(H,181,228)(H,182,231)(H,183,218)(H,184,207)(H,185,221)(H,186,205)(H,187,206)(H,188,226)(H,189,223)(H,190,224)(H,201,202)(H,203,204)(H,232,233)(H4,156,157,161)(H4,158,159,162)/t75-,76-,77-,78+,79+,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116-,117-/m0/s1
DMRJ5LP	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N
DMRJ5LP	IK	VBUWHHLIZKOSMS-RIWXPGAOSA-N
DMRJ5LP	IU	(2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid
DMRJ5LP	CA	CAS 37221-79-7
DMRJ5LP	DE	Pulmonary arterial hypertension; Chronic obstructive pulmonary disease

DMY0UEQ	ID	DMY0UEQ
DMY0UEQ	DN	VATALANIB
DMY0UEQ	HS	Phase 2
DMY0UEQ	SN	Vatalanib; 212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919
DMY0UEQ	DT	Small molecular drug
DMY0UEQ	PC	151194
DMY0UEQ	MW	346.8
DMY0UEQ	FM	C20H15ClN4
DMY0UEQ	IC	InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)
DMY0UEQ	CS	C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4
DMY0UEQ	IK	YCOYDOIWSSHVCK-UHFFFAOYSA-N
DMY0UEQ	IU	N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
DMY0UEQ	CA	CAS 212141-54-3
DMY0UEQ	CB	CHEBI:90620
DMY0UEQ	DE	Solid tumour/cancer

DM3V7QO	ID	DM3V7QO
DM3V7QO	DN	Vatelizumab
DM3V7QO	HS	Phase 2
DM3V7QO	CP	Pharmaceuticals
DM3V7QO	DT	Antibody
DM3V7QO	DE	Multiple sclerosis

DML2CPW	ID	DML2CPW
DML2CPW	DN	VAY736
DML2CPW	HS	Phase 2
DML2CPW	CP	MorphoSys; Novartis Pharmaceuticals
DML2CPW	DT	Antibody
DML2CPW	DE	Sjogren syndrome; Pemphigus vulgaris; Rheumatoid arthritis

DM0YWQ4	ID	DM0YWQ4
DM0YWQ4	DN	VB 1953
DM0YWQ4	HS	Phase 2
DM0YWQ4	CP	Vyome Therapeutics
DM0YWQ4	DE	Acne vulgaris

DM047HI	ID	DM047HI
DM047HI	DN	VBP15
DM047HI	HS	Phase 2
DM047HI	SN	vamorolone; Vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317
DM047HI	CP	ReveraGen BioPharma Rockville, MD
DM047HI	PC	3035000
DM047HI	MW	356.5
DM047HI	FM	C22H28O4
DM047HI	IC	InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1
DM047HI	CS	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@]1(C(=O)CO)O)C)C
DM047HI	IK	ZYTXTXAMMDTYDQ-DGEXFFLYSA-N
DM047HI	IU	(8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one
DM047HI	CA	CAS 13209-41-1
DM047HI	DE	Duchenne dystrophy; Inflammatory bowel disease; Multiple sclerosis; Rheumatoid arthritis

DMAJ85O	ID	DMAJ85O
DMAJ85O	DN	VDA-1102
DMAJ85O	HS	Phase 2
DMAJ85O	CP	Vidac Pharma Jerusalem, Israel
DMAJ85O	DE	Actinic keratosis

DME6I03	ID	DME6I03
DME6I03	DN	VDA-1102
DME6I03	HS	Phase 2
DME6I03	SN	SB18685; 941277-00-5
DME6I03	CP	Vidac Pharma
DME6I03	DT	Small molecular drug
DME6I03	PC	135905444
DME6I03	DE	Actinic keratosis

DM5BL4C	ID	DM5BL4C
DM5BL4C	DN	Veltuzumab
DM5BL4C	HS	Phase 2
DM5BL4C	CP	Takeda
DM5BL4C	DT	Monoclonal antibody
DM5BL4C	DE	Systemic lupus erythematosus; Non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Solid tumour/cancer; Thrombocytopenia

DMLPEZS	ID	DMLPEZS
DMLPEZS	DN	Venglustat
DMLPEZS	HS	Phase 2
DMLPEZS	SN	Ibiglustat; 1401090-53-6; UNII-BLP1XA3FZA; BLP1XA3FZA; (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate; Ibiglustat [INN]; SCHEMBL12615329; YFHRCLAKZBDRHN-MRXNPFEDSA-N; Ibiglustat(Genz-682452 pound(c); GZ-452; SAR402671; ZINC202143443; AKOS027337125; CS-6512; Carbamic acid, N-(1-(2-(4-fluorophenyl)-4-thiazolyl)-1-methylethyl)-, (3S)-1-azabicyclo(2.2.2)oct-3-yl ester; (3S)-1-Azabicyclo(2.2.2)octan-3-yl N-(2-(2-(4-fluorophenyl)-1,3-thiazol-4-yl)propan-2-yl)carbamate; GZ4026
DMLPEZS	CP	Genzyme, Cambridge, MA
DMLPEZS	PC	60199242
DMLPEZS	MW	389.5
DMLPEZS	FM	C20H24FN3O2S
DMLPEZS	IC	InChI=1S/C20H24FN3O2S/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25)/t16-/m1/s1
DMLPEZS	CS	CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)O[C@@H]3CN4CCC3CC4
DMLPEZS	IK	YFHRCLAKZBDRHN-MRXNPFEDSA-N
DMLPEZS	IU	[(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate
DMLPEZS	CA	CAS 1401090-53-6
DMLPEZS	DE	Fabry disease; Gaucher disease; Parkinson disease

DMFLZPC	ID	DMFLZPC
DMFLZPC	DN	VER 50589
DMFLZPC	HS	Phase 2
DMFLZPC	TC	Anticancer Agents
DMFLZPC	DT	Small molecular drug
DMFLZPC	PC	135446210
DMFLZPC	MW	388.8
DMFLZPC	FM	C19H17ClN2O5
DMFLZPC	IC	InChI=1S/C19H17ClN2O5/c1-3-21-19(25)17-16(10-4-6-11(26-2)7-5-10)18(27-22-17)12-8-13(20)15(24)9-14(12)23/h4-9,23-24H,3H2,1-2H3,(H,21,25)
DMFLZPC	CS	CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)OC)C3=CC(=C(C=C3O)O)Cl
DMFLZPC	IK	JXPCDMPJCKNLBY-UHFFFAOYSA-N
DMFLZPC	IU	5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)-1,2-oxazole-3-carboxamide
DMFLZPC	DE	Breast cancer

DM104SP	ID	DM104SP
DM104SP	DN	Vericigiuat
DM104SP	HS	Phase 2
DM104SP	CP	Bayer healthcare pharmaceutical
DM104SP	DE	Heart failure

DMBQC3L	ID	DMBQC3L
DMBQC3L	DN	Verubulin
DMBQC3L	HS	Phase 2
DMBQC3L	SN	Azixa; Verubulin hydrochloride; EP-128495; MPC-6827; Apoptosis inducer (cancer), Myriad; Caspase inducer (cancer), Myriad; Cell cycle arrest inducer (cancer), Myriad; Tubulin inhibitor (cancer), Myriad
DMBQC3L	CP	Maxim Pharmaceuticals Inc
DMBQC3L	DT	Small molecular drug
DMBQC3L	PC	11414799
DMBQC3L	MW	279.34
DMBQC3L	FM	C17H17N3O
DMBQC3L	IC	InChI=1S/C17H17N3O/c1-12-18-16-7-5-4-6-15(16)17(19-12)20(2)13-8-10-14(21-3)11-9-13/h4-11H,1-3H3
DMBQC3L	CS	CC1=NC2=CC=CC=C2C(=N1)N(C)C3=CC=C(C=C3)OC
DMBQC3L	IK	SNHCRNMVYDHVDT-UHFFFAOYSA-N
DMBQC3L	IU	N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine
DMBQC3L	CA	CAS 827031-83-4
DMBQC3L	DE	Solid tumour/cancer; Brain metastases; Glioblastoma multiforme; Recurrent glioblastoma

DM0POWG	ID	DM0POWG
DM0POWG	DN	Vidofludimus
DM0POWG	HS	Phase 2
DM0POWG	SN	Vidofludimus; 717824-30-1; 4SC-101; UNII-8Y1PJ3VG81; SC12267; Vidofludimus(4SC-101; SC12267); CHEMBL197194; 8Y1PJ3VG81; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; 2-{[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid; 2-[[2-fluoranyl-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid; Vidofludimus [INN]; SC 12267; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; DTXSID50431325; MolPort-039-193-851; BCP14555; AOB87354; s7262; ZINC14960644
DM0POWG	CP	4SC AG
DM0POWG	DT	Small molecular drug
DM0POWG	PC	9820008
DM0POWG	MW	355.4
DM0POWG	FM	C20H18FNO4
DM0POWG	IC	InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
DM0POWG	CS	COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
DM0POWG	IK	XPRDUGXOWVXZLL-UHFFFAOYSA-N
DM0POWG	IU	2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
DM0POWG	CA	CAS 717824-30-1
DM0POWG	DE	Inflammatory bowel disease; Rheumatoid arthritis

DME7VZD	ID	DME7VZD
DME7VZD	DN	Vilaprisan
DME7VZD	HS	Phase 2
DME7VZD	SN	Vilaprisan; UNII-IN59K53GI9; BAY1002670; IN59K53GI9; 1262108-14-4; Vilaprisan [INN]; BAY 1002670; Vilaprisan [USAN:INN]; Vilaprisan (USAN/INN); SCHEMBL2121854; CHEMBL3989936; BCP24069; DB11971; 20,20,21,21,21-Pentafluoro-17-hydroxy-11beta-(4-(methanesulfonyl)phenyl)-19-nor-17alpha-pregna-4,9-dien-3-one; 19-Norpregna-4,9-dien-3-one, 20,20,21,21,21-pentafluoro-17-hydroxy-11-(4-(methylsulfonyl)phenyl)-, (11beta,17alpha)-
DME7VZD	DT	Small molecular drug
DME7VZD	PC	50915138
DME7VZD	MW	544.6
DME7VZD	FM	C27H29F5O4S
DME7VZD	IC	InChI=1S/C27H29F5O4S/c1-24-14-21(15-3-7-18(8-4-15)37(2,35)36)23-19-10-6-17(33)13-16(19)5-9-20(23)22(24)11-12-25(24,34)26(28,29)27(30,31)32/h3-4,7-8,13,20-22,34H,5-6,9-12,14H2,1-2H3/t20-,21+,22-,24-,25-/m0/s1
DME7VZD	CS	C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C(C(F)(F)F)(F)F)O)C5=CC=C(C=C5)S(=O)(=O)C
DME7VZD	IK	JUFWQQVHQFDUOD-ANRPBIDPSA-N
DME7VZD	IU	(8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-methylsulfonylphenyl)-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DME7VZD	CA	CAS 1262108-14-4
DME7VZD	DE	Endometriosis

DM2X0SP	ID	DM2X0SP
DM2X0SP	DN	VIR-2218
DM2X0SP	HS	Phase 2
DM2X0SP	SN	ALN-HBV02
DM2X0SP	CP	Alnylam Pharmaceuticals; Vir Biotechnology
DM2X0SP	DT	Small interfering RNA
DM2X0SP	DE	Hepatitis B virus infection

DMEXMV5	ID	DMEXMV5
DMEXMV5	DN	Virexxa
DMEXMV5	HS	Phase 2
DMEXMV5	CP	Pharmsynthez ZAO
DMEXMV5	DE	Endometrial cancer

DM1G6ME	ID	DM1G6ME
DM1G6ME	DN	VIS410
DM1G6ME	HS	Phase 2
DM1G6ME	CP	Visterra
DM1G6ME	DT	Antibody
DM1G6ME	DE	Influenza A virus infection

DMY5NUR	ID	DMY5NUR
DMY5NUR	DN	VK-2809
DMY5NUR	HS	Phase 2
DMY5NUR	CP	Viking Therapeutics San Diego, CA
DMY5NUR	DE	Hypercholesterolaemia

DMLT94F	ID	DMLT94F
DMLT94F	DN	VLS-101
DMLT94F	HS	Phase 2
DMLT94F	CP	VelosBio
DMLT94F	DT	Antibody drug conjugate
DMLT94F	DE	Solid tumour/cancer

DM4O17U	ID	DM4O17U
DM4O17U	DN	VLTS-589
DM4O17U	HS	Phase 2
DM4O17U	SN	Deltavasc; Del-1 gene therapy, Valentis; Gene therapy (Del-1, PINC), Valentis
DM4O17U	CP	Valentis
DM4O17U	DE	Peripheral vascular disease

DM9KNJT	ID	DM9KNJT
DM9KNJT	DN	Vobarilizumab
DM9KNJT	HS	Phase 2
DM9KNJT	SN	ALX-0061
DM9KNJT	CP	Ablynx
DM9KNJT	DT	Antibody
DM9KNJT	DE	Rheumatoid arthritis; Systemic lupus erythematosus

DMQMYP5	ID	DMQMYP5
DMQMYP5	DN	VOFOPITANT HYDROCHLORIDE
DMQMYP5	HS	Phase 2
DMQMYP5	SN	GR-205171A; Vofopitant hydrochloride < Prop INNM; GR-205171 (free base); (2S,3S)-N-[2-Methoxy-5-[5-(trifluoromethyl)-1-tetrazolyl]benzyl]-N-(2-phenylpiperidin-3-yl)amine dihydrochloride
DMQMYP5	DT	Small molecular drug
DMQMYP5	PC	6918330
DMQMYP5	MW	505.4
DMQMYP5	FM	C21H25Cl2F3N6O
DMQMYP5	IC	InChI=1S/C21H23F3N6O.2ClH/c1-31-18-10-9-16(30-20(21(22,23)24)27-28-29-30)12-15(18)13-26-17-8-5-11-25-19(17)14-6-3-2-4-7-14;;/h2-4,6-7,9-10,12,17,19,25-26H,5,8,11,13H2,1H3;2*1H/t17-,19-;;/m0../s1
DMQMYP5	CS	COC1=C(C=C(C=C1)N2C(=NN=N2)C(F)(F)F)CN[C@H]3CCCN[C@H]3C4=CC=CC=C4.Cl.Cl
DMQMYP5	IK	YVNRXILPJNISEM-FFUVTKDNSA-N
DMQMYP5	IU	(2S,3S)-N-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine;dihydrochloride
DMQMYP5	CA	CAS 168266-51-1
DMQMYP5	DE	Vomiting

DMNQG24	ID	DMNQG24
DMNQG24	DN	Volociximab
DMNQG24	HS	Phase 2
DMNQG24	CP	Abbott Laboratories
DMNQG24	DT	Antibody
DMNQG24	DE	Non-small-cell lung cancer

DMIM1U9	ID	DMIM1U9
DMIM1U9	DN	Vorolanib
DMIM1U9	HS	Phase 2
DMIM1U9	SN	UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-
DMIM1U9	CP	Xcovery
DMIM1U9	DT	Small molecular drug
DMIM1U9	PC	59215954
DMIM1U9	MW	439.5
DMIM1U9	FM	C23H26FN5O3
DMIM1U9	IC	InChI=1S/C23H26FN5O3/c1-12-19(10-17-16-9-14(24)5-6-18(16)27-21(17)30)25-13(2)20(12)22(31)26-15-7-8-29(11-15)23(32)28(3)4/h5-6,9-10,15,25H,7-8,11H2,1-4H3,(H,26,31)(H,27,30)/b17-10-/t15-/m0/s1
DMIM1U9	CS	CC1=C(NC(=C1C(=O)N[C@H]2CCN(C2)C(=O)N(C)C)C)/C=C\\3/C4=C(C=CC(=C4)F)NC3=O
DMIM1U9	IK	KMIOJWCYOHBUJS-HAKPAVFJSA-N
DMIM1U9	IU	N-[(3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DMIM1U9	CA	CAS 1013920-15-4
DMIM1U9	DE	Non-small cell lung cancer

DMW4LTI	ID	DMW4LTI
DMW4LTI	DN	Votucalis
DMW4LTI	HS	Phase 2
DMW4LTI	SN	EV-131; REV-131; Tick-derived compounds, Evolutec; Votucalis (intranasal), Evolutec; Votucalis (ophthalmic), Evolutec; Votucalis (respiratory disease), Evolutec; REV-131 (intranasal), Evolutec; REV-131 (ophthalmic), Evolutec; REV-131 (respiratory disease), Evolutec
DMW4LTI	CP	Evolutec Group plc; Evolutec
DMW4LTI	DE	Allergic rhinitis

DMUQZT4	ID	DMUQZT4
DMUQZT4	DN	VPI-2690B
DMUQZT4	HS	Phase 2
DMUQZT4	CP	Vascular Pharmaceuticals Research Triangle Park, NC
DMUQZT4	DE	Diabetic nephropathy

DMHET8R	ID	DMHET8R
DMHET8R	DN	VRC-HIVDNA016-00-VP
DMHET8R	HS	Phase 2
DMHET8R	CP	Vaccine Research Center (NIAID)
DMHET8R	DT	Vaccine
DMHET8R	DE	Human immunodeficiency virus infection

DMGBLI3	ID	DMGBLI3
DMGBLI3	DN	VS-6063
DMGBLI3	HS	Phase 2
DMGBLI3	SN	Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu
DMGBLI3	CP	Verastem
DMGBLI3	DT	Small molecular drug
DMGBLI3	PC	25117126
DMGBLI3	MW	510.5
DMGBLI3	FM	C20H21F3N8O3S
DMGBLI3	IC	InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)
DMGBLI3	CS	CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F
DMGBLI3	IK	FWLMVFUGMHIOAA-UHFFFAOYSA-N
DMGBLI3	IU	N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
DMGBLI3	CA	CAS 1073154-85-4
DMGBLI3	DE	Solid tumour/cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer

DMY9ZGN	ID	DMY9ZGN
DMY9ZGN	DN	VT-111a
DMY9ZGN	HS	Phase 2
DMY9ZGN	CP	Viron therapeutics
DMY9ZGN	DE	Acute coronary syndrome

DMCGK9H	ID	DMCGK9H
DMCGK9H	DN	VT-1129
DMCGK9H	HS	Phase 2
DMCGK9H	SN	Metalloenzyme inhibitors (fungal infection); VT-1161; VT-1235; Metalloenzyme inhibitors (fungal infection), Viamet
DMCGK9H	CP	Viamet pharmaceuticals
DMCGK9H	PC	91886002
DMCGK9H	MW	513.4
DMCGK9H	FM	C22H14F7N5O2
DMCGK9H	IC	InChI=1S/C22H14F7N5O2/c23-15-4-7-17(18(24)9-15)20(35,11-34-12-31-32-33-34)21(25,26)19-8-3-14(10-30-19)13-1-5-16(6-2-13)36-22(27,28)29/h1-10,12,35H,11H2/t20-/m0/s1
DMCGK9H	CS	C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OC(F)(F)F
DMCGK9H	IK	NCEHACHJIXJSPD-FQEVSTJZSA-N
DMCGK9H	IU	(2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(trifluoromethoxy)phenyl]pyridin-2-yl]propan-2-ol
DMCGK9H	CA	CAS 1340593-70-5
DMCGK9H	DE	Onchocerciasis; Cryptococcal meningitis infection; Onychomycosis

DMNY3J0	ID	DMNY3J0
DMNY3J0	DN	VTB-38543
DMNY3J0	HS	Phase 2
DMNY3J0	CP	Allergan Parsippany, NJ
DMNY3J0	DE	Atopic dermatitis

DMCA8G1	ID	DMCA8G1
DMCA8G1	DN	VTP-43742
DMCA8G1	HS	Phase 2
DMCA8G1	CP	Vitae PharmaceuticalsFort Washington, PA
DMCA8G1	PC	118282339
DMCA8G1	MW	552.7
DMCA8G1	FM	C27H35F3N4O3S
DMCA8G1	IC	InChI=1S/C27H35F3N4O3S/c1-4-38(36,37)23-10-9-22(31-14-23)13-33-26(35)19-11-20-16-34(25(17(2)3)24(20)32-12-19)15-18-5-7-21(8-6-18)27(28,29)30/h9-12,14,17-18,21,25H,4-8,13,15-16H2,1-3H3,(H,33,35)/t18?,21?,25-/m1/s1
DMCA8G1	CS	CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C([C@H](N(C3)CC4CCC(CC4)C(F)(F)F)C(C)C)N=C2
DMCA8G1	IK	XUYMIRYNRKXKOR-JBWFSBJDSA-N
DMCA8G1	IU	(7R)-N-[(5-ethylsulfonylpyridin-2-yl)methyl]-7-propan-2-yl-6-[[4-(trifluoromethyl)cyclohexyl]methyl]-5,7-dihydropyrrolo[3,4-b]pyridine-3-carboxamide
DMCA8G1	DE	Autoimmune disease; Psoriasis vulgaris

DMN6J18	ID	DMN6J18
DMN6J18	DN	Vupanorsen
DMN6J18	HS	Phase 2
DMN6J18	SN	IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx
DMN6J18	CP	Akcea Therapeutics; Ionis Pharmaceuticals
DMN6J18	DT	Antisense oligonucleotide
DMN6J18	DE	Hypertriglyceridemia; Non-alcoholic fatty liver disease; Type 2 diabetes

DM6BKG2	ID	DM6BKG2
DM6BKG2	DN	VVP-808
DM6BKG2	HS	Phase 2
DM6BKG2	SN	Insulin sensitizer (type 2 diabetes), Verva Pharmaceuticals
DM6BKG2	CP	Verva Pharmaceuticals Ltd
DM6BKG2	DE	Type-2 diabetes

DMDKWA3	ID	DMDKWA3
DMDKWA3	DN	Vx-001
DMDKWA3	HS	Phase 2
DMDKWA3	SN	HTERT572Y peptide vaccine (cancer), Vaxon; HLA-A2 monopeptide vaccine (cancer), Vaxon; TERT572 + TERT572Y peptide (cancer), Vaxon
DMDKWA3	CP	Vaxon Biotech SA
DMDKWA3	DT	Vaccine
DMDKWA3	DE	Breast cancer

DMZ3FE8	ID	DMZ3FE8
DMZ3FE8	DN	VX-135
DMZ3FE8	HS	Phase 2
DMZ3FE8	CP	Vertex pharmaceuticals
DMZ3FE8	DE	Hepatitis C virus infection

DMLWM4G	ID	DMLWM4G
DMLWM4G	DN	VX-15
DMLWM4G	HS	Phase 2
DMLWM4G	SN	VX-15/2503; Plexin B1 antagonist (autoimmune disease/cancer), Vaccinex; Anti-CD100 MAb (autoimmune disease/cancer), Vaccinex;Anti-semaphorin 4D monoclonal antibody (autoimmune disease/cancer), Vaccinex
DMLWM4G	CP	Vaccinex Inc
DMLWM4G	DT	Antibody
DMLWM4G	DE	Multiple sclerosis; Huntington disease; Non-small-cell lung cancer

DMGDB21	ID	DMGDB21
DMGDB21	DN	VX-150
DMGDB21	HS	Phase 2
DMGDB21	CP	Vertex Pharmaceuticals Boston, MA
DMGDB21	DE	Neuropathic pain

DMO3U4W	ID	DMO3U4W
DMO3U4W	DN	VX-222
DMO3U4W	HS	Phase 2
DMO3U4W	SN	VX-222; Lomibuvir; 1026785-59-0; 1026785-55-6; VX 222; VX-222 (VCH-222, Lomibuvir); UNII-37L2LF4A2D; VCH222; VCH-222; VX222; 37L2LF4A2D; Lomibuvir (VX-222, VCH-222); 2-Thiophenecarboxylic acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-[(trans-4-hydroxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-;2-Thiophenecarboxylic acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-[(trans-4-hydroxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-
DMO3U4W	CP	Vertex
DMO3U4W	DT	Small molecular drug
DMO3U4W	PC	24798764
DMO3U4W	MW	445.6
DMO3U4W	FM	C25H35NO4S
DMO3U4W	IC	InChI=1S/C25H35NO4S/c1-16-5-7-17(8-6-16)23(28)26(18-9-11-19(27)12-10-18)21-15-20(13-14-25(2,3)4)31-22(21)24(29)30/h15-19,27H,5-12H2,1-4H3,(H,29,30)
DMO3U4W	CS	CC1CCC(CC1)C(=O)N(C2CCC(CC2)O)C3=C(SC(=C3)C#CC(C)(C)C)C(=O)O
DMO3U4W	IK	WPMJNLCLKAKMLA-UHFFFAOYSA-N
DMO3U4W	IU	5-(3,3-dimethylbut-1-ynyl)-3-[(4-hydroxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylic acid
DMO3U4W	CA	CAS 1026785-55-6
DMO3U4W	CB	CHEBI:94757
DMO3U4W	DE	Hepatitis C virus infection

DMSTHG1	ID	DMSTHG1
DMSTHG1	DN	VX-371
DMSTHG1	HS	Phase 2
DMSTHG1	CP	Vertex
DMSTHG1	DE	Cystic fibrosis; Primary ciliary dyskinesia

DM93YKJ	ID	DM93YKJ
DM93YKJ	DN	VX-680
DM93YKJ	HS	Phase 2
DM93YKJ	SN	Tozasertib; MK 0457; VX 680; VX6; L-001281814; MK-045; MK-0457; Tozasertib (USAN); VX-68; MK-0457, Tozasertib, VX680, VX-680; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide; Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide; Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide
DM93YKJ	CP	Vertex; Merck
DM93YKJ	TC	Anticancer Agents
DM93YKJ	DT	Small molecular drug
DM93YKJ	PC	5494449
DM93YKJ	MW	464.6
DM93YKJ	FM	C23H28N8OS
DM93YKJ	IC	InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)
DM93YKJ	CS	CC1=CC(=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)C4CC4)N5CCN(CC5)C
DM93YKJ	IK	GCIKSSRWRFVXBI-UHFFFAOYSA-N
DM93YKJ	IU	N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
DM93YKJ	CA	CAS 639089-54-6
DM93YKJ	CB	CHEBI:91336
DM93YKJ	DE	Solid tumour/cancer

DMJAEG6	ID	DMJAEG6
DMJAEG6	DN	VX-745
DMJAEG6	HS	Phase 2
DMJAEG6	SN	5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One;  VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)
DMJAEG6	CP	Vertex Pharma
DMJAEG6	DT	Small molecular drug
DMJAEG6	PC	3038525
DMJAEG6	MW	436.3
DMJAEG6	FM	C19H9Cl2F2N3OS
DMJAEG6	IC	InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H
DMJAEG6	CS	C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl
DMJAEG6	IK	VEPKQEUBKLEPRA-UHFFFAOYSA-N
DMJAEG6	IU	5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one
DMJAEG6	CA	CAS 209410-46-8
DMJAEG6	CB	CHEBI:90528
DMJAEG6	DE	Rheumatoid arthritis; Alzheimer disease

DMJUSM8	ID	DMJUSM8
DMJUSM8	DN	VX-759
DMJUSM8	HS	Phase 2
DMJUSM8	SN	CHEMBL352911; 3-{isopropyl[(Trans-4-Methylcyclohexyl)carbonyl]amino}-5-Phenylthiophene-2-Carboxylic Acid; 3-[Isopropyl-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid; VX-759; 3-[isopropyl-(4-methylcyclohexanecarbonyl)amino]-5-phenyl-thiophene-2-carboxylic acid; VX759; NN3; VX 759; thiophene scaffold, 21; AC1L9XFB; NNI-2; 478025-29-5; SCHEMBL102322; CHEMBL561360; SCHEMBL1666872; SCHEMBL14376078; SCHEMBL13249635; BDBM35554; BDBM50139678; DB08279
DMJUSM8	CP	Vertex
DMJUSM8	DT	Small molecular drug
DMJUSM8	PC	503536
DMJUSM8	MW	385.5
DMJUSM8	FM	C22H27NO3S
DMJUSM8	IC	InChI=1S/C22H27NO3S/c1-14(2)23(21(24)17-11-9-15(3)10-12-17)18-13-19(27-20(18)22(25)26)16-7-5-4-6-8-16/h4-8,13-15,17H,9-12H2,1-3H3,(H,25,26)
DMJUSM8	CS	CC1CCC(CC1)C(=O)N(C2=C(SC(=C2)C3=CC=CC=C3)C(=O)O)C(C)C
DMJUSM8	IK	RZXQBIKGWSLVEK-UHFFFAOYSA-N
DMJUSM8	IU	3-[(4-methylcyclohexanecarbonyl)-propan-2-ylamino]-5-phenylthiophene-2-carboxylic acid
DMJUSM8	CA	CAS 478025-29-5
DMJUSM8	DE	Hepatitis C virus infection

DME321B	ID	DME321B
DME321B	DN	VX-944
DME321B	HS	Phase 2
DME321B	SN	AVN-944; AVN944; 297730-17-7; AVN 944; UNII-I3NPL1V48Q; I3NPL1V48Q; 501345-02-4; VX 944; SCHEMBL19784823; CHEMBL3349001; DTXSID80183921; EX-A778; AOB5557; ZINC3963015; AKOS027340045; CS-3427; NCGC00345803-01; NCGC00345803-05; HY-13560; AS-16899; SC-82478; (R)-1-cyanobutan-2-yl ((S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethyl)carbamate; Carbamic acid, ((1S)-1-(3-((((3-methoxy-4-(5-  oxazolyl)phenyl)amino)carbonyl)amino)phenyl)ethyl)-, (1R)-1-(cyanomethyl)propyl ester; (2R)-1-cyanobutan-2-yl N-[(1S)-1-[3-({[3-metho
DME321B	CP	Avalon Pharmaceuticals
DME321B	DT	Small molecular drug
DME321B	PC	9918559
DME321B	MW	477.5
DME321B	FM	C25H27N5O5
DME321B	IC	InChI=1S/C25H27N5O5/c1-4-20(10-11-26)35-25(32)28-16(2)17-6-5-7-18(12-17)29-24(31)30-19-8-9-21(22(13-19)33-3)23-14-27-15-34-23/h5-9,12-16,20H,4,10H2,1-3H3,(H,28,32)(H2,29,30,31)/t16-,20+/m0/s1
DME321B	CS	CC[C@H](CC#N)OC(=O)N[C@@H](C)C1=CC(=CC=C1)NC(=O)NC2=CC(=C(C=C2)C3=CN=CO3)OC
DME321B	IK	GYCPCOJTCINIFZ-OXJNMPFZSA-N
DME321B	IU	[(2R)-1-cyanobutan-2-yl] N-[(1S)-1-[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]ethyl]carbamate
DME321B	CA	CAS 297730-17-7
DME321B	DE	Solid tumour/cancer

DMPSBTL	ID	DMPSBTL
DMPSBTL	DN	VY-AADC
DMPSBTL	HS	Phase 2
DMPSBTL	CP	Voyager Therapeutics
DMPSBTL	DT	Gene therapy
DMPSBTL	DE	Parkinson disease

DMH6XJG	ID	DMH6XJG
DMH6XJG	DN	WCK-2349
DMH6XJG	HS	Phase 2
DMH6XJG	SN	WCK-177 prodrug (MRSA infection), Wockhardt
DMH6XJG	CP	Wockhardt
DMH6XJG	PC	16734914
DMH6XJG	MW	431.5
DMH6XJG	FM	C22H26FN3O5
DMH6XJG	IC	InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
DMH6XJG	CS	C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)OC(=O)[C@H](C)N)F)C(=O)O
DMH6XJG	IK	OUXXDXXQNWKOIF-RYUDHWBXSA-N
DMH6XJG	IU	(12S)-8-[4-[(2S)-2-aminopropanoyl]oxypiperidin-1-yl]-7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
DMH6XJG	CA	CAS 706809-20-3
DMH6XJG	DE	MRSA infection

DMVQARP	ID	DMVQARP
DMVQARP	DN	WCK-771
DMVQARP	HS	Phase 2
DMVQARP	SN	WCK-771A
DMVQARP	CP	Wockhardt Ltd
DMVQARP	DT	Small molecular drug
DMVQARP	PC	9850037
DMVQARP	MW	534.6
DMVQARP	FM	C25H35FN6O6
DMVQARP	IC	InChI=1S/C19H21FN2O4.C6H14N4O2/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21;7-4(5(11)12)2-1-3-10-6(8)9/h8-11,23H,2-7H2,1H3,(H,25,26);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t10-;4-/m00/s1
DMVQARP	CS	C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)O)F)C(=O)O.C(C[C@@H](C(=O)O)N)CN=C(N)N
DMVQARP	IK	WIFOPRFVQIVWTB-YBVIJTQESA-N
DMVQARP	IU	(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(12S)-7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
DMVQARP	CA	CAS 306748-89-0
DMVQARP	DE	Bacterial infection

DMZ67Q0	ID	DMZ67Q0
DMZ67Q0	DN	WT1 peptide vaccine
DMZ67Q0	HS	Phase 2
DMZ67Q0	SN	WT1 peptide vaccine (cancer); WT1 peptide vaccine (cancer), Charity Medical School of the Humboldt University of Berlin; Cancer vaccine (Wilms tumor gene 1 + KLH + GM-CSF advuvants), Humboldt University of Berlin
DMZ67Q0	CP	Charity Medical School of the Humboldt University of Berlin
DMZ67Q0	DT	Vaccine
DMZ67Q0	DE	leukaemia

DMNFZYE	ID	DMNFZYE
DMNFZYE	DN	WT1-targeted autologous dendritic cell vaccine
DMNFZYE	HS	Phase 2
DMNFZYE	SN	WT1-targeted autologous dendritic cell vaccine (cancer)
DMNFZYE	CP	University of Antwerp; Argos Therapeutics Durham; NC Geron; Dendreon Seattle; WA; ImmunoCellular Therapeutics
DMNFZYE	DT	Vaccine
DMNFZYE	DE	Acute myeloid leukaemia

DMFVNSB	ID	DMFVNSB
DMFVNSB	DN	WY-50295-tromethamine
DMFVNSB	HS	Phase 2
DMFVNSB	SN	WY-50295T; Wy-49232
DMFVNSB	CP	Wyeth-Ayerst Pharmaceuticals Inc
DMFVNSB	DT	Small molecular drug
DMFVNSB	PC	10435196
DMFVNSB	MW	478.5
DMFVNSB	FM	C27H30N2O6
DMFVNSB	IC	InChI=1S/C23H19NO3.C4H11NO3/c1-15(23(25)26)17-6-7-19-13-21(11-9-18(19)12-17)27-14-20-10-8-16-4-2-3-5-22(16)24-20;5-4(1-6,2-7)3-8/h2-13,15H,14H2,1H3,(H,25,26);6-8H,1-3,5H2/t15-;/m0./s1
DMFVNSB	CS	C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O.C(C(CO)(CO)N)O
DMFVNSB	IK	FKKBZYRUPFNJJC-RSAXXLAASA-N
DMFVNSB	IU	2-amino-2-(hydroxymethyl)propane-1,3-diol;(2S)-2-[6-(quinolin-2-ylmethoxy)naphthalen-2-yl]propanoic acid
DMFVNSB	CA	CAS 133899-56-6
DMFVNSB	DE	Asthma

DMW1NKO	ID	DMW1NKO
DMW1NKO	DN	X-82
DMW1NKO	HS	Phase 2
DMW1NKO	CP	Tyrogenex West Palm Beach
DMW1NKO	DE	Macular degeneration; Solid tumour/cancer; Age-related macular degeneration

DMXG5WU	ID	DMXG5WU
DMXG5WU	DN	Xanomeline tartrate
DMXG5WU	HS	Phase 2
DMXG5WU	SN	Memcor; Xanomeline tartrate [USAN]; LY 246708 tartrate; Xanomeline tartrate (USAN); Pyridine, 3-(4-(hexyloxy0-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1); Pyridine, 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); 3-(4-(Hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine L-(+)-tartrate (1:1); 3-hexoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DMXG5WU	CP	Sauerberg
DMXG5WU	DT	Small molecular drug
DMXG5WU	PC	71456
DMXG5WU	MW	431.5
DMXG5WU	FM	C18H29N3O7S
DMXG5WU	IC	InChI=1S/C14H23N3OS.C4H6O6/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12;5-1(3(7)8)2(6)4(9)10/h8H,3-7,9-11H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
DMXG5WU	CS	CCCCCCOC1=NSN=C1C2=CCCN(C2)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMXG5WU	IK	SJSVWTMVMBGIHQ-LREBCSMRSA-N
DMXG5WU	IU	(2R,3R)-2,3-dihydroxybutanedioic acid;3-hexoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DMXG5WU	CA	CAS 152854-19-8
DMXG5WU	DE	Parkinson disease

DM0NFMS	ID	DM0NFMS
DM0NFMS	DN	XEN-2174
DM0NFMS	HS	Phase 2
DM0NFMS	CP	Xenome
DM0NFMS	DE	Cancer related pain

DMR69CG	ID	DMR69CG
DMR69CG	DN	XEN-402
DMR69CG	HS	Phase 2
DMR69CG	CP	Xenon Pharmaceuticals Inc
DMR69CG	DT	Small molecular drug
DMR69CG	PC	49836093
DMR69CG	MW	429.3
DMR69CG	FM	C22H14F3NO5
DMR69CG	IC	InChI=1S/C22H14F3NO5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8H,9-11H2/t21-/m0/s1
DMR69CG	CS	C1[C@]2(C3=CC=CC=C3N(C2=O)CC4=CC=C(O4)C(F)(F)F)C5=CC6=C(C=C5O1)OCO6
DMR69CG	IK	NEBUOXBYNAHKFV-NRFANRHFSA-N
DMR69CG	IU	(7S)-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[6H-furo[2,3-f][1,3]benzodioxole-7,3'-indole]-2'-one
DMR69CG	CA	CAS 1259933-16-8
DMR69CG	DE	Osteoarthritis; Vasodilatation of extremities; Pain

DMG7PDY	ID	DMG7PDY
DMG7PDY	DN	XEN-D0501
DMG7PDY	HS	Phase 2
DMG7PDY	SN	XEN-D501; Ion channel modulator 1 (overactive bladder), Xention; TRPV1 antagonist (overactive bladder), Xention;VR1 antagonist (overactive bladder), Xention; Vanilloid receptor-1 antagonist (overactive bladder), Xention; Ion channel modulator (overactive bladder), Xention/Scion/Bristol-Myers Squibb
DMG7PDY	CP	Bristol-Myers Squibb Co
DMG7PDY	DE	Overactive bladder

DM4ZIDH	ID	DM4ZIDH
DM4ZIDH	DN	Xentuzumab
DM4ZIDH	HS	Phase 2
DM4ZIDH	CP	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DM4ZIDH	DE	Prostate cancer; Breast cancer

DMML7BE	ID	DMML7BE
DMML7BE	DN	Xl147
DMML7BE	HS	Phase 2
DMML7BE	SN	N-[3-(2,1,3-Benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide; 956958-53-5; XL147 analogue; PI3K inhibitor X; XL 147; Pilaralisib analogue; N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide; N-[3-(2,1,3-Benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methylbenzenesulfonamide; CHEBI:71957; C21H16N6O2S2; N-(3-(benzo[c][1,2,5]thiadiazol-5-ylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide; Benzenesulfonamide, N-[3-(2,1,3-benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methyl-; 1033110-57-4; PubChem22457; XL-147 derivative 2; cc-43; AC1Q2LO8; AC1LZ6F0; SAR245408 + MSC1936369B
DMML7BE	CP	Exelixis
DMML7BE	TC	Anticancer Agents
DMML7BE	DT	Small molecular drug
DMML7BE	PC	1893730
DMML7BE	MW	448.5
DMML7BE	FM	C21H16N6O2S2
DMML7BE	IC	InChI=1S/C21H16N6O2S2/c1-13-6-9-15(10-7-13)31(28,29)27-21-20(23-16-4-2-3-5-17(16)24-21)22-14-8-11-18-19(12-14)26-30-25-18/h2-12H,1H3,(H,22,23)(H,24,27)
DMML7BE	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4
DMML7BE	IK	MQMKRQLTIWPEDM-UHFFFAOYSA-N
DMML7BE	IU	N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide
DMML7BE	CA	CAS 1033110-57-4
DMML7BE	CB	CHEBI:71957
DMML7BE	DE	Solid tumour/cancer

DMMHX9K	ID	DMMHX9K
DMMHX9K	DN	XL-820
DMMHX9K	HS	Phase 2
DMMHX9K	SN	EXEL-9820
DMMHX9K	CP	Exelixis
DMMHX9K	DE	Solid tumour/cancer

DMHJTR2	ID	DMHJTR2
DMHJTR2	DN	XL880
DMHJTR2	HS	Phase 2
DMHJTR2	SN	GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors
DMHJTR2	CP	Exelixis; GlaxoSmithKline
DMHJTR2	TC	Anticancer Agents
DMHJTR2	DT	Small molecular drug
DMHJTR2	PC	42642645
DMHJTR2	MW	632.7
DMHJTR2	FM	C34H34F2N4O6
DMHJTR2	IC	InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
DMHJTR2	CS	COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
DMHJTR2	IK	CXQHYVUVSFXTMY-UHFFFAOYSA-N
DMHJTR2	IU	1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMHJTR2	CA	CAS 849217-64-7
DMHJTR2	CB	CHEBI:91418
DMHJTR2	DE	Squamous head and neck cell carcinom; Renal cell carcinoma; Gastric adenocarcinoma; Solid tumour/cancer; Breast cancer

DMVB8EO	ID	DMVB8EO
DMVB8EO	DN	XLCART001
DMVB8EO	HS	Phase 2
DMVB8EO	CP	The First Affiliated Hospital with Nanjing Medical University
DMVB8EO	DT	CAR T Cell Therapy
DMVB8EO	DE	B-cell lymphoma

DMLIPY1	ID	DMLIPY1
DMLIPY1	DN	Xmab 5871
DMLIPY1	HS	Phase 2
DMLIPY1	SN	XmAb 5871 (TN)
DMLIPY1	CP	Amgen; Xencor
DMLIPY1	DE	Rheumatoid arthritis; Autoimmune diabetes; IgG4 related disease; Systemic lupus erythematosus

DMWEB07	ID	DMWEB07
DMWEB07	DN	XOMA-629
DMWEB07	HS	Phase 2
DMWEB07	SN	Acne therapy, XOMA; BPI peptides, XOMA; XMP-629; XMP.629; BPI peptide (acne, Staphylococcus infection, impetigo), Xoma; Bactericidal permeability increasing protein (acne, Staphylococcus infection, impetigo), XOMA
DMWEB07	CP	XOMA Ltd
DMWEB07	DE	Acne vulgaris

DM8N3ZQ	ID	DM8N3ZQ
DM8N3ZQ	DN	XP-21279
DM8N3ZQ	HS	Phase 2
DM8N3ZQ	SN	Levodopa transported prodrug (Parkinson's disease), XenoPort; L-dopa transported prodrug (Parkinson's disease), XenoPort
DM8N3ZQ	CP	Xenoport
DM8N3ZQ	DE	Parkinson disease

DMELUYN	ID	DMELUYN
DMELUYN	DN	XP-23829
DMELUYN	HS	Phase 2
DMELUYN	SN	Methylhydrogenfumarate prodrug (multiple sclerosis), XenoPort
DMELUYN	CP	Xenoport
DMELUYN	PC	46179632
DMELUYN	MW	243.26
DMELUYN	FM	C11H17NO5
DMELUYN	IC	InChI=1S/C11H17NO5/c1-4-12(5-2)9(13)8-17-11(15)7-6-10(14)16-3/h6-7H,4-5,8H2,1-3H3/b7-6+
DMELUYN	CS	CCN(CC)C(=O)COC(=O)/C=C/C(=O)OC
DMELUYN	IK	AKUGRXRLHCCENI-VOTSOKGWSA-N
DMELUYN	IU	4-O-[2-(diethylamino)-2-oxoethyl] 1-O-methyl (E)-but-2-enedioate
DMELUYN	CA	CAS 1208229-58-6
DMELUYN	DE	Multiple sclerosis; Plaque psoriasis

DMOKUA5	ID	DMOKUA5
DMOKUA5	DN	XR-5000
DMOKUA5	HS	Phase 2
DMOKUA5	SN	DACA; SN-22995
DMOKUA5	CP	Xenova
DMOKUA5	DE	Colorectal cancer

DMPI6N0	ID	DMPI6N0
DMPI6N0	DN	XZK-monascus
DMPI6N0	HS	Phase 2
DMPI6N0	CP	Beijing peking university wbl biotech
DMPI6N0	DE	Hyperlipidaemia

DM54MAJ	ID	DM54MAJ
DM54MAJ	DN	YF-476
DM54MAJ	HS	Phase 2
DM54MAJ	SN	Sograzepide; FE-999008; Gastrin inhibitor, Ferring; YM-476
DM54MAJ	CP	Ferring Pharmaceuticals Inc
DM54MAJ	DT	Small molecular drug
DM54MAJ	PC	9870520
DM54MAJ	MW	498.6
DM54MAJ	FM	C28H30N6O3
DM54MAJ	IC	InChI=1S/C28H30N6O3/c1-28(2,3)23(35)17-34-22-14-6-5-12-20(22)24(21-13-7-8-15-30-21)32-25(26(34)36)33-27(37)31-19-11-9-10-18(16-19)29-4/h5-16,25,29H,17H2,1-4H3,(H2,31,33,37)/t25-/m0/s1
DM54MAJ	CS	CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=N[C@H](C1=O)NC(=O)NC3=CC=CC(=C3)NC)C4=CC=CC=N4
DM54MAJ	IK	YDZYKNJZCVIKPP-VWLOTQADSA-N
DM54MAJ	IU	1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3H-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea
DM54MAJ	CA	CAS 155488-25-8
DM54MAJ	DE	Stomach ulcer

DMCHFB0	ID	DMCHFB0
DMCHFB0	DN	YH-4808
DMCHFB0	HS	Phase 2
DMCHFB0	SN	Second generation acid pump antagonist, Yuhan
DMCHFB0	CP	Yuhan Corp
DMCHFB0	DE	Duodenal ulcer

DM740LV	ID	DM740LV
DM740LV	DN	YKP-GI
DM740LV	HS	Phase 2
DM740LV	SN	SKL-IBS; YKP-10811; 5-HT 4 receptor partial agonist (irritable bowel syndrome/constipation), SK Life science
DM740LV	CP	SK Life Science
DM740LV	DT	Small molecular drug
DM740LV	PC	45275554
DM740LV	MW	493
DM740LV	FM	C24H30ClFN4O4
DM740LV	IC	InChI=1S/C24H30ClFN4O4/c1-33-22-13-20(27)19(25)12-18(22)23(31)29-14-15-6-9-30(10-7-15)11-8-21(34-24(28)32)16-2-4-17(26)5-3-16/h2-5,12-13,15,21H,6-11,14,27H2,1H3,(H2,28,32)(H,29,31)/t21-/m0/s1
DM740LV	CS	COC1=CC(=C(C=C1C(=O)NCC2CCN(CC2)CC[C@@H](C3=CC=C(C=C3)F)OC(=O)N)Cl)N
DM740LV	IK	KGMMSPVVHZGPHL-NRFANRHFSA-N
DM740LV	IU	[(1S)-3-[4-[[(4-amino-5-chloro-2-methoxybenzoyl)amino]methyl]piperidin-1-yl]-1-(4-fluorophenyl)propyl] carbamate
DM740LV	CA	CAS 1221416-43-8
DM740LV	DE	Constipation

DM5Q1W4	ID	DM5Q1W4
DM5Q1W4	DN	Ym155
DM5Q1W4	HS	Phase 2
DM5Q1W4	SN	Sepantronium
DM5Q1W4	CP	Astellas Pharma
DM5Q1W4	DT	Small molecular drug
DM5Q1W4	PC	11178236
DM5Q1W4	MW	443.3
DM5Q1W4	FM	C20H19BrN4O3
DM5Q1W4	IC	InChI=1S/C20H19N4O3.BrH/c1-13-23(9-10-27-2)17-18(24(13)12-14-11-21-7-8-22-14)20(26)16-6-4-3-5-15(16)19(17)25;/h3-8,11H,9-10,12H2,1-2H3;1H/q+1;/p-1
DM5Q1W4	CS	CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]
DM5Q1W4	IK	QBIYUDDJPRGKNJ-UHFFFAOYSA-M
DM5Q1W4	IU	1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione;bromide
DM5Q1W4	CA	CAS 781661-94-7
DM5Q1W4	CB	CHEBI:139608
DM5Q1W4	DE	Non-hodgkin lymphoma; Breast cancer

DMAZNVX	ID	DMAZNVX
DMAZNVX	DN	YM-264
DMAZNVX	HS	Phase 2
DMAZNVX	SN	YM 264; 131888-54-5; 1-(3-Methyl-3-phenylbutyl)-4-(2-(3-pyridyl)thiazolidin-4-ylcarbonyl)piperazine fumarate; 1-(3-methyl-3-phenylbutyl]-4-[2-(3-pyridyl)thiazolidin-4-ylcarbonyl]piperazine fumarate; AC1O5RFQ; SCHEMBL9819914; SCHEMBL9819910; LBPPBLYOJCIZRW-WLHGVMLRSA-N; BCP20243; HY-101833; CS-0021927
DMAZNVX	CP	Yamanouchi Pharmaceutical Co Ltd
DMAZNVX	DT	Small molecular drug
DMAZNVX	PC	6439322
DMAZNVX	MW	540.7
DMAZNVX	FM	C28H36N4O5S
DMAZNVX	IC	InChI=1S/C24H32N4OS.C4H4O4/c1-24(2,20-8-4-3-5-9-20)10-12-27-13-15-28(16-14-27)23(29)21-18-30-22(26-21)19-7-6-11-25-17-19;5-3(6)1-2-4(7)8/h3-9,11,17,21-22,26H,10,12-16,18H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMAZNVX	CS	CC(C)(CCN1CCN(CC1)C(=O)C2CSC(N2)C3=CN=CC=C3)C4=CC=CC=C4.C(=C/C(=O)O)\\C(=O)O
DMAZNVX	IK	LBPPBLYOJCIZRW-WLHGVMLRSA-N
DMAZNVX	IU	(E)-but-2-enedioic acid;[4-(3-methyl-3-phenylbutyl)piperazin-1-yl]-(2-pyridin-3-yl-1,3-thiazolidin-4-yl)methanone
DMAZNVX	CA	CAS 131888-54-5
DMAZNVX	DE	Sepsis

DMS7609	ID	DMS7609
DMS7609	DN	YM-358
DMS7609	HS	Phase 2
DMS7609	SN	2,7-Diethyl-5-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-5H-pyrazolo[1,5-b][1,2,4]triazole potassium salt monohydrate
DMS7609	DT	Small molecular drug
DMS7609	PC	9801006
DMS7609	MW	398.5
DMS7609	FM	C22H22N8
DMS7609	IC	InChI=1S/C22H22N8/c1-3-16-14-29(30-22(16)23-20(4-2)26-30)13-15-9-11-17(12-10-15)18-7-5-6-8-19(18)21-24-27-28-25-21/h5-12,14H,3-4,13H2,1-2H3,(H,24,25,27,28)
DMS7609	CS	CCC1=CN(N2C1=NC(=N2)CC)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMS7609	IK	LASWNZRBIPFGHP-UHFFFAOYSA-N
DMS7609	IU	2,7-diethyl-5-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrazolo[1,5-b][1,2,4]triazole
DMS7609	DE	Hypertension

DMKJF6H	ID	DMKJF6H
DMKJF6H	DN	YM-430
DMKJF6H	HS	Phase 2
DMKJF6H	SN	YM-15430-1; YM-15430-2; YM-15430-3; YM-15430-4
DMKJF6H	CP	Yamanouchi Pharmaceutical Co Ltd
DMKJF6H	PC	9850612
DMKJF6H	MW	553.6
DMKJF6H	FM	C29H35N3O8
DMKJF6H	IC	InChI=1S/C29H35N3O8/c1-19-25(28(34)38-3)27(21-10-9-11-22(16-21)32(36)37)26(20(2)31-19)29(35)39-15-8-7-14-30-17-23(33)18-40-24-12-5-4-6-13-24/h4-6,9-13,16,23,27,30-31,33H,7-8,14-15,17-18H2,1-3H3/t23-,27-/m0/s1
DMKJF6H	CS	CC1=C([C@@H](C(=C(N1)C)C(=O)OCCCCNC[C@@H](COC2=CC=CC=C2)O)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMKJF6H	IK	HBXMSJLNXYLVTA-HOFKKMOUSA-N
DMKJF6H	IU	5-O-[4-[[(2S)-2-hydroxy-3-phenoxypropyl]amino]butyl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMKJF6H	DE	Hypertension

DMRZBPI	ID	DMRZBPI
DMRZBPI	DN	YM-543
DMRZBPI	HS	Phase 2
DMRZBPI	SN	ASP-543; SGLT-2 inhibitor (oral, diabetes), Astellas/Kotobuki
DMRZBPI	CP	Kotobuki Pharmaceutical Co Ltd
DMRZBPI	PC	11998655
DMRZBPI	MW	499.6
DMRZBPI	FM	C28H37NO7
DMRZBPI	IC	InChI=1S/C23H24O6.C5H14NO/c24-12-19-20(26)21(27)22(28)23(29-19)17-11-13(6-7-18(17)25)8-14-9-15-4-2-1-3-5-16(15)10-14;1-6(2,3)4-5-7/h1-7,9-11,19-28H,8,12H2;7H,4-5H2,1-3H3/q;+1/p-1/t19-,20-,21+,22-,23+;/m1./s1
DMRZBPI	CS	C[N+](C)(C)CCO.C1=CC=C2C=C(C=C2C=C1)CC3=CC(=C(C=C3)[O-])[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DMRZBPI	IK	UKOOBSDARBTSHN-NGOMLPPMSA-M
DMRZBPI	IU	4-(azulen-2-ylmethyl)-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenolate;2-hydroxyethyl(trimethyl)azanium
DMRZBPI	CA	CAS 1610007-47-0
DMRZBPI	DE	Type-2 diabetes

DMUPJWH	ID	DMUPJWH
DMUPJWH	DN	YM-598
DMUPJWH	HS	Phase 2
DMUPJWH	CP	Astellas
DMUPJWH	PC	12093171
DMUPJWH	MW	529.6
DMUPJWH	FM	C24H20KN5O5S
DMUPJWH	IC	InChI=1S/C24H20N5O5S.K/c1-32-18-11-6-7-12-19(18)34-20-21(29-35(30,31)16-13-17-9-4-3-5-10-17)27-23(28-24(20)33-2)22-25-14-8-15-26-22;/h3-16H,1-2H3;/q-1;+1/b16-13+;
DMUPJWH	CS	COC1=CC=CC=C1OC2=C(N=C(N=C2OC)C3=NC=CC=N3)[N-]S(=O)(=O)/C=C/C4=CC=CC=C4.[K+]
DMUPJWH	IK	WOPWEXSDEXIRNG-ZUQRMPMESA-N
DMUPJWH	IU	potassium;[6-methoxy-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]-[(E)-2-phenylethenyl]sulfonylazanide
DMUPJWH	CA	CAS 342005-82-7
DMUPJWH	DE	Prostate cancer

DMU79X2	ID	DMU79X2
DMU79X2	DN	Ym-758
DMU79X2	HS	Phase 2
DMU79X2	SN	YM 758 Phosphate; (R)-(-)-N-[2-[3-[(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl]piperidino]ethyl]-4-fluorobenzamide monophosphate; YM 758; N-[2-[(3R)-3-[(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)carbonyl]-1-piperidinyl]ethyl]-4-fluorobenzamide Phosphate
DMU79X2	DT	Small molecular drug
DMU79X2	PC	9894205
DMU79X2	MW	469.5
DMU79X2	FM	C26H32FN3O4
DMU79X2	IC	InChI=1S/C26H32FN3O4/c1-33-23-14-19-9-12-30(17-21(19)15-24(23)34-2)26(32)20-4-3-11-29(16-20)13-10-28-25(31)18-5-7-22(27)8-6-18/h5-8,14-15,20H,3-4,9-13,16-17H2,1-2H3,(H,28,31)/t20-/m1/s1
DMU79X2	CS	COC1=C(C=C2CN(CCC2=C1)C(=O)[C@@H]3CCCN(C3)CCNC(=O)C4=CC=C(C=C4)F)OC
DMU79X2	IK	MWLKUSHZNSYRKK-HXUWFJFHSA-N
DMU79X2	IU	N-[2-[(3R)-3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)piperidin-1-yl]ethyl]-4-fluorobenzamide
DMU79X2	CA	CAS 312752-85-5
DMU79X2	DE	Angina pectoris

DM7KR4C	ID	DM7KR4C
DM7KR4C	DN	YM-934
DM7KR4C	HS	Phase 2
DM7KR4C	SN	YM-934; YM 934; UNII-Z0E489238B; 136544-11-1; 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)pyridine N-oxide; Z0E489238B; 2H-1,4-Benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, N-oxide; CHEMBL93539; SCHEMBL4260665; AC1L305E; DTXSID90159834; GOTJEXSHEQBBSV-UHFFFAOYSA-N; LS-41736
DM7KR4C	DT	Small molecular drug
DM7KR4C	PC	131974
DM7KR4C	MW	301.3
DM7KR4C	FM	C15H15N3O4
DM7KR4C	IC	InChI=1S/C15H15N3O4/c1-15(2)10-16(14-5-3-4-8-17(14)19)12-9-11(18(20)21)6-7-13(12)22-15/h3-9H,10H2,1-2H3
DM7KR4C	CS	CC1(CN(C2=C(O1)C=CC(=C2)[N+](=O)[O-])C3=CC=CC=[N+]3[O-])C
DM7KR4C	IK	GOTJEXSHEQBBSV-UHFFFAOYSA-N
DM7KR4C	IU	2,2-dimethyl-6-nitro-4-(1-oxidopyridin-1-ium-2-yl)-3H-1,4-benzoxazine
DM7KR4C	CA	CAS 136544-11-1
DM7KR4C	DE	Angina pectoris

DM0K8U7	ID	DM0K8U7
DM0K8U7	DN	YSIL6
DM0K8U7	HS	Phase 2
DM0K8U7	CP	Y's Therapeutics
DM0K8U7	DE	Crohn disease

DM3YVKQ	ID	DM3YVKQ
DM3YVKQ	DN	YT-146
DM3YVKQ	HS	Phase 2
DM3YVKQ	SN	Adenosine A2 agonists, Yamasa
DM3YVKQ	CP	Yamasa Shoyu Co Ltd
DM3YVKQ	DT	Small molecular drug
DM3YVKQ	PC	146207
DM3YVKQ	MW	375.4
DM3YVKQ	FM	C18H25N5O4
DM3YVKQ	IC	InChI=1S/C18H25N5O4/c1-2-3-4-5-6-7-8-12-21-16(19)13-17(22-12)23(10-20-13)18-15(26)14(25)11(9-24)27-18/h10-11,14-15,18,24-26H,2-6,9H2,1H3,(H2,19,21,22)/t11-,14-,15-,18-/m1/s1
DM3YVKQ	CS	CCCCCCC#CC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DM3YVKQ	IK	NVGGIHKSKVAPEY-XKLVTHTNSA-N
DM3YVKQ	IU	(2R,3R,4S,5R)-2-(6-amino-2-oct-1-ynylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM3YVKQ	CA	CAS 90596-75-1
DM3YVKQ	DE	Hypertension

DM2M80G	ID	DM2M80G
DM2M80G	DN	Z 360
DM2M80G	HS	Phase 2
DM2M80G	SN	Z-360
DM2M80G	TC	Anticancer Agents
DM2M80G	DT	Small molecular drug
DM2M80G	PC	9872609
DM2M80G	MW	520.6
DM2M80G	FM	C29H36N4O5
DM2M80G	IC	InChI=1S/C29H36N4O5/c1-29(2,3)25(34)18-33-24-15-8-7-14-23(24)32(21-12-5-4-6-13-21)17-22(26(33)35)31-28(38)30-20-11-9-10-19(16-20)27(36)37/h7-11,14-16,21-22H,4-6,12-13,17-18H2,1-3H3,(H,36,37)(H2,30,31,38)/t22-/m1/s1
DM2M80G	CS	CC(C)(C)C(=O)CN1C2=CC=CC=C2N(C[C@H](C1=O)NC(=O)NC3=CC=CC(=C3)C(=O)O)C4CCCCC4
DM2M80G	IK	VIJCCFFEBCOOIE-JOCHJYFZSA-N
DM2M80G	IU	3-[[(3R)-1-cyclohexyl-5-(3,3-dimethyl-2-oxobutyl)-4-oxo-2,3-dihydro-1,5-benzodiazepin-3-yl]carbamoylamino]benzoic acid
DM2M80G	CA	CAS 209219-38-5
DM2M80G	DE	Discovery agent

DMUT9OE	ID	DMUT9OE
DMUT9OE	DN	Zadaxin/lamivudine
DMUT9OE	HS	Phase 2
DMUT9OE	CP	SciClone Pharmaceuticals
DMUT9OE	DE	Hepatitis B virus infection

DMJN3BA	ID	DMJN3BA
DMJN3BA	DN	Zalospirone
DMJN3BA	HS	Phase 2
DMJN3BA	SN	Zalospirone hydrochloride; Wy-47846
DMJN3BA	CP	Wyeth
DMJN3BA	DT	Small molecular drug
DMJN3BA	PC	163925
DMJN3BA	MW	419.5
DMJN3BA	FM	C24H29N5O2
DMJN3BA	IC	InChI=1S/C24H29N5O2/c30-22-20-18-6-7-19(17-5-4-16(17)18)21(20)23(31)29(22)11-2-1-10-27-12-14-28(15-13-27)24-25-8-3-9-26-24/h3-9,16-21H,1-2,10-15H2/t16-,17+,18-,19+,20-,21+
DMJN3BA	CS	C1CN(CCN1CCCCN2C(=O)[C@@H]3[C@@H]4C=C[C@H]([C@@H]3C2=O)[C@@H]5[C@H]4C=C5)C6=NC=CC=N6
DMJN3BA	IK	AERLHOTUXIJQFV-RCPZPFRWSA-N
DMJN3BA	IU	(1S,2S,6R,7R,8R,11S)-4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatetracyclo[5.4.2.02,6.08,11]trideca-9,12-diene-3,5-dione
DMJN3BA	CA	CAS 114298-18-9
DMJN3BA	DE	Anxiety disorder

DMTYD8Q	ID	DMTYD8Q
DMTYD8Q	DN	ZD2079
DMTYD8Q	HS	Phase 2
DMTYD8Q	SN	Talibegron hydrochloride; ZD 2079; 178600-17-4; Talibegron HCl; ICID2079; UNII-N251Q608VU; ZD-2079; Talibegron hydrochloride [USAN]; ZD2079; SCH 417849; N251Q608VU; NCGC00092315-01; 4-[2-[[(2R)-2-HYDROXY-2-PHENYLETHYL]AMINO]ETHOXY]-BENZENEACETIC ACID HYDROCHLORIDE; DSSTox_RID_83233; DSSTox_CID_28968; DSSTox_GSID_49042; Talibegron hydrochloride (USAN); Benzeneacetic acid, 4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethoxy)-, hydrochloride; CAS-178600-17-4; Talibegron  hydrochloride; ZD 2079 hydrochloride; AC1L4KMI; C18H21NO4.HCl
DMTYD8Q	DT	Small molecular drug
DMTYD8Q	PC	158793
DMTYD8Q	MW	351.8
DMTYD8Q	FM	C18H22ClNO4
DMTYD8Q	IC	InChI=1S/C18H21NO4.ClH/c20-17(15-4-2-1-3-5-15)13-19-10-11-23-16-8-6-14(7-9-16)12-18(21)22;/h1-9,17,19-20H,10-13H2,(H,21,22);1H/t17-;/m0./s1
DMTYD8Q	CS	C1=CC=C(C=C1)[C@H](CNCCOC2=CC=C(C=C2)CC(=O)O)O.Cl
DMTYD8Q	IK	KCEFVYIWOQSJCH-LMOVPXPDSA-N
DMTYD8Q	IU	2-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl]acetic acid;hydrochloride
DMTYD8Q	CA	CAS 178600-17-4
DMTYD8Q	DE	Diabetic complication

DMH85M0	ID	DMH85M0
DMH85M0	DN	ZD-6126
DMH85M0	HS	Phase 2
DMH85M0	SN	219923-05-4; ZD6126; ZD-6126; UNII-GBO3S6M9W7; GBO3S6M9W7; N-Acetylcochinol-O-phosphate; AZD-6126; N-Acetylcolchicinol dihydrogenphosphate; ZD 6126; SCHEMBL1285000; CHEMBL257662; ANG 453; AZD6126, ANG453; ZINC3993833; AZD 6126; BCP9000366; DB11872; BCP0726000110; ZM 445526; Acetamide, N-((5S)-6,7-dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5H-dibenzo(a,c)cyclohepten-5-yl)-
DMH85M0	CP	Angiogene Pharmaceuticals Ltd; Angiogene
DMH85M0	DT	Small molecular drug
DMH85M0	PC	9896434
DMH85M0	MW	437.4
DMH85M0	FM	C20H24NO8P
DMH85M0	IC	InChI=1S/C20H24NO8P/c1-11(22)21-16-8-5-12-9-17(26-2)19(27-3)20(28-4)18(12)14-7-6-13(10-15(14)16)29-30(23,24)25/h6-7,9-10,16H,5,8H2,1-4H3,(H,21,22)(H2,23,24,25)/t16-/m0/s1
DMH85M0	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=C1C=C(C=C3)OP(=O)(O)O)OC)OC)OC
DMH85M0	IK	UGBMEXLBFDAOGL-INIZCTEOSA-N
DMH85M0	IU	[(8S)-8-acetamido-13,14,15-trimethoxy-5-tricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,5,11,13-hexaenyl] dihydrogen phosphate
DMH85M0	CA	CAS 219923-05-4
DMH85M0	DE	Solid tumour/cancer

DMPE2B9	ID	DMPE2B9
DMPE2B9	DN	ZD-7288
DMPE2B9	HS	Phase 2
DMPE2B9	SN	N-ethyl-1,2-dimethyl-6-methylimino-N-phenylpyrimidin-4-amine; AC1L3XOD; SCHEMBL9380740; GTPL2359; ZINC100058922; N-Ethyl-1,6-dihydro-1,2-dimethyl-6-(methylimino)-N-phenyl-4-pyrimidinamine; AKOS027381051; ZINC255004003
DMPE2B9	CP	Zeneca Group plc
DMPE2B9	DT	Small molecular drug
DMPE2B9	PC	9796088
DMPE2B9	MW	292.81
DMPE2B9	FM	C15H21ClN4
DMPE2B9	IC	InChI=1S/C15H20N4.ClH/c1-5-19(13-9-7-6-8-10-13)15-11-14(16-3)18(4)12(2)17-15;/h6-11H,5H2,1-4H3;1H
DMPE2B9	CS	CCN(C1=CC=CC=C1)C2=CC(=[N+](C(=N2)C)C)NC.[Cl-]
DMPE2B9	IK	DUWKUHWHTPRMAP-UHFFFAOYSA-N
DMPE2B9	IU	4-N-ethyl-6-N,1,2-trimethyl-4-N-phenylpyrimidin-1-ium-4,6-diamine;chloride
DMPE2B9	CA	CAS 133059-99-1
DMPE2B9	DE	Angina pectoris

DM6VQTF	ID	DM6VQTF
DM6VQTF	DN	ZEN-3694
DM6VQTF	HS	Phase 2
DM6VQTF	CP	Zenith Epigenetics
DM6VQTF	DT	Small molecular drug
DM6VQTF	DE	Prostate cancer

DM9KB7A	ID	DM9KB7A
DM9KB7A	DN	ZGN-1061
DM9KB7A	HS	Phase 2
DM9KB7A	SN	Aclimostat; UNII-X150A3JK8R; X150A3JK8R; 2082752-83-6; (3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3- methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl 3-[2-(morpholin-4-yl)ethyl]azetidine-1-carboxylate; Aclimostat [INN]; CHEMBL4297651; SCHEMBL18497467; BDBM148432; US9682965, 1; (3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(2.5)octan-6-yl 3-(2-(morpholin-4-yl)ethyl)azetidine-1-carboxylate; (3R,4S,5S,6R)5Methoxy4((2R,3R)2methyl3(3methylbut2en1yl)oxiran2yl)1oxaspiro(2.5)octan6yl 3(2(morpholin4yl)ethyl)azetidine1carboxylate; 1-Azetidinecarboxylic acid, 3-(2-(4-morpholinyl)ethyl)-, (3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl)-1-oxaspiro(2.5)oct-6-yl ester
DM9KB7A	CP	Zafgen
DM9KB7A	DT	Small molecular drug
DM9KB7A	PC	126573394
DM9KB7A	MW	478.6
DM9KB7A	FM	C26H42N2O6
DM9KB7A	IC	InChI=1S/C26H42N2O6/c1-18(2)5-6-21-25(3,34-21)23-22(30-4)20(7-9-26(23)17-32-26)33-24(29)28-15-19(16-28)8-10-27-11-13-31-14-12-27/h5,19-23H,6-17H2,1-4H3/t20-,21-,22-,23-,25+,26+/m1/s1
DM9KB7A	CS	CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)N4CC(C4)CCN5CCOCC5)OC)C
DM9KB7A	IK	QJWJPMLDQYEPPW-AUKZVGPFSA-N
DM9KB7A	IU	[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] 3-(2-morpholin-4-ylethyl)azetidine-1-carboxylate
DM9KB7A	CA	CAS 2082752-83-6
DM9KB7A	DE	Type 2 diabetes

DMJ94L0	ID	DMJ94L0
DMJ94L0	DN	ZK-91587
DMJ94L0	HS	Phase 2
DMJ94L0	SN	SH-D515; 15beta, 16beta-Methylenemexrenone
DMJ94L0	DT	Small molecular drug
DMJ94L0	PC	122017
DMJ94L0	MW	412.5
DMJ94L0	FM	C25H32O5
DMJ94L0	IC	InChI=1S/C25H32O5/c1-23-7-4-14(26)10-13(23)11-16(22(28)29-3)20-17(23)5-8-24(2)21(20)15-12-18(15)25(24)9-6-19(27)30-25/h10,15-18,20-21H,4-9,11-12H2,1-3H3/t15-,16-,17+,18+,20-,21+,23+,24+,25+/m1/s1
DMJ94L0	CS	C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3[C@@H]5C[C@@H]5[C@@]46CCC(=O)O6)C)C(=O)OC
DMJ94L0	IK	YDIQJONNFLVNGD-FPMRONRSSA-N
DMJ94L0	IU	methyl (1'R,2S,2'S,3'S,5'S,7'S,10'S,11'R,18'R)-7',11'-dimethyl-5,14'-dioxospiro[oxolane-2,6'-pentacyclo[8.8.0.02,7.03,5.011,16]octadec-15-ene]-18'-carboxylate
DMJ94L0	CA	CAS 84542-26-7
DMJ94L0	DE	Cardiovascular disease

DM4MSLY	ID	DM4MSLY
DM4MSLY	DN	ZN-c3
DM4MSLY	HS	Phase 2
DM4MSLY	CP	Zentalis Pharmaceuticals
DM4MSLY	DT	Small molecular drug
DM4MSLY	DE	Uterine serous carcinoma

DMG7YI9	ID	DMG7YI9
DMG7YI9	DN	ZYH7
DMG7YI9	HS	Phase 2
DMG7YI9	CP	Zydus Cadila
DMG7YI9	DT	Small molecular drug
DMG7YI9	DE	Lipid metabolism disorder; Dyslipidemia

DMTXBUV	ID	DMTXBUV
DMTXBUV	DN	BT1718
DMTXBUV	HS	Phase 1/2a
DMTXBUV	CP	Bicycle Therapeutics
DMTXBUV	DT	Bicycle toxin conjugate
DMTXBUV	DE	Solid tumour/cancer

DM824EG	ID	DM824EG
DM824EG	DN	COVA322
DM824EG	HS	Phase 1/2a
DM824EG	CP	Covagen/Johnson & Johnson
DM824EG	DT	Monoclonal antibody
DM824EG	DE	Psoriasis vulgaris

DMJ1NG4	ID	DMJ1NG4
DMJ1NG4	DN	Dalazatide
DMJ1NG4	HS	Phase 1b/2a
DMJ1NG4	SN	Dalazatide [INN]; UNII-6U0259J807; 1081110-69-1; o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamide; 6U0259J807
DMJ1NG4	CP	KV1.3 Therapeutics
DMJ1NG4	PC	86278334
DMJ1NG4	MW	4442
DMJ1NG4	FM	C184H296N57O55PS7
DMJ1NG4	IC	InChI=1S/C184H296N57O55PS7/c1-14-94(5)139-172(283)223-124(79-138(254)255)162(273)238-144(100(11)249)176(287)236-140(95(6)15-2)178(289)240-68-33-46-135(240)171(282)217-112(41-24-28-61-187)152(263)224-125(82-242)163(274)212-116(45-32-66-204-182(197)198)153(264)229-134-91-304-303-89-132-168(279)214-114(43-30-64-202-180(193)194)148(259)210-113(42-25-29-62-188)156(267)237-143(99(10)248)175(286)232-130(147(258)206-81-137(253)234-141(97(8)246)174(285)227-129(145(192)256)86-299-301-90-133(169(280)235-139)231-166(277)128(85-245)233-179(290)184(58-34-67-205-183(199)200,295-71-70-294-69-63-189)241(101(12)250)177(288)109(190)74-104-49-53-108(54-50-104)296-297(291,292)293)87-300-302-88-131(228-154(265)117(55-56-136(191)252)215-158(269)120(75-102-35-18-16-19-36-102)218-146(257)96(7)208-173(284)142(98(9)247)239-170(134)281)167(278)213-111(40-23-27-60-186)150(261)222-123(78-106-80-201-92-207-106)161(272)226-126(83-243)164(275)216-118(57-72-298-13)155(266)209-110(39-22-26-59-185)149(260)220-122(77-105-47-51-107(251)52-48-105)159(270)211-115(44-31-65-203-181(195)196)151(262)219-119(73-93(3)4)157(268)225-127(84-244)165(276)221-121(160(271)230-132)76-103-37-20-17-21-38-103/h16-21,35-38,47-54,80,92-100,109-135,139-144,242-249,251H,14-15,22-34,39-46,55-79,81-91,185-190H2,1-13H3,(H2,191,252)(H2,192,256)(H,201,207)(H,206,258)(H,208,284)(H,209,266)(H,210,259)(H,211,270)(H,212,274)(H,213,278)(H,214,279)(H,215,269)(H,216,275)(H,217,282)(H,218,257)(H,219,262)(H,220,260)(H,221,276)(H,222,261)(H,223,283)(H,224,263)(H,225,268)(H,226,272)(H,227,285)(H,228,265)(H,229,264)(H,230,271)(H,231,277)(H,232,286)(H,233,290)(H,234,253)(H,235,280)(H,236,287)(H,237,267)(H,238,273)(H,239,281)(H,254,255)(H4,193,194,202)(H4,195,196,203)(H4,197,198,204)(H4,199,200,205)(H2,291,292,293)/t94-,95-,96-,97+,98+,99+,100+,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130?,131-,132-,133-,134-,135-,139-,140-,141-,142-,143-,144-,184+/m0/s1
DMJ1NG4	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]3CSSC[C@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NC(CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC5=CC=CC=C5)CO)CC(C)C)CCCNC(=N)N)CC6=CC=C(C=C6)O)CCCCN)CCSC)CO)CC7=CNC=N7)CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC3=O)[C@@H](C)O)C)CC8=CC=CC=C8)CCC(=O)N)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@](CCCNC(=N)N)(N(C(=O)C)C(=O)[C@H](CC9=CC=C(C=C9)OP(=O)(O)O)N)OCCOCCN)C(=O)N)[C@@H](C)O)[C@@H](C)O)CCCCN)CCCNC(=N)N)CCCNC(=N)N)CO)CCCCN)[C@@H](C)CC)[C@@H](C)O)CC(=O)O
DMJ1NG4	IK	GORAHSAIYZMTHZ-LBFSFEBVSA-N
DMJ1NG4	IU	2-[(1R,2aS,4S,7S,10S,13S,19S,22S,25S,28S,31R,36R,39S,48S,51S,54S,57R,60S,63S,66S,69S,72S,75S,78S,81S,84S,87S,90R,93S,96S,99S)-31-[[(2S)-2-[[(2R)-2-[acetyl-[(2S)-2-amino-3-(4-phosphonooxyphenyl)propanoyl]amino]-2-[2-(2-aminoethoxy)ethoxy]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-10,51,75,87-tetrakis(4-aminobutyl)-93-(3-amino-3-oxopropyl)-60,96-dibenzyl-19,28-bis[(2S)-butan-2-yl]-4,54,69-tris(3-carbamimidamidopropyl)-36-carbamoyl-2a,22,39,48-tetrakis[(1R)-1-hydroxyethyl]-7,63,81-tris(hydroxymethyl)-72-[(4-hydroxyphenyl)methyl]-84-(1H-imidazol-4-ylmethyl)-99-methyl-66-(2-methylpropyl)-78-(2-methylsulfanylethyl)-1a,3,4a,6,9,12,18,21,24,27,30,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98-dotriacontaoxo-6a,7a,10a,11a,33,34-hexathia-a,2,3a,5,8,11,17,20,23,26,29,37,40,43,46,49,52,55,58,61,64,67,70,73,76,79,82,85,88,91,94,97-dotriacontazatetracyclo[55.47.4.445,90.013,17]dodecahectan-25-yl]acetic acid
DMJ1NG4	CA	CAS 1081110-69-1
DMJ1NG4	DE	Plaque psoriasis; Inclusion body myositis; Psoriasis vulgaris

DMV401D	ID	DMV401D
DMV401D	DN	Debio-0824
DMV401D	HS	Phase 1b/2a
DMV401D	SN	Shk-192; ShK analogs (Subcutaneous formulation, autoimmune disease), Kineta; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease); Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (Subcutaneous formulation, autoimmune disease), Airmid; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (injectable peptide, autoimmune disease), Davis; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease), Kineta One
DMV401D	CP	Kineta
DMV401D	DE	Psoriatic arthritis; Psoriasis vulgaris

DMT17XU	ID	DMT17XU
DMT17XU	DN	131I-radretumab
DMT17XU	HS	Phase 1/2
DMT17XU	SN	L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP
DMT17XU	CP	ETH Zurich
DMT17XU	DT	Antibody
DMT17XU	DE	Non-small-cell lung cancer

DMVZ9XL	ID	DMVZ9XL
DMVZ9XL	DN	177Lu-labelled DOTA-JR11
DMVZ9XL	HS	Phase 1/2
DMVZ9XL	CP	Ipsen
DMVZ9XL	DT	Radiopharmaceutical therapy agent
DMVZ9XL	DE	Neuroendocrine cancer

DMWPD7N	ID	DMWPD7N
DMWPD7N	DN	177Lu-labelled PSMA-R2
DMWPD7N	HS	Phase 1/2
DMWPD7N	CP	Novartis/AAA
DMWPD7N	DT	Radiopharmaceutical therapy agent
DMWPD7N	DE	Prostate cancer

DM6JLNT	ID	DM6JLNT
DM6JLNT	DN	177-Lu-NeoB
DM6JLNT	HS	Phase 1/2
DM6JLNT	CP	Advanced Accelerator Applications
DM6JLNT	DT	Small molecular drug
DM6JLNT	DE	Solid tumour/cancer

DMF4AOE	ID	DMF4AOE
DMF4AOE	DN	177-Lu-PSMA-R2
DMF4AOE	HS	Phase 1/2
DMF4AOE	CP	Advanced Accelerator Applications
DMF4AOE	DT	Small molecular drug
DMF4AOE	DE	Prostate cancer

DMCLKA4	ID	DMCLKA4
DMCLKA4	DN	2-hydroxyoleic acid
DMCLKA4	HS	Phase 1/2
DMCLKA4	SN	2R-hydroxy-oleic acid; 2R-hydroxy-9Z-octadecenoic acid; R-Hydroxy-olsaure; (R)-2-Hydroxyoleic acid; SCHEMBL378127; ZINC14210872; LMFA02000056; UNII-OSV3KVO1BT component JBSOOFITVPOOSY-DOOKAGJSSA-N
DMCLKA4	CP	Bridge BioResearch International Ltd
DMCLKA4	DT	Small molecular drug
DMCLKA4	PC	9796304
DMCLKA4	MW	298.5
DMCLKA4	FM	C18H34O3
DMCLKA4	IC	InChI=1S/C18H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h9-10,17,19H,2-8,11-16H2,1H3,(H,20,21)/b10-9-
DMCLKA4	CS	CCCCCCCC/C=C\\CCCCCCC(C(=O)O)O
DMCLKA4	IK	JBSOOFITVPOOSY-KTKRTIGZSA-N
DMCLKA4	IU	(Z)-2-hydroxyoctadec-9-enoic acid
DMCLKA4	CA	CAS 56472-29-8
DMCLKA4	CB	CHEBI:143096
DMCLKA4	DE	Hypertension

DMYPQT4	ID	DMYPQT4
DMYPQT4	DN	4SCAR19 and 4SCAR123
DMYPQT4	HS	Phase 1/2
DMYPQT4	CP	Shenzhen Geno-Immune Medical Institute
DMYPQT4	DT	CAR T Cell Therapy (Dual specific)
DMYPQT4	DE	B-cell lymphoma

DMFVTSG	ID	DMFVTSG
DMFVTSG	DN	4SCAR19 and 4SCAR20
DMFVTSG	HS	Phase 1/2
DMFVTSG	CP	Shenzhen Geno-Immune Medical Institute
DMFVTSG	DT	CAR T Cell Therapy (Dual specific)
DMFVTSG	DE	B-cell lymphoma

DM8CMUW	ID	DM8CMUW
DM8CMUW	DN	4SCAR19 and 4SCAR22
DM8CMUW	HS	Phase 1/2
DM8CMUW	CP	Shenzhen Geno-Immune Medical Institute
DM8CMUW	DT	CAR T Cell Therapy (Dual specific)
DM8CMUW	DE	B-cell lymphoma

DMUYFS1	ID	DMUYFS1
DMUYFS1	DN	4SCAR19 and 4SCAR30
DMUYFS1	HS	Phase 1/2
DMUYFS1	CP	Shenzhen Geno-Immune Medical Institute
DMUYFS1	DT	CAR T Cell Therapy (Dual specific)
DMUYFS1	DE	B-cell lymphoma

DMZKFU7	ID	DMZKFU7
DMZKFU7	DN	4SCAR19 and 4SCAR38
DMZKFU7	HS	Phase 1/2
DMZKFU7	CP	Shenzhen Geno-Immune Medical Institute
DMZKFU7	DT	CAR T Cell Therapy (Dual specific)
DMZKFU7	DE	B-cell lymphoma

DMKC8F9	ID	DMKC8F9
DMKC8F9	DN	4SCAR19 and 4SCAR70
DMKC8F9	HS	Phase 1/2
DMKC8F9	CP	Shenzhen Geno-Immune Medical Institute
DMKC8F9	DT	CAR T Cell Therapy (Dual specific)
DMKC8F9	DE	B-cell lymphoma

DMIY1ZB	ID	DMIY1ZB
DMIY1ZB	DN	4SCAR19 cells
DMIY1ZB	HS	Phase 1/2
DMIY1ZB	CP	Shenzhen Geno-Immune Medical Institute
DMIY1ZB	DT	CAR T Cell Therapy
DMIY1ZB	DE	B-cell lymphoma

DMI8TW3	ID	DMI8TW3
DMI8TW3	DN	4SCAR19/22 T cells
DMI8TW3	HS	Phase 1/2
DMI8TW3	CP	Zhujiang Hospital
DMI8TW3	DT	CAR T Cell Therapy (Dual specific)
DMI8TW3	DE	B-cell lymphoma; leukaemia

DMEGSU5	ID	DMEGSU5
DMEGSU5	DN	4SCAR-GD2
DMEGSU5	HS	Phase 1/2
DMEGSU5	CP	Shenzhen Geno-Immune Medical Institute
DMEGSU5	DT	CAR T Cell Therapy
DMEGSU5	DE	Tumour

DMM8J5W	ID	DMM8J5W
DMM8J5W	DN	4SCAR-PSMA
DMM8J5W	HS	Phase 1/2
DMM8J5W	CP	Shenzhen Geno-Immune Medical Institute
DMM8J5W	DT	CAR T Cell Therapy
DMM8J5W	DE	Bladder cancer

DM129VT	ID	DM129VT
DM129VT	DN	514G3
DM129VT	HS	Phase 1/2
DM129VT	CP	XBiotech
DM129VT	DT	Antibody
DM129VT	DE	Staphylococcus infection

DMFAMNH	ID	DMFAMNH
DMFAMNH	DN	99mTc-rBitistatin
DMFAMNH	HS	Phase 1/2
DMFAMNH	CP	Temple University
DMFAMNH	DE	Embolism

DMGTOIX	ID	DMGTOIX
DMGTOIX	DN	A166
DMGTOIX	HS	Phase 1/2
DMGTOIX	CP	KLUS Pharma
DMGTOIX	DT	Antibody drug conjugate
DMGTOIX	DE	Solid tumour/cancer

DMAPUZY	ID	DMAPUZY
DMAPUZY	DN	AAV1-FS344
DMAPUZY	HS	Phase 1/2
DMAPUZY	CP	Milo biotechnology
DMAPUZY	DE	Macular degeneration; Duchenne dystrophy; Inclusion body myositis

DMI27RF	ID	DMI27RF
DMI27RF	DN	AAV-AQP1
DMI27RF	HS	Phase 1/2
DMI27RF	CP	MeiraGTx
DMI27RF	DT	Gene therapy
DMI27RF	DE	Xerostomia

DMNZJAE	ID	DMNZJAE
DMNZJAE	DN	AAV-CNGA3
DMNZJAE	HS	Phase 1/2
DMNZJAE	CP	Janssen; MeiraGTx
DMNZJAE	DT	Gene therapy
DMNZJAE	DE	Achromatopsia

DM0CJAN	ID	DM0CJAN
DM0CJAN	DN	AAV-CNGB3
DM0CJAN	HS	Phase 1/2
DM0CJAN	CP	MeiraGTx
DM0CJAN	DT	Gene therapy
DM0CJAN	DE	Achromatopsia

DMAH6UJ	ID	DMAH6UJ
DMAH6UJ	DN	AAV-RPE65
DMAH6UJ	HS	Phase 1/2
DMAH6UJ	CP	MeiraGTx
DMAH6UJ	DT	Gene therapy
DMAH6UJ	DE	Leber congenital amaurosis

DM7TF49	ID	DM7TF49
DM7TF49	DN	AAV-RPGR
DM7TF49	HS	Phase 1/2
DM7TF49	CP	MeiraGTx
DM7TF49	DT	Gene therapy
DM7TF49	DE	Retinitis pigmentosa

DMDOXMN	ID	DMDOXMN
DMDOXMN	DN	AB928
DMDOXMN	HS	Phase 1/2
DMDOXMN	CP	Arcus Biosciences Hayward, CA
DMDOXMN	PC	135242184
DMDOXMN	MW	426.5
DMDOXMN	FM	C23H22N8O
DMDOXMN	IC	InChI=1S/C23H22N8O/c1-14-15(11-24)6-4-8-17(14)18-10-19(28-22(25)27-18)20-13-31(30-29-20)12-16-7-5-9-21(26-16)23(2,3)32/h4-10,13,32H,12H2,1-3H3,(H2,25,27,28)
DMDOXMN	CS	CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N
DMDOXMN	IK	BUXIAWLTBSXYSW-UHFFFAOYSA-N
DMDOXMN	IU	3-[2-amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile
DMDOXMN	CA	CAS 2239273-34-6
DMDOXMN	DE	Solid tumour/cancer; Metastatic colorectal cancer

DMUBLC3	ID	DMUBLC3
DMUBLC3	DN	ABO-101
DMUBLC3	HS	Phase 1/2
DMUBLC3	CP	Abeona Therapeutics
DMUBLC3	DT	Gene therapy
DMUBLC3	DE	Mucopolysaccharidosis

DMFJB35	ID	DMFJB35
DMFJB35	DN	ABO-102
DMFJB35	HS	Phase 1/2
DMFJB35	CP	Abeona Therapeutics
DMFJB35	DT	Gene therapy
DMFJB35	DE	Mucopolysaccharidosis

DM31NJU	ID	DM31NJU
DM31NJU	DN	ABY-025
DM31NJU	HS	Phase 1/2
DM31NJU	CP	Affibody Holding AB
DM31NJU	DE	Bladder cancer

DMIRGTZ	ID	DMIRGTZ
DMIRGTZ	DN	ACHM-CNGA3
DMIRGTZ	HS	Phase 1/2
DMIRGTZ	CP	Applied Genetic Technologies
DMIRGTZ	DT	Gene therapy
DMIRGTZ	DE	Achromatopsia

DMC4ZQD	ID	DMC4ZQD
DMC4ZQD	DN	ACHM-CNGB3
DMC4ZQD	HS	Phase 1/2
DMC4ZQD	CP	Applied Genetic Technologies
DMC4ZQD	DT	Gene therapy
DMC4ZQD	DE	Achromatopsia

DM5YDSU	ID	DM5YDSU
DM5YDSU	DN	ACI-24
DM5YDSU	HS	Phase 1/2
DM5YDSU	SN	Beta amyloid vaccine (liposomal/SupraAntigen, Alzheimer's disease/Down syndrome), AC Immune
DM5YDSU	CP	AC Immune SA
DM5YDSU	DT	Vaccine
DM5YDSU	DE	Alzheimer disease

DM7IWTF	ID	DM7IWTF
DM7IWTF	DN	ACP-319
DM7IWTF	HS	Phase 1/2
DM7IWTF	CP	Acerta pharma
DM7IWTF	DE	Chronic lymphocytic leukaemia

DMEU86T	ID	DMEU86T
DMEU86T	DN	ACT017
DMEU86T	HS	Phase 1/2
DMEU86T	CP	Acticor Biotech
DMEU86T	DT	Small molecular drug
DMEU86T	DE	Cerebral ischemia

DM4L28K	ID	DM4L28K
DM4L28K	DN	Ad35-GRIN
DM4L28K	HS	Phase 1/2
DM4L28K	SN	Adenovirus serotype 35 vector-delivered gag/rt/int/nef vaccine (HIV infection), International AIDS Vaccine Initiative
DM4L28K	CP	International AIDS Vaccine Initiative
DM4L28K	DT	Vaccine
DM4L28K	DE	Human immunodeficiency virus infection

DMEGPSW	ID	DMEGPSW
DMEGPSW	DN	AdCh63 AMA1
DMEGPSW	HS	Phase 1/2
DMEGPSW	SN	MVA AMA1; Recombinant adenovirus-poxvirus prime-boost malaria vaccine, Oxford University/MRC/Wellcome
DMEGPSW	CP	University of Oxford
DMEGPSW	DT	Vaccine
DMEGPSW	DE	Malaria

DMBGXH5	ID	DMBGXH5
DMBGXH5	DN	AdCh63-MSP1
DMBGXH5	HS	Phase 1/2
DMBGXH5	SN	MVA-MSP1; MSP1 prime-boost vaccine (Plasmodium infection); MSP1 prime-boost vaccine (Plasmodium infection), University of Oxford
DMBGXH5	CP	University of Oxford
DMBGXH5	DT	Vaccine
DMBGXH5	DE	Malaria

DMYOMSC	ID	DMYOMSC
DMYOMSC	DN	Aderbasib
DMYOMSC	HS	Phase 1/2
DMYOMSC	SN	INCB-007839; INCB-7839; Sheddase inhibitors (anticancer), Incyte; ADAM inhibitors (oral, cancer), Incyte
DMYOMSC	CP	Incyte Corp
DMYOMSC	DT	Small molecular drug
DMYOMSC	PC	16070111
DMYOMSC	MW	416.5
DMYOMSC	FM	C21H28N4O5
DMYOMSC	IC	InChI=1S/C21H28N4O5/c1-30-20(28)25-14-21(7-8-21)13-16(18(26)22-29)17(25)19(27)24-11-9-23(10-12-24)15-5-3-2-4-6-15/h2-6,16-17,29H,7-14H2,1H3,(H,22,26)/t16-,17-/m0/s1
DMYOMSC	CS	COC(=O)N1CC2(CC2)C[C@@H]([C@H]1C(=O)N3CCN(CC3)C4=CC=CC=C4)C(=O)NO
DMYOMSC	IK	DJXMSZSZEIKLQZ-IRXDYDNUSA-N
DMYOMSC	IU	methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate
DMYOMSC	CA	CAS 791828-58-5
DMYOMSC	DE	Breast cancer

DM87H0S	ID	DM87H0S
DM87H0S	DN	ADG106
DM87H0S	HS	Phase 1/2
DM87H0S	CP	Adagene
DM87H0S	DT	Antibody
DM87H0S	DE	Non-hodgkin lymphoma; Solid tumour/cancer

DMB19IO	ID	DMB19IO
DMB19IO	DN	Ad-IL-12 DNA therapeutic
DMB19IO	HS	Phase 1/2
DMB19IO	SN	INXN-2001
DMB19IO	CP	ZIOPHARM Oncology
DMB19IO	DE	Melanoma; Recurrent glioblastoma

DMOPVET	ID	DMOPVET
DMOPVET	DN	ADXS-PSA
DMOPVET	HS	Phase 1/2
DMOPVET	SN	Advaxis PSA; Lovaxin P; Lm CLLO CPSA; ADXS31-142; PSA/Listeria vector (cancer), Advaxis; Prostate specific antigen/Listeria vector (cancer), Advaxis
DMOPVET	CP	Advaxis Inc
DMOPVET	DT	Antibody
DMOPVET	DE	Prostate cancer

DMEOS5K	ID	DMEOS5K
DMEOS5K	DN	AEE-788
DMEOS5K	HS	Phase 1/2
DMEOS5K	SN	AEE; AEE 788; AEE788; GNF-Pf-5343; AEE-788, NVP-AEE 788, AEE788
DMEOS5K	CP	Novartis AG
DMEOS5K	TC	Anticancer Agents
DMEOS5K	DT	Small molecular drug
DMEOS5K	PC	10297043
DMEOS5K	MW	440.6
DMEOS5K	FM	C27H32N6
DMEOS5K	IC	InChI=1S/C27H32N6/c1-3-32-13-15-33(16-14-32)18-21-9-11-23(12-10-21)25-17-24-26(28-19-29-27(24)31-25)30-20(2)22-7-5-4-6-8-22/h4-12,17,19-20H,3,13-16,18H2,1-2H3,(H2,28,29,30,31)/t20-/m1/s1
DMEOS5K	CS	CCN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5
DMEOS5K	IK	OONFNUWBHFSNBT-HXUWFJFHSA-N
DMEOS5K	IU	6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
DMEOS5K	CA	CAS 497839-62-0
DMEOS5K	DE	Solid tumour/cancer

DM2HRYD	ID	DM2HRYD
DM2HRYD	DN	AEG35156
DM2HRYD	HS	Phase 1/2
DM2HRYD	CP	Aegera Therapeutics
DM2HRYD	TC	siRNA
DM2HRYD	DT	siRNA drug
DM2HRYD	DE	Solid tumour/cancer

DMMNIBY	ID	DMMNIBY
DMMNIBY	DN	Aflunov
DMMNIBY	HS	Phase 1/2
DMMNIBY	SN	Aflunov (TN)
DMMNIBY	CP	Novartis Vaccines & Diagnostics
DMMNIBY	DT	Vaccine
DMMNIBY	DE	Influenza A virus H5N1 infection

DMFTZX0	ID	DMFTZX0
DMFTZX0	DN	AFM24
DMFTZX0	HS	Phase 1/2
DMFTZX0	CP	Affimed Therapeutics
DMFTZX0	DT	Antibody
DMFTZX0	DE	Solid tumour/cancer

DMRET3H	ID	DMRET3H
DMRET3H	DN	AG-013958
DMRET3H	HS	Phase 1/2
DMRET3H	SN	AG-13958
DMRET3H	CP	Pfizer Inc
DMRET3H	PC	9934283
DMRET3H	MW	467.5
DMRET3H	FM	C26H22FN7O
DMRET3H	IC	InChI=1S/C26H22FN7O/c1-16-13-25(34(2)33-16)26(35)30-24-15-19(7-10-21(24)27)29-18-6-9-20-22(31-32-23(20)14-18)11-8-17-5-3-4-12-28-17/h3-15,29H,1-2H3,(H,30,35)(H,31,32)/b11-8+
DMRET3H	CS	CC1=NN(C(=C1)C(=O)NC2=C(C=CC(=C2)NC3=CC4=C(C=C3)C(=NN4)/C=C/C5=CC=CC=N5)F)C
DMRET3H	IK	JXSVVZKPEDIRTN-DHZHZOJOSA-N
DMRET3H	IU	N-[2-fluoro-5-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]amino]phenyl]-2,5-dimethylpyrazole-3-carboxamide
DMRET3H	CA	CAS 319460-94-1
DMRET3H	DE	Age-related macular degeneration

DMEN2L7	ID	DMEN2L7
DMEN2L7	DN	AG019
DMEN2L7	HS	Phase 1/2
DMEN2L7	CP	Intrexon T1D Partners; ActoBio Therapeutics
DMEN2L7	DT	Gene therapy
DMEN2L7	DE	Type-1 diabetes

DMAP5B4	ID	DMAP5B4
DMAP5B4	DN	AGEN1884
DMAP5B4	HS	Phase 1/2
DMAP5B4	CP	Agenus Lexington, MA
DMAP5B4	DE	Solid tumour/cancer; Cervical cancer

DMHZUF8	ID	DMHZUF8
DMHZUF8	DN	AGN-208397
DMHZUF8	HS	Phase 1/2
DMHZUF8	CP	Allergan Inc
DMHZUF8	DE	Retina venous occlusion

DMTS51C	ID	DMTS51C
DMTS51C	DN	AGTC-501
DMTS51C	HS	Phase 1/2
DMTS51C	CP	Applied Genetic Technologies
DMTS51C	DT	Gene therapy
DMTS51C	DE	Retinitis pigmentosa

DMJVGIH	ID	DMJVGIH
DMJVGIH	DN	AIGIV
DMJVGIH	HS	Phase 1/2
DMJVGIH	SN	Anthrax immune globulin therapy (intravenous); Anthrax immune globulin therapy (intravenous), Emergent
DMJVGIH	CP	Adma biologics; emergent biosolutions
DMJVGIH	DE	Diabetic neuropathy

DML0GIU	ID	DML0GIU
DML0GIU	DN	AIV001
DML0GIU	HS	Phase 1/2
DML0GIU	CP	AiViva BioPharma
DML0GIU	DT	Small molecular drug
DML0GIU	DE	Basal cell carcinoma

DMNXLOT	ID	DMNXLOT
DMNXLOT	DN	ALAMIFOVIR
DMNXLOT	HS	Phase 1/2
DMNXLOT	SN	LY-582563; MCC-478; Alamifovir; 2-[2-Amino-6-(4-methoxyphenylsulfanyl)-9H-purin-9-yl]ethoxymethylphosphonic acid bis(2,2,2-trifluoroethyl) diester
DMNXLOT	CP	Eli Lilly
DMNXLOT	DT	Small molecular drug
DMNXLOT	PC	491022
DMNXLOT	MW	575.4
DMNXLOT	FM	C19H20F6N5O5PS
DMNXLOT	IC	InChI=1S/C19H20F6N5O5PS/c1-32-12-2-4-13(5-3-12)37-16-14-15(28-17(26)29-16)30(10-27-14)6-7-33-11-36(31,34-8-18(20,21)22)35-9-19(23,24)25/h2-5,10H,6-9,11H2,1H3,(H2,26,28,29)
DMNXLOT	CS	COC1=CC=C(C=C1)SC2=NC(=NC3=C2N=CN3CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F)N
DMNXLOT	IK	VDBGPMJFHCJMOL-UHFFFAOYSA-N
DMNXLOT	IU	9-[2-[bis(2,2,2-trifluoroethoxy)phosphorylmethoxy]ethyl]-6-(4-methoxyphenyl)sulfanylpurin-2-amine
DMNXLOT	CA	CAS 193681-12-8
DMNXLOT	DE	Virus infection

DMGQX0U	ID	DMGQX0U
DMGQX0U	DN	ALX148
DMGQX0U	HS	Phase 1/2
DMGQX0U	CP	ALX Oncology
DMGQX0U	DT	Protein
DMGQX0U	DE	Non-hodgkin lymphoma; Solid tumour/cancer; Myelodysplastic syndrome

DMEF4L5	ID	DMEF4L5
DMEF4L5	DN	AMG888/U3-1287
DMEF4L5	HS	Phase 1/2
DMEF4L5	CP	Amgen
DMEF4L5	DE	Non-small-cell lung cancer

DM7RNKM	ID	DM7RNKM
DM7RNKM	DN	AMT-060
DM7RNKM	HS	Phase 1/2
DM7RNKM	SN	AAV gene therapy (hemophilia B), Amsterdam Molecular Therapeutics/St Jude
DM7RNKM	CP	Amsterdam Molecular Therapeutics BV
DM7RNKM	DE	Factor IX deficiency

DMR9H6B	ID	DMR9H6B
DMR9H6B	DN	AMXI 5001
DMR9H6B	HS	Phase 1/2
DMR9H6B	CP	AtlasMedx
DMR9H6B	DT	Small molecular drug
DMR9H6B	DE	Solid tumour/cancer

DMDHJNV	ID	DMDHJNV
DMDHJNV	DN	Annamycin
DMDHJNV	HS	Phase 1/2
DMDHJNV	SN	92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903
DMDHJNV	CP	Moleculin Biotech
DMDHJNV	DT	Small molecular drug
DMDHJNV	PC	115212
DMDHJNV	MW	640.4
DMDHJNV	FM	C26H25IO11
DMDHJNV	IC	InChI=1S/C26H25IO11/c1-9-19(30)24(35)18(27)25(37-9)38-13-7-26(36,14(29)8-28)6-12-15(13)23(34)17-16(22(12)33)20(31)10-4-2-3-5-11(10)21(17)32/h2-5,9,13,18-19,24-25,28,30,33-36H,6-8H2,1H3/t9-,13-,18+,19-,24-,25-,26-/m0/s1
DMDHJNV	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)CO)O)I)O)O
DMDHJNV	IK	CIDNKDMVSINJCG-GKXONYSUSA-N
DMDHJNV	IU	(7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione
DMDHJNV	CA	CAS 92689-49-1
DMDHJNV	DE	Acute myeloid leukaemia

DM4D3YF	ID	DM4D3YF
DM4D3YF	DN	Anti-BCMA CAR-T cells
DM4D3YF	HS	Phase 1/2
DM4D3YF	CP	Shenzhen BinDeBio Ltd.
DM4D3YF	DT	CAR T Cell Therapy
DM4D3YF	DE	Multiple myeloma

DMZ18IO	ID	DMZ18IO
DMZ18IO	DN	Anti-BCMA-CAR-transduced T cells
DMZ18IO	HS	Phase 1/2
DMZ18IO	CP	Southwest Hospital, China
DMZ18IO	DT	CAR T Cell Therapy
DMZ18IO	DE	leukaemia; Lymphoma; Multiple myeloma

DMFV6TY	ID	DMFV6TY
DMFV6TY	DN	Anti-CD123-CAR-transduced T cells
DMFV6TY	HS	Phase 1/2
DMFV6TY	CP	Southwest Hospital, China
DMFV6TY	DT	CAR T Cell Therapy
DMFV6TY	DE	leukaemia

DMLFB25	ID	DMLFB25
DMLFB25	DN	Anti-CD19 and Anti-CD20 CAR-T Cells
DMLFB25	HS	Phase 1/2
DMLFB25	CP	Shanghai Longyao Biotechnology Inc., Ltd.
DMLFB25	DT	CAR T Cell Therapy (Dual specific)
DMLFB25	DE	B-cell lymphoma

DMS326R	ID	DMS326R
DMS326R	DN	Anti-CD19 CAR T cells
DMS326R	HS	Phase 1/2
DMS326R	CP	Peking University
DMS326R	DT	CAR T Cell Therapy
DMS326R	DE	B-cell lymphoma

DMHSLVJ	ID	DMHSLVJ
DMHSLVJ	DN	Anti-CD19 CAR transduced T cells
DMHSLVJ	HS	Phase 1/2
DMHSLVJ	CP	Second Affiliated Hospital of Guangzhou Medical University
DMHSLVJ	DT	CAR T Cell Therapy
DMHSLVJ	DE	Acute lymphocytic leukaemia; Chronic lymphocytic leukaemia; Lymphoma

DM04HNB	ID	DM04HNB
DM04HNB	DN	Anti-CD19 CAR-T
DM04HNB	HS	Phase 1/2
DM04HNB	CP	The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
DM04HNB	DT	CAR T Cell Therapy
DM04HNB	DE	Haematopoietic/lymphoid cancer

DM1EH9D	ID	DM1EH9D
DM1EH9D	DN	Anti-CD19 CAR-T cells
DM1EH9D	HS	Phase 1/2
DM1EH9D	CP	Shenzhen BinDeBio Ltd.
DM1EH9D	DT	CAR T Cell Therapy
DM1EH9D	DE	leukaemia; Lymphoma

DM92CUG	ID	DM92CUG
DM92CUG	DN	Anti-CD19 CAR-T cells
DM92CUG	HS	Phase 1/2
DM92CUG	CP	Wuhan Sian Medical Technology Co., Ltd
DM92CUG	DT	CAR T Cell Therapy
DM92CUG	DE	Acute lymphoblastic leukaemia; B-cell lymphoma

DMDRYZK	ID	DMDRYZK
DMDRYZK	DN	Anti-CD19 CAR-T cells
DMDRYZK	HS	Phase 1/2
DMDRYZK	CP	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
DMDRYZK	DT	CAR T Cell Therapy
DMDRYZK	DE	Acute lymphocytic leukaemia; B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma

DMSFEOC	ID	DMSFEOC
DMSFEOC	DN	Anti-CD19 CAR-T cells
DMSFEOC	HS	Phase 1/2
DMSFEOC	CP	Kai Lin Xu; Jun Nian Zheng
DMSFEOC	DT	CAR T Cell Therapy
DMSFEOC	DE	B-cell chronic lymphocytic leukaemia

DMMUSHR	ID	DMMUSHR
DMMUSHR	DN	Anti-CD19/22-CAR vector-transduced T cells
DMMUSHR	HS	Phase 1/2
DMMUSHR	CP	Chinese PLA General Hospital
DMMUSHR	DT	CAR T Cell Therapy (Dual specific)
DMMUSHR	DE	Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Prolymphocytic leukaemia

DM1WB8H	ID	DM1WB8H
DM1WB8H	DN	Anti-CD19-CAR PBL
DM1WB8H	HS	Phase 1/2
DM1WB8H	CP	National Cancer Institute (NCI)
DM1WB8H	DT	CAR T Cell Therapy
DM1WB8H	DE	Mantle cell lymphoma; Primary mediastinal B-cell lymphoma; Diffuse large B-cell lymphoma

DMQXU4C	ID	DMQXU4C
DMQXU4C	DN	Anti-CD19-CAR vector-transduced T cells
DMQXU4C	HS	Phase 1/2
DMQXU4C	CP	Chinese PLA General Hospital
DMQXU4C	DT	CAR T Cell Therapy
DMQXU4C	DE	Mantle cell lymphoma; B-cell non-hodgkin lymphoma; Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Haematopoietic/lymphoid cancer; Prolymphocytic leukaemia

DMNTP23	ID	DMNTP23
DMNTP23	DN	Anti-CD19-CAR-T cells
DMNTP23	HS	Phase 1/2
DMNTP23	CP	Shanghai GeneChem Co., Ltd.
DMNTP23	DT	CAR T Cell Therapy
DMNTP23	DE	leukaemia

DM4WEZL	ID	DM4WEZL
DM4WEZL	DN	Anti-CD20 CAR-T cells
DM4WEZL	HS	Phase 1/2
DM4WEZL	CP	Southwest Hospital, China
DM4WEZL	DT	CAR T Cell Therapy (Dual specific)
DM4WEZL	DE	Diffuse large B-cell lymphoma

DMCDUJY	ID	DMCDUJY
DMCDUJY	DN	Anti-CD20-CAR vector-transduced autologous T cells
DMCDUJY	HS	Phase 1/2
DMCDUJY	CP	Chinese PLA General Hospital
DMCDUJY	DT	CAR T Cell Therapy
DMCDUJY	DE	Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Haematopoietic/lymphoid cancer; Mantle cell lymphoma; Prolymphocytic leukaemia

DMXMK30	ID	DMXMK30
DMXMK30	DN	Anti-CD20-CAR-transduced T cells
DMXMK30	HS	Phase 1/2
DMXMK30	CP	Southwest Hospital, China
DMXMK30	DT	CAR T Cell Therapy
DMXMK30	DE	leukaemia; Lymphoma

DMY6U8R	ID	DMY6U8R
DMY6U8R	DN	Anti-CD22 CAR-T cells
DMY6U8R	HS	Phase 1/2
DMY6U8R	CP	Shenzhen BinDeBio Ltd.
DMY6U8R	DT	CAR T Cell Therapy
DMY6U8R	DE	leukaemia; Lymphoma

DMTO9VF	ID	DMTO9VF
DMTO9VF	DN	Anti-CD22-CAR-transduced T cells
DMTO9VF	HS	Phase 1/2
DMTO9VF	CP	Affiliated Hospital to Academy of Military Medical Sciences
DMTO9VF	DT	CAR T Cell Therapy
DMTO9VF	DE	leukaemia; Lymphoma

DM8139V	ID	DM8139V
DM8139V	DN	Anti-CD30 CAR T cells
DM8139V	HS	Phase 1/2
DM8139V	CP	Peking University
DM8139V	DT	CAR T Cell Therapy
DM8139V	DE	Lymphoma

DMTZSPJ	ID	DMTZSPJ
DMTZSPJ	DN	Anti-CD30-CAR-transduced T cells
DMTZSPJ	HS	Phase 1/2
DMTZSPJ	CP	Southwest Hospital, China
DMTZSPJ	DT	CAR T Cell Therapy
DMTZSPJ	DE	leukaemia; Lymphoma

DM9NPF6	ID	DM9NPF6
DM9NPF6	DN	Anti-CD33 CAR-T cells
DM9NPF6	HS	Phase 1/2
DM9NPF6	CP	Shenzhen BinDeBio Ltd.
DM9NPF6	DT	CAR T Cell Therapy
DM9NPF6	DE	Myeloid leukaemia

DMTVXBY	ID	DMTVXBY
DMTVXBY	DN	Anti-CD38 CAR-T cells
DMTVXBY	HS	Phase 1/2
DMTVXBY	CP	Shenzhen BinDeBio Ltd.
DMTVXBY	DT	CAR T Cell Therapy
DMTVXBY	DE	Multiple myeloma

DMV5H0S	ID	DMV5H0S
DMV5H0S	DN	Anti-C-met CAR-T cells
DMV5H0S	HS	Phase 1/2
DMV5H0S	CP	Shenzhen BinDeBio Ltd.
DMV5H0S	DT	CAR T Cell Therapy
DMV5H0S	DE	Colorectal cancer; Hepatocellular carcinoma; Ovarian cancer; Renal cell carcinoma

DMYKZB3	ID	DMYKZB3
DMYKZB3	DN	Anti-DR5 cells
DMYKZB3	HS	Phase 1/2
DMYKZB3	CP	Shenzhen BinDeBio Ltd.
DMYKZB3	DT	CAR T Cell Therapy
DMYKZB3	DE	Hepatocellular carcinoma

DM8EAGV	ID	DM8EAGV
DM8EAGV	DN	Anti-EGFR V III CAR-T cells
DM8EAGV	HS	Phase 1/2
DM8EAGV	CP	Shenzhen BinDeBio Ltd.
DM8EAGV	DT	CAR T Cell Therapy
DM8EAGV	DE	Glioma; Hepatocellular carcinoma; Lung cancer

DMDKTYU	ID	DMDKTYU
DMDKTYU	DN	Anti-EGFRvIII CAR transduced PBL
DMDKTYU	HS	Phase 1/2
DMDKTYU	CP	National Cancer Institute (NCI)
DMDKTYU	DT	CAR T Cell Therapy
DMDKTYU	DE	Brain cancer; Malignant glioma; Recurrent glioblastoma

DM8ENKS	ID	DM8ENKS
DM8ENKS	DN	Anti-Factor D
DM8ENKS	HS	Phase 1/2
DM8ENKS	CP	Genentech
DM8ENKS	DT	Antibody
DM8ENKS	DE	Age-related macular degeneration

DMQD6B9	ID	DMQD6B9
DMQD6B9	DN	Anti-HER2 CAR-T
DMQD6B9	HS	Phase 1/2
DMQD6B9	CP	Zhi Yang
DMQD6B9	DT	CAR T Cell Therapy
DMQD6B9	DE	Colorectal cancer; Gastric adenocarcinoma; Glioma; Lung cancer; Ovarian cancer; Pancreatic cancer

DMQZJ3B	ID	DMQZJ3B
DMQZJ3B	DN	Anti-HIV ribozyme therapy
DMQZJ3B	HS	Phase 1/2
DMQZJ3B	SN	OZ1; RRZ2; HIV ribozyme gene therapy, Gene Shears; Gene therapy (HIV), Gene Shears; Anti-HIV ribozyme therapy, Johnson & Johnson; Anti-HIV-1 gene transfer product, Johnson & Johnson
DMQZJ3B	CP	Gene Shears Pty Ltd
DMQZJ3B	DE	Human immunodeficiency virus infection

DMXI03L	ID	DMXI03L
DMXI03L	DN	Anti-mesothelin CAR transduced PBL
DMXI03L	HS	Phase 1/2
DMXI03L	CP	National Cancer Institute (NCI)
DMXI03L	DT	CAR T Cell Therapy
DMXI03L	DE	Cervical cancer; Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer

DM4NMBW	ID	DM4NMBW
DM4NMBW	DN	Anti-Mesothelin CAR-T cells
DM4NMBW	HS	Phase 1/2
DM4NMBW	CP	Shenzhen BinDeBio Ltd.
DM4NMBW	DT	CAR T Cell Therapy
DM4NMBW	DE	Gastric adenocarcinoma; Mesothelioma; Pancreatic cancer

DM0C1IX	ID	DM0C1IX
DM0C1IX	DN	Anti-MUC1 CAR T Cells
DM0C1IX	HS	Phase 1/2
DM0C1IX	CP	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
DM0C1IX	DT	CAR T Cell Therapy
DM0C1IX	DE	Breast cancer; Hepatocellular carcinoma; Pancreatic cancer

DMDHKN1	ID	DMDHKN1
DMDHKN1	DN	Anti-MUC1 CAR T Cells
DMDHKN1	HS	Phase 1/2
DMDHKN1	CP	The First Affiliated Hospital of Guangdong Pharmaceutical University
DMDHKN1	DT	CAR T Cell Therapy
DMDHKN1	DE	Lung cancer; Non-small-cell lung cancer

DMTQIB2	ID	DMTQIB2
DMTQIB2	DN	Anti-MUC1 CAR-T cells
DMTQIB2	HS	Phase 1/2
DMTQIB2	CP	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
DMTQIB2	DT	CAR T Cell Therapy
DMTQIB2	DE	Colorectal cancer; Gastric adenocarcinoma; Malignant glioma

DMXYOTP	ID	DMXYOTP
DMXYOTP	DN	Anti-MUC1 CAR-T cells
DMXYOTP	HS	Phase 1/2
DMXYOTP	CP	The First Affiliated Hospital of Guangdong Pharmaceutical University
DMXYOTP	DT	CAR T Cell Therapy
DMXYOTP	DE	Esophageal cancer

DM26VCZ	ID	DM26VCZ
DM26VCZ	DN	Anti-NY-ESO-1 CAR-T cells
DM26VCZ	HS	Phase 1/2
DM26VCZ	CP	Shenzhen BinDeBio Ltd.
DM26VCZ	DT	CAR T Cell Therapy
DM26VCZ	DE	Esophageal cancer; Lung cancer; Multiple myeloma; Synovial sarcoma

DM2910G	ID	DM2910G
DM2910G	DN	Anti-VEGFR2 CD8 cell therapy
DM2910G	HS	Phase 1/2
DM2910G	SN	Anti-VEGFR2 CD8 cell therapy (cancer)
DM2910G	CP	Pervasis Therapeutics
DM2910G	DE	Solid tumour/cancer

DMXU98C	ID	DMXU98C
DMXU98C	DN	AO-176
DMXU98C	HS	Phase 1/2
DMXU98C	CP	Arch Oncology
DMXU98C	DT	Antibody
DMXU98C	DE	Solid tumour/cancer

DMBGA35	ID	DMBGA35
DMBGA35	DN	AP-1030
DMBGA35	HS	Phase 1/2
DMBGA35	SN	AP-1102; AP-1130; MS-05; Combined MC1/MC4 receptor agonists, Action Pharma; Melanocortin-1/-4 receptor agonists, ActionPharma; Melanocortin-1/melanocortin-4 receptor agonists, Action Pharma
DMBGA35	CP	Action Pharma A/S
DMBGA35	DE	Metabolic disorder

DM2LU8M	ID	DM2LU8M
DM2LU8M	DN	AP1903
DM2LU8M	HS	Phase 1/2
DM2LU8M	SN	Rimiducid; AP1903; 195514-63-7; UNII-H564L1W5J2; AP 1903; AP-1903; H564L1W5J2; Rimiducid [INN]; Rimiducid [USAN:INN]; CHEMBL269259; SCHEMBL10111062; DTXSID80173226; EX-A1711; AKOS030238859; CS-3162; KB-74710; HY-16046; Z-3163; 2-Piperidinecarboxylic acid, 1-(1-oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-(3,4-dimethoxyphenyl)propylidene)) ester, (2S-(1(R*),2R*(S*(S*(1(R*),2R*)))))-
DM2LU8M	CP	Bellicum Pharmaceuticals
DM2LU8M	PC	16135625
DM2LU8M	MW	1411.6
DM2LU8M	FM	C78H98N4O20
DM2LU8M	IC	InChI=1S/C78H98N4O20/c1-13-57(53-43-67(93-7)73(97-11)68(44-53)94-8)75(85)81-37-17-15-25-59(81)77(87)101-61(31-27-49-29-33-63(89-3)65(39-49)91-5)51-21-19-23-55(41-51)99-47-71(83)79-35-36-80-72(84)48-100-56-24-20-22-52(42-56)62(32-28-50-30-34-64(90-4)66(40-50)92-6)102-78(88)60-26-16-18-38-82(60)76(86)58(14-2)54-45-69(95-9)74(98-12)70(46-54)96-10/h19-24,29-30,33-34,39-46,57-62H,13-18,25-28,31-32,35-38,47-48H2,1-12H3,(H,79,83)(H,80,84)/t57-,58-,59-,60-,61+,62+/m0/s1
DM2LU8M	CS	CC[C@@H](C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCC[C@H]2C(=O)O[C@H](CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)NCCNC(=O)COC5=CC=CC(=C5)[C@@H](CCC6=CC(=C(C=C6)OC)OC)OC(=O)[C@@H]7CCCCN7C(=O)[C@@H](CC)C8=CC(=C(C(=C8)OC)OC)OC
DM2LU8M	IK	GQLCLPLEEOUJQC-ZTQDTCGGSA-N
DM2LU8M	IU	[(1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[[2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]phenyl]propyl] (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate
DM2LU8M	CA	CAS 195514-63-7
DM2LU8M	DE	Transplant rejection

DMJLMEF	ID	DMJLMEF
DMJLMEF	DN	AP-30663
DMJLMEF	HS	Phase 1/2
DMJLMEF	CP	Acesion Pharma
DMJLMEF	DE	Atrial fibrillation

DM71I53	ID	DM71I53
DM71I53	DN	APC-100
DM71I53	HS	Phase 1/2
DM71I53	CP	Adamis Pharmaceuticals
DM71I53	PC	99479
DM71I53	MW	220.31
DM71I53	FM	C14H20O2
DM71I53	IC	InChI=1S/C14H20O2/c1-8-9(2)13-11(10(3)12(8)15)6-7-14(4,5)16-13/h15H,6-7H2,1-5H3
DM71I53	CS	CC1=C(C2=C(CCC(O2)(C)C)C(=C1O)C)C
DM71I53	IK	SEBPXHSZHLFWRL-UHFFFAOYSA-N
DM71I53	IU	2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-ol
DM71I53	CA	CAS 950-99-2
DM71I53	DE	Prostate cancer

DM8O3R9	ID	DM8O3R9
DM8O3R9	DN	APG-1252
DM8O3R9	HS	Phase 1/2
DM8O3R9	CP	Ascentage Pharma
DM8O3R9	DT	Small molecular drug
DM8O3R9	DE	Small-cell lung cancer; Solid tumour/cancer

DMPWBM2	ID	DMPWBM2
DMPWBM2	DN	APG-2575
DMPWBM2	HS	Phase 1/2
DMPWBM2	SN	Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-
DMPWBM2	CP	Ascentage Pharma
DMPWBM2	DT	Small molecular drug
DMPWBM2	PC	137355972
DMPWBM2	MW	882.4
DMPWBM2	FM	C45H48ClN7O8S
DMPWBM2	IC	InChI=1S/C45H48ClN7O8S/c46-33-4-2-30(3-5-33)39-25-45(12-1-13-45)14-10-32(39)28-51-16-18-52(19-17-51)34-6-8-38(42(23-34)61-35-22-31-11-15-47-43(31)49-26-35)44(54)50-62(57,58)37-7-9-40(41(24-37)53(55)56)48-27-36-29-59-20-21-60-36/h2-9,11,15,22-24,26,36,48H,1,10,12-14,16-21,25,27-29H2,(H,47,49)(H,50,54)/t36-/m0/s1
DMPWBM2	CS	C1CC2(C1)CCC(=C(C2)C3=CC=C(C=C3)Cl)CN4CCN(CC4)C5=CC(=C(C=C5)C(=O)NS(=O)(=O)C6=CC(=C(C=C6)NC[C@H]7COCCO7)[N+](=O)[O-])OC8=CN=C9C(=C8)C=CN9
DMPWBM2	IK	FNBXDBIYRAPDPI-BHVANESWSA-N
DMPWBM2	IU	4-[4-[[8-(4-chlorophenyl)spiro[3.5]non-7-en-7-yl]methyl]piperazin-1-yl]-N-[4-[[(2S)-1,4-dioxan-2-yl]methylamino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
DMPWBM2	CA	CAS 2180923-05-9
DMPWBM2	DE	Chronic lymphocytic leukaemia; Small lymphocytic lymphoma

DMV7Q6X	ID	DMV7Q6X
DMV7Q6X	DN	APN-201
DMV7Q6X	HS	Phase 1/2
DMV7Q6X	SN	Lipoxysan; Liposomal SOD (wound healing), Polymun; Liposomal SOD (Peyronie's disease), Polymun; RhSOD (liposomal, dermatitis), Apeiron; Liposomal superoxide dismutase (recombinant, encapsulated, topical), Polymun
DMV7Q6X	CP	Polymun Scientific Immunobiologische Forschung GmbH
DMV7Q6X	DE	Dermatitis

DM76S3X	ID	DM76S3X
DM76S3X	DN	ARO-HBV
DM76S3X	HS	Phase 1/2
DM76S3X	SN	JNJ-3989
DM76S3X	CP	Arrowhead Pharmaceuticals
DM76S3X	DT	Small interfering RNA
DM76S3X	DE	Hepatitis B

DMI17NX	ID	DMI17NX
DMI17NX	DN	ART621
DMI17NX	HS	Phase 1/2
DMI17NX	CP	Arana Therapeutics
DMI17NX	DE	Psoriasis vulgaris; Rheumatoid arthritis

DMYCID5	ID	DMYCID5
DMYCID5	DN	ARV-110
DMYCID5	HS	Phase 1/2
DMYCID5	CP	Arvinas
DMYCID5	DT	Small molecular drug
DMYCID5	DE	Prostate cancer

DM276Y8	ID	DM276Y8
DM276Y8	DN	ARV-471
DM276Y8	HS	Phase 1/2
DM276Y8	CP	Arvinas
DM276Y8	DT	Small molecular drug
DM276Y8	DE	Breast cancer

DMVNCSK	ID	DMVNCSK
DMVNCSK	DN	ASC-101
DMVNCSK	HS	Phase 1/2
DMVNCSK	SN	Engraftin; Recombinant enzyme (bone marrow transplant), America Stem Cell
DMVNCSK	CP	America stem cell
DMVNCSK	DE	Haematological malignancy

DM8V0UL	ID	DM8V0UL
DM8V0UL	DN	ASP-9521
DM8V0UL	HS	Phase 1/2
DM8V0UL	CP	Astellas Pharma Inc
DM8V0UL	PC	25210792
DM8V0UL	MW	330.4
DM8V0UL	FM	C19H26N2O3
DM8V0UL	IC	InChI=1S/C19H26N2O3/c1-19(2,23)12-13-6-8-21(9-7-13)18(22)17-11-14-10-15(24-3)4-5-16(14)20-17/h4-5,10-11,13,20,23H,6-9,12H2,1-3H3
DM8V0UL	CS	CC(C)(CC1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)OC)O
DM8V0UL	IK	OXSCPDKUZWPWFR-UHFFFAOYSA-N
DM8V0UL	IU	[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(5-methoxy-1H-indol-2-yl)methanone
DM8V0UL	DE	Prostate cancer

DMVZXIA	ID	DMVZXIA
DMVZXIA	DN	ASTX029
DMVZXIA	HS	Phase 1/2
DMVZXIA	CP	Astex Pharmaceuticals
DMVZXIA	DT	Small molecular drug
DMVZXIA	DE	Solid tumour/cancer

DM9EM5G	ID	DM9EM5G
DM9EM5G	DN	ASTX295
DM9EM5G	HS	Phase 1/2
DM9EM5G	CP	Astex Pharmaceuticals
DM9EM5G	DT	Small molecular drug
DM9EM5G	DE	Solid tumour/cancer

DMSOQ6E	ID	DMSOQ6E
DMSOQ6E	DN	AT-342
DMSOQ6E	HS	Phase 1/2
DMSOQ6E	CP	Audentes Therapeutics
DMSOQ6E	DT	Gene therapy
DMSOQ6E	DE	Crigler-Najjar syndrome

DM7O89Q	ID	DM7O89Q
DM7O89Q	DN	AT-777
DM7O89Q	HS	Phase 1/2
DM7O89Q	CP	Atea Pharmaceuticals
DM7O89Q	DT	Small molecular drug
DM7O89Q	DE	Hepatitis C

DMB5X7Z	ID	DMB5X7Z
DMB5X7Z	DN	ATG002
DMB5X7Z	HS	Phase 1/2
DMB5X7Z	CP	CoMentis
DMB5X7Z	DE	Diabetic foot ulcer

DM84YEC	ID	DM84YEC
DM84YEC	DN	Atiprimod
DM84YEC	HS	Phase 1/2
DM84YEC	SN	Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine
DM84YEC	CP	Callisto Pharm.
DM84YEC	DT	Small molecular drug
DM84YEC	PC	129869
DM84YEC	MW	336.6
DM84YEC	FM	C22H44N2
DM84YEC	IC	InChI=1S/C22H44N2/c1-5-10-21(11-6-2)12-14-22(15-13-21)16-19-24(20-22)18-9-17-23(7-3)8-4/h5-20H2,1-4H3
DM84YEC	CS	CCCC1(CCC2(CC1)CCN(C2)CCCN(CC)CC)CCC
DM84YEC	IK	SERHTTSLBVGRBY-UHFFFAOYSA-N
DM84YEC	IU	3-(8,8-dipropyl-2-azaspiro[4.5]decan-2-yl)-N,N-diethylpropan-1-amine
DM84YEC	CA	CAS 123018-47-3
DM84YEC	DE	Multiple myeloma

DM75QY9	ID	DM75QY9
DM75QY9	DN	ATL-313
DM75QY9	HS	Phase 1/2
DM75QY9	SN	DE-112; ATL-313 (ocular disease), Adenosine Therapeutics; ATL-313 (ocular disease), Clinical Data
DM75QY9	CP	University of Virginia
DM75QY9	DT	Small molecular drug
DM75QY9	PC	11627443
DM75QY9	MW	499.5
DM75QY9	FM	C23H29N7O6
DM75QY9	IC	InChI=1S/C23H29N7O6/c1-35-23(34)29-9-7-12(8-10-29)3-2-4-14-27-19(24)15-20(28-14)30(11-25-15)22-17(32)16(31)18(36-22)21(33)26-13-5-6-13/h11-13,16-18,22,31-32H,3,5-10H2,1H3,(H,26,33)(H2,24,27,28)/t16-,17+,18-,22+/m0/s1
DM75QY9	CS	COC(=O)N1CCC(CC1)CC#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)C(=O)NC5CC5)O)O)N
DM75QY9	IK	SQJXTUJMBYVDBB-RQXXJAGISA-N
DM75QY9	IU	methyl 4-[3-[6-amino-9-[(2R,3R,4S,5S)-5-(cyclopropylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]prop-2-ynyl]piperidine-1-carboxylate
DM75QY9	CA	CAS 844873-47-8
DM75QY9	DE	Arteriosclerosis

DMLAKPI	ID	DMLAKPI
DMLAKPI	DN	AU101
DMLAKPI	HS	Phase 1/2
DMLAKPI	CP	Aurora BioPharma Cambridge, MA
DMLAKPI	DE	Osteosarcoma; Recurrent glioblastoma; Recurring respiratory infection; Sarcoma

DMPAZ3U	ID	DMPAZ3U
DMPAZ3U	DN	AU105
DMPAZ3U	HS	Phase 1/2
DMPAZ3U	CP	Aurora BioPharma Cambridge, MA
DMPAZ3U	DE	Recurrent glioblastoma

DMG9OAV	ID	DMG9OAV
DMG9OAV	DN	AUTO1
DMG9OAV	HS	Phase 1/2
DMG9OAV	CP	Autolus Therapeutics
DMG9OAV	DT	CAR T Cell Therapy
DMG9OAV	DE	Acute lymphoblastic leukaemia

DM0PWX2	ID	DM0PWX2
DM0PWX2	DN	AUTO2
DM0PWX2	HS	Phase 1/2
DM0PWX2	CP	Autolus Limited
DM0PWX2	DT	CAR T Cell Therapy (Dual specific)
DM0PWX2	DE	Multiple myeloma

DMC5NSO	ID	DMC5NSO
DMC5NSO	DN	AUTO3
DMC5NSO	HS	Phase 1/2
DMC5NSO	CP	Autolus Limited
DMC5NSO	DT	CAR T Cell Therapy (Dual specific)
DMC5NSO	DE	Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma

DM2YTGQ	ID	DM2YTGQ
DM2YTGQ	DN	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
DM2YTGQ	HS	Phase 1/2
DM2YTGQ	CP	Fred Hutchinson Cancer Research Center
DM2YTGQ	DT	CAR T Cell Therapy
DM2YTGQ	DE	Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Mantle cell lymphoma; Non-hodgkin lymphoma

DMLOGI4	ID	DMLOGI4
DMLOGI4	DN	Autologous CD19-targeting CAR T cells
DMLOGI4	HS	Phase 1/2
DMLOGI4	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMLOGI4	DT	CAR T Cell Therapy
DMLOGI4	DE	leukaemia

DMRS58M	ID	DMRS58M
DMRS58M	DN	Avrina
DMRS58M	HS	Phase 1/2
DMRS58M	SN	NF-KB Decoy
DMRS58M	CP	Anesiva
DMRS58M	DE	Skin infection

DMC1XHK	ID	DMC1XHK
DMC1XHK	DN	AVR-RD-01
DMC1XHK	HS	Phase 1/2
DMC1XHK	CP	AVROBIO
DMC1XHK	DT	Gene therapy
DMC1XHK	DE	Fabry disease

DMOPVIQ	ID	DMOPVIQ
DMOPVIQ	DN	AVX701
DMOPVIQ	HS	Phase 1/2
DMOPVIQ	SN	Cea cancer immunotherapy
DMOPVIQ	CP	Alphavax
DMOPVIQ	DE	Colorectal cancer; Rectosigmoid junction cancer

DM7O29W	ID	DM7O29W
DM7O29W	DN	AVX901
DM7O29W	HS	Phase 1/2
DM7O29W	SN	HER2 cancer immunotherapy
DM7O29W	CP	Alphavax
DM7O29W	DE	Breast cancer

DMWLZI6	ID	DMWLZI6
DMWLZI6	DN	AZD0466
DMWLZI6	HS	Phase 1/2
DMWLZI6	CP	AstraZeneca
DMWLZI6	DT	Small molecular drug
DMWLZI6	DE	Hematologic tumour

DMT2FAP	ID	DMT2FAP
DMT2FAP	DN	AZD-2836
DMT2FAP	HS	Phase 1/2
DMT2FAP	SN	A-00060058; A-00060617; A-48504; A-48756; A-48773; A-831; HCV NS5A inhibitors, Arrow Therapeutics; Hepatitis C virus therapeutics (NS5A inhibitors), Arrow
DMT2FAP	CP	AstraZeneca
DMT2FAP	DE	Hepatitis C virus infection

DMD9Y5T	ID	DMD9Y5T
DMD9Y5T	DN	AZD7648
DMD9Y5T	HS	Phase 1/2
DMD9Y5T	SN	AZD-7648; 2230820-11-6; UNII-97A09L5JCK; 97A09L5JCK; 7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one; 7-Methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-7H-purin-8(9H)-one; 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(oxan-4-yl)purin-8-one; CHEMBL4439259; SCHEMBL20299477; GTPL10601; US10407446, Example 3; BDBM413450; BCP30676; EX-A2988; AZD 7648;AZD7648; MFCD32062688; NSC817043; s8843; ZB1555; NSC-817043; SB23233; compound 16 [PMID: 31851518]; AC-31586; BS-16016; HY-111783; CS-0091859; CN1C(=O)N(C2CCOCC2)C2=NC(NC3=CN4N=CN=C4C=C3C)=NC=C12; 7-Methyl-2-((7-methyl(1,2,4)triazolo(1,5- a)pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran- 4-yl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one, 7,9-dihydro-7-methyl-2-((7- methyl(1,2,4)triazolo(1,5-a)pyridin-6- yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-
DMD9Y5T	CP	AstraZeneca
DMD9Y5T	DT	Small molecular drug
DMD9Y5T	PC	135151360
DMD9Y5T	MW	380.4
DMD9Y5T	FM	C18H20N8O2
DMD9Y5T	IC	InChI=1S/C18H20N8O2/c1-11-7-15-20-10-21-25(15)9-13(11)22-17-19-8-14-16(23-17)26(18(27)24(14)2)12-3-5-28-6-4-12/h7-10,12H,3-6H2,1-2H3,(H,19,22,23)
DMD9Y5T	CS	CC1=CC2=NC=NN2C=C1NC3=NC=C4C(=N3)N(C(=O)N4C)C5CCOCC5
DMD9Y5T	IK	XISVSTPEXYIKJL-UHFFFAOYSA-N
DMD9Y5T	IU	7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(oxan-4-yl)purin-8-one
DMD9Y5T	CA	CAS 2230820-11-6
DMD9Y5T	DE	Solid tumour/cancer

DMPFGL8	ID	DMPFGL8
DMPFGL8	DN	BAL-101553
DMPFGL8	HS	Phase 1/2
DMPFGL8	CP	Basilea Pharmaceutica International Ltd
DMPFGL8	DT	Small molecular drug
DMPFGL8	PC	45259014
DMPFGL8	MW	515.6
DMPFGL8	FM	C26H29N9O3
DMPFGL8	IC	InChI=1S/C26H29N9O3/c27-13-4-3-6-19(29)26(37)31-18-11-9-17(10-12-18)22(36)16-35-21-8-2-1-7-20(21)32-25(35)23-24(34-38-33-23)30-15-5-14-28/h1-2,7-12,19H,3-6,13,15-16,27,29H2,(H,30,34)(H,31,37)/t19-/m0/s1
DMPFGL8	CS	C1=CC=C2C(=C1)N=C(N2CC(=O)C3=CC=C(C=C3)NC(=O)[C@H](CCCCN)N)C4=NON=C4NCCC#N
DMPFGL8	IK	NIPZLALJRAHABJ-IBGZPJMESA-N
DMPFGL8	IU	(2S)-2,6-diamino-N-[4-[2-[2-[4-(2-cyanoethylamino)-1,2,5-oxadiazol-3-yl]benzimidazol-1-yl]acetyl]phenyl]hexanamide
DMPFGL8	CA	CAS 1263384-43-5
DMPFGL8	DE	Solid tumour/cancer; Recurrent glioblastoma

DMFA4CK	ID	DMFA4CK
DMFA4CK	DN	BAY 1902607
DMFA4CK	HS	Phase 1/2
DMFA4CK	CP	Bayer
DMFA4CK	DT	Small molecular drug
DMFA4CK	DE	Cough

DMH70A9	ID	DMH70A9
DMH70A9	DN	BCMA CAR T cells
DMH70A9	HS	Phase 1/2
DMH70A9	CP	Shenzhen Geno-Immune Medical Institute
DMH70A9	DT	CAR T Cell Therapy
DMH70A9	DE	Multiple myeloma

DM1DHPO	ID	DM1DHPO
DM1DHPO	DN	BCMA CAR-T
DM1DHPO	HS	Phase 1/2
DM1DHPO	CP	Henan Cancer Hospital
DM1DHPO	DT	CAR T Cell Therapy
DM1DHPO	DE	Multiple myeloma

DMZK7IT	ID	DMZK7IT
DMZK7IT	DN	BCT-100
DMZK7IT	HS	Phase 1/2
DMZK7IT	SN	RhArg-peg; Pegylated recombinant human arginase (cancer), BCT
DMZK7IT	CP	Bio-Cancer Treatment International Ltd
DMZK7IT	DE	Solid tumour/cancer

DMJ5MPG	ID	DMJ5MPG
DMJ5MPG	DN	BDC-1001
DMJ5MPG	HS	Phase 1/2
DMJ5MPG	CP	Bolt Biotherapeutics
DMJ5MPG	DT	Antibody drug conjugate
DMJ5MPG	DE	Solid tumour/cancer

DMODTX5	ID	DMODTX5
DMODTX5	DN	BDTX-189
DMODTX5	HS	Phase 1/2
DMODTX5	SN	2414572-47-5; EX-A4379
DMODTX5	CP	Black Diamond Therapeutics
DMODTX5	DT	Small molecular drug
DMODTX5	PC	154824631
DMODTX5	MW	561
DMODTX5	FM	C29H29ClN6O4
DMODTX5	IC	InChI=1S/C29H29ClN6O4/c1-2-28(37)35-25-16-22-24(17-27(25)39-14-11-36-9-12-38-13-10-36)32-19-33-29(22)34-20-6-7-26(23(30)15-20)40-18-21-5-3-4-8-31-21/h2-8,15-17,19H,1,9-14,18H2,(H,35,37)(H,32,33,34)
DMODTX5	CS	C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)OCCN5CCOCC5
DMODTX5	IK	HIBPKFXWOPYJPZ-UHFFFAOYSA-N
DMODTX5	IU	N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-morpholin-4-ylethoxy)quinazolin-6-yl]prop-2-enamide
DMODTX5	DE	Solid tumour/cancer

DMXVRI0	ID	DMXVRI0
DMXVRI0	DN	Beclanorsen
DMXVRI0	HS	Phase 1/2
DMXVRI0	SN	SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris
DMXVRI0	CP	Santaris Pharma A/S
DMXVRI0	DT	Antisense drug
DMXVRI0	DE	leukaemia

DMVYTG7	ID	DMVYTG7
DMVYTG7	DN	BGB-283
DMVYTG7	HS	Phase 1/2
DMVYTG7	SN	Lifirafenib
DMVYTG7	DT	Small molecular drug
DMVYTG7	PC	89670174
DMVYTG7	MW	478.4
DMVYTG7	FM	C25H17F3N4O3
DMVYTG7	IC	InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1
DMVYTG7	CS	C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5C6=NC7=C(N6)C=C(C=C7)C(F)(F)F
DMVYTG7	IK	NGFFVZQXSRKHBM-FKBYEOEOSA-N
DMVYTG7	IU	5-[[(1R,1aS,6bR)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one
DMVYTG7	CA	CAS 1446090-79-4
DMVYTG7	DE	Solid tumour/cancer

DM5VG6S	ID	DM5VG6S
DM5VG6S	DN	BGB-A333
DM5VG6S	HS	Phase 1/2
DM5VG6S	CP	BeiGene
DM5VG6S	DT	Antibody
DM5VG6S	DE	Solid tumour/cancer

DMI42Q0	ID	DMI42Q0
DMI42Q0	DN	BGB-A425
DMI42Q0	HS	Phase 1/2
DMI42Q0	CP	BeiGene
DMI42Q0	DT	Antibody
DMI42Q0	DE	Solid tumour/cancer; Non-small cell lung cancer

DMXKDUL	ID	DMXKDUL
DMXKDUL	DN	BGT226
DMXKDUL	HS	Phase 1/2
DMXKDUL	SN	BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939
DMXKDUL	CP	Novartis
DMXKDUL	DT	Small molecular drug
DMXKDUL	PC	11978790
DMXKDUL	MW	534.5
DMXKDUL	FM	C28H25F3N6O2
DMXKDUL	IC	InChI=1S/C28H25F3N6O2/c1-35-24-16-33-22-6-3-17(18-4-8-25(39-2)34-15-18)13-20(22)26(24)37(27(35)38)19-5-7-23(21(14-19)28(29,30)31)36-11-9-32-10-12-36/h3-8,13-16,32H,9-12H2,1-2H3
DMXKDUL	CS	CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC
DMXKDUL	IK	BMMXYEBLEBULND-UHFFFAOYSA-N
DMXKDUL	IU	8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one
DMXKDUL	CA	CAS 915020-55-2
DMXKDUL	CB	CHEBI:71967
DMXKDUL	DE	Solid tumour/cancer

DMTOMWB	ID	DMTOMWB
DMTOMWB	DN	BI 1206
DMTOMWB	HS	Phase 1/2
DMTOMWB	CP	BioInvent
DMTOMWB	DT	Antibody
DMTOMWB	DE	Chronic lymphocytic leukaemia; B-cell lymphoma; leukaemia

DMR8EPF	ID	DMR8EPF
DMR8EPF	DN	BIIB-087
DMR8EPF	HS	Phase 1/2
DMR8EPF	SN	rAAV2tYF-CB-hRS1
DMR8EPF	CP	Applied Genetic Technologies
DMR8EPF	DT	Gene therapy
DMR8EPF	DE	X-linked retinoschisis

DMV1EA9	ID	DMV1EA9
DMV1EA9	DN	BIL010t
DMV1EA9	HS	Phase 1/2
DMV1EA9	CP	Biosceptre
DMV1EA9	DE	Solid tumour/cancer; Alzheimer disease

DMZEA9X	ID	DMZEA9X
DMZEA9X	DN	BIW-8962
DMZEA9X	HS	Phase 1/2
DMZEA9X	CP	Kyowa Hakko Kirin Pharma
DMZEA9X	DT	Antibody
DMZEA9X	DE	Multiple myeloma

DMFKA4G	ID	DMFKA4G
DMFKA4G	DN	BLZ-100
DMFKA4G	HS	Phase 1/2
DMFKA4G	SN	Tozuleristide; UNII-835UH424TU; 835UH424TU; Tozuleristide [INN]; Tozuleristide [USAN]; 1673565-40-6
DMFKA4G	CP	Blaze Bioscience
DMFKA4G	PC	121488172
DMFKA4G	MW	4766
DMFKA4G	FM	C203H296N58O52S12
DMFKA4G	IC	InChI=1S/C203H296N58O52S12/c1-107(2)85-130-178(291)253-139(185(298)240-129(196(309)310)50-36-76-223-201(215)216)100-319-317-98-137-171(284)225-93-154(268)224-94-155(269)231-120(46-32-72-219-197(207)208)168(281)226-95-156(270)232-121(47-33-73-220-198(209)210)169(282)227-96-157(271)233-122(45-27-28-71-218-153(267)55-22-17-29-77-258-145-64-58-113-41-23-25-43-117(113)162(145)202(6,7)149(258)53-20-14-13-15-21-54-150-203(8,9)163-118-44-26-24-42-114(118)59-65-146(163)259(150)78-30-31-84-325(311,312)313)173(286)250-141-102-322-324-105-144-189(302)243-132(86-111-39-18-16-19-40-111)183(296)256-165(110(5)263)194(307)257-164(109(4)262)193(306)247-136(91-161(277)278)181(294)244-133(88-115-92-217-106-229-115)179(292)236-125(62-66-151(205)265)176(289)237-127(69-82-315-11)172(285)230-108(3)166(279)234-123(48-34-74-221-199(211)212)174(287)235-124(49-35-75-222-200(213)214)175(288)251-142(103-321-320-101-140(186(299)241-130)252-177(290)126(63-67-152(206)266)238-191(304)147-51-37-79-260(147)158(272)97-228-170(283)131(242-187(141)300)87-112-56-60-116(264)61-57-112)188(301)246-134(89-159(273)274)180(293)245-135(90-160(275)276)182(295)254-143(190(303)249-137)104-323-318-99-138(248-167(280)119(204)68-81-314-10)184(297)239-128(70-83-316-12)195(308)261-80-38-52-148(261)192(305)255-144/h13-16,18-21,23-26,39-44,53-54,56-61,64-65,92,106-110,119-144,147-148,164-165,262-263H,17,22,27-38,45-52,55,62-63,66-91,93-105,204H2,1-12H3,(H64-,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,264,265,266,267,268,269,270,271,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,309,310,311,312,313)/t108-,109+,110+,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,147-,148-,164-,165-/m0/s1
DMFKA4G	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]4C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCSC)CCC(=O)N)CC5=CNC=N5)CC(=O)O)[C@@H](C)O)[C@@H](C)O)CC6=CC=CC=C6)NC(=O)[C@@H]7CCCN7C(=O)[C@@H](NC(=O)[C@H](CSSC[C@@H](C(=O)N4)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC(=O)O)CC(=O)O)NC(=O)[C@H](CCSC)N)CCSC)C(=O)N[C@H](C(=O)NCC(=O)N8CCC[C@H]8C(=O)N[C@H](C(=O)N3)CCC(=O)N)CC9=CC=C(C=C9)O)CCCCNC(=O)CCCCCN\\1C2=C(C3=CC=CC=C3C=C2)C(/C1=C/C=C/C=C/C=C/C1=[N+](C2=C(C1(C)C)C1=CC=CC=C1C=C2)CCCCS(=O)(=O)[O-])(C)C)CCCNC(=N)N)CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)CC(C)C)CCCNC(=N)N)CCCNC(=N)N
DMFKA4G	IK	LWXYOERUKGQNKQ-IQDTYCCDSA-N
DMFKA4G	IU	4-[2-[(1E,3E,5E,7Z)-7-[3-[6-[4-[(1R,4R,5aR,8aS,9R,12S,17aS,18S,20aS,21R,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54R,59R,62S,65S,74S,77R,80S,86S,92S)-9-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-39,62-bis(3-amino-3-oxopropyl)-24-benzyl-5a-[[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl]-48,51,86,92-tetrakis(3-carbamimidamidopropyl)-17a,20a,33-tris(carboxymethyl)-27,30-bis[(1R)-1-hydroxyethyl]-74-[(4-hydroxyphenyl)methyl]-36-(1H-imidazol-4-ylmethyl)-45-methyl-8a-(2-methylpropyl)-12,42-bis(2-methylsulfanylethyl)-a,3,7a,10,10a,13,15a,18a,19,21a,22,25,28,31,34,37,40,43,46,49,52,61,64,70,73,76,79,82,85,88,91,94,97-tritriacontaoxo-2a,3a,6,7,12a,13a,56,57-octathia-2,6a,9a,11,14,16a,19a,20,22a,23,26,29,32,35,38,41,44,47,50,53,60,63,69,72,75,78,81,84,87,90,93,96,99-tritriacontazahexacyclo[57.41.10.84,54.421,77.014,18.065,69]docosahectan-80-yl]butylamino]-6-oxohexyl]-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]butane-1-sulfonate
DMFKA4G	CA	CAS 1673565-40-6
DMFKA4G	DE	Glioma; Malignant primary brain tumour

DMDQO0S	ID	DMDQO0S
DMDQO0S	DN	BMS-753493
DMDQO0S	HS	Phase 1/2
DMDQO0S	SN	Epofolate; Epothilone folate conjugate; BMS-493; BMS-748285 folate conjugate, Bristol-Myers Squibb; Targeted epothilone-folate conjugate (Endocyte technology, cancer), BMS; Targeted epothilone-folate conjugate (Endocyte technology, cancer), Bristol-Myers Squibb
DMDQO0S	CP	Bristol-Myers Squibb Co
DMDQO0S	DT	Small molecular drug
DMDQO0S	PC	135566069
DMDQO0S	MW	1569.7
DMDQO0S	FM	C67H92N16O22S3
DMDQO0S	IC	InChI=1S/C67H92N16O22S3/c1-32-9-7-11-45-46(26-47(33(2)23-38-30-106-35(4)74-38)105-52(90)27-48(84)67(5,6)55(92)34(3)54(32)91)83(45)19-20-103-66(102)104-21-22-107-108-31-44(63(100)101)80-60(96)43(25-51(88)89)79-58(94)40(10-8-18-71-64(68)69)77-59(95)42(24-50(86)87)76-49(85)17-16-41(62(98)99)78-57(93)36-12-14-37(15-13-36)72-28-39-29-73-56-53(75-39)61(97)82-65(70)81-56/h12-15,23,29-30,32,34,40-48,54,72,84,91H,7-11,16-22,24-28,31H2,1-6H3,(H,76,85)(H,77,95)(H,78,93)(H,79,94)(H,80,96)(H,86,87)(H,88,89)(H,98,99)(H,100,101)(H4,68,69,71)(H3,70,73,81,82,97)/b33-23+/t32-,34+,40-,41-,42-,43-,44-,45+,46-,47-,48-,54-,83?/m0/s1
DMDQO0S	CS	C[C@H]1CCC[C@@H]2[C@@H](N2CCOC(=O)OCCSSC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C3=CC=C(C=C3)NCC4=CN=C5C(=N4)C(=O)NC(=N5)N)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C6=CSC(=N6)C)/C
DMDQO0S	IK	TURJYGRXEJIBGT-OCOMGVANSA-N
DMDQO0S	IU	(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-[2-[2-[(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-5,9-dioxo-4-oxa-17-azabicyclo[14.1.0]heptadecan-17-yl]ethoxycarbonyloxy]ethyldisulfanyl]ethyl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDQO0S	CA	CAS 958646-17-8
DMDQO0S	DE	Solid tumour/cancer

DMGM7QD	ID	DMGM7QD
DMGM7QD	DN	BMS-777607
DMGM7QD	HS	Phase 1/2
DMGM7QD	SN	BMS-777607; 1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
DMGM7QD	DT	Small molecular drug
DMGM7QD	PC	24794418
DMGM7QD	MW	512.9
DMGM7QD	FM	C25H19ClF2N4O4
DMGM7QD	IC	InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)
DMGM7QD	CS	CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F
DMGM7QD	IK	VNBRGSXVFBYQNN-UHFFFAOYSA-N
DMGM7QD	IU	N-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide
DMGM7QD	CA	CAS 1025720-94-8
DMGM7QD	CB	CHEBI:91409

DM5HUY8	ID	DM5HUY8
DM5HUY8	DN	BMS-863233
DM5HUY8	HS	Phase 1/2
DM5HUY8	CP	Bristol Myers Squibb 
DM5HUY8	DT	Small molecular drug
DM5HUY8	PC	135564632
DM5HUY8	MW	289.71
DM5HUY8	FM	C14H12ClN3O2
DM5HUY8	IC	InChI=1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)/t9-/m0/s1
DM5HUY8	CS	C1C[C@H](NC1)C2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Cl
DM5HUY8	IK	JJWLXRKVUJDJKG-VIFPVBQESA-N
DM5HUY8	IU	8-chloro-2-[(2S)-pyrrolidin-2-yl]-3H-[1]benzofuro[3,2-d]pyrimidin-4-one
DM5HUY8	CA	CAS 1169558-38-6
DM5HUY8	DE	Haematological malignancy

DMDCHM7	ID	DMDCHM7
DMDCHM7	DN	BMS-986016
DMDCHM7	HS	Phase 1/2
DMDCHM7	CP	Bristol-Myers Squibb
DMDCHM7	DE	Solid tumour/cancer; Hematologic tumour

DM6LDI4	ID	DM6LDI4
DM6LDI4	DN	BMS-986158
DM6LDI4	HS	Phase 1/2
DM6LDI4	SN	KGERZPVQIRYWRK-GDLZYMKVSA-N; 1800340-40-2; UNII-X8BW0MQ5PI; X8BW0MQ5PI; SCHEMBL16861831; EX-A2678; CS-7497; HY-101567; (S)-2-(3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-(phenyl(tetrahydro-2H-pyran-4-yl)methyl)-5H-pyrido[3,2-b]indol-7-yl)propan-2-ol
DM6LDI4	CP	Bristol-Myers Squibb Princeton, NJ
DM6LDI4	PC	118196485
DM6LDI4	MW	495.6
DM6LDI4	FM	C30H33N5O2
DM6LDI4	IC	InChI=1S/C30H33N5O2/c1-19-28(34(4)33-32-19)22-16-26-27(31-18-22)24-11-10-23(30(2,3)36)17-25(24)35(26)29(20-8-6-5-7-9-20)21-12-14-37-15-13-21/h5-11,16-18,21,29,36H,12-15H2,1-4H3/t29-/m1/s1
DM6LDI4	CS	CC1=C(N(N=N1)C)C2=CC3=C(C4=C(N3[C@@H](C5CCOCC5)C6=CC=CC=C6)C=C(C=C4)C(C)(C)O)N=C2
DM6LDI4	IK	KGERZPVQIRYWRK-GDLZYMKVSA-N
DM6LDI4	IU	2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol
DM6LDI4	CA	CAS 1800340-40-2
DM6LDI4	DE	Solid tumour/cancer

DMM10J4	ID	DMM10J4
DMM10J4	DN	BMS-986288
DMM10J4	HS	Phase 1/2
DMM10J4	CP	Bristol-Myers Squibb
DMM10J4	DT	Probody
DMM10J4	DE	Solid tumour/cancer

DMTEY1L	ID	DMTEY1L
DMTEY1L	DN	BMS-986315
DMTEY1L	HS	Phase 1/2
DMTEY1L	CP	Bristol-Myers Squibb
DMTEY1L	DT	Antibody
DMTEY1L	DE	Solid tumour/cancer

DMA9MP5	ID	DMA9MP5
DMA9MP5	DN	BN-2629
DMA9MP5	HS	Phase 1/2
DMA9MP5	SN	SG-2000; SJG-136; SP-2001
DMA9MP5	CP	Spirogen Ltd
DMA9MP5	PC	393111
DMA9MP5	MW	556.6
DMA9MP5	FM	C31H32N4O6
DMA9MP5	IC	InChI=1S/C31H32N4O6/c1-18-8-20-14-32-24-12-28(26(38-3)10-22(24)30(36)34(20)16-18)40-6-5-7-41-29-13-25-23(11-27(29)39-4)31(37)35-17-19(2)9-21(35)15-33-25/h10-15,20-21H,1-2,5-9,16-17H2,3-4H3/t20-,21-/m0/s1
DMA9MP5	CS	COC1=C(C=C2C(=C1)C(=O)N3CC(=C)C[C@H]3C=N2)OCCCOC4=C(C=C5C(=C4)N=C[C@@H]6CC(=C)CN6C5=O)OC
DMA9MP5	IK	RWZVMMQNDHPRQD-SFTDATJTSA-N
DMA9MP5	IU	(6aS)-3-[3-[[(6aS)-2-methoxy-8-methylidene-11-oxo-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-8-methylidene-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-11-one
DMA9MP5	CA	CAS 232931-57-6
DMA9MP5	DE	Solid tumour/cancer

DMGF2PU	ID	DMGF2PU
DMGF2PU	DN	BNT411
DMGF2PU	HS	Phase 1/2
DMGF2PU	CP	BioNTech
DMGF2PU	DT	Small molecular drug
DMGF2PU	DE	Small-cell lung cancer

DMIMA4V	ID	DMIMA4V
DMIMA4V	DN	BPX-501
DMIMA4V	HS	Phase 1/2
DMIMA4V	CP	Bellicum pharmaceuticals
DMIMA4V	DE	Osteoporosis; Immunodeficiency; Hematopoietic stem cell transplantation; Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Solid tumour/cancer

DMV9QGW	ID	DMV9QGW
DMV9QGW	DN	BPX-601
DMV9QGW	HS	Phase 1/2
DMV9QGW	CP	Bellicum Pharmaceuticals
DMV9QGW	DT	CAR T Cell Therapy
DMV9QGW	DE	Gastric adenocarcinoma; Pancreatic cancer; Prostate cancer

DMCEGP2	ID	DMCEGP2
DMCEGP2	DN	BrevaRex
DMCEGP2	HS	Phase 1/2
DMCEGP2	SN	BrevaRex MAb; monoclonal antibody
DMCEGP2	CP	Tapimmune; mabvax therapeutics
DMCEGP2	DT	Monoclonal antibody
DMCEGP2	DE	Pancreatic cancer

DMQKXSW	ID	DMQKXSW
DMQKXSW	DN	BRN-3122594
DMQKXSW	HS	Phase 1/2
DMQKXSW	SN	FLUOCORTOLONE; Flucortolone; Fluocortolon; Fluocortolona [INN-Spanish]; Fluocortolone [USAN:INN:BAN]; Fluocortolonum [INN-Latin]; Fluorcortolone; Fluorocortolone; SH 742; Ultralan oral; 152-97-6; 6-alpha-Fluoro-16-alpha-methyl-1-dehydrocorticosterone; 6-alpha-Fluoro-16-alpha-methylpregna-1,4-diene-11-beta,21-diol-3,20-dione; 65VXC1MH0J; 6alpha-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; BRN 3122594; EINECS 205-811-5; UNII-65VXC1MH0J
DMQKXSW	PC	9053
DMQKXSW	MW	376.5
DMQKXSW	FM	C22H29FO4
DMQKXSW	IC	GAKMQHDJQHZUTJ-ULHLPKEOSA-N
DMQKXSW	CS	CC1CC2C3CC(C4=CC(=O)C=CC4(C3C(CC2(C1C(=O)CO)C)O)C)F
DMQKXSW	IK	1S/C22H29FO4/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-21(15,2)20(13)17(26)9-22(14,3)19(11)18(27)10-24/h4-5,7,11,13-14,16-17,19-20,24,26H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20-,21+,22+/m1/s1
DMQKXSW	IU	(6S,8S,9S,10R,11S,13S,14S,16R,17S)-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMQKXSW	CA	CAS 152-97-6
DMQKXSW	CB	CHEBI:135581
DMQKXSW	DE	Haemorrhoid

DMYBKMV	ID	DMYBKMV
DMYBKMV	DN	BT5528
DMYBKMV	HS	Phase 1/2
DMYBKMV	CP	Bicycle Therapeutics
DMYBKMV	DT	Bicycle?toxin conjugate
DMYBKMV	DE	Solid tumour/cancer

DM1FJW6	ID	DM1FJW6
DM1FJW6	DN	BT8009
DM1FJW6	HS	Phase 1/2
DM1FJW6	CP	Bicycle Therapeutics
DM1FJW6	DT	Bicycle?toxin conjugate
DM1FJW6	DE	Solid tumour/cancer

DMEWXFK	ID	DMEWXFK
DMEWXFK	DN	C 82
DMEWXFK	HS	Phase 1/2
DMEWXFK	SN	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82
DMEWXFK	CP	PRISM Pharma Yokohama, Japan
DMEWXFK	PC	75202656
DMEWXFK	MW	194.62
DMEWXFK	FM	C8H7ClN4
DMEWXFK	IC	InChI=1S/C8H7ClN4/c9-6-1-3-7(4-2-6)11-8-5-10-13-12-8/h1-5H,(H2,10,11,12,13)
DMEWXFK	CS	C1=CC(=CC=C1NC2=NNN=C2)Cl
DMEWXFK	IK	IUTZKZLVPUPHDA-UHFFFAOYSA-N
DMEWXFK	IU	N-(4-chlorophenyl)-2H-triazol-4-amine
DMEWXFK	DE	Scleroderma

DMPJLS4	ID	DMPJLS4
DMPJLS4	DN	CAD-1883
DMPJLS4	HS	Phase 1/2
DMPJLS4	CP	Cadent Therapeutics
DMPJLS4	DE	Ataxic disorder

DMUZIRY	ID	DMUZIRY
DMUZIRY	DN	Cal-1
DMUZIRY	HS	Phase 1/2
DMUZIRY	SN	Cal-1-transduced hematopoietic
DMUZIRY	CP	Calimmune
DMUZIRY	DE	Human immunodeficiency virus-1 infection

DM6ZXWY	ID	DM6ZXWY
DM6ZXWY	DN	CAR.CD30 cells
DM6ZXWY	HS	Phase 1/2
DM6ZXWY	CP	UNC Lineberger Comprehensive Cancer Center
DM6ZXWY	DT	CAR T Cell Therapy
DM6ZXWY	DE	Immune System disease; Immunoproliferative disorder; Lymphatic disease; Lymphoma; Neoplasm

DMOI5PB	ID	DMOI5PB
DMOI5PB	DN	CARCIK-CD19
DMOI5PB	HS	Phase 1/2
DMOI5PB	CP	Fondazione Matilde Tettamanti Menotti De Marchi Onlus
DMOI5PB	DT	CAR T Cell Therapy
DMOI5PB	DE	Acute lymphocytic leukaemia

DMENIQ7	ID	DMENIQ7
DMENIQ7	DN	CAR-T cells targeting BCMA
DMENIQ7	HS	Phase 1/2
DMENIQ7	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMENIQ7	DT	CAR T Cell Therapy
DMENIQ7	DE	leukaemia; Lymphoma; Multiple myeloma

DMIM9TZ	ID	DMIM9TZ
DMIM9TZ	DN	CAR-T cells targeting CD19
DMIM9TZ	HS	Phase 1/2
DMIM9TZ	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMIM9TZ	DT	CAR T Cell Therapy
DMIM9TZ	DE	leukaemia; Lymphoma; Multiple myeloma

DMJVENR	ID	DMJVENR
DMJVENR	DN	CAR-T cells targeting CD2
DMJVENR	HS	Phase 1/2
DMJVENR	CP	Shenzhen Geno-Immune Medical Institute
DMJVENR	DT	CAR T Cell Therapy
DMJVENR	DE	Cervical cancer

DMVFHL9	ID	DMVFHL9
DMVFHL9	DN	CAR-T cells targeting CD22
DMVFHL9	HS	Phase 1/2
DMVFHL9	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMVFHL9	DT	CAR T Cell Therapy
DMVFHL9	DE	leukaemia; Lymphoma; Multiple myeloma

DMZHJV8	ID	DMZHJV8
DMZHJV8	DN	CAR-T cells targeting CD30
DMZHJV8	HS	Phase 1/2
DMZHJV8	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMZHJV8	DT	CAR T Cell Therapy
DMZHJV8	DE	leukaemia; Lymphoma; Multiple myeloma

DM6VCPX	ID	DM6VCPX
DM6VCPX	DN	CAR-T cells targeting CEA
DM6VCPX	HS	Phase 1/2
DM6VCPX	CP	Shanghai GeneChem Co., Ltd.
DM6VCPX	DT	CAR T Cell Therapy
DM6VCPX	DE	Colorectal cancer

DMCPM92	ID	DMCPM92
DMCPM92	DN	CAR-T cells targeting CLL1
DMCPM92	HS	Phase 1/2
DMCPM92	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMCPM92	DT	CAR T Cell Therapy
DMCPM92	DE	leukaemia; Lymphoma; Multiple myeloma

DMREQCF	ID	DMREQCF
DMREQCF	DN	CAR-T Cells targeting EpCAM
DMREQCF	HS	Phase 1/2
DMREQCF	CP	First Affiliated Hospital of Chengdu Medical College
DMREQCF	DT	CAR T Cell Therapy
DMREQCF	DE	Colon cancer; Esophageal cancer; Gastric adenocarcinoma; Hepatocellular carcinoma; Pancreatic cancer; Prostate cancer

DMN3C2I	ID	DMN3C2I
DMN3C2I	DN	CAR-T cells targeting EphA2
DMN3C2I	HS	Phase 1/2
DMN3C2I	CP	Fuda Cancer Hospital, Guangzhou
DMN3C2I	DT	CAR T Cell Therapy
DMN3C2I	DE	Malignant glioma

DMFCPG0	ID	DMFCPG0
DMFCPG0	DN	CAR-T cells targeting GD2
DMFCPG0	HS	Phase 1/2
DMFCPG0	CP	Fuda Cancer Hospital, Guangzhou
DMFCPG0	DT	CAR T Cell Therapy
DMFCPG0	DE	Glioma

DMT89K2	ID	DMT89K2
DMT89K2	DN	CAR-T cells targeting GD2
DMT89K2	HS	Phase 1/2
DMT89K2	CP	Shenzhen Geno-Immune Medical Institute
DMT89K2	DT	CAR T Cell Therapy
DMT89K2	DE	Glioblastoma multiforme; Lung cancer

DMDSKR2	ID	DMDSKR2
DMDSKR2	DN	CAR-T cells targeting Glypican-3 (GPC3)
DMDSKR2	HS	Phase 1/2
DMDSKR2	CP	Fuda Cancer Hospital, Guangzhou
DMDSKR2	DT	CAR T Cell Therapy
DMDSKR2	DE	Hepatocellular carcinoma

DM6H1MQ	ID	DM6H1MQ
DM6H1MQ	DN	CAR-T cells targeting GPC3
DM6H1MQ	HS	Phase 1/2
DM6H1MQ	CP	Shanghai GeneChem Co., Ltd.
DM6H1MQ	DT	CAR T Cell Therapy
DM6H1MQ	DE	Hepatocellular carcinoma

DM1W7LV	ID	DM1W7LV
DM1W7LV	DN	CAR-T cells targeting MAGE-A1
DM1W7LV	HS	Phase 1/2
DM1W7LV	CP	Shenzhen Geno-Immune Medical Institute
DM1W7LV	DT	CAR T Cell Therapy
DM1W7LV	DE	Lung cancer

DMUBEX4	ID	DMUBEX4
DMUBEX4	DN	CAR-T cells targeting MAGE-A4
DMUBEX4	HS	Phase 1/2
DMUBEX4	CP	Shenzhen Geno-Immune Medical Institute
DMUBEX4	DT	CAR T Cell Therapy
DMUBEX4	DE	Lung cancer

DMMAQJ7	ID	DMMAQJ7
DMMAQJ7	DN	CAR-T cells targeting Mesothelin
DMMAQJ7	HS	Phase 1/2
DMMAQJ7	CP	Shenzhen Geno-Immune Medical Institute
DMMAQJ7	DT	CAR T Cell Therapy
DMMAQJ7	DE	Cervical cancer; Lung cancer

DMPK35H	ID	DMPK35H
DMPK35H	DN	CAR-T cells targeting mesothelin
DMPK35H	HS	Phase 1/2
DMPK35H	CP	Shanghai GeneChem Co., Ltd.
DMPK35H	DT	CAR T Cell Therapy
DMPK35H	DE	Pancreatic cancer

DM5FKU1	ID	DM5FKU1
DM5FKU1	DN	CAR-T cells targeting Muc1
DM5FKU1	HS	Phase 1/2
DM5FKU1	CP	Shenzhen Geno-Immune Medical Institute
DM5FKU1	DT	CAR T Cell Therapy
DM5FKU1	DE	Cervical cancer

DMBPN4K	ID	DMBPN4K
DMBPN4K	DN	CAR-T cells targeting MucI
DMBPN4K	HS	Phase 1/2
DMBPN4K	CP	Shenzhen Geno-Immune Medical Institute
DMBPN4K	DT	CAR T Cell Therapy
DMBPN4K	DE	Glioblastoma multiforme; Lung cancer

DMW340V	ID	DMW340V
DMW340V	DN	CAR-T cells targeting PSMA
DMW340V	HS	Phase 1/2
DMW340V	CP	Shenzhen Geno-Immune Medical Institute
DMW340V	DT	CAR T Cell Therapy
DMW340V	DE	Cervical cancer

DM0MCTJ	ID	DM0MCTJ
DM0MCTJ	DN	CART-123 cells
DM0MCTJ	HS	Phase 1/2
DM0MCTJ	CP	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
DM0MCTJ	DT	CAR T Cell Therapy
DM0MCTJ	DE	Acute myeloid leukaemia

DMB4HEW	ID	DMB4HEW
DMB4HEW	DN	CART-138 cells
DMB4HEW	HS	Phase 1/2
DMB4HEW	CP	The First Affiliated Hospital of Soochow University
DMB4HEW	DT	CAR T Cell Therapy
DMB4HEW	DE	Multiple myeloma

DMUS79V	ID	DMUS79V
DMUS79V	DN	CART-138 cells
DMUS79V	HS	Phase 1/2
DMUS79V	CP	Chinese PLA General Hospital
DMUS79V	DT	CAR T Cell Therapy
DMUS79V	DE	Multiple myeloma

DMWYT4K	ID	DMWYT4K
DMWYT4K	DN	CART-19 cells
DMWYT4K	HS	Phase 1/2
DMWYT4K	CP	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
DMWYT4K	DT	CAR T Cell Therapy
DMWYT4K	DE	Acute lymphoblastic leukaemia

DMX0R1E	ID	DMX0R1E
DMX0R1E	DN	CART-19/22
DMX0R1E	HS	Phase 1/2
DMX0R1E	CP	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
DMX0R1E	DT	CAR T Cell Therapy (Dual specific)
DMX0R1E	DE	leukaemia

DMVW1GY	ID	DMVW1GY
DMVW1GY	DN	CART-19/BCMA
DMVW1GY	HS	Phase 1/2
DMVW1GY	CP	The First Affiliated Hospital of Soochow University
DMVW1GY	DT	CAR T Cell Therapy (Dual specific)
DMVW1GY	DE	Multiple myeloma

DMKGU5F	ID	DMKGU5F
DMKGU5F	DN	CART20
DMKGU5F	HS	Phase 1/2
DMKGU5F	CP	Beijing Biohealthcare Biotechnology Co.,Ltd
DMKGU5F	DT	CAR T Cell Therapy
DMKGU5F	DE	B-cell lymphoma

DMLE8T9	ID	DMLE8T9
DMLE8T9	DN	CART30
DMLE8T9	HS	Phase 1/2
DMLE8T9	CP	Chinese PLA General Hospital
DMLE8T9	DT	CAR T Cell Therapy
DMLE8T9	DE	Non-hodgkin lymphoma; Hodgkin lymphoma

DM81JIT	ID	DM81JIT
DM81JIT	DN	CART33 cells
DM81JIT	HS	Phase 1/2
DM81JIT	CP	Chinese PLA General Hospital
DM81JIT	DT	CAR T Cell Therapy
DM81JIT	DE	Myeloid leukaemia

DMWOYNT	ID	DMWOYNT
DMWOYNT	DN	CART-BCMA cells
DMWOYNT	HS	Phase 1/2
DMWOYNT	CP	The First Affiliated Hospital of Soochow University
DMWOYNT	DT	CAR T Cell Therapy
DMWOYNT	DE	Multiple myeloma

DM3I267	ID	DM3I267
DM3I267	DN	CART-EGFR
DM3I267	HS	Phase 1/2
DM3I267	CP	Chinese PLA General Hospital
DM3I267	DT	CAR T Cell Therapy
DM3I267	DE	Solid tumour/cancer

DMMTDK1	ID	DMMTDK1
DMMTDK1	DN	CART-HER-2
DMMTDK1	HS	Phase 1/2
DMMTDK1	CP	Chinese PLA General Hospital
DMMTDK1	DT	CAR T Cell Therapy
DMMTDK1	DE	Solid tumour/cancer

DMKCJ75	ID	DMKCJ75
DMKCJ75	DN	CBL0102
DMKCJ75	HS	Phase 1/2
DMKCJ75	CP	Cleveland biolabs
DMKCJ75	DE	Hepatocellular carcinoma

DMCWVPU	ID	DMCWVPU
DMCWVPU	DN	CBP-501
DMCWVPU	HS	Phase 1/2
DMCWVPU	SN	UNII-XH2662798I; 565434-85-7; XH2662798I; Cdc25C phosphatase (211-221); CBP501; CBP 501; SCHEMBL17101340; Z-3278; D-Arginine, 4-benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3-cyclohexyl-D-alanyl-D-arginyl-D-  arginyl-D-arginyl-D-glutaminyl-D-arginyl-
DMCWVPU	CP	CanBas
DMCWVPU	DT	Small molecular drug
DMCWVPU	PC	16156006
DMCWVPU	MW	1929.1
DMCWVPU	FM	C86H122F5N29O17
DMCWVPU	IC	InChI=1S/C86H122F5N29O17/c87-64-49(65(88)67(90)68(91)66(64)89)39-60(118-80(135)62(42-122)120-77(132)59(38-47-40-109-51-19-8-7-18-48(47)51)117-79(134)61(41-121)119-70(125)50(92)36-44-25-27-46(28-26-44)69(124)45-16-5-2-6-17-45)78(133)116-58(37-43-14-3-1-4-15-43)76(131)113-54(22-11-33-106-84(98)99)72(127)110-52(20-9-31-104-82(94)95)71(126)111-53(21-10-32-105-83(96)97)73(128)114-56(29-30-63(93)123)75(130)112-55(23-12-34-107-85(100)101)74(129)115-57(81(136)137)24-13-35-108-86(102)103/h2,5-8,16-19,25-28,40,43,50,52-62,109,121-122H,1,3-4,9-15,20-24,29-39,41-42,92H2,(H2,93,123)(H,110,127)(H,111,126)(H,112,130)(H,113,131)(H,114,128)(H,115,129)(H,116,133)(H,117,134)(H,118,135)(H,119,125)(H,120,132)(H,136,137)(H4,94,95,104)(H4,96,97,105)(H4,98,99,106)(H4,100,101,107)(H4,102,103,108)/t50-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-/m1/s1
DMCWVPU	CS	C1CCC(CC1)C[C@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H](CC2=C(C(=C(C(=C2F)F)F)F)F)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC5=CC=C(C=C5)C(=O)C6=CC=CC=C6)N
DMCWVPU	IK	DEZJGRPRBZSAKI-KMGSDFBDSA-N
DMCWVPU	IU	(2R)-2-[[(2R)-2-[[(2R)-5-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-(4-benzoylphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(2,3,4,5,6-pentafluorophenyl)propanoyl]amino]-3-cyclohexylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoic acid
DMCWVPU	CA	CAS 565434-85-7
DMCWVPU	DE	Mesothelioma; Solid tumour/cancer

DMMQYL9	ID	DMMQYL9
DMMQYL9	DN	CC-223
DMMQYL9	HS	Phase 1/2
DMMQYL9	SN	GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661
DMMQYL9	CP	Celgene
DMMQYL9	DT	Small molecular drug
DMMQYL9	PC	58298316
DMMQYL9	MW	397.5
DMMQYL9	FM	C21H27N5O3
DMMQYL9	IC	InChI=1S/C21H27N5O3/c1-21(2,28)17-9-4-13(10-22-17)16-11-23-19-20(25-16)26(18(27)12-24-19)14-5-7-15(29-3)8-6-14/h4,9-11,14-15,28H,5-8,12H2,1-3H3,(H,23,24)
DMMQYL9	CS	CC(C)(C1=NC=C(C=C1)C2=CN=C3C(=N2)N(C(=O)CN3)C4CCC(CC4)OC)O
DMMQYL9	IK	UFKLYTOEMRFKAD-UHFFFAOYSA-N
DMMQYL9	IU	3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(4-methoxycyclohexyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one
DMMQYL9	CA	CAS 1228013-30-6
DMMQYL9	DE	Solid tumour/cancer

DM9UZM1	ID	DM9UZM1
DM9UZM1	DN	CCS1477
DM9UZM1	HS	Phase 1/2
DM9UZM1	SN	CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
DM9UZM1	CP	CellCentric
DM9UZM1	DT	Small molecular drug
DM9UZM1	PC	134457551
DM9UZM1	MW	534.6
DM9UZM1	FM	C30H32F2N4O3
DM9UZM1	IC	InChI=1S/C30H32F2N4O3/c1-17-29(18(2)39-34-17)19-7-14-26-25(15-19)33-30(36(26)20-8-11-22(38-3)12-9-20)27-5-4-6-28(37)35(27)21-10-13-23(31)24(32)16-21/h7,10,13-16,20,22,27H,4-6,8-9,11-12H2,1-3H3/t20?,22?,27-/m0/s1
DM9UZM1	CS	CC1=C(C(=NO1)C)C2=CC3=C(C=C2)N(C(=N3)[C@@H]4CCCC(=O)N4C5=CC(=C(C=C5)F)F)C6CCC(CC6)OC
DM9UZM1	IK	SKDNDJWEBPQKCS-RIQBOWGZSA-N
DM9UZM1	IU	(6S)-1-(3,4-difluorophenyl)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one
DM9UZM1	DE	Solid tumour/cancer

DM2B1V0	ID	DM2B1V0
DM2B1V0	DN	CCT301-38 (targeting ROR2)
DM2B1V0	HS	Phase 1/2
DM2B1V0	CP	Shanghai Sinobioway Sunterra Biotech
DM2B1V0	DT	CAR T Cell Therapy
DM2B1V0	DE	Renal cell carcinoma

DM0F9CD	ID	DM0F9CD
DM0F9CD	DN	CCT301-59 (targeting ROR2)
DM0F9CD	HS	Phase 1/2
DM0F9CD	CP	Shanghai Sinobioway Sunterra Biotech
DM0F9CD	DT	CAR T Cell Therapy
DM0F9CD	DE	Renal cell carcinoma

DMHOWU5	ID	DMHOWU5
DMHOWU5	DN	CD123-specific gene-engineered T cells
DMHOWU5	HS	Phase 1/2
DMHOWU5	CP	Shenzhen Geno-Immune Medical Institute
DMHOWU5	DT	CAR T Cell Therapy
DMHOWU5	DE	Acute myeloid leukaemia

DMHMC19	ID	DMHMC19
DMHMC19	DN	CD137 CAR-T Cell
DMHMC19	HS	Phase 1/2
DMHMC19	CP	Wuhan Sian Medical Technology Co., Ltd
DMHMC19	DT	CAR T Cell Therapy
DMHMC19	DE	Acute lymphoblastic leukaemia; B-cell lymphoma

DMCSGNU	ID	DMCSGNU
DMCSGNU	DN	CD138 CAR T cells
DMCSGNU	HS	Phase 1/2
DMCSGNU	CP	Shenzhen Geno-Immune Medical Institute
DMCSGNU	DT	CAR T Cell Therapy
DMCSGNU	DE	Multiple myeloma

DMRJ3ND	ID	DMRJ3ND
DMRJ3ND	DN	CD19 and CD20 CAR-T Cells
DMRJ3ND	HS	Phase 1/2
DMRJ3ND	CP	Chinese PLA General Hospital
DMRJ3ND	DT	CAR T Cell Therapy (Dual specific)
DMRJ3ND	DE	B-cell lymphoma; leukaemia

DM581CS	ID	DM581CS
DM581CS	DN	CD19 and CD22 CAR-T Cells
DM581CS	HS	Phase 1/2
DM581CS	CP	Ruijin Hospital
DM581CS	DT	CAR T Cell Therapy (Dual specific)
DM581CS	DE	Lymphoma

DMQB7SZ	ID	DMQB7SZ
DMQB7SZ	DN	CD19 and CD22 CAR-T Cells
DMQB7SZ	HS	Phase 1/2
DMQB7SZ	CP	Chinese PLA General Hospital
DMQB7SZ	DT	CAR T Cell Therapy (Dual specific)
DMQB7SZ	DE	B-cell lymphoma; leukaemia

DMQJ6YL	ID	DMQJ6YL
DMQJ6YL	DN	CD19 CAR Gene Transduced T Lymphocytes
DMQJ6YL	HS	Phase 1/2
DMQJ6YL	CP	Jichi Medical University
DMQJ6YL	DT	CAR T Cell Therapy
DMQJ6YL	DE	Non-hodgkin lymphoma

DMMHLJQ	ID	DMMHLJQ
DMMHLJQ	DN	CD19 CAR T cells
DMMHLJQ	HS	Phase 1/2
DMMHLJQ	CP	Sheba Medical Center
DMMHLJQ	DT	CAR T Cell Therapy
DMMHLJQ	DE	Acute lymphoblastic leukaemia; B-cell non-hodgkin lymphoma

DMUARWH	ID	DMUARWH
DMUARWH	DN	CD19 CAR T Cells
DMUARWH	HS	Phase 1/2
DMUARWH	CP	Fred Hutchinson Cancer Research Center
DMUARWH	DT	CAR T Cell Therapy
DMUARWH	DE	Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Large cell lymphoma; Mantle cell lymphoma

DM69A1W	ID	DM69A1W
DM69A1W	DN	CD19 CART
DM69A1W	HS	Phase 1/2
DM69A1W	CP	Shanghai Bioray Laboratory Inc.
DM69A1W	DT	CAR T Cell Therapy
DM69A1W	DE	Acute lymphoblastic leukaemia

DMU348C	ID	DMU348C
DMU348C	DN	CD19 CART
DMU348C	HS	Phase 1/2
DMU348C	CP	Shenzhen Second People's Hospital
DMU348C	DT	CAR T Cell Therapy
DMU348C	DE	B-cell lymphoma

DMECGKO	ID	DMECGKO
DMECGKO	DN	CD19 CAR-T Cells
DMECGKO	HS	Phase 1/2
DMECGKO	CP	Henan Cancer Hospital
DMECGKO	DT	CAR T Cell Therapy
DMECGKO	DE	Acute lymphoblastic leukaemia

DM8KESD	ID	DM8KESD
DM8KESD	DN	CD19 CAR-T lymphocytes
DM8KESD	HS	Phase 1/2
DM8KESD	CP	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
DM8KESD	DT	CAR T Cell Therapy
DM8KESD	DE	Acute lymphoblastic leukaemia

DMGDK9C	ID	DMGDK9C
DMGDK9C	DN	CD19 specific CAR T cells
DMGDK9C	HS	Phase 1/2
DMGDK9C	CP	Seattle Children's Hospital
DMGDK9C	DT	CAR T Cell Therapy
DMGDK9C	DE	Acute leukaemia

DM8RXFB	ID	DM8RXFB
DM8RXFB	DN	CD19 targeted chimeric antigen receptor T cells
DM8RXFB	HS	Phase 1/2
DM8RXFB	CP	Zhejiang University
DM8RXFB	DT	CAR T Cell Therapy
DM8RXFB	DE	B-cell lymphoma

DM79GPF	ID	DM79GPF
DM79GPF	DN	CD19.CAR T Cells
DM79GPF	HS	Phase 1/2
DM79GPF	CP	University Hospital Heidelberg
DM79GPF	DT	CAR T Cell Therapy
DM79GPF	DE	Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle cell lymphoma

DMNZ7F2	ID	DMNZ7F2
DMNZ7F2	DN	CD19.CAR-T cells
DMNZ7F2	HS	Phase 1/2
DMNZ7F2	CP	Xinqiao Hospital of Chongqing
DMNZ7F2	DT	CAR T Cell Therapy
DMNZ7F2	DE	Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma

DMQE7TW	ID	DMQE7TW
DMQE7TW	DN	CD19-CAR T cell
DMQE7TW	HS	Phase 1/2
DMQE7TW	CP	Bambino Ges&#249; Hospital and Research Institute
DMQE7TW	DT	CAR T Cell Therapy
DMQE7TW	DE	Acute lymphoblastic leukaemia; Non-hodgkin lymphoma

DMKQRUJ	ID	DMKQRUJ
DMKQRUJ	DN	CD19-directed CAR-T cells
DMKQRUJ	HS	Phase 1/2
DMKQRUJ	CP	Shanghai Tongji Hospital, Tongji University School of Medicine
DMKQRUJ	DT	CAR T Cell Therapy
DMKQRUJ	DE	leukaemia; Lymphoma

DMI2OVA	ID	DMI2OVA
DMI2OVA	DN	CD19-targeting CAR T Cells
DMI2OVA	HS	Phase 1/2
DMI2OVA	CP	Fuda Cancer Hospital, Guangzhou
DMI2OVA	DT	CAR T Cell Therapy
DMI2OVA	DE	B-cell lymphoma

DM4MBUI	ID	DM4MBUI
DM4MBUI	DN	CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells
DM4MBUI	HS	Phase 1/2
DM4MBUI	CP	Xuzhou Medical University
DM4MBUI	DT	CAR T Cell Therapy (Dual specific)
DM4MBUI	DE	Haematopoietic/lymphoid cancer

DMHPZ8G	ID	DMHPZ8G
DMHPZ8G	DN	CD20-Specific CAR T Cells
DMHPZ8G	HS	Phase 1/2
DMHPZ8G	CP	Fred Hutchinson Cancer Research Center
DMHPZ8G	DT	CAR T Cell Therapy
DMHPZ8G	DE	Chronic lymphocytic leukaemia; Follicular lymphoma; Large cell lymphoma; Lymphoma; Mantle cell lymphoma; Non-hodgkin lymphoma

DM40NEB	ID	DM40NEB
DM40NEB	DN	CD22 CAR-T
DM40NEB	HS	Phase 1/2
DM40NEB	CP	Kai Lin Xu; Jun Nian Zheng
DM40NEB	DT	CAR T Cell Therapy
DM40NEB	DE	B-cell lymphoma

DM61MBG	ID	DM61MBG
DM61MBG	DN	CD22-Targeted CAR-T cells
DM61MBG	HS	Phase 1/2
DM61MBG	CP	Southwest Hospital, China
DM61MBG	DT	CAR T Cell Therapy
DM61MBG	DE	leukaemia; Lymphoma

DMM35D2	ID	DMM35D2
DMM35D2	DN	CD33-specific gene-engineered T cells
DMM35D2	HS	Phase 1/2
DMM35D2	CP	Shenzhen Geno-Immune Medical Institute
DMM35D2	DT	CAR T Cell Therapy
DMM35D2	DE	Acute myeloid leukaemia

DMFZS8A	ID	DMFZS8A
DMFZS8A	DN	CD38 and BCMA CAR-T Cells
DMFZS8A	HS	Phase 1/2
DMFZS8A	CP	Chinese PLA General Hospital
DMFZS8A	DT	CAR T Cell Therapy (Dual specific)
DMFZS8A	DE	Multiple myeloma

DMPS3I6	ID	DMPS3I6
DMPS3I6	DN	CD38 CAR T cells
DMPS3I6	HS	Phase 1/2
DMPS3I6	CP	Shenzhen Geno-Immune Medical Institute
DMPS3I6	DT	CAR T Cell Therapy
DMPS3I6	DE	Multiple myeloma

DM0USBX	ID	DM0USBX
DM0USBX	DN	CD38 CAR-T Cell
DM0USBX	HS	Phase 1/2
DM0USBX	CP	Chinese PLA General Hospital
DM0USBX	DT	CAR T Cell Therapy
DM0USBX	DE	Acute lymphoblastic leukaemia

DMCH98G	ID	DMCH98G
DMCH98G	DN	CD38-specific gene-engineered T cells
DMCH98G	HS	Phase 1/2
DMCH98G	CP	Shenzhen Geno-Immune Medical Institute
DMCH98G	DT	CAR T Cell Therapy
DMCH98G	DE	Acute myeloid leukaemia

DMS5OL0	ID	DMS5OL0
DMS5OL0	DN	CD56 CAR T cells
DMS5OL0	HS	Phase 1/2
DMS5OL0	CP	Shenzhen Geno-Immune Medical Institute
DMS5OL0	DT	CAR T Cell Therapy
DMS5OL0	DE	Multiple myeloma

DM35XCT	ID	DM35XCT
DM35XCT	DN	CD56-specific gene-engineered T cells
DM35XCT	HS	Phase 1/2
DM35XCT	CP	Shenzhen Geno-Immune Medical Institute
DM35XCT	DT	CAR T Cell Therapy
DM35XCT	DE	Acute myeloid leukaemia

DMD1V7I	ID	DMD1V7I
DMD1V7I	DN	Celgosivir
DMD1V7I	HS	Phase 1/2
DMD1V7I	SN	BuCast; MDL 28574; B-CAST; MBI-3253; MDL 28,574; MDL 28,574A; MDL-28574; MX-3253; VIR-222; Butanoic acid, (1S,6S,7S,8R,8aR)-octahydro-1,7,8-trihydroxy-6-indolizinyl ester; [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate; (1S,6S,7S,8R,8aR)-Octahydro-1,7,8-trihydroxy-6-indolizinyl butyrate;6-O-Butanoylcastanospermine
DMD1V7I	CP	Migenix
DMD1V7I	DT	Small molecular drug
DMD1V7I	PC	60734
DMD1V7I	MW	259.3
DMD1V7I	FM	C12H21NO5
DMD1V7I	IC	InChI=1S/C12H21NO5/c1-2-3-9(15)18-8-6-13-5-4-7(14)10(13)12(17)11(8)16/h7-8,10-12,14,16-17H,2-6H2,1H3/t7-,8-,10+,11+,12+/m0/s1
DMD1V7I	CS	CCCC(=O)O[C@H]1CN2CC[C@@H]([C@@H]2[C@H]([C@@H]1O)O)O
DMD1V7I	IK	HTJGLYIJVSDQAE-VWNXEWBOSA-N
DMD1V7I	IU	[(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate
DMD1V7I	CA	CAS 121104-96-9
DMD1V7I	DE	Dengue fever

DMAO04B	ID	DMAO04B
DMAO04B	DN	CEP-32496
DMAO04B	HS	Phase 1/2
DMAO04B	SN	AB-024; B-RAF kinase inhibitors (melanoma), Ambit/Cephalon
DMAO04B	CP	Teva pharmaceutical
DMAO04B	DT	Small molecular drug
DMAO04B	PC	56846693
DMAO04B	MW	517.5
DMAO04B	FM	C24H22F3N5O5
DMAO04B	IC	InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)
DMAO04B	CS	CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F
DMAO04B	IK	DKNUPRMJNUQNHR-UHFFFAOYSA-N
DMAO04B	IU	1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea
DMAO04B	CA	CAS 1188910-76-0
DMAO04B	DE	Solid tumour/cancer

DMY8NUF	ID	DMY8NUF
DMY8NUF	DN	CEP-9722
DMY8NUF	HS	Phase 1/2
DMY8NUF	CP	Cephalon
DMY8NUF	PC	24780387
DMY8NUF	MW	418.5
DMY8NUF	FM	C24H26N4O3
DMY8NUF	IC	InChI=1S/C24H26N4O3/c1-26-9-11-27(12-10-26)13-28-23(29)18-14-5-3-6-15(14)22-20(21(18)24(28)30)19-16(25-22)7-4-8-17(19)31-2/h4,7-8,25H,3,5-6,9-13H2,1-2H3
DMY8NUF	CS	CN1CCN(CC1)CN2C(=O)C3=C(C2=O)C4=C(C5=C3CCC5)NC6=C4C(=CC=C6)OC
DMY8NUF	IK	CTLOSZHDGZLOQE-UHFFFAOYSA-N
DMY8NUF	IU	14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione
DMY8NUF	CA	CAS 916574-83-9
DMY8NUF	DE	Non-small-cell lung cancer; Cerebrovascular ischaemia

DMCR7EF	ID	DMCR7EF
DMCR7EF	DN	CEQ-508
DMCR7EF	HS	Phase 1/2
DMCR7EF	SN	CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina
DMCR7EF	CP	Cequent Pharmaceuticals Inc
DMCR7EF	DT	siRNA drug
DMCR7EF	DE	Familial adenomatous polyposis

DMUW6KP	ID	DMUW6KP
DMUW6KP	DN	CERC-803
DMUW6KP	HS	Phase 1/2
DMUW6KP	SN	Fucopyranose, L- (7CI); Fucose; L-Fucose; L-Galactopyranose, 6-deoxy-; L-fucopyranose; L-galactomethylose; fucopyranose; (-)-L-Fucose; (3S,4R,5S,6S)-6-Methyltetrahydro-2H-pyran-2,3,4,5-tetraol; 6-Deoxy-Galactopyranose; 6-Deoxy-Galactopyranoside; 6-Deoxy-Galactose; 6-Deoxy-L-Galactopyranose; 6-Deoxy-L-Galactopyranoside; 6-Deoxy-L-Galactose; 6-Deoxy-L-beta-galactose; 6-Desoxygalactose; 6-methyltetrahydropyran-2,3,4,5-tetraol; 6696-41-9; 87-96-7; CHEBI:2181; CHEMBL469449; Epitope ID:152214; Fuc; L-Fuc; SCHEMBL63943; bmse000036
DMUW6KP	PC	17106
DMUW6KP	MW	164.16
DMUW6KP	FM	C6H12O5
DMUW6KP	IC	SHZGCJCMOBCMKK-DHVFOXMCSA-N
DMUW6KP	CS	CC1C(C(C(C(O1)O)O)O)O
DMUW6KP	IK	1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6?/m0/s1
DMUW6KP	IU	(3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol
DMUW6KP	CA	CAS 87-96-7
DMUW6KP	CB	CHEBI:2181
DMUW6KP	DE	Glycosylation disorder

DMD3XMW	ID	DMD3XMW
DMD3XMW	DN	Cethrin
DMD3XMW	HS	Phase 1/2
DMD3XMW	SN	Quinacrine, Dihydrochloride
DMD3XMW	CP	Alseres Pharmaceuticals Purchased rights for Cethrin from BioAxone Therapeutic
DMD3XMW	DT	Small molecular drug
DMD3XMW	PC	16760629
DMD3XMW	MW	472.9
DMD3XMW	FM	C23H32Cl3N3O
DMD3XMW	IC	InChI=1S/C23H30ClN3O.2ClH/c1-5-27(6-2)11-7-8-16(3)25-22-14-18(24)15-23-20(22)13-17-12-19(28-4)9-10-21(17)26-23;;/h9-10,12-16,25H,5-8,11H2,1-4H3;2*1H
DMD3XMW	CS	CCN(CC)CCCC(C)NC1=CC(=CC2=C1C=C3C=C(C=CC3=N2)OC)Cl.Cl.Cl
DMD3XMW	IK	QKAZHUGLNKCCGY-UHFFFAOYSA-N
DMD3XMW	IU	4-N-(3-chloro-7-methoxyacridin-1-yl)-1-N,1-N-diethylpentane-1,4-diamine;dihydrochloride
DMD3XMW	DE	Spinal cord injury

DMJBQ96	ID	DMJBQ96
DMJBQ96	DN	Cetrelimab
DMJBQ96	HS	Phase 1/2
DMJBQ96	SN	JNJ-63723283
DMJBQ96	CP	Janssen
DMJBQ96	DT	Antibody
DMJBQ96	DE	Solid tumour/cancer

DM2BXDU	ID	DM2BXDU
DM2BXDU	DN	CFG920
DM2BXDU	HS	Phase 1/2
DM2BXDU	CP	Novartis pharmaceuticals
DM2BXDU	PC	49871869
DM2BXDU	MW	288.73
DM2BXDU	FM	C14H13ClN4O
DM2BXDU	IC	InChI=1S/C14H13ClN4O/c1-10-2-4-16-9-12(10)19-7-6-18(14(19)20)11-3-5-17-13(15)8-11/h2-5,8-9H,6-7H2,1H3
DM2BXDU	CS	CC1=C(C=NC=C1)N2CCN(C2=O)C3=CC(=NC=C3)Cl
DM2BXDU	IK	ZVIFCOOHWGNPHJ-UHFFFAOYSA-N
DM2BXDU	IU	1-(2-chloropyridin-4-yl)-3-(4-methylpyridin-3-yl)imidazolidin-2-one
DM2BXDU	CA	CAS 1260006-20-9
DM2BXDU	DE	Prostate cancer

DMB5KRA	ID	DMB5KRA
DMB5KRA	DN	CFI-402411
DMB5KRA	HS	Phase 1/2
DMB5KRA	CP	Treadwell Therapeutics
DMB5KRA	DT	Small molecular drug
DMB5KRA	DE	Solid tumour/cancer

DMPYW28	ID	DMPYW28
DMPYW28	DN	CG-806
DMPYW28	HS	Phase 1/2
DMPYW28	SN	1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; CG-806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-
DMPYW28	CP	Aptose Biosciences
DMPYW28	DT	Small molecular drug
DMPYW28	PC	66981446
DMPYW28	MW	509.5
DMPYW28	FM	C26H19F4N5O2
DMPYW28	IC	InChI=1S/C26H19F4N5O2/c1-13-11-31-23(33-13)19-8-7-17(20-12-32-24(36)22(19)20)18-6-5-16(10-21(18)27)35-25(37)34-15-4-2-3-14(9-15)26(28,29)30/h2-11H,12H2,1H3,(H,31,33)(H,32,36)(H2,34,35,37)
DMPYW28	CS	CC1=CN=C(N1)C2=C3C(=C(C=C2)C4=C(C=C(C=C4)NC(=O)NC5=CC=CC(=C5)C(F)(F)F)F)CNC3=O
DMPYW28	IK	BOLRZWTVMUHQQU-UHFFFAOYSA-N
DMPYW28	IU	1-[3-fluoro-4-[7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydroisoindol-4-yl]phenyl]-3-[3-(trifluoromethyl)phenyl]urea
DMPYW28	CA	CAS 1370466-81-1
DMPYW28	DE	Acute myeloid leukaemia

DMHNFXR	ID	DMHNFXR
DMHNFXR	DN	Chimeric Antigen Receptor Modified T cells Targeting CD19
DMHNFXR	HS	Phase 1/2
DMHNFXR	CP	Southwest Hospital, China
DMHNFXR	DT	CAR T Cell Therapy
DMHNFXR	DE	leukaemia; Lymphoma

DMIXPNG	ID	DMIXPNG
DMIXPNG	DN	CHR-3996
DMIXPNG	HS	Phase 1/2
DMIXPNG	SN	CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma
DMIXPNG	CP	Chroma Therapeutics Ltd
DMIXPNG	DT	Small molecular drug
DMIXPNG	PC	49857317
DMIXPNG	MW	394.4
DMIXPNG	FM	C20H19FN6O2
DMIXPNG	IC	InChI=1S/C20H19FN6O2/c21-13-2-4-17-11(5-13)1-3-14(25-17)8-22-18-15-9-27(10-16(15)18)20-23-6-12(7-24-20)19(28)26-29/h1-7,15-16,18,22,29H,8-10H2,(H,26,28)/t15-,16+,18?
DMIXPNG	CS	C1[C@@H]2[C@@H](C2NCC3=NC4=C(C=C3)C=C(C=C4)F)CN1C5=NC=C(C=N5)C(=O)NO
DMIXPNG	IK	QRGHOAATPOLDPF-BYICEURKSA-N
DMIXPNG	IU	2-[(1S,5R)-6-[(6-fluoroquinolin-2-yl)methylamino]-3-azabicyclo[3.1.0]hexan-3-yl]-N-hydroxypyrimidine-5-carboxamide
DMIXPNG	CA	CAS 1256448-47-1
DMIXPNG	DE	Solid tumour/cancer; Lymphoma

DM90BUD	ID	DM90BUD
DM90BUD	DN	ChronSeal
DM90BUD	HS	Phase 1/2
DM90BUD	SN	Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep
DM90BUD	CP	Linkoping University
DM90BUD	DE	Fibrosis

DMRSI1O	ID	DMRSI1O
DMRSI1O	DN	ChronVac-C hepatitis C DNA vaccine
DMRSI1O	HS	Phase 1/2
DMRSI1O	SN	ChronVac-C (TN)
DMRSI1O	CP	Inovio Pharmaceuticals; ChronTech Pharma
DMRSI1O	DT	Vaccine
DMRSI1O	DE	Hepatitis C virus infection

DMTV4L7	ID	DMTV4L7
DMTV4L7	DN	CHS-828
DMTV4L7	HS	Phase 1/2
DMTV4L7	SN	Cancer therapeutics, LEO Pharma; GMX-1778
DMTV4L7	CP	LEO Pharma A/S
DMTV4L7	DT	Small molecular drug
DMTV4L7	PC	148198
DMTV4L7	MW	371.9
DMTV4L7	FM	C19H22ClN5O
DMTV4L7	IC	InChI=1S/C19H22ClN5O/c20-16-5-7-18(8-6-16)26-14-4-2-1-3-11-23-19(24-15-21)25-17-9-12-22-13-10-17/h5-10,12-13H,1-4,11,14H2,(H2,22,23,24,25)
DMTV4L7	CS	C1=CC(=CC=C1OCCCCCCN=C(NC#N)NC2=CC=NC=C2)Cl
DMTV4L7	IK	BOIPLTNGIAPDBY-UHFFFAOYSA-N
DMTV4L7	IU	2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine
DMTV4L7	CA	CAS 200484-11-3
DMTV4L7	CB	CHEBI:95016
DMTV4L7	DE	Solid tumour/cancer

DMMVWSY	ID	DMMVWSY
DMMVWSY	DN	CK-101
DMMVWSY	HS	Phase 1/2
DMMVWSY	SN	IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena
DMMVWSY	CP	Checkpoint Therapeutics New York, NY
DMMVWSY	PC	117909640
DMMVWSY	MW	530.6
DMMVWSY	FM	C29H28F2N6O2
DMMVWSY	IC	InChI=1S/C29H28F2N6O2/c1-2-25(39)33-21-7-3-5-19(17-21)22-8-4-6-20-18-32-29(35-28(20)22)34-23-9-10-24(27(31)26(23)30)37-13-11-36(12-14-37)15-16-38/h2-10,17-18,38H,1,11-16H2,(H,33,39)(H,32,34,35)
DMMVWSY	CS	C=CC(=O)NC1=CC=CC(=C1)C2=CC=CC3=CN=C(N=C32)NC4=C(C(=C(C=C4)N5CCN(CC5)CCO)F)F
DMMVWSY	IK	IDRGFNPZDVBSSE-UHFFFAOYSA-N
DMMVWSY	IU	N-[3-[2-[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino]quinazolin-8-yl]phenyl]prop-2-enamide
DMMVWSY	CA	CAS 1660963-42-7
DMMVWSY	DE	Non-small-cell lung cancer

DML8US9	ID	DML8US9
DML8US9	DN	CLIC-1901
DML8US9	HS	Phase 1/2
DML8US9	CP	Ottawa Hospital Research Institute
DML8US9	DT	CAR T Cell Therapy
DML8US9	DE	Acute lymphoblastic leukaemia; Non-hodgkin lymphoma

DMCT917	ID	DMCT917
DMCT917	DN	CLL1-specific gene-engineered T cells
DMCT917	HS	Phase 1/2
DMCT917	CP	Shenzhen Geno-Immune Medical Institute
DMCT917	DT	CAR T Cell Therapy
DMCT917	DE	Acute myeloid leukaemia

DM2FSM5	ID	DM2FSM5
DM2FSM5	DN	CLR-1401
DM2FSM5	HS	Phase 1/2
DM2FSM5	SN	COLD (cancer), Novelos; 18-(p-iodophenyl)octadecyl phosphocholine
DM2FSM5	CP	Cellectar LLC
DM2FSM5	PC	11377191
DM2FSM5	MW	637.6
DM2FSM5	FM	C29H53INO4P
DM2FSM5	IC	InChI=1S/C29H53INO4P/c1-31(2,3)25-27-35-36(32,33)34-26-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-28-21-23-29(30)24-22-28/h21-24H,4-20,25-27H2,1-3H3
DM2FSM5	CS	C[N+](C)(C)CCOP(=O)([O-])OCCCCCCCCCCCCCCCCCCC1=CC=C(C=C1)I
DM2FSM5	IK	ZOAIEFWMQLYMTF-UHFFFAOYSA-N
DM2FSM5	IU	18-(4-iodophenyl)octadecyl 2-(trimethylazaniumyl)ethyl phosphate
DM2FSM5	CA	CAS 208986-26-9
DM2FSM5	DE	Solid tumour/cancer

DM64FY7	ID	DM64FY7
DM64FY7	DN	CLR457
DM64FY7	HS	Phase 1/2
DM64FY7	CP	Novartis pharmaceuticals
DM64FY7	DE	Advanced solid tumour

DMWZOD7	ID	DMWZOD7
DMWZOD7	DN	CNVN-202
DMWZOD7	HS	Phase 1/2
DMWZOD7	CP	MD Anderson Cancer Center
DMWZOD7	DE	Non-small-cell lung cancer

DM1ZGUX	ID	DM1ZGUX
DM1ZGUX	DN	CPHPC
DM1ZGUX	HS	Phase 1/2
DM1ZGUX	SN	Amyloid beta inhibitor; SAP binding inhibitor, Roche; Serum amyloid P binding inhibitor, Roche; Ro-63-8695
DM1ZGUX	CP	F Hoffmann-La Roche Ltd
DM1ZGUX	DT	Small molecular drug
DM1ZGUX	PC	125516
DM1ZGUX	MW	340.37
DM1ZGUX	FM	C16H24N2O6
DM1ZGUX	IC	InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1
DM1ZGUX	CS	C1C[C@@H](N(C1)C(=O)CCCCC(=O)N2CCC[C@@H]2C(=O)O)C(=O)O
DM1ZGUX	IK	HZLAWYIBLZNRFZ-VXGBXAGGSA-N
DM1ZGUX	IU	(2R)-1-[6-[(2R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid
DM1ZGUX	CA	CAS 224624-80-0
DM1ZGUX	DE	Parkinson disease

DMJEXLI	ID	DMJEXLI
DMJEXLI	DN	CPI-0209
DMJEXLI	HS	Phase 1/2
DMJEXLI	DT	Small molecular drug
DMJEXLI	DE	Solid tumour/cancer

DM3XWJ8	ID	DM3XWJ8
DM3XWJ8	DN	CPI-1205
DM3XWJ8	HS	Phase 1/2
DM3XWJ8	SN	HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-
DM3XWJ8	CP	Constellation Pharmaceuticals Cambridge, MA
DM3XWJ8	PC	78320408
DM3XWJ8	MW	518.6
DM3XWJ8	FM	C27H33F3N4O3
DM3XWJ8	IC	InChI=1S/C27H33F3N4O3/c1-16-13-23(37-4)21(25(35)32-16)14-31-26(36)24-18(3)34(22-8-6-5-7-20(22)24)17(2)19-9-11-33(12-10-19)15-27(28,29)30/h5-8,13,17,19H,9-12,14-15H2,1-4H3,(H,31,36)(H,32,35)/t17-/m1/s1
DM3XWJ8	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)[C@H](C)C4CCN(CC4)CC(F)(F)F)C)OC
DM3XWJ8	IK	HPODOLXTMDHLLC-QGZVFWFLSA-N
DM3XWJ8	IU	N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide
DM3XWJ8	CA	CAS 1621862-70-1
DM3XWJ8	DE	B-cell lymphoma; Prostate cancer

DM6078F	ID	DM6078F
DM6078F	DN	CT84.66
DM6078F	HS	Phase 1/2
DM6078F	SN	T84.66; Anti-CEA IgG1 radioimmunotherapeutic, City of Hope; Anti-carcinoembryonic antigen IgG1 radioimmunotherapeutic, City ofHope
DM6078F	CP	City of Hope
DM6078F	DE	Breast cancer

DM95XR8	ID	DM95XR8
DM95XR8	DN	CTCE-9908
DM95XR8	HS	Phase 1/2
DM95XR8	SN	Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019
DM95XR8	CP	Chemokine Therapeutics Corp; Chemokine Therapeutics
DM95XR8	PC	16186350
DM95XR8	MW	1927.3
DM95XR8	FM	C86H147N27O23
DM95XR8	IC	InChI=1S/C86H147N27O23/c1-45(2)35-58(104-81(133)64(43-116)110-83(135)68(47(5)6)112-66(120)39-99-71(123)53(89)17-9-12-30-87)75(127)108-62(41-114)79(131)106-60(37-49-22-26-51(118)27-23-49)77(129)102-56(20-15-33-97-85(92)93)73(125)96-32-14-11-19-55(70(91)122)101-74(126)57(21-16-34-98-86(94)95)103-78(130)61(38-50-24-28-52(119)29-25-50)107-80(132)63(42-115)109-76(128)59(36-46(3)4)105-82(134)65(44-117)111-84(136)69(48(7)8)113-67(121)40-100-72(124)54(90)18-10-13-31-88/h22-29,45-48,53-65,68-69,114-119H,9-21,30-44,87-90H2,1-8H3,(H2,91,122)(H,96,125)(H,99,123)(H,100,124)(H,101,126)(H,102,129)(H,103,130)(H,104,133)(H,105,134)(H,106,131)(H,107,132)(H,108,127)(H,109,128)(H,110,135)(H,111,136)(H,112,120)(H,113,121)(H4,92,93,97)(H4,94,95,98)/t53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,68-,69-/m0/s1
DM95XR8	CS	CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCCCC[C@@H](C(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCCN)N)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCCN)N
DM95XR8	IK	VUYRSKROGTWHDC-HZGLMRDYSA-N
DM95XR8	IU	(2S)-2,6-diamino-N-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(5S)-6-amino-5-[[(2S)-5-carbamimidamido-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2,6-diaminohexanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-6-oxohexyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]hexanamide
DM95XR8	CA	CAS 1030384-98-5
DM95XR8	DE	Sarcoma

DM90XQC	ID	DM90XQC
DM90XQC	DN	CTX001
DM90XQC	HS	Phase 1/2
DM90XQC	CP	CRISPR Therapeutics; Vertex Pharmaceuticals
DM90XQC	DT	Gene therapy
DM90XQC	DE	Sickle-cell disorder; Beta thalassemia

DMJ7LP0	ID	DMJ7LP0
DMJ7LP0	DN	CTX110
DMJ7LP0	HS	Phase 1/2
DMJ7LP0	CP	CRISPR Therapeutics
DMJ7LP0	DT	Gene therapy
DMJ7LP0	DE	Non-hodgkin lymphoma

DMHIQDC	ID	DMHIQDC
DMHIQDC	DN	CUDC-907
DMHIQDC	HS	Phase 1/2
DMHIQDC	SN	CUDC-907; 1339928-25-4; Fimepinostat; CUDC 907; UNII-3S9RX35S5X; CUDC907; 3S9RX35S5X; CHEMBL3622533; N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide; Fimepinostat [USAN]; PI3K/HDAC Inhibitor centn; MLS006010994; SCHEMBL1284705; GTPL8952; KS-00000TDO; EX-A742; AOB6775; DTXSID90712307; MolPort-023-293-550; JOWXJLIFIIOYMS-UHFFFAOYSA-N; HMS3656H04; BCP06870; s2759; BDBM50188961; 2341AH; ZINC73488511; ABP001045; AKOS026750340; SB16569; CUDC-907 (PI3K/HDAC Inhibi
DMHIQDC	CP	Curis
DMHIQDC	DT	Small molecular drug
DMHIQDC	PC	54575456
DMHIQDC	MW	508.6
DMHIQDC	FM	C23H24N8O4S
DMHIQDC	IC	InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)
DMHIQDC	CS	CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO
DMHIQDC	IK	JOWXJLIFIIOYMS-UHFFFAOYSA-N
DMHIQDC	IU	N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide
DMHIQDC	CA	CAS 1339928-25-4
DMHIQDC	DE	Diffuse large B-cell lymphoma; Neuroblastoma; Solid tumour/cancer; Acute myelogenous leukaemia

DMCPZYT	ID	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	HS	Phase 1/2
DMCPZYT	SN	CV-9201-1; CV-9201-2; CV-9201-3; CV-9201-4; CV-9201-5; RNA-based vaccine (NY-ESO-1, MAGE-C1/CT7, MAGE-C2/CT10, NSCLC), CureVac
DMCPZYT	CP	CureVac GmbH
DMCPZYT	DT	Vaccine
DMCPZYT	DE	Non-small-cell lung cancer

DM03LWZ	ID	DM03LWZ
DM03LWZ	DN	CVX-060
DM03LWZ	HS	Phase 1/2
DM03LWZ	CP	CovX
DM03LWZ	DT	Antibody
DM03LWZ	DE	Solid tumour/cancer

DMBUYIK	ID	DMBUYIK
DMBUYIK	DN	CWP232291
DMBUYIK	HS	Phase 1/2
DMBUYIK	CP	JW Pharmaceutical
DMBUYIK	DT	Small molecular drug
DMBUYIK	DE	Multiple myeloma; Acute myeloid leukaemia

DMUGMFN	ID	DMUGMFN
DMUGMFN	DN	CXB-909
DMUGMFN	HS	Phase 1/2
DMUGMFN	CP	Krenitsky Pharmaceuticals Inc
DMUGMFN	DE	Neurodegenerative disorder

DME6NMJ	ID	DME6NMJ
DME6NMJ	DN	CYT-0851
DME6NMJ	HS	Phase 1/2
DME6NMJ	CP	Cyteir Therapeutics
DME6NMJ	DT	Small molecular drug
DME6NMJ	DE	Solid tumour/cancer; B-cell lymphoma

DMJPSIL	ID	DMJPSIL
DMJPSIL	DN	Dapivirine
DMJPSIL	HS	Phase 1/2
DMJPSIL	SN	Dapivirinum; R 147681; R147681; TMC 120; TMC120; GEL-002; R-147681; TMC-120; TMC120-R147681; TMC-120/R-147681; 4-((4-((2,4,6-Trimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; 4-({4-[(2,4,6-Trimethylphenyl)amino]pyrimidin-2-yl}amino)benzenecarbonitrile; 4-[4-(2,4,6-TRIMETHYL-PHENYLAMINO)-PYRIMIDIN-2-YLAMINO]-BENZONITRILE; 4-[[4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile
DMJPSIL	CP	International Partnership for Microbicides, Inc. 
DMJPSIL	DT	Small molecular drug
DMJPSIL	PC	214347
DMJPSIL	MW	329.4
DMJPSIL	FM	C20H19N5
DMJPSIL	IC	InChI=1S/C20H19N5/c1-13-10-14(2)19(15(3)11-13)24-18-8-9-22-20(25-18)23-17-6-4-16(12-21)5-7-17/h4-11H,1-3H3,(H2,22,23,24,25)
DMJPSIL	CS	CC1=CC(=C(C(=C1)C)NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C
DMJPSIL	IK	ILAYIAGXTHKHNT-UHFFFAOYSA-N
DMJPSIL	IU	4-[[4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile
DMJPSIL	CA	CAS 244767-67-7
DMJPSIL	DE	Human immunodeficiency virus infection

DMJKFNU	ID	DMJKFNU
DMJKFNU	DN	DCC-2036
DMJKFNU	HS	Phase 1/2
DMJKFNU	SN	REBASTINIB; DCC-2036; 1020172-07-9; DCC-2036 (Rebastinib); DCC 2036; CHEBI:62166; UNII-75017Q6I97; Rebastinib(DCC-2036); 4-(4-(3-(3-(tert-butyl)-1-(quinolin-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; DCC2036; DP-1919; 4-[4-({[3-Tert-Butyl-1-(Quinolin-6-Yl)-1h-Pyrazol-5-Yl]carbamoyl}amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide; 75017Q6I97; 4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,4-methylbenzenesulfonic acid;4-[4-[(
DMJKFNU	CP	Deciphera Pharmaceuticals
DMJKFNU	DT	Small molecular drug
DMJKFNU	PC	25066467
DMJKFNU	MW	553.6
DMJKFNU	FM	C30H28FN7O3
DMJKFNU	IC	InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
DMJKFNU	CS	CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5
DMJKFNU	IK	WVXNSAVVKYZVOE-UHFFFAOYSA-N
DMJKFNU	IU	4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
DMJKFNU	CA	CAS 1020172-07-9
DMJKFNU	CB	CHEBI:62166
DMJKFNU	DE	Acute lymphoblastic leukaemia; Breast cancer; Chronic myeloid leukaemia

DMHW289	ID	DMHW289
DMHW289	DN	DCC-3014
DMHW289	HS	Phase 1/2
DMHW289	SN	Vimseltinib; UNII-PX9FTM69BF; PX9FTM69BF; DCC3014; 1628606-05-2; 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one; 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one; Vimseltinib [INN]; SCHEMBL16047448; GTPL11190; EX-A4700; NSC828316; NSC-828316; example 10 [WO2014145025A2]; HY-136256; CS-0121044; 3-Methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3H)-pyrimidinone; 4(3H)-Pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-
DMHW289	CP	Deciphera Pharmaceuticals
DMHW289	DT	Small molecular drug
DMHW289	PC	86267612
DMHW289	MW	431.5
DMHW289	FM	C23H25N7O2
DMHW289	IC	InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
DMHW289	CS	CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C
DMHW289	IK	TVGAHWWPABTBCX-UHFFFAOYSA-N
DMHW289	IU	3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one
DMHW289	CA	CAS 1628606-05-2
DMHW289	DE	Solid tumour/cancer

DMWE205	ID	DMWE205
DMWE205	DN	DCR-MYC
DMWE205	HS	Phase 1/2
DMWE205	CP	Dicerna pharmaceuticals
DMWE205	DT	siRNA drug
DMWE205	DE	Hepatocellular carcinoma

DM0I5LM	ID	DM0I5LM
DM0I5LM	DN	DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells
DM0I5LM	HS	Phase 1/2
DM0I5LM	SN	BLT-HIV; Lentiviral vector delivered DNA-directed RNAi therapeutic (HIV infection), Benitec; RHIV7-shl-TAR-CCR5RZ; T-cell therapy (HIV infection), Benitec; Lentiviral vector delivered DNA-directed RNAi therapeutic (HIV-associated lymphoma), Benitec; DdRNAi therapy (rHIV7-shl-TAR-CCR5RZ, T-cells, HIV), Benitec; DdRNAi therapy (rHIV7-shl-TAR-CCR5RZ, stem cells, HIV/lymphoma), Benitec
DM0I5LM	CP	Benitec Ltd
DM0I5LM	DT	RNAi therapeutics
DM0I5LM	DE	Human immunodeficiency virus infection

DMCMT4V	ID	DMCMT4V
DMCMT4V	DN	Dexamethasone palmitate
DMCMT4V	HS	Phase 1/2
DMCMT4V	SN	Cortiject; Dexamethasone palmitate, Novagali; NOVA-22026; NOVA-22032; NOVA-63035; Corticosteroid therapy (ophthalmic emulsion, Novasorb), Novagali; Retinopathy therapy (ophthalmic emulsion, Novasorb), Novagali
DMCMT4V	CP	Santen
DMCMT4V	DT	Small molecular drug
DMCMT4V	PC	63044
DMCMT4V	MW	630.9
DMCMT4V	FM	C38H59FO6
DMCMT4V	IC	InChI=1S/C38H59FO6/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-34(43)45-26-33(42)38(44)27(2)23-31-30-20-19-28-24-29(40)21-22-35(28,3)37(30,39)32(41)25-36(31,38)4/h21-22,24,27,30-32,41,44H,5-20,23,25-26H2,1-4H3/t27-,30+,31+,32+,35+,36+,37+,38+/m1/s1
DMCMT4V	CS	CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)O
DMCMT4V	IK	WDPYZTKOEFDTCU-WDJQFAPHSA-N
DMCMT4V	IU	[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] hexadecanoate
DMCMT4V	CA	CAS 14899-36-6
DMCMT4V	CB	CHEBI:31471
DMCMT4V	DE	Choroidal neovascularization

DMACPQO	ID	DMACPQO
DMACPQO	DN	Dihydrexidine
DMACPQO	HS	Phase 1/2
DMACPQO	SN	DIHYDREXIDINE; (+)-Dihydrexidine; UNII-Q3PJ4B4D0X; Q3PJ4B4D0X; CHEMBL25856; Dihydrexidine hydrochloride; (6aR,12bS)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol; (6aR,12bS)-5,6,6a,7,8,12b-Hexahydrobenzo(a)phenanthridine-10,11-diol; Rel-Dihydrexidine; Dihydrexidine, (+)-; Lopac-D-5814; Biomol-NT_000033; AC1O7G2G; Lopac0_000380; 5,6,6a,7,8,12b-Hexahydro-benzo[a]phenanthridine-10,11-diol; BPBio1_001227; SCHEMBL4614575; CHEBI:124993; DAR-0100; IP-202; BDBM50010686; ZINC25758512; CCG-204474; NCGC00024845-04
DMACPQO	DT	Small molecular drug
DMACPQO	PC	5311070
DMACPQO	MW	267.32
DMACPQO	FM	C17H17NO2
DMACPQO	IC	InChI=1S/C17H17NO2/c19-15-7-10-5-6-14-17(13(10)8-16(15)20)12-4-2-1-3-11(12)9-18-14/h1-4,7-8,14,17-20H,5-6,9H2/t14-,17-/m0/s1
DMACPQO	CS	C1CC2=CC(=C(C=C2[C@H]3[C@H]1NCC4=CC=CC=C34)O)O
DMACPQO	IK	BGOQGUHWXBGXJW-YOEHRIQHSA-N
DMACPQO	IU	(6aS,12bR)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol
DMACPQO	CA	CAS 123039-93-0
DMACPQO	DE	Psychotic disorder

DM71BFM	ID	DM71BFM
DM71BFM	DN	DNA-Ad
DM71BFM	HS	Phase 1/2
DM71BFM	SN	DNA-prime/adenovirus (Ad5)-boost CSP-and AMA1-encoding malaria vaccine (Biojector2000, intramuscular), US NavalMedical Research Center (NMRC)/Bioject/Vical/GenVec
DM71BFM	CP	US Naval Medical Research Center
DM71BFM	DT	Vaccine
DM71BFM	DE	Malaria

DMK4VY9	ID	DMK4VY9
DMK4VY9	DN	DS-7300
DMK4VY9	HS	Phase 1/2
DMK4VY9	SN	O-(3,5-dichlorophenyl)hydroxylamine; 99907-90-1; 3,5-Dichlorophenoxyamine; Hydroxylamine, O-(3,5-dichlorophenyl)-; SCHEMBL4210449; DTXSID00471352; MFCD09029771; ZINC21987339; AKOS006290319; AK141702
DMK4VY9	CP	Daiichi Sankyo
DMK4VY9	DT	Antibody drug conjugate
DMK4VY9	DE	Solid tumour/cancer

DM7WK6N	ID	DM7WK6N
DM7WK6N	DN	DSP-0509
DM7WK6N	HS	Phase 1/2
DM7WK6N	CP	Sumitomo Dainippon Pharma
DM7WK6N	DT	Small molecular drug
DM7WK6N	DE	Solid tumour/cancer

DM8K0PR	ID	DM8K0PR
DM8K0PR	DN	DSP-107
DM8K0PR	HS	Phase 1/2
DM8K0PR	CP	KAHR Medical
DM8K0PR	DT	Recombinant?protein
DM8K0PR	DE	Solid tumour/cancer

DMRXQCL	ID	DMRXQCL
DMRXQCL	DN	DT388IL-3
DMRXQCL	HS	Phase 1/2
DMRXQCL	CP	Wake Forest University
DMRXQCL	DE	Acute myeloid leukaemia

DM8M71U	ID	DM8M71U
DM8M71U	DN	DTX301
DM8M71U	HS	Phase 1/2
DM8M71U	CP	Ultragenyx Pharmaceutical
DM8M71U	DT	Gene therapy
DM8M71U	DE	Ornithine transcarbamylase deficiency

DM72DU3	ID	DM72DU3
DM72DU3	DN	DZD9008
DM72DU3	HS	Phase 1/2
DM72DU3	CP	Dizal Pharmaceuticals
DM72DU3	DT	Small molecular drug
DM72DU3	DE	Non-small cell lung cancer

DMH2NKD	ID	DMH2NKD
DMH2NKD	DN	EB-101
DMH2NKD	HS	Phase 1/2
DMH2NKD	SN	Beta amyloid vaccine (Alzheimer's disease), Atlas Pharmaceuticals
DMH2NKD	CP	Atlas Pharmaceuticals Inc
DMH2NKD	DT	Vaccine
DMH2NKD	DE	Alzheimer disease; Dystrophic epidermolysis bullosa

DMI71FN	ID	DMI71FN
DMI71FN	DN	EDO-S101
DMI71FN	HS	Phase 1/2
DMI71FN	SN	Tinostamustine; Minomustine; 1236199-60-2; UNII-29DKI2H2NY; 29DKI2H2NY; Tinostamustine [USAN]; SCHEMBL7915449; CHEMBL3989941; EDO-S-101; EDO-S 101; MolPort-046-033-566; EX-A1322; ZINC68244536; AKOS030526024; CS-6484; HY-101780; EDO-S101,1236199-60-2, EDO-S101,EDO S101,EDOS101; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-
DMI71FN	CP	Mundipharma Cambridge, United Kingdom
DMI71FN	PC	46836227
DMI71FN	MW	415.4
DMI71FN	FM	C19H28Cl2N4O2
DMI71FN	IC	InChI=1S/C19H28Cl2N4O2/c1-24-17-9-8-15(25(12-10-20)13-11-21)14-16(17)22-18(24)6-4-2-3-5-7-19(26)23-27/h8-9,14,27H,2-7,10-13H2,1H3,(H,23,26)
DMI71FN	CS	CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO
DMI71FN	IK	GISXTRIGVCKQBX-UHFFFAOYSA-N
DMI71FN	IU	7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide
DMI71FN	CA	CAS 1236199-60-2
DMI71FN	DE	Solid tumour/cancer; Haematological malignancy

DMHRCQI	ID	DMHRCQI
DMHRCQI	DN	eFT226
DMHRCQI	HS	Phase 1/2
DMHRCQI	SN	Zotatifin; EFT226; UNII-2EWN8Z05CN; 2EWN8Z05CN; 2098191-53-6; EFT-226; Zotatifin [INN]; 4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5ah-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)benzonitrile; 4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl)benzonitrile; Zotatifin [USAN]; Zotatifin (USAN/INN); CHEMBL4303782; SCHEMBL18864788; EX-A4623; NSC818001; NSC828584; WHO 10998; NSC-818001; NSC-828584; HY-112163; CS-0043584; D11837; Benzonitrile, 4-((5aR,6S,7S,8R,8aS)-7-((dimethylamino)methyl)-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5ah-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)-
DMHRCQI	CP	eFFECTOR Therapeutics
DMHRCQI	DT	Small molecular drug
DMHRCQI	PC	129138801
DMHRCQI	MW	487.5
DMHRCQI	FM	C28H29N3O5
DMHRCQI	IC	InChI=1S/C28H29N3O5/c1-31(2)16-20-23(18-8-6-5-7-9-18)28(19-12-10-17(15-29)11-13-19)27(33,25(20)32)24-21(36-28)14-22(34-3)30-26(24)35-4/h5-14,20,23,25,32-33H,16H2,1-4H3/t20-,23-,25-,27+,28+/m1/s1
DMHRCQI	CS	CN(C)C[C@@H]1[C@H]([C@]2([C@@]([C@@H]1O)(C3=C(N=C(C=C3O2)OC)OC)O)C4=CC=C(C=C4)C#N)C5=CC=CC=C5
DMHRCQI	IK	QYCXWOACFWMQFO-WZWZCULESA-N
DMHRCQI	IU	4-[(2S,3R,4S,5S,6R)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-6-yl]benzonitrile
DMHRCQI	CA	CAS 2098191-53-6
DMHRCQI	DE	Solid tumour/cancer

DMF7EX8	ID	DMF7EX8
DMF7EX8	DN	EGFR antisense DNA
DMF7EX8	HS	Phase 1/2
DMF7EX8	SN	Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh
DMF7EX8	CP	University of Pittsburgh
DMF7EX8	DT	Antisense drug
DMF7EX8	DE	Head and neck cancer

DMDWCOF	ID	DMDWCOF
DMDWCOF	DN	EGFR CART
DMDWCOF	HS	Phase 1/2
DMDWCOF	CP	Shenzhen Second People's Hospital
DMDWCOF	DT	CAR T Cell Therapy
DMDWCOF	DE	Colorectal cancer

DMC284G	ID	DMC284G
DMC284G	DN	EGFRvIII CAR
DMC284G	HS	Phase 1/2
DMC284G	CP	Kite pharma santa monica; national cancer institute
DMC284G	DE	Glioblastoma multiforme

DM5FCO4	ID	DM5FCO4
DM5FCO4	DN	Elpamotide
DM5FCO4	HS	Phase 1/2
DM5FCO4	SN	OTS-102; VEGFR2-169; Epitope peptide vaccine (pancreatic cancer), Wakayama University; VEGFR2-epitope peptide, Wakayama
DM5FCO4	CP	OncoTherapy Science Inc
DM5FCO4	DT	Vaccine
DM5FCO4	DE	Biliary cancer

DM7CLEZ	ID	DM7CLEZ
DM7CLEZ	DN	Eltanexor oral
DM7CLEZ	HS	Phase 1/2
DM7CLEZ	SN	KPT-8602; Eltanexor; UNII-Q59IQJ9NTK; Q59IQJ9NTK; 1642300-52-4; Eltanexor [INN]; Eltanexor [WHO-DD]; SCHEMBL16324809; MolPort-044-830-659; s8397; AKOS032945053; CS-5947; HY-100423; (E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide; 5-Pyrimidineacetamide, alpha-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)methylene)-, (alphaE)-; (2E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-enamide
DM7CLEZ	CP	Karyopharm Therapeutics Newton, MA
DM7CLEZ	PC	86345880
DM7CLEZ	MW	428.29
DM7CLEZ	FM	C17H10F6N6O
DM7CLEZ	IC	InChI=1S/C17H10F6N6O/c18-16(19,20)11-1-9(2-12(3-11)17(21,22)23)15-27-8-29(28-15)6-13(14(24)30)10-4-25-7-26-5-10/h1-8H,(H2,24,30)/b13-6+
DM7CLEZ	CS	C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)C2=NN(C=N2)/C=C(\\C3=CN=CN=C3)/C(=O)N
DM7CLEZ	IK	JFBAVWVBLRIWHM-AWNIVKPZSA-N
DM7CLEZ	IU	(E)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-2-pyrimidin-5-ylprop-2-enamide
DM7CLEZ	CA	CAS 1642300-52-4
DM7CLEZ	DE	Colorectal cancer; Myelodysplastic syndrome; Prostate cancer

DMCAUKW	ID	DMCAUKW
DMCAUKW	DN	EMB-01
DMCAUKW	HS	Phase 1/2
DMCAUKW	CP	EpimAb Biotherapeutics
DMCAUKW	DT	Antibody
DMCAUKW	DE	Neoplasm; Non-small cell lung cancer

DMMD10S	ID	DMMD10S
DMMD10S	DN	EMD 55900
DMMD10S	HS	Phase 1/2
DMMD10S	SN	27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468
DMMD10S	DT	Antibody
DMMD10S	DE	Glioma

DMIOUFK	ID	DMIOUFK
DMIOUFK	DN	Emfilermin
DMIOUFK	HS	Phase 1/2
DMIOUFK	SN	AM-424; Leukemia inhibitory factor, AMRAD; RhLIF, AMRAD; RhLIF, Serono; Recombinant LIF protein, AMRAD/Serono; R-LIF, AMRAD/Serono
DMIOUFK	CP	Zenyth Therapeutics Ltd
DMIOUFK	DE	Infertility

DM1PQJO	ID	DM1PQJO
DM1PQJO	DN	Enapotamab vedotin
DM1PQJO	HS	Phase 1/2
DM1PQJO	CP	GenMab
DM1PQJO	DT	Antibody
DM1PQJO	DE	Solid tumour/cancer

DMN0EMP	ID	DMN0EMP
DMN0EMP	DN	Epicatechin
DMN0EMP	HS	Phase 1/2
DMN0EMP	SN	(-)-Epicatechin; Epicatechin; 490-46-0; L-Epicatechin; (-)-Epicatechol; l-Acacatechin; (2R,3R)-2-(3,4-Dihydroxyphenyl)chroman-3,5,7-triol; Epicatechol; l-Epicatechol; (-)epicatechin; (2R,3R)-(-)-Epicatechin; UNII-34PHS7TU43; epi-Catechin; epi-Catechol; CCRIS 7097; EINECS 207-710-1; NSC 81161; Epicatechol, (-)-; CHEBI:90; 34PHS7TU43; PFTAWBLQPZVEMU-UKRRQHHQSA-N; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol; (-)-(2R:3R)-5,7,3',4'-Tetrahydroxyflavan-3-ol; AK105372; C15H14O6
DMN0EMP	DT	Small molecular drug
DMN0EMP	PC	72276
DMN0EMP	MW	290.27
DMN0EMP	FM	C15H14O6
DMN0EMP	IC	InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15-/m1/s1
DMN0EMP	CS	C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O
DMN0EMP	IK	PFTAWBLQPZVEMU-UKRRQHHQSA-N
DMN0EMP	IU	(2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
DMN0EMP	CA	CAS 17334-50-8
DMN0EMP	CB	CHEBI:90
DMN0EMP	DE	Duchenne dystrophy; Friedreich's ataxia

DMWSGZU	ID	DMWSGZU
DMWSGZU	DN	Epithalon
DMWSGZU	HS	Phase 1/2
DMWSGZU	SN	Epitalon; BDM-E; Epitalon (Russian Academy of Medical Sciences); Retinal disease therapeutic, Biodiem; L-Alanyl-L-glutamyl-L-aspartyl-glycine
DMWSGZU	CP	BioDiem Ltd
DMWSGZU	DT	Small molecular drug
DMWSGZU	PC	219042
DMWSGZU	MW	390.35
DMWSGZU	FM	C14H22N4O9
DMWSGZU	IC	InChI=1S/C14H22N4O9/c1-6(15)12(25)17-7(2-3-9(19)20)14(27)18-8(4-10(21)22)13(26)16-5-11(23)24/h6-8H,2-5,15H2,1H3,(H,16,26)(H,17,25)(H,18,27)(H,19,20)(H,21,22)(H,23,24)/t6-,7-,8-/m0/s1
DMWSGZU	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N
DMWSGZU	IK	HGHOBRRUMWJWCU-FXQIFTODSA-N
DMWSGZU	IU	(4S)-4-[[(2S)-2-aminopropanoyl]amino]-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMWSGZU	CA	CAS 64082-79-7
DMWSGZU	DE	Ocular inflammation

DMTY96S	ID	DMTY96S
DMTY96S	DN	Eptacog beta
DMTY96S	HS	Phase 1/2
DMTY96S	CP	Hema Biologics
DMTY96S	DT	Small molecular drug
DMTY96S	DE	Non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Mantle cell lymphoma

DMN2FS3	ID	DMN2FS3
DMN2FS3	DN	EPZ-5676
DMN2FS3	HS	Phase 1/2
DMN2FS3	SN	pinometostat; EPZ-5676; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine
DMN2FS3	CP	Epizyme
DMN2FS3	DT	Small molecular drug
DMN2FS3	PC	57345410
DMN2FS3	MW	562.7
DMN2FS3	FM	C30H42N8O3
DMN2FS3	IC	InChI=1S/C30H42N8O3/c1-16(2)37(13-22-25(39)26(40)29(41-22)38-15-34-24-27(31)32-14-33-28(24)38)19-10-17(11-19)6-9-23-35-20-8-7-18(30(3,4)5)12-21(20)36-23/h7-8,12,14-17,19,22,25-26,29,39-40H,6,9-11,13H2,1-5H3,(H,35,36)(H2,31,32,33)/t17?,19?,22-,25-,26-,29-/m1/s1
DMN2FS3	CS	CC(C)N(C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C
DMN2FS3	IK	LXFOLMYKSYSZQS-XKHGBIBOSA-N
DMN2FS3	IU	(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[[3-[2-(6-tert-butyl-1H-benzimidazol-2-yl)ethyl]cyclobutyl]-propan-2-ylamino]methyl]oxolane-3,4-diol
DMN2FS3	CA	CAS 1380288-87-8
DMN2FS3	CB	CHEBI:124919
DMN2FS3	DE	Acute lymphoblastic leukaemia; Acute lymphocytic leukaemia; Acute myeloid leukaemia

DMNZ6VA	ID	DMNZ6VA
DMNZ6VA	DN	Erythropoietin-transfected autologous cell therapy
DMNZ6VA	HS	Phase 1/2
DMNZ6VA	SN	Epodure; Erythropoietin-transfected autologous cell therapy (Biopump); Erythropoietin-transfected autologous cell therapy (Biopump), Medgenics
DMNZ6VA	CP	Medgenics
DMNZ6VA	DE	Anemia

DMUNM4D	ID	DMUNM4D
DMUNM4D	DN	ESR0114
DMUNM4D	HS	Phase 1/2
DMUNM4D	CP	Escalier Biosciences Encinitas, CA
DMUNM4D	DE	Plaque psoriasis

DMIREUZ	ID	DMIREUZ
DMIREUZ	DN	Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy
DMIREUZ	HS	Phase 1/2
DMIREUZ	SN	Adenosine deaminase-transduced hematopoietic stem cell therapy; Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy (ADA-SCID)
DMIREUZ	CP	San Raffaele Telethon Institute for Gene Therapy
DMIREUZ	DE	Immunodeficiency

DM64PM7	ID	DM64PM7
DM64PM7	DN	EXO-230
DM64PM7	HS	Phase 1/2
DM64PM7	SN	GLY-230
DM64PM7	CP	Glycadia Inc
DM64PM7	DE	Diabetic neuropathy

DML6EVJ	ID	DML6EVJ
DML6EVJ	DN	F-14512
DML6EVJ	HS	Phase 1/2
DML6EVJ	SN	Polyamine-epipodophyllotoxin conjugate (cancer), Pierre Fabre
DML6EVJ	CP	Pierre Fabre SA
DML6EVJ	DT	Small molecular drug
DML6EVJ	PC	25229664
DML6EVJ	MW	641.8
DML6EVJ	FM	C33H47N5O8
DML6EVJ	IC	InChI=1S/C33H47N5O8/c1-42-26-13-20(14-27(43-2)32(26)40)29-21-15-24-25(46-19-45-24)16-22(21)31(23-18-44-33(41)30(23)29)38-28(39)17-37-12-6-11-36-9-4-3-8-35-10-5-7-34/h13-16,23,29-31,35-37,40H,3-12,17-19,34H2,1-2H3,(H,38,39)/t23-,29+,30-,31+/m0/s1
DML6EVJ	CS	COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)NC(=O)CNCCCNCCCCNCCCN
DML6EVJ	IK	NUZMJDHDPVKFJN-TYDXHICZSA-N
DML6EVJ	IU	N-[(5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]-2-[3-[4-(3-aminopropylamino)butylamino]propylamino]acetamide
DML6EVJ	CA	CAS 866874-63-7
DML6EVJ	DE	Solid tumour/cancer

DM49BX1	ID	DM49BX1
DM49BX1	DN	F-16-131I
DM49BX1	HS	Phase 1/2
DM49BX1	SN	Tenarad; Radiolabeled scFv antibody F-16 (solid tumor/hematological malignancy), Philogen
DM49BX1	CP	Philogen SpA
DM49BX1	DT	Antibody
DM49BX1	DE	Haematological malignancy

DMQSF5C	ID	DMQSF5C
DMQSF5C	DN	FBT-A05
DMQSF5C	HS	Phase 1/2
DMQSF5C	SN	Lymphomun; Bi-20; TPBs-05; Anti-CD20 bivalent monoclonal antibody (hematological cancer), Fresenius Biotech; Trifunctional antibody therapy (blood malignancy), Fresenius/Trion; Anti-CD20 bivalent monoclonal antibody (B-cell lymphoma, Triomab), Trion/Fresenius
DMQSF5C	CP	TRION Pharma GmbH
DMQSF5C	DT	Antibody
DMQSF5C	DE	Chronic lymphocytic leukaemia

DMQ8VUW	ID	DMQ8VUW
DMQ8VUW	DN	FCN-437
DMQ8VUW	HS	Phase 1/2
DMQ8VUW	CP	Fochon Pharmaceuticals
DMQ8VUW	DE	Breast cancer

DMRHOFB	ID	DMRHOFB
DMRHOFB	DN	Ferritarg P
DMRHOFB	HS	Phase 1/2
DMRHOFB	SN	Ferritarg; Ferrotarg P; Hodgkins disease therapy (polyclonal antibody), MAT Biopharma; Y90 anti-ferritin polyclonal antibody (Hodgkins disease), MAT Biopharma; Yttrium-90 anti-ferritin polyclonal antibody (Hodgkins disease), MAT Biopharma; Yttrium-90 anti-ferritin polyclonal antibody (refractory Hodgkin! s disease), MAT Biopharma; 90Y-labelled anti-ferritin polyclonal antibody (Hodgkins disease), MAT Biopharma; 90Y-labelled polyclonal IgG (Hodgkins disease), MAT Biopharma; 90Y-labelled polyclonal immunoglobulin G (Hogkinsdisease), MAT biopharma
DMRHOFB	CP	MAT Biopharma
DMRHOFB	DT	Antibody
DMRHOFB	DE	Lymphoma

DM1XIMU	ID	DM1XIMU
DM1XIMU	DN	FF-10101
DM1XIMU	HS	Phase 1/2
DM1XIMU	SN	1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-
DM1XIMU	CP	FUJIFILM Pharmaceuticals
DM1XIMU	DT	Small molecular drug
DM1XIMU	PC	90052320
DM1XIMU	MW	530.7
DM1XIMU	FM	C29H38N8O2
DM1XIMU	IC	InChI=1S/C29H38N8O2/c1-6-17-31-27-24(21-33-29(35-27)34-25-15-13-23(20-30)14-16-25)11-8-7-9-18-32-28(39)22(2)37(5)26(38)12-10-19-36(3)4/h10,12-16,21-22H,6-7,9,17-19H2,1-5H3,(H,32,39)(H2,31,33,34,35)/b12-10+/t22-/m0/s1
DM1XIMU	CS	CCCNC1=NC(=NC=C1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C)NC2=CC=C(C=C2)C#N
DM1XIMU	IK	HJFSVYUFOXAVAA-YUAYGMJFSA-N
DM1XIMU	IU	(E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide
DM1XIMU	CA	CAS 1472797-69-5
DM1XIMU	DE	Acute myeloid leukaemia

DM0HSJK	ID	DM0HSJK
DM0HSJK	DN	FF-10501-01
DM0HSJK	HS	Phase 1/2
DM0HSJK	CP	FUJIFILM Pharmaceuticals U.S.A. Cambridge, MA
DM0HSJK	DE	Acute myeloid leukaemia; Chronic myelogenous leukaemia; Myelodysplastic syndrome; Haematological malignancy

DM72JE4	ID	DM72JE4
DM72JE4	DN	FF-10502
DM72JE4	HS	Phase 1/2
DM72JE4	SN	UNII-R5B1HX1HUY; R5B1HX1HUY; 184302-49-6; 4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one; 4'-Thio-fac; SCHEMBL1986004; 4-amino-1-[(2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one; 2'beta-Fluoro-4'-O-thia-2'-deoxycytidine; 1-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)cytosine
DM72JE4	CP	FUJIFILM Pharmaceuticals
DM72JE4	DT	Small molecular drug
DM72JE4	PC	9903330
DM72JE4	MW	261.279
DM72JE4	FM	C9H12FN3O3S
DM72JE4	IC	InChI=1S/C9H12FN3O3S/c10-6-7(15)4(3-14)17-8(6)13-2-1-5(11)12-9(13)16/h1-2,4,6-8,14-15H,3H2,(H2,11,12,16)/t4-,6+,7-,8-/m1/s1
DM72JE4	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](S2)CO)O)F
DM72JE4	IK	NIDPJRZOVFIBQB-PXBUCIJWSA-N
DM72JE4	IU	4-amino-1-[(2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one
DM72JE4	CA	CAS 184302-49-6
DM72JE4	DE	Solid tumour/cancer

DMWEJ0C	ID	DMWEJ0C
DMWEJ0C	DN	FGF401
DMWEJ0C	HS	Phase 1/2
DMWEJ0C	SN	Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341
DMWEJ0C	CP	Novartis Oncology East Hanover, NJ
DMWEJ0C	PC	118036971
DMWEJ0C	MW	506.6
DMWEJ0C	FM	C25H30N8O4
DMWEJ0C	IC	InChI=1S/C25H30N8O4/c1-31-7-8-32(23(35)15-31)14-18-10-17-4-3-6-33(24(17)29-21(18)16-34)25(36)30-22-11-20(27-5-9-37-2)19(12-26)13-28-22/h10-11,13,16H,3-9,14-15H2,1-2H3,(H2,27,28,30,36)
DMWEJ0C	CS	CN1CCN(C(=O)C1)CC2=C(N=C3C(=C2)CCCN3C(=O)NC4=NC=C(C(=C4)NCCOC)C#N)C=O
DMWEJ0C	IK	BHKDKKZMPODMIQ-UHFFFAOYSA-N
DMWEJ0C	IU	N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide
DMWEJ0C	CA	CAS 1708971-55-4
DMWEJ0C	DE	Hepatocellular carcinoma; Solid tumour/cancer

DMI7S39	ID	DMI7S39
DMI7S39	DN	FLX475
DMI7S39	HS	Phase 1/2
DMI7S39	CP	FLX BioSouth San Francisco, CA
DMI7S39	DT	Small molecular drug
DMI7S39	DE	Solid tumour/cancer

DME2W4T	ID	DME2W4T
DME2W4T	DN	Forodesine
DME2W4T	HS	Phase 1/2
DME2W4T	SN	Immucillin H; Fodosine; Immucillin-H; 209799-67-7; BCX-1777; 1,4-dideoxy-4-aza-1-(s)-(9-deazahypoxanthin-9-yl)-d-ribitol; UNII-426X066ELK; CHEMBL218291; CHEBI:43362; 426X066ELK; (1S)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-D-ribitol; IMH; 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; (2R,3R,4S,5S)-2-(hydroxymethyl)-5-(4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidine-3,4-diol; Fodosine (TN)
DME2W4T	CP	BioCryst Pharma.
DME2W4T	TC	Anticancer Agents
DME2W4T	DT	Small molecular drug
DME2W4T	PC	135409409
DME2W4T	MW	266.25
DME2W4T	FM	C11H14N4O4
DME2W4T	IC	InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1
DME2W4T	CS	C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
DME2W4T	IK	IWKXDMQDITUYRK-KUBHLMPHSA-N
DME2W4T	IU	7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DME2W4T	CA	CAS 209799-67-7
DME2W4T	CB	CHEBI:43362
DME2W4T	DE	B-cell acute lymphoblastic leukaemia; Cutaneous T-cell lymphoma

DM3ZN6Y	ID	DM3ZN6Y
DM3ZN6Y	DN	FPA-008
DM3ZN6Y	HS	Phase 1/2
DM3ZN6Y	CP	Five prime therapeutics
DM3ZN6Y	DE	Autoimmune diabetes; Pigmented villonodular synovitis; Tenosynovial giant cell tumour

DMXV6YP	ID	DMXV6YP
DMXV6YP	DN	Fus-1 tumor suppressor gene therapy
DMXV6YP	HS	Phase 1/2
DMXV6YP	SN	Fus-1 tumor suppres; INGN-401; P53 bystander effector, Introgen; DOTAP:chol-TUSC2; FUS1-DOTAP:cholesterol; Fus-1 tumor suppressor gene therapy - nanoparticle formulation (cancer); Fus-1 tumor suppressor gene therapy-nanoparticle formulation (cancer), MD Anderson
DMXV6YP	CP	Genprex
DMXV6YP	DE	Non-small-cell lung cancer

DMG48WN	ID	DMG48WN
DMG48WN	DN	G0-203-2c
DMG48WN	HS	Phase 1/2
DMG48WN	CP	Genus 0ncology
DMG48WN	DE	Acute myeloid leukaemia; Pancreatic cancer

DMTV42K	ID	DMTV42K
DMTV42K	DN	G1
DMTV42K	HS	Phase 1/2
DMTV42K	SN	CHEMBL569766; 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethanone; 1-(4-(6-Bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone; SR-01000506928; AC1NT1SF; GTPL1014; SCHEMBL12700948; cid_5322399; cid_3136849; MolPort-003-004-976; ML051; HMS3650I22; ZINC4172149; BDBM50303803; STK330808; AKOS015969580; HY-107216; CS-0027669; UNM000011063001; UNM000000675701; SR-01000506928-1; SR-01000506928-3; 925419-53-0
DMTV42K	DT	Small molecular drug
DMTV42K	PC	5322399
DMTV42K	MW	412.3
DMTV42K	FM	C21H18BrNO3
DMTV42K	IC	InChI=1S/C21H18BrNO3/c1-11(24)12-5-6-18-15(7-12)13-3-2-4-14(13)21(23-18)16-8-19-20(9-17(16)22)26-10-25-19/h2-3,5-9,13-14,21,23H,4,10H2,1H3/t13-,14+,21-/m1/s1
DMTV42K	CS	CC(=O)C1=CC2=C(C=C1)N[C@H]([C@@H]3[C@H]2C=CC3)C4=CC5=C(C=C4Br)OCO5
DMTV42K	IK	VHSVKVWHYFBIFJ-HKZYLEAXSA-N
DMTV42K	IU	1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethanone
DMTV42K	CA	CAS 881639-98-1
DMTV42K	CB	CHEBI:156296
DMTV42K	DE	Lymphoma; Solid tumour/cancer

DM32AKH	ID	DM32AKH
DM32AKH	DN	G-207 virus construct
DM32AKH	HS	Phase 1/2
DM32AKH	SN	HrR3; G-207; G-47; G-47delta; G-207 virus construct, Catherex; G-207 virus construct, MediGene; HSV mutants (glioma), NCI; Oncolytic herpes simplex virus (glioma), Catherex/MediGene
DM32AKH	CP	MediGene Inc
DM32AKH	DE	Glioma

DMQU4EI	ID	DMQU4EI
DMQU4EI	DN	Galnobax
DMQU4EI	HS	Phase 1/2
DMQU4EI	CP	NovaLead Pharma Shrewsbury, MA
DMQU4EI	DE	Diabetic foot ulcer

DMN7QBE	ID	DMN7QBE
DMN7QBE	DN	GANTACURIUM CHLORIDE
DMN7QBE	HS	Phase 1/2
DMN7QBE	SN	AV-430A; GW-0430; GW-280430A; Gantacurium chloride; (Z)-2-Chlorofumaric acid 1-[3-[6,7-dimethoxy-2(S)-methyl-1(R)-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinium-2-yl]propyl] 4-[3-[6,7-dimethoxy-2(R)-methyl-1(S)-(3,4,5-trimethoxyphenyl)-1,2,3
DMN7QBE	CP	Avera Pharmaceuticals
DMN7QBE	PC	10772467
DMN7QBE	MW	1064.5
DMN7QBE	FM	C53H69Cl3N2O14
DMN7QBE	IC	InChI=1S/C53H69ClN2O14.2ClH/c1-55(19-15-34-26-41(59-3)43(61-5)30-37(34)40(55)23-33-24-45(63-7)51(67-11)46(25-33)64-8)17-13-22-70-53(58)39(54)32-49(57)69-21-14-18-56(2)20-16-35-27-42(60-4)44(62-6)31-38(35)50(56)36-28-47(65-9)52(68-12)48(29-36)66-10;;/h24-32,40,50H,13-23H2,1-12H3;2*1H/q+2;;/p-2/b39-32-;;/t40-,50+,55-,56+;;/m1../s1
DMN7QBE	CS	C[N@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)/C(=C/C(=O)OCCC[N@+]4(CCC5=CC(=C(C=C5[C@@H]4C6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C)/Cl.[Cl-].[Cl-]
DMN7QBE	IK	SDIFKXLSGXCGEN-WJUBNSBASA-L
DMN7QBE	IU	4-O-[3-[(1S,2R)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] 1-O-[3-[(1R,2S)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (Z)-2-chlorobut-2-enedioate;dichloride
DMN7QBE	CA	CAS 213998-46-0
DMN7QBE	DE	Anaesthesia

DMCT9NG	ID	DMCT9NG
DMCT9NG	DN	GB1275
DMCT9NG	HS	Phase 1/2
DMCT9NG	CP	Gossamer Bio
DMCT9NG	DE	Pancreatic cancer

DM5VF04	ID	DM5VF04
DM5VF04	DN	GD2-CART01
DM5VF04	HS	Phase 1/2
DM5VF04	CP	Bambino Ges&#249; Hospital and Research Institute
DM5VF04	DT	CAR T Cell Therapy
DM5VF04	DE	Neuroblastoma

DM8J0MK	ID	DM8J0MK
DM8J0MK	DN	GEA-6414
DM8J0MK	HS	Phase 1/2
DM8J0MK	SN	Tolfenamic acid; Acide tolfenamique; Acido tolfenamico; Acidum tolfenamicum; Bifenac; Clotam; GEA 6414; Tolfedine; tolfenamic acid; 13710-19-5; 2-(3-Chloro-2-methylanilino)benzoic acid; 2-[(3-Chloro-2-methylphenyl)amino]benzoic Acid; 3G943U18KM; Anthranilic acid, N-(3-chloro-o-tolyl)-; Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]-; CAS-13710-19-5; CHEBI:32243; N-(2-Methyl-3-chlorophenyl)anthranilic acid; N-(3-Chloro-2-methylphenyl)anthranilic acid; N-(3-Chloro-o-tolyl)-anthranilic acid; NCGC00016705-05; UNII-3G943U18KM
DM8J0MK	PC	610479
DM8J0MK	MW	261.7
DM8J0MK	FM	C14H12ClNO2
DM8J0MK	IC	YEZNLOUZAIOMLT-UHFFFAOYSA-N
DM8J0MK	CS	CC1=C(C=CC=C1Cl)NC2=CC=CC=C2C(=O)O
DM8J0MK	IK	1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)
DM8J0MK	IU	2-(3-chloro-2-methylanilino)benzoic acid
DM8J0MK	CA	CAS 13710-19-5
DM8J0MK	CB	CHEBI:32243
DM8J0MK	DE	Parkinsonism

DMD8RLY	ID	DMD8RLY
DMD8RLY	DN	GEN3009
DMD8RLY	HS	Phase 1/2
DMD8RLY	CP	AbbVie; Genmab
DMD8RLY	DT	Antibody
DMD8RLY	DE	B-cell non-hodgkin lymphoma

DMZABYH	ID	DMZABYH
DMZABYH	DN	GEN3013
DMZABYH	HS	Phase 1/2
DMZABYH	DT	Antibody
DMZABYH	DE	Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma

DMY1CP9	ID	DMY1CP9
DMY1CP9	DN	GLG-801
DMY1CP9	HS	Phase 1/2
DMY1CP9	CP	GLG Pharma Jupiter, FL
DMY1CP9	DE	Chronic lymphocytic leukaemia

DM7DWLY	ID	DM7DWLY
DM7DWLY	DN	GLR2007
DM7DWLY	HS	Phase 1/2
DM7DWLY	CP	Gan & Lee Pharmaceuticals
DM7DWLY	DE	Non-small-cell lung cancer; Glioblastoma of brain

DMGN679	ID	DMGN679
DMGN679	DN	GPC3-CART cells
DMGN679	HS	Phase 1/2
DMGN679	CP	Shanghai GeneChem Co., Ltd.
DMGN679	DT	CAR T Cell Therapy
DMGN679	DE	Hepatocellular carcinoma

DM1GE67	ID	DM1GE67
DM1GE67	DN	GS-4224
DM1GE67	HS	Phase 1/2
DM1GE67	SN	Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632
DM1GE67	CP	Gilead Sciences
DM1GE67	DT	Small molecular drug
DM1GE67	PC	12439252
DM1GE67	MW	138.12
DM1GE67	FM	C6H6N2O2
DM1GE67	IC	InChI=1S/C6H6N2O2/c1-10-6(9)5-2-3-7-8-4-5/h2-4H,1H3
DM1GE67	CS	COC(=O)C1=CN=NC=C1
DM1GE67	IK	IJFLWNYKGMQQOW-UHFFFAOYSA-N
DM1GE67	IU	methyl pyridazine-4-carboxylate
DM1GE67	CA	CAS 34231-77-1
DM1GE67	DE	Solid tumour/cancer

DMTJQ8S	ID	DMTJQ8S
DMTJQ8S	DN	GS-9219
DMTJQ8S	HS	Phase 1/2
DMTJQ8S	SN	PMEG prodrug (cancer), Gilead
DMTJQ8S	CP	Gilead Sciences Inc
DMTJQ8S	DT	Small molecular drug
DMTJQ8S	PC	16047979
DMTJQ8S	MW	526.5
DMTJQ8S	FM	C21H35N8O6P
DMTJQ8S	IC	InChI=1S/C21H35N8O6P/c1-5-34-19(30)13(3)27-36(32,28-14(4)20(31)35-6-2)12-33-10-9-29-11-23-16-17(24-15-7-8-15)25-21(22)26-18(16)29/h11,13-15H,5-10,12H2,1-4H3,(H2,27,28,32)(H3,22,24,25,26)/t13-,14-/m0/s1
DMTJQ8S	CS	CCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C(N=C(N=C21)N)NC3CC3)N[C@@H](C)C(=O)OCC
DMTJQ8S	IK	ANSPEDQTHURSFQ-KBPBESRZSA-N
DMTJQ8S	IU	ethyl (2S)-2-[[2-[2-amino-6-(cyclopropylamino)purin-9-yl]ethoxymethyl-[[(2S)-1-ethoxy-1-oxopropan-2-yl]amino]phosphoryl]amino]propanoate
DMTJQ8S	CA	CAS 859209-74-8
DMTJQ8S	DE	Solid tumour/cancer

DM059OH	ID	DM059OH
DM059OH	DN	GSK3145095
DM059OH	HS	Phase 1/2
DM059OH	SN	1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK-3145095; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)
DM059OH	CP	GlaxoSmithKline
DM059OH	DT	Small molecular drug
DM059OH	PC	118557502
DM059OH	MW	397.4
DM059OH	FM	C20H17F2N5O2
DM059OH	IC	InChI=1S/C20H17F2N5O2/c21-13-9-12-6-7-15(19(28)25-17(12)14(22)10-13)23-20(29)18-24-16(26-27-18)8-11-4-2-1-3-5-11/h1-5,9-10,15H,6-8H2,(H,23,29)(H,25,28)(H,24,26,27)/t15-/m0/s1
DM059OH	CS	C1CC2=C(C(=CC(=C2)F)F)NC(=O)[C@H]1NC(=O)C3=NNC(=N3)CC4=CC=CC=C4
DM059OH	IK	ATQAGKAMBISZQM-HNNXBMFYSA-N
DM059OH	IU	5-benzyl-N-[(3S)-7,9-difluoro-2-oxo-1,3,4,5-tetrahydro-1-benzazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide
DM059OH	CA	CAS 1622849-43-7
DM059OH	DE	Pancreatic cancer

DMK2RIB	ID	DMK2RIB
DMK2RIB	DN	GTB-3550
DMK2RIB	HS	Phase 1/2
DMK2RIB	SN	OXS-3550
DMK2RIB	CP	GT Biopharma
DMK2RIB	DT	Recombinant protein
DMK2RIB	DE	Myelodysplastic syndrome; Systemic mastocytosis; Acute myelogenous leukaemia; Mast cell leukaemia

DM0S24D	ID	DM0S24D
DM0S24D	DN	GTU-TB vaccine
DM0S24D	HS	Phase 1/2
DM0S24D	SN	DNA vaccine (Mycobacterium tuberculosis infection), FIT Biotech
DM0S24D	CP	VaxOnco; National Institute of Allergy and Infectious Diseases; National Institutes of Health
DM0S24D	DT	Vaccine
DM0S24D	DE	Mycobacterium infection

DMIFCY2	ID	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	HS	Phase 1/2
DMIFCY2	SN	JPFTZIJTXCHJNE-HMOQVRKWSA-N; SCHEMBL18261010; HY-112596; CS-0047714; (2e)-N,N-dimethyl-4-{[2-({5-[(1z)-4,4,4-trifluoro-1-(3-fluoro-1h-indazol-5-yl)-2-phenylbut-1-en-1-yl]pyridin-2-yl}oxy)ethyl]amino}but-2-enamide
DMIFCY2	CP	EisaiWoodcliff Lake, NJH3 Biomedicine Cambridge, MA
DMIFCY2	PC	124091040
DMIFCY2	MW	567.6
DMIFCY2	FM	C30H29F4N5O2
DMIFCY2	IC	InChI=1S/C30H29F4N5O2/c1-39(2)27(40)9-6-14-35-15-16-41-26-13-11-22(19-36-26)28(21-10-12-25-23(17-21)29(31)38-37-25)24(18-30(32,33)34)20-7-4-3-5-8-20/h3-13,17,19,35H,14-16,18H2,1-2H3,(H,37,38)/b9-6+,28-24-
DMIFCY2	CS	CN(C)C(=O)/C=C/CNCCOC1=NC=C(C=C1)/C(=C(/CC(F)(F)F)\\C2=CC=CC=C2)/C3=CC4=C(NN=C4C=C3)F
DMIFCY2	IK	JPFTZIJTXCHJNE-HMOQVRKWSA-N
DMIFCY2	IU	(E)-N,N-dimethyl-4-[2-[5-[(Z)-4,4,4-trifluoro-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]pyridin-2-yl]oxyethylamino]but-2-enamide
DMIFCY2	DE	Breast cancer

DMQWI7V	ID	DMQWI7V
DMQWI7V	DN	Hematopoietic stem cell gene therapy
DMQWI7V	HS	Phase 1/2
DMQWI7V	SN	Hematopoietic stem cell gene therapy (Wiskott-Aldrich syndrome)
DMQWI7V	CP	Advantagene
DMQWI7V	DE	Wiskott-Aldrich syndrome

DM1U6VX	ID	DM1U6VX
DM1U6VX	DN	HER-2-targeting CAR T Cells
DM1U6VX	HS	Phase 1/2
DM1U6VX	CP	Fuda Cancer Hospital, Guangzhou
DM1U6VX	DT	CAR T Cell Therapy
DM1U6VX	DE	Breast cancer

DM0C5MV	ID	DM0C5MV
DM0C5MV	DN	HH2710
DM0C5MV	HS	Phase 1/2
DM0C5MV	CP	HaiHe Biopharma
DM0C5MV	DE	Solid tumour/cancer

DMJDVCW	ID	DMJDVCW
DMJDVCW	DN	HL-085
DMJDVCW	HS	Phase 1/2
DMJDVCW	CP	Kechow Pharma
DMJDVCW	DE	Melanoma

DMDFG1O	ID	DMDFG1O
DMDFG1O	DN	HLF 1-11
DMDFG1O	HS	Phase 1/2
DMDFG1O	SN	Antimicrobial peptides, AM-Pharma; HLF(1-11); Antimicrobial peptides (bacterial infections), AM-Pharma; Antimicrobial peptides (fungal infections), AM-Pharma; HLF 1-11, AM-Pharma; Human lactoferrin 1-11, AM-Pharma; Human lactoferrin peptides (antibacterial), AM-Pharma
DMDFG1O	CP	Pharming Group NV
DMDFG1O	DT	Peptide
DMDFG1O	DE	Bacterial infection; Bacteremia; Candidemia

DMV1SDA	ID	DMV1SDA
DMV1SDA	DN	HM43239
DMV1SDA	HS	Phase 1/2
DMV1SDA	CP	Hanmi Pharmaceutical
DMV1SDA	DT	Small molecular drug
DMV1SDA	DE	Acute myeloid leukaemia

DM1ZHML	ID	DM1ZHML
DM1ZHML	DN	HPN328
DM1ZHML	HS	Phase 1/2
DM1ZHML	CP	Harpoon Therapeutics
DM1ZHML	DE	Small-cell lung cancer

DM86OJ0	ID	DM86OJ0
DM86OJ0	DN	HPN536
DM86OJ0	HS	Phase 1/2
DM86OJ0	CP	Harpoon Therapeutics
DM86OJ0	DE	Solid tumour/cancer

DMEY1AP	ID	DMEY1AP
DMEY1AP	DN	HSDB-3165
DMEY1AP	HS	Phase 1/2
DMEY1AP	SN	D-Gluconic acid potassium salt; Potassium gluconate; D-Gluconic acid, potassium salt; Gluconic acid potassium salt; Gluconic acid, monopotassium salt; Gluconsan; Gluconsan K; Kalium Gluconate; Kalium-beta; Kaon elixir; Katorin; Monopotassium D-gluconate; Potalium; Potasoral; Potassium D-gluconate; Potassuril; Sirokal; 12H3K5QKN9; 299-27-4; D-Gluconic acid, monopotassium salt; EINECS 206-074-2; HSDB 3165; K-Iao; KOK; Kaon; MFCD00064211; UNII-12H3K5QKN9; potassium (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
DMEY1AP	PC	16760467
DMEY1AP	MW	234.25
DMEY1AP	FM	C6H11KO7
DMEY1AP	IC	HLCFGWHYROZGBI-JJKGCWMISA-M
DMEY1AP	CS	C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[K+]
DMEY1AP	IK	1S/C6H12O7.K/c7-1-2(8)3(9)4(10)5(11)6(12)13;/h2-5,7-11H,1H2,(H,12,13);/q;+1/p-1/t2-,3-,4+,5-;/m1./s1
DMEY1AP	IU	potassium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
DMEY1AP	CA	CAS 299-27-4
DMEY1AP	CB	CHEBI:32032
DMEY1AP	DE	Essential hypertension

DM7C1AJ	ID	DM7C1AJ
DM7C1AJ	DN	HT-2157
DM7C1AJ	HS	Phase 1/2
DM7C1AJ	SN	HT-2157; 303149-14-6; SNAP 37889; UNII-WW4KZW83BX; WW4KZW83BX; HT 2157; CHEMBL210288; SNAP-37889; 1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1h-indol-2-one; 1-phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one; 1-Phenyl-3-((3-(trifluoromethyl)phenyl)imino)-1H-indol-2-one; SNAP37889; AC1LSUW9; UNII-J4DRJ9BFS1; UNII-EH5R4IAX6Q; J4DRJ9BFS1; EH5R4IAX6Q; Bionet1_002696; SCHEMBL916990; SCHEMBL8273294; GTPL6126; HMS576C18; MolPort-002-854-320; BDBM50187923; ZINC100301780; AKOS005078094; SNAP-37889, (E)-; CS-6094; HT-2157(SNAP37889)
DM7C1AJ	CP	Dart NeuroScience
DM7C1AJ	DT	Small molecular drug
DM7C1AJ	PC	1471834
DM7C1AJ	MW	366.3
DM7C1AJ	FM	C21H13F3N2O
DM7C1AJ	IC	InChI=1S/C21H13F3N2O/c22-21(23,24)14-7-6-8-15(13-14)25-19-17-11-4-5-12-18(17)26(20(19)27)16-9-2-1-3-10-16/h1-13H
DM7C1AJ	CS	C1=CC=C(C=C1)N2C3=CC=CC=C3C(=NC4=CC=CC(=C4)C(F)(F)F)C2=O
DM7C1AJ	IK	TXCGMRVPXUBHAL-UHFFFAOYSA-N
DM7C1AJ	IU	1-phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one
DM7C1AJ	CA	CAS 303149-14-6
DM7C1AJ	DE	Cognitive impairment

DMNHE43	ID	DMNHE43
DMNHE43	DN	HTU-PA
DMNHE43	HS	Phase 1/2
DMNHE43	SN	Human tissue urokinase type plasminogen activator, Global Biotech
DMNHE43	CP	Global Biotech Inc
DMNHE43	DE	Cerebrovascular ischaemia

DMIU1HY	ID	DMIU1HY
DMIU1HY	DN	HuM-195-Ac-225
DMIU1HY	HS	Phase 1/2
DMIU1HY	SN	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab
DMIU1HY	CP	PDL BioPharma Inc
DMIU1HY	DE	Acute myeloid leukaemia; Acute myelogenous leukaemia

DMOVF6E	ID	DMOVF6E
DMOVF6E	DN	Humanized CD19 CAR-T cells
DMOVF6E	HS	Phase 1/2
DMOVF6E	CP	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
DMOVF6E	DT	CAR T Cell Therapy
DMOVF6E	DE	Acute lymphoblastic leukaemia

DM7U458	ID	DM7U458
DM7U458	DN	IDX-184
DM7U458	HS	Phase 1/2
DM7U458	SN	B-102; B-184; B-299; IDX-102; Next-generation nucleotide polymerase inhibitors (HCV infection), Idenix; Next-generation nucleotide polymerase inhibitors (hepatitis C virus infection), Idenix; 2'-methyl guanosine prodrug (hepatitis C virus infection), Idenix
DM7U458	CP	Idenix Pharmaceuticals Inc
DM7U458	DT	Small molecular drug
DM7U458	PC	135565589
DM7U458	MW	626.6
DM7U458	FM	C25H35N6O9PS
DM7U458	IC	InChI=1S/C25H35N6O9PS/c1-24(2,13-32)22(35)42-10-9-38-41(37,28-11-15-7-5-4-6-8-15)39-12-16-18(33)25(3,36)21(40-16)31-14-27-17-19(31)29-23(26)30-20(17)34/h4-8,14,16,18,21,32-33,36H,9-13H2,1-3H3,(H,28,37)(H3,26,29,30,34)/t16-,18-,21-,25-,41?/m1/s1
DM7U458	CS	C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(NCC4=CC=CC=C4)OCCSC(=O)C(C)(C)CO)O)O
DM7U458	IK	FGHMGRXAHIXTBM-TWFJNEQDSA-N
DM7U458	IU	S-[2-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl]oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate
DM7U458	CA	CAS 1036915-08-8
DM7U458	DE	Hepatitis C virus infection

DMLEVFW	ID	DMLEVFW
DMLEVFW	DN	IFN alpha kinoid
DMLEVFW	HS	Phase 1/2
DMLEVFW	SN	Antiferon; IFNa kinoid; IFN-K; Inactivated IFN alpha + keyhole limpet hemocyanin (SLE/HIV), Neovacs; Anti-interferonalpha (HIV/SLE), Neovacs/sanofi pasteur
DMLEVFW	CP	Neovacs SA
DMLEVFW	DE	Human immunodeficiency virus infection

DM1CG47	ID	DM1CG47
DM1CG47	DN	IL-2 XL
DM1CG47	HS	Phase 1/2
DM1CG47	SN	IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel
DM1CG47	CP	Flamel Technologies SA
DM1CG47	DE	Renal cell carcinoma

DMJ9CY4	ID	DMJ9CY4
DMJ9CY4	DN	IL-2/gene-modified lymphocytes
DMJ9CY4	HS	Phase 1/2
DMJ9CY4	CP	National Cancer Institute
DMJ9CY4	DE	Ovarian cancer

DMKV5D6	ID	DMKV5D6
DMKV5D6	DN	IM19 CAR-T
DMKV5D6	HS	Phase 1/2
DMKV5D6	CP	Beijing Immunochina Medical Science &amp; Technology Co., Ltd.
DMKV5D6	DT	CAR T Cell Therapy
DMKV5D6	DE	leukaemia

DMHQ2U8	ID	DMHQ2U8
DMHQ2U8	DN	IMC-F106C
DMHQ2U8	HS	Phase 1/2
DMHQ2U8	CP	Immunocore
DMHQ2U8	DT	Recombinant protein
DMHQ2U8	DE	Solid tumour/cancer

DM09JOZ	ID	DM09JOZ
DM09JOZ	DN	ImMucin
DM09JOZ	HS	Phase 1/2
DM09JOZ	SN	MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/Hadassah Medical
DM09JOZ	CP	Hadassah Medical Organization
DM09JOZ	DT	Vaccine
DM09JOZ	DE	Multiple myeloma

DM18ZLW	ID	DM18ZLW
DM18ZLW	DN	IMP-321
DM18ZLW	HS	Phase 1/2
DM18ZLW	SN	Soluble CD223 (cancer), Immutep; Soluble LAG-3 (cancer), Immutep
DM18ZLW	CP	Immutep SA
DM18ZLW	PC	72941955
DM18ZLW	MW	1259.4
DM18ZLW	FM	C56H78N18O14S
DM18ZLW	IC	InChI=1S/C56H78N18O14S/c57-23-3-1-6-41(70-55(88)43(27-34-7-13-39(75)14-8-34)72-52(85)35-9-11-36(12-10-35)68-56(89)73-59)53(86)71-42(15-20-50(82)83)54(87)69-40(51(58)84)5-2-4-26-74(48(80)30-64-46(78)18-16-44(76)62-24-21-37-28-60-32-66-37)49(81)31-65-47(79)19-17-45(77)63-25-22-38-29-61-33-67-38/h7-14,28-29,32-33,40-43,75H,1-6,15-27,30-31,57,59H2,(H2,58,84)(H,60,66)(H,61,67)(H,62,76)(H,63,77)(H,64,78)(H,65,79)(H,69,87)(H,70,88)(H,71,86)(H,72,85)(H,82,83)(H2,68,73,89)/t40-,41-,42-,43-/m1/s1
DM18ZLW	CS	C1=CC(=CC=C1C[C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCCN(C(=O)CNC(=O)CCC(=O)NCCC2=CN=CN2)C(=O)CNC(=O)CCC(=O)NCCC3=CN=CN3)C(=O)N)NC(=O)C4=CC=C(C=C4)NC(=S)NN)O
DM18ZLW	IK	ONKCBKDTKZIWHZ-MRWFHJSOSA-N
DM18ZLW	IU	(4R)-4-[[(2R)-6-amino-2-[[(2R)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2R)-1-amino-6-[bis[2-[[4-[2-(1H-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DM18ZLW	CA	CAS 928150-91-8
DM18ZLW	DE	Allergy

DM43ICH	ID	DM43ICH
DM43ICH	DN	IMSA101
DM43ICH	HS	Phase 1/2
DM43ICH	CP	ImmuneSensor Therapeutics
DM43ICH	DT	Small molecular drug
DM43ICH	DE	Solid tumour/cancer

DMNHZS4	ID	DMNHZS4
DMNHZS4	DN	IMX-110
DMNHZS4	HS	Phase 1/2
DMNHZS4	CP	Immix Biopharma Los Angeles, CA
DMNHZS4	DE	Solid tumour/cancer

DM8XN4A	ID	DM8XN4A
DM8XN4A	DN	INCAGN1876
DM8XN4A	HS	Phase 1/2
DM8XN4A	CP	Agenus Lexington, MA Incyte Wilmington, DE
DM8XN4A	DE	Solid tumour/cancer

DM7OE3X	ID	DM7OE3X
DM7OE3X	DN	INCAGN1949
DM7OE3X	HS	Phase 1/2
DM7OE3X	CP	Agenus Lexington, MA Incyte Wilmington, DE
DM7OE3X	DE	Solid tumour/cancer

DM8124R	ID	DM8124R
DM8124R	DN	INCB01158
DM8124R	HS	Phase 1/2
DM8124R	SN	CB-1158
DM8124R	CP	Calithera Biosciences; Incyte
DM8124R	DE	Solid tumour/cancer

DM7TZL0	ID	DM7TZL0
DM7TZL0	DN	INCB054329
DM7TZL0	HS	Phase 1/2
DM7TZL0	SN	1628607-64-6; (S)-6-(3,5-dimethylisoxazol-4-yl)-3-(pyridin-2-yl)-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylen-2(1H)-one; Q50825078; SCHEMBL16038298; INCB54329; US9624241, Example 14; BDBM318469; INCB-54329; EX-A3126; INCB-054329; NSC816024; s8753; NSC-816024; HY-112504; CS-0046160; INCB054329 pound INCB-054329,INCB-54329 pound(c); CC1=NOC(C)=C1C1=CC=C2C3=C1OC[C@H](C=1N=CC=CC=1)N3C(=O)N2; (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one
DM7TZL0	CP	Incyte
DM7TZL0	DT	Small molecular drug
DM7TZL0	PC	90410660
DM7TZL0	MW	348.4
DM7TZL0	FM	C19H16N4O3
DM7TZL0	IC	InChI=1S/C19H16N4O3/c1-10-16(11(2)26-22-10)12-6-7-14-17-18(12)25-9-15(23(17)19(24)21-14)13-5-3-4-8-20-13/h3-8,15H,9H2,1-2H3,(H,21,24)/t15-/m1/s1
DM7TZL0	CS	CC1=C(C(=NO1)C)C2=C3C4=C(C=C2)NC(=O)N4[C@H](CO3)C5=CC=CC=N5
DM7TZL0	IK	XYLPKCDRAAYATL-OAHLLOKOSA-N
DM7TZL0	IU	(11S)-7-(3,5-dimethyl-1,2-oxazol-4-yl)-11-pyridin-2-yl-9-oxa-1,3-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-2-one
DM7TZL0	DE	Solid tumour/cancer; Refractory hematologic malignancy

DMG65CV	ID	DMG65CV
DMG65CV	DN	INCB057643
DMG65CV	HS	Phase 1/2
DMG65CV	SN	INCB-057643; 1820889-23-3; UNII-87TZD0JEBS; 87TZD0JEBS; 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one; 2,2,4-Trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo(2,3-C)pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo(b)(1,4)oxazin-3(4H)-one; CHEMBL4594412; SCHEMBL17200525; US9957268, Example 75; BDBM391587; BCP29506; EX-A1908; NSC807398; s8714; NSC-807398; BS-16298; HY-111485; AK00799038; CS-0042192; INCB057643; INCB 057643; CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C; 2,2,4-trimethyl-8-(6-methyl-7- oxo-6,7-dihydro-1H- pyrrolo[2,3-c]pyridin-4-yl)-6- (methylsulfonyl)-2H-1,4- benzoxazin-3(4H)-one; 2H-1,4-Benzoxazin-3(4H)-one, 8-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo(2,3-C)pyridin-4-yl)-2,2,4-trimethyl-6-(methylsulfonyl)-
DMG65CV	CP	Incyte
DMG65CV	DT	Small molecular drug
DMG65CV	PC	118467751
DMG65CV	MW	415.5
DMG65CV	FM	C20H21N3O5S
DMG65CV	IC	InChI=1S/C20H21N3O5S/c1-20(2)19(25)23(4)15-9-11(29(5,26)27)8-13(17(15)28-20)14-10-22(3)18(24)16-12(14)6-7-21-16/h6-10,21H,1-5H3
DMG65CV	CS	CC1(C(=O)N(C2=CC(=CC(=C2O1)C3=CN(C(=O)C4=C3C=CN4)C)S(=O)(=O)C)C)C
DMG65CV	IK	VZSAMEOETVNDQH-UHFFFAOYSA-N
DMG65CV	IU	2,2,4-trimethyl-8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-methylsulfonyl-1,4-benzoxazin-3-one
DMG65CV	CA	CAS 1820889-23-3
DMG65CV	DE	Solid tumour/cancer

DMED9QV	ID	DMED9QV
DMED9QV	DN	INCB40093
DMED9QV	HS	Phase 1/2
DMED9QV	SN	Dezapelisib; 1262440-25-4; UNII-2K59L7G59M; CHEMBL2216863; INCB040093; 2K59L7G59M; Dezapelisib (USAN); Dezapelisib [USAN]; (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; SCHEMBL975754; GTPL9728; INCB40093; RSIWALKZYXPAGW-NSHDSACASA-N; INCB 40093; BDBM50004547; SB18837; example 15 [WO2011008487]; compound 67 [PMID: 22924688]; D10924; 6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-(7H-purin-6-ylamino)ethyl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one; 6-(3-fluorophenyl)-3-methyl-7-((1S)-1-(9
DMED9QV	CP	Incyte
DMED9QV	DT	Small molecular drug
DMED9QV	PC	58111426
DMED9QV	MW	421.5
DMED9QV	FM	C20H16FN7OS
DMED9QV	IC	InChI=1S/C20H16FN7OS/c1-10-7-30-20-27-15(11(2)26-18-16-17(23-8-22-16)24-9-25-18)14(19(29)28(10)20)12-4-3-5-13(21)6-12/h3-9,11H,1-2H3,(H2,22,23,24,25,26)/t11-/m0/s1
DMED9QV	CS	CC1=CSC2=NC(=C(C(=O)N12)C3=CC(=CC=C3)F)[C@H](C)NC4=NC=NC5=C4NC=N5
DMED9QV	IK	RSIWALKZYXPAGW-NSHDSACASA-N
DMED9QV	IU	6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-(7H-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one
DMED9QV	CA	CAS 1262440-25-4
DMED9QV	DE	Lymphoma

DMKMSP2	ID	DMKMSP2
DMKMSP2	DN	INCB53914
DMKMSP2	HS	Phase 1/2
DMKMSP2	CP	Incyte Wilmington, DE
DMKMSP2	DE	Advanced malignancy

DMBGU7V	ID	DMBGU7V
DMBGU7V	DN	INCB57643
DMBGU7V	HS	Phase 1/2
DMBGU7V	CP	Incyte Wilmington, DE
DMBGU7V	DE	Advanced malignancy

DMRLV7G	ID	DMRLV7G
DMRLV7G	DN	INCB59872
DMRLV7G	HS	Phase 1/2
DMRLV7G	CP	IncyteWilmington, DE
DMRLV7G	DE	Acute myeloid leukaemia; Small-cell lung cancer

DMQO5UF	ID	DMQO5UF
DMQO5UF	DN	INCB62079
DMQO5UF	HS	Phase 1/2
DMQO5UF	CP	Incyte Wilmington, DE
DMQO5UF	DE	Liver cancer

DMKNA94	ID	DMKNA94
DMKNA94	DN	INO-8875
DMKNA94	HS	Phase 1/2
DMKNA94	SN	PJ-875; Adenosine A1 agonist (atrial fibrillation), Inotek; Adenosine A1 agonist (glaucoma), Inotek
DMKNA94	CP	Inotek pharmaceuticals
DMKNA94	PC	11610599
DMKNA94	MW	380.36
DMKNA94	FM	C15H20N6O6
DMKNA94	IC	InChI=1S/C15H20N6O6/c22-11-9(5-26-21(24)25)27-15(12(11)23)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,22-23H,1-5H2,(H,16,17,19)/t9-,11-,12-,15-/m1/s1
DMKNA94	CS	C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO[N+](=O)[O-])O)O
DMKNA94	IK	AQLVRTWKJDTWQQ-SDBHATRESA-N
DMKNA94	IU	[(2R,3S,4R,5R)-5-[6-(cyclopentylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl nitrate
DMKNA94	CA	CAS 871108-05-3
DMKNA94	DE	Glaucoma/ocular hypertension

DMMZSIB	ID	DMMZSIB
DMMZSIB	DN	Interferon alpha 5
DMMZSIB	HS	Phase 1/2
DMMZSIB	SN	Interferon alpha 5 (infection)
DMMZSIB	CP	Biotecnol SA
DMMZSIB	DE	Infectious disease

DM9PJZT	ID	DM9PJZT
DM9PJZT	DN	Ipamorelin
DM9PJZT	HS	Phase 1/2
DM9PJZT	SN	Ipamorelin [INN]; SCHEMBL18428173; DTXSID80168955; CI-304; 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide; 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide.; (2S)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(4H-imidazol-4-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; 2-methylalanyl-L-histidyl-3-naphthalen-2-yl-D-alanyl-D-phenylalanyl-L-lysinamide, 2-Methylalanyl-L-histidyl-3-(2-naph
DM9PJZT	CP	Sapphire therapeutics
DM9PJZT	DT	Small molecular drug
DM9PJZT	PC	9831659
DM9PJZT	MW	711.9
DM9PJZT	FM	C38H49N9O5
DM9PJZT	IC	InChI=1S/C38H49N9O5/c1-38(2,41)37(52)47-32(21-28-22-42-23-43-28)36(51)46-31(20-25-15-16-26-12-6-7-13-27(26)18-25)35(50)45-30(19-24-10-4-3-5-11-24)34(49)44-29(33(40)48)14-8-9-17-39/h3-7,10-13,15-16,18,22-23,29-32H,8-9,14,17,19-21,39,41H2,1-2H3,(H2,40,48)(H,42,43)(H,44,49)(H,45,50)(H,46,51)(H,47,52)/t29-,30+,31+,32-/m0/s1
DM9PJZT	CS	CC(C)(C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N)N
DM9PJZT	IK	NEHWBYHLYZGBNO-BVEPWEIPSA-N
DM9PJZT	IU	(2S)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
DM9PJZT	CA	CAS 170851-70-4
DM9PJZT	DE	Postoperative ileus

DM8E3N6	ID	DM8E3N6
DM8E3N6	DN	IPP-204106
DM8E3N6	HS	Phase 1/2
DM8E3N6	SN	NucAnt 6L; N-6-L; Nucleolin antagonist (cancer), ImmuPharma; Nucleolin antagonist (cancer), ImmuPharma/CNRS; Nucleolin antagonist (cancer), ImmuPharma/Centre National de la Recherche Scientifique
DM8E3N6	CP	Centre National de la Recherche Scientifique (CNRS)
DM8E3N6	DE	Solid tumour/cancer

DMQ5EYJ	ID	DMQ5EYJ
DMQ5EYJ	DN	ISA-P53-01
DMQ5EYJ	HS	Phase 1/2
DMQ5EYJ	SN	P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals
DMQ5EYJ	CP	ISA Pharmaceuticals BV
DMQ5EYJ	DT	Vaccine
DMQ5EYJ	DE	Colorectal cancer

DM1WD8F	ID	DM1WD8F
DM1WD8F	DN	ISB 1302
DM1WD8F	HS	Phase 1/2
DM1WD8F	CP	Ichnos Sciences
DM1WD8F	DT	Antibody
DM1WD8F	DE	HER2-positive breast cancer

DMG107N	ID	DMG107N
DMG107N	DN	ISB 1342
DMG107N	HS	Phase 1/2
DMG107N	SN	GBR1342
DMG107N	CP	Ichnos Sciences
DMG107N	DT	Antibody
DMG107N	DE	Multiple myeloma

DMH32LC	ID	DMH32LC
DMH32LC	DN	ISIS-DMPK
DMH32LC	HS	Phase 1/2
DMH32LC	DT	Antisense drug
DMH32LC	DE	Myotonic dystrophy

DMDTNFB	ID	DMDTNFB
DMDTNFB	DN	ISIS-STAT3
DMDTNFB	HS	Phase 1/2
DMDTNFB	CP	ISIS Pharm
DMDTNFB	DT	Antisense drug
DMDTNFB	DE	Solid tumour/cancer

DMA41DO	ID	DMA41DO
DMA41DO	DN	Isunakinra
DMA41DO	HS	Phase 1/2
DMA41DO	SN	EBI-005
DMA41DO	CP	Buzzard Pharmaceuticals
DMA41DO	DT	Recombinant protein
DMA41DO	DE	Solid tumour/cancer

DM08TH3	ID	DM08TH3
DM08TH3	DN	ITI-214
DM08TH3	HS	Phase 1/2
DM08TH3	CP	Intra-Cellular; Takeda
DM08TH3	PC	42639643
DM08TH3	MW	507.6
DM08TH3	FM	C29H26FN7O
DM08TH3	IC	InChI=1S/C29H26FN7O/c1-35-28(38)25-26(31-20-7-3-2-4-8-20)36(34-27(25)37-23-11-5-10-22(23)33-29(35)37)17-18-13-15-19(16-14-18)21-9-6-12-24(30)32-21/h2-4,6-9,12-16,22-23,31H,5,10-11,17H2,1H3/t22-,23+/m1/s1
DM08TH3	CS	CN1C(=O)C2=C(N(N=C2N3C1=N[C@H]4[C@@H]3CCC4)CC5=CC=C(C=C5)C6=NC(=CC=C6)F)NC7=CC=CC=C7
DM08TH3	IK	BBIPVJCGIASXJB-PKTZIBPZSA-N
DM08TH3	IU	(11R,15S)-5-anilino-4-[[4-(6-fluoropyridin-2-yl)phenyl]methyl]-8-methyl-1,3,4,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one
DM08TH3	CA	CAS 1160521-50-5
DM08TH3	DE	Schizophrenia; Complete androgen insensitivity syndrome; Immune dysregulation; Parkinson disease

DM3KXMG	ID	DM3KXMG
DM3KXMG	DN	IZONSTERIDE
DM3KXMG	HS	Phase 1/2
DM3KXMG	SN	Izonsteride < Prop INN; LY-320236; (4aR,10bR)-8-(4-Ethylbenzothiazol-2-ylsulfanyl)-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one
DM3KXMG	DT	Small molecular drug
DM3KXMG	PC	172988
DM3KXMG	MW	422.6
DM3KXMG	FM	C24H26N2OS2
DM3KXMG	IC	InChI=1S/C24H26N2OS2/c1-4-15-6-5-7-19-22(15)25-23(29-19)28-17-9-10-18-16(14-17)8-11-20-24(18,2)13-12-21(27)26(20)3/h5-7,9-10,14,20H,4,8,11-13H2,1-3H3/t20-,24-/m1/s1
DM3KXMG	CS	CCC1=C2C(=CC=C1)SC(=N2)SC3=CC4=C(C=C3)[C@]5(CCC(=O)N([C@@H]5CC4)C)C
DM3KXMG	IK	VMGWGDPZHXPFTC-HYBUGGRVSA-N
DM3KXMG	IU	(4aR,10bR)-8-[(4-ethyl-1,3-benzothiazol-2-yl)sulfanyl]-4,10b-dimethyl-2,4a,5,6-tetrahydro-1H-benzo[f]quinolin-3-one
DM3KXMG	CA	CAS 176975-26-1
DM3KXMG	DE	Hirsutism

DMNMV0D	ID	DMNMV0D
DMNMV0D	DN	JAB-3312
DMNMV0D	HS	Phase 1/2
DMNMV0D	CP	AbbVie; Jacobio Pharmaceuticals
DMNMV0D	DT	Small molecular drug
DMNMV0D	DE	Solid tumour/cancer

DMTMVEW	ID	DMTMVEW
DMTMVEW	DN	JCAR014
DMTMVEW	HS	Phase 1/2
DMTMVEW	CP	Fred Hutchinson Cancer Research Center
DMTMVEW	DT	CAR T Cell Therapy
DMTMVEW	DE	B-cell lymphoma; Mediastinal large B-cell lymphoma; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma; B-cell non-hodgkin lymphoma

DMJV2IF	ID	DMJV2IF
DMJV2IF	DN	JCAR017
DMJV2IF	HS	Phase 1/2
DMJV2IF	CP	Juno Therapeutics, Inc.
DMJV2IF	DT	CAR T Cell Therapy
DMJV2IF	DE	Mantle cell lymphoma; Non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Multiple myeloma; Follicular lymphoma; Primary mediastinal B-cell lymphoma; leukaemia; B-cell non-hodgkin lymphoma

DM8P7FC	ID	DM8P7FC
DM8P7FC	DN	JCARH125
DM8P7FC	HS	Phase 1/2
DM8P7FC	CP	Juno Therapeutics, Inc.
DM8P7FC	DT	CAR T Cell Therapy
DM8P7FC	DE	Multiple myeloma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle cell lymphoma; Non-hodgkin lymphoma

DMD9X6U	ID	DMD9X6U
DMD9X6U	DN	JNJ-68284528
DMD9X6U	HS	Phase 1/2
DMD9X6U	CP	Janssen Research &amp; Development, LLC
DMD9X6U	DT	CAR T Cell Therapy
DMD9X6U	DE	Multiple myeloma

DMGEZVF	ID	DMGEZVF
DMGEZVF	DN	JS016
DMGEZVF	HS	Phase 1/2
DMGEZVF	SN	LY-CoV016
DMGEZVF	CP	Lilly; Junshi Biosciences
DMGEZVF	DT	Antibody
DMGEZVF	DE	Coronavirus Disease 2019 (COVID-19)

DMELJDI	ID	DMELJDI
DMELJDI	DN	KAI-9803
DMELJDI	HS	Phase 1/2
DMELJDI	SN	DELCASERTIB; UNII-5G7N7E908H; 5G7N7E908H; KAI-9803; BMS-875944; Delcasertib [USAN:INN]; 949100-39-4; HY-106262; CS-0025460; L-Arginine, L-cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-, (1-&gt;1')-disulfide with L-cysteinyl-L-seryl-L-phenylalanyl-L- asparaginyl-L-seryl-L-tyrosyl-L-alpha-glutamyl-L-leucylglycyl-L-seryl-L-leucine; L-Cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L- arginyl-L-arginyl-L-arginine (1-&gt;1')-d
DMELJDI	CP	KAI Pharma.
DMELJDI	DT	Small molecular drug
DMELJDI	PC	56843747
DMELJDI	MW	2880.3
DMELJDI	FM	C120H199N45O34S2
DMELJDI	IC	InChI=1S/C120H199N45O34S2/c1-61(2)48-80(96(179)145-55-92(174)148-86(56-166)110(193)163-85(114(198)199)49-62(3)4)159-106(189)78(37-39-93(175)176)156-107(190)83(52-65-30-34-67(170)35-31-65)161-112(195)88(58-168)165-109(192)84(53-90(126)172)162-108(191)82(50-63-18-6-5-7-19-63)160-111(194)87(57-167)164-95(178)69(124)60-201-200-59-68(123)94(177)158-81(51-64-28-32-66(169)33-29-64)97(180)146-54-91(173)147-70(22-12-42-139-115(127)128)98(181)149-71(20-8-10-40-121)99(182)150-72(21-9-11-41-122)100(183)151-73(23-13-43-140-116(129)130)101(184)152-75(25-15-45-142-118(133)134)103(186)155-77(36-38-89(125)171)105(188)154-74(24-14-44-141-117(131)132)102(185)153-76(26-16-46-143-119(135)136)104(187)157-79(113(196)197)27-17-47-144-120(137)138/h5-7,18-19,28-35,61-62,68-88,166-170H,8-17,20-27,36-60,121-124H2,1-4H3,(H2,125,171)(H2,126,172)(H,145,179)(H,146,180)(H,147,173)(H,148,174)(H,149,181)(H,150,182)(H,151,183)(H,152,184)(H,153,185)(H,154,188)(H,155,186)(H,156,190)(H,157,187)(H,158,177)(H,159,189)(H,160,194)(H,161,195)(H,162,191)(H,163,193)(H,164,178)(H,165,192)(H,175,176)(H,196,197)(H,198,199)(H4,127,128,139)(H4,129,130,140)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)/t68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-/m0/s1
DMELJDI	CS	CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)N)N
DMELJDI	IK	XPXZTVWPRKJTAA-PJKOMPQUSA-N
DMELJDI	IU	(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-[[(2R)-2-amino-3-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoic acid
DMELJDI	CA	CAS 949100-39-4
DMELJDI	DE	Acute myocardial infarction

DM5U3IF	ID	DM5U3IF
DM5U3IF	DN	KB-004
DM5U3IF	HS	Phase 1/2
DM5U3IF	SN	Anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios
DM5U3IF	CP	KaloBios Pharmaceuticals Inc
DM5U3IF	DT	Antibody
DM5U3IF	DE	Haematological malignancy

DMI9FXE	ID	DMI9FXE
DMI9FXE	DN	KBP-5074
DMI9FXE	HS	Phase 1/2
DMI9FXE	CP	KBP Biosciences Princeton, NJ
DMI9FXE	PC	137796979
DMI9FXE	MW	504
DMI9FXE	FM	C28H30ClN5O2
DMI9FXE	IC	InChI=1S/C28H30ClN5O2/c29-23-15-19(6-5-18(23)16-30)34-27(17-3-1-2-4-17)22-8-9-24-21(26(22)32-34)7-10-25(31-24)28(36)33-13-11-20(35)12-14-33/h5-7,10,15,17,20,22,27,35H,1-4,8-9,11-14H2/t22-,27+/m1/s1
DMI9FXE	CS	C1CCC(C1)[C@H]2[C@@H]3CCC4=C(C3=NN2C5=CC(=C(C=C5)C#N)Cl)C=CC(=N4)C(=O)N6CCC(CC6)O
DMI9FXE	IK	UXHQLGLGLZKHTC-AMGIVPHBSA-N
DMI9FXE	IU	4-[(3S,3aS)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile
DMI9FXE	DE	Hypertension

DMZ416B	ID	DMZ416B
DMZ416B	DN	KD020
DMZ416B	HS	Phase 1/2
DMZ416B	CP	Kadmon pharmaceuticals
DMZ416B	DE	Kidney disease

DM0NZYC	ID	DM0NZYC
DM0NZYC	DN	KO-539
DM0NZYC	HS	Phase 1/2
DM0NZYC	SN	UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6
DM0NZYC	CP	Kura Oncology
DM0NZYC	DT	Small molecular drug
DM0NZYC	PC	138497449
DM0NZYC	MW	717.9
DM0NZYC	FM	C33H42F3N9O2S2
DM0NZYC	IC	InChI=1S/C33H42F3N9O2S2/c1-21(43-11-13-44(14-12-43)49(4,46)47)19-45-25(18-37)15-27-22(2)23(5-6-29(27)45)20-42-9-7-24(8-10-42)39-30-28-16-26(17-33(34,35)36)48-31(28)41-32(38-3)40-30/h5-6,15-16,21,24H,7-14,17,19-20H2,1-4H3,(H2,38,39,40,41)/t21-/m0/s1
DM0NZYC	CS	CC1=C(C=CC2=C1C=C(N2C[C@H](C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F
DM0NZYC	IK	BGGALFIXXQOTPY-NRFANRHFSA-N
DM0NZYC	IU	4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile
DM0NZYC	CA	CAS 2134675-36-6
DM0NZYC	DE	Acute myeloid leukaemia

DML29RF	ID	DML29RF
DML29RF	DN	KP-100
DML29RF	HS	Phase 1/2
DML29RF	CP	Kinetek Pharmaceuticals Inc
DML29RF	DE	Type-1 diabetes

DMA5B1S	ID	DMA5B1S
DMA5B1S	DN	KRN-330
DMA5B1S	HS	Phase 1/2
DMA5B1S	CP	Kyowa Hakko Kirin Pharma
DMA5B1S	DT	Antibody
DMA5B1S	DE	Colorectal cancer

DME8JW1	ID	DME8JW1
DME8JW1	DN	KTE-C19 CAR
DME8JW1	HS	Phase 1/2
DME8JW1	CP	Kite pharma santa monica; national cancer institute
DME8JW1	DE	Diffuse large B-cell lymphoma

DMXJ683	ID	DMXJ683
DMXJ683	DN	KY1044
DMXJ683	HS	Phase 1/2
DMXJ683	CP	Kymab
DMXJ683	DT	Antibody
DMXJ683	DE	Solid tumour/cancer

DMBEQ08	ID	DMBEQ08
DMBEQ08	DN	L-377202
DMBEQ08	HS	Phase 1/2
DMBEQ08	SN	N-[N-(4-Carboxybutyryl)-4(R)-hydroxy-L-prolyl-L-alanyl-L-seryl-L-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl]doxorubicin
DMBEQ08	DT	Small molecular drug
DMBEQ08	PC	56842144
DMBEQ08	MW	1396.4
DMBEQ08	FM	C65H89N9O25
DMBEQ08	IC	InChI=1S/C65H89N9O25/c1-28(2)19-37(60(91)69-36-21-47(98-30(4)53(36)84)99-42-23-65(96,43(79)27-77)22-34-49(42)57(88)51-50(55(34)86)54(85)33-13-9-14-41(97-5)48(33)56(51)87)70-61(92)38(25-75)72-59(90)35(17-18-44(66)80)68-64(95)52(31-11-7-6-8-12-31)73-62(93)39(26-76)71-58(89)29(3)67-63(94)40-20-32(78)24-74(40)45(81)15-10-16-46(82)83/h9,13-14,28-32,35-40,42,47,52-53,75-78,84,86,88,96H,6-8,10-12,15-27H2,1-5H3,(H2,66,80)(H,67,94)(H,68,95)(H,69,91)(H,70,92)(H,71,89)(H,72,90)(H,73,93)(H,82,83)/t29-,30-,32?,35-,36-,37-,38-,39-,40-,42-,47-,52-,53+,65-/m0/s1
DMBEQ08	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C6CCCCC6)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H]7CC(CN7C(=O)CCCC(=O)O)O)O
DMBEQ08	IK	CZXGBIFEWYVYJY-ATFCTERFSA-N
DMBEQ08	IU	5-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-2-[[(2S)-5-amino-1-[[(2S)-3-hydroxy-1-[[(2S)-1-[[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-cyclohexyl-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-4-hydroxypyrrolidin-1-yl]-5-oxopentanoic acid
DMBEQ08	DE	Solid tumour/cancer

DMFHV9L	ID	DMFHV9L
DMFHV9L	DN	Leber's congenital amaurosis gene therapy
DMFHV9L	HS	Phase 1/2
DMFHV9L	SN	LCA gene therapy, Applied Genetic Technologies; Leber's congenital amaurosis gene therapy, Applied Genetic Technologies; RAAV2-CB-hRPE65
DMFHV9L	CP	Applied Genetic Technologies Corp
DMFHV9L	DE	Visual disturbance; Leber congenital amaurosis

DMQN9ME	ID	DMQN9ME
DMQN9ME	DN	LGH-447
DMQN9ME	HS	Phase 1/2
DMQN9ME	CP	Novartis
DMQN9ME	PC	44814409
DMQN9ME	MW	440.5
DMQN9ME	FM	C24H23F3N4O
DMQN9ME	IC	InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1
DMQN9ME	CS	C[C@H]1C[C@H](C[C@H](C1)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=CC=C4F)F
DMQN9ME	IK	VRQXRVAKPDCRCI-ZNMIVQPWSA-N
DMQN9ME	IU	N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide
DMQN9ME	CA	CAS 1210608-43-7
DMQN9ME	DE	Multiple myeloma

DMENF5K	ID	DMENF5K
DMENF5K	DN	Liatermin
DMENF5K	HS	Phase 1/2
DMENF5K	SN	RGDNF; GDNF, Amgen; Glial derived neurotrophic factor, Amgen/Medtronic
DMENF5K	CP	Amgen Inc
DMENF5K	DE	Lateral sclerosis

DMEMRW0	ID	DMEMRW0
DMEMRW0	DN	Lipoteichoic acid
DMEMRW0	HS	Phase 1/2
DMEMRW0	SN	Oncomycin; Lipoteichoic acid (cancer); Lipoteichoic acid (cancer), Lunamed; TLR-2 modulator (subcutaneous, solid tumor), LUNAMeD; Toll like receptor-2 modulator (subcutaneous, solid tumor), LUNAMeD
DMEMRW0	CP	Lunamed Operations AG
DMEMRW0	PC	137349712
DMEMRW0	MW	775
DMEMRW0	FM	C39H70N2O13
DMEMRW0	IC	InChI=1S/C39H70N2O13/c1-5-7-9-11-12-13-14-15-16-17-18-20-22-31(45)52-28(24-49-30(44)21-19-10-8-6-2)25-50-39-36(48)37(34(46)29(23-42)53-39)54-38-33(41-27(4)43)35(47)32(40)26(3)51-38/h14-15,26,28-29,32-39,42,46-48H,5-13,16-25,40H2,1-4H3,(H,41,43)/b15-14+/t26-,28-,29-,32+,33-,34-,35+,36-,37+,38+,39+/m1/s1
DMEMRW0	CS	CCCCCCC/C=C/CCCCCC(=O)O[C@@H](CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)C)N)O)NC(=O)C)O)COC(=O)CCCCCC
DMEMRW0	IK	PANDRCFROUDETH-YLSOAJEOSA-N
DMEMRW0	IU	[(2S)-1-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3-acetamido-5-amino-4-hydroxy-6-methyloxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-heptanoyloxypropan-2-yl] (E)-pentadec-7-enoate
DMEMRW0	CA	CAS 56411-57-5
DMEMRW0	DE	Solid tumour/cancer

DMGTB5N	ID	DMGTB5N
DMGTB5N	DN	LJM716
DMGTB5N	HS	Phase 1/2
DMGTB5N	CP	Novartis pharmaceuticals
DMGTB5N	DT	Antibody
DMGTB5N	DE	Breast cancer

DM095HQ	ID	DM095HQ
DM095HQ	DN	LM11A-31
DM095HQ	HS	Phase 1/2
DM095HQ	SN	N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide
DM095HQ	CP	PharmatrophiX Menlo Park, CA
DM095HQ	DT	Small molecular drug
DM095HQ	PC	18604758
DM095HQ	MW	243.35
DM095HQ	FM	C12H25N3O2
DM095HQ	IC	InChI=1S/C12H25N3O2/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15/h10-11H,3-9,13H2,1-2H3,(H,14,16)/t10-,11-/m0/s1
DM095HQ	CS	CC[C@H](C)[C@@H](C(=O)NCCN1CCOCC1)N
DM095HQ	IK	YNMUTYLWSRFTPX-QWRGUYRKSA-N
DM095HQ	IU	(2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide
DM095HQ	CA	CAS 1243259-19-9
DM095HQ	DE	Alzheimer disease

DMCJ10K	ID	DMCJ10K
DMCJ10K	DN	LM11A-31
DMCJ10K	HS	Phase 1/2
DMCJ10K	DE	Alzheimer disease

DMW3QGJ	ID	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	HS	Phase 1/2
DMW3QGJ	SN	Bilcolic; Bilicante; Hymecromone; Cantabilin; Cantabiline; Cholestil; Cholonerton; Coumarin 4; Crodimon; Cumarote-C; Eurogale; Himecromona; Hymecromon; Hymecromonum; Imecromone; Imecromone [DCIT]; Medilla; Mendiaxon; Omega 127; Pilot 447; Resocyanine; beta-Methylumbelliferone; 2H-1-Benzopyran-2-one, 7-hydroxy-4-methyl-; 4-MU; 4-Methyl-7-hydroxycoumarin; 4-Methylumbelliferon; 4-methylumbelliferone; 7-HYDROXY-4-METHYLCOUMARIN; 7-Hydroxy-4-methyl-2-oxo-2H-1-benzopyran; 7-Hydroxy-4-methyl-2H-chromen-2-one; 90-33-5; LM 94; NSC 19026; NSC 9408
DMW3QGJ	PC	5280567
DMW3QGJ	MW	176.17
DMW3QGJ	FM	C10H8O3
DMW3QGJ	IC	HSHNITRMYYLLCV-UHFFFAOYSA-N
DMW3QGJ	CS	CC1=CC(=O)OC2=C1C=CC(=C2)O
DMW3QGJ	IK	1S/C10H8O3/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9/h2-5,11H,1H3
DMW3QGJ	IU	7-hydroxy-4-methylchromen-2-one
DMW3QGJ	CA	CAS 90-33-5
DMW3QGJ	CB	CHEBI:17224
DMW3QGJ	DE	Cholangitis

DMYGNDI	ID	DMYGNDI
DMYGNDI	DN	LMP1-CAR-T cells
DMYGNDI	HS	Phase 1/2
DMYGNDI	CP	The Second Hospital of Nanjing Medical University
DMYGNDI	DT	CAR T Cell Therapy
DMYGNDI	DE	Nasopharyngeal carcinoma

DMZNIAG	ID	DMZNIAG
DMZNIAG	DN	LS-172108
DMZNIAG	HS	Phase 1/2
DMZNIAG	SN	Tirilazad; Tirilazad (INN); LS-172108; PNU 74006F; RBKASMJPSJDQKY-RBFSKHHSSA-N; SCHEMBL483318; Tirilazad [INN:BAN]; Tirilazadum; Tirilazadum [INN-Latin]; U 74006; YD064E883I; ZINC43133316; tirilazad of tirilazad; 110101-66-1; 21-[4-(2,6-Di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methylpregna-1,4,9(11)-triene-3,20-dione; AC1L2XOZ; C38H52N6O2; CHEBI:135853; CHEMBL1630578; D08606; DB13050; Pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)erazinyl)-16-methyl-, (16alpha)-; S048; UNII-YD064E883I
DMZNIAG	PC	104903
DMZNIAG	MW	624.9
DMZNIAG	FM	C38H52N6O2
DMZNIAG	IC	RBKASMJPSJDQKY-RBFSKHHSSA-N
DMZNIAG	CS	CC1CC2C3CCC4=CC(=O)C=CC4(C3=CCC2(C1C(=O)CN5CCN(CC5)C6=NC(=NC(=C6)N7CCCC7)N8CCCC8)C)C
DMZNIAG	IK	1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1
DMZNIAG	IU	(8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
DMZNIAG	CA	CAS 110101-66-1
DMZNIAG	CB	CHEBI:135853
DMZNIAG	DE	Cerebral stroke

DM5N04G	ID	DM5N04G
DM5N04G	DN	LT-1951
DM5N04G	HS	Phase 1/2
DM5N04G	SN	Nona-arginine; Nona-l-arginine; UNII-PK7O6W0U44; 143413-47-2; PK7O6W0U44; (Arg)9; LT-1951; (Arg)9 peptide; H-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-OH; DB12648; L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-
DM5N04G	CP	Lumen Therapeutics
DM5N04G	PC	25077438
DM5N04G	MW	1423.7
DM5N04G	FM	C54H110N36O10
DM5N04G	IC	InChI=1S/C54H110N36O10/c55-28(10-1-19-74-46(56)57)37(91)83-29(11-2-20-75-47(58)59)38(92)84-30(12-3-21-76-48(60)61)39(93)85-31(13-4-22-77-49(62)63)40(94)86-32(14-5-23-78-50(64)65)41(95)87-33(15-6-24-79-51(66)67)42(96)88-34(16-7-25-80-52(68)69)43(97)89-35(17-8-26-81-53(70)71)44(98)90-36(45(99)100)18-9-27-82-54(72)73/h28-36H,1-27,55H2,(H,83,91)(H,84,92)(H,85,93)(H,86,94)(H,87,95)(H,88,96)(H,89,97)(H,90,98)(H,99,100)(H4,56,57,74)(H4,58,59,75)(H4,60,61,76)(H4,62,63,77)(H4,64,65,78)(H4,66,67,79)(H4,68,69,80)(H4,70,71,81)(H4,72,73,82)/t28-,29-,30-,31-,32-,33-,34-,35-,36-/m0/s1
DM5N04G	CS	C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)CN=C(N)N
DM5N04G	IK	XUNKPNYCNUKOAU-VXJRNSOOSA-N
DM5N04G	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM5N04G	CA	CAS 143413-47-2
DM5N04G	DE	Coronary artery disease

DM2LYIN	ID	DM2LYIN
DM2LYIN	DN	LX-7101
DM2LYIN	HS	Phase 1/2
DM2LYIN	CP	Lexicon Pharmaceuticals Inc
DM2LYIN	PC	56962369
DM2LYIN	MW	451.5
DM2LYIN	FM	C23H29N7O3
DM2LYIN	IC	InChI=1S/C23H29N7O3/c1-15-12-25-19-18(15)20(27-14-26-19)30-9-7-23(13-24,8-10-30)21(31)28-16-5-4-6-17(11-16)33-22(32)29(2)3/h4-6,11-12,14H,7-10,13,24H2,1-3H3,(H,28,31)(H,25,26,27)
DM2LYIN	CS	CC1=CNC2=C1C(=NC=N2)N3CCC(CC3)(CN)C(=O)NC4=CC(=CC=C4)OC(=O)N(C)C
DM2LYIN	IK	PWPNYABQEOGNNC-UHFFFAOYSA-N
DM2LYIN	IU	[3-[[4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] N,N-dimethylcarbamate
DM2LYIN	CA	CAS 1192189-69-7
DM2LYIN	DE	Glaucoma/ocular hypertension

DM65MEL	ID	DM65MEL
DM65MEL	DN	LXS196
DM65MEL	HS	Phase 1/2
DM65MEL	SN	XXJXHXJWQSCNPX-UHFFFAOYSA-N; 1874276-76-2; LXS-196; NVP-LXS196; SCHEMBL17506262; CHEMBL3982723; LXS 196; BDBM251460; EX-A2690; BCP20781; ZINC584641445; CS-7529; HY-101569; US9452998, 9; 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide
DM65MEL	CP	Novartis Oncology East Hanover, NJ
DM65MEL	PC	118873253
DM65MEL	MW	472.5
DM65MEL	FM	C22H23F3N8O
DM65MEL	IC	InChI=1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)
DM65MEL	CS	CC1(CCN(CC1)C2=C(N=CC=C2)NC(=O)C3=NC(=CN=C3N)C4=C(C=CC=N4)C(F)(F)F)N
DM65MEL	IK	XXJXHXJWQSCNPX-UHFFFAOYSA-N
DM65MEL	IU	3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide
DM65MEL	CA	CAS 1874276-76-2
DM65MEL	DE	Melanoma; Solid tumour/cancer

DMHXTNW	ID	DMHXTNW
DMHXTNW	DN	LY-2228820
DMHXTNW	HS	Phase 1/2
DMHXTNW	SN	Ralimetinib; 862505-00-8; LY-2228820 free base; UNII-73I34XW4HD; 73I34XW4HD; 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-Imidazo[4,5-b]pyridin-2-amine; C24H29FN6; Ralimetinib [USAN:INN]; LY2228820 free base; Ralimetinib (USAN/INN); GTPL7959; SCHEMBL3989306; SCHEMBL13826263; CHEMBL2364626; DTXSID00235456; MolPort-009-679-493; XPPBBJCBDOEXDN-UHFFFAOYSA-N; BCPP000180; BCP02033; ZINC34630490; ABP000309; 2526AH; ABP000548; AKOS027282678; SB16635; BCP9000871; DB11787; NCGC00346537-05;  LY-2180895; LY-2211877; LY-2228820 mesylate; LY-2231377; LY-2322600; LY-479754; LY-22288202MsOH; P38 MAP kinase inhibitors (inflammation, cancer), Lilly
DMHXTNW	CP	Lilly
DMHXTNW	DT	Small molecular drug
DMHXTNW	PC	11539025
DMHXTNW	MW	420.5
DMHXTNW	FM	C24H29FN6
DMHXTNW	IC	InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30)
DMHXTNW	CS	CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N
DMHXTNW	IK	XPPBBJCBDOEXDN-UHFFFAOYSA-N
DMHXTNW	IU	5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine
DMHXTNW	CA	CAS 862505-00-8
DMHXTNW	DE	Solid tumour/cancer

DMADEHZ	ID	DMADEHZ
DMADEHZ	DN	LY2880070
DMADEHZ	HS	Phase 1/2
DMADEHZ	SN	1375637-35-6; SCHEMBL15124196; BCP32047; EX-A3339; ZINC199531075; LY 2880070 pound>>LY-2880070; (R)-[5-(2-Methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy) -pyrazin-2-yl]-amine; (R)-[5-(2-methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy)-pyrazin-2-yl]-amine; N-[5-(2-methoxy-6-methylpyridin-3-yl)-1H-pyrazol-3-yl]-6-[(3R)-piperidin-3-yl]oxypyrazin-2-amine
DMADEHZ	CP	Esperas Pharma
DMADEHZ	DT	Small molecular drug
DMADEHZ	PC	56968075
DMADEHZ	MW	381.4
DMADEHZ	FM	C19H23N7O2
DMADEHZ	IC	InChI=1S/C19H23N7O2/c1-12-5-6-14(19(22-12)27-2)15-8-16(26-25-15)23-17-10-21-11-18(24-17)28-13-4-3-7-20-9-13/h5-6,8,10-11,13,20H,3-4,7,9H2,1-2H3,(H2,23,24,25,26)/t13-/m1/s1
DMADEHZ	CS	CC1=NC(=C(C=C1)C2=CC(=NN2)NC3=CN=CC(=N3)O[C@@H]4CCCNC4)OC
DMADEHZ	IK	LAEFIEWPUJMANC-CYBMUJFWSA-N
DMADEHZ	IU	N-[5-(2-methoxy-6-methylpyridin-3-yl)-1H-pyrazol-3-yl]-6-[(3R)-piperidin-3-yl]oxypyrazin-2-amine
DMADEHZ	DE	Solid tumour/cancer

DMTJWIQ	ID	DMTJWIQ
DMTJWIQ	DN	LY2940680
DMTJWIQ	HS	Phase 1/2
DMTJWIQ	SN	LY2940680; 1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]
DMTJWIQ	CP	Lilly
DMTJWIQ	DT	Small molecular drug
DMTJWIQ	PC	49848070
DMTJWIQ	MW	512.5
DMTJWIQ	FM	C26H24F4N6O
DMTJWIQ	IC	InChI=1S/C26H24F4N6O/c1-34(25(37)20-8-7-16(27)15-21(20)26(28,29)30)17-10-13-36(14-11-17)24-19-6-4-3-5-18(19)23(32-33-24)22-9-12-31-35(22)2/h3-9,12,15,17H,10-11,13-14H2,1-2H3
DMTJWIQ	CS	CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F
DMTJWIQ	IK	SZBGQDXLNMELTB-UHFFFAOYSA-N
DMTJWIQ	IU	4-fluoro-N-methyl-N-[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl]-2-(trifluoromethyl)benzamide
DMTJWIQ	CA	CAS 1258861-20-9
DMTJWIQ	DE	Solid tumour/cancer; Ovarian cancer

DM7T1CR	ID	DM7T1CR
DM7T1CR	DN	LY3016859
DM7T1CR	HS	Phase 1/2
DM7T1CR	SN	TGF-alpha.epiregulin mAb
DM7T1CR	CP	Eli lilly
DM7T1CR	DE	Chronic kidney disease

DMC5SAW	ID	DMC5SAW
DMC5SAW	DN	LY3039478
DMC5SAW	HS	Phase 1/2
DMC5SAW	SN	LY3039478; Crenigacestat; 1421438-81-4; LY-3039478; UNII-923X28214S; 4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide; 923X28214S; butanamide, n-[(1s)-2-[[(7s)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5h-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-; Butanamide, N-((1S)-2-(((7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido(3,2-a)(3)benzazepin-7-yl)amino)-1-methyl-2-oxoethyl)-4,4,4-trifluoro-
DMC5SAW	CP	Eli Lilly
DMC5SAW	DT	Small molecular drug
DMC5SAW	PC	71236992
DMC5SAW	MW	464.4
DMC5SAW	FM	C22H23F3N4O4
DMC5SAW	IC	InChI=1S/C22H23F3N4O4/c1-13(27-17(31)8-9-22(23,24)25)20(32)28-18-15-6-3-2-5-14(15)16-7-4-10-26-19(16)29(11-12-30)21(18)33/h2-7,10,13,18,30H,8-9,11-12H2,1H3,(H,27,31)(H,28,32)/t13-,18-/m0/s1
DMC5SAW	CS	C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2C3=C(N=CC=C3)N(C1=O)CCO)NC(=O)CCC(F)(F)F
DMC5SAW	IK	YCBAQKQAINQRFW-UGSOOPFHSA-N
DMC5SAW	IU	4,4,4-trifluoro-N-[(2S)-1-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide
DMC5SAW	CA	CAS 1421438-81-4
DMC5SAW	DE	Lymphoma; T-cell acute lymphoblastic leukaemia; Solid tumour/cancer

DM8RJTB	ID	DM8RJTB
DM8RJTB	DN	LY3295668
DM8RJTB	HS	Phase 1/2
DM8RJTB	SN	1919888-06-4; (2R,4R)-1-(3-Chloro-2-fluorobenzyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid; AK-01; LY-3295668; (2R,4R)-1-[(3-chloro-2-fluorophenyl)methyl]-4-({3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridin-2-yl}methyl)-2-methylpiperidine-4-carboxylic acid; UNII-1WX8O5XV4R; 1WX8O5XV4R; SCHEMBL17747406; NSC816863; NSC-816863; Aurora A kinase inhibitor LY3295668; HY-114258; CS-0080775; LY3295668 (AK-01); A16869; (2R,4R)-1-[(3-Chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid; 1-((3-Chloro-2-fluorophenyl)methyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-2-methyl-, (2R,4R)-,4-piperidinecarboxylic acid; 4-Piperidinecarboxylic acid, 1-((3-chloro-2-fluorophenyl)methyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-2-methyl-, (2R,4R)-; EG7
DM8RJTB	CP	Eli Lilly
DM8RJTB	DT	Small molecular drug
DM8RJTB	PC	121333423
DM8RJTB	MW	489.9
DM8RJTB	FM	C24H26ClF2N5O2
DM8RJTB	IC	InChI=1S/C24H26ClF2N5O2/c1-14-10-21(31-30-14)29-20-7-6-18(26)19(28-20)12-24(23(33)34)8-9-32(15(2)11-24)13-16-4-3-5-17(25)22(16)27/h3-7,10,15H,8-9,11-13H2,1-2H3,(H,33,34)(H2,28,29,30,31)/t15-,24-/m1/s1
DM8RJTB	CS	C[C@@H]1C[C@](CCN1CC2=C(C(=CC=C2)Cl)F)(CC3=C(C=CC(=N3)NC4=NNC(=C4)C)F)C(=O)O
DM8RJTB	IK	YQQZZYYQTCPEAS-OYLFLEFRSA-N
DM8RJTB	IU	(2R,4R)-1-[(3-chloro-2-fluorophenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridin-2-yl]methyl]-2-methylpiperidine-4-carboxylic acid
DM8RJTB	CA	CAS 1919888-06-4
DM8RJTB	DE	Solid tumour/cancer

DMA1CSR	ID	DMA1CSR
DMA1CSR	DN	LY3499446
DMA1CSR	HS	Phase 1/2
DMA1CSR	DT	Small molecular drug
DMA1CSR	DE	Solid tumour/cancer

DMK2L38	ID	DMK2L38
DMK2L38	DN	M3814
DMK2L38	HS	Phase 1/2
DMK2L38	SN	MOWXJLUYGFNTAL-DEOSSOPVSA-N; M-3814; 1637542-33-6; M-3814(nedisertib); nedisertib (proposed INN); UNII-GN429E725A; GTPL9766; SCHEMBL16235559; GN429E725A; MSC2490484A; EX-A1679; example 136 [WO2014183850]; HY-101570; CS-0021723; (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol
DMK2L38	CP	EMD Serono Rockland, MA
DMK2L38	PC	86292849
DMK2L38	MW	481.9
DMK2L38	FM	C24H21ClFN5O3
DMK2L38	IC	InChI=1S/C24H21ClFN5O3/c1-33-22-5-4-20(29-30-22)24(32)16-11-17(19(26)12-18(16)25)23-15-3-2-14(10-21(15)27-13-28-23)31-6-8-34-9-7-31/h2-5,10-13,24,32H,6-9H2,1H3/t24-/m0/s1
DMK2L38	CS	COC1=NN=C(C=C1)[C@H](C2=C(C=C(C(=C2)C3=NC=NC4=C3C=CC(=C4)N5CCOCC5)F)Cl)O
DMK2L38	IK	MOWXJLUYGFNTAL-DEOSSOPVSA-N
DMK2L38	IU	(S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol
DMK2L38	CA	CAS 1637542-33-6
DMK2L38	DE	Solid tumour/cancer; Locally advanced rectal cancer

DMIRG15	ID	DMIRG15
DMIRG15	DN	MaC46/M87o
DMIRG15	HS	Phase 1/2
DMIRG15	SN	HIV-1 infection gene therapy, Georg-Speyer-Haus
DMIRG15	CP	Takara bio
DMIRG15	DE	Human immunodeficiency virus-1 infection

DM6H3YS	ID	DM6H3YS
DM6H3YS	DN	MAGE-A10 TCR
DM6H3YS	HS	Phase 1/2
DM6H3YS	CP	Adaptimmune Philadelphia, PA
DM6H3YS	DE	Bladder cancer; Head and neck cancer; Melanoma; Merkel cell carcinoma

DMFK5IX	ID	DMFK5IX
DMFK5IX	DN	MAK683
DMFK5IX	HS	Phase 1/2
DMFK5IX	SN	XLIBABIFOBYHSV-UHFFFAOYSA-N; EED inhibitor-1; 1951408-58-4; MAK-683; N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; SCHEMBL17841485; EX-A1723; BCP29116; ACN-053195; CS-8054; AC-30344; HY-103663
DMFK5IX	CP	Novartis Oncology East Hanover, NJ
DMFK5IX	PC	121412508
DMFK5IX	MW	376.4
DMFK5IX	FM	C20H17FN6O
DMFK5IX	IC	InChI=1S/C20H17FN6O/c1-12-13(3-2-7-22-12)16-10-24-20(27-11-25-26-19(16)27)23-9-15-14-6-8-28-18(14)5-4-17(15)21/h2-5,7,10-11H,6,8-9H2,1H3,(H,23,24)
DMFK5IX	CS	CC1=C(C=CC=N1)C2=CN=C(N3C2=NN=C3)NCC4=C(C=CC5=C4CCO5)F
DMFK5IX	IK	XLIBABIFOBYHSV-UHFFFAOYSA-N
DMFK5IX	IU	N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine
DMFK5IX	CA	CAS 1951408-58-4
DMFK5IX	DE	Diffuse large B-cell lymphoma

DMBZ68C	ID	DMBZ68C
DMBZ68C	DN	MALP-2S
DMBZ68C	HS	Phase 1/2
DMBZ68C	CP	MBiotec GmbH
DMBZ68C	DE	Pancreatic cancer

DMH0ROP	ID	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	HS	Phase 1/2
DMH0ROP	SN	beta-maltose; Maltobiose; Maltose, pure; Advanctose 100; 4-O-alpha-D-glucopyranosyl-beta-D-glucopyranose; Cextromaltose; Maltodiose; Finetose; Sunmalt; Malt sugar; Finetose F; Sunmalt S; UNII-R4B6462NGR; D-Glucose, 4-O-alpha-D-glucopyranosyl-; AI3-09089; EINECS 200-716-5; BRN 0093798; 4-O-alpha-D-Glucopyranosyl-D-glucose; R4B6462NGR; 4-(alpha-D-Glucosido)-D-glucose; CHEBI:18147; beta-D-Cellobiose; GUBGYTABKSRVRQ-QUYVBRFLSA-N; beta-D-glucopyranose, 4-O-alpha-D-glucopyranosyl-
DMH0ROP	DT	Small molecular drug
DMH0ROP	PC	6255
DMH0ROP	MW	342.3
DMH0ROP	FM	C12H22O11
DMH0ROP	IC	InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7-,8-,9-,10-,11-,12-/m1/s1
DMH0ROP	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O
DMH0ROP	IK	GUBGYTABKSRVRQ-QUYVBRFLSA-N
DMH0ROP	IU	(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DMH0ROP	CA	CAS 133-99-3
DMH0ROP	CB	CHEBI:18147

DMXU7P6	ID	DMXU7P6
DMXU7P6	DN	MB-CART20.1
DMXU7P6	HS	Phase 1/2
DMXU7P6	CP	Miltenyi Biotec GmbH
DMXU7P6	DT	CAR T Cell Therapy
DMXU7P6	DE	Non-hodgkin lymphoma

DMS19IH	ID	DMS19IH
DMS19IH	DN	MBO7133
DMS19IH	HS	Phase 1/2
DMS19IH	CP	Metabasis Therapeutics Inc
DMS19IH	DE	Liver cancer

DMTCADJ	ID	DMTCADJ
DMTCADJ	DN	McN3377
DMTCADJ	HS	Phase 1/2
DMTCADJ	SN	Fenobamum; Fenobam (TN); Fenobamum [INN-Latin]; McN-3377; NPL-2009; N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)urea; N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea; 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4H-imidazol-2-yl)urea
DMTCADJ	CP	McNeil Laboratories
DMTCADJ	TC	Psychiatric
DMTCADJ	DT	Small molecular drug
DMTCADJ	PC	162834
DMTCADJ	DE	Fragile X syndrome

DM6JN19	ID	DM6JN19
DM6JN19	DN	ME-344
DM6JN19	HS	Phase 1/2
DM6JN19	SN	NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards
DM6JN19	CP	Mei pharma
DM6JN19	DT	Small molecular drug
DM6JN19	PC	68026984
DM6JN19	MW	348.4
DM6JN19	FM	C22H20O4
DM6JN19	IC	InChI=1S/C22H20O4/c1-13-20(25)11-10-18-21(15-4-8-17(24)9-5-15)19(12-26-22(13)18)14-2-6-16(23)7-3-14/h2-11,19,21,23-25H,12H2,1H3/t19-,21-/m0/s1
DM6JN19	CS	CC1=C(C=CC2=C1OC[C@H]([C@H]2C3=CC=C(C=C3)O)C4=CC=C(C=C4)O)O
DM6JN19	IK	QVCAATSEPLQVBX-FPOVZHCZSA-N
DM6JN19	IU	(3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol
DM6JN19	CA	CAS 1374524-68-1
DM6JN19	DE	Solid tumour/cancer; Breast cancer

DMMB5CV	ID	DMMB5CV
DMMB5CV	DN	Medusa IL-2
DMMB5CV	HS	Phase 1/2
DMMB5CV	CP	Flamel Technol
DMMB5CV	TC	Anticancer Agents
DMMB5CV	DE	Solid tumour/cancer

DMJVFK7	ID	DMJVFK7
DMJVFK7	DN	Meplazumab
DMJVFK7	HS	Phase 1/2
DMJVFK7	SN	Mepolizumab
DMJVFK7	TC	Antiviral Agents
DMJVFK7	DT	Monoclonal antibody
DMJVFK7	DE	Coronavirus Disease 2019 (COVID-19)

DMENFD6	ID	DMENFD6
DMENFD6	DN	Metelimumab
DMENFD6	HS	Phase 1/2
DMENFD6	SN	CAT-192; SL15A-IgG4; Anti-TGF beta 1 antibodies, Genzyme General/Cambridge Antibody Technologies
DMENFD6	CP	Cambridge Antibody Technology Group plc; MedImmune
DMENFD6	DT	Antibody
DMENFD6	DE	Scleroderma

DME6PB0	ID	DME6PB0
DME6PB0	DN	MG7-CART
DME6PB0	HS	Phase 1/2
DME6PB0	CP	Xijing Hospital
DME6PB0	DT	CAR T Cell Therapy
DME6PB0	DE	Acute myeloid leukaemia

DM1KZW0	ID	DM1KZW0
DM1KZW0	DN	MGC018
DM1KZW0	HS	Phase 1/2
DM1KZW0	CP	MacroGenics
DM1KZW0	DT	Antibody drug conjugate
DM1KZW0	DE	Solid tumour/cancer

DMAHWLR	ID	DMAHWLR
DMAHWLR	DN	MGD007
DMAHWLR	HS	Phase 1/2
DMAHWLR	CP	MacroGenics
DMAHWLR	DT	Monoclonal antibody
DMAHWLR	DE	Metastatic colorectal cancer; Colorectal cancer

DMCVMUL	ID	DMCVMUL
DMCVMUL	DN	MGD013
DMCVMUL	HS	Phase 1/2
DMCVMUL	CP	MacroGenics Rockville, MD
DMCVMUL	DT	Antibody
DMCVMUL	DE	Solid tumour/cancer; Hematologic tumour; Hepatocellular carcinoma

DM4H7UY	ID	DM4H7UY
DM4H7UY	DN	Milatuzumab
DM4H7UY	HS	Phase 1/2
DM4H7UY	CP	Immunomedics
DM4H7UY	DT	Antibody
DM4H7UY	DE	Chronic lymphocytic leukaemia; Systemic lupus erythematosus

DM25QKC	ID	DM25QKC
DM25QKC	DN	MK-1308
DM25QKC	HS	Phase 1/2
DM25QKC	SN	Quavonlimab 
DM25QKC	CP	Merck
DM25QKC	DT	Antibody
DM25QKC	DE	Solid tumour/cancer

DM21WBH	ID	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	HS	Phase 1/2
DM21WBH	SN	MK 2461
DM21WBH	DT	Small molecular drug
DM21WBH	PC	44137946
DM21WBH	MW	495.6
DM21WBH	FM	C24H25N5O5S
DM21WBH	IC	InChI=1S/C24H25N5O5S/c1-28-13-18(12-26-28)17-9-22-23(25-11-17)6-4-16-3-5-19(10-21(16)24(22)30)27-35(31,32)29(2)14-20-15-33-7-8-34-20/h3-6,9-13,20,27H,7-8,14-15H2,1-2H3/t20-/m1/s1
DM21WBH	CS	CN1C=C(C=N1)C2=CC3=C(C=CC4=C(C3=O)C=C(C=C4)NS(=O)(=O)N(C)C[C@@H]5COCCO5)N=C2
DM21WBH	IK	JGEBLDKNWBUGRZ-HXUWFJFHSA-N
DM21WBH	IU	14-[[[(2R)-1,4-dioxan-2-yl]methyl-methylsulfamoyl]amino]-5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene
DM21WBH	CA	CAS 917879-39-1
DM21WBH	DE	Alzheimer disease

DMCVBQD	ID	DMCVBQD
DMCVBQD	DN	MLN1117
DMCVBQD	HS	Phase 1/2
DMCVBQD	CP	Takeda
DMCVBQD	PC	70798655
DMCVBQD	MW	363.4
DMCVBQD	FM	C19H17N5O3
DMCVBQD	IC	InChI=1S/C19H17N5O3/c20-19-22-14-9-12(1-3-16(14)27-19)13-2-4-17-21-10-15(24(17)11-13)18(25)23-5-7-26-8-6-23/h1-4,9-11H,5-8H2,(H2,20,22)
DMCVBQD	CS	C1COCCN1C(=O)C2=CN=C3N2C=C(C=C3)C4=CC5=C(C=C4)OC(=N5)N
DMCVBQD	IK	BLGWHBSBBJNKJO-UHFFFAOYSA-N
DMCVBQD	IU	[6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone
DMCVBQD	CA	CAS 1268454-23-4
DMCVBQD	DE	Solid tumour/cancer

DMGC96P	ID	DMGC96P
DMGC96P	DN	MLN-2704
DMGC96P	HS	Phase 1/2
DMGC96P	SN	MLN-5591DM1; MLN-591DM1; ATG-J591: DM1
DMGC96P	CP	Millennium Pharmaceuticals
DMGC96P	DT	Antibody
DMGC96P	DE	Prostate cancer

DMG7XHE	ID	DMG7XHE
DMG7XHE	DN	Monalizumab
DMG7XHE	HS	Phase 1/2
DMG7XHE	SN	IPH2201
DMG7XHE	CP	AstraZeneca; Innate Pharma
DMG7XHE	DT	Antibody
DMG7XHE	DE	Chronic lymphocytic leukaemia; Solid tumour/cancer; Head and neck cancer

DMXVIQN	ID	DMXVIQN
DMXVIQN	DN	MOR-103
DMXVIQN	HS	Phase 1/2
DMXVIQN	SN	MOR-04357; Antibody (inflammation), MorphoSys; GM-CSF antibody (rheumatoid arthritis), MorphoSys; MOR-103 (rheumatoid arthritis), MorphoSys; GM-CSF antibody (iv infusion, inflammation), MorphoSys/Galapagos
DMXVIQN	CP	Glaxosmithkline
DMXVIQN	DT	Antibody
DMXVIQN	DE	Multiple sclerosis

DMR8AHJ	ID	DMR8AHJ
DMR8AHJ	DN	MOR-202
DMR8AHJ	HS	Phase 1/2
DMR8AHJ	SN	Anti-CD38 antibodies, MorphoSys; HuCAL-mAb1, MorphoSys; HuCAL-mAb2, MorphoSys; HuCAL-mAb3, MorphoSys
DMR8AHJ	CP	Celgene summit; nj morphosys
DMR8AHJ	DT	Antibody
DMR8AHJ	DE	Multiple myeloma

DMR3VCY	ID	DMR3VCY
DMR3VCY	DN	MP0250
DMR3VCY	HS	Phase 1/2
DMR3VCY	CP	Molecular Partners Zurich, Switzerland
DMR3VCY	DE	Non-small-cell lung cancer

DME7PBN	ID	DME7PBN
DME7PBN	DN	mRNA-3704
DME7PBN	HS	Phase 1/2
DME7PBN	CP	Moderna Therapeutics
DME7PBN	DT	mRNA therapy
DME7PBN	DE	Methylmalonic acidemia

DM35YFC	ID	DM35YFC
DM35YFC	DN	MS-1819
DM35YFC	HS	Phase 1/2
DM35YFC	SN	Recombinant lipase (exocrine pancreatic insufficiency), Laboratoires Mayoly Spindler
DM35YFC	CP	Laboratoires Mayoly Spindler
DM35YFC	PC	3613823
DM35YFC	MW	277.4
DM35YFC	FM	C16H23NOS
DM35YFC	IC	InChI=1S/C16H23NOS/c1-16(2,3)14-6-4-13(5-7-14)12-18-17-15-8-10-19-11-9-15/h4-7H,8-12H2,1-3H3
DM35YFC	CS	CC(C)(C)C1=CC=C(C=C1)CON=C2CCSCC2
DM35YFC	IK	QKZIKPBOHKELOB-UHFFFAOYSA-N
DM35YFC	IU	N-[(4-tert-butylphenyl)methoxy]thian-4-imine
DM35YFC	DE	Exocrine pancreatic insufficiency

DMIS75V	ID	DMIS75V
DMIS75V	DN	MTL-CEPBA
DMIS75V	HS	Phase 1/2
DMIS75V	CP	MiNA Therapeutics
DMIS75V	DT	Small activating RNA
DMIS75V	DE	Hepatocellular carcinoma

DMFUDHM	ID	DMFUDHM
DMFUDHM	DN	MUC-1 CART cell immunotherapy
DMFUDHM	HS	Phase 1/2
DMFUDHM	CP	Second Affiliated Hospital, School of Medicine, Zhejiang University
DMFUDHM	DT	CAR T Cell Therapy
DMFUDHM	DE	Intrahepatic cholangiocarcinoma

DMPNR0J	ID	DMPNR0J
DMPNR0J	DN	Muc1-specific gene-engineered T cells
DMPNR0J	HS	Phase 1/2
DMPNR0J	CP	Shenzhen Geno-Immune Medical Institute
DMPNR0J	DT	CAR T Cell Therapy
DMPNR0J	DE	Acute myeloid leukaemia

DMU6MJ1	ID	DMU6MJ1
DMU6MJ1	DN	NAHE-001
DMU6MJ1	HS	Phase 1/2
DMU6MJ1	SN	Interferon alpha 5 modulator (HCV infection), Digna Biotech
DMU6MJ1	CP	Digna Biotech SL
DMU6MJ1	DE	Hepatitis C virus infection

DM5O4GR	ID	DM5O4GR
DM5O4GR	DN	NB1011
DM5O4GR	HS	Phase 1/2
DM5O4GR	SN	Thymectacin; BVDU prodrug; NB1011; UNII-2ZRZ4TSW3F; 2ZRZ4TSW3F; 5-(2-Bromovinyl)-2'-deoxy-5'-uridyl-phenyl-alanylphosphoramidate, trans-; (E)-5-(2-Bromovinyl)-2'-deoxy-5'-uridyl phenyl L-methoxyalaninylphosphoramidate; L-Alanine, N-(5-((1E)-2-bromoethenyl)-2'-deoxy-P-phenyl-5'-uridylyl)-, methyl ester; E-5-(2-bromovinyl)-2'-deoxyuridine-5'-(L-methylalaninyl)-phenylphosphoramidate; 232925-18-7; Brivudine phosphoramidate; AC1O5U63; SCHEMBL13904642; DTXSID00177862; NB-1011; NB 1011; DB05116; LS-181955; J3.616.614B; methyl (2S)-2
DM5O4GR	DT	Small molecular drug
DM5O4GR	PC	6440764
DM5O4GR	MW	574.3
DM5O4GR	FM	C21H25BrN3O9P
DM5O4GR	IC	InChI=1S/C21H25BrN3O9P/c1-13(20(28)31-2)24-35(30,34-15-6-4-3-5-7-15)32-12-17-16(26)10-18(33-17)25-11-14(8-9-22)19(27)23-21(25)29/h3-9,11,13,16-18,26H,10,12H2,1-2H3,(H,24,30)(H,23,27,29)/b9-8+/t13-,16-,17+,18+,35?/m0/s1
DM5O4GR	CS	C[C@@H](C(=O)OC)NP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)/C=C/Br)O)OC3=CC=CC=C3
DM5O4GR	IK	CFBLUORPOFELCE-BACVZHSASA-N
DM5O4GR	IU	methyl (2S)-2-[[[(2R,3S,5R)-5-[5-[(E)-2-bromoethenyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DM5O4GR	CA	CAS 232925-18-7
DM5O4GR	DE	Breast cancer

DMTAODR	ID	DMTAODR
DMTAODR	DN	NBE-002
DMTAODR	HS	Phase 1/2
DMTAODR	CP	NBE-Therapeutics
DMTAODR	DT	Antibody drug conjugate
DMTAODR	DE	Solid tumour/cancer

DMZSIV1	ID	DMZSIV1
DMZSIV1	DN	NC410
DMZSIV1	HS	Phase 1/2
DMZSIV1	CP	NextCure
DMZSIV1	DT	Recombinant protein
DMZSIV1	DE	Solid tumour/cancer

DMCDQX0	ID	DMCDQX0
DMCDQX0	DN	ND-0801
DMCDQX0	HS	Phase 1/2
DMCDQX0	CP	NeuroDerm Ltd
DMCDQX0	DE	Attention deficit hyperactivity disorder

DMPMF6L	ID	DMPMF6L
DMPMF6L	DN	Nepadutant
DMPMF6L	HS	Phase 1/2
DMPMF6L	SN	MEN 11420; LS-55819; AC1MJ6M2; SCHEMBL1649325; GTPL2123; Cyclo(N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparginyl-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl-L-2,3-diaminopropionyl-L-leucyl), cyclic(2-5)-peptide; (2S)-2-[[(3S,6S,9S,12S)-12-[[(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1H-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methylpentanoic acid;  Nepadutant [INN]; MEN-11,420; Cyclo(Asn(2-deoxy-2-AcNH-beta-D-Glc)-Asp-Trp-Phe-Dap-Leu)cyclo(2beta,5beta); Cyclo(N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparaginyl-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl-L-2,3-diaminopropionyl-L-leucyl),cyclic(2-5)-peptide
DMPMF6L	CP	Menarini
DMPMF6L	DT	Small molecular drug
DMPMF6L	PC	3086682
DMPMF6L	MW	965
DMPMF6L	FM	C45H60N10O14
DMPMF6L	IC	InChI=1S/C45H60N10O14/c1-21(2)13-31(45(67)68)53-43(66)32-19-48-34(58)17-30(50-39(62)26(46)16-35(59)55-44-36(49-22(3)57)38(61)37(60)33(20-56)69-44)42(65)52-29(15-24-18-47-27-12-8-7-11-25(24)27)41(64)51-28(40(63)54-32)14-23-9-5-4-6-10-23/h4-12,18,21,26,28-33,36-38,44,47,56,60-61H,13-17,19-20,46H2,1-3H3,(H,48,58)(H,49,57)(H,50,62)(H,51,64)(H,52,65)(H,53,66)(H,54,63)(H,55,59)(H,67,68)/t26-,28-,29-,30-,31-,32-,33+,36+,37+,38+,44+/m0/s1
DMPMF6L	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(=O)N[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)NC(=O)C)N
DMPMF6L	IK	NPSVXOVMLVOMDD-SXRVEDALSA-N
DMPMF6L	IU	(2S)-2-[[(3S,6S,9S,12S)-12-[[(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1H-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methylpentanoic acid
DMPMF6L	DE	Postoperative ileus; Infantile colics

DMXKOUC	ID	DMXKOUC
DMXKOUC	DN	Neu-120
DMXKOUC	HS	Phase 1/2
DMXKOUC	SN	Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim
DMXKOUC	CP	Neurim Pharmaceuticals
DMXKOUC	DE	Parkinson disease

DMEOLVP	ID	DMEOLVP
DMEOLVP	DN	NI-0401
DMEOLVP	HS	Phase 1/2
DMEOLVP	SN	Anti-CD3 antibody, NovImmune/Merck Serono
DMEOLVP	CP	NovImmune
DMEOLVP	DT	Antibody
DMEOLVP	DE	Autoimmune diabetes

DMMOA2X	ID	DMMOA2X
DMMOA2X	DN	Nikkomycin Z
DMMOA2X	HS	Phase 1/2
DMMOA2X	SN	SP-920704
DMMOA2X	CP	Bayer AG
DMMOA2X	DT	Small molecular drug
DMMOA2X	PC	456557
DMMOA2X	MW	495.4
DMMOA2X	FM	C20H25N5O10
DMMOA2X	IC	InChI=1S/C20H25N5O10/c1-7(13(28)9-3-2-8(26)6-22-9)11(21)17(31)24-12(19(32)33)16-14(29)15(30)18(35-16)25-5-4-10(27)23-20(25)34/h2-7,11-16,18,26,28-30H,21H2,1H3,(H,24,31)(H,32,33)(H,23,27,34)/t7-,11-,12-,13-,14-,15+,16+,18+/m0/s1
DMMOA2X	CS	C[C@H]([C@@H](C1=NC=C(C=C1)O)O)[C@@H](C(=O)N[C@@H]([C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)C(=O)O)N
DMMOA2X	IK	WWJFFVUVFNBJTN-VHDFTHOZSA-N
DMMOA2X	IU	(2S)-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid
DMMOA2X	CA	CAS 59456-70-1
DMMOA2X	CB	CHEBI:623918
DMMOA2X	DE	Candidiasis

DM7SMNJ	ID	DM7SMNJ
DM7SMNJ	DN	NKTR-255
DM7SMNJ	HS	Phase 1/2
DM7SMNJ	CP	Nektar Therapeutics
DM7SMNJ	DE	Colorectal cancer; Head and neck cancer

DMYR8LF	ID	DMYR8LF
DMYR8LF	DN	NKTR-262
DMYR8LF	HS	Phase 1/2
DMYR8LF	CP	Nektar Therapeutics
DMYR8LF	DE	Solid tumour/cancer; Melanoma

DMDNJP5	ID	DMDNJP5
DMDNJP5	DN	NM21-1480
DMDNJP5	HS	Phase 1/2
DMDNJP5	CP	Numab Therapeutics
DMDNJP5	DT	Antibody
DMDNJP5	DE	Advanced solid tumour; Non-small cell lung cancer

DMDASRW	ID	DMDASRW
DMDASRW	DN	Norleucine
DMDASRW	HS	Phase 1/2
DMDASRW	SN	L-Norleucine; 327-57-1; H-Nle-OH; NORLEUCINE; (S)-2-Aminohexanoic acid; Glycoleucine; Caprine; L-(+)-Norleucine; L-2-Aminohexanoic acid; 2-Aminocaproic acid; L-2-Aminohexanoate; L-Aminohexanoate; alpha-Aminocaproic acid; (2S)-2-aminohexanoic acid; (S)-(+)-2-Aminohexanoic acid; Norleucine (VAN); L-Aminohexanoic acid; Hexanoic acid, 2-amino-, (S)-; 2S-amino-hexanoic acid; (S)-2-Aminocaproic acid; (S)-Norleucine; NSC 10378; L(+)-Norleucine; UNII-832C8OV84S; EINECS 206-321-4; BRN 1721750; NLE; CHEBI:18347; LRQKBLKVPFOOQJ-YFKPBYRVSA-N
DMDASRW	DT	Small molecular drug
DMDASRW	PC	21236
DMDASRW	MW	131.17
DMDASRW	FM	C6H13NO2
DMDASRW	IC	InChI=1S/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1
DMDASRW	CS	CCCC[C@@H](C(=O)O)N
DMDASRW	IK	LRQKBLKVPFOOQJ-YFKPBYRVSA-N
DMDASRW	IU	(2S)-2-aminohexanoic acid
DMDASRW	CA	CAS 327-57-1
DMDASRW	CB	CHEBI:18347

DM78KMT	ID	DM78KMT
DM78KMT	DN	NPB-001-056
DM78KMT	HS	Phase 1/2
DM78KMT	SN	KM-80; NPB-001-05; Bcr-abl kinase inhibitor (oral, cancer), Piramal Life Sciences; Bcr-abl kinase inhibitor(oral, cancer), NPIL Research & Development
DM78KMT	CP	Piramal Healthcare Ltd
DM78KMT	DE	Chronic myelogenous leukaemia

DMU9BCD	ID	DMU9BCD
DMU9BCD	DN	NS-018
DMU9BCD	HS	Phase 1/2
DMU9BCD	SN	NS-018; ilginatinib; 1239358-86-1; UNII-56R994WX4L; 56R994WX4L; GTPL7839; SCHEMBL14954406; UQTPDWDAYHAZNT-AWEZNQCLSA-N; NS018; ZINC68245917; HY-19631A; AKOS030526348; DB12784; CS-5358; SB16921; 2,6-Pyridinediamine, N2-((1S)-1-(4-fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-; (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2yl)pyridine-2,6-diamine; (S)-N-(1-(4-Fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6-diamine
DMU9BCD	CP	Nippon Shinyaku
DMU9BCD	DT	Small molecular drug
DMU9BCD	PC	46866319
DMU9BCD	MW	389.4
DMU9BCD	FM	C21H20FN7
DMU9BCD	IC	InChI=1S/C21H20FN7/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21/h3-14H,1-2H3,(H2,24,26,27,28)/t14-/m0/s1
DMU9BCD	CS	C[C@@H](C1=CC=C(C=C1)F)NC2=CC(=CC(=N2)NC3=NC=CN=C3)C4=CN(N=C4)C
DMU9BCD	IK	UQTPDWDAYHAZNT-AWEZNQCLSA-N
DMU9BCD	IU	6-N-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methylpyrazol-4-yl)-2-N-pyrazin-2-ylpyridine-2,6-diamine
DMU9BCD	CA	CAS 1239358-86-1
DMU9BCD	DE	Myelofibrosis

DMOYS1N	ID	DMOYS1N
DMOYS1N	DN	NT219
DMOYS1N	HS	Phase 1/2
DMOYS1N	SN	UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-
DMOYS1N	CP	Purple Biotech
DMOYS1N	DT	Small molecular drug
DMOYS1N	PC	135914977
DMOYS1N	MW	412.3
DMOYS1N	FM	C16H14BrNO5S
DMOYS1N	IC	InChI=1S/C16H14BrNO5S/c17-14-9(1-3-10(19)16(14)23)2-4-13(24)18-7-8-5-11(20)15(22)12(21)6-8/h1-6,19-23H,7H2,(H,18,24)/b4-2+
DMOYS1N	CS	C1=CC(=C(C(=C1/C=C/C(=S)NCC2=CC(=C(C(=C2)O)O)O)Br)O)O
DMOYS1N	IK	XDDQKKXXQHUUHJ-DUXPYHPUSA-N
DMOYS1N	IU	(E)-3-(2-bromo-3,4-dihydroxyphenyl)-N-[(3,4,5-trihydroxyphenyl)methyl]prop-2-enethioamide
DMOYS1N	CA	CAS 1198078-60-2
DMOYS1N	DE	Solid tumour/cancer

DMBQRGV	ID	DMBQRGV
DMBQRGV	DN	NT-501 CNTF
DMBQRGV	HS	Phase 1/2
DMBQRGV	CP	Neurotech usa
DMBQRGV	DE	Ovarian cancer

DMS0L6J	ID	DMS0L6J
DMS0L6J	DN	NY-ESO-TCR
DMS0L6J	HS	Phase 1/2
DMS0L6J	CP	Adaptimmune Philadelphia, PA GlaxoSmithKline Philadelphia, PA
DMS0L6J	DE	Melanoma; Multiple myeloma; Myxoid round cell liposarcoma; Ovarian cancer; Synovial sarcoma

DMD2L1U	ID	DMD2L1U
DMD2L1U	DN	OBI-888
DMD2L1U	HS	Phase 1/2
DMD2L1U	CP	OBI Pharma
DMD2L1U	DT	Antibody
DMD2L1U	DE	Solid tumour/cancer

DMPB9OD	ID	DMPB9OD
DMPB9OD	DN	OBI-999
DMPB9OD	HS	Phase 1/2
DMPB9OD	CP	OBI Pharma
DMPB9OD	DT	Antibody drug conjugate
DMPB9OD	DE	Solid tumour/cancer

DM9MF08	ID	DM9MF08
DM9MF08	DN	OBP-301
DM9MF08	HS	Phase 1/2
DM9MF08	CP	Oncolys Biopharma
DM9MF08	DE	Liver cancer; Head and neck cancer; Breast cancer

DMOKVJD	ID	DMOKVJD
DMOKVJD	DN	ODM-207
DMOKVJD	HS	Phase 1/2
DMOKVJD	SN	BET-IN-4; 1801503-93-4; ODM207; SCHEMBL16896828; NSC818620; NSC-818620; HY-111916; CS-0093944; COC1=C(C=C2C=C(C)C(=O)N(CC3=NC=CC=C3)C2=C1)C1=C(C)ON=C1C; 6-(3,5-Dimethylisoxazol-4-yl)-7-methoxy-3-methyl-1-(pyridin-2-ylmethyl)quinolin-2(1H)-one
DMOKVJD	CP	Orion
DMOKVJD	DT	Small molecular drug
DMOKVJD	PC	118224658
DMOKVJD	MW	375.4
DMOKVJD	FM	C22H21N3O3
DMOKVJD	IC	InChI=1S/C22H21N3O3/c1-13-9-16-10-18(21-14(2)24-28-15(21)3)20(27-4)11-19(16)25(22(13)26)12-17-7-5-6-8-23-17/h5-11H,12H2,1-4H3
DMOKVJD	CS	CC1=CC2=CC(=C(C=C2N(C1=O)CC3=CC=CC=N3)OC)C4=C(ON=C4C)C
DMOKVJD	IK	YVGWSVHZXWFLIT-UHFFFAOYSA-N
DMOKVJD	IU	6-(3,5-dimethyl-1,2-oxazol-4-yl)-7-methoxy-3-methyl-1-(pyridin-2-ylmethyl)quinolin-2-one
DMOKVJD	DE	Solid tumour/cancer

DMPLBDF	ID	DMPLBDF
DMPLBDF	DN	Omburtamab I-124
DMPLBDF	HS	Phase 1/2
DMPLBDF	CP	Y-mAbs Therapeutics New York, NY
DMPLBDF	DE	Glioma

DM2DHJS	ID	DM2DHJS
DM2DHJS	DN	ONC1-13B
DM2DHJS	HS	Phase 1/2
DM2DHJS	CP	Allachem
DM2DHJS	PC	77461273
DM2DHJS	MW	492.4
DM2DHJS	FM	C22H16F4N4O3S
DM2DHJS	IC	InChI=1S/C22H16F4N4O3S/c1-28-18(31)15-5-4-14(9-17(15)23)30-20(34)29(19(32)21(30)6-7-33-11-21)13-3-2-12(10-27)16(8-13)22(24,25)26/h2-5,8-9H,6-7,11H2,1H3,(H,28,31)/t21-/m1/s1
DM2DHJS	CS	CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)[C@]23CCOC3)C4=CC(=C(C=C4)C#N)C(F)(F)F)F
DM2DHJS	IK	QKKPJFTYJCXESR-OAQYLSRUSA-N
DM2DHJS	IU	4-[(5R)-3-[4-cyano-3-(trifluoromethyl)phenyl]-4-oxo-2-sulfanylidene-7-oxa-1,3-diazaspiro[4.4]nonan-1-yl]-2-fluoro-N-methylbenzamide
DM2DHJS	DE	Prostate cancer

DMV6GX7	ID	DMV6GX7
DMV6GX7	DN	ONO-7475
DMV6GX7	HS	Phase 1/2
DMV6GX7	SN	1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO-7475; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide
DMV6GX7	CP	Ono Pharmaceutical
DMV6GX7	DT	Small molecular drug
DMV6GX7	PC	90645873
DMV6GX7	MW	562.6
DMV6GX7	FM	C32H26N4O6
DMV6GX7	IC	InChI=1S/C32H26N4O6/c1-40-28-16-21-24(17-29(28)41-2)33-14-13-27(21)42-20-11-12-30(34-18-20)35-31(38)23-15-22-25(9-6-10-26(22)37)36(32(23)39)19-7-4-3-5-8-19/h3-5,7-8,11-18H,6,9-10H2,1-2H3,(H,34,35,38)
DMV6GX7	CS	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CN=C(C=C3)NC(=O)C4=CC5=C(CCCC5=O)N(C4=O)C6=CC=CC=C6
DMV6GX7	IK	WHMMKPWGWNYYFE-UHFFFAOYSA-N
DMV6GX7	IU	N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide
DMV6GX7	CA	CAS 1646839-59-9
DMV6GX7	DE	Myelodysplastic syndrome; Acute leukaemia

DMXLPYE	ID	DMXLPYE
DMXLPYE	DN	ONO-7579
DMXLPYE	HS	Phase 1/2
DMXLPYE	CP	Ono Pharmaceutical Osaka, Japan
DMXLPYE	DE	Solid tumour/cancer

DMGIN7J	ID	DMGIN7J
DMGIN7J	DN	Onyvax-105
DMGIN7J	HS	Phase 1/2
DMGIN7J	SN	Antibody therapy (colerectal cancer), CRC/Onyvax; Vaccine (colorectal cancer), CRC/ImClone; Vaccine (colorectal cancer), CRC/Onyvax
DMGIN7J	CP	Cancer Research Campaign; VaxOnco
DMGIN7J	DT	Vaccine
DMGIN7J	DE	Colorectal cancer; Prostate cancer

DMIU26T	ID	DMIU26T
DMIU26T	DN	OP-1250
DMIU26T	HS	Phase 1/2
DMIU26T	CP	Olema Pharmaceuticals; Otsuka America Pharmaceutical
DMIU26T	DT	Small interfering RNA
DMIU26T	DE	Breast cancer

DMELJIV	ID	DMELJIV
DMELJIV	DN	OPA-6566
DMELJIV	HS	Phase 1/2
DMELJIV	CP	Acucela; otsuka pharmaceutical
DMELJIV	DE	Glaucoma/ocular hypertension

DM6VGO3	ID	DM6VGO3
DM6VGO3	DN	OPB-31121
DM6VGO3	HS	Phase 1/2
DM6VGO3	CP	Otsuka America Pharmaceutical
DM6VGO3	DE	Hepatocellular carcinoma

DMZB6LO	ID	DMZB6LO
DMZB6LO	DN	OPC-167832
DMZB6LO	HS	Phase 1/2
DMZB6LO	SN	1883747-71-4; 5-(((3R,4R)-1-(4-Chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl)methoxy)-8-fluoro-3,4-dihydroquinolin-2(1H)-one; UNII-1PQN78P4S3; 1PQN78P4S3; SCHEMBL17543112
DMZB6LO	CP	Otsuka America Pharmaceutical
DMZB6LO	DT	Small molecular drug
DMZB6LO	PC	118904282
DMZB6LO	MW	456.8
DMZB6LO	FM	C21H20ClF3N2O4
DMZB6LO	IC	InChI=1S/C21H20ClF3N2O4/c22-11-7-14(24)20(15(25)8-11)27-6-5-21(30,17(28)9-27)10-31-16-3-2-13(23)19-12(16)1-4-18(29)26-19/h2-3,7-8,17,28,30H,1,4-6,9-10H2,(H,26,29)/t17-,21-/m1/s1
DMZB6LO	CS	C1CC(=O)NC2=C(C=CC(=C21)OC[C@@]3(CCN(C[C@H]3O)C4=C(C=C(C=C4F)Cl)F)O)F
DMZB6LO	IK	XZISSTDXPBUCJA-DYESRHJHSA-N
DMZB6LO	IU	5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy]-8-fluoro-3,4-dihydro-1H-quinolin-2-one
DMZB6LO	CA	CAS 1883747-71-4
DMZB6LO	DE	Tuberculosis

DM471ZH	ID	DM471ZH
DM471ZH	DN	ORE-1001
DM471ZH	HS	Phase 1/2
DM471ZH	SN	MLN-4760; UNII-4LD0ZHV25K; 4LD0ZHV25K; CHEMBL429844; MLN 4760; 305335-31-3; (S,S)-2-{1-CARBOXY-2-[3-(3,5-DICHLORO-BENZYL)-3H-IMIDAZOL-4-YL]-ETHYLAMINO}-4-METHYL-PENTANOIC ACID; XX5; N-[(1s)-1-carboxy-3-methylbutyl]-3-(3,5-dichlorobenzyl)-l-histidine; (2S)-2-[[(2S)-3-[3-[(3,5-dichlorophenyl)methyl]imidazol-4-yl]-1-hydroxy-1-oxopropan-2-yl]amino]-4-methylpentanoic acid; AC1L9LSK; GTPL7866; SCHEMBL1691048; BDBM21489; DTXSID70184609; ZINC1549629; DB12271; HY-19414; CS-0015513
DM471ZH	CP	Millennium Pharmaceuticals Inc
DM471ZH	DT	Small molecular drug
DM471ZH	PC	448281
DM471ZH	MW	428.3
DM471ZH	FM	C19H23Cl2N3O4
DM471ZH	IC	InChI=1S/C19H23Cl2N3O4/c1-11(2)3-16(18(25)26)23-17(19(27)28)7-15-8-22-10-24(15)9-12-4-13(20)6-14(21)5-12/h4-6,8,10-11,16-17,23H,3,7,9H2,1-2H3,(H,25,26)(H,27,28)/t16-,17-/m0/s1
DM471ZH	CS	CC(C)C[C@@H](C(=O)O)N[C@@H](CC1=CN=CN1CC2=CC(=CC(=C2)Cl)Cl)C(=O)O
DM471ZH	IK	NTCCRGGIJNDEAB-IRXDYDNUSA-N
DM471ZH	IU	(2S)-2-[[(1S)-1-carboxy-2-[3-[(3,5-dichlorophenyl)methyl]imidazol-4-yl]ethyl]amino]-4-methylpentanoic acid
DM471ZH	CA	CAS 305335-31-3
DM471ZH	CB	CHEBI:166834
DM471ZH	DE	Type-2 diabetes; Diabetic complication

DM27RXS	ID	DM27RXS
DM27RXS	DN	ORIN1001
DM27RXS	HS	Phase 1/2
DM27RXS	CP	Orinove
DM27RXS	DT	Small interfering RNA
DM27RXS	DE	Metastatic breast cancer

DMWCJ1F	ID	DMWCJ1F
DMWCJ1F	DN	OT-58
DMWCJ1F	HS	Phase 1/2
DMWCJ1F	CP	Orphan Technologies
DMWCJ1F	DT	Recombinant protein
DMWCJ1F	DE	Homocystinuria

DMYGK1D	ID	DMYGK1D
DMYGK1D	DN	OTL-300
DMYGK1D	HS	Phase 1/2
DMYGK1D	CP	Orchard Therapeutics
DMYGK1D	DT	Gene therapy
DMYGK1D	DE	Beta thalassemia

DMN0ZQ5	ID	DMN0ZQ5
DMN0ZQ5	DN	OTSGC-A24
DMN0ZQ5	HS	Phase 1/2
DMN0ZQ5	SN	Peptide vaccine (gastric cancer), OncoTherapy
DMN0ZQ5	CP	OncoTherapy Science Inc
DMN0ZQ5	DT	Vaccine
DMN0ZQ5	DE	Colorectal cancer

DMI8RG1	ID	DMI8RG1
DMI8RG1	DN	OTX-015
DMI8RG1	HS	Phase 1/2
DMI8RG1	SN	MK 8628
DMI8RG1	CP	Constellation pharmaceuticals
DMI8RG1	DT	Small molecular drug
DMI8RG1	PC	9936746
DMI8RG1	MW	492
DMI8RG1	FM	C25H22ClN5O2S
DMI8RG1	IC	InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)/t20-/m0/s1
DMI8RG1	CS	CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C
DMI8RG1	IK	GNMUEVRJHCWKTO-FQEVSTJZSA-N
DMI8RG1	IU	2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-(4-hydroxyphenyl)acetamide
DMI8RG1	CA	CAS 202590-98-5
DMI8RG1	DE	Myelodysplastic syndrome; Solid tumour/cancer; Acute myeloid leukaemia

DMXF9DM	ID	DMXF9DM
DMXF9DM	DN	OXB-102
DMXF9DM	HS	Phase 1/2
DMXF9DM	SN	AXO-Lenti-PD
DMXF9DM	CP	Oxford BioMedica; Axovant Sciences
DMXF9DM	DT	Gene therapy
DMXF9DM	DE	Parkinson disease

DMTH75R	ID	DMTH75R
DMTH75R	DN	OXY-111A
DMTH75R	HS	Phase 1/2
DMTH75R	SN	OXYRENS; Myo-inositol trispyrophosphate; Oxyren (oxygen release enhancer) haemoglobin-oxygen affinity allosteric modulators (Cardiovascular disease/cancer), NormOxys
DMTH75R	CP	NormOxys Inc
DMTH75R	DE	Cardiovascular disease

DM6V5OB	ID	DM6V5OB
DM6V5OB	DN	P-552-02
DM6V5OB	HS	Phase 1/2
DM6V5OB	SN	CF-552; KM-003; P-552; Sodium channel blocker (oral, dry mouth/ Sjogren's syndrome), Parion Sciences
DM6V5OB	CP	Parion Sciences Inc
DM6V5OB	DT	Small molecular drug
DM6V5OB	PC	10310524
DM6V5OB	MW	451.9
DM6V5OB	FM	C19H26ClN7O4
DM6V5OB	IC	InChI=1S/C19H26ClN7O4/c20-15-17(22)26-16(21)14(25-15)18(30)27-19(23)24-8-2-1-3-11-4-6-13(7-5-11)31-10-12(29)9-28/h4-7,12,28-29H,1-3,8-10H2,(H4,21,22,26)(H3,23,24,27,30)
DM6V5OB	CS	C1=CC(=CC=C1CCCCN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N)OCC(CO)O
DM6V5OB	IK	NTRKMGDUWYBLMS-UHFFFAOYSA-N
DM6V5OB	IU	3,5-diamino-6-chloro-N-[N'-[4-[4-(2,3-dihydroxypropoxy)phenyl]butyl]carbamimidoyl]pyrazine-2-carboxamide
DM6V5OB	CA	CAS 587879-32-1
DM6V5OB	DE	Cystic fibrosis

DMLSYJQ	ID	DMLSYJQ
DMLSYJQ	DN	PA-799
DMLSYJQ	HS	Phase 1/2
DMLSYJQ	SN	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134
DMLSYJQ	CP	Chugai Pharmaceutical Co Ltd
DMLSYJQ	DT	Small molecular drug
DMLSYJQ	PC	49784945
DMLSYJQ	MW	377.4
DMLSYJQ	FM	C15H19N7O3S
DMLSYJQ	IC	InChI=1S/C15H19N7O3S/c1-26(23,24)22-3-2-11-12(10-8-17-14(16)18-9-10)19-15(20-13(11)22)21-4-6-25-7-5-21/h8-9H,2-7H2,1H3,(H2,16,17,18)
DMLSYJQ	CS	CS(=O)(=O)N1CCC2=C(N=C(N=C21)N3CCOCC3)C4=CN=C(N=C4)N
DMLSYJQ	IK	JEGHXKRHKHPBJD-UHFFFAOYSA-N
DMLSYJQ	IU	5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine
DMLSYJQ	CA	CAS 1007207-67-1
DMLSYJQ	DE	Solid tumour/cancer; Colorectal cancer

DMZKFJO	ID	DMZKFJO
DMZKFJO	DN	PAT-SC1
DMZKFJO	HS	Phase 1/2
DMZKFJO	SN	SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab
DMZKFJO	CP	Universitat Wurzburg
DMZKFJO	DT	Antibody
DMZKFJO	DE	Gastric adenocarcinoma

DMJC2RU	ID	DMJC2RU
DMJC2RU	DN	PBCAR0191
DMJC2RU	HS	Phase 1/2
DMJC2RU	CP	Precision BioSciences, Inc.
DMJC2RU	DT	CAR T Cell Therapy
DMJC2RU	DE	Acute lymphoblastic leukaemia; Non-hodgkin lymphoma

DM7NKWQ	ID	DM7NKWQ
DM7NKWQ	DN	PBCAR20A
DM7NKWQ	HS	Phase 1/2
DM7NKWQ	CP	Precision Biosciences
DM7NKWQ	DT	CAR T Cell Therapy
DM7NKWQ	DE	Non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma

DMSGM2L	ID	DMSGM2L
DMSGM2L	DN	PBCAR269A
DMSGM2L	HS	Phase 1/2
DMSGM2L	CP	Precision Biosciences
DMSGM2L	DT	CAR T Cell Therapy
DMSGM2L	DE	Multiple myeloma

DMGFPQ0	ID	DMGFPQ0
DMGFPQ0	DN	PBF509
DMGFPQ0	HS	Phase 1/2
DMGFPQ0	SN	5-Bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine; 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine; SCHEMBL2546228; CHEMBL3694769; ATFXVNUWQOXRRU-UHFFFAOYSA-N; BDBM128295; ZINC72317391; AKOS030527812; DS-19509; US8796284, 1; 1337962-47-6
DMGFPQ0	CP	Novartis OncologyEast Hanover, NJ Palobiofarma Barcelona, Spain
DMGFPQ0	PC	53466958
DMGFPQ0	MW	306.12
DMGFPQ0	FM	C10H8BrN7
DMGFPQ0	IC	InChI=1S/C10H8BrN7/c11-7-8(12)15-10(18-6-2-4-14-18)16-9(7)17-5-1-3-13-17/h1-6H,(H2,12,15,16)
DMGFPQ0	CS	C1=CN(N=C1)C2=NC(=NC(=C2Br)N)N3C=CC=N3
DMGFPQ0	IK	ATFXVNUWQOXRRU-UHFFFAOYSA-N
DMGFPQ0	IU	5-bromo-2,6-di(pyrazol-1-yl)pyrimidin-4-amine
DMGFPQ0	CA	CAS 1337962-47-6
DMGFPQ0	DE	Non-small-cell lung cancer

DMSJ54W	ID	DMSJ54W
DMSJ54W	DN	PC14586
DMSJ54W	HS	Phase 1/2
DMSJ54W	CP	PMV Pharmaceuticals
DMSJ54W	DT	Small interfering RNA
DMSJ54W	DE	Solid tumour/cancer

DM9DR13	ID	DM9DR13
DM9DR13	DN	PCAR-019
DM9DR13	HS	Phase 1/2
DM9DR13	CP	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
DM9DR13	DT	CAR T Cell Therapy
DM9DR13	DE	Acute lymphocytic leukaemia; B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma

DM1D6BT	ID	DM1D6BT
DM1D6BT	DN	PEGylated hyaluronidase (human recombinant)
DM1D6BT	HS	Phase 1/2
DM1D6BT	SN	PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme
DM1D6BT	CP	Halozyme Therapeutics San Diego; CA
DM1D6BT	DE	Pancreatic cancer

DMMAUOK	ID	DMMAUOK
DMMAUOK	DN	PEN-221
DMMAUOK	HS	Phase 1/2
DMMAUOK	CP	Tarveda Therapeutics Watertown, MA
DMMAUOK	PC	118634103
DMMAUOK	MW	1786.6
DMMAUOK	FM	C83H109ClN14O20S4
DMMAUOK	IC	InChI=1S/C83H109ClN14O20S4/c1-44-18-17-24-65(115-9)83(113)39-64(116-81(112)96-83)45(2)71-82(5,118-71)66(38-68(102)98(7)62-35-50(32-44)36-63(114-8)69(62)84)117-80(111)46(3)97(6)67(101)29-31-119-120-41-59(72(87)103)92-78(109)61-43-122-121-42-60(93-73(104)54(86)33-48-19-11-10-12-20-48)77(108)90-57(34-49-25-27-52(100)28-26-49)75(106)91-58(37-51-40-88-55-22-14-13-21-53(51)55)76(107)89-56(23-15-16-30-85)74(105)95-70(47(4)99)79(110)94-61/h10-14,17-22,24-28,35-36,40,45-47,54,56-61,64-66,70-71,88,99-100,113H,15-16,23,29-34,37-39,41-43,85-86H2,1-9H3,(H2,87,103)(H,89,107)(H,90,108)(H,91,106)(H,92,109)(H,93,104)(H,94,110)(H,95,105)(H,96,112)/b24-17+,44-18+/t45-,46+,47-,54-,56+,57+,58-,59+,60+,61+,64+,65-,66+,70+,71+,82+,83+/m1/s1
DMMAUOK	CS	C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCSSC[C@@H](C(=O)N)NC(=O)[C@@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)[C@@H](C)O)CCCCN)CC6=CNC7=CC=CC=C76)CC8=CC=C(C=C8)O)NC(=O)[C@@H](CC9=CC=CC=C9)N)C)\\C)OC)(NC(=O)O2)O
DMMAUOK	IK	JVPMJFUBODFGNB-UFDFPQQFSA-N
DMMAUOK	IU	[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[3-[[(2R)-3-amino-2-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-oxopropyl]disulfanyl]propanoyl-methylamino]propanoate
DMMAUOK	CA	CAS 1853254-97-3
DMMAUOK	DE	Neuroendocrine cancer; Small-cell lung cancer

DMLPTOF	ID	DMLPTOF
DMLPTOF	DN	PEN-866
DMLPTOF	HS	Phase 1/2
DMLPTOF	CP	Tarveda Therapeutics Watertown, MA
DMLPTOF	PC	135564925
DMLPTOF	MW	880
DMLPTOF	FM	C49H49N7O9
DMLPTOF	IC	InChI=1S/C49H49N7O9/c1-5-31-33-20-30(8-9-38(33)50-43-35(31)24-55-40(43)22-37-36(45(55)59)25-64-46(60)49(37,63)6-2)65-48(62)54-16-12-27(13-17-54)11-15-53-18-14-28-19-29(7-10-39(28)53)56-44(51-52-47(56)61)34-21-32(26(3)4)41(57)23-42(34)58/h7-10,14,18-23,26-27,57-58,63H,5-6,11-13,15-17,24-25H2,1-4H3,(H,52,61)/t49-/m0/s1
DMLPTOF	CS	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)CCN7C=CC8=C7C=CC(=C8)N9C(=NNC9=O)C1=CC(=C(C=C1O)O)C(C)C
DMLPTOF	IK	QTPZAEAYDWMVJO-GGCSAXROSA-N
DMLPTOF	IU	[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-[2-[5-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-oxo-1H-1,2,4-triazol-4-yl]indol-1-yl]ethyl]piperidine-1-carboxylate
DMLPTOF	CA	CAS 1472614-83-7
DMLPTOF	DE	Solid tumour/cancer

DMM9L1R	ID	DMM9L1R
DMM9L1R	DN	PEP-223/CoVaccine HT
DMM9L1R	HS	Phase 1/2
DMM9L1R	SN	Prostate cancer vaccine, Pepscan/Novartis; Prostate cancer vaccine, Pepscan/PowderJect; Prostate cancer vaccine(anti-GnRH, TDK), Pepscan
DMM9L1R	CP	Pepscan Systems BV
DMM9L1R	DT	Vaccine
DMM9L1R	DE	Prostate cancer

DM03GDJ	ID	DM03GDJ
DM03GDJ	DN	Pepinemab
DM03GDJ	HS	Phase 1/2
DM03GDJ	SN	VX15/2503
DM03GDJ	CP	Vaccinex
DM03GDJ	DT	Antibody
DM03GDJ	DE	Squamous head and neck cell carcinom

DMBUJVX	ID	DMBUJVX
DMBUJVX	DN	Phenoxodiol
DMBUJVX	HS	Phase 1/2
DMBUJVX	SN	Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran
DMBUJVX	CP	Marshall Edwards
DMBUJVX	TC	Anticancer Agents
DMBUJVX	DT	Small molecular drug
DMBUJVX	PC	219100
DMBUJVX	MW	240.25
DMBUJVX	FM	C15H12O3
DMBUJVX	IC	InChI=1S/C15H12O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-8,16-17H,9H2
DMBUJVX	CS	C1C(=CC2=C(O1)C=C(C=C2)O)C3=CC=C(C=C3)O
DMBUJVX	IK	ZZUBHVMHNVYXRR-UHFFFAOYSA-N
DMBUJVX	IU	3-(4-hydroxyphenyl)-2H-chromen-7-ol
DMBUJVX	CA	CAS 81267-65-4
DMBUJVX	DE	Ovarian cancer

DMYEAB1	ID	DMYEAB1
DMYEAB1	DN	PIPERINE
DMYEAB1	HS	Phase 1/2
DMYEAB1	SN	piperine; 94-62-2; 1-Piperoylpiperidine; Piperin; Bioperine; Piperoylpiperidine; (E,E)-1-piperoylpiperidine; N-[(E,E)-Piperoyl]piperidine; Piperidine, 1-piperoyl-, (E,E)-; UNII-U71XL721QK; FEMA No. 2909; CCRIS 5572; Piperine (aliphatic); 1-Piperoylpiperidine, (E,E)-; 7780-20-3; C17H19NO3; EINECS 202-348-0; NSC 21727; 1-[(2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoyl]piperidine; N-(E,E)-piperoyl-piperidine; CHEMBL43185; U71XL721QK; CHEBI:28821; MXXWOMGUGJBKIW-YPCIICBESA-N; NSC21727; piperidine, 1-[(2E,4E)-5-(1,3-benzodioxol-5-yl)
DMYEAB1	DT	Small molecular drug
DMYEAB1	PC	638024
DMYEAB1	MW	285.34
DMYEAB1	FM	C17H19NO3
DMYEAB1	IC	InChI=1S/C17H19NO3/c19-17(18-10-4-1-5-11-18)7-3-2-6-14-8-9-15-16(12-14)21-13-20-15/h2-3,6-9,12H,1,4-5,10-11,13H2/b6-2+,7-3+
DMYEAB1	CS	C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3
DMYEAB1	IK	MXXWOMGUGJBKIW-YPCIICBESA-N
DMYEAB1	IU	(2E,4E)-5-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylpenta-2,4-dien-1-one
DMYEAB1	CA	CAS 94-62-2
DMYEAB1	CB	CHEBI:28821
DMYEAB1	DE	Vitiligo

DMX168L	ID	DMX168L
DMX168L	DN	PLX2853
DMX168L	HS	Phase 1/2
DMX168L	CP	Plexxikon
DMX168L	DT	Small molecular drug
DMX168L	DE	Acute myeloid leukaemia; Solid tumour/cancer

DM5DZEL	ID	DM5DZEL
DM5DZEL	DN	PLX9486
DM5DZEL	HS	Phase 1/2
DM5DZEL	SN	CGT9486
DM5DZEL	CP	Plexxikon
DM5DZEL	DT	Small molecular drug
DM5DZEL	DE	Solid tumour/cancer; Gastrointestinal stromal tumour

DMQOW0H	ID	DMQOW0H
DMQOW0H	DN	PP-1420
DMQOW0H	HS	Phase 1/2
DMQOW0H	SN	Pancreatic polypeptide analog (sc, obesity), Imperial College London
DMQOW0H	CP	Imperial College London
DMQOW0H	DE	Obesity

DM0HTEF	ID	DM0HTEF
DM0HTEF	DN	PRI-724
DM0HTEF	HS	Phase 1/2
DM0HTEF	CP	PRISM BioLab
DM0HTEF	PC	71509318
DM0HTEF	MW	658.6
DM0HTEF	FM	C33H35N6O7P
DM0HTEF	IC	InChI=1S/C33H35N6O7P/c1-22-31-38(29(40)21-36(2)39(31)33(42)35-19-24-8-4-3-5-9-24)28(18-23-13-15-27(16-14-23)46-47(43,44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17,22,28,31H,18-21H2,1-2H3,(H,35,42)(H2,43,44,45)/t22-,28-,31-/m0/s1
DM0HTEF	CS	C[C@H]1[C@H]2N([C@H](C(=O)N1CC3=CC=CC4=C3N=CC=C4)CC5=CC=C(C=C5)OP(=O)(O)O)C(=O)CN(N2C(=O)NCC6=CC=CC=C6)C
DM0HTEF	IK	VHOZWHQPEJGPCC-AZXNYEMZSA-N
DM0HTEF	IU	[4-[[(6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] dihydrogen phosphate
DM0HTEF	CA	CAS 1422253-38-0
DM0HTEF	DE	Acute myeloid leukaemia

DM8J5H1	ID	DM8J5H1
DM8J5H1	DN	PRLX93936
DM8J5H1	HS	Phase 1/2
DM8J5H1	CP	Prolexys Pharmaceuticals
DM8J5H1	DE	Solid tumour/cancer

DMJ42E6	ID	DMJ42E6
DMJ42E6	DN	ProSavin
DMJ42E6	HS	Phase 1/2
DMJ42E6	SN	Dopamine synthesis pathway gene therapy (Parkinson's disease), Oxford BioMedica
DMJ42E6	CP	Oxford BioMedica plc
DMJ42E6	DE	Parkinson disease

DMOUW65	ID	DMOUW65
DMOUW65	DN	PRX-102
DMOUW65	HS	Phase 1/2
DMOUW65	SN	Galactosidase enzyme replacement therapy (Fabry disease), Protalix
DMOUW65	CP	Protalix biotherapeutics
DMOUW65	PC	121488171
DMOUW65	MW	560.6
DMOUW65	FM	C24H44N6O9
DMOUW65	IC	InChI=1S/C24H44N6O9/c25-17(23(35)36)5-1-3-11-27-19(31)7-9-21(33)29-13-15-39-16-14-30-22(34)10-8-20(32)28-12-4-2-6-18(26)24(37)38/h17-18H,1-16,25-26H2,(H,27,31)(H,28,32)(H,29,33)(H,30,34)(H,35,36)(H,37,38)/t17-,18-/m0/s1
DMOUW65	CS	C(CCNC(=O)CCC(=O)NCCOCCNC(=O)CCC(=O)NCCCC[C@@H](C(=O)O)N)C[C@@H](C(=O)O)N
DMOUW65	IK	CQPWQUAJPPFCDP-ROUUACIJSA-N
DMOUW65	IU	(2S)-2-amino-6-[[4-[2-[2-[[4-[[(5S)-5-amino-5-carboxypentyl]amino]-4-oxobutanoyl]amino]ethoxy]ethylamino]-4-oxobutanoyl]amino]hexanoic acid
DMOUW65	CA	CAS 1644392-61-9
DMOUW65	DE	Fabry disease

DM2CDLS	ID	DM2CDLS
DM2CDLS	DN	QLT-091568
DM2CDLS	HS	Phase 1/2
DM2CDLS	SN	OT-730; Beta adrenoceptor antagonist prodrug (glaucoma/ocular hypertension), Othera
DM2CDLS	CP	Othera Pharmaceuticals Inc
DM2CDLS	PC	11554979
DM2CDLS	MW	492.6
DM2CDLS	FM	C25H36N2O8
DM2CDLS	IC	InChI=1S/C25H36N2O8/c1-15-9-19(28)20(29)10-18(15)22(31)34-13-17(35-23(32)25(4)6-7-25)11-27-24(2,3)14-26-21(30)16-5-8-33-12-16/h9-10,16-17,27-29H,5-8,11-14H2,1-4H3,(H,26,30)/t16?,17-/m0/s1
DM2CDLS	CS	CC1=CC(=C(C=C1C(=O)OC[C@H](CNC(C)(C)CNC(=O)C2CCOC2)OC(=O)C3(CC3)C)O)O
DM2CDLS	IK	ANXXSWNMHQHOQC-DJNXLDHESA-N
DM2CDLS	IU	[(2S)-2-(1-methylcyclopropanecarbonyl)oxy-3-[[2-methyl-1-(oxolane-3-carbonylamino)propan-2-yl]amino]propyl] 4,5-dihydroxy-2-methylbenzoate
DM2CDLS	CA	CAS 870809-51-1
DM2CDLS	DE	Glaucoma/ocular hypertension

DMZD7OA	ID	DMZD7OA
DMZD7OA	DN	Quaratusugene ozeplasmid
DMZD7OA	HS	Phase 1/2
DMZD7OA	SN	GPX-001; CNVN 202
DMZD7OA	CP	Genprex
DMZD7OA	DT	Gene therapy
DMZD7OA	DE	Non-small-cell lung cancer

DM614BA	ID	DM614BA
DM614BA	DN	Re-188-P-2045
DM614BA	HS	Phase 1/2
DM614BA	SN	Neotide; RE-P2045; Rhenium 188-P-2045; Rhenium-188-labeled peptide (lung cancer), Antisoma; Rhenium-188-labeled peptide (lung cancer), Bryan Oncor/ Antisoma
DM614BA	CP	Diatide Inc
DM614BA	DE	Lung cancer

DMY3TAD	ID	DMY3TAD
DMY3TAD	DN	Recombinant factor VIIa PEGylated liposomal
DMY3TAD	HS	Phase 1/2
DMY3TAD	SN	Recombinant factor VIIa; Recombinant factor VIIa (PEGylated liposomal (NecLip), Hemophilia A) Recoly
DMY3TAD	CP	Recoly NV
DMY3TAD	DE	Factor VII deficiency

DM7LOSK	ID	DM7LOSK
DM7LOSK	DN	REGN4018
DM7LOSK	HS	Phase 1/2
DM7LOSK	DT	Antibody
DM7LOSK	DE	Ovarian cancer

DMAGX0Q	ID	DMAGX0Q
DMAGX0Q	DN	REGN5458
DMAGX0Q	HS	Phase 1/2
DMAGX0Q	DT	Antibody
DMAGX0Q	DE	Multiple myeloma

DMRE0LU	ID	DMRE0LU
DMRE0LU	DN	REGN5459
DMRE0LU	HS	Phase 1/2
DMRE0LU	CP	Regeneron Pharmaceuticals; Sanofi
DMRE0LU	DT	Antibody
DMRE0LU	DE	Multiple myeloma

DM0Y6WU	ID	DM0Y6WU
DM0Y6WU	DN	REGN5678
DM0Y6WU	HS	Phase 1/2
DM0Y6WU	CP	Regeneron Pharmaceuticals
DM0Y6WU	DT	Antibody
DM0Y6WU	DE	Prostate cancer

DM5MFHO	ID	DM5MFHO
DM5MFHO	DN	REIC gene therapy
DM5MFHO	HS	Phase 1/2
DM5MFHO	CP	Momotaro-Gene
DM5MFHO	DE	Prostate cancer

DMDO6J1	ID	DMDO6J1
DMDO6J1	DN	Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
DMDO6J1	HS	Phase 1/2
DMDO6J1	CP	Xinqiao Hospital of Chongqing
DMDO6J1	DT	CAR T Cell Therapy
DMDO6J1	DE	Hepatocellular carcinoma

DMAGE91	ID	DMAGE91
DMAGE91	DN	RG7800
DMAGE91	HS	Phase 1/2
DMAGE91	PC	89741565
DMAGE91	MW	416.5
DMAGE91	FM	C24H28N6O
DMAGE91	IC	InChI=1S/C24H28N6O/c1-5-19-22-11-21(27-30(22)13-16(3)25-19)20-12-23(31)29-14-18(10-15(2)24(29)26-20)17-6-8-28(4)9-7-17/h10-14,17H,5-9H2,1-4H3
DMAGE91	CS	CCC1=NC(=CN2C1=CC(=N2)C3=CC(=O)N4C=C(C=C(C4=N3)C)C5CCN(CC5)C)C
DMAGE91	IK	GYFRQCMDLBNZSF-UHFFFAOYSA-N
DMAGE91	IU	2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methylpiperidin-4-yl)pyrido[1,2-a]pyrimidin-4-one
DMAGE91	DE	Spinal muscular atrophy

DM5AIKR	ID	DM5AIKR
DM5AIKR	DN	RGX-104
DM5AIKR	HS	Phase 1/2
DM5AIKR	SN	Rgx-104 hydrochloride; RGX-104 hydrochloride; 610318-03-1; UNII-D32013XLTX; SCHEMBL3975944; D32013XLTX; LCMIYQOJZLRHTO-GJFSDDNBSA-N; (r)-2-(3-{3-[[2chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid hydrochloride salt
DM5AIKR	CP	Rgenix New York, NY
DM5AIKR	PC	68861574
DM5AIKR	MW	632.5
DM5AIKR	FM	C34H34Cl2F3NO3
DM5AIKR	IC	InChI=1S/C34H33ClF3NO3.ClH/c1-24(18-19-42-29-16-8-10-25(20-29)21-32(40)41)39(22-28-15-9-17-31(33(28)35)34(36,37)38)23-30(26-11-4-2-5-12-26)27-13-6-3-7-14-27;/h2-17,20,24,30H,18-19,21-23H2,1H3,(H,40,41);1H/t24-;/m1./s1
DM5AIKR	CS	C[C@H](CCOC1=CC=CC(=C1)CC(=O)O)N(CC2=C(C(=CC=C2)C(F)(F)F)Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4.Cl
DM5AIKR	IK	LCMIYQOJZLRHTO-GJFSDDNBSA-N
DM5AIKR	IU	2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid;hydrochloride
DM5AIKR	CA	CAS 610318-03-1
DM5AIKR	DE	Lymphoma; Solid tumour/cancer; Non-small-cell lung cancer

DMU3PD7	ID	DMU3PD7
DMU3PD7	DN	RGX-121
DMU3PD7	HS	Phase 1/2
DMU3PD7	CP	REGENXBIO
DMU3PD7	DT	Gene therapy
DMU3PD7	DE	Mucopolysaccharidosis

DMSDZ8U	ID	DMSDZ8U
DMSDZ8U	DN	Rintatolimod
DMSDZ8U	HS	Phase 1/2
DMSDZ8U	SN	Ampligen
DMSDZ8U	TC	Antiviral Agents
DMSDZ8U	DT	Protein/peptide drug
DMSDZ8U	DE	Coronavirus Disease 2019 (COVID-19)

DM9FNC8	ID	DM9FNC8
DM9FNC8	DN	RP-3500
DM9FNC8	HS	Phase 1/2
DM9FNC8	CP	Repare Therapeutics
DM9FNC8	DT	Small molecular drug
DM9FNC8	DE	Solid tumour/cancer

DMKVMWO	ID	DMKVMWO
DMKVMWO	DN	RP-L201
DMKVMWO	HS	Phase 1/2
DMKVMWO	CP	Rocket Pharmaceuticals
DMKVMWO	DT	Gene therapy
DMKVMWO	DE	Leukocyte adhesion deficiency type 1

DMXYHC7	ID	DMXYHC7
DMXYHC7	DN	RU-101
DMXYHC7	HS	Phase 1/2
DMXYHC7	SN	RU-10; Recombinant human serum albumin (ocular, dry eye), R-Tech Ueno
DMXYHC7	CP	R-tech ueno
DMXYHC7	DE	Xerophthalmia

DM1LO8K	ID	DM1LO8K
DM1LO8K	DN	RVX-208
DM1LO8K	HS	Phase 1/2
DM1LO8K	CP	Resverlogix
DM1LO8K	DT	Small molecular drug
DM1LO8K	PC	24871506
DM1LO8K	DE	Alzheimer disease

DMCBQTF	ID	DMCBQTF
DMCBQTF	DN	S-3304
DMCBQTF	HS	Phase 1/2
DMCBQTF	SN	BPHA; BPHA, Shionogi; MMP inhibitors, Shionogi; Matrix metalloproteinase inhibitor, Shionogi
DMCBQTF	CP	Shionogi & Co Ltd
DMCBQTF	DT	Small molecular drug
DMCBQTF	PC	10718956
DMCBQTF	MW	464.6
DMCBQTF	FM	C24H20N2O4S2
DMCBQTF	IC	InChI=1S/C24H20N2O4S2/c1-16-6-8-17(9-7-16)10-11-19-12-13-23(31-19)32(29,30)26-22(24(27)28)14-18-15-25-21-5-3-2-4-20(18)21/h2-9,12-13,15,22,25-26H,14H2,1H3,(H,27,28)/t22-/m1/s1
DMCBQTF	CS	CC1=CC=C(C=C1)C#CC2=CC=C(S2)S(=O)(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)O
DMCBQTF	IK	YWCLDDLVLSQGSZ-JOCHJYFZSA-N
DMCBQTF	IU	(2R)-3-(1H-indol-3-yl)-2-[[5-[2-(4-methylphenyl)ethynyl]thiophen-2-yl]sulfonylamino]propanoic acid
DMCBQTF	CA	CAS 203640-27-1
DMCBQTF	DE	Solid tumour/cancer

DMVKQT8	ID	DMVKQT8
DMVKQT8	DN	SALACINOL
DMVKQT8	HS	Phase 1/2
DMVKQT8	SN	SALACINOL; 200399-47-9; CHEMBL239249; CHEMBL1208974; AC1O52U7; BDBM50180585; BDBM50330955; FT-0674499; 1,4-dideoxy-1,4-{(S)-[(2S,3S)-2,4-dihydroxy-3-(sulfooxy)butyl]episulfoniumylidene}-D-arabinitol; 1,4-Dideoxy-1,4-[(S)-[(2S,3S)-2,4-dihydroxy-3-(sulfooxy)butyl]episulfoniumylidene]-D-arabinitol Inner Salt; [(2S,3S)-4-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-1,3-dihydroxybutan-2-yl] sulfate
DMVKQT8	DT	Small molecular drug
DMVKQT8	PC	6451151
DMVKQT8	MW	334.4
DMVKQT8	FM	C9H18O9S2
DMVKQT8	IC	InChI=1S/C9H18O9S2/c10-1-7(18-20(15,16)17)5(12)3-19-4-6(13)9(14)8(19)2-11/h5-14H,1-4H2/t5-,6-,7+,8-,9+,19?/m1/s1
DMVKQT8	CS	C1[C@H]([C@@H]([C@H]([S+]1C[C@H]([C@H](CO)OS(=O)(=O)[O-])O)CO)O)O
DMVKQT8	IK	SOWRVDSZMRPKRG-XESHOGEWSA-N
DMVKQT8	IU	[(2S,3S)-4-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-1,3-dihydroxybutan-2-yl] sulfate
DMVKQT8	CA	CAS 200399-47-9

DMPXOGD	ID	DMPXOGD
DMPXOGD	DN	SAR-161271
DMPXOGD	HS	Phase 1/2
DMPXOGD	CP	Sanofi
DMPXOGD	DE	Type-1 diabetes

DM6M8O4	ID	DM6M8O4
DM6M8O4	DN	SAR440234
DM6M8O4	HS	Phase 1/2
DM6M8O4	CP	Sanofi
DM6M8O4	DT	Antibody
DM6M8O4	DE	Acute myeloid leukaemia; leukaemia

DMD20YH	ID	DMD20YH
DMD20YH	DN	SAR-650984
DMD20YH	HS	Phase 1/2
DMD20YH	SN	Anti-CD38 monoclonal antibody (leukemia), ImmunoGen/sanofi-aventis
DMD20YH	CP	ImmunoGen Inc
DMD20YH	DT	Antibody
DMD20YH	DE	Haematological malignancy

DMA8Z4N	ID	DMA8Z4N
DMA8Z4N	DN	SB-318
DMA8Z4N	HS	Phase 1/2
DMA8Z4N	CP	Sangamo Therapeutics
DMA8Z4N	DT	Gene therapy
DMA8Z4N	DE	Mucopolysaccharidosis

DM98YFK	ID	DM98YFK
DM98YFK	DN	SB-913
DM98YFK	HS	Phase 1/2
DM98YFK	CP	Sangamo Therapeutics
DM98YFK	DT	Gene therapy
DM98YFK	DE	Mucopolysaccharidosis

DMUP52Y	ID	DMUP52Y
DMUP52Y	DN	SB-FIX
DMUP52Y	HS	Phase 1/2
DMUP52Y	CP	Sangamo Therapeutics
DMUP52Y	DT	Gene therapy
DMUP52Y	DE	Haemophilia B

DMS1NMO	ID	DMS1NMO
DMS1NMO	DN	SCRI-huCAR19v1
DMS1NMO	HS	Phase 1/2
DMS1NMO	CP	Seattle Children's Hospital
DMS1NMO	DT	CAR T Cell Therapy
DMS1NMO	DE	leukaemia; Lymphoma

DMBFUOI	ID	DMBFUOI
DMBFUOI	DN	SECTA belomycin
DMBFUOI	HS	Phase 1/2
DMBFUOI	CP	Inovio
DMBFUOI	DE	Solid tumour/cancer

DMD37Q5	ID	DMD37Q5
DMD37Q5	DN	SEL24
DMD37Q5	HS	Phase 1/2
DMD37Q5	SN	MEN1703
DMD37Q5	CP	Menarini
DMD37Q5	DT	Small molecular drug
DMD37Q5	DE	Acute myeloid leukaemia

DMH064K	ID	DMH064K
DMH064K	DN	SEL-24
DMH064K	HS	Phase 1/2
DMH064K	SN	Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita
DMH064K	CP	Selvita Life Sciences Solutions
DMH064K	DE	Solid tumour/cancer; Acute myeloid leukaemia

DM4NK3J	ID	DM4NK3J
DM4NK3J	DN	SF0166
DM4NK3J	HS	Phase 1/2
DM4NK3J	CP	SciFluor Life Sciences Cambridge, MA
DM4NK3J	DE	Diabetic macular edema

DMRC7PI	ID	DMRC7PI
DMRC7PI	DN	SGN-CD33A
DMRC7PI	HS	Phase 1/2
DMRC7PI	CP	Seattle genetics
DMRC7PI	DT	Antibody
DMRC7PI	DE	Acute myeloid leukaemia

DMADNY3	ID	DMADNY3
DMADNY3	DN	SHR-1314
DMADNY3	HS	Phase 1/2
DMADNY3	CP	Jiangsu HengRui Medicine Shanghai, China
DMADNY3	DE	Plaque psoriasis

DMMUCH0	ID	DMMUCH0
DMMUCH0	DN	SHR2554
DMMUCH0	HS	Phase 1/2
DMMUCH0	CP	Jiangsu Hengrui
DMMUCH0	DT	Small molecular drug
DMMUCH0	DE	Haematopoietic/lymphoid cancer; Prostate cancer

DMZTQD8	ID	DMZTQD8
DMZTQD8	DN	Sirna-027
DMZTQD8	HS	Phase 1/2
DMZTQD8	CP	Sirna Therapeutics
DMZTQD8	DT	siRNA drug
DMZTQD8	DE	Neovascular age-related macular degeneration; Exudative age-related macular degeneration

DMSOX57	ID	DMSOX57
DMSOX57	DN	SJCAR19
DMSOX57	HS	Phase 1/2
DMSOX57	CP	St. Jude Children's Research Hospital
DMSOX57	DT	CAR T Cell Therapy
DMSOX57	DE	Acute lymphoblastic leukaemia

DMSTEFK	ID	DMSTEFK
DMSTEFK	DN	SKB264
DMSTEFK	HS	Phase 1/2
DMSTEFK	CP	KLUS Pharma
DMSTEFK	DT	Antibody drug conjugate
DMSTEFK	DE	Solid tumour/cancer

DMOCHVE	ID	DMOCHVE
DMOCHVE	DN	SL-401
DMOCHVE	HS	Phase 1/2
DMOCHVE	CP	Stemline Therapeutics
DMOCHVE	DE	Blastic plasmacytoid dendritic cell neoplasm; Acute myeloid leukaemia; Multiple myeloma; Myeloproliferative neoplasm

DMEJT5Z	ID	DMEJT5Z
DMEJT5Z	DN	SN-32793
DMEJT5Z	HS	Phase 1/2
DMEJT5Z	SN	PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha
DMEJT5Z	CP	University of Auckland
DMEJT5Z	DE	Non-small-cell lung cancer

DMCGX9Y	ID	DMCGX9Y
DMCGX9Y	DN	SNDX-5613
DMCGX9Y	HS	Phase 1/2
DMCGX9Y	SN	2169919-21-3; SNDX5613; SCHEMBL19693219; SCHEMBL19693428; EX-A4343; NSC825775; NSC-825775; HY-136175; CS-0120274
DMCGX9Y	CP	Syndax Pharmaceuticals
DMCGX9Y	DT	Small molecular drug
DMCGX9Y	PC	132212657
DMCGX9Y	MW	630.8
DMCGX9Y	FM	C32H47FN6O4S
DMCGX9Y	IC	InChI=1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3
DMCGX9Y	CS	CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC
DMCGX9Y	IK	FRVSRBKUQZKTOW-UHFFFAOYSA-N
DMCGX9Y	IU	N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide
DMCGX9Y	DE	T lymphoblastic leukaemia

DMNV8SY	ID	DMNV8SY
DMNV8SY	DN	SNN-0029
DMNV8SY	HS	Phase 1/2
DMNV8SY	SN	VEGF (intracerebroventricular, amyotrophic lateral sclerosis), NeuroNova/VIB/Genentech
DMNV8SY	CP	Flanders Interuniversity Institute for Biotechnology (VIB)
DMNV8SY	DE	Lateral sclerosis

DM2X3BR	ID	DM2X3BR
DM2X3BR	DN	SNN-0031
DM2X3BR	HS	Phase 1/2
DM2X3BR	SN	Platelet derived growth factor (parkinson's disease), NeuroNova; PDGF-BB (parkinson's disease), NeuroNova
DM2X3BR	CP	NeuroNova AB
DM2X3BR	DE	Brain injury

DMIU0VP	ID	DMIU0VP
DMIU0VP	DN	SNX-5422
DMIU0VP	HS	Phase 1/2
DMIU0VP	SN	908115-27-5; PF-04929113; SNX-5422; SNX 5422; SNX5422; UNII-BF52J69Q8T; PF 04929113; PF-04929113 (SNX-5422); BF52J69Q8T; PF04929113; PF-4929113; cc-40; MLS006011083; SCHEMBL1220791; SCHEMBL1220790; CHEMBL1195136; SCHEMBL15604989; DTXSID50238270; C25H30F3N5O4; MolPort-023-293-502; BCPP000065; HMS3656B09; EX-A2343; BCP02427; s2656; ZINC95616595; ABP000737; ZINC100071931; ZINC252517142; AKOS027276395; SB16643; DB06070; API0008143; RL05706; SNX-5422 /; CS-0272; NCGC00346640-01; NCGC00386184-02; Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrah
DMIU0VP	CP	Serenex
DMIU0VP	DT	Small molecular drug
DMIU0VP	PC	44195571
DMIU0VP	MW	521.5
DMIU0VP	FM	C25H30F3N5O4
DMIU0VP	IC	InChI=1S/C25H30F3N5O4/c1-24(2)10-18-21(19(34)11-24)22(25(26,27)28)32-33(18)14-5-8-16(23(30)36)17(9-14)31-13-3-6-15(7-4-13)37-20(35)12-29/h5,8-9,13,15,31H,3-4,6-7,10-12,29H2,1-2H3,(H2,30,36)
DMIU0VP	CS	CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)OC(=O)CN)C(F)(F)F)C
DMIU0VP	IK	AVDSOVJPJZVBTC-UHFFFAOYSA-N
DMIU0VP	IU	[4-[2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]anilino]cyclohexyl] 2-aminoacetate
DMIU0VP	CA	CAS 908115-27-5
DMIU0VP	DE	Haematological malignancy; Chronic lymphocytic leukaemia; Neuroendocrine cancer; Non-small-cell lung cancer

DMXNTR7	ID	DMXNTR7
DMXNTR7	DN	SOBI003
DMXNTR7	HS	Phase 1/2
DMXNTR7	CP	Swedish Orphan Biovitrum
DMXNTR7	DT	Recombinant protein
DMXNTR7	DE	Sanfilippo syndrome

DMST6A3	ID	DMST6A3
DMST6A3	DN	Sodium pyruvate
DMST6A3	HS	Phase 1/2
DMST6A3	SN	SODIUM PYRUVATE; 113-24-6; Pyruvic acid sodium salt; sodium 2-oxopropanoate; Pyruvic acid, sodium salt; Propanoic acid, 2-oxo-, sodium salt; Sodium alpha-ketopropionate; 2-Oxopropanoic acid sodium salt; UNII-POD38AIF08; POD38AIF08; CHEBI:50144; Natriumpyruvat; alpha-Ketopropionic acid sodium salt; MFCD00002586; Propanoic acid, 2-oxo-, sodium salt (1:1); S-6005; Pyruvic acid, sodium salt, 99+%; Pyruvate Sodium; Natrum pyruvicum; CHEMBL181886; sodiumpyruvate; Guna-flam; Guna-hypertension; EINECS 204-024-4; pyruvic acid na-salt;  N-115; Sodium pyruvate (inhaled); Reactive oxygen species antagonist (inhaled), EmphyCorp; Sodium pyruvate (inhaled), EmphyCorp; PYRUVATE SODIUM
DMST6A3	CP	EmphyCorp Inc
DMST6A3	DT	Small molecular drug
DMST6A3	PC	23662274
DMST6A3	MW	110.04
DMST6A3	FM	C3H3NaO3
DMST6A3	IC	InChI=1S/C3H4O3.Na/c1-2(4)3(5)6;/h1H3,(H,5,6);/q;+1/p-1
DMST6A3	CS	CC(=O)C(=O)[O-].[Na+]
DMST6A3	IK	DAEPDZWVDSPTHF-UHFFFAOYSA-M
DMST6A3	IU	sodium;2-oxopropanoate
DMST6A3	CA	CAS 113-24-6
DMST6A3	CB	CHEBI:50144
DMST6A3	DE	Asthma

DM3GO0J	ID	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	HS	Phase 1/2
DM3GO0J	SN	Sodium taurocholate (rectal gel, diabetes/ obesity)
DM3GO0J	CP	Satiogen Pharmaceuticals Inc
DM3GO0J	DT	Small molecular drug
DM3GO0J	PC	23666345
DM3GO0J	MW	537.7
DM3GO0J	FM	C26H44NNaO7S
DM3GO0J	IC	InChI=1S/C26H45NO7S.Na/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29;/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34);/q;+1/p-1/t15-,16+,17-,18-,19+,20+,21-,22+,24+,25+,26-;/m1./s1
DM3GO0J	CS	C[C@H](CCC(=O)NCCS(=O)(=O)[O-])[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C.[Na+]
DM3GO0J	IK	JAJWGJBVLPIOOH-IZYKLYLVSA-M
DM3GO0J	IU	sodium;2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate
DM3GO0J	CA	CAS 145-42-6
DM3GO0J	CB	CHEBI:36276
DM3GO0J	DE	Type-2 diabetes

DMEVGI9	ID	DMEVGI9
DMEVGI9	DN	SPK-7001
DMEVGI9	HS	Phase 1/2
DMEVGI9	CP	Spark Therapeutics
DMEVGI9	DT	Gene therapy
DMEVGI9	DE	Choroidal dystrophy

DM8K7CN	ID	DM8K7CN
DM8K7CN	DN	SPK-8011
DM8K7CN	HS	Phase 1/2
DM8K7CN	CP	Spark Therapeutics
DM8K7CN	DT	Gene therapy
DM8K7CN	DE	Haemophilia A

DMCP8F3	ID	DMCP8F3
DMCP8F3	DN	SPK-8016
DMCP8F3	HS	Phase 1/2
DMCP8F3	CP	Spark Therapeutics
DMCP8F3	DT	Gene therapy
DMCP8F3	DE	Haemophilia A

DMJDV0K	ID	DMJDV0K
DMJDV0K	DN	SPR720
DMJDV0K	HS	Phase 1/2
DMJDV0K	SN	UNII-1NL76YUU6E; 1NL76YUU6E; CHEMBL2221212; VXC-486 phosphate; SCHEMBL10323399; BDBM50112815; ZINC95566061; HY-135655A; CS-0127906; 1384984-31-9; 2-[5-[2-(ethylcarbamoylamino)-6-fluoro-7-[(2R)-oxolan-2-yl]-3H-benzimidazol-5-yl]pyrimidin-2-yl]propan-2-yl dihydrogen phosphate; N-Ethyl-N'-(6-fluoro-5-(2-(1-methyl-1-(phosphonooxy)ethyl)-5-pyrimidinyl)-7-((2R)-tetrahydro-2-furanyl)-1H-benzimidazol-2-yl)urea; Urea, N-ethyl-N'-(6-fluoro-5-(2-(1-methyl-1-(phosphonooxy)ethyl)-5-pyrimidinyl)-7-((2R)-tetrahydro-2-furanyl)-1H-benzimidazol-2-yl)-
DMJDV0K	CP	Spero Therapeutics
DMJDV0K	DT	Small molecular drug
DMJDV0K	PC	68108988
DMJDV0K	MW	508.4
DMJDV0K	FM	C21H26FN6O6P
DMJDV0K	IC	InChI=1S/C21H26FN6O6P/c1-4-23-20(29)28-19-26-13-8-12(16(22)15(17(13)27-19)14-6-5-7-33-14)11-9-24-18(25-10-11)21(2,3)34-35(30,31)32/h8-10,14H,4-7H2,1-3H3,(H2,30,31,32)(H3,23,26,27,28,29)/t14-/m1/s1
DMJDV0K	CS	CCNC(=O)NC1=NC2=C(N1)C=C(C(=C2[C@H]3CCCO3)F)C4=CN=C(N=C4)C(C)(C)OP(=O)(O)O
DMJDV0K	IK	COTQDURISRILOR-CQSZACIVSA-N
DMJDV0K	IU	2-[5-[2-(ethylcarbamoylamino)-6-fluoro-7-[(2R)-oxolan-2-yl]-3H-benzimidazol-5-yl]pyrimidin-2-yl]propan-2-yl dihydrogen phosphate
DMJDV0K	CA	CAS 1384984-31-9
DMJDV0K	DE	Mycobacterium infection

DMG8JLC	ID	DMG8JLC
DMG8JLC	DN	SRP-9003
DMG8JLC	HS	Phase 1/2
DMG8JLC	SN	MYO-101
DMG8JLC	CP	Sarepta Therapeutics
DMG8JLC	DT	Gene therapy
DMG8JLC	DE	Limb girdle muscular dystrophy

DMK095Z	ID	DMK095Z
DMK095Z	DN	SRP-9004
DMK095Z	HS	Phase 1/2
DMK095Z	CP	Sarepta Therapeutics
DMK095Z	DT	Gene therapy
DMK095Z	DE	Limb girdle muscular dystrophy

DMBCIXL	ID	DMBCIXL
DMBCIXL	DN	Stamulumab
DMBCIXL	HS	Phase 1/2
DMBCIXL	SN	MYO-028; MYO-029; RK-35; GDF-8 program, Wyeth BioPharma/Genetics Institute; Anti-myostatin antibody, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Wyeth BioPharma/Cambridge Antibody Technology
DMBCIXL	CP	Wyeth
DMBCIXL	DT	Antibody
DMBCIXL	DE	Duchenne dystrophy

DMX3CNS	ID	DMX3CNS
DMX3CNS	DN	Stargen
DMX3CNS	HS	Phase 1/2
DMX3CNS	SN	Juvenile degenerative retinal disease therapy, Oxford BioMedica; ABCR gene therapy (Stargardt disease, LentiVector), Oxford BioMedica
DMX3CNS	CP	Oxford BioMedica plc
DMX3CNS	DE	Retinitis pigmentosa

DMZM6I2	ID	DMZM6I2
DMZM6I2	DN	Sym013
DMZM6I2	HS	Phase 1/2
DMZM6I2	CP	Symphogen Somerville, NJ
DMZM6I2	DE	Epithelial ovarian cancer; Solid tumour/cancer

DM9B7Z5	ID	DM9B7Z5
DM9B7Z5	DN	Sym015
DM9B7Z5	HS	Phase 1/2
DM9B7Z5	CP	Symphogen Somerville, NJ
DM9B7Z5	DE	Solid tumour/cancer

DMB2NP8	ID	DMB2NP8
DMB2NP8	DN	T-1249
DMB2NP8	HS	Phase 1/2
DMB2NP8	SN	Tifuvirtide; Peptide T1249; UNII-M6W86MD258; M6W86MD258; 251562-00-2; Tifuvirtide [INN]; T 1249; DB05413; 111997-EP2298761A1; 111997-EP2272516A2
DMB2NP8	DT	Small molecular drug
DMB2NP8	PC	16130644
DMB2NP8	MW	5037
DMB2NP8	FM	C235H341N57O67
DMB2NP8	IC	InChI=1S/C235H341N57O67/c1-20-120(13)194(290-218(342)155(69-83-184(246)303)258-198(322)122(15)254-201(325)149(63-77-178(240)297)263-211(335)157(71-85-187(307)308)270-221(345)166(97-117(7)8)280-222(346)164(95-115(3)4)277-199(323)124(17)256-235(359)196(125(18)294)292-234(358)195(121(14)21-2)291-217(341)148(58-38-42-94-239)261-205(329)150(64-78-179(241)298)265-212(336)158(72-86-188(309)310)272-227(351)172(104-131-111-251-142-52-32-27-47-137(131)142)284-215(339)159(73-87-189(311)312)267-208(332)153(67-81-182(244)301)269-226(350)170(257-126(19)295)102-129-109-249-140-50-30-25-45-135(129)140)233(357)275-154(68-82-183(245)302)209(333)264-151(65-79-180(242)299)207(331)266-156(70-84-186(305)306)210(334)260-146(56-36-40-92-237)204(328)287-175(107-185(247)304)230(354)274-161(75-89-191(315)316)214(338)282-169(101-128-59-61-134(296)62-60-128)225(349)271-160(74-88-190(313)314)213(337)279-165(96-116(5)6)220(344)268-152(66-80-181(243)300)206(330)259-145(55-35-39-91-236)202(326)278-167(98-118(9)10)224(348)288-176(108-193(319)320)231(355)262-147(57-37-41-93-238)203(327)283-171(103-130-110-250-141-51-31-26-46-136(130)141)219(343)255-123(16)200(324)289-177(114-293)232(356)281-168(99-119(11)12)223(347)286-173(105-132-112-252-143-53-33-28-48-138(132)143)228(352)273-162(76-90-192(317)318)216(340)285-174(106-133-113-253-144-54-34-29-49-139(133)144)229(353)276-163(197(248)321)100-127-43-23-22-24-44-127/h22-34,43-54,59-62,109-113,115-125,145-177,194-196,249-253,293-294,296H,20-21,35-42,55-58,63-108,114,236-239H2,1-19H3,(H2,240,297)(H2,241,298)(H2,242,299)(H2,243,300)(H2,244,301)(H2,245,302)(H2,246,303)(H2,247,304)(H2,248,321)(H,254,325)(H,255,343)(H,256,359)(H,257,295)(H,258,322)(H,259,330)(H,260,334)(H,261,329)(H,262,355)(H,263,335)(H,264,333)(H,265,336)(H,266,331)(H,267,332)(H,268,344)(H,269,350)(H,270,345)(H,271,349)(H,272,351)(H,273,352)(H,274,354)(H,275,357)(H,276,353)(H,277,323)(H,278,326)(H,279,337)(H,280,346)(H,281,356)(H,282,338)(H,283,327)(H,284,339)(H,285,340)(H,286,347)(H,287,328)(H,288,348)(H,289,324)(H,290,342)(H,291,341)(H,292,358)(H,305,306)(H,307,308)(H,309,310)(H,311,312)(H,313,314)(H,315,316)(H,317,318)(H,319,320)/t120-,121-,122-,123-,124-,125+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,194-,195-,196-/m0/s1
DMB2NP8	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC9=CNC1=CC=CC=C19)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C
DMB2NP8	IK	ZFEAMMNVDPDEGE-LGRGJMMZSA-N
DMB2NP8	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-aminohexanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DMB2NP8	CA	CAS 251562-00-2
DMB2NP8	DE	Human immunodeficiency virus infection

DMWIH59	ID	DMWIH59
DMWIH59	DN	T2c-003
DMWIH59	HS	Phase 1/2
DMWIH59	SN	Bone marrow-derived progenitor cells therapy (intra-arterial infusion, diabetic neuropathy), t2cure
DMWIH59	CP	Johann Wolfgang Goethe-Universitat Frankfurt am Main
DMWIH59	DE	Diabetic neuropathy

DM1FY97	ID	DM1FY97
DM1FY97	DN	T3D-959
DM1FY97	HS	Phase 1/2
DM1FY97	CP	T3d therapeutics
DM1FY97	DE	Alzheimer disease

DMCFSZ5	ID	DMCFSZ5
DMCFSZ5	DN	TAI-GPC3-CART cells
DMCFSZ5	HS	Phase 1/2
DMCFSZ5	CP	Shanghai GeneChem Co., Ltd.
DMCFSZ5	DT	CAR T Cell Therapy
DMCFSZ5	DE	Hepatocellular carcinoma

DMJSQXT	ID	DMJSQXT
DMJSQXT	DN	TAK-007
DMJSQXT	HS	Phase 1/2
DMJSQXT	CP	Takeda
DMJSQXT	DT	CAR-NK Cell therapy
DMJSQXT	DE	Hematologic tumour

DM1AB4L	ID	DM1AB4L
DM1AB4L	DN	Talotrexin
DM1AB4L	HS	Phase 1/2
DM1AB4L	SN	Talvesta; Talotrexin ammonium; PT-523; PT-633; 10-deaza-PT-523
DM1AB4L	CP	Hana Biosciences; Dana-Farber Cancer Institute Inc
DM1AB4L	DT	Small molecular drug
DM1AB4L	PC	130731
DM1AB4L	MW	573.6
DM1AB4L	FM	C27H27N9O6
DM1AB4L	IC	InChI=1S/C27H27N9O6/c28-21-20-22(36-27(29)35-21)32-13-16(33-20)12-31-15-9-7-14(8-10-15)23(37)34-19(26(41)42)6-3-11-30-24(38)17-4-1-2-5-18(17)25(39)40/h1-2,4-5,7-10,13,19,31H,3,6,11-12H2,(H,30,38)(H,34,37)(H,39,40)(H,41,42)(H4,28,29,32,35,36)/t19-/m0/s1
DM1AB4L	CS	C1=CC=C(C(=C1)C(=O)NCCC[C@@H](C(=O)O)NC(=O)C2=CC=C(C=C2)NCC3=CN=C4C(=N3)C(=NC(=N4)N)N)C(=O)O
DM1AB4L	IK	NYQPLPNEESYGNO-IBGZPJMESA-N
DM1AB4L	IU	2-[[(4S)-4-carboxy-4-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]butyl]carbamoyl]benzoic acid
DM1AB4L	CA	CAS 113857-87-7
DM1AB4L	DE	Solid tumour/cancer

DM13AH8	ID	DM13AH8
DM13AH8	DN	TAS-0728
DM13AH8	HS	Phase 1/2
DM13AH8	CP	Taiho Oncology
DM13AH8	DT	Small molecular drug
DM13AH8	DE	Solid tumour/cancer

DM2LZ8F	ID	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	HS	Phase 1/2
DM2LZ8F	SN	Taurocholic acid; TAUROCHOLIC ACID; Taurocholate; Cholyltaurine; Cholaic acid; N-Choloyltaurine; Cholic acid taurine conjugate; 81-24-3; Taurine, N-choloyl-; Acidum cholatauricum; Taurine Cholate; UNII-5E090O0G3Z; HSDB 832; C26H45NO7S; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid 24-taurine; NSC25505; EINECS 201-336-2; NSC 25505; Ethanesulfonic acid, 2-(((3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl)amino)-; 2-((3-alpha,7-alpha,12-alpha-Trihydroxy-24-oxo-5-be ta-cholan-24-yl)amino)ethanesulfonic acid; [3H]taurocholic acid
DM2LZ8F	DT	Small molecular drug
DM2LZ8F	PC	6675
DM2LZ8F	MW	515.7
DM2LZ8F	FM	C26H45NO7S
DM2LZ8F	IC	InChI=1S/C26H45NO7S/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34)/t15-,16+,17-,18-,19+,20+,21-,22+,24+,25+,26-/m1/s1
DM2LZ8F	CS	C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
DM2LZ8F	IK	WBWWGRHZICKQGZ-HZAMXZRMSA-N
DM2LZ8F	IU	2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
DM2LZ8F	CA	CAS 81-24-3
DM2LZ8F	CB	CHEBI:28865
DM2LZ8F	DE	Type-2 diabetes

DM5NICF	ID	DM5NICF
DM5NICF	DN	TBI-1501
DM5NICF	HS	Phase 1/2
DM5NICF	CP	Takara Bio Inc.
DM5NICF	DT	CAR T Cell Therapy
DM5NICF	DE	Acute lymphoblastic leukaemia

DMR65X7	ID	DMR65X7
DMR65X7	DN	TC-110
DMR65X7	HS	Phase 1/2
DMR65X7	CP	TCR2 Therapeutics
DMR65X7	DT	TCR-T cell therapy
DMR65X7	DE	Non-hodgkin lymphoma; Acute lymphoblastic leukaemia

DM9S5I1	ID	DM9S5I1
DM9S5I1	DN	TC-210
DM9S5I1	HS	Phase 1/2
DM9S5I1	CP	TCR2 Therapeutics
DM9S5I1	DT	TCR-T cell therapy
DM9S5I1	DE	Ovarian cancer; Cholangiocarcinoma; Peritoneal mesothelioma; Non-small cell lung cancer

DMZFIGQ	ID	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	HS	Phase 1/2
DMZFIGQ	SN	SB1317; 937270-47-8; TG02; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884
DMZFIGQ	DT	Small molecular drug
DMZFIGQ	PC	16739650
DMZFIGQ	MW	372.5
DMZFIGQ	FM	C23H24N4O
DMZFIGQ	IC	InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+
DMZFIGQ	CS	CN1C/C=C/CCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1
DMZFIGQ	IK	VXBAJLGYBMTJCY-NSCUHMNNSA-N
DMZFIGQ	IU	(16E)-14-methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene
DMZFIGQ	CA	CAS 1204918-72-8
DMZFIGQ	DE	Solid tumour/cancer; Anaplastic astrocytoma; Recurrent glioblastoma

DMON4IL	ID	DMON4IL
DMON4IL	DN	TG100-115
DMON4IL	HS	Phase 1/2
DMON4IL	SN	TG-100115; TG-100-115; TG100115, TG100-115; 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol; 3-(2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl)phenol; 3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol
DMON4IL	CP	TargeGen
DMON4IL	DT	Small molecular drug
DMON4IL	PC	10427712
DMON4IL	MW	346.3
DMON4IL	FM	C18H14N6O2
DMON4IL	IC	InChI=1S/C18H14N6O2/c19-16-15-17(24-18(20)23-16)22-14(10-4-2-6-12(26)8-10)13(21-15)9-3-1-5-11(25)7-9/h1-8,25-26H,(H4,19,20,22,23,24)
DMON4IL	CS	C1=CC(=CC(=C1)O)C2=NC3=C(N=C(N=C3N=C2C4=CC(=CC=C4)O)N)N
DMON4IL	IK	UJIAQDJKSXQLIT-UHFFFAOYSA-N
DMON4IL	IU	3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol
DMON4IL	CA	CAS 677297-51-7
DMON4IL	CB	CHEBI:94691
DMON4IL	DE	Myocardial infarction; Angioedema

DMNKLZM	ID	DMNKLZM
DMNKLZM	DN	TgAAG76
DMNKLZM	HS	Phase 1/2
DMNKLZM	SN	RAAV 2/2.hRPE65p.hRPE65; AAV RPE65 gene therapy (RPE65-mediated blindness), Targeted Genetics/University of London/Moorfields
DMNKLZM	CP	University of London
DMNKLZM	DE	Blindness

DMDJLX7	ID	DMDJLX7
DMDJLX7	DN	Timcodar dimesilate
DMDJLX7	HS	Phase 1/2
DMDJLX7	SN	Timcodar dimesilate < Prop INNM; VX-853; N1-Benzyl-4-chloro-N2-methyl-N2-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]-N1-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]-L-phenylalaninamide dimethanesulfonate
DMDJLX7	CP	Vertex Pharmaceuticals
DMDJLX7	DT	Small molecular drug
DMDJLX7	PC	9811663
DMDJLX7	MW	941.5
DMDJLX7	FM	C45H53ClN4O12S2
DMDJLX7	IC	InChI=1S/C43H45ClN4O6.2CH4O3S/c1-47(43(51)40(49)34-27-38(52-2)41(54-4)39(28-34)53-3)37(26-32-10-14-35(44)15-11-32)42(50)48(29-33-8-6-5-7-9-33)36(16-12-30-18-22-45-23-19-30)17-13-31-20-24-46-25-21-31;2*1-5(2,3)4/h5-11,14-15,18-25,27-28,36-37H,12-13,16-17,26,29H2,1-4H3;2*1H3,(H,2,3,4)/t37-;;/m0../s1
DMDJLX7	CS	CN([C@@H](CC1=CC=C(C=C1)Cl)C(=O)N(CC2=CC=CC=C2)C(CCC3=CC=NC=C3)CCC4=CC=NC=C4)C(=O)C(=O)C5=CC(=C(C(=C5)OC)OC)OC.CS(=O)(=O)O.CS(=O)(=O)O
DMDJLX7	IK	LXIAWDJOQUWVQS-SHRURHRBSA-N
DMDJLX7	IU	(2S)-N-benzyl-3-(4-chlorophenyl)-N-(1,5-dipyridin-4-ylpentan-3-yl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]propanamide;methanesulfonic acid
DMDJLX7	CA	CAS 183313-30-6
DMDJLX7	DE	Solid tumour/cancer

DM0VXIM	ID	DM0VXIM
DM0VXIM	DN	TJ003234
DM0VXIM	HS	Phase 1/2
DM0VXIM	SN	TJ003234 mab
DM0VXIM	TC	Antiviral Agents
DM0VXIM	DT	Monoclonal antibody
DM0VXIM	DE	Coronavirus Disease 2019 (COVID-19)

DMLROMP	ID	DMLROMP
DMLROMP	DN	TKM-PLK1
DMLROMP	HS	Phase 1/2
DMLROMP	CP	Tekmira Pharmaceuticals
DMLROMP	DT	siRNA drug
DMLROMP	DE	Solid tumour/cancer

DM6AXV9	ID	DM6AXV9
DM6AXV9	DN	TOL-101
DM6AXV9	HS	Phase 1/2
DM6AXV9	SN	MAb (transplant rejection), Tolera Therapeutics; Monoclonal antibody (transplant rejection), Tolera Therapeutics; Anti-TCR alpha/beta antibody (transplant rejection/type 1 diabetes/multiple sclerosis), Tolera
DM6AXV9	CP	Tolera Therapeutics Inc
DM6AXV9	DT	Antibody
DM6AXV9	DE	Multiple sclerosis

DMHTG8P	ID	DMHTG8P
DMHTG8P	DN	TP-0903
DMHTG8P	HS	Phase 1/2
DMHTG8P	SN	YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide
DMHTG8P	CP	Tolero Pharmaceuticals Lehi, UT
DMHTG8P	PC	56839178
DMHTG8P	MW	516.1
DMHTG8P	FM	C24H30ClN7O2S
DMHTG8P	IC	InChI=1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29)
DMHTG8P	CS	CN1CCN(CC1)CC2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)N(C)C)Cl
DMHTG8P	IK	YUAALFPUEOYPNX-UHFFFAOYSA-N
DMHTG8P	IU	2-[[5-chloro-2-[4-[(4-methylpiperazin-1-yl)methyl]anilino]pyrimidin-4-yl]amino]-N,N-dimethylbenzenesulfonamide
DMHTG8P	CA	CAS 1341200-45-0
DMHTG8P	DE	Solid tumour/cancer; Chronic lymphocytic leukaemia

DM9FB2T	ID	DM9FB2T
DM9FB2T	DN	TPX-0005
DM9FB2T	HS	Phase 1/2
DM9FB2T	SN	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778
DM9FB2T	CP	TP Therapeutics San Diego, CA
DM9FB2T	PC	135565923
DM9FB2T	MW	355.4
DM9FB2T	FM	C18H18FN5O2
DM9FB2T	IC	InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1
DM9FB2T	CS	C[C@H]1CNC(=O)C2=C3N=C(C=CN3N=C2)N[C@@H](C4=C(O1)C=CC(=C4)F)C
DM9FB2T	IK	FIKPXCOQUIZNHB-WDEREUQCSA-N
DM9FB2T	IU	(3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one
DM9FB2T	CA	CAS 1802220-02-5
DM9FB2T	DE	Solid tumour/cancer

DMIVE67	ID	DMIVE67
DMIVE67	DN	TPX-0046
DMIVE67	HS	Phase 1/2
DMIVE67	CP	Turning Point Therapeutics
DMIVE67	DT	Small interfering RNA
DMIVE67	DE	Solid tumour/cancer

DM8D2LC	ID	DM8D2LC
DM8D2LC	DN	Tractinostat
DM8D2LC	HS	Phase 1/2
DM8D2LC	CP	Viracta Therapeutics Cardiff, CA
DM8D2LC	DE	Lymphoma; Solid tumour/cancer

DM1ZK4W	ID	DM1ZK4W
DM1ZK4W	DN	TRBC1
DM1ZK4W	HS	Phase 1/2
DM1ZK4W	CP	Autolus Limited
DM1ZK4W	DT	CAR T Cell Therapy
DM1ZK4W	DE	Anaplastic large cell lymphoma; Angioimmunoblastic T-cell Lymphoma; Non-hodgkin lymphoma; Peripheral T-cell lymphoma

DMXI8CD	ID	DMXI8CD
DMXI8CD	DN	TRC-253
DMXI8CD	HS	Phase 1/2
DMXI8CD	SN	OUEHJEYKNYQVRC-UHFFFAOYSA-N; TRC253; SCHEMBL19128768; EX-A1808; 2110426-27-0; 5-(8-oxo-5-(6-(piperidin-4-yloxy)pyridin-3-yl)-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-3-(trifluoromethyl)picolinonitrile
DMXI8CD	CP	Janssen Research & Development Raritan, NJTRACON PharmaceuticalsSan Diego, CA
DMXI8CD	PC	130229812
DMXI8CD	MW	502.5
DMXI8CD	FM	C23H21F3N6O2S
DMXI8CD	IC	InChI=1S/C23H21F3N6O2S/c24-23(25,26)17-10-15(13-29-18(17)11-27)31-20(33)22(6-1-7-22)32(21(31)35)14-2-3-19(30-12-14)34-16-4-8-28-9-5-16/h2-3,10,12-13,16,28H,1,4-9H2
DMXI8CD	CS	C1CC2(C1)C(=O)N(C(=S)N2C3=CN=C(C=C3)OC4CCNCC4)C5=CC(=C(N=C5)C#N)C(F)(F)F
DMXI8CD	IK	OUEHJEYKNYQVRC-UHFFFAOYSA-N
DMXI8CD	IU	5-[8-oxo-5-(6-piperidin-4-yloxypyridin-3-yl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile
DMXI8CD	DE	Prostate cancer

DML54PD	ID	DML54PD
DML54PD	DN	TriCAR-T-CD19
DML54PD	HS	Phase 1/2
DML54PD	CP	Timmune Biotech Inc.
DML54PD	DT	CAR T Cell Therapy
DML54PD	DE	Non-hodgkin lymphoma

DM8IC5H	ID	DM8IC5H
DM8IC5H	DN	Triciribine
DM8IC5H	HS	Phase 1/2
DM8IC5H	SN	NSC154020; Akt Inhibitor V, Triciribine; MLS002702033; Akt/PKB Signaling Inhibitor-2; NSC-154020; TCN; Akt inhibitor V; AC1Q7CGY; AC1L6DVE; tricyclic nucleoside (TCN); SCHEMBL61269; GTPL5920; CHEMBL1892348; CHEBI:91697; HMS3268N05; HMS3654C06; HMS3229A09; HSCI1_000386; CCG-206732; 5-methyl-1-pentofuranosyl-1,5-dihydro-1,4,5,6,8-pentaazaacenaphthylen-3-amine; SMR001565606; SC-89664; NCI60_001091; Akt/protein kinase B signaling inhibitor-2; BRD-A42649439-001-01-0; BRD-A42649439-001-02-8; 1,5,6,8-Pentaazaacennaphthylen-3-amine, 1,5-dih
DM8IC5H	DT	Small molecular drug
DM8IC5H	PC	65399
DM8IC5H	MW	320.3
DM8IC5H	FM	C13H16N6O4
DM8IC5H	IC	InChI=1S/C13H16N6O4/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(22)8(21)6(3-20)23-13/h2,4,6,8-9,13,20-22H,3H2,1H3,(H2,14,17)/t6-,8-,9-,13-/m1/s1
DM8IC5H	CS	CN1C2=NC=NC3=C2C(=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)C(=N1)N
DM8IC5H	IK	HOGVTUZUJGHKPL-HTVVRFAVSA-N
DM8IC5H	IU	(2R,3R,4S,5R)-2-(5-amino-7-methyl-2,6,7,9,11-pentazatricyclo[6.3.1.04,12]dodeca-1(12),3,5,8,10-pentaen-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM8IC5H	CA	CAS 35943-35-2
DM8IC5H	CB	CHEBI:65310
DM8IC5H	DE	Solid tumour/cancer

DMBN1XS	ID	DMBN1XS
DMBN1XS	DN	Triciribine prodrug
DMBN1XS	HS	Phase 1/2
DMBN1XS	SN	TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL
DMBN1XS	CP	Cahaba pharmaceuticals
DMBN1XS	DE	Solid tumour/cancer

DM9IQ4A	ID	DM9IQ4A
DM9IQ4A	DN	TRU-016
DM9IQ4A	HS	Phase 1/2
DM9IQ4A	CP	Emergent BioSolutions
DM9IQ4A	DE	Chronic lymphocytic leukaemia

DMQS5DY	ID	DMQS5DY
DMQS5DY	DN	TRX-518
DMQS5DY	HS	Phase 1/2
DMQS5DY	SN	GITR monoclonal antibody (cancer/viral infection), TolerRx; Glucocorticoid-induced TNF receptor monoclonal antibody (viral infection/cancer), TolerRx; GITR mAb (IgG/iv, cancer/viral infection), TolerRx
DMQS5DY	CP	Gitr
DMQS5DY	DT	Antibody
DMQS5DY	DE	Melanoma; Solid tumour/cancer

DMFOR9Y	ID	DMFOR9Y
DMFOR9Y	DN	TSR-011
DMFOR9Y	HS	Phase 1/2
DMFOR9Y	CP	Tesaro
DMFOR9Y	PC	57345941
DMFOR9Y	MW	577.7
DMFOR9Y	FM	C33H44FN5O3
DMFOR9Y	IC	InChI=1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41)
DMFOR9Y	CS	CC(C)NC(=O)C1CCC(CC1)N2C3=C(C=CC(=C3)CN4CCC(CC4)C(C)(C)O)N=C2NC(=O)C5=CC=C(C=C5)F
DMFOR9Y	IK	WSTUJEXAPHIEIM-UHFFFAOYSA-N
DMFOR9Y	IU	4-fluoro-N-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide
DMFOR9Y	CA	CAS 1357920-84-3
DMFOR9Y	DE	Non-small-cell lung cancer

DMH9RGV	ID	DMH9RGV
DMH9RGV	DN	TTP-814
DMH9RGV	HS	Phase 1/2
DMH9RGV	SN	PTP-1B inhibitors (oral, type 2 diabetes), TransTech Pharma
DMH9RGV	CP	TransTech Pharma Inc
DMH9RGV	DE	Diabetic complication

DMRJK26	ID	DMRJK26
DMRJK26	DN	UCART019
DMRJK26	HS	Phase 1/2
DMRJK26	CP	Chinese PLA General Hospital
DMRJK26	DT	CAR T Cell Therapy
DMRJK26	DE	B-cell lymphoma; leukaemia

DMI0H3B	ID	DMI0H3B
DMI0H3B	DN	UshStat
DMI0H3B	HS	Phase 1/2
DMI0H3B	SN	Myosin 7A gene therapy (Usher syndrome 1B, LentiVector), Oxford BioMedica; Myosin VIIA gene therapy (Usher syndrome 1B, LentiVector), Oxford BioMedica
DMI0H3B	CP	Sanofi us
DMI0H3B	DE	Deafness; Retinitis pigmentosa

DM6HPEC	ID	DM6HPEC
DM6HPEC	DN	USL311
DM6HPEC	HS	Phase 1/2
DM6HPEC	SN	Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; USL-311; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7
DM6HPEC	CP	Upsher-Smith Maple Grove, MN
DM6HPEC	PC	56961879
DM6HPEC	MW	422.6
DM6HPEC	FM	C24H34N6O
DM6HPEC	IC	InChI=1S/C24H34N6O/c1-19(2)28-15-9-21(10-16-28)29-13-4-14-30(18-17-29)23-6-3-5-22(27-23)24(31)26-20-7-11-25-12-8-20/h3,5-8,11-12,19,21H,4,9-10,13-18H2,1-2H3,(H,25,26,31)
DM6HPEC	CS	CC(C)N1CCC(CC1)N2CCCN(CC2)C3=CC=CC(=N3)C(=O)NC4=CC=NC=C4
DM6HPEC	IK	XNUNVQKARNSSEO-UHFFFAOYSA-N
DM6HPEC	IU	6-[4-(1-propan-2-ylpiperidin-4-yl)-1,4-diazepan-1-yl]-N-pyridin-4-ylpyridine-2-carboxamide
DM6HPEC	CA	CAS 1373268-67-7
DM6HPEC	DE	Recurring respiratory infection; Solid tumour/cancer

DMPWHU6	ID	DMPWHU6
DMPWHU6	DN	V81444
DMPWHU6	HS	Phase 1/2
DMPWHU6	CP	Vernalis
DMPWHU6	PC	44537963
DMPWHU6	MW	407.4
DMPWHU6	FM	C20H21N7O3
DMPWHU6	IC	InChI=1S/C20H21N7O3/c1-12-5-6-16(30-12)17-18-19(24-20(21)23-17)27(26-25-18)9-13-3-2-4-14(22-13)10-29-15-7-8-28-11-15/h2-6,15H,7-11H2,1H3,(H2,21,23,24)/t15-/m0/s1
DMPWHU6	CS	CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)CO[C@H]5CCOC5
DMPWHU6	IK	KURQKNMKCGYWRJ-HNNXBMFYSA-N
DMPWHU6	IU	7-(5-methylfuran-2-yl)-3-[[6-[[(3S)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine
DMPWHU6	CA	CAS 1202402-40-1
DMPWHU6	DE	Parkinson disease; Advanced cancer

DM8A5E0	ID	DM8A5E0
DM8A5E0	DN	Vecabrutinib
DM8A5E0	HS	Phase 1/2
DM8A5E0	SN	UNII-PQ7O0OB5GU; PQ7O0OB5GU; Vecabrutinib [INN]; BIIB-062; SCHEMBL16765727; BSK-4841; FP-182; 1510829-06-7
DM8A5E0	CP	Sunesis Pharmaceuticals South San Francisco, CA
DM8A5E0	PC	72547837
DM8A5E0	MW	529.9
DM8A5E0	FM	C22H24ClF4N7O2
DM8A5E0	IC	InChI=1S/C22H24ClF4N7O2/c23-12-6-11(22(25,26)27)7-13(8-12)32-15-2-1-4-34(21(15)36)16-9-33(5-3-14(16)19(29)35)20-17(24)18(28)30-10-31-20/h6-8,10,14-16,32H,1-5,9H2,(H2,29,35)(H2,28,30,31)/t14-,15+,16-/m0/s1
DM8A5E0	CS	C1C[C@H](C(=O)N(C1)[C@H]2CN(CC[C@@H]2C(=O)N)C3=NC=NC(=C3F)N)NC4=CC(=CC(=C4)C(F)(F)F)Cl
DM8A5E0	IK	QLRRJMOBVVGXEJ-XHSDSOJGSA-N
DM8A5E0	IU	(3R,4S)-1-(6-amino-5-fluoropyrimidin-4-yl)-3-[(3R)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxopiperidin-1-yl]piperidine-4-carboxamide
DM8A5E0	CA	CAS 1510829-06-7
DM8A5E0	DE	B-cell lymphoma

DMAN21O	ID	DMAN21O
DMAN21O	DN	VG-101
DMAN21O	HS	Phase 1/2
DMAN21O	SN	Seala; VG-101 analogs, Bionovo; Estrogen receptor beta selective agonists (topical intravaginal gel, vaginal dryness), Bionovo; VG-101 (topical intravaginal gel, vaginal dryness), Bionovo
DMAN21O	CP	Bionovo Inc
DMAN21O	DE	Menopause symptom

DMAMIU4	ID	DMAMIU4
DMAMIU4	DN	VIR-201
DMAMIU4	HS	Phase 1/2
DMAMIU4	CP	Virax Holdings Ltd
DMAMIU4	DE	Human immunodeficiency virus infection

DMN62MP	ID	DMN62MP
DMN62MP	DN	WASP gene therapy
DMN62MP	HS	Phase 1/2
DMN62MP	SN	WASP gene therapy (Wiskott-Aldrich syndrome, lentiviral vector)
DMN62MP	CP	Genethon
DMN62MP	DE	Wiskott-Aldrich syndrome

DMUGHWR	ID	DMUGHWR
DMUGHWR	DN	WP-1066
DMUGHWR	HS	Phase 1/2
DMUGHWR	SN	WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; WP-1066; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312
DMUGHWR	CP	MD Anderson Cancer Center
DMUGHWR	DT	Small molecular drug
DMUGHWR	PC	11210478
DMUGHWR	MW	356.2
DMUGHWR	FM	C17H14BrN3O
DMUGHWR	IC	InChI=1S/C17H14BrN3O/c1-12(13-6-3-2-4-7-13)20-17(22)14(11-19)10-15-8-5-9-16(18)21-15/h2-10,12H,1H3,(H,20,22)/b14-10+/t12-/m0/s1
DMUGHWR	CS	C[C@@H](C1=CC=CC=C1)NC(=O)/C(=C/C2=NC(=CC=C2)Br)/C#N
DMUGHWR	IK	VFUAJMPDXIRPKO-LQELWAHVSA-N
DMUGHWR	IU	(E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide
DMUGHWR	CA	CAS 857064-38-1
DMUGHWR	DE	Solid tumour/cancer; Brain cancer; Recurrent glioblastoma

DM3FIMD	ID	DM3FIMD
DM3FIMD	DN	WT-4869
DM3FIMD	HS	Phase 1/2
DM3FIMD	CP	Chugai Pharmaceutical Co Ltd
DM3FIMD	DE	leukaemia

DMRABOS	ID	DMRABOS
DMRABOS	DN	WX-554
DMRABOS	HS	Phase 1/2
DMRABOS	CP	UCB SA
DMRABOS	DE	Solid tumour/cancer

DMZ9VCF	ID	DMZ9VCF
DMZ9VCF	DN	X-396
DMZ9VCF	HS	Phase 1/2
DMZ9VCF	SN	ALK inhibitors (cancer); X-276; X-353; X-376; ALK inhibitors (cancer), Xcovery; Anaplastic lymphoma kinase inhibitors (cancer), Xcovery
DMZ9VCF	CP	Xcovery
DMZ9VCF	DT	Small molecular drug
DMZ9VCF	PC	56960447
DMZ9VCF	MW	547.4
DMZ9VCF	FM	C25H25Cl2FN6O3
DMZ9VCF	IC	InChI=1S/C25H25Cl2FN6O3/c1-14(21-17(26)7-8-18(28)22(21)27)37-20-13-19(31-32-23(20)29)24(35)30-16-5-3-15(4-6-16)25(36)34-11-9-33(2)10-12-34/h3-8,13-14H,9-12H2,1-2H3,(H2,29,32)(H,30,35)/t14-/m1/s1
DMZ9VCF	CS	C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=CC(=NN=C2N)C(=O)NC3=CC=C(C=C3)C(=O)N4CCN(CC4)C
DMZ9VCF	IK	ONPGOSVDVDPBCY-CQSZACIVSA-N
DMZ9VCF	IU	6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide
DMZ9VCF	CA	CAS 1365267-27-1
DMZ9VCF	DE	Advanced solid tumour

DMU6TG7	ID	DMU6TG7
DMU6TG7	DN	XMT-1592
DMU6TG7	HS	Phase 1/2
DMU6TG7	CP	Mersana Therapeutics
DMU6TG7	DT	Antibody drug conjugate
DMU6TG7	DE	Non-small-cell lung cancer; Ovarian cancer

DM148HX	ID	DM148HX
DM148HX	DN	XToll
DM148HX	HS	Phase 1/2
DM148HX	SN	Heat shock protein 10 (autoimmune diseases/inflammation), CBio; Hsp10 (autoimmune diseases/inflammation), CBio; Recombinant Cpn10 (autoimmune diseases/inflammation), CBio; Recombinant chaperonin 10 (autoimmune diseases/inflammation), CBio
DM148HX	CP	University of Queensland
DM148HX	DE	Autoimmune diabetes

DMXSEHF	ID	DMXSEHF
DMXSEHF	DN	Y-39983
DMXSEHF	HS	Phase 1/2
DMXSEHF	SN	RKI-983; SNJ-1656; ROCK inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis; Rho-associated protein kinase inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis
DMXSEHF	CP	Mitsubishi Pharma Corp
DMXSEHF	DT	Small molecular drug
DMXSEHF	PC	9810884
DMXSEHF	MW	280.32
DMXSEHF	FM	C16H16N4O
DMXSEHF	IC	InChI=1S/C16H16N4O/c1-10(17)11-2-4-12(5-3-11)16(21)20-14-7-9-19-15-13(14)6-8-18-15/h2-10H,17H2,1H3,(H2,18,19,20,21)/t10-/m1/s1
DMXSEHF	CS	C[C@H](C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2)N
DMXSEHF	IK	JTVBXQAYBIJXRP-SNVBAGLBSA-N
DMXSEHF	IU	4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide
DMXSEHF	CA	CAS 199433-58-4
DMXSEHF	CB	CHEBI:91412
DMXSEHF	DE	Glaucoma/ocular hypertension

DMIA9JD	ID	DMIA9JD
DMIA9JD	DN	YSCMA
DMIA9JD	HS	Phase 1/2
DMIA9JD	SN	YS-110; Anti-CD26 humanized antibody (cancer), Y's Therapeutics/Kissei Pharmaceutical
DMIA9JD	CP	Y's Therapeutics Co Ltd
DMIA9JD	DT	Antibody
DMIA9JD	DE	Haematological malignancy

DMMQGPE	ID	DMMQGPE
DMMQGPE	DN	Zenocutuzomab
DMMQGPE	HS	Phase 1/2
DMMQGPE	SN	MCLA-128; PB4188
DMMQGPE	CP	Merus
DMMQGPE	DT	Antibody
DMMQGPE	DE	Solid tumour/cancer

DMDJSOH	ID	DMDJSOH
DMDJSOH	DN	ZK-001
DMDJSOH	HS	Phase 1/2
DMDJSOH	SN	Anfibatide; Declotana; Antithrombosis agent (injectable, angina), Lee's Pharmaceutical Holdings; Thrombolysin (injectable, angina), Lee's Pharmaceutical Holdings
DMDJSOH	CP	Lee's Pharmaceutical Holdings (Hong Kong) Ltd
DMDJSOH	DE	Thrombosis

DMVG4OC	ID	DMVG4OC
DMVG4OC	DN	ZN-c5
DMVG4OC	HS	Phase 1/2
DMVG4OC	CP	Zentalis Pharmaceuticals
DMVG4OC	DT	Small molecular drug
DMVG4OC	DE	Breast cancer

DMLV4U1	ID	DMLV4U1
DMLV4U1	DN	ZN-e4
DMLV4U1	HS	Phase 1/2
DMLV4U1	CP	Zentalis Pharmaceuticals
DMLV4U1	DT	Small molecular drug
DMLV4U1	DE	Non-small-cell lung cancer

DMPZE2G	ID	DMPZE2G
DMPZE2G	DN	ZPL521
DMPZE2G	HS	Phase 1/2
DMPZE2G	CP	Novartis Pharmaceuticals East Hanover, NJ
DMPZE2G	DE	Atopic dermatitis

DM459Q7	ID	DM459Q7
DM459Q7	DN	BMS-833923
DM459Q7	HS	Phase 1b
DM459Q7	SN	BMS-833923; 1059734-66-5; BMS 833923; XL139; XL 139; BMS833923; UNII-41J7ZJ239R; N-(2-Methyl-5-((methylamino)methyl)phenyl)-4-((4-phenylquinazolin-2-yl)amino)benzamide; 41J7ZJ239R; XL-139; C30H27N5O; N-(2-methyl-5-((methylamino)methyl)phenyl)-4-(4-phenylquinazolin-2-ylamino)benzamide; Benzamide, N-[2-methyl-5-[(methylamino)methyl]phenyl]-4-[(4-phenyl-2-quinazolinyl)amino]-; BMS-833923 free base anhydrous; XL139 mesylate; SCHEMBL4138073; GTPL8202; CHEMBL3545403; EX-A789; MolPort-035-395-837; HMS3653O09; BCP07837; AOB87352
DM459Q7	CP	Exelixis; Bristol-Myers Squibb
DM459Q7	DT	Small molecular drug
DM459Q7	PC	57662985
DM459Q7	MW	473.6
DM459Q7	FM	C30H27N5O
DM459Q7	IC	InChI=1S/C30H27N5O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35)
DM459Q7	CS	CC1=C(C=C(C=C1)CNC)NC(=O)C2=CC=C(C=C2)NC3=NC4=CC=CC=C4C(=N3)C5=CC=CC=C5
DM459Q7	IK	KLRRGBHZCJLIEL-UHFFFAOYSA-N
DM459Q7	IU	N-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide
DM459Q7	CA	CAS 1059734-66-5
DM459Q7	DE	Solid tumour/cancer

DMNCOE1	ID	DMNCOE1
DMNCOE1	DN	FRM-6308
DMNCOE1	HS	Phase 1b
DMNCOE1	CP	Forum pharmaceuticals
DMNCOE1	DE	Schizophrenia

DMVWYOU	ID	DMVWYOU
DMVWYOU	DN	GGF
DMVWYOU	HS	Phase 1b
DMVWYOU	CP	Acorda Therapeutics
DMVWYOU	DE	Congestive heart failure

DMQGH76	ID	DMQGH76
DMQGH76	DN	S-222611
DMQGH76	HS	Phase 1b
DMQGH76	CP	Shionogi
DMQGH76	DE	Malignant solid tumour

DMG74BY	ID	DMG74BY
DMG74BY	DN	(-)-3PPP, Maryland
DMG74BY	HS	Phase 1
DMG74BY	DE	Schizophrenia

DM1CZSJ	ID	DM1CZSJ
DM1CZSJ	DN	(+)-JQ1
DM1CZSJ	HS	Phase 1
DM1CZSJ	SN	1268524-70-4; (+)-JQ-1; JQ1 compound; (+)-JQ1; JQ-1; UNII-1MRH0IMX0W; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-JQ1; 1MRH0IMX0W; JQ1; CHEMBL1957266; AK109409; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; (S)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3
DM1CZSJ	DT	Small molecular drug
DM1CZSJ	PC	46907787
DM1CZSJ	MW	457
DM1CZSJ	FM	C23H25ClN4O2S
DM1CZSJ	IC	InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1
DM1CZSJ	CS	CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C
DM1CZSJ	IK	DNVXATUJJDPFDM-KRWDZBQOSA-N
DM1CZSJ	IU	tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate
DM1CZSJ	CA	CAS 1268524-70-4
DM1CZSJ	CB	CHEBI:95080
DM1CZSJ	DE	Testicular cancer

DMBOXA1	ID	DMBOXA1
DMBOXA1	DN	[3H]fenobam
DMBOXA1	HS	Phase 1
DMBOXA1	SN	57653-26-6; 3-(3-chlorophenyl)-1-(1-methyl-4-oxo-5H-imidazol-2-yl)urea; SMR001456387; MLS006011708; ZINC1436; GTPL1434; GTPL1433; 1-(3-chlorophenyl)-3-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)urea; CTK8F9740; CTK5B9436; DWPQODZAOSWNHB-UHFFFAOYSA-N; LP00842; NCGC00092384-04; FT-0630701
DMBOXA1	DT	Small molecular drug
DMBOXA1	PC	135497698
DMBOXA1	MW	266.68
DMBOXA1	FM	C11H11ClN4O2
DMBOXA1	IC	InChI=1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18)
DMBOXA1	CS	CN1CC(=O)NC1=NC(=O)NC2=CC(=CC=C2)Cl
DMBOXA1	IK	DWPQODZAOSWNHB-UHFFFAOYSA-N
DMBOXA1	IU	1-(3-chlorophenyl)-3-(1-methyl-4-oxoimidazolidin-2-ylidene)urea
DMBOXA1	CA	CAS 57653-26-6
DMBOXA1	DE	Allodynia

DMSCV02	ID	DMSCV02
DMSCV02	DN	[N-methyl-3H(3)]AZ-10419369
DMSCV02	HS	Phase 1
DMSCV02	SN	AR-A2; AZ-01134; AZ-10419369; AZ-12320927; AZ-12333053; AZ-12426308; AZ-12426792; AZD-8129; M-519351; M-549715; M-555601; AR-A-000002; AR-A2 analogs, AstraZeneca
DMSCV02	CP	AstraZeneca
DMSCV02	DT	Small molecular drug
DMSCV02	PC	25067576
DMSCV02	MW	468.6
DMSCV02	FM	C26H30N4O4
DMSCV02	IC	InChI=1S/C26H30N4O4/c1-18-3-8-21(30-11-9-28(2)10-12-30)25-24(18)22(31)17-23(34-25)26(32)27-19-4-6-20(7-5-19)29-13-15-33-16-14-29/h3-8,17H,9-16H2,1-2H3,(H,27,32)/i2T3
DMSCV02	CS	[3H]C([3H])([3H])N1CCN(CC1)C2=C3C(=C(C=C2)C)C(=O)C=C(O3)C(=O)NC4=CC=C(C=C4)N5CCOCC5
DMSCV02	IK	JKPWOPNZKYPRPZ-BHTRQJOGSA-N
DMSCV02	IU	5-methyl-N-(4-morpholin-4-ylphenyl)-4-oxo-8-[4-(tritritiomethyl)piperazin-1-yl]chromene-2-carboxamide
DMSCV02	DE	Mood disorder

DMSMRC1	ID	DMSMRC1
DMSMRC1	DN	1069C
DMSMRC1	HS	Phase 1
DMSMRC1	SN	CHEMBL418565; 1069C85; 1069C; AC1OCF0R; SCHEMBL8965590; UMSHZWFCVXIDEO-UHFFFAOYSA-N; BDBM50280140; Methyl N-[6-(3,4,5-trimethoxybenzyloxy)imidazo[1,2-b]pyridazine-2-yl]carbamate; Methyl N-[6-(3,4,5-trimethoxybenzyloxy)imidazo[1,2-b]pyridazin-2yl]carbamate; [6-(3,4,5-Trimethoxy-benzyloxy)-imidazo[1,2-b]pyridazin-2-yl]-carbamic acid methyl ester; methyl N-[6-[(3,4,5-trimethoxyphenyl)methoxy]imidazo[1,2-b]pyridazin-2-yl]carbamate
DMSMRC1	DT	Small molecular drug
DMSMRC1	PC	6918099
DMSMRC1	MW	388.4
DMSMRC1	FM	C18H20N4O6
DMSMRC1	IC	InChI=1S/C18H20N4O6/c1-24-12-7-11(8-13(25-2)17(12)26-3)10-28-16-6-5-15-19-14(9-22(15)21-16)20-18(23)27-4/h5-9H,10H2,1-4H3,(H,20,23)
DMSMRC1	CS	COC1=CC(=CC(=C1OC)OC)COC2=NN3C=C(N=C3C=C2)NC(=O)OC
DMSMRC1	IK	UMSHZWFCVXIDEO-UHFFFAOYSA-N
DMSMRC1	IU	methyl N-[6-[(3,4,5-trimethoxyphenyl)methoxy]imidazo[1,2-b]pyridazin-2-yl]carbamate
DMSMRC1	DE	Solid tumour/cancer

DM5IPHE	ID	DM5IPHE
DM5IPHE	DN	1192U90
DM5IPHE	HS	Phase 1
DM5IPHE	SN	LS-25359; 2-Amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide; 2-Amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl] benzamide; 2-amino-N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzamide
DM5IPHE	CP	GlaxoSmithKline
DM5IPHE	DT	Small molecular drug
DM5IPHE	PC	127912
DM5IPHE	MW	409.5
DM5IPHE	FM	C22H27N5OS
DM5IPHE	IC	InChI=1S/C22H27N5OS/c23-19-9-3-1-7-17(19)22(28)24-11-5-6-12-26-13-15-27(16-14-26)21-18-8-2-4-10-20(18)29-25-21/h1-4,7-10H,5-6,11-16,23H2,(H,24,28)
DM5IPHE	CS	C1CN(CCN1CCCCNC(=O)C2=CC=CC=C2N)C3=NSC4=CC=CC=C43
DM5IPHE	IK	GMDXHLCLNHCEIC-UHFFFAOYSA-N
DM5IPHE	IU	2-amino-N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzamide
DM5IPHE	CA	CAS 155289-31-9
DM5IPHE	DE	Psychotic disorder; Schizophrenia

DMICUPT	ID	DMICUPT
DMICUPT	DN	11C-6-Me-BTA-1
DMICUPT	HS	Phase 1
DMICUPT	SN	Carbon-11-6-Me-BTA-1; 11C-BTA-1
DMICUPT	CP	University of Pittsburgh
DMICUPT	DE	Alzheimer disease

DMYVDXW	ID	DMYVDXW
DMYVDXW	DN	11C-AZD-2184
DMYVDXW	HS	Phase 1
DMYVDXW	SN	AZD-2184-[11C]; AZD-2184-[3H]; Tritium-AZD-2184; Beta amyloid modulator (iv PET ligand, AD), AstraZeneca; Carbon-11-AZD-2184; Hydrogen-3-AZD-2184; Beta amyloid modulator (iv PET ligand, Alzheimer's disease), AstraZeneca; 3H-AZD-2184
DMYVDXW	CP	AstraZeneca plc
DMYVDXW	DE	Alzheimer disease

DMQ0RXA	ID	DMQ0RXA
DMQ0RXA	DN	11C-GSK-215083
DMQ0RXA	HS	Phase 1
DMQ0RXA	SN	11C-5-HT 6 receptor antagonist (neurodegenerative disease), GlaxoSmithKline; 11C-GSK-215083 PET maging agent (neurodegenerative disease), GlaxoSmithKline
DMQ0RXA	CP	GlaxoSmithKline plc
DMQ0RXA	DE	Neurodegenerative disorder

DMCFPX8	ID	DMCFPX8
DMCFPX8	DN	123-Iodine-labeled MFE-23
DMCFPX8	HS	Phase 1
DMCFPX8	SN	CEA antibody program (cancer/imaging); MFE-23-albumin fusion protein; CEA antibody program (cancer/imaging), Cancer Research Technology/UCL/Novozymes Delta; Albumin-linked anti-CEA single chain antibody fragment (cancer), UCL/CRT/Novozymes; Anti-CEA scFv-albumin fusion (cancer), UCL/CRT/Novozymes; 123-Iodine-labeledMFE-23; 125-I-labeled MFE-23-his; 125-Iodine-labeled MFE-23; 99mTc-labeled MFE-23
DMCFPX8	CP	University College London
DMCFPX8	DT	Antibody
DMCFPX8	DE	Solid tumour/cancer

DM5ZC0E	ID	DM5ZC0E
DM5ZC0E	DN	124I-8H9
DM5ZC0E	HS	Phase 1
DM5ZC0E	CP	MRI Interventions
DM5ZC0E	DT	Antibody
DM5ZC0E	DE	Glioblastoma multiforme

DMD751X	ID	DMD751X
DMD751X	DN	1614235 + 2330672
DMD751X	HS	Phase 1
DMD751X	SN	AC1LUPX5
DMD751X	CP	GlaxoSmithKline
DMD751X	DT	Combination drug (small molecular drug)
DMD751X	PC	1614235
DMD751X	MW	342.5
DMD751X	FM	C21H28NO3+
DMD751X	IC	InChI=1S/C21H27NO3/c1-4-22(5-2)17(3)16-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,24H,4-5,16H2,1-3H3/p+1/t17-/m1/s1
DMD751X	CS	CC[NH+](CC)[C@H](C)COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O
DMD751X	IK	DULUETYTNBOZNG-QGZVFWFLSA-O
DMD751X	IU	diethyl-[(2R)-1-(2-hydroxy-2,2-diphenylacetyl)oxypropan-2-yl]azanium
DMD751X	DE	Type-2 diabetes

DMFG1YA	ID	DMFG1YA
DMFG1YA	DN	177Lu-AMBA
DMFG1YA	HS	Phase 1
DMFG1YA	SN	Ga67-AMBA; Ga68-AMBA; Galenium67-AMBA; Galenium68-AMBA; In111-AMBA; Indium-111-AMBA; Lutetium-111-AMBA; Gastrin releasing peptide receptor agonist (radiotherapeutic, cancer), Bracco; GRP-R agonist (radiotherapeutic, cancer), Bracco; 111In-AMBA; 177Lu-AMBA (cancer), Marillion Pharmaceuticals; 177Lu-DOTA-G-4-aminobenzoyl-QWAVGHLM-NH2; 67Ga-AMBA; 68Ga-AMBA
DMFG1YA	CP	Bracco SpA
DMFG1YA	DE	Breast cancer

DMM2V74	ID	DMM2V74
DMM2V74	DN	177Lu-labelled CTT-1403
DMM2V74	HS	Phase 1
DMM2V74	CP	Cancer Targeted Technologies
DMM2V74	DT	Radiopharmaceutical therapy agent
DMM2V74	DE	Prostate cancer

DMZ5YMX	ID	DMZ5YMX
DMZ5YMX	DN	18F-FEDAA-1106
DMZ5YMX	HS	Phase 1
DMZ5YMX	SN	ZK-6032924; FEDAA-1106-[18F]; Fluorine-18-FEDAA-1106; 18F-labeled PET imaging agent (Alzheimer's disease), Bayer; 18F-labeled PET imaging agent (multiple sclerosis), Bayer
DMZ5YMX	CP	Taisho Pharmaceutical Co Ltd
DMZ5YMX	DE	Alzheimer disease

DMGE3DY	ID	DMGE3DY
DMGE3DY	DN	18-MC
DMGE3DY	HS	Phase 1
DMGE3DY	CP	Savant HWP San Carlos, CA
DMGE3DY	DE	Substance use disorder

DMJ1SQY	ID	DMJ1SQY
DMJ1SQY	DN	19-28z T CELLS
DMJ1SQY	HS	Phase 1
DMJ1SQY	CP	Memorial Sloan Kettering Cancer Center
DMJ1SQY	DT	CAR T Cell Therapy
DMJ1SQY	DE	Non-hodgkin lymphoma

DMQ8NTZ	ID	DMQ8NTZ
DMQ8NTZ	DN	192C86
DMQ8NTZ	HS	Phase 1
DMQ8NTZ	SN	BW-192C86
DMQ8NTZ	CP	Burroughs Wellcome Inc
DMQ8NTZ	DT	Small molecular drug
DMQ8NTZ	PC	9576901
DMQ8NTZ	MW	411.6
DMQ8NTZ	FM	C20H33N3O4S
DMQ8NTZ	IC	InChI=1S/C20H33N3O4S/c1-2-22-16-11-15(28-10-6-9-19(25)26)12-17(16)23(20(22)27)21-13-18(24)14-7-4-3-5-8-14/h13-18,24H,2-12H2,1H3,(H,25,26)/b21-13+
DMQ8NTZ	CS	CCN1C2CC(CC2N(C1=O)/N=C/C(C3CCCCC3)O)SCCCC(=O)O
DMQ8NTZ	IK	YDMMNNOYPGHBEY-FYJGNVAPSA-N
DMQ8NTZ	IU	4-[[3-[(E)-(2-cyclohexyl-2-hydroxyethylidene)amino]-1-ethyl-2-oxo-4,5,6,6a-tetrahydro-3aH-cyclopenta[d]imidazol-5-yl]sulfanyl]butanoic acid
DMQ8NTZ	CA	CAS 139147-26-5
DMQ8NTZ	DE	Thrombosis

DMN9MPX	ID	DMN9MPX
DMN9MPX	DN	212Pb-labelled DOTAMTATE
DMN9MPX	HS	Phase 1
DMN9MPX	CP	OranoMed/Radiomedix
DMN9MPX	DT	Radiopharmaceutical therapy agent
DMN9MPX	DE	Neuroendocrine cancer

DM2SQBF	ID	DM2SQBF
DM2SQBF	DN	225Ac-labelled aCD33
DM2SQBF	HS	Phase 1
DM2SQBF	CP	Actinium Pharmaceuticals
DM2SQBF	DT	Radiopharmaceutical therapy agent
DM2SQBF	DE	Acute myeloid leukaemia

DM3E2IY	ID	DM3E2IY
DM3E2IY	DN	225Ac-labelled aCD38
DM3E2IY	HS	Phase 1
DM3E2IY	CP	Actinium Pharmaceuticals
DM3E2IY	DT	Radiopharmaceutical therapy agent
DM3E2IY	DE	Multiple myeloma

DM1ZY6M	ID	DM1ZY6M
DM1ZY6M	DN	227Th-labelled MSLN-TTC
DM1ZY6M	HS	Phase 1
DM1ZY6M	SN	BAY2287411
DM1ZY6M	CP	Bayer
DM1ZY6M	DT	Radiopharmaceutical therapy agent
DM1ZY6M	DE	Epithelioid mesothelioma

DM7L45S	ID	DM7L45S
DM7L45S	DN	227Th-labelled PSMA-TTC
DM7L45S	HS	Phase 1
DM7L45S	SN	BAY2315497 
DM7L45S	CP	Bayer
DM7L45S	DT	Radiopharmaceutical therapy agent
DM7L45S	DE	Prostate cancer

DMDFA3E	ID	DMDFA3E
DMDFA3E	DN	349U85.HCL
DMDFA3E	HS	Phase 1
DMDFA3E	SN	6-Piperidinoquinolin-2(1H)-one hydrochloride
DMDFA3E	DT	Small molecular drug
DMDFA3E	PC	164016
DMDFA3E	MW	264.75
DMDFA3E	FM	C14H17ClN2O
DMDFA3E	IC	InChI=1S/C14H16N2O.ClH/c17-14-7-4-11-10-12(5-6-13(11)15-14)16-8-2-1-3-9-16;/h4-7,10H,1-3,8-9H2,(H,15,17);1H
DMDFA3E	CS	C1CCN(CC1)C2=CC3=C(C=C2)NC(=O)C=C3.Cl
DMDFA3E	IK	KYTREJMWHJPVSI-UHFFFAOYSA-N
DMDFA3E	IU	6-piperidin-1-yl-1H-quinolin-2-one;hydrochloride
DMDFA3E	CA	CAS 116942-30-4
DMDFA3E	DE	Cardiovascular disease

DM4Z1CH	ID	DM4Z1CH
DM4Z1CH	DN	4-aminosalicylate sodium
DM4Z1CH	HS	Phase 1
DM4Z1CH	SN	AGI-022; Salicylate prodrug (oralcontrolled release, ulcerative colitis), AGI Therapeutics; 4-ASA-Na; 4-ASA-Na (oral, controlled release), AGI Therapeutics
DM4Z1CH	CP	Athpharma Ltd
DM4Z1CH	DT	Small molecular drug
DM4Z1CH	PC	2724368
DM4Z1CH	MW	175.12
DM4Z1CH	FM	C7H6NNaO3
DM4Z1CH	IC	InChI=1S/C7H7NO3.Na/c8-4-1-2-5(7(10)11)6(9)3-4;/h1-3,9H,8H2,(H,10,11);/q;+1/p-1
DM4Z1CH	CS	C1=CC(=C(C=C1N)O)C(=O)[O-].[Na+]
DM4Z1CH	IK	FVVDKUPCWXUVNP-UHFFFAOYSA-M
DM4Z1CH	IU	sodium;4-amino-2-hydroxybenzoate
DM4Z1CH	CA	133-10-8
DM4Z1CH	DE	Inflammatory bowel disease

DM8XMPT	ID	DM8XMPT
DM8XMPT	DN	4SC-203
DM8XMPT	HS	Phase 1
DM8XMPT	CP	4SC AG
DM8XMPT	PC	44467821
DM8XMPT	MW	642.8
DM8XMPT	FM	C33H38N8O4S
DM8XMPT	IC	InChI=1S/C33H38N8O4S/c1-21-6-9-27(43-3)26(16-21)37-32(42)39-33-38-24-8-7-22(17-30(24)46-33)36-31-23-18-28(44-4)29(19-25(23)34-20-35-31)45-15-5-10-41-13-11-40(2)12-14-41/h6-9,16-20H,5,10-15H2,1-4H3,(H,34,35,36)(H2,37,38,39,42)
DM8XMPT	CS	CC1=CC(=C(C=C1)OC)NC(=O)NC2=NC3=C(S2)C=C(C=C3)NC4=NC=NC5=CC(=C(C=C54)OC)OCCCN6CCN(CC6)C
DM8XMPT	IK	MAFACRSJGNJHCF-UHFFFAOYSA-N
DM8XMPT	IU	1-(2-methoxy-5-methylphenyl)-3-[6-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]amino]-1,3-benzothiazol-2-yl]urea
DM8XMPT	CA	CAS 895533-09-2
DM8XMPT	DE	Solid tumour/cancer

DMG75P3	ID	DMG75P3
DMG75P3	DN	4SC-205
DMG75P3	HS	Phase 1
DMG75P3	CP	4SC AG
DMG75P3	DE	Lymphoma

DM5RLM4	ID	DM5RLM4
DM5RLM4	DN	4SCAR19 cells
DM5RLM4	HS	Phase 1
DM5RLM4	CP	The First People's Hospital of Yunnan
DM5RLM4	DT	CAR T Cell Therapy
DM5RLM4	DE	Acute lymphoblastic leukaemia

DM0351T	ID	DM0351T
DM0351T	DN	5-FP
DM0351T	HS	Phase 1
DM0351T	SN	5-Fluoro-2(1H)-pyrimidinone
DM0351T	DT	Small molecular drug
DM0351T	PC	101498
DM0351T	MW	114.08
DM0351T	FM	C4H3FN2O
DM0351T	IC	InChI=1S/C4H3FN2O/c5-3-1-6-4(8)7-2-3/h1-2H,(H,6,7,8)
DM0351T	CS	C1=C(C=NC(=O)N1)F
DM0351T	IK	HPABFFGQPLJKBP-UHFFFAOYSA-N
DM0351T	IU	5-fluoro-1H-pyrimidin-2-one
DM0351T	CA	CAS 2022-78-8
DM0351T	CB	CHEBI:125539
DM0351T	DE	Solid tumour/cancer

DMOIE05	ID	DMOIE05
DMOIE05	DN	609A
DMOIE05	HS	Phase 1
DMOIE05	CP	3SBio
DMOIE05	DT	Antibody
DMOIE05	DE	Solid tumour/cancer

DMQ789Z	ID	DMQ789Z
DMQ789Z	DN	8H9
DMQ789Z	HS	Phase 1
DMQ789Z	CP	Memorial Sloan-Kettering Cancer Center
DMQ789Z	DT	Antibody
DMQ789Z	DE	Solid tumour/cancer; Brain cancer

DMJR6TC	ID	DMJR6TC
DMJR6TC	DN	90Y-cG250
DMJR6TC	HS	Phase 1
DMJR6TC	SN	Radiolabeled G250 derived mAb (cancer), Wilex/Ludwig Institute; 90Y-DOTA-cG250
DMJR6TC	CP	Wilex AG
DMJR6TC	DT	Antibody
DMJR6TC	DE	Solid tumour/cancer

DMJB6E2	ID	DMJB6E2
DMJB6E2	DN	99mTc-MIP-1405
DMJB6E2	HS	Phase 1
DMJB6E2	CP	Molecular Insight Pharmaceuticals
DMJB6E2	DE	Prostate cancer

DMYKPXJ	ID	DMYKPXJ
DMYKPXJ	DN	9cUAB-30
DMYKPXJ	HS	Phase 1
DMYKPXJ	SN	UAB-112; UAB-20; UAB-30; UAB-75; UAB-76; UAB-8; Retinoic acid analogs (cancer), University of Alabama; (9Z)-UAB-30
DMYKPXJ	CP	University of Alabama at Birmingham
DMYKPXJ	DE	Solid tumour/cancer

DMGJ7A4	ID	DMGJ7A4
DMGJ7A4	DN	A/Anhui/05
DMGJ7A4	HS	Phase 1
DMGJ7A4	SN	Inactivated H5N1 avian influenza vaccine, NIAID
DMGJ7A4	CP	Glaxosmithkline; novavax; vaxart
DMGJ7A4	DT	Vaccine
DMGJ7A4	DE	Influenza virus infection

DMRWTFG	ID	DMRWTFG
DMRWTFG	DN	A-337
DMRWTFG	HS	Phase 1
DMRWTFG	DT	Antibody
DMRWTFG	DE	Non-small-cell lung cancer

DM25CBW	ID	DM25CBW
DM25CBW	DN	A-348441
DM25CBW	HS	Phase 1
DM25CBW	SN	A-348441; CHEMBL219684; SCHEMBL699533; BDBM50195155; KB-3305
DM25CBW	DT	Small molecular drug
DM25CBW	PC	9854142
DM25CBW	MW	850.2
DM25CBW	FM	C54H75NO7
DM25CBW	IC	InChI=1S/C54H75NO7/c1-7-22-54(61)24-21-43-40-15-11-34-27-37(56)14-16-39(34)49(40)41(31-52(43,54)4)33-9-12-36(13-10-33)55(6)25-26-62-38-20-23-51(3)35(28-38)29-46(57)50-44-18-17-42(32(2)8-19-48(59)60)53(44,5)47(58)30-45(50)51/h9-10,12-13,27,32,35,38,40-47,50,57-58,61H,8,11,14-21,23-26,28-31H2,1-6H3,(H,59,60)/t32-,35+,38+,40+,41-,42-,43+,44+,45+,46-,47+,50+,51+,52+,53-,54+/m1/s1
DM25CBW	CS	CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)CCO[C@H]6CC[C@]7([C@@H](C6)C[C@H]([C@@H]8[C@@H]7C[C@@H]([C@]9([C@H]8CC[C@@H]9[C@H](C)CCC(=O)O)C)O)O)C)C)O
DM25CBW	IK	LEUWECPXLBIBOF-NZWIZOFBSA-N
DM25CBW	IU	(4R)-4-[(3S,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-[2-[4-[(8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-11-yl]-N-methylanilino]ethoxy]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM25CBW	DE	Type-2 diabetes

DMX0JLI	ID	DMX0JLI
DMX0JLI	DN	A-837093
DMX0JLI	HS	Phase 1
DMX0JLI	SN	3,4-dihydro-naphthalen-1-olate
DMX0JLI	CP	Abbott
DMX0JLI	DT	Small molecular drug
DMX0JLI	PC	135436761
DMX0JLI	MW	517.6
DMX0JLI	FM	C24H27N3O6S2
DMX0JLI	IC	InChI=1S/C24H27N3O6S2/c1-14(2)11-12-24(3)17-8-6-5-7-16(17)21(28)20(22(24)29)23-25-18-10-9-15(26-34(4,30)31)13-19(18)35(32,33)27-23/h5-10,13-14,26,28H,11-12H2,1-4H3,(H,25,27)/t24-/m1/s1
DMX0JLI	CS	CC(C)CC[C@@]1(C2=CC=CC=C2C(=C(C1=O)C3=NS(=O)(=O)C4=C(N3)C=CC(=C4)NS(=O)(=O)C)O)C
DMX0JLI	IK	ZTRJLSWOQIDJIS-XMMPIXPASA-N
DMX0JLI	IU	N-[3-[(4R)-1-hydroxy-4-methyl-4-(3-methylbutyl)-3-oxonaphthalen-2-yl]-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazin-7-yl]methanesulfonamide
DMX0JLI	CA	CAS 847442-84-6
DMX0JLI	DE	Hepatitis C virus infection

DM92RQT	ID	DM92RQT
DM92RQT	DN	AAB-003/PF-05236812
DM92RQT	HS	Phase 1
DM92RQT	CP	Janssen Alzheimer Immunotherapy; Pfizer
DM92RQT	DE	Alzheimer disease

DMG4RK0	ID	DMG4RK0
DMG4RK0	DN	AAD-2004
DMG4RK0	HS	Phase 1
DMG4RK0	SN	AAD-2004; 927685-43-6; UNII-11VWK61J69; 11VWK61J69; 2-Hydroxy-5-((4-(trifluoromethyl)phenethyl)amino)benzoic acid; Benzoic acid, 2-hydroxy-5-((2-(4-(trifluoromethyl)phenyl)ethyl)amino)-; Benzoic acid, 2-hydroxy-5-[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]-; UTMVACIBQLDZLP-UHFFFAOYSA-N; SCHEMBL608498; ZINC34885635; AKOS027338686; SB16954; AS-35180; 2-HYDROXY-5-(2-(4-TRIFLUOROMETHYL-PHENYL)-ETHYLAMINO)-BENZOIC ACID
DMG4RK0	CP	GNT Pharma Co Ltd
DMG4RK0	DT	Small molecular drug
DMG4RK0	PC	16042343
DMG4RK0	MW	325.28
DMG4RK0	FM	C16H14F3NO3
DMG4RK0	IC	InChI=1S/C16H14F3NO3/c17-16(18,19)11-3-1-10(2-4-11)7-8-20-12-5-6-14(21)13(9-12)15(22)23/h1-6,9,20-21H,7-8H2,(H,22,23)
DMG4RK0	CS	C1=CC(=CC=C1CCNC2=CC(=C(C=C2)O)C(=O)O)C(F)(F)F
DMG4RK0	IK	UTMVACIBQLDZLP-UHFFFAOYSA-N
DMG4RK0	IU	2-hydroxy-5-[2-[4-(trifluoromethyl)phenyl]ethylamino]benzoic acid
DMG4RK0	CA	CAS 927685-43-6
DMG4RK0	DE	Alzheimer disease

DMIX5HF	ID	DMIX5HF
DMIX5HF	DN	AAV2/8-LSPhGAA
DMIX5HF	HS	Phase 1
DMIX5HF	SN	ACTUS 101
DMIX5HF	CP	Actus Therapeutics
DMIX5HF	DT	Gene therapy
DMIX5HF	DE	Pompe disease

DMIDEKB	ID	DMIDEKB
DMIDEKB	DN	AAV2-hFIX16
DMIDEKB	HS	Phase 1
DMIDEKB	SN	AAV-F.IX, University of Pennsylvania; AAV-factor IX gene therapy (hemophilia B), University of Pennsylvania
DMIDEKB	CP	University of Pennsylvania
DMIDEKB	DE	Factor IX deficiency

DMBG9HI	ID	DMBG9HI
DMBG9HI	DN	AB023
DMBG9HI	HS	Phase 1
DMBG9HI	CP	Aronora
DMBG9HI	DT	Antibody
DMBG9HI	DE	End-stage renal disease

DMGONUE	ID	DMGONUE
DMGONUE	DN	AB680
DMGONUE	HS	Phase 1
DMGONUE	SN	AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH
DMGONUE	CP	Arcus Biosciences
DMGONUE	DT	Small molecular drug
DMGONUE	PC	130205852
DMGONUE	MW	580.8
DMGONUE	FM	C20H24ClFN4O9P2
DMGONUE	IC	InChI=1S/C20H24ClFN4O9P2/c1-10(11-4-2-3-5-13(11)22)24-14-6-16(21)25-19-12(14)7-23-26(19)20-18(28)17(27)15(35-20)8-34-37(32,33)9-36(29,30)31/h2-7,10,15,17-18,20,27-28H,8-9H2,1H3,(H,24,25)(H,32,33)(H2,29,30,31)/t10-,15+,17+,18+,20+/m0/s1
DMGONUE	CS	C[C@@H](C1=CC=CC=C1F)NC2=CC(=NC3=C2C=NN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(CP(=O)(O)O)O)O)O)Cl
DMGONUE	IK	MFYLCAMJNGIULC-KCVUFLITSA-N
DMGONUE	IU	[[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
DMGONUE	CA	CAS 2105904-82-1
DMGONUE	DE	Pancreatic cancer

DMYFB10	ID	DMYFB10
DMYFB10	DN	Abaperidone
DMYFB10	HS	Phase 1
DMYFB10	SN	FI-8602
DMYFB10	CP	Ferrer Internacional SA
DMYFB10	DT	Small molecular drug
DMYFB10	PC	3037308
DMYFB10	MW	452.5
DMYFB10	FM	C25H25FN2O5
DMYFB10	IC	InChI=1S/C25H25FN2O5/c26-18-2-4-20-23(12-18)33-27-24(20)16-6-9-28(10-7-16)8-1-11-31-19-3-5-21-22(13-19)32-15-17(14-29)25(21)30/h2-5,12-13,15-16,29H,1,6-11,14H2
DMYFB10	CS	C1CN(CCC1C2=NOC3=C2C=CC(=C3)F)CCCOC4=CC5=C(C=C4)C(=O)C(=CO5)CO
DMYFB10	IK	ICAXEUYZCLRXKY-UHFFFAOYSA-N
DMYFB10	IU	7-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one
DMYFB10	CA	CAS 183849-43-6
DMYFB10	DE	Schizophrenia

DMIQXDJ	ID	DMIQXDJ
DMIQXDJ	DN	ABBV-151
DMIQXDJ	HS	Phase 1
DMIQXDJ	CP	AbbVie
DMIQXDJ	DT	Antibody
DMIQXDJ	DE	Solid tumour/cancer

DM71Q69	ID	DM71Q69
DM71Q69	DN	ABBV-184
DM71Q69	HS	Phase 1
DM71Q69	CP	AbbVie
DM71Q69	DT	TCR-T cell therapy
DM71Q69	DE	Non-small-cell lung cancer; Acute myeloid leukaemia

DMUCF9L	ID	DMUCF9L
DMUCF9L	DN	ABBV-2451
DMUCF9L	HS	Phase 1
DMUCF9L	CP	AbbVie
DMUCF9L	DE	Cystic fibrosis

DMCZI8L	ID	DMCZI8L
DMCZI8L	DN	ABBV-257
DMCZI8L	HS	Phase 1
DMCZI8L	CP	AbbVieNorth Chicago, IL
DMCZI8L	DE	Rheumatoid arthritis

DMU6K37	ID	DMU6K37
DMU6K37	DN	ABBV-2737
DMU6K37	HS	Phase 1
DMU6K37	CP	AbbVie
DMU6K37	DE	Cystic fibrosis

DMB01L5	ID	DMB01L5
DMB01L5	DN	ABBV-3067
DMB01L5	HS	Phase 1
DMB01L5	CP	AbbVie
DMB01L5	DE	Cystic fibrosis

DM49O6Y	ID	DM49O6Y
DM49O6Y	DN	ABBV-323
DM49O6Y	HS	Phase 1
DM49O6Y	CP	AbbVieNorth Chicago, IL
DM49O6Y	DE	Crohn disease

DMQGPRE	ID	DMQGPRE
DMQGPRE	DN	ABBV-399
DMQGPRE	HS	Phase 1
DMQGPRE	CP	Abbvie
DMQGPRE	DE	Solid tumour/cancer

DMPD0KL	ID	DMPD0KL
DMPD0KL	DN	ABBV-428
DMPD0KL	HS	Phase 1
DMPD0KL	CP	AbbVieNorth Chicago, IL
DMPD0KL	DE	Solid tumour/cancer

DM87SM9	ID	DM87SM9
DM87SM9	DN	ABBV-467
DM87SM9	HS	Phase 1
DM87SM9	CP	AbbVie
DM87SM9	DT	Small molecular drug
DM87SM9	DE	Multiple myeloma

DM90EO3	ID	DM90EO3
DM90EO3	DN	ABBV-621
DM90EO3	HS	Phase 1
DM90EO3	CP	AbbVie
DM90EO3	DT	Small molecular drug
DM90EO3	DE	Haematological malignancy; Solid tumour/cancer; Hematologic tumour

DMTEA9C	ID	DMTEA9C
DMTEA9C	DN	ABBV-744
DMTEA9C	HS	Phase 1
DMTEA9C	SN	OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318
DMTEA9C	CP	AbbVieNorth Chicago, IL
DMTEA9C	PC	132010322
DMTEA9C	MW	491.6
DMTEA9C	FM	C28H30FN3O4
DMTEA9C	IC	InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)
DMTEA9C	CS	CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=C(C=CC(=C3)C(C)(C)O)OC4=C(C=C(C=C4C)F)C)C
DMTEA9C	IK	OEDSFMUSNZDJFD-UHFFFAOYSA-N
DMTEA9C	IU	N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
DMTEA9C	CA	CAS 2138861-99-9
DMTEA9C	DE	Prostate cancer; Acute myeloid leukaemia

DMZM0T8	ID	DMZM0T8
DMZM0T8	DN	ABBV-838
DMZM0T8	HS	Phase 1
DMZM0T8	CP	AbbVieNorth Chicago, IL
DMZM0T8	DE	Multiple myeloma

DMPXDL6	ID	DMPXDL6
DMPXDL6	DN	ABBV-CLS-579
DMPXDL6	HS	Phase 1
DMPXDL6	CP	AbbVie; Calico Life Sciences
DMPXDL6	DT	Antibody
DMPXDL6	DE	Solid tumour/cancer

DMUSOM9	ID	DMUSOM9
DMUSOM9	DN	ABBV-CX-2029
DMUSOM9	HS	Phase 1
DMUSOM9	CP	AbbVie; CytomX Therapeutics
DMUSOM9	DT	Antibody drug conjugate
DMUSOM9	DE	Hematologic tumour

DM1KD7U	ID	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	HS	Phase 1
DM1KD7U	CP	Celgene
DM1KD7U	DE	Solid tumour/cancer; Lymphoma

DM4TN6W	ID	DM4TN6W
DM4TN6W	DN	ABI-H3733
DM4TN6W	HS	Phase 1
DM4TN6W	CP	Assembly Biosciences
DM4TN6W	DT	Small molecular drug
DM4TN6W	DE	Hepatitis B

DMS1HR3	ID	DMS1HR3
DMS1HR3	DN	ABM-1310
DMS1HR3	HS	Phase 1
DMS1HR3	CP	ABM Therapeutics
DMS1HR3	DT	Small molecular drug
DMS1HR3	DE	Solid tumour/cancer

DMA4WEO	ID	DMA4WEO
DMA4WEO	DN	ABSK021
DMA4WEO	HS	Phase 1
DMA4WEO	CP	Abbisko Therapeutics
DMA4WEO	DT	Small molecular drug
DMA4WEO	DE	Solid tumour/cancer

DMG4H9Y	ID	DMG4H9Y
DMG4H9Y	DN	ABT-072
DMG4H9Y	HS	Phase 1
DMG4H9Y	CP	Abbott
DMG4H9Y	PC	57775240
DMG4H9Y	MW	469.6
DMG4H9Y	FM	C24H27N3O5S
DMG4H9Y	IC	InChI=1S/C24H27N3O5S/c1-24(2,3)20-15-19(27-13-12-21(28)25-23(27)29)14-17(22(20)32-4)9-6-16-7-10-18(11-8-16)26-33(5,30)31/h6-15,26H,1-5H3,(H,25,28,29)/b9-6+
DMG4H9Y	CS	CC(C)(C)C1=CC(=CC(=C1OC)/C=C/C2=CC=C(C=C2)NS(=O)(=O)C)N3C=CC(=O)NC3=O
DMG4H9Y	IK	XMZSTQYSBYEENY-RMKNXTFCSA-N
DMG4H9Y	IU	N-[4-[(E)-2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethenyl]phenyl]methanesulfonamide
DMG4H9Y	CA	CAS 1132936-00-5
DMG4H9Y	DE	Hepatitis C virus infection

DMJFWPR	ID	DMJFWPR
DMJFWPR	DN	ABT-102
DMJFWPR	HS	Phase 1
DMJFWPR	SN	3-(1H-indazol-4-yl)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)urea
DMJFWPR	CP	Abbott
DMJFWPR	TC	Analgesics
DMJFWPR	DT	Small molecular drug
DMJFWPR	PC	11256560
DMJFWPR	MW	348.4
DMJFWPR	FM	C21H24N4O
DMJFWPR	IC	InChI=1S/C21H24N4O/c1-21(2,3)14-8-9-15-13(11-14)7-10-18(15)24-20(26)23-17-5-4-6-19-16(17)12-22-25-19/h4-6,8-9,11-12,18H,7,10H2,1-3H3,(H,22,25)(H2,23,24,26)/t18-/m1/s1
DMJFWPR	CS	CC(C)(C)C1=CC2=C(C=C1)[C@@H](CC2)NC(=O)NC3=CC=CC4=C3C=NN4
DMJFWPR	IK	TYOYXJNGINZFET-GOSISDBHSA-N
DMJFWPR	IU	1-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-3-(1H-indazol-4-yl)urea
DMJFWPR	CA	CAS 808756-71-0
DMJFWPR	DE	Chronic pain

DM1F50I	ID	DM1F50I
DM1F50I	DN	ABT-110
DM1F50I	HS	Phase 1
DM1F50I	SN	Hu-alphaD11; PG-110; Humanized anti-NGF antibody (pain), Lay Line Genomics; Humanized anti-NGF antibody (pain), PanGenetics; Humanized anti-nerve growth factor antibody (pain), Lay Line Genomics; Humanized anti-nerve growth factor antibody (pain), PanGenetics
DM1F50I	CP	Abbvie
DM1F50I	DE	Chronic pain

DMQ3O1U	ID	DMQ3O1U
DMQ3O1U	DN	ABT-165
DMQ3O1U	HS	Phase 1
DMQ3O1U	CP	AbbVieNorth Chicago, IL
DMQ3O1U	DE	Solid tumour/cancer

DMR7OGL	ID	DMR7OGL
DMR7OGL	DN	ABT-239
DMR7OGL	HS	Phase 1
DMR7OGL	SN	4-[2-[2-(2-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl]benzonitrile
DMR7OGL	CP	Abbott
DMR7OGL	DT	Small molecular drug
DMR7OGL	PC	9818903
DMR7OGL	MW	330.4
DMR7OGL	FM	C22H22N2O
DMR7OGL	IC	InChI=1S/C22H22N2O/c1-16-3-2-11-24(16)12-10-21-14-20-13-19(8-9-22(20)25-21)18-6-4-17(15-23)5-7-18/h4-9,13-14,16H,2-3,10-12H2,1H3/t16-/m1/s1
DMR7OGL	CS	C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C4=CC=C(C=C4)C#N
DMR7OGL	IK	KFHYZKCRXNRKRC-MRXNPFEDSA-N
DMR7OGL	IU	4-[2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]-1-benzofuran-5-yl]benzonitrile
DMR7OGL	CA	CAS 460746-46-7
DMR7OGL	DE	Cognitive impairment

DM7TOWX	ID	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	HS	Phase 1
DM7TOWX	SN	Dasabuvir; 1132935-63-7; ABT-333; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; ABT333; UNII-DE54EQW8T1; ABT 333; Dasabuvir (ABT-333); DE54EQW8T1; CHEBI:85182; N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; C26H27N3O5S; Dasabuvir [INN]; N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide; Dasabuvir [USAN:INN]; Dasabuvir (USA
DM7TOWX	CP	Abbott
DM7TOWX	DT	Small molecular drug
DM7TOWX	PC	56640146
DM7TOWX	MW	493.6
DM7TOWX	FM	C26H27N3O5S
DM7TOWX	IC	InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)
DM7TOWX	CS	CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O
DM7TOWX	IK	NBRBXGKOEOGLOI-UHFFFAOYSA-N
DM7TOWX	IU	N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide
DM7TOWX	CA	CAS 1132935-63-7
DM7TOWX	CB	CHEBI:85182
DM7TOWX	DE	Hepatitis C virus infection

DMWN7D3	ID	DMWN7D3
DMWN7D3	DN	ABT-354
DMWN7D3	HS	Phase 1
DMWN7D3	CP	Abbvie
DMWN7D3	DE	Alzheimer disease

DM4KPV0	ID	DM4KPV0
DM4KPV0	DN	ABT-413
DM4KPV0	HS	Phase 1
DM4KPV0	DT	Antibody
DM4KPV0	DE	Solid tumour/cancer

DMVLPRT	ID	DMVLPRT
DMVLPRT	DN	ABT-700
DMVLPRT	HS	Phase 1
DMVLPRT	CP	Abbott Laboratories Abbott
DMVLPRT	DE	Advanced solid tumour

DMFH3JM	ID	DMFH3JM
DMFH3JM	DN	ABT-767
DMFH3JM	HS	Phase 1
DMFH3JM	CP	Abbott Laboratories Abbott
DMFH3JM	DE	Solid tumour/cancer

DMB9N4J	ID	DMB9N4J
DMB9N4J	DN	ABT-957
DMB9N4J	HS	Phase 1
DMB9N4J	CP	Abbott Laboratories
DMB9N4J	DE	Alzheimer disease

DM9SYVJ	ID	DM9SYVJ
DM9SYVJ	DN	ABX-1431
DM9SYVJ	HS	Phase 1
DM9SYVJ	SN	SQZJGTOZFRNWCX-UHFFFAOYSA-N; CHEMBL3945728; SCHEMBL15100632; BDBM180052; US9133148, 9aq
DM9SYVJ	CP	Abide Therapeutics San Diego, CA
DM9SYVJ	PC	71657619
DM9SYVJ	MW	507.4
DM9SYVJ	FM	C20H22F9N3O2
DM9SYVJ	IC	InChI=1S/C20H22F9N3O2/c21-18(22,23)14-4-3-13(15(11-14)31-5-1-2-6-31)12-30-7-9-32(10-8-30)17(33)34-16(19(24,25)26)20(27,28)29/h3-4,11,16H,1-2,5-10,12H2
DM9SYVJ	CS	C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CN3CCN(CC3)C(=O)OC(C(F)(F)F)C(F)(F)F
DM9SYVJ	IK	SQZJGTOZFRNWCX-UHFFFAOYSA-N
DM9SYVJ	IU	1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate
DM9SYVJ	CA	CAS 1446817-84-0
DM9SYVJ	DE	Neuropathic pain; Tourette syndrome

DMS3915	ID	DMS3915
DMS3915	DN	AC 165198
DMS3915	HS	Phase 1
DMS3915	CP	Amylin Pharmaceuticals; Biocon
DMS3915	DE	Diabetic complication

DMB5A63	ID	DMB5A63
DMB5A63	DN	AC0058TA
DMB5A63	HS	Phase 1
DMB5A63	CP	ACEA Biosciences San Diego, CA
DMB5A63	DE	Autoimmune disease

DM36WTQ	ID	DM36WTQ
DM36WTQ	DN	AC-262271
DM36WTQ	HS	Phase 1
DM36WTQ	SN	IOP lowering (glaucoma), Allergan; Muscarinic M1 agonists (pain, glaucoma), ACADIA/Allergan
DM36WTQ	CP	Acadia pharmaceuticals
DM36WTQ	DE	Glaucoma/ocular hypertension

DMPS6U9	ID	DMPS6U9
DMPS6U9	DN	AC430
DMPS6U9	HS	Phase 1
DMPS6U9	SN	152-97-6; SCHEMBL11862489; ZINC21981448; AKOS025402073
DMPS6U9	CP	Ambit Biosciences
DMPS6U9	DT	Small molecular drug
DMPS6U9	PC	46892373
DMPS6U9	MW	349.4
DMPS6U9	FM	C19H16FN5O
DMPS6U9	IC	InChI=1S/C19H16FN5O/c1-11-10-16(25-24-11)22-18-14-4-2-3-5-15(14)21-19(23-18)17(26)12-6-8-13(20)9-7-12/h2-10,17,26H,1H3,(H2,21,22,23,24,25)
DMPS6U9	CS	CC1=CC(=NN1)NC2=NC(=NC3=CC=CC=C32)C(C4=CC=C(C=C4)F)O
DMPS6U9	IK	DCRWIATZWHLIPN-UHFFFAOYSA-N
DMPS6U9	IU	(4-fluorophenyl)-[4-[(5-methyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]methanol
DMPS6U9	CA	CAS 1241914-87-3
DMPS6U9	DE	leukaemia

DMJ36YH	ID	DMJ36YH
DMJ36YH	DN	ACE-011
DMJ36YH	HS	Phase 1
DMJ36YH	SN	116496-76-5; 4-Acetamido-3-ethoxynitrobenzene; N-(2-ethoxy-4-nitrophenyl)acetamide; Acetamide,N-(2-ethoxy-4-nitrophenyl)-; 2'-ETHOXY-4'-NITROACETANILIDE; CDS1_004703; AC1MEGDI; ACMC-20c3rb; CBMicro_030367; 2-Ethoxy-4-nitroacetanilide; Oprea1_342150; DivK1c_005743; ACE011; SCHEMBL2204761; KS-00002AMW; CTK4A9819; DTXSID60387001; XZWVZJDHIDYKPB-UHFFFAOYSA-N; MolPort-000-279-575; ZX-AT005552; ZINC5061120; OR9529; AKOS001044796; PS-6223; VZ36467; MCULE-3006561606; AB07920; AS02565; KB-71958; CC-31292; AJ-53053; Acetamide, N-(2-ethoxy-4-nitrop
DMJ36YH	DT	Small molecular drug
DMJ36YH	PC	2877953
DMJ36YH	MW	224.21
DMJ36YH	FM	C10H12N2O4
DMJ36YH	IC	InChI=1S/C10H12N2O4/c1-3-16-10-6-8(12(14)15)4-5-9(10)11-7(2)13/h4-6H,3H2,1-2H3,(H,11,13)
DMJ36YH	CS	CCOC1=C(C=CC(=C1)[N+](=O)[O-])NC(=O)C
DMJ36YH	IK	XZWVZJDHIDYKPB-UHFFFAOYSA-N
DMJ36YH	IU	N-(2-ethoxy-4-nitrophenyl)acetamide
DMJ36YH	CA	CAS 116496-76-5
DMJ36YH	DE	Anemia

DMUBYFM	ID	DMUBYFM
DMUBYFM	DN	ACE-041
DMUBYFM	HS	Phase 1
DMUBYFM	SN	N-(5-bromo-2-methylpyridin-4-yl)acetamide; 1244949-22-1; ACE041; DTXSID10670359; 4605AA; ZINC38540942; AKOS016011880; FCH1349294; AJ-96556; EN001564; KB-258244; AX8247344; Acetamide, N-(5-bromo-2-methyl-4-pyridinyl)-
DMUBYFM	CP	Acceleron Pharma
DMUBYFM	DT	Small molecular drug
DMUBYFM	PC	45480413
DMUBYFM	MW	229.07
DMUBYFM	FM	C8H9BrN2O
DMUBYFM	IC	InChI=1S/C8H9BrN2O/c1-5-3-8(11-6(2)12)7(9)4-10-5/h3-4H,1-2H3,(H,10,11,12)
DMUBYFM	CS	CC1=CC(=C(C=N1)Br)NC(=O)C
DMUBYFM	IK	OMGSODSTISOTIL-UHFFFAOYSA-N
DMUBYFM	IU	N-(5-bromo-2-methylpyridin-4-yl)acetamide
DMUBYFM	CA	CAS 1244949-22-1
DMUBYFM	DE	Age-related macular degeneration

DM19UTO	ID	DM19UTO
DM19UTO	DN	Acebilustat
DM19UTO	HS	Phase 1
DM19UTO	SN	UNII-J64RI4D29U; J64RI4D29U; 943764-99-6; Acebilustat [INN]; Acebilustat(ZK322); Acebilustat [WHO-DD]; SCHEMBL3036353; MolPort-046-033-585; EX-A1277; EP-501; AKOS030632028; CS-5999; HY-17625; Benzoic acid, 4-(((1S,4S)-5-((4-(4-(2-oxazolyl)phenoxy)phenyl)methyl)-2,5-diazabicyclo(2.2.1)hept-2-yl)methyl)-
DM19UTO	CP	Celtaxsys Atlanta, GA
DM19UTO	PC	68488178
DM19UTO	MW	481.5
DM19UTO	FM	C29H27N3O4
DM19UTO	IC	InChI=1S/C29H27N3O4/c33-29(34)23-5-1-20(2-6-23)16-31-18-25-15-24(31)19-32(25)17-21-3-9-26(10-4-21)36-27-11-7-22(8-12-27)28-30-13-14-35-28/h1-14,24-25H,15-19H2,(H,33,34)/t24-,25-/m0/s1
DM19UTO	CS	C1[C@H]2CN([C@@H]1CN2CC3=CC=C(C=C3)OC4=CC=C(C=C4)C5=NC=CO5)CC6=CC=C(C=C6)C(=O)O
DM19UTO	IK	GERJIEKMNDGSCS-DQEYMECFSA-N
DM19UTO	IU	4-[[(1S,4S)-5-[[4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]benzoic acid
DM19UTO	CA	CAS 943764-99-6
DM19UTO	DE	Chronic blistering skin disorder

DMW6X0O	ID	DMW6X0O
DMW6X0O	DN	ACH-2684
DMW6X0O	HS	Phase 1
DMW6X0O	SN	Deldeprevir; ACH-2684; UNII-5ZT4SBY0BD; 5ZT4SBY0BD; ACH-0142684; Neceprevir [USAN]; Deldeprevir [USAN:INN]; CHEMBL3040582; SCHEMBL13291708; UDMJANYPQWEDFT-ZAWFUYGJSA-N; Cyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide, N- (cyclopropylsulfonyl)-6-(2-(3,3-difluoro-1-piperidinyl)-2-oxoethyl)- 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-((7-methoxy-8-methyl-2-(4-(1- methylethyl)-2-thiazolyl)-4-quinolinyl)oxy)-5,16-dioxo-, (2R,6R,12Z,13aS,14aR,16aS)-
DMW6X0O	CP	Achillion pharmaceuticals
DMW6X0O	DT	Small molecular drug
DMW6X0O	PC	56935739
DMW6X0O	MW	911.1
DMW6X0O	FM	C45H56F2N6O8S2
DMW6X0O	IC	InChI=1S/C45H56F2N6O8S2/c1-26(2)34-24-62-41(49-34)33-21-37(32-15-16-36(60-4)27(3)39(32)48-33)61-30-20-35-40(55)50-45(43(57)51-63(58,59)31-13-14-31)22-29(45)12-9-7-5-6-8-11-28(42(56)53(35)23-30)19-38(54)52-18-10-17-44(46,47)25-52/h9,12,15-16,21,24,26,28-31,35H,5-8,10-11,13-14,17-20,22-23,25H2,1-4H3,(H,50,55)(H,51,57)/b12-9-/t28-,29-,30-,35+,45-/m1/s1
DMW6X0O	CS	CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@H]4C(=O)N[C@@]5(C[C@H]5/C=C\\CCCCC[C@@H](C(=O)N4C3)CC(=O)N6CCCC(C6)(F)F)C(=O)NS(=O)(=O)C7CC7)C8=NC(=CS8)C(C)C)OC
DMW6X0O	IK	UDMJANYPQWEDFT-ZAWFUYGJSA-N
DMW6X0O	IU	(1S,4R,6S,7Z,14R,18R)-N-cyclopropylsulfonyl-14-[2-(3,3-difluoropiperidin-1-yl)-2-oxoethyl]-18-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
DMW6X0O	CA	CAS 1229626-28-1
DMW6X0O	DE	Hepatitis C virus infection

DM5SJO9	ID	DM5SJO9
DM5SJO9	DN	ACHN-975
DM5SJO9	HS	Phase 1
DM5SJO9	CP	Achaogen
DM5SJO9	PC	71466517
DM5SJO9	MW	369.4
DM5SJO9	FM	C20H23N3O4
DM5SJO9	IC	InChI=1S/C20H23N3O4/c1-20(2,21)17(19(26)23-27)22-18(25)14-9-7-13(8-10-14)5-3-4-6-15-11-16(15)12-24/h7-10,15-17,24,27H,11-12,21H2,1-2H3,(H,22,25)(H,23,26)/t15-,16+,17-/m1/s1
DM5SJO9	CS	CC(C)([C@@H](C(=O)NO)NC(=O)C1=CC=C(C=C1)C#CC#C[C@@H]2C[C@H]2CO)N
DM5SJO9	IK	GOCUUDXEOKIQRU-IXDOHACOSA-N
DM5SJO9	IU	N-[(2S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-4-[4-[(1R,2R)-2-(hydroxymethyl)cyclopropyl]buta-1,3-diynyl]benzamide
DM5SJO9	CA	CAS 1410809-36-7
DM5SJO9	DE	Pseudomonas infection

DMKVE8X	ID	DMKVE8X
DMKVE8X	DN	Acriflavine
DMKVE8X	HS	Phase 1
DMKVE8X	SN	Acriflavine; Xanthacridinum; Euflavine; Pantonsiletten; Flavinetten; Assiflavine; Choliflavin; Bialflavina; Vetaflavin; Buroflavin; Tolivalin; Isravin; Diacrid; Zoriflavin; Trachosept; Gonacin; Flavisept; Flavioform; Bovoflavin; Mediflavin; Bioacridin; Angiflan; Tripla-etilo; Glyco-flavine; Acriflavine neutral; Acriflavine [NF]; Caswell No. 008; Euflavin; Flavacridinum hydrochloricum; Trypaflavine Neutral; CCRIS 5617; UNII-1T3A50395T; EPA Pesticide Chemical Code 000501; Acridinium, 3,6-diamino-10-methyl-, chloride, mixt. with 3,6-acridined
DMKVE8X	DT	Small molecular drug
DMKVE8X	PC	443101
DMKVE8X	MW	469
DMKVE8X	FM	C27H25ClN6
DMKVE8X	IC	InChI=1S/C14H13N3.C13H11N3.ClH/c1-17-13-7-11(15)4-2-9(13)6-10-3-5-12(16)8-14(10)17;14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10;/h2-8H,1H3,(H3,15,16);1-7H,14-15H2;1H
DMKVE8X	CS	C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.[Cl-]
DMKVE8X	IK	PEJLNXHANOHNSU-UHFFFAOYSA-N
DMKVE8X	IU	acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride
DMKVE8X	CA	CAS 8048-52-0
DMKVE8X	DE	Human immunodeficiency virus infection

DMOZ3AT	ID	DMOZ3AT
DMOZ3AT	DN	ACT-178882
DMOZ3AT	HS	Phase 1
DMOZ3AT	SN	MK-1597
DMOZ3AT	CP	Actelion Ltd
DMOZ3AT	PC	12001785
DMOZ3AT	MW	647
DMOZ3AT	FM	C33H38Cl3N3O4
DMOZ3AT	IC	InChI=1S/C33H38Cl3N3O4/c1-21-15-29(35)32(30(36)16-21)43-14-13-42-31-8-4-23(18-38-31)26-9-11-37-19-27(26)33(40)39(25-5-6-25)20-24-17-22(10-12-41-2)3-7-28(24)34/h3-4,7-8,15-18,25-27,37H,5-6,9-14,19-20H2,1-2H3/t26-,27+/m1/s1
DMOZ3AT	CS	CC1=CC(=C(C(=C1)Cl)OCCOC2=NC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCOC)Cl)C5CC5)Cl
DMOZ3AT	IK	PGSRKJVMAOWDEC-SXOMAYOGSA-N
DMOZ3AT	IU	(3R,4S)-N-[[2-chloro-5-(2-methoxyethyl)phenyl]methyl]-N-cyclopropyl-4-[6-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]pyridin-3-yl]piperidine-3-carboxamide
DMOZ3AT	CA	CAS 1007392-69-9
DMOZ3AT	DE	Cardiovascular disease

DM5KMYQ	ID	DM5KMYQ
DM5KMYQ	DN	Actimab-M
DM5KMYQ	HS	Phase 1
DM5KMYQ	SN	Actinium-225; Actinium, isotope of mass 225; 225Ac; AC1L4Z7V; 14265-85-1
DM5KMYQ	CP	Actinium Pharmaceuticals New York, NY
DM5KMYQ	PC	167045
DM5KMYQ	MW	225.023
DM5KMYQ	FM	Ac
DM5KMYQ	IC	InChI=1S/Ac/i1-2
DM5KMYQ	CS	[225Ac]
DM5KMYQ	IK	QQINRWTZWGJFDB-YPZZEJLDSA-N
DM5KMYQ	IU	actinium-225
DM5KMYQ	CA	CAS 14265-85-1
DM5KMYQ	DE	Multiple myeloma

DMRDY0G	ID	DMRDY0G
DMRDY0G	DN	ACV-1
DMRDY0G	HS	Phase 1
DMRDY0G	CP	Metabolic Pharmaceuticals
DMRDY0G	TC	Analgesics
DMRDY0G	PC	90488812
DMRDY0G	MW	1807
DMRDY0G	FM	C71H103N23O25S4
DMRDY0G	IC	InChI=1S/C71H103N23O25S4/c1-3-32(2)55-68(117)89-44(56(74)105)27-120-122-30-47-65(114)88-43(26-95)62(111)87-42(23-54(103)104)70(119)94-18-6-8-48(94)66(115)81-36(7-4-16-78-71(75)76)57(106)90-46(29-123-121-28-45(63(112)91-47)80-51(98)24-72)64(113)84-39(21-50(73)97)60(109)83-38(19-33-10-12-35(96)13-11-33)59(108)85-40(22-53(101)102)61(110)86-41(20-34-25-77-31-79-34)69(118)93-17-5-9-49(93)67(116)82-37(58(107)92-55)14-15-52(99)100/h10-13,25,31-32,36-49,55,95-96H,3-9,14-24,26-30,72H2,1-2H3,(H2,73,97)(H2,74,105)(H,77,79)(H,80,98)(H,81,115)(H,82,116)(H,83,109)(H,84,113)(H,85,108)(H,86,110)(H,87,111)(H,88,114)(H,89,117)(H,90,106)(H,91,112)(H,92,107)(H,99,100)(H,101,102)(H,103,104)(H4,75,76,78)/t32-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,55-/m0/s1
DMRDY0G	CS	CC[C@H](C)[C@H]1C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N2)NC(=O)CN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)N1)CCC(=O)O)CC5=CNC=N5)CC(=O)O)CC6=CC=C(C=C6)O)CC(=O)N)CCCNC(=N)N)CC(=O)O)CO)C(=O)N
DMRDY0G	IK	KJQOYUHYAZGPIZ-PIJHVLQJSA-N
DMRDY0G	IU	3-[(1R,6R,9S,12S,15S,21S,24S,27S,30S,33R,36S,39S,45S,48S,53R)-53-[(2-aminoacetyl)amino]-30-(2-amino-2-oxoethyl)-9-[(2S)-butan-2-yl]-36-(3-carbamimidamidopropyl)-6-carbamoyl-24,45-bis(carboxymethyl)-48-(hydroxymethyl)-27-[(4-hydroxyphenyl)methyl]-21-(1H-imidazol-4-ylmethyl)-8,11,14,20,23,26,29,32,35,38,44,47,50,52-tetradecaoxo-3,4,55,56-tetrathia-7,10,13,19,22,25,28,31,34,37,43,46,49,51-tetradecazatetracyclo[31.17.7.015,19.039,43]heptapentacontan-12-yl]propanoic acid
DMRDY0G	CA	CAS 467428-30-4
DMRDY0G	DE	Neuropathic pain

DM8VQ1S	ID	DM8VQ1S
DM8VQ1S	DN	AD-337
DM8VQ1S	HS	Phase 1
DM8VQ1S	CP	Arakis
DM8VQ1S	DE	Chemotherapy-induced nausea; Myalgia; Fibromyalgia

DMG82ZA	ID	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	HS	Phase 1
DMG82ZA	SN	Ad35 vector-delivered gag/rt/int/nef + Ad35 vector-delivered env combination vaccine (HIV infection), International AIDS Vaccine Initiative
DMG82ZA	CP	International AIDS Vaccine Initiative
DMG82ZA	DT	Vaccine
DMG82ZA	DE	Human immunodeficiency virus infection

DMFTGHX	ID	DMFTGHX
DMFTGHX	DN	Ad5CMV-NIS
DMFTGHX	HS	Phase 1
DMFTGHX	SN	Sodium iodide symporter adenoviral gene therapy (prostate cancer); Sodium iodide symporter adenoviral gene therapy (prostate cancer), Mayo Clinic
DMFTGHX	CP	Mayo Foundation
DMFTGHX	DE	Prostate cancer

DMMBQV3	ID	DMMBQV3
DMMBQV3	DN	Ad5-ENVA-48
DMMBQV3	HS	Phase 1
DMMBQV3	SN	Ad26-ENVA-01; Ad5-HVR48-ENVA-01; HIV vaccine (ad35 vector), IAVI/Crucell; Recombinant envelope adenovirus 5 vaccine (HIV infection), Crucell/Harvard Medical School; Adenovirus vector vaccine (HIV infection), IAVI/Crucell/BIDMC/Harvard; HIV vaccine (rAd26 vector), IAVI/Crucell/Beth Israel Deaconess Medical Center/Harvard; HIV vaccine (AdVac, PER.C6), Crucell/IAVI/BIDMC/Harvard
DMMBQV3	CP	Crucell NV
DMMBQV3	DT	Vaccine
DMMBQV3	DE	Human immunodeficiency virus-1 infection

DM2UMGE	ID	DM2UMGE
DM2UMGE	DN	Ad5-TRAIL
DM2UMGE	HS	Phase 1
DM2UMGE	SN	Ad5-TRAIL adenoviral gene therapy (prostate cancer), University of Iowa
DM2UMGE	CP	University of Iowa
DM2UMGE	DE	Prostate cancer

DM16QSG	ID	DM16QSG
DM16QSG	DN	Adaphostin
DM16QSG	HS	Phase 1
DM16QSG	SN	NSC-680410; NSC-726814; 241127-58-2
DM16QSG	CP	Mayo Foundation
DM16QSG	DT	Small molecular drug
DM16QSG	PC	387042
DM16QSG	MW	393.5
DM16QSG	FM	C24H27NO4
DM16QSG	IC	InChI=1S/C24H27NO4/c26-21-5-6-22(27)19(10-21)14-25-20-3-1-18(2-4-20)23(28)29-24-11-15-7-16(12-24)9-17(8-15)13-24/h1-6,10,15-17,25-27H,7-9,11-14H2
DM16QSG	CS	C1C2CC3CC1CC(C2)(C3)OC(=O)C4=CC=C(C=C4)NCC5=C(C=CC(=C5)O)O
DM16QSG	IK	YJZSUCFGHXQWDM-UHFFFAOYSA-N
DM16QSG	IU	1-adamantyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate
DM16QSG	CA	CAS 241127-58-2
DM16QSG	DE	Chronic myelogenous leukaemia

DM59EUY	ID	DM59EUY
DM59EUY	DN	ADCI
DM59EUY	HS	Phase 1
DM59EUY	SN	SBG-017
DM59EUY	CP	National Institutes of Health
DM59EUY	DT	Small molecular drug
DM59EUY	PC	130099
DM59EUY	MW	250.29
DM59EUY	FM	C16H14N2O
DM59EUY	IC	InChI=1S/C16H14N2O/c17-15(19)16-12-7-3-1-5-10(12)9-14(18-16)11-6-2-4-8-13(11)16/h1-8,14,18H,9H2,(H2,17,19)
DM59EUY	CS	C1C2C3=CC=CC=C3C(N2)(C4=CC=CC=C41)C(=O)N
DM59EUY	IK	IFLVGRRVGPXYON-UHFFFAOYSA-N
DM59EUY	IU	16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene-1-carboxamide
DM59EUY	CA	CAS 124070-15-1
DM59EUY	DE	Epileptic seizures

DMEXT97	ID	DMEXT97
DMEXT97	DN	ADG116
DMEXT97	HS	Phase 1
DMEXT97	CP	Adagene
DMEXT97	DT	Antibody
DMEXT97	DE	Solid tumour/cancer

DMM45P9	ID	DMM45P9
DMM45P9	DN	Ad-IFN-alpha
DMM45P9	HS	Phase 1
DMM45P9	SN	Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI
DMM45P9	CP	MD Anderson Cancer Center
DMM45P9	DE	Bladder cancer

DMQVEZB	ID	DMQVEZB
DMQVEZB	DN	Adjustable basal insulin
DMQVEZB	HS	Phase 1
DMQVEZB	SN	Adjustable basal insulin (diabetes); BIOD-Adjustable Basal; BIOD-Basal; Adjustable basal insulin (diabetes), Biodel
DMQVEZB	CP	Biodel
DMQVEZB	DE	Diabetic complication

DM9GLHO	ID	DM9GLHO
DM9GLHO	DN	Ad-OC-hsvTK/valacyclovir
DM9GLHO	HS	Phase 1
DM9GLHO	SN	Ad-OC-hsvTK; Gene therapy (prostate cancer), Winship Cancer Institute; Adenovirus osteocalcin-promoter-driven HSV thymidine Kinase, Winship Cancer Institute; Ad-OC-hsvTK/valacyclovir, Winship Cancer Institute
DM9GLHO	CP	Winship Cancer Institute
DM9GLHO	DE	Prostate cancer

DMS6DPF	ID	DMS6DPF
DMS6DPF	DN	ADPT01
DMS6DPF	HS	Phase 1
DMS6DPF	CP	Novartis
DMS6DPF	DT	Antibody
DMS6DPF	DE	Breast cancer

DM6NUCA	ID	DM6NUCA
DM6NUCA	DN	ADR-851
DM6NUCA	HS	Phase 1
DM6NUCA	SN	Adr 851; 123805-17-4; UNII-303JW6Z3QJ; 303JW6Z3QJ; Adr-851; PCBGZTCWZUGEJX-QRPNPIFTSA-N; AC1L2WPB; SCHEMBL8785455; DTXSID00154097; 4-Amino-5-chloro-N-(2-pyrrolidinylmethyl)-2,3-dihydrobenzofuran-7-carboxamide hcl; KB-289941; 4-amino-5-chloro-N-[[(2S)-pyrrolidin-2-yl]methyl]-2,3-dihydro-1-benzofuran-7-carboxamide hydrochloride; 7-Benzofurancarboxamide, 4-amino-5-chloro-2,3-dihydro-N-(2-pyrrolidinylmethyl)-, monohydrochloride, (S)-; (S)-4-amino-5-chloro-N-(2-pyrrolidinylmethyl)-2,3-dihydrobenzo[b]furan-7-carboxamide hydro
DM6NUCA	CP	Adria Laboratories Inc
DM6NUCA	DT	Small molecular drug
DM6NUCA	PC	130053
DM6NUCA	MW	332.2
DM6NUCA	FM	C14H19Cl2N3O2
DM6NUCA	IC	InChI=1S/C14H18ClN3O2.ClH/c15-11-6-10(13-9(12(11)16)3-5-20-13)14(19)18-7-8-2-1-4-17-8;/h6,8,17H,1-5,7,16H2,(H,18,19);1H/t8-;/m0./s1
DM6NUCA	CS	C1C[C@H](NC1)CNC(=O)C2=CC(=C(C3=C2OCC3)N)Cl.Cl
DM6NUCA	IK	PCBGZTCWZUGEJX-QRPNPIFTSA-N
DM6NUCA	IU	4-amino-5-chloro-N-[[(2S)-pyrrolidin-2-yl]methyl]-2,3-dihydro-1-benzofuran-7-carboxamide;hydrochloride
DM6NUCA	CA	CAS 123805-17-4
DM6NUCA	DE	Nausea and vomiting

DMYHIAR	ID	DMYHIAR
DMYHIAR	DN	AdRTVP-1
DMYHIAR	HS	Phase 1
DMYHIAR	SN	AdRTVP-1, Baylor College of Medicine; Gene therapy (RTVP-1); Gene therapy (RTVP-1), Baylor College of Medicine; Related to Testes-Specific Vespid and Pathogenesis Protein-1 adenoviral gene therapy, BCM
DMYHIAR	CP	Baylor College of Medicine
DMYHIAR	DE	Prostate cancer

DMHIPF5	ID	DMHIPF5
DMHIPF5	DN	ADV-1002401
DMHIPF5	HS	Phase 1
DMHIPF5	SN	GKM-001; Hypoglycemic agent (diabetes), Advinus
DMHIPF5	CP	Advinus Therapeutics
DMHIPF5	DE	Type-2 diabetes

DMH8Z9W	ID	DMH8Z9W
DMH8Z9W	DN	ADVAX
DMH8Z9W	HS	Phase 1
DMH8Z9W	CP	Aaron Diamond AIDS Research Center; International AIDS Vaccine Initiative Ichor Medical Systems
DMH8Z9W	DE	Human immunodeficiency virus infection

DMBUOX4	ID	DMBUOX4
DMBUOX4	DN	ADX71149
DMBUOX4	HS	Phase 1
DMBUOX4	CP	Addex Pharmaceuticals; Johnson & Johnson Pharmaceutical
DMBUOX4	PC	25195461
DMBUOX4	MW	344.9
DMBUOX4	FM	C20H25ClN2O
DMBUOX4	IC	InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3
DMBUOX4	CS	CCCCN1C=CC(=C(C1=O)Cl)N2CCC(CC2)C3=CC=CC=C3
DMBUOX4	IK	HYOGJHCDLQSAHX-UHFFFAOYSA-N
DMBUOX4	IU	1-butyl-3-chloro-4-(4-phenylpiperidin-1-yl)pyridin-2-one
DMBUOX4	CA	CAS 1127498-03-6
DMBUOX4	DE	Anxiety disorder; Epilepsy; Psychiatric disorder

DM7X2HK	ID	DM7X2HK
DM7X2HK	DN	AE-08
DM7X2HK	HS	Phase 1
DM7X2HK	CP	Antigen express
DM7X2HK	DT	Vaccine
DM7X2HK	DE	Melanoma

DMQRKXP	ID	DMQRKXP
DMQRKXP	DN	AEA-35p
DMQRKXP	HS	Phase 1
DMQRKXP	SN	Peptide vaccines (H1N1 influenza virus infection), Antigen Express
DMQRKXP	CP	Antigen Express Inc
DMQRKXP	DT	Vaccine
DMQRKXP	DE	Influenza virus infection

DM8I4G0	ID	DM8I4G0
DM8I4G0	DN	AEB701
DM8I4G0	HS	Phase 1
DM8I4G0	DE	Melanoma

DMQF982	ID	DMQF982
DMQF982	DN	AEW-541
DMQF982	HS	Phase 1
DMQF982	SN	AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-
DMQF982	CP	Novartis AG
DMQF982	TC	Anticancer Agents
DMQF982	DT	Small molecular drug
DMQF982	PC	11476171
DMQF982	MW	439.6
DMQF982	FM	C27H29N5O
DMQF982	IC	InChI=1S/C27H29N5O/c28-26-25-24(21-8-4-9-23(14-21)33-17-19-6-2-1-3-7-19)16-32(27(25)30-18-29-26)22-12-20(13-22)15-31-10-5-11-31/h1-4,6-9,14,16,18,20,22H,5,10-13,15,17H2,(H2,28,29,30)
DMQF982	CS	C1CN(C1)CC2CC(C2)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC=C5)OCC6=CC=CC=C6
DMQF982	IK	AECDBHGVIIRMOI-UHFFFAOYSA-N
DMQF982	IU	7-[3-(azetidin-1-ylmethyl)cyclobutyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine
DMQF982	CA	CAS 475488-34-7
DMQF982	DE	Multiple myeloma

DM8LG2I	ID	DM8LG2I
DM8LG2I	DN	AF-130
DM8LG2I	HS	Phase 1
DM8LG2I	CP	Merck Kenilworth, NJ
DM8LG2I	DE	Hypertension

DMNF3GW	ID	DMNF3GW
DMNF3GW	DN	Afeletecan
DMNF3GW	HS	Phase 1
DMNF3GW	SN	Afeletecan hydrochloride; Camptothecin glycoconjugate, Bayer; Topoisomerase I inhibitors, Bayer
DMNF3GW	CP	Bayer AG
DMNF3GW	DT	Small molecular drug
DMNF3GW	PC	9941008
DMNF3GW	MW	896
DMNF3GW	FM	C45H49N7O11S
DMNF3GW	IC	InChI=1S/C45H49N7O11S/c1-6-45(30-17-33-35-25(15-24-9-7-8-10-31(24)49-35)19-52(33)40(56)29(30)20-60-43(45)58)63-41(57)34(22(2)3)51-39(55)32(16-27-18-46-21-47-27)50-44(64)48-26-11-13-28(14-12-26)62-42-37(54)38(59-5)36(53)23(4)61-42/h7-15,17-18,21-23,32,34,36-38,42,53-54H,6,16,19-20H2,1-5H3,(H,46,47)(H,51,55)(H2,48,50,64)/t23-,32-,34-,36+,37-,38+,42+,45-/m0/s1
DMNF3GW	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=S)NC7=CC=C(C=C7)O[C@@H]8[C@H]([C@@H]([C@@H]([C@@H](O8)C)O)OC)O
DMNF3GW	IK	SLOJCSGNHWIKIG-JNYZSSQASA-N
DMNF3GW	IU	[(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] (2S)-2-[[(2S)-2-[[4-[(2R,3S,4R,5R,6S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxyphenyl]carbamothioylamino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylbutanoate
DMNF3GW	CA	CAS 215604-75-4
DMNF3GW	DE	Breast cancer

DM0I8RZ	ID	DM0I8RZ
DM0I8RZ	DN	Affitope AD-01
DM0I8RZ	HS	Phase 1
DM0I8RZ	SN	AD-01; Amyloid beta 40-42 peptide vaccine (sc, Alzheimer's), AFFiRiS
DM0I8RZ	CP	Affiris GmbH
DM0I8RZ	DT	Vaccine
DM0I8RZ	DE	Alzheimer disease

DMIFJZD	ID	DMIFJZD
DMIFJZD	DN	AFM11
DMIFJZD	HS	Phase 1
DMIFJZD	CP	Affimed Therapeutics
DMIFJZD	DT	Antibody
DMIFJZD	DE	Non-hodgkin lymphoma; B-cell non-hodgkin lymphoma; leukaemia

DMSX24U	ID	DMSX24U
DMSX24U	DN	AFO-18
DMSX24U	HS	Phase 1
DMSX24U	SN	Peptide vaccine (CAF-01 adjuvanted, HIV-1 infection), Statens Serum Institut
DMSX24U	CP	Statens Serum Institut
DMSX24U	DT	Vaccine
DMSX24U	DE	Human immunodeficiency virus-1 infection

DMHBUMZ	ID	DMHBUMZ
DMHBUMZ	DN	AFP TCR
DMHBUMZ	HS	Phase 1
DMHBUMZ	CP	Adaptimmune Philadelphia, PA
DMHBUMZ	DE	Hepatocellular carcinoma

DMY4WVK	ID	DMY4WVK
DMY4WVK	DN	AG-024322
DMY4WVK	HS	Phase 1
DMY4WVK	SN	AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine
DMY4WVK	CP	Pfizer
DMY4WVK	DT	Small molecular drug
DMY4WVK	PC	135413565
DMY4WVK	MW	418.4
DMY4WVK	FM	C23H20F2N6
DMY4WVK	IC	InChI=1S/C23H20F2N6/c1-3-26-9-14-10-27-11-17(12(14)2)13-4-5-19-16(6-13)21(31-30-19)23-28-20-8-15(24)7-18(25)22(20)29-23/h4-8,10-11,26H,3,9H2,1-2H3,(H,28,29)(H,30,31)
DMY4WVK	CS	CCNCC1=CN=CC(=C1C)C2=CC3=C(C=C2)NN=C3C4=NC5=C(N4)C=C(C=C5F)F
DMY4WVK	IK	MEKASOQEXYKAKM-UHFFFAOYSA-N
DMY4WVK	IU	N-[[5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine
DMY4WVK	CA	CAS 837364-57-5
DMY4WVK	DE	Solid tumour/cancer

DMFU58V	ID	DMFU58V
DMFU58V	DN	AG2034
DMFU58V	HS	Phase 1
DMFU58V	DT	Small molecular drug
DMFU58V	PC	135465775
DMFU58V	MW	467.5
DMFU58V	FM	C18H21N5O6S2
DMFU58V	IC	InChI=1S/C18H21N5O6S2/c19-18-22-14-13(16(27)23-18)31-9(7-20-14)2-1-8-3-5-11(30-8)15(26)21-10(17(28)29)4-6-12(24)25/h3,5,9-10H,1-2,4,6-7H2,(H,21,26)(H,24,25)(H,28,29)(H4,19,20,22,23,27)/t9-,10-/m0/s1
DMFU58V	CS	C1[C@@H](SC2=C(N1)N=C(NC2=O)N)CCC3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMFU58V	IK	HHKAOUMVRGSKLS-UWVGGRQHSA-N
DMFU58V	IU	(2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-3,6,7,8-tetrahydropyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]thiophene-2-carbonyl]amino]pentanedioic acid
DMFU58V	CA	CAS 177575-17-6
DMFU58V	DE	Solid tumour/cancer

DMYTJG7	ID	DMYTJG7
DMYTJG7	DN	AG-270
DMYTJG7	HS	Phase 1
DMYTJG7	SN	REOUTEBTFSILJY-UHFFFAOYSA-N; AG 270; 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride; 6-(m-Methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-3(2H)-pyridazinone hydrochloride; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate [French]; 13299-99-5; AC1L496O; DTXSID20157888; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate; LS-130006; 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholin-4-ylethyl)pyridazin-3-one hydrochloride
DMYTJG7	CP	Agios Pharmaceuticals Cambridge, MA
DMYTJG7	PC	202785
DMYTJG7	MW	365.9
DMYTJG7	FM	C18H24ClN3O3
DMYTJG7	IC	InChI=1S/C18H23N3O3.ClH/c1-14-12-17(15-4-3-5-16(13-15)23-2)19-21(18(14)22)7-6-20-8-10-24-11-9-20;/h3-5,12-13H,6-11H2,1-2H3;1H
DMYTJG7	CS	CC1=CC(=NN(C1=O)CCN2CCOCC2)C3=CC(=CC=C3)OC.Cl
DMYTJG7	IK	REOUTEBTFSILJY-UHFFFAOYSA-N
DMYTJG7	IU	6-(3-methoxyphenyl)-4-methyl-2-(2-morpholin-4-ylethyl)pyridazin-3-one;hydrochloride
DMYTJG7	CA	CAS 13299-99-5
DMYTJG7	DE	Lymphoma; Solid tumour/cancer

DMZTMEJ	ID	DMZTMEJ
DMZTMEJ	DN	AG-270
DMZTMEJ	HS	Phase 1
DMZTMEJ	CP	Agios Pharmaceuticals
DMZTMEJ	DT	Small molecular drug
DMZTMEJ	DE	Lymphoma; Solid tumour/cancer

DM7PLMJ	ID	DM7PLMJ
DM7PLMJ	DN	AG-707
DM7PLMJ	HS	Phase 1
DM7PLMJ	CP	Agenus
DM7PLMJ	DE	Herpes simplex virus infection

DMV6JFK	ID	DMV6JFK
DMV6JFK	DN	AGEN1181
DMV6JFK	HS	Phase 1
DMV6JFK	CP	Agenus
DMV6JFK	DT	Antibody
DMV6JFK	DE	Solid tumour/cancer

DMAXVZ1	ID	DMAXVZ1
DMAXVZ1	DN	AGEN2373
DMAXVZ1	HS	Phase 1
DMAXVZ1	CP	Agenus; Gilead Sciences
DMAXVZ1	DT	Antibody
DMAXVZ1	DE	Solid tumour/cancer

DMVMIBY	ID	DMVMIBY
DMVMIBY	DN	AGG-523
DMVMIBY	HS	Phase 1
DMVMIBY	SN	PF-5212371, WAY-266523
DMVMIBY	CP	Pfizer
DMVMIBY	PC	16048422
DMVMIBY	MW	476.5
DMVMIBY	FM	C28H29FN2O4
DMVMIBY	IC	InChI=1S/C28H29FN2O4/c1-28(2,18-19-8-14-23(29)15-9-19)31-27(35)24(16-17-25(32)33)30-26(34)22-12-10-21(11-13-22)20-6-4-3-5-7-20/h3-15,24H,16-18H2,1-2H3,(H,30,34)(H,31,35)(H,32,33)/t24-/m0/s1
DMVMIBY	CS	CC(C)(CC1=CC=C(C=C1)F)NC(=O)[C@H](CCC(=O)O)NC(=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMVMIBY	IK	JWQMTWCFNZSLNR-DEOSSOPVSA-N
DMVMIBY	IU	(4S)-5-[[1-(4-fluorophenyl)-2-methylpropan-2-yl]amino]-5-oxo-4-[(4-phenylbenzoyl)amino]pentanoic acid
DMVMIBY	CA	CAS 920289-29-8
DMVMIBY	DE	Osteoarthritis

DMVHPOX	ID	DMVHPOX
DMVHPOX	DN	AGN-242266
DMVHPOX	HS	Phase 1
DMVHPOX	CP	AbbVie
DMVHPOX	DT	Small molecular drug
DMVHPOX	DE	Non-alcoholic steatohepatitis

DMU21JF	ID	DMU21JF
DMU21JF	DN	AGS-009
DMU21JF	HS	Phase 1
DMU21JF	DT	Antibody
DMU21JF	DE	Systemic lupus erythematosus

DMDUIO4	ID	DMDUIO4
DMDUIO4	DN	AGS-348
DMDUIO4	HS	Phase 1
DMDUIO4	CP	Agios pharmaceuticals
DMDUIO4	DE	Hereditary angioedema

DML79KE	ID	DML79KE
DML79KE	DN	AGT-182
DML79KE	HS	Phase 1
DML79KE	SN	HIRMAb-IDUS; Iduronidase/human insulin receptor-targeting chimeric mAb fusion protein (imucopolysaccharidosis type II), ArmaGen
DML79KE	CP	ArmaGen Technologies Inc
DML79KE	DT	Antibody
DML79KE	DE	Hunter syndrome

DMHMT49	ID	DMHMT49
DMHMT49	DN	AI3-23606
DMHMT49	HS	Phase 1
DMHMT49	SN	AMOT0097; FUBFWTUFPGFHOJ-UHFFFAOYSA-N; Furan, 2-nitro-; Furan, nitro-; LS-70264; Nitrofuran; Nitrofuran (VAN); Q-103253; Q27116311; TC-155289; TRA0000166; ZINC1689931; 17EZI4D981; 2-NITROFURAN; 2-Nitrofuran, 97%; 2-Nitrofurane; 27194-24-7; 5-17-01-00296 (Beilstein Handbook Reference); 5-Nitrofuran; 609-39-2; 9109AB; AI3-23606; AKOS015900364; AM20100483; ANW-66544; BCP23236; BRN 0112523; C-51401; C14414; CHEBI:34890; CTK1A5052; DB-002205; FCH1116845; FT-0632538; H118; NSC 59983; NSC-59983; NSC59983; SCHEMBL30623; UNII-17EZI4D981
DMHMT49	PC	11865
DMHMT49	MW	113.07
DMHMT49	FM	C4H3NO3
DMHMT49	IC	FUBFWTUFPGFHOJ-UHFFFAOYSA-N
DMHMT49	CS	C1=COC(=C1)[N+](=O)[O-]
DMHMT49	IK	1S/C4H3NO3/c6-5(7)4-2-1-3-8-4/h1-3H
DMHMT49	IU	2-nitrofuran
DMHMT49	CA	CAS 609-39-2
DMHMT49	CB	CHEBI:34890
DMHMT49	DE	Trypanosomiasis

DMDA1UB	ID	DMDA1UB
DMDA1UB	DN	AI-850
DMDA1UB	HS	Phase 1
DMDA1UB	CP	Acusphere
DMDA1UB	DE	Solid tumour/cancer

DMSPBOW	ID	DMSPBOW
DMSPBOW	DN	AIC100
DMSPBOW	HS	Phase 1
DMSPBOW	CP	AffyImmune Therapeutics
DMSPBOW	DT	CAR T Cell Therapy
DMSPBOW	DE	Thyroid cancer

DMNHBMC	ID	DMNHBMC
DMNHBMC	DN	AIC-292
DMNHBMC	HS	Phase 1
DMNHBMC	CP	AiCuris GmbH & Co KG
DMNHBMC	PC	44230181
DMNHBMC	MW	437.2
DMNHBMC	FM	C19H12Cl2F2N4O2
DMNHBMC	IC	InChI=1S/C19H12Cl2F2N4O2/c20-11-3-10(4-12(22)5-11)17-7-16(19(29)26-8-18(28)24-9-26)25-27(17)13-1-2-15(23)14(21)6-13/h1-7H,8-9H2,(H,24,28)
DMNHBMC	CS	C1C(=O)NCN1C(=O)C2=NN(C(=C2)C3=CC(=CC(=C3)Cl)F)C4=CC(=C(C=C4)F)Cl
DMNHBMC	IK	JPOJKNJIKXMZRB-UHFFFAOYSA-N
DMNHBMC	IU	1-[1-(3-chloro-4-fluorophenyl)-5-(3-chloro-5-fluorophenyl)pyrazole-3-carbonyl]imidazolidin-4-one
DMNHBMC	CA	CAS 1187917-12-9
DMNHBMC	DE	Human immunodeficiency virus infection

DMW9ZFS	ID	DMW9ZFS
DMW9ZFS	DN	AIKO-150
DMW9ZFS	HS	Phase 1
DMW9ZFS	SN	6beta-Naltrexol; beta-Naltrexol; 6beta-Hydroxynaltrexone; 6alpha-Hydroxynaltrexone; 49625-89-0; 6alpha-Naltrexol; UNII-J0W963M37T; CHEMBL140278; J0W963M37T; naltrexol; Naltrexone-6-beta-ol; alpha-Naltrexol; 6beta-Naltrexone; 6alpha-Naltrexone; 6-alpha-naltrexol; N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynorisomorphine; SCHEMBL679700; DTXSID80197942; JLVNEHKORQFVQJ-PYIJOLGTSA-N; ZINC6092289; BDBM50001709; NCGC00165851-01; FT-0672600; Opioid neutral antagonists (iv, pain), Aiko Biotechnology; 6-beta-naltrexol
DMW9ZFS	CP	Aiko Biotechnology Inc
DMW9ZFS	DT	Small molecular drug
DMW9ZFS	PC	5486554
DMW9ZFS	MW	343.4
DMW9ZFS	FM	C20H25NO4
DMW9ZFS	IC	InChI=1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15-,18+,19+,20-/m1/s1
DMW9ZFS	CS	C1C[C@]2([C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@@H]1O)OC5=C(C=C4)O)O
DMW9ZFS	IK	JLVNEHKORQFVQJ-PYIJOLGTSA-N
DMW9ZFS	IU	(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
DMW9ZFS	CA	CAS 49625-89-0
DMW9ZFS	DE	Opioid dependence

DMHCBI0	ID	DMHCBI0
DMHCBI0	DN	AIP-303
DMHCBI0	HS	Phase 1
DMHCBI0	CP	Advanced Innovative Partners
DMHCBI0	DT	Radiopharmaceutical therapy agent
DMHCBI0	DE	Breast cancer

DM6PN4H	ID	DM6PN4H
DM6PN4H	DN	AjvW2
DM6PN4H	HS	Phase 1
DM6PN4H	SN	2,6-Piperazinedione, 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-, rel-; Icrf 193; ICRF-193; 21416-88-6; BRN 3981691; 2,6-Piperazinedione, 4,4'-(1,2-dimethylethylene)di-, meso-; 2,6-Piperazinedione, 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-, (R*,S*)-; AC1L3O6B; meso-2,3-Bis(3,5-dioxopiperazine-1-yl)butane; KBioSS_000487; BSPBio_001147; KBioGR_000487; SCHEMBL438498; CHEMBL264684; KBio3_000893; KBio3_000894; KBio2_003055; CHEBI:93771; KBio2_000487; KBio2_005623; HMS1990I09; HMS1792I09; Bio2_000884; HMS3403I09; Bio2_000404; HMS1362I09; ICRF
DM6PN4H	DT	Antibody
DM6PN4H	DE	Thrombosis

DM4FOX0	ID	DM4FOX0
DM4FOX0	DN	AK107
DM4FOX0	HS	Phase 1
DM4FOX0	SN	2,5-Bis[4-(1H-imidazol-2-yl)phenyl]-1,3-oxazole; 2,5-bis[4-(1H-imidazol-2-yl)phenyl]-1,3-oxazole; AK.107; AC1LARBL; CTK5J5532; 2,5-bis[4-(1H-imidazol-2-yl)phenyl]oxazole; 2,5-Bis(4-imidazol-2-ylphenyl)-1,3-oxazole
DM4FOX0	CP	Akeso Biopharma Guangdong, China Merck Kenilworth, NJ
DM4FOX0	PC	473613
DM4FOX0	MW	353.4
DM4FOX0	FM	C21H15N5O
DM4FOX0	IC	InChI=1S/C21H15N5O/c1-3-15(19-22-9-10-23-19)4-2-14(1)18-13-26-21(27-18)17-7-5-16(6-8-17)20-24-11-12-25-20/h1-13H,(H,22,23)(H,24,25)
DM4FOX0	CS	C1=CC(=CC=C1C2=CN=C(O2)C3=CC=C(C=C3)C4=NC=CN4)C5=NC=CN5
DM4FOX0	IK	POIOBVFAFSUWGR-UHFFFAOYSA-N
DM4FOX0	IU	2,5-bis[4-(1H-imidazol-2-yl)phenyl]-1,3-oxazole
DM4FOX0	DE	Solid tumour/cancer

DM9JU8L	ID	DM9JU8L
DM9JU8L	DN	AKP-501
DM9JU8L	HS	Phase 1
DM9JU8L	SN	JR-041; Recombinant FSH (female infertility), JCR Pharamceuticals/ASKA Pharmaceutical; Recombinant follicle stimulating hormone (female infertility), JCR Pharamceuticals/ASKA Pharmaceutical
DM9JU8L	CP	JCR Pharmaceuticals Co Ltd
DM9JU8L	DE	Female infertility

DMHD615	ID	DMHD615
DMHD615	DN	ALB-109564(a)
DMHD615	HS	Phase 1
DMHD615	SN	ALB-109564; Vinca alkaloid analogs (cancer), Albany Molecular Research
DMHD615	CP	Bessor-brightwaters pharma
DMHD615	PC	46209467
DMHD615	MW	930
DMHD615	FM	C47H62Cl2N4O9S
DMHD615	IC	InChI=1S/C47H60N4O9S.2ClH/c1-9-43(55)23-28-24-46(41(53)58-6,37-30(14-18-50(25-28)26-43)31-20-29(61-8)12-13-34(31)48-37)33-21-32-35(22-36(33)57-5)49(4)39-45(32)16-19-51-17-11-15-44(10-2,38(45)51)40(60-27(3)52)47(39,56)42(54)59-7;;/h11-13,15,20-22,28,38-40,48,55-56H,9-10,14,16-19,23-26H2,1-8H3;2*1H/t28-,38-,39+,40+,43-,44+,45+,46-,47-;;/m0../s1
DMHD615	CS	CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=C(N3)C=CC(=C4)SC)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.Cl.Cl
DMHD615	IK	MTABGSVEFKMZFG-USKOTZBXSA-N
DMHD615	IU	methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-7-methylsulfanyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;dihydrochloride
DMHD615	CA	CAS 1300114-12-8
DMHD615	DE	Solid tumour/cancer

DMYTIP4	ID	DMYTIP4
DMYTIP4	DN	Aleplasinin
DMYTIP4	HS	Phase 1
DMYTIP4	SN	PAZ-417; PAI inhibitors (Alzheimers disease), Wyeth; Plasminogen activator inhibitor inhibitors (Alzheimers disease),Wyeth
DMYTIP4	CP	Wyeth
DMYTIP4	DT	Small molecular drug
DMYTIP4	PC	10224267
DMYTIP4	MW	425.5
DMYTIP4	FM	C28H27NO3
DMYTIP4	IC	InChI=1S/C28H27NO3/c1-18-6-5-7-20(14-18)21-10-13-25-23(15-21)24(26(30)27(31)32)17-29(25)16-19-8-11-22(12-9-19)28(2,3)4/h5-15,17H,16H2,1-4H3,(H,31,32)
DMYTIP4	CS	CC1=CC(=CC=C1)C2=CC3=C(C=C2)N(C=C3C(=O)C(=O)O)CC4=CC=C(C=C4)C(C)(C)C
DMYTIP4	IK	HSXLMAFNWCSZGP-UHFFFAOYSA-N
DMYTIP4	IU	2-[1-[(4-tert-butylphenyl)methyl]-5-(3-methylphenyl)indol-3-yl]-2-oxoacetic acid
DMYTIP4	CA	CAS 481629-87-2
DMYTIP4	DE	Alzheimer disease

DMXMK5S	ID	DMXMK5S
DMXMK5S	DN	Alfa-interferon
DMXMK5S	HS	Phase 1
DMXMK5S	CP	National Cancer Institute (NCI)
DMXMK5S	DE	Endometriosis

DMGIAND	ID	DMGIAND
DMGIAND	DN	ALLO-501
DMGIAND	HS	Phase 1
DMGIAND	CP	Allogene Therapeutics
DMGIAND	DT	CAR T Cell Therapy
DMGIAND	DE	Non-hodgkin lymphoma

DMHE3MD	ID	DMHE3MD
DMHE3MD	DN	ALLO-715
DMHE3MD	HS	Phase 1
DMHE3MD	CP	Allogene Therapeutics
DMHE3MD	DT	CAR T Cell Therapy
DMHE3MD	DE	Multiple myeloma

DMCYV26	ID	DMCYV26
DMCYV26	DN	Allogeneic CART-19
DMCYV26	HS	Phase 1
DMCYV26	CP	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
DMCYV26	DT	CAR T Cell Therapy
DMCYV26	DE	leukaemia

DM4RHM5	ID	DM4RHM5
DM4RHM5	DN	Allogeneic CART-33
DM4RHM5	HS	Phase 1
DM4RHM5	CP	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
DM4RHM5	DT	CAR T Cell Therapy
DM4RHM5	DE	Myeloid leukaemia

DMCSEUY	ID	DMCSEUY
DMCSEUY	DN	ALN-TTR01
DMCSEUY	HS	Phase 1
DMCSEUY	DT	Antisense oligonucleotide
DMCSEUY	DE	Amyloidosis; Transthyretin familial amyloid cardiomyopathy

DM89DHO	ID	DM89DHO
DM89DHO	DN	ALN-VSP
DM89DHO	HS	Phase 1
DM89DHO	CP	Alnylam Pharmaceuticals
DM89DHO	DT	RNAi therapeutics
DM89DHO	DE	Liver cancer

DMGFVYL	ID	DMGFVYL
DMGFVYL	DN	ALO-1567
DMGFVYL	HS	Phase 1
DMGFVYL	SN	AL01567; 2-Fluorospiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione
DMGFVYL	DT	Small molecular drug
DMGFVYL	PC	119155
DMGFVYL	MW	268.24
DMGFVYL	FM	C15H9FN2O2
DMGFVYL	IC	InChI=1S/C15H9FN2O2/c16-8-5-6-10-9-3-1-2-4-11(9)15(12(10)7-8)13(19)17-14(20)18-15/h1-7H,(H2,17,18,19,20)
DMGFVYL	CS	C1=CC=C2C(=C1)C3=C(C24C(=O)NC(=O)N4)C=C(C=C3)F
DMGFVYL	IK	JRGBXEJDIMXJAP-UHFFFAOYSA-N
DMGFVYL	IU	2-fluorospiro[fluorene-9,5'-imidazolidine]-2',4'-dione
DMGFVYL	CA	CAS 97677-19-5
DMGFVYL	DE	Glaucoma/ocular hypertension

DMIEKTF	ID	DMIEKTF
DMIEKTF	DN	Alofanib
DMIEKTF	HS	Phase 1
DMIEKTF	SN	1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT835; RPT-835; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid
DMIEKTF	DT	Small molecular drug
DMIEKTF	PC	86280646
DMIEKTF	MW	413.4
DMIEKTF	FM	C19H15N3O6S
DMIEKTF	IC	InChI=1S/C19H15N3O6S/c1-12-8-18(22(25)26)17(10-16(12)14-5-3-7-20-11-14)21-29(27,28)15-6-2-4-13(9-15)19(23)24/h2-11,21H,1H3,(H,23,24)
DMIEKTF	CS	CC1=CC(=C(C=C1C2=CN=CC=C2)NS(=O)(=O)C3=CC=CC(=C3)C(=O)O)[N+](=O)[O-]
DMIEKTF	IK	QUQGQIASFYWKAB-UHFFFAOYSA-N
DMIEKTF	IU	3-[(4-methyl-2-nitro-5-pyridin-3-ylphenyl)sulfamoyl]benzoic acid
DMIEKTF	CA	CAS 1612888-66-0
DMIEKTF	DE	Gastric adenocarcinoma

DMP9VXQ	ID	DMP9VXQ
DMP9VXQ	DN	ALPHA-FMH
DMP9VXQ	HS	Phase 1
DMP9VXQ	SN	Alpha-(Fluoromethyl)histidine
DMP9VXQ	DT	Small molecular drug
DMP9VXQ	PC	107653
DMP9VXQ	MW	187.17
DMP9VXQ	FM	C7H10FN3O2
DMP9VXQ	IC	InChI=1S/C7H10FN3O2/c8-3-7(9,6(12)13)1-5-2-10-4-11-5/h2,4H,1,3,9H2,(H,10,11)(H,12,13)
DMP9VXQ	CS	C1=C(NC=N1)CC(CF)(C(=O)O)N
DMP9VXQ	IK	AJFGLTPLWPTALJ-UHFFFAOYSA-N
DMP9VXQ	IU	2-amino-2-(fluoromethyl)-3-(1H-imidazol-5-yl)propanoic acid
DMP9VXQ	CA	CAS 70050-43-0
DMP9VXQ	DE	Pruritus

DMBVM1Q	ID	DMBVM1Q
DMBVM1Q	DN	AlphaMedix
DMBVM1Q	HS	Phase 1
DMBVM1Q	CP	Orano Med; RadioMedix
DMBVM1Q	DT	Peptide
DMBVM1Q	DE	Neuroendocrine cancer

DMTD4EF	ID	DMTD4EF
DMTD4EF	DN	ALPN-202
DMTD4EF	HS	Phase 1
DMTD4EF	CP	Alpine Immune Sciences
DMTD4EF	DT	Protein
DMTD4EF	DE	Solid tumour/cancer

DMUJCBT	ID	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	HS	Phase 1
DMUJCBT	CP	Deciphera pharmaceuticals
DMUJCBT	PC	54576299
DMUJCBT	MW	510.5
DMUJCBT	FM	C26H21F3N4O4
DMUJCBT	IC	InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)
DMUJCBT	CS	C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F
DMUJCBT	IK	GNNDEPIMDAZHRQ-UHFFFAOYSA-N
DMUJCBT	IU	1-N'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMUJCBT	CA	CAS 1345847-93-9
DMUJCBT	DE	Solid tumour/cancer

DM6KU93	ID	DM6KU93
DM6KU93	DN	Alvespimycin hydrochloride
DM6KU93	HS	Phase 1
DM6KU93	SN	Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG
DM6KU93	CP	Bristol-Myers Squibb; Kosan Biosci.
DM6KU93	TC	Anticancer Agents
DM6KU93	DT	Small molecular drug
DM6KU93	PC	9852573
DM6KU93	MW	653.2
DM6KU93	FM	C32H49ClN4O8
DM6KU93	IC	InChI=1S/C32H48N4O8.ClH/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8;/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40);1H/b11-9-,19-10+,21-16+;/t18-,20+,25+,26+,28-,30+;/m1./s1
DM6KU93	CS	C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)\\C)C)O)OC.Cl
DM6KU93	IK	DFSYBWLNYPEFJK-IHLRWNDRSA-N
DM6KU93	IU	[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[2-(dimethylamino)ethylamino]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate;hydrochloride
DM6KU93	CA	CAS 467214-21-7
DM6KU93	DE	Refractory hematologic malignancy; Ovarian cancer

DMBGI74	ID	DMBGI74
DMBGI74	DN	ALX-0141
DMBGI74	HS	Phase 1
DMBGI74	SN	Nanobody therapeutic (bone disease), Ablynx; Nanobody therapeutic (osteoporosis), Ablynx
DMBGI74	CP	Ablynx NV
DMBGI74	DE	Osteoporosis

DMIRYM8	ID	DMIRYM8
DMIRYM8	DN	ALX-0651
DMIRYM8	HS	Phase 1
DMIRYM8	SN	Anti-CXCR4 nanobodies (cancer), Ablynx
DMIRYM8	CP	Bristol-myers squibb
DMIRYM8	DE	Haematological malignancy

DMJ8ACF	ID	DMJ8ACF
DMJ8ACF	DN	ALX-0761
DMJ8ACF	HS	Phase 1
DMJ8ACF	CP	Ablynx
DMJ8ACF	DT	Monoclonal antibody
DMJ8ACF	DE	Psoriasis vulgaris

DMLJWPN	ID	DMLJWPN
DMLJWPN	DN	Alx-5407
DMLJWPN	HS	Phase 1
DMLJWPN	SN	2-[[(3R)-3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid
DMLJWPN	CP	NPS Pharmaceuticals
DMLJWPN	DT	Small molecular drug
DMLJWPN	PC	6604909
DMLJWPN	MW	393.4
DMLJWPN	FM	C24H24FNO3
DMLJWPN	IC	InChI=1S/C24H24FNO3/c1-26(17-24(27)28)16-15-23(20-7-11-21(25)12-8-20)29-22-13-9-19(10-14-22)18-5-3-2-4-6-18/h2-14,23H,15-17H2,1H3,(H,27,28)/t23-/m1/s1
DMLJWPN	CS	CN(CC[C@H](C1=CC=C(C=C1)F)OC2=CC=C(C=C2)C3=CC=CC=C3)CC(=O)O
DMLJWPN	IK	FDORQEIHOKEJNX-HSZRJFAPSA-N
DMLJWPN	IU	2-[[(3R)-3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid
DMLJWPN	CB	CHEBI:92943
DMLJWPN	DE	Schizophrenia

DMVXRYC	ID	DMVXRYC
DMVXRYC	DN	AM-211
DMVXRYC	HS	Phase 1
DMVXRYC	SN	AM-211; UNII-SZB129M7SZ; 1175526-27-8; SZB129M7SZ; CHEMBL2181753; AM211; [1,1'-Biphenyl]-3-acetic acid, 2'-[[ethyl[[(phenylmethyl)amino]carbonyl]amino]methyl]-6-methoxy-4'-(trifluoromethyl)-; SCHEMBL138450; DTXSID80151807; OPXIRFWNLBDKQB-UHFFFAOYSA-N; BDBM50397640; SB17010; HY-13213; CS-0003178; [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid
DMVXRYC	CP	Amira Pharmaceuticals Inc
DMVXRYC	DT	Small molecular drug
DMVXRYC	PC	44158492
DMVXRYC	MW	500.5
DMVXRYC	FM	C27H27F3N2O4
DMVXRYC	IC	InChI=1S/C27H27F3N2O4/c1-3-32(26(35)31-16-18-7-5-4-6-8-18)17-20-15-21(27(28,29)30)10-11-22(20)23-13-19(14-25(33)34)9-12-24(23)36-2/h4-13,15H,3,14,16-17H2,1-2H3,(H,31,35)(H,33,34)
DMVXRYC	CS	CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)O)OC)C(=O)NCC3=CC=CC=C3
DMVXRYC	IK	OPXIRFWNLBDKQB-UHFFFAOYSA-N
DMVXRYC	IU	2-[3-[2-[[benzylcarbamoyl(ethyl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxyphenyl]acetic acid
DMVXRYC	CA	CAS 1175526-27-8
DMVXRYC	DE	Asthma

DM7Z8NP	ID	DM7Z8NP
DM7Z8NP	DN	AM-461
DM7Z8NP	HS	Phase 1
DM7Z8NP	CP	Amira Pharmaceuticals Inc
DM7Z8NP	PC	44600763
DM7Z8NP	MW	459.6
DM7Z8NP	FM	C25H33NO5S
DM7Z8NP	IC	InChI=1S/C25H33NO5S/c1-24(2,3)23(29)26-18-9-11-19(17(14-18)15-32-25(4,5)6)31-21-12-16(13-22(27)28)8-10-20(21)30-7/h8-12,14H,13,15H2,1-7H3,(H,26,29)(H,27,28)
DM7Z8NP	CS	CC(C)(C)C(=O)NC1=CC(=C(C=C1)OC2=C(C=CC(=C2)CC(=O)O)OC)CSC(C)(C)C
DM7Z8NP	IK	SDHFXINHZHARIB-UHFFFAOYSA-N
DM7Z8NP	IU	2-[3-[2-(tert-butylsulfanylmethyl)-4-(2,2-dimethylpropanoylamino)phenoxy]-4-methoxyphenyl]acetic acid
DM7Z8NP	CA	CAS 1203503-64-3
DM7Z8NP	DE	Respiratory disease

DM7CD8Z	ID	DM7CD8Z
DM7CD8Z	DN	AMAP-102
DM7CD8Z	HS	Phase 1
DM7CD8Z	SN	5-HT antagonist (rheumatism), AnaMar
DM7CD8Z	CP	AnaMar Medical AB
DM7CD8Z	DE	Arthritis

DMFELMQ	ID	DMFELMQ
DMFELMQ	DN	AMEP
DMFELMQ	HS	Phase 1
DMFELMQ	SN	(Aminomethyl)phosphonic acid; 1066-51-9; AMINOMETHYLPHOSPHONIC ACID; Aminomethanephosphonic acid; AMeP; 1-Aminomethylphosphonic acid; 1-Aminomethylphosphonate; Amino methane phosphoric acid; Caswell No. 037C; Phosphaglycine; (1-Aminomethyl)phosphonic acid; Phosphonic acid, aminomethyl-; UNII-90825O5C1U; Phosphonic acid, (aminomethyl)-; Aminomethylphosphonic acid (AMPA); NSC 30076; EPA Pesticide Chemical Code 207800; CHEBI:28812; MGRVRXRGTBOSHW-UHFFFAOYSA-N; (Aminomethyl)phosphonic acid, 99%; MFCD00008105; GEO-00169; 90825O5C1U
DMFELMQ	CP	BioAlliance Pharma SA
DMFELMQ	DT	Small molecular drug
DMFELMQ	PC	14017
DMFELMQ	MW	111.04
DMFELMQ	FM	CH6NO3P
DMFELMQ	IC	InChI=1S/CH6NO3P/c2-1-6(3,4)5/h1-2H2,(H2,3,4,5)
DMFELMQ	CS	C(N)P(=O)(O)O
DMFELMQ	IK	MGRVRXRGTBOSHW-UHFFFAOYSA-N
DMFELMQ	IU	aminomethylphosphonic acid
DMFELMQ	CA	CAS 1066-51-9
DMFELMQ	CB	CHEBI:28812
DMFELMQ	DE	Melanoma

DMKF1O2	ID	DMKF1O2
DMKF1O2	DN	AMG 119
DMKF1O2	HS	Phase 1
DMKF1O2	CP	Amgen
DMKF1O2	DT	CAR T Cell Therapy
DMKF1O2	DE	Small-cell lung cancer

DMM0HNF	ID	DMM0HNF
DMM0HNF	DN	AMG 160
DMM0HNF	HS	Phase 1
DMM0HNF	DT	Antibody
DMM0HNF	DE	Non-small cell lung cancer

DMUETI2	ID	DMUETI2
DMUETI2	DN	AMG 167
DMUETI2	HS	Phase 1
DMUETI2	CP	Amgen Thousand
DMUETI2	DE	Osteoporosis

DMS72GN	ID	DMS72GN
DMS72GN	DN	AMG 172
DMS72GN	HS	Phase 1
DMS72GN	CP	Amgen
DMS72GN	DE	Renal cell carcinoma

DM0Q7NO	ID	DM0Q7NO
DM0Q7NO	DN	AMG 176
DM0Q7NO	HS	Phase 1
DM0Q7NO	SN	JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-
DM0Q7NO	CP	AmgenThousand Oaks, CA
DM0Q7NO	PC	118910268
DM0Q7NO	MW	613.2
DM0Q7NO	FM	C33H41ClN2O5S
DM0Q7NO	IC	InChI=1S/C33H41ClN2O5S/c1-21-6-4-8-30(40-3)27-12-9-25(27)18-36-19-33(15-5-7-23-16-26(34)11-13-28(23)33)20-41-31-14-10-24(17-29(31)36)32(37)35-42(38,39)22(21)2/h4,8,10-11,13-14,16-17,21-22,25,27,30H,5-7,9,12,15,18-20H2,1-3H3,(H,35,37)/b8-4+/t21-,22+,25-,27+,30-,33-/m0/s1
DM0Q7NO	CS	C[C@H]1C/C=C/[C@@H]([C@@H]2CC[C@H]2CN3C[C@@]4(CCCC5=C4C=CC(=C5)Cl)COC6=C3C=C(C=C6)C(=O)NS(=O)(=O)[C@@H]1C)OC
DM0Q7NO	IK	JQNINBDKGLWYMU-GEAQBIRJSA-N
DM0Q7NO	IU	(3'R,4S,6'R,7'S,8'E,11'S,12'R)-7-chloro-7'-methoxy-11',12'-dimethyl-13',13'-dioxospiro[2,3-dihydro-1H-naphthalene-4,22'-20-oxa-13lambda6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene]-15'-one
DM0Q7NO	CA	CAS 1883727-34-1
DM0Q7NO	DE	Multiple myeloma; Acute myeloid leukaemia

DMWG2K6	ID	DMWG2K6
DMWG2K6	DN	AMG 199
DMWG2K6	HS	Phase 1
DMWG2K6	CP	Amgen
DMWG2K6	DT	Antibody
DMWG2K6	DE	Gastric adenocarcinoma; Esophagogastric junction neoplasm

DMA1I04	ID	DMA1I04
DMA1I04	DN	AMG 211
DMA1I04	HS	Phase 1
DMA1I04	CP	AmgenThousand Oaks, CA MedImmune Gaithersburg, MD
DMA1I04	DE	Solid tumour/cancer

DMLQJ5P	ID	DMLQJ5P
DMLQJ5P	DN	AMG 228
DMLQJ5P	HS	Phase 1
DMLQJ5P	CP	Amgen
DMLQJ5P	DT	Antibody
DMLQJ5P	DE	Solid tumour/cancer

DMXYCZV	ID	DMXYCZV
DMXYCZV	DN	AMG 256
DMXYCZV	HS	Phase 1
DMXYCZV	CP	Amgen
DMXYCZV	DT	Protein
DMXYCZV	DE	Solid tumour/cancer

DM92YWD	ID	DM92YWD
DM92YWD	DN	AMG 282
DM92YWD	HS	Phase 1
DM92YWD	DT	Antibody
DM92YWD	DE	Asthma

DM9P0NA	ID	DM9P0NA
DM9P0NA	DN	AMG 319
DM9P0NA	HS	Phase 1
DM9P0NA	CP	Amgen Thousand
DM9P0NA	PC	68947304
DM9P0NA	MW	385.4
DM9P0NA	FM	C21H16FN7
DM9P0NA	IC	InChI=1S/C21H16FN7/c1-12(28-21-19-20(25-10-24-19)26-11-27-21)15-8-13-5-6-14(22)9-17(13)29-18(15)16-4-2-3-7-23-16/h2-12H,1H3,(H2,24,25,26,27,28)/t12-/m0/s1
DM9P0NA	CS	C[C@@H](C1=C(N=C2C=C(C=CC2=C1)F)C3=CC=CC=N3)NC4=NC=NC5=C4NC=N5
DM9P0NA	IK	KWRYMZHCQIOOEB-LBPRGKRZSA-N
DM9P0NA	IU	N-[(1S)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7H-purin-6-amine
DM9P0NA	CA	CAS 1608125-21-8
DM9P0NA	DE	Myeloid leukaemia; Hematologic tumour

DMC3G2E	ID	DMC3G2E
DMC3G2E	DN	AMG 330
DMC3G2E	HS	Phase 1
DMC3G2E	CP	Amgen
DMC3G2E	DT	Antibody
DMC3G2E	DE	Acute myeloid leukaemia

DM7CNTG	ID	DM7CNTG
DM7CNTG	DN	AMG 397
DM7CNTG	HS	Phase 1
DM7CNTG	SN	UNII-BO0V7196L2; BO0V7196L2; Murizatoclax; Murizatoclax [USAN]; SCHEMBL21040009; WHO 11281; (13S,31R,32R,4R,5E,8S,9R)-6'-Chloro-4-methoxy-8,9-dimethyl-4-(((9aR)-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl)methyl)-3',4'-dihydro-12H,14H,2'Hspiro(10lambda6-thia-11-aza-1(5,7)-(1,5)benzoxazepina-3(1,2)-cyclobutanacyclododecaphan-5-ene-13,1'-naphthalene)-10,10,12-trione; 2245848-05-7; Spiro(5,7-etheno-1H,11H-cyclobut(i)(1,4)oxazepino(3,4-f)(1,2,7)thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen)-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-16-(((9aR)-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl)methyl)-, 10,10-dioxide, (1'S,11R,12S,14E,16R,16aR,18aR)-
DM7CNTG	CP	Amgen
DM7CNTG	DT	Small molecular drug
DM7CNTG	PC	138669688
DM7CNTG	MW	765.4
DM7CNTG	FM	C42H57ClN4O5S
DM7CNTG	IC	InChI=1S/C42H57ClN4O5S/c1-29-8-6-18-42(51-3,27-45-20-21-46-19-5-4-10-35(46)25-45)37-14-11-33(37)24-47-26-41(17-7-9-31-22-34(43)13-15-36(31)41)28-52-39-16-12-32(23-38(39)47)40(48)44-53(49,50)30(29)2/h6,12-13,15-16,18,22-23,29-30,33,35,37H,4-5,7-11,14,17,19-21,24-28H2,1-3H3,(H,44,48)/b18-6+/t29-,30+,33-,35+,37+,41-,42-/m0/s1
DM7CNTG	CS	C[C@H]1C/C=C/[C@@]([C@@H]2CC[C@H]2CN3C[C@@]4(CCCC5=C4C=CC(=C5)Cl)COC6=C3C=C(C=C6)C(=O)NS(=O)(=O)[C@@H]1C)(CN7CCN8CCCC[C@@H]8C7)OC
DM7CNTG	IK	BJTFTQIBRVBSBH-VCQPVEJUSA-N
DM7CNTG	IU	(3'R,4S,6'R,7'R,8'E,11'S,12'R)-7'-[[(9aR)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methyl]-7-chloro-7'-methoxy-11',12'-dimethyl-13',13'-dioxospiro[2,3-dihydro-1H-naphthalene-4,22'-20-oxa-13lambda6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene]-15'-one
DM7CNTG	CA	CAS 2245848-05-7
DM7CNTG	DE	Refractory hematologic malignancy

DMVQX5K	ID	DMVQX5K
DMVQX5K	DN	AMG 404
DMVQX5K	HS	Phase 1
DMVQX5K	CP	Amgen
DMVQX5K	DT	Antibody
DMVQX5K	DE	Solid tumour/cancer

DMYFZLA	ID	DMYFZLA
DMYFZLA	DN	AMG 420
DMYFZLA	HS	Phase 1
DMYFZLA	CP	Amgen
DMYFZLA	DT	Antibody
DMYFZLA	DE	Multiple myeloma

DMLAP8F	ID	DMLAP8F
DMLAP8F	DN	AMG 424
DMLAP8F	HS	Phase 1
DMLAP8F	CP	Amgen
DMLAP8F	DT	Antibody
DMLAP8F	DE	Multiple myeloma

DMI7JO6	ID	DMI7JO6
DMI7JO6	DN	AMG 427
DMI7JO6	HS	Phase 1
DMI7JO6	CP	Amgen
DMI7JO6	DT	Antibody
DMI7JO6	DE	Acute myeloid leukaemia

DMG64PE	ID	DMG64PE
DMG64PE	DN	AMG 506
DMG64PE	HS	Phase 1
DMG64PE	DT	Protein
DMG64PE	DE	Solid tumour/cancer

DM2POGY	ID	DM2POGY
DM2POGY	DN	AMG 509
DM2POGY	HS	Phase 1
DM2POGY	CP	Amgen
DM2POGY	DT	Antibody
DM2POGY	DE	Prostate cancer

DMNEFQ6	ID	DMNEFQ6
DMNEFQ6	DN	AMG 529
DMNEFQ6	HS	Phase 1
DMNEFQ6	CP	Amgen Thousand Oaks, CA
DMNEFQ6	DE	Cardiovascular disease

DMQ0N5Z	ID	DMQ0N5Z
DMQ0N5Z	DN	AMG 562
DMQ0N5Z	HS	Phase 1
DMQ0N5Z	CP	Amgen
DMQ0N5Z	DT	Antibody
DMQ0N5Z	DE	Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma

DMRMC7U	ID	DMRMC7U
DMRMC7U	DN	AMG 579
DMRMC7U	HS	Phase 1
DMRMC7U	CP	Amgen
DMRMC7U	PC	59351313
DMRMC7U	MW	441.5
DMRMC7U	FM	C25H23N5O3
DMRMC7U	IC	InChI=1S/C25H23N5O3/c1-16(31)30-14-10-17(11-15-30)22-25(27-13-12-26-22)33-19-8-6-18(7-9-19)23(32)24-28-20-4-2-3-5-21(20)29-24/h2-9,12-13,17H,10-11,14-15H2,1H3,(H,28,29)
DMRMC7U	CS	CC(=O)N1CCC(CC1)C2=NC=CN=C2OC3=CC=C(C=C3)C(=O)C4=NC5=CC=CC=C5N4
DMRMC7U	IK	ZNPDAYJZIRPRFQ-UHFFFAOYSA-N
DMRMC7U	IU	1-[4-[3-[4-(1H-benzimidazole-2-carbonyl)phenoxy]pyrazin-2-yl]piperidin-1-yl]ethanone
DMRMC7U	CA	CAS 1227067-61-9
DMRMC7U	DE	Schizophrenia

DMJFKW3	ID	DMJFKW3
DMJFKW3	DN	AMG 595
DMJFKW3	HS	Phase 1
DMJFKW3	CP	Amgen
DMJFKW3	DE	Glioblastoma multiforme

DM4G1SP	ID	DM4G1SP
DM4G1SP	DN	AMG 596
DM4G1SP	HS	Phase 1
DM4G1SP	CP	Amgen
DM4G1SP	DT	Antibody
DM4G1SP	DE	Recurrent glioblastoma; Glioblastoma multiforme

DMA3B9T	ID	DMA3B9T
DMA3B9T	DN	AMG 673
DMA3B9T	HS	Phase 1
DMA3B9T	CP	Amgen
DMA3B9T	DT	Antibody
DMA3B9T	DE	Acute myeloid leukaemia

DM6IT3M	ID	DM6IT3M
DM6IT3M	DN	AMG 701
DM6IT3M	HS	Phase 1
DM6IT3M	CP	Amgen
DM6IT3M	DT	Antibody
DM6IT3M	DE	Multiple myeloma

DMLYP2N	ID	DMLYP2N
DMLYP2N	DN	AMG 757
DMLYP2N	HS	Phase 1
DMLYP2N	CP	Amgen
DMLYP2N	DT	Antibody
DMLYP2N	DE	Small-cell lung cancer; Neuroendocrine cancer

DMTGZN8	ID	DMTGZN8
DMTGZN8	DN	AMG 780
DMTGZN8	HS	Phase 1
DMTGZN8	DE	Solid tumour/cancer

DMEIMBP	ID	DMEIMBP
DMEIMBP	DN	AMG 811
DMEIMBP	HS	Phase 1
DMEIMBP	CP	Amgen
DMEIMBP	DE	Systemic lupus erythematosus; Discoid lupus erythematosus

DMB6Q19	ID	DMB6Q19
DMB6Q19	DN	AMG 820
DMB6Q19	HS	Phase 1
DMB6Q19	CP	Amgen Thousand
DMB6Q19	DE	Solid tumour/cancer

DM1FJ9C	ID	DM1FJ9C
DM1FJ9C	DN	AMG 876
DM1FJ9C	HS	Phase 1
DM1FJ9C	CP	Amgen
DM1FJ9C	DE	Type-2 diabetes

DMASGXJ	ID	DMASGXJ
DMASGXJ	DN	AMG 900
DMASGXJ	HS	Phase 1
DMASGXJ	SN	AMG-900; AMG 900; 945595-80-2; AMG900; UNII-9R2G075611; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; 9R2G075611; N-(4-((3-(2-aminopyrimidin-4-yl)pyridin-2-yl)oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen- 2-yl)phthalazin-1-amine; IVUGFMLRJOCGAS-UHFFFAOYSA-N
DMASGXJ	CP	Amgen Thousand
DMASGXJ	DT	Small molecular drug
DMASGXJ	PC	24856041
DMASGXJ	MW	503.6
DMASGXJ	FM	C28H21N7OS
DMASGXJ	IC	InChI=1S/C28H21N7OS/c1-17-15-24(37-16-17)25-20-5-2-3-6-21(20)26(35-34-25)32-18-8-10-19(11-9-18)36-27-22(7-4-13-30-27)23-12-14-31-28(29)33-23/h2-16H,1H3,(H,32,35)(H2,29,31,33)
DMASGXJ	CS	CC1=CSC(=C1)C2=NN=C(C3=CC=CC=C32)NC4=CC=C(C=C4)OC5=C(C=CC=N5)C6=NC(=NC=C6)N
DMASGXJ	IK	IVUGFMLRJOCGAS-UHFFFAOYSA-N
DMASGXJ	IU	N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine
DMASGXJ	CA	CAS 945595-80-2
DMASGXJ	DE	Solid tumour/cancer

DMCG7XL	ID	DMCG7XL
DMCG7XL	DN	AMG 910
DMCG7XL	HS	Phase 1
DMCG7XL	CP	Amgen
DMCG7XL	DT	Antibody
DMCG7XL	DE	Gastric adenocarcinoma; Esophagogastric junction neoplasm

DMZQ2DK	ID	DMZQ2DK
DMZQ2DK	DN	AMG 986
DMZQ2DK	HS	Phase 1
DMZQ2DK	SN	DOMQFIFVDIAOOT-ROUUACIJSA-N; UNII-4B8REJ8ZGY; 4B8REJ8ZGY; Azelaprag; Azelaprag [INN]; azelaprag (proposed INN); AMG986; SCHEMBL18247065; GTPL10061; AMG-986; 2049980-18-7; example 263 [WO2016187308A1]; (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide; 2-Pyrimidineethanesulfonamide, N-(4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl)-alpha,beta,5-trimethyl-, (alphaS,betaR)-
DMZQ2DK	CP	Amgen Thousand Oaks, CA
DMZQ2DK	PC	122702529
DMZQ2DK	MW	523.6
DMZQ2DK	FM	C25H29N7O4S
DMZQ2DK	IC	InChI=1S/C25H29N7O4S/c1-15-10-19(14-26-11-15)24-29-30-25(32(24)22-20(35-5)8-7-9-21(22)36-6)31-37(33,34)18(4)17(3)23-27-12-16(2)13-28-23/h7-14,17-18H,1-6H3,(H,30,31)/t17-,18-/m0/s1
DMZQ2DK	CS	CC1=CC(=CN=C1)C2=NN=C(N2C3=C(C=CC=C3OC)OC)NS(=O)(=O)[C@@H](C)[C@H](C)C4=NC=C(C=N4)C
DMZQ2DK	IK	DOMQFIFVDIAOOT-ROUUACIJSA-N
DMZQ2DK	IU	(2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide
DMZQ2DK	CA	CAS 2049980-18-7
DMZQ2DK	DE	Heart failure

DMEHOVF	ID	DMEHOVF
DMEHOVF	DN	AMG-139
DMEHOVF	HS	Phase 1
DMEHOVF	SN	Anti-inflammatory agent (psoriasis, IBD), Amgen
DMEHOVF	CP	Amgen; astrazeneca
DMEHOVF	DT	Antibody
DMEHOVF	DE	Crohn disease

DMSHK23	ID	DMSHK23
DMSHK23	DN	AMG-191
DMSHK23	HS	Phase 1
DMSHK23	CP	Amgen Inc
DMSHK23	DE	Inflammation

DMJQDUC	ID	DMJQDUC
DMJQDUC	DN	Aminoguanidine
DMJQDUC	HS	Phase 1
DMJQDUC	SN	aminoguanidine; Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284
DMJQDUC	DT	Small molecular drug
DMJQDUC	PC	2146
DMJQDUC	MW	74.09
DMJQDUC	FM	CH6N4
DMJQDUC	IC	InChI=1S/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)
DMJQDUC	CS	C(=NN)(N)N
DMJQDUC	IK	HAMNKKUPIHEESI-UHFFFAOYSA-N
DMJQDUC	IU	2-aminoguanidine
DMJQDUC	CA	CAS 79-17-4
DMJQDUC	CB	CHEBI:40618
DMJQDUC	DE	Rheumatoid arthritis; Insulin-resistant disorder; Diabetic retinopathy

DMH9M62	ID	DMH9M62
DMH9M62	DN	AMP-224
DMH9M62	HS	Phase 1
DMH9M62	CP	Amplimmune Gaithersburg, MD
DMH9M62	DT	Monoclonal antibody
DMH9M62	DE	Solid tumour/cancer; Colorectal cancer

DMT27PA	ID	DMT27PA
DMT27PA	DN	AMV564
DMT27PA	HS	Phase 1
DMT27PA	CP	Amphivena Therapeutics South San Francisco, CA
DMT27PA	DE	Acute myeloid leukaemia

DMR35U4	ID	DMR35U4
DMR35U4	DN	AMXT1501
DMR35U4	HS	Phase 1
DMR35U4	SN	(S)-N-(5-Amino-6-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-6-oxohexyl)palmitamide; 441022-64-6; CHEMBL474784; SCHEMBL10033849; N-(N6-Palmitoyl-L-lysyl)-4,9-diazadodecane-1,12-diamine
DMR35U4	CP	Aminex Therapeutics
DMR35U4	DT	Small molecular drug
DMR35U4	PC	9916009
DMR35U4	MW	568.9
DMR35U4	FM	C32H68N6O2
DMR35U4	IC	InChI=1S/C32H68N6O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-22-31(39)37-28-16-15-21-30(34)32(40)38-29-20-27-36-25-18-17-24-35-26-19-23-33/h30,35-36H,2-29,33-34H2,1H3,(H,37,39)(H,38,40)/t30-/m0/s1
DMR35U4	CS	CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)NCCCNCCCCNCCCN)N
DMR35U4	IK	USNCWPSRPOWEBG-PMERELPUSA-N
DMR35U4	IU	N-[(5S)-5-amino-6-[3-[4-(3-aminopropylamino)butylamino]propylamino]-6-oxohexyl]hexadecanamide
DMR35U4	DE	Solid tumour/cancer

DM8B2WQ	ID	DM8B2WQ
DM8B2WQ	DN	AN-2718
DM8B2WQ	HS	Phase 1
DM8B2WQ	SN	Boron-based leucyl-tRNA synthetase inhibitor (topical, fungal infections), Anacor
DM8B2WQ	CP	Anacor pharmaceuticals
DM8B2WQ	PC	11845944
DM8B2WQ	MW	168.39
DM8B2WQ	FM	C7H6BClO2
DM8B2WQ	IC	InChI=1S/C7H6BClO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
DM8B2WQ	CS	B1(C2=C(CO1)C=C(C=C2)Cl)O
DM8B2WQ	IK	HMAFTPZYFJFEHK-UHFFFAOYSA-N
DM8B2WQ	IU	5-chloro-1-hydroxy-3H-2,1-benzoxaborole
DM8B2WQ	CA	CAS 174672-06-1
DM8B2WQ	DE	Fungal infection

DM67OU4	ID	DM67OU4
DM67OU4	DN	ANAVEX 2-73
DM67OU4	HS	Phase 1
DM67OU4	CP	Anavex
DM67OU4	PC	46932299
DM67OU4	MW	317.9
DM67OU4	FM	C19H24ClNO
DM67OU4	IC	InChI=1S/C19H23NO.ClH/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17;/h3-12,18H,13-15H2,1-2H3;1H
DM67OU4	CS	CN(C)CC1CCOC1(C2=CC=CC=C2)C3=CC=CC=C3.Cl
DM67OU4	IK	FEQOLYDPQKHFTD-UHFFFAOYSA-N
DM67OU4	IU	1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine;hydrochloride
DM67OU4	CA	CAS 195615-84-0
DM67OU4	DE	Alzheimer disease; Infantile spasm; Parkinson disease; Rett syndrome; Cognitive impairment

DM39QWN	ID	DM39QWN
DM39QWN	DN	ANS-6637
DM39QWN	HS	Phase 1
DM39QWN	CP	Amygdala Neurosciences Palo Alto, CA
DM39QWN	DE	Substance use disorder

DM3OFZC	ID	DM3OFZC
DM3OFZC	DN	Anti-BCMA CAR T cells
DM3OFZC	HS	Phase 1
DM3OFZC	CP	Allife Medical Science and Technology Co., Ltd.
DM3OFZC	DT	CAR T Cell Therapy
DM3OFZC	DE	Multiple myeloma

DMNFO2B	ID	DMNFO2B
DMNFO2B	DN	Anti-BCMA CAR T cells
DMNFO2B	HS	Phase 1
DMNFO2B	CP	National Cancer Institute (NCI)
DMNFO2B	DT	CAR T Cell Therapy
DMNFO2B	DE	Multiple myeloma

DMUKNDO	ID	DMUKNDO
DMUKNDO	DN	Anti-BCMA CART Cells
DMUKNDO	HS	Phase 1
DMUKNDO	CP	Shenzhen Second People's Hospital
DMUKNDO	DT	CAR T Cell Therapy
DMUKNDO	DE	Multiple myeloma

DM2TFUD	ID	DM2TFUD
DM2TFUD	DN	Anti-BCMA CAR-T cells
DM2TFUD	HS	Phase 1
DM2TFUD	CP	The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
DM2TFUD	DT	CAR T Cell Therapy
DM2TFUD	DE	Multiple myeloma

DMK25QD	ID	DMK25QD
DMK25QD	DN	Anti-BCMA CAR-T cells
DMK25QD	HS	Phase 1
DMK25QD	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMK25QD	DT	CAR T Cell Therapy
DMK25QD	DE	leukaemia; Lymphoma

DMYIZFW	ID	DMYIZFW
DMYIZFW	DN	Anti-CD123 CAR-T cells
DMYIZFW	HS	Phase 1
DMYIZFW	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMYIZFW	DT	CAR T Cell Therapy
DMYIZFW	DE	leukaemia; Lymphoma

DM82OS7	ID	DM82OS7
DM82OS7	DN	Anti-CD123 CAR-T treatment
DM82OS7	HS	Phase 1
DM82OS7	CP	Second Affiliated Hospital of Xi'an Jiaotong University
DM82OS7	DT	CAR T Cell Therapy

DMGUM90	ID	DMGUM90
DMGUM90	DN	Anti-CD133-CAR vector-transduced T cells
DMGUM90	HS	Phase 1
DMGUM90	CP	Chinese PLA General Hospital
DMGUM90	DT	CAR T Cell Therapy
DMGUM90	DE	Brain cancer; Colorectal cancer; Liver cancer; Ovarian cancer; Pancreatic cancer

DMCABUR	ID	DMCABUR
DMCABUR	DN	Anti-CD19 anti-CD20 Bispecific CAR-T
DMCABUR	HS	Phase 1
DMCABUR	CP	Beijing Doing Biomedical Co., Ltd.
DMCABUR	DT	CAR T Cell Therapy (Dual specific)
DMCABUR	DE	leukaemia; Lymphoma

DMH789J	ID	DMH789J
DMH789J	DN	AntiCD19 CART
DMH789J	HS	Phase 1
DMH789J	CP	Case Comprehensive Cancer Center
DMH789J	DT	CAR T Cell Therapy
DMH789J	DE	Non-hodgkin lymphoma

DM9W1BS	ID	DM9W1BS
DM9W1BS	DN	Anti-CD19 CAR-T
DM9W1BS	HS	Phase 1
DM9W1BS	CP	First Affiliated Hospital of Wenzhou Medical University
DM9W1BS	DT	CAR T Cell Therapy
DM9W1BS	DE	Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Haematopoietic/lymphoid cancer

DMW549Y	ID	DMW549Y
DMW549Y	DN	Anti-CD19 CART Cells
DMW549Y	HS	Phase 1
DMW549Y	CP	Shenzhen Second People's Hospital
DMW549Y	DT	CAR T Cell Therapy
DMW549Y	DE	Multiple myeloma

DMUQ3C1	ID	DMUQ3C1
DMUQ3C1	DN	Anti-CD19 CAR-T cells
DMUQ3C1	HS	Phase 1
DMUQ3C1	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMUQ3C1	DT	CAR T Cell Therapy
DMUQ3C1	DE	leukaemia; Lymphoma

DMUVYC5	ID	DMUVYC5
DMUVYC5	DN	Anti-CD19 EBV CTL therapy
DMUVYC5	HS	Phase 1
DMUVYC5	CP	Atara Biotherapeutics
DMUVYC5	DT	CAR T Cell Therapy
DMUVYC5	DE	Acute lymphoblastic leukaemia

DMF93T2	ID	DMF93T2
DMF93T2	DN	Anti-CD19/BCMA CAR-T cells
DMF93T2	HS	Phase 1
DMF93T2	CP	Peng Liu
DMF93T2	DT	CAR T Cell Therapy (Dual specific)
DMF93T2	DE	Multiple myeloma

DMWKYSM	ID	DMWKYSM
DMWKYSM	DN	Anti-CD19-CAR
DMWKYSM	HS	Phase 1
DMWKYSM	CP	National Cancer Institute (NCI)
DMWKYSM	DT	CAR T Cell Therapy
DMWKYSM	DE	Acute lymphoblastic leukaemia; B-cell lymphoma; Large cell lymphoma; leukaemia; Non-hodgkin lymphoma

DMMRANJ	ID	DMMRANJ
DMMRANJ	DN	Anti-CD19-CAR T
DMMRANJ	HS	Phase 1
DMMRANJ	CP	Beijing Doing Biomedical Co., Ltd.
DMMRANJ	DT	CAR T Cell Therapy
DMMRANJ	DE	leukaemia; Lymphoma

DMYQFCN	ID	DMYQFCN
DMYQFCN	DN	Anti-CD19-CAR T cells
DMYQFCN	HS	Phase 1
DMYQFCN	CP	National Cancer Institute (NCI)
DMYQFCN	DT	CAR T Cell Therapy
DMYQFCN	DE	B-cell lymphoma; Non-hodgkin lymphoma

DMUFRDK	ID	DMUFRDK
DMUFRDK	DN	Anti-CD22
DMUFRDK	HS	Phase 1
DMUFRDK	CP	Seattle Genetics; Genentech
DMUFRDK	DT	Antibody
DMUFRDK	DE	Haematological malignancy

DMKL92E	ID	DMKL92E
DMKL92E	DN	Anti-CD22 CAR-T cells
DMKL92E	HS	Phase 1
DMKL92E	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMKL92E	DT	CAR T Cell Therapy
DMKL92E	DE	leukaemia; Lymphoma

DMTK78L	ID	DMTK78L
DMTK78L	DN	Anti-CD30 CAR-T cells
DMTK78L	HS	Phase 1
DMTK78L	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMTK78L	DT	CAR T Cell Therapy
DMTK78L	DE	leukaemia; Lymphoma

DM2IEB7	ID	DM2IEB7
DM2IEB7	DN	Anti-CD30-CAR T cells
DM2IEB7	HS	Phase 1
DM2IEB7	CP	National Cancer Institute (NCI)
DM2IEB7	DT	CAR T Cell Therapy
DM2IEB7	DE	Hodgkin lymphoma; Large cell lymphoma; Lymphoma

DMVSPZM	ID	DMVSPZM
DMVSPZM	DN	Anti-CD38 CAR-T cells
DMVSPZM	HS	Phase 1
DMVSPZM	CP	Sorrento Therapeutics, Inc.
DMVSPZM	DT	CAR T Cell Therapy
DMVSPZM	DE	Multiple myeloma

DMZ2D0G	ID	DMZ2D0G
DMZ2D0G	DN	Anti-CD45 mabs
DMZ2D0G	HS	Phase 1
DMZ2D0G	SN	AHCD45 therapy, Baylor College; YTH-24; YTH-24/54; YTH-25.4; YTH-54.12; Anti-CD45 mAbs (stem cell transplantation/cancer); Anti-CD45 mAbs (stem cell transplantation/cancer), Baylor College
DMZ2D0G	CP	Baylor College of Medicine
DMZ2D0G	DT	Antibody
DMZ2D0G	DE	Lymphoma

DMMFL2P	ID	DMMFL2P
DMMFL2P	DN	Anti-CD7 CAR-T cells
DMMFL2P	HS	Phase 1
DMMFL2P	CP	Hebei Senlang Biotechnology Inc., Ltd.
DMMFL2P	DT	CAR T Cell Therapy
DMMFL2P	DE	leukaemia; Lymphoma

DMA7L3O	ID	DMA7L3O
DMA7L3O	DN	Anti-CEA CAR-T cells
DMA7L3O	HS	Phase 1
DMA7L3O	CP	Roger Williams Medical Center
DMA7L3O	DT	CAR T Cell Therapy
DMA7L3O	DE	Acute myeloid leukaemia

DMDZR0V	ID	DMDZR0V
DMDZR0V	DN	Anti-CEA CAR-T cells
DMDZR0V	HS	Phase 1
DMDZR0V	CP	Sorrento Therapeutics, Inc.
DMDZR0V	DT	CAR T Cell Therapy
DMDZR0V	DE	Colorectal cancer; Gastric adenocarcinoma; Pancreatic cancer; Peritoneal metastasis

DMJA3H1	ID	DMJA3H1
DMJA3H1	DN	Anti-CEA-CAR T
DMJA3H1	HS	Phase 1
DMJA3H1	CP	Southwest Hospital, China
DMJA3H1	DT	CAR T Cell Therapy
DMJA3H1	DE	Colorectal cancer; Gastric adenocarcinoma; Lung cancer; Pancreatic cancer

DM0ZDJ5	ID	DM0ZDJ5
DM0ZDJ5	DN	Anti-EGFL7
DM0ZDJ5	HS	Phase 1
DM0ZDJ5	CP	Genentech
DM0ZDJ5	DT	Antibody
DM0ZDJ5	DE	Non-small-cell lung cancer

DMIVUX1	ID	DMIVUX1
DMIVUX1	DN	Anti-EGFR CAR T
DMIVUX1	HS	Phase 1
DMIVUX1	CP	RenJi Hospital
DMIVUX1	DT	CAR T Cell Therapy
DMIVUX1	DE	Glioma

DM73920	ID	DM73920
DM73920	DN	Anti-EGFRvIII CAR T cells
DM73920	HS	Phase 1
DM73920	CP	Beijing Sanbo Brain Hospital
DM73920	DT	CAR T Cell Therapy
DM73920	DE	Glioblastoma multiforme

DM6QENU	ID	DM6QENU
DM6QENU	DN	Anti-FGFR3
DM6QENU	HS	Phase 1
DM6QENU	CP	Genentech
DM6QENU	DT	Antibody
DM6QENU	DE	Multiple myeloma

DMBVUFL	ID	DMBVUFL
DMBVUFL	DN	Anti-GD2 T-cells (1RG-CART)
DMBVUFL	HS	Phase 1
DMBVUFL	CP	Cancer Research UK
DMBVUFL	DT	CAR T Cell Therapy
DMBVUFL	DE	Neuroblastoma

DMCNFZG	ID	DMCNFZG
DMCNFZG	DN	Anti-GD2-CAR engineered T cells
DMCNFZG	HS	Phase 1
DMCNFZG	CP	National Cancer Institute (NCI)
DMCNFZG	DT	CAR T Cell Therapy
DMCNFZG	DE	Neuroblastoma; Osteosarcoma; Sarcoma

DMUMWFK	ID	DMUMWFK
DMUMWFK	DN	Anti-GPC3 CAR T
DMUMWFK	HS	Phase 1
DMUMWFK	CP	RenJi Hospital
DMUMWFK	DT	CAR T Cell Therapy
DMUMWFK	DE	Hepatocellular carcinoma

DMK4GIS	ID	DMK4GIS
DMK4GIS	DN	Anti-hCD70 CAR transduced PBL
DMK4GIS	HS	Phase 1
DMK4GIS	CP	National Cancer Institute (NCI)
DMK4GIS	DT	CAR T Cell Therapy
DMK4GIS	DE	Ovarian cancer; Pancreatic cancer; Renal cell carcinoma

DMDMNJ6	ID	DMDMNJ6
DMDMNJ6	DN	Anti-HER3/EGFR DAF
DMDMNJ6	HS	Phase 1
DMDMNJ6	CP	Genentech
DMDMNJ6	DE	Metastatic epithelial tumour

DMY2MO4	ID	DMY2MO4
DMY2MO4	DN	Anti-meso-CAR T cells
DMY2MO4	HS	Phase 1
DMY2MO4	CP	Chinese PLA General Hospital
DMY2MO4	DT	CAR T Cell Therapy
DMY2MO4	DE	Mesothelin Positive tumour

DM5UQA9	ID	DM5UQA9
DM5UQA9	DN	Anti-meso-CAR vector transduced T cells
DM5UQA9	HS	Phase 1
DM5UQA9	CP	Chinese PLA General Hospital
DM5UQA9	DT	CAR T Cell Therapy
DM5UQA9	DE	Endometrial cancer; Malignant mesothelioma; Ovarian cancer; Pancreatic cancer; Triple negative breast cancer

DM5BIM1	ID	DM5BIM1
DM5BIM1	DN	Anti-mesothelin CAR T Cells
DM5BIM1	HS	Phase 1
DM5BIM1	CP	China Meitan General Hospital
DM5BIM1	DT	CAR T Cell Therapy
DM5BIM1	DE	Tumour

DMUKFCG	ID	DMUKFCG
DMUKFCG	DN	Anti-Mesothelin CAR-T cells
DMUKFCG	HS	Phase 1
DMUKFCG	CP	Chinese PLA General Hospital
DMUKFCG	DT	CAR T Cell Therapy
DMUKFCG	DE	Solid tumour/cancer

DMQ5ZND	ID	DMQ5ZND
DMQ5ZND	DN	Anti-MUC1 mab
DMQ5ZND	HS	Phase 1
DMQ5ZND	CP	Quest PharmaTech
DMQ5ZND	DT	Monoclonal antibody
DMQ5ZND	DE	Pancreatic cancer

DMRWI7E	ID	DMRWI7E
DMRWI7E	DN	Anti-N3pG-Abeta antibody
DMRWI7E	HS	Phase 1
DMRWI7E	DT	Antibody
DMRWI7E	DE	Alzheimer disease

DMFZ52G	ID	DMFZ52G
DMFZ52G	DN	Anti-OX40 mab
DMFZ52G	HS	Phase 1
DMFZ52G	CP	AgonOx
DMFZ52G	DT	Monoclonal antibody
DMFZ52G	DE	Prostate cancer

DM0UL47	ID	DM0UL47
DM0UL47	DN	Anti-PD-L1
DM0UL47	HS	Phase 1
DM0UL47	SN	BMS-936559
DM0UL47	CP	Bristol-Myers Squibb
DM0UL47	DT	Antibody
DM0UL47	DE	Solid tumour/cancer; Human immunodeficiency virus-1 infection

DMWIJL1	ID	DMWIJL1
DMWIJL1	DN	Anti-PD-L1 CSR T cells
DMWIJL1	HS	Phase 1
DMWIJL1	CP	Beijing Sanbo Brain Hospital
DMWIJL1	DT	CAR T Cell Therapy
DMWIJL1	DE	Glioblastoma multiforme

DMAESIY	ID	DMAESIY
DMAESIY	DN	ANX005
DMAESIY	HS	Phase 1
DMAESIY	CP	Annexon Biosciences South San Francisco, CA
DMAESIY	DE	Neurodegenerative disorder

DM7XES6	ID	DM7XES6
DM7XES6	DN	ANX-042
DM7XES6	HS	Phase 1
DM7XES6	SN	BNP sliced variant (heart failure), Anexon; B-type natriuretic peptide spliced variant (heart failure), Anexon
DM7XES6	CP	Teva Pharmaceuticals USA
DM7XES6	DE	Chronic heart failure

DMGDARN	ID	DMGDARN
DMGDARN	DN	AP32788
DMGDARN	HS	Phase 1
DMGDARN	CP	Takeda Oncology Cambridge, MA
DMGDARN	DE	Non-small-cell lung cancer

DM36FOG	ID	DM36FOG
DM36FOG	DN	APD-597
DM36FOG	HS	Phase 1
DM36FOG	SN	JNJ-38431055
DM36FOG	CP	Arena Pharmaceuticals Inc
DM36FOG	DT	Small molecular drug
DM36FOG	PC	11691484
DM36FOG	MW	479.6
DM36FOG	FM	C21H29N5O6S
DM36FOG	IC	InChI=1S/C21H29N5O6S/c1-13(2)31-21(27)26-10-8-15(9-11-26)32-20-18(30-4)19(22-12-23-20)25-16-6-7-17(24-14(16)3)33(5,28)29/h6-7,12-13,15H,8-11H2,1-5H3,(H,22,23,25)
DM36FOG	CS	CC1=C(C=CC(=N1)S(=O)(=O)C)NC2=C(C(=NC=N2)OC3CCN(CC3)C(=O)OC(C)C)OC
DM36FOG	IK	WPDCHTSXOPUOII-UHFFFAOYSA-N
DM36FOG	IU	propan-2-yl 4-[5-methoxy-6-[(2-methyl-6-methylsulfonylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate
DM36FOG	CA	CAS 897732-93-3
DM36FOG	DE	Type-2 diabetes

DMRGF9Q	ID	DMRGF9Q
DMRGF9Q	DN	APD-916
DMRGF9Q	HS	Phase 1
DMRGF9Q	SN	Histamine H3 antagonists (sleep disorder), Arena; Biphenyl derivatives/aryl ethers/anilines (sleep disorder), Arena
DMRGF9Q	CP	Arena Pharmaceuticals Inc
DMRGF9Q	DE	Sleep-wake disorder

DMLEKUY	ID	DMLEKUY
DMLEKUY	DN	APG-1387
DMLEKUY	HS	Phase 1
DMLEKUY	SN	AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706
DMLEKUY	CP	Ascentage Pharma Rockville, MD
DMLEKUY	PC	73336238
DMLEKUY	MW	1157.4
DMLEKUY	FM	C60H72N10O10S2
DMLEKUY	IC	InChI=1S/C60H72N10O10S2/c1-39(61-3)55(71)63-49-37-67(34-32-45-28-30-51(69(45)59(49)75)57(73)65-53(41-18-9-5-10-19-41)42-20-11-6-12-21-42)81(77,78)47-26-17-27-48(36-47)82(79,80)68-35-33-46-29-31-52(70(46)60(76)50(38-68)64-56(72)40(2)62-4)58(74)66-54(43-22-13-7-14-23-43)44-24-15-8-16-25-44/h5-27,36,39-40,45-46,49-54,61-62H,28-35,37-38H2,1-4H3,(H,63,71)(H,64,72)(H,65,73)(H,66,74)/t39-,40-,45+,46+,49-,50-,51-,52-/m0/s1
DMLEKUY	CS	C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)S(=O)(=O)C5=CC(=CC=C5)S(=O)(=O)N6CC[C@H]7CC[C@H](N7C(=O)[C@H](C6)NC(=O)[C@H](C)NC)C(=O)NC(C8=CC=CC=C8)C9=CC=CC=C9)NC
DMLEKUY	IK	AKLBERUGKZNEJY-RTEPGWBGSA-N
DMLEKUY	IU	(5S,8S,10aR)-3-[3-[[(5S,8S,10aR)-8-(benzhydrylcarbamoyl)-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-3-yl]sulfonyl]phenyl]sulfonyl-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
DMLEKUY	CA	CAS 1570231-89-8
DMLEKUY	DE	Haematological malignancy; Solid tumour/cancer; Nasopharyngeal carcinoma

DM6P93J	ID	DM6P93J
DM6P93J	DN	API-023
DM6P93J	HS	Phase 1
DM6P93J	SN	AGN-201904; Proton pump inhibitor prodrug, Alevium; Proton pump inhibitor prodrug, Allergan; AGN-201904-Z; Omeprazole prodrug (GERD), Alevium
DM6P93J	CP	Allergan Inc
DM6P93J	DE	Gastroesophageal reflux disease

DM4WAC2	ID	DM4WAC2
DM4WAC2	DN	APL-501
DM4WAC2	HS	Phase 1
DM4WAC2	CP	Apollomics
DM4WAC2	DT	Antibody
DM4WAC2	DE	Solid tumour/cancer

DMPJBCR	ID	DMPJBCR
DMPJBCR	DN	APO-010
DMPJBCR	HS	Phase 1
DMPJBCR	SN	MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget
DMPJBCR	CP	Apoxis SA
DMPJBCR	DE	Multiple myeloma

DMU8QD2	ID	DMU8QD2
DMU8QD2	DN	Apramycin
DMU8QD2	HS	Phase 1
DMU8QD2	SN	AC1O533Z; XZNUGFQTQHRASN-PHTOHMOASA-N
DMU8QD2	DT	Small molecular drug
DMU8QD2	PC	3081545
DMU8QD2	MW	539.6
DMU8QD2	FM	C21H41N5O11
DMU8QD2	IC	InChI=1S/C21H41N5O11/c1-26-11-14(30)18-8(33-20(11)37-21-16(32)13(29)10(25)9(4-27)34-21)3-7(24)19(36-18)35-17-6(23)2-5(22)12(28)15(17)31/h5-21,26-32H,2-4,22-25H2,1H3/t5-,6+,7-,8+,9-,10-,11+,12+,13+,14-,15-,16-,17-,18+,19+,20-,21-/m1/s1
DMU8QD2	CS	CN[C@H]1[C@H]([C@@H]2[C@H](C[C@H]([C@H](O2)O[C@@H]3[C@H](C[C@H]([C@@H]([C@H]3O)O)N)N)N)O[C@@H]1O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)N)O)O)O
DMU8QD2	IK	XZNUGFQTQHRASN-XQENGBIVSA-N
DMU8QD2	IU	(2R,3R,4S,5S,6S)-2-[[(2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy-4-hydroxy-3-(methylamino)-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-2-yl]oxy]-5-amino-6-(hydroxymethyl)oxane-3,4-diol
DMU8QD2	CA	CAS 37321-09-8
DMU8QD2	CB	CHEBI:2790
DMU8QD2	DE	Gram-negative bacterial infection

DMXIKYR	ID	DMXIKYR
DMXIKYR	DN	APTO-253
DMXIKYR	HS	Phase 1
DMXIKYR	CP	Aptose biosciences
DMXIKYR	PC	11960271
DMXIKYR	MW	367.4
DMXIKYR	FM	C22H14FN5
DMXIKYR	IC	InChI=1S/C22H14FN5/c1-11-17(15-10-12(23)6-7-16(15)26-11)22-27-20-13-4-2-8-24-18(13)19-14(21(20)28-22)5-3-9-25-19/h2-10,26H,1H3,(H,27,28)
DMXIKYR	CS	CC1=C(C2=C(N1)C=CC(=C2)F)C3=NC4=C5C=CC=NC5=C6C(=C4N3)C=CC=N6
DMXIKYR	IK	NIRXBXIPHUTNNI-UHFFFAOYSA-N
DMXIKYR	IU	2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10]phenanthroline
DMXIKYR	CA	CAS 916151-99-0
DMXIKYR	DE	Solid tumour/cancer

DMXDMH5	ID	DMXDMH5
DMXDMH5	DN	APVO414
DMXDMH5	HS	Phase 1
DMXDMH5	SN	MOR209/ES414
DMXDMH5	CP	Aptevo Therapeutics Seattle, WAMorphoSysPlanegg, Germany
DMXDMH5	DE	Prostate cancer

DMUAMZY	ID	DMUAMZY
DMUAMZY	DN	APVO436
DMUAMZY	HS	Phase 1
DMUAMZY	CP	Aptevo
DMUAMZY	DT	Antibody
DMUAMZY	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DMXIMQT	ID	DMXIMQT
DMXIMQT	DN	APX-3330
DMXIMQT	HS	Phase 1
DMXIMQT	SN	AR-03; E-3330; APE1 inhibitors (cancer/retinopathy), ApeX Therapeutics; APX-3330 analogs (cancer/retinopathy),ApeX Therapeutics; E-3330 analogs (cancer/retinopathy), ApeX Therapeutics
DMXIMQT	CP	ApeX Therapeutics
DMXIMQT	DE	Ocular cancer; Solid tumour/cancer

DM4RK6P	ID	DM4RK6P
DM4RK6P	DN	AR-12
DM4RK6P	HS	Phase 1
DM4RK6P	SN	2-Amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide; OSU-03012; 742112-33-0; OSU 03012; OSU03012; PDK1 inhibitor AR-12; OSU-03012 (AR-12); UNII-EX3O2Q61UV; 2-amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide; AR 12; EX3O2Q61UV; CHEMBL1650595; 2-amino-N-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide; 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]acetamide; PubChem22592; MLS006010170; SCHEMBL570472; GTPL8005; C26H19F3N4O; EX-A253; DTXSID50225206; CHEBI:131196; MolPort-009-019-120
DM4RK6P	DT	Small molecular drug
DM4RK6P	PC	10027278
DM4RK6P	MW	460.4
DM4RK6P	FM	C26H19F3N4O
DM4RK6P	IC	InChI=1S/C26H19F3N4O/c27-26(28,29)24-14-23(33(32-24)20-10-8-19(9-11-20)31-25(34)15-30)18-7-12-22-17(13-18)6-5-16-3-1-2-4-21(16)22/h1-14H,15,30H2,(H,31,34)
DM4RK6P	CS	C1=CC=C2C(=C1)C=CC3=C2C=CC(=C3)C4=CC(=NN4C5=CC=C(C=C5)NC(=O)CN)C(F)(F)F
DM4RK6P	IK	YULUCECVQOCQFQ-UHFFFAOYSA-N
DM4RK6P	IU	2-amino-N-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide
DM4RK6P	CA	CAS 742112-33-0
DM4RK6P	CB	CHEBI:131196
DM4RK6P	DE	Lymphoma

DMY0DPM	ID	DMY0DPM
DMY0DPM	DN	ARC-1905
DMY0DPM	HS	Phase 1
DMY0DPM	SN	Aptamer C5 inhibitors (age-related macular degeneration), Archemix/Ophthotech
DMY0DPM	CP	Archemix Corp
DMY0DPM	DT	Aptamer
DMY0DPM	DE	Macular degeneration

DMFJZK3	ID	DMFJZK3
DMFJZK3	DN	Arecoline
DMFJZK3	HS	Phase 1
DMFJZK3	SN	arecoline; Arecholine; Arecaline; 63-75-2; Methylarecaiden; Methylarecaidin; Arecolin; Arekolin; Arecoline base; Arecaidine methyl ester; Arecholin; methyl 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 1,2,5,6-tetrahydro-1-methyl-, methyl ester; Methyl N-methyltetrahydronicotinate; C8H13NO2; N-Methyltetrahydronicotinic acid, methyl ester; Methyl 1,2,5,6-tetrahydro-1-methylnicotinate; UNII-4ALN5933BH; NSC 56321; Methyl N-methyl-1,2,5,6-tetrahydronicotinate; CCRIS 7688
DMFJZK3	DT	Small molecular drug
DMFJZK3	PC	2230
DMFJZK3	MW	155.19
DMFJZK3	FM	C8H13NO2
DMFJZK3	IC	InChI=1S/C8H13NO2/c1-9-5-3-4-7(6-9)8(10)11-2/h4H,3,5-6H2,1-2H3
DMFJZK3	CS	CN1CCC=C(C1)C(=O)OC
DMFJZK3	IK	HJJPJSXJAXAIPN-UHFFFAOYSA-N
DMFJZK3	IU	methyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate
DMFJZK3	CA	CAS 63-75-2
DMFJZK3	CB	CHEBI:2814
DMFJZK3	DE	Parkinson disease

DMPLHBI	ID	DMPLHBI
DMPLHBI	DN	ARI-0001 cells
DMPLHBI	HS	Phase 1
DMPLHBI	CP	Sara V. Latorre
DMPLHBI	DT	CAR T Cell Therapy
DMPLHBI	DE	leukaemia; Lymphoma

DMN4D3A	ID	DMN4D3A
DMN4D3A	DN	ARI-2243
DMN4D3A	HS	Phase 1
DMN4D3A	CP	Arisaph Pharmaceuticals
DMN4D3A	DE	Type-2 diabetes

DMY5IM2	ID	DMY5IM2
DMY5IM2	DN	ARL-67085
DMY5IM2	HS	Phase 1
DMY5IM2	SN	AR-C 67085XX; AR-C67085MX; AR-C67775XX; FPL-67085; FPL-67085MX; SPL-67085
DMY5IM2	CP	Fisons plc
DMY5IM2	DT	Small molecular drug
DMY5IM2	PC	5310954
DMY5IM2	MW	648.2
DMY5IM2	FM	C14H22Cl2N5O12P3S
DMY5IM2	IC	InChI=1S/C14H22Cl2N5O12P3S/c1-2-3-37-13-19-10(17)7-11(20-13)21(5-18-7)12-9(23)8(22)6(32-12)4-31-36(29,30)33-35(27,28)14(15,16)34(24,25)26/h5-6,8-9,12,22-23H,2-4H2,1H3,(H,27,28)(H,29,30)(H2,17,19,20)(H2,24,25,26)/t6-,8-,9-,12-/m1/s1
DMY5IM2	CS	CCCSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)N
DMY5IM2	IK	ZLIAJZQKKBOFJR-WOUKDFQISA-N
DMY5IM2	IU	[[[[(2R,3S,4R,5R)-5-(6-amino-2-propylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-dichloromethyl]phosphonic acid
DMY5IM2	DE	Thrombosis

DMQUFNY	ID	DMQUFNY
DMQUFNY	DN	ARM210
DMQUFNY	HS	Phase 1
DMQUFNY	SN	Arm-210; UNII-1033GN605L; 1033GN605L; Rycal dmd; SCHEMBL15326996; ARM-210; JIGDAUOKKYKRKO-UHFFFAOYSA-N; s48168; S-48168; 4-((7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl)benzoic acid; Benzoic acid, 4-((2,3-dihydro-7-methoxy-1,4-benzothiazepin-4(5H)-yl)methyl)-; 4-((7-methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methyl)benzoic acid; 1467605-57-7
DMQUFNY	CP	ARMGO Pharma Tarrytown, NY
DMQUFNY	PC	71761628
DMQUFNY	MW	329.4
DMQUFNY	FM	C18H19NO3S
DMQUFNY	IC	InChI=1S/C18H19NO3S/c1-22-16-6-7-17-15(10-16)12-19(8-9-23-17)11-13-2-4-14(5-3-13)18(20)21/h2-7,10H,8-9,11-12H2,1H3,(H,20,21)
DMQUFNY	CS	COC1=CC2=C(C=C1)SCCN(C2)CC3=CC=C(C=C3)C(=O)O
DMQUFNY	IK	JIGDAUOKKYKRKO-UHFFFAOYSA-N
DMQUFNY	IU	4-[(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)methyl]benzoic acid
DMQUFNY	CA	CAS 1467605-57-7
DMQUFNY	DE	Duchenne dystrophy

DM4D85V	ID	DM4D85V
DM4D85V	DN	ARN-6039
DM4D85V	HS	Phase 1
DM4D85V	SN	BOS172767
DM4D85V	CP	Arrien Pharmaceuticals Salt Lake City, UT Boston Pharmaceuticals Cambridge, MA
DM4D85V	DE	Multiple sclerosis; Psoriasis vulgaris

DM5R7VI	ID	DM5R7VI
DM5R7VI	DN	ARN-6039
DM5R7VI	HS	Phase 1
DM5R7VI	SN	6-methoxy-5-morpholino-2-((3-(trifluoromethyl)pyridin-2-yl)methyl)-2,3-dihydro-1H-inden-1-one; 1675206-11-7; SCHEMBL16552820; COc1cc2C(=O)C(Cc3ncccc3C(F)(F)F)Cc2cc1N1CCOCC1
DM5R7VI	CP	Arrien Pharmaceuticals; Boston Pharmaceuticals
DM5R7VI	DT	Small molecular drug
DM5R7VI	PC	117940165
DM5R7VI	MW	406.4
DM5R7VI	FM	C21H21F3N2O3
DM5R7VI	IC	InChI=1S/C21H21F3N2O3/c1-28-19-12-15-13(11-18(19)26-5-7-29-8-6-26)9-14(20(15)27)10-17-16(21(22,23)24)3-2-4-25-17/h2-4,11-12,14H,5-10H2,1H3
DM5R7VI	CS	COC1=C(C=C2CC(C(=O)C2=C1)CC3=C(C=CC=N3)C(F)(F)F)N4CCOCC4
DM5R7VI	IK	CQSDLVKTQRLMJB-UHFFFAOYSA-N
DM5R7VI	IU	6-methoxy-5-morpholin-4-yl-2-[[3-(trifluoromethyl)pyridin-2-yl]methyl]-2,3-dihydroinden-1-one
DM5R7VI	DE	Multiple sclerosis

DMV5PEK	ID	DMV5PEK
DMV5PEK	DN	ARO-HIF2
DMV5PEK	HS	Phase 1
DMV5PEK	CP	Arrowhead Pharmaceuticals
DMV5PEK	DT	Antisense oligonucleotide
DMV5PEK	DE	Renal cell carcinoma

DMCRLQZ	ID	DMCRLQZ
DMCRLQZ	DN	ARQ 621
DMCRLQZ	HS	Phase 1
DMCRLQZ	SN	ARQ 621; 1095253-39-6; ARQ-621; UNII-UU55190C8S; ARQ621; UU55190C8S; (R)-N-(3-AMINOPROPYL)-3-CHLORO-N-(1-(7-CHLORO-4-OXO-3-(PHENYLAMINO)-3,4-DIHYDROQUINAZOLIN-2-YL)BUT-3-YN-1-YL)-2-FLUOROBENZAMIDE; Benzamide, N-(3-aminopropyl)-3-chloro-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylamino)-2-quinazolinyl]-3-butyn-1-yl]-2-fluoro-; SCHEMBL361201; C28H24Cl2FN5O2; DTXSID80148974; EX-A857; UPJSUQWHUVLLNW-XMMPIXPASA-N; MolPort-035-789-699; BCP28395; 2122AH; ZINC68203755; s7355; AKOS032945139; SB19448; NCGC00386362-01; KB-74734
DMCRLQZ	CP	ArQule
DMCRLQZ	DT	Small molecular drug
DMCRLQZ	PC	25110841
DMCRLQZ	MW	552.4
DMCRLQZ	FM	C28H24Cl2FN5O2
DMCRLQZ	IC	InChI=1S/C28H24Cl2FN5O2/c1-2-8-24(35(16-7-15-32)27(37)21-11-6-12-22(30)25(21)31)26-33-23-17-18(29)13-14-20(23)28(38)36(26)34-19-9-4-3-5-10-19/h1,3-6,9-14,17,24,34H,7-8,15-16,32H2/t24-/m1/s1
DMCRLQZ	CS	C#CC[C@H](C1=NC2=C(C=CC(=C2)Cl)C(=O)N1NC3=CC=CC=C3)N(CCCN)C(=O)C4=C(C(=CC=C4)Cl)F
DMCRLQZ	IK	UPJSUQWHUVLLNW-XMMPIXPASA-N
DMCRLQZ	IU	N-(3-aminopropyl)-N-[(1R)-1-(3-anilino-7-chloro-4-oxoquinazolin-2-yl)but-3-ynyl]-3-chloro-2-fluorobenzamide
DMCRLQZ	CA	CAS 1095253-39-6
DMCRLQZ	DE	Haematological malignancy

DMP9ZT1	ID	DMP9ZT1
DMP9ZT1	DN	ARQ 736
DMP9ZT1	HS	Phase 1
DMP9ZT1	CP	ArQule
DMP9ZT1	PC	46869123
DMP9ZT1	MW	674.5
DMP9ZT1	FM	C25H25N8Na2O8PS
DMP9ZT1	IC	InChI=1S/C25H27N8O8PS.2Na/c1-31-11-8-21(30-31)43(37,38)32-10-3-5-18(15-32)27-24-26-9-7-20(28-24)23-22(29-25-33(23)12-13-39-25)17-4-2-6-19(14-17)40-16-41-42(34,35)36;;/h2,4,6-9,11-14,18H,3,5,10,15-16H2,1H3,(H,26,27,28)(H2,34,35,36);;/q;2*+1/p-2/t18-;;/m1../s1
DMP9ZT1	CS	CN1C=CC(=N1)S(=O)(=O)N2CCC[C@H](C2)NC3=NC=CC(=N3)C4=C(N=C5N4C=CO5)C6=CC(=CC=C6)OCOP(=O)([O-])[O-].[Na+].[Na+]
DMP9ZT1	IK	HXINDCTZKGGRDE-JPKZNVRTSA-L
DMP9ZT1	IU	disodium;[3-[5-[2-[[(3R)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate
DMP9ZT1	CA	CAS 1228237-57-7
DMP9ZT1	DE	Solid tumour/cancer

DM7MWX0	ID	DM7MWX0
DM7MWX0	DN	ARQ 751
DM7MWX0	HS	Phase 1
DM7MWX0	CP	ArQule Burlington, MA
DM7MWX0	DE	Solid tumour/cancer

DM1FTEC	ID	DM1FTEC
DM1FTEC	DN	ARQ-171
DM1FTEC	HS	Phase 1
DM1FTEC	SN	ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule
DM1FTEC	CP	ArQule
DM1FTEC	DE	Solid tumour/cancer

DMBQWVR	ID	DMBQWVR
DMBQWVR	DN	ARQ-751
DMBQWVR	HS	Phase 1
DMBQWVR	CP	Merck
DMBQWVR	DT	Small molecular drug
DMBQWVR	DE	Solid tumour/cancer

DMMPTCK	ID	DMMPTCK
DMMPTCK	DN	ARRY-300
DMMPTCK	HS	Phase 1
DMMPTCK	CP	Array BioPharma; Novartis Pharmaceuticals
DMMPTCK	DE	Solid tumour/cancer

DMCNV0M	ID	DMCNV0M
DMCNV0M	DN	ARRY-380
DMCNV0M	HS	Phase 1
DMCNV0M	SN	937265-83-3; ARRY-380 Analog; ARRY-380 (analog ); UNII-H32S1659ED; HER2-Inhibitor-1; H32S1659ED; 6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine; HER2 Inhibitor 1; SCHEMBL10169911; C29H27N7O4S; DTXSID00239555; MolPort-023-293-540; HMS3656B04; BDBM185146; EX-A1261; AOB87708; BCP02833; ZINC73096245; 2227AH; s2752; AKOS026750520; CS-0484; SB16599; BCP9000319; NCGC00346672-01; NCGC00346672-06
DMCNV0M	CP	Array BioPharma
DMCNV0M	DT	Small molecular drug
DMCNV0M	PC	42598643
DMCNV0M	MW	569.6
DMCNV0M	FM	C29H27N7O4S
DMCNV0M	IC	InChI=1S/C29H27N7O4S/c1-19-13-21(4-7-26(19)39-22-9-11-36-28(15-22)32-18-34-36)35-29-24-14-20(3-6-25(24)31-17-33-29)27-8-5-23(40-27)16-30-10-12-41(2,37)38/h3-9,11,13-15,17-18,30H,10,12,16H2,1-2H3,(H,31,33,35)
DMCNV0M	CS	CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)C4=CC=C(O4)CNCCS(=O)(=O)C)OC5=CC6=NC=NN6C=C5
DMCNV0M	IK	QVMNYGOVNWWFKF-UHFFFAOYSA-N
DMCNV0M	IU	6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazolin-4-amine
DMCNV0M	CA	CAS 937265-83-3
DMCNV0M	DE	Solid tumour/cancer

DM4CZ2Y	ID	DM4CZ2Y
DM4CZ2Y	DN	ARX-424
DM4CZ2Y	HS	Phase 1
DM4CZ2Y	SN	Long-acting interferon beta (multiple sclerosis), Merck Serono/ Ambrx
DM4CZ2Y	CP	Ambrx
DM4CZ2Y	DE	Multiple sclerosis

DMM9ORD	ID	DMM9ORD
DMM9ORD	DN	ASG-15ME
DMM9ORD	HS	Phase 1
DMM9ORD	CP	Agensys; seattle genetics
DMM9ORD	DT	Antibody
DMM9ORD	DE	Bladder cancer; Urothelial carcinoma

DM0Z3JS	ID	DM0Z3JS
DM0Z3JS	DN	ASG-22ME
DM0Z3JS	HS	Phase 1
DM0Z3JS	CP	Seattle Genetics; Agensys
DM0Z3JS	DT	Antibody
DM0Z3JS	DE	Solid tumour/cancer

DMD0BMN	ID	DMD0BMN
DMD0BMN	DN	ASG-5ME
DMD0BMN	HS	Phase 1
DMD0BMN	CP	Seattle Genetics; Agensys
DMD0BMN	DT	Antibody
DMD0BMN	DE	Prostate cancer; Pancreatic cancer

DMJCX6D	ID	DMJCX6D
DMJCX6D	DN	ASN003
DMJCX6D	HS	Phase 1
DMJCX6D	CP	Asana BioSciences Lawrenceville, NJ
DMJCX6D	DE	Solid tumour/cancer

DMYHEUA	ID	DMYHEUA
DMYHEUA	DN	ASN007
DMYHEUA	HS	Phase 1
DMYHEUA	CP	Asana BioSciences Lawrenceville, NJ
DMYHEUA	DE	Solid tumour/cancer

DM8DBT6	ID	DM8DBT6
DM8DBT6	DN	ASP-0777
DM8DBT6	HS	Phase 1
DM8DBT6	CP	Astellas Pharma Inc
DM8DBT6	DE	Alzheimer disease

DMC80LV	ID	DMC80LV
DMC80LV	DN	ASP1948
DMC80LV	HS	Phase 1
DMC80LV	SN	PTZ-329
DMC80LV	CP	Astellas Pharma; Potenza Therapeutics
DMC80LV	DT	Antibody
DMC80LV	DE	Solid tumour/cancer

DMX4PWV	ID	DMX4PWV
DMX4PWV	DN	ASP1951
DMX4PWV	HS	Phase 1
DMX4PWV	SN	PTZ-522
DMX4PWV	CP	Astellas Pharma; Potenza Therapeutics
DMX4PWV	DT	Antibody
DMX4PWV	DE	Solid tumour/cancer

DMW72NJ	ID	DMW72NJ
DMW72NJ	DN	ASP3026
DMW72NJ	HS	Phase 1
DMW72NJ	SN	ASP3026; 1097917-15-1; ASP-3026; ASP 3026; N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine; UNII-HP4L6MXF10; HP4L6MXF10; 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine; MGGBYMDAPCCKCT-UHFFFAOYSA-N; MLS006011176; GTPL7740; SCHEMBL2827739; CHEMBL3545360; C29H40N8O3S; QCR-144; EX-A140; DTXSID90149038; AOB6601; MolPort-028-720-342; BCP06436; 2229AH; ZINC68120928; s8054
DMW72NJ	CP	Astellas Pharma
DMW72NJ	DT	Small molecular drug
DMW72NJ	PC	25134326
DMW72NJ	MW	580.7
DMW72NJ	FM	C29H40N8O3S
DMW72NJ	IC	InChI=1S/C29H40N8O3S/c1-21(2)41(38,39)27-8-6-5-7-25(27)33-29-31-20-30-28(34-29)32-24-10-9-23(19-26(24)40-4)36-13-11-22(12-14-36)37-17-15-35(3)16-18-37/h5-10,19-22H,11-18H2,1-4H3,(H2,30,31,32,33,34)
DMW72NJ	CS	CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=N2)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC
DMW72NJ	IK	MGGBYMDAPCCKCT-UHFFFAOYSA-N
DMW72NJ	IU	2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine
DMW72NJ	CA	CAS 1097917-15-1
DMW72NJ	DE	Diffuse large B-cell lymphoma

DM1RD0T	ID	DM1RD0T
DM1RD0T	DN	ASP-4058
DM1RD0T	HS	Phase 1
DM1RD0T	CP	Astellas Pharma Inc
DM1RD0T	PC	16755143
DM1RD0T	MW	442.3
DM1RD0T	FM	C19H12F6N4O2
DM1RD0T	IC	InChI=1S/C19H12F6N4O2/c1-9(18(20,21)22)30-15-5-3-11(6-12(15)19(23,24)25)17-28-16(29-31-17)10-2-4-13-14(7-10)27-8-26-13/h2-9H,1H3,(H,26,27)/t9-/m0/s1
DM1RD0T	CS	C[C@@H](C(F)(F)F)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC4=C(C=C3)N=CN4)C(F)(F)F
DM1RD0T	IK	NJNXCJPSMWKXHO-VIFPVBQESA-N
DM1RD0T	IU	3-(3H-benzimidazol-5-yl)-5-[3-(trifluoromethyl)-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxyphenyl]-1,2,4-oxadiazole
DM1RD0T	CA	CAS 952565-91-2
DM1RD0T	DE	Multiple sclerosis

DMA71OL	ID	DMA71OL
DMA71OL	DN	ASP8374
DMA71OL	HS	Phase 1
DMA71OL	SN	PTZ-201
DMA71OL	CP	Astellas Northbrook, IL Potenza Therapeutics Cambridge, MA
DMA71OL	DE	Solid tumour/cancer

DMCDMPW	ID	DMCDMPW
DMCDMPW	DN	ASP9801
DMCDMPW	HS	Phase 1
DMCDMPW	CP	Astellas Pharma
DMCDMPW	DT	Oncolytic virus therapy
DMCDMPW	DE	Solid tumour/cancer

DMCN7WI	ID	DMCN7WI
DMCN7WI	DN	AST-005
DMCN7WI	HS	Phase 1
DMCN7WI	CP	Exicure Skokie, IL Purdue Pharma Stamford, CT
DMCN7WI	DE	Psoriasis vulgaris

DM7C68W	ID	DM7C68W
DM7C68W	DN	AST-008
DM7C68W	HS	Phase 1
DM7C68W	CP	Exicure Skokie, IL
DM7C68W	DE	Solid tumour/cancer

DMD83WO	ID	DMD83WO
DMD83WO	DN	AST-1306
DMD83WO	HS	Phase 1
DMD83WO	SN	Allitinib; Allitinib tosylate
DMD83WO	CP	Allist Pharmaceutical Inc
DMD83WO	DT	Small molecular drug
DMD83WO	PC	24739943
DMD83WO	MW	448.9
DMD83WO	FM	C24H18ClFN4O2
DMD83WO	IC	InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)
DMD83WO	CS	C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl
DMD83WO	IK	MVZGYPSXNDCANY-UHFFFAOYSA-N
DMD83WO	IU	N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]prop-2-enamide
DMD83WO	CA	CAS 897383-62-9
DMD83WO	CB	CHEBI:91467
DMD83WO	DE	Solid tumour/cancer

DMD2BIT	ID	DMD2BIT
DMD2BIT	DN	AT001/r84
DMD2BIT	HS	Phase 1
DMD2BIT	CP	Affitech
DMD2BIT	DT	Antibody
DMD2BIT	DE	Solid tumour/cancer

DMYIPKJ	ID	DMYIPKJ
DMYIPKJ	DN	AT13148
DMYIPKJ	HS	Phase 1
DMYIPKJ	CP	Astex pharmaceuticals
DMYIPKJ	PC	24905401
DMYIPKJ	MW	313.8
DMYIPKJ	FM	C17H16ClN3O
DMYIPKJ	IC	InChI=1S/C17H16ClN3O/c18-16-7-5-15(6-8-16)17(22,11-19)14-3-1-12(2-4-14)13-9-20-21-10-13/h1-10,22H,11,19H2,(H,20,21)/t17-/m0/s1
DMYIPKJ	CS	C1=CC(=CC=C1C2=CNN=C2)[C@@](CN)(C3=CC=C(C=C3)Cl)O
DMYIPKJ	IK	IIRWNGPLJQXWFJ-KRWDZBQOSA-N
DMYIPKJ	IU	(1S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)phenyl]ethanol
DMYIPKJ	CA	CAS 1056901-62-2
DMYIPKJ	DE	Solid tumour/cancer

DM2B9E0	ID	DM2B9E0
DM2B9E0	DN	AT13387
DM2B9E0	HS	Phase 1
DM2B9E0	SN	AT-13387
DM2B9E0	CP	Astex Therape.
DM2B9E0	TC	Anticancer Agents
DM2B9E0	DT	Small molecular drug
DM2B9E0	PC	11955716
DM2B9E0	MW	409.5
DM2B9E0	FM	C24H31N3O3
DM2B9E0	IC	InChI=1S/C24H31N3O3/c1-16(2)20-11-21(23(29)12-22(20)28)24(30)27-14-18-5-4-17(10-19(18)15-27)13-26-8-6-25(3)7-9-26/h4-5,10-12,16,28-29H,6-9,13-15H2,1-3H3
DM2B9E0	CS	CC(C)C1=CC(=C(C=C1O)O)C(=O)N2CC3=C(C2)C=C(C=C3)CN4CCN(CC4)C
DM2B9E0	IK	IFRGXKKQHBVPCQ-UHFFFAOYSA-N
DM2B9E0	IU	(2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone
DM2B9E0	CA	CAS 912999-49-6
DM2B9E0	CB	CHEBI:140592
DM2B9E0	DE	Melanoma

DMCE08M	ID	DMCE08M
DMCE08M	DN	AT7519
DMCE08M	HS	Phase 1
DMCE08M	SN	LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide
DMCE08M	CP	Astex Therape.
DMCE08M	TC	Anticancer Agents
DMCE08M	DT	Small molecular drug
DMCE08M	PC	11338033
DMCE08M	MW	382.2
DMCE08M	FM	C16H17Cl2N5O2
DMCE08M	IC	InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)
DMCE08M	CS	C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl
DMCE08M	IK	OVPNQJVDAFNBDN-UHFFFAOYSA-N
DMCE08M	IU	4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide
DMCE08M	CA	CAS 844442-38-2
DMCE08M	CB	CHEBI:91326
DMCE08M	DE	Solid tumour/cancer

DMHYO38	ID	DMHYO38
DMHYO38	DN	AT-787
DMHYO38	HS	Phase 1
DMHYO38	CP	Atea Pharmaceuticals
DMHYO38	DT	Small molecular drug
DMHYO38	DE	Hepatitis C

DM6O0TM	ID	DM6O0TM
DM6O0TM	DN	ATA2271
DM6O0TM	HS	Phase 1
DM6O0TM	CP	Atara Biotherapeutics
DM6O0TM	DT	CAR T Cell Therapy
DM6O0TM	DE	Mesothelioma

DMIMH8L	ID	DMIMH8L
DMIMH8L	DN	ATD transdermal gel
DMIMH8L	HS	Phase 1
DMIMH8L	CP	Antares
DMIMH8L	DE	Contraception

DM96JTX	ID	DM96JTX
DM96JTX	DN	ATEVIRDINE
DM96JTX	HS	Phase 1
DM96JTX	SN	Atevirdine; 136816-75-6; Atevirdine mesylate; UNII-N24015WC6D; CHEMBL280527; N24015WC6D; U-87201E; 1-[(5-Methoxyindol-2-yl)carbonyl]-4-[3-(ethylamino)-2-pyridyl]piperazine; [4-[3-(ethylamino)-2-pyridyl]piperazin-1-yl]-(5-methoxy-1H-indol-2-yl)methanone; Atevirdine [INN]; Piperazine, 1-(3-(ethylamino)-2-pyridinyl)-4-((5-methoxy-1H-indol-2-yl)carbonyl)-; Piperazine, 1-[3-(ethylamino)-2-pyridinyl]-4-[(5-methoxy-1H-indol-2-yl)carbonyl]-; AC1Q5KK9; AC1L1U1S; SCHEMBL356038; bis(heteroaryl)piperazine analog; BDBM1437
DM96JTX	DT	Small molecular drug
DM96JTX	PC	60848
DM96JTX	MW	379.5
DM96JTX	FM	C21H25N5O2
DM96JTX	IC	InChI=1S/C21H25N5O2/c1-3-22-18-5-4-8-23-20(18)25-9-11-26(12-10-25)21(27)19-14-15-13-16(28-2)6-7-17(15)24-19/h4-8,13-14,22,24H,3,9-12H2,1-2H3
DM96JTX	CS	CCNC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)OC
DM96JTX	IK	UCPOMLWZWRTIAA-UHFFFAOYSA-N
DM96JTX	IU	[4-[3-(ethylamino)pyridin-2-yl]piperazin-1-yl]-(5-methoxy-1H-indol-2-yl)methanone
DM96JTX	CA	CAS 136816-75-6
DM96JTX	DE	Human immunodeficiency virus infection

DMWGKHZ	ID	DMWGKHZ
DMWGKHZ	DN	ATF-936
DMWGKHZ	HS	Phase 1
DMWGKHZ	CP	Novartis AG
DMWGKHZ	PC	44201334
DMWGKHZ	MW	482.6
DMWGKHZ	FM	C30H30N2O4
DMWGKHZ	IC	InChI=1S/C30H30N2O4/c1-6-16-36-24-13-14-26-25(18-24)29(23-11-9-22(10-12-23)20(3)4)31-30(33)32(26)19-21-8-15-27(34-5)28(17-21)35-7-2/h1,8-15,17-18,20H,7,16,19H2,2-5H3
DMWGKHZ	CS	CCOC1=C(C=CC(=C1)CN2C3=C(C=C(C=C3)OCC#C)C(=NC2=O)C4=CC=C(C=C4)C(C)C)OC
DMWGKHZ	IK	IIBRYYCFSIBSFT-UHFFFAOYSA-N
DMWGKHZ	IU	1-[(3-ethoxy-4-methoxyphenyl)methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one
DMWGKHZ	CA	CAS 717103-89-4
DMWGKHZ	DE	Osteoporosis

DMT5Z84	ID	DMT5Z84
DMT5Z84	DN	ATI-0917
DMT5Z84	HS	Phase 1
DMT5Z84	SN	FB-636
DMT5Z84	CP	The Procter & Gamble Co
DMT5Z84	DE	Human immunodeficiency virus infection

DMBKO2W	ID	DMBKO2W
DMBKO2W	DN	ATI-355
DMBKO2W	HS	Phase 1
DMBKO2W	SN	Atinumab; Anti-Nogo-A mAbs, Novartis; Anti-Nogo-A monoclonal antibodies, Novartis; 11C7; 7B12
DMBKO2W	CP	Novartis AG
DMBKO2W	DT	Antibody
DMBKO2W	DE	Nerve injury

DM6GKMU	ID	DM6GKMU
DM6GKMU	DN	ATI-9242
DM6GKMU	HS	Phase 1
DM6GKMU	SN	Antipsychotic agent (oral, psychiatric disorders), ARYx Therapeutics; Antipsychotic agent (oral, schizophrenia), ARYx Therapeutics
DM6GKMU	CP	ARYx Therapeutics Inc
DM6GKMU	DE	Schizophrenia

DMR93S5	ID	DMR93S5
DMR93S5	DN	ATL1103
DMR93S5	HS	Phase 1
DMR93S5	CP	ISIS Pharm; Antisense Therapeutics
DMR93S5	DT	Antisense drug
DMR93S5	DE	Acromegaly

DMZI4UX	ID	DMZI4UX
DMZI4UX	DN	ATLCAR.CD30 cells
DMZI4UX	HS	Phase 1
DMZI4UX	CP	UNC Lineberger Comprehensive Cancer Center
DMZI4UX	DT	CAR T Cell Therapy
DMZI4UX	DE	Immune System disease; Immunoproliferative disorder; Lymphatic disease; Lymphoma; Neoplasm

DM3IPSX	ID	DM3IPSX
DM3IPSX	DN	ATLCAR.CD30.CCR4 cells
DM3IPSX	HS	Phase 1
DM3IPSX	CP	UNC Lineberger Comprehensive Cancer Center
DM3IPSX	DT	CAR T Cell Therapy (Dual specific)
DM3IPSX	DE	Immune System disease; Immunoproliferative disorder; Lymphatic disease; Lymphoma; Neoplasm

DMU67HD	ID	DMU67HD
DMU67HD	DN	ATR-01
DMU67HD	HS	Phase 1
DMU67HD	CP	Millendo Therapeutics Ann Arbor, MI
DMU67HD	DE	Adrenocortical carcinoma

DMUMVXK	ID	DMUMVXK
DMUMVXK	DN	ATR-101
DMUMVXK	HS	Phase 1
DMUMVXK	CP	Atterocor
DMUMVXK	DT	Small molecular drug
DMUMVXK	PC	131678
DMUMVXK	MW	458.1
DMUMVXK	FM	C27H40ClN3O
DMUMVXK	IC	InChI=1S/C27H39N3O.ClH/c1-19(2)23-10-9-11-24(20(3)4)25(23)29-26(31)28-18-27(16-7-8-17-27)21-12-14-22(15-13-21)30(5)6;/h9-15,19-20H,7-8,16-18H2,1-6H3,(H2,28,29,31);1H
DMUMVXK	CS	CC(C)C1=C(C(=CC=C1)C(C)C)NC(=O)NCC2(CCCC2)C3=CC=C(C=C3)N(C)C.Cl
DMUMVXK	IK	SDOOGTHIDFZUNM-UHFFFAOYSA-N
DMUMVXK	IU	1-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-3-[2,6-di(propan-2-yl)phenyl]urea;hydrochloride
DMUMVXK	CA	CAS 133825-81-7
DMUMVXK	DE	Malignant adrenal gland cancer; Arteriosclerosis

DMBCATZ	ID	DMBCATZ
DMBCATZ	DN	ATR-107
DMBCATZ	HS	Phase 1
DMBCATZ	SN	PF-05230900
DMBCATZ	CP	Wyeth
DMBCATZ	DT	Antibody
DMBCATZ	DE	Crohn disease

DMTG9EV	ID	DMTG9EV
DMTG9EV	DN	ATRC-101
DMTG9EV	HS	Phase 1
DMTG9EV	CP	Atreca
DMTG9EV	DT	Antibody
DMTG9EV	DE	Solid tumour/cancer

DML4SIE	ID	DML4SIE
DML4SIE	DN	Atu-027
DML4SIE	HS	Phase 1
DML4SIE	SN	PI3K expression inhibitors (AtuPLEX, cancer), Atugen; Phosphoinositide 3 kinase expression inhibitors (AtuPLEX, cancer), Atugen
DML4SIE	CP	Silence Therapeutics AG
DML4SIE	DE	Solid tumour/cancer

DMKNMAE	ID	DMKNMAE
DMKNMAE	DN	Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
DMKNMAE	HS	Phase 1
DMKNMAE	CP	Fred Hutchinson Cancer Research Center
DMKNMAE	DT	CAR T Cell Therapy
DMKNMAE	DE	Plasma cell myeloma

DMQA1VT	ID	DMQA1VT
DMQA1VT	DN	Autologous cell based gene therapy
DMQA1VT	HS	Phase 1
DMQA1VT	SN	Autologous cell based gene therapy (pulmonary hypertension)
DMQA1VT	CP	University of Toronto
DMQA1VT	DE	Pulmonary hypertension

DMJW4TP	ID	DMJW4TP
DMJW4TP	DN	Autologous ET1402L1-CART cells
DMJW4TP	HS	Phase 1
DMJW4TP	CP	Aeon Therapeutics (Shanghai) Co., Ltd.
DMJW4TP	DT	CAR T Cell Therapy
DMJW4TP	DE	Hepatocellular carcinoma; Liver cancer; Metastatic liver cancer

DMARYFK	ID	DMARYFK
DMARYFK	DN	Autologous melanoma cell vaccine
DMARYFK	HS	Phase 1
DMARYFK	SN	Autologous melanoma cell vaccine (neoplasm)
DMARYFK	CP	Dana-Farber Cancer Institute Inc
DMARYFK	DE	Solid tumour/cancer

DMZ763A	ID	DMZ763A
DMZ763A	DN	Autologous T Cells Expressing MET scFv CAR
DMZ763A	HS	Phase 1
DMZ763A	CP	University of Pennsylvania
DMZ763A	DT	CAR T Cell Therapy
DMZ763A	DE	Melanoma; Breast cancer

DMTLU37	ID	DMTLU37
DMTLU37	DN	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
DMTLU37	HS	Phase 1
DMTLU37	CP	University of Pennsylvania
DMTLU37	DT	CAR T Cell Therapy
DMTLU37	DE	Pancreatic cancer

DMOAET3	ID	DMOAET3
DMOAET3	DN	Autologous T-cell therapy
DMOAET3	HS	Phase 1
DMOAET3	SN	Anti-PSMA designer T cells, Roger Williams; Gene therapy (chimeric anti-PSMA antibody-TCR), Roger Williams; Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer); Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center; Retrovirus-based ex vivo gene therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center
DMOAET3	CP	Roger Williams Medical Center
DMOAET3	DT	Antibody
DMOAET3	DE	Prostate cancer

DMZLCTD	ID	DMZLCTD
DMZLCTD	DN	AV-203
DMZLCTD	HS	Phase 1
DMZLCTD	SN	ErbB3-targeted antibodies (cancer), AVEO/Biogen Idec
DMZLCTD	CP	Aveo oncology
DMZLCTD	DT	Antibody
DMZLCTD	DE	Solid tumour/cancer

DME630T	ID	DME630T
DME630T	DN	AV4025
DME630T	HS	Phase 1
DME630T	CP	Allachem
DME630T	DE	Hepatitis C virus infection

DMVL87N	ID	DMVL87N
DMVL87N	DN	AV-965
DMVL87N	HS	Phase 1
DMVL87N	CP	Avera Pharmaceuticals Inc
DMVL87N	DE	Alzheimer disease

DMKCRMD	ID	DMKCRMD
DMKCRMD	DN	AVB-S6-500
DMKCRMD	HS	Phase 1
DMKCRMD	CP	Aravive Biologics Houston, TX
DMKCRMD	DE	Acute myeloid leukaemia; Solid tumour/cancer

DMSR91U	ID	DMSR91U
DMSR91U	DN	AVE0118
DMSR91U	HS	Phase 1
DMSR91U	SN	UNII-Q1B712V03A; AVE-0118; CHEMBL1671897; Q1B712V03A; 498577-53-0; CHDSRMIDIQABTP-UHFFFAOYSA-N; SCHEMBL498292; ZINC3986746; BDBM50417943; SB17438; NCGC00386732-01; (1,1'-Biphenyl)-2-carboxamide, 2'-((((4-methoxyphenyl)acetyl)amino)methyl)-N-(2-(3-pyridinyl)ethyl)-; 2'-((2-(4-Methoxyphenyl)acetylamino)methyl)biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)amide; (1,1'-Biphenyl)-2-carboxamide, 2'-(((2-(4-methoxyphenyl)acetyl)amino)methyl)-N-(2-(3-pyridinyl)ethyl)-
DMSR91U	CP	Sanofi-Aventis
DMSR91U	DT	Small molecular drug
DMSR91U	PC	9811357
DMSR91U	MW	479.6
DMSR91U	FM	C30H29N3O3
DMSR91U	IC	InChI=1S/C30H29N3O3/c1-36-25-14-12-22(13-15-25)19-29(34)33-21-24-8-2-3-9-26(24)27-10-4-5-11-28(27)30(35)32-18-16-23-7-6-17-31-20-23/h2-15,17,20H,16,18-19,21H2,1H3,(H,32,35)(H,33,34)
DMSR91U	CS	COC1=CC=C(C=C1)CC(=O)NCC2=CC=CC=C2C3=CC=CC=C3C(=O)NCCC4=CN=CC=C4
DMSR91U	IK	CHDSRMIDIQABTP-UHFFFAOYSA-N
DMSR91U	IU	2-[2-[[[2-(4-methoxyphenyl)acetyl]amino]methyl]phenyl]-N-(2-pyridin-3-ylethyl)benzamide
DMSR91U	CA	CAS 498577-53-0
DMSR91U	DE	Obstructive sleep apnea

DM56VG2	ID	DM56VG2
DM56VG2	DN	AVE0897
DM56VG2	HS	Phase 1
DM56VG2	CP	Sanofi-Aventis
DM56VG2	DE	Type-2 diabetes

DMJY35M	ID	DMJY35M
DMJY35M	DN	AVE1701
DMJY35M	HS	Phase 1
DMJY35M	CP	Sanofi-Aventis
DMJY35M	DE	Rheumatoid arthritis

DMZNTHJ	ID	DMZNTHJ
DMZNTHJ	DN	AVE-8112
DMZNTHJ	HS	Phase 1
DMZNTHJ	SN	AVE8112
DMZNTHJ	CP	The michael j. fox foundation for parkinson's research; sanofi us
DMZNTHJ	DE	Parkinson disease

DMVUW8A	ID	DMVUW8A
DMVUW8A	DN	AVI-6002
DMVUW8A	HS	Phase 1
DMVUW8A	SN	NeuGene Plus (Ebola virus), AVI; Neugene (Ebola virus), AVI BioPharma; Polymerase cofactor VP35 modulator (Ebola virus infection,TSO), AVI BioPharma; Viral membrane associated protein VP24 modulator (Ebola virus infection, TSO), AVI BioPharma; AVI-4537 + AVI-4538 + AVI-4539 (Ebola virus infection), AVI BioPharma
DMVUW8A	CP	AVI BioPharma Inc
DMVUW8A	DE	Ebola virus infection

DMIJSDO	ID	DMIJSDO
DMIJSDO	DN	AVI-6003
DMIJSDO	HS	Phase 1
DMIJSDO	SN	NeuGene Plus; NeuGene (Marburg virus, TSO), AVI BioPharma
DMIJSDO	CP	Genphar
DMIJSDO	DE	Marburg virus infection

DMVD327	ID	DMVD327
DMVD327	DN	AVI-7288
DMVD327	HS	Phase 1
DMVD327	CP	Sarepta therapeutics
DMVD327	DT	Antisense drug
DMVD327	DE	Marburg virus infection

DMLI9U6	ID	DMLI9U6
DMLI9U6	DN	AVI-7537
DMLI9U6	HS	Phase 1
DMLI9U6	CP	Sarepta therapeutics
DMLI9U6	DT	Antisense drug
DMLI9U6	DE	Ebola virus infection

DMZ39T6	ID	DMZ39T6
DMZ39T6	DN	AVID200
DMZ39T6	HS	Phase 1
DMZ39T6	CP	Bristol-Myers Squibb
DMZ39T6	DT	Small molecular drug
DMZ39T6	DE	Solid tumour/cancer

DMGAKR9	ID	DMGAKR9
DMGAKR9	DN	AVL-3288
DMGAKR9	HS	Phase 1
DMGAKR9	CP	Anvyl pharmaceuticals
DMGAKR9	PC	16005981
DMGAKR9	MW	388.2
DMGAKR9	FM	C19H15Cl2N3O2
DMGAKR9	IC	InChI=1S/C19H15Cl2N3O2/c1-12-10-18(26-24-12)17(11-22-15-6-2-13(20)3-7-15)19(25)23-16-8-4-14(21)5-9-16/h2-11,22H,1H3,(H,23,25)/b17-11-
DMGAKR9	CS	CC1=NOC(=C1)/C(=C/NC2=CC=C(C=C2)Cl)/C(=O)NC3=CC=C(C=C3)Cl
DMGAKR9	IK	VMAKIACTLSBBIY-BOPFTXTBSA-N
DMGAKR9	IU	(Z)-3-(4-chloroanilino)-N-(4-chlorophenyl)-2-(3-methyl-1,2-oxazol-5-yl)prop-2-enamide
DMGAKR9	CA	CAS 917837-54-8
DMGAKR9	DE	Cognitive impairment; Complete androgen insensitivity syndrome; Immune dysregulation

DMNIVFJ	ID	DMNIVFJ
DMNIVFJ	DN	AVN-322
DMNIVFJ	HS	Phase 1
DMNIVFJ	SN	1194574-68-9; N,7-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-2-amine hydrochloride; SB17475
DMNIVFJ	CP	Avineuro
DMNIVFJ	DT	Small molecular drug
DMNIVFJ	PC	135905417
DMNIVFJ	MW	393.9
DMNIVFJ	FM	C17H20ClN5O2S
DMNIVFJ	IC	InChI=1S/C17H19N5O2S.ClH/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16;/h3-7,10H,8-9,11H2,1-2H3,(H,18,20);1H
DMNIVFJ	CS	CNC1=NN2C3=C(CN(CC3)C)C=NC2=C1S(=O)(=O)C4=CC=CC=C4.Cl
DMNIVFJ	IK	HLQZXWFRTGIZIJ-UHFFFAOYSA-N
DMNIVFJ	IU	5-(benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-4-amine;hydrochloride
DMNIVFJ	DE	Alzheimer disease

DM8CYJ1	ID	DM8CYJ1
DM8CYJ1	DN	AVP-13358
DM8CYJ1	HS	Phase 1
DM8CYJ1	SN	IgE inhibitors, AVANIR; Allergy/asthma therapeutic, AVANIR
DM8CYJ1	CP	AVANIR Pharmaceuticals Inc
DM8CYJ1	DT	Small molecular drug
DM8CYJ1	PC	9805635
DM8CYJ1	MW	491.6
DM8CYJ1	FM	C30H29N5O2
DM8CYJ1	IC	InChI=1S/C30H29N5O2/c36-28(35-26-3-1-2-10-31-26)22-6-9-24-25(14-22)34-27(33-24)21-4-7-23(8-5-21)32-29(37)30-15-18-11-19(16-30)13-20(12-18)17-30/h1-10,14,18-20H,11-13,15-17H2,(H,32,37)(H,33,34)(H,31,35,36)
DM8CYJ1	CS	C1C2CC3CC1CC(C2)(C3)C(=O)NC4=CC=C(C=C4)C5=NC6=C(N5)C=C(C=C6)C(=O)NC7=CC=CC=N7
DM8CYJ1	IK	LUPHOOKVGNVAFT-UHFFFAOYSA-N
DM8CYJ1	IU	2-[4-(adamantane-1-carbonylamino)phenyl]-N-pyridin-2-yl-3H-benzimidazole-5-carboxamide
DM8CYJ1	CA	CAS 459805-03-9
DM8CYJ1	DE	Rhinitis

DMMWEH6	ID	DMMWEH6
DMMWEH6	DN	AVP-21D9
DMMWEH6	HS	Phase 1
DMMWEH6	SN	Thravixa; AVP-1C6; AVP-22G12; AVP-8C1; Anthrax antibody, AVANIR; Anthrax toxin Mab, Xenerex; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), AVANIR; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), Emergent
DMMWEH6	CP	Emergent biosolutions
DMMWEH6	DT	Antibody
DMMWEH6	DE	Bacillus anthracis infection

DMAKD0I	ID	DMAKD0I
DMAKD0I	DN	AVX-470
DMAKD0I	HS	Phase 1
DMAKD0I	SN	Anti-TNF antibody (oral, IBD), Avaxia Biologics
DMAKD0I	CP	Avaxia Biologics Inc
DMAKD0I	DT	Antibody
DMAKD0I	DE	Inflammatory bowel disease; Ulcerative colitis

DMRQ32K	ID	DMRQ32K
DMRQ32K	DN	AX-024
DMRQ32K	HS	Phase 1
DMRQ32K	SN	VMMKGVRPILDZML-UHFFFAOYSA-N; SCHEMBL903258; AKOS030622922; CS-8052; HY-107390; 1370544-73-2
DMRQ32K	CP	Artax Biopharma Cambridge, MA
DMRQ32K	PC	56949412
DMRQ32K	MW	339.4
DMRQ32K	FM	C21H22FNO2
DMRQ32K	IC	InChI=1S/C21H22FNO2/c1-24-18-8-9-20-19(12-18)21(15-4-6-17(22)7-5-15)16(14-25-20)13-23-10-2-3-11-23/h4-9,12H,2-3,10-11,13-14H2,1H3
DMRQ32K	CS	COC1=CC2=C(C=C1)OCC(=C2C3=CC=C(C=C3)F)CN4CCCC4
DMRQ32K	IK	VMMKGVRPILDZML-UHFFFAOYSA-N
DMRQ32K	IU	1-[[4-(4-fluorophenyl)-6-methoxy-2H-chromen-3-yl]methyl]pyrrolidine
DMRQ32K	DE	Multiple sclerosis

DMFBMU7	ID	DMFBMU7
DMFBMU7	DN	Axatilamab
DMFBMU7	HS	Phase 1
DMFBMU7	SN	SNDX-6352
DMFBMU7	CP	Syndax Pharmaceuticals
DMFBMU7	DT	Antibody
DMFBMU7	DE	Solid tumour/cancer

DM6L5IP	ID	DM6L5IP
DM6L5IP	DN	Axitirome
DM6L5IP	HS	Phase 1
DM6L5IP	SN	CGP-26214; CGS-25845; CGS-26214
DM6L5IP	CP	Novartis AG
DM6L5IP	DT	Small molecular drug
DM6L5IP	PC	166559
DM6L5IP	MW	453.5
DM6L5IP	FM	C25H24FNO6
DM6L5IP	IC	InChI=1S/C25H24FNO6/c1-4-32-25(31)24(30)27-18-11-14(2)23(15(3)12-18)33-19-9-10-21(28)20(13-19)22(29)16-5-7-17(26)8-6-16/h5-13,22,28-29H,4H2,1-3H3,(H,27,30)
DM6L5IP	CS	CCOC(=O)C(=O)NC1=CC(=C(C(=C1)C)OC2=CC(=C(C=C2)O)C(C3=CC=C(C=C3)F)O)C
DM6L5IP	IK	FUBBWDWIGBTUPQ-UHFFFAOYSA-N
DM6L5IP	IU	ethyl 2-[4-[3-[(4-fluorophenyl)-hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylanilino]-2-oxoacetate
DM6L5IP	CA	CAS 156740-57-7
DM6L5IP	DE	Hyperlipidaemia

DM7ZU3B	ID	DM7ZU3B
DM7ZU3B	DN	AXT-914
DM7ZU3B	HS	Phase 1
DM7ZU3B	CP	Novartis AG
DM7ZU3B	DE	Osteoporosis

DMWCJEU	ID	DMWCJEU
DMWCJEU	DN	AZD0156
DMWCJEU	HS	Phase 1
DMWCJEU	SN	AOTRIQLYUAFVSC-UHFFFAOYSA-N; 1821428-35-6; AZD-0156; UNII-P5T0XWC07Z; P5T0XWC07Z; GTPL9942; CHEMBL3960662; SCHEMBL17246146; AZD 0156 [WHO-DD]; MolPort-044-560-374; BDBM245474; BCP18990; EX-A1321; s8375; ZINC498035578; AKOS030629510; CS-5889; SB19769; AZD0156 (AZD-0156); AS-35329; compound 64  [PMID: 29683659]; HY-100016; US9428503, 1; 8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one; 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[
DMWCJEU	CP	AstraZeneca Wilmington, DE
DMWCJEU	PC	118502708
DMWCJEU	MW	461.6
DMWCJEU	FM	C26H31N5O3
DMWCJEU	IC	InChI=1S/C26H31N5O3/c1-29(2)11-4-12-34-24-8-6-19(16-28-24)18-5-7-22-21(15-18)25-23(17-27-22)30(3)26(32)31(25)20-9-13-33-14-10-20/h5-8,15-17,20H,4,9-14H2,1-3H3
DMWCJEU	CS	CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4CCOCC4)C5=CN=C(C=C5)OCCCN(C)C
DMWCJEU	IK	AOTRIQLYUAFVSC-UHFFFAOYSA-N
DMWCJEU	IU	8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one
DMWCJEU	CA	CAS 1821428-35-6
DMWCJEU	DE	Solid tumour/cancer

DMHBEKM	ID	DMHBEKM
DMHBEKM	DN	AZD0284
DMHBEKM	HS	Phase 1
DMHBEKM	CP	AstraZeneca Wilmington, DE
DMHBEKM	DE	Plaque psoriasis

DMMW72C	ID	DMMW72C
DMMW72C	DN	AZD-1152-HQPA
DMMW72C	HS	Phase 1
DMMW72C	SN	Barasertib
DMMW72C	DT	Small molecular drug
DMMW72C	PC	16007391
DMMW72C	MW	507.6
DMMW72C	FM	C26H30FN7O3
DMMW72C	IC	InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)
DMMW72C	CS	CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO
DMMW72C	IK	QYZOGCMHVIGURT-UHFFFAOYSA-N
DMMW72C	IU	2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide
DMMW72C	CA	CAS 722544-51-6
DMMW72C	CB	CHEBI:91367
DMMW72C	DE	Solid tumour/cancer

DMBEA6V	ID	DMBEA6V
DMBEA6V	DN	AZD1208
DMBEA6V	HS	Phase 1
DMBEA6V	SN	AZD1208; 1204144-28-4; AZD-1208; UNII-S98NFM1378; (R,Z)-5-((2-(3-aminopiperidin-1-yl)-[1,1'-biphenyl]-3-yl)methylene)thiazolidine-2,4-dione; CHEMBL2048872; S98NFM1378; AZD 1208; AK174910; GTPL7698; (5Z)-5-[[2-[(3R)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione; (5Z)-5-({2-[(3R)-3-Aminopiperidin-1-yl]-3-phenylphenyl}methylidene)-1,3-thiazolidine-2,4-dione; SCHEMBL1580644; MolPort-035-395-904; EX-A1804; AOB87151; s7104; 2236AH; ZINC84670255; BDBM50387298; AKOS025404917; CS-1668; QC-11435; HY-15604
DMBEA6V	CP	AstraZeneca
DMBEA6V	DT	Small molecular drug
DMBEA6V	PC	58423153
DMBEA6V	MW	379.5
DMBEA6V	FM	C21H21N3O2S
DMBEA6V	IC	InChI=1S/C21H21N3O2S/c22-16-9-5-11-24(13-16)19-15(12-18-20(25)23-21(26)27-18)8-4-10-17(19)14-6-2-1-3-7-14/h1-4,6-8,10,12,16H,5,9,11,13,22H2,(H,23,25,26)/b18-12-/t16-/m1/s1
DMBEA6V	CS	C1C[C@H](CN(C1)C2=C(C=CC=C2C3=CC=CC=C3)/C=C\\4/C(=O)NC(=O)S4)N
DMBEA6V	IK	MCUJKPPARUPFJM-UWCCDQBKSA-N
DMBEA6V	IU	(5Z)-5-[[2-[(3R)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione
DMBEA6V	CA	CAS 1204144-28-4
DMBEA6V	DE	Solid tumour/cancer

DMYBX4N	ID	DMYBX4N
DMYBX4N	DN	AZD1390
DMYBX4N	HS	Phase 1
DMYBX4N	SN	VQSZIPCGAGVRRP-UHFFFAOYSA-N; SCHEMBL18631972; AZD-1390; EX-A2670; CS-8217; 2089288-03-7; HY-109566
DMYBX4N	CP	AstraZeneca Wilmington, DE
DMYBX4N	PC	126689157
DMYBX4N	MW	477.6
DMYBX4N	FM	C27H32FN5O2
DMYBX4N	IC	InChI=1S/C27H32FN5O2/c1-18(2)33-26-21-14-20(22(28)15-23(21)29-17-24(26)31(3)27(33)34)19-8-9-25(30-16-19)35-13-7-12-32-10-5-4-6-11-32/h8-9,14-18H,4-7,10-13H2,1-3H3
DMYBX4N	CS	CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C
DMYBX4N	IK	VQSZIPCGAGVRRP-UHFFFAOYSA-N
DMYBX4N	IU	7-fluoro-3-methyl-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]quinolin-2-one
DMYBX4N	CA	CAS 2089288-03-7
DMYBX4N	DE	Recurrent glioblastoma

DM6UOXF	ID	DM6UOXF
DM6UOXF	DN	AZD1419
DM6UOXF	HS	Phase 1
DM6UOXF	DE	Asthma

DMQ1OX4	ID	DMQ1OX4
DMQ1OX4	DN	AZD1979
DMQ1OX4	HS	Phase 1
DMQ1OX4	PC	49801838
DMQ1OX4	MW	462.5
DMQ1OX4	FM	C25H26N4O5
DMQ1OX4	IC	InChI=1S/C25H26N4O5/c1-31-19-8-4-18(5-9-19)22-26-27-23(34-22)24(30)29-11-21(12-29)33-20-6-2-17(3-7-20)10-28-13-25(14-28)15-32-16-25/h2-9,21H,10-16H2,1H3
DMQ1OX4	CS	COC1=CC=C(C=C1)C2=NN=C(O2)C(=O)N3CC(C3)OC4=CC=C(C=C4)CN5CC6(C5)COC6
DMQ1OX4	IK	BKKPIQPFRAPEAY-UHFFFAOYSA-N
DMQ1OX4	IU	[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-[3-[4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy]azetidin-1-yl]methanone
DMQ1OX4	CA	CAS 1254035-84-1
DMQ1OX4	CB	CHEBI:139154
DMQ1OX4	DE	Obesity

DMZQEDY	ID	DMZQEDY
DMZQEDY	DN	AZD-2551
DMZQEDY	HS	Phase 1
DMZQEDY	CP	AstraZeneca plc
DMZQEDY	DE	Chronic obstructive pulmonary disease

DMXFYN0	ID	DMXFYN0
DMXFYN0	DN	AZD-3043
DMXFYN0	HS	Phase 1
DMXFYN0	SN	TD-4756; THRX-918661
DMXFYN0	CP	Theravance Inc
DMXFYN0	DT	Small molecular drug
DMXFYN0	PC	10286834
DMXFYN0	MW	351.4
DMXFYN0	FM	C19H29NO5
DMXFYN0	IC	InChI=1S/C19H29NO5/c1-5-11-24-19(22)13-15-9-10-16(17(12-15)23-8-4)25-14-18(21)20(6-2)7-3/h9-10,12H,5-8,11,13-14H2,1-4H3
DMXFYN0	CS	CCCOC(=O)CC1=CC(=C(C=C1)OCC(=O)N(CC)CC)OCC
DMXFYN0	IK	QPUVKSKJCNGSGT-UHFFFAOYSA-N
DMXFYN0	IU	propyl 2-[4-[2-(diethylamino)-2-oxoethoxy]-3-ethoxyphenyl]acetate
DMXFYN0	CA	CAS 579494-66-9
DMXFYN0	DE	Anaesthesia

DMICW7D	ID	DMICW7D
DMICW7D	DN	AZD-3161
DMICW7D	HS	Phase 1
DMICW7D	CP	AstraZeneca plc
DMICW7D	PC	56945146
DMICW7D	MW	474.4
DMICW7D	FM	C23H21F3N4O4
DMICW7D	IC	InChI=1S/C23H21F3N4O4/c1-32-21-10-28-19(9-29-21)17-3-2-4-20-18(17)7-16(12-34-20)30-22(31)14-5-6-15(27-8-14)11-33-13-23(24,25)26/h2-6,8-10,16H,7,11-13H2,1H3,(H,30,31)/t16-/m0/s1
DMICW7D	CS	COC1=NC=C(N=C1)C2=C3C[C@@H](COC3=CC=C2)NC(=O)C4=CN=C(C=C4)COCC(F)(F)F
DMICW7D	IK	LRHQXIQLHVPUNA-INIZCTEOSA-N
DMICW7D	IU	N-[(3S)-5-(5-methoxypyrazin-2-yl)-3,4-dihydro-2H-chromen-3-yl]-6-(2,2,2-trifluoroethoxymethyl)pyridine-3-carboxamide
DMICW7D	CA	CAS 1369501-46-1
DMICW7D	DE	Peripheral neuropathy

DMC1BXV	ID	DMC1BXV
DMC1BXV	DN	AZD-3514
DMC1BXV	HS	Phase 1
DMC1BXV	CP	AstraZeneca plc
DMC1BXV	PC	46893585
DMC1BXV	MW	519.6
DMC1BXV	FM	C25H32F3N7O2
DMC1BXV	IC	InChI=1S/C25H32F3N7O2/c1-18(36)33-14-12-32(13-15-33)16-17-37-21-4-2-19(3-5-21)20-8-10-34(11-9-20)23-7-6-22-29-30-24(25(26,27)28)35(22)31-23/h2-5,20H,6-17H2,1H3
DMC1BXV	CS	CC(=O)N1CCN(CC1)CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5C(F)(F)F)CC4
DMC1BXV	IK	JMEYDSHPKCSIJC-UHFFFAOYSA-N
DMC1BXV	IU	1-[4-[2-[4-[1-[3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl]phenoxy]ethyl]piperazin-1-yl]ethanone
DMC1BXV	CA	CAS 1240299-33-5
DMC1BXV	DE	Prostate cancer

DM72FOD	ID	DM72FOD
DM72FOD	DN	Azd-3839
DM72FOD	HS	Phase 1
DM72FOD	SN	GTPL6931; 4b05; (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-[3-(pyrimidin-5-yl)phenyl]-2,3-dihydro-1H-isoindol-1-amine; 32D
DM72FOD	CP	AstraZeneca plc
DM72FOD	DT	Small molecular drug
DM72FOD	PC	46202416
DM72FOD	MW	431.4
DM72FOD	FM	C24H16F3N5
DM72FOD	IC	InChI=1S/C24H16F3N5/c25-19-6-2-5-18-21(19)23(28)32-24(18,17-7-8-31-20(10-17)22(26)27)16-4-1-3-14(9-16)15-11-29-13-30-12-15/h1-13,22H,(H2,28,32)/t24-/m0/s1
DM72FOD	CS	C1=CC(=CC(=C1)[C@@]2(C3=C(C(=CC=C3)F)C(=N2)N)C4=CC(=NC=C4)C(F)F)C5=CN=CN=C5
DM72FOD	IK	MRXBCEQZNKUUIP-DEOSSOPVSA-N
DM72FOD	IU	(3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine
DM72FOD	CA	CAS 1227163-84-9
DM72FOD	DE	Alzheimer disease

DMOYPTK	ID	DMOYPTK
DMOYPTK	DN	AZD4573
DMOYPTK	HS	Phase 1
DMOYPTK	SN	AVIWDYSJSPOOAR-LSDHHAIUSA-N; 2057509-72-3; SCHEMBL18338402; HY-112088; CS-0043316; AZD-4573,AZD4573,AZD 4573; (1S,3R)-3-Acetamido-N-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide
DMOYPTK	CP	AstraZeneca Wilmington, DE
DMOYPTK	PC	124155204
DMOYPTK	MW	429.9
DMOYPTK	FM	C22H28ClN5O2
DMOYPTK	IC	InChI=1S/C22H28ClN5O2/c1-13(29)26-15-6-4-5-14(7-15)21(30)27-20-8-16(18(23)11-24-20)17-10-25-28-12-22(2,3)9-19(17)28/h8,10-11,14-15H,4-7,9,12H2,1-3H3,(H,26,29)(H,24,27,30)/t14-,15+/m0/s1
DMOYPTK	CS	CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)NC2=NC=C(C(=C2)C3=C4CC(CN4N=C3)(C)C)Cl
DMOYPTK	IK	AVIWDYSJSPOOAR-LSDHHAIUSA-N
DMOYPTK	IU	(1S,3R)-3-acetamido-N-[5-chloro-4-(5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl]cyclohexane-1-carboxamide
DMOYPTK	CA	CAS 2057509-72-3
DMOYPTK	DE	Haematological malignancy

DM36EY7	ID	DM36EY7
DM36EY7	DN	AZD4721
DM36EY7	HS	Phase 1
DM36EY7	CP	Astrazeneca
DM36EY7	DE	Chronic obstructive pulmonary disease

DMVWMUK	ID	DMVWMUK
DMVWMUK	DN	AZD4785
DMVWMUK	HS	Phase 1
DMVWMUK	SN	IONIS-KRAS-2.5RX
DMVWMUK	CP	AstraZeneca Wilmington, DEIonis Pharmaceuticals Carlsbad, CA
DMVWMUK	DE	Solid tumour/cancer

DMRP3N8	ID	DMRP3N8
DMRP3N8	DN	AZD4831
DMRP3N8	HS	Phase 1
DMRP3N8	CP	AstraZeneca Wilmington, DE
DMRP3N8	DE	Heart failure

DMQEO4V	ID	DMQEO4V
DMQEO4V	DN	AZD-5122
DMQEO4V	HS	Phase 1
DMQEO4V	CP	AstraZeneca plc
DMQEO4V	DE	Chronic obstructive pulmonary disease

DMW4GM2	ID	DMW4GM2
DMW4GM2	DN	AZD5153
DMW4GM2	HS	Phase 1
DMW4GM2	SN	RSMYFSPOTCDHHJ-GOSISDBHSA-N; AZD-5153; 1869912-39-9; UNII-C7C7U6YEAO; C7C7U6YEAO; SCHEMBL17477306; MolPort-044-561-768; AZD 5153 [WHO-DD]; AZD 5153; EX-A1317; BCP20057; ZINC575441177; AKOS030627661; SB18713; AS-35242; J3.544.368A; (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one; XNH; 2-Piperazinone, 4-(2-(4-(1-(3-methoxy-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1,3-dimethyl-, (3R)-; (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)pipe
DMW4GM2	CP	AstraZeneca Wilmington, DE
DMW4GM2	PC	118693659
DMW4GM2	MW	479.6
DMW4GM2	FM	C25H33N7O3
DMW4GM2	IC	InChI=1S/C25H33N7O3/c1-18-24(33)29(2)14-15-30(18)16-17-35-21-6-4-19(5-7-21)20-10-12-31(13-11-20)23-9-8-22-26-27-25(34-3)32(22)28-23/h4-9,18,20H,10-17H2,1-3H3/t18-/m1/s1
DMW4GM2	CS	C[C@@H]1C(=O)N(CCN1CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5OC)C=C4)C
DMW4GM2	IK	RSMYFSPOTCDHHJ-GOSISDBHSA-N
DMW4GM2	IU	(3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one
DMW4GM2	CA	CAS 1869912-39-9
DMW4GM2	DE	Solid tumour/cancer

DMBQ2TF	ID	DMBQ2TF
DMBQ2TF	DN	AZD-5438
DMBQ2TF	HS	Phase 1
DMBQ2TF	SN	602306-29-6; AZD5438; AZD-5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine
DMBQ2TF	DT	Small molecular drug
DMBQ2TF	PC	16747683
DMBQ2TF	MW	371.5
DMBQ2TF	FM	C18H21N5O2S
DMBQ2TF	IC	InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)
DMBQ2TF	CS	CC1=NC=C(N1C(C)C)C2=NC(=NC=C2)NC3=CC=C(C=C3)S(=O)(=O)C
DMBQ2TF	IK	WJRRGYBTGDJBFX-UHFFFAOYSA-N
DMBQ2TF	IU	4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine
DMBQ2TF	CA	CAS 602306-29-6
DMBQ2TF	CB	CHEBI:91419
DMBQ2TF	DE	Solid tumour/cancer

DMV6DF3	ID	DMV6DF3
DMV6DF3	DN	AZD5658
DMV6DF3	HS	Phase 1
DMV6DF3	CP	AstraZeneca
DMV6DF3	DE	Diabetic complication; Obesity

DM7QGHO	ID	DM7QGHO
DM7QGHO	DN	AZD5991
DM7QGHO	HS	Phase 1
DM7QGHO	SN	KBQCEQAXHPIRTF-UHFFFAOYSA-N; AZD-5991 (Racemate); 2143061-81-6; UNII-E3T5XXY9HX; E3T5XXY9HX; SCHEMBL19472011; EX-A2673; HY-101533A; CS-0077938; E4W
DM7QGHO	CP	AstraZeneca Wilmington, DE
DM7QGHO	PC	131634760
DM7QGHO	MW	672.3
DM7QGHO	FM	C35H34ClN5O3S2
DM7QGHO	IC	InChI=1S/C35H34ClN5O3S2/c1-20-31-29(38-40(20)3)19-45-17-22-15-23(41(4)37-22)18-46-24-14-21-8-5-6-9-25(21)30(16-24)44-13-7-10-26-27-11-12-28(36)32(31)33(27)39(2)34(26)35(42)43/h5-6,8-9,11-12,14-16H,7,10,13,17-19H2,1-4H3,(H,42,43)
DM7QGHO	CS	CC1=C2C(=NN1C)CSCC3=NN(C(=C3)CSC4=CC5=CC=CC=C5C(=C4)OCCCC6=C(N(C7=C6C=CC(=C27)Cl)C)C(=O)O)C
DM7QGHO	IK	KBQCEQAXHPIRTF-UHFFFAOYSA-N
DM7QGHO	IU	17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(36),4(38),6,11,14,16,18,20,23,29(37),30,32,34-tridecaene-23-carboxylic acid
DM7QGHO	CA	CAS 2143061-82-7
DM7QGHO	DE	Haematological malignancy

DM0WCR4	ID	DM0WCR4
DM0WCR4	DN	AZD-6088
DM0WCR4	HS	Phase 1
DM0WCR4	SN	SCHEMBL648624; ZXKUTOMRBVXFKV-OALUTQOASA-N; propan-2-yl 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahydro-3H-benzoimidazol-1-yl]-1-piperidyl]-4-methyl-piperidine-1-carboxylate
DM0WCR4	CP	AstraZeneca plc
DM0WCR4	DT	Small molecular drug
DM0WCR4	PC	25221108
DM0WCR4	MW	392.5
DM0WCR4	FM	C21H36N4O3
DM0WCR4	IC	InChI=1S/C21H36N4O3/c1-3-28-20(27)23-14-10-21(2,11-15-23)24-12-8-16(9-13-24)25-18-7-5-4-6-17(18)22-19(25)26/h16-18H,3-15H2,1-2H3,(H,22,26)/t17-,18-/m0/s1
DM0WCR4	CS	CCOC(=O)N1CCC(CC1)(C)N2CCC(CC2)N3[C@H]4CCCC[C@@H]4NC3=O
DM0WCR4	IK	IVJDEIANCSDDAO-ROUUACIJSA-N
DM0WCR4	IU	ethyl 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahydro-3H-benzimidazol-1-yl]piperidin-1-yl]-4-methylpiperidine-1-carboxylate
DM0WCR4	DE	Neuropathic pain

DMW4VQF	ID	DMW4VQF
DMW4VQF	DN	AZD6423
DMW4VQF	HS	Phase 1
DMW4VQF	CP	Astrazeneca
DMW4VQF	DE	Suicidal ideation

DM84WXZ	ID	DM84WXZ
DM84WXZ	DN	AZD-7295
DM84WXZ	HS	Phase 1
DM84WXZ	SN	A-689; HCV NS5a polymerase inhibitor, Arrow; HCV NS5a polymerase inhibitor, AstraZeneca
DM84WXZ	CP	Arrow Therapeutics Ltd
DM84WXZ	DT	Small molecular drug
DM84WXZ	PC	57339445
DM84WXZ	MW	644.7
DM84WXZ	FM	C32H35F3N4O5S
DM84WXZ	IC	InChI=1S/C32H35F3N4O5S/c1-2-19-45(42,43)39-17-15-38(16-18-39)21-22-3-11-26(12-4-22)36-30(40)24-7-5-23(6-8-24)28-20-27(37-31(41)25-9-10-25)13-14-29(28)44-32(33,34)35/h3-8,11-14,20,25H,2,9-10,15-19,21H2,1H3,(H,36,40)(H,37,41)
DM84WXZ	CS	CCCS(=O)(=O)N1CCN(CC1)CC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C4=C(C=CC(=C4)NC(=O)C5CC5)OC(F)(F)F
DM84WXZ	IK	MAQDQJWCSSCURR-UHFFFAOYSA-N
DM84WXZ	IU	4-[5-(cyclopropanecarbonylamino)-2-(trifluoromethoxy)phenyl]-N-[4-[(4-propylsulfonylpiperazin-1-yl)methyl]phenyl]benzamide
DM84WXZ	CA	CAS 929890-64-2
DM84WXZ	DE	Hepatitis C virus infection

DMS9I6A	ID	DMS9I6A
DMS9I6A	DN	AZD7687
DMS9I6A	HS	Phase 1
DMS9I6A	SN	AZD7687; 1166827-44-6; CHEMBL2178944; CHEMBL2178953; AZD-7687; AZD 7687; UNII-6QTJ9P2NYT; 6QTJ9P2NYT; SCHEMBL2252415; SCHEMBL5532381; SCHEMBL2252417; GTPL7827; SCHEMBL2255196; DTXSID60655297; YXFNPRHZMOGREC-SHTZXODSSA-N; 3466AH; ZINC43206395; BDBM50399684; BDBM50399710; AZD 7687;AZD-7687; ZINC101581684; AKOS030526281; CS-1026; NCGC00378858-01; HY-15497; KB-144428; W-5990; {4-[4-(6-Carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid; {trans-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid
DMS9I6A	CP	AstraZeneca
DMS9I6A	DT	Small molecular drug
DMS9I6A	PC	42636350
DMS9I6A	MW	367.4
DMS9I6A	FM	C21H25N3O3
DMS9I6A	IC	InChI=1S/C21H25N3O3/c1-12-19(24-20(21(22)27)13(2)23-12)17-9-7-16(8-10-17)15-5-3-14(4-6-15)11-18(25)26/h7-10,14-15H,3-6,11H2,1-2H3,(H2,22,27)(H,25,26)
DMS9I6A	CS	CC1=C(N=C(C(=N1)C)C(=O)N)C2=CC=C(C=C2)C3CCC(CC3)CC(=O)O
DMS9I6A	IK	YXFNPRHZMOGREC-UHFFFAOYSA-N
DMS9I6A	IU	2-[4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid
DMS9I6A	CA	CAS 1166827-44-6
DMS9I6A	DE	Diabetic complication; Obesity

DM1FW0C	ID	DM1FW0C
DM1FW0C	DN	AZD7762
DM1FW0C	HS	Phase 1
DM1FW0C	SN	AZD7762; 860352-01-8; AZD-7762; (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide; AZD 7762; UNII-5D822Y3L1H; 3-(Carbamoylamino)-5-(3-Fluorophenyl)-N-[(3s)-Piperidin-3-Yl]thiophene-2-Carboxamide; CHEMBL2041933; 5D822Y3L1H; J-502468; 5-(3-Fluorophenyl)-N-[(3s)-3-Piperidyl]-3-Ureido-Thiophene-2-Carboxamide; IAYGCINLNONXHY-LBPRGKRZSA-N; YDJ; AZD7762 hydrochloride; 5-(3-Fluorophenyl)-3-ureidothiophene-N-[(S)-piperidin-3-yl]-2-carboxamide; SCHEMBL1127614; GTPL7713; AOB1915; QCR-261; CHEBI:131156
DM1FW0C	CP	AstraZeneca
DM1FW0C	DT	Small molecular drug
DM1FW0C	PC	11152667
DM1FW0C	MW	362.4
DM1FW0C	FM	C17H19FN4O2S
DM1FW0C	IC	InChI=1S/C17H19FN4O2S/c18-11-4-1-3-10(7-11)14-8-13(22-17(19)24)15(25-14)16(23)21-12-5-2-6-20-9-12/h1,3-4,7-8,12,20H,2,5-6,9H2,(H,21,23)(H3,19,22,24)/t12-/m0/s1
DM1FW0C	CS	C1C[C@@H](CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N
DM1FW0C	IK	IAYGCINLNONXHY-LBPRGKRZSA-N
DM1FW0C	IU	3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide
DM1FW0C	CA	CAS 860352-01-8
DM1FW0C	CB	CHEBI:131156
DM1FW0C	DE	Solid tumour/cancer

DM8DMI0	ID	DM8DMI0
DM8DMI0	DN	AZD-8165
DM8DMI0	HS	Phase 1
DM8DMI0	SN	AZ-12971554; Thombin inhibitor prodrug (oral), AstraZeneca
DM8DMI0	CP	AstraZeneca plc
DM8DMI0	DT	Small molecular drug
DM8DMI0	PC	44548240
DM8DMI0	MW	513.9
DM8DMI0	FM	C23H21ClFN7O4
DM8DMI0	IC	InChI=1S/C23H21ClFN7O4/c1-2-20(33)36-21(14-3-6-17(25)7-4-14)23(35)32-19(9-10-28-32)22(34)26-12-15-11-16(24)5-8-18(15)31-13-27-29-30-31/h3-8,10-11,13,19,21H,2,9,12H2,1H3,(H,26,34)/t19-,21+/m0/s1
DM8DMI0	CS	CCC(=O)O[C@H](C1=CC=C(C=C1)F)C(=O)N2[C@@H](CC=N2)C(=O)NCC3=C(C=CC(=C3)Cl)N4C=NN=N4
DM8DMI0	IK	YUHNXUAATAMVKD-PZJWPPBQSA-N
DM8DMI0	IU	[(1R)-2-[(3S)-3-[[5-chloro-2-(tetrazol-1-yl)phenyl]methylcarbamoyl]-3,4-dihydropyrazol-2-yl]-1-(4-fluorophenyl)-2-oxoethyl] propanoate
DM8DMI0	CA	CAS 1201686-72-7
DM8DMI0	DE	Thrombosis

DMWYF1H	ID	DMWYF1H
DMWYF1H	DN	AZD8186
DMWYF1H	HS	Phase 1
DMWYF1H	SN	AZD8186; 1627494-13-6; AZD-8186; AIQ4OWD0RA; UNII-AIQ4OWD0RA; CHEMBL3408248; AZD 8186; 8-[(1R)-1-(3,5-difluoroanilino)ethyl]-N,N-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide; SCHEMBL1636956; GTPL8527; MolPort-039-137-739; EX-A1649; BDBM50070322; s7694; AKOS025404922; ZINC116734639; CS-4975; ACN-037528; SB16709; KS-0000063L; AK174916; AC-29024; HY-12330; KB-334360; B5950; AZD8186; 1627494-13-6; AZD-8186; AIQ4OWD0RA; UNII-AIQ4OWD0RA;
DMWYF1H	CP	Astrazeneca
DMWYF1H	DT	Small molecular drug
DMWYF1H	PC	52913813
DMWYF1H	MW	457.5
DMWYF1H	FM	C24H25F2N3O4
DMWYF1H	IC	InChI=1S/C24H25F2N3O4/c1-14(27-18-11-16(25)10-17(26)12-18)19-8-15(24(31)28(2)3)9-20-21(30)13-22(33-23(19)20)29-4-6-32-7-5-29/h8-14,27H,4-7H2,1-3H3/t14-/m1/s1
DMWYF1H	CS	C[C@H](C1=CC(=CC2=C1OC(=CC2=O)N3CCOCC3)C(=O)N(C)C)NC4=CC(=CC(=C4)F)F
DMWYF1H	IK	LMJFJIDLEAWOQJ-CQSZACIVSA-N
DMWYF1H	IU	8-[(1R)-1-(3,5-difluoroanilino)ethyl]-N,N-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide
DMWYF1H	CA	CAS 1627494-13-6
DMWYF1H	DE	Solid tumour/cancer

DMTD57A	ID	DMTD57A
DMTD57A	DN	AZD8329
DMTD57A	HS	Phase 1
DMTD57A	SN	AZD-8329; AZD 8329; UNII-5B38CV1212; 1048668-70-7; CHEMBL2177609; 5B38CV1212; 4-[4-(2-Adamantylcarbamoyl)-5-Tert-Butyl-Pyrazol-1-Yl]benzoic Acid; AZD8329; XWBXJBSVYVJAMZ-UHFFFAOYSA-N; SCHEMBL617351; GTPL7715; BDBM50399335; 4-(4-(Adamant-2-ylcarbamoyl)-5-tert-butylpyrazol-1-yl)benzoic acid; Benzoic acid, 4-(5-(1,1-dimethylethyl)-4-((tricyclo(3.3.1.13,7)dec-2-ylamino)carbonyl)-1H-pyrazol-1-yl)-; 4-[4-(2-adamantylcarbamoyl)-5-tertbutyl-pyrazol-1-yl]benzoic acid; 4-[4-(2-adamantylcarbamoyl)-5-tert-butylpyrazol-1-yl]benzoic ac
DMTD57A	CP	AstraZeneca
DMTD57A	DT	Small molecular drug
DMTD57A	PC	25006684
DMTD57A	MW	421.5
DMTD57A	FM	C25H31N3O3
DMTD57A	IC	InChI=1S/C25H31N3O3/c1-25(2,3)22-20(13-26-28(22)19-6-4-16(5-7-19)24(30)31)23(29)27-21-17-9-14-8-15(11-17)12-18(21)10-14/h4-7,13-15,17-18,21H,8-12H2,1-3H3,(H,27,29)(H,30,31)
DMTD57A	CS	CC(C)(C)C1=C(C=NN1C2=CC=C(C=C2)C(=O)O)C(=O)NC3C4CC5CC(C4)CC3C5
DMTD57A	IK	XWBXJBSVYVJAMZ-UHFFFAOYSA-N
DMTD57A	IU	4-[4-(2-adamantylcarbamoyl)-5-tert-butylpyrazol-1-yl]benzoic acid
DMTD57A	CA	CAS 1048668-70-7
DMTD57A	DE	Obesity; Diabetic complication

DM9X20P	ID	DM9X20P
DM9X20P	DN	AZD-8418
DM9X20P	HS	Phase 1
DM9X20P	CP	AstraZeneca plc
DM9X20P	PC	44556193
DM9X20P	MW	373.8
DM9X20P	FM	C19H20ClN3O3
DM9X20P	IC	InChI=1S/C19H20ClN3O3/c1-10(11-4-5-11)23-9-13-6-12(7-14(20)17(13)19(23)25)16-8-15(21-26-16)18(24)22(2)3/h6-8,10-11H,4-5,9H2,1-3H3/t10-/m0/s1
DM9X20P	CS	C[C@@H](C1CC1)N2CC3=C(C2=O)C(=CC(=C3)C4=CC(=NO4)C(=O)N(C)C)Cl
DM9X20P	IK	MCPBSUCAISQZQK-JTQLQIEISA-N
DM9X20P	IU	5-[7-chloro-2-[(1S)-1-cyclopropylethyl]-1-oxo-3H-isoindol-5-yl]-N,N-dimethyl-1,2-oxazole-3-carboxamide
DM9X20P	CA	CAS 1198309-73-7
DM9X20P	DE	Schizophrenia

DM3EWUX	ID	DM3EWUX
DM3EWUX	DN	AZD8701
DM3EWUX	HS	Phase 1
DM3EWUX	SN	ION736
DM3EWUX	CP	AstraZeneca; Ionis Pharmaceuticals
DM3EWUX	DT	Antisense oligonucleotide
DM3EWUX	DE	Solid tumour/cancer

DMPMDTH	ID	DMPMDTH
DMPMDTH	DN	Azd9496
DMPMDTH	HS	Phase 1
DMPMDTH	SN	DFBDRVGWBHBJNR-BBNFHIFMSA-N; 1639042-08-2; UNII-DA9P7LN909; DA9P7LN909; CHEMBL3623004; AZD-9496; (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid; (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid; SCHEMBL16266273; SCHEMBL16266275; MolPort-044-560-384; EX-A1326; s8372; BDBM50125052; ZINC219669733; AKOS030526632; AC-29011; HY-12870; Selective estrogen
DMPMDTH	CP	AstraZeneca Wilmington, DE
DMPMDTH	PC	86287635
DMPMDTH	MW	442.5
DMPMDTH	FM	C25H25F3N2O2
DMPMDTH	IC	InChI=1S/C25H25F3N2O2/c1-14-10-17-16-6-4-5-7-20(16)29-23(17)24(30(14)13-25(2,3)28)22-18(26)11-15(12-19(22)27)8-9-21(31)32/h4-9,11-12,14,24,29H,10,13H2,1-3H3,(H,31,32)/b9-8+/t14-,24-/m1/s1
DMPMDTH	CS	C[C@@H]1CC2=C([C@H](N1CC(C)(C)F)C3=C(C=C(C=C3F)/C=C/C(=O)O)F)NC4=CC=CC=C24
DMPMDTH	IK	DFBDRVGWBHBJNR-BBNFHIFMSA-N
DMPMDTH	IU	(E)-3-[3,5-difluoro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid
DMPMDTH	CA	CAS 1639042-08-2
DMPMDTH	DE	Breast cancer

DMAXHC0	ID	DMAXHC0
DMAXHC0	DN	AZD9567
DMAXHC0	HS	Phase 1
DMAXHC0	SN	ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide
DMAXHC0	CP	AstraZeneca Wilmington, DE
DMAXHC0	PC	121248172
DMAXHC0	MW	494.5
DMAXHC0	FM	C27H28F2N4O3
DMAXHC0	IC	InChI=1S/C27H28F2N4O3/c1-17(2)24(31-26(35)27(3,28)29)25(18-8-6-5-7-9-18)36-21-11-12-22-19(14-21)15-30-33(22)20-10-13-23(34)32(4)16-20/h5-17,24-25H,1-4H3,(H,31,35)/t24-,25+/m0/s1
DMAXHC0	CS	CC(C)[C@@H]([C@@H](C1=CC=CC=C1)OC2=CC3=C(C=C2)N(N=C3)C4=CN(C(=O)C=C4)C)NC(=O)C(C)(F)F
DMAXHC0	IK	ZQFNDBISEYQVRR-LOSJGSFVSA-N
DMAXHC0	IU	2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide
DMAXHC0	CA	CAS 1893415-00-3
DMAXHC0	DE	Rheumatoid arthritis

DMWYHXG	ID	DMWYHXG
DMWYHXG	DN	AZD-9819
DMWYHXG	HS	Phase 1
DMWYHXG	SN	Neutrophil elastase inhibitor (inhaled, COPD), AstraZeneca
DMWYHXG	CP	AstraZeneca plc
DMWYHXG	PC	24890141
DMWYHXG	MW	492.5
DMWYHXG	FM	C25H19F3N6O2
DMWYHXG	IC	InChI=1S/C25H19F3N6O2/c1-3-30-23(35)22-24(36)33(19-6-4-5-17(13-19)25(26,27)28)15(2)21(32-22)20-11-12-31-34(20)18-9-7-16(14-29)8-10-18/h4-13H,3H2,1-2H3,(H,30,35)
DMWYHXG	CS	CCNC(=O)C1=NC(=C(N(C1=O)C2=CC=CC(=C2)C(F)(F)F)C)C3=CC=NN3C4=CC=C(C=C4)C#N
DMWYHXG	IK	ZRJDPTREGVHMGQ-UHFFFAOYSA-N
DMWYHXG	IU	6-[2-(4-cyanophenyl)pyrazol-3-yl]-N-ethyl-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide
DMWYHXG	CA	CAS 956907-23-6
DMWYHXG	DE	Chronic obstructive pulmonary disease

DM0LKHV	ID	DM0LKHV
DM0LKHV	DN	B7-2/GM-CSF
DM0LKHV	HS	Phase 1
DM0LKHV	CP	NuVax Therapeutics
DM0LKHV	DT	Small molecular drug
DM0LKHV	PC	9862248
DM0LKHV	MW	328.4
DM0LKHV	FM	C20H24O4
DM0LKHV	IC	InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)
DM0LKHV	CS	CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O
DM0LKHV	IK	QNAZTOHXCZPOSA-UHFFFAOYSA-N
DM0LKHV	IU	2-[4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-3,5-dimethylphenoxy]acetic acid
DM0LKHV	CA	CAS 211110-63-3
DM0LKHV	CB	CHEBI:79988
DM0LKHV	DE	Dementia; Schizophrenia; Dyslipidemia; Solid tumour/cancer

DM5KU30	ID	DM5KU30
DM5KU30	DN	BAL-30072
DM5KU30	HS	Phase 1
DM5KU30	SN	UNII-LY97ZJM4QX; BAL30072; LY97ZJM4QX; CHEMBL1256967; BAL-30072; 941285-15-0; BAL 30072; SCHEMBL13318507; BDBM50327179; 4-Thiazoleacetamide, 2-amino-alpha-(((1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy)imino)-N-((3S)-2,2-dimethyl-4-oxo-1-(Sulfooxy)-3-azetidinyl)-, (alphaz)-; (S)-3-(2-(2-aminothiazol-4-yl)-2-((1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxyimino)acetamido)-2,2-dimethyl-4-oxoazetidin-1-yl hydrogen sulfate
DM5KU30	CP	Basilea Pharmaceutica International Ltd
DM5KU30	DT	Small molecular drug
DM5KU30	PC	135905457
DM5KU30	MW	518.5
DM5KU30	FM	C16H18N6O10S2
DM5KU30	IC	InChI=1S/C16H18N6O10S2/c1-16(2)12(14(26)22(16)32-34(28,29)30)19-13(25)11(8-6-33-15(17)18-8)20-31-5-7-3-9(23)10(24)4-21(7)27/h3-4,6,12,24,27H,5H2,1-2H3,(H2,17,18)(H,19,25)(H,28,29,30)/b20-11+/t12-/m1/s1
DM5KU30	CS	CC1([C@@H](C(=O)N1OS(=O)(=O)O)NC(=O)/C(=N/OCC2=CC(=O)C(=CN2O)O)/C3=CSC(=N3)N)C
DM5KU30	IK	KLFSEZJCLYBFKQ-ZICWZVMQSA-N
DM5KU30	IU	[(3S)-3-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1,5-dihydroxy-4-oxopyridin-2-yl)methoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate
DM5KU30	DE	Bacterial infection

DMAJPOX	ID	DMAJPOX
DMAJPOX	DN	Balapiravir
DMAJPOX	HS	Phase 1
DMAJPOX	SN	Balapiravir hydrochloride; HCV NS5B polymerase inhibitor, Roche; RO4588161-001; RNA polymerase inhibitor (HCV infection), Roche; RNA polymerase inhibitor (hepatitis C infection), Roche; R-1479 prodrug (HCV infection), Roche
DMAJPOX	CP	Roche
DMAJPOX	DT	Small molecular drug
DMAJPOX	PC	11691726
DMAJPOX	MW	494.5
DMAJPOX	FM	C21H30N6O8
DMAJPOX	IC	InChI=1S/C21H30N6O8/c1-10(2)17(28)32-9-21(25-26-23)15(34-19(30)12(5)6)14(33-18(29)11(3)4)16(35-21)27-8-7-13(22)24-20(27)31/h7-8,10-12,14-16H,9H2,1-6H3,(H2,22,24,31)/t14-,15+,16-,21-/m1/s1
DMAJPOX	CS	CC(C)C(=O)OC[C@@]1([C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)OC(=O)C(C)C)OC(=O)C(C)C)N=[N+]=[N-]
DMAJPOX	IK	VKXWOLCNTHXCLF-DXEZIKHYSA-N
DMAJPOX	IU	[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
DMAJPOX	CA	CAS 690270-29-2
DMAJPOX	DE	Hepatitis C virus infection

DM3415L	ID	DM3415L
DM3415L	DN	BAX-499
DM3415L	HS	Phase 1
DM3415L	SN	ARC-19499; Tissue factor pathway inhibitor (hemophilia A/hemophilia B), Archemix
DM3415L	CP	Archemix Corp
DM3415L	DE	Factor IX deficiency

DMLRGX1	ID	DMLRGX1
DMLRGX1	DN	BAY 1082439
DMLRGX1	HS	Phase 1
DMLRGX1	CP	Bayer HealthCare Pharmaceuticals
DMLRGX1	DT	Small molecular drug
DMLRGX1	PC	136336430
DMLRGX1	MW	494.5
DMLRGX1	FM	C25H30N6O5
DMLRGX1	IC	InChI=1S/C25H30N6O5/c1-16-18(4-3-7-26-16)24(33)29-25-28-21-19(23-27-8-9-31(23)25)5-6-20(22(21)34-2)36-15-17(32)14-30-10-12-35-13-11-30/h3-7,17,27,32H,8-15H2,1-2H3/t17-/m0/s1
DMLRGX1	CS	CC1=C(C=CC=N1)C(=O)N=C2N=C3C(=C4N2CCN4)C=CC(=C3OC)OC[C@H](CN5CCOCC5)O
DMLRGX1	IK	QJTLLKKDFGPDPF-KRWDZBQOSA-N
DMLRGX1	IU	N-[8-[(2S)-2-hydroxy-3-morpholin-4-ylpropoxy]-7-methoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]-2-methylpyridine-3-carboxamide
DMLRGX1	DE	Solid tumour/cancer

DMYPU8V	ID	DMYPU8V
DMYPU8V	DN	BAY 1238097
DMYPU8V	HS	Phase 1
DMYPU8V	CP	Bayer
DMYPU8V	DT	Small molecular drug
DMYPU8V	DE	Neoplasm

DMF9ALP	ID	DMF9ALP
DMF9ALP	DN	BAY 1817080
DMF9ALP	HS	Phase 1
DMF9ALP	SN	Eliapixant
DMF9ALP	CP	Bayer
DMF9ALP	DT	Small molecular drug
DMF9ALP	DE	Endometriosis; Cough

DMQIKZG	ID	DMQIKZG
DMQIKZG	DN	BAY 1834942
DMQIKZG	HS	Phase 1
DMQIKZG	SN	Tinurilimab
DMQIKZG	CP	Bayer
DMQIKZG	DT	Antibody
DMQIKZG	DE	Solid tumour/cancer

DMNVPI1	ID	DMNVPI1
DMNVPI1	DN	BAY 1905254
DMNVPI1	HS	Phase 1
DMNVPI1	CP	Bayer
DMNVPI1	DT	Antibody
DMNVPI1	DE	Solid tumour/cancer

DMD9N12	ID	DMD9N12
DMD9N12	DN	BAY 2416964
DMD9N12	HS	Phase 1
DMD9N12	SN	2242464-44-2; BAY2416964; SCHEMBL20471217; BCP33103; EX-A4271; MFCD32693912; NSC825713; s8995; NSC-825713; BAY-2416964; HY-135829; CS-0114330; BAY-2416964;BAY2416964; ClC1=CC=C(C=C1)C=1C=C(C(N(N=1)C=1C=NN(C=1)C)=O)C(=O)N[C@H](CO)C; (S)-6-(4-Chlorophenyl)-N-(1-hydroxypropan-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide
DMD9N12	CP	Bayer
DMD9N12	DT	Small molecular drug
DMD9N12	PC	135303769
DMD9N12	MW	387.8
DMD9N12	FM	C18H18ClN5O3
DMD9N12	IC	InChI=1S/C18H18ClN5O3/c1-11(10-25)21-17(26)15-7-16(12-3-5-13(19)6-4-12)22-24(18(15)27)14-8-20-23(2)9-14/h3-9,11,25H,10H2,1-2H3,(H,21,26)/t11-/m0/s1
DMD9N12	CS	C[C@@H](CO)NC(=O)C1=CC(=NN(C1=O)C2=CN(N=C2)C)C3=CC=C(C=C3)Cl
DMD9N12	IK	YAGSZKAJPHGVOV-NSHDSACASA-N
DMD9N12	IU	6-(4-chlorophenyl)-N-[(2S)-1-hydroxypropan-2-yl]-2-(1-methylpyrazol-4-yl)-3-oxopyridazine-4-carboxamide
DMD9N12	DE	Solid tumour/cancer

DM98EP5	ID	DM98EP5
DM98EP5	DN	BAY 2701439
DM98EP5	HS	Phase 1
DM98EP5	SN	HER2-TTC
DM98EP5	CP	Bayer
DM98EP5	DT	Antibody
DM98EP5	DE	Solid tumour/cancer

DM14XQN	ID	DM14XQN
DM14XQN	DN	BAY 79-4620
DM14XQN	HS	Phase 1
DM14XQN	CP	Bayer HealthCare Pharmaceuticals
DM14XQN	DT	Antibody
DM14XQN	DE	Solid tumour/cancer

DM31RQS	ID	DM31RQS
DM31RQS	DN	BAY 86-8050
DM31RQS	HS	Phase 1
DM31RQS	CP	Bayer HealthCare Pharmaceuticals
DM31RQS	DE	Heart failure

DMCQEL6	ID	DMCQEL6
DMCQEL6	DN	BAY 94-9343
DMCQEL6	HS	Phase 1
DMCQEL6	CP	Bayer HealthCare Pharmaceuticals
DMCQEL6	DE	Solid tumour/cancer

DM8U3Q2	ID	DM8U3Q2
DM8U3Q2	DN	BAY-1075553
DM8U3Q2	HS	Phase 1
DM8U3Q2	CP	Bayer AG
DM8U3Q2	DE	Prostate cancer

DMTB4R8	ID	DMTB4R8
DMTB4R8	DN	BAY1125976
DMTB4R8	HS	Phase 1
DMTB4R8	CP	Bayer healthcare pharmaceuticals
DMTB4R8	PC	70817911
DMTB4R8	MW	383.4
DMTB4R8	FM	C23H21N5O
DMTB4R8	IC	InChI=1S/C23H21N5O/c24-22(29)18-11-12-19-26-20(21(28(19)27-18)16-5-2-1-3-6-16)15-7-9-17(10-8-15)23(25)13-4-14-23/h1-3,5-12H,4,13-14,25H2,(H2,24,29)
DMTB4R8	CS	C1CC(C1)(C2=CC=C(C=C2)C3=C(N4C(=N3)C=CC(=N4)C(=O)N)C5=CC=CC=C5)N
DMTB4R8	IK	JBGYKRAZYDNCNV-UHFFFAOYSA-N
DMTB4R8	IU	2-[4-(1-aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide
DMTB4R8	CA	CAS 1402608-02-9
DMTB4R8	DE	Solid tumour/cancer

DMVPAZ7	ID	DMVPAZ7
DMVPAZ7	DN	BAY1143572
DMVPAZ7	HS	Phase 1
DMVPAZ7	CP	Bayer healthcare pharmaceuticals
DMVPAZ7	DE	Solid tumour/cancer

DMUK6YM	ID	DMUK6YM
DMUK6YM	DN	BAY1161909
DMUK6YM	HS	Phase 1
DMUK6YM	CP	Bayer healthcare pharmaceuticals
DMUK6YM	PC	71599640
DMUK6YM	MW	559.6
DMUK6YM	FM	C29H26FN5O4S
DMUK6YM	IC	InChI=1S/C29H26FN5O4S/c1-18(19-4-9-22(30)10-5-19)28(36)31-23-11-6-20(7-12-23)21-8-15-27-33-29(34-35(27)17-21)32-25-14-13-24(40(3,37)38)16-26(25)39-2/h4-18H,1-3H3,(H,31,36)(H,32,34)/t18-/m1/s1
DMUK6YM	CS	C[C@H](C1=CC=C(C=C1)F)C(=O)NC2=CC=C(C=C2)C3=CN4C(=NC(=N4)NC5=C(C=C(C=C5)S(=O)(=O)C)OC)C=C3
DMUK6YM	IK	NRJKIOCCERLIDG-GOSISDBHSA-N
DMUK6YM	IU	(2R)-2-(4-fluorophenyl)-N-[4-[2-(2-methoxy-4-methylsulfonylanilino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl]propanamide
DMUK6YM	CA	CAS 1443763-60-7
DMUK6YM	DE	Solid tumour/cancer

DM7L91K	ID	DM7L91K
DM7L91K	DN	BAY1179470
DM7L91K	HS	Phase 1
DM7L91K	CP	Bayer healthcare pharmaceuticals
DM7L91K	DE	Solid tumour/cancer

DMCJNRL	ID	DMCJNRL
DMCJNRL	DN	BAY1251152
DMCJNRL	HS	Phase 1
DMCJNRL	SN	YZCUMZWULWOUMD-UHFFFAOYSA-N; SCHEMBL15720569; (rac)-5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine; 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine
DMCJNRL	CP	Bayer Pharmaceuticals Whippany, NJ
DMCJNRL	PC	74767009
DMCJNRL	MW	404.4
DMCJNRL	FM	C19H18F2N4O2S
DMCJNRL	IC	InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)
DMCJNRL	CS	COC1=C(C=CC(=C1)F)C2=CC(=NC=C2F)NC3=NC=CC(=C3)CS(=N)(=O)C
DMCJNRL	IK	YZCUMZWULWOUMD-UHFFFAOYSA-N
DMCJNRL	IU	5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine
DMCJNRL	CA	CAS 1610358-59-2
DMCJNRL	DE	Haematological malignancy

DMPNBJ1	ID	DMPNBJ1
DMPNBJ1	DN	BAY1436032
DMPNBJ1	HS	Phase 1
DMPNBJ1	SN	RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid
DMPNBJ1	CP	Bayer Pharmaceuticals Whippany, NJ
DMPNBJ1	PC	118310260
DMPNBJ1	MW	489.5
DMPNBJ1	FM	C26H30F3N3O3
DMPNBJ1	IC	InChI=1S/C26H30F3N3O3/c1-16-12-19(15-25(2,3)14-16)32-22-10-4-17(5-11-23(33)34)13-21(22)31-24(32)30-18-6-8-20(9-7-18)35-26(27,28)29/h4,6-10,13,16,19H,5,11-12,14-15H2,1-3H3,(H,30,31)(H,33,34)/t16-,19+/m0/s1
DMPNBJ1	CS	C[C@H]1C[C@H](CC(C1)(C)C)N2C3=C(C=C(C=C3)CCC(=O)O)N=C2NC4=CC=C(C=C4)OC(F)(F)F
DMPNBJ1	IK	RNMAUIMMNAHKQR-QFBILLFUSA-N
DMPNBJ1	IU	3-[2-[4-(trifluoromethoxy)anilino]-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]benzimidazol-5-yl]propanoic acid
DMPNBJ1	DE	Acute myeloid leukaemia; Solid tumour/cancer

DMNL5G7	ID	DMNL5G7
DMNL5G7	DN	BAY-1817080
DMNL5G7	HS	Phase 1
DMNL5G7	CP	Bayer
DMNL5G7	DE	Endometriosis

DM8V62T	ID	DM8V62T
DM8V62T	DN	BAY1834845
DM8V62T	HS	Phase 1
DM8V62T	CP	Bayer Pharmaceuticals Whippany, NJ
DM8V62T	DE	Psoriasis vulgaris

DML781M	ID	DML781M
DML781M	DN	BAY1895344
DML781M	HS	Phase 1
DML781M	SN	YBXRSCXGRPSTMW-CYBMUJFWSA-N; BAY-1895344; 1876467-74-1; BAY 1895344; (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morpholine; UNII-7N13IK9LNH; 7N13IK9LNH; SCHEMBL17501318; MolPort-044-756-215; EX-A1662; AKOS032953592; ACN-051236; AC-30337; AK688481; (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine
DML781M	CP	Bayer Pharmaceuticals Whippany, NJ
DML781M	PC	118869362
DML781M	MW	375.4
DML781M	FM	C20H21N7O
DML781M	IC	InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)/t13-/m1/s1
DML781M	CS	C[C@@H]1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C
DML781M	IK	YBXRSCXGRPSTMW-CYBMUJFWSA-N
DML781M	IU	(3R)-3-methyl-4-[4-(2-methylpyrazol-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine
DML781M	CA	CAS 1876467-74-1
DML781M	DE	Lymphoma; Solid tumour/cancer

DMRL6W5	ID	DMRL6W5
DMRL6W5	DN	BAY2402234
DMRL6W5	HS	Phase 1
DMRL6W5	SN	KNVJMHHAXCPZHF-JTQLQIEISA-N; BAY-2402234; SCHEMBL20108031; HY-112645; CS-0058850
DMRL6W5	CP	Bayer Pharmaceuticals Whippany, NJ
DMRL6W5	PC	134470179
DMRL6W5	MW	520.799
DMRL6W5	FM	C21H18ClF5N4O4
DMRL6W5	IC	InChI=1S/C21H18ClF5N4O4/c1-3-30-17(9-32)29-31(20(30)34)15-8-16(35-10(2)21(25,26)27)11(7-14(15)24)19(33)28-18-12(22)5-4-6-13(18)23/h4-8,10,32H,3,9H2,1-2H3,(H,28,33)/t10-/m0/s1
DMRL6W5	CS	CCN1C(=NN(C1=O)C2=C(C=C(C(=C2)O[C@@H](C)C(F)(F)F)C(=O)NC3=C(C=CC=C3Cl)F)F)CO
DMRL6W5	IK	KNVJMHHAXCPZHF-JTQLQIEISA-N
DMRL6W5	IU	N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-1,2,4-triazol-1-yl]-5-fluoro-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxybenzamide
DMRL6W5	CA	CAS 2225819-06-5
DMRL6W5	DE	Myeloid leukaemia

DMXIDWE	ID	DMXIDWE
DMXIDWE	DN	BAY-60-5521
DMXIDWE	HS	Phase 1
DMXIDWE	SN	CETP inhibitors (dyslipidemia), Bayer; Cholesteryl ester transfer protein inhibitors (dyslipidemia), Bayer
DMXIDWE	CP	Bayer AG
DMXIDWE	PC	11691871
DMXIDWE	MW	503.6
DMXIDWE	FM	C30H37F4NO
DMXIDWE	IC	InChI=1S/C30H37F4NO/c1-29(2)16-22-25(23(36)17-29)24(18-8-4-3-5-9-18)26(28(35-22)20-10-6-7-11-20)27(31)19-12-14-21(15-13-19)30(32,33)34/h12-15,18,20,23,27,36H,3-11,16-17H2,1-2H3/t23-,27-/m0/s1
DMXIDWE	CS	CC1(C[C@@H](C2=C(C1)N=C(C(=C2C3CCCCC3)[C@H](C4=CC=C(C=C4)C(F)(F)F)F)C5CCCC5)O)C
DMXIDWE	IK	BHKIPHICFOJGLD-HOFKKMOUSA-N
DMXIDWE	IU	(5S)-4-cyclohexyl-2-cyclopentyl-3-[(S)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5H-quinolin-5-ol
DMXIDWE	CA	CAS 893409-49-9
DMXIDWE	DE	Arteriosclerosis

DMOUVE7	ID	DMOUVE7
DMOUVE7	DN	BAY-85-8102
DMOUVE7	HS	Phase 1
DMOUVE7	SN	Benzodiazepine receptor agonist (brain disease imaging), University of Sydney; DPA-714-[18F]; F-18 DPA-714; Fluorine-18-DPA-714; Translocator protein-specific ligand (brain disease imaging), University of Sydney; 18F-DPA-714
DMOUVE7	CP	University of Sydney
DMOUVE7	DE	Brain disease

DM195JA	ID	DM195JA
DM195JA	DN	BAY-86-7548
DM195JA	HS	Phase 1
DM195JA	SN	Bombesin-68Ga-labeled tracer (PET/CT cancer imaging), Bayer
DM195JA	CP	Bayer AG
DM195JA	DE	Solid tumour/cancer

DMSBWAQ	ID	DMSBWAQ
DMSBWAQ	DN	Bb21217
DMSBWAQ	HS	Phase 1
DMSBWAQ	CP	bluebird bio
DMSBWAQ	DT	CAR T Cell Therapy
DMSBWAQ	DE	Multiple myeloma

DMTG9WM	ID	DMTG9WM
DMTG9WM	DN	BBI-6000
DMTG9WM	HS	Phase 1
DMTG9WM	CP	Brickell Biotech Boulder, CO
DMTG9WM	DE	Psoriasis vulgaris

DM572ZL	ID	DM572ZL
DM572ZL	DN	BBP-398
DM572ZL	HS	Phase 1
DM572ZL	CP	NaVire Pharma
DM572ZL	DT	Small molecular drug
DM572ZL	DE	Solid tumour/cancer

DMGFABM	ID	DMGFABM
DMGFABM	DN	BC-3205
DMGFABM	HS	Phase 1
DMGFABM	SN	BC-3205 (oral); BC-3205 (oral), Nabriva; Pleuromutilin (oral, respiratory infection), Nabriva
DMGFABM	CP	Nabriva Therapeutics AG
DMGFABM	DT	Small molecular drug
DMGFABM	PC	44205184
DMGFABM	MW	576.8
DMGFABM	FM	C32H52N2O5S
DMGFABM	IC	InChI=1S/C32H52N2O5S/c1-8-30(6)16-24(31(7)20(4)11-13-32(21(5)28(30)37)14-12-23(35)27(31)32)39-25(36)18-40-22-10-9-15-34(17-22)29(38)26(33)19(2)3/h8,19-22,24,26-28,37H,1,9-18,33H2,2-7H3/t20-,21+,22?,24-,26-,27+,28+,30-,31+,32+/m1/s1
DMGFABM	CS	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4CCCN(C4)C(=O)[C@@H](C(C)C)N)C
DMGFABM	IK	AFYOQRIZFPJUAR-UBTCORFISA-N
DMGFABM	IU	[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[1-[(2R)-2-amino-3-methylbutanoyl]piperidin-3-yl]sulfanylacetate
DMGFABM	DE	Respiratory tract infection

DMM0VBU	ID	DMM0VBU
DMM0VBU	DN	BCA101
DMM0VBU	HS	Phase 1
DMM0VBU	CP	Bicara Therapeutics
DMM0VBU	DT	Antibody
DMM0VBU	DE	Solid tumour/cancer

DMZYCWT	ID	DMZYCWT
DMZYCWT	DN	BCI-632
DMZYCWT	HS	Phase 1
DMZYCWT	SN	LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,
DMZYCWT	CP	BrainCells
DMZYCWT	DT	Small molecular drug
DMZYCWT	PC	9886034
DMZYCWT	MW	378.2
DMZYCWT	FM	C15H14Cl2FNO5
DMZYCWT	IC	InChI=1S/C15H14Cl2FNO5/c16-8-2-1-6(3-9(8)17)5-24-10-4-7-11(14(7,18)12(20)21)15(10,19)13(22)23/h1-3,7,10-11H,4-5,19H2,(H,20,21)(H,22,23)/t7-,10-,11+,14-,15+/m1/s1
DMZYCWT	CS	C1[C@@H]2[C@@H]([C@]2(C(=O)O)F)[C@@]([C@@H]1OCC3=CC(=C(C=C3)Cl)Cl)(C(=O)O)N
DMZYCWT	IK	LFAGGDAZZKUVKO-JAGWWQSPSA-N
DMZYCWT	IU	(1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DMZYCWT	CA	CAS 569686-87-9
DMZYCWT	DE	Major depressive disorder; Alzheimer disease

DMRXDN3	ID	DMRXDN3
DMRXDN3	DN	BCI-838
DMRXDN3	HS	Phase 1
DMRXDN3	CP	BrainCells
DMRXDN3	DE	Major depressive disorder; Alzheimer disease

DMQ76B4	ID	DMQ76B4
DMQ76B4	DN	BCL11a shRNA
DMQ76B4	HS	Phase 1
DMQ76B4	CP	Boston Children's Hospital; bluebird bio
DMQ76B4	DT	Short hairpin RNA
DMQ76B4	DE	Sickle-cell disorder

DMZ51EX	ID	DMZ51EX
DMZ51EX	DN	BCL201
DMZ51EX	HS	Phase 1
DMZ51EX	CP	Novartis Oncology East Hanover, NJ
DMZ51EX	DE	Follicular lymphoma; Mantle cell lymphoma

DMJ37LH	ID	DMJ37LH
DMJ37LH	DN	BCMA CART
DMJ37LH	HS	Phase 1
DMJ37LH	CP	University of Pennsylvania
DMJ37LH	DT	CAR T Cell Therapy
DMJ37LH	DE	Multiple myeloma

DM2V4EO	ID	DM2V4EO
DM2V4EO	DN	BCMA CART and huCART19
DM2V4EO	HS	Phase 1
DM2V4EO	CP	University of Pennsylvania
DM2V4EO	DT	CAR T Cell Therapy (Dual specific)
DM2V4EO	DE	Multiple myeloma

DMJ4W5V	ID	DMJ4W5V
DMJ4W5V	DN	BCMA CAR-T Cells
DMJ4W5V	HS	Phase 1
DMJ4W5V	CP	The Pregene (ShenZhen) Biotechnology Company, Ltd.
DMJ4W5V	DT	CAR T Cell Therapy
DMJ4W5V	DE	Multiple myeloma

DMZDLHV	ID	DMZDLHV
DMZDLHV	DN	BCMA nanobody CAR-T cells
DMZDLHV	HS	Phase 1
DMZDLHV	CP	Henan Cancer Hospital
DMZDLHV	DT	CAR T Cell Therapy
DMZDLHV	DE	Multiple myeloma

DMZ13WQ	ID	DMZ13WQ
DMZ13WQ	DN	BCMA-CD19 cCAR
DMZ13WQ	HS	Phase 1
DMZ13WQ	CP	iCell Gene Therapeutics
DMZ13WQ	DT	CAR T Cell Therapy
DMZ13WQ	DE	Multiple myeloma

DMEPHMR	ID	DMEPHMR
DMEPHMR	DN	BCMA-CS1 cCAR
DMEPHMR	HS	Phase 1
DMEPHMR	CP	iCell Gene Therapeutics
DMEPHMR	DT	CAR T Cell Therapy
DMEPHMR	DE	Multiple myeloma

DMW0ZDF	ID	DMW0ZDF
DMW0ZDF	DN	BCMA-specific CAR-expressing T Lymphocytes
DMW0ZDF	HS	Phase 1
DMW0ZDF	CP	Fred Hutchinson Cancer Research Center
DMW0ZDF	DT	CAR T Cell Therapy
DMW0ZDF	DE	Plasma cell myeloma

DMGAP53	ID	DMGAP53
DMGAP53	DN	BDD-10103
DMGAP53	HS	Phase 1
DMGAP53	CP	Berolina Innovative Research and Development Services Pharma AG
DMGAP53	DE	Pain

DMUR49N	ID	DMUR49N
DMUR49N	DN	Begacestat
DMUR49N	HS	Phase 1
DMUR49N	SN	GSI-953; PF-05212362; PF-5212362; WAY-201953; WAY-210953
DMUR49N	CP	Wyeth
DMUR49N	DT	Small molecular drug
DMUR49N	PC	11269353
DMUR49N	MW	391.7
DMUR49N	FM	C9H8ClF6NO3S2
DMUR49N	IC	InChI=1S/C9H8ClF6NO3S2/c10-5-1-2-6(21-5)22(19,20)17-4(3-18)7(8(11,12)13)9(14,15)16/h1-2,4,7,17-18H,3H2/t4-/m1/s1
DMUR49N	CS	C1=C(SC(=C1)Cl)S(=O)(=O)N[C@H](CO)C(C(F)(F)F)C(F)(F)F
DMUR49N	IK	PSXOKXJMVRSARX-SCSAIBSYSA-N
DMUR49N	IU	5-chloro-N-[(2S)-4,4,4-trifluoro-1-hydroxy-3-(trifluoromethyl)butan-2-yl]thiophene-2-sulfonamide
DMUR49N	CA	CAS 769169-27-9
DMUR49N	DE	Alzheimer disease

DM9R0VA	ID	DM9R0VA
DM9R0VA	DN	Belerofon
DM9R0VA	HS	Phase 1
DM9R0VA	SN	IFNa
DM9R0VA	CP	Nautilus Biotech
DM9R0VA	DE	Hepatitis C virus infection

DM0ZNAR	ID	DM0ZNAR
DM0ZNAR	DN	Belvarafenib
DM0ZNAR	HS	Phase 1
DM0ZNAR	SN	1446113-23-0; UNII-31M3WLJ3KG; 31M3WLJ3KG; 4-Amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-{1-[(3-chloro-2-fluorophenyl)amino]-6-methylisoquinolin-5-yl}thieno[3,2-d]pyrimidine-7-carboxamide; CHEMBL3977543; SCHEMBL15066408; BDBM185591; BCP31233; EX-A3061; s8853; HM95573; BS-15746; HY-109080; CS-0039257; Belvarafenib(GDC5573, HM95573, RG6185); US9156852, 116; 4-Amino-N-(1-(3-chloro-2-fluorophenylamino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide; V1Y
DM0ZNAR	CP	Hanmi Pharmaceutical
DM0ZNAR	DT	Small molecular drug
DM0ZNAR	PC	89655386
DM0ZNAR	MW	478.9
DM0ZNAR	FM	C23H16ClFN6OS
DM0ZNAR	IC	InChI=1S/C23H16ClFN6OS/c1-11-5-6-13-12(7-8-27-22(13)30-16-4-2-3-15(24)17(16)25)18(11)31-23(32)14-9-33-20-19(14)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)
DM0ZNAR	CS	CC1=C(C2=C(C=C1)C(=NC=C2)NC3=C(C(=CC=C3)Cl)F)NC(=O)C4=CSC5=C4N=CN=C5N
DM0ZNAR	IK	KVCQTKNUUQOELD-UHFFFAOYSA-N
DM0ZNAR	IU	4-amino-N-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide
DM0ZNAR	CA	CAS 1446113-23-0
DM0ZNAR	DE	Solid tumour/cancer

DMN7J43	ID	DMN7J43
DMN7J43	DN	Benzo(a)pyrene
DMN7J43	HS	Phase 1
DMN7J43	SN	benzo[a]pyrene; 3,4-Benzopyrene; benzo[pqr]tetraphene; BENZO(A)PYRENE; 3,4-Benzpyrene; Benzpyrene; benzo[def]chrysene; 6,7-Benzopyrene; Benz[a]pyrene; 3,4-BP; 3,4-Benz[a]pyrene; 3,4-Benzopirene; 3,4-Benzpyren; Benzo[d,e,f]chrysene; Benz(a)pyrene; (B(a)P); B(a)P; BP; 3,4 Benzpyrene; RCRA waste number U022; Benzo(d,e,f)chrysene; 3,4-Benz(a)pyrene; NSC 21914; 3,4-Benzo(a)pyrene; B[a]p; 3,4-Benzpyren [German]; CCRIS 76; Benzo[A]-Pyrene; Benzo(def)chrysene; 3,4-benzylpyrene; 3,4-Benzopirene [Italian]
DMN7J43	PC	2336
DMN7J43	MW	252.3
DMN7J43	FM	C20H12
DMN7J43	IC	InChI=1S/C20H12/c1-2-7-17-15(4-1)12-16-9-8-13-5-3-6-14-10-11-18(17)20(16)19(13)14/h1-12H
DMN7J43	CS	C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3
DMN7J43	IK	FMMWHPNWAFZXNH-UHFFFAOYSA-N
DMN7J43	IU	benzo[a]pyrene
DMN7J43	CA	CAS 50-32-8
DMN7J43	CB	CHEBI:29865
DMN7J43	DE	Environmental exposure

DMMW4HV	ID	DMMW4HV
DMMW4HV	DN	Benzoylphenylurea
DMMW4HV	HS	Phase 1
DMMW4HV	SN	benzoylphenylurea; SCHEMBL83109
DMMW4HV	PC	19851629
DMMW4HV	MW	240.26
DMMW4HV	FM	C14H12N2O2
DMMW4HV	IC	InChI=1S/C14H12N2O2/c15-14(18)16(12-9-5-2-6-10-12)13(17)11-7-3-1-4-8-11/h1-10H,(H2,15,18)
DMMW4HV	CS	C1=CC=C(C=C1)C(=O)N(C2=CC=CC=C2)C(=O)N
DMMW4HV	IK	XYFMGGWVGACNEC-UHFFFAOYSA-N
DMMW4HV	IU	N-carbamoyl-N-phenylbenzamide
DMMW4HV	DE	Solid tumours

DMBUI2A	ID	DMBUI2A
DMBUI2A	DN	BETULINIC ACID
DMBUI2A	HS	Phase 1
DMBUI2A	SN	betulinic acid; 472-15-1; Mairin; Betulic acid; NSC 113090; CCRIS 6748; 3-Hydroxylup-20(29)-en-28-oic acid; UNII-4G6A18707N; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; EINECS 207-448-8; NSC677578; als-357; NSC 677578; CHEMBL269277; CHEBI:3087; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; 4G6A18707N; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; AK-72848; Lupatic Acid; SMR000445624
DMBUI2A	DT	Small molecular drug
DMBUI2A	PC	64971
DMBUI2A	MW	456.7
DMBUI2A	FM	C30H48O3
DMBUI2A	IC	InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
DMBUI2A	CS	CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C(=O)O
DMBUI2A	IK	QGJZLNKBHJESQX-FZFNOLFKSA-N
DMBUI2A	IU	(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
DMBUI2A	CA	CAS 472-15-1
DMBUI2A	CB	CHEBI:3087
DMBUI2A	DE	Melanoma

DM7RPSG	ID	DM7RPSG
DM7RPSG	DN	BF-1
DM7RPSG	HS	Phase 1
DM7RPSG	SN	BF-1; 518980-66-0; Piperidine, 4-(6-ethoxy-1-methoxy-9H-thioxanthen-9-ylidene)-1-methyl-; SCHEMBL4475418; GTPL8424; CTK1E4820; DTXSID70437783; SB18757; L022232
DM7RPSG	CP	Biofrontera
DM7RPSG	DT	Small molecular drug
DM7RPSG	PC	10287037
DM7RPSG	MW	367.5
DM7RPSG	FM	C22H25NO2S
DM7RPSG	IC	InChI=1S/C22H25NO2S/c1-4-25-16-8-9-17-20(14-16)26-19-7-5-6-18(24-3)22(19)21(17)15-10-12-23(2)13-11-15/h5-9,14H,4,10-13H2,1-3H3
DM7RPSG	CS	CCOC1=CC2=C(C=C1)C(=C3CCN(CC3)C)C4=C(C=CC=C4S2)OC
DM7RPSG	IK	ANZVBVKYXOGOQC-UHFFFAOYSA-N
DM7RPSG	IU	4-(6-ethoxy-1-methoxythioxanthen-9-ylidene)-1-methylpiperidine
DM7RPSG	CA	CAS 518980-66-0
DM7RPSG	DE	Cluster headache; Migraine

DMHELFU	ID	DMHELFU
DMHELFU	DN	BF-389
DMHELFU	HS	Phase 1
DMHELFU	SN	Biofor 389; BF-389; UNII-MGJ3XBS5KD; MGJ3XBS5KD; BF 389; 127245-22-1; 4-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-methyl-5,6-dihydro-2H-1,2-oxazin-3(4H)-one; Dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one; 2H-1,2-Oxazin-3(4H)-one, dihydro-4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-2-methyl-; 2H-1,2-Oxazin-3(4H)-one, 4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)dihydro-2-methyl-; Biofor-389; AC1O5RBB; SCHEMBL8291651; LS-100029
DMHELFU	CP	Biofor Inc
DMHELFU	DT	Small molecular drug
DMHELFU	PC	6439259
DMHELFU	MW	331.4
DMHELFU	FM	C20H29NO3
DMHELFU	IC	InChI=1S/C20H29NO3/c1-19(2,3)15-11-13(12-16(17(15)22)20(4,5)6)10-14-8-9-24-21(7)18(14)23/h10-12,22H,8-9H2,1-7H3/b14-10+
DMHELFU	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C/2\\CCON(C2=O)C
DMHELFU	IK	BWRYNNCGEDOTRW-GXDHUFHOSA-N
DMHELFU	IU	(4E)-4-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-2-methyloxazinan-3-one
DMHELFU	CA	CAS 127245-22-1
DMHELFU	DE	Rheumatoid arthritis

DM84LXE	ID	DM84LXE
DM84LXE	DN	BGB-10188
DM84LXE	HS	Phase 1
DM84LXE	DT	Small molecular drug
DM84LXE	DE	Solid tumour/cancer; B-cell lymphoma

DM7QTIC	ID	DM7QTIC
DM7QTIC	DN	BGB-11417
DM7QTIC	HS	Phase 1
DM7QTIC	CP	BeiGene
DM7QTIC	DT	Small molecular drug
DM7QTIC	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DMUP6M5	ID	DMUP6M5
DMUP6M5	DN	BGB-15025
DMUP6M5	HS	Phase 1
DMUP6M5	CP	BeiGene
DMUP6M5	DT	Small molecular drug
DMUP6M5	DE	Solid tumour/cancer

DMIF9DZ	ID	DMIF9DZ
DMIF9DZ	DN	BGB-3113
DMIF9DZ	HS	Phase 1
DMIF9DZ	CP	BeiGene Cambridge, MA
DMIF9DZ	DE	B-cell lymphoma

DMQMEDH	ID	DMQMEDH
DMQMEDH	DN	BGB-A445
DMQMEDH	HS	Phase 1
DMQMEDH	CP	BeiGene
DMQMEDH	DT	Antibody
DMQMEDH	DE	Solid tumour/cancer

DMED4AJ	ID	DMED4AJ
DMED4AJ	DN	BGC-20-1259
DMED4AJ	HS	Phase 1
DMED4AJ	SN	RS-1259
DMED4AJ	CP	Sankyo Co Ltd
DMED4AJ	DT	Small molecular drug
DMED4AJ	PC	6918634
DMED4AJ	MW	862.9
DMED4AJ	FM	C42H50N6O14
DMED4AJ	IC	InChI=1S/2C19H23N3O5.C4H4O4/c2*1-20-18(12-13-26-16-10-6-15(7-11-16)22(24)25)14-4-8-17(9-5-14)27-19(23)21(2)3;5-3(6)1-2-4(7)8/h2*4-11,18,20H,12-13H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*18-;/m00./s1
DMED4AJ	CS	CN[C@@H](CCOC1=CC=C(C=C1)[N+](=O)[O-])C2=CC=C(C=C2)OC(=O)N(C)C.CN[C@@H](CCOC1=CC=C(C=C1)[N+](=O)[O-])C2=CC=C(C=C2)OC(=O)N(C)C.C(=C/C(=O)O)\\C(=O)O
DMED4AJ	IK	JOSUCKKYZJUIPW-SOBORHNCSA-N
DMED4AJ	IU	(E)-but-2-enedioic acid;[4-[(1S)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl] N,N-dimethylcarbamate
DMED4AJ	DE	Parkinson disease

DMM2EZW	ID	DMM2EZW
DMM2EZW	DN	BHV-5000
DMM2EZW	HS	Phase 1
DMM2EZW	CP	Biohaven Pharmaceuticals New Haven, CT
DMM2EZW	DE	Rett syndrome

DMUJ1EL	ID	DMUJ1EL
DMUJ1EL	DN	BI 113823
DMUJ1EL	HS	Phase 1
DMUJ1EL	CP	Boehringer Ingelheim Pharmaceuticals
DMUJ1EL	DE	Osteoarthritis

DMGMFXJ	ID	DMGMFXJ
DMGMFXJ	DN	BI 1701963
DMGMFXJ	HS	Phase 1
DMGMFXJ	CP	Boehringer Ingelheim
DMGMFXJ	DT	Small molecular drug
DMGMFXJ	DE	Solid tumour/cancer

DMFJGUL	ID	DMFJGUL
DMFJGUL	DN	BI 3011441
DMFJGUL	HS	Phase 1
DMFJGUL	CP	Boehringer Ingelheim
DMFJGUL	DT	Small molecular drug
DMFJGUL	DE	Solid tumour/cancer

DMWHZFS	ID	DMWHZFS
DMWHZFS	DN	BI 754091
DMWHZFS	HS	Phase 1
DMWHZFS	CP	Boehringer Ingelheim
DMWHZFS	DT	Antibody
DMWHZFS	DE	Neoplasm

DMZMAOW	ID	DMZMAOW
DMZMAOW	DN	BI 765063
DMZMAOW	HS	Phase 1
DMZMAOW	SN	OSE-172
DMZMAOW	CP	Boehringer Ingelheim; OSE Immunotherapeutics
DMZMAOW	DT	Antibody
DMZMAOW	DE	Solid tumour/cancer

DMRI6YT	ID	DMRI6YT
DMRI6YT	DN	BI 836880
DMRI6YT	HS	Phase 1
DMRI6YT	CP	Boehringer Ingelheim
DMRI6YT	DT	Antibody
DMRI6YT	DE	Neoplasm; Wet age-related macular degeneration

DMMQ12N	ID	DMMQ12N
DMMQ12N	DN	BI 860585
DMMQ12N	HS	Phase 1
DMMQ12N	CP	Boehringer ingelheim pharmaceuticals
DMMQ12N	DE	Solid tumour/cancer

DM7W5N2	ID	DM7W5N2
DM7W5N2	DN	BI 894999
DM7W5N2	HS	Phase 1
DM7W5N2	CP	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DM7W5N2	PC	90647162
DM7W5N2	MW	429.5
DM7W5N2	FM	C25H27N5O2
DM7W5N2	IC	InChI=1S/C25H27N5O2/c1-16-13-21(28-29(3)25(16)31)24-27-22-15-26-20(19-9-11-32-12-10-19)14-23(22)30(24)17(2)18-7-5-4-6-8-18/h4-8,13-15,17,19H,9-12H2,1-3H3/t17-/m0/s1
DM7W5N2	CS	CC1=CC(=NN(C1=O)C)C2=NC3=CN=C(C=C3N2[C@@H](C)C4=CC=CC=C4)C5CCOCC5
DM7W5N2	IK	QNFGQQDKBYVNAS-KRWDZBQOSA-N
DM7W5N2	IU	2,4-dimethyl-6-[6-(oxan-4-yl)-1-[(1S)-1-phenylethyl]imidazo[4,5-c]pyridin-2-yl]pyridazin-3-one
DM7W5N2	CA	CAS 1660117-38-3
DM7W5N2	DE	Solid tumour/cancer

DMEPJ7C	ID	DMEPJ7C
DMEPJ7C	DN	BI 905677
DMEPJ7C	HS	Phase 1
DMEPJ7C	CP	Boehringer Ingelheim
DMEPJ7C	DT	Antibody
DMEPJ7C	DE	Solid tumour/cancer

DMXO3PV	ID	DMXO3PV
DMXO3PV	DN	BI 905681
DMXO3PV	HS	Phase 1
DMXO3PV	CP	Boehringer Ingelheim
DMXO3PV	DT	Antibody
DMXO3PV	DE	Solid tumour/cancer

DME9NYV	ID	DME9NYV
DME9NYV	DN	BI 905711
DME9NYV	HS	Phase 1
DME9NYV	CP	Boehringer Ingelheim
DME9NYV	DT	Antibody
DME9NYV	DE	Solid tumour/cancer

DM2Z4YQ	ID	DM2Z4YQ
DM2Z4YQ	DN	BI 907828
DM2Z4YQ	HS	Phase 1
DM2Z4YQ	CP	Boehringer Ingelheim
DM2Z4YQ	DT	Small molecular drug
DM2Z4YQ	DE	Solid tumour/cancer

DMKQHE5	ID	DMKQHE5
DMKQHE5	DN	BI-11634
DMKQHE5	HS	Phase 1
DMKQHE5	CP	Boehringer Ingelheim Corp
DMKQHE5	PC	117587663
DMKQHE5	MW	464.9
DMKQHE5	FM	C22H22ClN4NaO4
DMKQHE5	IC	InChI=1S/C22H23ClN4O4.Na/c1-13-9-14(3-6-19(13)27-7-8-31-12-20(27)28)22(29)26-18(11-30-2)21-24-16-5-4-15(23)10-17(16)25-21;/h3-6,9-10,18H,7-8,11-12H2,1-2H3,(H2,24,25,26,29);/q;+1/p-1/t18-;/m0./s1
DMKQHE5	CS	CC1=C(C=CC(=C1)C(=O)[N-][C@@H](COC)C2=NC3=C(N2)C=C(C=C3)Cl)N4CCOCC4=O.[Na+]
DMKQHE5	IK	OJSUHLVJVGHFKW-FERBBOLQSA-M
DMKQHE5	IU	sodium;[(1R)-1-(6-chloro-1H-benzimidazol-2-yl)-2-methoxyethyl]-[3-methyl-4-(3-oxomorpholin-4-yl)benzoyl]azanide
DMKQHE5	CA	CAS 1622159-00-5
DMKQHE5	DE	Thrombosis

DMLJOAF	ID	DMLJOAF
DMLJOAF	DN	BI-135585
DMLJOAF	HS	Phase 1
DMLJOAF	CP	Boehringer Ingelheim Pharmaceuticals
DMLJOAF	PC	44476893
DMLJOAF	MW	460.6
DMLJOAF	FM	C28H32N2O4
DMLJOAF	IC	InChI=1S/C28H32N2O4/c1-20(21-10-12-22(13-11-21)23-14-16-29(4)25(31)18-23)30-17-15-28(34-26(30)32,19-27(2,3)33)24-8-6-5-7-9-24/h5-14,16,18,20,33H,15,17,19H2,1-4H3/t20-,28-/m0/s1
DMLJOAF	CS	C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4
DMLJOAF	IK	TXNPQZGSVXLGGP-MMTVBGGISA-N
DMLJOAF	IU	(6S)-6-(2-hydroxy-2-methylpropyl)-3-[(1S)-1-[4-(1-methyl-2-oxopyridin-4-yl)phenyl]ethyl]-6-phenyl-1,3-oxazinan-2-one
DMLJOAF	CA	CAS 1114561-85-1
DMLJOAF	DE	Type-2 diabetes

DM2KVM0	ID	DM2KVM0
DM2KVM0	DN	BI-44847
DM2KVM0	HS	Phase 1
DM2KVM0	CP	Ajinomoto Co Inc
DM2KVM0	PC	10181733
DM2KVM0	MW	440.5
DM2KVM0	FM	C21H29FN2O7
DM2KVM0	IC	InChI=1S/C21H29FN2O7/c1-10(2)24-11(3)14(7-12-5-6-13(29-4)8-15(12)22)20(23-24)31-21-19(28)18(27)17(26)16(9-25)30-21/h5-6,8,10,16-19,21,25-28H,7,9H2,1-4H3/t16-,17-,18+,19-,21+/m1/s1
DM2KVM0	CS	CC1=C(C(=NN1C(C)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=C(C=C(C=C3)OC)F
DM2KVM0	IK	AOBLNYCSGWSIPG-YRIDSSQKSA-N
DM2KVM0	IU	(2S,3R,4S,5S,6R)-2-[4-[(2-fluoro-4-methoxyphenyl)methyl]-5-methyl-1-propan-2-ylpyrazol-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM2KVM0	CA	CAS 421592-30-5
DM2KVM0	DE	Type-2 diabetes

DM3JOIX	ID	DM3JOIX
DM3JOIX	DN	BI-754091
DM3JOIX	HS	Phase 1
DM3JOIX	CP	Boehringer Ingelheim
DM3JOIX	DT	Monoclonal antibody
DM3JOIX	DE	Solid tumour/cancer; Advanced malignancy

DMNUY32	ID	DMNUY32
DMNUY32	DN	BI-811283
DMNUY32	HS	Phase 1
DMNUY32	CP	Boehringer Ingelheim Pharmaceuticals
DMNUY32	DE	Acute myeloid leukaemia

DMOJZUE	ID	DMOJZUE
DMOJZUE	DN	BI-831266
DMOJZUE	HS	Phase 1
DMOJZUE	CP	Boehringer Ingelheim Pharmaceuticals
DMOJZUE	DE	Solid tumour/cancer

DM4T916	ID	DM4T916
DM4T916	DN	BI-836845
DM4T916	HS	Phase 1
DM4T916	CP	Boehringer Ingelheim Pharmaceuticals
DM4T916	DE	Solid tumour/cancer

DMGFH7T	ID	DMGFH7T
DMGFH7T	DN	BI-836880
DMGFH7T	HS	Phase 1
DMGFH7T	CP	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DMGFH7T	DE	Solid tumour/cancer

DMY4B6J	ID	DMY4B6J
DMY4B6J	DN	BI-847325
DMY4B6J	HS	Phase 1
DMY4B6J	CP	Boehringer Ingelheim Pharmaceuticals
DMY4B6J	PC	135567102
DMY4B6J	MW	464.6
DMY4B6J	FM	C29H28N4O2
DMY4B6J	IC	InChI=1S/C29H28N4O2/c1-4-30-26(34)17-13-20-12-16-24-25(18-20)32-29(35)27(24)28(22-8-6-5-7-9-22)31-23-14-10-21(11-15-23)19-33(2)3/h5-12,14-16,18,32,35H,4,19H2,1-3H3,(H,30,34)
DMY4B6J	CS	CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4
DMY4B6J	IK	OCUQMWSIGPQEMX-UHFFFAOYSA-N
DMY4B6J	IU	3-[3-[N-[4-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indol-6-yl]-N-ethylprop-2-ynamide
DMY4B6J	DE	Solid tumour/cancer

DMNOSYW	ID	DMNOSYW
DMNOSYW	DN	BI-853520
DMNOSYW	HS	Phase 1
DMNOSYW	CP	Boehringer Ingelheim Pharmaceuticals
DMNOSYW	DE	Solid tumour/cancer

DMP70FI	ID	DMP70FI
DMP70FI	DN	BIBT986
DMP70FI	HS	Phase 1
DMP70FI	SN	Tanogitran; UNII-X5QRR6Z56Q; X5QRR6Z56Q; CHEMBL1270156; Tanogitran [INN]; BIBT986; 637328-69-9; SCHEMBL2471738; MAOALPSHCIBFJZ-RUZDIDTESA-N; ZINC64527030; BDBM50328705; J3.538.630K; (R)-2-(4-Amidinophenylaminomethyl)-1-methyl-5-[l -(carboxymethylamino)-1-(pyrrolidinocarbonyl)-ethyl]-benzimidazole; (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-(pyrrolidinocarbonyl) -ethyl]-benzimidazole
DMP70FI	CP	Boehringer Ingelheim Pharmaceuticals
DMP70FI	DT	Small molecular drug
DMP70FI	PC	9826322
DMP70FI	MW	477.6
DMP70FI	FM	C25H31N7O3
DMP70FI	IC	InChI=1S/C25H31N7O3/c1-25(29-15-22(33)34,24(35)32-11-3-4-12-32)17-7-10-20-19(13-17)30-21(31(20)2)14-28-18-8-5-16(6-9-18)23(26)27/h5-10,13,28-29H,3-4,11-12,14-15H2,1-2H3,(H3,26,27)(H,33,34)/t25-/m1/s1
DMP70FI	CS	C[C@@](C1=CC2=C(C=C1)N(C(=N2)CNC3=CC=C(C=C3)C(=N)N)C)(C(=O)N4CCCC4)NCC(=O)O
DMP70FI	IK	MAOALPSHCIBFJZ-RUZDIDTESA-N
DMP70FI	IU	2-[[(2R)-2-[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazol-5-yl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]amino]acetic acid
DMP70FI	CA	CAS 637328-69-9
DMP70FI	DE	Thrombosis

DMUBMN5	ID	DMUBMN5
DMUBMN5	DN	BIBV 308
DMUBMN5	HS	Phase 1
DMUBMN5	SN	Terbogrel; UNII-5Z4KWQ5OGN; 149979-74-8; 5Z4KWQ5OGN; CHEMBL281398; Terbogrel [USAN:INN]; BIBV 308 SE; Terbogrel (USAN/INN); AC1O6AAX; SCHEMBL42848; BIBV-308-SE; SCHEMBL15413063; ZINC11726169; BDBM50075624; DB12204; CS-6743; (5E)-6-(m-(3-tert-Butyl-2-cyanoguanidino)phenyl)-6-(3-pyridyl)-5-hexenoic acid; 6-(3-(((Cyanoamino)((1,1-dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)hexenoic acid; HY-19189; D06077; L001474; 6-{3-[1-(tert-butylamino)-2-cyano-(E)-1-iminomethylamino]phenyl}-6-(3-pyridyl)-(E)-5-hexenoic acid
DMUBMN5	CP	Boehringer Ingelheim
DMUBMN5	DT	Small molecular drug
DMUBMN5	PC	6449876
DMUBMN5	MW	405.5
DMUBMN5	FM	C23H27N5O2
DMUBMN5	IC	InChI=1S/C23H27N5O2/c1-23(2,3)28-22(26-16-24)27-19-10-6-8-17(14-19)20(11-4-5-12-21(29)30)18-9-7-13-25-15-18/h6-11,13-15H,4-5,12H2,1-3H3,(H,29,30)(H2,26,27,28)/b20-11+
DMUBMN5	CS	CC(C)(C)N=C(NC#N)NC1=CC=CC(=C1)/C(=C\\CCCC(=O)O)/C2=CN=CC=C2
DMUBMN5	IK	XUTLOCQNGLJNSA-RGVLZGJSSA-N
DMUBMN5	IU	(E)-6-[3-[(N'-tert-butyl-N-cyanocarbamimidoyl)amino]phenyl]-6-pyridin-3-ylhex-5-enoic acid
DMUBMN5	CA	CAS 149979-74-8
DMUBMN5	DE	Peripheral vascular disease

DM79XGM	ID	DM79XGM
DM79XGM	DN	BIBX-1382
DM79XGM	HS	Phase 1
DM79XGM	SN	Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; BIBX-1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047
DM79XGM	CP	Boehringer Ingelheim Corp
DM79XGM	DT	Small molecular drug
DM79XGM	PC	6918508
DM79XGM	MW	387.8
DM79XGM	FM	C18H19ClFN7
DM79XGM	IC	InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)
DM79XGM	CS	CN1CCC(CC1)NC2=NC=C3C(=N2)C(=NC=N3)NC4=CC(=C(C=C4)F)Cl
DM79XGM	IK	FTFRZXFNZVCRSK-UHFFFAOYSA-N
DM79XGM	IU	4-N-(3-chloro-4-fluorophenyl)-6-N-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-4,6-diamine
DM79XGM	CA	CAS 196612-93-8
DM79XGM	CB	CHEBI:93243
DM79XGM	DE	Chronic lymphocytic leukaemia

DM5AW7J	ID	DM5AW7J
DM5AW7J	DN	BIIB 015
DM5AW7J	HS	Phase 1
DM5AW7J	CP	Biogen Idec
DM5AW7J	DT	Antibody
DM5AW7J	DE	Solid tumour/cancer

DMZ1V0E	ID	DMZ1V0E
DMZ1V0E	DN	BIIB 022
DMZ1V0E	HS	Phase 1
DMZ1V0E	CP	Biogen Idec
DMZ1V0E	DE	Non-small-cell lung cancer; Hepatocellular carcinoma

DMTRF71	ID	DMTRF71
DMTRF71	DN	BIIB 028
DMTRF71	HS	Phase 1
DMTRF71	CP	Biogen Idec
DMTRF71	DE	Solid tumour/cancer

DMVS87W	ID	DMVS87W
DMVS87W	DN	BIIB068
DMVS87W	HS	Phase 1
DMVS87W	CP	Biogen Cambridge, MA
DMVS87W	DE	Systemic lupus erythematosus

DMUC6EP	ID	DMUC6EP
DMUC6EP	DN	BIIB095
DMUC6EP	HS	Phase 1
DMUC6EP	CP	Biogen
DMUC6EP	DE	Pain

DM9UZD7	ID	DM9UZD7
DM9UZD7	DN	Bile acid
DM9UZD7	HS	Phase 1
DM9UZD7	SN	Bile Salts; Bile acid; Bile salt; CHEBI:22868
DM9UZD7	PC	439520
DM9UZD7	MW	408.6
DM9UZD7	FM	C24H40O5
DM9UZD7	IC	BHQCQFFYRZLCQQ-UMZBRFQRSA-N
DM9UZD7	CS	CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C
DM9UZD7	IK	1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13?,14-,15+,16?,17?,18?,19+,20-,22?,23?,24?/m0/s1
DM9UZD7	IU	4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM9UZD7	CB	CHEBI:22868
DM9UZD7	DE	Inflammatory bowel disease

DMBTSZD	ID	DMBTSZD
DMBTSZD	DN	BIMU-1
DMBTSZD	HS	Phase 1
DMBTSZD	SN	BIMU-8
DMBTSZD	CP	Boehringer Ingelheim Corp
DMBTSZD	DT	Small molecular drug
DMBTSZD	PC	9929033
DMBTSZD	MW	328.4
DMBTSZD	FM	C18H24N4O2
DMBTSZD	IC	InChI=1S/C18H24N4O2/c1-3-21-15-6-4-5-7-16(15)22(18(21)24)17(23)19-12-10-13-8-9-14(11-12)20(13)2/h4-7,12-14H,3,8-11H2,1-2H3,(H,19,23)/t12?,13-,14?/m0/s1
DMBTSZD	CS	CCN1C2=CC=CC=C2N(C1=O)C(=O)NC3C[C@@H]4CCC(C3)N4C
DMBTSZD	IK	MZRKHUUDDHJVHS-MOKVOYLWSA-N
DMBTSZD	IU	3-ethyl-N-[(5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxobenzimidazole-1-carboxamide
DMBTSZD	DE	Cognitive impairment

DMQ9KZW	ID	DMQ9KZW
DMQ9KZW	DN	Biomed 101
DMQ9KZW	HS	Phase 1
DMQ9KZW	SN	BioMed 101; SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390
DMQ9KZW	CP	Intarcia Therape.
DMQ9KZW	TC	Anticancer Agents
DMQ9KZW	DT	Small molecular drug
DMQ9KZW	PC	114999
DMQ9KZW	MW	484.6
DMQ9KZW	FM	C28H36O7
DMQ9KZW	IC	InChI=1S/C28H36O7/c1-5-8-21-23(13-10-19-11-14-25(28(30)31)35-26(19)21)33-16-7-17-34-24-15-12-20(18(3)29)27(32-4)22(24)9-6-2/h10,12-13,15,25H,5-9,11,14,16-17H2,1-4H3,(H,30,31)
DMQ9KZW	CS	CCCC1=C(C=CC2=C1OC(CC2)C(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)C)OC)CCC
DMQ9KZW	IK	ZVVCSBSDFGYRCB-UHFFFAOYSA-N
DMQ9KZW	IU	7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2H-chromene-2-carboxylic acid
DMQ9KZW	CA	CAS 120072-59-5
DMQ9KZW	DE	Renal cell carcinoma; Inflammatory bowel disease; Kidney cancer

DMS4P6K	ID	DMS4P6K
DMS4P6K	DN	Biostrophin
DMS4P6K	HS	Phase 1
DMS4P6K	SN	Duchenne muscular dystrophy therapy, Asklepios; Adeno-associated virus gene therapy (dystrophin), AskBio; Adeno-associated virus gene therapy (dystrophin), Asklepios
DMS4P6K	CP	Asklepios biopharmaceuticals
DMS4P6K	DE	Duchenne dystrophy

DMGAR9Y	ID	DMGAR9Y
DMGAR9Y	DN	BIT225
DMGAR9Y	HS	Phase 1
DMGAR9Y	SN	BIT-225; BIT225; 917909-71-8; SCHEMBL3109704; CHEMBL1242296; WVROWPPEIMRGAB-UHFFFAOYSA-N; ZINC43151503; 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-(1-methyl-1H-pyrazol-4-yl)-; SB16851; 5-(1-methyl-1H-pyrazol-4-yl)-2-naphthoylguanidine
DMGAR9Y	CP	Biotron
DMGAR9Y	DT	Small molecular drug
DMGAR9Y	PC	12004418
DMGAR9Y	MW	293.32
DMGAR9Y	FM	C16H15N5O
DMGAR9Y	IC	InChI=1S/C16H15N5O/c1-21-9-12(8-19-21)13-4-2-3-10-7-11(5-6-14(10)13)15(22)20-16(17)18/h2-9H,1H3,(H4,17,18,20,22)
DMGAR9Y	CS	CN1C=C(C=N1)C2=CC=CC3=C2C=CC(=C3)C(=O)N=C(N)N
DMGAR9Y	IK	WVROWPPEIMRGAB-UHFFFAOYSA-N
DMGAR9Y	IU	N-(diaminomethylidene)-5-(1-methylpyrazol-4-yl)naphthalene-2-carboxamide
DMGAR9Y	CA	CAS 917909-71-8
DMGAR9Y	DE	Hepatitis C virus infection

DM61JH5	ID	DM61JH5
DM61JH5	DN	BIWA 4
DM61JH5	HS	Phase 1
DM61JH5	CP	Boehringer Ingelheim
DM61JH5	DT	Antibody
DM61JH5	DE	Solid tumour/cancer

DMX9ER7	ID	DMX9ER7
DMX9ER7	DN	BIZELESIN
DMX9ER7	HS	Phase 1
DMX9ER7	SN	Bizelesin < Rec INN; U-77779; (S,S)-1,3-Bis[2-[1-(Chloromethyl)-5-hydroxy-8-methyl-1,2,3,6-tetrahydrobenzo[1,2-b:4,3-b']dipyrrol-3-ylcarbonyl]-1H-indol-5-yl]urea
DMX9ER7	DT	Small molecular drug
DMX9ER7	PC	60794
DMX9ER7	MW	815.7
DMX9ER7	FM	C43H36Cl2N8O5
DMX9ER7	IC	InChI=1S/C43H36Cl2N8O5/c1-19-15-46-39-33(54)11-31-37(35(19)39)23(13-44)17-52(31)41(56)29-9-21-7-25(3-5-27(21)50-29)48-43(58)49-26-4-6-28-22(8-26)10-30(51-28)42(57)53-18-24(14-45)38-32(53)12-34(55)40-36(38)20(2)16-47-40/h3-12,15-16,23-24,46-47,50-51,54-55H,13-14,17-18H2,1-2H3,(H2,48,49,58)/t23-,24-/m1/s1
DMX9ER7	CS	CC1=CNC2=C(C=C3C(=C12)[C@@H](CN3C(=O)C4=CC5=C(N4)C=CC(=C5)NC(=O)NC6=CC7=C(C=C6)NC(=C7)C(=O)N8C[C@H](C9=C1C(=CNC1=C(C=C98)O)C)CCl)CCl)O
DMX9ER7	IK	FONKWHRXTPJODV-DNQXCXABSA-N
DMX9ER7	IU	1,3-bis[2-[(8S)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indole-6-carbonyl]-1H-indol-5-yl]urea
DMX9ER7	CA	CAS 129655-21-6
DMX9ER7	DE	Skin disease

DMAYSFK	ID	DMAYSFK
DMAYSFK	DN	BL-1021
DMAYSFK	HS	Phase 1
DMAYSFK	SN	UNII-7Q35V52Q2Z; BL-1021; BL-1021 free; 7Q35V52Q2Z; Butanamide, 4-amino-N-[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]-N-methyl-, hydrochloride (1:1);Butanamide, 4-amino-N-[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]-N-methyl-, hydrochloride (1:1); 1002331-76-1; CHEMBL490932; Butanamide, 4-amino-N-(3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)propyl)-N-methyl-, hydrochloride (1:1)
DMAYSFK	CP	Tel Aviv University
DMAYSFK	DT	Small molecular drug
DMAYSFK	PC	24898306
DMAYSFK	MW	384.9
DMAYSFK	FM	C23H29ClN2O
DMAYSFK	IC	InChI=1S/C23H28N2O.ClH/c1-25(23(26)13-6-16-24)17-7-12-22-20-10-4-2-8-18(20)14-15-19-9-3-5-11-21(19)22;/h2-5,8-12H,6-7,13-17,24H2,1H3;1H
DMAYSFK	CS	CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)C(=O)CCCN.Cl
DMAYSFK	IK	DEKZAWRGNGHZKY-UHFFFAOYSA-N
DMAYSFK	IU	4-amino-N-methyl-N-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propyl]butanamide;hydrochloride
DMAYSFK	CA	CAS 1002331-76-1
DMAYSFK	DE	Pain

DM27J3D	ID	DM27J3D
DM27J3D	DN	BLU-554
DM27J3D	HS	Phase 1
DM27J3D	SN	MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide
DM27J3D	CP	Blueprint Medicines Cambridge, MA
DM27J3D	PC	91885617
DM27J3D	MW	503.4
DM27J3D	FM	C24H24Cl2N4O4
DM27J3D	IC	InChI=1S/C24H24Cl2N4O4/c1-4-20(31)28-16-7-8-34-12-17(16)30-24-27-11-14-9-13(5-6-15(14)29-24)21-22(25)18(32-2)10-19(33-3)23(21)26/h4-6,9-11,16-17H,1,7-8,12H2,2-3H3,(H,28,31)(H,27,29,30)/t16-,17+/m0/s1
DM27J3D	CS	COC1=CC(=C(C(=C1Cl)C2=CC3=CN=C(N=C3C=C2)N[C@@H]4COCC[C@@H]4NC(=O)C=C)Cl)OC
DM27J3D	IK	MGZKYOAQVGSSGC-DLBZAZTESA-N
DM27J3D	IU	N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]amino]oxan-4-yl]prop-2-enamide
DM27J3D	CA	CAS 1707289-21-1
DM27J3D	DE	Hepatocellular carcinoma

DMYHNV3	ID	DMYHNV3
DMYHNV3	DN	BLY719
DMYHNV3	HS	Phase 1
DMYHNV3	CP	Novartis pharmaceuticals
DMYHNV3	DE	Solid tumour/cancer

DMIRX3Z	ID	DMIRX3Z
DMIRX3Z	DN	BM-212
DMIRX3Z	HS	Phase 1
DMIRX3Z	SN	BM-212; BM212; UNII-U9HSU4GZWL; 146204-42-4; U9HSU4GZWL; 1-{[1,5-Bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl}-4-methylpiperazine; 1-[[1,5-bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl]-4-methylpiperazine; BM 212; AC1L9VRH; CHEMBL321077; SCHEMBL1452627; BCP24821; ZINC22445591; AKOS032944899; CS-5953; Piperazine, 1-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methyl-; HY-100725
DMIRX3Z	DT	Small molecular drug
DMIRX3Z	PC	456926
DMIRX3Z	MW	414.4
DMIRX3Z	FM	C23H25Cl2N3
DMIRX3Z	IC	InChI=1S/C23H25Cl2N3/c1-17-19(16-27-13-11-26(2)12-14-27)15-23(18-3-5-20(24)6-4-18)28(17)22-9-7-21(25)8-10-22/h3-10,15H,11-14,16H2,1-2H3
DMIRX3Z	CS	CC1=C(C=C(N1C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)CN4CCN(CC4)C
DMIRX3Z	IK	YWZIODCWLMCMMW-UHFFFAOYSA-N
DMIRX3Z	IU	1-[[1,5-bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl]-4-methylpiperazine
DMIRX3Z	CA	CAS 146204-42-4
DMIRX3Z	DE	Asthma

DM43RV5	ID	DM43RV5
DM43RV5	DN	BM-ca
DM43RV5	HS	Phase 1
DM43RV5	SN	Anti-CD20 antibodies (lymphoma), BioMedics
DM43RV5	CP	BioMedics Japan Inc
DM43RV5	DT	Antibody
DM43RV5	DE	Non-hodgkin lymphoma

DMJNFI2	ID	DMJNFI2
DMJNFI2	DN	BMEC-1217B
DMJNFI2	HS	Phase 1
DMJNFI2	SN	TCM-B; Cytokine regulator (asthma), Medigreen; 1217B; 1217B-AR
DMJNFI2	CP	Industrial Technology Research Institute
DMJNFI2	DE	Allergic rhinitis

DMTZ3A6	ID	DMTZ3A6
DMTZ3A6	DN	BMS-196085
DMTZ3A6	HS	Phase 1
DMTZ3A6	SN	BMS-196085; UNII-FM0D5L3W03; FM0D5L3W03; CHEMBL322862; 170686-10-9; SCHEMBL7042488; BDBM50106829; Methanesulfonamide, N-(5-((1R)-2-(((1R)-1-(4-(difluoromethoxy)phenyl)-2-phenylethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)-; Methanesulfonamide, N-(5-(2-((1-(4-(difluoromethoxy)phenyl)-2-phenylethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)-, (R-(R*,R*))-; N-(5-{(R)-2-[(R)-1-(4-Difluoromethoxy-phenyl)-2-phenyl-ethylamino]-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide
DMTZ3A6	DT	Small molecular drug
DMTZ3A6	PC	9870286
DMTZ3A6	MW	492.5
DMTZ3A6	FM	C24H26F2N2O5S
DMTZ3A6	IC	InChI=1S/C24H26F2N2O5S/c1-34(31,32)28-21-14-18(9-12-22(21)29)23(30)15-27-20(13-16-5-3-2-4-6-16)17-7-10-19(11-8-17)33-24(25)26/h2-12,14,20,23-24,27-30H,13,15H2,1H3/t20-,23+/m1/s1
DMTZ3A6	CS	CS(=O)(=O)NC1=C(C=CC(=C1)[C@H](CN[C@H](CC2=CC=CC=C2)C3=CC=C(C=C3)OC(F)F)O)O
DMTZ3A6	IK	XWLVOJZVWRCRMD-OFNKIYASSA-N
DMTZ3A6	IU	N-[5-[(1R)-2-[[(1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide
DMTZ3A6	CA	CAS 170686-10-9
DMTZ3A6	DE	Diabetic complication

DM5M48F	ID	DM5M48F
DM5M48F	DN	BMS214662
DM5M48F	HS	Phase 1
DM5M48F	SN	BMV; BMS 214662; BMS-214662; (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile; (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile; 3-BENZYL-1-(1H-IMIDAZOL-4-YLMETHYL)-4-(THIEN-2-YLSULFONYL)-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE-7-CARBONITRILE; 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine
DM5M48F	CP	Bristol-Myers Squibb
DM5M48F	TC	Anticancer Agents
DM5M48F	DT	Small molecular drug
DM5M48F	PC	448545
DM5M48F	MW	489.6
DM5M48F	FM	C25H23N5O2S2
DM5M48F	IC	InChI=1S/C25H23N5O2S2/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22/h1-11,14,18,23H,12,15-17H2,(H,27,28)/t23-/m1/s1
DM5M48F	CS	C1[C@H](N(CC2=C(N1CC3=CN=CN3)C=CC(=C2)C#N)S(=O)(=O)C4=CC=CS4)CC5=CC=CC=C5
DM5M48F	IK	OLCWFLWEHWLBTO-HSZRJFAPSA-N
DM5M48F	IU	(3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile
DM5M48F	CA	CAS 195987-41-8
DM5M48F	DE	Non-small-cell lung cancer

DMGDJQR	ID	DMGDJQR
DMGDJQR	DN	BMS-394136
DMGDJQR	HS	Phase 1
DMGDJQR	CP	Bristol-Myers Squibb
DMGDJQR	DE	Arrhythmia

DMPK32V	ID	DMPK32V
DMPK32V	DN	BMS-754807
DMPK32V	HS	Phase 1
DMPK32V	SN	BMS-754807; 1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin
DMPK32V	DT	Small molecular drug
DMPK32V	PC	24785538
DMPK32V	MW	461.5
DMPK32V	FM	C23H24FN9O
DMPK32V	IC	InChI=1S/C23H24FN9O/c1-23(21(34)26-15-7-8-18(24)25-13-15)9-3-10-32(23)22-28-20(17-4-2-11-33(17)31-22)27-19-12-16(29-30-19)14-5-6-14/h2,4,7-8,11-14H,3,5-6,9-10H2,1H3,(H,26,34)(H2,27,28,29,30,31)/t23-/m0/s1
DMPK32V	CS	C[C@]1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F
DMPK32V	IK	LQVXSNNAFNGRAH-QHCPKHFHSA-N
DMPK32V	IU	(2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide
DMPK32V	CA	CAS 1001350-96-4
DMPK32V	CB	CHEBI:88339

DMKR8S1	ID	DMKR8S1
DMKR8S1	DN	BMS-779788
DMKR8S1	HS	Phase 1
DMKR8S1	CP	Bristol-Myers Squibb; Exelixis
DMKR8S1	PC	59251511
DMKR8S1	MW	509.1
DMKR8S1	FM	C28H29ClN2O3S
DMKR8S1	IC	InChI=1S/C28H29ClN2O3S/c1-27(2,23-11-6-7-12-24(23)29)26-30-25(28(3,4)32)18-31(26)21-15-13-19(14-16-21)20-9-8-10-22(17-20)35(5,33)34/h6-18,32H,1-5H3
DMKR8S1	CS	CC(C)(C1=CC=CC=C1Cl)C2=NC(=CN2C3=CC=C(C=C3)C4=CC(=CC=C4)S(=O)(=O)C)C(C)(C)O
DMKR8S1	IK	JLPURTXCSILYLW-UHFFFAOYSA-N
DMKR8S1	IU	2-[2-[2-(2-chlorophenyl)propan-2-yl]-1-[4-(3-methylsulfonylphenyl)phenyl]imidazol-4-yl]propan-2-ol
DMKR8S1	DE	Arteriosclerosis

DM2WMJ7	ID	DM2WMJ7
DM2WMJ7	DN	BMS-816336
DM2WMJ7	HS	Phase 1
DM2WMJ7	SN	11B-HSD-1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), BMS; 11B-HSD-1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), Bristol-Myers Squibb; 11beta-hydroxysteroid dehydrogenase-type 1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), BMS; 11beta-hydroxysteroid dehydrogenase-type 1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), Bristol-Myers Squibb
DM2WMJ7	CP	Bristol-Myers Squibb Co
DM2WMJ7	PC	59336911
DM2WMJ7	MW	341.4
DM2WMJ7	FM	C21H27NO3
DM2WMJ7	IC	InChI=1S/C21H27NO3/c23-18-11-22(12-18)19(24)10-21(15-4-2-1-3-5-15)16-6-13-7-17(21)9-14(8-16)20(13)25/h1-5,13-14,16-18,20,23,25H,6-12H2
DM2WMJ7	CS	C1C2CC3CC(C2O)CC1C3(CC(=O)N4CC(C4)O)C5=CC=CC=C5
DM2WMJ7	IK	OAAZMUGLOXGVNH-UHFFFAOYSA-N
DM2WMJ7	IU	1-(3-hydroxyazetidin-1-yl)-2-(6-hydroxy-2-phenyl-2-adamantyl)ethanone
DM2WMJ7	DE	Lipid metabolism disorder

DMCX0H7	ID	DMCX0H7
DMCX0H7	DN	BMS-820132
DMCX0H7	HS	Phase 1
DMCX0H7	CP	Bristol-Myers Squibb Co
DMCX0H7	DE	Type-2 diabetes

DMPQ5XC	ID	DMPQ5XC
DMPQ5XC	DN	BMS-824383
DMPQ5XC	HS	Phase 1
DMPQ5XC	CP	Bristol-Myers Squibb
DMPQ5XC	DE	Hepatitis C virus infection

DMCW71N	ID	DMCW71N
DMCW71N	DN	BMS-830216
DMCW71N	HS	Phase 1
DMCW71N	CP	Bristol-Myers Squibb
DMCW71N	PC	44539266
DMCW71N	MW	548.9
DMCW71N	FM	C24H22ClN2O7PS
DMCW71N	IC	InChI=1S/C24H22ClN2O7PS/c1-32-20-10-17(8-9-19(20)33-12-21(14-2-3-14)34-35(29,30)31)27-13-26-18-11-22(36-23(18)24(27)28)15-4-6-16(25)7-5-15/h4-11,13-14,21H,2-3,12H2,1H3,(H2,29,30,31)/t21-/m0/s1
DMCW71N	CS	COC1=C(C=CC(=C1)N2C=NC3=C(C2=O)SC(=C3)C4=CC=C(C=C4)Cl)OC[C@@H](C5CC5)OP(=O)(O)O
DMCW71N	IK	YDTUJCNTIMWHPJ-NRFANRHFSA-N
DMCW71N	IU	[(1R)-2-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3-yl]-2-methoxyphenoxy]-1-cyclopropylethyl] dihydrogen phosphate
DMCW71N	CA	CAS 1197420-06-6
DMCW71N	DE	Obesity

DMZS1D2	ID	DMZS1D2
DMZS1D2	DN	BMS-852927
DMZS1D2	HS	Phase 1
DMZS1D2	CP	Bristol-myers squibb
DMZS1D2	PC	49787490
DMZS1D2	MW	609.5
DMZS1D2	FM	C29H28Cl2F2N2O4S
DMZS1D2	IC	InChI=1S/C29H28Cl2F2N2O4S/c1-28(2,26-19(30)7-6-8-20(26)31)27-34-25(29(3,4)37)14-35(27)23-10-9-16(11-22(23)33)17-12-21(32)18(15-36)24(13-17)40(5,38)39/h6-14,36-37H,15H2,1-5H3
DMZS1D2	CS	CC(C)(C1=CN(C(=N1)C(C)(C)C2=C(C=CC=C2Cl)Cl)C3=C(C=C(C=C3)C4=CC(=C(C(=C4)S(=O)(=O)C)CO)F)F)O
DMZS1D2	IK	HNAJDMYOTDNOBK-UHFFFAOYSA-N
DMZS1D2	IU	2-[2-[2-(2,6-dichlorophenyl)propan-2-yl]-1-[2-fluoro-4-[3-fluoro-4-(hydroxymethyl)-5-methylsulfonylphenyl]phenyl]imidazol-4-yl]propan-2-ol
DMZS1D2	DE	Arteriosclerosis

DM7JW0B	ID	DM7JW0B
DM7JW0B	DN	BMS-903452
DM7JW0B	HS	Phase 1
DM7JW0B	CP	Bristol-Myers Squibb Co
DM7JW0B	PC	53477157
DM7JW0B	MW	513.4
DM7JW0B	FM	C21H19Cl2FN4O4S
DM7JW0B	IC	InChI=1S/C21H19Cl2FN4O4S/c1-33(30,31)15-2-3-18(17(24)8-15)28-12-16(23)19(9-20(28)29)32-14-4-6-27(7-5-14)21-25-10-13(22)11-26-21/h2-3,8-12,14H,4-7H2,1H3
DM7JW0B	CS	CS(=O)(=O)C1=CC(=C(C=C1)N2C=C(C(=CC2=O)OC3CCN(CC3)C4=NC=C(C=N4)Cl)Cl)F
DM7JW0B	IK	OGIAVRWXUPYGGC-UHFFFAOYSA-N
DM7JW0B	IU	5-chloro-4-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]oxy-1-(2-fluoro-4-methylsulfonylphenyl)pyridin-2-one
DM7JW0B	CA	CAS 1339944-47-6
DM7JW0B	DE	Type-2 diabetes

DM3K8VM	ID	DM3K8VM
DM3K8VM	DN	BMS-908662
DM3K8VM	HS	Phase 1
DM3K8VM	SN	BMS-908662; XL281; BMS 908662; BMS-908662 free base; 870603-16-0; GTPL7968; SCHEMBL10049428; SCHEMBL20299316; CHEMBL3545027; EXEL-2819; Carbamic acid, (5-(2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydro; BMS908662; XL-281; XL 281; DB12854; Carbamic acid, N-(6-(2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)-1H-benzimidazol-2-yl)-, methyl ester; Methyl (5-(2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl)carbamate, (+/-)-; Methyl (5-(2-(5-chloro-2-methyl
DM3K8VM	CP	Exelixis; Bristol-Myers Squibb
DM3K8VM	DT	Small molecular drug
DM3K8VM	PC	56931136
DM3K8VM	MW	462.9
DM3K8VM	FM	C24H19ClN4O4
DM3K8VM	IC	InChI=1S/C24H19ClN4O4/c1-13-7-9-15(25)12-20(13)29-21(30)16-5-3-4-6-17(16)24(29,32)14-8-10-18-19(11-14)27-22(26-18)28-23(31)33-2/h3-12,32H,1-2H3,(H2,26,27,28,31)
DM3K8VM	CS	CC1=C(C=C(C=C1)Cl)N2C(=O)C3=CC=CC=C3C2(C4=CC5=C(C=C4)N=C(N5)NC(=O)OC)O
DM3K8VM	IK	MMNNTJYFHUDSKL-UHFFFAOYSA-N
DM3K8VM	IU	methyl N-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1H-benzimidazol-2-yl]carbamate
DM3K8VM	CA	CAS 870603-16-0
DM3K8VM	DE	Solid tumour/cancer

DMG3J6C	ID	DMG3J6C
DMG3J6C	DN	BMS-933043
DMG3J6C	HS	Phase 1
DMG3J6C	CP	Bristol-Myers Squibb
DMG3J6C	PC	59286554
DMG3J6C	MW	325.37
DMG3J6C	FM	C16H19N7O
DMG3J6C	IC	InChI=1S/C16H19N7O/c1-4-22-5-2-12(1)16(9-22)8-18-15(24-16)21-13-7-14(20-10-19-13)23-6-3-17-11-23/h3,6-7,10-12H,1-2,4-5,8-9H2,(H,18,19,20,21)/t16-/m0/s1
DMG3J6C	CS	C1CN2CCC1[C@@]3(C2)CN=C(O3)NC4=CC(=NC=N4)N5C=CN=C5
DMG3J6C	IK	RLXBHTUZCPORKT-INIZCTEOSA-N
DMG3J6C	IU	(3R)-N-(6-imidazol-1-ylpyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4H-1,3-oxazole]-2'-amine
DMG3J6C	DE	Psychiatric disorder

DMYIBFM	ID	DMYIBFM
DMYIBFM	DN	BMS-936561
DMYIBFM	HS	Phase 1
DMYIBFM	CP	Bristol-Myers Squibb
DMYIBFM	DE	Haematological malignancy

DMS4H1J	ID	DMS4H1J
DMS4H1J	DN	BMS-936564
DMS4H1J	HS	Phase 1
DMS4H1J	CP	Bristol-Myers Squibb
DMS4H1J	DE	B-cell chronic lymphocytic leukaemia; Acute myeloid leukaemia

DMZ4WMT	ID	DMZ4WMT
DMZ4WMT	DN	BMS-986104
DMZ4WMT	HS	Phase 1
DMZ4WMT	SN	Unii-KJ9D084FO4; UNII-KJ9D084FO4; KJ9D084FO4; 1622180-31-7; CHEMBL3806158; SCHEMBL15953811; BPMMYKAHRIEVDH-VOQZNFBZSA-N; J3.582.853B; ((1R,3 S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; ((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; Cyclopentanemethanol, 1-amino-3-((6R)-6-hexyl-5,6,7,8-tetrahydro-2-naphthalenyl)-, (1R,3S)-
DMZ4WMT	CP	Bristol-Myers SquibbPrinceton, NJ
DMZ4WMT	PC	77050638
DMZ4WMT	MW	329.5
DMZ4WMT	FM	C22H35NO
DMZ4WMT	IC	InChI=1S/C22H35NO/c1-2-3-4-5-6-17-7-8-19-14-20(10-9-18(19)13-17)21-11-12-22(23,15-21)16-24/h9-10,14,17,21,24H,2-8,11-13,15-16,23H2,1H3/t17-,21+,22-/m1/s1
DMZ4WMT	CS	CCCCCC[C@@H]1CCC2=C(C1)C=CC(=C2)[C@H]3CC[C@@](C3)(CO)N
DMZ4WMT	IK	BPMMYKAHRIEVDH-VOQZNFBZSA-N
DMZ4WMT	IU	[(1R,3S)-1-amino-3-[(6R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methanol
DMZ4WMT	CA	CAS 1622180-31-7
DMZ4WMT	DE	Rheumatoid arthritis

DMYLFQR	ID	DMYLFQR
DMYLFQR	DN	BMS-986120
DMYLFQR	HS	Phase 1
DMYLFQR	SN	1478712-37-6; UNII-WDT28B7071; WDT28B7071; 4-(4-(((6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)-5-methylthiazol-2-yl)morpholine; 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-5-methyl-1,3-thiazol-2-yl]morpholine; 4-(4-(((6-Methoxy-2-(2-methoxyimidazo(2,1-b)(1,3,4)thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)-5-methylthiazol-2-yl)morpholine; CHEMBL3716726; SCHEMBL15348871; GTPL10269; BDBM176061; EX-A3977; BMS986120; HY-19837; CS-0016978; US9688695, 94; 2-methoxy-6-[6-methoxy-4-[[5-methyl-2-(4-morpholinyl)-4-thiazolyl]methoxy]-2-benzofuranyl]-imidazo[2,1-b]-1,3,4-thiadiazole; Imidazo(2,1-b)-1,3,4-thiadiazole, 2-methoxy-6-(6-methoxy-4-((5-methyl-2-(4-morpholinyl)-4-thiazolyl)methoxy)-2-benzofuranyl)
DMYLFQR	CP	Bristol-Myers Squibb
DMYLFQR	DT	Small molecular drug
DMYLFQR	PC	72190270
DMYLFQR	MW	513.6
DMYLFQR	FM	C23H23N5O5S2
DMYLFQR	IC	InChI=1S/C23H23N5O5S2/c1-13-17(25-21(34-13)27-4-6-31-7-5-27)12-32-18-8-14(29-2)9-19-15(18)10-20(33-19)16-11-28-22(24-16)35-23(26-28)30-3/h8-11H,4-7,12H2,1-3H3
DMYLFQR	CS	CC1=C(N=C(S1)N2CCOCC2)COC3=CC(=CC4=C3C=C(O4)C5=CN6C(=N5)SC(=N6)OC)OC
DMYLFQR	IK	MINMDCMSHDBHKG-UHFFFAOYSA-N
DMYLFQR	IU	4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-5-methyl-1,3-thiazol-2-yl]morpholine
DMYLFQR	CA	CAS 1478712-37-6
DMYLFQR	DE	Thrombosis

DMXU5FK	ID	DMXU5FK
DMXU5FK	DN	BMS-986189
DMXU5FK	HS	Phase 1
DMXU5FK	CP	Bristol-Myers Squibb
DMXU5FK	DT	Small molecule immunotherapy 

DMHTEZ8	ID	DMHTEZ8
DMHTEZ8	DN	BMS-986249
DMHTEZ8	HS	Phase 1
DMHTEZ8	CP	Bristol-Myers Squibb
DMHTEZ8	DT	Antibody
DMHTEZ8	DE	Solid tumour/cancer

DMTMUWJ	ID	DMTMUWJ
DMTMUWJ	DN	BMS-986299
DMTMUWJ	HS	Phase 1
DMTMUWJ	CP	Bristol-Myers Squibb
DMTMUWJ	DT	Small molecular drug
DMTMUWJ	DE	Solid tumour/cancer

DMM3DBU	ID	DMM3DBU
DMM3DBU	DN	BMS-986301
DMM3DBU	HS	Phase 1
DMM3DBU	CP	Bristol-Myers Squibb
DMM3DBU	DT	Small molecular drug
DMM3DBU	DE	Solid tumour/cancer

DMB6FMH	ID	DMB6FMH
DMB6FMH	DN	BMTP-11
DMB6FMH	HS	Phase 1
DMB6FMH	SN	IL-11Ralpha targeted proapoptotic peptide (prostate cancer), MD Anderson Cancer Center; IL-11Ralpha targeted proapoptotic peptide (prostate cancer), Mercator
DMB6FMH	CP	MD Anderson Cancer Center
DMB6FMH	DE	Prostate cancer

DMW8VEH	ID	DMW8VEH
DMW8VEH	DN	BMY-43748
DMW8VEH	HS	Phase 1
DMW8VEH	SN	7-[3(S)-Aminopyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-5-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylicacid
DMW8VEH	DT	Small molecular drug
DMW8VEH	PC	488361
DMW8VEH	MW	418.4
DMW8VEH	FM	C20H17F3N4O3
DMW8VEH	IC	InChI=1S/C20H17F3N4O3/c1-9-15-17(28)12(20(29)30)8-27(14-3-2-10(21)6-13(14)22)18(15)25-19(16(9)23)26-5-4-11(24)7-26/h2-3,6,8,11H,4-5,7,24H2,1H3,(H,29,30)/t11-/m0/s1
DMW8VEH	CS	CC1=C2C(=O)C(=CN(C2=NC(=C1F)N3CC[C@@H](C3)N)C4=C(C=C(C=C4)F)F)C(=O)O
DMW8VEH	IK	SKYPQEVVXGJKIJ-NSHDSACASA-N
DMW8VEH	IU	7-[(3S)-3-aminopyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-5-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMW8VEH	DE	Bacterial infection

DMSBM6A	ID	DMSBM6A
DMSBM6A	DN	BNC-101
DMSBM6A	HS	Phase 1
DMSBM6A	CP	Bionomics
DMSBM6A	DT	Antibody
DMSBM6A	DE	Metastatic colorectal cancer

DMI4UY3	ID	DMI4UY3
DMI4UY3	DN	BNC375
DMI4UY3	HS	Phase 1
DMI4UY3	CP	Merck Kenilworth, NJ Bionomics Thebarton, Australia
DMI4UY3	PC	118160666
DMI4UY3	MW	394.9
DMI4UY3	FM	C19H23ClN2O3S
DMI4UY3	IC	InChI=1S/C19H23ClN2O3S/c1-19(2)15(11-22-16-10-13(20)6-9-17(16)25-3)18(19)12-4-7-14(8-5-12)26(21,23)24/h4-10,15,18,22H,11H2,1-3H3,(H2,21,23,24)/t15-,18-/m1/s1
DMI4UY3	CS	CC1([C@@H]([C@H]1C2=CC=C(C=C2)S(=O)(=O)N)CNC3=C(C=CC(=C3)Cl)OC)C
DMI4UY3	IK	LWWDCTBUJUEFDE-CRAIPNDOSA-N
DMI4UY3	IU	4-[(1R,3R)-3-[(5-chloro-2-methoxyanilino)methyl]-2,2-dimethylcyclopropyl]benzenesulfonamide
DMI4UY3	DE	Cognitive impairment

DMU790L	ID	DMU790L
DMU790L	DN	BOS172722
DMU790L	HS	Phase 1
DMU790L	SN	SGWLRDAOCLITOM-UHFFFAOYSA-N; SCHEMBL15515080; CHEMBL3924132; BDBM241338; US9409907, 182
DMU790L	CP	Boston Pharmaceuticals Cambridge, MA
DMU790L	PC	73386890
DMU790L	MW	446.5
DMU790L	FM	C24H30N8O
DMU790L	IC	InChI=1S/C24H30N8O/c1-7-33-19-11-16(22-31-27-14-32(22)6)8-9-18(19)29-23-25-12-17-10-15(2)28-21(20(17)30-23)26-13-24(3,4)5/h8-12,14H,7,13H2,1-6H3,(H,26,28)(H,25,29,30)
DMU790L	CS	CCOC1=C(C=CC(=C1)C2=NN=CN2C)NC3=NC=C4C=C(N=C(C4=N3)NCC(C)(C)C)C
DMU790L	IK	SGWLRDAOCLITOM-UHFFFAOYSA-N
DMU790L	IU	8-N-(2,2-dimethylpropyl)-2-N-[2-ethoxy-4-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-methylpyrido[3,4-d]pyrimidine-2,8-diamine
DMU790L	CA	CAS 1578245-44-9
DMU790L	DE	Solid tumour/cancer

DM9L0D8	ID	DM9L0D8
DM9L0D8	DN	BOS172738
DM9L0D8	HS	Phase 1
DM9L0D8	SN	UNII-EW27AA6XBH; EW27AA6XBH; Zeteletinib hemiadipate; BOS172738 hemiadipate; DS5010; BOS-172738; 2375837-06-0; Hexanedioic acid, compd. with 6-(6,7-dimethoxy-3-quinolinyl)-N-(3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl)-3-pyridineacetamide (1:2)
DM9L0D8	CP	Boston Pharmaceuticals
DM9L0D8	DT	Small molecular drug
DM9L0D8	PC	155801569
DM9L0D8	MW	1147.1
DM9L0D8	FM	C56H56F6N8O12
DM9L0D8	IC	InChI=1S/2C25H23F3N4O4.C6H10O4/c2*1-24(2,25(26,27)28)21-11-23(36-32-21)31-22(33)7-14-5-6-17(29-12-14)16-8-15-9-19(34-3)20(35-4)10-18(15)30-13-16;7-5(8)3-1-2-4-6(9)10/h2*5-6,8-13H,7H2,1-4H3,(H,31,33);1-4H2,(H,7,8)(H,9,10)
DM9L0D8	CS	CC(C)(C1=NOC(=C1)NC(=O)CC2=CN=C(C=C2)C3=CN=C4C=C(C(=CC4=C3)OC)OC)C(F)(F)F.CC(C)(C1=NOC(=C1)NC(=O)CC2=CN=C(C=C2)C3=CN=C4C=C(C(=CC4=C3)OC)OC)C(F)(F)F.C(CCC(=O)O)CC(=O)O
DM9L0D8	IK	KIKHVJAFGVCFGH-UHFFFAOYSA-N
DM9L0D8	IU	2-[6-(6,7-dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide;hexanedioic acid
DM9L0D8	CA	CAS 2375837-06-0
DM9L0D8	DE	Solid tumour/cancer

DMI826O	ID	DMI826O
DMI826O	DN	BP1002
DMI826O	HS	Phase 1
DMI826O	CP	Bio-Path Holdings
DMI826O	DT	Antisense oligonucleotide
DMI826O	DE	Haematopoietic/lymphoid cancer

DMNY0U5	ID	DMNY0U5
DMNY0U5	DN	BPI-9016 M
DMNY0U5	HS	Phase 1
DMNY0U5	CP	Betta Pharmaceutical
DMNY0U5	DT	Small molecular drug
DMNY0U5	DE	Solid tumour/cancer

DM51MSD	ID	DM51MSD
DM51MSD	DN	BPX-101
DM51MSD	HS	Phase 1
DM51MSD	CP	Bellicum Pharmaceuticals
DM51MSD	DT	Vaccine
DM51MSD	DE	Prostate cancer

DMYERSD	ID	DMYERSD
DMYERSD	DN	BPX-701
DMYERSD	HS	Phase 1
DMYERSD	CP	Bellicum Pharmaceuticals Houston, TX
DMYERSD	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DMOQ2GB	ID	DMOQ2GB
DMOQ2GB	DN	BR6819
DMOQ2GB	HS	Phase 1
DMOQ2GB	CP	Bayer HealthCare Pharmaceuticals Whippany, NJ
DMOQ2GB	DE	Heart failure

DM4R6UV	ID	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	HS	Phase 1
DM4R6UV	SN	BRADYKININ; Kallidin I; 58-82-2; L-Bradykinin; Synthetic bradykinin; Bradykinin (synthetic); Callidin I; UNII-S8TIM42R2W; Kallidin 9; BRS 640; PRS 640; S8TIM42R2W; CHEBI:3165; CHEMBL406291; Bradykinin, Lysyl; BK; Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg; EINECS 200-398-8; L-arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-L-arginine
DM4R6UV	DT	Small molecular drug
DM4R6UV	PC	439201
DM4R6UV	MW	1060.2
DM4R6UV	FM	C50H73N15O11
DM4R6UV	IC	InChI=1S/C50H73N15O11/c51-32(16-7-21-56-49(52)53)45(72)65-25-11-20-39(65)47(74)64-24-9-18-37(64)43(70)58-28-40(67)59-34(26-30-12-3-1-4-13-30)41(68)62-36(29-66)46(73)63-23-10-19-38(63)44(71)61-35(27-31-14-5-2-6-15-31)42(69)60-33(48(75)76)17-8-22-57-50(54)55/h1-6,12-15,32-39,66H,7-11,16-29,51H2,(H,58,70)(H,59,67)(H,60,69)(H,61,71)(H,62,68)(H,75,76)(H4,52,53,56)(H4,54,55,57)/t32-,33-,34-,35-,36-,37-,38-,39-/m0/s1
DM4R6UV	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)N)C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DM4R6UV	IK	QXZGBUJJYSLZLT-FDISYFBBSA-N
DM4R6UV	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM4R6UV	CA	CAS 58-82-2
DM4R6UV	CB	CHEBI:3165

DMK7BND	ID	DMK7BND
DMK7BND	DN	Briciclib
DMK7BND	HS	Phase 1
DMK7BND	SN	Briciclib; 865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); Briciclib; ON 014185; SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro
DMK7BND	CP	Onconova therapeutics
DMK7BND	DT	Small molecular drug
DMK7BND	PC	11248490
DMK7BND	MW	474.4
DMK7BND	FM	C19H23O10PS
DMK7BND	IC	InChI=1S/C19H23O10PS/c1-25-14-10-17(27-3)15(18(11-14)28-4)7-8-31(23,24)12-13-5-6-16(26-2)19(9-13)29-30(20,21)22/h5-11H,12H2,1-4H3,(H2,20,21,22)/b8-7+
DMK7BND	CS	COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)OP(=O)(O)O
DMK7BND	IK	LXENKEWVEVKKGV-BQYQJAHWSA-N
DMK7BND	IU	[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]phenyl] dihydrogen phosphate
DMK7BND	CA	CAS 865783-99-9
DMK7BND	DE	Solid tumour/cancer

DM1V9YG	ID	DM1V9YG
DM1V9YG	DN	BRL-52656
DM1V9YG	HS	Phase 1
DM1V9YG	SN	CHEMBL433508; BRL-52656; SCHEMBL7641140; BRL-52656A; BDBM50007164; 1-(2-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-(4-trifluoromethyl-phenyl)-ethanone; 1-((S)-2-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-(4-trifluoromethyl-phenyl)-ethanone; (S)-1-(2-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-(4-trifluoromethyl-phenyl)-ethanone(BRL 52656)
DM1V9YG	CP	SmithKline Beecham plc
DM1V9YG	DT	Small molecular drug
DM1V9YG	PC	9865223
DM1V9YG	MW	354.4
DM1V9YG	FM	C19H25F3N2O
DM1V9YG	IC	InChI=1S/C19H25F3N2O/c20-19(21,22)16-8-6-15(7-9-16)13-18(25)24-12-2-1-5-17(24)14-23-10-3-4-11-23/h6-9,17H,1-5,10-14H2/t17-/m0/s1
DM1V9YG	CS	C1CCN([C@@H](C1)CN2CCCC2)C(=O)CC3=CC=C(C=C3)C(F)(F)F
DM1V9YG	IK	RFTWMVGLYKJUCZ-KRWDZBQOSA-N
DM1V9YG	IU	1-[(2S)-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]-2-[4-(trifluoromethyl)phenyl]ethanone
DM1V9YG	DE	Pain

DMTDWIE	ID	DMTDWIE
DMTDWIE	DN	BRX-005
DMTDWIE	HS	Phase 1
DMTDWIE	SN	Arimoclomol maleate; BRX-220; Bimoclomol derivatives, Biorex
DMTDWIE	CP	Biorex Research and Development Co
DMTDWIE	DT	Small molecular drug
DMTDWIE	PC	6421776
DMTDWIE	MW	260.329
DMTDWIE	FM	C14H20N4O
DMTDWIE	IC	InChI=1S/C14H20N4O/c1-2-7-18(8-3-1)10-13-11-19-17-14(16-13)12-5-4-6-15-9-12/h4-6,9,13H,1-3,7-8,10-11H2,(H,16,17)
DMTDWIE	CS	C1CCN(CC1)CC2CONC(=N2)C3=CN=CC=C3
DMTDWIE	IK	QWVRTSZDKPRPDF-UHFFFAOYSA-N
DMTDWIE	IU	5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2H-1,2,4-oxadiazine
DMTDWIE	CA	CAS 276690-58-5
DMTDWIE	DE	Amyotrophic lateral sclerosis; Diabetic foot ulcer

DMS4H30	ID	DMS4H30
DMS4H30	DN	BT-063
DMS4H30	HS	Phase 1
DMS4H30	SN	Lupus monocloncal antibody, Biotest; SLE therapeutic antibody, Biotest
DMS4H30	CP	Biotest AG
DMS4H30	DT	Antibody
DMS4H30	DE	Autoimmune diabetes

DMC8XHQ	ID	DMC8XHQ
DMC8XHQ	DN	BTX-A51
DMC8XHQ	HS	Phase 1
DMC8XHQ	CP	BioTheryX
DMC8XHQ	DT	Small molecular drug
DMC8XHQ	DE	Non-hodgkin lymphoma; Advanced solid tumour

DMJ56MS	ID	DMJ56MS
DMJ56MS	DN	BUTYLATEDHYDROXYTOLUENE
DMJ56MS	HS	Phase 1
DMJ56MS	SN	2,6-Di-tert-butyl-4-methylphenol; 128-37-0; Butylated hydroxytoluene; Butylhydroxytoluene; 2,6-Di-tert-butyl-p-cresol; 2,6-Di-t-butyl-4-methylphenol; Ionol; DBPC; Stavox; Dibunol; BHT; Ionol CP; Topanol; Impruvol; Vianol; Dalpac; Ionole; Deenax; Antioxidant KB; 3,5-Di-tert-butyl-4-hydroxytoluene; Sumilizer BHT; Antioxidant 4K; Topanol O; Topanol OC; Vanlube PC; Vanlube PCX; Sustane BHT; Tenamene 3; Antioxidant DBPC; Antioxidant 29; Antioxidant 30; Tenox BHT; Nonox TBC; Chemanox 11; Ionol 1; Agidol; Catalin CAO-3; Advastab 401; Ionol (antioxidan
DMJ56MS	DT	Small molecular drug
DMJ56MS	PC	31404
DMJ56MS	MW	220.35
DMJ56MS	FM	C15H24O
DMJ56MS	IC	InChI=1S/C15H24O/c1-10-8-11(14(2,3)4)13(16)12(9-10)15(5,6)7/h8-9,16H,1-7H3
DMJ56MS	CS	CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C
DMJ56MS	IK	NLZUEZXRPGMBCV-UHFFFAOYSA-N
DMJ56MS	IU	2,6-ditert-butyl-4-methylphenol
DMJ56MS	CA	CAS 128-37-0
DMJ56MS	CB	CHEBI:34247

DM43GPX	ID	DM43GPX
DM43GPX	DN	BVI-007
DM43GPX	HS	Phase 1
DM43GPX	CP	BioVascular
DM43GPX	DE	Thrombotic stroke; Myocardial infarction

DMEP321	ID	DMEP321
DMEP321	DN	BVT-74316
DMEP321	HS	Phase 1
DMEP321	SN	BVT-5182; BVT-5182C; 5-HT6 antagonists (obesity), Biovitrum; 5-HT6 antagonists (obesity), Proximagen
DMEP321	CP	Swedish Orphan Biovitrum AB
DMEP321	DT	Small molecular drug
DMEP321	PC	16092139
DMEP321	MW	416.5
DMEP321	FM	C21H24N2O5S
DMEP321	IC	InChI=1S/C21H24N2O5S/c1-14-3-4-19(26-2)18(11-14)23-29(24,25)17-12-15-7-10-27-21(15)20(13-17)28-16-5-8-22-9-6-16/h3-4,7,10-13,16,22-23H,5-6,8-9H2,1-2H3
DMEP321	CS	CC1=CC(=C(C=C1)OC)NS(=O)(=O)C2=CC(=C3C(=C2)C=CO3)OC4CCNCC4
DMEP321	IK	UPQJYTNALAIZCC-UHFFFAOYSA-N
DMEP321	IU	N-(2-methoxy-5-methylphenyl)-7-piperidin-4-yloxy-1-benzofuran-5-sulfonamide
DMEP321	CA	CAS 917095-86-4
DMEP321	DE	Obesity

DMY9L4C	ID	DMY9L4C
DMY9L4C	DN	BXCL702
DMY9L4C	HS	Phase 1
DMY9L4C	CP	BioXcel Therapeutics Branford, CT
DMY9L4C	DE	Haematological malignancy

DMH6B9J	ID	DMH6B9J
DMH6B9J	DN	BZ-55
DMH6B9J	HS	Phase 1
DMH6B9J	SN	Alentin; Aminophenurobutane; Bucarban; Bucrol; Bukarban; Burcol; Butisulfina; Carbutamid; Carbutamide; Carbutamide [INN:BAN]; Diabetin; Diabetoplex; Diaboral; Diabutan; Emedan; Glucidoral; Glucofren; Glybutamide; Inbuton; Invenol; N'-(Butylcarbamoyl)sulfanilamide; N-Butyl-N'-sulfanilylurea; N-Butylsulfanilylurea; N-Sulfanilyl-N'-butylurea; Nadisan; Nadizan; Norboral; Oranil; Oranyl; Orasulin; Sulfonamide carbutamide; Urea, 1-butyl-3-sulfanilyl-; 1-BUTYL-3-SULFANILYLUREA; 339-43-5; 4-amino-N-[(butylamino)carbonyl]benzenesulfonamide; BZ 55
DMH6B9J	PC	9564
DMH6B9J	MW	271.34
DMH6B9J	FM	C11H17N3O3S
DMH6B9J	IC	VDTNNGKXZGSZIP-UHFFFAOYSA-N
DMH6B9J	CS	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)N
DMH6B9J	IK	1S/C11H17N3O3S/c1-2-3-8-13-11(15)14-18(16,17)10-6-4-9(12)5-7-10/h4-7H,2-3,8,12H2,1H3,(H2,13,14,15)
DMH6B9J	IU	1-(4-aminophenyl)sulfonyl-3-butylurea
DMH6B9J	CA	CAS 339-43-5
DMH6B9J	CB	CHEBI:135118
DMH6B9J	DE	Diabetes mellitus

DMOV2ZD	ID	DMOV2ZD
DMOV2ZD	DN	C188-9
DMOV2ZD	HS	Phase 1
DMOV2ZD	SN	QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9
DMOV2ZD	CP	StemMed Houston, TX
DMOV2ZD	PC	1324494
DMOV2ZD	MW	471.5
DMOV2ZD	FM	C27H21NO5S
DMOV2ZD	IC	InChI=1S/C27H21NO5S/c1-33-18-11-13-19(14-12-18)34(31,32)28-24-16-23(27(30)22-9-5-4-8-21(22)24)26-20-7-3-2-6-17(20)10-15-25(26)29/h2-16,28-30H,1H3
DMOV2ZD	CS	COC1=CC=C(C=C1)S(=O)(=O)NC2=CC(=C(C3=CC=CC=C32)O)C4=C(C=CC5=CC=CC=C54)O
DMOV2ZD	IK	QDCJDYWGYVPBDO-UHFFFAOYSA-N
DMOV2ZD	IU	N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide
DMOV2ZD	CA	CAS 432001-19-9
DMOV2ZD	DE	Solid tumour/cancer

DMOFT1V	ID	DMOFT1V
DMOFT1V	DN	C-2507
DMOFT1V	HS	Phase 1
DMOFT1V	SN	L-0008708100; L-870810; L-870812; L-900564; HIV integrase inhibitors, Merck & Co; Integric acid, Merck & Co
DMOFT1V	CP	Merck & Co Inc
DMOFT1V	DT	Small molecular drug
DMOFT1V	PC	56973024
DMOFT1V	MW	502.5
DMOFT1V	FM	C11H20F6N2O7S3
DMOFT1V	IC	InChI=1S/C9H19NO3S.C2HF6NO4S2/c11-14(12,13)9-5-4-8-10-6-2-1-3-7-10;3-1(4,5)14(10,11)9-15(12,13)2(6,7)8/h1-9H2,(H,11,12,13);9H
DMOFT1V	CS	C1CCN(CC1)CCCCS(=O)(=O)O.C(F)(F)(F)S(=O)(=O)NS(=O)(=O)C(F)(F)F
DMOFT1V	IK	IMVWFEMFPIUJGS-UHFFFAOYSA-N
DMOFT1V	IU	4-piperidin-1-ylbutane-1-sulfonic acid;1,1,1-trifluoro-N-(trifluoromethylsulfonyl)methanesulfonamide
DMOFT1V	DE	Human immunodeficiency virus infection

DMR0S8U	ID	DMR0S8U
DMR0S8U	DN	C326
DMR0S8U	HS	Phase 1
DMR0S8U	CP	Avidia
DMR0S8U	DE	Crohn disease

DMSO3JA	ID	DMSO3JA
DMSO3JA	DN	C7R-GD2.CART cells
DMSO3JA	HS	Phase 1
DMSO3JA	CP	Baylor College of Medicine
DMSO3JA	DT	CAR T Cell Therapy
DMSO3JA	DE	Neuroblastoma

DMPQ1TM	ID	DMPQ1TM
DMPQ1TM	DN	CA-011
DMPQ1TM	HS	Phase 1
DMPQ1TM	SN	2-Amino-4-(p-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-1,3-thiazol-2-amine; 2104/9/8; 2-Amino-4-(4-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-2-thiazolamine; 2-Thiazolamine, 4-(4-nitrophenyl)-; 4-(4-nitrophenyl)thiazol-2-amine; THIAZOLE, 2-AMINO-4-(p-NITROPHENYL)-; 4-(4-Nitrophenyl)thiazol-2-ylamine; 2-amino-4-(4'-nitrophenyl)-1,3-thiazole; RIKJWJIWXCUKQV-UHFFFAOYSA-N; BRN 0200321; 4-(4-Nitro-phenyl)-thiazol-2-ylamine; AI3-62320; 4-(4-nitrophenyl)-1,3-thiazole-2-ylamine; DSSTox_CID_65; AC1L27WX; Cambridge id 5156331; DSSTox_RID_
DMPQ1TM	CP	Concentric Analgesics Los Altos, CA
DMPQ1TM	PC	16420
DMPQ1TM	MW	221.24
DMPQ1TM	FM	C9H7N3O2S
DMPQ1TM	IC	InChI=1S/C9H7N3O2S/c10-9-11-8(5-15-9)6-1-3-7(4-2-6)12(13)14/h1-5H,(H2,10,11)
DMPQ1TM	CS	C1=CC(=CC=C1C2=CSC(=N2)N)[N+](=O)[O-]
DMPQ1TM	IK	RIKJWJIWXCUKQV-UHFFFAOYSA-N
DMPQ1TM	IU	4-(4-nitrophenyl)-1,3-thiazol-2-amine
DMPQ1TM	CA	CAS 2104-09-8
DMPQ1TM	DE	Chronic pain

DMYDNQ2	ID	DMYDNQ2
DMYDNQ2	DN	CA102N
DMYDNQ2	HS	Phase 1
DMYDNQ2	CP	Holy Stone Healthcare
DMYDNQ2	DT	Small molecular drug
DMYDNQ2	DE	Solid tumour/cancer

DMOUHR4	ID	DMOUHR4
DMOUHR4	DN	CA-170
DMOUHR4	HS	Phase 1
DMOUHR4	SN	3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097
DMOUHR4	CP	Curis Lexington, MA
DMOUHR4	DT	Small molecule immunotherapy 
DMOUHR4	PC	16212596
DMOUHR4	MW	159.05
DMOUHR4	FM	C4H12Cl2N2
DMOUHR4	IC	InChI=1S/C4H10N2.2ClH/c5-4-1-2-6-3-4;;/h4,6H,1-3,5H2;2*1H
DMOUHR4	CS	C1CNCC1N.Cl.Cl
DMOUHR4	IK	NJPNCMOUEXEGBL-UHFFFAOYSA-N
DMOUHR4	IU	pyrrolidin-3-amine;dihydrochloride
DMOUHR4	CA	CAS 103831-11-4
DMOUHR4	DE	Lymphoma; Solid tumour/cancer

DMQ2OP0	ID	DMQ2OP0
DMQ2OP0	DN	CA-170
DMQ2OP0	HS	Phase 1
DMQ2OP0	CP	Curis
DMQ2OP0	DT	Small molecular drug
DMQ2OP0	DE	Lymphoma; Solid tumour/cancer

DMWV8C6	ID	DMWV8C6
DMWV8C6	DN	CA-4948
DMWV8C6	HS	Phase 1
DMWV8C6	SN	RWIMETUXCNDSLE-UHFFFAOYSA-N; SCHEMBL16896371; GTPL10152; CA4948; AU4948; AU-4948; example 1 [WO2015104688A1]; HY-109585; CS-0032273; 6'-Amino-N-[2-(morpholin-4-yl)-[1,3]oxazolo[4,5-b]pyridin-6-yl]-[2,3'-bipyridine]-6-carboxamide; 6-(6-aminopyridin-3-yl)-N-(2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide
DMWV8C6	CP	Curis Lexington, MA
DMWV8C6	PC	118224238
DMWV8C6	MW	417.4
DMWV8C6	FM	C21H19N7O3
DMWV8C6	IC	InChI=1S/C21H19N7O3/c22-18-5-4-13(11-23-18)15-2-1-3-16(26-15)20(29)25-14-10-17-19(24-12-14)27-21(31-17)28-6-8-30-9-7-28/h1-5,10-12H,6-9H2,(H2,22,23)(H,25,29)
DMWV8C6	CS	C1COCCN1C2=NC3=C(O2)C=C(C=N3)NC(=O)C4=CC=CC(=N4)C5=CN=C(C=C5)N
DMWV8C6	IK	RWIMETUXCNDSLE-UHFFFAOYSA-N
DMWV8C6	IU	6-(6-aminopyridin-3-yl)-N-(2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide
DMWV8C6	DE	Lymphoma

DMA1QUC	ID	DMA1QUC
DMA1QUC	DN	CAD-1833
DMA1QUC	HS	Phase 1
DMA1QUC	CP	Cadent Therapeutics Cambridge, MA
DMA1QUC	DE	Essential tremor or related tremors; Spinocerebellar ataxia

DMQ7WJI	ID	DMQ7WJI
DMQ7WJI	DN	CAF-01
DMQ7WJI	HS	Phase 1
DMQ7WJI	SN	TDB; Liposomal adjuvant, Statens Serum Institut; Alpha,alpha'-trehalose 6,6'-dibehenate
DMQ7WJI	CP	Statens Serum Institut
DMQ7WJI	DE	Vaccination

DMT4Z5B	ID	DMT4Z5B
DMT4Z5B	DN	CALAA-01
DMT4Z5B	HS	Phase 1
DMT4Z5B	SN	Ribonucleotide reductase M2 subunit (RRM2)-targeted siRNA agent (RONDEL, intravenous, cancer), Calando
DMT4Z5B	CP	Calando pharmaceuticals
DMT4Z5B	DE	Solid tumour/cancer

DMQTUH8	ID	DMQTUH8
DMQTUH8	DN	Calanolide A
DMQTUH8	HS	Phase 1
DMQTUH8	SN	NSC-675451; NSC-664737 (racemate); (+)-(10R,11S,12S)-12-Hydroxy-6,6,10,11-tetramethyl-4-propyl-6,10,11,12-tetrahydro-2H-benzo[1,2-b:3,4-b':5,6-b'']tripyran-2-one; (+)-Calanolide A
DMQTUH8	CP	Sarawak MediChem Pharmaceuticals
DMQTUH8	DT	Small molecular drug
DMQTUH8	PC	64972
DMQTUH8	MW	370.4
DMQTUH8	FM	C22H26O5
DMQTUH8	IC	InChI=1S/C22H26O5/c1-6-7-13-10-15(23)26-21-16(13)20-14(8-9-22(4,5)27-20)19-17(21)18(24)11(2)12(3)25-19/h8-12,18,24H,6-7H2,1-5H3/t11-,12-,18+/m1/s1
DMQTUH8	CS	CCCC1=CC(=O)OC2=C1C3=C(C=CC(O3)(C)C)C4=C2[C@H]([C@@H]([C@H](O4)C)C)O
DMQTUH8	IK	NIDRYBLTWYFCFV-FMTVUPSXSA-N
DMQTUH8	IU	(16R,17S,18S)-18-hydroxy-10,10,16,17-tetramethyl-6-propyl-3,9,15-trioxatetracyclo[12.4.0.02,7.08,13]octadeca-1(14),2(7),5,8(13),11-pentaen-4-one
DMQTUH8	CA	CAS 142632-32-4
DMQTUH8	CB	CHEBI:65552
DMQTUH8	DE	Mycobacterium infection

DM1FLXD	ID	DM1FLXD
DM1FLXD	DN	CAN04
DM1FLXD	HS	Phase 1
DM1FLXD	CP	Cantargia
DM1FLXD	DT	Antibody
DM1FLXD	DE	Non-small-cell lung cancer

DM9ERH1	ID	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	HS	Phase 1
DM9ERH1	SN	AG-1549; S-1153; NNRTI (HIV infection), Pfizer
DM9ERH1	CP	Shionogi & Co Ltd
DM9ERH1	DT	Small molecular drug
DM9ERH1	PC	1783
DM9ERH1	MW	451.4
DM9ERH1	FM	C20H20Cl2N4O2S
DM9ERH1	IC	InChI=1S/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27)
DM9ERH1	CS	CC(C)C1=C(N(C(=N1)COC(=O)N)CC2=CC=NC=C2)SC3=CC(=CC(=C3)Cl)Cl
DM9ERH1	IK	YQXCVAGCMNFUMQ-UHFFFAOYSA-N
DM9ERH1	IU	[5-(3,5-dichlorophenyl)sulfanyl-4-propan-2-yl-1-(pyridin-4-ylmethyl)imidazol-2-yl]methyl carbamate
DM9ERH1	CA	CAS 178979-85-6
DM9ERH1	DE	Human immunodeficiency virus infection

DM8NLPI	ID	DM8NLPI
DM8NLPI	DN	CAR CD30 T cells
DM8NLPI	HS	Phase 1
DM8NLPI	CP	UNC Lineberger Comprehensive Cancer Center
DM8NLPI	DT	CAR T Cell Therapy
DM8NLPI	DE	Non-hodgkin lymphoma; Hodgkin lymphoma

DMA9M81	ID	DMA9M81
DMA9M81	DN	CAR138 T Cells
DMA9M81	HS	Phase 1
DMA9M81	CP	UNC Lineberger Comprehensive Cancer Center
DMA9M81	DT	CAR T Cell Therapy
DMA9M81	DE	Immune System disease; Multiple myeloma

DMXD4TC	ID	DMXD4TC
DMXD4TC	DN	CAR19 T cells carrying cytoplasmic activated PD-1
DMXD4TC	HS	Phase 1
DMXD4TC	CP	Henan Cancer Hospital
DMXD4TC	DT	CAR T Cell Therapy
DMXD4TC	DE	Non-hodgkin lymphoma

DM4CXE2	ID	DM4CXE2
DM4CXE2	DN	CAR-20/19-T Cells
DM4CXE2	HS	Phase 1
DM4CXE2	CP	Medical College of Wisconsin
DM4CXE2	DT	CAR T Cell Therapy (Dual specific)
DM4CXE2	DE	B-cell non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Pancreatic cancer

DM4SNK8	ID	DM4SNK8
DM4SNK8	DN	CARD-024
DM4SNK8	HS	Phase 1
DM4SNK8	SN	1-alpha-hydroxyvitamin D5 (cardiovascular diseases), Cardiavent; 1a(OH)VitD5 (cardiovascular diseases), Cardiavent
DM4SNK8	CP	Cardiavent Inc
DM4SNK8	PC	10025615
DM4SNK8	MW	428.7
DM4SNK8	FM	C29H48O2
DM4SNK8	IC	InChI=1S/C29H48O2/c1-7-22(19(2)3)11-10-20(4)26-14-15-27-23(9-8-16-29(26,27)6)12-13-24-17-25(30)18-28(31)21(24)5/h12-13,19-20,22,25-28,30-31H,5,7-11,14-18H2,1-4,6H3/b23-12+,24-13-/t20-,22-,25-,26-,27+,28+,29-/m1/s1
DM4SNK8	CS	CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C)C(C)C
DM4SNK8	IK	NWFOBODUYTUMNC-VPSCEVSQSA-N
DM4SNK8	IU	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM4SNK8	CA	CAS 187935-17-7
DM4SNK8	DE	Cardiovascular disease

DM5WKU1	ID	DM5WKU1
DM5WKU1	DN	Cardiotrophin-1
DM5WKU1	HS	Phase 1
DM5WKU1	SN	Cardiotrophin-1 (acute liver failure/obesity/interferon stimulator)
DM5WKU1	CP	Digna Biotech SL
DM5WKU1	DE	Acute liver failure

DMQH2DK	ID	DMQH2DK
DMQH2DK	DN	CAR-GPC3 T Cells
DMQH2DK	HS	Phase 1
DMQH2DK	CP	Carsgen Therapeutics, Ltd.
DMQH2DK	DT	CAR T Cell Therapy
DMQH2DK	DE	Lung squamous cell carcinoma

DMU6ZMX	ID	DMU6ZMX
DMU6ZMX	DN	Carmoxirole
DMU6ZMX	HS	Phase 1
DMU6ZMX	SN	Carmoxirole hydrochloride; EMD-45609
DMU6ZMX	CP	Merck KGaA
DMU6ZMX	DT	Small molecular drug
DMU6ZMX	PC	57364
DMU6ZMX	MW	374.5
DMU6ZMX	FM	C24H26N2O2
DMU6ZMX	IC	InChI=1S/C24H26N2O2/c27-24(28)20-9-10-23-22(16-20)21(17-25-23)8-4-5-13-26-14-11-19(12-15-26)18-6-2-1-3-7-18/h1-3,6-7,9-11,16-17,25H,4-5,8,12-15H2,(H,27,28)
DMU6ZMX	CS	C1CN(CC=C1C2=CC=CC=C2)CCCCC3=CNC4=C3C=C(C=C4)C(=O)O
DMU6ZMX	IK	AFSOIHMEOKEZJF-UHFFFAOYSA-N
DMU6ZMX	IU	3-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1H-indole-5-carboxylic acid
DMU6ZMX	CA	CAS 98323-83-2
DMU6ZMX	CB	CHEBI:64200
DMU6ZMX	DE	Hypertension

DMC7Y5F	ID	DMC7Y5F
DMC7Y5F	DN	CAR-T cells recognizing EpCAM
DMC7Y5F	HS	Phase 1
DMC7Y5F	CP	Sichuan University
DMC7Y5F	DT	CAR T Cell Therapy
DMC7Y5F	DE	Melanoma; Breast cancer

DMTZADW	ID	DMTZADW
DMTZADW	DN	CAR-T cells targeting BCMA
DMTZADW	HS	Phase 1
DMTZADW	CP	Second Affiliated Hospital of Xi'an Jiaotong University
DMTZADW	DT	CAR T Cell Therapy
DMTZADW	DE	Multiple myeloma

DM3AHNX	ID	DM3AHNX
DM3AHNX	DN	CAR-T Cells targeting CD19
DM3AHNX	HS	Phase 1
DM3AHNX	CP	Seattle Children's Hospital
DM3AHNX	DT	CAR T Cell Therapy
DM3AHNX	DE	Acute lymphoblastic leukaemia

DMJK1R0	ID	DMJK1R0
DMJK1R0	DN	CAR-T cells targeting CD19
DMJK1R0	HS	Phase 1
DMJK1R0	CP	Sinobioway Cell Therapy Co., Ltd.
DMJK1R0	DT	CAR T Cell Therapy
DMJK1R0	DE	Lymphoma

DM6Z7AD	ID	DM6Z7AD
DM6Z7AD	DN	CAR-T cells targeting CD80/86
DM6Z7AD	HS	Phase 1
DM6Z7AD	CP	Second Affiliated Hospital of Guangzhou Medical University
DM6Z7AD	DT	CAR T Cell Therapy
DM6Z7AD	DE	Solid tumour/cancer

DMX4ZDY	ID	DMX4ZDY
DMX4ZDY	DN	CAR-T Cells targeting CEA
DMX4ZDY	HS	Phase 1
DMX4ZDY	CP	First Affiliated Hospital of Harbin Medical University
DMX4ZDY	DT	CAR T Cell Therapy
DMX4ZDY	DE	Pancreatic cancer

DMRSG04	ID	DMRSG04
DMRSG04	DN	CAR-T cells targeting EGFRviii
DMRSG04	HS	Phase 1
DMRSG04	CP	Shenzhen Geno-Immune Medical Institute
DMRSG04	DT	CAR T Cell Therapy
DMRSG04	DE	Glioblastoma multiforme

DMWAMNT	ID	DMWAMNT
DMWAMNT	DN	CAR-T Cells targeting EGFRvIII
DMWAMNT	HS	Phase 1
DMWAMNT	CP	First Affiliated Hospital of Harbin Medical University
DMWAMNT	DT	CAR T Cell Therapy
DMWAMNT	DE	Pancreatic cancer

DMQ2Y1J	ID	DMQ2Y1J
DMQ2Y1J	DN	CAR-T cells targeting EpCAM
DMQ2Y1J	HS	Phase 1
DMQ2Y1J	CP	Jian-Kun Hu
DMQ2Y1J	DT	CAR T Cell Therapy
DMQ2Y1J	DE	Metastatic cancer; Gastric adenocarcinoma

DMLI5VG	ID	DMLI5VG
DMLI5VG	DN	CAR-T cells targeting HER2
DMLI5VG	HS	Phase 1
DMLI5VG	CP	Second Affiliated Hospital of Guangzhou Medical University
DMLI5VG	DT	CAR T Cell Therapy
DMLI5VG	DE	Solid tumour/cancer

DMYCMNR	ID	DMYCMNR
DMYCMNR	DN	CAR-T Cells targeting HER2
DMYCMNR	HS	Phase 1
DMYCMNR	CP	First Affiliated Hospital of Harbin Medical University
DMYCMNR	DT	CAR T Cell Therapy
DMYCMNR	DE	Pancreatic cancer

DMGI58S	ID	DMGI58S
DMGI58S	DN	CAR-T cells targeting Lewis-Y
DMGI58S	HS	Phase 1
DMGI58S	CP	Second Affiliated Hospital of Guangzhou Medical University
DMGI58S	DT	CAR T Cell Therapy
DMGI58S	DE	Solid tumour/cancer

DM6DULC	ID	DM6DULC
DM6DULC	DN	CAR-T Cells targeting Mesothelin
DM6DULC	HS	Phase 1
DM6DULC	CP	First Affiliated Hospital of Harbin Medical University
DM6DULC	DT	CAR T Cell Therapy
DM6DULC	DE	Pancreatic cancer

DMTZXSO	ID	DMTZXSO
DMTZXSO	DN	CAR-T cells targeting Mesothelin
DMTZXSO	HS	Phase 1
DMTZXSO	CP	Second Affiliated Hospital of Guangzhou Medical University
DMTZXSO	DT	CAR T Cell Therapy
DMTZXSO	DE	Solid tumour/cancer

DM6GRNC	ID	DM6GRNC
DM6GRNC	DN	CAR-T cells targeting MUC1
DM6GRNC	HS	Phase 1
DM6GRNC	CP	Second Affiliated Hospital of Guangzhou Medical University
DM6GRNC	DT	CAR T Cell Therapy
DM6GRNC	DE	Solid tumour/cancer

DMNH1Y5	ID	DMNH1Y5
DMNH1Y5	DN	CAR-T Cells targeting MUCI
DMNH1Y5	HS	Phase 1
DMNH1Y5	CP	First Affiliated Hospital of Harbin Medical University
DMNH1Y5	DT	CAR T Cell Therapy
DMNH1Y5	DE	Pancreatic cancer

DMU4G9J	ID	DMU4G9J
DMU4G9J	DN	CAR-T cells targeting PSCA
DMU4G9J	HS	Phase 1
DMU4G9J	CP	Second Affiliated Hospital of Guangzhou Medical University
DMU4G9J	DT	CAR T Cell Therapy
DMU4G9J	DE	Solid tumour/cancer

DMWIXLC	ID	DMWIXLC
DMWIXLC	DN	CAR-T Cells targeting PSCA
DMWIXLC	HS	Phase 1
DMWIXLC	CP	First Affiliated Hospital of Harbin Medical University
DMWIXLC	DT	CAR T Cell Therapy
DMWIXLC	DE	Pancreatic cancer

DMQ4UJ6	ID	DMQ4UJ6
DMQ4UJ6	DN	CART-10 cells
DMQ4UJ6	HS	Phase 1
DMQ4UJ6	CP	Zhujiang Hospital
DMQ4UJ6	DT	CAR T Cell Therapy
DMQ4UJ6	DE	Acute lymphoblastic leukaemia

DMAKZTW	ID	DMAKZTW
DMAKZTW	DN	CART-117 cells
DMAKZTW	HS	Phase 1
DMAKZTW	CP	Zhujiang Hospital
DMAKZTW	DT	CAR T Cell Therapy
DMAKZTW	DE	Myelodysplastic syndrome; Acute myeloid leukaemia

DMD0XWR	ID	DMD0XWR
DMD0XWR	DN	CART123 cells
DMD0XWR	HS	Phase 1
DMD0XWR	CP	University of Pennsylvania
DMD0XWR	DT	CAR T Cell Therapy
DMD0XWR	DE	Acute myeloid leukaemia

DMEN6YF	ID	DMEN6YF
DMEN6YF	DN	CART-123 cells
DMEN6YF	HS	Phase 1
DMEN6YF	CP	Zhujiang Hospital
DMEN6YF	DT	CAR T Cell Therapy
DMEN6YF	DE	Myelodysplastic syndrome; Acute myeloid leukaemia

DM1R8P4	ID	DM1R8P4
DM1R8P4	DN	CART-19
DM1R8P4	HS	Phase 1
DM1R8P4	CP	Henan Cancer Hospital
DM1R8P4	DT	CAR T Cell Therapy
DM1R8P4	DE	B-cell lymphoma

DM8R2ZX	ID	DM8R2ZX
DM8R2ZX	DN	CART-19
DM8R2ZX	HS	Phase 1
DM8R2ZX	CP	Beijing Sanwater Biological Technology Co., Ltd.
DM8R2ZX	DT	CAR T Cell Therapy
DM8R2ZX	DE	Acute lymphoblastic leukaemia

DMY218P	ID	DMY218P
DMY218P	DN	CART-19 autologous T-cells
DMY218P	HS	Phase 1
DMY218P	CP	University of Pennsylvania
DMY218P	DT	CAR T Cell Therapy
DMY218P	DE	Lymphoma

DMM95XS	ID	DMM95XS
DMM95XS	DN	CART19 cell
DMM95XS	HS	Phase 1
DMM95XS	CP	Shenzhen Second People's Hospital
DMM95XS	DT	CAR T Cell Therapy
DMM95XS	DE	B-cell prolymphocytic leukaemia

DMHWVY1	ID	DMHWVY1
DMHWVY1	DN	CART-19 cells
DMHWVY1	HS	Phase 1
DMHWVY1	CP	Zhujiang Hospital
DMHWVY1	DT	CAR T Cell Therapy
DMHWVY1	DE	Acute lymphoblastic leukaemia

DMKW27X	ID	DMKW27X
DMKW27X	DN	CART-19 cells
DMKW27X	HS	Phase 1
DMKW27X	CP	Henan Cancer Hospital
DMKW27X	DT	CAR T Cell Therapy
DMKW27X	DE	Acute lymphoblastic leukaemia

DMTCB8I	ID	DMTCB8I
DMTCB8I	DN	CART-19 T cells
DMTCB8I	HS	Phase 1
DMTCB8I	CP	University of Pennsylvania
DMTCB8I	DT	CAR T Cell Therapy
DMTCB8I	DE	Multiple myeloma

DMR0Z65	ID	DMR0Z65
DMR0Z65	DN	CART-20 cells
DMR0Z65	HS	Phase 1
DMR0Z65	CP	Zhujiang Hospital
DMR0Z65	DT	CAR T Cell Therapy
DMR0Z65	DE	Acute lymphoblastic leukaemia

DM6X82R	ID	DM6X82R
DM6X82R	DN	CART22 cells
DM6X82R	HS	Phase 1
DM6X82R	CP	University of Pennsylvania
DM6X82R	DT	CAR T Cell Therapy
DM6X82R	DE	Acute lymphoblastic leukaemia

DMLGJKE	ID	DMLGJKE
DMLGJKE	DN	CART-22 cells
DMLGJKE	HS	Phase 1
DMLGJKE	CP	Zhujiang Hospital
DMLGJKE	DT	CAR T Cell Therapy
DMLGJKE	DE	Acute lymphoblastic leukaemia

DMY3NWK	ID	DMY3NWK
DMY3NWK	DN	CART22 cells expressing anti-CD22 scFv TCRz:41BB
DMY3NWK	HS	Phase 1
DMY3NWK	CP	University of Pennsylvania
DMY3NWK	DT	CAR T Cell Therapy
DMY3NWK	DE	Acute lymphoblastic leukaemia

DM4XT15	ID	DM4XT15
DM4XT15	DN	CART22-65s cells
DM4XT15	HS	Phase 1
DM4XT15	CP	University of Pennsylvania
DM4XT15	DT	CAR T Cell Therapy
DM4XT15	DE	Acute lymphoblastic leukaemia

DMOJ1AH	ID	DMOJ1AH
DMOJ1AH	DN	CART22-65s cells and huCART19 Cells
DMOJ1AH	HS	Phase 1
DMOJ1AH	CP	University of Pennsylvania
DMOJ1AH	DT	CAR T Cell Therapy (Dual specific)
DMOJ1AH	DE	Acute lymphoblastic leukaemia

DMBHCSL	ID	DMBHCSL
DMBHCSL	DN	CART-33 cells
DMBHCSL	HS	Phase 1
DMBHCSL	CP	Zhujiang Hospital
DMBHCSL	DT	CAR T Cell Therapy
DMBHCSL	DE	Myelodysplastic syndrome; Acute myeloid leukaemia

DMRNIB9	ID	DMRNIB9
DMRNIB9	DN	CART-34 cells
DMRNIB9	HS	Phase 1
DMRNIB9	CP	Zhujiang Hospital
DMRNIB9	DT	CAR T Cell Therapy
DMRNIB9	DE	Myelodysplastic syndrome; Acute myeloid leukaemia

DMKN8XD	ID	DMKN8XD
DMKN8XD	DN	CART-38 cells
DMKN8XD	HS	Phase 1
DMKN8XD	CP	Zhujiang Hospital
DMKN8XD	DT	CAR T Cell Therapy
DMKN8XD	DE	Myelodysplastic syndrome; Acute myeloid leukaemia

DMQTOBF	ID	DMQTOBF
DMQTOBF	DN	CART-56 cells
DMQTOBF	HS	Phase 1
DMQTOBF	CP	Zhujiang Hospital
DMQTOBF	DT	CAR T Cell Therapy
DMQTOBF	DE	Myelodysplastic syndrome; Acute myeloid leukaemia

DMVK3M2	ID	DMVK3M2
DMVK3M2	DN	CART-BCMA
DMVK3M2	HS	Phase 1
DMVK3M2	CP	University of Pennsylvania
DMVK3M2	DT	CAR T Cell Therapy
DMVK3M2	DE	Multiple myeloma

DM4OWJ8	ID	DM4OWJ8
DM4OWJ8	DN	CART-ddBCMA
DM4OWJ8	HS	Phase 1
DM4OWJ8	CP	Arcellx
DM4OWJ8	DT	CAR T Cell Therapy
DM4OWJ8	DE	Multiple myeloma

DMGPR1C	ID	DMGPR1C
DMGPR1C	DN	CART-EGFRvIII T cells
DMGPR1C	HS	Phase 1
DMGPR1C	CP	University of Pennsylvania
DMGPR1C	DT	CAR T Cell Therapy
DMGPR1C	DE	Glioma; Recurrent glioblastoma

DM90QPK	ID	DM90QPK
DM90QPK	DN	CART-meso cells
DM90QPK	HS	Phase 1
DM90QPK	CP	University of Pennsylvania
DM90QPK	DT	CAR T Cell Therapy
DM90QPK	DE	Pancreatic cancer

DMV84ZR	ID	DMV84ZR
DMV84ZR	DN	CARTmeso/19
DMV84ZR	HS	Phase 1
DMV84ZR	CP	First Affiliated Hospital of Wenzhou Medical University
DMV84ZR	DT	CAR T Cell Therapy (Dual specific)
DMV84ZR	DE	Pancreatic cancer

DMZ4I03	ID	DMZ4I03
DMZ4I03	DN	CART-meso-19 T cells
DMZ4I03	HS	Phase 1
DMZ4I03	CP	University of Pennsylvania
DMZ4I03	DT	CAR T Cell Therapy (Dual specific)
DMZ4I03	DE	Pancreatic cancer

DMOJEXG	ID	DMOJEXG
DMOJEXG	DN	CART-Muc1 cells
DMOJEXG	HS	Phase 1
DMOJEXG	CP	Zhujiang Hospital
DMOJEXG	DT	CAR T Cell Therapy
DMOJEXG	DE	Myelodysplastic syndrome; Acute myeloid leukaemia

DM39LPN	ID	DM39LPN
DM39LPN	DN	CarVAC
DM39LPN	HS	Phase 1
DM39LPN	CP	iCell Gene Therapeutics
DM39LPN	DT	CAR T Cell Therapy
DM39LPN	DE	B-cell lymphoma

DMO53AD	ID	DMO53AD
DMO53AD	DN	Cavrotolimod
DMO53AD	HS	Phase 1
DMO53AD	CP	Exicure
DMO53AD	DT	Small molecular drug
DMO53AD	DE	Solid tumour/cancer

DM12GN7	ID	DM12GN7
DM12GN7	DN	CB-5083
DM12GN7	HS	Phase 1
DM12GN7	CP	Cleave biosciences
DM12GN7	PC	73051434
DM12GN7	MW	413.5
DM12GN7	FM	C24H23N5O2
DM12GN7	IC	InChI=1S/C24H23N5O2/c1-15-12-18-17(22(25)30)8-5-9-21(18)29(15)24-27-20-10-11-31-14-19(20)23(28-24)26-13-16-6-3-2-4-7-16/h2-9,12H,10-11,13-14H2,1H3,(H2,25,30)(H,26,27,28)
DM12GN7	CS	CC1=CC2=C(C=CC=C2N1C3=NC4=C(COCC4)C(=N3)NCC5=CC=CC=C5)C(=O)N
DM12GN7	IK	RDALZZCKQFLGJP-UHFFFAOYSA-N
DM12GN7	IU	1-[4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methylindole-4-carboxamide
DM12GN7	CA	CAS 1542705-92-9
DM12GN7	DE	Multiple myeloma; Solid tumour/cancer

DMOXDIY	ID	DMOXDIY
DMOXDIY	DN	CB-5339
DMOXDIY	HS	Phase 1
DMOXDIY	CP	Cleave Therapeutics
DMOXDIY	DT	Small molecular drug
DMOXDIY	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DMXQGKL	ID	DMXQGKL
DMXQGKL	DN	CB-813
DMXQGKL	HS	Phase 1
DMXQGKL	SN	CB-813d; Recombinant human factor VIIa (Alterase, hemophilia), Catalyst Biosciences; RhFVIIa (Alterase, hemophilia), Catalyst Biosciences; Recombinant human factor VIIa (Alterase, hemophilia), Catalyst Biosciences/Wyeth Pharmaceuticals
DMXQGKL	CP	Catalyst biosciences; pfizer
DMXQGKL	DT	Small molecular drug
DMXQGKL	PC	208688
DMXQGKL	MW	349.9
DMXQGKL	FM	C20H28ClNO2
DMXQGKL	IC	InChI=1S/C20H28ClNO2/c21-19-15-16(9-10-18(19)17-6-2-1-3-7-17)5-4-8-20(23)22-11-13-24-14-12-22/h9-10,15,17H,1-8,11-14H2
DMXQGKL	CS	C1CCC(CC1)C2=C(C=C(C=C2)CCCC(=O)N3CCOCC3)Cl
DMXQGKL	IK	GCECPNQPPJYYOR-UHFFFAOYSA-N
DMXQGKL	IU	4-(3-chloro-4-cyclohexylphenyl)-1-morpholin-4-ylbutan-1-one
DMXQGKL	CA	CAS 32808-74-5
DMXQGKL	DE	Hemophilia

DMORN60	ID	DMORN60
DMORN60	DN	CBL0137
DMORN60	HS	Phase 1
DMORN60	CP	Cleveland biolabs
DMORN60	PC	44519124
DMORN60	MW	336.4
DMORN60	FM	C21H24N2O2
DMORN60	IC	InChI=1S/C21H24N2O2/c1-13(2)22-9-10-23-20-7-5-16(14(3)24)11-18(20)19-12-17(15(4)25)6-8-21(19)23/h5-8,11-13,22H,9-10H2,1-4H3
DMORN60	CS	CC(C)NCCN1C2=C(C=C(C=C2)C(=O)C)C3=C1C=CC(=C3)C(=O)C
DMORN60	IK	JKCSODVERGVDLT-UHFFFAOYSA-N
DMORN60	IU	1-[6-acetyl-9-[2-(propan-2-ylamino)ethyl]carbazol-3-yl]ethanone
DMORN60	CA	CAS 1197996-80-7
DMORN60	CB	CHEBI:138650
DMORN60	DE	Advanced solid tumour

DMOTLN4	ID	DMOTLN4
DMOTLN4	DN	CBT-101
DMOTLN4	HS	Phase 1
DMOTLN4	SN	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride
DMOTLN4	DE	Glaucoma/ocular hypertension; Solid tumour/cancer

DMW1OKT	ID	DMW1OKT
DMW1OKT	DN	CBT-501
DMW1OKT	HS	Phase 1
DMW1OKT	CP	CBT Pharmaceuticals Santa Clara, CA
DMW1OKT	DE	Solid tumour/cancer

DM0SRAN	ID	DM0SRAN
DM0SRAN	DN	CC-122
DM0SRAN	HS	Phase 1
DM0SRAN	SN	cc-122; 1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995
DM0SRAN	CP	Celgene
DM0SRAN	DT	Small molecular drug
DM0SRAN	PC	24967599
DM0SRAN	MW	286.29
DM0SRAN	FM	C14H14N4O3
DM0SRAN	IC	InChI=1S/C14H14N4O3/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20/h2-4,10H,5-6,15H2,1H3,(H,17,19,20)
DM0SRAN	CS	CC1=NC2=CC=CC(=C2C(=O)N1C3CCC(=O)NC3=O)N
DM0SRAN	IK	RSNPAKAFCAAMBH-UHFFFAOYSA-N
DM0SRAN	IU	3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione
DM0SRAN	CA	CAS 1015474-32-4
DM0SRAN	DE	Solid tumour/cancer; Recurrent glioblastoma; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Hepatocellular carcinoma; Lymphoma; Multiple myeloma

DMAYHT4	ID	DMAYHT4
DMAYHT4	DN	CC-31244
DMAYHT4	HS	Phase 1
DMAYHT4	CP	Cocrystal Pharma
DMAYHT4	DT	Small molecular drug
DMAYHT4	DE	Hepatitis C virus infection

DMILHMC	ID	DMILHMC
DMILHMC	DN	CC8464
DMILHMC	HS	Phase 1
DMILHMC	SN	ASP1807
DMILHMC	CP	Astellas Northbrook, IL Chromocell North Brunswick, NJ
DMILHMC	DE	Neuropathic pain; Pain

DMXUT3Z	ID	DMXUT3Z
DMXUT3Z	DN	CC-8490
DMXUT3Z	HS	Phase 1
DMXUT3Z	CP	Celgene
DMXUT3Z	DE	Brain cancer

DMK0QDO	ID	DMK0QDO
DMK0QDO	DN	CC-90002
DMK0QDO	HS	Phase 1
DMK0QDO	DT	Antibody
DMK0QDO	DE	Acute myeloid leukaemia; Myelodysplastic syndrome; Non-hodgkin lymphoma; Solid tumour/cancer; leukaemia

DMHJLB6	ID	DMHJLB6
DMHJLB6	DN	CC-90006
DMHJLB6	HS	Phase 1
DMHJLB6	CP	AnaptysBio San Diego, CA Celgene Summit, NJ
DMHJLB6	DT	Antibody
DMHJLB6	DE	Psoriasis vulgaris

DMKH3Z9	ID	DMKH3Z9
DMKH3Z9	DN	CC-90010
DMKH3Z9	HS	Phase 1
DMKH3Z9	CP	CelgeneSummit, NJ
DMKH3Z9	DE	Non-hodgkin lymphoma; Solid tumour/cancer

DMO0AJE	ID	DMO0AJE
DMO0AJE	DN	CC-90010
DMO0AJE	HS	Phase 1
DMO0AJE	SN	UNII-K424WH3WU0; K424WH3WU0; 1706738-98-8; Trotabresib; Trotabresib [USAN]; SCHEMBL16650974; BDBM285044; EX-A4706; US10023592, Example 89; QC5487; WHO 11839; Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O; 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one; 1(2H)-Isoquinolinone, 4-(2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl)-2-methyl-; 4-(2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl)-2-methylisoquinolin-1(2H)-one; 4-[2-(cyclopropylmethoxy)- 5-methylsulfonylphenyl]-2- methylisoquinolin-1-one
DMO0AJE	CP	Bristol-Myers Squibb
DMO0AJE	DT	Small molecular drug
DMO0AJE	PC	118021883
DMO0AJE	MW	383.5
DMO0AJE	FM	C21H21NO4S
DMO0AJE	IC	InChI=1S/C21H21NO4S/c1-22-12-19(16-5-3-4-6-17(16)21(22)23)18-11-15(27(2,24)25)9-10-20(18)26-13-14-7-8-14/h3-6,9-12,14H,7-8,13H2,1-2H3
DMO0AJE	CS	CN1C=C(C2=CC=CC=C2C1=O)C3=C(C=CC(=C3)S(=O)(=O)C)OCC4CC4
DMO0AJE	IK	UWZAJPITKGWMFJ-UHFFFAOYSA-N
DMO0AJE	IU	4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one
DMO0AJE	CA	CAS 1706738-98-8
DMO0AJE	DE	Glioblastoma of brain; Astrocytoma

DM1GV6O	ID	DM1GV6O
DM1GV6O	DN	CC-90011
DM1GV6O	HS	Phase 1
DM1GV6O	CP	CelgeneSummit, NJ
DM1GV6O	DE	Non-hodgkin lymphoma; Solid tumour/cancer

DM1M4B8	ID	DM1M4B8
DM1M4B8	DN	CC-93269
DM1M4B8	HS	Phase 1
DM1M4B8	SN	BCMA TCE
DM1M4B8	CP	Bristol-Myers Squibb
DM1M4B8	DT	Antibody
DM1M4B8	DE	Multiple myeloma

DM4581B	ID	DM4581B
DM4581B	DN	CC-94676
DM4581B	HS	Phase 1
DM4581B	CP	Bristol-Myers Squibb
DM4581B	DE	Prostate cancer; Invasive prostate cancer

DM7E1W0	ID	DM7E1W0
DM7E1W0	DN	CC-95251
DM7E1W0	HS	Phase 1
DM7E1W0	CP	Bristol-Myers Squibb
DM7E1W0	DT	Antibody
DM7E1W0	DE	Solid tumour/cancer

DMJCIGN	ID	DMJCIGN
DMJCIGN	DN	CC-95775
DMJCIGN	HS	Phase 1
DMJCIGN	CP	Bristol-Myers Squibb
DMJCIGN	DT	Small molecular drug
DMJCIGN	DE	Non-hodgkin lymphoma

DMLONJG	ID	DMLONJG
DMLONJG	DN	CC-97540
DMLONJG	HS	Phase 1
DMLONJG	CP	Bristol-Myers Squibb
DMLONJG	DT	CAR T Cell Therapy
DMLONJG	DE	Non-hodgkin lymphoma

DM69YM1	ID	DM69YM1
DM69YM1	DN	CC-98633
DM69YM1	HS	Phase 1
DM69YM1	CP	Bristol-Myers Squibb
DM69YM1	DT	CAR T Cell Therapy
DM69YM1	DE	Multiple myeloma

DM1UEBR	ID	DM1UEBR
DM1UEBR	DN	CC-99712
DM1UEBR	HS	Phase 1
DM1UEBR	CP	Bristol-Myers Squibb
DM1UEBR	DT	Antibody drug conjugate
DM1UEBR	DE	Multiple myeloma

DM86CZJ	ID	DM86CZJ
DM86CZJ	DN	C-CAR011
DM86CZJ	HS	Phase 1
DM86CZJ	CP	Cellular Biomedicine Group Ltd.
DM86CZJ	DT	CAR T Cell Therapy
DM86CZJ	DE	Non-hodgkin lymphoma

DMT35N2	ID	DMT35N2
DMT35N2	DN	C-CAR088
DMT35N2	HS	Phase 1
DMT35N2	CP	Hebei Yanda Ludaopei Hospital
DMT35N2	DT	CAR T Cell Therapy
DMT35N2	DE	Multiple myeloma

DMCFMHR	ID	DMCFMHR
DMCFMHR	DN	CCR5 mab
DMCFMHR	HS	Phase 1
DMCFMHR	CP	Progenics Pharmaceuticals
DMCFMHR	DT	Antibody
DMCFMHR	DE	Human immunodeficiency virus infection

DMPTYE6	ID	DMPTYE6
DMPTYE6	DN	CCW702
DMPTYE6	HS	Phase 1
DMPTYE6	CP	AbbVie
DMPTYE6	DT	Antibody
DMPTYE6	DE	Prostate cancer

DMCWVS7	ID	DMCWVS7
DMCWVS7	DN	CCX-025
DMCWVS7	HS	Phase 1
DMCWVS7	SN	CCX-807; CCR9 chemokine receptor-targeting therapeutic (gastrointestinal diseases), ChemoCentryx
DMCWVS7	CP	ChemoCentryx Inc
DMCWVS7	DE	Crohn disease

DMO7TES	ID	DMO7TES
DMO7TES	DN	CCX507
DMO7TES	HS	Phase 1
DMO7TES	CP	ChemoCentryxMountain View, CA
DMO7TES	DE	Ulcerative colitis

DM0XDYT	ID	DM0XDYT
DM0XDYT	DN	CD10-CART
DM0XDYT	HS	Phase 1
DM0XDYT	CP	Zhujiang Hospital
DM0XDYT	DT	CAR T Cell Therapy (Dual specific)
DM0XDYT	DE	leukaemia

DMDFY1R	ID	DMDFY1R
DMDFY1R	DN	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
DMDFY1R	HS	Phase 1
DMDFY1R	CP	Affiliated Hospital to Academy of Military Medical Sciences
DMDFY1R	DT	CAR T Cell Therapy
DMDFY1R	DE	Acute myeloid leukaemia

DMUJF9T	ID	DMUJF9T
DMUJF9T	DN	CD123-CD33 Ccar
DMUJF9T	HS	Phase 1
DMUJF9T	CP	iCell Gene Therapeutics
DMUJF9T	DT	CAR T Cell Therapy
DMUJF9T	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DM2AHXW	ID	DM2AHXW
DM2AHXW	DN	CD171 specific CAR T cells expressing EGFRt
DM2AHXW	HS	Phase 1
DM2AHXW	CP	Seattle Children's Hospital
DM2AHXW	DT	CAR T Cell Therapy
DM2AHXW	DE	Ganglioneuroblastoma; Neuroblastoma

DM4PWNU	ID	DM4PWNU
DM4PWNU	DN	CD19 CAR T
DM4PWNU	HS	Phase 1
DM4PWNU	CP	Shanghai Tong Ren Hospital
DM4PWNU	DT	CAR T Cell Therapy
DM4PWNU	DE	Acute lymphoblastic leukaemia; B-cell lymphoma

DMB8RI6	ID	DMB8RI6
DMB8RI6	DN	CD19 CAR T cells
DMB8RI6	HS	Phase 1
DMB8RI6	CP	Institute of Hematology &amp; Blood Diseases Hospital
DMB8RI6	DT	CAR T Cell Therapy
DMB8RI6	DE	Acute lymphoblastic leukaemia; B-cell non-hodgkin lymphoma

DMCUBFR	ID	DMCUBFR
DMCUBFR	DN	CD19 CAR T Cells
DMCUBFR	HS	Phase 1
DMCUBFR	CP	Baylor College of Medicine
DMCUBFR	DT	CAR T Cell Therapy
DMCUBFR	DE	Acute lymphocytic leukaemia; Chronic lymphocytic leukaemia; Non-hodgkin lymphoma

DMJCT6Q	ID	DMJCT6Q
DMJCT6Q	DN	CD19 CAR T-cells
DMJCT6Q	HS	Phase 1
DMJCT6Q	CP	University College, London
DMJCT6Q	DT	CAR T Cell Therapy
DMJCT6Q	DE	Acute lymphoblastic leukaemia; Recurrent adult burkitt lymphoma

DMYFWQT	ID	DMYFWQT
DMYFWQT	DN	CD19 CAR T-cells
DMYFWQT	HS	Phase 1
DMYFWQT	CP	Third Military Medical University
DMYFWQT	DT	CAR T Cell Therapy
DMYFWQT	DE	Non-hodgkin lymphoma

DM6GNDP	ID	DM6GNDP
DM6GNDP	DN	CD19 CAR-T cells
DM6GNDP	HS	Phase 1
DM6GNDP	CP	Tianjin Mycure Medical Technology Co., Ltd
DM6GNDP	DT	CAR T Cell Therapy
DM6GNDP	DE	Acute lymphoblastic leukaemia

DMNDACU	ID	DMNDACU
DMNDACU	DN	CD19 CAR-T cells
DMNDACU	HS	Phase 1
DMNDACU	CP	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
DMNDACU	DT	CAR T Cell Therapy
DMNDACU	DE	Acute lymphoblastic leukaemia

DM49RAT	ID	DM49RAT
DM49RAT	DN	CD19 Redirected Autologous T Cells
DM49RAT	HS	Phase 1
DM49RAT	CP	Shanghai GeneChem Co., Ltd.
DM49RAT	DT	CAR T Cell Therapy
DM49RAT	DE	Systemic lupus erythematosus

DMMO2EJ	ID	DMMO2EJ
DMMO2EJ	DN	CD19.CAR-aNKT cells
DMMO2EJ	HS	Phase 1
DMMO2EJ	CP	Baylor College of Medicine
DMMO2EJ	DT	CAR T Cell Therapy
DMMO2EJ	DE	B-cell small lymphocytic lymphoma; Chronic lymphocytic leukaemia; Myeloid leukaemia; Non-hodgkin lymphoma

DMVONF0	ID	DMVONF0
DMVONF0	DN	CD19/CD22 CAR T cells
DMVONF0	HS	Phase 1
DMVONF0	CP	Crystal Mackall, MD
DMVONF0	DT	CAR T Cell Therapy (Dual specific)
DMVONF0	DE	Acute lymphoblastic leukaemia

DMKA2FL	ID	DMKA2FL
DMKA2FL	DN	CD19/CD22 CAR T-Cells
DMKA2FL	HS	Phase 1
DMKA2FL	CP	National Cancer Institute (NCI)
DMKA2FL	DT	CAR T Cell Therapy (Dual specific)
DMKA2FL	DE	Acute lymphocytic leukaemia; B-cell lymphoma; B-cell prolymphocytic leukaemia; leukaemia; Non-hodgkin lymphoma

DMPADR1	ID	DMPADR1
DMPADR1	DN	CD19/CD22 Chimeric Antigen Receptor T Cells
DMPADR1	HS	Phase 1
DMPADR1	CP	Crystal Mackall, MD
DMPADR1	DT	CAR T Cell Therapy (Dual specific)
DMPADR1	DE	Acute lymphoblastic leukaemia; B-cell lymphoma; Mediastinal large B-cell lymphoma

DMGUQ8V	ID	DMGUQ8V
DMGUQ8V	DN	CD19+ CAR T Cells
DMGUQ8V	HS	Phase 1
DMGUQ8V	CP	M.D. Anderson Cancer Center
DMGUQ8V	DT	CAR T Cell Therapy
DMGUQ8V	DE	leukaemia; Lymphoma

DMUR1MN	ID	DMUR1MN
DMUR1MN	DN	CD19-CAR and CD28-CAR T Cells
DMUR1MN	HS	Phase 1
DMUR1MN	CP	City of Hope Medical Center
DMUR1MN	DT	CAR T Cell Therapy (Dual specific)
DMUR1MN	DE	Acute lymphoblastic leukaemia

DMJIW5Z	ID	DMJIW5Z
DMJIW5Z	DN	CD19-CAR-T Cells
DMJIW5Z	HS	Phase 1
DMJIW5Z	CP	Bioceltech Therapeutics, Ltd.
DMJIW5Z	DT	CAR T Cell Therapy
DMJIW5Z	DE	Acute lymphoblastic leukaemia

DML07UZ	ID	DML07UZ
DML07UZ	DN	CD19-CAR-T2 Cells
DML07UZ	HS	Phase 1
DML07UZ	CP	Guangdong General Hospital
DML07UZ	DT	CAR T Cell Therapy
DML07UZ	DE	Acute lymphoblastic leukaemia

DM3LRAF	ID	DM3LRAF
DM3LRAF	DN	CD19CAT-41BBZ CAR T-cells
DM3LRAF	HS	Phase 1
DM3LRAF	CP	University College, London
DM3LRAF	DT	CAR T Cell Therapy
DM3LRAF	DE	Acute lymphoblastic leukaemia

DM2OEQ9	ID	DM2OEQ9
DM2OEQ9	DN	CD19-directed CAR-T cells
DM2OEQ9	HS	Phase 1
DM2OEQ9	CP	Peking Union Medical College Hospital
DM2OEQ9	DT	CAR T Cell Therapy
DM2OEQ9	DE	Non-hodgkin lymphoma

DMETGAQ	ID	DMETGAQ
DMETGAQ	DN	CD19-directed CAR-T cells
DMETGAQ	HS	Phase 1
DMETGAQ	CP	Chinese PLA General Hospital
DMETGAQ	DT	CAR T Cell Therapy
DMETGAQ	DE	leukaemia

DMCZ3A2	ID	DMCZ3A2
DMCZ3A2	DN	CD19-targeted CART cells
DMCZ3A2	HS	Phase 1
DMCZ3A2	CP	jiuwei cui
DMCZ3A2	DT	CAR T Cell Therapy
DMCZ3A2	DE	leukaemia

DMT7YOU	ID	DMT7YOU
DMT7YOU	DN	CD19t-haNK
DMT7YOU	HS	Phase 1
DMT7YOU	CP	NantKwest
DMT7YOU	DT	CAR-NK Cell therapy
DMT7YOU	DE	Diffuse large B-cell lymphoma

DMOHACZ	ID	DMOHACZ
DMOHACZ	DN	CD19-TriCAR-T
DMOHACZ	HS	Phase 1
DMOHACZ	CP	Timmune Biotech Inc.
DMOHACZ	DT	CAR T Cell Therapy
DMOHACZ	DE	Non-hodgkin lymphoma

DMGXS8L	ID	DMGXS8L
DMGXS8L	DN	CD20Bi aATC
DMGXS8L	HS	Phase 1
DMGXS8L	SN	CD20Bi activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; CD20Bi-armed ATC (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma); Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute
DMGXS8L	CP	Barbara Ann Karmanos Cancer Institute
DMGXS8L	DE	Non-hodgkin lymphoma

DMSJBUZ	ID	DMSJBUZ
DMSJBUZ	DN	CD20-CART
DMSJBUZ	HS	Phase 1
DMSJBUZ	CP	Zhujiang Hospital
DMSJBUZ	DT	CAR T Cell Therapy (Dual specific)
DMSJBUZ	DE	leukaemia

DM37OJN	ID	DM37OJN
DM37OJN	DN	CD20-CAR-T Cells
DM37OJN	HS	Phase 1
DM37OJN	CP	Xin Wang
DM37OJN	DT	CAR T Cell Therapy
DM37OJN	DE	B-cell lymphoma

DMUYTW3	ID	DMUYTW3
DMUYTW3	DN	CD20-CD19 cCAR
DMUYTW3	HS	Phase 1
DMUYTW3	CP	iCell Gene Therapeutics
DMUYTW3	DT	CAR T Cell Therapy
DMUYTW3	DE	B-cell lymphoma

DMHMPK1	ID	DMHMPK1
DMHMPK1	DN	CD22-CART
DMHMPK1	HS	Phase 1
DMHMPK1	CP	Zhujiang Hospital
DMHMPK1	DT	CAR T Cell Therapy (Dual specific)
DMHMPK1	DE	leukaemia

DMP5V83	ID	DMP5V83
DMP5V83	DN	CD22-specific CAR T-cells also expressing an EGFRt
DMP5V83	HS	Phase 1
DMP5V83	CP	Seattle Children's Hospital
DMP5V83	DT	CAR T Cell Therapy
DMP5V83	DE	leukaemia

DMFGQXB	ID	DMFGQXB
DMFGQXB	DN	CD28 and CD137 CAR-T Cells
DMFGQXB	HS	Phase 1
DMFGQXB	CP	Affiliated Hospital to Academy of Military Medical Sciences
DMFGQXB	DT	CAR T Cell Therapy (Dual specific)
DMFGQXB	DE	Acute lymphoblastic leukaemia

DM4VCJA	ID	DM4VCJA
DM4VCJA	DN	CD30 CAR T Cells
DM4VCJA	HS	Phase 1
DM4VCJA	CP	Baylor College of Medicine
DM4VCJA	DT	CAR T Cell Therapy
DM4VCJA	DE	Non-hodgkin lymphoma; Hodgkin lymphoma

DMYD31U	ID	DMYD31U
DMYD31U	DN	CD33-CAR-T Cell
DMYD31U	HS	Phase 1
DMYD31U	CP	M.D. Anderson Cancer Center
DMYD31U	DT	CAR T Cell Therapy
DMYD31U	DE	Haematopoietic/lymphoid cancer; Acute myeloid leukaemia

DMNX0V7	ID	DMNX0V7
DMNX0V7	DN	CD38 CAR-T
DMNX0V7	HS	Phase 1
DMNX0V7	CP	Celularity; Sorrento Therapeutics
DMNX0V7	DT	CAR T Cell Therapy
DMNX0V7	DE	Multiple myeloma

DM09SW6	ID	DM09SW6
DM09SW6	DN	CD4CAR
DM09SW6	HS	Phase 1
DM09SW6	CP	iCell Gene Therapeutics
DM09SW6	DT	CAR T Cell Therapy
DM09SW6	DE	T-cell leukaemia

DMHTNLJ	ID	DMHTNLJ
DMHTNLJ	DN	CD7.CAR/28zeta CAR T cells
DMHTNLJ	HS	Phase 1
DMHTNLJ	CP	Baylor College of Medicine
DMHTNLJ	DT	CAR T Cell Therapy
DMHTNLJ	DE	B-cell acute lymphoblastic leukaemia; Cutaneous T-cell lymphoma; Non-hodgkin lymphoma

DM8DWOL	ID	DM8DWOL
DM8DWOL	DN	CDNA vaccine
DM8DWOL	HS	Phase 1
DM8DWOL	SN	CDNA vaccine (prostate cancer)
DM8DWOL	CP	Colby Pharmaceuticals
DM8DWOL	DE	Prostate cancer

DMN8I5Q	ID	DMN8I5Q
DMN8I5Q	DN	CDP-7657
DMN8I5Q	HS	Phase 1
DMN8I5Q	CP	Biogen Idec
DMN8I5Q	DT	Antibody
DMN8I5Q	DE	Systemic lupus erythematosus

DM049IX	ID	DM049IX
DM049IX	DN	CDRI-97/78
DM049IX	HS	Phase 1
DM049IX	SN	Antimalarial compound, CDRI/IPCA labs
DM049IX	CP	Central Drug Research Institute
DM049IX	PC	9870599
DM049IX	MW	500.6
DM049IX	FM	C28H36O8
DM049IX	IC	InChI=1S/C28H36O8/c1-17(24-15-33-28(36-35-24)21-11-18-10-19(13-21)14-22(28)12-18)20-4-6-23(7-5-20)34-27(2,3)16-32-26(31)9-8-25(29)30/h4-7,18-19,21-22,24H,1,8-16H2,2-3H3,(H,29,30)
DM049IX	CS	CC(C)(COC(=O)CCC(=O)O)OC1=CC=C(C=C1)C(=C)C2COC3(C4CC5CC(C4)CC3C5)OO2
DM049IX	IK	LKAAAECAYCDCQW-UHFFFAOYSA-N
DM049IX	IU	4-[2-methyl-2-[4-(1-spiro[1,2,4-trioxane-3,2'-adamantane]-6-ylethenyl)phenoxy]propoxy]-4-oxobutanoic acid
DM049IX	DE	Malaria

DMKUXB5	ID	DMKUXB5
DMKUXB5	DN	CDT-fenofibrate
DMKUXB5	HS	Phase 1
DMKUXB5	CP	SCOLR Pharma
DMKUXB5	DE	Hyperlipidaemia

DMPVUGE	ID	DMPVUGE
DMPVUGE	DN	CDX-1127
DMPVUGE	HS	Phase 1
DMPVUGE	CP	Celldex Therapeutics
DMPVUGE	DE	Solid tumour/cancer; leukaemia; Lymphoma

DMS20X6	ID	DMS20X6
DMS20X6	DN	CDX-1135
DMS20X6	HS	Phase 1
DMS20X6	SN	SCR1; BRL-55730; Soluble complement receptor type 1, AVANT; Soluble complement receptor type 1, Celldex; YM-203; TP-10, AVANT Immunotherapeutics; TP-10, Celldex
DMS20X6	CP	Celldex therapeutics
DMS20X6	DE	Macular degeneration

DMUGN0J	ID	DMUGN0J
DMUGN0J	DN	CDX-1140
DMUGN0J	HS	Phase 1
DMUGN0J	CP	Celldex Therapeutics
DMUGN0J	DT	Antibody
DMUGN0J	DE	Solid tumour/cancer; Melanoma

DMVDIWO	ID	DMVDIWO
DMVDIWO	DN	CDX-527
DMVDIWO	HS	Phase 1
DMVDIWO	CP	Celldex Therapeutics
DMVDIWO	DT	Antibody
DMVDIWO	DE	Solid tumour/cancer

DM45BHM	ID	DM45BHM
DM45BHM	DN	CEA CAR-T
DM45BHM	HS	Phase 1
DM45BHM	CP	Sorrento Therapeutics
DM45BHM	DT	CAR T Cell Therapy
DM45BHM	DE	Ascites; Peritoneal metastasis

DMYDTJ6	ID	DMYDTJ6
DMYDTJ6	DN	CEP-11981
DMYDTJ6	HS	Phase 1
DMYDTJ6	SN	CEP-11981; UNII-J8AY0Z4CBP; 856691-93-5; J8AY0Z4CBP; CHEMBL2010872; BOL-303213X; compound 11b [PMID 22148921]; GTPL8189; SCHEMBL2439310; DTXSID80234942; CEP11981; BDBM50379186; CEP 11981; 4H-Indazolo(5,4-a)pyrrolo(3,4-C)carbazol-4-one, 2,5,6,11,12,13-hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-; Z-3152
DMYDTJ6	CP	Cephalon
DMYDTJ6	DT	Small molecular drug
DMYDTJ6	PC	11751922
DMYDTJ6	MW	477.6
DMYDTJ6	FM	C28H27N7O
DMYDTJ6	IC	InChI=1S/C28H27N7O/c1-15(2)13-35-22-8-5-16(32-28-29-9-4-10-30-28)11-18(22)24-19-12-31-27(36)25(19)23-17(26(24)35)6-7-21-20(23)14-34(3)33-21/h4-5,8-11,14-15H,6-7,12-13H2,1-3H3,(H,31,36)(H,29,30,32)
DMYDTJ6	CS	CC(C)CN1C2=C(C=C(C=C2)NC3=NC=CC=N3)C4=C1C5=C(C6=CN(N=C6CC5)C)C7=C4CNC7=O
DMYDTJ6	IK	AEULIVPVIDOLIN-UHFFFAOYSA-N
DMYDTJ6	IU	19-methyl-3-(2-methylpropyl)-7-(pyrimidin-2-ylamino)-3,13,19,20-tetrazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4(9),5,7,11(15),17,20-octaen-14-one
DMYDTJ6	CA	CAS 856691-93-5
DMYDTJ6	DE	Solid tumour/cancer

DMYXQBF	ID	DMYXQBF
DMYXQBF	DN	CEP-37251
DMYXQBF	HS	Phase 1
DMYXQBF	SN	ART-010; EGX-010; OVP (bone loss), Peptech; Osteoprotegerin variant protein (bone loss), Arana; Osteoprotegerin variant protein (bone loss), EvoGenix; Osteoprotegerin variant protein (bone loss), Peptech
DMYXQBF	CP	EvoGenix Pty Ltd
DMYXQBF	DE	Bone metastases

DMV632P	ID	DMV632P
DMV632P	DN	CEP-37440
DMV632P	HS	Phase 1
DMV632P	SN	Dual ALK/FAK inhibitor (cancer), Cephalon; Dual anaplastic lymphoma kinase/focal adhesion kinase inhibitor (cancer),Cephalon
DMV632P	CP	Teva pharmaceutical
DMV632P	DT	Small molecular drug
DMV632P	PC	71721648
DMV632P	MW	580.1
DMV632P	FM	C30H38ClN7O3
DMV632P	IC	InChI=1S/C30H38ClN7O3/c1-32-29(40)23-7-3-4-9-25(23)34-28-24(31)19-33-30(36-28)35-26-11-10-20-18-21(6-5-8-22(20)27(26)41-2)38-14-12-37(13-15-38)16-17-39/h3-4,7,9-11,19,21,39H,5-6,8,12-18H2,1-2H3,(H,32,40)(H2,33,34,35,36)/t21-/m0/s1
DMV632P	CS	CNC(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C4=C(C[C@H](CCC4)N5CCN(CC5)CCO)C=C3)OC
DMV632P	IK	BCSHRERPHLTPEE-NRFANRHFSA-N
DMV632P	IU	2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methylbenzamide
DMV632P	CA	CAS 1391712-60-9
DMV632P	DE	Solid tumour/cancer

DMLBKZV	ID	DMLBKZV
DMLBKZV	DN	CER-002
DMLBKZV	HS	Phase 1
DMLBKZV	CP	Cerenis Therapeutics
DMLBKZV	DE	Dyslipidemia

DMGAW0H	ID	DMGAW0H
DMGAW0H	DN	CER-522
DMGAW0H	HS	Phase 1
DMGAW0H	SN	ApoA-I peptide HDL mimetic (aortic valve stenosis), Cerenis/Montreal Heart Institute
DMGAW0H	CP	Montreal Heart Institute
DMGAW0H	DE	Aortic valve stenosis

DMH701Q	ID	DMH701Q
DMH701Q	DN	CFI-402257
DMH701Q	HS	Phase 1
DMH701Q	SN	1610759-22-2; CHEMBL4442392; CHEMBL4469414; SCHEMBL16729234; SCHEMBL17182976; SCHEMBL17190272; SCHEMBL22046104; SCHEMBL22875551; BCP31204; EX-A2577; BDBM50512456; BDBM50533120; NSC800888; ZINC669678971; CS-6527; NSC-800888; SB19839; AK685452; HY-101340; CFI 402257; CFI402257; J3.619.525H; 1610677-37-6; N-cyclopropyl-4-(7-((((1r,3r)-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-3-yloxy)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide; N-cyclopropyl-4-[7-[(3-hydroxy-3-methylcyclobutyl)methylamino]-5-pyridin-3-yloxypyrazolo[1,5-a]pyrimidin-3-yl]-2-methylbenzamide
DMH701Q	CP	Treadwell Therapeutics
DMH701Q	DT	Small molecular drug
DMH701Q	PC	118086034
DMH701Q	MW	498.6
DMH701Q	FM	C28H30N6O3
DMH701Q	IC	InChI=1S/C28H30N6O3/c1-17-10-19(5-8-22(17)27(35)32-20-6-7-20)23-16-31-34-24(30-14-18-12-28(2,36)13-18)11-25(33-26(23)34)37-21-4-3-9-29-15-21/h3-5,8-11,15-16,18,20,30,36H,6-7,12-14H2,1-2H3,(H,32,35)
DMH701Q	CS	CC1=C(C=CC(=C1)C2=C3N=C(C=C(N3N=C2)NCC4CC(C4)(C)O)OC5=CN=CC=C5)C(=O)NC6CC6
DMH701Q	IK	PMQUGSPFUBGJCZ-UHFFFAOYSA-N
DMH701Q	IU	N-cyclopropyl-4-[7-[(3-hydroxy-3-methylcyclobutyl)methylamino]-5-pyridin-3-yloxypyrazolo[1,5-a]pyrimidin-3-yl]-2-methylbenzamide
DMH701Q	DE	Solid tumour/cancer

DM3U2VY	ID	DM3U2VY
DM3U2VY	DN	CG-200745
DM3U2VY	HS	Phase 1
DM3U2VY	SN	CG-0006; CG-005; HDAC inhibitors (cancer, oral/intravenous), CrystalGenomics; Histone deacetylase inhibitors (cancer, oral/intravenous), CrystalGenomics
DM3U2VY	CP	CrystalGenomics Inc
DM3U2VY	PC	16117309
DM3U2VY	MW	427.5
DM3U2VY	FM	C24H33N3O4
DM3U2VY	IC	InChI=1S/C24H33N3O4/c1-27(2)17-9-16-25-24(29)20(11-4-3-5-15-23(28)26-30)18-31-22-14-8-12-19-10-6-7-13-21(19)22/h6-8,10-14,30H,3-5,9,15-18H2,1-2H3,(H,25,29)(H,26,28)/b20-11+
DM3U2VY	CS	CN(C)CCCNC(=O)/C(=C/CCCCC(=O)NO)/COC1=CC=CC2=CC=CC=C21
DM3U2VY	IK	AUGCSOFQTDKPSO-RGVLZGJSSA-N
DM3U2VY	IU	(E)-N-[3-(dimethylamino)propyl]-N'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide
DM3U2VY	CA	CAS 936221-33-9
DM3U2VY	DE	Solid tumour/cancer

DMTCLM3	ID	DMTCLM3
DMTCLM3	DN	CGM097
DMTCLM3	HS	Phase 1
DMTCLM3	CP	Novartis pharmaceuticals
DMTCLM3	PC	53240420
DMTCLM3	MW	659.3
DMTCLM3	FM	C38H47ClN4O4
DMTCLM3	IC	InChI=1S/C38H47ClN4O4/c1-25(2)47-35-22-33-28(20-34(35)46-5)21-36(44)43(38(33)27-8-10-29(39)11-9-27)32-16-14-30(15-17-32)41(4)23-26-6-12-31(13-7-26)42-19-18-40(3)37(45)24-42/h8-11,14-17,20,22,25-26,31,38H,6-7,12-13,18-19,21,23-24H2,1-5H3/t26?,31?,38-/m0/s1
DMTCLM3	CS	CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)N(C)CC5CCC(CC5)N6CCN(C(=O)C6)C)OC
DMTCLM3	IK	CLRSLRWKONPSRQ-CPOWQTMSSA-N
DMTCLM3	IU	(1S)-1-(4-chlorophenyl)-6-methoxy-2-[4-[methyl-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl]amino]phenyl]-7-propan-2-yloxy-1,4-dihydroisoquinolin-3-one
DMTCLM3	DE	Solid tumour/cancer

DMAY8I4	ID	DMAY8I4
DMAY8I4	DN	CGTG-102
DMAY8I4	HS	Phase 1
DMAY8I4	SN	Ad5/3-D24-GMCSF; Adenovirus-based gene therapy (breast cancer, injectable formulation), Oncos
DMAY8I4	CP	Oncos Therapeutics Ltd
DMAY8I4	DE	Solid tumour/cancer

DMSDNU1	ID	DMSDNU1
DMSDNU1	DN	CHF 5407
DMSDNU1	HS	Phase 1
DMSDNU1	CP	Chiesi
DMSDNU1	DE	Chronic obstructive pulmonary disease

DMTE18G	ID	DMTE18G
DMTE18G	DN	CHF-4227
DMTE18G	HS	Phase 1
DMTE18G	SN	CHF-3316; CHF-4056; SERMs, Chiesi; Selective estrogen receptor modulators, Chiesi; CHF-3316.01
DMTE18G	CP	Chiesi Farmaceutici SpA
DMTE18G	DT	Small molecular drug
DMTE18G	PC	9912639
DMTE18G	MW	471.6
DMTE18G	FM	C30H33NO4
DMTE18G	IC	InChI=1S/C30H33NO4/c1-33-25-12-7-23(8-13-25)29-21-35-30-20-24(32)9-14-27(30)28(29)19-22-5-10-26(11-6-22)34-18-17-31-15-3-2-4-16-31/h5-14,20,32H,2-4,15-19,21H2,1H3
DMTE18G	CS	COC1=CC=C(C=C1)C2=C(C3=C(C=C(C=C3)O)OC2)CC4=CC=C(C=C4)OCCN5CCCCC5
DMTE18G	IK	ZUDXUNPSRMREOJ-UHFFFAOYSA-N
DMTE18G	IU	3-(4-methoxyphenyl)-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2H-chromen-7-ol
DMTE18G	CA	CAS 444643-64-5
DMTE18G	DE	Osteoporosis

DMSOB5D	ID	DMSOB5D
DMSOB5D	DN	Chi Lob 7/4
DMSOB5D	HS	Phase 1
DMSOB5D	SN	Anti-CD40 MAb (chimeric, cancer), Cancer Research UK
DMSOB5D	CP	Cancer Research UK
DMSOB5D	DE	B-cell lymphoma

DM3L52Q	ID	DM3L52Q
DM3L52Q	DN	Chlorcyclizine
DM3L52Q	HS	Phase 1
DM3L52Q	SN	1-(4-Chlorobenzhydryl)-4-methylpiperazine; Alergicide; Chlorcycline; Chlorcyclizine [INN:BAN]; Chlorcyclizinum; Chlorcyclizinum [INN-Latin]; Chlorocycline; Chlorocyclizine; Clorciclizina; Clorciclizina [DCIT]; Clorciclizinio [INN-Spanish]; Compound 47-282; Di-Paralene; Di-paralen; Diparalene; HSDB 3217; Histachlorazene; Histantin; Histantine; N-Methyl-N'-(4-chlorobenzhydryl)piperazine; NSC 25246; Perazyl; Piparalene; Trihistan; chlorcyclizine
DM3L52Q	TC	Antihistamines
DM3L52Q	DT	Small molecular drug
DM3L52Q	PC	2710
DM3L52Q	MW	300.83
DM3L52Q	FM	C18H21ClN2
DM3L52Q	IC	InChI=1S/C18H21ClN2/c1-20-11-13-21(14-12-20)18(15-5-3-2-4-6-15)16-7-9-17(19)10-8-16/h2-10,18H,11-14H2,1H3
DM3L52Q	CS	CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DM3L52Q	IK	WFNAKBGANONZEQ-UHFFFAOYSA-N
DM3L52Q	IU	1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine
DM3L52Q	CA	CAS 82-93-9
DM3L52Q	CB	CHEBI:94402
DM3L52Q	DE	Hepatitis C virus infection

DMJLZ8T	ID	DMJLZ8T
DMJLZ8T	DN	CHT-25
DMJLZ8T	HS	Phase 1
DMJLZ8T	CP	University College London
DMJLZ8T	DE	Hodgkin lymphoma

DM2OB6S	ID	DM2OB6S
DM2OB6S	DN	CI-8993
DM2OB6S	HS	Phase 1
DM2OB6S	CP	Curis
DM2OB6S	DT	Antibody
DM2OB6S	DE	Solid tumour/cancer

DM6SCUK	ID	DM6SCUK
DM6SCUK	DN	CI-959
DM6SCUK	HS	Phase 1
DM6SCUK	SN	CI-959; UNII-1A8130P4IY; CI 959; CI 159; 104795-68-8; 1A8130P4IY; Benzo(b)thiophene-2-carboxamide, 5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-, monosodium salt; DSSTox_RID_82225; DSSTox_CID_27268; DSSTox_GSID_47268; DTXSID8047268; CHEMBL3183386; Tox21_300435; NCGC00254320-01; LS-41129
DM6SCUK	DT	Small molecular drug
DM6SCUK	PC	13961743
DM6SCUK	MW	355.35
DM6SCUK	FM	C14H14N5NaO3S
DM6SCUK	IC	InChI=1S/C14H15N5O3S.Na/c1-7(2)22-11-9-6-8(21-3)4-5-10(9)23-12(11)13(20)15-14-16-18-19-17-14;/h4-7H,1-3H3,(H2,15,16,17,18,19,20);/q;+1/p-1
DM6SCUK	CS	CC(C)OC1=C(SC2=C1C=C(C=C2)OC)C(=O)NC3=NN=N[N-]3.[Na+]
DM6SCUK	IK	UCLODRCAPZIYOW-UHFFFAOYSA-M
DM6SCUK	IU	sodium;5-methoxy-3-propan-2-yloxy-N-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)-1-benzothiophene-2-carboxamide
DM6SCUK	CA	CAS 104795-68-8
DM6SCUK	DE	Asthma

DM8T2KA	ID	DM8T2KA
DM8T2KA	DN	CI-966
DM8T2KA	HS	Phase 1
DM8T2KA	SN	1-[2-[Bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride
DM8T2KA	DT	Small molecular drug
DM8T2KA	PC	198693
DM8T2KA	MW	473.4
DM8T2KA	FM	C23H21F6NO3
DM8T2KA	IC	InChI=1S/C23H21F6NO3/c24-22(25,26)18-7-3-15(4-8-18)20(16-5-9-19(10-6-16)23(27,28)29)33-13-12-30-11-1-2-17(14-30)21(31)32/h2-10,20H,1,11-14H2,(H,31,32)
DM8T2KA	CS	C1CN(CC(=C1)C(=O)O)CCOC(C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F
DM8T2KA	IK	CMHQDSBIBSKHFP-UHFFFAOYSA-N
DM8T2KA	IU	1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid
DM8T2KA	CA	CAS 110283-79-9
DM8T2KA	CB	CHEBI:93185
DM8T2KA	DE	Convulsion

DMB2MKU	ID	DMB2MKU
DMB2MKU	DN	CIGB-128
DMB2MKU	HS	Phase 1
DMB2MKU	SN	HeberPAG; IFN alpha2b + IFN gamma (injectable, skin cancer), CIGB
DMB2MKU	CP	Center for Genetic Engineering and Biotechnology
DMB2MKU	DE	Basal cell carcinoma

DMJFPK6	ID	DMJFPK6
DMJFPK6	DN	CIGB-228
DMJFPK6	HS	Phase 1
DMJFPK6	SN	Therapeutic peptide subunit vaccine (E7 antigen, HPV), CIGB
DMJFPK6	CP	Center for Genetic Engineering and Biotechnology
DMJFPK6	DT	Vaccine
DMJFPK6	DE	Human papillomavirus infection

DM8XM72	ID	DM8XM72
DM8XM72	DN	CIGB-500
DM8XM72	HS	Phase 1
DM8XM72	SN	Cytoprotectant (GHRP-6, ischemia-reperfusion damage), CIGB
DM8XM72	CP	Center for Genetic Engineering and Biotechnology
DM8XM72	DE	Cerebrovascular ischaemia

DMSGRA7	ID	DMSGRA7
DMSGRA7	DN	CIGB-M3
DMSGRA7	HS	Phase 1
DMSGRA7	SN	131I-labeled anti-CEA diabody (cancer), CIGB
DMSGRA7	CP	Center for Genetic Engineering and Biotechnology
DMSGRA7	DT	Antibody
DMSGRA7	DE	Colorectal cancer

DM7EAG8	ID	DM7EAG8
DM7EAG8	DN	Cilobradine
DM7EAG8	HS	Phase 1
DM7EAG8	SN	Cilobradine; UNII-5O1LL04GJ3; 5O1LL04GJ3; 147541-45-5; Cilobradine [INN]; DK-AH269; SCHEMBL628133; GTPL2355; CHEMBL1436376; ZINC13829377; NCGC00165786-01
DM7EAG8	CP	Boehringer Ingelheim Corp
DM7EAG8	DT	Small molecular drug
DM7EAG8	PC	9869877
DM7EAG8	MW	482.6
DM7EAG8	FM	C28H38N2O5
DM7EAG8	IC	InChI=1S/C28H38N2O5/c1-32-24-8-7-20(14-25(24)33-2)9-12-29-11-5-6-21(18-29)19-30-13-10-22-15-26(34-3)27(35-4)16-23(22)17-28(30)31/h7-8,14-16,21H,5-6,9-13,17-19H2,1-4H3/t21-/m0/s1
DM7EAG8	CS	COC1=C(C=C(C=C1)CCN2CCC[C@@H](C2)CN3CCC4=CC(=C(C=C4CC3=O)OC)OC)OC
DM7EAG8	IK	OBUFMJDDZTXJPY-NRFANRHFSA-N
DM7EAG8	IU	3-[[(3S)-1-[2-(3,4-dimethoxyphenyl)ethyl]piperidin-3-yl]methyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
DM7EAG8	CA	CAS 147541-45-5
DM7EAG8	DE	Cardiac arrhythmias

DMJLNEF	ID	DMJLNEF
DMJLNEF	DN	Cipatinib
DMJLNEF	HS	Phase 1
DMJLNEF	SN	HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui
DMJLNEF	CP	Jiangsu Hengrui Medicine Co Ltd
DMJLNEF	DE	Solid tumour/cancer

DMQLODU	ID	DMQLODU
DMQLODU	DN	Citarinostat
DMQLODU	HS	Phase 1
DMQLODU	SN	ACY-241; 1316215-12-9; HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat [USAN]; Citarinostat (USAN); 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide; 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; Citarinostat (ACY-241); SCHEMBL2225863; GTPL942
DMQLODU	CP	Celgene Summit, NJ
DMQLODU	PC	53340426
DMQLODU	MW	467.9
DMQLODU	FM	C24H26ClN5O3
DMQLODU	IC	InChI=1S/C24H26ClN5O3/c25-20-12-7-8-13-21(20)30(19-10-4-3-5-11-19)24-27-16-18(17-28-24)23(32)26-15-9-2-1-6-14-22(31)29-33/h3-5,7-8,10-13,16-17,33H,1-2,6,9,14-15H2,(H,26,32)(H,29,31)
DMQLODU	CS	C1=CC=C(C=C1)N(C2=CC=CC=C2Cl)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO
DMQLODU	IK	VLIUIBXPEDFJRF-UHFFFAOYSA-N
DMQLODU	IU	2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide
DMQLODU	CA	CAS 1316215-12-9
DMQLODU	DE	Multiple myeloma

DMRJF2Q	ID	DMRJF2Q
DMRJF2Q	DN	Citatuzumab bogatox
DMRJF2Q	HS	Phase 1
DMRJF2Q	SN	VB6-845; Antibody therapeutic (ovary tumor), Viventia; Ovary cancer therapeutic (antibody), Viventia; Anti-EpCAM-bouganin conjugate (anticancer), Viventia
DMRJF2Q	CP	Viventia Biotech Inc
DMRJF2Q	DT	Antibody
DMRJF2Q	DE	Solid tumour/cancer

DMRQX9H	ID	DMRQX9H
DMRQX9H	DN	CJ-12255
DMRQX9H	HS	Phase 1
DMRQX9H	PC	22882070
DMRQX9H	MW	498.7
DMRQX9H	FM	C32H38N2O3
DMRQX9H	IC	InChI=1S/C32H38N2O3/c1-21(2)24-14-15-28(37-3)25(18-24)19-33-30-26-16-17-34(20-27(26)32(35)36)31(30)29(22-10-6-4-7-11-22)23-12-8-5-9-13-23/h4-15,18,21,26-27,29-31,33H,16-17,19-20H2,1-3H3,(H,35,36)/t26-,27-,30-,31-/m0/s1
DMRQX9H	CS	CC(C)C1=CC(=C(C=C1)OC)CN[C@H]2[C@H]3CCN([C@H]2C(C4=CC=CC=C4)C5=CC=CC=C5)C[C@@H]3C(=O)O
DMRQX9H	IK	UGYNIDYASJFWTR-FXZOGHEHSA-N
DMRQX9H	IU	(3R,4S,5S,6S)-6-benzhydryl-5-[(2-methoxy-5-propan-2-ylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-3-carboxylic acid
DMRQX9H	CA	CAS 146725-78-2
DMRQX9H	DE	Eczema

DMGSEB0	ID	DMGSEB0
DMGSEB0	DN	CKD-516
DMGSEB0	HS	Phase 1
DMGSEB0	SN	S-516; Tubulin polymerization inhibitor (iv, solid cancer), Chong Kun Dang
DMGSEB0	CP	Chong Kun Dang Pharmaceutical Corp
DMGSEB0	DT	Small molecular drug
DMGSEB0	PC	46929961
DMGSEB0	MW	573.1
DMGSEB0	FM	C26H29ClN6O5S
DMGSEB0	IC	InChI=1S/C26H28N6O5S.ClH/c1-14(2)22(27)25(34)31-26-30-18(11-38-26)15-6-7-17(19(8-15)32-13-28-12-29-32)23(33)16-9-20(35-3)24(37-5)21(10-16)36-4;/h6-14,22H,27H2,1-5H3,(H,30,31,34);1H/t22-;/m0./s1
DMGSEB0	CS	CC(C)[C@@H](C(=O)NC1=NC(=CS1)C2=CC(=C(C=C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)N4C=NC=N4)N.Cl
DMGSEB0	IK	FIAUXCMEQTWLQZ-FTBISJDPSA-N
DMGSEB0	IU	(2S)-2-amino-3-methyl-N-[4-[3-(1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl]-1,3-thiazol-2-yl]butanamide;hydrochloride
DMGSEB0	CA	CAS 1240321-53-2
DMGSEB0	DE	Solid tumour/cancer

DMJX6SM	ID	DMJX6SM
DMJX6SM	DN	CKD-712
DMJX6SM	HS	Phase 1
DMJX6SM	CP	Chong Kun Dang Pharmaceutical Corp
DMJX6SM	DE	Solid tumour/cancer

DM4UAPD	ID	DM4UAPD
DM4UAPD	DN	Clemizole
DM4UAPD	HS	Phase 1
DM4UAPD	SN	Clemizole; 442-52-4; Histacur; Clemizol; Histakool; Lergopenin; Clemizolum; Depocural; 1-(p-Chlorobenzyl)-2-pyrrolidylmethylenebenzimidazole; 1-(4-Chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazole; NSC 46261; UNII-T97CB3796L; CHEBI:52140; CJXAEXPPLWQRFR-UHFFFAOYSA-N; T97CB3796L; 1-[(4-chlorophenyl)methyl]-2-(pyrrolidin-1-ylmethyl)benzimidazole; 1H-Benzimidazole, 1-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinylmethyl)-; 1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzimidazole
DM4UAPD	CP	Eiger BioPharmaceuticals
DM4UAPD	DT	Small molecular drug
DM4UAPD	PC	2782
DM4UAPD	MW	325.8
DM4UAPD	FM	C19H20ClN3
DM4UAPD	IC	InChI=1S/C19H20ClN3/c20-16-9-7-15(8-10-16)13-23-18-6-2-1-5-17(18)21-19(23)14-22-11-3-4-12-22/h1-2,5-10H,3-4,11-14H2
DM4UAPD	CS	C1CCN(C1)CC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)Cl
DM4UAPD	IK	CJXAEXPPLWQRFR-UHFFFAOYSA-N
DM4UAPD	IU	1-[(4-chlorophenyl)methyl]-2-(pyrrolidin-1-ylmethyl)benzimidazole
DM4UAPD	CA	CAS 442-52-4
DM4UAPD	CB	CHEBI:52140
DM4UAPD	DE	Hepatitis C virus infection

DM5EM04	ID	DM5EM04
DM5EM04	DN	CLL1-CD33 cCART cell therapy
DM5EM04	HS	Phase 1
DM5EM04	CP	iCell Gene Therapeutics
DM5EM04	DT	CAR T Cell Therapy
DM5EM04	DE	Acute myeloid leukaemia

DM05R4C	ID	DM05R4C
DM05R4C	DN	CLN-081
DM05R4C	HS	Phase 1
DM05R4C	CP	Cullinan Oncology; Taiho Pharmaceutical
DM05R4C	DT	Small molecular drug
DM05R4C	DE	Non-small-cell lung cancer

DM2QBMI	ID	DM2QBMI
DM2QBMI	DN	CLP-1004
DM2QBMI	HS	Phase 1
DM2QBMI	CP	Sorbent therapeutics
DM2QBMI	DE	Hypertension

DM674MP	ID	DM674MP
DM674MP	DN	CLT030
DM674MP	HS	Phase 1
DM674MP	CP	Cellerant Therapeutics
DM674MP	DT	Antibody drug conjugate
DM674MP	DE	Acute myeloid leukaemia

DMJQG25	ID	DMJQG25
DMJQG25	DN	CLX-0921
DMJQG25	HS	Phase 1
DMJQG25	SN	CLX-090502; CLX-090503; CLX-090717; CLX-092402
DMJQG25	CP	Calyx Therapeutics Inc; Calyx Therapeutics
DMJQG25	PC	9958278
DMJQG25	MW	519.6
DMJQG25	FM	C28H25NO7S
DMJQG25	IC	InChI=1S/C28H25NO7S/c1-33-22-12-18(13-23(16-22)34-2)14-24(27(31)35-3)19-6-10-21(11-7-19)36-20-8-4-17(5-9-20)15-25-26(30)29-28(32)37-25/h4-14,16,25H,15H2,1-3H3,(H,29,30,32)/b24-14+
DMJQG25	CS	COC1=CC(=CC(=C1)/C=C(\\C2=CC=C(C=C2)OC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)/C(=O)OC)OC
DMJQG25	IK	IVAQJHSXBVHUQT-ZVHZXABRSA-N
DMJQG25	IU	methyl (E)-3-(3,5-dimethoxyphenyl)-2-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]prop-2-enoate
DMJQG25	CA	CAS 606932-81-4
DMJQG25	DE	Type-2 diabetes

DMMC6YR	ID	DMMC6YR
DMMC6YR	DN	CM2489
DMMC6YR	HS	Phase 1
DMMC6YR	CP	CalciMedica
DMMC6YR	DE	Psoriasis vulgaris

DMSJVX3	ID	DMSJVX3
DMSJVX3	DN	CM3.1-AC100
DMSJVX3	HS	Phase 1
DMSJVX3	SN	CM-3, CellMed/AstraZeneca; GLP-1 analog (diabetes), CellMed/AstraZeneca
DMSJVX3	CP	CellMed AG
DMSJVX3	DE	Diabetic complication

DMY5V4U	ID	DMY5V4U
DMY5V4U	DN	CM-CS1 T-cell
DMY5V4U	HS	Phase 1
DMY5V4U	CP	Celyad (formerly named Cardio3 BioSciences)
DMY5V4U	DT	CAR T Cell Therapy
DMY5V4U	DE	Multiple myeloma; Myelodysplastic syndrome; Acute myeloid leukaemia

DMHBNKP	ID	DMHBNKP
DMHBNKP	DN	C-Met/PD-L1 CAR-T Cell
DMHBNKP	HS	Phase 1
DMHBNKP	CP	The Second Hospital of Nanjing Medical University
DMHBNKP	DT	CAR T Cell Therapy (Dual specific)
DMHBNKP	DE	Hepatocellular carcinoma

DMGMI8P	ID	DMGMI8P
DMGMI8P	DN	CMP-001
DMGMI8P	HS	Phase 1
DMGMI8P	SN	vidutolimod
DMGMI8P	CP	Checkmate Pharmaceuticals
DMGMI8P	DE	Melanoma; Non-small-cell lung cancer

DM6NG3C	ID	DM6NG3C
DM6NG3C	DN	CMV glycoprotein B subunit vaccine
DM6NG3C	HS	Phase 1
DM6NG3C	SN	CMV gB subunit vaccine, GlaxoSmithKline; CMV glycoprotein B subunit vaccine, GlaxoSmithKline; Cytomegalovirus glycoprotein B subunit vaccine, GlaxoSmithKline; GSK-1492903-A
DM6NG3C	CP	Glaxosmithkline
DM6NG3C	DT	Vaccine
DM6NG3C	DE	Cytomegalovirus infection

DMMF0J3	ID	DMMF0J3
DMMF0J3	DN	CMX-157
DMMF0J3	HS	Phase 1
DMMF0J3	SN	Hexadecyloxypropyl tenofovir
DMMF0J3	CP	Chimerix
DMMF0J3	DT	Small molecular drug
DMMF0J3	PC	23628250
DMMF0J3	MW	569.7
DMMF0J3	FM	C28H52N5O5P
DMMF0J3	IC	InChI=1S/C28H52N5O5P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-36-19-17-20-38-39(34,35)24-37-25(2)21-33-23-32-26-27(29)30-22-31-28(26)33/h22-23,25H,3-21,24H2,1-2H3,(H,34,35)(H2,29,30,31)/t25-/m1/s1
DMMF0J3	CS	CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@H](C)CN1C=NC2=C(N=CN=C21)N)O
DMMF0J3	IK	SCTJKHUUZLXJIP-RUZDIDTESA-N
DMMF0J3	IU	[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
DMMF0J3	CA	CAS 911208-73-6
DMMF0J3	DE	Human immunodeficiency virus infection

DM8L36X	ID	DM8L36X
DM8L36X	DN	CNTO-3649
DM8L36X	HS	Phase 1
DM8L36X	CP	Centocor Ortho Biotech Inc
DM8L36X	DE	Type-2 diabetes

DMF8WAT	ID	DMF8WAT
DMF8WAT	DN	CNTO-5825
DMF8WAT	HS	Phase 1
DMF8WAT	CP	Janssen Biotech
DMF8WAT	DT	Antibody
DMF8WAT	DE	Allergic asthma

DMUBP0V	ID	DMUBP0V
DMUBP0V	DN	CNTO888
DMUBP0V	HS	Phase 1
DMUBP0V	DT	Antibody
DMUBP0V	DE	Solid tumour/cancer

DMJPEVA	ID	DMJPEVA
DMJPEVA	DN	CNTX-0290
DMJPEVA	HS	Phase 1
DMJPEVA	CP	Centrexion Therapeutics Boston, MA
DMJPEVA	DE	Chronic pain

DMCOJM7	ID	DMCOJM7
DMCOJM7	DN	CNTX-6970
DMCOJM7	HS	Phase 1
DMCOJM7	CP	Centrexion Therapeutics Boston, MA
DMCOJM7	DE	Inflammatory pain

DMMEFO0	ID	DMMEFO0
DMMEFO0	DN	COH29
DMMEFO0	HS	Phase 1
DMMEFO0	SN	Coh-29; COH-29; UNII-07802BU06S; 07802BU06S; 1190932-38-7; Rnr inhibitor COH29; SCHEMBL10036527; MolPort-044-567-552; AKOS032944935; CS-6153; HY-19931; N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide; Benzamide, N-(4-(3,4-dihydroxyphenyl)-5-phenyl-2-thiazolyl)-3,4-dihydroxy-
DMMEFO0	CP	Novonco Therapeutics Los Angeles, CA
DMMEFO0	PC	44253415
DMMEFO0	MW	420.4
DMMEFO0	FM	C22H16N2O5S
DMMEFO0	IC	InChI=1S/C22H16N2O5S/c25-15-8-6-13(10-17(15)27)19-20(12-4-2-1-3-5-12)30-22(23-19)24-21(29)14-7-9-16(26)18(28)11-14/h1-11,25-28H,(H,23,24,29)
DMMEFO0	CS	C1=CC=C(C=C1)C2=C(N=C(S2)NC(=O)C3=CC(=C(C=C3)O)O)C4=CC(=C(C=C4)O)O
DMMEFO0	IK	LGGDLPSXAGQFSG-UHFFFAOYSA-N
DMMEFO0	IU	N-[4-(3,4-dihydroxyphenyl)-5-phenyl-1,3-thiazol-2-yl]-3,4-dihydroxybenzamide
DMMEFO0	CA	CAS 1190932-38-7
DMMEFO0	DE	Solid tumour/cancer

DMXQOHV	ID	DMXQOHV
DMXQOHV	DN	COM701
DMXQOHV	HS	Phase 1
DMXQOHV	CP	Compugen
DMXQOHV	DT	Antibody
DMXQOHV	DE	Solid tumour/cancer

DMR6T8L	ID	DMR6T8L
DMR6T8L	DN	COM902
DMR6T8L	HS	Phase 1
DMR6T8L	CP	Compugen
DMR6T8L	DT	Antibody
DMR6T8L	DE	Solid tumour/cancer

DMTLP1N	ID	DMTLP1N
DMTLP1N	DN	Combinectin
DMTLP1N	HS	Phase 1
DMTLP1N	SN	GSK3732394
DMTLP1N	CP	ViiV Healthcare
DMTLP1N	DE	Human immunodeficiency virus infection

DMA7PWX	ID	DMA7PWX
DMA7PWX	DN	Combotox
DMA7PWX	HS	Phase 1
DMA7PWX	SN	IMTOX 22; Anti CD22/N97A; Anti CD22/ricin; Anti CD19 + anti CD22/N97A; Ricin-conjugated anti-CD22 and anti-CD19; IgG-RFB4-dgA and IgG-HD37-dgA
DMA7PWX	CP	University of Texas Southwestern Medical Center
DMA7PWX	DE	leukaemia

DMULBZM	ID	DMULBZM
DMULBZM	DN	Cosibelimab
DMULBZM	HS	Phase 1
DMULBZM	SN	CK-301/TG-1501
DMULBZM	CP	Checkpoint Therapeutics
DMULBZM	DT	Antibody
DMULBZM	DE	Non-small cell lung cancer

DM6K3JQ	ID	DM6K3JQ
DM6K3JQ	DN	COTI-2
DM6K3JQ	HS	Phase 1
DM6K3JQ	SN	Coti-2; UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide
DM6K3JQ	CP	Cotinga Pharmaceuticals London, Canada
DM6K3JQ	PC	91810660
DM6K3JQ	MW	366.5
DM6K3JQ	FM	C19H22N6S
DM6K3JQ	IC	InChI=1S/C19H22N6S/c26-19(23-22-16-7-3-5-15-6-4-10-21-18(15)16)25-13-11-24(12-14-25)17-8-1-2-9-20-17/h1-2,4,6,8-10H,3,5,7,11-14H2,(H,23,26)/b22-16+
DM6K3JQ	CS	C1CC2=C(/C(=N/NC(=S)N3CCN(CC3)C4=CC=CC=N4)/C1)N=CC=C2
DM6K3JQ	IK	UTDAKQMBNSHJJB-CJLVFECKSA-N
DM6K3JQ	IU	N-[(E)-6,7-dihydro-5H-quinolin-8-ylideneamino]-4-pyridin-2-ylpiperazine-1-carbothioamide
DM6K3JQ	CA	CAS 1039455-84-9
DM6K3JQ	DE	Cervical cancer; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Ovarian cancer; Peritoneal cavity cancer

DM32TFO	ID	DM32TFO
DM32TFO	DN	CP-870,893
DM32TFO	HS	Phase 1
DM32TFO	CP	Roche
DM32TFO	DT	Small molecular drug
DM32TFO	DE	Solid tumour/cancer

DM3J1T9	ID	DM3J1T9
DM3J1T9	DN	CPC-212
DM3J1T9	HS	Phase 1
DM3J1T9	CP	Allergan Parsippany, NJ Chase Pharmaceuticals Washington, DC
DM3J1T9	DE	Alzheimer disease

DMDQG4Y	ID	DMDQG4Y
DMDQG4Y	DN	CPC-250
DMDQG4Y	HS	Phase 1
DMDQG4Y	CP	Allergan Parsippany, NJ Chase Pharmaceuticals Washington, DC
DMDQG4Y	DE	Alzheimer disease

DMVDYTG	ID	DMVDYTG
DMVDYTG	DN	CPG 52364
DMVDYTG	HS	Phase 1
DMVDYTG	SN	SCHEMBL5049937
DMVDYTG	CP	Coley Pharma.
DMVDYTG	DT	Small molecular drug
DMVDYTG	PC	11774935
DMVDYTG	MW	436.5
DMVDYTG	FM	C24H32N6O2
DMVDYTG	IC	InChI=1S/C24H32N6O2/c1-28(2)11-10-25-23-19-16-21(31-3)22(32-4)17-20(19)26-24(27-23)30-14-12-29(13-15-30)18-8-6-5-7-9-18/h5-9,16-17H,10-15H2,1-4H3,(H,25,26,27)
DMVDYTG	CS	CN(C)CCNC1=NC(=NC2=CC(=C(C=C21)OC)OC)N3CCN(CC3)C4=CC=CC=C4
DMVDYTG	IK	NRDOWTUUBQCUMC-UHFFFAOYSA-N
DMVDYTG	IU	N-[6,7-dimethoxy-2-(4-phenylpiperazin-1-yl)quinazolin-4-yl]-N',N'-dimethylethane-1,2-diamine
DMVDYTG	DE	Systemic lupus erythematosus

DMJSFTX	ID	DMJSFTX
DMJSFTX	DN	CPI-006
DMJSFTX	HS	Phase 1
DMJSFTX	CP	Corvus Pharmaceuticals
DMJSFTX	DT	Antibody
DMJSFTX	DE	Advanced cancer; Solid tumour/cancer

DMMBQ20	ID	DMMBQ20
DMMBQ20	DN	CPI-818
DMMBQ20	HS	Phase 1
DMMBQ20	CP	Corvus Pharmaceuticals
DMMBQ20	DT	Small molecular drug
DMMBQ20	DE	T-cell lymphoma

DMFMGZR	ID	DMFMGZR
DMFMGZR	DN	CPL207-280CA
DMFMGZR	HS	Phase 1
DMFMGZR	DT	Small molecular drug
DMFMGZR	DE	Type 2 diabetes

DMQCHU3	ID	DMQCHU3
DMQCHU3	DN	CPP -15
DMQCHU3	HS	Phase 1
DMQCHU3	SN	CPP-15
DMQCHU3	CP	Catalyst pharmaceutical partners
DMQCHU3	DE	Infantile spasm

DMKWSFI	ID	DMKWSFI
DMKWSFI	DN	CR-002
DMKWSFI	HS	Phase 1
DMKWSFI	SN	CR-002 liquid API; Alpha 1 proteinase inhibitor (inhaled solution), CSL Behring; CR-002, CSL Behring
DMKWSFI	CP	CSL Behring
DMKWSFI	DE	Cystic fibrosis

DMT7L30	ID	DMT7L30
DMT7L30	DN	CR-3465
DMT7L30	HS	Phase 1
DMT7L30	DE	Allergy

DMHDSYF	ID	DMHDSYF
DMHDSYF	DN	CRX-675
DMHDSYF	HS	Phase 1
DMHDSYF	SN	RC-529
DMHDSYF	CP	GlaxoSmithKline
DMHDSYF	DE	Hepatitis virus infection

DMG0SPO	ID	DMG0SPO
DMG0SPO	DN	CS-0777
DMG0SPO	HS	Phase 1
DMG0SPO	SN	CS-0777; UNII-KCH74QG79A; KCH74QG79A; 827344-05-8; CS 0777; SCHEMBL1454408; CHEMBL1951587; YXEQXPNSBUIRDZ-OAQYLSRUSA-N; ZINC59872504; 1192731-63-7; 1-Butanone, 1-(5-((3R)-3-amino-4-hydroxy-3-methylbutyl)-1-methyl-1H-pyrrol-2-yl)-4-(4-methylphenyl)-
DMG0SPO	CP	Daiichi Sankyo
DMG0SPO	DT	Small molecular drug
DMG0SPO	PC	11371290
DMG0SPO	MW	342.5
DMG0SPO	FM	C21H30N2O2
DMG0SPO	IC	InChI=1S/C21H30N2O2/c1-16-7-9-17(10-8-16)5-4-6-20(25)19-12-11-18(23(19)3)13-14-21(2,22)15-24/h7-12,24H,4-6,13-15,22H2,1-3H3/t21-/m1/s1
DMG0SPO	CS	CC1=CC=C(C=C1)CCCC(=O)C2=CC=C(N2C)CC[C@](C)(CO)N
DMG0SPO	IK	YXEQXPNSBUIRDZ-OAQYLSRUSA-N
DMG0SPO	IU	1-[5-[(3R)-3-amino-4-hydroxy-3-methylbutyl]-1-methylpyrrol-2-yl]-4-(4-methylphenyl)butan-1-one
DMG0SPO	CA	CAS 827344-05-8
DMG0SPO	DE	Multiple sclerosis

DMU8OCN	ID	DMU8OCN
DMU8OCN	DN	CS1-CAR T Therapy
DMU8OCN	HS	Phase 1
DMU8OCN	CP	City of Hope Medical Center
DMU8OCN	DT	CAR T Cell Therapy
DMU8OCN	DE	Plasma cell myeloma

DMRH740	ID	DMRH740
DMRH740	DN	CS-8080
DMRH740	HS	Phase 1
DMRH740	SN	Liver X receptor modulator (artherosclerosis), Daiichi Sankyo Inc; LXR modulator (anti-arteriosclerotic), Daiichi Sankyo Inc
DMRH740	CP	Daiichi Sankyo Inc
DMRH740	PC	16212738
DMRH740	MW	959.9
DMRH740	FM	C61H99ClN2O4
DMRH740	IC	InChI=1S/C61H99N2.ClHO4/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-44-52-62-56-48-42-40-46-54(56)60(3,4)58(62)50-38-37-39-51-59-61(5,6)55-47-41-43-49-57(55)63(59)53-45-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-2;2-1(3,4)5/h37-43,46-51H,7-36,44-45,52-53H2,1-6H3;(H,2,3,4,5)/q+1;/p-1
DMRH740	CS	CCCCCCCCCCCCCCCCCCN\\1C2=CC=CC=C2C(/C1=C\\C=C\\C=C\\C3=[N+](C4=CC=CC=C4C3(C)C)CCCCCCCCCCCCCCCCCC)(C)C.[O-]Cl(=O)(=O)=O
DMRH740	IK	ZQSBJPAQPRVNHU-UHFFFAOYSA-M
DMRH740	IU	(2E)-2-[(2E,4E)-5-(3,3-dimethyl-1-octadecylindol-1-ium-2-yl)penta-2,4-dienylidene]-3,3-dimethyl-1-octadecylindole;perchlorate
DMRH740	CA	CAS 127274-91-3
DMRH740	CB	CHEBI:52027
DMRH740	DE	Arteriosclerosis

DMO97RV	ID	DMO97RV
DMO97RV	DN	CSL-362
DMO97RV	HS	Phase 1
DMO97RV	SN	CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3
DMO97RV	CP	Csl; janssen research & development
DMO97RV	DT	Antibody
DMO97RV	DE	Acute myeloid leukaemia

DM7I39W	ID	DM7I39W
DM7I39W	DN	CSL-362-AML
DM7I39W	HS	Phase 1
DM7I39W	CP	Janssen Biotech
DM7I39W	DT	Antibody
DM7I39W	DE	leukaemia

DMI7XMU	ID	DMI7XMU
DMI7XMU	DN	CT 868
DMI7XMU	HS	Phase 1
DMI7XMU	CP	Carmot Therapeutics
DMI7XMU	DT	Small molecular drug
DMI7XMU	DE	Type 2 diabetes

DMBCJW6	ID	DMBCJW6
DMBCJW6	DN	CT053
DMBCJW6	HS	Phase 1
DMBCJW6	CP	CARsgen Therapeutics
DMBCJW6	DT	CAR T Cell Therapy
DMBCJW6	DE	Multiple myeloma

DMW16VR	ID	DMW16VR
DMW16VR	DN	CT-200
DMW16VR	HS	Phase 1
DMW16VR	CP	Celleron Therapeutics
DMW16VR	DE	Solid tumour/cancer

DMHBK6L	ID	DMHBK6L
DMHBK6L	DN	CTAP-201
DMHBK6L	HS	Phase 1
DMHBK6L	SN	Vitamin D analogs, Cytochroma; Vitamin D analogs (iv, hyperparathyroidism), Cytochroma
DMHBK6L	CP	Cytochroma Inc
DMHBK6L	DE	Hyperparathyroidism

DM2HES0	ID	DM2HES0
DM2HES0	DN	CTCE-0214
DM2HES0	HS	Phase 1
DM2HES0	SN	CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics
DM2HES0	CP	Chemokine Therapeutics
DM2HES0	DE	Constitutional neutropenia

DMIKX01	ID	DMIKX01
DMIKX01	DN	CTP-298
DMIKX01	HS	Phase 1
DMIKX01	SN	C-10276; CTP-518; Deuterated atazanavir isotopologs (HIV infection), CoNCERT/GSK
DMIKX01	CP	CoNCERT Pharmaceuticals Inc
DMIKX01	DE	Human immunodeficiency virus infection

DM68I93	ID	DM68I93
DM68I93	DN	CTS-21166
DM68I93	HS	Phase 1
DM68I93	CP	CoMentis
DM68I93	DE	Alzheimer disease

DMAV86R	ID	DMAV86R
DMAV86R	DN	CTT1403
DMAV86R	HS	Phase 1
DMAV86R	CP	Cancer Targeted Technology
DMAV86R	DT	Small molecular drug
DMAV86R	DE	Prostate cancer

DMHK9WR	ID	DMHK9WR
DMHK9WR	DN	CTX-101
DMHK9WR	HS	Phase 1
DMHK9WR	CP	CRISPR Therapeutics
DMHK9WR	DT	CAR T Cell Therapy
DMHK9WR	DE	Non-hodgkin lymphoma; B-cell lymphoma

DMWS40H	ID	DMWS40H
DMWS40H	DN	CTX120
DMWS40H	HS	Phase 1
DMWS40H	CP	CRISPR Therapeutics
DMWS40H	DT	CAR T Cell Therapy
DMWS40H	DE	Multiple myeloma

DM926CH	ID	DM926CH
DM926CH	DN	CTX130
DM926CH	HS	Phase 1
DM926CH	CP	CRISPR Therapeutics
DM926CH	DT	CAR T Cell Therapy
DM926CH	DE	T-cell lymphoma

DMMPKN3	ID	DMMPKN3
DMMPKN3	DN	CTX-471
DMMPKN3	HS	Phase 1
DMMPKN3	CP	Compass Therapeutics
DMMPKN3	DT	Antibody
DMMPKN3	DE	Solid tumour/cancer

DM9ZOMD	ID	DM9ZOMD
DM9ZOMD	DN	CUDC-101
DM9ZOMD	HS	Phase 1
DM9ZOMD	SN	CUDC-101; 1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149
DM9ZOMD	CP	Curis
DM9ZOMD	DT	Small molecular drug
DM9ZOMD	PC	24756910
DM9ZOMD	MW	434.5
DM9ZOMD	FM	C24H26N4O4
DM9ZOMD	IC	InChI=1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27)
DM9ZOMD	CS	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO
DM9ZOMD	IK	PLIVFNIUGLLCEK-UHFFFAOYSA-N
DM9ZOMD	IU	7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide
DM9ZOMD	CA	CAS 1012054-59-9
DM9ZOMD	DE	Solid tumour/cancer

DMYD37G	ID	DMYD37G
DMYD37G	DN	CV8102
DMYD37G	HS	Phase 1
DMYD37G	CP	CureVac
DMYD37G	DE	Melanoma; Squamous cell carcinoma

DMTSIYZ	ID	DMTSIYZ
DMTSIYZ	DN	CVN058
DMTSIYZ	HS	Phase 1
DMTSIYZ	CP	Cerevance
DMTSIYZ	DT	Small molecular drug
DMTSIYZ	DE	Schizophrenia

DMY84TW	ID	DMY84TW
DMY84TW	DN	CVT-6883
DMY84TW	HS	Phase 1
DMY84TW	SN	CVT-6883; 752222-83-6; GS-6201; UNII-67CKV7X08G; CHEMBL260933; 67CKV7X08G; CVT 6883; GS 6201; 3-Ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione; 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione; Kinome_3621; SCHEMBL238694; GTPL5615; CVT6883; AOB4675; MolPort-035-765-814; CTV-6883; ZINC29055563; BDBM50236738; AKOS024458311; API0004749; 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7H-purine-2,6-dione
DMY84TW	DT	Small molecular drug
DMY84TW	PC	11270783
DMY84TW	MW	446.4
DMY84TW	FM	C21H21F3N6O2
DMY84TW	IC	InChI=1S/C21H21F3N6O2/c1-3-8-30-19(31)16-18(29(4-2)20(30)32)27-17(26-16)14-10-25-28(12-14)11-13-6-5-7-15(9-13)21(22,23)24/h5-7,9-10,12H,3-4,8,11H2,1-2H3,(H,26,27)
DMY84TW	CS	CCCN1C(=O)C2=C(N=C(N2)C3=CN(N=C3)CC4=CC(=CC=C4)C(F)(F)F)N(C1=O)CC
DMY84TW	IK	KOYXXLLNCXWUNF-UHFFFAOYSA-N
DMY84TW	IU	3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7H-purine-2,6-dione
DMY84TW	CA	CAS 752222-83-6
DMY84TW	DE	Asthma

DMO23R0	ID	DMO23R0
DMO23R0	DN	CVX 096
DMO23R0	HS	Phase 1
DMO23R0	SN	PF-04856883
DMO23R0	CP	Pfizer
DMO23R0	DE	Type-2 diabetes

DMV74JC	ID	DMV74JC
DMV74JC	DN	CVX-241
DMV74JC	HS	Phase 1
DMV74JC	CP	Pfizer
DMV74JC	DE	Solid tumour/cancer

DMRD2B0	ID	DMRD2B0
DMRD2B0	DN	CXD-101
DMRD2B0	HS	Phase 1
DMRD2B0	CP	AstraZeneca plc
DMRD2B0	PC	16225380
DMRD2B0	MW	403.5
DMRD2B0	FM	C24H29N5O
DMRD2B0	IC	InChI=1S/C24H29N5O/c1-17-21(15-28(2)27-17)16-29-13-11-19(12-14-29)18-7-9-20(10-8-18)24(30)26-23-6-4-3-5-22(23)25/h3-10,15,19H,11-14,16,25H2,1-2H3,(H,26,30)
DMRD2B0	CS	CC1=NN(C=C1CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N)C
DMRD2B0	IK	JHDZMASHNBKTPS-UHFFFAOYSA-N
DMRD2B0	IU	N-(2-aminophenyl)-4-[1-[(1,3-dimethylpyrazol-4-yl)methyl]piperidin-4-yl]benzamide
DMRD2B0	CA	CAS 934828-12-3
DMRD2B0	DE	Solid tumour/cancer

DM4GJ50	ID	DM4GJ50
DM4GJ50	DN	CXR-1002
DM4GJ50	HS	Phase 1
DM4GJ50	CP	CXR Biosciences Ltd
DM4GJ50	DE	Solid tumour/cancer

DMSM42V	ID	DMSM42V
DMSM42V	DN	CYAD-101
DMSM42V	HS	Phase 1
DMSM42V	CP	Celyad (formerly named Cardio3 BioSciences)
DMSM42V	DT	CAR T Cell Therapy
DMSM42V	DE	Colorectal cancer

DM9ODT6	ID	DM9ODT6
DM9ODT6	DN	CYC065
DM9ODT6	HS	Phase 1
DM9ODT6	SN	DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-
DM9ODT6	CP	Cyclacel Pharmaceuticals Berkeley Heights, NJ
DM9ODT6	PC	24983461
DM9ODT6	MW	397.5
DM9ODT6	FM	C21H31N7O
DM9ODT6	IC	InChI=1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)/t15-,17+/m1/s1
DM9ODT6	CS	CC[C@@H]([C@@H](C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=C(C=C3C)C
DM9ODT6	IK	DLPIYBKBHMZCJI-WBVHZDCISA-N
DM9ODT6	IU	(2R,3S)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol
DM9ODT6	CA	CAS 1070790-89-4
DM9ODT6	DE	Lymphoma; Solid tumour/cancer

DMUMHXT	ID	DMUMHXT
DMUMHXT	DN	CYC116
DMUMHXT	HS	Phase 1
DMUMHXT	SN	693228-63-6; CYC-116; CYC116; CHEMBL482967; Kinome_636; 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine; 4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amine; 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; 4-methyl-5-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)thiazol-2-amine; 2uue; CYC 116; GPSZYOIFQZPWEJ-UHFFFAOYSA-N; 2c5t; AC1O4WKE; MLS006011244; SCHEMBL2074998; SYN1034; EX-A753; CYC-116/CYC116; MolPort-009-679-476; HMS3244O12; HMS3244P11; BCPP000273
DMUMHXT	CP	Cyclacel Limited
DMUMHXT	TC	Anticancer Agents
DMUMHXT	DT	Small molecular drug
DMUMHXT	PC	6420138
DMUMHXT	MW	368.5
DMUMHXT	FM	C18H20N6OS
DMUMHXT	IC	InChI=1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23)
DMUMHXT	CS	CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4
DMUMHXT	IK	GPSZYOIFQZPWEJ-UHFFFAOYSA-N
DMUMHXT	IU	4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine
DMUMHXT	DE	Solid tumour/cancer

DMC6PKJ	ID	DMC6PKJ
DMC6PKJ	DN	CYC140
DMC6PKJ	HS	Phase 1
DMC6PKJ	SN	Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-
DMC6PKJ	CP	Cyclacel Pharmaceuticals
DMC6PKJ	DT	Small molecular drug
DMC6PKJ	PC	57336523
DMC6PKJ	MW	679.8
DMC6PKJ	FM	C36H53N7O6
DMC6PKJ	IC	InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30-/m0/s1
DMC6PKJ	CS	CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5
DMC6PKJ	IK	BBAWEDCPNXPBQM-YQYHUCGXSA-N
DMC6PKJ	IU	(3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide
DMC6PKJ	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DMI6EUB	ID	DMI6EUB
DMI6EUB	DN	Cyclolignan picropodophyllin
DMI6EUB	HS	Phase 1
DMI6EUB	SN	PPP; IGF-1R inhibitor (cancer), Karolinska
DMI6EUB	CP	Karolinska Institute
DMI6EUB	DE	Colorectal cancer

DMAWVTX	ID	DMAWVTX
DMAWVTX	DN	Cyclopentenylcytosine
DMAWVTX	HS	Phase 1
DMAWVTX	SN	cyclopentenyl cytosine; 90597-22-1; NSC-375575; CPE-C; UNII-69MO0NDN8K; NSC 375575; NSC375575; BRN 4258358; 69MO0NDN8K; CHEMBL63647; 1-((1R,2S,3R)-4-Hydroxymethyl-2,3-dihydroxy-4-cyclopenten-1-yl)cytosine; 4-amino-1-[(1R,4R,5S)-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one; 4-amino-1-[(1r,4r,5s)-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2(1h)-one; CPE-cytosine; 2(1H)-Pyrimidinone, 4-amino-1-((1R,4R,5S)-4,5-dihydroxy-3-(hydroxymethyl)-2-cyclopenten-1-yl)-
DMAWVTX	DT	Small molecular drug
DMAWVTX	PC	72828
DMAWVTX	MW	239.23
DMAWVTX	FM	C10H13N3O4
DMAWVTX	IC	InChI=1S/C10H13N3O4/c11-7-1-2-13(10(17)12-7)6-3-5(4-14)8(15)9(6)16/h1-3,6,8-9,14-16H,4H2,(H2,11,12,17)/t6-,8-,9+/m1/s1
DMAWVTX	CS	C1=CN(C(=O)N=C1N)[C@@H]2C=C([C@H]([C@H]2O)O)CO
DMAWVTX	IK	DUJGMZAICVPCBJ-VDAHYXPESA-N
DMAWVTX	IU	4-amino-1-[(1R,4R,5S)-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one
DMAWVTX	CA	CAS 90597-22-1
DMAWVTX	DE	Solid tumour/cancer

DMNICD4	ID	DMNICD4
DMNICD4	DN	CYT-013-IL1bQb
DMNICD4	HS	Phase 1
DMNICD4	SN	Immunodrug vaccines (IL-1 beta) (rheumatoid arthritis), Cytos
DMNICD4	CP	Cytos Biotechnology AG
DMNICD4	DT	Vaccine
DMNICD4	DE	Inflammation

DMTV09A	ID	DMTV09A
DMTV09A	DN	Cyt-1010
DMTV09A	HS	Phase 1
DMTV09A	CP	Tulane University
DMTV09A	PC	44129692
DMTV09A	MW	624.7
DMTV09A	FM	C35H40N6O5
DMTV09A	IC	InChI=1S/C35H40N6O5/c36-27(18-23-13-15-25(42)16-14-23)32(43)39-29-12-6-7-17-37-33(44)30(19-22-8-2-1-3-9-22)40-35(46)31(41-34(29)45)20-24-21-38-28-11-5-4-10-26(24)28/h1-5,8-11,13-16,21,27,29-31,38,42H,6-7,12,17-20,36H2,(H,37,44)(H,39,43)(H,40,46)(H,41,45)/t27-,29+,30-,31-/m0/s1
DMTV09A	CS	C1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5
DMTV09A	IK	CFVGCGXJRNVTFP-LYXINOJLSA-N
DMTV09A	IU	(2S)-2-amino-N-[(3S,6S,9R)-3-benzyl-6-(1H-indol-3-ylmethyl)-2,5,8-trioxo-1,4,7-triazacyclotridec-9-yl]-3-(4-hydroxyphenyl)propanamide
DMTV09A	DE	Pain

DMJ83Z7	ID	DMJ83Z7
DMJ83Z7	DN	CYT-609
DMJ83Z7	HS	Phase 1
DMJ83Z7	SN	Aurimune
DMJ83Z7	CP	CytImmune sciences INC
DMJ83Z7	DE	Solid tumour/cancer

DMAY6X2	ID	DMAY6X2
DMAY6X2	DN	CZ-48
DMAY6X2	HS	Phase 1
DMAY6X2	SN	Camptothecin-20-O-propionate; UNII-4S145C552U; CZ-48; 194414-69-2; 4S145C552U; SF 6A; CZ48; Camptothecin-20(S)-O-propionate; CZ 48; SCHEMBL1618775; CHEMBL124162; DTXSID30173074; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-(1-oxopropoxy)-, (S)-
DMAY6X2	DT	Small molecular drug
DMAY6X2	PC	9887472
DMAY6X2	MW	404.4
DMAY6X2	FM	C23H20N2O5
DMAY6X2	IC	InChI=1S/C23H20N2O5/c1-3-19(26)30-23(4-2)16-10-18-20-14(9-13-7-5-6-8-17(13)24-20)11-25(18)21(27)15(16)12-29-22(23)28/h5-10H,3-4,11-12H2,1-2H3/t23-/m0/s1
DMAY6X2	CS	CCC(=O)O[C@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)CC
DMAY6X2	IK	YCNIQYLWIPCLNY-QHCPKHFHSA-N
DMAY6X2	IU	[(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] propanoate
DMAY6X2	CA	CAS 194414-69-2
DMAY6X2	DE	Solid tumour/cancer; Lymphoma

DMGA1DS	ID	DMGA1DS
DMGA1DS	DN	D-0502
DMGA1DS	HS	Phase 1
DMGA1DS	CP	InventisBio
DMGA1DS	DT	Small molecular drug
DMGA1DS	DE	Breast cancer

DMTP9ER	ID	DMTP9ER
DMTP9ER	DN	D-20133
DMTP9ER	HS	Phase 1
DMTP9ER	SN	OMPEP; octadecyl-(2-(N-methylpiperidino)ethyl)phosphate; 146764-26-3; D 20133; 1-(2-((Hydroxy(octadecyloxy)phosphinyl)oxy)ethyl)-1-methylpiperidinium inner salt; Piperidinium, 1-(2-((hydroxy(octadecyloxy)phosphinyl)oxy)ethyl)-1-methyl-, inner salt; SCHEMBL2293548; AC1L31K0; DTXSID90163471; LS-116681; 2-(1-methylpiperidin-1-ium-1-yl)ethyl octadecyl phosphate
DMTP9ER	CP	ASTA Medica AG
DMTP9ER	DT	Small molecular drug
DMTP9ER	PC	132778
DMTP9ER	MW	476.7
DMTP9ER	FM	C26H55NO4P+
DMTP9ER	IC	InChI=1S/C26H54NO4P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-25-30-32(28,29)31-26-24-27(2)22-19-18-20-23-27/h3-26H2,1-2H3/p+1
DMTP9ER	CS	CCCCCCCCCCCCCCCCCCOP(=O)(O)OCC[N+]1(CCCCC1)C
DMTP9ER	IK	CUQJLYFFQBHUGW-UHFFFAOYSA-O
DMTP9ER	IU	2-(1-methylpiperidin-1-ium-1-yl)ethyl octadecyl hydrogen phosphate
DMTP9ER	DE	Solid tumour/cancer

DMIMK84	ID	DMIMK84
DMIMK84	DN	D2C7
DMIMK84	HS	Phase 1
DMIMK84	CP	Istari Oncology
DMIMK84	DT	Antibody
DMIMK84	DE	Glioblastoma of brain

DM7V2OM	ID	DM7V2OM
DM7V2OM	DN	D-3263
DM7V2OM	HS	Phase 1
DM7V2OM	SN	TDBTU; 125700-69-8; N,N,N',N'-Tetramethyl-O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)uronium tetrafluoroborate; O-(3,4-Dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; MFCD00077730; AK170015; o-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-n,n,n',n'-tetramethyluroniumtetrafluoroborate; 1,1,3,3-tetramethyl-2-(4-oxobenzo[d][1,2,3]triazin-3(4h)-yl)uronium tetrafluoroborate; TDBTU; N,N,N',N'-Tetramethyl-O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)uronium tetrafluoroborate
DM7V2OM	CP	Dendreon
DM7V2OM	DT	Small molecular drug
DM7V2OM	PC	44137358
DM7V2OM	MW	373.5
DM7V2OM	FM	C21H31N3O3
DM7V2OM	IC	InChI=1S/C21H31N3O3/c1-13(2)16-7-5-14(3)11-17(16)20(25)24-18-8-6-15(27-4)12-19(18)23(10-9-22)21(24)26/h6,8,12-14,16-17H,5,7,9-11,22H2,1-4H3/t14-,16+,17-/m1/s1
DM7V2OM	CS	C[C@@H]1CC[C@H]([C@@H](C1)C(=O)N2C3=C(C=C(C=C3)OC)N(C2=O)CCN)C(C)C
DM7V2OM	IK	ZGTYTFYRCIRWBL-HYVNUMGLSA-N
DM7V2OM	IU	3-(2-aminoethyl)-5-methoxy-1-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexanecarbonyl]benzimidazol-2-one
DM7V2OM	CA	CAS 947257-66-1
DM7V2OM	DE	Solid tumour/cancer

DM4OTWL	ID	DM4OTWL
DM4OTWL	DN	DA-1229
DM4OTWL	HS	Phase 1
DM4OTWL	SN	DPP-IV inhibitor (tablet, type II diabetes), Dong-A
DM4OTWL	CP	Dong-A Pharmaceutical Co Ltd
DM4OTWL	DT	Small molecular drug
DM4OTWL	PC	25022354
DM4OTWL	MW	401.4
DM4OTWL	FM	C19H26F3N3O3
DM4OTWL	IC	InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
DM4OTWL	CS	CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N
DM4OTWL	IK	LCDDAGSJHKEABN-MLGOLLRUSA-N
DM4OTWL	IU	(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one
DM4OTWL	CA	CAS 1222102-29-5
DM4OTWL	DE	Type-2 diabetes

DMPJA64	ID	DMPJA64
DMPJA64	DN	DA-1241
DMPJA64	HS	Phase 1
DMPJA64	CP	Dong-A ST
DMPJA64	DT	Small molecular drug
DMPJA64	DE	Type 2 diabetes

DM4JG0B	ID	DM4JG0B
DM4JG0B	DN	DA-3607
DM4JG0B	HS	Phase 1
DM4JG0B	SN	Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A
DM4JG0B	CP	Dong-A Pharmaceutical Co Ltd
DM4JG0B	DE	Brain cancer

DMKPAOD	ID	DMKPAOD
DMKPAOD	DN	DA-6886
DMKPAOD	HS	Phase 1
DMKPAOD	SN	5-HT4 agonist (IBS-c), Dong-A
DMKPAOD	CP	Dong-A Pharmaceutical Co Ltd
DMKPAOD	PC	54575171
DMKPAOD	MW	406.9
DMKPAOD	FM	C19H27ClN6O2
DMKPAOD	IC	InChI=1S/C19H27ClN6O2/c1-28-18-12-17(21)16(20)11-15(18)19(27)22-13-14-3-8-25(9-4-14)6-2-7-26-10-5-23-24-26/h5,10-12,14H,2-4,6-9,13,21H2,1H3,(H,22,27)
DMKPAOD	CS	COC1=CC(=C(C=C1C(=O)NCC2CCN(CC2)CCCN3C=CN=N3)Cl)N
DMKPAOD	IK	AULLTYAISZREAX-UHFFFAOYSA-N
DMKPAOD	IU	4-amino-5-chloro-2-methoxy-N-[[1-[3-(triazol-1-yl)propyl]piperidin-4-yl]methyl]benzamide
DMKPAOD	CA	CAS 1342815-16-0
DMKPAOD	DE	Irritable bowel syndrome

DMBRN2G	ID	DMBRN2G
DMBRN2G	DN	DA-697b
DMBRN2G	HS	Phase 1
DMBRN2G	SN	DZ-697b; Oral anticoagulants, Daiichi
DMBRN2G	CP	Daiichi Seiyaku Co Ltd
DMBRN2G	DE	Thrombosis

DM9KS1A	ID	DM9KS1A
DM9KS1A	DN	DA-727
DM9KS1A	HS	Phase 1
DM9KS1A	CP	Kotobuki Pharmaceutical Co Ltd
DM9KS1A	DE	Hypertension

DMQR4HA	ID	DMQR4HA
DMQR4HA	DN	DABIS MALEATE
DMQR4HA	HS	Phase 1
DMQR4HA	SN	E-83-041; 1,4-Bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane dimaleate
DMQR4HA	DT	Small molecular drug
DMQR4HA	PC	54599345
DMQR4HA	MW	340.2
DMQR4HA	FM	C13H21Cl2N2O4+
DMQR4HA	IC	InChI=1S/C9H18Cl2N2.C4H4O4/c10-1-3-12-5-7-13(9-12,4-2-11)8-6-12;5-3(6)1-2-4(7)8/h1-9H2;1-2H,(H,5,6)(H,7,8)/q+2;/p-1/b;2-1-
DMQR4HA	CS	C1C[N+]2(CC[N+]1(C2)CCCl)CCCl.C(=C\\C(=O)[O-])\\C(=O)O
DMQR4HA	IK	HKVBKOPISPWMSR-BTJKTKAUSA-M
DMQR4HA	IU	1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane;(Z)-4-hydroxy-4-oxobut-2-enoate
DMQR4HA	CA	CAS 73387-70-9
DMQR4HA	DE	Solid tumour/cancer

DM5TB76	ID	DM5TB76
DM5TB76	DN	DACRA 089
DM5TB76	HS	Phase 1
DM5TB76	SN	KBP-089
DM5TB76	CP	Eli Lilly
DM5TB76	DT	Peptide
DM5TB76	DE	Type 2 diabetes

DMWT5RS	ID	DMWT5RS
DMWT5RS	DN	Daniquidone
DMWT5RS	HS	Phase 1
DMWT5RS	SN	Batracylin
DMWT5RS	CP	National Cancer Institute
DMWT5RS	DT	Small molecular drug
DMWT5RS	PC	71750
DMWT5RS	MW	249.27
DMWT5RS	FM	C15H11N3O
DMWT5RS	IC	InChI=1S/C15H11N3O/c16-10-5-6-13-9(7-10)8-18-14(17-13)11-3-1-2-4-12(11)15(18)19/h1-7H,8,16H2
DMWT5RS	CS	C1C2=C(C=CC(=C2)N)N=C3N1C(=O)C4=CC=CC=C43
DMWT5RS	IK	SRIOCKJKFXAKHK-UHFFFAOYSA-N
DMWT5RS	IU	8-amino-10H-isoindolo[1,2-b]quinazolin-12-one
DMWT5RS	CA	CAS 67199-66-0
DMWT5RS	DE	Lymphoma

DM4A3U7	ID	DM4A3U7
DM4A3U7	DN	DAVLB-HYDRAZIDE
DM4A3U7	HS	Phase 1
DM4A3U7	SN	Desacetylvinblastine-3-carboxyhydrazide
DM4A3U7	DT	Small molecular drug
DM4A3U7	PC	6918076
DM4A3U7	MW	768.9
DM4A3U7	FM	C43H56N6O7
DM4A3U7	IC	InChI=1S/C43H56N6O7/c1-6-39(53)21-25-22-42(38(52)56-5,33-27(13-17-48(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)55-4)47(3)35-41(28)15-18-49-16-10-14-40(7-2,34(41)49)36(50)43(35,54)37(51)46-44/h8-12,14,19-20,25,34-36,45,50,53-54H,6-7,13,15-18,21-24,44H2,1-5H3,(H,46,51)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1
DM4A3U7	CS	CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)NN)O)O)CC)OC)C(=O)OC)O
DM4A3U7	IK	PPRGGNQLPSVURC-KOTLKJBCSA-N
DM4A3U7	IU	methyl (13S,15S,17S)-17-ethyl-13-[(1R,9R,10S,11R,12R,19R)-12-ethyl-10-(hydrazinecarbonyl)-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate
DM4A3U7	DE	Solid tumour/cancer

DM1K248	ID	DM1K248
DM1K248	DN	DB-053072
DM1K248	HS	Phase 1
DM1K248	SN	Methylglyoxylate; Pyruvate; Natriumpyruvat; Propanoic acid, 2-oxo-, ion(1-); Pyruvate ion; pyruvate; 10110-EP2277876A1; 10110-EP2292614A1; 10110-EP2295413A1; 10110-EP2295432A1; 10110-EP2295550A2; 10110-EP2298312A1; 10110-EP2308874A1; 10110-EP2311830A1; 10110-EP2316835A1; 2-Oxopropanoate; 2-oxidanylidenepropanoate; 2-oxo-Propanoic acid; 2-oxopropanoic acid, ion(1-); 2hzl; 57-60-3; BDBM50159792; CHEBI:15361; CHEMBL181886; CTK1H3219; DB-007695; DB-053072; DTXSID50205604; FT-0731491; HO43T60JMG; LCTONWCANYUPML-UHFFFAOYSA-M; UNII-HO43T60JMG
DM1K248	PC	107735
DM1K248	MW	87.05
DM1K248	FM	C3H3O3-
DM1K248	IC	LCTONWCANYUPML-UHFFFAOYSA-M
DM1K248	CS	CC(=O)C(=O)[O-]
DM1K248	IK	1S/C3H4O3/c1-2(4)3(5)6/h1H3,(H,5,6)/p-1
DM1K248	IU	2-oxopropanoate
DM1K248	CA	CAS 57-60-3
DM1K248	CB	CHEBI:15361
DM1K248	DE	Prostate cancer

DM6K47B	ID	DM6K47B
DM6K47B	DN	DC/I540/KLH vaccine
DM6K47B	HS	Phase 1
DM6K47B	SN	HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber
DM6K47B	CP	Dana-Farber Cancer Institute Inc
DM6K47B	DT	Vaccine
DM6K47B	DE	Brain cancer

DMLVG9D	ID	DMLVG9D
DMLVG9D	DN	DCC-3014
DMLVG9D	HS	Phase 1
DMLVG9D	CP	Deciphera Pharmaceuticals Waltham, MA
DMLVG9D	DE	Haematological malignancy; Solid tumour/cancer

DMQ8ACY	ID	DMQ8ACY
DMQ8ACY	DN	DCCCyB
DMQ8ACY	HS	Phase 1
DMQ8ACY	SN	DCCCyB; CHEMBL2146721; 916159-99-4; Benzamide,2,4-dichloro-N-[[1-(cyclopropylmethyl)-4-[(cyclopropylmethyl)sulfonyl]cyclohexyl]methyl]-; SCHEMBL678963; ZINC34807040; BDBM50391757; KB-74916; J3.560.315H
DMQ8ACY	CP	Merck
DMQ8ACY	DT	Small molecular drug
DMQ8ACY	PC	15951941
DMQ8ACY	MW	458.4
DMQ8ACY	FM	C22H29Cl2NO3S
DMQ8ACY	IC	InChI=1S/C22H29Cl2NO3S/c23-17-5-6-19(20(24)11-17)21(26)25-14-22(12-15-1-2-15)9-7-18(8-10-22)29(27,28)13-16-3-4-16/h5-6,11,15-16,18H,1-4,7-10,12-14H2,(H,25,26)
DMQ8ACY	CS	C1CC1CC2(CCC(CC2)S(=O)(=O)CC3CC3)CNC(=O)C4=C(C=C(C=C4)Cl)Cl
DMQ8ACY	IK	PSIMLOLEQCVVJV-UHFFFAOYSA-N
DMQ8ACY	IU	2,4-dichloro-N-[[1-(cyclopropylmethyl)-4-(cyclopropylmethylsulfonyl)cyclohexyl]methyl]benzamide
DMQ8ACY	DE	Schizophrenia

DMQIEFB	ID	DMQIEFB
DMQIEFB	DN	Debio 0827
DMQIEFB	HS	Phase 1
DMQIEFB	CP	Debiopharm
DMQIEFB	PC	16123252
DMQIEFB	MW	518.7
DMQIEFB	FM	C22H34N2O6S3
DMQIEFB	IC	InChI=1S/C22H34N2O6S3/c1-4-28-22(27)30-16(2)29-20(25)13-24-21(26)18(12-17-8-6-5-7-9-17)14-32-33-15-19(23)10-11-31-3/h5-9,16,18-19H,4,10-15,23H2,1-3H3,(H,24,26)
DMQIEFB	CS	CCOC(=O)OC(C)OC(=O)CNC(=O)C(CC1=CC=CC=C1)CSSCC(CCSC)N
DMQIEFB	IK	BJCNUZJDFWFVBY-UHFFFAOYSA-N
DMQIEFB	IU	1-ethoxycarbonyloxyethyl 2-[[2-[[(2-amino-4-methylsulfanylbutyl)disulfanyl]methyl]-3-phenylpropanoyl]amino]acetate
DMQIEFB	DE	Chronic pain

DMWP3G1	ID	DMWP3G1
DMWP3G1	DN	Debio 0932
DMWP3G1	HS	Phase 1
DMWP3G1	CP	Debiopharm
DMWP3G1	PC	44156921
DMWP3G1	MW	442.6
DMWP3G1	FM	C22H30N6O2S
DMWP3G1	IC	InChI=1S/C22H30N6O2S/c1-22(2,3)12-24-8-9-28-14-6-7-25-20(23)19(14)26-21(28)31-18-11-17-16(29-13-30-17)10-15(18)27(4)5/h6-7,10-11,24H,8-9,12-13H2,1-5H3,(H2,23,25)
DMWP3G1	CS	CC(C)(C)CNCCN1C2=C(C(=NC=C2)N)N=C1SC3=CC4=C(C=C3N(C)C)OCO4
DMWP3G1	IK	RVJIQAYFTOPTKK-UHFFFAOYSA-N
DMWP3G1	IU	2-[[6-(dimethylamino)-1,3-benzodioxol-5-yl]sulfanyl]-1-[2-(2,2-dimethylpropylamino)ethyl]imidazo[4,5-c]pyridin-4-amine
DMWP3G1	CA	CAS 1061318-81-7
DMWP3G1	DE	Solid tumour/cancer

DMPXLMB	ID	DMPXLMB
DMPXLMB	DN	Demobesin
DMPXLMB	HS	Phase 1
DMPXLMB	SN	Bombesin antagonist (prostate/breast/NSCL), Biomedica lifesciences; 99mTc-Demobesin-6
DMPXLMB	CP	Biomedica Life Sciences SA
DMPXLMB	DE	Breast cancer

DMTULGS	ID	DMTULGS
DMTULGS	DN	Demogastrin
DMTULGS	HS	Phase 1
DMTULGS	SN	Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
DMTULGS	CP	Biomedica Life Sciences SA
DMTULGS	DE	Thyroid cancer

DMURVPF	ID	DMURVPF
DMURVPF	DN	Dendritic cell vaccine
DMURVPF	HS	Phase 1
DMURVPF	SN	Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute
DMURVPF	CP	National Cancer Institute
DMURVPF	DT	Vaccine
DMURVPF	DE	Head and neck cancer

DMTR7EH	ID	DMTR7EH
DMTR7EH	DN	Desoxypeganine
DMTR7EH	HS	Phase 1
DMTR7EH	SN	Alcoholism therapy, HF Arzneimittelforschung; Desoxypeganine, HF Arzneimittelforschung
DMTR7EH	CP	HF Arzneimittelforschung GmbH & Co KG
DMTR7EH	DT	Small molecular drug
DMTR7EH	PC	442894
DMTR7EH	MW	172.23
DMTR7EH	FM	C11H12N2
DMTR7EH	IC	InChI=1S/C11H12N2/c1-2-5-10-9(4-1)8-13-7-3-6-11(13)12-10/h1-2,4-5H,3,6-8H2
DMTR7EH	CS	C1CC2=NC3=CC=CC=C3CN2C1
DMTR7EH	IK	WUFQLZTXIWKION-UHFFFAOYSA-N
DMTR7EH	IU	1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline
DMTR7EH	CA	CAS 495-59-0
DMTR7EH	CB	CHEBI:4428
DMTR7EH	DE	Alcohol dependence

DMAE9I0	ID	DMAE9I0
DMAE9I0	DN	Dexpirronium
DMAE9I0	HS	Phase 1
DMAE9I0	SN	Anticholinergic compound (COPD), Meda
DMAE9I0	CP	Meda AB
DMAE9I0	DE	Chronic obstructive pulmonary disease

DMI8QNB	ID	DMI8QNB
DMI8QNB	DN	DFP 13318
DMI8QNB	HS	Phase 1
DMI8QNB	CP	Delta-Fly Pharma Tokushima, Japan
DMI8QNB	DE	Solid tumour/cancer

DMY6QFH	ID	DMY6QFH
DMY6QFH	DN	DFP-11207
DMY6QFH	HS	Phase 1
DMY6QFH	CP	Delta-fly pharma
DMY6QFH	PC	52919121
DMY6QFH	MW	713
DMY6QFH	FM	C32H26ClFN4O12
DMY6QFH	IC	InChI=1S/C32H26ClFN4O12/c1-4-26(39)48-24-11-19(12-25(36-24)49-27(40)5-2)31(44)47-22-13-23(35-14-20(22)33)50-30(43)18-9-7-8-17(10-18)28(41)38-29(42)21(34)15-37(32(38)45)16-46-6-3/h7-15H,4-6,16H2,1-3H3
DMY6QFH	CS	CCC(=O)OC1=CC(=CC(=N1)OC(=O)CC)C(=O)OC2=CC(=NC=C2Cl)OC(=O)C3=CC=CC(=C3)C(=O)N4C(=O)C(=CN(C4=O)COCC)F
DMY6QFH	IK	WUQYJRNEHOAADL-UHFFFAOYSA-N
DMY6QFH	IU	[5-chloro-2-[3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoyl]oxypyridin-4-yl] 2,6-di(propanoyloxy)pyridine-4-carboxylate
DMY6QFH	CA	CAS 1296177-16-6
DMY6QFH	DE	Solid tumour/cancer

DMGO4XJ	ID	DMGO4XJ
DMGO4XJ	DN	DFP-14927
DMGO4XJ	HS	Phase 1
DMGO4XJ	CP	Delta-Fly Pharma
DMGO4XJ	DT	Small molecular drug
DMGO4XJ	DE	Solid tumour/cancer

DM6OJI1	ID	DM6OJI1
DM6OJI1	DN	DIAPLASININ
DM6OJI1	HS	Phase 1
DM6OJI1	SN	Diaplasinin < USAN; PAI-749; 1-Benzyl-3-pentyl-2-[6-(1H-tetrazol-5-ylmethoxy)naphthalen-2-yl]-1H-indole
DM6OJI1	DT	Small molecular drug
DM6OJI1	PC	6450820
DM6OJI1	MW	501.6
DM6OJI1	FM	C32H31N5O
DM6OJI1	IC	InChI=1S/C32H31N5O/c1-2-3-5-13-29-28-12-8-9-14-30(28)37(21-23-10-6-4-7-11-23)32(29)26-16-15-25-20-27(18-17-24(25)19-26)38-22-31-33-35-36-34-31/h4,6-12,14-20H,2-3,5,13,21-22H2,1H3,(H,33,34,35,36)
DM6OJI1	CS	CCCCCC1=C(N(C2=CC=CC=C21)CC3=CC=CC=C3)C4=CC5=C(C=C4)C=C(C=C5)OCC6=NNN=N6
DM6OJI1	IK	BDPXZFKVHDEPIQ-UHFFFAOYSA-N
DM6OJI1	IU	1-benzyl-3-pentyl-2-[6-(2H-tetrazol-5-ylmethoxy)naphthalen-2-yl]indole
DM6OJI1	CA	CAS 481631-45-2
DM6OJI1	DE	Thrombosis

DMPWOH9	ID	DMPWOH9
DMPWOH9	DN	DKY709
DMPWOH9	HS	Phase 1
DMPWOH9	CP	Novartis
DMPWOH9	DT	Small molecular drug
DMPWOH9	DE	Solid tumour/cancer

DMM8GZT	ID	DMM8GZT
DMM8GZT	DN	DL-017
DMM8GZT	HS	Phase 1
DMM8GZT	SN	3-[4-(2-Methoxyphenyl)piperazin-1-ylmethyl]-5-(methylsulfanyl)-2,3-dihydroimidazo[1,2-c]quinazoline
DMM8GZT	PC	9931976
DMM8GZT	MW	421.6
DMM8GZT	FM	C23H27N5OS
DMM8GZT	IC	InChI=1S/C23H27N5OS/c1-29-21-10-6-5-9-20(21)27-13-11-26(12-14-27)16-17-15-24-22-18-7-3-4-8-19(18)25-23(30-2)28(17)22/h3-10,17H,11-16H2,1-2H3
DMM8GZT	CS	COC1=CC=CC=C1N2CCN(CC2)CC3CN=C4N3C(=NC5=CC=CC=C54)SC
DMM8GZT	IK	DVYBIZHLZSDANU-UHFFFAOYSA-N
DMM8GZT	IU	3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-5-methylsulfanyl-2,3-dihydroimidazo[1,2-c]quinazoline
DMM8GZT	DE	Hypertension

DMCT4BA	ID	DMCT4BA
DMCT4BA	DN	DMUC-5754A
DMCT4BA	HS	Phase 1
DMCT4BA	CP	Genentech
DMCT4BA	DT	Antibody
DMCT4BA	DE	Ovarian cancer; Peritoneal cancer; Fallopian tube cancer

DMQFX8R	ID	DMQFX8R
DMQFX8R	DN	DN1406131
DMQFX8R	HS	Phase 1
DMQFX8R	CP	Jiangxi Qingfeng Pharmaceutical
DMQFX8R	DT	Small molecular drug
DMQFX8R	DE	Solid tumour/cancer

DM0JT9C	ID	DM0JT9C
DM0JT9C	DN	DN1508052
DM0JT9C	HS	Phase 1
DM0JT9C	CP	Shanghai De Novo Pharmatech
DM0JT9C	DT	Small molecular drug
DM0JT9C	DE	Solid tumour/cancer

DMOSCQ9	ID	DMOSCQ9
DMOSCQ9	DN	DNL104
DMOSCQ9	HS	Phase 1
DMOSCQ9	CP	Denali Therapeutics
DMOSCQ9	DT	Small molecular drug
DMOSCQ9	DE	Alzheimer disease

DMZT89C	ID	DMZT89C
DMZT89C	DN	DNL151
DMZT89C	HS	Phase 1
DMZT89C	CP	Denali Therapeutics South San Francisco, CA
DMZT89C	DE	Parkinson disease

DMFEORD	ID	DMFEORD
DMFEORD	DN	DNL201
DMFEORD	HS	Phase 1
DMFEORD	CP	Denali Therapeutics South San Francisco, CA
DMFEORD	DE	Parkinson disease

DMNSC0O	ID	DMNSC0O
DMNSC0O	DN	DNL747
DMNSC0O	HS	Phase 1
DMNSC0O	CP	Denali Therapeutics
DMNSC0O	DT	Small molecular drug
DMNSC0O	DE	Alzheimer disease; Amyotrophic lateral sclerosis

DMZS350	ID	DMZS350
DMZS350	DN	Donor-derived CD19/22 bispecific CAR-T cells
DMZS350	HS	Phase 1
DMZS350	CP	Chinese PLA General Hospital
DMZS350	DT	CAR T Cell Therapy (Dual specific)
DMZS350	DE	leukaemia

DMXZ6A0	ID	DMXZ6A0
DMXZ6A0	DN	DP-4088
DMXZ6A0	HS	Phase 1
DMXZ6A0	SN	DPOC-4088; Anticoagulant thrombin inhibitor (oral), Merck & Co; Anticoagulant thrombin inhibitor (oral, deep vein thrombosis), Diakron/ Orchid
DMXZ6A0	CP	Merck & Co Inc
DMXZ6A0	PC	9955534
DMXZ6A0	MW	452.8
DMXZ6A0	FM	C19H16ClF3N6O2
DMXZ6A0	IC	InChI=1S/C19H16ClF3N6O2/c20-15-9-27-17(28-11-19(22,23)14-5-1-2-6-25-14)18(31)29(15)10-16(30)26-8-13-12(21)4-3-7-24-13/h1-7,9H,8,10-11H2,(H,26,30)(H,27,28)
DMXZ6A0	CS	C1=CC=NC(=C1)C(CNC2=NC=C(N(C2=O)CC(=O)NCC3=C(C=CC=N3)F)Cl)(F)F
DMXZ6A0	IK	AATHXZYXWMKUFC-UHFFFAOYSA-N
DMXZ6A0	IU	2-[6-chloro-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-oxopyrazin-1-yl]-N-[(3-fluoropyridin-2-yl)methyl]acetamide
DMXZ6A0	CA	CAS 312904-62-4
DMXZ6A0	DE	Coagulation defect

DM4ZDOE	ID	DM4ZDOE
DM4ZDOE	DN	DpC
DM4ZDOE	HS	Phase 1
DM4ZDOE	CP	Oncochel Therapeutics
DM4ZDOE	DT	Small molecular drug
DM4ZDOE	DE	Solid tumour/cancer

DMJY9TW	ID	DMJY9TW
DMJY9TW	DN	DRF-1042
DMJY9TW	HS	Phase 1
DMJY9TW	SN	4(S)-Ethyl-4-hydroxy-12-(2-hydroxyethoxy)-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[2,1-b]quinoline-3,14-dione
DMJY9TW	DT	Small molecular drug
DMJY9TW	PC	23631031
DMJY9TW	MW	408.4
DMJY9TW	FM	C22H20N2O6
DMJY9TW	IC	InChI=1S/C22H20N2O6/c1-2-22(28)15-10-17-18-13(9-12-5-3-4-6-16(12)23-18)20(29-8-7-25)24(17)19(26)14(15)11-30-21(22)27/h3-6,9-10,20,25,28H,2,7-8,11H2,1H3/t20?,22-/m0/s1
DMJY9TW	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3C(C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)O
DMJY9TW	IK	XAKLYHGHEFMDAP-IAXKEJLGSA-N
DMJY9TW	IU	(19S)-19-ethyl-19-hydroxy-12-(2-hydroxyethoxy)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMJY9TW	CA	CAS 200619-13-2
DMJY9TW	DE	Solid tumour/cancer

DM0DJPE	ID	DM0DJPE
DM0DJPE	DN	Drug 2838232
DM0DJPE	HS	Phase 1
DM0DJPE	SN	2838232
DM0DJPE	DE	Human immunodeficiency virus infection

DMM57CS	ID	DMM57CS
DMM57CS	DN	Drug 2849330
DMM57CS	HS	Phase 1
DMM57CS	SN	2849330
DMM57CS	DT	Antibody
DMM57CS	DE	Solid tumour/cancer

DMNFEC6	ID	DMNFEC6
DMNFEC6	DN	Drug 2878175
DMNFEC6	HS	Phase 1
DMNFEC6	SN	2878175
DMNFEC6	DE	Hepatitis virus infection

DMWXQC9	ID	DMWXQC9
DMWXQC9	DN	Drug 2881078
DMWXQC9	HS	Phase 1
DMWXQC9	SN	2881078
DMWXQC9	DE	Heart failure

DMXCN37	ID	DMXCN37
DMXCN37	DN	DS-1040
DMXCN37	HS	Phase 1
DMXCN37	PC	260178
DMXCN37	MW	265.69
DMXCN37	FM	C13H12ClNO3
DMXCN37	IC	InChI=1S/C13H12ClNO3/c1-18-7-6-15-11-10(14)12(16)8-4-2-3-5-9(8)13(11)17/h2-5,15H,6-7H2,1H3
DMXCN37	CS	COCCNC1=C(C(=O)C2=CC=CC=C2C1=O)Cl
DMXCN37	IK	IAPJSKHYZZLKBU-UHFFFAOYSA-N
DMXCN37	IU	2-chloro-3-(2-methoxyethylamino)naphthalene-1,4-dione
DMXCN37	CA	CAS 22272-22-6
DMXCN37	DE	Ischemic stroke

DMPR3A6	ID	DMPR3A6
DMPR3A6	DN	DS-1055
DMPR3A6	HS	Phase 1
DMPR3A6	CP	Daiichi Sankyo
DMPR3A6	DT	Antibody
DMPR3A6	DE	Solid tumour/cancer

DM42KZW	ID	DM42KZW
DM42KZW	DN	DS-1093
DM42KZW	HS	Phase 1
DM42KZW	PC	2723758
DM42KZW	MW	130.15
DM42KZW	FM	C5H10N2O2
DM42KZW	IC	InChI=1S/C5H10N2O2/c8-5(9)4-3-6-1-2-7-4/h4,6-7H,1-3H2,(H,8,9)
DM42KZW	CS	C1CNC(CN1)C(=O)O
DM42KZW	IK	JSSXHAMIXJGYCS-UHFFFAOYSA-N
DM42KZW	IU	piperazine-2-carboxylic acid
DM42KZW	CA	CAS 2762-32-5
DM42KZW	DE	Anemia

DM029TQ	ID	DM029TQ
DM029TQ	DN	DS-1150b
DM029TQ	HS	Phase 1
DM029TQ	CP	Daiichi sankyo
DM029TQ	DE	Type-2 diabetes

DMXST9F	ID	DMXST9F
DMXST9F	DN	DS-1205
DMXST9F	HS	Phase 1
DMXST9F	CP	Daiichi Sankyo Parsippany, NJ
DMXST9F	DE	Non-small-cell lung cancer

DMNDGPT	ID	DMNDGPT
DMNDGPT	DN	DS-2969
DMNDGPT	HS	Phase 1
DMNDGPT	CP	Daiichi Sankyo
DMNDGPT	DT	Small molecular drug
DMNDGPT	DE	Clostridium infection

DMA2B5Y	ID	DMA2B5Y
DMA2B5Y	DN	DS-3032
DMA2B5Y	HS	Phase 1
DMA2B5Y	CP	Daiichi sankyo
DMA2B5Y	DE	Solid tumour/cancer; Haematological malignancy

DMG7I5J	ID	DMG7I5J
DMG7I5J	DN	DS-3078
DMG7I5J	HS	Phase 1
DMG7I5J	CP	Daiichi Sankyo
DMG7I5J	DE	Lymphoma; Solid tumour/cancer

DMRLPFG	ID	DMRLPFG
DMRLPFG	DN	DS-3201
DMRLPFG	HS	Phase 1
DMRLPFG	SN	QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione
DMRLPFG	CP	Daiichi Sankyo Basking Ridge, NJ
DMRLPFG	PC	22627096
DMRLPFG	MW	255.27
DMRLPFG	FM	C14H13N3O2
DMRLPFG	IC	InChI=1S/C14H13N3O2/c1-9-15-8-10(16-9)6-7-17-13(18)11-4-2-3-5-12(11)14(17)19/h2-5,8H,6-7H2,1H3,(H,15,16)
DMRLPFG	CS	CC1=NC=C(N1)CCN2C(=O)C3=CC=CC=C3C2=O
DMRLPFG	IK	QTGYNKYZRZATJB-UHFFFAOYSA-N
DMRLPFG	IU	2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]isoindole-1,3-dione
DMRLPFG	DE	Acute lymphoblastic leukaemia; Acute myeloid leukaemia

DM6WN9X	ID	DM6WN9X
DM6WN9X	DN	DS-3801
DM6WN9X	HS	Phase 1
DM6WN9X	PC	69388802
DM6WN9X	MW	280.16
DM6WN9X	FM	C10H18BrNO3
DM6WN9X	IC	InChI=1S/C10H18BrNO3/c1-10(2,3)15-9(13)12-4-5-14-8(6-11)7-12/h8H,4-7H2,1-3H3/t8-/m1/s1
DM6WN9X	CS	CC(C)(C)OC(=O)N1CCO[C@@H](C1)CBr
DM6WN9X	IK	RLXCSEPIBOWMOJ-MRVPVSSYSA-N
DM6WN9X	IU	tert-butyl (2S)-2-(bromomethyl)morpholine-4-carboxylate
DM6WN9X	CA	CAS 919286-71-8
DM6WN9X	DE	Constipation

DM0RD4F	ID	DM0RD4F
DM0RD4F	DN	DS-6051
DM0RD4F	HS	Phase 1
DM0RD4F	DE	Solid tumour/cancer

DMTKZ1Q	ID	DMTKZ1Q
DMTKZ1Q	DN	DS-6157
DMTKZ1Q	HS	Phase 1
DMTKZ1Q	CP	Daiichi Sankyo
DMTKZ1Q	DT	Antibody drug conjugate
DMTKZ1Q	DE	Gastrointestinal stromal tumour

DM7C4U9	ID	DM7C4U9
DM7C4U9	DN	DS-7309
DM7C4U9	HS	Phase 1
DM7C4U9	CP	Daiichi Sankyo
DM7C4U9	PC	22278920
DM7C4U9	MW	217.31
DM7C4U9	FM	C14H19NO
DM7C4U9	IC	InChI=1S/C14H19NO/c1-11-8-15(9-12(2)14(11)16)10-13-6-4-3-5-7-13/h3-7,11-12H,8-10H2,1-2H3
DM7C4U9	CS	CC1CN(CC(C1=O)C)CC2=CC=CC=C2
DM7C4U9	IK	KUUYMZATYJQLLZ-UHFFFAOYSA-N
DM7C4U9	IU	1-benzyl-3,5-dimethylpiperidin-4-one
DM7C4U9	CA	CAS 836-21-5
DM7C4U9	DE	Diabetic complication

DMCFJM3	ID	DMCFJM3
DMCFJM3	DN	DS-7423
DMCFJM3	HS	Phase 1
DMCFJM3	CP	Daiichi Sankyo
DMCFJM3	DE	Solid tumour/cancer

DMJPUDW	ID	DMJPUDW
DMJPUDW	DN	DS-8273
DMJPUDW	HS	Phase 1
DMJPUDW	CP	Daiichi Sankyo
DMJPUDW	DT	Antibody
DMJPUDW	DE	Solid tumour/cancer; Colorectal cancer

DM31VNC	ID	DM31VNC
DM31VNC	DN	DS-8895
DM31VNC	HS	Phase 1
DM31VNC	DT	Antibody
DM31VNC	DE	Solid tumour/cancer

DM4ZCY0	ID	DM4ZCY0
DM4ZCY0	DN	DSP-0337
DM4ZCY0	HS	Phase 1
DM4ZCY0	CP	Sumitomo Dainippon Pharma
DM4ZCY0	DT	Small molecular drug
DM4ZCY0	DE	Solid tumour/cancer

DMY95MZ	ID	DMY95MZ
DMY95MZ	DN	DSP-0565
DMY95MZ	HS	Phase 1
DMY95MZ	CP	Sunovion pharmaceuticals
DMY95MZ	PC	46189864
DMY95MZ	MW	229.25
DMY95MZ	FM	C14H12FNO
DMY95MZ	IC	InChI=1S/C14H12FNO/c15-13-8-4-3-7-12(13)11-6-2-1-5-10(11)9-14(16)17/h1-8H,9H2,(H2,16,17)
DMY95MZ	CS	C1=CC=C(C(=C1)CC(=O)N)C2=CC=CC=C2F
DMY95MZ	IK	MWAPNZXZUGCADE-UHFFFAOYSA-N
DMY95MZ	IU	2-[2-(2-fluorophenyl)phenyl]acetamide
DMY95MZ	DE	Epilepsy

DMJDP0E	ID	DMJDP0E
DMJDP0E	DN	DSP-1053
DMJDP0E	HS	Phase 1
DMJDP0E	CP	Sunovion Pharmaceuticals
DMJDP0E	PC	44182694
DMJDP0E	MW	502.4
DMJDP0E	FM	C26H32BrNO4
DMJDP0E	IC	InChI=1S/C26H32BrNO4/c1-30-14-15-32-26-18-21(2-4-23(26)27)16-20-7-11-28(12-8-20)10-6-19-3-5-25-22(17-19)24(29)9-13-31-25/h2-5,17-18,20H,6-16H2,1H3
DMJDP0E	CS	COCCOC1=C(C=CC(=C1)CC2CCN(CC2)CCC3=CC4=C(C=C3)OCCC4=O)Br
DMJDP0E	IK	ZSVLGHSNQJYODD-UHFFFAOYSA-N
DMJDP0E	IU	6-[2-[4-[[4-bromo-3-(2-methoxyethoxy)phenyl]methyl]piperidin-1-yl]ethyl]-2,3-dihydrochromen-4-one
DMJDP0E	DE	Major depressive disorder

DM4WSHG	ID	DM4WSHG
DM4WSHG	DN	DSP-1200
DM4WSHG	HS	Phase 1
DM4WSHG	CP	Sunovion Pharmaceuticals Marlborough, MA
DM4WSHG	DE	Depression

DM0WTMD	ID	DM0WTMD
DM0WTMD	DN	DSP-2230
DM0WTMD	HS	Phase 1
DM0WTMD	CP	Sumitomo Dainippon Pharma
DM0WTMD	PC	129080919
DM0WTMD	MW	419.4
DM0WTMD	FM	C20H20F3N5O2
DM0WTMD	IC	InChI=1S/C20H20F3N5O2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25H,2-4,9H2,1H3,(H2,24,29)/t10-/m0/s1
DM0WTMD	CS	C[C@@H](C(=O)N)NCC1=NC2=C(N1C3CCC3)N=C(C=C2)OC4=CC(=C(C(=C4)F)F)F
DM0WTMD	IK	HHXCJIMPEJSJTG-JTQLQIEISA-N
DM0WTMD	IU	(2S)-2-[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)imidazo[4,5-b]pyridin-2-yl]methylamino]propanamide
DM0WTMD	DE	Neuropathic pain

DMYHU24	ID	DMYHU24
DMYHU24	DN	DSP-3905
DMYHU24	HS	Phase 1
DMYHU24	CP	Sumitomo Dainippon Pharma
DMYHU24	DE	Neuropathic pain

DMM86OH	ID	DMM86OH
DMM86OH	DN	DSP-6745
DMM86OH	HS	Phase 1
DMM86OH	CP	Sunovion Pharmaceuticals Marlborough, MA
DMM86OH	DE	Parkinson disease

DM2PYE0	ID	DM2PYE0
DM2PYE0	DN	DSP-8658
DM2PYE0	HS	Phase 1
DM2PYE0	CP	Sunovion Pharmaceuticals
DM2PYE0	DE	Type-2 diabetes; Alzheimer disease

DM69ZBU	ID	DM69ZBU
DM69ZBU	DN	DST-2970
DM69ZBU	HS	Phase 1
DM69ZBU	CP	DisperSol Technologies
DM69ZBU	DT	Small molecular drug
DM69ZBU	DE	Prostate cancer

DMYFOJQ	ID	DMYFOJQ
DMYFOJQ	DN	DT-200
DMYFOJQ	HS	Phase 1
DMYFOJQ	CP	Akashi Therapeutics Cambridge, MA
DMYFOJQ	DE	Duchenne dystrophy

DM5AGKV	ID	DM5AGKV
DM5AGKV	DN	DTRMWXHS-12
DM5AGKV	HS	Phase 1
DM5AGKV	SN	DTRM-12
DM5AGKV	CP	Zhejiang DTRM Biopharma
DM5AGKV	DT	Small molecular drug
DM5AGKV	DE	B-cell lymphoma; Chronic lymphocytic leukaemia

DM1FX09	ID	DM1FX09
DM1FX09	DN	DT-TX-30
DM1FX09	HS	Phase 1
DM1FX09	SN	DT-TX-30-SE
DM1FX09	CP	Boehringer Ingelheim Corp
DM1FX09	DE	Angina pectoris

DM8WBNF	ID	DM8WBNF
DM8WBNF	DN	DTX401
DM8WBNF	HS	Phase 1
DM8WBNF	CP	Ultragenyx Pharmaceutical
DM8WBNF	DT	Gene therapy
DM8WBNF	DE	Pompe disease

DM3P0H1	ID	DM3P0H1
DM3P0H1	DN	Duvortuxizumab
DM3P0H1	HS	Phase 1
DM3P0H1	CP	Janssen Research & Development Raritan, NJ
DM3P0H1	DE	B-cell lymphoma

DMDSVRP	ID	DMDSVRP
DMDSVRP	DN	DV-1179
DMDSVRP	HS	Phase 1
DMDSVRP	CP	Dynavax Technologies
DMDSVRP	DE	Systemic lupus erythematosus; Autoimmune disease

DMJ0Y86	ID	DMJ0Y86
DMJ0Y86	DN	DV281
DMJ0Y86	HS	Phase 1
DMJ0Y86	CP	Dynavax Berkeley, CA
DMJ0Y86	DE	Non-small-cell lung cancer

DMQKDJZ	ID	DMQKDJZ
DMQKDJZ	DN	DWJ-208
DMQKDJZ	HS	Phase 1
DMQKDJZ	CP	Daewoong Pharmaceutical Co Ltd
DMQKDJZ	DE	Pain; Cancer related pain; Neuropathic pain

DM4XZY9	ID	DM4XZY9
DM4XZY9	DN	DWP-09031
DM4XZY9	HS	Phase 1
DM4XZY9	SN	DWJ-301
DM4XZY9	CP	Daewoong Pharmaceutical Co Ltd
DM4XZY9	DE	Alzheimer disease

DMS1NC8	ID	DMS1NC8
DMS1NC8	DN	DZ-2640
DMS1NC8	HS	Phase 1
DMS1NC8	SN	(1R,5S,6S)-2-[6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-6(S)-ylsulfanyl]-6-[1(R)-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester
DMS1NC8	PC	101700650
DMS1NC8	MW	463.5
DMS1NC8	FM	C22H29N3O6S
DMS1NC8	IC	InChI=1S/C22H29N3O6S/c1-11-16-15(12(2)26)19(27)25(16)17(20(28)30-10-31-21(29)22(3,4)5)18(11)32-13-8-14-23-6-7-24(14)9-13/h6-7,11-13,15-16,26H,8-10H2,1-5H3/t11-,12-,13+,15-,16+/m1/s1
DMS1NC8	CS	C[C@@H]1[C@H]2[C@H](C(=O)N2C(=C1S[C@H]3CC4=NC=CN4C3)C(=O)OCOC(=O)C(C)(C)C)[C@@H](C)O
DMS1NC8	IK	SVIXKYNOOFZUFA-QUEVPRLRSA-N
DMS1NC8	IU	2,2-dimethylpropanoyloxymethyl (4R,5R,6S)-3-[[(6S)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMS1NC8	DE	Bacterial infection

DMEQY4Z	ID	DMEQY4Z
DMEQY4Z	DN	DZD1516
DMEQY4Z	HS	Phase 1
DMEQY4Z	CP	Dizal Pharmaceuticals
DMEQY4Z	DT	Small molecular drug
DMEQY4Z	DE	HER2-positive breast cancer

DM3LOF1	ID	DM3LOF1
DM3LOF1	DN	E 7974
DM3LOF1	HS	Phase 1
DM3LOF1	SN	26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872
DM3LOF1	CP	Eisai Co. Ltd.
DM3LOF1	DT	Small molecular drug
DM3LOF1	PC	10127315
DM3LOF1	MW	437.6
DM3LOF1	FM	C24H43N3O4
DM3LOF1	IC	InChI=1S/C24H43N3O4/c1-15(2)19(14-17(5)23(30)31)26(9)22(29)20(24(6,7)8)25-21(28)18-12-10-11-13-27(18)16(3)4/h14-16,18-20H,10-13H2,1-9H3,(H,25,28)(H,30,31)/b17-14+/t18-,19-,20-/m1/s1
DM3LOF1	CS	CC(C)[C@@H](/C=C(\\C)/C(=O)O)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H]1CCCCN1C(C)C
DM3LOF1	IK	FWYMMXUDTATKLG-PGLMLKKXSA-N
DM3LOF1	IU	(E,4S)-4-[[(2S)-3,3-dimethyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid
DM3LOF1	CA	CAS 610787-07-0
DM3LOF1	DE	Ovarian cancer

DMNEVKA	ID	DMNEVKA
DMNEVKA	DN	E2012
DMNEVKA	HS	Phase 1
DMNEVKA	SN	870843-42-8; E 2012; (E)-1-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-3-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE]PIPERIDIN-2-ONE; E-2012; UNII-3LSD4Y5F0F; 3LSD4Y5F0F; CHEMBL1224151; J-501810; (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one; (e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one; PUOAETJYKQITMO-LANLRWRYSA-N
DMNEVKA	CP	Eisai
DMNEVKA	DT	Small molecular drug
DMNEVKA	PC	11560787
DMNEVKA	MW	419.5
DMNEVKA	FM	C25H26FN3O2
DMNEVKA	IC	InChI=1S/C25H26FN3O2/c1-17-15-28(16-27-17)23-11-6-19(14-24(23)31-3)13-21-5-4-12-29(25(21)30)18(2)20-7-9-22(26)10-8-20/h6-11,13-16,18H,4-5,12H2,1-3H3/b21-13+/t18-/m0/s1
DMNEVKA	CS	CC1=CN(C=N1)C2=C(C=C(C=C2)/C=C/3\\CCCN(C3=O)[C@@H](C)C4=CC=C(C=C4)F)OC
DMNEVKA	IK	PUOAETJYKQITMO-LANLRWRYSA-N
DMNEVKA	IU	(3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one
DMNEVKA	CA	CAS 870843-42-8
DMNEVKA	DE	Alzheimer disease

DMQDKYV	ID	DMQDKYV
DMQDKYV	DN	E-2212
DMQDKYV	HS	Phase 1
DMQDKYV	CP	Eisai Co Ltd
DMQDKYV	PC	46854987
DMQDKYV	MW	480.5
DMQDKYV	FM	C25H23F3N6O
DMQDKYV	IC	InChI=1S/C25H23F3N6O/c1-16-14-33(15-29-16)21-11-9-17(30-24(21)35-2)10-12-22-31-23-19(7-5-13-34(23)32-22)18-6-3-4-8-20(18)25(26,27)28/h3-4,6,8-12,14-15,19H,5,7,13H2,1-2H3/b12-10+/t19-/m0/s1
DMQDKYV	CS	CC1=CN(C=N1)C2=C(N=C(C=C2)/C=C/C3=NN4CCC[C@H](C4=N3)C5=CC=CC=C5C(F)(F)F)OC
DMQDKYV	IK	SSGLBUGNISHUAO-RDELFYGPSA-N
DMQDKYV	IU	(8S)-2-[(E)-2-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]ethenyl]-8-[2-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine
DMQDKYV	CA	CAS 1123193-82-7
DMQDKYV	DE	Alzheimer disease

DM4BD5U	ID	DM4BD5U
DM4BD5U	DN	E2730
DM4BD5U	HS	Phase 1
DM4BD5U	CP	Eisai Woodcliff Lake, NJ
DM4BD5U	DE	Epilepsy

DMFVT43	ID	DMFVT43
DMFVT43	DN	E7046
DMFVT43	HS	Phase 1
DMFVT43	SN	MKLKAQMPKHNQPR-NSHDSACASA-N; UNII-YWY620GU8I; 1369489-71-3; E-7046; YWY620GU8I; ER-886046; SCHEMBL881212; CHEMBL3670685; MolPort-044-561-624; BDBM119448; EX-A1726; ZINC114766778; CS-7559; Benzoic acid, 4-((1S)-1-(((3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazol-4-yl)carbonyl)amino)ethyl)-; AC-30338; HY-103088; US8686018, 107; (S)-4-(1-(3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazole-4-carboxamido)ethyl)benzoic acid; 4-[(1S)-1-[[3-(difluoromethyl)-1-methyl-5-[3-(trifluoromet
DMFVT43	CP	Adlai Nortye Hangzhou, China
DMFVT43	PC	56944705
DMFVT43	MW	483.4
DMFVT43	FM	C22H18F5N3O4
DMFVT43	IC	InChI=1S/C22H18F5N3O4/c1-11(12-6-8-13(9-7-12)21(32)33)28-19(31)16-17(18(23)24)29-30(2)20(16)34-15-5-3-4-14(10-15)22(25,26)27/h3-11,18H,1-2H3,(H,28,31)(H,32,33)/t11-/m0/s1
DMFVT43	CS	C[C@@H](C1=CC=C(C=C1)C(=O)O)NC(=O)C2=C(N(N=C2C(F)F)C)OC3=CC=CC(=C3)C(F)(F)F
DMFVT43	IK	MKLKAQMPKHNQPR-NSHDSACASA-N
DMFVT43	IU	4-[(1S)-1-[[3-(difluoromethyl)-1-methyl-5-[3-(trifluoromethyl)phenoxy]pyrazole-4-carbonyl]amino]ethyl]benzoic acid
DMFVT43	CA	CAS 1369489-71-3
DMFVT43	DE	Rectal adenocarcinoma

DMDOCNW	ID	DMDOCNW
DMDOCNW	DN	E-7050
DMDOCNW	HS	Phase 1
DMDOCNW	SN	C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai
DMDOCNW	CP	Eisai Co Ltd
DMDOCNW	DT	Small molecular drug
DMDOCNW	PC	16118392
DMDOCNW	MW	633.7
DMDOCNW	FM	C33H37F2N7O4
DMDOCNW	IC	InChI=1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)
DMDOCNW	CS	CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(=C3)OC4=CC(=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
DMDOCNW	IK	UQRCJCNVNUFYDX-UHFFFAOYSA-N
DMDOCNW	IU	1-N'-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMDOCNW	CA	CAS 928037-13-2
DMDOCNW	DE	Head and neck cancer

DM8TU5R	ID	DM8TU5R
DM8TU5R	DN	E7766
DM8TU5R	HS	Phase 1
DM8TU5R	CP	Eisai
DM8TU5R	DT	Small molecular drug
DM8TU5R	DE	Solid tumour/cancer

DM8RD4T	ID	DM8RD4T
DM8RD4T	DN	EC0489
DM8RD4T	HS	Phase 1
DM8RD4T	SN	EC-0489
DM8RD4T	CP	Endocyte
DM8RD4T	DT	Small molecular drug
DM8RD4T	PC	25229525
DM8RD4T	MW	2550.7
DM8RD4T	FM	C111H156N22O43S2
DM8RD4T	IC	InChI=1S/C111H156N22O43S2/c1-6-107(172)39-52-40-110(104(170)175-5,89-57(29-33-132(46-52)51-107)56-11-8-9-12-60(56)120-89)59-37-58-68(38-75(59)174-4)131(3)101-109(58)31-34-133-32-10-30-108(7-2,100(109)133)102(168)111(101,173)103(169)129-130-106(171)176-35-36-177-178-50-67(99(166)167)126-96(162)63(19-25-78(145)116-45-71(139)85(153)88(156)74(142)49-136)122-95(161)65(22-28-81(149)150)124-93(159)62(18-24-77(144)115-44-70(138)84(152)87(155)73(141)48-135)121-94(160)64(21-27-80(147)148)123-92(158)61(17-23-76(143)114-43-69(137)83(151)86(154)72(140)47-134)119-79(146)26-20-66(98(164)165)125-91(157)53-13-15-54(16-14-53)113-41-55-42-117-90-82(118-55)97(163)128-105(112)127-90/h8-16,30,37-38,42,52,61-67,69-74,83-88,100-102,113,120,134-142,151-156,168,172-173H,6-7,17-29,31-36,39-41,43-51H2,1-5H3,(H,114,143)(H,115,144)(H,116,145)(H,119,146)(H,121,160)(H,122,161)(H,123,158)(H,124,159)(H,125,157)(H,126,162)(H,129,169)(H,130,171)(H,147,148)(H,149,150)(H,164,165)(H,166,167)(H3,112,117,127,128,163)/t52-,61-,62-,63-,64-,65-,66-,67-,69-,70-,71-,72+,73+,74+,83+,84+,85+,86+,87+,88+,100-,101+,102+,107-,108+,109+,110-,111-/m0/s1
DM8RD4T	CS	CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)NNC(=O)OCCSSC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)NC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)NC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)NC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)NCC1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O)CC)OC)C(=O)OC)O
DM8RD4T	IK	PHCAWPRQWLBYTH-HCDHKMFTSA-N
DM8RD4T	IU	(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-[2-[[[(1R,9R,10S,11R,12R,19R)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carbonyl]amino]carbamoyloxy]ethyldisulfanyl]ethyl]amino]-1,5-dioxo-5-[[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]amino]-1,5-dioxo-5-[[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]amino]-1,5-dioxo-5-[[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]pentan-2-yl]amino]-5-oxopentanoic acid
DM8RD4T	DE	Solid tumour/cancer

DMXW07J	ID	DMXW07J
DMXW07J	DN	EDP-239
DMXW07J	HS	Phase 1
DMXW07J	SN	NS5a HCV inhibitors, Enanta
DMXW07J	CP	Enanta pharmaceuticals; novartis pharmaceuticals
DMXW07J	DE	Hepatitis C virus infection

DMWTVM1	ID	DMWTVM1
DMWTVM1	DN	EDP-322
DMWTVM1	HS	Phase 1
DMWTVM1	SN	EP-16322; Antibacterial (oral, Gram-positive infections), Enanta; EDP-MRSA-1 (oral), Enanta
DMWTVM1	CP	Enanta Pharmaceuticals Inc
DMWTVM1	DE	Bacterial infection

DM8KRA3	ID	DM8KRA3
DM8KRA3	DN	EDP-514
DM8KRA3	HS	Phase 1
DM8KRA3	CP	Enanta Pharmaceuticals
DM8KRA3	DT	Small molecular drug
DM8KRA3	DE	Chronic HBV infection

DM3AD65	ID	DM3AD65
DM3AD65	DN	EGFR806-specific CAR T cell
DM3AD65	HS	Phase 1
DM3AD65	CP	Seattle Children's Hospital
DM3AD65	DT	CAR T Cell Therapy
DM3AD65	DE	Atypical teratoid/rhabdoid tumour; Choroid plexus carcinoma; Ependymoma; Germ cell tumour; Glioma; Medulloblastoma; Pineoblastoma; Gastric adenocarcinoma

DMZN35T	ID	DMZN35T
DMZN35T	DN	EGFRt/19-28z/4-1BBL CAR T cells
DMZN35T	HS	Phase 1
DMZN35T	CP	Memorial Sloan Kettering Cancer Center
DMZN35T	DT	CAR T Cell Therapy
DMZN35T	DE	Chronic lymphocytic leukaemia

DM6XWV4	ID	DM6XWV4
DM6XWV4	DN	EGFRvIII CAR T cells
DM6XWV4	HS	Phase 1
DM6XWV4	CP	Gary Archer Ph.D.
DM6XWV4	DT	CAR T Cell Therapy
DM6XWV4	DE	Glioblastoma multiforme; Recurrent glioblastoma

DMA46RN	ID	DMA46RN
DMA46RN	DN	EGFRvIII-CARs
DMA46RN	HS	Phase 1
DMA46RN	CP	Gary Archer Ph.D.
DMA46RN	DT	CAR T Cell Therapy
DMA46RN	DE	Recurrent glioblastoma

DMDPGCS	ID	DMDPGCS
DMDPGCS	DN	EGT-0001474
DMDPGCS	HS	Phase 1
DMDPGCS	CP	Theracos
DMDPGCS	PC	75059718
DMDPGCS	MW	695.2
DMDPGCS	FM	C34H47ClN2O11
DMDPGCS	IC	InChI=1S/C24H29ClO7.2C5H9NO2/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18;2*7-5(8)4-2-1-3-6-4/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2;2*4,6H,1-3H2,(H,7,8)
DMDPGCS	CS	C1CC(NC1)C(=O)O.C1CC(NC1)C(=O)O.C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
DMDPGCS	IK	DAQOCDWUCJBXEI-UHFFFAOYSA-N
DMDPGCS	IU	2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;pyrrolidine-2-carboxylic acid
DMDPGCS	DE	Type-2 diabetes

DMXAUB7	ID	DMXAUB7
DMXAUB7	DN	EI1071
DMXAUB7	HS	Phase 1
DMXAUB7	CP	Elixiron Immunotherapeutics
DMXAUB7	DT	Small molecular drug
DMXAUB7	DE	Solid tumour/cancer

DMA4BRV	ID	DMA4BRV
DMA4BRV	DN	Elinogrel
DMA4BRV	HS	Phase 1
DMA4BRV	SN	Elinogrel; 936500-94-6; UNII-915Y8E749J; 915Y8E749J; 5-CHLORO-N-[[[4-[6-FLUORO-1,4-DIHYDRO-7-(METHYLAMINO)-2,4-DIOXO-3(2H)-QUINAZOLINYL]PHENYL]AMINO]CARBONYL]-2-THIOPHENESULFONAMIDE; PRT-060128; Elinogrel [USAN:INN]; PRT 060128; Elinogrel (USAN/INN); SCHEMBL160663; CHEMBL2103828; MolPort-035-941-202; ZINC43153259; BDBM50397204; AKOS025142086; NCGC00387478-01; AN-26210; FT-0724857; D09607; 500C946; 1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1H-quinazolin-3-yl]phenyl]urea
DMA4BRV	CP	Novartis Pharmaceuticals; Portola Pharmaceuticals
DMA4BRV	DT	Small molecular drug
DMA4BRV	PC	16066663
DMA4BRV	MW	523.9
DMA4BRV	FM	C20H15ClFN5O5S2
DMA4BRV	IC	InChI=1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29)
DMA4BRV	CS	CNC1=C(C=C2C(=C1)NC(=O)N(C2=O)C3=CC=C(C=C3)NC(=O)NS(=O)(=O)C4=CC=C(S4)Cl)F
DMA4BRV	IK	LGSDFTPAICUONK-UHFFFAOYSA-N
DMA4BRV	IU	1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1H-quinazolin-3-yl]phenyl]urea
DMA4BRV	CA	CAS 936500-94-6
DMA4BRV	DE	Myocardial infarction

DMM9S51	ID	DMM9S51
DMM9S51	DN	ELND-002
DMM9S51	HS	Phase 1
DMM9S51	SN	ELND-002 (oral, multiple sclerosis); Alpha-4 integrin antagonists (oral, autoimmune diseases), Elan; Alpha-4 integrin antagonists (oral, multiple sclerosis), Elan; ELND-002 (oral, multiple sclerosis), Elan
DMM9S51	CP	Elan Corp plc
DMM9S51	DE	Autoimmune diabetes

DMLQYVD	ID	DMLQYVD
DMLQYVD	DN	ELND-004
DMLQYVD	HS	Phase 1
DMLQYVD	CP	Elan Corp plc
DMLQYVD	DE	Autoimmune diabetes

DMQPI4V	ID	DMQPI4V
DMQPI4V	DN	ELOMOTECAN HYDROCHLORIDE
DMQPI4V	HS	Phase 1
DMQPI4V	SN	BN-80927; R-1559; Elomotecan hydrochloride; (+)-9-Chloro-5(R)-ethyl-5-hydroxy-10-methyl-12-(4-methylpiperidin-1-ylmethyl)-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione hydrochloride
DMQPI4V	DT	Small molecular drug
DMQPI4V	PC	216300
DMQPI4V	MW	558.5
DMQPI4V	FM	C29H33Cl2N3O4
DMQPI4V	IC	InChI=1S/C29H32ClN3O4.ClH/c1-4-29(36)12-26(34)37-15-21-22(29)10-25-27-20(14-33(25)28(21)35)19(13-32-7-5-16(2)6-8-32)18-9-17(3)23(30)11-24(18)31-27;/h9-11,16,36H,4-8,12-15H2,1-3H3;1H/t29-;/m1./s1
DMQPI4V	CS	CC[C@]1(CC(=O)OCC2=C1C=C3C4=NC5=C(C=C(C(=C5)Cl)C)C(=C4CN3C2=O)CN6CCC(CC6)C)O.Cl
DMQPI4V	IK	OLYFGLXPXPABOP-XXIQNXCHSA-N
DMQPI4V	IU	(20R)-6-chloro-20-ethyl-20-hydroxy-7-methyl-10-[(4-methylpiperidin-1-yl)methyl]-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4(9),5,7,10,15(21)-heptaene-14,18-dione;hydrochloride
DMQPI4V	CA	CAS 220997-99-9
DMQPI4V	DE	Solid tumour/cancer

DMIV04R	ID	DMIV04R
DMIV04R	DN	Elpetrigine
DMIV04R	HS	Phase 1
DMIV04R	SN	ELPETRIGINE; 212778-82-0; JZP-4; 3-(2,3,5-trichlorophenyl)pyrazine-2,6-diamine; UNII-1X64S9H3ZS; 1X64S9H3ZS; 2,6-DIAMINO-3-(2,3,5-TRICHLOROPHENYL)PYRAZINE; 2,6-DIAMINO-3-(2,3,5-TRICHLOROPHENYL)-PYRAZINE; JZP4; Elpetrigine [USAN:INN]; Elpetrigine (USAN/INN); CHEMBL29919; SCHEMBL978547; ZINC9967; CTK0J9586; NNXUYJFHOVCRSM-UHFFFAOYSA-N; AKOS015966238; AN-29755; ACM212778820; D09609; 778D820; 2,6-Diamino-3-(2,3,5-trichlorophenyl) pyrazine; 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)-; 2,6-Diamino-3- (2,3,5-trichlorophenyl) pyrazin
DMIV04R	CP	Jazz Pharmaceuticals
DMIV04R	DT	Small molecular drug
DMIV04R	PC	9926001
DMIV04R	MW	289.5
DMIV04R	FM	C10H7Cl3N4
DMIV04R	IC	InChI=1S/C10H7Cl3N4/c11-4-1-5(8(13)6(12)2-4)9-10(15)17-7(14)3-16-9/h1-3H,(H4,14,15,17)
DMIV04R	CS	C1=C(C=C(C(=C1C2=NC=C(N=C2N)N)Cl)Cl)Cl
DMIV04R	IK	NNXUYJFHOVCRSM-UHFFFAOYSA-N
DMIV04R	IU	3-(2,3,5-trichlorophenyl)pyrazine-2,6-diamine
DMIV04R	CA	CAS 212778-82-0
DMIV04R	DE	Bipolar disorder

DM4W7Z0	ID	DM4W7Z0
DM4W7Z0	DN	Emactuzumab
DM4W7Z0	HS	Phase 1
DM4W7Z0	CP	GenentechSouth San Francisco, CA
DM4W7Z0	DE	Solid tumour/cancer

DM6AMKZ	ID	DM6AMKZ
DM6AMKZ	DN	Embeconazole
DM6AMKZ	HS	Phase 1
DM6AMKZ	SN	CS-758; R-120758; Triazole derivative (oral, fungal infection), Daiichi Sankyo
DM6AMKZ	CP	Sankyo Co Ltd
DM6AMKZ	DT	Small molecular drug
DM6AMKZ	PC	6475890
DM6AMKZ	MW	542.6
DM6AMKZ	FM	C27H25F3N4O3S
DM6AMKZ	IC	InChI=1S/C27H25F3N4O3S/c1-18(27(35,15-34-17-32-16-33-34)23-9-8-21(28)11-25(23)30)38-22-13-36-26(37-14-22)5-3-2-4-20-7-6-19(12-31)10-24(20)29/h2-11,16-18,22,26,35H,13-15H2,1H3/b4-2+,5-3+/t18-,22?,26?,27-/m1/s1
DM6AMKZ	CS	C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)SC3COC(OC3)/C=C/C=C/C4=C(C=C(C=C4)C#N)F
DM6AMKZ	IK	XSRKBFUVSRRJDX-ILLAMVBCSA-N
DM6AMKZ	IU	4-[(1E,3E)-4-[5-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]sulfanyl-1,3-dioxan-2-yl]buta-1,3-dienyl]-3-fluorobenzonitrile
DM6AMKZ	CA	CAS 329744-44-7
DM6AMKZ	DE	Fungal infection

DM38JZU	ID	DM38JZU
DM38JZU	DN	EMD-1204831
DM38JZU	HS	Phase 1
DM38JZU	CP	Merck KGaA
DM38JZU	PC	25134692
DM38JZU	MW	473.5
DM38JZU	FM	C25H27N7O3
DM38JZU	IC	InChI=1S/C25H27N7O3/c1-30-18-21(14-28-30)23-5-6-24(33)32(29-23)17-19-3-2-4-20(13-19)25-26-15-22(16-27-25)35-12-9-31-7-10-34-11-8-31/h2-6,13-16,18H,7-12,17H2,1H3
DM38JZU	CS	CN1C=C(C=N1)C2=NN(C(=O)C=C2)CC3=CC(=CC=C3)C4=NC=C(C=N4)OCCN5CCOCC5
DM38JZU	IK	CIUKPBWULKEZMF-UHFFFAOYSA-N
DM38JZU	IU	6-(1-methylpyrazol-4-yl)-2-[[3-[5-(2-morpholin-4-ylethoxy)pyrimidin-2-yl]phenyl]methyl]pyridazin-3-one
DM38JZU	CA	CAS 1100598-15-9
DM38JZU	DE	Solid tumour/cancer

DMQ6YAZ	ID	DMQ6YAZ
DMQ6YAZ	DN	EMD-534085
DMQ6YAZ	HS	Phase 1
DMQ6YAZ	SN	EMD-534085; 858668-07-2; EMD534085; EMD 534085; UNII-AL67QX8036; CHEMBL1077204; AL67QX8036; 1-(2-(Dimethylamino)ethyl)-3-(((2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano(3,2-C)quinolin-2-yl)methyl)urea; 1-[2-(dimethylamino)ethyl]-3-{[(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methyl}urea
DMQ6YAZ	DT	Small molecular drug
DMQ6YAZ	PC	23634407
DMQ6YAZ	MW	476.5
DMQ6YAZ	FM	C25H31F3N4O2
DMQ6YAZ	IC	InChI=1S/C25H31F3N4O2/c1-32(2)13-12-29-24(33)30-15-18-9-10-19-22(16-6-4-3-5-7-16)31-21-11-8-17(25(26,27)28)14-20(21)23(19)34-18/h3-8,11,14,18-19,22-23,31H,9-10,12-13,15H2,1-2H3,(H2,29,30,33)/t18-,19+,22+,23+/m1/s1
DMQ6YAZ	CS	CN(C)CCNC(=O)NC[C@H]1CC[C@H]2[C@@H](NC3=C([C@H]2O1)C=C(C=C3)C(F)(F)F)C4=CC=CC=C4
DMQ6YAZ	IK	MARIUIDCPUZLKZ-FUKQBSRTSA-N
DMQ6YAZ	IU	1-[[(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methyl]-3-[2-(dimethylamino)ethyl]urea
DMQ6YAZ	CA	CAS 858668-07-2
DMQ6YAZ	DE	Haematological malignancy

DMBIPQL	ID	DMBIPQL
DMBIPQL	DN	Enavatuzumab
DMBIPQL	HS	Phase 1
DMBIPQL	CP	Abbott Laboratories
DMBIPQL	DT	Antibody
DMBIPQL	DE	Solid tumour/cancer

DMKPBVX	ID	DMKPBVX
DMKPBVX	DN	Englitazone sodium
DMKPBVX	HS	Phase 1
DMKPBVX	SN	Englitazone sodium < Rec INNM; CP-68722 (racemate); CP-72467-02; CP-72467-2; (-)-5-[2(R)-Benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl]thiazolidine-2,4-dione sodium salt
DMKPBVX	DT	Small molecular drug
DMKPBVX	PC	13728795
DMKPBVX	MW	375.4
DMKPBVX	FM	C20H18NNaO3S
DMKPBVX	IC	InChI=1S/C20H19NO3S.Na/c22-19-18(25-20(23)21-19)12-14-6-9-17-15(10-14)7-8-16(24-17)11-13-4-2-1-3-5-13;/h1-6,9-10,16,18H,7-8,11-12H2,(H,21,22,23);/q;+1/p-1/t16-,18?;/m1./s1
DMKPBVX	CS	C1CC2=C(C=CC(=C2)CC3C(=O)[N-]C(=O)S3)O[C@H]1CC4=CC=CC=C4.[Na+]
DMKPBVX	IK	JQWYNJRCVYGLMO-GPPXSFHXSA-M
DMKPBVX	IU	sodium;5-[[(2R)-2-benzyl-3,4-dihydro-2H-chromen-6-yl]methyl]-1,3-thiazolidin-3-ide-2,4-dione
DMKPBVX	CA	CAS 109229-57-4
DMKPBVX	DE	Type-2 diabetes

DMGLHYU	ID	DMGLHYU
DMGLHYU	DN	Enkastim-ev
DMGLHYU	HS	Phase 1
DMGLHYU	SN	Hsp 70 peptide-activated human natural killer cell therapy (cancer), multimmune GmbH
DMGLHYU	CP	Multimmune GmbH
DMGLHYU	DE	Solid tumour/cancer

DM9BJ3G	ID	DM9BJ3G
DM9BJ3G	DN	ENMD-1198
DM9BJ3G	HS	Phase 1
DM9BJ3G	SN	EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed
DM9BJ3G	CP	EntreMed
DM9BJ3G	DT	Small molecular drug
DM9BJ3G	PC	11483754
DM9BJ3G	MW	311.4
DM9BJ3G	FM	C20H25NO2
DM9BJ3G	IC	InChI=1S/C20H25NO2/c1-20-8-3-4-17(20)14-6-5-12-10-16(19(21)22)18(23-2)11-15(12)13(14)7-9-20/h3,8,10-11,13-14,17H,4-7,9H2,1-2H3,(H2,21,22)/t13-,14+,17-,20-/m0/s1
DM9BJ3G	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC=C2)CCC4=CC(=C(C=C34)OC)C(=O)N
DM9BJ3G	IK	YQJWOUQGXATDAE-ACNBBOPNSA-N
DM9BJ3G	IU	(8S,9S,13R,14S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carboxamide
DM9BJ3G	CA	CAS 864668-87-1
DM9BJ3G	DE	Solid tumour/cancer

DMMJXAR	ID	DMMJXAR
DMMJXAR	DN	Entolimod
DMMJXAR	HS	Phase 1
DMMJXAR	CP	Cleveland BioLabs Buffalo, NY
DMMJXAR	DE	Solid tumour/cancer; Colorectal cancer; Radiation syndrome

DMQ6GUY	ID	DMQ6GUY
DMQ6GUY	DN	EOS100850
DMQ6GUY	HS	Phase 1
DMQ6GUY	SN	UNII-HQ700V0X06; HQ700V0X06; Inupadenant; Inupadenant [INN]; Inupadenant [USAN]; SCHEMBL20521605; WHO 11380; UNII-L9RDR3F7GU component QYCCLUSYHJXDEX-RWYGWLOXSA-N; 2246607-08-7; Thiazolo(5,4-E)(1,2,4)triazolo(1,5-C)pyrimidin-2(3H)-one, 5-amino-3-(2-(4-(2,4-difluoro-5-(2-((S)-methylsulfinyl)ethoxy)phenyl)-1-piperazinyl)ethyl)-8-(2-furanyl)-; Thiazolo(5,4-E)(1,2,4)triazolo(1,5-C)pyrimidin-2(3H)-one, 5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)-1-piperazinyl)ethyl)-8-(2-furanyl)-, (+)-
DMQ6GUY	CP	iTeos Therapeutics
DMQ6GUY	DT	Small molecular drug
DMQ6GUY	PC	135346794
DMQ6GUY	MW	604.7
DMQ6GUY	FM	C25H26F2N8O4S2
DMQ6GUY	IC	InChI=1S/C25H26F2N8O4S2/c1-41(37)12-11-39-19-14-17(15(26)13-16(19)27)33-7-4-32(5-8-33)6-9-34-22-20(40-25(34)36)23-29-21(18-3-2-10-38-18)31-35(23)24(28)30-22/h2-3,10,13-14H,4-9,11-12H2,1H3,(H2,28,30)/t41-/m0/s1
DMQ6GUY	CS	C[S@](=O)CCOC1=C(C=C(C(=C1)N2CCN(CC2)CCN3C4=C(C5=NC(=NN5C(=N4)N)C6=CC=CO6)SC3=O)F)F
DMQ6GUY	IK	QYCCLUSYHJXDEX-RWYGWLOXSA-N
DMQ6GUY	IU	7-amino-10-[2-[4-[2,4-difluoro-5-[2-[(S)-methylsulfinyl]ethoxy]phenyl]piperazin-1-yl]ethyl]-4-(furan-2-yl)-12-thia-3,5,6,8,10-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7-tetraen-11-one
DMQ6GUY	CA	CAS 2246607-08-7
DMQ6GUY	DE	Solid tumour/cancer

DMKR3GD	ID	DMKR3GD
DMKR3GD	DN	EP-42675
DMKR3GD	HS	Phase 1
DMKR3GD	SN	NAPAP analogs, Organon; Factor IIa/Factor X dual inhibitors (thrombosis), Endotis; Factor IIa/Factor X dual inhibitors (thrombosis), Organon; NAPAP-PS conjugate (thrombosis), Endotis; NAPAP-PS conjugate (thrombosis), Organon
DMKR3GD	CP	Organon BioSciences
DMKR3GD	PC	124220520
DMKR3GD	MW	2477.2
DMKR3GD	FM	C79H125N7Na8O56S7
DMKR3GD	IC	InChI=1S/C79H125N7O56S7.8Na/c1-39-33-46(115-4)40(2)41(3)69(39)143(95,96)85-44(71(89)84-45(72(90)86-24-14-13-15-25-86)34-42-18-20-43(21-19-42)70(80)81)35-51(88)82-22-16-17-50(87)83-23-26-124-27-28-125-29-30-126-31-32-127-52-47(36-128-144(97,98)99)132-76(64(120-9)55(52)116-5)136-59-57(118-7)66(122-11)78(139-62(59)73(91)92)135-54-49(38-130-146(103,104)105)133-79(68(142-149(112,113)114)61(54)140-147(106,107)108)137-60-58(119-8)65(121-10)77(138-63(60)74(93)94)134-53-48(37-129-145(100,101)102)131-75(123-12)67(56(53)117-6)141-148(109,110)111;;;;;;;;/h18-21,33,44-45,47-49,52-68,75-79,85H,13-17,22-32,34-38H2,1-12H3,(H3,80,81)(H,82,88)(H,83,87)(H,84,89)(H,91,92)(H,93,94)(H,97,98,99)(H,100,101,102)(H,103,104,105)(H,106,107,108)(H,109,110,111)(H,112,113,114);;;;;;;;/t44-,45+,47+,48+,49+,52+,53+,54+,55-,56-,57-,58-,59-,60-,61-,62-,63+,64+,65+,66+,67+,68+,75-,76+,77+,78+,79+;;;;;;;;/m0......../s1
DMKR3GD	CS	CC1=CC(=C(C(=C1S(=O)(=O)N[C@@H](CC(=O)NCCCC(=O)NCCOCCOCCOCCO[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2OC)OC)O[C@H]3[C@@H]([C@H]([C@@H](O[C@@H]3C(=O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]5[C@@H]([C@H]([C@@H](O[C@H]5C(=O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OC)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)C(=O)N[C@H](CC7=CC=C(C=C7)C(=N)N)C(=O)N8CCCCC8)C)C)OC.[Na].[Na].[Na].[Na].[Na].[Na].[Na].[Na]
DMKR3GD	IK	QYMUZBCRFQFXJQ-KIDSDGJESA-N
DMKR3GD	CA	CAS 343776-67-0
DMKR3GD	DE	Thrombosis

DM49RI7	ID	DM49RI7
DM49RI7	DN	EP-51216
DM49RI7	HS	Phase 1
DM49RI7	SN	(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-(4-aminobutanoylamino)-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]hexanamide
DM49RI7	CP	Euro-peptides SA
DM49RI7	DT	Small molecular drug
DM49RI7	PC	6918424
DM49RI7	MW	831
DM49RI7	FM	C46H58N10O5
DM49RI7	IC	InChI=1S/C46H58N10O5/c1-26-32(29-13-4-7-16-35(29)50-26)23-39(53-42(57)20-12-22-48)44(59)55-41(25-34-28(3)52-37-18-9-6-15-31(34)37)46(61)56-40(45(60)54-38(43(49)58)19-10-11-21-47)24-33-27(2)51-36-17-8-5-14-30(33)36/h4-9,13-18,38-41,50-52H,10-12,19-25,47-48H2,1-3H3,(H2,49,58)(H,53,57)(H,54,60)(H,55,59)(H,56,61)/t38-,39+,40-,41+/m0/s1
DM49RI7	CS	CC1=C(C2=CC=CC=C2N1)C[C@H](C(=O)N[C@H](CC3=C(NC4=CC=CC=C43)C)C(=O)N[C@@H](CC5=C(NC6=CC=CC=C65)C)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)CCCN
DM49RI7	IK	DFXFDNPRHWLXON-AANMMBORSA-N
DM49RI7	IU	(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-(4-aminobutanoylamino)-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]hexanamide
DM49RI7	DE	Eating disorder

DMW739O	ID	DMW739O
DMW739O	DN	EP-51389
DMW739O	HS	Phase 1
DMW739O	CP	Euro-peptides SA
DMW739O	PC	9827407
DMW739O	MW	502.6
DMW739O	FM	C28H34N6O3
DMW739O	IC	InChI=1S/C28H34N6O3/c1-15-19(17-9-5-7-11-21(17)31-15)13-23(25(29)35)33-26(36)24(34-27(37)28(3,4)30)14-20-16(2)32-22-12-8-6-10-18(20)22/h5-12,23-24,31-32H,13-14,30H2,1-4H3,(H2,29,35)(H,33,36)(H,34,37)/t23-,24-/m1/s1
DMW739O	CS	CC1=C(C2=CC=CC=C2N1)C[C@H](C(=O)N)NC(=O)[C@@H](CC3=C(NC4=CC=CC=C43)C)NC(=O)C(C)(C)N
DMW739O	IK	RVAXPKJGCHKWJV-DNQXCXABSA-N
DMW739O	IU	2-amino-N-[(2R)-1-[[(2R)-1-amino-3-(2-methyl-1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(2-methyl-1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
DMW739O	DE	Eating disorder

DMV0MHI	ID	DMV0MHI
DMV0MHI	DN	EP-7041
DMV0MHI	HS	Phase 1
DMV0MHI	SN	QPVLDUCHRPJGCJ-QBIMZIAESA-N; SCHEMBL16998942
DMV0MHI	CP	eXIthera Pharmaceuticals Westborough, MA
DMV0MHI	PC	91827409
DMV0MHI	MW	402.5
DMV0MHI	FM	C21H30N4O4
DMV0MHI	IC	InChI=1S/C21H30N4O4/c1-13(15-7-5-3-2-4-6-8-15)24-21(29)25-18(20(27)28)16(19(25)26)11-14-9-10-23-17(22)12-14/h9-10,12-13,15-16,18H,2-8,11H2,1H3,(H2,22,23)(H,24,29)(H,27,28)/t13-,16-,18+/m1/s1
DMV0MHI	CS	C[C@H](C1CCCCCCC1)NC(=O)N2[C@@H]([C@H](C2=O)CC3=CC(=NC=C3)N)C(=O)O
DMV0MHI	IK	QPVLDUCHRPJGCJ-QBIMZIAESA-N
DMV0MHI	IU	(2S,3R)-3-[(2-aminopyridin-4-yl)methyl]-1-[[(1R)-1-cyclooctylethyl]carbamoyl]-4-oxoazetidine-2-carboxylic acid
DMV0MHI	DE	Thrombosis

DMUFN29	ID	DMUFN29
DMUFN29	DN	EPI-7386
DMUFN29	HS	Phase 1
DMUFN29	CP	ESSA Pharma
DMUFN29	DT	Small molecular drug
DMUFN29	DE	Prostate cancer

DMAQYRL	ID	DMAQYRL
DMAQYRL	DN	Eptacog alfa
DMAQYRL	HS	Phase 1
DMAQYRL	SN	Alfa; Eptacog alfa (GlycoPEGylation, intravenous, hemophilia), Novo Nordisk; Eptacog alfa (GlycoPEGylation, subcutaneous, hemophilia), Novo Nordisk
DMAQYRL	CP	Neose Technologies Inc
DMAQYRL	SQ	DB00036 sequence: ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP
DMAQYRL	DE	Hemophilia

DMXI9P4	ID	DMXI9P4
DMXI9P4	DN	EPX-100
DMXI9P4	HS	Phase 1
DMXI9P4	CP	Epygenix Therapeutics Paramus, NJ
DMXI9P4	DE	Dravet syndrome

DMKMR2X	ID	DMKMR2X
DMKMR2X	DN	ERB-257
DMKMR2X	HS	Phase 1
DMKMR2X	CP	Wyeth
DMKMR2X	DE	Sepsis

DM9YNTO	ID	DM9YNTO
DM9YNTO	DN	ERY974
DM9YNTO	HS	Phase 1
DM9YNTO	CP	Chugai Pharma USA Berkeley Heights, NJ
DM9YNTO	DE	Solid tumour/cancer

DMY0HU6	ID	DMY0HU6
DMY0HU6	DN	ETC-1922159
DMY0HU6	HS	Phase 1
DMY0HU6	SN	Etc-159; ETC-159; UNII-5L854240DQ; 1638250-96-0; CHEMBL3633802; 5L854240DQ; SCHEMBL17626176; MolPort-044-728-903; KS-00000TT9; BDBM50133866; ZINC175660737; AKOS030526630; CS-5162; 2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide; HY-18988; 2-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide
DMY0HU6	CP	Biomedical Sciences Institute SingaporeD3 (Drug Product and Development) Singapore
DMY0HU6	PC	86280523
DMY0HU6	MW	391.4
DMY0HU6	FM	C19H17N7O3
DMY0HU6	IC	InChI=1S/C19H17N7O3/c1-24-17-16(18(28)25(2)19(24)29)26(11-20-17)10-15(27)21-14-9-8-13(22-23-14)12-6-4-3-5-7-12/h3-9,11H,10H2,1-2H3,(H,21,23,27)
DMY0HU6	CS	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)NC3=NN=C(C=C3)C4=CC=CC=C4
DMY0HU6	IK	QTRXIFVSTWXRJJ-UHFFFAOYSA-N
DMY0HU6	IU	2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide
DMY0HU6	CA	CAS 1638250-96-0
DMY0HU6	DE	Solid tumour/cancer

DMS436I	ID	DMS436I
DMS436I	DN	ETX201
DMS436I	HS	Phase 1
DMS436I	CP	ETX Pharma, Maryland
DMS436I	DE	Crohn disease

DMY9ZAS	ID	DMY9ZAS
DMY9ZAS	DN	EUK-189
DMY9ZAS	HS	Phase 1
DMY9ZAS	SN	EUK-189 (topical formulation, radiation burns); EUK-189 (topical formulation, radiation burns), Minerva/Proteome; EUK-189 (topicalformulation, radiation burns), Minerva/Tyrian
DMY9ZAS	CP	Eukarion Inc
DMY9ZAS	DT	Small molecular drug
DMY9ZAS	PC	146157762
DMY9ZAS	MW	469.4
DMY9ZAS	FM	C22H26MnN2O6-2
DMY9ZAS	IC	InChI=1S/C20H24N2O4.C2H4O2.Mn/c1-3-25-17-9-5-7-15(19(17)23)13-21-11-12-22-14-16-8-6-10-18(20(16)24)26-4-2;1-2(3)4;/h5-10,13-14,23-24H,3-4,11-12H2,1-2H3;1H3,(H,3,4);/p-2
DMY9ZAS	CS	CCOC1=CC=CC(=C1[O-])C=NCCN=CC2=C(C(=CC=C2)OCC)[O-].CC(=O)O.[Mn]
DMY9ZAS	IK	SZYIPDLZPMRUNA-UHFFFAOYSA-L
DMY9ZAS	IU	acetic acid;2-ethoxy-6-[2-[(3-ethoxy-2-oxidophenyl)methylideneamino]ethyliminomethyl]phenolate;manganese
DMY9ZAS	DE	Skin burns

DMOG8IE	ID	DMOG8IE
DMOG8IE	DN	EVT 401
DMOG8IE	HS	Phase 1
DMOG8IE	CP	Evotec
DMOG8IE	DE	Rheumatoid arthritis

DMAKWQD	ID	DMAKWQD
DMAKWQD	DN	EVT100
DMAKWQD	HS	Phase 1
DMAKWQD	CP	EvotecHamburg, GermanyJanssen Research & Development Raritan, NJ
DMAKWQD	DE	Major depressive disorder

DM3VC6T	ID	DM3VC6T
DM3VC6T	DN	EW-A-401
DM3VC6T	HS	Phase 1
DM3VC6T	CP	Sangamo BioSciences
DM3VC6T	DE	Peripheral vascular disease

DM2NBC7	ID	DM2NBC7
DM2NBC7	DN	EZN-2968
DM2NBC7	HS	Phase 1
DM2NBC7	CP	Santaris Pharma A/S
DM2NBC7	DE	Solid tumour/cancer

DMXFY18	ID	DMXFY18
DMXFY18	DN	EZN-3042
DMXFY18	HS	Phase 1
DMXFY18	CP	Santaris Pharma A/S
DMXFY18	DE	Solid tumour/cancer

DMNPS59	ID	DMNPS59
DMNPS59	DN	EZN-4176
DMNPS59	HS	Phase 1
DMNPS59	CP	Santaris Pharma A/S
DMNPS59	DT	Antisense drug
DMNPS59	DE	Prostate cancer

DMAH12E	ID	DMAH12E
DMAH12E	DN	F-15845
DMAH12E	HS	Phase 1
DMAH12E	SN	UNII-3VKL9K971D; 3VKL9K971D; F-15845; (-)-F-15845; 2H-1,5-Benzoxathiepin-3-amine, 3,4-dihydro-N-((2S)-3-((2-methoxyphenyl)thio)-2-methylpropyl)-, hydrobromide, (3R)-; 3-(R)-(3-(2-Methoxyphenylthio-2-(S)-methylpropyl)amino)-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate; (-)-(3R)-N-((2S)-3-((2-Methoxyphenyl)sulfanyl)-2-methylpropyl)-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine hydrobromide
DMAH12E	CP	Pierre Fabre SA
DMAH12E	DT	Small molecular drug
DMAH12E	PC	72941926
DMAH12E	MW	456.5
DMAH12E	FM	C20H26BrNO2S2
DMAH12E	IC	InChI=1S/C20H25NO2S2.BrH/c1-15(13-24-19-9-5-3-7-17(19)22-2)11-21-16-12-23-18-8-4-6-10-20(18)25-14-16;/h3-10,15-16,21H,11-14H2,1-2H3;1H/t15-,16+;/m0./s1
DMAH12E	CS	C[C@@H](CN[C@@H]1COC2=CC=CC=C2SC1)CSC3=CC=CC=C3OC.Br
DMAH12E	IK	CUWFVJMNULNBTG-IDVLALEDSA-N
DMAH12E	IU	(3R)-N-[(2S)-3-(2-methoxyphenyl)sulfanyl-2-methylpropyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine;hydrobromide
DMAH12E	CA	CAS 866760-23-8
DMAH12E	DE	Angina pectoris

DML4JXZ	ID	DML4JXZ
DML4JXZ	DN	F-7TG
DML4JXZ	HS	Phase 1
DML4JXZ	SN	Recombinant human factor VIIa (hemophilia), GTC/LFB; RhFVIIa (hemophilia), GTC/LFB
DML4JXZ	CP	Catalyst biosciences; pfizer
DML4JXZ	DE	Hemophilia

DM71HLX	ID	DM71HLX
DM71HLX	DN	FAZ053
DM71HLX	HS	Phase 1
DM71HLX	CP	Novartis Pharmaceuticals East Hanover, NJ
DM71HLX	DT	Monoclonal antibody
DM71HLX	DE	Solid tumour/cancer; Advanced cancer

DM13YK0	ID	DM13YK0
DM13YK0	DN	Ferroportin mab
DM13YK0	HS	Phase 1
DM13YK0	CP	Eli Lilly
DM13YK0	DT	Antibody
DM13YK0	DE	Anemia

DMS1O56	ID	DMS1O56
DMS1O56	DN	FF-10101-01
DMS1O56	HS	Phase 1
DMS1O56	CP	FUJIFILM Pharmaceuticals U.S.A. Cambridge, MA
DMS1O56	DE	Acute myeloid leukaemia

DMX5290	ID	DMX5290
DMX5290	DN	FF-10502-01
DMX5290	HS	Phase 1
DMX5290	CP	FUJIFILM Pharmaceuticals U.S.A Valhalla, NJ
DMX5290	DE	Lymphoma; Solid tumour/cancer

DM2GHIP	ID	DM2GHIP
DM2GHIP	DN	FFC-14A
DM2GHIP	HS	Phase 1
DM2GHIP	SN	KP 1019; KP-692; HInd(RuInd2CI4), University of Vienna; KP-1019 (anhydrous); Ruthenium(III) complex, Faustus Forschung
DM2GHIP	CP	Faustus Forschungs Cie Translational Cancer Research GmbH
DM2GHIP	DE	Solid tumour/cancer

DM8U2IE	ID	DM8U2IE
DM8U2IE	DN	FGI-101-1A6
DM8U2IE	HS	Phase 1
DM8U2IE	SN	FGI-101; Anti-tumor susceptibility gene protein 101 mAb (viral infection), Functional Genetics; Anti-TSG101 monoclonal antibody (viral infection/prostate cancer), Functional Genetics
DM8U2IE	CP	Functional genetics
DM8U2IE	DT	Antibody
DM8U2IE	DE	Influenza virus infection

DMY61GX	ID	DMY61GX
DMY61GX	DN	FGLL
DMY61GX	HS	Phase 1
DMY61GX	SN	NCAM mimetics (Alzheimer's disease), Enkam
DMY61GX	CP	ENKAM Pharmaceuticals A/S
DMY61GX	DE	Alzheimer disease

DMLH2Q6	ID	DMLH2Q6
DMLH2Q6	DN	Figopitant
DMLH2Q6	HS	Phase 1
DMLH2Q6	SN	BIIF-1149; BIIF-1149CL; NK1 antagonists, Boehringer Ingelheim
DMLH2Q6	CP	Boehringer Ingelheim Corp
DMLH2Q6	DT	Small molecular drug
DMLH2Q6	PC	9914857
DMLH2Q6	MW	527.5
DMLH2Q6	FM	C27H31F6N3O
DMLH2Q6	IC	InChI=1S/C27H31F6N3O/c1-34(10-9-20-15-22(26(28,29)30)17-23(16-20)27(31,32)33)25(37)24(21-5-3-2-4-6-21)36-13-11-35(12-14-36)18-19-7-8-19/h2-6,15-17,19,24H,7-14,18H2,1H3/t24-/m0/s1
DMLH2Q6	CS	CN(CCC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C(=O)[C@H](C2=CC=CC=C2)N3CCN(CC3)CC4CC4
DMLH2Q6	IK	HUTHJVYJUPXHDF-DEOSSOPVSA-N
DMLH2Q6	IU	(2S)-N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-[4-(cyclopropylmethyl)piperazin-1-yl]-N-methyl-2-phenylacetamide
DMLH2Q6	CA	CAS 502422-74-4
DMLH2Q6	DE	Diabetic complication

DM2SALJ	ID	DM2SALJ
DM2SALJ	DN	Flanvotumab
DM2SALJ	HS	Phase 1
DM2SALJ	SN	IMC-20D7S; Gp75 monoclonal antibodies (melanoma), ImClone; Gp75 mAb (melanoma), ImClone/Eli Lilly; GP75/TRP1 mAbs (melanoma), ImClone/Eli Lilly
DM2SALJ	CP	Eli lilly
DM2SALJ	DT	Antibody
DM2SALJ	DE	Melanoma

DM7BMD6	ID	DM7BMD6
DM7BMD6	DN	FN-1501
DM7BMD6	HS	Phase 1
DM7BMD6	SN	1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide
DM7BMD6	CP	Fosun Pharmaceutical
DM7BMD6	DT	Small molecular drug
DM7BMD6	PC	72195175
DM7BMD6	MW	431.5
DM7BMD6	FM	C22H25N9O
DM7BMD6	IC	InChI=1S/C22H25N9O/c1-30-8-10-31(11-9-30)13-15-2-4-16(5-3-15)27-22(32)19-18(12-26-29-19)28-21-17-6-7-23-20(17)24-14-25-21/h2-7,12,14H,8-11,13H2,1H3,(H,26,29)(H,27,32)(H2,23,24,25,28)
DM7BMD6	CS	CN1CCN(CC1)CC2=CC=C(C=C2)NC(=O)C3=C(C=NN3)NC4=NC=NC5=C4C=CN5
DM7BMD6	IK	VXLAKHWYGRKCGI-UHFFFAOYSA-N
DM7BMD6	IU	N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide
DM7BMD6	CA	CAS 1429515-59-2
DM7BMD6	DE	Solid tumour/cancer

DMKX174	ID	DMKX174
DMKX174	DN	FOR46
DMKX174	HS	Phase 1
DMKX174	CP	Fortis Therapeutics
DMKX174	DT	Antibody drug conjugate
DMKX174	DE	Multiple myeloma

DMH1NXO	ID	DMH1NXO
DMH1NXO	DN	FP-025
DMH1NXO	HS	Phase 1
DMH1NXO	DE	Asthma

DMV9FTH	ID	DMV9FTH
DMV9FTH	DN	FP-045
DMV9FTH	HS	Phase 1
DMV9FTH	CP	Foresee Pharmaceuticals Newark, DE
DMV9FTH	DE	Cardiovascular disease

DM8BG0M	ID	DM8BG0M
DM8BG0M	DN	FP-253-GDEPT
DM8BG0M	HS	Phase 1
DM8BG0M	SN	FP-253; PNP-GDEPT; GDEPT (prostate cancer), Mayne; GDEPT (fludarabine phosphate, prostate cancer), CSIRO; Gene-directed enzyme prodrug therapy (prostate cancer), Mayne; OAdV gene therapy (PNP/ fludarabine phosphate), Mayne; Ovine adenovirus gene therapy (purine nucleoside phosphorylase/fludarabine phosphate), Mayne; OAdV GDEPT (E coli PNP/fludarabine phosphate, prostate cancer), Broadvector; Ovine atadenovirus GDEPT (purine nucleoside phosphorylase/fludarabine phosphate, prostate cancer), Biotech Equity Partners
DM8BG0M	CP	Pnp therapeutics
DM8BG0M	DE	Prostate cancer

DM1EBRK	ID	DM1EBRK
DM1EBRK	DN	FPA144
DM1EBRK	HS	Phase 1
DM1EBRK	CP	Five Prime Therapeutics South San Francisco, ca
DM1EBRK	DE	Bladder cancer; Gastric adenocarcinoma

DMI9A1Z	ID	DMI9A1Z
DMI9A1Z	DN	FPI-1434
DMI9A1Z	HS	Phase 1
DMI9A1Z	CP	Fusion Pharmaceuticals
DMI9A1Z	DT	Radiopharmaceutical therapy
DMI9A1Z	DE	Solid tumour/cancer

DMUI8F3	ID	DMUI8F3
DMUI8F3	DN	Friulimicin
DMUI8F3	HS	Phase 1
DMUI8F3	SN	Friulimicin B; Friulimicin (antibacterial), Combinature; Friulimicin (antibiotic), Combinature; Friulimicin (iv, bacterial infection), Combinature; Friulimicin (iv, bacterial infection), Merlion; Friulimicin (topical, bacterial infection), Merlion
DMUI8F3	CP	MerLion Pharmaceuticals Pte Ltd; Combinature Biopharm AG
DMUI8F3	PC	56842195
DMUI8F3	MW	1303.5
DMUI8F3	FM	C59H94N14O19
DMUI8F3	IC	InChI=1S/C59H94N14O19/c1-30(2)19-14-12-10-8-9-11-13-15-22-41(75)65-35(25-40(61)74)52(84)71-49-34(7)64-53(85)39-21-18-24-73(39)57(89)46(31(3)4)69-56(88)48(33(6)60)68-43(77)29-63-50(82)36(26-44(78)79)66-42(76)28-62-51(83)37(27-45(80)81)67-55(87)47(32(5)59(91)92)70-54(86)38-20-16-17-23-72(38)58(49)90/h13,15,30-39,46-49H,8-12,14,16-29,60H2,1-7H3,(H2,61,74)(H,62,83)(H,63,82)(H,64,85)(H,65,75)(H,66,76)(H,67,87)(H,68,77)(H,69,88)(H,70,86)(H,71,84)(H,78,79)(H,80,81)(H,91,92)/b15-13-/t32-,33+,34-,35-,36-,37-,38+,39-,46-,47-,48+,49-/m0/s1
DMUI8F3	CS	C[C@H]1[C@@H](C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N1)C(C)C)[C@@H](C)N)CC(=O)O)CC(=O)O)[C@H](C)C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)C/C=C\\CCCCCCCC(C)C
DMUI8F3	IK	HVYFVLAUKMGKHL-USKUEUQVSA-N
DMUI8F3	IU	(2S)-2-[(3S,4S,7S,13S,16R,22S,28S,31S,34R)-16-[(1R)-1-aminoethyl]-3-[[(2S)-4-amino-2-[[(Z)-12-methyltridec-3-enoyl]amino]-4-oxobutanoyl]amino]-22,28-bis(carboxymethyl)-4-methyl-2,6,12,15,18,21,24,27,30,33-decaoxo-13-propan-2-yl-1,5,11,14,17,20,23,26,29,32-decazatricyclo[32.4.0.07,11]octatriacontan-31-yl]propanoic acid
DMUI8F3	CA	239802-15-4
DMUI8F3	DE	Bacterial infection

DM0QH9K	ID	DM0QH9K
DM0QH9K	DN	FS118
DM0QH9K	HS	Phase 1
DM0QH9K	CP	F-star Biotechnology Cambridge, United Kingdom
DM0QH9K	DT	Antibody
DM0QH9K	DE	Advanced malignancy; Advanced cancer

DMPENAL	ID	DMPENAL
DMPENAL	DN	FSI-189
DMPENAL	HS	Phase 1
DMPENAL	CP	Gilead Sciences
DMPENAL	DT	Antibody
DMPENAL	DE	Non-hodgkin lymphoma

DMZOAT3	ID	DMZOAT3
DMZOAT3	DN	FT-1101
DMZOAT3	HS	Phase 1
DMZOAT3	CP	FORMA Therapeutics Watertown, MA
DMZOAT3	DE	Haematological malignancy

DMCK3OI	ID	DMCK3OI
DMCK3OI	DN	FT-7051
DMCK3OI	HS	Phase 1
DMCK3OI	CP	FORMA Therapeutics
DMCK3OI	DE	Prostate cancer

DMGJNTQ	ID	DMGJNTQ
DMGJNTQ	DN	FT-819
DMGJNTQ	HS	Phase 1
DMGJNTQ	CP	Fate Therapeutics
DMGJNTQ	DT	CAR T Cell Therapy
DMGJNTQ	DE	Chronic lymphocytic leukaemia

DML028U	ID	DML028U
DML028U	DN	G1T28-1
DML028U	HS	Phase 1
DML028U	DE	Solid tumour/cancer

DMRGP72	ID	DMRGP72
DMRGP72	DN	G1T-48
DMRGP72	HS	Phase 1
DMRGP72	CP	G1 Therapeutics
DMRGP72	DE	Breast cancer

DM3H6YC	ID	DM3H6YC
DM3H6YC	DN	G-619
DM3H6YC	HS	Phase 1
DM3H6YC	SN	4-Methoxy-N3-(3-picolyl)-1,3-benzenedicarboxamide; 4-Methoxy-N3-(3-pyridylmethyl)-1,3-benzenedicarboxamide
DM3H6YC	DT	Small molecular drug
DM3H6YC	PC	130587
DM3H6YC	MW	285.3
DM3H6YC	FM	C15H15N3O3
DM3H6YC	IC	InChI=1S/C15H15N3O3/c1-21-13-5-4-11(14(16)19)7-12(13)15(20)18-9-10-3-2-6-17-8-10/h2-8H,9H2,1H3,(H2,16,19)(H,18,20)
DM3H6YC	CS	COC1=C(C=C(C=C1)C(=O)N)C(=O)NCC2=CN=CC=C2
DM3H6YC	IK	QWZWECXMQXZQOG-UHFFFAOYSA-N
DM3H6YC	IU	4-methoxy-3-N-(pyridin-3-ylmethyl)benzene-1,3-dicarboxamide
DM3H6YC	CA	CAS 108828-56-4
DM3H6YC	DE	Thrombosis

DMJLIQ2	ID	DMJLIQ2
DMJLIQ2	DN	GALAMUSTINE HYDROCHLORIDE
DMJLIQ2	HS	Phase 1
DMJLIQ2	SN	C6-GLM; C6-GalM; C6-Galactose mustard; G-6-M; Galamustine hydrochloride; 6-[Bis(2-chloroethyl)amino]-6-deoxy-D-galactopyranose hydrochloride
DMJLIQ2	DT	Small molecular drug
DMJLIQ2	PC	135696
DMJLIQ2	MW	340.6
DMJLIQ2	FM	C10H20Cl3NO5
DMJLIQ2	IC	InChI=1S/C10H19Cl2NO5.ClH/c11-1-3-13(4-2-12)5-6-7(14)8(15)9(16)10(17)18-6;/h6-10,14-17H,1-5H2;1H/t6-,7+,8+,9-,10?;/m1./s1
DMJLIQ2	CS	C(CCl)N(CCCl)C[C@@H]1[C@@H]([C@@H]([C@H](C(O1)O)O)O)O.Cl
DMJLIQ2	IK	YPEQSOJVCFFDKJ-IBUKJIQJSA-N
DMJLIQ2	IU	(3R,4S,5R,6R)-6-[bis(2-chloroethyl)aminomethyl]oxane-2,3,4,5-tetrol;hydrochloride
DMJLIQ2	CA	CAS 107811-63-2
DMJLIQ2	DE	Solid tumour/cancer

DMG9C4I	ID	DMG9C4I
DMG9C4I	DN	Galidesivir
DMG9C4I	HS	Phase 1
DMG9C4I	SN	1EL1K52SH1; BCX 4430; BCX 4430 HCl; BCX4430; CS-3778; Galidesivir (hydrochloride); HY-18649; Immucillin-A; SB16943; SCHEMBL4838048; UNII-1EL1K52SH1
DMG9C4I	TC	Antiviral Agents
DMG9C4I	DT	Small molecular drug
DMG9C4I	PC	10445549
DMG9C4I	MW	265.27
DMG9C4I	FM	C11H15N5O3
DMG9C4I	IC	InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1
DMG9C4I	CS	C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
DMG9C4I	IK	AMFDITJFBUXZQN-KUBHLMPHSA-N
DMG9C4I	IU	(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
DMG9C4I	CA	CAS 249503-25-1
DMG9C4I	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMIXMQE	ID	DMIXMQE
DMIXMQE	DN	GAP T cells
DMIXMQE	HS	Phase 1
DMIXMQE	CP	Baylor College of Medicine
DMIXMQE	DT	CAR T Cell Therapy
DMIXMQE	DE	Solid tumour/cancer

DM52O7W	ID	DM52O7W
DM52O7W	DN	GBR1302
DM52O7W	HS	Phase 1
DM52O7W	CP	Glenmark Pharmaceuticals
DM52O7W	DT	Antibody
DM52O7W	DE	Solid tumour/cancer

DMQBEYV	ID	DMQBEYV
DMQBEYV	DN	GC021109
DMQBEYV	HS	Phase 1
DMQBEYV	CP	GliaCure Boston, MA
DMQBEYV	DE	Alzheimer disease

DM6R4DO	ID	DM6R4DO
DM6R4DO	DN	GC-1008
DM6R4DO	HS	Phase 1
DM6R4DO	SN	TGF-beta; TGF-Beta; Tgfbeta; TGF beta; Milk growth factor; Transforming Growth Factor beta; Platelet Transforming Growth Factor; Bone-Derived Transforming Growth Factor;  TGF-beta; D016212000; 122304-04-5
DM6R4DO	CP	Genzyme
DM6R4DO	DT	Small molecular drug
DM6R4DO	PC	56842206
DM6R4DO	MW	4760
DM6R4DO	FM	C211H345N61O62S
DM6R4DO	IC	InChI=1S/C211H345N61O62S/c1-32-107(20)161(265-170(297)112(25)233-167(294)109(22)237-195(322)159(105(16)17)263-189(316)136(86-101(8)9)251-171(298)122(212)73-82-335-31)198(325)248-129(63-68-149(213)280)180(307)260-144(96-273)191(318)234-108(21)166(293)231-94-152(283)239-133(83-98(2)3)188(315)267-162(114(27)275)199(326)249-132(67-72-157(291)292)181(308)266-163(115(28)276)200(327)254-135(85-100(6)7)183(310)253-140(92-150(214)281)186(313)242-124(52-40-75-227-208(218)219)175(302)244-128(64-69-154(285)286)172(299)232-95-153(284)262-158(104(14)15)196(323)256-139(91-120-59-61-121(279)62-60-120)190(317)268-165(117(30)278)202(329)264-160(106(18)19)197(324)255-137(89-118-47-35-33-36-48-118)182(309)238-113(26)203(330)270-79-44-57-147(270)194(321)269-164(116(29)277)201(328)257-141(93-151(215)282)187(314)246-130(65-70-155(287)288)174(301)236-110(23)168(295)250-138(90-119-49-37-34-38-50-119)185(312)241-123(51-39-74-226-207(216)217)173(300)235-111(24)169(296)258-142(87-102(10)11)204(331)272-81-46-58-148(272)205(332)271-80-45-56-146(271)193(320)247-127(55-43-78-230-211(224)225)176(303)245-131(66-71-156(289)290)179(306)240-126(54-42-77-229-210(222)223)178(305)261-145(97-274)192(319)243-125(53-41-76-228-209(220)221)177(304)252-134(84-99(4)5)184(311)259-143(206(333)334)88-103(12)13/h33-38,47-50,59-62,98-117,122-148,158-165,273-279H,32,39-46,51-58,63-97,212H2,1-31H3,(H2,213,280)(H2,214,281)(H2,215,282)(H,231,293)(H,232,299)(H,233,294)(H,234,318)(H,235,300)(H,236,301)(H,237,322)(H,238,309)(H,239,283)(H,240,306)(H,241,312)(H,242,313)(H,243,319)(H,244,302)(H,245,303)(H,246,314)(H,247,320)(H,248,325)(H,249,326)(H,250,295)(H,251,298)(H,252,304)(H,253,310)(H,254,327)(H,255,324)(H,256,323)(H,257,328)(H,258,296)(H,259,311)(H,260,307)(H,261,305)(H,262,284)(H,263,316)(H,264,329)(H,265,297)(H,266,308)(H,267,315)(H,268,317)(H,269,321)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,333,334)(H4,216,217,226)(H4,218,219,227)(H4,220,221,228)(H4,222,223,229)(H4,224,225,230)/t107-,108-,109-,110-,111-,112-,113-,114+,115+,116+,117+,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,158-,159-,160-,161-,162-,163-,164-,165-/m0/s1
DM6R4DO	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)N
DM6R4DO	IK	ZRKFYGHZFMAOKI-QMGMOQQFSA-N
DM6R4DO	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoic acid
DM6R4DO	CA	CAS 122304-04-5
DM6R4DO	DE	Pleural disease; Idiopathic pulmonary fibrosis

DMK96CE	ID	DMK96CE
DMK96CE	DN	GC-1113
DMK96CE	HS	Phase 1
DMK96CE	DE	Anemia

DMJ7WRI	ID	DMJ7WRI
DMJ7WRI	DN	GCC-1290K
DMJ7WRI	HS	Phase 1
DMJ7WRI	SN	GC-1290K; GC-2101; GCC-1290A; GCC-1290K (salt formulation, oral), Green Cross; Dopamine modulators (Parkinson's disease, oral), Kangwon University/Green Cross; (+)-3-hydroxymorphinan; 3-HM; 3-HM prodrugs (Parkinson's disease), Green Cross; 3-hydroxymorphinan prodrugs (Parkinson's disease), Green Cross
DMJ7WRI	CP	Kangwon University Pharmaceutical College
DMJ7WRI	DE	Parkinson disease

DMHMZC7	ID	DMHMZC7
DMHMZC7	DN	GCC-4401
DMHMZC7	HS	Phase 1
DMHMZC7	CP	Green cross
DMHMZC7	DE	Thrombosis

DM9TD2N	ID	DM9TD2N
DM9TD2N	DN	GD2 T cells
DM9TD2N	HS	Phase 1
DM9TD2N	CP	Baylor College of Medicine
DM9TD2N	DT	CAR T Cell Therapy
DM9TD2N	DE	Neuroblastoma; Osteosarcoma

DMSE19U	ID	DMSE19U
DMSE19U	DN	GDC0134
DMSE19U	HS	Phase 1
DMSE19U	SN	RG6000
DMSE19U	CP	DLK-1 protein inhibitor
DMSE19U	DE	Amyotrophic lateral sclerosis

DM1B3UM	ID	DM1B3UM
DM1B3UM	DN	GDC-0152
DM1B3UM	HS	Phase 1
DM1B3UM	SN	GDC 0152; GDC0152
DM1B3UM	DT	Small molecular drug
DM1B3UM	PC	46940575
DM1B3UM	MW	498.6
DM1B3UM	FM	C25H34N6O3S
DM1B3UM	IC	InChI=1S/C25H34N6O3S/c1-16(26-2)22(32)27-21(18-12-7-4-8-13-18)25(34)31-15-9-14-19(31)23(33)28-24-20(29-30-35-24)17-10-5-3-6-11-17/h3,5-6,10-11,16,18-19,21,26H,4,7-9,12-15H2,1-2H3,(H,27,32)(H,28,33)/t16-,19-,21-/m0/s1
DM1B3UM	CS	C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=C(N=NS3)C4=CC=CC=C4)NC
DM1B3UM	IK	WZRFLSDVFPIXOV-LRQRDZAKSA-N
DM1B3UM	IU	(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-(4-phenylthiadiazol-5-yl)pyrrolidine-2-carboxamide
DM1B3UM	CA	CAS 873652-48-3
DM1B3UM	DE	Obesity; Solid tumour/cancer

DMUNFEP	ID	DMUNFEP
DMUNFEP	DN	GDC0310
DMUNFEP	HS	Phase 1
DMUNFEP	SN	RG6029; FCTMRPTVPHVTTN-UHFFFAOYSA-N; SCHEMBL16770884; BDBM71258; BCP25347; US9694002, 346; 1788066-71-6
DMUNFEP	CP	Genentech South San Francisco, CA Xenon Pharmaceuticals Burnaby, Canada
DMUNFEP	PC	118120526
DMUNFEP	MW	599
DMUNFEP	FM	C25H25ClF6N2O4S
DMUNFEP	IC	InChI=1S/C25H25ClF6N2O4S/c1-39(36,37)33-23(35)18-10-17(14-2-3-14)21(11-20(18)27)38-13-24(29)4-6-34(7-5-24)12-15-8-16(25(30,31)32)9-19(26)22(15)28/h8-11,14H,2-7,12-13H2,1H3,(H,33,35)
DMUNFEP	CS	CS(=O)(=O)NC(=O)C1=C(C=C(C(=C1)C2CC2)OCC3(CCN(CC3)CC4=C(C(=CC(=C4)C(F)(F)F)Cl)F)F)F
DMUNFEP	IK	FCTMRPTVPHVTTN-UHFFFAOYSA-N
DMUNFEP	IU	4-[[1-[[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-fluoropiperidin-4-yl]methoxy]-5-cyclopropyl-2-fluoro-N-methylsulfonylbenzamide
DMUNFEP	DE	Chronic pain

DM3Z2JB	ID	DM3Z2JB
DM3Z2JB	DN	GDC-0349
DM3Z2JB	HS	Phase 1
DM3Z2JB	SN	MTORC1/2 inhibitors
DM3Z2JB	CP	Genentech
DM3Z2JB	DT	Small molecular drug
DM3Z2JB	PC	59239165
DM3Z2JB	MW	452.5
DM3Z2JB	FM	C24H32N6O3
DM3Z2JB	IC	InChI=1S/C24H32N6O3/c1-3-25-24(31)26-18-6-4-17(5-7-18)22-27-21-12-29(19-14-33-15-19)9-8-20(21)23(28-22)30-10-11-32-13-16(30)2/h4-7,16,19H,3,8-15H2,1-2H3,(H2,25,26,31)/t16-/m0/s1
DM3Z2JB	CS	CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4COC4)C(=N2)N5CCOC[C@@H]5C
DM3Z2JB	IK	RGJOJUGRHPQXGF-INIZCTEOSA-N
DM3Z2JB	IU	1-ethyl-3-[4-[4-[(3S)-3-methylmorpholin-4-yl]-7-(oxetan-3-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea
DM3Z2JB	CA	CAS 1207360-89-1
DM3Z2JB	DE	Non-hodgkin lymphoma

DMDZ26X	ID	DMDZ26X
DMDZ26X	DN	GDC-0425
DMDZ26X	HS	Phase 1
DMDZ26X	CP	Genentech
DMDZ26X	PC	58266779
DMDZ26X	MW	321.4
DMDZ26X	FM	C18H19N5O
DMDZ26X	IC	InChI=1S/C18H19N5O/c1-2-23-8-5-12(6-9-23)24-17-14(10-19)21-11-15-16(17)13-4-3-7-20-18(13)22-15/h3-4,7,11-12H,2,5-6,8-9H2,1H3,(H,20,22)
DMDZ26X	CS	CCN1CCC(CC1)OC2=C3C4=C(NC3=CN=C2C#N)N=CC=C4
DMDZ26X	IK	XEZLBMHDUXSICI-UHFFFAOYSA-N
DMDZ26X	IU	3-(1-ethylpiperidin-4-yl)oxy-5,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2,4,6,10,12-hexaene-4-carbonitrile
DMDZ26X	CA	CAS 1627539-18-7
DMDZ26X	DE	Lymphoma

DMDY08K	ID	DMDY08K
DMDY08K	DN	GDC-0623
DMDY08K	HS	Phase 1
DMDY08K	SN	1168091-68-6; GDC 0623; UNII-HW67545I4Q; RG 7421; GDC0623; HW67545I4Q; G-868; Imidazo[1,5-a]pyridine-6-carboxamide, 5-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-; 5-((2-FLUORO-4-IODOPHENYL)AMINO)-N-(2-HYDROXYETHOXY)IMIDAZO[1,5-A]PYRIDINE-6-CARBOXAMIDE; RFWVETIZUQEJEF-UHFFFAOYSA-N; GTPL9909; SCHEMBL1615104; CHEMBL3330650; MolPort-039-193-834; BCP28689; AOB87143; EX-A2060; s7553; ZINC43206499; BDBM50025226; AKOS027253679; DB11982; SB16957; CS-2281; BC600628; HY-15610; KB-144448; FT-0769207; Z-3311
DMDY08K	CP	Genentech
DMDY08K	DT	Small molecular drug
DMDY08K	PC	42642654
DMDY08K	MW	456.21
DMDY08K	FM	C16H14FIN4O3
DMDY08K	IC	InChI=1S/C16H14FIN4O3/c17-13-7-10(18)1-4-14(13)20-15-12(16(24)21-25-6-5-23)3-2-11-8-19-9-22(11)15/h1-4,7-9,20,23H,5-6H2,(H,21,24)
DMDY08K	CS	C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO
DMDY08K	IK	RFWVETIZUQEJEF-UHFFFAOYSA-N
DMDY08K	IU	5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide
DMDY08K	CA	CAS 1168091-68-6
DMDY08K	DE	Solid tumour/cancer

DMFC2OY	ID	DMFC2OY
DMFC2OY	DN	GDC-0994
DMFC2OY	HS	Phase 1
DMFC2OY	CP	Genentech
DMFC2OY	PC	71727581
DMFC2OY	MW	440.9
DMFC2OY	FM	C21H18ClFN6O2
DMFC2OY	IC	InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1
DMFC2OY	CS	CN1C(=CC=N1)NC2=NC=CC(=N2)C3=CC(=O)N(C=C3)[C@H](CO)C4=CC(=C(C=C4)Cl)F
DMFC2OY	IK	RZUOCXOYPYGSKL-GOSISDBHSA-N
DMFC2OY	IU	1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one
DMFC2OY	CA	CAS 1453848-26-4
DMFC2OY	DE	Solid tumour/cancer

DMJA27W	ID	DMJA27W
DMJA27W	DN	GDC-5573
DMJA27W	HS	Phase 1
DMJA27W	SN	RG6185
DMJA27W	CP	GenentechSouth San Francisco, CA
DMJA27W	DE	Solid tumour/cancer

DMMF6UB	ID	DMMF6UB
DMMF6UB	DN	GE-1170A
DMMF6UB	HS	Phase 1
DMMF6UB	SN	Elongation factor Tu inhibitors (bacterial infection); LDI-028; LDK-733; Elongation factor Tu inhibitors (bacterial infection), Novartis
DMMF6UB	CP	Novartis Institutes for BioMedical Research Inc
DMMF6UB	DE	Bacterial infection

DMJK7V0	ID	DMJK7V0
DMJK7V0	DN	Ge2270a
DMJK7V0	HS	Phase 1
DMJK7V0	SN	GE 2770; GE-2270; 134861-34-0; SCHEMBL12519961; CHEBI:29584; LS-187584; LS-186934
DMJK7V0	DT	Small molecular drug
DMJK7V0	PC	16129640
DMJK7V0	MW	1290.5
DMJK7V0	FM	C56H55N15O10S6
DMJK7V0	IC	InChI=1S/C56H55N15O10S6/c1-24(2)39-55-70-42(36(87-55)19-80-5)47(77)59-17-38(73)67-43(44(74)26-10-7-6-8-11-26)54-66-34(23-85-54)52-63-31(20-83-52)41-27(50-64-32(21-82-50)46(76)61-29(16-37(72)58-4)53-69-40(25(3)86-53)48(78)68-39)13-14-28(60-41)51-65-33(22-84-51)49-62-30(18-81-49)56(79)71-15-9-12-35(71)45(57)75/h6-8,10-11,13-14,20-24,29-30,35,39,43-44,74H,9,12,15-19H2,1-5H3,(H2,57,75)(H,58,72)(H,59,77)(H,61,76)(H,67,73)(H,68,78)
DMJK7V0	CS	CC1=C2C(=O)NC(C3=NC(=C(S3)COC)C(=O)NCC(=O)NC(C4=NC(=CS4)C5=NC(=CS5)C6=C(C=CC(=N6)C7=NC(=CS7)C8=NC(CO8)C(=O)N9CCCC9C(=O)N)C3=NC(=CS3)C(=O)NC(C(=N2)S1)CC(=O)NC)C(C1=CC=CC=C1)O)C(C)C
DMJK7V0	IK	JMDULECOHIXMNX-UHFFFAOYSA-N
DMJK7V0	IU	1-[2-[2-[35-[hydroxy(phenyl)methyl]-28-(methoxymethyl)-21-methyl-18-[2-(methylamino)-2-oxoethyl]-16,23,30,33-tetraoxo-25-propan-2-yl-3,13,20,27,37-pentathia-7,17,24,31,34,39,40,41,42,43-decazaheptacyclo[34.2.1.12,5.112,15.119,22.126,29.06,11]tritetraconta-1(38),2(43),4,6(11),7,9,12(42),14,19(41),21,26(40),28,36(39)-tridecaen-8-yl]-1,3-thiazol-4-yl]-4,5-dihydro-1,3-oxazole-4-carbonyl]pyrrolidine-2-carboxamide
DMJK7V0	CB	CHEBI:29584
DMJK7V0	DE	Bacterial infection

DMDMKVL	ID	DMDMKVL
DMDMKVL	DN	GEM333
DMDMKVL	HS	Phase 1
DMDMKVL	CP	Gemoab
DMDMKVL	DT	Antibody
DMDMKVL	DE	Acute myeloid leukaemia

DM3GSPR	ID	DM3GSPR
DM3GSPR	DN	GEM3PSCA
DM3GSPR	HS	Phase 1
DM3GSPR	CP	Gemoab
DM3GSPR	DT	Antibody
DM3GSPR	DE	Non-small cell lung cancer

DMV8IWJ	ID	DMV8IWJ
DMV8IWJ	DN	GEN1029
DMV8IWJ	HS	Phase 1
DMV8IWJ	CP	GenMab
DMV8IWJ	DT	Antibody
DMV8IWJ	DE	Solid tumour/cancer

DMNP6T3	ID	DMNP6T3
DMNP6T3	DN	GEN1042
DMNP6T3	HS	Phase 1
DMNP6T3	CP	GenMab
DMNP6T3	DT	Antibody
DMNP6T3	DE	Solid tumour/cancer

DMQ9317	ID	DMQ9317
DMQ9317	DN	GEN1044
DMQ9317	HS	Phase 1
DMQ9317	CP	AbbVie
DMQ9317	DT	Antibody
DMQ9317	DE	Solid tumour/cancer

DMEWRNZ	ID	DMEWRNZ
DMEWRNZ	DN	GEN1046
DMEWRNZ	HS	Phase 1
DMEWRNZ	CP	GenMab
DMEWRNZ	DT	Antibody
DMEWRNZ	DE	Solid tumour/cancer

DMWR93D	ID	DMWR93D
DMWR93D	DN	Genaconazole
DMWR93D	HS	Phase 1
DMWR93D	SN	SM-8668; SM-8668 analogs; SM-9164; Sch-39304; Sch-42426; Sch-42427
DMWR93D	CP	Sumitomo Pharmaceuticals Co Ltd
DMWR93D	DT	Small molecular drug
DMWR93D	PC	452261
DMWR93D	MW	331.34
DMWR93D	FM	C13H15F2N3O3S
DMWR93D	IC	InChI=1S/C13H15F2N3O3S/c1-9(22(2,20)21)13(19,6-18-8-16-7-17-18)11-4-3-10(14)5-12(11)15/h3-5,7-9,19H,6H2,1-2H3/t9-,13-/m1/s1
DMWR93D	CS	C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)S(=O)(=O)C
DMWR93D	IK	HFGZFHCWKKQGIS-NOZJJQNGSA-N
DMWR93D	IU	(2R,3R)-2-(2,4-difluorophenyl)-3-methylsulfonyl-1-(1,2,4-triazol-1-yl)butan-2-ol
DMWR93D	CA	CAS 120924-80-3
DMWR93D	DE	Fungal infection

DMJP83V	ID	DMJP83V
DMJP83V	DN	Gene therapy, IFN-b
DMJP83V	HS	Phase 1
DMJP83V	SN	Gene therapy (IFN-b)
DMJP83V	CP	Nagoya University
DMJP83V	DE	Glioblastoma multiforme

DMTGN0U	ID	DMTGN0U
DMTGN0U	DN	Genz 644282
DMTGN0U	HS	Phase 1
DMTGN0U	SN	GENZ-644282; Genz 644282; genz644282; UNII-717I541I2R; 717I541I2R; 2,3-dimethoxy-12-(2-(methylamino)ethyl)-[1,3]dioxolo[4',5':4,5]benzo[1,2-h]benzo[c][1,6]naphthyridin-13(12H)-one; SCHEMBL241696; CHEMBL191958; EX-A481; AOB87160; BCP20983; ZINC6718458; SAR402674; AKOS030526835; CS-1525; SAR 402674; SAR-402674; HY-16228; Benzo(C)(1,3)benzodioxolo(5,6-H)(1,6)naphthyridin-13(12H)-one, 2,3-dimethoxy-12-(2-(methylamino)ethyl)-; BC600645; DA-42192; GENZ-644282/GENZ644282; FT-0700324; A3434; W-6112; A13206
DMTGN0U	PC	10294813
DMTGN0U	MW	407.4
DMTGN0U	FM	C22H21N3O5
DMTGN0U	IC	InChI=1S/C22H21N3O5/c1-23-4-5-25-21-14-8-19-20(30-11-29-19)9-16(14)24-10-15(21)12-6-17(27-2)18(28-3)7-13(12)22(25)26/h6-10,23H,4-5,11H2,1-3H3
DMTGN0U	CS	CNCCN1C2=C(C=NC3=CC4=C(C=C32)OCO4)C5=CC(=C(C=C5C1=O)OC)OC
DMTGN0U	IK	BAORCAMWLWRZQG-UHFFFAOYSA-N
DMTGN0U	IU	16,17-dimethoxy-21-[2-(methylamino)ethyl]-5,7-dioxa-11,21-diazapentacyclo[11.8.0.02,10.04,8.014,19]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-one
DMTGN0U	CA	CAS 529488-28-6
DMTGN0U	DE	Solid tumours

DMIXABW	ID	DMIXABW
DMIXABW	DN	Genz-644282
DMIXABW	HS	Phase 1
DMIXABW	SN	Genz-644283; Anticancer compound (cancer), Genzyme
DMIXABW	CP	Genzyme Corp
DMIXABW	DT	Small molecular drug
DMIXABW	PC	10294813
DMIXABW	MW	407.4
DMIXABW	FM	C22H21N3O5
DMIXABW	IC	InChI=1S/C22H21N3O5/c1-23-4-5-25-21-14-8-19-20(30-11-29-19)9-16(14)24-10-15(21)12-6-17(27-2)18(28-3)7-13(12)22(25)26/h6-10,23H,4-5,11H2,1-3H3
DMIXABW	CS	CNCCN1C2=C(C=NC3=CC4=C(C=C32)OCO4)C5=CC(=C(C=C5C1=O)OC)OC
DMIXABW	IK	BAORCAMWLWRZQG-UHFFFAOYSA-N
DMIXABW	IU	16,17-dimethoxy-21-[2-(methylamino)ethyl]-5,7-dioxa-11,21-diazapentacyclo[11.8.0.02,10.04,8.014,19]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-one
DMIXABW	CA	CAS 529488-28-6
DMIXABW	DE	Solid tumour/cancer

DMA9UX2	ID	DMA9UX2
DMA9UX2	DN	Gerilimzumab
DMA9UX2	HS	Phase 1
DMA9UX2	CP	Bird Rock Bio, La Jolla, CA
DMA9UX2	DE	Rheumatoid arthritis

DMDMPKC	ID	DMDMPKC
DMDMPKC	DN	GGF-2
DMDMPKC	HS	Phase 1
DMDMPKC	SN	Glial growth factor 2, Cambridge Neuroscience; RhGGF2, Cambridge Neuroscience; GGF-2, CeNeS; GGF-2 (cardiac failure/neurodegenerative disorders); GGF-2 (cardiac failure/neurodegenerative disorders), Acorda
DMDMPKC	CP	Acorda therapeutics
DMDMPKC	DE	Heart failure

DM8U23L	ID	DM8U23L
DM8U23L	DN	GGTI-2418
DM8U23L	HS	Phase 1
DM8U23L	CP	Kirax
DM8U23L	PC	11539477
DM8U23L	MW	441.5
DM8U23L	FM	C23H31N5O4
DM8U23L	IC	InChI=1S/C23H31N5O4/c1-15(2)11-18(22(30)31)26-23(32)28-10-9-27(13-19-16(3)24-14-25-19)21(29)20(28)12-17-7-5-4-6-8-17/h4-8,14-15,18,20H,9-13H2,1-3H3,(H,24,25)(H,26,32)(H,30,31)/t18-,20-/m0/s1
DM8U23L	CS	CC1=C(N=CN1)CN2CCN([C@H](C2=O)CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)O
DM8U23L	IK	COLCNDRDBCLVOC-ICSRJNTNSA-N
DM8U23L	IU	(2S)-2-[[(2S)-2-benzyl-4-[(5-methyl-1H-imidazol-4-yl)methyl]-3-oxopiperazine-1-carbonyl]amino]-4-methylpentanoic acid
DM8U23L	CA	CAS 501010-06-6
DM8U23L	DE	Solid tumour/cancer

DMKY1L4	ID	DMKY1L4
DMKY1L4	DN	Glucose-6-phosphate
DMKY1L4	HS	Phase 1
DMKY1L4	SN	Robison ester; Glucose 6-phosphate; 6-O-phosphono-D-glucopyranose; D-glucopyranose 6-phosphate; D-glucopyranose, 6-(dihydrogen phosphate); Glucose 6-(dihydrogen phosphate); 299-31-0; {[(2R,3S,4S,5R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}phosphonic acid; D-glucose-6P; Glc6P; D-glucose-6-P; a-D-glucose 6- phosphate; AC1L1LI0; SCHEMBL48379; CHEBI:4170; GTPL4647; AC1Q28E3; D-Glucopyranose 6-phosphoric acid
DMKY1L4	DT	Small molecular drug
DMKY1L4	PC	5958
DMKY1L4	MW	260.14
DMKY1L4	FM	C6H13O9P
DMKY1L4	IC	InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6?/m1/s1
DMKY1L4	CS	C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)OP(=O)(O)O
DMKY1L4	IK	NBSCHQHZLSJFNQ-GASJEMHNSA-N
DMKY1L4	IU	[(2R,3S,4S,5R)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl dihydrogen phosphate
DMKY1L4	CA	CAS 299-31-0
DMKY1L4	CB	CHEBI:4170

DM1PK0T	ID	DM1PK0T
DM1PK0T	DN	GLYCAR T cells
DM1PK0T	HS	Phase 1
DM1PK0T	CP	Baylor College of Medicine
DM1PK0T	DT	CAR T Cell Therapy
DM1PK0T	DE	Hepatocellular carcinoma

DMCKZUT	ID	DMCKZUT
DMCKZUT	DN	GlyT1 PET radiotracers
DMCKZUT	HS	Phase 1
DMCKZUT	SN	GlyT1 PET radiotracers (schizophrenia); Glycine transporter 1 positron emission tomography radiotracers, Merck; [11C]-CMPyPB; Fluorine-18-CFpyPB; [18F]-MK-6577; GlyT1 PET radiotracers (schizophrenia), Merck & Co; 18F-CFpyPB
DMCKZUT	CP	Merck & Co Inc
DMCKZUT	DE	Schizophrenia

DML1KSA	ID	DML1KSA
DML1KSA	DN	GMI-1359
DML1KSA	HS	Phase 1
DML1KSA	CP	GlycoMimetics
DML1KSA	DT	Small molecular drug
DML1KSA	DE	Solid tumour/cancer; Breast cancer

DMIFSN2	ID	DMIFSN2
DMIFSN2	DN	GMX1777
DMIFSN2	HS	Phase 1
DMIFSN2	SN	Teglarinad chloride; GMX1777; UNII-D6V5QYX9MZ; 432037-57-5; D6V5QYX9MZ; EB1627; 1-[[[[2-[2-[2-[2-Methoxyethoxy]ethoxy]ethoxy]ethoxy]carbonyl]oxy]methyl]-4-[N'-cyano-N''-[6-[4-chlorophenoxy]hexyl]guanidino]pyridinium chloride; Teglarinad chloride [USAN:INN]; GMX 1777; GMX-1777 chloride; CHEMBL190412; SCHEMBL2672343; CTK1D4865; Teglarinad chloride (USAN/INN); EB-1627; D09678
DMIFSN2	CP	Gemin X
DMIFSN2	TC	Anticancer Agents
DMIFSN2	DT	Small molecular drug
DMIFSN2	PC	9961434
DMIFSN2	MW	672.6
DMIFSN2	FM	C30H43Cl2N5O8
DMIFSN2	IC	InChI=1S/C30H42ClN5O8.ClH/c1-38-16-17-39-18-19-40-20-21-41-22-23-43-30(37)44-25-36-13-10-27(11-14-36)35-29(34-24-32)33-12-4-2-3-5-15-42-28-8-6-26(31)7-9-28;/h6-11,13-14H,2-5,12,15-23,25H2,1H3,(H,33,34);1H
DMIFSN2	CS	COCCOCCOCCOCCOC(=O)OC[N+]1=CC=C(C=C1)NC(=NCCCCCCOC2=CC=C(C=C2)Cl)NC#N.[Cl-]
DMIFSN2	IK	DAHMXVAETAAQOZ-UHFFFAOYSA-N
DMIFSN2	IU	[4-[[N'-[6-(4-chlorophenoxy)hexyl]-N-cyanocarbamimidoyl]amino]pyridin-1-ium-1-yl]methyl 2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethyl carbonate;chloride
DMIFSN2	CA	CAS 432037-57-5
DMIFSN2	DE	Solid tumour/cancer

DMD6H8B	ID	DMD6H8B
DMD6H8B	DN	GMZ-2
DMD6H8B	HS	Phase 1
DMD6H8B	SN	Adjuvanted PfGLURP + PfMSP3 vaccine (malaria), AMANET; GLURP-MSP3 bivalent vaccine (malaria), EMVI; Malaria vaccine (PfGLURP + PfMSP3 + aluminium hydroxide adjuvant), EMVI
DMD6H8B	CP	African Malaria Network Trust
DMD6H8B	DT	Vaccine
DMD6H8B	DE	Malaria

DMURO94	ID	DMURO94
DMURO94	DN	GNE Lipoplex
DMURO94	HS	Phase 1
DMURO94	SN	GNE Lipoplex (intramuscular, HIBM-2)
DMURO94	CP	Gradalis
DMURO94	DE	Myopathy

DMYWDT4	ID	DMYWDT4
DMYWDT4	DN	GNKG-168
DMYWDT4	HS	Phase 1
DMYWDT4	CP	SBI Biotech
DMYWDT4	DE	Chronic lymphocytic leukaemia

DMKMU2S	ID	DMKMU2S
DMKMU2S	DN	GNX102
DMKMU2S	HS	Phase 1
DMKMU2S	CP	GlycoNex
DMKMU2S	DT	Antibody
DMKMU2S	DE	Solid tumour/cancer

DM035LO	ID	DM035LO
DM035LO	DN	GP-3269
DM035LO	HS	Phase 1
DM035LO	SN	GP-1-3269
DM035LO	CP	Metabasis Therapeutics Inc
DM035LO	DE	Convulsion

DM9JV80	ID	DM9JV80
DM9JV80	DN	Gp41 HIV-1 vaccine
DM9JV80	HS	Phase 1
DM9JV80	SN	FIV inhibitors, Mymetics; MYM-V101; N-36E; S-291; Anti-retrovirals, Mymetics; Gp41 HIV-1 vaccine (virosomes); Gp41-derived peptides, Mymetics; HIV-1 therapeutics, Mymetics; Gp41 HIV-1 vaccine (virosomes), Mymetics
DM9JV80	CP	Mymetics
DM9JV80	DE	Human immunodeficiency virus infection

DM2MILF	ID	DM2MILF
DM2MILF	DN	GPA-TriMAR-T cells
DM2MILF	HS	Phase 1
DM2MILF	CP	Timmune Biotech Inc.
DM2MILF	DT	CAR T Cell Therapy
DM2MILF	DE	Melanoma

DMVWHS1	ID	DMVWHS1
DMVWHS1	DN	GPC3 targeting CAR-T cells
DMVWHS1	HS	Phase 1
DMVWHS1	CP	Second Affiliated Hospital of Guangzhou Medical University
DMVWHS1	DT	CAR T Cell Therapy
DMVWHS1	DE	Hepatocellular carcinoma; Lung squamous cell carcinoma

DM0ZQ48	ID	DM0ZQ48
DM0ZQ48	DN	GPI-16072
DM0ZQ48	HS	Phase 1
DM0ZQ48	CP	MGI Pharma
DM0ZQ48	TC	Analgesics
DM0ZQ48	DT	Small molecular drug
DM0ZQ48	PC	56603712
DM0ZQ48	MW	226.12
DM0ZQ48	FM	C6H11O7P
DM0ZQ48	IC	InChI=1S/C6H11O7P/c7-5(8)2-1-4(6(9)10)3-14(12)13-11/h4,11-12H,1-3H2,(H,7,8)(H,9,10)
DM0ZQ48	CS	C(CC(=O)O)C(CP(O)OO)C(=O)O
DM0ZQ48	IK	HKANXFJUBKMWSW-UHFFFAOYSA-N
DM0ZQ48	IU	2-[[hydroperoxy(hydroxy)phosphanyl]methyl]pentanedioic acid
DM0ZQ48	DE	Neuropathic pain

DM8MGSH	ID	DM8MGSH
DM8MGSH	DN	GPRC5D CAR-T cell therapy
DM8MGSH	HS	Phase 1
DM8MGSH	CP	Bristol-Myers Squibb; Eureka Therapeutics
DM8MGSH	DT	CAR T Cell Therapy
DM8MGSH	DE	Multiple myeloma

DMFA2XQ	ID	DMFA2XQ
DMFA2XQ	DN	GQ1001
DMFA2XQ	HS	Phase 1
DMFA2XQ	CP	GeneQuantum Healthcare
DMFA2XQ	DT	Antibody drug conjugate
DMFA2XQ	DE	Solid tumour/cancer

DMZ0D3V	ID	DMZ0D3V
DMZ0D3V	DN	GRC-6211
DMZ0D3V	HS	Phase 1
DMZ0D3V	SN	Oxolinic acid; oxolinic acid; 14698-29-4; Nidantin; Prodoxol; Prodoxal; Emyrenil; Dioxacin; Gramurin; Oxolinic; Oksaren; Ossian; Uroxol; Utibid; Urotrate; Uritrate; Pietil; Oxoboi; Ultibid; Starner; Acido oxolinico; Uro-alvar; Acide oxolinique; Acidum oxolinicum; Cistopax; Tiurasin; Orthurine; Acido ossolico; 5-Ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; NSC-110364; Urinox; Acido ossolico [DCIT]; 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4-quinolone-3-carboxylic acid;  GRC-6127; TRPV1 antagonists (asthma), Glenmark/Lilly; TRPV1 antagonists (incontinence), Glenmark/Lilly; TRPV1 antagonists (pain), Glenmark/Lilly; Transient receptor potential vanilloid sub-family 1 (pain), Glenmark/ Lilly; Vanilloid receptor VR1 antagonists (incontinence/pain/asthma), Glenmark/Lilly
DMZ0D3V	CP	Glenmark Pharmaceuticals Ltd
DMZ0D3V	DT	Small molecular drug
DMZ0D3V	PC	138393987
DMZ0D3V	MW	377.4
DMZ0D3V	FM	C22H20FN3O2
DMZ0D3V	IC	InChI=1S/C22H20FN3O2/c23-15-5-6-20-17(11-15)19(12-22(28-20)8-2-9-22)26-21(27)25-18-4-1-3-14-13-24-10-7-16(14)18/h1,3-7,10-11,13,19H,2,8-9,12H2,(H2,25,26,27)/t19-/m1/s1
DMZ0D3V	CS	C1CC2(C1)C[C@H](C3=C(O2)C=CC(=C3)F)NC(=O)NC4=CC=CC5=C4C=CN=C5
DMZ0D3V	IK	JADKHWDNSKIILG-LJQANCHMSA-N
DMZ0D3V	IU	1-[(4R)-6-fluorospiro[3,4-dihydrochromene-2,1'-cyclobutane]-4-yl]-3-isoquinolin-5-ylurea
DMZ0D3V	DE	Asthma

DMGF71W	ID	DMGF71W
DMGF71W	DN	GRN163
DMGF71W	HS	Phase 1
DMGF71W	CP	Geron Corp
DMGF71W	DT	Small molecular drug
DMGF71W	PC	56603713
DMGF71W	MW	534.9
DMGF71W	FM	C15H26B3N3O8P2S2-2
DMGF71W	IC	InChI=1S/C15H28B3N3O8P2S2/c16-13-1-7(19)11(28-13)5-25-31(24,33)21-9-3-15(18)29-12(9)6-26-30(23,32)20-8-2-14(17)27-10(8)4-22/h7-15,22H,1-6,19H2,(H2,20,23,32)(H2,21,24,33)/p-2
DMGF71W	CS	[B]C1CC(C(O1)COP(=S)(NC2CC(OC2COP(=S)(NC3CC(OC3CO)[B])[O-])[B])[O-])N
DMGF71W	IK	HHVGDFKKILAWTA-UHFFFAOYSA-L
DMGF71W	DE	Multiple myeloma

DMI319T	ID	DMI319T
DMI319T	DN	GS 9667
DMI319T	HS	Phase 1
DMI319T	SN	GS-9667; CVT-3619; UNII-6E68796C40; 618380-90-8; 6E68796C40; IZRXENCTXNMAMI-DIJFLQFKSA-N; CVT 3619; GTPL5593; SCHEMBL1150300; CHEMBL3545011; DTXSID40210823; EX-A2686; BDBM50149592; GS9667
DMI319T	CP	Gilead Sciences
DMI319T	DT	Small molecular drug
DMI319T	PC	11561692
DMI319T	MW	461.5
DMI319T	FM	C21H24FN5O4S
DMI319T	IC	InChI=1S/C21H24FN5O4S/c22-11-4-1-2-7-15(11)32-8-14-17(29)18(30)21(31-14)27-10-25-16-19(23-9-24-20(16)27)26-12-5-3-6-13(12)28/h1-2,4,7,9-10,12-14,17-18,21,28-30H,3,5-6,8H2,(H,23,24,26)/t12-,13-,14-,17-,18-,21-/m1/s1
DMI319T	CS	C1C[C@H]([C@@H](C1)O)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CSC5=CC=CC=C5F)O)O
DMI319T	IK	IZRXENCTXNMAMI-DIJFLQFKSA-N
DMI319T	IU	(2S,3S,4R,5R)-2-[(2-fluorophenyl)sulfanylmethyl]-5-[6-[[(1R,2R)-2-hydroxycyclopentyl]amino]purin-9-yl]oxolane-3,4-diol
DMI319T	CA	CAS 618380-90-8
DMI319T	DE	Hypertriglyceridemia

DMS25DL	ID	DMS25DL
DMS25DL	DN	GS-1423
DMS25DL	HS	Phase 1
DMS25DL	SN	AGEN 1423
DMS25DL	CP	Agenus; Gilead Sciences
DMS25DL	DT	Antibody
DMS25DL	DE	Solid tumour/cancer

DMZVFOQ	ID	DMZVFOQ
DMZVFOQ	DN	GS-5829
DMZVFOQ	HS	Phase 1
DMZVFOQ	CP	Gilead Sciences Foster City, CA
DMZVFOQ	DE	Solid tumour/cancer

DMRDNPC	ID	DMRDNPC
DMRDNPC	DN	GS-6620
DMRDNPC	HS	Phase 1
DMRDNPC	SN	GS-441326; NS5B polymerase inhibitor (HCV infection), Gilead Sciences
DMRDNPC	CP	Gilead Sciences Inc
DMRDNPC	DT	Small molecular drug
DMRDNPC	PC	58059494
DMRDNPC	MW	644.6
DMRDNPC	FM	C29H37N6O9P
DMRDNPC	IC	InChI=1S/C29H37N6O9P/c1-17(2)26(36)42-24-22(43-29(15-30,28(24,6)38)23-13-12-21-25(31)32-16-33-35(21)23)14-40-45(39,44-20-10-8-7-9-11-20)34-19(5)27(37)41-18(3)4/h7-13,16-19,22,24,38H,14H2,1-6H3,(H,34,39)(H2,31,32,33)/t19-,22+,24+,28+,29-,45?/m0/s1
DMRDNPC	CS	C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)(C)O)OC(=O)C(C)C)OC4=CC=CC=C4
DMRDNPC	IK	YAAQYJCOIFNMKX-CVANIGNKSA-N
DMRDNPC	IU	[(2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyl-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate
DMRDNPC	CA	CAS 1350735-70-4
DMRDNPC	DE	Hepatitis C virus infection

DMXG3T1	ID	DMXG3T1
DMXG3T1	DN	GS-6637
DMXG3T1	HS	Phase 1
DMXG3T1	PC	3862902
DMXG3T1	MW	125.96
DMXG3T1	FM	C6H11BO2
DMXG3T1	IC	InChI=1S/C6H11BO2/c8-7(9)6-4-2-1-3-5-6/h4,8-9H,1-3,5H2
DMXG3T1	CS	B(C1=CCCCC1)(O)O
DMXG3T1	IK	XZWQKJXJNKYMAP-UHFFFAOYSA-N
DMXG3T1	IU	cyclohexen-1-ylboronic acid
DMXG3T1	CA	CAS 89490-05-1
DMXG3T1	DE	Substance use disorder

DMNX3US	ID	DMNX3US
DMNX3US	DN	GS-9820
DMNX3US	HS	Phase 1
DMNX3US	CP	Gilead Sciences
DMNX3US	PC	11618268
DMNX3US	MW	401.4
DMNX3US	FM	C21H16FN7O
DMNX3US	IC	InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1
DMNX3US	CS	C[C@@H](C1=NC2=C(C=C(C=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DMNX3US	IK	DOCINCLJNAXZQF-LBPRGKRZSA-N
DMNX3US	IU	6-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)ethyl]quinazolin-4-one
DMNX3US	CA	CAS 870281-34-8
DMNX3US	DE	Lymphoma; Chronic lymphocytic leukaemia

DMMF5IE	ID	DMMF5IE
DMMF5IE	DN	GS-9883
DMMF5IE	HS	Phase 1
DMMF5IE	SN	Bictegravir; Bictegravir (USAN/INN); Bictegravir [INN]; Bictegravir [USAN:INN]; SB18851; SOLUWJRYJLAZCX-LYOVBCGYSA-N; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 1611493-60-7; 8GB79LOJ07; BCP25703; BDBM330048; CHEMBL3989866; DB11799; GS 9883; GS-9883; GS-9883-01; SCHEMBL15914278; UNII-8GB79LOJ07
DMMF5IE	PC	90311989
DMMF5IE	MW	449.4
DMMF5IE	FM	C21H18F3N3O5
DMMF5IE	IC	SOLUWJRYJLAZCX-LYOVBCGYSA-N
DMMF5IE	CS	C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
DMMF5IE	IK	1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1
DMMF5IE	IU	(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide
DMMF5IE	CA	CAS 1611493-60-7
DMMF5IE	DE	Human immunodeficiency virus infection

DMGHN98	ID	DMGHN98
DMGHN98	DN	GS-9901
DMGHN98	HS	Phase 1
DMGHN98	PC	86763204
DMGHN98	MW	477.9
DMGHN98	FM	C22H17ClFN9O
DMGHN98	IC	InChI=1S/C22H17ClFN9O/c23-13-5-6-14(24)17-15(13)21(34)33(11-2-1-7-28-9-11)20(30-17)16(10-3-4-10)29-19-12(8-25)18(26)31-22(27)32-19/h1-2,5-7,9-10,16H,3-4H2,(H5,26,27,29,31,32)/t16-/m0/s1
DMGHN98	CS	C1CC1[C@@H](C2=NC3=C(C=CC(=C3C(=O)N2C4=CN=CC=C4)Cl)F)NC5=NC(=NC(=C5C#N)N)N
DMGHN98	IK	XDSXYMOZKDUASY-INIZCTEOSA-N
DMGHN98	IU	2,4-diamino-6-[[(S)-(5-chloro-8-fluoro-4-oxo-3-pyridin-3-ylquinazolin-2-yl)-cyclopropylmethyl]amino]pyrimidine-5-carbonitrile
DMGHN98	CA	CAS 1640247-87-5
DMGHN98	DE	Haematological malignancy

DMSR5HD	ID	DMSR5HD
DMSR5HD	DN	GSI-136
DMSR5HD	HS	Phase 1
DMSR5HD	SN	WAY-179642; WAY-208983; WAY-GSI-A; WAY-GSI-B; Gamma-secretase inhibitors (oral, Alzheimer's disease), Wyeth
DMSR5HD	CP	Wyeth
DMSR5HD	DT	Small molecular drug
DMSR5HD	PC	11358855
DMSR5HD	MW	311.9
DMSR5HD	FM	C11H18ClNO3S2
DMSR5HD	IC	InChI=1S/C11H18ClNO3S2/c1-3-8(4-2)9(7-14)13-18(15,16)11-6-5-10(12)17-11/h5-6,8-9,13-14H,3-4,7H2,1-2H3/t9-/m1/s1
DMSR5HD	CS	CCC(CC)[C@@H](CO)NS(=O)(=O)C1=CC=C(S1)Cl
DMSR5HD	IK	PYZFRRVBPNGCBX-SECBINFHSA-N
DMSR5HD	IU	5-chloro-N-[(2S)-3-ethyl-1-hydroxypentan-2-yl]thiophene-2-sulfonamide
DMSR5HD	CA	CAS 443989-01-3
DMSR5HD	DE	Alzheimer disease

DMO87YS	ID	DMO87YS
DMO87YS	DN	GSK065
DMO87YS	HS	Phase 1
DMO87YS	SN	CHEMBL4091152; (R)-3-(5-Chloro-6-(1-(pyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid; 3-[5-Chloranyl-6-[(1~{r})-1-Pyridin-2-Ylethoxy]-1,2-Benzoxazol-3-Yl]propanoic Acid; 1953156-61-0; 8R5; SCHEMBL17844622; GTPL10358; BDBM50266003; GSK3335065; inhibitor C1 [PMID: 28604669]; ClC=1C(=CC2=C(C(=NO2)CCC(=O)O)C=1)O[C@H](C)C1=NC=CC=C1
DMO87YS	CP	GlaxoSmithKline
DMO87YS	DT	Small molecular drug
DMO87YS	PC	121415134
DMO87YS	MW	346.8
DMO87YS	FM	C17H15ClN2O4
DMO87YS	IC	InChI=1S/C17H15ClN2O4/c1-10(13-4-2-3-7-19-13)23-16-9-15-11(8-12(16)18)14(20-24-15)5-6-17(21)22/h2-4,7-10H,5-6H2,1H3,(H,21,22)/t10-/m1/s1
DMO87YS	CS	C[C@H](C1=CC=CC=N1)OC2=C(C=C3C(=C2)ON=C3CCC(=O)O)Cl
DMO87YS	IK	WPAHVUADNLXSOM-SNVBAGLBSA-N
DMO87YS	IU	3-[5-chloro-6-[(1R)-1-pyridin-2-ylethoxy]-1,2-benzoxazol-3-yl]propanoic acid
DMO87YS	DE	Pancreatitis

DMXRPT6	ID	DMXRPT6
DMXRPT6	DN	GSK1070916
DMXRPT6	HS	Phase 1
DMXRPT6	SN	GSK-1070916
DMXRPT6	CP	GlaxoSmith-Kline
DMXRPT6	DT	Small molecular drug
DMXRPT6	PC	46885626
DMXRPT6	MW	507.6
DMXRPT6	FM	C30H33N7O
DMXRPT6	IC	InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17,19H,6,18H2,1-5H3,(H,31,33)(H,32,38)
DMXRPT6	CS	CCN1C=C(C(=N1)C2=CC=C(C=C2)NC(=O)N(C)C)C3=C4C=C(NC4=NC=C3)C5=CC=CC(=C5)CN(C)C
DMXRPT6	IK	QTBWCSQGBMPECM-UHFFFAOYSA-N
DMXRPT6	IU	3-[4-[4-[2-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-ethylpyrazol-3-yl]phenyl]-1,1-dimethylurea
DMXRPT6	CA	CAS 942918-07-2
DMXRPT6	CB	CHEBI:91362
DMXRPT6	DE	Advanced solid tumour

DMCJUI9	ID	DMCJUI9
DMCJUI9	DN	GSK1070916A
DMCJUI9	HS	Phase 1
DMCJUI9	CP	GlaxoSmithKline
DMCJUI9	DE	Solid tumour/cancer

DMK3S9J	ID	DMK3S9J
DMK3S9J	DN	GSK1144814
DMK3S9J	HS	Phase 1
DMK3S9J	CP	GSK
DMK3S9J	DE	Schizophrenia; Alcohol dependence

DMNYGB8	ID	DMNYGB8
DMNYGB8	DN	GSK-1322888
DMNYGB8	HS	Phase 1
DMNYGB8	SN	1322888
DMNYGB8	CP	GlaxoSmithKline plc
DMNYGB8	DE	Gastroparesis

DMZC9XU	ID	DMZC9XU
DMZC9XU	DN	GSK-1360707
DMZC9XU	HS	Phase 1
DMZC9XU	SN	Monoamine reuptake inhibitors (depression), GlaxoSmithKline; Serotonin/dopamine/norepinephrine reuptake inhibitors (depression), GlaxoSmithKline
DMZC9XU	CP	GlaxoSmithKline plc
DMZC9XU	PC	24802841
DMZC9XU	MW	286.2
DMZC9XU	FM	C14H17Cl2NO
DMZC9XU	IC	InChI=1S/C14H17Cl2NO/c1-18-9-13-7-14(13,4-5-17-8-13)10-2-3-11(15)12(16)6-10/h2-3,6,17H,4-5,7-9H2,1H3/t13-,14-/m0/s1
DMZC9XU	CS	COC[C@@]12C[C@@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl
DMZC9XU	IK	ICXJGCSEMJXNQF-KBPBESRZSA-N
DMZC9XU	IU	(1S,6R)-6-(3,4-dichlorophenyl)-1-(methoxymethyl)-3-azabicyclo[4.1.0]heptane
DMZC9XU	CA	CAS 1013098-04-8
DMZC9XU	DE	Major depressive disorder

DMEJMTR	ID	DMEJMTR
DMEJMTR	DN	GSK1440115
DMEJMTR	HS	Phase 1
DMEJMTR	SN	UNII-GCT6G5G3C7; GCT6G5G3C7; GSK 1440115; SCHEMBL2957737; 4'-(1-(((6,7-Dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-diphenylcarboxylic acid; (1,1'-Biphenyl)-4-carboxylic acid, 4'-((1R)-1-((2-(6,7-dichloro-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)acetyl)methylamino)-2-(4-morpholinyl)ethyl)-
DMEJMTR	CP	GlaxoSmithKline
DMEJMTR	DT	Small molecular drug
DMEJMTR	PC	24760693
DMEJMTR	MW	598.5
DMEJMTR	FM	C30H29Cl2N3O6
DMEJMTR	IC	InChI=1S/C30H29Cl2N3O6/c1-33(28(36)17-35-25-14-23(31)24(32)15-27(25)41-18-29(35)37)26(16-34-10-12-40-13-11-34)21-6-2-19(3-7-21)20-4-8-22(9-5-20)30(38)39/h2-9,14-15,26H,10-13,16-18H2,1H3,(H,38,39)/t26-/m0/s1
DMEJMTR	CS	CN([C@@H](CN1CCOCC1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)O)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl
DMEJMTR	IK	YNBJTYUXPHTSFF-SANMLTNESA-N
DMEJMTR	IU	4-[4-[(1R)-1-[[2-(6,7-dichloro-3-oxo-1,4-benzoxazin-4-yl)acetyl]-methylamino]-2-morpholin-4-ylethyl]phenyl]benzoic acid
DMEJMTR	CA	CAS 1003878-16-7
DMEJMTR	DE	Asthma

DMWDQOV	ID	DMWDQOV
DMWDQOV	DN	GSK1482160
DMWDQOV	HS	Phase 1
DMWDQOV	CP	GSK
DMWDQOV	TC	Analgesics
DMWDQOV	PC	45273136
DMWDQOV	MW	334.72
DMWDQOV	FM	C14H14ClF3N2O2
DMWDQOV	IC	InChI=1S/C14H14ClF3N2O2/c1-20-10(5-6-11(20)21)13(22)19-7-8-3-2-4-9(12(8)15)14(16,17)18/h2-4,10H,5-7H2,1H3,(H,19,22)
DMWDQOV	CS	CN1C(CCC1=O)C(=O)NCC2=C(C(=CC=C2)C(F)(F)F)Cl
DMWDQOV	IK	BJEMSIVBBUBXMZ-UHFFFAOYSA-N
DMWDQOV	IU	N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-5-oxopyrrolidine-2-carboxamide
DMWDQOV	DE	Pain

DM2L7TH	ID	DM2L7TH
DM2L7TH	DN	GSK1521498
DM2L7TH	HS	Phase 1
DM2L7TH	SN	GSK-1521498; GSK-1521498B
DM2L7TH	CP	GlaxoSmithKline
DM2L7TH	DT	Small molecular drug
DM2L7TH	PC	24737629
DM2L7TH	MW	402.4
DM2L7TH	FM	C24H20F2N4
DM2L7TH	IC	InChI=1S/C24H20F2N4/c25-22-11-19(15-6-3-7-18(8-15)24-28-14-29-30-24)12-23(26)21(22)13-27-20-9-16-4-1-2-5-17(16)10-20/h1-8,11-12,14,20,27H,9-10,13H2,(H,28,29,30)
DM2L7TH	CS	C1C(CC2=CC=CC=C21)NCC3=C(C=C(C=C3F)C4=CC(=CC=C4)C5=NC=NN5)F
DM2L7TH	IK	WIEDUMBCZQRGSY-UHFFFAOYSA-N
DM2L7TH	IU	N-[[2,6-difluoro-4-[3-(1H-1,2,4-triazol-5-yl)phenyl]phenyl]methyl]-2,3-dihydro-1H-inden-2-amine
DM2L7TH	CA	CAS 1007573-18-3
DM2L7TH	DE	Obesity

DM7I1AQ	ID	DM7I1AQ
DM7I1AQ	DN	GSK1614235
DM7I1AQ	HS	Phase 1
DM7I1AQ	CP	GSK
DM7I1AQ	DE	Type-2 diabetes

DMC6QE4	ID	DMC6QE4
DMC6QE4	DN	GSK1795091
DMC6QE4	HS	Phase 1
DMC6QE4	CP	GlaxoSmithKline Research Triangle Park, NC
DMC6QE4	DE	Solid tumour/cancer

DMA41JD	ID	DMA41JD
DMA41JD	DN	GSK-1827771
DMA41JD	HS	Phase 1
DMA41JD	SN	IL-1 antagonist (antibody, rheumatoid arthritis), GSK
DMA41JD	CP	GlaxoSmithKline plc
DMA41JD	DT	Antibody
DMA41JD	DE	Rheumatoid arthritis

DMC14KV	ID	DMC14KV
DMC14KV	DN	GSK1995057
DMC14KV	HS	Phase 1
DMC14KV	CP	Quark Pharmaceuticals
DMC14KV	DT	Antibody
DMC14KV	DE	Adult respiratory distress syndrome

DMRU4YV	ID	DMRU4YV
DMRU4YV	DN	GSK-2018682
DMRU4YV	HS	Phase 1
DMRU4YV	SN	PPI-4621; PPI-4667; PPI-4939; PPI-4955; PPI-4667-P; PPI-5955-P; S1P1 receptor agonists (immune disorder), GlaxoSmithKline
DMRU4YV	CP	Praecis Pharmaceuticals Inc
DMRU4YV	PC	24988201
DMRU4YV	MW	440.9
DMRU4YV	FM	C22H21ClN4O4
DMRU4YV	IC	InChI=1S/C22H21ClN4O4/c1-13(2)30-22-17(23)11-14(12-24-22)21-25-20(26-31-21)16-5-3-6-18-15(16)8-10-27(18)9-4-7-19(28)29/h3,5-6,8,10-13H,4,7,9H2,1-2H3,(H,28,29)
DMRU4YV	CS	CC(C)OC1=C(C=C(C=N1)C2=NC(=NO2)C3=C4C=CN(C4=CC=C3)CCCC(=O)O)Cl
DMRU4YV	IK	NFIGDBFIDKDNIG-UHFFFAOYSA-N
DMRU4YV	IU	4-[4-[5-(5-chloro-6-propan-2-yloxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid
DMRU4YV	CA	CAS 1034688-30-6
DMRU4YV	DE	Immune System disease

DMM7ZXR	ID	DMM7ZXR
DMM7ZXR	DN	GSK2126458
DMM7ZXR	HS	Phase 1
DMM7ZXR	SN	1086062-66-9; Omipalisib; GSK-2126458; GSK 2126458; UNII-1X8F5A3NA0; 2,4-difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide; 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide; 2,4-Difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide; 1X8F5A3NA0; Omipalisib (GSK2126458, GSK458); C25H17F2N5O3S; Omipalisib [USAN:INN]
DMM7ZXR	CP	GlaxoSmithKline
DMM7ZXR	DT	Small molecular drug
DMM7ZXR	PC	25167777
DMM7ZXR	MW	505.5
DMM7ZXR	FM	C25H17F2N5O3S
DMM7ZXR	IC	InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3
DMM7ZXR	CS	COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F
DMM7ZXR	IK	CGBJSGAELGCMKE-UHFFFAOYSA-N
DMM7ZXR	IU	2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide
DMM7ZXR	CA	CAS 1086062-66-9
DMM7ZXR	CB	CHEBI:95093
DMM7ZXR	DE	Lymphoma

DMRXW9P	ID	DMRXW9P
DMRXW9P	DN	GSK-2130579A
DMRXW9P	HS	Phase 1
DMRXW9P	SN	Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline
DMRXW9P	CP	Glaxosmithkline
DMRXW9P	DT	Vaccine
DMRXW9P	DE	Acute myeloid leukaemia

DMUNVXR	ID	DMUNVXR
DMUNVXR	DN	GSK-2239633
DMUNVXR	HS	Phase 1
DMUNVXR	CP	GlaxoSmithKline plc
DMUNVXR	PC	46861584
DMUNVXR	MW	549.1
DMUNVXR	FM	C24H25ClN4O5S2
DMUNVXR	IC	InChI=1S/C24H25ClN4O5S2/c1-24(2,31)23(30)26-13-15-6-4-7-16(12-15)14-29-17-8-5-9-18(34-3)21(17)22(27-29)28-36(32,33)20-11-10-19(25)35-20/h4-12,31H,13-14H2,1-3H3,(H,26,30)(H,27,28)
DMUNVXR	CS	CC(C)(C(=O)NCC1=CC(=CC=C1)CN2C3=C(C(=CC=C3)OC)C(=N2)NS(=O)(=O)C4=CC=C(S4)Cl)O
DMUNVXR	IK	YTEVTHHGQMUPHC-UHFFFAOYSA-N
DMUNVXR	IU	N-[[3-[[3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-methoxyindazol-1-yl]methyl]phenyl]methyl]-2-hydroxy-2-methylpropanamide
DMUNVXR	CA	CAS 1240516-71-5
DMUNVXR	DE	Asthma

DM5VS7B	ID	DM5VS7B
DM5VS7B	DN	GSK-2241658A
DM5VS7B	HS	Phase 1
DM5VS7B	SN	NY-ESO-1 ASCI (melanoma), GSK; Recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma), GlaxoSmithKline; 2241658A
DM5VS7B	CP	GlaxoSmithKline plc
DM5VS7B	DT	Vaccine
DM5VS7B	DE	Melanoma

DMR24MI	ID	DMR24MI
DMR24MI	DN	GSK-2256098
DMR24MI	HS	Phase 1
DMR24MI	SN	Focal adhesion kinase inhibitor (oral, cancer), GlaxoSmithKline
DMR24MI	CP	GlaxoSmithKline
DMR24MI	DT	Small molecular drug
DMR24MI	PC	46214930
DMR24MI	MW	414.9
DMR24MI	FM	C20H23ClN6O2
DMR24MI	IC	InChI=1S/C20H23ClN6O2/c1-12(2)27-19(9-13(3)25-27)24-18-10-17(15(21)11-22-18)23-16-8-6-5-7-14(16)20(28)26-29-4/h5-12H,1-4H3,(H,26,28)(H2,22,23,24)
DMR24MI	CS	CC1=NN(C(=C1)NC2=NC=C(C(=C2)NC3=CC=CC=C3C(=O)NOC)Cl)C(C)C
DMR24MI	IK	BVAHPPKGOOJSPU-UHFFFAOYSA-N
DMR24MI	IU	2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-N-methoxybenzamide
DMR24MI	CA	CAS 1224887-10-8
DMR24MI	DE	Solid tumour/cancer; Pulmonary arterial hypertension

DM7FN12	ID	DM7FN12
DM7FN12	DN	GSK2256294
DM7FN12	HS	Phase 1
DM7FN12	SN	GSK-2256294
DM7FN12	CP	GlaxoSmithKline
DM7FN12	PC	59448236
DM7FN12	MW	447.5
DM7FN12	FM	C21H24F3N7O
DM7FN12	IC	InChI=1S/C21H24F3N7O/c1-12-28-19(26-2)31-20(29-12)30-16-5-3-4-14(9-16)18(32)27-11-15-7-6-13(10-25)8-17(15)21(22,23)24/h6-8,14,16H,3-5,9,11H2,1-2H3,(H,27,32)(H2,26,28,29,30,31)/t14-,16+/m1/s1
DM7FN12	CS	CC1=NC(=NC(=N1)N[C@H]2CCC[C@H](C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)NC
DM7FN12	IK	LQHDJQIMETZMPH-ZBFHGGJFSA-N
DM7FN12	IU	(1R,3S)-N-[[4-cyano-2-(trifluoromethyl)phenyl]methyl]-3-[[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino]cyclohexane-1-carboxamide
DM7FN12	CA	CAS 1142090-23-0
DM7FN12	DE	Chronic obstructive pulmonary disease

DMOWTRL	ID	DMOWTRL
DMOWTRL	DN	GSK-2315698
DMOWTRL	HS	Phase 1
DMOWTRL	SN	GSK-2315698A; Serum amyloid P depleter (iv, amyloidosis), GlaxoSmithKline
DMOWTRL	CP	GlaxoSmithKline plc
DMOWTRL	DT	Antibody
DMOWTRL	DE	Amyloidosis

DMZ5A6D	ID	DMZ5A6D
DMZ5A6D	DN	GSK2398852
DMZ5A6D	HS	Phase 1
DMZ5A6D	SN	2398852
DMZ5A6D	DT	Antibody
DMZ5A6D	DE	Amyloidosis

DMIVHDN	ID	DMIVHDN
DMIVHDN	DN	GSK2618960
DMIVHDN	HS	Phase 1
DMIVHDN	CP	Glaxosmithkline
DMIVHDN	DE	Multiple sclerosis; Sjogren syndrome

DMCBGLW	ID	DMCBGLW
DMCBGLW	DN	GSK2636771
DMCBGLW	HS	Phase 1
DMCBGLW	SN	GSK2636771; 1372540-25-4; GSK-2636771; 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid; UNII-DW94IAT0LS; DW94IAT0LS; GSK 2636771; 2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid; 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid; lic acid; XTKLTGBKIDQGQL-UHFFFAOYSA-N
DMCBGLW	CP	GlaxoSmithKline
DMCBGLW	DT	Small molecular drug
DMCBGLW	PC	56949517
DMCBGLW	MW	433.4
DMCBGLW	FM	C22H22F3N3O3
DMCBGLW	IC	InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)
DMCBGLW	CS	CC1=C(C=CC=C1C(F)(F)F)CN2C(=NC3=C(C=C(C=C32)N4CCOCC4)C(=O)O)C
DMCBGLW	IK	XTKLTGBKIDQGQL-UHFFFAOYSA-N
DMCBGLW	IU	2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid
DMCBGLW	CA	CAS 1372540-25-4
DMCBGLW	DE	Solid tumour/cancer; Prostate cancer

DMQOM5V	ID	DMQOM5V
DMQOM5V	DN	GSK2646264
DMQOM5V	HS	Phase 1
DMQOM5V	SN	CQLSAYKHANAIMX-UHFFFAOYSA-N; GTPL10108; compound 44 [PMID: 30249354]; 7-{2-methoxy-6-[(4-methylpyridin-2-yl)methoxy]phenyl}-2,3,4,5,5a,9a-hexahydro-1H-3-benzazepine
DMQOM5V	CP	GlaxoSmithKline Research Triangle Park, NC
DMQOM5V	PC	60194098
DMQOM5V	MW	374.5
DMQOM5V	FM	C24H26N2O2
DMQOM5V	IC	InChI=1S/C24H26N2O2/c1-17-8-13-26-21(14-17)16-28-23-5-3-4-22(27-2)24(23)20-7-6-18-9-11-25-12-10-19(18)15-20/h3-8,13-15,25H,9-12,16H2,1-2H3
DMQOM5V	CS	CC1=CC(=NC=C1)COC2=CC=CC(=C2C3=CC4=C(CCNCC4)C=C3)OC
DMQOM5V	IK	KYANYGKXMNYFBX-UHFFFAOYSA-N
DMQOM5V	IU	7-[2-methoxy-6-[(4-methylpyridin-2-yl)methoxy]phenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine
DMQOM5V	CA	CAS 1398695-47-0
DMQOM5V	DE	Cutaneous lupus erythematosus; Urticaria

DM3KARJ	ID	DM3KARJ
DM3KARJ	DN	GSK2647544
DM3KARJ	HS	Phase 1
DM3KARJ	SN	GSK-2647544
DM3KARJ	CP	GlaxoSmithKline
DM3KARJ	DE	Alzheimer disease

DMAK89L	ID	DMAK89L
DMAK89L	DN	GSK2661380
DMAK89L	HS	Phase 1
DMAK89L	SN	GSK-2661380
DMAK89L	CP	GlaxoSmithKline
DMAK89L	DT	Antibody
DMAK89L	DE	Solid tumour/cancer

DMSGNVK	ID	DMSGNVK
DMSGNVK	DN	GSK2793660
DMSGNVK	HS	Phase 1
DMSGNVK	SN	2793660
DMSGNVK	CP	Glaxosmithkline
DMSGNVK	DE	Bronchiectasis

DMJDVW4	ID	DMJDVW4
DMJDVW4	DN	GSK2816126
DMJDVW4	HS	Phase 1
DMJDVW4	SN	GSK 126; GSK-126
DMJDVW4	CP	Glaxosmithkline
DMJDVW4	DT	Small molecular drug
DMJDVW4	PC	68210102
DMJDVW4	MW	526.7
DMJDVW4	FM	C31H38N6O2
DMJDVW4	IC	InChI=1S/C31H38N6O2/c1-6-22(5)37-18-20(3)29-25(30(38)34-17-26-19(2)13-21(4)35-31(26)39)14-24(15-27(29)37)23-7-8-28(33-16-23)36-11-9-32-10-12-36/h7-8,13-16,18,22,32H,6,9-12,17H2,1-5H3,(H,34,38)(H,35,39)/t22-/m0/s1
DMJDVW4	CS	CC[C@H](C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C
DMJDVW4	IK	FKSFKBQGSFSOSM-QFIPXVFZSA-N
DMJDVW4	IU	1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide
DMJDVW4	CA	CAS 1346574-57-9
DMJDVW4	CB	CHEBI:124921
DMJDVW4	DE	Solid tumour/cancer

DMU1X8K	ID	DMU1X8K
DMU1X8K	DN	GSK2820151
DMU1X8K	HS	Phase 1
DMU1X8K	CP	GlaxoSmithKline
DMU1X8K	DT	Small molecular drug
DMU1X8K	DE	Solid tumour/cancer

DMC47M9	ID	DMC47M9
DMC47M9	DN	GSK2831781
DMC47M9	HS	Phase 1
DMC47M9	CP	GlaxoSmithKline Research Triangle Park, NC
DMC47M9	DE	Autoimmune disease; Plaque psoriasis

DM6KE4G	ID	DM6KE4G
DM6KE4G	DN	GSK2849330
DM6KE4G	HS	Phase 1
DM6KE4G	CP	Glaxosmithkline
DM6KE4G	DT	Antibody
DM6KE4G	DE	Solid tumour/cancer

DMT3V2W	ID	DMT3V2W
DMT3V2W	DN	GSK2879552
DMT3V2W	HS	Phase 1
DMT3V2W	CP	Glaxosmithkline
DMT3V2W	PC	66571643
DMT3V2W	MW	364.5
DMT3V2W	FM	C23H28N2O2
DMT3V2W	IC	InChI=1S/C23H28N2O2/c26-23(27)20-8-6-18(7-9-20)16-25-12-10-17(11-13-25)15-24-22-14-21(22)19-4-2-1-3-5-19/h1-9,17,21-22,24H,10-16H2,(H,26,27)/t21-,22+/m0/s1
DMT3V2W	CS	C1CN(CCC1CN[C@@H]2C[C@H]2C3=CC=CC=C3)CC4=CC=C(C=C4)C(=O)O
DMT3V2W	IK	LRULVYSBRWUVGR-FCHUYYIVSA-N
DMT3V2W	IU	4-[[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]benzoic acid
DMT3V2W	CA	CAS 1401966-69-5
DMT3V2W	DE	Small-cell lung cancer

DM4ZK6G	ID	DM4ZK6G
DM4ZK6G	DN	GSK3050002
DM4ZK6G	HS	Phase 1
DM4ZK6G	CP	GlaxoSmithKline Research Triangle Park, NC
DM4ZK6G	DE	Psoriatic arthritis

DMCKNJX	ID	DMCKNJX
DMCKNJX	DN	GSK3052230
DMCKNJX	HS	Phase 1
DMCKNJX	CP	Glaxosmithkline
DMCKNJX	DE	Solid tumour/cancer

DM70DYV	ID	DM70DYV
DM70DYV	DN	GSK311739
DM70DYV	HS	Phase 1
DM70DYV	CP	Glaxosmithkline
DM70DYV	DE	Rhinovirus infection

DMQZSXD	ID	DMQZSXD
DMQZSXD	DN	GSK3117391
DMQZSXD	HS	Phase 1
DMQZSXD	CP	Glaxosmithkline
DMQZSXD	DT	Small molecular drug
DMQZSXD	PC	53630042
DMQZSXD	MW	403.5
DMQZSXD	FM	C22H33N3O4
DMQZSXD	IC	InChI=1S/C22H33N3O4/c26-20(25-28)13-12-18-11-10-16(14-23-18)15-24-21(17-6-2-1-3-7-17)22(27)29-19-8-4-5-9-19/h10-11,14,17,19,21,24,28H,1-9,12-13,15H2,(H,25,26)/t21-/m0/s1
DMQZSXD	CS	C1CCC(CC1)[C@@H](C(=O)OC2CCCC2)NCC3=CN=C(C=C3)CCC(=O)NO
DMQZSXD	IK	AFDPFLDWOXXHQM-NRFANRHFSA-N
DMQZSXD	IU	cyclopentyl (2S)-2-cyclohexyl-2-[[6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl]methylamino]acetate
DMQZSXD	CA	CAS 1018673-42-1
DMQZSXD	DE	Rheumatoid arthritis

DM2KCIP	ID	DM2KCIP
DM2KCIP	DN	GSK3179106
DM2KCIP	HS	Phase 1
DM2KCIP	SN	RET Kinase inhibitor 1; SCHEMBL16055027; CHEMBL3355009; IDXKJSSOUXWLDB-UHFFFAOYSA-N; CS-7799; HY-100459; 1627856-64-7; 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
DM2KCIP	CP	GlaxoSmithKline Research Triangle Park, NC
DM2KCIP	PC	78427026
DM2KCIP	MW	467.4
DM2KCIP	FM	C22H21F4N3O4
DM2KCIP	IC	InChI=1S/C22H21F4N3O4/c1-4-32-16-9-19(30)27-11-14(16)12-5-6-13(15(23)7-12)8-20(31)28-18-10-17(33-29-18)21(2,3)22(24,25)26/h5-7,9-11H,4,8H2,1-3H3,(H,27,30)(H,28,29,31)
DM2KCIP	CS	CCOC1=CC(=O)NC=C1C2=CC(=C(C=C2)CC(=O)NC3=NOC(=C3)C(C)(C)C(F)(F)F)F
DM2KCIP	IK	IDXKJSSOUXWLDB-UHFFFAOYSA-N
DM2KCIP	IU	2-[4-(4-ethoxy-6-oxo-1H-pyridin-3-yl)-2-fluorophenyl]-N-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]acetamide
DM2KCIP	CA	CAS 1627856-64-7
DM2KCIP	DE	Inflammatory bowel disease

DMJAVN7	ID	DMJAVN7
DMJAVN7	DN	GSK3186899
DMJAVN7	HS	Phase 1
DMJAVN7	SN	CHEMBL4563818; 1972617-87-0; 3,3,3-Trifluoro-N-(trans-4-((3-((S)-2-methylmorpholino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide; SCHEMBL17948393; SCHEMBL20878264; SCHEMBL20878281; BDBM50517287; TQ0152; DDD-853651; SB18814; HY-112622; CS-0058580; 3,3,3-trifluoro-N-((1S,4r)-4-((3-((S)-2-methylmorpholino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide
DMJAVN7	CP	GlaxoSmithKline
DMJAVN7	DT	Small molecular drug
DMJAVN7	PC	122429808
DMJAVN7	MW	491.5
DMJAVN7	FM	C19H28F3N7O3S
DMJAVN7	IC	InChI=1S/C19H28F3N7O3S/c1-12-11-29(7-8-32-12)17-15-10-23-18(25-16(15)26-27-17)24-13-2-4-14(5-3-13)28-33(30,31)9-6-19(20,21)22/h10,12-14,28H,2-9,11H2,1H3,(H2,23,24,25,26,27)/t12-,13?,14?/m0/s1
DMJAVN7	CS	C[C@H]1CN(CCO1)C2=NNC3=NC(=NC=C32)NC4CCC(CC4)NS(=O)(=O)CCC(F)(F)F
DMJAVN7	IK	RQWCISVRFNZHMJ-HSBZDZAISA-N
DMJAVN7	IU	3,3,3-trifluoro-N-[4-[[3-[(2S)-2-methylmorpholin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]cyclohexyl]propane-1-sulfonamide
DMJAVN7	DE	Leishmaniasis

DMVEGND	ID	DMVEGND
DMVEGND	DN	GSK3368715
DMVEGND	HS	Phase 1
DMVEGND	SN	1629013-22-4; N~1~-({5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)-N~1~,N~2~-dimethylethane-1,2-diamine; EPZ019997; SCHEMBL16121956; EX-A4367; NSC823806; EPZ-019997; NSC-823806; GSK-3368715; HY-128717; CS-0099584; KZS; N1-((3-(4,4-Bis(ethoxymethyl)cyclohexyl)-1H-pyrazol-4-yl)methyl)-N1,N2-dimethylethane-1,2-diamine
DMVEGND	CP	GlaxoSmithKline
DMVEGND	DT	Small molecular drug
DMVEGND	PC	90462880
DMVEGND	MW	366.5
DMVEGND	FM	C20H38N4O2
DMVEGND	IC	InChI=1S/C20H38N4O2/c1-5-25-15-20(16-26-6-2)9-7-17(8-10-20)19-18(13-22-23-19)14-24(4)12-11-21-3/h13,17,21H,5-12,14-16H2,1-4H3,(H,22,23)
DMVEGND	CS	CCOCC1(CCC(CC1)C2=C(C=NN2)CN(C)CCNC)COCC
DMVEGND	IK	SPEGERVLTUWZPA-UHFFFAOYSA-N
DMVEGND	IU	N'-[[5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl]methyl]-N,N'-dimethylethane-1,2-diamine
DMVEGND	DE	Solid tumour/cancer

DMIEAMU	ID	DMIEAMU
DMIEAMU	DN	GSK-356278
DMIEAMU	HS	Phase 1
DMIEAMU	SN	PDE4 inhibitor (oral, depression/anxiety), GlaxoSmithKline
DMIEAMU	CP	Glaxosmithkline
DMIEAMU	DT	Small molecular drug
DMIEAMU	PC	10252640
DMIEAMU	MW	439.5
DMIEAMU	FM	C21H25N7O2S
DMIEAMU	IC	InChI=1S/C21H25N7O2S/c1-4-28-20-15(11-23-28)19(25-14-5-7-29-8-6-14)16(10-22-20)21-27-26-18(30-21)9-17-12(2)24-13(3)31-17/h10-11,14H,4-9H2,1-3H3,(H,22,25)
DMIEAMU	CS	CCN1C2=NC=C(C(=C2C=N1)NC3CCOCC3)C4=NN=C(O4)CC5=C(N=C(S5)C)C
DMIEAMU	IK	AWDJJMXJUOHGLC-UHFFFAOYSA-N
DMIEAMU	IU	5-[5-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine
DMIEAMU	CA	CAS 720704-34-7
DMIEAMU	DE	Huntington disease

DMRYNJD	ID	DMRYNJD
DMRYNJD	DN	GSK3745417
DMRYNJD	HS	Phase 1
DMRYNJD	CP	GlaxoSmithKline
DMRYNJD	DE	Solid tumour/cancer

DM1UQ4Y	ID	DM1UQ4Y
DM1UQ4Y	DN	GSK3845097
DM1UQ4Y	HS	Phase 1
DM1UQ4Y	CP	GlaxoSmithKline
DM1UQ4Y	DT	TCR-T cell therapy
DM1UQ4Y	DE	Solid tumour/cancer

DMN4I7P	ID	DMN4I7P
DMN4I7P	DN	GSK3901961
DMN4I7P	HS	Phase 1
DMN4I7P	CP	GlaxoSmithKline
DMN4I7P	DT	TCR-T cell therapy
DMN4I7P	DE	Solid tumour/cancer

DMI3FU6	ID	DMI3FU6
DMI3FU6	DN	GSK4074386
DMI3FU6	HS	Phase 1
DMI3FU6	SN	TSR-033
DMI3FU6	CP	AnaptysBio; GlaxoSmithKline
DMI3FU6	DT	Antibody
DMI3FU6	DE	Solid tumour/cancer

DM0P729	ID	DM0P729
DM0P729	DN	GSK461364
DM0P729	HS	Phase 1
DM0P729	SN	GSK461364; 929095-18-1; GSK-461364; 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide; GSK 461364; UNII-8QO27TK6Q4; GSK-461364A; (R)-5-(6-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide; 8QO27TK6Q4; CHEMBL1908394; GSK461364A; ZHJGWYRLJUCMRT-QGZVFWFLSA-N; SCHEMBL310080; GTPL5684; C27H28F3N5O2S; CTK8B7590; CHEBI:91333; DTXSID60239197; MolPort-016-633-304; BCP01720; GSK 461364A
DM0P729	CP	GlaxoSmithKline
DM0P729	TC	Anticancer Agents
DM0P729	DT	Small molecular drug
DM0P729	PC	15983966
DM0P729	MW	543.6
DM0P729	FM	C27H28F3N5O2S
DM0P729	IC	InChI=1S/C27H28F3N5O2S/c1-17(19-5-3-4-6-20(19)27(28,29)30)37-23-14-24(38-25(23)26(31)36)35-16-32-21-8-7-18(13-22(21)35)15-34-11-9-33(2)10-12-34/h3-8,13-14,16-17H,9-12,15H2,1-2H3,(H2,31,36)/t17-/m1/s1
DM0P729	CS	C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)CN5CCN(CC5)C)C(=O)N
DM0P729	IK	ZHJGWYRLJUCMRT-QGZVFWFLSA-N
DM0P729	IU	5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide
DM0P729	CA	CAS 929095-18-1
DM0P729	CB	CHEBI:91333
DM0P729	DE	Non-hodgkin lymphoma; Solid tumour/cancer

DMPAWBN	ID	DMPAWBN
DMPAWBN	DN	GSK525762
DMPAWBN	HS	Phase 1
DMPAWBN	SN	GSK-525762
DMPAWBN	CP	GlaxoSmithKline
DMPAWBN	DT	Small molecular drug
DMPAWBN	PC	46943432
DMPAWBN	MW	423.9
DMPAWBN	FM	C22H22ClN5O2
DMPAWBN	IC	InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1
DMPAWBN	CS	CCNC(=O)C[C@H]1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C
DMPAWBN	IK	AAAQFGUYHFJNHI-SFHVURJKSA-N
DMPAWBN	IU	2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide
DMPAWBN	CA	CAS 1260907-17-2
DMPAWBN	CB	CHEBI:95082
DMPAWBN	DE	Solid tumour/cancer; Haematological malignancy

DM5E9LX	ID	DM5E9LX
DM5E9LX	DN	GSK586529
DM5E9LX	HS	Phase 1
DM5E9LX	CP	GSK
DM5E9LX	DE	Anxiety disorder; Depression

DMWI0AL	ID	DMWI0AL
DMWI0AL	DN	GSK6097608
DMWI0AL	HS	Phase 1
DMWI0AL	CP	GlaxoSmithKline
DMWI0AL	DT	Antibody
DMWI0AL	DE	Solid tumour/cancer

DMJPXZ4	ID	DMJPXZ4
DMJPXZ4	DN	GSK618334
DMJPXZ4	HS	Phase 1
DMJPXZ4	SN	Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride
DMJPXZ4	CP	GSK
DMJPXZ4	DT	Small molecular drug
DMJPXZ4	PC	107969
DMJPXZ4	MW	343.9
DMJPXZ4	FM	C19H34ClNO2
DMJPXZ4	IC	InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
DMJPXZ4	CS	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
DMJPXZ4	IK	SWZTYAVBMYWFGS-UHFFFAOYSA-N
DMJPXZ4	IU	2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride
DMJPXZ4	CA	CAS 162359-56-0
DMJPXZ4	CB	CHEBI:63112
DMJPXZ4	DE	Drug abuse; Nasopharyngeal carcinoma

DM7CIN4	ID	DM7CIN4
DM7CIN4	DN	GSK-625433
DM7CIN4	HS	Phase 1
DM7CIN4	SN	NS5B HCV polymerase inhibitors, GlaxoSmithKline; SB-711845; SB-750330; 625433
DM7CIN4	CP	GlaxoSmithKline plc
DM7CIN4	DT	Small molecular drug
DM7CIN4	PC	11569786
DM7CIN4	MW	512.6
DM7CIN4	FM	C26H32N4O5S
DM7CIN4	IC	InChI=1S/C26H32N4O5S/c1-25(2,3)19-8-7-17(13-20(19)35-5)23(31)30-21(22-27-10-12-36-22)18(15-34-4)14-26(30,24(32)33)16-29-11-6-9-28-29/h6-13,18,21H,14-16H2,1-5H3,(H,32,33)/t18-,21-,26-/m1/s1
DM7CIN4	CS	CC(C)(C)C1=C(C=C(C=C1)C(=O)N2[C@H]([C@H](C[C@@]2(CN3C=CC=N3)C(=O)O)COC)C4=NC=CS4)OC
DM7CIN4	IK	HLQXYDHLDZTWDW-KAWPREARSA-N
DM7CIN4	IU	(2R,4S,5R)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(methoxymethyl)-2-(pyrazol-1-ylmethyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid
DM7CIN4	CA	CAS 885264-71-1
DM7CIN4	DE	Hepatitis C virus infection

DMRBVHE	ID	DMRBVHE
DMRBVHE	DN	GSK690693
DMRBVHE	HS	Phase 1
DMRBVHE	SN	937174-76-0; GSK690693; GSK-690693; GSK 690693; UNII-GWH480321B; (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol; CHEBI:90677; GWH480321B; 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol; 4-{2-(4-Amino-1,2,5-Oxadiazol-3-Yl)-1-Ethyl-7-[(3s)-Piperidin-3-Ylmethoxy]-1h-Imidazo[4,5-C]pyridin-4-Yl}-2-Methylbut-3-Yn-2-Ol; J-502225; C21H27N7O3
DMRBVHE	TC	Anticancer Agents
DMRBVHE	DT	Small molecular drug
DMRBVHE	PC	16725726
DMRBVHE	MW	425.5
DMRBVHE	FM	C21H27N7O3
DMRBVHE	IC	InChI=1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27)/t13-/m0/s1
DMRBVHE	CS	CCN1C2=C(C(=NC=C2OC[C@H]3CCCNC3)C#CC(C)(C)O)N=C1C4=NON=C4N
DMRBVHE	IK	KGPGFQWBCSZGEL-ZDUSSCGKSA-N
DMRBVHE	IU	4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-piperidin-3-yl]methoxy]imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol
DMRBVHE	CA	CAS 937174-76-0
DMRBVHE	CB	CHEBI:90677
DMRBVHE	DE	Haematological malignancy

DM4LR0Y	ID	DM4LR0Y
DM4LR0Y	DN	GSK-958108
DM4LR0Y	HS	Phase 1
DM4LR0Y	CP	GlaxoSmithKline plc
DM4LR0Y	DE	Premature ejaculation

DMX2J57	ID	DMX2J57
DMX2J57	DN	GT103
DMX2J57	HS	Phase 1
DMX2J57	CP	Grid Therapeutics
DMX2J57	DT	Antibody
DMX2J57	DE	Non-small-cell lung cancer

DM20HS7	ID	DM20HS7
DM20HS7	DN	GTP-004
DM20HS7	HS	Phase 1
DM20HS7	CP	GT Biopharma Washington, DC
DM20HS7	DE	Myasthenia gravis

DM4T5LH	ID	DM4T5LH
DM4T5LH	DN	Guanosine
DM4T5LH	HS	Phase 1
DM4T5LH	DT	Small molecular drug
DM4T5LH	PC	135398635
DM4T5LH	MW	283.24
DM4T5LH	FM	C10H13N5O5
DM4T5LH	IC	InChI=1S/C10H13N5O5/c11-10-13-7-4(8(19)14-10)12-2-15(7)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)/t3-,5-,6-,9-/m1/s1
DM4T5LH	CS	C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N=C(NC2=O)N
DM4T5LH	IK	NYHBQMYGNKIUIF-UUOKFMHZSA-N
DM4T5LH	IU	2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DM4T5LH	CA	CAS 118-00-3
DM4T5LH	CB	CHEBI:16750

DMM1RB6	ID	DMM1RB6
DMM1RB6	DN	GW-328267
DMM1RB6	HS	Phase 1
DMM1RB6	SN	UNII-DJF621DE4F; DJF621DE4F; GW-328267; CHEMBL186113; GW328267; (S)-2-[[6-Amino-9-[4-(2-ethyl-2H-tetrazole-5-yl)-4-de(hydroxymethyl)-1-deoxy-beta-D-ribofuranose-1-yl]-9H-purine-2-yl]amino]-3-phenyl-1-propanol; (S)-2-((6-Amino-9-(4-(2-ethyl-2H-tetrazole-5-yl)-4-de(hydroxymethyl)-1-deoxy-beta-D-ribofuranose-1-yl)-9H-purine-2-yl)amino)-3-phenyl-1-propanol; SCHEMBL1979140; BDBM50150766; J2.047.755E
DMM1RB6	DT	Small molecular drug
DMM1RB6	PC	9869857
DMM1RB6	MW	482.5
DMM1RB6	FM	C21H26N10O4
DMM1RB6	IC	InChI=1S/C21H26N10O4/c1-2-31-28-18(27-29-31)16-14(33)15(34)20(35-16)30-10-23-13-17(22)25-21(26-19(13)30)24-12(9-32)8-11-6-4-3-5-7-11/h3-7,10,12,14-16,20,32-34H,2,8-9H2,1H3,(H3,22,24,25,26)/t12-,14-,15+,16-,20+/m0/s1
DMM1RB6	CS	CCN1N=C(N=N1)[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=C(N=C43)N[C@@H](CC5=CC=CC=C5)CO)N)O)O
DMM1RB6	IK	FLBKPDIBGNWXMT-NIQZGXKPSA-N
DMM1RB6	IU	(2R,3R,4S,5R)-2-[6-amino-2-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]purin-9-yl]-5-(2-ethyltetrazol-5-yl)oxolane-3,4-diol
DMM1RB6	CA	CAS 210237-78-8
DMM1RB6	DE	Allergic rhinitis

DMOE5SZ	ID	DMOE5SZ
DMOE5SZ	DN	GW-409544
DMOE5SZ	HS	Phase 1
DMOE5SZ	SN	GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo
DMOE5SZ	CP	Ligand Pharmaceuticals Inc
DMOE5SZ	DT	Small molecular drug
DMOE5SZ	PC	446642
DMOE5SZ	MW	510.6
DMOE5SZ	FM	C31H30N2O5
DMOE5SZ	IC	InChI=1S/C31H30N2O5/c1-21(19-29(34)24-9-5-3-6-10-24)32-28(31(35)36)20-23-13-15-26(16-14-23)37-18-17-27-22(2)38-30(33-27)25-11-7-4-8-12-25/h3-16,19,28,32H,17-18,20H2,1-2H3,(H,35,36)/b21-19-/t28-/m0/s1
DMOE5SZ	CS	CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H](C(=O)O)N/C(=C\\C(=O)C4=CC=CC=C4)/C
DMOE5SZ	IK	GGUVRMBIEPYOKL-WMVCGJOFSA-N
DMOE5SZ	IU	(2S)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-[[(Z)-4-oxo-4-phenylbut-2-en-2-yl]amino]propanoic acid
DMOE5SZ	CA	CAS 258345-41-4
DMOE5SZ	CB	CHEBI:79990
DMOE5SZ	DE	Hyperlipidaemia

DMBDW93	ID	DMBDW93
DMBDW93	DN	GW-695634
DMBDW93	HS	Phase 1
DMBDW93	SN	GW-5634; GW-5634 Na salt; GW-5634 sodium salt; GW-678248; GW-8248; GW-8635; Non-nucleoside reverse transcriptase inhibitor (hiv infection), GlaxoSmithKline; 678248; 695634
DMBDW93	CP	GlaxoSmithKline plc
DMBDW93	PC	9916697
DMBDW93	MW	574.4
DMBDW93	FM	C26H21Cl2N3O6S
DMBDW93	IC	InChI=1S/C26H21Cl2N3O6S/c1-3-24(32)31-38(35,36)20-5-6-22(15(2)8-20)30-25(33)14-37-23-7-4-18(27)12-21(23)26(34)17-9-16(13-29)10-19(28)11-17/h4-12H,3,14H2,1-2H3,(H,30,33)(H,31,32)
DMBDW93	CS	CCC(=O)NS(=O)(=O)C1=CC(=C(C=C1)NC(=O)COC2=C(C=C(C=C2)Cl)C(=O)C3=CC(=CC(=C3)C#N)Cl)C
DMBDW93	IK	GAQZNFUDILDDDI-UHFFFAOYSA-N
DMBDW93	IU	N-[4-[[2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonylpropanamide
DMBDW93	DE	Human immunodeficiency virus infection

DMQ46DN	ID	DMQ46DN
DMQ46DN	DN	GW-796406
DMQ46DN	HS	Phase 1
DMQ46DN	SN	N-[3-Methyl-2(S)-(sulfanylmethyl)butyryl]-4-(1H-pyrazol-1-yl)-L-phenylalanine; 796406
DMQ46DN	DE	Hypotension

DMGO6M1	ID	DMGO6M1
DMGO6M1	DN	GZ402666
DMGO6M1	HS	Phase 1
DMGO6M1	DE	Pompe disease; Type 2 glycogen storage disease

DME6VX4	ID	DME6VX4
DME6VX4	DN	GZ402668
DME6VX4	HS	Phase 1
DME6VX4	DT	Antibody
DME6VX4	DE	Multiple sclerosis

DMTWNLY	ID	DMTWNLY
DMTWNLY	DN	GZ402674
DMTWNLY	HS	Phase 1
DMTWNLY	CP	Sanofi
DMTWNLY	DE	Solid tumour/cancer

DMRCHOU	ID	DMRCHOU
DMRCHOU	DN	H-103
DMRCHOU	HS	Phase 1
DMRCHOU	SN	Oncolytic adenovirus (metastasis), Shanghai Sunway Biotech
DMRCHOU	CP	Shanghai Sunway Biotech Co Ltd
DMRCHOU	DE	Metastatic malignant neoplasm

DMAYTRK	ID	DMAYTRK
DMAYTRK	DN	H3B-6527
DMAYTRK	HS	Phase 1
DMAYTRK	SN	MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla
DMAYTRK	CP	EisaiWoodcliff Lake, NJH3 Biomedicine Cambridge, MA
DMAYTRK	PC	118029202
DMAYTRK	MW	629.5
DMAYTRK	FM	C29H34Cl2N8O4
DMAYTRK	IC	InChI=1S/C29H34Cl2N8O4/c1-6-25(40)35-20-14-18(39-12-10-38(7-2)11-13-39)8-9-19(20)34-23-16-24(33-17-32-23)37(3)29(41)36-28-26(30)21(42-4)15-22(43-5)27(28)31/h6,8-9,14-17H,1,7,10-13H2,2-5H3,(H,35,40)(H,36,41)(H,32,33,34)
DMAYTRK	CS	CCN1CCN(CC1)C2=CC(=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl)NC(=O)C=C
DMAYTRK	IK	MBWRLLRCTIYXDW-UHFFFAOYSA-N
DMAYTRK	IU	N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide
DMAYTRK	CA	CAS 1702259-66-2
DMAYTRK	DE	Hepatocellular carcinoma

DMMVXGR	ID	DMMVXGR
DMMVXGR	DN	H3B-8800
DMMVXGR	HS	Phase 1
DMMVXGR	SN	(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017
DMMVXGR	CP	H3 Biomedicine
DMMVXGR	DT	Small molecular drug
DMMVXGR	PC	92135969
DMMVXGR	MW	555.7
DMMVXGR	FM	C31H45N3O6
DMMVXGR	IC	InChI=1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1
DMMVXGR	CS	C[C@H]1/C=C/[C@@H]([C@](CC[C@H](CC(=O)O[C@@H]1/C(=C/C=C/[C@@H](C)C2=CC=CC=N2)/C)O)(C)O)OC(=O)N3CCN(CC3)C
DMMVXGR	IK	YOIQWBAHJZGRFW-WVRLKXNASA-N
DMMVXGR	IU	[(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-pyridin-2-ylhepta-2,4-dien-2-yl]-1-oxacyclododec-4-en-6-yl] 4-methylpiperazine-1-carboxylate
DMMVXGR	CA	CAS 1825302-42-8
DMMVXGR	DE	Myelodysplastic syndrome; Chronic myelomonocytic leukaemia; Acute myeloid leukaemia

DMHI8RS	ID	DMHI8RS
DMHI8RS	DN	HCBE-11
DMHI8RS	HS	Phase 1
DMHI8RS	CP	Biogen Inc
DMHI8RS	DT	Antibody
DMHI8RS	DE	Solid tumour/cancer

DMVRTCW	ID	DMVRTCW
DMVRTCW	DN	HDM201
DMVRTCW	HS	Phase 1
DMVRTCW	CP	Novartis pharmaceuticals
DMVRTCW	PC	71678098
DMVRTCW	MW	555.4
DMVRTCW	FM	C26H24Cl2N6O4
DMVRTCW	IC	InChI=1S/C26H24Cl2N6O4/c1-13(2)33-21-19(30-22(33)17-11-29-26(38-5)31-23(17)37-4)25(36)34(18-10-16(28)12-32(3)24(18)35)20(21)14-6-8-15(27)9-7-14/h6-13,20H,1-5H3/t20-/m0/s1
DMVRTCW	CS	CC(C)N1C2=C(C(=O)N([C@H]2C3=CC=C(C=C3)Cl)C4=CC(=CN(C4=O)C)Cl)N=C1C5=CN=C(N=C5OC)OC
DMVRTCW	IK	AGBSXNCBIWWLHD-FQEVSTJZSA-N
DMVRTCW	IU	(4S)-5-(5-chloro-1-methyl-2-oxopyridin-3-yl)-4-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4H-pyrrolo[3,4-d]imidazol-6-one
DMVRTCW	CA	CAS 1448867-41-1
DMVRTCW	DE	Haematological malignancy; Liposarcoma; Solid tumour/cancer

DMM7VOB	ID	DMM7VOB
DMM7VOB	DN	Hepapoietin
DMM7VOB	HS	Phase 1
DMM7VOB	SN	APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals
DMM7VOB	CP	SnowBrand Pharmaceuticals Inc
DMM7VOB	DE	Liver disease

DMBFYSR	ID	DMBFYSR
DMBFYSR	DN	Hepcidin mab
DMBFYSR	HS	Phase 1
DMBFYSR	CP	Eli Lilly
DMBFYSR	DT	Antibody
DMBFYSR	DE	Anemia

DMXETUQ	ID	DMXETUQ
DMXETUQ	DN	HER-2/HER-1 vaccine
DMXETUQ	HS	Phase 1
DMXETUQ	SN	HER-2/HER-1 vaccine (solid tumors)
DMXETUQ	CP	Ohio State University
DMXETUQ	DT	Vaccine
DMXETUQ	DE	Solid tumour/cancer

DMZXDBN	ID	DMZXDBN
DMZXDBN	DN	HER2-CAR T Cells
DMZXDBN	HS	Phase 1
DMZXDBN	CP	City of Hope Medical Center
DMZXDBN	DT	CAR T Cell Therapy
DMZXDBN	DE	Malignant neoplasm; Metastatic malignant neoplasm

DMJ52F9	ID	DMJ52F9
DMJ52F9	DN	HER2p63-71 peptide vaccine
DMJ52F9	HS	Phase 1
DMJ52F9	SN	Cancer vaccine, Mie University; HER2p63-71 peptide vaccine, Mie University; HER2p780-788 peptide vaccine, Mie University
DMJ52F9	CP	Mie University School of Medicine
DMJ52F9	DT	Vaccine
DMJ52F9	DE	Solid tumour/cancer

DMJKBWO	ID	DMJKBWO
DMJKBWO	DN	HER2-specific CAR T cell
DMJKBWO	HS	Phase 1
DMJKBWO	CP	Seattle Children's Hospital
DMJKBWO	DT	CAR T Cell Therapy
DMJKBWO	DE	Atypical teratoid/rhabdoid tumour; Choroid plexus carcinoma; Ependymoma; Germ cell tumour; Glioma; Medulloblastoma; Pineoblastoma; Gastric adenocarcinoma

DM7UJ6E	ID	DM7UJ6E
DM7UJ6E	DN	HER2-specific T cells
DM7UJ6E	HS	Phase 1
DM7UJ6E	CP	Baylor College of Medicine
DM7UJ6E	DT	CAR T Cell Therapy
DM7UJ6E	DE	Recurrent glioblastoma

DMDZQ23	ID	DMDZQ23
DMDZQ23	DN	HF-0299
DMDZQ23	HS	Phase 1
DMDZQ23	CP	St Marianna University School of Medicine
DMDZQ23	DE	Pain

DMS9WXG	ID	DMS9WXG
DMS9WXG	DN	HGS-1029
DMS9WXG	HS	Phase 1
DMS9WXG	SN	AEG-40056; AEG-40057; AEG-40706; AEG-40730; AEG-40826; XIAP antagonists (anticancer), Aegera; Inhibitor of apoptosis (IAP) protein antagonists (cancer), Aegera/HGS; XIAP antagonists (small molecule, cancer), Aegera/HGS; Inhibitory apoptosis protein (IAP) antagonists (apoptosis stimulators, cancer), Aegera/HGS
DMS9WXG	CP	Aegera Therapeutics Inc
DMS9WXG	DE	Haematological malignancy; Solid tumour/cancer

DMQIE58	ID	DMQIE58
DMQIE58	DN	HH2853
DMQIE58	HS	Phase 1
DMQIE58	CP	HaiHe Biopharma
DMQIE58	DT	Small molecular drug
DMQIE58	DE	Non-hodgkin lymphoma; Solid tumour/cancer

DMRQ4L6	ID	DMRQ4L6
DMRQ4L6	DN	HHCYH33
DMRQ4L6	HS	Phase 1
DMRQ4L6	SN	CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate
DMRQ4L6	CP	HaiHe Biopharma
DMRQ4L6	DT	Small molecular drug
DMRQ4L6	PC	72550012
DMRQ4L6	MW	598.6
DMRQ4L6	FM	C24H29F3N8O5S
DMRQ4L6	IC	InChI=1S/C24H29F3N8O5S/c1-39-23(36)29-20-12-18(24(25,26)27)17(13-28-20)21-30-22(33-7-9-40-10-8-33)19-11-16(15-35(19)31-21)14-32-3-5-34(6-4-32)41(2,37)38/h11-13,15H,3-10,14H2,1-2H3,(H,28,29,36)
DMRQ4L6	CS	COC(=O)NC1=NC=C(C(=C1)C(F)(F)F)C2=NN3C=C(C=C3C(=N2)N4CCOCC4)CN5CCN(CC5)S(=O)(=O)C
DMRQ4L6	IK	KTLQDDGRBDLKMN-UHFFFAOYSA-N
DMRQ4L6	IU	methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate
DMRQ4L6	CA	CAS 1494684-28-4
DMRQ4L6	DE	Breast cancer

DM45MR0	ID	DM45MR0
DM45MR0	DN	HIP-2B
DM45MR0	HS	Phase 1
DM45MR0	CP	CureDM
DM45MR0	DE	Type-1/2 diabetes; Type-2 diabetes

DMT3HKZ	ID	DMT3HKZ
DMT3HKZ	DN	HL-018
DMT3HKZ	HS	Phase 1
DMT3HKZ	CP	HanAll Biopharma Co Ltd
DMT3HKZ	DE	Diabetic complication

DME4D7H	ID	DME4D7H
DME4D7H	DN	HM71224
DME4D7H	HS	Phase 1
DME4D7H	SN	Poseltinib; 1353552-97-2; UNII-D01E4B1U35; D01E4B1U35; LY3337641; N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Poseltinib [INN]; GTPL9862; CHEMBL4163691; SCHEMBL14915064; BDBM50369724; BS-15248; HM-71224; LY333764; Example 228 [WO2011162515A2]; HY-109010; CS-0030508; Q27275916; 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-; N-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
DME4D7H	CP	Hanmi Pharmaceutical
DME4D7H	DT	Small molecular drug
DME4D7H	PC	56644522
DME4D7H	MW	470.5
DME4D7H	FM	C26H26N6O3
DME4D7H	IC	InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
DME4D7H	CS	CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)OC=C4
DME4D7H	IK	LZMJNVRJMFMYQS-UHFFFAOYSA-N
DME4D7H	IU	N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
DME4D7H	CA	CAS 1353552-97-2
DME4D7H	DE	Rheumatoid arthritis

DMXZ1A8	ID	DMXZ1A8
DMXZ1A8	DN	HMPL-523
DMXZ1A8	HS	Phase 1
DMXZ1A8	CP	Hutchison MediPharma
DMXZ1A8	DT	Small molecular drug
DMXZ1A8	DE	Non-hodgkin lymphoma

DMEGN5I	ID	DMEGN5I
DMEGN5I	DN	HMPL-689
DMEGN5I	HS	Phase 1
DMEGN5I	CP	Hutchison MediPharma
DMEGN5I	DT	Small molecular drug
DMEGN5I	DE	Lymphoma

DM695QT	ID	DM695QT
DM695QT	DN	HMR-1031
DM695QT	HS	Phase 1
DM695QT	SN	MDL-819767; 3(S)-[2(S)-[4,4-Dimethyl-3-[4-[3-(2-methylphenyl)ureido]benzyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoylamino]-3-phenylpropionic acid
DM695QT	PC	9809368
DM695QT	MW	627.7
DM695QT	FM	C35H41N5O6
DM695QT	IC	InChI=1S/C35H41N5O6/c1-22(2)19-29(31(43)37-28(20-30(41)42)25-12-7-6-8-13-25)40-32(44)35(4,5)39(34(40)46)21-24-15-17-26(18-16-24)36-33(45)38-27-14-10-9-11-23(27)3/h6-18,22,28-29H,19-21H2,1-5H3,(H,37,43)(H,41,42)(H2,36,38,45)/t28-,29-/m0/s1
DM695QT	CS	CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CN3C(=O)N(C(=O)C3(C)C)[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C4=CC=CC=C4
DM695QT	IK	OPZVCXYTOHAOHN-VMPREFPWSA-N
DM695QT	IU	(3S)-3-[[(2S)-2-[4,4-dimethyl-3-[[4-[(2-methylphenyl)carbamoylamino]phenyl]methyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoyl]amino]-3-phenylpropanoic acid
DM695QT	CA	CAS 479203-71-9
DM695QT	DE	Arthritis

DMRYM03	ID	DMRYM03
DMRYM03	DN	HMS5552
DMRYM03	HS	Phase 1
DMRYM03	SN	Dorzagliatin; UNII-X59W6980E8; X59W6980E8; 1191995-00-2; Sinogliatin; RO5305552; Dorzagliatin [INN]; Dorzagliatin [USAN:INN]; SCHEMBL1079619; HMUMWSORCUWQJO-QAPCUYQASA-N; HMS-5552; AKOS030527745; RO-5305552; (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5; (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R; (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amide; (2S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1
DMRYM03	CP	Hua Medicine Shanghai, China
DMRYM03	PC	57920094
DMRYM03	MW	462.9
DMRYM03	FM	C22H27ClN4O5
DMRYM03	IC	InChI=1S/C22H27ClN4O5/c1-14(2)9-18(22(31)24-20-7-8-26(25-20)11-15(29)13-28)27-12-16(10-21(27)30)32-19-6-4-3-5-17(19)23/h3-8,10,14-15,18,28-29H,9,11-13H2,1-2H3,(H,24,25,31)/t15-,18+/m1/s1
DMRYM03	CS	CC(C)C[C@@H](C(=O)NC1=NN(C=C1)C[C@H](CO)O)N2CC(=CC2=O)OC3=CC=CC=C3Cl
DMRYM03	IK	HMUMWSORCUWQJO-QAPCUYQASA-N
DMRYM03	IU	(2S)-2-[3-(2-chlorophenoxy)-5-oxo-2H-pyrrol-1-yl]-N-[1-[(2R)-2,3-dihydroxypropyl]pyrazol-3-yl]-4-methylpentanamide
DMRYM03	CA	CAS 1191995-00-2
DMRYM03	DE	Type-2 diabetes

DMI0KQW	ID	DMI0KQW
DMI0KQW	DN	HPN217
DMI0KQW	HS	Phase 1
DMI0KQW	CP	AbbVie
DMI0KQW	DE	Multiple myeloma

DMLZDVR	ID	DMLZDVR
DMLZDVR	DN	HPN424
DMLZDVR	HS	Phase 1
DMLZDVR	CP	Harpoon Therapeutics
DMLZDVR	DE	Prostate cancer

DMUEZ7V	ID	DMUEZ7V
DMUEZ7V	DN	HPP404
DMUEZ7V	HS	Phase 1
DMUEZ7V	CP	TransTech Pharma Inc
DMUEZ7V	DE	Allergic rhinitis

DM5VSZR	ID	DM5VSZR
DM5VSZR	DN	HPP-607
DM5VSZR	HS	Phase 1
DM5VSZR	CP	TransTech Pharma Inc
DM5VSZR	DE	Solid tumour/cancer

DMSLDHG	ID	DMSLDHG
DMSLDHG	DN	HPP-854
DMSLDHG	HS	Phase 1
DMSLDHG	CP	High Point Pharmaceuticals
DMSLDHG	DE	Alzheimer disease

DMZXG7Q	ID	DMZXG7Q
DMZXG7Q	DN	HPP971
DMZXG7Q	HS	Phase 1
DMZXG7Q	SN	ANT 401
DMZXG7Q	CP	vTv Therapeutics
DMZXG7Q	DT	Small molecular drug
DMZXG7Q	DE	Non-alcoholic steatohepatitis

DMJG4WR	ID	DMJG4WR
DMJG4WR	DN	HSDB-674
DMJG4WR	HS	Phase 1
DMJG4WR	SN	Alcool butylique secondaire; Butan-2-ol; Butanol secondaire; Butanol secondaire [French]; Butanol-2; Butyl alcohol, sec-; Butylene hydrate; Ethyl methyl carbinol; Ethylmethyl carbinol; Methyl ethyl carbinol; Methylethyl carbinol; Methylethylcarbinol; R-(-)-2-Butanol; SEC-BUTYL ALCOHOL; n-Butan-2-ol; s-Butanol; s-Butyl alcohol; sec-Butanol; sec-C4H9OH; 1-Methyl propanol; 1-Methyl-1-propanol; 1-Methylpropyl alcohol; 2-Butanol; 2-Butanol (natural); 2-Butyl alcohol; 2-Hydroxybutane; 78-92-2; CCS 301; Caswell No. 119C; NSC 25499
DMJG4WR	PC	6568
DMJG4WR	MW	74.12
DMJG4WR	FM	C4H10O
DMJG4WR	IC	BTANRVKWQNVYAZ-UHFFFAOYSA-N
DMJG4WR	CS	CCC(C)O
DMJG4WR	IK	1S/C4H10O/c1-3-4(2)5/h4-5H,3H2,1-2H3
DMJG4WR	IU	butan-2-ol
DMJG4WR	CA	CAS 78-92-2
DMJG4WR	CB	CHEBI:35687
DMJG4WR	DE	Rheumatoid arthritis

DML6HP3	ID	DML6HP3
DML6HP3	DN	HSP-990
DML6HP3	HS	Phase 1
DML6HP3	SN	NVP-HSP990; 934343-74-5; HSP-990; UNII-E0WBA7B62L; HSP990 (NVP-HSP990); E0WBA7B62L; HSP990; NVP-HSP990(HSP990); SCHEMBL1351184; CHEMBL3360305; (7r)-2-Amino-7-[4-Fluoro-2-(6-Methoxypyridin-2-Yl)phenyl]-4-Methyl-7,8-Dihydropyrido[4,3-D]pyrimidin-5(6h)-One; NVP-HSP-990; HSP990 (NVP-HSP); NVP-HSP990,HSP990; DTXSID50239429; MolPort-023-219-119; 4u93; HSP990, NVP-HSP990; EX-A1560; AOB87737; NVP-HSP990 (HSP990); ZINC60329723; 2608AH; s7097; BDBM50031735; AKOS025404948; CS-3941; SB16642; BCP9001013
DML6HP3	CP	Novartis AG
DML6HP3	DT	Small molecular drug
DML6HP3	PC	46216556
DML6HP3	MW	379.4
DML6HP3	FM	C20H18FN5O2
DML6HP3	IC	InChI=1S/C20H18FN5O2/c1-10-18-16(26-20(22)23-10)9-15(25-19(18)27)12-7-6-11(21)8-13(12)14-4-3-5-17(24-14)28-2/h3-8,15H,9H2,1-2H3,(H,25,27)(H2,22,23,26)/t15-/m1/s1
DML6HP3	CS	CC1=C2C(=NC(=N1)N)C[C@@H](NC2=O)C3=C(C=C(C=C3)F)C4=NC(=CC=C4)OC
DML6HP3	IK	WSMQUUGTQYPVPD-OAHLLOKOSA-N
DML6HP3	IU	(7R)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one
DML6HP3	CA	CAS 934343-74-5
DML6HP3	DE	Solid tumour/cancer

DMI4TEC	ID	DMI4TEC
DMI4TEC	DN	HTI-1090
DMI4TEC	HS	Phase 1
DMI4TEC	SN	SHR9146
DMI4TEC	CP	Atridia; Hengrui Therapeutics
DMI4TEC	DT	Small molecular drug
DMI4TEC	DE	Solid tumour/cancer

DMB3LQU	ID	DMB3LQU
DMB3LQU	DN	HuA33
DMB3LQU	HS	Phase 1
DMB3LQU	SN	CDP-833; A33-radionuclides, American Cyanamid; A33-radionuclides, Celltech; HuA33, Ludwig Institute for Cancer Research/Life Science Pharmaceuticals
DMB3LQU	CP	UCB Celltech
DMB3LQU	DT	Antibody
DMB3LQU	DE	Colorectal cancer

DM9VB4I	ID	DM9VB4I
DM9VB4I	DN	Hu-CART meso cells
DM9VB4I	HS	Phase 1
DM9VB4I	CP	University of Pennsylvania
DM9VB4I	DT	CAR T Cell Therapy
DM9VB4I	DE	Fallopian tube cancer; Lung cancer; Ovarian cancer; Peritoneal mesothelioma; Pleural mesothelioma

DMNAR29	ID	DMNAR29
DMNAR29	DN	HuCART19
DMNAR29	HS	Phase 1
DMNAR29	CP	University of Pennsylvania
DMNAR29	DT	CAR T Cell Therapy
DMNAR29	DE	leukaemia; Lymphoma

DM4F8AU	ID	DM4F8AU
DM4F8AU	DN	HuCART-meso cells
DM4F8AU	HS	Phase 1
DM4F8AU	CP	University of Pennsylvania
DM4F8AU	DT	CAR T Cell Therapy
DM4F8AU	DE	Lymphatic disease; Pancreatic cancer; Pediatric cancer

DMDZBTY	ID	DMDZBTY
DMDZBTY	DN	HuM195/rGel
DMDZBTY	HS	Phase 1
DMDZBTY	SN	HuM195/rGel, MD Anderson; Conjugated anti-CD33 antibodies (cancer), MD Anderson; HuM195-gelonin immunotoxin (leukemia), Targa Therapeutics; HuM195/rGel (leukemia), Targa Therapeutics; Anti-CD33 immunotoxin (leukemia), Memorial Sloan-Kettering; HuM195-gelonin immunotoxin, Memorial Sloan-Kettering/MD Anderson; HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome); HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome), Targa Therapeutics; HuM195/rGel (intravenous infusion, acute myelogenous leukemia/chronic myelogenous leukemia/meylodisplastic syndrome), Targa Therapeutics
DMDZBTY	CP	Targa therapeutics
DMDZBTY	DT	Antibody
DMDZBTY	DE	leukaemia

DM0W275	ID	DM0W275
DM0W275	DN	Human CD19 targeted T Cells
DM0W275	HS	Phase 1
DM0W275	CP	Hrain Biotechnology Co., Ltd.
DM0W275	DT	CAR T Cell Therapy
DM0W275	DE	Follicular lymphoma; Diffuse large B-cell lymphoma

DMVGBA1	ID	DMVGBA1
DMVGBA1	DN	HuMNC2-CAR44 T cells
DMVGBA1	HS	Phase 1
DMVGBA1	CP	Minerva Biotechnologies
DMVGBA1	DT	CAR T Cell Therapy
DMVGBA1	DE	Breast cancer

DMFRM15	ID	DMFRM15
DMFRM15	DN	HX-100
DMFRM15	HS	Phase 1
DMFRM15	CP	Hydra Biosciences Cambridge, MA
DMFRM15	DE	Diabetic neuropathy

DMRE6UT	ID	DMRE6UT
DMRE6UT	DN	IBC-VS01
DMRE6UT	HS	Phase 1
DMRE6UT	CP	Orban Biotech
DMRE6UT	DE	Type-1 diabetes

DMXUJ1P	ID	DMXUJ1P
DMXUJ1P	DN	IBI188
DMXUJ1P	HS	Phase 1
DMXUJ1P	CP	Innovent Biologics
DMXUJ1P	DT	Antibody
DMXUJ1P	DE	Myelodysplastic syndrome

DMYBHIR	ID	DMYBHIR
DMYBHIR	DN	IBI-20089
DMYBHIR	HS	Phase 1
DMYBHIR	CP	Icon Bioscience Sunnyvale, CA
DMYBHIR	DE	Diabetic macular edema

DMB83V4	ID	DMB83V4
DMB83V4	DN	IBI318
DMB83V4	HS	Phase 1
DMB83V4	CP	Innovent Biologics
DMB83V4	DT	Antibody
DMB83V4	DE	Non-small cell lung cancer

DMHS29U	ID	DMHS29U
DMHS29U	DN	Iboctadekin
DMHS29U	HS	Phase 1
DMHS29U	CP	GlaxoSmithKline
DMHS29U	DE	Ovarian cancer; Non-hodgkin lymphoma

DMW1ZAM	ID	DMW1ZAM
DMW1ZAM	DN	Iboctadekin + Doxil
DMW1ZAM	HS	Phase 1
DMW1ZAM	CP	GSK
DMW1ZAM	DT	Combination drug
DMW1ZAM	PC	5478883; 31703
DMW1ZAM	DE	Ovarian cancer

DMZCBMS	ID	DMZCBMS
DMZCBMS	DN	Iboctadekin + Rituximab
DMZCBMS	HS	Phase 1
DMZCBMS	SN	Pepstatin A; 26305-03-3; Pepstatine; Ahpatinin C; UNII-V6Y2T27Q1U; MLS002222329; Iva-Val-Val-Sta-Ala-Sta-OH; V6Y2T27Q1U; CHEMBL296588; 39324-30-6; FAXGPCHRFPCXOO-LXTPJMTPSA-N; C34H63N5O9; NCGC00161670-06; Pepstatin (nonspecific); DSSTox_RID_81334; DSSTox_CID_26095; DSSTox_GSID_46095; CCRIS 3603; Pepstatina; Pepstatinum; Pepstatin (VAN); Ia Quinidine
DMZCBMS	CP	GSK
DMZCBMS	DT	Combination drug (Antibody)
DMZCBMS	DE	Follicular lymphoma; Non-hodgkin lymphoma; Atrial fibrillation

DMMPFZO	ID	DMMPFZO
DMMPFZO	DN	IC9.GD2.CAR.IL-15 T-cells
DMMPFZO	HS	Phase 1
DMMPFZO	CP	UNC Lineberger Comprehensive Cancer Center
DMMPFZO	DT	CAR T Cell Therapy
DMMPFZO	DE	Neuroblastoma

DMP1ZF8	ID	DMP1ZF8
DMP1ZF8	DN	IC9-CAR19 cells
DMP1ZF8	HS	Phase 1
DMP1ZF8	CP	UNC Lineberger Comprehensive Cancer Center
DMP1ZF8	DT	CAR T Cell Therapy
DMP1ZF8	DE	Acute lymphoblastic leukaemia; Immune System disease; Immunoproliferative disorder

DMNCBIU	ID	DMNCBIU
DMNCBIU	DN	IC9-CAR19 T cells
DMNCBIU	HS	Phase 1
DMNCBIU	CP	UNC Lineberger Comprehensive Cancer Center
DMNCBIU	DT	CAR T Cell Therapy
DMNCBIU	DE	B-cell lymphoma; Immune System disease; Immunoproliferative disorder; Lymphoma

DMRYHWA	ID	DMRYHWA
DMRYHWA	DN	IC9-GD2-CD28-OX40
DMRYHWA	HS	Phase 1
DMRYHWA	CP	Baylor College of Medicine
DMRYHWA	DT	CAR T Cell Therapy
DMRYHWA	DE	Neuroblastoma

DMHG4Q9	ID	DMHG4Q9
DMHG4Q9	DN	ICAR19 CAR-T cells
DMHG4Q9	HS	Phase 1
DMHG4Q9	CP	Immune Cell, Inc.
DMHG4Q9	DT	CAR T Cell Therapy
DMHG4Q9	DE	B-cell lymphoma; leukaemia

DM3YZCV	ID	DM3YZCV
DM3YZCV	DN	ICAR30 T cells
DM3YZCV	HS	Phase 1
DM3YZCV	CP	Immune Cell, Inc.
DM3YZCV	DT	CAR T Cell Therapy
DM3YZCV	DE	Anaplastic large cell lymphoma; Hodgkin lymphoma

DMY6V5T	ID	DMY6V5T
DMY6V5T	DN	ICasp9M28z T cell
DMY6V5T	HS	Phase 1
DMY6V5T	CP	Memorial Sloan Kettering Cancer Center
DMY6V5T	DT	CAR T Cell Therapy
DMY6V5T	DE	Lung cancer; Malignant pleural effusion; Mesothelioma; Metastatic malignant neoplasm

DM79W8K	ID	DM79W8K
DM79W8K	DN	ICo-007
DM79W8K	HS	Phase 1
DM79W8K	CP	ISIS Pharm; iCo Therapeutics
DM79W8K	TC	Antisense
DM79W8K	DT	Antisense drug
DM79W8K	DE	Diabetic retinopathy; Diabetic macular edema

DM64LVS	ID	DM64LVS
DM64LVS	DN	ICT-121
DM64LVS	HS	Phase 1
DM64LVS	CP	Immunocellular therapeutics
DM64LVS	DT	Vaccine
DM64LVS	DE	Solid tumour/cancer; Recurrent glioblastoma

DMNWPMO	ID	DMNWPMO
DMNWPMO	DN	IDH305
DMNWPMO	HS	Phase 1
DMNWPMO	SN	DCGDPJCUIKLTDU-SUNYJGFJSA-N; IDH-305; 1628805-46-8; UNII-A791KH7YZW; A791KH7YZW; CHEMBL3947537; SCHEMBL16045032; BDBM247859; CS-8084; HY-104036; US9434719, 466; (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one; (4R)-4-[(1S)-1-fluoroethyl]-3-[2-({(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl}amino)pyrimidin-4-yl]-1,3-oxazolidin-2-one; C81
DMNWPMO	CP	Novartis Oncology East Hanover, NJ
DMNWPMO	PC	90415637
DMNWPMO	MW	490.5
DMNWPMO	FM	C23H22F4N6O2
DMNWPMO	IC	InChI=1S/C23H22F4N6O2/c1-12-8-17(30-10-16(12)15-4-6-28-19(9-15)23(25,26)27)14(3)31-21-29-7-5-20(32-21)33-18(13(2)24)11-35-22(33)34/h4-10,13-14,18H,11H2,1-3H3,(H,29,31,32)/t13-,14-,18+/m0/s1
DMNWPMO	CS	CC1=CC(=NC=C1C2=CC(=NC=C2)C(F)(F)F)[C@H](C)NC3=NC=CC(=N3)N4[C@H](COC4=O)[C@H](C)F
DMNWPMO	IK	DCGDPJCUIKLTDU-SUNYJGFJSA-N
DMNWPMO	IU	(4R)-4-[(1S)-1-fluoroethyl]-3-[2-[[(1S)-1-[4-methyl-5-[2-(trifluoromethyl)pyridin-4-yl]pyridin-2-yl]ethyl]amino]pyrimidin-4-yl]-1,3-oxazolidin-2-one
DMNWPMO	CA	CAS 1628805-46-8
DMNWPMO	DE	Advanced malignancy

DM1RNT7	ID	DM1RNT7
DM1RNT7	DN	IDR-1018
DM1RNT7	HS	Phase 1
DM1RNT7	SN	IMX-003 series; Innate defense regulators (bacterial infection), Inimex
DM1RNT7	CP	Inimex Pharmaceuticals Inc
DM1RNT7	DE	Bacterial infection

DMYG3PZ	ID	DMYG3PZ
DMYG3PZ	DN	IDX-189
DMYG3PZ	HS	Phase 1
DMYG3PZ	CP	Idenix
DMYG3PZ	DE	Hepatitis C virus infection

DMMPINS	ID	DMMPINS
DMMPINS	DN	IGM-2323
DMMPINS	HS	Phase 1
DMMPINS	CP	IGM Biosciences
DMMPINS	DT	Antibody
DMMPINS	DE	Non-hodgkin lymphoma

DMFJXDZ	ID	DMFJXDZ
DMFJXDZ	DN	IGM-8444
DMFJXDZ	HS	Phase 1
DMFJXDZ	CP	IGM Biosciences
DMFJXDZ	DT	Antibody
DMFJXDZ	DE	Solid tumour/cancer; Hematologic tumour

DM1MY26	ID	DM1MY26
DM1MY26	DN	IGN523
DM1MY26	HS	Phase 1
DM1MY26	CP	Igenica
DM1MY26	DT	Antibody
DM1MY26	DE	Acute myeloid leukaemia

DMDU54Y	ID	DMDU54Y
DMDU54Y	DN	IK-175
DMDU54Y	HS	Phase 1
DMDU54Y	CP	Ikena Oncology
DMDU54Y	DT	Small molecular drug
DMDU54Y	DE	Urothelial carcinoma

DMQ01MP	ID	DMQ01MP
DMQ01MP	DN	ILV-095
DMQ01MP	HS	Phase 1
DMQ01MP	SN	PF-05212368, WAY-264095
DMQ01MP	CP	Wyeth; pfizer
DMQ01MP	DT	Antibody
DMQ01MP	DE	Psoriasis vulgaris

DM4MY9C	ID	DM4MY9C
DM4MY9C	DN	IM156
DM4MY9C	HS	Phase 1
DM4MY9C	CP	ImmunoMetHouston, TX
DM4MY9C	DE	Solid tumour/cancer

DM43X0Q	ID	DM43X0Q
DM43X0Q	DN	IM19
DM43X0Q	HS	Phase 1
DM43X0Q	CP	Beijing Immunochina Medical Science &amp; Technology Co., Ltd.
DM43X0Q	DT	CAR T Cell Therapy
DM43X0Q	DE	Haematological malignancy; Non-hodgkin lymphoma

DMTNYIB	ID	DMTNYIB
DMTNYIB	DN	IM21 CART
DMTNYIB	HS	Phase 1
DMTNYIB	CP	Peking Union Medical College Hospital
DMTNYIB	DT	CAR T Cell Therapy
DMTNYIB	DE	Multiple myeloma

DML5O7T	ID	DML5O7T
DML5O7T	DN	IM23
DML5O7T	HS	Phase 1
DML5O7T	CP	Beijing Immunochina Medical Science &amp; Technology Co., Ltd.
DML5O7T	DT	CAR T Cell Therapy
DML5O7T	DE	Acute myeloid leukaemia

DMD9U5Q	ID	DMD9U5Q
DMD9U5Q	DN	IMA 203
DMD9U5Q	HS	Phase 1
DMD9U5Q	CP	Immatics
DMD9U5Q	DT	Cell therapy
DMD9U5Q	DE	Solid tumour/cancer; Hematologic tumour

DMWSI04	ID	DMWSI04
DMWSI04	DN	IMC-002
DMWSI04	HS	Phase 1
DMWSI04	CP	ImmuneOncia Therapeutics
DMWSI04	DT	Antibody
DMWSI04	DE	Lymphoma; Solid tumour/cancer

DMXI5ON	ID	DMXI5ON
DMXI5ON	DN	IMC-3C5
DMXI5ON	HS	Phase 1
DMXI5ON	DE	Solid tumour/cancer

DMUYN26	ID	DMUYN26
DMUYN26	DN	IMC-CS4
DMUYN26	HS	Phase 1
DMUYN26	DE	Solid tumour/cancer

DMCZQNJ	ID	DMCZQNJ
DMCZQNJ	DN	IMC-EB10
DMCZQNJ	HS	Phase 1
DMCZQNJ	SN	Anti-Flt-3 Mab
DMCZQNJ	CP	Eli Lilly
DMCZQNJ	DT	Antibody
DMCZQNJ	DE	Acute myeloid leukaemia

DMOFSLE	ID	DMOFSLE
DMOFSLE	DN	IMD-0354
DMOFSLE	HS	Phase 1
DMOFSLE	SN	IMD-2560; IMD-2560); I-kappaB kinase beta inhibitor (dermatological, atopic dermatitis/acne), Institute of Medicinal MolecularDesign; I-kappaB kinase beta inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD; IKK-beta inhibitor (dermatological, atopic dermatitis/acne), IMMD; IL-6 release inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD
DMOFSLE	CP	Institute of Medicinal Molecular Design Inc
DMOFSLE	DT	Small molecular drug
DMOFSLE	PC	5081913
DMOFSLE	MW	383.67
DMOFSLE	FM	C15H8ClF6NO2
DMOFSLE	IC	InChI=1S/C15H8ClF6NO2/c16-9-1-2-12(24)11(6-9)13(25)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6,24H,(H,23,25)
DMOFSLE	CS	C1=CC(=C(C=C1Cl)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)O
DMOFSLE	IK	CHILCFMQWMQVAL-UHFFFAOYSA-N
DMOFSLE	IU	N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide
DMOFSLE	CA	CAS 978-62-1
DMOFSLE	CB	CHEBI:93310
DMOFSLE	DE	Acne vulgaris

DMUVLC4	ID	DMUVLC4
DMUVLC4	DN	IMGC936
DMUVLC4	HS	Phase 1
DMUVLC4	CP	ImmunoGen; MacroGenics
DMUVLC4	DT	Antibody drug conjugate
DMUVLC4	DE	Solid tumour/cancer

DMT9MHE	ID	DMT9MHE
DMT9MHE	DN	IMGN289
DMT9MHE	HS	Phase 1
DMT9MHE	CP	Immunogen
DMT9MHE	DE	Solid tumour/cancer

DMSYB83	ID	DMSYB83
DMSYB83	DN	IMGN-388
DMSYB83	HS	Phase 1
DMSYB83	SN	Intetumumab-DM4; CNTO-95-DM4; Integrin-targeting antibody (TAP), Centocor; Integrin-targeting antibody (TAP), ImmunoGen
DMSYB83	CP	Centocor Ortho Biotech Inc
DMSYB83	DT	Antibody
DMSYB83	DE	Solid tumour/cancer

DMR8OG2	ID	DMR8OG2
DMR8OG2	DN	IMGN-853
DMR8OG2	HS	Phase 1
DMR8OG2	SN	HuFR107-SPDB-DM4; FOLR1-targeting DM4 conjugates (cancer), Immunogen
DMR8OG2	CP	Immunogen
DMR8OG2	DE	Solid tumour/cancer

DMTFUM4	ID	DMTFUM4
DMTFUM4	DN	IMMU-114
DMTFUM4	HS	Phase 1
DMTFUM4	SN	HLA-DR mAb (cancer), Immunomedics
DMTFUM4	CP	Immunomedics
DMTFUM4	DT	Antibody
DMTFUM4	DE	leukaemia; Haematological malignancy

DMEHWPC	ID	DMEHWPC
DMEHWPC	DN	IMO-9200
DMEHWPC	HS	Phase 1
DMEHWPC	CP	Idera Pharmaceuticals Cambridge, MA
DMEHWPC	DE	Autoimmune disease

DMXSMF9	ID	DMXSMF9
DMXSMF9	DN	IMP-701
DMXSMF9	HS	Phase 1
DMXSMF9	SN	Anti-membrane bound LAG-3 monoclonal antibody (cancer, infectious disease), Immutep
DMXSMF9	CP	Immutep SA
DMXSMF9	DT	Antibody
DMXSMF9	DE	Solid tumour/cancer

DMPXOVA	ID	DMPXOVA
DMPXOVA	DN	IN10018
DMPXOVA	HS	Phase 1
DMPXOVA	CP	InxMed
DMPXOVA	DT	Small molecular drug
DMPXOVA	DE	Metastatic melanoma

DMCQTLG	ID	DMCQTLG
DMCQTLG	DN	INB03
DMCQTLG	HS	Phase 1
DMCQTLG	CP	INmune Bio
DMCQTLG	DT	Protein
DMCQTLG	DE	Solid tumour/cancer

DM2FH10	ID	DM2FH10
DM2FH10	DN	INBRX-105
DM2FH10	HS	Phase 1
DM2FH10	CP	Inhibrx
DM2FH10	DT	Antibody
DM2FH10	DE	Solid tumour/cancer

DMUNSPI	ID	DMUNSPI
DMUNSPI	DN	INBRX-109
DMUNSPI	HS	Phase 1
DMUNSPI	CP	Inhibrx
DMUNSPI	DT	Antibody drug conjugate
DMUNSPI	DE	Solid tumour/cancer

DMDSZNC	ID	DMDSZNC
DMDSZNC	DN	INCAGN2385
DMDSZNC	HS	Phase 1
DMDSZNC	CP	Agenis; Incyte
DMDSZNC	DT	Antibody
DMDSZNC	DE	Melanoma

DM5SO1T	ID	DM5SO1T
DM5SO1T	DN	INCAGN2390
DM5SO1T	HS	Phase 1
DM5SO1T	CP	Agenis; Incyte
DM5SO1T	DT	Antibody
DM5SO1T	DE	Solid tumour/cancer

DMW7CLY	ID	DMW7CLY
DMW7CLY	DN	INCB15050
DMW7CLY	HS	Phase 1
DMW7CLY	CP	Incyte
DMW7CLY	DE	Human immunodeficiency virus infection

DMFOXGB	ID	DMFOXGB
DMFOXGB	DN	INCB81776
DMFOXGB	HS	Phase 1
DMFOXGB	SN	INCB081776
DMFOXGB	CP	Incyte
DMFOXGB	DT	Small molecular drug
DMFOXGB	DE	Solid tumour/cancer

DM5WCBM	ID	DM5WCBM
DM5WCBM	DN	ING-1
DM5WCBM	HS	Phase 1
DM5WCBM	DT	Antibody
DM5WCBM	DE	Solid tumour/cancer

DM601GL	ID	DM601GL
DM601GL	DN	INNO-105
DM601GL	HS	Phase 1
DM601GL	SN	Opioid growth factor (cancer), Innovive/Penn State; (MEt5)-enkephalin (cancer), Innovive/Penn State
DM601GL	CP	Pennsylvania State University
DM601GL	DE	Solid tumour/cancer

DMG6S8U	ID	DMG6S8U
DMG6S8U	DN	INNO-305
DMG6S8U	HS	Phase 1
DMG6S8U	CP	CytRx
DMG6S8U	DE	Lung cancer; Acute myeloid leukaemia

DM90P1K	ID	DM90P1K
DM90P1K	DN	INO-3401
DM90P1K	HS	Phase 1
DM90P1K	SN	DNA vaccine (intradermal Cellectra electroporation, H5N1 influenza), Inovio
DM90P1K	CP	Inovio pharmaceuticals
DM90P1K	DT	Vaccine
DM90P1K	DE	Influenza A virus H5N1 infection

DMP6I9T	ID	DMP6I9T
DMP6I9T	DN	INO-3510
DMP6I9T	HS	Phase 1
DMP6I9T	CP	Inovio Pharmaceuticals
DMP6I9T	DT	Vaccine
DMP6I9T	DE	Influenza A virus H1N1/H5N1 infection

DMA46DO	ID	DMA46DO
DMA46DO	DN	INS-117548
DMA46DO	HS	Phase 1
DMA46DO	SN	ROCKI/ROCKII inhibitor (ophthalmic solution, ocular hypertension/glaucoma), Wisconsin Alumni Research Foundation (WARF)/Inspire
DMA46DO	CP	University of Wisconsin-Madison
DMA46DO	DE	Glaucoma/ocular hypertension

DMMR7CH	ID	DMMR7CH
DMMR7CH	DN	Insulin oral sublingual
DMMR7CH	HS	Phase 1
DMMR7CH	CP	Biodel
DMMR7CH	DE	Type-1 diabetes

DM93QP2	ID	DM93QP2
DM93QP2	DN	Insulin transdermal
DM93QP2	HS	Phase 1
DM93QP2	CP	Transdermal Global
DM93QP2	DE	Type-1/2 diabetes

DMXPLMN	ID	DMXPLMN
DMXPLMN	DN	INTOPLICINE
DMXPLMN	HS	Phase 1
DMXPLMN	SN	RP-60475; Intoplicine; 11-[3-(Dimethylamino)propylamino]-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-3-ol
DMXPLMN	DT	Small molecular drug
DMXPLMN	PC	65954
DMXPLMN	MW	348.4
DMXPLMN	FM	C21H24N4O
DMXPLMN	IC	InChI=1S/C21H24N4O/c1-13-12-23-21(22-9-4-10-25(2)3)19-18-16-7-6-15(26)11-14(16)5-8-17(18)24-20(13)19/h5-8,11-12,24,26H,4,9-10H2,1-3H3,(H,22,23)
DMXPLMN	CS	CC1=CN=C(C2=C1NC3=C2C4=C(C=C3)C=C(C=C4)O)NCCCN(C)C
DMXPLMN	IK	QROONAIPJKQFMC-UHFFFAOYSA-N
DMXPLMN	IU	16-[3-(dimethylamino)propylamino]-13-methyl-11,15-diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),2(7),3,5,8,12(17),13,15-octaen-5-ol
DMXPLMN	CA	CAS 125974-72-3
DMXPLMN	CB	CHEBI:135474
DMXPLMN	DE	Solid tumour/cancer

DMU03WD	ID	DMU03WD
DMU03WD	DN	IO-202
DMU03WD	HS	Phase 1
DMU03WD	CP	Immune-Onc Therapeutics
DMU03WD	DT	Antibody
DMU03WD	DE	Acute myeloid leukaemia; Chronic myelomonocytic leukaemia

DMNBPKS	ID	DMNBPKS
DMNBPKS	DN	Iofolastat I-124
DMNBPKS	HS	Phase 1
DMNBPKS	SN	Trofex (TN)
DMNBPKS	CP	Molecular Insight Pharmaceuticals
DMNBPKS	DT	Small molecular drug
DMNBPKS	PC	25194767
DMNBPKS	MW	531.3
DMNBPKS	FM	C19H26IN3O7
DMNBPKS	IC	InChI=1S/C19H26IN3O7/c20-13-6-4-12(5-7-13)11-21-10-2-1-3-14(17(26)27)22-19(30)23-15(18(28)29)8-9-16(24)25/h4-7,14-15,21H,1-3,8-11H2,(H,24,25)(H,26,27)(H,28,29)(H2,22,23,30)/t14-,15-/m0/s1/i20-4
DMNBPKS	CS	C1=CC(=CC=C1CNCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)[123I]
DMNBPKS	IK	OXUUJYOSVPMNKP-ZANJDRPYSA-N
DMNBPKS	IU	(2S)-2-[[(1S)-1-carboxy-5-[(4-(123I)iodanylphenyl)methylamino]pentyl]carbamoylamino]pentanedioic acid
DMNBPKS	CA	CAS 949575-24-0
DMNBPKS	DE	Prostate cancer

DMY0QL7	ID	DMY0QL7
DMY0QL7	DN	Iomab-ACT
DMY0QL7	HS	Phase 1
DMY0QL7	CP	Actinium Pharmaceuticals
DMY0QL7	DT	Antibody
DMY0QL7	DE	Diffuse large B-cell lymphoma; B-cell acute lymphoblastic leukaemia

DMD7LHM	ID	DMD7LHM
DMD7LHM	DN	ION 224
DMD7LHM	HS	Phase 1
DMD7LHM	SN	IONIS-DGAT2-Rx
DMD7LHM	CP	Ionis Pharmaceuticals
DMD7LHM	DT	Antisense oligonucleotide
DMD7LHM	DE	Non-alcoholic steatohepatitis

DMGN96R	ID	DMGN96R
DMGN96R	DN	Ipafricept
DMGN96R	HS	Phase 1
DMGN96R	CP	Bayer healthcare pharmaceuticals; oncomed pharmaceuticals
DMGN96R	DE	Ovarian cancer

DMFEI6T	ID	DMFEI6T
DMFEI6T	DN	IPH5201
DMFEI6T	HS	Phase 1
DMFEI6T	CP	AstraZeneca
DMFEI6T	DT	Antibody
DMFEI6T	DE	Solid tumour/cancer

DMEIM5G	ID	DMEIM5G
DMEIM5G	DN	IPI-940
DMEIM5G	HS	Phase 1
DMEIM5G	CP	Infinity Pharmaceuticals Inc
DMEIM5G	DE	Pain

DMPKH6Y	ID	DMPKH6Y
DMPKH6Y	DN	IPL 550,260
DMPKH6Y	HS	Phase 1
DMPKH6Y	CP	Inflazyme Pharmaceuticals
DMPKH6Y	DE	Inflammation

DMHW1LI	ID	DMHW1LI
DMHW1LI	DN	Iptakalim
DMHW1LI	HS	Phase 1
DMHW1LI	SN	2,3-Dimethyl-N-isopropyl-2-butanamine hydrochloride
DMHW1LI	DT	Small molecular drug
DMHW1LI	PC	10057607
DMHW1LI	MW	143.27
DMHW1LI	FM	C9H21N
DMHW1LI	IC	InChI=1S/C9H21N/c1-7(2)9(5,6)10-8(3)4/h7-8,10H,1-6H3
DMHW1LI	CS	CC(C)C(C)(C)NC(C)C
DMHW1LI	IK	RGWFHCMKBAMWDX-UHFFFAOYSA-N
DMHW1LI	IU	2,3-dimethyl-N-propan-2-ylbutan-2-amine
DMHW1LI	CA	642407-44-1
DMHW1LI	DE	Hypertension

DMET0H4	ID	DMET0H4
DMET0H4	DN	IQB-9302
DMET0H4	HS	Phase 1
DMET0H4	PC	9927200
DMET0H4	MW	286.4
DMET0H4	FM	C18H26N2O
DMET0H4	IC	InChI=1S/C18H26N2O/c1-13-6-5-7-14(2)17(13)19-18(21)16-8-3-4-11-20(16)12-15-9-10-15/h5-7,15-16H,3-4,8-12H2,1-2H3,(H,19,21)
DMET0H4	CS	CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2CC3CC3
DMET0H4	IK	DNUYDQISHIJMLD-UHFFFAOYSA-N
DMET0H4	IU	1-(cyclopropylmethyl)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DMET0H4	CA	CAS 166181-63-1
DMET0H4	DE	Pain

DMHP71R	ID	DMHP71R
DMHP71R	DN	IQ-DAA
DMHP71R	HS	Phase 1
DMHP71R	SN	Anti-anthrax toxin mAb, IQ; Human monoclonal antibodies (anthrax), IQ; IQN-protective antigen (human mAb), IQ corporation; MAb-based immunotherapy (anthrax), IQ; IQNLF + IQNPA (human mAbs, Bacillus anthracis infection), IQ Therapeutics
DMHP71R	CP	IQ Therapeutics BV
DMHP71R	DE	Bacillus anthracis infection

DMR3E4L	ID	DMR3E4L
DMR3E4L	DN	Irdabisant
DMR3E4L	HS	Phase 1
DMR3E4L	SN	CEP-26401
DMR3E4L	CP	Cephalon
DMR3E4L	DT	Small molecular drug
DMR3E4L	PC	25070031
DMR3E4L	MW	313.4
DMR3E4L	FM	C18H23N3O2
DMR3E4L	IC	InChI=1S/C18H23N3O2/c1-14-4-2-11-21(14)12-3-13-23-16-7-5-15(6-8-16)17-9-10-18(22)20-19-17/h5-10,14H,2-4,11-13H2,1H3,(H,20,22)/t14-/m1/s1
DMR3E4L	CS	C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3
DMR3E4L	IK	XUKROCVZGZNGSI-CQSZACIVSA-N
DMR3E4L	IU	3-[4-[3-[(2R)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1H-pyridazin-6-one
DMR3E4L	CA	CAS 1005402-19-6
DMR3E4L	DE	Cognitive impairment

DM5YUOM	ID	DM5YUOM
DM5YUOM	DN	Irofulven/Taxotere
DM5YUOM	HS	Phase 1
DM5YUOM	SN	MGI 114/docetaxel
DM5YUOM	CP	MGI Pharma
DM5YUOM	DE	Solid tumour/cancer

DM9SCME	ID	DM9SCME
DM9SCME	DN	IRX4204
DM9SCME	HS	Phase 1
DM9SCME	SN	220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid
DM9SCME	CP	Io Therapeutics
DM9SCME	DT	Small molecular drug
DM9SCME	PC	9863341
DM9SCME	MW	352.5
DM9SCME	FM	C24H32O2
DM9SCME	IC	InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+/t18-,24-/m1/s1
DM9SCME	CS	C/C(=C\\C(=O)O)/C=C/[C@@H]1C[C@]1(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C
DM9SCME	IK	BOOOLEGQBVUTKC-NVQSDHBMSA-N
DM9SCME	IU	(2E,4E)-3-methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid
DM9SCME	CA	CAS 220619-73-8
DM9SCME	DE	Prostate cancer; Breast cancer; Pancreatic cancer; Non-small-cell lung cancer

DMCED9U	ID	DMCED9U
DMCED9U	DN	IRX-5183
DMCED9U	HS	Phase 1
DMCED9U	SN	AGN-195183; NRX-195183; NRX-5183; VTP-195183; VTP-5183; IRX-5183 (oral, autoimmune disease), Io Therapeutics; RARa (oral, cancer/autoimmune disease), Io Therapeutics; RARa agonist (topical, skin/eye diseases), Io Therapeutics; Retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics; Retinoic acid receptor alpha agonist (topical, skin/eye diseases), Io Therapeutics; IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics; IRX-5183 (topical, skin/eye diseases), Io Therapeutics
DMCED9U	CP	Vitae Pharmaceuticals
DMCED9U	PC	9867758
DMCED9U	MW	437.9
DMCED9U	FM	C22H22ClF2NO4
DMCED9U	IC	InChI=1S/C22H22ClF2NO4/c1-21(2)5-6-22(3,4)16-12(21)9-11(18(27)17(16)23)19(28)26-10-7-13(24)15(20(29)30)14(25)8-10/h7-9,27H,5-6H2,1-4H3,(H,26,28)(H,29,30)
DMCED9U	CS	CC1(CCC(C2=C1C=C(C(=C2Cl)O)C(=O)NC3=CC(=C(C(=C3)F)C(=O)O)F)(C)C)C
DMCED9U	IK	PNAWUIKCVQSLFG-UHFFFAOYSA-N
DMCED9U	IU	4-[(4-chloro-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]-2,6-difluorobenzoic acid
DMCED9U	CA	CAS 367273-07-2
DMCED9U	DE	Solid tumour/cancer

DMKO7EA	ID	DMKO7EA
DMKO7EA	DN	ISF-402
DMKO7EA	HS	Phase 1
DMKO7EA	SN	Urinary tetrapeptide (diabetes), Monash University/International Diabetes Institute/Pallane; Urinary tetrapeptide (diabetes), Monash University/International Diabetes Institute/Dia-B Tech Ltd
DMKO7EA	CP	Dia-B Tech
DMKO7EA	DE	Type-2 diabetes

DMEJ4B7	ID	DMEJ4B7
DMEJ4B7	DN	ISIS 325568
DMEJ4B7	HS	Phase 1
DMEJ4B7	SN	BDBM231666; N-(2-(1H-indol-3-yl)ethyl)-3-(3-thiazol-2-ylureido)benzenesulfonamide (1b)
DMEJ4B7	CP	Licensed to Ortho-McNeil, Inc.
DMEJ4B7	TC	Antisense
DMEJ4B7	DT	Antisense drug
DMEJ4B7	DE	Type-2 diabetes

DM9Y51T	ID	DM9Y51T
DM9Y51T	DN	ISIS-ANGPTL3
DM9Y51T	HS	Phase 1
DM9Y51T	DT	Antisense drug
DM9Y51T	DE	Hyperlipidaemia

DMX3FN4	ID	DMX3FN4
DMX3FN4	DN	ISIS-APOCIII
DMX3FN4	HS	Phase 1
DMX3FN4	CP	ISIS Pharm
DMX3FN4	DT	Antisense drug
DMX3FN4	DE	Metabolic syndrome x; Atherosclerosis; Hyperlipemia; Inflammation

DM8P3N5	ID	DM8P3N5
DM8P3N5	DN	ISIS-AR
DM8P3N5	HS	Phase 1
DM8P3N5	DT	Antisense drug
DM8P3N5	DE	Prostate cancer

DMQDUG4	ID	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	HS	Phase 1
DMQDUG4	SN	1-(Tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; 172889-27-9; pp2; PP 2; 1-(tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; AG 1879; 1-tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; PP2; 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine; AG-1879; CHEMBL406845; CHEBI:78331; AK-60369; 1-tert-butyl-3-(4-chlorophenyl)pyrazolo[3,4-d]pyrimidin-4-amine; 3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H16ClN5; 1qpe; 4few; PBBRWFOVCUAONR-UHFFFAOYSA-N; AG1879; PP 2 (AG 1879)
DMQDUG4	CP	ISIS Pharm
DMQDUG4	DT	Antisense drug
DMQDUG4	DE	Inflammation; Cardiovascular disease

DMDKAIC	ID	DMDKAIC
DMDKAIC	DN	ISIS-SGLT2
DMDKAIC	HS	Phase 1
DMDKAIC	CP	ISIS Pharm
DMDKAIC	DT	Antisense drug
DMDKAIC	DE	Type-2 diabetes

DMV1BTP	ID	DMV1BTP
DMV1BTP	DN	ISIS-SOD1
DMV1BTP	HS	Phase 1
DMV1BTP	CP	ISIS Pharm
DMV1BTP	DT	Antisense drug
DMV1BTP	DE	Motor neurone disease; Amyotrophic lateral sclerosis

DMDB7KU	ID	DMDB7KU
DMDB7KU	DN	ISO-1
DMDB7KU	HS	Phase 1
DMDB7KU	SN	478336-92-4; MIF Antagonist, ISO-1; methyl 2-(3-(4-hydroxyphenyl)-4,5-dihydroisoxazol-5-yl)acetate; CHEMBL210858; IN1228; 5-Isoxazoleacetic acid, 4,5-dihydro-3-(4-hydroxyphenyl)-, methyl ester; Macrophage Migration Inhibitory Factor Antagonist, ISO-1; (S,R)-3-(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid, methyl ester; 4,5-DIHYDRO-3-(4-HYDROXYPHENYL)-5-ISOXAZOLEACETIC ACID, METHYL ESTER; AC1O1KG2; SCHEMBL668287; GTPL9984; CTK8E8677; MolPort-027-836-626; BCP15471; EX-A2475; BDBM50186426; 6540AB
DMDB7KU	DT	Small molecular drug
DMDB7KU	PC	4633677
DMDB7KU	MW	235.24
DMDB7KU	FM	C12H13NO4
DMDB7KU	IC	InChI=1S/C12H13NO4/c1-16-12(15)7-10-6-11(13-17-10)8-2-4-9(14)5-3-8/h2-5,10,14H,6-7H2,1H3
DMDB7KU	CS	COC(=O)CC1CC(=NO1)C2=CC=C(C=C2)O
DMDB7KU	IK	AIXMJTYHQHQJLU-UHFFFAOYSA-N
DMDB7KU	IU	methyl 2-[3-(4-hydroxyphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetate
DMDB7KU	CA	CAS 478336-92-4

DMBQ8CA	ID	DMBQ8CA
DMBQ8CA	DN	ISO-901
DMBQ8CA	HS	Phase 1
DMBQ8CA	SN	FOLITIXORIN; Modufolin; Tetrahydromethylenefolate; 3432-99-3; 5,10-Methylene-tetrahydrofolate; 5,10-Methylenetetrahydrofolic acid; 5,10-methylenetetrahydrofolate; CH2H4folate; CHEBI:20502; L-Glutamic acid,N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-; MTHF; N-(4-(3-Amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9H)-yl)benzoyl)-L-glutamic acid; N-{4-[3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl]benzoyl}-L-glutamic acid
DMBQ8CA	PC	135400185
DMBQ8CA	MW	457.4
DMBQ8CA	FM	C20H23N7O6
DMBQ8CA	IC	QYNUQALWYRSVHF-ABLWVSNPSA-N
DMBQ8CA	CS	C1C2CN(CN2C3=C(N1)N=C(NC3=O)N)C4=CC=C(C=C4)C(=O)NC(CCC(=O)O)C(=O)O
DMBQ8CA	IK	1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12?,13-/m0/s1
DMBQ8CA	IU	(2S)-2-[[4-(3-amino-1-oxo-2,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl)benzoyl]amino]pentanedioic acid
DMBQ8CA	CA	CAS 3432-99-3
DMBQ8CA	CB	CHEBI:9139
DMBQ8CA	DE	Rheumatoid arthritis

DMR17YI	ID	DMR17YI
DMR17YI	DN	Isoquine
DMR17YI	HS	Phase 1
DMR17YI	SN	ISOQUINE; CHEMBL147587; NINDS_000687; Spectrum_000046; Spectrum4_000147; Spectrum2_000768; Spectrum5_000808; Spectrum3_000299; AC1L1D2I; KBioSS_000426; BSPBio_001838; KBioGR_000594; DivK1c_000687; SPBio_000816; SCHEMBL5836418; KBio2_000426; KBio1_000687; KBio3_001338; KBio2_002994; CTK6E7963; KBio2_005562; ZINC36378506; BDBM50134931; IDI1_000687; NCGC00178968-01; SBI-0051280.P003; AB00053418_02; 5-(7-chloroquinolin-4-ylamino)-2-diethylaminomethylphenol; 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
DMR17YI	DT	Small molecular drug
DMR17YI	PC	2166
DMR17YI	MW	355.9
DMR17YI	FM	C20H22ClN3O
DMR17YI	IC	InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-5-7-16(12-20(14)25)23-18-9-10-22-19-11-15(21)6-8-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)
DMR17YI	CS	CCN(CC)CC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O
DMR17YI	IK	QGFYFOHMBDMGBZ-UHFFFAOYSA-N
DMR17YI	IU	5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
DMR17YI	DE	Malaria

DMBPV9W	ID	DMBPV9W
DMBPV9W	DN	IT-139
DMBPV9W	HS	Phase 1
DMBPV9W	CP	Intezyne
DMBPV9W	DE	Solid tumour/cancer

DMAYD7O	ID	DMAYD7O
DMAYD7O	DN	IT-141
DMAYD7O	HS	Phase 1
DMAYD7O	CP	IntezyneTampa, FL
DMAYD7O	DE	Solid tumour/cancer

DMY1DFK	ID	DMY1DFK
DMY1DFK	DN	ITASETRON
DMY1DFK	HS	Phase 1
DMY1DFK	SN	DAU6215CL; DAU-6215; Itasetron < Rec INN; U-98079A; N-(endo-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide; 2-Oxo-N-(1alphaH,5alphaH-tropan-3alpha-yl)-1-benzimidazoline-1-carboxamide
DMY1DFK	DT	Small molecular drug
DMY1DFK	PC	6918106
DMY1DFK	MW	300.36
DMY1DFK	FM	C16H20N4O2
DMY1DFK	IC	InChI=1S/C16H20N4O2/c1-19-11-6-7-12(19)9-10(8-11)17-15(21)20-14-5-3-2-4-13(14)18-16(20)22/h2-5,10-12H,6-9H2,1H3,(H,17,21)(H,18,22)/t10?,11-,12+
DMY1DFK	CS	CN1[C@@H]2CC[C@H]1CC(C2)NC(=O)N3C4=CC=CC=C4NC3=O
DMY1DFK	IK	RWXRJSRJIITQAK-YOGCLGLASA-N
DMY1DFK	IU	N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-3H-benzimidazole-1-carboxamide
DMY1DFK	CA	CAS 123258-84-4
DMY1DFK	CB	CHEBI:140079
DMY1DFK	DE	Nausea

DM702MU	ID	DM702MU
DM702MU	DN	ITX-5061
DM702MU	HS	Phase 1
DM702MU	SN	ITX5061; UNII-J4RA8K2Q2A; J4RA8K2Q2A; ITX-5061; 1252679-52-9; ITX 5061; CHEMBL3402567; HY-19900; CS-0016951; 1-Naphthaleneacetamide, N-(5-(1,1-dimethylethyl)-2-methoxy-3-    ((methylsulfonyl)amino)phenyl)-4-(2-(4-morpholinyl)ethoxy)-alpha-oxo-,     hydrochloride (1:1)
DM702MU	CP	Itherx
DM702MU	DT	Small molecular drug
DM702MU	PC	56843466
DM702MU	MW	620.2
DM702MU	FM	C30H38ClN3O7S
DM702MU	IC	InChI=1S/C30H37N3O7S.ClH/c1-30(2,3)20-18-24(28(38-4)25(19-20)32-41(5,36)37)31-29(35)27(34)23-10-11-26(22-9-7-6-8-21(22)23)40-17-14-33-12-15-39-16-13-33;/h6-11,18-19,32H,12-17H2,1-5H3,(H,31,35);1H
DM702MU	CS	CC(C)(C)C1=CC(=C(C(=C1)NS(=O)(=O)C)OC)NC(=O)C(=O)C2=CC=C(C3=CC=CC=C32)OCCN4CCOCC4.Cl
DM702MU	IK	ICIJBYYMEBOTQP-UHFFFAOYSA-N
DM702MU	IU	N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide;hydrochloride
DM702MU	CA	CAS 1252679-52-9
DM702MU	DE	Human immunodeficiency virus-1 infection

DMSGEU6	ID	DMSGEU6
DMSGEU6	DN	JAB-3068
DMSGEU6	HS	Phase 1
DMSGEU6	SN	SHP2-IN-6; SCHEMBL19704279; JAB3068; NSC827676; NSC-827676; HY-131132; CS-0129188; 2169223-48-5
DMSGEU6	CP	AbbVie; Jacobio Pharmaceuticals
DMSGEU6	DT	Small molecular drug
DMSGEU6	PC	132222602
DMSGEU6	MW	476.5
DMSGEU6	FM	C22H26F2N6O2S
DMSGEU6	IC	InChI=1S/C22H26F2N6O2S/c1-13(31)30-11-22(23,24)18-14(30)3-2-4-15(18)33-20-19(26)28-17(9-27-20)29-7-5-21(6-8-29)12-32-10-16(21)25/h2-4,9,16H,5-8,10-12,25H2,1H3,(H2,26,28)/t16-/m1/s1
DMSGEU6	CS	CC(=O)N1CC(C2=C1C=CC=C2SC3=NC=C(N=C3N)N4CCC5(CC4)COC[C@H]5N)(F)F
DMSGEU6	IK	HGYTYZKWKUXRKA-MRXNPFEDSA-N
DMSGEU6	IU	1-[4-[3-amino-5-[(4S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]sulfanyl-3,3-difluoro-2H-indol-1-yl]ethanone
DMSGEU6	DE	Solid tumour/cancer

DM7XAV1	ID	DM7XAV1
DM7XAV1	DN	JBH492
DM7XAV1	HS	Phase 1
DM7XAV1	CP	Novartis
DM7XAV1	DT	Antibody drug conjugate
DM7XAV1	DE	Chronic lymphocytic leukaemia; Non-hodgkin lymphoma

DMR3SO5	ID	DMR3SO5
DMR3SO5	DN	JCAR018
DMR3SO5	HS	Phase 1
DMR3SO5	CP	Juno Therapeutics Seattle, WA
DMR3SO5	DE	Acute lymphoblastic leukaemia; Non-hodgkin lymphoma

DM1T8KN	ID	DM1T8KN
DM1T8KN	DN	JCAR020
DM1T8KN	HS	Phase 1
DM1T8KN	CP	Juno Therapeutics Seattle, WA
DM1T8KN	DE	Ovarian cancer

DM324RM	ID	DM324RM
DM324RM	DN	JCAR023
DM324RM	HS	Phase 1
DM324RM	CP	Juno Therapeutics Seattle, WA
DM324RM	DE	Neuroblastoma

DMYR3IE	ID	DMYR3IE
DMYR3IE	DN	JES-9501
DMYR3IE	HS	Phase 1
DMYR3IE	SN	DHED; Dehydroevodiamine; Dehydroevodiamine hydrochloride
DMYR3IE	CP	Seoul University
DMYR3IE	DE	Alzheimer disease

DMMI4XR	ID	DMMI4XR
DMMI4XR	DN	JNJ-17305600
DMMI4XR	HS	Phase 1
DMMI4XR	CP	Johnson & Johnson Pharmaceutical Research & Development
DMMI4XR	DE	Schizophrenia

DMSQ3AZ	ID	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	HS	Phase 1
DMSQ3AZ	SN	MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson
DMSQ3AZ	CP	Johnson & Johnson
DMSQ3AZ	DE	Solid tumour/cancer

DMNSJ3C	ID	DMNSJ3C
DMNSJ3C	DN	JNJ-26854165
DMNSJ3C	HS	Phase 1
DMNSJ3C	SN	Serdemetan; 881202-45-5; N1-(2-(1H-Indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine; JNJ-26854165 (Serdemetan); UNII-ID6YB4W3V8; ID6YB4W3V8; C21H20N4; n-(2-(1h-indol-3-yl)ethyl)-n'-(4-pyridinyl)-1,4-benzenediamine; N-[2-(1H-INDOL-3-YL)ETHYL]-N'-(4-PYRIDINYL)-1,4-BENZENEDIAMINE; Serdemetan [INN]; MLS006011022; SCHEMBL3012498; CHEMBL2137530; CTK8C1936; EX-A267; DTXSID30236830; MolPort-009-679-468; HMS3654A16; JNJ 26854165 (Serdemetan); BCP02124; AOB87702; QC-534; ANW-67474
DMNSJ3C	CP	Johnson & Johnson Pharmaceutical
DMNSJ3C	DT	Small molecular drug
DMNSJ3C	PC	11609586
DMNSJ3C	MW	328.4
DMNSJ3C	FM	C21H20N4
DMNSJ3C	IC	InChI=1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25)
DMNSJ3C	CS	C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4
DMNSJ3C	IK	CEGSUKYESLWKJP-UHFFFAOYSA-N
DMNSJ3C	IU	1-N-[2-(1H-indol-3-yl)ethyl]-4-N-pyridin-4-ylbenzene-1,4-diamine
DMNSJ3C	CA	CAS 881202-45-5
DMNSJ3C	DE	Prostate cancer; Non-small-cell lung cancer; Solid tumour/cancer

DM49VWQ	ID	DM49VWQ
DM49VWQ	DN	JNJ-3534
DM49VWQ	HS	Phase 1
DM49VWQ	CP	Janssen Research & Development Raritan, NJ
DM49VWQ	DE	Psoriasis vulgaris

DMDIPW8	ID	DMDIPW8
DMDIPW8	DN	JNJ-38877605
DMDIPW8	HS	Phase 1
DMDIPW8	SN	C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD
DMDIPW8	CP	Johnson & Johnson Pharmaceutical Research & Development LLC
DMDIPW8	DT	Small molecular drug
DMDIPW8	PC	46911863
DMDIPW8	MW	377.3
DMDIPW8	FM	C19H13F2N7
DMDIPW8	IC	InChI=1S/C19H13F2N7/c1-27-11-13(10-23-27)16-6-7-17-24-25-18(28(17)26-16)19(20,21)14-4-5-15-12(9-14)3-2-8-22-15/h2-11H,1H3
DMDIPW8	CS	CN1C=C(C=N1)C2=NN3C(=NN=C3C(C4=CC5=C(C=C4)N=CC=C5)(F)F)C=C2
DMDIPW8	IK	JRWCBEOAFGHNNU-UHFFFAOYSA-N
DMDIPW8	IU	6-[difluoro-[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline
DMDIPW8	CA	CAS 943540-75-8
DMDIPW8	CB	CHEBI:91417
DMDIPW8	DE	Solid tumour/cancer

DM45SGE	ID	DM45SGE
DM45SGE	DN	JNJ-39439335
DM45SGE	HS	Phase 1
DM45SGE	SN	Mavatrep; 956274-94-5; JNJ-39439335; UNII-F197218T99; F197218T99; Mavatrep [USAN:INN]; Mavatrep (USAN); JNJ 39439335; SCHEMBL1796599; SCHEMBL1797450; CHEMBL2364618; Mavatrep(JNJ-39439335); Mavatrep; JNJ-39439335; DTXSID90241905; BCP23936; EX-A2266; ZINC43175494; BDBM50086717; AKOS030527038; DB12875; CS-4591; SB17026; trans-2-(2-(2-(2-(4-Trifluoromethylphenyl)vinyl)-1H-benzimidazol-5-yl)phenyl)propan-2-ol; BC600772; HY-16935; B5930; J3.561.747G; D10370
DM45SGE	CP	Johnson & Johnson Pharmaceutical Research & Development
DM45SGE	DT	Small molecular drug
DM45SGE	PC	17751090
DM45SGE	MW	422.4
DM45SGE	FM	C25H21F3N2O
DM45SGE	IC	InChI=1S/C25H21F3N2O/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31H,1-2H3,(H,29,30)/b14-9+
DM45SGE	CS	CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)/C=C/C4=CC=C(C=C4)C(F)(F)F)O
DM45SGE	IK	ORDHXXHTBUZRCN-NTEUORMPSA-N
DM45SGE	IU	2-[2-[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3H-benzimidazol-5-yl]phenyl]propan-2-ol
DM45SGE	CA	CAS 956274-94-5
DM45SGE	DE	Musculoskeletal pain

DMOL9JR	ID	DMOL9JR
DMOL9JR	DN	JNJ-42491293
DMOL9JR	HS	Phase 1
DMOL9JR	SN	MGlu2 receptor PET ligand (psychiatric disease); MGlu2 receptor PET ligand (psychiatric disease), Johnson & Johnson
DMOL9JR	CP	Johnson & Johnson Pharmaceutical Research & Development LLC
DMOL9JR	DE	Psychiatric disorder

DMQ5ZVK	ID	DMQ5ZVK
DMQ5ZVK	DN	JNJ-54175446
DMQ5ZVK	HS	Phase 1
DMQ5ZVK	SN	CWFVVQFVGMFTBD-SECBINFHSA-N; UNII-32524GLF40; 32524GLF40; 1627902-21-9; SCHEMBL16036477; BDBM254266; AKOS032947046; AS-35269; J3.655.327H; US9464084, 158; (R)-(2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone; (r)-(2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-1,4,6,7-tetrahydro-5h-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone; Methanone, (2-chloro-3-(trifluoromethyl)phenyl)((4R)-1-(5-fluoro-2-py
DMQ5ZVK	CP	Janssen Research & Development Raritan, NJ
DMQ5ZVK	PC	90409366
DMQ5ZVK	MW	440.8
DMQ5ZVK	FM	C18H13ClF4N6O
DMQ5ZVK	IC	InChI=1S/C18H13ClF4N6O/c1-9-15-13(29(27-26-15)17-24-7-10(20)8-25-17)5-6-28(9)16(30)11-3-2-4-12(14(11)19)18(21,22)23/h2-4,7-9H,5-6H2,1H3/t9-/m1/s1
DMQ5ZVK	CS	C[C@@H]1C2=C(CCN1C(=O)C3=C(C(=CC=C3)C(F)(F)F)Cl)N(N=N2)C4=NC=C(C=N4)F
DMQ5ZVK	IK	CWFVVQFVGMFTBD-SECBINFHSA-N
DMQ5ZVK	IU	[2-chloro-3-(trifluoromethyl)phenyl]-[(4R)-1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridin-5-yl]methanone
DMQ5ZVK	CA	CAS 1627902-21-9
DMQ5ZVK	DE	Major depressive disorder

DMBV3P8	ID	DMBV3P8
DMBV3P8	DN	JNJ-54728518
DMBV3P8	HS	Phase 1
DMBV3P8	CP	Janssen Research & Development Raritan, NJ
DMBV3P8	DE	Type-2 diabetes

DM0QZJX	ID	DM0QZJX
DM0QZJX	DN	JNJ-55308942
DM0QZJX	HS	Phase 1
DM0QZJX	CP	Johnson & Johnson
DM0QZJX	DE	Anhedonia; Mood disorder; Neuroinflammation

DMSPQDM	ID	DMSPQDM
DMSPQDM	DN	JNJ-61610588
DMSPQDM	HS	Phase 1
DMSPQDM	CP	Janssen Research & Development Raritan, NJ
DMSPQDM	DE	Solid tumour/cancer

DM5SZAK	ID	DM5SZAK
DM5SZAK	DN	JNJ-63709178
DM5SZAK	HS	Phase 1
DM5SZAK	CP	Janssen
DM5SZAK	DT	Antibody
DM5SZAK	DE	Acute myeloid leukaemia

DMJFK6X	ID	DMJFK6X
DMJFK6X	DN	JNJ-63898081
DMJFK6X	HS	Phase 1
DMJFK6X	CP	Janssen
DMJFK6X	DT	Antibody
DMJFK6X	DE	Solid tumour/cancer

DMLYAGD	ID	DMLYAGD
DMLYAGD	DN	JNJ-64264681
DMLYAGD	HS	Phase 1
DMLYAGD	CP	Janssen
DMLYAGD	DE	Non-hodgkin lymphoma; Chronic lymphocytic leukaemia

DMYJCUP	ID	DMYJCUP
DMYJCUP	DN	JNJ-64417184
DMYJCUP	HS	Phase 1
DMYJCUP	CP	Janssen
DMYJCUP	DE	Respiratory syncytial virus infection

DMDBW2N	ID	DMDBW2N
DMDBW2N	DN	JNJ-64619178
DMDBW2N	HS	Phase 1
DMDBW2N	SN	2086772-26-9; UNII-N8VKI8FPW0; N8VKI8FPW0; JNJ64619178; CHEMBL4249337; (1S,2R,3S,5R)-3-(2-(2-Amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; Onametostat; (1S,2R,3S,5R)-3-(2-(2-Amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo(2,3-d)pyrimidin-7-yl)cyclopentane-1,2-diol; entane-1,2-diol; Onametostat [INN]; SCHEMBL18572106; EX-A2791; BDBM50462572; NSC808507; NSC-808507; JNJ45031882; HY-101564; CS-0021720; S8624; A16861; (1~{S},2~{R},3~{S},5~{R})-3-[2-(2-azanyl-3-bromanyl-quinolin-7-yl)ethyl]-5-(4-azanylpyrrolo[2,3-d]pyrimidin-7-yl)cyclop; (1~{S},2~{R},3~{S},5~{R})-3-[2-(2-azanyl-3-bromanyl-quinolin-7-yl)ethyl]-5-(4-azanylpyrrolo[2,3-d]pyrimidin-7-yl)cyclop entane-1,2-diol; 1,2-Cyclopentanediol, 3-(2-(2-amino-3-bromo-7-quinolinyl)ethyl)-5-(4-amino-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-, (1S,2R,3S,5R)-; K8N
DMDBW2N	CP	Janssen
DMDBW2N	DT	Small molecular drug
DMDBW2N	PC	126637809
DMDBW2N	MW	483.4
DMDBW2N	FM	C22H23BrN6O2
DMDBW2N	IC	InChI=1S/C22H23BrN6O2/c23-15-8-12-3-1-11(7-16(12)28-21(15)25)2-4-13-9-17(19(31)18(13)30)29-6-5-14-20(24)26-10-27-22(14)29/h1,3,5-8,10,13,17-19,30-31H,2,4,9H2,(H2,25,28)(H2,24,26,27)/t13-,17+,18+,19-/m0/s1
DMDBW2N	CS	C1[C@@H]([C@H]([C@H]([C@@H]1N2C=CC3=C(N=CN=C32)N)O)O)CCC4=CC5=NC(=C(C=C5C=C4)Br)N
DMDBW2N	IK	DBSMLQTUDJVICQ-CJODITQLSA-N
DMDBW2N	IU	(1S,2R,3S,5R)-3-[2-(2-amino-3-bromoquinolin-7-yl)ethyl]-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
DMDBW2N	CA	CAS 2086772-26-9
DMDBW2N	DE	Myelodysplastic syndrome; Solid tumour/cancer

DMQOHRA	ID	DMQOHRA
DMQOHRA	DN	JNJ-67571244
DMQOHRA	HS	Phase 1
DMQOHRA	CP	Janssen
DMQOHRA	DT	Antibody
DMQOHRA	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DM6URNJ	ID	DM6URNJ
DM6URNJ	DN	JNJ-67856633
DM6URNJ	HS	Phase 1
DM6URNJ	CP	Janssen
DM6URNJ	DE	Non-hodgkin lymphoma; Chronic lymphocytic leukaemia

DM6VR13	ID	DM6VR13
DM6VR13	DN	JNJ-69086420
DM6VR13	HS	Phase 1
DM6VR13	CP	Janssen
DM6VR13	DT	Antibody
DM6VR13	DE	Prostate cancer

DMY7CW1	ID	DMY7CW1
DMY7CW1	DN	JNJ-74699157
DMY7CW1	HS	Phase 1
DMY7CW1	CP	Janssen
DMY7CW1	DE	Solid tumour/cancer

DMFMWLQ	ID	DMFMWLQ
DMFMWLQ	DN	JS004
DMFMWLQ	HS	Phase 1
DMFMWLQ	SN	TAB004
DMFMWLQ	CP	Junshi Biosciences
DMFMWLQ	DT	Antibody
DMFMWLQ	DE	Solid tumour/cancer

DMVJWBS	ID	DMVJWBS
DMVJWBS	DN	JSI-1187
DMVJWBS	HS	Phase 1
DMVJWBS	CP	JS InnoPharm
DMVJWBS	DT	Small molecular drug
DMVJWBS	DE	Solid tumour/cancer

DM4QIOH	ID	DM4QIOH
DM4QIOH	DN	JSM 6427
DM4QIOH	HS	Phase 1
DM4QIOH	CP	Jerini AG
DM4QIOH	DE	Macular degeneration

DM01JU8	ID	DM01JU8
DM01JU8	DN	JTE-451
DM01JU8	HS	Phase 1
DM01JU8	CP	Akros Pharma Princeton, NJ
DM01JU8	DE	Plaque psoriasis

DMHMDC0	ID	DMHMDC0
DMHMDC0	DN	JWCAR029
DMHMDC0	HS	Phase 1
DMHMDC0	CP	Peking University
DMHMDC0	DT	CAR T Cell Therapy
DMHMDC0	DE	Non-hodgkin lymphoma

DMW5J9B	ID	DMW5J9B
DMW5J9B	DN	JX-929
DMW5J9B	HS	Phase 1
DMW5J9B	CP	Jennerex Biotherapeutics
DMW5J9B	DE	Solid tumour/cancer

DMFKEVO	ID	DMFKEVO
DMFKEVO	DN	KA2237
DMFKEVO	HS	Phase 1
DMFKEVO	CP	Karus Therapeutics Oxfordshire, United Kingdom
DMFKEVO	DE	B-cell lymphoma

DMW0H9Y	ID	DMW0H9Y
DMW0H9Y	DN	KA2507
DMW0H9Y	HS	Phase 1
DMW0H9Y	CP	Karus Therapeutics Oxfordshire, United Kingdom
DMW0H9Y	DE	Solid tumour/cancer

DMXYN1H	ID	DMXYN1H
DMXYN1H	DN	KAR5585
DMXYN1H	HS	Phase 1
DMXYN1H	SN	Rodatristat; Rodatristat [USAN]; UNII-507FY6OL37; SCHEMBL16573975; TZSZZENYCISATO-WIOPSUGQSA-N; 507FY6OL37; Ethyl (3S)-8-(2-amino-6-((1R)-1-(5-chloro(1,1'-biphenyl)-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro(4.5)decane-3-carboxylate; (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate; 2,8-Diazaspiro(4.5)decane-3-carboxylic acid, 8-(2-amino-6-((1R)-1-(5-chloro(1,1'-biphenyl)-2-yl)-2,2,2-trifluoroethoxy)-4
DMXYN1H	CP	Karos Pharmaceuticals New Haven, CT
DMXYN1H	PC	92045025
DMXYN1H	MW	590
DMXYN1H	FM	C29H31ClF3N5O3
DMXYN1H	IC	InChI=1S/C29H31ClF3N5O3/c1-2-40-26(39)22-16-28(17-35-22)10-12-38(13-11-28)23-15-24(37-27(34)36-23)41-25(29(31,32)33)20-9-8-19(30)14-21(20)18-6-4-3-5-7-18/h3-9,14-15,22,25,35H,2,10-13,16-17H2,1H3,(H2,34,36,37)/t22-,25+/m0/s1
DMXYN1H	CS	CCOC(=O)[C@@H]1CC2(CCN(CC2)C3=CC(=NC(=N3)N)O[C@H](C4=C(C=C(C=C4)Cl)C5=CC=CC=C5)C(F)(F)F)CN1
DMXYN1H	IK	TZSZZENYCISATO-WIOPSUGQSA-N
DMXYN1H	IU	ethyl (3S)-8-[2-amino-6-[(1R)-1-(4-chloro-2-phenylphenyl)-2,2,2-trifluoroethoxy]pyrimidin-4-yl]-2,8-diazaspiro[4.5]decane-3-carboxylate
DMXYN1H	CA	CAS 1673571-51-1
DMXYN1H	DE	Pulmonary arterial hypertension

DMTYNRB	ID	DMTYNRB
DMTYNRB	DN	KD033
DMTYNRB	HS	Phase 1
DMTYNRB	CP	Kadmon
DMTYNRB	DT	Recombinant protein
DMTYNRB	DE	Solid tumour/cancer

DMNFDYE	ID	DMNFDYE
DMNFDYE	DN	KD3010
DMNFDYE	HS	Phase 1
DMNFDYE	CP	Kalypsys
DMNFDYE	DE	Obesity; Metabolic disorder

DMZK7N8	ID	DMZK7N8
DMZK7N8	DN	Keratinocyte growth factor
DMZK7N8	HS	Phase 1
DMZK7N8	SN	RHu-KGF
DMZK7N8	CP	Amgen
DMZK7N8	DE	Solid tumour/cancer

DMQ6DLZ	ID	DMQ6DLZ
DMQ6DLZ	DN	KF-17837
DMQ6DLZ	HS	Phase 1
DMQ6DLZ	SN	CHEMBL27508; (E)-8-(3,4-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine; 141807-96-7; 1H-Purine-2,6-dione, 3,7-dihydro-8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-dipropyl-7-methyl-, (E)-; UQGGPCQNHJCOPS-PKNBQFBNSA-N; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-7-methyl-1,3-dipropylpurine-2,6-dione; AC1O68AZ; SCHEMBL537086; SCHEMBL537085; SCHEMBL9364001; 8-[2-(3,4-Dimethoxy-phenyl)-vinyl]-7-methyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; BDBM50006710; KF-17387; LS-126824; L006852
DMQ6DLZ	DT	Small molecular drug
DMQ6DLZ	PC	6448585
DMQ6DLZ	MW	412.5
DMQ6DLZ	FM	C22H28N4O4
DMQ6DLZ	IC	InChI=1S/C22H28N4O4/c1-6-12-25-20-19(21(27)26(13-7-2)22(25)28)24(3)18(23-20)11-9-15-8-10-16(29-4)17(14-15)30-5/h8-11,14H,6-7,12-13H2,1-5H3/b11-9+
DMQ6DLZ	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)N(C(=N2)/C=C/C3=CC(=C(C=C3)OC)OC)C
DMQ6DLZ	IK	UQGGPCQNHJCOPS-PKNBQFBNSA-N
DMQ6DLZ	IU	8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-7-methyl-1,3-dipropylpurine-2,6-dione
DMQ6DLZ	CA	CAS 141807-96-7
DMQ6DLZ	DE	Parkinson disease

DMR14VE	ID	DMR14VE
DMR14VE	DN	KH-901
DMR14VE	HS	Phase 1
DMR14VE	SN	Comfeagen; GM-CSF gene-carrying recombinant adenovirus vaccine (solid tumor), Kanghong Biotechnologies
DMR14VE	CP	Chengdu Kanghong Biotechnologies Co Ltd
DMR14VE	DT	Vaccine
DMR14VE	DE	Solid tumour/cancer

DMLSUQ8	ID	DMLSUQ8
DMLSUQ8	DN	KHK2455
DMLSUQ8	HS	Phase 1
DMLSUQ8	CP	Kyowa Kirin Princeton, NJ
DMLSUQ8	DE	Solid tumour/cancer

DMR7EF6	ID	DMR7EF6
DMR7EF6	DN	KHK-2866
DMR7EF6	HS	Phase 1
DMR7EF6	CP	Kyowa Hakko Kirin Pharma
DMR7EF6	DT	Antibody
DMR7EF6	DE	Ovarian cancer

DMIAVBL	ID	DMIAVBL
DMIAVBL	DN	Ki23819
DMIAVBL	HS	Phase 1
DMIAVBL	DE	Solid tumour/cancer

DMUB3H9	ID	DMUB3H9
DMUB3H9	DN	KITE-439
DMUB3H9	HS	Phase 1
DMUB3H9	CP	Gilead Sciences; Kite Pharma
DMUB3H9	DT	TCR-T cell therapy
DMUB3H9	DE	Cervical cancer; Solid tumour/cancer

DMXR6HI	ID	DMXR6HI
DMXR6HI	DN	KITE-585
DMXR6HI	HS	Phase 1
DMXR6HI	CP	Kite, A Gilead Company
DMXR6HI	DT	CAR T Cell Therapy
DMXR6HI	DE	Multiple myeloma

DMBSI6Y	ID	DMBSI6Y
DMBSI6Y	DN	KITE-718
DMBSI6Y	HS	Phase 1
DMBSI6Y	CP	Kite Pharma
DMBSI6Y	DT	TCR-T cell therapy
DMBSI6Y	DE	Solid tumour/cancer

DME8DUV	ID	DME8DUV
DME8DUV	DN	KM-023
DME8DUV	HS	Phase 1
DME8DUV	CP	Kainos Medicine Inc
DME8DUV	DE	Human immunodeficiency virus infection

DMRAWGC	ID	DMRAWGC
DMRAWGC	DN	KM-819
DMRAWGC	HS	Phase 1
DMRAWGC	CP	Kainos Medicine
DMRAWGC	DE	Parkinson disease

DM1D2O0	ID	DM1D2O0
DM1D2O0	DN	KML-001
DM1D2O0	HS	Phase 1
DM1D2O0	CP	Komipharm International Co Ltd
DM1D2O0	PC	60356606
DM1D2O0	MW	334.75
DM1D2O0	FM	C16H15ClN2O4
DM1D2O0	IC	InChI=1S/C16H15ClN2O4/c1-11(12-2-4-13(17)5-3-12)18-16(20)10-23-15-8-6-14(7-9-15)19(21)22/h2-9,11H,10H2,1H3,(H,18,20)
DM1D2O0	CS	CC(C1=CC=C(C=C1)Cl)NC(=O)COC2=CC=C(C=C2)[N+](=O)[O-]
DM1D2O0	IK	FIOKOSHFWPOUGX-UHFFFAOYSA-N
DM1D2O0	IU	N-[1-(4-chlorophenyl)ethyl]-2-(4-nitrophenoxy)acetamide
DM1D2O0	DE	Solid tumour/cancer

DMZMSBI	ID	DMZMSBI
DMZMSBI	DN	KO-947
DMZMSBI	HS	Phase 1
DMZMSBI	SN	ODIUJYZERXVGEI-UHFFFAOYSA-N; KO947; 1695533-89-1; GTPL9976; SCHEMBL16619993; EX-A1980; BCP25116; HY-112181; CS-0043627; 6-benzyl-3-pyridin-4-yl-2,5-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one; 6-benzyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[4,3-g]quinazolin-7-one; KO947,1695533-89-1,1,5,6,8-Tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one,KO947,KO-947,KO 947
DMZMSBI	CP	Kura Oncology San Diego, CA
DMZMSBI	PC	136653617
DMZMSBI	MW	355.4
DMZMSBI	FM	C21H17N5O
DMZMSBI	IC	InChI=1S/C21H17N5O/c27-21-23-18-11-19-17(20(25-24-19)15-6-8-22-9-7-15)10-16(18)13-26(21)12-14-4-2-1-3-5-14/h1-11H,12-13H2,(H,23,27)(H,24,25)
DMZMSBI	CS	C1C2=CC3=C(C=C2NC(=O)N1CC4=CC=CC=C4)NN=C3C5=CC=NC=C5
DMZMSBI	IK	ODIUJYZERXVGEI-UHFFFAOYSA-N
DMZMSBI	IU	6-benzyl-3-pyridin-4-yl-5,8-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one
DMZMSBI	DE	Solid tumour/cancer

DM4953W	ID	DM4953W
DM4953W	DN	KOS-2187
DM4953W	HS	Phase 1
DM4953W	CP	Kosan Biosci.
DM4953W	DT	Small molecular drug
DM4953W	PC	56603679
DM4953W	MW	812
DM4953W	FM	C43H73NO13
DM4953W	IC	InChI=1S/C43H73NO13/c1-22(2)44(12)30-19-24(4)53-40(33(30)46)57-37-26(6)34(55-31-21-42(10,52-13)36(48)28(8)54-31)27(7)39(49)56-38(29-17-15-14-16-18-29)43(11,51)35(47)25(5)32(45)23(3)20-41(37,9)50/h14-18,22-28,30-38,40,45-48,50-51H,19-21H2,1-13H3/t23-,24?,25+,26+,27-,28?,30?,31?,32+,33?,34+,35-,36?,37-,38-,40?,41-,42?,43+/m1/s1
DM4953W	CS	C[C@@H]1C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O[C@@H]([C@@]([C@@H]([C@H]([C@H]1O)C)O)(C)O)C2=CC=CC=C2)C)OC3CC(C(C(O3)C)O)(C)OC)C)OC4C(C(CC(O4)C)N(C)C(C)C)O)(C)O
DM4953W	IK	BCKWPVFDVOGCTM-AFGVNUEFSA-N
DM4953W	IU	(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-7,10,12,13-tetrahydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-6-[3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-14-phenyl-oxacyclotetradecan-2-one
DM4953W	DE	Gastroesophageal reflux disease; Gastrointestinal disease

DMSKI8W	ID	DMSKI8W
DMSKI8W	DN	KPG-121
DMSKI8W	HS	Phase 1
DMSKI8W	CP	Kangpu Biopharmaceuticals
DMSKI8W	DT	Small molecular drug
DMSKI8W	DE	Prostate cancer

DM1O2X6	ID	DM1O2X6
DM1O2X6	DN	KPG-818
DM1O2X6	HS	Phase 1
DM1O2X6	CP	Kangpu Biopharmaceuticals
DM1O2X6	DT	Small molecular drug
DM1O2X6	DE	Systemic lupus erythematosus

DMYBHER	ID	DMYBHER
DMYBHER	DN	KPL-716
DMYBHER	HS	Phase 1
DMYBHER	CP	Kiniksa Pharmaceuticals Lexington, MA
DMYBHER	DE	Atopic dermatitis; Nodular prurigo

DM9JXMD	ID	DM9JXMD
DM9JXMD	DN	KPT-9274
DM9JXMD	HS	Phase 1
DM9JXMD	SN	Pak4-IN-1; PAK4-IN-1; 1643913-93-2; UNII-9T56TV18X7; 9T56TV18X7; SCHEMBL16345416; SCHEMBL16348032; KPT9274; EX-A563; BCP10637; KPT 9274;KPT9274; ZINC253387914; AKOS030526635; CS-5146; SB19836; PAK4-IN-1 pound KPT9274 pound(c); NCGC00484085-01; HY-12793; J-690230; 2-Propenamide, 3-(6-amino-3-pyridinyl)-N-((5-(4-((4,4-difluoro-1-piperidinyl)carbonyl)phenyl)-7-(4-fluorophenyl)-2-benzofuranyl)methyl)-, (2E)-; 4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide; (E)-3-(6-aminopyridin-3-
DM9JXMD	CP	Karyopharm Therapeutics Newton, MA
DM9JXMD	PC	117779453
DM9JXMD	MW	610.6
DM9JXMD	FM	C35H29F3N4O3
DM9JXMD	IC	InChI=1S/C35H29F3N4O3/c36-28-9-7-24(8-10-28)30-19-26(23-3-5-25(6-4-23)34(44)42-15-13-35(37,38)14-16-42)17-27-18-29(45-33(27)30)21-41-32(43)12-2-22-1-11-31(39)40-20-22/h1-12,17-20H,13-16,21H2,(H2,39,40)(H,41,43)/b12-2+
DM9JXMD	CS	C1CN(CCC1(F)F)C(=O)C2=CC=C(C=C2)C3=CC(=C4C(=C3)C=C(O4)CNC(=O)/C=C/C5=CN=C(C=C5)N)C6=CC=C(C=C6)F
DM9JXMD	IK	MRFOPLWJZULAQD-SWGQDTFXSA-N
DM9JXMD	IU	(E)-3-(6-aminopyridin-3-yl)-N-[[5-[4-(4,4-difluoropiperidine-1-carbonyl)phenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl]methyl]prop-2-enamide
DM9JXMD	CA	CAS 1643913-93-2
DM9JXMD	DE	Non-hodgkin lymphoma; Solid tumour/cancer

DMK0BTN	ID	DMK0BTN
DMK0BTN	DN	KQ-791
DMK0BTN	HS	Phase 1
DMK0BTN	CP	Kaneq Bioscience Montreal, Canada
DMK0BTN	DE	Type-2 diabetes

DMODGJU	ID	DMODGJU
DMODGJU	DN	KRN633
DMODGJU	HS	Phase 1
DMODGJU	SN	KRN-633; VEGF Receptor Tyrosine Kinase Inhibitor III, KRN633; KRN633, KRN-633, KRN 633; N-(2-Chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N&prime;-propylurea
DMODGJU	CP	Kirin
DMODGJU	TC	Anticancer Agents
DMODGJU	DT	Small molecular drug
DMODGJU	PC	9549295
DMODGJU	MW	416.9
DMODGJU	FM	C20H21ClN4O4
DMODGJU	IC	InChI=1S/C20H21ClN4O4/c1-4-7-22-20(26)25-15-6-5-12(8-14(15)21)29-19-13-9-17(27-2)18(28-3)10-16(13)23-11-24-19/h5-6,8-11H,4,7H2,1-3H3,(H2,22,25,26)
DMODGJU	CS	CCCNC(=O)NC1=C(C=C(C=C1)OC2=NC=NC3=CC(=C(C=C32)OC)OC)Cl
DMODGJU	IK	VPBYZLCHOKSGRX-UHFFFAOYSA-N
DMODGJU	IU	1-[2-chloro-4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-propylurea
DMODGJU	CA	CAS 286370-15-8
DMODGJU	DE	Solid tumour/cancer; Glioma

DM8FQPX	ID	DM8FQPX
DM8FQPX	DN	KTN3379
DM8FQPX	HS	Phase 1
DM8FQPX	CP	Kolltan pharmaceuticals
DM8FQPX	DT	Antibody
DM8FQPX	DE	Solid tumour/cancer

DMTFWLE	ID	DMTFWLE
DMTFWLE	DN	KUC-7483
DMTFWLE	HS	Phase 1
DMTFWLE	SN	Ritobegron ethyl ester; KUC-7322; Beta 3 adrenoceptor agonists (urinary incontinence), Kissei; N-phenylglycine derivatives, Kissei; 4-hydroxynorephedrine derivative (urinary incontinence), Kissei
DMTFWLE	CP	Kissei Pharmaceutical Co Ltd
DMTFWLE	PC	9820882
DMTFWLE	MW	373.4
DMTFWLE	FM	C21H27NO5
DMTFWLE	IC	InChI=1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1
DMTFWLE	CS	CC1=CC(=C(C=C1OCC(=O)O)C)CCN[C@@H](C)[C@@H](C2=CC=C(C=C2)O)O
DMTFWLE	IK	VMMYRRFPMAGXNP-BTYIYWSLSA-N
DMTFWLE	IU	2-[4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid
DMTFWLE	CA	CAS 255734-04-4
DMTFWLE	DE	Overactive bladder

DMKFVX5	ID	DMKFVX5
DMKFVX5	DN	KUL-7211
DMKFVX5	HS	Phase 1
DMKFVX5	CP	Kissei Pharmaceutical Co Ltd
DMKFVX5	PC	9798256
DMKFVX5	MW	345.4
DMKFVX5	FM	C19H23NO5
DMKFVX5	IC	InChI=1S/C19H23NO5/c1-13(19(24)15-4-6-16(21)7-5-15)20-11-10-14-2-8-17(9-3-14)25-12-18(22)23/h2-9,13,19-21,24H,10-12H2,1H3,(H,22,23)/t13-,19-/m0/s1
DMKFVX5	CS	C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)OCC(=O)O
DMKFVX5	IK	KKXPBQQLKHBRDA-DJJJIMSYSA-N
DMKFVX5	IU	2-[4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenoxy]acetic acid
DMKFVX5	DE	Neurogenic bladder dysfunction

DMKMN5R	ID	DMKMN5R
DMKMN5R	DN	KUR-501
DMKMN5R	HS	Phase 1
DMKMN5R	SN	CMD-501
DMKMN5R	CP	Kuur Therapeutics
DMKMN5R	DT	CAR-NKT Cell therapy
DMKMN5R	DE	Neuroblastoma

DMS9LVC	ID	DMS9LVC
DMS9LVC	DN	KUR-502
DMS9LVC	HS	Phase 1
DMS9LVC	CP	Kuur Therapeutics
DMS9LVC	DT	CAR T Cell Therapy
DMS9LVC	DE	B-cell lymphoma

DMFO7RP	ID	DMFO7RP
DMFO7RP	DN	KW-2449
DMFO7RP	HS	Phase 1
DMFO7RP	SN	Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo
DMFO7RP	CP	Kyowa Hakko Kogyo Co Ltd
DMFO7RP	DT	Small molecular drug
DMFO7RP	PC	11427553
DMFO7RP	MW	332.4
DMFO7RP	FM	C20H20N4O
DMFO7RP	IC	InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10,21H,11-14H2,(H,22,23)/b10-7+
DMFO7RP	CS	C1CN(CCN1)C(=O)C2=CC=C(C=C2)/C=C/C3=NNC4=CC=CC=C43
DMFO7RP	IK	YYLKKYCXAOBSRM-JXMROGBWSA-N
DMFO7RP	IU	[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone
DMFO7RP	CA	CAS 841258-76-2
DMFO7RP	CB	CHEBI:91441
DMFO7RP	DE	Acute myeloid leukaemia

DMALK7F	ID	DMALK7F
DMALK7F	DN	KW-5092
DMALK7F	HS	Phase 1
DMALK7F	SN	Propanedinitrile, (1-(2-(((5-(1-piperidinylmethyl)-2-furanyl)methyl)amino)ethyl)-2-imidazolidinylidene)-, (E)-2-butenedioate (1:1); Propanedinitrile, (1-(2-(((5-(1-piperidinylmethyl)-2-furanyl)methyl)amino)etyhyl)-2-imidazolidinylidene)-, (E)-2-butenedioate (1:1); 135017-85-5; C19H26N6O.C4H4O4; AC1O5RKQ; LS-120041; (1-(2-(((5-(piperidinomethyl)-2-furanyl)methyl)amino)ethyl)-2-imidazolidinylidene)propanedinitrile fumarate
DMALK7F	DT	Small molecular drug
DMALK7F	PC	6439389
DMALK7F	MW	470.5
DMALK7F	FM	C23H30N6O5
DMALK7F	IC	InChI=1S/C19H26N6O.C4H4O4/c20-12-16(13-21)19-23-7-11-25(19)10-6-22-14-17-4-5-18(26-17)15-24-8-2-1-3-9-24;5-3(6)1-2-4(7)8/h4-5,22-23H,1-3,6-11,14-15H2;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMALK7F	CS	C1CCN(CC1)CC2=CC=C(O2)CNCCN3CCNC3=C(C#N)C#N.C(=C/C(=O)O)\\C(=O)O
DMALK7F	IK	ULJCVCIVEVXIKD-WLHGVMLRSA-N
DMALK7F	IU	(E)-but-2-enedioic acid;2-[1-[2-[[5-(piperidin-1-ylmethyl)furan-2-yl]methylamino]ethyl]imidazolidin-2-ylidene]propanedinitrile
DMALK7F	CA	CAS 135017-85-5
DMALK7F	DE	Pain

DML4H05	ID	DML4H05
DML4H05	DN	KX2-361
DML4H05	HS	Phase 1
DML4H05	SN	KX-02
DML4H05	CP	Kinex pharmaceuticals
DML4H05	PC	11545920
DML4H05	MW	405.5
DML4H05	FM	C24H24FN3O2
DML4H05	IC	InChI=1S/C24H24FN3O2/c25-21-3-1-2-18(14-21)16-27-24(29)15-22-7-4-20(17-26-22)19-5-8-23(9-6-19)28-10-12-30-13-11-28/h1-9,14,17H,10-13,15-16H2,(H,27,29)
DML4H05	CS	C1COCCN1C2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC(=CC=C4)F
DML4H05	IK	CMKKPJNMYLOUCE-UHFFFAOYSA-N
DML4H05	IU	N-[(3-fluorophenyl)methyl]-2-[5-(4-morpholin-4-ylphenyl)pyridin-2-yl]acetamide
DML4H05	CA	CAS 897016-26-1
DML4H05	DE	Brain cancer; Glioblastoma multiforme

DMWSC5L	ID	DMWSC5L
DMWSC5L	DN	L-778123
DMWSC5L	HS	Phase 1
DMWSC5L	SN	183499-57-2; L-778123; UNII-31ZXM8ZKQ3; 4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE; 31ZXM8ZKQ3; CHEMBL279433; 4-((5-((4-(3-chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)benzonitrile; L-778123 free base; 4-[[5-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile; 4-[(5-{[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl}imidazol-1-yl)methyl]benzonitrile; SCHEMBL1683541; AC1L50Q0; CTK7C7787; 1s63; 1s64; BDBM50097071; ZINC53070632
DMWSC5L	DT	Small molecular drug
DMWSC5L	PC	216454
DMWSC5L	MW	405.9
DMWSC5L	FM	C22H20ClN5O
DMWSC5L	IC	InChI=1S/C22H20ClN5O/c23-19-2-1-3-20(10-19)28-9-8-26(15-22(28)29)14-21-12-25-16-27(21)13-18-6-4-17(11-24)5-7-18/h1-7,10,12,16H,8-9,13-15H2
DMWSC5L	CS	C1CN(C(=O)CN1CC2=CN=CN2CC3=CC=C(C=C3)C#N)C4=CC(=CC=C4)Cl
DMWSC5L	IK	JNUGFGAVPBYSHF-UHFFFAOYSA-N
DMWSC5L	IU	4-[[5-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile
DMWSC5L	CA	CAS 183499-57-2
DMWSC5L	DE	Lymphoma

DMXKO1L	ID	DMXKO1L
DMXKO1L	DN	L-796568
DMXKO1L	HS	Phase 1
DMXKO1L	SN	UNII-P50A5YTO0O; L-796568; P50A5YTO0O; CHEMBL111201; AC1MI4YO; L-796568 free base; SCHEMBL1276546; BDBM50092645; N-{4-[2-((R)-2-hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-4-[3-(4-trifluoromethyl-phenyl)-thiazol-2-yl]-benzenesulfonamide; (R)-N-(4-(2-((2-Hydroxy-2-(pyridin-3-yl)ethyl)amino)ethyl)phenyl)-4-(4-(4-trifluoromethylphenyl)thiazol-2-yl)benzenesulfonamide; (1R)-1-(3-Pyridyl)-2-[4-[[4-[4-[4-(trifluoromethyl)phenyl]-2-thiazolyl]phenyl]sulfonylamino]phenethylamino]ethanol
DMXKO1L	DT	Small molecular drug
DMXKO1L	PC	3038500
DMXKO1L	MW	624.7
DMXKO1L	FM	C31H27F3N4O3S2
DMXKO1L	IC	InChI=1S/C31H27F3N4O3S2/c32-31(33,34)25-9-5-22(6-10-25)28-20-42-30(37-28)23-7-13-27(14-8-23)43(40,41)38-26-11-3-21(4-12-26)15-17-36-19-29(39)24-2-1-16-35-18-24/h1-14,16,18,20,29,36,38-39H,15,17,19H2/t29-/m0/s1
DMXKO1L	CS	C1=CC(=CN=C1)[C@H](CNCCC2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=NC(=CS4)C5=CC=C(C=C5)C(F)(F)F)O
DMXKO1L	IK	MSOUIIHPMJCUNI-LJAQVGFWSA-N
DMXKO1L	IU	N-[4-[2-[[(2R)-2-hydroxy-2-pyridin-3-ylethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]benzenesulfonamide
DMXKO1L	CA	CAS 211031-01-5
DMXKO1L	DE	Obesity

DM8ANIM	ID	DM8ANIM
DM8ANIM	DN	Lactermin
DM8ANIM	HS	Phase 1
DM8ANIM	SN	PV-701, GroPep
DM8ANIM	CP	Novozymes GroPep Limited
DM8ANIM	DE	Oral mucositis

DMO4GPK	ID	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	HS	Phase 1
DMO4GPK	SN	Aletobiose; D-(+)-Lactose; D-Lactose; Fast-flo; Fast-flo Lactose; Galactinum; Lactin; Lactobiose; Lactose; Lactose [JAN]; Lactose anhydrous; Lactosum anhydricum; Milk sugar; Pharmatose 450M; Saccharum lactin; beta-D-Lactose; beta-Lactose; (+)-Lactose; .beta.-Lactose; 4-(beta-D-Galactosido)-D-glucose; 4-O-beta-D-Galactopyranosyl-D-glucose; 4-O-beta-D-Galactopyranosyl-beta-D-glucopyranose; 5965-66-2; D-Glucose, 4-O-beta-D-galactopyranosyl; EINECS 227-751-9; UNII-13Q3A43E0S; beta-D-Glucopyranose, 4-O-beta-D-galactopyranosyl-
DMO4GPK	PC	6134
DMO4GPK	MW	342.3
DMO4GPK	FM	C12H22O11
DMO4GPK	IC	GUBGYTABKSRVRQ-DCSYEGIMSA-N
DMO4GPK	CS	C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)O)CO)O)O)O)O
DMO4GPK	IK	1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12+/m1/s1
DMO4GPK	IU	(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DMO4GPK	CA	CAS 5965-66-2
DMO4GPK	CB	CHEBI:36218
DMO4GPK	DE	Lactose intolerance

DMC0VJF	ID	DMC0VJF
DMC0VJF	DN	Laevo-Bambuterol
DMC0VJF	HS	Phase 1
DMC0VJF	SN	R-Bambuterol; R-bambuterol hydrochloride
DMC0VJF	CP	Dongguan Kaifa Biomedicine Inc
DMC0VJF	DE	Asthma

DM7JNHU	ID	DM7JNHU
DM7JNHU	DN	LAM-001
DM7JNHU	HS	Phase 1
DM7JNHU	CP	LAM Therapeutics Guilford, CT
DM7JNHU	DE	Lymphangioleiomyomatosis

DMQHWMJ	ID	DMQHWMJ
DMQHWMJ	DN	LAM-003
DMQHWMJ	HS	Phase 1
DMQHWMJ	CP	AI Therapeutics
DMQHWMJ	DE	Acute myeloid leukaemia; Non-hodgkin lymphoma

DM1C4UM	ID	DM1C4UM
DM1C4UM	DN	LAMB3-transduced autologous epidermal stem cells
DM1C4UM	HS	Phase 1
DM1C4UM	SN	LAMB3-transduced autologous epidermal stem cells (retroviral vector, junctionalepidermolysis bullosa), University of Modena and Reggio Emilia/Holostem; LAMB3-transduced autologous epidermal stem cells (ZFN-mediated transduction, epidermolysis bullosa), University of Modena and Reggio Amilia/San Raffaele-Telethon Institute for Gene Therapy/Sangamo
DM1C4UM	CP	University of Modena; Reggio Emilia
DM1C4UM	DE	Epidermolysis bullosa

DMV80DP	ID	DMV80DP
DMV80DP	DN	LAS-186323
DMV80DP	HS	Phase 1
DMV80DP	SN	DHODH inhibitor (autoimmune disease), Alimirall; DHODH inhibitor (rheumatoid arthritis/multiple sclerosis), Almirall
DMV80DP	CP	Almirall Prodesfarma SA
DMV80DP	DE	Multiple sclerosis

DM4YA0D	ID	DM4YA0D
DM4YA0D	DN	LBR-101
DM4YA0D	HS	Phase 1
DM4YA0D	CP	Labrys biologics
DM4YA0D	DT	Antibody
DM4YA0D	DE	Migraine

DMJEACT	ID	DMJEACT
DMJEACT	DN	LC-1
DMJEACT	HS	Phase 1
DMJEACT	SN	Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix
DMJEACT	CP	Leuchemix Inc
DMJEACT	DE	Acute myeloid leukaemia

DMHT3CB	ID	DMHT3CB
DMHT3CB	DN	LC-350189
DMHT3CB	HS	Phase 1
DMHT3CB	DE	Gout

DMEY2LK	ID	DMEY2LK
DMEY2LK	DN	LCAR-B4822M CAR-T Cell
DMEY2LK	HS	Phase 1
DMEY2LK	CP	Second Affiliated Hospital of Xi'an Jiaotong University
DMEY2LK	DT	CAR T Cell Therapy
DMEY2LK	DE	Multiple myeloma

DM9LYXQ	ID	DM9LYXQ
DM9LYXQ	DN	Leflunomide
DM9LYXQ	HS	Phase 1
DM9LYXQ	SN	leflunomide; 75706-12-6; Arava; lefunamide; Leflunomidum; Leflunomida; HWA 486; Leflunomidum [INN-Latin]; HWA-486; Leflunomida [INN-Spanish]; SU 101 (pharmaceutical); SU101; Arava (TN); UNII-G162GK9U4W; S; Leflunomide
DM9LYXQ	TC	Antiviral Agents
DM9LYXQ	DT	Small molecular drug
DM9LYXQ	PC	3899
DM9LYXQ	MW	270.21
DM9LYXQ	FM	C12H9F3N2O2
DM9LYXQ	IC	InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
DM9LYXQ	CS	CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
DM9LYXQ	IK	VHOGYURTWQBHIL-UHFFFAOYSA-N
DM9LYXQ	IU	5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
DM9LYXQ	CA	CAS 75706-12-6
DM9LYXQ	CB	CHEBI:6402
DM9LYXQ	DE	Coronavirus Disease 2019 (COVID-19)

DMKZVLH	ID	DMKZVLH
DMKZVLH	DN	Lefradafiban
DMKZVLH	HS	Phase 1
DMKZVLH	SN	BIBU-104; BIBU-104XX; BIBV-104
DMKZVLH	CP	Boehringer Ingelheim Corp
DMKZVLH	DT	Small molecular drug
DMKZVLH	PC	9576916
DMKZVLH	MW	439.5
DMKZVLH	FM	C23H25N3O6
DMKZVLH	IC	InChI=1S/C23H25N3O6/c1-30-20(27)12-17-11-18(25-22(17)28)13-32-19-9-7-15(8-10-19)14-3-5-16(6-4-14)21(24)26-23(29)31-2/h3-10,17-18H,11-13H2,1-2H3,(H,25,28)(H2,24,26,29)/t17-,18-/m0/s1
DMKZVLH	CS	COC(=O)C[C@@H]1C[C@H](NC1=O)COC2=CC=C(C=C2)C3=CC=C(C=C3)/C(=N/C(=O)OC)/N
DMKZVLH	IK	PGCFXITVMNNKON-ROUUACIJSA-N
DMKZVLH	IU	methyl 2-[(3S,5S)-5-[[4-[4-[(Z)-N'-methoxycarbonylcarbamimidoyl]phenyl]phenoxy]methyl]-2-oxopyrrolidin-3-yl]acetate
DMKZVLH	CA	CAS 149503-79-7
DMKZVLH	CB	CHEBI:60634
DMKZVLH	DE	Angina pectoris

DM5INZP	ID	DM5INZP
DM5INZP	DN	LEQ-506
DM5INZP	HS	Phase 1
DM5INZP	PC	45100669
DM5INZP	MW	432.6
DM5INZP	FM	C25H32N6O
DM5INZP	IC	InChI=1S/C25H32N6O/c1-17-16-30(11-12-31(17)23-15-26-22(14-27-23)25(4,5)32)24-19(3)18(2)21(28-29-24)13-20-9-7-6-8-10-20/h6-10,14-15,17,32H,11-13,16H2,1-5H3/t17-/m1/s1
DM5INZP	CS	C[C@@H]1CN(CCN1C2=NC=C(N=C2)C(C)(C)O)C3=NN=C(C(=C3C)C)CC4=CC=CC=C4
DM5INZP	IK	POERAARDVFVDLO-QGZVFWFLSA-N
DM5INZP	IU	2-[5-[(2R)-4-(6-benzyl-4,5-dimethylpyridazin-3-yl)-2-methylpiperazin-1-yl]pyrazin-2-yl]propan-2-ol
DM5INZP	CA	CAS 1204975-42-7
DM5INZP	DE	Solid tumour/cancer

DMNHPOT	ID	DMNHPOT
DMNHPOT	DN	LErafAON
DMNHPOT	HS	Phase 1
DMNHPOT	SN	RafAON; Antisense raf oligonucleotide, NeoPharm; LErafAON, Insys; LErafAON-ETU; Liposomal antisense therapy, NeoPharm; Cancer therapeutic (antisense), NeoPharm; Liposome encapsulated c-raf antisense oligodeoxynucleotide, NeoPharm; Antisense oligonucleotides (liposome-encapsulated), NeoPharm
DMNHPOT	CP	NeoPharm
DMNHPOT	DT	Antisense drug
DMNHPOT	DE	Solid tumour/cancer

DM2B0TJ	ID	DM2B0TJ
DM2B0TJ	DN	Leukocyte interleukin
DM2B0TJ	HS	Phase 1
DM2B0TJ	SN	Multikine (TN)
DM2B0TJ	CP	CEL-SCI
DM2B0TJ	DE	Human immunodeficiency virus infection; Head and neck cancer

DMI4O92	ID	DMI4O92
DMI4O92	DN	LFA-102
DMI4O92	HS	Phase 1
DMI4O92	CP	Novartis AG
DMI4O92	DT	Antibody
DMI4O92	DE	Solid tumour/cancer

DMAG6BV	ID	DMAG6BV
DMAG6BV	DN	LGK974
DMAG6BV	HS	Phase 1
DMAG6BV	SN	1243244-14-5; LGK974; LGK-974; 2-(2',3-Dimethyl-[2,4'-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide; WNT-974; LGK 974; UNII-U27F40013Q; CHEBI:78030; CHEMBL3188386; U27F40013Q; AK165831; 2-(2',3-dimethyl-2,4'-bipyridin-5-yl)-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide; MLS006011002; SCHEMBL1723611; KS-00000SUI; MolPort-029-945-290; HMS3653G11; BCP08495; EX-A1402; ZINC95930187; STL556617; BDBM50133870; BBL102809; 2140AH; s7143; AKOS025211913; SB19314; CS-2807; DB12561; NCGC00347950-07; NCGC00347950-01; OR302651; QC-11701
DMAG6BV	DT	Small molecular drug
DMAG6BV	PC	46926973
DMAG6BV	MW	396.4
DMAG6BV	FM	C23H20N6O
DMAG6BV	IC	InChI=1S/C23H20N6O/c1-15-9-17(12-28-23(15)18-5-6-25-16(2)10-18)11-22(30)29-21-4-3-19(13-27-21)20-14-24-7-8-26-20/h3-10,12-14H,11H2,1-2H3,(H,27,29,30)
DMAG6BV	CS	CC1=CC(=CN=C1C2=CC(=NC=C2)C)CC(=O)NC3=NC=C(C=C3)C4=NC=CN=C4
DMAG6BV	IK	XXYGTCZJJLTAGH-UHFFFAOYSA-N
DMAG6BV	IU	2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-(5-pyrazin-2-ylpyridin-2-yl)acetamide
DMAG6BV	CA	CAS 1243244-14-5
DMAG6BV	CB	CHEBI:78030
DMAG6BV	DE	Solid tumour/cancer

DMYK52O	ID	DMYK52O
DMYK52O	DN	LHC165
DMYK52O	HS	Phase 1
DMYK52O	SN	LHC-165; 1258595-14-0; 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid; UNII-RD02U4QLM1; RD02U4QLM1; SCHEMBL174281; US9597326, Compound 20; BDBM301804; NSC819211; s8838; NSC-819211; HY-111786; CS-0091872; 3-(5-amino-2-(4-(2-(3,3-difluoro-3-phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid; Benzo(F)(1,7)naphthyridine-8-propanoic acid, 5-amino-2-(2-(4-(2-(3,3-difluoro-3-phosphonopropoxy)ethoxy)-2-methylphenyl)ethyl)-
DMYK52O	CP	Novartis
DMYK52O	DT	Small molecular drug
DMYK52O	PC	49838259
DMYK52O	MW	603.5
DMYK52O	FM	C29H32F2N3O7P
DMYK52O	IC	InChI=1S/C29H32F2N3O7P/c1-18-14-22(41-13-12-40-11-10-29(30,31)42(37,38)39)7-6-21(18)5-2-20-15-24-23-8-3-19(4-9-26(35)36)16-25(23)34-28(32)27(24)33-17-20/h3,6-8,14-17H,2,4-5,9-13H2,1H3,(H2,32,34)(H,35,36)(H2,37,38,39)
DMYK52O	CS	CC1=C(C=CC(=C1)OCCOCCC(F)(F)P(=O)(O)O)CCC2=CC3=C4C=CC(=CC4=NC(=C3N=C2)N)CCC(=O)O
DMYK52O	IK	SDLWKRZBLTZSEL-UHFFFAOYSA-N
DMYK52O	IU	3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid
DMYK52O	CA	CAS 1258595-14-0
DMYK52O	DE	Solid tumour/cancer

DMFNSHM	ID	DMFNSHM
DMFNSHM	DN	LHF-535
DMFNSHM	HS	Phase 1
DMFNSHM	SN	BET7FM8SQG; UNII-BET7FM8SQG; 1450929-77-7; (Z)-2-(4-(2-(1-(4-Isopropoxyphenyl)-1H-benzo[d]imidazol-5-yl)vinyl)phenyl)propan-2-ol; CHEMBL4537239; SCHEMBL15201523; HY-112762; CS-0063343; 2-[4-[(Z)-2-[1-(4-propan-2-yloxyphenyl)benzimidazol-5-yl]ethenyl]phenyl]propan-2-ol; Benzenemethanol, alpha,alpha-dimethyl-4-((1Z)-2-(1-(4-(1-methylethoxy)phenyl)-1H-benzimidazol-5-yl)ethenyl)-
DMFNSHM	CP	Kineta
DMFNSHM	DT	Small molecular drug
DMFNSHM	PC	71711529
DMFNSHM	MW	412.5
DMFNSHM	FM	C27H28N2O2
DMFNSHM	IC	InChI=1S/C27H28N2O2/c1-19(2)31-24-14-12-23(13-15-24)29-18-28-25-17-21(9-16-26(25)29)6-5-20-7-10-22(11-8-20)27(3,4)30/h5-19,30H,1-4H3/b6-5-
DMFNSHM	CS	CC(C)OC1=CC=C(C=C1)N2C=NC3=C2C=CC(=C3)/C=C\\C4=CC=C(C=C4)C(C)(C)O
DMFNSHM	IK	DBNZTRPIBJSUIX-WAYWQWQTSA-N
DMFNSHM	IU	2-[4-[(Z)-2-[1-(4-propan-2-yloxyphenyl)benzimidazol-5-yl]ethenyl]phenyl]propan-2-ol
DMFNSHM	CA	CAS 1450929-77-7
DMFNSHM	DE	Lassa fever

DMJRALD	ID	DMJRALD
DMJRALD	DN	LIPO-4
DMJRALD	HS	Phase 1
DMJRALD	SN	HIV vaccine (four peptide), INRS
DMJRALD	CP	INRS-Institut Armand-Frappier
DMJRALD	DT	Vaccine
DMJRALD	DE	Human immunodeficiency virus infection

DMESZQU	ID	DMESZQU
DMESZQU	DN	Litenimod
DMESZQU	HS	Phase 1
DMESZQU	SN	Li-28; CpG oligonucleotide immunomodulator (cancer), Oligovax
DMESZQU	CP	Oligovax SAS
DMESZQU	PC	56841944
DMESZQU	MW	8370
DMESZQU	FM	C256H322N95O129P25S25
DMESZQU	IC	InChI=1S/C256H322N95O129P25S25/c1-101-44-330(248(371)317-227(101)354)166-18-110(353)137(431-166)54-405-481(380,506)468-123-31-179(339-88-292-192-205(261)274-79-283-214(192)339)444-150(123)67-418-483(382,508)457-112-20-167(326-14-10-162(257)305-244(326)367)432-138(112)55-407-487(386,512)461-116-24-172(332-46-103(3)229(356)319-250(332)373)440-146(116)63-415-499(398,524)477-132-40-188(348-97-301-201-223(348)309-240(270)313-236(201)363)452-158(132)75-426-484(383,509)460-115-23-170(329-17-13-165(260)308-247(329)370)435-141(115)58-410-496(395,521)471-127-35-183(343-92-296-196-209(265)278-83-287-218(196)343)451-157(127)74-425-505(404,530)480-135-43-191(351-100-304-204-226(351)312-243(273)316-239(204)366)455-161(135)78-429-493(392,518)467-122-30-178(338-52-109(9)235(362)325-256(338)379)439-145(122)62-414-498(397,523)473-129-37-185(345-94-298-198-211(267)280-85-289-220(198)345)446-152(129)69-420-491(390,516)465-120-28-176(336-50-107(7)233(360)323-254(336)377)437-143(120)60-412-489(388,514)463-118-26-174(334-48-105(5)231(358)321-252(334)375)442-148(118)65-417-500(399,525)478-133-41-189(349-98-302-202-224(349)310-241(271)314-237(202)364)453-159(133)76-427-485(384,510)458-113-21-168(327-15-11-163(258)306-245(327)368)433-139(113)56-408-494(393,519)469-125-33-181(341-90-294-194-207(263)276-81-285-216(194)341)448-154(125)71-423-503(402,528)475-130-38-186(346-95-299-199-212(268)281-86-290-221(199)346)447-153(130)70-421-492(391,517)466-121-29-177(337-51-108(8)234(361)324-255(337)378)438-144(121)61-413-497(396,522)472-128-36-184(344-93-297-197-210(266)279-84-288-219(197)344)445-151(128)68-419-490(389,515)464-119-27-175(335-49-106(6)232(359)322-253(335)376)436-142(119)59-411-488(387,513)462-117-25-173(333-47-104(4)230(357)320-251(333)374)441-147(117)64-416-501(400,526)479-134-42-190(350-99-303-203-225(350)311-242(272)315-238(203)365)454-160(134)77-428-486(385,511)459-114-22-169(328-16-12-164(259)307-246(328)369)434-140(114)57-409-495(394,520)470-126-34-182(342-91-295-195-208(264)277-82-286-217(195)342)449-155(126)72-424-504(403,529)476-131-39-187(347-96-300-200-213(269)282-87-291-222(200)347)450-156(131)73-422-502(401,527)474-124-32-180(340-89-293-193-206(262)275-80-284-215(193)340)443-149(124)66-406-482(381,507)456-111-19-171(430-136(111)53-352)331-45-102(2)228(355)318-249(331)372/h10-17,44-52,79-100,110-161,166-191,352-353H,18-43,53-78H2,1-9H3,(H,380,506)(H,381,507)(H,382,508)(H,383,509)(H,384,510)(H,385,511)(H,386,512)(H,387,513)(H,388,514)(H,389,515)(H,390,516)(H,391,517)(H,392,518)(H,393,519)(H,394,520)(H,395,521)(H,396,522)(H,397,523)(H,398,524)(H,399,525)(H,400,526)(H,401,527)(H,402,528)(H,403,529)(H,404,530)(H2,257,305,367)(H2,258,306,368)(H2,259,307,369)(H2,260,308,370)(H2,261,274,283)(H2,262,275,284)(H2,263,276,285)(H2,264,277,286)(H2,265,278,287)(H2,266,279,288)(H2,267,280,289)(H2,268,281,290)(H2,269,282,291)(H,317,354,371)(H,318,355,372)(H,319,356,373)(H,320,357,374)(H,321,358,375)(H,322,359,376)(H,323,360,377)(H,324,361,378)(H,325,362,379)(H3,270,309,313,363)(H3,271,310,314,364)(H3,272,311,315,365)(H3,273,312,316,366)
DMESZQU	CS	CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)O
DMESZQU	IK	CJZRVARTODENJN-UHFFFAOYSA-N
DMESZQU	IU	1-[5-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[5-(6-aminopurin-9-yl)-2-[[[5-(6-aminopurin-9-yl)-2-[[[5-(6-aminopurin-9-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMESZQU	DE	Glioblastoma multiforme

DMR7LKC	ID	DMR7LKC
DMR7LKC	DN	LM-CD45
DMR7LKC	HS	Phase 1
DMR7LKC	SN	Anti-CD45, Baxter; Anti-CD45, Cantab
DMR7LKC	CP	Cantab Biopharmaceuticals Ltd
DMR7LKC	DT	Antibody
DMR7LKC	DE	Transplant rejection

DMU901D	ID	DMU901D
DMU901D	DN	L-MDAM
DMU901D	HS	Phase 1
DMU901D	SN	L-MDAM; 176857-41-3; UNII-W9CXL7O6LL; W9CXL7O6LL; GAMMA-METHYLENE-10-DEAZAAMINOPTERIN; MDAM; SCHEMBL1065136; ZINC1542008; KB-78169; Z-3290; L-Glutamic acid, N-(4-(2-(2,4-diamino-6-pteridinyl)ethyl)benzoyl)-4-methylene-; (2S)-2-[4-[2-(2,4-Diamino-6-pteridinyl)ethyl]benzoylamino]-4-methyleneglutaric acid
DMU901D	CP	BioNumerik Pharmaceuticals
DMU901D	DT	Small molecular drug
DMU901D	PC	9803852
DMU901D	MW	451.4
DMU901D	FM	C21H21N7O5
DMU901D	IC	InChI=1S/C21H21N7O5/c1-10(19(30)31)8-14(20(32)33)26-18(29)12-5-2-11(3-6-12)4-7-13-9-24-17-15(25-13)16(22)27-21(23)28-17/h2-3,5-6,9,14H,1,4,7-8H2,(H,26,29)(H,30,31)(H,32,33)(H4,22,23,24,27,28)/t14-/m0/s1
DMU901D	CS	C=C(C[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)CCC2=CN=C3C(=N2)C(=NC(=N3)N)N)C(=O)O
DMU901D	IK	QCLDSHDOWCMFBV-AWEZNQCLSA-N
DMU901D	IU	(2S)-2-[[4-[2-(2,4-diaminopteridin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid
DMU901D	CA	CAS 176857-41-3
DMU901D	DE	Solid tumour/cancer

DMZU2G1	ID	DMZU2G1
DMZU2G1	DN	LMP-1/LMP-2 CTLs
DMZU2G1	HS	Phase 1
DMZU2G1	SN	Ad5f35LMPd1-2; LMP-1/LMP-2 CTLs, Baylor College of Medicine/NCI; LMP-1/LMP-2 specific cytotoxic T-lymphocytes (gene therapy,nasopharyngeal cancer/lymphoma), Baylor College of Medicine/NCI
DMZU2G1	CP	Baylor College of Medicine
DMZU2G1	DE	Lymphoma

DM4FW2E	ID	DM4FW2E
DM4FW2E	DN	LMP400
DM4FW2E	HS	Phase 1
DM4FW2E	SN	INDOTECAN; 915303-09-2; UNII-BTA69L5M8D; NSC-724998; BTA69L5M8D; 2,3-dimethoxy-6-(3-morpholinopropyl)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; LMP-400; NSC724998; Indotecan(LMP400); Indotecan (LMP400); CHEMBL216462; SCHEMBL7712572; DTXSID90238613; BCP34018; EX-A3020; Indotecan hydrochloride (LMP-400); ZB1545; SB16793; HY-18351; CS-0007476; LMP400; LMP-400; LMP 400; Q27274872; 3-[(Morpholine)-1-propyl]-5,3-dimethoxy-8,9-meth ylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
DM4FW2E	CP	LMP400
DM4FW2E	DT	Small molecular drug
DM4FW2E	PC	11533060
DM4FW2E	MW	478.5
DM4FW2E	FM	C26H26N2O7
DM4FW2E	IC	InChI=1S/C26H26N2O7/c1-31-19-10-15-18(13-20(19)32-2)26(30)28(5-3-4-27-6-8-33-9-7-27)24-16-11-21-22(35-14-34-21)12-17(16)25(29)23(15)24/h10-13H,3-9,14H2,1-2H3
DM4FW2E	CS	COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCN6CCOCC6)OC
DM4FW2E	IK	FMFIFGLHVOZDEL-UHFFFAOYSA-N
DM4FW2E	IU	15,16-dimethoxy-20-(3-morpholin-4-ylpropyl)-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione
DM4FW2E	CA	CAS 915303-09-2
DM4FW2E	DE	Lymphoma; Neoplasm

DMUCQYW	ID	DMUCQYW
DMUCQYW	DN	LMP744
DMUCQYW	HS	Phase 1
DMUCQYW	SN	LMP-744; 308246-52-8; MJ-III-65; LMP744 free base; UNII-29BY7HQV0T; NSC-706744; 29BY7HQV0T; NCI60_037977; CHEMBL126159; 308246-52-8 (free base); 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; AC1L9FIC; SCHEMBL4162998; DTXSID30327954; BCP34017; EX-A3021; BDBM50237809; HY-U00248; NSC706743; CS-7432; NSC-706743; Q27894415; 20-[3-(2-Hydroxyethylamino)propyl]-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione; 5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-; 5H-[1,6]indeno[1,2-c]isoquinoline- 5,12(6H)-dione,6-[3-[(2-hydroxyethyl)amino]propyl]-2,3-dimethoxy-; 6-[3-(2-Hydroxyethyl)aminopropyl]-5,11-diketo-2,3-dimethoxy-8,9-(methylenedioxy)- 11H-indeno[1,2-c]isoquinoline
DMUCQYW	CP	Gibson Oncology
DMUCQYW	DT	Small molecular drug
DMUCQYW	PC	397888
DMUCQYW	MW	452.5
DMUCQYW	FM	C24H24N2O7
DMUCQYW	IC	InChI=1S/C24H24N2O7/c1-30-17-8-13-16(11-18(17)31-2)24(29)26(6-3-4-25-5-7-27)22-14-9-19-20(33-12-32-19)10-15(14)23(28)21(13)22/h8-11,25,27H,3-7,12H2,1-2H3
DMUCQYW	CS	COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCNCCO)OC
DMUCQYW	IK	QCSDJDQOJBQTDV-UHFFFAOYSA-N
DMUCQYW	IU	20-[3-(2-hydroxyethylamino)propyl]-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione
DMUCQYW	CA	CAS 308246-52-8
DMUCQYW	DE	Solid tumour/cancer

DM9OA35	ID	DM9OA35
DM9OA35	DN	Long-acting erythropoietin conjugate
DM9OA35	HS	Phase 1
DM9OA35	SN	HM-10760; HM-10760A; LAPS-EPO; Long-acting erythropoietin conjugate (LAPS, anemia); Long-acting erythropoietin conjugate (LAPS, anemia), Hanmi
DM9OA35	CP	Hanmi pharmaceutical
DM9OA35	DE	Anemia

DMCKE90	ID	DMCKE90
DMCKE90	DN	Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules
DMCKE90	HS	Phase 1
DMCKE90	SN	Aluviran + norvir + interferon apha + traditional Chinese Medicines granules
DMCKE90	TC	Antiviral Agents
DMCKE90	DT	Combination drug
DMCKE90	DE	Coronavirus Disease 2019 (COVID-19)

DMDLTCU	ID	DMDLTCU
DMDLTCU	DN	Lotilibcin
DMDLTCU	HS	Phase 1
DMDLTCU	SN	Lotilibcin; JA-002; JA-003; WAP-8294A2; Acne therapy (dermatological formulation), Janus; Lotilibcin (injectable), aRigen; MRSA infection therapy (gel), Janus; S aureus infection therapy (gel), Janus; Lotilibcin (cream, acne), Janus; Lotilibcin (dermatological cream, acne), aRigen; Lotilibcin (gel, Staphycoccus infection), aRigen; Lotilibcin (gel, skin infections), Janus; WAP-8294A2 (injectable), aRigen; WAP-8294A2 (cream, acne), Janus; WAP-8294A2 (dermatological cream, acne), aRigen; WAP-8294A2 (gel, MRSA), aRigen; WAP-8294A2 (gel, skin infections), Janus
DMDLTCU	CP	Wakamoto Pharmaceutical Co Ltd
DMDLTCU	PC	16184172
DMDLTCU	MW	1562.8
DMDLTCU	FM	C73H111N17O21
DMDLTCU	IC	InChI=1S/C73H111N17O21/c1-38(2)17-14-20-43-32-56(94)80-53(37-92)69(106)88-59(61(98)62(77)99)71(108)87-52(36-91)63(100)79-35-57(95)89(7)54(30-41-18-10-9-11-19-41)70(107)86-49(29-39(3)4)66(103)81-46(23-15-27-74)64(101)82-47(25-26-58(96)97)65(102)85-51(33-55(76)93)68(105)84-50(31-42-34-78-45-22-13-12-21-44(42)45)67(104)83-48(24-16-28-75)72(109)90(8)60(40(5)6)73(110)111-43/h9-13,18-19,21-22,34,38-40,43,46-54,59-61,78,91-92,98H,14-17,20,23-33,35-37,74-75H2,1-8H3,(H2,76,93)(H2,77,99)(H,79,100)(H,80,94)(H,81,103)(H,82,101)(H,83,104)(H,84,105)(H,85,102)(H,86,107)(H,87,108)(H,88,106)(H,96,97)/t43-,46-,47+,48-,49+,50-,51-,52+,53+,54-,59-,60+,61-/m1/s1
DMDLTCU	CS	CC(C)CCC[C@@H]1CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)O1)C(C)C)C)CCCN)CC2=CNC3=CC=CC=C32)CC(=O)N)CCC(=O)O)CCCN)CC(C)C)CC4=CC=CC=C4)C)CO)[C@H](C(=O)N)O)CO
DMDLTCU	IK	LEKBQPKGXGFBAN-MMXTXZKOSA-N
DMDLTCU	IU	3-[(3S,6R,9R,12R,15S,18R,21S,24R,30S,33R,36S,40R)-33-[(1R)-2-amino-1-hydroxy-2-oxoethyl]-12-(2-amino-2-oxoethyl)-6,18-bis(3-aminopropyl)-24-benzyl-30,36-bis(hydroxymethyl)-9-(1H-indol-3-ylmethyl)-4,25-dimethyl-40-(4-methylpentyl)-21-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxo-3-propan-2-yl-1-oxa-4,7,10,13,16,19,22,25,28,31,34,37-dodecazacyclotetracont-15-yl]propanoic acid
DMDLTCU	CA	169148-84-9
DMDLTCU	DE	Bacterial infection

DMDXFBJ	ID	DMDXFBJ
DMDXFBJ	DN	LOXO-195
DMDXFBJ	HS	Phase 1
DMDXFBJ	SN	OEBIHOVSAMBXIB-SJKOYZFVSA-N; LOXO195; UNII-0J45910S3X; 2097002-61-2; 0J45910S3X; LOXO-195 (S racemic); LOXO 195; SCHEMBL18823882; EX-A1873; HY-101977; CS-0022378; Cas registry number 2097002-61-2 ~1~1 C20 H21 F N6 O 10H-5,7-ethenopyrazolo(3,4-d)pyrido(2,3-k)pyrrolo(2,1-m)(1,3,7)triazacyclotridecin-10-one, 17-fluoro-1,2,3,11,12,13,14,18b-octahydro-12-methyl-, (12R,18bR)-; 12H-15,17-Ethenopyrazolo[3,4-d]pyrido[2,3-k]pyrrolo[2,1-m][1,3,7]triazacyclotridecin-12-one, 5-fluoro-1,2,3,3a,8,9,10,11-octahydro-10-methyl-, (3aR,10R)-; (13E,14E,22R,6R
DMDXFBJ	CP	Bayer Pharmaceuticals Whippany, NJ; Loxo Oncology Stamford, CT
DMDXFBJ	PC	129103609
DMDXFBJ	MW	380.4
DMDXFBJ	FM	C20H21FN6O
DMDXFBJ	IC	InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1
DMDXFBJ	CS	C[C@@H]1CCC2=C(C=C(C=N2)F)[C@H]3CCCN3C4=NC5=C(C=NN5C=C4)C(=O)N1
DMDXFBJ	IK	OEBIHOVSAMBXIB-SJKOYZFVSA-N
DMDXFBJ	IU	(6R,15R)-9-fluoro-15-methyl-2,11,16,20,21,24-hexazapentacyclo[16.5.2.02,6.07,12.021,25]pentacosa-1(24),7(12),8,10,18(25),19,22-heptaen-17-one
DMDXFBJ	CA	CAS 2097002-61-2
DMDXFBJ	DE	Solid tumour/cancer

DMYIXQZ	ID	DMYIXQZ
DMYIXQZ	DN	LP-108
DMYIXQZ	HS	Phase 1
DMYIXQZ	CP	Newave Pharmaceuticals
DMYIXQZ	DE	Acute myeloid leukaemia; Myelodysplastic syndrome; Chronic myelomonocytic leukaemia

DM8VBQJ	ID	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	HS	Phase 1
DM8VBQJ	SN	Dietade Dietary Foods; Fructooligosaccharides; Fructose, furanose form; Frutooligosaccharides; SCHEMBL3966; beta-D-Arabino-hexulose; beta-D-Fructose; beta-D-fructofuranose; beta-Fruit sugar; beta-Levulose; (2,1-beta-D-Fructosyl)n; (2-&gt;1)-beta-D-fructan; (2R,3S,4S,5R)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol; .beta.-D-Fructofuranose; 2x7x; 470-23-5; B986VTP17J; CAS-57-48-7; CHEBI:28645; DSSTox_CID_3081; DSSTox_GSID_23081; DSSTox_RID_76866; UNII-B986VTP17J; beta-D-fructofuranose (closed ring structure)
DM8VBQJ	PC	439709
DM8VBQJ	MW	180.16
DM8VBQJ	FM	C6H12O6
DM8VBQJ	IC	RFSUNEUAIZKAJO-ARQDHWQXSA-N
DM8VBQJ	CS	C(C1C(C(C(O1)(CO)O)O)O)O
DM8VBQJ	IK	1S/C6H12O6/c7-1-3-4(9)5(10)6(11,2-8)12-3/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m1/s1
DM8VBQJ	IU	(2R,3S,4S,5R)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol
DM8VBQJ	CA	CAS 53188-23-1
DM8VBQJ	CB	CHEBI:28645
DM8VBQJ	DE	Chronic myelogenous leukaemia

DM94E6W	ID	DM94E6W
DM94E6W	DN	LTT462
DM94E6W	HS	Phase 1
DM94E6W	CP	Novartis Oncology East Hanover, NJ
DM94E6W	DE	Solid tumour/cancer

DMQ0K95	ID	DMQ0K95
DMQ0K95	DN	Lu-02-750
DMQ0K95	HS	Phase 1
DMQ0K95	SN	Dopamine receptor agonist (Parkinson's disease), H Lundbeck
DMQ0K95	CP	Axon Biochemicals BV
DMQ0K95	DE	Parkinson disease

DMP9UO0	ID	DMP9UO0
DMP9UO0	DN	Lu-AE04621
DMP9UO0	HS	Phase 1
DMP9UO0	CP	H Lundbeck A/S
DMP9UO0	DE	Parkinson disease

DMQI970	ID	DMQI970
DMQI970	DN	Lumoxiti
DMQI970	HS	Phase 1
DMQI970	SN	Moxetumumab pasudotox-tdfk
DMQI970	CP	Innate Pharma
DMQI970	DT	Antibody
DMQI970	DE	Hairy cell leukaemia

DMPQE2S	ID	DMPQE2S
DMPQE2S	DN	LVGN6051
DMPQE2S	HS	Phase 1
DMPQE2S	CP	Lyvgen Biopharma
DMPQE2S	DT	Antibody
DMPQE2S	DE	Solid tumour/cancer

DM8ZS7T	ID	DM8ZS7T
DM8ZS7T	DN	LX2761
DM8ZS7T	HS	Phase 1
DM8ZS7T	SN	1610954-97-6; LX-2761; N-(1-((2-(Dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)-butanamide; CHEMBL4074614; SCHEMBL15741132; BDBM176714; EX-A2828; ACN-053194; AC-31562; HY-101122; CS-0020883; N-[2-(dimethylamino)ethyl]-2-methyl-2-[4-[4-[[2-methyl-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]phenyl]methyl]phenyl]butanoylamino]propanamide; US9688710, 136 N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide
DM8ZS7T	CP	Lexicon Pharmaceuticals
DM8ZS7T	DT	Small molecular drug
DM8ZS7T	PC	76070894
DM8ZS7T	MW	601.8
DM8ZS7T	FM	C32H47N3O6S
DM8ZS7T	IC	InChI=1S/C32H47N3O6S/c1-20-10-15-23(29-27(38)26(37)28(39)30(41-29)42-6)19-24(20)18-22-13-11-21(12-14-22)8-7-9-25(36)34-32(2,3)31(40)33-16-17-35(4)5/h10-15,19,26-30,37-39H,7-9,16-18H2,1-6H3,(H,33,40)(H,34,36)/t26-,27-,28+,29+,30-/m1/s1
DM8ZS7T	CS	CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)SC)O)O)O)CC3=CC=C(C=C3)CCCC(=O)NC(C)(C)C(=O)NCCN(C)C
DM8ZS7T	IK	BNPZTRDIESRGTC-IXYVTWBDSA-N
DM8ZS7T	IU	N-[2-(dimethylamino)ethyl]-2-methyl-2-[4-[4-[[2-methyl-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]phenyl]methyl]phenyl]butanoylamino]propanamide
DM8ZS7T	DE	Type 2 diabetes

DMO548K	ID	DMO548K
DMO548K	DN	LX9211
DMO548K	HS	Phase 1
DMO548K	CP	Lexicon Pharmaceuticals The Woodlands, TX
DMO548K	DE	Neuropathic pain

DMQE9PS	ID	DMQE9PS
DMQE9PS	DN	LXH254
DMQE9PS	HS	Phase 1
DMQE9PS	SN	UEPXBTCUIIGYCY-UHFFFAOYSA-N; SCHEMBL16094629; BDBM88120; HY-112089; CS-0043317; US9694016, 1156; 1800398-38-2; N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide
DMQE9PS	CP	Novartis Oncology East Hanover, NJ
DMQE9PS	PC	90456533
DMQE9PS	MW	502.5
DMQE9PS	FM	C25H25F3N4O4
DMQE9PS	IC	InChI=1S/C25H25F3N4O4/c1-16-2-3-19(30-24(34)17-4-5-29-21(12-17)25(26,27)28)15-20(16)18-13-22(32-6-9-35-10-7-32)31-23(14-18)36-11-8-33/h2-5,12-15,33H,6-11H2,1H3,(H,30,34)
DMQE9PS	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=NC=C2)C(F)(F)F)C3=CC(=NC(=C3)OCCO)N4CCOCC4
DMQE9PS	IK	UEPXBTCUIIGYCY-UHFFFAOYSA-N
DMQE9PS	IU	N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide
DMQE9PS	CA	CAS 1800398-38-2
DMQE9PS	DE	Non-small-cell lung cancer

DM3OP41	ID	DM3OP41
DM3OP41	DN	LXR 623
DM3OP41	HS	Phase 1
DM3OP41	SN	LXR-623
DM3OP41	DT	Small molecular drug
DM3OP41	PC	16734800
DM3OP41	MW	422.8
DM3OP41	FM	C21H12ClF5N2
DM3OP41	IC	InChI=1S/C21H12ClF5N2/c22-18-10-15(24)9-6-13(18)11-29-20(12-4-7-14(23)8-5-12)16-2-1-3-17(19(16)28-29)21(25,26)27/h1-10H,11H2
DM3OP41	CS	C1=CC2=C(N(N=C2C(=C1)C(F)(F)F)CC3=C(C=C(C=C3)F)Cl)C4=CC=C(C=C4)F
DM3OP41	IK	KYWWJENKIMRJBI-UHFFFAOYSA-N
DM3OP41	IU	2-[(2-chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)indazole
DM3OP41	CA	CAS 875787-07-8
DM3OP41	DE	Arteriosclerosis

DMCBV20	ID	DMCBV20
DMCBV20	DN	LY-2334737
DMCBV20	HS	Phase 1
DMCBV20	SN	Gem prodrug (cancer), Eli Lilly; Gemcitabine prodrug (cancer), Lilly
DMCBV20	CP	Eli Lilly & Co
DMCBV20	DT	Small molecular drug
DMCBV20	PC	11646777
DMCBV20	MW	389.4
DMCBV20	FM	C17H25F2N3O5
DMCBV20	IC	InChI=1S/C17H25F2N3O5/c1-3-5-10(6-4-2)14(25)20-12-7-8-22(16(26)21-12)15-17(18,19)13(24)11(9-23)27-15/h7-8,10-11,13,15,23-24H,3-6,9H2,1-2H3,(H,20,21,25,26)/t11-,13-,15-/m1/s1
DMCBV20	CS	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
DMCBV20	IK	MEOYFIHNRBNEPI-UXIGCNINSA-N
DMCBV20	IU	N-[1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-propylpentanamide
DMCBV20	CA	CAS 892128-60-8
DMCBV20	DE	Solid tumour/cancer

DML8M3B	ID	DML8M3B
DML8M3B	DN	LY-2584702
DML8M3B	HS	Phase 1
DML8M3B	SN	LY-S6K1; LY-S6K1 HCl; LY-S6K1 tosylate; P70 S6 kinase inhibitor (cancer), Eli Lilly
DML8M3B	CP	Eli Lilly & Co
DML8M3B	DT	Small molecular drug
DML8M3B	PC	25118925
DML8M3B	MW	445.4
DML8M3B	FM	C21H19F4N7
DML8M3B	IC	InChI=1S/C21H19F4N7/c1-31-10-17(13-2-3-16(22)15(8-13)21(23,24)25)29-19(31)12-4-6-32(7-5-12)20-14-9-28-30-18(14)26-11-27-20/h2-3,8-12H,4-7H2,1H3,(H,26,27,28,30)
DML8M3B	CS	CN1C=C(N=C1C2CCN(CC2)C3=NC=NC4=C3C=NN4)C5=CC(=C(C=C5)F)C(F)(F)F
DML8M3B	IK	FYXRSVDHGLUMHB-UHFFFAOYSA-N
DML8M3B	IU	4-[4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-methylimidazol-2-yl]piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
DML8M3B	CA	CAS 1082949-67-4
DML8M3B	DE	Solid tumour/cancer

DM289Z4	ID	DM289Z4
DM289Z4	DN	LY2624587
DM289Z4	HS	Phase 1
DM289Z4	CP	Eli Lilly & Co
DM289Z4	DT	Antibody
DM289Z4	DE	Solid tumour/cancer; Metastatic cancer

DM93AJW	ID	DM93AJW
DM93AJW	DN	LY2780301
DM93AJW	HS	Phase 1
DM93AJW	SN	P70 S6 Kinase and AKT Dual Inhibitor
DM93AJW	CP	Lilly
DM93AJW	DE	Solid tumour/cancer

DM9NYHT	ID	DM9NYHT
DM9NYHT	DN	LY2787106
DM9NYHT	HS	Phase 1
DM9NYHT	DT	Antibody
DM9NYHT	DE	Anemia

DM8LGWR	ID	DM8LGWR
DM8LGWR	DN	LY-2811376
DM8LGWR	HS	Phase 1
DM8LGWR	SN	LY2811376; 1194044-20-6; (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; LY-2811376; LY 2811376; UNII-UR18YJ97SJ; UR18YJ97SJ; CHEMBL2333941; (4s)-4-[2,4-Difluoro-5-(Pyrimidin-5-Yl)phenyl]-4-Methyl-5,6-Dihydro-4h-1,3-Thiazin-2-Amine; (4S)-4-[2,4-Difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-4H-1,3-thiazin-2-amine; J-501480; MJQMRGWYPNIERM-HNNXBMFYSA-N; 4H-1,3-Thiazin-2-amine, 4-(2,4-difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-, (4S)-; 4H-1,3-Thiazin-2-amine, 
DM8LGWR	CP	Eli Lilly & Co
DM8LGWR	DT	Small molecular drug
DM8LGWR	PC	44251605
DM8LGWR	MW	320.4
DM8LGWR	FM	C15H14F2N4S
DM8LGWR	IC	InChI=1S/C15H14F2N4S/c1-15(2-3-22-14(18)21-15)11-4-10(12(16)5-13(11)17)9-6-19-8-20-7-9/h4-8H,2-3H2,1H3,(H2,18,21)/t15-/m0/s1
DM8LGWR	CS	C[C@]1(CCSC(=N1)N)C2=C(C=C(C(=C2)C3=CN=CN=C3)F)F
DM8LGWR	IK	MJQMRGWYPNIERM-HNNXBMFYSA-N
DM8LGWR	IU	(4S)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine
DM8LGWR	CA	CAS 1194044-20-6
DM8LGWR	DE	Alzheimer disease

DM5EXJV	ID	DM5EXJV
DM5EXJV	DN	LY-2881835
DM5EXJV	HS	Phase 1
DM5EXJV	CP	Eli Lilly & Co
DM5EXJV	DT	Small molecular drug
DM5EXJV	PC	51049992
DM5EXJV	MW	491.6
DM5EXJV	FM	C33H33NO3
DM5EXJV	IC	InChI=1S/C33H33NO3/c1-2-5-29(22-32(35)36)27-12-14-30(15-13-27)37-24-26-10-8-25(9-11-26)23-34-20-18-33(19-21-34)17-16-28-6-3-4-7-31(28)33/h3-4,6-17,29H,18-24H2,1H3,(H,35,36)/t29-/m0/s1
DM5EXJV	CS	CC#C[C@@H](CC(=O)O)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC4(CC3)C=CC5=CC=CC=C45
DM5EXJV	IK	FHRWHNJJQGSCQC-LJAQVGFWSA-N
DM5EXJV	IU	(3S)-3-[4-[[4-(spiro[indene-1,4'-piperidine]-1'-ylmethyl)phenyl]methoxy]phenyl]hex-4-ynoic acid
DM5EXJV	CA	CAS 1292290-38-0
DM5EXJV	DE	Type-2 diabetes

DMGLTE2	ID	DMGLTE2
DMGLTE2	DN	LY2922470
DMGLTE2	HS	Phase 1
DMGLTE2	SN	1423018-12-5; CHEMBL3955132; (S)-3-(4-((5-((8-Methoxy-3,4-dihydroquinolin-1(2H)-yl)methyl)thiophen-2-yl)methoxy)phenyl)hex-4-ynoic acid; LY-2922470; SCHEMBL14695980; BCP24962; BDBM50204012; HY-19835; CS-0016977; (3S)-3-[4-[[5-[(8-methoxy-3,4-dihydro-2H-quinolin-1-yl)methyl]thiophen-2-yl]methoxy]phenyl]hex-4-ynoic acid
DMGLTE2	DT	Small molecular drug
DMGLTE2	PC	71257551
DMGLTE2	MW	475.6
DMGLTE2	FM	C28H29NO4S
DMGLTE2	IC	InChI=1S/C28H29NO4S/c1-3-6-22(17-27(30)31)20-10-12-23(13-11-20)33-19-25-15-14-24(34-25)18-29-16-5-8-21-7-4-9-26(32-2)28(21)29/h4,7,9-15,22H,5,8,16-19H2,1-2H3,(H,30,31)/t22-/m0/s1
DMGLTE2	CS	CC#C[C@@H](CC(=O)O)C1=CC=C(C=C1)OCC2=CC=C(S2)CN3CCCC4=C3C(=CC=C4)OC
DMGLTE2	IK	VJVDLRVFJTVWEO-QFIPXVFZSA-N
DMGLTE2	IU	(3S)-3-[4-[[5-[(8-methoxy-3,4-dihydro-2H-quinolin-1-yl)methyl]thiophen-2-yl]methoxy]phenyl]hex-4-ynoic acid
DMGLTE2	CA	CAS 1423018-12-5
DMGLTE2	DE	Type 2 diabetes

DMY1AFS	ID	DMY1AFS
DMY1AFS	DN	LY294002
DMY1AFS	HS	Phase 1
DMY1AFS	SN	2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 154447-36-6; LY 294002; LY-294002; 2-morpholino-8-phenyl-4H-chromen-4-one; 2-morpholin-4-yl-8-phenyl-4H-chromen-4-one; UNII-31M2U1DVID; LY-294,002; 2-(morpholin-4-yl)-8-phenyl-4H-chromen-4-one; 31M2U1DVID; 2-MORPHOLIN-4-YL-7-PHENYL-4H-CHROMEN-4-ONE; CHEMBL98350; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-; CHEBI:65329; 2-morpholino-8-phenyl-chromen-4-one; AK162301; 2-(morpholin-4-yl)-8-phenylchromen-4-one; LY2; 15447-36-6; IN1266; IN1268; Lys 294002; BMK1-D5; H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-(9CI); 2-(4-Morpholino)-8-phenyl-4H-1-benzopyran-4-one; 2-morpholin-4-yl-8-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-(9CI); 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one; 2-(4-Morpholinyl)-8-Phenyl-4h-1-Benzopyran-4-One
DMY1AFS	CP	Genentech
DMY1AFS	DT	Small molecular drug
DMY1AFS	PC	3973
DMY1AFS	MW	307.3
DMY1AFS	FM	C19H17NO3
DMY1AFS	IC	InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2
DMY1AFS	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DMY1AFS	IK	CZQHHVNHHHRRDU-UHFFFAOYSA-N
DMY1AFS	IU	2-morpholin-4-yl-8-phenylchromen-4-one
DMY1AFS	CA	CAS 154447-36-6
DMY1AFS	CB	CHEBI:65329
DMY1AFS	DE	Neuroblastoma

DM16IX2	ID	DM16IX2
DM16IX2	DN	LY-2979165
DM16IX2	HS	Phase 1
DM16IX2	SN	Bipolar disorder therapy, Eli Lilly
DM16IX2	CP	Eli Lilly & Co
DM16IX2	DT	Small molecular drug
DM16IX2	PC	53246986
DM16IX2	MW	355.37
DM16IX2	FM	C13H17N5O5S
DM16IX2	IC	InChI=1S/C13H17N5O5S/c1-4(14)9(19)17-13(11(22)23)2-5(24-12-15-3-16-18-12)6-7(8(6)13)10(20)21/h3-8H,2,14H2,1H3,(H,17,19)(H,20,21)(H,22,23)(H,15,16,18)/t4-,5+,6-,7-,8-,13-/m0/s1
DM16IX2	CS	C[C@@H](C(=O)N[C@]1(C[C@H]([C@@H]2[C@H]1[C@H]2C(=O)O)SC3=NC=NN3)C(=O)O)N
DM16IX2	IK	BBGHHIUQOKQCBW-LDZWZCGGSA-N
DM16IX2	IU	(1R,2S,4R,5R,6R)-2-[[(2S)-2-aminopropanoyl]amino]-4-(1H-1,2,4-triazol-5-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DM16IX2	CA	CAS 1311385-35-9
DM16IX2	DE	Bipolar disorder

DM6PFCN	ID	DM6PFCN
DM6PFCN	DN	LY3009120
DM6PFCN	HS	Phase 1
DM6PFCN	CP	Lilly
DM6PFCN	PC	71721540
DM6PFCN	MW	424.5
DM6PFCN	FM	C23H29FN6O
DM6PFCN	IC	InChI=1S/C23H29FN6O/c1-13-9-18(24)19(29-22(31)26-8-7-23(3,4)5)11-16(13)17-10-15-12-27-21(25-6)30-20(15)28-14(17)2/h9-12H,7-8H2,1-6H3,(H2,26,29,31)(H,25,27,28,30)
DM6PFCN	CS	CC1=CC(=C(C=C1C2=C(N=C3C(=C2)C=NC(=N3)NC)C)NC(=O)NCCC(C)(C)C)F
DM6PFCN	IK	HHCBMISMPSAZBF-UHFFFAOYSA-N
DM6PFCN	IU	1-(3,3-dimethylbutyl)-3-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]urea
DM6PFCN	CA	CAS 1454682-72-4
DM6PFCN	DE	Solid tumour/cancer

DMJPCHK	ID	DMJPCHK
DMJPCHK	DN	LY309887
DMJPCHK	HS	Phase 1
DMJPCHK	DT	Small molecular drug
DMJPCHK	PC	135430850
DMJPCHK	MW	449.5
DMJPCHK	FM	C19H23N5O6S
DMJPCHK	IC	InChI=1S/C19H23N5O6S/c20-19-23-15-11(16(27)24-19)7-9(8-21-15)1-2-10-3-5-13(31-10)17(28)22-12(18(29)30)4-6-14(25)26/h3,5,9,12H,1-2,4,6-8H2,(H,22,28)(H,25,26)(H,29,30)(H4,20,21,23,24,27)/t9-,12+/m1/s1
DMJPCHK	CS	C1[C@H](CNC2=C1C(=O)NC(=N2)N)CCC3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMJPCHK	IK	GQCXGHHHNACOGE-SKDRFNHKSA-N
DMJPCHK	IU	(2S)-2-[[5-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]thiophene-2-carbonyl]amino]pentanedioic acid
DMJPCHK	CA	CAS 127228-54-0
DMJPCHK	DE	Solid tumour/cancer

DM5OP86	ID	DM5OP86
DM5OP86	DN	LY3127804
DM5OP86	HS	Phase 1
DM5OP86	CP	Eli Lilly Indianapolis, IN
DM5OP86	DE	Solid tumour/cancer

DM9RTXM	ID	DM9RTXM
DM9RTXM	DN	LY3164530
DM9RTXM	HS	Phase 1
DM9RTXM	CP	Eli Lilly
DM9RTXM	DT	Monoclonal antibody
DM9RTXM	DE	Advanced cancer; Solid tumour/cancer

DMQP6VB	ID	DMQP6VB
DMQP6VB	DN	LY3200882
DMQP6VB	HS	Phase 1
DMQP6VB	SN	PNPFMWIDAKQFPY-UHFFFAOYSA-N; 1898283-02-7; LY-3200882; 2-{4-[(4-{[1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy}pyridin-2-yl)amino]pyridin-2-yl}propan-2-ol; 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol; SCHEMBL17645407; EX-A1680; BCP20882; HY-103021; CS-0023129
DMQP6VB	CP	Eli Lilly Indianapolis, IN
DMQP6VB	PC	121249291
DMQP6VB	MW	435.5
DMQP6VB	FM	C24H29N5O3
DMQP6VB	IC	InChI=1S/C24H29N5O3/c1-24(2,30)21-13-17(5-9-25-21)27-22-14-19(6-10-26-22)32-20-15-29(18-3-4-18)28-23(20)16-7-11-31-12-8-16/h5-6,9-10,13-16,18,30H,3-4,7-8,11-12H2,1-2H3,(H,25,26,27)
DMQP6VB	CS	CC(C)(C1=NC=CC(=C1)NC2=NC=CC(=C2)OC3=CN(N=C3C4CCOCC4)C5CC5)O
DMQP6VB	IK	PNPFMWIDAKQFPY-UHFFFAOYSA-N
DMQP6VB	IU	2-[4-[[4-[1-cyclopropyl-3-(oxan-4-yl)pyrazol-4-yl]oxypyridin-2-yl]amino]pyridin-2-yl]propan-2-ol
DMQP6VB	CA	CAS 1898283-02-7
DMQP6VB	DE	Solid tumour/cancer

DMFDAY7	ID	DMFDAY7
DMFDAY7	DN	LY3214996
DMFDAY7	HS	Phase 1
DMFDAY7	SN	JNPRPMBJODOFEC-UHFFFAOYSA-N; 1951483-29-6; GTPL9975; SCHEMBL17837273; MolPort-046-033-624; EX-A2560; BCP19982; CS-6974; HY-101494; LY 3214996; 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one; 6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one
DMFDAY7	CP	Eli Lilly Indianapolis, IN
DMFDAY7	PC	121408882
DMFDAY7	MW	453.6
DMFDAY7	FM	C22H27N7O2S
DMFDAY7	IC	InChI=1S/C22H27N7O2S/c1-22(2)19-15(20(30)29(22)9-8-28-10-12-31-13-11-28)14-17(32-19)16-4-6-23-21(25-16)26-18-5-7-24-27(18)3/h4-7,14H,8-13H2,1-3H3,(H,23,25,26)
DMFDAY7	CS	CC1(C2=C(C=C(S2)C3=NC(=NC=C3)NC4=CC=NN4C)C(=O)N1CCN5CCOCC5)C
DMFDAY7	IK	JNPRPMBJODOFEC-UHFFFAOYSA-N
DMFDAY7	IU	6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one
DMFDAY7	CA	CAS 1951483-29-6
DMFDAY7	DE	Solid tumour/cancer

DMOV2ML	ID	DMOV2ML
DMOV2ML	DN	LY3300054
DMOV2ML	HS	Phase 1
DMOV2ML	CP	Eli Lilly Indianapolis, IN
DMOV2ML	DT	Monoclonal antibody
DMOV2ML	DE	Solid tumour/cancer; Advanced malignancy

DMG6HLE	ID	DMG6HLE
DMG6HLE	DN	LY3303560
DMG6HLE	HS	Phase 1
DMG6HLE	CP	Eli Lilly Indianapolis, IN
DMG6HLE	DE	Alzheimer disease

DMD51GC	ID	DMD51GC
DMD51GC	DN	LY3321367
DMD51GC	HS	Phase 1
DMD51GC	CP	Eli Lilly Indianapolis, IN
DMD51GC	DE	Solid tumour/cancer

DMONZ1L	ID	DMONZ1L
DMONZ1L	DN	LY3381916
DMONZ1L	HS	Phase 1
DMONZ1L	CP	Eli Lilly Indianapolis, IN
DMONZ1L	DE	Solid tumour/cancer

DMB51K2	ID	DMB51K2
DMB51K2	DN	LY3405105
DMB51K2	HS	Phase 1
DMB51K2	SN	SCHEMBL20971700; GTPL11356; (3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl 4-{[5-methyl-3-(propan-2-yl)pyrazolo[1,5-a]pyrimidin-7-yl]amino}piperidine-1-carboxylate
DMB51K2	CP	Eli Lilly
DMB51K2	DT	Small molecular drug
DMB51K2	PC	138608760
DMB51K2	MW	497.6
DMB51K2	FM	C26H39N7O3
DMB51K2	IC	InChI=1S/C26H39N7O3/c1-18(2)22-16-27-33-23(15-19(3)28-25(22)33)29-20-8-12-31(13-9-20)26(35)36-21-10-14-32(17-21)24(34)7-6-11-30(4)5/h6-7,15-16,18,20-21,29H,8-14,17H2,1-5H3/b7-6+/t21-/m0/s1
DMB51K2	CS	CC1=NC2=C(C=NN2C(=C1)NC3CCN(CC3)C(=O)O[C@H]4CCN(C4)C(=O)/C=C/CN(C)C)C(C)C
DMB51K2	IK	GRDAHPJRLCTJNA-BXKJMJEDSA-N
DMB51K2	IU	[(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(5-methyl-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate
DMB51K2	DE	Solid tumour/cancer

DMFU0H5	ID	DMFU0H5
DMFU0H5	DN	LY3410738
DMFU0H5	HS	Phase 1
DMFU0H5	CP	Eli Lilly
DMFU0H5	DT	Small molecular drug
DMFU0H5	DE	Solid tumour/cancer

DM5QO1A	ID	DM5QO1A
DM5QO1A	DN	LY3415244
DM5QO1A	HS	Phase 1
DM5QO1A	CP	Eli Lilly
DM5QO1A	DT	Antibody
DM5QO1A	DE	Solid tumour/cancer

DMZLIWX	ID	DMZLIWX
DMZLIWX	DN	LY3475070
DMZLIWX	HS	Phase 1
DMZLIWX	CP	Eli Lilly
DMZLIWX	DE	Solid tumour/cancer

DMY8W3S	ID	DMY8W3S
DMY8W3S	DN	LY3484356
DMY8W3S	HS	Phase 1
DMY8W3S	CP	Eli Lilly
DMY8W3S	DE	Breast cancer

DMLXGAI	ID	DMLXGAI
DMLXGAI	DN	LYS-6KAKT1
DMLXGAI	HS	Phase 1
DMLXGAI	CP	Eli Lilly & Co
DMLXGAI	DE	Solid tumour/cancer

DMHDCSL	ID	DMHDCSL
DMHDCSL	DN	LZM009
DMHDCSL	HS	Phase 1
DMHDCSL	CP	Livzon Pharmaceutical Zhuhai City, China
DMHDCSL	DT	Monoclonal antibody
DMHDCSL	DE	Solid tumour/cancer; Advanced malignancy

DMK7UNL	ID	DMK7UNL
DMK7UNL	DN	M-0004
DMK7UNL	HS	Phase 1
DMK7UNL	SN	Gastroprokinetic compound (pediatric reflux), Janssen; Gastroprokinetic compound (pediatric reflux), Movetis
DMK7UNL	CP	Janssen Pharmaceutica NV
DMK7UNL	DE	Gastroesophageal reflux disease

DME6UNO	ID	DME6UNO
DME6UNO	DN	M012
DME6UNO	HS	Phase 1
DME6UNO	SN	Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; alpha,alpha-Dichlorotoluene; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard
DME6UNO	CP	Merganser Biotech
DME6UNO	DT	Small molecular drug
DME6UNO	PC	7411
DME6UNO	MW	161.03
DME6UNO	FM	C7H6Cl2
DME6UNO	IC	InChI=1S/C7H6Cl2/c8-7(9)6-4-2-1-3-5-6/h1-5,7H
DME6UNO	CS	C1=CC=C(C=C1)C(Cl)Cl
DME6UNO	IK	CAHQGWAXKLQREW-UHFFFAOYSA-N
DME6UNO	IU	dichloromethylbenzene
DME6UNO	CA	CAS 98-87-3
DME6UNO	CB	CHEBI:82273
DME6UNO	DE	Myelodysplastic syndrome; Polycythemia vera; Thalassemia

DMP8QY2	ID	DMP8QY2
DMP8QY2	DN	M1774
DMP8QY2	HS	Phase 1
DMP8QY2	SN	674783-97-2; 9-Mesityl-10-methylacridinium Perchlorate; 10-methyl-9-(2,4,6-trimethylphenyl)acridin-10-ium;perchlorate; MFCD09038536; Acridinium, 10-methyl-9-(2,4,6-trimethylphenyl)-, perchlorate; ACMC-209nz7; 9-Mesityl-10-methyl-10-acridinium Perchlorate; [Acr-Mes]+(ClO4)-; SCHEMBL10009695; 10-Methyl-9-(2,4,6-trimethylphenyl)acridinium Perchlorate; DTXSID60580419; ANW-35345; AKOS015843774; SY076797; 9-mesityl-10-methyl-acridinium perchlorate; CS-0103389; 9-Mesityl-10-methylacridin-10-ium perchlorate; 9-Mesityl-10-methylacridinium perchlorate, 95%; 9-Mesityl-10-methylacridinium perchlorate, AldrichCPR; 10-METHYL-9-(2,4,6-TRIMETHYLPHENYL)ACRIDIN-10-IUM PERCHLORATE
DMP8QY2	CP	EMD Serono
DMP8QY2	DT	Small molecular drug
DMP8QY2	PC	15953479
DMP8QY2	MW	411.9
DMP8QY2	FM	C23H22ClNO4
DMP8QY2	IC	InChI=1S/C23H22N.ClHO4/c1-15-13-16(2)22(17(3)14-15)23-18-9-5-7-11-20(18)24(4)21-12-8-6-10-19(21)23;2-1(3,4)5/h5-14H,1-4H3;(H,2,3,4,5)/q+1;/p-1
DMP8QY2	CS	CC1=CC(=C(C(=C1)C)C2=C3C=CC=CC3=[N+](C4=CC=CC=C42)C)C.[O-]Cl(=O)(=O)=O
DMP8QY2	IK	LFMBERYWDLWXNO-UHFFFAOYSA-M
DMP8QY2	IU	10-methyl-9-(2,4,6-trimethylphenyl)acridin-10-ium;perchlorate
DMP8QY2	CA	CAS 674783-97-2
DMP8QY2	DE	Solid tumour/cancer

DM3PVBJ	ID	DM3PVBJ
DM3PVBJ	DN	M2698
DM3PVBJ	HS	Phase 1
DM3PVBJ	SN	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)
DM3PVBJ	CP	EMD Serono Rockland, MA
DM3PVBJ	PC	89808643
DM3PVBJ	MW	449.9
DM3PVBJ	FM	C21H19ClF3N5O
DM3PVBJ	IC	InChI=1S/C21H19ClF3N5O/c22-16-6-5-12(9-15(16)21(23,24)25)17(10-30-7-2-8-30)29-20-14-4-1-3-13(19(26)31)18(14)27-11-28-20/h1,3-6,9,11,17H,2,7-8,10H2,(H2,26,31)(H,27,28,29)/t17-/m1/s1
DM3PVBJ	CS	C1CN(C1)C[C@H](C2=CC(=C(C=C2)Cl)C(F)(F)F)NC3=NC=NC4=C3C=CC=C4C(=O)N
DM3PVBJ	IK	HXAUJHZZPCBFPN-QGZVFWFLSA-N
DM3PVBJ	IU	4-[[(1S)-2-(azetidin-1-yl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino]quinazoline-8-carboxamide
DM3PVBJ	CA	CAS 1379545-95-5
DM3PVBJ	DE	Solid tumour/cancer

DM6PI5B	ID	DM6PI5B
DM6PI5B	DN	M3258
DM6PI5B	HS	Phase 1
DM6PI5B	SN	LMP7-IN-1; 2285330-15-4; NSC818432; NSC-818432; HY-111790; CS-0091883; ((R)-2-(Benzofuran-3-yl)-1-((1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carboxamido)ethyl)boronic acid
DM6PI5B	CP	EMD Serono
DM6PI5B	DT	Small molecular drug
DM6PI5B	PC	138319683
DM6PI5B	MW	329.2
DM6PI5B	FM	C17H20BNO5
DM6PI5B	IC	InChI=1S/C17H20BNO5/c20-17(13-8-11-5-6-15(13)24-11)19-16(18(21)22)7-10-9-23-14-4-2-1-3-12(10)14/h1-4,9,11,13,15-16,21-22H,5-8H2,(H,19,20)/t11-,13-,15+,16+/m1/s1
DM6PI5B	CS	B([C@H](CC1=COC2=CC=CC=C21)NC(=O)[C@@H]3C[C@H]4CC[C@@H]3O4)(O)O
DM6PI5B	IK	RFQDLTYXNINJON-OYNZBZHQSA-N
DM6PI5B	IU	[(1R)-2-(1-benzofuran-3-yl)-1-[[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carbonyl]amino]ethyl]boronic acid
DM6PI5B	DE	Multiple myeloma

DMG98QO	ID	DMG98QO
DMG98QO	DN	M3541
DMG98QO	HS	Phase 1
DMG98QO	SN	Aminomalonic acid; 1068-84-4; Aminomalonate; 2-Aminomalonic acid; 2-Aminopropanedioic Acid; alpha-Aminomalonic acid; Propanedioic acid, amino-; aminopropanedioic acid; Propanedioic acid,2-amino-; CHEBI:17475; C00872; Q-102736; Malonic acid, amino-; Aminomalonicacid; Aminopropanedioate; amino-Propanedioate; amino-Malonic acid; a-aminomalonic acid; NSC 352096; amino-Propanedioic acid; AC1L2PBO; .alpha.-Aminomalonic acid; AC1Q5S2H; Propanedioic acid, 2-amino-; SCHEMBL209221; Malonic acid, amino- (8CI); Jsp000609; CHEMBL1232731; KS-00000K
DMG98QO	CP	EMD Serono Rockland, MA
DMG98QO	PC	100714
DMG98QO	MW	119.08
DMG98QO	FM	C3H5NO4
DMG98QO	IC	InChI=1S/C3H5NO4/c4-1(2(5)6)3(7)8/h1H,4H2,(H,5,6)(H,7,8)
DMG98QO	CS	C(C(=O)O)(C(=O)O)N
DMG98QO	IK	JINBYESILADKFW-UHFFFAOYSA-N
DMG98QO	IU	2-aminopropanedioic acid
DMG98QO	CA	CAS 1068-84-4
DMG98QO	CB	CHEBI:17475
DMG98QO	DE	Solid tumour/cancer

DMQBO3V	ID	DMQBO3V
DMQBO3V	DN	M4344
DMQBO3V	HS	Phase 1
DMQBO3V	SN	VX-803; Butanehydrazide; Butyrohydrazide; Butyric acid hydrazide; 3538-65-6; butanehydrazide; Butanohydrazide; Butyrylhydrazine; Butanoic acid, hydrazide; n-Butyric acid hydrazide; butyric hydrazide; butanoic acid hydrazide; FCCCRBDJBTVFSJ-UHFFFAOYSA-N; butyryl hydrazine; Butanohydrazide #; EINECS 222-579-0; N-butanoyl-hydrazine; butryic acid hydrazide; ACMC-1AEKP; AC1L2SBF; AC1Q5PVE; SCHEMBL924945; Mr-I-33; ARONIS010643; SCHEMBL11029887; CTK3J2024; DTXSID70188869; MolPort-000-152-665; BDBM233138; NSC41957; NSC24021; KS-000041YT; ALBB-002745; ZINC1608800; NSC-240
DMQBO3V	CP	EMD Serono Rockland, MA; Vertex Pharmaceuticals Boston, MA
DMQBO3V	PC	86720912
DMQBO3V	MW	541.6
DMQBO3V	FM	C25H29F2N9O3
DMQBO3V	IC	InChI=1S/C25H29F2N9O3/c26-16-9-30-23-20(22(28)32-36(23)12-16)24(37)31-19-11-29-10-18(27)21(19)34-3-1-15(2-4-34)25(38)35-7-5-33(6-8-35)17-13-39-14-17/h9-12,15,17H,1-8,13-14H2,(H2,28,32)(H,31,37)
DMQBO3V	CS	C1CN(CCC1C(=O)N2CCN(CC2)C3COC3)C4=C(C=NC=C4NC(=O)C5=C6N=CC(=CN6N=C5N)F)F
DMQBO3V	IK	QAYHKBLKSXWOEO-UHFFFAOYSA-N
DMQBO3V	IU	2-amino-6-fluoro-N-[5-fluoro-4-[4-[4-(oxetan-3-yl)piperazine-1-carbonyl]piperidin-1-yl]pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
DMQBO3V	DE	Solid tumour/cancer

DM6J085	ID	DM6J085
DM6J085	DN	M6223
DM6J085	HS	Phase 1
DM6J085	CP	EMD Serono
DM6J085	DT	Antibody
DM6J085	DE	Solid tumour/cancer

DMDK4MG	ID	DMDK4MG
DMDK4MG	DN	M7583
DMDK4MG	HS	Phase 1
DMDK4MG	SN	ZAXMFSSGOARPBM-UHFFFAOYSA-N; 51123-09-2; 5-amino-n-ethyl-2-methyl-n-phenylbenzenesulfonamide; 5-Amino-N-ethyl-2-methyl-N-phenylbenzenesulphonamide; 4-AMINO TOLUENE-2-(N-ETHYL) SULFONANILIDE; 5-AMINO-N-ETHYL-O-TOLUENESULFONANILIDE; Q-200530; AMINO-4-METHYL-BENZENE-3-(N-ETHYL)-SULFANILIDE; 5-amino-N-ethyl-2-methyl-N-phenylbenzene-1-sulfonamide; NSC84161; EINECS 256-998-5; NSC 84161; AC1Q2YPH; AC1L3WX0; AC1Q6V7C; AC1Q2YP6; SCHEMBL9072675; 4-Aminotoluol-2-sulfethylanilid; Benzenesulfonamide, 3-amino-N-ethyl-6-methyl-N-phenyl-; CTK4J3696; MolPort-001-759-851
DMDK4MG	CP	EMD Serono Rockland, MA
DMDK4MG	PC	96649
DMDK4MG	MW	290.4
DMDK4MG	FM	C15H18N2O2S
DMDK4MG	IC	InChI=1S/C15H18N2O2S/c1-3-17(14-7-5-4-6-8-14)20(18,19)15-11-13(16)10-9-12(15)2/h4-11H,3,16H2,1-2H3
DMDK4MG	CS	CCN(C1=CC=CC=C1)S(=O)(=O)C2=C(C=CC(=C2)N)C
DMDK4MG	IK	ZAXMFSSGOARPBM-UHFFFAOYSA-N
DMDK4MG	IU	5-amino-N-ethyl-2-methyl-N-phenylbenzenesulfonamide
DMDK4MG	CA	CAS 51123-09-2
DMDK4MG	DE	Haematological malignancy

DM132EG	ID	DM132EG
DM132EG	DN	M802
DM132EG	HS	Phase 1
DM132EG	DT	Antibody
DM132EG	DE	Solid tumour/cancer

DMZ9NVP	ID	DMZ9NVP
DMZ9NVP	DN	M8891
DMZ9NVP	HS	Phase 1
DMZ9NVP	CP	EMD Serono Rockland, MA
DMZ9NVP	DE	Solid tumour/cancer

DMZUM67	ID	DMZUM67
DMZUM67	DN	M9241
DMZUM67	HS	Phase 1
DMZUM67	SN	NHS-IL12
DMZUM67	CP	EMD Serono
DMZUM67	DE	Pancreatic cancer

DM59TI2	ID	DM59TI2
DM59TI2	DN	M9831
DM59TI2	HS	Phase 1
DM59TI2	SN	2-Methyl-1,3-benzothiazole-5-carboxylic acid; 24851-69-2; 2-Methylbenzo[d]thiazole-5-carboxylic acid; 2-Methyl-benzothiazole-5-carboxylic acid; 2-methyl-1,3-benzothiazole-5-carboxylic acid; 5-Benzothiazolecarboxylic acid, 2-methyl-; 2-methylbenzothiazole-5-carboxylic acid; SMR000015267; MLS000030206; AC1LDLFR; AC1Q2PD7; SCHEMBL1105986; cid_649953; CHEMBL1480093; CTK0J4554; KS-00000IVD; BDBM87603; DTXSID50349491; MolPort-002-499-021; TVUFPZOJUJGDDD-UHFFFAOYSA-N; HMS2396B08; ZINC873707; ZX-CM001754; ZX-AL001070; ANW-56675; AKOS000320290; FCH1781098; CS-W019372; MCULE-8154234969; FS
DM59TI2	CP	EMD Serono Rockland, MA
DM59TI2	PC	649953
DM59TI2	MW	193.22
DM59TI2	FM	C9H7NO2S
DM59TI2	IC	InChI=1S/C9H7NO2S/c1-5-10-7-4-6(9(11)12)2-3-8(7)13-5/h2-4H,1H3,(H,11,12)
DM59TI2	CS	CC1=NC2=C(S1)C=CC(=C2)C(=O)O
DM59TI2	IK	TVUFPZOJUJGDDD-UHFFFAOYSA-N
DM59TI2	IU	2-methyl-1,3-benzothiazole-5-carboxylic acid
DM59TI2	CA	CAS 24851-69-2
DM59TI2	DE	Solid tumour/cancer

DM0HKU7	ID	DM0HKU7
DM0HKU7	DN	Macozinone
DM0HKU7	HS	Phase 1
DM0HKU7	SN	PBTZ169; 1377239-83-2; PBTZ-169; 2-(4-(cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one; UNII-A3M1353L40; A3M1353L40; 2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one; 4H-1,3-Benzothiazin-4-one, 2-(4-(cyclohexylmethyl)-1-piperazinyl)-8-nitro-6-(trifluoromethyl)-; 4H-1,3-Benzothiazin-4-one, 2-[4-(cyclohexylmethyl)-1-piperazinyl]-8-nitro-6-(trifluoromethyl)-; Macozinone [INN]; SCHEMBL6128230; CHEMBL3330226; BTZ-169; PBTZ 169;PBTZ-169; BCP18094; EX-A1013; PBTZ-169;PBTZ 169;Macozinone; BDBM50515570; MFCD28902203; s6549; AKOS030526001; ZINC141433347; CS-5777; DB14821; SB19755; YH65042; BS-15317; HY-12903; DS-015880; 2-(4-(Cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one
DM0HKU7	DT	Small molecular drug
DM0HKU7	PC	57331386
DM0HKU7	MW	456.5
DM0HKU7	FM	C20H23F3N4O3S
DM0HKU7	IC	InChI=1S/C20H23F3N4O3S/c21-20(22,23)14-10-15-17(16(11-14)27(29)30)31-19(24-18(15)28)26-8-6-25(7-9-26)12-13-4-2-1-3-5-13/h10-11,13H,1-9,12H2
DM0HKU7	CS	C1CCC(CC1)CN2CCN(CC2)C3=NC(=O)C4=C(S3)C(=CC(=C4)C(F)(F)F)[N+](=O)[O-]
DM0HKU7	IK	BJDZBXGJNBMCAV-UHFFFAOYSA-N
DM0HKU7	IU	2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one
DM0HKU7	CA	CAS 1377239-83-2
DM0HKU7	DE	Mycobacterium infection

DM9F15C	ID	DM9F15C
DM9F15C	DN	MAU868
DM9F15C	HS	Phase 1
DM9F15C	CP	Amplyx Pharmaceuticals
DM9F15C	DT	Antibody
DM9F15C	DE	Epstein barr virus infection

DMMP7XG	ID	DMMP7XG
DMMP7XG	DN	MAXY-4
DMMP7XG	HS	Phase 1
DMMP7XG	SN	CTLA4-Ig proteins (rheumatoid arthritis), Maxygen
DMMP7XG	CP	Maxygen Inc
DMMP7XG	DE	Autoimmune diabetes

DMSZ8HT	ID	DMSZ8HT
DMSZ8HT	DN	MazF gene therapy
DMSZ8HT	HS	Phase 1
DMSZ8HT	SN	MazF gene therapy (HIV)
DMSZ8HT	CP	Takara bio
DMSZ8HT	DE	Human immunodeficiency virus-1 infection

DMLA1QD	ID	DMLA1QD
DMLA1QD	DN	MB-101
DMLA1QD	HS	Phase 1
DMLA1QD	CP	Mustang Bio New York, NY
DMLA1QD	DE	Recurrent glioblastoma

DMS0P5O	ID	DMS0P5O
DMS0P5O	DN	MB-103
DMS0P5O	HS	Phase 1
DMS0P5O	CP	Mustang Bio
DMS0P5O	DT	CAR T Cell Therapy
DMS0P5O	DE	Glioblastoma multiforme

DMRP4BM	ID	DMRP4BM
DMRP4BM	DN	MB-104
DMRP4BM	HS	Phase 1
DMRP4BM	CP	Mustang Bio
DMRP4BM	DT	CAR T Cell Therapy
DMRP4BM	DE	Multiple myeloma

DMVGTP6	ID	DMVGTP6
DMVGTP6	DN	MB-105
DMVGTP6	HS	Phase 1
DMVGTP6	CP	Mustang Bio
DMVGTP6	DT	CAR T Cell Therapy
DMVGTP6	DE	Prostate cancer

DMPE0KD	ID	DMPE0KD
DMPE0KD	DN	MB-110
DMPE0KD	HS	Phase 1
DMPE0KD	SN	DBPR-110; UNII-78GIB3SHQQ; 78GIB3SHQQ; 1310694-75-7; CHEMBL4468585; DBPR110; DBPR 110; SCHEMBL12547715; BDBM50522267; SB18773; Cyclopropanecarboxamide, N,N'-((1,1'-biphenyl)-4,4'-diylbis(5,2-thiazolediyl-(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))bis-; Q27266669; N-[(1R)-2-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2R)-2-(cyclopropanecarbonylamino)-2-phenyl-acetyl]pyrrolidin-2-yl]thiazol-5-yl]phenyl]phenyl]thiazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenyl-ethyl]cyclopropanecarboxamide; N-[(1R)-2-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2R)-2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]phenyl]phenyl]-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide
DMPE0KD	CP	Microbio
DMPE0KD	DT	Small molecular drug
DMPE0KD	PC	53247390
DMPE0KD	MW	861.1
DMPE0KD	FM	C50H48N6O4S2
DMPE0KD	IC	InChI=1S/C50H48N6O4S2/c57-45(37-23-24-37)53-43(35-9-3-1-4-10-35)49(59)55-27-7-13-39(55)47-51-29-41(61-47)33-19-15-31(16-20-33)32-17-21-34(22-18-32)42-30-52-48(62-42)40-14-8-28-56(40)50(60)44(36-11-5-2-6-12-36)54-46(58)38-25-26-38/h1-6,9-12,15-22,29-30,37-40,43-44H,7-8,13-14,23-28H2,(H,53,57)(H,54,58)/t39-,40-,43+,44+/m0/s1
DMPE0KD	CS	C1C[C@H](N(C1)C(=O)[C@@H](C2=CC=CC=C2)NC(=O)C3CC3)C4=NC=C(S4)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CN=C(S7)[C@@H]8CCCN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)C1CC1
DMPE0KD	IK	FZCLQOXUWMCXCV-XCIZVNRNSA-N
DMPE0KD	IU	N-[(1R)-2-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2R)-2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]phenyl]phenyl]-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide
DMPE0KD	CA	CAS 1310694-75-7
DMPE0KD	DE	Hepatitis C virus infection

DM85AXS	ID	DM85AXS
DM85AXS	DN	MBS301
DM85AXS	HS	Phase 1
DM85AXS	CP	Beijing Mabworks Biotech
DM85AXS	DT	Antibody
DM85AXS	DE	Solid tumour/cancer

DMTXIZ1	ID	DMTXIZ1
DMTXIZ1	DN	MBX-700
DMTXIZ1	HS	Phase 1
DMTXIZ1	CP	Microbiotix
DMTXIZ1	DE	Hepatitis C virus infection

DMFIS4D	ID	DMFIS4D
DMFIS4D	DN	MCD-386
DMFIS4D	HS	Phase 1
DMFIS4D	SN	CDD-0102; CDD-0262; CDD-0264; CDD-102; MCD-386 Forte; MCD-386 Transderm; MCD-386CR; MCD-386 Forte/Transderm; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), Cognitive Pharmaceuticals; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), University of Toledo; Tetrahydropyrimidine muscarinicM1 agonists (Alzheimer's disease), Mithridion; MCD-386 (oral controlled release, CNS disorders), Mithridion; MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (high dose, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (transdermal, Alzheimer's disease/schizophrenia), Mithridion
DMFIS4D	CP	Mithridion Inc; University of Toledo
DMFIS4D	DE	Alzheimer disease

DM8CGUV	ID	DM8CGUV
DM8CGUV	DN	MCLA-145
DM8CGUV	HS	Phase 1
DM8CGUV	CP	Merus
DM8CGUV	DT	Antibody
DM8CGUV	DE	Lymphoma; Solid tumour/cancer

DMF0O3X	ID	DMF0O3X
DMF0O3X	DN	MCLA-158
DMF0O3X	HS	Phase 1
DMF0O3X	CP	Merus
DMF0O3X	DT	Antibody
DMF0O3X	DE	Solid tumour/cancer

DMW9YOJ	ID	DMW9YOJ
DMW9YOJ	DN	MCP-201
DMW9YOJ	HS	Phase 1
DMW9YOJ	CP	Mt Cook Pharma
DMW9YOJ	DE	Pain

DM65B7G	ID	DM65B7G
DM65B7G	DN	MCP-202
DM65B7G	HS	Phase 1
DM65B7G	SN	Delta receptor agonist (overactive bladder, oral), Mt Cook Pharma
DM65B7G	CP	Mt Cook Pharma
DM65B7G	DE	Overactive bladder

DMAESQI	ID	DMAESQI
DMAESQI	DN	MCY-M11
DMAESQI	HS	Phase 1
DMAESQI	CP	MaxCyte
DMAESQI	DT	CAR-PBMC Cell therapy
DMAESQI	DE	Ovarian cancer; Peritoneal cancer; Fallopian tube cancer; Peritoneal mesothelioma

DM1DISM	ID	DM1DISM
DM1DISM	DN	MDAM (y-methylene-10-deazaaminopterin)
DM1DISM	HS	Phase 1
DM1DISM	CP	BioNumerik Pharmaceuticals
DM1DISM	DE	Solid tumour/cancer

DMAQ24G	ID	DMAQ24G
DMAQ24G	DN	MDCO-216
DMAQ24G	HS	Phase 1
DMAQ24G	CP	The Medicines Company
DMAQ24G	DE	Arteriosclerosis; Acute coronary syndrome

DMC60S8	ID	DMC60S8
DMC60S8	DN	MDL-27531
DMC60S8	HS	Phase 1
DMC60S8	SN	4-Methyl-5-(methylsulfonyl)-3-phenyl-1,2,4-triazole
DMC60S8	DT	Small molecular drug
DMC60S8	PC	164013
DMC60S8	MW	237.28
DMC60S8	FM	C10H11N3O2S
DMC60S8	IC	InChI=1S/C10H11N3O2S/c1-13-9(8-6-4-3-5-7-8)11-12-10(13)16(2,14)15/h3-7H,1-2H3
DMC60S8	CS	CN1C(=NN=C1S(=O)(=O)C)C2=CC=CC=C2
DMC60S8	IK	DPGDRICHXKQXEN-UHFFFAOYSA-N
DMC60S8	IU	4-methyl-3-methylsulfonyl-5-phenyl-1,2,4-triazole
DMC60S8	CA	CAS 116850-44-3
DMC60S8	DE	Epilepsy

DML5FX2	ID	DML5FX2
DML5FX2	DN	MDX-018
DML5FX2	HS	Phase 1
DML5FX2	SN	HuMax-IL8; HuMax-Inflam; Anti-inflammatory antibody, Medarex/Genmab; Anti-inflammatory therapeutic, Genmab/Medarex
DML5FX2	CP	Genmab A/S
DML5FX2	DE	Autoimmune diabetes; Solid tumour/cancer

DM0RIQF	ID	DM0RIQF
DM0RIQF	DN	MDX-1203
DM0RIQF	HS	Phase 1
DM0RIQF	SN	Alkylating agent-antibody conjugate (cancer), Medarex
DM0RIQF	CP	Medarex Inc
DM0RIQF	DT	Antibody
DM0RIQF	DE	Solid tumour/cancer

DM3402P	ID	DM3402P
DM3402P	DN	MDX-1411
DM3402P	HS	Phase 1
DM3402P	CP	Medarex Inc
DM3402P	DT	Antibody
DM3402P	DE	Solid tumour/cancer

DMEMQ5J	ID	DMEMQ5J
DMEMQ5J	DN	ME-1071
DMEMQ5J	HS	Phase 1
DMEMQ5J	SN	CP-3242; MBL inhibitor (intravenous, bacterial infection), Meiji Seika Kaisha; Metallo-beta-lactamase inhibitor (intravenous, bacterial infection), Meiji Seika Kaisha
DMEMQ5J	CP	Meiji Seika Kaisha Ltd
DMEMQ5J	PC	16064853
DMEMQ5J	MW	216.14
DMEMQ5J	FM	C8H10Na2O4
DMEMQ5J	IC	InChI=1S/C8H12O4.2Na/c1-3-5(7(9)10)6(4-2)8(11)12;;/h3-4H2,1-2H3,(H,9,10)(H,11,12);;/q;2*+1/p-2/b6-5-;;
DMEMQ5J	CS	CC/C(=C(\\CC)/C(=O)[O-])/C(=O)[O-].[Na+].[Na+]
DMEMQ5J	IK	GLJFFZOATODZQQ-XNOMRPDFSA-L
DMEMQ5J	IU	disodium;(Z)-2,3-diethylbut-2-enedioate
DMEMQ5J	DE	Bacterial infection

DM39PSZ	ID	DM39PSZ
DM39PSZ	DN	ME1100
DM39PSZ	HS	Phase 1
DM39PSZ	SN	Arbekacin inhalation
DM39PSZ	CP	Meiji seika pharma
DM39PSZ	DE	Bacterial pneumonia

DMFNYQ9	ID	DMFNYQ9
DMFNYQ9	DN	ME-401
DMFNYQ9	HS	Phase 1
DMFNYQ9	CP	MEI Pharma San Diego,CA
DMFNYQ9	DE	Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Lymphoma

DMYVBU6	ID	DMYVBU6
DMYVBU6	DN	MEDI0562
DMYVBU6	HS	Phase 1
DMYVBU6	CP	MedImmune Gaithersburg, MD
DMYVBU6	DE	Solid tumour/cancer

DMPLFBV	ID	DMPLFBV
DMPLFBV	DN	MEDI0680
DMPLFBV	HS	Phase 1
DMPLFBV	CP	Medimmune
DMPLFBV	DT	Monoclonal antibody
DMPLFBV	DE	Solid tumour/cancer

DMD9OVI	ID	DMD9OVI
DMD9OVI	DN	MEDI1191
DMD9OVI	HS	Phase 1
DMD9OVI	CP	AstraZeneca; Moderna Therapeutics
DMD9OVI	DT	mRNA therapy
DMD9OVI	DE	Solid tumour/cancer

DMQDBSU	ID	DMQDBSU
DMQDBSU	DN	MEDI1341
DMQDBSU	HS	Phase 1
DMQDBSU	CP	MedImmune Gaithersburg, MD
DMQDBSU	DE	Parkinson disease

DMX0DUH	ID	DMX0DUH
DMX0DUH	DN	MEDI2228
DMX0DUH	HS	Phase 1
DMX0DUH	CP	AstraZeneca
DMX0DUH	DT	Antibody drug conjugate
DMX0DUH	DE	Multiple myeloma

DMCMYPX	ID	DMCMYPX
DMCMYPX	DN	MEDI-2338
DMCMYPX	HS	Phase 1
DMCMYPX	CP	MedImmune
DMCMYPX	DE	Chronic obstructive pulmonary disease

DM0H5JD	ID	DM0H5JD
DM0H5JD	DN	MEDI3617
DM0H5JD	HS	Phase 1
DM0H5JD	CP	Astrazeneca; medimmune
DM0H5JD	DT	Antibody
DM0H5JD	DE	Solid tumour/cancer; Ovarian cancer

DMBI4EN	ID	DMBI4EN
DMBI4EN	DN	MEDI4212
DMBI4EN	HS	Phase 1
DMBI4EN	CP	AstraZeneca
DMBI4EN	DE	Asthma

DMNI60O	ID	DMNI60O
DMNI60O	DN	MEDI4276
DMNI60O	HS	Phase 1
DMNI60O	CP	MedImmune Gaithersburg, MD
DMNI60O	DE	Solid tumour/cancer

DME7BMT	ID	DME7BMT
DME7BMT	DN	MEDI4920
DME7BMT	HS	Phase 1
DME7BMT	DE	Sjogren syndrome; Rheumatoid arthritis

DM3IJQ5	ID	DM3IJQ5
DM3IJQ5	DN	MEDI5117
DM3IJQ5	HS	Phase 1
DM3IJQ5	CP	AstraZeneca
DM3IJQ5	DE	Rheumatoid arthritis

DM3WP70	ID	DM3WP70
DM3WP70	DN	MEDI-547
DM3WP70	HS	Phase 1
DM3WP70	SN	MedImmune, MedImmune/AstraZeneca
DM3WP70	CP	AstraZeneca
DM3WP70	DT	Antibody
DM3WP70	DE	Solid tumour/cancer

DM6ADMG	ID	DM6ADMG
DM6ADMG	DN	MEDI-557
DM6ADMG	HS	Phase 1
DM6ADMG	CP	AstraZeneca
DM6ADMG	DT	Antibody
DM6ADMG	DE	Respiratory syncytial virus infection

DMFWPLQ	ID	DMFWPLQ
DMFWPLQ	DN	MEDI-565
DMFWPLQ	HS	Phase 1
DMFWPLQ	CP	MedImmune
DMFWPLQ	DT	Monoclonal antibody
DMFWPLQ	DE	Gastrointestinal cancer

DMCJFLS	ID	DMCJFLS
DMCJFLS	DN	MEDI-570
DMCJFLS	HS	Phase 1
DMCJFLS	CP	AstraZeneca; MedImmune
DMCJFLS	DE	Systemic lupus erythematosus

DMNL8MO	ID	DMNL8MO
DMNL8MO	DN	MEDI-573
DMNL8MO	HS	Phase 1
DMNL8MO	CP	MedImmune
DMNL8MO	DE	Solid tumour/cancer

DMJ1E24	ID	DMJ1E24
DMJ1E24	DN	MEDI5752
DMJ1E24	HS	Phase 1
DMJ1E24	CP	AstraZeneca
DMJ1E24	DT	Antibody
DMJ1E24	DE	Solid tumour/cancer; Non-small cell lung cancer

DMPW21Z	ID	DMPW21Z
DMPW21Z	DN	MEDI-578
DMPW21Z	HS	Phase 1
DMPW21Z	DE	Pain

DM1YSMD	ID	DM1YSMD
DM1YSMD	DN	MEDI6383
DM1YSMD	HS	Phase 1
DM1YSMD	DT	Antibody
DM1YSMD	DE	Solid tumour/cancer

DM8BXDI	ID	DM8BXDI
DM8BXDI	DN	MEDI7814
DM8BXDI	HS	Phase 1
DM8BXDI	CP	AstraZeneca
DM8BXDI	DE	Chronic obstructive pulmonary disease

DM0J7UR	ID	DM0J7UR
DM0J7UR	DN	MEDI9197
DM0J7UR	HS	Phase 1
DM0J7UR	SN	RRTPWQXEERTRRK-UHFFFAOYSA-N; UNII-16598XQ2BT; 16598XQ2BT; 1359993-59-1; N-(4-((4-Amino-2-butyl-1H-imidazo(4,5-C)quinolin-1-yl)oxy)butyl)octadecanamide; N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide; SCHEMBL671176; MEDI-9197; AKOS032946368; Octadecanamide, N-(4-((4-amino-2-butyl-1H-imidazo(4,5-C)quinolin-1-yl)oxy)butyl)-
DM0J7UR	CP	MedImmune Gaithersburg, MD
DM0J7UR	PC	56833311
DM0J7UR	MW	593.9
DM0J7UR	FM	C36H59N5O2
DM0J7UR	IC	InChI=1S/C36H59N5O2/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-18-19-27-33(42)38-28-22-23-29-43-41-32(26-6-4-2)40-34-35(41)30-24-20-21-25-31(30)39-36(34)37/h20-21,24-25H,3-19,22-23,26-29H2,1-2H3,(H2,37,39)(H,38,42)
DM0J7UR	CS	CCCCCCCCCCCCCCCCCC(=O)NCCCCON1C(=NC2=C1C3=CC=CC=C3N=C2N)CCCC
DM0J7UR	IK	RRTPWQXEERTRRK-UHFFFAOYSA-N
DM0J7UR	IU	N-[4-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)oxybutyl]octadecanamide
DM0J7UR	CA	CAS 1359993-59-1
DM0J7UR	DE	Solid tumour/cancer

DM1ALHT	ID	DM1ALHT
DM1ALHT	DN	MEDl-551
DM1ALHT	HS	Phase 1
DM1ALHT	CP	Astrazeneca; medimmune
DM1ALHT	DT	Antibody
DM1ALHT	DE	Scleroderma

DMA1KQV	ID	DMA1KQV
DMA1KQV	DN	MEM-1414
DMA1KQV	HS	Phase 1
DMA1KQV	SN	R-1533; PDE 4 inhibitor (Alzheimer's), Memory; PDE 4 inhibitor (Alzheimer's), Memory/Roche
DMA1KQV	CP	Memory Pharmaceuticals Corp
DMA1KQV	DE	Mood disorder

DME18UM	ID	DME18UM
DME18UM	DN	MER-102
DME18UM	HS	Phase 1
DME18UM	CP	Merrion Pharmaceuticals
DME18UM	DE	Thrombosis

DMQSJ9T	ID	DMQSJ9T
DMQSJ9T	DN	Meso-CART
DMQSJ9T	HS	Phase 1
DMQSJ9T	CP	Shanghai GeneChem Co., Ltd.
DMQSJ9T	DT	CAR T Cell Therapy
DMQSJ9T	DE	Pancreatic cancer

DMHXA79	ID	DMHXA79
DMHXA79	DN	Mesothelin-targeted T cells
DMHXA79	HS	Phase 1
DMHXA79	CP	Memorial Sloan Kettering Cancer Center
DMHXA79	DT	CAR T Cell Therapy
DMHXA79	DE	Breast cancer

DMTQ4PN	ID	DMTQ4PN
DMTQ4PN	DN	Metastat
DMTQ4PN	HS	Phase 1
DMTQ4PN	DT	Small molecular drug
DMTQ4PN	PC	54678924
DMTQ4PN	MW	371.3
DMTQ4PN	FM	C19H17NO7
DMTQ4PN	IC	InChI=1S/C19H17NO7/c20-18(26)14-11(22)6-9-5-8-4-7-2-1-3-10(21)12(7)15(23)13(8)16(24)19(9,27)17(14)25/h1-3,8-9,21,23,25,27H,4-6H2,(H2,20,26)/t8-,9-,19-/m0/s1
DMTQ4PN	CS	C1[C@@H]2CC3=C(C(=CC=C3)O)C(=C2C(=O)[C@]4([C@@H]1CC(=O)C(=C4O)C(=O)N)O)O
DMTQ4PN	IK	NBRQRXRBIHVLGI-OWXODZSWSA-N
DMTQ4PN	IU	(4aS,5aR,12aR)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMTQ4PN	CA	CAS 15866-90-7
DMTQ4PN	DE	Acne vulgaris

DMQE4IX	ID	DMQE4IX
DMQE4IX	DN	MG-1102
DMQE4IX	HS	Phase 1
DMQE4IX	DE	Solid tumour/cancer

DM2PVLH	ID	DM2PVLH
DM2PVLH	DN	MGA271
DM2PVLH	HS	Phase 1
DM2PVLH	CP	MacroGenics
DM2PVLH	DE	Metastatic cancer

DMQB4VN	ID	DMQB4VN
DMQB4VN	DN	MGD006
DMQB4VN	HS	Phase 1
DMQB4VN	CP	MacroGenics
DMQB4VN	DT	Monoclonal antibody
DMQB4VN	DE	Acute myeloid lymphoma; Acute lymphoblastic leukaemia

DME4B8I	ID	DME4B8I
DME4B8I	DN	MGD009
DME4B8I	HS	Phase 1
DME4B8I	CP	MacroGenics Rockville, MD
DME4B8I	DE	Solid tumour/cancer

DMA368V	ID	DMA368V
DMA368V	DN	MGD010
DMA368V	HS	Phase 1
DMA368V	CP	MacroGenicsRockville, MDTakeda Pharmaceuticals
DMA368V	DE	Autoimmune disease

DMZN5QX	ID	DMZN5QX
DMZN5QX	DN	MGD014
DMZN5QX	HS	Phase 1
DMZN5QX	CP	MacroGenics
DMZN5QX	DT	Antibody
DMZN5QX	DE	Human immunodeficiency virus-1 infection

DM2BYWI	ID	DM2BYWI
DM2BYWI	DN	MGD019
DM2BYWI	HS	Phase 1
DM2BYWI	CP	MacroGenics
DM2BYWI	DT	Antibody
DM2BYWI	DE	Solid tumour/cancer

DMTS5VF	ID	DMTS5VF
DMTS5VF	DN	MGN-1706
DMTS5VF	HS	Phase 1
DMTS5VF	DE	Solid tumour/cancer

DMU9VDS	ID	DMU9VDS
DMU9VDS	DN	Mibefradil
DMU9VDS	HS	Phase 1
DMU9VDS	SN	Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics
DMU9VDS	CP	Tau therapeutics; cavion
DMU9VDS	DT	Small molecular drug
DMU9VDS	PC	60663
DMU9VDS	MW	495.6
DMU9VDS	FM	C29H38FN3O3
DMU9VDS	IC	InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1
DMU9VDS	CS	CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
DMU9VDS	IK	HBNPJJILLOYFJU-VMPREFPWSA-N
DMU9VDS	IU	[(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate
DMU9VDS	CA	CAS 116644-53-2
DMU9VDS	CB	CHEBI:6920
DMU9VDS	DE	Ovarian cancer; Glioblastoma multiforme

DMTUVCG	ID	DMTUVCG
DMTUVCG	DN	MIK665
DMTUVCG	HS	Phase 1
DMTUVCG	SN	1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; MIK665; S-64315; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5
DMTUVCG	CP	Novartis; Servier
DMTUVCG	DT	Small molecular drug
DMTUVCG	PC	118157243
DMTUVCG	MW	875.4
DMTUVCG	FM	C47H44ClFN6O6S
DMTUVCG	IC	InChI=1S/C47H44ClFN6O6S/c1-29-34(16-17-38(42(29)48)59-25-24-55-22-20-54(2)21-23-55)40-41-45(51-28-52-46(41)62-43(40)30-12-14-32(49)15-13-30)61-39(47(56)57)26-31-8-4-6-10-36(31)60-27-33-18-19-50-44(53-33)35-9-5-7-11-37(35)58-3/h4-19,28,39H,20-27H2,1-3H3,(H,56,57)/t39-/m1/s1
DMTUVCG	CS	CC1=C(C=CC(=C1Cl)OCCN2CCN(CC2)C)C3=C(SC4=NC=NC(=C34)O[C@H](CC5=CC=CC=C5OCC6=NC(=NC=C6)C7=CC=CC=C7OC)C(=O)O)C8=CC=C(C=C8)F
DMTUVCG	IK	PKYIMGFMRFVOMB-LDLOPFEMSA-N
DMTUVCG	IU	(2R)-2-[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid
DMTUVCG	DE	Acute myeloid leukaemia

DMDER9S	ID	DMDER9S
DMDER9S	DN	Minnelide
DMDER9S	HS	Phase 1
DMDER9S	SN	UNII-1CIV2UMO40; 1CIV2UMO40; 14-O-Phosphonooxymethyltriptolide disodium salt; CHEMBL3740500; Triptolide O-Methyl Phosphate Disodium Salt; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-C)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-((phosphonooxy)methoxy)-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-; 1254702-87-8
DMDER9S	CP	Minneamrita Therapeutics Tampa, FL
DMDER9S	PC	46203139
DMDER9S	MW	514.4
DMDER9S	FM	C21H25Na2O10P
DMDER9S	IC	InChI=1S/C21H27O10P.2Na/c1-9(2)19-14(30-19)15-21(31-15)18(3)5-4-10-11(7-26-16(10)22)12(18)6-13-20(21,29-13)17(19)27-8-28-32(23,24)25;;/h9,12-15,17H,4-8H2,1-3H3,(H2,23,24,25);;/q;2*+1/p-2/t12-,13-,14-,15-,17+,18-,19-,20+,21+;;/m0../s1
DMDER9S	CS	CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2OCOP(=O)([O-])[O-])O7)COC6=O)C.[Na+].[Na+]
DMDER9S	IK	ZHBJMVNZRZUQEP-KIKMAQITSA-L
DMDER9S	IU	disodium;[(1S,2S,4S,5S,7S,8R,9R,11S,13S)-1-methyl-17-oxo-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-8-yl]oxymethyl phosphate
DMDER9S	CA	CAS 1254702-87-8
DMDER9S	DE	Solid tumour/cancer

DM5VEN9	ID	DM5VEN9
DM5VEN9	DN	Minnelide 001
DM5VEN9	HS	Phase 1
DM5VEN9	CP	Minneamrita therapeutics
DM5VEN9	DE	Gastrointestinal cancer; Gastric adenocarcinoma

DMCPF90	ID	DMCPF90
DMCPF90	DN	Mivebresib
DMCPF90	HS	Phase 1
DMCPF90	SN	ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815
DMCPF90	CP	AbbVieNorth Chicago, IL
DMCPF90	PC	71600087
DMCPF90	MW	459.5
DMCPF90	FM	C22H19F2N3O4S
DMCPF90	IC	InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3
DMCPF90	CS	CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C
DMCPF90	IK	RDONXGFGWSSFMY-UHFFFAOYSA-N
DMCPF90	IU	N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide
DMCPF90	CA	CAS 1445993-26-9
DMCPF90	DE	Acute myeloid leukaemia; Multiple myeloma; Solid tumour/cancer

DMFLP21	ID	DMFLP21
DMFLP21	DN	MK 8719
DMFLP21	HS	Phase 1
DMFLP21	CP	Alectos Therapeutics Vancouver, Canada Merck Whitehouse Station, NJ
DMFLP21	DE	Progressive supranuclear palsy

DM2TAUR	ID	DM2TAUR
DM2TAUR	DN	MK-0731
DM2TAUR	HS	Phase 1
DM2TAUR	SN	C-4251; MK-731
DM2TAUR	CP	Merck & Co Inc
DM2TAUR	DT	Small molecular drug
DM2TAUR	PC	11655511
DM2TAUR	MW	459.5
DM2TAUR	FM	C25H28F3N3O2
DM2TAUR	IC	InChI=1S/C25H28F3N3O2/c1-29-11-10-23(22(28)15-29)30(2)24(33)31-14-17(20-12-19(26)8-9-21(20)27)13-25(31,16-32)18-6-4-3-5-7-18/h3-9,12-13,22-23,32H,10-11,14-16H2,1-2H3/t22-,23+,25-/m1/s1
DM2TAUR	CS	CN1CC[C@@H]([C@@H](C1)F)N(C)C(=O)N2CC(=C[C@@]2(CO)C3=CC=CC=C3)C4=C(C=CC(=C4)F)F
DM2TAUR	IK	MYBGWENAVMIGMM-GIFXNVAJSA-N
DM2TAUR	IU	(5S)-3-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-5-(hydroxymethyl)-N-methyl-5-phenyl-2H-pyrrole-1-carboxamide
DM2TAUR	CA	CAS 845256-65-7
DM2TAUR	DE	Solid tumour/cancer

DMHS79I	ID	DMHS79I
DMHS79I	DN	MK-1092
DMHS79I	HS	Phase 1
DMHS79I	CP	Merck
DMHS79I	DE	Type-1 diabetes

DME1ZAH	ID	DME1ZAH
DME1ZAH	DN	MK-1496
DME1ZAH	HS	Phase 1
DME1ZAH	CP	Merck
DME1ZAH	PC	67313626
DME1ZAH	MW	236.35
DME1ZAH	FM	C14H24N2O
DME1ZAH	IC	InChI=1S/C14H24N2O/c1-10(15)11-5-7-12(8-6-11)13(17)9-16-14(2,3)4/h5-8,10,13,16-17H,9,15H2,1-4H3/t10-,13+/m0/s1
DME1ZAH	CS	C[C@@H](C1=CC=C(C=C1)[C@@H](CNC(C)(C)C)O)N
DME1ZAH	IK	KUHBBYPXWKYKKR-GXFFZTMASA-N
DME1ZAH	IU	(1S)-1-[4-[(1S)-1-aminoethyl]phenyl]-2-(tert-butylamino)ethanol
DME1ZAH	CA	CAS 1037254-47-9
DME1ZAH	DE	Solid tumour/cancer

DMKNH8B	ID	DMKNH8B
DMKNH8B	DN	MK-2118
DMKNH8B	HS	Phase 1
DMKNH8B	CP	Merck
DMKNH8B	DT	Small molecular drug
DMKNH8B	DE	Lymphoma; Solid tumour/cancer

DMUHOJP	ID	DMUHOJP
DMUHOJP	DN	MK-2637
DMUHOJP	HS	Phase 1
DMUHOJP	CP	Merck
DMUHOJP	DE	Schizophrenia

DM5EFPS	ID	DM5EFPS
DM5EFPS	DN	MK-3134
DM5EFPS	HS	Phase 1
DM5EFPS	CP	Merck
DM5EFPS	PC	11973780
DM5EFPS	MW	457.5
DM5EFPS	FM	C25H26F3N3O2
DM5EFPS	IC	InChI=1S/C25H26F3N3O2/c1-16-29-22-7-3-6-21(25(26,27)28)23(22)24(32)31(16)18-8-10-19(11-9-18)33-20-12-14-30(15-13-20)17-4-2-5-17/h3,6-11,17,20H,2,4-5,12-15H2,1H3
DM5EFPS	CS	CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5)C(F)(F)F
DM5EFPS	IK	ZWUFGBNOUKQGBR-UHFFFAOYSA-N
DM5EFPS	IU	3-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-methyl-5-(trifluoromethyl)quinazolin-4-one
DM5EFPS	CA	CAS 862310-66-5
DM5EFPS	DE	Dementia

DMG0Q27	ID	DMG0Q27
DMG0Q27	DN	MK-3281
DMG0Q27	HS	Phase 1
DMG0Q27	SN	MK-3281; UNII-3593C180JO; CHEMBL1233524; 3593C180JO; (7r)-14-Cyclohexyl-7-{[2-(Dimethylamino)ethyl](Methyl)amino}-7,8-Dihydro-6h-Indolo[1,2-E][1,5]benzoxazocine-11-Carboxylic Acid; MK3281; cyclohexyl-[2-dimethylaminoethyl(methyl)amino][ ]carboxylic acid; SCHEMBL3073622; BDBM50335314; 1187645-92-6
DMG0Q27	CP	Merck
DMG0Q27	DT	Small molecular drug
DMG0Q27	PC	49800096
DMG0Q27	MW	475.6
DMG0Q27	FM	C29H37N3O3
DMG0Q27	IC	InChI=1S/C29H37N3O3/c1-30(2)15-16-31(3)22-18-32-25-17-21(29(33)34)13-14-23(25)27(20-9-5-4-6-10-20)28(32)24-11-7-8-12-26(24)35-19-22/h7-8,11-14,17,20,22H,4-6,9-10,15-16,18-19H2,1-3H3,(H,33,34)/t22-/m1/s1
DMG0Q27	CS	CN(C)CCN(C)[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)C(=C2C4=CC=CC=C4OC1)C5CCCCC5
DMG0Q27	IK	YQUCBFIQSJVCOR-JOCHJYFZSA-N
DMG0Q27	IU	(10R)-19-cyclohexyl-10-[2-(dimethylamino)ethyl-methylamino]-8-oxa-12-azatetracyclo[10.7.0.02,7.013,18]nonadeca-1(19),2,4,6,13(18),14,16-heptaene-15-carboxylic acid
DMG0Q27	CA	CAS 886041-60-7
DMG0Q27	DE	Hepatitis C virus infection

DMW2O5D	ID	DMW2O5D
DMW2O5D	DN	MK-3328
DMW2O5D	HS	Phase 1
DMW2O5D	SN	UNII-4I12ES557C; MK-3328 F-18; 4I12ES557C; 1201324-21-1; (18F)MK-3328; [18F]MK-3328; CHEMBL2203396; SCHEMBL12268073
DMW2O5D	CP	Merck
DMW2O5D	DT	Small molecular drug
DMW2O5D	PC	44555286
DMW2O5D	MW	268.25
DMW2O5D	FM	C14H9FN4O
DMW2O5D	IC	InChI=1S/C14H9FN4O/c1-19-5-4-8-6-9(7-16-12(8)19)13-17-10-2-3-11(15)18-14(10)20-13/h2-7H,1H3
DMW2O5D	CS	CN1C=CC2=CC(=CN=C21)C3=NC4=C(O3)N=C(C=C4)F
DMW2O5D	IK	WYQHKOHCTMNFAU-UHFFFAOYSA-N
DMW2O5D	IU	5-fluoro-2-(1-methylpyrrolo[2,3-b]pyridin-5-yl)-[1,3]oxazolo[5,4-b]pyridine
DMW2O5D	CA	CAS 1201323-97-8
DMW2O5D	DE	Alzheimer disease

DML5V76	ID	DML5V76
DML5V76	DN	MK-4166
DML5V76	HS	Phase 1
DML5V76	CP	Merck
DML5V76	DT	Antibody
DML5V76	DE	Solid tumour/cancer

DMCA1NX	ID	DMCA1NX
DMCA1NX	DN	MK-4280
DMCA1NX	HS	Phase 1
DMCA1NX	CP	Merck
DMCA1NX	DT	Antibody
DMCA1NX	DE	Solid tumour/cancer; Neoplasm

DMN40DU	ID	DMN40DU
DMN40DU	DN	MK-4621
DMN40DU	HS	Phase 1
DMN40DU	CP	Merck
DMN40DU	DE	Solid tumour/cancer

DMCT37W	ID	DMCT37W
DMCT37W	DN	MK-4830
DMCT37W	HS	Phase 1
DMCT37W	CP	Merck
DMCT37W	DT	Antibody
DMCT37W	DE	Solid tumour/cancer

DMFGYKS	ID	DMFGYKS
DMFGYKS	DN	MK-5108
DMFGYKS	HS	Phase 1
DMFGYKS	SN	1010085-13-8; VX-689; MK 5108; MK5108; MK-5108 (VX-689); UNII-H8J407531S; VX689; VX 689; CHEMBL3600873; H8J407531S; 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid; 4-(3-Chloranyl-2-Fluoranyl-Phenoxy)-1-[[6-(1,3-Thiazol-2-Ylamino)pyridin-2-Yl]methyl]cyclohexane-1-Carboxylic Acid; (1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid,; MK-5108/VX-689
DMFGYKS	DT	Small molecular drug
DMFGYKS	PC	24748204
DMFGYKS	MW	461.9
DMFGYKS	FM	C22H21ClFN3O3S
DMFGYKS	IC	InChI=1S/C22H21ClFN3O3S/c23-16-4-2-5-17(19(16)24)30-15-7-9-22(10-8-15,20(28)29)13-14-3-1-6-18(26-14)27-21-25-11-12-31-21/h1-6,11-12,15H,7-10,13H2,(H,28,29)(H,25,26,27)
DMFGYKS	CS	C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O
DMFGYKS	IK	LCVIRAZGMYMNNT-UHFFFAOYSA-N
DMFGYKS	IU	4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid
DMFGYKS	CA	CAS 1010085-13-8
DMFGYKS	CB	CHEBI:125340
DMFGYKS	DE	Solid tumour/cancer

DMSA27Z	ID	DMSA27Z
DMSA27Z	DN	MK-6186
DMSA27Z	HS	Phase 1
DMSA27Z	SN	MK-6186; UNII-K3978U665M; 1034474-19-5; K3978U665M; MK 6186; SCHEMBL2878768; CHEMBL1939499; FZBAOOQVQXATRL-UHFFFAOYSA-N; ZINC73240561; DB12999; DA-16093; 3-(1-((1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)-5-chloro-1H-indazol-4-yloxy)-5-chlorobenzonitrile; FT-0726721; 3-((1-((2H-pyrazolo[3,4-b]pyridin-3-yl)methyl)-5-chloro-1H-indazol-4-yl)oxy)-5-chlorobenzonitrile; 3-chloro-5-{[5-chloro-1-(1H-pyrazolo[3,4- b]pyridin-3-ylmethyl)-1H-indazol-4-yl]oxy}benzonitrile
DMSA27Z	CP	Merck & Co Inc
DMSA27Z	DT	Small molecular drug
DMSA27Z	PC	24988948
DMSA27Z	MW	435.3
DMSA27Z	FM	C21H12Cl2N6O
DMSA27Z	IC	InChI=1S/C21H12Cl2N6O/c22-13-6-12(9-24)7-14(8-13)30-20-16-10-26-29(19(16)4-3-17(20)23)11-18-15-2-1-5-25-21(15)28-27-18/h1-8,10H,11H2,(H,25,27,28)
DMSA27Z	CS	C1=CC2=C(NN=C2N=C1)CN3C4=C(C=N3)C(=C(C=C4)Cl)OC5=CC(=CC(=C5)C#N)Cl
DMSA27Z	IK	FZBAOOQVQXATRL-UHFFFAOYSA-N
DMSA27Z	IU	3-chloro-5-[5-chloro-1-(2H-pyrazolo[3,4-b]pyridin-3-ylmethyl)indazol-4-yl]oxybenzonitrile
DMSA27Z	CA	CAS 1034474-19-5
DMSA27Z	DE	Human immunodeficiency virus infection

DMZUA5C	ID	DMZUA5C
DMZUA5C	DN	MK-6302
DMZUA5C	HS	Phase 1
DMZUA5C	SN	INS-20; Pegylated GCSF, Insmed/Merck
DMZUA5C	CP	Insmed Inc
DMZUA5C	DE	Neutropenia

DMV8BI4	ID	DMV8BI4
DMV8BI4	DN	MK-6325
DMV8BI4	HS	Phase 1
DMV8BI4	CP	Merck
DMV8BI4	DT	Small molecular drug
DMV8BI4	PC	121596640
DMV8BI4	MW	821
DMV8BI4	FM	C42H56N6O9S
DMV8BI4	IC	InChI=1S/C42H56N6O9S/c1-41(20-21-41)58(53,54)47-39(51)42-24-27(42)14-8-4-3-5-9-16-32-38(50)48-25-29(23-34(48)36(49)46-42)56-37-31(43-30-19-18-28(55-2)22-33(30)44-37)15-10-6-7-12-26-13-11-17-35(26)57-40(52)45-32/h8,14,18-19,22,26-27,29,32,34-35H,3-7,9-13,15-17,20-21,23-25H2,1-2H3,(H,45,52)(H,46,49)(H,47,51)/b14-8+/t26-,27-,29-,32+,34+,35-,42-/m1/s1
DMV8BI4	CS	CC1(CC1)S(=O)(=O)NC(=O)[C@@]23C[C@H]2/C=C/CCCCC[C@H]4C(=O)N5C[C@@H](C[C@H]5C(=O)N3)OC6=NC7=C(C=CC(=C7)OC)N=C6CCCCC[C@@H]8CCC[C@H]8OC(=O)N4
DMV8BI4	IK	BLFKRFGLQFYXDF-WAZRELCSSA-N
DMV8BI4	IU	(3R,20R,24R,28S,34E,36S,38R,41S)-9-methoxy-N-(1-methylcyclopropyl)sulfonyl-26,40,42-trioxo-4,25-dioxa-1,6,13,27,39-pentazaheptacyclo[26.13.1.13,41.05,14.07,12.020,24.036,38]tritetraconta-5,7(12),8,10,13,34-hexaene-38-carboxamide
DMV8BI4	CA	CAS 1263814-52-3
DMV8BI4	DE	Hepatitis C virus infection

DMBSXZ1	ID	DMBSXZ1
DMBSXZ1	DN	MK-7162
DMBSXZ1	HS	Phase 1
DMBSXZ1	CP	Merck
DMBSXZ1	DE	Solid tumour/cancer

DMLQOF1	ID	DMLQOF1
DMLQOF1	DN	MK-7246
DMLQOF1	HS	Phase 1
DMLQOF1	SN	IDDBCP261213; IDDBCP271467
DMLQOF1	CP	Merck & Co Inc
DMLQOF1	DT	Small molecular drug
DMLQOF1	PC	45268455
DMLQOF1	MW	416.5
DMLQOF1	FM	C21H21FN2O4S
DMLQOF1	IC	InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-21(25)26)17-4-2-3-5-19(17)24(20)13-15/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)/t15-/m1/s1
DMLQOF1	CS	CN([C@@H]1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F
DMLQOF1	IK	JTCAGRAKUAAYDY-OAHLLOKOSA-N
DMLQOF1	IU	2-[(7R)-7-[(4-fluorophenyl)sulfonyl-methylamino]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]acetic acid
DMLQOF1	CA	CAS 1218918-62-7
DMLQOF1	DE	Respiratory disease

DMJ2Q6H	ID	DMJ2Q6H
DMJ2Q6H	DN	MK-7288
DMJ2Q6H	HS	Phase 1
DMJ2Q6H	CP	Merck
DMJ2Q6H	DE	Excessive daytime sleepiness

DMA1EDN	ID	DMA1EDN
DMA1EDN	DN	MK-8033
DMA1EDN	HS	Phase 1
DMA1EDN	SN	MK-8033; 1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide
DMA1EDN	CP	Merck
DMA1EDN	DT	Small molecular drug
DMA1EDN	PC	45142457
DMA1EDN	MW	471.5
DMA1EDN	FM	C25H21N5O3S
DMA1EDN	IC	InChI=1S/C25H21N5O3S/c1-30-15-20(13-28-30)19-11-23-24(27-12-19)8-7-18-6-5-17(10-22(18)25(23)31)16-34(32,33)29-14-21-4-2-3-9-26-21/h2-13,15,29H,14,16H2,1H3
DMA1EDN	CS	CN1C=C(C=N1)C2=CC3=C(C=CC4=C(C3=O)C=C(C=C4)CS(=O)(=O)NCC5=CC=CC=N5)N=C2
DMA1EDN	IK	VMJFTOSOFDEKTM-UHFFFAOYSA-N
DMA1EDN	IU	1-[5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-14-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide
DMA1EDN	CA	CAS 1001917-37-8
DMA1EDN	DE	Solid tumour/cancer

DMLCTI5	ID	DMLCTI5
DMLCTI5	DN	MK-8353
DMLCTI5	HS	Phase 1
DMLCTI5	SN	KPQQGHGDBBJGFA-QNGWXLTQSA-N; GTPL9974; SCHEMBL10236331; MK8353; (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide
DMLCTI5	CP	Merck Kenilworth, NJ
DMLCTI5	PC	58282870
DMLCTI5	MW	691.8
DMLCTI5	FM	C37H41N9O3S
DMLCTI5	IC	InChI=1S/C37H41N9O3S/c1-24(2)49-32-12-9-28(20-38-32)34-30-19-29(10-11-31(30)41-42-34)40-36(48)37(50-4)15-18-45(22-37)21-33(47)46-16-13-26(14-17-46)25-5-7-27(8-6-25)35-39-23-44(3)43-35/h5-13,19-20,23-24H,14-18,21-22H2,1-4H3,(H,40,48)(H,41,42)/t37-/m0/s1
DMLCTI5	CS	CC(C)OC1=NC=C(C=C1)C2=NNC3=C2C=C(C=C3)NC(=O)[C@@]4(CCN(C4)CC(=O)N5CCC(=CC5)C6=CC=C(C=C6)C7=NN(C=N7)C)SC
DMLCTI5	IK	KPQQGHGDBBJGFA-QNGWXLTQSA-N
DMLCTI5	IU	(3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide
DMLCTI5	DE	Solid tumour/cancer

DMHTWBL	ID	DMHTWBL
DMHTWBL	DN	MK-8504
DMHTWBL	HS	Phase 1
DMHTWBL	CP	Merck
DMHTWBL	DT	Small molecular drug
DMHTWBL	DE	Human immunodeficiency virus-1 infection

DMQHPME	ID	DMQHPME
DMQHPME	DN	MK-8583
DMQHPME	HS	Phase 1
DMQHPME	CP	Merck
DMQHPME	DT	Small molecular drug
DMQHPME	DE	Human immunodeficiency virus-1 infection

DMETIBD	ID	DMETIBD
DMETIBD	DN	MK-8719
DMETIBD	HS	Phase 1
DMETIBD	SN	1382799-40-7; (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5H-pyrano[3,2-d]thiazole-6,7-diol; (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol; SCHEMBL9956073; CHEMBL4111094; GTPL10508; BDBM205424; MK8719; s8890; compound 42 [PMID: 31487175]; US9243020, 19; Q66885447; (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-ethylimino-1,3a,5,6,7,7a-hexahydropyrano[3,2-d][1,3]thiazole-6,7-diol; (3AR,5S,6S,7R,7aR,E)-5-(difluoromethyl)-2-(ethylimino)hexahydro-5H-pyrano[3,2-d]thiazole-6,7-diol
DMETIBD	CP	Alectos
DMETIBD	DT	Small molecular drug
DMETIBD	PC	136416849
DMETIBD	MW	268.28
DMETIBD	FM	C9H14F2N2O3S
DMETIBD	IC	InChI=1S/C9H14F2N2O3S/c1-2-12-9-13-3-4(14)5(15)6(7(10)11)16-8(3)17-9/h3-8,14-15H,2H2,1H3,(H,12,13)/t3-,4-,5+,6+,8-/m1/s1
DMETIBD	CS	CCN=C1N[C@@H]2[C@H]([C@@H]([C@H](O[C@@H]2S1)C(F)F)O)O
DMETIBD	IK	UDQTXCHQKHIQMH-KYGLGHNPSA-N
DMETIBD	IU	(3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-ethylimino-1,3a,5,6,7,7a-hexahydropyrano[3,2-d][1,3]thiazole-6,7-diol
DMETIBD	DE	Progressive supranuclear palsy

DMAS1RB	ID	DMAS1RB
DMAS1RB	DN	MK-8776
DMAS1RB	HS	Phase 1
DMAS1RB	SN	MK-8776 Racemate; MK-8776 S-isomer; SCH900776 (Racemate); CHEMBL1643208; 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine; 891495-88-8; SCH900776 S-isomer; GTPL7943; SCHEMBL10380123; CHEBI:131165; HMS3656J19; 6-BROMO-3-(1-METHYLPYRAZOL-4-YL)-5-[(3R)-PIPERIDIN-3-YL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE; BCP02883; BDBM50334854; NSC764659; AKOS026750519; MK 8776; NSC-764659; NCGC00387868-02; DA-40779; BCP0726000317; FT-0700501; FT-0771683; J3.517.083I; Q27086899; SCH 900776 (CAS:891494-64-7); 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3S)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[5,1-b]pyrimidin-7-amine
DMAS1RB	DT	Small molecular drug
DMAS1RB	PC	16224745
DMAS1RB	MW	376.25
DMAS1RB	FM	C15H18BrN7
DMAS1RB	IC	InChI=1S/C15H18BrN7/c1-22-8-10(6-19-22)11-7-20-23-14(17)12(16)13(21-15(11)23)9-3-2-4-18-5-9/h6-9,18H,2-5,17H2,1H3
DMAS1RB	CS	CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4
DMAS1RB	IK	GMIZZEXBPRLVIV-UHFFFAOYSA-N
DMAS1RB	IU	6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine
DMAS1RB	CB	CHEBI:131165
DMAS1RB	DE	Hodgkin lymphoma

DMDB3OK	ID	DMDB3OK
DMDB3OK	DN	MLN-3126
DMDB3OK	HS	Phase 1
DMDB3OK	SN	CCR9 antagonist (oral, Crohn's disease), Millennium
DMDB3OK	CP	Millennium Pharmaceuticals Inc
DMDB3OK	DE	Sjogren syndrome

DMCVO2Y	ID	DMCVO2Y
DMCVO2Y	DN	MLN-576
DMCVO2Y	HS	Phase 1
DMCVO2Y	SN	XR-11576
DMCVO2Y	CP	Xenova Group plc
DMCVO2Y	DE	Acute lymphoblastic leukaemia

DMWK951	ID	DMWK951
DMWK951	DN	MLN7243
DMWK951	HS	Phase 1
DMWK951	CP	Millennium pharmaceuticals
DMWK951	DE	Solid tumour/cancer

DMUANF3	ID	DMUANF3
DMUANF3	DN	MLN8054
DMUANF3	HS	Phase 1
DMUANF3	SN	ZZL; MLN-8054
DMUANF3	CP	Millenium; Takeda
DMUANF3	TC	Anticancer Agents
DMUANF3	DT	Small molecular drug
DMUANF3	PC	11712649
DMUANF3	MW	476.9
DMUANF3	FM	C25H15ClF2N4O2
DMUANF3	IC	InChI=1S/C25H15ClF2N4O2/c26-15-6-9-17-18(10-15)23(21-19(27)2-1-3-20(21)28)29-11-14-12-30-25(32-22(14)17)31-16-7-4-13(5-8-16)24(33)34/h1-10,12H,11H2,(H,33,34)(H,30,31,32)
DMUANF3	CS	C1C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)C(=N1)C4=C(C=CC=C4F)F)NC5=CC=C(C=C5)C(=O)O
DMUANF3	IK	HHFBDROWDBDFBR-UHFFFAOYSA-N
DMUANF3	IU	4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid
DMUANF3	CA	CAS 869363-13-3
DMUANF3	CB	CHEBI:91366
DMUANF3	DE	Solid tumour/cancer

DMXQHZC	ID	DMXQHZC
DMXQHZC	DN	MM-151
DMXQHZC	HS	Phase 1
DMXQHZC	CP	Merrimack Pharmaceuticals
DMXQHZC	DE	Solid tumour/cancer

DMYSJTR	ID	DMYSJTR
DMYSJTR	DN	MM-302
DMYSJTR	HS	Phase 1
DMYSJTR	CP	Merrimack Pharmaceuticals
DMYSJTR	DE	Breast cancer

DMIMVEX	ID	DMIMVEX
DMIMVEX	DN	MMI-0100
DMIMVEX	HS	Phase 1
DMIMVEX	SN	Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix
DMIMVEX	CP	Moerae Matrix Inc
DMIMVEX	DE	Fibrosis; Airway inflammation

DMAQJHO	ID	DMAQJHO
DMAQJHO	DN	Monohydroxyethylrutoside
DMAQJHO	HS	Phase 1
DMAQJHO	SN	Frederine; MonoHER; VUF-5434; Mono-7-hydroxyethylrutoside
DMAQJHO	CP	Universiteit Maastricht
DMAQJHO	DE	Cardiovascular disease

DMM7TBO	ID	DMM7TBO
DMM7TBO	DN	MORAb-022
DMM7TBO	HS	Phase 1
DMM7TBO	SN	Antibody (inflammation/autoimmune disease), Morphotek
DMM7TBO	CP	Eisai
DMM7TBO	DT	Antibody
DMM7TBO	DE	Autoimmune diabetes; Rheumatoid arthritis

DMTUKW9	ID	DMTUKW9
DMTUKW9	DN	MORAb-066
DMTUKW9	HS	Phase 1
DMTUKW9	SN	Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek
DMTUKW9	CP	Eisai
DMTUKW9	DT	Antibody
DMTUKW9	DE	Pancreatic cancer; Solid tumour/cancer

DMJOMD4	ID	DMJOMD4
DMJOMD4	DN	MP-0112
DMJOMD4	HS	Phase 1
DMJOMD4	SN	DARPin (age related macular degeneration), Molecular Partners/Allergan; VEGF-A specific DARPin, Molecular Partners/Allergan
DMJOMD4	CP	Molecular Partners AG
DMJOMD4	PC	10464700
DMJOMD4	MW	168.15
DMJOMD4	FM	C7H8N2O3
DMJOMD4	IC	InChI=1S/C7H8N2O3/c1-12-6-4-2-3-5(8)7(6)9(10)11/h2-4H,8H2,1H3
DMJOMD4	CS	COC1=CC=CC(=C1[N+](=O)[O-])N
DMJOMD4	IK	RITQAMSEQYWFML-UHFFFAOYSA-N
DMJOMD4	IU	3-methoxy-2-nitroaniline
DMJOMD4	CA	CAS 16554-47-5
DMJOMD4	DE	Macular degeneration

DMQRNTG	ID	DMQRNTG
DMQRNTG	DN	MP-124
DMQRNTG	HS	Phase 1
DMQRNTG	CP	Mitsubishi Tanabe Pharma
DMQRNTG	DE	Ischemic stroke; Stroke

DM5VXWO	ID	DM5VXWO
DM5VXWO	DN	MP-157
DM5VXWO	HS	Phase 1
DM5VXWO	CP	Mitsubishi Tanabe Pharma Corp
DM5VXWO	DE	Hypertension

DME7JFM	ID	DME7JFM
DME7JFM	DN	MR1-1
DME7JFM	HS	Phase 1
DME7JFM	SN	MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX
DME7JFM	CP	IVAX Corp
DME7JFM	DE	Brain cancer

DMVNLGW	ID	DMVNLGW
DMVNLGW	DN	MR-1817
DMVNLGW	HS	Phase 1
DMVNLGW	CP	Mochida Pharmaceutical Co Ltd
DMVNLGW	DE	Pain

DMUVGMS	ID	DMUVGMS
DMUVGMS	DN	MRG-110
DMUVGMS	HS	Phase 1
DMUVGMS	CP	miRagen Therapeutics
DMUVGMS	DT	Oligonucleotide
DMUVGMS	DE	Heart failure

DMFTAWU	ID	DMFTAWU
DMFTAWU	DN	mRNA-2416
DMFTAWU	HS	Phase 1
DMFTAWU	SN	mRNA-OX40L
DMFTAWU	CP	Moderna Therapeutics
DMFTAWU	DT	mRNA therapy
DMFTAWU	DE	Lymphoma; Solid tumour/cancer; Ovarian cancer

DMUKBI2	ID	DMUKBI2
DMUKBI2	DN	mRNA-2752
DMUKBI2	HS	Phase 1
DMUKBI2	SN	mRNA-OX40L/IL-23/IL-36 gamma
DMUKBI2	CP	Moderna Therapeutics
DMUKBI2	DT	mRNA therapy
DMUKBI2	DE	Solid tumour/cancer

DMM5N8P	ID	DMM5N8P
DMM5N8P	DN	MRX-2843
DMM5N8P	HS	Phase 1
DMM5N8P	SN	1429882-07-4; UNC-2371A; UNII-2MT30EHI63; 2MT30EHI63; CHEMBL3326007; (1r,4r)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; UNC2371A; SCHEMBL14854108; SCHEMBL17175579; BDBM350861; BCP30180; BDBM50055490; MFCD28502224; ZINC299829706; CS-8117; SB17283; AS-35252; HY-101549; US9795606, B20; A16958; UNC2371;UNC-2371;UNC 2371;MRX 2843 ;MRX2843; Cyclohexanol, 4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-, trans-; trans-(1R,4R)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; trans-4-(2-((2-Cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)cyclohexanol
DMM5N8P	CP	Meryx
DMM5N8P	DT	Small molecular drug
DMM5N8P	PC	89495685
DMM5N8P	MW	488.7
DMM5N8P	FM	C29H40N6O
DMM5N8P	IC	InChI=1S/C29H40N6O/c1-33-14-16-34(17-15-33)19-22-4-6-23(7-5-22)27-20-35(24-8-10-25(36)11-9-24)28-26(27)18-31-29(32-28)30-13-12-21-2-3-21/h4-7,18,20-21,24-25,36H,2-3,8-17,19H2,1H3,(H,30,31,32)
DMM5N8P	CS	CN1CCN(CC1)CC2=CC=C(C=C2)C3=CN(C4=NC(=NC=C34)NCCC5CC5)C6CCC(CC6)O
DMM5N8P	IK	LBEJYFVJIPQSNX-UHFFFAOYSA-N
DMM5N8P	IU	4-[2-(2-cyclopropylethylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol
DMM5N8P	CA	CAS 89495685
DMM5N8P	DE	Solid tumour/cancer

DMWKDOQ	ID	DMWKDOQ
DMWKDOQ	DN	MRX34
DMWKDOQ	HS	Phase 1
DMWKDOQ	CP	Mirna therapeutics
DMWKDOQ	DE	Liver cancer

DM7ER9J	ID	DM7ER9J
DM7ER9J	DN	MS-553
DM7ER9J	HS	Phase 1
DM7ER9J	CP	MingSight Pharmaceuticals
DM7ER9J	DE	Chronic lymphocytic leukaemia; Small lymphocytic lymphoma

DMH8VXE	ID	DMH8VXE
DMH8VXE	DN	MSB2311
DMH8VXE	HS	Phase 1
DMH8VXE	CP	MabSpace Biosciences Suzhou, China
DMH8VXE	DT	Monoclonal antibody
DMH8VXE	DE	Solid tumour/cancer; Advanced malignancy

DM6XTZL	ID	DM6XTZL
DM6XTZL	DN	MSC-1
DM6XTZL	HS	Phase 1
DM6XTZL	CP	AstraZeneca
DM6XTZL	DT	Antibody
DM6XTZL	DE	Solid tumour/cancer

DM6XC8H	ID	DM6XC8H
DM6XC8H	DN	MSC110
DM6XC8H	HS	Phase 1
DM6XC8H	SN	Lacnotuzumab
DM6XC8H	CP	Novartis
DM6XC8H	DT	Antibody
DM6XC8H	DE	Pigmented villonodular synovitis

DMEP7HO	ID	DMEP7HO
DMEP7HO	DN	MSH-372
DMEP7HO	HS	Phase 1
DMEP7HO	SN	MIV-150; MIV-150)
DMEP7HO	CP	Medivir AB
DMEP7HO	DT	Small molecular drug
DMEP7HO	PC	468179
DMEP7HO	MW	368.4
DMEP7HO	FM	C19H17FN4O3
DMEP7HO	IC	InChI=1S/C19H17FN4O3/c1-2-15(25)11-4-5-13(20)17(18(11)26)12-7-14(12)23-19(27)24-16-6-3-10(8-21)9-22-16/h3-6,9,12,14,26H,2,7H2,1H3,(H2,22,23,24,27)/t12-,14+/m0/s1
DMEP7HO	CS	CCC(=O)C1=C(C(=C(C=C1)F)[C@H]2C[C@H]2NC(=O)NC3=NC=C(C=C3)C#N)O
DMEP7HO	IK	NKPHEWJJTGPRSL-GXTWGEPZSA-N
DMEP7HO	IU	1-(5-cyanopyridin-2-yl)-3-[(1R,2R)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea
DMEP7HO	DE	Human immunodeficiency virus infection

DM1N9YS	ID	DM1N9YS
DM1N9YS	DN	MSX-122
DM1N9YS	HS	Phase 1
DM1N9YS	CP	Metastatix
DM1N9YS	TC	Anticancer Agents
DM1N9YS	DT	Small molecular drug
DM1N9YS	PC	11687907
DM1N9YS	MW	292.34
DM1N9YS	FM	C16H16N6
DM1N9YS	IC	InChI=1S/C16H16N6/c1-7-17-15(18-8-1)21-11-13-3-5-14(6-4-13)12-22-16-19-9-2-10-20-16/h1-10H,11-12H2,(H,17,18,21)(H,19,20,22)
DM1N9YS	CS	C1=CN=C(N=C1)NCC2=CC=C(C=C2)CNC3=NC=CC=N3
DM1N9YS	IK	PXZXYRKDDXKDTK-UHFFFAOYSA-N
DM1N9YS	IU	N-[[4-[(pyrimidin-2-ylamino)methyl]phenyl]methyl]pyrimidin-2-amine
DM1N9YS	CA	CAS 897657-95-3
DM1N9YS	DE	Solid tumour/cancer

DMPCUN5	ID	DMPCUN5
DMPCUN5	DN	MT-110
DMPCUN5	HS	Phase 1
DMPCUN5	SN	MuS110; Bispecific EpCAM/CD3 antibody (cancer), Micromet
DMPCUN5	CP	Micromet AG
DMPCUN5	DT	Antibody
DMPCUN5	DE	Solid tumour/cancer

DMT0EBU	ID	DMT0EBU
DMT0EBU	DN	MT-112
DMT0EBU	HS	Phase 1
DMT0EBU	SN	BiTE antibody (solid tumor), Micromet/Bayer
DMT0EBU	CP	Amgenl; bayer healthcare pharmaceuticals
DMT0EBU	DT	Antibody
DMT0EBU	DE	Solid tumour/cancer

DM5SN0A	ID	DM5SN0A
DM5SN0A	DN	MT-5111
DM5SN0A	HS	Phase 1
DM5SN0A	CP	Molecular Templates
DM5SN0A	DT	Recombinant?protein
DM5SN0A	DE	Solid tumour/cancer

DMG4QDT	ID	DMG4QDT
DMG4QDT	DN	MUC-1 dendritic cancer vaccine
DMG4QDT	HS	Phase 1
DMG4QDT	CP	Microvax
DMG4QDT	DT	Vaccine
DMG4QDT	DE	Solid tumour/cancer

DMAGCHE	ID	DMAGCHE
DMAGCHE	DN	Multi-envelope HIV vaccine
DMAGCHE	HS	Phase 1
DMAGCHE	SN	PolyEnv1; AIDS vaccine, St Jude; HIV vaccine, St Jude; Multi-envelope AIDS vaccine, St Jude; Multi-envelope HIV vaccine, St Jude; Vaccine (HIV), St Jude
DMAGCHE	CP	St Jude Children's Research Hospital
DMAGCHE	DT	Vaccine
DMAGCHE	DE	Human immunodeficiency virus infection

DM3JUXW	ID	DM3JUXW
DM3JUXW	DN	MVA HER-2 AutoVac
DM3JUXW	HS	Phase 1
DM3JUXW	SN	MVA-BN HER-2 AutoVac; MVA-BN-HER2; PX-103.2; MVA-BN Breast (cancer vaccine), Bavarian Nordic; MVA-BN breast cancer vaccine, BN ImmunoTherapeutics/ Pharmexa; MVA-BN/Her-2/Neu
DM3JUXW	CP	Pharmexa A/S
DM3JUXW	DT	Vaccine
DM3JUXW	DE	Breast cancer

DMFMW5C	ID	DMFMW5C
DMFMW5C	DN	MVA-BN Breast
DMFMW5C	HS	Phase 1
DMFMW5C	SN	MVA-BN-pRo (TN)
DMFMW5C	CP	BN ImmunoTherapeutics
DMFMW5C	DE	Prostate cancer

DM1FUAR	ID	DM1FUAR
DM1FUAR	DN	MV-CEA
DM1FUAR	HS	Phase 1
DM1FUAR	SN	Measles virus derivative producing cea; Carcinoembryonic antigen-expressing measles virus (cancer), NCI; Mv-cea (ovarian and peritoneal cavity cancer), NCI
DM1FUAR	CP	National Cancer Institute
DM1FUAR	DE	Glioblastoma multiforme

DMEJ4C1	ID	DMEJ4C1
DMEJ4C1	DN	MVT-5873
DMEJ4C1	HS	Phase 1
DMEJ4C1	CP	MabVax Therapeutics San Diego, CA
DMEJ4C1	DE	Colorectal cancer; Pancreatic cancer; Prostate cancer; Solid tumour/cancer

DM5O4X9	ID	DM5O4X9
DM5O4X9	DN	Mycophenolic acid glucuronide
DM5O4X9	HS	Phase 1
DM5O4X9	SN	MPAG; Mycophenolic acid glucosiduronate; mycophenolic acid glucuronide; UNII-54TS5J9T0K; 54TS5J9T0K; AC1O5XMV; BYFGTSAYQQIUCN-HGIHDBQLSA-N; Mycophenolic Acid ; A-D-Glucuronide; ZINC13550000; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[[5-[(E)-6-hydroxy-3-methyl-6-oxohex-2-enyl]-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-4-yl]oxy]oxane-2-carboxylic acid; 5-[(2E)-5-Carboxy-3-methyl-2-penten-1-yl]-1,3-dihydro-6-methoxy-7-methyl-3-oxo-4-isobenzofuranyl
DM5O4X9	PC	6442661
DM5O4X9	MW	496.5
DM5O4X9	FM	C23H28O12
DM5O4X9	IC	InChI=1S/C23H28O12/c1-9(5-7-13(24)25)4-6-11-18(32-3)10(2)12-8-33-22(31)14(12)19(11)34-23-17(28)15(26)16(27)20(35-23)21(29)30/h4,15-17,20,23,26-28H,5-8H2,1-3H3,(H,24,25)(H,29,30)/b9-4+/t15-,16-,17+,20-,23+/m0/s1
DM5O4X9	CS	CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)OC3C(C(C(C(O3)C(=O)O)O)O)O
DM5O4X9	IK	BYFGTSAYQQIUCN-HGIHDBQLSA-N
DM5O4X9	IU	(2S,3S,4S,5R,6S)-6-[[5-[(E)-5-carboxy-3-methylpent-2-enyl]-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-4-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DM5O4X9	CA	CAS 31528-44-6
DM5O4X9	DE	Lung transplantation

DMHO6XP	ID	DMHO6XP
DMHO6XP	DN	MyoDys
DMHO6XP	HS	Phase 1
DMHO6XP	SN	PTG11025; TG-5001; Gene therapy (DMD), Transgene; Gene therapy (Duchenne muscular dystrophy), Transgene; Gene therapy (DMD/ BMD), Transgene; Gene therapy (Duchenne muscular dystrophy/ Becker muscular dystrophy), Transgene
DMHO6XP	CP	Transgene SA
DMHO6XP	DE	Duchenne dystrophy

DM4ZN8M	ID	DM4ZN8M
DM4ZN8M	DN	N-803
DM4ZN8M	HS	Phase 1
DM4ZN8M	SN	Anktiva; ALT-803
DM4ZN8M	CP	ImmunityBio
DM4ZN8M	DT	Recombinant protein
DM4ZN8M	DE	Human immunodeficiency virus infection

DM3PC0J	ID	DM3PC0J
DM3PC0J	DN	N-8295
DM3PC0J	HS	Phase 1
DM3PC0J	SN	Universal flu vaccine; M2e-ISS; NP-ISS; ISS vaccine (influenza), Dynavax; M2e/NP-ISS; Influenza vaccine (immunostimulatory sequence-based), Dynavax; Influenza vaccine (ND-ISS-based), Dynavax
DM3PC0J	CP	Dynavax Technologies Corp
DM3PC0J	DT	Vaccine
DM3PC0J	DE	Influenza virus infection

DM3IT6R	ID	DM3IT6R
DM3IT6R	DN	N9-GP
DM3IT6R	HS	Phase 1
DM3IT6R	SN	NN7999
DM3IT6R	CP	Novo Nordisk
DM3IT6R	DE	Factor IX deficiency

DM3E20L	ID	DM3E20L
DM3E20L	DN	Nagrestipen
DM3E20L	HS	Phase 1
DM3E20L	SN	EMIP; BB-10010; ECI-301; Macrophage inflammatory protein 1a, British Biotech; Stem cell protector, British Biotech; MIP-1a, British Biotech; MIP-1 alpha derivatives (cancer), Effector
DM3E20L	CP	Vernalis plc
DM3E20L	DE	Bone marrow transplantation

DMMKZYV	ID	DMMKZYV
DMMKZYV	DN	Namitecan
DMMKZYV	HS	Phase 1
DMMKZYV	SN	ST-1968; ST-1976; ST-2649; ST-2724; ST-3280; ST-3833; ST-4167; ST-4215; ST-5548; Peptide-camptothecin conjugates (cancer); Topoisomerase I inhibiting camptothecin analog (cancer), Sigma-Tau; Topoisomerase I inhibitor (cancer), Sigma-Tau; Peptide-camptothecin conjugates (cancer), Sigma-Tau
DMMKZYV	CP	Sigma-Tau Ind Farm Riunite SpA
DMMKZYV	DT	Small molecular drug
DMMKZYV	PC	10950142
DMMKZYV	MW	434.4
DMMKZYV	FM	C23H22N4O5
DMMKZYV	IC	InChI=1S/C23H22N4O5/c1-2-23(30)17-9-19-20-15(11-27(19)21(28)16(17)12-31-22(23)29)14(10-25-32-8-7-24)13-5-3-4-6-18(13)26-20/h3-6,9-10,30H,2,7-8,11-12,24H2,1H3/b25-10+/t23-/m0/s1
DMMKZYV	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)/C=N/OCCN)O
DMMKZYV	IK	IBTISPLPBBHVSU-UVOOVGFISA-N
DMMKZYV	IU	(19S)-10-[(E)-2-aminoethoxyiminomethyl]-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMMKZYV	CA	CAS 372105-27-6
DMMKZYV	DE	Solid tumour/cancer

DMHAZLM	ID	DMHAZLM
DMHAZLM	DN	Naringenin
DMHAZLM	HS	Phase 1
DMHAZLM	SN	naringenin; 5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone
DMHAZLM	DT	Small molecular drug
DMHAZLM	PC	932
DMHAZLM	MW	272.25
DMHAZLM	FM	C15H12O5
DMHAZLM	IC	InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2
DMHAZLM	CS	C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O
DMHAZLM	IK	FTVWIRXFELQLPI-UHFFFAOYSA-N
DMHAZLM	IU	5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMHAZLM	CA	CAS 67604-48-2
DMHAZLM	CB	CHEBI:50202

DMZ2G69	ID	DMZ2G69
DMZ2G69	DN	Navicixizumab
DMZ2G69	HS	Phase 1
DMZ2G69	CP	OncoMed Pharmaceuticals Redwood City, CA
DMZ2G69	DE	Colorectal cancer; Fallopian tube cancer; Metastatic colorectal cancer; Ovarian cancer; Peritoneal cavity cancer

DMG0SWE	ID	DMG0SWE
DMG0SWE	DN	NBF-006
DMG0SWE	HS	Phase 1
DMG0SWE	CP	Nitto Biopharma
DMG0SWE	DT	Small interfering RNA
DMG0SWE	DE	Colorectal cancer; Non-small-cell lung cancer; Pancreatic cancer

DM5BQK3	ID	DM5BQK3
DM5BQK3	DN	NBI-34041
DM5BQK3	HS	Phase 1
DM5BQK3	CP	Neurocrine Biosciences; GlaxoSmithKline
DM5BQK3	DT	Small molecular drug
DM5BQK3	PC	9888194
DM5BQK3	MW	417.4
DM5BQK3	FM	C22H26Cl2N4
DM5BQK3	IC	InChI=1S/C22H26Cl2N4/c1-4-6-16(7-5-2)27-10-11-28-22-19(27)12-14(3)25-21(22)20(26-28)17-9-8-15(23)13-18(17)24/h8-9,12-13,16H,4-7,10-11H2,1-3H3
DM5BQK3	CS	CCCC(CCC)N1CCN2C3=C1C=C(N=C3C(=N2)C4=C(C=C(C=C4)Cl)Cl)C
DM5BQK3	IK	AKLMUGFDGONMAA-UHFFFAOYSA-N
DM5BQK3	IU	3-(2,4-dichlorophenyl)-9-heptan-4-yl-6-methyl-1,2,5,9-tetrazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene
DM5BQK3	CA	CAS 268545-87-5
DM5BQK3	DE	Eating disorder

DM5OWXA	ID	DM5OWXA
DM5OWXA	DN	NBM-BMX
DM5OWXA	HS	Phase 1
DM5OWXA	CP	NatureWise Biotech & Medicals
DM5OWXA	DT	Small molecular drug
DM5OWXA	DE	Solid tumour/cancer

DMPHZI5	ID	DMPHZI5
DMPHZI5	DN	NBQX
DMPHZI5	HS	Phase 1
DMPHZI5	SN	nbqx; 118876-58-7; FG 9202; 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline; 6-Nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione; CHEMBL222519; CHEBI:31073; SBB066176; 6-nitro-2,3-dioxo-1,4-dihydrobenzo[f]quinoxaline-7-sulfonamide; 1,2,3,4-Tetrahydro-6-nitro-2,3-dioxobenzo(f)quinoxaline-8-sulfonamide; 6-Nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione; 6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione; 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline
DMPHZI5	DT	Small molecular drug
DMPHZI5	PC	3272524
DMPHZI5	MW	336.28
DMPHZI5	FM	C12H8N4O6S
DMPHZI5	IC	InChI=1S/C12H8N4O6S/c13-23(21,22)8-3-1-2-5-9(8)7(16(19)20)4-6-10(5)15-12(18)11(17)14-6/h1-4H,(H,14,17)(H,15,18)(H2,13,21,22)
DMPHZI5	CS	C1=CC2=C3C(=CC(=C2C(=C1)S(=O)(=O)N)[N+](=O)[O-])NC(=O)C(=O)N3
DMPHZI5	IK	UQNAFPHGVPVTAL-UHFFFAOYSA-N
DMPHZI5	IU	6-nitro-2,3-dioxo-1,4-dihydrobenzo[f]quinoxaline-7-sulfonamide
DMPHZI5	CA	CAS 118876-58-7
DMPHZI5	CB	CHEBI:31073
DMPHZI5	DE	Neurological disorder

DMF3MN1	ID	DMF3MN1
DMF3MN1	DN	NBXT-001+Nobilis inhalation device
DMF3MN1	HS	Phase 1
DMF3MN1	CP	Nobilis Therapeutics Portland, OR
DMF3MN1	DE	Alzheimer disease

DMM2SNG	ID	DMM2SNG
DMM2SNG	DN	NC-4016
DMM2SNG	HS	Phase 1
DMM2SNG	CP	Nanocarrier
DMM2SNG	DE	Solid tumour/cancer

DMUSPW5	ID	DMUSPW5
DMUSPW5	DN	NCO-48
DMUSPW5	HS	Phase 1
DMUSPW5	CP	Nucorion Pharmaceuticals
DMUSPW5	DT	Small molecular drug
DMUSPW5	DE	Hepatitis B virus infection

DMKJRQS	ID	DMKJRQS
DMKJRQS	DN	NCX-1015
DMKJRQS	HS	Phase 1
DMKJRQS	SN	Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone
DMKJRQS	CP	NicOx SA
DMKJRQS	PC	101123241
DMKJRQS	MW	540.6
DMKJRQS	FM	C29H34NO9+
DMKJRQS	IC	InChI=1S/C29H34NO9/c1-27-11-9-20(31)13-19(27)7-8-21-22-10-12-29(35,28(22,2)14-23(32)25(21)27)24(33)16-38-26(34)18-5-3-17(4-6-18)15-39-30(36)37/h3-6,9,11,13,21-23,25,32,35H,7-8,10,12,14-16H2,1-2H3,(H,36,37)/q+1/t21-,22-,23-,25+,27-,28-,29-/m0/s1
DMKJRQS	CS	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)C4=CC=C(C=C4)CO[N+](=O)O)O)CCC5=CC(=O)C=C[C@]35C)O
DMKJRQS	IK	HSVTZTOFRYKVEA-KGWLDMEJSA-N
DMKJRQS	IU	[4-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]carbonylphenyl]methoxy-hydroxy-oxoazanium
DMKJRQS	DE	Rheumatoid arthritis

DMM7RC5	ID	DMM7RC5
DMM7RC5	DN	NCX-6560
DMM7RC5	HS	Phase 1
DMM7RC5	SN	NCX 6560
DMM7RC5	CP	NicOx
DMM7RC5	PC	11239321
DMM7RC5	MW	675.7
DMM7RC5	FM	C37H42FN3O8
DMM7RC5	IC	InChI=1S/C37H42FN3O8/c1-25(2)35-34(37(45)39-29-13-7-4-8-14-29)33(26-11-5-3-6-12-26)36(27-15-17-28(38)18-16-27)40(35)20-19-30(42)23-31(43)24-32(44)48-21-9-10-22-49-41(46)47/h3-8,11-18,25,30-31,42-43H,9-10,19-24H2,1-2H3,(H,39,45)/t30-,31-/m1/s1
DMM7RC5	CS	CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)OCCCCO[N+](=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMM7RC5	IK	QBBIDMMGINYIJJ-FIRIVFDPSA-N
DMM7RC5	IU	4-nitrooxybutyl (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
DMM7RC5	DE	Cardiovascular disease

DMVQAEK	ID	DMVQAEK
DMVQAEK	DN	ND-1.1
DMVQAEK	HS	Phase 1
DMVQAEK	SN	Avian influenza vaccine, West Coast Biologicals; Ad-HA-dsRNA; H5N1 avian influenza vaccine (oral, adenoviral vector,dsRNA adjuvant), Vaxart
DMVQAEK	CP	Glaxosmithkline; novavax; vaxart
DMVQAEK	DT	Vaccine
DMVQAEK	DE	Influenza virus infection

DMUBTC6	ID	DMUBTC6
DMUBTC6	DN	ND7001
DMUBTC6	HS	Phase 1
DMUBTC6	CP	Neuro3d
DMUBTC6	DE	Mood disorder

DM830EN	ID	DM830EN
DM830EN	DN	NEO-201
DM830EN	HS	Phase 1
DM830EN	CP	Precision Biologics
DM830EN	DT	Antibody
DM830EN	DE	Solid tumour/cancer

DMXTYWJ	ID	DMXTYWJ
DMXTYWJ	DN	Neovastat
DMXTYWJ	HS	Phase 1
DMXTYWJ	CP	Ferrer; Hospira; LG Life Sciences; AEterna Zentaris
DMXTYWJ	TC	Anticancer Agents
DMXTYWJ	DE	Renal cell carcinoma; Non-small-cell lung cancer

DM59ZDN	ID	DM59ZDN
DM59ZDN	DN	Nesvacumab
DM59ZDN	HS	Phase 1
DM59ZDN	SN	REGN910; SAR307746
DM59ZDN	DT	Antibody
DM59ZDN	DE	Solid tumour/cancer

DMNJTLC	ID	DMNJTLC
DMNJTLC	DN	Neu-2000
DMNJTLC	HS	Phase 1
DMNJTLC	SN	NMDA antagonists , GNT Pharma; NMDA antagonists, Neurotech; Neu-2000KL
DMNJTLC	CP	Gnt pharma
DMNJTLC	PC	9951955
DMNJTLC	MW	383.22
DMNJTLC	FM	C15H8F7NO3
DMNJTLC	IC	InChI=1S/C15H8F7NO3/c16-10-7(11(17)13(19)9(12(10)18)15(20,21)22)4-23-5-1-2-8(24)6(3-5)14(25)26/h1-3,23-24H,4H2,(H,25,26)
DMNJTLC	CS	C1=CC(=C(C=C1NCC2=C(C(=C(C(=C2F)F)C(F)(F)F)F)F)C(=O)O)O
DMNJTLC	IK	HABROHXUHNHQMY-UHFFFAOYSA-N
DMNJTLC	IU	2-hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoic acid
DMNJTLC	CA	CAS 640290-67-1
DMNJTLC	DE	Cardiac arrest

DMQK5ET	ID	DMQK5ET
DMQK5ET	DN	NG-350A
DMQK5ET	HS	Phase 1
DMQK5ET	CP	PsiOxus Therapeutics
DMQK5ET	DT	Gene therapy
DMQK5ET	DE	Solid tumour/cancer

DMITVHM	ID	DMITVHM
DMITVHM	DN	NG-641
DMITVHM	HS	Phase 1
DMITVHM	CP	PsiOxus Therapeutics
DMITVHM	DT	Gene therapy
DMITVHM	DE	Solid tumour/cancer

DMM1Y8F	ID	DMM1Y8F
DMM1Y8F	DN	NGD 94-1
DMM1Y8F	HS	Phase 1
DMM1Y8F	SN	2-[4-[(2-Phenyl-1H-imidazol-5-yl)methyl]piperazin-1-yl]pyrimidine; Ngd 94-1; 178928-68-2; UNII-DO9M06BFRJ; Ngd-94-1; DO9M06BFRJ; CHEMBL103772; 179333-18-7; 2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]piperazin-1-yl]pyrimidine; 2-[4-[(2-Phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]-pyrimidine; 2-[4-[(2-phenyl-3H-imidazol-4-yl)methyl]piperazin-1-yl]pyrimidine; [3H]NGD941; [3H]-NGD941; [3H]NGD 94-1; AC1L4NQX; ngd94-1; 2-{4-[(2-phenyl-1h-imidazol-4-yl)methyl]piperazin-1-yl}pyrimidine; 2-Phenyl-4(5)-((4-(2-pyrimidinyl)-piperazin-1-yl)methyl)imidazole dimaleate; AC1Q4X5G; GTPL979; SCHEMBL6901339;  Ngd-94-1; Diphenylbutylpiperidines pimozide
DMM1Y8F	CP	Schering-Plough
DMM1Y8F	DT	Small molecular drug
DMM1Y8F	PC	188942
DMM1Y8F	MW	320.4
DMM1Y8F	FM	C18H20N6
DMM1Y8F	IC	InChI=1S/C18H20N6/c1-2-5-15(6-3-1)17-21-13-16(22-17)14-23-9-11-24(12-10-23)18-19-7-4-8-20-18/h1-8,13H,9-12,14H2,(H,21,22)
DMM1Y8F	CS	C1CN(CCN1CC2=CN=C(N2)C3=CC=CC=C3)C4=NC=CC=N4
DMM1Y8F	IK	OTVQCHUIPJYASM-UHFFFAOYSA-N
DMM1Y8F	IU	2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]piperazin-1-yl]pyrimidine
DMM1Y8F	CA	CAS 178928-68-2
DMM1Y8F	DE	Schizophrenia

DMF21XQ	ID	DMF21XQ
DMF21XQ	DN	NGM120
DMF21XQ	HS	Phase 1
DMF21XQ	CP	NGM Biopharmaceuticals
DMF21XQ	DT	Antibody
DMF21XQ	DE	Solid tumour/cancer

DMYNSRH	ID	DMYNSRH
DMYNSRH	DN	NGM313
DMYNSRH	HS	Phase 1
DMYNSRH	CP	NGM Biopharmaceuticals South San Francisco, CA
DMYNSRH	DE	Type-2 diabetes

DMTVQH2	ID	DMTVQH2
DMTVQH2	DN	NGP 555
DMTVQH2	HS	Phase 1
DMTVQH2	SN	WDEKUGNKKOGFOA-UHFFFAOYSA-N; NGP555; 1304630-27-0; UNII-1XA7T7L527; CHEMBL2151100; SCHEMBL16198584; NGP-455; 1XA7T7L527; HY-108714; CS-0030521; 2-Thiazolamine, N-(5-ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-; N-(5-Ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methylimidazol-1-yl)phenyl)-1,3-thiazol-2-amine
DMTVQH2	CP	NeuroGenetic Pharmaceuticals Rancho Santa Fe, CA
DMTVQH2	PC	46853593
DMTVQH2	MW	406.5
DMTVQH2	FM	C23H23FN4S
DMTVQH2	IC	InChI=1S/C23H23FN4S/c1-5-17-10-20(15(3)8-14(17)2)26-23-27-21(12-29-23)18-6-7-22(19(24)9-18)28-11-16(4)25-13-28/h6-13H,5H2,1-4H3,(H,26,27)
DMTVQH2	CS	CCC1=CC(=C(C=C1C)C)NC2=NC(=CS2)C3=CC(=C(C=C3)N4C=C(N=C4)C)F
DMTVQH2	IK	WDEKUGNKKOGFOA-UHFFFAOYSA-N
DMTVQH2	IU	N-(5-ethyl-2,4-dimethylphenyl)-4-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1,3-thiazol-2-amine
DMTVQH2	CA	CAS 1304630-27-0
DMTVQH2	DE	Alzheimer disease

DMU6CQ7	ID	DMU6CQ7
DMU6CQ7	DN	NHS-IL 12
DMU6CQ7	HS	Phase 1
DMU6CQ7	SN	NHS-IL12
DMU6CQ7	CP	Emd serono; national cancer institute
DMU6CQ7	DE	Solid tumour/cancer

DM31FOP	ID	DM31FOP
DM31FOP	DN	NI-0101
DM31FOP	HS	Phase 1
DM31FOP	SN	TLR4 monoclonal antibody therapy (autoimmune and inflammatory diseases), Novimmune
DM31FOP	CP	NovImmune SA
DM31FOP	DT	Antibody
DM31FOP	DE	Autoimmune diabetes

DM32VKQ	ID	DM32VKQ
DM32VKQ	DN	NI-0701
DM32VKQ	HS	Phase 1
DM32VKQ	SN	Alpha-RANTES; RANTES ligand inhibitor (iv, autoimmune/inflammatory disease), NovImmune
DM32VKQ	CP	NovImmune SA
DM32VKQ	DE	Autoimmune diabetes

DM8J3WE	ID	DM8J3WE
DM8J3WE	DN	Nibentan
DM8J3WE	HS	Phase 1
DM8J3WE	SN	HE-11; Rac-N-[5-(Diethylamino)-1-phenylpentyl]-4-nitrobenzamide hydrochloride
DM8J3WE	DT	Small molecular drug
DM8J3WE	PC	177905
DM8J3WE	MW	419.9
DM8J3WE	FM	C22H30ClN3O3
DM8J3WE	IC	InChI=1S/C22H29N3O3.ClH/c1-3-24(4-2)17-9-8-12-21(18-10-6-5-7-11-18)23-22(26)19-13-15-20(16-14-19)25(27)28;/h5-7,10-11,13-16,21H,3-4,8-9,12,17H2,1-2H3,(H,23,26);1H
DM8J3WE	CS	CCN(CC)CCCCC(C1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)[N+](=O)[O-].Cl
DM8J3WE	IK	CHCBAYRWJULIDW-UHFFFAOYSA-N
DM8J3WE	IU	N-[5-(diethylamino)-1-phenylpentyl]-4-nitrobenzamide;hydrochloride
DM8J3WE	CA	CAS 157832-56-9
DM8J3WE	DE	Cardiac arrhythmias

DMJBYSE	ID	DMJBYSE
DMJBYSE	DN	Nicotinamide riboside
DMJBYSE	HS	Phase 1
DMJBYSE	SN	nicotinamide riboside; nicotinamide ribose; nicotinamide-beta-riboside; nicotinamide ribonucleoside; N-ribosylnicotinamide; 1341-23-7; ribosylnicotinamide; 1-(beta-D-Ribofuranosyl)nicotinamide; UNII-0I8H2M0L7N; 0I8H2M0L7N; CHEBI:15927; 3-Carbamoyl-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium; SRT647; SRT-647; SRT 647; N-ribosyl-nicotinamide; AC1L98BO; beta-nicotinamide D-riboside; SCHEMBL938611; N-Ribosyl-Nicotinamide   New; Pyridinium, 3-(aminocarbonyl)-1-beta-D-ribofuranosyl-; CHEMBL43849
DMJBYSE	CP	ChromaDex Irvine, CA
DMJBYSE	PC	439924
DMJBYSE	MW	255.25
DMJBYSE	FM	C11H15N2O5+
DMJBYSE	IC	InChI=1S/C11H14N2O5/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18-11/h1-4,7-9,11,14-16H,5H2,(H-,12,17)/p+1/t7-,8-,9-,11-/m1/s1
DMJBYSE	CS	C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DMJBYSE	IK	JLEBZPBDRKPWTD-TURQNECASA-O
DMJBYSE	IU	1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide
DMJBYSE	CA	CAS 1341-23-7
DMJBYSE	CB	CHEBI:15927
DMJBYSE	DE	Mitochondrial myopathy

DM0PYEQ	ID	DM0PYEQ
DM0PYEQ	DN	NIP-004
DM0PYEQ	HS	Phase 1
DM0PYEQ	SN	Blood clotting modulator, Nissan; NIP-022; ONO-7746; ONO-7746); Peptidomimetic thrombopoietin agonist (thrombocytopenia), Nissan Chemical; Peptidomimetic thrombopoietin agonist (thrombocytopenia), Nissan Chemical/Ono
DM0PYEQ	CP	Nissan Chemical Industries Ltd
DM0PYEQ	PC	87416054
DM0PYEQ	MW	455.3
DM0PYEQ	FM	C18H12Cl2N2O4S2
DM0PYEQ	IC	InChI=1S/C18H12Cl2N2O4S2/c1-8(21-22-17(24)13-4-5-14(28-13)18(25)26)10-7-27-16(15(10)23)9-2-3-11(19)12(20)6-9/h2-7,23H,1H3,(H,22,24)(H,25,26)/b21-8-
DM0PYEQ	CS	C/C(=N/NC(=O)C1=CC=C(S1)C(=O)O)/C2=CSC(=C2O)C3=CC(=C(C=C3)Cl)Cl
DM0PYEQ	IK	JYODIYJKYDDIDN-WNFQYIGGSA-N
DM0PYEQ	IU	5-[[(Z)-1-[5-(3,4-dichlorophenyl)-4-hydroxythiophen-3-yl]ethylideneamino]carbamoyl]thiophene-2-carboxylic acid
DM0PYEQ	DE	Thrombocytopenia

DM4I02O	ID	DM4I02O
DM4I02O	DN	NJA-730
DM4I02O	HS	Phase 1
DM4I02O	CP	NapaJen Pharma
DM4I02O	DT	Antisense oligonucleotide
DM4I02O	DE	Graft-versus-host disease

DMSENTW	ID	DMSENTW
DMSENTW	DN	NJH395
DMSENTW	HS	Phase 1
DMSENTW	CP	Novartis
DMSENTW	DT	Antibody drug conjugate
DMSENTW	DE	HER2-positive metastatic breast cancer

DMGSDPL	ID	DMGSDPL
DMGSDPL	DN	NK-314
DMGSDPL	HS	Phase 1
DMGSDPL	SN	Topoisomerase modulator, Nippon Kayaku
DMGSDPL	CP	Nippon Kayaku Co Ltd
DMGSDPL	DE	Solid tumour/cancer

DM5AWK1	ID	DM5AWK1
DM5AWK1	DN	NKP-1339
DM5AWK1	HS	Phase 1
DM5AWK1	SN	197723-00-5; KP-1339; EX-A1916; BCP26252; Z-3126; 1H-indazole; tetrachlororuthenium(1-) sodium salt
DM5AWK1	CP	Niiki Pharma
DM5AWK1	DT	Small molecular drug
DM5AWK1	PC	25134754
DM5AWK1	MW	502.1
DM5AWK1	FM	C14H12Cl4N4NaRu
DM5AWK1	IC	InChI=1S/2C7H6N2.4ClH.Na.Ru/c2*1-2-4-7-6(3-1)5-8-9-7;;;;;;/h2*1-5H,(H,8,9);4*1H;;/q;;;;;;+1;+3/p-4
DM5AWK1	CS	C1=CC=C2C(=C1)C=NN2.C1=CC=C2C(=C1)C=NN2.[Na+].Cl[Ru-](Cl)(Cl)Cl
DM5AWK1	IK	WVVOCRYXBTVDRN-UHFFFAOYSA-J
DM5AWK1	IU	sodium;1H-indazole;tetrachlororuthenium(1-)
DM5AWK1	DE	Solid tumour/cancer

DMDLJM1	ID	DMDLJM1
DMDLJM1	DN	NKR-2 CAR-T Cells
DMDLJM1	HS	Phase 1
DMDLJM1	CP	Celyad (formerly named Cardio3 BioSciences)
DMDLJM1	DT	CAR T Cell Therapy
DMDLJM1	DE	Myelodysplastic syndrome; Acute myeloid leukaemia

DMR5ATX	ID	DMR5ATX
DMR5ATX	DN	NKR-2 cells
DMR5ATX	HS	Phase 1
DMR5ATX	CP	Celyad (formerly named Cardio3 BioSciences)
DMR5ATX	DT	CAR T Cell Therapy
DMR5ATX	DE	Acute myeloid leukaemia

DMI7ZK3	ID	DMI7ZK3
DMI7ZK3	DN	NKTT-120
DMI7ZK3	HS	Phase 1
DMI7ZK3	SN	INKT mAb; Natural killer T cell antibody (asthma/COPD/Dermatitis); NKT cell antibody (asthma/COPD/Dermatitis), NKT; Natural killer T cell antibody (asthma/COPD/Dermatitis), NKT Therapeutics
DMI7ZK3	CP	Nkt therapeutics
DMI7ZK3	DT	Antibody
DMI7ZK3	DE	Sickle-cell disorder

DMP9J5V	ID	DMP9J5V
DMP9J5V	DN	NLG802
DMP9J5V	HS	Phase 1
DMP9J5V	CP	NewLink Genetics Ames, IA
DMP9J5V	DE	Solid tumour/cancer

DMYPWHD	ID	DMYPWHD
DMYPWHD	DN	NLG919
DMYPWHD	HS	Phase 1
DMYPWHD	SN	NLG919; 1402836-58-1; 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol; NLG 919; CHEMBL3629569; AK166956; 1-Cyclohexyl-2-(5H-imidazo-[5,1-a]isoindol-5-yl)ethanol; alpha-Cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol; 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol; YTRRAUACYORZLX-UHFFFAOYSA-N; GTPL9019; SCHEMBL13280897; GDC0919; EX-A574; DTXSID20735206; MolPort-035-395-785; HMS3653M05; AOB87373; GDC 0919; NLG919(GDC-0919); 2588AH; RG6078; BDBM50126144; s7111; AKOS025287054; CS-3512; SB16495; ACN-028914; KS-0000062W
DMYPWHD	CP	Newlink genetics
DMYPWHD	DT	Small molecular drug
DMYPWHD	PC	66558287
DMYPWHD	MW	282.4
DMYPWHD	FM	C18H22N2O
DMYPWHD	IC	InChI=1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-16-14-8-4-5-9-15(14)17-11-19-12-20(16)17/h4-5,8-9,11-13,16,18,21H,1-3,6-7,10H2
DMYPWHD	CS	C1CCC(CC1)C(CC2C3=CC=CC=C3C4=CN=CN24)O
DMYPWHD	IK	YTRRAUACYORZLX-UHFFFAOYSA-N
DMYPWHD	IU	1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol
DMYPWHD	CA	CAS 1402836-58-1
DMYPWHD	DE	Solid tumour/cancer

DMPJMB7	ID	DMPJMB7
DMPJMB7	DN	NLX-101
DMPJMB7	HS	Phase 1
DMPJMB7	SN	F-15599; F 15599; F-15,599; F15599
DMPJMB7	DT	Small molecular drug
DMPJMB7	PC	11741361
DMPJMB7	MW	394.8
DMPJMB7	FM	C19H21ClF2N4O
DMPJMB7	IC	InChI=1S/C19H21ClF2N4O/c1-13-9-24-17(25-10-13)11-23-12-19(22)4-6-26(7-5-19)18(27)14-2-3-16(21)15(20)8-14/h2-3,8-10,23H,4-7,11-12H2,1H3
DMPJMB7	CS	CC1=CN=C(N=C1)CNCC2(CCN(CC2)C(=O)C3=CC(=C(C=C3)F)Cl)F
DMPJMB7	IK	WAAXKNFGOFTGLP-UHFFFAOYSA-N
DMPJMB7	IU	(3-chloro-4-fluorophenyl)-[4-fluoro-4-[[(5-methylpyrimidin-2-yl)methylamino]methyl]piperidin-1-yl]methanone
DMPJMB7	CA	CAS 635323-95-4
DMPJMB7	DE	Rett syndrome

DM5INE7	ID	DM5INE7
DM5INE7	DN	NM-3
DM5INE7	HS	Phase 1
DM5INE7	SN	NM-3; 181427-78-1; isocoumarin NM-3; NM 3 (isocoumarin); NM 3; NM-3 (isocoumarin); AC1NUU2Q; SCHEMBL3191297; CTK4D7870; 2-(8-Hydroxy-6-methoxy-1-oxo-1H-isochromen-3-yl)propionic acid; 8-Hydroxy-6-methoxy-alpha-methyl-1-oxo-1H-2-benzopyran-3-acetic acid; AKOS030619018; DB12818; FT-0717128; 2-(8-hydroxy-6-methoxy-1-oxoisochromen-3-yl)propanoic acid; 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid; 2-(8-hydroxy-6-methoxy-1-oxo-1H-isochromen-3-yl)propanoic acid; 1H-2-Benzopyran-3-aceticacid, 8-hydroxy-6-methox
DM5INE7	CP	Genzyme
DM5INE7	DT	Small molecular drug
DM5INE7	PC	5493470
DM5INE7	MW	264.23
DM5INE7	FM	C13H12O6
DM5INE7	IC	InChI=1S/C13H12O6/c1-6(12(15)16)10-4-7-3-8(18-2)5-9(14)11(7)13(17)19-10/h3-6,14H,1-2H3,(H,15,16)
DM5INE7	CS	CC(C1=CC2=CC(=CC(=C2C(=O)O1)O)OC)C(=O)O
DM5INE7	IK	BPZCXUROMKDLGX-UHFFFAOYSA-N
DM5INE7	IU	2-(8-hydroxy-6-methoxy-1-oxoisochromen-3-yl)propanoic acid
DM5INE7	CA	CAS 181427-78-1
DM5INE7	DE	Solid tumour/cancer

DM2XIRW	ID	DM2XIRW
DM2XIRW	DN	NMS-03305293
DM2XIRW	HS	Phase 1
DM2XIRW	SN	NMS-P293
DM2XIRW	CP	Nerviano Medical Sciences
DM2XIRW	DT	Small molecular drug
DM2XIRW	DE	Solid tumour/cancer

DMDGCHR	ID	DMDGCHR
DMDGCHR	DN	NN-1218
DMDGCHR	HS	Phase 1
DMDGCHR	CP	Novo Nordisk A/S
DMDGCHR	DE	Diabetic complication; Type-1 diabetes; Type-2 diabetes

DMRJEXM	ID	DMRJEXM
DMRJEXM	DN	NN-414
DMRJEXM	HS	Phase 1
DMRJEXM	SN	NNC-55-0414
DMRJEXM	CP	Novo Nordisk A/S
DMRJEXM	DT	Small molecular drug
DMRJEXM	PC	135410911
DMRJEXM	MW	291.8
DMRJEXM	FM	C9H10ClN3O2S2
DMRJEXM	IC	InChI=1S/C9H10ClN3O2S2/c1-9(2-3-9)12-8-11-5-4-6(10)16-7(5)17(14,15)13-8/h4H,2-3H2,1H3,(H2,11,12,13)
DMRJEXM	CS	CC1(CC1)N=C2NC3=C(SC(=C3)Cl)S(=O)(=O)N2
DMRJEXM	IK	KYSFUHHFTIGRJN-UHFFFAOYSA-N
DMRJEXM	IU	6-chloro-N-(1-methylcyclopropyl)-1,1-dioxo-4H-thieno[3,2-e][1,2,4]thiadiazin-3-imine
DMRJEXM	CA	CAS 279215-43-9
DMRJEXM	DE	Type-1 diabetes

DMHVIZC	ID	DMHVIZC
DMHVIZC	DN	NN-7415
DMHVIZC	HS	Phase 1
DMHVIZC	SN	NNC-0172-0000-2021
DMHVIZC	CP	Novo Nordisk A/S
DMHVIZC	DE	Factor IX deficiency

DMYXDB9	ID	DMYXDB9
DMYXDB9	DN	NN-8828
DMYXDB9	HS	Phase 1
DMYXDB9	SN	NNC-114-0005; NNC-0114-0000-0005; Anti-IL-21 (inflammation), Novo Nordisk; MIL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), Novo Nordisk; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics
DMYXDB9	CP	ZymoGenetics Inc
DMYXDB9	DT	Antibody
DMYXDB9	DE	Autoimmune diabetes

DM1RBT8	ID	DM1RBT8
DM1RBT8	DN	NN-9926
DM1RBT8	HS	Phase 1
DM1RBT8	SN	NNC-0113-0987
DM1RBT8	CP	Novo Nordisk A/S
DM1RBT8	DE	Type-2 diabetes

DMUPA7C	ID	DMUPA7C
DMUPA7C	DN	NOCICEPTIN
DMUPA7C	HS	Phase 1
DMUPA7C	SN	Nociceptin; Orphanin FQ; Nociceptin/orphanin FQ; 170713-75-4; Orphanin FQ (rat); Orphanin FQ (swine); Orphanin FQ (human); Nociceptin (1-17); UNII-7AYI9N34FF; Orphanin FQ (pig); 7AYI9N34FF; CHEBI:80266; Human nociceptin; L-Glutamine, L-phenylalanylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-alanyl-L-asparaginyl-; Nociceptin (human); Nociceptin(1-17)-OH; FGGFTGARKSARKLANQ; Orphaninfq(swine)(9ci); GTPL1681; CHEMBL396460; BDBM50004178; AKOS024458690; nociceptin/orphanin FQ
DMUPA7C	PC	16131448
DMUPA7C	MW	1809
DMUPA7C	FM	C79H129N27O22
DMUPA7C	IC	InChI=1S/C79H129N27O22/c1-41(2)33-54(72(122)95-44(5)66(116)103-56(36-59(84)110)73(123)102-53(77(127)128)27-28-58(83)109)104-70(120)49(23-13-15-29-80)100-69(119)52(26-18-32-90-79(87)88)99-65(115)43(4)96-75(125)57(40-107)105-71(121)50(24-14-16-30-81)101-68(118)51(25-17-31-89-78(85)86)98-64(114)42(3)94-61(112)39-93-76(126)63(45(6)108)106-74(124)55(35-47-21-11-8-12-22-47)97-62(113)38-91-60(111)37-92-67(117)48(82)34-46-19-9-7-10-20-46/h7-12,19-22,41-45,48-57,63,107-108H,13-18,23-40,80-82H2,1-6H3,(H2,83,109)(H2,84,110)(H,91,111)(H,92,117)(H,93,126)(H,94,112)(H,95,122)(H,96,125)(H,97,113)(H,98,114)(H,99,115)(H,100,119)(H,101,118)(H,102,123)(H,103,116)(H,104,120)(H,105,121)(H,106,124)(H,127,128)(H4,85,86,89)(H4,87,88,90)/t42-,43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,63-/m0/s1
DMUPA7C	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMUPA7C	IK	PULGYDLMFSFVBL-SMFNREODSA-N
DMUPA7C	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMUPA7C	CA	CAS 170713-75-4
DMUPA7C	CB	CHEBI:80266
DMUPA7C	DE	Headache

DM2ILSJ	ID	DM2ILSJ
DM2ILSJ	DN	Norbuprenorphine
DM2ILSJ	HS	Phase 1
DM2ILSJ	SN	Norbuprenorphine; N-Desalkylbuprenorphine; Des(cyclopropylmethyl)buprenorphine; UNII-7E53B4O073; 7E53B4O073; 6,14-Ethenomorphinan-7-methanol, alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-; AC1L3GBB; SCHEMBL14408877; CHEMBL1743323; YOYLLRBMGQRFTN-IOMBULRVSA-N; ZINC6031944; LS-67705; 6,14-ethenomorphinan-3-ol, 4,5-epoxy-18,19-dihydro-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,6beta,14beta,18R)-
DM2ILSJ	PC	114976
DM2ILSJ	MW	413.5
DM2ILSJ	FM	C25H35NO4
DM2ILSJ	IC	InChI=1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1
DM2ILSJ	CS	CC(C)(C)C(C)(C1CC23CCC1(C4C25CCNC3CC6=C5C(=C(C=C6)O)O4)OC)O
DM2ILSJ	IK	YOYLLRBMGQRFTN-IOMBULRVSA-N
DM2ILSJ	IU	(1S,2S,6R,14R,15R,16R)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DM2ILSJ	CA	CAS 78715-23-8
DM2ILSJ	DE	Human immunodeficiency virus infection

DME2QUZ	ID	DME2QUZ
DME2QUZ	DN	NOV1501
DME2QUZ	HS	Phase 1
DME2QUZ	SN	ABL001; TR009
DME2QUZ	CP	ABL Bio
DME2QUZ	DT	Antibody
DME2QUZ	DE	Solid tumour/cancer

DMMYRHV	ID	DMMYRHV
DMMYRHV	DN	NOX-700
DMMYRHV	HS	Phase 1
DMMYRHV	CP	Medinox
DMMYRHV	DE	Type-2 diabetes

DMMKN4Q	ID	DMMKN4Q
DMMKN4Q	DN	NOX-A12
DMMKN4Q	HS	Phase 1
DMMKN4Q	SN	Ocular antineovascularisation agent/angiogenesis inhibitor (diabetic retinopathy/AMD), NOXXON; SDF-1 inhbitor (spiegelmer, stem cell transplantation), NOXXON; CXCL12 inhibitor (spiegelmer, diabetic retinopathy/AMD/stem cell transplantation), Noxxon
DMMKN4Q	CP	NOXXON Pharma AG
DMMKN4Q	DE	Macular degeneration

DMHARE7	ID	DMHARE7
DMHARE7	DN	NP-500
DMHARE7	HS	Phase 1
DMHARE7	CP	Napo Pharmaceuticals
DMHARE7	DE	Type-2 diabetes; Metabolic syndrome x

DMZ72BD	ID	DMZ72BD
DMZ72BD	DN	NP-G2-044
DMZ72BD	HS	Phase 1
DMZ72BD	SN	1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6
DMZ72BD	CP	Novita Pharmaceuticals New York, NY
DMZ72BD	PC	91844684
DMZ72BD	MW	399.4
DMZ72BD	FM	C21H16F3N3O2
DMZ72BD	IC	InChI=1S/C21H16F3N3O2/c1-13-16(10-11-29-13)20(28)25-19-17-4-2-3-5-18(17)27(26-19)12-14-6-8-15(9-7-14)21(22,23)24/h2-11H,12H2,1H3,(H,25,26,28)
DMZ72BD	CS	CC1=C(C=CO1)C(=O)NC2=NN(C3=CC=CC=C32)CC4=CC=C(C=C4)C(F)(F)F
DMZ72BD	IK	XLLRLAABUFOJPC-UHFFFAOYSA-N
DMZ72BD	IU	2-methyl-N-[1-[[4-(trifluoromethyl)phenyl]methyl]indazol-3-yl]furan-3-carboxamide
DMZ72BD	CA	CAS 1807454-59-6
DMZ72BD	DE	Solid tumour/cancer

DMFDBV5	ID	DMFDBV5
DMFDBV5	DN	NPT200-11
DMFDBV5	HS	Phase 1
DMFDBV5	CP	Neuropore Therapies
DMFDBV5	DT	Small molecular drug
DMFDBV5	DE	Multiple system atrophy; Parkinson disease

DMX8LY4	ID	DMX8LY4
DMX8LY4	DN	NS-8
DMX8LY4	HS	Phase 1
DMX8LY4	SN	NS-8; 186033-14-7; 2-amino-3-cyano-4-methyl-5-(2-fluorophenyl)pyrrole; 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile; KVDWOQGDMAEJLM-UHFFFAOYSA-N; CHEMBL42661; SCHEMBL4624842; ZINC21886; MolPort-005-943-258; AKOS027201108; EN300-254366; 2-amino-3-cyano-4-methyl-5-(2fluorophenyl)pyrrole; Z2306534448
DMX8LY4	CP	Nippon Shinyaku Co Ltd
DMX8LY4	DT	Small molecular drug
DMX8LY4	PC	10176749
DMX8LY4	MW	215.23
DMX8LY4	FM	C12H10FN3
DMX8LY4	IC	InChI=1S/C12H10FN3/c1-7-9(6-14)12(15)16-11(7)8-4-2-3-5-10(8)13/h2-5,16H,15H2,1H3
DMX8LY4	CS	CC1=C(NC(=C1C#N)N)C2=CC=CC=C2F
DMX8LY4	IK	KVDWOQGDMAEJLM-UHFFFAOYSA-N
DMX8LY4	IU	2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile
DMX8LY4	DE	Urinary incontinence

DMRAX19	ID	DMRAX19
DMRAX19	DN	NSC-14983
DMRAX19	HS	Phase 1
DMRAX19	SN	Aspartic acid, N-carbamoyl-; Carbamoylaspartic acid; Carbamyl-L-aspartic acid; Carbamylaspartic acid; L-N-Carbamoylaspartic acid; L-Ureidosuccinate; L-Ureidosuccinic acid; N-(aminocarbonyl)-L-aspartic acid; N-Carbamoyl-L-aspartic acid; N-Carbamoyl-S-aspartic acid; N-Carbamoylaspartic acid; N-carbamoyl-L-aspartate; R2521024DK; Succinic acid, ureido-; Ureidosuccinate; carbamyl-aspartate; 13184-27-5; 2-Ureidobutanedioic acid; EINECS 236-134-3; L-Aspartic acid, N-(aminocarbonyl)-; NSC 14983; UNII-R2521024DK
DMRAX19	PC	93072
DMRAX19	MW	176.13
DMRAX19	FM	C5H8N2O5
DMRAX19	IC	HLKXYZVTANABHZ-REOHCLBHSA-N
DMRAX19	CS	C(C(C(=O)O)NC(=O)N)C(=O)O
DMRAX19	IK	1S/C5H8N2O5/c6-5(12)7-2(4(10)11)1-3(8)9/h2H,1H2,(H,8,9)(H,10,11)(H3,6,7,12)/t2-/m0/s1
DMRAX19	IU	(2S)-2-(carbamoylamino)butanedioic acid
DMRAX19	CA	CAS 13184-27-5
DMRAX19	CB	CHEBI:15859
DMRAX19	DE	Dyslipidaemia

DM6093Y	ID	DM6093Y
DM6093Y	DN	NSC-172130
DM6093Y	HS	Phase 1
DM6093Y	SN	Depresym; Dosulepin HCl; Dothiepin HCl; Dothiepin hydrochloride; Prothiaden hydrochloride; Prothiadene; Prothiadene hydrochloride; Prothiadiene; Xerenal; (3E)-3-(6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine;hydrochloride; 25627-36-5; 3H0042311V; 897-15-4; CHEBI:36805; Dibenzo(b,e)thiepin-delta(sup 11(6H),gamma)-propylamine, N,N-dimethyl-, hydrochloride, (E)-; EINECS 212-978-8; Idom; N,N-Dimethyldibenzo(b,e)thiepin-delta(sup 11(6H),gamma)-propylamine hydrochloride; NSC 172130; NSC172130; UNII-3H0042311V
DM6093Y	PC	9884029
DM6093Y	MW	331.9
DM6093Y	FM	C19H22ClNS
DM6093Y	IC	XUPZAARQDNSRJB-SJDTYFKWSA-N
DM6093Y	CS	CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31.Cl
DM6093Y	IK	1S/C19H21NS.ClH/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19;/h3-6,8-12H,7,13-14H2,1-2H3;1H/b17-11+;
DM6093Y	IU	(3E)-3-(6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine;hydrochloride
DM6093Y	CA	CAS 897-15-4
DM6093Y	CB	CHEBI:36805
DM6093Y	DE	Depression

DM96RD5	ID	DM96RD5
DM96RD5	DN	NSC-38348
DM96RD5	HS	Phase 1
DM96RD5	SN	Camphophyline; Corafil; Diaethylaminoaethyl-theophyllin; Dietamiphylline; Diethylaminoethyl theophylline; Diethylaminoethyltheophylline; Etamifilina [INN-Spanish]; Etamifillina [DCIT]; Etaminophylline; Etamiphyllin; Etamiphyllin [INN]; Etamiphylline; Etamiphylline [INN-French]; Etamiphyllinum [INN-Latin]; Milliphylline; Millophyline; Millophylline; Parephyllin; Queryl; R-3588; Solufilina; Soluphyline; 7-(2-(Diethylamino)ethyl)theophylline; 7-(Diethylaminoethyl)theophylline; NSC 38348; UNII-221A91BQ2S
DM96RD5	PC	28329
DM96RD5	MW	279.34
DM96RD5	FM	C13H21N5O2
DM96RD5	IC	AWKLBIOQCIORSB-UHFFFAOYSA-N
DM96RD5	CS	CCN(CC)CCN1C=NC2=C1C(=O)N(C(=O)N2C)C
DM96RD5	IK	1S/C13H21N5O2/c1-5-17(6-2)7-8-18-9-14-11-10(18)12(19)16(4)13(20)15(11)3/h9H,5-8H2,1-4H3
DM96RD5	IU	7-[2-(diethylamino)ethyl]-1,3-dimethylpurine-2,6-dione
DM96RD5	CA	CAS 314-35-2
DM96RD5	CB	CHEBI:135157
DM96RD5	DE	Asthma

DMTYGWV	ID	DMTYGWV
DMTYGWV	DN	NSC-639829
DMTYGWV	HS	Phase 1
DMTYGWV	SN	N-[4-(5-Bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea
DMTYGWV	DT	Small molecular drug
DMTYGWV	PC	368697
DMTYGWV	MW	470.3
DMTYGWV	FM	C21H20BrN5O3
DMTYGWV	IC	InChI=1S/C21H20BrN5O3/c1-13-10-15(8-9-18(13)30-21-23-11-14(22)12-24-21)25-20(29)26-19(28)16-6-4-5-7-17(16)27(2)3/h4-12H,1-3H3,(H2,25,26,28,29)
DMTYGWV	CS	CC1=C(C=CC(=C1)NC(=O)NC(=O)C2=CC=CC=C2N(C)C)OC3=NC=C(C=N3)Br
DMTYGWV	IK	JNGQUJZDVFZPEN-UHFFFAOYSA-N
DMTYGWV	IU	N-[[4-(5-bromopyrimidin-2-yl)oxy-3-methylphenyl]carbamoyl]-2-(dimethylamino)benzamide
DMTYGWV	CA	CAS 134742-19-1
DMTYGWV	DE	Solid tumour/cancer

DM5QHID	ID	DM5QHID
DM5QHID	DN	NSD-788
DM5QHID	HS	Phase 1
DM5QHID	SN	GABA-A receptor modulator (anxiety/depression), NeuroSearch
DM5QHID	CP	NeuroSearch A/S
DM5QHID	DE	Anxiety disorder

DM1ITDN	ID	DM1ITDN
DM1ITDN	DN	NsG-0202
DM1ITDN	HS	Phase 1
DM1ITDN	SN	ECB-AD; ECT-AD; ECT-NGF; ECT (Alzheimers Disease), NsGene; Encapsulated cell technology (Alzheimers Disease), NsGene; Encapsulated ARPE-19 cells (Alzheimers disease), NsGene
DM1ITDN	CP	NsGene A/S
DM1ITDN	DE	Alzheimer disease

DMSWJ6D	ID	DMSWJ6D
DMSWJ6D	DN	NU-206
DMSWJ6D	HS	Phase 1
DMSWJ6D	SN	HRSpo-1; Secreted proteins (IBD), ARCA; Secreted proteins (mucositis), ARCA; Secreted proteins (GI and bone diseases),Kyowa Hakko Kirin/ARCA; Secreted proteins (IBD), Kirin/ARCA; Secreted proteins (inflammatory bowel disease), ARCA/Kirin; Secreted proteins (mucositis), Kirin/ARCA; Human R-Spondin-1 (GI and bone diseases), ARCA; Low-density lipoprotein receptor related protein 6 (IBD), Kirin/ARCA
DMSWJ6D	CP	Kirin Brewery Co Ltd
DMSWJ6D	DE	Gastrointestinal disease

DMQ0F5P	ID	DMQ0F5P
DMQ0F5P	DN	NUC-3373
DMQ0F5P	HS	Phase 1
DMQ0F5P	SN	Fosifloxuridine nafalbenamide; 1332837-31-6; CHEMBL2181367; EX-A4413; DB14859; J3.616.613D; UNII-4YO6QT3SZ9 component BIOWRMNRHMERIO-XWVUVRNUSA-N; L-Alanine, N-(-2'-deoxy-2',2'-difluoro-p-1-naphthalenyl-5'-cytidylyl)-, phenylmethyl ester
DMQ0F5P	CP	NuCana
DMQ0F5P	DT	Small molecular drug
DMQ0F5P	PC	53373585
DMQ0F5P	MW	613.5
DMQ0F5P	FM	C29H29FN3O9P
DMQ0F5P	IC	InChI=1S/C29H29FN3O9P/c1-18(28(36)39-16-19-8-3-2-4-9-19)32-43(38,42-24-13-7-11-20-10-5-6-12-21(20)24)40-17-25-23(34)14-26(41-25)33-15-22(30)27(35)31-29(33)37/h2-13,15,18,23,25-26,34H,14,16-17H2,1H3,(H,32,38)(H,31,35,37)/t18-,23-,25+,26+,43?/m0/s1
DMQ0F5P	CS	C[C@@H](C(=O)OCC1=CC=CC=C1)NP(=O)(OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)F)O)OC4=CC=CC5=CC=CC=C54
DMQ0F5P	IK	BIOWRMNRHMERIO-ZVAHOJSLSA-N
DMQ0F5P	IU	benzyl (2S)-2-[[[(2R,3S,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate
DMQ0F5P	CA	CAS 1332837-31-6
DMQ0F5P	DE	Solid tumour/cancer

DMNF09S	ID	DMNF09S
DMNF09S	DN	NV-04
DMNF09S	HS	Phase 1
DMNF09S	SN	Phenolic hormone (cardiovascular), Novogen; Trans-NV-04
DMNF09S	CP	Novogen
DMNF09S	DE	Cardiovascular disease

DMLKS7W	ID	DMLKS7W
DMLKS7W	DN	NV-5138
DMLKS7W	HS	Phase 1
DMLKS7W	SN	UNII-06CA9QMG6Z; 4-(difluoromethyl)-L-leucine; 2095886-80-7; SCHEMBL18762589; ZINC585143195; HY-114384; N[C@H](C(=O)O)CC(C(F)F)(C)C; CS-0084893; ((S)-2-Amino-5,5-difluoro-4,4-dimethylpentanoic acid; Pentanoic acid, 2-amino-5,5-difluoro-4,4-dimethyl-, (2S)-; K94
DMLKS7W	CP	Navitor Pharmaceuticals
DMLKS7W	DT	Small molecular drug
DMLKS7W	PC	129050791
DMLKS7W	MW	181.18
DMLKS7W	FM	C7H13F2NO2
DMLKS7W	IC	InChI=1S/C7H13F2NO2/c1-7(2,6(8)9)3-4(10)5(11)12/h4,6H,3,10H2,1-2H3,(H,11,12)/t4-/m0/s1
DMLKS7W	CS	CC(C)(C[C@@H](C(=O)O)N)C(F)F
DMLKS7W	IK	HRFIMCJTDKEPPV-BYPYZUCNSA-N
DMLKS7W	IU	(2S)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid
DMLKS7W	CA	CAS 2095886-80-7
DMLKS7W	DE	Major depressive disorder

DM0UOA9	ID	DM0UOA9
DM0UOA9	DN	NV-52
DM0UOA9	HS	Phase 1
DM0UOA9	CP	Novogen
DM0UOA9	DE	Inflammatory bowel disease

DM0EKUQ	ID	DM0EKUQ
DM0EKUQ	DN	NY-ESO-1 vaccine
DM0EKUQ	HS	Phase 1
DM0EKUQ	SN	Cancer vaccine (peptides), Ludwig Institute; NY-ESO-1b; NY-ESO-1 OLP-4; NY-ESO-1 peptide immunotherapy, Ludwig Institute; NY-ESO-1 vaccine (peptides); NY-ESO-1 DP4 peptide (157-170); NY-ESO-1 vaccine (peptides), Ludwig Institute
DM0EKUQ	CP	Ludwig Institute for Cancer Research
DM0EKUQ	DT	Vaccine
DM0EKUQ	DE	Solid tumour/cancer

DMWN2FP	ID	DMWN2FP
DMWN2FP	DN	NZV930
DMWN2FP	HS	Phase 1
DMWN2FP	SN	SRF 373
DMWN2FP	CP	Surface oncology
DMWN2FP	DT	Antibody
DMWN2FP	DE	Solid tumour/cancer

DMPLV9G	ID	DMPLV9G
DMPLV9G	DN	OBP-801
DMPLV9G	HS	Phase 1
DMPLV9G	CP	Astellas Pharma Inc
DMPLV9G	PC	11178958
DMPLV9G	MW	473.6
DMPLV9G	FM	C20H31N3O6S2
DMPLV9G	IC	InChI=1S/C20H31N3O6S2/c1-11(2)18-15(24)9-17(26)29-13-6-4-5-7-30-31-10-14(20(28)23-18)22-19(27)12(3)21-16(25)8-13/h4,6,11-15,18,24H,5,7-10H2,1-3H3,(H,21,25)(H,22,27)(H,23,28)/b6-4+/t12-,13-,14-,15+,18-/m1/s1
DMPLV9G	CS	C[C@@H]1C(=O)N[C@@H]2CSSCC/C=C/[C@H](CC(=O)N1)OC(=O)C[C@@H]([C@H](NC2=O)C(C)C)O
DMPLV9G	IK	XFLBOEMFLGLWFF-HDXRNPEWSA-N
DMPLV9G	IU	(1S,5S,6R,9S,15E,20R)-5-hydroxy-20-methyl-6-propan-2-yl-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docos-15-ene-3,8,18,21-tetrone
DMPLV9G	CA	CAS 328548-11-4
DMPLV9G	DE	Solid tumour/cancer

DMW4JRY	ID	DMW4JRY
DMW4JRY	DN	OBT076
DMW4JRY	HS	Phase 1
DMW4JRY	SN	MEN1309
DMW4JRY	CP	Oxford BioTherapeutics
DMW4JRY	DT	Antibody drug conjugate
DMW4JRY	DE	Breast cancer

DMOSRFZ	ID	DMOSRFZ
DMOSRFZ	DN	OC-10X
DMOSRFZ	HS	Phase 1
DMOSRFZ	SN	AMD therapy, OcuCure
DMOSRFZ	CP	Ocucure therapeutics
DMOSRFZ	PC	4793207
DMOSRFZ	MW	300.4
DMOSRFZ	FM	C20H16N2O
DMOSRFZ	IC	InChI=1S/C20H16N2O/c23-20-17-8-4-5-9-18(17)21-19(22-20)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13,19,21H,(H,22,23)
DMOSRFZ	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C3NC4=CC=CC=C4C(=O)N3
DMOSRFZ	IK	XRUAOBKXCFNPCK-UHFFFAOYSA-N
DMOSRFZ	IU	2-(4-phenylphenyl)-2,3-dihydro-1H-quinazolin-4-one
DMOSRFZ	DE	Macular degeneration; Proliferative diabetic retinopathy

DMZK1GW	ID	DMZK1GW
DMZK1GW	DN	OG987SC
DMZK1GW	HS	Phase 1
DMZK1GW	SN	NN9927
DMZK1GW	CP	Novo Nordisk
DMZK1GW	DE	Type-2 diabetes

DMH0D5M	ID	DMH0D5M
DMH0D5M	DN	OI287GT
DMH0D5M	HS	Phase 1
DMH0D5M	SN	NN1956
DMH0D5M	CP	Novo Nordisk
DMH0D5M	DE	Type-1/2 diabetes

DMERDMV	ID	DMERDMV
DMERDMV	DN	OI362GT
DMERDMV	HS	Phase 1
DMERDMV	SN	NN1954
DMERDMV	CP	Novo Nordisk
DMERDMV	DE	Type-1/2 diabetes

DMSJWTE	ID	DMSJWTE
DMSJWTE	DN	OKI 179
DMSJWTE	HS	Phase 1
DMSJWTE	CP	OnKure Therapeutics
DMSJWTE	DT	Small molecular drug
DMSJWTE	DE	Solid tumour/cancer

DMLVNWO	ID	DMLVNWO
DMLVNWO	DN	Oleclumab
DMLVNWO	HS	Phase 1
DMLVNWO	CP	MedImmune Gaithersburg, MD
DMLVNWO	DE	Solid tumour/cancer

DM2THBX	ID	DM2THBX
DM2THBX	DN	OM-174
DM2THBX	HS	Phase 1
DM2THBX	SN	UNII-HC3530GGGG; HC3530GGGG; Defoslimod [INN]; OM 174 lipid; 2-Deoxy-6-o-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate.; 2-Deoxy-6-O-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate
DM2THBX	CP	OM Pharma
DM2THBX	PC	9833422
DM2THBX	MW	1135.3
DM2THBX	FM	C52H100N2O20P2
DM2THBX	IC	InChI=1S/C52H100N2O20P2/c1-4-7-10-13-16-19-22-25-28-31-38(56)34-42(57)53-45-48(61)47(60)41(72-52(45)74-76(66,67)68)37-69-51-46(49(62)50(40(36-55)71-51)73-75(63,64)65)54-43(58)35-39(32-29-26-23-20-17-14-11-8-5-2)70-44(59)33-30-27-24-21-18-15-12-9-6-3/h38-41,45-52,55-56,60-62H,4-37H2,1-3H3,(H,53,57)(H,54,58)(H2,63,64,65)(H2,66,67,68)/t38-,39-,40-,41-,45-,46-,47-,48-,49-,50-,51-,52-/m1/s1
DM2THBX	CS	CCCCCCCCCCC[C@H](CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)OP(=O)(O)O)O)NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)O)O)O
DM2THBX	IK	GOWLTLODGKPXMN-MWJFIXGVSA-N
DM2THBX	IU	[(3R)-1-[[(2R,3R,4R,5S,6R)-2-[[(2R,3S,4R,5R,6R)-3,4-dihydroxy-5-[[(3R)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-2-yl]methoxy]-4-hydroxy-6-(hydroxymethyl)-5-phosphonooxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] dodecanoate
DM2THBX	CA	CAS 171092-39-0
DM2THBX	DE	Solid tumour/cancer

DMWHZEG	ID	DMWHZEG
DMWHZEG	DN	OMN-54
DMWHZEG	HS	Phase 1
DMWHZEG	CP	Omnitura therapeutics
DMWHZEG	DE	Solid tumour/cancer

DMTFU8Q	ID	DMTFU8Q
DMTFU8Q	DN	OMP-131R10
DMTFU8Q	HS	Phase 1
DMTFU8Q	CP	OncoMed
DMTFU8Q	DT	Antibody
DMTFU8Q	DE	Solid tumour/cancer

DMWK679	ID	DMWK679
DMWK679	DN	OMP-18R5
DMWK679	HS	Phase 1
DMWK679	SN	Vantictumab; Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals
DMWK679	CP	Oncomed pharmaceuticals; Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
DMWK679	DE	Solid tumour/cancer

DMX1D0S	ID	DMX1D0S
DMX1D0S	DN	OMP-21M18
DMX1D0S	HS	Phase 1
DMX1D0S	CP	GlaxoSmithKline
DMX1D0S	DE	Solid tumour/cancer

DMGWC86	ID	DMGWC86
DMGWC86	DN	OMP-52M51
DMGWC86	HS	Phase 1
DMGWC86	CP	Glaxosmithkline; oncomed pharmaceuticals
DMGWC86	DT	Antibody
DMGWC86	DE	Solid tumour/cancer

DMO0JP1	ID	DMO0JP1
DMO0JP1	DN	OMS527
DMO0JP1	HS	Phase 1
DMO0JP1	CP	Omeros
DMO0JP1	DT	Small interfering RNA
DMO0JP1	DE	Substance use disorder

DMWYEDX	ID	DMWYEDX
DMWYEDX	DN	ON-01210.Na
DMWYEDX	HS	Phase 1
DMWYEDX	SN	Ex-RAD; Tyrosine kinase inhibitor (radiation protection), Onconova; ON-01210.Na (oral, radiation sickness); ON-01210.Na (oral, radiation sickness), Onconova; ON-01210.Na (sc, radiation sickness), Onconova Therapeutics
DMWYEDX	CP	Onconova Therapeutics Inc
DMWYEDX	DT	Small molecular drug
DMWYEDX	PC	23668369
DMWYEDX	MW	358.8
DMWYEDX	FM	C16H12ClNaO4S
DMWYEDX	IC	InChI=1S/C16H13ClO4S.Na/c17-15-7-3-13(4-8-15)11-22(20,21)10-9-12-1-5-14(6-2-12)16(18)19;/h1-10H,11H2,(H,18,19);/q;+1/p-1/b10-9+;
DMWYEDX	CS	C1=CC(=CC=C1CS(=O)(=O)/C=C/C2=CC=C(C=C2)C(=O)[O-])Cl.[Na+]
DMWYEDX	IK	PRFBWBYKWZVQJF-RRABGKBLSA-M
DMWYEDX	IU	sodium;4-[(E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]benzoate
DMWYEDX	CA	CAS 922139-31-9
DMWYEDX	DE	Radiation syndrome; Acute radiation syndrome

DM5VY23	ID	DM5VY23
DM5VY23	DN	ONC206
DM5VY23	HS	Phase 1
DM5VY23	SN	UNII-OW6LM47PNK; OW6LM47PNK; 1638178-87-6; 7-benzyl-4-(2,4-difluorobenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one; SCHEMBL20464679; ONC-206; NSC783746; s6853; NSC-783746; HY-135147; CS-0109614; 4-((2,4-Difluorophenyl)methyl)-2,4,6,7,8,9-hexahydro-7-(phenylmethyl)imidazo(1,2-a)pyrido(3,4-E)pyrimidin-5(1H)-one; 7-Benzyl-4-(2,4-difluorobenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one
DM5VY23	CP	Oncoceutics
DM5VY23	DT	Small molecular drug
DM5VY23	PC	135297777
DM5VY23	MW	408.4
DM5VY23	FM	C23H22F2N4O
DM5VY23	IC	InChI=1S/C23H22F2N4O/c24-18-7-6-17(20(25)12-18)14-29-22(30)19-15-27(13-16-4-2-1-3-5-16)10-8-21(19)28-11-9-26-23(28)29/h1-7,12H,8-11,13-15H2
DM5VY23	CS	C1CN(CC2=C1N3CCN=C3N(C2=O)CC4=C(C=C(C=C4)F)F)CC5=CC=CC=C5
DM5VY23	IK	ITMGVSSHWMTJRR-UHFFFAOYSA-N
DM5VY23	IU	11-benzyl-7-[(2,4-difluorophenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one
DM5VY23	CA	CAS 1638178-87-6
DM5VY23	DE	Brain and central nervous system tumour

DM8B40M	ID	DM8B40M
DM8B40M	DN	ONC-392
DM8B40M	HS	Phase 1
DM8B40M	CP	OncoImmune
DM8B40M	DT	Antibody
DM8B40M	DE	Non-small-cell lung cancer; Solid tumour/cancer

DMC29LV	ID	DMC29LV
DMC29LV	DN	ONO-4059
DMC29LV	HS	Phase 1
DMC29LV	CP	ONO Pharmaceutical
DMC29LV	DE	B-cell lymphoma

DMO4SD2	ID	DMO4SD2
DMO4SD2	DN	ONO-4232
DMO4SD2	HS	Phase 1
DMO4SD2	CP	Ono pharma usa
DMO4SD2	DE	Acute heart failure

DME63VK	ID	DME63VK
DME63VK	DN	ONO-4578
DME63VK	HS	Phase 1
DME63VK	SN	BMS-986310
DME63VK	CP	Ono Pharmaceutical; Bristol-Myers Squibb
DME63VK	DE	Solid tumour/cancer

DMGBKCJ	ID	DMGBKCJ
DMGBKCJ	DN	ONO-7475
DMGBKCJ	HS	Phase 1
DMGBKCJ	CP	Ono Pharmaceutical Osaka, Japan
DMGBKCJ	DE	Acute myeloid leukaemia

DMUZFVH	ID	DMUZFVH
DMUZFVH	DN	ONT-10
DMUZFVH	HS	Phase 1
DMUZFVH	CP	Oncothyreon
DMUZFVH	DT	Vaccine
DMUZFVH	DE	Solid tumour/cancer

DMBVZND	ID	DMBVZND
DMBVZND	DN	ONYX-015
DMBVZND	HS	Phase 1
DMBVZND	SN	Dl1520; E1B-deleted adenovirus (cancer), ONYX
DMBVZND	CP	Onyx Pharmaceuticals Inc
DMBVZND	DE	Head and neck cancer

DMECVP9	ID	DMECVP9
DMECVP9	DN	OP-0595
DMECVP9	HS	Phase 1
DMECVP9	SN	Nacubactam; 1452458-86-4; RG6080; RG-6080; UNII-832O37V7MZ; RO7079901; 832O37V7MZ; FPI-1459; 1452458-86-4 (free acid); RO-7079901; (1R,2S,5R)-2-((2-aminoethoxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; Nacubactam [INN]; Nacubactam (USAN); Nacubactam [USAN:INN]; CHEMBL3989959; SCHEMBL15206610; SCHEMBL17975933; GTPL10833; MFCD28986228; OP0595; ZINC207610051; DB15353; SB17180; AS-35134; HY-109008; CS-0030506; D11329; Q27269383; (1R,2S,5R)-2-((2-Aminoethoxy)carbamoyl)-7-oxo- 1,6-diazabicyclo(3.2.1)octan-6-yl hydrogen sulfate; (2S,5R)-2-(2-Aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; (2S,5R)-N-(2-Aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; [(2S,5R)-2-(2-aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate; Sulfuric acid, mono((1R,2S,5R)-2-(((2-aminoethoxy)amino)carbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester; Sulfuric acid, mono((1R,2S,5R)-2-(((2-aminoethoxy)amino)carbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester, (-)-
DMECVP9	CP	Meiji Seika Pharma
DMECVP9	DT	Small molecular drug
DMECVP9	PC	73386748
DMECVP9	MW	324.31
DMECVP9	FM	C9H16N4O7S
DMECVP9	IC	InChI=1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)/t6-,7+/m1/s1
DMECVP9	CS	C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NOCCN
DMECVP9	IK	RSBPYSTVZQAADE-RQJHMYQMSA-N
DMECVP9	IU	[(2S,5R)-2-(2-aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
DMECVP9	CA	CAS 1452458-86-4
DMECVP9	DE	Bacterial infection

DM7YFW5	ID	DM7YFW5
DM7YFW5	DN	OPB-111077
DM7YFW5	HS	Phase 1
DM7YFW5	CP	Rockville
DM7YFW5	DT	Small interfering RNA
DM7YFW5	DE	Hepatocellular carcinoma; Haematological malignancy; Solid tumour/cancer

DM760FA	ID	DM760FA
DM760FA	DN	OPB-51602
DM760FA	HS	Phase 1
DM760FA	CP	Otsuka America Pharmaceutical
DM760FA	DE	Solid tumour/cancer

DMZWFKQ	ID	DMZWFKQ
DMZWFKQ	DN	OPC-14117
DMZWFKQ	HS	Phase 1
DMZWFKQ	SN	N-(7-Hydroxy-2,2,4,6-trimethylindan-1-yl)-2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamide; 7-Hydroxy-1-[2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamido]-2,2,4,6-tetramethylindan
DMZWFKQ	DT	Small molecular drug
DMZWFKQ	PC	59739
DMZWFKQ	MW	437.6
DMZWFKQ	FM	C26H35N3O3
DMZWFKQ	IC	InChI=1S/C26H35N3O3/c1-17-13-18(2)24(31)23-21(17)15-26(3,4)25(23)27-22(30)16-28-9-11-29(12-10-28)19-7-6-8-20(14-19)32-5/h6-8,13-14,25,31H,9-12,15-16H2,1-5H3,(H,27,30)
DMZWFKQ	CS	CC1=CC(=C(C2=C1CC(C2NC(=O)CN3CCN(CC3)C4=CC(=CC=C4)OC)(C)C)O)C
DMZWFKQ	IK	LYAUICDWKQJAGX-UHFFFAOYSA-N
DMZWFKQ	IU	N-(7-hydroxy-2,2,4,6-tetramethyl-1,3-dihydroinden-1-yl)-2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamide
DMZWFKQ	CA	CAS 103233-65-4
DMZWFKQ	DE	Neurological disorder

DMLUYAJ	ID	DMLUYAJ
DMLUYAJ	DN	OPK-0018
DMLUYAJ	HS	Phase 1
DMLUYAJ	CP	OPKO Health
DMLUYAJ	DE	Asthma

DM3HOUX	ID	DM3HOUX
DM3HOUX	DN	OPL-CCL2-LPM
DM3HOUX	HS	Phase 1
DM3HOUX	SN	CCR2 targeting agent (arthritis/nephritis/cardiovascular/pulmonaryl/CNS); Leukocyte population modulator (arthritis/nephritis/cardiovascular/pulmonary/CNS), Osprey
DM3HOUX	CP	Osprey Pharmaceuticals Ltd
DM3HOUX	DE	Arthritis

DMH6SNO	ID	DMH6SNO
DMH6SNO	DN	OP-R003
DMH6SNO	HS	Phase 1
DMH6SNO	SN	VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK
DMH6SNO	CP	Vaccinex Inc
DMH6SNO	DE	Haematological malignancy

DMBG534	ID	DMBG534
DMBG534	DN	Org-25435
DMBG534	HS	Phase 1
DMBG534	SN	Org 25435; CHEMBL325728
DMBG534	CP	Organon BioSciences
DMBG534	DT	Small molecular drug
DMBG534	PC	9885653
DMBG534	MW	369.5
DMBG534	FM	C19H31NO6
DMBG534	IC	InChI=1S/C19H31NO6/c1-7-15(20(8-10-22-3)9-11-23-4)19(21)26-18-16(24-5)12-14(2)13-17(18)25-6/h12-13,15H,7-11H2,1-6H3/t15-/m1/s1
DMBG534	CS	CC[C@H](C(=O)OC1=C(C=C(C=C1OC)C)OC)N(CCOC)CCOC
DMBG534	IK	GKRFHHRXDUACIN-OAHLLOKOSA-N
DMBG534	IU	(2,6-dimethoxy-4-methylphenyl) (2R)-2-[bis(2-methoxyethyl)amino]butanoate
DMBG534	CA	CAS 256456-73-2
DMBG534	DE	Epilepsy

DME0WX2	ID	DME0WX2
DME0WX2	DN	Org-43902
DME0WX2	HS	Phase 1
DME0WX2	SN	LH-ago1; ORG-41247; ORG-42619; ORG-43311; SC-20565; Luteinizing hormone receptor (LHR) agonist, NV Organon; Oral LH agonist, Schering-Plough; Low molecular weight luteinizing hormone (LMW LH) receptor agonist, Merck & Co; Luteinizing hormone agonist (oral), Merck & Co; Luteinizing hormone agonist (oral), Schering-Plough
DME0WX2	CP	Organon BioSciences
DME0WX2	DE	Infertility

DMR12S0	ID	DMR12S0
DMR12S0	DN	ORIC-101
DMR12S0	HS	Phase 1
DMR12S0	SN	VNLTWJIWEYPBIF-SXJSTINISA-N; 2222344-98-9
DMR12S0	CP	ORIC Pharmaceuticals South San Francisco, CA
DMR12S0	PC	134415769
DMR12S0	MW	501.7
DMR12S0	FM	C34H47NO2
DMR12S0	IC	InChI=1S/C34H47NO2/c1-22(2)35(7)25-11-8-23(9-12-25)29-21-33(6)30(16-17-34(33,37)19-18-32(3,4)5)28-14-10-24-20-26(36)13-15-27(24)31(28)29/h8-9,11-12,20,22,27-31,37H,10,13-17,21H2,1-7H3/t27-,28-,29+,30-,31+,33-,34+/m0/s1
DMR12S0	CS	CC(C)N(C)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(C#CC(C)(C)C)O)[C@H]4[C@H]2[C@H]5CCC(=O)C=C5CC4)C
DMR12S0	IK	VNLTWJIWEYPBIF-KMSLUKAPSA-N
DMR12S0	IU	(8R,9S,10R,11S,13S,14S,17S)-17-(3,3-dimethylbut-1-ynyl)-17-hydroxy-13-methyl-11-[4-[methyl(propan-2-yl)amino]phenyl]-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DMR12S0	DE	Solid tumour/cancer

DMS8NM5	ID	DMS8NM5
DMS8NM5	DN	OS2966
DMS8NM5	HS	Phase 1
DMS8NM5	CP	OncoSynergy
DMS8NM5	DT	Antibody
DMS8NM5	DE	Glioblastoma of brain

DMF2CZ9	ID	DMF2CZ9
DMF2CZ9	DN	OSI-930
DMF2CZ9	HS	Phase 1
DMF2CZ9	SN	OSI 930; OSI930; OSI-930 is a multi-targeted tyrosine kinase inhibitor; 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide
DMF2CZ9	CP	OSI Pharmaceuticals
DMF2CZ9	TC	Anticancer Agents
DMF2CZ9	DT	Small molecular drug
DMF2CZ9	PC	9868037
DMF2CZ9	MW	443.4
DMF2CZ9	FM	C22H16F3N3O2S
DMF2CZ9	IC	InChI=1S/C22H16F3N3O2S/c23-22(24,25)30-16-7-5-15(6-8-16)28-21(29)20-19(10-12-31-20)27-13-14-9-11-26-18-4-2-1-3-17(14)18/h1-12,27H,13H2,(H,28,29)
DMF2CZ9	CS	C1=CC=C2C(=C1)C(=CC=N2)CNC3=C(SC=C3)C(=O)NC4=CC=C(C=C4)OC(F)(F)F
DMF2CZ9	IK	FGTCROZDHDSNIO-UHFFFAOYSA-N
DMF2CZ9	IU	3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide
DMF2CZ9	CA	CAS 728033-96-3
DMF2CZ9	CB	CHEBI:91433
DMF2CZ9	DE	Solid tumour/cancer

DMI24RF	ID	DMI24RF
DMI24RF	DN	OT-82
DMI24RF	HS	Phase 1
DMI24RF	SN	1800487-55-1; N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-(pyridin-4-yl)benzamide; OT82; SCHEMBL16869651; NSC826040; NSC-826040; HY-136241; CS-0120951
DMI24RF	CP	OncoTartis
DMI24RF	DT	Small molecular drug
DMI24RF	PC	118203189
DMI24RF	MW	424.5
DMI24RF	FM	C26H21FN4O
DMI24RF	IC	InChI=1S/C26H21FN4O/c27-24-8-4-19(5-9-24)3-6-22-16-23(7-10-25(22)21-11-14-28-15-12-21)26(32)29-13-1-2-20-17-30-31-18-20/h4-5,7-12,14-18H,1-2,13H2,(H,29,32)(H,30,31)
DMI24RF	CS	C1=CC(=CC=C1C#CC2=C(C=CC(=C2)C(=O)NCCCC3=CNN=C3)C4=CC=NC=C4)F
DMI24RF	IK	CEPAXRIKSUXHHB-UHFFFAOYSA-N
DMI24RF	IU	3-[2-(4-fluorophenyl)ethynyl]-N-[3-(1H-pyrazol-4-yl)propyl]-4-pyridin-4-ylbenzamide
DMI24RF	DE	Lymphoma

DMWIEC1	ID	DMWIEC1
DMWIEC1	DN	OTSA-101-DTPA-90Y
DMWIEC1	HS	Phase 1
DMWIEC1	CP	University of Tokyo/Centre Leon-Berard
DMWIEC1	DT	Antibody
DMWIEC1	DE	Synovial sarcoma

DMF5KNO	ID	DMF5KNO
DMF5KNO	DN	OTSSP167
DMF5KNO	HS	Phase 1
DMF5KNO	SN	OTSSP 167; OTSSP-167; AMX10201
DMF5KNO	DT	Small molecular drug
DMF5KNO	PC	135398499
DMF5KNO	MW	487.4
DMF5KNO	FM	C25H28Cl2N4O2
DMF5KNO	IC	InChI=1S/C25H28Cl2N4O2/c1-14(32)18-12-28-22-9-8-21(16-10-19(26)25(33)20(27)11-16)30-24(22)23(18)29-17-6-4-15(5-7-17)13-31(2)3/h8-12,15,17,33H,4-7,13H2,1-3H3,(H,28,29)
DMF5KNO	CS	CC(=O)C1=CN=C2C=CC(=NC2=C1NC3CCC(CC3)CN(C)C)C4=CC(=C(C(=C4)Cl)O)Cl
DMF5KNO	IK	DKZYXHCYPUVGAF-UHFFFAOYSA-N
DMF5KNO	IU	1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone
DMF5KNO	CA	CAS 1431697-89-0
DMF5KNO	CB	CHEBI:95088
DMF5KNO	DE	Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Myelodysplastic syndrome; Myeloproliferative neoplasm

DMN4LMT	ID	DMN4LMT
DMN4LMT	DN	Oxeglitazar
DMN4LMT	HS	Phase 1
DMN4LMT	SN	EMD-336340; EML-16156; EML-4156; LM-4156
DMN4LMT	CP	Merck Sante SA
DMN4LMT	DT	Small molecular drug
DMN4LMT	PC	6445229
DMN4LMT	MW	314.4
DMN4LMT	FM	C19H22O4
DMN4LMT	IC	InChI=1S/C19H22O4/c1-13(9-18(20)21)5-6-14-11-19(2,3)12-23-17-8-7-15(22-4)10-16(14)17/h5-11H,12H2,1-4H3,(H,20,21)/b6-5+,13-9+
DMN4LMT	CS	C/C(=C\\C(=O)O)/C=C/C1=CC(COC2=C1C=C(C=C2)OC)(C)C
DMN4LMT	IK	FVGXANXBVWECQE-BYWGDBCOSA-N
DMN4LMT	IU	(2E,4E)-5-(7-methoxy-3,3-dimethyl-2H-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid
DMN4LMT	CA	CAS 280585-34-4
DMN4LMT	DE	Gout

DMXZOI0	ID	DMXZOI0
DMXZOI0	DN	P11187
DMXZOI0	HS	Phase 1
DMXZOI0	CP	Piramal enterprises
DMXZOI0	DE	Type-2 diabetes

DMXHKYJ	ID	DMXHKYJ
DMXHKYJ	DN	P1446A-05
DMXHKYJ	HS	Phase 1
DMXHKYJ	CP	Nicholas Piramal
DMXHKYJ	PC	67409219
DMXHKYJ	MW	469.8
DMXHKYJ	FM	C22H19ClF3NO5
DMXHKYJ	IC	InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1
DMXHKYJ	CS	CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=C(C=C(C=C4)C(F)(F)F)Cl)O)O
DMXHKYJ	IK	MRPGRAKIAJJGMM-OCCSQVGLSA-N
DMXHKYJ	IU	2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one
DMXHKYJ	CA	CAS 1000023-04-0
DMXHKYJ	DE	Solid tumour/cancer

DMJ3PNS	ID	DMJ3PNS
DMJ3PNS	DN	P-2745
DMJ3PNS	HS	Phase 1
DMJ3PNS	CP	Piramal Life Sciences Ltd
DMJ3PNS	DE	Chronic myelogenous leukaemia

DMIYQEM	ID	DMIYQEM
DMIYQEM	DN	P-7170
DMIYQEM	HS	Phase 1
DMIYQEM	CP	Piramal Life Sciences Ltd
DMIYQEM	DE	Solid tumour/cancer

DMNZQU5	ID	DMNZQU5
DMNZQU5	DN	P-7435
DMNZQU5	HS	Phase 1
DMNZQU5	SN	DGAT1 inhibitors (diabetes/metabolic disorder), Piramal Life Sciences
DMNZQU5	CP	Piramal enterprises
DMNZQU5	DE	Diabetic complication

DMYQUIP	ID	DMYQUIP
DMYQUIP	DN	PAC1
DMYQUIP	HS	Phase 1
DMYQUIP	SN	PAC-1
DMYQUIP	DT	Small molecular drug
DMYQUIP	PC	135421197
DMYQUIP	MW	392.5
DMYQUIP	FM	C23H28N4O2
DMYQUIP	IC	InChI=1S/C23H28N4O2/c1-2-7-20-10-6-11-21(23(20)29)16-24-25-22(28)18-27-14-12-26(13-15-27)17-19-8-4-3-5-9-19/h2-6,8-11,16,29H,1,7,12-15,17-18H2,(H,25,28)/b24-16+
DMYQUIP	CS	C=CCC1=C(C(=CC=C1)/C=N/NC(=O)CN2CCN(CC2)CC3=CC=CC=C3)O
DMYQUIP	IK	YQNRVGJCPCNMKT-LFVJCYFKSA-N
DMYQUIP	IU	2-(4-benzylpiperazin-1-yl)-N-[(E)-(2-hydroxy-3-prop-2-enylphenyl)methylideneamino]acetamide
DMYQUIP	CA	CAS 315183-21-2
DMYQUIP	DE	Anaplastic astrocytoma; Recurrent glioblastoma

DMX9AK6	ID	DMX9AK6
DMX9AK6	DN	PACAP38
DMX9AK6	HS	Phase 1
DMX9AK6	SN	H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-OH
DMX9AK6	DE	Nerve injury

DMXQ4NO	ID	DMXQ4NO
DMXQ4NO	DN	Palomid-529
DMXQ4NO	HS	Phase 1
DMXQ4NO	SN	Palomid 529; 914913-88-5; P529; Palomid 529 (P529); 8-(1-Hydroxyethyl)-2-methoxy-3-((4-methoxybenzyl)oxy)-6H-benzo[c]chromen-6-one; SG 00529; SG-00529; P-529; 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one; UNII-XV9409EWG4; 6H-Dibenzo(b,d)pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-; 8-(1-hydroxyethyl)-2-methoxy-3-(4-methoxybenzyloxy)-6H-benzo[c]chromen-6-one; Palomid529; 6H-Dibenzo[b,d]pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]-; 8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxybenzyl)oxy]-6H-benzo[c]chromen-6-one; RES-529; XV9409EWG4; Palomid 529,P529; cc-513; MLS006011187; Palomid 529 - P529; SCHEMBL290034; C22H26Cl2N2O8; CHEMBL2141712; EX-A254; QCR-215; SYN5215; BCPP000131; HMS3655L14; HMS3673G05; AMY22735; BCP02474; ABP000907; MFCD18633224; NSC775306; NSC801008; s2238; 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo(c)chromen-6-one; AKOS024463339; ACN-030389; BCP9001049; CCG-268719; CS-0258; DB12812; NSC-775306; NSC-801008; Palomid 529 (P529) /P529; SB16564; SG00529; 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-6h-dibenzo(b,d)pyran-6-one; NCGC00263125-01; NCGC00263125-10; AC-31523; AK160239; AS-16573; HY-14581; SMR004702956; AB0008147; SW219676-1; Y0291; W-5766; J-519339; Q27294013
DMXQ4NO	DT	Small molecular drug
DMXQ4NO	PC	11998575
DMXQ4NO	MW	406.4
DMXQ4NO	FM	C24H22O6
DMXQ4NO	IC	InChI=1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3
DMXQ4NO	CS	CC(C1=CC2=C(C=C1)C3=CC(=C(C=C3OC2=O)OCC4=CC=C(C=C4)OC)OC)O
DMXQ4NO	IK	YEAHTLOYHVWAKW-UHFFFAOYSA-N
DMXQ4NO	IU	8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one
DMXQ4NO	CA	CAS 914913-88-5
DMXQ4NO	DE	Macular degeneration

DMY9LG1	ID	DMY9LG1
DMY9LG1	DN	PAN-90806
DMY9LG1	HS	Phase 1
DMY9LG1	CP	OSI Pharmaceuticals Inc
DMY9LG1	DE	Solid tumour/cancer; Diabetic retinopathy

DMZSD3T	ID	DMZSD3T
DMZSD3T	DN	Patient-derived CD19- and CD22 specific CAR
DMZSD3T	HS	Phase 1
DMZSD3T	CP	Seattle Children's Hospital
DMZSD3T	DT	CAR T Cell Therapy (Dual specific)
DMZSD3T	DE	leukaemia; Lymphoma

DMFSMCB	ID	DMFSMCB
DMFSMCB	DN	Patritumab
DMFSMCB	HS	Phase 1
DMFSMCB	CP	Daiichi sankyo
DMFSMCB	DT	Antibody
DMFSMCB	DE	Non-small-cell lung cancer

DMDC9TB	ID	DMDC9TB
DMDC9TB	DN	P-BCMA-101 CAR-T cells
DMDC9TB	HS	Phase 1
DMDC9TB	CP	Poseida Therapeutics, Inc.
DMDC9TB	DT	CAR T Cell Therapy
DMDC9TB	DE	Multiple myeloma

DMOPGXM	ID	DMOPGXM
DMOPGXM	DN	PBF-1129
DMOPGXM	HS	Phase 1
DMOPGXM	CP	Palobiofarma Barcelona, Spain
DMOPGXM	DE	Non-small-cell lung cancer

DMBSQH9	ID	DMBSQH9
DMBSQH9	DN	PBF-999
DMBSQH9	HS	Phase 1
DMBSQH9	SN	CHEMBL3942498; SCHEMBL15905362; BDBM247392; SB18883; US9447095, 42; 5-bromo-4-N-prop-2-ynyl-2-(1,2,4-triazol-1-yl)pyrimidine-4,6-diamine; 1620909-95-6
DMBSQH9	CP	Palobiofarma
DMBSQH9	DT	Small molecular drug
DMBSQH9	PC	77107498
DMBSQH9	MW	294.11
DMBSQH9	FM	C9H8BrN7
DMBSQH9	IC	InChI=1S/C9H8BrN7/c1-2-3-13-8-6(10)7(11)15-9(16-8)17-5-12-4-14-17/h1,4-5H,3H2,(H3,11,13,15,16)
DMBSQH9	CS	C#CCNC1=NC(=NC(=C1Br)N)N2C=NC=N2
DMBSQH9	IK	OQCWNHHZPYJHQR-UHFFFAOYSA-N
DMBSQH9	IU	5-bromo-4-N-prop-2-ynyl-2-(1,2,4-triazol-1-yl)pyrimidine-4,6-diamine
DMBSQH9	DE	Solid tumour/cancer; Huntington disease

DM0O2N4	ID	DM0O2N4
DM0O2N4	DN	pbi-shRNA EWS-FLI-Type 1
DM0O2N4	HS	Phase 1
DM0O2N4	CP	Gradalis
DM0O2N4	DT	Short hairpin RNA
DM0O2N4	DE	Ewing sarcoma

DM529QO	ID	DM529QO
DM529QO	DN	pbi-shRNA STMN1
DM529QO	HS	Phase 1
DM529QO	CP	Gradalis
DM529QO	DT	Short hairpin RNA
DM529QO	DE	Breast cancer; Solid tumour/cancer

DMMR4E7	ID	DMMR4E7
DMMR4E7	DN	PBSVax
DMMR4E7	HS	Phase 1
DMMR4E7	CP	Profectus biosciences
DMMR4E7	DE	Human immunodeficiency virus infection

DM23K45	ID	DM23K45
DM23K45	DN	Pc4
DM23K45	HS	Phase 1
DM23K45	SN	Pc4; Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC
DM23K45	CP	Case Western Reserve University
DM23K45	DE	Psoriasis vulgaris

DMNHSI8	ID	DMNHSI8
DMNHSI8	DN	PCO371
DMNHSI8	HS	Phase 1
DMNHSI8	SN	Pco-371; UNII-TE53TU0WSQ; TE53TU0WSQ; PCO-371; 1613373-33-3; SCHEMBL17104864; CHEMBL3976807; US9428505, Compound 7; BDBM64562; PC-0371; J3.591.565F; 2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-
DMNHSI8	CP	Chugai Pharma USA Berkeley Heights, NJ
DMNHSI8	PC	76283707
DMNHSI8	MW	635.7
DMNHSI8	FM	C29H32F3N5O6S
DMNHSI8	IC	InChI=1S/C29H32F3N5O6S/c1-17-15-20(37-26(40)34-24(38)27(37,3)4)16-18(2)22(17)9-14-44(41,42)36-12-10-28(11-13-36)25(39)33-23(35-28)19-5-7-21(8-6-19)43-29(30,31)32/h5-8,15-16H,9-14H2,1-4H3,(H,33,35,39)(H,34,38,40)
DMNHSI8	CS	CC1=CC(=CC(=C1CCS(=O)(=O)N2CCC3(CC2)C(=O)NC(=N3)C4=CC=C(C=C4)OC(F)(F)F)C)N5C(=O)NC(=O)C5(C)C
DMNHSI8	IK	LDZJFVOUPUFOHX-UHFFFAOYSA-N
DMNHSI8	IU	1-[3,5-dimethyl-4-[2-[[4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl]sulfonyl]ethyl]phenyl]-5,5-dimethylimidazolidine-2,4-dione
DMNHSI8	CA	CAS 1613373-33-3
DMNHSI8	DE	Hypoparathyroidism

DMH86KO	ID	DMH86KO
DMH86KO	DN	PCSK9 Adnectin
DMH86KO	HS	Phase 1
DMH86KO	SN	PCSK9 Adnectin (cardiovascular); Adnectin program (cardiovascular disease), Adnexus/BMS; PCSK9 Adnectin (cardiovascular), Bristol-Myers Squibb
DMH86KO	CP	Bristol-myers squibb
DMH86KO	DE	Cardiovascular disease

DM74YO8	ID	DM74YO8
DM74YO8	DN	PDC-41
DM74YO8	HS	Phase 1
DM74YO8	SN	THG-113; THG-113.31; PDC-31 (iv, premature labor); PGF2 alpha antagonist (primary dysmenorrhea/topical), PDC Biotech; Prostaglandin F2 alpha antagonist (primary dysmenorrhea/topical), PDC Biotech; PDC-31 (iv, premature labor), PDC; PGF2 alpha antagonist (injectable, premature labor/dysmenorrhea), PDC Biotech; Prostaglandin F2 alpha antagonist (injectable, premature labor/dysmenorrhea), PDC Biotech
DM74YO8	CP	Theratechnologies Inc
DM74YO8	DE	Dysmenorrhea

DMLJHM2	ID	DMLJHM2
DMLJHM2	DN	PD-L1 t-haNK
DMLJHM2	HS	Phase 1
DMLJHM2	CP	ImmunityBio; NantKwest
DMLJHM2	DT	CAR T Cell Therapy
DMLJHM2	DE	Solid tumour/cancer

DM4CY2G	ID	DM4CY2G
DM4CY2G	DN	PEDF gene therapy
DM4CY2G	HS	Phase 1
DM4CY2G	SN	AdPEDF; AdGVPEDF.11D; PEDF gene therapy (ophthalmic); PEDF gene therapy (ophthalmic), GenVec; Pigment epithelium-derived factor gene therapy, GenVec
DM4CY2G	CP	GenVec Inc
DM4CY2G	DE	Macular degeneration

DMB5JWX	ID	DMB5JWX
DMB5JWX	DN	Pegadricase
DMB5JWX	HS	Phase 1
DMB5JWX	CP	3SBio
DMB5JWX	PC	86278331
DMB5JWX	MW	304.34
DMB5JWX	FM	C13H24N2O6
DMB5JWX	IC	InChI=1S/C13H24N2O6/c1-20-8-9-21-12(17)6-5-11(16)15-7-3-2-4-10(14)13(18)19/h10H,2-9,14H2,1H3,(H,15,16)(H,18,19)/t10-/m0/s1
DMB5JWX	CS	COCCOC(=O)CCC(=O)NCCCC[C@@H](C(=O)O)N
DMB5JWX	IK	PNFORBBPPMQASU-JTQLQIEISA-N
DMB5JWX	IU	(2S)-2-amino-6-[[4-(2-methoxyethoxy)-4-oxobutanoyl]amino]hexanoic acid
DMB5JWX	CA	CAS 1040753-26-1
DMB5JWX	DE	Gout

DMW7VGZ	ID	DMW7VGZ
DMW7VGZ	DN	PegCNTF
DMW7VGZ	HS	Phase 1
DMW7VGZ	SN	Piperidine, 1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-; Sch-37370; 117796-52-8; Sch 37370; UNII-GA60WRR45J; N-Acetyldesloratadine; GA60WRR45J; CHEMBL10971; RESPATADINE; ethanone, 1-[4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]-; AC1L1TPN; AC1Q5KQ9; SCHEMBL3071641; GTPL1853; DTXSID10151911; FLTBEMVEAFMWDD-UHFFFAOYSA-N; ZINC596712; BDBM50007473; 1-Acetyl-4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cycloheptal(1,2-b)pyridin-11-ylidine)piperidine; SCH-37370
DMW7VGZ	CP	Nektar/Regeneron
DMW7VGZ	DT	Small molecular drug
DMW7VGZ	PC	60680
DMW7VGZ	MW	352.9
DMW7VGZ	FM	C21H21ClN2O
DMW7VGZ	IC	InChI=1S/C21H21ClN2O/c1-14(25)24-11-8-15(9-12-24)20-19-7-6-18(22)13-17(19)5-4-16-3-2-10-23-21(16)20/h2-3,6-7,10,13H,4-5,8-9,11-12H2,1H3
DMW7VGZ	CS	CC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
DMW7VGZ	IK	FLTBEMVEAFMWDD-UHFFFAOYSA-N
DMW7VGZ	IU	1-[4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidin-1-yl]ethanone
DMW7VGZ	CA	CAS 117796-52-8
DMW7VGZ	DE	Obesity

DM0E37K	ID	DM0E37K
DM0E37K	DN	Pegdinetanib
DM0E37K	HS	Phase 1
DM0E37K	SN	BMS-844203
DM0E37K	CP	Bristol-Myers Squibb
DM0E37K	PC	86278317
DM0E37K	MW	694.8
DM0E37K	FM	C27H46N6O13S
DM0E37K	IC	InChI=1S/C27H46N6O13S/c1-42-12-8-31-26(40)45-15-18(16-46-27(41)32-9-13-43-2)44-11-3-4-21(34)29-6-7-30-22(35)5-10-33-23(36)14-20(24(33)37)47-17-19(28)25(38)39/h18-20H,3-17,28H2,1-2H3,(H,29,34)(H,30,35)(H,31,40)(H,32,41)(H,38,39)/t19-,20?/m0/s1
DM0E37K	CS	COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCNC(=O)CCN1C(=O)CC(C1=O)SC[C@@H](C(=O)O)N
DM0E37K	IK	PQEJXGNZBLONLG-XJDOXCRVSA-N
DM0E37K	IU	(2R)-2-amino-3-[1-[3-[2-[4-[1,3-bis(2-methoxyethylcarbamoyloxy)propan-2-yloxy]butanoylamino]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid
DM0E37K	CA	CAS 906450-24-6
DM0E37K	DE	Non-small-cell lung cancer

DMQ4Z1P	ID	DMQ4Z1P
DMQ4Z1P	DN	Peginterferon beta
DMQ4Z1P	HS	Phase 1
DMQ4Z1P	SN	AZ-01; AZ-60; Jak2 inhibitors (myeloproliferative disorders); Jak2 inhibitors (myeloproliferative disorders), AstraZeneca
DMQ4Z1P	CP	Allozyne
DMQ4Z1P	DE	Multiple sclerosis

DMMEPKR	ID	DMMEPKR
DMMEPKR	DN	PEG-Interferon lambda (IL-29)
DMMEPKR	HS	Phase 1
DMMEPKR	CP	ZymoGenetics
DMMEPKR	DE	Virus infection

DMHV58T	ID	DMHV58T
DMHV58T	DN	Peldesine
DMHV58T	HS	Phase 1
DMHV58T	DT	Small molecular drug
DMHV58T	PC	135413525
DMHV58T	MW	241.25
DMHV58T	FM	C12H11N5O
DMHV58T	IC	InChI=1S/C12H11N5O/c13-12-16-9-8(4-7-2-1-3-14-5-7)6-15-10(9)11(18)17-12/h1-3,5-6,15H,4H2,(H3,13,16,17,18)
DMHV58T	CS	C1=CC(=CN=C1)CC2=CNC3=C2N=C(NC3=O)N
DMHV58T	IK	DOHVAKFYAHLCJP-UHFFFAOYSA-N
DMHV58T	IU	2-amino-7-(pyridin-3-ylmethyl)-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMHV58T	CA	CAS 133432-71-0

DMTEG6B	ID	DMTEG6B
DMTEG6B	DN	PENCLOMEDINE
DMTEG6B	HS	Phase 1
DMTEG6B	SN	Penclomidine; CRC-88-04; 3,5-Dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine
DMTEG6B	DT	Small molecular drug
DMTEG6B	PC	60203
DMTEG6B	MW	325.4
DMTEG6B	FM	C8H6Cl5NO2
DMTEG6B	IC	InChI=1S/C8H6Cl5NO2/c1-15-5-3(9)6(8(11,12)13)14-7(16-2)4(5)10/h1-2H3
DMTEG6B	CS	COC1=C(C(=NC(=C1Cl)OC)C(Cl)(Cl)Cl)Cl
DMTEG6B	IK	DZVPGIORVGSQMC-UHFFFAOYSA-N
DMTEG6B	IU	3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine
DMTEG6B	CA	CAS 108030-77-9
DMTEG6B	DE	Solid tumour/cancer

DM0BNLC	ID	DM0BNLC
DM0BNLC	DN	PENNVAX-6
DM0BNLC	HS	Phase 1
DM0BNLC	CP	Inovio pharmaceuticals; national institute of allergy and infectious diseases
DM0BNLC	DE	Human immunodeficiency virus infection

DMUTISK	ID	DMUTISK
DMUTISK	DN	Pennvax-B
DMUTISK	HS	Phase 1
DMUTISK	SN	Pennvax-B (TN)
DMUTISK	CP	Inovio Pharmaceuticals
DMUTISK	DT	Vaccine
DMUTISK	DE	Human immunodeficiency virus infection

DM7YX8G	ID	DM7YX8G
DM7YX8G	DN	Pennvax-G
DM7YX8G	HS	Phase 1
DM7YX8G	SN	Pennvax-G (TN)
DM7YX8G	CP	Inovio Pharmaceuticals
DM7YX8G	DT	Vaccine
DM7YX8G	DE	Human immunodeficiency virus infection

DMVYRH2	ID	DMVYRH2
DMVYRH2	DN	Perifosine
DMVYRH2	HS	Phase 1
DMVYRH2	SN	D 21266; NKA17; D-21266; KRX-0401; KRX-0401, NSC 639966; Octadecyl-(1,1-dimethyl-4-piperidylio)phosphate; Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt; Piperidinium, 4-((hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethyl-, inner salt; (1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate; 4-((Hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethylpiperidinium inner salt
DMVYRH2	CP	AEterna Zentaris
DMVYRH2	TC	Anticancer Agents
DMVYRH2	DT	Small molecular drug
DMVYRH2	PC	148177
DMVYRH2	MW	461.7
DMVYRH2	FM	C25H52NO4P
DMVYRH2	IC	InChI=1S/C25H52NO4P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-29-31(27,28)30-25-20-22-26(2,3)23-21-25/h25H,4-24H2,1-3H3
DMVYRH2	CS	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C
DMVYRH2	IK	SZFPYBIJACMNJV-UHFFFAOYSA-N
DMVYRH2	IU	(1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate
DMVYRH2	CA	CAS 157716-52-4
DMVYRH2	CB	CHEBI:67272
DMVYRH2	DE	Solid tumour/cancer

DM5PUO0	ID	DM5PUO0
DM5PUO0	DN	PF-00337210
DM5PUO0	HS	Phase 1
DM5PUO0	SN	PF-00337210; N,2-Dimethyl-6-{[7-(2-Morpholin-4-Ylethoxy)quinolin-4-Yl]oxy}-1-Benzofuran-3-Carboxamide; SCHEMBL899025; LGXVKMDGSIWEHL-UHFFFAOYSA-N; ZINC34783303; PF-337210; N,2-dimethyl-6-[7-(2-morpholinoethoxy)quinolin-4-yloxy]benzofuran-3-carboxamide
DM5PUO0	CP	Pfizer New York, NY
DM5PUO0	DT	Small molecular drug
DM5PUO0	PC	11236560
DM5PUO0	MW	461.5
DM5PUO0	FM	C26H27N3O5
DM5PUO0	IC	InChI=1S/C26H27N3O5/c1-17-25(26(30)27-2)21-6-4-19(16-24(21)33-17)34-23-7-8-28-22-15-18(3-5-20(22)23)32-14-11-29-9-12-31-13-10-29/h3-8,15-16H,9-14H2,1-2H3,(H,27,30)
DM5PUO0	CS	CC1=C(C2=C(O1)C=C(C=C2)OC3=C4C=CC(=CC4=NC=C3)OCCN5CCOCC5)C(=O)NC
DM5PUO0	IK	LGXVKMDGSIWEHL-UHFFFAOYSA-N
DM5PUO0	IU	N,2-dimethyl-6-[7-(2-morpholin-4-ylethoxy)quinolin-4-yl]oxy-1-benzofuran-3-carboxamide
DM5PUO0	CA	CAS 854514-88-8
DM5PUO0	DE	Solid tumour/cancer

DM93LMS	ID	DM93LMS
DM93LMS	DN	PF-01247324
DM93LMS	HS	Phase 1
DM93LMS	SN	Nav1.8 blockers (pain); Nav1.8 blockers (pain), Pfizer; Voltage-gated sodium channel 1.8 blockers (pain), Pfizer
DM93LMS	CP	Pfizer Inc
DM93LMS	DT	Small molecular drug
DM93LMS	PC	11659955
DM93LMS	MW	330.6
DM93LMS	FM	C13H10Cl3N3O
DM93LMS	IC	InChI=1S/C13H10Cl3N3O/c1-18-13(20)10-3-2-7(12(17)19-10)8-4-6(14)5-9(15)11(8)16/h2-5H,1H3,(H2,17,19)(H,18,20)
DM93LMS	CS	CNC(=O)C1=NC(=C(C=C1)C2=C(C(=CC(=C2)Cl)Cl)Cl)N
DM93LMS	IK	HPIUHDCRVYDAEJ-UHFFFAOYSA-N
DM93LMS	IU	6-amino-N-methyl-5-(2,3,5-trichlorophenyl)pyridine-2-carboxamide
DM93LMS	CA	CAS 875051-72-2
DM93LMS	DE	Pain

DMLGD0V	ID	DMLGD0V
DMLGD0V	DN	PF-04776548
DMLGD0V	HS	Phase 1
DMLGD0V	SN	PF-04776548 (oral, HIV infection)
DMLGD0V	CP	Pfizer Inc
DMLGD0V	DE	Human immunodeficiency virus infection

DMDSCQG	ID	DMDSCQG
DMDSCQG	DN	PF-04840082
DMDSCQG	HS	Phase 1
DMDSCQG	CP	Pfizer New York, NY
DMDSCQG	DE	Osteoporosis

DMZ8QRI	ID	DMZ8QRI
DMZ8QRI	DN	PF-04995274
DMZ8QRI	HS	Phase 1
DMZ8QRI	SN	UNII-XI179PG9LV; PF 04995274; XI179PG9LV; 1331782-27-4; CHEMBL2152922; (R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol; PF04995274; compound 2d [PMID: 22974325]; SCHEMBL619629; GTPL9059; WLLOFQROROXOMO-GOSISDBHSA-N; ZINC95577747; BDBM50398598; DB12675; NCGC00386746-01; PF-04995274, &gt; 4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol
DMZ8QRI	CP	Pfizer Inc
DMZ8QRI	DT	Small molecular drug
DMZ8QRI	PC	53354764
DMZ8QRI	MW	432.5
DMZ8QRI	FM	C23H32N2O6
DMZ8QRI	IC	InChI=1S/C23H32N2O6/c26-23(7-12-27-13-8-23)16-25-9-4-17(5-10-25)14-29-22-21-19(30-18-6-11-28-15-18)2-1-3-20(21)31-24-22/h1-3,17-18,26H,4-16H2/t18-/m1/s1
DMZ8QRI	CS	C1COC[C@@H]1OC2=CC=CC3=C2C(=NO3)OCC4CCN(CC4)CC5(CCOCC5)O
DMZ8QRI	IK	WLLOFQROROXOMO-GOSISDBHSA-N
DMZ8QRI	IU	4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol
DMZ8QRI	CA	CAS 1331782-27-4
DMZ8QRI	DE	Alzheimer disease

DMAEK3L	ID	DMAEK3L
DMAEK3L	DN	PF-05082566
DMAEK3L	HS	Phase 1
DMAEK3L	CP	Pfizer
DMAEK3L	DE	Non-hodgkin lymphoma; Solid tumour/cancer

DM4QPT0	ID	DM4QPT0
DM4QPT0	DN	PF-05105679
DM4QPT0	HS	Phase 1
DM4QPT0	CP	Pfizer Inc
DM4QPT0	PC	60195662
DM4QPT0	MW	428.5
DM4QPT0	FM	C26H21FN2O3
DM4QPT0	IC	InChI=1S/C26H21FN2O3/c1-17(19-9-11-23(27)12-10-19)29(16-18-5-4-7-21(13-18)26(31)32)25(30)22-14-20-6-2-3-8-24(20)28-15-22/h2-15,17H,16H2,1H3,(H,31,32)/t17-/m1/s1
DM4QPT0	CS	C[C@H](C1=CC=C(C=C1)F)N(CC2=CC(=CC=C2)C(=O)O)C(=O)C3=CC4=CC=CC=C4N=C3
DM4QPT0	IK	BXNMZRPTQFVRFA-QGZVFWFLSA-N
DM4QPT0	IU	3-[[[(1R)-1-(4-fluorophenyl)ethyl]-(quinoline-3-carbonyl)amino]methyl]benzoic acid
DM4QPT0	CA	CAS 1398583-31-7
DM4QPT0	DE	Pain

DMUF6W9	ID	DMUF6W9
DMUF6W9	DN	PF-05186462
DMUF6W9	HS	Phase 1
DMUF6W9	CP	Pfizer Inc
DMUF6W9	DE	Pain

DM7B2JC	ID	DM7B2JC
DM7B2JC	DN	PF-05190457
DM7B2JC	HS	Phase 1
DM7B2JC	CP	Pfizer Inc
DM7B2JC	PC	58438464
DM7B2JC	MW	512.7
DM7B2JC	FM	C29H32N6OS
DM7B2JC	IC	InChI=1S/C29H32N6OS/c1-19-11-25(31-18-30-19)22-3-5-24-21(12-22)4-6-26(24)35-16-29(17-35)7-9-33(10-8-29)27(36)13-23-15-34-14-20(2)37-28(34)32-23/h3,5,11-12,14-15,18,26H,4,6-10,13,16-17H2,1-2H3/t26-/m1/s1
DM7B2JC	CS	CC1=CC(=NC=N1)C2=CC3=C(C=C2)[C@@H](CC3)N4CC5(C4)CCN(CC5)C(=O)CC6=CN7C=C(SC7=N6)C
DM7B2JC	IK	ZIUDADZJCKGWKR-AREMUKBSSA-N
DM7B2JC	IU	2-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-1-[2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone
DM7B2JC	CA	CAS 1334782-79-4
DM7B2JC	DE	Type-2 diabetes

DM7OC9K	ID	DM7OC9K
DM7OC9K	DN	PF-05230905
DM7OC9K	HS	Phase 1
DM7OC9K	SN	ATN-192
DM7OC9K	CP	Pfizer New York, NY
DM7OC9K	DE	Rheumatoid arthritis

DM7GSZL	ID	DM7GSZL
DM7GSZL	DN	PF-05230907
DM7GSZL	HS	Phase 1
DM7GSZL	DE	Nontraumatic intracerebral hemorrhage

DMQYBSH	ID	DMQYBSH
DMQYBSH	DN	PF-05231023
DMQYBSH	HS	Phase 1
DMQYBSH	CP	Pfizer
DMQYBSH	DT	Antibody
DMQYBSH	DE	Type-2 diabetes

DM2NTBL	ID	DM2NTBL
DM2NTBL	DN	PF-05241328
DM2NTBL	HS	Phase 1
DM2NTBL	CP	Pfizer Inc
DM2NTBL	PC	68109743
DM2NTBL	MW	436.9
DM2NTBL	FM	C19H21ClN4O4S
DM2NTBL	IC	InChI=1S/C19H21ClN4O4S/c1-11(2)10-28-19-16(20)8-14(9-21-19)24-17-6-5-13(7-15(17)12(3)22-24)18(25)23-29(4,26)27/h5-9,11H,10H2,1-4H3,(H,23,25)
DM2NTBL	CS	CC1=NN(C2=C1C=C(C=C2)C(=O)NS(=O)(=O)C)C3=CC(=C(N=C3)OCC(C)C)Cl
DM2NTBL	IK	RVTSXVZXEGFIPW-UHFFFAOYSA-N
DM2NTBL	IU	1-[5-chloro-6-(2-methylpropoxy)pyridin-3-yl]-3-methyl-N-methylsulfonylindazole-5-carboxamide
DM2NTBL	CA	CAS 1387633-03-5
DM2NTBL	DE	Pain

DM5KBDY	ID	DM5KBDY
DM5KBDY	DN	PF-06263507
DM5KBDY	HS	Phase 1
DM5KBDY	CP	Pfizer
DM5KBDY	DT	Antibody
DM5KBDY	DE	Solid tumour/cancer

DMASKX9	ID	DMASKX9
DMASKX9	DN	PF-06342674
DMASKX9	HS	Phase 1
DMASKX9	CP	Pfizer
DMASKX9	DE	Type-1 diabetes; Type-2 diabetes

DMGB32Z	ID	DMGB32Z
DMGB32Z	DN	PF-06427878
DMGB32Z	HS	Phase 1
DMGB32Z	DE	Hyperlipidaemia; Cardiovascular disease

DM9UZTO	ID	DM9UZTO
DM9UZTO	DN	PF-06444752
DM9UZTO	HS	Phase 1
DM9UZTO	DE	Asthma

DMNLK5Y	ID	DMNLK5Y
DMNLK5Y	DN	PF-06647020
DMNLK5Y	HS	Phase 1
DMNLK5Y	CP	PfizerNew York, NY StemcentrxSouth San Francisco, CA
DMNLK5Y	DE	Solid tumour/cancer

DM056JD	ID	DM056JD
DM056JD	DN	PF-06648671
DM056JD	HS	Phase 1
DM056JD	SN	1587727-31-8; 2-[(1S)-1-[(2S,5R)-5-[4-Chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione; CHEMBL3951810; SCHEMBL15611304; BDBM193081; HY-120789; CS-0079177; US9193726, 69; Q29213634; 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione
DM056JD	CP	Pfizer
DM056JD	DT	Small molecular drug
DM056JD	PC	73441910
DM056JD	MW	538.9
DM056JD	FM	C25H23ClF4N4O3
DM056JD	IC	InChI=1S/C25H23ClF4N4O3/c1-13-11-32(12-31-13)19-3-4-20-24(36)33(7-8-34(20)23(19)35)14(2)21-5-6-22(37-21)15-9-18(27)17(26)10-16(15)25(28,29)30/h3-4,9-12,14,21-22H,5-8H2,1-2H3/t14-,21-,22+/m0/s1
DM056JD	CS	CC1=CN(C=N1)C2=CC=C3C(=O)N(CCN3C2=O)[C@@H](C)[C@@H]4CC[C@@H](O4)C5=CC(=C(C=C5C(F)(F)F)Cl)F
DM056JD	IK	AKCDDYGYIGPEKL-JQOQJDEVSA-N
DM056JD	IU	2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione
DM056JD	DE	Alzheimer disease

DMGUKRN	ID	DMGUKRN
DMGUKRN	DN	PF-06648671
DMGUKRN	HS	Phase 1
DMGUKRN	CP	Pfizer New York, NY
DMGUKRN	DE	Alzheimer disease

DMK19V6	ID	DMK19V6
DMK19V6	DN	PF-06671008
DMK19V6	HS	Phase 1
DMK19V6	CP	PfizerNew York, NY
DMK19V6	DE	Solid tumour/cancer

DM2ZJ1C	ID	DM2ZJ1C
DM2ZJ1C	DN	PF-06747143
DM2ZJ1C	HS	Phase 1
DM2ZJ1C	CP	PfizerNew York, NY
DM2ZJ1C	DE	Acute myeloid leukaemia

DMQUNRW	ID	DMQUNRW
DMQUNRW	DN	PF-06763809
DMQUNRW	HS	Phase 1
DMQUNRW	CP	Pfizer New York, NY
DMQUNRW	DE	Plaque psoriasis

DMDE9I6	ID	DMDE9I6
DMDE9I6	DN	PF-06801591
DMDE9I6	HS	Phase 1
DMDE9I6	CP	Pfizer New York, NY
DMDE9I6	DT	Antibody
DMDE9I6	DE	Solid tumour/cancer; Advanced malignancy; Non-hodgkin lymphoma

DMSJOTL	ID	DMSJOTL
DMSJOTL	DN	PF-06817024
DMSJOTL	HS	Phase 1
DMSJOTL	CP	Pfizer New York, NY
DMSJOTL	DE	Atopic dermatitis

DML3WT6	ID	DML3WT6
DML3WT6	DN	PF-06821497
DML3WT6	HS	Phase 1
DML3WT6	SN	UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD
DML3WT6	CP	Pfizer
DML3WT6	DT	Small molecular drug
DML3WT6	PC	118572065
DML3WT6	MW	467.3
DML3WT6	FM	C22H24Cl2N2O5
DML3WT6	IC	InChI=1S/C22H24Cl2N2O5/c1-11-6-17(29-2)15(21(27)25-11)8-26-5-4-13-16(23)7-14(19(24)18(13)22(26)28)20(30-3)12-9-31-10-12/h6-7,12,20H,4-5,8-10H2,1-3H3,(H,25,27)/t20-/m1/s1
DML3WT6	CS	CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)[C@@H](C4COC4)OC)Cl)OC
DML3WT6	IK	RXCVUHMIWHRLDF-HXUWFJFHSA-N
DML3WT6	IU	5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one
DML3WT6	CA	CAS 1844849-10-0
DML3WT6	DE	Small-cell lung cancer; Follicular lymphoma; Prostate cancer; Diffuse large B-cell lymphoma

DMRGVT9	ID	DMRGVT9
DMRGVT9	DN	PF-06826647
DMRGVT9	HS	Phase 1
DMRGVT9	CP	Pfizer New York, NY
DMRGVT9	DE	Plaque psoriasis

DMOX6EJ	ID	DMOX6EJ
DMOX6EJ	DN	PF-06840003
DMOX6EJ	HS	Phase 1
DMOX6EJ	SN	3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione; 198474-05-4; PF06840003; 2,5-Pyrrolidinedione, 3-(5-fluoro-1H-indol-3-yl)-; 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione; SCHEMBL5463464; GTPL9565; CTK0A0183; DTXSID00630149; MXKLDYKORJEOPR-UHFFFAOYSA-N; KS-000008MY; EX-A1186; EOS200271; AKOS027252536; CS-6186; AS-51973; HY-101111; 3-(5-Fluoro-1H-indol-3-yl)-pyrrolidine-2,5-dione
DMOX6EJ	CP	iTeos Therapeutics Gosselies, Belgium Pfizer New York, NY
DMOX6EJ	PC	23063810
DMOX6EJ	MW	232.21
DMOX6EJ	FM	C12H9FN2O2
DMOX6EJ	IC	InChI=1S/C12H9FN2O2/c13-6-1-2-10-7(3-6)9(5-14-10)8-4-11(16)15-12(8)17/h1-3,5,8,14H,4H2,(H,15,16,17)
DMOX6EJ	CS	C1C(C(=O)NC1=O)C2=CNC3=C2C=C(C=C3)F
DMOX6EJ	IK	MXKLDYKORJEOPR-UHFFFAOYSA-N
DMOX6EJ	IU	3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione
DMOX6EJ	CA	CAS 198474-05-4
DMOX6EJ	DE	Glioma

DMRZHV6	ID	DMRZHV6
DMRZHV6	DN	PF-06873600
DMRZHV6	HS	Phase 1
DMRZHV6	SN	QIEKHLDZKRQLLN-FOIQADDNSA-N; SCHEMBL19857421; HY-114177; CS-0078633
DMRZHV6	CP	Pfizer New York, NY
DMRZHV6	PC	134247638
DMRZHV6	MW	471.5
DMRZHV6	FM	C20H27F2N5O4S
DMRZHV6	IC	InChI=1S/C20H27F2N5O4S/c1-20(29)7-3-4-15(20)27-17-12(10-14(16(21)22)18(27)28)11-23-19(25-17)24-13-5-8-26(9-6-13)32(2,30)31/h10-11,13,15-16,29H,3-9H2,1-2H3,(H,23,24,25)/t15-,20-/m1/s1
DMRZHV6	CS	C[C@]1(CCC[C@H]1N2C3=NC(=NC=C3C=C(C2=O)C(F)F)NC4CCN(CC4)S(=O)(=O)C)O
DMRZHV6	IK	QIEKHLDZKRQLLN-FOIQADDNSA-N
DMRZHV6	IU	6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one
DMRZHV6	CA	CAS 2185857-97-8
DMRZHV6	DE	Breast cancer

DM7BOFR	ID	DM7BOFR
DM7BOFR	DN	PF-06939999
DM7BOFR	HS	Phase 1
DM7BOFR	CP	Pfizer
DM7BOFR	DE	Solid tumour/cancer

DMYP9WR	ID	DMYP9WR
DMYP9WR	DN	PF-06940434
DMYP9WR	HS	Phase 1
DMYP9WR	CP	Pfizer
DMYP9WR	DE	Solid tumour/cancer

DMDQJEZ	ID	DMDQJEZ
DMDQJEZ	DN	PF-06952229
DMDQJEZ	HS	Phase 1
DMDQJEZ	SN	SCHEMBL16879380; BDBM280355; US10030004, Compound 22; NSC826119; NSC-826119; HY-136244; CS-0120989; PF06952229; ClC=1C=CC(=C(C1)C1=NC=C(C(=C1)NC1=CC=NC=C1C(=O)NC(CO)CO)C(C)C)F; 1801333-55-0; Synthesis of 4-[[2-(5-chloro-2-fluoro-phenyl)-5-isopropyl-4-pyridyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]pyridine-3-carboxamide
DMDQJEZ	CP	Pfizer
DMDQJEZ	DT	Small molecular drug
DMDQJEZ	PC	118211239
DMDQJEZ	MW	458.9
DMDQJEZ	FM	C23H24ClFN4O3
DMDQJEZ	IC	InChI=1S/C23H24ClFN4O3/c1-13(2)17-10-27-21(16-7-14(24)3-4-19(16)25)8-22(17)29-20-5-6-26-9-18(20)23(32)28-15(11-30)12-31/h3-10,13,15,30-31H,11-12H2,1-2H3,(H,28,32)(H,26,27,29)
DMDQJEZ	CS	CC(C)C1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NC(CO)CO)C3=C(C=CC(=C3)Cl)F
DMDQJEZ	IK	IPBLCOKXDQHSQW-UHFFFAOYSA-N
DMDQJEZ	IU	4-[[2-(5-chloro-2-fluorophenyl)-5-propan-2-ylpyridin-4-yl]amino]-N-(1,3-dihydroxypropan-2-yl)pyridine-3-carboxamide
DMDQJEZ	DE	Solid tumour/cancer

DME3BJL	ID	DME3BJL
DME3BJL	DN	PF-07062119
DME3BJL	HS	Phase 1
DME3BJL	CP	Pfizer
DME3BJL	DT	Antibody
DME3BJL	DE	Solid tumour/cancer

DMMJZ2E	ID	DMMJZ2E
DMMJZ2E	DN	PF-07104091
DMMJZ2E	HS	Phase 1
DMMJZ2E	CP	Pfizer
DMMJZ2E	DT	Small molecular drug
DMMJZ2E	DE	Triple negative breast cancer; Small-cell lung cancer; Non-small cell lung cancer

DMPKO84	ID	DMPKO84
DMPKO84	DN	PF-07220060
DMPKO84	HS	Phase 1
DMPKO84	CP	Pfizer
DMPKO84	DE	Prostate cancer; Liposarcoma

DMSMNRQ	ID	DMSMNRQ
DMSMNRQ	DN	PF-07265807
DMSMNRQ	HS	Phase 1
DMSMNRQ	SN	PF-5807; ARRY-067
DMSMNRQ	CP	Pfizer
DMSMNRQ	DT	Small molecular drug
DMSMNRQ	DE	Solid tumour/cancer

DMCOUHT	ID	DMCOUHT
DMCOUHT	DN	PF-2413873
DMCOUHT	HS	Phase 1
DMCOUHT	SN	PF-02413873
DMCOUHT	CP	Pfizer Inc
DMCOUHT	DT	Small molecular drug
DMCOUHT	PC	16662425
DMCOUHT	MW	359.4
DMCOUHT	FM	C18H21N3O3S
DMCOUHT	IC	InChI=1S/C18H21N3O3S/c1-11-7-15(8-12(2)16(11)9-19)24-18-13(3)21(10-25(4,22)23)20-17(18)14-5-6-14/h7-8,14H,5-6,10H2,1-4H3
DMCOUHT	CS	CC1=CC(=CC(=C1C#N)C)OC2=C(N(N=C2C3CC3)CS(=O)(=O)C)C
DMCOUHT	IK	QSFGZNVRVZHUGV-UHFFFAOYSA-N
DMCOUHT	IU	4-[3-cyclopropyl-5-methyl-1-(methylsulfonylmethyl)pyrazol-4-yl]oxy-2,6-dimethylbenzonitrile
DMCOUHT	CA	CAS 936345-35-6
DMCOUHT	DE	Endometriosis

DMG2IE5	ID	DMG2IE5
DMG2IE5	DN	PF-3732010
DMG2IE5	HS	Phase 1
DMG2IE5	SN	P-cadherin MAb, PF-03072010, PF-03732010
DMG2IE5	CP	Pfizer
DMG2IE5	DT	Antibody
DMG2IE5	DE	Solid tumour/cancer

DM36PKZ	ID	DM36PKZ
DM36PKZ	DN	PF-3758309
DM36PKZ	HS	Phase 1
DM36PKZ	SN	PF-309
DM36PKZ	CP	Pfizer
DM36PKZ	DT	Small molecular drug
DM36PKZ	PC	25227462
DM36PKZ	MW	490.6
DM36PKZ	FM	C25H30N8OS
DM36PKZ	IC	InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1
DM36PKZ	CS	CC1=NC2=C(C(=N1)NC3=NNC4=C3CN(C4(C)C)C(=O)N[C@H](CN(C)C)C5=CC=CC=C5)SC=C2
DM36PKZ	IK	AYCPARAPKDAOEN-LJQANCHMSA-N
DM36PKZ	IU	N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide
DM36PKZ	CA	CAS 898044-15-0
DM36PKZ	CB	CHEBI:93751
DM36PKZ	DE	Solid tumour/cancer

DML0OCD	ID	DML0OCD
DML0OCD	DN	PF-3864086
DML0OCD	HS	Phase 1
DML0OCD	CP	Pfizer Inc
DML0OCD	DE	Pain

DMU2A6D	ID	DMU2A6D
DMU2A6D	DN	PF-4217903
DMU2A6D	HS	Phase 1
DMU2A6D	SN	2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N;  PF-04217903
DMU2A6D	CP	Pfizer
DMU2A6D	DT	Small molecular drug
DMU2A6D	PC	17754438
DMU2A6D	MW	372.4
DMU2A6D	FM	C19H16N8O
DMU2A6D	IC	InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2
DMU2A6D	CS	C1=CC2=C(C=CC(=C2)CN3C4=NC(=CN=C4N=N3)C5=CN(N=C5)CCO)N=C1
DMU2A6D	IK	PDMUGYOXRHVNMO-UHFFFAOYSA-N
DMU2A6D	IU	2-[4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyrazin-5-yl]pyrazol-1-yl]ethanol
DMU2A6D	CA	CAS 956905-27-4
DMU2A6D	CB	CHEBI:91425
DMU2A6D	DE	Solid tumour/cancer

DMMETU8	ID	DMMETU8
DMMETU8	DN	PF-4418948
DMMETU8	HS	Phase 1
DMMETU8	SN	PF-04418948; Prostaglandin E2 EP2 subtype antagonist (endometriosis), Pfizer
DMMETU8	CP	Pfizer Inc
DMMETU8	DT	Small molecular drug
DMMETU8	PC	25114442
DMMETU8	MW	409.4
DMMETU8	FM	C23H20FNO5
DMMETU8	IC	InChI=1S/C23H20FNO5/c1-29-19-8-4-17-11-20(9-5-16(17)10-19)30-14-23(22(27)28)12-25(13-23)21(26)15-2-6-18(24)7-3-15/h2-11H,12-14H2,1H3,(H,27,28)
DMMETU8	CS	COC1=CC2=C(C=C1)C=C(C=C2)OCC3(CN(C3)C(=O)C4=CC=C(C=C4)F)C(=O)O
DMMETU8	IK	LWJGMYMNSNVCEM-UHFFFAOYSA-N
DMMETU8	IU	1-(4-fluorobenzoyl)-3-[(6-methoxynaphthalen-2-yl)oxymethyl]azetidine-3-carboxylic acid
DMMETU8	CA	CAS 1078166-57-0
DMMETU8	DE	Endometriosis

DM3427C	ID	DM3427C
DM3427C	DN	PF-4427429
DM3427C	HS	Phase 1
DM3427C	SN	PF-04427429; RI-307; Anti-CGRP antibodies (migraine), Pfizer
DM3427C	CP	Labrys biologics
DM3427C	DE	Migraine

DMYR7XP	ID	DMYR7XP
DMYR7XP	DN	PF-4455242
DMYR7XP	HS	Phase 1
DMYR7XP	SN	PF-04455242
DMYR7XP	CP	Pfizer Inc
DMYR7XP	DT	Small molecular drug
DMYR7XP	PC	53465410
DMYR7XP	MW	409
DMYR7XP	FM	C21H29ClN2O2S
DMYR7XP	IC	InChI=1S/C21H28N2O2S.ClH/c1-17(2)15-22-16-18-9-11-19(12-10-18)20-7-3-4-8-21(20)26(24,25)23-13-5-6-14-23;/h3-4,7-12,17,22H,5-6,13-16H2,1-2H3;1H
DMYR7XP	CS	CC(C)CNCC1=CC=C(C=C1)C2=CC=CC=C2S(=O)(=O)N3CCCC3.Cl
DMYR7XP	IK	WRNZYMZEVIVCFL-UHFFFAOYSA-N
DMYR7XP	IU	2-methyl-N-[[4-(2-pyrrolidin-1-ylsulfonylphenyl)phenyl]methyl]propan-1-amine;hydrochloride
DMYR7XP	CA	CAS 1322001-35-3
DMYR7XP	DE	Bipolar disorder

DMKOE84	ID	DMKOE84
DMKOE84	DN	PF-4603629
DMKOE84	HS	Phase 1
DMKOE84	SN	BRX-1177; PF-04603629; Exendin-4 transferrin fusion protein (diabetes), Pfizer/BioRexis
DMKOE84	CP	Biorexis Pharmaceutical Corp
DMKOE84	DE	Type-2 diabetes

DMSLE03	ID	DMSLE03
DMSLE03	DN	PF-562271
DMSLE03	HS	Phase 1
DMSLE03	SN	PF-00562271
DMSLE03	CP	Pfizer
DMSLE03	DT	Small molecular drug
DMSLE03	PC	11713159
DMSLE03	MW	507.5
DMSLE03	FM	C21H20F3N7O3S
DMSLE03	IC	InChI=1S/C21H20F3N7O3S/c1-31(35(2,33)34)19-12(4-3-7-25-19)10-26-18-15(21(22,23)24)11-27-20(30-18)28-14-5-6-16-13(8-14)9-17(32)29-16/h3-8,11H,9-10H2,1-2H3,(H,29,32)(H2,26,27,28,30)
DMSLE03	CS	CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C
DMSLE03	IK	MZDKLVOWGIOKTN-UHFFFAOYSA-N
DMSLE03	IU	N-methyl-N-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide
DMSLE03	CA	CAS 717907-75-0
DMSLE03	CB	CHEBI:91370
DMSLE03	DE	Solid tumour/cancer

DMGLEM1	ID	DMGLEM1
DMGLEM1	DN	PF9601N
DMGLEM1	HS	Phase 1
DMGLEM1	SN	PF9601N; 133845-63-3; CHEMBL45069; FA-3; SYN5118; AOB1749; BDBM50087800; ZINC29405716; NCGC00370705-03; AS-16482
DMGLEM1	CP	Pfizer
DMGLEM1	DT	Small molecular drug
DMGLEM1	PC	9947954
DMGLEM1	MW	290.4
DMGLEM1	FM	C19H18N2O
DMGLEM1	IC	InChI=1S/C19H18N2O/c1-2-10-20-13-17-11-16-12-18(8-9-19(16)21-17)22-14-15-6-4-3-5-7-15/h1,3-9,11-12,20-21H,10,13-14H2
DMGLEM1	CS	C#CCNCC1=CC2=C(N1)C=CC(=C2)OCC3=CC=CC=C3
DMGLEM1	IK	YFPNAYXYKXAKJC-UHFFFAOYSA-N
DMGLEM1	IU	N-[(5-phenylmethoxy-1H-indol-2-yl)methyl]prop-2-yn-1-amine
DMGLEM1	DE	Parkinson disease

DMLDZX1	ID	DMLDZX1
DMLDZX1	DN	PfAMA-1
DMLDZX1	HS	Phase 1
DMLDZX1	SN	PfAMA-1-FVO[25-545]; Apical membrane antigen 1 vaccine (Plasmodium infection), African Malaria Network Trust/European Malaria Vaccine Initiative/Biomedical Primate Research Centre; AMA-1 vaccine (malaria), AMANET/EMVI/BPRC
DMLDZX1	CP	Biomedical Primate Research Centre
DMLDZX1	DT	Vaccine
DMLDZX1	DE	Malaria

DM6ER9L	ID	DM6ER9L
DM6ER9L	DN	Pfizer 10
DM6ER9L	HS	Phase 1
DM6ER9L	CP	Pfizer
DM6ER9L	DE	Female sexual arousal dysfunction

DMME5P8	ID	DMME5P8
DMME5P8	DN	Pfizer 4
DMME5P8	HS	Phase 1
DMME5P8	CP	Pfizer
DMME5P8	DE	Female sexual arousal dysfunction

DMIR21F	ID	DMIR21F
DMIR21F	DN	PFK-158
DMIR21F	HS	Phase 1
DMIR21F	CP	Advanced cancer therapeutics
DMIR21F	PC	71730058
DMIR21F	MW	328.3
DMIR21F	FM	C18H11F3N2O
DMIR21F	IC	InChI=1S/C18H11F3N2O/c19-18(20,21)14-3-1-12-2-4-15(23-16(12)11-14)5-6-17(24)13-7-9-22-10-8-13/h1-11H/b6-5+
DMIR21F	CS	C1=CC(=CC2=C1C=CC(=N2)/C=C/C(=O)C3=CC=NC=C3)C(F)(F)F
DMIR21F	IK	IAJOMYABKVAZCN-AATRIKPKSA-N
DMIR21F	IU	(E)-1-pyridin-4-yl-3-[7-(trifluoromethyl)quinolin-2-yl]prop-2-en-1-one
DMIR21F	CA	CAS 1462249-75-7
DMIR21F	DE	Solid tumour/cancer

DM68D3O	ID	DM68D3O
DM68D3O	DN	PG-545
DM68D3O	HS	Phase 1
DM68D3O	SN	PG-457; PG-500; PG-501; PG-502; PG-503; PG-504; PG-505; PG-506; PG-507; PG-508; PG-509; PG-510; PG-511; PG-512; PG-513; PG-514;PG-536; PG-546; PG-547; PG-554; PG-562; PG-500 series (heparan sulfate mimetics), Progen
DM68D3O	CP	Progen Pharmaceuticals Ltd
DM68D3O	DT	?
DM68D3O	PC	57412324
DM68D3O	MW	2363.8
DM68D3O	FM	C51H75Na13O60S13
DM68D3O	IC	InChI=1S/C51H88O60S13.13Na/c1-22(2)7-6-8-23(3)27-11-12-28-26-10-9-24-17-25(13-15-50(24,4)29(26)14-16-51(27,28)5)95-46-42(108-121(79,80)81)38(104-117(67,68)69)34(30(96-46)18-91-112(52,53)54)100-47-43(109-122(82,83)84)39(105-118(70,71)72)35(31(97-47)19-92-113(55,56)57)101-48-44(110-123(85,86)87)40(106-119(73,74)75)36(32(98-48)20-93-114(58,59)60)102-49-45(111-124(88,89)90)41(107-120(76,77)78)37(103-116(64,65)66)33(99-49)21-94-115(61,62)63;;;;;;;;;;;;;/h22-49H,6-21H2,1-5H3,(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H,88,89,90);;;;;;;;;;;;;/q;13*+1/p-13/t23-,24+,25+,26+,27-,28+,29+,30-,31-,32-,33-,34-,35-,36-,37-,38+,39+,40+,41+,42-,43-,44-,45-,46-,47-,48-,49-,50+,51-;;;;;;;;;;;;;/m1............./s1
DM68D3O	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@H](C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)COS(=O)(=O)[O-])O[C@@H]7[C@@H]([C@H]([C@@H]([C@H](O7)COS(=O)(=O)[O-])O[C@@H]8[C@@H]([C@H]([C@@H]([C@H](O8)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])C)C.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM68D3O	IK	PHIUHBOJEMIHQZ-YAPWIAIGSA-A
DM68D3O	IU	tridecasodium;[(2R,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[[(3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate
DM68D3O	CA	CAS 1144492-69-2
DM68D3O	DE	Ocular disease

DM2Y4FG	ID	DM2Y4FG
DM2Y4FG	DN	PHA-793887
DM2Y4FG	HS	Phase 1
DM2Y4FG	SN	Cyclin-dependent kinase inhibitor (cancer), Nerviano
DM2Y4FG	CP	Nerviano Medical Sciences Srl
DM2Y4FG	DT	Small molecular drug
DM2Y4FG	PC	46191454
DM2Y4FG	MW	361.5
DM2Y4FG	FM	C19H31N5O2
DM2Y4FG	IC	InChI=1S/C19H31N5O2/c1-12(2)10-15(25)20-17-14-11-24(19(3,4)16(14)21-22-17)18(26)13-6-8-23(5)9-7-13/h12-13H,6-11H2,1-5H3,(H2,20,21,22,25)
DM2Y4FG	CS	CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C
DM2Y4FG	IK	HUXYBQXJVXOMKX-UHFFFAOYSA-N
DM2Y4FG	IU	N-[6,6-dimethyl-5-(1-methylpiperidine-4-carbonyl)-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide
DM2Y4FG	CA	CAS 718630-59-2
DM2Y4FG	CB	CHEBI:91371
DM2Y4FG	DE	Solid tumour/cancer

DMUANF9	ID	DMUANF9
DMUANF9	DN	PHE-377
DMUANF9	HS	Phase 1
DMUANF9	SN	V 377; 2-(Diisopropylamino)-2',6'-acetoxylidide, hydrochloride; 2',6'-ACETOXYLIDIDE, 2-(DIISOPROPYLAMINO)-, HYDROCHLORIDE; AC1Q1RXG; AC1L1G06; LS-13907; 77966-84-8; [2-(2,6-dimethylanilino)-2-oxoethyl]-di(propan-2-yl)azanium chloride; [2-[(2,6-dimethylphenyl)amino]-2-oxoethyl]-di(propan-2-yl)azanium chloride
DMUANF9	CP	PharmEste SRL
DMUANF9	DT	Small molecular drug
DMUANF9	PC	53956
DMUANF9	MW	298.8
DMUANF9	FM	C16H27ClN2O
DMUANF9	IC	InChI=1S/C16H26N2O.ClH/c1-11(2)18(12(3)4)10-15(19)17-16-13(5)8-7-9-14(16)6;/h7-9,11-12H,10H2,1-6H3,(H,17,19);1H
DMUANF9	CS	CC1=C(C(=CC=C1)C)NC(=O)C[NH+](C(C)C)C(C)C.[Cl-]
DMUANF9	IK	OJTPHJHZGWBMET-UHFFFAOYSA-N
DMUANF9	IU	[2-(2,6-dimethylanilino)-2-oxoethyl]-di(propan-2-yl)azanium;chloride
DMUANF9	CA	CAS 77966-84-8
DMUANF9	DE	Pain

DMBZ2QT	ID	DMBZ2QT
DMBZ2QT	DN	PHE885
DMBZ2QT	HS	Phase 1
DMBZ2QT	CP	Novartis
DMBZ2QT	DT	CAR T Cell Therapy
DMBZ2QT	DE	Multiple myeloma

DMERJ6V	ID	DMERJ6V
DMERJ6V	DN	PHX-1766
DMERJ6V	HS	Phase 1
DMERJ6V	SN	HCV protease inhibitors, Phenomix; Hepatitis c virus protease inhibitors, Phenomix; PHX-1176
DMERJ6V	CP	Phenomix Corp
DMERJ6V	DE	Hepatitis C virus infection

DMU26OE	ID	DMU26OE
DMU26OE	DN	PIM447
DMU26OE	HS	Phase 1
DMU26OE	SN	VRQXRVAKPDCRCI-ZNMIVQPWSA-N; PIM-447; 1210608-43-7; PIM447 (LGH447); N-{4-[(1r,3s,5s)-3-Amino-5-Methylcyclohexyl]pyridin-3-Yl}-6-(2,6-Difluorophenyl)-5-Fluoropyridine-2-Carboxamide; N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide; UNII-9TG5O4V25H; SCHEMBL3215332; GTPL9790; 9TG5O4V25H; CHEMBL3651966; PIM 447 [WHO-DD]; BDBM106870; ZINC116907270; AKOS032945086; CS-5929; compound 8 [PMID: 26505898]; HY-19322; J3.552.648J; US8592455, 70; 5H7; 2-Pyr
DMU26OE	CP	Novartis Oncology East Hanover, NJ
DMU26OE	PC	44814409
DMU26OE	MW	440.5
DMU26OE	FM	C24H23F3N4O
DMU26OE	IC	InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1
DMU26OE	CS	C[C@H]1C[C@H](C[C@H](C1)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=CC=C4F)F
DMU26OE	IK	VRQXRVAKPDCRCI-ZNMIVQPWSA-N
DMU26OE	IU	N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide
DMU26OE	CA	CAS 1210608-43-7
DMU26OE	DE	Myelofibrosis

DMF3IBC	ID	DMF3IBC
DMF3IBC	DN	Plasma derived human butyrylcholinesterase
DMF3IBC	HS	Phase 1
DMF3IBC	SN	Plasma derived human butyrylcholinesterase (im, drug induced neurotoxicity); HuBChE (im, drug induced neurotoxicity), Dynport; Bioscavenger (im, drug induced neurotoxicity), Dynport/Baxter; Plasma derived human butyrylcholinesterase (im, drug induced neurotoxicity), Dynport/Baxter
DMF3IBC	CP	DynPort Vaccine Company LLC
DMF3IBC	DE	Neurotoxicity

DMBK9AM	ID	DMBK9AM
DMBK9AM	DN	PLX-4720
DMBK9AM	HS	Phase 1
DMBK9AM	SN	PLX 4720; PLX4720 (BRAF inhibitor)
DMBK9AM	DT	Small molecular drug
DMBK9AM	PC	24180719
DMBK9AM	MW	413.8
DMBK9AM	FM	C17H14ClF2N3O3S
DMBK9AM	IC	InChI=1S/C17H14ClF2N3O3S/c1-2-5-27(25,26)23-13-4-3-12(19)14(15(13)20)16(24)11-8-22-17-10(11)6-9(18)7-21-17/h3-4,6-8,23H,2,5H2,1H3,(H,21,22)
DMBK9AM	CS	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F
DMBK9AM	IK	YZDJQTHVDDOVHR-UHFFFAOYSA-N
DMBK9AM	IU	N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide
DMBK9AM	CA	CAS 918505-84-7
DMBK9AM	CB	CHEBI:90295
DMBK9AM	DE	Cutaneous melanoma

DMXLHVW	ID	DMXLHVW
DMXLHVW	DN	PLX51107
DMXLHVW	HS	Phase 1
DMXLHVW	SN	AMSUHYUVOVCWTP-INIZCTEOSA-N; SCHEMBL16085681; HY-111422; CS-0040568; 4-[6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl]benzoic acid
DMXLHVW	CP	Plexxikon Berkeley, CA
DMXLHVW	PC	90448953
DMXLHVW	MW	438.5
DMXLHVW	FM	C26H22N4O3
DMXLHVW	IC	InChI=1S/C26H22N4O3/c1-15-24(17(3)33-29-15)20-12-23-25(28-13-20)21(18-7-9-19(10-8-18)26(31)32)14-30(23)16(2)22-6-4-5-11-27-22/h4-14,16H,1-3H3,(H,31,32)/t16-/m0/s1
DMXLHVW	CS	CC1=C(C(=NO1)C)C2=CC3=C(C(=CN3[C@@H](C)C4=CC=CC=N4)C5=CC=C(C=C5)C(=O)O)N=C2
DMXLHVW	IK	AMSUHYUVOVCWTP-INIZCTEOSA-N
DMXLHVW	IU	4-[6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1S)-1-pyridin-2-ylethyl]pyrrolo[3,2-b]pyridin-3-yl]benzoic acid
DMXLHVW	CA	CAS 1627929-55-8
DMXLHVW	DE	Haematological malignancy; Solid tumour/cancer

DMK4PWM	ID	DMK4PWM
DMK4PWM	DN	PLX-5622
DMK4PWM	HS	Phase 1
DMK4PWM	CP	Plexxikon Inc
DMK4PWM	DE	Autoimmune diabetes

DMED2WN	ID	DMED2WN
DMED2WN	DN	PLX73086
DMED2WN	HS	Phase 1
DMED2WN	CP	Plexxikon Berkeley, CA
DMED2WN	DE	Solid tumour/cancer

DM0IVGU	ID	DM0IVGU
DM0IVGU	DN	PLX7486
DM0IVGU	HS	Phase 1
DM0IVGU	CP	Daiichi sankyo
DM0IVGU	DE	Pancreatic cancer; Solid tumour/cancer

DMIS8BV	ID	DMIS8BV
DMIS8BV	DN	PMD-026
DMIS8BV	HS	Phase 1
DMIS8BV	CP	Phoenix Molecular Designs
DMIS8BV	DT	Small molecular drug
DMIS8BV	DE	Triple negative breast cancer; Metastatic breast cancer

DMY9XWB	ID	DMY9XWB
DMY9XWB	DN	PMI-005
DMY9XWB	HS	Phase 1
DMY9XWB	CP	Louisiana State University
DMY9XWB	DE	Osteoarthritis

DMQ82SH	ID	DMQ82SH
DMQ82SH	DN	PMZ-2123
DMQ82SH	HS	Phase 1
DMQ82SH	CP	Pharmazz Willowbrook, IL
DMQ82SH	DE	Cerebral oedema in diabetic ketoacidosis

DM9B68S	ID	DM9B68S
DM9B68S	DN	POL-6014
DM9B68S	HS	Phase 1
DM9B68S	SN	Serine protease inhibitors (inhaled, PEM, asthma/COPD), Polyphor
DM9B68S	CP	Polyphor Ltd
DM9B68S	DE	Chronic obstructive pulmonary disease; Cystic fibrosis

DMTOLI5	ID	DMTOLI5
DMTOLI5	DN	Pomaglumetad
DMTOLI5	HS	Phase 1
DMTOLI5	CP	Eli Lilly
DMTOLI5	DE	Schizophrenia

DMCU54M	ID	DMCU54M
DMCU54M	DN	Posiphen R-phenserine
DMCU54M	HS	Phase 1
DMCU54M	CP	Qr pharma
DMCU54M	DE	Alzheimer disease

DM2D7Z0	ID	DM2D7Z0
DM2D7Z0	DN	PPC-5650
DM2D7Z0	HS	Phase 1
DM2D7Z0	CP	Antalium Inc
DM2D7Z0	DE	Pain

DMSAQBC	ID	DMSAQBC
DMSAQBC	DN	PPI-2458
DMSAQBC	HS	Phase 1
DMSAQBC	SN	Metapro; 6-O-[N-[1(R)-Carbamoyl-2-methylpropyl]carbamoyl]fumagillol
DMSAQBC	CP	Praecis Pharmaceuticals
DMSAQBC	DT	Small molecular drug
DMSAQBC	PC	6918653
DMSAQBC	MW	424.5
DMSAQBC	FM	C22H36N2O6
DMSAQBC	IC	InChI=1S/C22H36N2O6/c1-12(2)7-8-15-21(5,30-15)18-17(27-6)14(9-10-22(18)11-28-22)29-20(26)24-16(13(3)4)19(23)25/h7,13-18H,8-11H2,1-6H3,(H2,23,25)(H,24,26)/t14-,15-,16-,17-,18-,21+,22+/m1/s1
DMSAQBC	CS	CC(C)[C@H](C(=O)N)NC(=O)O[C@@H]1CC[C@]2(CO2)[C@H]([C@@H]1OC)[C@@]3([C@H](O3)CC=C(C)C)C
DMSAQBC	IK	QBDVVYNLLXGUGN-XGTBZJOHSA-N
DMSAQBC	IU	[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-[(2R)-1-amino-3-methyl-1-oxobutan-2-yl]carbamate
DMSAQBC	CA	CAS 431077-35-9
DMSAQBC	DE	Autoimmune diabetes

DMEOJUN	ID	DMEOJUN
DMEOJUN	DN	PPI-383
DMEOJUN	HS	Phase 1
DMEOJUN	CP	Presidio pharmaceuticals
DMEOJUN	DE	Hepatitis C virus infection

DMTOXLG	ID	DMTOXLG
DMTOXLG	DN	PPI-461
DMTOXLG	HS	Phase 1
DMTOXLG	CP	Presidio
DMTOXLG	DE	Hepatitis C virus infection

DMOYUPM	ID	DMOYUPM
DMOYUPM	DN	PPL-100
DMOYUPM	HS	Phase 1
DMOYUPM	SN	HIV protease inhibitors, Ambrilia; HIV protease inhibitors, Pharmacor; HIV protease inhibitors, Procyon; HIV protease inhibitors, TaiMed; MK-8122; P-1946; PL-337; HIV protease inhibitors, Merck & Co
DMOYUPM	CP	Pharmacor Inc
DMOYUPM	DT	Small molecular drug
DMOYUPM	PC	513956
DMOYUPM	MW	624.8
DMOYUPM	FM	C33H44N4O6S
DMOYUPM	IC	InChI=1S/C33H44N4O6S/c1-24(2)22-37(44(41,42)29-19-17-27(34)18-20-29)28(23-38)16-10-11-21-35-32(39)31(36-33(40)43-3)30(25-12-6-4-7-13-25)26-14-8-5-9-15-26/h4-9,12-15,17-20,24,28,30-31,38H,10-11,16,21-23,34H2,1-3H3,(H,35,39)(H,36,40)/t28-,31-/m0/s1
DMOYUPM	CS	CC(C)CN([C@@H](CCCCNC(=O)[C@H](C(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)OC)CO)S(=O)(=O)C3=CC=C(C=C3)N
DMOYUPM	IK	QAHLFXYLXBBCPS-IZEXYCQBSA-N
DMOYUPM	IU	methyl N-[(2S)-1-[[(5S)-5-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-6-hydroxyhexyl]amino]-1-oxo-3,3-diphenylpropan-2-yl]carbamate
DMOYUPM	CA	CAS 612547-11-2
DMOYUPM	DE	Human immunodeficiency virus infection

DMY2GDQ	ID	DMY2GDQ
DMY2GDQ	DN	P-PSMA-101
DMY2GDQ	HS	Phase 1
DMY2GDQ	CP	Poseida Therapeutics
DMY2GDQ	DT	CAR T Cell Therapy
DMY2GDQ	DE	Prostate cancer

DMHIS3M	ID	DMHIS3M
DMHIS3M	DN	PRAX-330
DMHIS3M	HS	Phase 1
DMHIS3M	CP	Praxis Precision Medicines Cambridge, MA
DMHIS3M	DE	Epilepsy

DMCUE71	ID	DMCUE71
DMCUE71	DN	PRGN-3005
DMCUE71	HS	Phase 1
DMCUE71	CP	Precigen
DMCUE71	DT	CAR T Cell Therapy
DMCUE71	DE	Refractory hematologic malignancy

DMR7BAO	ID	DMR7BAO
DMR7BAO	DN	PRN1371
DMR7BAO	HS	Phase 1
DMR7BAO	SN	PUIXMSRTTHLNKI-UHFFFAOYSA-N; 1802929-43-6; PRN-1371; UNII-S3OPE9IA3Q; S3OPE9IA3Q; 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one; GTPL9788; US9567334, Example 6; SCHEMBL16993012; BDBM286984; BCP20493; s8578; AKOS032954157; CS-7485; compound 34 [PMID: 28665128]; HY-101768; J3.662.238E; 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one
DMR7BAO	CP	Principia Biopharma South San Francisco, CA
DMR7BAO	PC	118295624
DMR7BAO	MW	561.5
DMR7BAO	FM	C26H30Cl2N6O4
DMR7BAO	IC	InChI=1S/C26H30Cl2N6O4/c1-5-20(35)33-11-9-32(10-12-33)7-6-8-34-24-16(15-30-26(29-2)31-24)13-17(25(34)36)21-22(27)18(37-3)14-19(38-4)23(21)28/h5,13-15H,1,6-12H2,2-4H3,(H,29,30,31)
DMR7BAO	CS	CNC1=NC=C2C=C(C(=O)N(C2=N1)CCCN3CCN(CC3)C(=O)C=C)C4=C(C(=CC(=C4Cl)OC)OC)Cl
DMR7BAO	IK	PUIXMSRTTHLNKI-UHFFFAOYSA-N
DMR7BAO	IU	6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one
DMR7BAO	CA	CAS 1802929-43-6
DMR7BAO	DE	Solid tumour/cancer

DMQNS51	ID	DMQNS51
DMQNS51	DN	PRN2246
DMQNS51	HS	Phase 1
DMQNS51	SN	SAR442168
DMQNS51	CP	Principia Biopharma South San Francisco, CA Sanofi Bridgewater, NJ
DMQNS51	DE	Multiple sclerosis

DMLKF3H	ID	DMLKF3H
DMLKF3H	DN	Prolanta
DMLKF3H	HS	Phase 1
DMLKF3H	CP	Oncolix Houston, TX
DMLKF3H	DE	Fallopian tube cancer; Ovarian cancer; Peritoneal cavity cancer

DME1Y9W	ID	DME1Y9W
DME1Y9W	DN	Protexia
DME1Y9W	HS	Phase 1
DME1Y9W	SN	RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene
DME1Y9W	CP	Nexia Biotechnologies Inc
DME1Y9W	DE	Alzheimer disease

DMBL7CW	ID	DMBL7CW
DMBL7CW	DN	PRT-062607
DMBL7CW	HS	Phase 1
DMBL7CW	SN	P-14276; P-505-15; Syk tyrosine kinase inhibitors (oral, cancers/inflammatory diseases/thrombosis), Portola
DMBL7CW	CP	Portola Pharmaceuticals Inc
DMBL7CW	DT	Small molecular drug
DMBL7CW	PC	44462758
DMBL7CW	MW	393.4
DMBL7CW	FM	C19H23N9O
DMBL7CW	IC	InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1
DMBL7CW	CS	C1CC[C@H]([C@H](C1)N)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)N4N=CC=N4)C(=O)N
DMBL7CW	IK	TXGKRVFSSHPBAJ-JKSUJKDBSA-N
DMBL7CW	IU	2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide
DMBL7CW	CA	CAS 1370261-96-3
DMBL7CW	DE	Chronic lymphocytic leukaemia

DMIKE0O	ID	DMIKE0O
DMIKE0O	DN	PRT1419
DMIKE0O	HS	Phase 1
DMIKE0O	CP	Prelude Therapeutics
DMIKE0O	DT	Small molecular drug
DMIKE0O	DE	Melanoma

DMHNZ3U	ID	DMHNZ3U
DMHNZ3U	DN	PRT543
DMHNZ3U	HS	Phase 1
DMHNZ3U	CP	Prelude Therapeutics
DMHNZ3U	DT	Small molecular drug
DMHNZ3U	DE	Solid tumour/cancer; Hematologic tumour

DMP5CLY	ID	DMP5CLY
DMP5CLY	DN	PRT6207
DMP5CLY	HS	Phase 1
DMP5CLY	DE	Solid tumour/cancer

DMW3MCX	ID	DMW3MCX
DMW3MCX	DN	PRT811
DMW3MCX	HS	Phase 1
DMW3MCX	CP	Prelude Therapeutics
DMW3MCX	DT	Small molecular drug
DMW3MCX	DE	Glioma

DM5KI6X	ID	DM5KI6X
DM5KI6X	DN	PRX003
DM5KI6X	HS	Phase 1
DM5KI6X	CP	Prothena Biosciences South San Francisco, CA
DM5KI6X	DE	Psoriasis vulgaris

DM5TLAP	ID	DM5TLAP
DM5TLAP	DN	PRX-07034
DM5TLAP	HS	Phase 1
DM5TLAP	SN	5-HT 6 antagonists (obesity/cognitive impairment), EPIX; 5-HT 6 antagonists (obesity/cognitive impairment), Predix
DM5TLAP	CP	Epix Pharmaceutical
DM5TLAP	DT	Small molecular drug
DM5TLAP	PC	23653584
DM5TLAP	MW	490.4
DM5TLAP	FM	C21H29Cl2N3O4S
DM5TLAP	IC	InChI=1S/C21H28ClN3O4S.ClH/c1-14(17-11-15(22)12-19(28-2)21(17)29-3)24-18-13-16(25-9-7-23-8-10-25)5-6-20(18)30(4,26)27;/h5-6,11-14,23-24H,7-10H2,1-4H3;1H
DM5TLAP	CS	CC(C1=C(C(=CC(=C1)Cl)OC)OC)NC2=C(C=CC(=C2)N3CCNCC3)S(=O)(=O)C.Cl
DM5TLAP	IK	PILCQJJJAFRKHO-UHFFFAOYSA-N
DM5TLAP	IU	N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline;hydrochloride
DM5TLAP	CA	CAS 903580-39-2
DM5TLAP	DE	Obesity

DMWT8RI	ID	DMWT8RI
DMWT8RI	DN	PRX-105
DMWT8RI	HS	Phase 1
DMWT8RI	SN	Acetylcholinesterase (poison intoxication, ProCellEx), Protalix/Hebrew University of Jerusalem; Acetylcholinesterase (poison intoxication, plant cell-expression), Protalix/Hebrew University of Jerusalem
DMWT8RI	CP	Hebrew University of Jerusalem
DMWT8RI	DE	Poison intoxication

DM2594H	ID	DM2594H
DM2594H	DN	PS-178990
DM2594H	HS	Phase 1
DM2594H	SN	SARMs (muscle wasting disease), BMS; SARMs (muscle wasting disease), Ligand; SARMs (muscle wasting disease), Pharmacopeia; Selective androgen receptor modulators (muscle wasting disease), BMS; Selective androgen receptor modulators (muscle wasting disease), Ligand; Selective androgen receptor modulators (muscle wasting disease), Pharmacopeia
DM2594H	CP	Bristol-Myers Squibb Co
DM2594H	DE	Muscle atrophy

DM75FWO	ID	DM75FWO
DM75FWO	DN	PSI-697
DM75FWO	HS	Phase 1
DM75FWO	SN	PSI-697; UNII-LH1XC916ME; 851546-61-7; LH1XC916ME; CHEMBL219046; 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid; 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid; SCHEMBL43527; DIEPFYNZGUUVHD-UHFFFAOYSA-N; ZINC28603970; BDBM50201984; AKOS032945074; CS-5867; DB12211; HY-15526; LS-193902; 2-(4-chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]-quinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic 
DM75FWO	CP	Pfizer
DM75FWO	DT	Small molecular drug
DM75FWO	PC	12004316
DM75FWO	MW	367.8
DM75FWO	FM	C21H18ClNO3
DM75FWO	IC	InChI=1S/C21H18ClNO3/c22-14-8-5-12(6-9-14)11-17-20(24)18(21(25)26)16-10-7-13-3-1-2-4-15(13)19(16)23-17/h5-10,24H,1-4,11H2,(H,25,26)
DM75FWO	CS	C1CCC2=C(C1)C=CC3=C(C(=C(N=C23)CC4=CC=C(C=C4)Cl)O)C(=O)O
DM75FWO	IK	DIEPFYNZGUUVHD-UHFFFAOYSA-N
DM75FWO	IU	2-[(4-chlorophenyl)methyl]-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid
DM75FWO	CA	CAS 851546-61-7
DM75FWO	DE	Thrombosis; Atherosclerosis

DM5ZR4Q	ID	DM5ZR4Q
DM5ZR4Q	DN	PSI-938
DM5ZR4Q	HS	Phase 1
DM5ZR4Q	SN	PSI-352938; PSI-938; UNII-3Z30JH9QX1; 3Z30JH9QX1; PSI938; PSI 938; 1231747-17-3; 1199809-32-9; SCHEMBL2679397; CHEMBL2160007; CS-6672; HY-15231; Guanosine, 2'-deoxy-6-O-ethyl-2'-fluoro-2'-methyl-, cyclic 3',5'-(1-methylethyl (R)-phosphate), (2'R)-; 9-[(4aR,6R,7R,7aR)-7-Fluoro-2-isopropoxy-7-methyl-2-oxo-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxy-purin-2-amine
DM5ZR4Q	CP	Pharmasset
DM5ZR4Q	DT	Small molecular drug
DM5ZR4Q	PC	46863668
DM5ZR4Q	MW	431.36
DM5ZR4Q	FM	C16H23FN5O6P
DM5ZR4Q	IC	InChI=1S/C16H23FN5O6P/c1-5-24-13-10-12(20-15(18)21-13)22(7-19-10)14-16(4,17)11-9(26-14)6-25-29(23,28-11)27-8(2)3/h7-9,11,14H,5-6H2,1-4H3,(H2,18,20,21)/t9-,11-,14-,16-,29?/m1/s1
DM5ZR4Q	CS	CCOC1=NC(=NC2=C1N=CN2[C@H]3[C@]([C@H]4[C@H](O3)COP(=O)(O4)OC(C)C)(C)F)N
DM5ZR4Q	IK	PVRFQJIRERYGTQ-UYISCHNFSA-N
DM5ZR4Q	IU	9-[(4aR,6R,7R,7aR)-7-fluoro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxypurin-2-amine
DM5ZR4Q	CA	CAS 1231747-17-3
DM5ZR4Q	DE	Hepatitis C virus infection

DM8Y1M9	ID	DM8Y1M9
DM8Y1M9	DN	PSMA CAR-T cell therapy
DM8Y1M9	HS	Phase 1
DM8Y1M9	CP	Tmunity
DM8Y1M9	DT	CAR T Cell Therapy
DM8Y1M9	DE	Prostate cancer

DMRHQTU	ID	DMRHQTU
DMRHQTU	DN	PSMA subunit vaccine
DMRHQTU	HS	Phase 1
DMRHQTU	SN	Recombinant soluble PSMA vaccine; RsPSMA vaccine; PSMA subunit vaccine (prostate cancer); PSMA recombinant soluble protein vaccine, CYTOGEN/Progenics; PSMA rs protein vaccine, CYTOGEN/Progenics; PSMA protein vaccine (prostate cancer), Progenics/CYTOGEN; PSMA purified protein vaccine (prostate cancer), Progenics/CYTOGEN; PSMA subunit vaccine (prostate cancer), Progenics/CYTOGEN; PSMA-based therapeutics, CYTOGEN/Progenics
DMRHQTU	CP	Alphavax
DMRHQTU	DT	Vaccine
DMRHQTU	DE	Prostate cancer

DMOYX6W	ID	DMOYX6W
DMOYX6W	DN	PSMA-targeted tubulysin B conjugates
DMOYX6W	HS	Phase 1
DMOYX6W	SN	DUPA-TubH III; DUPA-tubulysin III; EC-1069; PSMA-targeted tubulysin B conjugates (prostate cancer); PSMA-targeted tubulysin B conjugates (prostate cancer), Endocyte/Purdue University
DMOYX6W	CP	Endocyte
DMOYX6W	DE	Prostate cancer

DM03O8T	ID	DM03O8T
DM03O8T	DN	PSMA-VRP
DM03O8T	HS	Phase 1
DM03O8T	SN	Alphavirus vector vaccine (prostate cancer), Progenics/Cytogen; PSMA antigen vaccine (prostate cancer), PSMA Co LLC/AlphaVax;PSMA viral vector vaccine (prostate cancer), PSMA Co LLC/AlphaVax; PSMA viral vector vaccine (prostate cancer), Progenics/CYTOGEN; PSMA antigen vaccine (prostate cancer), CYTOGEN/Progenics/AlphaVax
DM03O8T	CP	Alphavax
DM03O8T	DT	Vaccine
DM03O8T	DE	Prostate cancer

DMB6M1P	ID	DMB6M1P
DMB6M1P	DN	PT-112
DMB6M1P	HS	Phase 1
DMB6M1P	SN	167683-61-6; Thiourea, N-(5-bromo-2-pyridinyl)-N'-(2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl)-; 1-(5-bromopyridin-2-yl)-3-[2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl]thiourea; N-(2-(2-Chloro-3-ethoxy-6-fluorophenethyl))-N'-(2-(5-bromopyridyl))thiourea; PETT deriv. 9; N-[2-(2-Chloro-3-ethoxy-6-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]thiourea; Thiourea, N-(5-bromo-2-pyridinyl)-N'-[2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl]-; PT-112; AC1MHDLZ; SCHEMBL6906082; CHEMBL398891; BDBM2859; LY300046HCl Analog 10; DTXSID70168348
DMB6M1P	DT	Small molecular drug
DMB6M1P	PC	3001152
DMB6M1P	MW	432.7
DMB6M1P	FM	C16H16BrClFN3OS
DMB6M1P	IC	InChI=1S/C16H16BrClFN3OS/c1-2-23-13-5-4-12(19)11(15(13)18)7-8-20-16(24)22-14-6-3-10(17)9-21-14/h3-6,9H,2,7-8H2,1H3,(H2,20,21,22,24)
DMB6M1P	CS	CCOC1=C(C(=C(C=C1)F)CCNC(=S)NC2=NC=C(C=C2)Br)Cl
DMB6M1P	IK	DTHZUSMREBJMBT-UHFFFAOYSA-N
DMB6M1P	IU	1-(5-bromopyridin-2-yl)-3-[2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl]thiourea
DMB6M1P	CA	CAS 167683-61-6
DMB6M1P	DE	Solid tumour/cancer

DMWBA1S	ID	DMWBA1S
DMWBA1S	DN	PT-302
DMWBA1S	HS	Phase 1
DMWBA1S	SN	149485-77-8; Thiourea, N-(2-(4-fluorophenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(4-fluorophenyl)ethyl]-N'-2-thiazolyl-; PETT Analog 4; AC1MHDMB; CHEMBL253996; BDBM1897; DTXSID00164292; 1-[2-(4-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; AKOS030030877; 1-(2-Thiazolyl)-3-[4-fluorophenethyl]thiourea; N-(2-(4-Fluorophenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(4-fluorophenyl)ethyl]-3-thiazol-2-yl-thiourea
DMWBA1S	DT	Small molecular drug
DMWBA1S	PC	3001164
DMWBA1S	MW	281.4
DMWBA1S	FM	C12H12FN3S2
DMWBA1S	IC	InChI=1S/C12H12FN3S2/c13-10-3-1-9(2-4-10)5-6-14-11(17)16-12-15-7-8-18-12/h1-4,7-8H,5-6H2,(H2,14,15,16,17)
DMWBA1S	CS	C1=CC(=CC=C1CCNC(=S)NC2=NC=CS2)F
DMWBA1S	IK	WGSDLRNUZBUXDV-UHFFFAOYSA-N
DMWBA1S	IU	1-[2-(4-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMWBA1S	CA	CAS 149485-77-8

DMQNRGE	ID	DMQNRGE
DMQNRGE	DN	PTG-100
DMQNRGE	HS	Phase 1
DMQNRGE	CP	Protagonist Therapeutics Milpitas, CA
DMQNRGE	DE	Ulcerative colitis

DMRQ5YT	ID	DMRQ5YT
DMRQ5YT	DN	PTH(7-34) liposomal cream
DMRQ5YT	HS	Phase 1
DMRQ5YT	SN	PTH(7-34); PTH(7-34) liposomal cream (Novasome); PTH(7-34) liposomal cream (Novasome), IGI
DMRQ5YT	CP	IGI Inc
DMRQ5YT	DT	Small molecular drug
DMRQ5YT	PC	16131009
DMRQ5YT	MW	3481
DMRQ5YT	FM	C156H243N47O40S2
DMRQ5YT	IC	InChI=1S/C156H243N47O40S2/c1-80(2)57-106(189-148(237)114(67-120(162)207)196-146(235)112(65-90-72-169-78-176-90)195-139(228)103(48-55-244-13)179-129(218)93(160)61-86-31-17-15-18-32-86)130(219)174-74-121(208)178-95(37-23-26-50-157)131(220)194-111(64-89-71-168-77-175-89)145(234)192-109(60-83(7)8)143(232)200-118(76-205)152(241)201-117(75-204)151(240)186-104(49-56-245-14)138(227)184-101(43-46-122(209)210)135(224)182-99(41-30-54-172-156(166)167)140(229)202-126(84(9)10)153(242)187-102(44-47-123(211)212)137(226)193-110(63-88-70-173-94-36-22-21-35-92(88)94)144(233)191-108(59-82(5)6)141(230)183-98(40-29-53-171-155(164)165)133(222)180-96(38-24-27-51-158)132(221)181-97(39-25-28-52-159)134(223)190-107(58-81(3)4)142(231)185-100(42-45-119(161)206)136(225)197-116(69-125(215)216)150(239)203-127(85(11)12)154(243)199-113(66-91-73-170-79-177-91)147(236)198-115(68-124(213)214)149(238)188-105(128(163)217)62-87-33-19-16-20-34-87/h15-22,31-36,70-73,77-85,93,95-118,126-127,173,204-205H,23-30,37-69,74-76,157-160H2,1-14H3,(H2,161,206)(H2,162,207)(H2,163,217)(H,168,175)(H,169,176)(H,170,177)(H,174,219)(H,178,208)(H,179,218)(H,180,222)(H,181,221)(H,182,224)(H,183,230)(H,184,227)(H,185,231)(H,186,240)(H,187,242)(H,188,238)(H,189,237)(H,190,223)(H,191,233)(H,192,234)(H,193,226)(H,194,220)(H,195,228)(H,196,235)(H,197,225)(H,198,236)(H,199,243)(H,200,232)(H,201,241)(H,202,229)(H,203,239)(H,209,210)(H,211,212)(H,213,214)(H,215,216)(H4,164,165,171)(H4,166,167,172)/t93-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-/m0/s1
DMRQ5YT	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC7=CC=CC=C7)N
DMRQ5YT	IK	YKGRXSLQYRREKO-DFOPOJAZSA-N
DMRQ5YT	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoic acid
DMRQ5YT	CA	CAS 101380-54-5
DMRQ5YT	DE	Alopecia

DMV5X8M	ID	DMV5X8M
DMV5X8M	DN	PTI-125
DMV5X8M	HS	Phase 1
DMV5X8M	CP	Pain Therapeutics Austin, TX
DMV5X8M	DE	Alzheimer disease

DMNO91Q	ID	DMNO91Q
DMNO91Q	DN	PTI-202
DMNO91Q	HS	Phase 1
DMNO91Q	CP	Pain therapeutics
DMNO91Q	DE	Pain

DM0A6N9	ID	DM0A6N9
DM0A6N9	DN	PTI-80
DM0A6N9	HS	Phase 1
DM0A6N9	CP	Proteotech
DM0A6N9	DE	Alzheimer disease

DMAWO5I	ID	DMAWO5I
DMAWO5I	DN	PTX-100
DMAWO5I	HS	Phase 1
DMAWO5I	CP	Prescient Therapeutics South Melbourne, Australia
DMAWO5I	DE	Solid tumour/cancer

DM38F50	ID	DM38F50
DM38F50	DN	PTX-35
DM38F50	HS	Phase 1
DM38F50	CP	Pelican Therapeutics
DM38F50	DT	Antibody
DM38F50	DE	Solid tumour/cancer

DMJO0BP	ID	DMJO0BP
DMJO0BP	DN	PU3
DMJO0BP	HS	Phase 1
DMJO0BP	SN	PU3; 9-BUTYL-8-(3,4,5-TRIMETHOXYBENZYL)-9H-PURIN-6-AMINE; 352519-21-2; CHEMBL113690; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]purin-6-amine; 1uym; 1uy6; Purine-Based Inhibitor 1; AC1L9MK5; PU-3; SCHEMBL2604975; BDBM15374; CTK1B7081; DTXSID40332291; ZINC3832013; AKOS030562182; DB02754; KB-275186; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-
DMJO0BP	TC	Anticancer Agents
DMJO0BP	DT	Small molecular drug
DMJO0BP	PC	448965
DMJO0BP	MW	371.4
DMJO0BP	FM	C19H25N5O3
DMJO0BP	IC	InChI=1S/C19H25N5O3/c1-5-6-7-24-15(23-16-18(20)21-11-22-19(16)24)10-12-8-13(25-2)17(27-4)14(9-12)26-3/h8-9,11H,5-7,10H2,1-4H3,(H2,20,21,22)
DMJO0BP	CS	CCCCN1C(=NC2=C(N=CN=C21)N)CC3=CC(=C(C(=C3)OC)OC)OC
DMJO0BP	IK	TUOSCZDRWRYPRS-UHFFFAOYSA-N
DMJO0BP	IU	9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]purin-6-amine
DMJO0BP	CA	CAS 352519-21-2
DMJO0BP	DE	Solid tumour/cancer

DMKSU35	ID	DMKSU35
DMKSU35	DN	PU-AD
DMKSU35	HS	Phase 1
DMKSU35	CP	Samus Therapeutics Topsfield, MA
DMKSU35	DE	Alzheimer disease; Encephalopathy

DMIYHAW	ID	DMIYHAW
DMIYHAW	DN	PU-H71
DMIYHAW	HS	Phase 1
DMIYHAW	SN	PU-H71; 873436-91-0; PU H71; PU-H 71; UNII-06IVK87M04; CHEMBL200102; 06IVK87M04; 6-amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-n-(1-methylethyl)-9h-purine-9-propanamine; NSC 750424; 8-[(6-Iodo-1,3-Benzodioxol-5-Yl)thio]-9-[3-(Isopropylamino)propyl]-9h-Purin-6-Amine; 8-(6-Iodobenzo[d][1,3]dioxol-5-ylthio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine; 8-((6-Iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine; H71; PUH-71; 2fwz; PU-H-71
DMIYHAW	DT	Small molecular drug
DMIYHAW	PC	9549213
DMIYHAW	MW	512.4
DMIYHAW	FM	C18H21IN6O2S
DMIYHAW	IC	InChI=1S/C18H21IN6O2S/c1-10(2)21-4-3-5-25-17-15(16(20)22-8-23-17)24-18(25)28-14-7-13-12(6-11(14)19)26-9-27-13/h6-8,10,21H,3-5,9H2,1-2H3,(H2,20,22,23)
DMIYHAW	CS	CC(C)NCCCN1C2=NC=NC(=C2N=C1SC3=C(C=C4C(=C3)OCO4)I)N
DMIYHAW	IK	SUPVGFZUWFMATN-UHFFFAOYSA-N
DMIYHAW	IU	8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-ylamino)propyl]purin-6-amine
DMIYHAW	CA	CAS 873436-91-0
DMIYHAW	DE	Solid tumour/cancer; Breast cancer; Myelofibrosis

DMX5LB7	ID	DMX5LB7
DMX5LB7	DN	PUR0200
DMX5LB7	HS	Phase 1
DMX5LB7	CP	Pulmatrix
DMX5LB7	DE	Chronic obstructive pulmonary disease

DMJY15D	ID	DMJY15D
DMJY15D	DN	PWT-33597
DMJY15D	HS	Phase 1
DMJY15D	SN	PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics
DMJY15D	CP	Pathway Therapeutics Ltd
DMJY15D	PC	46917355
DMJY15D	MW	588.6
DMJY15D	FM	C26H30F2N8O4S
DMJY15D	IC	InChI=1S/C26H30F2N8O4S/c1-34(2)13-16-41(37,38)33-18-9-7-17(8-10-18)23-30-25(35-11-14-40-15-12-35)32-26(31-23)36-19-5-4-6-20(39-3)21(19)29-24(36)22(27)28/h4-10,22,33H,11-16H2,1-3H3
DMJY15D	CS	CN(C)CCS(=O)(=O)NC1=CC=C(C=C1)C2=NC(=NC(=N2)N3CCOCC3)N4C5=C(C(=CC=C5)OC)N=C4C(F)F
DMJY15D	IK	GDCJHDUWWAKBIW-UHFFFAOYSA-N
DMJY15D	IU	N-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide
DMJY15D	CA	CAS 1246203-32-6
DMJY15D	DE	Solid tumour/cancer

DMWU682	ID	DMWU682
DMWU682	DN	PX-102
DMWU682	HS	Phase 1
DMWU682	SN	Px-102; PX20606 trans-isomer; UNII-378SU5NO8S; 378SU5NO8S; CHEMBL3822773; 1268244-85-4 (trans-isomer); 4-((1S,2S)-2-(2-CHLORO-4-((5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)ISOXAZOL-4-YL)METHOXY)PHENYL)CYCLOPROPYL)BENZOIC ACID; Px-104; 2020096-17-5; 1268244-85-4; PX 20606; SCHEMBL17087854; 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid; BDBM50185707; ZINC115372389; DB15416; 4-(2-(2-Chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid; AC-30349; PX-20606; PX-102(PX-20606); UNII-6TU6SUZ3BY component XBUXXJUEBFDQHD-NHCUHLMSSA-N; Benzoic acid, 4-((1R,2R)-2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)-, rel-(-)-; Benzoic acid, 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)-
DMWU682	DT	Small molecular drug
DMWU682	PC	118374999
DMWU682	MW	554.8
DMWU682	FM	C29H22Cl3NO4
DMWU682	IC	InChI=1S/C29H22Cl3NO4/c30-23-2-1-3-24(31)26(23)27-22(28(37-33-27)16-6-7-16)14-36-18-10-11-19(25(32)12-18)21-13-20(21)15-4-8-17(9-5-15)29(34)35/h1-5,8-12,16,20-21H,6-7,13-14H2,(H,34,35)/t20-,21-/m1/s1
DMWU682	CS	C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)[C@H]5C[C@@H]5C6=CC=C(C=C6)C(=O)O)Cl
DMWU682	IK	XBUXXJUEBFDQHD-NHCUHLMSSA-N
DMWU682	IU	4-[(1S,2S)-2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]cyclopropyl]benzoic acid
DMWU682	CA	CAS 1268244-85-4
DMWU682	DE	Hepatic fibrosis

DM4AU8K	ID	DM4AU8K
DM4AU8K	DN	PX-478
DM4AU8K	HS	Phase 1
DM4AU8K	SN	PX-478; 685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di
DM4AU8K	TC	Anticancer Agents
DM4AU8K	DT	Small molecular drug
DM4AU8K	PC	11234794
DM4AU8K	MW	394.1
DM4AU8K	FM	C13H20Cl4N2O3
DM4AU8K	IC	InChI=1S/C13H18Cl2N2O3.2ClH/c14-5-7-17(20,8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19;;/h1-4,12H,5-9,16H2,(H,18,19);2*1H/t12-;;/m0../s1
DM4AU8K	CS	C1=CC(=CC=C1C[C@@H](C(=O)O)N)[N+](CCCl)(CCCl)[O-].Cl.Cl
DM4AU8K	IK	GIGCDIVNDFQKRA-LTCKWSDVSA-N
DM4AU8K	IU	4-[(2S)-2-amino-2-carboxyethyl]-N,N-bis(2-chloroethyl)benzeneamine oxide;dihydrochloride
DM4AU8K	CA	CAS 685898-44-6
DM4AU8K	DE	Solid tumour/cancer

DMVQJOS	ID	DMVQJOS
DMVQJOS	DN	PXS-25
DMVQJOS	HS	Phase 1
DMVQJOS	CP	Pharmaxis Ltd
DMVQJOS	DE	Fibrosis

DMW7K39	ID	DMW7K39
DMW7K39	DN	Pyrotinib
DMW7K39	HS	Phase 1
DMW7K39	SN	UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho
DMW7K39	CP	Hengrui Therapeutics Princeton, NJ
DMW7K39	PC	51039030
DMW7K39	MW	583.1
DMW7K39	FM	C32H31ClN6O3
DMW7K39	IC	InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1
DMW7K39	CS	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/[C@H]5CCCN5C
DMW7K39	IK	SADXACCFNXBCFY-IYNHSRRRSA-N
DMW7K39	IU	(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide
DMW7K39	CA	CAS 1269662-73-8
DMW7K39	DE	Solid tumour/cancer

DMRGWDB	ID	DMRGWDB
DMRGWDB	DN	PZ01 CAR-T cells
DMRGWDB	HS	Phase 1
DMRGWDB	CP	Pinze Lifetechnology Co. Ltd.
DMRGWDB	DT	CAR T Cell Therapy
DMRGWDB	DE	Acute lymphoblastic leukaemia; B-cell lymphoma

DMP3QSA	ID	DMP3QSA
DMP3QSA	DN	Quinazoline derivative 9
DMP3QSA	HS	Phase 1
DMP3QSA	SN	PMID26161698-Compound-47
DMP3QSA	CP	SENEX BIOTECHNOLOGY INC
DMP3QSA	DT	Small molecular drug
DMP3QSA	PC	71661259
DMP3QSA	MW	450.5
DMP3QSA	FM	C27H26N6O
DMP3QSA	IC	InChI=1S/C27H26N6O/c1-32-10-12-33(13-11-32)27(34)23-6-5-21-14-19(2-4-22(21)16-23)8-9-29-26-24-15-20(17-28)3-7-25(24)30-18-31-26/h2-7,14-16,18H,8-13H2,1H3,(H,29,30,31)
DMP3QSA	CS	CN1CCN(CC1)C(=O)C2=CC3=C(C=C2)C=C(C=C3)CCNC4=NC=NC5=C4C=C(C=C5)C#N
DMP3QSA	IK	VNADJTWHOAMTLY-UHFFFAOYSA-N
DMP3QSA	IU	4-[2-[6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl]ethylamino]quinazoline-6-carbonitrile
DMP3QSA	CA	CAS 1449228-40-3
DMP3QSA	DE	Breast cancer

DM64U1Y	ID	DM64U1Y
DM64U1Y	DN	R-1663
DM64U1Y	HS	Phase 1
DM64U1Y	CP	Roche Holding AG
DM64U1Y	DE	Coagulation defect

DMSKHIC	ID	DMSKHIC
DMSKHIC	DN	R4996
DMSKHIC	HS	Phase 1
DMSKHIC	CP	Roche
DMSKHIC	PC	738660
DMSKHIC	MW	208.64
DMSKHIC	FM	C11H9ClO2
DMSKHIC	IC	InChI=1S/C11H9ClO2/c12-9-3-1-8(2-4-9)11-6-5-10(7-13)14-11/h1-6,13H,7H2
DMSKHIC	CS	C1=CC(=CC=C1C2=CC=C(O2)CO)Cl
DMSKHIC	IK	PMHZVTQIEAIJBK-UHFFFAOYSA-N
DMSKHIC	IU	[5-(4-chlorophenyl)furan-2-yl]methanol
DMSKHIC	CA	CAS 33342-29-9
DMSKHIC	DE	Neurological disorder

DM5XCRQ	ID	DM5XCRQ
DM5XCRQ	DN	R552
DM5XCRQ	HS	Phase 1
DM5XCRQ	SN	2-(Methylthio)thiazole; 5053-24-7; 2-Methylthiothiazole; 2-methylthio thiazole; 2-Methylthio-1,3-thiazole; Thiazole, 2-(methylthio)-; 2-methylsulfanyl-1,3-thiazole; 2-(methylsulfanyl)-1,3-thiazole; MFCD00858981; ACMC-209knn; 2-(methylthio) thiazole; 2-methylsulfanyl-thiazole; 2-(Methylmercapto)thiazole; 2-Methylthiothiazole, 97%; C4H5NS2; SCHEMBL496215; DTXSID60375024; ZINC2570798; ANW-31041; AKOS006223218; GS-6827; FT-0658231; M1712; A828155; Q-100565
DM5XCRQ	CP	Rigel
DM5XCRQ	DT	Small molecular drug
DM5XCRQ	PC	2760100
DM5XCRQ	MW	131.2
DM5XCRQ	FM	C4H5NS2
DM5XCRQ	IC	InChI=1S/C4H5NS2/c1-6-4-5-2-3-7-4/h2-3H,1H3
DM5XCRQ	CS	CSC1=NC=CS1
DM5XCRQ	IK	VQNOAXZUEKPSJC-UHFFFAOYSA-N
DM5XCRQ	IU	2-methylsulfanyl-1,3-thiazole
DM5XCRQ	CA	CAS 5053-24-7
DM5XCRQ	DE	Nervous system paraneoplastic or autoimmune disorders

DMVA186	ID	DMVA186
DMVA186	DN	R7334
DMVA186	HS	Phase 1
DMVA186	SN	R 7334; 2-Nitro-6,7,8,9-tetrahydronaphtho(1,2-b)furan; 2-nitro-6,7,8,9-tetrahydrobenzo[g][1]benzofuran; 6,7,8,9-Tetrahydro-2-nitronaphtho(1,2-b)furan
DMVA186	CP	Roche
DMVA186	DT	Antibody
DMVA186	DE	Macular degeneration

DME0CJ9	ID	DME0CJ9
DME0CJ9	DN	R763
DME0CJ9	HS	Phase 1
DME0CJ9	TC	Anticancer Agents
DME0CJ9	DT	Small molecular drug
DME0CJ9	PC	11569967
DME0CJ9	MW	451.5
DME0CJ9	FM	C24H30FN7O
DME0CJ9	IC	InChI=1S/C24H30FN7O/c1-14-11-17(5-6-19(14)32-9-7-31(2)8-10-32)28-24-27-13-18(25)23(30-24)29-21-16-4-3-15(12-16)20(21)22(26)33/h3-6,11,13,15-16,20-21H,7-10,12H2,1-2H3,(H2,26,33)(H2,27,28,29,30)/t15-,16+,20+,21-/m1/s1
DME0CJ9	CS	CC1=C(C=CC(=C1)NC2=NC=C(C(=N2)N[C@@H]3[C@@H]4C[C@H]([C@@H]3C(=O)N)C=C4)F)N5CCN(CC5)C
DME0CJ9	IK	KSOVGRCOLZZTPF-QMKUDKLTSA-N
DME0CJ9	IU	(1S,2S,3R,4R)-3-[[5-fluoro-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide
DME0CJ9	CA	CAS 871357-89-0
DME0CJ9	DE	Haematological malignancy

DM1N8PZ	ID	DM1N8PZ
DM1N8PZ	DN	rAAV1.tMCK.human-alpha-sarcoglycan
DM1N8PZ	HS	Phase 1
DM1N8PZ	SN	alpha-sarcoglycan adenoviral gene therapy
DM1N8PZ	DE	Discovery agent

DMNVDI2	ID	DMNVDI2
DMNVDI2	DN	RAD-140
DMNVDI2	HS	Phase 1
DMNVDI2	SN	RAD-35010; Selective androgen receptor modulators (oral, sarcopenia/osteoporosis), Radius Health
DMNVDI2	CP	Radius Health Inc
DMNVDI2	DT	Small molecular drug
DMNVDI2	PC	44200882
DMNVDI2	MW	393.8
DMNVDI2	FM	C20H16ClN5O2
DMNVDI2	IC	InChI=1S/C20H16ClN5O2/c1-11-16(8-7-15(10-23)17(11)21)24-18(12(2)27)20-26-25-19(28-20)14-5-3-13(9-22)4-6-14/h3-8,12,18,24,27H,1-2H3/t12-,18+/m0/s1
DMNVDI2	CS	CC1=C(C=CC(=C1Cl)C#N)N[C@@H](C2=NN=C(O2)C3=CC=C(C=C3)C#N)[C@H](C)O
DMNVDI2	IK	XMBUPPIEVAFYHO-KPZWWZAWSA-N
DMNVDI2	IU	2-chloro-4-[[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile
DMNVDI2	CA	CAS 1182367-47-0
DMNVDI2	DE	Osteoporosis; Breast cancer

DMIEJ0W	ID	DMIEJ0W
DMIEJ0W	DN	Radiolabelled-huA33
DMIEJ0W	HS	Phase 1
DMIEJ0W	SN	Radiolabelled-huA33 (colorectal cancer); Radiolabelled-huA33 (colorectal cancer), Ludwig; 124I-huA33; 125I-huA33
DMIEJ0W	CP	Ludwig Institute for Cancer Research
DMIEJ0W	DT	Antibody
DMIEJ0W	DE	Colorectal cancer

DM4VTX6	ID	DM4VTX6
DM4VTX6	DN	RASV-Sp
DM4VTX6	HS	Phase 1
DM4VTX6	SN	Recombinant attenuated Salmonella Typhi vaccine vectors expressing the Streptococcus pneumoniae surface protein (PspA) alpha-helical domain fused to B-lactamase (oral, Streptococcus pneumoniae infection), Arizona State University
DM4VTX6	CP	Arizona State University
DM4VTX6	DT	Vaccine
DM4VTX6	DE	Streptococcus infection

DMAP6CS	ID	DMAP6CS
DMAP6CS	DN	RBN-2397
DMAP6CS	HS	Phase 1
DMAP6CS	SN	2381037-82-5; Atamparib; Atamparib [INN]; UNII-B1MW2ME77A; B1MW2ME77A; SCHEMBL21521281; RBN2397; BCP33764; EX-A4038; RBN2397;RBN 2397; NSC825956; s8993; NSC-825956; HY-136174; CS-0120272; 3(2H)-Pyridazinone, 5-(((1S)-1-methyl-2-(3-oxo-3-(4-(5-(trifluoromethyl)-2-pyrimidinyl)-1-piperazinyl)propoxy)ethyl)amino)-4-(trifluoromethyl)-; 5-(((2S)-1-(3-Oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2- yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4- (trifluoromethyl)pyridazin-3(2H)-one
DMAP6CS	CP	Ribon Therapeutics
DMAP6CS	DT	Small molecular drug
DMAP6CS	PC	146047148
DMAP6CS	MW	523.4
DMAP6CS	FM	C20H23F6N7O3
DMAP6CS	IC	InChI=1S/C20H23F6N7O3/c1-12(30-14-10-29-31-17(35)16(14)20(24,25)26)11-36-7-2-15(34)32-3-5-33(6-4-32)18-27-8-13(9-28-18)19(21,22)23/h8-10,12H,2-7,11H2,1H3,(H2,30,31,35)/t12-/m0/s1
DMAP6CS	CS	C[C@@H](COCCC(=O)N1CCN(CC1)C2=NC=C(C=N2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F
DMAP6CS	IK	UQZCQKXJAXKZQH-LBPRGKRZSA-N
DMAP6CS	IU	4-[[(2S)-1-[3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy]propan-2-yl]amino]-5-(trifluoromethyl)-1H-pyridazin-6-one
DMAP6CS	CA	CAS 2381037-82-5
DMAP6CS	DE	Solid tumour/cancer

DM25GIA	ID	DM25GIA
DM25GIA	DN	REC-01
DM25GIA	HS	Phase 1
DM25GIA	CP	Recardio San Francisco, CA
DM25GIA	DE	Acute myocardial infarction

DMHT5XV	ID	DMHT5XV
DMHT5XV	DN	REC-02
DMHT5XV	HS	Phase 1
DMHT5XV	CP	Recardio San Francisco, CA
DMHT5XV	DE	Congestive heart failure

DMK9Y71	ID	DMK9Y71
DMK9Y71	DN	Recombinant human Erbb3 fragment therapeutic tumor vaccine
DMK9Y71	HS	Phase 1
DMK9Y71	SN	Fragment therapeutic tumor vaccine; Recombinant human Erbb3 fragment therapeutic tumor vaccine (injectable, Erbb2-overexpressing cancer)
DMK9Y71	CP	Zensun (Shanghai) Sci-Tech Co Ltd
DMK9Y71	DT	Vaccine
DMK9Y71	DE	Solid tumour/cancer

DMYBELW	ID	DMYBELW
DMYBELW	DN	REGN1193
DMYBELW	HS	Phase 1
DMYBELW	CP	Regeneron Pharmaceuticals; Sanofi
DMYBELW	DT	Antibody
DMYBELW	DE	Type-2 diabetes

DME3VU8	ID	DME3VU8
DME3VU8	DN	REGN1400
DME3VU8	HS	Phase 1
DME3VU8	DT	Antibody
DME3VU8	DE	Solid tumour/cancer

DM0E3ZG	ID	DM0E3ZG
DM0E3ZG	DN	REGN3048
DM0E3ZG	HS	Phase 1
DM0E3ZG	DT	Antibody
DM0E3ZG	DE	Coronavirus infection

DM7LIV2	ID	DM7LIV2
DM7LIV2	DN	REGN3051
DM7LIV2	HS	Phase 1
DM7LIV2	CP	Regeneron Pharmaceuticals; Sanofi
DM7LIV2	DT	Antibody
DM7LIV2	DE	Coronavirus infection

DMWJ0IH	ID	DMWJ0IH
DMWJ0IH	DN	REGN-421
DMWJ0IH	HS	Phase 1
DMWJ0IH	SN	Dll4 antibody; Dll4-Fc; Delta-like ligand 4 antibody (VelociSuite), Regeneron, sanofi-aventis
DMWJ0IH	CP	Regeneron pharmaceuticals; sanofi us
DMWJ0IH	DT	Antibody
DMWJ0IH	DE	Solid tumour/cancer

DM3720L	ID	DM3720L
DM3720L	DN	REGN5093
DM3720L	HS	Phase 1
DM3720L	CP	Regeneron Pharmaceuticals
DM3720L	DT	Antibody
DM3720L	DE	Non-small-cell lung cancer

DM0ZMNI	ID	DM0ZMNI
DM0ZMNI	DN	REGN6569
DM0ZMNI	HS	Phase 1
DM0ZMNI	CP	Regeneron Pharmaceuticals
DM0ZMNI	DT	Antibody
DM0ZMNI	DE	Squamous head and neck cell carcinom

DMHR7D4	ID	DMHR7D4
DMHR7D4	DN	REGN-910
DMHR7D4	HS	Phase 1
DMHR7D4	SN	SAR-3077646; Anti-angiopoietin-2 antibody (cancer), Regeneron/sanofi-aventis
DMHR7D4	CP	Regeneron Pharmaceuticals Inc
DMHR7D4	DT	Antibody
DMHR7D4	DE	Solid tumour/cancer

DMZJH23	ID	DMZJH23
DMZJH23	DN	REP8839
DMZJH23	HS	Phase 1
DMZJH23	SN	REP-8839; SB-682150; 2-[3-[4-Bromo-5-(1-fluorovinyl)-3-methylthien-2-ylmethylamino]propylamino]quinolin-4(1H)-one
DMZJH23	CP	Replidyne
DMZJH23	DT	Small molecular drug
DMZJH23	PC	9868368
DMZJH23	MW	450.4
DMZJH23	FM	C20H21BrFN3OS
DMZJH23	IC	InChI=1S/C20H21BrFN3OS/c1-12-17(27-20(13(2)22)19(12)21)11-23-8-5-9-24-18-10-16(26)14-6-3-4-7-15(14)25-18/h3-4,6-7,10,23H,2,5,8-9,11H2,1H3,(H2,24,25,26)
DMZJH23	CS	CC1=C(SC(=C1Br)C(=C)F)CNCCCNC2=CC(=O)C3=CC=CC=C3N2
DMZJH23	IK	BGJMKHPWCFXMOW-UHFFFAOYSA-N
DMZJH23	IU	2-[3-[[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen-2-yl]methylamino]propylamino]-1H-quinolin-4-one
DMZJH23	CA	CAS 757942-43-1
DMZJH23	DE	Bacterial infection

DMZ8WAQ	ID	DMZ8WAQ
DMZ8WAQ	DN	Retroviral vector-transduced autologous T cells to express CD22-specific CARs
DMZ8WAQ	HS	Phase 1
DMZ8WAQ	CP	Xinqiao Hospital of Chongqing
DMZ8WAQ	DT	CAR T Cell Therapy
DMZ8WAQ	DE	Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma

DMLHIMO	ID	DMLHIMO
DMLHIMO	DN	REV-576
DMLHIMO	HS	Phase 1
DMLHIMO	SN	Complement C5a inhibitor (inflammatory disorders/reperfusion injury), Evolutec
DMLHIMO	CP	Evolutec Group plc
DMLHIMO	DE	Autoimmune diabetes

DM7B650	ID	DM7B650
DM7B650	DN	RG-2833
DM7B650	HS	Phase 1
DM7B650	SN	RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen
DM7B650	CP	Repligen
DM7B650	DT	Small molecular drug
DM7B650	PC	56654642
DM7B650	MW	339.4
DM7B650	FM	C20H25N3O2
DM7B650	IC	InChI=1S/C20H25N3O2/c1-15-10-12-16(13-11-15)20(25)22-14-6-2-3-9-19(24)23-18-8-5-4-7-17(18)21/h4-5,7-8,10-13H,2-3,6,9,14,21H2,1H3,(H,22,25)(H,23,24)
DM7B650	CS	CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N
DM7B650	IK	VOPDXHFYDJAYNS-UHFFFAOYSA-N
DM7B650	IU	N-[6-(2-aminoanilino)-6-oxohexyl]-4-methylbenzamide
DM7B650	CA	CAS 1215493-56-3
DM7B650	DE	Friedreich's ataxia

DM8GC65	ID	DM8GC65
DM8GC65	DN	RG3039
DM8GC65	HS	Phase 1
DM8GC65	CP	Repligen
DM8GC65	PC	53258905
DM8GC65	MW	432.3
DM8GC65	FM	C21H23Cl2N5O
DM8GC65	IC	InChI=1S/C21H23Cl2N5O/c22-15-3-1-4-16(23)14(15)11-28-9-7-13(8-10-28)12-29-18-6-2-5-17-19(18)20(24)27-21(25)26-17/h1-6,13H,7-12H2,(H4,24,25,26,27)
DM8GC65	CS	C1CN(CCC1COC2=CC=CC3=C2C(=NC(=N3)N)N)CC4=C(C=CC=C4Cl)Cl
DM8GC65	IK	MNLHFGXIUJNDAF-UHFFFAOYSA-N
DM8GC65	IU	5-[[1-[(2,6-dichlorophenyl)methyl]piperidin-4-yl]methoxy]quinazoline-2,4-diamine
DM8GC65	CA	CAS 1005504-62-0
DM8GC65	DE	Spinal muscular atrophy

DM45HT6	ID	DM45HT6
DM45HT6	DN	RG6062
DM45HT6	HS	Phase 1
DM45HT6	SN	Glofitamab
DM45HT6	CP	Roche/Genentech
DM45HT6	DT	Antibody
DM45HT6	DE	Follicular lymphoma

DMO9BGI	ID	DMO9BGI
DMO9BGI	DN	RG6076
DMO9BGI	HS	Phase 1
DMO9BGI	CP	Roche/Genentech
DMO9BGI	DT	Recombinant protein
DMO9BGI	DE	Hematologic tumour

DM9QNMB	ID	DM9QNMB
DM9QNMB	DN	RG6084
DM9QNMB	HS	Phase 1
DM9QNMB	CP	Roche
DM9QNMB	DT	Antisense oligonucleotide
DM9QNMB	DE	Hepatitis B virus infection

DM6TLPD	ID	DM6TLPD
DM6TLPD	DN	RG6115
DM6TLPD	HS	Phase 1
DM6TLPD	SN	RO7119929
DM6TLPD	CP	Roche/Genentech
DM6TLPD	DE	Hepatocellular carcinoma

DMX8YO1	ID	DMX8YO1
DMX8YO1	DN	RG6125
DMX8YO1	HS	Phase 1
DMX8YO1	CP	RocheBasel, Switzerland
DMX8YO1	DE	Rheumatoid arthritis

DMJFM3O	ID	DMJFM3O
DMJFM3O	DN	RG6139
DMJFM3O	HS	Phase 1
DMJFM3O	CP	Roche/Genentech
DMJFM3O	DT	Antibody
DMJFM3O	DE	Solid tumour/cancer

DMIHC4R	ID	DMIHC4R
DMIHC4R	DN	RG6146
DMIHC4R	HS	Phase 1
DMIHC4R	CP	Roche/Genentech South San Francisco, CA
DMIHC4R	DE	Haematological malignancy; Solid tumour/cancer

DMSM0IJ	ID	DMSM0IJ
DMSM0IJ	DN	RG6279
DMSM0IJ	HS	Phase 1
DMSM0IJ	SN	RO7284755
DMSM0IJ	CP	Roche/Genentech
DMSM0IJ	DT	Recombinant protein
DMSM0IJ	DE	Solid tumour/cancer

DMBRYZ7	ID	DMBRYZ7
DMBRYZ7	DN	RG6292
DMBRYZ7	HS	Phase 1
DMBRYZ7	SN	CD25 mAb
DMBRYZ7	CP	Roche/Genentech
DMBRYZ7	DT	Antibody
DMBRYZ7	DE	Solid tumour/cancer

DMEFUSJ	ID	DMEFUSJ
DMEFUSJ	DN	RG6296
DMEFUSJ	HS	Phase 1
DMEFUSJ	SN	AFM-26
DMEFUSJ	CP	Affimed Therapeutics; Roche/Genentech
DMEFUSJ	DT	Antibody
DMEFUSJ	DE	Multiple myeloma

DMSX5NJ	ID	DMSX5NJ
DMSX5NJ	DN	RG6330
DMSX5NJ	HS	Phase 1
DMSX5NJ	SN	GDC-6036
DMSX5NJ	CP	Roche/Genentech
DMSX5NJ	DE	Solid tumour/cancer

DMOWYKS	ID	DMOWYKS
DMOWYKS	DN	RG6346
DMOWYKS	HS	Phase 1
DMOWYKS	CP	Dicerna Pharmaceuticals; Roche
DMOWYKS	DT	Small interfering RNA
DMOWYKS	DE	Hepatitis B virus infection

DMMWS3O	ID	DMMWS3O
DMMWS3O	DN	RG-7010
DMMWS3O	HS	Phase 1
DMMWS3O	SN	R-7010; PEGylated IGF1 (amyotrophic lateral sclerosis), Roche
DMMWS3O	CP	F Hoffmann-La Roche Ltd
DMMWS3O	DE	Motor neurone disease

DM2IDQ9	ID	DM2IDQ9
DM2IDQ9	DN	RG-7103
DM2IDQ9	HS	Phase 1
DM2IDQ9	SN	R-7103; RO-5024118; VPAC2 agonist (COPD), Roche
DM2IDQ9	CP	F Hoffmann-La Roche Ltd
DM2IDQ9	PC	90871060
DM2IDQ9	MW	3576.1
DM2IDQ9	FM	C161H260N46O46
DM2IDQ9	IC	InChI=1S/C161H260N46O46/c1-18-19-38-99(136(230)180-85(10)132(226)179-86(11)133(227)183-100(40-24-30-59-163)137(231)187-103-44-28-34-63-174-123(218)74-117(200-152(246)116(73-122(169)217)199-148(242)110(67-83(6)7)194-149(243)111(196-141(103)235)69-93-46-50-96(213)51-47-93)153(247)195-109(66-82(4)5)147(241)188-102(42-26-32-61-165)138(232)184-98(39-23-29-58-162)135(229)177-77-124(219)176-78-125(220)204-128(88(13)209)131(170)225)185-143(237)106(54-56-120(167)215)190-139(233)101(41-25-31-60-164)186-140(234)105(45-35-64-175-160(171)172)189-146(240)108(65-81(2)3)193-142(236)104(43-27-33-62-166)191-157(251)129(89(14)210)205-154(248)112(70-94-48-52-97(214)53-49-94)197-151(245)115(72-121(168)216)198-144(238)107(55-57-126(221)222)192-158(252)130(90(15)211)206-155(249)113(68-92-36-21-20-22-37-92)203-159(253)161(17,84(8)9)207-134(228)87(12)181-145(239)118(75-127(223)224)201-156(250)119(79-208)202-150(244)114(182-91(16)212)71-95-76-173-80-178-95/h20-22,36-37,46-53,76,80-90,98-119,128-130,208-211,213-214H,18-19,23-35,38-45,54-75,77-79,162-166H2,1-17H3,(H2,167,215)(H2,168,216)(H2,169,217)(H2,170,225)(H,173,178)(H,174,218)(H,176,219)(H,177,229)(H,179,226)(H,180,230)(H,181,239)(H,182,212)(H,183,227)(H,184,232)(H,185,237)(H,186,234)(H,187,231)(H,188,241)(H,189,240)(H,190,233)(H,191,251)(H,192,252)(H,193,236)(H,194,243)(H,195,247)(H,196,235)(H,197,245)(H,198,238)(H,199,242)(H,200,246)(H,201,250)(H,202,244)(H,203,253)(H,204,220)(H,205,248)(H,206,249)(H,207,228)(H,221,222)(H,223,224)(H4,171,172,175)/t85-,86-,87-,88?,89?,90?,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,128-,129-,130-,161-/m0/s1
DM2IDQ9	CS	CCCC[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CCCCNC(=O)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC=C(C=C2)O)CC(C)C)CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)O)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CN=CN5)NC(=O)C
DM2IDQ9	IK	AXQOGBKHHSARHC-CEPMLMOKSA-N
DM2IDQ9	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-2,3-dimethylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S,5S,8S,11S,19S)-11-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[2-[[2-[[(2S)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]-8-(2-amino-2-oxoethyl)-2-[(4-hydroxyphenyl)methyl]-5-(2-methylpropyl)-3,6,9,13,20-pentaoxo-1,4,7,10,14-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid
DM2IDQ9	CA	CAS 1001080-55-2
DM2IDQ9	DE	Chronic obstructive pulmonary disease

DM6XVCO	ID	DM6XVCO
DM6XVCO	DN	RG7116
DM6XVCO	HS	Phase 1
DM6XVCO	CP	Roche
DM6XVCO	DE	Solid tumour/cancer

DMTWSM2	ID	DMTWSM2
DMTWSM2	DN	RG7129
DMTWSM2	HS	Phase 1
DMTWSM2	CP	Roche
DMTWSM2	PC	53241828
DMTWSM2	MW	389.3
DMTWSM2	FM	C18H14F3N5O2
DMTWSM2	IC	InChI=1S/C18H14F3N5O2/c1-17(18(20,21)9-28-16(23)26-17)12-6-11(3-4-13(12)19)25-15(27)14-5-2-10(7-22)8-24-14/h2-6,8H,9H2,1H3,(H2,23,26)(H,25,27)/t17-/m1/s1
DMTWSM2	CS	C[C@]1(C(COC(=N1)N)(F)F)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F
DMTWSM2	IK	DVMUZHLUMHPCGZ-QGZVFWFLSA-N
DMTWSM2	IU	N-[3-[(4R)-2-amino-5,5-difluoro-4-methyl-6H-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
DMTWSM2	CA	CAS 1310347-50-2
DMTWSM2	DE	Alzheimer disease

DMYX4NP	ID	DMYX4NP
DMYX4NP	DN	RG7203
DMYX4NP	HS	Phase 1
DMYX4NP	CP	Roche
DMYX4NP	DE	Schizophrenia

DMGFAVQ	ID	DMGFAVQ
DMGFAVQ	DN	RG7304
DMGFAVQ	HS	Phase 1
DMGFAVQ	CP	Chugai; Roche
DMGFAVQ	PC	74890577
DMGFAVQ	MW	228.25
DMGFAVQ	FM	C12H12N4O
DMGFAVQ	IC	InChI=1S/C12H12N4O/c1-16(11-7-12(17)15-13-9-11)14-8-10-5-3-2-4-6-10/h2-9H,1H3,(H,15,17)/b14-8-
DMGFAVQ	CS	CN(C1=CC(=O)NN=C1)/N=C\\C2=CC=CC=C2
DMGFAVQ	IK	CTGDOGPKSFBVDA-ZSOIEALJSA-N
DMGFAVQ	IU	4-[[(Z)-benzylideneamino]-methylamino]-1H-pyridazin-6-one
DMGFAVQ	DE	Solid tumour/cancer

DMIW5NG	ID	DMIW5NG
DMIW5NG	DN	RG7342
DMIW5NG	HS	Phase 1
DMIW5NG	DE	Schizophrenia

DMOE5NQ	ID	DMOE5NQ
DMOE5NQ	DN	RG7347
DMOE5NQ	HS	Phase 1
DMOE5NQ	CP	Genentech; Roche
DMOE5NQ	DE	Solid tumour/cancer

DMFDKS7	ID	DMFDKS7
DMFDKS7	DN	RG-7348
DMFDKS7	HS	Phase 1
DMFDKS7	SN	MB-11362; Nucleosides (HepDirect, HCV infection), Roche/Metabasis
DMFDKS7	CP	Roche Holding AG
DMFDKS7	DE	Hepatitis C virus infection

DMFGR98	ID	DMFGR98
DMFGR98	DN	RG-7351
DMFGR98	HS	Phase 1
DMFGR98	SN	TAAR1 part agonist (depression), Roche; Trace amine-associated receptor 1 part agonist (depression), Roche
DMFGR98	CP	Roche Holding AG
DMFGR98	DE	Major depressive disorder

DM1NHEA	ID	DM1NHEA
DM1NHEA	DN	RG7450
DM1NHEA	HS	Phase 1
DM1NHEA	SN	Anti-STEAP1, DSTP3086S
DM1NHEA	CP	Seattle Genetics; Roche
DM1NHEA	DE	Prostate cancer

DM5OTGR	ID	DM5OTGR
DM5OTGR	DN	RG7461
DM5OTGR	HS	Phase 1
DM5OTGR	CP	Roche/Genentech South San Francisco, CA
DM5OTGR	DE	Solid tumour/cancer

DMK6P9J	ID	DMK6P9J
DMK6P9J	DN	RG7741
DMK6P9J	HS	Phase 1
DMK6P9J	SN	GDC-0575
DMK6P9J	CP	Roche
DMK6P9J	DE	Lymphoma; Solid tumour/cancer

DMXBS6U	ID	DMXBS6U
DMXBS6U	DN	RG7775
DMXBS6U	HS	Phase 1
DMXBS6U	CP	Genentech
DMXBS6U	DE	Acute myeloid leukaemia

DMACLIH	ID	DMACLIH
DMACLIH	DN	RG7813
DMACLIH	HS	Phase 1
DMACLIH	SN	Cergutuzumab amunaleukin
DMACLIH	CP	GenentechSouth San Francisco, CA
DMACLIH	DE	Solid tumour/cancer

DMD16JK	ID	DMD16JK
DMD16JK	DN	RG-7816
DMD16JK	HS	Phase 1
DMD16JK	CP	Roche
DMD16JK	DE	Autism spectrum disorder

DMRGHKN	ID	DMRGHKN
DMRGHKN	DN	RG7827
DMRGHKN	HS	Phase 1
DMRGHKN	CP	Roche/Genentech
DMRGHKN	DT	Recombinant protein
DMRGHKN	DE	Solid tumour/cancer

DMCUBZO	ID	DMCUBZO
DMCUBZO	DN	RG7828
DMCUBZO	HS	Phase 1
DMCUBZO	CP	GenentechSouth San Francisco, CA
DMCUBZO	DE	Haematological malignancy

DMGLXQ9	ID	DMGLXQ9
DMGLXQ9	DN	RG7854
DMGLXQ9	HS	Phase 1
DMGLXQ9	CP	Roche
DMGLXQ9	DT	Small molecular drug
DMGLXQ9	DE	Hepatitis B virus infection

DM2E5Z7	ID	DM2E5Z7
DM2E5Z7	DN	RG7882
DM2E5Z7	HS	Phase 1
DM2E5Z7	CP	Genentech
DM2E5Z7	DT	Antibody
DM2E5Z7	DE	Ovarian cancer; Pancreatic cancer

DM1R4MQ	ID	DM1R4MQ
DM1R4MQ	DN	RG7893
DM1R4MQ	HS	Phase 1
DM1R4MQ	DE	Pain

DMKVIS5	ID	DMKVIS5
DMKVIS5	DN	RG7907
DMKVIS5	HS	Phase 1
DMKVIS5	SN	CPAM
DMKVIS5	CP	Roche
DMKVIS5	DT	Small molecular drug
DMKVIS5	PC	139202885
DMKVIS5	MW	352.15
DMKVIS5	FM	C15H11BrFNO3
DMKVIS5	IC	InChI=1S/C15H11BrFNO3/c16-11-8-10(17)3-4-12(11)18-15(21)6-2-9-1-5-13(19)14(20)7-9/h1-8,19-20H,(H,18,21)/b6-2+
DMKVIS5	CS	C1=CC(=C(C=C1/C=C/C(=O)NC2=C(C=C(C=C2)F)Br)O)O
DMKVIS5	IK	XOHNWHLPLQQICZ-QHHAFSJGSA-N
DMKVIS5	IU	(E)-N-(2-bromo-4-fluorophenyl)-3-(3,4-dihydroxyphenyl)prop-2-enamide
DMKVIS5	DE	Hepatitis B

DMEGOQP	ID	DMEGOQP
DMEGOQP	DN	RGB-286638
DMEGOQP	HS	Phase 1
DMEGOQP	SN	GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech
DMEGOQP	CP	GPC Biotech AG
DMEGOQP	DT	Small molecular drug
DMEGOQP	PC	11285001
DMEGOQP	MW	618.6
DMEGOQP	FM	C29H37Cl2N7O4
DMEGOQP	IC	InChI=1S/C29H35N7O4.2ClH/c1-39-16-13-34-9-11-35(12-10-34)19-20-5-7-21(8-6-20)26-25-27(32-31-26)22-3-2-4-23(24(22)28(25)37)30-29(38)33-36-14-17-40-18-15-36;;/h2-8H,9-19H2,1H3,(H,31,32)(H2,30,33,38);2*1H
DMEGOQP	CS	COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6.Cl.Cl
DMEGOQP	IK	WJVMGQMXUBAAPL-UHFFFAOYSA-N
DMEGOQP	IU	1-[3-[4-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]phenyl]-4-oxo-1H-indeno[1,2-c]pyrazol-5-yl]-3-morpholin-4-ylurea;dihydrochloride
DMEGOQP	CA	CAS 784210-87-3
DMEGOQP	DE	Haematological malignancy

DMVJMF1	ID	DMVJMF1
DMVJMF1	DN	RGD-891
DMVJMF1	HS	Phase 1
DMVJMF1	SN	Klerval; RPR-109039; N-Ethyl-N-[4-(4-piperidyl)butyryl]-glycyl-L-aspartyl-L-(3-cyclohexyl)alaninamide
DMVJMF1	PC	9806811
DMVJMF1	MW	523.7
DMVJMF1	FM	C26H45N5O6
DMVJMF1	IC	InChI=1S/C26H45N5O6/c1-2-31(23(33)10-6-9-18-11-13-28-14-12-18)17-22(32)29-21(16-24(34)35)26(37)30-20(25(27)36)15-19-7-4-3-5-8-19/h18-21,28H,2-17H2,1H3,(H2,27,36)(H,29,32)(H,30,37)(H,34,35)/t20-,21-/m0/s1
DMVJMF1	CS	CCN(CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N)C(=O)CCCC2CCNCC2
DMVJMF1	IK	PWINFPFVCZSLBF-SFTDATJTSA-N
DMVJMF1	IU	(3S)-4-[[(2S)-1-amino-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-[[2-[ethyl(4-piperidin-4-ylbutanoyl)amino]acetyl]amino]-4-oxobutanoic acid
DMVJMF1	CA	CAS 169512-56-5
DMVJMF1	DE	Angina pectoris; Thrombosis

DMQAIU1	ID	DMQAIU1
DMQAIU1	DN	RGLS4326
DMQAIU1	HS	Phase 1
DMQAIU1	SN	UNII-UCH3QQH1C0; UCH3QQH1C0; RGLS-4326; 2229964-07-0
DMQAIU1	CP	Regulus Therapeutics
DMQAIU1	DT	Oligonucleotide
DMQAIU1	PC	154824286
DMQAIU1	MW	3082.4
DMQAIU1	FM	C95H115F3N32O51P8S8
DMQAIU1	IC	InChI=1S/C95H115F3N32O51P8S8/c1-32-92(22-131)65(61(162-32)83(170-92)128-29-110-50-69(102)106-27-108-71(50)128)179-189(150,197)160-25-95-35(4)164-63(84(173-95)130-31-112-52-73(130)119-86(104)121-75(52)137)67(95)180-186(147,194)157-21-40-56(58(151-5)79(168-40)124-13-8-42(100)114-88(124)139)177-185(146,193)155-19-38-55(48(98)78(167-38)127-28-109-49-68(101)105-26-107-70(49)127)176-183(144,191)154-17-36-53(46(96)76(165-36)122-12-7-41(99)113-87(122)138)174-182(143,190)153-18-37-54(47(97)77(166-37)123-14-9-43(132)115-89(123)140)175-184(145,192)156-20-39-57(59(152-6)80(169-39)125-15-10-44(133)116-90(125)141)178-187(148,195)159-24-94-34(3)163-62(82(172-94)126-16-11-45(134)117-91(126)142)66(94)181-188(149,196)158-23-93-33(2)161-60(64(93)135)81(171-93)129-30-111-51-72(129)118-85(103)120-74(51)136/h7-16,26-40,46-48,53-67,76-84,131,135H,17-25H2,1-6H3,(H,143,190)(H,144,191)(H,145,192)(H,146,193)(H,147,194)(H,148,195)(H,149,196)(H,150,197)(H2,99,113,138)(H2,100,114,139)(H2,101,105,107)(H2,102,106,108)(H,115,132,140)(H,116,133,141)(H,117,134,142)(H3,103,118,120,136)(H3,104,119,121,137)/t32-,33-,34-,35-,36+,37+,38+,39+,40+,46+,47+,48+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64-,65-,66-,67-,76+,77+,78+,79+,80+,81+,82+,83+,84+,92-,93-,94-,95-,182?,183?,184?,185?,186?,187?,188?,189?/m0/s1
DMQAIU1	CS	C[C@H]1[C@]2([C@H]([C@@H](O1)[C@@H](O2)N3C=NC4=C(N=CN=C43)N)OP(=S)(O)OC[C@]56[C@@H](O[C@H]([C@@H]5OP(=O)(OC[C@@H]7[C@H]([C@H]([C@@H](O7)N8C=CC(=NC8=O)N)OC)OP(=S)(O)OC[C@@H]9[C@H]([C@H]([C@@H](O9)N1C=NC2=C(N=CN=C21)N)F)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=NC1=O)N)F)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=O)NC1=O)F)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=O)NC1=O)OC)OP(=S)(O)OC[C@]12[C@@H](O[C@H]([C@@H]1OP(=S)(O)OC[C@]13[C@@H](O[C@H]([C@@H]1O)[C@@H](O3)N1C=NC3=C1N=C(NC3=O)N)C)[C@@H](O2)N1C=CC(=O)NC1=O)C)S)[C@@H](O6)N1C=NC2=C1N=C(NC2=O)N)C)CO
DMQAIU1	IK	WAVSYQSKUSIMAY-IOHKGNKKSA-N
DMQAIU1	IU	1-[(1S,3R,4R,6S,7S)-1-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(1S,3R,4R,6S,7S)-3-(2-amino-6-oxo-1H-purin-9-yl)-1-[[[(1S,3R,4R,6S,7S)-3-(6-aminopurin-9-yl)-1-(hydroxymethyl)-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-fluorooxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluorooxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-fluorooxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-7-[[(1R,3R,4R,6S,7S)-3-(2-amino-6-oxo-1H-purin-9-yl)-7-hydroxy-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-3-yl]pyrimidine-2,4-dione
DMQAIU1	CA	CAS 2229964-07-0
DMQAIU1	DE	Autosomal dominant polycystic kidney disease

DMU87HW	ID	DMU87HW
DMU87HW	DN	RGX-111
DMU87HW	HS	Phase 1
DMU87HW	CP	REGENXBIO
DMU87HW	DT	Gene therapy
DMU87HW	DE	Mucopolysaccharidosis

DM8VGRX	ID	DM8VGRX
DM8VGRX	DN	RGX-202
DM8VGRX	HS	Phase 1
DM8VGRX	CP	Rgenix
DM8VGRX	DT	Small molecular drug
DM8VGRX	DE	Gastrointestinal cancer

DMDM85L	ID	DMDM85L
DMDM85L	DN	RH 1
DMDM85L	HS	Phase 1
DMDM85L	SN	RH-1
DMDM85L	TC	Anticancer Agents
DMDM85L	DT	Small molecular drug
DMDM85L	PC	394347
DMDM85L	MW	234.25
DMDM85L	FM	C12H14N2O3
DMDM85L	IC	InChI=1S/C12H14N2O3/c1-7-9(13-2-3-13)12(17)8(6-15)10(11(7)16)14-4-5-14/h15H,2-6H2,1H3
DMDM85L	CS	CC1=C(C(=O)C(=C(C1=O)N2CC2)CO)N3CC3
DMDM85L	IK	JKDLOGLNPDVUCX-UHFFFAOYSA-N
DMDM85L	IU	2,5-bis(aziridin-1-yl)-3-(hydroxymethyl)-6-methylcyclohexa-2,5-diene-1,4-dione
DMDM85L	CA	CAS 221635-42-3
DMDM85L	DE	Discovery agent

DM1HUA3	ID	DM1HUA3
DM1HUA3	DN	RHIgM12B7
DM1HUA3	HS	Phase 1
DM1HUA3	SN	SHIgM12; B7-DC-crosslinking recombinant human monoclonal antibody (cancer), Mayo Clinic
DM1HUA3	CP	Mayo Foundation
DM1HUA3	DT	Antibody
DM1HUA3	DE	Solid tumour/cancer

DM2A1DP	ID	DM2A1DP
DM2A1DP	DN	Ribavirin
DM2A1DP	HS	Phase 1
DM2A1DP	SN	ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Ribavirine; Copegus; Vilona; Ribamide; Ribasphere; Ribamidil; Viramid; Ribamidyl; Ribavirinum; Ribavirina; Rebetron; Varazid; RTCA; Ribavirin Capsules; Ribavirinum [INN-Latin]; Ribavirine [INN-French]; Ribavirina [INN-Spanish]; ICN-1229; Rebretron; Virazid; Ribav; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; DRG-0028; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; UNII-49717AWG6K; Ribavirin (Copegus);  Copegus; Cotronak; RBV; RTC; Ravanex; Ribacine; Ribovirin; Viramide; Virazide; R 9644; SCH 18908; C-Virin; Copegus (TN); Drug: Ribavirin; KS-1104; R-964; RG-964; Rebetol (TN); Ribasphere (TN); Ribavirin [USAN:INN]; Vilona (TN); Virazole (Ribavirin) Inhalation Solution; Virazole (TN); AA-504/07617051; Ro 20-9963/000; Ro-20-9963; Ribavirin (JAN/USP/INN); 1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; RBI034 (2-5A antisense compound) + Ribavirin
DM2A1DP	CP	Hoffmann-La Roche pharmaceutical company
DM2A1DP	TC	Antiviral Agents
DM2A1DP	DT	Small molecular drug
DM2A1DP	PC	37542
DM2A1DP	MW	244.2
DM2A1DP	FM	C8H12N4O5
DM2A1DP	IC	InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
DM2A1DP	CS	C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DM2A1DP	IK	IWUCXVSUMQZMFG-AFCXAGJDSA-N
DM2A1DP	IU	1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
DM2A1DP	CA	CAS 36791-04-5
DM2A1DP	CB	CHEBI:63580
DM2A1DP	DE	Hepatitis C virus infection; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMB9861	ID	DMB9861
DMB9861	DN	Rilapladib
DMB9861	HS	Phase 1
DMB9861	CP	GSK
DMB9861	DT	Small molecular drug
DMB9861	PC	9918381
DMB9861	MW	735.8
DMB9861	FM	C40H38F5N3O3S
DMB9861	IC	InChI=1S/C40H38F5N3O3S/c1-51-22-21-46-19-17-32(18-20-46)47(24-27-9-11-28(12-10-27)29-13-15-31(16-14-29)40(43,44)45)37(50)25-48-35-8-3-2-6-33(35)36(49)23-38(48)52-26-30-5-4-7-34(41)39(30)42/h2-16,23,32H,17-22,24-26H2,1H3
DMB9861	CS	COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C5=CC=CC=C5C(=O)C=C4SCC6=C(C(=CC=C6)F)F
DMB9861	IK	NNBGCSGCRSCFEA-UHFFFAOYSA-N
DMB9861	IU	2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
DMB9861	CA	CAS 412950-08-4
DMB9861	DE	Cardiovascular disease; Arteriosclerosis

DMUT4YZ	ID	DMUT4YZ
DMUT4YZ	DN	RLY-1971
DMUT4YZ	HS	Phase 1
DMUT4YZ	CP	Relay Therapeutics
DMUT4YZ	DT	Small molecular drug
DMUT4YZ	DE	Solid tumour/cancer

DM3O52N	ID	DM3O52N
DM3O52N	DN	RLY-4008
DM3O52N	HS	Phase 1
DM3O52N	CP	Relay Therapeutics
DM3O52N	DT	Small molecular drug
DM3O52N	DE	Solid tumour/cancer

DMQ65YW	ID	DMQ65YW
DMQ65YW	DN	RO-09-4889
DMQ65YW	HS	Phase 1
DMQ65YW	SN	Ro-0094889; 2',3'-Di-O-acetyl-5'-deoxy-5-vinylcytidine
DMQ65YW	DE	Solid tumour/cancer

DM95F8B	ID	DM95F8B
DM95F8B	DN	RO-14
DM95F8B	HS	Phase 1
DM95F8B	SN	Very low molecular weight heparin (venous thromboembolism), Rovi
DM95F8B	CP	Laboratorios Farmaceuticos Rovi SA
DM95F8B	DE	Phlebothrombosis

DM9PQ2N	ID	DM9PQ2N
DM9PQ2N	DN	RO-23-7553
DM9PQ2N	HS	Phase 1
DM9PQ2N	SN	BXL-353; ILX-23-7553; (1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19),16-tetraen-23-yne-1,3,25-triol; 1alpha,25-Dihydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol; 1alpha,25-Dihydroxy-16,17,23,23,24,24-hexadehydrovitamin D3
DM9PQ2N	DT	Small molecular drug
DM9PQ2N	PC	6438384
DM9PQ2N	MW	410.6
DM9PQ2N	FM	C27H38O3
DM9PQ2N	IC	InChI=1S/C27H38O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-12,18,22,24-25,28-30H,2,7-9,13,15-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,24+,25+,27-/m1/s1
DM9PQ2N	CS	C[C@H](CC#CC(C)(C)O)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM9PQ2N	IK	JKFZMIQMKFWJAY-RQJQXFIZSA-N
DM9PQ2N	IU	(1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM9PQ2N	CA	CAS 118694-43-2
DM9PQ2N	DE	Prostate disease

DML4C3Q	ID	DML4C3Q
DML4C3Q	DN	RO-5212054
DML4C3Q	HS	Phase 1
DML4C3Q	SN	PLX-3603
DML4C3Q	CP	Hoffmann-La Roche AG
DML4C3Q	DE	Solid tumour/cancer

DMVXQ5W	ID	DMVXQ5W
DMVXQ5W	DN	RO-5458640
DMVXQ5W	HS	Phase 1
DMVXQ5W	SN	Anti-TWEAK humanized monoclonal antibody (iv, cancer), Hoffmann-La Roche
DMVXQ5W	CP	Scantibodies Laboratory; biogen Idec
DMVXQ5W	DE	Solid tumour/cancer

DM7H6XI	ID	DM7H6XI
DM7H6XI	DN	RO6870810
DM7H6XI	HS	Phase 1
DM7H6XI	SN	JQ-35, (S)-; (S)-JQ-35; 1349719-98-7; (S)-JQ35; Bet inhibitor TEN-010; UNII-TA3QN7788D; TA3QN7788D; TEN-010; Ro-6870810; (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)acetamide; SCHEMBL881288; TEN010; CHEMBL4297423; Rg 6146; EX-A3890; NSC816555; DB15151; NSC-816555; SB19675; HY-117286; CS-0064969; Q27896195; C1CN(C)CCN1CCCNC(=O)C[C@H]1C2=NN=C(C)N2C(SC(C)=C2C)=C2C(C=2C=CC(Cl)=CC=2)=N1; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-chlorophenyl)-2,3,9-trimethyl-N-(3-(4-methyl-1-piperazinyl)propyl)-, (6S)-
DM7H6XI	CP	Roche
DM7H6XI	DT	Small molecular drug
DM7H6XI	PC	54670351
DM7H6XI	MW	540.1
DM7H6XI	FM	C27H34ClN7OS
DM7H6XI	IC	InChI=1S/C27H34ClN7OS/c1-17-18(2)37-27-24(17)25(20-6-8-21(28)9-7-20)30-22(26-32-31-19(3)35(26)27)16-23(36)29-10-5-11-34-14-12-33(4)13-15-34/h6-9,22H,5,10-16H2,1-4H3,(H,29,36)/t22-/m0/s1
DM7H6XI	CS	CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NCCCN4CCN(CC4)C)C5=CC=C(C=C5)Cl)C
DM7H6XI	IK	PKQXLRYFPSZKDU-QFIPXVFZSA-N
DM7H6XI	IU	2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]acetamide
DM7H6XI	CA	CAS 1349719-98-7
DM7H6XI	DE	Multiple myeloma

DMDRBNJ	ID	DMDRBNJ
DMDRBNJ	DN	ROCICLOVIR
DMDRBNJ	HS	Phase 1
DMDRBNJ	SN	Hoe-602; Rociclovir; 2-Amino-9-[1,3-bis(isopropoxy)-2-propyloxymethyl]purine; 6-Deoxy-9-(1-isopropoxymethyl-2-isopropoxyethoxymethyl)guanine
DMDRBNJ	DT	Small molecular drug
DMDRBNJ	PC	65905
DMDRBNJ	MW	323.39
DMDRBNJ	FM	C15H25N5O3
DMDRBNJ	IC	InChI=1S/C15H25N5O3/c1-10(2)21-6-12(7-22-11(3)4)23-9-20-8-18-13-5-17-15(16)19-14(13)20/h5,8,10-12H,6-7,9H2,1-4H3,(H2,16,17,19)
DMDRBNJ	CS	CC(C)OCC(COC(C)C)OCN1C=NC2=CN=C(N=C21)N
DMDRBNJ	IK	FBHWXSOQXQBXER-UHFFFAOYSA-N
DMDRBNJ	IU	9-[1,3-di(propan-2-yloxy)propan-2-yloxymethyl]purin-2-amine
DMDRBNJ	CA	CAS 108436-80-2
DMDRBNJ	DE	Virus infection

DM82KWY	ID	DM82KWY
DM82KWY	DN	Ronomilast
DM82KWY	HS	Phase 1
DM82KWY	SN	ELB-353; PDE4 inhibitor, BioTie; PDE4 inhibitor, elbion; AWD-12-353
DM82KWY	CP	Elbion AG
DM82KWY	DT	Small molecular drug
DM82KWY	PC	9803446
DM82KWY	MW	443.3
DM82KWY	FM	C21H13Cl2FN4O2
DM82KWY	IC	InChI=1S/C21H13Cl2FN4O2/c22-16-8-25-9-17(23)18(16)27-21(30)19(29)15-11-28(20-14(15)2-1-7-26-20)10-12-3-5-13(24)6-4-12/h1-9,11H,10H2,(H,25,27,30)
DM82KWY	CS	C1=CC2=C(N=C1)N(C=C2C(=O)C(=O)NC3=C(C=NC=C3Cl)Cl)CC4=CC=C(C=C4)F
DM82KWY	IK	JERXUPDBWDWFCF-UHFFFAOYSA-N
DM82KWY	IU	N-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]pyrrolo[2,3-b]pyridin-3-yl]-2-oxoacetamide
DM82KWY	CA	CAS 418794-42-0
DM82KWY	DE	Chronic obstructive pulmonary disease

DM5EUIY	ID	DM5EUIY
DM5EUIY	DN	ROR1 CAR-specific Autologous T-Lymphocytes
DM5EUIY	HS	Phase 1
DM5EUIY	CP	Fred Hutchinson Cancer Research Center
DM5EUIY	DT	CAR T Cell Therapy
DM5EUIY	DE	Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Mantle cell lymphoma

DMIAK9P	ID	DMIAK9P
DMIAK9P	DN	ROR1R-CAR-T Cell
DMIAK9P	HS	Phase 1
DMIAK9P	CP	M.D. Anderson Cancer Center
DMIAK9P	DT	CAR T Cell Therapy
DMIAK9P	DE	leukaemia

DM9O3RY	ID	DM9O3RY
DM9O3RY	DN	Rosmantuzumab
DM9O3RY	HS	Phase 1
DM9O3RY	CP	OncoMed Pharmaceuticals Redwood City, CA
DM9O3RY	DE	Colorectal cancer; Solid tumour/cancer

DME9UTO	ID	DME9UTO
DME9UTO	DN	RP4010
DME9UTO	HS	Phase 1
DME9UTO	CP	Rhizen PharmaceuticalsLa Chaux-de-Fonds, Switzerland
DME9UTO	DE	Non-hodgkin lymphoma

DMHZ24N	ID	DMHZ24N
DMHZ24N	DN	RP-A501
DMHZ24N	HS	Phase 1
DMHZ24N	CP	Rocket Pharmaceuticals
DMHZ24N	DT	Gene therapy
DMHZ24N	DE	Type 2 glycogen storage disease

DMXKFOQ	ID	DMXKFOQ
DMXKFOQ	DN	RPI-78M
DMXKFOQ	HS	Phase 1
DMXKFOQ	SN	Antiviral agent, Receptogen; RPI-78M; Receptin (injectable), ReceptoPharm; Receptin (oral), ReceptoPharm; RPI-78M (injectable), ReceptoPharm; RPI-78M (oral), ReceptoPharm
DMXKFOQ	CP	ReceptoPharm Inc; ReceptoPharm
DMXKFOQ	DE	Multiple sclerosis; Rheumatoid arthritis

DM5OXPZ	ID	DM5OXPZ
DM5OXPZ	DN	RPI-MN
DM5OXPZ	HS	Phase 1
DM5OXPZ	SN	Pepteron (oral, HIV), ReceptoPharm; RPI-MN (oral, HIV); RPI-MN (oral, HIV), ReceptoPharm
DM5OXPZ	CP	ReceptoPharm Inc
DM5OXPZ	DE	Human immunodeficiency virus infection; Amyotrophic lateral sclerosis

DMA6JME	ID	DMA6JME
DMA6JME	DN	RTA 901
DMA6JME	HS	Phase 1
DMA6JME	CP	Reata Pharmaceuticals
DMA6JME	DT	Small molecular drug
DMA6JME	DE	Diabetic neuropathy

DM7C062	ID	DM7C062
DM7C062	DN	RTA-901
DM7C062	HS	Phase 1
DM7C062	CP	Reata Pharmaceuticals Irving, TX
DM7C062	DE	Diabetic neuropathy

DMY8D5O	ID	DMY8D5O
DMY8D5O	DN	RTI-336
DMY8D5O	HS	Phase 1
DMY8D5O	SN	CHEMBL432878; RTI-336; 3-(4-Chloro-phenyl)-8-methyl-2-(3-p-tolyl-isoxazol-5-yl)-8-aza-bicyclo[3.2.1]octane
DMY8D5O	CP	Research Triangle Institute
DMY8D5O	DT	Small molecular drug
DMY8D5O	PC	11524766
DMY8D5O	MW	429.4
DMY8D5O	FM	C24H26Cl2N2O
DMY8D5O	IC	InChI=1S/C24H25ClN2O.ClH/c1-15-3-5-17(6-4-15)21-14-23(28-26-21)24-20(16-7-9-18(25)10-8-16)13-19-11-12-22(24)27(19)2;/h3-10,14,19-20,22,24H,11-13H2,1-2H3;1H/t19-,20+,22+,24-;/m0./s1
DMY8D5O	CS	CC1=CC=C(C=C1)C2=NOC(=C2)[C@@H]3[C@H]4CC[C@H](N4C)C[C@@H]3C5=CC=C(C=C5)Cl.Cl
DMY8D5O	IK	IZMZEMAKFSYLMD-SXBQIKTFSA-N
DMY8D5O	IU	5-[(1R,2S,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-3-(4-methylphenyl)-1,2-oxazole;hydrochloride
DMY8D5O	CA	CAS 204069-50-1
DMY8D5O	DE	Cocaine addiction

DM1B4CQ	ID	DM1B4CQ
DM1B4CQ	DN	RTL-1000
DM1B4CQ	HS	Phase 1
DM1B4CQ	SN	VG-1000; VGI-303; Recombinant t-cell ligand (multiple sclerosis), Artielle
DM1B4CQ	CP	Artielle immunotherapeutics
DM1B4CQ	DE	Multiple sclerosis

DMYRPC8	ID	DMYRPC8
DMYRPC8	DN	RVSVIN HIV-1 gag vaccine
DMYRPC8	HS	Phase 1
DMYRPC8	SN	RVSVIN HIV-1 gag vaccine, Profectus Biosciences; RVSV vector-based HIV-1 vaccine, Profectus BioSciences; Recombinant VSV vector-based HIV-1 vaccine, Profectus BioSciences; Recombinant vesicular stomatitis virus vector-based HIV-1 vaccine, Profectus BioSciences
DMYRPC8	CP	Wyeth Pharmaceuticals
DMYRPC8	DT	Vaccine
DMYRPC8	DE	Human immunodeficiency virus infection

DM0YCG3	ID	DM0YCG3
DM0YCG3	DN	RVT-103+RVT-104
DM0YCG3	HS	Phase 1
DM0YCG3	CP	Axovant Sciences New York, NY
DM0YCG3	DE	Alzheimer disease

DMJVCS1	ID	DMJVCS1
DMJVCS1	DN	RWJ-671818
DMJVCS1	HS	Phase 1
DMJVCS1	SN	RWJ-671818; CHEMBL1083499; N-[2-(Carbamimidamidooxy)ethyl]-2-{3-[(2,2-Difluoro-2-Phenylethyl)amino]-6-Methyl-2-Oxopyrazin-1(2h)-Yl}acetamide; SCHEMBL3243104; BDBM50312651; NLI
DMJVCS1	DT	Small molecular drug
DMJVCS1	PC	9866964
DMJVCS1	MW	423.4
DMJVCS1	FM	C18H23F2N7O3
DMJVCS1	IC	InChI=1S/C18H23F2N7O3/c1-12-9-24-15(25-11-18(19,20)13-5-3-2-4-6-13)16(29)27(12)10-14(28)23-7-8-30-26-17(21)22/h2-6,9H,7-8,10-11H2,1H3,(H,23,28)(H,24,25)(H4,21,22,26)
DMJVCS1	CS	CC1=CN=C(C(=O)N1CC(=O)NCCON=C(N)N)NCC(C2=CC=CC=C2)(F)F
DMJVCS1	IK	IDCKXHIGLKQWMM-UHFFFAOYSA-N
DMJVCS1	IU	N-[2-(diaminomethylideneamino)oxyethyl]-2-[3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxopyrazin-1-yl]acetamide
DMJVCS1	DE	Thrombosis

DM6YAGE	ID	DM6YAGE
DM6YAGE	DN	RWJ-67657
DM6YAGE	HS	Phase 1
DM6YAGE	SN	215303-72-3; RWJ-67657; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol
DM6YAGE	TC	Analgesics
DM6YAGE	DT	Small molecular drug
DM6YAGE	PC	3008319
DM6YAGE	MW	425.5
DM6YAGE	FM	C27H24FN3O
DM6YAGE	IC	InChI=1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2
DM6YAGE	CS	C1=CC=C(C=C1)CCCN2C(=NC(=C2C3=CC=NC=C3)C4=CC=C(C=C4)F)C#CCCO
DM6YAGE	IK	QSUSKMBNZQHHPA-UHFFFAOYSA-N
DM6YAGE	IU	4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-pyridin-4-ylimidazol-2-yl]but-3-yn-1-ol
DM6YAGE	CA	CAS 215303-72-3
DM6YAGE	DE	Arthritis

DM4O07Q	ID	DM4O07Q
DM4O07Q	DN	RWJ-68023
DM4O07Q	HS	Phase 1
DM4O07Q	SN	Motilin receptor antagonists, RW Johnson
DM4O07Q	CP	RW Johnson Pharmaceutical Research Institute
DM4O07Q	PC	9809991
DM4O07Q	MW	672
DM4O07Q	FM	C34H37Cl3N4O4
DM4O07Q	IC	InChI=1S/C34H37Cl3N4O4/c35-34(36,37)31(42)39-33(23-26-8-3-1-4-9-26)15-14-27(24-33)25-41(32(43)38-28-10-5-2-6-11-28)29-12-7-13-30(22-29)45-21-18-40-16-19-44-20-17-40/h1-13,22,24H,14-21,23,25H2,(H,38,43)(H,39,42)/t33-/m1/s1
DM4O07Q	CS	C1C[C@](C=C1CN(C2=CC(=CC=C2)OCCN3CCOCC3)C(=O)NC4=CC=CC=C4)(CC5=CC=CC=C5)NC(=O)C(Cl)(Cl)Cl
DM4O07Q	IK	DPBURRXPRULCQN-MGBGTMOVSA-N
DM4O07Q	IU	N-[(1R)-1-benzyl-3-[[3-(2-morpholin-4-ylethoxy)-N-(phenylcarbamoyl)anilino]methyl]cyclopent-2-en-1-yl]-2,2,2-trichloroacetamide
DM4O07Q	DE	Irritable bowel syndrome

DM4XETK	ID	DM4XETK
DM4XETK	DN	RX108
DM4XETK	HS	Phase 1
DM4XETK	CP	NeuPharma
DM4XETK	DT	Small molecular drug
DM4XETK	DE	Solid tumour/cancer

DM6NVTR	ID	DM6NVTR
DM6NVTR	DN	RXDX-106
DM6NVTR	HS	Phase 1
DM6NVTR	SN	CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide
DM6NVTR	CP	Ignyta
DM6NVTR	DT	Small molecular drug
DM6NVTR	PC	71576419
DM6NVTR	MW	588.6
DM6NVTR	FM	C31H26F2N4O6
DM6NVTR	IC	InChI=1S/C31H26F2N4O6/c1-17(2)36-16-22(30(39)37(31(36)40)20-8-5-18(32)6-9-20)29(38)35-19-7-10-26(23(33)13-19)43-25-11-12-34-24-15-28(42-4)27(41-3)14-21(24)25/h5-17H,1-4H3,(H,35,38)
DM6NVTR	CS	CC(C)N1C=C(C(=O)N(C1=O)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C5C=C(C(=CC5=NC=C4)OC)OC)F
DM6NVTR	IK	FKCWHHYUMFGOPY-UHFFFAOYSA-N
DM6NVTR	IU	N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide
DM6NVTR	CA	CAS 1437321-24-8
DM6NVTR	DE	Solid tumour/cancer

DMYR1K8	ID	DMYR1K8
DMYR1K8	DN	S-17092-1
DMYR1K8	HS	Phase 1
DMYR1K8	SN	NXSXRIHXEQSYEZ-KNJMJIDISA-N; S 17092; CHEMBL1086968; 176797-26-5; S-17092; s17092; SCHEMBL194654; GTPL6565; DTXSID70433003; ZINC3825778; BDBM50316818; NCGC00485216-01; S 17092, &gt; ((2S,3aS,7aS)-1-((1R,2R)-2-phenylcyclopropanecarbonyl)octahydro-1H-indol-2-yl)(thiazolidin-3-yl)methanone; (2S,3aS,7aS)-1-(((R,R)-2-Phenylcyclopropyl)carbonyl)-2-((thiazolidin-3-yl)carbonyl)octahydro-1H-indole; [(2S,3aS,7aS)-Octahydro-1-[[(1R,2R)-2-phenylcyclopropyl]carbonyl]-1H-indol-2-yl]-3-thiazolidinyl--methanone; S-17092 (undefined isomer); (2S,3aS,7aS)-1-[(1R,2R)-2-Phenylcyclopropylcarbonyl]-2-(thiazolidin-3-ylcarbonyl)perhydroindole
DMYR1K8	DT	Small molecular drug
DMYR1K8	PC	9929984
DMYR1K8	MW	384.5
DMYR1K8	FM	C22H28N2O2S
DMYR1K8	IC	InChI=1S/C22H28N2O2S/c25-21(18-13-17(18)15-6-2-1-3-7-15)24-19-9-5-4-8-16(19)12-20(24)22(26)23-10-11-27-14-23/h1-3,6-7,16-20H,4-5,8-14H2/t16-,17-,18+,19-,20-/m0/s1
DMYR1K8	CS	C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@@H]3C[C@H]3C4=CC=CC=C4)C(=O)N5CCSC5
DMYR1K8	IK	NXSXRIHXEQSYEZ-KNJMJIDISA-N
DMYR1K8	IU	[(2S,3aS,7aS)-2-(1,3-thiazolidine-3-carbonyl)-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-[(1R,2R)-2-phenylcyclopropyl]methanone
DMYR1K8	CA	CAS 176797-26-5
DMYR1K8	DE	Non-small-cell lung cancer; Cognitive impairment

DMDQRWT	ID	DMDQRWT
DMDQRWT	DN	S-265744 LAP
DMDQRWT	HS	Phase 1
DMDQRWT	CP	Shionogi & GlaxoSmithKline
DMDQRWT	DE	Human immunodeficiency virus infection

DM6XZRL	ID	DM6XZRL
DM6XZRL	DN	SA-5845
DM6XZRL	HS	Phase 1
DM6XZRL	SN	Carbon-11 labeled sigma opioid receptor ligands, Santen; FE-SA-4503; FE-SA-5845; Carbon-11-SA-4503; Carbon-11-SA-5845; 11C-SA-4503; 11C-SA-5845
DM6XZRL	CP	Santen Pharmaceutical Co Ltd
DM6XZRL	DE	Central nervous system disease; Psychotic disorder

DMBGUDR	ID	DMBGUDR
DMBGUDR	DN	Safingol
DMBGUDR	HS	Phase 1
DMBGUDR	SN	Kynac; Kynacyte; SPC-100270; Safingol < Rec INN; L-threo-Dihydrosphingosine; SPC-100271 (HCl); (2S,3S)-2-Aminooctadecane-1,3-diol
DMBGUDR	DT	Small molecular drug
DMBGUDR	PC	3058739
DMBGUDR	MW	301.5
DMBGUDR	FM	C18H39NO2
DMBGUDR	IC	InChI=1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3/t17-,18-/m0/s1
DMBGUDR	CS	CCCCCCCCCCCCCCC[C@@H]([C@H](CO)N)O
DMBGUDR	IK	OTKJDMGTUTTYMP-ROUUACIJSA-N
DMBGUDR	IU	(2S,3S)-2-aminooctadecane-1,3-diol
DMBGUDR	CA	CAS 15639-50-6
DMBGUDR	DE	Psoriasis vulgaris

DM1UIQP	ID	DM1UIQP
DM1UIQP	DN	SAFIRONIL
DM1UIQP	HS	Phase 1
DM1UIQP	SN	Hoe-277; Safironil; N,N'-Bis(3-methoxypropyl)pyridine-2,4-dicarboxamide
DM1UIQP	DT	Small molecular drug
DM1UIQP	PC	65973
DM1UIQP	MW	309.36
DM1UIQP	FM	C15H23N3O4
DM1UIQP	IC	InChI=1S/C15H23N3O4/c1-21-9-3-6-17-14(19)12-5-8-16-13(11-12)15(20)18-7-4-10-22-2/h5,8,11H,3-4,6-7,9-10H2,1-2H3,(H,17,19)(H,18,20)
DM1UIQP	CS	COCCCNC(=O)C1=CC(=NC=C1)C(=O)NCCCOC
DM1UIQP	IK	HLSXICGBWKECLM-UHFFFAOYSA-N
DM1UIQP	IU	2-N,4-N-bis(3-methoxypropyl)pyridine-2,4-dicarboxamide
DM1UIQP	CA	CAS 134377-69-8
DM1UIQP	DE	Transplant rejection

DMJ3HQY	ID	DMJ3HQY
DMJ3HQY	DN	Salvinorin A
DMJ3HQY	HS	Phase 1
DMJ3HQY	SN	Salvinorin A; Salvinorin; Divinorin A; 83729-01-5; UNII-T56W91NG6J; CHEMBL445332; T56W91NG6J; CHEBI:67900; 2H-Naphtho(2,1-c)pyran-7-carboxylic acid, 9-(acetyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-, methyl ester, (2S-(2alpha,4aalpha,6abeta,7beta,9beta,10aalpha,10bbeta))-; (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(3-furanyl)dodechydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester; (-)-Salvinorin A; herbal ecstasy; Mexican mint; salvinorin-A; Salvonorin A; Diviner's S
DMJ3HQY	DT	Small molecular drug
DMJ3HQY	PC	128563
DMJ3HQY	MW	432.5
DMJ3HQY	FM	C23H28O8
DMJ3HQY	IC	InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1
DMJ3HQY	CS	CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DMJ3HQY	IK	OBSYBRPAKCASQB-AGQYDFLVSA-N
DMJ3HQY	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMJ3HQY	CA	CAS 83729-01-5
DMJ3HQY	CB	CHEBI:67900
DMJ3HQY	DE	Cerebral vasospasm

DMDHQYA	ID	DMDHQYA
DMDHQYA	DN	SAM-6
DMDHQYA	HS	Phase 1
DMDHQYA	CP	Pack of Parker; OncoMab GmbH
DMDHQYA	DT	Antibody
DMDHQYA	DE	Melanoma

DMWU71N	ID	DMWU71N
DMWU71N	DN	SAN-134
DMWU71N	HS	Phase 1
DMWU71N	SN	GLP-2 (osteoporosis), SANOS; Glucagon-like peptide-2 (osteoporosis), SANOS
DMWU71N	CP	SANOS Bioscience A/S
DMWU71N	DE	Osteoporosis

DMQ9ZY0	ID	DMQ9ZY0
DMQ9ZY0	DN	SAR-104772
DMQ9ZY0	HS	Phase 1
DMQ9ZY0	SN	TAFIa inhibitor (stroke), sanofi-aventis; SAR-104772 (oral, stroke), sanofi-aventis
DMQ9ZY0	CP	Sanofi
DMQ9ZY0	DE	Cerebrovascular ischaemia

DMRIH0S	ID	DMRIH0S
DMRIH0S	DN	SAR113244
DMRIH0S	HS	Phase 1
DMRIH0S	SN	LPA-1/LPA-3
DMRIH0S	CP	Sanofi
DMRIH0S	DE	Systemic lupus erythematosus

DMZ1XR5	ID	DMZ1XR5
DMZ1XR5	DN	SAR-114137
DMZ1XR5	HS	Phase 1
DMZ1XR5	CP	Sanofi
DMZ1XR5	PC	9828551
DMZ1XR5	MW	534.6
DMZ1XR5	FM	C25H34N4O7S
DMZ1XR5	IC	InChI=1S/C25H34N4O7S/c1-4-20(22(31)23-27-25(36-28-23)18-8-6-5-7-9-18)26-24(32)19(16-37(33,34)15-17(2)3)14-21(30)29-10-12-35-13-11-29/h5-9,17,19-20H,4,10-16H2,1-3H3,(H,26,32)/t19?,20-/m0/s1
DMZ1XR5	CS	CC[C@@H](C(=O)C1=NOC(=N1)C2=CC=CC=C2)NC(=O)C(CC(=O)N3CCOCC3)CS(=O)(=O)CC(C)C
DMZ1XR5	IK	IUMMRYVGHFJSRD-ANYOKISRSA-N
DMZ1XR5	IU	2-(2-methylpropylsulfonylmethyl)-4-morpholin-4-yl-4-oxo-N-[(2S)-1-oxo-1-(5-phenyl-1,2,4-oxadiazol-3-yl)butan-2-yl]butanamide
DMZ1XR5	CA	CAS 537706-31-3
DMZ1XR5	DE	Pain

DMD2VRY	ID	DMD2VRY
DMD2VRY	DN	SAR-115740
DMD2VRY	HS	Phase 1
DMD2VRY	DE	Pain

DMKHM7O	ID	DMKHM7O
DMKHM7O	DN	SAR-126119
DMKHM7O	HS	Phase 1
DMKHM7O	SN	SAR-104772 (intravenous, stroke), sanofi-aventis
DMKHM7O	CP	Sanofi
DMKHM7O	DE	Cerebrovascular ischaemia

DMQ98MW	ID	DMQ98MW
DMQ98MW	DN	SAR164653
DMQ98MW	HS	Phase 1
DMQ98MW	CP	Sanofi
DMQ98MW	DE	Diabetic complication

DMO8QY1	ID	DMO8QY1
DMO8QY1	DN	SAR-21609
DMO8QY1	HS	Phase 1
DMO8QY1	SN	TLR9 agonist (asthma/viral respiratory tract infection), sanofi-aventis
DMO8QY1	CP	Coley Pharmaceutical Group Inc
DMO8QY1	DE	Asthma

DMTFAGU	ID	DMTFAGU
DMTFAGU	DN	SAR228810
DMTFAGU	HS	Phase 1
DMTFAGU	CP	Sanofi
DMTFAGU	DT	Antibody
DMTFAGU	DE	Alzheimer disease

DMUAJZD	ID	DMUAJZD
DMUAJZD	DN	SAR247799
DMUAJZD	HS	Phase 1
DMUAJZD	CP	Sanofi Bridgewater, NJ
DMUAJZD	DE	Cardiovascular disease

DM15PG9	ID	DM15PG9
DM15PG9	DN	SAR351034
DM15PG9	HS	Phase 1
DM15PG9	CP	Sanofi-Aventis
DM15PG9	DE	Dyslipidemia; Type-2 diabetes

DMA6O9R	ID	DMA6O9R
DMA6O9R	DN	SAR-389644
DMA6O9R	HS	Phase 1
DMA6O9R	SN	SAR-389644C; Prostaglandin D2 antagonist (asthma/allergic rhinitis), sanofi-aventis
DMA6O9R	CP	Sanofi
DMA6O9R	DE	Allergic rhinitis

DMC1AZP	ID	DMC1AZP
DMC1AZP	DN	SAR-405838
DMC1AZP	HS	Phase 1
DMC1AZP	SN	AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis
DMC1AZP	CP	Ascenta Therapeutics; Sanofi US
DMC1AZP	DT	Small molecular drug
DMC1AZP	PC	53476877
DMC1AZP	MW	562.5
DMC1AZP	FM	C29H34Cl2FN3O3
DMC1AZP	IC	InChI=1S/C29H34Cl2FN3O3/c1-28(2,3)14-22-29(19-12-7-15(30)13-21(19)34-27(29)38)23(18-5-4-6-20(31)24(18)32)25(35-22)26(37)33-16-8-10-17(36)11-9-16/h4-7,12-13,16-17,22-23,25,35-36H,8-11,14H2,1-3H3,(H,33,37)(H,34,38)/t16?,17?,22-,23-,25+,29+/m0/s1
DMC1AZP	CS	CC(C)(C)C[C@H]1[C@@]2([C@H]([C@@H](N1)C(=O)NC3CCC(CC3)O)C4=C(C(=CC=C4)Cl)F)C5=C(C=C(C=C5)Cl)NC2=O
DMC1AZP	IK	IDKAKZRYYDCJDU-AEPXTFJPSA-N
DMC1AZP	IU	(2'R,3R,3'S,5'S)-6-chloro-3'-(3-chloro-2-fluorophenyl)-5'-(2,2-dimethylpropyl)-N-(4-hydroxycyclohexyl)-2-oxospiro[1H-indole-3,4'-pyrrolidine]-2'-carboxamide
DMC1AZP	CA	CAS 1303607-60-4
DMC1AZP	DE	Solid tumour/cancer

DM53IPE	ID	DM53IPE
DM53IPE	DN	SAR425899
DM53IPE	HS	Phase 1
DM53IPE	DE	Diabetic complication; Type-2 diabetes

DM7QO05	ID	DM7QO05
DM7QO05	DN	SAR438335
DM7QO05	HS	Phase 1
DM7QO05	CP	Sanofi US Bridgewater, NJ
DM7QO05	DE	Type-2 diabetes

DM5UXAB	ID	DM5UXAB
DM5UXAB	DN	SAR442085
DM5UXAB	HS	Phase 1
DM5UXAB	CP	Sanofi
DM5UXAB	DT	Antibody
DM5UXAB	DE	Plasma cell myeloma

DMXD5QP	ID	DMXD5QP
DMXD5QP	DN	SAR442257
DMXD5QP	HS	Phase 1
DMXD5QP	CP	Sanofi
DMXD5QP	DT	Antibody
DMXD5QP	DE	Malignant neoplasm

DMTAOPC	ID	DMTAOPC
DMTAOPC	DN	SAR442720
DMTAOPC	HS	Phase 1
DMTAOPC	SN	RMC-4630
DMTAOPC	CP	Revolution Medicines
DMTAOPC	DT	Small molecular drug
DMTAOPC	DE	Solid tumour/cancer

DM6UN42	ID	DM6UN42
DM6UN42	DN	SAR444245
DM6UN42	HS	Phase 1
DM6UN42	SN	THOR-707
DM6UN42	CP	Sanofi
DM6UN42	DT	Recombinant protein
DM6UN42	DE	Solid tumour/cancer

DMZ9YWG	ID	DMZ9YWG
DMZ9YWG	DN	SB 11285
DMZ9YWG	HS	Phase 1
DMZ9YWG	CP	F-star Therapeutics
DMZ9YWG	DE	Melanoma; Head-neck squamous cell carcinoma

DMXTKYR	ID	DMXTKYR
DMXTKYR	DN	SB-1578
DMXTKYR	HS	Phase 1
DMXTKYR	CP	S*BIO Pte Ltd
DMXTKYR	PC	16750271
DMXTKYR	MW	462.5
DMXTKYR	FM	C26H30N4O4
DMXTKYR	IC	InChI=1S/C26H30N4O4/c1-2-12-30(11-1)13-16-33-24-7-5-21-17-20(24)18-31-14-3-4-15-32-19-22-6-8-25(34-22)23-9-10-27-26(28-21)29-23/h3-10,17H,1-2,11-16,18-19H2,(H,27,28,29)/b4-3+
DMXTKYR	CS	C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC=C(O4)C5=NC(=NC=C5)NC(=C3)C=C2
DMXTKYR	IK	NNXDIGHYPZHXTR-ONEGZZNKSA-N
DMXTKYR	IU	(9E)-15-(2-pyrrolidin-1-ylethoxy)-7,12,26-trioxa-19,21,24-triazatetracyclo[18.3.1.12,5.114,18]hexacosa-1(24),2,4,9,14,16,18(25),20,22-nonaene
DMXTKYR	CA	CAS 937273-04-6
DMXTKYR	DE	Solid tumour/cancer

DMLPB0X	ID	DMLPB0X
DMLPB0X	DN	SB-436811
DMLPB0X	HS	Phase 1
DMLPB0X	SN	SB-436811; CHEMBL366221; 346729-66-6; Benzamide,3,4-dichloro-N-[(3S)-1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-3-pyrrolidinyl]-; SCHEMBL6949936; GTPL2164; ZINC3964101; BDBM50240963; KB-74923; 3,4-Dichloro-N-{(S)-1-[4-(3-dimethylamino-propoxy)-benzyl]-pyrrolidin-3-yl}-benzamide; (S)-3,4-dichloro-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)benzamide; (S)-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)-3,4-dichlorobenzamide
DMLPB0X	DT	Small molecular drug
DMLPB0X	PC	9846574
DMLPB0X	MW	450.4
DMLPB0X	FM	C23H29Cl2N3O2
DMLPB0X	IC	InChI=1S/C23H29Cl2N3O2/c1-27(2)11-3-13-30-20-7-4-17(5-8-20)15-28-12-10-19(16-28)26-23(29)18-6-9-21(24)22(25)14-18/h4-9,14,19H,3,10-13,15-16H2,1-2H3,(H,26,29)/t19-/m0/s1
DMLPB0X	CS	CN(C)CCCOC1=CC=C(C=C1)CN2CC[C@@H](C2)NC(=O)C3=CC(=C(C=C3)Cl)Cl
DMLPB0X	IK	AMSSIFVGNFEEFU-IBGZPJMESA-N
DMLPB0X	IU	3,4-dichloro-N-[(3S)-1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]pyrrolidin-3-yl]benzamide
DMLPB0X	DE	Asthma

DMSZIP5	ID	DMSZIP5
DMSZIP5	DN	SB-639
DMSZIP5	HS	Phase 1
DMSZIP5	SN	SB-639; CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide
DMSZIP5	CP	GlaxoSmithKline
DMSZIP5	TC	Anticancer Agents
DMSZIP5	DT	Small molecular drug
DMSZIP5	PC	6918877
DMSZIP5	MW	404.5
DMSZIP5	FM	C24H28N4O2
DMSZIP5	IC	InChI=1S/C24H28N4O2/c29-24(26-30)13-10-20-8-11-22-21(18-20)25-23(12-9-19-6-2-1-3-7-19)28(22)17-16-27-14-4-5-15-27/h1-3,6-8,10-11,13,18,30H,4-5,9,12,14-17H2,(H,26,29)/b13-10+
DMSZIP5	CS	C1CCN(C1)CCN2C3=C(C=C(C=C3)/C=C/C(=O)NO)N=C2CCC4=CC=CC=C4
DMSZIP5	IK	RCDIZKAYZBEALO-JLHYYAGUSA-N
DMSZIP5	IU	(E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide
DMSZIP5	DE	Solid tumour/cancer

DMXU2GS	ID	DMXU2GS
DMXU2GS	DN	SBS-1000
DMXU2GS	HS	Phase 1
DMXU2GS	SN	PrInsulin; Diabetes therapy, SemBioSys; Human insulin (safflower), SemBioSys; Plant-derived insulin (diabetes), SemBioSys; Safflower seed-derived human insulin (diabetes), SemBioSys
DMXU2GS	CP	SemBioSys Genetics Inc
DMXU2GS	DE	Diabetic complication

DMHBD3T	ID	DMHBD3T
DMHBD3T	DN	SBT6050
DMHBD3T	HS	Phase 1
DMHBD3T	CP	Silverback Therapeutics
DMHBD3T	DT	Antibody drug conjugate
DMHBD3T	DE	Solid tumour/cancer

DM7GSLB	ID	DM7GSLB
DM7GSLB	DN	SC-20713
DM7GSLB	HS	Phase 1
DM7GSLB	SN	Etynodiol; Aethynodiolum; CHEBI:50785; CHEMBL1201406; DB13866; DTXSID1023025; EINECS 214-971-5; Ethinodiol; Etinodiol; Etinodiol [INN-Spanish]; Etinodiolo; Etinodiolo [DCIT]; Etynodiol (INN); Etynodiol [INN:BAN]; Etynodiolum; Etynodiolum [INN-Latin]; HSDB 7897; LS-97401; (3-beta,17-alpha)-19-Norpregn-4-en-20-yne-3,17-diol; (3beta,17alpha)-19-Norpregn-4-en-20-yne-3,17-diol; (3beta,17beta)-17-ethynylestr-4-ene-3,17-diol; 1231-93-2; 17-alpha-Ethynyl-19-norandrost-4-ene-3-beta,17-beta-diol; 17alpha-Ethynyl-19-norandrost-4-ene-3beta,17beta-diol; 17alpha-Ethynyl-estra-4-ene-3beta,17beta-diol; 17alpha-ethynylestr-4-ene-3beta,17beta-diol; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol; 3beta-hydroxynorethisterone; 9E01C36A9S; SCHEMBL140933; UNII-9E01C36A9S; ZINC30691629; ethynodiol; ZINC000030691629
DM7GSLB	PC	14309340
DM7GSLB	MW	300.4
DM7GSLB	FM	C20H28O2
DM7GSLB	IC	JYILPERKVHXLNF-UHFFFAOYSA-N
DM7GSLB	CS	CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(CCC34)O
DM7GSLB	IK	1S/C20H28O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,14-18,21-22H,4-11H2,2H3
DM7GSLB	IU	17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
DM7GSLB	CA	CAS 1231-93-2
DM7GSLB	DE	Contraception

DMQ2K1V	ID	DMQ2K1V
DMQ2K1V	DN	SCH-442416
DMQ2K1V	HS	Phase 1
DMQ2K1V	SN	316173-57-6; SCH 442416; SCH-442416; UNII-ZMC4G1W59S; 2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; SCH442416; ZMC4G1W59S; CHEMBL136689; SCH-442,416; 2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo-[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; SCHEMBL981184; GTPL3283; CTK8B9468; CHEBI:92814; DTXSID70443263; MolPort-023-276-442; ZINC602847; HMS3269G07; BCP01942; MFCD08703126; BDBM50094037; ANW-62570; AKOS016003924; SCH442,416; NCGC00159575-01; AJ-23684; AC-27414
DMQ2K1V	DT	Small molecular drug
DMQ2K1V	PC	10668061
DMQ2K1V	MW	389.4
DMQ2K1V	FM	C20H19N7O2
DMQ2K1V	IC	InChI=1S/C20H19N7O2/c1-28-14-8-6-13(7-9-14)4-2-10-26-18-15(12-22-26)19-23-17(16-5-3-11-29-16)25-27(19)20(21)24-18/h3,5-9,11-12H,2,4,10H2,1H3,(H2,21,24)
DMQ2K1V	CS	COC1=CC=C(C=C1)CCCN2C3=C(C=N2)C4=NC(=NN4C(=N3)N)C5=CC=CO5
DMQ2K1V	IK	AEULVFLPCJOBCE-UHFFFAOYSA-N
DMQ2K1V	IU	4-(furan-2-yl)-10-[3-(4-methoxyphenyl)propyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
DMQ2K1V	CA	CAS 316173-57-6
DMQ2K1V	CB	CHEBI:92814

DMDP6UF	ID	DMDP6UF
DMDP6UF	DN	SCH-721015
DMDP6UF	HS	Phase 1
DMDP6UF	SN	RAd-IFN, Merck & Co; RAd-IFN, Schering-Plough; Ad.hIFN-alpha2b, Merck & Co; Recombinant adenovirus vector expressing hybrid-interferon (bladder neoplasm), Merck & Co
DMDP6UF	CP	Fkd therapies
DMDP6UF	DE	Mesothelioma

DM7A6R5	ID	DM7A6R5
DM7A6R5	DN	SCH-900117
DM7A6R5	HS	Phase 1
DM7A6R5	CP	Merck
DM7A6R5	DE	Rheumatoid arthritis

DMRD1IW	ID	DMRD1IW
DMRD1IW	DN	SCO-088
DMRD1IW	HS	Phase 1
DMRD1IW	SN	Vodobatinib; UNII-N8Q12KU2SW; N8Q12KU2SW; Vodobatinib (USAN); Vodobatinib [USAN]; K0706; 2-chloro-6-methyl-N'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide; 1388803-90-4; SUNK706; SCO088; SUN-K706; CHEMBL4130229; SCHEMBL15363815; GTPL11191; WHO 11506; D11786; 4-Methyl-3-quinolin-3-ylethynylbenzoic acid N'-(2-chloro-6-methylbenzoyl) hydrazide
DMRD1IW	CP	Sun Pharma Advanced Research Company
DMRD1IW	DT	Small molecular drug
DMRD1IW	PC	89884852
DMRD1IW	MW	453.9
DMRD1IW	FM	C27H20ClN3O2
DMRD1IW	IC	InChI=1S/C27H20ClN3O2/c1-17-10-12-22(26(32)30-31-27(33)25-18(2)6-5-8-23(25)28)15-20(17)13-11-19-14-21-7-3-4-9-24(21)29-16-19/h3-10,12,14-16H,1-2H3,(H,30,32)(H,31,33)
DMRD1IW	CS	CC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)C#CC3=CC4=CC=CC=C4N=C3
DMRD1IW	IK	ZQOBVMHBVWNVBG-UHFFFAOYSA-N
DMRD1IW	IU	2-chloro-6-methyl-N'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide
DMRD1IW	CA	CAS 1388803-90-4
DMRD1IW	DE	Chronic myeloid leukaemia

DMB1MZS	ID	DMB1MZS
DMB1MZS	DN	SCO-120
DMB1MZS	HS	Phase 1
DMB1MZS	CP	Sun Pharma Advanced Research Company
DMB1MZS	DE	Breast cancer

DMU0Q6L	ID	DMU0Q6L
DMU0Q6L	DN	SDX-7320
DMU0Q6L	HS	Phase 1
DMU0Q6L	CP	SynDevRx Cambridge, MA
DMU0Q6L	DT	Polymer drug conjugate
DMU0Q6L	DE	Solid tumour/cancer

DMU9ZGN	ID	DMU9ZGN
DMU9ZGN	DN	SDZ-GPI-562
DMU9ZGN	HS	Phase 1
DMU9ZGN	SN	GPI-562
DMU9ZGN	CP	Sandoz AG
DMU9ZGN	DE	Thrombosis

DM8SINB	ID	DM8SINB
DM8SINB	DN	SDZ-LAV-694
DM8SINB	HS	Phase 1
DM8SINB	SN	LAV-694; 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethylquinazoline
DM8SINB	DE	Actinic keratosis

DML6QJN	ID	DML6QJN
DML6QJN	DN	SDZ-MKS-492
DML6QJN	HS	Phase 1
DML6QJN	SN	MKS-492
DML6QJN	CP	Novartis AG
DML6QJN	DT	Small molecular drug
DML6QJN	PC	163931
DML6QJN	MW	433.5
DML6QJN	FM	C20H27N5O6
DML6QJN	IC	InChI=1S/C20H27N5O6/c1-23-17-16(18(27)24(2)20(23)28)25(8-9-29-3)19(22-17)21-13(11-26)12-6-7-14(30-4)15(10-12)31-5/h6-7,10,13,26H,8-9,11H2,1-5H3,(H,21,22)/t13-/m0/s1
DML6QJN	CS	CN1C2=C(C(=O)N(C1=O)C)N(C(=N2)N[C@@H](CO)C3=CC(=C(C=C3)OC)OC)CCOC
DML6QJN	IK	VZLFAVFWNOZVFM-ZDUSSCGKSA-N
DML6QJN	IU	8-[[(1R)-1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]amino]-7-(2-methoxyethyl)-1,3-dimethylpurine-2,6-dione
DML6QJN	CA	CAS 114606-56-3
DML6QJN	DE	Asthma

DMX94YF	ID	DMX94YF
DMX94YF	DN	SEA-CD70
DMX94YF	HS	Phase 1
DMX94YF	CP	Seagen
DMX94YF	DT	Antibody
DMX94YF	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DM7GUH3	ID	DM7GUH3
DM7GUH3	DN	SEA-TGT
DM7GUH3	HS	Phase 1
DM7GUH3	CP	Seagen
DM7GUH3	DT	Antibody
DM7GUH3	DE	Solid tumour/cancer

DMCP7SD	ID	DMCP7SD
DMCP7SD	DN	Seclidemstat
DMCP7SD	HS	Phase 1
DMCP7SD	SN	UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide
DMCP7SD	CP	Salarius Pharmaceuticals
DMCP7SD	DT	Small molecular drug
DMCP7SD	PC	135565033
DMCP7SD	MW	450.9
DMCP7SD	FM	C20H23ClN4O4S
DMCP7SD	IC	InChI=1S/C20H23ClN4O4S/c1-14(18-13-16(21)6-7-19(18)26)22-23-20(27)15-4-3-5-17(12-15)30(28,29)25-10-8-24(2)9-11-25/h3-7,12-13,26H,8-11H2,1-2H3,(H,23,27)/b22-14+
DMCP7SD	CS	C/C(=N\\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)/C3=C(C=CC(=C3)Cl)O
DMCP7SD	IK	MVSQDUZRRVBYLA-HYARGMPZSA-N
DMCP7SD	IU	N-[(E)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide
DMCP7SD	CA	CAS 1423715-37-0
DMCP7SD	DE	Ewing sarcoma

DMHCUZV	ID	DMHCUZV
DMHCUZV	DN	SEL120
DMHCUZV	HS	Phase 1
DMHCUZV	SN	SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride
DMHCUZV	CP	Ryvu Therapeutics
DMHCUZV	DT	Small molecular drug
DMHCUZV	PC	73776232
DMHCUZV	MW	450.6
DMHCUZV	FM	C15H19Br2ClN4
DMHCUZV	IC	InChI=1S/C15H18Br2N4.ClH/c1-9-11(16)12(17)10-3-2-6-21-14(10)13(9)19-15(21)20-7-4-18-5-8-20;/h18H,2-8H2,1H3;1H
DMHCUZV	CS	CC1=C2C3=C(CCCN3C(=N2)N4CCNCC4)C(=C1Br)Br.Cl
DMHCUZV	IK	GQXLWUCQESKBSC-UHFFFAOYSA-N
DMHCUZV	IU	6,7-dibromo-5-methyl-2-piperazin-1-yl-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene;hydrochloride
DMHCUZV	CA	CAS 1609452-30-3
DMHCUZV	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DMF89ZT	ID	DMF89ZT
DMF89ZT	DN	SEP-228432
DMF89ZT	HS	Phase 1
DMF89ZT	CP	Sunovion Pharmaceuticals
DMF89ZT	DE	Neuropathic pain; Depression

DMTZ983	ID	DMTZ983
DMTZ983	DN	SER-101
DMTZ983	HS	Phase 1
DMTZ983	SN	RO-1160367
DMTZ983	CP	Roche Holding AG
DMTZ983	DE	Congestive heart failure

DMD2GKF	ID	DMD2GKF
DMD2GKF	DN	SFLT-01
DMD2GKF	HS	Phase 1
DMD2GKF	SN	AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme
DMD2GKF	CP	Applied Genetic Technologies Corp
DMD2GKF	DE	Macular degeneration

DMDAHEL	ID	DMDAHEL
DMDAHEL	DN	SGM-1019
DMDAHEL	HS	Phase 1
DMDAHEL	CP	Second Genome South San Francisco, CA
DMDAHEL	DE	Inflammatory bowel disease

DMVBQ2L	ID	DMVBQ2L
DMVBQ2L	DN	SGN LIV1A
DMVBQ2L	HS	Phase 1
DMVBQ2L	CP	Seattle genetics
DMVBQ2L	DT	Antibody
DMVBQ2L	DE	Breast cancer

DMXA7W9	ID	DMXA7W9
DMXA7W9	DN	SGN-70
DMXA7W9	HS	Phase 1
DMXA7W9	CP	Seattle Genetics
DMXA7W9	DT	Antibody
DMXA7W9	DE	Autoimmune diabetes

DMATJL9	ID	DMATJL9
DMATJL9	DN	SGN-B6A
DMATJL9	HS	Phase 1
DMATJL9	CP	Seagen
DMATJL9	DT	Antibody drug conjugate
DMATJL9	DE	Solid tumour/cancer

DMSVD2R	ID	DMSVD2R
DMSVD2R	DN	SGN-CD228A
DMSVD2R	HS	Phase 1
DMSVD2R	CP	Seagen
DMSVD2R	DT	Antibody drug conjugate
DMSVD2R	DE	Solid tumour/cancer

DMKW10G	ID	DMKW10G
DMKW10G	DN	SGN-CD30C
DMKW10G	HS	Phase 1
DMKW10G	CP	Seagen
DMKW10G	DT	Antibody drug conjugate
DMKW10G	DE	Lymphoma

DMMJ1PO	ID	DMMJ1PO
DMMJ1PO	DN	SGN-CD70A
DMMJ1PO	HS	Phase 1
DMMJ1PO	CP	Seattle genetics
DMMJ1PO	DT	Antibody
DMMJ1PO	DE	Non-hodgkin lymphoma

DM3RSMF	ID	DM3RSMF
DM3RSMF	DN	Sgx523
DM3RSMF	HS	Phase 1
DM3RSMF	SN	SGX-523; SGX523, SGX-523
DM3RSMF	CP	SGX Pharma; Eli Lilly
DM3RSMF	TC	Anticancer Agents
DM3RSMF	DT	Small molecular drug
DM3RSMF	PC	24779724
DM3RSMF	MW	359.4
DM3RSMF	FM	C18H13N7S
DM3RSMF	IC	InChI=1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3
DM3RSMF	CS	CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2
DM3RSMF	IK	BCZUAADEACICHN-UHFFFAOYSA-N
DM3RSMF	IU	6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline
DM3RSMF	CA	CAS 1022150-57-7
DM3RSMF	CB	CHEBI:90624
DM3RSMF	DE	Solid tumour/cancer

DMO0CA8	ID	DMO0CA8
DMO0CA8	DN	SHP616
DMO0CA8	HS	Phase 1
DMO0CA8	CP	ShireLexington, MA
DMO0CA8	DE	Neuromyelitis optica

DMGFTAI	ID	DMGFTAI
DMGFTAI	DN	SHR0534
DMGFTAI	HS	Phase 1
DMGFTAI	CP	Jiangsu Hengrui
DMGFTAI	DE	Type 2 diabetes

DMDSFEB	ID	DMDSFEB
DMDSFEB	DN	SI-B001
DMDSFEB	HS	Phase 1
DMDSFEB	CP	Baili pharm
DMDSFEB	DT	Antibody
DMDSFEB	DE	Metastatic epithelial tumour

DMJW5R0	ID	DMJW5R0
DMJW5R0	DN	SI-B003
DMJW5R0	HS	Phase 1
DMJW5R0	CP	SystImmune
DMJW5R0	DT	Antibody
DMJW5R0	DE	Solid tumour/cancer

DMFK7UR	ID	DMFK7UR
DMFK7UR	DN	Simotaxel
DMFK7UR	HS	Phase 1
DMFK7UR	SN	MST-997; TL-909
DMFK7UR	CP	Taxolog Inc
DMFK7UR	DT	Small molecular drug
DMFK7UR	PC	11286005
DMFK7UR	MW	896
DMFK7UR	FM	C46H57NO15S
DMFK7UR	IC	InChI=1S/C46H57NO15S/c1-23(2)58-42(55)47-33(29-18-13-19-63-29)34(50)41(54)59-28-21-46(56)38(61-40(53)27-14-9-8-10-15-27)36-44(7,30(49)20-31-45(36,22-57-31)62-25(4)48)37(51)35(32(24(28)3)43(46,5)6)60-39(52)26-16-11-12-17-26/h8-10,13-15,18-19,23,26,28,30-31,33-36,38,49-50,56H,11-12,16-17,20-22H2,1-7H3,(H,47,55)/t28-,30-,31+,33-,34+,35+,36-,38-,44+,45-,46+/m0/s1
DMFK7UR	CS	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CS5)NC(=O)OC(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C7CCCC7
DMFK7UR	IK	SLGIWUWTSWJBQE-VLCCYYTCSA-N
DMFK7UR	IU	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-12-(cyclopentanecarbonyloxy)-1,9-dihydroxy-15-[(2R,3R)-2-hydroxy-3-(propan-2-yloxycarbonylamino)-3-thiophen-2-ylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMFK7UR	CA	CAS 791635-59-1
DMFK7UR	DE	Solid tumour/cancer

DMG7XKP	ID	DMG7XKP
DMG7XKP	DN	SKF-105494
DMG7XKP	HS	Phase 1
DMG7XKP	CP	SmithKline Beecham plc
DMG7XKP	PC	9963434
DMG7XKP	MW	1102.3
DMG7XKP	FM	C54H83N15O10
DMG7XKP	IC	InChI=1S/C54H83N15O10/c1-4-79-35-21-19-34(20-22-35)29-39-48(75)67-40(28-33-14-7-5-8-15-33)50(77)69-44(32(2)3)51(78)68-41(30-42(55)70)49(76)66-37(16-11-25-54(31-43(71)63-39)23-9-6-10-24-54)47(74)65-38(18-13-27-62-53(59)60)46(73)64-36(45(56)72)17-12-26-61-52(57)58/h5,7-8,14-15,19-22,32,36-41,44H,4,6,9-13,16-18,23-31H2,1-3H3,(H2,55,70)(H2,56,72)(H,63,71)(H,64,73)(H,65,74)(H,66,76)(H,67,75)(H,68,78)(H,69,77)(H4,57,58,61)(H4,59,60,62)/t36-,37+,38+,39-,40+,41+,44+/m1/s1
DMG7XKP	CS	CCOC1=CC=C(C=C1)C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCC3(CCCCC3)CC(=O)N2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N)CC(=O)N)C(C)C)CC4=CC=CC=C4
DMG7XKP	IK	PZEDOGNXHJQAKP-CQRSLYTBSA-N
DMG7XKP	IU	(10R,13S,16S,19S,22S)-N-[(2S)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-19-(2-amino-2-oxoethyl)-13-benzyl-10-[(4-ethoxyphenyl)methyl]-8,11,14,17,20-pentaoxo-16-propan-2-yl-9,12,15,18,21-pentazaspiro[5.19]pentacosane-22-carboxamide
DMG7XKP	CA	CAS 114923-99-8
DMG7XKP	DE	Diuretic vasodilator

DMUN7EQ	ID	DMUN7EQ
DMUN7EQ	DN	SKF-105809
DMUN7EQ	HS	Phase 1
DMUN7EQ	SN	SKF-105561
DMUN7EQ	CP	SmithKline Beecham plc
DMUN7EQ	DT	Small molecular drug
DMUN7EQ	PC	129725
DMUN7EQ	MW	323.4
DMUN7EQ	FM	C18H17N3OS
DMUN7EQ	IC	InChI=1S/C18H17N3OS/c1-23(22)15-6-4-13(5-7-15)17-18(14-8-10-19-11-9-14)21-12-2-3-16(21)20-17/h4-11H,2-3,12H2,1H3
DMUN7EQ	CS	CS(=O)C1=CC=C(C=C1)C2=C(N3CCCC3=N2)C4=CC=NC=C4
DMUN7EQ	IK	KSEJZTWORQXILM-UHFFFAOYSA-N
DMUN7EQ	IU	2-(4-methylsulfinylphenyl)-3-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
DMUN7EQ	CA	CAS 122454-69-7
DMUN7EQ	DE	Pain

DM4I92Z	ID	DM4I92Z
DM4I92Z	DN	SKI-G-801
DM4I92Z	HS	Phase 1
DM4I92Z	CP	Genosco
DM4I92Z	DT	Small molecular drug
DM4I92Z	DE	Acute myeloid leukaemia

DMTSKXR	ID	DMTSKXR
DMTSKXR	DN	SKI-O-703
DMTSKXR	HS	Phase 1
DMTSKXR	CP	OscotecChonan, South Korea
DMTSKXR	DE	Rheumatoid arthritis

DMW64UZ	ID	DMW64UZ
DMW64UZ	DN	SKL-10406
DMW64UZ	HS	Phase 1
DMW64UZ	CP	SK Life Science
DMW64UZ	DE	Major depressive disorder

DM8YNI6	ID	DM8YNI6
DM8YNI6	DN	SKL-PSY
DM8YNI6	HS	Phase 1
DM8YNI6	SN	5-HT 1a receptor modulator (psychiatric disorder), SK Life Science; 5-HT 1a receptor modulator (schizophrenia/depression), SK Life science
DM8YNI6	CP	SK Life Science
DM8YNI6	DE	Bipolar disorder

DMN3D72	ID	DMN3D72
DMN3D72	DN	SL-172154
DMN3D72	HS	Phase 1
DMN3D72	CP	Shattuck Labs
DMN3D72	DT	Recombinant protein
DMN3D72	DE	Ovarian cancer

DMIVGYK	ID	DMIVGYK
DMIVGYK	DN	SL-801
DMIVGYK	HS	Phase 1
DMIVGYK	SN	CMASLSTVVOYJQY-UHFFFAOYSA-N; 1076235-04-5; SCHEMBL1592515; S-03747; 1H-Pyrrole-2,5-dione, 1-[[6-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]-3-[(3,3-dimethylbutoxy)methyl]-4-methyl-
DMIVGYK	CP	Stemline Therapeutics New York, NY
DMIVGYK	PC	25103750
DMIVGYK	MW	419.8
DMIVGYK	FM	C18H21ClF3N3O3
DMIVGYK	IC	InChI=1S/C18H21ClF3N3O3/c1-10-11(9-28-8-7-17(2,3)4)16(27)25(15(10)26)24-13-6-5-12(14(19)23-13)18(20,21)22/h5-6H,7-9H2,1-4H3,(H,23,24)
DMIVGYK	CS	CC1=C(C(=O)N(C1=O)NC2=NC(=C(C=C2)C(F)(F)F)Cl)COCCC(C)(C)C
DMIVGYK	IK	CMASLSTVVOYJQY-UHFFFAOYSA-N
DMIVGYK	IU	1-[[6-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]-3-(3,3-dimethylbutoxymethyl)-4-methylpyrrole-2,5-dione
DMIVGYK	CA	CAS 1076235-04-5
DMIVGYK	DE	Solid tumour/cancer

DMVUL1H	ID	DMVUL1H
DMVUL1H	DN	Sleeping Beauty CAR-TCR
DMVUL1H	HS	Phase 1
DMVUL1H	CP	Ziopharm Oncology
DMVUL1H	DT	CAR T Cell Therapy
DMVUL1H	DE	leukaemia

DMIAOU6	ID	DMIAOU6
DMIAOU6	DN	SLN124
DMIAOU6	HS	Phase 1
DMIAOU6	CP	Silence Therapeutics
DMIAOU6	DT	Small interfering RNA
DMIAOU6	DE	Beta thalassemia

DM7WKTM	ID	DM7WKTM
DM7WKTM	DN	SLV-338
DM7WKTM	HS	Phase 1
DM7WKTM	CP	Solvay SA
DM7WKTM	DE	Cardiovascular disease

DM491NI	ID	DM491NI
DM491NI	DN	SM04755
DM491NI	HS	Phase 1
DM491NI	CP	Samumed
DM491NI	DE	Liver cancer; Plaque psoriasis

DM4KLNA	ID	DM4KLNA
DM4KLNA	DN	SM08502
DM4KLNA	HS	Phase 1
DM4KLNA	CP	Samumed San Diego, CA
DM4KLNA	DE	Solid tumour/cancer

DM73YG5	ID	DM73YG5
DM73YG5	DN	SM09419
DM73YG5	HS	Phase 1
DM73YG5	CP	Biosplice
DM73YG5	DT	Small molecular drug
DM73YG5	DE	Hematologic tumour

DM8L1GJ	ID	DM8L1GJ
DM8L1GJ	DN	SNA-125
DM8L1GJ	HS	Phase 1
DM8L1GJ	CP	Sienna Biopharmaceuticals Westlake Village, CA
DM8L1GJ	DE	Atopic dermatitis; Pruritus; Psoriasis vulgaris

DM8ZROW	ID	DM8ZROW
DM8ZROW	DN	SNDX-6352
DM8ZROW	HS	Phase 1
DM8ZROW	CP	Syndax Pharmaceuticals Waltham, MA
DM8ZROW	DE	Solid tumour/cancer

DMEITAS	ID	DMEITAS
DMEITAS	DN	SNS-032
DMEITAS	HS	Phase 1
DMEITAS	SN	BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
DMEITAS	CP	Sunesis; Bristol Myers Squibb
DMEITAS	TC	Anticancer Agents
DMEITAS	DT	Small molecular drug
DMEITAS	PC	3025986
DMEITAS	MW	380.5
DMEITAS	FM	C17H24N4O2S2
DMEITAS	IC	InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)
DMEITAS	CS	CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)C3CCNCC3
DMEITAS	IK	OUSFTKFNBAZUKL-UHFFFAOYSA-N
DMEITAS	IU	N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
DMEITAS	CA	CAS 345627-80-7
DMEITAS	CB	CHEBI:91399
DMEITAS	DE	Solid tumour/cancer

DMAC5F2	ID	DMAC5F2
DMAC5F2	DN	SNS-314
DMAC5F2	HS	Phase 1
DMAC5F2	SN	SN-314
DMAC5F2	CP	Sunesis Pharma
DMAC5F2	TC	Anticancer Agents
DMAC5F2	DT	Small molecular drug
DMAC5F2	PC	24995524
DMAC5F2	MW	430.9
DMAC5F2	FM	C18H15ClN6OS2
DMAC5F2	IC	InChI=1S/C18H15ClN6OS2/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26)
DMAC5F2	CS	C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4
DMAC5F2	IK	FAYAUAZLLLJJGH-UHFFFAOYSA-N
DMAC5F2	IU	1-(3-chlorophenyl)-3-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl]urea
DMAC5F2	CA	CAS 1057249-41-8
DMAC5F2	CB	CHEBI:94720
DMAC5F2	DE	Solid tumour/cancer

DMCGPU8	ID	DMCGPU8
DMCGPU8	DN	SNX281
DMCGPU8	HS	Phase 1
DMCGPU8	CP	Silicon Therapeutics
DMCGPU8	DT	Small molecular drug
DMCGPU8	DE	Lymphoma; Solid tumour/cancer

DMB3WJF	ID	DMB3WJF
DMB3WJF	DN	Solulin
DMB3WJF	HS	Phase 1
DMB3WJF	SN	PN-02; Recombinant thrombomodulin, PAION
DMB3WJF	CP	Bayer Schering Pharma AG
DMB3WJF	DE	Thrombosis

DMB3YZJ	ID	DMB3YZJ
DMB3YZJ	DN	Sonepcizumab
DMB3YZJ	HS	Phase 1
DMB3YZJ	CP	Lpath
DMB3YZJ	DT	Antibody
DMB3YZJ	DE	Macular degeneration

DMBKL6O	ID	DMBKL6O
DMBKL6O	DN	SOR-C13
DMBKL6O	HS	Phase 1
DMBKL6O	CP	Soricimed biopharma
DMBKL6O	PC	121596688
DMBKL6O	MW	1565.8
DMBKL6O	FM	C72H116N20O19
DMBKL6O	IC	InChI=1S/C72H116N20O19/c1-39(2)31-48(84-63(102)49(33-42-17-8-7-9-18-42)85-60(99)46(24-25-56(94)95)81-59(98)44(75)19-10-12-26-73)62(101)88-52(34-43-36-78-38-80-43)70(109)92-30-16-23-55(92)67(106)89-53(37-93)65(104)82-45(20-11-13-27-74)61(100)90-58(41(5)6)68(107)86-50(35-57(96)97)64(103)87-51(32-40(3)4)69(108)91-29-15-22-54(91)66(105)83-47(71(110)111)21-14-28-79-72(76)77/h7-9,17-18,36,38-41,44-55,58,93H,10-16,19-35,37,73-75H2,1-6H3,(H,78,80)(H,81,98)(H,82,104)(H,83,105)(H,84,102)(H,85,99)(H,86,107)(H,87,103)(H,88,101)(H,89,106)(H,90,100)(H,94,95)(H,96,97)(H,110,111)(H4,76,77,79)/t44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,58-/m0/s1
DMBKL6O	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N
DMBKL6O	IK	LGANPTNILMNMES-TVNHODDRSA-N
DMBKL6O	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoic acid
DMBKL6O	CA	CAS 1187852-48-7
DMBKL6O	DE	Ovarian cancer; Solid tumour/cancer; Alzheimer disease

DMAD6HS	ID	DMAD6HS
DMAD6HS	DN	SPC4955
DMAD6HS	HS	Phase 1
DMAD6HS	CP	Santaris Pharma A/S
DMAD6HS	DE	High blood cholesterol level

DMUPQ70	ID	DMUPQ70
DMUPQ70	DN	SPC5001
DMUPQ70	HS	Phase 1
DMUPQ70	CP	Santaris Pharma A/S
DMUPQ70	DE	Hyperlipidaemia

DMO1FTI	ID	DMO1FTI
DMO1FTI	DN	Sphingosine
DMO1FTI	HS	Phase 1
DMO1FTI	SN	sphingosine; D-erythro-Sphingosine; 123-78-4; 4-Sphingenine; D-Sphingosine; Sphing-4-enine; cerebroside; trans-D-erythro-2-Amino-4-octadecene-1,3-diol; Sphingenine; (4E)-Sphingenine; 4-trans-Sphingenine; (2S,3R,4E)-2-Amino-4-octadecene-1,3-diol; Sphingoid; D-erythro-Sphingosine (synthetic); UNII-NGZ37HRE42; D-erythro-C18-Sphingosine; (E)-2-Amino-4-octadecan-1,3-diol; (2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol; trans-4-Sphingenine; CCRIS 6899; NGZ37HRE42; (2S,3R)-2-aminooctadec-4-ene-1,3-diol
DMO1FTI	DT	Small molecular drug
DMO1FTI	PC	5280335
DMO1FTI	MW	299.5
DMO1FTI	FM	C18H37NO2
DMO1FTI	IC	InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h14-15,17-18,20-21H,2-13,16,19H2,1H3/b15-14+/t17-,18+/m0/s1
DMO1FTI	CS	CCCCCCCCCCCCC/C=C/[C@H]([C@H](CO)N)O
DMO1FTI	IK	WWUZIQQURGPMPG-KRWOKUGFSA-N
DMO1FTI	IU	(E,2S,3R)-2-aminooctadec-4-ene-1,3-diol
DMO1FTI	CA	CAS 123-78-4
DMO1FTI	CB	CHEBI:16393

DMJCQKA	ID	DMJCQKA
DMJCQKA	DN	Sphingosine-1-Phosphate
DMJCQKA	HS	Phase 1
DMJCQKA	SN	Sphingosine 1-phosphate; sphingosine-1-phosphate; 26993-30-6; D-erythro-Sphingosine-1-phosphate; C18-Sphingosine 1-phosphate; Sphing-4-enine 1-phosphate; S1P; CHEBI:37550; D-erythro-sphingosine 1-phosphate; UNII-YVE187NJ1U; Sphingosine 1-phosphic acid; (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate; Sphing-4-enine-1-phosphate; YVE187NJ1U; CHEMBL225155; DUYSYHSSBDVJSM-KRWOKUGFSA-N; 4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (2S,3R,4E)-; (2S,3R,4E)-2-Amino-4-octadecene-1,3-diol 1-(Dihydroge
DMJCQKA	DT	Small molecular drug
DMJCQKA	PC	5283560
DMJCQKA	MW	379.5
DMJCQKA	FM	C18H38NO5P
DMJCQKA	IC	InChI=1S/C18H38NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)17(19)16-24-25(21,22)23/h14-15,17-18,20H,2-13,16,19H2,1H3,(H2,21,22,23)/b15-14+/t17-,18+/m0/s1
DMJCQKA	CS	CCCCCCCCCCCCC/C=C/[C@H]([C@H](COP(=O)(O)O)N)O
DMJCQKA	IK	DUYSYHSSBDVJSM-KRWOKUGFSA-N
DMJCQKA	IU	[(E,2S,3R)-2-amino-3-hydroxyoctadec-4-enyl] dihydrogen phosphate
DMJCQKA	CA	CAS 26993-30-6
DMJCQKA	CB	CHEBI:37550
DMJCQKA	DE	Acne vulgaris

DM5IPUS	ID	DM5IPUS
DM5IPUS	DN	SPI-014
DM5IPUS	HS	Phase 1
DM5IPUS	SN	SPI-1802; SPI-1810; Amyloid beta peptide 1-42 deposition inhibitor (AD), Satori; Gamma-secretase modulators (Alzheimers disease), Satori Pharmaceuticals
DM5IPUS	CP	Satori Pharmaceuticals Inc
DM5IPUS	PC	46221695
DM5IPUS	MW	369.82
DM5IPUS	FM	CLa2O5
DM5IPUS	IC	InChI=1S/CH2O3.2La.2O/c2-1(3)4;;;;/h(H2,2,3,4);;;;/q;2*+3;2*-2/p-2
DM5IPUS	CS	C(=O)([O-])[O-].[O-2].[O-2].[La+3].[La+3]
DM5IPUS	IK	VMVUIGXLELJYAZ-UHFFFAOYSA-L
DM5IPUS	IU	lanthanum(3+);oxygen(2-);carbonate
DM5IPUS	CA	CAS 1347739-77-8
DM5IPUS	DE	Hypophosphatasia; Alzheimer disease

DM8O2AQ	ID	DM8O2AQ
DM8O2AQ	DN	SPN-803
DM8O2AQ	HS	Phase 1
DM8O2AQ	CP	Supernus Pharmaceuticals Inc
DM8O2AQ	DT	Antisense drug
DM8O2AQ	DE	Parkinson disease

DMO5760	ID	DMO5760
DMO5760	DN	SR13668
DMO5760	HS	Phase 1
DMO5760	DT	Small molecular drug
DMO5760	PC	9845566
DMO5760	MW	430.5
DMO5760	FM	C25H22N2O5
DMO5760	IC	InChI=1S/C25H22N2O5/c1-4-31-24(28)13-6-8-19-15(10-13)17-12-18-16-11-14(25(29)32-5-2)7-9-20(16)27-22(18)23(30-3)21(17)26-19/h6-12,26-27H,4-5H2,1-3H3
DMO5760	CS	CCOC(=O)C1=CC2=C(C=C1)NC3=C(C4=C(C=C23)C5=C(N4)C=CC(=C5)C(=O)OCC)OC
DMO5760	IK	BMTPVPNVQOYGAP-UHFFFAOYSA-N
DMO5760	IU	diethyl 6-methoxy-5,7-dihydroindolo[2,3-b]carbazole-2,10-dicarboxylate
DMO5760	CA	CAS 637774-61-9
DMO5760	DE	Solid tumour/cancer

DMYRPBI	ID	DMYRPBI
DMYRPBI	DN	SR-4554
DMYRPBI	HS	Phase 1
DMYRPBI	SN	CRC-94/17; N-(3,3,3-Trifluoro-2-hydroxypropyl)-2-(2-nitro-1-imidazolyl)acetamide
DMYRPBI	DT	Small molecular drug
DMYRPBI	PC	9882197
DMYRPBI	MW	282.18
DMYRPBI	FM	C8H9F3N4O4
DMYRPBI	IC	InChI=1S/C8H9F3N4O4/c9-8(10,11)5(16)3-13-6(17)4-14-2-1-12-7(14)15(18)19/h1-2,5,16H,3-4H2,(H,13,17)
DMYRPBI	CS	C1=CN(C(=N1)[N+](=O)[O-])CC(=O)NCC(C(F)(F)F)O
DMYRPBI	IK	BTLNRJMECFTISR-UHFFFAOYSA-N
DMYRPBI	IU	2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoro-2-hydroxypropyl)acetamide
DMYRPBI	CA	CAS 167648-73-9
DMYRPBI	DE	Diagnostic imaging

DMQMO4N	ID	DMQMO4N
DMQMO4N	DN	SRF388
DMQMO4N	HS	Phase 1
DMQMO4N	CP	Surface oncology
DMQMO4N	DT	Antibody
DMQMO4N	DE	Solid tumour/cancer; Liver cancer

DMTK1BV	ID	DMTK1BV
DMTK1BV	DN	SRF617
DMTK1BV	HS	Phase 1
DMTK1BV	CP	Surface oncology
DMTK1BV	DT	Antibody
DMTK1BV	DE	Solid tumour/cancer

DM0EWMT	ID	DM0EWMT
DM0EWMT	DN	SRK-181
DM0EWMT	HS	Phase 1
DM0EWMT	CP	Scholar Rock
DM0EWMT	DT	Antibody
DM0EWMT	DE	Solid tumour/cancer

DM7DAKX	ID	DM7DAKX
DM7DAKX	DN	SRT2379
DM7DAKX	HS	Phase 1
DM7DAKX	CP	Sirtris
DM7DAKX	DE	Type-2 diabetes

DMRAXFH	ID	DMRAXFH
DMRAXFH	DN	SRT3025
DMRAXFH	HS	Phase 1
DMRAXFH	CP	Sirtris
DMRAXFH	PC	46245047
DMRAXFH	MW	569.7
DMRAXFH	FM	C31H31N5O2S2
DMRAXFH	IC	InChI=1S/C31H31N5O2S2/c1-38-17-9-14-26-27(35-29(39-26)22-10-3-2-4-11-22)28(37)33-24-13-6-5-12-23(24)30-34-25-18-21(19-32-31(25)40-30)20-36-15-7-8-16-36/h2-6,10-13,18-19H,7-9,14-17,20H2,1H3,(H,33,37)
DMRAXFH	CS	COCCCC1=C(N=C(S1)C2=CC=CC=C2)C(=O)NC3=CC=CC=C3C4=NC5=C(S4)N=CC(=C5)CN6CCCC6
DMRAXFH	IK	MRRXPMZNBRXCPZ-UHFFFAOYSA-N
DMRAXFH	IU	5-(3-methoxypropyl)-2-phenyl-N-[2-[6-(pyrrolidin-1-ylmethyl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]phenyl]-1,3-thiazole-4-carboxamide
DMRAXFH	DE	Type-2 diabetes

DMO1N8A	ID	DMO1N8A
DMO1N8A	DN	SRX-251
DMO1N8A	HS	Phase 1
DMO1N8A	SN	AVN-246; SRX-108; SRX-31; SRX-74; Vasopressin V1a antagonist (Raynauds disease/dysmenorrhea), Azevan Pharmaceuticals; Vasopressin V1a antagonist (psychiatric disorders/dysmenorrhea), Azevan
DMO1N8A	CP	Azevan Pharmaceuticals Inc
DMO1N8A	PC	11686429
DMO1N8A	MW	771.9
DMO1N8A	FM	C43H48F3N5O5
DMO1N8A	IC	InChI=1S/C43H48F3N5O5/c1-47(28-31-14-11-17-33(26-31)43(44,45)46)40(53)36(27-38(52)49-24-20-34(21-25-49)48-22-9-4-10-23-48)50-35(19-18-30-12-5-2-6-13-30)39(41(50)54)51-37(29-56-42(51)55)32-15-7-3-8-16-32/h2-3,5-8,11-19,26,34-37,39H,4,9-10,20-25,27-29H2,1H3/b19-18+/t35-,36-,37-,39+/m1/s1
DMO1N8A	CS	CN(CC1=CC(=CC=C1)C(F)(F)F)C(=O)[C@@H](CC(=O)N2CCC(CC2)N3CCCCC3)N4[C@@H]([C@@H](C4=O)N5[C@H](COC5=O)C6=CC=CC=C6)/C=C/C7=CC=CC=C7
DMO1N8A	IK	GOQPVIZMGXUXOL-GRLAPFOSSA-N
DMO1N8A	IU	(2R)-N-methyl-4-oxo-2-[(3S,4R)-2-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]-4-[(E)-2-phenylethenyl]azetidin-1-yl]-4-(4-piperidin-1-ylpiperidin-1-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]butanamide
DMO1N8A	DE	Dysmenorrhea

DMSUFW6	ID	DMSUFW6
DMSUFW6	DN	SSR-125047
DMSUFW6	HS	Phase 1
DMSUFW6	SN	Tolrestat; TOLRESTAT; 82964-04-3; Alredase; Lorestat; Tolrestatin; Tolrestatum; Tolrestatum [Latin]; AY-27773; 2-(6-Methoxy-N-methyl-5-(trifluoromethyl)naphthalene-1-carbothioamido)acetic acid; UNII-0T93LG5NMK; AY 27773; AY-27,773; CHEMBL436; 0T93LG5NMK; CHEBI:48549; LUBHDINQXIHVLS-UHFFFAOYSA-N; N-{[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]carbonothioyl}-N-methylglycine; NCGC00183862-01; N-(6-Methoxythio-5-(trifluoromethyl)-1-naphthoyl)sarcosine; N-{[6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbonothioyl}-N-methylglycine
DMSUFW6	CP	Sanofi-Aventis
DMSUFW6	DT	Small molecular drug
DMSUFW6	PC	53359
DMSUFW6	MW	357.3
DMSUFW6	FM	C16H14F3NO3S
DMSUFW6	IC	InChI=1S/C16H14F3NO3S/c1-20(8-13(21)22)15(24)11-5-3-4-10-9(11)6-7-12(23-2)14(10)16(17,18)19/h3-7H,8H2,1-2H3,(H,21,22)
DMSUFW6	CS	CN(CC(=O)O)C(=S)C1=CC=CC2=C1C=CC(=C2C(F)(F)F)OC
DMSUFW6	IK	LUBHDINQXIHVLS-UHFFFAOYSA-N
DMSUFW6	IU	2-[[6-methoxy-5-(trifluoromethyl)naphthalene-1-carbothioyl]-methylamino]acetic acid
DMSUFW6	CA	CAS 82964-04-3
DMSUFW6	CB	CHEBI:48549
DMSUFW6	DE	Schizophrenia; Diabetic cataract

DMG6NI8	ID	DMG6NI8
DMG6NI8	DN	SSR-125329A
DMG6NI8	HS	Phase 1
DMG6NI8	SN	SR-125329; N-[3-[4-(2-Adamantyl)-3,5-dichlorophenyl]-2(Z)-propenyl]-N-cyclohexyl-N-ethylamine
DMG6NI8	DE	Immune System disease

DMOJA7N	ID	DMOJA7N
DMOJA7N	DN	SSR-128428
DMOJA7N	HS	Phase 1
DMOJA7N	CP	Sanofi-Synthelabo
DMOJA7N	DE	Thrombosis

DMXQF1T	ID	DMXQF1T
DMXQF1T	DN	SSR-181507
DMXQF1T	HS	Phase 1
DMXQF1T	SN	UNII-H276H25KW0; H276H25KW0; SSR-181507; 8-Azabicyclo(3.2.1)octane-3-methanamine, 8-benzoyl-N-(((2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-, (3-exo)-
DMXQF1T	CP	Sanofi-Aventis
DMXQF1T	DT	Small molecular drug
DMXQF1T	PC	56603722
DMXQF1T	MW	426.9
DMXQF1T	FM	C24H27ClN2O3
DMXQF1T	IC	InChI=1S/C24H27ClN2O3/c25-18-6-9-22-23(12-18)30-21(15-29-22)14-26-13-16-10-19-7-8-20(11-16)27(19)24(28)17-4-2-1-3-5-17/h1-6,9,12,16,19-21,26H,7-8,10-11,13-15H2/t16?,19-,20+,21-/m0/s1
DMXQF1T	CS	C1C[C@H]2CC(C[C@@H]1N2C(=O)C3=CC=CC=C3)CNC[C@H]4COC5=C(O4)C=C(C=C5)Cl
DMXQF1T	IK	VDQJQKSTXHXBME-DTHFOOOUSA-N
DMXQF1T	IU	[(1S,5R)-3-[[[(3S)-6-chloro-2,3-dihydro-1,4-benzodioxin-3-yl]methylamino]methyl]-8-azabicyclo[3.2.1]octan-8-yl]-phenylmethanone
DMXQF1T	CA	CAS 737743-26-9
DMXQF1T	DE	Schizophrenia

DMX6V1L	ID	DMX6V1L
DMX6V1L	DN	ST-1141
DMX6V1L	HS	Phase 1
DMX6V1L	SN	Ghrelin agonist (oral, opioid-induced bowel dysfunction), Helsinn
DMX6V1L	CP	Sapphire Therapeutics Inc
DMX6V1L	DE	Functional bowel disorder

DMGPIV0	ID	DMGPIV0
DMGPIV0	DN	STA-5312
DMGPIV0	HS	Phase 1
DMGPIV0	SN	2-[3-(4-Cyanobenzyl)indolizin-1-yl]-N-(3-methylisothiazol-5-yl)-2-oxoacetamide
DMGPIV0	DT	Small molecular drug
DMGPIV0	PC	9843935
DMGPIV0	MW	400.5
DMGPIV0	FM	C22H16N4O2S
DMGPIV0	IC	InChI=1S/C22H16N4O2S/c1-14-10-20(29-25-14)24-22(28)21(27)18-12-17(26-9-3-2-4-19(18)26)11-15-5-7-16(13-23)8-6-15/h2-10,12H,11H2,1H3,(H,24,28)
DMGPIV0	CS	CC1=NSC(=C1)NC(=O)C(=O)C2=C3C=CC=CN3C(=C2)CC4=CC=C(C=C4)C#N
DMGPIV0	IK	IZZYUABKZYIINT-UHFFFAOYSA-N
DMGPIV0	IU	2-[3-[(4-cyanophenyl)methyl]indolizin-1-yl]-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide
DMGPIV0	CA	CAS 501948-05-6
DMGPIV0	DE	Solid tumour/cancer

DMDF29A	ID	DMDF29A
DMDF29A	DN	STM 434
DMDF29A	HS	Phase 1
DMDF29A	CP	Atara Biotherapeutics South San Francisco, CA
DMDF29A	DE	Ovarian cancer

DMXCJP8	ID	DMXCJP8
DMXCJP8	DN	STP1002
DMXCJP8	HS	Phase 1
DMXCJP8	CP	ST Pharm
DMXCJP8	DT	Small molecular drug
DMXCJP8	DE	Solid tumour/cancer

DMC5HXI	ID	DMC5HXI
DMC5HXI	DN	STRO-002
DMC5HXI	HS	Phase 1
DMC5HXI	CP	Sutro Biopharma
DMC5HXI	DT	Antibody drug conjugate
DMC5HXI	DE	Ovarian cancer

DMJAPRK	ID	DMJAPRK
DMJAPRK	DN	STX 64
DMJAPRK	HS	Phase 1
DMJAPRK	SN	BN-83495; STX-64; (6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-3-yl) sulfamate; 6-OXO-8,9,10,11-TETRAHYDRO-7H-CYCLOHEPTA[C][1]BENZOPYRAN-3-O-SULFAMATE; 667-Coumate
DMJAPRK	CP	Amgen
DMJAPRK	TC	Anticancer Agents
DMJAPRK	DT	Small molecular drug
DMJAPRK	PC	5287541
DMJAPRK	MW	309.34
DMJAPRK	FM	C14H15NO5S
DMJAPRK	IC	InChI=1S/C14H15NO5S/c15-21(17,18)20-9-6-7-11-10-4-2-1-3-5-12(10)14(16)19-13(11)8-9/h6-8H,1-5H2,(H2,15,17,18)
DMJAPRK	CS	C1CCC2=C(CC1)C(=O)OC3=C2C=CC(=C3)OS(=O)(=O)N
DMJAPRK	IK	DSLPMJSGSBLWRE-UHFFFAOYSA-N
DMJAPRK	IU	(6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-3-yl) sulfamate
DMJAPRK	CA	CAS 288628-05-7
DMJAPRK	DE	Prostate cancer

DMMAS3K	ID	DMMAS3K
DMMAS3K	DN	SULFAMIDE
DMMAS3K	HS	Phase 1
DMMAS3K	SN	Sulfuric diamide; 7803-58-9; Sulfamamide; Sulfuryl amide; Sulfuryl diamide; Sulfonyl diamide; sulfamoylamine; sulphamide; Sulphuric diamide; UNII-VS7TZW634V; Imidosulfamic acid; H4N2O2S; H2NSO2NH2; VS7TZW634V; CHEMBL355001; CHEBI:29368; NVBFHJWHLNUMCV-UHFFFAOYSA-N; MFCD00011606; Sulfamide, 98+%; Imidosulfamic acid (VAN); aminosulfonamide; NSC 252; diamidodioxidosulfur; EINECS 232-262-9; Sulfamide, 99%; AI3-30237; NH2SO2NH2; AC1Q55HN; KSC377O7F; NSC252; AC1L332P; DTXSID5064885; CTK2H7772; BDBM26995; NSC-252; MolPort-000-146-081
DMMAS3K	DT	Small molecular drug
DMMAS3K	PC	82267
DMMAS3K	MW	96.11
DMMAS3K	FM	H4N2O2S
DMMAS3K	IC	InChI=1S/H4N2O2S/c1-5(2,3)4/h(H4,1,2,3,4)
DMMAS3K	CS	NS(=O)(=O)N
DMMAS3K	IK	NVBFHJWHLNUMCV-UHFFFAOYSA-N
DMMAS3K	IU	sulfamide
DMMAS3K	CA	CAS 7803-58-9
DMMAS3K	CB	CHEBI:29368

DMIF8RY	ID	DMIF8RY
DMIF8RY	DN	SUN-K0706
DMIF8RY	HS	Phase 1
DMIF8RY	CP	Sun Pharma Advanced Research Mumbai, India
DMIF8RY	DE	Chronic lymphocytic leukaemia; Parkinson disease

DMDOSL0	ID	DMDOSL0
DMDOSL0	DN	SUN-N8075
DMDOSL0	HS	Phase 1
DMDOSL0	SN	SUN-8075; SUN-N5030; Sodium/calcium ion exchange inhibitor (acute ischemic stroke), Asubio Pharma; Sodium/calcium ion exchange inhibitor (acute ischemic stroke), Daiichi Sankyo
DMDOSL0	CP	Daiichi Suntory Biomedical Research Co Ltd
DMDOSL0	DE	Cerebral infarction

DMTOUY9	ID	DMTOUY9
DMTOUY9	DN	Suramin
DMTOUY9	HS	Phase 1
DMTOUY9	SN	Antrypol; Belganyl; Farma; Fourneau; Germanin; Moranyl; Naganil; Naganin; Naganine; Naganol; Naphuride; SVR; Suramine; SURAMIN SODIUM; Sodium suramin; Suramine sodium; Farma 939; Naganol 6 Na; Germanin (TN); SGCTO-001
DMTOUY9	CP	Bayer Pharmaceuticals Corporation
DMTOUY9	TC	Antinematodal Agents
DMTOUY9	DT	Small molecular drug
DMTOUY9	PC	5361
DMTOUY9	MW	1297.3
DMTOUY9	FM	C51H40N6O23S6
DMTOUY9	IC	InChI=1S/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)
DMTOUY9	CS	CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C
DMTOUY9	IK	FIAFUQMPZJWCLV-UHFFFAOYSA-N
DMTOUY9	IU	8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonic acid
DMTOUY9	CA	CAS 145-63-1
DMTOUY9	CB	CHEBI:45906
DMTOUY9	DE	African trypanosomiasis

DMZP671	ID	DMZP671
DMZP671	DN	SUVN 911
DMZP671	HS	Phase 1
DMZP671	CP	Suven Life Sciences
DMZP671	DT	Small molecular drug
DMZP671	DE	Major depressive disorder

DMLPBVF	ID	DMLPBVF
DMLPBVF	DN	SUVN-911
DMLPBVF	HS	Phase 1
DMLPBVF	SN	Alpha 4 beta 2 nicotinic acetylcholine receptor (nAChR) antagonist (depression), Suven
DMLPBVF	CP	Suven Life Sciences Ltd
DMLPBVF	DE	Major depressive disorder

DM6ZOD2	ID	DM6ZOD2
DM6ZOD2	DN	SUVN-D4010
DM6ZOD2	HS	Phase 1
DM6ZOD2	SN	DWTFBJGTRBMHPG-UHFFFAOYSA-N; UNII-GNQ25KYD72; GNQ25KYD72; 1428862-32-1; SCHEMBL14810657; 1-isopropyl-3-{5-[1-(3-methoxy propyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole; 1-isopropyl-3-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole
DM6ZOD2	CP	Suven Life Sciences Hyderabad, India
DM6ZOD2	PC	71508291
DM6ZOD2	MW	383.5
DM6ZOD2	FM	C21H29N5O2
DM6ZOD2	IC	InChI=1S/C21H29N5O2/c1-15(2)26-18-8-5-4-7-17(18)19(24-26)21-23-22-20(28-21)16-9-12-25(13-10-16)11-6-14-27-3/h4-5,7-8,15-16H,6,9-14H2,1-3H3
DM6ZOD2	CS	CC(C)N1C2=CC=CC=C2C(=N1)C3=NN=C(O3)C4CCN(CC4)CCCOC
DM6ZOD2	IK	DWTFBJGTRBMHPG-UHFFFAOYSA-N
DM6ZOD2	IU	2-[1-(3-methoxypropyl)piperidin-4-yl]-5-(1-propan-2-ylindazol-3-yl)-1,3,4-oxadiazole
DM6ZOD2	CA	CAS 1428862-32-1
DM6ZOD2	DE	Alzheimer disease

DMHMG6X	ID	DMHMG6X
DMHMG6X	DN	SX-682
DMHMG6X	HS	Phase 1
DMHMG6X	SN	1648843-04-2; UNII-H5212R2DPM; H5212R2DPM; SX682; (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; CHEMBL4297480; GTPL10165; BCP32154; EX-A4295; MFCD28502254; s8947; SX 682; SX682; SB17394; HY-119339; CS-0067128; [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid; 2-(2-Dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide; B-(2-(((5-(((4-Fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; Boronic acid, B-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-
DMHMG6X	CP	Syntrix Biosystems
DMHMG6X	DT	Small molecular drug
DMHMG6X	PC	90467234
DMHMG6X	MW	467.2
DMHMG6X	FM	C19H14BF4N3O4S
DMHMG6X	IC	InChI=1S/C19H14BF4N3O4S/c21-13-1-3-14(4-2-13)27-17(28)12-8-25-18(26-9-12)32-10-11-7-15(31-19(22,23)24)5-6-16(11)20(29)30/h1-9,29-30H,10H2,(H,27,28)
DMHMG6X	CS	B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O
DMHMG6X	IK	SDUDZBCEHIZMFZ-UHFFFAOYSA-N
DMHMG6X	IU	[2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid
DMHMG6X	CA	CAS 1648843-04-2
DMHMG6X	DE	Melanoma; Myelodysplastic syndrome

DMK48PM	ID	DMK48PM
DMK48PM	DN	SY-1365
DMK48PM	HS	Phase 1
DMK48PM	SN	QYQWRTVXDYKLRC-BLLGGJCASA-N; SCHEMBL17150548
DMK48PM	CP	Syros Pharmaceuticals Cambridge, MA
DMK48PM	PC	118426108
DMK48PM	MW	587.1
DMK48PM	FM	C31H35ClN8O2
DMK48PM	IC	InChI=1S/C31H35ClN8O2/c1-31(39-29(42)26-13-12-21(17-33-26)36-27(41)11-7-15-40(2)3)14-6-8-20(16-31)37-30-35-19-24(32)28(38-30)23-18-34-25-10-5-4-9-22(23)25/h4-5,7,9-13,17-20,34H,6,8,14-16H2,1-3H3,(H,36,41)(H,39,42)(H,35,37,38)/b11-7+/t20-,31+/m1/s1
DMK48PM	CS	C[C@@]1(CCC[C@H](C1)NC2=NC=C(C(=N2)C3=CNC4=CC=CC=C43)Cl)NC(=O)C5=NC=C(C=C5)NC(=O)/C=C/CN(C)C
DMK48PM	IK	SCJNYBYSTCRPAO-LXBQGUBHSA-N
DMK48PM	IU	N-[(1S,3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-1-methylcyclohexyl]-5-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyridine-2-carboxamide
DMK48PM	CA	CAS 1816989-16-8
DMK48PM	DE	Solid tumour/cancer

DMH8UF0	ID	DMH8UF0
DMH8UF0	DN	SY-1425
DMH8UF0	HS	Phase 1
DMH8UF0	CP	Syros Pharmaceuticals Cambridge, MA
DMH8UF0	DE	Acute myeloid leukaemia; Myelodysplastic syndrome

DMNW3LH	ID	DMNW3LH
DMNW3LH	DN	SY-5609
DMNW3LH	HS	Phase 1
DMNW3LH	CP	Syros Pharmaceuticals
DMNW3LH	DT	Small molecular drug
DMNW3LH	DE	Solid tumour/cancer

DMVXLS5	ID	DMVXLS5
DMVXLS5	DN	Sym021
DMVXLS5	HS	Phase 1
DMVXLS5	CP	Symphogen Somerville, NJ
DMVXLS5	DT	Monoclonal antibody
DMVXLS5	DE	Solid tumour/cancer; Advanced malignancy; Lymphoma; Non-hodgkin lymphoma

DMCK2YR	ID	DMCK2YR
DMCK2YR	DN	Sym022
DMCK2YR	HS	Phase 1
DMCK2YR	CP	Symphogen
DMCK2YR	DT	Antibody
DMCK2YR	DE	Lymphoma; Solid tumour/cancer

DMV3L62	ID	DMV3L62
DMV3L62	DN	Sym023
DMV3L62	HS	Phase 1
DMV3L62	CP	Symphogen
DMV3L62	DT	Antibody
DMV3L62	DE	Lymphoma; Solid tumour/cancer

DM0EZ69	ID	DM0EZ69
DM0EZ69	DN	SYN004
DM0EZ69	HS	Phase 1
DM0EZ69	CP	Synermore Biologics Taipei, Taiwan
DM0EZ69	DE	Solid tumour/cancer

DMX05W8	ID	DMX05W8
DMX05W8	DN	SYN-1001
DMX05W8	HS	Phase 1
DMX05W8	CP	Synta Pharma
DMX05W8	DE	Pain

DM4UVTO	ID	DM4UVTO
DM4UVTO	DN	SYN125
DM4UVTO	HS	Phase 1
DM4UVTO	CP	Symphogen
DM4UVTO	DT	Antibody
DM4UVTO	DE	Solid tumour/cancer; Uterine serous carcinoma

DMZJNHM	ID	DMZJNHM
DMZJNHM	DN	SYNB1891
DMZJNHM	HS	Phase 1
DMZJNHM	CP	Symphogen
DMZJNHM	DE	Lymphoma; Neoplasm

DM83E5B	ID	DM83E5B
DM83E5B	DN	Synthetic neutrophil inhibitor peptide
DM83E5B	HS	Phase 1
DM83E5B	SN	SNIP; Nalpha-Acetyl-L-arginyl-L-glutamyl-glycyl-L-seryl-L-tyrosyl-L-phenylalanyl-L-phenylalanyl-glycyl-L-aspartyl-L-asparaginyl-L-alaninamide
DM83E5B	DT	Small molecular drug
DM83E5B	PC	71482
DM83E5B	MW	324.68
DM83E5B	FM	C9H10ClN2O5PS
DM83E5B	IC	InChI=1S/C9H10ClN2O5PS/c1-15-18(14,16-2)19-5-12-8-7(17-9(12)13)3-6(10)4-11-8/h3-4H,5H2,1-2H3
DM83E5B	CS	COP(=O)(OC)SCN1C2=C(C=C(C=N2)Cl)OC1=O
DM83E5B	IK	VNKBTWQZTQIWDV-UHFFFAOYSA-N
DM83E5B	IU	6-chloro-3-(dimethoxyphosphorylsulfanylmethyl)-[1,3]oxazolo[4,5-b]pyridin-2-one
DM83E5B	CA	CAS 35575-96-3
DM83E5B	CB	CHEBI:38578
DM83E5B	DE	Rhinitis

DMH76KD	ID	DMH76KD
DMH76KD	DN	Syntropin
DMH76KD	HS	Phase 1
DMH76KD	SN	Human growth hormone (subcutaneous, dwarfism), Phage Biotechnology
DMH76KD	CP	Phage Biotechnology Corp
DMH76KD	DE	Dwarfism

DMD23AX	ID	DMD23AX
DMD23AX	DN	Systebryl
DMD23AX	HS	Phase 1
DMD23AX	SN	PTI-19; PTI-51; Systemic AA amyloidosis therapy, ProteoTech
DMD23AX	CP	ProteoTech Inc
DMD23AX	PC	10038269
DMD23AX	MW	261.23
DMD23AX	FM	C13H11NO5
DMD23AX	IC	InChI=1S/C13H11NO5/c15-9-3-1-7(5-11(9)17)13(19)14-8-2-4-10(16)12(18)6-8/h1-6,15-18H,(H,14,19)
DMD23AX	CS	C1=CC(=C(C=C1C(=O)NC2=CC(=C(C=C2)O)O)O)O
DMD23AX	IK	XIKSEDLKDYKPTO-UHFFFAOYSA-N
DMD23AX	IU	N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide
DMD23AX	CA	CAS 633700-15-9
DMD23AX	DE	Amyloidosis

DMNE9Z0	ID	DMNE9Z0
DMNE9Z0	DN	T-0128
DMNE9Z0	HS	Phase 1
DMNE9Z0	SN	M salt; MEN-4901; Glycylglycyl-N-[3-[(4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yloxy]propyl]glycinamide compound with dextran carboxymethyl ether sodiu
DMNE9Z0	DT	Small molecular drug
DMNE9Z0	PC	129631910
DMNE9Z0	MW	1716.3
DMNE9Z0	FM	C87H170N6O26
DMNE9Z0	IC	InChI=1S/C20H36O16.C11H11N.C7H15NO2.C7H12O3.C6H6O.C5H13N.C4H8N2O2.6C4H10.C3H7NO.H2O/c1-3-6-9(21)12(24)15(27)18(33-6)31-4-7-10(22)13(25)16(28)19(34-7)32-5-8-11(23)14(26)17(30-2)20(35-8)36-29;1-2-9-7-8-12-11-6-4-3-5-10(9)11;1-3-7(9)8-5-4-6-10-2;1-2-7(9)4-3-5-10-6(7)8;7-6-4-2-1-3-5-6;1-3-4-5-6-2;1-3(7)6-2-4(5)8;6*1-3-4-2;1-3(5)4-2;/h6-29H,3-5H2,1-2H3;3-8H,2H2,1H3;3-6H2,1-2H3,(H,8,9);9H,2-5H2,1H3;1-4H,5H2;6H,3-5H2,1-2H3;2H2,1H3,(H2,5,8)(H,6,7);6*3-4H2,1-2H3;1-2H3,(H,4,5);1H2/t6-,7?,8-,9-,10-,11-,12+,13+,14+,15-,16-,17-,18+,19+,20-;;;7-;;;;;;;;;;;/m1..0.........../s1
DMNE9Z0	CS	CCCC.CCCC.CCCC.CCCC.CCCC.CCCC.CCCCNC.CC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OCC2[C@H]([C@@H]([C@H]([C@H](O2)OC[C@@H]3[C@H]([C@@H]([C@H]([C@H](O3)OO)OC)O)O)O)O)O)O)O)O.CCC1=CC=NC2=CC=CC=C12.CCC(=O)NCCCOC.CC[C@@]1(CCCOC1=O)O.CC(=O)NC.CC(=O)NCC(=O)N.C1C=CC=CC1=O.O
DMNE9Z0	IK	HYSLQFLGTWXGPE-JCQKILSGSA-N
DMNE9Z0	IU	2-acetamidoacetamide;butane;cyclohexa-2,4-dien-1-one;(2R,3S,4S,5R,6S)-2-ethyl-6-[[(3S,4S,5R,6S)-6-[[(2R,3S,4S,5R,6R)-6-hydroperoxy-3,4-dihydroxy-5-methoxyoxan-2-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]oxane-3,4,5-triol;(3S)-3-ethyl-3-hydroxyoxan-2-one;4-ethylquinoline;N-(3-methoxypropyl)propanamide;N-methylacetamide;N-methylbutan-1-amine;hydrate
DMNE9Z0	DE	Solid tumour/cancer

DMV8IQW	ID	DMV8IQW
DMV8IQW	DN	Tafluposide
DMV8IQW	HS	Phase 1
DMV8IQW	SN	F-11782
DMV8IQW	CP	Pierre Fabre SA
DMV8IQW	PC	9877073
DMV8IQW	MW	1116.7
DMV8IQW	FM	C45H35F10O20P
DMV8IQW	IC	InChI=1S/C45H35F10O20P/c1-13-64-9-22-39(70-13)42(72-23(56)10-65-40-33(52)29(48)27(46)30(49)34(40)53)43(73-24(57)11-66-41-35(54)31(50)28(47)32(51)36(41)55)45(71-22)74-37-16-7-19-18(68-12-69-19)6-15(16)25(26-17(37)8-67-44(26)58)14-4-20(62-2)38(21(5-14)63-3)75-76(59,60)61/h4-7,13,17,22,25-26,37,39,42-43,45H,8-12H2,1-3H3,(H2,59,60,61)/t13-,17+,22-,25-,26+,37-,39-,42+,43-,45+/m1/s1
DMV8IQW	CS	C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)OP(=O)(O)O)OC)OC(=O)COC8=C(C(=C(C(=C8F)F)F)F)F)OC(=O)COC9=C(C(=C(C(=C9F)F)F)F)F
DMV8IQW	IK	RTJVUHUGTUDWRK-CSLCKUBZSA-N
DMV8IQW	IU	[(2R,4aR,6R,7R,8S,8aR)-6-[[(5S,5aR,8aR,9R)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-8-yl] 2-(2,3,4,5,6-pentafluorophenoxy)acetate
DMV8IQW	CA	CAS 179067-42-6
DMV8IQW	DE	Solid tumour/cancer

DM6OKH4	ID	DM6OKH4
DM6OKH4	DN	TAK-020
DM6OKH4	HS	Phase 1
DM6OKH4	CP	Takeda Pharmaceuticals Deerfield, IL
DM6OKH4	DE	Rheumatoid arthritis

DM0ZQ7J	ID	DM0ZQ7J
DM0ZQ7J	DN	TAK-041
DM0ZQ7J	HS	Phase 1
DM0ZQ7J	CP	Takeda Deerfield, IL
DM0ZQ7J	DE	XY disorder of sex development due to androgen resistance

DMX9EA0	ID	DMX9EA0
DMX9EA0	DN	TAK-058
DMX9EA0	HS	Phase 1
DMX9EA0	DE	Schizophrenia; XY disorder of sex development due to androgen resistance

DMKUT08	ID	DMKUT08
DMKUT08	DN	TAK-071
DMKUT08	HS	Phase 1
DMKUT08	SN	WFSARWQASFQZMG-FGZHOGPDSA-N; 1820812-16-5
DMKUT08	CP	Takeda Pharmaceuticals Deerfield, IL
DMKUT08	PC	92042879
DMKUT08	MW	421.5
DMKUT08	FM	C24H24FN3O3
DMKUT08	IC	InChI=1S/C24H24FN3O3/c1-15-17(11-16-3-5-18(6-4-16)28-9-2-8-26-28)12-19-20(23(15)25)13-27(24(19)30)21-14-31-10-7-22(21)29/h2-6,8-9,12,21-22,29H,7,10-11,13-14H2,1H3/t21-,22-/m0/s1
DMKUT08	CS	CC1=C(C2=C(C=C1CC3=CC=C(C=C3)N4C=CC=N4)C(=O)N(C2)[C@H]5COCC[C@@H]5O)F
DMKUT08	IK	WFSARWQASFQZMG-VXKWHMMOSA-N
DMKUT08	IU	4-fluoro-2-[(3S,4S)-4-hydroxyoxan-3-yl]-5-methyl-6-[(4-pyrazol-1-ylphenyl)methyl]-3H-isoindol-1-one
DMKUT08	CA	CAS 1820812-16-5
DMKUT08	DE	Alzheimer disease

DMD79TX	ID	DMD79TX
DMD79TX	DN	TAK-102
DMD79TX	HS	Phase 1
DMD79TX	CP	Takeda
DMD79TX	DT	CAR T Cell Therapy
DMD79TX	DE	Solid tumour/cancer

DMTXE19	ID	DMTXE19
DMTXE19	DN	TAK-114
DMTXE19	HS	Phase 1
DMTXE19	DE	Ulcerative colitis

DMYG704	ID	DMYG704
DMYG704	DN	TAK-137
DMYG704	HS	Phase 1
DMYG704	PC	56649286
DMYG704	MW	352.4
DMYG704	FM	C19H16N2O3S
DMYG704	IC	InChI=1S/C19H16N2O3S/c22-25(23)14-13-21-12-4-7-18(19(21)20-25)15-8-10-17(11-9-15)24-16-5-2-1-3-6-16/h1-12H,13-14H2
DMYG704	CS	C1CS(=O)(=O)N=C2N1C=CC=C2C3=CC=C(C=C3)OC4=CC=CC=C4
DMYG704	IK	VKKLOYOLCCDGLD-UHFFFAOYSA-N
DMYG704	IU	9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide
DMYG704	CA	CAS 1358749-55-9
DMYG704	DE	Psychiatric disorder

DMRINBJ	ID	DMRINBJ
DMRINBJ	DN	TAK-169
DMRINBJ	HS	Phase 1
DMRINBJ	CP	Molecular Templates
DMRINBJ	DT	Recombinant protein
DMRINBJ	DE	Multiple myeloma

DMVYEFZ	ID	DMVYEFZ
DMVYEFZ	DN	TAK-202
DMVYEFZ	HS	Phase 1
DMVYEFZ	CP	Takeda Oncology Deerfield, IL
DMVYEFZ	DE	Melanoma; Solid tumour/cancer

DMW10HM	ID	DMW10HM
DMW10HM	DN	Tak-220
DMW10HM	HS	Phase 1
DMW10HM	SN	AIDS228341; TAK220; TBR220; TBR-220; 1-acetyl-N-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
DMW10HM	CP	Takeda
DMW10HM	DT	Small molecular drug
DMW10HM	PC	5275766
DMW10HM	MW	553.1
DMW10HM	FM	C31H41ClN4O3
DMW10HM	IC	InChI=1S/C31H41ClN4O3/c1-22-4-9-28(21-29(22)32)36(31(39)27-12-18-35(19-13-27)23(2)37)15-3-14-34-16-10-25(11-17-34)20-24-5-7-26(8-6-24)30(33)38/h4-9,21,25,27H,3,10-20H2,1-2H3,(H2,33,38)
DMW10HM	CS	CC1=C(C=C(C=C1)N(CCCN2CCC(CC2)CC3=CC=C(C=C3)C(=O)N)C(=O)C4CCN(CC4)C(=O)C)Cl
DMW10HM	IK	ASSJTMUEFHUKMJ-UHFFFAOYSA-N
DMW10HM	IU	1-acetyl-N-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
DMW10HM	CA	CAS 333994-00-6
DMW10HM	DE	Human immunodeficiency virus-1 infection

DM4GKV2	ID	DM4GKV2
DM4GKV2	DN	TAK-243
DM4GKV2	HS	Phase 1
DM4GKV2	SN	Tak-243; V9GGV0YCDI; UNII-V9GGV0YCDI; Uae inhibitor MLN7243; SCHEMBL15191794; KJDAGXLMHXUAGV-DGWLBADLSA-N; Sulfamic acid, ((1R,2R,3S,4R)-2,3-dihydroxy-4-((2-(3-((trifluoromethyl)thio)phenyl)pyrazolo(1,5-a)pyrimidin-7-yl)amino)cyclopentyl)methyl ester; ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio)phenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate; ((1R,2R,3S,4R)-2,3-Dihydroxy-4-((2-(3-(trifluoromethylsulfanyl)phenyl)pyrazolo(1,5-a)pyrimidin-7-yl)amino)cyclopentyl)methyl sulfamate
DM4GKV2	CP	Takeda Oncology Deerfield, IL
DM4GKV2	PC	71715374
DM4GKV2	MW	519.5
DM4GKV2	FM	C19H20F3N5O5S2
DM4GKV2	IC	InChI=1S/C19H20F3N5O5S2/c20-19(21,22)33-12-3-1-2-10(6-12)13-8-16-24-5-4-15(27(16)26-13)25-14-7-11(17(28)18(14)29)9-32-34(23,30)31/h1-6,8,11,14,17-18,25,28-29H,7,9H2,(H2,23,30,31)/t11-,14-,17-,18+/m1/s1
DM4GKV2	CS	C1[C@@H]([C@H]([C@H]([C@@H]1NC2=CC=NC3=CC(=NN23)C4=CC(=CC=C4)SC(F)(F)F)O)O)COS(=O)(=O)N
DM4GKV2	IK	KJDAGXLMHXUAGV-DGWLBADLSA-N
DM4GKV2	IU	[(1R,2R,3S,4R)-2,3-dihydroxy-4-[[2-[3-(trifluoromethylsulfanyl)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]cyclopentyl]methyl sulfamate
DM4GKV2	CA	CAS 1450833-55-2
DM4GKV2	DE	Solid tumour/cancer

DM1AKNI	ID	DM1AKNI
DM1AKNI	DN	TAK-252
DM1AKNI	HS	Phase 1
DM1AKNI	SN	SL-279252
DM1AKNI	CP	Takeda
DM1AKNI	DT	Recombinant protein
DM1AKNI	DE	Solid tumour/cancer

DM6KOBZ	ID	DM6KOBZ
DM6KOBZ	DN	TAK-285
DM6KOBZ	HS	Phase 1
DM6KOBZ	SN	TAK-285; 871026-44-7; TAK 285; TAK285; UNII-70CCB438L6; N-(2-(4-(3-CHLORO-4-(3-(TRIFLUOROMETHYL)PHENOXY)PHENYLAMINO)-5H-PYRROLO[3,2-D]PYRIMIDIN-5-YL)ETHYL)-3-HYDROXY-3-METHYLBUTANAMIDE; CHEMBL1614725; 70CCB438L6; N-{2-[4-({3-Chloro-4-[3-(Trifluoromethyl)phenoxy]phenyl}amino)-5h-Pyrrolo[3,2-D]pyrimidin-5-Yl]ethyl}-3-Hydroxy-3-Methylbutanamide; n-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5h-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide; C26H25ClF3N5O3
DM6KOBZ	DT	Small molecular drug
DM6KOBZ	PC	11620908
DM6KOBZ	MW	548
DM6KOBZ	FM	C26H25ClF3N5O3
DM6KOBZ	IC	InChI=1S/C26H25ClF3N5O3/c1-25(2,37)14-22(36)31-9-11-35-10-8-20-23(35)24(33-15-32-20)34-17-6-7-21(19(27)13-17)38-18-5-3-4-16(12-18)26(28,29)30/h3-8,10,12-13,15,37H,9,11,14H2,1-2H3,(H,31,36)(H,32,33,34)
DM6KOBZ	CS	CC(C)(CC(=O)NCCN1C=CC2=C1C(=NC=N2)NC3=CC(=C(C=C3)OC4=CC=CC(=C4)C(F)(F)F)Cl)O
DM6KOBZ	IK	ZYQXEVJIFYIBHZ-UHFFFAOYSA-N
DM6KOBZ	IU	N-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide
DM6KOBZ	CA	CAS 871026-44-7
DM6KOBZ	DE	Solid tumour/cancer

DMMWNQP	ID	DMMWNQP
DMMWNQP	DN	TAK-329
DMMWNQP	HS	Phase 1
DMMWNQP	CP	Takeda Pharmaceuticals U.S.A.
DMMWNQP	DE	Diabetic complication

DM7DFBL	ID	DM7DFBL
DM7DFBL	DN	TAK-441
DM7DFBL	HS	Phase 1
DM7DFBL	SN	TAK-441; 1186231-83-3; CHEMBL2205230; TAK 441; SCHEMBL1061476; GTPL8200; BCP20946; ZINC43207688; BDBM50401323; LM2094; SB18887; KB-80790; Z-3185; 6-ethyl-N-[1-(2-hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-phenacyl-3-(2,2,2-trifluoroethoxy)pyrrolo[3,2-c]pyridine-2-carboxamide
DM7DFBL	CP	Millennium Pharmaceuticals
DM7DFBL	DT	Small molecular drug
DM7DFBL	PC	44187367
DM7DFBL	MW	576.6
DM7DFBL	FM	C28H31F3N4O6
DM7DFBL	IC	InChI=1S/C28H31F3N4O6/c1-3-19-13-20-23(27(40)35(19)14-21(37)17-7-5-4-6-8-17)25(41-16-28(29,30)31)24(33(20)2)26(39)32-18-9-11-34(12-10-18)22(38)15-36/h4-8,13,18,36H,3,9-12,14-16H2,1-2H3,(H,32,39)
DM7DFBL	CS	CCC1=CC2=C(C(=C(N2C)C(=O)NC3CCN(CC3)C(=O)CO)OCC(F)(F)F)C(=O)N1CC(=O)C4=CC=CC=C4
DM7DFBL	IK	ZADWXQMNNVICKB-UHFFFAOYSA-N
DM7DFBL	IU	6-ethyl-N-[1-(2-hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-phenacyl-3-(2,2,2-trifluoroethoxy)pyrrolo[3,2-c]pyridine-2-carboxamide
DM7DFBL	CA	CAS 1186231-83-3
DM7DFBL	DE	Solid tumour/cancer

DMUXAP1	ID	DMUXAP1
DMUXAP1	DN	TAK-573
DMUXAP1	HS	Phase 1
DMUXAP1	CP	Takeda
DMUXAP1	DT	Recombinant protein
DMUXAP1	DE	Refractory multiple myeloma; Multiple myeloma

DMNFZOT	ID	DMNFZOT
DMNFZOT	DN	TAK-593
DMNFZOT	HS	Phase 1
DMNFZOT	SN	TAK-593; 1005780-62-0; UNII-H3I42X8XX7; H3I42X8XX7; CHEMBL2180604; 1H-Pyrazole-5-carboxamide, N-[5-[[2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl]oxy]-2-methylphenyl]-1,3-dimethyl-;1H-Pyrazole-5-carboxamide, N-[5-[[2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl]oxy]-2-methylphenyl]-1,3-dimethyl-; TAK 593; SCHEMBL2515478; DZFZXPPHBWCXPQ-UHFFFAOYSA-N; ZINC95579919; BDBM50399537; AKOS030526192; CS-2403; DB13093; NCGC00485933-01; 1H-Pyrazole-5-carboxamide, N-(5-((2-((cyclopropylcarbonyl)amino)imidazo
DMNFZOT	DT	Small molecular drug
DMNFZOT	PC	24767976
DMNFZOT	MW	445.5
DMNFZOT	FM	C23H23N7O3
DMNFZOT	IC	InChI=1S/C23H23N7O3/c1-13-4-7-16(11-17(13)24-23(32)18-10-14(2)27-29(18)3)33-21-9-8-20-25-19(12-30(20)28-21)26-22(31)15-5-6-15/h4,7-12,15H,5-6H2,1-3H3,(H,24,32)(H,26,31)
DMNFZOT	CS	CC1=C(C=C(C=C1)OC2=NN3C=C(N=C3C=C2)NC(=O)C4CC4)NC(=O)C5=CC(=NN5C)C
DMNFZOT	IK	DZFZXPPHBWCXPQ-UHFFFAOYSA-N
DMNFZOT	IU	N-[5-[2-(cyclopropanecarbonylamino)imidazo[1,2-b]pyridazin-6-yl]oxy-2-methylphenyl]-2,5-dimethylpyrazole-3-carboxamide
DMNFZOT	CA	CAS 1005780-62-0
DMNFZOT	DE	Solid tumour/cancer

DMQ8YKR	ID	DMQ8YKR
DMQ8YKR	DN	TAK-648
DMQ8YKR	HS	Phase 1
DMQ8YKR	CP	Takeda
DMQ8YKR	DE	Type 2 diabetes

DMCKF5J	ID	DMCKF5J
DMCKF5J	DN	TAK-676
DMCKF5J	HS	Phase 1
DMCKF5J	CP	Takeda
DMCKF5J	DE	Solid tumour/cancer

DML3M0O	ID	DML3M0O
DML3M0O	DN	TAK-701
DML3M0O	HS	Phase 1
DML3M0O	SN	SCHEMBL131582
DML3M0O	CP	Takeda
DML3M0O	DT	Small molecular drug
DML3M0O	PC	16760691
DML3M0O	MW	380.5
DML3M0O	FM	C18H16N6S2
DML3M0O	IC	InChI=1S/C18H16N6S2/c1-24-16(18(23)26-15-9-5-3-7-13(15)21)11(10-19)17(22)25-14-8-4-2-6-12(14)20/h2-9H,20-23H2/b17-11+,18-16-
DML3M0O	CS	[C-]#[N+]/C(=C(/N)\\SC1=CC=CC=C1N)/C(=C(\\N)/SC2=CC=CC=C2N)/C#N
DML3M0O	IK	OSXOBXXOVNWNOP-UNEKJRSWSA-N
DML3M0O	IU	(Z,2Z)-4-amino-2-[amino-(2-aminophenyl)sulfanylmethylidene]-4-(2-aminophenyl)sulfanyl-3-isocyanobut-3-enenitrile
DML3M0O	DE	Advanced malignancy

DMC4RNA	ID	DMC4RNA
DMC4RNA	DN	TAK-733
DMC4RNA	HS	Phase 1
DMC4RNA	SN	TAK-733; 1035555-63-5; TAK733; TAK 733; UNII-5J61HSP0QJ; (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione; 5J61HSP0QJ; CHEMBL1615025; 3-[(2r)-2,3-Dihydroxypropyl]-6-Fluoro-5-[(2-Fluoro-4-Iodophenyl)amino]-8-Methylpyrido[2,3-D]pyrimidine-4,7(3h,8h)-Dione; MLS006011054; SCHEMBL1528606; GTPL9911; DTXSID20648089; MolPort-023-293-497; RCLQNICOARASSR-SECBINFHSA-N; example 18 [US8470837]; AOB87182; EX-A2164; BCP06625
DMC4RNA	CP	Millennium Pharmaceuticals
DMC4RNA	DT	Small molecular drug
DMC4RNA	PC	24963252
DMC4RNA	MW	504.23
DMC4RNA	FM	C17H15F2IN4O4
DMC4RNA	IC	InChI=1S/C17H15F2IN4O4/c1-23-15-12(16(27)24(7-21-15)5-9(26)6-25)14(13(19)17(23)28)22-11-3-2-8(20)4-10(11)18/h2-4,7,9,22,25-26H,5-6H2,1H3/t9-/m1/s1
DMC4RNA	CS	CN1C2=C(C(=C(C1=O)F)NC3=C(C=C(C=C3)I)F)C(=O)N(C=N2)C[C@H](CO)O
DMC4RNA	IK	RCLQNICOARASSR-SECBINFHSA-N
DMC4RNA	IU	3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione
DMC4RNA	CA	CAS 1035555-63-5
DMC4RNA	DE	Solid tumour/cancer

DMW43DL	ID	DMW43DL
DMW43DL	DN	TAK-828
DMW43DL	HS	Phase 1
DMW43DL	SN	ICMFYVOUDGRBLG-NJMNTPMDSA-N; TAK828F; GTPL9867; TAK-828F; SCHEMBL17390967; SCHEMBL17390969; SCHEMBL17391123; ICMFYVOUDGRBLG-VFHHBZAHSA-N; ICMFYVOUDGRBLG-XVNUGVHUSA-N; compound 10 [PMID: 29510038]; E3V; {cis-3-[(5R)-5-[(7-fluoro-1,1-dimethyl-1H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridine-6(5H)-carbonyl]cyclobutyl}acetic acid; (cis-3-(((5R)-5-((7-fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl)-2-methoxy-7,8-dihydro-1,6-naphthyridin-6 (5H)-yl)carbonyl)cyclobutyl)acetic acid; (cis-3-(((5R)-5-((7-fluoro-1,1-dimethyl-2
DMW43DL	CP	Takeda Pharmaceuticals Deerfield, IL
DMW43DL	PC	118622692
DMW43DL	MW	509.6
DMW43DL	FM	C28H32FN3O5
DMW43DL	IC	InChI=1S/C28H32FN3O5/c1-28(2)8-6-16-13-18(14-20(29)24(16)28)30-26(35)25-19-4-5-22(37-3)31-21(19)7-9-32(25)27(36)17-10-15(11-17)12-23(33)34/h4-5,13-15,17,25H,6-12H2,1-3H3,(H,30,35)(H,33,34)/t15?,17?,25-/m1/s1
DMW43DL	CS	CC1(CCC2=C1C(=CC(=C2)NC(=O)[C@H]3C4=C(CCN3C(=O)C5CC(C5)CC(=O)O)N=C(C=C4)OC)F)C
DMW43DL	IK	ICMFYVOUDGRBLG-NJMNTPMDSA-N
DMW43DL	IU	2-[3-[(5R)-5-[(7-fluoro-1,1-dimethyl-2,3-dihydroinden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-5H-1,6-naphthyridine-6-carbonyl]cyclobutyl]acetic acid
DMW43DL	DE	Crohn disease

DM5KDGI	ID	DM5KDGI
DM5KDGI	DN	TAK-901
DM5KDGI	HS	Phase 1
DM5KDGI	SN	TAK-901; 934541-31-8; TAK901; TAK 901; UNII-DM9UIR23R7; 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; DM9UIR23R7; 5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-9H-pyrido[2,3-b]indole-7-carboxamide; C28H32N4O3S; 5-[3-(ethanesulfonyl)phenyl]-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; 5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; cc-11; MLS006010174
DM5KDGI	CP	Takeda
DM5KDGI	DT	Small molecular drug
DM5KDGI	PC	16124208
DM5KDGI	MW	504.6
DM5KDGI	FM	C28H32N4O3S
DM5KDGI	IC	InChI=1S/C28H32N4O3S/c1-5-36(34,35)21-8-6-7-19(14-21)23-15-22(28(33)30-20-9-11-32(4)12-10-20)18(3)26-25(23)24-13-17(2)16-29-27(24)31-26/h6-8,13-16,20H,5,9-12H2,1-4H3,(H,29,31)(H,30,33)
DM5KDGI	CS	CCS(=O)(=O)C1=CC=CC(=C1)C2=CC(=C(C3=C2C4=C(N3)N=CC(=C4)C)C)C(=O)NC5CCN(CC5)C
DM5KDGI	IK	WKDACQVEJIVHMZ-UHFFFAOYSA-N
DM5KDGI	IU	5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide
DM5KDGI	CA	CAS 934541-31-8
DM5KDGI	DE	Haematological malignancy

DM1ALY9	ID	DM1ALY9
DM1ALY9	DN	TAK-931
DM1ALY9	HS	Phase 1
DM1ALY9	SN	XGVXKJKTISMIOW-ZDUSSCGKSA-N; UNII-LST350G3XU; LST350G3XU; 1330782-76-7; SCHEMBL19410618; SCHEMBL12459022; EX-A2702; HY-100888; CS-0020550; Thieno(3,2-d)pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo(2.2.2)oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-; 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4 (3H)-one
DM1ALY9	CP	Takeda Oncology Deerfield, IL
DM1ALY9	PC	135564531
DM1ALY9	MW	341.4
DM1ALY9	FM	C17H19N5OS
DM1ALY9	IC	InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)/t13-/m0/s1
DM1ALY9	CS	CC1=C(C=NN1)C2=CC3=C(S2)C(=O)NC(=N3)[C@@H]4CC5CCN4CC5
DM1ALY9	IK	XGVXKJKTISMIOW-ZDUSSCGKSA-N
DM1ALY9	IU	2-[(2S)-1-azabicyclo[2.2.2]octan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one
DM1ALY9	CA	CAS 1330782-76-7
DM1ALY9	DE	Solid tumour/cancer

DMN4OGH	ID	DMN4OGH
DMN4OGH	DN	TAK-960
DMN4OGH	HS	Phase 1
DMN4OGH	SN	TAK-960; 1137868-52-0; TAK960; TAK 960; CHEMBL2392545; AK172385; benzamide, 4-[(9-cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methyl-4-piperidinyl)-; 4-[(9-Cyclopentyl-7,7-Difluoro-5-Methyl-6-Oxo-6,7,8,9-Tetrahydro-5h-Pyrimido[4,5-B][1,4]diazepin-2-Yl)amino]-2-Fluoro-5-Methoxy-N-(1-Methylpiperidin-4-Yl)benzamide
DMN4OGH	CP	Millennium Pharmaceuticals
DMN4OGH	DT	Small molecular drug
DMN4OGH	PC	53357478
DMN4OGH	MW	561.6
DMN4OGH	FM	C27H34F3N7O3
DMN4OGH	IC	InChI=1S/C27H34F3N7O3/c1-35-10-8-16(9-11-35)32-24(38)18-12-22(40-3)20(13-19(18)28)33-26-31-14-21-23(34-26)37(17-6-4-5-7-17)15-27(29,30)25(39)36(21)2/h12-14,16-17H,4-11,15H2,1-3H3,(H,32,38)(H,31,33,34)
DMN4OGH	CS	CN1CCC(CC1)NC(=O)C2=CC(=C(C=C2F)NC3=NC=C4C(=N3)N(CC(C(=O)N4C)(F)F)C5CCCC5)OC
DMN4OGH	IK	GWRSATNRNFYMDI-UHFFFAOYSA-N
DMN4OGH	IU	4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-N-(1-methylpiperidin-4-yl)benzamide
DMN4OGH	DE	Solid tumour/cancer

DMSQZEP	ID	DMSQZEP
DMSQZEP	DN	TAR-200
DMSQZEP	HS	Phase 1
DMSQZEP	CP	TARIS Biomedical Lexington, MA
DMSQZEP	DE	Bladder cancer

DM5WDKY	ID	DM5WDKY
DM5WDKY	DN	TAS-103
DM5WDKY	HS	Phase 1
DM5WDKY	DT	Small molecular drug
DM5WDKY	PC	135413533
DM5WDKY	MW	333.4
DM5WDKY	FM	C20H19N3O2
DM5WDKY	IC	InChI=1S/C20H19N3O2/c1-23(2)10-9-21-20-18-17(13-5-3-4-6-14(13)19(18)25)15-8-7-12(24)11-16(15)22-20/h3-8,11,24H,9-10H2,1-2H3,(H,21,22)
DM5WDKY	CS	CN(C)CCNC1=NC2=C(C=CC(=C2)O)C3=C1C(=O)C4=CC=CC=C43
DM5WDKY	IK	ROWSTIYZUWEOMM-UHFFFAOYSA-N
DM5WDKY	IU	6-[2-(dimethylamino)ethylamino]-3-hydroxyindeno[2,1-c]quinolin-7-one
DM5WDKY	CA	CAS 174634-08-3
DM5WDKY	DE	Solid tumour/cancer

DMRX530	ID	DMRX530
DMRX530	DN	TAS-116
DMRX530	HS	Phase 1
DMRX530	SN	Tas-116; 1260533-36-5; UNII-PLO044MUDZ; PLO044MUDZ; SCHEMBL2694525; CHEMBL3661115; BDBM126083; ZINC169703510; KB-334563; US8779142, 102; Benzamide, 3-ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)-; 3-ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide; 3-Ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)benzamide
DMRX530	CP	Taiho Oncology Princeton, NJ
DMRX530	PC	67501411
DMRX530	MW	454.5
DMRX530	FM	C25H26N8O
DMRX530	IC	InChI=1S/C25H26N8O/c1-5-16-10-17(24(26)34)6-7-20(16)33-25-22(23(30-33)15(2)3)21(8-9-27-25)32-13-19(28-14-32)18-11-29-31(4)12-18/h6-15H,5H2,1-4H3,(H2,26,34)
DMRX530	CS	CCC1=C(C=CC(=C1)C(=O)N)N2C3=NC=CC(=C3C(=N2)C(C)C)N4C=C(N=C4)C5=CN(N=C5)C
DMRX530	IK	NVVPMZUGELHVMH-UHFFFAOYSA-N
DMRX530	IU	3-ethyl-4-[4-[4-(1-methylpyrazol-4-yl)imidazol-1-yl]-3-propan-2-ylpyrazolo[3,4-b]pyridin-1-yl]benzamide
DMRX530	CA	CAS 1260533-36-5
DMRX530	DE	Solid tumour/cancer

DMJXBVP	ID	DMJXBVP
DMJXBVP	DN	TAS-119
DMJXBVP	HS	Phase 1
DMJXBVP	CP	Taiho oncology
DMJXBVP	DE	Solid tumour/cancer

DMHIA7Y	ID	DMHIA7Y
DMHIA7Y	DN	TAS-1440
DMHIA7Y	HS	Phase 1
DMHIA7Y	CP	Taiho Oncology; Astex Pharmaceuticals
DMHIA7Y	DT	Small molecular drug
DMHIA7Y	DE	Acute myeloid leukaemia

DMFG6ML	ID	DMFG6ML
DMFG6ML	DN	TAS3681
DMFG6ML	HS	Phase 1
DMFG6ML	CP	Taiho Oncology Princeton, NJ
DMFG6ML	DE	Prostate cancer

DMKW4AJ	ID	DMKW4AJ
DMKW4AJ	DN	Tasidotin hydrochloride
DMKW4AJ	HS	Phase 1
DMKW4AJ	SN	Tasidotin HCl; BSF 223651; ILX 651; LU 223651; Tasidotin hydrochloride (USAN)
DMKW4AJ	CP	Genzyme
DMKW4AJ	DT	Small molecular drug
DMKW4AJ	PC	11479259
DMKW4AJ	MW	643.3
DMKW4AJ	FM	C32H59ClN6O5
DMKW4AJ	IC	InChI=1S/C32H58N6O5.ClH/c1-19(2)24(33-28(40)25(20(3)4)35(10)11)30(42)36(12)26(21(5)6)31(43)38-18-14-16-23(38)29(41)37-17-13-15-22(37)27(39)34-32(7,8)9;/h19-26H,13-18H2,1-12H3,(H,33,40)(H,34,39);1H/t22-,23-,24-,25-,26-;/m0./s1
DMKW4AJ	CS	CC(C)[C@@H](C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NC(C)(C)C)NC(=O)[C@H](C(C)C)N(C)C.Cl
DMKW4AJ	IK	OOKIODJYZSVHDO-QMYFOHRPSA-N
DMKW4AJ	IU	(2S)-N-tert-butyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride
DMKW4AJ	CA	CAS 623174-20-9
DMKW4AJ	DE	Solid tumour/cancer

DM9CDPO	ID	DM9CDPO
DM9CDPO	DN	TBC-M4
DM9CDPO	HS	Phase 1
DM9CDPO	SN	MVA-based HIV subtype C vaccine, IAVI; Modified vaccinia Ankara-based HIV subtype C vaccine, International AIDS Vaccine Initiative
DM9CDPO	CP	National Institute of Cholera and Enteric Diseases
DM9CDPO	DT	Vaccine
DM9CDPO	DE	Human immunodeficiency virus infection

DM4W92J	ID	DM4W92J
DM4W92J	DN	TC-2216
DM4W92J	HS	Phase 1
DM4W92J	SN	NNR Therapeutics; TC-5685; Nicotinic ACh modulators (schizophrenia), Targacept; Alpha-4 beta-2 neuronal nicotinic receptor (schizophrenia, depression), Targacept; Oral alpha-4/beta-2 neuronal nicotinic receptor stimulator (shizophrenia/depression), Targacept
DM4W92J	CP	Targacept
DM4W92J	DT	Small molecular drug
DM4W92J	PC	10176607
DM4W92J	MW	203.28
DM4W92J	FM	C12H17N3
DM4W92J	IC	InChI=1S/C12H17N3/c1-3-11(9-13-6-1)15-8-5-12(10-15)4-2-7-14-12/h1,3,6,9,14H,2,4-5,7-8,10H2
DM4W92J	CS	C1CC2(CCN(C2)C3=CN=CC=C3)NC1
DM4W92J	IK	NXIPMBQVNTWEEX-UHFFFAOYSA-N
DM4W92J	IU	7-pyridin-3-yl-1,7-diazaspiro[4.4]nonane
DM4W92J	CA	CAS 646055-67-6
DM4W92J	DE	Mood disorder

DMJEBK8	ID	DMJEBK8
DMJEBK8	DN	TCD-717
DMJEBK8	HS	Phase 1
DMJEBK8	SN	Choline kinase alpha inhibitor (iv, solid tumors), TCD Pharma
DMJEBK8	CP	TCD Pharma
DMJEBK8	PC	11239949
DMJEBK8	MW	717.7
DMJEBK8	FM	C46H38Cl2N4+2
DMJEBK8	IC	InChI=1S/C46H38Cl2N4/c1-49(39-23-19-37(47)20-24-39)43-27-29-51(45-9-5-3-7-41(43)45)31-33-11-15-35(16-12-33)36-17-13-34(14-18-36)32-52-30-28-44(42-8-4-6-10-46(42)52)50(2)40-25-21-38(48)22-26-40/h3-30H,31-32H2,1-2H3/q+2
DMJEBK8	CS	CN(C1=CC=C(C=C1)Cl)C2=CC=[N+](C3=CC=CC=C32)CC4=CC=C(C=C4)C5=CC=C(C=C5)C[N+]6=CC=C(C7=CC=CC=C76)N(C)C8=CC=C(C=C8)Cl
DMJEBK8	IK	QGYGTMZEJNOHNU-UHFFFAOYSA-N
DMJEBK8	IU	1-[[4-[4-[[4-(4-chloro-N-methylanilino)quinolin-1-ium-1-yl]methyl]phenyl]phenyl]methyl]-N-(4-chlorophenyl)-N-methylquinolin-1-ium-4-amine
DMJEBK8	CA	CAS 850993-73-6
DMJEBK8	DE	Solid tumour/cancer

DMV0AH8	ID	DMV0AH8
DMV0AH8	DN	TCN-P
DMV0AH8	HS	Phase 1
DMV0AH8	SN	TRICIRIBINE PHOSPHATE; 61966-08-3; TCN-P; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594
DMV0AH8	CP	Cahaba Pharmaceuticals
DMV0AH8	DT	Small molecular drug
DMV0AH8	PC	43860
DMV0AH8	MW	400.28
DMV0AH8	FM	C13H17N6O7P
DMV0AH8	IC	InChI=1S/C13H17N6O7P/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(21)8(20)6(26-13)3-25-27(22,23)24/h2,4,6,8-9,13,20-21H,3H2,1H3,(H2,14,17)(H2,22,23,24)/t6-,8-,9-,13-/m1/s1
DMV0AH8	CS	CN1C2=NC=NC3=C2C(=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)C(=N1)N
DMV0AH8	IK	URLYINUFLXOMHP-HTVVRFAVSA-N
DMV0AH8	IU	[(2R,3S,4R,5R)-5-(5-amino-7-methyl-2,6,7,9,11-pentazatricyclo[6.3.1.04,12]dodeca-1(12),3,5,8,10-pentaen-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMV0AH8	CA	CAS 61966-08-3
DMV0AH8	DE	Acute myeloid leukaemia

DMO8L6T	ID	DMO8L6T
DMO8L6T	DN	TD-0714
DMO8L6T	HS	Phase 1
DMO8L6T	CP	Theravance Biopharma South San Francisco, CA
DMO8L6T	DE	Heart failure

DMJG7AY	ID	DMJG7AY
DMJG7AY	DN	TD-1473
DMJG7AY	HS	Phase 1
DMJG7AY	CP	Theravance Biopharma South San Francisco, CA
DMJG7AY	DE	Ulcerative colitis

DM58J7E	ID	DM58J7E
DM58J7E	DN	Tedalinab
DM58J7E	HS	Phase 1
DM58J7E	SN	Tedalinab; UNII-5R7X34Y6Q1; 916591-01-0; CHEMBL3234681; 5R7X34Y6Q1; Tedalinab [INN]; SCHEMBL1431320; ZINC72266313; GRC-10693; BDBM50005917; (4S,7R)-N-tert-butyl-1-(2,4-difluorophenyl)-4,5,6,7-tetrahydro-1H-4,7-methanoindazole-3-carboxamide; KB-80825; 4,7-Methano-1H-indazole-3-carboxamide, 1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-, (4S,7R)-
DM58J7E	CP	Glenmark Pharmaceuticals Ltd
DM58J7E	DT	Small molecular drug
DM58J7E	PC	67029278
DM58J7E	MW	345.4
DM58J7E	FM	C19H21F2N3O
DM58J7E	IC	InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1
DM58J7E	CS	CC(C)(C)NC(=O)C1=NN(C2=C1[C@H]3CC[C@@H]2C3)C4=C(C=C(C=C4)F)F
DM58J7E	IK	NTPZXHMTJGOMCJ-WDEREUQCSA-N
DM58J7E	IU	(1R,7S)-N-tert-butyl-3-(2,4-difluorophenyl)-3,4-diazatricyclo[5.2.1.02,6]deca-2(6),4-diene-5-carboxamide
DM58J7E	CA	CAS 916591-01-0
DM58J7E	DE	Pain

DMV5LGJ	ID	DMV5LGJ
DMV5LGJ	DN	Tedatioxetine
DMV5LGJ	HS	Phase 1
DMV5LGJ	SN	TEDATIOXETINE; 508233-95-2; UNII-5H681S8O3S; Lu AA24530; 5H681S8O3S; Tedatioxetine [USAN:INN]; Tedatioxetine (USAN); 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine; SCHEMBL547653; Lu-AA24530; CHEMBL2104986; Lu-AA-24530; ZINC34003654; DB12641; SB16713; D10170; Piperidine, 4-(2-((4-methylphenyl)thio)phenyl)-
DMV5LGJ	CP	Lundbeck; Takeda Pharmaceuticals
DMV5LGJ	DT	Small molecular drug
DMV5LGJ	PC	9878913
DMV5LGJ	MW	283.4
DMV5LGJ	FM	C18H21NS
DMV5LGJ	IC	InChI=1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3
DMV5LGJ	CS	CC1=CC=C(C=C1)SC2=CC=CC=C2C3CCNCC3
DMV5LGJ	IK	CVASBKDYSQKLSO-UHFFFAOYSA-N
DMV5LGJ	IU	4-[2-(4-methylphenyl)sulfanylphenyl]piperidine
DMV5LGJ	CA	CAS 508233-95-2
DMV5LGJ	DE	Major depressive disorder; Generalized anxiety disorder

DMZG9U0	ID	DMZG9U0
DMZG9U0	DN	TeloB-Vax
DMZG9U0	HS	Phase 1
DMZG9U0	CP	Adamis Pharmaceuticals
DMZG9U0	DE	Prostate cancer

DM7Q4EX	ID	DM7Q4EX
DM7Q4EX	DN	Temanogrel
DM7Q4EX	HS	Phase 1
DM7Q4EX	SN	Temanogrel hydrochloride; APD-791; 5-HT 2a inverse agonist (arterial thrombosis), Arena Pharmaceutical
DM7Q4EX	CP	Arena Pharmaceuticals; Arena Pharmaceuticals Inc
DM7Q4EX	DT	Small molecular drug
DM7Q4EX	PC	11604525
DM7Q4EX	MW	436.5
DM7Q4EX	FM	C24H28N4O4
DM7Q4EX	IC	InChI=1S/C24H28N4O4/c1-27-22(8-9-25-27)21-17-19(26-24(29)18-4-3-5-20(16-18)30-2)6-7-23(21)32-15-12-28-10-13-31-14-11-28/h3-9,16-17H,10-15H2,1-2H3,(H,26,29)
DM7Q4EX	CS	CN1C(=CC=N1)C2=C(C=CC(=C2)NC(=O)C3=CC(=CC=C3)OC)OCCN4CCOCC4
DM7Q4EX	IK	ZEOQUKRCASTCFR-UHFFFAOYSA-N
DM7Q4EX	IU	3-methoxy-N-[3-(2-methylpyrazol-3-yl)-4-(2-morpholin-4-ylethoxy)phenyl]benzamide
DM7Q4EX	CA	CAS 887936-68-7
DM7Q4EX	DE	Cardiovascular disease

DM4UOY5	ID	DM4UOY5
DM4UOY5	DN	TEN010
DM4UOY5	HS	Phase 1
DM4UOY5	CP	Tensha Therapeutics
DM4UOY5	DE	Advanced solid tumour; Solid tumour/cancer

DMGJCDR	ID	DMGJCDR
DMGJCDR	DN	Teneligliptin
DMGJCDR	HS	Phase 1
DMGJCDR	SN	Teneligliptin; 760937-92-6; UNII-28ZHI4CF9C; Teneligliptin [INN]; 28ZHI4CF9C; Teneligliptin hydrobromide; CHEMBL2147777; MP-513; Teneligliptin (INN); [(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone; C22H30N6OS; {(2s,4s)-4-[4-(3-Methyl-1-Phenyl-1h-Pyrazol-5-Yl)piperazin-1-Yl]pyrrolidin-2-Yl}(1,3-Thiazolidin-3-Yl)methanone; 906093-29-6; Teneli; SCHEMBL161778; GTPL9906; WGRQANOPCQRCME-PMACEKPBSA-N; CHEBI:136042; MolPort-039-139-824; MP513; ZINC36520254; BDBM50391565
DMGJCDR	CP	Mitsubishi Pharma America
DMGJCDR	DT	Small molecular drug
DMGJCDR	PC	11949652
DMGJCDR	MW	426.6
DMGJCDR	FM	C22H30N6OS
DMGJCDR	IC	InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
DMGJCDR	CS	CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5
DMGJCDR	IK	WGRQANOPCQRCME-PMACEKPBSA-N
DMGJCDR	IU	[(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone
DMGJCDR	CA	CAS 760937-92-6
DMGJCDR	CB	CHEBI:136042
DMGJCDR	DE	Type-2 diabetes

DMC84Y9	ID	DMC84Y9
DMC84Y9	DN	Tepoditamab
DMC84Y9	HS	Phase 1
DMC84Y9	SN	MCLA-117
DMC84Y9	DT	Antibody
DMC84Y9	DE	Acute myelogenous leukaemia

DM3DUHL	ID	DM3DUHL
DM3DUHL	DN	TESTOSTERONE BUCICLATE
DM3DUHL	HS	Phase 1
DM3DUHL	SN	CDB-1781; Testosterone buciclate; Testosterone trans-4-n-butylcyclohexylcarboxylate; [17beta(trans)]-(4-Butylcyclohexylcarbonyloxy)androst-4-en-3-one; 20 Aet-1
DM3DUHL	DT	Small molecular drug
DM3DUHL	PC	114819
DM3DUHL	MW	454.7
DM3DUHL	FM	C30H46O3
DM3DUHL	IC	InChI=1S/C30H46O3/c1-4-5-6-20-7-9-21(10-8-20)28(32)33-27-14-13-25-24-12-11-22-19-23(31)15-17-29(22,2)26(24)16-18-30(25,27)3/h19-21,24-27H,4-18H2,1-3H3/t20?,21?,24-,25-,26-,27-,29-,30-/m0/s1
DM3DUHL	CS	CCCCC1CCC(CC1)C(=O)O[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C
DM3DUHL	IK	ODZDZTOROXGJAV-IRWJKHRASA-N
DM3DUHL	IU	[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 4-butylcyclohexane-1-carboxylate
DM3DUHL	CA	CAS 105165-22-8
DM3DUHL	DE	Contraception

DMAOJBX	ID	DMAOJBX
DMAOJBX	DN	Tetrandrine
DMAOJBX	HS	Phase 1
DMAOJBX	SN	Tetrandrine, Millenia Hope; Tetrandrine, West Virginia University; Tranex-18
DMAOJBX	CP	West Virginia University
DMAOJBX	DT	Small molecular drug
DMAOJBX	PC	73078
DMAOJBX	MW	622.7
DMAOJBX	FM	C38H42N2O6
DMAOJBX	IC	InChI=1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29-,30-/m0/s1
DMAOJBX	CS	CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC
DMAOJBX	IK	WVTKBKWTSCPRNU-KYJUHHDHSA-N
DMAOJBX	IU	(1S,14S)-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene
DMAOJBX	CA	CAS 518-34-3
DMAOJBX	CB	CHEBI:49
DMAOJBX	DE	Colorectal cancer; Sarcoma

DMNDHKL	ID	DMNDHKL
DMNDHKL	DN	TG-1701
DMNDHKL	HS	Phase 1
DMNDHKL	CP	TG Therapeutics
DMNDHKL	DT	Small molecular drug
DMNDHKL	DE	Non-hodgkin lymphoma; Chronic lymphocytic leukaemia

DM3K4FY	ID	DM3K4FY
DM3K4FY	DN	TG-1801
DM3K4FY	HS	Phase 1
DM3K4FY	SN	NI-1701
DM3K4FY	CP	TG Therapeutics
DM3K4FY	DT	Antibody
DM3K4FY	DE	B-cell lymphoma

DMWBQ2Z	ID	DMWBQ2Z
DMWBQ2Z	DN	TGF-BR2 mab
DMWBQ2Z	HS	Phase 1
DMWBQ2Z	CP	Lilly
DMWBQ2Z	DT	Antibody
DMWBQ2Z	DE	Solid tumour/cancer

DMC1HRA	ID	DMC1HRA
DMC1HRA	DN	Thiarabine
DMC1HRA	HS	Phase 1
DMC1HRA	SN	THIARABINE; 26599-17-7; UNII-YCO2764D5Z; YCO2764D5Z; Thio-Cytarabine; 4'-Thioaracytidine; 4'-Thio-ara-C; T-araC; OSI 7836; 4'-Thio-1- beta-D-arabinofuranosylcytosine; cytidine, 4'-thio-arabino-; AC1L524F; SCHEMBL1955046; CHEMBL1631221; 4-Amino-1-(4-thio-beta-D-arabinofuranosyl)-2(1H)-pyrimidinone; ZINC17378676; 2(1H)-Pyrimidinone, 4-amino-1-(4-thio-beta-D-arabinofuranosyl)-; SB18955; KB-81109; HY-16496; LS-193593; CS-0006364
DMC1HRA	CP	Access Pharmaceuticals
DMC1HRA	DT	Small molecular drug
DMC1HRA	PC	168566
DMC1HRA	MW	259.279
DMC1HRA	FM	C9H13N3O4S
DMC1HRA	IC	InChI=1S/C9H13N3O4S/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
DMC1HRA	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](S2)CO)O)O
DMC1HRA	IK	GAKJJSAXUFZQTL-CCXZUQQUSA-N
DMC1HRA	IU	4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one
DMC1HRA	CA	CAS 26599-17-7
DMC1HRA	DE	Solid tumour/cancer

DMOLFAU	ID	DMOLFAU
DMOLFAU	DN	Thiopilocarpine
DMOLFAU	HS	Phase 1
DMOLFAU	SN	ENS-163; SDZ ENA-163; SDZ-ENS-163
DMOLFAU	CP	Novartis AG
DMOLFAU	DT	Small molecular drug
DMOLFAU	PC	189508
DMOLFAU	MW	322.32
DMOLFAU	FM	C11H19N2O5PS
DMOLFAU	IC	InChI=1S/C11H16N2OS.H3O4P/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2;1-5(2,3)4/h5,7-8,10H,3-4,6H2,1-2H3;(H3,1,2,3,4)/t8-,10-;/m0./s1
DMOLFAU	CS	CC[C@H]1[C@H](CSC1=O)CC2=CN=CN2C.OP(=O)(O)O
DMOLFAU	IK	PSRPKRDUWXFVQS-GNAZCLTHSA-N
DMOLFAU	IU	(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]thiolan-2-one;phosphoric acid
DMOLFAU	CA	CAS 117707-51-4
DMOLFAU	DE	Cognitive impairment

DMHRY8A	ID	DMHRY8A
DMHRY8A	DN	THR-687
DMHRY8A	HS	Phase 1
DMHRY8A	CP	Oxurion
DMHRY8A	DT	Small molecular drug
DMHRY8A	DE	Diabetic macular edema; Diabetic retinopathy

DMO8SGD	ID	DMO8SGD
DMO8SGD	DN	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy
DMO8SGD	HS	Phase 1
DMO8SGD	SN	Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama
DMO8SGD	CP	University of Alabama at Birmingham
DMO8SGD	DE	Solid tumour/cancer

DMSVO92	ID	DMSVO92
DMSVO92	DN	Tigapotide
DMSVO92	HS	Phase 1
DMSVO92	CP	Kotinos Pharmaceuticals
DMSVO92	SQ	PCK3145 (PSP-94 [31-45]) Sequence: PGDSTRKCMDLKGNK
DMSVO92	PC	16155604
DMSVO92	MW	2039.1
DMSVO92	FM	C82H119N21O34S3
DMSVO92	IC	InChI=1S/C82H119N21O34S3/c1-35(104)64(100-69(123)48(17-20-58(84)112)90-73(127)52(93-68(122)46(83)16-21-60(114)115)25-43-28-86-47-11-9-8-10-45(43)47)79(133)96-54(27-63(120)121)75(129)95-53(26-59(85)113)74(128)97-55(29-138-32-87-39(5)108)76(130)92-49(18-22-61(116)117)70(124)101-65(36(2)105)80(134)99-57(31-140-34-89-41(7)110)78(132)102-66(37(3)106)81(135)98-56(30-139-33-88-40(6)109)77(131)94-51(24-42-12-14-44(111)15-13-42)72(126)91-50(19-23-62(118)119)71(125)103-67(38(4)107)82(136)137/h8-15,28,35-38,46,48-57,64-67,86,104-107,111H,16-27,29-34,83H2,1-7H3,(H2,84,112)(H2,85,113)(H,87,108)(H,88,109)(H,89,110)(H,90,127)(H,91,126)(H,92,130)(H,93,122)(H,94,131)(H,95,129)(H,96,133)(H,97,128)(H,98,135)(H,99,134)(H,100,123)(H,101,124)(H,102,132)(H,103,125)(H,114,115)(H,116,117)(H,118,119)(H,120,121)(H,136,137)/t35-,36-,37-,38-,46+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,64+,65+,66+,67+/m1/s1
DMSVO92	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CSCNC(=O)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSCNC(=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSCNC(=O)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)O)N)O
DMSVO92	IK	ZRXXHPDJLAQCPC-SFJRRRFZSA-N
DMSVO92	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2R)-3-(acetamidomethylsulfanyl)-1-[[(2S)-1-[[(2S,3R)-1-[[(2R)-3-(acetamidomethylsulfanyl)-1-[[(2S,3R)-1-[[(2R)-3-(acetamidomethylsulfanyl)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-amino-1,4-dioxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-amino-1,5-dioxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-amino-5-oxopentanoic acid
DMSVO92	CA	CAS 414903-37-0
DMSVO92	DE	Prostate cancer

DMM3U2Q	ID	DMM3U2Q
DMM3U2Q	DN	TJ4309
DMM3U2Q	HS	Phase 1
DMM3U2Q	SN	TJ00439
DMM3U2Q	CP	I-MAB Biopharma; TRACON Pharmaceuticals
DMM3U2Q	DT	Antibody
DMM3U2Q	DE	Solid tumour/cancer

DMLUOVS	ID	DMLUOVS
DMLUOVS	DN	TJC4
DMLUOVS	HS	Phase 1
DMLUOVS	SN	TJ011133
DMLUOVS	CP	I-MAB Biopharma
DMLUOVS	DT	Antibody
DMLUOVS	DE	Lymphoma; Solid tumour/cancer

DMTGLOY	ID	DMTGLOY
DMTGLOY	DN	TK216
DMTGLOY	HS	Phase 1
DMTGLOY	CP	Oncternal Therapeutics San Diego, CA
DMTGLOY	DE	Ewing sarcoma

DMCFGD4	ID	DMCFGD4
DMCFGD4	DN	TM38837
DMCFGD4	HS	Phase 1
DMCFGD4	SN	TM-38837; compound 8; CHEMBL3341897; 1253641-65-4; TM38837; GTPL8705; SCHEMBL16127787; BCP24151; BDBM50044129; AKOS030525391; 1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-yl-5-[5-[2-[4-(trifluoromethyl)phenyl]ethynyl]thiophen-2-yl]pyrazole-3-carboxamide; 1-(2,4-Dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-1H-pyrazole-3-carboxamide
DMCFGD4	CP	7TM Pharma A/S
DMCFGD4	DT	Small molecular drug
DMCFGD4	PC	49779607
DMCFGD4	MW	617.5
DMCFGD4	FM	C30H25Cl2F3N4OS
DMCFGD4	IC	InChI=1S/C30H25Cl2F3N4OS/c1-2-23-27(29(40)37-38-16-4-3-5-17-38)36-39(25-14-11-21(31)18-24(25)32)28(23)26-15-13-22(41-26)12-8-19-6-9-20(10-7-19)30(33,34)35/h6-7,9-11,13-15,18H,2-5,16-17H2,1H3,(H,37,40)
DMCFGD4	CS	CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(S4)C#CC5=CC=C(C=C5)C(F)(F)F
DMCFGD4	IK	VQOCBFYUDSBDCZ-UHFFFAOYSA-N
DMCFGD4	IU	1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-yl-5-[5-[2-[4-(trifluoromethyl)phenyl]ethynyl]thiophen-2-yl]pyrazole-3-carboxamide
DMCFGD4	DE	Metabolic disorder; Obesity

DMH3E5C	ID	DMH3E5C
DMH3E5C	DN	TMB-365
DMH3E5C	HS	Phase 1
DMH3E5C	CP	TaiMed Biologics
DMH3E5C	DT	Antibody
DMH3E5C	DE	Human immunodeficiency virus-1 infection

DMYEALO	ID	DMYEALO
DMYEALO	DN	TMC-647055
DMYEALO	HS	Phase 1
DMYEALO	SN	TMC647055; 1204416-97-6; TMC-647055; UNII-11BD024G7J; TMC 647055; 11BD024G7J; 113-cyclohexyl-13-methoxy-5,11-dimethyl-17H-8-oxa-4-thia-3,5,11-triaza-1(10,6)-benzo[3,4]azepino[1,2-a]indolacyclododecaphane-2,12-dione 4,4-dioxide; TMC647055 Choline; SCHEMBL1239667; CHEMBL2043025; DTXSID90152860; BDBM243456; EX-A1252; AOB87185; BCP06459; ZINC84726167; AKOS030627003; SB16907; DB11822; NCGC00482982-02; DA-47229; BC600546; 2,19-Methano-3,7:4,1-dimetheno-1H,11H-14,10,2,9,11,17-benzoxathiatetraazacyclodocosine-8,18(9H,15H)-dione, 27-cycl
DMYEALO	CP	Janssen research & development
DMYEALO	DT	Small molecular drug
DMYEALO	PC	44556044
DMYEALO	MW	606.7
DMYEALO	FM	C32H38N4O6S
DMYEALO	IC	InChI=1S/C32H38N4O6S/c1-34-13-15-42-16-14-35(2)43(39,40)33-31(37)22-9-11-27-28(19-22)36-20-24(32(34)38)17-23-18-25(41-3)10-12-26(23)30(36)29(27)21-7-5-4-6-8-21/h9-12,17-19,21H,4-8,13-16,20H2,1-3H3,(H,33,37)
DMYEALO	CS	CN1CCOCCN(S(=O)(=O)NC(=O)C2=CC3=C(C=C2)C(=C4N3CC(=CC5=C4C=CC(=C5)OC)C1=O)C6CCCCC6)C
DMYEALO	IK	UOBYJVFBFSLCTQ-UHFFFAOYSA-N
DMYEALO	IU	28-cyclohexyl-22-methoxy-10,16-dimethyl-9,9-dioxo-13-oxa-9lambda6-thia-1,8,10,16-tetrazapentacyclo[16.8.1.12,6.13,26.020,25]nonacosa-2,4,6(29),18,20(25),21,23,26(28)-octaene-7,17-dione
DMYEALO	CA	CAS 1204416-97-6
DMYEALO	DE	Hepatitis C virus infection

DMAOV7M	ID	DMAOV7M
DMAOV7M	DN	TMC649128
DMAOV7M	HS	Phase 1
DMAOV7M	CP	Medivir; Tibotec
DMAOV7M	PC	24769037
DMAOV7M	MW	422.4
DMAOV7M	FM	C18H26N6O6
DMAOV7M	IC	InChI=1S/C18H26N6O6/c1-9(2)15(25)28-8-18(22-23-20)13(29-16(26)10(3)4)11(5)14(30-18)24-7-6-12(19)21-17(24)27/h6-7,9-11,13-14H,8H2,1-5H3,(H2,19,21,27)/t11-,13-,14+,18+/m0/s1
DMAOV7M	CS	C[C@H]1[C@@H]([C@](O[C@H]1N2C=CC(=NC2=O)N)(COC(=O)C(C)C)N=[N+]=[N-])OC(=O)C(C)C
DMAOV7M	IK	XJBILYMRFVHPJB-XJQUKVTJSA-N
DMAOV7M	IU	[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
DMAOV7M	CA	CAS 1019639-33-8
DMAOV7M	DE	Hepatitis C virus infection

DMAI0SH	ID	DMAI0SH
DMAI0SH	DN	TNB-383B
DMAI0SH	HS	Phase 1
DMAI0SH	CP	AbbVie
DMAI0SH	DT	Antibody
DMAI0SH	DE	Multiple myeloma

DMSRICG	ID	DMSRICG
DMSRICG	DN	TNB-486
DMSRICG	HS	Phase 1
DMSRICG	CP	Teneobio
DMSRICG	DT	Antibody
DMSRICG	DE	B-cell lymphoma

DMHD6PA	ID	DMHD6PA
DMHD6PA	DN	TnMUC-1 CAR-T cell therapy
DMHD6PA	HS	Phase 1
DMHD6PA	CP	Tmunity
DMHD6PA	DT	CAR T Cell Therapy
DMHD6PA	DE	Solid tumour/cancer

DMZ60X4	ID	DMZ60X4
DMZ60X4	DN	TNO155
DMZ60X4	HS	Phase 1
DMZ60X4	CP	Novartis Oncology East Hanover, NJ
DMZ60X4	DE	Solid tumour/cancer

DMSKF29	ID	DMSKF29
DMSKF29	DN	TNT009
DMSKF29	HS	Phase 1
DMSKF29	CP	South San Francisco, CA
DMSKF29	DE	Bullous pemphigoid; Cold type autoimmune haemolytic anemia

DMD0NA1	ID	DMD0NA1
DMD0NA1	DN	TP 6076
DMD0NA1	HS	Phase 1
DMD0NA1	CP	Tetraphase Pharmaceuticals
DMD0NA1	DT	Small molecular drug
DMD0NA1	DE	Multidrug resistant infection

DMJVZBC	ID	DMJVZBC
DMJVZBC	DN	TP-0184
DMJVZBC	HS	Phase 1
DMJVZBC	SN	Itacnosertib; UNII-22Z53X5LHF; 22Z53X5LHF; 1628870-27-8; methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine; N4-([2,2'-bipyridin]-3-yl)-N2-[3-methoxy-4-(4-; 2-N-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-4-N-(2-pyridin-2-ylpyridin-3-yl)pyrimidine-2,4-diamine; Itacnosertib [INN]; SCHEMBL16129103; GTPL10632; TP0184; example 11 [WO2014151871A9]; 2,4-Pyrimidinediamine, N4-(2,2'-bipyridin)-3-yl-N2-(3-methoxy-4-(4-methyl-1-piperazinyl)phenyl)-; N2-(3-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)-N4-(2-(pyridin-2-yl)pyridin-3-yl)pyrimidine-2,4-diamine
DMJVZBC	CP	Sumitomo Dainippon Pharma
DMJVZBC	DT	Small molecular drug
DMJVZBC	PC	86290265
DMJVZBC	MW	468.6
DMJVZBC	FM	C26H28N8O
DMJVZBC	IC	InChI=1S/C26H28N8O/c1-33-14-16-34(17-15-33)22-9-8-19(18-23(22)35-2)30-26-29-13-10-24(32-26)31-21-7-5-12-28-25(21)20-6-3-4-11-27-20/h3-13,18H,14-17H2,1-2H3,(H2,29,30,31,32)
DMJVZBC	CS	CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=N3)NC4=C(N=CC=C4)C5=CC=CC=N5)OC
DMJVZBC	IK	XSQKEVGTZSBVBR-UHFFFAOYSA-N
DMJVZBC	IU	2-N-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-4-N-(2-pyridin-2-ylpyridin-3-yl)pyrimidine-2,4-diamine
DMJVZBC	CA	CAS 1628870-27-8
DMJVZBC	DE	Solid tumour/cancer

DM3Z07E	ID	DM3Z07E
DM3Z07E	DN	TP-1287
DM3Z07E	HS	Phase 1
DM3Z07E	SN	UNII-7MPP85IIJ3; 7MPP85IIJ3; CHEMBL4594423; SCHEMBL18251861; 2044686-42-0; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-((3S,4R)-3-hydroxy-1-methyl-4-piperidinyl)-7-(phosphonooxy)-
DM3Z07E	CP	Sumitomo Dainippon Pharma
DM3Z07E	DT	Small molecular drug
DM3Z07E	PC	124083048
DM3Z07E	MW	481.8
DM3Z07E	FM	C21H21ClNO8P
DM3Z07E	IC	InChI=1S/C21H21ClNO8P/c1-23-7-6-12(16(26)10-23)19-18(31-32(27,28)29)9-15(25)20-14(24)8-17(30-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,16,25-26H,6-7,10H2,1H3,(H2,27,28,29)/t12-,16+/m0/s1
DM3Z07E	CS	CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)OP(=O)(O)O
DM3Z07E	IK	YRNFLVUMZIRYKY-BLLLJJGKSA-N
DM3Z07E	IU	[2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4-oxochromen-7-yl] dihydrogen phosphate
DM3Z07E	CA	CAS 2044686-42-0
DM3Z07E	DE	Solid tumour/cancer

DMBTL2M	ID	DMBTL2M
DMBTL2M	DN	TP-1454
DMBTL2M	HS	Phase 1
DMBTL2M	CP	Sumitomo Dainippon Pharma
DMBTL2M	DE	Solid tumour/cancer

DM3PJSE	ID	DM3PJSE
DM3PJSE	DN	TP-271
DM3PJSE	HS	Phase 1
DM3PJSE	SN	UNII-Y6IUM7395Q; Y6IUM7395Q; 1207284-17-0; (S)-N-((5aR,6aS,7S,10aS)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,8,10a,11-tetrahydroxy-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl)-1-methylpyrrolidine-2-carboxamide; (2S)-N-((5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl)-1-methylpyrrolidine-2-carboxamide; (2S)-N-[(5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-1-methylpyrrolidine-2-carboxamide; CHEMBL2057236; SCHEMBL13397803; GTPL11013; TP271; DB15040
DM3PJSE	CP	Tetraphase Pharmaceuticals
DM3PJSE	DT	Small molecular drug
DM3PJSE	PC	54726193
DM3PJSE	MW	558.6
DM3PJSE	FM	C27H31FN4O8
DM3PJSE	IC	InChI=1S/C27H31FN4O8/c1-31(2)19-12-8-10-7-11-13(28)9-14(30-26(39)15-5-4-6-32(15)3)20(33)17(11)21(34)16(10)23(36)27(12,40)24(37)18(22(19)35)25(29)38/h9-10,12,15,19,33-34,37,40H,4-8H2,1-3H3,(H2,29,38)(H,30,39)/t10-,12-,15-,19-,27-/m0/s1
DM3PJSE	CS	CN1CCC[C@H]1C(=O)NC2=CC(=C3C[C@H]4C[C@H]5[C@@H](C(=O)C(=C([C@]5(C(=O)C4=C(C3=C2O)O)O)O)C(=O)N)N(C)C)F
DM3PJSE	IK	VIWUYPVRNWIKLS-HMFHYXQTSA-N
DM3PJSE	IU	(2S)-N-[(5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-1-methylpyrrolidine-2-carboxamide
DM3PJSE	CA	CAS 1207284-17-0
DM3PJSE	DE	Respiratory tract infection; Pneumonia

DMBQ6XY	ID	DMBQ6XY
DMBQ6XY	DN	TP-3654
DMBQ6XY	HS	Phase 1
DMBQ6XY	SN	1361951-15-6; TP3654; UNII-EOB0N7BOY4; EOB0N7BOY4; SGI-9481; 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; SCHEMBL102560; CHEMBL3975308; SCHEMBL19986953; SCHEMBL20794171; SCHEMBL22421478; BDBM242374; BCP30070; EX-A1828; NSC805149; AKOS032960444; CS-6293; NSC-805149; SB17245; TP3654; TP 3654; BS-15262; HY-101126; AK00792306; S6774; US9416132, 8-31; 2-(4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; 4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino) -trans-cyclohexyl)propan-2-ol
DMBQ6XY	CP	Sumitomo Dainippon Pharma
DMBQ6XY	DT	Small molecular drug
DMBQ6XY	PC	66598080
DMBQ6XY	MW	418.5
DMBQ6XY	FM	C22H25F3N4O
DMBQ6XY	IC	InChI=1S/C22H25F3N4O/c1-21(2,30)15-6-8-17(9-7-15)27-19-10-11-20-26-13-18(29(20)28-19)14-4-3-5-16(12-14)22(23,24)25/h3-5,10-13,15,17,30H,6-9H2,1-2H3,(H,27,28)
DMBQ6XY	CS	CC(C)(C1CCC(CC1)NC2=NN3C(=NC=C3C4=CC(=CC=C4)C(F)(F)F)C=C2)O
DMBQ6XY	IK	XRNVABDYQLHODA-UHFFFAOYSA-N
DMBQ6XY	IU	2-[4-[[3-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexyl]propan-2-ol
DMBQ6XY	CA	CAS 1361951-15-6
DMBQ6XY	DE	Solid tumour/cancer

DM5RIT8	ID	DM5RIT8
DM5RIT8	DN	TP-6076
DM5RIT8	HS	Phase 1
DM5RIT8	CP	Tetraphase Pharmaceuticals
DM5RIT8	DT	Small interfering RNA
DM5RIT8	DE	Enterobacteriaceae infection; Multidrug resistant infection

DMG4U32	ID	DMG4U32
DMG4U32	DN	TPST-1120
DMG4U32	HS	Phase 1
DMG4U32	CP	Tempest Therapeutics
DMG4U32	DE	Solid tumour/cancer

DM3GSB2	ID	DM3GSB2
DM3GSB2	DN	TPST-1495
DM3GSB2	HS	Phase 1
DM3GSB2	CP	Tempest Therapeutics
DM3GSB2	DE	Solid tumour/cancer

DMC2IJN	ID	DMC2IJN
DMC2IJN	DN	TPX-0022
DMC2IJN	HS	Phase 1
DMC2IJN	SN	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5
DMC2IJN	CP	Turning Point Therapeutics
DMC2IJN	DT	Small molecular drug
DMC2IJN	PC	137455315
DMC2IJN	MW	409.4
DMC2IJN	FM	C20H20FN7O2
DMC2IJN	IC	InChI=1S/C20H20FN7O2/c1-3-27-10-13-12(8-22)14(21)4-5-15(13)30-11(2)9-24-20(29)17-18(23)26-28-7-6-16(27)25-19(17)28/h4-7,11H,3,9-10H2,1-2H3,(H2,23,26)(H,24,29)/t11-/m0/s1
DMC2IJN	CS	CCN1CC2=C(C=CC(=C2C#N)F)O[C@H](CNC(=O)C3=C4N=C1C=CN4N=C3N)C
DMC2IJN	IK	UUDPUQDMSHQSKH-NSHDSACASA-N
DMC2IJN	IU	(11S)-16-amino-2-ethyl-6-fluoro-11-methyl-14-oxo-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaene-5-carbonitrile
DMC2IJN	DE	Solid tumour/cancer

DMGC2AT	ID	DMGC2AT
DMGC2AT	DN	TR1801-ADC
DMGC2AT	HS	Phase 1
DMGC2AT	CP	Tanabe Research Laboratories
DMGC2AT	DT	Antibody drug conjugate
DMGC2AT	DE	Solid tumour/cancer

DMMRDUN	ID	DMMRDUN
DMMRDUN	DN	TrasGEX
DMMRDUN	HS	Phase 1
DMMRDUN	CP	Glycotope GmbH
DMMRDUN	DT	Antibody
DMMRDUN	DE	Solid tumour/cancer

DM1DIVY	ID	DM1DIVY
DM1DIVY	DN	TRemelimumab + MEDI0562
DM1DIVY	HS	Phase 1
DM1DIVY	CP	MedImmune Gaithersburg, MD
DM1DIVY	DE	Solid tumour/cancer

DMQ7UN6	ID	DMQ7UN6
DMQ7UN6	DN	Trodusquemine
DMQ7UN6	HS	Phase 1
DMQ7UN6	SN	Produlestan; Trodulamine; Aminosterol 1436; MSI-1436; Aminosterols (obesity, type 2 diabetes), Genaera
DMQ7UN6	CP	Genaera
DMQ7UN6	DT	Small molecular drug
DMQ7UN6	PC	9917968
DMQ7UN6	MW	685.1
DMQ7UN6	FM	C37H72N4O5S
DMQ7UN6	IC	InChI=1S/C37H72N4O5S/c1-26(2)34(46-47(43,44)45)13-10-27(3)30-11-12-31-35-32(15-17-37(30,31)5)36(4)16-14-29(24-28(36)25-33(35)42)41-23-9-22-40-20-7-6-19-39-21-8-18-38/h26-35,39-42H,6-25,38H2,1-5H3,(H,43,44,45)/t27-,28-,29+,30-,31+,32+,33-,34-,35+,36+,37-/m1/s1
DMQ7UN6	CS	C[C@H](CC[C@H](C(C)C)OS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@@H]4[C@@]3(CC[C@@H](C4)NCCCNCCCCNCCCN)C)O)C
DMQ7UN6	IK	WUJVPODXELZABP-FWJXURDUSA-N
DMQ7UN6	IU	[(3R,6R)-6-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-3-[3-[4-(3-aminopropylamino)butylamino]propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate
DMQ7UN6	CA	CAS 186139-09-3
DMQ7UN6	DE	Obesity; Breast cancer

DMDSF0Q	ID	DMDSF0Q
DMDSF0Q	DN	TROVIRDINE HYDROCHLORIDE
DMDSF0Q	HS	Phase 1
DMDSF0Q	SN	TROVIRDINE HYDROCHLORIDE; 148311-89-1; UNII-70714531RJ; 70714531RJ; AC1NS2PN; CHEMBL543611; SCHEMBL2231102; KB-81362; 1-(5-bromopyridin-2-yl)-3-(2-pyridin-2-ylethyl)thiourea hydrochloride
DMDSF0Q	DT	Small molecular drug
DMDSF0Q	PC	5327620
DMDSF0Q	MW	373.7
DMDSF0Q	FM	C13H14BrClN4S
DMDSF0Q	IC	InChI=1S/C13H13BrN4S.ClH/c14-10-4-5-12(17-9-10)18-13(19)16-8-6-11-3-1-2-7-15-11;/h1-5,7,9H,6,8H2,(H2,16,17,18,19);1H
DMDSF0Q	CS	C1=CC=NC(=C1)CCNC(=S)NC2=NC=C(C=C2)Br.Cl
DMDSF0Q	IK	IUQKLSJRANLIKE-UHFFFAOYSA-N
DMDSF0Q	IU	1-(5-bromopyridin-2-yl)-3-(2-pyridin-2-ylethyl)thiourea;hydrochloride
DMDSF0Q	CA	CAS 148311-89-1
DMDSF0Q	DE	Human immunodeficiency virus infection

DMSLQW2	ID	DMSLQW2
DMSLQW2	DN	TRPH-222
DMSLQW2	HS	Phase 1
DMSLQW2	CP	Triphase Accelerator
DMSLQW2	DT	Antibody drug conjugate
DMSLQW2	DE	Non-hodgkin lymphoma; B-cell lymphoma

DM2WZ86	ID	DM2WZ86
DM2WZ86	DN	TRV250
DM2WZ86	HS	Phase 1
DM2WZ86	CP	Trevena Chesterbrook, PA
DM2WZ86	DE	Migraine

DMHD8CF	ID	DMHD8CF
DMHD8CF	DN	TRV734
DMHD8CF	HS	Phase 1
DMHD8CF	CP	Trevena Chesterbrook, PA
DMHD8CF	DE	Chronic pain

DM9IDUH	ID	DM9IDUH
DM9IDUH	DN	TRX518
DM9IDUH	HS	Phase 1
DM9IDUH	CP	Leap Therapeutics
DM9IDUH	DT	Antibody
DM9IDUH	DE	Solid tumour/cancer

DMVGN42	ID	DMVGN42
DMVGN42	DN	TRX-818
DMVGN42	HS	Phase 1
DMVGN42	SN	CVM-1118; ZRPWVAHVWBPHID-UHFFFAOYSA-L; TRX-818 sodium; TRX818; EX-A580; MolPort-044-567-575; CVM-1118(CVM1118); B5932; J-690105; (2'S,3R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-N-((1r,4R)-4-hydroxycyclohexyl)-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrroli dine]-5'-carboxamide
DMVGN42	CP	TaiRx Taipei, Taiwan
DMVGN42	PC	124080980
DMVGN42	MW	393.21
DMVGN42	FM	C16H11FNNa2O5P
DMVGN42	IC	InChI=1S/C16H13FNO5P.2Na/c1-23-14-6-5-11-15(16(14)24(20,21)22)13(19)8-12(18-11)9-3-2-4-10(17)7-9;;/h2-8H,1H3,(H,18,19)(H2,20,21,22);;/q;2*+1/p-2
DMVGN42	CS	COC1=C(C2=C(C=C1)NC(=CC2=O)C3=CC(=CC=C3)F)P(=O)([O-])[O-].[Na+].[Na+]
DMVGN42	IK	ZRPWVAHVWBPHID-UHFFFAOYSA-L
DMVGN42	IU	disodium;2-(3-fluorophenyl)-6-methoxy-5-phosphonato-1H-quinolin-4-one
DMVGN42	DE	Solid tumour/cancer

DMNTVUK	ID	DMNTVUK
DMNTVUK	DN	TS01
DMNTVUK	HS	Phase 1
DMNTVUK	DE	Stroke

DM56PFL	ID	DM56PFL
DM56PFL	DN	TSR-042
DM56PFL	HS	Phase 1
DM56PFL	CP	TESARO Waltham, MA
DM56PFL	DT	Monoclonal antibody
DM56PFL	DE	Solid tumour/cancer; Advanced malignancy; Metastatic cancer

DMZ9EMO	ID	DMZ9EMO
DMZ9EMO	DN	TST001
DMZ9EMO	HS	Phase 1
DMZ9EMO	CP	Transcenta
DMZ9EMO	DT	Antibody
DMZ9EMO	DE	Solid tumour/cancer

DMT5AEF	ID	DMT5AEF
DMT5AEF	DN	TST-10088
DMT5AEF	HS	Phase 1
DMT5AEF	CP	Cangene Winnipeg, Canada
DMT5AEF	DE	Solid tumour/cancer

DMLDSX8	ID	DMLDSX8
DMLDSX8	DN	TT-30
DMLDSX8	HS	Phase 1
DMLDSX8	SN	CR2/factor H modulator (fusion protein, autoimmune/inflammatory disease), Alexion; CR2/factor H modulator (fusion protein, autoimmune/inflammatory disease), Taligen
DMLDSX8	CP	Taligen Therapeutics Inc
DMLDSX8	DE	Autoimmune diabetes

DM4QV8Y	ID	DM4QV8Y
DM4QV8Y	DN	TT-301
DM4QV8Y	HS	Phase 1
DM4QV8Y	SN	Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics
DM4QV8Y	CP	Northwestern University
DM4QV8Y	PC	54576073
DM4QV8Y	MW	395.5
DM4QV8Y	FM	C23H21N7
DM4QV8Y	IC	InChI=1S/C23H21N7/c1-2-5-19(6-3-1)21-17-20(18-7-11-24-12-8-18)22(28-27-21)29-13-15-30(16-14-29)23-25-9-4-10-26-23/h1-12,17H,13-16H2
DM4QV8Y	CS	C1CN(CCN1C2=NN=C(C=C2C3=CC=NC=C3)C4=CC=CC=C4)C5=NC=CC=N5
DM4QV8Y	IK	ZPJGUEPHFXPAQF-UHFFFAOYSA-N
DM4QV8Y	IU	6-phenyl-4-pyridin-4-yl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine
DM4QV8Y	CA	CAS 886208-76-0
DM4QV8Y	DE	Alzheimer disease

DM7CHZ2	ID	DM7CHZ2
DM7CHZ2	DN	TTC-352
DM7CHZ2	HS	Phase 1
DM7CHZ2	CP	TTC Oncology Edina, MN
DM7CHZ2	DE	Breast cancer

DM7E6V2	ID	DM7E6V2
DM7E6V2	DN	TTC-352
DM7E6V2	HS	Phase 1
DM7E6V2	SN	Sherpa TTC-352; UNII-65ILH3Y0MI; 65ILH3Y0MI; CHEMBL3763743; 1607819-68-0; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophene-6-ol; 3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)-benzo[b]thiophene-6-ol; SCHEMBL15658409; BDBM50145856; J3.603.123I; 2-(4-Hydroxyphenoxy)-3-(4-fluorophenyl)benzo[b]thiophene-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol; 3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo(b)thiophene-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxyl)benzo[b]thiophen-6-ol; Selective human estrogen-receptor alpha partial agonist TTC-352; Benzo(b)thiophene-6-ol, 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-; V9J
DM7E6V2	CP	TTC Oncology
DM7E6V2	DT	Small molecular drug
DM7E6V2	PC	74222430
DM7E6V2	MW	352.4
DM7E6V2	FM	C20H13FO3S
DM7E6V2	IC	InChI=1S/C20H13FO3S/c21-13-3-1-12(2-4-13)19-17-10-7-15(23)11-18(17)25-20(19)24-16-8-5-14(22)6-9-16/h1-11,22-23H
DM7E6V2	CS	C1=CC(=CC=C1C2=C(SC3=C2C=CC(=C3)O)OC4=CC=C(C=C4)O)F
DM7E6V2	IK	UDBMVVLTKJMPCJ-UHFFFAOYSA-N
DM7E6V2	IU	3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol
DM7E6V2	CA	CAS 1607819-68-0
DM7E6V2	DE	Metastatic melanoma

DMDNPAV	ID	DMDNPAV
DMDNPAV	DN	TTI-621
DMDNPAV	HS	Phase 1
DMDNPAV	CP	Trillium Therapeutics Mississauga, Canada
DMDNPAV	DT	Recombinant protein
DMDNPAV	DE	Melanoma; Merkel cell carcinoma; Mycosis fungoides; Squamous cell carcinoma; Haematological malignancy; Solid tumour/cancer

DMOCQ4K	ID	DMOCQ4K
DMOCQ4K	DN	TTI-622
DMOCQ4K	HS	Phase 1
DMOCQ4K	CP	Trillium Therapeutics
DMOCQ4K	DT	Recombinant protein
DMOCQ4K	DE	Lymphoma; Myeloma

DMCG01R	ID	DMCG01R
DMCG01R	DN	TTP-4000
DMCG01R	HS	Phase 1
DMCG01R	SN	Extracellular RAGE domain (diabetic nephropathy), TransTech; Extracellular RAGE domain (Alzheimer's disease), TransTech
DMCG01R	CP	Transtech pharma
DMCG01R	DE	Alzheimer disease

DMYFUOP	ID	DMYFUOP
DMYFUOP	DN	TTP-547
DMYFUOP	HS	Phase 1
DMYFUOP	SN	Glucokinase activator (diabetes), TransTech Pharma
DMYFUOP	CP	TransTech Pharma Inc
DMYFUOP	DE	Diabetic complication

DM8H2AG	ID	DM8H2AG
DM8H2AG	DN	TTX-030
DM8H2AG	HS	Phase 1
DM8H2AG	CP	AbbVie
DM8H2AG	DT	Antibody
DM8H2AG	DE	Lymphoma; Solid tumour/cancer

DM6GKYF	ID	DM6GKYF
DM6GKYF	DN	TTX-080
DM6GKYF	HS	Phase 1
DM6GKYF	CP	Tizona Therapeutics
DM6GKYF	DT	Antibody
DM6GKYF	DE	Solid tumour/cancer

DM36ONA	ID	DM36ONA
DM36ONA	DN	Turofexorate isopropyl
DM36ONA	HS	Phase 1
DM36ONA	SN	629664-81-9; Turofexorate isopropyl; WAY-362450; XL335; isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate; FXR-450; Turofexorate Isopropyl (XL335); UNII-S6KDM312I5; WAY 362450; S6KDM312I5; WAY362450; XL-335; 3-(3,4-difluorobenzoyl)-1,2,3,6-tetrahydro-1,1-dimethyl-Azepino[4,5-b]indole-5-carboxylic acid 1-methylethyl ester; 1-methylethyl 3-[(3,4-difluorophenyl)carbonyl]-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate; FXR 450; Turofexorate isopropyl [USAN:I
DM36ONA	CP	Pfizer New York, NY
DM36ONA	DT	Small molecular drug
DM36ONA	PC	10026128
DM36ONA	MW	438.5
DM36ONA	FM	C25H24F2N2O3
DM36ONA	IC	InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3
DM36ONA	CS	CC(C)OC(=O)C1=CN(CC(C2=C1NC3=CC=CC=C32)(C)C)C(=O)C4=CC(=C(C=C4)F)F
DM36ONA	IK	INASOKQDNHHMRE-UHFFFAOYSA-N
DM36ONA	IU	propan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-2,6-dihydroazepino[4,5-b]indole-5-carboxylate
DM36ONA	CA	CAS 629664-81-9
DM36ONA	DE	Hyperlipidaemia

DMZIK8R	ID	DMZIK8R
DMZIK8R	DN	TXA709
DMZIK8R	HS	Phase 1
DMZIK8R	CP	TAXIS Pharmaceuticals
DMZIK8R	DT	Small interfering RNA
DMZIK8R	DE	MRSA infection

DMWOE62	ID	DMWOE62
DMWOE62	DN	U3-1565
DMWOE62	HS	Phase 1
DMWOE62	CP	Amgen Thousand; Daiichi
DMWOE62	DE	Solid tumour/cancer

DM5XMHB	ID	DM5XMHB
DM5XMHB	DN	UC-781
DM5XMHB	HS	Phase 1
DM5XMHB	SN	Thiocarboxanilide; UC-040; UC-10; UC-82; Oxathiin carboxanilide analogs, Biosyn/CONRAD; UC analogs, Biosyn/CONRAD; Oxathiin carboxanilide analogs, Uniroyal/NCI/Southern Research Institute; UC analogs, Uniroyal/NCI/Southern Research Institute
DM5XMHB	CP	Biosyn
DM5XMHB	DT	Small molecular drug
DM5XMHB	PC	3000926
DM5XMHB	MW	335.8
DM5XMHB	FM	C17H18ClNO2S
DM5XMHB	IC	InChI=1S/C17H18ClNO2S/c1-11(2)6-8-21-16-10-13(4-5-15(16)18)19-17(22)14-7-9-20-12(14)3/h4-7,9-10H,8H2,1-3H3,(H,19,22)
DM5XMHB	CS	CC1=C(C=CO1)C(=S)NC2=CC(=C(C=C2)Cl)OCC=C(C)C
DM5XMHB	IK	YZHIXLCGPOTQNB-UHFFFAOYSA-N
DM5XMHB	IU	N-[4-chloro-3-(3-methylbut-2-enoxy)phenyl]-2-methylfuran-3-carbothioamide
DM5XMHB	CA	CAS 178870-32-1
DM5XMHB	DE	Human immunodeficiency virus infection

DMG7FLI	ID	DMG7FLI
DMG7FLI	DN	UCART123
DMG7FLI	HS	Phase 1
DMG7FLI	CP	Cellectis S.A.
DMG7FLI	DT	CAR T Cell Therapy
DMG7FLI	DE	Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm

DMARHU4	ID	DMARHU4
DMARHU4	DN	UCART-22
DMARHU4	HS	Phase 1
DMARHU4	CP	Cellectis
DMARHU4	DT	CAR T Cell Therapy
DMARHU4	DE	B-cell acute lymphoblastic leukaemia

DM2Y4D7	ID	DM2Y4D7
DM2Y4D7	DN	UCARTCS1
DM2Y4D7	HS	Phase 1
DM2Y4D7	CP	Cellectis
DM2Y4D7	DT	CAR T Cell Therapy
DM2Y4D7	DE	Multiple myeloma

DMSCXB7	ID	DMSCXB7
DMSCXB7	DN	UK-240455
DMSCXB7	HS	Phase 1
DMSCXB7	SN	UK-212189 (racemate); (aR)-N-(6,7-Dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-(2-hydroxyethyl)methanesulfonamide
DMSCXB7	DT	Small molecular drug
DMSCXB7	PC	9842188
DMSCXB7	MW	368.2
DMSCXB7	FM	C11H11Cl2N3O5S
DMSCXB7	IC	InChI=1S/C11H11Cl2N3O5S/c1-22(20,21)16(2-3-17)9-7(13)5(12)4-6-8(9)15-11(19)10(18)14-6/h4,17H,2-3H2,1H3,(H,14,18)(H,15,19)
DMSCXB7	CS	CS(=O)(=O)N(CCO)C1=C2C(=CC(=C1Cl)Cl)NC(=O)C(=O)N2
DMSCXB7	IK	BGJHUMNCODFLCH-UHFFFAOYSA-N
DMSCXB7	IU	N-(6,7-dichloro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)-N-(2-hydroxyethyl)methanesulfonamide
DMSCXB7	CA	CAS 178908-09-3
DMSCXB7	DE	Nerve injury

DMI8795	ID	DMI8795
DMI8795	DN	UK-371800
DMI8795	HS	Phase 1
DMI8795	DT	Small molecular drug
DMI8795	PC	135430955
DMI8795	MW	519.6
DMI8795	FM	C23H33N7O5S
DMI8795	IC	InChI=1S/C23H33N7O5S/c1-6-18-19-20(27-28(18)4)22(31)26-21(25-19)17-12-16(13-24-23(17)35-15(3)14-34-5)36(32,33)30-10-8-29(7-2)9-11-30/h12-13,15H,6-11,14H2,1-5H3,(H,25,26,31)/t15-/m1/s1
DMI8795	CS	CCC1=C2C(=NN1C)C(=O)NC(=N2)C3=C(N=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)O[C@H](C)COC
DMI8795	IK	WKISNFXGTYNPOO-OAHLLOKOSA-N
DMI8795	IU	3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(2R)-1-methoxypropan-2-yl]oxypyridin-3-yl]-2-methyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DMI8795	DE	Erectile dysfunction

DMFYKDX	ID	DMFYKDX
DMFYKDX	DN	UK-396082
DMFYKDX	HS	Phase 1
DMFYKDX	SN	UK-396082; UNII-2Q5861SUIG; UK-396,082; UK 396082; 2Q5861SUIG; CHEMBL398110; 400044-47-5; (2s)-5-Amino-2-[(1-Propyl-1h-Imidazol-4-Yl)methyl]pentanoic Acid; SCHEMBL3841442; GTPL8657; DTXSID70193074; BDBM50226610; DB12099; compound 21 [PMID: 17990866]; (2S)-5-amino-2-[(1-propylimidazol-4-yl)methyl]pentanoic acid; (S)-5-amino-2-((1-propyl-1H-imidazol-4-yl)methyl)pentanoic acid; (S)-2-(1-Propyl-1H-imidazole-4-ylmethyl)-5-aminopentanoic acid; 1H-Imidazole-4-propanoic acid, alpha-(3-aminopropyl)-1-propyl-, (alphaS)-
DMFYKDX	DT	Small molecular drug
DMFYKDX	PC	11241908
DMFYKDX	MW	239.31
DMFYKDX	FM	C12H21N3O2
DMFYKDX	IC	InChI=1S/C12H21N3O2/c1-2-6-15-8-11(14-9-15)7-10(12(16)17)4-3-5-13/h8-10H,2-7,13H2,1H3,(H,16,17)/t10-/m0/s1
DMFYKDX	CS	CCCN1C=C(N=C1)C[C@H](CCCN)C(=O)O
DMFYKDX	IK	OTDGPKRCQXSTPV-JTQLQIEISA-N
DMFYKDX	IU	(2S)-5-amino-2-[(1-propylimidazol-4-yl)methyl]pentanoic acid
DMFYKDX	CA	CAS 400044-47-5
DMFYKDX	DE	Thrombosis

DMO8Z1D	ID	DMO8Z1D
DMO8Z1D	DN	UK-66914
DMO8Z1D	HS	Phase 1
DMO8Z1D	SN	UK-66914; 113049-11-9; Methanesulfonamide, N-[4-[1-hydroxy-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]phenyl]-; Methanesulfonamide, N-(4-(1-hydroxy-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl)phenyl)-; UK66914; UK 66914; UK-66,914; AC1MIZ8F; SCHEMBL6375438
DMO8Z1D	CP	Pfizer Ltd
DMO8Z1D	DT	Small molecular drug
DMO8Z1D	PC	3082653
DMO8Z1D	MW	376.5
DMO8Z1D	FM	C18H24N4O3S
DMO8Z1D	IC	InChI=1S/C18H24N4O3S/c1-26(24,25)20-16-4-2-15(3-5-16)18(23)14-21-10-12-22(13-11-21)17-6-8-19-9-7-17/h2-9,18,20,23H,10-14H2,1H3
DMO8Z1D	CS	CS(=O)(=O)NC1=CC=C(C=C1)C(CN2CCN(CC2)C3=CC=NC=C3)O
DMO8Z1D	IK	MXVFGNOLZDAKQJ-UHFFFAOYSA-N
DMO8Z1D	IU	N-[4-[1-hydroxy-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl]phenyl]methanesulfonamide
DMO8Z1D	CA	CAS 113049-11-9
DMO8Z1D	DE	Cardiac arrhythmias

DMHG7DZ	ID	DMHG7DZ
DMHG7DZ	DN	UltraCD40L
DMHG7DZ	HS	Phase 1
DMHG7DZ	SN	SP-D-CD40L; 4-trimer SP-D-CD40L (anticancer, adjuvant), Multimeric Biotherapeutics
DMHG7DZ	CP	Biogen Idec
DMHG7DZ	DE	Systemic lupus erythematosus

DMTLNGV	ID	DMTLNGV
DMTLNGV	DN	Umespirone
DMTLNGV	HS	Phase 1
DMTLNGV	SN	KC-7218; KC-9172
DMTLNGV	CP	Solvay SA
DMTLNGV	DT	Small molecular drug
DMTLNGV	PC	65902
DMTLNGV	MW	512.6
DMTLNGV	FM	C28H40N4O5
DMTLNGV	IC	InChI=1S/C28H40N4O5/c1-5-6-14-31-24(33)22-26(35)32(27(36)23(25(31)34)28(22,2)3)15-10-9-13-29-16-18-30(19-17-29)20-11-7-8-12-21(20)37-4/h7-8,11-12,22-23H,5-6,9-10,13-19H2,1-4H3
DMTLNGV	CS	CCCCN1C(=O)C2C(=O)N(C(=O)C(C1=O)C2(C)C)CCCCN3CCN(CC3)C4=CC=CC=C4OC
DMTLNGV	IK	BXNRTMZZILHVNJ-UHFFFAOYSA-N
DMTLNGV	IU	3-butyl-7-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetrone
DMTLNGV	CA	CAS 107736-98-1
DMTLNGV	DE	Anxiety disorder

DMI5UEB	ID	DMI5UEB
DMI5UEB	DN	Unacylated ghrelin
DMI5UEB	HS	Phase 1
DMI5UEB	SN	AZP-01; Diabetes therapeutic peptide, Theratechnologies; TH-0332; Un-octanoylated ghrelin; Unacylated ghrelin (diabetes); Ghrelin inhibitor peptides (diabetes), Theratechnologies; UAG (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Theratechnologies; Un-octanoylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma/Eli Lilly
DMI5UEB	CP	Theratechnologies Inc
DMI5UEB	DE	Type-1 diabetes

DMR38M4	ID	DMR38M4
DMR38M4	DN	UNBS-1450
DMR38M4	HS	Phase 1
DMR38M4	SN	UNBS-1244; Na+ K+ ATPase inhibitor, (intravenous, cancer), Unibioscreen; 2''-oxovoruscharin
DMR38M4	CP	Unibioscreen SA
DMR38M4	DT	Small molecular drug
DMR38M4	PC	154731948
DMR38M4	DE	Solid tumour/cancer

DMIKV9W	ID	DMIKV9W
DMIKV9W	DN	Utomilumab
DMIKV9W	HS	Phase 1
DMIKV9W	SN	PF-05082566
DMIKV9W	CP	Pfizer
DMIKV9W	DT	Antibody
DMIKV9W	DE	Solid tumour/cancer

DMJSX9N	ID	DMJSX9N
DMJSX9N	DN	V-24343
DMJSX9N	HS	Phase 1
DMJSX9N	SN	CB1 antagonists, Vernalis; Cannabinoid CB1 receptor antagonists, Vernalis
DMJSX9N	CP	Vernalis
DMJSX9N	DE	Type-2 diabetes

DMYAIUB	ID	DMYAIUB
DMYAIUB	DN	Valortim
DMYAIUB	HS	Phase 1
DMYAIUB	SN	Anthrax antibody, Medarex; MDX-1303; Anthrax antibody, Medarex/PharmAthene; Anti-B anthracis, Bristol Myers Squibb/PharmAthene; Anti-B anthracis PA (anthrax), Medarex/BMS/PharmAthene
DMYAIUB	CP	Pharmathene
DMYAIUB	DT	Antibody
DMYAIUB	DE	Bacterial infection

DM3ZW6A	ID	DM3ZW6A
DM3ZW6A	DN	VAN-10-4-eluting stent
DM3ZW6A	HS	Phase 1
DM3ZW6A	SN	INC-105-eluting stent, Inncardio/University of Strathclyde; VAN-10-4-eluting stent, University of Strathclyde; Marigold compound (drug-eluting stent, restenosis), Inncardio/University of Strathclyde
DM3ZW6A	CP	University of Strathclyde
DM3ZW6A	DE	Artery stenosis

DMULRYC	ID	DMULRYC
DMULRYC	DN	VBY- 036
DMULRYC	HS	Phase 1
DMULRYC	SN	VBY-036
DMULRYC	CP	Virobay
DMULRYC	DE	Neuropathic pain

DMTKPH4	ID	DMTKPH4
DMTKPH4	DN	VBY- 891
DMTKPH4	HS	Phase 1
DMTKPH4	SN	VBY-891
DMTKPH4	CP	Virobay Inc
DMTKPH4	DE	Autoimmune diabetes

DM4YIWK	ID	DM4YIWK
DM4YIWK	DN	VBY-129
DM4YIWK	HS	Phase 1
DM4YIWK	SN	Cathepsin S inhibitor (oral, psoriasis), Virobay
DM4YIWK	CP	Virobay Inc
DM4YIWK	DE	Autoimmune diabetes; Crohn disease; Neuropathic pain

DMU263R	ID	DMU263R
DMU263R	DN	VBY-376
DMU263R	HS	Phase 1
DMU263R	SN	Protease inhibitor (hepatitis C virus infection), Virobay
DMU263R	CP	Virobay Inc
DMU263R	DE	Hepatitis C virus infection

DMMKUOZ	ID	DMMKUOZ
DMMKUOZ	DN	VCH-286
DMMKUOZ	HS	Phase 1
DMMKUOZ	CP	ViroChem Pharma Inc
DMMKUOZ	PC	124582705
DMMKUOZ	MW	600.8
DMMKUOZ	FM	C34H50F2N4O3
DMMKUOZ	IC	InChI=1S/C34H50F2N4O3/c1-24(2)40-32(42)38(22-25-13-18-43-19-14-25)23-33(40)20-28-8-9-29(21-33)39(28)17-12-30(26-6-4-3-5-7-26)37-31(41)27-10-15-34(35,36)16-11-27/h3-7,24-25,27-30H,8-23H2,1-2H3,(H,37,41)/t28-,29+,30-,33?/m0/s1
DMMKUOZ	CS	CC(C)N1C(=O)N(CC12C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)CC6CCOCC6
DMMKUOZ	IK	YZGXEGUSPLSQOJ-VUQZBIHUSA-N
DMMKUOZ	IU	4,4-difluoro-N-[(1S)-3-[(1S,5R)-1'-(oxan-4-ylmethyl)-2'-oxo-3'-propan-2-ylspiro[8-azabicyclo[3.2.1]octane-3,4'-imidazolidine]-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
DMMKUOZ	DE	Human immunodeficiency virus infection

DMS9EKG	ID	DMS9EKG
DMS9EKG	DN	VCL-1M01
DMS9EKG	HS	Phase 1
DMS9EKG	SN	VCL-IM01; EPT (plasmid DNA), Vical; IL-2/EP; MedPulser, cancer (plasmid DNA), Vical; Plasmid DNA (transdermal, EPT), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma); IL-2 gene therapy (pVCL-1102 plasmid DNA vector, melanoma), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma), Vical
DMS9EKG	CP	Vical Inc
DMS9EKG	DE	Melanoma

DMDSC63	ID	DMDSC63
DMDSC63	DN	VEL-0230
DMDSC63	HS	Phase 1
DMDSC63	SN	NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar
DMDSC63	CP	Nippon Chemiphar Co Ltd
DMDSC63	DT	Small molecular drug
DMDSC63	PC	25102841
DMDSC63	MW	309.33
DMDSC63	FM	C14H24NNaO5
DMDSC63	IC	InChI=1S/C14H25NO5.Na/c1-8(2)5-10(7-19-6-9(3)4)15-13(16)11-12(20-11)14(17)18;/h8-12H,5-7H2,1-4H3,(H,15,16)(H,17,18);/q;+1/p-1/t10-,11-,12-;/m0./s1
DMDSC63	CS	CC(C)C[C@@H](COCC(C)C)NC(=O)[C@@H]1[C@H](O1)C(=O)[O-].[Na+]
DMDSC63	IK	SGAKODIXAHVUKL-LFELFHSZSA-M
DMDSC63	IU	sodium;(2S,3S)-3-[[(2S)-4-methyl-1-(2-methylpropoxy)pentan-2-yl]carbamoyl]oxirane-2-carboxylate
DMDSC63	CA	CAS 221144-20-3
DMDSC63	DE	Rheumatoid arthritis

DM9OEK1	ID	DM9OEK1
DM9OEK1	DN	Velpatasvir
DM9OEK1	HS	Phase 1
DM9OEK1	SN	GS 5816; GS-5816; GS5816; KCU0C7RS7Z; UNII-KCU0C7RS7Z; Velpatasvir; Velpatasvir [USAN:INN]; Verpatasvir; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
DM9OEK1	TC	Antiviral Agent
DM9OEK1	DT	Small molecular drug
DM9OEK1	PC	67683363
DM9OEK1	MW	883.019
DM9OEK1	FM	C49H54N8O8
DM9OEK1	IC	InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
DM9OEK1	CS	CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC
DM9OEK1	IK	FHCUMDQMBHQXKK-CDIODLITSA-N
DM9OEK1	IU	methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
DM9OEK1	CA	CAS 1377049-84-7
DM9OEK1	CB	CHEBI:133009
DM9OEK1	DE	Hepatitis C virus infection

DM9GC4R	ID	DM9GC4R
DM9GC4R	DN	VGX-100
DM9GC4R	HS	Phase 1
DM9GC4R	CP	Circadian Technologies
DM9GC4R	DE	Solid tumour/cancer

DMM1N5C	ID	DMM1N5C
DMM1N5C	DN	VGX-1027
DMM1N5C	HS	Phase 1
DMM1N5C	SN	VGX-1027; 6501-72-0; GIT 27; git-27; 2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid; 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID; 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic Acid; GIT27; SCHEMBL1404343; CHEMBL1320667; CTK5C2027; VGX-127; EX-A366; DTXSID50445023; AOB1858; MUFJHYRCIHHATF-UHFFFAOYSA-N; MolPort-022-917-316; HMS3653J11; BCP09284; VGX 1027; VGX-1027(GIT 27); MFCD08696167; s7515; 2792AH; GIT-27 (VGX-1027); AKOS022538967; AKOS000282755; CS-2737; NCGC00186000-02; NCGC00186000-01; AK175225; HY-15507; AB0279943; KB-272590
DMM1N5C	CP	Inovio Pharmaceuticals
DMM1N5C	DT	Small molecular drug
DMM1N5C	PC	10798271
DMM1N5C	MW	205.21
DMM1N5C	FM	C11H11NO3
DMM1N5C	IC	InChI=1S/C11H11NO3/c13-11(14)7-9-6-10(12-15-9)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,14)
DMM1N5C	CS	C1C(ON=C1C2=CC=CC=C2)CC(=O)O
DMM1N5C	IK	MUFJHYRCIHHATF-UHFFFAOYSA-N
DMM1N5C	IU	2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
DMM1N5C	CA	CAS 6501-72-0
DMM1N5C	DE	Rheumatoid arthritis

DMGMEH7	ID	DMGMEH7
DMGMEH7	DN	VGX-3400
DMGMEH7	HS	Phase 1
DMGMEH7	CP	Inovio Pharmaceuticals
DMGMEH7	DT	Vaccine
DMGMEH7	DE	Influenza A virus H5N1 infection

DMDFC2Y	ID	DMDFC2Y
DMDFC2Y	DN	VIC-1911
DMDFC2Y	HS	Phase 1
DMDFC2Y	SN	TAS 119
DMDFC2Y	CP	VITRAC Therapeutics
DMDFC2Y	DE	Solid tumour/cancer

DM6LQIU	ID	DM6LQIU
DM6LQIU	DN	VIR-2482
DM6LQIU	HS	Phase 1
DM6LQIU	CP	Vir Biotechnology
DM6LQIU	DT	Antibody
DM6LQIU	DE	Influenza A virus infection

DMB3I04	ID	DMB3I04
DMB3I04	DN	VM-206
DMB3I04	HS	Phase 1
DMB3I04	CP	ViroMed Co Ltd
DMB3I04	DT	Vaccine
DMB3I04	DE	Solid tumour/cancer

DM4AXPT	ID	DM4AXPT
DM4AXPT	DN	VMD-928
DM4AXPT	HS	Phase 1
DM4AXPT	CP	VM Oncology
DM4AXPT	DT	Small molecular drug
DM4AXPT	DE	Lymphoma; Solid tumour/cancer

DMNZ6XH	ID	DMNZ6XH
DMNZ6XH	DN	VNRX-5133
DMNZ6XH	HS	Phase 1
DMNZ6XH	SN	Taniborbactam; UNII-8IGQ156Z07; 8IGQ156Z07; 1613267-49-4; (3R)-3-[[2-[4-(2-aminoethylamino)cyclohexyl]acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid; (3~{R})-3-[2-[4-(2-azanylethylamino)cyclohexyl]ethanoylamino]-2-oxidanyl-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid; Taniborbactam [INN]; Taniborbactam [USAN]; Taniborbactam (USAN/INN); VNRX5133; CHEMBL4463697; CHEMBL4584705; CHEMBL4594290; SCHEMBL15778142; SCHEMBL15778144; SCHEMBL15779391; GTPL10774; WHO 10817; HY-109124; CS-0078360; D11718; (3R)-3-(((trans-4-((2-Aminoethyl)amino)cyclohexyl)acetyl)amino)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborinine-8-carboxylic acid; (R)-3-(2-((1S,4R)-rel-4-((2-Aminoethyl)amino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid; (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid; 2H-1,2-Benzoxaborin-8-carboxylic acid, 3-((2-(trans-4-((2-aminoethyl)amino)cyclohexyl)acetyl)amino)-3,4-dihydro-2-hydroxy-, (3R)-
DMNZ6XH	CP	VenatoRx Pharmaceuticals
DMNZ6XH	DT	Small molecular drug
DMNZ6XH	PC	76902493
DMNZ6XH	MW	389.3
DMNZ6XH	FM	C19H28BN3O5
DMNZ6XH	IC	InChI=1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1
DMNZ6XH	CS	B1([C@H](CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O
DMNZ6XH	IK	PFZUWUXKQPRWAL-PXCJXSSVSA-N
DMNZ6XH	IU	(3R)-3-[[2-[4-(2-aminoethylamino)cyclohexyl]acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid
DMNZ6XH	CA	CAS 1613267-49-4
DMNZ6XH	DE	Bacterial infection

DMDG30Q	ID	DMDG30Q
DMDG30Q	DN	VOB560
DMDG30Q	HS	Phase 1
DMDG30Q	SN	S 65487
DMDG30Q	CP	Novartis
DMDG30Q	DT	Small molecular drug
DMDG30Q	DE	Multiple myeloma; Acute myeloid leukaemia; Non-hodgkin lymphoma

DM215XO	ID	DM215XO
DM215XO	DN	Voxilaprevir
DM215XO	HS	Phase 1
DM215XO	SN	0570F37359; DB12026; GS-9857; J3.665.048F; SCHEMBL15412621; UNII-0570F37359; Voxilaprevir; Voxilaprevir (USAN/INN); Voxilaprevir [USAN:INN]
DM215XO	TC	Antiviral Agent
DM215XO	DT	Small molecular drug
DM215XO	PC	89921642
DM215XO	MW	868.943
DM215XO	FM	C40H52F4N6O9S
DM215XO	IC	InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
DM215XO	CS	CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C
DM215XO	IK	MZBLZLWXUBZHSL-FZNJKFJKSA-N
DM215XO	IU	(1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DM215XO	CA	CAS 1535212-07-7
DM215XO	DE	Hepatitis C virus infection

DM0S9OT	ID	DM0S9OT
DM0S9OT	DN	VRC07-523LS
DM0S9OT	HS	Phase 1
DM0S9OT	CP	TaiMed Biologics
DM0S9OT	DT	Antibody
DM0S9OT	DE	Human immunodeficiency virus-1 infection

DMN9JCD	ID	DMN9JCD
DMN9JCD	DN	VS-4718
DMN9JCD	HS	Phase 1
DMN9JCD	SN	PND-1186
DMN9JCD	CP	Verastem
DMN9JCD	PC	25073775
DMN9JCD	MW	501.5
DMN9JCD	FM	C25H26F3N5O3
DMN9JCD	IC	InChI=1S/C25H26F3N5O3/c1-29-24(34)17-5-3-4-6-19(17)31-21-14-23(30-15-18(21)25(26,27)28)32-20-8-7-16(13-22(20)35-2)33-9-11-36-12-10-33/h3-8,13-15H,9-12H2,1-2H3,(H,29,34)(H2,30,31,32)
DMN9JCD	CS	CNC(=O)C1=CC=CC=C1NC2=CC(=NC=C2C(F)(F)F)NC3=C(C=C(C=C3)N4CCOCC4)OC
DMN9JCD	IK	IGUBBWJDMLCRIK-UHFFFAOYSA-N
DMN9JCD	IU	2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-N-methylbenzamide
DMN9JCD	CA	CAS 1061353-68-1
DMN9JCD	DE	Solid tumour/cancer

DMMO3G5	ID	DMMO3G5
DMMO3G5	DN	VS-5584
DMMO3G5	HS	Phase 1
DMMO3G5	SN	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877
DMMO3G5	CP	Verastem
DMMO3G5	DT	Small molecular drug
DMMO3G5	PC	46912230
DMMO3G5	MW	354.4
DMMO3G5	FM	C17H22N8O
DMMO3G5	IC	InChI=1S/C17H22N8O/c1-10(2)25-11(3)21-14-13(12-8-19-16(18)20-9-12)22-17(23-15(14)25)24-4-6-26-7-5-24/h8-10H,4-7H2,1-3H3,(H2,18,19,20)
DMMO3G5	CS	CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N
DMMO3G5	IK	QYBGBLQCOOISAR-UHFFFAOYSA-N
DMMO3G5	IU	5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine
DMMO3G5	CA	CAS 1246560-33-7
DMMO3G5	DE	Solid tumour/cancer; Malignant mesothelioma

DMQEOD6	ID	DMQEOD6
DMQEOD6	DN	VTP-27999
DMQEOD6	HS	Phase 1
DMQEOD6	SN	VTP-27999; C26H41ClN4O5; 6076AC; CS-0311; HY-50768; W-5512; 142C510; Carbamic acid, N-[2-[(R)-(3-chlorophenyl)[(3R)-1-[[[(2S)-2-(methylamino)-3-[(3R)-tetrahydro-2H-pyran-3-yl]propyl]amino]carbonyl]-3-piperidinyl]methoxy]ethyl]-, methyl ester
DMQEOD6	CP	Vitae Pharmaceuticals
DMQEOD6	DT	Small molecular drug
DMQEOD6	PC	16126898
DMQEOD6	MW	525.1
DMQEOD6	FM	C26H41ClN4O5
DMQEOD6	IC	InChI=1S/C26H41ClN4O5/c1-28-23(14-19-6-5-12-35-18-19)16-30-25(32)31-11-4-8-21(17-31)24(20-7-3-9-22(27)15-20)36-13-10-29-26(33)34-2/h3,7,9,15,19,21,23-24,28H,4-6,8,10-14,16-18H2,1-2H3,(H,29,33)(H,30,32)/t19-,21-,23+,24+/m1/s1
DMQEOD6	CS	CN[C@@H](C[C@H]1CCCOC1)CNC(=O)N2CCC[C@H](C2)[C@H](C3=CC(=CC=C3)Cl)OCCNC(=O)OC
DMQEOD6	IK	NXWASIVXQMMPLM-ZXMXYHOLSA-N
DMQEOD6	IU	methyl N-[2-[(R)-(3-chlorophenyl)-[(3R)-1-[[(2S)-2-(methylamino)-3-[(3R)-oxan-3-yl]propyl]carbamoyl]piperidin-3-yl]methoxy]ethyl]carbamate
DMQEOD6	CA	CAS 942142-51-0
DMQEOD6	DE	Hypertension

DM9W0B6	ID	DM9W0B6
DM9W0B6	DN	VTR-297
DM9W0B6	HS	Phase 1
DM9W0B6	CP	Vanda Pharmaceuticals Washington, DC
DM9W0B6	DT	Small molecular drug
DM9W0B6	DE	Hematologic tumour

DM4ZIRK	ID	DM4ZIRK
DM4ZIRK	DN	VTX-1463
DM4ZIRK	HS	Phase 1
DM4ZIRK	SN	TLR-8 agonist (allergic rhinitis), VentiRx
DM4ZIRK	CP	VentiRx Pharmaceuticals Inc
DM4ZIRK	DE	Allergic rhinitis

DMC8J0G	ID	DMC8J0G
DMC8J0G	DN	VX-128
DMC8J0G	HS	Phase 1
DMC8J0G	CP	Vertex Pharmaceuticals Boston, MA
DMC8J0G	DE	Pain

DM8UTPJ	ID	DM8UTPJ
DM8UTPJ	DN	VX-500
DM8UTPJ	HS	Phase 1
DM8UTPJ	CP	Vertex
DM8UTPJ	DE	Hepatitis C virus infection

DMAJ2T4	ID	DMAJ2T4
DMAJ2T4	DN	VX-916
DMAJ2T4	HS	Phase 1
DMAJ2T4	CP	Vertex
DMAJ2T4	DE	Hepatitis C virus infection

DMR9PCT	ID	DMR9PCT
DMR9PCT	DN	VX-970
DMR9PCT	HS	Phase 1
DMR9PCT	SN	VE 822
DMR9PCT	CP	Vertex pharmaceuticals
DMR9PCT	PC	59472121
DMR9PCT	MW	463.6
DMR9PCT	FM	C24H25N5O3S
DMR9PCT	IC	InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)
DMR9PCT	CS	CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N
DMR9PCT	IK	JZCWLJDSIRUGIN-UHFFFAOYSA-N
DMR9PCT	IU	3-[3-[4-(methylaminomethyl)phenyl]-1,2-oxazol-5-yl]-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine
DMR9PCT	CA	CAS 1232416-25-9
DMR9PCT	CB	CHEBI:131166
DMR9PCT	DE	Solid tumour/cancer

DMC9N7D	ID	DMC9N7D
DMC9N7D	DN	VYR 006
DMC9N7D	HS	Phase 1
DMC9N7D	CP	Vyera Pharmaceuticals
DMC9N7D	DT	Small molecular drug
DMC9N7D	DE	Toxoplasmosis

DMJ2R69	ID	DMJ2R69
DMJ2R69	DN	W-198
DMJ2R69	HS	Phase 1
DMJ2R69	SN	5-Bromotetrandrine
DMJ2R69	CP	Chengdu Kanghong Pharmaceutical Group Co Ltd
DMJ2R69	DT	Small molecular drug
DMJ2R69	PC	9831563
DMJ2R69	MW	701.6
DMJ2R69	FM	C38H41BrN2O6
DMJ2R69	IC	InChI=1S/C38H41BrN2O6/c1-40-15-13-24-20-31(43-4)33-21-27(24)28(40)17-22-7-10-25(11-8-22)46-32-19-23(9-12-30(32)42-3)18-29-34-26(14-16-41(29)2)35(39)37(44-5)38(45-6)36(34)47-33/h7-12,19-21,28-29H,13-18H2,1-6H3/t28-,29-/m0/s1
DMJ2R69	CS	CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(CCN6C)C(=C(C(=C7O3)OC)OC)Br)OC)OC
DMJ2R69	IK	ANJMFZGRGHQXMA-VMPREFPWSA-N
DMJ2R69	IU	(1S,14S)-19-bromo-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18(33),19,21,24,26,31-dodecaene
DMJ2R69	DE	Solid tumour/cancer

DMJQHTN	ID	DMJQHTN
DMJQHTN	DN	WCK-1152
DMJQHTN	HS	Phase 1
DMJQHTN	SN	Antibacterial fluoroquinolones, Wockhardt; WCK-1153; WCK-1457; WCK-783; WCK-919; WCK-993A
DMJQHTN	CP	Wockhardt Ltd
DMJQHTN	PC	11619057
DMJQHTN	MW	403.4
DMJQHTN	FM	C21H26FN3O4
DMJQHTN	IC	InChI=1S/C21H26FN3O4/c1-21(2)10-24(7-6-15(21)23)17-14(22)8-12-16(19(17)29-3)25(11-4-5-11)9-13(18(12)26)20(27)28/h8-9,11,15H,4-7,10,23H2,1-3H3,(H,27,28)/t15-/m0/s1
DMJQHTN	CS	CC1(CN(CC[C@@H]1N)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F)C
DMJQHTN	IK	PMBHAWNZPPNADR-HNNXBMFYSA-N
DMJQHTN	IU	7-[(4S)-4-amino-3,3-dimethylpiperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMJQHTN	DE	Respiratory tract inflammation

DM57FHW	ID	DM57FHW
DM57FHW	DN	WF-11605
DM57FHW	HS	Phase 1
DM57FHW	SN	9-Acetoxy-2-(1,2-dimethylpropyl)-8-(hexopyranosyloxy)-2,4a,7,7,10a,12a-hexamethyl-1,2,3,4,4a,5,6,6a,7,8,9,10,10a,11,12,12a-hexadecahydrochrysene-1-carboxylic acid
DM57FHW	DT	Small molecular drug
DM57FHW	PC	3081238
DM57FHW	MW	692.9
DM57FHW	FM	C38H60O11
DM57FHW	IC	InChI=1S/C38H60O11/c1-18(2)19(3)38(10)26(41)16-37(9)22-11-12-25-34(5,6)31(49-33-29(44)28(43)27(42)24(17-39)48-33)23(47-20(4)40)15-35(25,7)21(22)13-14-36(37,8)30(38)32(45)46/h18-19,23-25,27-31,33,39,42-44H,11-17H2,1-10H3,(H,45,46)/t19?,23-,24-,25+,27-,28+,29-,30-,31+,33+,35-,36+,37-,38+/m1/s1
DM57FHW	CS	CC(C)C(C)[C@@]1([C@@H]([C@@]2(CCC3=C([C@]2(CC1=O)C)CC[C@@H]4[C@@]3(C[C@H]([C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)OC(=O)C)C)C)C(=O)O)C
DM57FHW	IK	FBAPXRMZLULGNA-LEAUMUBASA-N
DM57FHW	IU	(1R,2R,4aS,6aR,8R,9R,10aS,12aS)-9-acetyloxy-2,4a,7,7,10a,12a-hexamethyl-2-(3-methylbutan-2-yl)-3-oxo-8-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4,5,6,6a,8,9,10,11,12-decahydrochrysene-1-carboxylic acid
DM57FHW	CA	CAS 127475-47-2
DM57FHW	DE	Bacterial infection

DM8RNSB	ID	DM8RNSB
DM8RNSB	DN	WP1220
DM8RNSB	HS	Phase 1
DM8RNSB	SN	mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide
DM8RNSB	CP	Moleculin Biotech
DM8RNSB	DT	Small molecular drug
DM8RNSB	PC	44554865
DM8RNSB	MW	382.3
DM8RNSB	FM	C19H16BrN3O
DM8RNSB	IC	InChI=1S/C19H16BrN3O/c1-14(15-7-3-2-4-8-15)22-19(24)16(13-21)9-5-10-17-11-6-12-18(20)23-17/h2-12,14H,1H3,(H,22,24)/b10-5+,16-9+/t14-/m0/s1
DM8RNSB	CS	C[C@@H](C1=CC=CC=C1)NC(=O)/C(=C/C=C/C2=NC(=CC=C2)Br)/C#N
DM8RNSB	IK	IVAUEQVCSQZMGV-QIUCFAMLSA-N
DM8RNSB	IU	(2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide
DM8RNSB	CA	CAS 1204306-34-2
DM8RNSB	DE	Cutaneous T-cell lymphoma

DM9PNR6	ID	DM9PNR6
DM9PNR6	DN	WST-057
DM9PNR6	HS	Phase 1
DM9PNR6	CP	WinSanTor San Diego, CA
DM9PNR6	DE	Peripheral neuropathy

DM7MS10	ID	DM7MS10
DM7MS10	DN	WVT078
DM7MS10	HS	Phase 1
DM7MS10	CP	Novartis
DM7MS10	DT	Antibody
DM7MS10	DE	Multiple myeloma

DMFBOQ7	ID	DMFBOQ7
DMFBOQ7	DN	Xanthine
DMFBOQ7	HS	Phase 1
DMFBOQ7	SN	xanthine; 69-89-6; 2,6-Dihydroxypurine; Xanthin; 2,6-dioxopurine; Pseudoxanthine; Isoxanthine; 1H-Purine-2,6(3H,7H)-dione; Xanthic oxide; 1H-Purine-2,6-diol; 9H-Purine-2,6-diol; Purine-2,6-diol; 3,7-Dihydro-1H-purine-2,6-dione; 2,6(1,3)-Purinedion; 1H-Purine-2,6-dione, 3,7-dihydro-; 3,7-dihydropurine-2,6-dione; USAF CB-17; XAN; Purine-2(3H),6(1H)-dione; 2,6-Dioxo-1,2,3,6-tetrahydropurine; 3,9-dihydro-1H-purine-2,6-dione; 9H-Purine-2,6-(1H,3H)-dione; 1H-Purine-2,6-dione, 3,9-dihydro-; Purine-2,6-(1H,3H)-dione; 9H-xanthine
DMFBOQ7	CP	Schering-Plough
DMFBOQ7	DT	Small molecular drug
DMFBOQ7	PC	1188
DMFBOQ7	MW	152.11
DMFBOQ7	FM	C5H4N4O2
DMFBOQ7	IC	InChI=1S/C5H4N4O2/c10-4-2-3(7-1-6-2)8-5(11)9-4/h1H,(H3,6,7,8,9,10,11)
DMFBOQ7	CS	C1=NC2=C(N1)C(=O)NC(=O)N2
DMFBOQ7	IK	LRFVTYWOQMYALW-UHFFFAOYSA-N
DMFBOQ7	IU	3,7-dihydropurine-2,6-dione
DMFBOQ7	CA	CAS 69-89-6
DMFBOQ7	CB	CHEBI:17712
DMFBOQ7	DE	Apnea

DM1UIOA	ID	DM1UIOA
DM1UIOA	DN	XB-947
DM1UIOA	HS	Phase 1
DM1UIOA	SN	XR-469R; (+)-2(R)-[4-(7-Chloroquinoxalin-2-yloxy)phenoxy]propionic acid sodium salt; (R)-(+)-XK-469
DM1UIOA	DT	Small molecular drug
DM1UIOA	PC	157156
DM1UIOA	MW	358.8
DM1UIOA	FM	C18H15ClN2O4
DM1UIOA	IC	InChI=1S/C18H15ClN2O4/c1-11(18(22)23-2)24-13-4-6-14(7-5-13)25-17-10-20-15-8-3-12(19)9-16(15)21-17/h3-11H,1-2H3
DM1UIOA	CS	CC(C(=O)OC)OC1=CC=C(C=C1)OC2=CN=C3C=CC(=CC3=N2)Cl
DM1UIOA	IK	NPUWJNOFOGQLSR-UHFFFAOYSA-N
DM1UIOA	IU	methyl 2-[4-(7-chloroquinoxalin-2-yl)oxyphenoxy]propanoate
DM1UIOA	CA	CAS 78104-71-9
DM1UIOA	DE	Solid tumour/cancer

DMNKV3O	ID	DMNKV3O
DMNKV3O	DN	XEN007
DMNKV3O	HS	Phase 1
DMNKV3O	CP	Xenon
DMNKV3O	DE	Migraine

DMJVL57	ID	DMJVL57
DMJVL57	DN	XEN1101
DMJVL57	HS	Phase 1
DMJVL57	CP	Xenon
DMJVL57	DE	Epilepsy

DMRP9YF	ID	DMRP9YF
DMRP9YF	DN	XEN901
DMRP9YF	HS	Phase 1
DMRP9YF	CP	Xenon
DMRP9YF	DE	Epilepsy

DMU0V45	ID	DMU0V45
DMU0V45	DN	XEN-D0101
DMU0V45	HS	Phase 1
DMU0V45	SN	XEN-D101; Potassium channel Kv1.5 modulator (atrial fibillation), Xention
DMU0V45	CP	BioFocus DPI
DMU0V45	DE	Atrial fibrillation

DMR0U4V	ID	DMR0U4V
DMR0U4V	DN	XEN-D0103
DMR0U4V	HS	Phase 1
DMR0U4V	SN	KCNA voltage-gated potassium channel-5 inhibitor (atrial fibrillation), Xention
DMR0U4V	CP	Xention Ltd
DMR0U4V	DE	Atrial fibrillation

DMVYO41	ID	DMVYO41
DMVYO41	DN	XK-469
DMVYO41	HS	Phase 1
DMVYO41	SN	Rac-2-[4-(7-Chloroquinoxalin-2-yloxy)phenoxy]propionic acid sodium salt
DMVYO41	DT	Small molecular drug
DMVYO41	PC	23675947
DMVYO41	MW	366.7
DMVYO41	FM	C17H12ClN2NaO4
DMVYO41	IC	InChI=1S/C17H13ClN2O4.Na/c1-10(17(21)22)23-12-3-5-13(6-4-12)24-16-9-19-14-7-2-11(18)8-15(14)20-16;/h2-10H,1H3,(H,21,22);/q;+1/p-1
DMVYO41	CS	CC(C(=O)[O-])OC1=CC=C(C=C1)OC2=CN=C3C=CC(=CC3=N2)Cl.[Na+]
DMVYO41	IK	OJENKXNXJPNEPU-UHFFFAOYSA-M
DMVYO41	IU	sodium;2-[4-(7-chloroquinoxalin-2-yl)oxyphenoxy]propanoate
DMVYO41	CA	CAS 157434-99-6
DMVYO41	DE	Solid tumour/cancer

DMYSQHT	ID	DMYSQHT
DMYSQHT	DN	XL-041
DMYSQHT	HS	Phase 1
DMYSQHT	SN	XCT-0179628; XCT-628; XL-652; XL-652); LXR modulator, X-Ceptor Therapeutics; LXR modulators, Exelixis/Sankyo; Liver X receptormodulator, Exelixis/Sankyo; Liver X receptor modulator, X-Ceptor; LXR agonist (atherosclerosis), BMS/Exelixis; LXR modulators, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulator, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulators (cardiovascular disorders), Exelixis/Bristol-Myers Squibb
DMYSQHT	CP	Exelixis; X-Ceptor Therapeutics Inc
DMYSQHT	DE	Arteriosclerosis

DM3LRAC	ID	DM3LRAC
DM3LRAC	DN	XL092
DM3LRAC	HS	Phase 1
DM3LRAC	SN	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2
DM3LRAC	CP	Exelixis
DM3LRAC	DT	Small molecular drug
DM3LRAC	PC	139350422
DM3LRAC	MW	528.5
DM3LRAC	FM	C29H25FN4O5
DM3LRAC	IC	InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37)
DM3LRAC	CS	CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
DM3LRAC	IK	JSPCKALGNNVYOO-UHFFFAOYSA-N
DM3LRAC	IU	1-N'-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
DM3LRAC	DE	Solid tumour/cancer

DME0F5W	ID	DME0F5W
DME0F5W	DN	XL418
DME0F5W	HS	Phase 1
DME0F5W	CP	Exelixis
DME0F5W	TC	Anticancer Agents
DME0F5W	PC	56963011
DME0F5W	MW	609.5
DME0F5W	FM	C26H32BrF3N8O
DME0F5W	IC	InChI=1S/C26H32BrF3N8O/c1-17-19(31-6-9-36-7-2-3-8-36)14-18(21(39)4-5-26(28,29)30)15-20(17)37-10-12-38(13-11-37)25-22-23(27)34-35-24(22)32-16-33-25/h14-16,31H,2-13H2,1H3,(H,32,33,34,35)
DME0F5W	CS	CC1=C(C=C(C=C1N2CCN(CC2)C3=NC=NC4=NNC(=C43)Br)C(=O)CCC(F)(F)F)NCCN5CCCC5
DME0F5W	IK	IKBSEBRGSVFUHM-UHFFFAOYSA-N
DME0F5W	IU	1-[3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-4,4,4-trifluorobutan-1-one
DME0F5W	CA	CAS 871343-09-8
DME0F5W	DE	Solid tumour/cancer

DMY93SW	ID	DMY93SW
DMY93SW	DN	XL550
DMY93SW	HS	Phase 1
DMY93SW	CP	Exelixis; Daiichi-Sankyo
DMY93SW	DE	Type-2 diabetes

DM89NML	ID	DM89NML
DM89NML	DN	XL652/XL014
DM89NML	HS	Phase 1
DM89NML	CP	Exelixis; Bristol-Myers Squibb
DM89NML	DE	Metabolic disorder; Cardiovascular disease

DMYS13R	ID	DMYS13R
DMYS13R	DN	XL999
DMYS13R	HS	Phase 1
DMYS13R	CP	Exelixis
DMYS13R	TC	Anticancer Agents
DMYS13R	PC	10433653
DMYS13R	MW	445.5
DMYS13R	FM	C26H28FN5O
DMYS13R	IC	InChI=1S/C26H28FN5O/c1-3-32-11-9-19(10-12-32)30-20-7-8-22-21(14-20)24(26(33)31-22)23(25-28-15-16(2)29-25)17-5-4-6-18(27)13-17/h4-8,13-15,19,30H,3,9-12H2,1-2H3,(H,28,29)(H,31,33)/b24-23-
DMYS13R	CS	CCN1CCC(CC1)NC2=CC\\3=C(C=C2)NC(=O)/C3=C(/C4=CC(=CC=C4)F)\\C5=NC=C(N5)C
DMYS13R	IK	DMQYDVBIPXAAJA-VHXPQNKSSA-N
DMYS13R	IU	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)-(5-methyl-1H-imidazol-2-yl)methylidene]-1H-indol-2-one
DMYS13R	CA	CAS 705946-27-6
DMYS13R	DE	Advanced malignancy

DMXTOCE	ID	DMXTOCE
DMXTOCE	DN	XmAb13676
DMXTOCE	HS	Phase 1
DMXTOCE	CP	XencorMonrovia, CA
DMXTOCE	DE	B-cell lymphoma; Non-hodgkin lymphoma

DMJIH83	ID	DMJIH83
DMJIH83	DN	XmAb20717
DMJIH83	HS	Phase 1
DMJIH83	SN	XmAb717
DMJIH83	CP	Xencor
DMJIH83	DT	Antibody
DMJIH83	DE	Solid tumour/cancer; Advanced malignancy; Melanoma; Breast cancer

DMQB3HD	ID	DMQB3HD
DMQB3HD	DN	XmAb22841
DMQB3HD	HS	Phase 1
DMQB3HD	SN	XmAb841
DMQB3HD	CP	Xencor
DMQB3HD	DT	Antibody
DMQB3HD	DE	Solid tumour/cancer

DMK9XUQ	ID	DMK9XUQ
DMK9XUQ	DN	XmAb23104
DMK9XUQ	HS	Phase 1
DMK9XUQ	SN	XmAb104
DMK9XUQ	CP	Xencor
DMK9XUQ	DT	Antibody
DMK9XUQ	DE	Solid tumour/cancer

DM6V0KY	ID	DM6V0KY
DM6V0KY	DN	Xmab-2513
DM6V0KY	HS	Phase 1
DM6V0KY	SN	XENP-0367; XENP-0522; XmAb antibodies (infusion, cancer), Xencor; Anti-CD30 humanized mAb (infusion, cancer), Xencor
DM6V0KY	CP	Xencor
DM6V0KY	DT	Antibody
DM6V0KY	DE	Lymphoma

DME7IVL	ID	DME7IVL
DME7IVL	DN	Xmab-7195
DME7IVL	HS	Phase 1
DME7IVL	SN	IgE inhibitor (asthma/allergy), Xencor
DME7IVL	CP	Xencor Inc
DME7IVL	DE	Asthma

DM4MDCH	ID	DM4MDCH
DM4MDCH	DN	XMT-1001
DM4MDCH	HS	Phase 1
DM4MDCH	CP	Mersana Therapeutics
DM4MDCH	DE	Solid tumour/cancer

DMK0AW6	ID	DMK0AW6
DMK0AW6	DN	XOMA-3AB
DMK0AW6	HS	Phase 1
DMK0AW6	SN	Botulism therapy, XOMA; Botulinum type A neurotoxin mAbs (botulism), XOMA; Anti-type A botulinum neurotoxin monoclonal antibodies (botulism), XOMA/NIAID
DMK0AW6	CP	Xoma; national institute of allergy and infectious diseases
DMK0AW6	DT	Antibody
DMK0AW6	DE	Clostridium infection

DMO9KZE	ID	DMO9KZE
DMO9KZE	DN	XR-5944
DMO9KZE	HS	Phase 1
DMO9KZE	SN	MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942
DMO9KZE	CP	Xenova Group plc
DMO9KZE	DT	Small molecular drug
DMO9KZE	PC	439035
DMO9KZE	MW	586.7
DMO9KZE	FM	C34H34N8O2
DMO9KZE	IC	InChI=1S/C34H34N8O2/c1-21-7-3-11-25-29(21)41-31-23(9-5-13-27(31)39-25)33(43)37-19-17-35-15-16-36-18-20-38-34(44)24-10-6-14-28-32(24)42-30-22(2)8-4-12-26(30)40-28/h3-14,35-36H,15-20H2,1-2H3,(H,37,43)(H,38,44)
DMO9KZE	CS	CC1=C2C(=CC=C1)N=C3C=CC=C(C3=N2)C(=O)NCCNCCNCCNC(=O)C4=CC=CC5=NC6=CC=CC(=C6N=C54)C
DMO9KZE	IK	SFOADSRLCHRTKT-UHFFFAOYSA-N
DMO9KZE	IU	9-methyl-N-[2-[2-[2-[(9-methylphenazine-1-carbonyl)amino]ethylamino]ethylamino]ethyl]phenazine-1-carboxamide
DMO9KZE	CA	CAS 343247-32-5
DMO9KZE	DE	Gastric adenocarcinoma

DML3K9N	ID	DML3K9N
DML3K9N	DN	XTL-6865
DML3K9N	HS	Phase 1
DML3K9N	CP	XTL Biopharmaceuticals
DML3K9N	DE	Hepatitis C virus infection

DMKHVNE	ID	DMKHVNE
DMKHVNE	DN	YKP-1358
DMKHVNE	HS	Phase 1
DMKHVNE	CP	SK Pharmaceuticals
DMKHVNE	DE	Schizoaffective disorder; Schizophrenia

DMW2HS8	ID	DMW2HS8
DMW2HS8	DN	YM-116
DMW2HS8	HS	Phase 1
DMW2HS8	CP	Yamanouchi Pharmaceutical Co Ltd
DMW2HS8	PC	9795793
DMW2HS8	MW	247.29
DMW2HS8	FM	C16H13N3
DMW2HS8	IC	InChI=1S/C16H13N3/c1-2-4-15-13(3-1)14-6-5-11(8-16(14)19-15)7-12-9-17-10-18-12/h1-6,8-10,19H,7H2,(H,17,18)
DMW2HS8	CS	C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)CC4=CN=CN4
DMW2HS8	IK	SHWQRVBJVFBWGP-UHFFFAOYSA-N
DMW2HS8	IU	2-(1H-imidazol-5-ylmethyl)-9H-carbazole
DMW2HS8	DE	Solid tumour/cancer

DMNLY9R	ID	DMNLY9R
DMNLY9R	DN	YM-16151-4
DMNLY9R	HS	Phase 1
DMNLY9R	SN	YM-151; YM-16151-1; (-)-YM-16151-1
DMNLY9R	CP	Yamanouchi Pharmaceutical Co Ltd
DMNLY9R	DT	Small molecular drug
DMNLY9R	PC	128387
DMNLY9R	MW	583.6
DMNLY9R	FM	C30H37N3O9
DMNLY9R	IC	InChI=1S/C30H37N3O9/c1-19-26(29(35)39-3)28(27(20(2)32-19)30(36)40-4)24-16-21(33(37)38)12-13-25(24)41-15-9-8-14-31-17-22(34)18-42-23-10-6-5-7-11-23/h5-7,10-13,16,22,28,31-32,34H,8-9,14-15,17-18H2,1-4H3
DMNLY9R	CS	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=C(C=CC(=C2)[N+](=O)[O-])OCCCCNCC(COC3=CC=CC=C3)O)C(=O)OC
DMNLY9R	IK	GQJFGCIETONRNJ-UHFFFAOYSA-N
DMNLY9R	IU	dimethyl 4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMNLY9R	CA	CAS 103434-30-6
DMNLY9R	DE	Hypertension

DMS31YW	ID	DMS31YW
DMS31YW	DN	YM-57158
DMS31YW	HS	Phase 1
DMS31YW	SN	YM-158; 3-(4-tert-Butylthiazol-2-ylmethoxy)-N-[5-[3-(4-chlorophenylsulfonyl)propyl]-2-(1H-tetrazol-5-ylmethoxy)phenyl]benzamide monosodium salt monohydrate
DMS31YW	DT	Small molecular drug
DMS31YW	PC	5312140
DMS31YW	MW	721.2
DMS31YW	FM	C32H34ClN6NaO6S2
DMS31YW	IC	InChI=1S/C32H33ClN6O5S2.Na.H2O/c1-32(2,3)28-20-45-30(35-28)19-43-24-8-4-7-22(17-24)31(40)34-26-16-21(9-14-27(26)44-18-29-36-38-39-37-29)6-5-15-46(41,42)25-12-10-23(33)11-13-25;;/h4,7-14,16-17,20H,5-6,15,18-19H2,1-3H3,(H2,34,36,37,38,39,40);;1H2/q;+1;/p-1
DMS31YW	CS	CC(C)(C)C1=CSC(=N1)COC2=CC=CC(=C2)C(=O)[N-]C3=C(C=CC(=C3)CCCS(=O)(=O)C4=CC=C(C=C4)Cl)OCC5=NNN=N5.O.[Na+]
DMS31YW	IK	XHOMMMSIYBSJNL-UHFFFAOYSA-M
DMS31YW	IU	sodium;[3-[(4-tert-butyl-1,3-thiazol-2-yl)methoxy]benzoyl]-[5-[3-(4-chlorophenyl)sulfonylpropyl]-2-(2H-tetrazol-5-ylmethoxy)phenyl]azanide;hydrate
DMS31YW	DE	Allergic rhinitis

DMCM0K6	ID	DMCM0K6
DMCM0K6	DN	YPEG-Somatropin
DMCM0K6	HS	Phase 1
DMCM0K6	SN	YPEG-Somatropin (growth hormone deficiency)
DMCM0K6	CP	Xiamen Amoytop Biotech Co Ltd
DMCM0K6	DE	Growth hormone deficiency

DM5BMIO	ID	DM5BMIO
DM5BMIO	DN	YTB323
DM5BMIO	HS	Phase 1
DM5BMIO	CP	Novartis
DM5BMIO	DT	CAR T Cell Therapy
DM5BMIO	DE	Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma

DM1H75D	ID	DM1H75D
DM1H75D	DN	Z-100
DM1H75D	HS	Phase 1
DM1H75D	SN	Ancer; SSM; Specific Substance of Maruyama; Ancer 20
DM1H75D	CP	Zeria Pharmaceutical Co Ltd
DM1H75D	DE	Human immunodeficiency virus infection

DMZQP7N	ID	DMZQP7N
DMZQP7N	DN	ZD7114
DMZQP7N	HS	Phase 1
DMZQP7N	SN	Zeneca ZD7114; ZD7114; ZD 7114; ICI D7114; UNII-EF5S87KTK2; EF5S87KTK2; (S)-4-(2-Hydroxy-3-phenoxypropylaminoethoxy)-N-(2-methoxyethyl)phenoxyacetamide; Acetamide, 2-(4-(2-((2-hydroxy-3-phenoxypropyl)amino)ethoxy)phenoxy)-N-(2-methoxyethyl)-, (S)-; C22H30N2O6; 129689-30-1; AC1L3TKA; SCHEMBL304881; CHEMBL1788312; ICI-D-7114; ZINC3793213; LS-9736; API0009229; 2-[4-[2-[[(2S)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]-N-(2-methoxyethyl)acetamide; NCGC00163153-01; AJ-45629
DMZQP7N	DT	Small molecular drug
DMZQP7N	PC	121877
DMZQP7N	MW	418.5
DMZQP7N	FM	C22H30N2O6
DMZQP7N	IC	InChI=1S/C22H30N2O6/c1-27-13-12-24-22(26)17-30-21-9-7-20(8-10-21)28-14-11-23-15-18(25)16-29-19-5-3-2-4-6-19/h2-10,18,23,25H,11-17H2,1H3,(H,24,26)/t18-/m0/s1
DMZQP7N	CS	COCCNC(=O)COC1=CC=C(C=C1)OCCNC[C@@H](COC2=CC=CC=C2)O
DMZQP7N	IK	RVMBDLSFFNKKLG-SFHVURJKSA-N
DMZQP7N	IU	2-[4-[2-[[(2S)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]-N-(2-methoxyethyl)acetamide
DMZQP7N	CA	CAS 129689-30-1
DMZQP7N	DE	Diabetic complication

DM3KYO4	ID	DM3KYO4
DM3KYO4	DN	ZD-9379
DM3KYO4	HS	Phase 1
DM3KYO4	CP	AstraZeneca plc
DM3KYO4	PC	9843028
DM3KYO4	MW	383.8
DM3KYO4	FM	C19H14ClN3O4
DM3KYO4	IC	InChI=1S/C19H14ClN3O4/c1-9-7-11(27-2)4-6-14(9)23-19(26)15-16(18(25)22-23)21-13-8-10(20)3-5-12(13)17(15)24/h3-8H,1-2H3,(H,21,24)(H,22,25)
DM3KYO4	CS	CC1=C(C=CC(=C1)OC)N2C(=O)C3=C(C(=O)N2)NC4=C(C3=O)C=CC(=C4)Cl
DM3KYO4	IK	PSTDMIAVUUYOOQ-UHFFFAOYSA-N
DM3KYO4	IU	7-chloro-2-(4-methoxy-2-methylphenyl)-3,5-dihydropyridazino[4,5-b]quinoline-1,4,10-trione
DM3KYO4	DE	Cerebrovascular ischaemia

DM2S04R	ID	DM2S04R
DM2S04R	DN	Zemab
DM2S04R	HS	Phase 1
DM2S04R	CP	Novartis AG
DM2S04R	DT	Antibody
DM2S04R	DE	Solid tumour/cancer

DM72GZV	ID	DM72GZV
DM72GZV	DN	ZEN003694
DM72GZV	HS	Phase 1
DM72GZV	CP	Zenith Epigenetics
DM72GZV	DT	Small molecular drug
DM72GZV	DE	Prostate cancer

DM2LHPU	ID	DM2LHPU
DM2LHPU	DN	ZK-200775
DM2LHPU	HS	Phase 1
DM2LHPU	SN	Fanapanel; MPQX; 161605-73-8; ZK 200775; ZK200775; Fanapanel [INN]; UNII-E3AP71EM0O; ZK-200775; E3AP71EM0O; NCGC00159553-01; [7-morpholin-4-yl-2,3-dioxo-6-(trifluoromethyl)-4H-quinoxalin-1-yl]methylphosphonic acid; DSSTox_RID_81332; DSSTox_CID_26093; DSSTox_GSID_46093; ((3,4-Dihydro-7-morpholino-2,3-dioxo-6-(trifluoromethyl)-1(2H)-quinoxalinyl)methyl)phosphonic acid; {[7-Morpholin-4-Yl-2,3-Dioxo-6-(Trifluoromethyl)-3,4-Dihydroquinoxalin-1(2h)-Yl]methyl}phosphonic Acid; CAS-161605-73-8; C14H15F3N3O6P; ZK1; AC1L4LOG; AC1Q6RR4
DM2LHPU	DT	Small molecular drug
DM2LHPU	PC	208953
DM2LHPU	MW	409.25
DM2LHPU	FM	C14H15F3N3O6P
DM2LHPU	IC	InChI=1S/C14H15F3N3O6P/c15-14(16,17)8-5-9-11(6-10(8)19-1-3-26-4-2-19)20(7-27(23,24)25)13(22)12(21)18-9/h5-6H,1-4,7H2,(H,18,21)(H2,23,24,25)
DM2LHPU	CS	C1COCCN1C2=CC3=C(C=C2C(F)(F)F)NC(=O)C(=O)N3CP(=O)(O)O
DM2LHPU	IK	WZMQMKNCWDCCMT-UHFFFAOYSA-N
DM2LHPU	IU	[7-morpholin-4-yl-2,3-dioxo-6-(trifluoromethyl)-4H-quinoxalin-1-yl]methylphosphonic acid
DM2LHPU	CA	CAS 161605-73-8
DM2LHPU	DE	Coronary artery disease

DMTNUA4	ID	DMTNUA4
DMTNUA4	DN	ZL-1201
DMTNUA4	HS	Phase 1
DMTNUA4	CP	ZAI Lab
DMTNUA4	DT	Antibody
DMTNUA4	DE	Solid tumour/cancer

DMX6AJ8	ID	DMX6AJ8
DMX6AJ8	DN	ZM-H1505R
DMX6AJ8	HS	Phase 1
DMX6AJ8	CP	Shanghai Zhimeng Biopharma
DMX6AJ8	DT	Small molecular drug
DMX6AJ8	DE	Hepatitis B

DMGTL8Z	ID	DMGTL8Z
DMGTL8Z	DN	ZP-1848
DMGTL8Z	HS	Phase 1
DMGTL8Z	SN	Glucagon-like peptide-2 analog (inflammatory bowel disease/ Crohn's disease), Zealand
DMGTL8Z	CP	Zealand Pharma A/S
DMGTL8Z	DE	Inflammatory bowel disease

DMRVDUM	ID	DMRVDUM
DMRVDUM	DN	ZP2929
DMRVDUM	HS	Phase 1
DMRVDUM	CP	Zealand Pharma A/S
DMRVDUM	DE	Diabetic complication; Obesity; Type-1 diabetes

DMVIMQX	ID	DMVIMQX
DMVIMQX	DN	ZSTK474
DMVIMQX	HS	Phase 1
DMVIMQX	SN	ZSTK474; 475110-96-4; ZSTK-474; 4,4'-(6-(2-(Difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazine-2,4-diyl)dimorpholine; ZSTK 474; TCMDC-137004; UNII-K0068GK39A; CHEMBL586702; CHEBI:90545; K0068GK39A; 2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine; 2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine; AK-40326; 2-(Difluoromethyl)-1-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)-1h-Benzimidazole; C19H21F2N7O2; 2wxl; PubChem22461; SCHEMBL373282; QCR-72; GTPL7965; CTK8B6247; SYN1099
DMVIMQX	TC	Anticancer Agents
DMVIMQX	DT	Small molecular drug
DMVIMQX	PC	11647372
DMVIMQX	MW	417.4
DMVIMQX	FM	C19H21F2N7O2
DMVIMQX	IC	InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2
DMVIMQX	CS	C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5
DMVIMQX	IK	HGVNLRPZOWWDKD-UHFFFAOYSA-N
DMVIMQX	IU	4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine
DMVIMQX	CA	CAS 475110-96-4
DMVIMQX	CB	CHEBI:90545
DMVIMQX	DE	Solid tumour/cancer

DMO2WYX	ID	DMO2WYX
DMO2WYX	DN	ZT-1
DMO2WYX	HS	Phase 1
DMO2WYX	SN	(5R,9R)-5-(5-Chloro-2-hydroxy-3-methoxybenzylideneamino)-11-ethylidene-7-methyl-1,2,5,6,9,10-hexahydro-5,9-methanocycloocta[b]pyridin-2-one; 180694-97-7
DMO2WYX	DT	Small molecular drug
DMO2WYX	PC	135543744
DMO2WYX	MW	410.9
DMO2WYX	FM	C23H23ClN2O3
DMO2WYX	IC	InChI=1S/C23H23ClN2O3/c1-4-17-14-7-13(2)11-23(17,18-5-6-21(27)26-19(18)9-14)25-12-15-8-16(24)10-20(29-3)22(15)28/h4-8,10,12,14,28H,9,11H2,1-3H3,(H,26,27)/b17-4+,25-12?/t14-,23+/m0/s1
DMO2WYX	CS	C/C=C/1\\[C@@H]2CC3=C([C@]1(CC(=C2)C)N=CC4=C(C(=CC(=C4)Cl)OC)O)C=CC(=O)N3
DMO2WYX	IK	UYRWZANUXPUEPQ-OWNLDCJBSA-N
DMO2WYX	IU	(1R,9R,13E)-1-[(5-chloro-2-hydroxy-3-methoxyphenyl)methylideneamino]-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one
DMO2WYX	CA	CAS 180694-97-7
DMO2WYX	DE	Parkinson disease

DMAU8L9	ID	DMAU8L9
DMAU8L9	DN	ZW49
DMAU8L9	HS	Phase 1
DMAU8L9	CP	Zymeworks
DMAU8L9	DT	Antibody drug conjugate
DMAU8L9	DE	Solid tumour/cancer

DMSLPTO	ID	DMSLPTO
DMSLPTO	DN	ZY01
DMSLPTO	HS	Phase 1
DMSLPTO	CP	Zydus Cadila Group
DMSLPTO	DE	Diabetic complication; Obesity

DM796RI	ID	DM796RI
DM796RI	DN	ZYAN1
DM796RI	HS	Phase 1
DM796RI	SN	Desidustat; 1616690-16-4; UNII-Y962PQA4KS; Y962PQA4KS; 1,2-dihydroquinoline-3-carbonyl]glycine; N-[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-; 2-(1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)acetic acid; ZYAN1 compound; Desidustat [INN]; SCHEMBL15846922; BCP29692; EX-A2999; s9699; ZB1514; CS-8034; BS-16050; HY-103227; A16921; 2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid; Glycine, N-((1-(cyclopropylmethoxy)-1,2-dihydro-4-hydroxy-2-oxo-3-quinolinyl)carbonyl)-; N-(1-(Cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine
DM796RI	CP	Zydus Cadila
DM796RI	DT	Small molecular drug
DM796RI	PC	75593290
DM796RI	MW	332.31
DM796RI	FM	C16H16N2O6
DM796RI	IC	InChI=1S/C16H16N2O6/c19-12(20)7-17-15(22)13-14(21)10-3-1-2-4-11(10)18(16(13)23)24-8-9-5-6-9/h1-4,9,21H,5-8H2,(H,17,22)(H,19,20)
DM796RI	CS	C1CC1CON2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O
DM796RI	IK	IKRKQQLJYBAPQT-UHFFFAOYSA-N
DM796RI	IU	2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid
DM796RI	CA	CAS 1616690-16-4
DM796RI	DE	Anaemia

DMU2D0B	ID	DMU2D0B
DMU2D0B	DN	ZYDPLA 1
DMU2D0B	HS	Phase 1
DMU2D0B	CP	Cadila Healthcare Gujarat, India
DMU2D0B	DE	Type-2 diabetes

DM4IG16	ID	DM4IG16
DM4IG16	DN	ZYGK-1
DM4IG16	HS	Phase 1
DM4IG16	SN	Glucokinase activator (oral, diabetes), Zydus-Cadila
DM4IG16	CP	Zydus-Cadila Group
DM4IG16	DE	Diabetic complication

DMZ6042	ID	DMZ6042
DMZ6042	DN	ZYOG1
DMZ6042	HS	Phase 1
DMZ6042	CP	Zydus Cadila Group
DMZ6042	DE	Diabetic complication

DM1XOZK	ID	DM1XOZK
DM1XOZK	DN	ZYT-1
DM1XOZK	HS	Phase 1
DM1XOZK	SN	Lipid lowering molecule (dyslipidemia), Zydus-Cadila
DM1XOZK	CP	Zydus-Cadila Group
DM1XOZK	DE	Lipid metabolism disorder

DMX1ZQV	ID	DMX1ZQV
DMX1ZQV	DN	(S)-DRF-1042
DMX1ZQV	HS	Clinical trial
DMX1ZQV	SN	5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT
DMX1ZQV	DT	Small molecular drug
DMX1ZQV	PC	91623363
DMX1ZQV	MW	408.4
DMX1ZQV	FM	C22H20N2O6
DMX1ZQV	IC	InChI=1S/C22H20N2O6/c1-2-22(28)11-13-10-16-17-14(9-12-5-3-4-6-15(12)23-17)20(29-8-7-25)24(16)19(26)18(13)30-21(22)27/h3-6,9-10,20,25,28H,2,7-8,11H2,1H3/t20-,22-/m0/s1
DMX1ZQV	CS	CC[C@@]1(CC2=C(C(=O)N3[C@H](C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)OC1=O)O
DMX1ZQV	IK	UPAYPYZHFCRCMO-UNMCSNQZSA-N
DMX1ZQV	IU	(12S,18S)-18-ethyl-18-hydroxy-12-(2-hydroxyethoxy)-16-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,17-dione
DMX1ZQV	DE	Bladder cancer

DMN2I3P	ID	DMN2I3P
DMN2I3P	DN	alpha-ketothiazole analogue 36
DMN2I3P	HS	Clinical trial
DMN2I3P	SN	alpha-ketothiazole analogue 36; GTPL6549; CHEMBL273653; BDBM12976; (2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide
DMN2I3P	DT	Small molecular drug
DMN2I3P	PC	16098914
DMN2I3P	MW	723.7
DMN2I3P	FM	C29H43BrN10O5S
DMN2I3P	IC	InChI=1S/C29H43BrN10O5S/c1-16(2)22(25(43)38-20(6-4-12-35-27(31)32)23(41)26-34-14-15-46-26)40-24(42)21(7-5-13-36-28(33)44)39-29(45)37-17(3)18-8-10-19(30)11-9-18/h8-11,14-17,20-22H,4-7,12-13H2,1-3H3,(H,38,43)(H,40,42)(H4,31,32,35)(H3,33,36,44)(H2,37,39,45)/t17-,20+,21+,22+/m1/s1
DMN2I3P	CS	C[C@H](C1=CC=C(C=C1)Br)NC(=O)N[C@@H](CCCNC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)C2=NC=CS2
DMN2I3P	IK	BGBJLVHKOHYLME-MNAPGUCWSA-N
DMN2I3P	IU	(2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide
DMN2I3P	DE	Alzheimer disease

DM6NVPT	ID	DM6NVPT
DM6NVPT	DN	Anti-CD19 Chimeric Antigen Receptor T Cells
DM6NVPT	HS	Clinical trial
DM6NVPT	CP	National Taiwan University Hospital
DM6NVPT	DT	CAR T Cell Therapy
DM6NVPT	DE	leukaemia

DM3M9OY	ID	DM3M9OY
DM3M9OY	DN	Anti-CD19/20-CAR vector-transduced T cells
DM3M9OY	HS	Clinical trial
DM3M9OY	CP	Chinese PLA General Hospital
DM3M9OY	DT	CAR T Cell Therapy (Dual specific)
DM3M9OY	DE	Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Prolymphocytic leukaemia

DMGPTFL	ID	DMGPTFL
DMGPTFL	DN	AZ-4217
DMGPTFL	HS	Clinical trial
DMGPTFL	SN	AZ4217; AZ 4217
DMGPTFL	DT	Small molecular drug
DMGPTFL	PC	57406537
DMGPTFL	MW	476.5
DMGPTFL	FM	C30H25FN4O
DMGPTFL	IC	InChI=1S/C30H25FN4O/c1-4-8-20-14-22(17-33-16-20)21-9-6-10-23(15-21)30(24-13-19(3)29(36)35(5-2)18-24)25-11-7-12-26(31)27(25)28(32)34-30/h6-7,9-18H,5H2,1-3H3,(H2,32,34)/t30-/m0/s1
DMGPTFL	CS	CCN1C=C(C=C(C1=O)C)[C@]2(C3=C(C(=CC=C3)F)C(=N2)N)C4=CC=CC(=C4)C5=CN=CC(=C5)C#CC
DMGPTFL	IK	TUGLMYZSOPKJOA-PMERELPUSA-N
DMGPTFL	IU	5-[(1R)-3-amino-4-fluoro-1-[3-(5-prop-1-ynylpyridin-3-yl)phenyl]isoindol-1-yl]-1-ethyl-3-methylpyridin-2-one
DMGPTFL	DE	Rheumatoid arthritis

DMCEPKM	ID	DMCEPKM
DMCEPKM	DN	BCMA-CART
DMCEPKM	HS	Clinical trial
DMCEPKM	CP	Shanghai Bioray Laboratory Inc.
DMCEPKM	DT	CAR T Cell Therapy
DMCEPKM	DE	Multiple myeloma

DMWXGRQ	ID	DMWXGRQ
DMWXGRQ	DN	BCMA-UCART
DMWXGRQ	HS	Clinical trial
DMWXGRQ	CP	Shanghai Bioray Laboratory Inc.
DMWXGRQ	DT	CAR T Cell Therapy
DMWXGRQ	DE	Multiple myeloma

DM531SA	ID	DM531SA
DM531SA	DN	bimatoprost (free acid form)
DM531SA	HS	Clinical trial
DM531SA	SN	17-phenyl-omega-trinor-PGF2alpha
DM531SA	DT	Small molecular drug
DM531SA	PC	5283081
DM531SA	MW	388.5
DM531SA	FM	C23H32O5
DM531SA	IC	InChI=1S/C23H32O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,14-15,18-22,24-26H,2,7,10-13,16H2,(H,27,28)/b6-1-,15-14+/t18-,19+,20+,21-,22+/m0/s1
DM531SA	CS	C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](CCC2=CC=CC=C2)O)C/C=C\\CCCC(=O)O)O
DM531SA	IK	YFHHIZGZVLHBQZ-KDACTHKWSA-N
DM531SA	IU	(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]hept-5-enoic acid
DM531SA	CA	CAS 38344-08-0
DM531SA	CB	CHEBI:73773
DM531SA	DE	Alzheimer disease

DMN2EI1	ID	DMN2EI1
DMN2EI1	DN	bis-triazole derivative 10
DMN2EI1	HS	Clinical trial
DMN2EI1	SN	CHEMBL2016873; bis-triazole derivative 10; GTPL6537; SCHEMBL15308834
DMN2EI1	DT	Small molecular drug
DMN2EI1	PC	56599309
DMN2EI1	MW	681.8
DMN2EI1	FM	C33H35N11O4S
DMN2EI1	IC	InChI=1S/C33H35N11O4S/c34-31(35)26-11-9-22(10-12-26)16-36-32(45)29-14-27-19-43(41-38-27)17-24-7-4-8-25(13-24)18-44-20-28(39-42-44)15-30(33(46)37-29)40-49(47,48)21-23-5-2-1-3-6-23/h1-13,19-20,29-30,40H,14-18,21H2,(H3,34,35)(H,36,45)(H,37,46)/t29-,30+/m0/s1
DMN2EI1	CS	C1[C@H](C(=O)N[C@@H](CC2=CN(CC3=CC=CC(=C3)CN4C=C1N=N4)N=N2)C(=O)NCC5=CC=C(C=C5)C(=N)N)NS(=O)(=O)CC6=CC=CC=C6
DMN2EI1	IK	BKSCOHJNKDJECO-XZWHSSHBSA-N
DMN2EI1	IU	(8S,11R)-11-(benzylsulfonylamino)-N-[(4-carbamimidoylphenyl)methyl]-10-oxo-3,4,5,9,14,15,16-heptazatetracyclo[16.3.1.13,6.113,16]tetracosa-1(21),4,6(24),13(23),14,18(22),19-heptaene-8-carboxamide
DMN2EI1	DE	Otitis media

DMLF2UY	ID	DMLF2UY
DMLF2UY	DN	CAR-BCMA T cell
DMLF2UY	HS	Clinical trial
DMLF2UY	CP	Kang YU
DMLF2UY	DT	CAR T Cell Therapy
DMLF2UY	DE	Multiple myeloma

DMXU2D1	ID	DMXU2D1
DMXU2D1	DN	CAR-CD19 T cell
DMXU2D1	HS	Clinical trial
DMXU2D1	CP	Kang YU
DMXU2D1	DT	CAR T Cell Therapy
DMXU2D1	DE	B-cell lymphoma; leukaemia

DM6ZHTV	ID	DM6ZHTV
DM6ZHTV	DN	CAR-CLD18 T cell
DM6ZHTV	HS	Clinical trial
DM6ZHTV	CP	Kang YU
DM6ZHTV	DT	CAR T Cell Therapy
DM6ZHTV	DE	Adenocarcinoma; Pancreatic cancer

DMBDT3V	ID	DMBDT3V
DMBDT3V	DN	CAR-GPC3 T cell
DMBDT3V	HS	Clinical trial
DMBDT3V	CP	Kang YU
DMBDT3V	DT	CAR T Cell Therapy
DMBDT3V	DE	Hepatocellular carcinoma

DM0RX5E	ID	DM0RX5E
DM0RX5E	DN	CAR-GPC3 T cells
DM0RX5E	HS	Clinical trial
DM0RX5E	CP	RenJi Hospital
DM0RX5E	DT	CAR T Cell Therapy
DM0RX5E	DE	Hepatocellular carcinoma

DMGW10M	ID	DMGW10M
DMGW10M	DN	CAR-T cells targeting BCMA
DMGW10M	HS	Clinical trial
DMGW10M	CP	Zhujiang Hospital
DMGW10M	DT	CAR T Cell Therapy
DMGW10M	DE	Multiple myeloma

DMHBQYU	ID	DMHBQYU
DMHBQYU	DN	CAR-T cells targeting CD138
DMHBQYU	HS	Clinical trial
DMHBQYU	CP	Zhujiang Hospital
DMHBQYU	DT	CAR T Cell Therapy
DMHBQYU	DE	Multiple myeloma

DMH5C37	ID	DMH5C37
DMH5C37	DN	CAR-T cells targeting CD38
DMH5C37	HS	Clinical trial
DMH5C37	CP	Zhujiang Hospital
DMH5C37	DT	CAR T Cell Therapy
DMH5C37	DE	Multiple myeloma; Acute myeloid leukaemia

DMAK1ME	ID	DMAK1ME
DMAK1ME	DN	CAR-T cells targeting CD56
DMAK1ME	HS	Clinical trial
DMAK1ME	CP	Zhujiang Hospital
DMAK1ME	DT	CAR T Cell Therapy
DMAK1ME	DE	Multiple myeloma; Acute myeloid leukaemia

DMUEQ6C	ID	DMUEQ6C
DMUEQ6C	DN	CART-meso cells
DMUEQ6C	HS	Clinical trial
DMUEQ6C	CP	Shenzhen BinDeBio Ltd.
DMUEQ6C	DT	CAR T Cell Therapy
DMUEQ6C	DE	Pancreatic cancer

DM2V6R7	ID	DM2V6R7
DM2V6R7	DN	CD19-CAR T Cells
DM2V6R7	HS	Clinical trial
DM2V6R7	CP	First Affiliated Hospital of Harbin Medical University
DM2V6R7	DT	CAR T Cell Therapy
DM2V6R7	DE	Acute lymphoblastic leukaemia

DMF936G	ID	DMF936G
DMF936G	DN	CD19CART
DMF936G	HS	Clinical trial
DMF936G	CP	Innovative Cellular Therapeutics Co., Ltd.
DMF936G	DT	CAR T Cell Therapy
DMF936G	DE	B-cell lymphoma; leukaemia

DMLPAFG	ID	DMLPAFG
DMLPAFG	DN	CD19-targeted CAR-T cells
DMLPAFG	HS	Clinical trial
DMLPAFG	CP	Qingdao Central Hospital
DMLPAFG	DT	CAR T Cell Therapy
DMLPAFG	DE	leukaemia

DMS87UT	ID	DMS87UT
DMS87UT	DN	CD19-targeted CAR-T cells
DMS87UT	HS	Clinical trial
DMS87UT	CP	Sinobioway Cell Therapy Co., Ltd.
DMS87UT	DT	CAR T Cell Therapy
DMS87UT	DE	leukaemia; Lymphoma

DM8VTF2	ID	DM8VTF2
DM8VTF2	DN	CD19-UCART
DM8VTF2	HS	Clinical trial
DM8VTF2	CP	Shanghai Bioray Laboratory Inc.
DM8VTF2	DT	CAR T Cell Therapy
DM8VTF2	DE	Acute lymphoblastic leukaemia; Non-hodgkin lymphoma

DMXM19W	ID	DMXM19W
DMXM19W	DN	dequalinium
DMXM19W	HS	Clinical trial
DMXM19W	SN	dequalinium; Dequadin; 6707-58-0; UNII-E7QC7V26B8; Dequavagyn; Decamine; Labosept; Sorot; GNF-Pf-5483; E7QC7V26B8; CHEBI:41872; Polycidine; Dequavet; Dekadin; Rumilet; Dekamin; Sentril; Sanoral; Oralgol; Ivazil; Dequadin chloride; Dequalin chloride; C30H40N4; DEQ; 1,1'-decane-1,10-diylbis(4-amino-2-methylquinolinium); Solvidont; Quinolinium, 1,1'-(1,10-decanediyl)bis(4-amino-2-methyl-; 1-[10-(4-amino-2-methylquinolyl)decyl]-2-methyl-4-quinolylamine; CHEMBL121663
DMXM19W	DT	Small molecular drug
DMXM19W	PC	2993
DMXM19W	MW	456.7
DMXM19W	FM	C30H40N4+2
DMXM19W	IC	InChI=1S/C30H38N4/c1-23-21-27(31)25-15-9-11-17-29(25)33(23)19-13-7-5-3-4-6-8-14-20-34-24(2)22-28(32)26-16-10-12-18-30(26)34/h9-12,15-18,21-22,31-32H,3-8,13-14,19-20H2,1-2H3/p+2
DMXM19W	CS	CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C
DMXM19W	IK	PCSWXVJAIHCTMO-UHFFFAOYSA-P
DMXM19W	IU	1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium-4-amine
DMXM19W	CA	CAS 6707-58-0
DMXM19W	CB	CHEBI:41872
DMXM19W	DE	Myelopathy

DMV6RMB	ID	DMV6RMB
DMV6RMB	DN	EPCAM-targeted CAR-T cells
DMV6RMB	HS	Clinical trial
DMV6RMB	CP	Sinobioway Cell Therapy Co., Ltd.
DMV6RMB	DT	CAR T Cell Therapy
DMV6RMB	DE	Liver cancer; Gastric adenocarcinoma

DM2N653	ID	DM2N653
DM2N653	DN	example 98 (WO2011020806)
DM2N653	HS	Clinical trial
DM2N653	SN	GTPL6540; SCHEMBL1173236; example 98 [WO2011020806]
DM2N653	DT	Small molecular drug
DM2N653	PC	50991498
DM2N653	MW	376.8
DM2N653	FM	C18H18ClFN4O2
DM2N653	IC	InChI=1S/C18H18ClFN4O2/c1-10-5-11(19)7-22-16(10)17(25)23-12-3-4-14(20)13(6-12)18(2)9-26-8-15(21)24-18/h3-7H,8-9H2,1-2H3,(H2,21,24)(H,23,25)/t18-/m0/s1
DM2N653	CS	CC1=CC(=CN=C1C(=O)NC2=CC(=C(C=C2)F)[C@@]3(COCC(=N3)N)C)Cl
DM2N653	IK	RAFVKOLBEOKYJW-SFHVURJKSA-N
DM2N653	IU	N-[3-[(3R)-5-amino-3-methyl-2,6-dihydro-1,4-oxazin-3-yl]-4-fluorophenyl]-5-chloro-3-methylpyridine-2-carboxamide
DM2N653	DE	Focal segmental glomerulosclerosis

DM87BTM	ID	DM87BTM
DM87BTM	DN	GD2-targeted CAR-T cells
DM87BTM	HS	Clinical trial
DM87BTM	CP	Sinobioway Cell Therapy Co., Ltd.
DM87BTM	DT	CAR T Cell Therapy
DM87BTM	DE	Neuroblastoma

DM7W6YN	ID	DM7W6YN
DM7W6YN	DN	GR148672X
DM7W6YN	HS	Clinical trial
DM7W6YN	DT	Small molecular drug
DM7W6YN	PC	135457124
DM7W6YN	MW	340.3
DM7W6YN	FM	C15H11F3N2O2S
DM7W6YN	IC	InChI=1S/C15H11F3N2O2S/c1-9-4-2-5-10(8-9)19-20-12(14(22)15(16,17)18)13(21)11-6-3-7-23-11/h2-8,21H,1H3
DM7W6YN	CS	CC1=CC(=CC=C1)N=NC(=C(C2=CC=CS2)O)C(=O)C(F)(F)F
DM7W6YN	IK	OETQEFUTOKYBSL-UHFFFAOYSA-N
DM7W6YN	IU	1,1,1-trifluoro-4-hydroxy-3-[(3-methylphenyl)diazenyl]-4-thiophen-2-ylbut-3-en-2-one
DM7W6YN	CA	CAS 263890-70-6
DM7W6YN	DE	Acute lymphoblastic leukaemia

DMCV5ND	ID	DMCV5ND
DMCV5ND	DN	GSK-264220A
DMCV5ND	HS	Clinical trial
DMCV5ND	SN	GSK 264220A; 685506-42-7; CHEMBL513349; 3-[2-methyl-5-(piperidine-1-sulfonyl)furan-3-yl]-1-phenylurea; GSK-264220A; AC1MDFFU; AC1Q2G0T; MLS000850100; GTPL6697; SCHEMBL15798229; CTK8F0072; DTXSID30384608; MolPort-001-806-822; HMS2799K10; HMS3648O15; ZINC4324633; 1-(2-methyl-5-piperidin-1-ylsulfonylfuran-3-yl)-3-phenylurea; BDBM50254290; AKOS024457788; MCULE-4804513903; CCG-242835; NCGC00344077-02; SMR000456118; RT-013120; SR-01000774442; SR-01000774442-2; N-[2-methyl-5-(piperidinosulfonyl)-3-furyl]-N'-phenylurea
DMCV5ND	DT	Small molecular drug
DMCV5ND	PC	2810413
DMCV5ND	MW	363.4
DMCV5ND	FM	C17H21N3O4S
DMCV5ND	IC	InChI=1S/C17H21N3O4S/c1-13-15(19-17(21)18-14-8-4-2-5-9-14)12-16(24-13)25(22,23)20-10-6-3-7-11-20/h2,4-5,8-9,12H,3,6-7,10-11H2,1H3,(H2,18,19,21)
DMCV5ND	CS	CC1=C(C=C(O1)S(=O)(=O)N2CCCCC2)NC(=O)NC3=CC=CC=C3
DMCV5ND	IK	LVOVQRPAMXCXTM-UHFFFAOYSA-N
DMCV5ND	IU	1-(2-methyl-5-piperidin-1-ylsulfonylfuran-3-yl)-3-phenylurea
DMCV5ND	CA	CAS 685506-42-7
DMCV5ND	DE	Coagulation defect

DM5I2HL	ID	DM5I2HL
DM5I2HL	DN	GSK269962A
DM5I2HL	HS	Clinical trial
DM5I2HL	SN	GSK-269962A; GSK269962; GSK 269962; GSK-269962; aminofurazanyl-azabenzimidazole 6n
DM5I2HL	DT	Small molecular drug
DM5I2HL	PC	16095342
DM5I2HL	MW	570.6
DM5I2HL	FM	C29H30N8O5
DM5I2HL	IC	InChI=1S/C29H30N8O5/c1-2-37-24-17-25(31-18-23(24)33-28(37)26-27(30)35-42-34-26)41-22-5-3-4-20(16-22)32-29(38)19-6-8-21(9-7-19)40-15-12-36-10-13-39-14-11-36/h3-9,16-18H,2,10-15H2,1H3,(H2,30,35)(H,32,38)
DM5I2HL	CS	CCN1C2=CC(=NC=C2N=C1C3=NON=C3N)OC4=CC=CC(=C4)NC(=O)C5=CC=C(C=C5)OCCN6CCOCC6
DM5I2HL	IK	YOVNFNXUCOWYSG-UHFFFAOYSA-N
DM5I2HL	IU	N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide
DM5I2HL	CA	CAS 925213-63-4
DM5I2HL	DE	Inflammation

DM21Y8J	ID	DM21Y8J
DM21Y8J	DN	isatin sulfonamide 34
DM21Y8J	HS	Clinical trial
DM21Y8J	SN	CHEMBL439753; Isatin Sulfonamide 34; JMC522188 Compound 2; Pyrrolidine Isatin Analogue 2; GTPL6515; SCHEMBL2264739; BDBM10323; PKOUAUWPBMZQCH-FQEVSTJZSA-N; isatin sulfonamide 34 [PMID: 11384246]; (S)-1-Benzyl-5-{1-[2-(phenoxymethyl)pyrrolidinyl]sulfonyl}isatin; (s)-1-benzyl-5-[1-[2-(phenoxymethyl)pyrrolidinyl]sulfonyl]-isatin; 5-[(2S)-2-(phenoxymethyl)pyrrolidin-1-yl]sulfonyl-1-(phenylmethyl)indole-2,3-dione; (S)-1-benzyl-5-(2-phenoxymethyl-pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione
DM21Y8J	DT	Small molecular drug
DM21Y8J	PC	9847835
DM21Y8J	MW	476.5
DM21Y8J	FM	C26H24N2O5S
DM21Y8J	IC	InChI=1S/C26H24N2O5S/c29-25-23-16-22(13-14-24(23)27(26(25)30)17-19-8-3-1-4-9-19)34(31,32)28-15-7-10-20(28)18-33-21-11-5-2-6-12-21/h1-6,8-9,11-14,16,20H,7,10,15,17-18H2/t20-/m0/s1
DM21Y8J	CS	C1C[C@H](N(C1)S(=O)(=O)C2=CC3=C(C=C2)N(C(=O)C3=O)CC4=CC=CC=C4)COC5=CC=CC=C5
DM21Y8J	IK	PKOUAUWPBMZQCH-FQEVSTJZSA-N
DM21Y8J	IU	1-benzyl-5-[(2S)-2-(phenoxymethyl)pyrrolidin-1-yl]sulfonylindole-2,3-dione
DM21Y8J	DE	Cystic fibrosis

DMDU6GN	ID	DMDU6GN
DMDU6GN	DN	JNJ-479655
DMDU6GN	HS	Clinical trial
DMDU6GN	SN	1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, &gt; Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide
DMDU6GN	DT	Small molecular drug
DMDU6GN	PC	66553218
DMDU6GN	MW	488.6
DMDU6GN	FM	C28H32N4O2S
DMDU6GN	IC	InChI=1S/C28H32N4O2S/c33-26(25-12-7-15-29-27(25)35-24-10-5-2-6-11-24)30-22-28(13-20-34-21-14-28)32-18-16-31(17-19-32)23-8-3-1-4-9-23/h1-12,15H,13-14,16-22H2,(H,30,33)
DMDU6GN	CS	C1COCCC1(CNC(=O)C2=C(N=CC=C2)SC3=CC=CC=C3)N4CCN(CC4)C5=CC=CC=C5
DMDU6GN	IK	XREFXUCWSYMIOG-UHFFFAOYSA-N
DMDU6GN	IU	N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide
DMDU6GN	DE	Alzheimer disease

DM2NZ6K	ID	DM2NZ6K
DM2NZ6K	DN	KGP94
DM2NZ6K	HS	Clinical trial
DM2NZ6K	SN	CHEMBL1269632; BDBM50330030
DM2NZ6K	DT	Small molecular drug
DM2NZ6K	PC	25234575
DM2NZ6K	MW	350.24
DM2NZ6K	FM	C14H12BrN3OS
DM2NZ6K	IC	InChI=1S/C14H12BrN3OS/c15-11-5-1-3-9(7-11)13(17-18-14(16)20)10-4-2-6-12(19)8-10/h1-8,19H,(H3,16,18,20)/b17-13+
DM2NZ6K	CS	C1=CC(=CC(=C1)O)/C(=N/NC(=S)N)/C2=CC(=CC=C2)Br
DM2NZ6K	IK	ZDBKSZKTCPOBFR-GHRIWEEISA-N
DM2NZ6K	IU	[(Z)-[(3-bromophenyl)-(3-hydroxyphenyl)methylidene]amino]thiourea
DM2NZ6K	DE	Coagulation defect

DMR1NYF	ID	DMR1NYF
DMR1NYF	DN	KH064
DMR1NYF	HS	Clinical trial
DMR1NYF	SN	sPLA2-2A inhibitor,  compound 2b
DMR1NYF	DT	Small molecular drug
DMR1NYF	PC	446400
DMR1NYF	MW	487.6
DMR1NYF	FM	C31H37NO4
DMR1NYF	IC	InChI=1S/C31H37NO4/c33-30(16-10-2-1-5-11-25-12-6-3-7-13-25)32-28(19-22-31(34)35)23-26-17-20-29(21-18-26)36-24-27-14-8-4-9-15-27/h3-4,6-9,12-15,17-18,20-21,28H,1-2,5,10-11,16,19,22-24H2,(H,32,33)(H,34,35)/t28-/m0/s1
DMR1NYF	CS	C1=CC=C(C=C1)CCCCCCC(=O)N[C@@H](CCC(=O)O)CC2=CC=C(C=C2)OCC3=CC=CC=C3
DMR1NYF	IK	KWLUIYFCMHKLKY-NDEPHWFRSA-N
DMR1NYF	IU	(4S)-4-(7-phenylheptanoylamino)-5-(4-phenylmethoxyphenyl)pentanoic acid
DMR1NYF	CA	CAS 393569-31-8
DMR1NYF	DE	Breast cancer

DMWA5XP	ID	DMWA5XP
DMWA5XP	DN	KU-60019
DMWA5XP	HS	Clinical trial
DMWA5XP	SN	KU-60019; 925701-49-1; ku60019; 925701-46-8; KU 60019; UNII-IAN358A69K; IAN358A69K; CHEMBL2140173; 2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-N-[5-(6-morpholin-4-yl-4-oxopyran-2-yl)-9H-thioxanthen-2-yl]acetamide; C30H33N3O5S; 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide; 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-N-{5-[6-(morpholin-4-yl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl}acetamide; MLS006011020; cc-509; SCHEMBL3681453; GTPL8041; EX-A658; DTXSID00580453; AOB3627
DMWA5XP	DT	Small molecular drug
DMWA5XP	PC	15953870
DMWA5XP	MW	547.7
DMWA5XP	FM	C30H33N3O5S
DMWA5XP	IC	InChI=1S/C30H33N3O5S/c1-19-16-32(17-20(2)37-19)18-28(35)31-23-6-7-27-22(13-23)12-21-4-3-5-25(30(21)39-27)26-14-24(34)15-29(38-26)33-8-10-36-11-9-33/h3-7,13-15,19-20H,8-12,16-18H2,1-2H3,(H,31,35)/t19-,20+
DMWA5XP	CS	C[C@@H]1CN(C[C@@H](O1)C)CC(=O)NC2=CC3=C(C=C2)SC4=C(C3)C=CC=C4C5=CC(=O)C=C(O5)N6CCOCC6
DMWA5XP	IK	SCELLOWTHJGVIC-BGYRXZFFSA-N
DMWA5XP	IU	2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-N-[5-(6-morpholin-4-yl-4-oxopyran-2-yl)-9H-thioxanthen-2-yl]acetamide
DMWA5XP	CA	CAS 925701-49-1
DMWA5XP	DE	Non-small-cell lung cancer

DMCMOS8	ID	DMCMOS8
DMCMOS8	DN	L-Cysteine
DMCMOS8	HS	Clinical trial
DMCMOS8	SN	52-90-4; Cystein; Half-cystine; (R)-Cysteine; Thioserine; (R)-2-Amino-3-mercaptopropanoic acid; L-(+)-Cysteine; L-Cystein; (2R)-2-amino-3-sulfanylpropanoic acid; beta-Mercaptoalanine; Half cystine; FREE CYSTEINE; Cysteine, L-; L-Cys; L-Alanine, 3-mercapto-; L-Zystein; H-Cys-OH; Cisteinum [Latin]; L-2-Amino-3-mercaptopropionic acid; Cisteina [Spanish]; cisteina; Polycysteine; Cysteinum; Cisteinum; (R)-2-Amino-3-mercaptopropionic acid; L Cysteine; alpha-Amino-beta-thiolpropionic acid; L-2-Amino-3-mercaptopropanoic a
DMCMOS8	DT	Small molecular drug
DMCMOS8	PC	5862
DMCMOS8	MW	121.16
DMCMOS8	FM	C3H7NO2S
DMCMOS8	IC	InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1
DMCMOS8	CS	C([C@@H](C(=O)O)N)S
DMCMOS8	IK	XUJNEKJLAYXESH-REOHCLBHSA-N
DMCMOS8	IU	(2R)-2-amino-3-sulfanylpropanoic acid
DMCMOS8	CA	CAS 52-90-4
DMCMOS8	CB	CHEBI:17561
DMCMOS8	DE	Non-small-cell lung cancer

DMW15TC	ID	DMW15TC
DMW15TC	DN	methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate
DMW15TC	HS	Clinical trial
DMW15TC	SN	MLS001003740; SMR000347588; methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate; AC1M4T6W; Oprea1_530669; Oprea1_180448; GTPL6553; SCHEMBL14688402; CHEMBL1595992; cid_2314952; BDBM33902; CHEBI:109731; HMS2702F21; methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate; AB00577675-02; SR-01000028101; SR-01000028101-1; 3-[[(4-tert-butylphenyl)-oxomethyl]amino]-1H-1,2,4-triazole-5-carboxylic acid methyl ester; methyl 3-[(4-tert-butylphenyl)carbonylamino]-1H-1,2,4-triazole-5-carboxylate
DMW15TC	DT	Small molecular drug
DMW15TC	PC	2314952
DMW15TC	MW	302.33
DMW15TC	FM	C15H18N4O3
DMW15TC	IC	InChI=1S/C15H18N4O3/c1-15(2,3)10-7-5-9(6-8-10)12(20)17-14-16-11(18-19-14)13(21)22-4/h5-8H,1-4H3,(H2,16,17,18,19,20)
DMW15TC	CS	CC(C)(C)C1=CC=C(C=C1)C(=O)NC2=NNC(=N2)C(=O)OC
DMW15TC	IK	LVKKWCOINMSBPK-UHFFFAOYSA-N
DMW15TC	IU	methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate
DMW15TC	CA	CAS 326618-93-3
DMW15TC	CB	CHEBI:109731
DMW15TC	DE	Alzheimer disease

DMAPV6J	ID	DMAPV6J
DMAPV6J	DN	MK-0249
DMAPV6J	HS	Clinical trial
DMAPV6J	SN	MK 0249; MK0249
DMAPV6J	DT	Small molecular drug
DMAPV6J	PC	11697697
DMAPV6J	MW	431.4
DMAPV6J	FM	C23H24F3N3O2
DMAPV6J	IC	InChI=1S/C23H24F3N3O2/c1-16-27-20-7-4-6-19(23(24,25)26)21(20)22(30)29(16)17-8-10-18(11-9-17)31-15-5-14-28-12-2-3-13-28/h4,6-11H,2-3,5,12-15H2,1H3
DMAPV6J	CS	CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OCCCN4CCCC4)C(F)(F)F
DMAPV6J	IK	DDDZBLNULGDPGA-UHFFFAOYSA-N
DMAPV6J	IU	2-methyl-3-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-5-(trifluoromethyl)quinazolin-4-one
DMAPV6J	CA	CAS 1167574-41-5
DMAPV6J	DE	Insulin-resistant disorder

DM3ADQW	ID	DM3ADQW
DM3ADQW	DN	NIA-114
DM3ADQW	HS	Clinical trial
DM3ADQW	CP	Niadyne Pharma Fort Worth, TX
DM3ADQW	DE	Plaque psoriasis

DMXFI90	ID	DMXFI90
DMXFI90	DN	oxazine 89
DMXFI90	HS	Clinical trial
DMXFI90	SN	CHEMBL2347208; N-{3-[(4s,6s)-2-Amino-4-Methyl-6-(Trifluoromethyl)-5,6-Dihydro-4h-1,3-Oxazin-4-Yl]-4-Fluorophenyl}-5-Cyanopyridine-2-Carboxamide; oxazine 89; GTPL6944; SCHEMBL15991481; BDBM50432601; 1HL
DMXFI90	DT	Small molecular drug
DMXFI90	PC	71305058
DMXFI90	MW	421.3
DMXFI90	FM	C19H15F4N5O2
DMXFI90	IC	InChI=1S/C19H15F4N5O2/c1-18(7-15(19(21,22)23)30-17(25)28-18)12-6-11(3-4-13(12)20)27-16(29)14-5-2-10(8-24)9-26-14/h2-6,9,15H,7H2,1H3,(H2,25,28)(H,27,29)/t15-,18-/m0/s1
DMXFI90	CS	C[C@]1(C[C@H](OC(=N1)N)C(F)(F)F)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F
DMXFI90	IK	MELQHVBGGSKVJQ-YJBOKZPZSA-N
DMXFI90	IU	N-[3-[(4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
DMXFI90	DE	Diabetic nephropathy

DMO0892	ID	DMO0892
DMO0892	DN	PF-4708671
DMO0892	HS	Clinical trial
DMO0892	SN	PF4708671; PF 4708671
DMO0892	DT	Small molecular drug
DMO0892	PC	51371303
DMO0892	MW	390.4
DMO0892	FM	C19H21F3N6
DMO0892	IC	InChI=1S/C19H21F3N6/c1-2-13-10-23-12-24-18(13)28-7-5-27(6-8-28)11-17-25-15-4-3-14(19(20,21)22)9-16(15)26-17/h3-4,9-10,12H,2,5-8,11H2,1H3,(H,25,26)
DMO0892	CS	CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F
DMO0892	IK	FBLPQCAQRNSVHB-UHFFFAOYSA-N
DMO0892	IU	2-[[4-(5-ethylpyrimidin-4-yl)piperazin-1-yl]methyl]-6-(trifluoromethyl)-1H-benzimidazole
DMO0892	CA	CAS 1255517-76-0
DMO0892	DE	Ulcerative colitis

DM4XAU7	ID	DM4XAU7
DM4XAU7	DN	PGF2alpha
DM4XAU7	HS	Clinical trial
DM4XAU7	SN	Amoglandin; Cerviprost; Cyclosin; Enzaprost; Panacelan; prostaglandin F2alpha
DM4XAU7	DT	Small molecular drug
DM4XAU7	PC	5280363
DM4XAU7	MW	354.5
DM4XAU7	FM	C20H34O5
DM4XAU7	IC	InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
DM4XAU7	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O
DM4XAU7	IK	PXGPLTODNUVGFL-YNNPMVKQSA-N
DM4XAU7	IU	(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
DM4XAU7	CA	CAS 551-11-1
DM4XAU7	CB	CHEBI:15553
DM4XAU7	DE	Solid tumour/cancer

DMXE0F2	ID	DMXE0F2
DMXE0F2	DN	PMID10498202C1
DMXE0F2	HS	Clinical trial
DMXE0F2	SN	4oc6; GTPL6541; BDBM50080960
DMXE0F2	DT	Small molecular drug
DMXE0F2	PC	9876120
DMXE0F2	MW	889.6
DMXE0F2	FM	C44H40BrCl2N3O8
DMXE0F2	IC	InChI=1S/C44H40BrCl2N3O8/c1-56-39-24-34(35(45)25-40(39)57-2)42(53)48-37(22-27-9-8-12-31(21-27)58-30-10-4-3-5-11-30)38(51)26-49(19-17-28-15-16-29(46)23-36(28)47)41(52)18-20-50-43(54)32-13-6-7-14-33(32)44(50)55/h3-16,21,23-25,37-38,51H,17-20,22,26H2,1-2H3,(H,48,53)/t37-,38-/m0/s1
DMXE0F2	CS	COC1=C(C=C(C(=C1)C(=O)N[C@@H](CC2=CC(=CC=C2)OC3=CC=CC=C3)[C@H](CN(CCC4=C(C=C(C=C4)Cl)Cl)C(=O)CCN5C(=O)C6=CC=CC=C6C5=O)O)Br)OC
DMXE0F2	IK	DQHKQRXAVNDAFY-UWXQCODUSA-N
DMXE0F2	IU	2-bromo-N-[(2S,3S)-4-[2-(2,4-dichlorophenyl)ethyl-[3-(1,3-dioxoisoindol-2-yl)propanoyl]amino]-3-hydroxy-1-(3-phenoxyphenyl)butan-2-yl]-4,5-dimethoxybenzamide
DMXE0F2	DE	Multiple sclerosis

DMJGFLD	ID	DMJGFLD
DMJGFLD	DN	PMID15026062C41
DMJGFLD	HS	Clinical trial
DMJGFLD	SN	GTPL6702; BDBM50142719
DMJGFLD	DT	Small molecular drug
DMJGFLD	PC	10453818
DMJGFLD	MW	403.5
DMJGFLD	FM	C22H33N3O4
DMJGFLD	IC	InChI=1S/C22H33N3O4/c1-22(2,3)17-6-4-16(5-7-17)20(26)23-18-8-10-19(11-9-18)29-21(27)24-25-12-14-28-15-13-25/h8-11,16-17H,4-7,12-15H2,1-3H3,(H,23,26)(H,24,27)
DMJGFLD	CS	CC(C)(C)C1CCC(CC1)C(=O)NC2=CC=C(C=C2)OC(=O)NN3CCOCC3
DMJGFLD	IK	XSLDWDIQZLTRHG-UHFFFAOYSA-N
DMJGFLD	IU	[4-[(4-tert-butylcyclohexanecarbonyl)amino]phenyl] N-morpholin-4-ylcarbamate
DMJGFLD	DE	Pancreatitis

DMO1IHL	ID	DMO1IHL
DMO1IHL	DN	PMID17935984C1
DMO1IHL	HS	Clinical trial
DMO1IHL	SN	CHEBI:45030; 1you; AC1LCVYP; GTPL6526; BDBM50224854; DB08388
DMO1IHL	DT	Small molecular drug
DMO1IHL	PC	657061
DMO1IHL	MW	402.4
DMO1IHL	FM	C20H19FN2O6
DMO1IHL	IC	InChI=1S/C20H19FN2O6/c1-2-27-12-11-20(17(24)22-19(26)23-18(20)25)29-16-9-7-15(8-10-16)28-14-5-3-13(21)4-6-14/h3-10H,2,11-12H2,1H3,(H2,22,23,24,25,26)
DMO1IHL	CS	CCOCCC1(C(=O)NC(=O)NC1=O)OC2=CC=C(C=C2)OC3=CC=C(C=C3)F
DMO1IHL	IK	XRSYNYGEEYTXJV-UHFFFAOYSA-N
DMO1IHL	IU	5-(2-ethoxyethyl)-5-[4-(4-fluorophenoxy)phenoxy]-1,3-diazinane-2,4,6-trione
DMO1IHL	CB	CHEBI:45030
DMO1IHL	DE	Pain

DMHPME3	ID	DMHPME3
DMHPME3	DN	PMID18163548C4
DMHPME3	HS	Clinical trial
DMHPME3	SN	7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12
DMHPME3	DT	Small molecular drug
DMHPME3	PC	449051
DMHPME3	MW	477.5
DMHPME3	FM	C21H27N5O6S
DMHPME3	IC	InChI=1S/C21H27N5O6S/c22-19(23)16-8-6-14(7-9-16)10-24-20(29)17(11-27)25-21(30)18(12-28)26-33(31,32)13-15-4-2-1-3-5-15/h1-9,17-18,26-28H,10-13H2,(H3,22,23)(H,24,29)(H,25,30)/t17-,18+/m0/s1
DMHPME3	CS	C1=CC=C(C=C1)CS(=O)(=O)N[C@H](CO)C(=O)N[C@@H](CO)C(=O)NCC2=CC=C(C=C2)C(=N)N
DMHPME3	IK	ZNOKJHWJKULOGM-ZWKOTPCHSA-N
DMHPME3	IU	(2S)-2-[[(2R)-2-(benzylsulfonylamino)-3-hydroxypropanoyl]amino]-N-[(4-carbamimidoylphenyl)methyl]-3-hydroxypropanamide
DMHPME3	DE	Reperfusion injury; Myocardial ischemia

DM5UWH3	ID	DM5UWH3
DM5UWH3	DN	PMID22911925C2
DM5UWH3	HS	Clinical trial
DM5UWH3	SN	compound 37 [PMID: 22468684]; GTPL6950; BDBM50397703; 0K9
DM5UWH3	DT	Small molecular drug
DM5UWH3	PC	60202321
DM5UWH3	MW	592.8
DM5UWH3	FM	C33H44N4O4S
DM5UWH3	IC	InChI=1S/C33H44N4O4S/c1-21(40-5)29(39)37-26(16-22-8-6-9-24(14-22)31-34-12-13-42-31)28(38)20-35-27-18-33(10-7-11-33)41-30-25(27)15-23(19-36-30)17-32(2,3)4/h6,8-9,12-15,19,21,26-28,35,38H,7,10-11,16-18,20H2,1-5H3,(H,37,39)/t21-,26+,27+,28-/m1/s1
DM5UWH3	CS	C[C@H](C(=O)N[C@@H](CC1=CC(=CC=C1)C2=NC=CS2)[C@@H](CN[C@H]3CC4(CCC4)OC5=C3C=C(C=N5)CC(C)(C)C)O)OC
DM5UWH3	IK	IUSARDYWEPUTPN-OZBXUNDUSA-N
DM5UWH3	IU	(2R)-N-[(2S,3R)-4-[[(4S)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide
DM5UWH3	DE	Diabetic complication

DMX1IZ9	ID	DMX1IZ9
DMX1IZ9	DN	PMID23981898C11d 
DMX1IZ9	HS	Clinical trial
DMX1IZ9	SN	GTPL6946; BDBM50440419
DMX1IZ9	DT	Small molecular drug
DMX1IZ9	PC	51003469
DMX1IZ9	MW	560.6
DMX1IZ9	FM	C27H36F4N2O4S
DMX1IZ9	IC	InChI=1S/C27H36F4N2O4S/c1-26(2,3)19-7-5-6-16(9-19)12-33-21-15-38(35)14-18(25(21)34)8-17-10-20(28)24(32)22(11-17)37-23(13-36-4)27(29,30)31/h5-7,9-11,18,21,23,25,33-34H,8,12-15,32H2,1-4H3/t18-,21+,23-,25+,38-/m1/s1
DMX1IZ9	CS	CC(C)(C)C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F
DMX1IZ9	IK	FIUDDEQHPBHZBI-XPLIUGCLSA-N
DMX1IZ9	IU	(1R,3S,4S,5R)-3-[[4-amino-3-fluoro-5-[(2R)-1,1,1-trifluoro-3-methoxypropan-2-yl]oxyphenyl]methyl]-5-[(3-tert-butylphenyl)methylamino]-1-oxothian-4-ol
DMX1IZ9	DE	Cardiovascular disease

DMCM5GK	ID	DMCM5GK
DMCM5GK	DN	TAK-070
DMCM5GK	HS	Clinical trial
DMCM5GK	SN	UNII-PNM9E64544; PNM9E64544; TAK-070; (2R)-N,N-Dimethyl-6-(4-biphenylylmethoxy)-1,2,3,4-tetrahydronaphthalene-2alpha-ethanamine; TAK-070 free base; N,N-dimethyl-2-[(2R)-6-[(4-phenylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]ethanamine; N,N-Dimethyl-2-((2R)-6-((4-phenylphenyl)methoxy)-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine; SCHEMBL361018; GTPL6940; 212571-56-7; J3.229.705F; 2-((2R)-6-(4-Biphenylylmethoxy)-1,2,3,4-tetrahydro-2-naphthalenyl)-N,N-dimethylethanamine; 2-Naphthaleneethanamine, 6-((1,1'-biphenyl)-
DMCM5GK	DT	Small molecular drug
DMCM5GK	PC	23519711
DMCM5GK	MW	440
DMCM5GK	FM	C27H34ClNO2
DMCM5GK	IC	InChI=1S/C27H31NO.ClH.H2O/c1-28(2)17-16-21-8-13-26-19-27(15-14-25(26)18-21)29-20-22-9-11-24(12-10-22)23-6-4-3-5-7-23;;/h3-7,9-12,14-15,19,21H,8,13,16-18,20H2,1-2H3;1H;1H2/t21-;;/m0../s1
DMCM5GK	CS	CN(C)CC[C@@H]1CCC2=C(C1)C=CC(=C2)OCC3=CC=C(C=C3)C4=CC=CC=C4.O.Cl
DMCM5GK	IK	VBMPTAUGUUBFJK-FGJQBABTSA-N
DMCM5GK	IU	N,N-dimethyl-2-[(2R)-6-[(4-phenylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]ethanamine;hydrate;hydrochloride
DMCM5GK	CA	CAS 365276-12-6
DMCM5GK	DE	Solid tumour/cancer

DMGANIC	ID	DMGANIC
DMGANIC	DN	tamatinib
DMGANIC	HS	Clinical trial
DMGANIC	SN	R 406; R-406; R406 free base
DMGANIC	DT	Small molecular drug
DMGANIC	PC	11213558
DMGANIC	MW	470.5
DMGANIC	FM	C22H23FN6O5
DMGANIC	IC	InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)
DMGANIC	CS	CC1(C(=O)NC2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)C
DMGANIC	IK	NHHQJBCNYHBUSI-UHFFFAOYSA-N
DMGANIC	IU	6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
DMGANIC	CA	CAS 841290-80-0
DMGANIC	CB	CHEBI:91348
DMGANIC	DE	Solid tumour/cancer

DMZO6CV	ID	DMZO6CV
DMZO6CV	DN	tiratricol
DMZO6CV	HS	Clinical trial
DMZO6CV	SN	TRIAC; 3,3',5-triiodothyroacetic acid
DMZO6CV	DT	Small molecular drug
DMZO6CV	PC	5803
DMZO6CV	MW	621.93
DMZO6CV	FM	C14H9I3O4
DMZO6CV	IC	InChI=1S/C14H9I3O4/c15-9-6-8(1-2-12(9)18)21-14-10(16)3-7(4-11(14)17)5-13(19)20/h1-4,6,18H,5H2,(H,19,20)
DMZO6CV	CS	C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(=O)O)I)I)O
DMZO6CV	IK	UOWZUVNAGUAEQC-UHFFFAOYSA-N
DMZO6CV	IU	2-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid
DMZO6CV	CA	CAS 51-24-1
DMZO6CV	DE	Wound healing

DMSRK2A	ID	DMSRK2A
DMSRK2A	DN	UK-356202
DMSRK2A	HS	Clinical trial
DMSRK2A	SN	compound 13j [PMID: 15149680]; UK-356,202
DMSRK2A	DT	Small molecular drug
DMSRK2A	PC	9885167
DMSRK2A	MW	340.8
DMSRK2A	FM	C17H13ClN4O2
DMSRK2A	IC	InChI=1S/C17H13ClN4O2/c18-14-8-21-15(22-17(19)20)13-7-10(4-5-12(13)14)9-2-1-3-11(6-9)16(23)24/h1-8H,(H,23,24)(H4,19,20,21,22)
DMSRK2A	CS	C1=CC(=CC(=C1)C(=O)O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl
DMSRK2A	IK	UXNWIRHZMHGOCE-UHFFFAOYSA-N
DMSRK2A	IU	3-[4-chloro-1-(diaminomethylideneamino)isoquinolin-7-yl]benzoic acid
DMSRK2A	CA	CAS 223671-94-1
DMSRK2A	DE	Myocardial hypertrophy

DMOI0TN	ID	DMOI0TN
DMOI0TN	DN	VU0364739
DMOI0TN	HS	Clinical trial
DMOI0TN	SN	VU 0364739
DMOI0TN	DT	Small molecular drug
DMOI0TN	PC	46937439
DMOI0TN	MW	446.5
DMOI0TN	FM	C26H27FN4O2
DMOI0TN	IC	InChI=1S/C26H27FN4O2/c27-22-6-3-7-23(17-22)31-18-29-25(33)26(31)10-13-30(14-11-26)15-12-28-24(32)21-9-8-19-4-1-2-5-20(19)16-21/h1-9,16-17H,10-15,18H2,(H,28,32)(H,29,33)
DMOI0TN	CS	C1CN(CCC12C(=O)NCN2C3=CC(=CC=C3)F)CCNC(=O)C4=CC5=CC=CC=C5C=C4
DMOI0TN	IK	MSTXJJGAXXJCBY-UHFFFAOYSA-N
DMOI0TN	IU	N-[2-[1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]ethyl]naphthalene-2-carboxamide
DMOI0TN	DE	Coagulation defect

DMMLQAS	ID	DMMLQAS
DMMLQAS	DN	(-)-deprenyl
DMMLQAS	HS	Patented
DMMLQAS	CP	BRANDON UNIVERSITY
DMMLQAS	DE	Alopecia

DMGYZQ2	ID	DMGYZQ2
DMGYZQ2	DN	1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1
DMGYZQ2	HS	Patented
DMGYZQ2	SN	PMID25416646-Compound-Figure5-F
DMGYZQ2	CP	KOWA COMPANY, LTD.  MIURA, Toru  YAMADA, Hajime  TAGASHIRA, Junya  WATANABE, Gen
DMGYZQ2	DT	Small molecular drug

DMW5DC1	ID	DMW5DC1
DMW5DC1	DN	1,2,3,4-tetrahydroisoquinoline derivative 1
DMW5DC1	HS	Patented
DMW5DC1	SN	PMID28454500-Compound-61
DMW5DC1	CP	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY THE BROAD INSTITUTE, INC
DMW5DC1	DT	Small molecular drug

DMKHF39	ID	DMKHF39
DMKHF39	DN	1,2,3-triazole derivative 1
DMKHF39	HS	Patented
DMKHF39	SN	PMID26161824-Compound-90
DMKHF39	DT	Small molecular drug
DMKHF39	PC	44571486
DMKHF39	MW	473.2
DMKHF39	FM	C20H17Cl4N3O2
DMKHF39	IC	InChI=1S/C20H17Cl4N3O2/c1-2-3-8-29-18(28)11-27-25-19(14-6-4-12(21)9-16(14)23)20(26-27)15-7-5-13(22)10-17(15)24/h4-7,9-10H,2-3,8,11H2,1H3
DMKHF39	CS	CCCCOC(=O)CN1N=C(C(=N1)C2=C(C=C(C=C2)Cl)Cl)C3=C(C=C(C=C3)Cl)Cl
DMKHF39	IK	JHYLDWFPNBXQGK-UHFFFAOYSA-N
DMKHF39	IU	butyl 2-[4,5-bis(2,4-dichlorophenyl)triazol-2-yl]acetate
DMKHF39	DE	Obesity

DMFR23C	ID	DMFR23C
DMFR23C	DN	1,2,3-triazole derivative 2
DMFR23C	HS	Patented
DMFR23C	SN	PMID26161824-Compound-91
DMFR23C	DT	Small molecular drug
DMFR23C	PC	44571565
DMFR23C	MW	524.2
DMFR23C	FM	C23H15Cl4FN4O
DMFR23C	IC	InChI=1S/C23H15Cl4FN4O/c24-14-3-7-17(19(26)9-14)22-23(18-8-4-15(25)10-20(18)27)31-32(30-22)12-21(33)29-11-13-1-5-16(28)6-2-13/h1-10H,11-12H2,(H,29,33)
DMFR23C	CS	C1=CC(=CC=C1CNC(=O)CN2N=C(C(=N2)C3=C(C=C(C=C3)Cl)Cl)C4=C(C=C(C=C4)Cl)Cl)F
DMFR23C	IK	MDVQABZPIQBGMA-UHFFFAOYSA-N
DMFR23C	IU	2-[4,5-bis(2,4-dichlorophenyl)triazol-2-yl]-N-[(4-fluorophenyl)methyl]acetamide
DMFR23C	DE	Obesity

DMLAYG7	ID	DMLAYG7
DMLAYG7	DN	1,2,4,5-tetra-substituted imidazole derivative 1
DMLAYG7	HS	Patented
DMLAYG7	SN	PMID26161824-Compound-81
DMLAYG7	DT	Small molecular drug
DMLAYG7	PC	46889224
DMLAYG7	MW	481.8
DMLAYG7	FM	C21H19Cl3N4OS
DMLAYG7	IC	InChI=1S/C21H19Cl3N4OS/c1-30-21-18(20(29)26-27-10-2-3-11-27)25-19(16-9-6-14(23)12-17(16)24)28(21)15-7-4-13(22)5-8-15/h4-9,12H,2-3,10-11H2,1H3,(H,26,29)
DMLAYG7	CS	CSC1=C(N=C(N1C2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)Cl)Cl)C(=O)NN4CCCC4
DMLAYG7	IK	HYQPTXFCPLFWMJ-UHFFFAOYSA-N
DMLAYG7	IU	1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylsulfanyl-N-pyrrolidin-1-ylimidazole-4-carboxamide
DMLAYG7	DE	Obesity

DMMCYI5	ID	DMMCYI5
DMMCYI5	DN	1,2,4,5-tetra-substituted imidazole derivative 2
DMMCYI5	HS	Patented
DMMCYI5	SN	PMID26161824-Compound-82
DMMCYI5	DT	Small molecular drug
DMMCYI5	PC	11555526
DMMCYI5	MW	527.8
DMMCYI5	FM	C22H21Cl3N4O3S
DMMCYI5	IC	InChI=1S/C22H21Cl3N4O3S/c1-33(31,32)22-19(21(30)27-28-11-3-2-4-12-28)26-20(17-10-7-15(24)13-18(17)25)29(22)16-8-5-14(23)6-9-16/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMMCYI5	CS	CS(=O)(=O)C1=C(N=C(N1C2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)Cl)Cl)C(=O)NN4CCCCC4
DMMCYI5	IK	XHUGETFAQBCPHR-UHFFFAOYSA-N
DMMCYI5	IU	1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylsulfonyl-N-piperidin-1-ylimidazole-4-carboxamide
DMMCYI5	DE	Obesity

DMESOA8	ID	DMESOA8
DMESOA8	DN	1,2,4-oxadiazole derivative 1
DMESOA8	HS	Patented
DMESOA8	SN	PMID30107136-Compound-Example39
DMESOA8	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMESOA8	DT	Small molecule immunotherapy 
DMESOA8	PC	134354913
DMESOA8	MW	338.36
DMESOA8	FM	C14H22N6O4
DMESOA8	IC	InChI=1S/C14H22N6O4/c15-11(22)6-10(17-12(23)9-5-8(21)7-16-9)13-18-14(19-24-13)20-3-1-2-4-20/h8-10,16,21H,1-7H2,(H2,15,22)(H,17,23)/t8-,9-,10-/m0/s1
DMESOA8	CS	C1CCN(C1)C2=NOC(=N2)[C@H](CC(=O)N)NC(=O)[C@@H]3C[C@@H](CN3)O
DMESOA8	IK	SFGGVDXQGJRZAI-GUBZILKMSA-N
DMESOA8	IU	(2S,4S)-N-[(1S)-3-amino-3-oxo-1-(3-pyrrolidin-1-yl-1,2,4-oxadiazol-5-yl)propyl]-4-hydroxypyrrolidine-2-carboxamide
DMESOA8	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMA42SB	ID	DMA42SB
DMA42SB	DN	1,2,4-oxadiazole derivative 2
DMA42SB	HS	Patented
DMA42SB	SN	PMID30107136-Compound-Example40
DMA42SB	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMA42SB	DT	Small molecule immunotherapy 
DMA42SB	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMT6EDP	ID	DMT6EDP
DMT6EDP	DN	1,2,4-oxadiazole derivative 4
DMT6EDP	HS	Patented
DMT6EDP	SN	PMID30107136-Compound-Example31
DMT6EDP	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMT6EDP	DT	Small molecule immunotherapy 
DMT6EDP	PC	91663290
DMT6EDP	MW	215.21
DMT6EDP	FM	C7H13N5O3
DMT6EDP	IC	InChI=1S/C7H13N5O3/c8-3(1-5(10)14)7-11-6(12-15-7)4(9)2-13/h3-4,13H,1-2,8-9H2,(H2,10,14)/t3-,4-/m0/s1
DMT6EDP	CS	C([C@@H](C1=NC(=NO1)[C@H](CO)N)N)C(=O)N
DMT6EDP	IK	GBRIVGUQMYWVTC-IMJSIDKUSA-N
DMT6EDP	IU	(3S)-3-amino-3-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]propanamide
DMT6EDP	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM683R7	ID	DM683R7
DM683R7	DN	1,2,4-oxadiazole derivative 5
DM683R7	HS	Patented
DM683R7	SN	PMID30107136-Compound-Example32
DM683R7	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DM683R7	DT	Small molecule immunotherapy 
DM683R7	PC	117943678
DM683R7	MW	360.32
DM683R7	FM	C12H20N6O7
DM683R7	IC	InChI=1S/C12H20N6O7/c1-4(20)8(11(22)23)16-12(24)15-6(2-7(14)21)10-17-9(18-25-10)5(13)3-19/h4-6,8,19-20H,2-3,13H2,1H3,(H2,14,21)(H,22,23)(H2,15,16,24)/t4?,5-,6-,8+/m0/s1
DM683R7	CS	CC([C@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NC(=NO1)[C@H](CO)N)O
DM683R7	IK	HFOBENSCBRZVSP-FMKRDQFVSA-N
DM683R7	IU	(2R)-2-[[(1S)-3-amino-1-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-3-oxopropyl]carbamoylamino]-3-hydroxybutanoic acid
DM683R7	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMFYKBJ	ID	DMFYKBJ
DMFYKBJ	DN	1,2,4-oxadiazole derivative 6
DMFYKBJ	HS	Patented
DMFYKBJ	SN	PMID30107136-Compound-Example35
DMFYKBJ	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMFYKBJ	DT	Small molecule immunotherapy 
DMFYKBJ	PC	122541621
DMFYKBJ	MW	416.43
DMFYKBJ	FM	C16H28N6O7
DMFYKBJ	IC	InChI=1S/C16H28N6O7/c1-3-6-18-11(25)5-4-10(14-21-13(22-29-14)9(17)7-23)19-16(28)20-12(8(2)24)15(26)27/h8-10,12,23-24H,3-7,17H2,1-2H3,(H,18,25)(H,26,27)(H2,19,20,28)/t8?,9-,10-,12-/m0/s1
DMFYKBJ	CS	CCCNC(=O)CC[C@@H](C1=NC(=NO1)[C@H](CO)N)NC(=O)N[C@@H](C(C)O)C(=O)O
DMFYKBJ	IK	YZLYUYDWVJSYRO-BCBKFXIMSA-N
DMFYKBJ	IU	(2S)-2-[[(1S)-1-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-4-oxo-4-(propylamino)butyl]carbamoylamino]-3-hydroxybutanoic acid
DMFYKBJ	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMBT4RJ	ID	DMBT4RJ
DMBT4RJ	DN	1,2,4-oxadiazole derivative 7
DMBT4RJ	HS	Patented
DMBT4RJ	SN	PMID30107136-Compound-Example36
DMBT4RJ	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMBT4RJ	DT	Small molecule immunotherapy 
DMBT4RJ	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMQF62D	ID	DMQF62D
DMQF62D	DN	1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 1
DMQF62D	HS	Patented
DMQF62D	SN	PMID27321640-Compound-39
DMQF62D	CP	DART NEUROSCIENCE (CAYMAN) LTD
DMQF62D	DT	Small molecular drug

DM8KWQ9	ID	DM8KWQ9
DM8KWQ9	DN	1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 2
DM8KWQ9	HS	Patented
DM8KWQ9	SN	PMID27321640-Compound-40
DM8KWQ9	CP	DART NEUROSCIENCE (CAYMAN) LTD
DM8KWQ9	DT	Small molecular drug

DMR1QP4	ID	DMR1QP4
DMR1QP4	DN	1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 3
DMR1QP4	HS	Patented
DMR1QP4	SN	PMID27321640-Compound-41
DMR1QP4	CP	DART NEUROSCIENCE (CAYMAN) LTD
DMR1QP4	DT	Small molecular drug

DMD9QW2	ID	DMD9QW2
DMD9QW2	DN	1,2,4-triazole [4,3-a]quinoxaline derivative 1
DMD9QW2	HS	Patented
DMD9QW2	SN	PMID27321640-Compound-33
DMD9QW2	CP	BOEHRINGER INGELHEIM INTERNATIONAL GmbH 
DMD9QW2	DT	Small molecular drug
DMD9QW2	PC	56933838
DMD9QW2	MW	294.74
DMD9QW2	FM	C16H11ClN4
DMD9QW2	IC	InChI=1S/C16H11ClN4/c1-10-15-19-20-16(11-6-2-3-7-12(11)17)21(15)14-9-5-4-8-13(14)18-10/h2-9H,1H3
DMD9QW2	CS	CC1=NC2=CC=CC=C2N3C1=NN=C3C4=CC=CC=C4Cl
DMD9QW2	IK	CTBSIWZADWNGPL-UHFFFAOYSA-N
DMD9QW2	IU	1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline

DM3DIW9	ID	DM3DIW9
DM3DIW9	DN	1,2,4-triazole [4,3-a]quinoxaline derivative 2
DM3DIW9	HS	Patented
DM3DIW9	SN	PMID27321640-Compound-34
DM3DIW9	CP	BOEHRINGER INGELHEIM INTERNATIONAL GmbH 
DM3DIW9	DT	Small molecular drug
DM3DIW9	PC	60151243
DM3DIW9	MW	366.8
DM3DIW9	FM	C20H19ClN4O
DM3DIW9	IC	InChI=1S/C20H19ClN4O/c1-3-4-11-26-14-9-10-16(21)15(12-14)20-24-23-19-13(2)22-17-7-5-6-8-18(17)25(19)20/h5-10,12H,3-4,11H2,1-2H3
DM3DIW9	CS	CCCCOC1=CC(=C(C=C1)Cl)C2=NN=C3N2C4=CC=CC=C4N=C3C
DM3DIW9	IK	ITEIGISUTJIFPA-UHFFFAOYSA-N
DM3DIW9	IU	1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline

DMKXRYM	ID	DMKXRYM
DMKXRYM	DN	1,2,4-triazole [4,3-a]quinoxaline derivative 3
DMKXRYM	HS	Patented
DMKXRYM	SN	PMID27321640-Compound-35
DMKXRYM	CP	BOEHRINGER INGELHEIM INTERNATIONAL GmbH 
DMKXRYM	DT	Small molecular drug

DME8MN1	ID	DME8MN1
DME8MN1	DN	1,2,4-triazole derivative 1
DME8MN1	HS	Patented
DME8MN1	SN	PMID26161824-Compound-92
DME8MN1	DT	Small molecular drug
DME8MN1	PC	10005052
DME8MN1	MW	436.7
DME8MN1	FM	C19H16Cl3N5O
DME8MN1	IC	InChI=1S/C19H16Cl3N5O/c20-13-5-3-12(4-6-13)18-23-17(19(28)25-26-9-1-2-10-26)24-27(18)16-8-7-14(21)11-15(16)22/h3-8,11H,1-2,9-10H2,(H,25,28)
DME8MN1	CS	C1CCN(C1)NC(=O)C2=NN(C(=N2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl
DME8MN1	IK	ONYKENLNZNVNBN-UHFFFAOYSA-N
DME8MN1	IU	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-pyrrolidin-1-yl-1,2,4-triazole-3-carboxamide
DME8MN1	DE	Obesity

DM91Z8B	ID	DM91Z8B
DM91Z8B	DN	1,2,4-triazole derivative 2
DM91Z8B	HS	Patented
DM91Z8B	SN	PMID26161824-Compound-93
DM91Z8B	DT	Small molecular drug
DM91Z8B	DE	Obesity

DMU9XMV	ID	DMU9XMV
DMU9XMV	DN	1,2,4-triazole derivative 3
DMU9XMV	HS	Patented
DMU9XMV	SN	PMID28051882-Compound-2
DMU9XMV	CP	LABORATORIOS DEL DR. ESTEVE, S.A
DMU9XMV	DT	Small molecular drug
DMU9XMV	PC	24794804
DMU9XMV	MW	371.3
DMU9XMV	FM	C16H20Cl2N4S
DMU9XMV	IC	InChI=1S/C16H20Cl2N4S/c1-12-19-16(23-10-9-21-7-3-2-4-8-21)20-22(12)13-5-6-14(17)15(18)11-13/h5-6,11H,2-4,7-10H2,1H3
DMU9XMV	CS	CC1=NC(=NN1C2=CC(=C(C=C2)Cl)Cl)SCCN3CCCCC3
DMU9XMV	IK	BCOSIWNFJNBROD-UHFFFAOYSA-N
DMU9XMV	IU	1-[2-[[1-(3,4-dichlorophenyl)-5-methyl-1,2,4-triazol-3-yl]sulfanyl]ethyl]piperidine

DMHBJFN	ID	DMHBJFN
DMHBJFN	DN	1,2,4-triazole derivative 4
DMHBJFN	HS	Patented
DMHBJFN	SN	PMID28051882-Compound-II
DMHBJFN	CP	LABORATORIOS DEL DR. ESTEVE, S.A
DMHBJFN	DT	Small molecular drug

DMIUPSA	ID	DMIUPSA
DMIUPSA	DN	1,2,4-triazolo[1,5a]pyridine derivative 1
DMIUPSA	HS	Patented
DMIUPSA	SN	PMID27774824-Compound-Figure8compoundA
DMIUPSA	CP	CEPHALON, INC
DMIUPSA	DT	Small molecular drug

DMZFILT	ID	DMZFILT
DMZFILT	DN	1,2,4-triazolo[1,5a]pyridine derivative 2
DMZFILT	HS	Patented
DMZFILT	SN	PMID27774824-Compound-Figure8compoundIII
DMZFILT	CP	CEPHALON, INC
DMZFILT	DT	Small molecular drug

DMMNVZ5	ID	DMMNVZ5
DMMNVZ5	DN	1,2,4-tri-substituted imidazoline derivative 1
DMMNVZ5	HS	Patented
DMMNVZ5	SN	PMID26161824-Compound-113
DMMNVZ5	DT	Small molecular drug
DMMNVZ5	PC	16755469
DMMNVZ5	MW	450.8
DMMNVZ5	FM	C22H22Cl3N3O
DMMNVZ5	IC	InChI=1S/C22H22Cl3N3O/c23-14-6-9-17(10-7-14)28-13-20(22(29)26-16-4-2-1-3-5-16)27-21(28)18-11-8-15(24)12-19(18)25/h6-12,16,20H,1-5,13H2,(H,26,29)
DMMNVZ5	CS	C1CCC(CC1)NC(=O)C2CN(C(=N2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMMNVZ5	IK	AUDPPCIKFUVJJY-UHFFFAOYSA-N
DMMNVZ5	IU	1-(4-chlorophenyl)-N-cyclohexyl-2-(2,4-dichlorophenyl)-4,5-dihydroimidazole-4-carboxamide
DMMNVZ5	DE	Obesity

DMNH8GW	ID	DMNH8GW
DMNH8GW	DN	1,2-diamino cyclopentane-based derivative 1
DMNH8GW	HS	Patented
DMNH8GW	SN	PMID26593218-Compound-23
DMNH8GW	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMNH8GW	DT	Small molecular drug

DM3ZF95	ID	DM3ZF95
DM3ZF95	DN	1,2-diamino cyclopentane-based derivative 10
DM3ZF95	HS	Patented
DM3ZF95	SN	PMID26593218-Compound-32
DM3ZF95	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM3ZF95	DT	Small molecular drug
DM3ZF95	PC	118034926
DM3ZF95	MW	433.9
DM3ZF95	FM	C20H20ClN3O4S
DM3ZF95	IC	InChI=1S/C20H20ClN3O4S/c1-26-15-4-3-5-16(27-2)18(15)19(25)22-13-9-28-10-14(13)24-20-23-12-7-6-11(21)8-17(12)29-20/h3-8,13-14H,9-10H2,1-2H3,(H,22,25)(H,23,24)
DM3ZF95	CS	COC1=C(C(=CC=C1)OC)C(=O)NC2COCC2NC3=NC4=C(S3)C=C(C=C4)Cl
DM3ZF95	IK	VWEKNQAXJFBOQH-UHFFFAOYSA-N
DM3ZF95	IU	N-[4-[(6-chloro-1,3-benzothiazol-2-yl)amino]oxolan-3-yl]-2,6-dimethoxybenzamide

DMPZECW	ID	DMPZECW
DMPZECW	DN	1,2-diamino cyclopentane-based derivative 11
DMPZECW	HS	Patented
DMPZECW	SN	PMID26593218-Compound-33
DMPZECW	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMPZECW	DT	Small molecular drug

DMWV53X	ID	DMWV53X
DMWV53X	DN	1,2-diamino cyclopentane-based derivative 12
DMWV53X	HS	Patented
DMWV53X	SN	PMID26593218-Compound-34
DMWV53X	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMWV53X	DT	Small molecular drug

DM10UX4	ID	DM10UX4
DM10UX4	DN	1,2-diamino cyclopentane-based derivative 13
DM10UX4	HS	Patented
DM10UX4	SN	PMID26593218-Compound-35
DM10UX4	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM10UX4	DT	Small molecular drug
DM10UX4	PC	123568419
DM10UX4	MW	431.9
DM10UX4	FM	C21H22ClN3O3S
DM10UX4	IC	InChI=1S/C21H22ClN3O3S/c1-27-16-7-4-8-17(28-2)19(16)20(26)23-13-5-3-6-14(13)24-21-25-15-10-9-12(22)11-18(15)29-21/h4,7-11,13-14H,3,5-6H2,1-2H3,(H,23,26)(H,24,25)
DM10UX4	CS	COC1=C(C(=CC=C1)OC)C(=O)NC2CCCC2NC3=NC4=C(S3)C=C(C=C4)Cl
DM10UX4	IK	XFIKRNAXHULGOU-UHFFFAOYSA-N
DM10UX4	IU	N-[2-[(6-chloro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2,6-dimethoxybenzamide

DMTZDUV	ID	DMTZDUV
DMTZDUV	DN	1,2-diamino cyclopentane-based derivative 14
DMTZDUV	HS	Patented
DMTZDUV	SN	PMID26593218-Compound-36
DMTZDUV	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMTZDUV	DT	Small molecular drug
DMTZDUV	PC	118025684
DMTZDUV	MW	421.5
DMTZDUV	FM	C22H20FN5OS
DMTZDUV	IC	InChI=1S/C22H20FN5OS/c23-14-9-10-18-20(13-14)30-22(27-18)26-17-7-3-6-16(17)25-21(29)15-5-1-2-8-19(15)28-12-4-11-24-28/h1-2,4-5,8-13,16-17H,3,6-7H2,(H,25,29)(H,26,27)/t16-,17-/m0/s1
DMTZDUV	CS	C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3C=CC=N3)NC4=NC5=C(S4)C=C(C=C5)F
DMTZDUV	IK	IJDOZFOBWAKVFH-IRXDYDNUSA-N
DMTZDUV	IU	N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-pyrazol-1-ylbenzamide

DMBY65W	ID	DMBY65W
DMBY65W	DN	1,2-diamino cyclopentane-based derivative 15
DMBY65W	HS	Patented
DMBY65W	SN	PMID26593218-Compound-37
DMBY65W	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMBY65W	DT	Small molecular drug
DMBY65W	PC	122438665
DMBY65W	MW	440.5
DMBY65W	FM	C21H18F2N6OS
DMBY65W	IC	InChI=1S/C21H18F2N6OS/c22-12-5-7-18(29-24-8-9-25-29)14(10-12)20(30)26-15-2-1-3-16(15)27-21-28-17-6-4-13(23)11-19(17)31-21/h4-11,15-16H,1-3H2,(H,26,30)(H,27,28)/t15-,16-/m0/s1
DMBY65W	CS	C1C[C@@H]([C@H](C1)NC(=O)C2=C(C=CC(=C2)F)N3N=CC=N3)NC4=NC5=C(S4)C=C(C=C5)F
DMBY65W	IK	WLEKLMFGOMPGEX-HOTGVXAUSA-N
DMBY65W	IU	5-fluoro-N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide

DMHEX1Q	ID	DMHEX1Q
DMHEX1Q	DN	1,2-diamino cyclopentane-based derivative 16
DMHEX1Q	HS	Patented
DMHEX1Q	SN	PMID26593218-Compound-38
DMHEX1Q	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMHEX1Q	DT	Small molecular drug
DMHEX1Q	PC	122438757
DMHEX1Q	MW	437.5
DMHEX1Q	FM	C22H20FN5O2S
DMHEX1Q	IC	InChI=1S/C22H20FN5O2S/c1-12-24-21(30-28-12)15-6-3-2-5-14(15)20(29)25-16-7-4-8-17(16)26-22-27-18-10-9-13(23)11-19(18)31-22/h2-3,5-6,9-11,16-17H,4,7-8H2,1H3,(H,25,29)(H,26,27)/t16-,17-/m0/s1
DMHEX1Q	CS	CC1=NOC(=N1)C2=CC=CC=C2C(=O)N[C@H]3CCC[C@@H]3NC4=NC5=C(S4)C=C(C=C5)F
DMHEX1Q	IK	HAQWTGIMJAZGBJ-IRXDYDNUSA-N
DMHEX1Q	IU	N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide

DMBC9UK	ID	DMBC9UK
DMBC9UK	DN	1,2-diamino cyclopentane-based derivative 17
DMBC9UK	HS	Patented
DMBC9UK	SN	PMID26593218-Compound-39
DMBC9UK	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMBC9UK	DT	Small molecular drug
DMBC9UK	PC	118034890
DMBC9UK	MW	435.5
DMBC9UK	FM	C23H22FN5OS
DMBC9UK	IC	InChI=1S/C23H22FN5OS/c1-28(22(30)16-6-2-3-8-19(16)29-13-5-12-25-29)20-9-4-7-17(20)26-23-27-18-11-10-15(24)14-21(18)31-23/h2-3,5-6,8,10-14,17,20H,4,7,9H2,1H3,(H,26,27)/t17-,20-/m0/s1
DMBC9UK	CS	CN([C@H]1CCC[C@@H]1NC2=NC3=C(S2)C=C(C=C3)F)C(=O)C4=CC=CC=C4N5C=CC=N5
DMBC9UK	IK	OQAWFCAOFHFFQS-PXNSSMCTSA-N
DMBC9UK	IU	N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-N-methyl-2-pyrazol-1-ylbenzamide

DMCNQAF	ID	DMCNQAF
DMCNQAF	DN	1,2-diamino cyclopentane-based derivative 18
DMCNQAF	HS	Patented
DMCNQAF	SN	PMID26593218-Compound-40
DMCNQAF	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMCNQAF	DT	Small molecular drug
DMCNQAF	PC	118034891
DMCNQAF	MW	454.5
DMCNQAF	FM	C22H20F2N6OS
DMCNQAF	IC	InChI=1S/C22H20F2N6OS/c1-29(21(31)15-11-13(23)6-8-18(15)30-25-9-10-26-30)19-4-2-3-16(19)27-22-28-17-7-5-14(24)12-20(17)32-22/h5-12,16,19H,2-4H2,1H3,(H,27,28)/t16-,19-/m0/s1
DMCNQAF	CS	CN([C@H]1CCC[C@@H]1NC2=NC3=C(S2)C=C(C=C3)F)C(=O)C4=C(C=CC(=C4)F)N5N=CC=N5
DMCNQAF	IK	AWDZNHIULYTTNC-LPHOPBHVSA-N
DMCNQAF	IU	5-fluoro-N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-N-methyl-2-(triazol-2-yl)benzamide

DMCBPI4	ID	DMCBPI4
DMCBPI4	DN	1,2-diamino cyclopentane-based derivative 19
DMCBPI4	HS	Patented
DMCBPI4	SN	PMID26593218-Compound-41
DMCBPI4	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMCBPI4	DT	Small molecular drug
DMCBPI4	PC	118034933
DMCBPI4	MW	451.5
DMCBPI4	FM	C23H22FN5O2S
DMCBPI4	IC	InChI=1S/C23H22FN5O2S/c1-13-25-21(31-28-13)15-6-3-4-7-16(15)22(30)29(2)19-9-5-8-17(19)26-23-27-18-11-10-14(24)12-20(18)32-23/h3-4,6-7,10-12,17,19H,5,8-9H2,1-2H3,(H,26,27)/t17-,19-/m0/s1
DMCBPI4	CS	CC1=NOC(=N1)C2=CC=CC=C2C(=O)N(C)[C@H]3CCC[C@@H]3NC4=NC5=C(S4)C=C(C=C5)F
DMCBPI4	IK	ZZOMOANEXSPUDO-HKUYNNGSSA-N
DMCBPI4	IU	N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-N-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide

DM7RG5I	ID	DM7RG5I
DM7RG5I	DN	1,2-diamino cyclopentane-based derivative 2
DM7RG5I	HS	Patented
DM7RG5I	SN	PMID26593218-Compound-24
DM7RG5I	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM7RG5I	DT	Small molecular drug
DM7RG5I	PC	122438624
DM7RG5I	MW	392.5
DM7RG5I	FM	C22H24N4O3
DM7RG5I	IC	InChI=1S/C22H24N4O3/c1-28-18-11-6-12-19(29-2)21(18)22(27)26-17-10-5-9-16(17)25-20-13-23-14-7-3-4-8-15(14)24-20/h3-4,6-8,11-13,16-17H,5,9-10H2,1-2H3,(H,24,25)(H,26,27)/t16-,17-/m0/s1
DM7RG5I	CS	COC1=C(C(=CC=C1)OC)C(=O)N[C@H]2CCC[C@@H]2NC3=NC4=CC=CC=C4N=C3
DM7RG5I	IK	GIWGNHDZELXXNP-IRXDYDNUSA-N
DM7RG5I	IU	2,6-dimethoxy-N-[(1S,2S)-2-(quinoxalin-2-ylamino)cyclopentyl]benzamide

DM9PHIK	ID	DM9PHIK
DM9PHIK	DN	1,2-diamino cyclopentane-based derivative 20
DM9PHIK	HS	Patented
DM9PHIK	SN	PMID26593218-Compound-42
DM9PHIK	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM9PHIK	DT	Small molecular drug
DM9PHIK	PC	118025611
DM9PHIK	MW	388.4
DM9PHIK	FM	C21H20N6O2
DM9PHIK	IC	InChI=1S/C21H20N6O2/c28-20(14-6-1-3-10-18(14)27-22-12-13-23-27)24-15-8-5-9-16(15)25-21-26-17-7-2-4-11-19(17)29-21/h1-4,6-7,10-13,15-16H,5,8-9H2,(H,24,28)(H,25,26)/t15-,16-/m0/s1
DM9PHIK	CS	C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=CC=CC=C5O4
DM9PHIK	IK	BYPDPBCQZDTPSH-HOTGVXAUSA-N
DM9PHIK	IU	N-[(1S,2S)-2-(1,3-benzoxazol-2-ylamino)cyclopentyl]-2-(triazol-2-yl)benzamide

DM5Y1DC	ID	DM5Y1DC
DM5Y1DC	DN	1,2-diamino cyclopentane-based derivative 21
DM5Y1DC	HS	Patented
DM5Y1DC	SN	PMID26593218-Compound-43
DM5Y1DC	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM5Y1DC	DT	Small molecular drug
DM5Y1DC	PC	122438916
DM5Y1DC	MW	404.5
DM5Y1DC	FM	C21H20N6OS
DM5Y1DC	IC	InChI=1S/C21H20N6OS/c28-20(14-6-1-3-10-18(14)27-22-12-13-23-27)24-15-8-5-9-16(15)25-21-26-17-7-2-4-11-19(17)29-21/h1-4,6-7,10-13,15-16H,5,8-9H2,(H,24,28)(H,25,26)/t15-,16-/m0/s1
DM5Y1DC	CS	C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=CC=CC=C5S4
DM5Y1DC	IK	XAHDEDDXRWKNQO-HOTGVXAUSA-N
DM5Y1DC	IU	N-[(1S,2S)-2-(1,3-benzothiazol-2-ylamino)cyclopentyl]-2-(triazol-2-yl)benzamide

DMXRLI6	ID	DMXRLI6
DMXRLI6	DN	1,2-diamino cyclopentane-based derivative 22
DMXRLI6	HS	Patented
DMXRLI6	SN	PMID26593218-Compound-44
DMXRLI6	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMXRLI6	DT	Small molecular drug
DMXRLI6	PC	122438723
DMXRLI6	MW	406.4
DMXRLI6	FM	C21H19FN6O2
DMXRLI6	IC	InChI=1S/C21H19FN6O2/c22-13-8-9-19-17(12-13)27-21(30-19)26-16-6-3-5-15(16)25-20(29)14-4-1-2-7-18(14)28-23-10-11-24-28/h1-2,4,7-12,15-16H,3,5-6H2,(H,25,29)(H,26,27)/t15-,16-/m0/s1
DMXRLI6	CS	C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=C(O4)C=CC(=C5)F
DMXRLI6	IK	JFPYMDXVSVUGTP-HOTGVXAUSA-N
DMXRLI6	IU	N-[(1S,2S)-2-[(5-fluoro-1,3-benzoxazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide

DM0HIQU	ID	DM0HIQU
DM0HIQU	DN	1,2-diamino cyclopentane-based derivative 23
DM0HIQU	HS	Patented
DM0HIQU	SN	PMID26593218-Compound-45
DM0HIQU	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM0HIQU	DT	Small molecular drug
DM0HIQU	PC	122438724
DM0HIQU	MW	422.5
DM0HIQU	FM	C21H19FN6OS
DM0HIQU	IC	InChI=1S/C21H19FN6OS/c22-13-8-9-19-17(12-13)27-21(30-19)26-16-6-3-5-15(16)25-20(29)14-4-1-2-7-18(14)28-23-10-11-24-28/h1-2,4,7-12,15-16H,3,5-6H2,(H,25,29)(H,26,27)/t15-,16-/m0/s1
DM0HIQU	CS	C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=C(S4)C=CC(=C5)F
DM0HIQU	IK	QOKFERXTHYZAHW-HOTGVXAUSA-N
DM0HIQU	IU	N-[(1S,2S)-2-[(5-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide

DMC26MT	ID	DMC26MT
DMC26MT	DN	1,2-diamino cyclopentane-based derivative 24
DMC26MT	HS	Patented
DMC26MT	SN	PMID26593218-Compound-46
DMC26MT	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMC26MT	DT	Small molecular drug
DMC26MT	PC	122438643
DMC26MT	MW	438.9
DMC26MT	FM	C21H19ClN6OS
DMC26MT	IC	InChI=1S/C21H19ClN6OS/c22-13-8-9-19-17(12-13)27-21(30-19)26-16-6-3-5-15(16)25-20(29)14-4-1-2-7-18(14)28-23-10-11-24-28/h1-2,4,7-12,15-16H,3,5-6H2,(H,25,29)(H,26,27)/t15-,16-/m0/s1
DMC26MT	CS	C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=C(S4)C=CC(=C5)Cl
DMC26MT	IK	XRCGVDTUCHXOPF-HOTGVXAUSA-N
DMC26MT	IU	N-[(1S,2S)-2-[(5-chloro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide

DMEW0AT	ID	DMEW0AT
DMEW0AT	DN	1,2-diamino cyclopentane-based derivative 25
DMEW0AT	HS	Patented
DMEW0AT	SN	PMID26593218-Compound-47
DMEW0AT	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMEW0AT	DT	Small molecular drug
DMEW0AT	PC	122438685
DMEW0AT	MW	438.9
DMEW0AT	FM	C21H19ClN6OS
DMEW0AT	IC	InChI=1S/C21H19ClN6OS/c22-13-8-9-17-19(12-13)30-21(27-17)26-16-6-3-5-15(16)25-20(29)14-4-1-2-7-18(14)28-23-10-11-24-28/h1-2,4,7-12,15-16H,3,5-6H2,(H,25,29)(H,26,27)/t15-,16-/m0/s1
DMEW0AT	CS	C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=C(S4)C=C(C=C5)Cl
DMEW0AT	IK	PCFLJOMEOCZUJL-HOTGVXAUSA-N
DMEW0AT	IU	N-[(1S,2S)-2-[(6-chloro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide

DMTFG4J	ID	DMTFG4J
DMTFG4J	DN	1,2-diamino cyclopentane-based derivative 26
DMTFG4J	HS	Patented
DMTFG4J	SN	PMID26593218-Compound-48
DMTFG4J	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMTFG4J	DT	Small molecular drug

DM5LQJW	ID	DM5LQJW
DM5LQJW	DN	1,2-diamino cyclopentane-based derivative 27
DM5LQJW	HS	Patented
DM5LQJW	SN	PMID26593218-Compound-49
DM5LQJW	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM5LQJW	DT	Small molecular drug

DMUTF17	ID	DMUTF17
DMUTF17	DN	1,2-diamino cyclopentane-based derivative 28
DMUTF17	HS	Patented
DMUTF17	SN	PMID26593218-Compound-5
DMUTF17	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMUTF17	DT	Small molecular drug

DM5FVH0	ID	DM5FVH0
DM5FVH0	DN	1,2-diamino cyclopentane-based derivative 29
DM5FVH0	HS	Patented
DM5FVH0	SN	PMID26593218-Compound-50
DM5FVH0	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM5FVH0	DT	Small molecular drug
DM5FVH0	PC	118308114
DM5FVH0	MW	431.4
DM5FVH0	FM	C20H20F3N7O
DM5FVH0	IC	InChI=1S/C20H20F3N7O/c1-19(29-17-12-24-16(11-25-17)20(21,22)23)8-4-7-15(19)28-18(31)13-5-2-3-6-14(13)30-26-9-10-27-30/h2-3,5-6,9-12,15H,4,7-8H2,1H3,(H,25,29)(H,28,31)/t15-,19-/m0/s1
DM5FVH0	CS	C[C@@]1(CCC[C@@H]1NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC=C(N=C4)C(F)(F)F
DM5FVH0	IK	HMHQKDBOHKCIIS-KXBFYZLASA-N
DM5FVH0	IU	N-[(1S,2S)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-(triazol-2-yl)benzamide

DM143OK	ID	DM143OK
DM143OK	DN	1,2-diamino cyclopentane-based derivative 3
DM143OK	HS	Patented
DM143OK	SN	PMID26593218-Compound-25
DM143OK	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM143OK	DT	Small molecular drug
DM143OK	PC	122438686
DM143OK	MW	397.5
DM143OK	FM	C21H23N3O3S
DM143OK	IC	InChI=1S/C21H23N3O3S/c1-26-16-10-6-11-17(27-2)19(16)20(25)22-13-8-5-9-14(13)23-21-24-15-7-3-4-12-18(15)28-21/h3-4,6-7,10-14H,5,8-9H2,1-2H3,(H,22,25)(H,23,24)/t13-,14+/m0/s1
DM143OK	CS	COC1=C(C(=CC=C1)OC)C(=O)N[C@H]2CCC[C@H]2NC3=NC4=CC=CC=C4S3
DM143OK	IK	PQSRJJBKNVQRDI-UONOGXRCSA-N
DM143OK	IU	N-[(1S,2R)-2-(1,3-benzothiazol-2-ylamino)cyclopentyl]-2,6-dimethoxybenzamide

DMZ4NJQ	ID	DMZ4NJQ
DMZ4NJQ	DN	1,2-diamino cyclopentane-based derivative 30
DMZ4NJQ	HS	Patented
DMZ4NJQ	SN	PMID26593218-Compound-51
DMZ4NJQ	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMZ4NJQ	DT	Small molecular drug

DMVZ5EP	ID	DMVZ5EP
DMVZ5EP	DN	1,2-diamino cyclopentane-based derivative 31
DMVZ5EP	HS	Patented
DMVZ5EP	SN	PMID26593218-Compound-52
DMVZ5EP	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMVZ5EP	DT	Small molecular drug
DMVZ5EP	PC	118308285
DMVZ5EP	MW	465.9
DMVZ5EP	FM	C20H19ClF3N7O
DMVZ5EP	IC	InChI=1S/C20H19ClF3N7O/c1-19(30-17-11-25-16(10-26-17)20(22,23)24)6-2-3-15(19)29-18(32)13-9-12(21)4-5-14(13)31-27-7-8-28-31/h4-5,7-11,15H,2-3,6H2,1H3,(H,26,30)(H,29,32)/t15-,19-/m0/s1
DMVZ5EP	CS	C[C@@]1(CCC[C@@H]1NC(=O)C2=C(C=CC(=C2)Cl)N3N=CC=N3)NC4=NC=C(N=C4)C(F)(F)F
DMVZ5EP	IK	WFGSTTYRNIKJJI-KXBFYZLASA-N
DMVZ5EP	IU	5-chloro-N-[(1S,2S)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-(triazol-2-yl)benzamide

DMQX8SD	ID	DMQX8SD
DMQX8SD	DN	1,2-diamino cyclopentane-based derivative 32
DMQX8SD	HS	Patented
DMQX8SD	SN	PMID26593218-Compound-53
DMQX8SD	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMQX8SD	DT	Small molecular drug
DMQX8SD	PC	118308140
DMQX8SD	MW	442.4
DMQX8SD	FM	C22H21F3N6O
DMQX8SD	IC	InChI=1S/C22H21F3N6O/c1-21(31-18-13-28-17(12-29-18)22(23,24)25)9-4-8-16(21)30-20(32)15-7-3-2-6-14(15)19-26-10-5-11-27-19/h2-3,5-7,10-13,16H,4,8-9H2,1H3,(H,29,31)(H,30,32)/t16-,21-/m0/s1
DMQX8SD	CS	C[C@@]1(CCC[C@@H]1NC(=O)C2=CC=CC=C2C3=NC=CC=N3)NC4=NC=C(N=C4)C(F)(F)F
DMQX8SD	IK	WZNUKPZCVKITNK-KKSFZXQISA-N
DMQX8SD	IU	N-[(1S,2S)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-pyrimidin-2-ylbenzamide

DMBOLSU	ID	DMBOLSU
DMBOLSU	DN	1,2-diamino cyclopentane-based derivative 33
DMBOLSU	HS	Patented
DMBOLSU	SN	PMID26593218-Compound-54
DMBOLSU	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMBOLSU	DT	Small molecular drug

DMVHL3W	ID	DMVHL3W
DMVHL3W	DN	1,2-diamino cyclopentane-based derivative 34
DMVHL3W	HS	Patented
DMVHL3W	SN	PMID26593218-Compound-55
DMVHL3W	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMVHL3W	DT	Small molecular drug
DMVHL3W	PC	126666451
DMVHL3W	MW	422.5
DMVHL3W	FM	C21H19FN6OS
DMVHL3W	IC	InChI=1S/C21H19FN6OS/c22-13-7-8-16-18(12-13)30-21(27-16)26-15-5-1-4-14(15)25-20(29)19-17(6-2-9-23-19)28-11-3-10-24-28/h2-3,6-12,14-15H,1,4-5H2,(H,25,29)(H,26,27)/t14-,15-/m0/s1
DMVHL3W	CS	C1C[C@@H]([C@H](C1)NC(=O)C2=C(C=CC=N2)N3C=CC=N3)NC4=NC5=C(S4)C=C(C=C5)F
DMVHL3W	IK	ZNHYIIOVQSLYRA-GJZGRUSLSA-N
DMVHL3W	IU	N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-3-pyrazol-1-ylpyridine-2-carboxamide

DMFBPSX	ID	DMFBPSX
DMFBPSX	DN	1,2-diamino cyclopentane-based derivative 4
DMFBPSX	HS	Patented
DMFBPSX	SN	PMID26593218-Compound-26
DMFBPSX	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMFBPSX	DT	Small molecular drug

DMCP15K	ID	DMCP15K
DMCP15K	DN	1,2-diamino cyclopentane-based derivative 5
DMCP15K	HS	Patented
DMCP15K	SN	PMID26593218-Compound-27
DMCP15K	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMCP15K	DT	Small molecular drug
DMCP15K	PC	122438647
DMCP15K	MW	415.5
DMCP15K	FM	C21H22FN3O3S
DMCP15K	IC	InChI=1S/C21H22FN3O3S/c1-27-16-7-4-8-17(28-2)19(16)20(26)23-13-5-3-6-14(13)24-21-25-15-10-9-12(22)11-18(15)29-21/h4,7-11,13-14H,3,5-6H2,1-2H3,(H,23,26)(H,24,25)/t13-,14-/m0/s1
DMCP15K	CS	COC1=C(C(=CC=C1)OC)C(=O)N[C@H]2CCC[C@@H]2NC3=NC4=C(S3)C=C(C=C4)F
DMCP15K	IK	FFLQAHCLFLUGAV-KBPBESRZSA-N
DMCP15K	IU	N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2,6-dimethoxybenzamide

DMJ4ACP	ID	DMJ4ACP
DMJ4ACP	DN	1,2-diamino cyclopentane-based derivative 6
DMJ4ACP	HS	Patented
DMJ4ACP	SN	PMID26593218-Compound-28
DMJ4ACP	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMJ4ACP	DT	Small molecular drug
DMJ4ACP	PC	122438920
DMJ4ACP	MW	429.5
DMJ4ACP	FM	C22H24FN3O3S
DMJ4ACP	IC	InChI=1S/C22H24FN3O3S/c1-26(22-25-15-11-10-13(23)12-19(15)30-22)16-7-4-6-14(16)24-21(27)20-17(28-2)8-5-9-18(20)29-3/h5,8-12,14,16H,4,6-7H2,1-3H3,(H,24,27)/t14-,16-/m0/s1
DMJ4ACP	CS	CN([C@H]1CCC[C@@H]1NC(=O)C2=C(C=CC=C2OC)OC)C3=NC4=C(S3)C=C(C=C4)F
DMJ4ACP	IK	TWWJAOFWTFXPRC-HOCLYGCPSA-N
DMJ4ACP	IU	N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)-methylamino]cyclopentyl]-2,6-dimethoxybenzamide

DMHIV24	ID	DMHIV24
DMHIV24	DN	1,2-diamino cyclopentane-based derivative 7
DMHIV24	HS	Patented
DMHIV24	SN	PMID26593218-Compound-29
DMHIV24	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMHIV24	DT	Small molecular drug
DMHIV24	PC	122438852
DMHIV24	MW	429.5
DMHIV24	FM	C22H24FN3O3S
DMHIV24	IC	InChI=1S/C22H24FN3O3S/c1-26(21(27)20-17(28-2)8-5-9-18(20)29-3)16-7-4-6-14(16)24-22-25-15-11-10-13(23)12-19(15)30-22/h5,8-12,14,16H,4,6-7H2,1-3H3,(H,24,25)/t14-,16-/m0/s1
DMHIV24	CS	CN([C@H]1CCC[C@@H]1NC2=NC3=C(S2)C=C(C=C3)F)C(=O)C4=C(C=CC=C4OC)OC
DMHIV24	IK	QIQQOZYTKFYTFE-HOCLYGCPSA-N
DMHIV24	IU	N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2,6-dimethoxy-N-methylbenzamide

DM7JX8U	ID	DM7JX8U
DM7JX8U	DN	1,2-diamino cyclopentane-based derivative 8
DM7JX8U	HS	Patented
DM7JX8U	SN	PMID26593218-Compound-30
DM7JX8U	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM7JX8U	DT	Small molecular drug
DM7JX8U	PC	118034889
DM7JX8U	MW	567.1
DM7JX8U	FM	C28H27ClN4O5S
DM7JX8U	IC	InChI=1S/C28H27ClN4O5S/c1-36-22-9-6-10-23(37-2)25(22)26(34)30-20-14-33(28(35)38-16-17-7-4-3-5-8-17)15-21(20)32-27-31-19-12-11-18(29)13-24(19)39-27/h3-13,20-21H,14-16H2,1-2H3,(H,30,34)(H,31,32)
DM7JX8U	CS	COC1=C(C(=CC=C1)OC)C(=O)NC2CN(CC2NC3=NC4=C(S3)C=C(C=C4)Cl)C(=O)OCC5=CC=CC=C5
DM7JX8U	IK	YUAQEWZWSNKNGF-UHFFFAOYSA-N
DM7JX8U	IU	benzyl 3-[(6-chloro-1,3-benzothiazol-2-yl)amino]-4-[(2,6-dimethoxybenzoyl)amino]pyrrolidine-1-carboxylate

DM7I8ZV	ID	DM7I8ZV
DM7I8ZV	DN	1,2-diamino cyclopentane-based derivative 9
DM7I8ZV	HS	Patented
DM7I8ZV	SN	PMID26593218-Compound-31
DM7I8ZV	CP	TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM7I8ZV	DT	Small molecular drug

DMRFXMB	ID	DMRFXMB
DMRFXMB	DN	1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1
DMRFXMB	HS	Patented
DMRFXMB	SN	PMID25684022-Compound-WO2010120854
DMRFXMB	CP	GLAXOSMITHKLINE LLC AXTEN, Jeffrey, Michael BRADY, Gerald, Patrick, Jr. GALLAGHER, Timothy, Francis HEERDING, Dirk, A. MEDINA, Jesus, Raul ROMERIL, Stuart, Paul
DMRFXMB	DT	Small molecular drug
DMRFXMB	DE	Solid tumour/cancer; Metastatic cancer

DMJMCNP	ID	DMJMCNP
DMJMCNP	DN	1,3,4-oxadiazole derivative 1
DMJMCNP	HS	Patented
DMJMCNP	SN	PMID30107136-Compound-Example37
DMJMCNP	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMJMCNP	DT	Small molecule immunotherapy 
DMJMCNP	PC	134358044
DMJMCNP	MW	438.5
DMJMCNP	FM	C19H26N4O6S
DMJMCNP	IC	InChI=1S/C19H26N4O6S/c1-27-12-11-20-17(24)10-9-15(23-30(25,26)13-7-8-13)19-22-21-18(29-19)14-5-3-4-6-16(14)28-2/h3-6,13,15,23H,7-12H2,1-2H3,(H,20,24)/t15-/m0/s1
DMJMCNP	CS	COCCNC(=O)CC[C@@H](C1=NN=C(O1)C2=CC=CC=C2OC)NS(=O)(=O)C3CC3
DMJMCNP	IK	FYAJXXVCAGXKAN-HNNXBMFYSA-N
DMJMCNP	IU	(4S)-4-(cyclopropylsulfonylamino)-N-(2-methoxyethyl)-4-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]butanamide
DMJMCNP	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMH26EO	ID	DMH26EO
DMH26EO	DN	1,3,4-oxadiazole derivative 2
DMH26EO	HS	Patented
DMH26EO	SN	PMID30107136-Compound-Example38
DMH26EO	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMH26EO	DT	Small molecule immunotherapy 
DMH26EO	PC	134358045
DMH26EO	MW	471.5
DMH26EO	FM	C22H25N5O5S
DMH26EO	IC	InChI=1S/C22H25N5O5S/c1-31-19-7-3-2-6-17(19)21-25-26-22(32-21)18(27-33(29,30)16-8-9-16)10-11-20(28)24-14-15-5-4-12-23-13-15/h2-7,12-13,16,18,27H,8-11,14H2,1H3,(H,24,28)/t18-/m0/s1
DMH26EO	CS	COC1=CC=CC=C1C2=NN=C(O2)[C@H](CCC(=O)NCC3=CN=CC=C3)NS(=O)(=O)C4CC4
DMH26EO	IK	JHNLLRMWPHPFLP-SFHVURJKSA-N
DMH26EO	IU	(4S)-4-(cyclopropylsulfonylamino)-4-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-N-(pyridin-3-ylmethyl)butanamide
DMH26EO	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMSR0X6	ID	DMSR0X6
DMSR0X6	DN	1,3,4-oxadiazole derivative 3
DMSR0X6	HS	Patented
DMSR0X6	SN	PMID30107136-Compound-Example25
DMSR0X6	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMSR0X6	DT	Small molecule immunotherapy 
DMSR0X6	PC	122535659
DMSR0X6	MW	429.43
DMSR0X6	FM	C16H27N7O7
DMSR0X6	IC	InChI=1S/C16H27N7O7/c17-6-2-1-3-8(18)13-22-23-14(30-13)10(7-11(19)24)21-16(29)20-9(15(27)28)4-5-12(25)26/h8-10H,1-7,17-18H2,(H2,19,24)(H,25,26)(H,27,28)(H2,20,21,29)/t8-,9-,10-/m0/s1
DMSR0X6	CS	C(CCN)C[C@@H](C1=NN=C(O1)[C@H](CC(=O)N)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)N
DMSR0X6	IK	SIMOVBGEPUKIIM-GUBZILKMSA-N
DMSR0X6	IU	(2S)-2-[[(1S)-3-amino-1-[5-[(1S)-1,5-diaminopentyl]-1,3,4-oxadiazol-2-yl]-3-oxopropyl]carbamoylamino]pentanedioic acid
DMSR0X6	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM4GR2C	ID	DM4GR2C
DM4GR2C	DN	1,3,4-oxadiazole derivative 4
DM4GR2C	HS	Patented
DM4GR2C	SN	PMID30107136-Compound-Example26
DM4GR2C	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DM4GR2C	DT	Small molecule immunotherapy 
DM4GR2C	PC	122535663
DM4GR2C	MW	459.5
DM4GR2C	FM	C20H25N7O6
DM4GR2C	IC	InChI=1S/C20H25N7O6/c21-12(7-10-8-23-13-4-2-1-3-11(10)13)17-26-27-18(33-17)15(9-28)25-20(32)24-14(19(30)31)5-6-16(22)29/h1-4,8,12,14-15,23,28H,5-7,9,21H2,(H2,22,29)(H,30,31)(H2,24,25,32)/t12-,14-,15-/m0/s1
DM4GR2C	CS	C1=CC=C2C(=C1)C(=CN2)C[C@@H](C3=NN=C(O3)[C@H](CO)NC(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DM4GR2C	IK	WXNTYOHOKYKDDS-QEJZJMRPSA-N
DM4GR2C	IU	(2S)-5-amino-2-[[(1S)-1-[5-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-1,3,4-oxadiazol-2-yl]-2-hydroxyethyl]carbamoylamino]-5-oxopentanoic acid
DM4GR2C	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMI5VZN	ID	DMI5VZN
DMI5VZN	DN	1,3,4-oxadiazole derivative 5
DMI5VZN	HS	Patented
DMI5VZN	SN	PMID30107136-Compound-Example27
DMI5VZN	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMI5VZN	DT	Small molecule immunotherapy 
DMI5VZN	PC	122542131
DMI5VZN	MW	379.33
DMI5VZN	FM	C14H17N7O6
DMI5VZN	IC	InChI=1S/C14H17N7O6/c1-6(22)10(13(24)25)19-14(26)18-7(4-9(15)23)11-20-21-12(27-11)8-5-16-2-3-17-8/h2-3,5-7,10,22H,4H2,1H3,(H2,15,23)(H,24,25)(H2,18,19,26)/t6?,7-,10-/m0/s1
DMI5VZN	CS	CC([C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NN=C(O1)C2=NC=CN=C2)O
DMI5VZN	IK	FQAXMNWDINGSGZ-MXMVMAASSA-N
DMI5VZN	IU	(2S)-2-[[(1S)-3-amino-3-oxo-1-(5-pyrazin-2-yl-1,3,4-oxadiazol-2-yl)propyl]carbamoylamino]-3-hydroxybutanoic acid
DMI5VZN	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMIEZ6L	ID	DMIEZ6L
DMIEZ6L	DN	1,3,4-oxadiazole derivative 6
DMIEZ6L	HS	Patented
DMIEZ6L	SN	PMID30107136-Compound-Example28
DMIEZ6L	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMIEZ6L	DT	Small molecule immunotherapy 
DMIEZ6L	PC	122542123
DMIEZ6L	MW	434.4
DMIEZ6L	FM	C19H26N6O6
DMIEZ6L	IC	InChI=1S/C19H26N6O6/c1-30-14-8-3-2-6-11(14)16-24-25-17(31-16)13(10-15(21)26)23-19(29)22-12(18(27)28)7-4-5-9-20/h2-3,6,8,12-13H,4-5,7,9-10,20H2,1H3,(H2,21,26)(H,27,28)(H2,22,23,29)/t12-,13-/m0/s1
DMIEZ6L	CS	COC1=CC=CC=C1C2=NN=C(O2)[C@H](CC(=O)N)NC(=O)N[C@@H](CCCCN)C(=O)O
DMIEZ6L	IK	SAUWXUYDAXFMAR-STQMWFEESA-N
DMIEZ6L	IU	(2S)-6-amino-2-[[(1S)-3-amino-1-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-3-oxopropyl]carbamoylamino]hexanoic acid
DMIEZ6L	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMAB8QF	ID	DMAB8QF
DMAB8QF	DN	1,3,4-thiadiazole derivative 1
DMAB8QF	HS	Patented
DMAB8QF	SN	PMID30107136-Compound-Example29
DMAB8QF	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMAB8QF	DT	Small molecule immunotherapy 
DMAB8QF	PC	117947861
DMAB8QF	MW	360.32
DMAB8QF	FM	C12H20N6O7
DMAB8QF	IC	InChI=1S/C12H20N6O7/c1-4(20)8(11(22)23)16-12(24)15-6(2-7(14)21)10-18-17-9(25-10)5(13)3-19/h4-6,8,19-20H,2-3,13H2,1H3,(H2,14,21)(H,22,23)(H2,15,16,24)/t4?,5-,6-,8-/m0/s1
DMAB8QF	CS	CC([C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NN=C(O1)[C@H](CO)N)O
DMAB8QF	IK	HODUKYLKCHJNCA-WHFCDURNSA-N
DMAB8QF	IU	(2S)-2-[[(1S)-3-amino-1-[5-[(1S)-1-amino-2-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3-oxopropyl]carbamoylamino]-3-hydroxybutanoic acid
DMAB8QF	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMXIG07	ID	DMXIG07
DMXIG07	DN	1,3,4-thiadiazole derivative 2
DMXIG07	HS	Patented
DMXIG07	SN	PMID30107136-Compound-Example30
DMXIG07	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMXIG07	DT	Small molecule immunotherapy 
DMXIG07	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMLD7JU	ID	DMLD7JU
DMLD7JU	DN	1,3,5-triazine derivative 1
DMLD7JU	HS	Patented
DMLD7JU	SN	PMID27215781-Compound-17
DMLD7JU	CP	SANOFI
DMLD7JU	DT	Small molecular drug

DMUS7O3	ID	DMUS7O3
DMUS7O3	DN	1,3-dihydroxy phenyl derivative 1
DMUS7O3	HS	Patented
DMUS7O3	SN	PMID30107136-Compound-Example5
DMUS7O3	CP	BRISTOL-MYERS SQUIBB COMPANY
DMUS7O3	DT	Small molecule immunotherapy 
DMUS7O3	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM63NX5	ID	DM63NX5
DM63NX5	DN	1,3-dihydroxy phenyl derivative 2
DM63NX5	HS	Patented
DM63NX5	SN	PMID30107136-Compound-Example6
DM63NX5	CP	BRISTOL-MYERS SQUIBB COMPANY
DM63NX5	DT	Small molecule immunotherapy 
DM63NX5	PC	138748934
DM63NX5	MW	624.1
DM63NX5	FM	C34H30ClN5O5
DM63NX5	IC	InChI=1S/C34H30ClN5O5/c1-21-24(6-5-7-26(21)30-17-38-28-8-3-4-9-29(28)40-30)19-45-32-12-31(44-18-23-10-22(13-36)14-37-15-23)25(11-27(32)35)16-39-34(2,20-41)33(42)43/h3-12,14-15,17,39,41H,16,18-20H2,1-2H3,(H,42,43)/t34-/m1/s1
DM63NX5	CS	CC1=C(C=CC=C1C2=NC3=CC=CC=C3N=C2)COC4=C(C=C(C(=C4)OCC5=CC(=CN=C5)C#N)CN[C@](C)(CO)C(=O)O)Cl
DM63NX5	IK	KJGBSKXWCFJEDI-UUWRZZSWSA-N
DM63NX5	IU	(2R)-2-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[(2-methyl-3-quinoxalin-2-ylphenyl)methoxy]phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid
DM63NX5	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMZY3HC	ID	DMZY3HC
DMZY3HC	DN	1,5-diphenylpyrrolidin-2-one derivative 1
DMZY3HC	HS	Patented
DMZY3HC	SN	PMID26161824-Compound-114
DMZY3HC	CP	ELI LILLY AND COMPANY SCHAUS, John, Mehner
DMZY3HC	DT	Small molecular drug
DMZY3HC	DE	Obesity

DMBR2Y9	ID	DMBR2Y9
DMBR2Y9	DN	1,5-diphenylpyrrolidin-2-one derivative 2
DMBR2Y9	HS	Patented
DMBR2Y9	SN	PMID26161824-Compound-115
DMBR2Y9	CP	ELI LILLY AND COMPANY SCHAUS, John, Mehner
DMBR2Y9	DT	Small molecular drug
DMBR2Y9	PC	44468756
DMBR2Y9	MW	524.5
DMBR2Y9	FM	C25H22F6N4O2
DMBR2Y9	IC	InChI=1S/C25H22F6N4O2/c1-23(2,20-12-13-32-22(33-20)24(26,27)28)34-18-14-19(15-6-4-3-5-7-15)35(21(18)36)16-8-10-17(11-9-16)37-25(29,30)31/h3-13,18-19,34H,14H2,1-2H3/t18-,19-/m1/s1
DMBR2Y9	CS	CC(C)(C1=NC(=NC=C1)C(F)(F)F)N[C@@H]2C[C@@H](N(C2=O)C3=CC=C(C=C3)OC(F)(F)F)C4=CC=CC=C4
DMBR2Y9	IK	RZNGNBDYOQOCCY-RTBURBONSA-N
DMBR2Y9	IU	(3R,5R)-5-phenyl-1-[4-(trifluoromethoxy)phenyl]-3-[2-[2-(trifluoromethyl)pyrimidin-4-yl]propan-2-ylamino]pyrrolidin-2-one
DMBR2Y9	DE	Obesity

DMEUO8G	ID	DMEUO8G
DMEUO8G	DN	1,5-di-substituted pyridine derivative 1
DMEUO8G	HS	Patented
DMEUO8G	SN	PMID26161698-Compound-26
DMEUO8G	CP	LEAD DISCOVERY CENTER GMBH [DEBAYER IP GMBH [DE];
DMEUO8G	DT	Small molecular drug
DMEUO8G	PC	60197050
DMEUO8G	MW	369.4
DMEUO8G	FM	C19H19N3O3S
DMEUO8G	IC	InChI=1S/C19H19N3O3S/c1-25-18-8-3-2-7-17(18)15-9-10-21-19(12-15)22-16-6-4-5-14(11-16)13-26(20,23)24/h2-12H,13H2,1H3,(H,21,22)(H2,20,23,24)
DMEUO8G	CS	COC1=CC=CC=C1C2=CC(=NC=C2)NC3=CC=CC(=C3)CS(=O)(=O)N
DMEUO8G	IK	WIMRMIUJTYQVQS-UHFFFAOYSA-N
DMEUO8G	IU	[3-[[4-(2-methoxyphenyl)pyridin-2-yl]amino]phenyl]methanesulfonamide

DMUQ9CF	ID	DMUQ9CF
DMUQ9CF	DN	1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1
DMUQ9CF	HS	Patented
DMUQ9CF	SN	PMID27410995-Compound-Figure3e
DMUQ9CF	DT	Small molecular drug

DMPZ0U8	ID	DMPZ0U8
DMPZ0U8	DN	1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2
DMPZ0U8	HS	Patented
DMPZ0U8	SN	PMID27410995-Compound-Figure3f
DMPZ0U8	DT	Small molecular drug

DMF6W2Y	ID	DMF6W2Y
DMF6W2Y	DN	1,6-naphyridine-4-ketone fused heterocyclic derivative 1
DMF6W2Y	HS	Patented
DMF6W2Y	SN	PMID28621580-Compound-WO2013097753c65
DMF6W2Y	CP	JIANGSU SIMCERE PHARMACEUTICAL CO LTD [CN]
DMF6W2Y	DT	Small molecular drug

DMHNPSO	ID	DMHNPSO
DMHNPSO	DN	1190312-92-5
DMHNPSO	HS	Patented
DMHNPSO	SN	3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 1190312-92-5; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid
DMHNPSO	DT	Small molecular drug
DMHNPSO	PC	53412620
DMHNPSO	MW	196.59
DMHNPSO	FM	C8H5ClN2O2
DMHNPSO	IC	InChI=1S/C8H5ClN2O2/c9-5-3-11-6-4(8(12)13)1-2-10-7(5)6/h1-3,11H,(H,12,13)
DMHNPSO	CS	C1=CN=C2C(=CNC2=C1C(=O)O)Cl
DMHNPSO	IK	UAFNSWUBMGTOQA-UHFFFAOYSA-N
DMHNPSO	IU	3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid

DMJRK9D	ID	DMJRK9D
DMJRK9D	DN	1313212-89-3
DMJRK9D	HS	Patented
DMJRK9D	SN	Ethyl N-[(4-Aminobenzyl)carbamoyl]glycinate; ethyl 2-(3-(4-aminobenzyl)ureido)acetate; SCHEMBL2044119; CHEMBL3647424; BDBM139995; 1313212-89-3; US8901295, F428
DMJRK9D	DT	Small molecular drug
DMJRK9D	PC	53259809
DMJRK9D	MW	251.28
DMJRK9D	FM	C12H17N3O3
DMJRK9D	IC	InChI=1S/C12H17N3O3/c1-2-18-11(16)8-15-12(17)14-7-9-3-5-10(13)6-4-9/h3-6H,2,7-8,13H2,1H3,(H2,14,15,17)
DMJRK9D	CS	CCOC(=O)CNC(=O)NCC1=CC=C(C=C1)N
DMJRK9D	IK	UCMPTJMHPJQEED-UHFFFAOYSA-N
DMJRK9D	IU	ethyl 2-[(4-aminophenyl)methylcarbamoylamino]acetate

DMM2N4T	ID	DMM2N4T
DMM2N4T	DN	1607004-34-1
DMM2N4T	HS	Patented
DMM2N4T	SN	ADAMTS Inhibitor C7; SCHEMBL15692551; CHEMBL3980860; BDBM194644; 1607004-34-1; US9206139, 3
DMM2N4T	DT	Small molecular drug
DMM2N4T	PC	74221072
DMM2N4T	MW	409.4
DMM2N4T	FM	C20H22F3N3O3
DMM2N4T	IC	InChI=1S/C20H22F3N3O3/c21-20(22,23)14-5-1-11(2-6-14)9-15(12-3-4-12)16(27)24-10-19(13-7-8-13)17(28)25-18(29)26-19/h1-2,5-6,12-13,15H,3-4,7-10H2,(H,24,27)(H2,25,26,28,29)/t15-,19-/m0/s1
DMM2N4T	CS	C1CC1[C@H](CC2=CC=C(C=C2)C(F)(F)F)C(=O)NC[C@@]3(C(=O)NC(=O)N3)C4CC4
DMM2N4T	IK	JHOUEQAOHDTLPY-KXBFYZLASA-N
DMM2N4T	IU	(2S)-2-cyclopropyl-N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-3-[4-(trifluoromethyl)phenyl]propanamide

DMWNKQ8	ID	DMWNKQ8
DMWNKQ8	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 1
DMWNKQ8	HS	Patented
DMWNKQ8	SN	PMID27321640-Compound-[18F]-46
DMWNKQ8	CP	JANSSEN PHARMACEUTICA NV [BE]
DMWNKQ8	DT	Small molecular drug

DMU6ST7	ID	DMU6ST7
DMU6ST7	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 2
DMU6ST7	HS	Patented
DMU6ST7	SN	PMID27321640-Compound-[3H]-44
DMU6ST7	CP	JANSSEN PHARMACEUTICA NV [BE]
DMU6ST7	DT	Small molecular drug

DM62K40	ID	DM62K40
DM62K40	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3
DM62K40	HS	Patented
DM62K40	SN	PMID27321640-Compound-42
DM62K40	CP	JANSSEN PHARMACEUTICA NV [BE]
DM62K40	DT	Small molecular drug

DMQSTG9	ID	DMQSTG9
DMQSTG9	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4
DMQSTG9	HS	Patented
DMQSTG9	SN	PMID27321640-Compound-43
DMQSTG9	CP	JANSSEN PHARMACEUTICA NV [BE]
DMQSTG9	DT	Small molecular drug

DM9E0ZD	ID	DM9E0ZD
DM9E0ZD	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5
DM9E0ZD	HS	Patented
DM9E0ZD	SN	PMID27321640-Compound-44
DM9E0ZD	CP	JANSSEN PHARMACEUTICA NV [BE]
DM9E0ZD	DT	Small molecular drug

DM826JW	ID	DM826JW
DM826JW	DN	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6
DM826JW	HS	Patented
DM826JW	SN	PMID27321640-Compound-45
DM826JW	CP	JANSSEN PHARMACEUTICA NV [BE]
DM826JW	DT	Small molecular drug

DML8RVS	ID	DML8RVS
DML8RVS	DN	1-Benzyl-3-bromo-1H-pyrrole-2,5-dione
DML8RVS	HS	Patented
DML8RVS	SN	1-benzyl-3-bromo-1H-pyrrole-2,5-dione; 112749-49-2; 3-bromo-2,5-dihydro-1-benzyl-1h-pyrrole-2,5-dione; SCHEMBL4848605; CHEMBL3653656; LLBVECSKMXUDOT-UHFFFAOYSA-N; BDBM136369; ZINC34614650; AKOS027470535; 1-BENZYL-3-BROMOPYRROLE-2,5-DIONE; US8865750, CCG- 203780
DML8RVS	DT	Small molecular drug
DML8RVS	PC	15628904
DML8RVS	MW	266.09
DML8RVS	FM	C11H8BrNO2
DML8RVS	IC	InChI=1S/C11H8BrNO2/c12-9-6-10(14)13(11(9)15)7-8-4-2-1-3-5-8/h1-6H,7H2
DML8RVS	CS	C1=CC=C(C=C1)CN2C(=O)C=C(C2=O)Br
DML8RVS	IK	LLBVECSKMXUDOT-UHFFFAOYSA-N
DML8RVS	IU	1-benzyl-3-bromopyrrole-2,5-dione

DMWY9GM	ID	DMWY9GM
DMWY9GM	DN	1-Benzyl-3-p-tolyl-1H-pyrrole-2,5-dione
DMWY9GM	HS	Patented
DMWY9GM	SN	CHEMBL2037371; SCHEMBL13517162; PLQCDKKQKRJJDK-UHFFFAOYSA-N; BDBM50384773; 1-benzyl-3-p-tolyl-1H-pyrrole-2,5-dione
DMWY9GM	DT	Small molecular drug
DMWY9GM	PC	70690209
DMWY9GM	MW	277.3
DMWY9GM	FM	C18H15NO2
DMWY9GM	IC	InChI=1S/C18H15NO2/c1-13-7-9-15(10-8-13)16-11-17(20)19(18(16)21)12-14-5-3-2-4-6-14/h2-11H,12H2,1H3
DMWY9GM	CS	CC1=CC=C(C=C1)C2=CC(=O)N(C2=O)CC3=CC=CC=C3
DMWY9GM	IK	PLQCDKKQKRJJDK-UHFFFAOYSA-N
DMWY9GM	IU	1-benzyl-3-(4-methylphenyl)pyrrole-2,5-dione

DMK75BT	ID	DMK75BT
DMK75BT	DN	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1
DMK75BT	HS	Patented
DMK75BT	SN	PMID25553724-Compound-US2014000406629
DMK75BT	DT	Small molecular drug
DMK75BT	DE	Skin disease; Muscular wasting

DMIWQZ5	ID	DMIWQZ5
DMIWQZ5	DN	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2
DMIWQZ5	HS	Patented
DMIWQZ5	SN	PMID25553724-Compound-US2014000406829
DMIWQZ5	DT	Small molecular drug
DMIWQZ5	DE	Skin disease; Muscular wasting

DMNXAUZ	ID	DMNXAUZ
DMNXAUZ	DN	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3
DMNXAUZ	HS	Patented
DMNXAUZ	SN	PMID25553724-Compound-US2014000527529
DMNXAUZ	DT	Small molecular drug
DMNXAUZ	DE	Skin disease; Muscular wasting

DMV2W9Z	ID	DMV2W9Z
DMV2W9Z	DN	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4
DMV2W9Z	HS	Patented
DMV2W9Z	SN	PMID25553724-Compound-US2014000527629
DMV2W9Z	DT	Small molecular drug
DMV2W9Z	DE	Skin disease; Muscular wasting

DMS5EHL	ID	DMS5EHL
DMS5EHL	DN	1-phenyl-1,3,4-triazole derivative 1
DMS5EHL	HS	Patented
DMS5EHL	SN	PMID28454500-Compound-76
DMS5EHL	CP	THE GENERAL HOSPITAL CORPORATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
DMS5EHL	DT	Small molecular drug
DMS5EHL	PC	74229666
DMS5EHL	MW	455.5
DMS5EHL	FM	C24H17N5O3S
DMS5EHL	IC	InChI=1S/C24H17N5O3S/c30-29(31)20-13-14-21(23-19(20)12-7-15-25-23)33-24-27-26-22(16-32-18-10-5-2-6-11-18)28(24)17-8-3-1-4-9-17/h1-15H,16H2
DMS5EHL	CS	C1=CC=C(C=C1)N2C(=NN=C2SC3=C4C(=C(C=C3)[N+](=O)[O-])C=CC=N4)COC5=CC=CC=C5
DMS5EHL	IK	RVYWJVIYWKCDEE-UHFFFAOYSA-N
DMS5EHL	IU	5-nitro-8-[[5-(phenoxymethyl)-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]quinoline

DMO7310	ID	DMO7310
DMO7310	DN	1-phenyl-1,3,4-triazole derivative 2
DMO7310	HS	Patented
DMO7310	SN	PMID28454500-Compound-77
DMO7310	CP	THE GENERAL HOSPITAL CORPORATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
DMO7310	DT	Small molecular drug
DMO7310	PC	1327659
DMO7310	MW	405.4
DMO7310	FM	C20H15N5O3S
DMO7310	IC	InChI=1S/C20H15N5O3S/c26-25(27)16-11-12-19(21-13-16)29-20-23-22-18(14-28-17-9-5-2-6-10-17)24(20)15-7-3-1-4-8-15/h1-13H,14H2
DMO7310	CS	C1=CC=C(C=C1)N2C(=NN=C2SC3=NC=C(C=C3)[N+](=O)[O-])COC4=CC=CC=C4
DMO7310	IK	OZUBDKIROJPQGE-UHFFFAOYSA-N
DMO7310	IU	5-nitro-2-[[5-(phenoxymethyl)-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]pyridine

DMU8FC1	ID	DMU8FC1
DMU8FC1	DN	1-phenyl-1,3,4-triazole derivative 3
DMU8FC1	HS	Patented
DMU8FC1	SN	PMID28454500-Compound-78
DMU8FC1	CP	THE GENERAL HOSPITAL CORPORATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
DMU8FC1	DT	Small molecular drug
DMU8FC1	PC	3071025
DMU8FC1	MW	425.5
DMU8FC1	FM	C23H15N5O2S
DMU8FC1	IC	InChI=1S/C23H15N5O2S/c29-28(30)19-13-14-20(21-18(19)12-7-15-24-21)31-23-26-25-22(16-8-3-1-4-9-16)27(23)17-10-5-2-6-11-17/h1-15H
DMU8FC1	CS	C1=CC=C(C=C1)C2=NN=C(N2C3=CC=CC=C3)SC4=C5C(=C(C=C4)[N+](=O)[O-])C=CC=N5
DMU8FC1	IK	RAPJMMAHETVTFD-UHFFFAOYSA-N
DMU8FC1	IU	8-[(4,5-diphenyl-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline
DMU8FC1	CA	CAS 87236-38-2

DMOY5EK	ID	DMOY5EK
DMOY5EK	DN	2-(substituted ethynyl)quinoline derivative 1
DMOY5EK	HS	Patented
DMOY5EK	SN	PMID28067079-Compound-34
DMOY5EK	CP	Korea Institute of Science and Technology
DMOY5EK	DT	Small molecular drug
DMOY5EK	PC	71562840
DMOY5EK	MW	259.3
DMOY5EK	FM	C18H13NO
DMOY5EK	IC	InChI=1S/C18H13NO/c1-20-18-9-5-8-17-16(18)13-12-15(19-17)11-10-14-6-3-2-4-7-14/h2-9,12-13H,1H3
DMOY5EK	CS	COC1=CC=CC2=C1C=CC(=N2)C#CC3=CC=CC=C3
DMOY5EK	IK	JKTIXUXRNOXCFC-UHFFFAOYSA-N
DMOY5EK	IU	5-methoxy-2-(2-phenylethynyl)quinoline

DMPCYSW	ID	DMPCYSW
DMPCYSW	DN	2-(substituted ethynyl)quinoline derivative 2
DMPCYSW	HS	Patented
DMPCYSW	SN	PMID28067079-Compound-35
DMPCYSW	CP	Korea Institute of Science and Technology
DMPCYSW	DT	Small molecular drug

DMMF8A1	ID	DMMF8A1
DMMF8A1	DN	2-(substituted ethynyl)quinoline derivative 3
DMMF8A1	HS	Patented
DMMF8A1	SN	PMID28067079-Compound-36
DMMF8A1	CP	Korea Institute of Science and Technology
DMMF8A1	DT	Small molecular drug

DMTXZUF	ID	DMTXZUF
DMTXZUF	DN	2-(substituted ethynyl)quinoline derivative 4
DMTXZUF	HS	Patented
DMTXZUF	SN	PMID28067079-Compound-37
DMTXZUF	CP	Korea Institute of Science and Technology
DMTXZUF	DT	Small molecular drug
DMTXZUF	PC	71563215
DMTXZUF	MW	255.27
DMTXZUF	FM	C17H9N3
DMTXZUF	IC	InChI=1S/C17H9N3/c18-12-16-6-3-5-14(19-16)10-11-15-9-8-13-4-1-2-7-17(13)20-15/h1-9H
DMTXZUF	CS	C1=CC=C2C(=C1)C=CC(=N2)C#CC3=NC(=CC=C3)C#N
DMTXZUF	IK	SAXYXSCAJSSRCR-UHFFFAOYSA-N
DMTXZUF	IU	6-(2-quinolin-2-ylethynyl)pyridine-2-carbonitrile

DMRTDOA	ID	DMRTDOA
DMRTDOA	DN	2,2-bipyridyl derivative 1
DMRTDOA	HS	Patented
DMRTDOA	SN	PMID25468267-Compound-17
DMRTDOA	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMRTDOA	DT	Small molecular drug

DMYLQZ1	ID	DMYLQZ1
DMYLQZ1	DN	2,2-bipyridyl derivative 2
DMYLQZ1	HS	Patented
DMYLQZ1	SN	PMID25468267-Compound-18
DMYLQZ1	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMYLQZ1	DT	Small molecular drug

DMPQF78	ID	DMPQF78
DMPQF78	DN	2,2-bipyridyl derivative 3
DMPQF78	HS	Patented
DMPQF78	SN	PMID25468267-Compound-19
DMPQF78	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMPQF78	DT	Small molecular drug

DMTYPBM	ID	DMTYPBM
DMTYPBM	DN	2,2-bipyridyl derivative 4
DMTYPBM	HS	Patented
DMTYPBM	SN	PMID25468267-Compound-20
DMTYPBM	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMTYPBM	DT	Small molecular drug

DMEJOPL	ID	DMEJOPL
DMEJOPL	DN	2,2-bipyridyl derivative 5
DMEJOPL	HS	Patented
DMEJOPL	SN	PMID25468267-Compound-21
DMEJOPL	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMEJOPL	DT	Small molecular drug

DMWRBSP	ID	DMWRBSP
DMWRBSP	DN	2,2-dimethylbenzopyran derivative 1
DMWRBSP	HS	Patented
DMWRBSP	SN	PMID26882240-Compound-10
DMWRBSP	CP	EMORY UNIVERSITY GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION VAN MEIR, Erwin WANG, Binghe
DMWRBSP	DT	Small molecular drug
DMWRBSP	PC	54575622
DMWRBSP	MW	444.5
DMWRBSP	FM	C23H28N2O5S
DMWRBSP	IC	InChI=1S/C23H28N2O5S/c1-23(2)13-12-19-20(30-23)10-8-16(24-19)15-25(17-6-5-7-17)31(26,27)18-9-11-21(28-3)22(14-18)29-4/h8-14,17H,5-7,15H2,1-4H3
DMWRBSP	CS	CC1(C=CC2=C(O1)C=CC(=N2)CN(C3CCC3)S(=O)(=O)C4=CC(=C(C=C4)OC)OC)C
DMWRBSP	IK	CQGIUFASDNXPRB-UHFFFAOYSA-N
DMWRBSP	IU	N-cyclobutyl-N-[(2,2-dimethylpyrano[3,2-b]pyridin-6-yl)methyl]-3,4-dimethoxybenzenesulfonamide

DM9XUYM	ID	DM9XUYM
DM9XUYM	DN	2,2-dimethylbenzopyran derivative 2
DM9XUYM	HS	Patented
DM9XUYM	SN	PMID26882240-Compound-11
DM9XUYM	CP	SNU R&DB Foundation, S. Korea
DM9XUYM	DT	Small molecular drug
DM9XUYM	PC	71453910
DM9XUYM	MW	368.4
DM9XUYM	FM	C22H24O5
DM9XUYM	IC	InChI=1S/C22H24O5/c1-22(2)11-10-16-18(27-22)9-7-15(21(16)26-5)17(23)12-14-6-8-19(24-3)20(13-14)25-4/h6-11,13H,12H2,1-5H3
DM9XUYM	CS	CC1(C=CC2=C(O1)C=CC(=C2OC)C(=O)CC3=CC(=C(C=C3)OC)OC)C
DM9XUYM	IK	TZRPLTHVBYHDBJ-UHFFFAOYSA-N
DM9XUYM	IU	2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethylchromen-6-yl)ethanone

DMTCPSQ	ID	DMTCPSQ
DMTCPSQ	DN	2,2-dimethylbenzopyran derivative 3
DMTCPSQ	HS	Patented
DMTCPSQ	SN	PMID26882240-Compound-12
DMTCPSQ	CP	Shenyang Pharmaceutical University, Peop. Rep. China
DMTCPSQ	DT	Small molecular drug
DMTCPSQ	PC	42636766
DMTCPSQ	MW	352.4
DMTCPSQ	FM	C21H20O5
DMTCPSQ	IC	InChI=1S/C21H20O5/c1-21(2)11-10-15-18(26-21)9-6-14(20(15)24)16(22)7-4-13-5-8-19(25-3)17(23)12-13/h4-12,23-24H,1-3H3/b7-4+
DMTCPSQ	CS	CC1(C=CC2=C(O1)C=CC(=C2O)C(=O)/C=C/C3=CC(=C(C=C3)OC)O)C
DMTCPSQ	IK	XCJXATSREUCGQN-QPJJXVBHSA-N
DMTCPSQ	IU	(E)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-en-1-one

DMD2KRW	ID	DMD2KRW
DMD2KRW	DN	2,3-diamino-benzo[b]thiophene derivative 1
DMD2KRW	HS	Patented
DMD2KRW	SN	PMID27172114-Compound-31
DMD2KRW	CP	CURADEV PHARMA PRIVATE LTDCuradev Pharma Private Ltd
DMD2KRW	DT	Small molecular drug

DMDYXKT	ID	DMDYXKT
DMDYXKT	DN	2,3-diamino-benzo[b]thiophene derivative 2
DMDYXKT	HS	Patented
DMDYXKT	SN	PMID27172114-Compound-33
DMDYXKT	CP	CURADEV PHARMA PRIVATE LTD
DMDYXKT	DT	Small molecular drug

DMR7QKL	ID	DMR7QKL
DMR7QKL	DN	2,3-diamino-benzo[b]thiophene derivative 3
DMR7QKL	HS	Patented
DMR7QKL	SN	PMID27172114-Compound-34
DMR7QKL	CP	CURADEV PHARMA PRIVATE LTD
DMR7QKL	DT	Small molecular drug

DMEDFNC	ID	DMEDFNC
DMEDFNC	DN	2,3-diamino-benzo[b]thiophene derivative 4
DMEDFNC	HS	Patented
DMEDFNC	SN	PMID27172114-Compound-35
DMEDFNC	CP	CURADEV PHARMA PRIVATE LTD
DMEDFNC	DT	Small molecular drug

DM05WXD	ID	DM05WXD
DM05WXD	DN	2,3-diamino-benzo[b]thiophene derivative 5
DM05WXD	HS	Patented
DM05WXD	SN	PMID27172114-Compound-36
DM05WXD	CP	CURADEV PHARMA PRIVATE LTD
DM05WXD	DT	Small molecular drug

DMINE6V	ID	DMINE6V
DMINE6V	DN	2,3-diamino-benzo[b]thiophene derivative 6
DMINE6V	HS	Patented
DMINE6V	SN	PMID27172114-Compound-37
DMINE6V	CP	CURADEV PHARMA PRIVATE LTD
DMINE6V	DT	Small molecular drug

DMQVMNJ	ID	DMQVMNJ
DMQVMNJ	DN	2,3-diamino-benzo[b]thiophene derivative 7
DMQVMNJ	HS	Patented
DMQVMNJ	SN	PMID27172114-Compound-38
DMQVMNJ	CP	CURADEV PHARMA PRIVATE LTD
DMQVMNJ	DT	Small molecular drug

DM5O8K0	ID	DM5O8K0
DM5O8K0	DN	2,3-diamino-benzo[b]thiophene derivative 8
DM5O8K0	HS	Patented
DM5O8K0	SN	PMID27172114-Compound-40
DM5O8K0	CP	CURADEV PHARMA PRIVATE LTD
DM5O8K0	DT	Small molecular drug

DMMFZKC	ID	DMMFZKC
DMMFZKC	DN	2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivative 1
DMMFZKC	HS	Patented
DMMFZKC	SN	PMID26560530-Compound-36
DMMFZKC	CP	Dongguk University Industry-Academic Cooperation Foundation
DMMFZKC	DT	Small molecular drug
DMMFZKC	PC	56682080
DMMFZKC	MW	344.4
DMMFZKC	FM	C21H20N4O
DMMFZKC	IC	InChI=1S/C21H20N4O/c1-2-7-17(8-3-1)10-11-19-21(26-16-15-25-13-4-5-14-25)24-18-9-6-12-22-20(18)23-19/h1-3,6-9,12H,4-5,13-16H2
DMMFZKC	CS	C1CCN(C1)CCOC2=NC3=C(N=CC=C3)N=C2C#CC4=CC=CC=C4
DMMFZKC	IK	MNYJJHBAEYKXEG-UHFFFAOYSA-N
DMMFZKC	IU	3-(2-phenylethynyl)-2-(2-pyrrolidin-1-ylethoxy)pyrido[2,3-b]pyrazine

DMLXQET	ID	DMLXQET
DMLXQET	DN	2-cycloalkyl resorcinol cannabinoid ligand derivative 1
DMLXQET	HS	Patented
DMLXQET	SN	PMID27215781-Compound-43
DMLXQET	CP	NORTHEASTERN UNIVERSITY
DMLXQET	DT	Small molecular drug

DMB65TO	ID	DMB65TO
DMB65TO	DN	2-cycloalkyl resorcinol cannabinoid ligand derivative 2
DMB65TO	HS	Patented
DMB65TO	SN	PMID27215781-Compound-44
DMB65TO	CP	NORTHEASTERN UNIVERSITY
DMB65TO	DT	Small molecular drug

DMTJ1G8	ID	DMTJ1G8
DMTJ1G8	DN	2-cyclopropyl-4-substituted-phenoxy-quinoline derivative 1
DMTJ1G8	HS	Patented
DMTJ1G8	SN	PMID27537201-Compound-Figure13e
DMTJ1G8	CP	the Shanghai Institute of Pharmaceutical Industry
DMTJ1G8	DT	Small molecular drug

DMHYIAV	ID	DMHYIAV
DMHYIAV	DN	2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1
DMHYIAV	HS	Patented
DMHYIAV	SN	PMID27414413-Compound-Figure10
DMHYIAV	CP	Shenyang Pharmaceutical University and Santa (ZhangJiakou) Pharmaceutical Co., Ltd
DMHYIAV	DT	Small molecular drug

DMER2ZQ	ID	DMER2ZQ
DMER2ZQ	DN	2-hydroxybenzamide derivative 1
DMER2ZQ	HS	Patented
DMER2ZQ	SN	PMID28454500-Compound-38
DMER2ZQ	CP	Keio University
DMER2ZQ	DT	Small molecular drug

DM9FRN6	ID	DM9FRN6
DM9FRN6	DN	2-hydroxybenzamide derivative 2
DM9FRN6	HS	Patented
DM9FRN6	SN	PMID28454500-Compound-39
DM9FRN6	CP	Keio University
DM9FRN6	DT	Small molecular drug

DMI4KBC	ID	DMI4KBC
DMI4KBC	DN	2-PAM derivative 1
DMI4KBC	HS	Patented
DMI4KBC	SN	PMID27967267-Compound-45
DMI4KBC	CP	University of Iowa Research Foundation
DMI4KBC	DT	Small molecular drug

DMQ1FAH	ID	DMQ1FAH
DMQ1FAH	DN	2-piperidine thiazole derivative 1
DMQ1FAH	HS	Patented
DMQ1FAH	SN	PMID27539678-Compound-1
DMQ1FAH	CP	Merck Patent GmBH
DMQ1FAH	DT	Small molecular drug

DMSJ1C0	ID	DMSJ1C0
DMSJ1C0	DN	2-piperidine thiazole derivative 2
DMSJ1C0	HS	Patented
DMSJ1C0	SN	PMID27539678-Compound-2
DMSJ1C0	CP	Merck Patent GmBH
DMSJ1C0	DT	Small molecular drug

DMWXUS4	ID	DMWXUS4
DMWXUS4	DN	2-pyrazinone derivative 1
DMWXUS4	HS	Patented
DMWXUS4	SN	PMID26118988-Compound-28
DMWXUS4	DT	Small molecular drug

DMLEH4U	ID	DMLEH4U
DMLEH4U	DN	2-pyrazinone derivative 2
DMLEH4U	HS	Patented
DMLEH4U	SN	PMID26118988-Compound-29
DMLEH4U	DT	Small molecular drug
DMLEH4U	PC	68752099
DMLEH4U	MW	464.4
DMLEH4U	FM	C23H15F3N6O2
DMLEH4U	IC	InChI=1S/C23H15F3N6O2/c1-13-19(18-9-10-29-32(18)16-7-5-14(12-27)6-8-16)30-20(21(28)33)22(34)31(13)17-4-2-3-15(11-17)23(24,25)26/h2-11H,1H3,(H2,28,33)
DMLEH4U	CS	CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)N)C3=CC=NN3C4=CC=C(C=C4)C#N
DMLEH4U	IK	IKJNJNORSFGSID-UHFFFAOYSA-N
DMLEH4U	IU	6-[2-(4-cyanophenyl)pyrazol-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide

DME5WLD	ID	DME5WLD
DME5WLD	DN	2-pyrazinone derivative 3
DME5WLD	HS	Patented
DME5WLD	SN	PMID26118988-Compound-30
DME5WLD	DT	Small molecular drug
DME5WLD	PC	59564942
DME5WLD	MW	473.8
DME5WLD	FM	C22H15ClF3N5O2
DME5WLD	IC	InChI=1S/C22H15ClF3N5O2/c1-12-18(17-9-10-28-31(17)15-7-5-14(23)6-8-15)29-19(20(27)32)21(33)30(12)16-4-2-3-13(11-16)22(24,25)26/h2-11H,1H3,(H2,27,32)
DME5WLD	CS	CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)N)C3=CC=NN3C4=CC=C(C=C4)Cl
DME5WLD	IK	CESXSDAPOCNYPG-UHFFFAOYSA-N
DME5WLD	IU	6-[2-(4-chlorophenyl)pyrazol-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide

DMJRHS4	ID	DMJRHS4
DMJRHS4	DN	2-pyrazinone derivative 4
DMJRHS4	HS	Patented
DMJRHS4	SN	PMID26118988-Compound-31
DMJRHS4	DT	Small molecular drug
DMJRHS4	PC	59564944
DMJRHS4	MW	474.8
DMJRHS4	FM	C21H14ClF3N6O2
DMJRHS4	IC	InChI=1S/C21H14ClF3N6O2/c1-11-17(15-7-8-28-31(15)16-6-5-13(22)10-27-16)29-18(19(26)32)20(33)30(11)14-4-2-3-12(9-14)21(23,24)25/h2-10H,1H3,(H2,26,32)
DMJRHS4	CS	CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)N)C3=CC=NN3C4=NC=C(C=C4)Cl
DMJRHS4	IK	DZKSYFBPXVHKDO-UHFFFAOYSA-N
DMJRHS4	IU	6-[2-(5-chloropyridin-2-yl)pyrazol-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide

DMBIRMA	ID	DMBIRMA
DMBIRMA	DN	2-pyrazinone derivative 5
DMBIRMA	HS	Patented
DMBIRMA	SN	PMID26118988-Compound-32
DMBIRMA	DT	Small molecular drug

DMHIEBN	ID	DMHIEBN
DMHIEBN	DN	2-pyrazinone derivative 6
DMHIEBN	HS	Patented
DMHIEBN	SN	PMID26118988-Compound-33
DMHIEBN	DT	Small molecular drug
DMHIEBN	PC	59564943
DMHIEBN	MW	461.5
DMHIEBN	FM	C26H19N7O2
DMHIEBN	IC	InChI=1S/C26H19N7O2/c1-16-23(22-11-12-29-33(22)20-9-5-17(14-27)6-10-20)31-24(25(34)30-19-7-8-19)26(35)32(16)21-4-2-3-18(13-21)15-28/h2-6,9-13,19H,7-8H2,1H3,(H,30,34)
DMHIEBN	CS	CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C#N)C(=O)NC3CC3)C4=CC=NN4C5=CC=C(C=C5)C#N
DMHIEBN	IK	GJIYKCWSHGJDFQ-UHFFFAOYSA-N
DMHIEBN	IU	4-(3-cyanophenyl)-6-[2-(4-cyanophenyl)pyrazol-3-yl]-N-cyclopropyl-5-methyl-3-oxopyrazine-2-carboxamide

DMTG6X9	ID	DMTG6X9
DMTG6X9	DN	2-pyrazinone derivative 7
DMTG6X9	HS	Patented
DMTG6X9	SN	PMID26118988-Compound-34
DMTG6X9	DT	Small molecular drug
DMTG6X9	PC	25263589
DMTG6X9	MW	494.5
DMTG6X9	FM	C25H21F3N6O2
DMTG6X9	IC	InChI=1S/C25H21F3N6O2/c1-14-19(22-32-24(2,3)13-33(22)17-9-7-15(12-29)8-10-17)31-20(21(30)35)23(36)34(14)18-6-4-5-16(11-18)25(26,27)28/h4-11H,13H2,1-3H3,(H2,30,35)
DMTG6X9	CS	CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)N)C3=NC(CN3C4=CC=C(C=C4)C#N)(C)C
DMTG6X9	IK	CMHWRRKHSAWOMT-UHFFFAOYSA-N
DMTG6X9	IU	6-[3-(4-cyanophenyl)-5,5-dimethyl-4H-imidazol-2-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide

DM0DYAU	ID	DM0DYAU
DM0DYAU	DN	3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DM0DYAU	HS	Patented
DM0DYAU	SN	CHEMBL2069315; SCHEMBL14574842; CHEMBL2079230; BDBM50389688; 3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DM0DYAU	DT	Small molecular drug
DM0DYAU	PC	53344793
DM0DYAU	MW	414.5
DM0DYAU	FM	C24H26N6O
DM0DYAU	IC	InChI=1S/C24H26N6O/c1-2-11-31-20-6-5-17-12-19(4-3-18(17)13-20)22-21-23(25)27-15-28-24(21)30(29-22)14-16-7-9-26-10-8-16/h2-6,12-13,15-16,26H,1,7-11,14H2,(H2,25,27,28)
DM0DYAU	CS	C=CCOC1=CC2=C(C=C1)C=C(C=C2)C3=NN(C4=NC=NC(=C34)N)CC5CCNCC5
DM0DYAU	IK	LQRGSXMDDSWGQL-UHFFFAOYSA-N
DM0DYAU	IU	1-(piperidin-4-ylmethyl)-3-(6-prop-2-enoxynaphthalen-2-yl)pyrazolo[3,4-d]pyrimidin-4-amine

DM9YJWU	ID	DM9YJWU
DM9YJWU	DN	3-(phenoxymethyl) benzylamine derivative 1
DM9YJWU	HS	Patented
DM9YJWU	SN	PMID26815044-Compound-102
DM9YJWU	DT	Small molecular drug
DM9YJWU	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMGN9IX	ID	DMGN9IX
DMGN9IX	DN	3-(phenoxymethyl) benzylamine derivative 2
DMGN9IX	HS	Patented
DMGN9IX	SN	PMID26815044-Compound-103
DMGN9IX	DT	Small molecular drug
DMGN9IX	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM43EKN	ID	DM43EKN
DM43EKN	DN	3-(phenoxymethyl) benzylamine derivative 3
DM43EKN	HS	Patented
DM43EKN	SN	PMID26815044-Compound-104
DM43EKN	DT	Small molecular drug
DM43EKN	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM58X6N	ID	DM58X6N
DM58X6N	DN	3-(phenoxymethyl) benzylamine derivative 4
DM58X6N	HS	Patented
DM58X6N	SN	PMID26815044-Compound-105
DM58X6N	DT	Small molecular drug
DM58X6N	PC	18070637
DM58X6N	MW	249.31
DM58X6N	FM	C17H15NO
DM58X6N	IC	InChI=1S/C17H15NO/c18-15-8-3-5-13(11-15)12-19-17-10-4-7-14-6-1-2-9-16(14)17/h1-11H,12,18H2
DM58X6N	CS	C1=CC=C2C(=C1)C=CC=C2OCC3=CC(=CC=C3)N
DM58X6N	IK	OPMLHBFHZXOITN-UHFFFAOYSA-N
DM58X6N	IU	3-(naphthalen-1-yloxymethyl)aniline
DM58X6N	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM84HG2	ID	DM84HG2
DM84HG2	DN	3-(phenoxymethyl) benzylamine derivative 5
DM84HG2	HS	Patented
DM84HG2	SN	PMID26815044-Compound-106
DM84HG2	DT	Small molecular drug
DM84HG2	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM0WBM3	ID	DM0WBM3
DM0WBM3	DN	3-(phenoxymethyl) benzylamine derivative 6
DM0WBM3	HS	Patented
DM0WBM3	SN	PMID26815044-Compound-107
DM0WBM3	DT	Small molecular drug
DM0WBM3	PC	54126573
DM0WBM3	MW	255.35
DM0WBM3	FM	C17H21NO
DM0WBM3	IC	InChI=1S/C17H21NO/c1-3-18(4-2)16-10-8-9-15(13-16)14-19-17-11-6-5-7-12-17/h5-13H,3-4,14H2,1-2H3
DM0WBM3	CS	CCN(CC)C1=CC=CC(=C1)COC2=CC=CC=C2
DM0WBM3	IK	NRJLSCXDEWCXHU-UHFFFAOYSA-N
DM0WBM3	IU	N,N-diethyl-3-(phenoxymethyl)aniline
DM0WBM3	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM4O3DW	ID	DM4O3DW
DM4O3DW	DN	3,4-Dihydroxybenzaldehyde
DM4O3DW	HS	Patented
DM4O3DW	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM4O3DW	PC	8768
DM4O3DW	MW	138.12
DM4O3DW	FM	C7H6O3
DM4O3DW	IC	InChI=1S/C7H6O3/c8-4-5-1-2-6(9)7(10)3-5/h1-4,9-10H
DM4O3DW	CS	C1=CC(=C(C=C1C=O)O)O
DM4O3DW	IK	IBGBGRVKPALMCQ-UHFFFAOYSA-N
DM4O3DW	IU	3,4-dihydroxybenzaldehyde
DM4O3DW	CA	CAS 139-85-5
DM4O3DW	CB	CHEBI:50205

DM8L0MN	ID	DM8L0MN
DM8L0MN	DN	3-acylidene-2-oxoindole derivative 1
DM8L0MN	HS	Patented
DM8L0MN	SN	PMID26560530-Compound-29
DM8L0MN	CP	NUMERATE, INC. THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY GRIFFIN, John RAIMUNDO, Brian MADRID, Peter KHOSLA, Chaitan JIN, Xi KLOECK, Cornelius
DM8L0MN	DT	Small molecular drug
DM8L0MN	PC	54586674
DM8L0MN	MW	360.8
DM8L0MN	FM	C21H13ClN2O2
DM8L0MN	IC	InChI=1S/C21H13ClN2O2/c22-17-9-4-10-18-20(17)16(12-19(25)14-6-5-11-23-13-14)21(26)24(18)15-7-2-1-3-8-15/h1-13H/b16-12+
DM8L0MN	CS	C1=CC=C(C=C1)N2C3=C(C(=CC=C3)Cl)/C(=C\\C(=O)C4=CN=CC=C4)/C2=O
DM8L0MN	IK	MAXLUMXHDRQNGJ-FOWTUZBSSA-N
DM8L0MN	IU	(3E)-4-chloro-3-(2-oxo-2-pyridin-3-ylethylidene)-1-phenylindol-2-one

DMJ98VG	ID	DMJ98VG
DMJ98VG	DN	3-acylidene-2-oxoindole derivative 2
DMJ98VG	HS	Patented
DMJ98VG	SN	PMID26560530-Compound-30
DMJ98VG	CP	NUMERATE, INC. THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY GRIFFIN, John RAIMUNDO, Brian MADRID, Peter KHOSLA, Chaitan JIN, Xi KLOECK, Cornelius
DMJ98VG	DT	Small molecular drug
DMJ98VG	PC	54584758
DMJ98VG	MW	313.7
DMJ98VG	FM	C17H12ClNO3
DMJ98VG	IC	InChI=1S/C17H12ClNO3/c1-22-15-8-3-2-5-10(15)14(20)9-11-16-12(18)6-4-7-13(16)19-17(11)21/h2-9H,1H3,(H,19,21)/b11-9+
DMJ98VG	CS	COC1=CC=CC=C1C(=O)/C=C/2\\C3=C(C=CC=C3Cl)NC2=O
DMJ98VG	IK	ULAXMAMZNHGQMV-PKNBQFBNSA-N
DMJ98VG	IU	(3E)-4-chloro-3-[2-(2-methoxyphenyl)-2-oxoethylidene]-1H-indol-2-one

DMFDURZ	ID	DMFDURZ
DMFDURZ	DN	3-amino-5-benzyl-substituted indazole derivative 1
DMFDURZ	HS	Patented
DMFDURZ	SN	PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)
DMFDURZ	CP	NERVIANO MEDICAL 
DMFDURZ	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMB6M3Y	ID	DMB6M3Y
DMB6M3Y	DN	3-benzyloxyphenyloxoacetic acid derivative 1
DMB6M3Y	HS	Patented
DMB6M3Y	SN	PMID27414413-Compound-Figure4down
DMB6M3Y	CP	WELLSTAT THERAPEUTICS CORPORATION SHARMA, Shalini VON BORSTEL, Reid, W
DMB6M3Y	DT	Small molecular drug

DM9GPKR	ID	DM9GPKR
DM9GPKR	DN	3-Hydroxy-2-butanone
DM9GPKR	HS	Patented
DM9GPKR	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM9GPKR	DT	Small molecular drug
DM9GPKR	PC	179
DM9GPKR	MW	88.11
DM9GPKR	FM	C4H8O2
DM9GPKR	IC	InChI=1S/C4H8O2/c1-3(5)4(2)6/h3,5H,1-2H3
DM9GPKR	CS	CC(C(=O)C)O
DM9GPKR	IK	ROWKJAVDOGWPAT-UHFFFAOYSA-N
DM9GPKR	IU	3-hydroxybutan-2-one
DM9GPKR	CA	CAS 513-86-0
DM9GPKR	CB	CHEBI:15688

DMAR2OX	ID	DMAR2OX
DMAR2OX	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1
DMAR2OX	HS	Patented
DMAR2OX	SN	PMID27841036-Compound-6
DMAR2OX	CP	Nerviano Medical Sciences S.r.l
DMAR2OX	DT	Small molecular drug

DMEVMU9	ID	DMEVMU9
DMEVMU9	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2
DMEVMU9	HS	Patented
DMEVMU9	SN	PMID27841036-Compound-7
DMEVMU9	CP	Nerviano Medical Sciences S.r.l
DMEVMU9	DT	Small molecular drug

DMRQ74I	ID	DMRQ74I
DMRQ74I	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3
DMRQ74I	HS	Patented
DMRQ74I	SN	PMID27841036-Compound-8
DMRQ74I	CP	Nerviano Medical Sciences S.r.l
DMRQ74I	DT	Small molecular drug

DM8Q19H	ID	DM8Q19H
DM8Q19H	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4
DM8Q19H	HS	Patented
DM8Q19H	SN	PMID27841036-Compound-9
DM8Q19H	CP	Nerviano Medical Sciences S.r.l
DM8Q19H	DT	Small molecular drug

DMXJ837	ID	DMXJ837
DMXJ837	DN	3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5
DMXJ837	HS	Patented
DMXJ837	SN	PMID27841036-Compound-IV
DMXJ837	CP	Nerviano Medical Sciences S.r.l
DMXJ837	DT	Small molecular drug

DMXMV6N	ID	DMXMV6N
DMXMV6N	DN	3-phenyl acrylic acid derivative 1
DMXMV6N	HS	Patented
DMXMV6N	SN	PMID25416646-Compound-Figure2-B
DMXMV6N	CP	Galderma Research & Development
DMXMV6N	DT	Small molecular drug

DMB40HC	ID	DMB40HC
DMB40HC	DN	3-phenyl isoquinolin-1(2H) derivative 1
DMB40HC	HS	Patented
DMB40HC	SN	PMID27841036-Compound-20
DMB40HC	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMB40HC	DT	Small molecular drug
DMB40HC	PC	89588629
DMB40HC	MW	413.7
DMB40HC	FM	C17H15BrClFN2O2
DMB40HC	IC	InChI=1S/C17H14BrFN2O2.ClH/c18-11-3-1-10(2-4-11)15-16(23-8-7-20)13-6-5-12(19)9-14(13)17(22)21-15;/h1-6,9H,7-8,20H2,(H,21,22);1H
DMB40HC	CS	C1=CC(=CC=C1C2=C(C3=C(C=C(C=C3)F)C(=O)N2)OCCN)Br.Cl
DMB40HC	IK	BSCLHAQBYMRPSH-UHFFFAOYSA-N
DMB40HC	IU	4-(2-aminoethoxy)-3-(4-bromophenyl)-7-fluoro-2H-isoquinolin-1-one;hydrochloride

DMA749P	ID	DMA749P
DMA749P	DN	3-phenyl isoquinolin-1(2H) derivative 2
DMA749P	HS	Patented
DMA749P	SN	PMID27841036-Compound-VII
DMA749P	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMA749P	DT	Small molecular drug

DMW86YI	ID	DMW86YI
DMW86YI	DN	3-phenyl propanoic derivative 1
DMW86YI	HS	Patented
DMW86YI	SN	PMID28454500-Compound-67
DMW86YI	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ASTEX THERAPEUTICS LIMITED
DMW86YI	DT	Small molecular drug
DMW86YI	PC	4685764
DMW86YI	MW	183.61
DMW86YI	FM	C9H8ClO2-
DMW86YI	IC	InChI=1S/C9H9ClO2/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-2,4-5H,3,6H2,(H,11,12)/p-1
DMW86YI	CS	C1=CC(=CC=C1CCC(=O)[O-])Cl
DMW86YI	IK	BBSLOKZINKEUCR-UHFFFAOYSA-M
DMW86YI	IU	3-(4-chlorophenyl)propanoate

DM17D30	ID	DM17D30
DM17D30	DN	3-phenyl propanoic derivative 2
DM17D30	HS	Patented
DM17D30	SN	PMID28454500-Compound-68
DM17D30	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ASTEX THERAPEUTICS LIMITED
DM17D30	DT	Small molecular drug

DM5GKS6	ID	DM5GKS6
DM5GKS6	DN	3-phenyl propanoic derivative 3
DM5GKS6	HS	Patented
DM5GKS6	SN	PMID28454500-Compound-69
DM5GKS6	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ASTEX THERAPEUTICS LIMITED
DM5GKS6	DT	Small molecular drug

DM3VB6G	ID	DM3VB6G
DM3VB6G	DN	3-phenyl pyrazole derivative 1
DM3VB6G	HS	Patented
DM3VB6G	SN	PMID26609882-Compound-33
DM3VB6G	CP	Arena Pharmaceuticals, Inc
DM3VB6G	DT	Small molecular drug

DMB1JG2	ID	DMB1JG2
DMB1JG2	DN	3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1
DMB1JG2	HS	Patented
DMB1JG2	SN	PMID28621580-Compound-WO2013101954c67
DMB1JG2	CP	ALLERGAN, INC
DMB1JG2	DT	Small molecular drug
DMB1JG2	DE	Cell proliferative disorder; Metabolic disorder; Blood vessel proliferative disorder

DMWCT04	ID	DMWCT04
DMWCT04	DN	3-substituted-1,2,4-oxadiazole derivative 1
DMWCT04	HS	Patented
DMWCT04	SN	PMID30107136-Compound-Example33
DMWCT04	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMWCT04	DT	Small molecule immunotherapy 
DMWCT04	PC	122541390
DMWCT04	MW	384.39
DMWCT04	FM	C15H24N6O6
DMWCT04	IC	InChI=1S/C15H24N6O6/c1-8(22)11(13(24)25)18-15(26)17-9(7-10(16)23)12-19-14(20-27-12)21-5-3-2-4-6-21/h8-9,11,22H,2-7H2,1H3,(H2,16,23)(H,24,25)(H2,17,18,26)/t8?,9-,11-/m0/s1
DMWCT04	CS	CC([C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NC(=NO1)N2CCCCC2)O
DMWCT04	IK	YPPJFPAGRYMZTM-PCFYAGROSA-N
DMWCT04	IU	(2S)-2-[[(1S)-3-amino-3-oxo-1-(3-piperidin-1-yl-1,2,4-oxadiazol-5-yl)propyl]carbamoylamino]-3-hydroxybutanoic acid
DMWCT04	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMB3806	ID	DMB3806
DMB3806	DN	3-substituted-1,2,4-oxadiazole derivative 2
DMB3806	HS	Patented
DMB3806	SN	PMID30107136-Compound-Example34
DMB3806	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMB3806	DT	Small molecule immunotherapy 
DMB3806	PC	122541471
DMB3806	MW	360.32
DMB3806	FM	C15H16N6O5
DMB3806	IC	InChI=1S/C15H16N6O5/c1-3-4-9(18-15(25)19-11(8(2)22)14(23)24)13-20-12(21-26-13)10-7-16-5-6-17-10/h1,5-9,11,22H,4H2,2H3,(H,23,24)(H2,18,19,25)/t8?,9-,11-/m0/s1
DMB3806	CS	CC([C@@H](C(=O)O)NC(=O)N[C@@H](CC#C)C1=NC(=NO1)C2=NC=CN=C2)O
DMB3806	IK	DGLNBPSKIUYJIJ-PCFYAGROSA-N
DMB3806	IU	(2S)-3-hydroxy-2-[[(1S)-1-(3-pyrazin-2-yl-1,2,4-oxadiazol-5-yl)but-3-ynyl]carbamoylamino]butanoic acid
DMB3806	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMKEOH8	ID	DMKEOH8
DMKEOH8	DN	3-substituted-2-furancarboxylic acid hydrazide derivative 1
DMKEOH8	HS	Patented
DMKEOH8	SN	PMID25828189-Compound-1
DMKEOH8	CP	DAINIPPON SUMITOMO PHARMA CO [JPDAINIPPON SUMITOMO PHARMA CO., LTD.  FUJII, Akihito  NIIDOME, Kazumi  MIGIHASHI, Chiaki
DMKEOH8	DT	Small molecular drug

DMLK29E	ID	DMLK29E
DMLK29E	DN	3-substituted-2-furancarboxylic acid hydrazide derivative 5
DMLK29E	HS	Patented
DMLK29E	SN	PMID25828189-Compound-5
DMLK29E	CP	DAINIPPON SUMITOMO PHARMA CO [JP]
DMLK29E	DT	Small molecular drug
DMLK29E	PC	70805956
DMLK29E	MW	487.5
DMLK29E	FM	C26H21N3O7
DMLK29E	IC	InChI=1S/C26H21N3O7/c1-16-2-9-20(10-3-16)36-15-17-4-6-18(7-5-17)21-12-13-35-24(21)26(32)28-27-25(31)19-8-11-23(30)22(14-19)29(33)34/h2-14,30H,15H2,1H3,(H,27,31)(H,28,32)
DMLK29E	CS	CC1=CC=C(C=C1)OCC2=CC=C(C=C2)C3=C(OC=C3)C(=O)NNC(=O)C4=CC(=C(C=C4)O)[N+](=O)[O-]
DMLK29E	IK	BTGUVNBWMLTDRT-UHFFFAOYSA-N
DMLK29E	IU	N'-(4-hydroxy-3-nitrobenzoyl)-3-[4-[(4-methylphenoxy)methyl]phenyl]furan-2-carbohydrazide

DMCJHK2	ID	DMCJHK2
DMCJHK2	DN	3ts4
DMCJHK2	HS	Patented
DMCJHK2	SN	N-{3-[4-(4-Phenylthiophen-2-Yl)phenyl]propanoyl}-L-Alpha-Glutamyl-L-Alpha-Glutamyl-Amide; US8691753, 96; 3ts4; SCHEMBL6868348; CHEMBL1232492; BDBM120246; US8691753, 95; N-{3-[4-(4-phenylthiophen-2-yl)phenyl]propanoyl}-L-alpha-glutamyl-L-alpha-glutamine
DMCJHK2	DT	Small molecular drug
DMCJHK2	PC	46861563
DMCJHK2	MW	565.6
DMCJHK2	FM	C29H31N3O7S
DMCJHK2	IC	InChI=1S/C29H31N3O7S/c30-28(38)22(11-14-26(34)35)32-29(39)23(12-15-27(36)37)31-25(33)13-8-18-6-9-20(10-7-18)24-16-21(17-40-24)19-4-2-1-3-5-19/h1-7,9-10,16-17,22-23H,8,11-15H2,(H2,30,38)(H,31,33)(H,32,39)(H,34,35)(H,36,37)/t22-,23-/m0/s1
DMCJHK2	CS	C1=CC=C(C=C1)C2=CSC(=C2)C3=CC=C(C=C3)CCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N
DMCJHK2	IK	MMIHYNVQXYWTFM-GOTSBHOMSA-N
DMCJHK2	IU	(4S)-5-amino-4-[[(2S)-4-carboxy-2-[3-[4-(4-phenylthiophen-2-yl)phenyl]propanoylamino]butanoyl]amino]-5-oxopentanoic acid

DME30O6	ID	DME30O6
DME30O6	DN	4-(2-cyclohexylethoxy) aniline derivative 1
DME30O6	HS	Patented
DME30O6	SN	PMID28454500-Compound-87
DME30O6	CP	Korea institute of radiological & medical sciences, S
DME30O6	DT	Small molecular drug
DME30O6	PC	15943048
DME30O6	MW	219.32
DME30O6	FM	C14H21NO
DME30O6	IC	InChI=1S/C14H21NO/c15-13-6-8-14(9-7-13)16-11-10-12-4-2-1-3-5-12/h6-9,12H,1-5,10-11,15H2
DME30O6	CS	C1CCC(CC1)CCOC2=CC=C(C=C2)N
DME30O6	IK	KZIPKNLJWRDAKV-UHFFFAOYSA-N
DME30O6	IU	4-(2-cyclohexylethoxy)aniline
DME30O6	CA	CAS 76253-34-4

DM8F4QP	ID	DM8F4QP
DM8F4QP	DN	4-(2-cyclohexylethoxy) aniline derivative 2
DM8F4QP	HS	Patented
DM8F4QP	SN	PMID28454500-Compound-88
DM8F4QP	CP	Korea institute of radiological & medical sciences, S
DM8F4QP	DT	Small molecular drug
DM8F4QP	PC	3365475
DM8F4QP	MW	319.4
DM8F4QP	FM	C18H25NO4
DM8F4QP	IC	InChI=1S/C18H25NO4/c20-17(10-11-18(21)22)19-15-6-8-16(9-7-15)23-13-12-14-4-2-1-3-5-14/h6-9,14H,1-5,10-13H2,(H,19,20)(H,21,22)
DM8F4QP	CS	C1CCC(CC1)CCOC2=CC=C(C=C2)NC(=O)CCC(=O)O
DM8F4QP	IK	NUDKZKXLJIDEDG-UHFFFAOYSA-N
DM8F4QP	IU	4-[4-(2-cyclohexylethoxy)anilino]-4-oxobutanoic acid

DMJU0SO	ID	DMJU0SO
DMJU0SO	DN	4-(2-cyclohexylethoxy) aniline derivative 3
DMJU0SO	HS	Patented
DMJU0SO	SN	PMID28454500-Compound-89
DMJU0SO	CP	Korea institute of radiological & medical sciences, S
DMJU0SO	DT	Small molecular drug
DMJU0SO	PC	15943058
DMJU0SO	MW	261.36
DMJU0SO	FM	C16H23NO2
DMJU0SO	IC	InChI=1S/C16H23NO2/c1-13(18)17-15-7-9-16(10-8-15)19-12-11-14-5-3-2-4-6-14/h7-10,14H,2-6,11-12H2,1H3,(H,17,18)
DMJU0SO	CS	CC(=O)NC1=CC=C(C=C1)OCCC2CCCCC2
DMJU0SO	IK	XXEWOEJZHUIISK-UHFFFAOYSA-N
DMJU0SO	IU	N-[4-(2-cyclohexylethoxy)phenyl]acetamide

DMPULIC	ID	DMPULIC
DMPULIC	DN	4-(2-cyclohexylethoxy) aniline derivative 4
DMPULIC	HS	Patented
DMPULIC	SN	PMID28454500-Compound-90
DMPULIC	CP	Korea institute of radiological & medical sciences, S
DMPULIC	DT	Small molecular drug
DMPULIC	PC	3886018
DMPULIC	MW	489.4
DMPULIC	FM	C24H29BrN2O4
DMPULIC	IC	InChI=1S/C24H29BrN2O4/c25-19-7-4-8-21(15-19)27-24(29)17-30-16-23(28)26-20-9-11-22(12-10-20)31-14-13-18-5-2-1-3-6-18/h4,7-12,15,18H,1-3,5-6,13-14,16-17H2,(H,26,28)(H,27,29)
DMPULIC	CS	C1CCC(CC1)CCOC2=CC=C(C=C2)NC(=O)COCC(=O)NC3=CC(=CC=C3)Br
DMPULIC	IK	SUIJKJPCTOXCER-UHFFFAOYSA-N
DMPULIC	IU	2-[2-(3-bromoanilino)-2-oxoethoxy]-N-[4-(2-cyclohexylethoxy)phenyl]acetamide

DM7B81V	ID	DM7B81V
DM7B81V	DN	4-(thiazol-5-yl)-pyrimidine derivative 1
DM7B81V	HS	Patented
DM7B81V	SN	PMID26161698-Compound-35
DM7B81V	CP	THE UNIVERSITY OF NOTTINGHAM WANG, Shudong SHI, Shenhua ZAYTSEV, Andrey FISCHER, Peter MartiCYCLACEL LIMITED WANG, Shudong MEADES, Christopher WOOD, Gavin OSNOWSKI, Andrew FISCHER, Peter, MartiCYCLACEL LIMITED FISCHER, Peter, Martin WANG, Shudong WOOD, Gavin
DM7B81V	DT	Small molecular drug
DM7B81V	PC	44253187
DM7B81V	MW	338.4
DM7B81V	FM	C16H14N6OS
DM7B81V	IC	InChI=1S/C16H14N6OS/c1-9-14(24-16(18-2)20-9)13-10(7-17)8-19-15(22-13)21-11-4-3-5-12(23)6-11/h3-6,8,23H,1-2H3,(H,18,20)(H,19,21,22)
DM7B81V	CS	CC1=C(SC(=N1)NC)C2=NC(=NC=C2C#N)NC3=CC(=CC=C3)O
DM7B81V	IK	NYRVLHGVDPPWJS-UHFFFAOYSA-N
DM7B81V	IU	2-(3-hydroxyanilino)-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidine-5-carbonitrile

DMMQFCN	ID	DMMQFCN
DMMQFCN	DN	4-(thiazol-5-yl)-pyrimidine derivative 2
DMMQFCN	HS	Patented
DMMQFCN	SN	PMID26161698-Compound-36
DMMQFCN	CP	CHANGZHOU LE SUN PHARMACEUTICALS LIMITED
DMMQFCN	DT	Small molecular drug
DMMQFCN	PC	71561915
DMMQFCN	MW	394.5
DMMQFCN	FM	C15H15FN6O2S2
DMMQFCN	IC	InChI=1S/C15H15FN6O2S2/c1-8-13(25-15(18-2)20-8)12-11(16)7-19-14(22-12)21-9-4-3-5-10(6-9)26(17,23)24/h3-7H,1-2H3,(H,18,20)(H2,17,23,24)(H,19,21,22)
DMMQFCN	CS	CC1=C(SC(=N1)NC)C2=NC(=NC=C2F)NC3=CC(=CC=C3)S(=O)(=O)N
DMMQFCN	IK	GAIOPWBQKZMUNO-UHFFFAOYSA-N
DMMQFCN	IU	3-[[5-fluoro-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide

DMCISHW	ID	DMCISHW
DMCISHW	DN	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 1
DMCISHW	HS	Patented
DMCISHW	SN	PMID27788040-Compound-2
DMCISHW	CP	RESEARCH TRIANGLE INSTITUTE
DMCISHW	DT	Small molecular drug

DMPTRQD	ID	DMPTRQD
DMPTRQD	DN	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 2
DMPTRQD	HS	Patented
DMPTRQD	SN	PMID27788040-Compound-2a
DMPTRQD	CP	RESEARCH TRIANGLE INSTITUTE
DMPTRQD	DT	Small molecular drug
DMPTRQD	PC	89615818
DMPTRQD	MW	502.6
DMPTRQD	FM	C30H38N4O3
DMPTRQD	IC	InChI=1S/C30H38N4O3/c1-22(2)19-30(24-10-5-4-6-11-24)26-21-34(14-13-25(26)28(35)37-30)29(36)31-20-23-9-7-8-12-27(23)33-17-15-32(3)16-18-33/h4-12,22H,13-21H2,1-3H3,(H,31,36)
DMPTRQD	CS	CC(C)CC1(C2=C(CCN(C2)C(=O)NCC3=CC=CC=C3N4CCN(CC4)C)C(=O)O1)C5=CC=CC=C5
DMPTRQD	IK	VAJNMLPRDFYTCT-UHFFFAOYSA-N
DMPTRQD	IU	N-[[2-(4-methylpiperazin-1-yl)phenyl]methyl]-3-(2-methylpropyl)-1-oxo-3-phenyl-6,7-dihydro-4H-furo[3,4-c]pyridine-5-carboxamide

DMFOBM9	ID	DMFOBM9
DMFOBM9	DN	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 3
DMFOBM9	HS	Patented
DMFOBM9	SN	PMID27788040-Compound-2b
DMFOBM9	CP	RESEARCH TRIANGLE INSTITUTE
DMFOBM9	DT	Small molecular drug
DMFOBM9	PC	89615787
DMFOBM9	MW	424.6
DMFOBM9	FM	C26H36N2O3
DMFOBM9	IC	InChI=1S/C26H36N2O3/c1-20(2)18-26(21-10-6-5-7-11-21)23-19-28(17-12-22(23)25(30)31-26)24(29)13-16-27-14-8-3-4-9-15-27/h5-7,10-11,20H,3-4,8-9,12-19H2,1-2H3
DMFOBM9	CS	CC(C)CC1(C2=C(CCN(C2)C(=O)CCN3CCCCCC3)C(=O)O1)C4=CC=CC=C4
DMFOBM9	IK	GPTJWUZEJKIMBY-UHFFFAOYSA-N
DMFOBM9	IU	5-[3-(azepan-1-yl)propanoyl]-3-(2-methylpropyl)-3-phenyl-6,7-dihydro-4H-furo[3,4-c]pyridin-1-one

DM6MCBU	ID	DM6MCBU
DM6MCBU	DN	4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 4
DM6MCBU	HS	Patented
DM6MCBU	SN	PMID27788040-Compound-2c
DM6MCBU	CP	RESEARCH TRIANGLE INSTITUTE
DM6MCBU	DT	Small molecular drug
DM6MCBU	PC	78118680
DM6MCBU	MW	430.5
DM6MCBU	FM	C27H30N2O3
DM6MCBU	IC	InChI=1S/C27H30N2O3/c1-18(2)15-27(21-10-4-3-5-11-21)23-17-29(13-12-22(23)26(31)32-27)25(30)24-14-19-8-6-7-9-20(19)16-28-24/h3-11,18,24,28H,12-17H2,1-2H3
DM6MCBU	CS	CC(C)CC1(C2=C(CCN(C2)C(=O)C3CC4=CC=CC=C4CN3)C(=O)O1)C5=CC=CC=C5
DM6MCBU	IK	XMIBEMVACFABOS-UHFFFAOYSA-N
DM6MCBU	IU	3-(2-methylpropyl)-3-phenyl-5-(1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-6,7-dihydro-4H-furo[3,4-c]pyridin-1-one

DMMELYI	ID	DMMELYI
DMMELYI	DN	4-amino-3,5-di-substituted-thiazole derivative 1
DMMELYI	HS	Patented
DMMELYI	SN	PMID26161698-Compound-54
DMMELYI	DT	Small molecular drug

DMEMYDZ	ID	DMEMYDZ
DMEMYDZ	DN	4-aryl quinol derivative 1
DMEMYDZ	HS	Patented
DMEMYDZ	SN	PMID27977313-Compound-20
DMEMYDZ	CP	CANCER RESEARCH TECHNOLOGY LIMITED
DMEMYDZ	DT	Small molecular drug
DMEMYDZ	PC	482698
DMEMYDZ	MW	242.29
DMEMYDZ	FM	C14H10O2S
DMEMYDZ	IC	InChI=1S/C14H10O2S/c15-11-5-7-14(16,8-6-11)13-9-10-3-1-2-4-12(10)17-13/h1-9,16H
DMEMYDZ	CS	C1=CC=C2C(=C1)C=C(S2)C3(C=CC(=O)C=C3)O
DMEMYDZ	IK	TXEIZQHZDIXJLD-UHFFFAOYSA-N
DMEMYDZ	IU	4-(1-benzothiophen-2-yl)-4-hydroxycyclohexa-2,5-dien-1-one

DM7TW5Z	ID	DM7TW5Z
DM7TW5Z	DN	4-aryl quinol derivative 2
DM7TW5Z	HS	Patented
DM7TW5Z	SN	PMID27977313-Compound-21
DM7TW5Z	CP	CANCER RESEARCH TECHNOLOGY LIMITED
DM7TW5Z	DT	Small molecular drug
DM7TW5Z	PC	482697
DM7TW5Z	MW	243.28
DM7TW5Z	FM	C13H9NO2S
DM7TW5Z	IC	InChI=1S/C13H9NO2S/c15-9-5-7-13(16,8-6-9)12-14-10-3-1-2-4-11(10)17-12/h1-8,16H
DM7TW5Z	CS	C1=CC=C2C(=C1)N=C(S2)C3(C=CC(=O)C=C3)O
DM7TW5Z	IK	SDYBYKXWYDVVKP-UHFFFAOYSA-N
DM7TW5Z	IU	4-(1,3-benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-one
DM7TW5Z	CA	CAS 485842-97-5

DM05V8Q	ID	DM05V8Q
DM05V8Q	DN	4-aryl quinol derivative 3
DM05V8Q	HS	Patented
DM05V8Q	SN	PMID27977313-Compound-22
DM05V8Q	CP	CANCER RESEARCH TECHNOLOGY LIMITED
DM05V8Q	DT	Small molecular drug
DM05V8Q	PC	9907134
DM05V8Q	MW	365.4
DM05V8Q	FM	C20H15NO4S
DM05V8Q	IC	InChI=1S/C20H15NO4S/c22-16-10-12-20(23,13-11-16)19-14-15-6-4-5-9-18(15)21(19)26(24,25)17-7-2-1-3-8-17/h1-14,23H
DM05V8Q	CS	C1=CC=C(C=C1)S(=O)(=O)N2C3=CC=CC=C3C=C2C4(C=CC(=O)C=C4)O
DM05V8Q	IK	HWKQYGBAAMKHDY-UHFFFAOYSA-N
DM05V8Q	IU	4-[1-(benzenesulfonyl)indol-2-yl]-4-hydroxycyclohexa-2,5-dien-1-one
DM05V8Q	CA	CAS 719308-90-4

DM5IWX2	ID	DM5IWX2
DM5IWX2	DN	4-aryl quinol derivative 4
DM5IWX2	HS	Patented
DM5IWX2	SN	PMID27977313-Compound-23
DM5IWX2	CP	CANCER RESEARCH TECHNOLOGY LIMITED
DM5IWX2	DT	Small molecular drug
DM5IWX2	PC	10430033
DM5IWX2	MW	383.4
DM5IWX2	FM	C20H14FNO4S
DM5IWX2	IC	InChI=1S/C20H14FNO4S/c21-15-6-7-18-14(12-15)13-19(20(24)10-8-16(23)9-11-20)22(18)27(25,26)17-4-2-1-3-5-17/h1-13,24H
DM5IWX2	CS	C1=CC=C(C=C1)S(=O)(=O)N2C3=C(C=C(C=C3)F)C=C2C4(C=CC(=O)C=C4)O
DM5IWX2	IK	KASRNHWIQQCDNO-UHFFFAOYSA-N
DM5IWX2	IU	4-[1-(benzenesulfonyl)-5-fluoroindol-2-yl]-4-hydroxycyclohexa-2,5-dien-1-one

DMWB2YX	ID	DMWB2YX
DMWB2YX	DN	4-aryl quinol derivative 5
DMWB2YX	HS	Patented
DMWB2YX	SN	PMID27977313-Compound-24
DMWB2YX	CP	CANCER RESEARCH TECHNOLOGY LIMITED
DMWB2YX	DT	Small molecular drug
DMWB2YX	PC	10474852
DMWB2YX	MW	379.4
DMWB2YX	FM	C21H17NO4S
DMWB2YX	IC	InChI=1S/C21H17NO4S/c1-15-6-8-18(9-7-15)27(25,26)22-19-5-3-2-4-16(19)14-20(22)21(24)12-10-17(23)11-13-21/h2-14,24H,1H3
DMWB2YX	CS	CC1=CC=C(C=C1)S(=O)(=O)N2C3=CC=CC=C3C=C2C4(C=CC(=O)C=C4)O
DMWB2YX	IK	NLFCLJPNQJYXHL-UHFFFAOYSA-N
DMWB2YX	IU	4-hydroxy-4-[1-(4-methylphenyl)sulfonylindol-2-yl]cyclohexa-2,5-dien-1-one

DMC3KTB	ID	DMC3KTB
DMC3KTB	DN	4-aryl quinol derivative 7
DMC3KTB	HS	Patented
DMC3KTB	SN	PMID27977313-Compound-Figure5a
DMC3KTB	CP	CANCER RESEARCH TECHNOLOGY LIMITED
DMC3KTB	DT	Small molecular drug

DMZDUNT	ID	DMZDUNT
DMZDUNT	DN	4-benzylidene-1-(cyclobutylo)piperidine derivative 1
DMZDUNT	HS	Patented
DMZDUNT	SN	PMID29334795-Compound-54
DMZDUNT	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMZDUNT	DT	Small molecular drug

DMM9I1R	ID	DMM9I1R
DMM9I1R	DN	4-Carboxamido-isoindolinone derivative 1
DMM9I1R	HS	Patented
DMM9I1R	SN	PMID27841036-Compound-2
DMM9I1R	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMM9I1R	DT	Small molecular drug

DM3EHSN	ID	DM3EHSN
DM3EHSN	DN	4-Carboxamido-isoindolinone derivative 2
DM3EHSN	HS	Patented
DM3EHSN	SN	PMID27841036-Compound-3
DM3EHSN	CP	NERVIANO MEDICAL SCIENCES S.R.L
DM3EHSN	DT	Small molecular drug

DM43YA0	ID	DM43YA0
DM43YA0	DN	4-Carboxamido-isoindolinone derivative 3
DM43YA0	HS	Patented
DM43YA0	SN	PMID27841036-Compound-4
DM43YA0	CP	NERVIANO MEDICAL SCIENCES S.R.L
DM43YA0	DT	Small molecular drug

DMTGEFW	ID	DMTGEFW
DMTGEFW	DN	4-Carboxamido-isoindolinone derivative 4
DMTGEFW	HS	Patented
DMTGEFW	SN	PMID27841036-Compound-5
DMTGEFW	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMTGEFW	DT	Small molecular drug

DMIYVOC	ID	DMIYVOC
DMIYVOC	DN	4-Carboxamido-isoindolinone derivative 5
DMIYVOC	HS	Patented
DMIYVOC	SN	PMID27841036-Compound-III
DMIYVOC	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMIYVOC	DT	Small molecular drug

DM9L5KO	ID	DM9L5KO
DM9L5KO	DN	4-Hydroxy-2,5-dimethyl-3(2H)-furanone
DM9L5KO	HS	Patented
DM9L5KO	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM9L5KO	PC	19309
DM9L5KO	MW	128.13
DM9L5KO	FM	C6H8O3
DM9L5KO	IC	InChI=1S/C6H8O3/c1-3-5(7)6(8)4(2)9-3/h3,8H,1-2H3
DM9L5KO	CS	CC1C(=O)C(=C(O1)C)O
DM9L5KO	IK	INAXVXBDKKUCGI-UHFFFAOYSA-N
DM9L5KO	IU	4-hydroxy-2,5-dimethylfuran-3-one
DM9L5KO	CA	CAS 3658-77-3
DM9L5KO	CB	CHEBI:76247

DM471P5	ID	DM471P5
DM471P5	DN	4-hydroxybenzaldehyde
DM471P5	HS	Patented
DM471P5	SN	4-hydroxybenzaldehyde; p-Hydroxybenzaldehyde; 123-08-0; 4-Formylphenol; p-Formylphenol; p-Oxybenzaldehyde; Benzaldehyde, 4-hydroxy-; Parahydroxybenzaldehyde; Benzaldehyde, p-hydroxy-; 4-HYDROXY-BENZALDEHYDE; USAF M-6; 4-Hydroxy benzaldehyde; NSC 2127; p-Hydroxy-benzaldehyde; UNII-O1738X3Y38; Para-Hydroxybenzaldehyde; 4-Hydroxybenzenecarbonal; EINECS 204-599-1; BRN 0471352; CHEMBL14193; AI3-15366; PARA-HYDROXY BENZALDEHYDE; CHEBI:17597; RGHHSNMVTDWUBI-UHFFFAOYSA-N; MFCD00006939; O1738X3Y38; 4-Hydroxybenzaldehyde, 99%; Benzaldehyde, 4-
DM471P5	DT	Small molecular drug
DM471P5	PC	126
DM471P5	MW	122.12
DM471P5	FM	C7H6O2
DM471P5	IC	InChI=1S/C7H6O2/c8-5-6-1-3-7(9)4-2-6/h1-5,9H
DM471P5	CS	C1=CC(=CC=C1C=O)O
DM471P5	IK	RGHHSNMVTDWUBI-UHFFFAOYSA-N
DM471P5	IU	4-hydroxybenzaldehyde
DM471P5	CA	CAS 123-08-0
DM471P5	CB	CHEBI:17597
DM471P5	DE	Discovery agent

DM3WQNY	ID	DM3WQNY
DM3WQNY	DN	4-Hydroxybenzoicacid
DM3WQNY	HS	Patented
DM3WQNY	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM3WQNY	PC	135
DM3WQNY	MW	138.12
DM3WQNY	FM	C7H6O3
DM3WQNY	IC	InChI=1S/C7H6O3/c8-6-3-1-5(2-4-6)7(9)10/h1-4,8H,(H,9,10)
DM3WQNY	CS	C1=CC(=CC=C1C(=O)O)O
DM3WQNY	IK	FJKROLUGYXJWQN-UHFFFAOYSA-N
DM3WQNY	IU	4-hydroxybenzoic acid
DM3WQNY	CA	CAS 99-96-7
DM3WQNY	CB	CHEBI:30763

DMKDZMQ	ID	DMKDZMQ
DMKDZMQ	DN	4-Hydroxybenzylalcohol
DMKDZMQ	HS	Patented
DMKDZMQ	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DMKDZMQ	PC	125
DMKDZMQ	MW	124.14
DMKDZMQ	FM	C7H8O2
DMKDZMQ	IC	InChI=1S/C7H8O2/c8-5-6-1-3-7(9)4-2-6/h1-4,8-9H,5H2
DMKDZMQ	CS	C1=CC(=CC=C1CO)O
DMKDZMQ	IK	BVJSUAQZOZWCKN-UHFFFAOYSA-N
DMKDZMQ	IU	4-(hydroxymethyl)phenol
DMKDZMQ	CA	CAS 623-05-2
DMKDZMQ	CB	CHEBI:67410

DMN6GTZ	ID	DMN6GTZ
DMN6GTZ	DN	4-Methoxybenzaldehyde
DMN6GTZ	HS	Patented
DMN6GTZ	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DMN6GTZ	PC	31244
DMN6GTZ	MW	136.15
DMN6GTZ	FM	C8H8O2
DMN6GTZ	IC	InChI=1S/C8H8O2/c1-10-8-4-2-7(6-9)3-5-8/h2-6H,1H3
DMN6GTZ	CS	COC1=CC=C(C=C1)C=O
DMN6GTZ	IK	ZRSNZINYAWTAHE-UHFFFAOYSA-N
DMN6GTZ	IU	4-methoxybenzaldehyde
DMN6GTZ	CA	CAS 123-11-5
DMN6GTZ	CB	CHEBI:28235

DMNTOZV	ID	DMNTOZV
DMNTOZV	DN	4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1
DMNTOZV	HS	Patented
DMNTOZV	SN	PMID26161824-Compound-112
DMNTOZV	CP	LABORATORIOS DEL DR. ESTEVE, S. A. VELA HERNANDEZ, Jose, Miguel YENES MINGUEZ, Susan
DMNTOZV	DT	Small molecular drug
DMNTOZV	DE	Obesity

DMWFHKR	ID	DMWFHKR
DMWFHKR	DN	4-oxadiazole derivative 1
DMWFHKR	HS	Patented
DMWFHKR	SN	PMID25470667-Compound-Figure5-11
DMWFHKR	CP	ASTRAZENECA AB ASTRAZENECA UK LIMITED BIRCH, Alan Martin PAL, Sharmistha PETTERSEN, Anna TOMKINSON, Gary Peter
DMWFHKR	DT	Small molecular drug

DMN37BI	ID	DMN37BI
DMN37BI	DN	4-PAM derivative 1
DMN37BI	HS	Patented
DMN37BI	SN	PMID27967267-Compound-46
DMN37BI	CP	Mississippi State University
DMN37BI	DT	Small molecular drug

DMMBUGK	ID	DMMBUGK
DMMBUGK	DN	4-pyridone derivative 1
DMMBUGK	HS	Patented
DMMBUGK	SN	PMID26118988-Compound-37
DMMBUGK	DT	Small molecular drug

DMS1O0G	ID	DMS1O0G
DMS1O0G	DN	4-pyridone derivative 2
DMS1O0G	HS	Patented
DMS1O0G	SN	PMID26118988-Compound-38
DMS1O0G	DT	Small molecular drug

DMN2B87	ID	DMN2B87
DMN2B87	DN	5-azolone derivative 1
DMN2B87	HS	Patented
DMN2B87	SN	PMID25399719-Compound-2
DMN2B87	CP	UNIV ALCALA HENARES [ES]
DMN2B87	DT	Small molecular drug

DMHXKFB	ID	DMHXKFB
DMHXKFB	DN	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1
DMHXKFB	HS	Patented
DMHXKFB	SN	PMID26161698-Compound-28
DMHXKFB	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMHXKFB	DT	Small molecular drug
DMHXKFB	PC	74767011
DMHXKFB	MW	434.5
DMHXKFB	FM	C20H20F2N4O3S
DMHXKFB	IC	InChI=1S/C20H20F2N4O3S/c1-28-17-8-13(21)4-5-14(17)15-9-18(24-10-16(15)22)25-19-6-12(11-30(3,23)27)7-20(26-19)29-2/h4-10,23H,11H2,1-3H3,(H,24,25,26)
DMHXKFB	CS	COC1=CC(=CC(=N1)NC2=NC=C(C(=C2)C3=C(C=C(C=C3)F)OC)F)CS(=N)(=O)C
DMHXKFB	IK	OOPSDSZASQDBNK-UHFFFAOYSA-N
DMHXKFB	IU	N-[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]-6-methoxy-4-[(methylsulfonimidoyl)methyl]pyridin-2-amine

DMOIKB3	ID	DMOIKB3
DMOIKB3	DN	5-Hydrazino-1H-tetrazole
DMOIKB3	HS	Patented
DMOIKB3	SN	5-Hydrazino-1H-tetrazole; 5-hydrazinyl-1H-tetrazole; FXYYVODGZXUHLT-UHFFFAOYSA-N; 5-hydrazinotetrazole; AC1LA0KS; 2H-tetrazol-5-ylhydrazine; 1H-tetrazol-5-ylhydrazine; SCHEMBL94795; CTK7F1894; ZX-AN011348; ALBB-012551; NSC206227; STL421139; AKOS000295392; ZINC100158257; NSC-206227; 1H-1,2,3,4-Tetrazole, 5-hydrazino-; 1H-tetrazole, 5-hydrazino-, hydrochloride; BB 0259716
DMOIKB3	DT	Small molecular drug
DMOIKB3	PC	459489
DMOIKB3	MW	100.08
DMOIKB3	FM	CH4N6
DMOIKB3	IC	InChI=1S/CH4N6/c2-3-1-4-6-7-5-1/h2H2,(H2,3,4,5,6,7)
DMOIKB3	CS	C1(=NNN=N1)NN
DMOIKB3	IK	FXYYVODGZXUHLT-UHFFFAOYSA-N
DMOIKB3	IU	2H-tetrazol-5-ylhydrazine
DMOIKB3	CA	CAS 40925-73-3

DM0VEBI	ID	DM0VEBI
DM0VEBI	DN	6,6-fused nitrogenous heterocyclic compound 1
DM0VEBI	HS	Patented
DM0VEBI	SN	PMID25656651-Compound-32a
DM0VEBI	CP	F. HOFFMANN-LA ROCHE AG GAZZARD, Lewis J. HANAN, Emily KINTZ, Samuel LYSSIKATOS, Joseph P. PURKEY, Hans Edward
DM0VEBI	DT	Small molecular drug
DM0VEBI	PC	68095484
DM0VEBI	MW	318.4
DM0VEBI	FM	C20H18N2O2
DM0VEBI	IC	InChI=1S/C20H18N2O2/c1-12-2-7-17(23)10-18(12)15-6-5-14-9-19(21-11-16(14)8-15)22-20(24)13-3-4-13/h2,5-11,13,23H,3-4H2,1H3,(H,21,22,24)
DM0VEBI	CS	CC1=C(C=C(C=C1)O)C2=CC3=CN=C(C=C3C=C2)NC(=O)C4CC4
DM0VEBI	IK	JLLTUBSBILQEOE-UHFFFAOYSA-N
DM0VEBI	IU	N-[7-(5-hydroxy-2-methylphenyl)isoquinolin-3-yl]cyclopropanecarboxamide

DMB1EAW	ID	DMB1EAW
DMB1EAW	DN	6,6-fused nitrogenous heterocyclic compound 2
DMB1EAW	HS	Patented
DMB1EAW	SN	PMID25656651-Compound-32b
DMB1EAW	CP	F. HOFFMANN-LA ROCHE AG GAZZARD, Lewis J. HANAN, Emily KINTZ, Samuel LYSSIKATOS, Joseph P. PURKEY, Hans Edward
DMB1EAW	DT	Small molecular drug
DMB1EAW	PC	67974814
DMB1EAW	MW	321.3
DMB1EAW	FM	C19H16FN3O
DMB1EAW	IC	InChI=1S/C19H16FN3O/c1-11-16(9-21-10-17(11)20)14-5-4-13-7-18(22-8-15(13)6-14)23-19(24)12-2-3-12/h4-10,12H,2-3H2,1H3,(H,22,23,24)
DMB1EAW	CS	CC1=C(C=NC=C1C2=CC3=CN=C(C=C3C=C2)NC(=O)C4CC4)F
DMB1EAW	IK	GSLMJIPSSNUWRV-UHFFFAOYSA-N
DMB1EAW	IU	N-[7-(5-fluoro-4-methylpyridin-3-yl)isoquinolin-3-yl]cyclopropanecarboxamide

DMX3VCO	ID	DMX3VCO
DMX3VCO	DN	6,6-fused nitrogenous heterocyclic compound 3
DMX3VCO	HS	Patented
DMX3VCO	SN	PMID25656651-Compound-32c
DMX3VCO	CP	F. HOFFMANN-LA ROCHE AG GAZZARD, Lewis J. HANAN, Emily KINTZ, Samuel LYSSIKATOS, Joseph P. PURKEY, Hans Edward
DMX3VCO	DT	Small molecular drug
DMX3VCO	PC	71140595
DMX3VCO	MW	419.4
DMX3VCO	FM	C21H17F4N3O2
DMX3VCO	IC	InChI=1S/C21H17F4N3O2/c1-10-4-17(19(29)21(23,24)25)26-9-15(10)12-3-2-11-6-18(27-8-13(11)5-12)28-20(30)14-7-16(14)22/h2-6,8-9,14,16,19,29H,7H2,1H3,(H,27,28,30)/t14-,16+,19+/m1/s1
DMX3VCO	CS	CC1=CC(=NC=C1C2=CC3=CN=C(C=C3C=C2)NC(=O)[C@@H]4C[C@@H]4F)[C@@H](C(F)(F)F)O
DMX3VCO	IK	LTXJULOSIPKSDB-ALKREAHSSA-N
DMX3VCO	IU	(1S,2S)-2-fluoro-N-[7-[4-methyl-6-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]pyridin-3-yl]isoquinolin-3-yl]cyclopropane-1-carboxamide

DMJL1MB	ID	DMJL1MB
DMJL1MB	DN	67S
DMJL1MB	HS	Patented
DMJL1MB	SN	CHEMBL3814206; {2-[(2r)-4-[4-(Hydroxymethyl)-3-(Methylsulfonyl)phenyl]-2-(Propan-2-Yl)piperazin-1-Yl]-4-(Trifluoromethyl)pyrimidin-5-Yl}methanol; SCHEMBL17519333; BDBM50177015; 67S
DMJL1MB	DT	Small molecular drug
DMJL1MB	PC	91827457
DMJL1MB	MW	488.5
DMJL1MB	FM	C21H27F3N4O4S
DMJL1MB	IC	InChI=1S/C21H27F3N4O4S/c1-13(2)17-10-27(16-5-4-14(11-29)18(8-16)33(3,31)32)6-7-28(17)20-25-9-15(12-30)19(26-20)21(22,23)24/h4-5,8-9,13,17,29-30H,6-7,10-12H2,1-3H3/t17-/m0/s1
DMJL1MB	CS	CC(C)[C@@H]1CN(CCN1C2=NC=C(C(=N2)C(F)(F)F)CO)C3=CC(=C(C=C3)CO)S(=O)(=O)C
DMJL1MB	IK	FPVIRRAMNBCEDK-KRWDZBQOSA-N
DMJL1MB	IU	[4-[(3R)-4-[5-(hydroxymethyl)-4-(trifluoromethyl)pyrimidin-2-yl]-3-propan-2-ylpiperazin-1-yl]-2-methylsulfonylphenyl]methanol

DMTXGYS	ID	DMTXGYS
DMTXGYS	DN	6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 1
DMTXGYS	HS	Patented
DMTXGYS	SN	PMID28067079-Compound-109
DMTXGYS	DT	Small molecular drug
DMTXGYS	PC	121263121
DMTXGYS	MW	350.4
DMTXGYS	FM	C17H14N6OS
DMTXGYS	IC	InChI=1S/C17H14N6OS/c1-10-3-4-18-6-14(10)12-5-13(15-19-9-20-23(15)7-12)16(24)22-17-21-11(2)8-25-17/h3-9H,1-2H3,(H,21,22,24)
DMTXGYS	CS	CC1=C(C=NC=C1)C2=CN3C(=NC=N3)C(=C2)C(=O)NC4=NC(=CS4)C
DMTXGYS	IK	BKRWMNODROTBAW-UHFFFAOYSA-N
DMTXGYS	IU	6-(4-methylpyridin-3-yl)-N-(4-methyl-1,3-thiazol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide

DMFKTBM	ID	DMFKTBM
DMFKTBM	DN	6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 2
DMFKTBM	HS	Patented
DMFKTBM	SN	PMID28067079-Compound-110
DMFKTBM	DT	Small molecular drug
DMFKTBM	PC	121263153
DMFKTBM	MW	339.4
DMFKTBM	FM	C15H13N7OS
DMFKTBM	IC	InChI=1S/C15H13N7OS/c1-8-3-12(21-20-8)10-4-11(13-16-7-17-22(13)5-10)14(23)19-15-18-9(2)6-24-15/h3-7H,1-2H3,(H,20,21)(H,18,19,23)
DMFKTBM	CS	CC1=CC(=NN1)C2=CN3C(=NC=N3)C(=C2)C(=O)NC4=NC(=CS4)C
DMFKTBM	IK	VNZBTWWCDKRKLN-UHFFFAOYSA-N
DMFKTBM	IU	6-(5-methyl-1H-pyrazol-3-yl)-N-(4-methyl-1,3-thiazol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide

DMXMTLP	ID	DMXMTLP
DMXMTLP	DN	6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 3
DMXMTLP	HS	Patented
DMXMTLP	SN	PMID28067079-Compound-111
DMXMTLP	DT	Small molecular drug
DMXMTLP	PC	121263181
DMXMTLP	MW	339.4
DMXMTLP	FM	C15H13N7OS
DMXMTLP	IC	InChI=1S/C15H13N7OS/c1-9-7-24-15(19-9)20-14(23)11-5-10(12-3-4-17-21(12)2)6-22-13(11)16-8-18-22/h3-8H,1-2H3,(H,19,20,23)
DMXMTLP	CS	CC1=CSC(=N1)NC(=O)C2=CC(=CN3C2=NC=N3)C4=CC=NN4C
DMXMTLP	IK	POJPLPZXVLFMAM-UHFFFAOYSA-N
DMXMTLP	IU	6-(2-methylpyrazol-3-yl)-N-(4-methyl-1,3-thiazol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide

DMN082G	ID	DMN082G
DMN082G	DN	6EP
DMN082G	HS	Patented
DMN082G	SN	2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19); 6EP
DMN082G	DT	Small molecular drug
DMN082G	PC	74766595
DMN082G	MW	343.8
DMN082G	FM	C17H14ClN3O3
DMN082G	IC	InChI=1S/C17H14ClN3O3/c1-11-8-14(18)3-2-13(11)10-24-16-5-7-20-21(16)15-9-12(17(22)23)4-6-19-15/h2-9H,10H2,1H3,(H,22,23)
DMN082G	CS	CC1=C(C=CC(=C1)Cl)COC2=CC=NN2C3=NC=CC(=C3)C(=O)O
DMN082G	IK	PSOBPHXKKHPWMU-UHFFFAOYSA-N
DMN082G	IU	2-[5-[(4-chloro-2-methylphenyl)methoxy]pyrazol-1-yl]pyridine-4-carboxylic acid

DMV5XR7	ID	DMV5XR7
DMV5XR7	DN	6-Phenylquinazolin-4-amine
DMV5XR7	HS	Patented
DMV5XR7	SN	CHEMBL3262570; 6-phenyl quinazolin-4-amine; SCHEMBL15587451; BDBM50011551
DMV5XR7	DT	Small molecular drug
DMV5XR7	PC	90054733
DMV5XR7	MW	221.26
DMV5XR7	FM	C14H11N3
DMV5XR7	IC	InChI=1S/C14H11N3/c15-14-12-8-11(10-4-2-1-3-5-10)6-7-13(12)16-9-17-14/h1-9H,(H2,15,16,17)
DMV5XR7	CS	C1=CC=C(C=C1)C2=CC3=C(C=C2)N=CN=C3N
DMV5XR7	IK	KLSNPRMSQXGJND-UHFFFAOYSA-N
DMV5XR7	IU	6-phenylquinazolin-4-amine

DMQL5B7	ID	DMQL5B7
DMQL5B7	DN	7-azaindole derivative 1
DMQL5B7	HS	Patented
DMQL5B7	SN	PMID25991433-Compound-I1
DMQL5B7	CP	EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMQL5B7	DT	Small molecular drug
DMQL5B7	PC	10040667
DMQL5B7	MW	303.4
DMQL5B7	FM	C18H17N5
DMQL5B7	IC	InChI=1S/C18H17N5/c1-23(2)15-5-3-12(4-6-15)13-7-16-17(14-9-21-22-10-14)11-20-18(16)19-8-13/h3-11H,1-2H3,(H,19,20)(H,21,22)
DMQL5B7	CS	CN(C)C1=CC=C(C=C1)C2=CC3=C(NC=C3C4=CNN=C4)N=C2
DMQL5B7	IK	IPPNJZWFNCNYSG-UHFFFAOYSA-N
DMQL5B7	IU	N,N-dimethyl-4-[3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]aniline

DMZRM2Q	ID	DMZRM2Q
DMZRM2Q	DN	7-azaindole derivative 2
DMZRM2Q	HS	Patented
DMZRM2Q	SN	PMID25991433-Compound-I2
DMZRM2Q	CP	EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMZRM2Q	DT	Small molecular drug

DMQ7BV4	ID	DMQ7BV4
DMQ7BV4	DN	7-azaindole derivative 3
DMQ7BV4	HS	Patented
DMQ7BV4	SN	PMID25991433-Compound-I3
DMQ7BV4	CP	EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMQ7BV4	DT	Small molecular drug

DMW3EMH	ID	DMW3EMH
DMW3EMH	DN	7-azaindole derivative 4
DMW3EMH	HS	Patented
DMW3EMH	SN	PMID25991433-Compound-I4
DMW3EMH	CP	EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMW3EMH	DT	Small molecular drug

DMV3H98	ID	DMV3H98
DMV3H98	DN	7-azaindole derivative 5
DMV3H98	HS	Patented
DMV3H98	SN	PMID25991433-Compound-I5
DMV3H98	CP	EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMV3H98	DT	Small molecular drug
DMV3H98	PC	59238862
DMV3H98	MW	280.37
DMV3H98	FM	C17H20N4
DMV3H98	IC	InChI=1S/C17H20N4/c1-21-11-14(9-20-21)16-10-19-17-15(16)7-13(8-18-17)12-5-3-2-4-6-12/h7-12H,2-6H2,1H3,(H,18,19)
DMV3H98	CS	CN1C=C(C=N1)C2=CNC3=C2C=C(C=N3)C4CCCCC4
DMV3H98	IK	FZQRKZMGFGTWJG-UHFFFAOYSA-N
DMV3H98	IU	5-cyclohexyl-3-(1-methylpyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine

DM8X5GP	ID	DM8X5GP
DM8X5GP	DN	7-azaindole derivative 6
DM8X5GP	HS	Patented
DM8X5GP	SN	PMID25991433-Compound-I6
DM8X5GP	CP	EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DM8X5GP	DT	Small molecular drug
DM8X5GP	PC	44633908
DM8X5GP	MW	281.36
DM8X5GP	FM	C16H19N5
DM8X5GP	IC	InChI=1S/C16H19N5/c1-21-10-13(9-18-21)15-14-7-12(8-17-16(14)20-19-15)11-5-3-2-4-6-11/h7-11H,2-6H2,1H3,(H,17,19,20)
DM8X5GP	CS	CN1C=C(C=N1)C2=C3C=C(C=NC3=NN2)C4CCCCC4
DM8X5GP	IK	RKYRUOWFAUYZLA-UHFFFAOYSA-N
DM8X5GP	IU	5-cyclohexyl-3-(1-methylpyrazol-4-yl)-2H-pyrazolo[3,4-b]pyridine

DMB1WQZ	ID	DMB1WQZ
DMB1WQZ	DN	7-azaindole derivative 7
DMB1WQZ	HS	Patented
DMB1WQZ	SN	PMID25991433-Compound-I7
DMB1WQZ	CP	EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMB1WQZ	DT	Small molecular drug
DMB1WQZ	PC	44622836
DMB1WQZ	MW	281.36
DMB1WQZ	FM	C16H19N5
DMB1WQZ	IC	InChI=1S/C16H19N5/c1-21-10-12(7-19-21)13-8-17-16-15(13)20-14(9-18-16)11-5-3-2-4-6-11/h7-11H,2-6H2,1H3,(H,17,18)
DMB1WQZ	CS	CN1C=C(C=N1)C2=CNC3=NC=C(N=C23)C4CCCCC4
DMB1WQZ	IK	KOKYJLMPOHNWTA-UHFFFAOYSA-N
DMB1WQZ	IU	2-cyclohexyl-7-(1-methylpyrazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine

DMO1920	ID	DMO1920
DMO1920	DN	7-azaindole derivative 8
DMO1920	HS	Patented
DMO1920	SN	PMID27841036-Compound-10
DMO1920	CP	SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A
DMO1920	DT	Small molecular drug
DMO1920	PC	73669300
DMO1920	MW	334.4
DMO1920	FM	C20H22N4O
DMO1920	IC	InChI=1S/C20H22N4O/c21-20(25)24-13-10-17-8-9-18(22-19(17)24)16-6-4-15(5-7-16)14-23-11-2-1-3-12-23/h4-10,13H,1-3,11-12,14H2,(H2,21,25)
DMO1920	CS	C1CCN(CC1)CC2=CC=C(C=C2)C3=NC4=C(C=C3)C=CN4C(=O)N
DMO1920	IK	HIBOPBGHLVWFCH-UHFFFAOYSA-N
DMO1920	IU	6-[4-(piperidin-1-ylmethyl)phenyl]pyrrolo[2,3-b]pyridine-1-carboxamide

DMAY4G1	ID	DMAY4G1
DMAY4G1	DN	7-azaindole derivative 9
DMAY4G1	HS	Patented
DMAY4G1	SN	PMID27841036-Compound-VI
DMAY4G1	CP	SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A
DMAY4G1	DT	Small molecular drug

DMP04Z6	ID	DMP04Z6
DMP04Z6	DN	879325-11-8
DMP04Z6	HS	Patented
DMP04Z6	SN	3-bromo-8-formyl-7-hydroxy-4-methylcoumarin; 879325-11-8; SCHEMBL2555897; CHEMBL272811; BDBM160334; US9040714, 1
DMP04Z6	DT	Small molecular drug
DMP04Z6	PC	24799272
DMP04Z6	MW	283.07
DMP04Z6	FM	C11H7BrO4
DMP04Z6	IC	InChI=1S/C11H7BrO4/c1-5-6-2-3-8(14)7(4-13)10(6)16-11(15)9(5)12/h2-4,14H,1H3
DMP04Z6	CS	CC1=C(C(=O)OC2=C1C=CC(=C2C=O)O)Br
DMP04Z6	IK	YMUFHKSSNMFQIZ-UHFFFAOYSA-N
DMP04Z6	IU	3-bromo-7-hydroxy-4-methyl-2-oxochromene-8-carbaldehyde

DMPQ2L9	ID	DMPQ2L9
DMPQ2L9	DN	936563-93-8
DMPQ2L9	HS	Patented
DMPQ2L9	SN	SCHEMBL793463; SCHEMBL793304; SCHEMBL201745; SCHEMBL460731; SCHEMBL201744; CHEMBL3647967; CHEMBL3912266; BDBM97672; BDBM191614; 936563-93-8; US9181263, 10; US8476284, 40; 2-PropenaMide,N-[cis-4-[4-aMino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]cyclohexyl]; 
DMPQ2L9	DT	Small molecular drug
DMPQ2L9	PC	24821881
DMPQ2L9	MW	454.5
DMPQ2L9	FM	C26H26N6O2
DMPQ2L9	IC	InChI=1S/C26H26N6O2/c1-2-22(33)30-18-10-12-19(13-11-18)32-26-23(25(27)28-16-29-26)24(31-32)17-8-14-21(15-9-17)34-20-6-4-3-5-7-20/h2-9,14-16,18-19H,1,10-13H2,(H,30,33)(H2,27,28,29)
DMPQ2L9	CS	C=CC(=O)NC1CCC(CC1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
DMPQ2L9	IK	SSDFTYWIYVWCIE-UHFFFAOYSA-N
DMPQ2L9	IU	N-[4-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]prop-2-enamide

DM9ESPR	ID	DM9ESPR
DM9ESPR	DN	A1-10436
DM9ESPR	HS	Patented
DM9ESPR	SN	N-{[4-(2-tert-Butylphenyl)piperazin-1-yl]carbonyl}glycine; SCHEMBL630380; CHEMBL3644467; BAZIXHMBHKLDIK-UHFFFAOYSA-N; BDBM135826; US8853215, 6; A1-10436
DM9ESPR	DT	Small molecular drug
DM9ESPR	PC	46931248
DM9ESPR	MW	319.4
DM9ESPR	FM	C17H25N3O3
DM9ESPR	IC	InChI=1S/C17H25N3O3/c1-17(2,3)13-6-4-5-7-14(13)19-8-10-20(11-9-19)16(23)18-12-15(21)22/h4-7H,8-12H2,1-3H3,(H,18,23)(H,21,22)
DM9ESPR	CS	CC(C)(C)C1=CC=CC=C1N2CCN(CC2)C(=O)NCC(=O)O
DM9ESPR	IK	BAZIXHMBHKLDIK-UHFFFAOYSA-N
DM9ESPR	IU	2-[[4-(2-tert-butylphenyl)piperazine-1-carbonyl]amino]acetic acid

DMJD1S6	ID	DMJD1S6
DMJD1S6	DN	A1-10438
DMJD1S6	HS	Patented
DMJD1S6	SN	3-[4-(2-tert-butylphenyl)piperazin-1-yl]-3-oxopropanoic acid; SCHEMBL631591; CHEMBL3644468; BJJSTQNQWBMPNN-UHFFFAOYSA-N; BDBM135827; US8853215, 9; A1-10438
DMJD1S6	DT	Small molecular drug
DMJD1S6	PC	49764239
DMJD1S6	MW	304.4
DMJD1S6	FM	C17H24N2O3
DMJD1S6	IC	InChI=1S/C17H24N2O3/c1-17(2,3)13-6-4-5-7-14(13)18-8-10-19(11-9-18)15(20)12-16(21)22/h4-7H,8-12H2,1-3H3,(H,21,22)
DMJD1S6	CS	CC(C)(C)C1=CC=CC=C1N2CCN(CC2)C(=O)CC(=O)O
DMJD1S6	IK	BJJSTQNQWBMPNN-UHFFFAOYSA-N
DMJD1S6	IU	3-[4-(2-tert-butylphenyl)piperazin-1-yl]-3-oxopropanoic acid

DMFWYKE	ID	DMFWYKE
DMFWYKE	DN	AC1LCOK0
DMFWYKE	HS	Patented
DMFWYKE	SN	CHEMBL349763; 2-(2-Iodo-phenyl)-6,7-dimethoxy-benzo[d][1,3]oxazin-4-one; 2-(2-Iodophenyl)-6,7-dimethoxy-4H-3,1-benzoxazin-4-one; BAS 00763013; AC1LCOK0; Oprea1_230794; Oprea1_104130; SCHEMBL913416; HKRJBRGRGFMQJI-UHFFFAOYSA-N; ZINC832897; STK295881; BDBM50289001; AKOS000642901; MCULE-9727934711; ST50239885; AB00095356-01; SR-01000441631; SR-01000441631-1; 2-(2-iodophenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one; 2-(2-iodophenyl)-6,7-dimethoxybenzo[d]1,3-oxazin-4-one; 2-(2-Iodophenyl)-6,7-dimethoxy-4H-3,1-benzoxazin-4-one #
DMFWYKE	DT	Small molecular drug
DMFWYKE	PC	634264
DMFWYKE	MW	409.17
DMFWYKE	FM	C16H12INO4
DMFWYKE	IC	InChI=1S/C16H12INO4/c1-20-13-7-10-12(8-14(13)21-2)18-15(22-16(10)19)9-5-3-4-6-11(9)17/h3-8H,1-2H3
DMFWYKE	CS	COC1=C(C=C2C(=C1)C(=O)OC(=N2)C3=CC=CC=C3I)OC
DMFWYKE	IK	HKRJBRGRGFMQJI-UHFFFAOYSA-N
DMFWYKE	IU	2-(2-iodophenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one

DMKTMCH	ID	DMKTMCH
DMKTMCH	DN	AC1LDDOQ
DMKTMCH	HS	Patented
DMKTMCH	SN	SMR000046381; AC1LDDOQ; MLS002583553; MLS000082533; SCHEMBL17225576; CHEMBL1583701; HMS2304B12; BDBM289593; ZINC4295838; US10092575, Example 81; STL226884; AKOS025272232; MCULE-1732953744; 6-(2-chlorobenzyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one; 6-(2-Chlorobenzyl)-8,9,10,11-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one; 861645-11-6
DMKTMCH	DT	Small molecular drug
DMKTMCH	PC	665384
DMKTMCH	MW	370.9
DMKTMCH	FM	C18H15ClN4OS
DMKTMCH	IC	InChI=1S/C18H15ClN4OS/c19-13-7-3-1-5-11(13)9-22-17-15(12-6-2-4-8-14(12)25-17)16-20-10-21-23(16)18(22)24/h1,3,5,7,10H,2,4,6,8-9H2
DMKTMCH	CS	C1CCC2=C(C1)C3=C(S2)N(C(=O)N4C3=NC=N4)CC5=CC=CC=C5Cl
DMKTMCH	IK	CXMQSCNDPBVQEJ-UHFFFAOYSA-N
DMKTMCH	IU	8-[(2-chlorophenyl)methyl]-10-thia-3,5,6,8-tetrazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),2,4,11(16)-tetraen-7-one

DMPOR3G	ID	DMPOR3G
DMPOR3G	DN	AC1LE05K
DMPOR3G	HS	Patented
DMPOR3G	SN	2-cyclohexyl-N-(4H-1,2,4-triazol-3-yl)acetamide; MLS-0072999.0001; 2-cyclohexyl-N-(1H-1,2,4-triazol-5-yl)acetamide; 2-Cyclohexyl-N-(4H-[1,2,4]triazol-3-yl)-acetamide; AC1LE05K; Cambridge id 6726786; MLS000527850; cid_704227; SCHEMBL13934556; CHEMBL1408713; BDBM51399; HMS3315G01; HMS2154C10; ZINC5731798; STK222766; AKOS000643541; MCULE-3724123277; SMR000120424; BAS 04087149; EU-0013407; MLS-0072999.0002; 2-cyclohexyl-N-(1H-1,2,4-triazol-5-yl)ethanamide; Z57261898; 432007-38-0
DMPOR3G	DT	Small molecular drug
DMPOR3G	PC	704227
DMPOR3G	MW	208.26
DMPOR3G	FM	C10H16N4O
DMPOR3G	IC	InChI=1S/C10H16N4O/c15-9(13-10-11-7-12-14-10)6-8-4-2-1-3-5-8/h7-8H,1-6H2,(H2,11,12,13,14,15)
DMPOR3G	CS	C1CCC(CC1)CC(=O)NC2=NC=NN2
DMPOR3G	IK	WOQYWVDZSFPTSS-UHFFFAOYSA-N
DMPOR3G	IU	2-cyclohexyl-N-(1H-1,2,4-triazol-5-yl)acetamide

DMXI3O0	ID	DMXI3O0
DMXI3O0	DN	AC1LFGWU
DMXI3O0	HS	Patented
DMXI3O0	SN	AC1LFGWU; Oprea1_144688; SCHEMBL16409995; ZINC310666; STK508156; AKOS003273711; MCULE-1481833521; ST45014551; SR-01000248344; SR-01000248344-1; 8-(4-methyl(1,2,4-triazol-3-ylthio))-5-nitroquinoline; 8-[(4-methyl-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline; 8-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline
DMXI3O0	DT	Small molecular drug
DMXI3O0	PC	802800
DMXI3O0	MW	287.3
DMXI3O0	FM	C12H9N5O2S
DMXI3O0	IC	InChI=1S/C12H9N5O2S/c1-16-7-14-15-12(16)20-10-5-4-9(17(18)19)8-3-2-6-13-11(8)10/h2-7H,1H3
DMXI3O0	CS	CN1C=NN=C1SC2=C3C(=C(C=C2)[N+](=O)[O-])C=CC=N3
DMXI3O0	IK	RMYCZXRLBFQOFF-UHFFFAOYSA-N
DMXI3O0	IU	8-[(4-methyl-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline
DMXI3O0	CA	CAS 345991-02-8

DMEVBZW	ID	DMEVBZW
DMEVBZW	DN	AC1LFXA6
DMEVBZW	HS	Patented
DMEVBZW	SN	2-(3-methylphenyl)-2,3-dihydro-1H-perimidine; CHEMBL1449583; AC1LFXA6; ChemDiv1_022121; CBMicro_008460; AC1Q2H4W; Oprea1_720651; MLS001197334; SCHEMBL2031646; HMS649N11; HMS2885F10; ZINC232263; SMSF0013139; STL335355; BDBM50069104; AKOS001615822; CCG-107154; MCULE-2061703540; SMR000555270; 315231-02-8; BIM-0008433.P001; SR-01000439027; SR-01000439027-1; 3-(3-methylphenyl)-2,4-diazatricyclo[7.3.1.0^{5,13}]trideca-1(12),5,7,9(13),10-pentaene
DMEVBZW	DT	Small molecular drug
DMEVBZW	PC	761639
DMEVBZW	MW	260.3
DMEVBZW	FM	C18H16N2
DMEVBZW	IC	InChI=1S/C18H16N2/c1-12-5-2-8-14(11-12)18-19-15-9-3-6-13-7-4-10-16(20-18)17(13)15/h2-11,18-20H,1H3
DMEVBZW	CS	CC1=CC(=CC=C1)C2NC3=CC=CC4=C3C(=CC=C4)N2
DMEVBZW	IK	HPFJVSRZYNTHHT-UHFFFAOYSA-N
DMEVBZW	IU	2-(3-methylphenyl)-2,3-dihydro-1H-perimidine

DM9Q0EC	ID	DM9Q0EC
DM9Q0EC	DN	AC1LJNG0
DM9Q0EC	HS	Patented
DM9Q0EC	SN	NadD inhibitor 3_15; AC1LJNG0; SCHEMBL10016382; CHEMBL1552586; BDBM81358; ZINC660291; HMS1801G16; RSC005720; MCULE-5644016932; NCGC00100440-01; US8785499, 3_15; 3-amino-N-(4-chloro-2-fluorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide; 3-amino-N-(4-chloro-2-fluorophenyl)-6-thien-2-ylthieno[2,3-b]pyridine-2-carboxamide
DM9Q0EC	DT	Small molecular drug
DM9Q0EC	PC	1003444
DM9Q0EC	MW	403.9
DM9Q0EC	FM	C18H11ClFN3OS2
DM9Q0EC	IC	InChI=1S/C18H11ClFN3OS2/c19-9-3-5-12(11(20)8-9)22-17(24)16-15(21)10-4-6-13(23-18(10)26-16)14-2-1-7-25-14/h1-8H,21H2,(H,22,24)
DM9Q0EC	CS	C1=CSC(=C1)C2=NC3=C(C=C2)C(=C(S3)C(=O)NC4=C(C=C(C=C4)Cl)F)N
DM9Q0EC	IK	NSFJHJZRXLGMGP-UHFFFAOYSA-N
DM9Q0EC	IU	3-amino-N-(4-chloro-2-fluorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide

DMVX9NK	ID	DMVX9NK
DMVX9NK	DN	AC1LOJYQ
DMVX9NK	HS	Patented
DMVX9NK	SN	AC1LOJYQ; SCHEMBL16409996; ZINC1076986; 3-[(4-nitrophenyl)methylsulfanyl]-5-(phenoxymethyl)-4-phenyl-1,2,4-triazole; MCULE-8783896159
DMVX9NK	DT	Small molecular drug
DMVX9NK	PC	1264500
DMVX9NK	MW	418.5
DMVX9NK	FM	C22H18N4O3S
DMVX9NK	IC	InChI=1S/C22H18N4O3S/c27-26(28)19-13-11-17(12-14-19)16-30-22-24-23-21(15-29-20-9-5-2-6-10-20)25(22)18-7-3-1-4-8-18/h1-14H,15-16H2
DMVX9NK	CS	C1=CC=C(C=C1)N2C(=NN=C2SCC3=CC=C(C=C3)[N+](=O)[O-])COC4=CC=CC=C4
DMVX9NK	IK	WMFDORZAJHGLBJ-UHFFFAOYSA-N
DMVX9NK	IU	3-[(4-nitrophenyl)methylsulfanyl]-5-(phenoxymethyl)-4-phenyl-1,2,4-triazole

DMEW5LD	ID	DMEW5LD
DMEW5LD	DN	AC1M1SP5
DMEW5LD	HS	Patented
DMEW5LD	SN	3-(2-methoxyphenyl)-2-(propylthio)-6,7-dihydrothieno[3,2-d]pyrimidin-4(3H)-one; 850915-31-0; AC1M1SP5; SCHEMBL16200721; CHEMBL3913943; BDBM86646; ZINC2719834; AKOS024584906; MCULE-4663000139; BC11-38-4; SR-01000120201; SR-01000120201-1; F0579-0260; 3-(2-methoxyphenyl)-2-propylsulfanyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one
DMEW5LD	DT	Small molecular drug
DMEW5LD	PC	2155273
DMEW5LD	MW	334.5
DMEW5LD	FM	C16H18N2O2S2
DMEW5LD	IC	InChI=1S/C16H18N2O2S2/c1-3-9-22-16-17-11-8-10-21-14(11)15(19)18(16)12-6-4-5-7-13(12)20-2/h4-7H,3,8-10H2,1-2H3
DMEW5LD	CS	CCCSC1=NC2=C(C(=O)N1C3=CC=CC=C3OC)SCC2
DMEW5LD	IK	MXDVDZKXHJWBLR-UHFFFAOYSA-N
DMEW5LD	IU	3-(2-methoxyphenyl)-2-propylsulfanyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one

DM6293C	ID	DM6293C
DM6293C	DN	AC1MOZOL
DM6293C	HS	Patented
DM6293C	SN	686770-82-1; AC1MOZOL; CHEMBL3919432; SCHEMBL16200742; BDBM86644; AKOS024584761; MCULE-1812319467; BC11-38-2; EU-0022203; SR-01000120183; SR-01000120183-1; F0579-0063; 2-(sec-butylthio)-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-4(3H)-one; 2-butan-2-ylsulfanyl-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one
DM6293C	DT	Small molecular drug
DM6293C	PC	3403301
DM6293C	MW	318.5
DM6293C	FM	C16H18N2OS2
DM6293C	IC	InChI=1S/C16H18N2OS2/c1-3-11(2)21-16-17-13-9-10-20-14(13)15(19)18(16)12-7-5-4-6-8-12/h4-8,11H,3,9-10H2,1-2H3
DM6293C	CS	CCC(C)SC1=NC2=C(C(=O)N1C3=CC=CC=C3)SCC2
DM6293C	IK	UWXVMIBCJRNBBP-UHFFFAOYSA-N
DM6293C	IU	2-butan-2-ylsulfanyl-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one

DMO4YAB	ID	DMO4YAB
DMO4YAB	DN	Acrylamide compound 1
DMO4YAB	HS	Patented
DMO4YAB	SN	PMID29334795-Compound-50
DMO4YAB	CP	SUVEN LIFE SCIENCES LIMITED
DMO4YAB	DT	Small molecular drug

DM7EOG4	ID	DM7EOG4
DM7EOG4	DN	Acrylamide compound 2
DM7EOG4	HS	Patented
DM7EOG4	SN	PMID29334795-Compound-51A
DM7EOG4	CP	SUVEN LIFE SCIENCES LIMITED
DM7EOG4	DT	Small molecular drug
DM7EOG4	PC	73295197
DM7EOG4	MW	370.5
DM7EOG4	FM	C22H30N2O3
DM7EOG4	IC	InChI=1S/C22H30N2O3/c25-22(24-14-16-26-17-15-24)9-6-18-4-7-20(8-5-18)27-21-10-12-23(13-11-21)19-2-1-3-19/h4-9,19,21H,1-3,10-17H2/b9-6+
DM7EOG4	CS	C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)/C=C/C(=O)N4CCOCC4
DM7EOG4	IK	MXFWFZGVHOHBHI-RMKNXTFCSA-N
DM7EOG4	IU	(E)-3-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-1-morpholin-4-ylprop-2-en-1-one

DM7JARB	ID	DM7JARB
DM7JARB	DN	Acrylamide compound 3
DM7JARB	HS	Patented
DM7JARB	SN	PMID29334795-Compound-51B
DM7JARB	CP	SUVEN LIFE SCIENCES LIMITED
DM7JARB	DT	Small molecular drug
DM7JARB	PC	73295197
DM7JARB	MW	370.5
DM7JARB	FM	C22H30N2O3
DM7JARB	IC	InChI=1S/C22H30N2O3/c25-22(24-14-16-26-17-15-24)9-6-18-4-7-20(8-5-18)27-21-10-12-23(13-11-21)19-2-1-3-19/h4-9,19,21H,1-3,10-17H2/b9-6+
DM7JARB	CS	C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)/C=C/C(=O)N4CCOCC4
DM7JARB	IK	MXFWFZGVHOHBHI-RMKNXTFCSA-N
DM7JARB	IU	(E)-3-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-1-morpholin-4-ylprop-2-en-1-one

DMZL6D8	ID	DMZL6D8
DMZL6D8	DN	Acrylamide compound 4
DMZL6D8	HS	Patented
DMZL6D8	SN	PMID29334795-Compound-53
DMZL6D8	CP	SUVEN LIFE SCIENCES LIMITED
DMZL6D8	DT	Small molecular drug

DMXTUE1	ID	DMXTUE1
DMXTUE1	DN	Acyl oxymethyl acrylamide ester derivative 1
DMXTUE1	HS	Patented
DMXTUE1	SN	PMID27977313-Compound-26
DMXTUE1	CP	INST CHEMII ORGANICZNEJ POLSKIEJ AKADEMII NAUK [PLWARSZAWSKI UNIV MEDYCZNY [PL]
DMXTUE1	DT	Small molecular drug
DMXTUE1	PC	56945839
DMXTUE1	MW	540.5
DMXTUE1	FM	C23H26F6N2O6
DMXTUE1	IC	InChI=1S/C23H26F6N2O6/c1-5-36-17(32)10-30-20(34)16(9-12(2)3)31-19(33)13(4)11-37-21(35)18-14(22(24,25)26)7-6-8-15(18)23(27,28)29/h6-8,12,16H,4-5,9-11H2,1-3H3,(H,30,34)(H,31,33)
DMXTUE1	CS	CCOC(=O)CNC(=O)C(CC(C)C)NC(=O)C(=C)COC(=O)C1=C(C=CC=C1C(F)(F)F)C(F)(F)F
DMXTUE1	IK	PIBIRGYHHYAZIQ-UHFFFAOYSA-N
DMXTUE1	IU	2-[[1-[(2-ethoxy-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]prop-2-enyl 2,6-bis(trifluoromethyl)benzoate

DMU8OIL	ID	DMU8OIL
DMU8OIL	DN	Acyl oxymethyl acrylamide ester derivative 2
DMU8OIL	HS	Patented
DMU8OIL	SN	PMID27977313-Compound-Figure5b
DMU8OIL	CP	INST CHEMII ORGANICZNEJ POLSKIEJ AKADEMII NAUK [PLWARSZAWSKI UNIV MEDYCZNY [PL]
DMU8OIL	DT	Small molecular drug

DMX9J1C	ID	DMX9J1C
DMX9J1C	DN	Acyl piperidine derivative 1
DMX9J1C	HS	Patented
DMX9J1C	SN	PMID29473428-Compound-31
DMX9J1C	CP	NEWLINK GENETICS CORPORATION MAUTINO, Mario KUMAR, Sanjeev WALDO, Jesse JAIPURI, Firoz KESHARWANI, Tanay ZHANG, Xiaoxia
DMX9J1C	DT	Small molecular drug
DMX9J1C	PC	70874141
DMX9J1C	MW	393.5
DMX9J1C	FM	C24H31N3O2
DMX9J1C	IC	InChI=1S/C24H31N3O2/c28-23(14-21-19-8-4-5-9-20(19)22-15-25-16-27(21)22)17-10-12-26(13-11-17)24(29)18-6-2-1-3-7-18/h4-5,8-9,15-18,21,23,28H,1-3,6-7,10-14H2
DMX9J1C	CS	C1CCC(CC1)C(=O)N2CCC(CC2)C(CC3C4=CC=CC=C4C5=CN=CN35)O
DMX9J1C	IK	FDUHADIZUWTWAZ-UHFFFAOYSA-N
DMX9J1C	IU	cyclohexyl-[4-[1-hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]methanone

DM2FUIB	ID	DM2FUIB
DM2FUIB	DN	Acyl piperidine derivative 2
DM2FUIB	HS	Patented
DM2FUIB	SN	PMID26560530-Compound-44
DM2FUIB	CP	ASTON UNIVERSITY
DM2FUIB	DT	Small molecular drug
DM2FUIB	PC	73504704
DM2FUIB	MW	456.3
DM2FUIB	FM	C18H22BrN3O6
DM2FUIB	IC	InChI=1S/C18H22BrN3O6/c1-27-17(25)14-4-2-13(3-5-14)12-28-18(26)22-8-6-21(7-9-22)16(24)11-20-15(23)10-19/h2-5H,6-12H2,1H3,(H,20,23)
DM2FUIB	CS	COC(=O)C1=CC=C(C=C1)COC(=O)N2CCN(CC2)C(=O)CNC(=O)CBr
DM2FUIB	IK	DHKHYJYAEPJCDA-UHFFFAOYSA-N
DM2FUIB	IU	(4-methoxycarbonylphenyl)methyl 4-[2-[(2-bromoacetyl)amino]acetyl]piperazine-1-carboxylate

DMIDUB4	ID	DMIDUB4
DMIDUB4	DN	Acyl piperidine derivative 3
DMIDUB4	HS	Patented
DMIDUB4	SN	PMID26560530-Compound-45
DMIDUB4	CP	ASTON UNIVERSITY
DMIDUB4	DT	Small molecular drug
DMIDUB4	PC	73775396
DMIDUB4	MW	426.3
DMIDUB4	FM	C19H28BrN3O3
DMIDUB4	IC	InChI=1S/C19H28BrN3O3/c20-11-16(24)21-12-17(25)22-1-3-23(4-2-22)18(26)19-8-13-5-14(9-19)7-15(6-13)10-19/h13-15H,1-12H2,(H,21,24)
DMIDUB4	CS	C1CN(CCN1C(=O)CNC(=O)CBr)C(=O)C23CC4CC(C2)CC(C4)C3
DMIDUB4	IK	SCSKGYPISIGLDU-UHFFFAOYSA-N
DMIDUB4	IU	N-[2-[4-(adamantane-1-carbonyl)piperazin-1-yl]-2-oxoethyl]-2-bromoacetamide

DMA1RVN	ID	DMA1RVN
DMA1RVN	DN	Ac-YVAD-cmk
DMA1RVN	HS	Patented
DMA1RVN	CP	UNIVERSITY OF COPENHAGEN
DMA1RVN	DT	Peptide
DMA1RVN	DE	Photocontact dermatitis; Irritant contact dermatitis; Allergic contact dermatitis

DM7K256	ID	DM7K256
DM7K256	DN	Ac-YVAD-FMK
DM7K256	HS	Patented
DM7K256	CP	UNIVERSITY OF COPENHAGEN
DM7K256	DT	Peptide
DM7K256	DE	Photocontact dermatitis; Irritant contact dermatitis; Allergic contact dermatitis

DMD94MP	ID	DMD94MP
DMD94MP	DN	Adamantyl derivative 1
DMD94MP	HS	Patented
DMD94MP	SN	PMID27215781-Compound-10
DMD94MP	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMD94MP	DT	Small molecular drug
DMD94MP	PC	90022221
DMD94MP	MW	296.4
DMD94MP	FM	C19H24N2O
DMD94MP	IC	InChI=1S/C19H24N2O/c22-18(21-6-5-16-3-1-2-4-17(16)21)20-19-10-13-7-14(11-19)9-15(8-13)12-19/h1-4,13-15H,5-12H2,(H,20,22)
DMD94MP	CS	C1CN(C2=CC=CC=C21)C(=O)NC34CC5CC(C3)CC(C5)C4
DMD94MP	IK	CQDFSOMWSQOSOR-UHFFFAOYSA-N
DMD94MP	IU	N-(1-adamantyl)-2,3-dihydroindole-1-carboxamide

DM2L83Y	ID	DM2L83Y
DM2L83Y	DN	AGGGWZCOULSEER-PYUWXLGESA-N
DM2L83Y	HS	Patented
DM2L83Y	SN	CHEMBL1922121; SCHEMBL3858001; AGGGWZCOULSEER-PYUWXLGESA-N; BDBM50358222; (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol; US8846696, (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol; (3RS, 4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol
DM2L83Y	DT	Small molecular drug
DM2L83Y	PC	12111411
DM2L83Y	MW	397.5
DM2L83Y	FM	C21H31N7O
DM2L83Y	IC	InChI=1S/C21H31N7O/c1-6-16(18(29)13(2)3)25-21-26-19(23-11-15-8-7-9-22-10-15)17-20(27-21)28(12-24-17)14(4)5/h7-10,12-14,16,18,29H,6,11H2,1-5H3,(H2,23,25,26,27)/t16-,18?/m1/s1
DM2L83Y	CS	CC[C@H](C(C(C)C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=CC=C3
DM2L83Y	IK	AGGGWZCOULSEER-PYUWXLGESA-N
DM2L83Y	IU	(4R)-2-methyl-4-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]hexan-3-ol

DM0P2U3	ID	DM0P2U3
DM0P2U3	DN	AKOS003197197
DM0P2U3	HS	Patented
DM0P2U3	SN	CHEMBL3207533; SCHEMBL16922115; AKOS003197197
DM0P2U3	DT	Small molecular drug
DM0P2U3	PC	9693619
DM0P2U3	MW	222.63
DM0P2U3	FM	C8H7ClN6
DM0P2U3	IC	InChI=1S/C8H7ClN6/c9-7-3-1-6(2-4-7)5-10-11-8-12-14-15-13-8/h1-5H,(H2,11,12,13,14,15)/b10-5+
DM0P2U3	CS	C1=CC(=CC=C1/C=N/NC2=NNN=N2)Cl
DM0P2U3	IK	SZFUMFNPTAQHAI-BJMVGYQFSA-N
DM0P2U3	IU	N-[(E)-(4-chlorophenyl)methylideneamino]-2H-tetrazol-5-amine

DMWHN1O	ID	DMWHN1O
DMWHN1O	DN	AKOS020330481
DMWHN1O	HS	Patented
DMWHN1O	SN	3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; AKOS020330481; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid
DMWHN1O	DT	Small molecular drug
DMWHN1O	PC	59699608
DMWHN1O	MW	258.269
DMWHN1O	FM	C14H14N2O3
DMWHN1O	IC	InChI=1S/C14H14N2O3/c1-19-11-4-2-10(3-5-11)8-16-13-9-15-7-6-12(13)14(17)18/h2-7,9,16H,8H2,1H3,(H,17,18)
DMWHN1O	CS	COC1=CC=C(C=C1)CNC2=C(C=CN=C2)C(=O)O
DMWHN1O	IK	XKZFNTZMCLZYHZ-UHFFFAOYSA-N
DMWHN1O	IU	3-[(4-methoxyphenyl)methylamino]pyridine-4-carboxylic acid

DMNIE4M	ID	DMNIE4M
DMNIE4M	DN	AKOS020330656
DMNIE4M	HS	Patented
DMNIE4M	SN	CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; AKOS020330656; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid
DMNIE4M	DT	Small molecular drug
DMNIE4M	PC	77106317
DMNIE4M	MW	248.3
DMNIE4M	FM	C12H12N2O2S
DMNIE4M	IC	InChI=1S/C12H12N2O2S/c1-8-2-3-9(17-8)6-14-11-7-13-5-4-10(11)12(15)16/h2-5,7,14H,6H2,1H3,(H,15,16)
DMNIE4M	CS	CC1=CC=C(S1)CNC2=C(C=CN=C2)C(=O)O
DMNIE4M	IK	RFUZGPWCXINBNW-UHFFFAOYSA-N
DMNIE4M	IU	3-[(5-methylthiophen-2-yl)methylamino]pyridine-4-carboxylic acid

DMPXAGD	ID	DMPXAGD
DMPXAGD	DN	Alkaloid derivative 4
DMPXAGD	HS	Patented
DMPXAGD	SN	PMID26882240-Compound-37
DMPXAGD	CP	UCL BUSINESS PLC
DMPXAGD	DT	Small molecular drug
DMPXAGD	PC	3246466
DMPXAGD	MW	418.6
DMPXAGD	FM	C27H34N2O2
DMPXAGD	IC	InChI=1S/C27H34N2O2/c1-4-18-17-29-12-10-19-7-5-6-8-22(19)25(29)14-21(18)13-24-23-16-27(31-3)26(30-2)15-20(23)9-11-28-24/h5-8,15-16,24-25,28H,4,9-14,17H2,1-3H3/t24-,25+/m1/s1
DMPXAGD	CS	CCC1=C(C[C@H]2C3=CC=CC=C3CCN2C1)C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC
DMPXAGD	IK	GAUYNTGXYGJOSH-RPBOFIJWSA-N
DMPXAGD	IU	(11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine

DMW57UB	ID	DMW57UB
DMW57UB	DN	Alkyl mannoside derivative 1
DMW57UB	HS	Patented
DMW57UB	SN	PMID26651364-Compound-1a
DMW57UB	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DMW57UB	DT	Small molecular drug
DMW57UB	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMHD51F	ID	DMHD51F
DMHD51F	DN	Alkyl mannoside derivative 10
DMHD51F	HS	Patented
DMHD51F	SN	PMID26651364-Compound-Table2R1=n-aryl01
DMHD51F	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DMHD51F	DT	Carbohydrates
DMHD51F	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMNZ2U	ID	DMMNZ2U
DMMNZ2U	DN	Alkyl mannoside derivative 11
DMMNZ2U	HS	Patented
DMMNZ2U	SN	PMID26651364-Compound-Table2R1=n-aryl02
DMMNZ2U	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DMMNZ2U	DT	Carbohydrates
DMMNZ2U	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMX1OZF	ID	DMX1OZF
DMX1OZF	DN	Alkyl mannoside derivative 12
DMX1OZF	HS	Patented
DMX1OZF	SN	PMID26651364-Compound-Table2R1=n-aryl03
DMX1OZF	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DMX1OZF	DT	Carbohydrates
DMX1OZF	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMNQUKP	ID	DMNQUKP
DMNQUKP	DN	Alkyl mannoside derivative 2
DMNQUKP	HS	Patented
DMNQUKP	SN	PMID26651364-Compound-1b
DMNQUKP	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMNQUKP	DT	Small molecular drug
DMNQUKP	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DML2B58	ID	DML2B58
DML2B58	DN	Alkyl mannoside derivative 3
DML2B58	HS	Patented
DML2B58	SN	PMID26651364-Compound-Table2R1=n-alkyl01
DML2B58	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DML2B58	DT	Carbohydrates
DML2B58	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMZR71O	ID	DMZR71O
DMZR71O	DN	Alkyl mannoside derivative 4
DMZR71O	HS	Patented
DMZR71O	SN	PMID26651364-Compound-Table2R1=n-alkyl02
DMZR71O	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DMZR71O	DT	Carbohydrates
DMZR71O	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM04ZJ2	ID	DM04ZJ2
DM04ZJ2	DN	Alkyl mannoside derivative 5
DM04ZJ2	HS	Patented
DM04ZJ2	SN	PMID26651364-Compound-Table2R1=n-alkyl03
DM04ZJ2	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DM04ZJ2	DT	Carbohydrates
DM04ZJ2	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMCIV32	ID	DMCIV32
DMCIV32	DN	Alkyl mannoside derivative 6
DMCIV32	HS	Patented
DMCIV32	SN	PMID26651364-Compound-Table2R1=n-alkyl04
DMCIV32	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DMCIV32	DT	Carbohydrates
DMCIV32	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMBLSH1	ID	DMBLSH1
DMBLSH1	DN	Alkyl mannoside derivative 7
DMBLSH1	HS	Patented
DMBLSH1	SN	PMID26651364-Compound-Table2R1=n-alkyl05
DMBLSH1	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DMBLSH1	DT	Carbohydrates
DMBLSH1	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMZP1JT	ID	DMZP1JT
DMZP1JT	DN	Alkyl mannoside derivative 8
DMZP1JT	HS	Patented
DMZP1JT	SN	PMID26651364-Compound-Table2R1=n-alkyl06
DMZP1JT	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DMZP1JT	DT	Carbohydrates
DMZP1JT	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMV1QUX	ID	DMV1QUX
DMV1QUX	DN	Alkyl mannoside derivative 9
DMV1QUX	HS	Patented
DMV1QUX	SN	PMID26651364-Compound-Table2R1=n-alkyl07
DMV1QUX	CP	VIB vzw VRIJE UNIVERSITEIT BRUSSEL 
DMV1QUX	DT	Carbohydrates
DMV1QUX	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM06U3J	ID	DM06U3J
DM06U3J	DN	Alkyl sulfone derivative 1
DM06U3J	HS	Patented
DM06U3J	SN	PMID26161698-Compound-29
DM06U3J	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DM06U3J	DT	Small molecular drug
DM06U3J	PC	73672849
DM06U3J	MW	519.4
DM06U3J	FM	C18H13F8N3O2S2
DM06U3J	IC	InChI=1S/C18H13F8N3O2S2/c1-32(30,31)9-10-4-12(7-13(5-10)33(22,23,24,25)26)28-18-27-8-16(21)17(29-18)14-3-2-11(19)6-15(14)20/h2-8H,9H2,1H3,(H,27,28,29)
DM06U3J	CS	CS(=O)(=O)CC1=CC(=CC(=C1)S(F)(F)(F)(F)F)NC2=NC=C(C(=N2)C3=C(C=C(C=C3)F)F)F
DM06U3J	IK	QPEXAIXCVQPMDQ-UHFFFAOYSA-N
DM06U3J	IU	4-(2,4-difluorophenyl)-5-fluoro-N-[3-(methylsulfonylmethyl)-5-(pentafluoro-lambda6-sulfanyl)phenyl]pyrimidin-2-amine

DMEZDQ4	ID	DMEZDQ4
DMEZDQ4	DN	Alkynyl-heteroaromatic ring compound 1
DMEZDQ4	HS	Patented
DMEZDQ4	SN	PMID25656651-Compound-39
DMEZDQ4	CP	NANJING SANHOME PHARMACEUTICAL CO LTD [CN]
DMEZDQ4	DT	Small molecular drug
DMEZDQ4	PC	73504220
DMEZDQ4	MW	543.6
DMEZDQ4	FM	C31H28F3N5O
DMEZDQ4	IC	InChI=1S/C31H28F3N5O/c1-21-6-7-24(16-23(21)9-8-22-4-3-5-29-27(22)18-35-20-36-29)30(40)37-26-11-10-25(28(17-26)31(32,33)34)19-39-14-12-38(2)13-15-39/h3-7,10-11,16-18,20H,12-15,19H2,1-2H3,(H,37,40)
DMEZDQ4	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=C5C=NC=NC5=CC=C4
DMEZDQ4	IK	KLHNJZVWTSMTCC-UHFFFAOYSA-N
DMEZDQ4	IU	4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-(2-quinazolin-5-ylethynyl)benzamide

DMK7DJ2	ID	DMK7DJ2
DMK7DJ2	DN	Alkynyl-substituted pyrimidinyl-pyrrole derivative 1
DMK7DJ2	HS	Patented
DMK7DJ2	SN	PMID27774822-Compound-Figure3compound11
DMK7DJ2	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMK7DJ2	DT	Small molecular drug

DMWX0QK	ID	DMWX0QK
DMWX0QK	DN	Alpha-substituted pirinixic acid and pirinixic acid ester derivative 1
DMWX0QK	HS	Patented
DMWX0QK	SN	PMID28627961-Compound-38
DMWX0QK	CP	MEDEON PHARMACEUTICALS GMBH UNIVERSIT TINGEN WERZ, Oliver KOEBERLE, Andreas SCHUBERT-ZSILAVECZ, Manfred POPESCU, Laura SYHA, Yvonne
DMWX0QK	DT	Small molecular drug

DMO64LA	ID	DMO64LA
DMO64LA	DN	Amide derivative 1
DMO64LA	HS	Patented
DMO64LA	SN	PMID26161824-Compound-21
DMO64LA	DT	Small molecular drug
DMO64LA	PC	9868408
DMO64LA	MW	450.8
DMO64LA	FM	C22H22Cl3N3O
DMO64LA	IC	InChI=1S/C22H22Cl3N3O/c1-3-4-5-12-26-22(29)20-14(2)21(15-6-8-16(23)9-7-15)28(27-20)19-11-10-17(24)13-18(19)25/h6-11,13H,3-5,12H2,1-2H3,(H,26,29)
DMO64LA	CS	CCCCCNC(=O)C1=NN(C(=C1C)C2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)Cl)Cl
DMO64LA	IK	JDBOTXIRNSWBCG-UHFFFAOYSA-N
DMO64LA	IU	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-pentylpyrazole-3-carboxamide
DMO64LA	CA	CAS 336615-64-6
DMO64LA	DE	Obesity

DMBKIR0	ID	DMBKIR0
DMBKIR0	DN	Amide derivative 2
DMBKIR0	HS	Patented
DMBKIR0	SN	PMID29473428-Compound-73
DMBKIR0	CP	FLEXUS BIOSCIENCES, INC
DMBKIR0	DT	Small molecular drug

DM1FUOY	ID	DM1FUOY
DM1FUOY	DN	amidepsines
DM1FUOY	HS	Patented

DMUPT9A	ID	DMUPT9A
DMUPT9A	DN	Amidine compound 1
DMUPT9A	HS	Patented
DMUPT9A	SN	PMID26936077-Compound-28
DMUPT9A	CP	PROXIMAGEN LIMITED
DMUPT9A	DT	Small molecular drug
DMUPT9A	PC	72737267
DMUPT9A	MW	343.4
DMUPT9A	FM	C22H21N3O
DMUPT9A	IC	InChI=1S/C22H21N3O/c1-15-19(17-6-3-2-4-7-17)8-5-9-20(15)22(26)25-14-16-10-12-18(13-11-16)21(23)24/h2-13H,14H2,1H3,(H3,23,24)(H,25,26)
DMUPT9A	CS	CC1=C(C=CC=C1C(=O)NCC2=CC=C(C=C2)C(=N)N)C3=CC=CC=C3
DMUPT9A	IK	RNDNSLVKMYCGOO-UHFFFAOYSA-N
DMUPT9A	IU	N-[(4-carbamimidoylphenyl)methyl]-2-methyl-3-phenylbenzamide
DMUPT9A	DE	Inflammation

DM2UWSX	ID	DM2UWSX
DM2UWSX	DN	Amidine compound 2
DM2UWSX	HS	Patented
DM2UWSX	SN	PMID26936077-Compound-29
DM2UWSX	CP	PROXIMAGEN LIMITED
DM2UWSX	DT	Small molecular drug
DM2UWSX	PC	73051852
DM2UWSX	MW	363.8
DM2UWSX	FM	C21H18ClN3O
DM2UWSX	IC	InChI=1S/C21H18ClN3O/c22-19-17(15-5-2-1-3-6-15)7-4-8-18(19)21(26)25-13-14-9-11-16(12-10-14)20(23)24/h1-12H,13H2,(H3,23,24)(H,25,26)
DM2UWSX	CS	C1=CC=C(C=C1)C2=C(C(=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N)Cl
DM2UWSX	IK	HZBJZCWAIZICKW-UHFFFAOYSA-N
DM2UWSX	IU	N-[(4-carbamimidoylphenyl)methyl]-2-chloro-3-phenylbenzamide
DM2UWSX	DE	Inflammation

DMV0QJ4	ID	DMV0QJ4
DMV0QJ4	DN	Amidine compound 3
DMV0QJ4	HS	Patented
DMV0QJ4	SN	PMID26936077-Compound-30
DMV0QJ4	CP	PROXIMAGEN LIMITED
DMV0QJ4	DT	Small molecular drug
DMV0QJ4	PC	73051857
DMV0QJ4	MW	408.5
DMV0QJ4	FM	C21H20N4O3S
DMV0QJ4	IC	InChI=1S/C21H20N4O3S/c22-20(23)16-6-4-14(5-7-16)13-25-21(26)18-3-1-2-17(12-18)15-8-10-19(11-9-15)29(24,27)28/h1-12H,13H2,(H3,22,23)(H,25,26)(H2,24,27,28)
DMV0QJ4	CS	C1=CC(=CC(=C1)C(=O)NCC2=CC=C(C=C2)C(=N)N)C3=CC=C(C=C3)S(=O)(=O)N
DMV0QJ4	IK	TZCOUVBQGJRRJR-UHFFFAOYSA-N
DMV0QJ4	IU	N-[(4-carbamimidoylphenyl)methyl]-3-(4-sulfamoylphenyl)benzamide
DMV0QJ4	DE	Inflammation

DM9EGVN	ID	DM9EGVN
DM9EGVN	DN	Amidine compound 4
DM9EGVN	HS	Patented
DM9EGVN	SN	PMID26936077-Compound-31
DM9EGVN	CP	PROXIMAGEN LIMITED
DM9EGVN	DT	Small molecular drug
DM9EGVN	PC	73052013
DM9EGVN	MW	436.5
DM9EGVN	FM	C23H24N4O3S
DM9EGVN	IC	InChI=1S/C23H24N4O3S/c1-27(2)31(29,30)21-9-4-3-8-20(21)18-6-5-7-19(14-18)23(28)26-15-16-10-12-17(13-11-16)22(24)25/h3-14H,15H2,1-2H3,(H3,24,25)(H,26,28)
DM9EGVN	CS	CN(C)S(=O)(=O)C1=CC=CC=C1C2=CC(=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N
DM9EGVN	IK	PJHSDMZESVNZHU-UHFFFAOYSA-N
DM9EGVN	IU	N-[(4-carbamimidoylphenyl)methyl]-3-[2-(dimethylsulfamoyl)phenyl]benzamide
DM9EGVN	DE	Inflammation

DMMN8OY	ID	DMMN8OY
DMMN8OY	DN	Amidine compound 5
DMMN8OY	HS	Patented
DMMN8OY	SN	PMID26936077-Compound-32
DMMN8OY	CP	PROXIMAGEN LIMITED
DMMN8OY	DT	Small molecular drug
DMMN8OY	PC	73052182
DMMN8OY	MW	422.5
DMMN8OY	FM	C22H22N4O3S
DMMN8OY	IC	InChI=1S/C22H22N4O3S/c1-14-11-19(30(25,28)29)9-10-20(14)17-3-2-4-18(12-17)22(27)26-13-15-5-7-16(8-6-15)21(23)24/h2-12H,13H2,1H3,(H3,23,24)(H,26,27)(H2,25,28,29)
DMMN8OY	CS	CC1=C(C=CC(=C1)S(=O)(=O)N)C2=CC(=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N
DMMN8OY	IK	QDCYPEUVWUOSBP-UHFFFAOYSA-N
DMMN8OY	IU	N-[(4-carbamimidoylphenyl)methyl]-3-(2-methyl-4-sulfamoylphenyl)benzamide
DMMN8OY	DE	Inflammation

DMFNK0L	ID	DMFNK0L
DMFNK0L	DN	Amidine compound 6
DMFNK0L	HS	Patented
DMFNK0L	SN	PMID26936077-Compound-33
DMFNK0L	CP	PROXIMAGEN LIMITED
DMFNK0L	DT	Small molecular drug
DMFNK0L	DE	Inflammation

DM8STUQ	ID	DM8STUQ
DM8STUQ	DN	Amidine oxime derivative 1
DM8STUQ	HS	Patented
DM8STUQ	SN	PMID27967267-Compound-50
DM8STUQ	CP	HUMAN BIOMOLECULAR RESEARCH INSTITUTE CASHMAN, John, R. KALISIAK, Jaroslaw
DM8STUQ	DT	Small molecular drug

DM5X92S	ID	DM5X92S
DM5X92S	DN	Amidopyrazole derivative 1
DM5X92S	HS	Patented
DM5X92S	SN	PMID27310003-Compound-40
DM5X92S	CP	MERCK SHARP & DOHME CORP. SEGANISH, W. Michael MCELROY, William, T. BRUMFIELD, Stephanie HERR, R. Jason YET, Larry YANG, Jinhai HARDING, James, P., III HO, Ginny Dai TULSHIAN, Deen, B. YU, Wensheng WONG, Michael, K. C. LAVEY, Brian, J. KOZLOWSKI, Joseph, A
DM5X92S	DT	Small molecular drug

DMGO9WY	ID	DMGO9WY
DMGO9WY	DN	Amidopyrazole derivative 2
DMGO9WY	HS	Patented
DMGO9WY	SN	PMID27310003-Compound-41
DMGO9WY	CP	MERCK SHARP & DOHME CORP. SEGANISH, W. Michael MCELROY, William, T. BRUMFIELD, Stephanie HERR, R. Jason YET, Larry YANG, Jinhai HARDING, James, P., III HO, Ginny Dai TULSHIAN, Deen, B. YU, Wensheng WONG, Michael, K. C. LAVEY, Brian, J. KOZLOWSKI, Joseph, A
DMGO9WY	DT	Small molecular drug

DMTHS3L	ID	DMTHS3L
DMTHS3L	DN	Amidopyrazole derivative 3
DMTHS3L	HS	Patented
DMTHS3L	SN	PMID27310003-Compound-42
DMTHS3L	CP	Astellas Pharma Inc.  INAMI, Hiroshi  MIZUTANI, Tsuyoshi  MAEDA, Junko  USUDA, Hiroyuki  NAGASHIMA, Shinya  ITO, Tomonori  AOYAMA, Naohiro
DMTHS3L	DT	Small molecular drug

DMF6N7Z	ID	DMF6N7Z
DMF6N7Z	DN	Amidopyrazole derivative 4
DMF6N7Z	HS	Patented
DMF6N7Z	SN	PMID27310003-Compound-61
DMF6N7Z	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMF6N7Z	DT	Small molecular drug

DMJ37V2	ID	DMJ37V2
DMJ37V2	DN	Amidopyrazole derivative 5
DMJ37V2	HS	Patented
DMJ37V2	SN	PMID27310003-Compound-62
DMJ37V2	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMJ37V2	DT	Small molecular drug

DMJZ1IG	ID	DMJZ1IG
DMJZ1IG	DN	Amidopyrazole derivative 6
DMJZ1IG	HS	Patented
DMJZ1IG	SN	PMID27310003-Compound-63
DMJZ1IG	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMJZ1IG	DT	Small molecular drug

DMQVZY5	ID	DMQVZY5
DMQVZY5	DN	Aminoarylpyridine derivative 1
DMQVZY5	HS	Patented
DMQVZY5	SN	PMID26161698-Compound-42
DMQVZY5	CP	NOVARTIS AG 
DMQVZY5	DT	Small molecular drug

DMNI0M1	ID	DMNI0M1
DMNI0M1	DN	Aminoazetidine derivative 1
DMNI0M1	HS	Patented
DMNI0M1	SN	PMID26161824-Compound-164
DMNI0M1	DT	Small molecular drug
DMNI0M1	PC	44194212
DMNI0M1	MW	590.4
DMNI0M1	FM	C29H27Cl2F2N3O4
DMNI0M1	IC	InChI=1S/C29H27Cl2F2N3O4/c1-2-40-28(39)15-34-26(37)14-27(38)36(24-12-22(32)11-23(33)13-24)25-16-35(17-25)29(18-3-7-20(30)8-4-18)19-5-9-21(31)10-6-19/h3-13,25,29H,2,14-17H2,1H3,(H,34,37)
DMNI0M1	CS	CCOC(=O)CNC(=O)CC(=O)N(C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)F)F
DMNI0M1	IK	JLIDBGJVXRJCFP-UHFFFAOYSA-N
DMNI0M1	IU	ethyl 2-[[3-(N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-3,5-difluoroanilino)-3-oxopropanoyl]amino]acetate
DMNI0M1	DE	Obesity

DMHSNA5	ID	DMHSNA5
DMHSNA5	DN	Aminoazetidine derivative 2
DMHSNA5	HS	Patented
DMHSNA5	SN	PMID26161824-Compound-165
DMHSNA5	DT	Small molecular drug
DMHSNA5	DE	Obesity

DMOQHA9	ID	DMOQHA9
DMOQHA9	DN	Aminoazetidine derivative 3
DMOQHA9	HS	Patented
DMOQHA9	SN	PMID26161824-Compound-166
DMOQHA9	DT	Small molecular drug
DMOQHA9	DE	Obesity

DM50E4Y	ID	DM50E4Y
DM50E4Y	DN	Aminoazetidine derivative 4
DM50E4Y	HS	Patented
DM50E4Y	SN	PMID26161824-Compound-167
DM50E4Y	DT	Small molecular drug
DM50E4Y	DE	Obesity

DMYPD4Z	ID	DMYPD4Z
DMYPD4Z	DN	Aminoazetidine derivative 5
DMYPD4Z	HS	Patented
DMYPD4Z	SN	PMID26161824-Compound-168
DMYPD4Z	DT	Small molecular drug
DMYPD4Z	PC	44180558
DMYPD4Z	MW	569.4
DMYPD4Z	FM	C26H24Cl2F2N2O4S
DMYPD4Z	IC	InChI=1S/C26H24Cl2F2N2O4S/c1-3-36-26(33)25-23(32(37(2,34)35)22-13-20(29)12-21(30)14-22)15-31(25)24(16-4-8-18(27)9-5-16)17-6-10-19(28)11-7-17/h4-14,23-25H,3,15H2,1-2H3
DMYPD4Z	CS	CCOC(=O)C1C(CN1C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)N(C4=CC(=CC(=C4)F)F)S(=O)(=O)C
DMYPD4Z	IK	LOJPJQZCZJCZBS-UHFFFAOYSA-N
DMYPD4Z	IU	ethyl 1-[bis(4-chlorophenyl)methyl]-3-(3,5-difluoro-N-methylsulfonylanilino)azetidine-2-carboxylate
DMYPD4Z	DE	Obesity

DM3LNQG	ID	DM3LNQG
DM3LNQG	DN	Aminoazetidine derivative 7
DM3LNQG	HS	Patented
DM3LNQG	SN	PMID26161824-Compound-170
DM3LNQG	DT	Small molecular drug
DM3LNQG	DE	Obesity

DMLOIHD	ID	DMLOIHD
DMLOIHD	DN	Aminoazetidine derivative 8
DMLOIHD	HS	Patented
DMLOIHD	SN	PMID26161824-Compound-171
DMLOIHD	DT	Small molecular drug
DMLOIHD	DE	Obesity

DMUASHT	ID	DMUASHT
DMUASHT	DN	Aminoazetidine derivative 9
DMUASHT	HS	Patented
DMUASHT	SN	PMID26161824-Compound-172
DMUASHT	DT	Small molecular drug
DMUASHT	PC	44180784
DMUASHT	MW	512.4
DMUASHT	FM	C24H23Cl2F2N2O2S+
DMUASHT	IC	InChI=1S/C24H23Cl2F2N2O2S/c1-30(24(16-3-7-18(25)8-4-16)17-5-9-19(26)10-6-17)14-23(15-30)29(33(2,31)32)22-12-20(27)11-21(28)13-22/h3-13,23-24H,14-15H2,1-2H3/q+1
DMUASHT	CS	C[N+]1(CC(C1)N(C2=CC(=CC(=C2)F)F)S(=O)(=O)C)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl
DMUASHT	IK	DQQUOWSXOJKTEJ-UHFFFAOYSA-N
DMUASHT	IU	N-[1-[bis(4-chlorophenyl)methyl]-1-methylazetidin-1-ium-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide
DMUASHT	DE	Obesity

DM1RQIU	ID	DM1RQIU
DM1RQIU	DN	Aminobenzoxazole analog 1
DM1RQIU	HS	Patented
DM1RQIU	SN	PMID27724045-Compound-11
DM1RQIU	CP	Roche
DM1RQIU	DT	Small molecular drug
DM1RQIU	PC	67955081
DM1RQIU	MW	468.5
DM1RQIU	FM	C24H21FN2O5S
DM1RQIU	IC	InChI=1S/C24H21FN2O5S/c1-33(30,31)19-9-5-17(6-10-19)20(12-15-2-7-18(25)8-3-15)23(29)27-24-26-21-11-4-16(14-28)13-22(21)32-24/h2-11,13,20,28H,12,14H2,1H3,(H,26,27,29)
DM1RQIU	CS	CS(=O)(=O)C1=CC=C(C=C1)C(CC2=CC=C(C=C2)F)C(=O)NC3=NC4=C(O3)C=C(C=C4)CO
DM1RQIU	IK	BSRLERQMZLOWBH-UHFFFAOYSA-N
DM1RQIU	IU	3-(4-fluorophenyl)-N-[6-(hydroxymethyl)-1,3-benzoxazol-2-yl]-2-(4-methylsulfonylphenyl)propanamide

DMYHRJD	ID	DMYHRJD
DMYHRJD	DN	Aminocyclopentenone compound 1
DMYHRJD	HS	Patented
DMYHRJD	SN	PMID26924192-Compound-93
DMYHRJD	CP	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DMYHRJD	DT	Small molecular drug
DMYHRJD	PC	117928501
DMYHRJD	MW	354.8
DMYHRJD	FM	C20H19ClN2O2
DMYHRJD	IC	InChI=1S/C20H19ClN2O2/c1-12-5-3-4-6-15(12)20(25)22-14-7-8-16(21)18(11-14)23-17-9-10-19(24)13(17)2/h3-8,11,23H,9-10H2,1-2H3,(H,22,25)
DMYHRJD	CS	CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)Cl)NC3=C(C(=O)CC3)C
DMYHRJD	IK	FVUVHLFQVZUBCL-UHFFFAOYSA-N
DMYHRJD	IU	N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]-2-methylbenzamide

DMAYHNI	ID	DMAYHNI
DMAYHNI	DN	Aminocyclopentenone compound 2
DMAYHNI	HS	Patented
DMAYHNI	SN	PMID26924192-Compound-94
DMAYHNI	CP	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DMAYHNI	DT	Small molecular drug
DMAYHNI	PC	117928438
DMAYHNI	MW	390.9
DMAYHNI	FM	C23H19ClN2O2
DMAYHNI	IC	InChI=1S/C23H19ClN2O2/c1-14-20(11-12-22(14)27)26-21-13-16(9-10-19(21)24)25-23(28)18-8-4-6-15-5-2-3-7-17(15)18/h2-10,13,26H,11-12H2,1H3,(H,25,28)
DMAYHNI	CS	CC1=C(CCC1=O)NC2=C(C=CC(=C2)NC(=O)C3=CC=CC4=CC=CC=C43)Cl
DMAYHNI	IK	HRGRBMHGQQBNSK-UHFFFAOYSA-N
DMAYHNI	IU	N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]naphthalene-1-carboxamide

DMFXK03	ID	DMFXK03
DMFXK03	DN	Aminocyclopentenone compound 3
DMFXK03	HS	Patented
DMFXK03	SN	PMID26924192-Compound-95
DMFXK03	CP	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DMFXK03	DT	Small molecular drug
DMFXK03	PC	117928427
DMFXK03	MW	390.9
DMFXK03	FM	C19H19ClN2O3S
DMFXK03	IC	InChI=1S/C19H19ClN2O3S/c1-13-17(9-10-19(13)23)21-18-11-15(7-8-16(18)20)22-26(24,25)12-14-5-3-2-4-6-14/h2-8,11,21-22H,9-10,12H2,1H3
DMFXK03	CS	CC1=C(CCC1=O)NC2=C(C=CC(=C2)NS(=O)(=O)CC3=CC=CC=C3)Cl
DMFXK03	IK	NCJRKRWVOHVDGS-UHFFFAOYSA-N
DMFXK03	IU	N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]-1-phenylmethanesulfonamide

DM745TN	ID	DM745TN
DM745TN	DN	Aminocyclopentenone compound 4
DM745TN	HS	Patented
DM745TN	SN	PMID26924192-Compound-96
DM745TN	CP	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DM745TN	DT	Small molecular drug
DM745TN	PC	117928624
DM745TN	MW	390.9
DM745TN	FM	C19H19ClN2O3S
DM745TN	IC	InChI=1S/C19H19ClN2O3S/c1-12-5-3-4-6-19(12)26(24,25)22-14-7-8-15(20)17(11-14)21-16-9-10-18(23)13(16)2/h3-8,11,21-22H,9-10H2,1-2H3
DM745TN	CS	CC1=CC=CC=C1S(=O)(=O)NC2=CC(=C(C=C2)Cl)NC3=C(C(=O)CC3)C
DM745TN	IK	GGISCUHENYTWDU-UHFFFAOYSA-N
DM745TN	IU	N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]-2-methylbenzenesulfonamide

DMPW9ES	ID	DMPW9ES
DMPW9ES	DN	Aminocyclopentenone compound 5
DMPW9ES	HS	Patented
DMPW9ES	SN	PMID26924192-Compound-97
DMPW9ES	CP	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DMPW9ES	DT	Small molecular drug
DMPW9ES	PC	117928680
DMPW9ES	MW	383.9
DMPW9ES	FM	C17H22ClN3O3S
DMPW9ES	IC	InChI=1S/C17H22ClN3O3S/c1-12-15(7-8-17(12)22)19-16-11-13(5-6-14(16)18)20-25(23,24)21-9-3-2-4-10-21/h5-6,11,19-20H,2-4,7-10H2,1H3
DMPW9ES	CS	CC1=C(CCC1=O)NC2=C(C=CC(=C2)NS(=O)(=O)N3CCCCC3)Cl
DMPW9ES	IK	SJCLYADRAFNYBC-UHFFFAOYSA-N
DMPW9ES	IU	N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]piperidine-1-sulfonamide

DM0NJFZ	ID	DM0NJFZ
DM0NJFZ	DN	Aminocyclopentenone compound 6
DM0NJFZ	HS	Patented
DM0NJFZ	SN	PMID26924192-Compound-98
DM0NJFZ	CP	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DM0NJFZ	DT	Small molecular drug

DMDHGPN	ID	DMDHGPN
DMDHGPN	DN	Aminooxazole carboxamide derivative 1
DMDHGPN	HS	Patented
DMDHGPN	SN	PMID27774822-Compound-Figure6Example25
DMDHGPN	CP	SAREUM LIMITED
DMDHGPN	DT	Small molecular drug

DMFKTJL	ID	DMFKTJL
DMFKTJL	DN	Aminopiperidine derivative 1
DMFKTJL	HS	Patented
DMFKTJL	SN	PMID25482888-Compound-48
DMFKTJL	CP	CADILA HEALTHCARE LIMITED
DMFKTJL	DT	Small molecular drug
DMFKTJL	PC	73673008
DMFKTJL	MW	415.5
DMFKTJL	FM	C19H27F2N3O3S
DMFKTJL	IC	InChI=1S/C19H27F2N3O3S/c1-28(25,26)24-7-5-19(12-24)4-6-23(11-19)14-9-17(22)18(27-10-14)15-8-13(20)2-3-16(15)21/h2-3,8,14,17-18H,4-7,9-12,22H2,1H3/t14-,17+,18-,19?/m1/s1
DMFKTJL	CS	CS(=O)(=O)N1CCC2(C1)CCN(C2)[C@@H]3C[C@@H]([C@H](OC3)C4=C(C=CC(=C4)F)F)N
DMFKTJL	IK	ICJHPFIPAVQZIX-HCGGPHHBSA-N
DMFKTJL	IU	(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-2,7-diazaspiro[4.4]nonan-7-yl)oxan-3-amine

DM4JDHO	ID	DM4JDHO
DM4JDHO	DN	Aminopiperidine derivative 2
DM4JDHO	HS	Patented
DM4JDHO	SN	PMID25482888-Compound-49
DM4JDHO	CP	CADILA HEALTHCARE LIMITED
DM4JDHO	DT	Small molecular drug
DM4JDHO	PC	73673132
DM4JDHO	MW	430.5
DM4JDHO	FM	C19H28F2N4O3S
DM4JDHO	IC	InChI=1S/C19H28F2N4O3S/c1-23(2)29(26,27)25-9-12-7-24(8-13(12)10-25)15-6-18(22)19(28-11-15)16-5-14(20)3-4-17(16)21/h3-5,12-13,15,18-19H,6-11,22H2,1-2H3/t12?,13?,15-,18+,19-/m1/s1
DM4JDHO	CS	CN(C)S(=O)(=O)N1CC2CN(CC2C1)[C@@H]3C[C@@H]([C@H](OC3)C4=C(C=CC(=C4)F)F)N
DM4JDHO	IK	YOZMZFRQIDLSLZ-RVBDROBCSA-N
DM4JDHO	IU	2-[(3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)oxan-3-yl]-N,N-dimethyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-sulfonamide

DMYE1A7	ID	DMYE1A7
DMYE1A7	DN	Aminopyridine derivative 1
DMYE1A7	HS	Patented
DMYE1A7	SN	PMID27774822-Compound-Figure9Example1bottomleft
DMYE1A7	DT	Small molecular drug

DMUGZNL	ID	DMUGZNL
DMUGZNL	DN	Aminopyridine derivative 2
DMUGZNL	HS	Patented
DMUGZNL	SN	PMID28117607-Compound-8
DMUGZNL	CP	LUNDBECK & CO AS H [DKVERNALIS R & D LTD [GB] 
DMUGZNL	DT	Small molecular drug

DMSLJE8	ID	DMSLJE8
DMSLJE8	DN	Aminopyridine derivative 3
DMSLJE8	HS	Patented
DMSLJE8	SN	PMID28117607-Compound-9
DMSLJE8	CP	LUNDBECK & CO AS H [DKVERNALIS R & D LTD [GB] 
DMSLJE8	DT	Small molecular drug

DMK1UJV	ID	DMK1UJV
DMK1UJV	DN	Aminopyrimidine derivative 1
DMK1UJV	HS	Patented
DMK1UJV	SN	PMID25656651-Compound-12a
DMK1UJV	CP	VERTEX PHARMACEUTICALS INCORPORATED 
DMK1UJV	DT	Small molecular drug
DMK1UJV	PC	25071810
DMK1UJV	MW	506.7
DMK1UJV	FM	C26H34N8OS
DMK1UJV	IC	InChI=1S/C26H34N8OS/c1-4-24(35)27-19-5-7-20(8-6-19)36-25-29-21(28-22-15-18(2)31-32-22)16-23(30-25)34-13-10-26(11-14-34)9-12-33(3)17-26/h5-8,15-16H,4,9-14,17H2,1-3H3,(H,27,35)(H2,28,29,30,31,32)
DMK1UJV	CS	CCC(=O)NC1=CC=C(C=C1)SC2=NC(=CC(=N2)N3CCC4(CCN(C4)C)CC3)NC5=NNC(=C5)C
DMK1UJV	IK	ODMCGDLIMBCHLX-UHFFFAOYSA-N
DMK1UJV	IU	N-[4-[4-(2-methyl-2,8-diazaspiro[4.5]decan-8-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]propanamide

DM2TF64	ID	DM2TF64
DM2TF64	DN	Aminopyrimidine derivative 10
DM2TF64	HS	Patented
DM2TF64	SN	PMID26293650-Compound-47
DM2TF64	CP	Myrexis
DM2TF64	DT	Small molecular drug
DM2TF64	PC	67114635
DM2TF64	MW	530.6
DM2TF64	FM	C29H34N6O4
DM2TF64	IC	InChI=1S/C29H34N6O4/c1-34(2)13-14-35(3)28(36)24-7-6-22(18-27(24)37-4)32-29-31-12-9-25(33-29)20-5-8-26(21(17-20)19-30)39-23-10-15-38-16-11-23/h5-9,12,17-18,23H,10-11,13-16H2,1-4H3,(H,31,32,33)
DM2TF64	CS	CN(C)CCN(C)C(=O)C1=C(C=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)OC4CCOCC4)C#N)OC
DM2TF64	IK	XAXIBPFXBWPLTP-UHFFFAOYSA-N
DM2TF64	IU	4-[[4-[3-cyano-4-(oxan-4-yloxy)phenyl]pyrimidin-2-yl]amino]-N-[2-(dimethylamino)ethyl]-2-methoxy-N-methylbenzamide

DMKNITP	ID	DMKNITP
DMKNITP	DN	Aminopyrimidine derivative 2
DMKNITP	HS	Patented
DMKNITP	SN	PMID25656651-Compound-12b
DMKNITP	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMKNITP	DT	Small molecular drug

DMDP4GY	ID	DMDP4GY
DMDP4GY	DN	Aminopyrimidine derivative 3
DMDP4GY	HS	Patented
DMDP4GY	SN	PMID25656651-Compound-12c
DMDP4GY	CP	VERTEX PHARMACEUTICALS INCORPORATED 
DMDP4GY	DT	Small molecular drug
DMDP4GY	PC	25072757
DMDP4GY	MW	560.6
DMDP4GY	FM	C26H31F3N8OS
DMDP4GY	IC	InChI=1S/C26H31F3N8OS/c1-17-14-22(35-34-17)31-21-15-23(37-12-8-19(9-13-37)36-10-2-3-11-36)33-25(32-21)39-20-6-4-18(5-7-20)30-24(38)16-26(27,28)29/h4-7,14-15,19H,2-3,8-13,16H2,1H3,(H,30,38)(H2,31,32,33,34,35)
DMDP4GY	CS	CC1=CC(=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)CC(F)(F)F)N4CCC(CC4)N5CCCC5
DMDP4GY	IK	SFNFDXQNCXVCLJ-UHFFFAOYSA-N
DMDP4GY	IU	3,3,3-trifluoro-N-[4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidin-2-yl]sulfanylphenyl]propanamide

DMW039D	ID	DMW039D
DMW039D	DN	Aminopyrimidine derivative 4
DMW039D	HS	Patented
DMW039D	SN	PMID25656651-Compound-13
DMW039D	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMW039D	DT	Small molecular drug
DMW039D	PC	25015762
DMW039D	MW	583.7
DMW039D	FM	C28H32F3N9S
DMW039D	IC	InChI=1S/C28H32F3N9S/c1-18-15-25(37-36-18)33-24-17-26(40-13-11-39(12-14-40)20-7-9-38(2)10-8-20)35-27(34-24)41-21-4-5-22-19(16-21)3-6-23(32-22)28(29,30)31/h3-6,15-17,20H,7-14H2,1-2H3,(H2,33,34,35,36,37)
DMW039D	CS	CC1=CC(=NN1)NC2=CC(=NC(=N2)SC3=CC4=C(C=C3)N=C(C=C4)C(F)(F)F)N5CCN(CC5)C6CCN(CC6)C
DMW039D	IK	CBMIRUJKKBNHQV-UHFFFAOYSA-N
DMW039D	IU	6-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)quinolin-6-yl]sulfanylpyrimidin-4-amine

DM5OZPV	ID	DM5OZPV
DM5OZPV	DN	Aminopyrimidine derivative 5
DM5OZPV	HS	Patented
DM5OZPV	SN	PMID27774822-Compound-Figure9Example1bottomright
DM5OZPV	DT	Small molecular drug

DMZF0DK	ID	DMZF0DK
DMZF0DK	DN	Aminopyrimidine derivative 6
DMZF0DK	HS	Patented
DMZF0DK	SN	PMID26293650-Compound-43
DMZF0DK	CP	Myrexis
DMZF0DK	DT	Small molecular drug
DMZF0DK	PC	51357830
DMZF0DK	MW	456.5
DMZF0DK	FM	C26H28N6O2
DMZF0DK	IC	InChI=1S/C26H28N6O2/c1-18(2)15-25(33)30-23-8-3-19(16-20(23)17-27)24-9-10-28-26(31-24)29-21-4-6-22(7-5-21)32-11-13-34-14-12-32/h3-10,16,18H,11-15H2,1-2H3,(H,30,33)(H,28,29,31)
DMZF0DK	CS	CC(C)CC(=O)NC1=C(C=C(C=C1)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4)C#N
DMZF0DK	IK	MIMBVFVOQLKELD-UHFFFAOYSA-N
DMZF0DK	IU	N-[2-cyano-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]-3-methylbutanamide

DMW98RI	ID	DMW98RI
DMW98RI	DN	Aminopyrimidine derivative 7
DMW98RI	HS	Patented
DMW98RI	SN	PMID26293650-Compound-44
DMW98RI	CP	Myrexis
DMW98RI	DT	Small molecular drug
DMW98RI	PC	51049969
DMW98RI	MW	457.5
DMW98RI	FM	C26H27N5O3
DMW98RI	IC	InChI=1S/C26H27N5O3/c27-18-20-17-19(1-6-25(20)34-23-8-13-32-14-9-23)24-7-10-28-26(30-24)29-21-2-4-22(5-3-21)31-11-15-33-16-12-31/h1-7,10,17,23H,8-9,11-16H2,(H,28,29,30)
DMW98RI	CS	C1COCCC1OC2=C(C=C(C=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCOCC5)C#N
DMW98RI	IK	BWABTWGSXHTHCG-UHFFFAOYSA-N
DMW98RI	IU	5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-2-(oxan-4-yloxy)benzonitrile

DML83KW	ID	DML83KW
DML83KW	DN	Aminopyrimidine derivative 8
DML83KW	HS	Patented
DML83KW	SN	PMID26293650-Compound-45
DML83KW	CP	Myrexis
DML83KW	DT	Small molecular drug
DML83KW	PC	67114730
DML83KW	MW	530.6
DML83KW	FM	C29H34N6O4
DML83KW	IC	InChI=1S/C29H34N6O4/c1-37-27-19-21(18-22(20-30)28(27)39-25-7-16-38-17-8-25)26-6-9-31-29(33-26)32-23-2-4-24(5-3-23)35-12-10-34(11-13-35)14-15-36/h2-6,9,18-19,25,36H,7-8,10-17H2,1H3,(H,31,32,33)
DML83KW	CS	COC1=CC(=CC(=C1OC2CCOCC2)C#N)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCN(CC5)CCO
DML83KW	IK	XDKGLOMIIQBBCB-UHFFFAOYSA-N
DML83KW	IU	5-[2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino]pyrimidin-4-yl]-3-methoxy-2-(oxan-4-yloxy)benzonitrile

DM5VRXW	ID	DM5VRXW
DM5VRXW	DN	Aminopyrimidine derivative 9
DM5VRXW	HS	Patented
DM5VRXW	SN	PMID26293650-Compound-46
DM5VRXW	CP	Myrexis
DM5VRXW	DT	Small molecular drug
DM5VRXW	PC	67114761
DM5VRXW	MW	443.5
DM5VRXW	FM	C25H25N5O3
DM5VRXW	IC	InChI=1S/C25H25N5O3/c1-17(31)28-16-18-2-5-21(6-3-18)29-25-27-11-8-23(30-25)19-4-7-24(20(14-19)15-26)33-22-9-12-32-13-10-22/h2-8,11,14,22H,9-10,12-13,16H2,1H3,(H,28,31)(H,27,29,30)
DM5VRXW	CS	CC(=O)NCC1=CC=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)OC4CCOCC4)C#N
DM5VRXW	IK	AZLRFMPKDVYEQH-UHFFFAOYSA-N
DM5VRXW	IU	N-[[4-[[4-[3-cyano-4-(oxan-4-yloxy)phenyl]pyrimidin-2-yl]amino]phenyl]methyl]acetamide

DMW2LZ0	ID	DMW2LZ0
DMW2LZ0	DN	Aminotriazolopyridine derivative 1
DMW2LZ0	HS	Patented
DMW2LZ0	SN	PMID27774824-Compound-Figure11Example1down
DMW2LZ0	CP	GALAPAGOS NV
DMW2LZ0	DT	Small molecular drug

DM2V31C	ID	DM2V31C
DM2V31C	DN	Ampicidin analog 1
DM2V31C	HS	Patented
DM2V31C	SN	PMID26566576-Compound-3
DM2V31C	DT	Small molecular drug

DMZH8S9	ID	DMZH8S9
DMZH8S9	DN	Ampicidin analog 2
DMZH8S9	HS	Patented
DMZH8S9	SN	PMID26566576-Compound-4
DMZH8S9	DT	Small molecular drug

DMDSUGF	ID	DMDSUGF
DMDSUGF	DN	Aniline derivative 1
DMDSUGF	HS	Patented
DMDSUGF	SN	PMID26161698-Compound-33
DMDSUGF	CP	GILEAD SCIENCES, INC. MELVIN, Lawrence, S., Jr. GRAUPE, Michael VENKATARAMANI, Chandrasekar
DMDSUGF	DT	Small molecular drug
DMDSUGF	PC	59176838
DMDSUGF	MW	346.3
DMDSUGF	FM	C18H14N6O2
DMDSUGF	IC	InChI=1S/C18H14N6O2/c25-17(23-26)12-4-6-13(7-5-12)21-18-19-9-8-14(22-18)15-11-20-16-3-1-2-10-24(15)16/h1-11,26H,(H,23,25)(H,19,21,22)
DMDSUGF	CS	C1=CC2=NC=C(N2C=C1)C3=NC(=NC=C3)NC4=CC=C(C=C4)C(=O)NO
DMDSUGF	IK	YUKQHEDCOBZZTJ-UHFFFAOYSA-N
DMDSUGF	IU	N-hydroxy-4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzamide

DMY5J23	ID	DMY5J23
DMY5J23	DN	Antibodie derivative 1
DMY5J23	HS	Patented
DMY5J23	SN	PMID28621580-Compound-WO2012004631
DMY5J23	CP	TUBITAK ERDAG, Berrin
DMY5J23	DT	Antibody

DMGP5AR	ID	DMGP5AR
DMGP5AR	DN	Antibodie derivative 10
DMGP5AR	HS	Patented
DMGP5AR	SN	PMID28621580-Compound-WO2016057726
DMGP5AR	CP	KADMON CORPORATION, LLC
DMGP5AR	DT	Antibody
DMGP5AR	DE	Neoplasm; Angiogenesis disorder

DMPG3Y8	ID	DMPG3Y8
DMPG3Y8	DN	Antibodie derivative 11
DMPG3Y8	HS	Patented
DMPG3Y8	SN	PMID28621580-Compound-WO2016059057
DMPG3Y8	CP	AFFIBODY AB
DMPG3Y8	DT	Antibody

DMU7YC2	ID	DMU7YC2
DMU7YC2	DN	Antibodie derivative 2
DMU7YC2	HS	Patented
DMU7YC2	SN	PMID28621580-Compound-WO2012088563
DMU7YC2	CP	VEGENICS PTY LIMITED 
DMU7YC2	DT	Antibody

DMNPBRG	ID	DMNPBRG
DMNPBRG	DN	Antibodie derivative 3
DMNPBRG	HS	Patented
DMNPBRG	SN	PMID28621580-Compound-WO2012125123
DMNPBRG	CP	NATIONAL UNIVERSITY OF SINGAPORE RAGHUNATH, Michael BLOCKI, Anna
DMNPBRG	DT	Antibody

DM2WMGO	ID	DM2WMGO
DM2WMGO	DN	Antibodie derivative 4
DM2WMGO	HS	Patented
DM2WMGO	SN	PMID28621580-Compound-WO2012161372
DM2WMGO	CP	PHARMABCINE INC.          SAMSUNG LIFE PUBLIC WELFARE FOUNDATION                 YOO, Jin San     LEE, Sang Hoon     LEE, Weon Sup     KIM, Sung-Woo     SHIM, Sang Ryeol     YOO, Jin Sang     KIM, Yeun Ju     SHIN, Hee Young     KIM, Joong Kyu     NAM, Ju Ryung
DM2WMGO	DT	Antibody

DMRTZE4	ID	DMRTZE4
DMRTZE4	DN	Antibodie derivative 5
DMRTZE4	HS	Patented
DMRTZE4	SN	PMID28621580-Compound-WO2013137686
DMRTZE4	CP	SNU R&amp;DB FOUNDATION KIM, Hyun Kee
DMRTZE4	DT	Antibody

DMUG6YT	ID	DMUG6YT
DMUG6YT	DN	Antibodie derivative 6
DMUG6YT	HS	Patented
DMUG6YT	SN	PMID28621580-Compound-WO2014019520
DMUG6YT	CP	SUZHOU INSTITUTE OF NANO-TECH AND NANO-BIONICS(SINANO), CAS
DMUG6YT	DT	Antibody

DMJN37O	ID	DMJN37O
DMJN37O	DN	Antibodie derivative 7
DMJN37O	HS	Patented
DMJN37O	SN	PMID28621580-Compound-WO2014055998
DMJN37O	CP	KADMON CORPORATION, LLC
DMJN37O	DT	Antibody
DMJN37O	DE	Solid tumour/cancer

DM0CEJM	ID	DM0CEJM
DM0CEJM	DN	Antibodie derivative 8
DM0CEJM	HS	Patented
DM0CEJM	SN	PMID28621580-Compound-WO2014081202
DM0CEJM	CP	PHARMABCINE INC
DM0CEJM	DT	Antibody

DMDRJ31	ID	DMDRJ31
DMDRJ31	DN	Antibodie derivative 9
DMDRJ31	HS	Patented
DMDRJ31	SN	PMID28621580-Compound-WO2016044219
DMDRJ31	CP	TRUSTEES OF BOSTON UNIVERSITY
DMDRJ31	DT	Antibody
DMDRJ31	DE	Corneal neovascularization; Carotid artery disease; Macular degeneration; Solid tumour/cancer

DMLQ8N1	ID	DMLQ8N1
DMLQ8N1	DN	AphanamgrandiolA
DMLQ8N1	HS	Patented

DM7AXSM	ID	DM7AXSM
DM7AXSM	DN	Apogossypolone
DM7AXSM	HS	Patented
DM7AXSM	DT	Small molecular drug
DM7AXSM	PC	135513044
DM7AXSM	MW	490.5
DM7AXSM	FM	C28H26O8
DM7AXSM	IC	InChI=1S/C28H26O8/c1-9(2)17-21-13(7-15(29)27(17)35)25(33)19(11(5)23(21)31)20-12(6)24(32)22-14(26(20)34)8-16(30)28(36)18(22)10(3)4/h7-10,29,31,33,35H,1-6H3
DM7AXSM	CS	CC1=C(C(=O)C2=CC(=O)C(=O)C(=C2C1=O)C(C)C)C3=C(C4=CC(=C(C(=C4C(=C3C)O)C(C)C)O)O)O
DM7AXSM	IK	PXSGRWNXASCGTJ-UHFFFAOYSA-N
DM7AXSM	IU	3-methyl-5-propan-2-yl-2-(1,4,6,7-tetrahydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,4,6,7-tetrone
DM7AXSM	CA	CAS 886578-07-0

DMUPN01	ID	DMUPN01
DMUPN01	DN	AR-A014418
DMUPN01	HS	Patented
DMUPN01	SN	487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N&amp; -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be
DMUPN01	DT	Small molecular drug
DMUPN01	PC	448014
DMUPN01	MW	308.32
DMUPN01	FM	C12H12N4O4S
DMUPN01	IC	InChI=1S/C12H12N4O4S/c1-20-9-4-2-8(3-5-9)6-13-11(17)15-12-14-7-10(21-12)16(18)19/h2-5,7H,6H2,1H3,(H2,13,14,15,17)
DMUPN01	CS	COC1=CC=C(C=C1)CNC(=O)NC2=NC=C(S2)[N+](=O)[O-]
DMUPN01	IK	YAEMHJKFIIIULI-UHFFFAOYSA-N
DMUPN01	IU	1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea
DMUPN01	CA	CAS 487021-52-3
DMUPN01	DE	Ovarian cancer

DMGR6X1	ID	DMGR6X1
DMGR6X1	DN	Aromatic acetylene derivative 1
DMGR6X1	HS	Patented
DMGR6X1	SN	PMID30107136-Compound-Example24
DMGR6X1	CP	UANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD [CN] 
DMGR6X1	DT	Small molecule immunotherapy 
DMGR6X1	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMXW0PV	ID	DMXW0PV
DMXW0PV	DN	Aromatic and heteroaryl compound 1
DMXW0PV	HS	Patented
DMXW0PV	SN	PMID26882240-Compound-17
DMXW0PV	CP	Leland Stanford Junior University, USA
DMXW0PV	DT	Small molecular drug
DMXW0PV	PC	421494
DMXW0PV	MW	418.6
DMXW0PV	FM	C27H34N2O2
DMXW0PV	IC	InChI=1S/C27H34N2O2/c1-4-18-17-29-12-10-20-15-26(30-2)27(31-3)16-23(20)25(29)14-21(18)13-24-22-8-6-5-7-19(22)9-11-28-24/h5-8,15-16,24-25,28H,4,9-14,17H2,1-3H3
DMXW0PV	CS	CCC1=C(CC2C3=CC(=C(C=C3CCN2C1)OC)OC)CC4C5=CC=CC=C5CCN4
DMXW0PV	IK	HDIJLRXRAJUXQB-UHFFFAOYSA-N
DMXW0PV	IU	3-ethyl-9,10-dimethoxy-2-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine

DMVLQ2P	ID	DMVLQ2P
DMVLQ2P	DN	Aromatic bicyclic compound 1
DMVLQ2P	HS	Patented
DMVLQ2P	SN	PMID26394986-Compound-34
DMVLQ2P	CP	DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DMVLQ2P	DT	Small molecular drug
DMVLQ2P	PC	53354771
DMVLQ2P	MW	615.6
DMVLQ2P	FM	C33H32F3N7O2
DMVLQ2P	IC	InChI=1S/C33H32F3N7O2/c1-21-6-7-25(38-30(44)22-4-3-5-23(18-22)33(34,35)36)19-29(21)43-13-12-28-27(31(43)45)20-37-32(40-28)39-24-8-10-26(11-9-24)42-16-14-41(2)15-17-42/h3-11,18-20H,12-17H2,1-2H3,(H,38,44)(H,37,39,40)
DMVLQ2P	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)N3CCC4=NC(=NC=C4C3=O)NC5=CC=C(C=C5)N6CCN(CC6)C
DMVLQ2P	IK	WVGSOXRZIVSEQO-UHFFFAOYSA-N
DMVLQ2P	IU	N-[4-methyl-3-[2-[4-(4-methylpiperazin-1-yl)anilino]-5-oxo-7,8-dihydropyrido[4,3-d]pyrimidin-6-yl]phenyl]-3-(trifluoromethyl)benzamide

DMKFV67	ID	DMKFV67
DMKFV67	DN	Aromatic bicyclic compound 2
DMKFV67	HS	Patented
DMKFV67	SN	PMID26394986-Compound-35
DMKFV67	CP	DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DMKFV67	DT	Small molecular drug
DMKFV67	PC	53372213
DMKFV67	MW	636.1
DMKFV67	FM	C32H29ClF3N7O2
DMKFV67	IC	InChI=1S/C32H29ClF3N7O2/c1-41-13-15-42(16-14-41)24-8-5-22(6-9-24)39-31-37-19-25-27(40-31)11-12-43(30(25)45)28-18-23(7-10-26(28)33)38-29(44)20-3-2-4-21(17-20)32(34,35)36/h2-10,17-19H,11-16H2,1H3,(H,38,44)(H,37,39,40)
DMKFV67	CS	CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C4C(=N3)CCN(C4=O)C5=C(C=CC(=C5)NC(=O)C6=CC(=CC=C6)C(F)(F)F)Cl
DMKFV67	IK	SGLDXZLAQLSXFP-UHFFFAOYSA-N
DMKFV67	IU	N-[4-chloro-3-[2-[4-(4-methylpiperazin-1-yl)anilino]-5-oxo-7,8-dihydropyrido[4,3-d]pyrimidin-6-yl]phenyl]-3-(trifluoromethyl)benzamide

DMRXN94	ID	DMRXN94
DMRXN94	DN	Aromatic bicyclic compound 3
DMRXN94	HS	Patented
DMRXN94	SN	PMID26394986-Compound-36
DMRXN94	CP	DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DMRXN94	DT	Small molecular drug

DM3E75P	ID	DM3E75P
DM3E75P	DN	Aromatic bicyclic compound 4
DM3E75P	HS	Patented
DM3E75P	SN	PMID26394986-Compound-37
DM3E75P	CP	DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DM3E75P	DT	Small molecular drug

DMALF06	ID	DMALF06
DMALF06	DN	Aromatic bicyclic compound 5
DMALF06	HS	Patented
DMALF06	SN	PMID26394986-Compound-38
DMALF06	CP	DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DMALF06	DT	Small molecular drug

DM8L3KM	ID	DM8L3KM
DM8L3KM	DN	Aromatic bicyclic compound 6
DM8L3KM	HS	Patented
DM8L3KM	SN	PMID26394986-Compound-39
DM8L3KM	CP	DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DM8L3KM	DT	Small molecular drug

DMSRKON	ID	DMSRKON
DMSRKON	DN	Aromatic ethylene derivative 1
DMSRKON	HS	Patented
DMSRKON	SN	PMID30107136-Compound-Example23
DMSRKON	CP	UANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD [CN] 
DMSRKON	DT	Small molecule immunotherapy 
DMSRKON	PC	138632287
DMSRKON	MW	527.5
DMSRKON	FM	C29H28F3NO5
DMSRKON	IC	InChI=1S/C29H28F3NO5/c1-18-20(4-3-5-23(18)21-9-11-25-26(15-21)38-13-12-37-25)7-8-22-14-19(6-10-24(22)29(30,31)32)16-33-28(2,17-34)27(35)36/h3-11,14-15,33-34H,12-13,16-17H2,1-2H3,(H,35,36)/b8-7+
DMSRKON	CS	CC1=C(C=CC=C1C2=CC3=C(C=C2)OCCO3)/C=C/C4=C(C=CC(=C4)CNC(C)(CO)C(=O)O)C(F)(F)F
DMSRKON	IK	PTGUEPRQUFAZLN-BQYQJAHWSA-N
DMSRKON	IU	2-[[3-[(E)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid
DMSRKON	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMJ8X7A	ID	DMJ8X7A
DMJ8X7A	DN	Aromatic hydrazine carboxyimidoamide derivative 1
DMJ8X7A	HS	Patented
DMJ8X7A	SN	PMID26815044-Compound-108
DMJ8X7A	DT	Small molecular drug
DMJ8X7A	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMYH4D1	ID	DMYH4D1
DMYH4D1	DN	Aromatic hydrazine carboxyimidoamide derivative 2
DMYH4D1	HS	Patented
DMYH4D1	SN	PMID26815044-Compound-109
DMYH4D1	DT	Small molecular drug
DMYH4D1	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DML63B7	ID	DML63B7
DML63B7	DN	Aromatic hydrazine carboxyimidoamide derivative 3
DML63B7	HS	Patented
DML63B7	SN	PMID26815044-Compound-110
DML63B7	DT	Small molecular drug
DML63B7	PC	90229391
DML63B7	MW	292.33
DML63B7	FM	C17H16N4O
DML63B7	IC	InChI=1S/C17H16N4O/c18-17(19-11-13-6-2-1-3-7-13)21-20-12-15-10-14-8-4-5-9-16(14)22-15/h1-10,12H,11H2,(H3,18,19,21)/b20-12+
DML63B7	CS	C1=CC=C(C=C1)CN=C(N)N/N=C/C2=CC3=CC=CC=C3O2
DML63B7	IK	BUHIWIPIXBWCOP-UDWIEESQSA-N
DML63B7	IU	1-[(E)-1-benzofuran-2-ylmethylideneamino]-2-benzylguanidine
DML63B7	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMKE5PB	ID	DMKE5PB
DMKE5PB	DN	Aromatic hydrazine carboxyimidoamide derivative 4
DMKE5PB	HS	Patented
DMKE5PB	SN	PMID26815044-Compound-111
DMKE5PB	DT	Small molecular drug
DMKE5PB	PC	90229466
DMKE5PB	MW	350.4
DMKE5PB	FM	C19H18N4O3
DMKE5PB	IC	InChI=1S/C19H18N4O3/c1-25-18(24)14-8-6-13(7-9-14)11-21-19(20)23-22-12-16-10-15-4-2-3-5-17(15)26-16/h2-10,12H,11H2,1H3,(H3,20,21,23)/b22-12+
DMKE5PB	CS	COC(=O)C1=CC=C(C=C1)CN=C(N)N/N=C/C2=CC3=CC=CC=C3O2
DMKE5PB	IK	WGIBSILJKFPWDM-WSDLNYQXSA-N
DMKE5PB	IU	methyl 4-[[[amino-[(2E)-2-(1-benzofuran-2-ylmethylidene)hydrazinyl]methylidene]amino]methyl]benzoate
DMKE5PB	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM4AM1E	ID	DM4AM1E
DM4AM1E	DN	Aromatic hydrazine carboxyimidoamide derivative 5
DM4AM1E	HS	Patented
DM4AM1E	SN	PMID26815044-Compound-112
DM4AM1E	DT	Small molecular drug
DM4AM1E	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM8HDQT	ID	DM8HDQT
DM8HDQT	DN	Aromatic hydrazine carboxyimidoamide derivative 6
DM8HDQT	HS	Patented
DM8HDQT	SN	PMID26815044-Compound-113
DM8HDQT	DT	Small molecular drug
DM8HDQT	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMJX6DV	ID	DMJX6DV
DMJX6DV	DN	Aromatic ring compound 1
DMJX6DV	HS	Patented
DMJX6DV	SN	PMID25828189-Compound-41
DMJX6DV	DT	Small molecular drug

DMMAS3G	ID	DMMAS3G
DMMAS3G	DN	Aromatic ring compound 2
DMMAS3G	HS	Patented
DMMAS3G	SN	PMID25828189-Compound-42
DMMAS3G	DT	Small molecular drug
DMMAS3G	PC	71748058
DMMAS3G	MW	561
DMMAS3G	FM	C28H28ClF3N4O3
DMMAS3G	IC	InChI=1S/C28H28ClF3N4O3/c1-17-13-19(25-33-14-21(29)15-34-25)6-9-23(17)24(10-11-28(30,31)32)35-22-7-4-18(5-8-22)26(37)36-12-2-3-20(16-36)27(38)39/h4-9,13-15,20,24,35H,2-3,10-12,16H2,1H3,(H,38,39)/t20-,24?/m1/s1
DMMAS3G	CS	CC1=C(C=CC(=C1)C2=NC=C(C=N2)Cl)C(CCC(F)(F)F)NC3=CC=C(C=C3)C(=O)N4CCC[C@H](C4)C(=O)O
DMMAS3G	IK	IDBHHYNBIVBFSI-CGHJUBPDSA-N
DMMAS3G	IU	(3R)-1-[4-[[1-[4-(5-chloropyrimidin-2-yl)-2-methylphenyl]-4,4,4-trifluorobutyl]amino]benzoyl]piperidine-3-carboxylic acid

DM43APD	ID	DM43APD
DM43APD	DN	Aromatic ring compound 3
DM43APD	HS	Patented
DM43APD	SN	PMID25828189-Compound-43
DM43APD	DT	Small molecular drug
DM43APD	PC	71767732
DM43APD	MW	594.5
DM43APD	FM	C29H28F6N4O3
DM43APD	IC	InChI=1S/C29H28F6N4O3/c1-17-13-19(25-36-14-21(15-37-25)29(33,34)35)6-9-23(17)24(10-11-28(30,31)32)38-22-7-4-18(5-8-22)26(40)39-12-2-3-20(16-39)27(41)42/h4-9,13-15,20,24,38H,2-3,10-12,16H2,1H3,(H,41,42)/t20-,24?/m1/s1
DM43APD	CS	CC1=C(C=CC(=C1)C2=NC=C(C=N2)C(F)(F)F)C(CCC(F)(F)F)NC3=CC=C(C=C3)C(=O)N4CCC[C@H](C4)C(=O)O
DM43APD	IK	HYBIWCXMSAEBQK-CGHJUBPDSA-N
DM43APD	IU	(3R)-1-[4-[[4,4,4-trifluoro-1-[2-methyl-4-[5-(trifluoromethyl)pyrimidin-2-yl]phenyl]butyl]amino]benzoyl]piperidine-3-carboxylic acid

DMXGLST	ID	DMXGLST
DMXGLST	DN	Aromatic ring compound 4
DMXGLST	HS	Patented
DMXGLST	SN	PMID25828189-Compound-44
DMXGLST	DT	Small molecular drug
DMXGLST	PC	71767733
DMXGLST	MW	568.6
DMXGLST	FM	C31H35F3N4O3
DMXGLST	IC	InChI=1S/C31H35F3N4O3/c1-20-17-25(38-19-22-5-2-3-7-27(22)36-38)12-13-26(20)28(14-15-31(32,33)34)35-24-10-8-21(9-11-24)29(39)37-16-4-6-23(18-37)30(40)41/h8-13,17,19,23,28,35H,2-7,14-16,18H2,1H3,(H,40,41)/t23-,28?/m1/s1
DMXGLST	CS	CC1=C(C=CC(=C1)N2C=C3CCCCC3=N2)C(CCC(F)(F)F)NC4=CC=C(C=C4)C(=O)N5CCC[C@H](C5)C(=O)O
DMXGLST	IK	ZEUDUNQWXOYIFC-YFIOFSHDSA-N
DMXGLST	IU	(3R)-1-[4-[[4,4,4-trifluoro-1-[2-methyl-4-(4,5,6,7-tetrahydroindazol-2-yl)phenyl]butyl]amino]benzoyl]piperidine-3-carboxylic acid

DMSDRNQ	ID	DMSDRNQ
DMSDRNQ	DN	Aryl 1,2-diamine derivative 1
DMSDRNQ	HS	Patented
DMSDRNQ	SN	PMID29473428-Compound-67
DMSDRNQ	CP	INVENTISBIO INC
DMSDRNQ	DT	Small molecular drug
DMSDRNQ	PC	130331124
DMSDRNQ	MW	420.5
DMSDRNQ	FM	C24H28N4O3
DMSDRNQ	IC	InChI=1S/C24H28N4O3/c1-2-28(20-8-12-31-13-9-20)22-21(27-19-6-4-17(15-25)5-7-19)14-18(16-26-22)24(23(29)30)10-3-11-24/h4-7,14,16,20,27H,2-3,8-13H2,1H3,(H,29,30)
DMSDRNQ	CS	CCN(C1CCOCC1)C2=C(C=C(C=N2)C3(CCC3)C(=O)O)NC4=CC=C(C=C4)C#N
DMSDRNQ	IK	OQNDTVBPYVYWIY-UHFFFAOYSA-N
DMSDRNQ	IU	1-[5-(4-cyanoanilino)-6-[ethyl(oxan-4-yl)amino]pyridin-3-yl]cyclobutane-1-carboxylic acid

DM417XY	ID	DM417XY
DM417XY	DN	Aryl alkanolamine derivative 1
DM417XY	HS	Patented
DM417XY	SN	PMID28051882-Compound-7
DM417XY	CP	UNIVERSITA' DEGLI STUDI DI PAVIA
DM417XY	DT	Small molecular drug
DM417XY	PC	91884637
DM417XY	MW	309.4
DM417XY	FM	C21H27NO
DM417XY	IC	InChI=1S/C21H27NO/c23-17-21(13-16-22-14-5-2-6-15-22)20-11-9-19(10-12-20)18-7-3-1-4-8-18/h1,3-4,7-12,21,23H,2,5-6,13-17H2
DM417XY	CS	C1CCN(CC1)CCC(CO)C2=CC=C(C=C2)C3=CC=CC=C3
DM417XY	IK	DUVDSTKOGVWACP-UHFFFAOYSA-N
DM417XY	IU	2-(4-phenylphenyl)-4-piperidin-1-ylbutan-1-ol

DMUP0WH	ID	DMUP0WH
DMUP0WH	DN	Aryl alkanolamine derivative 2
DMUP0WH	HS	Patented
DMUP0WH	SN	PMID28051882-Compound-V
DMUP0WH	CP	UNIVERSITA' DEGLI STUDI DI PAVIA
DMUP0WH	DT	Small molecular drug

DMA9B0V	ID	DMA9B0V
DMA9B0V	DN	Aryl azepine derivative 1
DMA9B0V	HS	Patented
DMA9B0V	SN	PMID30185082-Compound-36
DMA9B0V	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMA9B0V	DT	Small molecular drug

DMI4XBC	ID	DMI4XBC
DMI4XBC	DN	Aryl azepine derivative 2
DMI4XBC	HS	Patented
DMI4XBC	SN	PMID30185082-Compound-37
DMI4XBC	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMI4XBC	DT	Small molecular drug

DMGZHRT	ID	DMGZHRT
DMGZHRT	DN	Aryl carbamate analog 1
DMGZHRT	HS	Patented
DMGZHRT	SN	PMID26882240-Compound-19
DMGZHRT	CP	Italfarmaco, S.A., Spain
DMGZHRT	DT	Small molecular drug
DMGZHRT	PC	71541820
DMGZHRT	MW	377.4
DMGZHRT	FM	C21H19N3O4
DMGZHRT	IC	InChI=1S/C21H19N3O4/c1-24(16-7-3-2-4-8-16)21(27)28-17-9-10-19(25)18(12-17)20(26)23-14-15-6-5-11-22-13-15/h2-13,25H,14H2,1H3,(H,23,26)
DMGZHRT	CS	CN(C1=CC=CC=C1)C(=O)OC2=CC(=C(C=C2)O)C(=O)NCC3=CN=CC=C3
DMGZHRT	IK	DSHOFHQFNJBXHY-UHFFFAOYSA-N
DMGZHRT	IU	[4-hydroxy-3-(pyridin-3-ylmethylcarbamoyl)phenyl] N-methyl-N-phenylcarbamate

DMTZRCW	ID	DMTZRCW
DMTZRCW	DN	Aryl carboxamide derivative 1
DMTZRCW	HS	Patented
DMTZRCW	SN	PMID25539043-Compound-WO2010137351Example37
DMTZRCW	CP	RAQUALIA PHARMA INC. INOUE, Tadashi WATANABE, Shuzo YAMAGISHI, Tatsuya ARANO, Yoshimasa MORITA, Mikio SHIMADA, Kaoru
DMTZRCW	DT	Small molecular drug

DM146TA	ID	DM146TA
DM146TA	DN	Aryl carboxamide derivative 2
DM146TA	HS	Patented
DM146TA	SN	PMID25539043-Compound-WO2010137351Example38
DM146TA	CP	RAQUALIA PHARMA INC. INOUE, Tadashi WATANABE, Shuzo YAMAGISHI, Tatsuya ARANO, Yoshimasa MORITA, Mikio SHIMADA, Kaoru
DM146TA	DT	Small molecular drug

DM6FQ8L	ID	DM6FQ8L
DM6FQ8L	DN	Aryl carboxamide derivative 3
DM6FQ8L	HS	Patented
DM6FQ8L	SN	PMID25539043-Compound-WO2011058766Example39
DM6FQ8L	CP	RAQUALIA PHARMA INC. YAMAGISHI, Tatsuya ARANO, Yoshimasa MORITA, Mikio INOUE, Tadashi
DM6FQ8L	DT	Small molecular drug

DMNBW8P	ID	DMNBW8P
DMNBW8P	DN	Aryl carboxamide derivative 4
DMNBW8P	HS	Patented
DMNBW8P	SN	PMID25539043-Compound-WO2011103196Example36
DMNBW8P	CP	AMGEN INC. BREGMAN, Howard BUCHANAN, John, L. CHAKKA, Nagasree DIMAURO, Erin, F. DU, Bingfan NGUYEN, Hanh, Nho ZHENG, Xiao, Mei
DMNBW8P	DT	Small molecular drug

DMZECH7	ID	DMZECH7
DMZECH7	DN	Aryl cyclopropylamine derivative 3
DMZECH7	HS	Patented
DMZECH7	SN	PMID27019002-Compound-25a
DMZECH7	CP	Duke University, USA
DMZECH7	DT	Small molecular drug

DM0C1ZO	ID	DM0C1ZO
DM0C1ZO	DN	Aryl cyclopropylamine derivative 4
DM0C1ZO	HS	Patented
DM0C1ZO	SN	PMID27019002-Compound-25b
DM0C1ZO	CP	Duke University, USA
DM0C1ZO	DT	Small molecular drug

DM6CK7J	ID	DM6CK7J
DM6CK7J	DN	Aryl cyclopropylamine derivative 5
DM6CK7J	HS	Patented
DM6CK7J	SN	PMID27019002-Compound-25c
DM6CK7J	CP	Duke University, USA
DM6CK7J	DT	Small molecular drug

DM1TV6F	ID	DM1TV6F
DM1TV6F	DN	Aryl mannoside derivative 1
DM1TV6F	HS	Patented
DM1TV6F	SN	PMID26651364-Compound-12
DM1TV6F	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM1TV6F	DT	Carbohydrates
DM1TV6F	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM251GL	ID	DM251GL
DM251GL	DN	Aryl mannoside derivative 10
DM251GL	HS	Patented
DM251GL	SN	PMID26651364-Compound-21
DM251GL	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM251GL	DT	Carbohydrates
DM251GL	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMRVIPL	ID	DMRVIPL
DMRVIPL	DN	Aryl mannoside derivative 11
DMRVIPL	HS	Patented
DMRVIPL	SN	PMID26651364-Compound-22
DMRVIPL	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMRVIPL	DT	Carbohydrates
DMRVIPL	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMOG8XT	ID	DMOG8XT
DMOG8XT	DN	Aryl mannoside derivative 12
DMOG8XT	HS	Patented
DMOG8XT	SN	PMID26651364-Compound-23
DMOG8XT	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMOG8XT	DT	Carbohydrates
DMOG8XT	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM2W7JE	ID	DM2W7JE
DM2W7JE	DN	Aryl mannoside derivative 13
DM2W7JE	HS	Patented
DM2W7JE	SN	PMID26651364-Compound-24
DM2W7JE	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM2W7JE	DT	Carbohydrates
DM2W7JE	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMR648Z	ID	DMR648Z
DMR648Z	DN	Aryl mannoside derivative 14
DMR648Z	HS	Patented
DMR648Z	SN	PMID26651364-Compound-76
DMR648Z	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMR648Z	DT	Carbohydrates
DMR648Z	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMQS8CF	ID	DMQS8CF
DMQS8CF	DN	Aryl mannoside derivative 15
DMQS8CF	HS	Patented
DMQS8CF	SN	PMID26651364-Compound-77
DMQS8CF	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMQS8CF	DT	Carbohydrates
DMQS8CF	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMP6QEC	ID	DMP6QEC
DMP6QEC	DN	Aryl mannoside derivative 16
DMP6QEC	HS	Patented
DMP6QEC	SN	PMID26651364-Compound-78
DMP6QEC	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMP6QEC	DT	Carbohydrates
DMP6QEC	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM0FSPQ	ID	DM0FSPQ
DM0FSPQ	DN	Aryl mannoside derivative 17
DM0FSPQ	HS	Patented
DM0FSPQ	SN	PMID26651364-Compound-79
DM0FSPQ	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM0FSPQ	DT	Carbohydrates
DM0FSPQ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM0YUBR	ID	DM0YUBR
DM0YUBR	DN	Aryl mannoside derivative 18
DM0YUBR	HS	Patented
DM0YUBR	SN	PMID26651364-Compound-80
DM0YUBR	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM0YUBR	DT	Carbohydrates
DM0YUBR	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM6K29H	ID	DM6K29H
DM6K29H	DN	Aryl mannoside derivative 19
DM6K29H	HS	Patented
DM6K29H	SN	PMID26651364-Compound-81
DM6K29H	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM6K29H	DT	Carbohydrates
DM6K29H	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM4S2U5	ID	DM4S2U5
DM4S2U5	DN	Aryl mannoside derivative 2
DM4S2U5	HS	Patented
DM4S2U5	SN	PMID26651364-Compound-13
DM4S2U5	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM4S2U5	DT	Carbohydrates
DM4S2U5	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMZ2RV3	ID	DMZ2RV3
DMZ2RV3	DN	Aryl mannoside derivative 20
DMZ2RV3	HS	Patented
DMZ2RV3	SN	PMID26651364-Compound-82
DMZ2RV3	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMZ2RV3	DT	Carbohydrates
DMZ2RV3	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMJBY68	ID	DMJBY68
DMJBY68	DN	Aryl mannoside derivative 21
DMJBY68	HS	Patented
DMJBY68	SN	PMID26651364-Compound-83
DMJBY68	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMJBY68	DT	Carbohydrates
DMJBY68	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMJFDNB	ID	DMJFDNB
DMJFDNB	DN	Aryl mannoside derivative 22
DMJFDNB	HS	Patented
DMJFDNB	SN	PMID26651364-Compound-84
DMJFDNB	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMJFDNB	DT	Carbohydrates
DMJFDNB	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMWUNRV	ID	DMWUNRV
DMWUNRV	DN	Aryl mannoside derivative 23
DMWUNRV	HS	Patented
DMWUNRV	SN	PMID26651364-Compound-85
DMWUNRV	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMWUNRV	DT	Carbohydrates
DMWUNRV	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMF5XU8	ID	DMF5XU8
DMF5XU8	DN	Aryl mannoside derivative 3
DMF5XU8	HS	Patented
DMF5XU8	SN	PMID26651364-Compound-14
DMF5XU8	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMF5XU8	DT	Carbohydrates
DMF5XU8	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMO19Y6	ID	DMO19Y6
DMO19Y6	DN	Aryl mannoside derivative 4
DMO19Y6	HS	Patented
DMO19Y6	SN	PMID26651364-Compound-15
DMO19Y6	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMO19Y6	DT	Carbohydrates
DMO19Y6	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMC31R	ID	DMMC31R
DMMC31R	DN	Aryl mannoside derivative 5
DMMC31R	HS	Patented
DMMC31R	SN	PMID26651364-Compound-16
DMMC31R	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMMC31R	DT	Carbohydrates
DMMC31R	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM5MIEC	ID	DM5MIEC
DM5MIEC	DN	Aryl mannoside derivative 6
DM5MIEC	HS	Patented
DM5MIEC	SN	PMID26651364-Compound-17
DM5MIEC	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM5MIEC	DT	Carbohydrates
DM5MIEC	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM9YS40	ID	DM9YS40
DM9YS40	DN	Aryl mannoside derivative 7
DM9YS40	HS	Patented
DM9YS40	SN	PMID26651364-Compound-18
DM9YS40	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM9YS40	DT	Carbohydrates
DM9YS40	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMK6PFQ	ID	DMK6PFQ
DMK6PFQ	DN	Aryl mannoside derivative 8
DMK6PFQ	HS	Patented
DMK6PFQ	SN	PMID26651364-Compound-19
DMK6PFQ	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMK6PFQ	DT	Carbohydrates
DMK6PFQ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMNSK7U	ID	DMNSK7U
DMNSK7U	DN	Aryl mannoside derivative 9
DMNSK7U	HS	Patented
DMNSK7U	SN	PMID26651364-Compound-20
DMNSK7U	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMNSK7U	DT	Carbohydrates
DMNSK7U	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMBWH3O	ID	DMBWH3O
DMBWH3O	DN	Aryl methoxyacrylate derivative 1
DMBWH3O	HS	Patented
DMBWH3O	SN	PMID26882240-Compound-20A
DMBWH3O	CP	OSCOTEC INC [KR]
DMBWH3O	DT	Small molecular drug
DMBWH3O	PC	88531173
DMBWH3O	MW	397.5
DMBWH3O	FM	C23H27NO5
DMBWH3O	IC	InChI=1S/C23H27NO5/c1-15-12-22(16(2)11-20(15)17(3)24-28-6)29-13-18-9-7-8-10-19(18)21(14-26-4)23(25)27-5/h7-12,14H,13H2,1-6H3/b21-14+,24-17+
DMBWH3O	CS	CC1=CC(=C(C=C1OCC2=CC=CC=C2/C(=C\\OC)/C(=O)OC)C)/C(=N/OC)/C
DMBWH3O	IK	LMRXZYBAUUHKCX-UDLHRNPOSA-N
DMBWH3O	IU	methyl (E)-3-methoxy-2-[2-[[4-[(E)-N-methoxy-C-methylcarbonimidoyl]-2,5-dimethylphenoxy]methyl]phenyl]prop-2-enoate

DMNC0RX	ID	DMNC0RX
DMNC0RX	DN	Aryl methoxyacrylate derivative 2
DMNC0RX	HS	Patented
DMNC0RX	SN	PMID26882240-Compound-20B
DMNC0RX	CP	OSCOTEC INC [KR]
DMNC0RX	DT	Small molecular drug
DMNC0RX	PC	88531325
DMNC0RX	MW	439.5
DMNC0RX	FM	C26H33NO5
DMNC0RX	IC	InChI=1S/C26H33NO5/c1-7-13-32-27-24(8-2)22-14-19(4)25(15-18(22)3)31-16-20-11-9-10-12-21(20)23(17-29-5)26(28)30-6/h9-12,14-15,17H,7-8,13,16H2,1-6H3/b23-17+,27-24+
DMNC0RX	CS	CCCO/N=C(\\CC)/C1=C(C=C(C(=C1)C)OCC2=CC=CC=C2/C(=C\\OC)/C(=O)OC)C
DMNC0RX	IK	SLZOIVOTSYQKJP-FQGYVBMWSA-N
DMNC0RX	IU	methyl (E)-2-[2-[[4-[(E)-C-ethyl-N-propoxycarbonimidoyl]-2,5-dimethylphenoxy]methyl]phenyl]-3-methoxyprop-2-enoate

DML1IXV	ID	DML1IXV
DML1IXV	DN	Aryl oxyanilide derivative 1
DML1IXV	HS	Patented
DML1IXV	SN	PMID27607364-Compound-52
DML1IXV	CP	TAISHO PHARMACEUTICAL CO., LTD. NIHON, NOHYAKU CO., LTD. NAKAZATO, Atsuro OKUBO, Taketoshi NAKAMURA, Toshio CHAKI, Shigeyuki TOMISAWA, Kazuyuki NAGAMINE, Masashi YAMAMOTO, Kenji HARADA, Koichiro YOSHIDA, Masanori
DML1IXV	DT	Small molecular drug
DML1IXV	PC	9844410
DML1IXV	MW	409.9
DML1IXV	FM	C24H24ClNO3
DML1IXV	IC	InChI=1S/C24H24ClNO3/c1-17(2)28-23-12-8-7-9-19(23)16-26(18(3)27)22-14-13-20(25)15-24(22)29-21-10-5-4-6-11-21/h4-15,17H,16H2,1-3H3
DML1IXV	CS	CC(C)OC1=CC=CC=C1CN(C2=C(C=C(C=C2)Cl)OC3=CC=CC=C3)C(=O)C
DML1IXV	IK	CGUBOFYHGYNUDL-UHFFFAOYSA-N
DML1IXV	IU	N-(4-chloro-2-phenoxyphenyl)-N-[(2-propan-2-yloxyphenyl)methyl]acetamide
DML1IXV	CA	CAS 220551-79-1

DM47V3I	ID	DM47V3I
DM47V3I	DN	Aryl oxyanilide derivative 2
DM47V3I	HS	Patented
DM47V3I	SN	PMID27607364-Compound-54
DM47V3I	DT	Small molecular drug

DMSGO7D	ID	DMSGO7D
DMSGO7D	DN	Aryl oxyanilide derivative 3
DMSGO7D	HS	Patented
DMSGO7D	SN	PMID27607364-Compound-9
DMSGO7D	CP	TAISHO PHARMACEUTICAL CO., LTD. NIHON, NOHYAKU CO., LTD. NAKAZATO, Atsuro OKUBO, Taketoshi NAKAMURA, Toshio CHAKI, Shigeyuki TOMISAWA, Kazuyuki NAGAMINE, Masashi YAMAMOTO, Kenji HARADA, Koichiro YOSHIDA, Masanor
DMSGO7D	DT	Small molecular drug
DMSGO7D	PC	10430788
DMSGO7D	MW	395.4
DMSGO7D	FM	C23H22FNO4
DMSGO7D	IC	InChI=1S/C23H22FNO4/c1-16(26)25(15-17-13-20(27-2)10-12-22(17)28-3)21-14-18(24)9-11-23(21)29-19-7-5-4-6-8-19/h4-14H,15H2,1-3H3
DMSGO7D	CS	CC(=O)N(CC1=C(C=CC(=C1)OC)OC)C2=C(C=CC(=C2)F)OC3=CC=CC=C3
DMSGO7D	IK	DCRZYADKQRHHSF-UHFFFAOYSA-N
DMSGO7D	IU	N-[(2,5-dimethoxyphenyl)methyl]-N-(5-fluoro-2-phenoxyphenyl)acetamide
DMSGO7D	CA	CAS 220551-92-8

DM9DJGU	ID	DM9DJGU
DM9DJGU	DN	Aryl piperazine derivative 1
DM9DJGU	HS	Patented
DM9DJGU	SN	PMID30124346-Compound-I-1
DM9DJGU	CP	SHANGHAI INST PHARM INDUSTRY [CNCAI ZHENGYAN [CNZHOU WEICHENG [CNHAO QUN [CN
DM9DJGU	DT	Small molecular drug

DM5EGBY	ID	DM5EGBY
DM5EGBY	DN	Aryl piperazine derivative 10
DM5EGBY	HS	Patented
DM5EGBY	SN	PMID26609882-Compound-48
DM5EGBY	CP	ARENA PHARMACEUTICALS, INC
DM5EGBY	DT	Small molecular drug

DMY8NEL	ID	DMY8NEL
DMY8NEL	DN	Aryl piperazine derivative 14
DMY8NEL	HS	Patented
DMY8NEL	SN	PMID30124346-Compound-31TABLE3
DMY8NEL	DT	Small molecular drug
DMY8NEL	PC	118190937
DMY8NEL	MW	501.6
DMY8NEL	FM	C32H31N5O
DMY8NEL	IC	InChI=1S/C32H31N5O/c33-22-24-8-13-31-30(21-24)26(23-34-31)6-3-4-15-35-17-19-36(20-18-35)27-9-11-28(12-10-27)37-16-14-25-5-1-2-7-29(25)32(37)38/h1-2,5,7-14,16,21,23,34H,3-4,6,15,17-20H2
DMY8NEL	CS	C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC=C(C=C4)N5C=CC6=CC=CC=C6C5=O
DMY8NEL	IK	AMDZNENPETWKSQ-UHFFFAOYSA-N
DMY8NEL	IU	3-[4-[4-[4-(1-oxoisoquinolin-2-yl)phenyl]piperazin-1-yl]butyl]-1H-indole-5-carbonitrile

DMRK4IE	ID	DMRK4IE
DMRK4IE	DN	Aryl piperazine derivative 15
DMRK4IE	HS	Patented
DMRK4IE	SN	PMID30124346-Compound-33TABLE3
DMRK4IE	DT	Small molecular drug
DMRK4IE	PC	118190855
DMRK4IE	MW	502.6
DMRK4IE	FM	C31H30N6O
DMRK4IE	IC	InChI=1S/C31H30N6O/c32-21-23-6-11-29-28(20-23)24(22-34-29)4-1-2-14-35-16-18-36(19-17-35)25-7-9-26(10-8-25)37-15-12-30-27(31(37)38)5-3-13-33-30/h3,5-13,15,20,22,34H,1-2,4,14,16-19H2
DMRK4IE	CS	C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC=C(C=C4)N5C=CC6=C(C5=O)C=CC=N6
DMRK4IE	IK	FGYLPIJGSRWQAL-UHFFFAOYSA-N
DMRK4IE	IU	3-[4-[4-[4-(5-oxo-1,6-naphthyridin-6-yl)phenyl]piperazin-1-yl]butyl]-1H-indole-5-carbonitrile

DM63XHT	ID	DM63XHT
DM63XHT	DN	Aryl piperazine derivative 16
DM63XHT	HS	Patented
DM63XHT	SN	PMID30124346-Compound-34TABLE3
DM63XHT	DT	Small molecular drug
DM63XHT	PC	118191039
DM63XHT	MW	488.6
DM63XHT	FM	C30H28N6O
DM63XHT	IC	InChI=1S/C30H28N6O/c31-20-22-5-10-28-27(19-22)23(21-33-28)3-2-13-34-15-17-35(18-16-34)24-6-8-25(9-7-24)36-14-11-29-26(30(36)37)4-1-12-32-29/h1,4-12,14,19,21,33H,2-3,13,15-18H2
DM63XHT	CS	C1CN(CCN1CCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC=C(C=C4)N5C=CC6=C(C5=O)C=CC=N6
DM63XHT	IK	QGUBOPJCHFVENQ-UHFFFAOYSA-N
DM63XHT	IU	3-[3-[4-[4-(5-oxo-1,6-naphthyridin-6-yl)phenyl]piperazin-1-yl]propyl]-1H-indole-5-carbonitrile

DMZ3DS5	ID	DMZ3DS5
DMZ3DS5	DN	Aryl piperazine derivative 6
DMZ3DS5	HS	Patented
DMZ3DS5	SN	PMID30124346-Compound-III-2
DMZ3DS5	CP	SHANGHAI INST PHARM INDUSTRY [CNCAI ZHENGYAN [CNZHOU WEICHENG [CNHAO QUN [CN
DMZ3DS5	DT	Small molecular drug

DM7BRIT	ID	DM7BRIT
DM7BRIT	DN	Aryl piperazine derivative 8
DM7BRIT	HS	Patented
DM7BRIT	SN	PMID26609882-Compound-46
DM7BRIT	CP	ARENA PHARMACEUTICALS, INC
DM7BRIT	DT	Small molecular drug

DMLKNWF	ID	DMLKNWF
DMLKNWF	DN	Aryl piperazine derivative 9
DMLKNWF	HS	Patented
DMLKNWF	SN	PMID26609882-Compound-47
DMLKNWF	CP	ARENA PHARMACEUTICALS, INC
DMLKNWF	DT	Small molecular drug

DM3CVWU	ID	DM3CVWU
DM3CVWU	DN	Aryl pyrimidine derivative 1
DM3CVWU	HS	Patented
DM3CVWU	SN	PMID26161698-Compound-43
DM3CVWU	CP	INGENIUM PHARMACEUTICALS GMBH ALLGEIER, HANS AUGUSTIN, MARTIN MUELLER, ANKE ZEITLMANN, LUTZ MARQUARDT, ANDREAS PLEISS, MICHAEL A. HEISER, ULRICH NIESTROJ, ANDR JOHANNES
DM3CVWU	DT	Small molecular drug
DM3CVWU	PC	25227433
DM3CVWU	MW	312.37
DM3CVWU	FM	C17H20N4O2
DM3CVWU	IC	InChI=1S/C17H20N4O2/c1-23-15-7-3-2-6-13(15)14-9-16(20-11-19-14)21-17(22)12-5-4-8-18-10-12/h2-3,6-7,9,11-12,18H,4-5,8,10H2,1H3,(H,19,20,21,22)
DM3CVWU	CS	COC1=CC=CC=C1C2=CC(=NC=N2)NC(=O)C3CCCNC3
DM3CVWU	IK	HWNURWPCYJPMQP-UHFFFAOYSA-N
DM3CVWU	IU	N-[6-(2-methoxyphenyl)pyrimidin-4-yl]piperidine-3-carboxamide

DMU9Y4B	ID	DMU9Y4B
DMU9Y4B	DN	Aryl pyrimidine derivative 2
DMU9Y4B	HS	Patented
DMU9Y4B	SN	PMID27172114-Compound-41
DMU9Y4B	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMU9Y4B	DT	Small molecular drug

DMXND26	ID	DMXND26
DMXND26	DN	Aryl pyrimidine derivative 3
DMXND26	HS	Patented
DMXND26	SN	PMID27172114-Compound-42
DMXND26	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMXND26	DT	Small molecular drug

DMWSAL5	ID	DMWSAL5
DMWSAL5	DN	Aryl pyrimidine derivative 4
DMWSAL5	HS	Patented
DMWSAL5	SN	PMID27172114-Compound-43
DMWSAL5	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMWSAL5	DT	Small molecular drug

DMEP9O8	ID	DMEP9O8
DMEP9O8	DN	Aryl pyrimidine derivative 5
DMEP9O8	HS	Patented
DMEP9O8	SN	PMID27172114-Compound-46
DMEP9O8	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMEP9O8	DT	Small molecular drug

DMMF9U6	ID	DMMF9U6
DMMF9U6	DN	Aryl pyrimidine derivative 6
DMMF9U6	HS	Patented
DMMF9U6	SN	PMID27172114-Compound-48
DMMF9U6	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMMF9U6	DT	Small molecular drug

DM8FAW3	ID	DM8FAW3
DM8FAW3	DN	Aryl pyrimidine derivative 7
DM8FAW3	HS	Patented
DM8FAW3	SN	PMID27172114-Compound-51
DM8FAW3	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DM8FAW3	DT	Small molecular drug

DM7OA9E	ID	DM7OA9E
DM7OA9E	DN	Aryl pyrimidine derivative 8
DM7OA9E	HS	Patented
DM7OA9E	SN	PMID27172114-Compound-52
DM7OA9E	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DM7OA9E	DT	Small molecular drug

DMBEYD1	ID	DMBEYD1
DMBEYD1	DN	Aryl pyrimidine derivative 9
DMBEYD1	HS	Patented
DMBEYD1	SN	PMID27172114-Compound-53
DMBEYD1	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMBEYD1	DT	Small molecular drug

DMW7HKS	ID	DMW7HKS
DMW7HKS	DN	Aryl sulphoxide imine derivative 1
DMW7HKS	HS	Patented
DMW7HKS	SN	PMID29473428-Compound-19
DMW7HKS	DT	Small molecular drug
DMW7HKS	PC	137199860
DMW7HKS	MW	435.27
DMW7HKS	FM	C13H16BrFN6O3S
DMW7HKS	IC	InChI=1S/C13H16BrFN6O3S/c1-16-25(2,23)6-5-17-12-11(20-24-21-12)13(19-22)18-8-3-4-10(15)9(14)7-8/h3-4,7,22H,5-6H2,1-2H3,(H,17,21)(H,18,19)
DMW7HKS	CS	CN=S(=O)(C)CCNC1=NON=C1C(=NC2=CC(=C(C=C2)F)Br)NO
DMW7HKS	IK	LLCCKYPCVYUSQH-UHFFFAOYSA-N
DMW7HKS	IU	N'-(3-bromo-4-fluorophenyl)-4-[2-(N,S-dimethylsulfonimidoyl)ethylamino]-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide

DM0B9SP	ID	DM0B9SP
DM0B9SP	DN	Aryl urea derivative 1
DM0B9SP	HS	Patented
DM0B9SP	SN	PMID26413912-Compound-36
DM0B9SP	CP	PFIZER INC. FAY, Lorraine Kathleen JOHNSON, Douglas Scott MEYERS, Marvin Jay THORARENSEN, Atli WANG, Lijuan Jane
DM0B9SP	DT	Small molecular drug

DMQWJ12	ID	DMQWJ12
DMQWJ12	DN	Aryl urea derivative 2
DMQWJ12	HS	Patented
DMQWJ12	SN	PMID26413912-Compound-37
DMQWJ12	CP	PFIZER INC
DMQWJ12	DT	Small molecular drug

DM1G7KI	ID	DM1G7KI
DM1G7KI	DN	Aryl urea derivative 3
DM1G7KI	HS	Patented
DM1G7KI	SN	PMID26413912-Compound-38
DM1G7KI	CP	PFIZER INC
DM1G7KI	DT	Small molecular drug

DM0HOJW	ID	DM0HOJW
DM0HOJW	DN	Aryl urea derivative 4
DM0HOJW	HS	Patented
DM0HOJW	SN	PMID26413912-Compound-39
DM0HOJW	CP	PFIZER INC
DM0HOJW	DT	Small molecular drug

DM54V1R	ID	DM54V1R
DM54V1R	DN	Aryl urea derivative 5
DM54V1R	HS	Patented
DM54V1R	SN	PMID26413912-Compound-40
DM54V1R	CP	PFIZER INC. LONG, Scott Allen MEYERS, Marvin Jay PELC, Matthew James SCHWEITZER, Barbara Ann THORARENSEN, Atli WANG, Lijuan Jane
DM54V1R	DT	Small molecular drug

DMGM72Q	ID	DMGM72Q
DMGM72Q	DN	A-substituted phenylpropionic acid derivative 1
DMGM72Q	HS	Patented
DMGM72Q	SN	PMID25416646-Compound-Figure2-c
DMGM72Q	DT	Small molecular drug

DMH5FEO	ID	DMH5FEO
DMH5FEO	DN	A-substituted phenylpropionic acid derivative 2
DMH5FEO	HS	Patented
DMH5FEO	SN	PMID25416646-Compound-Figure2-E
DMH5FEO	CP	Okayama University
DMH5FEO	DT	Small molecular drug

DMRG1NL	ID	DMRG1NL
DMRG1NL	DN	Atorvastatin lactole derivative 1
DMRG1NL	HS	Patented
DMRG1NL	SN	PMID27537201-Compound-Figure3
DMRG1NL	CP	REDX PHARMA LIMITED LINDSAY, Derek JACKSON, PeteREDX PHARMA LIMITED LINDSAY, Derek JACKSON, Peter HINDLEY, Stephen BHAMRA, IndeREDX PHARMA LTD [GB]BRADFORD PHARMA LTD [GBREDX PHARMA LTD [GBBRADFORD PHARMA LTD [GB]REDX PHARMA LTBRADFORD PHARMA LTD
DMRG1NL	DT	Small molecular drug

DMVD5TA	ID	DMVD5TA
DMVD5TA	DN	Azachalcone derivative 1
DMVD5TA	HS	Patented
DMVD5TA	SN	PMID26560530-Compound-41
DMVD5TA	CP	Universit de Montral
DMVD5TA	DT	Small molecular drug
DMVD5TA	PC	5872358
DMVD5TA	MW	254.24
DMVD5TA	FM	C14H10N2O3
DMVD5TA	IC	InChI=1S/C14H10N2O3/c17-14(12-2-1-9-15-10-12)8-5-11-3-6-13(7-4-11)16(18)19/h1-10H/b8-5+
DMVD5TA	CS	C1=CC(=CN=C1)C(=O)/C=C/C2=CC=C(C=C2)[N+](=O)[O-]
DMVD5TA	IK	DFXQMCHHZQLWHB-VMPITWQZSA-N
DMVD5TA	IU	(E)-3-(4-nitrophenyl)-1-pyridin-3-ylprop-2-en-1-one

DMJWH4B	ID	DMJWH4B
DMJWH4B	DN	Azaindazole amide derivative 1
DMJWH4B	HS	Patented
DMJWH4B	SN	PMID28270021-Compound-WO2014016434Example30
DMJWH4B	CP	PIERRE FABRE MEDICAMENT
DMJWH4B	DE	Pruritus; Chronic pain; Neuropathic pain; Thymic cancer

DM3S0LI	ID	DM3S0LI
DM3S0LI	DN	Azaindazole derivative 1
DM3S0LI	HS	Patented
DM3S0LI	SN	PMID28117607-Compound-31
DM3S0LI	CP	Genentech, Inc., USA. assignee
DM3S0LI	DT	Small molecular drug

DMEYS3V	ID	DMEYS3V
DMEYS3V	DN	Azaindazole derivative 2
DMEYS3V	HS	Patented
DMEYS3V	SN	PMID28117607-Compound-32
DMEYS3V	CP	Genentech, Inc., USA. assignee
DMEYS3V	DT	Small molecular drug

DMOV9XA	ID	DMOV9XA
DMOV9XA	DN	Azaindazole derivative 3
DMOV9XA	HS	Patented
DMOV9XA	SN	PMID28117607-Compound-33
DMOV9XA	CP	Genentech, Inc., USA. assignee
DMOV9XA	DT	Small molecular drug

DMX3MNT	ID	DMX3MNT
DMX3MNT	DN	Azaindazole derivative 4
DMX3MNT	HS	Patented
DMX3MNT	SN	PMID28117607-Compound-34
DMX3MNT	CP	Genentech, Inc., USA. assignee
DMX3MNT	DT	Small molecular drug

DMSMXK3	ID	DMSMXK3
DMSMXK3	DN	Azaindole derivative 1
DMSMXK3	HS	Patented
DMSMXK3	SN	PMID25656651-Compound-43
DMSMXK3	CP	ORIBASE PHARMA
DMSMXK3	DT	Small molecular drug
DMSMXK3	PC	90269487
DMSMXK3	MW	580.6
DMSMXK3	FM	C30H31F3N6O3
DMSMXK3	IC	InChI=1S/C30H31F3N6O3/c1-18-3-6-23(12-22(18)15-34-24-11-21-14-26(29(41)42)37-27(21)35-16-24)36-28(40)19-4-5-20(25(13-19)30(31,32)33)17-39-9-7-38(2)8-10-39/h3-6,11-14,16,34H,7-10,15,17H2,1-2H3,(H,35,37)(H,36,40)(H,41,42)
DMSMXK3	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)CNC4=CN=C5C(=C4)C=C(N5)C(=O)O
DMSMXK3	IK	DZMBOVWOPRYRNU-UHFFFAOYSA-N
DMSMXK3	IU	5-[[2-methyl-5-[[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzoyl]amino]phenyl]methylamino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid

DMXBYHV	ID	DMXBYHV
DMXBYHV	DN	Azaindole derivative 2
DMXBYHV	HS	Patented
DMXBYHV	SN	PMID25656651-Compound-44
DMXBYHV	CP	ORIBASE PHARMA
DMXBYHV	DT	Small molecular drug
DMXBYHV	PC	76903081
DMXBYHV	MW	482.5
DMXBYHV	FM	C25H21F3N4O3
DMXBYHV	IC	InChI=1S/C25H21F3N4O3/c1-14-6-7-19(31-23(33)15-4-3-5-18(8-15)25(26,27)28)10-17(14)12-29-20-9-16-11-21(24(34)35-2)32-22(16)30-13-20/h3-11,13,29H,12H2,1-2H3,(H,30,32)(H,31,33)
DMXBYHV	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)CNC3=CN=C4C(=C3)C=C(N4)C(=O)OC
DMXBYHV	IK	QERVGYYPIGRNLQ-UHFFFAOYSA-N
DMXBYHV	IU	methyl 5-[[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]methylamino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate

DM2EDOM	ID	DM2EDOM
DM2EDOM	DN	Azaindole derivative 3
DM2EDOM	HS	Patented
DM2EDOM	SN	PMID27841045-Compound-138
DM2EDOM	CP	Kissei Pharmaceutical Co. Ltd
DM2EDOM	DT	Small molecular drug
DM2EDOM	PC	56949434
DM2EDOM	MW	309.28
DM2EDOM	FM	C16H11N3O4
DM2EDOM	IC	InChI=1S/C16H11N3O4/c1-23-15-5-4-13-12(7-10(8-17)19(13)18-15)9-2-3-11(16(21)22)14(20)6-9/h2-7,20H,1H3,(H,21,22)
DM2EDOM	CS	COC1=NN2C(=C(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O)C=C1
DM2EDOM	IK	QEYWGQCVGIFYQF-UHFFFAOYSA-N
DM2EDOM	IU	4-(7-cyano-2-methoxypyrrolo[1,2-b]pyridazin-5-yl)-2-hydroxybenzoic acid

DMCKSJ8	ID	DMCKSJ8
DMCKSJ8	DN	Azaindole derivative 4
DMCKSJ8	HS	Patented
DMCKSJ8	SN	PMID27841045-Compound-139
DMCKSJ8	CP	Kissei Pharmaceutical Co. Ltd
DMCKSJ8	DT	Small molecular drug

DMD2BL3	ID	DMD2BL3
DMD2BL3	DN	Azaindole derivative 5
DMD2BL3	HS	Patented
DMD2BL3	SN	PMID27841045-Compound-140
DMD2BL3	CP	Kissei Pharmaceutical Co. Ltd
DMD2BL3	DT	Small molecular drug
DMD2BL3	PC	56949445
DMD2BL3	MW	279.25
DMD2BL3	FM	C15H9N3O3
DMD2BL3	IC	InChI=1S/C15H9N3O3/c16-8-10-6-13(18-12(10)2-1-5-17-18)9-3-4-11(15(20)21)14(19)7-9/h1-7,19H,(H,20,21)
DMD2BL3	CS	C1=CC2=C(C=C(N2N=C1)C3=CC(=C(C=C3)C(=O)O)O)C#N
DMD2BL3	IK	NSOWXVMDKNRRTI-UHFFFAOYSA-N
DMD2BL3	IU	4-(5-cyanopyrrolo[1,2-b]pyridazin-7-yl)-2-hydroxybenzoic acid

DMJBGHL	ID	DMJBGHL
DMJBGHL	DN	Azaindole derivative 6
DMJBGHL	HS	Patented
DMJBGHL	SN	PMID27841045-Compound-141
DMJBGHL	CP	Kissei Pharmaceutical Co. Ltd
DMJBGHL	DT	Small molecular drug
DMJBGHL	PC	56949422
DMJBGHL	MW	293.28
DMJBGHL	FM	C16H11N3O3
DMJBGHL	IC	InChI=1S/C16H11N3O3/c1-9-2-5-14-13(7-11(8-17)19(14)18-9)10-3-4-12(16(21)22)15(20)6-10/h2-7,20H,1H3,(H,21,22)
DMJBGHL	CS	CC1=NN2C(=C(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O)C=C1
DMJBGHL	IK	OVRDXWKIIUUQMR-UHFFFAOYSA-N
DMJBGHL	IU	4-(7-cyano-2-methylpyrrolo[1,2-b]pyridazin-5-yl)-2-hydroxybenzoic acid

DMA2JGU	ID	DMA2JGU
DMA2JGU	DN	Azaindole derivative 7
DMA2JGU	HS	Patented
DMA2JGU	SN	PMID27841045-Compound-142
DMA2JGU	CP	Kissei Pharmaceutical Co. Ltd
DMA2JGU	DT	Small molecular drug
DMA2JGU	PC	56949332
DMA2JGU	MW	279.25
DMA2JGU	FM	C15H9N3O3
DMA2JGU	IC	InChI=1S/C15H9N3O3/c16-8-10-7-12(13-2-1-5-17-18(10)13)9-3-4-11(15(20)21)14(19)6-9/h1-7,19H,(H,20,21)
DMA2JGU	CS	C1=CC2=C(C=C(N2N=C1)C#N)C3=CC(=C(C=C3)C(=O)O)O
DMA2JGU	IK	CMWZLOJCASLPFW-UHFFFAOYSA-N
DMA2JGU	IU	4-(7-cyanopyrrolo[1,2-b]pyridazin-5-yl)-2-hydroxybenzoic acid

DMEUHCD	ID	DMEUHCD
DMEUHCD	DN	Aza-phenalene-3-ketone derivative 1
DMEUHCD	HS	Patented
DMEUHCD	SN	PMID27841036-Compound-27
DMEUHCD	CP	Suzhou Kangrun Pharmaceutical Inc
DMEUHCD	DT	Small molecular drug

DM76XH4	ID	DM76XH4
DM76XH4	DN	Azepan-4-one derivative 1
DM76XH4	HS	Patented
DM76XH4	SN	PMID26077642-Compound-Figure3E
DM76XH4	DT	Small molecular drug

DM7O0MD	ID	DM7O0MD
DM7O0MD	DN	Azepan-4-one derivative 2
DM7O0MD	HS	Patented
DM7O0MD	SN	PMID26077642-Compound-Figure3F
DM7O0MD	DT	Small molecular drug

DMXEFUD	ID	DMXEFUD
DMXEFUD	DN	Azetidine derivative 1
DMXEFUD	HS	Patented
DMXEFUD	SN	PMID26161824-Compound-157
DMXEFUD	DT	Small molecular drug
DMXEFUD	PC	11167515
DMXEFUD	MW	479.4
DMXEFUD	FM	C23H21Cl2FN2O2S
DMXEFUD	IC	InChI=1S/C23H21Cl2FN2O2S/c1-15-22(27-31(29,30)21-12-10-20(26)11-13-21)14-28(15)23(16-2-6-18(24)7-3-16)17-4-8-19(25)9-5-17/h2-13,15,22-23,27H,14H2,1H3/t15-,22?/m0/s1
DMXEFUD	CS	C[C@H]1C(CN1C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)NS(=O)(=O)C4=CC=C(C=C4)F
DMXEFUD	IK	BNBGRXOGPFOPLL-UEDXYCIISA-N
DMXEFUD	IU	N-[(2S)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-fluorobenzenesulfonamide
DMXEFUD	DE	Obesity

DMTB3KS	ID	DMTB3KS
DMTB3KS	DN	Azetidine derivative 2
DMTB3KS	HS	Patented
DMTB3KS	SN	PMID28594589-Compound-TABLE3c11
DMTB3KS	CP	Exelixis
DMTB3KS	DT	Small molecular drug
DMTB3KS	PC	16222298
DMTB3KS	MW	519.299
DMTB3KS	FM	C19H17F3IN3O3
DMTB3KS	IC	InChI=1S/C19H17F3IN3O3/c20-13-3-2-12(19(29)26-8-10(9-26)18(28)24-5-6-27)17(16(13)22)25-15-4-1-11(23)7-14(15)21/h1-4,7,10,25,27H,5-6,8-9H2,(H,24,28)
DMTB3KS	CS	C1C(CN1C(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)F)C(=O)NCCO
DMTB3KS	IK	GNOFJPRIPYVPCR-UHFFFAOYSA-N
DMTB3KS	IU	1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-N-(2-hydroxyethyl)azetidine-3-carboxamide

DMIKSVG	ID	DMIKSVG
DMIKSVG	DN	Azetidine derivative 3
DMIKSVG	HS	Patented
DMIKSVG	SN	PMID26161824-Compound-173
DMIKSVG	DT	Small molecular drug
DMIKSVG	PC	68631346
DMIKSVG	MW	630.5
DMIKSVG	FM	C28H28Cl2F3N3O4S
DMIKSVG	IC	InChI=1S/C28H28Cl2F3N3O4S/c1-17(16-37)34-27(38)20-11-21(28(31,32)33)13-24(12-20)36(41(2,39)40)25-14-35(15-25)26(18-3-7-22(29)8-4-18)19-5-9-23(30)10-6-19/h3-13,17,25-26,37H,14-16H2,1-2H3,(H,34,38)
DMIKSVG	CS	CC(CO)NC(=O)C1=CC(=CC(=C1)N(C2CN(C2)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)S(=O)(=O)C)C(F)(F)F
DMIKSVG	IK	CVPMSFUZFFYDBR-UHFFFAOYSA-N
DMIKSVG	IU	3-[[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-methylsulfonylamino]-N-(1-hydroxypropan-2-yl)-5-(trifluoromethyl)benzamide
DMIKSVG	DE	Obesity

DMXL2V9	ID	DMXL2V9
DMXL2V9	DN	Azetidine derivative 4
DMXL2V9	HS	Patented
DMXL2V9	SN	PMID26161824-Compound-174
DMXL2V9	DT	Small molecular drug
DMXL2V9	PC	68639490
DMXL2V9	MW	660.5
DMXL2V9	FM	C29H30Cl2F3N3O5S
DMXL2V9	IC	InChI=1S/C29H30Cl2F3N3O5S/c1-28(16-38,17-39)35-27(40)20-11-21(29(32,33)34)13-24(12-20)37(43(2,41)42)25-14-36(15-25)26(18-3-7-22(30)8-4-18)19-5-9-23(31)10-6-19/h3-13,25-26,38-39H,14-17H2,1-2H3,(H,35,40)
DMXL2V9	CS	CC(CO)(CO)NC(=O)C1=CC(=CC(=C1)N(C2CN(C2)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)S(=O)(=O)C)C(F)(F)F
DMXL2V9	IK	OMKQCMZJBZXEKN-UHFFFAOYSA-N
DMXL2V9	IU	3-[[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-methylsulfonylamino]-N-(1,3-dihydroxy-2-methylpropan-2-yl)-5-(trifluoromethyl)benzamide
DMXL2V9	DE	Obesity

DMJ9U0E	ID	DMJ9U0E
DMJ9U0E	DN	Azetidine derivative 5
DMJ9U0E	HS	Patented
DMJ9U0E	SN	PMID29473428-Compound-32
DMJ9U0E	CP	NEWLINK GENETICS CORPORATION MAUTINO, Mario KUMAR, Sanjeev WALDO, Jesse JAIPURI, Firoz KESHARWANI, Tanay ZHANG, Xiaoxia
DMJ9U0E	DT	Small molecular drug
DMJ9U0E	PC	70874002
DMJ9U0E	MW	373.4
DMJ9U0E	FM	C23H23N3O2
DMJ9U0E	IC	InChI=1S/C23H23N3O2/c27-22(17-13-25(14-17)23(28)10-16-6-2-1-3-7-16)11-20-18-8-4-5-9-19(18)21-12-24-15-26(20)21/h1-9,12,15,17,20,22,27H,10-11,13-14H2
DMJ9U0E	CS	C1C(CN1C(=O)CC2=CC=CC=C2)C(CC3C4=CC=CC=C4C5=CN=CN35)O
DMJ9U0E	IK	XCPKPBVNKDRBNO-UHFFFAOYSA-N
DMJ9U0E	IU	1-[3-[1-hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl]azetidin-1-yl]-2-phenylethanone

DMH942E	ID	DMH942E
DMH942E	DN	Azetidine urea derivative 1
DMH942E	HS	Patented
DMH942E	SN	PMID26413912-Compound-43
DMH942E	CP	VERNALIS (R&D) LTD. ROUGHLEY, Stephen WALLS, Steven HART, Terrence PARSONS, Rachel BROUGH, Paul GRAHAM, Christopher MACIAS, Alba
DMH942E	DT	Small molecular drug

DMJY8XI	ID	DMJY8XI
DMJY8XI	DN	Azetidine urea derivative 2
DMJY8XI	HS	Patented
DMJY8XI	SN	PMID26413912-Compound-50
DMJY8XI	CP	JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. TICHENOR, Mark, S. MERIT, Jeffrey, E. HAWRYLUK, Natalie, A. CHAMBERS, Alison, L. KEITH, John, M
DMJY8XI	DT	Small molecular drug
DMJY8XI	PC	49839765
DMJY8XI	MW	463.9
DMJY8XI	FM	C24H22ClN5O3
DMJY8XI	IC	InChI=1S/C24H22ClN5O3/c25-18-6-8-19(9-7-18)33-21-4-1-3-20(13-21)32-12-10-17-15-29(16-17)24(31)28-23-14-26-22-5-2-11-27-30(22)23/h1-9,11,13-14,17H,10,12,15-16H2,(H,28,31)
DMJY8XI	CS	C1C(CN1C(=O)NC2=CN=C3N2N=CC=C3)CCOC4=CC(=CC=C4)OC5=CC=C(C=C5)Cl
DMJY8XI	IK	DUGFOZRFNIVGIA-UHFFFAOYSA-N
DMJY8XI	IU	3-[2-[3-(4-chlorophenoxy)phenoxy]ethyl]-N-imidazo[1,2-b]pyridazin-3-ylazetidine-1-carboxamide

DM48PIO	ID	DM48PIO
DM48PIO	DN	Azetidine urea derivative 3
DM48PIO	HS	Patented
DM48PIO	SN	PMID26413912-Compound-51
DM48PIO	CP	JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. TICHENOR, Mark, S. MERIT, Jeffrey, E. HAWRYLUK, Natalie, A. CHAMBERS, Alison, L. KEITH, John, M
DM48PIO	DT	Small molecular drug
DM48PIO	PC	49838571
DM48PIO	MW	462.9
DM48PIO	FM	C25H23ClN4O3
DM48PIO	IC	InChI=1S/C25H23ClN4O3/c26-19-4-6-21(7-5-19)33-23-3-1-2-22(13-23)32-11-9-17-15-30(16-17)25(31)29-20-12-18-8-10-27-24(18)28-14-20/h1-8,10,12-14,17H,9,11,15-16H2,(H,27,28)(H,29,31)
DM48PIO	CS	C1C(CN1C(=O)NC2=CN=C3C(=C2)C=CN3)CCOC4=CC(=CC=C4)OC5=CC=C(C=C5)Cl
DM48PIO	IK	XAYGGDSGTNLICL-UHFFFAOYSA-N
DM48PIO	IU	3-[2-[3-(4-chlorophenoxy)phenoxy]ethyl]-N-(1H-pyrrolo[2,3-b]pyridin-5-yl)azetidine-1-carboxamide

DMZX8Y0	ID	DMZX8Y0
DMZX8Y0	DN	Azetidine-1-carboxamide derivative 1
DMZX8Y0	HS	Patented
DMZX8Y0	SN	PMID26161824-Compound-161
DMZX8Y0	DT	Small molecular drug
DMZX8Y0	PC	68904215
DMZX8Y0	MW	407.3
DMZX8Y0	FM	C21H24Cl2N2O2
DMZX8Y0	IC	InChI=1S/C21H24Cl2N2O2/c1-21(2,3)24-20(26)25-12-18(13-25)27-19(14-4-8-16(22)9-5-14)15-6-10-17(23)11-7-15/h4-11,18-19H,12-13H2,1-3H3,(H,24,26)
DMZX8Y0	CS	CC(C)(C)NC(=O)N1CC(C1)OC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMZX8Y0	IK	JIJVOTYIBJGZDJ-UHFFFAOYSA-N
DMZX8Y0	IU	3-[bis(4-chlorophenyl)methoxy]-N-tert-butylazetidine-1-carboxamide
DMZX8Y0	DE	Obesity

DMONQ4L	ID	DMONQ4L
DMONQ4L	DN	Azetidine-1-carboxamide derivative 2
DMONQ4L	HS	Patented
DMONQ4L	SN	PMID26161824-Compound-162
DMONQ4L	DT	Small molecular drug
DMONQ4L	PC	9935850
DMONQ4L	MW	503.3
DMONQ4L	FM	C22H23BrF4N2O2
DMONQ4L	IC	InChI=1S/C22H23BrF4N2O2/c1-21(2,3)28-20(30)29-11-14(12-29)31-19(16-9-8-13(23)10-18(16)24)15-6-4-5-7-17(15)22(25,26)27/h4-10,14,19H,11-12H2,1-3H3,(H,28,30)
DMONQ4L	CS	CC(C)(C)NC(=O)N1CC(C1)OC(C2=C(C=C(C=C2)Br)F)C3=CC=CC=C3C(F)(F)F
DMONQ4L	IK	PTVKXSFBTUPKHX-UHFFFAOYSA-N
DMONQ4L	IU	3-[(4-bromo-2-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-N-tert-butylazetidine-1-carboxamide
DMONQ4L	DE	Obesity

DM2UGK3	ID	DM2UGK3
DM2UGK3	DN	Azetidine-1-carboxamide derivative 3
DM2UGK3	HS	Patented
DM2UGK3	SN	PMID26161824-Compound-163
DM2UGK3	DT	Small molecular drug
DM2UGK3	PC	68902536
DM2UGK3	MW	440.9
DM2UGK3	FM	C22H24ClF3N2O2
DM2UGK3	IC	InChI=1S/C22H24ClF3N2O2/c1-21(2,3)27-20(29)28-12-16(13-28)30-19(14-8-10-15(23)11-9-14)17-6-4-5-7-18(17)22(24,25)26/h4-11,16,19H,12-13H2,1-3H3,(H,27,29)/t19-/m1/s1
DM2UGK3	CS	CC(C)(C)NC(=O)N1CC(C1)O[C@H](C2=CC=C(C=C2)Cl)C3=CC=CC=C3C(F)(F)F
DM2UGK3	IK	BNLYOVHLLDBOFZ-LJQANCHMSA-N
DM2UGK3	IU	N-tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide
DM2UGK3	DE	Obesity

DMRMED4	ID	DMRMED4
DMRMED4	DN	Azetidine-benzoxazin-3(4H)-one derivative 1
DMRMED4	HS	Patented
DMRMED4	SN	PMID29053063-Compound-16a
DMRMED4	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMRMED4	DT	Small molecular drug

DMMSPX7	ID	DMMSPX7
DMMSPX7	DN	Azetidine-benzoxazin-3(4H)-one derivative 2
DMMSPX7	HS	Patented
DMMSPX7	SN	PMID29053063-Compound-16b
DMMSPX7	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMMSPX7	DT	Small molecular drug

DMA430E	ID	DMA430E
DMA430E	DN	Azetidine-benzoxazin-3(4H)-one derivative 3
DMA430E	HS	Patented
DMA430E	SN	PMID29053063-Compound-16c
DMA430E	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMA430E	DT	Small molecular drug

DMMWK3E	ID	DMMWK3E
DMMWK3E	DN	Azetidinyl-piperazine derivative 1
DMMWK3E	HS	Patented
DMMWK3E	SN	PMID29053063-Compound-1
DMMWK3E	CP	JANSSEN PHARMACEUTICA NV FLORES, Christopher, M. NELEN, Marina, I. NULTON, Erica, L. PROUTY, Stephen TODD, Matthew ZHANG, Sui-PJANSSEN PHARMACEUTICA NV CHEVALIER, Kristen, M. DAX, Scott, L. FLORES, Christopher, M. LIU, Li MACIELAG, Mark, J. MCDONNELL, Mark, E. NELEN, Marina, I. PROUTY, Stephen TODD, Matthew ZHANG, Sui-Po ZHU, Bin NULTON, Erica, L. CLEMENTE, Jose
DMMWK3E	DT	Small molecular drug

DM0C48S	ID	DM0C48S
DM0C48S	DN	Azetidinyl-piperazine derivative 2
DM0C48S	HS	Patented
DM0C48S	SN	PMID29053063-Compound-2a
DM0C48S	CP	JANSSEN PHARMACEUTICA NV
DM0C48S	DT	Small molecular drug

DM3WHL2	ID	DM3WHL2
DM3WHL2	DN	Azetidinyl-piperazine derivative 3
DM3WHL2	HS	Patented
DM3WHL2	SN	PMID29053063-Compound-2b
DM3WHL2	CP	JANSSEN PHARMACEUTICA NV
DM3WHL2	DT	Small molecular drug
DM3WHL2	PC	66840555
DM3WHL2	MW	515
DM3WHL2	FM	C21H18ClF3N4O2S2
DM3WHL2	IC	InChI=1S/C21H18ClF3N4O2S2/c22-17-14-2-1-12(21(23,24)25)7-16(14)33-18(17)20(31)29-8-13(9-29)27-3-5-28(6-4-27)19(30)15-10-32-11-26-15/h1-2,7,10-11,13H,3-6,8-9H2
DM3WHL2	CS	C1CN(CCN1C2CN(C2)C(=O)C3=C(C4=C(S3)C=C(C=C4)C(F)(F)F)Cl)C(=O)C5=CSC=N5
DM3WHL2	IK	HKKPDZNDQBHUOD-UHFFFAOYSA-N
DM3WHL2	IU	[4-[1-[3-chloro-6-(trifluoromethyl)-1-benzothiophene-2-carbonyl]azetidin-3-yl]piperazin-1-yl]-(1,3-thiazol-4-yl)methanone

DM0IJYQ	ID	DM0IJYQ
DM0IJYQ	DN	Azetidinyl-piperidine derivative 1
DM0IJYQ	HS	Patented
DM0IJYQ	SN	PMID29053063-Compound-3a
DM0IJYQ	DT	Small molecular drug

DMNQLJU	ID	DMNQLJU
DMNQLJU	DN	Azetidinyl-piperidine derivative 2
DMNQLJU	HS	Patented
DMNQLJU	SN	PMID29053063-Compound-3b
DMNQLJU	DT	Small molecular drug

DM2UDV8	ID	DM2UDV8
DM2UDV8	DN	Azetidinyl-piperidine derivative 3
DM2UDV8	HS	Patented
DM2UDV8	SN	PMID29053063-Compound-6
DM2UDV8	CP	INSERM INST NAT DE LA SANT  ET DE LA RECH M DICALE [FRUNIVERSIT  PARIS DIDEROT PARIS 7 [FRCENTRE NAT RECH SCIENT [FR]
DM2UDV8	DT	Small molecular drug

DM0E8YF	ID	DM0E8YF
DM0E8YF	DN	Azole benzene derivative 1
DM0E8YF	HS	Patented
DM0E8YF	SN	PMID27841045-Compound-146
DM0E8YF	CP	Teizin Pharma Ltd
DM0E8YF	DT	Small molecular drug
DM0E8YF	PC	76900398
DM0E8YF	MW	358.4
DM0E8YF	FM	C17H18N4O3S
DM0E8YF	IC	InChI=1S/C17H18N4O3S/c1-10(2)9-24-14-5-4-12(8-13(14)21-7-6-18-20-21)16-19-11(3)15(25-16)17(22)23/h4-8,10H,9H2,1-3H3,(H,22,23)
DM0E8YF	CS	CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)N3C=CN=N3)C(=O)O
DM0E8YF	IK	VBUUZRSRCDYYFW-UHFFFAOYSA-N
DM0E8YF	IU	4-methyl-2-[4-(2-methylpropoxy)-3-(triazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid

DMJG7M6	ID	DMJG7M6
DMJG7M6	DN	Azole benzene derivative 2
DMJG7M6	HS	Patented
DMJG7M6	SN	PMID27841045-Compound-147
DMJG7M6	CP	Teizin Pharma Ltd
DMJG7M6	DT	Small molecular drug
DMJG7M6	PC	78322305
DMJG7M6	MW	345.4
DMJG7M6	FM	C15H15N5O3S
DMJG7M6	IC	InChI=1S/C15H15N5O3S/c1-8(2)23-12-5-4-10(6-11(12)20-7-16-18-19-20)14-17-9(3)13(24-14)15(21)22/h4-8H,1-3H3,(H,21,22)
DMJG7M6	CS	CC1=C(SC(=N1)C2=CC(=C(C=C2)OC(C)C)N3C=NN=N3)C(=O)O
DMJG7M6	IK	GTRJSEARYANTGP-UHFFFAOYSA-N
DMJG7M6	IU	4-methyl-2-[4-propan-2-yloxy-3-(tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid

DMH8Q4T	ID	DMH8Q4T
DMH8Q4T	DN	Azole benzene derivative 3
DMH8Q4T	HS	Patented
DMH8Q4T	SN	PMID27841045-Compound-148
DMH8Q4T	CP	Teizin Pharma Ltd
DMH8Q4T	DT	Small molecular drug
DMH8Q4T	PC	78322612
DMH8Q4T	MW	359.4
DMH8Q4T	FM	C16H17N5O3S
DMH8Q4T	IC	InChI=1S/C16H17N5O3S/c1-9(2)7-24-13-5-4-11(6-12(13)21-8-17-19-20-21)15-18-10(3)14(25-15)16(22)23/h4-6,8-9H,7H2,1-3H3,(H,22,23)
DMH8Q4T	CS	CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)N3C=NN=N3)C(=O)O
DMH8Q4T	IK	DKEWYKIZSPDHOY-UHFFFAOYSA-N
DMH8Q4T	IU	4-methyl-2-[4-(2-methylpropoxy)-3-(tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid

DMDPHT1	ID	DMDPHT1
DMDPHT1	DN	Azole benzene derivative 4
DMDPHT1	HS	Patented
DMDPHT1	SN	PMID27841045-Compound-149
DMDPHT1	CP	Teizin Pharma Ltd
DMDPHT1	DT	Small molecular drug
DMDPHT1	PC	118555053
DMDPHT1	MW	372.4
DMDPHT1	FM	C18H20N4O3S
DMDPHT1	IC	InChI=1S/C18H20N4O3S/c1-11-15(17(23)24)26-16(20-11)12-5-6-14(25-10-18(2,3)4)13(9-12)22-8-7-19-21-22/h5-9H,10H2,1-4H3,(H,23,24)
DMDPHT1	CS	CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)(C)C)N3C=CN=N3)C(=O)O
DMDPHT1	IK	MWDSDCKUTZIOBZ-UHFFFAOYSA-N
DMDPHT1	IU	2-[4-(2,2-dimethylpropoxy)-3-(triazol-1-yl)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid

DM76HXA	ID	DM76HXA
DM76HXA	DN	Azole derivative 1
DM76HXA	HS	Patented
DM76HXA	SN	PMID26413912-Compound-64
DM76HXA	CP	MERCK SHARP &amDOHME CORP. LIN, Linus, S. CHANG, Linda, L. CHOBANIAN, Harry NARGUND, Ravi, P
DM76HXA	DT	Small molecular drug

DMOPNJ6	ID	DMOPNJ6
DMOPNJ6	DN	Azole derivative 2
DMOPNJ6	HS	Patented
DMOPNJ6	SN	PMID26413912-Compound-65
DMOPNJ6	CP	MERCK SHARP &amDOHME CORP. LIN, Linus, S. CHIODA, Marc, D. LIU, Ping NARGUND, Ravi, P
DMOPNJ6	DT	Small molecular drug

DMN9KTJ	ID	DMN9KTJ
DMN9KTJ	DN	Azole derivative 3
DMN9KTJ	HS	Patented
DMN9KTJ	SN	PMID26413912-Compound-66
DMN9KTJ	CP	MERCK SHARP & DOHME CORP. YANG, ZhiQiang NANTERMET, Philippe, G. KREATSOULAS, Constantine MOORE, Keith, P. SHALEN, Evan Foster
DMN9KTJ	DT	Small molecular drug

DMOW01E	ID	DMOW01E
DMOW01E	DN	Azole derivative 4
DMOW01E	HS	Patented
DMOW01E	SN	PMID26413912-Compound-67
DMOW01E	CP	MERCK SHARP & DOHME CORP. WALJI, Abbas, M. NANTERMET, Philippe, G. MOORE, Keith, P. STORR, Rachel Anne VASSALLO, Laura KREATSOULAS, Constantine
DMOW01E	DT	Small molecular drug

DM36QM5	ID	DM36QM5
DM36QM5	DN	Azole derivative 5
DM36QM5	HS	Patented
DM36QM5	SN	PMID26413912-Compound-68
DM36QM5	CP	MERCK SHARP &amDOHME CORP. LIU, Ping DEVITA, Robert, J. LIN, Linus, S. CHIODA, Marc, D. HAMILL, Terence, G. LI, Wenping
DM36QM5	DT	Small molecular drug

DMTMJ7S	ID	DMTMJ7S
DMTMJ7S	DN	Azole derivative 6
DMTMJ7S	HS	Patented
DMTMJ7S	SN	PMID25470667-Compound-Figure5-10
DMTMJ7S	CP	MERCK SHARP &amDOHME CORP. DEVITA, Robert, J. YU, Yang LIU, Jian HE, Shuwen KRIKORIAN, Arto, D. MILLER, Daniel, J. WU, Zhicai YANG, Ginger Xu-Qiang HONG, Quingmei LAI, Zhong ZORN, Nicolas TING, Pauline, C
DMTMJ7S	DT	Small molecular drug
DMTMJ7S	PC	71696715
DMTMJ7S	MW	439.9
DMTMJ7S	FM	C23H19ClFN3O3
DMTMJ7S	IC	InChI=1S/C23H19ClFN3O3/c1-23(2,22(29)30)12-31-20-8-4-14(11-26-20)13-3-6-16(17(25)9-13)21-27-18-7-5-15(24)10-19(18)28-21/h3-11H,12H2,1-2H3,(H,27,28)(H,29,30)
DMTMJ7S	CS	CC(C)(COC1=NC=C(C=C1)C2=CC(=C(C=C2)C3=NC4=C(N3)C=C(C=C4)Cl)F)C(=O)O
DMTMJ7S	IK	VDSPJLXCWHECIK-UHFFFAOYSA-N
DMTMJ7S	IU	3-[5-[4-(6-chloro-1H-benzimidazol-2-yl)-3-fluorophenyl]pyridin-2-yl]oxy-2,2-dimethylpropanoic acid

DMVUJGI	ID	DMVUJGI
DMVUJGI	DN	Azole derivative 7
DMVUJGI	HS	Patented
DMVUJGI	SN	PMID25470667-Compound-Figure5-9
DMVUJGI	CP	MERCK SHARP &amDOHME CORP. DEVITA, Robert, J. HE, Shuwen LIU, Jian CERNAK, Timothy, A. KRIKORIAN, Arto, D. YANG, Ginger XuQiang WU, Zhicai YU, Yang SHEN, Dong-Ming LAI, Zhong HONG, Qingmei NARGUND, Ravi, P
DMVUJGI	DT	Small molecular drug
DMVUJGI	PC	71585251
DMVUJGI	MW	456.5
DMVUJGI	FM	C27H25FN4O2
DMVUJGI	IC	InChI=1S/C27H25FN4O2/c28-23-3-1-2-21(15-23)26-30-27(32-31-26)22-12-13-24(29-16-22)20-10-8-19(9-11-20)18-6-4-17(5-7-18)14-25(33)34/h1-3,8-13,15-18H,4-7,14H2,(H,33,34)(H,30,31,32)
DMVUJGI	CS	C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)C4=NNC(=N4)C5=CC(=CC=C5)F
DMVUJGI	IK	IMVHPASOWCDZEL-UHFFFAOYSA-N
DMVUJGI	IU	2-[4-[4-[5-[5-(3-fluorophenyl)-1H-1,2,4-triazol-3-yl]pyridin-2-yl]phenyl]cyclohexyl]acetic acid

DM2DT6L	ID	DM2DT6L
DM2DT6L	DN	BB 0223767
DM2DT6L	HS	Patented
DM2DT6L	SN	2-Hydroxy-5-(5-pyrimidinyl)benzaldehyde; 893737-59-2; 2-hydroxy-5-(pyrimidin-5-yl)benzaldehyde; SCHEMBL6639266; CHEMBL3639592; BDBM111246; ZINC16947735; AKOS004118729; BB 0223767; US8614253, 43-6
DM2DT6L	DT	Small molecular drug
DM2DT6L	PC	20100145
DM2DT6L	MW	200.19
DM2DT6L	FM	C11H8N2O2
DM2DT6L	IC	InChI=1S/C11H8N2O2/c14-6-9-3-8(1-2-11(9)15)10-4-12-7-13-5-10/h1-7,15H
DM2DT6L	CS	C1=CC(=C(C=C1C2=CN=CN=C2)C=O)O
DM2DT6L	IK	HPQAHGRGPPOWML-UHFFFAOYSA-N
DM2DT6L	IU	2-hydroxy-5-pyrimidin-5-ylbenzaldehyde

DMTWIE2	ID	DMTWIE2
DMTWIE2	DN	BC11-28
DMTWIE2	HS	Patented
DMTWIE2	SN	BDBM86641; 7-(4-fluorophenyl)-N-(2-methylphenyl)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine; AC1MM8WN; Oprea1_524381; CHEMBL2132713; SCHEMBL14998917; BDBM60812; HMS1911I05; ZINC2713985; STK859438; AKOS002104616; MCULE-7713625102; BC11-28; NCGC00138975-01; ST50069829; EU-0095146; US9173884, BC11-28; SR-01000567887; SR-01000567887-1; K405-0344; 7-(4-fluorophenyl)-N-(2-methylphenyl)-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine; [7-(4-fluorophenyl)-5-phenylpyrrolo[3,2-e]pyrimidin-4-yl](2-methylphenyl)amine
DMTWIE2	DT	Small molecular drug
DMTWIE2	PC	3257208
DMTWIE2	MW	394.4
DMTWIE2	FM	C25H19FN4
DMTWIE2	IC	InChI=1S/C25H19FN4/c1-17-7-5-6-10-22(17)29-24-23-21(18-8-3-2-4-9-18)15-30(25(23)28-16-27-24)20-13-11-19(26)12-14-20/h2-16H,1H3,(H,27,28,29)
DMTWIE2	CS	CC1=CC=CC=C1NC2=C3C(=CN(C3=NC=N2)C4=CC=C(C=C4)F)C5=CC=CC=C5
DMTWIE2	IK	KCNWFXKVXRZIGO-UHFFFAOYSA-N
DMTWIE2	IU	7-(4-fluorophenyl)-N-(2-methylphenyl)-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine

DMZD6IJ	ID	DMZD6IJ
DMZD6IJ	DN	BDBM108945
DMZD6IJ	HS	Patented
DMZD6IJ	SN	SCHEMBL12780004; BDBM108945
DMZD6IJ	DT	Small molecular drug
DMZD6IJ	PC	58170113
DMZD6IJ	MW	405.5
DMZD6IJ	FM	C26H23N5
DMZD6IJ	IC	InChI=1S/C26H23N5/c1-2-4-25-23(3-1)22(11-14-28-25)24-16-30-31-17-21(15-29-26(24)31)19-7-5-18(6-8-19)20-9-12-27-13-10-20/h1-8,11,14-17,20,27H,9-10,12-13H2
DMZD6IJ	CS	C1CNCCC1C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3
DMZD6IJ	IK	WTMROIBZVGJXRP-UHFFFAOYSA-N
DMZD6IJ	IU	4-[6-(4-piperidin-4-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline

DMW5SD6	ID	DMW5SD6
DMW5SD6	DN	BDBM50011552
DMW5SD6	HS	Patented
DMW5SD6	SN	CHEMBL3262571; SCHEMBL15587269; BDBM50011552
DMW5SD6	DT	Small molecular drug
DMW5SD6	PC	90054621
DMW5SD6	MW	251.28
DMW5SD6	FM	C15H13N3O
DMW5SD6	IC	InChI=1S/C15H13N3O/c1-19-14-5-3-2-4-11(14)10-6-7-13-12(8-10)15(16)18-9-17-13/h2-9H,1H3,(H2,16,17,18)
DMW5SD6	CS	COC1=CC=CC=C1C2=CC3=C(C=C2)N=CN=C3N
DMW5SD6	IK	CUSAKFRCIPMPMS-UHFFFAOYSA-N
DMW5SD6	IU	6-(2-methoxyphenyl)quinazolin-4-amine

DMHNYQU	ID	DMHNYQU
DMHNYQU	DN	BDBM50011553
DMHNYQU	HS	Patented
DMHNYQU	SN	CHEMBL3262572; SCHEMBL15587284; BDBM50011553
DMHNYQU	DT	Small molecular drug
DMHNYQU	PC	90054634
DMHNYQU	MW	251.28
DMHNYQU	FM	C15H13N3O
DMHNYQU	IC	InChI=1S/C15H13N3O/c1-19-12-4-2-3-10(7-12)11-5-6-14-13(8-11)15(16)18-9-17-14/h2-9H,1H3,(H2,16,17,18)
DMHNYQU	CS	COC1=CC=CC(=C1)C2=CC3=C(C=C2)N=CN=C3N
DMHNYQU	IK	HAFNABUNLVCDOP-UHFFFAOYSA-N
DMHNYQU	IU	6-(3-methoxyphenyl)quinazolin-4-amine

DMA7JB6	ID	DMA7JB6
DMA7JB6	DN	BDBM50054344
DMA7JB6	HS	Patented
DMA7JB6	SN	CHEMBL3319356; SCHEMBL16375396; BDBM50054344
DMA7JB6	DT	Small molecular drug
DMA7JB6	PC	86298439
DMA7JB6	MW	637.4
DMA7JB6	FM	C28H20IN3O5S
DMA7JB6	IC	InChI=1S/C28H20IN3O5S/c1-32-22-13-23(33)21(28(36)37)12-20(22)24(29)25(32)16-3-2-4-19(11-16)31-27(35)26(34)30-18-7-5-15(6-8-18)17-9-10-38-14-17/h2-14,33H,1H3,(H,30,34)(H,31,35)(H,36,37)
DMA7JB6	CS	CN1C2=CC(=C(C=C2C(=C1C3=CC(=CC=C3)NC(=O)C(=O)NC4=CC=C(C=C4)C5=CSC=C5)I)C(=O)O)O
DMA7JB6	IK	WILZWITYAQZYKV-UHFFFAOYSA-N
DMA7JB6	IU	6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid

DMQ4TUE	ID	DMQ4TUE
DMQ4TUE	DN	BDBM50061601
DMQ4TUE	HS	Patented
DMQ4TUE	SN	CHEMBL3394073; SCHEMBL12696208; BDBM50061601
DMQ4TUE	DT	Small molecular drug
DMQ4TUE	PC	68356857
DMQ4TUE	MW	379.4
DMQ4TUE	FM	C18H17N7OS
DMQ4TUE	IC	InChI=1S/C18H17N7OS/c19-18-24-23-17(27-18)11-1-2-14-12(7-11)13(8-21-14)15-9-20-10-16(22-15)25-3-5-26-6-4-25/h1-2,7-10,21H,3-6H2,(H2,19,24)
DMQ4TUE	CS	C1COCCN1C2=NC(=CN=C2)C3=CNC4=C3C=C(C=C4)C5=NN=C(S5)N
DMQ4TUE	IK	JHCXRIDGVGVKMB-UHFFFAOYSA-N
DMQ4TUE	IU	5-[3-(6-morpholin-4-ylpyrazin-2-yl)-1H-indol-5-yl]-1,3,4-thiadiazol-2-amine

DM3MRD9	ID	DM3MRD9
DM3MRD9	DN	BDBM50061608
DM3MRD9	HS	Patented
DM3MRD9	SN	CHEMBL3394165; SCHEMBL12696206; BDBM50061608
DM3MRD9	DT	Small molecular drug
DM3MRD9	PC	68356855
DM3MRD9	MW	391.5
DM3MRD9	FM	C20H21N7S
DM3MRD9	IC	InChI=1S/C20H21N7S/c21-20-27-26-19(28-20)12-6-7-16-14(8-12)15(9-23-16)17-10-22-11-18(25-17)24-13-4-2-1-3-5-13/h6-11,13,23H,1-5H2,(H2,21,27)(H,24,25)
DM3MRD9	CS	C1CCC(CC1)NC2=NC(=CN=C2)C3=CNC4=C3C=C(C=C4)C5=NN=C(S5)N
DM3MRD9	IK	NZRCHCMMQGWKLZ-UHFFFAOYSA-N
DM3MRD9	IU	5-[3-[6-(cyclohexylamino)pyrazin-2-yl]-1H-indol-5-yl]-1,3,4-thiadiazol-2-amine

DMM8IDC	ID	DMM8IDC
DMM8IDC	DN	BDBM50061612
DMM8IDC	HS	Patented
DMM8IDC	SN	CHEMBL3394168; SCHEMBL12614651; BDBM50061612
DMM8IDC	DT	Small molecular drug
DMM8IDC	PC	68327881
DMM8IDC	MW	377.5
DMM8IDC	FM	C20H19N5OS
DMM8IDC	IC	InChI=1S/C20H19N5OS/c21-20-25-24-19(27-20)12-8-9-16-14(10-12)15(11-22-16)17-6-3-7-18(23-17)26-13-4-1-2-5-13/h3,6-11,13,22H,1-2,4-5H2,(H2,21,25)
DMM8IDC	CS	C1CCC(C1)OC2=CC=CC(=N2)C3=CNC4=C3C=C(C=C4)C5=NN=C(S5)N
DMM8IDC	IK	PNAYFCPGKVJMMN-UHFFFAOYSA-N
DMM8IDC	IU	5-[3-(6-cyclopentyloxypyridin-2-yl)-1H-indol-5-yl]-1,3,4-thiadiazol-2-amine

DM4I829	ID	DM4I829
DM4I829	DN	BDBM50080408
DM4I829	HS	Patented
DM4I829	SN	BDBM50080408
DM4I829	DT	Small molecular drug
DM4I829	PC	118988040
DM4I829	MW	579.4
DM4I829	FM	C23H23Cl2F3N4O4S
DM4I829	IC	InChI=1S/C23H23Cl2F3N4O4S/c1-2-37(35,36)18-4-3-14(24)9-13(18)11-32-21(33)15-10-17(23(26,27)28)16(12-31-7-5-29-6-8-31)19(25)20(15)30-22(32)34/h3-4,9-10,19,29H,2,5-8,11-12H2,1H3
DM4I829	CS	CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CN2C(=O)C3=CC(=C(C(C3=NC2=O)Cl)CN4CCNCC4)C(F)(F)F
DM4I829	IK	MFENBMQVIBVYSX-UHFFFAOYSA-N
DM4I829	IU	8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-7-(piperazin-1-ylmethyl)-6-(trifluoromethyl)-8H-quinazoline-2,4-dione

DMJNOB9	ID	DMJNOB9
DMJNOB9	DN	BDBM50080559
DMJNOB9	HS	Patented
DMJNOB9	SN	CHEMBL3126433; SCHEMBL16055655; BDBM50080559
DMJNOB9	DT	Small molecular drug
DMJNOB9	PC	76325522
DMJNOB9	MW	480.6
DMJNOB9	FM	C26H32N4O5
DMJNOB9	IC	InChI=1S/C26H32N4O5/c1-3-17-11-20(10-16(2)24(17)34-15-21(32)13-28-23(33)14-31)25-29-26(35-30-25)19-8-9-27-22(12-19)18-6-4-5-7-18/h8-12,18,21,31-32H,3-7,13-15H2,1-2H3,(H,28,33)/t21-/m0/s1
DMJNOB9	CS	CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC=C3)C4CCCC4)C)OC[C@H](CNC(=O)CO)O
DMJNOB9	IK	XRJPXSNXMMSPIZ-NRFANRHFSA-N
DMJNOB9	IU	N-[(2S)-3-[4-[5-(2-cyclopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide

DM3VNK0	ID	DM3VNK0
DM3VNK0	DN	BDBM50080563
DM3VNK0	HS	Patented
DM3VNK0	SN	CHEMBL3422425; SCHEMBL16055775; BDBM50080563
DM3VNK0	DT	Small molecular drug
DM3VNK0	PC	86299710
DM3VNK0	MW	482.6
DM3VNK0	FM	C26H34N4O5
DM3VNK0	IC	InChI=1S/C26H34N4O5/c1-5-18-11-20(10-17(4)24(18)34-15-22(32)13-28-23(33)14-31)25-29-26(35-30-25)19-8-9-27-21(12-19)7-6-16(2)3/h8-12,16,22,31-32H,5-7,13-15H2,1-4H3,(H,28,33)/t22-/m0/s1
DM3VNK0	CS	CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC=C3)CCC(C)C)C)OC[C@H](CNC(=O)CO)O
DM3VNK0	IK	PFJWQQDDQKRIRR-QFIPXVFZSA-N
DM3VNK0	IU	N-[(2S)-3-[2-ethyl-6-methyl-4-[5-[2-(3-methylbutyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide

DMLJU5P	ID	DMLJU5P
DMLJU5P	DN	BDBM50080570
DMLJU5P	HS	Patented
DMLJU5P	SN	CHEMBL3126605; SCHEMBL16055394; BDBM50080570
DMLJU5P	DT	Small molecular drug
DMLJU5P	PC	76325532
DMLJU5P	MW	468.5
DMLJU5P	FM	C25H32N4O5
DMLJU5P	IC	InChI=1S/C25H32N4O5/c1-5-17-10-19(9-16(4)23(17)33-14-21(31)12-27-22(32)13-30)24-28-25(34-29-24)18-6-7-26-20(11-18)8-15(2)3/h6-7,9-11,15,21,30-31H,5,8,12-14H2,1-4H3,(H,27,32)/t21-/m0/s1
DMLJU5P	CS	CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC=C3)CC(C)C)C)OC[C@H](CNC(=O)CO)O
DMLJU5P	IK	FIZLCOHGMMUGTO-NRFANRHFSA-N
DMLJU5P	IU	N-[(2S)-3-[2-ethyl-6-methyl-4-[5-[2-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide

DMS7ZLK	ID	DMS7ZLK
DMS7ZLK	DN	BDBM50158703
DMS7ZLK	HS	Patented
DMS7ZLK	SN	CHEMBL3785832; SCHEMBL15777940; BDBM50158703
DMS7ZLK	DT	Small molecular drug
DMS7ZLK	PC	90204862
DMS7ZLK	MW	329.74
DMS7ZLK	FM	C16H12ClN3O3
DMS7ZLK	IC	InChI=1S/C16H12ClN3O3/c17-13-3-1-11(2-4-13)10-23-15-6-8-19-20(15)14-9-12(16(21)22)5-7-18-14/h1-9H,10H2,(H,21,22)
DMS7ZLK	CS	C1=CC(=CC=C1COC2=CC=NN2C3=NC=CC(=C3)C(=O)O)Cl
DMS7ZLK	IK	SMXDPQZYSIFABV-UHFFFAOYSA-N
DMS7ZLK	IU	2-[5-[(4-chlorophenyl)methoxy]pyrazol-1-yl]pyridine-4-carboxylic acid

DMYJF70	ID	DMYJF70
DMYJF70	DN	BDBM50158755
DMYJF70	HS	Patented
DMYJF70	SN	CHEMBL3786579; SCHEMBL15778210; BDBM50158755
DMYJF70	DT	Small molecular drug
DMYJF70	PC	90205053
DMYJF70	MW	357.3
DMYJF70	FM	C18H16FN3O4
DMYJF70	IC	InChI=1S/C18H16FN3O4/c19-15-3-1-12(2-4-15)11-26-17-14(6-8-23)10-21-22(17)16-9-13(18(24)25)5-7-20-16/h1-5,7,9-10,23H,6,8,11H2,(H,24,25)
DMYJF70	CS	C1=CC(=CC=C1COC2=C(C=NN2C3=NC=CC(=C3)C(=O)O)CCO)F
DMYJF70	IK	MAYCQAAYKTWJKJ-UHFFFAOYSA-N
DMYJF70	IU	2-[5-[(4-fluorophenyl)methoxy]-4-(2-hydroxyethyl)pyrazol-1-yl]pyridine-4-carboxylic acid

DMU07MO	ID	DMU07MO
DMU07MO	DN	BDBM50158791
DMU07MO	HS	Patented
DMU07MO	SN	CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964; BDBM50158791
DMU07MO	DT	Small molecular drug
DMU07MO	PC	77106319
DMU07MO	MW	286.37
DMU07MO	FM	C17H22N2O2
DMU07MO	IC	InChI=1S/C17H22N2O2/c20-16(21)14-1-2-18-9-15(14)19-10-17-6-11-3-12(7-17)5-13(4-11)8-17/h1-2,9,11-13,19H,3-8,10H2,(H,20,21)
DMU07MO	CS	C1C2CC3CC1CC(C2)(C3)CNC4=C(C=CN=C4)C(=O)O
DMU07MO	IK	TUXVCHDESZTZON-UHFFFAOYSA-N
DMU07MO	IU	3-(1-adamantylmethylamino)pyridine-4-carboxylic acid

DMWJZU9	ID	DMWJZU9
DMWJZU9	DN	BDBM50158794
DMWJZU9	HS	Patented
DMWJZU9	SN	CHEMBL3785470; SCHEMBL15792416; BDBM50158794
DMWJZU9	DT	Small molecular drug
DMWJZU9	PC	76282772
DMWJZU9	MW	340.4
DMWJZU9	FM	C18H17FN4O2
DMWJZU9	IC	InChI=1S/C18H17FN4O2/c19-11-5-6-16-14(9-11)17(22-23(16)12-3-1-2-4-12)21-15-10-20-8-7-13(15)18(24)25/h5-10,12H,1-4H2,(H,21,22)(H,24,25)
DMWJZU9	CS	C1CCC(C1)N2C3=C(C=C(C=C3)F)C(=N2)NC4=C(C=CN=C4)C(=O)O
DMWJZU9	IK	LJHFNRZRNINLGH-UHFFFAOYSA-N
DMWJZU9	IU	3-[(1-cyclopentyl-5-fluoroindazol-3-yl)amino]pyridine-4-carboxylic acid

DMTWI1H	ID	DMTWI1H
DMTWI1H	DN	BDBM50158803
DMTWI1H	HS	Patented
DMTWI1H	SN	CHEMBL3787438; SCHEMBL15792889; BDBM50158803
DMTWI1H	DT	Small molecular drug
DMTWI1H	PC	90216982
DMTWI1H	MW	352.4
DMTWI1H	FM	C18H17FN6O
DMTWI1H	IC	InChI=1S/C18H17FN6O/c1-11(2)9-25-16-4-3-12(19)7-14(16)17(24-25)23-15-8-21-6-5-13(15)18(26)22-10-20/h3-8,11H,9H2,1-2H3,(H,22,26)(H,23,24)
DMTWI1H	CS	CC(C)CN1C2=C(C=C(C=C2)F)C(=N1)NC3=C(C=CN=C3)C(=O)NC#N
DMTWI1H	IK	HHHITATYTCPWBZ-UHFFFAOYSA-N
DMTWI1H	IU	N-cyano-3-[[5-fluoro-1-(2-methylpropyl)indazol-3-yl]amino]pyridine-4-carboxamide

DMSTD28	ID	DMSTD28
DMSTD28	DN	BDBM50173306
DMSTD28	HS	Patented
DMSTD28	SN	CHEMBL3808565; SCHEMBL17525405; BDBM50173306
DMSTD28	DT	Small molecular drug
DMSTD28	PC	118888923
DMSTD28	MW	513.5
DMSTD28	FM	C27H24FN7O3
DMSTD28	IC	InChI=1S/C27H24FN7O3/c1-15-23(26(37)33-19-3-5-22-18(12-19)14-31-35-22)24(34-27(38)32-15)17-2-4-21(28)20(13-17)25(36)30-11-8-16-6-9-29-10-7-16/h2-7,9-10,12-14,24H,8,11H2,1H3,(H,30,36)(H,31,35)(H,33,37)(H2,32,34,38)
DMSTD28	CS	CC1=C(C(NC(=O)N1)C2=CC(=C(C=C2)F)C(=O)NCCC3=CC=NC=C3)C(=O)NC4=CC5=C(C=C4)NN=C5
DMSTD28	IK	GJTSGDBPSODHKH-UHFFFAOYSA-N
DMSTD28	IU	4-[4-fluoro-3-(2-pyridin-4-ylethylcarbamoyl)phenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide

DM7RTQP	ID	DM7RTQP
DM7RTQP	DN	BDBM50173323
DM7RTQP	HS	Patented
DM7RTQP	SN	CHEMBL3808621; SCHEMBL17525424; BDBM50173323
DM7RTQP	DT	Small molecular drug
DM7RTQP	PC	118888942
DM7RTQP	MW	534.5
DM7RTQP	FM	C27H21F3N6O3
DM7RTQP	IC	InChI=1S/C27H21F3N6O3/c1-13-23(26(38)34-16-6-8-22-15(9-16)11-32-36-22)24(35-27(39)33-13)14-5-7-21(30)17(10-14)25(37)31-12-18-19(28)3-2-4-20(18)29/h2-11,24H,12H2,1H3,(H,31,37)(H,32,36)(H,34,38)(H2,33,35,39)
DM7RTQP	CS	CC1=C(C(NC(=O)N1)C2=CC(=C(C=C2)F)C(=O)NCC3=C(C=CC=C3F)F)C(=O)NC4=CC5=C(C=C4)NN=C5
DM7RTQP	IK	YJQKIQOVJOGHMP-UHFFFAOYSA-N
DM7RTQP	IU	4-[3-[(2,6-difluorophenyl)methylcarbamoyl]-4-fluorophenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide

DMKEVDL	ID	DMKEVDL
DMKEVDL	DN	BDBM50173327
DMKEVDL	HS	Patented
DMKEVDL	SN	CHEMBL3808499; SCHEMBL17525395; BDBM50173327
DMKEVDL	DT	Small molecular drug
DMKEVDL	PC	118888913
DMKEVDL	MW	540.6
DMKEVDL	FM	C30H29FN6O3
DMKEVDL	IC	InChI=1S/C30H29FN6O3/c1-16-5-4-6-17(2)23(16)15-32-26(38)13-20-11-19(7-9-24(20)31)28-27(18(3)34-30(40)36-28)29(39)35-22-8-10-25-21(12-22)14-33-37-25/h4-12,14,28H,13,15H2,1-3H3,(H,32,38)(H,33,37)(H,35,39)(H2,34,36,40)
DMKEVDL	CS	CC1=C(C(=CC=C1)C)CNC(=O)CC2=C(C=CC(=C2)C3C(=C(NC(=O)N3)C)C(=O)NC4=CC5=C(C=C4)NN=C5)F
DMKEVDL	IK	IDOAXNXBZZZOFX-UHFFFAOYSA-N
DMKEVDL	IU	4-[3-[2-[(2,6-dimethylphenyl)methylamino]-2-oxoethyl]-4-fluorophenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide

DM1PU37	ID	DM1PU37
DM1PU37	DN	BDBM50173330
DM1PU37	HS	Patented
DM1PU37	SN	CHEMBL3808657; SCHEMBL17525387; BDBM50173330
DM1PU37	DT	Small molecular drug
DM1PU37	PC	118888905
DM1PU37	MW	634.5
DM1PU37	FM	C29H21F7N6O3
DM1PU37	IC	InChI=1S/C29H21F7N6O3/c1-13-23(26(44)40-19-3-5-22-16(8-19)12-38-42-22)24(41-27(45)39-13)15-2-4-21(30)20(9-15)25(43)37-11-14-6-17(28(31,32)33)10-18(7-14)29(34,35)36/h2-10,12,24H,11H2,1H3,(H,37,43)(H,38,42)(H,40,44)(H2,39,41,45)
DM1PU37	CS	CC1=C(C(NC(=O)N1)C2=CC(=C(C=C2)F)C(=O)NCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)NC4=CC5=C(C=C4)NN=C5
DM1PU37	IK	VUCAOBMPSJTWFL-UHFFFAOYSA-N
DM1PU37	IU	4-[3-[[3,5-bis(trifluoromethyl)phenyl]methylcarbamoyl]-4-fluorophenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide

DM52IQF	ID	DM52IQF
DM52IQF	DN	BDBM50177012
DM52IQF	HS	Patented
DM52IQF	SN	CHEMBL3814153; SCHEMBL17519222; BDBM50177012
DM52IQF	DT	Small molecular drug
DM52IQF	PC	118883427
DM52IQF	MW	446.5
DM52IQF	FM	C19H22F4N4O2S
DM52IQF	IC	InChI=1S/C19H22F4N4O2S/c1-12(2)15-11-26(13-4-5-14(20)16(10-13)30(3,28)29)8-9-27(15)18-24-7-6-17(25-18)19(21,22)23/h4-7,10,12,15H,8-9,11H2,1-3H3/t15-/m0/s1
DM52IQF	CS	CC(C)[C@@H]1CN(CCN1C2=NC=CC(=N2)C(F)(F)F)C3=CC(=C(C=C3)F)S(=O)(=O)C
DM52IQF	IK	YTEDTWJJQBCOTI-HNNXBMFYSA-N
DM52IQF	IU	2-[(2R)-4-(4-fluoro-3-methylsulfonylphenyl)-2-propan-2-ylpiperazin-1-yl]-4-(trifluoromethyl)pyrimidine

DMEL28G	ID	DMEL28G
DMEL28G	DN	BDBM50177019
DMEL28G	HS	Patented
DMEL28G	SN	CHEMBL3813863; SCHEMBL17519302; BDBM50177019
DMEL28G	DT	Small molecular drug
DMEL28G	PC	118883505
DMEL28G	MW	488.5
DMEL28G	FM	C21H27F3N4O4S
DMEL28G	IC	InChI=1S/C21H27F3N4O4S/c1-13(2)17-10-27(16-5-4-14(11-29)18(8-16)33(3,31)32)6-7-28(17)20-25-9-15(12-30)19(26-20)21(22,23)24/h4-5,8-9,13,17,29-30H,6-7,10-12H2,1-3H3/t17-/m1/s1
DMEL28G	CS	CC(C)[C@H]1CN(CCN1C2=NC=C(C(=N2)C(F)(F)F)CO)C3=CC(=C(C=C3)CO)S(=O)(=O)C
DMEL28G	IK	FPVIRRAMNBCEDK-QGZVFWFLSA-N
DMEL28G	IU	[4-[(3S)-4-[5-(hydroxymethyl)-4-(trifluoromethyl)pyrimidin-2-yl]-3-propan-2-ylpiperazin-1-yl]-2-methylsulfonylphenyl]methanol

DM7TASJ	ID	DM7TASJ
DM7TASJ	DN	BDBM50363773
DM7TASJ	HS	Patented
DM7TASJ	SN	CHEMBL1945137; CHEMBL1962885; BDBM50363773
DM7TASJ	DT	Small molecular drug
DM7TASJ	PC	49847196
DM7TASJ	MW	440.6
DM7TASJ	FM	C24H32N4O2S
DM7TASJ	IC	InChI=1S/C24H32N4O2S/c1-17(2)18-8-10-19(11-9-18)23(30)27-24(31)26-21-14-12-20(13-15-21)25-22(29)7-5-6-16-28(3)4/h8-15,17H,5-7,16H2,1-4H3,(H,25,29)(H2,26,27,30,31)
DM7TASJ	CS	CC(C)C1=CC=C(C=C1)C(=O)NC(=S)NC2=CC=C(C=C2)NC(=O)CCCCN(C)C
DM7TASJ	IK	UTQHGPPEEJLEOE-UHFFFAOYSA-N
DM7TASJ	IU	N-[[4-[5-(dimethylamino)pentanoylamino]phenyl]carbamothioyl]-4-propan-2-ylbenzamide

DM46UPM	ID	DM46UPM
DM46UPM	DN	BDBM50363780
DM46UPM	HS	Patented
DM46UPM	SN	CHEMBL1945260; CHEMBL1962973; BDBM50363780
DM46UPM	DT	Small molecular drug
DM46UPM	PC	49847188
DM46UPM	MW	477.4
DM46UPM	FM	C21H25BrN4O2S
DM46UPM	IC	InChI=1S/C21H25BrN4O2S/c1-26(2)14-4-3-5-19(27)23-17-10-12-18(13-11-17)24-21(29)25-20(28)15-6-8-16(22)9-7-15/h6-13H,3-5,14H2,1-2H3,(H,23,27)(H2,24,25,28,29)
DM46UPM	CS	CN(C)CCCCC(=O)NC1=CC=C(C=C1)NC(=S)NC(=O)C2=CC=C(C=C2)Br
DM46UPM	IK	NWWFPYSNQAXIIL-UHFFFAOYSA-N
DM46UPM	IU	4-bromo-N-[[4-[5-(dimethylamino)pentanoylamino]phenyl]carbamothioyl]benzamide

DMUQI15	ID	DMUQI15
DMUQI15	DN	BDBM50363782
DMUQI15	HS	Patented
DMUQI15	SN	CHEMBL1945264; CHEMBL1962780; BDBM50363782
DMUQI15	DT	Small molecular drug
DMUQI15	PC	49847118
DMUQI15	MW	477.4
DMUQI15	FM	C21H25BrN4O2S
DMUQI15	IC	InChI=1S/C21H25BrN4O2S/c1-26(2)13-4-3-8-19(27)23-17-9-11-18(12-10-17)24-21(29)25-20(28)15-6-5-7-16(22)14-15/h5-7,9-12,14H,3-4,8,13H2,1-2H3,(H,23,27)(H2,24,25,28,29)
DMUQI15	CS	CN(C)CCCCC(=O)NC1=CC=C(C=C1)NC(=S)NC(=O)C2=CC(=CC=C2)Br
DMUQI15	IK	UZNNTHWEMCFBAY-UHFFFAOYSA-N
DMUQI15	IU	3-bromo-N-[[4-[5-(dimethylamino)pentanoylamino]phenyl]carbamothioyl]benzamide

DMPOVZ6	ID	DMPOVZ6
DMPOVZ6	DN	BDBM50379214
DMPOVZ6	HS	Patented
DMPOVZ6	SN	CHEMBL2011291; SCHEMBL14839289; BDBM50379214
DMPOVZ6	DT	Small molecular drug
DMPOVZ6	PC	56924694
DMPOVZ6	MW	433.7
DMPOVZ6	FM	C20H12Cl3FN4
DMPOVZ6	IC	InChI=1S/C20H12Cl3FN4/c21-13-9-15(22)19(16(23)10-13)28-20(25)17(11-1-3-14(24)4-2-11)18(27-28)12-5-7-26-8-6-12/h1-10H,25H2
DMPOVZ6	CS	C1=CC(=CC=C1C2=C(N(N=C2C3=CC=NC=C3)C4=C(C=C(C=C4Cl)Cl)Cl)N)F
DMPOVZ6	IK	MOHYPRXHKRXDSE-UHFFFAOYSA-N
DMPOVZ6	IU	4-(4-fluorophenyl)-5-pyridin-4-yl-2-(2,4,6-trichlorophenyl)pyrazol-3-amine

DMQJ5S8	ID	DMQJ5S8
DMQJ5S8	DN	BDBM50382283
DMQJ5S8	HS	Patented
DMQJ5S8	SN	CHEMBL2022530; SCHEMBL15138748; BDBM50382283
DMQJ5S8	DT	Small molecular drug
DMQJ5S8	PC	66561557
DMQJ5S8	MW	343.3
DMQJ5S8	FM	C18H15F2N3O2
DMQJ5S8	IC	InChI=1S/C18H15F2N3O2/c19-18(20)8-13(9-21)23(11-18)16(24)10-22-17(25)15-7-3-5-12-4-1-2-6-14(12)15/h1-7,13H,8,10-11H2,(H,22,25)/t13-/m0/s1
DMQJ5S8	CS	C1[C@H](N(CC1(F)F)C(=O)CNC(=O)C2=CC=CC3=CC=CC=C32)C#N
DMQJ5S8	IK	YJNMDFARAFJSEZ-ZDUSSCGKSA-N
DMQJ5S8	IU	N-[2-[(2S)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]naphthalene-1-carboxamide

DM6DFTX	ID	DM6DFTX
DM6DFTX	DN	BDBM50434164
DM6DFTX	HS	Patented
DM6DFTX	SN	CHEMBL2385272; SCHEMBL15129855; BDBM50434164
DM6DFTX	DT	Small molecular drug
DM6DFTX	PC	73356493
DM6DFTX	MW	342.8
DM6DFTX	FM	C17H15ClN4O2
DM6DFTX	IC	InChI=1S/C17H15ClN4O2/c18-11-3-4-13-14(5-6-20-15(13)8-11)17(24)21-10-16(23)22-7-1-2-12(22)9-19/h3-6,8,12H,1-2,7,10H2,(H,21,24)/t12-/m0/s1
DM6DFTX	CS	C1C[C@H](N(C1)C(=O)CNC(=O)C2=C3C=CC(=CC3=NC=C2)Cl)C#N
DM6DFTX	IK	NERXNBIHCGOYFQ-LBPRGKRZSA-N
DM6DFTX	IU	7-chloro-N-[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]quinoline-4-carboxamide

DMDTYJ9	ID	DMDTYJ9
DMDTYJ9	DN	BDBM50434165
DMDTYJ9	HS	Patented
DMDTYJ9	SN	CHEMBL2385271; SCHEMBL15129912; BDBM50434165
DMDTYJ9	DT	Small molecular drug
DMDTYJ9	PC	71667377
DMDTYJ9	MW	338.4
DMDTYJ9	FM	C18H18N4O3
DMDTYJ9	IC	InChI=1S/C18H18N4O3/c1-25-13-4-5-16-15(9-13)14(6-7-20-16)18(24)21-11-17(23)22-8-2-3-12(22)10-19/h4-7,9,12H,2-3,8,11H2,1H3,(H,21,24)/t12-/m0/s1
DMDTYJ9	CS	COC1=CC2=C(C=CN=C2C=C1)C(=O)NCC(=O)N3CCC[C@H]3C#N
DMDTYJ9	IK	YPWQFVMQCFSLCP-LBPRGKRZSA-N
DMDTYJ9	IU	N-[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]-6-methoxyquinoline-4-carboxamide

DM9GLQB	ID	DM9GLQB
DM9GLQB	DN	BDBM50444058
DM9GLQB	HS	Patented
DM9GLQB	SN	CHEMBL3092769; SCHEMBL16435582; BDBM50444058
DM9GLQB	DT	Small molecular drug
DM9GLQB	PC	72793043
DM9GLQB	MW	315.4
DM9GLQB	FM	C17H25N5O
DM9GLQB	IC	InChI=1S/C17H25N5O/c1-2-3-9-20-17-21-13-14(15-8-4-5-10-18-15)16(22-17)19-11-6-7-12-23/h4-5,8,10,13,23H,2-3,6-7,9,11-12H2,1H3,(H2,19,20,21,22)
DM9GLQB	CS	CCCCNC1=NC=C(C(=N1)NCCCCO)C2=CC=CC=N2
DM9GLQB	IK	KKAICBOHJLVDCE-UHFFFAOYSA-N
DM9GLQB	IU	4-[[2-(butylamino)-5-pyridin-2-ylpyrimidin-4-yl]amino]butan-1-ol

DMS0EMU	ID	DMS0EMU
DMS0EMU	DN	BDBM50444059
DMS0EMU	HS	Patented
DMS0EMU	SN	CHEMBL3092768; SCHEMBL16435583; BDBM50444059
DMS0EMU	DT	Small molecular drug
DMS0EMU	PC	72793042
DMS0EMU	MW	301.39
DMS0EMU	FM	C16H23N5O
DMS0EMU	IC	InChI=1S/C16H23N5O/c1-2-3-8-19-16-20-12-13(14-7-4-5-9-17-14)15(21-16)18-10-6-11-22/h4-5,7,9,12,22H,2-3,6,8,10-11H2,1H3,(H2,18,19,20,21)
DMS0EMU	CS	CCCCNC1=NC=C(C(=N1)NCCCO)C2=CC=CC=N2
DMS0EMU	IK	BQWLIDAUTKRGNB-UHFFFAOYSA-N
DMS0EMU	IU	3-[[2-(butylamino)-5-pyridin-2-ylpyrimidin-4-yl]amino]propan-1-ol

DMR2UGC	ID	DMR2UGC
DMR2UGC	DN	BDBM50444062
DMR2UGC	HS	Patented
DMR2UGC	SN	CHEMBL3092765; SCHEMBL16438343; BDBM50444062
DMR2UGC	DT	Small molecular drug
DMR2UGC	PC	72792975
DMR2UGC	MW	340.5
DMR2UGC	FM	C19H28N6
DMR2UGC	IC	InChI=1S/C19H28N6/c1-2-3-9-22-19-24-14-16(17-6-4-5-10-21-17)18(25-19)23-13-15-7-11-20-12-8-15/h4-6,10,14-15,20H,2-3,7-9,11-13H2,1H3,(H2,22,23,24,25)
DMR2UGC	CS	CCCCNC1=NC=C(C(=N1)NCC2CCNCC2)C3=CC=CC=N3
DMR2UGC	IK	HVIDXJFXDHKCMO-UHFFFAOYSA-N
DMR2UGC	IU	2-N-butyl-4-N-(piperidin-4-ylmethyl)-5-pyridin-2-ylpyrimidine-2,4-diamine

DMDOCTB	ID	DMDOCTB
DMDOCTB	DN	Benzamide derivative 1
DMDOCTB	HS	Patented
DMDOCTB	SN	PMID28051882-Compound-18
DMDOCTB	CP	Washington University
DMDOCTB	DT	Small molecular drug
DMDOCTB	PC	9543532
DMDOCTB	MW	503.4
DMDOCTB	FM	C24H31BrN2O5
DMDOCTB	IC	InChI=1S/C24H31BrN2O5/c1-29-20-11-16-7-10-27(15-17(16)12-21(20)30-2)9-6-5-8-26-24(28)19-13-18(25)14-22(31-3)23(19)32-4/h11-14H,5-10,15H2,1-4H3,(H,26,28)/i25-4
DMDOCTB	CS	COC1=CC(=CC(=C1OC)C(=O)NCCCCN2CCC3=CC(=C(C=C3C2)OC)OC)[76Br]
DMDOCTB	IK	UNYNHWPKQAKANT-VEFBWTBNSA-N
DMDOCTB	IU	5-(76Br)bromanyl-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)butyl]-2,3-dimethoxybenzamide

DM9PKU2	ID	DM9PKU2
DM9PKU2	DN	Benzamide derivative 10
DM9PKU2	HS	Patented
DM9PKU2	SN	PMID30185082-Compound-61
DM9PKU2	CP	UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DM9PKU2	DT	Small molecular drug

DM4V3Y5	ID	DM4V3Y5
DM4V3Y5	DN	Benzamide derivative 11
DM4V3Y5	HS	Patented
DM4V3Y5	SN	PMID30185082-Compound-62
DM4V3Y5	CP	UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DM4V3Y5	DT	Small molecular drug
DM4V3Y5	PC	41306362
DM4V3Y5	MW	316.8
DM4V3Y5	FM	C18H21ClN2O
DM4V3Y5	IC	InChI=1S/C18H21ClN2O/c1-21(14-15-6-3-2-4-7-15)13-5-12-20-18(22)16-8-10-17(19)11-9-16/h2-4,6-11H,5,12-14H2,1H3,(H,20,22)
DM4V3Y5	CS	CN(CCCNC(=O)C1=CC=C(C=C1)Cl)CC2=CC=CC=C2
DM4V3Y5	IK	TVEZSZAKGLHZOD-UHFFFAOYSA-N
DM4V3Y5	IU	N-[3-[benzyl(methyl)amino]propyl]-4-chlorobenzamide

DMS527F	ID	DMS527F
DMS527F	DN	Benzamide derivative 12
DMS527F	HS	Patented
DMS527F	SN	PMID27724045-Compound-18
DMS527F	CP	ACTELION PHARMACEUTICALS LTD HILPERT, Kurt HUBLER, Francis MURPHY, Mark RENNEBERG, Dorte
DMS527F	DT	Small molecular drug
DMS527F	PC	60152975
DMS527F	MW	393.9
DMS527F	FM	C18H20ClN3O3S
DMS527F	IC	InChI=1S/C18H20ClN3O3S/c19-14-5-4-12(26-15-6-9-20-17(24)22-15)10-13(14)16(23)21-11-18(25)7-2-1-3-8-18/h4-6,9-10,25H,1-3,7-8,11H2,(H,21,23)(H,20,22,24)
DMS527F	CS	C1CCC(CC1)(CNC(=O)C2=C(C=CC(=C2)SC3=CC=NC(=O)N3)Cl)O
DMS527F	IK	VFMSFNBMUAXYTM-UHFFFAOYSA-N
DMS527F	IU	2-chloro-N-[(1-hydroxycyclohexyl)methyl]-5-[(2-oxo-1H-pyrimidin-6-yl)sulfanyl]benzamide

DMYSH9J	ID	DMYSH9J
DMYSH9J	DN	Benzamide derivative 13
DMYSH9J	HS	Patented
DMYSH9J	SN	PMID27724045-Compound-34
DMYSH9J	CP	Pfizer Product Inc
DMYSH9J	DT	Small molecular drug
DMYSH9J	PC	21093787
DMYSH9J	MW	439.7
DMYSH9J	FM	C18H13Cl3N4O3
DMYSH9J	IC	InChI=1S/C18H13Cl3N4O3/c19-13-4-2-11(25-18(28)24-16(26)9-23-25)8-12(13)17(27)22-6-5-10-1-3-14(20)15(21)7-10/h1-4,7-9H,5-6H2,(H,22,27)(H,24,26,28)
DMYSH9J	CS	C1=CC(=C(C=C1CCNC(=O)C2=C(C=CC(=C2)N3C(=O)NC(=O)C=N3)Cl)Cl)Cl
DMYSH9J	IK	VLOHQHGTVRQRSC-UHFFFAOYSA-N
DMYSH9J	IU	2-chloro-N-[2-(3,4-dichlorophenyl)ethyl]-5-(3,5-dioxo-1,2,4-triazin-2-yl)benzamide

DMP2LDC	ID	DMP2LDC
DMP2LDC	DN	Benzamide derivative 14
DMP2LDC	HS	Patented
DMP2LDC	SN	PMID28627961-Compound-17
DMP2LDC	CP	NOVASAID AB WANNBERG, Johan ALTERMAN, Mathias STENBERG, Patric WESTMAN, Jacob
DMP2LDC	DT	Small molecular drug
DMP2LDC	PC	44206332
DMP2LDC	MW	482.4
DMP2LDC	FM	C23H16F6N2O3
DMP2LDC	IC	InChI=1S/C23H16F6N2O3/c24-22(25,26)18-10-3-2-9-17(18)21(33)31-16-8-5-7-14(12-16)20(32)30-13-15-6-1-4-11-19(15)34-23(27,28)29/h1-12H,13H2,(H,30,32)(H,31,33)
DMP2LDC	CS	C1=CC=C(C(=C1)CNC(=O)C2=CC(=CC=C2)NC(=O)C3=CC=CC=C3C(F)(F)F)OC(F)(F)F
DMP2LDC	IK	BLXNFXQRCFAJKN-UHFFFAOYSA-N
DMP2LDC	IU	N-[3-[[2-(trifluoromethoxy)phenyl]methylcarbamoyl]phenyl]-2-(trifluoromethyl)benzamide

DMAEBJ4	ID	DMAEBJ4
DMAEBJ4	DN	Benzamide derivative 15
DMAEBJ4	HS	Patented
DMAEBJ4	SN	PMID28627961-Compound-18
DMAEBJ4	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PRIEPKE, Henning DOODS, Henri KUELZER, Raimund PFAU, Roland STENKAMP, Dirk ROENN, Robert PELCMAN, Benjamin
DMAEBJ4	DT	Small molecular drug
DMAEBJ4	PC	52919085
DMAEBJ4	MW	577.3
DMAEBJ4	FM	C26H24BrCl2N3O3
DMAEBJ4	IC	InChI=1S/C26H24BrCl2N3O3/c1-26(2,3)25(35)30-14-15-4-10-21(28)19(12-15)23(33)32-18-9-11-22(29)20(13-18)24(34)31-17-7-5-16(27)6-8-17/h4-13H,14H2,1-3H3,(H,30,35)(H,31,34)(H,32,33)
DMAEBJ4	CS	CC(C)(C)C(=O)NCC1=CC(=C(C=C1)Cl)C(=O)NC2=CC(=C(C=C2)Cl)C(=O)NC3=CC=C(C=C3)Br
DMAEBJ4	IK	YFQGXIHVHCEKFN-UHFFFAOYSA-N
DMAEBJ4	IU	N-[3-[(4-bromophenyl)carbamoyl]-4-chlorophenyl]-2-chloro-5-[(2,2-dimethylpropanoylamino)methyl]benzamide

DMOAXKF	ID	DMOAXKF
DMOAXKF	DN	Benzamide derivative 16
DMOAXKF	HS	Patented
DMOAXKF	SN	PMID28627961-Compound-19
DMOAXKF	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PRIEPKE, Henning DOODS, Henri KUELZER, Raimund PFAU, Roland STENKAMP, Dirk ROENN, Robert PELCMAN, Benjamin
DMOAXKF	DT	Small molecular drug
DMOAXKF	PC	52919477
DMOAXKF	MW	663.3
DMOAXKF	FM	C29H20BrCl2F2N3O4
DMOAXKF	IC	InChI=1S/C29H20BrCl2F2N3O4/c1-41-24-11-7-18(13-20(24)28(39)36-17-5-3-16(30)4-6-17)37-27(38)19-12-15(2-8-21(19)31)14-35-29(40)25-22(33)9-10-23(34)26(25)32/h2-13H,14H2,1H3,(H,35,40)(H,36,39)(H,37,38)
DMOAXKF	CS	COC1=C(C=C(C=C1)NC(=O)C2=C(C=CC(=C2)CNC(=O)C3=C(C=CC(=C3Cl)F)F)Cl)C(=O)NC4=CC=C(C=C4)Br
DMOAXKF	IK	OKMLKFQCNOUSOP-UHFFFAOYSA-N
DMOAXKF	IU	N-[[3-[[3-[(4-bromophenyl)carbamoyl]-4-methoxyphenyl]carbamoyl]-4-chlorophenyl]methyl]-2-chloro-3,6-difluorobenzamide

DMD7640	ID	DMD7640
DMD7640	DN	Benzamide derivative 18
DMD7640	HS	Patented
DMD7640	SN	PMID28627961-Compound-24
DMD7640	CP	GLENMARK PHARMACEUTICALS S.A
DMD7640	DT	Small molecular drug

DM5YNTM	ID	DM5YNTM
DM5YNTM	DN	Benzamide derivative 19
DM5YNTM	HS	Patented
DM5YNTM	SN	PMID25470667-Compound-Figure5-14
DM5YNTM	CP	ELI LILLY AND COMPANY ARNOLD, Macklin, Brian BEAUCHAMP, Thomas, James CANADA, Emily, Jane HEMBRE, Erik, James LU, Jianliang RIZZO, John, Robert SCHAUS, John, Mehnert SHI, Qing
DM5YNTM	DT	Small molecular drug
DM5YNTM	PC	53242014
DM5YNTM	MW	430.5
DM5YNTM	FM	C25H26N4O3
DM5YNTM	IC	InChI=1S/C25H26N4O3/c1-2-32-19-10-7-18(8-11-19)23(30)28-25(13-14-25)24(31)27-20-12-9-17-5-3-4-6-21(17)29-16-15-26-22(20)29/h3-8,10-11,15-16,20H,2,9,12-14H2,1H3,(H,27,31)(H,28,30)/t20-/m1/s1
DM5YNTM	CS	CCOC1=CC=C(C=C1)C(=O)NC2(CC2)C(=O)N[C@@H]3CCC4=CC=CC=C4N5C3=NC=C5
DM5YNTM	IK	JIKPZJNVLNBRBQ-HXUWFJFHSA-N
DM5YNTM	IU	N-[1-[[(4R)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]carbamoyl]cyclopropyl]-4-ethoxybenzamide

DM0UWNY	ID	DM0UWNY
DM0UWNY	DN	Benzamide derivative 2
DM0UWNY	HS	Patented
DM0UWNY	SN	PMID28051882-Compound-VI
DM0UWNY	CP	Washington University
DM0UWNY	DT	Small molecular drug

DMFY78L	ID	DMFY78L
DMFY78L	DN	Benzamide derivative 3
DMFY78L	HS	Patented
DMFY78L	SN	PMID28051882-Compound-VII
DMFY78L	CP	Washington University
DMFY78L	DT	Small molecular drug

DMNKYL9	ID	DMNKYL9
DMNKYL9	DN	Benzamide derivative 4
DMNKYL9	HS	Patented
DMNKYL9	SN	PMID28051882-Compound-VIII
DMNKYL9	CP	Washington University
DMNKYL9	DT	Small molecular drug

DM6W0TM	ID	DM6W0TM
DM6W0TM	DN	Benzamide derivative 5
DM6W0TM	HS	Patented
DM6W0TM	SN	PMID28454500-Compound-85
DM6W0TM	CP	THE JOHNS HOPKINS UNIVERSITY The National Institutes of Health
DM6W0TM	DT	Small molecular drug

DM80TDC	ID	DM80TDC
DM80TDC	DN	Benzamide derivative 6
DM80TDC	HS	Patented
DM80TDC	SN	PMID28454500-Compound-86
DM80TDC	CP	THE JOHNS HOPKINS UNIVERSITY The National Institutes of Health
DM80TDC	DT	Small molecular drug
DM80TDC	PC	90448888
DM80TDC	MW	477.6
DM80TDC	FM	C26H27N3O4S
DM80TDC	IC	InChI=1S/C26H27N3O4S/c30-26(27-23-7-11-25(12-8-23)34(31,32)29-15-17-33-18-16-29)21-5-9-24(10-6-21)28-14-13-20-3-1-2-4-22(20)19-28/h1-12H,13-19H2,(H,27,30)
DM80TDC	CS	C1CN(CC2=CC=CC=C21)C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)S(=O)(=O)N5CCOCC5
DM80TDC	IK	AXIVYOPFBOAPKD-UHFFFAOYSA-N
DM80TDC	IU	4-(3,4-dihydro-1H-isoquinolin-2-yl)-N-(4-morpholin-4-ylsulfonylphenyl)benzamide

DM7UEJT	ID	DM7UEJT
DM7UEJT	DN	Benzamide derivative 7
DM7UEJT	HS	Patented
DM7UEJT	SN	PMID30185082-Compound-58
DM7UEJT	CP	UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DM7UEJT	DT	Small molecular drug

DMAIJHC	ID	DMAIJHC
DMAIJHC	DN	Benzamide derivative 8
DMAIJHC	HS	Patented
DMAIJHC	SN	PMID30185082-Compound-59
DMAIJHC	CP	UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DMAIJHC	DT	Small molecular drug
DMAIJHC	PC	118607347
DMAIJHC	MW	351.3
DMAIJHC	FM	C18H20Cl2N2O
DMAIJHC	IC	InChI=1S/C18H20Cl2N2O/c1-22(13-14-6-3-2-4-7-14)9-5-8-21-18(23)15-10-16(19)12-17(20)11-15/h2-4,6-7,10-12H,5,8-9,13H2,1H3,(H,21,23)
DMAIJHC	CS	CN(CCCNC(=O)C1=CC(=CC(=C1)Cl)Cl)CC2=CC=CC=C2
DMAIJHC	IK	KXRBNMSGFUSFLX-UHFFFAOYSA-N
DMAIJHC	IU	N-[3-[benzyl(methyl)amino]propyl]-3,5-dichlorobenzamide

DMVFSJZ	ID	DMVFSJZ
DMVFSJZ	DN	Benzamide derivative 9
DMVFSJZ	HS	Patented
DMVFSJZ	SN	PMID30185082-Compound-60
DMVFSJZ	CP	UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DMVFSJZ	DT	Small molecular drug

DM4TOGU	ID	DM4TOGU
DM4TOGU	DN	Benzanilide compound 1
DM4TOGU	HS	Patented
DM4TOGU	SN	PMID26882240-Compound-21A
DM4TOGU	CP	Eisai R & D Management Co., Ltd., Japan
DM4TOGU	DT	Small molecular drug
DM4TOGU	PC	101913833
DM4TOGU	MW	515.6
DM4TOGU	FM	C32H29N5O2
DM4TOGU	IC	InChI=1S/C32H29N5O2/c33-30-29(7-4-18-34-30)32(39)37-21-19-36(20-22-37)23-26-10-14-27(15-11-26)31(38)35-28-16-12-25(13-17-28)9-8-24-5-2-1-3-6-24/h1-7,10-18H,19-23H2,(H2,33,34)(H,35,38)
DM4TOGU	CS	C1CN(CCN1CC2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C#CC4=CC=CC=C4)C(=O)C5=C(N=CC=C5)N
DM4TOGU	IK	YPMOWWPVPPPBET-UHFFFAOYSA-N
DM4TOGU	IU	4-[[4-(2-aminopyridine-3-carbonyl)piperazin-1-yl]methyl]-N-[4-(2-phenylethynyl)phenyl]benzamide

DMDM806	ID	DMDM806
DMDM806	DN	Benzanilide compound 2
DMDM806	HS	Patented
DMDM806	SN	PMID26882240-Compound-21B
DMDM806	CP	Eisai R & D Management Co., Ltd., Japan
DMDM806	DT	Small molecular drug

DMA3BCU	ID	DMA3BCU
DMA3BCU	DN	Benzazepine derivative 1
DMA3BCU	HS	Patented
DMA3BCU	SN	PMID26609882-Compound-40
DMA3BCU	CP	ARENA PHARMACEUTICALS, INC
DMA3BCU	DT	Small molecular drug

DMKREJ2	ID	DMKREJ2
DMKREJ2	DN	Benzazepine derivative 2
DMKREJ2	HS	Patented
DMKREJ2	SN	PMID26609882-Compound-41
DMKREJ2	CP	ARENA PHARMACEUTICALS, INC
DMKREJ2	DT	Small molecular drug

DM3BGEN	ID	DM3BGEN
DM3BGEN	DN	Benzazepine derivative 3
DM3BGEN	HS	Patented
DM3BGEN	SN	PMID26609882-Compound-42
DM3BGEN	CP	ARENA PHARMACEUTICALS, INC
DM3BGEN	DT	Small molecular drug

DMM72LS	ID	DMM72LS
DMM72LS	DN	Benzazepine derivative 4
DMM72LS	HS	Patented
DMM72LS	SN	PMID26609882-Compound-43
DMM72LS	CP	ARENA PHARMACEUTICALS, INC
DMM72LS	DT	Small molecular drug

DM6XRDH	ID	DM6XRDH
DM6XRDH	DN	Benzazepine derivative 5
DM6XRDH	HS	Patented
DM6XRDH	SN	PMID26609882-Compound-44
DM6XRDH	CP	ARENA PHARMACEUTICALS, INC
DM6XRDH	DT	Small molecular drug

DMCGX5S	ID	DMCGX5S
DMCGX5S	DN	Benzazepine derivative 6
DMCGX5S	HS	Patented
DMCGX5S	SN	PMID26609882-Compound-45
DMCGX5S	CP	ARENA PHARMACEUTICALS, INC
DMCGX5S	DT	Small molecular drug

DM6PMZC	ID	DM6PMZC
DM6PMZC	DN	Benzenamine derivative 1
DM6PMZC	HS	Patented
DM6PMZC	SN	PMID27019002-Compound-14
DM6PMZC	CP	THE JOHNS HOPKINS UNIVERSITY CASERO, Robert, A. BYTHEWAY, Ian WOSTER, Patrick, M
DM6PMZC	DT	Small molecular drug

DMDZ7QS	ID	DMDZ7QS
DMDZ7QS	DN	Benzenamine derivative 2
DMDZ7QS	HS	Patented
DMDZ7QS	SN	PMID27019002-Compound-35
DMDZ7QS	CP	THE JOHNS HOPKINS UNIVERSITY CASERO, Robert, A. BYTHEWAY, Ian WOSTER, Patrick, M
DMDZ7QS	DT	Small molecular drug

DM8UXZ3	ID	DM8UXZ3
DM8UXZ3	DN	Benzenamine derivative 3
DM8UXZ3	HS	Patented
DM8UXZ3	SN	PMID27019002-Compound-35a
DM8UXZ3	CP	THE JOHNS HOPKINS UNIVERSITY CASERO, Robert, A. BYTHEWAY, Ian WOSTER, Patrick, M
DM8UXZ3	DT	Small molecular drug

DMQT7HV	ID	DMQT7HV
DMQT7HV	DN	Benzenamine derivative 4
DMQT7HV	HS	Patented
DMQT7HV	SN	PMID27019002-Compound-36
DMQT7HV	CP	THE JOHNS HOPKINS UNIVERSITY CASERO, Robert, A. BYTHEWAY, Ian WOSTER, Patrick, M
DMQT7HV	DT	Small molecular drug

DMB9VEH	ID	DMB9VEH
DMB9VEH	DN	Benzene sulfonamide derivative 1
DMB9VEH	HS	Patented
DMB9VEH	SN	PMID27172114-Compound-65
DMB9VEH	CP	The J. David Gladstone InstitutUniversity of Maryland
DMB9VEH	DT	Small molecular drug

DML9TF7	ID	DML9TF7
DML9TF7	DN	Benzene sulfonamide derivative 11
DML9TF7	HS	Patented
DML9TF7	SN	PMID25539043-Compound-WO2013064983Example54
DML9TF7	CP	XENON PHARMACEUTICALS INC
DML9TF7	DT	Small molecular drug

DMESKY1	ID	DMESKY1
DMESKY1	DN	Benzene sulfonamide derivative 12
DMESKY1	HS	Patented
DMESKY1	SN	PMID25539043-Compound-WO2013064983Example55
DMESKY1	CP	XENON PHARMACEUTICALS INC
DMESKY1	DT	Small molecular drug

DMFJTE9	ID	DMFJTE9
DMFJTE9	DN	Benzene sulfonamide derivative 15
DMFJTE9	HS	Patented
DMFJTE9	SN	PMID25539043-Compound-WO2014061970Example56
DMFJTE9	CP	DAEWOONG PHARMACEUTICAL CO., LTD
DMFJTE9	DT	Small molecular drug

DMATBZW	ID	DMATBZW
DMATBZW	DN	Benzene sulfonamide derivative 16
DMATBZW	HS	Patented
DMATBZW	SN	PMID27414413-Compound-Figure3upright
DMATBZW	CP	PFIZER LIMITED
DMATBZW	DT	Small molecular drug
DMATBZW	PC	46840946
DMATBZW	MW	500.4
DMATBZW	FM	C18H12Cl2FN5O3S2
DMATBZW	IC	InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25)
DMATBZW	CS	C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F
DMATBZW	IK	ZYSCOUXLBXGGIM-UHFFFAOYSA-N
DMATBZW	IU	4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide
DMATBZW	CA	CAS 1235403-62-9

DMUZQLR	ID	DMUZQLR
DMUZQLR	DN	Benzene sulfonamide derivative 2
DMUZQLR	HS	Patented
DMUZQLR	SN	PMID27172114-Compound-66
DMUZQLR	DT	Small molecular drug

DMCQLJY	ID	DMCQLJY
DMCQLJY	DN	Benzene sulfonamide derivative 3
DMCQLJY	HS	Patented
DMCQLJY	SN	PMID27172114-Compound-67
DMCQLJY	DT	Small molecular drug
DMCQLJY	PC	24812126
DMCQLJY	MW	518.6
DMCQLJY	FM	C23H26N4O6S2
DMCQLJY	IC	InChI=1S/C23H26N4O6S2/c1-32-19-10-9-18(14-20(19)33-2)35(30,31)25-23-24-22(16-7-6-8-17(13-16)27(28)29)21(34-23)15-26-11-4-3-5-12-26/h6-10,13-14H,3-5,11-12,15H2,1-2H3,(H,24,25)
DMCQLJY	CS	COC1=C(C=C(C=C1)S(=O)(=O)NC2=NC(=C(S2)CN3CCCCC3)C4=CC(=CC=C4)[N+](=O)[O-])OC
DMCQLJY	IK	AOZLMMDVJOGGEQ-UHFFFAOYSA-N
DMCQLJY	IU	3,4-dimethoxy-N-[4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)-1,3-thiazol-2-yl]benzenesulfonamide
DMCQLJY	CA	CAS 1008119-83-2

DMXCUEG	ID	DMXCUEG
DMXCUEG	DN	Benzene sulfonamide derivative 4
DMXCUEG	HS	Patented
DMXCUEG	SN	PMID27172114-Compound-68
DMXCUEG	DT	Small molecular drug
DMXCUEG	PC	24812127
DMXCUEG	MW	520.6
DMXCUEG	FM	C22H24N4O7S2
DMXCUEG	IC	InChI=1S/C22H24N4O7S2/c1-31-18-7-6-17(13-19(18)32-2)35(29,30)24-22-23-21(15-4-3-5-16(12-15)26(27)28)20(34-22)14-25-8-10-33-11-9-25/h3-7,12-13H,8-11,14H2,1-2H3,(H,23,24)
DMXCUEG	CS	COC1=C(C=C(C=C1)S(=O)(=O)NC2=NC(=C(S2)CN3CCOCC3)C4=CC(=CC=C4)[N+](=O)[O-])OC
DMXCUEG	IK	GOWBSGKWACGSGN-UHFFFAOYSA-N
DMXCUEG	IU	3,4-dimethoxy-N-[5-(morpholin-4-ylmethyl)-4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide

DMW4NXV	ID	DMW4NXV
DMW4NXV	DN	Benzene sulfonamide derivative 5
DMW4NXV	HS	Patented
DMW4NXV	SN	PMID27172114-Compound-69
DMW4NXV	DT	Small molecular drug

DMD4UMP	ID	DMD4UMP
DMD4UMP	DN	Benzene sulfonamide derivative 6
DMD4UMP	HS	Patented
DMD4UMP	SN	PMID27172114-Compound-70
DMD4UMP	DT	Small molecular drug

DM0TKP2	ID	DM0TKP2
DM0TKP2	DN	Benzene sulfonamide derivative 7
DM0TKP2	HS	Patented
DM0TKP2	SN	PMID27172114-Compound-71
DM0TKP2	DT	Small molecular drug

DMATU1X	ID	DMATU1X
DMATU1X	DN	Benzene sulfonamide derivative 8
DMATU1X	HS	Patented
DMATU1X	SN	PMID26882240-Compound-13
DMATU1X	CP	INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY             KWON, Ho Jeong     HAN, Gyoon Hee
DMATU1X	DT	Small molecular drug
DMATU1X	PC	894213
DMATU1X	MW	325.4
DMATU1X	FM	C18H15NO3S
DMATU1X	IC	InChI=1S/C18H15NO3S/c20-17-10-8-16(9-11-17)19-23(21,22)18-12-6-15(7-13-18)14-4-2-1-3-5-14/h1-13,19-20H
DMATU1X	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NC3=CC=C(C=C3)O
DMATU1X	IK	SZOPCHOOHZIDKC-UHFFFAOYSA-N
DMATU1X	IU	N-(4-hydroxyphenyl)-4-phenylbenzenesulfonamide

DMLET14	ID	DMLET14
DMLET14	DN	Benzene sulfonamide derivative 9
DMLET14	HS	Patented
DMLET14	SN	PMID25539043-Compound-WO2012004706Example53
DMLET14	CP	PFIZER LIMITED ICAGEN, INC. MARKWORTH, Christopher John MARRON, Brian Edward RAWSON, David James STORER, Robert Ian SWAIN, Nigel Alan WEST, Christopher William ZHOU, Shulan
DMLET14	DT	Small molecular drug

DM1IZA7	ID	DM1IZA7
DM1IZA7	DN	Benzimidazole
DM1IZA7	HS	Patented
DM1IZA7	SN	BENZIMIDAZOLE; 51-17-2; 1H-Benzimidazole; 1H-Benzo[d]imidazole; 1,3-Benzodiazole; Benzoimidazole; o-Benzimidazole; 3-Azaindole; Benziminazole; Benzoglyoxaline; Azindole; 1,3-Diazaindene; 1H-Benzoimidazole; N,N'-Methenyl-o-phenylenediamine; NSC 759; Benzimidazol; 1H-1,3-benzodiazole; BZI; UNII-E24GX49LD8; CCRIS 5967; Benzimidazole, 98%; CHEBI:41275; HSDB 2797; EINECS 200-081-4; BRN 0109682; AI3-03737; E24GX49LD8; HYZJCKYKOHLVJF-UHFFFAOYSA-N; DSSTox_CID_4573; DSSTox_RID_77454; DSSTox_GSID_24573; F3366-5347; CAS-51-17-2; bezimidazole
DM1IZA7	DT	Small molecular drug
DM1IZA7	PC	5798
DM1IZA7	MW	118.14
DM1IZA7	FM	C7H6N2
DM1IZA7	IC	InChI=1S/C7H6N2/c1-2-4-7-6(3-1)8-5-9-7/h1-5H,(H,8,9)
DM1IZA7	CS	C1=CC=C2C(=C1)NC=N2
DM1IZA7	IK	HYZJCKYKOHLVJF-UHFFFAOYSA-N
DM1IZA7	IU	1H-benzimidazole
DM1IZA7	CA	CAS 51-17-2
DM1IZA7	CB	CHEBI:41275
DM1IZA7	DE	Cytomegalovirus Disease

DM2G83R	ID	DM2G83R
DM2G83R	DN	Benzimidazole and imadazopyridine carboximidamide compound 1
DM2G83R	HS	Patented
DM2G83R	SN	PMID29473428-Compound-23
DM2G83R	DT	Small molecular drug
DM2G83R	PC	122687657
DM2G83R	MW	468.9
DM2G83R	FM	C20H20ClF3N6O2
DM2G83R	IC	InChI=1S/C20H20ClF3N6O2/c1-32-11-8-30(9-11)5-4-25-20-27-17-12(7-15(23)16(24)18(17)28-20)19(29-31)26-10-2-3-14(22)13(21)6-10/h2-3,6-7,11,31H,4-5,8-9H2,1H3,(H,26,29)(H2,25,27,28)
DM2G83R	CS	COC1CN(C1)CCNC2=NC3=C(N2)C(=CC(=C3F)F)C(=NC4=CC(=C(C=C4)F)Cl)NO
DM2G83R	IK	DZOQWZPMCBWTQQ-UHFFFAOYSA-N
DM2G83R	IU	N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(3-methoxyazetidin-1-yl)ethylamino]-3H-benzimidazole-4-carboximidamide

DMJ2CIY	ID	DMJ2CIY
DMJ2CIY	DN	Benzimidazole and imadazopyridine carboximidamide compound 2
DMJ2CIY	HS	Patented
DMJ2CIY	SN	PMID29473428-Compound-24
DMJ2CIY	DT	Small molecular drug
DMJ2CIY	PC	137097618
DMJ2CIY	MW	332.16
DMJ2CIY	FM	C13H10BrN5O
DMJ2CIY	IC	InChI=1S/C13H10BrN5O/c14-8-2-1-3-9(6-8)18-12(19-20)10-4-5-15-13-11(10)16-7-17-13/h1-7,20H,(H,18,19)(H,15,16,17)
DMJ2CIY	CS	C1=CC(=CC(=C1)Br)N=C(C2=C3C(=NC=C2)N=CN3)NO
DMJ2CIY	IK	UPPKJOIPXZWQCK-UHFFFAOYSA-N
DMJ2CIY	IU	N'-(3-bromophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide

DMIXERP	ID	DMIXERP
DMIXERP	DN	Benzimidazole and imidazopyridine derivative 1
DMIXERP	HS	Patented
DMIXERP	SN	PMID25684022-Compound-WO2011006567
DMIXERP	CP	MERCK PATENT GMBH 
DMIXERP	DT	Small molecular drug
DMIXERP	DE	Solid tumour/cancer; Metastatic cancer

DMB1L32	ID	DMB1L32
DMB1L32	DN	Benzimidazole carboxamide derivative 1
DMB1L32	HS	Patented
DMB1L32	SN	PMID27841036-Compound-I
DMB1L32	CP	Angion Biomedica Corp
DMB1L32	DT	Small molecular drug

DML8W16	ID	DML8W16
DML8W16	DN	Benzimidazole derivative 1
DML8W16	HS	Patented
DML8W16	SN	PMID26161824-Compound-179
DML8W16	CP	ASTRAZENECA AB BROWN, William PAGE, Daniel SRIVASTAVA, Sanjay WALPOLE, Christopher WEI, Zhong-yong YANG, Hua
DML8W16	DT	Small molecular drug
DML8W16	PC	24872457
DML8W16	MW	464.6
DML8W16	FM	C28H40N4O2
DML8W16	IC	InChI=1S/C28H40N4O2/c1-28(2,3)27-30-23-17-21(9-12-24(23)32(27)18-19-7-5-4-6-8-19)26(34)31-15-13-20(14-16-31)25(33)29-22-10-11-22/h9,12,17,19-20,22H,4-8,10-11,13-16,18H2,1-3H3,(H,29,33)
DML8W16	CS	CC(C)(C)C1=NC2=C(N1CC3CCCCC3)C=CC(=C2)C(=O)N4CCC(CC4)C(=O)NC5CC5
DML8W16	IK	UNNYHANBNOQKCU-UHFFFAOYSA-N
DML8W16	IU	1-[2-tert-butyl-1-(cyclohexylmethyl)benzimidazole-5-carbonyl]-N-cyclopropylpiperidine-4-carboxamide
DML8W16	DE	Obesity

DML3PE4	ID	DML3PE4
DML3PE4	DN	Benzimidazole derivative 10
DML3PE4	HS	Patented
DML3PE4	SN	PMID26936077-Compound-27
DML3PE4	CP	NEOPHARM CO.,LTD. ( )    GWAK, Hyung Sub     KIM, Yong Zu     KIM, Uk Il     PARK, Byeong Deog     PARK, Tae Kyo     WOO, Sung Ho
DML3PE4	DT	Small molecular drug
DML3PE4	PC	56848369
DML3PE4	MW	430.5
DML3PE4	FM	C26H30N4O2
DML3PE4	IC	InChI=1S/C26H30N4O2/c1-19-24(20-8-4-2-5-9-20)30-18-22(12-13-23(30)27-19)26(32)29-16-14-28(15-17-29)25(31)21-10-6-3-7-11-21/h2,4-5,8-9,12-13,18,21H,3,6-7,10-11,14-17H2,1H3
DML3PE4	CS	CC1=C(N2C=C(C=CC2=N1)C(=O)N3CCN(CC3)C(=O)C4CCCCC4)C5=CC=CC=C5
DML3PE4	IK	BQTLJTZGAMQFGS-UHFFFAOYSA-N
DML3PE4	IU	cyclohexyl-[4-(2-methyl-3-phenylimidazo[1,2-a]pyridine-6-carbonyl)piperazin-1-yl]methanone

DMGRD8B	ID	DMGRD8B
DMGRD8B	DN	Benzimidazole derivative 11
DMGRD8B	HS	Patented
DMGRD8B	SN	PMID28627961-Compound-10
DMGRD8B	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PRIEPKE, Henning DOODS, Henri KUELZER, Raimund PFAU, Roland STENKAMP, Dirk PELCMAN, Benjamin ROENN, Robert
DMGRD8B	DT	Small molecular drug
DMGRD8B	PC	86669641
DMGRD8B	MW	638.9
DMGRD8B	FM	C29H28Cl3F2N5O3
DMGRD8B	IC	InChI=1S/C29H28Cl3F2N5O3/c1-29(2,3)27(41)35-14-15-5-7-18(30)25(24(15)32)38-28-37-21-12-17(23(42-10-9-33)13-22(21)39(28)4)26(40)36-16-6-8-20(34)19(31)11-16/h5-8,11-13H,9-10,14H2,1-4H3,(H,35,41)(H,36,40)(H,37,38)
DMGRD8B	CS	CC(C)(C)C(=O)NCC1=C(C(=C(C=C1)Cl)NC2=NC3=C(N2C)C=C(C(=C3)C(=O)NC4=CC(=C(C=C4)F)Cl)OCCF)Cl
DMGRD8B	IK	MJNRUPMNPGZLRT-UHFFFAOYSA-N
DMGRD8B	IU	N-(3-chloro-4-fluorophenyl)-2-[2,6-dichloro-3-[(2,2-dimethylpropanoylamino)methyl]anilino]-6-(2-fluoroethoxy)-1-methylbenzimidazole-5-carboxamide

DMOHERV	ID	DMOHERV
DMOHERV	DN	Benzimidazole derivative 12
DMOHERV	HS	Patented
DMOHERV	SN	PMID28627961-Compound-11
DMOHERV	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH 
DMOHERV	DT	Small molecular drug
DMOHERV	PC	57336796
DMOHERV	MW	689.5
DMOHERV	FM	C31H35Cl2F5N6O2
DMOHERV	IC	InChI=1S/C31H35Cl2F5N6O2/c1-29(2,3)27(46)39-15-16-5-6-20(32)25(24(16)33)42-28-41-21-11-19(26(45)40-18-13-30(34,35)14-18)22(12-23(21)43(28)4)44-9-7-17(8-10-44)31(36,37)38/h5-6,11-12,17-18H,7-10,13-15H2,1-4H3,(H,39,46)(H,40,45)(H,41,42)
DMOHERV	CS	CC(C)(C)C(=O)NCC1=C(C(=C(C=C1)Cl)NC2=NC3=C(N2C)C=C(C(=C3)C(=O)NC4CC(C4)(F)F)N5CCC(CC5)C(F)(F)F)Cl
DMOHERV	IK	WROFUPVHFCAUPE-UHFFFAOYSA-N
DMOHERV	IU	2-[2,6-dichloro-3-[(2,2-dimethylpropanoylamino)methyl]anilino]-N-(3,3-difluorocyclobutyl)-1-methyl-6-[4-(trifluoromethyl)piperidin-1-yl]benzimidazole-5-carboxamide

DMV4DQI	ID	DMV4DQI
DMV4DQI	DN	Benzimidazole derivative 13
DMV4DQI	HS	Patented
DMV4DQI	SN	PMID28627961-Compound-12
DMV4DQI	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH 
DMV4DQI	DT	Small molecular drug

DMCY5M7	ID	DMCY5M7
DMCY5M7	DN	Benzimidazole derivative 14
DMCY5M7	HS	Patented
DMCY5M7	SN	PMID28627961-Compound-13
DMCY5M7	CP	Boehringer Ingelheim International GMBH
DMCY5M7	DT	Small molecular drug
DMCY5M7	PC	57336792
DMCY5M7	MW	685.5
DMCY5M7	FM	C31H28Cl2F6N6O
DMCY5M7	IC	InChI=1S/C31H28Cl2F6N6O/c1-43-26-16-25(45-12-10-44(11-13-45)20-5-3-19(4-6-20)30(34,35)36)22(33)15-24(26)42-28(43)41-23-14-18(2-7-21(23)32)17-40-27(46)29(8-9-29)31(37,38)39/h2-7,14-16H,8-13,17H2,1H3,(H,40,46)(H,41,42)
DMCY5M7	CS	CN1C2=CC(=C(C=C2N=C1NC3=C(C=CC(=C3)CNC(=O)C4(CC4)C(F)(F)F)Cl)Cl)N5CCN(CC5)C6=CC=C(C=C6)C(F)(F)F
DMCY5M7	IK	YVXLODVZVGRVRR-UHFFFAOYSA-N
DMCY5M7	IU	N-[[4-chloro-3-[[5-chloro-1-methyl-6-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]benzimidazol-2-yl]amino]phenyl]methyl]-1-(trifluoromethyl)cyclopropane-1-carboxamide

DMJ3AZ4	ID	DMJ3AZ4
DMJ3AZ4	DN	Benzimidazole derivative 15
DMJ3AZ4	HS	Patented
DMJ3AZ4	SN	PMID28627961-Compound-7
DMJ3AZ4	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri KLINDER, Klaus KUELZER, Raimund LUBRIKS, Dimitrijs MACK, Juergen PELCMAN, Benjamin PRIEPKE, Henning ROENN, Robert STENKAMP, Dirk SUNA, Edgars
DMJ3AZ4	DT	Small molecular drug
DMJ3AZ4	PC	46909123
DMJ3AZ4	MW	663.6
DMJ3AZ4	FM	C30H33F8N5O3
DMJ3AZ4	IC	InChI=1S/C30H33F8N5O3/c1-28(2,3)26(45)39-13-15-4-9-19(30(36,37)38)20(10-15)41-27-42-21-11-18(23(12-22(21)43-27)46-14-24(31)32)25(44)40-17-7-5-16(6-8-17)29(33,34)35/h4,9-12,16-17,24H,5-8,13-14H2,1-3H3,(H,39,45)(H,40,44)(H2,41,42,43)
DMJ3AZ4	CS	CC(C)(C)C(=O)NCC1=CC(=C(C=C1)C(F)(F)F)NC2=NC3=C(N2)C=C(C(=C3)OCC(F)F)C(=O)NC4CCC(CC4)C(F)(F)F
DMJ3AZ4	IK	QUJFMVVWDBGGPL-UHFFFAOYSA-N
DMJ3AZ4	IU	6-(2,2-difluoroethoxy)-2-[5-[(2,2-dimethylpropanoylamino)methyl]-2-(trifluoromethyl)anilino]-N-[4-(trifluoromethyl)cyclohexyl]-3H-benzimidazole-5-carboxamide

DMHEQDT	ID	DMHEQDT
DMHEQDT	DN	Benzimidazole derivative 16
DMHEQDT	HS	Patented
DMHEQDT	SN	PMID28627961-Compound-8
DMHEQDT	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri HAUEL, Norbert KLINDER, Klaus KUELZER, Raimund MACK, Juergen PRIEPKE, Henning STENKAMP, Dirk
DMHEQDT	DT	Small molecular drug
DMHEQDT	PC	58562295
DMHEQDT	MW	473
DMHEQDT	FM	C25H30ClFN4O2
DMHEQDT	IC	InChI=1S/C25H30ClFN4O2/c1-14-6-7-17(26)22(21(14)27)30-24-29-18-12-16(20(33-5)13-19(18)31(24)4)23(32)28-15-8-10-25(2,3)11-9-15/h6-7,12-13,15H,8-11H2,1-5H3,(H,28,32)(H,29,30)
DMHEQDT	CS	CC1=C(C(=C(C=C1)Cl)NC2=NC3=C(N2C)C=C(C(=C3)C(=O)NC4CCC(CC4)(C)C)OC)F
DMHEQDT	IK	GHWPMCBIOYWZCT-UHFFFAOYSA-N
DMHEQDT	IU	2-(6-chloro-2-fluoro-3-methylanilino)-N-(4,4-dimethylcyclohexyl)-6-methoxy-1-methylbenzimidazole-5-carboxamide

DM1DXME	ID	DM1DXME
DM1DXME	DN	Benzimidazole derivative 17
DM1DXME	HS	Patented
DM1DXME	SN	PMID28627961-Compound-9
DM1DXME	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri HAUEL, Norbert KLINDER, Klaus KUELZER, Raimund MACK, Juergen STENKAMP, Dirk
DM1DXME	DT	Small molecular drug

DM4ZUDY	ID	DM4ZUDY
DM4ZUDY	DN	Benzimidazole derivative 2
DM4ZUDY	HS	Patented
DM4ZUDY	SN	PMID26161824-Compound-180
DM4ZUDY	CP	ASTRAZENECA AB BROWN, William PAGE, Daniel SRIVASTAVA, Sanjay WALPOLE, Christopher WEI, Zhong-yong YANG, Hua
DM4ZUDY	DT	Small molecular drug
DM4ZUDY	PC	59608060
DM4ZUDY	MW	500.6
DM4ZUDY	FM	C28H38F2N4O2
DM4ZUDY	IC	InChI=1S/C28H38F2N4O2/c1-27(2,3)26-32-22-16-20(4-7-23(22)34(26)17-18-8-12-28(29,30)13-9-18)25(36)33-14-10-19(11-15-33)24(35)31-21-5-6-21/h4,7,16,18-19,21H,5-6,8-15,17H2,1-3H3,(H,31,35)
DM4ZUDY	CS	CC(C)(C)C1=NC2=C(N1CC3CCC(CC3)(F)F)C=CC(=C2)C(=O)N4CCC(CC4)C(=O)NC5CC5
DM4ZUDY	IK	XZJQGNKKTKJFJW-UHFFFAOYSA-N
DM4ZUDY	IU	1-[2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]benzimidazole-5-carbonyl]-N-cyclopropylpiperidine-4-carboxamide
DM4ZUDY	DE	Obesity

DMY93WG	ID	DMY93WG
DMY93WG	DN	Benzimidazole derivative 3
DMY93WG	HS	Patented
DMY93WG	SN	PMID26815044-Compound-42
DMY93WG	DT	Small molecular drug
DMY93WG	PC	5268800
DMY93WG	MW	226.23
DMY93WG	FM	C13H10N2O2
DMY93WG	IC	InChI=1S/C13H10N2O2/c16-8-5-6-9(12(17)7-8)13-14-10-3-1-2-4-11(10)15-13/h1-7,16-17H,(H,14,15)
DMY93WG	CS	C1=CC=C2C(=C1)NC(=N2)C3=C(C=C(C=C3)O)O
DMY93WG	IK	MTDSHRDWHUXPQH-UHFFFAOYSA-N
DMY93WG	IU	4-(1H-benzimidazol-2-yl)benzene-1,3-diol
DMY93WG	CA	CAS 63899-32-1
DMY93WG	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM9PL3F	ID	DM9PL3F
DM9PL3F	DN	Benzimidazole derivative 4
DM9PL3F	HS	Patented
DM9PL3F	SN	PMID26815044-Compound-43
DM9PL3F	DT	Small molecular drug
DM9PL3F	PC	135665562
DM9PL3F	MW	270.28
DM9PL3F	FM	C15H14N2O3
DM9PL3F	IC	InChI=1S/C15H14N2O3/c1-19-12-7-9(8-13(20-2)14(12)18)15-16-10-5-3-4-6-11(10)17-15/h3-8,18H,1-2H3,(H,16,17)
DM9PL3F	CS	COC1=CC(=CC(=C1O)OC)C2=NC3=CC=CC=C3N2
DM9PL3F	IK	LEEVVCNLICRBQX-UHFFFAOYSA-N
DM9PL3F	IU	4-(1H-benzimidazol-2-yl)-2,6-dimethoxyphenol
DM9PL3F	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMWOJLX	ID	DMWOJLX
DMWOJLX	DN	Benzimidazole derivative 5
DMWOJLX	HS	Patented
DMWOJLX	SN	PMID27774822-Compound-Figure1Example21(compound 121)
DMWOJLX	CP	LIGAND PHARMACEUTICALS INCORPORATED COLE, Andrew, G. JAMES, Ray, A. SHAO, Yuefei LETOURNEAU, Jeffrey, J. QUINTERO, Jorge, G. RIVIELLO, Christopher, Mark ZHI, Lin

DMV7TMB	ID	DMV7TMB
DMV7TMB	DN	Benzimidazole derivative 6
DMV7TMB	HS	Patented
DMV7TMB	SN	PMID28270010-Compound-Figure7-1
DMV7TMB	CP	TESARO, INCAMGEN INC. BOEZIO, Christiane M. CHENG, Alan, C. CHOQUETTE, Deborah LEWIS, Richard, T. POTASHMAN, Michele, H. ROMERO, Karina STELLWAGEN, John, C. WHITTINGTON, Douglas, A
DMV7TMB	DT	Small molecular drug
DMV7TMB	PC	57345941
DMV7TMB	MW	577.7
DMV7TMB	FM	C33H44FN5O3
DMV7TMB	IC	InChI=1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41)
DMV7TMB	CS	CC(C)NC(=O)C1CCC(CC1)N2C3=C(C=CC(=C3)CN4CCC(CC4)C(C)(C)O)N=C2NC(=O)C5=CC=C(C=C5)F
DMV7TMB	IK	WSTUJEXAPHIEIM-UHFFFAOYSA-N
DMV7TMB	IU	4-fluoro-N-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide
DMV7TMB	CA	CAS 1357920-84-3
DMV7TMB	DE	Solid tumour/cancer

DMDK4RI	ID	DMDK4RI
DMDK4RI	DN	Benzimidazole derivative 7
DMDK4RI	HS	Patented
DMDK4RI	SN	PMID27774824-Compound-Figure11Example15
DMDK4RI	CP	GALAPAGOS NV
DMDK4RI	DT	Small molecular drug

DMQ75BN	ID	DMQ75BN
DMQ75BN	DN	Benzimidazole derivative 8
DMQ75BN	HS	Patented
DMQ75BN	SN	PMID26936077-Compound-25
DMQ75BN	CP	NEOPHARM CO.,LTD. ( )    GWAK, Hyung Sub     KIM, Yong Zu     KIM, Uk Il     PARK, Byeong Deog     PARK, Tae Kyo     WOO, Sung Ho
DMQ75BN	DT	Small molecular drug
DMQ75BN	PC	56848967
DMQ75BN	MW	347.5
DMQ75BN	FM	C22H25N3O
DMQ75BN	IC	InChI=1S/C22H25N3O/c1-16-7-6-8-18(13-16)15-25-17(2)23-20-14-19(9-10-21(20)25)22(26)24-11-4-3-5-12-24/h6-10,13-14H,3-5,11-12,15H2,1-2H3
DMQ75BN	CS	CC1=CC(=CC=C1)CN2C(=NC3=C2C=CC(=C3)C(=O)N4CCCCC4)C
DMQ75BN	IK	FWLBCCWBWAZRLY-UHFFFAOYSA-N
DMQ75BN	IU	[2-methyl-1-[(3-methylphenyl)methyl]benzimidazol-5-yl]-piperidin-1-ylmethanone
DMQ75BN	CA	CAS 1234208-67-3

DMHJ98M	ID	DMHJ98M
DMHJ98M	DN	Benzimidazole derivative 9
DMHJ98M	HS	Patented
DMHJ98M	SN	PMID26936077-Compound-26
DMHJ98M	CP	NEOPHARM CO.,LTD. ( )    GWAK, Hyung Sub     KIM, Yong Zu     KIM, Uk Il     PARK, Byeong Deog     PARK, Tae Kyo     WOO, Sung Ho
DMHJ98M	DT	Small molecular drug
DMHJ98M	PC	56832519
DMHJ98M	MW	333.4
DMHJ98M	FM	C21H23N3O
DMHJ98M	IC	InChI=1S/C21H23N3O/c1-15-7-6-8-17(13-15)20-16(2)22-19-10-9-18(14-24(19)20)21(25)23-11-4-3-5-12-23/h6-10,13-14H,3-5,11-12H2,1-2H3
DMHJ98M	CS	CC1=CC(=CC=C1)C2=C(N=C3N2C=C(C=C3)C(=O)N4CCCCC4)C
DMHJ98M	IK	RKISYXMPLQOYPU-UHFFFAOYSA-N
DMHJ98M	IU	[2-methyl-3-(3-methylphenyl)imidazo[1,2-a]pyridin-6-yl]-piperidin-1-ylmethanone

DMRZELF	ID	DMRZELF
DMRZELF	DN	Benzimidazolone acetamide derivative 1
DMRZELF	HS	Patented
DMRZELF	SN	PMID27607364-Compound-181
DMRZELF	DT	Small molecular drug
DMRZELF	PC	23153799
DMRZELF	MW	357.4
DMRZELF	FM	C22H19N3O2
DMRZELF	IC	InChI=1S/C22H19N3O2/c1-24(18-10-6-3-7-11-18)21(26)15-25-20-14-17(16-8-4-2-5-9-16)12-13-19(20)23-22(25)27/h2-14H,15H2,1H3,(H,23,27)
DMRZELF	CS	CN(C1=CC=CC=C1)C(=O)CN2C3=C(C=CC(=C3)C4=CC=CC=C4)NC2=O
DMRZELF	IK	ORIMXDOWDCMRCI-UHFFFAOYSA-N
DMRZELF	IU	N-methyl-2-(2-oxo-6-phenyl-3H-benzimidazol-1-yl)-N-phenylacetamide

DMD9VC1	ID	DMD9VC1
DMD9VC1	DN	Benzimidazolone acetamide derivative 2
DMD9VC1	HS	Patented
DMD9VC1	SN	PMID27607364-Compound-182
DMD9VC1	DT	Small molecular drug
DMD9VC1	PC	71716969
DMD9VC1	MW	371.4
DMD9VC1	FM	C23H21N3O2
DMD9VC1	IC	InChI=1S/C23H21N3O2/c1-24(19-11-7-4-8-12-19)22(27)16-26-21-15-18(17-9-5-3-6-10-17)13-14-20(21)25(2)23(26)28/h3-15H,16H2,1-2H3
DMD9VC1	CS	CN1C2=C(C=C(C=C2)C3=CC=CC=C3)N(C1=O)CC(=O)N(C)C4=CC=CC=C4
DMD9VC1	IK	KWRWRRZPFCLHLS-UHFFFAOYSA-N
DMD9VC1	IU	N-methyl-2-(3-methyl-2-oxo-6-phenylbenzimidazol-1-yl)-N-phenylacetamide

DMF01AR	ID	DMF01AR
DMF01AR	DN	Benzisoselenazolone difluorocytidine derivative 1
DMF01AR	HS	Patented
DMF01AR	SN	PMID27977313-Compound-Figure6b
DMF01AR	DT	Small molecular drug

DM4VXY1	ID	DM4VXY1
DM4VXY1	DN	Benzo(b)carbazol-11-one compound 1
DM4VXY1	HS	Patented
DM4VXY1	SN	PMID27646564-Compound-10
DM4VXY1	CP	Chugai Pharmaceutical
DM4VXY1	DT	Small molecular drug

DMGCHW9	ID	DMGCHW9
DMGCHW9	DN	Benzo(b)carbazol-11-one compound 2
DMGCHW9	HS	Patented
DMGCHW9	SN	PMID27646564-Compound-10-1
DMGCHW9	CP	Chugai Pharmaceutical
DMGCHW9	DT	Small molecular drug

DMKXD2V	ID	DMKXD2V
DMKXD2V	DN	Benzo[d]oxazol-2(3H)-one derivative 1
DMKXD2V	HS	Patented
DMKXD2V	SN	PMID29334795-Compound-63
DMKXD2V	CP	AAPA B.V
DMKXD2V	DT	Small molecular drug

DM47KWB	ID	DM47KWB
DM47KWB	DN	Benzo[d]oxazol-2(3H)-one derivative 2
DM47KWB	HS	Patented
DM47KWB	SN	PMID29334795-Compound-64
DM47KWB	CP	AAPA B.V
DM47KWB	DT	Small molecular drug
DM47KWB	PC	71816205
DM47KWB	MW	453.6
DM47KWB	FM	C26H35N3O4
DM47KWB	IC	InChI=1S/C26H35N3O4/c1-3-24(26-25(4-1)32-19-20-33-26)29-12-10-27(11-13-29)9-2-16-31-23-7-5-22(6-8-23)21-28-14-17-30-18-15-28/h1,3-8H,2,9-21H2
DM47KWB	CS	C1CN(CCN1CCCOC2=CC=C(C=C2)CN3CCOCC3)C4=C5C(=CC=C4)OCCO5
DM47KWB	IK	VZAPQDNGQVGEES-UHFFFAOYSA-N
DM47KWB	IU	4-[[4-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propoxy]phenyl]methyl]morpholine

DM3Z5UQ	ID	DM3Z5UQ
DM3Z5UQ	DN	Benzo[d]oxazol-2(3H)-one derivative 3
DM3Z5UQ	HS	Patented
DM3Z5UQ	SN	PMID29334795-Compound-65
DM3Z5UQ	CP	AAPA B.V
DM3Z5UQ	DT	Small molecular drug
DM3Z5UQ	PC	118064262
DM3Z5UQ	MW	463.6
DM3Z5UQ	FM	C28H37N3O3
DM3Z5UQ	IC	InChI=1S/C28H37N3O3/c1-3-23(4-1)30-13-11-25(12-14-30)34-24-9-7-22(8-10-24)21-29-15-17-31(18-16-29)26-5-2-6-27-28(26)33-20-19-32-27/h2,5-10,23,25H,1,3-4,11-21H2
DM3Z5UQ	CS	C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)CN4CCN(CC4)C5=C6C(=CC=C5)OCCO6
DM3Z5UQ	IK	DOVAYWNSWPTVKL-UHFFFAOYSA-N
DM3Z5UQ	IU	1-[[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]methyl]-4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine

DMNIPE6	ID	DMNIPE6
DMNIPE6	DN	Benzo[d]oxazole derivative 1
DMNIPE6	HS	Patented
DMNIPE6	SN	PMID28454500-Compound-79
DMNIPE6	CP	Korea Institute of Radiological & Medical Sciences, S
DMNIPE6	DT	Small molecular drug
DMNIPE6	PC	736095
DMNIPE6	MW	339.2
DMNIPE6	FM	C17H11BrN2O
DMNIPE6	IC	InChI=1S/C17H11BrN2O/c18-14-6-2-3-11-12(14)4-1-5-13(11)17-20-15-9-10(19)7-8-16(15)21-17/h1-9H,19H2
DMNIPE6	CS	C1=CC2=C(C=CC=C2Br)C(=C1)C3=NC4=C(O3)C=CC(=C4)N
DMNIPE6	IK	XWSBTBHNERIRTD-UHFFFAOYSA-N
DMNIPE6	IU	2-(5-bromonaphthalen-1-yl)-1,3-benzoxazol-5-amine

DMR5V2A	ID	DMR5V2A
DMR5V2A	DN	Benzo[d]oxazole derivative 2
DMR5V2A	HS	Patented
DMR5V2A	SN	PMID28454500-Compound-80
DMR5V2A	CP	Korea Institute of Radiological & Medical Sciences, S
DMR5V2A	DT	Small molecular drug
DMR5V2A	PC	650480
DMR5V2A	MW	260.29
DMR5V2A	FM	C17H12N2O
DMR5V2A	IC	InChI=1S/C17H12N2O/c18-12-8-9-16-15(10-12)19-17(20-16)14-7-3-5-11-4-1-2-6-13(11)14/h1-10H,18H2
DMR5V2A	CS	C1=CC=C2C(=C1)C=CC=C2C3=NC4=C(O3)C=CC(=C4)N
DMR5V2A	IK	NCQQMVULPNMPEH-UHFFFAOYSA-N
DMR5V2A	IU	2-naphthalen-1-yl-1,3-benzoxazol-5-amine

DM712Y0	ID	DM712Y0
DM712Y0	DN	Benzo[d]oxazole derivative 3
DM712Y0	HS	Patented
DM712Y0	SN	PMID28454500-Compound-81
DM712Y0	CP	Korea Institute of Radiological & Medical Sciences, S
DM712Y0	DT	Small molecular drug

DM0RAC6	ID	DM0RAC6
DM0RAC6	DN	Benzo[d]oxazole derivative 4
DM0RAC6	HS	Patented
DM0RAC6	SN	PMID28454500-Compound-82
DM0RAC6	CP	Korea Institute of Radiological & Medical Sciences, S
DM0RAC6	DT	Small molecular drug
DM0RAC6	PC	17609434
DM0RAC6	MW	300.31
DM0RAC6	FM	C16H16N2O4
DM0RAC6	IC	InChI=1S/C16H16N2O4/c1-19-13-6-9(7-14(20-2)15(13)21-3)16-18-11-8-10(17)4-5-12(11)22-16/h4-8H,17H2,1-3H3
DM0RAC6	CS	COC1=CC(=CC(=C1OC)OC)C2=NC3=C(O2)C=CC(=C3)N
DM0RAC6	IK	HVSQIFZUOAJQOV-UHFFFAOYSA-N
DM0RAC6	IU	2-(3,4,5-trimethoxyphenyl)-1,3-benzoxazol-5-amine

DMFXC5L	ID	DMFXC5L
DMFXC5L	DN	Benzodiazepine derivative 1
DMFXC5L	HS	Patented
DMFXC5L	SN	PMID27607364-Compound-3
DMFXC5L	CP	COCENSYS, INC
DMFXC5L	DT	Small molecular drug
DMFXC5L	PC	1688
DMFXC5L	MW	319.2
DMFXC5L	FM	C16H12Cl2N2O
DMFXC5L	IC	InChI=1S/C16H12Cl2N2O/c1-20-14-7-6-12(18)8-13(14)16(19-9-15(20)21)10-2-4-11(17)5-3-10/h2-8H,9H2,1H3
DMFXC5L	CS	CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl
DMFXC5L	IK	PUMYFTJOWAJIKF-UHFFFAOYSA-N
DMFXC5L	IU	7-chloro-5-(4-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMFXC5L	CA	CAS 14439-61-3

DM5ZGNK	ID	DM5ZGNK
DM5ZGNK	DN	Benzodiazepine derivative 2
DM5ZGNK	HS	Patented
DM5ZGNK	SN	PMID27321640-Compound-15
DM5ZGNK	CP	NEURO3D UNIVERSITE LOUIS PASTEUR CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE FORENAP BOURGUIGNON, Jean-Jacques LUGNIER, Claire ABARGHAZ, Mustapha LAGOUGE, Yan WAGNER, Patrick MONDADORI, Cesare MACHER, Jean-Paul SCHULTZ, Dominique RABOISSON, PierrNeuro3d
DM5ZGNK	DT	Small molecular drug

DM249KU	ID	DM249KU
DM249KU	DN	Benzodihydroisofuran derivative 1
DM249KU	HS	Patented
DM249KU	SN	PMID28699813-Compound-6
DM249KU	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason LouiMerck & Co., Inc., Kenilworth, NJ, USA
DM249KU	DT	Small molecular drug
DM249KU	PC	54577783
DM249KU	MW	474.9
DM249KU	FM	C25H22ClF3N2O2
DM249KU	IC	InChI=1S/C25H22ClF3N2O2/c26-18-9-12-30-22(15-18)23-20-3-1-2-4-21(20)24(33-23)10-13-31(14-11-24)16-17-5-7-19(8-6-17)32-25(27,28)29/h1-9,12,15,23H,10-11,13-14,16H2
DM249KU	CS	C1CN(CCC12C3=CC=CC=C3C(O2)C4=NC=CC(=C4)Cl)CC5=CC=C(C=C5)OC(F)(F)F
DM249KU	IK	LFFCKQUVNSOFQR-UHFFFAOYSA-N
DM249KU	IU	1-(4-chloropyridin-2-yl)-1'-[[4-(trifluoromethoxy)phenyl]methyl]spiro[1H-2-benzofuran-3,4'-piperidine]

DMGK0FD	ID	DMGK0FD
DMGK0FD	DN	Benzodihydroisofuran derivative 2
DMGK0FD	HS	Patented
DMGK0FD	SN	PMID28699813-Compound-7
DMGK0FD	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason LouiMerck & Co., Inc., Kenilworth, NJ, USA
DMGK0FD	DT	Small molecular drug
DMGK0FD	PC	57393568
DMGK0FD	MW	503.9
DMGK0FD	FM	C26H25ClF3N3O2
DMGK0FD	IC	InChI=1S/C26H25ClF3N3O2/c1-24(2,17-5-7-19(8-6-17)34-26(28,29)30)33-14-10-25(11-15-33)23-20(4-3-12-32-23)22(35-25)21-16-18(27)9-13-31-21/h3-9,12-13,16,22H,10-11,14-15H2,1-2H3
DMGK0FD	CS	CC(C)(C1=CC=C(C=C1)OC(F)(F)F)N2CCC3(CC2)C4=C(C=CC=N4)C(O3)C5=NC=CC(=C5)Cl
DMGK0FD	IK	YOXWNCRWJMZYKR-UHFFFAOYSA-N
DMGK0FD	IU	5-(4-chloropyridin-2-yl)-1'-[2-[4-(trifluoromethoxy)phenyl]propan-2-yl]spiro[5H-furo[3,4-b]pyridine-7,4'-piperidine]

DMF6B1I	ID	DMF6B1I
DMF6B1I	DN	Benzodihydroisofuran derivative 3
DMF6B1I	HS	Patented
DMF6B1I	SN	PMID28699813-Compound-8
DMF6B1I	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason LouiMerck & Co., Inc., Kenilworth, NJ, USA
DMF6B1I	DT	Small molecular drug
DMF6B1I	PC	57404019
DMF6B1I	MW	509.3
DMF6B1I	FM	C25H21Cl2F3N2O2
DMF6B1I	IC	InChI=1S/C25H21Cl2F3N2O2/c26-18-12-17(13-19(27)14-18)22-21-2-1-9-31-23(21)24(34-22)7-10-32(11-8-24)15-16-3-5-20(6-4-16)33-25(28,29)30/h1-6,9,12-14,22H,7-8,10-11,15H2
DMF6B1I	CS	C1CN(CCC12C3=C(C=CC=N3)C(O2)C4=CC(=CC(=C4)Cl)Cl)CC5=CC=C(C=C5)OC(F)(F)F
DMF6B1I	IK	LKCGVBONYVRCLD-UHFFFAOYSA-N
DMF6B1I	IU	5-(3,5-dichlorophenyl)-1'-[[4-(trifluoromethoxy)phenyl]methyl]spiro[5H-furo[3,4-b]pyridine-7,4'-piperidine]

DM5IH2O	ID	DM5IH2O
DM5IH2O	DN	Benzodihydroisofuran derivative 4
DM5IH2O	HS	Patented
DM5IH2O	SN	PMID28699813-Compound-A
DM5IH2O	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason LouiMerck & Co., Inc., Kenilworth, NJ, USA
DM5IH2O	DT	Small molecular drug

DM4198Z	ID	DM4198Z
DM4198Z	DN	Benzofurans derivative 1
DM4198Z	HS	Patented
DM4198Z	SN	PMID27414413-Compound-Figure6left
DM4198Z	CP	J-PHARMA CO., LTD. WEMPE, Michael, F. ENDOU, Hitoshi
DM4198Z	DT	Small molecular drug

DM3K25J	ID	DM3K25J
DM3K25J	DN	Benzoheterocyclic compound 1
DM3K25J	HS	Patented
DM3K25J	SN	PMID28594589-Compound-TABLE3c5
DM3K25J	CP	Shanghai Kechow Pharma
DM3K25J	DT	Small molecular drug
DM3K25J	PC	71668126
DM3K25J	MW	550.9
DM3K25J	FM	C19H18BrClFN3O4S2
DM3K25J	IC	InChI=1S/C19H18BrClFN3O4S2/c20-10-1-2-13(12(21)5-10)24-17-14(6-15-18(16(17)22)23-9-30-15)25-31(28,29)19(3-4-19)7-11(27)8-26/h1-2,5-6,9,11,24-27H,3-4,7-8H2
DM3K25J	CS	C1CC1(CC(CO)O)S(=O)(=O)NC2=CC3=C(C(=C2NC4=C(C=C(C=C4)Br)Cl)F)N=CS3
DM3K25J	IK	AITYBOUARXLEQK-UHFFFAOYSA-N
DM3K25J	IU	N-[5-(4-bromo-2-chloroanilino)-4-fluoro-1,3-benzothiazol-6-yl]-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide

DM5ZKR2	ID	DM5ZKR2
DM5ZKR2	DN	Benzoic acid derivative 1
DM5ZKR2	HS	Patented
DM5ZKR2	SN	PMID27414413-Compound-Figure4up
DM5ZKR2	CP	WELLSTAT THERAPEUTICS CORPORATION SHARMA, Shalini VON BORSTEL, Reid, W
DM5ZKR2	DT	Small molecular drug

DMND8R0	ID	DMND8R0
DMND8R0	DN	Benzoic acid linked peptide analog 1
DMND8R0	HS	Patented
DMND8R0	SN	PMID26815044-Compound-79
DMND8R0	DT	Peptide
DMND8R0	SQ	Gallic acid KECG
DMND8R0	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMUBG20	ID	DMUBG20
DMUBG20	DN	Benzoic acid linked peptide analog 2
DMUBG20	HS	Patented
DMUBG20	SN	PMID26815044-Compound-80
DMUBG20	DT	Peptide
DMUBG20	SQ	(Gallic acid)2 KECG
DMUBG20	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM42BU9	ID	DM42BU9
DM42BU9	DN	Benzoic acid linked peptide analog 3
DM42BU9	HS	Patented
DM42BU9	SN	PMID26815044-Compound-81
DM42BU9	DT	Peptide
DM42BU9	SQ	Gallic acid ECG
DM42BU9	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMNX5EU	ID	DMNX5EU
DMNX5EU	DN	Benzoic acid linked peptide analog 4
DMNX5EU	HS	Patented
DMNX5EU	SN	PMID26815044-Compound-82
DMNX5EU	DT	Peptide
DMNX5EU	SQ	Gallic acid YHY
DMNX5EU	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMNIZAR	ID	DMNIZAR
DMNIZAR	DN	Benzoic acid linked peptide analog 5
DMNIZAR	HS	Patented
DMNIZAR	SN	PMID26815044-Compound-83
DMNIZAR	DT	Peptide
DMNIZAR	SQ	(Gallic acid)2 KYHY
DMNIZAR	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMTHKES	ID	DMTHKES
DMTHKES	DN	Benzoic acid linked peptide analog 6
DMTHKES	HS	Patented
DMTHKES	SN	PMID26815044-Compound-84
DMTHKES	DT	Peptide
DMTHKES	SQ	Gallic acid YGGFLRFKYPK
DMTHKES	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMUJFCK	ID	DMUJFCK
DMUJFCK	DN	Benzoimidazole derivative 1
DMUJFCK	HS	Patented
DMUJFCK	SN	PMID28594589-Compound-TABLE3c6
DMUJFCK	CP	Array BioPharma
DMUJFCK	DT	Small molecular drug
DMUJFCK	PC	73775787
DMUJFCK	MW	497.3
DMUJFCK	FM	C21H23BrF2N4O3
DMUJFCK	IC	InChI=1S/C21H23BrF2N4O3/c1-21(2,3)30-7-8-31-27-20(29)13-10-16-19(25-11-28(16)4)17(24)18(13)26-15-6-5-12(22)9-14(15)23/h5-6,9-11,26H,7-8H2,1-4H3,(H,27,29)
DMUJFCK	CS	CC(C)(C)OCCONC(=O)C1=CC2=C(C(=C1NC3=C(C=C(C=C3)Br)F)F)N=CN2C
DMUJFCK	IK	MZHRFHRSYBBMON-UHFFFAOYSA-N
DMUJFCK	IU	6-(4-bromo-2-fluoroanilino)-7-fluoro-3-methyl-N-[2-[(2-methylpropan-2-yl)oxy]ethoxy]benzimidazole-5-carboxamide
DMUJFCK	CA	CAS 1604812-70-5

DMHX5VO	ID	DMHX5VO
DMHX5VO	DN	Benzoimidazole derivative 2
DMHX5VO	HS	Patented
DMHX5VO	SN	PMID28594589-Compound-TABLE3c7
DMHX5VO	CP	Array BioPharma
DMHX5VO	DT	Small molecular drug

DMM9J34	ID	DMM9J34
DMM9J34	DN	Benzonaphthyridine derivative 1
DMM9J34	HS	Patented
DMM9J34	SN	PMID25684022-Compound-WO2008109599
DMM9J34	CP	WYETH WISSNER, Allan VENKATESAN, Aranapakam, M
DMM9J34	DT	Small molecular drug
DMM9J34	DE	Solid tumour/cancer; Metastatic cancer

DMB74LZ	ID	DMB74LZ
DMB74LZ	DN	Benzonaphthyridine derivative 2
DMB74LZ	HS	Patented
DMB74LZ	SN	PMID25684022-Compound-WO2008109613
DMB74LZ	CP	WYETH WISSNER, Allan FLOYD, Middleton, Brawner, Jr. DUSHIN, Russell FRASER, Heidi, L. HU, Yongbo MADERNA, Andreas NITTOLI, Thomas WANG, Yanong, Daniel
DMB74LZ	DT	Small molecular drug
DMB74LZ	DE	Solid tumour/cancer; Metastatic cancer

DM9FPK1	ID	DM9FPK1
DM9FPK1	DN	Benzothiazepine analog 1
DM9FPK1	HS	Patented
DM9FPK1	SN	PMID27607364-Compound-67
DM9FPK1	CP	THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giusepp
DM9FPK1	DT	Small molecular drug
DM9FPK1	PC	10317281
DM9FPK1	MW	374.4
DM9FPK1	FM	C23H22N2O3
DM9FPK1	IC	InChI=1S/C23H22N2O3/c1-3-24(4-2)23(26)28-22-19-14-10-16-25(19)18-13-8-9-15-20(18)27-21(22)17-11-6-5-7-12-17/h5-16H,3-4H2,1-2H3
DM9FPK1	CS	CCN(CC)C(=O)OC1=C(OC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DM9FPK1	IK	ZLLBRSQVPPSYMP-UHFFFAOYSA-N
DM9FPK1	IU	(6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N,N-diethylcarbamate

DMR6XF4	ID	DMR6XF4
DMR6XF4	DN	Benzothiazepine analog 10
DMR6XF4	HS	Patented
DMR6XF4	SN	PMID26924192-Compound-100
DMR6XF4	CP	FORMA THERAPEUTICS, INC
DMR6XF4	DT	Small molecular drug
DMR6XF4	PC	118079255
DMR6XF4	MW	430.5
DMR6XF4	FM	C22H27FN4O4
DMR6XF4	IC	InChI=1S/C22H27FN4O4/c1-14-9-25(21(29)31-13-22(3,4)23)20-7-16(5-6-19(20)27(14)15(2)28)17-8-24-26(10-17)18-11-30-12-18/h5-8,10,14,18H,9,11-13H2,1-4H3/t14-/m0/s1
DMR6XF4	CS	C[C@H]1CN(C2=C(N1C(=O)C)C=CC(=C2)C3=CN(N=C3)C4COC4)C(=O)OCC(C)(C)F
DMR6XF4	IK	HUMZKOSJUNGVKQ-AWEZNQCLSA-N
DMR6XF4	IU	(2-fluoro-2-methylpropyl) (3S)-4-acetyl-3-methyl-7-[1-(oxetan-3-yl)pyrazol-4-yl]-2,3-dihydroquinoxaline-1-carboxylate

DMVC51O	ID	DMVC51O
DMVC51O	DN	Benzothiazepine analog 11
DMVC51O	HS	Patented
DMVC51O	SN	PMID26924192-Compound-101
DMVC51O	CP	FORMA THERAPEUTICS, INC
DMVC51O	DT	Small molecular drug
DMVC51O	PC	118080527
DMVC51O	MW	486.6
DMVC51O	FM	C24H30N4O5S
DMVC51O	IC	InChI=1S/C24H30N4O5S/c1-16-14-26(24(30)33-21-4-3-5-21)23-12-18(6-7-22(23)28(16)17(2)29)19-13-25-27(15-19)20-8-10-34(31,32)11-9-20/h6-7,12-13,15-16,20-21H,3-5,8-11,14H2,1-2H3/t16-/m0/s1
DMVC51O	CS	C[C@H]1CN(C2=C(N1C(=O)C)C=CC(=C2)C3=CN(N=C3)C4CCS(=O)(=O)CC4)C(=O)OC5CCC5
DMVC51O	IK	OCRGMHCAJOHZLW-INIZCTEOSA-N
DMVC51O	IU	cyclobutyl (3S)-4-acetyl-7-[1-(1,1-dioxothian-4-yl)pyrazol-4-yl]-3-methyl-2,3-dihydroquinoxaline-1-carboxylate

DM7XQ18	ID	DM7XQ18
DM7XQ18	DN	Benzothiazepine analog 12
DM7XQ18	HS	Patented
DM7XQ18	SN	PMID26924192-Compound-99
DM7XQ18	CP	FORMA THERAPEUTICS, INC
DM7XQ18	DT	Small molecular drug
DM7XQ18	PC	118080061
DM7XQ18	MW	422.5
DM7XQ18	FM	C24H30N4O3
DM7XQ18	IC	InChI=1S/C24H30N4O3/c1-16-14-26(24(30)31-21-8-3-4-9-21)23-12-18(10-11-22(23)28(16)17(2)29)19-13-25-27(15-19)20-6-5-7-20/h10-13,15-16,20-21H,3-9,14H2,1-2H3/t16-/m0/s1
DM7XQ18	CS	C[C@H]1CN(C2=C(N1C(=O)C)C=CC(=C2)C3=CN(N=C3)C4CCC4)C(=O)OC5CCCC5
DM7XQ18	IK	YYISYQUFPYKFLD-INIZCTEOSA-N
DM7XQ18	IU	cyclopentyl (3S)-4-acetyl-7-(1-cyclobutylpyrazol-4-yl)-3-methyl-2,3-dihydroquinoxaline-1-carboxylate

DMZ3NSJ	ID	DMZ3NSJ
DMZ3NSJ	DN	Benzothiazepine analog 2
DMZ3NSJ	HS	Patented
DMZ3NSJ	SN	PMID27607364-Compound-68
DMZ3NSJ	CP	THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMZ3NSJ	DT	Small molecular drug
DMZ3NSJ	PC	10668139
DMZ3NSJ	MW	390.5
DMZ3NSJ	FM	C23H22N2O2S
DMZ3NSJ	IC	InChI=1S/C23H22N2O2S/c1-3-24(4-2)23(26)27-21-19-14-10-16-25(19)18-13-8-9-15-20(18)28-22(21)17-11-6-5-7-12-17/h5-16H,3-4H2,1-2H3
DMZ3NSJ	CS	CCN(CC)C(=O)OC1=C(SC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DMZ3NSJ	IK	LEFJQLQZGXZKSP-UHFFFAOYSA-N
DMZ3NSJ	IU	(6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-yl) N,N-diethylcarbamate

DM24NZG	ID	DM24NZG
DM24NZG	DN	Benzothiazepine analog 3
DM24NZG	HS	Patented
DM24NZG	SN	PMID27607364-Compound-69
DM24NZG	CP	THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DM24NZG	DT	Small molecular drug
DM24NZG	PC	9950117
DM24NZG	MW	346.4
DM24NZG	FM	C21H18N2O3
DM24NZG	IC	InChI=1S/C21H18N2O3/c1-22(2)21(24)26-20-17-12-8-14-23(17)16-11-6-7-13-18(16)25-19(20)15-9-4-3-5-10-15/h3-14H,1-2H3
DM24NZG	CS	CN(C)C(=O)OC1=C(OC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DM24NZG	IK	ROZBXXFOBQMJQB-UHFFFAOYSA-N
DM24NZG	IU	(6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N,N-dimethylcarbamate

DMV4OTD	ID	DMV4OTD
DMV4OTD	DN	Benzothiazepine analog 4
DMV4OTD	HS	Patented
DMV4OTD	SN	PMID27607364-Compound-70
DMV4OTD	CP	THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMV4OTD	DT	Small molecular drug
DMV4OTD	PC	10338693
DMV4OTD	MW	362.4
DMV4OTD	FM	C21H18N2O2S
DMV4OTD	IC	InChI=1S/C21H18N2O2S/c1-22(2)21(24)25-19-17-12-8-14-23(17)16-11-6-7-13-18(16)26-20(19)15-9-4-3-5-10-15/h3-14H,1-2H3
DMV4OTD	CS	CN(C)C(=O)OC1=C(SC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DMV4OTD	IK	FGXDSIINDRBSII-UHFFFAOYSA-N
DMV4OTD	IU	(6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-yl) N,N-dimethylcarbamate

DMCH1WX	ID	DMCH1WX
DMCH1WX	DN	Benzothiazepine analog 5
DMCH1WX	HS	Patented
DMCH1WX	SN	PMID27607364-Compound-71
DMCH1WX	CP	THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMCH1WX	DT	Small molecular drug
DMCH1WX	PC	9927532
DMCH1WX	MW	331.4
DMCH1WX	FM	C21H17NO3
DMCH1WX	IC	InChI=1S/C21H17NO3/c1-14-9-11-16(12-10-14)20-21(24-15(2)23)18-7-5-13-22(18)17-6-3-4-8-19(17)25-20/h3-13H,1-2H3
DMCH1WX	CS	CC1=CC=C(C=C1)C2=C(C3=CC=CN3C4=CC=CC=C4O2)OC(=O)C
DMCH1WX	IK	SJEIIHOXPXOSSN-UHFFFAOYSA-N
DMCH1WX	IU	[6-(4-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7-yl] acetate

DMB5KLD	ID	DMB5KLD
DMB5KLD	DN	Benzothiazepine analog 6
DMB5KLD	HS	Patented
DMB5KLD	SN	PMID27607364-Compound-72
DMB5KLD	CP	THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMB5KLD	DT	Small molecular drug
DMB5KLD	PC	9798976
DMB5KLD	MW	360.4
DMB5KLD	FM	C22H20N2O3
DMB5KLD	IC	InChI=1S/C22H20N2O3/c1-15-10-12-16(13-11-15)20-21(27-22(25)23(2)3)18-8-6-14-24(18)17-7-4-5-9-19(17)26-20/h4-14H,1-3H3
DMB5KLD	CS	CC1=CC=C(C=C1)C2=C(C3=CC=CN3C4=CC=CC=C4O2)OC(=O)N(C)C
DMB5KLD	IK	KVEJUNNTLYYMDH-UHFFFAOYSA-N
DMB5KLD	IU	[6-(4-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7-yl] N,N-dimethylcarbamate

DM25ZY4	ID	DM25ZY4
DM25ZY4	DN	Benzothiazepine analog 7
DM25ZY4	HS	Patented
DM25ZY4	SN	PMID27607364-Compound-73
DM25ZY4	CP	THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DM25ZY4	DT	Small molecular drug
DM25ZY4	PC	10045805
DM25ZY4	MW	388.5
DM25ZY4	FM	C24H24N2O3
DM25ZY4	IC	InChI=1S/C24H24N2O3/c1-4-25(5-2)24(27)29-23-20-10-8-16-26(20)19-9-6-7-11-21(19)28-22(23)18-14-12-17(3)13-15-18/h6-16H,4-5H2,1-3H3
DM25ZY4	CS	CCN(CC)C(=O)OC1=C(OC2=CC=CC=C2N3C1=CC=C3)C4=CC=C(C=C4)C
DM25ZY4	IK	DUPMTWWDEZKFAZ-UHFFFAOYSA-N
DM25ZY4	IU	[6-(4-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7-yl] N,N-diethylcarbamate

DMAXDV5	ID	DMAXDV5
DMAXDV5	DN	Benzothiazepine analog 8
DMAXDV5	HS	Patented
DMAXDV5	SN	PMID27607364-Compound-74
DMAXDV5	CP	THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMAXDV5	DT	Small molecular drug
DMAXDV5	PC	10809833
DMAXDV5	MW	380.8
DMAXDV5	FM	C21H17ClN2O3
DMAXDV5	IC	InChI=1S/C21H17ClN2O3/c1-23(2)21(25)27-20-17-12-7-13-24(17)16-11-6-10-15(22)19(16)26-18(20)14-8-4-3-5-9-14/h3-13H,1-2H3
DMAXDV5	CS	CN(C)C(=O)OC1=C(OC2=C(C=CC=C2Cl)N3C1=CC=C3)C4=CC=CC=C4
DMAXDV5	IK	PGDWEEZRRKJANX-UHFFFAOYSA-N
DMAXDV5	IU	(4-chloro-6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N,N-dimethylcarbamate

DMONDMG	ID	DMONDMG
DMONDMG	DN	Benzothiazepine analog 9
DMONDMG	HS	Patented
DMONDMG	SN	PMID27607364-Compound-75
DMONDMG	CP	THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMONDMG	DT	Small molecular drug
DMONDMG	PC	10250172
DMONDMG	MW	396.9
DMONDMG	FM	C21H17ClN2O2S
DMONDMG	IC	InChI=1S/C21H17ClN2O2S/c1-23(2)21(25)26-18-16-12-7-13-24(16)17-11-6-10-15(22)20(17)27-19(18)14-8-4-3-5-9-14/h3-13H,1-2H3
DMONDMG	CS	CN(C)C(=O)OC1=C(SC2=C(C=CC=C2Cl)N3C1=CC=C3)C4=CC=CC=C4
DMONDMG	IK	VCZPXCAFIGMLIM-UHFFFAOYSA-N
DMONDMG	IU	(4-chloro-6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-yl) N,N-dimethylcarbamate

DMMVHY4	ID	DMMVHY4
DMMVHY4	DN	Benzothiazine derivative 1
DMMVHY4	HS	Patented
DMMVHY4	SN	PMID26161698-Compound-50
DMMVHY4	DT	Small molecular drug
DMMVHY4	PC	90074871
DMMVHY4	MW	537.4
DMMVHY4	FM	C22H14Cl2N2O6S2
DMMVHY4	IC	InChI=1S/C22H14Cl2N2O6S2/c23-15-2-1-3-16(24)14(15)11-34(31,32)13-5-7-20-17(10-13)25-22(28)21(33-20)9-12-4-6-19(27)18(8-12)26(29)30/h1-10,27H,11H2,(H,25,28)/b21-9-
DMMVHY4	CS	C1=CC(=C(C(=C1)Cl)CS(=O)(=O)C2=CC3=C(C=C2)S/C(=C\\C4=CC(=C(C=C4)O)[N+](=O)[O-])/C(=O)N3)Cl
DMMVHY4	IK	DOMBZVXKSRQDOJ-NKVSQWTQSA-N
DMMVHY4	IU	(2Z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(4-hydroxy-3-nitrophenyl)methylidene]-4H-1,4-benzothiazin-3-one

DMJ51VZ	ID	DMJ51VZ
DMJ51VZ	DN	Benzothiazine-carboxamide compound 1
DMJ51VZ	HS	Patented
DMJ51VZ	SN	PMID26936077-Compound-35
DMJ51VZ	CP	Amorepacific Corp
DMJ51VZ	DT	Small molecular drug
DMJ51VZ	DE	Skin inflammation

DMMP2RT	ID	DMMP2RT
DMMP2RT	DN	Benzothiazine-carboxamide compound 2
DMMP2RT	HS	Patented
DMMP2RT	SN	PMID26936077-Compound-36
DMMP2RT	CP	Amorepacific Corp
DMMP2RT	DT	Small molecular drug
DMMP2RT	DE	Skin inflammation

DMI31OD	ID	DMI31OD
DMI31OD	DN	Benzothiazine-carboxamide compound 3
DMI31OD	HS	Patented
DMI31OD	SN	PMID26936077-Compound-37
DMI31OD	CP	Amorepacific Corp
DMI31OD	DT	Small molecular drug
DMI31OD	DE	Skin inflammation

DMSR918	ID	DMSR918
DMSR918	DN	Benzothiazine-carboxamide compound 4
DMSR918	HS	Patented
DMSR918	SN	PMID26936077-Compound-38
DMSR918	CP	Amorepacific Corp
DMSR918	DT	Small molecular drug
DMSR918	DE	Skin inflammation

DMM7N5E	ID	DMM7N5E
DMM7N5E	DN	Benzothiazine-carboxamide compound 5
DMM7N5E	HS	Patented
DMM7N5E	SN	PMID26936077-Compound-39
DMM7N5E	CP	Amorepacific Corp
DMM7N5E	DT	Small molecular drug
DMM7N5E	DE	Skin inflammation

DMW94IQ	ID	DMW94IQ
DMW94IQ	DN	Benzothiazine-carboxamide compound 6
DMW94IQ	HS	Patented
DMW94IQ	SN	PMID26936077-Compound-40
DMW94IQ	CP	Amorepacific Corp
DMW94IQ	DT	Small molecular drug
DMW94IQ	DE	Skin inflammation

DMHXFCQ	ID	DMHXFCQ
DMHXFCQ	DN	Benzothiazole analog 1
DMHXFCQ	HS	Patented
DMHXFCQ	SN	PMID26815044-Compound-36
DMHXFCQ	DT	Small molecular drug
DMHXFCQ	PC	95745
DMHXFCQ	MW	227.28
DMHXFCQ	FM	C13H9NOS
DMHXFCQ	IC	InChI=1S/C13H9NOS/c15-10-7-5-9(6-8-10)13-14-11-3-1-2-4-12(11)16-13/h1-8,15H
DMHXFCQ	CS	C1=CC=C2C(=C1)N=C(S2)C3=CC=C(C=C3)O
DMHXFCQ	IK	ODMDLCWSMSFWCW-UHFFFAOYSA-N
DMHXFCQ	IU	4-(1,3-benzothiazol-2-yl)phenol
DMHXFCQ	CA	CAS 6265-55-0
DMHXFCQ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMUKNXF	ID	DMUKNXF
DMUKNXF	DN	Benzothiazole analog 2
DMUKNXF	HS	Patented
DMUKNXF	SN	PMID26815044-Compound-37
DMUKNXF	DT	Small molecular drug
DMUKNXF	PC	136165239
DMUKNXF	MW	311.28
DMUKNXF	FM	C14H8F3NO2S
DMUKNXF	IC	InChI=1S/C14H8F3NO2S/c15-14(16,17)7-1-4-12-10(5-7)18-13(21-12)9-3-2-8(19)6-11(9)20/h1-6,19-20H
DMUKNXF	CS	C1=CC2=C(C=C1C(F)(F)F)N=C(S2)C3=C(C=C(C=C3)O)O
DMUKNXF	IK	XQUCXFZBRZZCKD-UHFFFAOYSA-N
DMUKNXF	IU	4-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]benzene-1,3-diol
DMUKNXF	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMDLY38	ID	DMDLY38
DMDLY38	DN	Benzothiazole analog 3
DMDLY38	HS	Patented
DMDLY38	SN	PMID26815044-Compound-38
DMDLY38	DT	Small molecular drug
DMDLY38	PC	1190414
DMDLY38	MW	497.7
DMDLY38	FM	C24H23N3O3S3
DMDLY38	IC	InChI=1S/C24H23N3O3S3/c1-16-4-9-20-21(15-16)32-24(26-20)18-5-7-19(8-6-18)25-23(28)17-10-12-27(13-11-17)33(29,30)22-3-2-14-31-22/h2-9,14-15,17H,10-13H2,1H3,(H,25,28)
DMDLY38	CS	CC1=CC2=C(C=C1)N=C(S2)C3=CC=C(C=C3)NC(=O)C4CCN(CC4)S(=O)(=O)C5=CC=CS5
DMDLY38	IK	IVGKSFUEBSXSAE-UHFFFAOYSA-N
DMDLY38	IU	N-[4-(6-methyl-1,3-benzothiazol-2-yl)phenyl]-1-thiophen-2-ylsulfonylpiperidine-4-carboxamide
DMDLY38	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMNDAT0	ID	DMNDAT0
DMNDAT0	DN	Benzothiazole analog 4
DMNDAT0	HS	Patented
DMNDAT0	SN	PMID26815044-Compound-39
DMNDAT0	DT	Small molecular drug
DMNDAT0	PC	136183500
DMNDAT0	MW	277.73
DMNDAT0	FM	C13H8ClNO2S
DMNDAT0	IC	InChI=1S/C13H8ClNO2S/c14-8-2-4-12-9(6-8)15-13(18-12)7-1-3-10(16)11(17)5-7/h1-6,16-17H
DMNDAT0	CS	C1=CC(=C(C=C1C2=NC3=C(S2)C=CC(=C3)Cl)O)O
DMNDAT0	IK	XSTUFGUKBUSBMM-UHFFFAOYSA-N
DMNDAT0	IU	4-(5-chloro-1,3-benzothiazol-2-yl)benzene-1,2-diol
DMNDAT0	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMN1J09	ID	DMN1J09
DMN1J09	DN	Benzothiazole analog 5
DMN1J09	HS	Patented
DMN1J09	SN	PMID26815044-Compound-40
DMN1J09	DT	Small molecular drug
DMN1J09	PC	68279301
DMN1J09	MW	347.8
DMN1J09	FM	C17H14ClNO3S
DMN1J09	IC	InChI=1S/C17H14ClNO3S/c1-17(2,16(20)21)22-12-6-3-10(4-7-12)15-19-13-9-11(18)5-8-14(13)23-15/h3-9H,1-2H3,(H,20,21)
DMN1J09	CS	CC(C)(C(=O)O)OC1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)Cl
DMN1J09	IK	HJOJVKDSEPDKSE-UHFFFAOYSA-N
DMN1J09	IU	2-[4-(5-chloro-1,3-benzothiazol-2-yl)phenoxy]-2-methylpropanoic acid
DMN1J09	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMJDC5T	ID	DMJDC5T
DMJDC5T	DN	Benzothiazoline derivative 1
DMJDC5T	HS	Patented
DMJDC5T	SN	PMID26815044-Compound-41
DMJDC5T	DT	Small molecular drug
DMJDC5T	PC	68279544
DMJDC5T	MW	323.8
DMJDC5T	FM	C15H14ClNO3S
DMJDC5T	IC	InChI=1S/C15H14ClNO3S/c1-19-11-5-8(6-12(20-2)14(11)18)15-17-10-7-9(16)3-4-13(10)21-15/h3-7,15,17-18H,1-2H3
DMJDC5T	CS	COC1=CC(=CC(=C1O)OC)C2NC3=C(S2)C=CC(=C3)Cl
DMJDC5T	IK	LQDWIAAYFSZPAR-UHFFFAOYSA-N
DMJDC5T	IU	4-(5-chloro-2,3-dihydro-1,3-benzothiazol-2-yl)-2,6-dimethoxyphenol
DMJDC5T	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMCO0ZS	ID	DMCO0ZS
DMCO0ZS	DN	Benzotriazole derivative 1
DMCO0ZS	HS	Patented
DMCO0ZS	SN	PMID26560530-Compound-40
DMCO0ZS	CP	Universit de Montral
DMCO0ZS	DT	Small molecular drug
DMCO0ZS	PC	25023511
DMCO0ZS	MW	364.4
DMCO0ZS	FM	C20H20N4O3
DMCO0ZS	IC	InChI=1S/C20H20N4O3/c1-20(2,3)27-19(26)21-15-11-8-14(9-12-15)10-13-18(25)24-17-7-5-4-6-16(17)22-23-24/h4-13H,1-3H3,(H,21,26)/b13-10+
DMCO0ZS	CS	CC(C)(C)OC(=O)NC1=CC=C(C=C1)/C=C/C(=O)N2C3=CC=CC=C3N=N2
DMCO0ZS	IK	HXHBNXDLCDLAKO-JLHYYAGUSA-N
DMCO0ZS	IU	tert-butyl N-[4-[(E)-3-(benzotriazol-1-yl)-3-oxoprop-1-enyl]phenyl]carbamate

DMIYXS8	ID	DMIYXS8
DMIYXS8	DN	Benzoxazepine analog 1
DMIYXS8	HS	Patented
DMIYXS8	SN	PMID27607364-Compound-76
DMIYXS8	DT	Small molecular drug
DMIYXS8	PC	9798301
DMIYXS8	MW	346.4
DMIYXS8	FM	C21H18N2O3
DMIYXS8	IC	InChI=1S/C21H18N2O3/c1-2-22-21(24)26-20-17-12-8-14-23(17)16-11-6-7-13-18(16)25-19(20)15-9-4-3-5-10-15/h3-14H,2H2,1H3,(H,22,24)
DMIYXS8	CS	CCNC(=O)OC1=C(OC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DMIYXS8	IK	KPYJFQDJNXSVFL-UHFFFAOYSA-N
DMIYXS8	IU	(6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N-ethylcarbamate

DM4FHTG	ID	DM4FHTG
DM4FHTG	DN	Benzoxazinone derivative 2
DM4FHTG	HS	Patented
DM4FHTG	SN	PMID29171765-Compound-Figure3
DM4FHTG	CP	UNIVERSITEIT ANTWERPESIXERA PHARMA AUNIVERSITE PIERRE ET MARIE CURIE (PARIS 6QUEENSLAND UNIVERSITY OF TECHNOLOGY HARRIS, Jonathan Malcolm DE VEER, Simon John SWEDBERG, Joakim Erik

DMY01FU	ID	DMY01FU
DMY01FU	DN	Benzoxazole derivative 1
DMY01FU	HS	Patented
DMY01FU	SN	PMID26413912-Compound-83
DMY01FU	CP	RENOVIS, INC. KAUB, Carl GOWLUGARI, Sumithra KINCAID, John JOHNSON, Russell, James O'MAHONY, Donogh, John Roger ESTIARTE-MARTINEZ, Maria, de los Angeles DUNCTON, Matthew
DMY01FU	DT	Small molecular drug
DMY01FU	PC	45109843
DMY01FU	MW	379.5
DMY01FU	FM	C25H21N3O
DMY01FU	IC	InChI=1S/C25H21N3O/c1-2-27-12-11-19-13-17(7-9-23(19)27)18-8-10-24-22(14-18)26-25(29-24)28-15-20-5-3-4-6-21(20)16-28/h3-14H,2,15-16H2,1H3
DMY01FU	CS	CCN1C=CC2=C1C=CC(=C2)C3=CC4=C(C=C3)OC(=N4)N5CC6=CC=CC=C6C5
DMY01FU	IK	JRHOETSWOCHDIA-UHFFFAOYSA-N
DMY01FU	IU	2-(1,3-dihydroisoindol-2-yl)-5-(1-ethylindol-5-yl)-1,3-benzoxazole

DMJBOL0	ID	DMJBOL0
DMJBOL0	DN	Benzoyl-piperidine derivative 1
DMJBOL0	HS	Patented
DMJBOL0	SN	PMID26609882-Compound-59
DMJBOL0	CP	F. HOFFMANN-LA ROCHE AG GOBBI, Luca JAESCHKE, Georg RODRIGUEZ SARMIENTO, Rosa Maria STEWARD, LucindHoffmann-La Roche Inc
DMJBOL0	DT	Small molecular drug

DMFKX1M	ID	DMFKX1M
DMFKX1M	DN	Benzoyl-piperidine derivative 2
DMFKX1M	HS	Patented
DMFKX1M	SN	PMID26609882-Compound-60
DMFKX1M	CP	F. HOFFMANN-LA ROCHE AG GOBBI, Luca JAESCHKE, Georg RODRIGUEZ SARMIENTO, Rosa Maria STEWARD, LucindHoffmann-La Roche Inc
DMFKX1M	DT	Small molecular drug

DMOU84B	ID	DMOU84B
DMOU84B	DN	Benzyl amine derivative 1
DMOU84B	HS	Patented
DMOU84B	SN	PMID29171765-Compound-Figure2a
DMOU84B	CP	Kalvista Pharmaceuticals Limited
DMOU84B	DT	Small molecular drug
DMOU84B	PC	86290439
DMOU84B	MW	428.5
DMOU84B	FM	C25H28N6O
DMOU84B	IC	InChI=1S/C25H28N6O/c1-18-11-28-30(14-18)15-20-3-5-21(6-4-20)16-31-17-24(13-29-31)25(32)27-12-23-8-7-22(10-26)9-19(23)2/h3-9,11,13-14,17H,10,12,15-16,26H2,1-2H3,(H,27,32)
DMOU84B	CS	CC1=C(C=CC(=C1)CN)CNC(=O)C2=CN(N=C2)CC3=CC=C(C=C3)CN4C=C(C=N4)C
DMOU84B	IK	KMRPNZXNLYKBNI-UHFFFAOYSA-N
DMOU84B	IU	N-[[4-(aminomethyl)-2-methylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide

DMFK7EL	ID	DMFK7EL
DMFK7EL	DN	Benzyl amine derivative 2
DMFK7EL	HS	Patented
DMFK7EL	SN	PMID29171765-Compound-Figure2b
DMFK7EL	CP	Kalvista Pharmaceuticals Limited
DMFK7EL	DT	Small molecular drug
DMFK7EL	PC	86290530
DMFK7EL	MW	514.5
DMFK7EL	FM	C26H26F4N6O
DMFK7EL	IC	InChI=1S/C26H26F4N6O/c1-16-10-33-35(12-16)13-18-3-5-19(6-4-18)14-36-15-22(24(34-36)26(28,29)30)25(37)32-11-21-8-7-20(9-31)23(27)17(21)2/h3-8,10,12,15H,9,11,13-14,31H2,1-2H3,(H,32,37)
DMFK7EL	CS	CC1=CN(N=C1)CC2=CC=C(C=C2)CN3C=C(C(=N3)C(F)(F)F)C(=O)NCC4=C(C(=C(C=C4)CN)F)C
DMFK7EL	IK	PKZHZUNPMZRBCV-UHFFFAOYSA-N
DMFK7EL	IU	N-[[4-(aminomethyl)-3-fluoro-2-methylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide

DM6PTOX	ID	DM6PTOX
DM6PTOX	DN	Benzyl phenyl ether derivative 1
DM6PTOX	HS	Patented
DM6PTOX	SN	PMID30107136-Compound-Example19
DM6PTOX	CP	INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DM6PTOX	DT	Small molecule immunotherapy 
DM6PTOX	PC	132181249
DM6PTOX	MW	621.9
DM6PTOX	FM	C31H26BrClN2O5
DM6PTOX	IC	InChI=1S/C31H26BrClN2O5/c32-30-23(10-5-11-25(30)22-8-2-1-3-9-22)19-40-29-14-28(39-18-21-7-4-6-20(12-21)15-34)24(13-26(29)33)16-35-27(17-36)31(37)38/h1-14,27,35-36H,16-19H2,(H,37,38)
DM6PTOX	CS	C1=CC=C(C=C1)C2=CC=CC(=C2Br)COC3=C(C=C(C(=C3)OCC4=CC(=CC=C4)C#N)CNC(CO)C(=O)O)Cl
DM6PTOX	IK	GSJUKYYDHBOJEP-UHFFFAOYSA-N
DM6PTOX	IU	2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-5-chloro-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanoic acid
DM6PTOX	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMMS4EI	ID	DMMS4EI
DMMS4EI	DN	Benzyl phenyl ether derivative 2
DMMS4EI	HS	Patented
DMMS4EI	SN	PMID30107136-Compound-Example20
DMMS4EI	CP	INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMMS4EI	DT	Small molecule immunotherapy 
DMMS4EI	PC	132181275
DMMS4EI	MW	577.9
DMMS4EI	FM	C30H26BrClN2O3
DMMS4EI	IC	InChI=1S/C30H26BrClN2O3/c31-30-24(10-5-11-26(30)23-8-2-1-3-9-23)20-37-29-16-28(25(15-27(29)32)18-34-12-13-35)36-19-22-7-4-6-21(14-22)17-33/h1-11,14-16,34-35H,12-13,18-20H2
DMMS4EI	CS	C1=CC=C(C=C1)C2=CC=CC(=C2Br)COC3=C(C=C(C(=C3)OCC4=CC(=CC=C4)C#N)CNCCO)Cl
DMMS4EI	IK	WFKSDDBJJFYOET-UHFFFAOYSA-N
DMMS4EI	IU	3-[[5-[(2-bromo-3-phenylphenyl)methoxy]-4-chloro-2-[(2-hydroxyethylamino)methyl]phenoxy]methyl]benzonitrile
DMMS4EI	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMIAB94	ID	DMIAB94
DMIAB94	DN	Benzyl pyrrolyloxoacetamide derivative 1
DMIAB94	HS	Patented
DMIAB94	SN	PMID26413912-Compound-89
DMIAB94	CP	IRONWOOD PHARMACEUTICALS, INC. HUDSON, Colleen BARDEN, Timothy, C. JIA, James MERMERIAN, Ara PENG, Bo YANG, Jane YU, Xiang, Y. SPROTT, Kevin FRETZEN, AngelikIRONWOOD PHARMACEUTICALS, INC. SPROTT, Kevin TALLEY, John, Jeffrey YANG, Jane PENG, Bo
DMIAB94	DT	Small molecular drug
DMIAB94	PC	53482754
DMIAB94	MW	453.9
DMIAB94	FM	C23H20ClN3O3S
DMIAB94	IC	InChI=1S/C23H20ClN3O3S/c1-13-10-18-22(31-13)20(14(2)27(18)12-15-4-6-16(24)7-5-15)21(28)23(29)26-17-8-9-25-19(11-17)30-3/h4-11H,12H2,1-3H3,(H,25,26,29)
DMIAB94	CS	CC1=CC2=C(S1)C(=C(N2CC3=CC=C(C=C3)Cl)C)C(=O)C(=O)NC4=CC(=NC=C4)OC
DMIAB94	IK	KJJWMDHJTAKZAD-UHFFFAOYSA-N
DMIAB94	IU	2-[4-[(4-chlorophenyl)methyl]-2,5-dimethylthieno[3,2-b]pyrrol-6-yl]-N-(2-methoxypyridin-4-yl)-2-oxoacetamide

DMHOLQF	ID	DMHOLQF
DMHOLQF	DN	Benzyl pyrrolyloxoacetamide derivative 2
DMHOLQF	HS	Patented
DMHOLQF	SN	PMID26413912-Compound-90
DMHOLQF	CP	IRONWOOD PHARMACEUTICALS, INCIRONWOOD PHARMACEUTICALS, INC
DMHOLQF	DT	Small molecular drug
DMHOLQF	PC	67984463
DMHOLQF	MW	484.4
DMHOLQF	FM	C24H19F3N4O4
DMHOLQF	IC	InChI=1S/C24H19F3N4O4/c1-12-22(23(32)24(33)30-14-4-5-28-21(7-14)35-3)15-8-20(34-2)17(27)9-19(15)31(12)11-18-16(26)6-13(25)10-29-18/h4-10H,11H2,1-3H3,(H,28,30,33)
DMHOLQF	CS	CC1=C(C2=CC(=C(C=C2N1CC3=C(C=C(C=N3)F)F)F)OC)C(=O)C(=O)NC4=CC(=NC=C4)OC
DMHOLQF	IK	SUOOBQNAIURDKV-UHFFFAOYSA-N
DMHOLQF	IU	2-[1-[(3,5-difluoropyridin-2-yl)methyl]-6-fluoro-5-methoxy-2-methylindol-3-yl]-N-(2-methoxypyridin-4-yl)-2-oxoacetamide

DMD7Z3H	ID	DMD7Z3H
DMD7Z3H	DN	Benzylcinnamate
DMD7Z3H	HS	Patented
DMD7Z3H	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DMD7Z3H	DT	Small molecular drug
DMD7Z3H	PC	5273469
DMD7Z3H	MW	238.28
DMD7Z3H	FM	C16H14O2
DMD7Z3H	IC	InChI=1S/C16H14O2/c17-16(12-11-14-7-3-1-4-8-14)18-13-15-9-5-2-6-10-15/h1-12H,13H2/b12-11+
DMD7Z3H	CS	C1=CC=C(C=C1)COC(=O)/C=C/C2=CC=CC=C2
DMD7Z3H	IK	NGHOLYJTSCBCGC-VAWYXSNFSA-N
DMD7Z3H	IU	benzyl (E)-3-phenylprop-2-enoate
DMD7Z3H	CA	CAS 103-41-3
DMD7Z3H	CB	CHEBI:146174

DMZKTHL	ID	DMZKTHL
DMZKTHL	DN	Beta-cyclodextrin conjugate derivative 1
DMZKTHL	HS	Patented
DMZKTHL	SN	PMID26651364-Compound-129
DMZKTHL	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DMZKTHL	DT	Carbohydrates
DMZKTHL	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM9W1FO	ID	DM9W1FO
DM9W1FO	DN	Beta-cyclodextrin conjugate derivative 2
DM9W1FO	HS	Patented
DM9W1FO	SN	PMID26651364-Compound-130
DM9W1FO	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DM9W1FO	DT	Carbohydrates
DM9W1FO	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMQJF4P	ID	DMQJF4P
DMQJF4P	DN	Beta-cyclodextrin conjugate derivative 3
DMQJF4P	HS	Patented
DMQJF4P	SN	PMID26651364-Compound-131
DMQJF4P	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DMQJF4P	DT	Carbohydrates
DMQJF4P	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMO9RE8	ID	DMO9RE8
DMO9RE8	DN	Beta-cyclodextrin conjugate derivative 4
DMO9RE8	HS	Patented
DMO9RE8	SN	PMID26651364-Compound-132
DMO9RE8	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DMO9RE8	DT	Carbohydrates
DMO9RE8	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DML2B7G	ID	DML2B7G
DML2B7G	DN	Beta-cyclodextrin conjugate derivative 5
DML2B7G	HS	Patented
DML2B7G	SN	PMID26651364-Compound-133
DML2B7G	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DML2B7G	DT	Carbohydrates
DML2B7G	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMCDR7	ID	DMMCDR7
DMMCDR7	DN	Betais-sulfonylamino derivative 1
DMMCDR7	HS	Patented
DMMCDR7	SN	PMID28627961-Compound-40
DMMCDR7	CP	ASTRAZENECA AB [SE]
DMMCDR7	DT	Small molecular drug
DMMCDR7	PC	42596932
DMMCDR7	MW	486.5
DMMCDR7	FM	C22H18N2O7S2
DMMCDR7	IC	InChI=1S/C22H18N2O7S2/c1-30-18-13-15(10-11-16(18)19-12-14-6-2-3-7-17(14)31-19)22(25)24-33(28,29)21-9-5-4-8-20(21)32(23,26)27/h2-13H,1H3,(H,24,25)(H2,23,26,27)
DMMCDR7	CS	COC1=C(C=CC(=C1)C(=O)NS(=O)(=O)C2=CC=CC=C2S(=O)(=O)N)C3=CC4=CC=CC=C4O3
DMMCDR7	IK	JTTOZXONFHYBAF-UHFFFAOYSA-N
DMMCDR7	IU	4-(1-benzofuran-2-yl)-3-methoxy-N-(2-sulfamoylphenyl)sulfonylbenzamide

DM5KTDY	ID	DM5KTDY
DM5KTDY	DN	Beta-naphthylacetic acids derivative 1
DM5KTDY	HS	Patented
DM5KTDY	SN	PMID28895472-Compound-26
DM5KTDY	CP	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA VANDERBILT UNIVERSITY
DM5KTDY	DT	Small molecular drug
DM5KTDY	PC	66706413
DM5KTDY	MW	244.28
DM5KTDY	FM	C15H16O3
DM5KTDY	IC	InChI=1S/C15H16O3/c1-3-14(15(16)17)12-5-4-11-9-13(18-2)7-6-10(11)8-12/h4-9,14H,3H2,1-2H3,(H,16,17)/t14-/m1/s1
DM5KTDY	CS	CC[C@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
DM5KTDY	IK	LSDAHSHHKKHOKE-CQSZACIVSA-N
DM5KTDY	IU	(2R)-2-(6-methoxynaphthalen-2-yl)butanoic acid

DM8D3FG	ID	DM8D3FG
DM8D3FG	DN	Beta-phe compound 1
DM8D3FG	HS	Patented
DM8D3FG	SN	PMID25482888-Compound-39
DM8D3FG	DT	Peptide

DM786OD	ID	DM786OD
DM786OD	DN	Beta-phe compound 2
DM786OD	HS	Patented
DM786OD	SN	PMID25482888-Compound-40
DM786OD	DT	Peptide

DM0G8XP	ID	DM0G8XP
DM0G8XP	DN	Beta-phe compound 3
DM0G8XP	HS	Patented
DM0G8XP	SN	PMID25482888-Compound-41
DM0G8XP	DT	Peptide

DM79WI1	ID	DM79WI1
DM79WI1	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1
DM79WI1	HS	Patented
DM79WI1	SN	PMID26815044-Compound-65
DM79WI1	DT	Small molecular drug
DM79WI1	PC	1276529
DM79WI1	MW	221.23
DM79WI1	FM	C10H7NO3S
DM79WI1	IC	InChI=1S/C10H7NO3S/c12-7-3-1-6(2-4-7)5-8-9(13)11-10(14)15-8/h1-5,12H,(H,11,13,14)/b8-5-
DM79WI1	CS	C1=CC(=CC=C1/C=C\\2/C(=O)NC(=O)S2)O
DM79WI1	IK	ARHIHDVVUHVQCP-YVMONPNESA-N
DM79WI1	IU	(5Z)-5-[(4-hydroxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
DM79WI1	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMRXMCH	ID	DMRXMCH
DMRXMCH	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10
DMRXMCH	HS	Patented
DMRXMCH	SN	PMID26815044-Compound-74
DMRXMCH	DT	Small molecular drug
DMRXMCH	PC	5751025
DMRXMCH	MW	253.3
DMRXMCH	FM	C10H7NO3S2
DMRXMCH	IC	InChI=1S/C10H7NO3S2/c12-6-2-1-5(7(13)4-6)3-8-9(14)11-10(15)16-8/h1-4,12-13H,(H,11,14,15)/b8-3-
DMRXMCH	CS	C1=CC(=C(C=C1O)O)/C=C\\2/C(=O)NC(=S)S2
DMRXMCH	IK	GZGFGVYXIOPNPH-BAQGIRSFSA-N
DMRXMCH	IU	(5Z)-5-[(2,4-dihydroxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
DMRXMCH	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMVPR1D	ID	DMVPR1D
DMVPR1D	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11
DMVPR1D	HS	Patented
DMVPR1D	SN	PMID26815044-Compound-75
DMVPR1D	DT	Small molecular drug
DMVPR1D	PC	1379698
DMVPR1D	MW	267.3
DMVPR1D	FM	C11H9NO3S2
DMVPR1D	IC	InChI=1S/C11H9NO3S2/c1-15-8-3-2-6(4-7(8)13)5-9-10(14)12-11(16)17-9/h2-5,13H,1H3,(H,12,14,16)/b9-5-
DMVPR1D	CS	COC1=C(C=C(C=C1)/C=C\\2/C(=O)NC(=S)S2)O
DMVPR1D	IK	PCTZLDOIVAVMME-UITAMQMPSA-N
DMVPR1D	IU	(5Z)-5-[(3-hydroxy-4-methoxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
DMVPR1D	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMOHBCN	ID	DMOHBCN
DMOHBCN	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12
DMOHBCN	HS	Patented
DMOHBCN	SN	PMID26815044-Compound-76
DMOHBCN	DT	Small molecular drug
DMOHBCN	PC	5851417
DMOHBCN	MW	250.28
DMOHBCN	FM	C11H10N2O3S
DMOHBCN	IC	InChI=1S/C11H10N2O3S/c1-16-8-3-2-6(4-7(8)14)5-9-10(15)13-11(12)17-9/h2-5,14H,1H3,(H2,12,13,15)/b9-5-
DMOHBCN	CS	COC1=C(C=C(C=C1)/C=C\\2/C(=O)N=C(S2)N)O
DMOHBCN	IK	WCHCAGWRYJMMPY-UITAMQMPSA-N
DMOHBCN	IU	(5Z)-2-amino-5-[(3-hydroxy-4-methoxyphenyl)methylidene]-1,3-thiazol-4-one
DMOHBCN	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMKDBQG	ID	DMKDBQG
DMKDBQG	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13
DMKDBQG	HS	Patented
DMKDBQG	SN	PMID26815044-Compound-77
DMKDBQG	DT	Small molecular drug
DMKDBQG	PC	46861776
DMKDBQG	MW	285.29
DMKDBQG	FM	C16H15NO4
DMKDBQG	IC	InChI=1S/C16H15NO4/c1-21-13-6-4-12(5-7-13)17-16(20)9-3-11-2-8-14(18)15(19)10-11/h2-10,18-19H,1H3,(H,17,20)/b9-3+
DMKDBQG	CS	COC1=CC=C(C=C1)NC(=O)/C=C/C2=CC(=C(C=C2)O)O
DMKDBQG	IK	MGXQKQSEWXXTPE-YCRREMRBSA-N
DMKDBQG	IU	(E)-3-(3,4-dihydroxyphenyl)-N-(4-methoxyphenyl)prop-2-enamide
DMKDBQG	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMWUAXM	ID	DMWUAXM
DMWUAXM	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14
DMWUAXM	HS	Patented
DMWUAXM	SN	PMID26815044-Compound-78
DMWUAXM	DT	Small molecular drug
DMWUAXM	PC	46932910
DMWUAXM	MW	362.2
DMWUAXM	FM	C17H16BrNO3
DMWUAXM	IC	InChI=1S/C17H16BrNO3/c18-14-5-1-12(2-6-14)9-10-19-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-8,11,20-21H,9-10H2,(H,19,22)/b8-4+
DMWUAXM	CS	C1=CC(=CC=C1CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)Br
DMWUAXM	IK	QIQBGDXOXRDDBP-XBXARRHUSA-N
DMWUAXM	IU	(E)-N-[2-(4-bromophenyl)ethyl]-3-(3,4-dihydroxyphenyl)prop-2-enamide
DMWUAXM	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMAEQ0I	ID	DMAEQ0I
DMAEQ0I	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2
DMAEQ0I	HS	Patented
DMAEQ0I	SN	PMID26815044-Compound-66
DMAEQ0I	DT	Small molecular drug
DMAEQ0I	PC	6280959
DMAEQ0I	MW	237.23
DMAEQ0I	FM	C10H7NO4S
DMAEQ0I	IC	InChI=1S/C10H7NO4S/c12-6-2-1-5(7(13)4-6)3-8-9(14)11-10(15)16-8/h1-4,12-13H,(H,11,14,15)/b8-3-
DMAEQ0I	CS	C1=CC(=C(C=C1O)O)/C=C\\2/C(=O)NC(=O)S2
DMAEQ0I	IK	CPVBTHMWQGHRIR-BAQGIRSFSA-N
DMAEQ0I	IU	(5Z)-5-[(2,4-dihydroxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
DMAEQ0I	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMGV8T9	ID	DMGV8T9
DMGV8T9	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3
DMGV8T9	HS	Patented
DMGV8T9	SN	PMID26815044-Compound-67
DMGV8T9	DT	Small molecular drug
DMGV8T9	PC	1394178
DMGV8T9	MW	251.26
DMGV8T9	FM	C11H9NO4S
DMGV8T9	IC	InChI=1S/C11H9NO4S/c1-16-8-3-2-6(4-7(8)13)5-9-10(14)12-11(15)17-9/h2-5,13H,1H3,(H,12,14,15)/b9-5-
DMGV8T9	CS	COC1=C(C=C(C=C1)/C=C\\2/C(=O)NC(=O)S2)O
DMGV8T9	IK	MHRJJGJJVMGLRQ-UITAMQMPSA-N
DMGV8T9	IU	(5Z)-5-[(3-hydroxy-4-methoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
DMGV8T9	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMNQF9S	ID	DMNQF9S
DMNQF9S	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4
DMNQF9S	HS	Patented
DMNQF9S	SN	PMID26815044-Compound-68
DMNQF9S	DT	Small molecular drug
DMNQF9S	PC	5337602
DMNQF9S	MW	248.19
DMNQF9S	FM	C11H8N2O5
DMNQF9S	IC	InChI=1S/C11H8N2O5/c14-7-2-1-5(4-8(7)15)3-6-9(16)12-11(18)13-10(6)17/h1-4,14-15H,(H2,12,13,16,17,18)
DMNQF9S	CS	C1=CC(=C(C=C1C=C2C(=O)NC(=O)NC2=O)O)O
DMNQF9S	IK	PJCLRLDOILEINS-UHFFFAOYSA-N
DMNQF9S	IU	5-[(3,4-dihydroxyphenyl)methylidene]-1,3-diazinane-2,4,6-trione
DMNQF9S	CA	CAS 5131-88-4
DMNQF9S	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMBC48K	ID	DMBC48K
DMBC48K	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5
DMBC48K	HS	Patented
DMBC48K	SN	PMID26815044-Compound-69
DMBC48K	DT	Small molecular drug
DMBC48K	PC	5497727
DMBC48K	MW	248.19
DMBC48K	FM	C11H8N2O5
DMBC48K	IC	InChI=1S/C11H8N2O5/c14-6-2-1-5(8(15)4-6)3-7-9(16)12-11(18)13-10(7)17/h1-4,14-15H,(H2,12,13,16,17,18)
DMBC48K	CS	C1=CC(=C(C=C1O)O)C=C2C(=O)NC(=O)NC2=O
DMBC48K	IK	XGRANFKYXNDTDO-UHFFFAOYSA-N
DMBC48K	IU	5-[(2,4-dihydroxyphenyl)methylidene]-1,3-diazinane-2,4,6-trione
DMBC48K	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMK9XV8	ID	DMK9XV8
DMK9XV8	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6
DMK9XV8	HS	Patented
DMK9XV8	SN	PMID26815044-Compound-70
DMK9XV8	DT	Small molecular drug
DMK9XV8	PC	10059907
DMK9XV8	MW	234.21
DMK9XV8	FM	C11H10N2O4
DMK9XV8	IC	InChI=1S/C11H10N2O4/c1-17-9-3-2-6(5-8(9)14)4-7-10(15)13-11(16)12-7/h2-5,14H,1H3,(H2,12,13,15,16)/b7-4-
DMK9XV8	CS	COC1=C(C=C(C=C1)/C=C\\2/C(=O)NC(=O)N2)O
DMK9XV8	IK	CVEPZWFFKVWAMM-DAXSKMNVSA-N
DMK9XV8	IU	(5Z)-5-[(3-hydroxy-4-methoxyphenyl)methylidene]imidazolidine-2,4-dione
DMK9XV8	CA	CAS 4368-00-7
DMK9XV8	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMES41R	ID	DMES41R
DMES41R	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7
DMES41R	HS	Patented
DMES41R	SN	PMID26815044-Compound-71
DMES41R	DT	Small molecular drug
DMES41R	PC	89613043
DMES41R	MW	219.19
DMES41R	FM	C11H9NO4
DMES41R	IC	InChI=1S/C11H9NO4/c13-8-2-1-6(9(14)5-8)3-7-4-10(15)12-11(7)16/h1-3,5,13-14H,4H2,(H,12,15,16)/b7-3+
DMES41R	CS	C1/C(=C\\C2=C(C=C(C=C2)O)O)/C(=O)NC1=O
DMES41R	IK	PTHHGONJHHJYIU-XVNBXDOJSA-N
DMES41R	IU	(3E)-3-[(2,4-dihydroxyphenyl)methylidene]pyrrolidine-2,5-dione
DMES41R	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMRIPVG	ID	DMRIPVG
DMRIPVG	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8
DMRIPVG	HS	Patented
DMRIPVG	SN	PMID26815044-Compound-72
DMRIPVG	DT	Small molecular drug
DMRIPVG	PC	89928116
DMRIPVG	MW	233.22
DMRIPVG	FM	C12H11NO4
DMRIPVG	IC	InChI=1S/C12H11NO4/c1-17-10-3-2-7(5-9(10)14)4-8-6-11(15)13-12(8)16/h2-5,14H,6H2,1H3,(H,13,15,16)/b8-4+
DMRIPVG	CS	COC1=C(C=C(C=C1)/C=C/2\\CC(=O)NC2=O)O
DMRIPVG	IK	NXKPYDPDZWALNH-XBXARRHUSA-N
DMRIPVG	IU	(3E)-3-[(3-hydroxy-4-methoxyphenyl)methylidene]pyrrolidine-2,5-dione
DMRIPVG	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM7U20W	ID	DM7U20W
DM7U20W	DN	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9
DM7U20W	HS	Patented
DM7U20W	SN	PMID26815044-Compound-73
DM7U20W	DT	Small molecular drug
DM7U20W	PC	5331378
DM7U20W	MW	264.26
DM7U20W	FM	C11H8N2O4S
DM7U20W	IC	InChI=1S/C11H8N2O4S/c14-7-2-1-5(4-8(7)15)3-6-9(16)12-11(18)13-10(6)17/h1-4,14-15H,(H2,12,13,16,17,18)
DM7U20W	CS	C1=CC(=C(C=C1C=C2C(=O)NC(=S)NC2=O)O)O
DM7U20W	IK	DELWWBDBFMAAMG-UHFFFAOYSA-N
DM7U20W	IU	5-[(3,4-dihydroxyphenyl)methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
DM7U20W	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMJG1ZS	ID	DMJG1ZS
DMJG1ZS	DN	Biaromatic compound 1
DMJG1ZS	HS	Patented
DMJG1ZS	SN	PMID25416646-Compound-Figure2-A
DMJG1ZS	CP	Galderma Researh & Development
DMJG1ZS	DT	Small molecular drug

DMHEAJQ	ID	DMHEAJQ
DMHEAJQ	DN	Biaryl compound 1
DMHEAJQ	HS	Patented
DMHEAJQ	SN	PMID30107136-Compound-Example10
DMHEAJQ	CP	BRISTOL-MYERS SQUIBB COMPANY
DMHEAJQ	DT	Small molecule immunotherapy 
DMHEAJQ	PC	134298944
DMHEAJQ	MW	900.8
DMHEAJQ	FM	C49H43Cl2N5O8
DMHEAJQ	IC	InChI=1S/C49H43Cl2N5O8/c1-29-36(26-63-46-15-44(61-24-34-11-32(17-52)19-54-21-34)38(13-42(46)50)23-56-49(4,28-57)48(59)60)7-5-9-39(29)40-10-6-8-37(30(40)2)27-64-47-16-45(41(31(3)58)14-43(47)51)62-25-35-12-33(18-53)20-55-22-35/h5-16,19-22,56-57H,23-28H2,1-4H3,(H,59,60)
DMHEAJQ	CS	CC1=C(C=CC=C1C2=CC=CC(=C2C)COC3=C(C=C(C(=C3)OCC4=CC(=CN=C4)C#N)C(=O)C)Cl)COC5=C(C=C(C(=C5)OCC6=CC(=CN=C6)C#N)CNC(C)(CO)C(=O)O)Cl
DMHEAJQ	IK	LBEJCLGFPBJTDE-UHFFFAOYSA-N
DMHEAJQ	IU	2-[[4-[[3-[3-[[4-acetyl-2-chloro-5-[(5-cyanopyridin-3-yl)methoxy]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid
DMHEAJQ	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMS8VYE	ID	DMS8VYE
DMS8VYE	DN	Biaryl compound 2
DMS8VYE	HS	Patented
DMS8VYE	SN	PMID30107136-Compound-Example9
DMS8VYE	CP	BRISTOL-MYERS SQUIBB COMPANY
DMS8VYE	DT	Small molecule immunotherapy 
DMS8VYE	PC	134282588
DMS8VYE	MW	989.9
DMS8VYE	FM	C52H50Cl2N6O10
DMS8VYE	IC	InChI=1S/C52H50Cl2N6O10/c1-31-37(27-69-47-15-45(67-25-35-11-33(17-55)19-57-21-35)39(13-43(47)53)23-59-51(3,29-61)49(63)64)7-5-9-41(31)42-10-6-8-38(32(42)2)28-70-48-16-46(68-26-36-12-34(18-56)20-58-22-36)40(14-44(48)54)24-60-52(4,30-62)50(65)66/h5-16,19-22,59-62H,23-30H2,1-4H3,(H,63,64)(H,65,66)
DMS8VYE	CS	CC1=C(C=CC=C1C2=CC=CC(=C2C)COC3=C(C=C(C(=C3)OCC4=CC(=CN=C4)C#N)CNC(C)(CO)C(=O)O)Cl)COC5=C(C=C(C(=C5)OCC6=CC(=CN=C6)C#N)CNC(C)(CO)C(=O)O)Cl
DMS8VYE	IK	JQCFAYBBTOJHLG-UHFFFAOYSA-N
DMS8VYE	IU	2-[[4-[[3-[3-[[4-[[(2-carboxy-1-hydroxypropan-2-yl)amino]methyl]-2-chloro-5-[(5-cyanopyridin-3-yl)methoxy]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid
DMS8VYE	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMX6YGS	ID	DMX6YGS
DMX6YGS	DN	Biaryl mannoside derivative 1
DMX6YGS	HS	Patented
DMX6YGS	SN	PMID26651364-Compound-2a
DMX6YGS	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMX6YGS	DT	Carbohydrates
DMX6YGS	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMPF37N	ID	DMPF37N
DMPF37N	DN	Biaryl mannoside derivative 10
DMPF37N	HS	Patented
DMPF37N	SN	PMID26651364-Compound-3b
DMPF37N	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMPF37N	DT	Carbohydrates
DMPF37N	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMKES0G	ID	DMKES0G
DMKES0G	DN	Biaryl mannoside derivative 11
DMKES0G	HS	Patented
DMKES0G	SN	PMID26651364-Compound-3c
DMKES0G	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMKES0G	DT	Carbohydrates
DMKES0G	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM5T29W	ID	DM5T29W
DM5T29W	DN	Biaryl mannoside derivative 12
DM5T29W	HS	Patented
DM5T29W	SN	PMID26651364-Compound-3d
DM5T29W	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM5T29W	DT	Carbohydrates
DM5T29W	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM1Y8OM	ID	DM1Y8OM
DM1Y8OM	DN	Biaryl mannoside derivative 13
DM1Y8OM	HS	Patented
DM1Y8OM	SN	PMID26651364-Compound-3e
DM1Y8OM	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM1Y8OM	DT	Carbohydrates
DM1Y8OM	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM4C5QY	ID	DM4C5QY
DM4C5QY	DN	Biaryl mannoside derivative 14
DM4C5QY	HS	Patented
DM4C5QY	SN	PMID26651364-Compound-3f
DM4C5QY	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM4C5QY	DT	Carbohydrates
DM4C5QY	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMKXT7H	ID	DMKXT7H
DMKXT7H	DN	Biaryl mannoside derivative 15
DMKXT7H	HS	Patented
DMKXT7H	SN	PMID26651364-Compound-3g
DMKXT7H	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMKXT7H	DT	Carbohydrates
DMKXT7H	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMP9742	ID	DMP9742
DMP9742	DN	Biaryl mannoside derivative 16
DMP9742	HS	Patented
DMP9742	SN	PMID26651364-Compound-3h
DMP9742	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMP9742	DT	Carbohydrates
DMP9742	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMIXV6G	ID	DMIXV6G
DMIXV6G	DN	Biaryl mannoside derivative 17
DMIXV6G	HS	Patented
DMIXV6G	SN	PMID26651364-Compound-3i
DMIXV6G	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMIXV6G	DT	Carbohydrates
DMIXV6G	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMHOPE0	ID	DMHOPE0
DMHOPE0	DN	Biaryl mannoside derivative 18
DMHOPE0	HS	Patented
DMHOPE0	SN	PMID26651364-Compound-40
DMHOPE0	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMHOPE0	DT	Carbohydrates
DMHOPE0	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DME8DQ0	ID	DME8DQ0
DME8DQ0	DN	Biaryl mannoside derivative 19
DME8DQ0	HS	Patented
DME8DQ0	SN	PMID26651364-Compound-41
DME8DQ0	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DME8DQ0	DT	Carbohydrates
DME8DQ0	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMB60X	ID	DMMB60X
DMMB60X	DN	Biaryl mannoside derivative 2
DMMB60X	HS	Patented
DMMB60X	SN	PMID26651364-Compound-2b
DMMB60X	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMMB60X	DT	Carbohydrates
DMMB60X	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMNC5S0	ID	DMNC5S0
DMNC5S0	DN	Biaryl mannoside derivative 20
DMNC5S0	HS	Patented
DMNC5S0	SN	PMID26651364-Compound-42
DMNC5S0	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMNC5S0	DT	Carbohydrates
DMNC5S0	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMGSLHN	ID	DMGSLHN
DMGSLHN	DN	Biaryl mannoside derivative 21
DMGSLHN	HS	Patented
DMGSLHN	SN	PMID26651364-Compound-43
DMGSLHN	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMGSLHN	DT	Carbohydrates
DMGSLHN	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMYLVB3	ID	DMYLVB3
DMYLVB3	DN	Biaryl mannoside derivative 22
DMYLVB3	HS	Patented
DMYLVB3	SN	PMID26651364-Compound-44
DMYLVB3	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMYLVB3	DT	Carbohydrates
DMYLVB3	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM2YVGH	ID	DM2YVGH
DM2YVGH	DN	Biaryl mannoside derivative 23
DM2YVGH	HS	Patented
DM2YVGH	SN	PMID26651364-Compound-59
DM2YVGH	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DM2YVGH	DT	Carbohydrates
DM2YVGH	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMF5TB4	ID	DMF5TB4
DMF5TB4	DN	Biaryl mannoside derivative 24
DMF5TB4	HS	Patented
DMF5TB4	SN	PMID26651364-Compound-60
DMF5TB4	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMF5TB4	DT	Carbohydrates
DMF5TB4	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMRM3E9	ID	DMRM3E9
DMRM3E9	DN	Biaryl mannoside derivative 25
DMRM3E9	HS	Patented
DMRM3E9	SN	PMID26651364-Compound-61
DMRM3E9	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMRM3E9	DT	Carbohydrates
DMRM3E9	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMYXLCJ	ID	DMYXLCJ
DMYXLCJ	DN	Biaryl mannoside derivative 26
DMYXLCJ	HS	Patented
DMYXLCJ	SN	PMID26651364-Compound-62
DMYXLCJ	CP	WASHINGTON UNIVERSITY
DMYXLCJ	DT	Carbohydrates
DMYXLCJ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMTDPHY	ID	DMTDPHY
DMTDPHY	DN	Biaryl mannoside derivative 27
DMTDPHY	HS	Patented
DMTDPHY	SN	PMID26651364-Compound-63
DMTDPHY	CP	WASHINGTON UNIVERSITY
DMTDPHY	DT	Carbohydrates
DMTDPHY	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMSNMZ2	ID	DMSNMZ2
DMSNMZ2	DN	Biaryl mannoside derivative 28
DMSNMZ2	HS	Patented
DMSNMZ2	SN	PMID26651364-Compound-64
DMSNMZ2	CP	WASHINGTON UNIVERSITY
DMSNMZ2	DT	Carbohydrates
DMSNMZ2	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMCLTY3	ID	DMCLTY3
DMCLTY3	DN	Biaryl mannoside derivative 29
DMCLTY3	HS	Patented
DMCLTY3	SN	PMID26651364-Compound-65
DMCLTY3	CP	WASHINGTON UNIVERSITY
DMCLTY3	DT	Carbohydrates
DMCLTY3	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMAITK3	ID	DMAITK3
DMAITK3	DN	Biaryl mannoside derivative 3
DMAITK3	HS	Patented
DMAITK3	SN	PMID26651364-Compound-2c
DMAITK3	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMAITK3	DT	Carbohydrates
DMAITK3	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMPLAWQ	ID	DMPLAWQ
DMPLAWQ	DN	Biaryl mannoside derivative 30
DMPLAWQ	HS	Patented
DMPLAWQ	SN	PMID26651364-Compound-66
DMPLAWQ	CP	WASHINGTON UNIVERSITY
DMPLAWQ	DT	Carbohydrates
DMPLAWQ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMPJ3E	ID	DMMPJ3E
DMMPJ3E	DN	Biaryl mannoside derivative 31
DMMPJ3E	HS	Patented
DMMPJ3E	SN	PMID26651364-Compound-67
DMMPJ3E	CP	WASHINGTON UNIVERSITY
DMMPJ3E	DT	Carbohydrates
DMMPJ3E	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMVF63N	ID	DMVF63N
DMVF63N	DN	Biaryl mannoside derivative 4
DMVF63N	HS	Patented
DMVF63N	SN	PMID26651364-Compound-2d
DMVF63N	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMVF63N	DT	Carbohydrates
DMVF63N	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMRS1WG	ID	DMRS1WG
DMRS1WG	DN	Biaryl mannoside derivative 5
DMRS1WG	HS	Patented
DMRS1WG	SN	PMID26651364-Compound-2e
DMRS1WG	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMRS1WG	DT	Carbohydrates
DMRS1WG	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMEWA7U	ID	DMEWA7U
DMEWA7U	DN	Biaryl mannoside derivative 6
DMEWA7U	HS	Patented
DMEWA7U	SN	PMID26651364-Compound-2f
DMEWA7U	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMEWA7U	DT	Carbohydrates
DMEWA7U	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMD7053	ID	DMD7053
DMD7053	DN	Biaryl mannoside derivative 7
DMD7053	HS	Patented
DMD7053	SN	PMID26651364-Compound-2g
DMD7053	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMD7053	DT	Carbohydrates
DMD7053	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMWF2VG	ID	DMWF2VG
DMWF2VG	DN	Biaryl mannoside derivative 8
DMWF2VG	HS	Patented
DMWF2VG	SN	PMID26651364-Compound-2h
DMWF2VG	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMWF2VG	DT	Carbohydrates
DMWF2VG	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM1Q7AL	ID	DM1Q7AL
DM1Q7AL	DN	Biaryl mannoside derivative 9
DM1Q7AL	HS	Patented
DM1Q7AL	SN	PMID26651364-Compound-3a
DM1Q7AL	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM1Q7AL	DT	Carbohydrates
DM1Q7AL	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMDK7LQ	ID	DMDK7LQ
DMDK7LQ	DN	Bicarboxylic and tricarboxylic ethynyl derivative 1
DMDK7LQ	HS	Patented
DMDK7LQ	SN	PMID28067079-Compound-24
DMDK7LQ	CP	H. LUNDBECK A/S
DMDK7LQ	DT	Small molecular drug

DMG9O7D	ID	DMG9O7D
DMG9O7D	DN	Bicarboxylic and tricarboxylic ethynyl derivative 2
DMG9O7D	HS	Patented
DMG9O7D	SN	PMID28067079-Compound-25
DMG9O7D	CP	H. LUNDBECK A/S
DMG9O7D	DT	Small molecular drug
DMG9O7D	PC	117702606
DMG9O7D	MW	331.4
DMG9O7D	FM	C21H21N3O
DMG9O7D	IC	InChI=1S/C21H21N3O/c25-19(18-7-2-4-15-23-18)24-21-10-5-9-20(16-21,12-13-21)11-8-17-6-1-3-14-22-17/h1-4,6-7,14-15H,5,9-10,12-13,16H2,(H,24,25)/t20-,21+/m1/s1
DMG9O7D	CS	C1C[C@]2(CC[C@@](C1)(C2)NC(=O)C3=CC=CC=N3)C#CC4=CC=CC=N4
DMG9O7D	IK	ISUZZRVMDCKBEJ-RTWAWAEBSA-N
DMG9O7D	IU	N-[(1S,5R)-5-(2-pyridin-2-ylethynyl)-1-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide

DM1KVTZ	ID	DM1KVTZ
DM1KVTZ	DN	Bicarboxylic and tricarboxylic ethynyl derivative 3
DM1KVTZ	HS	Patented
DM1KVTZ	SN	PMID28067079-Compound-26
DM1KVTZ	CP	H. LUNDBECK A/S
DM1KVTZ	DT	Small molecular drug
DM1KVTZ	PC	71536957
DM1KVTZ	MW	372.5
DM1KVTZ	FM	C23H24N4O
DM1KVTZ	IC	InChI=1S/C23H24N4O/c1-16-12-25-14-20(26-16)21(28)27-23-10-18-7-19(11-23)9-22(8-18,15-23)5-4-17-3-2-6-24-13-17/h2-3,6,12-14,18-19H,7-11,15H2,1H3,(H,27,28)
DM1KVTZ	CS	CC1=CN=CC(=N1)C(=O)NC23CC4CC(C2)CC(C4)(C3)C#CC5=CN=CC=C5
DM1KVTZ	IK	LHOOHRUEDKJGBG-UHFFFAOYSA-N
DM1KVTZ	IU	6-methyl-N-[3-(2-pyridin-3-ylethynyl)-1-adamantyl]pyrazine-2-carboxamide

DMOFI09	ID	DMOFI09
DMOFI09	DN	Bicyclic heteroaryl amide derivative 1
DMOFI09	HS	Patented
DMOFI09	SN	PMID27724045-Compound-23
DMOFI09	CP	H. LUNDBECK A/S
DMOFI09	DT	Small molecular drug
DMOFI09	PC	25164165
DMOFI09	MW	425.5
DMOFI09	FM	C26H27N5O
DMOFI09	IC	InChI=1S/C26H27N5O/c1-19-8-5-10-22-23(19)21(17-31(22)25-28-14-7-15-29-25)24(32)30-18-26(11-3-2-4-12-26)20-9-6-13-27-16-20/h5-10,13-17H,2-4,11-12,18H2,1H3,(H,30,32)
DMOFI09	CS	CC1=C2C(=CC=C1)N(C=C2C(=O)NCC3(CCCCC3)C4=CN=CC=C4)C5=NC=CC=N5
DMOFI09	IK	OIKQYDBRBPIGDB-UHFFFAOYSA-N
DMOFI09	IU	4-methyl-N-[(1-pyridin-3-ylcyclohexyl)methyl]-1-pyrimidin-2-ylindole-3-carboxamide

DM69HL5	ID	DM69HL5
DM69HL5	DN	Bicyclic heteroaryl amide derivative 2
DM69HL5	HS	Patented
DM69HL5	SN	PMID27724045-Compound-24
DM69HL5	CP	H. LUNDBECK A/S
DM69HL5	DT	Small molecular drug
DM69HL5	PC	89521474
DM69HL5	MW	426.5
DM69HL5	FM	C24H31FN4O2
DM69HL5	IC	InChI=1S/C24H31FN4O2/c1-24(2)16-7-6-15(18(24)12-16)13-26-22(30)20-4-3-5-21-27-19(14-29(20)21)23(31)28-10-8-17(25)9-11-28/h3-5,14-18H,6-13H2,1-2H3,(H,26,30)/t15-,16-,18-/m0/s1
DM69HL5	CS	CC1([C@H]2CC[C@H]([C@@H]1C2)CNC(=O)C3=CC=CC4=NC(=CN43)C(=O)N5CCC(CC5)F)C
DM69HL5	IK	AOWWKPWFEIOIDV-BQFCYCMXSA-N
DM69HL5	IU	N-[[(1S,2R,5S)-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]methyl]-2-(4-fluoropiperidine-1-carbonyl)imidazo[1,2-a]pyridine-5-carboxamide

DM0OYCX	ID	DM0OYCX
DM0OYCX	DN	Bicyclic heteroaryl amide derivative 3
DM0OYCX	HS	Patented
DM0OYCX	SN	PMID27724045-Compound-25
DM0OYCX	CP	H. LUNDBECK A/S
DM0OYCX	DT	Small molecular drug
DM0OYCX	PC	25097947
DM0OYCX	MW	421.5
DM0OYCX	FM	C24H31N5O2
DM0OYCX	IC	InChI=1S/C24H31N5O2/c25-18-3-5-28(14-18)23(31)20-9-21-19(2-1-4-29(21)27-20)26-22(30)13-24-10-15-6-16(11-24)8-17(7-15)12-24/h1-2,4,9,15-18H,3,5-8,10-14,25H2,(H,26,30)/t15?,16?,17?,18-,24?/m1/s1
DM0OYCX	CS	C1CN(C[C@@H]1N)C(=O)C2=NN3C=CC=C(C3=C2)NC(=O)CC45CC6CC(C4)CC(C6)C5
DM0OYCX	IK	CHANXFBBIWKIAI-ZWGBCBFGSA-N
DM0OYCX	IU	2-(1-adamantyl)-N-[2-[(3R)-3-aminopyrrolidine-1-carbonyl]pyrazolo[1,5-a]pyridin-4-yl]acetamide

DMTBWC9	ID	DMTBWC9
DMTBWC9	DN	Bicyclic heteroaryl benzamide derivative 1
DMTBWC9	HS	Patented
DMTBWC9	SN	PMID28270021-Compound-WO2015148354Example21(R or S)
DMTBWC9	CP	MERCK SHARP & DOHME CORP
DMTBWC9	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM5MT4R	ID	DM5MT4R
DM5MT4R	DN	Bicyclic heteroaryl benzamide derivative 2
DM5MT4R	HS	Patented
DM5MT4R	SN	PMID28270021-Compound-WO2015148354Example33(R or S)
DM5MT4R	CP	MERCK SHARP & DOHME CORP
DM5MT4R	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM54EV2	ID	DM54EV2
DM54EV2	DN	Bicyclic heteroaryl benzamide derivative 3
DM54EV2	HS	Patented
DM54EV2	SN	PMID28270021-Compound-WO2015148354Example41
DM54EV2	CP	MERCK SHARP & DOHME CORP
DM54EV2	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMUBDYG	ID	DMUBDYG
DMUBDYG	DN	Bicyclic heteroaryl benzamide derivative 4
DMUBDYG	HS	Patented
DMUBDYG	SN	PMID28270021-Compound-WO2015148354Example99
DMUBDYG	CP	MERCK SHARP & DOHME CORP
DMUBDYG	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMFOVPT	ID	DMFOVPT
DMFOVPT	DN	Bicyclic heteroaryl benzamide derivative 5
DMFOVPT	HS	Patented
DMFOVPT	SN	PMID28270021-Compound-WO2015148373Example104
DMFOVPT	CP	MERCK SHARP & DOHME CORP
DMFOVPT	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMQGYWV	ID	DMQGYWV
DMQGYWV	DN	Bicyclic heteroaryl benzamide derivative 6
DMQGYWV	HS	Patented
DMQGYWV	SN	PMID28270021-Compound-WO2015148373Example111
DMQGYWV	CP	MERCK SHARP & DOHME CORP
DMQGYWV	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMM1LKF	ID	DMM1LKF
DMM1LKF	DN	Bicyclic heteroaryl benzamide derivative 7
DMM1LKF	HS	Patented
DMM1LKF	SN	PMID28270021-Compound-WO2015148373Example36
DMM1LKF	CP	MERCK SHARP & DOHME CORP
DMM1LKF	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMVBQJ1	ID	DMVBQJ1
DMVBQJ1	DN	Bicyclic heteroaryl benzamide derivative 8
DMVBQJ1	HS	Patented
DMVBQJ1	SN	PMID28270021-Compound-WO2015148373Example41(S)
DMVBQJ1	CP	MERCK SHARP & DOHME CORP
DMVBQJ1	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMGONY4	ID	DMGONY4
DMGONY4	DN	Bicyclic heteroaryl benzamide derivative 9
DMGONY4	HS	Patented
DMGONY4	SN	PMID28270021-Compound-WO2015148373Example42(R)
DMGONY4	CP	MERCK SHARP & DOHME CORP
DMGONY4	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMB5XDM	ID	DMB5XDM
DMB5XDM	DN	Bicyclic heteroaryl carboxamide analog 1
DMB5XDM	HS	Patented
DMB5XDM	SN	PMID28067079-Compound-101
DMB5XDM	DT	Small molecular drug
DMB5XDM	PC	50990953
DMB5XDM	MW	330.3
DMB5XDM	FM	C15H11FN4O2S
DMB5XDM	IC	InChI=1S/C15H11FN4O2S/c1-9-7-23-15(19-9)20-14(21)10-2-11(16)4-12(3-10)22-13-5-17-8-18-6-13/h2-8H,1H3,(H,19,20,21)
DMB5XDM	CS	CC1=CSC(=N1)NC(=O)C2=CC(=CC(=C2)F)OC3=CN=CN=C3
DMB5XDM	IK	AXVLPJHYYFHCHK-UHFFFAOYSA-N
DMB5XDM	IU	3-fluoro-N-(4-methyl-1,3-thiazol-2-yl)-5-pyrimidin-5-yloxybenzamide

DMKT7MD	ID	DMKT7MD
DMKT7MD	DN	Bicyclic heteroaryl carboxamide analog 2
DMKT7MD	HS	Patented
DMKT7MD	SN	PMID28067079-Compound-102
DMKT7MD	DT	Small molecular drug
DMKT7MD	PC	60197821
DMKT7MD	MW	342.3
DMKT7MD	FM	C17H12F2N4O2
DMKT7MD	IC	InChI=1S/C17H12F2N4O2/c1-10-4-13(25-14-5-12(19)7-20-9-14)6-15(22-10)17(24)23-16-3-2-11(18)8-21-16/h2-9H,1H3,(H,21,23,24)
DMKT7MD	CS	CC1=CC(=CC(=N1)C(=O)NC2=NC=C(C=C2)F)OC3=CC(=CN=C3)F
DMKT7MD	IK	MBSANIMQXDBICP-UHFFFAOYSA-N
DMKT7MD	IU	N-(5-fluoropyridin-2-yl)-4-(5-fluoropyridin-3-yl)oxy-6-methylpyridine-2-carboxamide

DM3QMA0	ID	DM3QMA0
DM3QMA0	DN	Bicyclic heteroaryl carboxamide analog 3
DM3QMA0	HS	Patented
DM3QMA0	SN	PMID28067079-Compound-114
DM3QMA0	DT	Small molecular drug
DM3QMA0	PC	91886057
DM3QMA0	MW	397.4
DM3QMA0	FM	C19H13F2N5OS
DM3QMA0	IC	InChI=1S/C19H13F2N5OS/c1-11-9-28-18(25-11)26-17(27)15-6-13(5-12-3-2-4-24-16(12)15)19(20,21)14-7-22-10-23-8-14/h2-10H,1H3,(H,25,26,27)
DM3QMA0	CS	CC1=CSC(=N1)NC(=O)C2=C3C(=CC(=C2)C(C4=CN=CN=C4)(F)F)C=CC=N3
DM3QMA0	IK	WMANVHZDYKNLDT-UHFFFAOYSA-N
DM3QMA0	IU	6-[difluoro(pyrimidin-5-yl)methyl]-N-(4-methyl-1,3-thiazol-2-yl)quinoline-8-carboxamide

DMWTCM8	ID	DMWTCM8
DMWTCM8	DN	Bicyclic hexapeptide derivative 1
DMWTCM8	HS	Patented
DMWTCM8	SN	PMID25726713-Compound-40
DMWTCM8	DT	Small molecular drug

DMJP1IK	ID	DMJP1IK
DMJP1IK	DN	Bicyclic hexapeptide derivative 2
DMJP1IK	HS	Patented
DMJP1IK	SN	PMID25726713-Compound-41
DMJP1IK	DT	Small molecular drug

DMAJ74C	ID	DMAJ74C
DMAJ74C	DN	Bicyclic pyrimidine derivative 1
DMAJ74C	HS	Patented
DMAJ74C	SN	PMID25470667-Compound-Figure6-21
DMAJ74C	CP	DAINIPPON SUMITOMO PHARMA CO [JP]
DMAJ74C	DT	Small molecular drug

DMJP16K	ID	DMJP16K
DMJP16K	DN	Bicyclic pyrimidine derivative 2
DMJP16K	HS	Patented
DMJP16K	SN	PMID27718763-Compound-4
DMJP16K	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
DMJP16K	DT	Small molecular drug
DMJP16K	PC	76853231
DMJP16K	MW	464.4
DMJP16K	FM	C22H20F4N4O3
DMJP16K	IC	InChI=1S/C22H20F4N4O3/c1-21(2)12-30-19(29(21)3)8-18(28-20(30)31)32-11-13-4-5-17(16(23)6-13)33-15-7-14(9-27-10-15)22(24,25)26/h4-10H,11-12H2,1-3H3
DMJP16K	CS	CC1(CN2C(=CC(=NC2=O)OCC3=CC(=C(C=C3)OC4=CN=CC(=C4)C(F)(F)F)F)N1C)C
DMJP16K	IK	PPKNPJKYLRQSCE-UHFFFAOYSA-N
DMJP16K	IU	7-[[3-fluoro-4-[5-(trifluoromethyl)pyridin-3-yl]oxyphenyl]methoxy]-1,2,2-trimethyl-3H-imidazo[1,2-c]pyrimidin-5-one

DMGESCP	ID	DMGESCP
DMGESCP	DN	Bicyclo-heptan-2-amine derivative 1
DMGESCP	HS	Patented
DMGESCP	SN	PMID28051882-Compound-19
DMGESCP	DT	Small molecular drug
DMGESCP	PC	57519221
DMGESCP	MW	312.5
DMGESCP	FM	C21H32N2
DMGESCP	IC	InChI=1S/C21H32N2/c1-3-8-19(9-4-1)21(17-18-10-11-20(21)16-18)22-12-7-15-23-13-5-2-6-14-23/h1,3-4,8-9,18,20,22H,2,5-7,10-17H2
DMGESCP	CS	C1CCN(CC1)CCCNC2(CC3CCC2C3)C4=CC=CC=C4
DMGESCP	IK	XUIHNTYMWPNMJK-UHFFFAOYSA-N
DMGESCP	IU	2-phenyl-N-(3-piperidin-1-ylpropyl)bicyclo[2.2.1]heptan-2-amine

DM9WUH5	ID	DM9WUH5
DM9WUH5	DN	Bicyclo-heptan-2-amine derivative 2
DM9WUH5	HS	Patented
DM9WUH5	SN	PMID28051882-Compound-20
DM9WUH5	DT	Small molecular drug
DM9WUH5	PC	57519222
DM9WUH5	MW	330.5
DM9WUH5	FM	C21H31FN2
DM9WUH5	IC	InChI=1S/C21H31FN2/c22-20-9-7-18(8-10-20)21(16-17-5-6-19(21)15-17)23-11-4-14-24-12-2-1-3-13-24/h7-10,17,19,23H,1-6,11-16H2
DM9WUH5	CS	C1CCN(CC1)CCCNC2(CC3CCC2C3)C4=CC=C(C=C4)F
DM9WUH5	IK	DJXNOCLZKSUJMI-UHFFFAOYSA-N
DM9WUH5	IU	2-(4-fluorophenyl)-N-(3-piperidin-1-ylpropyl)bicyclo[2.2.1]heptan-2-amine

DM8ZRXE	ID	DM8ZRXE
DM8ZRXE	DN	Bicyclo-heptan-2-amine derivative 3
DM8ZRXE	HS	Patented
DM8ZRXE	SN	PMID28051882-Compound-21
DM8ZRXE	DT	Small molecular drug

DMPRIS0	ID	DMPRIS0
DMPRIS0	DN	Bicyclo-heptan-2-amine derivative 4
DMPRIS0	HS	Patented
DMPRIS0	SN	PMID28051882-Compound-IX
DMPRIS0	DT	Small molecular drug

DMB08D3	ID	DMB08D3
DMB08D3	DN	Bidentate ligands of Markush derivative 1
DMB08D3	HS	Patented
DMB08D3	SN	PMID28117607-Compound-35
DMB08D3	CP	THE SCRIPPS RESEARCH INSTITUTE
DMB08D3	DT	Small molecular drug

DM2QNMC	ID	DM2QNMC
DM2QNMC	DN	Bidentate ligands of Markush derivative 2
DM2QNMC	HS	Patented
DM2QNMC	SN	PMID28117607-Compound-36
DM2QNMC	CP	THE SCRIPPS RESEARCH INSTITUTE
DM2QNMC	DT	Small molecular drug

DMPWKAH	ID	DMPWKAH
DMPWKAH	DN	Bidentate pyrazolopyrimidine acetamide analog 1
DMPWKAH	HS	Patented
DMPWKAH	SN	PMID27607364-Compound-142
DMPWKAH	DT	Small molecular drug

DM6SPTJ	ID	DM6SPTJ
DM6SPTJ	DN	Bidentate pyrazolopyrimidine acetamide analog 2
DM6SPTJ	HS	Patented
DM6SPTJ	SN	PMID27607364-Compound-143
DM6SPTJ	DT	Small molecular drug

DMC7UHT	ID	DMC7UHT
DMC7UHT	DN	Bidentate pyrazolopyrimidine acetamide analog 3
DMC7UHT	HS	Patented
DMC7UHT	SN	PMID27607364-Compound-144
DMC7UHT	DT	Small molecular drug

DMKZLCQ	ID	DMKZLCQ
DMKZLCQ	DN	Bidentate pyrazolopyrimidine acetamide analog 4
DMKZLCQ	HS	Patented
DMKZLCQ	SN	PMID27607364-Compound-145
DMKZLCQ	DT	Small molecular drug
DMKZLCQ	PC	58299418
DMKZLCQ	MW	744.9
DMKZLCQ	FM	C43H52N8O4
DMKZLCQ	IC	InChI=1S/C43H52N8O4/c1-9-48(10-2)38(52)26-36-40(46-50-30(7)24-28(5)44-42(36)50)32-14-18-34(19-15-32)54-22-13-23-55-35-20-16-33(17-21-35)41-37(27-39(53)49(11-3)12-4)43-45-29(6)25-31(8)51(43)47-41/h14-21,24-25H,9-13,22-23,26-27H2,1-8H3
DMKZLCQ	CS	CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC=C(C=C3)OCCCOC4=CC=C(C=C4)C5=NN6C(=CC(=NC6=C5CC(=O)N(CC)CC)C)C)C)C
DMKZLCQ	IK	NTCLVQPBPKMEFJ-UHFFFAOYSA-N
DMKZLCQ	IU	2-[2-[4-[3-[4-[3-[2-(diethylamino)-2-oxoethyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl]phenoxy]propoxy]phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]-N,N-diethylacetamide

DM5WN0U	ID	DM5WN0U
DM5WN0U	DN	Binuclear gold(I) compound 1
DM5WN0U	HS	Patented
DM5WN0U	SN	PMID27977313-Compound-15
DM5WN0U	CP	THE UNIVERSITY OF HONG KON
DM5WN0U	DT	Small molecular drug

DM5WAGC	ID	DM5WAGC
DM5WAGC	DN	Binuclear gold(I) compound 2
DM5WAGC	HS	Patented
DM5WAGC	SN	PMID27977313-Compound-16
DM5WAGC	CP	THE UNIVERSITY OF HONG KON
DM5WAGC	DT	Small molecular drug

DM94TKW	ID	DM94TKW
DM94TKW	DN	Binuclear gold(I) compound 3
DM94TKW	HS	Patented
DM94TKW	SN	PMID27977313-Compound-Figure4f
DM94TKW	CP	THE UNIVERSITY OF HONG KON
DM94TKW	DT	Small molecular drug

DM1VYZ9	ID	DM1VYZ9
DM1VYZ9	DN	Biphenyl 1,2-diamine derivative 1
DM1VYZ9	HS	Patented
DM1VYZ9	SN	PMID29473428-Compound-66
DM1VYZ9	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DM1VYZ9	DT	Small molecular drug
DM1VYZ9	PC	126722195
DM1VYZ9	MW	490.7
DM1VYZ9	FM	C28H34N4O2S
DM1VYZ9	IC	InChI=1S/C28H34N4O2S/c1-18(2)17-32(21-8-4-3-5-9-21)25-15-14-20(22-10-6-7-11-23(22)27(33)34)16-24(25)29-28-31-30-26(35-28)19-12-13-19/h6-7,10-11,14-16,18-19,21H,3-5,8-9,12-13,17H2,1-2H3,(H,29,31)(H,33,34)
DM1VYZ9	CS	CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)C3=CC=CC=C3C(=O)O)NC4=NN=C(S4)C5CC5
DM1VYZ9	IK	PWIBECCFTAUDGG-UHFFFAOYSA-N
DM1VYZ9	IU	2-[4-[cyclohexyl(2-methylpropyl)amino]-3-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)amino]phenyl]benzoic acid

DM6803W	ID	DM6803W
DM6803W	DN	Biphenyl carboxamidopropanoic acid derivative 1
DM6803W	HS	Patented
DM6803W	SN	PMID25828189-Compound-6
DM6803W	CP	JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj GRECO, Michael, N. SHOOK, Brian XU, Guozhang ZHANG, RuJANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj KREUTTER, Kevin POWELL, Mark SHOOK, Brian SONG, Fengbin XU, Guozhang YANG, Shyh-ming ZHANG, Rui ZHAO, Bao-pin
DM6803W	DT	Small molecular drug

DMQF2XN	ID	DMQF2XN
DMQF2XN	DN	Biphenyl carboxamidopropanoic acid derivative 2
DMQF2XN	HS	Patented
DMQF2XN	SN	PMID25828189-Compound-7
DMQF2XN	CP	JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj GRECO, Michael, N. SHOOK, Brian XU, Guozhang ZHANG, Rui
DMQF2XN	DT	Small molecular drug
DMQF2XN	PC	71472289
DMQF2XN	MW	635
DMQF2XN	FM	C32H25ClF6N2O3
DMQF2XN	IC	InChI=1S/C32H25ClF6N2O3/c1-18-14-22(31(34,35)36)8-10-25(18)26-11-9-24(16-28(26)33)41-17-21-6-7-23(32(37,38)39)15-27(21)19-2-4-20(5-3-19)30(44)40-13-12-29(42)43/h2-11,14-16,41H,12-13,17H2,1H3,(H,40,44)(H,42,43)
DMQF2XN	CS	CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=C(C=C2)NCC3=C(C=C(C=C3)C(F)(F)F)C4=CC=C(C=C4)C(=O)NCCC(=O)O)Cl
DMQF2XN	IK	XNDCNDSKAXXGMD-UHFFFAOYSA-N
DMQF2XN	IU	3-[[4-[2-[[3-chloro-4-[2-methyl-4-(trifluoromethyl)phenyl]anilino]methyl]-5-(trifluoromethyl)phenyl]benzoyl]amino]propanoic acid

DMLOVMP	ID	DMLOVMP
DMLOVMP	DN	Biphenyl carboxamidopropanoic acid derivative 3
DMLOVMP	HS	Patented
DMLOVMP	SN	PMID25828189-Compound-8
DMLOVMP	CP	JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj GRECO, Michael, N. SHOOK, Brian XU, Guozhang ZHANG, Rui
DMLOVMP	DT	Small molecular drug
DMLOVMP	PC	71059966
DMLOVMP	MW	533.4
DMLOVMP	FM	C30H26Cl2N2O3
DMLOVMP	IC	InChI=1S/C30H26Cl2N2O3/c1-19(34-26-13-8-21(9-14-26)20-6-10-24(31)11-7-20)27-15-12-25(32)18-28(27)22-2-4-23(5-3-22)30(37)33-17-16-29(35)36/h2-15,18-19,34H,16-17H2,1H3,(H,33,37)(H,35,36)
DMLOVMP	CS	CC(C1=C(C=C(C=C1)Cl)C2=CC=C(C=C2)C(=O)NCCC(=O)O)NC3=CC=C(C=C3)C4=CC=C(C=C4)Cl
DMLOVMP	IK	VTPFIFMNWSMPMA-UHFFFAOYSA-N
DMLOVMP	IU	3-[[4-[5-chloro-2-[1-[4-(4-chlorophenyl)anilino]ethyl]phenyl]benzoyl]amino]propanoic acid

DM715E8	ID	DM715E8
DM715E8	DN	Biphenyl carboxamidopropanoic acid derivative 4
DM715E8	HS	Patented
DM715E8	SN	PMID25828189-Compound-9
DM715E8	CP	JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj GRECO, Michael, N. SHOOK, Brian XU, Guozhang ZHANG, Rui
DM715E8	DT	Small molecular drug
DM715E8	PC	71472344
DM715E8	MW	649
DM715E8	FM	C33H27ClF6N2O3
DM715E8	IC	InChI=1S/C33H27ClF6N2O3/c1-18-13-20(31(45)41-12-11-30(43)44)4-8-26(18)28-15-23(33(38,39)40)5-3-21(28)17-42-24-7-10-27(29(34)16-24)25-9-6-22(14-19(25)2)32(35,36)37/h3-10,13-16,42H,11-12,17H2,1-2H3,(H,41,45)(H,43,44)
DM715E8	CS	CC1=C(C=CC(=C1)C(=O)NCCC(=O)O)C2=C(C=CC(=C2)C(F)(F)F)CNC3=CC(=C(C=C3)C4=C(C=C(C=C4)C(F)(F)F)C)Cl
DM715E8	IK	DUDZHUBPDPKULT-UHFFFAOYSA-N
DM715E8	IU	3-[[4-[2-[[3-chloro-4-[2-methyl-4-(trifluoromethyl)phenyl]anilino]methyl]-5-(trifluoromethyl)phenyl]-3-methylbenzoyl]amino]propanoic acid

DMPWFJN	ID	DMPWFJN
DMPWFJN	DN	Biphenyl carboxylic acid derivative 1
DMPWFJN	HS	Patented
DMPWFJN	SN	PMID27744724-Compound-1
DMPWFJN	CP	ABBOTT LABORATORIES WENDT, Michael, D. SHEN, Wang DICKMAN, Daniel, A. DING, Hong THOMAS, Sheela, A. AUGERI, David ELMORE, Steven, W
DMPWFJN	DT	Small molecular drug

DM6TXF4	ID	DM6TXF4
DM6TXF4	DN	Biphenyl carboxylic acid derivative 2
DM6TXF4	HS	Patented
DM6TXF4	SN	PMID27744724-Compound-Fomula1
DM6TXF4	CP	ABBOTT LABORATORIES WENDT, Michael, D. SHEN, Wang DICKMAN, Daniel, A. DING, Hong THOMAS, Sheela, A. AUGERI, David ELMORE, Steven, W
DM6TXF4	DT	Small molecular drug

DMG4WQB	ID	DMG4WQB
DMG4WQB	DN	Biphenyl derivative 1
DMG4WQB	HS	Patented
DMG4WQB	SN	PMID29473428-Compound-55
DMG4WQB	CP	BRISTOL-MYERS SQUIBB COMPANY
DMG4WQB	DT	Small molecular drug
DMG4WQB	PC	121354643
DMG4WQB	MW	510.7
DMG4WQB	FM	C31H38N6O
DMG4WQB	IC	InChI=1S/C31H38N6O/c1-6-25(7-2)37(20-21(3)4)29-17-16-24(26-10-8-9-11-27(26)31-33-35-36-34-31)19-28(29)32-30(38)18-23-14-12-22(5)13-15-23/h8-17,19,21,25H,6-7,18,20H2,1-5H3,(H,32,38)(H,33,34,35,36)
DMG4WQB	CS	CCC(CC)N(CC(C)C)C1=C(C=C(C=C1)C2=CC=CC=C2C3=NNN=N3)NC(=O)CC4=CC=C(C=C4)C
DMG4WQB	IK	CERFYCIXDOVMJH-UHFFFAOYSA-N
DMG4WQB	IU	2-(4-methylphenyl)-N-[2-[2-methylpropyl(pentan-3-yl)amino]-5-[2-(2H-tetrazol-5-yl)phenyl]phenyl]acetamide

DMJ4TZX	ID	DMJ4TZX
DMJ4TZX	DN	Biphenyl derivative 2
DMJ4TZX	HS	Patented
DMJ4TZX	SN	PMID29473428-Compound-56
DMJ4TZX	CP	BRISTOL-MYERS SQUIBB COMPANY
DMJ4TZX	DT	Small molecular drug
DMJ4TZX	PC	121474565
DMJ4TZX	MW	540
DMJ4TZX	FM	C29H31ClFN3O4
DMJ4TZX	IC	InChI=1S/C29H31ClFN3O4/c1-38-16-15-34(21-7-3-2-4-8-21)27-14-11-19(22-9-5-6-10-23(22)28(35)36)17-26(27)33-29(37)32-25-13-12-20(30)18-24(25)31/h5-6,9-14,17-18,21H,2-4,7-8,15-16H2,1H3,(H,35,36)(H2,32,33,37)
DMJ4TZX	CS	COCCN(C1CCCCC1)C2=C(C=C(C=C2)C3=CC=CC=C3C(=O)O)NC(=O)NC4=C(C=C(C=C4)Cl)F
DMJ4TZX	IK	KUVXHGKRYSVGPP-UHFFFAOYSA-N
DMJ4TZX	IU	2-[3-[(4-chloro-2-fluorophenyl)carbamoylamino]-4-[cyclohexyl(2-methoxyethyl)amino]phenyl]benzoic acid

DMM3SWV	ID	DMM3SWV
DMM3SWV	DN	Biphenyl derivative 3
DMM3SWV	HS	Patented
DMM3SWV	SN	PMID29473428-Compound-57
DMM3SWV	CP	BRISTOL-MYERS SQUIBB COMPANY
DMM3SWV	DT	Small molecular drug
DMM3SWV	PC	121469252
DMM3SWV	MW	655.6
DMM3SWV	FM	C32H27F6N7O2
DMM3SWV	IC	InChI=1S/C32H27F6N7O2/c1-20-6-11-23(12-7-20)39-30(46)40-27-18-22(25-4-2-3-5-26(25)29-41-43-44-42-29)10-15-28(27)45(17-16-31(33,34)35)19-21-8-13-24(14-9-21)47-32(36,37)38/h2-15,18H,16-17,19H2,1H3,(H2,39,40,46)(H,41,42,43,44)
DMM3SWV	CS	CC1=CC=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C3=CC=CC=C3C4=NNN=N4)N(CCC(F)(F)F)CC5=CC=C(C=C5)OC(F)(F)F
DMM3SWV	IK	ZBBKUFMLKWFYDD-UHFFFAOYSA-N
DMM3SWV	IU	1-(4-methylphenyl)-3-[5-[2-(2H-tetrazol-5-yl)phenyl]-2-[[4-(trifluoromethoxy)phenyl]methyl-(3,3,3-trifluoropropyl)amino]phenyl]urea

DMIPVYW	ID	DMIPVYW
DMIPVYW	DN	Biphenyl derivative 4
DMIPVYW	HS	Patented
DMIPVYW	SN	PMID29334795-Compound-29
DMIPVYW	CP	ARENA PHARMACEUTICALS, INC
DMIPVYW	DT	Small molecular drug
DMIPVYW	DE	Histamine H3-associated disorder

DMS5UFX	ID	DMS5UFX
DMS5UFX	DN	Biphenyl mannoside derivative 1
DMS5UFX	HS	Patented
DMS5UFX	SN	PMID26651364-Compound-25
DMS5UFX	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, CorinnTHE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMS5UFX	DT	Carbohydrates
DMS5UFX	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMITLPW	ID	DMITLPW
DMITLPW	DN	Biphenyl mannoside derivative 10
DMITLPW	HS	Patented
DMITLPW	SN	PMID26651364-Compound-34
DMITLPW	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMITLPW	DT	Carbohydrates
DMITLPW	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMZF5XI	ID	DMZF5XI
DMZF5XI	DN	Biphenyl mannoside derivative 11
DMZF5XI	HS	Patented
DMZF5XI	SN	PMID26651364-Compound-35
DMZF5XI	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMZF5XI	DT	Carbohydrates
DMZF5XI	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMU0YST	ID	DMU0YST
DMU0YST	DN	Biphenyl mannoside derivative 12
DMU0YST	HS	Patented
DMU0YST	SN	PMID26651364-Compound-36
DMU0YST	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMU0YST	DT	Carbohydrates
DMU0YST	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM83LTH	ID	DM83LTH
DM83LTH	DN	Biphenyl mannoside derivative 13
DM83LTH	HS	Patented
DM83LTH	SN	PMID26651364-Compound-37
DM83LTH	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, CorinnTHE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM83LTH	DT	Carbohydrates
DM83LTH	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMRTWG	ID	DMMRTWG
DMMRTWG	DN	Biphenyl mannoside derivative 14
DMMRTWG	HS	Patented
DMMRTWG	SN	PMID26651364-Compound-38
DMMRTWG	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMMRTWG	DT	Carbohydrates
DMMRTWG	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM97BIQ	ID	DM97BIQ
DM97BIQ	DN	Biphenyl mannoside derivative 15
DM97BIQ	HS	Patented
DM97BIQ	SN	PMID26651364-Compound-39
DM97BIQ	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DM97BIQ	DT	Carbohydrates
DM97BIQ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMECZVG	ID	DMECZVG
DMECZVG	DN	Biphenyl mannoside derivative 16
DMECZVG	HS	Patented
DMECZVG	SN	PMID26651364-Compound-51
DMECZVG	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMECZVG	DT	Carbohydrates
DMECZVG	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM7L8T5	ID	DM7L8T5
DM7L8T5	DN	Biphenyl mannoside derivative 17
DM7L8T5	HS	Patented
DM7L8T5	SN	PMID26651364-Compound-52
DM7L8T5	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DM7L8T5	DT	Carbohydrates
DM7L8T5	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM2GZ5Y	ID	DM2GZ5Y
DM2GZ5Y	DN	Biphenyl mannoside derivative 18
DM2GZ5Y	HS	Patented
DM2GZ5Y	SN	PMID26651364-Compound-53
DM2GZ5Y	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DM2GZ5Y	DT	Carbohydrates
DM2GZ5Y	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMGA0R6	ID	DMGA0R6
DMGA0R6	DN	Biphenyl mannoside derivative 19
DMGA0R6	HS	Patented
DMGA0R6	SN	PMID26651364-Compound-54
DMGA0R6	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMGA0R6	DT	Carbohydrates
DMGA0R6	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMQB4DR	ID	DMQB4DR
DMQB4DR	DN	Biphenyl mannoside derivative 2
DMQB4DR	HS	Patented
DMQB4DR	SN	PMID26651364-Compound-26
DMQB4DR	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, CorinnTHE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMQB4DR	DT	Carbohydrates
DMQB4DR	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMDIYJ1	ID	DMDIYJ1
DMDIYJ1	DN	Biphenyl mannoside derivative 20
DMDIYJ1	HS	Patented
DMDIYJ1	SN	PMID26651364-Compound-55
DMDIYJ1	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMDIYJ1	DT	Carbohydrates
DMDIYJ1	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMTR6BX	ID	DMTR6BX
DMTR6BX	DN	Biphenyl mannoside derivative 21
DMTR6BX	HS	Patented
DMTR6BX	SN	PMID26651364-Compound-56
DMTR6BX	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMTR6BX	DT	Carbohydrates
DMTR6BX	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMQGFKY	ID	DMQGFKY
DMQGFKY	DN	Biphenyl mannoside derivative 22
DMQGFKY	HS	Patented
DMQGFKY	SN	PMID26651364-Compound-68a
DMQGFKY	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DMQGFKY	DT	Carbohydrates
DMQGFKY	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMC8OVU	ID	DMC8OVU
DMC8OVU	DN	Biphenyl mannoside derivative 23
DMC8OVU	HS	Patented
DMC8OVU	SN	PMID26651364-Compound-68b
DMC8OVU	CP	WASHINGTON UNIVERSITY
DMC8OVU	DT	Carbohydrates
DMC8OVU	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMLUZ3K	ID	DMLUZ3K
DMLUZ3K	DN	Biphenyl mannoside derivative 24
DMLUZ3K	HS	Patented
DMLUZ3K	SN	PMID26651364-Compound-69
DMLUZ3K	CP	WASHINGTON UNIVERSITY
DMLUZ3K	DT	Carbohydrates
DMLUZ3K	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMBWQ8L	ID	DMBWQ8L
DMBWQ8L	DN	Biphenyl mannoside derivative 25
DMBWQ8L	HS	Patented
DMBWQ8L	SN	PMID26651364-Compound-70
DMBWQ8L	CP	WASHINGTON UNIVERSITY
DMBWQ8L	DT	Carbohydrates
DMBWQ8L	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM5Q4T2	ID	DM5Q4T2
DM5Q4T2	DN	Biphenyl mannoside derivative 26
DM5Q4T2	HS	Patented
DM5Q4T2	SN	PMID26651364-Compound-71
DM5Q4T2	CP	WASHINGTON UNIVERSITY
DM5Q4T2	DT	Carbohydrates
DM5Q4T2	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMWQ6FJ	ID	DMWQ6FJ
DMWQ6FJ	DN	Biphenyl mannoside derivative 27
DMWQ6FJ	HS	Patented
DMWQ6FJ	SN	PMID26651364-Compound-72
DMWQ6FJ	CP	WASHINGTON UNIVERSITY
DMWQ6FJ	DT	Carbohydrates
DMWQ6FJ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMOTWK	ID	DMMOTWK
DMMOTWK	DN	Biphenyl mannoside derivative 28
DMMOTWK	HS	Patented
DMMOTWK	SN	PMID26651364-Compound-73
DMMOTWK	CP	WASHINGTON UNIVERSITY
DMMOTWK	DT	Carbohydrates
DMMOTWK	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM9H0Q3	ID	DM9H0Q3
DM9H0Q3	DN	Biphenyl mannoside derivative 29
DM9H0Q3	HS	Patented
DM9H0Q3	SN	PMID26651364-Compound-74
DM9H0Q3	CP	WASHINGTON UNIVERSITY
DM9H0Q3	DT	Carbohydrates
DM9H0Q3	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMOKJEP	ID	DMOKJEP
DMOKJEP	DN	Biphenyl mannoside derivative 3
DMOKJEP	HS	Patented
DMOKJEP	SN	PMID26651364-Compound-27
DMOKJEP	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMOKJEP	DT	Carbohydrates
DMOKJEP	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM81RIY	ID	DM81RIY
DM81RIY	DN	Biphenyl mannoside derivative 30
DM81RIY	HS	Patented
DM81RIY	SN	PMID26651364-Compound-75
DM81RIY	CP	WASHINGTON UNIVERSITY
DM81RIY	DT	Carbohydrates
DM81RIY	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM0VR23	ID	DM0VR23
DM0VR23	DN	Biphenyl mannoside derivative 4
DM0VR23	HS	Patented
DM0VR23	SN	PMID26651364-Compound-28
DM0VR23	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM0VR23	DT	Carbohydrates
DM0VR23	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMOS03R	ID	DMOS03R
DMOS03R	DN	Biphenyl mannoside derivative 5
DMOS03R	HS	Patented
DMOS03R	SN	PMID26651364-Compound-29
DMOS03R	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMOS03R	DT	Carbohydrates
DMOS03R	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM93VEB	ID	DM93VEB
DM93VEB	DN	Biphenyl mannoside derivative 6
DM93VEB	HS	Patented
DM93VEB	SN	PMID26651364-Compound-30
DM93VEB	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM93VEB	DT	Carbohydrates
DM93VEB	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM46NRV	ID	DM46NRV
DM46NRV	DN	Biphenyl mannoside derivative 7
DM46NRV	HS	Patented
DM46NRV	SN	PMID26651364-Compound-31
DM46NRV	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM46NRV	DT	Carbohydrates
DM46NRV	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMZCWM5	ID	DMZCWM5
DMZCWM5	DN	Biphenyl mannoside derivative 8
DMZCWM5	HS	Patented
DMZCWM5	SN	PMID26651364-Compound-32
DMZCWM5	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMZCWM5	DT	Carbohydrates
DMZCWM5	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMP52HJ	ID	DMP52HJ
DMP52HJ	DN	Biphenyl mannoside derivative 9
DMP52HJ	HS	Patented
DMP52HJ	SN	PMID26651364-Compound-33
DMP52HJ	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMP52HJ	DT	Carbohydrates
DMP52HJ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM6KGUB	ID	DM6KGUB
DM6KGUB	DN	Bipyrazole derivative 1
DM6KGUB	HS	Patented
DM6KGUB	SN	PMID27774824-Compound-Figure13Example17
DM6KGUB	CP	INCYTE CORPORATION
DM6KGUB	DT	Small molecular drug

DMPUXL3	ID	DMPUXL3
DMPUXL3	DN	Bipyridine derivative 1
DMPUXL3	HS	Patented
DMPUXL3	SN	PMID26161698-Compound-39
DMPUXL3	CP	NOVARTIS AG BARSANTI, Paul A. HU, Cheng JIN, Xianming NG, Simon C. PFISTER, Keith B. SENDZIK, Martin SUTTON, James
DMPUXL3	DT	Small molecular drug

DMQL34C	ID	DMQL34C
DMQL34C	DN	Bis-aminopyrimidine derivative 1
DMQL34C	HS	Patented
DMQL34C	SN	PMID27774824-Compound-Figure7compound23
DMQL34C	CP	CELLZOME LIMITED FREEMAN, Jay READER, Valerie ADDISON, Glynn RAMSDEN, Nigel SCANLON, Jane Elizabeth HARRISON, Richard John

DMJXNO1	ID	DMJXNO1
DMJXNO1	DN	Bis-aminopyrimidine derivative 2
DMJXNO1	HS	Patented
DMJXNO1	SN	PMID27774824-Compound-Figure7Example103
DMJXNO1	CP	CELLZOME LIMITED HOBSON, Andrew ADDISON, Glynn RAMSDEN, Nigel HARRISON, John
DMJXNO1	DT	Small molecular drug

DMUNSYX	ID	DMUNSYX
DMUNSYX	DN	Bis-aminopyrimidine derivative 3
DMUNSYX	HS	Patented
DMUNSYX	SN	PMID27774824-Compound-Figure7Example25
DMUNSYX	CP	CELLZOME LIMITED HOBSON, Andrew ADDISON, Glynn RAMSDEN, Nigel HARRISON, John
DMUNSYX	DT	Small molecular drug

DMO1ZIG	ID	DMO1ZIG
DMO1ZIG	DN	Bis-aminopyrimidine derivative 4
DMO1ZIG	HS	Patented
DMO1ZIG	SN	PMID27774824-Compound-Figure7Example83
DMO1ZIG	CP	CELLZOME LIMITED HOBSON, Andrew ADDISON, Glynn RAMSDEN, Nigel HARRISON, John
DMO1ZIG	DT	Small molecular drug

DMWXLK1	ID	DMWXLK1
DMWXLK1	DN	Bis-aminopyrimidine derivative 5
DMWXLK1	HS	Patented
DMWXLK1	SN	PMID27774824-Compound-Figure7ExampleI-13
DMWXLK1	CP	CELLZOME LIMITED HARRISON, Richard John RAMSDEN, Nigel MAJOR, Jeremy MOREL, Adeline CONVERY, Laura SUNOSE, Mihiro LYNCH, Rosemary ADREGO, Rita JONES, Alison
DMWXLK1	DT	Small molecular drug

DMOR9ZA	ID	DMOR9ZA
DMOR9ZA	DN	Bis-indolylmaleimide derivative 1
DMOR9ZA	HS	Patented
DMOR9ZA	SN	PMID25684022-Compound-WO2005041953
DMOR9ZA	CP	ELI LILLY AND COMPANY GRAFF, Jeremy, Richard
DMOR9ZA	DT	Small molecular drug
DMOR9ZA	DE	Solid tumour/cancer; Metastatic cancer

DMLV9UR	ID	DMLV9UR
DMLV9UR	DN	Bis-sulfonamide derivative 1
DMLV9UR	HS	Patented
DMLV9UR	SN	PMID27977313-Compound-49
DMLV9UR	CP	UNIVERSITY OF SUNDERLAND
DMLV9UR	DT	Small molecular drug
DMLV9UR	PC	75593317
DMLV9UR	MW	525.6
DMLV9UR	FM	C25H23N3O6S2
DMLV9UR	IC	InChI=1S/C25H23N3O6S2/c1-17-5-10-20(11-6-17)35(30,31)27-22-14-9-19(26-25(29)24-4-3-15-34-24)16-23(22)28-36(32,33)21-12-7-18(2)8-13-21/h3-16,27-28H,1-2H3,(H,26,29)
DMLV9UR	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(C=C2)NC(=O)C3=CC=CO3)NS(=O)(=O)C4=CC=C(C=C4)C
DMLV9UR	IK	CFHMKQXRBRHXQD-UHFFFAOYSA-N
DMLV9UR	IU	N-[3,4-bis[(4-methylphenyl)sulfonylamino]phenyl]furan-2-carboxamide

DMR0ANI	ID	DMR0ANI
DMR0ANI	DN	Bis-sulfonamide derivative 2
DMR0ANI	HS	Patented
DMR0ANI	SN	PMID27977313-Compound-Figure7a
DMR0ANI	CP	UNIVERSITY OF SUNDERLAND
DMR0ANI	DT	Small molecular drug

DM6YQO3	ID	DM6YQO3
DM6YQO3	DN	BK3
DM6YQO3	HS	Patented
DM6YQO3	SN	CHEMBL1231372; MMV676182; 3-(Naphthalen-1-Ylmethyl)-1-(Piperidin-4-Ylmethyl)-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine; BK3; SCHEMBL12437018; BDBM50345712; 3-(1-naphthylmethyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DM6YQO3	DT	Small molecular drug
DM6YQO3	PC	46398830
DM6YQO3	MW	372.5
DM6YQO3	FM	C22H24N6
DM6YQO3	IC	InChI=1S/C22H24N6/c23-21-20-19(12-17-6-3-5-16-4-1-2-7-18(16)17)27-28(22(20)26-14-25-21)13-15-8-10-24-11-9-15/h1-7,14-15,24H,8-13H2,(H2,23,25,26)
DM6YQO3	CS	C1CNCCC1CN2C3=NC=NC(=C3C(=N2)CC4=CC=CC5=CC=CC=C54)N
DM6YQO3	IK	MMRLNUFECMEMSQ-UHFFFAOYSA-N
DM6YQO3	IU	3-(naphthalen-1-ylmethyl)-1-(piperidin-4-ylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine

DMQD4X2	ID	DMQD4X2
DMQD4X2	DN	BK7
DMQD4X2	HS	Patented
DMQD4X2	SN	CHEMBL2030554; 3-(6-Ethoxynaphthalen-2-Yl)-1-(Piperidin-4-Ylmethyl)-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine; BK7; SCHEMBL14574630; BDBM50383381; RM-1-132; 3-(6-ethoxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DMQD4X2	DT	Small molecular drug
DMQD4X2	PC	53346432
DMQD4X2	MW	402.5
DMQD4X2	FM	C23H26N6O
DMQD4X2	IC	InChI=1S/C23H26N6O/c1-2-30-19-6-5-16-11-18(4-3-17(16)12-19)21-20-22(24)26-14-27-23(20)29(28-21)13-15-7-9-25-10-8-15/h3-6,11-12,14-15,25H,2,7-10,13H2,1H3,(H2,24,26,27)
DMQD4X2	CS	CCOC1=CC2=C(C=C1)C=C(C=C2)C3=NN(C4=NC=NC(=C34)N)CC5CCNCC5
DMQD4X2	IK	DLMBMHOJKBPKLK-UHFFFAOYSA-N
DMQD4X2	IU	3-(6-ethoxynaphthalen-2-yl)-1-(piperidin-4-ylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine

DMMRXEQ	ID	DMMRXEQ
DMMRXEQ	DN	Boronic acid derivative 1
DMMRXEQ	HS	Patented
DMMRXEQ	SN	PMID26413912-Compound-58
DMMRXEQ	CP	INFINITY PHARMACEUTICALS, INC. AUSTAD, Brian, C. GRENIER, Louis GROGAN, Michael, J. LIU, Tao LO, Ching Kam MARTINOT, Theodore, A. YU, Lin-Chen
DMMRXEQ	DT	Small molecular drug
DMMRXEQ	PC	53328040
DMMRXEQ	MW	234.01
DMMRXEQ	FM	C12H9BF2O2
DMMRXEQ	IC	InChI=1S/C12H9BF2O2/c14-10-3-1-2-8(6-10)9-4-5-11(13(16)17)12(15)7-9/h1-7,16-17H
DMMRXEQ	CS	B(C1=C(C=C(C=C1)C2=CC(=CC=C2)F)F)(O)O
DMMRXEQ	IK	WAWBMXWYDGQRBT-UHFFFAOYSA-N
DMMRXEQ	IU	[2-fluoro-4-(3-fluorophenyl)phenyl]boronic acid

DMLJH5T	ID	DMLJH5T
DMLJH5T	DN	Boronic acid derivative 2
DMLJH5T	HS	Patented
DMLJH5T	SN	PMID26413912-Compound-59
DMLJH5T	CP	INFINITY PHARMACEUTICALS, INC BEHNKE, Mark, L. CASTRO, Alfredo, C. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LIU, Tao SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMLJH5T	DT	Small molecular drug

DMQ8X94	ID	DMQ8X94
DMQ8X94	DN	Boronic acid derivative 3
DMQ8X94	HS	Patented
DMQ8X94	SN	PMID26413912-Compound-60
DMQ8X94	CP	INFINITY PHARMACEUTICALS, INC BEHNKE, Mark, L. CASTRO, Alfredo, C. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LIU, Tao SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMQ8X94	DT	Small molecular drug
DMQ8X94	PC	58343925
DMQ8X94	MW	267.05
DMQ8X94	FM	C13H10BN3O3
DMQ8X94	IC	InChI=1S/C13H10BN3O3/c18-14(19)11-5-3-9(4-6-11)12-16-17-13(20-12)10-2-1-7-15-8-10/h1-8,18-19H
DMQ8X94	CS	B(C1=CC=C(C=C1)C2=NN=C(O2)C3=CN=CC=C3)(O)O
DMQ8X94	IK	GUJFLRGCBMMKFL-UHFFFAOYSA-N
DMQ8X94	IU	[4-(5-pyridin-3-yl-1,3,4-oxadiazol-2-yl)phenyl]boronic acid

DMVIFXR	ID	DMVIFXR
DMVIFXR	DN	Boronic acid derivative 4
DMVIFXR	HS	Patented
DMVIFXR	SN	PMID26413912-Compound-61
DMVIFXR	CP	INFINITY PHARMACEUTICALS, INC. CASTRO, Alfredo, C. GROGAN, Michael, J. SNYDER, Daniel, A
DMVIFXR	DT	Small molecular drug
DMVIFXR	PC	46917082
DMVIFXR	MW	293.1
DMVIFXR	FM	C17H16BNO3
DMVIFXR	IC	InChI=1S/C17H16BNO3/c20-17-16-7-6-15(18(21)22)12-14(16)9-11-19(17)10-8-13-4-2-1-3-5-13/h1-7,9,11-12,21-22H,8,10H2
DMVIFXR	CS	B(C1=CC2=C(C=C1)C(=O)N(C=C2)CCC3=CC=CC=C3)(O)O
DMVIFXR	IK	MPFOFZNQFUHKAK-UHFFFAOYSA-N
DMVIFXR	IU	[1-oxo-2-(2-phenylethyl)isoquinolin-6-yl]boronic acid

DMUCW9Y	ID	DMUCW9Y
DMUCW9Y	DN	Boronic acid derivative 5
DMUCW9Y	HS	Patented
DMUCW9Y	SN	PMID26413912-Compound-62
DMUCW9Y	CP	INFINITY PHARMACEUTICALS, INC. CASTRO, Alfredo, C. GROGAN, Michael, J. SNYDER, Daniel, A
DMUCW9Y	DT	Small molecular drug
DMUCW9Y	PC	46947813
DMUCW9Y	MW	281.1
DMUCW9Y	FM	C16H16BNO3
DMUCW9Y	IC	InChI=1S/C16H16BNO3/c19-16-15-7-6-14(17(20)21)10-13(15)11-18(16)9-8-12-4-2-1-3-5-12/h1-7,10,20-21H,8-9,11H2
DMUCW9Y	CS	B(C1=CC2=C(C=C1)C(=O)N(C2)CCC3=CC=CC=C3)(O)O
DMUCW9Y	IK	OWKXCKRUGQYZKS-UHFFFAOYSA-N
DMUCW9Y	IU	[1-oxo-2-(2-phenylethyl)-3H-isoindol-5-yl]boronic acid

DMLMV4O	ID	DMLMV4O
DMLMV4O	DN	Boronic acid derivative 6
DMLMV4O	HS	Patented
DMLMV4O	SN	PMID26413912-Compound-63
DMLMV4O	CP	INFINITY PHARMACEUTICALS, INC. CASTRO, Alfredo, C. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J
DMLMV4O	DT	Small molecular drug
DMLMV4O	PC	46940954
DMLMV4O	MW	289.2
DMLMV4O	FM	C16H24BNO3
DMLMV4O	IC	InChI=1S/C16H24BNO3/c19-16(18-12-10-15(11-13-18)17(20)21)9-5-4-8-14-6-2-1-3-7-14/h1-3,6-7,15,20-21H,4-5,8-13H2
DMLMV4O	CS	B(C1CCN(CC1)C(=O)CCCCC2=CC=CC=C2)(O)O
DMLMV4O	IK	WOTYQRKKBABLCX-UHFFFAOYSA-N
DMLMV4O	IU	[1-(5-phenylpentanoyl)piperidin-4-yl]boronic acid

DMCLB5D	ID	DMCLB5D
DMCLB5D	DN	Boswellia acid derivative 1
DMCLB5D	HS	Patented
DMCLB5D	SN	PMID28627961-Compound-42
DMCLB5D	CP	AureliaSan GBH 
DMCLB5D	DT	Small molecular drug
DMCLB5D	PC	46195157
DMCLB5D	MW	454.7
DMCLB5D	FM	C30H46O3
DMCLB5D	IC	InChI=1S/C30H46O3/c1-19(2)9-8-10-20(26(32)33)21-13-17-30(7)23-11-12-24-27(3,4)25(31)15-16-28(24,5)22(23)14-18-29(21,30)6/h9,20-21,24H,8,10-18H2,1-7H3,(H,32,33)/t20-,21-,24?,28?,29-,30+/m0/s1
DMCLB5D	CS	CC(=CCC[C@@H]([C@@H]1CC[C@]2([C@]1(CCC3=C2CCC4C3(CCC(=O)C4(C)C)C)C)C)C(=O)O)C
DMCLB5D	IK	XLPAINGDLCDYQV-MSEQJIGISA-N
DMCLB5D	IU	(2S)-6-methyl-2-[(13S,14S,17S)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]hept-5-enoic acid

DMMXQJU	ID	DMMXQJU
DMMXQJU	DN	Bromo benzyl ether derivative 1
DMMXQJU	HS	Patented
DMMXQJU	SN	PMID30107136-Compound-Example17
DMMXQJU	CP	INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMMXQJU	DT	Small molecule immunotherapy 
DMMXQJU	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMVBAUC	ID	DMVBAUC
DMVBAUC	DN	Bromo benzyl ether derivative 2
DMVBAUC	HS	Patented
DMVBAUC	SN	PMID30107136-Compound-Example18
DMVBAUC	CP	INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMVBAUC	DT	Small molecule immunotherapy 
DMVBAUC	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMVYNJZ	ID	DMVYNJZ
DMVYNJZ	DN	BUTAPROST
DMVYNJZ	HS	Patented
DMVYNJZ	SN	Butaprost; (R)-Butaprost; 69648-38-0; UNII-HP16WVP23Y; TR-4979; HP16WVP23Y; NCGC00165753-01; Butaprostum; (1R,2R,3R)-3-Hydroxy-2-[(1E,4R)-4-hydroxy-4-(1-propylcyclobutyl)-1-butenyl]-5-oxo-cyclopentaneheptanoic acid methyl ester; Butaprostum [Latin]; Bay q 4218; Butaprost [USAN:INN:BAN]; Butaprost (free acid); AC1NSJVB; Butaprost (USAN/INN); DSSTox_RID_83186; DSSTox_CID_28919; SCHEMBL94764; DSSTox_GSID_48993; CHEMBL271896; GTPL3379; DTXSID8048993; BDBM85602; BAY-Q-4218; ZINC4215145; Tox21_113480; MFCD00867055; 1090AH; PDSP2_001674
DMVYNJZ	DT	Small molecular drug
DMVYNJZ	PC	5311035
DMVYNJZ	MW	408.6
DMVYNJZ	FM	C24H40O5
DMVYNJZ	IC	InChI=1S/C24H40O5/c1-3-14-24(15-9-16-24)22(27)12-8-11-19-18(20(25)17-21(19)26)10-6-4-5-7-13-23(28)29-2/h8,11,18-19,21-22,26-27H,3-7,9-10,12-17H2,1-2H3/b11-8+/t18-,19-,21-,22-/m1/s1
DMVYNJZ	CS	CCCC1(CCC1)[C@@H](C/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)OC)O)O
DMVYNJZ	IK	XRISENIKJUKIHD-LHQZMKCDSA-N
DMVYNJZ	IU	methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E,4R)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoate
DMVYNJZ	CA	CAS 69648-38-0
DMVYNJZ	DE	Discovery agent

DMJPW7C	ID	DMJPW7C
DMJPW7C	DN	C06909
DMJPW7C	HS	Patented
DMJPW7C	SN	Cidofovir - Vistide; AC1LAD1W; SCHEMBL151807; CHEMBL27710; US10071110, Compound CDV; BDBM275767; AKOS015901501; RL00545; US10071110, Compound Cidofovir(CDV); SC-20872; AB0109968; C06909; A803101; I14-14184; Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-; [1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; [1-(4-amino-2-oxo-1-pyrimidinyl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; [1-[(4-amino-2-oxo-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methylphosphon
DMJPW7C	DT	Small molecular drug
DMJPW7C	PC	466146
DMJPW7C	MW	279.19
DMJPW7C	FM	C8H14N3O6P
DMJPW7C	IC	InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)
DMJPW7C	CS	C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O
DMJPW7C	IK	VWFCHDSQECPREK-UHFFFAOYSA-N
DMJPW7C	IU	[1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid

DMW46GY	ID	DMW46GY
DMW46GY	DN	CAMBINOL
DMW46GY	HS	Patented
DMW46GY	SN	cambinol; 14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040
DMW46GY	DT	Small molecular drug
DMW46GY	PC	3246390
DMW46GY	MW	360.4
DMW46GY	FM	C21H16N2O2S
DMW46GY	IC	InChI=1S/C21H16N2O2S/c24-18-11-10-13-6-4-5-9-15(13)16(18)12-17-19(14-7-2-1-3-8-14)22-21(26)23-20(17)25/h1-11,24H,12H2,(H2,22,23,25,26)
DMW46GY	CS	C1=CC=C(C=C1)C2=C(C(=O)NC(=S)N2)CC3=C(C=CC4=CC=CC=C43)O
DMW46GY	IK	RVNSQVIUFZVNAU-UHFFFAOYSA-N
DMW46GY	IU	5-[(2-hydroxynaphthalen-1-yl)methyl]-6-phenyl-2-sulfanylidene-1H-pyrimidin-4-one
DMW46GY	CA	CAS 14513-15-6
DMW46GY	DE	Discovery agent

DM81SYN	ID	DM81SYN
DM81SYN	DN	Cannabinoid quinone derivative 1
DM81SYN	HS	Patented
DM81SYN	SN	PMID25416646-Compound-Figure3-A
DM81SYN	CP	VIVACELL BIOTECHNOLOGY ESPANA S L [ES]
DM81SYN	DT	Small molecular drug

DMNDPEA	ID	DMNDPEA
DMNDPEA	DN	Carbamate derivative 1
DMNDPEA	HS	Patented
DMNDPEA	SN	PMID26413912-Compound-25
DMNDPEA	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA UNIVERSITA DEGLI STUDI DI URBINO &quot;CARLO BO&quoUNIVERSITA DEGLI STUDI DI PARMA PIOMELLI, Daniele CLAPPER, Jason, R. MORENO-SANZ, Guillermo DURANTI, Andrea TONTINI, Andrea MOR, Marco TARZIA, Giorgio
DMNDPEA	DT	Small molecular drug

DMP98CL	ID	DMP98CL
DMP98CL	DN	Carbamate derivative 10
DMP98CL	HS	Patented
DMP98CL	SN	PMID29053063-Compound-10b
DMP98CL	CP	PFIZER INC
DMP98CL	DT	Small molecular drug

DM3CF91	ID	DM3CF91
DM3CF91	DN	Carbamate derivative 11
DM3CF91	HS	Patented
DM3CF91	SN	PMID29053063-Compound-10c
DM3CF91	CP	PFIZER INC
DM3CF91	DT	Small molecular drug

DMMH27J	ID	DMMH27J
DMMH27J	DN	Carbamate derivative 12
DMMH27J	HS	Patented
DMMH27J	SN	PMID29053063-Compound-10d
DMMH27J	CP	PFIZER INC
DMMH27J	DT	Small molecular drug

DMLH45M	ID	DMLH45M
DMLH45M	DN	Carbamate derivative 13
DMLH45M	HS	Patented
DMLH45M	SN	PMID29053063-Compound-10e
DMLH45M	CP	PFIZER INC
DMLH45M	DT	Small molecular drug

DMZS0HT	ID	DMZS0HT
DMZS0HT	DN	Carbamate derivative 14
DMZS0HT	HS	Patented
DMZS0HT	SN	PMID29053063-Compound-10f
DMZS0HT	CP	PFIZER INC
DMZS0HT	DT	Small molecular drug

DMOKC41	ID	DMOKC41
DMOKC41	DN	Carbamate derivative 15
DMOKC41	HS	Patented
DMOKC41	SN	PMID29053063-Compound-10g
DMOKC41	CP	PFIZER INC
DMOKC41	DT	Small molecular drug
DMOKC41	PC	126502896
DMOKC41	MW	494.5
DMOKC41	FM	C21H29F3N2O6S
DMOKC41	IC	InChI=1S/C21H29F3N2O6S/c1-15(2)26(33(29,30)17-6-4-3-5-7-17)16-12-20(31-14-16)8-10-25(11-9-20)19(28)32-18(13-27)21(22,23)24/h3-7,15-16,18,27H,8-14H2,1-2H3/t16-,18-/m1/s1
DMOKC41	CS	CC(C)N([C@@H]1CC2(CCN(CC2)C(=O)O[C@H](CO)C(F)(F)F)OC1)S(=O)(=O)C3=CC=CC=C3
DMOKC41	IK	FNERRHFFFPJRAG-SJLPKXTDSA-N
DMOKC41	IU	[(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] (3R)-3-[benzenesulfonyl(propan-2-yl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate

DMPLZSE	ID	DMPLZSE
DMPLZSE	DN	Carbamate derivative 16
DMPLZSE	HS	Patented
DMPLZSE	SN	PMID29053063-Compound-10h
DMPLZSE	CP	PFIZER INC
DMPLZSE	DT	Small molecular drug

DMYSRPT	ID	DMYSRPT
DMYSRPT	DN	Carbamate derivative 17
DMYSRPT	HS	Patented
DMYSRPT	SN	PMID29053063-Compound-12d
DMYSRPT	CP	NORTHEASTERN UNIVERSITY
DMYSRPT	DT	Small molecular drug

DMEWPQ6	ID	DMEWPQ6
DMEWPQ6	DN	Carbamate derivative 2
DMEWPQ6	HS	Patented
DMEWPQ6	SN	PMID26413912-Compound-27
DMEWPQ6	CP	FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA
DMEWPQ6	DT	Small molecular drug

DMO6NWD	ID	DMO6NWD
DMO6NWD	DN	Carbamate derivative 3
DMO6NWD	HS	Patented
DMO6NWD	SN	PMID26413912-Compound-30
DMO6NWD	CP	SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. CABRI, Walter MINETTI, Patrizia CAMPIANI, Giuseppe BUTINI, Stefania
DMO6NWD	DT	Small molecular drug

DM9MFDH	ID	DM9MFDH
DM9MFDH	DN	Carbamate derivative 4
DM9MFDH	HS	Patented
DM9MFDH	SN	PMID26413912-Compound-31
DM9MFDH	CP	SANOFI-AVENTIS 
DM9MFDH	DT	Small molecular drug

DMHB5XG	ID	DMHB5XG
DMHB5XG	DN	Carbamate derivative 5
DMHB5XG	HS	Patented
DMHB5XG	SN	PMID26413912-Compound-32
DMHB5XG	CP	SANOFI-AVENTIS ABOUABDELLAH, Ahmed CHEREZE, Nathalie FAYOL, Aude SAADY, Mourad VACHE, Julien VERONIQUE, Corinne YAICHE, Philippe
DMHB5XG	DT	Small molecular drug

DMMOSKZ	ID	DMMOSKZ
DMMOSKZ	DN	Carbamate derivative 6
DMMOSKZ	HS	Patented
DMMOSKZ	SN	PMID26413912-Compound-33
DMMOSKZ	CP	SANOFI 
DMMOSKZ	DT	Small molecular drug

DMOPF9N	ID	DMOPF9N
DMOPF9N	DN	Carbamate derivative 7
DMOPF9N	HS	Patented
DMOPF9N	SN	PMID26413912-Compound-34
DMOPF9N	CP	Astellas Pharma Inc.  AOKI,&nbsp;Satoshi  MUNAKATA,&nbsp;Ryosuke  KAWANO,&nbsp;Noriyuki 
DMOPF9N	DT	Small molecular drug

DMEAO42	ID	DMEAO42
DMEAO42	DN	Carbamate derivative 8
DMEAO42	HS	Patented
DMEAO42	SN	PMID26413912-Compound-35
DMEAO42	CP	Astellas Pharma Inc.  AOKI,&nbsp;Satoshi  MUNAKATA,&nbsp;Ryosuke  KAWANO,&nbsp;Noriyuki 
DMEAO42	DT	Small molecular drug

DMW4B1U	ID	DMW4B1U
DMW4B1U	DN	Carbamate derivative 9
DMW4B1U	HS	Patented
DMW4B1U	SN	PMID29053063-Compound-10a
DMW4B1U	CP	PFIZER INC
DMW4B1U	DT	Small molecular drug
DMW4B1U	PC	126502770
DMW4B1U	MW	452.4
DMW4B1U	FM	C18H23F3N2O6S
DMW4B1U	IC	InChI=1S/C18H23F3N2O6S/c19-18(20,21)15(11-24)29-16(25)23-8-6-17(7-9-23)10-13(12-28-17)22-30(26,27)14-4-2-1-3-5-14/h1-5,13,15,22,24H,6-12H2/t13-,15-/m1/s1
DMW4B1U	CS	C1CN(CCC12C[C@H](CO2)NS(=O)(=O)C3=CC=CC=C3)C(=O)O[C@H](CO)C(F)(F)F
DMW4B1U	IK	KBPUJKKMMQDFKB-UKRRQHHQSA-N
DMW4B1U	IU	[(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] (3R)-3-(benzenesulfonamido)-1-oxa-8-azaspiro[4.5]decane-8-carboxylate

DMXQTPJ	ID	DMXQTPJ
DMXQTPJ	DN	Carbamide derivative 1
DMXQTPJ	HS	Patented
DMXQTPJ	SN	PMID26413912-Compound-49
DMXQTPJ	CP	JANSSEN PHARMACEUTICA NV KEITH, John, M. LIU, Jing
DMXQTPJ	DT	Small molecular drug
DMXQTPJ	PC	54576693
DMXQTPJ	MW	410.8
DMXQTPJ	FM	C18H17ClF2N4O3
DMXQTPJ	IC	InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)
DMXQTPJ	CS	C1CN(CCN1CC2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=CN=C4)Cl
DMXQTPJ	IK	YWGYNGCRVZLMCS-UHFFFAOYSA-N
DMXQTPJ	IU	N-(4-chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide
DMXQTPJ	CA	CAS 1346528-50-4

DM9O56W	ID	DM9O56W
DM9O56W	DN	Carbamide derivative 10
DM9O56W	HS	Patented
DM9O56W	SN	PMID28074661-Compound-WO2003053958c50
DM9O56W	CP	CELLTECH R&D LIMITED DYKE, Hazel, Joan RICHARD, Marianna, Dilani HAUGHAN, Alan, Findlay SHARPE, Andrew
DM9O56W	DT	Small molecular drug

DMK7DJR	ID	DMK7DJR
DMK7DJR	DN	Carbamide derivative 11
DMK7DJR	HS	Patented
DMK7DJR	SN	PMID28074661-Compound-WO2003053958c51
DMK7DJR	CP	CELLTECH R&D LIMITED DYKE, Hazel, Joan RICHARD, Marianna, Dilani HAUGHAN, Alan, Findlay SHARPE, Andrew
DMK7DJR	DT	Small molecular drug

DMCAD64	ID	DMCAD64
DMCAD64	DN	Carbamide derivative 13
DMCAD64	HS	Patented
DMCAD64	SN	PMID29473428-Compound-74
DMCAD64	CP	FLEXUS BIOSCIENCES, INC
DMCAD64	DT	Small molecular drug

DMU04PM	ID	DMU04PM
DMU04PM	DN	Carbamide derivative 14
DMU04PM	HS	Patented
DMU04PM	SN	PMID28621580-Compound-US20140256819c19
DMU04PM	CP	Allergan, Inc
DMU04PM	DT	Small molecular drug

DM2TDXW	ID	DM2TDXW
DM2TDXW	DN	Carbamide derivative 15
DM2TDXW	HS	Patented
DM2TDXW	SN	PMID28621580-Compound-US20160096828c21
DM2TDXW	CP	Allergan, Inc
DM2TDXW	DT	Small molecular drug

DMLPOUR	ID	DMLPOUR
DMLPOUR	DN	Carbamide derivative 16
DMLPOUR	HS	Patented
DMLPOUR	SN	PMID28621580-Compound-WO2012028106c12
DMLPOUR	CP	ASCEPION PHARMACEUTICALS, INC. JIANG, Shan GAO, Xiaoyong WANG, Qishan
DMLPOUR	DT	Small molecular drug

DMUF5AC	ID	DMUF5AC
DMUF5AC	DN	Carbamide derivative 17
DMUF5AC	HS	Patented
DMUF5AC	SN	PMID28621580-Compound-WO2012089137c13
DMUF5AC	CP	SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY  ZHANG, Qingwen
DMUF5AC	DT	Small molecular drug

DMZ37XI	ID	DMZ37XI
DMZ37XI	DN	Carbamide derivative 18
DMZ37XI	HS	Patented
DMZ37XI	SN	PMID28621580-Compound-WO2012094451c15
DMZ37XI	CP	BETA PHARMA CANADA INC. WANG, Zhaoyin YU, Chunrong
DMZ37XI	DT	Small molecular drug

DMLDXOB	ID	DMLDXOB
DMLDXOB	DN	Carbamide derivative 19
DMLDXOB	HS	Patented
DMLDXOB	SN	PMID28621580-Compound-WO2012139499c14
DMLDXOB	CP	SHANGHAI INSITITUTE OF PHARMACEUTICAL INDUSTRY  ZHANG, Qingwen
DMLDXOB	DT	Small molecular drug

DMW5GI3	ID	DMW5GI3
DMW5GI3	DN	Carbamide derivative 2
DMW5GI3	HS	Patented
DMW5GI3	SN	PMID25470667-Compound-Figure5-19
DMW5GI3	CP	GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMW5GI3	DT	Small molecular drug
DMW5GI3	PC	71473500
DMW5GI3	MW	526.5
DMW5GI3	FM	C27H25F3N4O4
DMW5GI3	IC	InChI=1S/C27H25F3N4O4/c1-2-16-3-6-19(7-4-16)33-25(38)34-22-14-31-21(13-32-22)18-5-8-20-17(11-18)9-10-26(24(20)37,12-23(35)36)15-27(28,29)30/h3-8,11,13-14H,2,9-10,12,15H2,1H3,(H,35,36)(H2,32,33,34,38)
DMW5GI3	CS	CCC1=CC=C(C=C1)NC(=O)NC2=NC=C(N=C2)C3=CC4=C(C=C3)C(=O)C(CC4)(CC(=O)O)CC(F)(F)F
DMW5GI3	IK	YPGWBIYAJJSEDN-UHFFFAOYSA-N
DMW5GI3	IU	2-[6-[5-[(4-ethylphenyl)carbamoylamino]pyrazin-2-yl]-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydronaphthalen-2-yl]acetic acid

DMYSWG1	ID	DMYSWG1
DMYSWG1	DN	Carbamide derivative 20
DMYSWG1	HS	Patented
DMYSWG1	SN	PMID28621580-Compound-WO2013037292c17
DMYSWG1	CP	HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD
DMYSWG1	DT	Small molecular drug
DMYSWG1	PC	60171803
DMYSWG1	MW	487.9
DMYSWG1	FM	C23H17ClF3N5O2
DMYSWG1	IC	InChI=1S/C23H17ClF3N5O2/c1-28-21-20-16(8-10-30-21)19(9-11-29-20)34-15-5-2-13(3-6-15)31-22(33)32-14-4-7-18(24)17(12-14)23(25,26)27/h2-12H,1H3,(H,28,30)(H2,31,32,33)
DMYSWG1	CS	CNC1=NC=CC2=C(C=CN=C21)OC3=CC=C(C=C3)NC(=O)NC4=CC(=C(C=C4)Cl)C(F)(F)F
DMYSWG1	IK	ORNWLDOEVOUMBW-UHFFFAOYSA-N
DMYSWG1	IU	1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[4-[[8-(methylamino)-1,7-naphthyridin-4-yl]oxy]phenyl]urea

DMD03J5	ID	DMD03J5
DMD03J5	DN	Carbamide derivative 21
DMD03J5	HS	Patented
DMD03J5	SN	PMID28621580-Compound-WO2013107225c16
DMD03J5	CP	HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD
DMD03J5	DT	Small molecular drug

DMC3TJI	ID	DMC3TJI
DMC3TJI	DN	Carbamide derivative 22
DMC3TJI	HS	Patented
DMC3TJI	SN	PMID28621580-Compound-WO2014040243c18
DMC3TJI	CP	HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD. ZHANG, Shixi
DMC3TJI	DT	Small molecular drug

DM0IRPO	ID	DM0IRPO
DM0IRPO	DN	Carbamide derivative 23
DM0IRPO	HS	Patented
DM0IRPO	SN	PMID28621580-Compound-WO2014201127c20
DM0IRPO	CP	Kala Pharmaceuticals, Inc
DM0IRPO	DT	Small molecular drug

DMD6Y73	ID	DMD6Y73
DMD6Y73	DN	Carbamide derivative 24
DMD6Y73	HS	Patented
DMD6Y73	SN	PMID29053063-Compound-12a
DMD6Y73	CP	NORTHEASTERN UNIVERSITY
DMD6Y73	DT	Small molecular drug

DM8ONCL	ID	DM8ONCL
DM8ONCL	DN	Carbamide derivative 25
DM8ONCL	HS	Patented
DM8ONCL	SN	PMID29053063-Compound-12b
DM8ONCL	CP	NORTHEASTERN UNIVERSITY
DM8ONCL	DT	Small molecular drug

DMDU9XF	ID	DMDU9XF
DMDU9XF	DN	Carbamide derivative 26
DMDU9XF	HS	Patented
DMDU9XF	SN	PMID29053063-Compound-12c
DMDU9XF	CP	NORTHEASTERN UNIVERSITY
DMDU9XF	DT	Small molecular drug

DM4ISCQ	ID	DM4ISCQ
DM4ISCQ	DN	Carbamide derivative 3
DM4ISCQ	HS	Patented
DM4ISCQ	SN	PMID25470667-Compound-Figure5-3
DM4ISCQ	CP	BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DM4ISCQ	DT	Small molecular drug

DM5V2D9	ID	DM5V2D9
DM5V2D9	DN	Carbamide derivative 4
DM5V2D9	HS	Patented
DM5V2D9	SN	PMID28074661-Compound-US20056919335BMS-566419
DM5V2D9	DT	Small molecular drug

DM951HL	ID	DM951HL
DM951HL	DN	Carbamide derivative 5
DM951HL	HS	Patented
DM951HL	SN	PMID28074661-Compound-US20056919335c41
DM951HL	CP	Bristol-Myers Squibb Co
DM951HL	DT	Small molecular drug

DMORBE3	ID	DMORBE3
DMORBE3	DN	Carbamide derivative 6
DMORBE3	HS	Patented
DMORBE3	SN	PMID28074661-Compound-US20056919335c42
DMORBE3	CP	Bristol-Myers Squibb Co
DMORBE3	DT	Small molecular drug

DMWKXN4	ID	DMWKXN4
DMWKXN4	DN	Carbamide derivative 7
DMWKXN4	HS	Patented
DMWKXN4	SN	PMID28074661-Compound-US20056919335c45
DMWKXN4	DT	Small molecular drug

DMZ3FJO	ID	DMZ3FJO
DMZ3FJO	DN	Carbamide derivative 8
DMZ3FJO	HS	Patented
DMZ3FJO	SN	PMID28074661-Compound-US20067008958c52
DMZ3FJO	CP	Bristol-Myers Squibb Co
DMZ3FJO	DT	Small molecular drug

DMY06VC	ID	DMY06VC
DMY06VC	DN	Carbamide derivative 9
DMY06VC	HS	Patented
DMY06VC	SN	PMID28074661-Compound-WO2003053958c49
DMY06VC	CP	CELLTECH R&D LIMITED DYKE, Hazel, Joan RICHARD, Marianna, Dilani HAUGHAN, Alan, Findlay SHARPE, Andrew
DMY06VC	DT	Small molecular drug

DM0EBS8	ID	DM0EBS8
DM0EBS8	DN	Carbamoyl oxime derivative 1
DM0EBS8	HS	Patented
DM0EBS8	SN	PMID26413912-Compound-29
DM0EBS8	CP	SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. MINETTI, Patrizia CABRI, Walter BORSINI, Franco CAPRIOLI, Antonio PENCO, Sergio DALLAVALLE, Sabrina MERLINI, Lucio MACCARRONE, Mauro
DM0EBS8	DT	Small molecular drug

DM3B5RS	ID	DM3B5RS
DM3B5RS	DN	Carbazole-3-carboxamide analog 1
DM3B5RS	HS	Patented
DM3B5RS	SN	PMID27215781-Compound-35
DM3B5RS	DT	Small molecular drug
DM3B5RS	PC	46871948
DM3B5RS	MW	378.5
DM3B5RS	FM	C24H30N2O2
DM3B5RS	IC	InChI=1S/C24H30N2O2/c1-3-4-6-15-26-22-12-9-18(24(27)25-13-7-5-8-14-25)16-21(22)20-11-10-19(28-2)17-23(20)26/h9-12,16-17H,3-8,13-15H2,1-2H3
DM3B5RS	CS	CCCCCN1C2=C(C=C(C=C2)C(=O)N3CCCCC3)C4=C1C=C(C=C4)OC
DM3B5RS	IK	LHILAHDXYGCIPJ-UHFFFAOYSA-N
DM3B5RS	IU	(7-methoxy-9-pentylcarbazol-3-yl)-piperidin-1-ylmethanone

DM5GEBH	ID	DM5GEBH
DM5GEBH	DN	Carboxamide derivative 1
DM5GEBH	HS	Patented
DM5GEBH	SN	PMID26161824-Compound-94
DM5GEBH	DT	Small molecular drug
DM5GEBH	PC	6918856
DM5GEBH	MW	417.3
DM5GEBH	FM	C21H22Cl2N4O
DM5GEBH	IC	InChI=1S/C21H22Cl2N4O/c22-16-9-10-19(17(23)13-16)27-20(15-7-3-1-4-8-15)14-18(24-27)21(28)25-26-11-5-2-6-12-26/h1,3-4,7-10,13,20H,2,5-6,11-12,14H2,(H,25,28)
DM5GEBH	CS	C1CCN(CC1)NC(=O)C2=NN(C(C2)C3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl
DM5GEBH	IK	IAMSOYSVSFMFLR-UHFFFAOYSA-N
DM5GEBH	IU	2-(2,4-dichlorophenyl)-3-phenyl-N-piperidin-1-yl-3,4-dihydropyrazole-5-carboxamide
DM5GEBH	DE	Obesity

DM5WMO9	ID	DM5WMO9
DM5WMO9	DN	Carboxamide derivative 10
DM5WMO9	HS	Patented
DM5WMO9	SN	PMID25399719-Compound-8
DM5WMO9	CP	ABBVIE DEUTSCHLAND [DEABBVIE INC [US] 
DM5WMO9	DT	Small molecular drug

DM1DN94	ID	DM1DN94
DM1DN94	DN	Carboxamide derivative 11
DM1DN94	HS	Patented
DM1DN94	SN	PMID25399719-Compound-9
DM1DN94	CP	ABBVIE DEUTSCHLAND [DEABBVIE INC [US] 
DM1DN94	DT	Small molecular drug
DM1DN94	PC	117932484
DM1DN94	MW	502.6
DM1DN94	FM	C27H30N6O4
DM1DN94	IC	InChI=1S/C27H30N6O4/c34-24(27(36)29-20-8-9-20)23(17-19-5-2-1-3-6-19)30-26(35)22-7-4-11-28-25(22)33-12-10-21(31-33)18-32-13-15-37-16-14-32/h1-7,10-12,20,23H,8-9,13-18H2,(H,29,36)(H,30,35)
DM1DN94	CS	C1CC1NC(=O)C(=O)C(CC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)N4C=CC(=N4)CN5CCOCC5
DM1DN94	IK	POGBERZVWORYJW-UHFFFAOYSA-N
DM1DN94	IU	N-[4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]-2-[3-(morpholin-4-ylmethyl)pyrazol-1-yl]pyridine-3-carboxamide

DMU5GKC	ID	DMU5GKC
DMU5GKC	DN	Carboxamide derivative 4
DMU5GKC	HS	Patented
DMU5GKC	SN	PMID27646564-Compound-11-V
DMU5GKC	CP	ASTELLAS PHARMA INC.  KOTOBUKI PHARMACEUTICAL CO., LTD.  SHIMADA, Itsuro  MATSUYA, Takahiro  KUROSAWA, Kazuo  IIKUBO, Kazuhiko  KAMIKAWA, Akio  KUROMITSU, Sadao  SHINDOU, Nobuaki
DMU5GKC	DT	Small molecular drug

DM149WN	ID	DM149WN
DM149WN	DN	Carboxamide derivative 5
DM149WN	HS	Patented
DM149WN	SN	PMID25399719-Compound-3
DM149WN	DT	Small molecular drug

DM6GZW4	ID	DM6GZW4
DM6GZW4	DN	Carboxamide derivative 6
DM6GZW4	HS	Patented
DM6GZW4	SN	PMID25399719-Compound-4
DM6GZW4	DT	Small molecular drug
DM6GZW4	PC	66644706
DM6GZW4	MW	484.5
DM6GZW4	FM	C28H28N4O4
DM6GZW4	IC	InChI=1S/C28H28N4O4/c33-25-15-14-23(31-25)28(36)32(19-21-11-5-2-6-12-21)24(17-20-9-3-1-4-10-20)26(34)27(35)30-18-22-13-7-8-16-29-22/h1-13,16,23-24H,14-15,17-19H2,(H,30,35)(H,31,33)/t23-,24?/m0/s1
DM6GZW4	CS	C1CC(=O)N[C@@H]1C(=O)N(CC2=CC=CC=C2)C(CC3=CC=CC=C3)C(=O)C(=O)NCC4=CC=CC=N4
DM6GZW4	IK	BRJIMUOJPNOLKS-UXMRNZNESA-N
DM6GZW4	IU	(2S)-N-benzyl-N-[3,4-dioxo-1-phenyl-4-(pyridin-2-ylmethylamino)butan-2-yl]-5-oxopyrrolidine-2-carboxamide

DM8TQS4	ID	DM8TQS4
DM8TQS4	DN	Carboxamide derivative 7
DM8TQS4	HS	Patented
DM8TQS4	SN	PMID25399719-Compound-5
DM8TQS4	CP	ABBVIE DEUTSCHLAND [DEABBVIE INC [US] 
DM8TQS4	DT	Small molecular drug

DM6HI34	ID	DM6HI34
DM6HI34	DN	Carboxamide derivative 8
DM6HI34	HS	Patented
DM6HI34	SN	PMID25399719-Compound-6
DM6HI34	CP	ABBVIE DEUTSCHLAND [DEABBVIE INC [US] 
DM6HI34	DT	Small molecular drug

DMVISYC	ID	DMVISYC
DMVISYC	DN	Carboxamide derivative 9
DMVISYC	HS	Patented
DMVISYC	SN	PMID25399719-Compound-7
DMVISYC	CP	ABBVIE DEUTSCHLAND [DEABBVIE INC [US] 
DMVISYC	DT	Small molecular drug
DMVISYC	PC	89852695
DMVISYC	MW	462.5
DMVISYC	FM	C24H26N6O4
DMVISYC	IC	InChI=1S/C24H26N6O4/c25-22(32)21(31)20(15-17-5-2-1-3-6-17)27-24(33)19-7-4-9-26-23(19)30-10-8-18(28-30)16-29-11-13-34-14-12-29/h1-10,20H,11-16H2,(H2,25,32)(H,27,33)
DMVISYC	CS	C1COCCN1CC2=NN(C=C2)C3=C(C=CC=N3)C(=O)NC(CC4=CC=CC=C4)C(=O)C(=O)N
DMVISYC	IK	LNYKWHMNUSKRNS-UHFFFAOYSA-N
DMVISYC	IU	N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-2-[3-(morpholin-4-ylmethyl)pyrazol-1-yl]pyridine-3-carboxamide

DM86E2P	ID	DM86E2P
DM86E2P	DN	Carboxylic acid derivative 1
DM86E2P	HS	Patented
DM86E2P	SN	PMID28627961-Compound-37
DM86E2P	CP	ELI LILLY AND COMPANY
DM86E2P	DT	Small molecular drug
DM86E2P	DE	Neoplasm; Angiogenesis disorder

DM7INA1	ID	DM7INA1
DM7INA1	DN	Central azetidine derivative 1
DM7INA1	HS	Patented
DM7INA1	SN	PMID28067079-Compound-27
DM7INA1	CP	HUA MEDICINE (SHANGHAI) LTD
DM7INA1	DT	Small molecular drug
DM7INA1	PC	77108120
DM7INA1	MW	286.73
DM7INA1	FM	C16H12ClFN2
DM7INA1	IC	InChI=1S/C16H12ClFN2/c17-13-4-3-6-15(10-13)20-11-16(18,12-20)8-7-14-5-1-2-9-19-14/h1-6,9-10H,11-12H2
DM7INA1	CS	C1C(CN1C2=CC(=CC=C2)Cl)(C#CC3=CC=CC=N3)F
DM7INA1	IK	KUOSCBGVFZTWCN-UHFFFAOYSA-N
DM7INA1	IU	2-[2-[1-(3-chlorophenyl)-3-fluoroazetidin-3-yl]ethynyl]pyridine

DM2BLJ6	ID	DM2BLJ6
DM2BLJ6	DN	Central azetidine derivative 2
DM2BLJ6	HS	Patented
DM2BLJ6	SN	PMID28067079-Compound-28
DM2BLJ6	CP	HUA MEDICINE (SHANGHAI) LTD
DM2BLJ6	DT	Small molecular drug
DM2BLJ6	PC	86291449
DM2BLJ6	MW	300.8
DM2BLJ6	FM	C17H14ClFN2
DM2BLJ6	IC	InChI=1S/C17H14ClFN2/c1-13-6-8-20-15(9-13)5-7-17(19)11-21(12-17)16-4-2-3-14(18)10-16/h2-4,6,8-10H,11-12H2,1H3
DM2BLJ6	CS	CC1=CC(=NC=C1)C#CC2(CN(C2)C3=CC(=CC=C3)Cl)F
DM2BLJ6	IK	CCKHKYMAGHMQLN-UHFFFAOYSA-N
DM2BLJ6	IU	2-[2-[1-(3-chlorophenyl)-3-fluoroazetidin-3-yl]ethynyl]-4-methylpyridine

DMSMBCO	ID	DMSMBCO
DMSMBCO	DN	Chalcone derivative 1
DMSMBCO	HS	Patented
DMSMBCO	SN	PMID28454500-Compound-16
DMSMBCO	CP	THE JOHNS HOPKINS UNIVERSITY BISWAL, Shyam THIMMULAPPA, Rajesh KUMAR, Sarvesh MALHOTRA, Sanjay, V. KUMAR, Vineet JUNG-HYUN, Kim
DMSMBCO	DT	Small molecular drug
DMSMBCO	PC	53262706
DMSMBCO	MW	306.28
DMSMBCO	FM	C17H13F3O2
DMSMBCO	IC	InChI=1S/C17H13F3O2/c1-22-16-9-5-3-7-13(16)15(21)11-10-12-6-2-4-8-14(12)17(18,19)20/h2-11H,1H3/b11-10+
DMSMBCO	CS	COC1=CC=CC=C1C(=O)/C=C/C2=CC=CC=C2C(F)(F)F
DMSMBCO	IK	BDZOPPCXQXPRKH-ZHACJKMWSA-N
DMSMBCO	IU	(E)-1-(2-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one

DMG84D3	ID	DMG84D3
DMG84D3	DN	Chalcone derivative 2
DMG84D3	HS	Patented
DMG84D3	SN	PMID28454500-Compound-17
DMG84D3	CP	CUREVEDA, LLC
DMG84D3	DT	Small molecular drug
DMG84D3	PC	118567519
DMG84D3	MW	307.27
DMG84D3	FM	C16H12F3NO2
DMG84D3	IC	InChI=1S/C16H12F3NO2/c1-22-15-8-9-20-10-12(15)14(21)7-6-11-4-2-3-5-13(11)16(17,18)19/h2-10H,1H3/b7-6+
DMG84D3	CS	COC1=C(C=NC=C1)C(=O)/C=C/C2=CC=CC=C2C(F)(F)F
DMG84D3	IK	ZYPJWXKOHCZQCI-VOTSOKGWSA-N
DMG84D3	IU	(E)-1-(4-methoxypyridin-3-yl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one

DMFS7C3	ID	DMFS7C3
DMFS7C3	DN	Chalcone derivative 3
DMFS7C3	HS	Patented
DMFS7C3	SN	PMID28454500-Compound-18
DMFS7C3	CP	CUREVEDA, LLC
DMFS7C3	DT	Small molecular drug

DM45COR	ID	DM45COR
DM45COR	DN	Chalcone derivative 4
DM45COR	HS	Patented
DM45COR	SN	PMID28454500-Compound-19
DM45COR	CP	CUREVEDA, LLC
DM45COR	DT	Small molecular drug
DM45COR	PC	118567653
DM45COR	MW	273.71
DM45COR	FM	C15H12ClNO2
DM45COR	IC	InChI=1S/C15H12ClNO2/c1-19-14-7-4-10-17-15(14)13(18)9-8-11-5-2-3-6-12(11)16/h2-10H,1H3/b9-8+
DM45COR	CS	COC1=C(N=CC=C1)C(=O)/C=C/C2=CC=CC=C2Cl
DM45COR	IK	ADUCKBZUFASKCP-CMDGGOBGSA-N
DM45COR	IU	(E)-3-(2-chlorophenyl)-1-(3-methoxypyridin-2-yl)prop-2-en-1-one

DMJZGT8	ID	DMJZGT8
DMJZGT8	DN	Chalcone derivative 5
DMJZGT8	HS	Patented
DMJZGT8	SN	PMID26560530-Compound-37
DMJZGT8	CP	Toray Industries, Inc
DMJZGT8	DT	Small molecular drug

DMB8MNU	ID	DMB8MNU
DMB8MNU	DN	CHIR-99021
DMB8MNU	HS	Patented
DMB8MNU	SN	CHIR99021; CHIR 99021; CT-99021; CT99021
DMB8MNU	DT	Small molecular drug
DMB8MNU	PC	9956119
DMB8MNU	MW	465.3
DMB8MNU	FM	C22H18Cl2N8
DMB8MNU	IC	InChI=1S/C22H18Cl2N8/c1-13-10-29-21(31-13)17-12-30-22(32-20(17)16-4-3-15(23)8-18(16)24)27-7-6-26-19-5-2-14(9-25)11-28-19/h2-5,8,10-12H,6-7H2,1H3,(H,26,28)(H,29,31)(H,27,30,32)
DMB8MNU	CS	CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C#N
DMB8MNU	IK	AQGNHMOJWBZFQQ-UHFFFAOYSA-N
DMB8MNU	IU	6-[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethylamino]pyridine-3-carbonitrile
DMB8MNU	CA	CAS 252917-06-9
DMB8MNU	CB	CHEBI:91091
DMB8MNU	DE	Graft rejection; Allergic inflammation

DMW4J0P	ID	DMW4J0P
DMW4J0P	DN	Chloroacetyl ester derivative 1
DMW4J0P	HS	Patented
DMW4J0P	SN	PMID26560530-Compound-10
DMW4J0P	CP	N Zyme Biotech GmbH
DMW4J0P	DT	Small molecular drug
DMW4J0P	PC	88174183
DMW4J0P	MW	372.76
DMW4J0P	FM	C15H17ClN2O7
DMW4J0P	IC	InChI=1S/C15H17ClN2O7/c16-6-13(21)24-9-11(14(22)17-7-12(19)20)18-15(23)25-8-10-4-2-1-3-5-10/h1-5,11H,6-9H2,(H,17,22)(H,18,23)(H,19,20)/t11-/m0/s1
DMW4J0P	CS	C1=CC=C(C=C1)COC(=O)N[C@@H](COC(=O)CCl)C(=O)NCC(=O)O
DMW4J0P	IK	UEILGHHGUUQOCS-NSHDSACASA-N
DMW4J0P	IU	2-[[(2S)-3-(2-chloroacetyl)oxy-2-(phenylmethoxycarbonylamino)propanoyl]amino]acetic acid

DMR39ZY	ID	DMR39ZY
DMR39ZY	DN	Chlorobenzamide derivative 1
DMR39ZY	HS	Patented
DMR39ZY	SN	PMID27724045-Compound-26
DMR39ZY	CP	H. LUNDBECK A/S
DMR39ZY	DT	Small molecular drug
DMR39ZY	PC	73673308
DMR39ZY	MW	450.8
DMR39ZY	FM	C20H17ClF6N2O
DMR39ZY	IC	InChI=1S/C20H17ClF6N2O/c21-15-4-2-1-3-14(15)17(30)29-11-13(9-18(7-8-18)20(25,26)27)12-5-6-16(28-10-12)19(22,23)24/h1-6,10,13H,7-9,11H2,(H,29,30)
DMR39ZY	CS	C1CC1(CC(CNC(=O)C2=CC=CC=C2Cl)C3=CN=C(C=C3)C(F)(F)F)C(F)(F)F
DMR39ZY	IK	GRQCSOYTLVIPEY-UHFFFAOYSA-N
DMR39ZY	IU	2-chloro-N-[3-[1-(trifluoromethyl)cyclopropyl]-2-[6-(trifluoromethyl)pyridin-3-yl]propyl]benzamide

DMKS7O3	ID	DMKS7O3
DMKS7O3	DN	Chlorobenzamide derivative 2
DMKS7O3	HS	Patented
DMKS7O3	SN	PMID27724045-Compound-27
DMKS7O3	CP	H. LUNDBECK A/S
DMKS7O3	DT	Small molecular drug
DMKS7O3	PC	73442861
DMKS7O3	MW	431.3
DMKS7O3	FM	C20H19Cl2F3N2O
DMKS7O3	IC	InChI=1S/C20H19Cl2F3N2O/c21-16-3-1-2-15(18(16)22)19(28)26-12-17(13-4-6-14(23)7-5-13)27-10-8-20(24,25)9-11-27/h1-7,17H,8-12H2,(H,26,28)
DMKS7O3	CS	C1CN(CCC1(F)F)C(CNC(=O)C2=C(C(=CC=C2)Cl)Cl)C3=CC=C(C=C3)F
DMKS7O3	IK	ASROAJWWBQODIW-UHFFFAOYSA-N
DMKS7O3	IU	2,3-dichloro-N-[2-(4,4-difluoropiperidin-1-yl)-2-(4-fluorophenyl)ethyl]benzamide

DM7SOZN	ID	DM7SOZN
DM7SOZN	DN	Chromene derivative 1
DM7SOZN	HS	Patented
DM7SOZN	SN	PMID26609882-Compound-86
DM7SOZN	CP	WYETH HEFFERNAN, Gavin, David STACK, Gary, Paul GROSS, Jonathan, Laird ZHOU, Dahui GAO, Hong
DM7SOZN	DT	Small molecular drug

DMINXMY	ID	DMINXMY
DMINXMY	DN	CID 138805970
DMINXMY	HS	Patented
DMINXMY	DT	Small molecular drug
DMINXMY	PC	138805970
DMINXMY	MW	399.4
DMINXMY	FM	C23H21N5O2
DMINXMY	IC	InChI=1S/C23H21N5O2/c1-15-11-24-23(30)21-10-17-9-19(7-8-20(17)28(15)21)26-22(29)18-12-25-27(14-18)13-16-5-3-2-4-6-16/h2-10,12,14-15H,11,13H2,1H3,(H,24,30)(H,26,29)/t15-/m1/s1
DMINXMY	CS	C[C@@H]1CNC(=O)C2=CC3=C(N12)C=CC(=C3)NC(=O)C4=CN(N=C4)CC5=CC=CC=C5
DMINXMY	IK	DWRUMXZDNGCUDK-OAHLLOKOSA-N
DMINXMY	IU	1-benzyl-N-[(4R)-4-methyl-1-oxo-3,4-dihydro-2H-pyrazino[1,2-a]indol-8-yl]pyrazole-4-carboxamide

DMITX1G	ID	DMITX1G
DMITX1G	DN	Citalopram derivative 1
DMITX1G	HS	Patented
DMITX1G	SN	PMID29334795-Compound-59
DMITX1G	DT	Small molecular drug
DMITX1G	PC	2771
DMITX1G	MW	324.4
DMITX1G	FM	C20H21FN2O
DMITX1G	IC	InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
DMITX1G	CS	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
DMITX1G	IK	WSEQXVZVJXJVFP-UHFFFAOYSA-N
DMITX1G	IU	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DMITX1G	CA	CAS 59729-33-8
DMITX1G	CB	CHEBI:77397

DMV6H95	ID	DMV6H95
DMV6H95	DN	C-linked disaccharide biphenyl mannoside derivative 1
DMV6H95	HS	Patented
DMV6H95	SN	PMID26651364-Compound-86
DMV6H95	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMV6H95	DT	Carbohydrates
DMV6H95	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMJT1WG	ID	DMJT1WG
DMJT1WG	DN	C-linked disaccharide biphenyl mannoside derivative 2
DMJT1WG	HS	Patented
DMJT1WG	SN	PMID26651364-Compound-87
DMJT1WG	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMJT1WG	DT	Carbohydrates
DMJT1WG	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMY10T2	ID	DMY10T2
DMY10T2	DN	C-linked disaccharide biphenyl mannoside derivative 3
DMY10T2	HS	Patented
DMY10T2	SN	PMID26651364-Compound-88
DMY10T2	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMY10T2	DT	Carbohydrates
DMY10T2	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMRLE65	ID	DMRLE65
DMRLE65	DN	C-linked disaccharide biphenyl mannoside derivative 4
DMRLE65	HS	Patented
DMRLE65	SN	PMID26651364-Compound-89
DMRLE65	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMRLE65	DT	Carbohydrates
DMRLE65	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMUG7E9	ID	DMUG7E9
DMUG7E9	DN	C-linked disaccharide biphenyl mannoside derivative 5
DMUG7E9	HS	Patented
DMUG7E9	SN	PMID26651364-Compound-90
DMUG7E9	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMUG7E9	DT	Carbohydrates
DMUG7E9	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMUILMD	ID	DMUILMD
DMUILMD	DN	C-linked disaccharide biphenyl mannoside derivative 6
DMUILMD	HS	Patented
DMUILMD	SN	PMID26651364-Compound-91
DMUILMD	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMUILMD	DT	Carbohydrates
DMUILMD	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMWYJF6	ID	DMWYJF6
DMWYJF6	DN	Complex heterocyclic compound 1
DMWYJF6	HS	Patented
DMWYJF6	SN	PMID28447479-Compound-30
DMWYJF6	CP	GALAPAGOS NV
DMWYJF6	DT	Small molecular drug
DMWYJF6	PC	78427770
DMWYJF6	MW	592.7
DMWYJF6	FM	C29H30F2N8O2S
DMWYJF6	IC	InChI=1S/C29H30F2N8O2S/c1-3-23-28(35(2)29-34-26(24(13-32)42-29)18-4-6-19(30)7-5-18)39-14-20(12-22(31)27(39)33-23)37-10-8-36(9-11-37)17-25(41)38-15-21(40)16-38/h4-7,12,14,21,40H,3,8-11,15-17H2,1-2H3
DMWYJF6	CS	CCC1=C(N2C=C(C=C(C2=N1)F)N3CCN(CC3)CC(=O)N4CC(C4)O)N(C)C5=NC(=C(S5)C#N)C6=CC=C(C=C6)F
DMWYJF6	IK	XWIATKKSLBPZTC-UHFFFAOYSA-N
DMWYJF6	IU	2-[[2-ethyl-8-fluoro-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]imidazo[1,2-a]pyridin-3-yl]-methylamino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile
DMWYJF6	DE	Inflammation

DMLZMIG	ID	DMLZMIG
DMLZMIG	DN	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1
DMLZMIG	HS	Patented
DMLZMIG	SN	PMID28621580-Compound-WO2012084683c62
DMLZMIG	CP	UNIV MAINZ JOHANNES GUTENBERG [DE]
DMLZMIG	DT	Small molecular drug
DMLZMIG	DE	Gastric adenocarcinoma

DM3ZGBH	ID	DM3ZGBH
DM3ZGBH	DN	Coumaricacid
DM3ZGBH	HS	Patented
DM3ZGBH	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER

DMI1BKA	ID	DMI1BKA
DMI1BKA	DN	Coumarin/resveratrol hybrid derivative 1
DMI1BKA	HS	Patented
DMI1BKA	SN	PMID29324067-Compound-63
DMI1BKA	CP	University Hefei Technology
DMI1BKA	DT	Small molecular drug

DMK12OT	ID	DMK12OT
DMK12OT	DN	Coumarin/resveratrol hybrid derivative 2
DMK12OT	HS	Patented
DMK12OT	SN	PMID29324067-Compound-71
DMK12OT	CP	University Hefei Technology
DMK12OT	DT	Small molecular drug

DMXP073	ID	DMXP073
DMXP073	DN	CQ7
DMXP073	HS	Patented
DMXP073	SN	cc-671; 1618658-88-0; CC671; 4-{[4-(Cyclopentyloxy)-5-(2-Methyl-1,3-Benzoxazol-6-Yl)-7h-Pyrrolo[2,3-D]pyrimidin-2-Yl]amino}-3-Methoxy-N-Methylbenzamide; SCHEMBL16476100; CHEMBL4062218; US9623028, Compound 38; BDBM317462; EX-A1868; CS-8218; 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide; HY-108709; 4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide; CQ7
DMXP073	DT	Small molecular drug
DMXP073	PC	117881270
DMXP073	MW	512.6
DMXP073	FM	C28H28N6O4
DMXP073	IC	InChI=1S/C28H28N6O4/c1-15-31-21-10-8-16(12-23(21)37-15)19-14-30-25-24(19)27(38-18-6-4-5-7-18)34-28(33-25)32-20-11-9-17(26(35)29-2)13-22(20)36-3/h8-14,18H,4-7H2,1-3H3,(H,29,35)(H2,30,32,33,34)
DMXP073	CS	CC1=NC2=C(O1)C=C(C=C2)C3=CNC4=C3C(=NC(=N4)NC5=C(C=C(C=C5)C(=O)NC)OC)OC6CCCC6
DMXP073	IK	CWJLAVRXVFHDSJ-UHFFFAOYSA-N
DMXP073	IU	4-[[4-cyclopentyloxy-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxy-N-methylbenzamide

DMBV5Z0	ID	DMBV5Z0
DMBV5Z0	DN	CRWCYVOHVXAEMF-LBPRGKRZSA-N
DMBV5Z0	HS	Patented
DMBV5Z0	SN	CHEMBL2385270; SCHEMBL15138926; CRWCYVOHVXAEMF-LBPRGKRZSA-N; BDBM50434166; (S)-N-(2-(2-Cyanopyrrolidine-1-yl)-2-oxoethyl)-6-fluoroquinoline-4-carboxamide
DMBV5Z0	DT	Small molecular drug
DMBV5Z0	PC	71667229
DMBV5Z0	MW	326.32
DMBV5Z0	FM	C17H15FN4O2
DMBV5Z0	IC	InChI=1S/C17H15FN4O2/c18-11-3-4-15-14(8-11)13(5-6-20-15)17(24)21-10-16(23)22-7-1-2-12(22)9-19/h3-6,8,12H,1-2,7,10H2,(H,21,24)/t12-/m0/s1
DMBV5Z0	CS	C1C[C@H](N(C1)C(=O)CNC(=O)C2=C3C=C(C=CC3=NC=C2)F)C#N
DMBV5Z0	IK	CRWCYVOHVXAEMF-LBPRGKRZSA-N
DMBV5Z0	IU	N-[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]-6-fluoroquinoline-4-carboxamide

DM76Q10	ID	DM76Q10
DM76Q10	DN	Crystalline anhydrous toluene derivative 1
DM76Q10	HS	Patented
DM76Q10	SN	PMID25416646-Compound-Figure2-H
DM76Q10	CP	MERCK & CO., INC. LEYES, Aquiles, E
DM76Q10	DT	Small molecular drug

DM5BFJO	ID	DM5BFJO
DM5BFJO	DN	CS-W011402
DM5BFJO	HS	Patented
DM5BFJO	SN	DICHLOROBIS[DI-TERT-BUTYL(4-DIMETHYLAMINOPHENYL)PHOSPHINO]PALLADIUM(II); bis(di-tert-butyl(4-dimethylaminophenyl)-phosphine)dichloropalladium(II); DICHLOROBIS[DI-TERT-BUTYL(4-DIMETHYLAMINOPHENYL)PHOSPHINE]PALLADIUM(II); SCHEMBL113074; US9598421, Example 8; KS-00000ESS; AWOFSUFKCXRJMV-UHFFFAOYSA-N; XRZMZNIQMNUFBE-UHFFFAOYSA-L; AJBUBMMXJAOMTF-UHFFFAOYSA-N; BDBM302439; CS-W011402; bis(di-tert-butyl(4-dimethylaminophenyl)phosphino)dichloropalladium; dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]phosphoranyl})palladium
DM5BFJO	DT	Small molecular drug
DM5BFJO	PC	58567970
DM5BFJO	MW	710.1
DM5BFJO	FM	C32H58Cl2N2P2Pd+2
DM5BFJO	IC	InChI=1S/2C16H28NP.2ClH.Pd/c2*1-15(2,3)18(16(4,5)6)14-11-9-13(10-12-14)17(7)8;;;/h2*9-12H,1-8H3;2*1H;/q;;;;+2
DM5BFJO	CS	CC(C)(C)[PH+](C1=CC=C(C=C1)N(C)C)C(C)(C)C.CC(C)(C)[PH+](C1=CC=C(C=C1)N(C)C)C(C)(C)C.Cl[Pd]Cl
DM5BFJO	IK	DWOZNANUEDYIOF-UHFFFAOYSA-N
DM5BFJO	IU	ditert-butyl-[4-(dimethylamino)phenyl]phosphanium;dichloropalladium

DM4765M	ID	DM4765M
DM4765M	DN	Curcumin analog 1
DM4765M	HS	Patented
DM4765M	SN	PMID26394986-Compound-32
DM4765M	CP	The Ohio State University Research Foundation
DM4765M	DT	Small molecular drug
DM4765M	PC	11487078
DM4765M	MW	424.5
DM4765M	FM	C25H28O6
DM4765M	IC	InChI=1S/C25H28O6/c1-25(2,23(26)13-9-17-7-11-19(28-3)21(15-17)30-5)24(27)14-10-18-8-12-20(29-4)22(16-18)31-6/h7-16H,1-6H3/b13-9+,14-10+
DM4765M	CS	CC(C(=O)/C=C/C1=CC(=C(C=C1)OC)OC)(C(=O)/C=C/C2=CC(=C(C=C2)OC)OC)C
DM4765M	IK	VMMZAMVBGQWOHT-UTLPMFLDSA-N
DM4765M	IU	(1E,6E)-1,7-bis(3,4-dimethoxyphenyl)-4,4-dimethylhepta-1,6-diene-3,5-dione
DM4765M	CA	CAS 52328-97-9

DMZ8S6X	ID	DMZ8S6X
DMZ8S6X	DN	Curcumin analog 2
DMZ8S6X	HS	Patented
DMZ8S6X	SN	PMID26394986-Compound-33
DMZ8S6X	CP	The Ohio State University Research Foundation
DMZ8S6X	DT	Small molecular drug
DMZ8S6X	PC	68019246
DMZ8S6X	MW	464.5
DMZ8S6X	FM	C28H32O6
DMZ8S6X	IC	InChI=1S/C28H32O6/c1-31-22-12-8-20(18-24(22)33-3)10-14-26(29)28(16-6-5-7-17-28)27(30)15-11-21-9-13-23(32-2)25(19-21)34-4/h8-15,18-19H,5-7,16-17H2,1-4H3/b14-10+,15-11+
DMZ8S6X	CS	COC1=C(C=C(C=C1)/C=C/C(=O)C2(CCCCC2)C(=O)/C=C/C3=CC(=C(C=C3)OC)OC)OC
DMZ8S6X	IK	NQDROBVIYYEMDQ-WFYKWJGLSA-N
DMZ8S6X	IU	(E)-3-(3,4-dimethoxyphenyl)-1-[1-[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]cyclohexyl]prop-2-en-1-one

DMMX1ZE	ID	DMMX1ZE
DMMX1ZE	DN	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1
DMMX1ZE	HS	Patented
DMMX1ZE	SN	PMID27215781-Compound-14
DMMX1ZE	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMMX1ZE	DT	Small molecular drug
DMMX1ZE	PC	86297384
DMMX1ZE	MW	348.4
DMMX1ZE	FM	C18H28N4O3
DMMX1ZE	IC	InChI=1S/C18H28N4O3/c1-17(2,12-19)14-10-15(25-21-14)20-16(23)18(3,4)22(5)11-13-6-8-24-9-7-13/h10,13H,6-9,11H2,1-5H3,(H,20,23)
DMMX1ZE	CS	CC(C)(C#N)C1=NOC(=C1)NC(=O)C(C)(C)N(C)CC2CCOCC2
DMMX1ZE	IK	OLLDWVBPHQUDHP-UHFFFAOYSA-N
DMMX1ZE	IU	N-[3-(2-cyanopropan-2-yl)-1,2-oxazol-5-yl]-2-methyl-2-[methyl(oxan-4-ylmethyl)amino]propanamide

DM6GTDM	ID	DM6GTDM
DM6GTDM	DN	Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2
DM6GTDM	HS	Patented
DM6GTDM	SN	PMID27215781-Compound-15
DM6GTDM	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DM6GTDM	DT	Small molecular drug
DM6GTDM	PC	49849167
DM6GTDM	MW	367.5
DM6GTDM	FM	C19H33N3O4
DM6GTDM	IC	InChI=1S/C19H33N3O4/c1-18(2,13-24-6)15-11-16(26-21-15)20-17(23)19(3,4)22(5)12-14-7-9-25-10-8-14/h11,14H,7-10,12-13H2,1-6H3,(H,20,23)
DM6GTDM	CS	CC(C)(COC)C1=NOC(=C1)NC(=O)C(C)(C)N(C)CC2CCOCC2
DM6GTDM	IK	FTTMRXSESRGDGE-UHFFFAOYSA-N
DM6GTDM	IU	N-[3-(1-methoxy-2-methylpropan-2-yl)-1,2-oxazol-5-yl]-2-methyl-2-[methyl(oxan-4-ylmethyl)amino]propanamide

DMD198F	ID	DMD198F
DMD198F	DN	Cyanomethyl pypazole carboxamide derivative 1
DMD198F	HS	Patented
DMD198F	SN	PMID27774822-Compound-Figure2Example40-85
DMD198F	CP	MERCK SHARP & DOHME CORP. BRUBAKER, Jason CHILDERS, Matthew Lloyd CHRISTOPHER, Matthew CLOSE, Joshua, T. KATZ, Jason David JUNG, Joon PETERSON, Scott SILIPHAIVANH, Phieng SIU, Tony SMITH, Graham Frank TORRES, Luis, E. WOO, Hyun Chong YOUNG, Jonathan, R. ZHANG, Hongjun
DMD198F	DT	Small molecular drug

DMSVMUT	ID	DMSVMUT
DMSVMUT	DN	Cyclic compound 1
DMSVMUT	HS	Patented
DMSVMUT	SN	PMID30107136-Compound-Example80
DMSVMUT	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMSVMUT	DT	Small molecule immunotherapy 
DMSVMUT	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMGRBAJ	ID	DMGRBAJ
DMGRBAJ	DN	Cyclic compound 2
DMGRBAJ	HS	Patented
DMGRBAJ	SN	PMID30107136-Compound-Example81
DMGRBAJ	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMGRBAJ	DT	Small molecule immunotherapy 
DMGRBAJ	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMVOEN7	ID	DMVOEN7
DMVOEN7	DN	Cyclic compound 3
DMVOEN7	HS	Patented
DMVOEN7	SN	PMID30107136-Compound-Example82
DMVOEN7	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMVOEN7	DT	Small molecule immunotherapy 
DMVOEN7	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM2BZI0	ID	DM2BZI0
DM2BZI0	DN	Cyclic cyanoethypypazole derivative 1
DM2BZI0	HS	Patented
DM2BZI0	SN	PMID27774822-Compound-Figure2Example14-1
DM2BZI0	CP	MERCK SHARP & DOHME [US]
DM2BZI0	DT	Small molecular drug

DM0K62M	ID	DM0K62M
DM0K62M	DN	Cyclic hydroxamate derivative 1
DM0K62M	HS	Patented
DM0K62M	SN	PMID29473428-Compound-28
DM0K62M	CP	CURADEV PHARMA PVT. LTD
DM0K62M	DT	Small molecular drug
DM0K62M	PC	130405851
DM0K62M	MW	350.29
DM0K62M	FM	C17H13F3N2O3
DM0K62M	IC	InChI=1S/C17H13F3N2O3/c18-17(19,20)13-8-4-7-12(9-13)15-21(10-14(23)22(15)25)16(24)11-5-2-1-3-6-11/h1-9,15,25H,10H2
DM0K62M	CS	C1C(=O)N(C(N1C(=O)C2=CC=CC=C2)C3=CC(=CC=C3)C(F)(F)F)O
DM0K62M	IK	KDNAARNFNBRRTM-UHFFFAOYSA-N
DM0K62M	IU	1-benzoyl-3-hydroxy-2-[3-(trifluoromethyl)phenyl]imidazolidin-4-one

DM1ZIPN	ID	DM1ZIPN
DM1ZIPN	DN	Cyclic octapeptide derivative 1
DM1ZIPN	HS	Patented
DM1ZIPN	SN	PMID26882240-Compound-33
DM1ZIPN	CP	ONCOIMMUNE INC. SUNVITA THERAPEUTICS, 
DM1ZIPN	DT	Small molecular drug

DM78NOU	ID	DM78NOU
DM78NOU	DN	Cyclic peptide derivative 1
DM78NOU	HS	Patented
DM78NOU	SN	PMID27019002-Compound-compound11
DM78NOU	CP	MUSC Foundation for Research Development, USA
DM78NOU	DT	Peptide

DMV2UQ5	ID	DMV2UQ5
DMV2UQ5	DN	Cyclic peptidomimetic derivative 1
DMV2UQ5	HS	Patented
DMV2UQ5	SN	PMID30107136-Compound-Example77
DMV2UQ5	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMV2UQ5	DT	Small molecule immunotherapy 
DMV2UQ5	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMWH3FP	ID	DMWH3FP
DMWH3FP	DN	Cyclic peptidomimetic derivative 2
DMWH3FP	HS	Patented
DMWH3FP	SN	PMID30107136-Compound-Example78
DMWH3FP	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMWH3FP	DT	Small molecule immunotherapy 
DMWH3FP	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMI7KG4	ID	DMI7KG4
DMI7KG4	DN	Cyclic peptidomimetic derivative 3
DMI7KG4	HS	Patented
DMI7KG4	SN	PMID30107136-Compound-Example79
DMI7KG4	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMI7KG4	DT	Small molecule immunotherapy 
DMI7KG4	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMJMWDV	ID	DMJMWDV
DMJMWDV	DN	Cyclic sulfonamide derivative 1
DMJMWDV	HS	Patented
DMJMWDV	SN	PMID25726713-Compound-52
DMJMWDV	CP	NANT HOLDINGS IP, LLC
DMJMWDV	DT	Small molecular drug

DMXSZ5B	ID	DMXSZ5B
DMXSZ5B	DN	Cyclic sulfonamide derivative 2
DMXSZ5B	HS	Patented
DMXSZ5B	SN	PMID25726713-Compound-53
DMXSZ5B	CP	NANT HOLDINGS IP, LLC
DMXSZ5B	DT	Small molecular drug

DMBANT7	ID	DMBANT7
DMBANT7	DN	Cyclic sulfonamide derivative 3
DMBANT7	HS	Patented
DMBANT7	SN	PMID25726713-Compound-54
DMBANT7	CP	NANT HOLDINGS IP, LLC
DMBANT7	DT	Small molecular drug

DMWAU49	ID	DMWAU49
DMWAU49	DN	Cyclic sulfonamide derivative 4
DMWAU49	HS	Patented
DMWAU49	SN	PMID25726713-Compound-55
DMWAU49	CP	NANT HOLDINGS IP, LLC
DMWAU49	DT	Small molecular drug

DMXMGSP	ID	DMXMGSP
DMXMGSP	DN	Cycloalkyl acid derivative 1
DMXMGSP	HS	Patented
DMXMGSP	SN	PMID27414413-Compound-Figure9left
DMXMGSP	CP	SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. JIANGSU HENGRUI MEDICINE CO., LTD
DMXMGSP	DT	Small molecular drug

DM09LY3	ID	DM09LY3
DM09LY3	DN	Cycloalkyl acid derivative 2
DM09LY3	HS	Patented
DM09LY3	SN	PMID27414413-Compound-Figure9right
DM09LY3	CP	SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. JIANGSU HENGRUI MEDICINE CO., LTD
DM09LY3	DT	Small molecular drug
DM09LY3	PC	86294127
DM09LY3	MW	338.22
DM09LY3	FM	C14H12BrNO2S
DM09LY3	IC	InChI=1S/C14H12BrNO2S/c15-9-2-3-11-10(8-9)12(4-7-16-11)19-14(13(17)18)5-1-6-14/h2-4,7-8H,1,5-6H2,(H,17,18)
DM09LY3	CS	C1CC(C1)(C(=O)O)SC2=C3C=C(C=CC3=NC=C2)Br
DM09LY3	IK	QGBWIYLNOBYNDL-UHFFFAOYSA-N
DM09LY3	IU	1-(6-bromoquinolin-4-yl)sulfanylcyclobutane-1-carboxylic acid
DM09LY3	CA	CAS 1638327-48-6

DM3RK0S	ID	DM3RK0S
DM3RK0S	DN	Cycloalkyl nitrile pyrazole carboxamide derivative 1
DM3RK0S	HS	Patented
DM3RK0S	SN	PMID27774822-Compound-Figure2Example1-4
DM3RK0S	CP	MERCK SHARP & DOHME CORP. BRUBAKER, Jason DINSMORE, Christopher J. HOFFMAN, Dawn Marie JUNG, Joon LIU, Duan PETERSON, Scott SIU, Tony TORRES, Luis E. ZHANG, Hongjun WEI, Zhongyong SHI, Feng
DM3RK0S	DT	Small molecular drug

DMD3LK1	ID	DMD3LK1
DMD3LK1	DN	Cycloalkyl nitrile pyrazolo pyridone derivative 1
DMD3LK1	HS	Patented
DMD3LK1	SN	PMID27774822-Compound-Figure2Example15-71
DMD3LK1	CP	MERCK SHARP & DOHME CORP. CHILDERS, Matthew Lloyd DINSMORE, Christopher FULLER, Peter GUERIN, David KATZ, Jason David PU, Qinglin SCOTT, Mark E. THOMPSON, Christopher F. ZHANG, Hongjun FALCONE, Danielle TORRES, Luis BRUBAKER, Jason ZENG, Hongbo CAI, Jiaqiang DU, Xiaoxing WANG, Chonggang BAI, Yunfeng KONG, Norman LIU, Yumei ZHENG, Zhixiang
DMD3LK1	DT	Small molecular drug

DMW4JB0	ID	DMW4JB0
DMW4JB0	DN	Cycloalkyl nitrile pyrazolo pyridone derivative 2
DMW4JB0	HS	Patented
DMW4JB0	SN	PMID27774822-Compound-Figure2Example3-9
DMW4JB0	CP	MERCK SHARP & DOHME CORP. CHILDERS, Matthew L. DINSMORE, Christopher FULLER, Peter H. GUERIN, David J. KATZ, Jason David PU, Qinglin SCOTT, Mark E. THOMPSON, Christopher F. ZHANG, Hongjun CAI, Jiaqiang DU, Xiaoxing WANG, Chonggang KONG, Norman LIU, Yumei
DMW4JB0	DT	Small molecular drug

DMN3WID	ID	DMN3WID
DMN3WID	DN	Cyclohexane carboxamide derivative 1
DMN3WID	HS	Patented
DMN3WID	SN	PMID28699813-Compound-17
DMN3WID	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMN3WID	DT	Small molecular drug
DMN3WID	PC	54670056
DMN3WID	MW	586.9
DMN3WID	FM	C29H30BrClFN3O2
DMN3WID	IC	InChI=1S/C29H30BrClFN3O2/c30-22-5-1-19(2-6-22)26-18-24(35-13-15-37-16-14-35)9-10-25(26)29(36)34-28(20-3-7-23(31)8-4-20)21-11-12-33-27(32)17-21/h1-8,11-12,17,24-26,28H,9-10,13-16,18H2,(H,34,36)/t24-,25-,26+,28?/m1/s1
DMN3WID	CS	C1C[C@H]([C@@H](C[C@@H]1N2CCOCC2)C3=CC=C(C=C3)Br)C(=O)NC(C4=CC=C(C=C4)Cl)C5=CC(=NC=C5)F
DMN3WID	IK	ABJSOROVZZKJGI-OCYUSGCXSA-N
DMN3WID	IU	(1R,2R,4R)-2-(4-bromophenyl)-N-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide

DM1A0WU	ID	DM1A0WU
DM1A0WU	DN	Cyclohexane carboxamide derivative 2
DM1A0WU	HS	Patented
DM1A0WU	SN	PMID28699813-Compound-18
DM1A0WU	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DM1A0WU	DT	Small molecular drug
DM1A0WU	PC	54670150
DM1A0WU	MW	570.5
DM1A0WU	FM	C29H30BrF2N3O2
DM1A0WU	IC	InChI=1S/C29H30BrF2N3O2/c30-22-5-1-19(2-6-22)26-18-24(35-13-15-37-16-14-35)9-10-25(26)29(36)34-28(20-3-7-23(31)8-4-20)21-11-12-33-27(32)17-21/h1-8,11-12,17,24-26,28H,9-10,13-16,18H2,(H,34,36)/t24-,25-,26+,28?/m1/s1
DM1A0WU	CS	C1C[C@H]([C@@H](C[C@@H]1N2CCOCC2)C3=CC=C(C=C3)Br)C(=O)NC(C4=CC=C(C=C4)F)C5=CC(=NC=C5)F
DM1A0WU	IK	SPLGKYRHYYLJLJ-OCYUSGCXSA-N
DM1A0WU	IU	(1R,2R,4R)-2-(4-bromophenyl)-N-[(4-fluorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide

DMQLZUW	ID	DMQLZUW
DMQLZUW	DN	Cyclohexane carboxamide derivative 3
DMQLZUW	HS	Patented
DMQLZUW	SN	PMID28699813-Compound-I
DMQLZUW	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMQLZUW	DT	Small molecular drug

DMRBI5X	ID	DMRBI5X
DMRBI5X	DN	Cyclohexyl azetidine derivative 1
DMRBI5X	HS	Patented
DMRBI5X	SN	PMID27774824-Compound-Figure13Example1
DMRBI5X	CP	INCYTE CORPORATION RODGERS, James D. ARVANITIS, Argyrios G
DMRBI5X	DT	Small molecular drug

DMORFPT	ID	DMORFPT
DMORFPT	DN	Cyclohexyl carbamate derivative 1
DMORFPT	HS	Patented
DMORFPT	SN	PMID26815044-Compound-85
DMORFPT	DT	Small molecular drug
DMORFPT	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM6VPIR	ID	DM6VPIR
DM6VPIR	DN	Cyclohexyl carbamate derivative 2
DM6VPIR	HS	Patented
DM6VPIR	SN	PMID26815044-Compound-86
DM6VPIR	DT	Small molecular drug
DM6VPIR	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMVIZTY	ID	DMVIZTY
DMVIZTY	DN	Cyclohexyl carbamate derivative 3
DMVIZTY	HS	Patented
DMVIZTY	SN	PMID26815044-Compound-87
DMVIZTY	DT	Small molecular drug
DMVIZTY	PC	54670072
DMVIZTY	MW	275.4
DMVIZTY	FM	C17H25NO2
DMVIZTY	IC	InChI=1S/C17H25NO2/c1-17(2,3)14-11-7-8-12-15(14)20-16(19)18-13-9-5-4-6-10-13/h4-6,9-10,14-15H,7-8,11-12H2,1-3H3,(H,18,19)
DMVIZTY	CS	CC(C)(C)C1CCCCC1OC(=O)NC2=CC=CC=C2
DMVIZTY	IK	IQFJKVNORUXJJY-UHFFFAOYSA-N
DMVIZTY	IU	(2-tert-butylcyclohexyl) N-phenylcarbamate
DMVIZTY	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMLD49W	ID	DMLD49W
DMLD49W	DN	Cyclohexyl carbamate derivative 4
DMLD49W	HS	Patented
DMLD49W	SN	PMID26815044-Compound-88
DMLD49W	DT	Small molecular drug
DMLD49W	PC	49787364
DMLD49W	MW	277.36
DMLD49W	FM	C16H23NO3
DMLD49W	IC	InChI=1S/C16H23NO3/c1-11-8-12(10-16(2,3)9-11)20-15(19)17-13-6-4-5-7-14(13)18/h4-7,11-12,18H,8-10H2,1-3H3,(H,17,19)
DMLD49W	CS	CC1CC(CC(C1)(C)C)OC(=O)NC2=CC=CC=C2O
DMLD49W	IK	XMUAVVZKNAMDEP-UHFFFAOYSA-N
DMLD49W	IU	(3,3,5-trimethylcyclohexyl) N-(2-hydroxyphenyl)carbamate
DMLD49W	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMS68DP	ID	DMS68DP
DMS68DP	DN	Cyclohexyl carbamate derivative 5
DMS68DP	HS	Patented
DMS68DP	SN	PMID26815044-Compound-89
DMS68DP	DT	Small molecular drug
DMS68DP	PC	49787363
DMS68DP	MW	257.37
DMS68DP	FM	C14H27NO3
DMS68DP	IC	InChI=1S/C14H27NO3/c1-11-8-12(10-14(2,3)9-11)18-13(16)15-6-5-7-17-4/h11-12H,5-10H2,1-4H3,(H,15,16)
DMS68DP	CS	CC1CC(CC(C1)(C)C)OC(=O)NCCCOC
DMS68DP	IK	XKPVQQCVMUKNEK-UHFFFAOYSA-N
DMS68DP	IU	(3,3,5-trimethylcyclohexyl) N-(3-methoxypropyl)carbamate
DMS68DP	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMSD2TN	ID	DMSD2TN
DMSD2TN	DN	Cyclohexyl carbamate derivative 6
DMSD2TN	HS	Patented
DMSD2TN	SN	PMID26815044-Compound-90
DMSD2TN	DT	Small molecular drug
DMSD2TN	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM2URPE	ID	DM2URPE
DM2URPE	DN	Cyclohexyl carbamate derivative 7
DM2URPE	HS	Patented
DM2URPE	SN	PMID26815044-Compound-91
DM2URPE	DT	Small molecular drug
DM2URPE	PC	46898982
DM2URPE	MW	227.34
DM2URPE	FM	C13H25NO2
DM2URPE	IC	InChI=1S/C13H25NO2/c1-4-5-9-14-13(15)16-12-8-6-7-10(2)11(12)3/h10-12H,4-9H2,1-3H3,(H,14,15)
DM2URPE	CS	CCCCNC(=O)OC1CCCC(C1C)C
DM2URPE	IK	NRBLABNDLCTIGX-UHFFFAOYSA-N
DM2URPE	IU	(2,3-dimethylcyclohexyl) N-butylcarbamate
DM2URPE	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMB9DEO	ID	DMB9DEO
DMB9DEO	DN	Cyclohexyl carbamate derivative 8
DMB9DEO	HS	Patented
DMB9DEO	SN	PMID26815044-Compound-92
DMB9DEO	DT	Small molecular drug
DMB9DEO	PC	46899063
DMB9DEO	MW	241.37
DMB9DEO	FM	C14H27NO2
DMB9DEO	IC	InChI=1S/C14H27NO2/c1-6-11(3)15-13(16)17-12-7-10(2)8-14(4,5)9-12/h10-12H,6-9H2,1-5H3,(H,15,16)
DMB9DEO	CS	CCC(C)NC(=O)OC1CC(CC(C1)(C)C)C
DMB9DEO	IK	UJUIRNFIDXYYDT-UHFFFAOYSA-N
DMB9DEO	IU	(3,3,5-trimethylcyclohexyl) N-butan-2-ylcarbamate
DMB9DEO	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMI2T1D	ID	DMI2T1D
DMI2T1D	DN	Cyclohexyl-ethyl-substituted diaza and triaza-tricyclic compound 1
DMI2T1D	HS	Patented
DMI2T1D	SN	PMID29473428-Compound-38
DMI2T1D	CP	MERCK PATENT GMBH SHERER, Brian A
DMI2T1D	DT	Small molecular drug
DMI2T1D	PC	118917034
DMI2T1D	MW	318.4
DMI2T1D	FM	C18H20F2N2O
DMI2T1D	IC	InChI=1S/C18H20F2N2O/c19-14-3-1-2-13-16-10-21-11-22(16)15(17(13)14)6-9-18(20)7-4-12(23)5-8-18/h1-3,10-12,15,23H,4-9H2
DMI2T1D	CS	C1CC(CCC1O)(CCC2C3=C(C=CC=C3F)C4=CN=CN24)F
DMI2T1D	IK	AHMWQTITKYANIA-UHFFFAOYSA-N
DMI2T1D	IU	4-fluoro-4-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexan-1-ol

DMKM6BY	ID	DMKM6BY
DMKM6BY	DN	Cyclopenta[d]pyrimidine derivative 1
DMKM6BY	HS	Patented
DMKM6BY	SN	PMID28270010-Compound-Figure28
DMKM6BY	CP	MEDIVATION TECHNOLOGIES, INC
DMKM6BY	DT	Small molecular drug
DMKM6BY	PC	76283234
DMKM6BY	MW	450.5
DMKM6BY	FM	C23H27FN8O
DMKM6BY	IC	InChI=1S/C23H27FN8O/c1-13(2)17-11-20(31-30-17)28-21-15-5-3-6-16(15)27-23(29-21)32-10-4-7-18(32)22(33)26-14-8-9-19(24)25-12-14/h8-9,11-13,18H,3-7,10H2,1-2H3,(H,26,33)(H2,27,28,29,30,31)
DMKM6BY	CS	CC(C)C1=CC(=NN1)NC2=NC(=NC3=C2CCC3)N4CCCC4C(=O)NC5=CN=C(C=C5)F
DMKM6BY	IK	GZDATWXVIVEVAM-UHFFFAOYSA-N
DMKM6BY	IU	N-(6-fluoropyridin-3-yl)-1-[4-[(5-propan-2-yl-1H-pyrazol-3-yl)amino]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

DMH7PGC	ID	DMH7PGC
DMH7PGC	DN	Cyclopentane carboxamide derivative 1
DMH7PGC	HS	Patented
DMH7PGC	SN	PMID28699813-Compound-20
DMH7PGC	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMH7PGC	DT	Small molecular drug
DMH7PGC	PC	72837058
DMH7PGC	MW	575.5
DMH7PGC	FM	C30H34Cl2F2N4O
DMH7PGC	IC	InChI=1S/C30H34Cl2F2N4O/c1-18-13-28(38(35-18)21-6-8-25(31)26(32)15-21)19-9-11-37(12-10-19)29(39)24-17-30(2,36(3)4)16-23(24)22-7-5-20(33)14-27(22)34/h5-8,13-15,19,23-24H,9-12,16-17H2,1-4H3/t23-,24+,30-/m0/s1
DMH7PGC	CS	CC1=NN(C(=C1)C2CCN(CC2)C(=O)[C@@H]3C[C@@](C[C@H]3C4=C(C=C(C=C4)F)F)(C)N(C)C)C5=CC(=C(C=C5)Cl)Cl
DMH7PGC	IK	XMOICBGWKUUJPT-BBANNHEPSA-N
DMH7PGC	IU	[4-[2-(3,4-dichlorophenyl)-5-methylpyrazol-3-yl]piperidin-1-yl]-[(1R,2R,4S)-2-(2,4-difluorophenyl)-4-(dimethylamino)-4-methylcyclopentyl]methanone

DMYP5FK	ID	DMYP5FK
DMYP5FK	DN	Cyclopentane carboxamide derivative 2
DMYP5FK	HS	Patented
DMYP5FK	SN	PMID28699813-Compound-J
DMYP5FK	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMYP5FK	DT	Small molecular drug

DMNXBPQ	ID	DMNXBPQ
DMNXBPQ	DN	Cyclopropane 1-carboxylic acid derivative 1
DMNXBPQ	HS	Patented
DMNXBPQ	SN	PMID27172114-Compound-72
DMNXBPQ	CP	CHDI FOUNDATION, INC
DMNXBPQ	DT	Small molecular drug

DM3M169	ID	DM3M169
DM3M169	DN	Cyclopropane 1-carboxylic acid derivative 10
DM3M169	HS	Patented
DM3M169	SN	PMID27172114-Compound-81
DM3M169	CP	CHDI FOUNDATION, INC
DM3M169	DT	Small molecular drug

DMSXB58	ID	DMSXB58
DMSXB58	DN	Cyclopropane 1-carboxylic acid derivative 2
DMSXB58	HS	Patented
DMSXB58	SN	PMID27172114-Compound-73
DMSXB58	CP	CHDI FOUNDATION, INC
DMSXB58	DT	Small molecular drug

DM6K59I	ID	DM6K59I
DM6K59I	DN	Cyclopropane 1-carboxylic acid derivative 3
DM6K59I	HS	Patented
DM6K59I	SN	PMID27172114-Compound-74
DM6K59I	CP	CHDI FOUNDATION, INC
DM6K59I	DT	Small molecular drug
DM6K59I	PC	117902626
DM6K59I	MW	273.11
DM6K59I	FM	C12H10Cl2O3
DM6K59I	IC	InChI=1S/C12H10Cl2O3/c1-5-9(10(5)12(16)17)11(15)6-2-3-7(13)8(14)4-6/h2-5,9-10H,1H3,(H,16,17)/t5-,9-,10-/m0/s1
DM6K59I	CS	C[C@H]1[C@@H]([C@H]1C(=O)O)C(=O)C2=CC(=C(C=C2)Cl)Cl
DM6K59I	IK	JFJFPXNBPGWPNH-AGEOJFDCSA-N
DM6K59I	IU	(1S,2S,3S)-2-(3,4-dichlorobenzoyl)-3-methylcyclopropane-1-carboxylic acid

DM8PVN3	ID	DM8PVN3
DM8PVN3	DN	Cyclopropane 1-carboxylic acid derivative 4
DM8PVN3	HS	Patented
DM8PVN3	SN	PMID27172114-Compound-75
DM8PVN3	CP	CHDI FOUNDATION, INC
DM8PVN3	DT	Small molecular drug

DMCSIYG	ID	DMCSIYG
DMCSIYG	DN	Cyclopropane 1-carboxylic acid derivative 5
DMCSIYG	HS	Patented
DMCSIYG	SN	PMID27172114-Compound-76
DMCSIYG	CP	CHDI FOUNDATION, INC
DMCSIYG	DT	Small molecular drug
DMCSIYG	PC	117903050
DMCSIYG	MW	287.13
DMCSIYG	FM	C13H12Cl2O3
DMCSIYG	IC	InChI=1S/C13H12Cl2O3/c1-13(2)9(10(13)12(17)18)11(16)6-3-4-7(14)8(15)5-6/h3-5,9-10H,1-2H3,(H,17,18)/t9-,10-/m0/s1
DMCSIYG	CS	CC1([C@@H]([C@H]1C(=O)O)C(=O)C2=CC(=C(C=C2)Cl)Cl)C
DMCSIYG	IK	LZXZDLJRRHTOOA-UWVGGRQHSA-N
DMCSIYG	IU	(1R,3R)-3-(3,4-dichlorobenzoyl)-2,2-dimethylcyclopropane-1-carboxylic acid

DM0OMBW	ID	DM0OMBW
DM0OMBW	DN	Cyclopropane 1-carboxylic acid derivative 6
DM0OMBW	HS	Patented
DM0OMBW	SN	PMID27172114-Compound-77
DM0OMBW	CP	CHDI FOUNDATION, INC
DM0OMBW	DT	Small molecular drug

DM4RTMO	ID	DM4RTMO
DM4RTMO	DN	Cyclopropane 1-carboxylic acid derivative 7
DM4RTMO	HS	Patented
DM4RTMO	SN	PMID27172114-Compound-78
DM4RTMO	CP	CHDI FOUNDATION, INC
DM4RTMO	DT	Small molecular drug

DM4P9HL	ID	DM4P9HL
DM4P9HL	DN	Cyclopropane 1-carboxylic acid derivative 8
DM4P9HL	HS	Patented
DM4P9HL	SN	PMID27172114-Compound-79
DM4P9HL	CP	CHDI FOUNDATION, INC
DM4P9HL	DT	Small molecular drug

DMLH9AQ	ID	DMLH9AQ
DMLH9AQ	DN	Cyclopropane 1-carboxylic acid derivative 9
DMLH9AQ	HS	Patented
DMLH9AQ	SN	PMID27172114-Compound-80
DMLH9AQ	CP	CHDI FOUNDATION, INC
DMLH9AQ	DT	Small molecular drug

DMXN361	ID	DMXN361
DMXN361	DN	Cyclopropylamine derivative 1
DMXN361	HS	Patented
DMXN361	SN	PMID27019002-Compound-23
DMXN361	CP	ORYZON GENOMICS SA [ESORYZON GENOMICS S.A
DMXN361	DT	Small molecular drug

DMZ5WN8	ID	DMZ5WN8
DMZ5WN8	DN	Cyclopropylamine derivative 10
DMZ5WN8	HS	Patented
DMZ5WN8	SN	PMID27019002-Compound-33b
DMZ5WN8	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMZ5WN8	DT	Small molecular drug

DMMJ0YN	ID	DMMJ0YN
DMMJ0YN	DN	Cyclopropylamine derivative 11
DMMJ0YN	HS	Patented
DMMJ0YN	SN	PMID27019002-Compound-33c
DMMJ0YN	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMMJ0YN	DT	Small molecular drug

DMV4I0K	ID	DMV4I0K
DMV4I0K	DN	Cyclopropylamine derivative 12
DMV4I0K	HS	Patented
DMV4I0K	SN	PMID27019002-Compound-33d
DMV4I0K	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMV4I0K	DT	Small molecular drug

DMXNVD4	ID	DMXNVD4
DMXNVD4	DN	Cyclopropylamine derivative 13
DMXNVD4	HS	Patented
DMXNVD4	SN	PMID27019002-Compound-33e
DMXNVD4	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMXNVD4	DT	Small molecular drug

DM6E9L4	ID	DM6E9L4
DM6E9L4	DN	Cyclopropylamine derivative 3
DM6E9L4	HS	Patented
DM6E9L4	SN	PMID27019002-Compound-29a
DM6E9L4	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DM6E9L4	DT	Small molecular drug

DMOCF4Y	ID	DMOCF4Y
DMOCF4Y	DN	Cyclopropylamine derivative 4
DMOCF4Y	HS	Patented
DMOCF4Y	SN	PMID27019002-Compound-29b
DMOCF4Y	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DMOCF4Y	DT	Small molecular drug

DM5BCGD	ID	DM5BCGD
DM5BCGD	DN	Cyclopropylamine derivative 5
DM5BCGD	HS	Patented
DM5BCGD	SN	PMID27019002-Compound-29c
DM5BCGD	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DM5BCGD	DT	Small molecular drug

DMB2RKC	ID	DMB2RKC
DMB2RKC	DN	Cyclopropylamine derivative 6
DMB2RKC	HS	Patented
DMB2RKC	SN	PMID27019002-Compound-29d
DMB2RKC	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DMB2RKC	DT	Small molecular drug

DM3X4PJ	ID	DM3X4PJ
DM3X4PJ	DN	Cyclopropylamine derivative 7
DM3X4PJ	HS	Patented
DM3X4PJ	SN	PMID27019002-Compound-29e
DM3X4PJ	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DM3X4PJ	DT	Small molecular drug

DMA89WQ	ID	DMA89WQ
DMA89WQ	DN	Cyclopropylamine derivative 8
DMA89WQ	HS	Patented
DMA89WQ	SN	PMID27019002-Compound-32
DMA89WQ	CP	Incyte Corporation, USA
DMA89WQ	DT	Small molecular drug

DMX7YAL	ID	DMX7YAL
DMX7YAL	DN	Cyclopropylamine derivative 9
DMX7YAL	HS	Patented
DMX7YAL	SN	PMID27019002-Compound-33a
DMX7YAL	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMX7YAL	DT	Small molecular drug

DM0YTGS	ID	DM0YTGS
DM0YTGS	DN	Cyclopropyl-spiro piperidine derivative 1
DM0YTGS	HS	Patented
DM0YTGS	SN	PMID25539043-Compound-WO2012047703Example19
DM0YTGS	CP	MERCK SHARP & DOHME CORP. HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R
DM0YTGS	DT	Small molecular drug

DMM0R65	ID	DMM0R65
DMM0R65	DN	Cyclopropyl-spiro piperidine derivative 2
DMM0R65	HS	Patented
DMM0R65	SN	PMID25539043-Compound-WO2012047703Example20
DMM0R65	CP	MERCK SHARP & DOHME CORP. HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R
DMM0R65	DT	Small molecular drug

DM0IZW8	ID	DM0IZW8
DM0IZW8	DN	Cyclopropyl-spiro piperidine derivative 3
DM0IZW8	HS	Patented
DM0IZW8	SN	PMID25539043-Compound-WO2012047703Example21
DM0IZW8	CP	MERCK SHARP & DOHME CORP. HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R
DM0IZW8	DT	Small molecular drug

DM2ZWSM	ID	DM2ZWSM
DM2ZWSM	DN	Cyclopropyl-spiro piperidine derivative 4
DM2ZWSM	HS	Patented
DM2ZWSM	SN	PMID25539043-Compound-WO2012047703Example22
DM2ZWSM	CP	MERCK SHARP & DOHME CORP. HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R
DM2ZWSM	DT	Small molecular drug

DMXKUMJ	ID	DMXKUMJ
DMXKUMJ	DN	Decyle nelycorine dibromo salt derivative 1
DMXKUMJ	HS	Patented
DMXKUMJ	SN	PMID29757691-Compound-12
DMXKUMJ	DT	Small molecular drug

DM3Q9OX	ID	DM3Q9OX
DM3Q9OX	DN	Deuterated 3-cyanoquinoline derivative 1
DM3Q9OX	HS	Patented
DM3Q9OX	SN	PMID25656651-Compound-45
DM3Q9OX	CP	SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
DM3Q9OX	DT	Small molecular drug
DM3Q9OX	PC	76283824
DM3Q9OX	MW	537.1
DM3Q9OX	FM	C29H34ClN5O3
DM3Q9OX	IC	InChI=1S/C29H34ClN5O3/c1-34-8-10-35(11-9-34)7-4-12-38-28-15-24-22(14-27(28)37-3)29(20(17-31)18-32-24)33-25-16-26(36-2)23(30)13-21(25)19-5-6-19/h13-16,18-19H,4-12H2,1-3H3,(H,32,33)/i1D
DM3Q9OX	CS	[2H]CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4C5CC5)Cl)OC)C#N)OC
DM3Q9OX	IK	YHGWVQSJPYSYIE-MICDWDOJSA-N
DM3Q9OX	IU	4-(4-chloro-2-cyclopropyl-5-methoxyanilino)-7-[3-[4-(deuteriomethyl)piperazin-1-yl]propoxy]-6-methoxyquinoline-3-carbonitrile

DM02V5Q	ID	DM02V5Q
DM02V5Q	DN	Diamidothiazole derivative 1
DM02V5Q	HS	Patented
DM02V5Q	SN	PMID26161698-Compound-53
DM02V5Q	CP	SCHERING CORPORATION TADIKONDA, Praveen, K. CAUBLE, David, F., Jr. GUZI, Timothy, J. SIDDIQUI, Arshad, MSCHERING CORPORATION LABROLI, Marc, A. POKER, Cory, Seth WONG, Tzu, T. REDDY, Panduranga, Adulla, P. GUZI, Timothy, J. SIDDIQUI, M. ArshaSCHERING CORPORATION SHIPPS, Gerald, W., Jr. RICHARDS, Matthew CHENG, Cliff, C. HUANG, Xiaohua
DM02V5Q	DT	Small molecular drug
DM02V5Q	PC	25256147
DM02V5Q	MW	409.5
DM02V5Q	FM	C19H19N7O2S
DM02V5Q	IC	InChI=1S/C19H19N7O2S/c27-17(23-13-2-1-4-21-10-13)15-12-29-19(25-15)18(28)24-14-11-22-5-3-16(14)26-8-6-20-7-9-26/h1-5,10-12,20H,6-9H2,(H,23,27)(H,24,28)
DM02V5Q	CS	C1CN(CCN1)C2=C(C=NC=C2)NC(=O)C3=NC(=CS3)C(=O)NC4=CN=CC=C4
DM02V5Q	IK	VFDWSNCXADMJQH-UHFFFAOYSA-N
DM02V5Q	IU	2-N-(4-piperazin-1-ylpyridin-3-yl)-4-N-pyridin-3-yl-1,3-thiazole-2,4-dicarboxamide

DMUG69Q	ID	DMUG69Q
DMUG69Q	DN	Diamine derivative 1
DMUG69Q	HS	Patented
DMUG69Q	SN	PMID26815044-Compound-100
DMUG69Q	DT	Small molecular drug
DMUG69Q	PC	51362613
DMUG69Q	MW	282.4
DMUG69Q	FM	C19H26N2
DMUG69Q	IC	InChI=1S/C19H26N2/c1-17-9-11-19(12-10-17)16-21(14-13-20(2)3)15-18-7-5-4-6-8-18/h4-12H,13-16H2,1-3H3
DMUG69Q	CS	CC1=CC=C(C=C1)CN(CCN(C)C)CC2=CC=CC=C2
DMUG69Q	IK	FAKZYZYSFVGBEY-UHFFFAOYSA-N
DMUG69Q	IU	N'-benzyl-N,N-dimethyl-N'-[(4-methylphenyl)methyl]ethane-1,2-diamine
DMUG69Q	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMQEYTJ	ID	DMQEYTJ
DMQEYTJ	DN	Diamine derivative 2
DMQEYTJ	HS	Patented
DMQEYTJ	SN	PMID26815044-Compound-101
DMQEYTJ	DT	Small molecular drug
DMQEYTJ	PC	129279
DMQEYTJ	MW	268.4
DMQEYTJ	FM	C18H24N2
DMQEYTJ	IC	InChI=1S/C18H24N2/c1-19(2)13-14-20(15-17-9-5-3-6-10-17)16-18-11-7-4-8-12-18/h3-12H,13-16H2,1-2H3
DMQEYTJ	CS	CN(C)CCN(CC1=CC=CC=C1)CC2=CC=CC=C2
DMQEYTJ	IK	XFOYZAKVZYMLET-UHFFFAOYSA-N
DMQEYTJ	IU	N',N'-dibenzyl-N,N-dimethylethane-1,2-diamine
DMQEYTJ	CA	CAS 68156-59-2
DMQEYTJ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMSYX4U	ID	DMSYX4U
DMSYX4U	DN	Diamine derivative 3
DMSYX4U	HS	Patented
DMSYX4U	SN	PMID26815044-Compound-99
DMSYX4U	DT	Small molecular drug
DMSYX4U	PC	20628588
DMSYX4U	MW	318.5
DMSYX4U	FM	C22H26N2
DMSYX4U	IC	InChI=1S/C22H26N2/c1-23(2)14-15-24(17-19-8-4-3-5-9-19)18-20-12-13-21-10-6-7-11-22(21)16-20/h3-13,16H,14-15,17-18H2,1-2H3
DMSYX4U	CS	CN(C)CCN(CC1=CC=CC=C1)CC2=CC3=CC=CC=C3C=C2
DMSYX4U	IK	MOXMQBPFKXNWCD-UHFFFAOYSA-N
DMSYX4U	IU	N'-benzyl-N,N-dimethyl-N'-(naphthalen-2-ylmethyl)ethane-1,2-diamine
DMSYX4U	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMPUH4Z	ID	DMPUH4Z
DMPUH4Z	DN	Diaminopyridine analog 4
DMPUH4Z	HS	Patented
DMPUH4Z	SN	PMID27310003-Compound-21
DMPUH4Z	CP	BRISTOL-MYERS SQUIBB COMPANY
DMPUH4Z	DT	Small molecular drug
DMPUH4Z	PC	71656368
DMPUH4Z	MW	522.7
DMPUH4Z	FM	C24H26N8O2S2
DMPUH4Z	IC	InChI=1S/C24H26N8O2S2/c1-13(2)27-19-9-21(29-15-4-5-18-20(8-15)35-12-26-18)25-10-17(19)22-30-31-23(36-22)24(34)32-7-6-16(11-32)28-14(3)33/h4-5,8-10,12-13,16H,6-7,11H2,1-3H3,(H,28,33)(H2,25,27,29)
DMPUH4Z	CS	CC(C)NC1=CC(=NC=C1C2=NN=C(S2)C(=O)N3CCC(C3)NC(=O)C)NC4=CC5=C(C=C4)N=CS5
DMPUH4Z	IK	OYYXHUJLHDYELY-UHFFFAOYSA-N
DMPUH4Z	IU	N-[1-[5-[6-(1,3-benzothiazol-6-ylamino)-4-(propan-2-ylamino)pyridin-3-yl]-1,3,4-thiadiazole-2-carbonyl]pyrrolidin-3-yl]acetamide

DM5B0F3	ID	DM5B0F3
DM5B0F3	DN	Diaminopyridine analog 5
DM5B0F3	HS	Patented
DM5B0F3	SN	PMID27310003-Compound-22
DM5B0F3	CP	BRISTOL-MYERS SQUIBB COMPANY
DM5B0F3	DT	Small molecular drug

DM06MJH	ID	DM06MJH
DM06MJH	DN	Diaryl amine derivative 1
DM06MJH	HS	Patented
DM06MJH	SN	PMID26161698-Compound-23
DM06MJH	CP	BAYER INTELLECTUAL PROPERTY GMBBAYER IP GMBH [DE]
DM06MJH	DT	Small molecular drug
DM06MJH	PC	71515733
DM06MJH	MW	443.5
DM06MJH	FM	C21H19F2N5O2S
DM06MJH	IC	InChI=1S/C21H19F2N5O2S/c1-3-31(29,26-13-24)12-14-5-4-6-16(9-14)27-21-25-11-18(23)20(28-21)17-8-7-15(22)10-19(17)30-2/h4-11H,3,12H2,1-2H3,(H,25,27,28)
DM06MJH	CS	CCS(=NC#N)(=O)CC1=CC(=CC=C1)NC2=NC=C(C(=N2)C3=C(C=C(C=C3)F)OC)F
DM06MJH	IK	QEYANDLEJXFZFA-UHFFFAOYSA-N
DM06MJH	IU	[ethyl-[[3-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyrimidin-2-yl]amino]phenyl]methyl]-oxo-lambda6-sulfanylidene]cyanamide

DMRBYAV	ID	DMRBYAV
DMRBYAV	DN	Diaryl amine derivative 2
DMRBYAV	HS	Patented
DMRBYAV	SN	PMID28092474-Compound-10
DMRBYAV	CP	PRESIDENT AND FELLOWS OF HARVARD COLLEGE DANA-FARBER CANCER INSTITUTE, INC. TANG, Weiping BRADNER, James, Elliot SCHREIBER, Stuart, L
DMRBYAV	DT	Small molecular drug

DMLBN1T	ID	DMLBN1T
DMLBN1T	DN	Diaryl amine derivative 3
DMLBN1T	HS	Patented
DMLBN1T	SN	PMID28092474-Compound-11
DMLBN1T	CP	KARUS THERAPEUTICS LIMITED SHUTTLEWORTH, Stephen Joseph TOMASSI, Cyrille Davy
DMLBN1T	DT	Small molecular drug

DMZL6AX	ID	DMZL6AX
DMZL6AX	DN	Diaryl amine derivative 4
DMZL6AX	HS	Patented
DMZL6AX	SN	PMID28092474-Compound-9
DMZL6AX	CP	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMZL6AX	DT	Small molecular drug

DMIQOY7	ID	DMIQOY7
DMIQOY7	DN	Diaryl morpholine derivative 1
DMIQOY7	HS	Patented
DMIQOY7	SN	PMID26161824-Compound-124
DMIQOY7	CP	SCHERING CORPORATION SCOTT, Jack, D. STAMFORD, Andre
DMIQOY7	DT	Small molecular drug
DMIQOY7	PC	25125705
DMIQOY7	MW	470.8
DMIQOY7	FM	C22H22Cl3NO4
DMIQOY7	IC	InChI=1S/C22H22Cl3NO4/c1-22(2,3)30-20(27)11-19-21(28)26(15-7-4-13(23)5-8-15)18(12-29-19)16-9-6-14(24)10-17(16)25/h4-10,18-19H,11-12H2,1-3H3
DMIQOY7	CS	CC(C)(C)OC(=O)CC1C(=O)N(C(CO1)C2=C(C=C(C=C2)Cl)Cl)C3=CC=C(C=C3)Cl
DMIQOY7	IK	XAGXRDZNWDXEAM-UHFFFAOYSA-N
DMIQOY7	IU	tert-butyl 2-[4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-3-oxomorpholin-2-yl]acetate
DMIQOY7	DE	Obesity

DMERQ7V	ID	DMERQ7V
DMERQ7V	DN	Diaryl piperazine derivative 1
DMERQ7V	HS	Patented
DMERQ7V	SN	PMID26161824-Compound-127
DMERQ7V	CP	INTERVET INTERNATIONAL B.V. DEMONG, Duane, Eugene MILLER, Michael, W. GILBERT, Eric, J. SCOTT, Jack, D. STAMFORD, Andrew GREENLEE, William, J. CELLY, Chander, Shekher
DMERQ7V	DT	Small molecular drug
DMERQ7V	PC	25165933
DMERQ7V	MW	441.3
DMERQ7V	FM	C24H22Cl2N2O2
DMERQ7V	IC	InChI=1S/C24H22Cl2N2O2/c1-30-23-10-6-5-9-19(23)24(29)27-13-14-28(21-12-11-18(25)15-20(21)26)22(16-27)17-7-3-2-4-8-17/h2-12,15,22H,13-14,16H2,1H3
DMERQ7V	CS	COC1=CC=CC=C1C(=O)N2CCN(C(C2)C3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl
DMERQ7V	IK	HXMSNSZTEVRLDE-UHFFFAOYSA-N
DMERQ7V	IU	[4-(2,4-dichlorophenyl)-3-phenylpiperazin-1-yl]-(2-methoxyphenyl)methanone
DMERQ7V	DE	Obesity

DMDOB20	ID	DMDOB20
DMDOB20	DN	Diaryl piperazine derivative 2
DMDOB20	HS	Patented
DMDOB20	SN	PMID26161824-Compound-128
DMDOB20	CP	INTERVET INTERNATIONAL B.V. DEMONG, Duane, Eugene MILLER, Michael, W. GILBERT, Eric, J. SCOTT, Jack, D. STAMFORD, Andrew GREENLEE, William, J. CELLY, Chander, Shekher
DMDOB20	DT	Small molecular drug
DMDOB20	DE	Obesity

DMXFNOD	ID	DMXFNOD
DMXFNOD	DN	Diarylamine and arylheteroarylamine pyrazole derivative 1
DMXFNOD	HS	Patented
DMXFNOD	SN	PMID26609882-Compound-37
DMXFNOD	CP	Arena Pharmaceuticals, Inc
DMXFNOD	DT	Small molecular drug
DMXFNOD	PC	9978021
DMXFNOD	MW	396.2
DMXFNOD	FM	C17H13BrF3N3
DMXFNOD	IC	InChI=1S/C17H13BrF3N3/c1-24-16(15(18)10-22-24)11-3-2-4-14(9-11)23-13-7-5-12(6-8-13)17(19,20)21/h2-10,23H,1H3
DMXFNOD	CS	CN1C(=C(C=N1)Br)C2=CC(=CC=C2)NC3=CC=C(C=C3)C(F)(F)F
DMXFNOD	IK	ZAIICAYGFBFTHL-UHFFFAOYSA-N
DMXFNOD	IU	3-(4-bromo-2-methylpyrazol-3-yl)-N-[4-(trifluoromethyl)phenyl]aniline

DM6NR9Y	ID	DM6NR9Y
DM6NR9Y	DN	Diarylamine and arylheteroarylamine pyrazole derivative 2
DM6NR9Y	HS	Patented
DM6NR9Y	SN	PMID26609882-Compound-38
DM6NR9Y	CP	Arena Pharmaceuticals, Inc
DM6NR9Y	DT	Small molecular drug
DM6NR9Y	PC	10361306
DM6NR9Y	MW	362.65
DM6NR9Y	FM	C16H13BrClN3
DM6NR9Y	IC	InChI=1S/C16H13BrClN3/c1-21-16(15(17)10-19-21)11-3-2-4-14(9-11)20-13-7-5-12(18)6-8-13/h2-10,20H,1H3
DM6NR9Y	CS	CN1C(=C(C=N1)Br)C2=CC(=CC=C2)NC3=CC=C(C=C3)Cl
DM6NR9Y	IK	CEDWMDLRVLLSQK-UHFFFAOYSA-N
DM6NR9Y	IU	3-(4-bromo-2-methylpyrazol-3-yl)-N-(4-chlorophenyl)aniline

DMLZ1UB	ID	DMLZ1UB
DMLZ1UB	DN	Diarylamine and arylheteroarylamine pyrazole derivative 3
DMLZ1UB	HS	Patented
DMLZ1UB	SN	PMID26609882-Compound-39
DMLZ1UB	CP	Arena Pharmaceuticals, Inc
DMLZ1UB	DT	Small molecular drug

DM9YD0Q	ID	DM9YD0Q
DM9YD0Q	DN	Diazepinone derivative 1
DM9YD0Q	HS	Patented
DM9YD0Q	SN	PMID28067079-Compound-84
DM9YD0Q	CP	NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DM9YD0Q	DT	Small molecular drug
DM9YD0Q	PC	73334944
DM9YD0Q	MW	322.4
DM9YD0Q	FM	C19H18N2O3
DM9YD0Q	IC	InChI=1S/C19H18N2O3/c1-12-6-7-18(24-12)15-10-16-13-4-3-5-17(23-2)14(13)8-9-21(16)19(22)11-20-15/h3-7,10H,8-9,11H2,1-2H3
DM9YD0Q	CS	CC1=CC=C(O1)C2=NCC(=O)N3CCC4=C(C3=C2)C=CC=C4OC
DM9YD0Q	IK	JTMQTEDUASKITJ-UHFFFAOYSA-N
DM9YD0Q	IU	9-methoxy-2-(5-methylfuran-2-yl)-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DM9YD0Q	DE	Reflux disease; Parkinson disease

DMLQ7PG	ID	DMLQ7PG
DMLQ7PG	DN	Diazepinone derivative 2
DMLQ7PG	HS	Patented
DMLQ7PG	SN	PMID28067079-Compound-85
DMLQ7PG	CP	NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DMLQ7PG	DT	Small molecular drug
DMLQ7PG	PC	73335337
DMLQ7PG	MW	446.3
DMLQ7PG	FM	C19H19IN4O
DMLQ7PG	IC	InChI=1S/C19H19IN4O/c1-12(2)24-11-13(9-22-24)17-8-18-15-4-3-5-16(20)14(15)6-7-23(18)19(25)10-21-17/h3-5,8-9,11-12H,6-7,10H2,1-2H3
DMLQ7PG	CS	CC(C)N1C=C(C=N1)C2=NCC(=O)N3CCC4=C(C3=C2)C=CC=C4I
DMLQ7PG	IK	WBNYTWXVORUJBL-UHFFFAOYSA-N
DMLQ7PG	IU	9-iodo-2-(1-propan-2-ylpyrazol-4-yl)-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DMLQ7PG	DE	Reflux disease; Parkinson disease

DMPTZ69	ID	DMPTZ69
DMPTZ69	DN	Diazepinone derivative 3
DMPTZ69	HS	Patented
DMPTZ69	SN	PMID28067079-Compound-86
DMPTZ69	CP	NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DMPTZ69	DT	Small molecular drug
DMPTZ69	PC	73334942
DMPTZ69	MW	324.4
DMPTZ69	FM	C18H16N2O2S
DMPTZ69	IC	InChI=1S/C18H16N2O2S/c1-22-16-5-2-4-12-13(16)7-8-20-15(12)10-14(19-11-18(20)21)17-6-3-9-23-17/h2-6,9-10H,7-8,11H2,1H3
DMPTZ69	CS	COC1=CC=CC2=C1CCN3C2=CC(=NCC3=O)C4=CC=CS4
DMPTZ69	IK	ZCPJZMIIRATEAI-UHFFFAOYSA-N
DMPTZ69	IU	9-methoxy-2-thiophen-2-yl-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DMPTZ69	DE	Reflux disease; Parkinson disease

DM389YD	ID	DM389YD
DM389YD	DN	Diazepinone derivative 4
DM389YD	HS	Patented
DM389YD	SN	PMID28067079-Compound-87
DM389YD	CP	NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DM389YD	DT	Small molecular drug
DM389YD	PC	73335441
DM389YD	MW	414.4
DM389YD	FM	C24H19FN4O2
DM389YD	IC	InChI=1S/C24H19FN4O2/c1-31-23-11-15(7-9-26-23)20-12-21-19-4-2-3-17(16-5-6-22(25)28-13-16)18(19)8-10-29(21)24(30)14-27-20/h2-7,9,11-13H,8,10,14H2,1H3
DM389YD	CS	COC1=NC=CC(=C1)C2=NCC(=O)N3CCC4=C(C=CC=C4C3=C2)C5=CN=C(C=C5)F
DM389YD	IK	GISRGWUSGUAUMX-UHFFFAOYSA-N
DM389YD	IU	9-(6-fluoropyridin-3-yl)-2-(2-methoxypyridin-4-yl)-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DM389YD	DE	Reflux disease; Parkinson disease

DM2U1QH	ID	DM2U1QH
DM2U1QH	DN	Diazepinone derivative 5
DM2U1QH	HS	Patented
DM2U1QH	SN	PMID28067079-Compound-91
DM2U1QH	CP	NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DM2U1QH	DT	Small molecular drug
DM2U1QH	PC	73335827
DM2U1QH	MW	347.4
DM2U1QH	FM	C20H21N5O
DM2U1QH	IC	InChI=1S/C20H21N5O/c1-13-22-12-25(23-13)19-10-18-17-7-3-6-15(14-4-2-5-14)16(17)8-9-24(18)20(26)11-21-19/h3,6-7,10,12,14H,2,4-5,8-9,11H2,1H3
DM2U1QH	CS	CC1=NN(C=N1)C2=NCC(=O)N3CCC4=C(C=CC=C4C3=C2)C5CCC5
DM2U1QH	IK	DDWMQMPXDUENHH-UHFFFAOYSA-N
DM2U1QH	IU	9-cyclobutyl-2-(3-methyl-1,2,4-triazol-1-yl)-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DM2U1QH	DE	Reflux disease; Parkinson disease

DMRM5I1	ID	DMRM5I1
DMRM5I1	DN	Dibenzo [c,f]-[2,7]naphthyridine derivative 1
DMRM5I1	HS	Patented
DMRM5I1	SN	PMID25684022-Compound-US20070135429
DMRM5I1	CP	Wyeth
DMRM5I1	DT	Small molecular drug
DMRM5I1	DE	Solid tumour/cancer; Metastatic cancer

DMUNFAT	ID	DMUNFAT
DMUNFAT	DN	Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1
DMUNFAT	HS	Patented
DMUNFAT	SN	PMID25539043-Compound-WO2013122897Example51
DMUNFAT	CP	AMGEN INC
DMUNFAT	DT	Small molecular drug

DMC3IN2	ID	DMC3IN2
DMC3IN2	DN	Dihydrodiazepinocarbazolone derivative 1
DMC3IN2	HS	Patented
DMC3IN2	SN	PMID27841036-Compound-26
DMC3IN2	CP	BeiGene Ltd
DMC3IN2	DT	Small molecular drug
DMC3IN2	PC	71626523
DMC3IN2	MW	364.5
DMC3IN2	FM	C22H28N4O
DMC3IN2	IC	InChI=1S/C22H28N4O/c1-22(2)13-16-20-18(14-22)26(12-11-25-9-4-3-5-10-25)17-8-6-7-15(19(17)20)21(27)24-23-16/h6-8H,3-5,9-14H2,1-2H3,(H,24,27)
DMC3IN2	CS	CC1(CC2=C3C(=NNC(=O)C4=C3C(=CC=C4)N2CCN5CCCCC5)C1)C
DMC3IN2	IK	LNWPRZVIPZXIHL-UHFFFAOYSA-N
DMC3IN2	IU	3,3-dimethyl-16-(2-piperidin-1-ylethyl)-6,7,16-triazatetracyclo[11.2.1.05,15.09,14]hexadeca-1(15),5,9(14),10,12-pentaen-8-one

DM1R0FJ	ID	DM1R0FJ
DM1R0FJ	DN	Dihydrodiazepinocarbazolone derivative 2
DM1R0FJ	HS	Patented
DM1R0FJ	SN	PMID27841036-Compound-XIV
DM1R0FJ	CP	BeiGene Ltd
DM1R0FJ	DT	Small molecular drug

DM5UPGZ	ID	DM5UPGZ
DM5UPGZ	DN	Dihydroisoquinoline carboxamide analog 1
DM5UPGZ	HS	Patented
DM5UPGZ	SN	PMID27724045-Compound-28
DM5UPGZ	CP	Evotec
DM5UPGZ	DT	Small molecular drug

DMQRECT	ID	DMQRECT
DMQRECT	DN	Dihydroisoxazole derivative 1
DMQRECT	HS	Patented
DMQRECT	SN	PMID26560530-Compound-51
DMQRECT	CP	Leland Stanford Junior University
DMQRECT	DT	Small molecular drug
DMQRECT	PC	644315
DMQRECT	MW	499.4
DMQRECT	FM	C23H23BrN4O4
DMQRECT	IC	InChI=1S/C23H23BrN4O4/c24-21-11-17(32-28-21)13-26-22(29)20(10-16-12-25-19-9-5-4-8-18(16)19)27-23(30)31-14-15-6-2-1-3-7-15/h1-9,12,17,20,25H,10-11,13-14H2,(H,26,29)(H,27,30)/t17?,20-/m0/s1
DMQRECT	CS	C1C(ON=C1Br)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)OCC4=CC=CC=C4
DMQRECT	IK	MAQVWGRATZCTBU-OZBJMMHXSA-N
DMQRECT	IU	benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamate
DMQRECT	CA	CAS 744198-17-2

DMLTZKX	ID	DMLTZKX
DMLTZKX	DN	Dihydroisoxazole derivative 2
DMLTZKX	HS	Patented
DMLTZKX	SN	PMID26560530-Compound-52
DMLTZKX	CP	Leland Stanford Junior University
DMLTZKX	DT	Small molecular drug
DMLTZKX	PC	16094738
DMLTZKX	MW	568.4
DMLTZKX	FM	C26H23BrFN5O4
DMLTZKX	IC	InChI=1S/C26H23BrFN5O4/c27-24-10-19(37-33-24)13-31-25(34)23(8-17-12-30-22-6-5-18(28)9-20(17)22)32-26(35)36-14-15-7-16-3-1-2-4-21(16)29-11-15/h1-7,9,11-12,19,23,30H,8,10,13-14H2,(H,31,34)(H,32,35)/t19?,23-/m0/s1
DMLTZKX	CS	C1C(ON=C1Br)CNC(=O)[C@H](CC2=CNC3=C2C=C(C=C3)F)NC(=O)OCC4=CC5=CC=CC=C5N=C4
DMLTZKX	IK	SUDBOOMQYSPULE-BVHINDKJSA-N
DMLTZKX	IU	quinolin-3-ylmethyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(5-fluoro-1H-indol-3-yl)-1-oxopropan-2-yl]carbamate

DM16M4A	ID	DM16M4A
DM16M4A	DN	Dihydropyridine compound 1
DM16M4A	HS	Patented
DM16M4A	SN	PMID27646564-Compound-6-1
DM16M4A	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DM16M4A	DT	Small molecular drug

DM6RGOY	ID	DM6RGOY
DM6RGOY	DN	Dihydropyridine compound 2
DM6RGOY	HS	Patented
DM6RGOY	SN	PMID27646564-Compound-6-2
DM6RGOY	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DM6RGOY	DT	Small molecular drug

DMR3AVK	ID	DMR3AVK
DMR3AVK	DN	Dihydropyridine compound 3
DMR3AVK	HS	Patented
DMR3AVK	SN	PMID27646564-Compound-6-3
DMR3AVK	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DMR3AVK	DT	Small molecular drug

DMIFZLG	ID	DMIFZLG
DMIFZLG	DN	Dihydropyridine compound 4
DMIFZLG	HS	Patented
DMIFZLG	SN	PMID27646564-Compound-6-4
DMIFZLG	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DMIFZLG	DT	Small molecular drug

DMC41TK	ID	DMC41TK
DMC41TK	DN	Dihydropyridine compound 5
DMC41TK	HS	Patented
DMC41TK	SN	PMID27646564-Compound-6a
DMC41TK	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DMC41TK	DT	Small molecular drug

DMEXT6J	ID	DMEXT6J
DMEXT6J	DN	Dihydropyridine compound 6
DMEXT6J	HS	Patented
DMEXT6J	SN	PMID27646564-Compound-6b
DMEXT6J	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DMEXT6J	DT	Small molecular drug

DMWIYFQ	ID	DMWIYFQ
DMWIYFQ	DN	Dihydropyrido phthalazinone derivative 1
DMWIYFQ	HS	Patented
DMWIYFQ	SN	PMID27841036-Compound-21
DMWIYFQ	DT	Small molecular drug
DMWIYFQ	PC	136265073
DMWIYFQ	MW	394.4
DMWIYFQ	FM	C20H16F2N6O
DMWIYFQ	IC	InChI=1S/C20H16F2N6O/c1-28-19(24-9-25-28)17-14(10-2-4-11(21)5-3-10)8-23-15-7-12(22)6-13-16(15)18(17)26-27-20(13)29/h2-7,9,14,17,23H,8H2,1H3,(H,27,29)
DMWIYFQ	CS	CN1C(=NC=N1)C2C(CNC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
DMWIYFQ	IK	BGMPCZSIPWMURU-UHFFFAOYSA-N
DMWIYFQ	IU	7-fluoro-12-(4-fluorophenyl)-13-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.4.1.05,14]tetradeca-1,5(14),6,8-tetraen-4-one

DMR4PQN	ID	DMR4PQN
DMR4PQN	DN	Dihydropyrido phthalazinone derivative 2
DMR4PQN	HS	Patented
DMR4PQN	SN	PMID27841036-Compound-22
DMR4PQN	DT	Small molecular drug
DMR4PQN	PC	136334008
DMR4PQN	MW	395.4
DMR4PQN	FM	C19H15F2N7O
DMR4PQN	IC	InChI=1S/C19H15F2N7O/c1-28-18(22-8-23-28)15-16(9-2-4-10(20)5-3-9)25-24-13-7-11(21)6-12-14(13)17(15)26-27-19(12)29/h2-8,15-16,24-25H,1H3,(H,27,29)
DMR4PQN	CS	CN1C(=NC=N1)C2C(NNC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
DMR4PQN	IK	VGIBCJTZZYLWON-UHFFFAOYSA-N
DMR4PQN	IU	7-fluoro-12-(4-fluorophenyl)-13-(2-methyl-1,2,4-triazol-3-yl)-2,3,10,11-tetrazatricyclo[7.4.1.05,14]tetradeca-1,5(14),6,8-tetraen-4-one

DMMFBI3	ID	DMMFBI3
DMMFBI3	DN	Dihydropyrido phthalazinone derivative 3
DMMFBI3	HS	Patented
DMMFBI3	SN	PMID27841036-Compound-IX
DMMFBI3	CP	BIOMARIN PHARMACEUTICAL INC. FENG, Ying GUTIERREZ, Andres, A. SHEN, Yuqiao WANG, Evelyn, W. OKHAMAFE, Augustus, O. PRICE, Christopher, P. CHOU, TianweBIOMARIN PHARMACEUTICAL INC. WANG, Bing CHU, Daniel
DMMFBI3	DT	Small molecular drug

DMWEJ6U	ID	DMWEJ6U
DMWEJ6U	DN	Dihydropyrido phthalazinone derivative 4
DMWEJ6U	HS	Patented
DMWEJ6U	SN	PMID27841036-Compound-X
DMWEJ6U	DT	Small molecular drug

DM8S7NQ	ID	DM8S7NQ
DM8S7NQ	DN	Dihydropyrido pyrazinone compound 1
DM8S7NQ	HS	Patented
DM8S7NQ	SN	PMID26924192-Compound-58
DM8S7NQ	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DM8S7NQ	DT	Small molecular drug

DMOTG2Y	ID	DMOTG2Y
DMOTG2Y	DN	Dihydropyrido pyrazinone compound 2
DMOTG2Y	HS	Patented
DMOTG2Y	SN	PMID26924192-Compound-59
DMOTG2Y	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMOTG2Y	DT	Small molecular drug

DM3PEUN	ID	DM3PEUN
DM3PEUN	DN	Dihydropyrido pyrazinone compound 3
DM3PEUN	HS	Patented
DM3PEUN	SN	PMID26924192-Compound-60
DM3PEUN	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DM3PEUN	DT	Small molecular drug

DMSTC9Z	ID	DMSTC9Z
DMSTC9Z	DN	Dihydropyrido pyrimidine derivative 1
DMSTC9Z	HS	Patented
DMSTC9Z	SN	PMID28447479-Compound-3
DMSTC9Z	CP	ELI LILLY AND COMPANY
DMSTC9Z	DT	Small molecular drug

DMA25XH	ID	DMA25XH
DMA25XH	DN	Dihydropyrimidinone derivative 1
DMA25XH	HS	Patented
DMA25XH	SN	PMID26118988-Compound-19
DMA25XH	DT	Small molecular drug

DM5Y13R	ID	DM5Y13R
DM5Y13R	DN	Dihydropyrimidinone derivative 2
DM5Y13R	HS	Patented
DM5Y13R	SN	PMID26118988-Compound-20
DM5Y13R	DT	Small molecular drug

DMA1S6Q	ID	DMA1S6Q
DMA1S6Q	DN	Dihydropyrimidinone derivative 3
DMA1S6Q	HS	Patented
DMA1S6Q	SN	PMID25470667-Compound-Figure6-24
DMA1S6Q	CP	BRISTOL-MYERS SQUIBB COMPANY
DMA1S6Q	DT	Small molecular drug

DMNEKOZ	ID	DMNEKOZ
DMNEKOZ	DN	Dihydropyrimidinone derivative 4
DMNEKOZ	HS	Patented
DMNEKOZ	SN	PMID25470667-Compound-Figure6-25
DMNEKOZ	CP	BRISTOL-MYERS SQUIBB COMPANY
DMNEKOZ	DT	Small molecular drug

DMHGE1T	ID	DMHGE1T
DMHGE1T	DN	Dihydropyrrolopyrazole derivative 1
DMHGE1T	HS	Patented
DMHGE1T	SN	PMID25482888-Compound-47
DMHGE1T	CP	MERCK SHARP & DOHME CORP. BIFTU, Tesfaye KHAN, Tanweer, A
DMHGE1T	DT	Small molecular drug

DMUJ3XK	ID	DMUJ3XK
DMUJ3XK	DN	Dihydrothieno [2,3-e]indazole derivative 1
DMUJ3XK	HS	Patented
DMUJ3XK	SN	PMID25553724-Compound-WO2011077502 17
DMUJ3XK	CP	KYORIN SEIYAKU KK [JPTAKAHASHI HIROYASU [JPHIGUCHI HIROMI [JP]

DM0D3HU	ID	DM0D3HU
DM0D3HU	DN	Dihydrothieno [2,3-e]indazole derivative 2
DM0D3HU	HS	Patented
DM0D3HU	SN	PMID25553724-Compound-WO2011077502 18
DM0D3HU	CP	KYORIN SEIYAKU KK [JPTAKAHASHI HIROYASU [JPHIGUCHI HIROMI [JP]

DM85VQR	ID	DM85VQR
DM85VQR	DN	Dihydrothieno [2,3-e]indazole derivative 3
DM85VQR	HS	Patented
DM85VQR	SN	PMID25553724-Compound-WO2011077502 19
DM85VQR	CP	KYORIN SEIYAKU KK [JPTAKAHASHI HIROYASU [JPHIGUCHI HIROMI [JP]

DMR4LPO	ID	DMR4LPO
DMR4LPO	DN	Dihydrothieno [2,3-e]indazole derivative 4
DMR4LPO	HS	Patented
DMR4LPO	SN	PMID25553724-Compound-WO2011077502 20
DMR4LPO	CP	KYORIN SEIYAKU KK [JPTAKAHASHI HIROYASU [JPHIGUCHI HIROMI [JP]

DMAH1EP	ID	DMAH1EP
DMAH1EP	DN	Dihydroxyfumaric acid derivative 1
DMAH1EP	HS	Patented
DMAH1EP	SN	PMID26815044-Compound-119
DMAH1EP	DT	Small molecular drug
DMAH1EP	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMZ4B3W	ID	DMZ4B3W
DMZ4B3W	DN	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1
DMZ4B3W	HS	Patented
DMZ4B3W	SN	PMID27998201-Compound-16
DMZ4B3W	DT	Small molecular drug
DMZ4B3W	PC	1720818
DMZ4B3W	MW	264.3
DMZ4B3W	FM	C12H12N2O3S
DMZ4B3W	IC	InChI=1S/C12H12N2O3S/c1-16-8-3-7(4-9(6-8)17-2)5-10-11(15)14-12(18)13-10/h3-6H,1-2H3,(H2,13,14,15,18)/b10-5-
DMZ4B3W	CS	COC1=CC(=CC(=C1)/C=C\\2/C(=O)NC(=S)N2)OC
DMZ4B3W	IK	SXBGOUWIALXAOL-YHYXMXQVSA-N
DMZ4B3W	IU	(5Z)-5-[(3,5-dimethoxyphenyl)methylidene]-2-sulfanylideneimidazolidin-4-one
DMZ4B3W	DE	Cerebral ischemia

DM2OTJS	ID	DM2OTJS
DM2OTJS	DN	Dipeptide analog 1
DM2OTJS	HS	Patented
DM2OTJS	SN	PMID29865878-Compound-2
DM2OTJS	CP	THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL MOUNT SINAL SCHOOL OF MEDICINE ORLOWSKI, Robert, Z. ORLOWSKI, Marian
DM2OTJS	DT	Small molecular drug

DMMAF2S	ID	DMMAF2S
DMMAF2S	DN	Dipeptide analog 2
DMMAF2S	HS	Patented
DMMAF2S	SN	PMID26560530-Compound-20
DMMAF2S	CP	Aston University
DMMAF2S	DT	Small molecular drug

DM6RLTV	ID	DM6RLTV
DM6RLTV	DN	Dipeptide analog 3
DM6RLTV	HS	Patented
DM6RLTV	SN	PMID26560530-Compound-21
DM6RLTV	CP	Aston University
DM6RLTV	DT	Small molecular drug

DMXOPIJ	ID	DMXOPIJ
DMXOPIJ	DN	Dipeptide analog 4
DMXOPIJ	HS	Patented
DMXOPIJ	SN	PMID26560530-Compound-22
DMXOPIJ	CP	Aston University
DMXOPIJ	DT	Small molecular drug

DM2DYMS	ID	DM2DYMS
DM2DYMS	DN	Diphenyl purine derivative 1
DM2DYMS	HS	Patented
DM2DYMS	SN	PMID26161824-Compound-150
DM2DYMS	CP	RESEARCH TRIANGLE INSTITUTE
DM2DYMS	DT	Small molecular drug
DM2DYMS	PC	71714624
DM2DYMS	MW	560.5
DM2DYMS	FM	C25H27Cl2N7O2S
DM2DYMS	IC	InChI=1S/C25H27Cl2N7O2S/c26-18-9-11-19(12-10-18)34-24(20-3-1-2-4-21(20)27)33-22-23(30-15-31-25(22)34)29-13-16-5-7-17(8-6-16)14-32-37(28,35)36/h1-4,9-12,15-17,32H,5-8,13-14H2,(H2,28,35,36)(H,29,30,31)
DM2DYMS	CS	C1CC(CCC1CNC2=C3C(=NC=N2)N(C(=N3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl)CNS(=O)(=O)N
DM2DYMS	IK	FSGQETVZTNOSAH-UHFFFAOYSA-N
DM2DYMS	IU	8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-[[4-[(sulfamoylamino)methyl]cyclohexyl]methylamino]purine
DM2DYMS	DE	Obesity

DMG8MCJ	ID	DMG8MCJ
DMG8MCJ	DN	Diphenyl purine derivative 2
DMG8MCJ	HS	Patented
DMG8MCJ	SN	PMID26161824-Compound-151
DMG8MCJ	CP	RESEARCH TRIANGLE INSTITUTE
DMG8MCJ	DT	Small molecular drug
DMG8MCJ	PC	72713199
DMG8MCJ	MW	535.5
DMG8MCJ	FM	C28H28Cl2N6O
DMG8MCJ	IC	InChI=1S/C28H28Cl2N6O/c29-19-9-11-21(12-10-19)36-25(22-7-3-4-8-23(22)30)34-24-26(31-17-32-27(24)36)35-15-13-20(14-16-35)33-28(37)18-5-1-2-6-18/h3-4,7-12,17-18,20H,1-2,5-6,13-16H2,(H,33,37)
DMG8MCJ	CS	C1CCC(C1)C(=O)NC2CCN(CC2)C3=NC=NC4=C3N=C(N4C5=CC=C(C=C5)Cl)C6=CC=CC=C6Cl
DMG8MCJ	IK	XCAAVBMCEMDRAB-UHFFFAOYSA-N
DMG8MCJ	IU	N-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidin-4-yl]cyclopentanecarboxamide
DMG8MCJ	DE	Obesity

DMY5CFW	ID	DMY5CFW
DMY5CFW	DN	Diphenyl purine derivative 3
DMY5CFW	HS	Patented
DMY5CFW	SN	PMID26161824-Compound-152
DMY5CFW	CP	RESEARCH TRIANGLE INSTITUTE
DMY5CFW	DT	Small molecular drug
DMY5CFW	PC	72713197
DMY5CFW	MW	563.5
DMY5CFW	FM	C30H32Cl2N6O
DMY5CFW	IC	InChI=1S/C30H32Cl2N6O/c31-21-10-12-23(13-11-21)38-28(24-8-4-5-9-25(24)32)36-27-29(33-19-34-30(27)38)37-16-14-22(15-17-37)35-26(39)18-20-6-2-1-3-7-20/h4-5,8-13,19-20,22H,1-3,6-7,14-18H2,(H,35,39)
DMY5CFW	CS	C1CCC(CC1)CC(=O)NC2CCN(CC2)C3=NC=NC4=C3N=C(N4C5=CC=C(C=C5)Cl)C6=CC=CC=C6Cl
DMY5CFW	IK	ZGMMGSCAIDATIP-UHFFFAOYSA-N
DMY5CFW	IU	N-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidin-4-yl]-2-cyclohexylacetamide
DMY5CFW	DE	Obesity

DMP3JF4	ID	DMP3JF4
DMP3JF4	DN	Diphenyl purine derivative 4
DMP3JF4	HS	Patented
DMP3JF4	SN	PMID26161824-Compound-153
DMP3JF4	CP	RESEARCH TRIANGLE INSTITUTE
DMP3JF4	DT	Small molecular drug
DMP3JF4	PC	72712999
DMP3JF4	MW	511.4
DMP3JF4	FM	C25H24Cl2N6O2
DMP3JF4	IC	InChI=1S/C25H24Cl2N6O2/c1-2-35-25(34)30-17-11-13-32(14-12-17)23-21-24(29-15-28-23)33(18-9-7-16(26)8-10-18)22(31-21)19-5-3-4-6-20(19)27/h3-10,15,17H,2,11-14H2,1H3,(H,30,34)
DMP3JF4	CS	CCOC(=O)NC1CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMP3JF4	IK	YNFZOBCSHAKXPA-UHFFFAOYSA-N
DMP3JF4	IU	ethyl N-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidin-4-yl]carbamate
DMP3JF4	DE	Obesity

DMC2T4H	ID	DMC2T4H
DMC2T4H	DN	Diphenyl purine derivative 5
DMC2T4H	HS	Patented
DMC2T4H	SN	PMID26161824-Compound-154
DMC2T4H	CP	RESEARCH TRIANGLE INSTITUTE
DMC2T4H	DT	Small molecular drug
DMC2T4H	PC	72713196
DMC2T4H	MW	523.5
DMC2T4H	FM	C27H28Cl2N6O
DMC2T4H	IC	InChI=1S/C27H28Cl2N6O/c1-2-3-8-23(36)32-19-13-15-34(16-14-19)26-24-27(31-17-30-26)35(20-11-9-18(28)10-12-20)25(33-24)21-6-4-5-7-22(21)29/h4-7,9-12,17,19H,2-3,8,13-16H2,1H3,(H,32,36)
DMC2T4H	CS	CCCCC(=O)NC1CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMC2T4H	IK	JSIOAJBHLWGADL-UHFFFAOYSA-N
DMC2T4H	IU	N-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidin-4-yl]pentanamide
DMC2T4H	DE	Obesity

DM3OCXI	ID	DM3OCXI
DM3OCXI	DN	Di-substituted piperidine derivative 1
DM3OCXI	HS	Patented
DM3OCXI	SN	PMID29757691-Compound-3a
DM3OCXI	CP	UNIVERZA V LJUBLJANI [SI]
DM3OCXI	DT	Small molecular drug

DM23XQL	ID	DM23XQL
DM23XQL	DN	Di-substituted piperidine derivative 2
DM23XQL	HS	Patented
DM23XQL	SN	PMID29757691-Compound-3a-i
DM23XQL	CP	UNIVERZA V LJUBLJANI [SI]
DM23XQL	DT	Small molecular drug

DM2IBX9	ID	DM2IBX9
DM2IBX9	DN	Di-substituted piperidine derivative 3
DM2IBX9	HS	Patented
DM2IBX9	SN	PMID29757691-Compound-3b
DM2IBX9	CP	UNIVERZA V LJUBLJANI [SI]
DM2IBX9	DT	Small molecular drug

DMTYL68	ID	DMTYL68
DMTYL68	DN	Disulfide compound 1
DMTYL68	HS	Patented
DMTYL68	SN	PMID27977313-Compound-38
DMTYL68	DT	Small molecular drug
DMTYL68	PC	219104
DMTYL68	MW	188.3
DMTYL68	FM	C7H12N2S2
DMTYL68	IC	InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)
DMTYL68	CS	CCC(C)SSC1=NC=CN1
DMTYL68	IK	BPBPYQWMFCTCNG-UHFFFAOYSA-N
DMTYL68	IU	2-(butan-2-yldisulfanyl)-1H-imidazole
DMTYL68	CA	CAS 141400-58-0
DMTYL68	CB	CHEBI:94291

DM6ON31	ID	DM6ON31
DM6ON31	DN	Disulfide compound 2
DM6ON31	HS	Patented
DM6ON31	SN	PMID27977313-Compound-Figure6a
DM6ON31	DT	Small molecular drug

DMOEFD3	ID	DMOEFD3
DMOEFD3	DN	Disulfiram analog 1
DMOEFD3	HS	Patented
DMOEFD3	SN	PMID25468267-Compound-26
DMOEFD3	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DMOEFD3	DT	Small molecular drug
DMOEFD3	PC	6451399
DMOEFD3	MW	240.4
DMOEFD3	FM	C6H12N2S4
DMOEFD3	IC	InChI=1S/C6H12N2S4/c1-3-7-5(9)11-12-6(10)8-4-2/h3-4H2,1-2H3,(H,7,9)(H,8,10)
DMOEFD3	CS	CCNC(=S)SSC(=S)NCC
DMOEFD3	IK	AMFIBVNSEBYBAM-UHFFFAOYSA-N
DMOEFD3	IU	ethylcarbamothioylsulfanyl N-ethylcarbamodithioate
DMOEFD3	CA	CAS 2438-91-7

DMOMGU5	ID	DMOMGU5
DMOMGU5	DN	Disulfiram analog 2
DMOMGU5	HS	Patented
DMOMGU5	SN	PMID25468267-Compound-27
DMOMGU5	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DMOMGU5	DT	Small molecular drug
DMOMGU5	PC	575125
DMOMGU5	MW	292.5
DMOMGU5	FM	C10H16N2S4
DMOMGU5	IC	InChI=1S/C10H16N2S4/c13-9(11-5-1-2-6-11)15-16-10(14)12-7-3-4-8-12/h1-8H2
DMOMGU5	CS	C1CCN(C1)C(=S)SSC(=S)N2CCCC2
DMOMGU5	IK	KCGUGVQODCQMBI-UHFFFAOYSA-N
DMOMGU5	IU	pyrrolidine-1-carbothioylsulfanyl pyrrolidine-1-carbodithioate
DMOMGU5	CA	CAS 496-08-2

DMYQHER	ID	DMYQHER
DMYQHER	DN	Diterpene triepoxide derivative 1
DMYQHER	HS	Patented
DMYQHER	SN	PMID27977313-Compound-37
DMYQHER	DT	Small molecular drug
DMYQHER	PC	133613148
DMYQHER	MW	360.4
DMYQHER	FM	C20H24O6
DMYQHER	IC	InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m1/s1
DMYQHER	CS	CC(C)[C@]12[C@H](O1)[C@@H]3[C@]4(O3)[C@@]5(CCC6=C([C@H]5C[C@@H]7[C@@]4([C@H]2O)O7)COC6=O)C
DMYQHER	IK	DFBIRQPKNDILPW-IJWWASSVSA-N
DMYQHER	IU	(1R,2R,4R,5R,7S,8S,9R,11R,13R)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one
DMYQHER	CA	CAS 38748-32-2

DMAZOH4	ID	DMAZOH4
DMAZOH4	DN	Diterpenoid derivative 1
DMAZOH4	HS	Patented
DMAZOH4	SN	PMID28454500-Compound-47
DMAZOH4	CP	BIOGEN MA INC
DMAZOH4	DT	Small molecular drug
DMAZOH4	PC	132210477
DMAZOH4	MW	320.4
DMAZOH4	FM	C19H28O4
DMAZOH4	IC	InChI=1S/C19H28O4/c1-11-4-6-15-12(2)16(20)8-9-19(15,3)14(11)7-5-13-17(21)10-23-18(13)22/h5,12,14-17,20-21H,1,4,6-10H2,2-3H3/b13-5+/t12-,14-,15-,16-,17-,19+/m1/s1
DMAZOH4	CS	C[C@@H]1[C@H]2CCC(=C)[C@H]([C@@]2(CC[C@H]1O)C)C/C=C/3\\[C@@H](COC3=O)O
DMAZOH4	IK	VIGAUKOHNZARKF-YGQNBZPJSA-N
DMAZOH4	IU	(3E,4S)-3-[2-[(1R,4aR,5R,6R,8aR)-6-hydroxy-5,8a-dimethyl-2-methylidene-1,3,4,4a,5,6,7,8-octahydronaphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one

DMKT19M	ID	DMKT19M
DMKT19M	DN	Diterpenoid derivative 2
DMKT19M	HS	Patented
DMKT19M	SN	PMID28454500-Compound-48
DMKT19M	CP	BIOGEN MA INC
DMKT19M	DT	Small molecular drug
DMKT19M	PC	132210549
DMKT19M	MW	388.4
DMKT19M	FM	C20H27F3O4
DMKT19M	IC	InChI=1S/C20H27F3O4/c1-11-4-6-15-12(2)19(26,20(21,22)23)9-8-18(15,3)14(11)7-5-13-16(24)10-27-17(13)25/h5,12,14-16,24,26H,1,4,6-10H2,2-3H3/b13-5+/t12-,14-,15-,16-,18+,19+/m1/s1
DMKT19M	CS	C[C@@H]1[C@H]2CCC(=C)[C@H]([C@@]2(CC[C@]1(C(F)(F)F)O)C)C/C=C/3\\[C@@H](COC3=O)O
DMKT19M	IK	NDMPTVODOMVTKE-YDWKZQRASA-N
DMKT19M	IU	(3E,4S)-3-[2-[(1R,4aR,5R,6S,8aR)-6-hydroxy-5,8a-dimethyl-2-methylidene-6-(trifluoromethyl)-3,4,4a,5,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one

DM6BU7N	ID	DM6BU7N
DM6BU7N	DN	Doramapimod
DM6BU7N	HS	Patented
DM6BU7N	SN	Doramapimod; 285983-48-4; BIRB-796; BIRB 796; BIRB 796 (Doramapimod); BIRB796; UNII-HO1A8B3YVV; 1-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA; 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea; HO1A8B3YVV; CHEMBL103667; 3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea; CHEBI:40953; MVCOAUNKQVWQHZ-UHFFFAOYSA-N; C31H37N5O3; 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(2
DM6BU7N	DT	Small molecular drug
DM6BU7N	PC	156422
DM6BU7N	MW	527.7
DM6BU7N	FM	C31H37N5O3
DM6BU7N	IC	InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)
DM6BU7N	CS	CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5
DM6BU7N	IK	MVCOAUNKQVWQHZ-UHFFFAOYSA-N
DM6BU7N	IU	1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea
DM6BU7N	CA	CAS 285983-48-4
DM6BU7N	CB	CHEBI:40953
DM6BU7N	DE	Inflammatory bowel disease

DM2HLGC	ID	DM2HLGC
DM2HLGC	DN	DZ9
DM2HLGC	HS	Patented
DM2HLGC	SN	CHEMBL1084955; 3-amino-N-(3-fluorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide; 3hfj; NadD inhibitor 3_02; AC1MMP3S; SCHEMBL11887601; HMS1801K16; RSC004746; BDBM50318653; NCGC00100444-01; EU-0014464; US8785499, 3_02; 3-amino-N-(3-fluorophenyl)-6-(thiophen-2-yl)thieno[2,3-b]pyridine-2-carboxamide; DZ9
DM2HLGC	DT	Small molecular drug
DM2HLGC	PC	3289443
DM2HLGC	MW	369.4
DM2HLGC	FM	C18H12FN3OS2
DM2HLGC	IC	InChI=1S/C18H12FN3OS2/c19-10-3-1-4-11(9-10)21-17(23)16-15(20)12-6-7-13(22-18(12)25-16)14-5-2-8-24-14/h1-9H,20H2,(H,21,23)
DM2HLGC	CS	C1=CC(=CC(=C1)F)NC(=O)C2=C(C3=C(S2)N=C(C=C3)C4=CC=CS4)N
DM2HLGC	IK	UCTSEHMMSSIODN-UHFFFAOYSA-N
DM2HLGC	IU	3-amino-N-(3-fluorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide

DM5UM8I	ID	DM5UM8I
DM5UM8I	DN	EEA
DM5UM8I	HS	Patented
DM5UM8I	SN	N-{3-[3-(3'-Chlorobiphenyl-4-Yl)isoxazol-5-Yl]propanoyl}-L-Alpha-Glutamyl-L-Alpha-Glutamyl-Amide; SCHEMBL14122533; CHEMBL1232487; BDBM120155; US8691753, 3; N-{3-[3-(3'-chlorobiphenyl-4-yl)-1,2-oxazol-5-yl]propanoyl}-L-alpha-glutamyl-L-alpha-glutamine; EEA
DM5UM8I	DT	Small molecular drug
DM5UM8I	PC	46861564
DM5UM8I	MW	585
DM5UM8I	FM	C28H29ClN4O8
DM5UM8I	IC	InChI=1S/C28H29ClN4O8/c29-19-3-1-2-18(14-19)16-4-6-17(7-5-16)23-15-20(41-33-23)8-11-24(34)31-22(10-13-26(37)38)28(40)32-21(27(30)39)9-12-25(35)36/h1-7,14-15,21-22H,8-13H2,(H2,30,39)(H,31,34)(H,32,40)(H,35,36)(H,37,38)/t21-,22-/m0/s1
DM5UM8I	CS	C1=CC(=CC(=C1)Cl)C2=CC=C(C=C2)C3=NOC(=C3)CCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N
DM5UM8I	IK	KOVQMCGGWATESY-VXKWHMMOSA-N
DM5UM8I	IU	(4S)-5-amino-4-[[(2S)-4-carboxy-2-[3-[3-[4-(3-chlorophenyl)phenyl]-1,2-oxazol-5-yl]propanoylamino]butanoyl]amino]-5-oxopentanoic acid

DMR9IE5	ID	DMR9IE5
DMR9IE5	DN	EEC
DMR9IE5	HS	Patented
DMR9IE5	SN	N-[3-(3-Phenylisoxazol-5-Yl)propanoyl]-L-Alpha-Glutamyl-L-Alpha-Glutamyl-Amide; SCHEMBL14122610; CHEMBL1232489; BDBM120166; US8691753, 14; N-[3-(3-phenyl-1,2-oxazol-5-yl)propanoyl]-L-alpha-glutamyl-L-alpha-glutamine; EEC
DMR9IE5	DT	Small molecular drug
DMR9IE5	PC	46861565
DMR9IE5	MW	474.5
DMR9IE5	FM	C22H26N4O8
DMR9IE5	IC	InChI=1S/C22H26N4O8/c23-21(32)15(7-10-19(28)29)25-22(33)16(8-11-20(30)31)24-18(27)9-6-14-12-17(26-34-14)13-4-2-1-3-5-13/h1-5,12,15-16H,6-11H2,(H2,23,32)(H,24,27)(H,25,33)(H,28,29)(H,30,31)/t15-,16-/m0/s1
DMR9IE5	CS	C1=CC=C(C=C1)C2=NOC(=C2)CCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N
DMR9IE5	IK	LIIRZRQVACDFBI-HOTGVXAUSA-N
DMR9IE5	IU	(4S)-5-amino-4-[[(2S)-4-carboxy-2-[3-(3-phenyl-1,2-oxazol-5-yl)propanoylamino]butanoyl]amino]-5-oxopentanoic acid

DMQF1UM	ID	DMQF1UM
DMQF1UM	DN	Egonol compound 1
DMQF1UM	HS	Patented
DMQF1UM	SN	PMID27967267-Compound-44
DMQF1UM	CP	Univ Guangzhou Chinese Medicine
DMQF1UM	DT	Small molecular drug

DMNBAZH	ID	DMNBAZH
DMNBAZH	DN	Enol carbamate derivative 1
DMNBAZH	HS	Patented
DMNBAZH	SN	PMID26413912-Compound-28
DMNBAZH	CP	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. MINETTI, Patrizia CABRI, Walter DALLAVALLE, Sabrina MERLINI, Lucio PENCO, Sergio BORSINI, Franco CAPRIOLI, Antonio MACCARRONE, Mauro
DMNBAZH	DT	Small molecular drug

DMJSIN8	ID	DMJSIN8
DMJSIN8	DN	Enzoxazolinone sulfonamide derivative 1
DMJSIN8	HS	Patented
DMJSIN8	SN	PMID25539043-Compound-WO2013063459Example50
DMJSIN8	CP	MERCK SHARP &amDOHME CORP. LAYTON, Mark, E. PERO, Joseph, E. FIJI, Hannah KELLY, Michael, J., III DE LEON, Pablo ROSSI, Michael, A. GILBERT, Kevin, F. ROECKER, Anthony, J. ZHAO, Zhijian MERCER, Swati Pal WOLKENBERG, Scott MULHEARN, James ZHAO, Lianyun LI, Dansu
DMJSIN8	DT	Small molecular drug

DMU8LPN	ID	DMU8LPN
DMU8LPN	DN	Epoxysuccinate derivative 1
DMU8LPN	HS	Patented
DMU8LPN	SN	PMID25399719-Compound-18
DMU8LPN	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMU8LPN	DT	Small molecular drug

DMYF39U	ID	DMYF39U
DMYF39U	DN	Epoxysuccinate derivative 10
DMYF39U	HS	Patented
DMYF39U	SN	PMID25399719-Compound-27
DMYF39U	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMYF39U	DT	Small molecular drug

DMEV9O3	ID	DMEV9O3
DMEV9O3	DN	Epoxysuccinate derivative 2
DMEV9O3	HS	Patented
DMEV9O3	SN	PMID25399719-Compound-19
DMEV9O3	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMEV9O3	DT	Small molecular drug
DMEV9O3	PC	71679189
DMEV9O3	MW	356.32
DMEV9O3	FM	C16H18F2N2O5
DMEV9O3	IC	InChI=1S/C16H18F2N2O5/c1-7(2)6-10(19-15(22)12-13(25-12)16(23)24)14(21)20-11-8(17)4-3-5-9(11)18/h3-5,7,10,12-13H,6H2,1-2H3,(H,19,22)(H,20,21)(H,23,24)/t10-,12-,13-/m0/s1
DMEV9O3	CS	CC(C)C[C@@H](C(=O)NC1=C(C=CC=C1F)F)NC(=O)[C@@H]2[C@H](O2)C(=O)O
DMEV9O3	IK	RZWURLBUPSDTKT-DRZSPHRISA-N
DMEV9O3	IU	(2S,3S)-3-[[(2S)-1-(2,6-difluoroanilino)-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid

DMMETW5	ID	DMMETW5
DMMETW5	DN	Epoxysuccinate derivative 3
DMMETW5	HS	Patented
DMMETW5	SN	PMID25399719-Compound-20
DMMETW5	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMMETW5	DT	Small molecular drug
DMMETW5	PC	71818387
DMMETW5	MW	356.32
DMMETW5	FM	C16H18F2N2O5
DMMETW5	IC	InChI=1S/C16H18F2N2O5/c1-7(2)6-10(19-15(22)12-13(25-12)16(23)24)14(21)20-11-8(17)4-3-5-9(11)18/h3-5,7,10,12-13H,6H2,1-2H3,(H,19,22)(H,20,21)(H,23,24)/t10-,12+,13+/m0/s1
DMMETW5	CS	CC(C)C[C@@H](C(=O)NC1=C(C=CC=C1F)F)NC(=O)[C@H]2[C@@H](O2)C(=O)O
DMMETW5	IK	RZWURLBUPSDTKT-CYZMBNFOSA-N
DMMETW5	IU	(2R,3R)-3-[[(2S)-1-(2,6-difluoroanilino)-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid

DMCF6M8	ID	DMCF6M8
DMCF6M8	DN	Epoxysuccinate derivative 4
DMCF6M8	HS	Patented
DMCF6M8	SN	PMID25399719-Compound-21
DMCF6M8	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMCF6M8	DT	Small molecular drug
DMCF6M8	PC	71679021
DMCF6M8	MW	421.4
DMCF6M8	FM	C19H20FN3O5S
DMCF6M8	IC	InChI=1S/C19H20FN3O5S/c1-9(2)7-12(21-17(25)14-15(28-14)18(26)27)16(24)23-19-22-13(8-29-19)10-3-5-11(20)6-4-10/h3-6,8-9,12,14-15H,7H2,1-2H3,(H,21,25)(H,26,27)(H,22,23,24)/t12-,14-,15-/m0/s1
DMCF6M8	CS	CC(C)C[C@@H](C(=O)NC1=NC(=CS1)C2=CC=C(C=C2)F)NC(=O)[C@@H]3[C@H](O3)C(=O)O
DMCF6M8	IK	WVMZJHSGEWZNEO-QEJZJMRPSA-N
DMCF6M8	IU	(2S,3S)-3-[[(2S)-1-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid

DM37MCN	ID	DM37MCN
DM37MCN	DN	Epoxysuccinate derivative 5
DM37MCN	HS	Patented
DM37MCN	SN	PMID25399719-Compound-22
DM37MCN	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DM37MCN	DT	Small molecular drug

DMQM6ZS	ID	DMQM6ZS
DMQM6ZS	DN	Epoxysuccinate derivative 6
DMQM6ZS	HS	Patented
DMQM6ZS	SN	PMID25399719-Compound-23
DMQM6ZS	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMQM6ZS	DT	Small molecular drug
DMQM6ZS	PC	71817936
DMQM6ZS	MW	361.4
DMQM6ZS	FM	C16H15N3O5S
DMQM6ZS	IC	InChI=1S/C16H15N3O5S/c20-14(18-9-4-2-1-3-5-9)11(6-10-7-25-8-17-10)19-15(21)12-13(24-12)16(22)23/h1-5,7-8,11-13H,6H2,(H,18,20)(H,19,21)(H,22,23)/t11-,12-,13-/m0/s1
DMQM6ZS	CS	C1=CC=C(C=C1)NC(=O)[C@H](CC2=CSC=N2)NC(=O)[C@@H]3[C@H](O3)C(=O)O
DMQM6ZS	IK	SLAUAVANSQIASN-AVGNSLFASA-N
DMQM6ZS	IU	(2S,3S)-3-[[(2S)-1-anilino-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]carbamoyl]oxirane-2-carboxylic acid

DMTSPVF	ID	DMTSPVF
DMTSPVF	DN	Epoxysuccinate derivative 7
DMTSPVF	HS	Patented
DMTSPVF	SN	PMID25399719-Compound-24
DMTSPVF	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMTSPVF	DT	Small molecular drug
DMTSPVF	PC	89737599
DMTSPVF	MW	462.5
DMTSPVF	FM	C19H15FN4O5S2
DMTSPVF	IC	InChI=1S/C19H15FN4O5S2/c20-10-3-1-9(2-4-10)13-7-31-19(23-13)24-16(25)12(5-11-6-30-8-21-11)22-17(26)14-15(29-14)18(27)28/h1-4,6-8,12,14-15H,5H2,(H,22,26)(H,27,28)(H,23,24,25)/t12-,14+,15+/m0/s1
DMTSPVF	CS	C1=CC(=CC=C1C2=CSC(=N2)NC(=O)[C@H](CC3=CSC=N3)NC(=O)[C@H]4[C@@H](O4)C(=O)O)F
DMTSPVF	IK	WRGOUJJZKXTKBL-NWANDNLSSA-N
DMTSPVF	IU	(2R,3R)-3-[[(2S)-1-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]carbamoyl]oxirane-2-carboxylic acid

DMQTVPC	ID	DMQTVPC
DMQTVPC	DN	Epoxysuccinate derivative 8
DMQTVPC	HS	Patented
DMQTVPC	SN	PMID25399719-Compound-25
DMQTVPC	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMQTVPC	DT	Small molecular drug

DM49FU0	ID	DM49FU0
DM49FU0	DN	Epoxysuccinate derivative 9
DM49FU0	HS	Patented
DM49FU0	SN	PMID25399719-Compound-26
DM49FU0	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DM49FU0	DT	Small molecular drug
DM49FU0	PC	73356676
DM49FU0	MW	445.4
DM49FU0	FM	C19H16FN5O5S
DM49FU0	IC	InChI=1S/C19H16FN5O5S/c20-10-3-1-9(2-4-10)13-7-31-19(24-13)25-16(26)12(5-11-6-21-8-22-11)23-17(27)14-15(30-14)18(28)29/h1-4,6-8,12,14-15H,5H2,(H,21,22)(H,23,27)(H,28,29)(H,24,25,26)/t12-,14+,15+/m0/s1
DM49FU0	CS	C1=CC(=CC=C1C2=CSC(=N2)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H]4[C@@H](O4)C(=O)O)F
DM49FU0	IK	LWEKDSQGUMPMSP-NWANDNLSSA-N
DM49FU0	IU	(2R,3R)-3-[[(2S)-1-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl]oxirane-2-carboxylic acid

DM7XYRA	ID	DM7XYRA
DM7XYRA	DN	Eptastatin derivative 1
DM7XYRA	HS	Patented
DM7XYRA	SN	PMID27537201-Compound-Figure14right
DM7XYRA	DT	Small molecular drug

DMLOBAQ	ID	DMLOBAQ
DMLOBAQ	DN	Ethinyl-pyrazole derivative 1
DMLOBAQ	HS	Patented
DMLOBAQ	SN	PMID25435285-Compound-68
DMLOBAQ	CP	TAISHO PHARMACEUTICAL CO., LTD.  NAKAMURA Toshio  SAKAGAMI Kazunari  KONISHI Kazuhide  YAMAMOTO Kanako  MASUDA Seiji 
DMLOBAQ	DT	Small molecular drug

DMA3PE7	ID	DMA3PE7
DMA3PE7	DN	Ethinyl-pyrazole derivative 2
DMA3PE7	HS	Patented
DMA3PE7	SN	PMID25435285-Compound-72
DMA3PE7	CP	TAISHO PHARMACEUTICAL CO., LTD.  NAKAMURA Toshio  SAKAGAMI Kazunari  KONISHI Kazuhide  YAMAMOTO Kanako  MASUDA Seiji 
DMA3PE7	DT	Small molecular drug
DMA3PE7	PC	56642741
DMA3PE7	MW	435.4
DMA3PE7	FM	C20H16F3N3O3S
DMA3PE7	IC	InChI=1S/C20H16F3N3O3S/c1-26-19(13-29-17-9-7-16(8-10-17)20(21,22)23)15(12-25-26)6-5-14-3-2-4-18(11-14)30(24,27)28/h2-4,7-12H,13H2,1H3,(H2,24,27,28)
DMA3PE7	CS	CN1C(=C(C=N1)C#CC2=CC(=CC=C2)S(=O)(=O)N)COC3=CC=C(C=C3)C(F)(F)F
DMA3PE7	IK	RTQHVIORPPJRPP-UHFFFAOYSA-N
DMA3PE7	IU	3-[2-[1-methyl-5-[[4-(trifluoromethyl)phenoxy]methyl]pyrazol-4-yl]ethynyl]benzenesulfonamide

DM87DOX	ID	DM87DOX
DM87DOX	DN	Ethinyl-pyrazole derivative 3
DM87DOX	HS	Patented
DM87DOX	SN	PMID25435285-Compound-73
DM87DOX	CP	TAISHO PHARMACEUTICAL CO., LTD.  NAKAMURA Toshio  SAKAGAMI Kazunari  KONISHI Kazuhide  YAMAMOTO Kanako  MASUDA Seiji 
DM87DOX	DT	Small molecular drug
DM87DOX	PC	56642739
DM87DOX	MW	412.9
DM87DOX	FM	C20H17ClN4O2S
DM87DOX	IC	InChI=1S/C20H17ClN4O2S/c1-24-20(25-12-16-6-7-18(21)10-17(16)13-25)15(11-23-24)5-2-14-3-8-19(9-4-14)28(22,26)27/h3-4,6-11H,12-13H2,1H3,(H2,22,26,27)
DM87DOX	CS	CN1C(=C(C=N1)C#CC2=CC=C(C=C2)S(=O)(=O)N)N3CC4=C(C3)C=C(C=C4)Cl
DM87DOX	IK	CAOKQZMINRCCBM-UHFFFAOYSA-N
DM87DOX	IU	4-[2-[5-(5-chloro-1,3-dihydroisoindol-2-yl)-1-methylpyrazol-4-yl]ethynyl]benzenesulfonamide

DMTBG39	ID	DMTBG39
DMTBG39	DN	Ethylaminopyrimidine derivative 1
DMTBG39	HS	Patented
DMTBG39	SN	PMID26413912-Compound-73
DMTBG39	CP	JANSSEN PHARMACEUTICA N.V. APODACA, Richard BREITENBUCHER, J., Guy CHAMBERS, Alison, L. DENG, Xiaohu HAWRYLUK, Natalie, A. KEITH, John, M. MANI, Neelakandha, S. MERIT, Jeffrey, E. PIERCE, Joan, M. SEIERSTAD, Mark XIAO, Wei
DMTBG39	DT	Small molecular drug
DMTBG39	PC	44203832
DMTBG39	MW	369.8
DMTBG39	FM	C20H20ClN3O2
DMTBG39	IC	InChI=1S/C20H20ClN3O2/c1-2-26-19-9-8-15(10-16(19)21)17-11-20(24-13-23-17)22-12-18(25)14-6-4-3-5-7-14/h3-11,13,18,25H,2,12H2,1H3,(H,22,23,24)/t18-/m0/s1
DMTBG39	CS	CCOC1=C(C=C(C=C1)C2=CC(=NC=N2)NC[C@@H](C3=CC=CC=C3)O)Cl
DMTBG39	IK	MOEQPDYTFQLEOK-SFHVURJKSA-N
DMTBG39	IU	(1R)-2-[[6-(3-chloro-4-ethoxyphenyl)pyrimidin-4-yl]amino]-1-phenylethanol

DM9WMJ1	ID	DM9WMJ1
DM9WMJ1	DN	Ethylvanillin
DM9WMJ1	HS	Patented
DM9WMJ1	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM9WMJ1	PC	8467
DM9WMJ1	MW	166.17
DM9WMJ1	FM	C9H10O3
DM9WMJ1	IC	InChI=1S/C9H10O3/c1-2-12-9-5-7(6-10)3-4-8(9)11/h3-6,11H,2H2,1H3
DM9WMJ1	CS	CCOC1=C(C=CC(=C1)C=O)O
DM9WMJ1	IK	CBOQJANXLMLOSS-UHFFFAOYSA-N
DM9WMJ1	IU	3-ethoxy-4-hydroxybenzaldehyde
DM9WMJ1	CA	CAS 121-32-4
DM9WMJ1	CB	CHEBI:48408

DMWXKRZ	ID	DMWXKRZ
DMWXKRZ	DN	Ethynyl compound 1
DMWXKRZ	HS	Patented
DMWXKRZ	SN	PMID28067079-Compound-13
DMWXKRZ	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMWXKRZ	DT	Small molecular drug
DMWXKRZ	PC	73775704
DMWXKRZ	MW	355.8
DMWXKRZ	FM	C19H18ClN3O2
DMWXKRZ	IC	InChI=1S/C19H18ClN3O2/c1-19(2)13-25-9-8-23(19)18(24)17-21-11-15(12-22-17)7-6-14-4-3-5-16(20)10-14/h3-5,10-12H,8-9,13H2,1-2H3
DMWXKRZ	CS	CC1(COCCN1C(=O)C2=NC=C(C=N2)C#CC3=CC(=CC=C3)Cl)C
DMWXKRZ	IK	UOYREAVBKXAAFN-UHFFFAOYSA-N
DMWXKRZ	IU	[5-[2-(3-chlorophenyl)ethynyl]pyrimidin-2-yl]-(3,3-dimethylmorpholin-4-yl)methanone

DMJDG37	ID	DMJDG37
DMJDG37	DN	Ethynyl compound 2
DMJDG37	HS	Patented
DMJDG37	SN	PMID28067079-Compound-19
DMJDG37	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMJDG37	DT	Small molecular drug

DMD9PZQ	ID	DMD9PZQ
DMD9PZQ	DN	Ethynyl compound 3
DMD9PZQ	HS	Patented
DMD9PZQ	SN	PMID28067079-Compound-3
DMD9PZQ	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMD9PZQ	DT	Small molecular drug

DMLDMO8	ID	DMLDMO8
DMLDMO8	DN	Ethynyl compound 4
DMLDMO8	HS	Patented
DMLDMO8	SN	PMID28067079-Compound-4
DMLDMO8	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMLDMO8	DT	Small molecular drug

DM53ZPE	ID	DM53ZPE
DM53ZPE	DN	Ethynyl compound 5
DM53ZPE	HS	Patented
DM53ZPE	SN	PMID28067079-Compound-5
DM53ZPE	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM53ZPE	DT	Small molecular drug

DMDOEFC	ID	DMDOEFC
DMDOEFC	DN	Ethynyl compound 6
DMDOEFC	HS	Patented
DMDOEFC	SN	PMID28067079-Compound-6
DMDOEFC	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMDOEFC	DT	Small molecular drug

DMPUG2M	ID	DMPUG2M
DMPUG2M	DN	Ethynyl compound 7
DMPUG2M	HS	Patented
DMPUG2M	SN	PMID28067079-Compound-9
DMPUG2M	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMPUG2M	DT	Small molecular drug

DM7US1H	ID	DM7US1H
DM7US1H	DN	Eugenol
DM7US1H	HS	Patented
DM7US1H	SN	eugenol; 97-53-0; 4-Allyl-2-methoxyphenol; 4-Allylguaiacol; Eugenic acid; Allylguaiacol; Caryophyllic acid; p-Allylguaiacol; p-Eugenol; 2-Methoxy-4-prop-2-enylphenol; Engenol; 2-Methoxy-4-allylphenol; Phenol, 2-methoxy-4-(2-propenyl)-; 1,3,4-Eugenol; 4-Allylcatechol-2-methyl ether; Synthetic eugenol; 2-Methoxy-4-(2-propenyl)phenol; 2-Methoxy-1-hydroxy-4-allylbenzene; 4-Allyl-1-hydroxy-2-methoxybenzene; 1-Hydroxy-2-methoxy-4-allylbenzene; 5-Allylguaiacol; 1-Hydroxy-2-methoxy-4-prop-2-enylbenzene
DM7US1H	DT	Small molecular drug
DM7US1H	PC	3314
DM7US1H	MW	164.2
DM7US1H	FM	C10H12O2
DM7US1H	IC	InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3
DM7US1H	CS	COC1=C(C=CC(=C1)CC=C)O
DM7US1H	IK	RRAFCDWBNXTKKO-UHFFFAOYSA-N
DM7US1H	IU	2-methoxy-4-prop-2-enylphenol
DM7US1H	CA	CAS 97-53-0
DM7US1H	CB	CHEBI:4917
DM7US1H	DE	Discovery agent

DMJC7NF	ID	DMJC7NF
DMJC7NF	DN	Ferulic Acid
DMJC7NF	HS	Patented
DMJC7NF	SN	ferulic acid; trans-Ferulic Acid; 1135-24-6; 4-Hydroxy-3-methoxycinnamic acid; 537-98-4; trans-4-Hydroxy-3-methoxycinnamic acid; 3-(4-Hydroxy-3-methoxyphenyl)acrylic acid; (E)-Ferulic acid; ferulate; Coniferic acid; Ferulic acid, trans-; (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; Cinnamic acid, 4-hydroxy-3-methoxy-; 3-methoxy-4-hydroxycinnamic acid; (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; UNII-AVM951ZWST; Cinnamic acid, 4-hydroxy-3-methoxy-, (E)-
DMJC7NF	DT	Small molecular drug
DMJC7NF	PC	445858
DMJC7NF	MW	194.18
DMJC7NF	FM	C10H10O4
DMJC7NF	IC	InChI=1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+
DMJC7NF	CS	COC1=C(C=CC(=C1)/C=C/C(=O)O)O
DMJC7NF	IK	KSEBMYQBYZTDHS-HWKANZROSA-N
DMJC7NF	IU	(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid
DMJC7NF	CA	CAS 537-98-4
DMJC7NF	CB	CHEBI:17620
DMJC7NF	DE	Discovery agent

DMPFAST	ID	DMPFAST
DMPFAST	DN	Five membered heterocyclic benzamide derivative 1
DMPFAST	HS	Patented
DMPFAST	SN	PMID28270021-Compound-WO2015148350Example36
DMPFAST	CP	MERCK SHARP & DOHME CORP
DMPFAST	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM4U63E	ID	DM4U63E
DM4U63E	DN	Five membered heterocyclic benzamide derivative 2
DM4U63E	HS	Patented
DM4U63E	SN	PMID28270021-Compound-WO2015148350Example76
DM4U63E	CP	MERCK SHARP & DOHME CORP
DM4U63E	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMUS4Z0	ID	DMUS4Z0
DMUS4Z0	DN	Five membered heterocyclic benzamide derivative 3
DMUS4Z0	HS	Patented
DMUS4Z0	SN	PMID28270021-Compound-WO2015148350Example81
DMUS4Z0	CP	MERCK SHARP & DOHME CORP
DMUS4Z0	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM7SK5Q	ID	DM7SK5Q
DM7SK5Q	DN	Five-and-six-membered heterocyclic compound 1
DM7SK5Q	HS	Patented
DM7SK5Q	SN	PMID27774822-Compound-Figure8compoundT-38
DM7SK5Q	CP	SHANGHAI YUNYI HEALTHCARE MANAGEMENT CO., LTD CHINA GATEWAY TECHNOLOGY DEVELOPMENT
DM7SK5Q	DT	Small molecular drug

DMO8UKD	ID	DMO8UKD
DMO8UKD	DN	Five-membered heteroaromatic compound 1
DMO8UKD	HS	Patented
DMO8UKD	SN	PMID29473428-Compound-44
DMO8UKD	DT	Small molecular drug
DMO8UKD	PC	130361031
DMO8UKD	MW	288.4
DMO8UKD	FM	C16H20N2OS
DMO8UKD	IC	InChI=1S/C16H20N2OS/c19-15(11-4-2-1-3-5-11)8-13-16-12(6-7-20-16)14-9-17-10-18(13)14/h6-7,9-11,13,15,19H,1-5,8H2
DMO8UKD	CS	C1CCC(CC1)C(CC2C3=C(C=CS3)C4=CN=CN24)O
DMO8UKD	IK	ZPMZNNITKQQNAG-UHFFFAOYSA-N
DMO8UKD	IU	1-cyclohexyl-2-(9-thia-4,6-diazatricyclo[6.3.0.02,6]undeca-1(8),2,4,10-tetraen-7-yl)ethanol

DM1QH8Z	ID	DM1QH8Z
DM1QH8Z	DN	Five-membered heteroaromatic compound 2
DM1QH8Z	HS	Patented
DM1QH8Z	SN	PMID29473428-Compound-45
DM1QH8Z	DT	Small molecular drug

DMS0P9E	ID	DMS0P9E
DMS0P9E	DN	Five-membered heteroaromatic compound 3
DMS0P9E	HS	Patented
DMS0P9E	SN	PMID29473428-Compound-46
DMS0P9E	DT	Small molecular drug
DMS0P9E	PC	130360247
DMS0P9E	MW	290.4
DMS0P9E	FM	C16H19FN2S
DMS0P9E	IC	InChI=1S/C16H19FN2S/c17-16(6-2-1-3-7-16)8-4-13-15-12(5-9-20-15)14-10-18-11-19(13)14/h5,9-11,13H,1-4,6-8H2
DMS0P9E	CS	C1CCC(CC1)(CCC2C3=C(C=CS3)C4=CN=CN24)F
DMS0P9E	IK	AQNGWMVFAXPUTC-UHFFFAOYSA-N
DMS0P9E	IU	7-[2-(1-fluorocyclohexyl)ethyl]-9-thia-4,6-diazatricyclo[6.3.0.02,6]undeca-1(8),2,4,10-tetraene

DMCQP0B	ID	DMCQP0B
DMCQP0B	DN	Flavonoid derivative 1
DMCQP0B	HS	Patented
DMCQP0B	SN	PMID26394986-Compound-45
DMCQP0B	CP	UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMCQP0B	DT	Small molecular drug
DMCQP0B	PC	5280445
DMCQP0B	MW	286.24
DMCQP0B	FM	C15H10O6
DMCQP0B	IC	InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H
DMCQP0B	CS	C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMCQP0B	IK	IQPNAANSBPBGFQ-UHFFFAOYSA-N
DMCQP0B	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMCQP0B	CA	CAS 491-70-3
DMCQP0B	CB	CHEBI:15864

DMWZARV	ID	DMWZARV
DMWZARV	DN	Flavonoid derivative 2
DMWZARV	HS	Patented
DMWZARV	SN	PMID26394986-Compound-46
DMWZARV	CP	UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMWZARV	DT	Small molecular drug

DMT7ZEL	ID	DMT7ZEL
DMT7ZEL	DN	Flavonoid derivative 3
DMT7ZEL	HS	Patented
DMT7ZEL	SN	PMID26394986-Compound-47
DMT7ZEL	CP	UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMT7ZEL	DT	Small molecular drug
DMT7ZEL	PC	5281612
DMT7ZEL	MW	300.26
DMT7ZEL	FM	C16H12O6
DMT7ZEL	IC	InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3
DMT7ZEL	CS	COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
DMT7ZEL	IK	MBNGWHIJMBWFHU-UHFFFAOYSA-N
DMT7ZEL	IU	5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one
DMT7ZEL	CA	CAS 520-34-3
DMT7ZEL	CB	CHEBI:4630

DMMOSVD	ID	DMMOSVD
DMMOSVD	DN	Flavonoid derivative 4
DMMOSVD	HS	Patented
DMMOSVD	SN	PMID26394986-Compound-48
DMMOSVD	CP	UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMMOSVD	DT	Small molecular drug
DMMOSVD	PC	5280343
DMMOSVD	MW	302.23
DMMOSVD	FM	C15H10O7
DMMOSVD	IC	InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H
DMMOSVD	CS	C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
DMMOSVD	IK	REFJWTPEDVJJIY-UHFFFAOYSA-N
DMMOSVD	IU	2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
DMMOSVD	CA	CAS 117-39-5
DMMOSVD	CB	CHEBI:16243

DMTWAJX	ID	DMTWAJX
DMTWAJX	DN	Flavonoid derivative 5
DMTWAJX	HS	Patented
DMTWAJX	SN	PMID26394986-Compound-49
DMTWAJX	CP	UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMTWAJX	DT	Small molecular drug

DM0E38G	ID	DM0E38G
DM0E38G	DN	Flavonoid derivative 6
DM0E38G	HS	Patented
DM0E38G	SN	PMID25468267-Compound-1
DM0E38G	CP	Kenhavns Universitet CLOOS, Paul AGGER, Karl CHRISTENSEN, Jesper HANSEN, Klaus H. HELIN, Kristian
DM0E38G	DT	Small molecular drug

DM6A9UR	ID	DM6A9UR
DM6A9UR	DN	Flavonoid derivative 7
DM6A9UR	HS	Patented
DM6A9UR	SN	PMID26161698-Compound-6
DM6A9UR	CP	THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY IP, Nancy Yuk-Yu IP, Fanny Chui-Fun FU, Wing Yu FU, Guangmiao
DM6A9UR	DT	Small molecular drug
DM6A9UR	PC	74978523
DM6A9UR	MW	448.4
DM6A9UR	FM	C21H20O11
DM6A9UR	IC	InChI=1S/C21H20O11/c1-7-13(25)15(27)17(29)21(30-7)32-19-11(24)6-10(23)12-14(26)16(28)18(31-20(12)19)8-2-4-9(22)5-3-8/h2-7,13,15,17,21-25,27-29H,1H3
DM6A9UR	CS	CC1C(C(C(C(O1)OC2=C(C=C(C3=C2OC(=C(C3=O)O)C4=CC=C(C=C4)O)O)O)O)O)O
DM6A9UR	IK	PJZKCQPCHMMPJZ-UHFFFAOYSA-N
DM6A9UR	IU	3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxychromen-4-one

DM4O9T3	ID	DM4O9T3
DM4O9T3	DN	Flavonoid derivative 8
DM4O9T3	HS	Patented
DM4O9T3	SN	PMID25416646-Compound-Figure5-B
DM4O9T3	CP	Huawei Technologies Co., Ltd
DM4O9T3	DT	Small molecular drug

DMXL3A5	ID	DMXL3A5
DMXL3A5	DN	Flavopiridol analog 1
DMXL3A5	HS	Patented
DMXL3A5	SN	PMID26161698-Compound-5
DMXL3A5	CP	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
DMXL3A5	DT	Small molecular drug
DMXL3A5	PC	86272549
DMXL3A5	MW	462.3
DMXL3A5	FM	C23H21Cl2NO5
DMXL3A5	IC	InChI=1S/C23H21Cl2NO5/c1-26-8-7-14(20(30)11-26)21-18(28)10-19(29)22-17(27)9-12(31-23(21)22)5-6-13-15(24)3-2-4-16(13)25/h2-6,9-10,14,20,28-30H,7-8,11H2,1H3/b6-5+
DMXL3A5	CS	CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)/C=C/C4=C(C=CC=C4Cl)Cl)O)O
DMXL3A5	IK	NFTJDXGFOUFNKG-AATRIKPKSA-N
DMXL3A5	IU	2-[(E)-2-(2,6-dichlorophenyl)ethenyl]-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)chromen-4-one

DMGOSN2	ID	DMGOSN2
DMGOSN2	DN	Fluorinated compound 1
DMGOSN2	HS	Patented
DMGOSN2	SN	PMID26161698-Compound-15
DMGOSN2	CP	ANYGEN CO., LTD. KIM, Yong-Chul KIM, Jae-Il BAN, Soo-Ho JEONG, Soon-Young CHOI, Soo-Jeong LEE, Jung-Eun
DMGOSN2	DT	Small molecular drug

DMQOGHN	ID	DMQOGHN
DMQOGHN	DN	Fluorinated donepezil derivative 1
DMQOGHN	HS	Patented
DMQOGHN	SN	PMID27967267-Compound-1
DMQOGHN	DT	Small molecular drug
DMQOGHN	PC	72710841
DMQOGHN	MW	415.5
DMQOGHN	FM	C24H27F2NO3
DMQOGHN	IC	InChI=1S/C24H27F2NO3/c1-29-20-12-18-14-24(26,22(28)19(18)13-21(20)30-2)16-23(25)8-10-27(11-9-23)15-17-6-4-3-5-7-17/h3-7,12-13H,8-11,14-16H2,1-2H3
DMQOGHN	CS	COC1=C(C=C2C(=C1)CC(C2=O)(CC3(CCN(CC3)CC4=CC=CC=C4)F)F)OC
DMQOGHN	IK	FMFDCMLVUWZCIV-UHFFFAOYSA-N
DMQOGHN	IU	2-[(1-benzyl-4-fluoropiperidin-4-yl)methyl]-2-fluoro-5,6-dimethoxy-3H-inden-1-one

DMV1SCA	ID	DMV1SCA
DMV1SCA	DN	Fluorinated donepezil derivative 2
DMV1SCA	HS	Patented
DMV1SCA	SN	PMID27967267-Compound-2
DMV1SCA	DT	Small molecular drug

DMTS8O9	ID	DMTS8O9
DMTS8O9	DN	Fluorophenyl-substituted heterocyclic amide analog 1
DMTS8O9	HS	Patented
DMTS8O9	SN	PMID27724045-Compound-9
DMTS8O9	CP	Roche
DMTS8O9	DT	Small molecular drug
DMTS8O9	PC	46220501
DMTS8O9	MW	361.4
DMTS8O9	FM	C21H16FN3O2
DMTS8O9	IC	InChI=1S/C21H16FN3O2/c22-15-8-6-14(7-9-15)20-13-16(26)10-12-25(20)21(27)24-19-5-1-4-18-17(19)3-2-11-23-18/h1-12,20H,13H2,(H,24,27)/t20-/m0/s1
DMTS8O9	CS	C1[C@H](N(C=CC1=O)C(=O)NC2=CC=CC3=C2C=CC=N3)C4=CC=C(C=C4)F
DMTS8O9	IK	ZREAHQPXWUVTDX-FQEVSTJZSA-N
DMTS8O9	IU	(2S)-2-(4-fluorophenyl)-4-oxo-N-quinolin-5-yl-2,3-dihydropyridine-1-carboxamide

DM2QXVW	ID	DM2QXVW
DM2QXVW	DN	Furopyridine derivative 1
DM2QXVW	HS	Patented
DM2QXVW	SN	PMID26161824-Compound-120
DM2QXVW	DT	Small molecular drug
DM2QXVW	PC	25062281
DM2QXVW	MW	565.4
DM2QXVW	FM	C28H22Cl2N4O5
DM2QXVW	IC	InChI=1S/C28H22Cl2N4O5/c1-28(2,3)25(37)24-23(32-21(36)12-35)19-11-18(14-4-7-16(29)8-5-14)22(33-27(19)39-24)17-9-6-15(10-20(17)30)26-31-13-38-34-26/h4-11,13,35H,12H2,1-3H3,(H,32,36)
DM2QXVW	CS	CC(C)(C)C(=O)C1=C(C2=CC(=C(N=C2O1)C3=C(C=C(C=C3)C4=NOC=N4)Cl)C5=CC=C(C=C5)Cl)NC(=O)CO
DM2QXVW	IK	SPKFHHXBXRKREW-UHFFFAOYSA-N
DM2QXVW	IU	N-[6-[2-chloro-4-(1,2,4-oxadiazol-3-yl)phenyl]-5-(4-chlorophenyl)-2-(2,2-dimethylpropanoyl)furo[2,3-b]pyridin-3-yl]-2-hydroxyacetamide
DM2QXVW	DE	Obesity

DMEU3J9	ID	DMEU3J9
DMEU3J9	DN	Furopyridine derivative 2
DMEU3J9	HS	Patented
DMEU3J9	SN	PMID26161824-Compound-121
DMEU3J9	DT	Small molecular drug
DMEU3J9	DE	Obesity

DM4EUFL	ID	DM4EUFL
DM4EUFL	DN	Fused aromatic compound 1
DM4EUFL	HS	Patented
DM4EUFL	SN	PMID25416646-Compound-Figure2-F
DM4EUFL	CP	MERCK & CO., INC. MEINKE, Peter, T. DENKER, Andrew MEININGER, Gary, E. UEMURA, Naoto WAGNER, John, A. CHARNICK, Steven
DM4EUFL	DT	Small molecular drug

DMFAM8B	ID	DMFAM8B
DMFAM8B	DN	Fused aryl carbocycle derivative 1
DMFAM8B	HS	Patented
DMFAM8B	SN	PMID30185082-Compound-44
DMFAM8B	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMFAM8B	DT	Small molecular drug

DMAQBJP	ID	DMAQBJP
DMAQBJP	DN	Fused aryl carbocycle derivative 2
DMAQBJP	HS	Patented
DMAQBJP	SN	PMID30185082-Compound-45
DMAQBJP	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMAQBJP	DT	Small molecular drug

DM5I4CA	ID	DM5I4CA
DM5I4CA	DN	Fused aryl carbocycle derivative 3
DM5I4CA	HS	Patented
DM5I4CA	SN	PMID30185082-Compound-46
DM5I4CA	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DM5I4CA	DT	Small molecular drug

DMOU8T3	ID	DMOU8T3
DMOU8T3	DN	Fused aryl carbocycle derivative 4
DMOU8T3	HS	Patented
DMOU8T3	SN	PMID30185082-Compound-47
DMOU8T3	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMOU8T3	DT	Small molecular drug

DMPBMEU	ID	DMPBMEU
DMPBMEU	DN	Fused aryl carbocycle derivative 8
DMPBMEU	HS	Patented
DMPBMEU	SN	PMID30185082-Compound-51
DMPBMEU	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMPBMEU	DT	Small molecular drug

DMQ2X6O	ID	DMQ2X6O
DMQ2X6O	DN	Fused aryl carbocycle derivative 9
DMQ2X6O	HS	Patented
DMQ2X6O	SN	PMID30185082-Compound-52
DMQ2X6O	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMQ2X6O	DT	Small molecular drug
DMQ2X6O	PC	132060412
DMQ2X6O	MW	421.6
DMQ2X6O	FM	C26H35N3O2
DMQ2X6O	IC	InChI=1S/C26H35N3O2/c1-3-15-28-16-18-29(19-17-28)25-14-8-11-22-23(25)12-7-13-24(22)27(2)26(30)31-20-21-9-5-4-6-10-21/h4-6,8-11,14,24H,3,7,12-13,15-20H2,1-2H3
DMQ2X6O	CS	CCCN1CCN(CC1)C2=CC=CC3=C2CCCC3N(C)C(=O)OCC4=CC=CC=C4
DMQ2X6O	IK	YZQOEMNLUIMOMX-UHFFFAOYSA-N
DMQ2X6O	IU	benzyl N-methyl-N-[5-(4-propylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamate

DMKLO2H	ID	DMKLO2H
DMKLO2H	DN	Fused benzoheterocycle amide derivative 1
DMKLO2H	HS	Patented
DMKLO2H	SN	PMID27310003-Compound-4
DMKLO2H	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED ANIMA, Boruah HOSAHALLI, Subramanya SUBHENDU, Mukherjee
DMKLO2H	DT	Small molecular drug

DM9NMHS	ID	DM9NMHS
DM9NMHS	DN	Fused benzoheterocycle amide derivative 2
DM9NMHS	HS	Patented
DM9NMHS	SN	PMID27310003-Compound-5
DM9NMHS	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED ANIMA, Boruah HOSAHALLI, Subramanya SUBHENDU, Mukherjee
DM9NMHS	DT	Small molecular drug

DMVU9RG	ID	DMVU9RG
DMVU9RG	DN	Fused heterocyclic compound 1
DMVU9RG	HS	Patented
DMVU9RG	SN	PMID27841045-Compound-123
DMVU9RG	CP	Kissei Pharmaceutical Co. Ltd
DMVU9RG	DT	Small molecular drug
DMVU9RG	PC	58400451
DMVU9RG	MW	317.32
DMVU9RG	FM	C14H11N3O4S
DMVU9RG	IC	InChI=1S/C14H11N3O4S/c1-7-12(14(18)19)22-13(15-7)9-5-8-3-4-16(2)11(8)10(6-9)17(20)21/h3-6H,1-2H3,(H,18,19)
DMVU9RG	CS	CC1=C(SC(=N1)C2=CC(=C3C(=C2)C=CN3C)[N+](=O)[O-])C(=O)O
DMVU9RG	IK	YGQCHVOXQFVYAB-UHFFFAOYSA-N
DMVU9RG	IU	4-methyl-2-(1-methyl-7-nitroindol-5-yl)-1,3-thiazole-5-carboxylic acid

DMALDZ6	ID	DMALDZ6
DMALDZ6	DN	Fused heterocyclic compound 10
DMALDZ6	HS	Patented
DMALDZ6	SN	PMID27841045-Compound-153
DMALDZ6	CP	Kissei Pharmaceutical Co. Ltd
DMALDZ6	DT	Small molecular drug

DMJC4UZ	ID	DMJC4UZ
DMJC4UZ	DN	Fused heterocyclic compound 11
DMJC4UZ	HS	Patented
DMJC4UZ	SN	PMID27841045-Compound-154
DMJC4UZ	CP	Kissei Pharmaceutical Co. Ltd
DMJC4UZ	DT	Small molecular drug

DMSYD6Z	ID	DMSYD6Z
DMSYD6Z	DN	Fused heterocyclic compound 12
DMSYD6Z	HS	Patented
DMSYD6Z	SN	PMID27414413-Compound-Figure8left
DMSYD6Z	DT	Small molecular drug

DM361J8	ID	DM361J8
DM361J8	DN	Fused heterocyclic compound 2
DM361J8	HS	Patented
DM361J8	SN	PMID27841045-Compound-124
DM361J8	CP	Kissei Pharmaceutical Co. Ltd
DM361J8	DT	Small molecular drug

DM2QVHY	ID	DM2QVHY
DM2QVHY	DN	Fused heterocyclic compound 3
DM2QVHY	HS	Patented
DM2QVHY	SN	PMID27841045-Compound-125
DM2QVHY	CP	Kissei Pharmaceutical Co. Ltd
DM2QVHY	DT	Small molecular drug

DMHTS5G	ID	DMHTS5G
DMHTS5G	DN	Fused heterocyclic compound 4
DMHTS5G	HS	Patented
DMHTS5G	SN	PMID27841045-Compound-126
DMHTS5G	CP	Kissei Pharmaceutical Co. Ltd
DMHTS5G	DT	Small molecular drug
DMHTS5G	PC	46199345
DMHTS5G	MW	283.31
DMHTS5G	FM	C14H9N3O2S
DMHTS5G	IC	InChI=1S/C14H9N3O2S/c1-7-12(14(18)19)20-13(17-7)9-4-8-2-3-16-11(8)10(5-9)6-15/h2-5,16H,1H3,(H,18,19)
DMHTS5G	CS	CC1=C(SC(=N1)C2=CC(=C3C(=C2)C=CN3)C#N)C(=O)O
DMHTS5G	IK	QJWAUWFGCGISKV-UHFFFAOYSA-N
DMHTS5G	IU	2-(7-cyano-1H-indol-5-yl)-4-methyl-1,3-thiazole-5-carboxylic acid

DM10CGB	ID	DM10CGB
DM10CGB	DN	Fused heterocyclic compound 5
DM10CGB	HS	Patented
DM10CGB	SN	PMID27841045-Compound-127
DM10CGB	CP	Kissei Pharmaceutical Co. Ltd
DM10CGB	DT	Small molecular drug
DM10CGB	PC	46199187
DM10CGB	MW	297.3
DM10CGB	FM	C15H11N3O2S
DM10CGB	IC	InChI=1S/C15H11N3O2S/c1-8-13(15(19)20)21-14(17-8)10-5-9-3-4-18(2)12(9)11(6-10)7-16/h3-6H,1-2H3,(H,19,20)
DM10CGB	CS	CC1=C(SC(=N1)C2=CC(=C3C(=C2)C=CN3C)C#N)C(=O)O
DM10CGB	IK	UKMCFVVQXUWRFF-UHFFFAOYSA-N
DM10CGB	IU	2-(7-cyano-1-methylindol-5-yl)-4-methyl-1,3-thiazole-5-carboxylic acid

DM9DC3U	ID	DM9DC3U
DM9DC3U	DN	Fused heterocyclic compound 6
DM9DC3U	HS	Patented
DM9DC3U	SN	PMID27841045-Compound-128
DM9DC3U	CP	Kissei Pharmaceutical Co. Ltd
DM9DC3U	DT	Small molecular drug

DMGNWJD	ID	DMGNWJD
DMGNWJD	DN	Fused heterocyclic compound 7
DMGNWJD	HS	Patented
DMGNWJD	SN	PMID27841045-Compound-150
DMGNWJD	CP	Kissei Pharmaceutical Co. Ltd
DMGNWJD	DT	Small molecular drug

DMO8JE7	ID	DMO8JE7
DMO8JE7	DN	Fused heterocyclic compound 8
DMO8JE7	HS	Patented
DMO8JE7	SN	PMID27841045-Compound-151
DMO8JE7	CP	Kissei Pharmaceutical Co. Ltd
DMO8JE7	DT	Small molecular drug

DM25IMA	ID	DM25IMA
DM25IMA	DN	Fused heterocyclic compound 9
DM25IMA	HS	Patented
DM25IMA	SN	PMID27841045-Compound-152
DM25IMA	CP	Kissei Pharmaceutical Co. Ltd
DM25IMA	DT	Small molecular drug

DMPHL3J	ID	DMPHL3J
DMPHL3J	DN	Fused ring compound 1
DMPHL3J	HS	Patented
DMPHL3J	SN	PMID25416646-Compound-Figure2-G
DMPHL3J	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED TAWARAISHI, Taisuke IMOTO, Hiroshi CHO, Nobuo
DMPHL3J	DT	Small molecular drug

DMV7IX4	ID	DMV7IX4
DMV7IX4	DN	Fused thiophene derivative 1
DMV7IX4	HS	Patented
DMV7IX4	SN	PMID28117607-Compound-17
DMV7IX4	CP	MERCK SHARP & DOHME CORP
DMV7IX4	DT	Small molecular drug

DM4Z72S	ID	DM4Z72S
DM4Z72S	DN	Fused triazoloamino-phenyl analog 1
DM4Z72S	HS	Patented
DM4Z72S	SN	PMID27724045-Compound-10
DM4Z72S	CP	Roche
DM4Z72S	DT	Small molecular drug

DM5BVCS	ID	DM5BVCS
DM5BVCS	DN	Galantamine analog 1
DM5BVCS	HS	Patented
DM5BVCS	SN	PMID27967267-Compound-5
DM5BVCS	CP	Univ East China Science & Tech
DM5BVCS	DT	Small molecular drug

DMK6RFS	ID	DMK6RFS
DMK6RFS	DN	Geminally-substituted cyanoethylpypazolo pyridone derivative 1
DMK6RFS	HS	Patented
DMK6RFS	SN	PMID27774822-Compound-Figure2Example17-32
DMK6RFS	CP	MERCK SHARP & DOHME CORP. CHILDERS, Matthew L. FULLER, Peter H. GUERIN, David J. KATZ, Jason David MARTINEZ, Michelle PU, Qinglin SCOTT, Mark E. THOMPSON, Christopher F. CAI, Jiaqiang KONG, Norman LIU, Yumei
DMK6RFS	DT	Small molecular drug

DMB2INX	ID	DMB2INX
DMB2INX	DN	Geminally-substituted cyanoethylpypazolo pyridone derivative 2
DMB2INX	HS	Patented
DMB2INX	SN	PMID27774822-Compound-Figure2Example5-84
DMB2INX	CP	MERCK SHARP & DOHME CORP. CHILDERS, Matthew L. FULLER, Peter H. GUERIN, David J. KATZ, Jason David MARTINEZ, Michelle PU, Qinglin SCOTT, Mark E. THOMPSON, Christopher F. CAI, Jiaqiang KONG, Norman LIU, Yumei
DMB2INX	DT	Small molecular drug

DMT1EH9	ID	DMT1EH9
DMT1EH9	DN	Gold-complexed thiosaccharide derivative 1
DMT1EH9	HS	Patented
DMT1EH9	SN	PMID26394986-Compound-66
DMT1EH9	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM PRIEBE, Waldemar KATO, Takayuki FOKT, Izabela CONRAD, Charles MADDEN, Timothy SKORA, Stanislaw
DMT1EH9	DT	Small molecular drug

DM9U4OZ	ID	DM9U4OZ
DM9U4OZ	DN	Gold-complexed thiosaccharide derivative 2
DM9U4OZ	HS	Patented
DM9U4OZ	SN	PMID26394986-Compound-67
DM9U4OZ	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM PRIEBE, Waldemar KATO, Takayuki FOKT, Izabela CONRAD, Charles MADDEN, Timothy SKORA, Stanislaw
DM9U4OZ	DT	Small molecular drug
DM9U4OZ	PC	56946870
DM9U4OZ	MW	678.5
DM9U4OZ	FM	C20H34AuO9PS
DM9U4OZ	IC	InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13+,14+;;/m1../s1
DM9U4OZ	CS	CCP(CC)CC.CC(=O)OC[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]
DM9U4OZ	IK	AUJRCFUBUPVWSZ-QAZNCASESA-M
DM9U4OZ	IU	gold(1+);(2S,3S,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane

DMMOGL8	ID	DMMOGL8
DMMOGL8	DN	Gold-complexed thiosaccharide derivative 3
DMMOGL8	HS	Patented
DMMOGL8	SN	PMID26394986-Compound-68
DMMOGL8	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM PRIEBE, Waldemar KATO, Takayuki FOKT, Izabela CONRAD, Charles MADDEN, Timothy SKORA, Stanislaw
DMMOGL8	DT	Small molecular drug

DMVAKUI	ID	DMVAKUI
DMVAKUI	DN	Golden phosphorous acetyletic compound 1
DMVAKUI	HS	Patented
DMVAKUI	SN	PMID27977313-Compound-11
DMVAKUI	DT	Small molecular drug

DMYJ15A	ID	DMYJ15A
DMYJ15A	DN	Golden phosphorous acetyletic compound 2
DMYJ15A	HS	Patented
DMYJ15A	SN	PMID27977313-Compound-12
DMYJ15A	DT	Small molecular drug

DMRUCK8	ID	DMRUCK8
DMRUCK8	DN	Golden phosphorous acetyletic compound 3
DMRUCK8	HS	Patented
DMRUCK8	SN	PMID27977313-Compound-Figure4d
DMRUCK8	DT	Small molecular drug

DMFHC0O	ID	DMFHC0O
DMFHC0O	DN	GypensapogeninA
DMFHC0O	HS	Patented

DMX4ET5	ID	DMX4ET5
DMX4ET5	DN	GypensapogeninB
DMX4ET5	HS	Patented

DMM78UR	ID	DMM78UR
DMM78UR	DN	H3K7T
DMM78UR	HS	Patented
DMM78UR	CP	CORNELL UNIVERSITY LIN, Hening CERIONE, Richard

DMPA5WD	ID	DMPA5WD
DMPA5WD	DN	Harmine
DMPA5WD	HS	Patented
DMPA5WD	SN	Harmine; 442-51-3; 7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole; Banisterine; Leucoharmine; Telepathine; Yageine; Yajeine; 7-Methoxy-1-methyl-9H-beta-carboline; 9H-Pyrido[3,4-b]indole, 7-methoxy-1-methyl-; Telepathin; Banisterin; Yagein; Harmin; 1-Methyl-7-methoxy-beta-carboline; UNII-4FHH5G48T7; 7-Methoxy-1-methyl-9H-pyrido(3,4-b)indole; Harmin hydrochloride; Harmine, 98%; Banisterine monohydrate; EINECS 207-131-4; 9H-Pyrido(3,4-b)indole, 7-methoxy-1-methyl-; BRN 0178813; 4FHH5G48T7; C13H12N2O; CHEBI:28121; 7-METHOXY-1-METHYL-9H-BETA-CARBOLINE
DMPA5WD	DT	Small molecular drug
DMPA5WD	PC	5280953
DMPA5WD	MW	212.25
DMPA5WD	FM	C13H12N2O
DMPA5WD	IC	InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3
DMPA5WD	CS	CC1=NC=CC2=C1NC3=C2C=CC(=C3)OC
DMPA5WD	IK	BXNJHAXVSOCGBA-UHFFFAOYSA-N
DMPA5WD	IU	7-methoxy-1-methyl-9H-pyrido[3,4-b]indole
DMPA5WD	CA	CAS 442-51-3
DMPA5WD	CB	CHEBI:28121
DMPA5WD	DE	Discovery agent

DMI732U	ID	DMI732U
DMI732U	DN	Heteroaromatic ring derivative 1
DMI732U	HS	Patented
DMI732U	SN	PMID28447479-Compound-16
DMI732U	CP	FURMINGER, Vikki HUGHES, Owen LEGRAND, Darren STANLEY, Emily THOMSON, Christopher WILLIAMS, Gareth NOVARTIS ANOVARTIS AG FURMINGER, Vikki HUGHES, Owen THOMSON, Christopher LEGRAND, Darren, Mark STANLEY, Emil
DMI732U	DT	Small molecular drug

DM5YD4W	ID	DM5YD4W
DM5YD4W	DN	Heteroaromatic ring derivative 2
DM5YD4W	HS	Patented
DM5YD4W	SN	PMID28447479-Compound-17
DM5YD4W	CP	FURMINGER, Vikki HUGHES, Owen LEGRAND, Darren STANLEY, Emily THOMSON, Christopher WILLIAMS, Gareth NOVARTIS ANOVARTIS AG FURMINGER, Vikki HUGHES, Owen THOMSON, Christopher LEGRAND, Darren, Mark STANLEY, Emil
DM5YD4W	DT	Small molecular drug
DM5YD4W	PC	75203906
DM5YD4W	MW	440.3
DM5YD4W	FM	C19H23Cl2N5O3
DM5YD4W	IC	InChI=1S/C19H23Cl2N5O3/c20-14-8-13(9-15(21)10-14)12-29-19(28)26-6-4-16(5-7-26)23-18(27)3-1-2-17-11-22-25-24-17/h8-11,16H,1-7,12H2,(H,23,27)(H,22,24,25)
DM5YD4W	CS	C1CN(CCC1NC(=O)CCCC2=NNN=C2)C(=O)OCC3=CC(=CC(=C3)Cl)Cl
DM5YD4W	IK	GAMSNABJTRSYDT-UHFFFAOYSA-N
DM5YD4W	IU	(3,5-dichlorophenyl)methyl 4-[4-(2H-triazol-4-yl)butanoylamino]piperidine-1-carboxylate

DMKJL5T	ID	DMKJL5T
DMKJL5T	DN	Heteroaromatic ring derivative 3
DMKJL5T	HS	Patented
DMKJL5T	SN	PMID28447479-Compound-18
DMKJL5T	CP	NOVARTIS AG BEATTIE, David BAETTIG, Urs LEGRAND, Darren Mark LISTER, Andrew Stuart MCKENNA, Jeffrey PEARCE, David William SANDHAM, David Andrew STEWARD, Oliver Ross THOMSON, Christopher
DMKJL5T	DT	Small molecular drug

DM9IL5Q	ID	DM9IL5Q
DM9IL5Q	DN	Heteroaromatic ring derivative 4
DM9IL5Q	HS	Patented
DM9IL5Q	SN	PMID28447479-Compound-19
DM9IL5Q	CP	NOVARTIS AG BEATTIE, David BAETTIG, Urs LEGRAND, Darren Mark LISTER, Andrew Stuart MCKENNA, Jeffrey PEARCE, David William SANDHAM, David Andrew STEWARD, Oliver Ross THOMSON, Christopher
DM9IL5Q	DT	Small molecular drug
DM9IL5Q	PC	117822606
DM9IL5Q	MW	518.6
DM9IL5Q	FM	C25H33F3N8O
DM9IL5Q	IC	InChI=1S/C25H33F3N8O/c1-18-30-34-36(32-18)17-21-15-22(25(26,27)28)9-7-20(21)8-10-24(37)35-13-11-19(12-14-35)5-3-2-4-6-23-16-29-33-31-23/h7,9,15-16,19H,2-6,8,10-14,17H2,1H3,(H,29,31,33)
DM9IL5Q	CS	CC1=NN(N=N1)CC2=C(C=CC(=C2)C(F)(F)F)CCC(=O)N3CCC(CC3)CCCCCC4=NNN=C4
DM9IL5Q	IK	KVDZWWLIQHBBCT-UHFFFAOYSA-N
DM9IL5Q	IU	3-[2-[(5-methyltetrazol-2-yl)methyl]-4-(trifluoromethyl)phenyl]-1-[4-[5-(2H-triazol-4-yl)pentyl]piperidin-1-yl]propan-1-one

DMDOQKY	ID	DMDOQKY
DMDOQKY	DN	Heteroaryl-azepine derivative 1
DMDOQKY	HS	Patented
DMDOQKY	SN	PMID26609882-Compound-64
DMDOQKY	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMDOQKY	DT	Small molecular drug

DMMZ8LE	ID	DMMZ8LE
DMMZ8LE	DN	Heteroaryl-azepine derivative 10
DMMZ8LE	HS	Patented
DMMZ8LE	SN	PMID26609882-Compound-73
DMMZ8LE	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMMZ8LE	DT	Small molecular drug

DM5BF6H	ID	DM5BF6H
DM5BF6H	DN	Heteroaryl-azepine derivative 11
DM5BF6H	HS	Patented
DM5BF6H	SN	PMID26609882-Compound-74
DM5BF6H	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DM5BF6H	DT	Small molecular drug

DMOG72B	ID	DMOG72B
DMOG72B	DN	Heteroaryl-azepine derivative 12
DMOG72B	HS	Patented
DMOG72B	SN	PMID26609882-Compound-75
DMOG72B	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMOG72B	DT	Small molecular drug

DME86DP	ID	DME86DP
DME86DP	DN	Heteroaryl-azepine derivative 13
DME86DP	HS	Patented
DME86DP	SN	PMID26609882-Compound-76
DME86DP	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DME86DP	DT	Small molecular drug

DMG1TIF	ID	DMG1TIF
DMG1TIF	DN	Heteroaryl-azepine derivative 14
DMG1TIF	HS	Patented
DMG1TIF	SN	PMID26609882-Compound-77
DMG1TIF	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMG1TIF	DT	Small molecular drug

DMS3WEJ	ID	DMS3WEJ
DMS3WEJ	DN	Heteroaryl-azepine derivative 15
DMS3WEJ	HS	Patented
DMS3WEJ	SN	PMID26609882-Compound-78
DMS3WEJ	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMS3WEJ	DT	Small molecular drug

DMDFL6B	ID	DMDFL6B
DMDFL6B	DN	Heteroaryl-azepine derivative 2
DMDFL6B	HS	Patented
DMDFL6B	SN	PMID26609882-Compound-65
DMDFL6B	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMDFL6B	DT	Small molecular drug

DMG14E3	ID	DMG14E3
DMG14E3	DN	Heteroaryl-azepine derivative 3
DMG14E3	HS	Patented
DMG14E3	SN	PMID26609882-Compound-66
DMG14E3	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMG14E3	DT	Small molecular drug

DMZVLH2	ID	DMZVLH2
DMZVLH2	DN	Heteroaryl-azepine derivative 4
DMZVLH2	HS	Patented
DMZVLH2	SN	PMID26609882-Compound-67
DMZVLH2	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMZVLH2	DT	Small molecular drug

DMON5RD	ID	DMON5RD
DMON5RD	DN	Heteroaryl-azepine derivative 5
DMON5RD	HS	Patented
DMON5RD	SN	PMID26609882-Compound-68
DMON5RD	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMON5RD	DT	Small molecular drug

DM3O7UG	ID	DM3O7UG
DM3O7UG	DN	Heteroaryl-azepine derivative 6
DM3O7UG	HS	Patented
DM3O7UG	SN	PMID26609882-Compound-69
DM3O7UG	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DM3O7UG	DT	Small molecular drug

DMS6HOG	ID	DMS6HOG
DMS6HOG	DN	Heteroaryl-azepine derivative 7
DMS6HOG	HS	Patented
DMS6HOG	SN	PMID26609882-Compound-70
DMS6HOG	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMS6HOG	DT	Small molecular drug

DMBJH8N	ID	DMBJH8N
DMBJH8N	DN	Heteroaryl-azepine derivative 8
DMBJH8N	HS	Patented
DMBJH8N	SN	PMID26609882-Compound-71
DMBJH8N	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMBJH8N	DT	Small molecular drug
DMBJH8N	PC	46849907
DMBJH8N	MW	223.34
DMBJH8N	FM	C12H17NOS
DMBJH8N	IC	InChI=1S/C12H17NOS/c1-8(2)12-11(14-3)9-4-6-13-7-5-10(9)15-12/h13H,1,4-7H2,2-3H3
DMBJH8N	CS	CC(=C)C1=C(C2=C(S1)CCNCC2)OC
DMBJH8N	IK	BQUIRHQLEFJFBK-UHFFFAOYSA-N
DMBJH8N	IU	3-methoxy-2-prop-1-en-2-yl-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine

DMUZR3X	ID	DMUZR3X
DMUZR3X	DN	Heteroaryl-azepine derivative 9
DMUZR3X	HS	Patented
DMUZR3X	SN	PMID26609882-Compound-72
DMUZR3X	CP	ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE] 
DMUZR3X	DT	Small molecular drug

DMPRF1K	ID	DMPRF1K
DMPRF1K	DN	Heteroaryl-carboxamide derivative 1
DMPRF1K	HS	Patented
DMPRF1K	SN	PMID25684022-Compound-WO2012058176 24(47)
DMPRF1K	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMPRF1K	DE	Solid tumour/cancer; Metastatic cancer

DMVTARK	ID	DMVTARK
DMVTARK	DN	Heteroaryl-carboxamide derivative 10
DMVTARK	HS	Patented
DMVTARK	SN	PMID25684022-Compound-WO2012058176 33(21)
DMVTARK	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMVTARK	DE	Solid tumour/cancer; Metastatic cancer

DM1CWU7	ID	DM1CWU7
DM1CWU7	DN	Heteroaryl-carboxamide derivative 11
DM1CWU7	HS	Patented
DM1CWU7	SN	PMID29171765-Compound-Figure2
DM1CWU7	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBNOVARTIS AKalvista Pharmaceuticals LimiteRa Rharmaceuticals Inc

DMGEFIW	ID	DMGEFIW
DMGEFIW	DN	Heteroaryl-carboxamide derivative 2
DMGEFIW	HS	Patented
DMGEFIW	SN	PMID25684022-Compound-WO2012058176 25(3)
DMGEFIW	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMGEFIW	DE	Solid tumour/cancer; Metastatic cancer

DMBGTNM	ID	DMBGTNM
DMBGTNM	DN	Heteroaryl-carboxamide derivative 3
DMBGTNM	HS	Patented
DMBGTNM	SN	PMID25684022-Compound-WO2012058176 26(5)
DMBGTNM	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMBGTNM	DE	Solid tumour/cancer; Metastatic cancer

DMHUIXR	ID	DMHUIXR
DMHUIXR	DN	Heteroaryl-carboxamide derivative 4
DMHUIXR	HS	Patented
DMHUIXR	SN	PMID25684022-Compound-WO2012058176 27(6)
DMHUIXR	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMHUIXR	DE	Solid tumour/cancer; Metastatic cancer

DMMX6V4	ID	DMMX6V4
DMMX6V4	DN	Heteroaryl-carboxamide derivative 5
DMMX6V4	HS	Patented
DMMX6V4	SN	PMID25684022-Compound-WO2012058176 28(7)
DMMX6V4	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMMX6V4	DE	Solid tumour/cancer; Metastatic cancer

DM9IPDU	ID	DM9IPDU
DM9IPDU	DN	Heteroaryl-carboxamide derivative 6
DM9IPDU	HS	Patented
DM9IPDU	SN	PMID25684022-Compound-WO2012058176 29(8)
DM9IPDU	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DM9IPDU	DE	Solid tumour/cancer; Metastatic cancer

DMOAYEV	ID	DMOAYEV
DMOAYEV	DN	Heteroaryl-carboxamide derivative 7
DMOAYEV	HS	Patented
DMOAYEV	SN	PMID25684022-Compound-WO2012058176 30(12)
DMOAYEV	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMOAYEV	DE	Solid tumour/cancer; Metastatic cancer

DMJTN91	ID	DMJTN91
DMJTN91	DN	Heteroaryl-carboxamide derivative 8
DMJTN91	HS	Patented
DMJTN91	SN	PMID25684022-Compound-WO2012058176 31(13)
DMJTN91	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMJTN91	DE	Solid tumour/cancer; Metastatic cancer

DMI627Z	ID	DMI627Z
DMI627Z	DN	Heteroaryl-carboxamide derivative 9
DMI627Z	HS	Patented
DMI627Z	SN	PMID25684022-Compound-WO2012058176 32(20)
DMI627Z	CP	MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMI627Z	DE	Solid tumour/cancer; Metastatic cancer

DMRF58Q	ID	DMRF58Q
DMRF58Q	DN	Heteroaryl-cyclopropylamine derivative 1
DMRF58Q	HS	Patented
DMRF58Q	SN	PMID27019002-Compound-22d
DMRF58Q	CP	ORYZON GENOMICS, S.AORYZON GENOMICS SA [ES]
DMRF58Q	DT	Small molecular drug

DM9NE5T	ID	DM9NE5T
DM9NE5T	DN	Heteroaryl-cyclopropylamine derivative 2
DM9NE5T	HS	Patented
DM9NE5T	SN	PMID27019002-Compound-22a
DM9NE5T	CP	ORYZON GENOMICS SA [ES]
DM9NE5T	DT	Small molecular drug

DMH9EQ1	ID	DMH9EQ1
DMH9EQ1	DN	Heteroaryl-cyclopropylamine derivative 3
DMH9EQ1	HS	Patented
DMH9EQ1	SN	PMID27019002-Compound-22b
DMH9EQ1	CP	ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, CarloORYZON GENOMICS SA [ES]
DMH9EQ1	DT	Small molecular drug

DMMU01R	ID	DMMU01R
DMMU01R	DN	Heteroaryl-cyclopropylamine derivative 4
DMMU01R	HS	Patented
DMMU01R	SN	PMID27019002-Compound-22c
DMMU01R	CP	ORYZON GENOMICS SA [ESORYZON GENOMICS S.A. BAKER, Jonathan, Alleman CASTRO PALOMINO, Julio FYFE, Matthew, Colin, Thor MAES, Tamara MARTINELL PEDEMONTE, MarORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos
DMMU01R	DT	Small molecular drug

DM9LQCH	ID	DM9LQCH
DM9LQCH	DN	Heteroaryl-pyrazole derivative 1
DM9LQCH	HS	Patented
DM9LQCH	SN	PMID25435285-Compound-69
DM9LQCH	DT	Small molecular drug

DMIG0TQ	ID	DMIG0TQ
DMIG0TQ	DN	Heteroaryl-pyrazole derivative 2
DMIG0TQ	HS	Patented
DMIG0TQ	SN	PMID25435285-Compound-74
DMIG0TQ	DT	Small molecular drug
DMIG0TQ	PC	89585736
DMIG0TQ	MW	479.4
DMIG0TQ	FM	C20H16F3N5O4S
DMIG0TQ	IC	InChI=1S/C20H16F3N5O4S/c1-28-17(11-31-14-7-5-13(6-8-14)20(21,22)23)16(10-25-28)19-26-18(27-32-19)12-3-2-4-15(9-12)33(24,29)30/h2-10H,11H2,1H3,(H2,24,29,30)
DMIG0TQ	CS	CN1C(=C(C=N1)C2=NC(=NO2)C3=CC(=CC=C3)S(=O)(=O)N)COC4=CC=C(C=C4)C(F)(F)F
DMIG0TQ	IK	ZHBWEWSSDGSLAK-UHFFFAOYSA-N
DMIG0TQ	IU	3-[5-[1-methyl-5-[[4-(trifluoromethyl)phenoxy]methyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]benzenesulfonamide

DMO45G3	ID	DMO45G3
DMO45G3	DN	Heteroaryl-pyrazole derivative 3
DMO45G3	HS	Patented
DMO45G3	SN	PMID25435285-Compound-75
DMO45G3	DT	Small molecular drug
DMO45G3	PC	89585740
DMO45G3	MW	495.5
DMO45G3	FM	C21H17F4N5O3S
DMO45G3	IC	InChI=1S/C21H17F4N5O3S/c22-12-30-18(9-6-13-4-7-15(8-5-13)21(23,24)25)17(11-27-30)20-28-19(29-33-20)14-2-1-3-16(10-14)34(26,31)32/h1-5,7-8,10-11H,6,9,12H2,(H2,26,31,32)
DMO45G3	CS	C1=CC(=CC(=C1)S(=O)(=O)N)C2=NOC(=N2)C3=C(N(N=C3)CF)CCC4=CC=C(C=C4)C(F)(F)F
DMO45G3	IK	ZBFNZSWRIVRSIR-UHFFFAOYSA-N
DMO45G3	IU	3-[5-[1-(fluoromethyl)-5-[2-[4-(trifluoromethyl)phenyl]ethyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]benzenesulfonamide

DM2BM1L	ID	DM2BM1L
DM2BM1L	DN	Heteroaryl-substituted urea derivative 1
DM2BM1L	HS	Patented
DM2BM1L	SN	PMID26413912-Compound-44
DM2BM1L	CP	JANSSEN PHARMACEUTICA NV BREITENBUCHER, J., Guy KEITH, John, M. TICHENOR, Mark, S. CHAMBERS, Alison, L. JONES, William, M. HAWRYLUK, Natalie, A. TIMMONS, Amy, K. MERIT, Jeffrey, E. SEIERSTAD, Mark, JJanssen Pharmaceutica N.V
DM2BM1L	DT	Small molecular drug

DMHFQLC	ID	DMHFQLC
DMHFQLC	DN	Heteroaryl-substituted urea derivative 2
DMHFQLC	HS	Patented
DMHFQLC	SN	PMID26413912-Compound-45
DMHFQLC	CP	JANSSEN PHARMACEUTICA NV BREITENBUCHER, J., Guy KEITH, John, M. TICHENOR, Mark, S. CHAMBERS, Alison, L. JONES, William, M. HAWRYLUK, Natalie, A. TIMMONS, Amy, K. MERIT, Jeffrey, E. SEIERSTAD, Mark, JJanssen Pharmaceutica N.V
DMHFQLC	DT	Small molecular drug

DM8PHBG	ID	DM8PHBG
DM8PHBG	DN	Heterocycle-containing compound 1
DM8PHBG	HS	Patented
DM8PHBG	SN	PMID25828189-Compound-13
DM8PHBG	CP	PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DM8PHBG	DT	Small molecular drug

DM2KVMT	ID	DM2KVMT
DM2KVMT	DN	Heterocycle-containing compound 2
DM2KVMT	HS	Patented
DM2KVMT	SN	PMID25828189-Compound-14
DM2KVMT	CP	PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DM2KVMT	DT	Small molecular drug
DM2KVMT	PC	11591405
DM2KVMT	MW	499.5
DM2KVMT	FM	C28H28F3NO4
DM2KVMT	IC	InChI=1S/C28H28F3NO4/c1-18(2)17-25(21-3-5-22(6-4-21)27(35)32-16-15-26(33)34)36-24-13-9-20(10-14-24)19-7-11-23(12-8-19)28(29,30)31/h3-14,18,25H,15-17H2,1-2H3,(H,32,35)(H,33,34)
DM2KVMT	CS	CC(C)CC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)OC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F
DM2KVMT	IK	KVQXZASOMKRHSG-UHFFFAOYSA-N
DM2KVMT	IU	3-[[4-[3-methyl-1-[4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]benzoyl]amino]propanoic acid

DMHMTF7	ID	DMHMTF7
DMHMTF7	DN	Heterocycle-containing compound 3
DMHMTF7	HS	Patented
DMHMTF7	SN	PMID25828189-Compound-15
DMHMTF7	CP	PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DMHMTF7	DT	Small molecular drug
DMHMTF7	PC	57389844
DMHMTF7	MW	514.5
DMHMTF7	FM	C27H29F3N4O3
DMHMTF7	IC	InChI=1S/C27H29F3N4O3/c1-16(2)12-23(22-9-6-19(14-32-22)26(37)31-11-10-24(35)36)34-21-13-17(3)25(33-15-21)18-4-7-20(8-5-18)27(28,29)30/h4-9,13-16,23,34H,10-12H2,1-3H3,(H,31,37)(H,35,36)
DMHMTF7	CS	CC1=CC(=CN=C1C2=CC=C(C=C2)C(F)(F)F)NC(CC(C)C)C3=NC=C(C=C3)C(=O)NCCC(=O)O
DMHMTF7	IK	XWKCFFJMDVSXKD-UHFFFAOYSA-N
DMHMTF7	IU	3-[[6-[3-methyl-1-[[5-methyl-6-[4-(trifluoromethyl)phenyl]pyridin-3-yl]amino]butyl]pyridine-3-carbonyl]amino]propanoic acid

DM6IRJL	ID	DM6IRJL
DM6IRJL	DN	Heterocycle-containing compound 4
DM6IRJL	HS	Patented
DM6IRJL	SN	PMID25828189-Compound-16
DM6IRJL	CP	PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DM6IRJL	DT	Small molecular drug
DM6IRJL	PC	67981277
DM6IRJL	MW	500.5
DM6IRJL	FM	C26H27F3N4O3
DM6IRJL	IC	InChI=1S/C26H27F3N4O3/c1-16(2)13-22(33-23-10-7-19(14-32-23)25(36)30-12-11-24(34)35)18-5-3-17(4-6-18)21-9-8-20(15-31-21)26(27,28)29/h3-10,14-16,22H,11-13H2,1-2H3,(H,30,36)(H,32,33)(H,34,35)/t22-/m0/s1
DM6IRJL	CS	CC(C)C[C@@H](C1=CC=C(C=C1)C2=NC=C(C=C2)C(F)(F)F)NC3=NC=C(C=C3)C(=O)NCCC(=O)O
DM6IRJL	IK	MSWXTYSARYGQHP-QFIPXVFZSA-N
DM6IRJL	IU	3-[[6-[[(1S)-3-methyl-1-[4-[5-(trifluoromethyl)pyridin-2-yl]phenyl]butyl]amino]pyridine-3-carbonyl]amino]propanoic acid

DM6EY5Z	ID	DM6EY5Z
DM6EY5Z	DN	Heterocycle-containing compound 5
DM6EY5Z	HS	Patented
DM6EY5Z	SN	PMID25828189-Compound-17
DM6EY5Z	CP	PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DM6EY5Z	DT	Small molecular drug
DM6EY5Z	PC	57388936
DM6EY5Z	MW	501.5
DM6EY5Z	FM	C25H26F3N5O3
DM6EY5Z	IC	InChI=1S/C25H26F3N5O3/c1-15(2)11-20(33-21-8-5-17(12-30-21)24(36)29-10-9-22(34)35)18-13-31-23(32-14-18)16-3-6-19(7-4-16)25(26,27)28/h3-8,12-15,20H,9-11H2,1-2H3,(H,29,36)(H,30,33)(H,34,35)/t20-/m0/s1
DM6EY5Z	CS	CC(C)C[C@@H](C1=CN=C(N=C1)C2=CC=C(C=C2)C(F)(F)F)NC3=NC=C(C=C3)C(=O)NCCC(=O)O
DM6EY5Z	IK	DROAORWMIULFBS-FQEVSTJZSA-N
DM6EY5Z	IU	3-[[6-[[(1S)-3-methyl-1-[2-[4-(trifluoromethyl)phenyl]pyrimidin-5-yl]butyl]amino]pyridine-3-carbonyl]amino]propanoic acid

DMJ5X46	ID	DMJ5X46
DMJ5X46	DN	Heterocyclic derivative 1
DMJ5X46	HS	Patented
DMJ5X46	SN	PMID28067079-Compound-21
DMJ5X46	CP	Merz Pharma GmbH & Co KGaA
DMJ5X46	DT	Small molecular drug
DMJ5X46	PC	71766537
DMJ5X46	MW	307.4
DMJ5X46	FM	C19H21N3O
DMJ5X46	IC	InChI=1S/C19H21N3O/c1-19(2)10-16-15(17(11-19)23-3)9-13(12-21-16)7-8-14-5-4-6-18(20)22-14/h4-6,9,12,17H,10-11H2,1-3H3,(H2,20,22)
DMJ5X46	CS	CC1(CC(C2=C(C1)N=CC(=C2)C#CC3=NC(=CC=C3)N)OC)C
DMJ5X46	IK	MVVPJGFFGSEZEE-UHFFFAOYSA-N
DMJ5X46	IU	6-[2-(5-methoxy-7,7-dimethyl-6,8-dihydro-5H-quinolin-3-yl)ethynyl]pyridin-2-amine

DMN580F	ID	DMN580F
DMN580F	DN	Heterocyclic derivative 10
DMN580F	HS	Patented
DMN580F	SN	PMID25684022-Compound-US20120208819 7(402)
DMN580F	DE	Solid tumour/cancer; Metastatic cancer

DMUOI92	ID	DMUOI92
DMUOI92	DN	Heterocyclic derivative 11
DMUOI92	HS	Patented
DMUOI92	SN	PMID25684022-Compound-US20120208819 8(443)
DMUOI92	DE	Solid tumour/cancer; Metastatic cancer

DMQJW9R	ID	DMQJW9R
DMQJW9R	DN	Heterocyclic derivative 12
DMQJW9R	HS	Patented
DMQJW9R	SN	PMID25684022-Compound-WO2012044157 1(1.5)
DMQJW9R	CP	BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMQJW9R	DE	Solid tumour/cancer; Metastatic cancer

DMWOBHM	ID	DMWOBHM
DMWOBHM	DN	Heterocyclic derivative 13
DMWOBHM	HS	Patented
DMWOBHM	SN	PMID25684022-Compound-WO2012044157 2(2.4)
DMWOBHM	CP	BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMWOBHM	DE	Solid tumour/cancer; Metastatic cancer

DMJ0WVR	ID	DMJ0WVR
DMJ0WVR	DN	Heterocyclic derivative 14
DMJ0WVR	HS	Patented
DMJ0WVR	SN	PMID25684022-Compound-WO2012044157 3(7.6)
DMJ0WVR	CP	BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMJ0WVR	DE	Solid tumour/cancer; Metastatic cancer

DMWZNDO	ID	DMWZNDO
DMWZNDO	DN	Heterocyclic derivative 15
DMWZNDO	HS	Patented
DMWZNDO	SN	PMID25684022-Compound-WO2012044157 4(58)
DMWZNDO	CP	BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMWZNDO	DE	Solid tumour/cancer; Metastatic cancer

DM6NJV7	ID	DM6NJV7
DM6NJV7	DN	Heterocyclic derivative 16
DM6NJV7	HS	Patented
DM6NJV7	SN	PMID25684022-Compound-WO2012044157 5(355)
DM6NJV7	CP	BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DM6NJV7	DE	Solid tumour/cancer; Metastatic cancer

DMD1K7E	ID	DMD1K7E
DMD1K7E	DN	Heterocyclic derivative 17
DMD1K7E	HS	Patented
DMD1K7E	SN	PMID25684022-Compound-WO2012044157 6(360)
DMD1K7E	CP	BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMD1K7E	DE	Solid tumour/cancer; Metastatic cancer

DMFUEDL	ID	DMFUEDL
DMFUEDL	DN	Heterocyclic derivative 18
DMFUEDL	HS	Patented
DMFUEDL	SN	PMID25684022-Compound-WO2012044157 7(402)
DMFUEDL	CP	BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMFUEDL	DE	Solid tumour/cancer; Metastatic cancer

DMNG0WH	ID	DMNG0WH
DMNG0WH	DN	Heterocyclic derivative 19
DMNG0WH	HS	Patented
DMNG0WH	SN	PMID25684022-Compound-WO2012044157 8(443)
DMNG0WH	CP	BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMNG0WH	DE	Solid tumour/cancer; Metastatic cancer

DM2QCBF	ID	DM2QCBF
DM2QCBF	DN	Heterocyclic derivative 2
DM2QCBF	HS	Patented
DM2QCBF	SN	PMID28067079-Compound-22
DM2QCBF	CP	Merz Pharma GmbH & Co KGaA
DM2QCBF	DT	Small molecular drug
DM2QCBF	PC	71767411
DM2QCBF	MW	330.4
DM2QCBF	FM	C20H18N4O
DM2QCBF	IC	InChI=1S/C20H18N4O/c1-23(2)20(25)24-9-8-19-18(14-24)11-17(13-22-19)7-6-15-4-3-5-16(10-15)12-21/h3-5,10-11,13H,8-9,14H2,1-2H3
DM2QCBF	CS	CN(C)C(=O)N1CCC2=C(C1)C=C(C=N2)C#CC3=CC(=CC=C3)C#N
DM2QCBF	IK	TUOMBETVTQCJRF-UHFFFAOYSA-N
DM2QCBF	IU	3-[2-(3-cyanophenyl)ethynyl]-N,N-dimethyl-7,8-dihydro-5H-1,6-naphthyridine-6-carboxamide

DM56T1P	ID	DM56T1P
DM56T1P	DN	Heterocyclic derivative 26
DM56T1P	HS	Patented
DM56T1P	SN	PMID27410995-Compound-Figure3h
DM56T1P	DT	Small molecular drug

DMCD0MS	ID	DMCD0MS
DMCD0MS	DN	Heterocyclic derivative 3
DMCD0MS	HS	Patented
DMCD0MS	SN	PMID28067079-Compound-23
DMCD0MS	CP	Merz Pharma GmbH & Co KGaA
DMCD0MS	DT	Small molecular drug
DMCD0MS	PC	71767837
DMCD0MS	MW	297.4
DMCD0MS	FM	C17H15NO2S
DMCD0MS	IC	InChI=1S/C17H15NO2S/c1-13-3-2-4-14(9-13)5-6-15-10-16-12-21(19,20)8-7-17(16)18-11-15/h2-4,9-11H,7-8,12H2,1H3
DMCD0MS	CS	CC1=CC(=CC=C1)C#CC2=CC3=C(CCS(=O)(=O)C3)N=C2
DMCD0MS	IK	QSNHNADSPWYHPP-UHFFFAOYSA-N
DMCD0MS	IU	3-[2-(3-methylphenyl)ethynyl]-7,8-dihydro-5H-thiopyrano[4,3-b]pyridine 6,6-dioxide

DM7VP8M	ID	DM7VP8M
DM7VP8M	DN	Heterocyclic derivative 4
DM7VP8M	HS	Patented
DM7VP8M	SN	PMID25684022-Compound-US20120208819 1(1.5)
DM7VP8M	DE	Solid tumour/cancer; Metastatic cancer

DMWJDEO	ID	DMWJDEO
DMWJDEO	DN	Heterocyclic derivative 5
DMWJDEO	HS	Patented
DMWJDEO	SN	PMID25684022-Compound-US20120208819 2(2.4)
DMWJDEO	DE	Solid tumour/cancer; Metastatic cancer

DM6HWN3	ID	DM6HWN3
DM6HWN3	DN	Heterocyclic derivative 6
DM6HWN3	HS	Patented
DM6HWN3	SN	PMID25684022-Compound-US20120208819 3(7.6)
DM6HWN3	DE	Solid tumour/cancer; Metastatic cancer

DMU6LS4	ID	DMU6LS4
DMU6LS4	DN	Heterocyclic derivative 7
DMU6LS4	HS	Patented
DMU6LS4	SN	PMID25684022-Compound-US20120208819 4(58)
DMU6LS4	DE	Solid tumour/cancer; Metastatic cancer

DMKPSIA	ID	DMKPSIA
DMKPSIA	DN	Heterocyclic derivative 8
DMKPSIA	HS	Patented
DMKPSIA	SN	PMID25684022-Compound-US20120208819 5(355)
DMKPSIA	DE	Solid tumour/cancer; Metastatic cancer

DMY4LB7	ID	DMY4LB7
DMY4LB7	DN	Heterocyclic derivative 9
DMY4LB7	HS	Patented
DMY4LB7	SN	PMID25684022-Compound-US20120208819 6(360)
DMY4LB7	DE	Solid tumour/cancer; Metastatic cancer

DMA91IJ	ID	DMA91IJ
DMA91IJ	DN	Heterocyclic-carboxamide derivative 1
DMA91IJ	HS	Patented
DMA91IJ	SN	PMID25684022-Compound-WO2010065384
DMA91IJ	CP	Merck & Co., Inc
DMA91IJ	DT	Small molecular drug
DMA91IJ	DE	Solid tumour/cancer; Metastatic cancer

DMSQK50	ID	DMSQK50
DMSQK50	DN	Heterocyclic-carboxamide derivative 2
DMSQK50	HS	Patented
DMSQK50	SN	PMID25684022-Compound-WO2011044157
DMSQK50	CP	Sunesis & Biogen
DMSQK50	DT	Small molecular drug
DMSQK50	DE	Solid tumour/cancer; Metastatic cancer

DMEGK3Q	ID	DMEGK3Q
DMEGK3Q	DN	Heterocyclic-fused piperazine derivative 1
DMEGK3Q	HS	Patented
DMEGK3Q	SN	PMID27724045-Compound-5
DMEGK3Q	CP	GSK
DMEGK3Q	DT	Small molecular drug
DMEGK3Q	PC	66599260
DMEGK3Q	MW	413.8
DMEGK3Q	FM	C16H11ClF3N5OS
DMEGK3Q	IC	InChI=1S/C16H11ClF3N5OS/c17-13-9(2-1-3-10(13)16(18,19)20)15(26)24-4-5-25-12(6-24)22-23-14(25)11-7-27-8-21-11/h1-3,7-8H,4-6H2
DMEGK3Q	CS	C1CN2C(=NN=C2C3=CSC=N3)CN1C(=O)C4=C(C(=CC=C4)C(F)(F)F)Cl
DMEGK3Q	IK	BDKXTJZVSCTDFF-UHFFFAOYSA-N
DMEGK3Q	IU	[2-chloro-3-(trifluoromethyl)phenyl]-[3-(1,3-thiazol-4-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone

DMJEX3D	ID	DMJEX3D
DMJEX3D	DN	Heterocyclic-substituted 3-alkyl azetidine derivative 1
DMJEX3D	HS	Patented
DMJEX3D	SN	PMID26161824-Compound-158
DMJEX3D	CP	MERCK & CO., INC. BAKER, Robert, K. HALE, Jeffrey, J. MIAO, Shouwu RUPPRECHT, Kathleen, M
DMJEX3D	DT	Small molecular drug
DMJEX3D	PC	58882003
DMJEX3D	MW	535
DMJEX3D	FM	C29H25ClF2N4O2
DMJEX3D	IC	InChI=1S/C29H25ClF2N4O2/c1-29(2,32)25(20-11-21(13-24(31)12-20)27-34-35-28(37)38-27)22-15-36(16-22)26(18-6-8-23(30)9-7-18)19-5-3-4-17(10-19)14-33/h3-13,22,25-26H,15-16H2,1-2H3,(H,35,37)/t25-,26?/m1/s1
DMJEX3D	CS	CC(C)([C@@H](C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=CC(=C3)C#N)C4=CC(=CC(=C4)C5=NNC(=O)O5)F)F
DMJEX3D	IK	DQKCYKJTBAXWFL-DCWQJPKNSA-N
DMJEX3D	IU	3-[(4-chlorophenyl)-[3-[(1S)-2-fluoro-1-[3-fluoro-5-(2-oxo-3H-1,3,4-oxadiazol-5-yl)phenyl]-2-methylpropyl]azetidin-1-yl]methyl]benzonitrile
DMJEX3D	DE	Obesity

DMEX7PV	ID	DMEX7PV
DMEX7PV	DN	Heterocyclic-substituted 3-alkyl azetidine derivative 2
DMEX7PV	HS	Patented
DMEX7PV	SN	PMID26161824-Compound-159
DMEX7PV	CP	MERCK & CO., INC. BAKER, Robert, K. HALE, Jeffrey, J. MIAO, Shouwu RUPPRECHT, Kathleen, M
DMEX7PV	DT	Small molecular drug
DMEX7PV	PC	68977099
DMEX7PV	MW	524.6
DMEX7PV	FM	C30H26F2N6O
DMEX7PV	IC	InChI=1S/C30H26F2N6O/c1-30(2,32)26(23-10-19(15-34)11-25(31)13-23)24-16-38(17-24)27(20-8-6-18(14-33)7-9-20)21-4-3-5-22(12-21)28-36-37-29(35)39-28/h3-13,24,26-27H,16-17H2,1-2H3,(H2,35,37)
DMEX7PV	CS	CC(C)(C(C1CN(C1)C(C2=CC=C(C=C2)C#N)C3=CC=CC(=C3)C4=NN=C(O4)N)C5=CC(=CC(=C5)C#N)F)F
DMEX7PV	IK	AKSVEYGFHNXCSL-UHFFFAOYSA-N
DMEX7PV	IU	3-[1-[1-[[3-(5-amino-1,3,4-oxadiazol-2-yl)phenyl]-(4-cyanophenyl)methyl]azetidin-3-yl]-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile
DMEX7PV	DE	Obesity

DMO1Y30	ID	DMO1Y30
DMO1Y30	DN	Heterocyclic-substituted 3-alkyl azetidine derivative 3
DMO1Y30	HS	Patented
DMO1Y30	SN	PMID26161824-Compound-160
DMO1Y30	CP	MERCK & CO., INC. BAKER, Robert, K. HALE, Jeffrey, J. MIAO, Shouwu RUPPRECHT, Kathleen, M
DMO1Y30	DT	Small molecular drug
DMO1Y30	PC	68394740
DMO1Y30	MW	518.5
DMO1Y30	FM	C29H25F3N4O2
DMO1Y30	IC	InChI=1S/C29H25F3N4O2/c1-29(2,32)25(21-11-23(30)13-24(31)12-21)22-15-36(16-22)26(20-5-3-4-17(10-20)14-33)18-6-8-19(9-7-18)27-34-35-28(37)38-27/h3-13,22,25-26H,15-16H2,1-2H3,(H,35,37)
DMO1Y30	CS	CC(C)(C(C1CN(C1)C(C2=CC=C(C=C2)C3=NNC(=O)O3)C4=CC=CC(=C4)C#N)C5=CC(=CC(=C5)F)F)F
DMO1Y30	IK	SROKVDFDVQITLS-UHFFFAOYSA-N
DMO1Y30	IU	3-[[3-[1-(3,5-difluorophenyl)-2-fluoro-2-methylpropyl]azetidin-1-yl]-[4-(2-oxo-3H-1,3,4-oxadiazol-5-yl)phenyl]methyl]benzonitrile
DMO1Y30	DE	Obesity

DMNJVR6	ID	DMNJVR6
DMNJVR6	DN	Heterocyclic-tetracyclic tetrahydrofuran derivative 1
DMNJVR6	HS	Patented
DMNJVR6	SN	PMID26609882-Compound-49
DMNJVR6	CP	JANSSEN PHARMACEUTICA NV [BE]
DMNJVR6	DT	Small molecular drug

DMC1ZIX	ID	DMC1ZIX
DMC1ZIX	DN	Hexahydro azepinone derivative 1
DMC1ZIX	HS	Patented
DMC1ZIX	SN	PMID28048944-Compound-27
DMC1ZIX	DT	Small molecular drug

DMT2Z0I	ID	DMT2Z0I
DMT2Z0I	DN	Hexahydro naphthalene derivative 1
DMT2Z0I	HS	Patented
DMT2Z0I	SN	PMID27537201-Compound-Figure10left
DMT2Z0I	CP	Academia Sinica (Taipei, TW), National Taiwan University (Taipei, TW)
DMT2Z0I	DT	Small molecular drug

DMFG9HP	ID	DMFG9HP
DMFG9HP	DN	Hexahydro naphthalene derivative 2
DMFG9HP	HS	Patented
DMFG9HP	SN	PMID27537201-Compound-Figure9left
DMFG9HP	DT	Small molecular drug

DM1KT4I	ID	DM1KT4I
DM1KT4I	DN	Hexahydro naphthalene derivative 3
DM1KT4I	HS	Patented
DM1KT4I	SN	PMID27537201-Compound-Figure9right
DM1KT4I	CP	BEIJING LABWORLD BIO MEDICINE TECHNOLOGY CO LTD
DM1KT4I	DT	Small molecular drug

DM4VNWX	ID	DM4VNWX
DM4VNWX	DN	Hexahydro quinoline derivative 1
DM4VNWX	HS	Patented
DM4VNWX	SN	PMID29473428-Compound-77
DM4VNWX	CP	IOMET PHARMA LTD
DM4VNWX	DT	Small molecular drug
DM4VNWX	PC	121325265
DM4VNWX	MW	346.4
DM4VNWX	FM	C18H22N2O3S
DM4VNWX	IC	InChI=1S/C18H22N2O3S/c1-13(2)23-15-6-8-16(9-7-15)24(21,22)20-18-5-3-4-14-12-19-11-10-17(14)18/h6-13,18,20H,3-5H2,1-2H3
DM4VNWX	CS	CC(C)OC1=CC=C(C=C1)S(=O)(=O)NC2CCCC3=C2C=CN=C3
DM4VNWX	IK	XINKWGLXVLWLIU-UHFFFAOYSA-N
DM4VNWX	IU	4-propan-2-yloxy-N-(5,6,7,8-tetrahydroisoquinolin-5-yl)benzenesulfonamide

DMU5JC0	ID	DMU5JC0
DMU5JC0	DN	HouttuynoidA
DMU5JC0	HS	Patented

DMFIG8C	ID	DMFIG8C
DMFIG8C	DN	Hydoxyamidine derivative 1
DMFIG8C	HS	Patented
DMFIG8C	SN	PMID29473428-Compound-18
DMFIG8C	CP	INCYTE CORPORATIOINCYTE HOLDINGS CORPORATION
DMFIG8C	DT	Small molecular drug

DMUA740	ID	DMUA740
DMUA740	DN	Hydrazide derivative 1
DMUA740	HS	Patented
DMUA740	SN	PMID26161824-Compound-22
DMUA740	DT	Small molecular drug
DMUA740	DE	Obesity

DM3U79M	ID	DM3U79M
DM3U79M	DN	Hydrazide derivative 3
DM3U79M	HS	Patented
DM3U79M	SN	PMID28117607-Compound-23
DM3U79M	CP	ELAN PHARMACEUTICALS, LLC
DM3U79M	DT	Small molecular drug
DM3U79M	PC	86293786
DM3U79M	MW	369.8
DM3U79M	FM	C14H9ClFN3O2S2
DM3U79M	IC	InChI=1S/C14H9ClFN3O2S2/c15-11-6-5-10(23-11)13(21)17-18-14-19(12(20)7-22-14)9-3-1-8(16)2-4-9/h1-6H,7H2,(H,17,21)/b18-14+
DM3U79M	CS	C1C(=O)N(/C(=N\\NC(=O)C2=CC=C(S2)Cl)/S1)C3=CC=C(C=C3)F
DM3U79M	IK	SDAYOLNMRBBFQH-NBVRZTHBSA-N
DM3U79M	IU	5-chloro-N-[(E)-[3-(4-fluorophenyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]thiophene-2-carboxamide

DM1HI8Q	ID	DM1HI8Q
DM1HI8Q	DN	Hydrazide derivative 4
DM1HI8Q	HS	Patented
DM1HI8Q	SN	PMID28117607-Compound-24
DM1HI8Q	CP	ELAN PHARMACEUTICALS, LLC
DM1HI8Q	DT	Small molecular drug

DM6RLVB	ID	DM6RLVB
DM6RLVB	DN	Hydrazide derivative 5
DM6RLVB	HS	Patented
DM6RLVB	SN	PMID28117607-Compound-25
DM6RLVB	CP	ELAN PHARMACEUTICALS, LLC
DM6RLVB	DT	Small molecular drug

DMEQBTO	ID	DMEQBTO
DMEQBTO	DN	Hydrazinoacetic acid
DMEQBTO	HS	Patented
DMEQBTO	SN	Hydrazinoacetic acid; 2-hydrazinylacetic acid; 14150-64-2; EINECS 237-995-8; 2-diazanylethanoic acid; Acetic acid, hydrazino-; Acetic acid,2-hydrazinyl-; AC1Q5WP6; AC1L371G; CTK4C2660; DTXSID40161745; ZINC19170177; FT-0717156; A808018
DMEQBTO	DT	Small molecular drug
DMEQBTO	PC	84227
DMEQBTO	MW	90.08
DMEQBTO	FM	C2H6N2O2
DMEQBTO	IC	InChI=1S/C2H6N2O2/c3-4-1-2(5)6/h4H,1,3H2,(H,5,6)
DMEQBTO	CS	C(C(=O)O)NN
DMEQBTO	IK	RRBZUCWNYQUCTR-UHFFFAOYSA-N
DMEQBTO	IU	2-hydrazinylacetic acid
DMEQBTO	CA	CAS 14150-64-2

DMGATHZ	ID	DMGATHZ
DMGATHZ	DN	Hydroxamate analog 1
DMGATHZ	HS	Patented
DMGATHZ	SN	PMID25468267-Compound-31
DMGATHZ	DT	Small molecular drug

DMBMG1S	ID	DMBMG1S
DMBMG1S	DN	Hydroxamate analog 2
DMBMG1S	HS	Patented
DMBMG1S	SN	PMID25468267-Compound-32
DMBMG1S	DT	Small molecular drug

DMDQYJ1	ID	DMDQYJ1
DMDQYJ1	DN	Hydroxamate analog 3
DMDQYJ1	HS	Patented
DMDQYJ1	SN	PMID25468267-Compound-33
DMDQYJ1	DT	Small molecular drug

DMBHIL2	ID	DMBHIL2
DMBHIL2	DN	Hydroxy amidine derivative 1
DMBHIL2	HS	Patented
DMBHIL2	SN	PMID29473428-Compound-25
DMBHIL2	CP	JIANGSU HENGRUI MEDICINE CO., LTD. SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD
DMBHIL2	DT	Small molecular drug

DM7SUFJ	ID	DM7SUFJ
DM7SUFJ	DN	Hydroxy amidine derivative 2
DM7SUFJ	HS	Patented
DM7SUFJ	SN	PMID29473428-Compound-26
DM7SUFJ	CP	JIANGSU HENGRUI MEDICINE CO., LTD. SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD
DM7SUFJ	DT	Small molecular drug

DMAJFDT	ID	DMAJFDT
DMAJFDT	DN	Hydroxyqunoline analog 1
DMAJFDT	HS	Patented
DMAJFDT	SN	PMID25468267-Compound-41
DMAJFDT	DT	Small molecular drug
DMAJFDT	PC	459617
DMAJFDT	MW	189.17
DMAJFDT	FM	C10H7NO3
DMAJFDT	IC	InChI=1S/C10H7NO3/c12-8-4-3-7(10(13)14)6-2-1-5-11-9(6)8/h1-5,12H,(H,13,14)
DMAJFDT	CS	C1=CC2=C(C=CC(=C2N=C1)O)C(=O)O
DMAJFDT	IK	JGRPKOGHYBAVMW-UHFFFAOYSA-N
DMAJFDT	IU	8-hydroxyquinoline-5-carboxylic acid
DMAJFDT	CA	CAS 5852-78-8
DMAJFDT	CB	CHEBI:93239

DMX3TZ7	ID	DMX3TZ7
DMX3TZ7	DN	Hydroxyqunoline analog 2
DMX3TZ7	HS	Patented
DMX3TZ7	SN	PMID25468267-Compound-42
DMX3TZ7	DT	Small molecular drug
DMX3TZ7	PC	97394
DMX3TZ7	MW	189.17
DMX3TZ7	FM	C10H7NO3
DMX3TZ7	IC	InChI=1S/C10H7NO3/c12-8-3-1-2-6-7(10(13)14)4-5-11-9(6)8/h1-5,12H,(H,13,14)
DMX3TZ7	CS	C1=CC2=C(C=CN=C2C(=C1)O)C(=O)O
DMX3TZ7	IK	KPTUKANGPPVLMD-UHFFFAOYSA-N
DMX3TZ7	IU	8-hydroxyquinoline-4-carboxylic acid
DMX3TZ7	CA	CAS 55698-67-4

DMCMKIL	ID	DMCMKIL
DMCMKIL	DN	Hydroxyqunoline analog 3
DMCMKIL	HS	Patented
DMCMKIL	SN	PMID25468267-Compound-43
DMCMKIL	DT	Small molecular drug
DMCMKIL	PC	49853311
DMCMKIL	MW	349.4
DMCMKIL	FM	C21H23N3O2
DMCMKIL	IC	InChI=1S/C21H23N3O2/c1-24(2)12-4-11-22-21(26)16-9-7-15(8-10-16)18-13-17-5-3-6-19(25)20(17)23-14-18/h3,5-10,13-14,25H,4,11-12H2,1-2H3,(H,22,26)
DMCMKIL	CS	CN(C)CCCNC(=O)C1=CC=C(C=C1)C2=CN=C3C(=C2)C=CC=C3O
DMCMKIL	IK	USYGLVCNYUDJNL-UHFFFAOYSA-N
DMCMKIL	IU	N-[3-(dimethylamino)propyl]-4-(8-hydroxyquinolin-3-yl)benzamide

DMGQMCZ	ID	DMGQMCZ
DMGQMCZ	DN	Hydroxyqunoline analog 4
DMGQMCZ	HS	Patented
DMGQMCZ	SN	PMID25468267-Compound-44
DMGQMCZ	DT	Small molecular drug
DMGQMCZ	PC	44143209
DMGQMCZ	MW	349.4
DMGQMCZ	FM	C21H23N3O2
DMGQMCZ	IC	InChI=1S/C21H23N3O2/c1-24(2)12-4-11-23-21(26)16-8-6-15(7-9-16)18-13-17-5-3-10-22-20(17)19(25)14-18/h3,5-10,13-14,25H,4,11-12H2,1-2H3,(H,23,26)
DMGQMCZ	CS	CN(C)CCCNC(=O)C1=CC=C(C=C1)C2=CC(=C3C(=C2)C=CC=N3)O
DMGQMCZ	IK	QDBVSOZTVKXUES-UHFFFAOYSA-N
DMGQMCZ	IU	N-[3-(dimethylamino)propyl]-4-(8-hydroxyquinolin-6-yl)benzamide

DM5QAKR	ID	DM5QAKR
DM5QAKR	DN	Hydroxyqunoline analog 5
DM5QAKR	HS	Patented
DM5QAKR	SN	PMID25468267-Compound-45
DM5QAKR	DT	Small molecular drug
DM5QAKR	PC	70679266
DM5QAKR	MW	472.6
DM5QAKR	FM	C29H36N4O2
DM5QAKR	IC	InChI=1S/C29H36N4O2/c1-31(2)20-21-8-13-32(14-9-21)26-10-15-33(16-11-26)29(35)24-6-3-5-22(17-24)25-18-23-7-4-12-30-28(23)27(34)19-25/h3-7,12,17-19,21,26,34H,8-11,13-16,20H2,1-2H3
DM5QAKR	CS	CN(C)CC1CCN(CC1)C2CCN(CC2)C(=O)C3=CC=CC(=C3)C4=CC(=C5C(=C4)C=CC=N5)O
DM5QAKR	IK	CILGUWSVIMKGON-UHFFFAOYSA-N
DM5QAKR	IU	[4-[4-[(dimethylamino)methyl]piperidin-1-yl]piperidin-1-yl]-[3-(8-hydroxyquinolin-6-yl)phenyl]methanone

DMMFI5G	ID	DMMFI5G
DMMFI5G	DN	Hypersulfated disaccharide compound 1
DMMFI5G	HS	Patented
DMMFI5G	SN	PMID26118988-Compound-40
DMMFI5G	DT	Small molecular drug

DMMJTUW	ID	DMMJTUW
DMMJTUW	DN	Imatinib and nilotinib derivative 1
DMMJTUW	HS	Patented
DMMJTUW	SN	PMID30074415-Compound-22
DMMJTUW	CP	UNIVERSITY OF TAMPERE SUPURAN, Claudiu PARKKILA, Seppo
DMMJTUW	DT	Small molecular drug
DMMJTUW	PC	4369496
DMMJTUW	MW	479.6
DMMJTUW	FM	C28H29N7O
DMMJTUW	IC	InChI=1S/C28H29N7O/c1-34-14-16-35(17-15-34)20-21-7-9-22(10-8-21)27(36)31-24-5-2-6-25(18-24)32-28-30-13-11-26(33-28)23-4-3-12-29-19-23/h2-13,18-19H,14-17,20H2,1H3,(H,31,36)(H,30,32,33)
DMMJTUW	CS	CN1CCN(CC1)CC2=CC=C(C=C2)C(=O)NC3=CC=CC(=C3)NC4=NC=CC(=N4)C5=CN=CC=C5
DMMJTUW	IK	JHMBUEWQJDGKGS-UHFFFAOYSA-N
DMMJTUW	IU	4-[(4-methylpiperazin-1-yl)methyl]-N-[3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMMJTUW	DE	Cas mediated disorder

DM34NZ8	ID	DM34NZ8
DM34NZ8	DN	Imatinib and nilotinib derivative 2
DM34NZ8	HS	Patented
DM34NZ8	SN	PMID30074415-Compound-23
DM34NZ8	CP	UNIVERSITY OF TAMPERE SUPURAN, Claudiu PARKKILA, Seppo
DM34NZ8	DT	Small molecular drug
DM34NZ8	DE	Cas mediated disorder

DMWUFKO	ID	DMWUFKO
DMWUFKO	DN	Imidamide derivative 1
DMWUFKO	HS	Patented
DMWUFKO	SN	PMID27539678-Compound-5
DMWUFKO	CP	UNIVERSITY OF VIRGINIA PATENT FOUNDATION LYNCH, Kevin, R. MACDONALD, Timothy, L. MATHEWS, Thomas, P. KENNEDY, Andrew KHAREL, Yugesh
DMWUFKO	DT	Small molecular drug
DMWUFKO	PC	88866380
DMWUFKO	MW	395.6
DMWUFKO	FM	C22H41N3O3
DMWUFKO	IC	InChI=1S/C22H41N3O3/c23-20(25-27)22(14-15-22)21(26)24-16-10-5-3-1-2-4-6-11-17-28-18-19-12-8-7-9-13-19/h19,27H,1-18H2,(H2,23,25)(H,24,26)
DMWUFKO	CS	C1CCC(CC1)COCCCCCCCCCCNC(=O)C2(CC2)/C(=N/O)/N
DMWUFKO	IK	CHCOBYPQLKIPPD-UHFFFAOYSA-N
DMWUFKO	IU	N-[10-(cyclohexylmethoxy)decyl]-1-[(Z)-N'-hydroxycarbamimidoyl]cyclopropane-1-carboxamide

DMWABOJ	ID	DMWABOJ
DMWABOJ	DN	Imidazo [1,2-a]pyridine compound 1
DMWABOJ	HS	Patented
DMWABOJ	SN	PMID26882240-Compound-18
DMWABOJ	CP	ELARA PHARMACEUTICALS GMBH [DE]
DMWABOJ	DT	Small molecular drug
DMWABOJ	PC	60203900
DMWABOJ	MW	413.5
DMWABOJ	FM	C24H23N5O2
DMWABOJ	IC	InChI=1S/C24H23N5O2/c30-29(31)21-9-6-19(7-10-21)24-22(17-27-14-12-25-13-15-27)28-16-20(8-11-23(28)26-24)18-4-2-1-3-5-18/h1-11,16,25H,12-15,17H2
DMWABOJ	CS	C1CN(CCN1)CC2=C(N=C3N2C=C(C=C3)C4=CC=CC=C4)C5=CC=C(C=C5)[N+](=O)[O-]
DMWABOJ	IK	VFRSRPDPDQUSDK-UHFFFAOYSA-N
DMWABOJ	IU	2-(4-nitrophenyl)-6-phenyl-3-(piperazin-1-ylmethyl)imidazo[1,2-a]pyridine

DM01RXU	ID	DM01RXU
DM01RXU	DN	Imidazo bicyclic iminium derivative 1
DM01RXU	HS	Patented
DM01RXU	SN	PMID26666870-Compound-17
DM01RXU	CP	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITThe Board of Trustees of the Leland Stanford Junior University
DM01RXU	DT	Small molecular drug

DMA7DI6	ID	DMA7DI6
DMA7DI6	DN	Imidazo bicyclic iminium derivative 2
DMA7DI6	HS	Patented
DMA7DI6	SN	PMID26666870-Compound-18
DMA7DI6	CP	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITThe Board of Trustees of the Leland Stanford Junior University
DMA7DI6	DT	Small molecular drug

DMENYZ0	ID	DMENYZ0
DMENYZ0	DN	Imidazo bicyclic iminium derivative 3
DMENYZ0	HS	Patented
DMENYZ0	SN	PMID25726713-Compound-71
DMENYZ0	CP	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMENYZ0	DT	Small molecular drug

DMHRV8J	ID	DMHRV8J
DMHRV8J	DN	Imidazo bicyclic iminium derivative 4
DMHRV8J	HS	Patented
DMHRV8J	SN	PMID25726713-Compound-72
DMHRV8J	CP	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMHRV8J	DT	Small molecular drug

DMS8GIU	ID	DMS8GIU
DMS8GIU	DN	Imidazo bicyclic iminium derivative 5
DMS8GIU	HS	Patented
DMS8GIU	SN	PMID25726713-Compound-73
DMS8GIU	CP	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMS8GIU	DT	Small molecular drug

DMEP5MJ	ID	DMEP5MJ
DMEP5MJ	DN	Imidazo bicyclic iminium derivative 6
DMEP5MJ	HS	Patented
DMEP5MJ	SN	PMID25726713-Compound-74
DMEP5MJ	CP	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMEP5MJ	DT	Small molecular drug

DM0Y4X8	ID	DM0Y4X8
DM0Y4X8	DN	Imidazo bicyclic iminium derivative 7
DM0Y4X8	HS	Patented
DM0Y4X8	SN	PMID25726713-Compound-75
DM0Y4X8	CP	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DM0Y4X8	DT	Small molecular drug

DMBMFPC	ID	DMBMFPC
DMBMFPC	DN	Imidazo bicyclic iminium derivative 8
DMBMFPC	HS	Patented
DMBMFPC	SN	PMID25726713-Compound-76
DMBMFPC	CP	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMBMFPC	DT	Small molecular drug

DMQXCT1	ID	DMQXCT1
DMQXCT1	DN	Imidazo bicyclic iminium derivative 9
DMQXCT1	HS	Patented
DMQXCT1	SN	PMID25726713-Compound-77
DMQXCT1	CP	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMQXCT1	DT	Small molecular drug

DM34ZCG	ID	DM34ZCG
DM34ZCG	DN	Imidazo cyclohexylamine derivative 1
DM34ZCG	HS	Patented
DM34ZCG	SN	PMID25482888-Compound-42
DM34ZCG	CP	SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong LEI, Ming ZHANG, Huajie WANG, Longcheng ZHANG, Jian FANG, Bo LIU, Xia ZHOU, Zuwen
DM34ZCG	DT	Small molecular drug

DMKPAN3	ID	DMKPAN3
DMKPAN3	DN	Imidazo cyclohexylamine derivative 2
DMKPAN3	HS	Patented
DMKPAN3	SN	PMID25482888-Compound-43
DMKPAN3	CP	SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong LEI, Ming ZHANG, Huajie WANG, Longcheng ZHANG, Jian FANG, Bo LIU, Xia ZHOU, Zuwen
DMKPAN3	DT	Small molecular drug

DMCQBZK	ID	DMCQBZK
DMCQBZK	DN	Imidazo cyclohexylamine derivative 3
DMCQBZK	HS	Patented
DMCQBZK	SN	PMID25482888-Compound-44
DMCQBZK	CP	SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong LEI, Ming ZHANG, Huajie WANG, Longcheng ZHANG, Jian FANG, Bo LIU, Xia ZHOU, Zuwen
DMCQBZK	DT	Small molecular drug

DM1JXKY	ID	DM1JXKY
DM1JXKY	DN	Imidazo isoindole derivative 1
DM1JXKY	HS	Patented
DM1JXKY	SN	PMID29473428-Compound-35
DM1JXKY	CP	JIANGSU HENGRUI MEDICINE CO [CNSHANGHAI HENGRUI PHARMACEUTICAL CO LTD [CN]
DM1JXKY	DT	Small molecular drug
DM1JXKY	PC	122650373
DM1JXKY	MW	413.5
DM1JXKY	FM	C25H24FN5
DM1JXKY	IC	InChI=1S/C25H24FN5/c1-29-15-19(13-28-29)17-5-7-20(8-6-17)30-11-9-18(10-12-30)25-24-21(3-2-4-22(24)26)23-14-27-16-31(23)25/h2-8,13-16,18,25H,9-12H2,1H3/t25-/m0/s1
DM1JXKY	CS	CN1C=C(C=N1)C2=CC=C(C=C2)N3CCC(CC3)[C@H]4C5=C(C=CC=C5F)C6=CN=CN46
DM1JXKY	IK	UJGQDAMZVUNFBQ-VWLOTQADSA-N
DM1JXKY	IU	(5S)-6-fluoro-5-[1-[4-(1-methylpyrazol-4-yl)phenyl]piperidin-4-yl]-5H-imidazo[5,1-a]isoindole

DMCXHGW	ID	DMCXHGW
DMCXHGW	DN	Imidazo pyridine derivative 1
DMCXHGW	HS	Patented
DMCXHGW	SN	PMID28270021-Compound-WO2015200341Example96
DMCXHGW	CP	DR. REDDY'S LABORATORIES LTD
DMCXHGW	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMC49SV	ID	DMC49SV
DMC49SV	DN	Imidazo pyridine derivative 2
DMC49SV	HS	Patented
DMC49SV	SN	PMID25482888-Compound-51
DMC49SV	CP	SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong ZOU, Chunlan ZHANG, Huajie ZHANG, Weipeng LIU, Caiping TIAN, Qiang
DMC49SV	DT	Small molecular drug

DMPCLZB	ID	DMPCLZB
DMPCLZB	DN	Imidazo pyridine derivative 3
DMPCLZB	HS	Patented
DMPCLZB	SN	PMID26161698-Compound-22
DMPCLZB	CP	NOVARTIS AG ASTEX THERAPEUTICS LIMITED HOWARD, Steven MORTENSON, Paul Neil HISCOCK, Steven Douglas WOOLFORD, Alison Jo-Anne WOODHEAD, Andrew James CHESSARI, Gianni O'REILLY, Marc CONGREVE, Miles Stuart DAGOSTIN, Claudio CHO, Young Shin YANG, Fan CHEN, Christine Hiu-Tung BRAIN, Christopher Thomas LAGU, Bharat WANG, Yaping KIM, Sunkyu GRIALDES, John LUZZIO, Michael Joseph PEREZ, Lawrence Blas LU, Yipin
DMPCLZB	DT	Small molecular drug
DMPCLZB	PC	46937330
DMPCLZB	MW	501.6
DMPCLZB	FM	C30H27N7O
DMPCLZB	IC	InChI=1S/C30H27N7O/c1-36(2)22-11-13-37(14-12-22)27-10-9-26-29(34-27)35-30(33-26)28(38)19-7-8-20(16-31)24(15-19)25-18-32-17-21-5-3-4-6-23(21)25/h3-10,15,17-18,22H,11-14H2,1-2H3,(H,33,34,35)
DMPCLZB	CS	CN(C)C1CCN(CC1)C2=NC3=C(C=C2)NC(=N3)C(=O)C4=CC(=C(C=C4)C#N)C5=CN=CC6=CC=CC=C65
DMPCLZB	IK	AZXYPCBAGCXZPP-UHFFFAOYSA-N
DMPCLZB	IU	4-[5-[4-(dimethylamino)piperidin-1-yl]-1H-imidazo[4,5-b]pyridine-2-carbonyl]-2-isoquinolin-4-ylbenzonitrile

DM3YMHP	ID	DM3YMHP
DM3YMHP	DN	Imidazo pyridine derivative 4
DM3YMHP	HS	Patented
DM3YMHP	SN	PMID27788040-Compound-4
DM3YMHP	CP	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES MARUGAN, Juan J. PATNAIK, Samarjit HEILIG, Markus A. SOUTHALL, Noel T. ZHENG, Wei
DM3YMHP	DT	Small molecular drug

DMOVJ35	ID	DMOVJ35
DMOVJ35	DN	Imidazo pyridine derivative 5
DMOVJ35	HS	Patented
DMOVJ35	SN	PMID27788040-Compound-4a
DMOVJ35	CP	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES MARUGAN, Juan J. PATNAIK, Samarjit HEILIG, Markus A. SOUTHALL, Noel T. ZHENG, Wei
DMOVJ35	DT	Small molecular drug

DMG6W3O	ID	DMG6W3O
DMG6W3O	DN	Imidazo pyridine derivative 6
DMG6W3O	HS	Patented
DMG6W3O	SN	PMID27788040-Compound-4b
DMG6W3O	CP	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES MARUGAN, Juan J. PATNAIK, Samarjit HEILIG, Markus A. SOUTHALL, Noel T. ZHENG, Wei
DMG6W3O	DT	Small molecular drug

DMGDMWA	ID	DMGDMWA
DMGDMWA	DN	Imidazo quinoline derivative 1
DMGDMWA	HS	Patented
DMGDMWA	SN	PMID25684022-Compound-WO2008054238
DMGDMWA	CP	KUTUSHOV MIKHAIL VLADIMIROVICH [RUGERMANOV EVGENY PAVLOVICH [RU]
DMGDMWA	DT	Small molecular drug
DMGDMWA	DE	Solid tumour/cancer; Metastatic cancer

DMLVY7A	ID	DMLVY7A
DMLVY7A	DN	Imidazo triazine derivative 1
DMLVY7A	HS	Patented
DMLVY7A	SN	PMID27321640-Compound-64
DMLVY7A	CP	Pfizer Incorporated
DMLVY7A	DT	Small molecular drug
DMLVY7A	PC	68182028
DMLVY7A	MW	401.4
DMLVY7A	FM	C19H18F3N7
DMLVY7A	IC	InChI=1S/C19H18F3N7/c1-11-26-15(17-18(27(2)3)23-10-25-29(11)17)14-9-24-28(4)16(14)12-5-7-13(8-6-12)19(20,21)22/h5-10H,1-4H3
DMLVY7A	CS	CC1=NC(=C2N1N=CN=C2N(C)C)C3=C(N(N=C3)C)C4=CC=C(C=C4)C(F)(F)F
DMLVY7A	IK	UXZUQMRCSXERSI-UHFFFAOYSA-N
DMLVY7A	IU	N,N,7-trimethyl-5-[1-methyl-5-[4-(trifluoromethyl)phenyl]pyrazol-4-yl]imidazo[5,1-f][1,2,4]triazin-4-amine

DMZFG68	ID	DMZFG68
DMZFG68	DN	Imidazo triazine derivative 2
DMZFG68	HS	Patented
DMZFG68	SN	PMID27321640-Compound-65
DMZFG68	CP	Pfizer Incorporated
DMZFG68	DT	Small molecular drug

DM142HI	ID	DM142HI
DM142HI	DN	Imidazo triazine derivative 3
DM142HI	HS	Patented
DM142HI	SN	PMID27321640-Compound-66
DM142HI	CP	Pfizer Incorporated
DM142HI	DT	Small molecular drug

DMZTS2O	ID	DMZTS2O
DMZTS2O	DN	Imidazo triazine derivative 4
DMZTS2O	HS	Patented
DMZTS2O	SN	PMID27321640-Compound-67
DMZTS2O	CP	Pfizer Incorporated
DMZTS2O	DT	Small molecular drug

DM18P4N	ID	DM18P4N
DM18P4N	DN	Imidazo triazine derivative 5
DM18P4N	HS	Patented
DM18P4N	SN	PMID27321640-Compound-68
DM18P4N	CP	Pfizer Incorporated
DM18P4N	DT	Small molecular drug

DM5NEQ2	ID	DM5NEQ2
DM5NEQ2	DN	Imidazo[1,2-a]pyridine derivative 1
DM5NEQ2	HS	Patented
DM5NEQ2	SN	PMID28067079-Compound-46
DM5NEQ2	DT	Small molecular drug

DM654Z0	ID	DM654Z0
DM654Z0	DN	Imidazo[1,2-b]pyridazine acetamide derivative 1
DM654Z0	HS	Patented
DM654Z0	SN	PMID27607364-Compound-146
DM654Z0	DT	Small molecular drug

DMVX7YB	ID	DMVX7YB
DMVX7YB	DN	Imidazo[1,2-b]pyridazine acetamide derivative 2
DMVX7YB	HS	Patented
DMVX7YB	SN	PMID27607364-Compound-147
DMVX7YB	DT	Small molecular drug
DMVX7YB	PC	44197007
DMVX7YB	MW	366.5
DMVX7YB	FM	C21H26N4O2
DMVX7YB	IC	InChI=1S/C21H26N4O2/c1-6-24(7-2)19(26)13-18-20(16-8-10-17(27-5)11-9-16)22-21-14(3)12-15(4)23-25(18)21/h8-12H,6-7,13H2,1-5H3
DMVX7YB	CS	CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)OC
DMVX7YB	IK	RGPSCAJBNWAKNP-UHFFFAOYSA-N
DMVX7YB	IU	N,N-diethyl-2-[2-(4-methoxyphenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]acetamide

DMARLZ6	ID	DMARLZ6
DMARLZ6	DN	Imidazo[1,2-b]pyridazine acetamide derivative 3
DMARLZ6	HS	Patented
DMARLZ6	SN	PMID27607364-Compound-148
DMARLZ6	DT	Small molecular drug
DMARLZ6	PC	44197008
DMARLZ6	MW	350.5
DMARLZ6	FM	C21H26N4O
DMARLZ6	IC	InChI=1S/C21H26N4O/c1-6-24(7-2)19(26)13-18-20(17-10-8-14(3)9-11-17)22-21-15(4)12-16(5)23-25(18)21/h8-12H,6-7,13H2,1-5H3
DMARLZ6	CS	CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)C
DMARLZ6	IK	CUGGTIFWWSZRMG-UHFFFAOYSA-N
DMARLZ6	IU	2-[6,8-dimethyl-2-(4-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N,N-diethylacetamide

DM5J09E	ID	DM5J09E
DM5J09E	DN	Imidazo[1,2-b]pyridazine acetamide derivative 4
DM5J09E	HS	Patented
DM5J09E	SN	PMID27607364-Compound-149
DM5J09E	DT	Small molecular drug
DM5J09E	PC	44197009
DM5J09E	MW	370.9
DM5J09E	FM	C20H23ClN4O
DM5J09E	IC	InChI=1S/C20H23ClN4O/c1-5-24(6-2)18(26)12-17-19(15-7-9-16(21)10-8-15)22-20-13(3)11-14(4)23-25(17)20/h7-11H,5-6,12H2,1-4H3
DM5J09E	CS	CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)Cl
DM5J09E	IK	SNOFNBFMBXYLMZ-UHFFFAOYSA-N
DM5J09E	IU	2-[2-(4-chlorophenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]-N,N-diethylacetamide

DMGWYJR	ID	DMGWYJR
DMGWYJR	DN	Imidazo[1,2-b]pyridazine acetamide derivative 5
DMGWYJR	HS	Patented
DMGWYJR	SN	PMID27607364-Compound-150
DMGWYJR	DT	Small molecular drug
DMGWYJR	PC	44197010
DMGWYJR	MW	415.3
DMGWYJR	FM	C20H23BrN4O
DMGWYJR	IC	InChI=1S/C20H23BrN4O/c1-5-24(6-2)18(26)12-17-19(15-7-9-16(21)10-8-15)22-20-13(3)11-14(4)23-25(17)20/h7-11H,5-6,12H2,1-4H3
DMGWYJR	CS	CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)Br
DMGWYJR	IK	WBBNDNCIVIIEMF-UHFFFAOYSA-N
DMGWYJR	IU	2-[2-(4-bromophenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]-N,N-diethylacetamide

DM73ESA	ID	DM73ESA
DM73ESA	DN	Imidazo[1,2-b]pyridazine acetamide derivative 6
DM73ESA	HS	Patented
DM73ESA	SN	PMID27607364-Compound-151
DM73ESA	DT	Small molecular drug
DM73ESA	PC	44197027
DM73ESA	MW	354.4
DM73ESA	FM	C20H23FN4O
DM73ESA	IC	InChI=1S/C20H23FN4O/c1-5-24(6-2)18(26)12-17-19(15-7-9-16(21)10-8-15)22-20-13(3)11-14(4)23-25(17)20/h7-11H,5-6,12H2,1-4H3
DM73ESA	CS	CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)F
DM73ESA	IK	DARQBLUTJIXEJM-UHFFFAOYSA-N
DM73ESA	IU	N,N-diethyl-2-[2-(4-fluorophenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]acetamide

DMQLJU2	ID	DMQLJU2
DMQLJU2	DN	Imidazo[1,2-b]pyridazine acetamide derivative 7
DMQLJU2	HS	Patented
DMQLJU2	SN	PMID27607364-Compound-152
DMQLJU2	DT	Small molecular drug
DMQLJU2	PC	44197028
DMQLJU2	MW	352.4
DMQLJU2	FM	C20H24N4O2
DMQLJU2	IC	InChI=1S/C20H24N4O2/c1-5-23(6-2)18(26)12-17-19(15-7-9-16(25)10-8-15)21-20-13(3)11-14(4)22-24(17)20/h7-11,25H,5-6,12H2,1-4H3
DMQLJU2	CS	CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)O
DMQLJU2	IK	AHZVLZZEKQYWAC-UHFFFAOYSA-N
DMQLJU2	IU	N,N-diethyl-2-[2-(4-hydroxyphenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]acetamide

DMULTAI	ID	DMULTAI
DMULTAI	DN	Imidazo[1,2-b]pyridazine derivative 1
DMULTAI	HS	Patented
DMULTAI	SN	PMID28270010-Compound-Figure22-1
DMULTAI	DT	Small molecular drug
DMULTAI	PC	72695720
DMULTAI	MW	417.5
DMULTAI	FM	C24H24FN5O
DMULTAI	IC	InChI=1S/C24H24FN5O/c1-16(18-3-2-4-19(25)13-18)28-23-9-10-24-27-14-22(30(24)29-23)17-5-7-21(8-6-17)31-15-20-11-12-26-20/h2-10,13-14,16,20,26H,11-12,15H2,1H3,(H,28,29)/t16-,20+/m1/s1
DMULTAI	CS	C[C@H](C1=CC(=CC=C1)F)NC2=NN3C(=NC=C3C4=CC=C(C=C4)OC[C@@H]5CCN5)C=C2
DMULTAI	IK	FQCGOBGLJQWKJA-UZLBHIALSA-N
DMULTAI	IU	3-[4-[[(2S)-azetidin-2-yl]methoxy]phenyl]-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine
DMULTAI	DE	Solid tumour/cancer

DM1JYNW	ID	DM1JYNW
DM1JYNW	DN	Imidazo[1,2-b]pyridazine derivative 2
DM1JYNW	HS	Patented
DM1JYNW	SN	PMID28270010-Compound-Figure22-2
DM1JYNW	DT	Small molecular drug
DM1JYNW	PC	72695721
DM1JYNW	MW	405.5
DM1JYNW	FM	C23H24FN5O
DM1JYNW	IC	InChI=1S/C23H24FN5O/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18/h3-13,15-16H,14,25H2,1-2H3,(H,27,28)/t15-,16+/m0/s1
DM1JYNW	CS	C[C@@H](COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)N[C@H](C)C4=CC(=CC=C4)F)N
DM1JYNW	IK	HEVHTYMYEMEBPX-JKSUJKDBSA-N
DM1JYNW	IU	3-[4-[(2S)-2-aminopropoxy]phenyl]-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine
DM1JYNW	DE	Solid tumour/cancer

DMPDTG0	ID	DMPDTG0
DMPDTG0	DN	Imidazo[1,2-b]pyridazine derivative 3
DMPDTG0	HS	Patented
DMPDTG0	SN	PMID28270010-Compound-Figure22-3
DMPDTG0	DT	Small molecular drug
DMPDTG0	DE	Solid tumour/cancer

DM2DL4I	ID	DM2DL4I
DM2DL4I	DN	Imidazo[1,2-b]pyridazine derivative 4
DM2DL4I	HS	Patented
DM2DL4I	SN	PMID28270010-Compound-Figure8-1
DM2DL4I	CP	ARRAY BIOPHARMA INC. ANDREWS, Steven, W. HAAS, Julia JIANG, Yutong ZHANG, Gan
DM2DL4I	DT	Small molecular drug
DM2DL4I	PC	45274003
DM2DL4I	MW	428.4
DM2DL4I	FM	C21H22F2N6O2
DM2DL4I	IC	InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)17-2-1-8-28(17)19-6-5-18-24-11-20(29(18)26-19)25-21(31)27-9-7-14(30)12-27/h3-6,10-11,14,17,30H,1-2,7-9,12H2,(H,25,31)/t14-,17+/m0/s1
DM2DL4I	CS	C1C[C@@H](N(C1)C2=NN3C(=NC=C3NC(=O)N4CC[C@@H](C4)O)C=C2)C5=C(C=CC(=C5)F)F
DM2DL4I	IK	JSJOUFCSIYXYAC-WMLDXEAASA-N
DM2DL4I	IU	(3S)-N-[6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]-3-hydroxypyrrolidine-1-carboxamide

DMK8V7A	ID	DMK8V7A
DMK8V7A	DN	Imidazo[1,2-b]pyridazine derivative 5
DMK8V7A	HS	Patented
DMK8V7A	SN	PMID28270010-Compound-Figure8-2
DMK8V7A	CP	ARRAY BIOPHARMA INC. ANDREWS, Steven, W. HAAS, Julia JIANG, Yutong ZHANG, Gan
DMK8V7A	DT	Small molecular drug

DMSIRC2	ID	DMSIRC2
DMSIRC2	DN	Imidazo[1,2-b]pyridazine derivative 6
DMSIRC2	HS	Patented
DMSIRC2	SN	PMID28270010-Compound-Figure8-3
DMSIRC2	CP	ARRAY BIOPHARMA INC. ANDREWS, Steven, W. HAAS, Julia JIANG, Yutong ZHANG, Gan
DMSIRC2	DT	Small molecular drug

DMDQLUP	ID	DMDQLUP
DMDQLUP	DN	Imidazo[1,2-b]pyridazine derivative 7
DMDQLUP	HS	Patented
DMDQLUP	SN	PMID28270010-Compound-Figure8-4
DMDQLUP	CP	ARRAY BIOPHARMA INC. ANDREWS, Steven, W. HAAS, Julia JIANG, Yutong ZHANG, Gan
DMDQLUP	DT	Small molecular drug
DMDQLUP	PC	46182706
DMDQLUP	MW	512.5
DMDQLUP	FM	C24H22F2N6O3S
DMDQLUP	IC	InChI=1S/C24H22F2N6O3S/c1-36(34,35)30-17-7-4-15(5-8-17)24(33)28-23-14-27-21-10-11-22(29-32(21)23)31-12-2-3-20(31)18-13-16(25)6-9-19(18)26/h4-11,13-14,20,30H,2-3,12H2,1H3,(H,28,33)/t20-/m1/s1
DMDQLUP	CS	CS(=O)(=O)NC1=CC=C(C=C1)C(=O)NC2=CN=C3N2N=C(C=C3)N4CCC[C@@H]4C5=C(C=CC(=C5)F)F
DMDQLUP	IK	CDMQMPKUGUVGIR-HXUWFJFHSA-N
DMDQLUP	IU	N-[6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]-4-(methanesulfonamido)benzamide

DMFIP0D	ID	DMFIP0D
DMFIP0D	DN	Imidazo[1,5-a]pyridine derivative 1
DMFIP0D	HS	Patented
DMFIP0D	SN	PMID29473428-Compound-12
DMFIP0D	CP	BEIGENE, LTD. WANG, Hexiang
DMFIP0D	DT	Small molecular drug
DMFIP0D	PC	122604981
DMFIP0D	MW	264.75
DMFIP0D	FM	C14H17ClN2O
DMFIP0D	IC	InChI=1S/C14H17ClN2O/c15-11-6-12-8-16-9-17(12)13(7-11)14(18)10-4-2-1-3-5-10/h6-10,14,18H,1-5H2/t14-/m0/s1
DMFIP0D	CS	C1CCC(CC1)[C@@H](C2=CC(=CC3=CN=CN23)Cl)O
DMFIP0D	IK	AVJCRIIDMDBAQC-AWEZNQCLSA-N
DMFIP0D	IU	(S)-(7-chloroimidazo[1,5-a]pyridin-5-yl)-cyclohexylmethanol

DMU3PAR	ID	DMU3PAR
DMU3PAR	DN	Imidazo[1,5-a]pyridine derivative 2
DMU3PAR	HS	Patented
DMU3PAR	SN	PMID29473428-Compound-13
DMU3PAR	CP	BEIGENE, LTD. WANG, Hexiang
DMU3PAR	DT	Small molecular drug
DMU3PAR	PC	122609311
DMU3PAR	MW	282.4
DMU3PAR	FM	C18H22N2O
DMU3PAR	IC	InChI=1S/C18H22N2O/c21-18(15-8-11-1-2-13(15)7-11)17-14(12-3-4-12)5-6-20-10-19-9-16(17)20/h5-6,9-13,15,18,21H,1-4,7-8H2/t11?,13?,15?,18-/m0/s1
DMU3PAR	CS	C1CC1C2=C(C3=CN=CN3C=C2)[C@H](C4CC5CCC4C5)O
DMU3PAR	IK	AYNGHFYFVHELEJ-NNIVULJMSA-N
DMU3PAR	IU	(S)-2-bicyclo[2.2.1]heptanyl-(7-cyclopropylimidazo[1,5-a]pyridin-8-yl)methanol

DM4KBZQ	ID	DM4KBZQ
DM4KBZQ	DN	Imidazo[4,5-c]pyridine derivative 1
DM4KBZQ	HS	Patented
DM4KBZQ	SN	PMID27774824-Compound-Figure11Example228
DM4KBZQ	CP	GALAPAGOS NV
DM4KBZQ	DT	Small molecular drug

DMFDRJT	ID	DMFDRJT
DMFDRJT	DN	Imidazo[4,5-c]pyridine derivative 2
DMFDRJT	HS	Patented
DMFDRJT	SN	PMID27774824-Compound-Figure11Example82
DMFDRJT	CP	GALAPAGOS NV
DMFDRJT	DT	Small molecular drug

DMUB4QL	ID	DMUB4QL
DMUB4QL	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 1
DMUB4QL	HS	Patented
DMUB4QL	SN	PMID27321640-Compound-19
DMUB4QL	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael S. ERDEI, James Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMUB4QL	DT	Small molecular drug

DMB8AJP	ID	DMB8AJP
DMB8AJP	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 2
DMB8AJP	HS	Patented
DMB8AJP	SN	PMID27321640-Compound-20
DMB8AJP	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael S. ERDEI, James Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMB8AJP	DT	Small molecular drug

DMYX684	ID	DMYX684
DMYX684	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 3
DMYX684	HS	Patented
DMYX684	SN	PMID27321640-Compound-21
DMYX684	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael S. ERDEI, James Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMYX684	DT	Small molecular drug

DMWF4S7	ID	DMWF4S7
DMWF4S7	DN	Imidazo[5,1-c][1,2,4]benzotriazine derivative 4
DMWF4S7	HS	Patented
DMWF4S7	SN	PMID27321640-Compound-22
DMWF4S7	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael S. ERDEI, James Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMWF4S7	DT	Small molecular drug

DMQBH81	ID	DMQBH81
DMQBH81	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1
DMQBH81	HS	Patented
DMQBH81	SN	PMID27321640-Compound-23
DMQBH81	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMQBH81	DT	Small molecular drug

DMS3ROL	ID	DMS3ROL
DMS3ROL	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2
DMS3ROL	HS	Patented
DMS3ROL	SN	PMID27321640-Compound-24
DMS3ROL	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMS3ROL	DT	Small molecular drug

DMZ61T8	ID	DMZ61T8
DMZ61T8	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3
DMZ61T8	HS	Patented
DMZ61T8	SN	PMID27321640-Compound-25
DMZ61T8	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMZ61T8	DT	Small molecular drug
DMZ61T8	PC	46200734
DMZ61T8	MW	339.32
DMZ61T8	FM	C17H14FN5O2
DMZ61T8	IC	InChI=1S/C17H14FN5O2/c1-9-15-22-21-13-6-7-14(25-3)20-17(13)23(15)16(19-9)11-8-10(24-2)4-5-12(11)18/h4-8H,1-3H3
DMZ61T8	CS	CC1=C2N=NC3=C(N2C(=N1)C4=C(C=CC(=C4)OC)F)N=C(C=C3)OC
DMZ61T8	IK	HLUWBLAYMFWHOF-UHFFFAOYSA-N
DMZ61T8	IU	3-(2-fluoro-5-methoxyphenyl)-12-methoxy-5-methyl-2,4,7,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene

DMKR5ZO	ID	DMKR5ZO
DMKR5ZO	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4
DMKR5ZO	HS	Patented
DMKR5ZO	SN	PMID27321640-Compound-26
DMKR5ZO	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMKR5ZO	DT	Small molecular drug

DM7UAKH	ID	DM7UAKH
DM7UAKH	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5
DM7UAKH	HS	Patented
DM7UAKH	SN	PMID27321640-Compound-27
DM7UAKH	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DM7UAKH	DT	Small molecular drug

DMKRUAN	ID	DMKRUAN
DMKRUAN	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6
DMKRUAN	HS	Patented
DMKRUAN	SN	PMID27321640-Compound-28
DMKRUAN	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMKRUAN	DT	Small molecular drug

DMINBJM	ID	DMINBJM
DMINBJM	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7
DMINBJM	HS	Patented
DMINBJM	SN	PMID27321640-Compound-29
DMINBJM	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMINBJM	DT	Small molecular drug

DM42EST	ID	DM42EST
DM42EST	DN	Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8
DM42EST	HS	Patented
DM42EST	SN	PMID27321640-Compound-30
DM42EST	CP	STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DM42EST	DT	Small molecular drug

DM0SOKJ	ID	DM0SOKJ
DM0SOKJ	DN	Imidazole benzamide derivative 1
DM0SOKJ	HS	Patented
DM0SOKJ	SN	PMID28627961-Compound-21
DM0SOKJ	CP	ELI LILLY AND COMPANY HUGHES, Norman Earle WOODS, Timothy Andrew NORMAN, Bryan Hurst
DM0SOKJ	DT	Small molecular drug
DM0SOKJ	PC	71059525
DM0SOKJ	MW	495.4
DM0SOKJ	FM	C23H22F5N5O2
DM0SOKJ	IC	InChI=1S/C23H22F5N5O2/c1-11(2)20(34)30-10-13-8-16(18(19(24)25)29-9-13)21(35)33-22-31-12(3)17(32-22)14-4-6-15(7-5-14)23(26,27)28/h4-9,11,19H,10H2,1-3H3,(H,30,34)(H2,31,32,33,35)
DM0SOKJ	CS	CC1=C(N=C(N1)NC(=O)C2=C(N=CC(=C2)CNC(=O)C(C)C)C(F)F)C3=CC=C(C=C3)C(F)(F)F
DM0SOKJ	IK	BZYSILFNUIGABU-UHFFFAOYSA-N
DM0SOKJ	IU	2-(difluoromethyl)-5-[(2-methylpropanoylamino)methyl]-N-[5-methyl-4-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
DM0SOKJ	DE	Knee pain

DM14KHX	ID	DM14KHX
DM14KHX	DN	Imidazole derivative 1
DM14KHX	HS	Patented
DM14KHX	SN	PMID26161824-Compound-83
DM14KHX	CP	GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeongmin JUNG, Myung Eun KIM, Jong Yup AHN, Kwangwoo SEO, Hee Jeong LEE, Sung-Han LEE, Suk Ho
DM14KHX	DT	Small molecular drug
DM14KHX	DE	Obesity

DMI7W3K	ID	DMI7W3K
DMI7W3K	DN	Imidazole derivative 10
DMI7W3K	HS	Patented
DMI7W3K	SN	PMID26560362-Compound-19
DMI7W3K	DT	Small molecular drug

DMTJ0DP	ID	DMTJ0DP
DMTJ0DP	DN	Imidazole derivative 11
DMTJ0DP	HS	Patented
DMTJ0DP	SN	PMID26560362-Compound-20
DMTJ0DP	DT	Small molecular drug
DMTJ0DP	PC	9930072
DMTJ0DP	MW	386.5
DMTJ0DP	FM	C17H14N4O3S2
DMTJ0DP	IC	InChI=1S/C17H14N4O3S2/c1-24-14-7-6-11(16-19-12-4-2-8-18-17(12)20-16)10-13(14)21-26(22,23)15-5-3-9-25-15/h2-10,21H,1H3,(H,18,19,20)
DMTJ0DP	CS	COC1=C(C=C(C=C1)C2=NC3=C(N2)C=CC=N3)NS(=O)(=O)C4=CC=CS4
DMTJ0DP	IK	WCSLLVSWFDOVCR-UHFFFAOYSA-N
DMTJ0DP	IU	N-[5-(1H-imidazo[4,5-b]pyridin-2-yl)-2-methoxyphenyl]thiophene-2-sulfonamide

DM8GCVO	ID	DM8GCVO
DM8GCVO	DN	Imidazole derivative 2
DM8GCVO	HS	Patented
DM8GCVO	SN	PMID26161824-Compound-84
DM8GCVO	CP	GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeongmin JUNG, Myung Eun KIM, Jong Yup AHN, Kwangwoo SEO, Hee Jeong LEE, Sung-Han LEE, Suk Ho
DM8GCVO	DT	Small molecular drug
DM8GCVO	PC	25003715
DM8GCVO	MW	519.299
DM8GCVO	FM	C24H22BrCl2N3O
DM8GCVO	IC	InChI=1S/C24H22BrCl2N3O/c1-5-19-21(23-28-13-20(31-23)24(2,3)4)29-22(17-11-8-15(26)12-18(17)27)30(19)16-9-6-14(25)7-10-16/h6-13H,5H2,1-4H3
DM8GCVO	CS	CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C4=NC=C(O4)C(C)(C)C
DM8GCVO	IK	PLHFPYNOQHOWQO-UHFFFAOYSA-N
DM8GCVO	IU	2-[1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethylimidazol-4-yl]-5-tert-butyl-1,3-oxazole
DM8GCVO	DE	Obesity

DMV1ER2	ID	DMV1ER2
DMV1ER2	DN	Imidazole derivative 3
DMV1ER2	HS	Patented
DMV1ER2	SN	PMID26161824-Compound-85
DMV1ER2	CP	GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeongmin JUNG, Myung Eun KIM, Jong Yup AHN, Kwangwoo SEO, Hee Jeong LEE, Sung-Han LEE, Suk Ho
DMV1ER2	DT	Small molecular drug
DMV1ER2	DE	Obesity

DMPGMX2	ID	DMPGMX2
DMPGMX2	DN	Imidazole derivative 4
DMPGMX2	HS	Patented
DMPGMX2	SN	PMID26161824-Compound-86
DMPGMX2	CP	GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeongmin JUNG, Myung Eun KIM, Jong Yup AHN, Kwangwoo SEO, Hee Jeong LEE, Sung-Han LEE, Suk Ho
DMPGMX2	DT	Small molecular drug
DMPGMX2	PC	59786166
DMPGMX2	MW	580.8
DMPGMX2	FM	C24H15Cl3F3N7O
DMPGMX2	IC	InChI=1S/C24H15Cl3F3N7O/c25-13-1-4-15(5-2-13)37-18(10-36-12-31-11-32-36)19(33-20(37)16-6-3-14(26)9-17(16)27)21-34-35-22(38-21)23(7-8-23)24(28,29)30/h1-6,9,11-12H,7-8,10H2
DMPGMX2	CS	C1CC1(C2=NN=C(O2)C3=C(N(C(=N3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)CN6C=NC=N6)C(F)(F)F
DMPGMX2	IK	UFJZESYUYSJRPI-UHFFFAOYSA-N
DMPGMX2	IU	2-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(1,2,4-triazol-1-ylmethyl)imidazol-4-yl]-5-[1-(trifluoromethyl)cyclopropyl]-1,3,4-oxadiazole
DMPGMX2	DE	Obesity

DMVSXUM	ID	DMVSXUM
DMVSXUM	DN	Imidazole derivative 5
DMVSXUM	HS	Patented
DMVSXUM	SN	PMID26161824-Compound-87
DMVSXUM	DT	Small molecular drug
DMVSXUM	DE	Obesity

DMOXHZJ	ID	DMOXHZJ
DMOXHZJ	DN	Imidazole derivative 6
DMOXHZJ	HS	Patented
DMOXHZJ	SN	PMID26161824-Compound-88
DMOXHZJ	DT	Small molecular drug
DMOXHZJ	PC	11541445
DMOXHZJ	MW	569.3
DMOXHZJ	FM	C23H23Cl2IN4O
DMOXHZJ	IC	InChI=1S/C23H23Cl2IN4O/c1-14-21(29-23(31)27-17-5-3-2-4-6-17)28-22(19-12-7-15(24)13-20(19)25)30(14)18-10-8-16(26)9-11-18/h7-13,17H,2-6H2,1H3,(H2,27,29,31)
DMOXHZJ	CS	CC1=C(N=C(N1C2=CC=C(C=C2)I)C3=C(C=C(C=C3)Cl)Cl)NC(=O)NC4CCCCC4
DMOXHZJ	IK	KINYNFFISOBDBZ-UHFFFAOYSA-N
DMOXHZJ	IU	1-cyclohexyl-3-[2-(2,4-dichlorophenyl)-1-(4-iodophenyl)-5-methylimidazol-4-yl]urea
DMOXHZJ	DE	Obesity

DMLPQ7E	ID	DMLPQ7E
DMLPQ7E	DN	Imidazole derivative 7
DMLPQ7E	HS	Patented
DMLPQ7E	SN	PMID26161824-Compound-89
DMLPQ7E	DT	Small molecular drug
DMLPQ7E	PC	11606083
DMLPQ7E	MW	522.4
DMLPQ7E	FM	C26H25Cl2N7O
DMLPQ7E	IC	InChI=1S/C26H25Cl2N7O/c1-18-24(26(36)33(2)34-15-4-3-5-16-34)31-25(22-13-10-20(27)17-23(22)28)35(18)21-11-8-19(9-12-21)7-6-14-30-32-29/h8-13,17H,3-5,14-16H2,1-2H3
DMLPQ7E	CS	CC1=C(N=C(N1C2=CC=C(C=C2)C#CCN=[N+]=[N-])C3=C(C=C(C=C3)Cl)Cl)C(=O)N(C)N4CCCCC4
DMLPQ7E	IK	ZHBIOSWRXRWSAO-UHFFFAOYSA-N
DMLPQ7E	IU	1-[4-(3-azidoprop-1-ynyl)phenyl]-2-(2,4-dichlorophenyl)-N,5-dimethyl-N-piperidin-1-ylimidazole-4-carboxamide
DMLPQ7E	DE	Obesity

DMK9P7S	ID	DMK9P7S
DMK9P7S	DN	Imidazole derivative 8
DMK9P7S	HS	Patented
DMK9P7S	SN	PMID28699813-Compound-16
DMK9P7S	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMK9P7S	DT	Small molecular drug
DMK9P7S	PC	54670731
DMK9P7S	MW	444
DMK9P7S	FM	C26H26ClN5
DMK9P7S	IC	InChI=1S/C26H26ClN5/c27-22-9-7-21(8-10-22)25-30-23(24(31-25)26-28-14-4-15-29-26)20-12-17-32(18-13-20)16-11-19-5-2-1-3-6-19/h1-10,14-15,20H,11-13,16-18H2,(H,30,31)
DMK9P7S	CS	C1CN(CCC1C2=C(N=C(N2)C3=CC=C(C=C3)Cl)C4=NC=CC=N4)CCC5=CC=CC=C5
DMK9P7S	IK	CQQKTUASFMHQMA-UHFFFAOYSA-N
DMK9P7S	IU	2-[2-(4-chlorophenyl)-5-[1-(2-phenylethyl)piperidin-4-yl]-1H-imidazol-4-yl]pyrimidine

DMSV42L	ID	DMSV42L
DMSV42L	DN	Imidazole derivative 9
DMSV42L	HS	Patented
DMSV42L	SN	PMID28699813-Compound-H
DMSV42L	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMSV42L	DT	Small molecular drug

DM7UMW2	ID	DM7UMW2
DM7UMW2	DN	Imidazoleisoindoles derivative 1
DM7UMW2	HS	Patented
DM7UMW2	SN	PMID29473428-Compound-36
DM7UMW2	CP	HANGZHOU INNOGATE PHARMA CO., LTD
DM7UMW2	DT	Small molecular drug
DM7UMW2	PC	122628163
DM7UMW2	MW	342.4
DM7UMW2	FM	C20H23FN2O2
DM7UMW2	IC	InChI=1S/C20H23FN2O2/c21-14-3-1-2-13-16-11-22-12-23(16)15(18(13)14)10-17(24)19-4-7-20(25,8-5-19)9-6-19/h1-3,11-12,15,17,24-25H,4-10H2
DM7UMW2	CS	C1CC2(CCC1(CC2)C(CC3C4=C(C=CC=C4F)C5=CN=CN35)O)O
DM7UMW2	IK	IUJILQYRZOXDQY-UHFFFAOYSA-N
DM7UMW2	IU	4-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]bicyclo[2.2.2]octan-1-ol

DMRJKIQ	ID	DMRJKIQ
DMRJKIQ	DN	Imidazoleisoindoles derivative 2
DMRJKIQ	HS	Patented
DMRJKIQ	SN	PMID29473428-Compound-37
DMRJKIQ	CP	HANGZHOU INNOGATE PHARMA CO., LTD
DMRJKIQ	DT	Small molecular drug
DMRJKIQ	PC	122498962
DMRJKIQ	MW	368.4
DMRJKIQ	FM	C22H25FN2O2
DMRJKIQ	IC	InChI=1S/C22H25FN2O2/c23-16-3-1-2-15-18-10-24-11-25(18)17(20(15)16)6-19(26)22-7-12-4-13(8-22)21(27)14(5-12)9-22/h1-3,10-14,17,19,21,26-27H,4-9H2
DMRJKIQ	CS	C1C2CC3CC(C2)(CC1C3O)C(CC4C5=C(C=CC=C5F)C6=CN=CN46)O
DMRJKIQ	IK	SPKRAWSVCLOAAN-UHFFFAOYSA-N
DMRJKIQ	IU	5-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]adamantan-2-ol

DMECJDM	ID	DMECJDM
DMECJDM	DN	Imidazolidine derivative 1
DMECJDM	HS	Patented
DMECJDM	SN	PMID27724045-Compound-1
DMECJDM	CP	GSK
DMECJDM	DT	Small molecular drug
DMECJDM	PC	25097731
DMECJDM	MW	413.8
DMECJDM	FM	C17H15ClF3N5O2
DMECJDM	IC	InChI=1S/C17H15ClF3N5O2/c1-25-12(9-26(16(25)28)15-22-6-3-7-23-15)14(27)24-8-10-4-2-5-11(13(10)18)17(19,20)21/h2-7,12H,8-9H2,1H3,(H,24,27)
DMECJDM	CS	CN1C(CN(C1=O)C2=NC=CC=N2)C(=O)NCC3=C(C(=CC=C3)C(F)(F)F)Cl
DMECJDM	IK	VEJSCJTUSBXATQ-UHFFFAOYSA-N
DMECJDM	IU	N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-3-methyl-2-oxo-1-pyrimidin-2-ylimidazolidine-4-carboxamide

DMUFSQ2	ID	DMUFSQ2
DMUFSQ2	DN	Imidazolidine-2,4-dione derivative 1
DMUFSQ2	HS	Patented
DMUFSQ2	SN	PMID26161824-Compound-175
DMUFSQ2	DT	Small molecular drug
DMUFSQ2	PC	58257169
DMUFSQ2	MW	430.6
DMUFSQ2	FM	C26H26N2O2S
DMUFSQ2	IC	InChI=1S/C26H26N2O2S/c1-26(2)24(29)28(22-14-9-15-23(17-22)31-3)25(30)27(26)18-21-13-8-7-12-20(21)16-19-10-5-4-6-11-19/h4-15,17H,16,18H2,1-3H3
DMUFSQ2	CS	CC1(C(=O)N(C(=O)N1CC2=CC=CC=C2CC3=CC=CC=C3)C4=CC(=CC=C4)SC)C
DMUFSQ2	IK	WURWRZROHLTLFU-UHFFFAOYSA-N
DMUFSQ2	IU	1-[(2-benzylphenyl)methyl]-5,5-dimethyl-3-(3-methylsulfanylphenyl)imidazolidine-2,4-dione
DMUFSQ2	DE	Obesity

DMVMD2O	ID	DMVMD2O
DMVMD2O	DN	Imidazolidine-2,4-dione derivative 2
DMVMD2O	HS	Patented
DMVMD2O	SN	PMID26161824-Compound-176
DMVMD2O	DT	Small molecular drug
DMVMD2O	DE	Obesity

DM847I2	ID	DM847I2
DM847I2	DN	Imidazolyl urea derivative 1
DM847I2	HS	Patented
DM847I2	SN	PMID26413912-Compound-56
DM847I2	CP	NORTHEASTERN UNIVERSITY MAKRIYANNIS, Alexandros PANDARINATHAN, Lakshimpathi ZVONOK, Nikolai PARKKARI, Teija CHAPMAN, Lauren
DM847I2	DT	Small molecular drug
DM847I2	PC	44252357
DM847I2	MW	291.77
DM847I2	FM	C15H18ClN3O
DM847I2	IC	InChI=1S/C15H18ClN3O/c1-18(10-6-5-9-16)15(20)19-11-14(17-12-19)13-7-3-2-4-8-13/h2-4,7-8,11-12H,5-6,9-10H2,1H3
DM847I2	CS	CN(CCCCCl)C(=O)N1C=C(N=C1)C2=CC=CC=C2
DM847I2	IK	ULOIHJOBJLPNOI-UHFFFAOYSA-N
DM847I2	IU	N-(4-chlorobutyl)-N-methyl-4-phenylimidazole-1-carboxamide

DMEY6L8	ID	DMEY6L8
DMEY6L8	DN	Imidazopyridazine derivative 1
DMEY6L8	HS	Patented
DMEY6L8	SN	PMID27774824-Compound-Figure5Example1
DMEY6L8	CP	BRISTOL-MYERS SQUIBB COMPANY
DMEY6L8	DT	Small molecular drug

DMZORKY	ID	DMZORKY
DMZORKY	DN	Imidazopyridazine derivative 2
DMZORKY	HS	Patented
DMZORKY	SN	PMID27774824-Compound-Figure5Example75
DMZORKY	CP	BRISTOL-MYERS SQUIBB COMPANY
DMZORKY	DT	Small molecular drug

DMXVOP3	ID	DMXVOP3
DMXVOP3	DN	Imidazopyridazine derivative 3
DMXVOP3	HS	Patented
DMXVOP3	SN	PMID26936077-Compound-41
DMXVOP3	DT	Small molecular drug
DMXVOP3	PC	16000598
DMXVOP3	MW	480.9
DMXVOP3	FM	C22H20ClF3N4O3
DMXVOP3	IC	InChI=1S/C22H20ClF3N4O3/c1-2-33-21(32)14-7-9-29(10-8-14)20(31)17-12-19-27-16(13-3-5-15(23)6-4-13)11-18(22(24,25)26)30(19)28-17/h3-6,11-12,14H,2,7-10H2,1H3
DMXVOP3	CS	CCOC(=O)C1CCN(CC1)C(=O)C2=NN3C(=CC(=NC3=C2)C4=CC=C(C=C4)Cl)C(F)(F)F
DMXVOP3	IK	GQAPMAOCKZPCGZ-UHFFFAOYSA-N
DMXVOP3	IU	ethyl 1-[5-(4-chlorophenyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carbonyl]piperidine-4-carboxylate
DMXVOP3	DE	Pain; Inflammation

DMIAJMO	ID	DMIAJMO
DMIAJMO	DN	Imidazopyridazine derivative 4
DMIAJMO	HS	Patented
DMIAJMO	SN	PMID26936077-Compound-42
DMIAJMO	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMIAJMO	DT	Small molecular drug
DMIAJMO	PC	117977934
DMIAJMO	MW	423.5
DMIAJMO	FM	C23H26FN5O2
DMIAJMO	IC	InChI=1S/C23H26FN5O2/c1-22(2,3)16-12-17(14-6-8-15(24)9-7-14)27-29-13-18(26-19(16)29)20(30)28-11-10-25-21(31)23(28,4)5/h6-9,12-13H,10-11H2,1-5H3,(H,25,31)
DMIAJMO	CS	CC1(C(=O)NCCN1C(=O)C2=CN3C(=N2)C(=CC(=N3)C4=CC=C(C=C4)F)C(C)(C)C)C
DMIAJMO	IK	DTASTQAQBOZSRR-UHFFFAOYSA-N
DMIAJMO	IU	4-[8-tert-butyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazin-2-one
DMIAJMO	DE	Pain; Inflammation

DM9SXYH	ID	DM9SXYH
DM9SXYH	DN	Imidazopyridazine derivative 5
DM9SXYH	HS	Patented
DM9SXYH	SN	PMID26936077-Compound-43
DM9SXYH	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM9SXYH	DT	Small molecular drug
DM9SXYH	PC	91667550
DM9SXYH	MW	503.6
DM9SXYH	FM	C27H30FN7O2
DM9SXYH	IC	InChI=1S/C27H30FN7O2/c1-26(2,3)19-14-21(17-6-8-18(28)9-7-17)32-35-15-22(30-23(19)35)25(37)34-13-12-33(16-27(34,4)5)24(36)20-10-11-29-31-20/h6-11,14-15H,12-13,16H2,1-5H3,(H,29,31)
DM9SXYH	CS	CC1(CN(CCN1C(=O)C2=CN3C(=N2)C(=CC(=N3)C4=CC=C(C=C4)F)C(C)(C)C)C(=O)C5=CC=NN5)C
DM9SXYH	IK	DUTWPNVXOWFNEY-UHFFFAOYSA-N
DM9SXYH	IU	[4-[8-tert-butyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazin-1-yl]-(1H-pyrazol-5-yl)methanone
DM9SXYH	DE	Pain; Inflammation

DM5F1LR	ID	DM5F1LR
DM5F1LR	DN	Imidazopyridazine derivative 6
DM5F1LR	HS	Patented
DM5F1LR	SN	PMID26936077-Compound-44
DM5F1LR	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM5F1LR	DT	Small molecular drug
DM5F1LR	DE	Pain; Inflammation

DM5X160	ID	DM5X160
DM5X160	DN	Imidazopyridazine derivative 7
DM5X160	HS	Patented
DM5X160	SN	PMID26936077-Compound-45
DM5X160	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM5X160	DT	Small molecular drug
DM5X160	PC	117977937
DM5X160	MW	473.5
DM5X160	FM	C24H26F3N5O2
DM5X160	IC	InChI=1S/C24H26F3N5O2/c1-22(2,3)16-12-17(14-6-8-15(9-7-14)24(25,26)27)30-32-13-18(29-19(16)32)20(33)31-11-10-28-21(34)23(31,4)5/h6-9,12-13H,10-11H2,1-5H3,(H,28,34)
DM5X160	CS	CC1(C(=O)NCCN1C(=O)C2=CN3C(=N2)C(=CC(=N3)C4=CC=C(C=C4)C(F)(F)F)C(C)(C)C)C
DM5X160	IK	GVNHDAXNAQFWSN-UHFFFAOYSA-N
DM5X160	IU	4-[8-tert-butyl-6-[4-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazin-2-one
DM5X160	DE	Pain; Inflammation

DMF7NXJ	ID	DMF7NXJ
DMF7NXJ	DN	Imidazopyridazine derivative 8
DMF7NXJ	HS	Patented
DMF7NXJ	SN	PMID26936077-Compound-46
DMF7NXJ	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMF7NXJ	DT	Small molecular drug
DMF7NXJ	PC	117978132
DMF7NXJ	MW	518.6
DMF7NXJ	FM	C27H31FN8O2
DMF7NXJ	IC	InChI=1S/C27H31FN8O2/c1-16-29-22(32-31-16)25(38)34-11-12-35(27(5,6)15-34)24(37)21-14-36-23(30-21)19(26(2,3)4)13-20(33-36)17-7-9-18(28)10-8-17/h7-10,13-14H,11-12,15H2,1-6H3,(H,29,31,32)
DMF7NXJ	CS	CC1=NC(=NN1)C(=O)N2CCN(C(C2)(C)C)C(=O)C3=CN4C(=N3)C(=CC(=N4)C5=CC=C(C=C5)F)C(C)(C)C
DMF7NXJ	IK	DWEGVIUHJKAMGX-UHFFFAOYSA-N
DMF7NXJ	IU	[8-tert-butyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazin-2-yl]-[2,2-dimethyl-4-(5-methyl-1H-1,2,4-triazole-3-carbonyl)piperazin-1-yl]methanone
DMF7NXJ	DE	Pain; Inflammation

DMO41ZB	ID	DMO41ZB
DMO41ZB	DN	Imidazopyridine acetamide analog 1
DMO41ZB	HS	Patented
DMO41ZB	SN	PMID27607364-Compound-109
DMO41ZB	DT	Small molecular drug

DMIKMBO	ID	DMIKMBO
DMIKMBO	DN	Imidazopyridine acetamide analog 2
DMIKMBO	HS	Patented
DMIKMBO	SN	PMID27607364-Compound-110
DMIKMBO	DT	Small molecular drug

DMZ08LD	ID	DMZ08LD
DMZ08LD	DN	Imidazopyridine acetamide analog 3
DMZ08LD	HS	Patented
DMZ08LD	SN	PMID27607364-Compound-111
DMZ08LD	DT	Small molecular drug

DMPHK87	ID	DMPHK87
DMPHK87	DN	Imidazopyridine acetamide analog 4
DMPHK87	HS	Patented
DMPHK87	SN	PMID27607364-Compound-112
DMPHK87	DT	Small molecular drug

DMMFCRU	ID	DMMFCRU
DMMFCRU	DN	Imidazopyridine acetamide analog 5
DMMFCRU	HS	Patented
DMMFCRU	SN	PMID27607364-Compound-113
DMMFCRU	DT	Small molecular drug

DME7M5R	ID	DME7M5R
DME7M5R	DN	Imidazopyridine acetamide analog 6
DME7M5R	HS	Patented
DME7M5R	SN	PMID27607364-Compound-114
DME7M5R	DT	Small molecular drug

DMQDA3I	ID	DMQDA3I
DMQDA3I	DN	Imidazopyridine acetamide analog 7
DMQDA3I	HS	Patented
DMQDA3I	SN	PMID27607364-Compound-115
DMQDA3I	DT	Small molecular drug

DMTUS0Y	ID	DMTUS0Y
DMTUS0Y	DN	Imidazopyridine and triazolopyridine compound 1
DMTUS0Y	HS	Patented
DMTUS0Y	SN	PMID28067079-Compound-105
DMTUS0Y	CP	VANDERBILT UNIVERSITY
DMTUS0Y	DT	Small molecular drug
DMTUS0Y	PC	118103874
DMTUS0Y	MW	367.3
DMTUS0Y	FM	C18H11F2N5O2
DMTUS0Y	IC	InChI=1S/C18H11F2N5O2/c19-11-1-2-16(23-8-11)24-18(26)15-6-14(10-25-4-3-22-17(15)25)27-13-5-12(20)7-21-9-13/h1-10H,(H,23,24,26)
DMTUS0Y	CS	C1=CC(=NC=C1F)NC(=O)C2=CC(=CN3C2=NC=C3)OC4=CC(=CN=C4)F
DMTUS0Y	IK	GVUNIJCXLHRUNZ-UHFFFAOYSA-N
DMTUS0Y	IU	N-(5-fluoropyridin-2-yl)-6-(5-fluoropyridin-3-yl)oxyimidazo[1,2-a]pyridine-8-carboxamide

DMYCLAM	ID	DMYCLAM
DMYCLAM	DN	Imidazopyridine and triazolopyridine compound 2
DMYCLAM	HS	Patented
DMYCLAM	SN	PMID28067079-Compound-106
DMYCLAM	CP	VANDERBILT UNIVERSITY
DMYCLAM	DT	Small molecular drug
DMYCLAM	PC	118096899
DMYCLAM	MW	368.3
DMYCLAM	FM	C17H10F2N6O2
DMYCLAM	IC	InChI=1S/C17H10F2N6O2/c18-10-1-2-15(21-6-10)23-17(26)14-4-13(8-25-9-22-24-16(14)25)27-12-3-11(19)5-20-7-12/h1-9H,(H,21,23,26)
DMYCLAM	CS	C1=CC(=NC=C1F)NC(=O)C2=CC(=CN3C2=NN=C3)OC4=CC(=CN=C4)F
DMYCLAM	IK	LDLCJJXQJNSUAB-UHFFFAOYSA-N
DMYCLAM	IU	N-(5-fluoropyridin-2-yl)-6-(5-fluoropyridin-3-yl)oxy-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide

DMWU8VM	ID	DMWU8VM
DMWU8VM	DN	Imidazopyridine and triazolopyridine compound 3
DMWU8VM	HS	Patented
DMWU8VM	SN	PMID28067079-Compound-107
DMWU8VM	CP	VANDERBILT UNIVERSITY
DMWU8VM	DT	Small molecular drug
DMWU8VM	PC	91799365
DMWU8VM	MW	368.3
DMWU8VM	FM	C17H10F2N6O2
DMWU8VM	IC	InChI=1S/C17H10F2N6O2/c18-10-1-2-15(21-6-10)24-17(26)14-4-13(8-25-16(14)22-9-23-25)27-12-3-11(19)5-20-7-12/h1-9H,(H,21,24,26)
DMWU8VM	CS	C1=CC(=NC=C1F)NC(=O)C2=CC(=CN3C2=NC=N3)OC4=CC(=CN=C4)F
DMWU8VM	IK	UQYDLTVGUNGXDW-UHFFFAOYSA-N
DMWU8VM	IU	N-(5-fluoropyridin-2-yl)-6-(5-fluoropyridin-3-yl)oxy-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide

DMI1OWK	ID	DMI1OWK
DMI1OWK	DN	Imidazopyridine and triazolopyridine compound 4
DMI1OWK	HS	Patented
DMI1OWK	SN	PMID28067079-Compound-108
DMI1OWK	CP	VANDERBILT UNIVERSITY
DMI1OWK	DT	Small molecular drug
DMI1OWK	PC	118096900
DMI1OWK	MW	351.29
DMI1OWK	FM	C16H10FN7O2
DMI1OWK	IC	InChI=1S/C16H10FN7O2/c17-10-1-2-14(20-4-10)23-16(25)13-3-11(7-24-15(13)21-9-22-24)26-12-5-18-8-19-6-12/h1-9H,(H,20,23,25)
DMI1OWK	CS	C1=CC(=NC=C1F)NC(=O)C2=CC(=CN3C2=NC=N3)OC4=CN=CN=C4
DMI1OWK	IK	CBMXXEDRQZKTGZ-UHFFFAOYSA-N
DMI1OWK	IU	N-(5-fluoropyridin-2-yl)-6-pyrimidin-5-yloxy-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide

DM8EB57	ID	DM8EB57
DM8EB57	DN	Imidazopyridine derivative 1
DM8EB57	HS	Patented
DM8EB57	SN	PMID27607364-Compound-107
DM8EB57	CP	AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION THE UNIVERSITY OF SYDNE
DM8EB57	DT	Small molecular drug

DM9FRV7	ID	DM9FRV7
DM9FRV7	DN	Imidazopyridine derivative 2
DM9FRV7	HS	Patented
DM9FRV7	SN	PMID27607364-Compound-108
DM9FRV7	CP	AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION THE UNIVERSITY OF SYDNEY
DM9FRV7	DT	Small molecular drug

DMJCSL3	ID	DMJCSL3
DMJCSL3	DN	Imidazopyridine derivative 3
DMJCSL3	HS	Patented
DMJCSL3	SN	PMID27774822-Compound-Figure7Example2
DMJCSL3	CP	F. HOFFMANN-LA ROCHE AG LAI, Yingjie LIANG, Jun MAGNUSON, Steven, R. ROBARGE, Kirk, D. TSUI, Vickie, Hsaio-Wei ZHANG, Birong
DMJCSL3	DT	Small molecular drug

DMP2AXV	ID	DMP2AXV
DMP2AXV	DN	Imidazopyridine derivative 4
DMP2AXV	HS	Patented
DMP2AXV	SN	PMID27774824-Compound-Figure12Example14
DMP2AXV	CP	HANMI PHARM. CO., LTD
DMP2AXV	DT	Small molecular drug

DMUKBGD	ID	DMUKBGD
DMUKBGD	DN	Imidazopyridine derivative 5
DMUKBGD	HS	Patented
DMUKBGD	SN	PMID28627961-Compound-14
DMUKBGD	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri HAUEL, Norbert KLINDER, Klaus KUELZER, Raimund
DMUKBGD	DT	Small molecular drug
DMUKBGD	PC	45137506
DMUKBGD	MW	481.3
DMUKBGD	FM	C20H13Cl2F3N6O
DMUKBGD	IC	InChI=1S/C20H13Cl2F3N6O/c1-31-15-9-27-14(18(32)29-16-7-10(5-6-26-16)20(23,24)25)8-13(15)28-19(31)30-17-11(21)3-2-4-12(17)22/h2-9H,1H3,(H,28,30)(H,26,29,32)
DMUKBGD	CS	CN1C2=CN=C(C=C2N=C1NC3=C(C=CC=C3Cl)Cl)C(=O)NC4=NC=CC(=C4)C(F)(F)F
DMUKBGD	IK	STCXSHUPLPUMJZ-UHFFFAOYSA-N
DMUKBGD	IU	2-(2,6-dichloroanilino)-3-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]imidazo[4,5-c]pyridine-6-carboxamide

DMA0V4F	ID	DMA0V4F
DMA0V4F	DN	Imidazopyridine derivative 6
DMA0V4F	HS	Patented
DMA0V4F	SN	PMID28627961-Compound-15
DMA0V4F	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri HAUEL, Norbert KLINDER, Klaus KUELZER, Raimund
DMA0V4F	DT	Small molecular drug
DMA0V4F	PC	45138740
DMA0V4F	MW	570.3
DMA0V4F	FM	C23H17BrF5N5O2
DMA0V4F	IC	InChI=1S/C23H17BrF5N5O2/c1-34-19-17(32-22(34)31-16-5-3-2-4-15(16)23(27,28)29)10-14(21(33-19)36-11-18(25)26)20(35)30-13-8-6-12(24)7-9-13/h2-10,18H,11H2,1H3,(H,30,35)(H,31,32)
DMA0V4F	CS	CN1C2=C(C=C(C(=N2)OCC(F)F)C(=O)NC3=CC=C(C=C3)Br)N=C1NC4=CC=CC=C4C(F)(F)F
DMA0V4F	IK	KPWHFPJALLFSPY-UHFFFAOYSA-N
DMA0V4F	IU	N-(4-bromophenyl)-5-(2,2-difluoroethoxy)-3-methyl-2-[2-(trifluoromethyl)anilino]imidazo[4,5-b]pyridine-6-carboxamide

DMI3XPJ	ID	DMI3XPJ
DMI3XPJ	DN	Imidazopyridine derivative 7
DMI3XPJ	HS	Patented
DMI3XPJ	SN	PMID28627961-Compound-16
DMI3XPJ	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PRIEPKE, Henning DOODS, Henri KUELZER, Raimund PFAU, Roland STENKAMP, Dirk PELCMAN, Benjamin ROENN, Robert LUBRIKS, Dimitrijs SUNA, Edgars
DMI3XPJ	DT	Small molecular drug

DMWN17V	ID	DMWN17V
DMWN17V	DN	Imidazopyrimidinone derivative 1
DMWN17V	HS	Patented
DMWN17V	SN	PMID28447479-Compound-5
DMWN17V	DT	Small molecular drug
DMWN17V	PC	118631422
DMWN17V	MW	486
DMWN17V	FM	C24H28ClN5O4
DMWN17V	IC	InChI=1S/C24H28ClN5O4/c1-2-3-4-11-29-20(28-12-5-6-19(28)23(34)26-14-22(32)33)13-21(31)30-15-18(27-24(29)30)16-7-9-17(25)10-8-16/h7-10,13,15,19H,2-6,11-12,14H2,1H3,(H,26,34)(H,32,33)/t19-/m0/s1
DMWN17V	CS	CCCCCN1C(=CC(=O)N2C1=NC(=C2)C3=CC=C(C=C3)Cl)N4CCC[C@H]4C(=O)NCC(=O)O
DMWN17V	IK	VHDLUVVGLIPRGY-IBGZPJMESA-N
DMWN17V	IU	2-[[(2S)-1-[2-(4-chlorophenyl)-5-oxo-8-pentylimidazo[1,2-a]pyrimidin-7-yl]pyrrolidine-2-carbonyl]amino]acetic acid

DMX34PU	ID	DMX34PU
DMX34PU	DN	Imidazotriazinone derivative 1
DMX34PU	HS	Patented
DMX34PU	SN	PMID27321640-Compound-12
DMX34PU	CP	BAYER AG [DE]
DMX34PU	DT	Small molecular drug

DMBURAZ	ID	DMBURAZ
DMBURAZ	DN	IncarviatoneA
DMBURAZ	HS	Patented
DMBURAZ	CP	Nanjing Zhengliang Med. Tech. CO

DMA6BCH	ID	DMA6BCH
DMA6BCH	DN	Indandione derivative 1
DMA6BCH	HS	Patented
DMA6BCH	SN	PMID27788040-Compound-3a
DMA6BCH	CP	ACTELION PHARMACEUTICALS LTD FRETZ, Heinz GATFIELD, John ISLER, Markus KIMMERLIN, Thierry KOBERSTEIN, Ralf LYOTHIER, Isabelle MONNIER, Lucile POTHIER, Julien VALDENAIRE, Anja
DMA6BCH	DT	Small molecular drug
DMA6BCH	PC	8088007
DMA6BCH	MW	396.5
DMA6BCH	FM	C26H24N2O2
DMA6BCH	IC	InChI=1S/C26H24N2O2/c29-24-22-13-7-8-14-23(22)25(30)26(24,21-11-5-2-6-12-21)28-17-15-27(16-18-28)19-20-9-3-1-4-10-20/h1-14H,15-19H2
DMA6BCH	CS	C1CN(CCN1CC2=CC=CC=C2)C3(C(=O)C4=CC=CC=C4C3=O)C5=CC=CC=C5
DMA6BCH	IK	NYQQLNFEZNJIIX-UHFFFAOYSA-N
DMA6BCH	IU	2-(4-benzylpiperazin-1-yl)-2-phenylindene-1,3-dione

DMVR04K	ID	DMVR04K
DMVR04K	DN	Indandione derivative 2
DMVR04K	HS	Patented
DMVR04K	SN	PMID27788040-Compound-3b
DMVR04K	CP	ACTELION PHARMACEUTICALS LTD FRETZ, Heinz GATFIELD, John ISLER, Markus KIMMERLIN, Thierry KOBERSTEIN, Ralf LYOTHIER, Isabelle MONNIER, Lucile POTHIER, Julien VALDENAIRE, Anja
DMVR04K	DT	Small molecular drug
DMVR04K	PC	89560333
DMVR04K	MW	410.5
DMVR04K	FM	C27H26N2O2
DMVR04K	IC	InChI=1S/C27H26N2O2/c1-20-9-5-6-10-21(20)19-28-15-17-29(18-16-28)27(22-11-3-2-4-12-22)25(30)23-13-7-8-14-24(23)26(27)31/h2-14H,15-19H2,1H3
DMVR04K	CS	CC1=CC=CC=C1CN2CCN(CC2)C3(C(=O)C4=CC=CC=C4C3=O)C5=CC=CC=C5
DMVR04K	IK	SOPZMNPHLBGVQQ-UHFFFAOYSA-N
DMVR04K	IU	2-[4-[(2-methylphenyl)methyl]piperazin-1-yl]-2-phenylindene-1,3-dione

DM0TURE	ID	DM0TURE
DM0TURE	DN	Indandione derivative 3
DM0TURE	HS	Patented
DM0TURE	SN	PMID27788040-Compound-3c
DM0TURE	CP	ACTELION PHARMACEUTICALS LTD FRETZ, Heinz GATFIELD, John ISLER, Markus KIMMERLIN, Thierry KOBERSTEIN, Ralf LYOTHIER, Isabelle MONNIER, Lucile POTHIER, Julien VALDENAIRE, Anja
DM0TURE	DT	Small molecular drug
DM0TURE	PC	89559486
DM0TURE	MW	426.5
DM0TURE	FM	C27H26N2O3
DM0TURE	IC	InChI=1S/C27H26N2O3/c1-32-24-14-8-5-9-20(24)19-28-15-17-29(18-16-28)27(21-10-3-2-4-11-21)25(30)22-12-6-7-13-23(22)26(27)31/h2-14H,15-19H2,1H3
DM0TURE	CS	COC1=CC=CC=C1CN2CCN(CC2)C3(C(=O)C4=CC=CC=C4C3=O)C5=CC=CC=C5
DM0TURE	IK	DLIPFFRYKOCUMK-UHFFFAOYSA-N
DM0TURE	IU	2-[4-[(2-methoxyphenyl)methyl]piperazin-1-yl]-2-phenylindene-1,3-dione

DMQPTEJ	ID	DMQPTEJ
DMQPTEJ	DN	Indanone and indandione derivative 1
DMQPTEJ	HS	Patented
DMQPTEJ	SN	PMID27788040-Compound-3
DMQPTEJ	CP	ACTELION PHARMACEUTICALS LTD FRETZ, Heinz GATFIELD, John ISLER, Markus KIMMERLIN, Thierry KOBERSTEIN, Ralf LYOTHIER, Isabelle MONNIER, Lucile POTHIER, Julien VALDENAIRE, Anja
DMQPTEJ	DT	Small molecular drug

DMKUT6S	ID	DMKUT6S
DMKUT6S	DN	Indazole amide derivative 1
DMKUT6S	HS	Patented
DMKUT6S	SN	PMID27310003-Compound-13
DMKUT6S	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMKUT6S	DT	Small molecular drug

DMRPT5O	ID	DMRPT5O
DMRPT5O	DN	Indazole amide derivative 2
DMRPT5O	HS	Patented
DMRPT5O	SN	PMID27310003-Compound-14
DMRPT5O	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMRPT5O	DT	Small molecular drug

DME8JTW	ID	DME8JTW
DME8JTW	DN	Indazole derivative 1
DME8JTW	HS	Patented
DME8JTW	SN	PMID25684022-Compound-WO2003064397
DME8JTW	CP	VERTEX PHARMACEUTICALS INCORPORATED BINCH, Hayley BRENCHLEY, Guy GOLEC, Julian, M., C. KNEGTEL, Ronald MORTIMORE, Michael PATEL, Sanjay RUTHERFORD, Alistair
DME8JTW	DT	Small molecular drug
DME8JTW	DE	Solid tumour/cancer; Metastatic cancer

DMV7AX9	ID	DMV7AX9
DMV7AX9	DN	Indazole derivative 2
DMV7AX9	HS	Patented
DMV7AX9	SN	PMID29473428-Compound-7
DMV7AX9	CP	IOMET PHARMA LTD
DMV7AX9	DT	Small molecular drug
DMV7AX9	PC	121326386
DMV7AX9	MW	342.8
DMV7AX9	FM	C14H19ClN4O2S
DMV7AX9	IC	InChI=1S/C14H19ClN4O2S/c1-14(2)9-18(4-5-19(14)22(3,20)21)13-7-10(15)6-12-11(13)8-16-17-12/h6-8H,4-5,9H2,1-3H3,(H,16,17)
DMV7AX9	CS	CC1(CN(CCN1S(=O)(=O)C)C2=CC(=CC3=C2C=NN3)Cl)C
DMV7AX9	IK	RJWPSUXKQOQTSP-UHFFFAOYSA-N
DMV7AX9	IU	6-chloro-4-(3,3-dimethyl-4-methylsulfonylpiperazin-1-yl)-1H-indazole

DMVUWLK	ID	DMVUWLK
DMVUWLK	DN	Indazole derivative 3
DMVUWLK	HS	Patented
DMVUWLK	SN	PMID29473428-Compound-8
DMVUWLK	CP	IOMET PHARMA LTD
DMVUWLK	DT	Small molecular drug
DMVUWLK	PC	121326772
DMVUWLK	MW	347.8
DMVUWLK	FM	C16H18ClN5O2
DMVUWLK	IC	InChI=1S/C16H18ClN5O2/c1-15(2)8-22(4-3-16(15)13(23)19-14(24)20-16)12-6-9(17)5-11-10(12)7-18-21-11/h5-7H,3-4,8H2,1-2H3,(H,18,21)(H2,19,20,23,24)
DMVUWLK	CS	CC1(CN(CCC12C(=O)NC(=O)N2)C3=CC(=CC4=C3C=NN4)Cl)C
DMVUWLK	IK	JZDRNRKIZBGYLY-UHFFFAOYSA-N
DMVUWLK	IU	8-(6-chloro-1H-indazol-4-yl)-6,6-dimethyl-1,3,8-triazaspiro[4.5]decane-2,4-dione

DMJ2CRO	ID	DMJ2CRO
DMJ2CRO	DN	Indazole derivative 4
DMJ2CRO	HS	Patented
DMJ2CRO	SN	PMID29473428-Compound-9
DMJ2CRO	DT	Small molecular drug

DMM1I8R	ID	DMM1I8R
DMM1I8R	DN	Indazole derivative 5
DMM1I8R	HS	Patented
DMM1I8R	SN	PMID25656651-Compound-35
DMM1I8R	CP	PFIZER INC
DMM1I8R	DT	Small molecular drug
DMM1I8R	PC	6450551
DMM1I8R	MW	386.5
DMM1I8R	FM	C22H18N4OS
DMM1I8R	IC	InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
DMM1I8R	CS	CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
DMM1I8R	IK	RITAVMQDGBJQJZ-FMIVXFBMSA-N
DMM1I8R	IU	N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
DMM1I8R	CA	CAS 319460-85-0
DMM1I8R	CB	CHEBI:66910

DMGO1CB	ID	DMGO1CB
DMGO1CB	DN	Indazole derivative 6
DMGO1CB	HS	Patented
DMGO1CB	SN	PMID27828716-Compound-12
DMGO1CB	DT	Small molecular drug
DMGO1CB	PC	71680628
DMGO1CB	MW	428.5
DMGO1CB	FM	C23H26F2N4O2
DMGO1CB	IC	InChI=1S/C23H26F2N4O2/c1-31-12-11-29-9-7-15(8-10-29)14-26-23(30)22-18-13-16(5-6-20(18)27-28-22)17-3-2-4-19(24)21(17)25/h2-6,13,15H,7-12,14H2,1H3,(H,26,30)(H,27,28)
DMGO1CB	CS	COCCN1CCC(CC1)CNC(=O)C2=NNC3=C2C=C(C=C3)C4=C(C(=CC=C4)F)F
DMGO1CB	IK	QCLXNOBXQUWUEW-UHFFFAOYSA-N
DMGO1CB	IU	5-(2,3-difluorophenyl)-N-[[1-(2-methoxyethyl)piperidin-4-yl]methyl]-1H-indazole-3-carboxamide

DMHJDU6	ID	DMHJDU6
DMHJDU6	DN	Indazoletriazolephenyl derivative 1
DMHJDU6	HS	Patented
DMHJDU6	SN	PMID27310003-Compound-34
DMHJDU6	CP	MERCK SERONO S.A. JORAND-LEBRUN, Catherine CROSIGNANI, Stefano DORBAIS, Jerome GRIPPI-VALLOTTON, Tania PRETRE, Adeline
DMHJDU6	DT	Small molecular drug

DMWZLK6	ID	DMWZLK6
DMWZLK6	DN	Indazoletriazolephenyl derivative 2
DMWZLK6	HS	Patented
DMWZLK6	SN	PMID27310003-Compound-35
DMWZLK6	CP	MERCK SERONO S.A. JORAND-LEBRUN, Catherine CROSIGNANI, Stefano DORBAIS, Jerome GRIPPI-VALLOTTON, Tania PRETRE, Adeline
DMWZLK6	DT	Small molecular drug

DMR2GW1	ID	DMR2GW1
DMR2GW1	DN	Indazolyl-thiadiazolamine derivative 1
DMR2GW1	HS	Patented
DMR2GW1	SN	PMID28048944-Compound-8
DMR2GW1	CP	LYCERA CORPORATION
DMR2GW1	DT	Small molecular drug
DMR2GW1	PC	122507561
DMR2GW1	MW	446.5
DMR2GW1	FM	C21H18N8O2S
DMR2GW1	IC	InChI=1S/C21H18N8O2S/c30-7-6-29-12-15(11-23-29)19(31)24-16-3-1-2-13(8-16)20-27-28-21(32-20)25-17-4-5-18-14(9-17)10-22-26-18/h1-5,8-12,30H,6-7H2,(H,22,26)(H,24,31)(H,25,28)
DMR2GW1	CS	C1=CC(=CC(=C1)NC(=O)C2=CN(N=C2)CCO)C3=NN=C(S3)NC4=CC5=C(C=C4)NN=C5
DMR2GW1	IK	QFQWUHMXGFJZJO-UHFFFAOYSA-N
DMR2GW1	IU	1-(2-hydroxyethyl)-N-[3-[5-(1H-indazol-5-ylamino)-1,3,4-thiadiazol-2-yl]phenyl]pyrazole-4-carboxamide

DMB8673	ID	DMB8673
DMB8673	DN	Indirubin derivative 1
DMB8673	HS	Patented
DMB8673	SN	PMID26394986-Compound-58
DMB8673	CP	City of Hope, Durate, CA
DMB8673	DT	Small molecular drug

DMLX183	ID	DMLX183
DMLX183	DN	Indirubin derivative 2
DMLX183	HS	Patented
DMLX183	SN	PMID27828716-Compound-BIO
DMLX183	CP	KATHOLIEKE UNIVERSITEIT LEUVEN VRIJE UNIVERSITEIT BRUSSEL UNIVERSITY OF STRATHCLYDE SALAMA NEUROSCIENCE CENTRCELLARTIS AB [SESTEM CELLS FOR SAFER MEDICINES LIMITED BONE, Heather Karyn TOSH, David WELHAM, Melanie Joann
DMLX183	DT	Small molecular drug

DM5F8J1	ID	DM5F8J1
DM5F8J1	DN	Indol-5-ol derivative 1
DM5F8J1	HS	Patented
DM5F8J1	SN	PMID25656651-Compound-41
DM5F8J1	CP	NANT HOLDINGS IP, LLC
DM5F8J1	DT	Small molecular drug
DM5F8J1	PC	74221651
DM5F8J1	MW	480.5
DM5F8J1	FM	C24H26F2N8O
DM5F8J1	IC	InChI=1S/C24H26F2N8O/c1-13-9-15-22(26)18(10-16(25)23(15)27-13)35-24-29-19(28-20-11-17(31-32-20)14-3-4-14)12-21(30-24)34-7-5-33(2)6-8-34/h9-12,14,27H,3-8H2,1-2H3,(H2,28,29,30,31,32)
DM5F8J1	CS	CC1=CC2=C(C(=CC(=C2N1)F)OC3=NC(=CC(=N3)N4CCN(CC4)C)NC5=NNC(=C5)C6CC6)F
DM5F8J1	IK	UUZGSTUXCIFCOJ-UHFFFAOYSA-N
DM5F8J1	IU	N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[(4,7-difluoro-2-methyl-1H-indol-5-yl)oxy]-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine

DMS0169	ID	DMS0169
DMS0169	DN	Indole and benzimidazole derivative 1
DMS0169	HS	Patented
DMS0169	SN	PMID26560362-Compound-15
DMS0169	DT	Small molecular drug
DMS0169	PC	10297819
DMS0169	MW	453.5
DMS0169	FM	C23H17F2N3O3S
DMS0169	IC	InChI=1S/C23H17F2N3O3S/c1-31-21-6-5-12(18-10-14-8-16(24)17(25)11-19(14)27-18)9-20(21)28-23(32)26-15-4-2-3-13(7-15)22(29)30/h2-11,27H,1H3,(H,29,30)(H2,26,28,32)
DMS0169	CS	COC1=C(C=C(C=C1)C2=CC3=CC(=C(C=C3N2)F)F)NC(=S)NC4=CC=CC(=C4)C(=O)O
DMS0169	IK	WDBLIHVXAGLYCZ-UHFFFAOYSA-N
DMS0169	IU	3-[[5-(5,6-difluoro-1H-indol-2-yl)-2-methoxyphenyl]carbamothioylamino]benzoic acid

DMLHGC9	ID	DMLHGC9
DMLHGC9	DN	Indole carboxamide derivative 1
DMLHGC9	HS	Patented
DMLHGC9	SN	PMID27724045-Compound-21
DMLHGC9	CP	ACTELION PHARMACEUTICALS LTD
DMLHGC9	DT	Small molecular drug

DMIGS81	ID	DMIGS81
DMIGS81	DN	Indole-based analog 1
DMIGS81	HS	Patented
DMIGS81	SN	PMID27744724-Compound-15
DMIGS81	CP	VANDERBILT UNIVERSITY
DMIGS81	DT	Small molecular drug

DMAM6YC	ID	DMAM6YC
DMAM6YC	DN	Indole-based analog 10
DMAM6YC	HS	Patented
DMAM6YC	SN	PMID27599163-Compound-(S)-70
DMAM6YC	CP	GE HEALTHCARE LIMITED
DMAM6YC	DT	Small molecular drug

DMVRX7S	ID	DMVRX7S
DMVRX7S	DN	Indole-based analog 11
DMVRX7S	HS	Patented
DMVRX7S	SN	PMID26161698-Compound-16
DMVRX7S	CP	GILEAD SCIENCES, INC. GRAUPE, Michael VENKATARAMANI, Chandrasekar
DMVRX7S	DT	Small molecular drug

DM1CNRH	ID	DM1CNRH
DM1CNRH	DN	Indole-based analog 12
DM1CNRH	HS	Patented
DM1CNRH	SN	PMID26161698-Compound-19
DM1CNRH	DT	Small molecular drug
DM1CNRH	PC	25164141
DM1CNRH	MW	352.4
DM1CNRH	FM	C24H20N2O
DM1CNRH	IC	InChI=1S/C24H20N2O/c27-24(21-12-5-4-10-18(21)17-8-2-1-3-9-17)26-15-14-20-19-11-6-7-13-22(19)25-23(20)16-26/h1-13,25H,14-16H2
DM1CNRH	CS	C1CN(CC2=C1C3=CC=CC=C3N2)C(=O)C4=CC=CC=C4C5=CC=CC=C5
DM1CNRH	IK	UCWAWBWZKYMCRY-UHFFFAOYSA-N
DM1CNRH	IU	(2-phenylphenyl)-(1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)methanone

DMV7DFM	ID	DMV7DFM
DMV7DFM	DN	Indole-based analog 13
DMV7DFM	HS	Patented
DMV7DFM	SN	PMID26161698-Compound-20
DMV7DFM	DT	Small molecular drug
DMV7DFM	PC	73293
DMV7DFM	MW	271.3
DMV7DFM	FM	C18H11N2O+
DMV7DFM	IC	InChI=1S/C18H10N2O/c21-18-13-6-2-4-8-15(13)20-10-9-12-11-5-1-3-7-14(11)19-16(12)17(18)20/h1-10H/p+1
DMV7DFM	CS	C1=CC=C2C(=C1)C3=C(N2)C4=[N+](C=C3)C5=CC=CC=C5C4=O
DMV7DFM	IK	WYQIPCUPNMRAKP-UHFFFAOYSA-O
DMV7DFM	IU	3-aza-13-azoniapentacyclo[11.7.0.02,10.04,9.014,19]icosa-1(13),2(10),4,6,8,11,14,16,18-nonaen-20-one
DMV7DFM	CB	CHEBI:93765

DMQURWZ	ID	DMQURWZ
DMQURWZ	DN	Indole-based analog 14
DMQURWZ	HS	Patented
DMQURWZ	SN	PMID27410995-Compound-Figure3a
DMQURWZ	DT	Small molecular drug
DMQURWZ	PC	53246690
DMQURWZ	MW	350.4
DMQURWZ	FM	C19H18N4O3
DMQURWZ	IC	InChI=1S/C19H18N4O3/c1-26-17-11-14(5-7-20-17)22-18(24)13-4-3-12-9-16-19(25)21-6-2-8-23(16)15(12)10-13/h3-5,7,9-11H,2,6,8H2,1H3,(H,21,25)(H,20,22,24)
DMQURWZ	CS	COC1=NC=CC(=C1)NC(=O)C2=CC3=C(C=C2)C=C4N3CCCNC4=O
DMQURWZ	IK	IGJVUIUYHUKAST-UHFFFAOYSA-N
DMQURWZ	IU	N-(2-methoxypyridin-4-yl)-1-oxo-2,3,4,5-tetrahydro-[1,4]diazepino[1,2-a]indole-8-carboxamide

DM0NEVC	ID	DM0NEVC
DM0NEVC	DN	Indole-based analog 2
DM0NEVC	HS	Patented
DM0NEVC	SN	PMID27744724-Compound-16
DM0NEVC	CP	VANDERBILT UNIVERSITY
DM0NEVC	DT	Small molecular drug

DMTEYQJ	ID	DMTEYQJ
DMTEYQJ	DN	Indole-based analog 3
DMTEYQJ	HS	Patented
DMTEYQJ	SN	PMID27744724-Compound-17
DMTEYQJ	CP	VANDERBILT UNIVERSITY
DMTEYQJ	DT	Small molecular drug

DM5JUR2	ID	DM5JUR2
DM5JUR2	DN	Indole-based analog 5
DM5JUR2	HS	Patented
DM5JUR2	SN	PMID27599163-Compound-(R)-56
DM5JUR2	CP	GE HEALTHCARE LIMITED
DM5JUR2	DT	Small molecular drug

DMFI2H6	ID	DMFI2H6
DMFI2H6	DN	Indole-based analog 9
DMFI2H6	HS	Patented
DMFI2H6	SN	PMID27599163-Compound-(S)-66
DMFI2H6	CP	GE HEALTHCARE LIMITED
DMFI2H6	DT	Small molecular drug

DMJ41UI	ID	DMJ41UI
DMJ41UI	DN	Indoline derivative 1
DMJ41UI	HS	Patented
DMJ41UI	SN	PMID29757691-Compound-1
DMJ41UI	DT	Small molecular drug
DMJ41UI	PC	46865499
DMJ41UI	MW	408.5
DMJ41UI	FM	C25H32N2O3
DMJ41UI	IC	InChI=1S/C25H32N2O3/c1-25(2)18-27(17-19-7-5-4-6-8-19)23-10-9-21(15-22(23)25)30-24(28)26(3)16-20-11-13-29-14-12-20/h4-10,15,20H,11-14,16-18H2,1-3H3
DMJ41UI	CS	CC1(CN(C2=C1C=C(C=C2)OC(=O)N(C)CC3CCOCC3)CC4=CC=CC=C4)C
DMJ41UI	IK	LZXDNQGOGJJABM-UHFFFAOYSA-N
DMJ41UI	IU	(1-benzyl-3,3-dimethyl-2H-indol-5-yl) N-methyl-N-(oxan-4-ylmethyl)carbamate

DMTPGRO	ID	DMTPGRO
DMTPGRO	DN	Indoline derivative 10
DMTPGRO	HS	Patented
DMTPGRO	SN	PMID27646439-Compound-18
DMTPGRO	CP	JANSSEN PHARMACEUTICA NV
DMTPGRO	DT	Small molecular drug
DMTPGRO	PC	86281829
DMTPGRO	MW	493.6
DMTPGRO	FM	C29H27N5O3
DMTPGRO	IC	InChI=1S/C29H27N5O3/c1-17-21(20-6-4-5-7-23(20)32-17)14-28(35)34-11-10-18-12-19(8-9-25(18)34)33-29-22-13-26(36-2)27(37-3)15-24(22)30-16-31-29/h4-9,12-13,15-16,32H,10-11,14H2,1-3H3,(H,30,31,33)
DMTPGRO	CS	CC1=C(C2=CC=CC=C2N1)CC(=O)N3CCC4=C3C=CC(=C4)NC5=NC=NC6=CC(=C(C=C65)OC)OC
DMTPGRO	IK	XPDZQQQJQXPBBO-UHFFFAOYSA-N
DMTPGRO	IU	1-[5-[(6,7-dimethoxyquinazolin-4-yl)amino]-2,3-dihydroindol-1-yl]-2-(2-methyl-1H-indol-3-yl)ethanone

DM6JR3X	ID	DM6JR3X
DM6JR3X	DN	Indoline derivative 11
DM6JR3X	HS	Patented
DM6JR3X	SN	PMID27646439-Compound-19
DM6JR3X	CP	JANSSEN PHARMACEUTICA NV
DM6JR3X	DT	Small molecular drug
DM6JR3X	PC	117636505
DM6JR3X	MW	523.4
DM6JR3X	FM	C24H23BrN6O3
DM6JR3X	IC	InChI=1S/C24H23BrN6O3/c1-30-20(17(25)12-28-30)11-23(32)31-7-6-14-8-15(4-5-19(14)31)29-24-16-9-21(33-2)22(34-3)10-18(16)26-13-27-24/h4-5,8-10,12-13H,6-7,11H2,1-3H3,(H,26,27,29)
DM6JR3X	CS	CN1C(=C(C=N1)Br)CC(=O)N2CCC3=C2C=CC(=C3)NC4=NC=NC5=CC(=C(C=C54)OC)OC
DM6JR3X	IK	KVVYJCRBQJOKHQ-UHFFFAOYSA-N
DM6JR3X	IU	2-(4-bromo-2-methylpyrazol-3-yl)-1-[5-[(6,7-dimethoxyquinazolin-4-yl)amino]-2,3-dihydroindol-1-yl]ethanone

DMJURBM	ID	DMJURBM
DMJURBM	DN	Indoline derivative 12
DMJURBM	HS	Patented
DMJURBM	SN	PMID28621580-Compound-WO2012088506c22
DMJURBM	CP	NEKTAR THERAPEUTICS RIGGS-SAUTHIER, Jennifer ALLUMS-DONALD, Stephanie CULBERTSON, Sean, M
DMJURBM	DT	Small molecular drug

DM982GD	ID	DM982GD
DM982GD	DN	Indoline derivative 13
DM982GD	HS	Patented
DM982GD	SN	PMID28621580-Compound-WO2012088506c23
DM982GD	CP	NEKTAR THERAPEUTICS RIGGS-SAUTHIER, Jennifer ALLUMS-DONALD, Stephanie CULBERTSON, Sean, M
DM982GD	DT	Small molecular drug

DM8DHRN	ID	DM8DHRN
DM8DHRN	DN	Indoline derivative 14
DM8DHRN	HS	Patented
DM8DHRN	SN	PMID28621580-Compound-WO2012139019c24
DM8DHRN	CP	BETA PHARMA, INC. ZHANG, Don XIE, Guojian
DM8DHRN	DT	Small molecular drug

DMRFEH4	ID	DMRFEH4
DMRFEH4	DN	Indoline derivative 15
DMRFEH4	HS	Patented
DMRFEH4	SN	PMID28621580-Compound-WO2012139019c25
DMRFEH4	CP	BETA PHARMA, INC. ZHANG, Don XIE, Guojian
DMRFEH4	DT	Small molecular drug

DM9AGBT	ID	DM9AGBT
DM9AGBT	DN	Indoline derivative 16
DM9AGBT	HS	Patented
DM9AGBT	SN	PMID28621580-Compound-WO2013037293c26
DM9AGBT	CP	HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD
DM9AGBT	DT	Small molecular drug

DMXSFJ8	ID	DMXSFJ8
DMXSFJ8	DN	Indoline derivative 17
DMXSFJ8	HS	Patented
DMXSFJ8	SN	PMID28621580-Compound-WO2014086102c28
DMXSFJ8	CP	KBP BIOSCIENCES CO., LTD
DMXSFJ8	DT	Small molecular drug

DMX640D	ID	DMX640D
DMX640D	DN	Indoline derivative 18
DMX640D	HS	Patented
DMX640D	SN	PMID28621580-Compound-WO2014086102c29
DMX640D	CP	KBP BIOSCIENCES CO., LTD
DMX640D	DT	Small molecular drug

DMOHITL	ID	DMOHITL
DMOHITL	DN	Indoline derivative 19
DMOHITL	HS	Patented
DMOHITL	SN	PMID28621580-Compound-WO2014102377c27
DMOHITL	CP	ORIBASE PHARMA
DMOHITL	DT	Small molecular drug

DMASXR5	ID	DMASXR5
DMASXR5	DN	Indoline derivative 2
DMASXR5	HS	Patented
DMASXR5	SN	PMID27646439-Compound-1
DMASXR5	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITEGLAXOSMITHKLINE LLC AXTEN, Jeffrey, Michael GRANT, Seth, Wilson HEERDING, Dirk, A. MEDINA, Jesus, Raul ROMERIL, Stuart, Paul TANG, Jun
DMASXR5	DT	Small molecular drug

DM4JNLQ	ID	DM4JNLQ
DM4JNLQ	DN	Indoline derivative 20
DM4JNLQ	HS	Patented
DM4JNLQ	SN	PMID28621580-Compound-WO2015117551c24
DM4JNLQ	CP	SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD
DM4JNLQ	DT	Small molecular drug

DM3YPX1	ID	DM3YPX1
DM3YPX1	DN	Indoline derivative 21
DM3YPX1	HS	Patented
DM3YPX1	SN	PMID28621580-Compound-WO2015117551c25
DM3YPX1	CP	SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD
DM3YPX1	DT	Small molecular drug

DM20YBJ	ID	DM20YBJ
DM20YBJ	DN	Indoline derivative 3
DM20YBJ	HS	Patented
DM20YBJ	SN	PMID27646439-Compound-2
DM20YBJ	CP	GLAXOSMITHKLINE LLC AXTEN, Jeffrey, Michael GRANT, Seth, Wilson HEERDING, Dirk, A. MEDINA, Jesus, Raul ROMERIL, Stuart, Paul TANG, Jun
DM20YBJ	DT	Small molecular drug

DMU5KWC	ID	DMU5KWC
DMU5KWC	DN	Indoline derivative 6
DMU5KWC	HS	Patented
DMU5KWC	SN	PMID27646439-Compound-5
DMU5KWC	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMU5KWC	DT	Small molecular drug

DMXS46Y	ID	DMXS46Y
DMXS46Y	DN	Indoline derivative 7
DMXS46Y	HS	Patented
DMXS46Y	SN	PMID27646439-Compound-15
DMXS46Y	CP	JANSSEN PHARMACEUTICA NV
DMXS46Y	DT	Small molecular drug

DMS8KMB	ID	DMS8KMB
DMS8KMB	DN	Indoline derivative 8
DMS8KMB	HS	Patented
DMS8KMB	SN	PMID27646439-Compound-16
DMS8KMB	CP	JANSSEN PHARMACEUTICA NV
DMS8KMB	DT	Small molecular drug
DMS8KMB	PC	85468833
DMS8KMB	MW	494.5
DMS8KMB	FM	C26H21F3N4O3
DMS8KMB	IC	InChI=1S/C26H21F3N4O3/c1-35-22-11-17-20(12-23(22)36-2)30-13-31-26(17)32-19-5-6-21-16(25(19)29)7-8-33(21)24(34)10-14-9-15(27)3-4-18(14)28/h3-6,9,11-13H,7-8,10H2,1-2H3,(H,30,31,32)
DMS8KMB	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=C(C4=C(C=C3)N(CC4)C(=O)CC5=C(C=CC(=C5)F)F)F)OC
DMS8KMB	IK	BJJFQLVMCHTWRM-UHFFFAOYSA-N
DMS8KMB	IU	2-(2,5-difluorophenyl)-1-[5-[(6,7-dimethoxyquinazolin-4-yl)amino]-4-fluoro-2,3-dihydroindol-1-yl]ethanone

DMCORT3	ID	DMCORT3
DMCORT3	DN	Indoline derivative 9
DMCORT3	HS	Patented
DMCORT3	SN	PMID27646439-Compound-17
DMCORT3	CP	JANSSEN PHARMACEUTICA NV
DMCORT3	DT	Small molecular drug

DMTC129	ID	DMTC129
DMTC129	DN	Indolinone derivative 1
DMTC129	HS	Patented
DMTC129	SN	PMID25684022-Compound-US200607105563
DMTC129	CP	Schering AG
DMTC129	DT	Small molecular drug
DMTC129	PC	11161844
DMTC129	MW	282.3
DMTC129	FM	C15H14N4O2
DMTC129	IC	InChI=1S/C15H14N4O2/c1-8(11-3-2-6-17-11)13-10-7-9(18-15(16)21)4-5-12(10)19-14(13)20/h2-7,17H,1H3,(H,19,20)(H3,16,18,21)/b13-8-
DMTC129	CS	C/C(=C/1\\C2=C(C=CC(=C2)NC(=O)N)NC1=O)/C3=CC=CN3
DMTC129	IK	DFURSNCTQGJRRX-JYRVWZFOSA-N
DMTC129	IU	[(3Z)-2-oxo-3-[1-(1H-pyrrol-2-yl)ethylidene]-1H-indol-5-yl]urea
DMTC129	CA	CAS 946843-63-6
DMTC129	DE	Solid tumour/cancer; Metastatic cancer

DM4GZBI	ID	DM4GZBI
DM4GZBI	DN	Indolizine derivative 1
DM4GZBI	HS	Patented
DM4GZBI	SN	PMID27718763-Compound-5
DM4GZBI	DT	Small molecular drug
DM4GZBI	PC	71679723
DM4GZBI	MW	407.4
DM4GZBI	FM	C24H16F3NO2
DM4GZBI	IC	InChI=1S/C24H16F3NO2/c1-15(29)22-20(16-7-3-2-4-8-16)21(19-9-5-6-14-28(19)22)23(30)17-10-12-18(13-11-17)24(25,26)27/h2-14H,1H3
DM4GZBI	CS	CC(=O)C1=C(C(=C2N1C=CC=C2)C(=O)C3=CC=C(C=C3)C(F)(F)F)C4=CC=CC=C4
DM4GZBI	IK	GLIRMGCILWOVQU-UHFFFAOYSA-N
DM4GZBI	IU	1-[2-phenyl-1-[4-(trifluoromethyl)benzoyl]indolizin-3-yl]ethanone

DM3E5V6	ID	DM3E5V6
DM3E5V6	DN	Indomethacin analog 1
DM3E5V6	HS	Patented
DM3E5V6	SN	PMID28895472-Compound-20
DM3E5V6	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIVANDERBILT UNIVERSITY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANI
DM3E5V6	DT	Small molecular drug
DM3E5V6	PC	11394647
DM3E5V6	MW	371.8
DM3E5V6	FM	C20H18ClNO4
DM3E5V6	IC	InChI=1S/C20H18ClNO4/c1-12-16(8-10-19(23)24)17-11-15(26-2)7-9-18(17)22(12)20(25)13-3-5-14(21)6-4-13/h3-7,9,11H,8,10H2,1-2H3,(H,23,24)
DM3E5V6	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CCC(=O)O
DM3E5V6	IK	ZXFPVIQVVULPBC-UHFFFAOYSA-N
DM3E5V6	IU	3-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]propanoic acid

DMKFPJ7	ID	DMKFPJ7
DMKFPJ7	DN	Indomethacin analog 2
DMKFPJ7	HS	Patented
DMKFPJ7	SN	PMID28895472-Compound-21
DMKFPJ7	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIVANDERBILT UNIVERSITY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANI
DMKFPJ7	DT	Small molecular drug
DMKFPJ7	PC	4711697
DMKFPJ7	MW	343.8
DMKFPJ7	FM	C18H14ClNO4
DMKFPJ7	IC	InChI=1S/C18H14ClNO4/c1-24-14-6-7-16-15(9-14)12(8-17(21)22)10-20(16)18(23)11-2-4-13(19)5-3-11/h2-7,9-10H,8H2,1H3,(H,21,22)
DMKFPJ7	CS	COC1=CC2=C(C=C1)N(C=C2CC(=O)O)C(=O)C3=CC=C(C=C3)Cl
DMKFPJ7	IK	DHEMTWWLRLOBKI-UHFFFAOYSA-N
DMKFPJ7	IU	2-[1-(4-chlorobenzoyl)-5-methoxyindol-3-yl]acetic acid
DMKFPJ7	CB	CHEBI:71026

DM53JXE	ID	DM53JXE
DM53JXE	DN	Indomethacin analog 3
DM53JXE	HS	Patented
DM53JXE	SN	PMID28895472-Compound-22
DM53JXE	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIVANDERBILT UNIVERSITY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANI
DM53JXE	DT	Small molecular drug
DM53JXE	PC	71523527
DM53JXE	MW	448.9
DM53JXE	FM	C21H21ClN2O5S
DM53JXE	IC	InChI=1S/C21H21ClN2O5S/c1-13-17-12-16(29-2)8-9-19(17)24(21(26)14-4-6-15(22)7-5-14)18(13)10-11-20(25)23-30(3,27)28/h4-9,12H,10-11H2,1-3H3,(H,23,25)
DM53JXE	CS	CC1=C(N(C2=C1C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl)CCC(=O)NS(=O)(=O)C
DM53JXE	IK	PLYKGAOPLXCEPT-UHFFFAOYSA-N
DM53JXE	IU	3-[1-(4-chlorobenzoyl)-5-methoxy-3-methylindol-2-yl]-N-methylsulfonylpropanamide

DMI3YO7	ID	DMI3YO7
DMI3YO7	DN	Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 1
DMI3YO7	HS	Patented
DMI3YO7	SN	PMID27607364-Compound-21
DMI3YO7	DT	Small molecular drug
DMI3YO7	PC	15870543
DMI3YO7	MW	448.3
DMI3YO7	FM	C20H18FIN2O
DMI3YO7	IC	InChI=1S/C20H18FIN2O/c1-24(12-6-11-21)20(25)18-13-14-7-2-3-8-15(14)19(23-18)16-9-4-5-10-17(16)22/h2-5,7-10,13H,6,11-12H2,1H3
DMI3YO7	CS	CN(CCCF)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC=CC=C3I
DMI3YO7	IK	JYVUQBFGPOGZEN-UHFFFAOYSA-N
DMI3YO7	IU	N-(3-fluoropropyl)-1-(2-iodophenyl)-N-methylisoquinoline-3-carboxamide

DM8LNXQ	ID	DM8LNXQ
DM8LNXQ	DN	Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 2
DM8LNXQ	HS	Patented
DM8LNXQ	SN	PMID27607364-Compound-22
DM8LNXQ	DT	Small molecular drug
DM8LNXQ	PC	19601673
DM8LNXQ	MW	448.3
DM8LNXQ	FM	C20H18FIN2O
DM8LNXQ	IC	InChI=1S/C20H18FIN2O/c1-24(11-5-10-21)20(25)18-13-14-6-2-3-9-17(14)19(23-18)15-7-4-8-16(22)12-15/h2-4,6-9,12-13H,5,10-11H2,1H3
DM8LNXQ	CS	CN(CCCF)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC(=CC=C3)I
DM8LNXQ	IK	KIEVJKCKQLQTJL-UHFFFAOYSA-N
DM8LNXQ	IU	N-(3-fluoropropyl)-1-(3-iodophenyl)-N-methylisoquinoline-3-carboxamide

DM39H1F	ID	DM39H1F
DM39H1F	DN	Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 3
DM39H1F	HS	Patented
DM39H1F	SN	PMID27607364-Compound-23
DM39H1F	DT	Small molecular drug
DM39H1F	PC	19601663
DM39H1F	MW	448.3
DM39H1F	FM	C20H18FIN2O
DM39H1F	IC	InChI=1S/C20H18FIN2O/c1-24(12-4-11-21)20(25)18-13-15-5-2-3-6-17(15)19(23-18)14-7-9-16(22)10-8-14/h2-3,5-10,13H,4,11-12H2,1H3
DM39H1F	CS	CN(CCCF)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC=C(C=C3)I
DM39H1F	IK	QJIFXKOIKACWEI-UHFFFAOYSA-N
DM39H1F	IU	N-(3-fluoropropyl)-1-(4-iodophenyl)-N-methylisoquinoline-3-carboxamide

DMDBK6O	ID	DMDBK6O
DMDBK6O	DN	Isochroman-4-ketone derivative 1
DMDBK6O	HS	Patented
DMDBK6O	SN	PMID29757691-Compound-9
DMDBK6O	DT	Small molecular drug
DMDBK6O	PC	122193616
DMDBK6O	MW	406.4
DMDBK6O	FM	C24H21FNO4+
DMDBK6O	IC	InChI=1S/C24H21FNO4/c1-28-21-8-7-19-20(24(21)29-2)15-30-22(23(19)27)13-16-9-11-26(12-10-16)14-17-3-5-18(25)6-4-17/h3-13H,14-15H2,1-2H3/q+1/b22-13-
DMDBK6O	CS	COC1=C(C2=C(C=C1)C(=O)/C(=C/C3=CC=[N+](C=C3)CC4=CC=C(C=C4)F)/OC2)OC
DMDBK6O	IK	WLIFEPXXMAJAQJ-XKZIYDEJSA-N
DMDBK6O	IU	(3Z)-3-[[1-[(4-fluorophenyl)methyl]pyridin-1-ium-4-yl]methylidene]-7,8-dimethoxy-1H-isochromen-4-one

DMMCWH9	ID	DMMCWH9
DMMCWH9	DN	Isoflavone derivative 1
DMMCWH9	HS	Patented
DMMCWH9	SN	PMID26666870-Compound-19
DMMCWH9	CP	UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMMCWH9	DT	Small molecular drug

DMTWAH3	ID	DMTWAH3
DMTWAH3	DN	Isoflavone derivative 2
DMTWAH3	HS	Patented
DMTWAH3	SN	PMID26666870-Compound-20
DMTWAH3	CP	UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMTWAH3	DT	Small molecular drug

DMYFKR2	ID	DMYFKR2
DMYFKR2	DN	Isoflavone derivative 3
DMYFKR2	HS	Patented
DMYFKR2	SN	PMID26666870-Compound-21
DMYFKR2	CP	UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMYFKR2	DT	Small molecular drug

DMYRU7I	ID	DMYRU7I
DMYRU7I	DN	Isoflavone derivative 4
DMYRU7I	HS	Patented
DMYRU7I	SN	PMID26666870-Compound-22
DMYRU7I	CP	UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMYRU7I	DT	Small molecular drug

DM2GL47	ID	DM2GL47
DM2GL47	DN	Isoflavone derivative 5
DM2GL47	HS	Patented
DM2GL47	SN	PMID26666870-Compound-23
DM2GL47	CP	UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DM2GL47	DT	Small molecular drug

DM2ZYVL	ID	DM2ZYVL
DM2ZYVL	DN	Isoflavone derivative 6
DM2ZYVL	HS	Patented
DM2ZYVL	SN	PMID26666870-Compound-24
DM2ZYVL	CP	UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DM2ZYVL	DT	Small molecular drug

DMNCHBL	ID	DMNCHBL
DMNCHBL	DN	Isoflavone derivative 7
DMNCHBL	HS	Patented
DMNCHBL	SN	PMID26666870-Compound-25
DMNCHBL	CP	UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMNCHBL	DT	Small molecular drug

DMN0XJQ	ID	DMN0XJQ
DMN0XJQ	DN	Isoflavone derivative 8
DMN0XJQ	HS	Patented
DMN0XJQ	SN	PMID26666870-Compound-26
DMN0XJQ	CP	UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMN0XJQ	DT	Small molecular drug

DMA78MD	ID	DMA78MD
DMA78MD	DN	Isoflavone derivative 9
DMA78MD	HS	Patented
DMA78MD	SN	PMID26666870-Compound-27
DMA78MD	CP	UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMA78MD	DT	Small molecular drug

DMWTU8X	ID	DMWTU8X
DMWTU8X	DN	Isoindole 1,3-dione analog 1
DMWTU8X	HS	Patented
DMWTU8X	SN	PMID27724045-Compound-12
DMWTU8X	CP	Roche
DMWTU8X	DT	Small molecular drug

DMD19QC	ID	DMD19QC
DMD19QC	DN	Isoindoline derivative 1
DMD19QC	HS	Patented
DMD19QC	SN	PMID30185082-Compound-66
DMD19QC	CP	COGNITION THERAPEUTICS, INC
DMD19QC	DT	Small molecular drug
DMD19QC	PC	118278079
DMD19QC	MW	423.5
DMD19QC	FM	C25H33N3O3
DMD19QC	IC	InChI=1S/C25H33N3O3/c1-25(2,10-9-18-7-8-22(29)23(15-18)31-3)28-16-19-5-4-6-20(21(19)17-28)24(30)27-13-11-26-12-14-27/h4-8,15,26,29H,9-14,16-17H2,1-3H3
DMD19QC	CS	CC(C)(CCC1=CC(=C(C=C1)O)OC)N2CC3=C(C2)C(=CC=C3)C(=O)N4CCNCC4
DMD19QC	IK	XNAGJLRFPOQPPM-UHFFFAOYSA-N
DMD19QC	IU	[2-[4-(4-hydroxy-3-methoxyphenyl)-2-methylbutan-2-yl]-1,3-dihydroisoindol-4-yl]-piperazin-1-ylmethanone

DMTE0S3	ID	DMTE0S3
DMTE0S3	DN	Isoindoline derivative 2
DMTE0S3	HS	Patented
DMTE0S3	SN	PMID30185082-Compound-67
DMTE0S3	CP	COGNITION THERAPEUTICS, INC
DMTE0S3	DT	Small molecular drug
DMTE0S3	PC	118282969
DMTE0S3	MW	380.3
DMTE0S3	FM	C20H23Cl2NO2
DMTE0S3	IC	InChI=1S/C20H23Cl2NO2/c1-13(4-5-14-6-7-17(21)18(22)8-14)23-11-15-9-19(24-2)20(25-3)10-16(15)12-23/h6-10,13H,4-5,11-12H2,1-3H3/t13-/m1/s1
DMTE0S3	CS	C[C@H](CCC1=CC(=C(C=C1)Cl)Cl)N2CC3=CC(=C(C=C3C2)OC)OC
DMTE0S3	IK	QOXCLDKXSCBOOF-CYBMUJFWSA-N
DMTE0S3	IU	2-[(2R)-4-(3,4-dichlorophenyl)butan-2-yl]-5,6-dimethoxy-1,3-dihydroisoindole

DM2MYL9	ID	DM2MYL9
DM2MYL9	DN	Isoindoline derivative 3
DM2MYL9	HS	Patented
DM2MYL9	SN	PMID30185082-Compound-68
DM2MYL9	CP	COGNITION THERAPEUTICS, INC
DM2MYL9	DT	Small molecular drug
DM2MYL9	PC	118282967
DM2MYL9	MW	370.3
DM2MYL9	FM	C22H21Cl2N
DM2MYL9	IC	InChI=1S/C22H21Cl2N/c1-15(6-7-16-8-11-21(23)22(24)12-16)25-13-18-10-9-17-4-2-3-5-19(17)20(18)14-25/h2-5,8-12,15H,6-7,13-14H2,1H3
DM2MYL9	CS	CC(CCC1=CC(=C(C=C1)Cl)Cl)N2CC3=C(C2)C4=CC=CC=C4C=C3
DM2MYL9	IK	SNYFWQWLZIRNKD-UHFFFAOYSA-N
DM2MYL9	IU	2-[4-(3,4-dichlorophenyl)butan-2-yl]-1,3-dihydrobenzo[e]isoindole

DMP1NKI	ID	DMP1NKI
DMP1NKI	DN	Isoindoline derivative 4
DMP1NKI	HS	Patented
DMP1NKI	SN	PMID30185082-Compound-69
DMP1NKI	CP	COGNITION THERAPEUTICS, INC
DMP1NKI	DT	Small molecular drug

DMIUTQW	ID	DMIUTQW
DMIUTQW	DN	Isoindoline derivative 5
DMIUTQW	HS	Patented
DMIUTQW	SN	PMID30185082-Compound-70
DMIUTQW	CP	COGNITION THERAPEUTICS, INC
DMIUTQW	DT	Small molecular drug
DMIUTQW	PC	118282942
DMIUTQW	MW	443.5
DMIUTQW	FM	C21H24F3NO4S
DMIUTQW	IC	InChI=1S/C21H24F3NO4S/c1-20(2,10-9-14-7-8-17(26)18(11-14)29-21(22,23)24)25-12-15-5-4-6-19(16(15)13-25)30(3,27)28/h4-8,11,26H,9-10,12-13H2,1-3H3
DMIUTQW	CS	CC(C)(CCC1=CC(=C(C=C1)O)OC(F)(F)F)N2CC3=C(C2)C(=CC=C3)S(=O)(=O)C
DMIUTQW	IK	ZBXIRNVCPMZPFS-UHFFFAOYSA-N
DMIUTQW	IU	4-[3-methyl-3-(4-methylsulfonyl-1,3-dihydroisoindol-2-yl)butyl]-2-(trifluoromethoxy)phenol

DMIYUAN	ID	DMIYUAN
DMIYUAN	DN	Isoquinoline 1,3-dione derivative 1
DMIYUAN	HS	Patented
DMIYUAN	SN	PMID26161698-Compound-49 

DMOAY3Q	ID	DMOAY3Q
DMOAY3Q	DN	Isoquinoline carboxamide derivative 1
DMOAY3Q	HS	Patented
DMOAY3Q	SN	PMID27607364-Compound-1
DMOAY3Q	CP	COCENSYS, INC
DMOAY3Q	DT	Small molecular drug
DMOAY3Q	PC	1345
DMOAY3Q	MW	352.9
DMOAY3Q	FM	C21H21ClN2O
DMOAY3Q	IC	InChI=1S/C21H21ClN2O/c1-4-14(2)24(3)21(25)19-13-15-9-5-6-10-16(15)20(23-19)17-11-7-8-12-18(17)22/h5-14H,4H2,1-3H3
DMOAY3Q	CS	CCC(C)N(C)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC=CC=C3Cl
DMOAY3Q	IK	RAVIZVQZGXBOQO-UHFFFAOYSA-N
DMOAY3Q	IU	N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide
DMOAY3Q	CA	CAS 85532-75-8
DMOAY3Q	CB	CHEBI:73290

DMR0Y3K	ID	DMR0Y3K
DMR0Y3K	DN	Isoquinoline derivative 1
DMR0Y3K	HS	Patented
DMR0Y3K	SN	PMID27215781-Compound-22
DMR0Y3K	CP	LUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu ZADE, Seema, Prabhakar SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar MAHANGARE, Sachin, Jaysing TALE, Prashant, Vitthalrao ZADE, Seema, Prabhakar PATIL, Amolsing, Dattu CHEEMALA, Narasimha, Murthy PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, Kumar
DMR0Y3K	DT	Small molecular drug
DMR0Y3K	PC	57525223
DMR0Y3K	MW	379.9
DMR0Y3K	FM	C22H22ClN3O
DMR0Y3K	IC	InChI=1S/C22H22ClN3O/c1-15-7-5-10-18-20(15)19(22(27)26-11-3-2-4-12-26)14-24-21(18)25-17-9-6-8-16(23)13-17/h5-10,13-14H,2-4,11-12H2,1H3,(H,24,25)
DMR0Y3K	CS	CC1=C2C(=CC=C1)C(=NC=C2C(=O)N3CCCCC3)NC4=CC(=CC=C4)Cl
DMR0Y3K	IK	RSQQKPIPFGRLQX-UHFFFAOYSA-N
DMR0Y3K	IU	[1-(3-chloroanilino)-5-methylisoquinolin-4-yl]-piperidin-1-ylmethanone
DMR0Y3K	DE	Neuropathic pain

DMRHBLD	ID	DMRHBLD
DMRHBLD	DN	Isoquinoline derivative 2
DMRHBLD	HS	Patented
DMRHBLD	SN	PMID27215781-Compound-23
DMRHBLD	CP	LUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu ZADE, Seema, Prabhakar SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar MAHANGARE, Sachin, Jaysing TALE, Prashant, Vitthalrao ZADE, Seema, Prabhakar PATIL, Amolsing, Dattu CHEEMALA, Narasimha, Murthy PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, Kumar
DMRHBLD	DT	Small molecular drug
DMRHBLD	PC	57411003
DMRHBLD	MW	365.4
DMRHBLD	FM	C21H20FN3O2
DMRHBLD	IC	InChI=1S/C21H20FN3O2/c1-14-4-2-7-17-19(14)18(21(26)25-8-10-27-11-9-25)13-23-20(17)24-16-6-3-5-15(22)12-16/h2-7,12-13H,8-11H2,1H3,(H,23,24)
DMRHBLD	CS	CC1=C2C(=CC=C1)C(=NC=C2C(=O)N3CCOCC3)NC4=CC(=CC=C4)F
DMRHBLD	IK	QKTNWXFWLOHPFJ-UHFFFAOYSA-N
DMRHBLD	IU	[1-(3-fluoroanilino)-5-methylisoquinolin-4-yl]-morpholin-4-ylmethanone
DMRHBLD	DE	Neuropathic pain

DM4R1MK	ID	DM4R1MK
DM4R1MK	DN	Isoquinoline derivative 3
DM4R1MK	HS	Patented
DM4R1MK	SN	PMID27215781-Compound-24
DM4R1MK	CP	LUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu ZADE, Seema, Prabhakar SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar MAHANGARE, Sachin, Jaysing TALE, Prashant, Vitthalrao ZADE, Seema, Prabhakar PATIL, Amolsing, Dattu CHEEMALA, Narasimha, Murthy PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, Kumar
DM4R1MK	DT	Small molecular drug
DM4R1MK	PC	57525218
DM4R1MK	MW	415.4
DM4R1MK	FM	C22H20F3N3O2
DM4R1MK	IC	InChI=1S/C22H20F3N3O2/c1-14-4-2-7-17-19(14)18(21(29)28-8-10-30-11-9-28)13-26-20(17)27-16-6-3-5-15(12-16)22(23,24)25/h2-7,12-13H,8-11H2,1H3,(H,26,27)
DM4R1MK	CS	CC1=C2C(=CC=C1)C(=NC=C2C(=O)N3CCOCC3)NC4=CC=CC(=C4)C(F)(F)F
DM4R1MK	IK	GPXLPNZECOPGPJ-UHFFFAOYSA-N
DM4R1MK	IU	[5-methyl-1-[3-(trifluoromethyl)anilino]isoquinolin-4-yl]-morpholin-4-ylmethanone
DM4R1MK	DE	Neuropathic pain

DMB5F8Q	ID	DMB5F8Q
DMB5F8Q	DN	Isoquinoline derivative 4
DMB5F8Q	HS	Patented
DMB5F8Q	SN	PMID28048944-Compound-10
DMB5F8Q	CP	AMAKEM NV
DMB5F8Q	DT	Small molecular drug

DMNJ2R9	ID	DMNJ2R9
DMNJ2R9	DN	Isoquinoline derivative 5
DMNJ2R9	HS	Patented
DMNJ2R9	SN	PMID28048944-Compound-9
DMNJ2R9	CP	AMAKEM NV
DMNJ2R9	DT	Small molecular drug

DMM5BDS	ID	DMM5BDS
DMM5BDS	DN	Isoquinoline sulfonamide derivative 1
DMM5BDS	HS	Patented
DMM5BDS	SN	PMID28048944-Compound-17
DMM5BDS	CP	MEDSHINE DISCOVERY INC
DMM5BDS	DT	Small molecular drug

DMQVYL0	ID	DMQVYL0
DMQVYL0	DN	Isoquinoline sulfonamide derivative 2
DMQVYL0	HS	Patented
DMQVYL0	SN	PMID28048944-Compound-18
DMQVYL0	CP	MEDSHINE DISCOVERY INC
DMQVYL0	DT	Small molecular drug

DMC5F3H	ID	DMC5F3H
DMC5F3H	DN	Isoquinoline sulfonyl derivative 1
DMC5F3H	HS	Patented
DMC5F3H	SN	PMID28048944-Compound-13
DMC5F3H	CP	MEDSHINE DISCOVERY INC
DMC5F3H	DT	Small molecular drug
DMC5F3H	PC	126511157
DMC5F3H	MW	331.4
DMC5F3H	FM	C17H21N3O2S
DMC5F3H	IC	InChI=1S/C17H21N3O2S/c1-12-8-18-9-13-4-2-6-16(17(12)13)23(21,22)20-10-14-5-3-7-19-15(14)11-20/h2,4,6,8-9,14-15,19H,3,5,7,10-11H2,1H3
DMC5F3H	CS	CC1=CN=CC2=C1C(=CC=C2)S(=O)(=O)N3CC4CCCNC4C3
DMC5F3H	IK	GPOFEWOVDWONOA-UHFFFAOYSA-N
DMC5F3H	IU	5-(1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-ylsulfonyl)-4-methylisoquinoline

DMT5E7M	ID	DMT5E7M
DMT5E7M	DN	Isoquinoline sulfonyl derivative 2
DMT5E7M	HS	Patented
DMT5E7M	SN	PMID28048944-Compound-14
DMT5E7M	CP	MEDSHINE DISCOVERY INC
DMT5E7M	DT	Small molecular drug

DMHIAVW	ID	DMHIAVW
DMHIAVW	DN	Isoquinoline sulfonyl derivative 3
DMHIAVW	HS	Patented
DMHIAVW	SN	PMID28048944-Compound-15
DMHIAVW	CP	MEDSHINE DISCOVERY INC
DMHIAVW	DT	Small molecular drug
DMHIAVW	PC	118488070
DMHIAVW	MW	331.4
DMHIAVW	FM	C17H21N3O2S
DMHIAVW	IC	InChI=1S/C17H21N3O2S/c1-12-10-18-11-13-4-2-6-16(17(12)13)23(21,22)20-9-7-14-15(20)5-3-8-19-14/h2,4,6,10-11,14-15,19H,3,5,7-9H2,1H3
DMHIAVW	CS	CC1=CN=CC2=C1C(=CC=C2)S(=O)(=O)N3CCC4C3CCCN4
DMHIAVW	IK	WDKSGCASJPRCLY-UHFFFAOYSA-N
DMHIAVW	IU	5-(2,3,3a,4,5,6,7,7a-octahydropyrrolo[3,2-b]pyridin-1-ylsulfonyl)-4-methylisoquinoline

DMW6R0H	ID	DMW6R0H
DMW6R0H	DN	Isoquinolone derivative 1
DMW6R0H	HS	Patented
DMW6R0H	SN	PMID28895472-Compound-27
DMW6R0H	CP	GTX, INC
DMW6R0H	DT	Small molecular drug

DMP2QDM	ID	DMP2QDM
DMP2QDM	DN	Isosteric imidazolyl pyrimidine derivative 1
DMP2QDM	HS	Patented
DMP2QDM	SN	PMID26161698-Compound-37
DMP2QDM	DT	Small molecular drug
DMP2QDM	PC	44555024
DMP2QDM	MW	358.4
DMP2QDM	FM	C16H18N6O2S
DMP2QDM	IC	InChI=1S/C16H18N6O2S/c1-9(2)22-10(3)18-8-12(22)11-6-7-17-16(19-11)20-14-5-4-13(25-14)15(23)21-24/h4-9,24H,1-3H3,(H,21,23)(H,17,19,20)
DMP2QDM	CS	CC1=NC=C(N1C(C)C)C2=NC(=NC=C2)NC3=CC=C(S3)C(=O)NO
DMP2QDM	IK	CKZXHZVEFKLZPB-UHFFFAOYSA-N
DMP2QDM	IU	N-hydroxy-5-[[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]thiophene-2-carboxamide

DMLSUH3	ID	DMLSUH3
DMLSUH3	DN	Isothiazolidine derivative 1
DMLSUH3	HS	Patented
DMLSUH3	SN	PMID27724045-Compound-2
DMLSUH3	CP	GLAXO GROUP LIMITED DEAN, David, Kenneth WALTER, Daryl, Simon
DMLSUH3	DT	Small molecular drug
DMLSUH3	PC	52912204
DMLSUH3	MW	385.79
DMLSUH3	FM	C13H15ClF3N3O3S
DMLSUH3	IC	InChI=1S/C13H15ClF3N3O3S/c1-19-7-10(20(2)24(19,22)23)12(21)18-6-8-4-3-5-9(11(8)14)13(15,16)17/h3-5,10H,6-7H2,1-2H3,(H,18,21)
DMLSUH3	CS	CN1CC(N(S1(=O)=O)C)C(=O)NCC2=C(C(=CC=C2)C(F)(F)F)Cl
DMLSUH3	IK	FDFVMILOAWFGGO-UHFFFAOYSA-N
DMLSUH3	IU	N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-2,5-dimethyl-1,1-dioxo-1,2,5-thiadiazolidine-3-carboxamide

DMHAJCM	ID	DMHAJCM
DMHAJCM	DN	Isothiazolone derivative 1
DMHAJCM	HS	Patented
DMHAJCM	SN	PMID26560362-Compound-33
DMHAJCM	DT	Small molecular drug
DMHAJCM	PC	23287881
DMHAJCM	MW	349.5
DMHAJCM	FM	C16H23N5O2S
DMHAJCM	IC	InChI=1S/C16H23N5O2S/c22-15-13-12-17-16(20-8-10-23-11-9-20)18-14(13)24-21(15)7-6-19-4-2-1-3-5-19/h12H,1-11H2
DMHAJCM	CS	C1CCN(CC1)CCN2C(=O)C3=CN=C(N=C3S2)N4CCOCC4
DMHAJCM	IK	YVQWBBJPPJKQIM-UHFFFAOYSA-N
DMHAJCM	IU	6-morpholin-4-yl-2-(2-piperidin-1-ylethyl)-[1,2]thiazolo[5,4-d]pyrimidin-3-one

DMK31M6	ID	DMK31M6
DMK31M6	DN	Isothiocyanate derivative 1
DMK31M6	HS	Patented
DMK31M6	SN	PMID26560530-Compound-9
DMK31M6	CP	Medicis Corp
DMK31M6	DT	Small molecular drug
DMK31M6	PC	10290770
DMK31M6	MW	116.14
DMK31M6	FM	C3H4N2OS
DMK31M6	IC	InChI=1S/C3H4N2OS/c4-3(6)1-5-2-7/h1H2,(H2,4,6)
DMK31M6	CS	C(C(=O)N)N=C=S
DMK31M6	IK	LXDZRHJIMQYSSD-UHFFFAOYSA-N
DMK31M6	IU	2-isothiocyanatoacetamide

DMUMPZX	ID	DMUMPZX
DMUMPZX	DN	Isoxazole derivative 1
DMUMPZX	HS	Patented
DMUMPZX	SN	PMID27774822-Compound-Figure11compound1
DMUMPZX	CP	ZHEJIANG DTRM BIOPHARMA [CN]
DMUMPZX	DT	Small molecular drug

DMT842O	ID	DMT842O
DMT842O	DN	Isoxazole derivative 2
DMT842O	HS	Patented
DMT842O	SN	PMID27774822-Compound-Figure11compound2
DMT842O	CP	ZHEJIANG DTRM BIOPHARMA [CN]
DMT842O	DT	Small molecular drug

DM5CXQT	ID	DM5CXQT
DM5CXQT	DN	Isoxazole-based bicyclic compound 1
DM5CXQT	HS	Patented
DM5CXQT	SN	PMID26924192-Compound-61
DM5CXQT	CP	ZENITH EPIGENETICS CORP
DM5CXQT	DT	Small molecular drug
DM5CXQT	PC	86566737
DM5CXQT	MW	318.4
DM5CXQT	FM	C19H18N4O
DM5CXQT	IC	InChI=1S/C19H18N4O/c1-12-18(13(2)24-22-12)15-8-16(20)19-17(9-15)23(11-21-19)10-14-6-4-3-5-7-14/h3-9,11H,10,20H2,1-2H3
DM5CXQT	CS	CC1=C(C(=NO1)C)C2=CC(=C3C(=C2)N(C=N3)CC4=CC=CC=C4)N
DM5CXQT	IK	JNHVPJQTAXBUHN-UHFFFAOYSA-N
DM5CXQT	IU	1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)benzimidazol-4-amine

DMAYKZ9	ID	DMAYKZ9
DMAYKZ9	DN	Isoxazole-based bicyclic compound 10
DMAYKZ9	HS	Patented
DMAYKZ9	SN	PMID26924192-Compound-70
DMAYKZ9	CP	ZENITH EPIGENETICS CORP
DMAYKZ9	DT	Small molecular drug

DM1G8SM	ID	DM1G8SM
DM1G8SM	DN	Isoxazole-based bicyclic compound 11
DM1G8SM	HS	Patented
DM1G8SM	SN	PMID26924192-Compound-71
DM1G8SM	CP	ZENITH EPIGENETICS CORP
DM1G8SM	DT	Small molecular drug

DMVA8KL	ID	DMVA8KL
DMVA8KL	DN	Isoxazole-based bicyclic compound 12
DMVA8KL	HS	Patented
DMVA8KL	SN	PMID26924192-Compound-72
DMVA8KL	CP	ZENITH EPIGENETICS CORP
DMVA8KL	DT	Small molecular drug

DM7OBVT	ID	DM7OBVT
DM7OBVT	DN	Isoxazole-based bicyclic compound 13
DM7OBVT	HS	Patented
DM7OBVT	SN	PMID26924192-Compound-73
DM7OBVT	CP	ZENITH EPIGENETICS CORP
DM7OBVT	DT	Small molecular drug

DMS3CDT	ID	DMS3CDT
DMS3CDT	DN	Isoxazole-based bicyclic compound 14
DMS3CDT	HS	Patented
DMS3CDT	SN	PMID26924192-Compound-74
DMS3CDT	CP	ZENITH EPIGENETICS CORP
DMS3CDT	DT	Small molecular drug

DMPXK1C	ID	DMPXK1C
DMPXK1C	DN	Isoxazole-based bicyclic compound 15
DMPXK1C	HS	Patented
DMPXK1C	SN	PMID26924192-Compound-75
DMPXK1C	CP	ZENITH EPIGENETICS CORP
DMPXK1C	DT	Small molecular drug

DM614F8	ID	DM614F8
DM614F8	DN	Isoxazole-based bicyclic compound 16
DM614F8	HS	Patented
DM614F8	SN	PMID26924192-Compound-76
DM614F8	CP	ORION CORPORATION
DM614F8	DT	Small molecular drug
DM614F8	PC	91824133
DM614F8	MW	384.9
DM614F8	FM	C21H21ClN2O3
DM614F8	IC	InChI=1S/C21H21ClN2O3/c1-13-21(14(2)27-23-13)17-10-20-18(11-19(17)25-3)24(8-9-26-20)12-15-4-6-16(22)7-5-15/h4-7,10-11H,8-9,12H2,1-3H3
DM614F8	CS	CC1=C(C(=NO1)C)C2=CC3=C(C=C2OC)N(CCO3)CC4=CC=C(C=C4)Cl
DM614F8	IK	QYWOLKVTQWOHRO-UHFFFAOYSA-N
DM614F8	IU	4-[(4-chlorophenyl)methyl]-7-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methoxy-2,3-dihydro-1,4-benzoxazine

DM2SUCK	ID	DM2SUCK
DM2SUCK	DN	Isoxazole-based bicyclic compound 17
DM2SUCK	HS	Patented
DM2SUCK	SN	PMID26924192-Compound-77
DM2SUCK	CP	ORION CORPORATION
DM2SUCK	DT	Small molecular drug
DM2SUCK	PC	118224715
DM2SUCK	MW	362.4
DM2SUCK	FM	C20H18N4O3
DM2SUCK	IC	InChI=1S/C20H18N4O3/c1-12-20(13(2)27-23-12)15-9-14-5-6-19(25)24(16(14)10-17(15)26-3)11-18-21-7-4-8-22-18/h4-10H,11H2,1-3H3
DM2SUCK	CS	CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)C=CC(=O)N3CC4=NC=CC=N4)OC
DM2SUCK	IK	NWOCKSNGLNHMMB-UHFFFAOYSA-N
DM2SUCK	IU	6-(3,5-dimethyl-1,2-oxazol-4-yl)-7-methoxy-1-(pyrimidin-2-ylmethyl)quinolin-2-one

DME8CQA	ID	DME8CQA
DME8CQA	DN	Isoxazole-based bicyclic compound 18
DME8CQA	HS	Patented
DME8CQA	SN	PMID26924192-Compound-78
DME8CQA	CP	ORION CORPORATION
DME8CQA	DT	Small molecular drug
DME8CQA	PC	124137024
DME8CQA	MW	391.4
DME8CQA	FM	C22H21N3O4
DME8CQA	IC	InChI=1S/C22H21N3O4/c1-14-22(15(2)29-24-14)18-11-16-6-7-21(27)25(13-17-5-3-4-8-23-17)19(16)12-20(18)28-10-9-26/h3-8,11-12,26H,9-10,13H2,1-2H3
DME8CQA	CS	CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)C=CC(=O)N3CC4=CC=CC=N4)OCCO
DME8CQA	IK	OAVYHERNZVHDFP-UHFFFAOYSA-N
DME8CQA	IU	6-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(2-hydroxyethoxy)-1-(pyridin-2-ylmethyl)quinolin-2-one

DM01FD3	ID	DM01FD3
DM01FD3	DN	Isoxazole-based bicyclic compound 19
DM01FD3	HS	Patented
DM01FD3	SN	PMID26924192-Compound-79
DM01FD3	CP	ORION CORPORATION
DM01FD3	DT	Small molecular drug
DM01FD3	PC	118224629
DM01FD3	MW	459.4
DM01FD3	FM	C23H20F3N3O4
DM01FD3	IC	InChI=1S/C23H20F3N3O4/c1-12-20(13(2)33-28-12)16-8-14-9-17(21(30)23(24,25)26)22(31)29(18(14)10-19(16)32-3)11-15-6-4-5-7-27-15/h4-10,21,30H,11H2,1-3H3
DM01FD3	CS	CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)C=C(C(=O)N3CC4=CC=CC=N4)C(C(F)(F)F)O)OC
DM01FD3	IK	KORFDBDOHJBIRP-UHFFFAOYSA-N
DM01FD3	IU	6-(3,5-dimethyl-1,2-oxazol-4-yl)-7-methoxy-1-(pyridin-2-ylmethyl)-3-(2,2,2-trifluoro-1-hydroxyethyl)quinolin-2-one

DMYLR2S	ID	DMYLR2S
DMYLR2S	DN	Isoxazole-based bicyclic compound 2
DMYLR2S	HS	Patented
DMYLR2S	SN	PMID26924192-Compound-62
DMYLR2S	CP	ZENITH EPIGENETICS CORP
DMYLR2S	DT	Small molecular drug
DMYLR2S	PC	87057166
DMYLR2S	MW	320.3
DMYLR2S	FM	C18H16N4O2
DMYLR2S	IC	InChI=1S/C18H16N4O2/c1-11-16(12(2)24-21-11)14-8-15-17(19-9-14)20-18(23)22(15)10-13-6-4-3-5-7-13/h3-9H,10H2,1-2H3,(H,19,20,23)
DMYLR2S	CS	CC1=C(C(=NO1)C)C2=CC3=C(NC(=O)N3CC4=CC=CC=C4)N=C2
DMYLR2S	IK	QUVHLUHSXDYNJU-UHFFFAOYSA-N
DMYLR2S	IU	1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-one

DMWMRKJ	ID	DMWMRKJ
DMWMRKJ	DN	Isoxazole-based bicyclic compound 3
DMWMRKJ	HS	Patented
DMWMRKJ	SN	PMID26924192-Compound-63
DMWMRKJ	CP	ZENITH EPIGENETICS CORP
DMWMRKJ	DT	Small molecular drug
DMWMRKJ	PC	87057247
DMWMRKJ	MW	334.4
DMWMRKJ	FM	C19H18N4O2
DMWMRKJ	IC	InChI=1S/C19H18N4O2/c1-11-17(12(2)25-22-11)14-8-15(20)18-16(9-14)23(19(24)21-18)10-13-6-4-3-5-7-13/h3-9H,10,20H2,1-2H3,(H,21,24)
DMWMRKJ	CS	CC1=C(C(=NO1)C)C2=CC(=C3C(=C2)N(C(=O)N3)CC4=CC=CC=C4)N
DMWMRKJ	IK	HWHJKVNNLYESRW-UHFFFAOYSA-N
DMWMRKJ	IU	7-amino-3-benzyl-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-benzimidazol-2-one

DMNI0PH	ID	DMNI0PH
DMNI0PH	DN	Isoxazole-based bicyclic compound 4
DMNI0PH	HS	Patented
DMNI0PH	SN	PMID26924192-Compound-64
DMNI0PH	CP	ZENITH EPIGENETICS CORP
DMNI0PH	DT	Small molecular drug
DMNI0PH	PC	87057249
DMNI0PH	MW	362.4
DMNI0PH	FM	C21H22N4O2
DMNI0PH	IC	InChI=1S/C21H22N4O2/c1-4-26-21-23-20-17(22)10-16(19-13(2)24-27-14(19)3)11-18(20)25(21)12-15-8-6-5-7-9-15/h5-11H,4,12,22H2,1-3H3
DMNI0PH	CS	CCOC1=NC2=C(C=C(C=C2N1CC3=CC=CC=C3)C4=C(ON=C4C)C)N
DMNI0PH	IK	AURDBDSAYLFHPT-UHFFFAOYSA-N
DMNI0PH	IU	1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-2-ethoxybenzimidazol-4-amine

DMT46PS	ID	DMT46PS
DMT46PS	DN	Isoxazole-based bicyclic compound 5
DMT46PS	HS	Patented
DMT46PS	SN	PMID26924192-Compound-65
DMT46PS	CP	ZENITH EPIGENETICS CORP
DMT46PS	DT	Small molecular drug
DMT46PS	PC	121375944
DMT46PS	MW	391.4
DMT46PS	FM	C21H21N5O3
DMT46PS	IC	InChI=1S/C21H21N5O3/c1-4-22-21-23-20-17(25(21)12-15-8-6-5-7-9-15)10-16(11-18(20)26(27)28)19-13(2)24-29-14(19)3/h5-11H,4,12H2,1-3H3,(H,22,23)
DMT46PS	CS	CCNC1=NC2=C(N1CC3=CC=CC=C3)C=C(C=C2[N+](=O)[O-])C4=C(ON=C4C)C
DMT46PS	IK	ANFSRXMOJNUJCH-UHFFFAOYSA-N
DMT46PS	IU	1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-N-ethyl-4-nitrobenzimidazol-2-amine

DMKSNZG	ID	DMKSNZG
DMKSNZG	DN	Isoxazole-based bicyclic compound 6
DMKSNZG	HS	Patented
DMKSNZG	SN	PMID26924192-Compound-66
DMKSNZG	CP	ZENITH EPIGENETICS CORP
DMKSNZG	DT	Small molecular drug

DM3T840	ID	DM3T840
DM3T840	DN	Isoxazole-based bicyclic compound 7
DM3T840	HS	Patented
DM3T840	SN	PMID26924192-Compound-67
DM3T840	CP	ZENITH EPIGENETICS CORP
DM3T840	DT	Small molecular drug

DM3IV7K	ID	DM3IV7K
DM3IV7K	DN	Isoxazole-based bicyclic compound 8
DM3IV7K	HS	Patented
DM3IV7K	SN	PMID26924192-Compound-68
DM3IV7K	CP	ZENITH EPIGENETICS CORP
DM3IV7K	DT	Small molecular drug

DMWA7RB	ID	DMWA7RB
DMWA7RB	DN	Isoxazole-based bicyclic compound 9
DMWA7RB	HS	Patented
DMWA7RB	SN	PMID26924192-Compound-69
DMWA7RB	CP	ZENITH EPIGENETICS CORP
DMWA7RB	DT	Small molecular drug

DMRML9B	ID	DMRML9B
DMRML9B	DN	Isoxazoles and isoxazoline derivative 1
DMRML9B	HS	Patented
DMRML9B	SN	PMID27172114-Compound-82
DMRML9B	DT	Small molecular drug

DMKCYSD	ID	DMKCYSD
DMKCYSD	DN	Isoxazoles and isoxazoline derivative 2
DMKCYSD	HS	Patented
DMKCYSD	SN	PMID27172114-Compound-83
DMKCYSD	DT	Small molecular drug
DMKCYSD	PC	44634450
DMKCYSD	MW	274.1
DMKCYSD	FM	C11H9Cl2NO3
DMKCYSD	IC	InChI=1S/C11H9Cl2NO3/c12-8-2-1-6(3-9(8)13)11-7(4-10(15)16)5-17-14-11/h1-3,7H,4-5H2,(H,15,16)
DMKCYSD	CS	C1C(C(=NO1)C2=CC(=C(C=C2)Cl)Cl)CC(=O)O
DMKCYSD	IK	JUWLIQWWDGCIRH-UHFFFAOYSA-N
DMKCYSD	IU	2-[3-(3,4-dichlorophenyl)-4,5-dihydro-1,2-oxazol-4-yl]acetic acid

DMULJOS	ID	DMULJOS
DMULJOS	DN	Isoxazoles and isoxazoline derivative 3
DMULJOS	HS	Patented
DMULJOS	SN	PMID27172114-Compound-84
DMULJOS	DT	Small molecular drug

DMW3JZV	ID	DMW3JZV
DMW3JZV	DN	Isoxazoles and isoxazoline derivative 4
DMW3JZV	HS	Patented
DMW3JZV	SN	PMID27172114-Compound-85
DMW3JZV	DT	Small molecular drug

DMCWFU1	ID	DMCWFU1
DMCWFU1	DN	Isoxazoles and isoxazoline derivative 5
DMCWFU1	HS	Patented
DMCWFU1	SN	PMID27172114-Compound-86
DMCWFU1	DT	Small molecular drug

DMIKBV5	ID	DMIKBV5
DMIKBV5	DN	Isoxazoles and isoxazoline derivative 6
DMIKBV5	HS	Patented
DMIKBV5	SN	PMID27172114-Compound-87
DMIKBV5	DT	Small molecular drug

DMLR8MS	ID	DMLR8MS
DMLR8MS	DN	Isoxazoline derivative 1
DMLR8MS	HS	Patented
DMLR8MS	SN	PMID26413912-Compound-85
DMLR8MS	CP	INFINITY PHARMACEUTICALS, INC. BEHNKE, Mark, L. CASTRO, Alfredo, C. CHAN, Lawrence, K. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LEBLANC, Yves LIU, Tao PELUSO, Stephane SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMLR8MS	DT	Small molecular drug
DMLR8MS	PC	58126505
DMLR8MS	MW	256.1
DMLR8MS	FM	C10H10BrNO2
DMLR8MS	IC	InChI=1S/C10H10BrNO2/c1-13-8-4-2-3-7(5-8)9-6-10(11)12-14-9/h2-5,9H,6H2,1H3/t9-/m1/s1
DMLR8MS	CS	COC1=CC=CC(=C1)[C@H]2CC(=NO2)Br
DMLR8MS	IK	IWLKUWXPADWQAT-SECBINFHSA-N
DMLR8MS	IU	(5R)-3-bromo-5-(3-methoxyphenyl)-4,5-dihydro-1,2-oxazole

DMK5M8Q	ID	DMK5M8Q
DMK5M8Q	DN	Isoxazoline derivative 2
DMK5M8Q	HS	Patented
DMK5M8Q	SN	PMID26413912-Compound-86
DMK5M8Q	CP	INFINITY PHARMACEUTICALS, INC. BEHNKE, Mark, L. CASTRO, Alfredo, C. CHAN, Lawrence, K. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LEBLANC, Yves LIU, Tao PELUSO, Stephane SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMK5M8Q	DT	Small molecular drug
DMK5M8Q	PC	58126487
DMK5M8Q	MW	256.1
DMK5M8Q	FM	C10H10BrNO2
DMK5M8Q	IC	InChI=1S/C10H10BrNO2/c1-13-8-4-2-3-7(5-8)9-6-10(11)12-14-9/h2-5,9H,6H2,1H3/t9-/m0/s1
DMK5M8Q	CS	COC1=CC=CC(=C1)[C@@H]2CC(=NO2)Br
DMK5M8Q	IK	IWLKUWXPADWQAT-VIFPVBQESA-N
DMK5M8Q	IU	(5S)-3-bromo-5-(3-methoxyphenyl)-4,5-dihydro-1,2-oxazole

DMBVDHK	ID	DMBVDHK
DMBVDHK	DN	Isoxazoline derivative 3
DMBVDHK	HS	Patented
DMBVDHK	SN	PMID26413912-Compound-87
DMBVDHK	CP	INFINITY PHARMACEUTICALS, INC. BEHNKE, Mark, L. CASTRO, Alfredo, C. CHAN, Lawrence, K. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LEBLANC, Yves LIU, Tao PELUSO, Stephane SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMBVDHK	DT	Small molecular drug
DMBVDHK	PC	88979391
DMBVDHK	MW	356.4
DMBVDHK	FM	C22H16N2O3
DMBVDHK	IC	InChI=1S/C22H16N2O3/c23-15-16-6-10-20(11-7-16)26-22-14-21(27-24-22)17-8-12-19(13-9-17)25-18-4-2-1-3-5-18/h1-13,21H,14H2/t21-/m1/s1
DMBVDHK	CS	C1[C@@H](ON=C1OC2=CC=C(C=C2)C#N)C3=CC=C(C=C3)OC4=CC=CC=C4
DMBVDHK	IK	QRYXBMPYZGEVSA-OAQYLSRUSA-N
DMBVDHK	IU	4-[[(5R)-5-(4-phenoxyphenyl)-4,5-dihydro-1,2-oxazol-3-yl]oxy]benzonitrile

DM01DG4	ID	DM01DG4
DM01DG4	DN	Isoxazoline derivative 4
DM01DG4	HS	Patented
DM01DG4	SN	PMID26413912-Compound-88
DM01DG4	CP	INFINITY PHARMACEUTICALS, INC. BEHNKE, Mark, L. CASTRO, Alfredo, C. CHAN, Lawrence, K. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LEBLANC, Yves LIU, Tao PELUSO, Stephane SNYDER, Daniel, A. TIBBITTS, Thomas, T
DM01DG4	DT	Small molecular drug
DM01DG4	PC	88979392
DM01DG4	MW	356.4
DM01DG4	FM	C22H16N2O3
DM01DG4	IC	InChI=1S/C22H16N2O3/c23-15-16-6-10-20(11-7-16)26-22-14-21(27-24-22)17-8-12-19(13-9-17)25-18-4-2-1-3-5-18/h1-13,21H,14H2/t21-/m0/s1
DM01DG4	CS	C1[C@H](ON=C1OC2=CC=C(C=C2)C#N)C3=CC=C(C=C3)OC4=CC=CC=C4
DM01DG4	IK	QRYXBMPYZGEVSA-NRFANRHFSA-N
DM01DG4	IU	4-[[(5S)-5-(4-phenoxyphenyl)-4,5-dihydro-1,2-oxazol-3-yl]oxy]benzonitrile

DMER7QX	ID	DMER7QX
DMER7QX	DN	JCXGHZCWAHCYGY-UHFFFAOYSA-N
DMER7QX	HS	Patented
DMER7QX	SN	CHEMBL1076723; N-(2-chloro-4-hydroxyphenyl)-6-(cyclohexylamino)pyrimidine-4-carboxamide; SCHEMBL3035358; JCXGHZCWAHCYGY-UHFFFAOYSA-N; BDBM50313327
DMER7QX	DT	Small molecular drug
DMER7QX	PC	25182746
DMER7QX	MW	346.8
DMER7QX	FM	C17H19ClN4O2
DMER7QX	IC	InChI=1S/C17H19ClN4O2/c18-13-8-12(23)6-7-14(13)22-17(24)15-9-16(20-10-19-15)21-11-4-2-1-3-5-11/h6-11,23H,1-5H2,(H,22,24)(H,19,20,21)
DMER7QX	CS	C1CCC(CC1)NC2=NC=NC(=C2)C(=O)NC3=C(C=C(C=C3)O)Cl
DMER7QX	IK	JCXGHZCWAHCYGY-UHFFFAOYSA-N
DMER7QX	IU	N-(2-chloro-4-hydroxyphenyl)-6-(cyclohexylamino)pyrimidine-4-carboxamide

DMS3HNM	ID	DMS3HNM
DMS3HNM	DN	Jte 013
DMS3HNM	HS	Patented
DMS3HNM	SN	Jte 013; JTE-013; 383150-41-2; CHEMBL1368758; S1P2 Receptor Antagonist, JTE-013; N-(2,6-dichloropyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide; 1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)amino]urea; 1-(1,3-Dimethyl-4-isopropyl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-(3,5-dichloro-4-pyridinyl)-semicarbazide; pyrazolopyridine analog; C17H19Cl2N7O; GTPL2917; SCHEMBL5911940; CHEBI:92763; CTK8F0047; SYN5010; DTXSID60436982; AOB1935; HMS3650O12; 
DMS3HNM	DT	Small molecular drug
DMS3HNM	PC	10223146
DMS3HNM	MW	408.3
DMS3HNM	FM	C17H19Cl2N7O
DMS3HNM	IC	InChI=1S/C17H19Cl2N7O/c1-8(2)11-7-14(22-16-15(11)9(3)25-26(16)4)23-24-17(27)20-10-5-12(18)21-13(19)6-10/h5-8H,1-4H3,(H,22,23)(H2,20,21,24,27)
DMS3HNM	CS	CC1=NN(C2=C1C(=CC(=N2)NNC(=O)NC3=CC(=NC(=C3)Cl)Cl)C(C)C)C
DMS3HNM	IK	RNSLRQNDXRSASX-UHFFFAOYSA-N
DMS3HNM	IU	1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)amino]urea
DMS3HNM	CA	CAS 383150-41-2
DMS3HNM	CB	CHEBI:92763
DMS3HNM	DE	Discovery agent

DMGTSCP	ID	DMGTSCP
DMGTSCP	DN	JWH-015
DMGTSCP	HS	Patented
DMGTSCP	SN	JWH-015; 155471-08-2; JWH 015; UNII-W4FL204T10; (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone; JWH015; (2-methyl-1-propylindol-3-yl)-naphthalen-1-ylmethanone; CHEMBL306764; W4FL204T10; MFCD02094630; (2-methyl-1-propyl-1H-indol-3-yl)(naphthalen-1-yl)methanone; JHW 015; SR-01000597570; (2-Methyl-1-propylindol-3-yl)(naphthalen-1-yl)methanone; NCGC00025117-01; Tocris-1341; PubChem19328; MLS002153392; SCHEMBL497044; GTPL5558; AC1N784D; BDBM21282; CHEBI:92318; DTXSID60165902; AOB5643; MolPort-003-983-602
DMGTSCP	DT	Small molecular drug
DMGTSCP	PC	4273754
DMGTSCP	MW	327.4
DMGTSCP	FM	C23H21NO
DMGTSCP	IC	InChI=1S/C23H21NO/c1-3-15-24-16(2)22(20-12-6-7-14-21(20)24)23(25)19-13-8-10-17-9-4-5-11-18(17)19/h4-14H,3,15H2,1-2H3
DMGTSCP	CS	CCCN1C(=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43)C
DMGTSCP	IK	LJSBBBWQTLXQEN-UHFFFAOYSA-N
DMGTSCP	IU	(2-methyl-1-propylindol-3-yl)-naphthalen-1-ylmethanone
DMGTSCP	CA	CAS 155471-08-2
DMGTSCP	CB	CHEBI:92318
DMGTSCP	DE	Organ transplant rejection

DM7UK5E	ID	DM7UK5E
DM7UK5E	DN	KadcoccitoneA
DM7UK5E	HS	Patented
DM7UK5E	CP	Nanjing Zhengliang Med. Tech. CO

DMAGVXW	ID	DMAGVXW
DMAGVXW	DN	KENPAULLONE
DMAGVXW	HS	Patented
DMAGVXW	SN	kenpaullone; 142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one
DMAGVXW	DT	Small molecular drug
DMAGVXW	PC	3820
DMAGVXW	MW	327.17
DMAGVXW	FM	C16H11BrN2O
DMAGVXW	IC	InChI=1S/C16H11BrN2O/c17-9-5-6-14-11(7-9)12-8-15(20)18-13-4-2-1-3-10(13)16(12)19-14/h1-7,19H,8H2,(H,18,20)
DMAGVXW	CS	C1C2=C(C3=CC=CC=C3NC1=O)NC4=C2C=C(C=C4)Br
DMAGVXW	IK	QQUXFYAWXPMDOE-UHFFFAOYSA-N
DMAGVXW	IU	9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one
DMAGVXW	CA	CAS 142273-20-9
DMAGVXW	CB	CHEBI:92658
DMAGVXW	DE	Discovery agent

DM1ZK7E	ID	DM1ZK7E
DM1ZK7E	DN	Ketoheterocycle derivative 1
DM1ZK7E	HS	Patented
DM1ZK7E	SN	PMID26413912-Compound-17
DM1ZK7E	CP	THE SCRIPPS RESEARCH INSTITUTE
DM1ZK7E	DT	Small molecular drug

DM3KW2A	ID	DM3KW2A
DM3KW2A	DN	Ketoheterocycle derivative 2
DM3KW2A	HS	Patented
DM3KW2A	SN	PMID26413912-Compound-18
DM3KW2A	CP	THE SCRIPPS RESEARCH INSTITUTE
DM3KW2A	DT	Small molecular drug

DMFHD05	ID	DMFHD05
DMFHD05	DN	Ketoheterocycle derivative 3
DMFHD05	HS	Patented
DMFHD05	SN	PMID26413912-Compound-22
DMFHD05	CP	Janssen Pharmaceutica N.V
DMFHD05	DT	Small molecular drug

DM2LQXY	ID	DM2LQXY
DM2LQXY	DN	Ketoheterocycle derivative 4
DM2LQXY	HS	Patented
DM2LQXY	SN	PMID26413912-Compound-23
DM2LQXY	CP	Janssen Pharmaceutica N.V
DM2LQXY	DT	Small molecular drug

DMRY7KV	ID	DMRY7KV
DMRY7KV	DN	KRDULPYOVRWKMA-UHFFFAOYSA-N
DMRY7KV	HS	Patented
DMRY7KV	SN	CHEMBL2216867; SCHEMBL2014247; KRDULPYOVRWKMA-UHFFFAOYSA-N; BDBM50004539; N-{1-[5-Chloro-8-(3-fluorophenyl)cinnolin-7-yl]ethyl}-9H-purin-6-amine
DMRY7KV	DT	Small molecular drug
DMRY7KV	PC	53235521
DMRY7KV	MW	419.8
DMRY7KV	FM	C21H15ClFN7
DMRY7KV	IC	InChI=1S/C21H15ClFN7/c1-11(29-21-19-20(25-9-24-19)26-10-27-21)15-8-16(22)14-5-6-28-30-18(14)17(15)12-3-2-4-13(23)7-12/h2-11H,1H3,(H2,24,25,26,27,29)
DMRY7KV	CS	CC(C1=CC(=C2C=CN=NC2=C1C3=CC(=CC=C3)F)Cl)NC4=NC=NC5=C4NC=N5
DMRY7KV	IK	KRDULPYOVRWKMA-UHFFFAOYSA-N
DMRY7KV	IU	N-[1-[5-chloro-8-(3-fluorophenyl)cinnolin-7-yl]ethyl]-7H-purin-6-amine

DMDYKPC	ID	DMDYKPC
DMDYKPC	DN	Lactam derivative 1
DMDYKPC	HS	Patented
DMDYKPC	SN	PMID25470667-Compound-Figure5-13
DMDYKPC	CP	ASTRAZENECA AB ASTRAZENECA UK LIMITED 
DMDYKPC	DT	Small molecular drug
DMDYKPC	PC	53472374
DMDYKPC	MW	401.2
DMDYKPC	FM	C19H14Cl2N4O2
DMDYKPC	IC	InChI=1S/C19H14Cl2N4O2/c20-12-3-6-14(15(21)9-12)11-1-4-13(5-2-11)25-7-8-27-18-16(19(25)26)17(22)23-10-24-18/h1-6,9-10H,7-8H2,(H2,22,23,24)
DMDYKPC	CS	C1COC2=NC=NC(=C2C(=O)N1C3=CC=C(C=C3)C4=C(C=C(C=C4)Cl)Cl)N
DMDYKPC	IK	QDUBGZSEYIQVEI-UHFFFAOYSA-N
DMDYKPC	IU	4-amino-6-[4-(2,4-dichlorophenyl)phenyl]-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one

DMT58QE	ID	DMT58QE
DMT58QE	DN	Lactam derivative 2
DMT58QE	HS	Patented
DMT58QE	SN	PMID25470667-Compound-Figure5-15
DMT58QE	CP	GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMT58QE	DT	Small molecular drug
DMT58QE	PC	71062853
DMT58QE	MW	406.8
DMT58QE	FM	C20H15ClN6O2
DMT58QE	IC	InChI=1S/C20H15ClN6O2/c21-13-2-1-3-14(9-13)26-5-4-12-8-15(10-23-18(12)26)27-6-7-29-19-16(20(27)28)17(22)24-11-25-19/h1-5,8-11H,6-7H2,(H2,22,24,25)
DMT58QE	CS	C1COC2=NC=NC(=C2C(=O)N1C3=CN=C4C(=C3)C=CN4C5=CC(=CC=C5)Cl)N
DMT58QE	IK	IHNUTZUAQGMDQV-UHFFFAOYSA-N
DMT58QE	IU	4-amino-6-[1-(3-chlorophenyl)pyrrolo[2,3-b]pyridin-5-yl]-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one

DMD0XIL	ID	DMD0XIL
DMD0XIL	DN	Lactam derivative 3
DMD0XIL	HS	Patented
DMD0XIL	SN	PMID25470667-Compound-Figure5-16
DMD0XIL	CP	GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMD0XIL	DT	Small molecular drug
DMD0XIL	PC	74763144
DMD0XIL	MW	455.4
DMD0XIL	FM	C22H16F3N5O3
DMD0XIL	IC	InChI=1S/C22H16F3N5O3/c23-22(24,25)33-16-3-1-2-14(11-16)29-7-6-13-10-15(4-5-17(13)29)30-8-9-32-20-18(21(30)31)19(26)27-12-28-20/h1-7,10-12H,8-9H2,(H2,26,27,28)
DMD0XIL	CS	C1COC2=NC=NC(=C2C(=O)N1C3=CC4=C(C=C3)N(C=C4)C5=CC(=CC=C5)OC(F)(F)F)N
DMD0XIL	IK	QBBURCWZLKKIPV-UHFFFAOYSA-N
DMD0XIL	IU	4-amino-6-[1-[3-(trifluoromethoxy)phenyl]indol-5-yl]-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one

DMJ3ZAI	ID	DMJ3ZAI
DMJ3ZAI	DN	Lactam derivative 4
DMJ3ZAI	HS	Patented
DMJ3ZAI	SN	PMID25470667-Compound-Figure5-7
DMJ3ZAI	CP	MERCK SHARP & DOHME CORP. GRAHAM, Thomas SHEN, Dong-Ming NARGUND, Ravi, P. WU, Zhicai LIU, Wenshen
DMJ3ZAI	DT	Small molecular drug
DMJ3ZAI	PC	60164075
DMJ3ZAI	MW	508.7
DMJ3ZAI	FM	C29H40N4O4
DMJ3ZAI	IC	InChI=1S/C29H40N4O4/c1-2-3-4-5-6-7-8-24-31-27(30)26-28(32-24)37-18-17-33(29(26)36)23-15-13-22(14-16-23)21-11-9-20(10-12-21)19-25(34)35/h13-16,20-21H,2-12,17-19H2,1H3,(H,34,35)(H2,30,31,32)
DMJ3ZAI	CS	CCCCCCCCC1=NC(=C2C(=N1)OCCN(C2=O)C3=CC=C(C=C3)C4CCC(CC4)CC(=O)O)N
DMJ3ZAI	IK	AGYANLSXRVBLRK-UHFFFAOYSA-N
DMJ3ZAI	IU	2-[4-[4-(4-amino-2-octyl-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid

DMX5FYZ	ID	DMX5FYZ
DMX5FYZ	DN	Lactam derivative 5
DMX5FYZ	HS	Patented
DMX5FYZ	SN	PMID25470667-Compound-Figure5-8
DMX5FYZ	CP	MERCK SHARP & DOHME CORP. GRAHAM, Thomas SHEN, Dong-Ming NARGUND, Ravi, P. WU, Zhicai LIU, Wenshen
DMX5FYZ	DT	Small molecular drug
DMX5FYZ	PC	60194497
DMX5FYZ	MW	510.6
DMX5FYZ	FM	C28H38N4O5
DMX5FYZ	IC	InChI=1S/C28H38N4O5/c1-2-3-4-5-6-16-37-28-30-25(29)24-26(31-28)36-17-15-32(27(24)35)22-13-11-21(12-14-22)20-9-7-19(8-10-20)18-23(33)34/h11-14,19-20H,2-10,15-18H2,1H3,(H,33,34)(H2,29,30,31)
DMX5FYZ	CS	CCCCCCCOC1=NC(=C2C(=N1)OCCN(C2=O)C3=CC=C(C=C3)C4CCC(CC4)CC(=O)O)N
DMX5FYZ	IK	ZERDUDAYCJCZOG-UHFFFAOYSA-N
DMX5FYZ	IU	2-[4-[4-(4-amino-2-heptoxy-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid

DMWC3P5	ID	DMWC3P5
DMWC3P5	DN	Lactol derivative 1
DMWC3P5	HS	Patented
DMWC3P5	SN	PMID27537201-Compound-Figure5down
DMWC3P5	CP	RedX Pharma Limited (Manchester, GB)
DMWC3P5	DT	Small molecular drug

DMP3GRA	ID	DMP3GRA
DMP3GRA	DN	Lactol derivative 2
DMP3GRA	HS	Patented
DMP3GRA	SN	PMID27537201-Compound-Figure6
DMP3GRA	CP	REDX PHARMA LIMITED LINDSAY, Derek JACKSON, PeteREDX PHARMA LIMITED LINDSAY, Derek JACKSON, Peter HINDLEY, Stephen BHAMRA, IndeREDX PHARMA LTD [GBREDX PHARMA LTD [GB]BRADFORD PHARMA LTD [GBBRADFORD PHARMA LTREDX PHARMA LTD
DMP3GRA	DT	Small molecular drug

DMCULK7	ID	DMCULK7
DMCULK7	DN	Lazabemide
DMCULK7	HS	Patented
DMCULK7	SN	103878-84-8; Ro-19-6327; N-(2-Aminoethyl)-5-chloropicolinamide; CCRIS 7301; UNII-420HD787N9; N-(2-aminoethyl)-5-chloropyridine-2-carboxamide; Ro 19-6327 hydrate; CHEMBL279390; Ro 19-6327/000; 420HD787N9; C8H10ClN3O; 2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide;N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide; NCGC00167737-01; Lazabemide [USAN:INN]; Lazabemide [USAN:INN:BAN];  Lazabemine; Pakio; Tempium; Ro-41-3776; Ro-19-6327/000; LAZEBEMIDE
DMCULK7	CP	Roche Holding AG
DMCULK7	DT	Small molecular drug
DMCULK7	PC	71307
DMCULK7	MW	199.64
DMCULK7	FM	C8H10ClN3O
DMCULK7	IC	InChI=1S/C8H10ClN3O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10/h1-2,5H,3-4,10H2,(H,11,13)
DMCULK7	CS	C1=CC(=NC=C1Cl)C(=O)NCCN
DMCULK7	IK	JZXRLKWWVNUZRB-UHFFFAOYSA-N
DMCULK7	IU	N-(2-aminoethyl)-5-chloropyridine-2-carboxamide
DMCULK7	CA	CAS 103878-84-8
DMCULK7	DE	Skin imperfections; Cognitive impairment

DM189D7	ID	DM189D7
DM189D7	DN	Lazabemide analog 1
DM189D7	HS	Patented
DM189D7	SN	PMID29324067-Compound-23
DM189D7	CP	University Zhejiang Technology
DM189D7	DT	Small molecular drug

DM1STAD	ID	DM1STAD
DM1STAD	DN	L-piperazino-3-phenyl-indane derivative 1
DM1STAD	HS	Patented
DM1STAD	SN	PMID26609882-Compound-57
DM1STAD	CP	H. LUNDBECK A/S HOLM, Ren BRUUN, LonH. Lundbeck A/S
DM1STAD	DT	Small molecular drug

DMGKQXP	ID	DMGKQXP
DMGKQXP	DN	Lycorine dimer salt derivative 1
DMGKQXP	HS	Patented
DMGKQXP	SN	PMID27967267-Compound-40
DMGKQXP	CP	Kunming Inst Botany CN ACAD
DMGKQXP	DT	Small molecular drug

DMN7I9C	ID	DMN7I9C
DMN7I9C	DN	Macrocycle derivative 1
DMN7I9C	HS	Patented
DMN7I9C	SN	PMID30107136-Compound-Example65
DMN7I9C	CP	Bristol-Myers Squibb Company
DMN7I9C	DT	Small molecule immunotherapy 
DMN7I9C	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM1KBSV	ID	DM1KBSV
DM1KBSV	DN	Macrocycle derivative 13
DM1KBSV	HS	Patented
DM1KBSV	SN	PMID28270010-Compound-Figure21-a
DM1KBSV	CP	CS THERAPEUTICS INC
DM1KBSV	DT	Small molecular drug
DM1KBSV	PC	123787452
DM1KBSV	MW	395.4
DM1KBSV	FM	C20H18FN5O3
DM1KBSV	IC	InChI=1S/C20H18FN5O3/c1-11-14-8-13(21)3-4-16(14)27-5-6-28-20-18(15(9-22)26(2)25-20)12-7-17(29-11)19(23)24-10-12/h3-4,7-8,10-11H,5-6H2,1-2H3,(H2,23,24)
DM1KBSV	CS	CC1C2=C(C=CC(=C2)F)OCCOC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C
DM1KBSV	IK	IAURDDBZTWBKOT-UHFFFAOYSA-N
DM1KBSV	IU	20-amino-14-fluoro-4,17-dimethyl-7,10,18-trioxa-4,5,21-triazatetracyclo[17.3.1.02,6.011,16]tricosa-1(23),2,5,11(16),12,14,19,21-octaene-3-carbonitrile
DM1KBSV	DE	Cell proliferative disorder

DMXSRPH	ID	DMXSRPH
DMXSRPH	DN	Macrocycle derivative 14
DMXSRPH	HS	Patented
DMXSRPH	SN	PMID26161698-Compound-7
DMXSRPH	CP	CT NAC INVESTIGACIONES ONCOLOGICAS CNIO [ES]
DMXSRPH	DT	Small molecular drug
DMXSRPH	PC	136644752
DMXSRPH	MW	309.4
DMXSRPH	FM	C17H19N5O
DMXSRPH	IC	InChI=1S/C17H19N5O/c1-3-13-11-14(4-1)23-10-9-18-7-2-8-19-16-5-6-17-20-12-15(13)22(17)21-16/h1,3-6,11-12,18H,2,7-10H2,(H,19,21)
DMXSRPH	CS	C1CNCCOC2=CC=CC(=C2)C3=CN=C4N3N=C(C=C4)NC1
DMXSRPH	IK	LGJSILJEEDDVAZ-UHFFFAOYSA-N
DMXSRPH	IU	7-oxa-10,14,19,21,22-pentazatetracyclo[13.5.2.12,6.018,21]tricosa-1(20),2(23),3,5,15(22),16,18-heptaene

DM5OEQZ	ID	DM5OEQZ
DM5OEQZ	DN	Macrocycle derivative 2
DM5OEQZ	HS	Patented
DM5OEQZ	SN	PMID30107136-Compound-Example66
DM5OEQZ	CP	Bristol-Myers Squibb Company
DM5OEQZ	DT	Small molecule immunotherapy 
DM5OEQZ	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMYGFTI	ID	DMYGFTI
DMYGFTI	DN	Macrocycle derivative 3
DMYGFTI	HS	Patented
DMYGFTI	SN	PMID30107136-Compound-Example67
DMYGFTI	CP	Bristol-Myers Squibb Company
DMYGFTI	DT	Small molecule immunotherapy 
DMYGFTI	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMOQBN4	ID	DMOQBN4
DMOQBN4	DN	Macrocycle derivative 4
DMOQBN4	HS	Patented
DMOQBN4	SN	PMID30107136-Compound-Example68
DMOQBN4	CP	BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMOQBN4	DT	Small molecule immunotherapy 
DMOQBN4	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMK3UJY	ID	DMK3UJY
DMK3UJY	DN	Macrocycle derivative 5
DMK3UJY	HS	Patented
DMK3UJY	SN	PMID30107136-Compound-Example69
DMK3UJY	CP	BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMK3UJY	DT	Small molecule immunotherapy 
DMK3UJY	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMQ84KW	ID	DMQ84KW
DMQ84KW	DN	Macrocycle derivative 6
DMQ84KW	HS	Patented
DMQ84KW	SN	PMID30107136-Compound-Example70
DMQ84KW	CP	BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMQ84KW	DT	Small molecule immunotherapy 
DMQ84KW	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMP2JF0	ID	DMP2JF0
DMP2JF0	DN	Macrocycle derivative 7
DMP2JF0	HS	Patented
DMP2JF0	SN	PMID30107136-Compound-Example71
DMP2JF0	CP	BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMP2JF0	DT	Small molecule immunotherapy 
DMP2JF0	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMOMTBE	ID	DMOMTBE
DMOMTBE	DN	Macrocycle derivative 8
DMOMTBE	HS	Patented
DMOMTBE	SN	PMID30107136-Compound-Example72
DMOMTBE	CP	BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMOMTBE	DT	Small molecule immunotherapy 
DMOMTBE	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMARU0E	ID	DMARU0E
DMARU0E	DN	Macrocycle derivative 9
DMARU0E	HS	Patented
DMARU0E	SN	PMID30107136-Compound-Example73
DMARU0E	CP	BRISTOL-MYERS SQUIBB COMPANY
DMARU0E	DT	Small molecule immunotherapy 
DMARU0E	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMS65IT	ID	DMS65IT
DMS65IT	DN	Macrocyclic peptide analog 1
DMS65IT	HS	Patented
DMS65IT	SN	PMID30107136-Compound-Example74
DMS65IT	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMS65IT	DT	Small molecule immunotherapy 
DMS65IT	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMOGLBZ	ID	DMOGLBZ
DMOGLBZ	DN	Macrocyclic peptide analog 2
DMOGLBZ	HS	Patented
DMOGLBZ	SN	PMID30107136-Compound-Example75
DMOGLBZ	CP	Aurigene Discovery Technologies Limited
DMOGLBZ	DT	Small molecule immunotherapy 
DMOGLBZ	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMV172W	ID	DMV172W
DMV172W	DN	Macrocyclic peptide analog 3
DMV172W	HS	Patented
DMV172W	SN	PMID30107136-Compound-Example76
DMV172W	CP	Aurigene Discovery Technologies Limited
DMV172W	DT	Small molecule immunotherapy 
DMV172W	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM0ON7S	ID	DM0ON7S
DM0ON7S	DN	Macrolactam derivative 1
DM0ON7S	HS	Patented
DM0ON7S	SN	PMID27310003-Compound-15
DM0ON7S	CP	BIOGEN MA INC
DM0ON7S	DT	Small molecular drug

DME72VA	ID	DME72VA
DME72VA	DN	Macrolactam derivative 2
DME72VA	HS	Patented
DME72VA	SN	PMID27310003-Compound-16
DME72VA	CP	BIOGEN MA INC
DME72VA	DT	Small molecular drug

DMFNGUV	ID	DMFNGUV
DMFNGUV	DN	Macrolactam derivative 3
DMFNGUV	HS	Patented
DMFNGUV	SN	PMID27310003-Compound-17
DMFNGUV	CP	BIOGEN MA INC
DMFNGUV	DT	Small molecular drug

DM5AXHF	ID	DM5AXHF
DM5AXHF	DN	Macrolactam derivative 4
DM5AXHF	HS	Patented
DM5AXHF	SN	PMID27310003-Compound-18
DM5AXHF	CP	BIOGEN MA INC
DM5AXHF	DT	Small molecular drug

DMINM8F	ID	DMINM8F
DMINM8F	DN	Maleimides derivative 1
DMINM8F	HS	Patented
DMINM8F	SN	PMID27828716-Compound-1M
DMINM8F	CP	STEM CELLS FOR SAFER MEDICINES LIMITED BONE, Heather Karyn TOSH, David WELHAM, Melanie Joanne
DMINM8F	DT	Small molecular drug

DMUVYWE	ID	DMUVYWE
DMUVYWE	DN	Maleimides derivative 2
DMUVYWE	HS	Patented
DMUVYWE	SN	PMID27828716-Compound-SB216763 
DMUVYWE	CP	RUDD, ChristopheChung-Ang University

DMEFQND	ID	DMEFQND
DMEFQND	DN	Maleimides derivative 3
DMEFQND	HS	Patented
DMEFQND	SN	PMID27828716-Compound-SB415286 
DMEFQND	CP	RUDD, Christopher

DMIE7U3	ID	DMIE7U3
DMIE7U3	DN	Mannoside derivative 1
DMIE7U3	HS	Patented
DMIE7U3	SN	PMID26651364-Compound-100
DMIE7U3	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMIE7U3	DT	Carbohydrates
DMIE7U3	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMZYRHN	ID	DMZYRHN
DMZYRHN	DN	Mannoside derivative 10
DMZYRHN	HS	Patented
DMZYRHN	SN	PMID26651364-Compound-96
DMZYRHN	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMZYRHN	DT	Carbohydrates
DMZYRHN	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM8I051	ID	DM8I051
DM8I051	DN	Mannoside derivative 11
DM8I051	HS	Patented
DM8I051	SN	PMID26651364-Compound-97
DM8I051	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM8I051	DT	Carbohydrates
DM8I051	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM4QUY0	ID	DM4QUY0
DM4QUY0	DN	Mannoside derivative 12
DM4QUY0	HS	Patented
DM4QUY0	SN	PMID26651364-Compound-98
DM4QUY0	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM4QUY0	DT	Carbohydrates
DM4QUY0	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM0U7P9	ID	DM0U7P9
DM0U7P9	DN	Mannoside derivative 13
DM0U7P9	HS	Patented
DM0U7P9	SN	PMID26651364-Compound-99
DM0U7P9	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM0U7P9	DT	Carbohydrates
DM0U7P9	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMFEQD2	ID	DMFEQD2
DMFEQD2	DN	Mannoside derivative 2
DMFEQD2	HS	Patented
DMFEQD2	SN	PMID26651364-Compound-101
DMFEQD2	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMFEQD2	DT	Carbohydrates
DMFEQD2	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMPF2UG	ID	DMPF2UG
DMPF2UG	DN	Mannoside derivative 3
DMPF2UG	HS	Patented
DMPF2UG	SN	PMID26651364-Compound-102
DMPF2UG	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMPF2UG	DT	Carbohydrates
DMPF2UG	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMZBY73	ID	DMZBY73
DMZBY73	DN	Mannoside derivative 4
DMZBY73	HS	Patented
DMZBY73	SN	PMID26651364-Compound-103
DMZBY73	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMZBY73	DT	Carbohydrates
DMZBY73	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMXNY8	ID	DMMXNY8
DMMXNY8	DN	Mannoside derivative 5
DMMXNY8	HS	Patented
DMMXNY8	SN	PMID26651364-Compound-104
DMMXNY8	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMMXNY8	DT	Carbohydrates
DMMXNY8	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMCM3NW	ID	DMCM3NW
DMCM3NW	DN	Mannoside derivative 6
DMCM3NW	HS	Patented
DMCM3NW	SN	PMID26651364-Compound-92
DMCM3NW	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMCM3NW	DT	Carbohydrates
DMCM3NW	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMOUT1F	ID	DMOUT1F
DMOUT1F	DN	Mannoside derivative 7
DMOUT1F	HS	Patented
DMOUT1F	SN	PMID26651364-Compound-93
DMOUT1F	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMOUT1F	DT	Carbohydrates
DMOUT1F	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMKTJAH	ID	DMKTJAH
DMKTJAH	DN	Mannoside derivative 8
DMKTJAH	HS	Patented
DMKTJAH	SN	PMID26651364-Compound-94
DMKTJAH	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMKTJAH	DT	Carbohydrates
DMKTJAH	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMIKZXD	ID	DMIKZXD
DMIKZXD	DN	Mannoside derivative 9
DMIKZXD	HS	Patented
DMIKZXD	SN	PMID26651364-Compound-95
DMIKZXD	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMIKZXD	DT	Carbohydrates
DMIKZXD	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMCS9P	ID	DMMCS9P
DMMCS9P	DN	Matairesinol derivative 1
DMMCS9P	HS	Patented
DMMCS9P	SN	PMID26882240-Compound-39
DMMCS9P	CP	Office of Research Affairs/UIF, Yonsei University, S. Korea
DMMCS9P	DT	Small molecular drug

DMUOW3T	ID	DMUOW3T
DMUOW3T	DN	Metal complex derivative 1
DMUOW3T	HS	Patented
DMUOW3T	SN	PMID27977313-Compound-13
DMUOW3T	DT	Small molecular drug

DM0BTH8	ID	DM0BTH8
DM0BTH8	DN	Metal complex derivative 2
DM0BTH8	HS	Patented
DM0BTH8	SN	PMID27977313-Compound-14
DM0BTH8	DT	Small molecular drug

DM31BMP	ID	DM31BMP
DM31BMP	DN	Metal complex derivative 3
DM31BMP	HS	Patented
DM31BMP	SN	PMID27977313-Compound-Figure4e
DM31BMP	DT	Small molecular drug

DM9BYJ0	ID	DM9BYJ0
DM9BYJ0	DN	Methyl 2-amino-4-phenylthiophene-3-carboxylate
DM9BYJ0	HS	Patented
DM9BYJ0	SN	methyl 2-amino-4-phenylthiophene-3-carboxylate; 67171-55-5; 2-Amino-4-phenyl-thiophene-3-carboxylic acid methyl ester; 2-Amino-4-phenylthiophene-3-carboxylic acid methyl ester; 2-amino-4-phenylthiophene-3-carboxylic acidmethyl ester; AC1LEGNM; SMR000122717; ChemDiv3_014276; MLS000523644; SCHEMBL688523; METHYL2-AMINO-4-PHENYLTHIOPHENE-3-CARBOXYLATE; CHEMBL1456242; CTK6I8713; ZINC52966; DTXSID30350681; HMS1513I20; BDBM139491; HMS2354F24; KS-00003KD2; ALBB-001671; BBL015795; SBB006989; MFCD01050444; 7878AE; STK256668; AKOS000220131; FS
DM9BYJ0	DT	Small molecular drug
DM9BYJ0	PC	685886
DM9BYJ0	MW	233.29
DM9BYJ0	FM	C12H11NO2S
DM9BYJ0	IC	InChI=1S/C12H11NO2S/c1-15-12(14)10-9(7-16-11(10)13)8-5-3-2-4-6-8/h2-7H,13H2,1H3
DM9BYJ0	CS	COC(=O)C1=C(SC=C1C2=CC=CC=C2)N
DM9BYJ0	IK	KHNSKPUYBBZGLW-UHFFFAOYSA-N
DM9BYJ0	IU	methyl 2-amino-4-phenylthiophene-3-carboxylate
DM9BYJ0	CA	CAS 67171-55-5

DMUNME2	ID	DMUNME2
DMUNME2	DN	Methylbenzenesulfonamide derivative 1
DMUNME2	HS	Patented
DMUNME2	SN	PMID27539678-Compound-15
DMUNME2	CP	UNIVERSITY OF SOUTH AUSTRALIA CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC
DMUNME2	DT	Small molecular drug

DM5PS6K	ID	DM5PS6K
DM5PS6K	DN	Methyl-piperidine compound 1
DM5PS6K	HS	Patented
DM5PS6K	SN	PMID28627961-Compound-36
DM5PS6K	CP	ELI LILLY AND COMPANY
DM5PS6K	DT	Small molecular drug
DM5PS6K	DE	Neoplasm; Angiogenesis disorder

DMHVZ4M	ID	DMHVZ4M
DMHVZ4M	DN	Methylsulfonylbenzamide derivative 2
DMHVZ4M	HS	Patented
DMHVZ4M	SN	PMID25539043-Compound-WO2013088315Example52
DMHVZ4M	CP	PFIZER LIMITED
DMHVZ4M	DT	Small molecular drug

DM8UOY6	ID	DM8UOY6
DM8UOY6	DN	MHHFJYABEVJNEG-UHFFFAOYSA-N
DM8UOY6	HS	Patented
DM8UOY6	SN	CHEMBL1076743; SCHEMBL3036046; MHHFJYABEVJNEG-UHFFFAOYSA-N; BDBM50313340; 6-(dipropylamino)-N-(2-methyl-4-sulfamoylphenyl)pyrimidine-4-carboxamide; N-[4-(aminosulfonyl)-2-methylphenyl]-6-(dipropylamino)pyrimidine-4-carboxamide
DM8UOY6	DT	Small molecular drug
DM8UOY6	PC	25182905
DM8UOY6	MW	391.5
DM8UOY6	FM	C18H25N5O3S
DM8UOY6	IC	InChI=1S/C18H25N5O3S/c1-4-8-23(9-5-2)17-11-16(20-12-21-17)18(24)22-15-7-6-14(10-13(15)3)27(19,25)26/h6-7,10-12H,4-5,8-9H2,1-3H3,(H,22,24)(H2,19,25,26)
DM8UOY6	CS	CCCN(CCC)C1=NC=NC(=C1)C(=O)NC2=C(C=C(C=C2)S(=O)(=O)N)C
DM8UOY6	IK	MHHFJYABEVJNEG-UHFFFAOYSA-N
DM8UOY6	IU	6-(dipropylamino)-N-(2-methyl-4-sulfamoylphenyl)pyrimidine-4-carboxamide

DMNEY58	ID	DMNEY58
DMNEY58	DN	ML272
DMNEY58	HS	Patented
DMNEY58	SN	N-(2-(4-(2-Oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-2-naphthamide; CHEMBL492797; 1130067-18-3; ML272; VU0155056-2; SCHEMBL2724877; BDBM87245; cid_53481919; CHEBI:131157; NCGC00386898-01; VU0155056-3; VU0155056-1; US9453017, 3; VU0156056 (1); N-[2-[4-(2-keto-3H-benzimidazol-1-yl)piperidino]ethyl]-2-naphthamide;hydrochloride; N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamide;hydrochloride; N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]naphthalene-2-carboxamide
DMNEY58	DT	Small molecular drug
DMNEY58	PC	25105704
DMNEY58	MW	414.5
DMNEY58	FM	C25H26N4O2
DMNEY58	IC	InChI=1S/C25H26N4O2/c30-24(20-10-9-18-5-1-2-6-19(18)17-20)26-13-16-28-14-11-21(12-15-28)29-23-8-4-3-7-22(23)27-25(29)31/h1-10,17,21H,11-16H2,(H,26,30)(H,27,31)
DMNEY58	CS	C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCNC(=O)C4=CC5=CC=CC=C5C=C4
DMNEY58	IK	IXLLRNNFUYEADZ-UHFFFAOYSA-N
DMNEY58	IU	N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]naphthalene-2-carboxamide
DMNEY58	CB	CHEBI:131157

DMRWNAY	ID	DMRWNAY
DMRWNAY	DN	Monoamine derivative 1
DMRWNAY	HS	Patented
DMRWNAY	SN	PMID26815044-Compound-94
DMRWNAY	CP	UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DMRWNAY	DT	Small molecular drug
DMRWNAY	PC	65055
DMRWNAY	MW	211.3
DMRWNAY	FM	C15H17N
DMRWNAY	IC	InChI=1S/C15H17N/c1-3-7-14(8-4-1)11-12-16-13-15-9-5-2-6-10-15/h1-10,16H,11-13H2
DMRWNAY	CS	C1=CC=C(C=C1)CCNCC2=CC=CC=C2
DMRWNAY	IK	UPABQMWFWCMOFV-UHFFFAOYSA-N
DMRWNAY	IU	N-benzyl-2-phenylethanamine
DMRWNAY	CA	CAS 3647-71-0
DMRWNAY	CB	CHEBI:52148
DMRWNAY	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMAZ6DI	ID	DMAZ6DI
DMAZ6DI	DN	Monoamine derivative 2
DMAZ6DI	HS	Patented
DMAZ6DI	SN	PMID26815044-Compound-95
DMAZ6DI	CP	UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DMAZ6DI	DT	Small molecular drug
DMAZ6DI	PC	4260604
DMAZ6DI	MW	303.4
DMAZ6DI	FM	C21H21NO
DMAZ6DI	IC	InChI=1S/C21H21NO/c1-3-8-18(9-4-1)14-15-22-17-19-10-7-13-21(16-19)23-20-11-5-2-6-12-20/h1-13,16,22H,14-15,17H2
DMAZ6DI	CS	C1=CC=C(C=C1)CCNCC2=CC(=CC=C2)OC3=CC=CC=C3
DMAZ6DI	IK	VXWOCJGIIONIQR-UHFFFAOYSA-N
DMAZ6DI	IU	N-[(3-phenoxyphenyl)methyl]-2-phenylethanamine
DMAZ6DI	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM4I75L	ID	DM4I75L
DM4I75L	DN	Monoamine derivative 3
DM4I75L	HS	Patented
DM4I75L	SN	PMID26815044-Compound-96
DM4I75L	CP	UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DM4I75L	DT	Small molecular drug
DM4I75L	PC	43220319
DM4I75L	MW	239.35
DM4I75L	FM	C17H21N
DM4I75L	IC	InChI=1S/C17H21N/c1-14-8-9-17(12-15(14)2)13-18-11-10-16-6-4-3-5-7-16/h3-9,12,18H,10-11,13H2,1-2H3
DM4I75L	CS	CC1=C(C=C(C=C1)CNCCC2=CC=CC=C2)C
DM4I75L	IK	XXTJZYJWHSDDJG-UHFFFAOYSA-N
DM4I75L	IU	N-[(3,4-dimethylphenyl)methyl]-2-phenylethanamine
DM4I75L	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMYFKP2	ID	DMYFKP2
DMYFKP2	DN	Monoamine derivative 4
DMYFKP2	HS	Patented
DMYFKP2	SN	PMID26815044-Compound-97
DMYFKP2	CP	UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DMYFKP2	DT	Small molecular drug
DMYFKP2	PC	1990821
DMYFKP2	MW	271.35
DMYFKP2	FM	C17H21NO2
DMYFKP2	IC	InChI=1S/C17H21NO2/c1-19-16-8-9-17(20-2)15(12-16)13-18-11-10-14-6-4-3-5-7-14/h3-9,12,18H,10-11,13H2,1-2H3
DMYFKP2	CS	COC1=CC(=C(C=C1)OC)CNCCC2=CC=CC=C2
DMYFKP2	IK	IAEIRIQVUSGNFI-UHFFFAOYSA-N
DMYFKP2	IU	N-[(2,5-dimethoxyphenyl)methyl]-2-phenylethanamine
DMYFKP2	CA	CAS 353773-38-3
DMYFKP2	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM3PF60	ID	DM3PF60
DM3PF60	DN	Monoamine derivative 5
DM3PF60	HS	Patented
DM3PF60	SN	PMID26815044-Compound-98
DM3PF60	CP	UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DM3PF60	DT	Small molecular drug
DM3PF60	PC	17206454
DM3PF60	MW	237.34
DM3PF60	FM	C14H23NO2
DM3PF60	IC	InChI=1S/C14H23NO2/c1-11(2)7-8-15-10-12-5-6-13(16-3)14(9-12)17-4/h5-6,9,11,15H,7-8,10H2,1-4H3
DM3PF60	CS	CC(C)CCNCC1=CC(=C(C=C1)OC)OC
DM3PF60	IK	BDUIJHAHSRAUGH-UHFFFAOYSA-N
DM3PF60	IU	N-[(3,4-dimethoxyphenyl)methyl]-3-methylbutan-1-amine
DM3PF60	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMCI6YH	ID	DMCI6YH
DMCI6YH	DN	Monoaryl-1,2-diamine derivative 1
DMCI6YH	HS	Patented
DMCI6YH	SN	PMID29473428-Compound-62
DMCI6YH	CP	BRISTOL-MYERS SQUIBB COMPANY
DMCI6YH	DT	Small molecular drug

DMXUNZ1	ID	DMXUNZ1
DMXUNZ1	DN	Monoaryl-1,2-diamine derivative 2
DMXUNZ1	HS	Patented
DMXUNZ1	SN	PMID29473428-Compound-63
DMXUNZ1	CP	BRISTOL-MYERS SQUIBB COMPANY
DMXUNZ1	DT	Small molecular drug
DMXUNZ1	PC	122587053
DMXUNZ1	MW	415
DMXUNZ1	FM	C24H31ClN2O2
DMXUNZ1	IC	InChI=1S/C24H31ClN2O2/c1-3-13-27(16-17-5-6-17)23-12-7-19(18(4-2)15-24(28)29)14-22(23)26-21-10-8-20(25)9-11-21/h7-12,14,17-18,26H,3-6,13,15-16H2,1-2H3,(H,28,29)
DMXUNZ1	CS	CCCN(CC1CC1)C2=C(C=C(C=C2)C(CC)CC(=O)O)NC3=CC=C(C=C3)Cl
DMXUNZ1	IK	XRVVTNJDVWWYSU-UHFFFAOYSA-N
DMXUNZ1	IU	3-[3-(4-chloroanilino)-4-[cyclopropylmethyl(propyl)amino]phenyl]pentanoic acid

DMAXKPC	ID	DMAXKPC
DMAXKPC	DN	Monoaryl-1,2-diamine derivative 3
DMAXKPC	HS	Patented
DMAXKPC	SN	PMID29473428-Compound-64
DMAXKPC	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMAXKPC	DT	Small molecular drug
DMAXKPC	PC	126722449
DMAXKPC	MW	482.6
DMAXKPC	FM	C23H29F3N4O2S
DMAXKPC	IC	InChI=1S/C23H29F3N4O2S/c1-13(2)12-30(15-6-4-3-5-7-15)19-9-8-14(16-11-17(16)20(31)32)10-18(19)27-22-28-21(29-33-22)23(24,25)26/h8-10,13,15-17H,3-7,11-12H2,1-2H3,(H,31,32)(H,27,28,29)
DMAXKPC	CS	CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)C3CC3C(=O)O)NC4=NC(=NS4)C(F)(F)F
DMAXKPC	IK	NXZKEHFQEXBLSD-UHFFFAOYSA-N
DMAXKPC	IU	2-[4-[cyclohexyl(2-methylpropyl)amino]-3-[[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]phenyl]cyclopropane-1-carboxylic acid

DMD8AKH	ID	DMD8AKH
DMD8AKH	DN	Monoaryl-1,2-diamine derivative 4
DMD8AKH	HS	Patented
DMD8AKH	SN	PMID29473428-Compound-65
DMD8AKH	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMD8AKH	DT	Small molecular drug

DMJ8YZK	ID	DMJ8YZK
DMJ8YZK	DN	Monofluorine derivative 1
DMJ8YZK	HS	Patented
DMJ8YZK	SN	PMID29473428-Compound-40
DMJ8YZK	CP	MERCK PATENT GMBH SHERER, Brian A
DMJ8YZK	DT	Small molecular drug
DMJ8YZK	PC	118917109
DMJ8YZK	MW	336.4
DMJ8YZK	FM	C18H19F3N2O
DMJ8YZK	IC	InChI=1S/C18H19F3N2O/c19-14-3-1-2-13-16-9-22-10-23(16)15(17(13)14)8-18(20,21)11-4-6-12(24)7-5-11/h1-3,9-12,15,24H,4-8H2
DMJ8YZK	CS	C1CC(CCC1C(CC2C3=C(C=CC=C3F)C4=CN=CN24)(F)F)O
DMJ8YZK	IK	UNSORNINUVZBRF-UHFFFAOYSA-N
DMJ8YZK	IU	4-[1,1-difluoro-2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexan-1-ol

DMNGQ3I	ID	DMNGQ3I
DMNGQ3I	DN	MRL20
DMNGQ3I	HS	Patented
DMNGQ3I	SN	MRL20; CHEMBL181937; (2s)-2-(2-{[1-(4-Methoxybenzoyl)-2-Methyl-5-(Trifluoromethoxy)-1h-Indol-3-Yl]methyl}phenoxy)propanoic Acid; SCHEMBL5172443; GTPL6742; BDBM50157936; (2S)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid; (2S)-2-[2-({1-[(4-methoxyphenyl)carbonyl]-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl}methyl)phenoxy]propanoic acid; (S)-2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid
DMNGQ3I	DT	Small molecular drug
DMNGQ3I	PC	10143056
DMNGQ3I	MW	527.5
DMNGQ3I	FM	C28H24F3NO6
DMNGQ3I	IC	InChI=1S/C28H24F3NO6/c1-16-22(14-19-6-4-5-7-25(19)37-17(2)27(34)35)23-15-21(38-28(29,30)31)12-13-24(23)32(16)26(33)18-8-10-20(36-3)11-9-18/h4-13,15,17H,14H2,1-3H3,(H,34,35)/t17-/m0/s1
DMNGQ3I	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)OC)C=CC(=C2)OC(F)(F)F)CC4=CC=CC=C4O[C@@H](C)C(=O)O
DMNGQ3I	IK	BWTOBMCYVACNJZ-KRWDZBQOSA-N
DMNGQ3I	IU	(2S)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid
DMNGQ3I	DE	Discovery agent

DM8NS7U	ID	DM8NS7U
DM8NS7U	DN	MRL24
DM8NS7U	HS	Patented
DM8NS7U	SN	MRL 24
DM8NS7U	DT	Small molecular drug
DM8NS7U	PC	9958543
DM8NS7U	MW	527.5
DM8NS7U	FM	C28H24F3NO6
DM8NS7U	IC	InChI=1S/C28H24F3NO6/c1-16-23(14-18-5-4-6-21(13-18)37-17(2)27(34)35)24-15-22(38-28(29,30)31)11-12-25(24)32(16)26(33)19-7-9-20(36-3)10-8-19/h4-13,15,17H,14H2,1-3H3,(H,34,35)/t17-/m0/s1
DM8NS7U	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)OC)C=CC(=C2)OC(F)(F)F)CC4=CC(=CC=C4)O[C@@H](C)C(=O)O
DM8NS7U	IK	OFCWBJAYEIROGZ-KRWDZBQOSA-N
DM8NS7U	IU	(2S)-2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid
DM8NS7U	DE	Discovery agent

DMOZTUE	ID	DMOZTUE
DMOZTUE	DN	Mycophenolic acid/nucleotide derivative 1
DMOZTUE	HS	Patented
DMOZTUE	SN	PMID28074661-Compound-US20040023901c70
DMOZTUE	CP	Biota Inc
DMOZTUE	DT	Small molecular drug

DMHD8RK	ID	DMHD8RK
DMHD8RK	DN	Mycophenolic acid/nucleotide derivative 10
DMHD8RK	HS	Patented
DMHD8RK	SN	PMID28074661-Compound-US20087427636c61
DMHD8RK	CP	Gilead Sciences Inc
DMHD8RK	DT	Small molecular drug

DMXWOAG	ID	DMXWOAG
DMXWOAG	DN	Mycophenolic acid/nucleotide derivative 11
DMXWOAG	HS	Patented
DMXWOAG	SN	PMID28074661-Compound-US20087427636c62
DMXWOAG	CP	Gilead Sciences Inc
DMXWOAG	DT	Small molecular drug

DM47L9Q	ID	DM47L9Q
DM47L9Q	DN	Mycophenolic acid/nucleotide derivative 12
DM47L9Q	HS	Patented
DM47L9Q	SN	PMID28074661-Compound-US20087427636c63
DM47L9Q	CP	Gilead Sciences Inc
DM47L9Q	DT	Small molecular drug

DMAT9NE	ID	DMAT9NE
DMAT9NE	DN	Mycophenolic acid/nucleotide derivative 2
DMAT9NE	HS	Patented
DMAT9NE	SN	PMID28074661-Compound-US20087427636c53
DMAT9NE	CP	Gilead Sciences Inc
DMAT9NE	DT	Small molecular drug

DM5UX7B	ID	DM5UX7B
DM5UX7B	DN	Mycophenolic acid/nucleotide derivative 3
DM5UX7B	HS	Patented
DM5UX7B	SN	PMID28074661-Compound-US20087427636c54
DM5UX7B	CP	Gilead Sciences Inc
DM5UX7B	DT	Small molecular drug

DMEHMKY	ID	DMEHMKY
DMEHMKY	DN	Mycophenolic acid/nucleotide derivative 4
DMEHMKY	HS	Patented
DMEHMKY	SN	PMID28074661-Compound-US20087427636c55
DMEHMKY	CP	Gilead Sciences Inc
DMEHMKY	DT	Small molecular drug

DM74UP5	ID	DM74UP5
DM74UP5	DN	Mycophenolic acid/nucleotide derivative 5
DM74UP5	HS	Patented
DM74UP5	SN	PMID28074661-Compound-US20087427636c56
DM74UP5	CP	Gilead Sciences Inc
DM74UP5	DT	Small molecular drug

DMGFORB	ID	DMGFORB
DMGFORB	DN	Mycophenolic acid/nucleotide derivative 6
DMGFORB	HS	Patented
DMGFORB	SN	PMID28074661-Compound-US20087427636c57
DMGFORB	CP	Gilead Sciences Inc
DMGFORB	DT	Small molecular drug

DMC27TO	ID	DMC27TO
DMC27TO	DN	Mycophenolic acid/nucleotide derivative 7
DMC27TO	HS	Patented
DMC27TO	SN	PMID28074661-Compound-US20087427636c58
DMC27TO	CP	Gilead Sciences Inc
DMC27TO	DT	Small molecular drug

DMWGIJS	ID	DMWGIJS
DMWGIJS	DN	Mycophenolic acid/nucleotide derivative 8
DMWGIJS	HS	Patented
DMWGIJS	SN	PMID28074661-Compound-US20087427636c59
DMWGIJS	CP	Gilead Sciences Inc
DMWGIJS	DT	Small molecular drug

DMYQTLK	ID	DMYQTLK
DMYQTLK	DN	Mycophenolic acid/nucleotide derivative 9
DMYQTLK	HS	Patented
DMYQTLK	SN	PMID28074661-Compound-US20087427636c60
DMYQTLK	CP	Gilead Sciences Inc
DMYQTLK	DT	Small molecular drug

DMA8BLZ	ID	DMA8BLZ
DMA8BLZ	DN	MyriberineA
DMA8BLZ	HS	Patented
DMA8BLZ	CP	Nanjing Zhengliang Med. Tech. CO

DMH7T8C	ID	DMH7T8C
DMH7T8C	DN	N-(2-phenylcyclopropyl) amino acid derivative 1
DMH7T8C	HS	Patented
DMH7T8C	SN	PMID27019002-Compound-19
DMH7T8C	CP	ORYZON GENOMICS SA [ESOryzon Genomics S.A., Spain
DMH7T8C	DT	Small molecular drug

DM6YV3O	ID	DM6YV3O
DM6YV3O	DN	N-(2-phenylcyclopropyl) amino acid derivative 2
DM6YV3O	HS	Patented
DM6YV3O	SN	PMID27019002-Compound-19a
DM6YV3O	CP	ORYZON GENOMICS SA [ESOryzon Genomics S.A., Spain
DM6YV3O	DT	Small molecular drug

DMFBRSL	ID	DMFBRSL
DMFBRSL	DN	N-(2-phenylcyclopropyl) amino acid derivative 3
DMFBRSL	HS	Patented
DMFBRSL	SN	PMID27019002-Compound-19b
DMFBRSL	CP	ORYZON GENOMICS SA [ESOryzon Genomics S.A., Spain
DMFBRSL	DT	Small molecular drug

DM6TYM0	ID	DM6TYM0
DM6TYM0	DN	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1
DM6TYM0	HS	Patented
DM6TYM0	SN	PMID26161824-Compound-186
DM6TYM0	CP	THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN GREIG, lain Robert ROSS, Ruth Alexandra PERTWEE, Roger Guy TREMBLEAU, Laurent Alain Claude ABDEL-RAHMAN, Mostafa Hamed BAILLIE, Gemma Louise
DM6TYM0	DT	Small molecular drug
DM6TYM0	PC	66547077
DM6TYM0	MW	346.4
DM6TYM0	FM	C17H18N2O4S
DM6TYM0	IC	InChI=1S/C17H18N2O4S/c1-22-14-5-3-12(4-6-14)11-18-24(20,21)17-10-13-9-15(23-2)7-8-16(13)19-17/h3-10,18-19H,11H2,1-2H3
DM6TYM0	CS	COC1=CC=C(C=C1)CNS(=O)(=O)C2=CC3=C(N2)C=CC(=C3)OC
DM6TYM0	IK	ZYAIUNMZKGHCRV-UHFFFAOYSA-N
DM6TYM0	IU	5-methoxy-N-[(4-methoxyphenyl)methyl]-1H-indole-2-sulfonamide
DM6TYM0	DE	Obesity

DM2MPN0	ID	DM2MPN0
DM2MPN0	DN	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2
DM2MPN0	HS	Patented
DM2MPN0	SN	PMID26161824-Compound-187
DM2MPN0	CP	THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN GREIG, lain Robert ROSS, Ruth Alexandra PERTWEE, Roger Guy TREMBLEAU, Laurent Alain Claude ABDEL-RAHMAN, Mostafa Hamed BAILLIE, Gemma Louise
DM2MPN0	DT	Small molecular drug
DM2MPN0	PC	66547073
DM2MPN0	MW	380.4
DM2MPN0	FM	C21H17FN2O2S
DM2MPN0	IC	InChI=1S/C21H17FN2O2S/c22-19-11-9-17(10-12-19)16-7-5-15(6-8-16)14-23-27(25,26)21-13-18-3-1-2-4-20(18)24-21/h1-13,23-24H,14H2
DM2MPN0	CS	C1=CC=C2C(=C1)C=C(N2)S(=O)(=O)NCC3=CC=C(C=C3)C4=CC=C(C=C4)F
DM2MPN0	IK	ZYXQIXCJTWOQOB-UHFFFAOYSA-N
DM2MPN0	IU	N-[[4-(4-fluorophenyl)phenyl]methyl]-1H-indole-2-sulfonamide
DM2MPN0	DE	Obesity

DM8GJA7	ID	DM8GJA7
DM8GJA7	DN	N-(arylamino)sulfonamide derivative 1
DM8GJA7	HS	Patented
DM8GJA7	SN	PMID28594589-Compound-TABLE3c8
DM8GJA7	CP	Ardea Biosciences
DM8GJA7	DT	Small molecular drug
DM8GJA7	PC	15985394
DM8GJA7	MW	560.3
DM8GJA7	FM	C18H17F4IN2O4S
DM8GJA7	IC	InChI=1S/C18H17F4IN2O4S/c19-11-5-9(23)1-2-14(11)24-17-15(22)12(20)6-13(21)16(17)25-30(28,29)18(3-4-18)7-10(27)8-26/h1-2,5-6,10,24-27H,3-4,7-8H2
DM8GJA7	CS	C1CC1(CC(CO)O)S(=O)(=O)NC2=C(C(=C(C=C2F)F)F)NC3=C(C=C(C=C3)I)F
DM8GJA7	IK	DDZSGPZIFZFUSF-UHFFFAOYSA-N
DM8GJA7	IU	1-(2,3-dihydroxypropyl)-N-[3,4,6-trifluoro-2-(2-fluoro-4-iodoanilino)phenyl]cyclopropane-1-sulfonamide

DMGQWKH	ID	DMGQWKH
DMGQWKH	DN	N-(benzimidazole/indole) benzoic acid derivative 1
DMGQWKH	HS	Patented
DMGQWKH	SN	PMID28895472-Compound-17
DMGQWKH	CP	ASTELLAS PHARMA INC.  FURUTANI, Takashi  ENJO, Kentaro  KIKUCHI, AyaAstellas Pharma Inc.  KAKEFUDA, Akio   KONDOH, Yutaka   HIRANO, Masaak
DMGQWKH	DT	Small molecular drug

DMOPUFM	ID	DMOPUFM
DMOPUFM	DN	N-(benzimidazole/indole) benzoic acid derivative 2
DMOPUFM	HS	Patented
DMOPUFM	SN	PMID28895472-Compound-18
DMOPUFM	CP	ASTELLAS PHARMA INC.  FURUTANI, Takashi  ENJO, Kentaro  KIKUCHI, AyaAstellas Pharma Inc.  KAKEFUDA, Akio   KONDOH, Yutaka   HIRANO, Masaak
DMOPUFM	DT	Small molecular drug

DM541QW	ID	DM541QW
DM541QW	DN	N-(benzimidazolylcarbonyl)-piperidine derivative 1
DM541QW	HS	Patented
DM541QW	SN	PMID28895472-Compound-14
DM541QW	DT	Small molecular drug
DM541QW	PC	46909812
DM541QW	MW	301.4
DM541QW	FM	C17H23N3O2
DM541QW	IC	InChI=1S/C17H23N3O2/c1-17(2,22)11-12-7-9-20(10-8-12)16(21)15-18-13-5-3-4-6-14(13)19-15/h3-6,12,22H,7-11H2,1-2H3,(H,18,19)
DM541QW	CS	CC(C)(CC1CCN(CC1)C(=O)C2=NC3=CC=CC=C3N2)O
DM541QW	IK	ZCKTVNQIWGZETA-UHFFFAOYSA-N
DM541QW	IU	1H-benzimidazol-2-yl-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone

DM0OMAL	ID	DM0OMAL
DM0OMAL	DN	N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1
DM0OMAL	HS	Patented
DM0OMAL	SN	PMID27774824-Compound-Figure5Example25
DM0OMAL	CP	CADILA HEALTHCARE LIMITED
DM0OMAL	DT	Small molecular drug

DMARHJ9	ID	DMARHJ9
DMARHJ9	DN	N-(indolylcarbonyl)-piperidine derivative 1
DMARHJ9	HS	Patented
DMARHJ9	SN	PMID28895472-Compound-15
DMARHJ9	CP	ASTELLAS PHARMA INC.  AZAMI, Hidenori  ABE, Tomoaki  KAKEFUDA, Akio
DMARHJ9	DT	Small molecular drug
DMARHJ9	PC	25210792
DMARHJ9	MW	330.4
DMARHJ9	FM	C19H26N2O3
DMARHJ9	IC	InChI=1S/C19H26N2O3/c1-19(2,23)12-13-6-8-21(9-7-13)18(22)17-11-14-10-15(24-3)4-5-16(14)20-17/h4-5,10-11,13,20,23H,6-9,12H2,1-3H3
DMARHJ9	CS	CC(C)(CC1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)OC)O
DMARHJ9	IK	OXSCPDKUZWPWFR-UHFFFAOYSA-N
DMARHJ9	IU	[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(5-methoxy-1H-indol-2-yl)methanone

DM310ES	ID	DM310ES
DM310ES	DN	N-(naphthylamino)-benzoate derivative 1
DM310ES	HS	Patented
DM310ES	SN	PMID28895472-Compound-28
DM310ES	DT	Small molecular drug
DM310ES	PC	56851703
DM310ES	MW	308.29
DM310ES	FM	C17H12N2O4
DM310ES	IC	InChI=1S/C17H12N2O4/c20-17(21)11-4-3-5-12(10-11)18-15-8-9-16(19(22)23)14-7-2-1-6-13(14)15/h1-10,18H,(H,20,21)
DM310ES	CS	C1=CC=C2C(=C1)C(=CC=C2[N+](=O)[O-])NC3=CC=CC(=C3)C(=O)O
DM310ES	IK	ZLIDMWNTWSBTSM-UHFFFAOYSA-N
DM310ES	IU	3-[(4-nitronaphthalen-1-yl)amino]benzoic acid

DMNIWVG	ID	DMNIWVG
DMNIWVG	DN	N-(phenylamino)-benzoate derivative 1
DMNIWVG	HS	Patented
DMNIWVG	SN	PMID28895472-Compound-24
DMNIWVG	CP	EXXONMOBIL RESEARCH AND ENGINEERING COMPANY OLIVERI, Christopher, G. LAI, Wenyih, Frank DANDEKAR, Ajit, B. WEIGEL, Scott, J. KAY, Robert, Ellis WU, Jianxin, Jaso
DMNIWVG	DT	Small molecular drug

DM0ZJX7	ID	DM0ZJX7
DM0ZJX7	DN	N-(phenylpyrazolyl)benzamide derivative 1
DM0ZJX7	HS	Patented
DM0ZJX7	SN	PMID28270021-Compound-WO2013132376Example157
DM0ZJX7	CP	PFIZER INC
DM0ZJX7	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM305UL	ID	DM305UL
DM305UL	DN	N-(pyridin-2-yl)pyridine methylsulfone derivative 1
DM305UL	HS	Patented
DM305UL	SN	PMID26161698-Compound-27
DM305UL	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DM305UL	DT	Small molecular drug
DM305UL	PC	73508010
DM305UL	MW	405.4
DM305UL	FM	C19H17F2N3O3S
DM305UL	IC	InChI=1S/C19H17F2N3O3S/c1-27-17-8-13(20)3-4-14(17)15-9-19(23-10-16(15)21)24-18-7-12(5-6-22-18)11-28(2,25)26/h3-10H,11H2,1-2H3,(H,22,23,24)
DM305UL	CS	COC1=C(C=CC(=C1)F)C2=CC(=NC=C2F)NC3=NC=CC(=C3)CS(=O)(=O)C
DM305UL	IK	VRHHAMWTRSVIEX-UHFFFAOYSA-N
DM305UL	IU	5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-(methylsulfonylmethyl)pyridin-2-yl]pyridin-2-amine

DMRE2I3	ID	DMRE2I3
DMRE2I3	DN	N-(pyridin-2-yl)pyrimidin-4-amine derivative 1
DMRE2I3	HS	Patented
DMRE2I3	SN	PMID26161698-Compound-24
DMRE2I3	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMRE2I3	DT	Small molecular drug
DMRE2I3	PC	73672657
DMRE2I3	MW	456.4
DMRE2I3	FM	C19H16F4N4O3S
DMRE2I3	IC	InChI=1S/C19H16F4N4O3S/c1-30-15-7-12(20)3-4-13(15)14-8-17(25-10-24-14)27-18-6-11(9-31(2,28)29)5-16(26-18)19(21,22)23/h3-8,10H,9H2,1-2H3,(H,24,25,26,27)
DMRE2I3	CS	COC1=C(C=CC(=C1)F)C2=CC(=NC=N2)NC3=CC(=CC(=N3)C(F)(F)F)CS(=O)(=O)C
DMRE2I3	IK	WUAZMKUDCHZMEP-UHFFFAOYSA-N
DMRE2I3	IU	6-(4-fluoro-2-methoxyphenyl)-N-[4-(methylsulfonylmethyl)-6-(trifluoromethyl)pyridin-2-yl]pyrimidin-4-amine

DMTZ6K9	ID	DMTZ6K9
DMTZ6K9	DN	N-(pyridin-2-yl)pyrimidin-4-amine derivative 2
DMTZ6K9	HS	Patented
DMTZ6K9	SN	PMID26161698-Compound-31
DMTZ6K9	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMTZ6K9	DT	Small molecular drug
DMTZ6K9	PC	73891126
DMTZ6K9	MW	455.4
DMTZ6K9	FM	C19H17F4N5O2S
DMTZ6K9	IC	InChI=1S/C19H17F4N5O2S/c1-30-15-7-12(20)3-4-13(15)14-8-17(26-10-25-14)28-18-6-11(9-31(2,24)29)5-16(27-18)19(21,22)23/h3-8,10,24H,9H2,1-2H3,(H,25,26,27,28)
DMTZ6K9	CS	COC1=C(C=CC(=C1)F)C2=CC(=NC=N2)NC3=CC(=CC(=N3)C(F)(F)F)CS(=N)(=O)C
DMTZ6K9	IK	BYCJOJLDGATDTD-UHFFFAOYSA-N
DMTZ6K9	IU	6-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]-6-(trifluoromethyl)pyridin-2-yl]pyrimidin-4-amine

DMA85UD	ID	DMA85UD
DMA85UD	DN	N-(pyridinepyrroylylcarbonyl)-piperidine derivative 1
DMA85UD	HS	Patented
DMA85UD	SN	PMID28895472-Compound-16
DMA85UD	CP	ASTELLAS PHARMA INC.  AZAMI, Hidenori  ABE, Tomoaki  KAKEFUDA, Akio  HIRANO, Masaaki  WATANABE, Kazushi 
DMA85UD	DT	Small molecular drug
DMA85UD	PC	70848785
DMA85UD	MW	301.4
DMA85UD	FM	C17H23N3O2
DMA85UD	IC	InChI=1S/C17H23N3O2/c1-17(2,22)10-12-4-7-20(8-5-12)16(21)14-9-13-3-6-18-11-15(13)19-14/h3,6,9,11-12,19,22H,4-5,7-8,10H2,1-2H3
DMA85UD	CS	CC(C)(CC1CCN(CC1)C(=O)C2=CC3=C(N2)C=NC=C3)O
DMA85UD	IK	HSSJHQZLKSLBPS-UHFFFAOYSA-N
DMA85UD	IU	[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(1H-pyrrolo[2,3-c]pyridin-2-yl)methanone

DMSD4G0	ID	DMSD4G0
DMSD4G0	DN	N,N-bis(5-pyrazoyl)urea derivative 1
DMSD4G0	HS	Patented
DMSD4G0	SN	PMID28270010-Compound-Figure15-a
DMSD4G0	CP	ARRAY BIOPHARMA INC
DMSD4G0	DT	Small molecular drug
DMSD4G0	PC	90168931
DMSD4G0	MW	506.5
DMSD4G0	FM	C25H21F3N8O
DMSD4G0	IC	InChI=1S/C25H21F3N8O/c1-16-22(17-14-29-34(2)15-17)33-36(19-11-7-4-8-12-19)23(16)31-24(37)30-21-13-20(25(26,27)28)32-35(21)18-9-5-3-6-10-18/h3-15H,1-2H3,(H2,30,31,37)
DMSD4G0	CS	CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)NC4=CC(=NN4C5=CC=CC=C5)C(F)(F)F
DMSD4G0	IK	QJVHIMLGONEYEE-UHFFFAOYSA-N
DMSD4G0	IU	1-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]-3-[2-phenyl-5-(trifluoromethyl)pyrazol-3-yl]urea

DMEXPAU	ID	DMEXPAU
DMEXPAU	DN	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1
DMEXPAU	HS	Patented
DMEXPAU	SN	PMID27215781-Compound-38
DMEXPAU	DT	Small molecular drug
DMEXPAU	PC	4296438
DMEXPAU	MW	401.5
DMEXPAU	FM	C25H27N3O2
DMEXPAU	IC	InChI=1S/C25H27N3O2/c1-28(2)22-15-13-21(14-16-22)25(26-23(29)17-19-9-5-3-6-10-19)27-24(30)18-20-11-7-4-8-12-20/h3-16,25H,17-18H2,1-2H3,(H,26,29)(H,27,30)
DMEXPAU	CS	CN(C)C1=CC=C(C=C1)C(NC(=O)CC2=CC=CC=C2)NC(=O)CC3=CC=CC=C3
DMEXPAU	IK	XZLHEBHGANHBEG-UHFFFAOYSA-N
DMEXPAU	IU	N-[[4-(dimethylamino)phenyl]-[(2-phenylacetyl)amino]methyl]-2-phenylacetamide
DMEXPAU	DE	Osteoporosis

DMD4CU5	ID	DMD4CU5
DMD4CU5	DN	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2
DMD4CU5	HS	Patented
DMD4CU5	SN	PMID27215781-Compound-39
DMD4CU5	DT	Small molecular drug
DMD4CU5	PC	71584280
DMD4CU5	MW	438.6
DMD4CU5	FM	C25H30N2O3S
DMD4CU5	IC	InChI=1S/C25H30N2O3S/c1-5-26(6-2)22-13-9-21(10-14-22)19-27(23-11-7-20(3)8-12-23)31(28,29)25-17-15-24(30-4)16-18-25/h7-18H,5-6,19H2,1-4H3
DMD4CU5	CS	CCN(CC)C1=CC=C(C=C1)CN(C2=CC=C(C=C2)C)S(=O)(=O)C3=CC=C(C=C3)OC
DMD4CU5	IK	FKEFNETYRMRPCY-UHFFFAOYSA-N
DMD4CU5	IU	N-[[4-(diethylamino)phenyl]methyl]-4-methoxy-N-(4-methylphenyl)benzenesulfonamide
DMD4CU5	DE	Osteoporosis

DMM78VS	ID	DMM78VS
DMM78VS	DN	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3
DMM78VS	HS	Patented
DMM78VS	SN	PMID27215781-Compound-40
DMM78VS	DT	Small molecular drug
DMM78VS	DE	Osteoporosis

DM6R34M	ID	DM6R34M
DM6R34M	DN	N-{4
DM6R34M	HS	Patented
DM6R34M	SN	LGB321; CHEMBL3105022; 1210417-75-6; N-{4-[(3r,4r,5s)-3-Amino-4-Hydroxy-5-Methylpiperidin-1-Yl]pyridin-3-Yl}-6-(2,6-Difluorophenyl)-5-Fluoropyridine-2-Carboxamide; N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide; NVP-LGB321; GTPL9367; SCHEMBL1711617; BDBM106896; EX-A1572; AMX10208; SB19299; n-(4-((3r,4r,5s)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; US8592455, 96; LGB321 1210415-88-5; N-{4
DM6R34M	DT	Small molecular drug
DM6R34M	PC	46179018
DM6R34M	MW	457.4
DM6R34M	FM	C23H22F3N5O2
DM6R34M	IC	InChI=1S/C23H22F3N5O2/c1-12-10-31(11-16(27)22(12)32)19-7-8-28-9-18(19)30-23(33)17-6-5-15(26)21(29-17)20-13(24)3-2-4-14(20)25/h2-9,12,16,22,32H,10-11,27H2,1H3,(H,30,33)/t12-,16+,22+/m0/s1
DM6R34M	CS	C[C@H]1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=CC=C4F)F
DM6R34M	IK	ODZZYKUYGVLOTQ-ONJZCGHCSA-N
DM6R34M	IU	N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide

DMRHVWA	ID	DMRHVWA
DMRHVWA	DN	N6-cyclopropyllydine derivative 1
DMRHVWA	HS	Patented
DMRHVWA	SN	PMID27019002-Compound-30
DMRHVWA	CP	IMAGO BIOSCIENCEKYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY EDUCATIONAL CORPORATION KANSAI BUNRI SOUGOUGAKUEN FRONTIER PHARMA INC. KYOTO UNIVERSITY
DMRHVWA	DT	Small molecular drug

DM5GCUR	ID	DM5GCUR
DM5GCUR	DN	N-acylpiperidine ether derivative 1
DM5GCUR	HS	Patented
DM5GCUR	SN	PMID28270021-Compound-WO2015092610Example113
DM5GCUR	CP	PFIZER LIMITED
DM5GCUR	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM02RQ4	ID	DM02RQ4
DM02RQ4	DN	N-acylpiperidine ether derivative 2
DM02RQ4	HS	Patented
DM02RQ4	SN	PMID28270021-Compound-WO2015092610Example114
DM02RQ4	CP	PFIZER LIMITED
DM02RQ4	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMXWE5R	ID	DMXWE5R
DMXWE5R	DN	N-acylpiperidine ether derivative 3
DMXWE5R	HS	Patented
DMXWE5R	SN	PMID28270021-Compound-WO2015092610Example164
DMXWE5R	CP	PFIZER LIMITED
DMXWE5R	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMBUQDR	ID	DMBUQDR
DMBUQDR	DN	N-acylpiperidine ether derivative 4
DMBUQDR	HS	Patented
DMBUQDR	SN	PMID28270021-Compound-WO2015092610Example2
DMBUQDR	CP	PFIZER LIMITED
DMBUQDR	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMQ2MKT	ID	DMQ2MKT
DMQ2MKT	DN	N-acylpiperidine ether derivative 5
DMQ2MKT	HS	Patented
DMQ2MKT	SN	PMID28270021-Compound-WO2015092610Example3
DMQ2MKT	CP	PFIZER LIMITED
DMQ2MKT	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMAS01P	ID	DMAS01P
DMAS01P	DN	N-acylpiperidine ether derivative 6
DMAS01P	HS	Patented
DMAS01P	SN	PMID28270021-Compound-WO2015092610Example9
DMAS01P	CP	PFIZER LIMITED
DMAS01P	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMCJR4N	ID	DMCJR4N
DMCJR4N	DN	N-acylpiperidine ether derivative 7
DMCJR4N	HS	Patented
DMCJR4N	SN	PMID28270021-Compound-WO2016009296Example15
DMCJR4N	CP	PFIZER INC
DMCJR4N	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMQ4ULC	ID	DMQ4ULC
DMQ4ULC	DN	N-acylpyrrolidine ether derivative 1
DMQ4ULC	HS	Patented
DMQ4ULC	SN	PMID28270021-Compound-WO2016020784Example11
DMQ4ULC	CP	PFIZER INC
DMQ4ULC	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMK4Y71	ID	DMK4Y71
DMK4Y71	DN	N-acylpyrrolidine ether derivative 2
DMK4Y71	HS	Patented
DMK4Y71	SN	PMID28270021-Compound-WO2016020784Example12
DMK4Y71	CP	PFIZER INC
DMK4Y71	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMU2WGL	ID	DMU2WGL
DMU2WGL	DN	N-alkyl-4-oxazolecar boxamide derivative 1
DMU2WGL	HS	Patented
DMU2WGL	SN	PMID26413912-Compound-92
DMU2WGL	CP	ALLERGAN, INC. WOODWARD, David F. MARTOS, Jose L. CARLING, William R. POLOSO, Neil J. WANG, Jenny W
DMU2WGL	DT	Small molecular drug
DMU2WGL	PC	70896334
DMU2WGL	MW	525.6
DMU2WGL	FM	C29H39N3O6
DMU2WGL	IC	InChI=1S/C29H39N3O6/c1-37-22-14-12-21(13-15-26(33)34)23(18-22)29(36)32-17-7-11-25(32)28-31-24(19-38-28)27(35)30-16-6-5-10-20-8-3-2-4-9-20/h12,14,18-20,25H,2-11,13,15-17H2,1H3,(H,30,35)(H,33,34)/t25-/m0/s1
DMU2WGL	CS	COC1=CC(=C(C=C1)CCC(=O)O)C(=O)N2CCC[C@H]2C3=NC(=CO3)C(=O)NCCCCC4CCCCC4
DMU2WGL	IK	CQXXOQIYQSPKKU-VWLOTQADSA-N
DMU2WGL	IU	3-[2-[(2S)-2-[4-(4-cyclohexylbutylcarbamoyl)-1,3-oxazol-2-yl]pyrrolidine-1-carbonyl]-4-methoxyphenyl]propanoic acid

DMR6YAD	ID	DMR6YAD
DMR6YAD	DN	N-alkyl-4-oxazolecar boxamide derivative 2
DMR6YAD	HS	Patented
DMR6YAD	SN	PMID26413912-Compound-93
DMR6YAD	CP	ALLERGAN, INC. WOODWARD, David F. MARTOS, Jose L. CARLING, William R. POLOSO, Neil J. WANG, Jenny W
DMR6YAD	DT	Small molecular drug
DMR6YAD	PC	66560857
DMR6YAD	MW	616.8
DMR6YAD	FM	C31H44N4O7S
DMR6YAD	IC	InChI=1S/C31H44N4O7S/c1-3-43(39,40)34-28(36)17-15-23-14-16-24(41-2)20-25(23)31(38)35-19-9-13-27(35)30-33-26(21-42-30)29(37)32-18-8-7-12-22-10-5-4-6-11-22/h14,16,20-22,27H,3-13,15,17-19H2,1-2H3,(H,32,37)(H,34,36)/t27-/m0/s1
DMR6YAD	CS	CCS(=O)(=O)NC(=O)CCC1=C(C=C(C=C1)OC)C(=O)N2CCC[C@H]2C3=NC(=CO3)C(=O)NCCCCC4CCCCC4
DMR6YAD	IK	CARRKGKFLQFOPT-MHZLTWQESA-N
DMR6YAD	IU	N-(4-cyclohexylbutyl)-2-[(2S)-1-[2-[3-(ethylsulfonylamino)-3-oxopropyl]-5-methoxybenzoyl]pyrrolidin-2-yl]-1,3-oxazole-4-carboxamide

DMXPBL5	ID	DMXPBL5
DMXPBL5	DN	N-alkylamide derivative 1
DMXPBL5	HS	Patented
DMXPBL5	SN	PMID28067079-Compound-48
DMXPBL5	DT	Small molecular drug
DMXPBL5	PC	118204326
DMXPBL5	MW	401.9
DMXPBL5	FM	C19H20ClN5OS
DMXPBL5	IC	InChI=1S/C19H20ClN5OS/c1-3-4-16(25-18(26)19-21-7-8-27-19)13-9-15(20)17(23-10-13)24-14-6-5-12(2)22-11-14/h5-11,16H,3-4H2,1-2H3,(H,23,24)(H,25,26)
DMXPBL5	CS	CCCC(C1=CC(=C(N=C1)NC2=CN=C(C=C2)C)Cl)NC(=O)C3=NC=CS3
DMXPBL5	IK	QMMHYPPKJAWXON-UHFFFAOYSA-N
DMXPBL5	IU	N-[1-[5-chloro-6-[(6-methylpyridin-3-yl)amino]pyridin-3-yl]butyl]-1,3-thiazole-2-carboxamide

DM568TX	ID	DM568TX
DM568TX	DN	N-alkylamide derivative 2
DM568TX	HS	Patented
DM568TX	SN	PMID28067079-Compound-50
DM568TX	DT	Small molecular drug

DMWLPEB	ID	DMWLPEB
DMWLPEB	DN	Naphthalene derivative 1
DMWLPEB	HS	Patented
DMWLPEB	SN	PMID28454500-Compound-62
DMWLPEB	CP	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY THE BROAD INSTITUTE, INC
DMWLPEB	DT	Small molecular drug
DMWLPEB	PC	3294285
DMWLPEB	MW	523.5
DMWLPEB	FM	C25H24F3NO6S
DMWLPEB	IC	InChI=1S/C25H24F3NO6S/c1-13(2)35-24(32)21(23(31)25(26,27)28)18-12-19(16-7-5-6-8-17(16)22(18)30)29-36(33,34)20-10-9-14(3)11-15(20)4/h5-13,21,29-30H,1-4H3
DMWLPEB	CS	CC1=CC(=C(C=C1)S(=O)(=O)NC2=CC(=C(C3=CC=CC=C32)O)C(C(=O)C(F)(F)F)C(=O)OC(C)C)C
DMWLPEB	IK	PCUXRYBEDDOJPT-UHFFFAOYSA-N
DMWLPEB	IU	propan-2-yl 2-[4-[(2,4-dimethylphenyl)sulfonylamino]-1-hydroxynaphthalen-2-yl]-4,4,4-trifluoro-3-oxobutanoate

DMTGIP7	ID	DMTGIP7
DMTGIP7	DN	Naphthyridine and isoquinoline derivative 1
DMTGIP7	HS	Patented
DMTGIP7	SN	PMID26161698-Compound-51
DMTGIP7	DT	Small molecular drug

DMQHAU1	ID	DMQHAU1
DMQHAU1	DN	N-arylmethyl-N-phenyl cyclic urea derivative 1
DMQHAU1	HS	Patented
DMQHAU1	SN	PMID28270010-Compound-Figure25-1
DMQHAU1	CP	GENZYME CORPORATION
DMQHAU1	DT	Small molecular drug
DMQHAU1	PC	59694319
DMQHAU1	MW	487.5
DMQHAU1	FM	C23H20F3N5O2S
DMQHAU1	IC	InChI=1S/C23H20F3N5O2S/c1-22(2)20(32)31(16-6-8-17(9-7-16)34-23(24,25)26)21(33)30(22)14-15-10-12-28-19(13-15)29-18-5-3-4-11-27-18/h3-13H,14H2,1-2H3,(H,27,28,29)
DMQHAU1	CS	CC1(C(=O)N(C(=O)N1CC2=CC(=NC=C2)NC3=CC=CC=N3)C4=CC=C(C=C4)SC(F)(F)F)C
DMQHAU1	IK	CYMSBDAPHJQPRL-UHFFFAOYSA-N
DMQHAU1	IU	5,5-dimethyl-1-[[2-(pyridin-2-ylamino)pyridin-4-yl]methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione

DMWVQDA	ID	DMWVQDA
DMWVQDA	DN	N-arylmethyl-N-phenyl cyclic urea derivative 2
DMWVQDA	HS	Patented
DMWVQDA	SN	PMID28270010-Compound-Figure25-2
DMWVQDA	CP	GENZYME CORPORATION
DMWVQDA	DT	Small molecular drug
DMWVQDA	PC	68914518
DMWVQDA	MW	538.6
DMWVQDA	FM	C24H29F3N6O3S
DMWVQDA	IC	InChI=1S/C24H29F3N6O3S/c1-23(2)20(34)33(17-6-8-18(9-7-17)37-24(25,26)27)22(36)32(23)15-16-10-12-28-19(14-16)30-21(35)29-11-5-13-31(3)4/h6-10,12,14H,5,11,13,15H2,1-4H3,(H2,28,29,30,35)
DMWVQDA	CS	CC1(C(=O)N(C(=O)N1CC2=CC(=NC=C2)NC(=O)NCCCN(C)C)C3=CC=C(C=C3)SC(F)(F)F)C
DMWVQDA	IK	GDSXQEMDEPFVIA-UHFFFAOYSA-N
DMWVQDA	IU	1-[3-(dimethylamino)propyl]-3-[4-[[5,5-dimethyl-2,4-dioxo-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidin-1-yl]methyl]pyridin-2-yl]urea

DMEU12W	ID	DMEU12W
DMEU12W	DN	NCGC00381656-01
DMEU12W	HS	Patented
DMEU12W	SN	CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; NCGC00381656-01; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid
DMEU12W	DT	Small molecular drug
DMEU12W	PC	117637389
DMEU12W	MW	344.8
DMEU12W	FM	C18H17ClN2O3
DMEU12W	IC	InChI=1S/C18H17ClN2O3/c1-2-9-24-17(11-5-3-4-6-13(11)19)15-10-14-16(21-15)12(18(22)23)7-8-20-14/h3-8,10,17,21H,2,9H2,1H3,(H,22,23)
DMEU12W	CS	CCCOC(C1=CC=CC=C1Cl)C2=CC3=NC=CC(=C3N2)C(=O)O
DMEU12W	IK	NXCXDWJNFKFGCO-UHFFFAOYSA-N
DMEU12W	IU	2-[(2-chlorophenyl)-propoxymethyl]-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid

DM6TMXL	ID	DM6TMXL
DM6TMXL	DN	N-containing heterocyclic derivative 1
DM6TMXL	HS	Patented
DM6TMXL	SN	PMID25470667-Compound-Figure6-22
DM6TMXL	DT	Small molecular drug

DMW1PL7	ID	DMW1PL7
DMW1PL7	DN	NG7
DMW1PL7	HS	Patented
DMW1PL7	SN	3-{2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide; 3-(2-(cyclopropanecarboxamido)thiazolo[5,4-b]pyridin-5-yl)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; HG-7-85-01; MLS003230942; SCHEMBL1696179; CHEMBL2148124; BDBM124970; SMR001913507; 1258391-13-7; US8765747, 2; NG7
DMW1PL7	DT	Small molecular drug
DMW1PL7	PC	51359962
DMW1PL7	MW	608.7
DMW1PL7	FM	C31H31F3N6O2S
DMW1PL7	IC	InChI=1S/C31H31F3N6O2S/c1-2-39-12-14-40(15-13-39)18-22-8-9-23(17-24(22)31(32,33)34)35-28(42)21-5-3-4-20(16-21)25-10-11-26-29(36-25)43-30(37-26)38-27(41)19-6-7-19/h3-5,8-11,16-17,19H,2,6-7,12-15,18H2,1H3,(H,35,42)(H,37,38,41)
DMW1PL7	CS	CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC=CC(=C3)C4=NC5=C(C=C4)N=C(S5)NC(=O)C6CC6)C(F)(F)F
DMW1PL7	IK	VTWWRKFUHCSCEW-UHFFFAOYSA-N
DMW1PL7	IU	3-[2-(cyclopropanecarbonylamino)-[1,3]thiazolo[5,4-b]pyridin-5-yl]-N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide

DMW2LD5	ID	DMW2LD5
DMW2LD5	DN	Nicotinyl hydroxamic acid derivative 1
DMW2LD5	HS	Patented
DMW2LD5	SN	PMID26815044-Compound-120
DMW2LD5	DT	Small molecular drug
DMW2LD5	PC	71211
DMW2LD5	MW	138.12
DMW2LD5	FM	C6H6N2O2
DMW2LD5	IC	InChI=1S/C6H6N2O2/c9-6(8-10)5-2-1-3-7-4-5/h1-4,10H,(H,8,9)
DMW2LD5	CS	C1=CC(=CN=C1)C(=O)NO
DMW2LD5	IK	IYCHDNQCHLMLJZ-UHFFFAOYSA-N
DMW2LD5	IU	N-hydroxypyridine-3-carboxamide
DMW2LD5	CA	CAS 5657-61-4
DMW2LD5	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMXDSYU	ID	DMXDSYU
DMXDSYU	DN	Nitrogen mustard derivative 1
DMXDSYU	HS	Patented
DMXDSYU	SN	PMID26161698-Compound-55
DMXDSYU	CP	EURO-CELTIQUE S.A. CRYSTAL BIOPHARMACEUTICALS LLC PURDUE PHARMACEUTICAL PRODUCTS L.P
DMXDSYU	DT	Small molecular drug
DMXDSYU	PC	71515463
DMXDSYU	MW	527.5
DMXDSYU	FM	C23H28Cl2N4O2S2
DMXDSYU	IC	InChI=1S/C23H28Cl2N4O2S2/c1-23(2,3)18-13-26-20(31-18)15-32-21-14-27-22(33-21)28-19(30)12-16-4-6-17(7-5-16)29(10-8-24)11-9-25/h4-7,13-14H,8-12,15H2,1-3H3,(H,27,28,30)
DMXDSYU	CS	CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)CC3=CC=C(C=C3)N(CCCl)CCCl
DMXDSYU	IK	WETDPIQQVIMQAF-UHFFFAOYSA-N
DMXDSYU	IU	2-[4-[bis(2-chloroethyl)amino]phenyl]-N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]acetamide

DMD7OW0	ID	DMD7OW0
DMD7OW0	DN	Nitrogen/sulfur-substituted estrene derivative 1
DMD7OW0	HS	Patented
DMD7OW0	SN	PMID28895472-Compound-30
DMD7OW0	CP	BAYER PHARMA AKTIENGESELLSCHAFBAYER INTELLECTUAL PROPERTY GMBH BAYER PHARMA AKTIENGESELLSCHAFT
DMD7OW0	DT	Small molecular drug

DMIVK7D	ID	DMIVK7D
DMIVK7D	DN	N-methylmethanesulfonamide derivative 1
DMIVK7D	HS	Patented
DMIVK7D	SN	PMID27774822-Compound-Figure4Example22
DMIVK7D	CP	NOVARTIS TIERGESUNDHEIT AG
DMIVK7D	DT	Small molecular drug

DMCVBPF	ID	DMCVBPF
DMCVBPF	DN	N-naphtyl-N-benzylurea derivative 1
DMCVBPF	HS	Patented
DMCVBPF	SN	PMID27828716-Compound-1
DMCVBPF	DT	Small molecular drug
DMCVBPF	PC	668231
DMCVBPF	MW	276.3
DMCVBPF	FM	C18H16N2O
DMCVBPF	IC	InChI=1S/C18H16N2O/c21-18(19-13-14-7-2-1-3-8-14)20-17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2,(H2,19,20,21)
DMCVBPF	CS	C1=CC=C(C=C1)CNC(=O)NC2=CC=CC3=CC=CC=C32
DMCVBPF	IK	FWIZGBBRZIIRBG-UHFFFAOYSA-N
DMCVBPF	IU	1-benzyl-3-naphthalen-1-ylurea

DM2P509	ID	DM2P509
DM2P509	DN	N-oxalyl-D-tyrosine derivative 1
DM2P509	HS	Patented
DM2P509	SN	PMID25468267-Compound-10
DM2P509	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM2P509	DT	Small molecular drug

DMWSZMC	ID	DMWSZMC
DMWSZMC	DN	N-oxalyl-D-tyrosine derivative 2
DMWSZMC	HS	Patented
DMWSZMC	SN	PMID25468267-Compound-11
DMWSZMC	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMWSZMC	DT	Small molecular drug

DM7XS9G	ID	DM7XS9G
DM7XS9G	DN	N-oxalyl-D-tyrosine derivative 3
DM7XS9G	HS	Patented
DM7XS9G	SN	PMID25468267-Compound-12
DM7XS9G	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM7XS9G	DT	Small molecular drug

DMUE7R5	ID	DMUE7R5
DMUE7R5	DN	N-oxalyl-D-tyrosine derivative 4
DMUE7R5	HS	Patented
DMUE7R5	SN	PMID25468267-Compound-13
DMUE7R5	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMUE7R5	DT	Small molecular drug

DM673GR	ID	DM673GR
DM673GR	DN	N-oxalyl-D-tyrosine derivative 5
DM673GR	HS	Patented
DM673GR	SN	PMID25468267-Compound-14
DM673GR	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM673GR	DT	Small molecular drug

DM106SU	ID	DM106SU
DM106SU	DN	N-oxalyl-D-tyrosine derivative 6
DM106SU	HS	Patented
DM106SU	SN	PMID25468267-Compound-15
DM106SU	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM106SU	DT	Small molecular drug

DM13K8R	ID	DM13K8R
DM13K8R	DN	N-oxalyl-D-tyrosine derivative 7
DM13K8R	HS	Patented
DM13K8R	SN	PMID25468267-Compound-16
DM13K8R	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM13K8R	DT	Small molecular drug

DMNV0OA	ID	DMNV0OA
DMNV0OA	DN	N-oxalyl-D-tyrosine derivative 8
DMNV0OA	HS	Patented
DMNV0OA	SN	PMID25468267-Compound-8
DMNV0OA	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMNV0OA	DT	Small molecular drug
DMNV0OA	PC	45376646
DMNV0OA	MW	449.5
DMNV0OA	FM	C21H23NO8S
DMNV0OA	IC	InChI=1S/C21H23NO8S/c1-21(2,3)14-6-10-16(11-7-14)31(28,29)30-15-8-4-13(5-9-15)12-17(19(24)25)22-18(23)20(26)27/h4-11,17H,12H2,1-3H3,(H,22,23)(H,24,25)(H,26,27)/t17-/m1/s1
DMNV0OA	CS	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)C[C@H](C(=O)O)NC(=O)C(=O)O
DMNV0OA	IK	GZIYVGKVNVGZAL-QGZVFWFLSA-N
DMNV0OA	IU	(2R)-3-[4-(4-tert-butylphenyl)sulfonyloxyphenyl]-2-(oxaloamino)propanoic acid

DMTMYJ6	ID	DMTMYJ6
DMTMYJ6	DN	N-oxalyl-D-tyrosine derivative 9
DMTMYJ6	HS	Patented
DMTMYJ6	SN	PMID25468267-Compound-9
DMTMYJ6	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMTMYJ6	DT	Small molecular drug
DMTMYJ6	PC	45376513
DMTMYJ6	MW	393.4
DMTMYJ6	FM	C17H15NO8S
DMTMYJ6	IC	InChI=1S/C17H15NO8S/c19-15(17(22)23)18-14(16(20)21)10-11-6-8-12(9-7-11)26-27(24,25)13-4-2-1-3-5-13/h1-9,14H,10H2,(H,18,19)(H,20,21)(H,22,23)/t14-/m1/s1
DMTMYJ6	CS	C1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)C[C@H](C(=O)O)NC(=O)C(=O)O
DMTMYJ6	IK	DNGSYQKIFPNAEQ-CQSZACIVSA-N
DMTMYJ6	IU	(2R)-3-[4-(benzenesulfonyloxy)phenyl]-2-(oxaloamino)propanoic acid

DMUHFLQ	ID	DMUHFLQ
DMUHFLQ	DN	N-oxalylglycine derivative 1
DMUHFLQ	HS	Patented
DMUHFLQ	SN	PMID25468267-Compound-2
DMUHFLQ	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMUHFLQ	DT	Small molecular drug

DMDJC96	ID	DMDJC96
DMDJC96	DN	N-oxalylglycine derivative 2
DMDJC96	HS	Patented
DMDJC96	SN	PMID25468267-Compound-3
DMDJC96	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMDJC96	DT	Small molecular drug

DMQF0RY	ID	DMQF0RY
DMQF0RY	DN	N-oxalylglycine derivative 3
DMQF0RY	HS	Patented
DMQF0RY	SN	PMID25468267-Compound-4
DMQF0RY	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMQF0RY	DT	Small molecular drug

DM9A8L5	ID	DM9A8L5
DM9A8L5	DN	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1
DM9A8L5	HS	Patented
DM9A8L5	SN	PMID26161824-Compound-100
DM9A8L5	DT	Small molecular drug
DM9A8L5	PC	44470246
DM9A8L5	MW	509.8
DM9A8L5	FM	C23H23Cl3N4O3
DM9A8L5	IC	InChI=1S/C23H23Cl3N4O3/c1-2-33-23(32)20-4-3-11-29(20)28-22(31)18-13-21(14-5-7-15(24)8-6-14)30(27-18)19-10-9-16(25)12-17(19)26/h5-10,12,20-21H,2-4,11,13H2,1H3,(H,28,31)
DM9A8L5	CS	CCOC(=O)C1CCCN1NC(=O)C2=NN(C(C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl
DM9A8L5	IK	SXZDWKSALIBFCB-UHFFFAOYSA-N
DM9A8L5	IU	ethyl 1-[[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-3,4-dihydropyrazole-5-carbonyl]amino]pyrrolidine-2-carboxylate
DM9A8L5	DE	Obesity

DM8T2LV	ID	DM8T2LV
DM8T2LV	DN	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2
DM8T2LV	HS	Patented
DM8T2LV	SN	PMID26161824-Compound-101
DM8T2LV	DT	Small molecular drug
DM8T2LV	DE	Obesity

DMEH0RC	ID	DMEH0RC
DMEH0RC	DN	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3
DMEH0RC	HS	Patented
DMEH0RC	SN	PMID26161824-Compound-102
DMEH0RC	DT	Small molecular drug
DMEH0RC	DE	Obesity

DMMDYAV	ID	DMMDYAV
DMMDYAV	DN	N-phenyl-pyridine-2-carboxamide derivative 1
DMMDYAV	HS	Patented
DMMDYAV	SN	PMID30107136-Compound-Example55
DMMDYAV	CP	INCYTE CORPORATION
DMMDYAV	DT	Small molecule immunotherapy 
DMMDYAV	PC	129240409
DMMDYAV	MW	375.5
DMMDYAV	FM	C23H25N3O2
DMMDYAV	IC	InChI=1S/C23H25N3O2/c1-16-13-22(25-15-19(16)14-24-11-12-27)23(28)26-21-10-6-9-20(17(21)2)18-7-4-3-5-8-18/h3-10,13,15,24,27H,11-12,14H2,1-2H3,(H,26,28)
DMMDYAV	CS	CC1=CC(=NC=C1CNCCO)C(=O)NC2=CC=CC(=C2C)C3=CC=CC=C3
DMMDYAV	IK	JIWMSDANMZCAFN-UHFFFAOYSA-N
DMMDYAV	IU	5-[(2-hydroxyethylamino)methyl]-4-methyl-N-(2-methyl-3-phenylphenyl)pyridine-2-carboxamide
DMMDYAV	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM6OG2Y	ID	DM6OG2Y
DM6OG2Y	DN	N-phenyl-pyridine-2-carboxamide derivative 2
DM6OG2Y	HS	Patented
DM6OG2Y	SN	PMID30107136-Compound-Example56
DM6OG2Y	CP	INCYTE CORPORATION
DM6OG2Y	DT	Small molecule immunotherapy 
DM6OG2Y	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMAV8LM	ID	DMAV8LM
DMAV8LM	DN	N-phenyl-pyrimidin-4-amine derivative 1
DMAV8LM	HS	Patented
DMAV8LM	SN	PMID26161698-Compound-30
DMAV8LM	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMAV8LM	DT	Small molecular drug
DMAV8LM	PC	74763288
DMAV8LM	MW	543.5
DMAV8LM	FM	C19H13F8N5OS2
DMAV8LM	IC	InChI=1S/C19H13F8N5OS2/c1-34(33,30-10-28)9-11-4-13(7-14(5-11)35(23,24,25,26)27)31-19-29-8-17(22)18(32-19)15-3-2-12(20)6-16(15)21/h2-8H,9H2,1H3,(H,29,31,32)
DMAV8LM	CS	CS(=NC#N)(=O)CC1=CC(=CC(=C1)S(F)(F)(F)(F)F)NC2=NC=C(C(=N2)C3=C(C=C(C=C3)F)F)F
DMAV8LM	IK	ASMMFFMWZUTPQZ-UHFFFAOYSA-N
DMAV8LM	IU	[[3-[[4-(2,4-difluorophenyl)-5-fluoropyrimidin-2-yl]amino]-5-(pentafluoro-lambda6-sulfanyl)phenyl]methyl-methyl-oxo-lambda6-sulfanylidene]cyanamide

DMLSK97	ID	DMLSK97
DMLSK97	DN	N-quinolin-benzene sulphonamide derivative 1
DMLSK97	HS	Patented
DMLSK97	SN	PMID25553724-Compound-US20140073668 22

DMH65CX	ID	DMH65CX
DMH65CX	DN	N-quinolin-benzene sulphonamide derivative 2
DMH65CX	HS	Patented
DMH65CX	SN	PMID25553724-Compound-US20140073668 23

DMU65YX	ID	DMU65YX
DMU65YX	DN	N-quinolin-benzene sulphonamide derivative 3
DMU65YX	HS	Patented
DMU65YX	SN	PMID25553724-Compound-US20140073668 24

DMEYKXL	ID	DMEYKXL
DMEYKXL	DN	NSC-87877
DMEYKXL	HS	Patented
DMEYKXL	SN	CHEMBL472004
DMEYKXL	DT	Small molecular drug
DMEYKXL	PC	92577
DMEYKXL	MW	459.5
DMEYKXL	FM	C19H13N3O7S2
DMEYKXL	IC	InChI=1S/C19H13N3O7S2/c23-19-16(10-17(31(27,28)29)15-2-1-7-20-18(15)19)22-21-13-5-3-12-9-14(30(24,25)26)6-4-11(12)8-13/h1-10,23H,(H,24,25,26)(H,27,28,29)
DMEYKXL	CS	C1=CC2=C(C=C(C(=C2N=C1)O)N=NC3=CC4=C(C=C3)C=C(C=C4)S(=O)(=O)O)S(=O)(=O)O
DMEYKXL	IK	XGMFVZOKHBRUTL-UHFFFAOYSA-N
DMEYKXL	IU	8-hydroxy-7-[(6-sulfonaphthalen-2-yl)diazenyl]quinoline-5-sulfonic acid
DMEYKXL	CA	CAS 56990-57-9
DMEYKXL	CB	CHEBI:95064
DMEYKXL	DE	Discovery agent

DMSU80N	ID	DMSU80N
DMSU80N	DN	N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 1
DMSU80N	HS	Patented
DMSU80N	SN	PMID28051882-Compound-10
DMSU80N	DT	Small molecular drug
DMSU80N	PC	24968537
DMSU80N	MW	386.3
DMSU80N	FM	C21H24BrNO
DMSU80N	IC	InChI=1S/C21H24BrNO/c22-18-8-4-7-16(11-18)21(24)14-23-19-9-10-20(23)13-17(12-19)15-5-2-1-3-6-15/h1-8,11,17,19-21,24H,9-10,12-14H2/t17?,19?,20?,21-/m0/s1
DMSU80N	CS	C1CC2CC(CC1N2C[C@@H](C3=CC(=CC=C3)Br)O)C4=CC=CC=C4
DMSU80N	IK	OPZPEBWJFYVOEI-SLQSYFLNSA-N
DMSU80N	IU	(1R)-1-(3-bromophenyl)-2-(3-phenyl-8-azabicyclo[3.2.1]octan-8-yl)ethanol

DMPW1GI	ID	DMPW1GI
DMPW1GI	DN	N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 2
DMPW1GI	HS	Patented
DMPW1GI	SN	PMID28051882-Compound-8
DMPW1GI	DT	Small molecular drug
DMPW1GI	PC	24968536
DMPW1GI	MW	403.6
DMPW1GI	FM	C23H37N3O3
DMPW1GI	IC	InChI=1S/C23H37N3O3/c1-17-10-11-22(28-2)21(14-17)25-23(27)29-20-15-18-8-7-9-19(16-20)26(18)13-6-4-3-5-12-24/h10-11,14,18-20H,3-9,12-13,15-16,24H2,1-2H3,(H,25,27)
DMPW1GI	CS	CC1=CC(=C(C=C1)OC)NC(=O)OC2CC3CCCC(C2)N3CCCCCCN
DMPW1GI	IK	LKFLCBUCBHTSTF-UHFFFAOYSA-N
DMPW1GI	IU	[9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3-yl] N-(2-methoxy-5-methylphenyl)carbamate

DMZF9TM	ID	DMZF9TM
DMZF9TM	DN	N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 3
DMZF9TM	HS	Patented
DMZF9TM	SN	PMID28051882-Compound-9
DMZF9TM	DT	Small molecular drug
DMZF9TM	PC	24968535
DMZF9TM	MW	437.6
DMZF9TM	FM	C26H35N3O3
DMZF9TM	IC	InChI=1S/C26H35N3O3/c1-18-8-13-25(31-4)24(14-18)27-26(30)32-23-15-21-6-5-7-22(16-23)29(21)17-19-9-11-20(12-10-19)28(2)3/h8-14,21-23H,5-7,15-17H2,1-4H3,(H,27,30)
DMZF9TM	CS	CC1=CC(=C(C=C1)OC)NC(=O)OC2CC3CCCC(C2)N3CC4=CC=C(C=C4)N(C)C
DMZF9TM	IK	LLKXKYKXJPUWCM-UHFFFAOYSA-N
DMZF9TM	IU	[9-[[4-(dimethylamino)phenyl]methyl]-9-azabicyclo[3.3.1]nonan-3-yl] N-(2-methoxy-5-methylphenyl)carbamate

DMHTVGM	ID	DMHTVGM
DMHTVGM	DN	N-substituted pyrazole derivative 1
DMHTVGM	HS	Patented
DMHTVGM	SN	PMID25435285-Compound-71
DMHTVGM	CP	TAISHO PHARMACEUTICAL CO., LTD
DMHTVGM	DT	Small molecular drug

DMQWODI	ID	DMQWODI
DMQWODI	DN	N-substituted pyrazole derivative 2
DMQWODI	HS	Patented
DMQWODI	SN	PMID25435285-Compound-79
DMQWODI	CP	TAISHO PHARMACEUTICAL CO., LTD
DMQWODI	DT	Small molecular drug

DM5TIFH	ID	DM5TIFH
DM5TIFH	DN	N-substituted pyrazole derivative 3
DM5TIFH	HS	Patented
DM5TIFH	SN	PMID25435285-Compound-80
DM5TIFH	CP	TAISHO PHARMACEUTICAL CO., LTD
DM5TIFH	DT	Small molecular drug
DM5TIFH	PC	89721849
DM5TIFH	MW	494.4
DM5TIFH	FM	C20H17F3N6O4S
DM5TIFH	IC	InChI=1S/C20H17F3N6O4S/c1-29-16(10-32-17-7-6-14(8-25-17)20(21,22)23)15(9-26-29)19-27-18(28-33-19)13-4-2-12(3-5-13)11-34(24,30)31/h2-9H,10-11H2,1H3,(H2,24,30,31)
DM5TIFH	CS	CN1C(=C(C=N1)C2=NC(=NO2)C3=CC=C(C=C3)CS(=O)(=O)N)COC4=NC=C(C=C4)C(F)(F)F
DM5TIFH	IK	VICSEUMXTLYERW-UHFFFAOYSA-N
DM5TIFH	IU	[4-[5-[1-methyl-5-[[5-(trifluoromethyl)pyridin-2-yl]oxymethyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]phenyl]methanesulfonamide

DM0ECWR	ID	DM0ECWR
DM0ECWR	DN	Octahydro-pyrrolo[3,4-c]-pyrrole derivative 1
DM0ECWR	HS	Patented
DM0ECWR	SN	PMID28447479-Compound-7
DM0ECWR	CP	HOFFMANN LA ROCHE [CHHOFFMANN LA ROCHE [US]
DM0ECWR	DT	Small molecular drug
DM0ECWR	PC	86299031
DM0ECWR	MW	529.5
DM0ECWR	FM	C23H23F4N3O5S
DM0ECWR	IC	InChI=1S/C23H23F4N3O5S/c24-20-9-18(35-23(25,26)27)5-1-14(20)4-8-21(31)29-10-16-12-30(13-17(16)11-29)22(32)15-2-6-19(7-3-15)36(28,33)34/h1-3,5-7,9,16-17H,4,8,10-13H2,(H2,28,33,34)/t16-,17+
DM0ECWR	CS	C1[C@@H]2CN(C[C@@H]2CN1C(=O)CCC3=C(C=C(C=C3)OC(F)(F)F)F)C(=O)C4=CC=C(C=C4)S(=O)(=O)N
DM0ECWR	IK	MRXFENNJFHPMOW-CALCHBBNSA-N
DM0ECWR	IU	4-[(3aS,6aR)-2-[3-[2-fluoro-4-(trifluoromethoxy)phenyl]propanoyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carbonyl]benzenesulfonamide

DMZIALN	ID	DMZIALN
DMZIALN	DN	Olenolic acid acetate derivative 1
DMZIALN	HS	Patented
DMZIALN	SN	PMID25553724-Compound-WO2012148247 21
DMZIALN	CP	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY           RHO, Mun Chual     LEE, Woo Song     OH, Hyun Mee     KIM, Young Min

DM74T5L	ID	DM74T5L
DM74T5L	DN	Oligooxopiperazine derivative 1
DM74T5L	HS	Patented
DM74T5L	SN	PMID26882240-Compound-29
DM74T5L	CP	NEW YORK UNIVERSITY UNIVERSITY OF SOUTHERN CALIFORNIA ARORA, Paramjit S. OLENYUK, Bogdan LAU, Brooke Bullock GRISHAGIN, Ivan
DM74T5L	DT	Small molecular drug
DM74T5L	PC	71664643
DM74T5L	MW	494.6
DM74T5L	FM	C24H42N6O5
DM74T5L	IC	InChI=1S/C24H42N6O5/c1-14(2)12-17-23(34)29(9-8-27-17)19(13-15(3)4)24(35)28-10-11-30(22(33)16(28)5)18(21(26)32)6-7-20(25)31/h14-19,27H,6-13H2,1-5H3,(H2,25,31)(H2,26,32)/t16-,17-,18-,19-/m0/s1
DM74T5L	CS	C[C@H]1C(=O)N(CCN1C(=O)[C@H](CC(C)C)N2CCN[C@H](C2=O)CC(C)C)[C@@H](CCC(=O)N)C(=O)N
DM74T5L	IK	FMTAQWMOLHFOLT-VJANTYMQSA-N
DM74T5L	IU	(2S)-2-[(3S)-3-methyl-4-[(2S)-4-methyl-2-[(3S)-3-(2-methylpropyl)-2-oxopiperazin-1-yl]pentanoyl]-2-oxopiperazin-1-yl]pentanediamide

DM7Y2RL	ID	DM7Y2RL
DM7Y2RL	DN	Oxazole derivative 1
DM7Y2RL	HS	Patented
DM7Y2RL	SN	PMID26394986-Compound-8
DM7Y2RL	CP	UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. TURKSON, James HAMILTON, Andrew, D. JOVE, Richard SEBTI, Said, MUniversity of Central Florida research foundation, Inc
DM7Y2RL	DT	Small molecular drug
DM7Y2RL	PC	24768190
DM7Y2RL	MW	508.5
DM7Y2RL	FM	C27H29N2O6P
DM7Y2RL	IC	InChI=1S/C27H29N2O6P/c1-2-3-4-7-17-28-26(30)25-24(18-19-13-15-21(16-14-19)35-36(31,32)33)34-27(29-25)23-12-8-10-20-9-5-6-11-22(20)23/h5-6,8-16H,2-4,7,17-18H2,1H3,(H,28,30)(H2,31,32,33)
DM7Y2RL	CS	CCCCCCNC(=O)C1=C(OC(=N1)C2=CC=CC3=CC=CC=C32)CC4=CC=C(C=C4)OP(=O)(O)O
DM7Y2RL	IK	NUEVMWXZKGBDPT-UHFFFAOYSA-N
DM7Y2RL	IU	[4-[[4-(hexylcarbamoyl)-2-naphthalen-1-yl-1,3-oxazol-5-yl]methyl]phenyl] dihydrogen phosphate

DMPZ81S	ID	DMPZ81S
DMPZ81S	DN	Oxazolo[3,4-a]pyrazine derivative 1
DMPZ81S	HS	Patented
DMPZ81S	SN	PMID27788040-Compound-1
DMPZ81S	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DMPZ81S	DT	Small molecular drug

DM28E0A	ID	DM28E0A
DM28E0A	DN	Oxazolo[3,4-a]pyrazine derivative 2
DM28E0A	HS	Patented
DM28E0A	SN	PMID27788040-Compound-1a
DM28E0A	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DM28E0A	DT	Small molecular drug
DM28E0A	PC	11374217
DM28E0A	MW	445.5
DM28E0A	FM	C26H24FN3O3
DM28E0A	IC	InChI=1S/C26H24FN3O3/c27-22-13-11-19(12-14-22)17-28-24(31)29-15-16-30-23(18-29)26(33-25(30)32,20-7-3-1-4-8-20)21-9-5-2-6-10-21/h1-14,23H,15-18H2,(H,28,31)
DM28E0A	CS	C1CN2C(CN1C(=O)NCC3=CC=C(C=C3)F)C(OC2=O)(C4=CC=CC=C4)C5=CC=CC=C5
DM28E0A	IK	SFRQIPRTNYHJHP-UHFFFAOYSA-N
DM28E0A	IU	N-[(4-fluorophenyl)methyl]-3-oxo-1,1-diphenyl-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide

DM1LPKH	ID	DM1LPKH
DM1LPKH	DN	Oxazolo[3,4-a]pyrazine derivative 3
DM1LPKH	HS	Patented
DM1LPKH	SN	PMID27788040-Compound-1b
DM1LPKH	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DM1LPKH	DT	Small molecular drug
DM1LPKH	PC	11177829
DM1LPKH	MW	427.5
DM1LPKH	FM	C26H25N3O3
DM1LPKH	IC	InChI=1S/C26H25N3O3/c30-24(27-18-20-10-4-1-5-11-20)28-16-17-29-23(19-28)26(32-25(29)31,21-12-6-2-7-13-21)22-14-8-3-9-15-22/h1-15,23H,16-19H2,(H,27,30)
DM1LPKH	CS	C1CN2C(CN1C(=O)NCC3=CC=CC=C3)C(OC2=O)(C4=CC=CC=C4)C5=CC=CC=C5
DM1LPKH	IK	WPBWKKIZKTUNIP-UHFFFAOYSA-N
DM1LPKH	IU	N-benzyl-3-oxo-1,1-diphenyl-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide

DM1B74D	ID	DM1B74D
DM1B74D	DN	Oxazolo[3,4-a]pyrazine derivative 4
DM1B74D	HS	Patented
DM1B74D	SN	PMID27788040-Compound-1c
DM1B74D	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DM1B74D	DT	Small molecular drug
DM1B74D	PC	23121947
DM1B74D	MW	448.6
DM1B74D	FM	C26H32N4O3
DM1B74D	IC	InChI=1S/C26H32N4O3/c31-24(27-14-17-28-15-8-3-9-16-28)29-18-19-30-23(20-29)26(33-25(30)32,21-10-4-1-5-11-21)22-12-6-2-7-13-22/h1-2,4-7,10-13,23H,3,8-9,14-20H2,(H,27,31)
DM1B74D	CS	C1CCN(CC1)CCNC(=O)N2CCN3C(C2)C(OC3=O)(C4=CC=CC=C4)C5=CC=CC=C5
DM1B74D	IK	JJDDRYMIPIEXKX-UHFFFAOYSA-N
DM1B74D	IU	3-oxo-1,1-diphenyl-N-(2-piperidin-1-ylethyl)-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide

DMC5G76	ID	DMC5G76
DMC5G76	DN	Oxazolo[3,4-a]pyrazine derivative 5
DMC5G76	HS	Patented
DMC5G76	SN	PMID27788040-Compound-1d
DMC5G76	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DMC5G76	DT	Small molecular drug
DMC5G76	PC	23122056
DMC5G76	MW	428.5
DMC5G76	FM	C25H24N4O3
DMC5G76	IC	InChI=1S/C25H24N4O3/c30-23(27-17-21-13-7-8-14-26-21)28-15-16-29-22(18-28)25(32-24(29)31,19-9-3-1-4-10-19)20-11-5-2-6-12-20/h1-14,22H,15-18H2,(H,27,30)
DMC5G76	CS	C1CN2C(CN1C(=O)NCC3=CC=CC=N3)C(OC2=O)(C4=CC=CC=C4)C5=CC=CC=C5
DMC5G76	IK	ONMOMQJIMXCMOJ-UHFFFAOYSA-N
DMC5G76	IU	3-oxo-1,1-diphenyl-N-(pyridin-2-ylmethyl)-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide

DM5DC9A	ID	DM5DC9A
DM5DC9A	DN	Oxazolo[3,4-a]pyrazine derivative 6
DM5DC9A	HS	Patented
DM5DC9A	SN	PMID27788040-Compound-1e
DM5DC9A	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DM5DC9A	DT	Small molecular drug

DMEX5VK	ID	DMEX5VK
DMEX5VK	DN	Oxazolo[3,4-a]pyrazine derivative 7
DMEX5VK	HS	Patented
DMEX5VK	SN	PMID27788040-Compound-1f
DMEX5VK	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DMEX5VK	DT	Small molecular drug

DMZM6FW	ID	DMZM6FW
DMZM6FW	DN	Oxazolyl methylthiothiazole derivative 1
DMZM6FW	HS	Patented
DMZM6FW	SN	PMID26161698-Compound-52
DMZM6FW	CP	CURIS, INC. QIAN, Changgeng CAI, Xiong ZHAI, Haixiao
DMZM6FW	DT	Small molecular drug
DMZM6FW	PC	25195503
DMZM6FW	MW	504.6
DMZM6FW	FM	C23H28N4O5S2
DMZM6FW	IC	InChI=1S/C23H28N4O5S2/c1-23(2,3)17-12-24-20(32-17)14-33-21-13-25-22(34-21)26-19(29)11-15-6-8-16(9-7-15)31-10-4-5-18(28)27-30/h6-9,12-13,30H,4-5,10-11,14H2,1-3H3,(H,27,28)(H,25,26,29)
DMZM6FW	CS	CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)CC3=CC=C(C=C3)OCCCC(=O)NO
DMZM6FW	IK	VGEVFXUUILGVIP-UHFFFAOYSA-N
DMZM6FW	IU	4-[4-[2-[[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]amino]-2-oxoethyl]phenoxy]-N-hydroxybutanamide

DMSB09X	ID	DMSB09X
DMSB09X	DN	Oxetane 3,3-dicarboxamide compound 1
DMSB09X	HS	Patented
DMSB09X	SN	PMID28621580-Compound-WO2013032797c63
DMSB09X	CP	NEW HOPE R & D BIOSCIENCE, INC. CHEN, Xiao-Tao
DMSB09X	DT	Small molecular drug
DMSB09X	DE	Virus infection

DMMCTAK	ID	DMMCTAK
DMMCTAK	DN	Oxetane 3,3-dicarboxamide compound 2
DMMCTAK	HS	Patented
DMMCTAK	SN	PMID28621580-Compound-WO2013032797c64
DMMCTAK	CP	NEW HOPE R & D BIOSCIENCE, INC. CHEN, Xiao-Tao
DMMCTAK	DT	Small molecular drug
DMMCTAK	DE	Virus infection

DMWUYIB	ID	DMWUYIB
DMWUYIB	DN	Oxime derivative 1
DMWUYIB	HS	Patented
DMWUYIB	SN	PMID29757691-Compound-13
DMWUYIB	DT	Small molecular drug

DMMSVW5	ID	DMMSVW5
DMMSVW5	DN	Oxindole derivative 1
DMMSVW5	HS	Patented
DMMSVW5	SN	PMID27321640-Compound-16
DMMSVW5	CP	PFIZER PRODUCTS INC. CHAMBERS, Robert, James LAM, Kelvin, T
DMMSVW5	DT	Small molecular drug

DM6ZYMC	ID	DM6ZYMC
DM6ZYMC	DN	Oxindole derivative 2
DM6ZYMC	HS	Patented
DM6ZYMC	SN	PMID28117607-Compound-37
DM6ZYMC	CP	CONSEJO SUPERIOR INVESTIGACION [ES]
DM6ZYMC	DT	Small molecular drug

DM0ENF3	ID	DM0ENF3
DM0ENF3	DN	Oxindole derivative 3
DM0ENF3	HS	Patented
DM0ENF3	SN	PMID28117607-Compound-39
DM0ENF3	CP	CONSEJO SUPERIOR INVESTIGACION [ES]
DM0ENF3	DT	Small molecular drug

DM3U58I	ID	DM3U58I
DM3U58I	DN	Oxindole derivative 4
DM3U58I	HS	Patented
DM3U58I	SN	PMID28117607-Compound-40
DM3U58I	CP	CONSEJO SUPERIOR INVESTIGACION [ES]
DM3U58I	DT	Small molecular drug

DM1SH5R	ID	DM1SH5R
DM1SH5R	DN	Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1
DM1SH5R	HS	Patented
DM1SH5R	SN	PMID27998201-Compound-14
DM1SH5R	CP	AMURA THERAPEUTICS LIMITED QUIBELL, Martin WATTS, John, Paul FLINN, Nicholas, Sean
DM1SH5R	DT	Small molecular drug
DM1SH5R	PC	44229370
DM1SH5R	MW	470.9
DM1SH5R	FM	C24H27ClN4O4
DM1SH5R	IC	InChI=1S/C24H27ClN4O4/c25-18-12-29(21-19(30)13-33-22(18)21)24(32)20(14-5-2-1-3-6-14)28-23(31)16-8-4-7-15(9-16)17-10-26-27-11-17/h4,7-11,14,18,20-22H,1-3,5-6,12-13H2,(H,26,27)(H,28,31)/t18-,20-,21+,22+/m0/s1
DM1SH5R	CS	C1CCC(CC1)[C@@H](C(=O)N2C[C@@H]([C@@H]3[C@H]2C(=O)CO3)Cl)NC(=O)C4=CC=CC(=C4)C5=CNN=C5
DM1SH5R	IK	CTSFUIJCUAXDOL-VXSCBNMQSA-N
DM1SH5R	IU	N-[(1S)-2-[(3aS,6S,6aS)-6-chloro-3-oxo-3a,5,6,6a-tetrahydrofuro[3,2-b]pyrrol-4-yl]-1-cyclohexyl-2-oxoethyl]-3-(1H-pyrazol-4-yl)benzamide
DM1SH5R	DE	Pain

DM0RI7F	ID	DM0RI7F
DM0RI7F	DN	Palbociclib/ribociclib analog 1
DM0RI7F	HS	Patented
DM0RI7F	SN	PMID26161698-Compound-4
DM0RI7F	CP	G1 THERAPEUTICS, INCG1 THERAPEUTICS, INC. STRUM, Jay C. TAVARES, Francis, X
DM0RI7F	DT	Small molecular drug
DM0RI7F	PC	89798202
DM0RI7F	MW	432.5
DM0RI7F	FM	C23H28N8O
DM0RI7F	IC	InChI=1S/C23H28N8O/c32-21-18-12-16-13-26-22(28-19-5-4-17(14-25-19)30-10-8-24-9-11-30)29-20(16)31(18)23(15-27-21)6-2-1-3-7-23/h4-5,12-14,24H,1-3,6-11,15H2,(H,27,32)(H,25,26,28,29)
DM0RI7F	CS	C1CCC2(CC1)CNC(=O)C3=CC4=CN=C(N=C4N23)NC5=NC=C(C=C5)N6CCNCC6
DM0RI7F	IK	TWTKMJWAXOPXSX-UHFFFAOYSA-N
DM0RI7F	IU	4-[(5-piperazin-1-ylpyridin-2-yl)amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
DM0RI7F	CA	CAS 1374743-01-7

DM859ZQ	ID	DM859ZQ
DM859ZQ	DN	Palmarumycin derivative 1
DM859ZQ	HS	Patented
DM859ZQ	SN	PMID27977313-Compound-33
DM859ZQ	CP	ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE UNIVERSITY OF ARIZONA UNIVERSITY OF PITTSBURGH POWIS, Garth WIPF, Pete
DM859ZQ	DT	Small molecular drug
DM859ZQ	PC	196959
DM859ZQ	MW	316.3
DM859ZQ	FM	C20H12O4
DM859ZQ	IC	InChI=1S/C20H12O4/c21-14-7-3-6-13-19(14)15(22)10-11-20(13)23-16-8-1-4-12-5-2-9-17(24-20)18(12)16/h1-11,21H
DM859ZQ	CS	C1=CC2=C3C(=C1)OC4(C=CC(=O)C5=C4C=CC=C5O)OC3=CC=C2
DM859ZQ	IK	LVOXAJYEGVDSQA-UHFFFAOYSA-N
DM859ZQ	IU	8'-hydroxyspiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,4'-naphthalene]-1'-one
DM859ZQ	CA	CAS 159933-90-1

DMRLWZI	ID	DMRLWZI
DMRLWZI	DN	Palmarumycin derivative 2
DMRLWZI	HS	Patented
DMRLWZI	SN	PMID27977313-Compound-34
DMRLWZI	CP	ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE UNIVERSITY OF ARIZONA UNIVERSITY OF PITTSBURGH POWIS, Garth WIPF, Pete
DMRLWZI	DT	Small molecular drug

DM198BY	ID	DM198BY
DM198BY	DN	Palmarumycin derivative 3
DM198BY	HS	Patented
DM198BY	SN	PMID27977313-Compound-35
DM198BY	CP	ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE UNIVERSITY OF ARIZONA UNIVERSITY OF PITTSBURGH POWIS, Garth WIPF, Pete
DM198BY	DT	Small molecular drug
DM198BY	PC	11684799
DM198BY	MW	503.4
DM198BY	FM	C24H16F3NO8
DM198BY	IC	InChI=1S/C22H15NO6.C2HF3O2/c23-11-19(26)27-16-7-8-18-20-12(16)3-1-6-17(20)28-22(29-18)10-9-15(25)21-13(22)4-2-5-14(21)24;3-2(4,5)1(6)7/h1-10,24H,11,23H2;(H,6,7)
DM198BY	CS	C1=CC2=C(C=CC3=C2C(=C1)OC4(O3)C=CC(=O)C5=C4C=CC=C5O)OC(=O)CN.C(=O)(C(F)(F)F)O
DM198BY	IK	BRTORUASIGAKNH-UHFFFAOYSA-N
DM198BY	IU	(5'-hydroxy-4'-oxospiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5(13),6,8,10-pentaene-3,1'-naphthalene]-8-yl) 2-aminoacetate;2,2,2-trifluoroacetic acid

DMZGI0R	ID	DMZGI0R
DMZGI0R	DN	Palmarumycin derivative 4
DMZGI0R	HS	Patented
DMZGI0R	SN	PMID27977313-Compound-36
DMZGI0R	CP	ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE UNIVERSITY OF ARIZONA UNIVERSITY OF PITTSBURGH POWIS, Garth WIPF, Pete
DMZGI0R	DT	Small molecular drug

DM231WS	ID	DM231WS
DM231WS	DN	P-coumaric acid derivative 1
DM231WS	HS	Patented
DM231WS	SN	PMID26815044-Compound-58
DM231WS	DT	Small molecular drug
DM231WS	PC	16119330
DM231WS	MW	329.3
DM231WS	FM	C18H19NO5
DM231WS	IC	InChI=1S/C18H19NO5/c1-24-17-11-12(3-6-15(17)21)4-7-18(23)19-9-8-13-2-5-14(20)16(22)10-13/h2-7,10-11,20-22H,8-9H2,1H3,(H,19,23)/b7-4+
DM231WS	CS	COC1=C(C=CC(=C1)/C=C/C(=O)NCCC2=CC(=C(C=C2)O)O)O
DM231WS	IK	ZRLYUFOWFPPSTD-QPJJXVBHSA-N
DM231WS	IU	(E)-N-[2-(3,4-dihydroxyphenyl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)prop-2-enamide
DM231WS	CA	CAS 142350-99-0
DM231WS	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMFTZBY	ID	DMFTZBY
DMFTZBY	DN	P-coumaric acid derivative 2
DMFTZBY	HS	Patented
DMFTZBY	SN	PMID26815044-Compound-59
DMFTZBY	DT	Small molecular drug
DMFTZBY	PC	10171904
DMFTZBY	MW	315.32
DMFTZBY	FM	C17H17NO5
DMFTZBY	IC	InChI=1S/C17H17NO5/c19-13-4-1-11(9-15(13)21)3-6-17(23)18-8-7-12-2-5-14(20)16(22)10-12/h1-6,9-10,19-22H,7-8H2,(H,18,23)/b6-3+
DMFTZBY	CS	C1=CC(=C(C=C1CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O
DMFTZBY	IK	FSMGGLPUXCKRGT-ZZXKWVIFSA-N
DMFTZBY	IU	(E)-3-(3,4-dihydroxyphenyl)-N-[2-(3,4-dihydroxyphenyl)ethyl]prop-2-enamide
DMFTZBY	CA	CAS 103188-49-4
DMFTZBY	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMFE4IY	ID	DMFE4IY
DMFE4IY	DN	P-coumaric acid derivative 3
DMFE4IY	HS	Patented
DMFE4IY	SN	PMID26815044-Compound-60
DMFE4IY	DT	Small molecular drug
DMFE4IY	PC	15086380
DMFE4IY	MW	343.4
DMFE4IY	FM	C19H21NO5
DMFE4IY	IC	InChI=1S/C19H21NO5/c1-24-17-7-4-14(12-18(17)25-2)9-10-20-19(23)8-5-13-3-6-15(21)16(22)11-13/h3-8,11-12,21-22H,9-10H2,1-2H3,(H,20,23)/b8-5+
DMFE4IY	CS	COC1=C(C=C(C=C1)CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC
DMFE4IY	IK	WWELEILTWYPGMY-VMPITWQZSA-N
DMFE4IY	IU	(E)-3-(3,4-dihydroxyphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]prop-2-enamide
DMFE4IY	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM5WQP3	ID	DM5WQP3
DM5WQP3	DN	P-coumaric acid derivative 4
DM5WQP3	HS	Patented
DM5WQP3	SN	PMID26815044-Compound-61
DM5WQP3	DT	Small molecular drug
DM5WQP3	PC	16119668
DM5WQP3	MW	301.34
DM5WQP3	FM	C17H19NO4
DM5WQP3	IC	InChI=1S/C17H19NO4/c19-14-5-1-12(2-6-14)9-10-18-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-3,5-7,11,19-21H,4,8-10H2,(H,18,22)
DM5WQP3	CS	C1=CC(=CC=C1CCNC(=O)CCC2=CC(=C(C=C2)O)O)O
DM5WQP3	IK	RIYORZPRGANLCW-UHFFFAOYSA-N
DM5WQP3	IU	3-(3,4-dihydroxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]propanamide
DM5WQP3	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMFKGZ7	ID	DMFKGZ7
DMFKGZ7	DN	P-coumaric acid derivative 5
DMFKGZ7	HS	Patented
DMFKGZ7	SN	PMID26815044-Compound-62
DMFKGZ7	DT	Small molecular drug
DMFKGZ7	PC	9994897
DMFKGZ7	MW	299.32
DMFKGZ7	FM	C17H17NO4
DMFKGZ7	IC	InChI=1S/C17H17NO4/c19-14-5-1-12(2-6-14)9-10-18-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-8,11,19-21H,9-10H2,(H,18,22)/b8-4+
DMFKGZ7	CS	C1=CC(=CC=C1CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)O
DMFKGZ7	IK	VSHUQLRHTJOKTA-XBXARRHUSA-N
DMFKGZ7	IU	(E)-3-(3,4-dihydroxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide
DMFKGZ7	CA	CAS 103188-48-3
DMFKGZ7	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMF4YGC	ID	DMF4YGC
DMF4YGC	DN	P-coumaric acid derivative 6
DMF4YGC	HS	Patented
DMF4YGC	SN	PMID26815044-Compound-63
DMF4YGC	DT	Small molecular drug
DMF4YGC	PC	5372945
DMF4YGC	MW	283.32
DMF4YGC	FM	C17H17NO3
DMF4YGC	IC	InChI=1S/C17H17NO3/c19-15-6-1-13(2-7-15)5-10-17(21)18-12-11-14-3-8-16(20)9-4-14/h1-10,19-20H,11-12H2,(H,18,21)/b10-5+
DMF4YGC	CS	C1=CC(=CC=C1CCNC(=O)/C=C/C2=CC=C(C=C2)O)O
DMF4YGC	IK	RXGUTQNKCXHALN-BJMVGYQFSA-N
DMF4YGC	IU	(E)-3-(4-hydroxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide
DMF4YGC	CA	CAS 36417-86-4
DMF4YGC	CB	CHEBI:65665
DMF4YGC	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMF3LIX	ID	DMF3LIX
DMF3LIX	DN	Peptide analog 1
DMF3LIX	HS	Patented
DMF3LIX	SN	PMID30107136-Compound-Example61
DMF3LIX	CP	Aurigene Discovery Technologies Limited
DMF3LIX	DT	Peptide
DMF3LIX	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMYKOAM	ID	DMYKOAM
DMYKOAM	DN	Peptide analog 10
DMYKOAM	HS	Patented
DMYKOAM	SN	PMID29865878-Compound-10
DMYKOAM	CP	ONYX THERAPEUTICS, INC
DMYKOAM	DT	Small molecular drug

DML9C64	ID	DML9C64
DML9C64	DN	Peptide analog 11
DML9C64	HS	Patented
DML9C64	SN	PMID29865878-Compound-11
DML9C64	CP	ONYX THERAPEUTICS, INC
DML9C64	DT	Small molecular drug

DMSJHV3	ID	DMSJHV3
DMSJHV3	DN	Peptide analog 12
DMSJHV3	HS	Patented
DMSJHV3	SN	PMID29865878-Compound-12
DMSJHV3	CP	ONYX THERAPEUTICS, INC
DMSJHV3	DT	Small molecular drug

DMWI6V3	ID	DMWI6V3
DMWI6V3	DN	Peptide analog 13
DMWI6V3	HS	Patented
DMWI6V3	SN	PMID29865878-Compound-13
DMWI6V3	CP	ONYX THERAPEUTICS, INC
DMWI6V3	DT	Small molecular drug

DMN97QF	ID	DMN97QF
DMN97QF	DN	Peptide analog 14
DMN97QF	HS	Patented
DMN97QF	SN	PMID29865878-Compound-14
DMN97QF	CP	ONYX THERAPEUTICS, INC
DMN97QF	DT	Small molecular drug

DM0K5Q1	ID	DM0K5Q1
DM0K5Q1	DN	Peptide analog 15
DM0K5Q1	HS	Patented
DM0K5Q1	SN	PMID29865878-Compound-15
DM0K5Q1	CP	KEZAR LIFE SCIENCES
DM0K5Q1	DT	Small molecular drug

DMKJ27D	ID	DMKJ27D
DMKJ27D	DN	Peptide analog 16
DMKJ27D	HS	Patented
DMKJ27D	SN	PMID29865878-Compound-16
DMKJ27D	CP	ONYX THERAPEUTICS, INC. SHENK, Kevin D. PARLATI, Francesco BENNETT, Mark K
DMKJ27D	DT	Small molecular drug

DMJ91EM	ID	DMJ91EM
DMJ91EM	DN	Peptide analog 17
DMJ91EM	HS	Patented
DMJ91EM	SN	PMID29865878-Compound-17
DMJ91EM	CP	ONYX THERAPEUTICS, INC. SHENK, Kevin D. PARLATI, Francesco BENNETT, Mark K
DMJ91EM	DT	Small molecular drug

DMF1TR6	ID	DMF1TR6
DMF1TR6	DN	Peptide analog 18
DMF1TR6	HS	Patented
DMF1TR6	SN	PMID29865878-Compound-18
DMF1TR6	CP	University of Kentucky Research Foundation
DMF1TR6	DT	Small molecular drug

DMLIVT6	ID	DMLIVT6
DMLIVT6	DN	Peptide analog 19
DMLIVT6	HS	Patented
DMLIVT6	SN	PMID29865878-Compound-19
DMLIVT6	CP	University of Kentucky Research Foundation
DMLIVT6	DT	Small molecular drug

DMYFUM6	ID	DMYFUM6
DMYFUM6	DN	Peptide analog 2
DMYFUM6	HS	Patented
DMYFUM6	SN	PMID30107136-Compound-Example62
DMYFUM6	CP	Aurigene Discovery Technologies Limited
DMYFUM6	DT	Peptide
DMYFUM6	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM2L9KI	ID	DM2L9KI
DM2L9KI	DN	Peptide analog 20
DM2L9KI	HS	Patented
DM2L9KI	SN	PMID29865878-Compound-20
DM2L9KI	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM2L9KI	DT	Small molecular drug

DMJDFS1	ID	DMJDFS1
DMJDFS1	DN	Peptide analog 21
DMJDFS1	HS	Patented
DMJDFS1	SN	PMID29865878-Compound-21
DMJDFS1	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMJDFS1	DT	Small molecular drug

DMTLO1E	ID	DMTLO1E
DMTLO1E	DN	Peptide analog 22
DMTLO1E	HS	Patented
DMTLO1E	SN	PMID29865878-Compound-22
DMTLO1E	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMTLO1E	DT	Small molecular drug

DMDU21R	ID	DMDU21R
DMDU21R	DN	Peptide analog 23
DMDU21R	HS	Patented
DMDU21R	SN	PMID29865878-Compound-23
DMDU21R	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMDU21R	DT	Small molecular drug

DM904T7	ID	DM904T7
DM904T7	DN	Peptide analog 24
DM904T7	HS	Patented
DM904T7	SN	PMID29865878-Compound-24
DM904T7	CP	PRINCIPIA BIOPHARMA INC
DM904T7	DT	Small molecular drug

DMFBQHZ	ID	DMFBQHZ
DMFBQHZ	DN	Peptide analog 25
DMFBQHZ	HS	Patented
DMFBQHZ	SN	PMID29865878-Compound-25
DMFBQHZ	CP	PRINCIPIA BIOPHARMA INC
DMFBQHZ	DT	Small molecular drug

DM8FGZB	ID	DM8FGZB
DM8FGZB	DN	Peptide analog 26
DM8FGZB	HS	Patented
DM8FGZB	SN	PMID29865878-Compound-26
DM8FGZB	CP	CORNELL UNIVERSITY
DM8FGZB	DT	Small molecular drug

DML4XJ2	ID	DML4XJ2
DML4XJ2	DN	Peptide analog 27
DML4XJ2	HS	Patented
DML4XJ2	SN	PMID29865878-Compound-27
DML4XJ2	CP	CORNELL UNIVERSITY
DML4XJ2	DT	Small molecular drug

DMHT4PF	ID	DMHT4PF
DMHT4PF	DN	Peptide analog 28
DMHT4PF	HS	Patented
DMHT4PF	SN	PMID29865878-Compound-28
DMHT4PF	CP	CORNELL UNIVERSITY
DMHT4PF	DT	Small molecular drug

DM1NMR6	ID	DM1NMR6
DM1NMR6	DN	Peptide analog 29
DM1NMR6	HS	Patented
DM1NMR6	SN	PMID29865878-Compound-29
DM1NMR6	CP	CORNELL UNIVERSITY
DM1NMR6	DT	Small molecular drug

DMYMJV3	ID	DMYMJV3
DMYMJV3	DN	Peptide analog 3
DMYMJV3	HS	Patented
DMYMJV3	SN	PMID30107136-Compound-Example63
DMYMJV3	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMYMJV3	DT	Peptide
DMYMJV3	PC	91664324
DMYMJV3	MW	405.41
DMYMJV3	FM	C14H27N7O7
DMYMJV3	IC	InChI=1S/C14H27N7O7/c15-4-2-1-3-8(13(26)27)18-14(28)19-9(5-10(17)23)12(25)21-20-11(24)7(16)6-22/h7-9,22H,1-6,15-16H2,(H2,17,23)(H,20,24)(H,21,25)(H,26,27)(H2,18,19,28)/t7-,8-,9-/m0/s1
DMYMJV3	CS	C(CCN)C[C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C(=O)NNC(=O)[C@H](CO)N
DMYMJV3	IK	ATJFXPNBJOTGGR-CIUDSAMLSA-N
DMYMJV3	IU	(2S)-6-amino-2-[[(2S)-4-amino-1-[2-[(2S)-2-amino-3-hydroxypropanoyl]hydrazinyl]-1,4-dioxobutan-2-yl]carbamoylamino]hexanoic acid
DMYMJV3	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMYEJV0	ID	DMYEJV0
DMYEJV0	DN	Peptide analog 30
DMYEJV0	HS	Patented
DMYEJV0	SN	PMID29865878-Compound-3
DMYEJV0	CP	UNIV DARMSTADT TECH [DECHARITE UNIVERSITAETSMEDIZIN [DE]
DMYEJV0	DT	Small molecular drug

DMS9O6I	ID	DMS9O6I
DMS9O6I	DN	Peptide analog 31
DMS9O6I	HS	Patented
DMS9O6I	SN	PMID29865878-Compound-30
DMS9O6I	CP	CORNELL UNIVERSITY
DMS9O6I	DT	Small molecular drug

DMGQ1PK	ID	DMGQ1PK
DMGQ1PK	DN	Peptide analog 32
DMGQ1PK	HS	Patented
DMGQ1PK	SN	PMID29865878-Compound-31
DMGQ1PK	CP	CORNELL UNIVERSITY
DMGQ1PK	DT	Small molecular drug

DML5P6O	ID	DML5P6O
DML5P6O	DN	Peptide analog 33
DML5P6O	HS	Patented
DML5P6O	SN	PMID29865878-Compound-32
DML5P6O	CP	CORNELL UNIVERSITY
DML5P6O	DT	Small molecular drug

DMG4EOP	ID	DMG4EOP
DMG4EOP	DN	Peptide analog 34
DMG4EOP	HS	Patented
DMG4EOP	SN	PMID29865878-Compound-33
DMG4EOP	CP	CORNELL UNIVERSITY
DMG4EOP	DT	Small molecular drug

DMSOQG7	ID	DMSOQG7
DMSOQG7	DN	Peptide analog 35
DMSOQG7	HS	Patented
DMSOQG7	SN	PMID29865878-Compound-34
DMSOQG7	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
DMSOQG7	DT	Small molecular drug

DMB4LNI	ID	DMB4LNI
DMB4LNI	DN	Peptide analog 36
DMB4LNI	HS	Patented
DMB4LNI	SN	PMID29865878-Compound-35
DMB4LNI	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
DMB4LNI	DT	Small molecular drug

DMVX71N	ID	DMVX71N
DMVX71N	DN	Peptide analog 37
DMVX71N	HS	Patented
DMVX71N	SN	PMID29865878-Compound-36
DMVX71N	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
DMVX71N	DT	Small molecular drug

DM9FL81	ID	DM9FL81
DM9FL81	DN	Peptide analog 38
DM9FL81	HS	Patented
DM9FL81	SN	PMID29865878-Compound-37
DM9FL81	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
DM9FL81	DT	Small molecular drug

DMYJOTP	ID	DMYJOTP
DMYJOTP	DN	Peptide analog 39
DMYJOTP	HS	Patented
DMYJOTP	SN	PMID29865878-Compound-4
DMYJOTP	CP	UNIV DARMSTADT TECH [DECHARITE UNIVERSITAETSMEDIZIN [DE]
DMYJOTP	DT	Small molecular drug

DM5KEVG	ID	DM5KEVG
DM5KEVG	DN	Peptide analog 4
DM5KEVG	HS	Patented
DM5KEVG	SN	PMID30107136-Compound-Example64
DM5KEVG	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DM5KEVG	DT	Peptide
DM5KEVG	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM12VO9	ID	DM12VO9
DM12VO9	DN	Peptide analog 40
DM12VO9	HS	Patented
DM12VO9	SN	PMID29865878-Compound-5
DM12VO9	CP	PROTEOLIX, INC. BENNETT, Mark, K. BUCHHOLZ, Tonia, J. DEMO, Susan LAIDIG, Guy, J. LEWIS, Evan, R. SMYTH, Mark, S
DM12VO9	DT	Small molecular drug

DM96KXE	ID	DM96KXE
DM96KXE	DN	Peptide analog 41
DM96KXE	HS	Patented
DM96KXE	SN	PMID29865878-Compound-6
DM96KXE	CP	PROTEOLIX, INC. BENNETT, Mark, K. BUCHHOLZ, Tonia, J. DEMO, Susan LAIDIG, Guy, J. LEWIS, Evan, R. SMYTH, Mark, S
DM96KXE	DT	Small molecular drug

DMF1MZ4	ID	DMF1MZ4
DMF1MZ4	DN	Peptide analog 42
DMF1MZ4	HS	Patented
DMF1MZ4	SN	PMID29865878-Compound-7
DMF1MZ4	CP	ONYX THERAPEUTICS, INC. PHIASIVONGSA, PasiPROTEOLIX, INC. SHENK, Kevin, D. PARLATI, Francesco ZHOU, Han-jie SYLVAIN, Catherine SMYTH, Mark, S. BENNETT, Mark, K. LAIDIG, Guy, J
DMF1MZ4	DT	Small molecular drug

DMYMPF9	ID	DMYMPF9
DMYMPF9	DN	Peptide analog 43
DMYMPF9	HS	Patented
DMYMPF9	SN	PMID29865878-Compound-9
DMYMPF9	CP	ONYX THERAPEUTICS, INC. PHIASIVONGSA, Pasit SEHL, Louis, C
DMYMPF9	DT	Small molecular drug

DMOJDQF	ID	DMOJDQF
DMOJDQF	DN	Peptide analog 44
DMOJDQF	HS	Patented
DMOJDQF	SN	PMID25482888-Compound-22
DMOJDQF	DT	Peptide

DMGA3U8	ID	DMGA3U8
DMGA3U8	DN	Peptide analog 45
DMGA3U8	HS	Patented
DMGA3U8	SN	PMID25482888-Compound-23
DMGA3U8	DT	Peptide

DMC48AX	ID	DMC48AX
DMC48AX	DN	Peptide analog 46
DMC48AX	HS	Patented
DMC48AX	SN	PMID25482888-Compound-24
DMC48AX	DT	Peptide

DM7U8WD	ID	DM7U8WD
DM7U8WD	DN	Peptide analog 47
DM7U8WD	HS	Patented
DM7U8WD	SN	PMID25482888-Compound-25
DM7U8WD	DT	Peptide

DMM2WA4	ID	DMM2WA4
DMM2WA4	DN	Peptide analog 48
DMM2WA4	HS	Patented
DMM2WA4	SN	PMID25482888-Compound-26
DMM2WA4	DT	Peptide

DMP5SA2	ID	DMP5SA2
DMP5SA2	DN	Peptide analog 49
DMP5SA2	HS	Patented
DMP5SA2	SN	PMID25482888-Compound-28
DMP5SA2	DT	Peptide

DM8B13I	ID	DM8B13I
DM8B13I	DN	Peptide analog 5
DM8B13I	HS	Patented
DM8B13I	SN	PMID30107136-Compound-General structure31
DM8B13I	CP	Aurigene Discovery Technologies Limited
DM8B13I	DT	Peptide
DM8B13I	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMM8K7R	ID	DMM8K7R
DMM8K7R	DN	Peptide analog 50
DMM8K7R	HS	Patented
DMM8K7R	SN	PMID25482888-Compound-29
DMM8K7R	DT	Peptide

DM1D7CE	ID	DM1D7CE
DM1D7CE	DN	Peptide analog 51
DM1D7CE	HS	Patented
DM1D7CE	SN	PMID25482888-Compound-30
DM1D7CE	DT	Peptide

DMDG5T9	ID	DMDG5T9
DMDG5T9	DN	Peptide analog 52
DMDG5T9	HS	Patented
DMDG5T9	SN	PMID26560530-Compound-38
DMDG5T9	CP	Zedira GmbH
DMDG5T9	DT	Small molecular drug

DM9FJXS	ID	DM9FJXS
DM9FJXS	DN	Peptide analog 53
DM9FJXS	HS	Patented
DM9FJXS	SN	PMID26560530-Compound-39
DM9FJXS	CP	Zedira GmbH
DM9FJXS	DT	Small molecular drug

DMZVB5U	ID	DMZVB5U
DMZVB5U	DN	Peptide analog 54
DMZVB5U	HS	Patented
DMZVB5U	SN	PMID26560530-Compound-43
DMZVB5U	CP	DOMINGUEZ, Celia PRIME, Michael MARSTON, Richard BROOKFIELD, Frederick, A. COURTNEY, Stephen, M. MACDONALD, Douglas WITYAK, John YARNOLD, Christopher, John VAIDYA, Darshan
DMZVB5U	DT	Small molecular drug
DMZVB5U	PC	71459385
DMZVB5U	MW	513
DMZVB5U	FM	C27H33ClN4O4
DMZVB5U	IC	InChI=1S/C27H33ClN4O4/c1-2-25(33)29-15-9-8-13-23(30-27(35)36-20-21-10-4-3-5-11-21)26(34)32-18-16-31(17-19-32)24-14-7-6-12-22(24)28/h2-7,10-12,14,23H,1,8-9,13,15-20H2,(H,29,33)(H,30,35)/t23-/m0/s1
DMZVB5U	CS	C=CC(=O)NCCCC[C@@H](C(=O)N1CCN(CC1)C2=CC=CC=C2Cl)NC(=O)OCC3=CC=CC=C3
DMZVB5U	IK	KYVYJVRZPFRADU-QHCPKHFHSA-N
DMZVB5U	IU	benzyl N-[(2S)-1-[4-(2-chlorophenyl)piperazin-1-yl]-1-oxo-6-(prop-2-enoylamino)hexan-2-yl]carbamate

DMVLP8H	ID	DMVLP8H
DMVLP8H	DN	Peptide analog 55
DMVLP8H	HS	Patented
DMVLP8H	SN	PMID26118988-Compound-10
DMVLP8H	DT	Peptide
DMVLP8H	SQ	AlaCysCysGlnIleNleProProSerThrTyr

DMBCFJU	ID	DMBCFJU
DMBCFJU	DN	Peptide analog 56
DMBCFJU	HS	Patented
DMBCFJU	SN	PMID26118988-Compound-11
DMBCFJU	DT	Peptide
DMBCFJU	SQ	AlaCysCysGlnGlnhPheOctGProProSerThr

DM6IQWE	ID	DM6IQWE
DM6IQWE	DN	Peptide analog 57
DM6IQWE	HS	Patented
DM6IQWE	SN	PMID26118988-Compound-12
DM6IQWE	DT	Small molecular drug

DM7X62M	ID	DM7X62M
DM7X62M	DN	Peptide analog 58
DM7X62M	HS	Patented
DM7X62M	SN	PMID26118988-Compound-13
DM7X62M	DT	Peptide
DM7X62M	SQ	AlaChaCysCysGlnhPhePheProProSerThr

DMZAMNX	ID	DMZAMNX
DMZAMNX	DN	Peptide analog 59
DMZAMNX	HS	Patented
DMZAMNX	SN	PMID26118988-Compound-14
DMZAMNX	DT	Small molecular drug

DM68M0G	ID	DM68M0G
DM68M0G	DN	Peptide analog 6
DM68M0G	HS	Patented
DM68M0G	SN	PMID30107136-Compound-General structure32
DM68M0G	CP	AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DM68M0G	DT	Peptide
DM68M0G	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMMSTNA	ID	DMMSTNA
DMMSTNA	DN	Peptide analog 60
DMMSTNA	HS	Patented
DMMSTNA	SN	PMID26118988-Compound-15
DMMSTNA	DT	Peptide
DMMSTNA	SQ	AlaChaCysCysGlnGlnhPheProProSerThr

DM45JMT	ID	DM45JMT
DM45JMT	DN	Peptide analog 61
DM45JMT	HS	Patented
DM45JMT	SN	PMID26118988-Compound-16
DM45JMT	DT	Peptide
DM45JMT	SQ	AlaChaCysCysGlnGlnOctGProPro4NHCOPheSerThr

DM28NK0	ID	DM28NK0
DM28NK0	DN	Peptide analog 62
DM28NK0	HS	Patented
DM28NK0	SN	PMID26118988-Compound-17
DM28NK0	DT	Small molecular drug

DMGC7NW	ID	DMGC7NW
DMGC7NW	DN	Peptide analog 63
DMGC7NW	HS	Patented
DMGC7NW	SN	PMID26118988-Compound-2
DMGC7NW	DT	Peptide
DMGC7NW	SQ	HLArgPhgLValPhgOH

DM1G2J5	ID	DM1G2J5
DM1G2J5	DN	Peptide analog 64
DM1G2J5	HS	Patented
DM1G2J5	SN	PMID26118988-Compound-3
DM1G2J5	DT	Peptide
DM1G2J5	SQ	HLArgPhgLValGlyOH

DMAJLM1	ID	DMAJLM1
DMAJLM1	DN	Peptide analog 65
DMAJLM1	HS	Patented
DMAJLM1	SN	PMID26118988-Compound-4
DMAJLM1	DT	Peptide
DMAJLM1	SQ	HLArgPhgLTrpPhgOH

DMW502M	ID	DMW502M
DMW502M	DN	Peptide analog 66
DMW502M	HS	Patented
DMW502M	SN	PMID26118988-Compound-5
DMW502M	DT	Peptide
DMW502M	SQ	AlaChaCysCysGlnOctGPheProProSerThr

DMJ8QTX	ID	DMJ8QTX
DMJ8QTX	DN	Peptide analog 67
DMJ8QTX	HS	Patented
DMJ8QTX	SN	PMID26118988-Compound-6
DMJ8QTX	DT	Peptide
DMJ8QTX	SQ	AlaChaCysCysGlnGlnOctGProProSerThr

DMFG2KT	ID	DMFG2KT
DMFG2KT	DN	Peptide analog 68
DMFG2KT	HS	Patented
DMFG2KT	SN	PMID26118988-Compound-7
DMFG2KT	DT	Peptide
DMFG2KT	SQ	AlaCysCysGlnhPheOctGProProSerThrTyr

DM2OXW3	ID	DM2OXW3
DM2OXW3	DN	Peptide analog 69
DM2OXW3	HS	Patented
DM2OXW3	SN	PMID26118988-Compound-8
DM2OXW3	DT	Peptide
DM2OXW3	SQ	AlaCysCysGlnGlnOctGOctGProProSerThr

DMKYOLV	ID	DMKYOLV
DMKYOLV	DN	Peptide analog 7
DMKYOLV	HS	Patented
DMKYOLV	SN	PMID26394986-Compound-1
DMKYOLV	CP	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES TARASOVA, Nadya I. TRINCHIERI, Giorgio YOUNG, Howard A. STEWART, C. Andrew CARDONE, Marco A. PERANTONI, Alan O
DMKYOLV	DT	Small molecular drug

DMN43Q5	ID	DMN43Q5
DMN43Q5	DN	Peptide analog 70
DMN43Q5	HS	Patented
DMN43Q5	SN	PMID26118988-Compound-9
DMN43Q5	DT	Peptide
DMN43Q5	SQ	AlaCysCysGlnGlnIleNleProProSerThr

DMSEKZG	ID	DMSEKZG
DMSEKZG	DN	Peptide analog 71
DMSEKZG	HS	Patented
DMSEKZG	SN	PMID26936077-Compound-1
DMSEKZG	CP	Peptron Inc
DMSEKZG	DT	Small molecular drug

DMXU71M	ID	DMXU71M
DMXU71M	DN	Peptide analog 72
DMXU71M	HS	Patented
DMXU71M	SN	PMID26936077-Compound-5
DMXU71M	CP	The University of Queensland
DMXU71M	DT	Small molecular drug

DMFG7A8	ID	DMFG7A8
DMFG7A8	DN	Peptide analog 8
DMFG7A8	HS	Patented
DMFG7A8	SN	PMID26394986-Compound-2
DMFG7A8	CP	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES TARASOVA, Nadya I. TRINCHIERI, Giorgio YOUNG, Howard A. STEWART, C. Andrew CARDONE, Marco A. PERANTONI, Alan O
DMFG7A8	DT	Small molecular drug

DM953EV	ID	DM953EV
DM953EV	DN	Peptide analog 9
DM953EV	HS	Patented
DM953EV	SN	PMID29865878-Compound-1
DM953EV	CP	THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL MOUNT SINAL SCHOOL OF MEDICINE ORLOWSKI, Robert, Z. ORLOWSKI, Marian
DM953EV	DT	Small molecular drug

DMMP9N7	ID	DMMP9N7
DMMP9N7	DN	Peptidomimetic analog 1
DMMP9N7	HS	Patented
DMMP9N7	SN	PMID26394986-Compound-3
DMMP9N7	DT	Small molecular drug

DMN2VZW	ID	DMN2VZW
DMN2VZW	DN	Peptidomimetic analog 2
DMN2VZW	HS	Patented
DMN2VZW	SN	PMID26394986-Compound-4
DMN2VZW	DT	Small molecular drug

DMPWS9N	ID	DMPWS9N
DMPWS9N	DN	Peptidomimetic analog 3
DMPWS9N	HS	Patented
DMPWS9N	SN	PMID26394986-Compound-5
DMPWS9N	DT	Small molecular drug
DMPWS9N	PC	24772856
DMPWS9N	MW	846.8
DMPWS9N	FM	C41H53F2N4O11P
DMPWS9N	IC	InChI=1S/C41H53F2N4O11P/c1-24(26-13-16-29(17-14-26)41(42,43)59(54,57-22-55-37(52)39(3,4)5)58-23-56-38(53)40(6,7)8)20-33(49)46-30-18-15-27-10-9-11-28-21-31(47(34(27)28)36(30)51)35(50)45-25(2)12-19-32(44)48/h9-11,13-14,16-17,20,25,30-31H,12,15,18-19,21-23H2,1-8H3,(H2,44,48)(H,45,50)(H,46,49)/b24-20+/t25-,30+,31+/m1/s1
DMPWS9N	CS	C[C@H](CCC(=O)N)NC(=O)[C@@H]1CC2=CC=CC3=C2N1C(=O)[C@H](CC3)NC(=O)/C=C(\\C)/C4=CC=C(C=C4)C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C
DMPWS9N	IK	FPJJYMKTWVMUCU-GCFVZNOFSA-N
DMPWS9N	IU	[[[4-[(E)-4-[[(2S,11S)-2-[[(2R)-5-amino-5-oxopentan-2-yl]carbamoyl]-12-oxo-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-11-yl]amino]-4-oxobut-2-en-2-yl]phenyl]-difluoromethyl]-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate

DM9Q0JS	ID	DM9Q0JS
DM9Q0JS	DN	Peptidomimetic analog 4
DM9Q0JS	HS	Patented
DM9Q0JS	SN	PMID26394986-Compound-6
DM9Q0JS	DT	Small molecular drug

DMF0DE2	ID	DMF0DE2
DMF0DE2	DN	Peptidomimetic analog 5
DMF0DE2	HS	Patented
DMF0DE2	SN	PMID26394986-Compound-7
DMF0DE2	CP	UNIVERSITY OF SOUTH FLORIDA TURKSON, James JOVE, Richard SEBTI, Said, M. HAMILTON, Andrew, D
DMF0DE2	DT	Small molecular drug
DMF0DE2	PC	9870708
DMF0DE2	MW	503.4
DMF0DE2	FM	C23H26N3O8P
DMF0DE2	IC	InChI=1S/C23H26N3O8P/c1-14(2)11-20(23(29)30)26-22(28)19(25-21(27)17-7-3-16(13-24)4-8-17)12-15-5-9-18(10-6-15)34-35(31,32)33/h3-10,14,19-20H,11-12H2,1-2H3,(H,25,27)(H,26,28)(H,29,30)(H2,31,32,33)/t19-,20-/m0/s1
DMF0DE2	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)OP(=O)(O)O)NC(=O)C2=CC=C(C=C2)C#N
DMF0DE2	IK	HXSAWUQKNZJUNW-PMACEKPBSA-N
DMF0DE2	IU	(2S)-2-[[(2S)-2-[(4-cyanobenzoyl)amino]-3-(4-phosphonooxyphenyl)propanoyl]amino]-4-methylpentanoic acid

DMSUD5X	ID	DMSUD5X
DMSUD5X	DN	Peptidomimetic analog 6
DMSUD5X	HS	Patented
DMSUD5X	SN	PMID26936077-Compound-2
DMSUD5X	CP	Peptron Inc
DMSUD5X	DT	Small molecular drug

DM15TMH	ID	DM15TMH
DM15TMH	DN	Peptidomimetic analog 7
DM15TMH	HS	Patented
DM15TMH	SN	PMID26882240-Compound-28
DM15TMH	CP	University of Southern California, USNew York University
DM15TMH	DT	Small molecular drug

DM0PBJT	ID	DM0PBJT
DM0PBJT	DN	Phenoxypiperidine derivative 1
DM0PBJT	HS	Patented
DM0PBJT	SN	PMID29334795-Compound-36
DM0PBJT	CP	RICHTER GEDEON NYRT
DM0PBJT	DT	Small molecular drug

DMC5G8P	ID	DMC5G8P
DMC5G8P	DN	Phenoxypiperidine derivative 2
DMC5G8P	HS	Patented
DMC5G8P	SN	PMID29334795-Compound-37
DMC5G8P	CP	RICHTER GEDEON NYRT
DMC5G8P	DT	Small molecular drug
DMC5G8P	PC	86299782
DMC5G8P	MW	318.5
DMC5G8P	FM	C19H30N2O2
DMC5G8P	IC	InChI=1S/C19H30N2O2/c1-2-13-21(14-3-1)15-4-16-22-17-5-7-18(8-6-17)23-19-9-11-20-12-10-19/h5-8,19-20H,1-4,9-16H2
DMC5G8P	CS	C1CCN(CC1)CCCOC2=CC=C(C=C2)OC3CCNCC3
DMC5G8P	IK	IRTTXYWMHFLYFK-UHFFFAOYSA-N
DMC5G8P	IU	1-[3-(4-piperidin-4-yloxyphenoxy)propyl]piperidine

DMVYP8K	ID	DMVYP8K
DMVYP8K	DN	Phenylalanine derivative 1
DMVYP8K	HS	Patented
DMVYP8K	SN	PMID27998201-Compound-21
DMVYP8K	DT	Small molecular drug
DMVYP8K	DE	Glioma

DMEO9QB	ID	DMEO9QB
DMEO9QB	DN	Phenylate derivative 1
DMEO9QB	HS	Patented
DMEO9QB	SN	PMID30107136-Compound-Example21
DMEO9QB	CP	INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMEO9QB	DT	Small molecule immunotherapy 
DMEO9QB	PC	132183784
DMEO9QB	MW	574.9
DMEO9QB	FM	C28H29BrClNO5
DMEO9QB	IC	InChI=1S/C28H29BrClNO5/c1-18(2)11-12-35-25-14-26(23(30)13-21(25)15-31-24(16-32)28(33)34)36-17-20-9-6-10-22(27(20)29)19-7-4-3-5-8-19/h3-11,13-14,24,31-32H,12,15-17H2,1-2H3,(H,33,34)
DMEO9QB	CS	CC(=CCOC1=CC(=C(C=C1CNC(CO)C(=O)O)Cl)OCC2=C(C(=CC=C2)C3=CC=CC=C3)Br)C
DMEO9QB	IK	HXFYELRCMXNMTR-UHFFFAOYSA-N
DMEO9QB	IU	2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-5-chloro-2-(3-methylbut-2-enoxy)phenyl]methylamino]-3-hydroxypropanoic acid
DMEO9QB	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMG0ZSY	ID	DMG0ZSY
DMG0ZSY	DN	Phenylate derivative 2
DMG0ZSY	HS	Patented
DMG0ZSY	SN	PMID30107136-Compound-Example22
DMG0ZSY	CP	INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMG0ZSY	DT	Small molecule immunotherapy 
DMG0ZSY	PC	132183436
DMG0ZSY	MW	644.9
DMG0ZSY	FM	C31H31BrClNO7
DMG0ZSY	IC	InChI=1S/C31H31BrClNO7/c32-30-20(2-1-3-23(30)19-6-7-26-29(11-19)39-9-8-38-26)17-41-28-13-27(40-16-18-4-5-18)21(10-24(28)33)14-34-15-22(35)12-25(34)31(36)37/h1-3,6-7,10-11,13,18,22,25,35H,4-5,8-9,12,14-17H2,(H,36,37)/t22-,25-/m0/s1
DMG0ZSY	CS	C1CC1COC2=CC(=C(C=C2CN3C[C@H](C[C@H]3C(=O)O)O)Cl)OCC4=C(C(=CC=C4)C5=CC6=C(C=C5)OCCO6)Br
DMG0ZSY	IK	JLLTUBDWNGWHPK-DHLKQENFSA-N
DMG0ZSY	IU	(2S,4S)-1-[[4-[[2-bromo-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]methoxy]-5-chloro-2-(cyclopropylmethoxy)phenyl]methyl]-4-hydroxypyrrolidine-2-carboxylic acid
DMG0ZSY	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM1BIY4	ID	DM1BIY4
DM1BIY4	DN	Phenylmethanesulfonamide derivative 1
DM1BIY4	HS	Patented
DM1BIY4	SN	PMID25470667-Compound-Figure6-23
DM1BIY4	CP	ELI LILLY AND COMPANY
DM1BIY4	DT	Small molecular drug

DMTEJRB	ID	DMTEJRB
DMTEJRB	DN	Phenylpropionic acid derivative 1
DMTEJRB	HS	Patented
DMTEJRB	SN	PMID25416646-Compound-Figure2-D
DMTEJRB	CP	DONG-A PHARM. CO., LTD. YUHAN CO., LTD. MOON, Ho-Sang YOO, Moo-Hi KIM, Soon-Hoe LIM, Joong-In SON, Moon-Ho KIM, Mi-Kyung SHIN, Chang-Yell KIM, Jin-Kwan PARK, Sang-Kuk CHAE, Yu-Na SHIM, Hyun-Joo JEON, Sun-Ho KIM, Hae-Sun WIE, Gil-Tae KIM, Dong-Hwan LEE, Byung-Kyu PARK, Chan-Sun AHN, Byung-Nak KIM, Eunkyung BAE, Myung-Ho SHIN, Young-Ah HUR, Youn LEE, Chun-Ho CHOI, Hyun-Ho KIM, Bongtae CHONG, Wonee KANG, So Mi
DMTEJRB	DT	Small molecular drug

DMVCKZT	ID	DMVCKZT
DMVCKZT	DN	Phenylpropylamine derivative 1
DMVCKZT	HS	Patented
DMVCKZT	SN	PMID28051882-Compound-3
DMVCKZT	CP	Wisconsin Alumni Research Foundation
DMVCKZT	DT	Small molecular drug
DMVCKZT	PC	20534903
DMVCKZT	MW	278.39
DMVCKZT	FM	C16H26N2O2
DMVCKZT	IC	InChI=1S/C16H26N2O2/c1-2-3-4-5-6-13-17-14-7-8-15-9-11-16(12-10-15)18(19)20/h9-12,17H,2-8,13-14H2,1H3
DMVCKZT	CS	CCCCCCCNCCCC1=CC=C(C=C1)[N+](=O)[O-]
DMVCKZT	IK	LAKCRRVRMIUBSO-UHFFFAOYSA-N
DMVCKZT	IU	N-[3-(4-nitrophenyl)propyl]heptan-1-amine

DMTDIA6	ID	DMTDIA6
DMTDIA6	DN	Phenylpropylamine derivative 2
DMTDIA6	HS	Patented
DMTDIA6	SN	PMID28051882-Compound-4
DMTDIA6	CP	Wisconsin Alumni Research Foundation
DMTDIA6	DT	Small molecular drug
DMTDIA6	PC	46196429
DMTDIA6	MW	348.5
DMTDIA6	FM	C21H36N2O2
DMTDIA6	IC	InChI=1S/C21H36N2O2/c1-2-3-4-5-6-7-8-9-10-11-18-22-19-12-13-20-14-16-21(17-15-20)23(24)25/h14-17,22H,2-13,18-19H2,1H3
DMTDIA6	CS	CCCCCCCCCCCCNCCCC1=CC=C(C=C1)[N+](=O)[O-]
DMTDIA6	IK	HPQAMSDOLBKJBM-UHFFFAOYSA-N
DMTDIA6	IU	N-[3-(4-nitrophenyl)propyl]dodecan-1-amine

DMH3FUR	ID	DMH3FUR
DMH3FUR	DN	Phenylpropylamine derivative 3
DMH3FUR	HS	Patented
DMH3FUR	SN	PMID28051882-Compound-5
DMH3FUR	CP	Wisconsin Alumni Research Foundation
DMH3FUR	DT	Small molecular drug
DMH3FUR	PC	46212857
DMH3FUR	MW	292.4
DMH3FUR	FM	C17H28N2O2
DMH3FUR	IC	InChI=1S/C17H28N2O2/c1-3-5-13-18(14-6-4-2)15-7-8-16-9-11-17(12-10-16)19(20)21/h9-12H,3-8,13-15H2,1-2H3
DMH3FUR	CS	CCCCN(CCCC)CCCC1=CC=C(C=C1)[N+](=O)[O-]
DMH3FUR	IK	RQYGHCATHJZLFY-UHFFFAOYSA-N
DMH3FUR	IU	N-butyl-N-[3-(4-nitrophenyl)propyl]butan-1-amine

DM0R653	ID	DM0R653
DM0R653	DN	Phenylpropylamine derivative 4
DM0R653	HS	Patented
DM0R653	SN	PMID28051882-Compound-6
DM0R653	CP	Wisconsin Alumni Research Foundation
DM0R653	DT	Small molecular drug

DMU0S2W	ID	DMU0S2W
DMU0S2W	DN	Phenylpropylamine derivative 5
DMU0S2W	HS	Patented
DMU0S2W	SN	PMID28051882-Compound-IV
DMU0S2W	CP	Wisconsin Alumni Research Foundation
DMU0S2W	DT	Small molecular drug

DMLSWKR	ID	DMLSWKR
DMLSWKR	DN	Phenylpurine acetamide analog 1
DMLSWKR	HS	Patented
DMLSWKR	SN	PMID27607364-Compound-165
DMLSWKR	DT	Small molecular drug

DMMGBLC	ID	DMMGBLC
DMMGBLC	DN	Phenylpurine acetamide analog 2
DMMGBLC	HS	Patented
DMMGBLC	SN	PMID27607364-Compound-5
DMMGBLC	DT	Small molecular drug

DMVHLQM	ID	DMVHLQM
DMVHLQM	DN	Phenylpyridine derivative 1
DMVHLQM	HS	Patented
DMVHLQM	SN	PMID26161698-Compound-40
DMVHLQM	CP	NOVARTIS AG PFISTER, Keith B SENDZIK, Martin
DMVHLQM	DT	Small molecular drug
DMVHLQM	PC	50991417
DMVHLQM	MW	429
DMVHLQM	FM	C23H29ClN4O2
DMVHLQM	IC	InChI=1S/C23H29ClN4O2/c24-21-15-27-22(28-23(29)18-4-2-8-25-14-18)12-20(21)17-3-1-5-19(11-17)26-13-16-6-9-30-10-7-16/h1,3,5,11-12,15-16,18,25-26H,2,4,6-10,13-14H2,(H,27,28,29)
DMVHLQM	CS	C1CC(CNC1)C(=O)NC2=NC=C(C(=C2)C3=CC(=CC=C3)NCC4CCOCC4)Cl
DMVHLQM	IK	UUPXZCDRKZMXRB-UHFFFAOYSA-N
DMVHLQM	IU	N-[5-chloro-4-[3-(oxan-4-ylmethylamino)phenyl]pyridin-2-yl]piperidine-3-carboxamide

DMTRPE6	ID	DMTRPE6
DMTRPE6	DN	Phenylpyridine derivative 2
DMTRPE6	HS	Patented
DMTRPE6	SN	PMID26161698-Compound-41
DMTRPE6	CP	NOVARTIS AG ANTONIOS-MCCREA, William R. BARSANTI, Paul A. HU, Cheng JIN, Xianming MARTIN, Eric J. PAN, Yue PFISTER, Keith B. SENDZIK, Martin SUTTON, James WAN, Lifeng
DMTRPE6	DT	Small molecular drug

DMDT5JI	ID	DMDT5JI
DMDT5JI	DN	Phenylpyridine derivative 3
DMDT5JI	HS	Patented
DMDT5JI	SN	PMID25416646-Compound-Figure5-G
DMDT5JI	DT	Small molecular drug

DMPAI5C	ID	DMPAI5C
DMPAI5C	DN	Phenylpyrrolidinone derivative 1
DMPAI5C	HS	Patented
DMPAI5C	SN	PMID27646439-Compound-10
DMPAI5C	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMPAI5C	DT	Small molecular drug
DMPAI5C	PC	118373075
DMPAI5C	MW	468.4
DMPAI5C	FM	C23H19F3N6O2
DMPAI5C	IC	InChI=1S/C23H19F3N6O2/c1-31-11-15(18-19(27)28-12-29-20(18)31)13-5-7-14(8-6-13)32-10-9-22(34,21(32)33)16-3-2-4-17(30-16)23(24,25)26/h2-8,11-12,34H,9-10H2,1H3,(H2,27,28,29)
DMPAI5C	CS	CN1C=C(C2=C(N=CN=C21)N)C3=CC=C(C=C3)N4CCC(C4=O)(C5=NC(=CC=C5)C(F)(F)F)O
DMPAI5C	IK	DHELRXCAKDZMKY-UHFFFAOYSA-N
DMPAI5C	IU	1-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-hydroxy-3-[6-(trifluoromethyl)pyridin-2-yl]pyrrolidin-2-one

DMF3NCO	ID	DMF3NCO
DMF3NCO	DN	Phenylpyrrolidinone derivative 2
DMF3NCO	HS	Patented
DMF3NCO	SN	PMID27646439-Compound-6
DMF3NCO	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMF3NCO	DT	Small molecular drug

DMPZKQN	ID	DMPZKQN
DMPZKQN	DN	Phenylpyrrolidinone derivative 3
DMPZKQN	HS	Patented
DMPZKQN	SN	PMID27646439-Compound-7
DMPZKQN	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMPZKQN	DT	Small molecular drug
DMPZKQN	PC	118368356
DMPZKQN	MW	397.5
DMPZKQN	FM	C24H23N5O
DMPZKQN	IC	InChI=1S/C24H23N5O/c1-24(17-6-4-3-5-7-17)12-13-29(23(24)30)18-10-8-16(9-11-18)19-14-28(2)22-20(19)21(25)26-15-27-22/h3-11,14-15H,12-13H2,1-2H3,(H2,25,26,27)
DMPZKQN	CS	CC1(CCN(C1=O)C2=CC=C(C=C2)C3=CN(C4=NC=NC(=C34)N)C)C5=CC=CC=C5
DMPZKQN	IK	CMUGNAXHKVXXNK-UHFFFAOYSA-N
DMPZKQN	IU	1-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-methyl-3-phenylpyrrolidin-2-one

DMSX47Q	ID	DMSX47Q
DMSX47Q	DN	Phenylpyrrolidinone derivative 4
DMSX47Q	HS	Patented
DMSX47Q	SN	PMID27646439-Compound-8
DMSX47Q	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMSX47Q	DT	Small molecular drug
DMSX47Q	PC	118373037
DMSX47Q	MW	437.4
DMSX47Q	FM	C23H18F3N5O
DMSX47Q	IC	InChI=1S/C23H18F3N5O/c1-30-10-18(20-21(27)28-11-29-22(20)30)17-3-2-15(9-19(17)26)31-5-4-16(23(31)32)12-6-13(24)8-14(25)7-12/h2-3,6-11,16H,4-5H2,1H3,(H2,27,28,29)
DMSX47Q	CS	CN1C=C(C2=C(N=CN=C21)N)C3=C(C=C(C=C3)N4CCC(C4=O)C5=CC(=CC(=C5)F)F)F
DMSX47Q	IK	JZSDPOSETBCTOH-UHFFFAOYSA-N
DMSX47Q	IU	1-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-3-(3,5-difluorophenyl)pyrrolidin-2-one

DMZSTLH	ID	DMZSTLH
DMZSTLH	DN	Phenylpyrrolidinone derivative 5
DMZSTLH	HS	Patented
DMZSTLH	SN	PMID27646439-Compound-9
DMZSTLH	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMZSTLH	DT	Small molecular drug
DMZSTLH	PC	118373061
DMZSTLH	MW	401.5
DMZSTLH	FM	C22H23N7O
DMZSTLH	IC	InChI=1S/C22H23N7O/c1-13-10-14(2)29(26-13)18-8-9-28(22(18)30)16-6-4-15(5-7-16)17-11-27(3)21-19(17)20(23)24-12-25-21/h4-7,10-12,18H,8-9H2,1-3H3,(H2,23,24,25)
DMZSTLH	CS	CC1=CC(=NN1C2CCN(C2=O)C3=CC=C(C=C3)C4=CN(C5=NC=NC(=C45)N)C)C
DMZSTLH	IK	WBRYMNNSAHRQTO-UHFFFAOYSA-N
DMZSTLH	IU	1-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-(3,5-dimethylpyrazol-1-yl)pyrrolidin-2-one

DM9NOP3	ID	DM9NOP3
DM9NOP3	DN	Phenylsulfonyl derivative 1
DM9NOP3	HS	Patented
DM9NOP3	SN	PMID29334795-Compound-46
DM9NOP3	CP	OXYGEN HEALTHCARE RESEARCH PVT. LTD SHIRSATH, Vikas S. PATEL, Shailesh M SHETH, Nehal M. SINGH, Jitendra K. PATIL, Pawan D. PAWAR, Anil D. MOTIVARAS, Jitendra D
DM9NOP3	DT	Small molecular drug
DM9NOP3	DE	Central nervous system disease

DM63128	ID	DM63128
DM63128	DN	Phenylsulfonyl derivative 2
DM63128	HS	Patented
DM63128	SN	PMID29334795-Compound-47
DM63128	CP	OXYGEN HEALTHCARE RESEARCH PVT. LTD SHIRSATH, Vikas S. PATEL, Shailesh M SHETH, Nehal M. SINGH, Jitendra K. PATIL, Pawan D. PAWAR, Anil D. MOTIVARAS, Jitendra D
DM63128	DT	Small molecular drug
DM63128	PC	89588522
DM63128	MW	409.5
DM63128	FM	C23H27N3O2S
DM63128	IC	InChI=1S/C23H27N3O2S/c27-22(9-6-14-25-12-4-5-13-25)24-19-10-11-21-20(17-19)26(15-16-29-21)23(28)18-7-2-1-3-8-18/h1-3,7-8,10-11,17H,4-6,9,12-16H2,(H,24,27)
DM63128	CS	C1CCN(C1)CCCC(=O)NC2=CC3=C(C=C2)SCCN3C(=O)C4=CC=CC=C4
DM63128	IK	NSMKNQYJLDRTTI-UHFFFAOYSA-N
DM63128	IU	N-(4-benzoyl-2,3-dihydro-1,4-benzothiazin-6-yl)-4-pyrrolidin-1-ylbutanamide
DM63128	DE	Central nervous system disease

DME6FLN	ID	DME6FLN
DME6FLN	DN	Phenylsulfonyl derivative 3
DME6FLN	HS	Patented
DME6FLN	SN	PMID29334795-Compound-48
DME6FLN	CP	OXYGEN HEALTHCARE RESEARCH PVT. LTD SHIRSATH, Vikas S. PATEL, Shailesh M SHETH, Nehal M. SINGH, Jitendra K. PATIL, Pawan D. PAWAR, Anil D. MOTIVARAS, Jitendra D
DME6FLN	DT	Small molecular drug
DME6FLN	PC	71555928
DME6FLN	MW	432.6
DME6FLN	FM	C22H28N2O3S2
DME6FLN	IC	InChI=1S/C22H28N2O3S2/c25-29(26,20-8-3-1-4-9-20)24-15-17-28-22-11-10-19(18-21(22)24)27-16-7-14-23-12-5-2-6-13-23/h1,3-4,8-11,18H,2,5-7,12-17H2
DME6FLN	CS	C1CCN(CC1)CCCOC2=CC3=C(C=C2)SCCN3S(=O)(=O)C4=CC=CC=C4
DME6FLN	IK	DHYQKBDAADLGAK-UHFFFAOYSA-N
DME6FLN	IU	4-(benzenesulfonyl)-6-(3-piperidin-1-ylpropoxy)-2,3-dihydro-1,4-benzothiazine
DME6FLN	DE	Central nervous system disease

DM1HYW4	ID	DM1HYW4
DM1HYW4	DN	Phenylsulfonyl derivative 4
DM1HYW4	HS	Patented
DM1HYW4	SN	PMID29334795-Compound-49
DM1HYW4	CP	OXYGEN HEALTHCARE RESEARCH PVT. LTD SHIRSATH, Vikas S. PATEL, Shailesh M SHETH, Nehal M. SINGH, Jitendra K. PATIL, Pawan D. PAWAR, Anil D. MOTIVARAS, Jitendra D
DM1HYW4	DT	Small molecular drug
DM1HYW4	PC	78119142
DM1HYW4	MW	432.6
DM1HYW4	FM	C22H28N2O3S2
DM1HYW4	IC	InChI=1S/C22H28N2O3S2/c1-18-7-5-12-23(18)13-6-15-27-19-10-11-22-21(17-19)24(14-16-28-22)29(25,26)20-8-3-2-4-9-20/h2-4,8-11,17-18H,5-7,12-16H2,1H3
DM1HYW4	CS	CC1CCCN1CCCOC2=CC3=C(C=C2)SCCN3S(=O)(=O)C4=CC=CC=C4
DM1HYW4	IK	OBXKKQAGOFTSNE-UHFFFAOYSA-N
DM1HYW4	IU	4-(benzenesulfonyl)-6-[3-(2-methylpyrrolidin-1-yl)propoxy]-2,3-dihydro-1,4-benzothiazine
DM1HYW4	DE	Central nervous system disease

DMTHXUC	ID	DMTHXUC
DMTHXUC	DN	Phenylthioacetate derivative 1
DMTHXUC	HS	Patented
DMTHXUC	SN	PMID27414413-Compound-Figure2right
DMTHXUC	CP	ARDEA BIOSCIENCES, INC. OUK, Samedy VERNIER, Jean-michel GUNIC, Esmir
DMTHXUC	DT	Small molecular drug

DMZPHN5	ID	DMZPHN5
DMZPHN5	DN	Phthalazine derivative 1
DMZPHN5	HS	Patented
DMZPHN5	SN	PMID27841036-Compound-14
DMZPHN5	CP	Janssen Pharmaceutica NV 
DMZPHN5	DT	Small molecular drug
DMZPHN5	PC	11514425
DMZPHN5	MW	258.32
DMZPHN5	FM	C14H18N4O
DMZPHN5	IC	InChI=1S/C14H18N4O/c15-9-10-5-7-18(8-6-10)13-11-3-1-2-4-12(11)14(19)17-16-13/h1-4,10H,5-9,15H2,(H,17,19)
DMZPHN5	CS	C1CN(CCC1CN)C2=NNC(=O)C3=CC=CC=C32
DMZPHN5	IK	CLUMMMKUUCOEBB-UHFFFAOYSA-N
DMZPHN5	IU	4-[4-(aminomethyl)piperidin-1-yl]-2H-phthalazin-1-one

DMODTSC	ID	DMODTSC
DMODTSC	DN	Phthalazine derivative 2
DMODTSC	HS	Patented
DMODTSC	SN	PMID27841036-Compound-15
DMODTSC	CP	Janssen Pharmaceutica NV 
DMODTSC	DT	Small molecular drug
DMODTSC	PC	11610964
DMODTSC	MW	397.4
DMODTSC	FM	C22H24FN3O3
DMODTSC	IC	InChI=1S/C22H24FN3O3/c23-16-5-7-18(8-6-16)29-14-17(27)13-26-11-9-15(10-12-26)21-19-3-1-2-4-20(19)22(28)25-24-21/h1-8,15,17,27H,9-14H2,(H,25,28)
DMODTSC	CS	C1CN(CCC1C2=NNC(=O)C3=CC=CC=C32)CC(COC4=CC=C(C=C4)F)O
DMODTSC	IK	KVBJGGXSNXZAOH-UHFFFAOYSA-N
DMODTSC	IU	4-[1-[3-(4-fluorophenoxy)-2-hydroxypropyl]piperidin-4-yl]-2H-phthalazin-1-one

DMA1OEF	ID	DMA1OEF
DMA1OEF	DN	Phthalazine derivative 3
DMA1OEF	HS	Patented
DMA1OEF	SN	PMID27841036-Compound-19
DMA1OEF	CP	Shanghai Institute of Materia Medica
DMA1OEF	DT	Small molecular drug
DMA1OEF	PC	71678316
DMA1OEF	MW	474.4
DMA1OEF	FM	C21H14F4N6O3
DMA1OEF	IC	InChI=1S/C21H14F4N6O3/c22-15-6-5-11(34-18-13-4-2-1-3-12(13)17(32)27-28-18)9-14(15)19(33)30-7-8-31-16(10-30)26-29-20(31)21(23,24)25/h1-6,9H,7-8,10H2,(H,27,32)
DMA1OEF	CS	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)OC4=NNC(=O)C5=CC=CC=C54)F
DMA1OEF	IK	MZFDEPWODAICMP-UHFFFAOYSA-N
DMA1OEF	IU	4-[4-fluoro-3-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl]phenoxy]-2H-phthalazin-1-one

DMD2R1H	ID	DMD2R1H
DMD2R1H	DN	Phthalazine ketone derivative 1
DMD2R1H	HS	Patented
DMD2R1H	SN	PMID27841036-Compound-16
DMD2R1H	CP	CHENGDU DI AO PHARMACEUTICAL GROUP CO LTD [CN]
DMD2R1H	DT	Small molecular drug
DMD2R1H	PC	89608436
DMD2R1H	MW	479.5
DMD2R1H	FM	C25H26FN5O4
DMD2R1H	IC	InChI=1S/C25H26FN5O4/c1-29(2)25(9-10-25)24(34)31-13-11-30(12-14-31)23(33)19-15-16(7-8-20(19)26)35-22-18-6-4-3-5-17(18)21(32)27-28-22/h3-8,15H,9-14H2,1-2H3,(H,27,32)
DMD2R1H	CS	CN(C)C1(CC1)C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)OC4=NNC(=O)C5=CC=CC=C54)F
DMD2R1H	IK	DZWVGXKLZPKLKS-UHFFFAOYSA-N
DMD2R1H	IU	4-[3-[4-[1-(dimethylamino)cyclopropanecarbonyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2H-phthalazin-1-one

DM07C1I	ID	DM07C1I
DM07C1I	DN	Phthalazine ketone derivative 2
DM07C1I	HS	Patented
DM07C1I	SN	PMID27841036-Compound-17
DM07C1I	CP	CHENGDU DI AO PHARMACEUTICAL GROUP CO LTD [CN]
DM07C1I	DT	Small molecular drug
DM07C1I	PC	71571973
DM07C1I	MW	466.5
DM07C1I	FM	C25H27FN4O4
DM07C1I	IC	InChI=1S/C25H27FN4O4/c1-3-16(4-2)24(32)29-11-13-30(14-12-29)25(33)20-15-17(9-10-21(20)26)34-23-19-8-6-5-7-18(19)22(31)27-28-23/h5-10,15-16H,3-4,11-14H2,1-2H3,(H,27,31)
DM07C1I	CS	CCC(CC)C(=O)N1CCN(CC1)C(=O)C2=C(C=CC(=C2)OC3=NNC(=O)C4=CC=CC=C43)F
DM07C1I	IK	IJSAVXZCXLCXRP-UHFFFAOYSA-N
DM07C1I	IU	4-[3-[4-(2-ethylbutanoyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2H-phthalazin-1-one

DMIWY93	ID	DMIWY93
DMIWY93	DN	Phthalazine ketone derivative 3
DMIWY93	HS	Patented
DMIWY93	SN	PMID27841036-Compound-18
DMIWY93	CP	CHENGDU DI AO PHARMACEUTICAL GROUP CO LTD [CN]
DMIWY93	DT	Small molecular drug
DMIWY93	PC	71598692
DMIWY93	MW	479.5
DMIWY93	FM	C25H26FN5O4
DMIWY93	IC	InChI=1S/C25H26FN5O4/c26-21-9-8-17(35-23-19-7-3-2-6-18(19)22(32)27-28-23)16-20(21)24(33)29-12-14-31(15-13-29)25(34)30-10-4-1-5-11-30/h2-3,6-9,16H,1,4-5,10-15H2,(H,27,32)
DMIWY93	CS	C1CCN(CC1)C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)OC4=NNC(=O)C5=CC=CC=C54)F
DMIWY93	IK	BCFBHNMOIFYWBS-UHFFFAOYSA-N
DMIWY93	IU	4-[4-fluoro-3-[4-(piperidine-1-carbonyl)piperazine-1-carbonyl]phenoxy]-2H-phthalazin-1-one

DMNA941	ID	DMNA941
DMNA941	DN	Phthalazinone derivative 1
DMNA941	HS	Patented
DMNA941	SN	PMID28627961-Compound-23
DMNA941	CP	GLENMARK PHARMACEUTICALS S.A
DMNA941	DT	Small molecular drug
DMNA941	PC	71525311
DMNA941	MW	524.9
DMNA941	FM	C27H23ClF2N4O3
DMNA941	IC	InChI=1S/C27H23ClF2N4O3/c1-27(2,3)26(37)31-13-15-4-8-21(28)20(10-15)24(35)33-18-7-5-16-14-32-34(25(36)19(16)12-18)23-9-6-17(29)11-22(23)30/h4-12,14H,13H2,1-3H3,(H,31,37)(H,33,35)
DMNA941	CS	CC(C)(C)C(=O)NCC1=CC(=C(C=C1)Cl)C(=O)NC2=CC3=C(C=C2)C=NN(C3=O)C4=C(C=C(C=C4)F)F
DMNA941	IK	UWLKNQSOSOPRPR-UHFFFAOYSA-N
DMNA941	IU	2-chloro-N-[3-(2,4-difluorophenyl)-4-oxophthalazin-6-yl]-5-[(2,2-dimethylpropanoylamino)methyl]benzamide

DM5H3R8	ID	DM5H3R8
DM5H3R8	DN	PhyllanthoidA
DM5H3R8	HS	Patented

DMM9F8D	ID	DMM9F8D
DMM9F8D	DN	Phytocannabinoid/aminoalkylindole derivative 1
DMM9F8D	HS	Patented
DMM9F8D	SN	PMID27215781-Compound-47
DMM9F8D	CP	NORTHEASTERN UNIVERSITY
DMM9F8D	DT	Small molecular drug

DMOXJ7Q	ID	DMOXJ7Q
DMOXJ7Q	DN	Phytocannabinoid/aminoalkylindole derivative 2
DMOXJ7Q	HS	Patented
DMOXJ7Q	SN	PMID27215781-Compound-48
DMOXJ7Q	CP	NORTHEASTERN UNIVERSITY
DMOXJ7Q	DT	Small molecular drug

DMUP4DX	ID	DMUP4DX
DMUP4DX	DN	Picolinamido propanoic acid derivative 1
DMUP4DX	HS	Patented
DMUP4DX	SN	PMID25828189-Compound-10
DMUP4DX	CP	JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj KREUTTER, Kevin POWELL, Mark SHOOK, Brian SONG, Fengbin XU, Guozhang YANG, Shyh-ming ZHANG, Rui ZHAO, Bao-pin
DMUP4DX	DT	Small molecular drug
DMUP4DX	PC	71472272
DMUP4DX	MW	636
DMUP4DX	FM	C31H24ClF6N3O3
DMUP4DX	IC	InChI=1S/C31H24ClF6N3O3/c1-17-12-20(30(33,34)35)5-7-23(17)24-8-6-22(14-26(24)32)40-15-18-2-4-21(31(36,37)38)13-25(18)19-3-9-27(41-16-19)29(44)39-11-10-28(42)43/h2-9,12-14,16,40H,10-11,15H2,1H3,(H,39,44)(H,42,43)
DMUP4DX	CS	CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=C(C=C2)NCC3=C(C=C(C=C3)C(F)(F)F)C4=CN=C(C=C4)C(=O)NCCC(=O)O)Cl
DMUP4DX	IK	GPKUFXAKPUJEDG-UHFFFAOYSA-N
DMUP4DX	IU	3-[[5-[2-[[3-chloro-4-[2-methyl-4-(trifluoromethyl)phenyl]anilino]methyl]-5-(trifluoromethyl)phenyl]pyridine-2-carbonyl]amino]propanoic acid

DMR74ET	ID	DMR74ET
DMR74ET	DN	Picolinamido propanoic acid derivative 2
DMR74ET	HS	Patented
DMR74ET	SN	PMID25828189-Compound-11
DMR74ET	CP	JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj KREUTTER, Kevin POWELL, Mark SHOOK, Brian SONG, Fengbin XU, Guozhang YANG, Shyh-ming ZHANG, Rui ZHAO, Bao-pin
DMR74ET	DT	Small molecular drug
DMR74ET	PC	71059831
DMR74ET	MW	602.4
DMR74ET	FM	C30H24Cl2F3N3O3
DMR74ET	IC	InChI=1S/C30H24Cl2F3N3O3/c1-17-12-21(31)5-8-23(17)18-2-6-22(7-3-18)37-16-25-24(13-20(14-26(25)32)30(33,34)35)19-4-9-27(38-15-19)29(41)36-11-10-28(39)40/h2-9,12-15,37H,10-11,16H2,1H3,(H,36,41)(H,39,40)
DMR74ET	CS	CC1=C(C=CC(=C1)Cl)C2=CC=C(C=C2)NCC3=C(C=C(C=C3Cl)C(F)(F)F)C4=CN=C(C=C4)C(=O)NCCC(=O)O
DMR74ET	IK	OUHVBZQQNWUOOU-UHFFFAOYSA-N
DMR74ET	IU	3-[[5-[3-chloro-2-[[4-(4-chloro-2-methylphenyl)anilino]methyl]-5-(trifluoromethyl)phenyl]pyridine-2-carbonyl]amino]propanoic acid

DMP1RV5	ID	DMP1RV5
DMP1RV5	DN	Picolinamido propanoic acid derivative 3
DMP1RV5	HS	Patented
DMP1RV5	SN	PMID25828189-Compound-12
DMP1RV5	CP	JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj KREUTTER, Kevin POWELL, Mark SHOOK, Brian SONG, Fengbin XU, Guozhang YANG, Shyh-ming ZHANG, Rui ZHAO, Bao-pin
DMP1RV5	DT	Small molecular drug
DMP1RV5	PC	71060110
DMP1RV5	MW	582
DMP1RV5	FM	C30H23ClF3N3O4
DMP1RV5	IC	InChI=1S/C30H23ClF3N3O4/c1-17-14-21(31)6-10-23(17)18-2-7-22(8-3-18)37-28(40)24-9-5-20(30(32,33)34)15-25(24)19-4-11-26(36-16-19)29(41)35-13-12-27(38)39/h2-11,14-16H,12-13H2,1H3,(H,35,41)(H,37,40)(H,38,39)
DMP1RV5	CS	CC1=C(C=CC(=C1)Cl)C2=CC=C(C=C2)NC(=O)C3=C(C=C(C=C3)C(F)(F)F)C4=CN=C(C=C4)C(=O)NCCC(=O)O
DMP1RV5	IK	QISSKZBXYOVUJU-UHFFFAOYSA-N
DMP1RV5	IU	3-[[5-[2-[[4-(4-chloro-2-methylphenyl)phenyl]carbamoyl]-5-(trifluoromethyl)phenyl]pyridine-2-carbonyl]amino]propanoic acid

DMCIXD4	ID	DMCIXD4
DMCIXD4	DN	Piperazine carbamate/urea derivative 1
DMCIXD4	HS	Patented
DMCIXD4	SN	PMID29334795-Compound-39
DMCIXD4	CP	NOVARTIS AG AUBERSON, Yves BOCK, Mark Gary BRAGA, Dario CURZI, Marco DODD, Stephanie Kay GIAFFREDA, Stefano Luca JIANG, Haiyang KARPINSKI, Piotr TROXLER, Thomas J. WANG, Tielin WANG, Xiaoyang ZHANG, XuechuNOVARTIS AG
DMCIXD4	DT	Small molecular drug

DMCG6BE	ID	DMCG6BE
DMCG6BE	DN	Piperazine carbamate/urea derivative 2
DMCG6BE	HS	Patented
DMCG6BE	SN	PMID29334795-Compound-40
DMCG6BE	CP	Novartis AG
DMCG6BE	DT	Small molecular drug
DMCG6BE	PC	71533679
DMCG6BE	MW	375.5
DMCG6BE	FM	C19H29N5O3
DMCG6BE	IC	InChI=1S/C19H29N5O3/c1-14(2)22-9-11-24(12-10-22)19(26)27-16-5-7-23(8-6-16)17-4-3-15(13-21-17)18(20)25/h3-4,13-14,16H,5-12H2,1-2H3,(H2,20,25)
DMCG6BE	CS	CC(C)N1CCN(CC1)C(=O)OC2CCN(CC2)C3=NC=C(C=C3)C(=O)N
DMCG6BE	IK	SLFVKTUERQHULI-UHFFFAOYSA-N
DMCG6BE	IU	[1-(5-carbamoylpyridin-2-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate

DM2R468	ID	DM2R468
DM2R468	DN	Piperazine carbamate/urea derivative 3
DM2R468	HS	Patented
DM2R468	SN	PMID29334795-Compound-41
DM2R468	CP	Novartis AG
DM2R468	DT	Small molecular drug
DM2R468	PC	89487899
DM2R468	MW	375.5
DM2R468	FM	C19H29N5O3
DM2R468	IC	InChI=1S/C19H29N5O3/c1-14(2)22-9-11-24(12-10-22)19(26)27-16-5-7-23(8-6-16)15-3-4-17(18(20)25)21-13-15/h3-4,13-14,16H,5-12H2,1-2H3,(H2,20,25)
DM2R468	CS	CC(C)N1CCN(CC1)C(=O)OC2CCN(CC2)C3=CN=C(C=C3)C(=O)N
DM2R468	IK	NJPLXPIWGPHUGQ-UHFFFAOYSA-N
DM2R468	IU	[1-(6-carbamoylpyridin-3-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate

DM75J4T	ID	DM75J4T
DM75J4T	DN	Piperazine carbamate/urea derivative 4
DM75J4T	HS	Patented
DM75J4T	SN	PMID29334795-Compound-42
DM75J4T	CP	Novartis AG
DM75J4T	DT	Small molecular drug
DM75J4T	PC	89487751
DM75J4T	MW	385.5
DM75J4T	FM	C21H31N5O2
DM75J4T	IC	InChI=1S/C21H31N5O2/c1-16(2)23-10-12-25(13-11-23)21(27)28-19-5-8-24(9-6-19)18-4-7-26-15-17(3)22-20(26)14-18/h4,7,14-16,19H,5-6,8-13H2,1-3H3
DM75J4T	CS	CC1=CN2C=CC(=CC2=N1)N3CCC(CC3)OC(=O)N4CCN(CC4)C(C)C
DM75J4T	IK	XAQBWJISZRMNHF-UHFFFAOYSA-N
DM75J4T	IU	[1-(2-methylimidazo[1,2-a]pyridin-7-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate

DMJ80IZ	ID	DMJ80IZ
DMJ80IZ	DN	Piperazine carbamate/urea derivative 5
DMJ80IZ	HS	Patented
DMJ80IZ	SN	PMID29334795-Compound-43
DMJ80IZ	CP	Novartis AG
DMJ80IZ	DT	Small molecular drug
DMJ80IZ	PC	72948213
DMJ80IZ	MW	363.5
DMJ80IZ	FM	C18H29N5O3
DMJ80IZ	IC	InChI=1S/C18H29N5O3/c1-14(2)21-10-12-23(13-11-21)18(25)26-15-6-8-22(9-7-15)16-4-5-17(24)20(3)19-16/h4-5,14-15H,6-13H2,1-3H3
DMJ80IZ	CS	CC(C)N1CCN(CC1)C(=O)OC2CCN(CC2)C3=NN(C(=O)C=C3)C
DMJ80IZ	IK	JXFIKXGRFYNISW-UHFFFAOYSA-N
DMJ80IZ	IU	[1-(1-methyl-6-oxopyridazin-3-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate

DMZEPU3	ID	DMZEPU3
DMZEPU3	DN	Piperazine carbamate/urea derivative 6
DMZEPU3	HS	Patented
DMZEPU3	SN	PMID29334795-Compound-44
DMZEPU3	CP	Novartis AG
DMZEPU3	DT	Small molecular drug
DMZEPU3	PC	72948405
DMZEPU3	MW	348.4
DMZEPU3	FM	C18H28N4O3
DMZEPU3	IC	InChI=1S/C18H28N4O3/c1-14(2)20-9-11-22(12-10-20)18(24)25-16-5-7-21(8-6-16)15-3-4-17(23)19-13-15/h3-4,13-14,16H,5-12H2,1-2H3,(H,19,23)
DMZEPU3	CS	CC(C)N1CCN(CC1)C(=O)OC2CCN(CC2)C3=CNC(=O)C=C3
DMZEPU3	IK	ONRCNWHOGZJSOB-UHFFFAOYSA-N
DMZEPU3	IU	[1-(6-oxo-1H-pyridin-3-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate

DM067UC	ID	DM067UC
DM067UC	DN	Piperazine carbamate/urea derivative 7
DM067UC	HS	Patented
DM067UC	SN	PMID29334795-Compound-45
DM067UC	CP	NOVARTIS AG AUBERSON, Yves BOCK, Mark Gary BRAGA, Dario CURZI, Marco DODD, Stephanie Kay GIAFFREDA, Stefano Luca JIANG, Haiyang KARPINSKI, Piotr TROXLER, Thomas J. WANG, Tielin WANG, Xiaoyang ZHANG, XuechuNOVARTIS AG
DM067UC	DT	Small molecular drug
DM067UC	PC	72948400
DM067UC	MW	375.5
DM067UC	FM	C19H29N5O3
DM067UC	IC	InChI=1S/C19H29N5O3/c1-21-18(25)6-5-17(20-21)23-9-7-16(8-10-23)27-19(26)24-13-11-22(12-14-24)15-3-2-4-15/h5-6,15-16H,2-4,7-14H2,1H3
DM067UC	CS	CN1C(=O)C=CC(=N1)N2CCC(CC2)OC(=O)N3CCN(CC3)C4CCC4
DM067UC	IK	BVUJMFFRMZRNAT-UHFFFAOYSA-N
DM067UC	IU	[1-(1-methyl-6-oxopyridazin-3-yl)piperidin-4-yl] 4-cyclobutylpiperazine-1-carboxylate

DMZSYU4	ID	DMZSYU4
DMZSYU4	DN	Piperazine carbamic compound 1
DMZSYU4	HS	Patented
DMZSYU4	SN	PMID29053063-Compound-8a
DMZSYU4	CP	ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMZSYU4	DT	Small molecular drug

DMMQ0ZO	ID	DMMQ0ZO
DMMQ0ZO	DN	Piperazine carbamic compound 2
DMMQ0ZO	HS	Patented
DMMQ0ZO	SN	PMID29053063-Compound-8b
DMMQ0ZO	CP	ABIDE THERAPEUTICS, INCABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMMQ0ZO	DT	Small molecular drug

DM8IU1G	ID	DM8IU1G
DM8IU1G	DN	Piperazine carbamic compound 3
DM8IU1G	HS	Patented
DM8IU1G	SN	PMID29053063-Compound-8c
DM8IU1G	CP	ABIDE THERAPEUTICS, INC
DM8IU1G	DT	Small molecular drug

DMKZUO4	ID	DMKZUO4
DMKZUO4	DN	Piperazine carbamic compound 4
DMKZUO4	HS	Patented
DMKZUO4	SN	PMID29053063-Compound-9a
DMKZUO4	CP	ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMKZUO4	DT	Small molecular drug

DMXH65Z	ID	DMXH65Z
DMXH65Z	DN	Piperazine carbamic compound 5
DMXH65Z	HS	Patented
DMXH65Z	SN	PMID29053063-Compound-9b
DMXH65Z	CP	ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMXH65Z	DT	Small molecular drug

DMJ7F1Q	ID	DMJ7F1Q
DMJ7F1Q	DN	Piperazine derivative 1
DMJ7F1Q	HS	Patented
DMJ7F1Q	SN	PMID26161824-Compound-129
DMJ7F1Q	CP	INTERVET INTERNATIONAL B.V. GILBERT, Eric, J. MILLER, Michael, W. SCOTT, Jack, D. DEMONG, Duane, Eugene STAMFORD, Andrew GREENLEE, William, J. CELLY, Chander, Shekhe
DMJ7F1Q	DT	Small molecular drug
DMJ7F1Q	PC	57662641
DMJ7F1Q	MW	504.4
DMJ7F1Q	FM	C24H27Cl2N5O3
DMJ7F1Q	IC	InChI=1S/C24H27Cl2N5O3/c25-18-3-1-17(2-4-18)23-15-29(7-8-30-14-21(24(27)33)28-16-30)9-10-31(23)22-6-5-19(13-20(22)26)34-12-11-32/h1-6,13-14,16,23,32H,7-12,15H2,(H2,27,33)/t23-/m0/s1
DMJ7F1Q	CS	C1CN([C@@H](CN1CCN2C=C(N=C2)C(=O)N)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)OCCO)Cl
DMJ7F1Q	IK	LYKRPBPENHGRNR-QHCPKHFHSA-N
DMJ7F1Q	IU	1-[2-[(3R)-4-[2-chloro-4-(2-hydroxyethoxy)phenyl]-3-(4-chlorophenyl)piperazin-1-yl]ethyl]imidazole-4-carboxamide
DMJ7F1Q	DE	Obesity

DM4JZ2T	ID	DM4JZ2T
DM4JZ2T	DN	Piperazine derivative 2
DM4JZ2T	HS	Patented
DM4JZ2T	SN	PMID26161824-Compound-130
DM4JZ2T	CP	INTERVET INTERNATIONAL B.V. GILBERT, Eric, J. MILLER, Michael, W. SCOTT, Jack, D. DEMONG, Duane, Eugene STAMFORD, Andrew GREENLEE, William, J. CELLY, Chander, Shekhe
DM4JZ2T	DT	Small molecular drug
DM4JZ2T	DE	Obesity

DM8MZR6	ID	DM8MZR6
DM8MZR6	DN	Piperazine derivative 3
DM8MZR6	HS	Patented
DM8MZR6	SN	PMID26609882-Compound-61
DM8MZR6	CP	F. HOFFMANN-LA ROCHE AG GOBBI, Luca JAESCHKE, Georg RODRIGUEZ SARMIENTO, Rosa Maria STEWARD, LucindHoffmann-La Roche Inc
DM8MZR6	DT	Small molecular drug

DM2XGNY	ID	DM2XGNY
DM2XGNY	DN	Piperazine derivative 4
DM2XGNY	HS	Patented
DM2XGNY	SN	PMID26609882-Compound-62
DM2XGNY	CP	F. HOFFMANN-LA ROCHE AG GOBBI, Luca JAESCHKE, Georg RODRIGUEZ SARMIENTO, Rosa Maria STEWARD, LucindHoffmann-La Roche Inc
DM2XGNY	DT	Small molecular drug

DMDFUBH	ID	DMDFUBH
DMDFUBH	DN	Piperazine derivative 5
DMDFUBH	HS	Patented
DMDFUBH	SN	PMID26936077-Compound-16
DMDFUBH	CP	NeoPharm Co. Ltd
DMDFUBH	DT	Small molecular drug
DMDFUBH	PC	53244427
DMDFUBH	MW	283.37
DMDFUBH	FM	C14H25N3O3
DMDFUBH	IC	InChI=1S/C14H25N3O3/c1-12(18)11-14(20)17-9-7-16(8-10-17)13(19)5-3-2-4-6-15/h2-11,15H2,1H3
DMDFUBH	CS	CC(=O)CC(=O)N1CCN(CC1)C(=O)CCCCCN
DMDFUBH	IK	ISBLYNHHDOKBBQ-UHFFFAOYSA-N
DMDFUBH	IU	1-[4-(6-aminohexanoyl)piperazin-1-yl]butane-1,3-dione
DMDFUBH	DE	Atopic dermatitis

DMDL3A5	ID	DMDL3A5
DMDL3A5	DN	Piperazine derivative 6
DMDL3A5	HS	Patented
DMDL3A5	SN	PMID27724045-Compound-4
DMDL3A5	CP	GSK
DMDL3A5	DT	Small molecular drug
DMDL3A5	PC	25241867
DMDL3A5	MW	418.7
DMDL3A5	FM	C18H12ClF5N2O2
DMDL3A5	IC	InChI=1S/C18H12ClF5N2O2/c19-16-11(2-1-3-12(16)18(22,23)24)17(28)25-6-7-26(15(27)9-25)14-5-4-10(20)8-13(14)21/h1-5,8H,6-7,9H2
DMDL3A5	CS	C1CN(C(=O)CN1C(=O)C2=C(C(=CC=C2)C(F)(F)F)Cl)C3=C(C=C(C=C3)F)F
DMDL3A5	IK	VNEYCAAUOFFQMB-UHFFFAOYSA-N
DMDL3A5	IU	4-[2-chloro-3-(trifluoromethyl)benzoyl]-1-(2,4-difluorophenyl)piperazin-2-one

DM9Y4ZV	ID	DM9Y4ZV
DM9Y4ZV	DN	Piperazine derivative 7
DM9Y4ZV	HS	Patented
DM9Y4ZV	SN	PMID28051882-Compound-XIII
DM9Y4ZV	CP	Merk Patent GMBH
DM9Y4ZV	DT	Small molecular drug

DM1XUVB	ID	DM1XUVB
DM1XUVB	DN	Piperazine derivative 8
DM1XUVB	HS	Patented
DM1XUVB	SN	PMID28447479-Compound-25
DM1XUVB	CP	BIOGEN MA INC
DM1XUVB	DT	Small molecular drug
DM1XUVB	PC	74767919
DM1XUVB	MW	456.7
DM1XUVB	FM	C28H44N2O3
DM1XUVB	IC	InChI=1S/C28H44N2O3/c1-2-3-4-5-6-7-22-33-25-10-8-24(9-11-25)30-20-18-29(19-21-30)23-27-12-15-28(16-13-27,17-14-27)26(31)32/h8-11H,2-7,12-23H2,1H3,(H,31,32)
DM1XUVB	CS	CCCCCCCCOC1=CC=C(C=C1)N2CCN(CC2)CC34CCC(CC3)(CC4)C(=O)O
DM1XUVB	IK	BBLBOXJIVAKNRT-UHFFFAOYSA-N
DM1XUVB	IU	4-[[4-(4-octoxyphenyl)piperazin-1-yl]methyl]bicyclo[2.2.2]octane-1-carboxylic acid

DMEWAQ9	ID	DMEWAQ9
DMEWAQ9	DN	Piperazine urea derivative 1
DMEWAQ9	HS	Patented
DMEWAQ9	SN	PMID26413912-Compound-13
DMEWAQ9	DT	Small molecular drug
DMEWAQ9	PC	2809273
DMEWAQ9	MW	365.5
DMEWAQ9	FM	C19H19N5OS
DMEWAQ9	IC	InChI=1S/C19H19N5OS/c25-18(20-16-9-5-2-6-10-16)23-11-13-24(14-12-23)19-21-17(22-26-19)15-7-3-1-4-8-15/h1-10H,11-14H2,(H,20,25)
DMEWAQ9	CS	C1CN(CCN1C2=NC(=NS2)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMEWAQ9	IK	BHBOSTKQCZEAJM-UHFFFAOYSA-N
DMEWAQ9	IU	N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide
DMEWAQ9	CA	CAS 681136-29-8

DM5OCM7	ID	DM5OCM7
DM5OCM7	DN	Piperazine urea derivative 2
DM5OCM7	HS	Patented
DM5OCM7	SN	PMID26413912-Compound-48
DM5OCM7	CP	JANSEN PHARMACEUTICA NV HAWRYLUK, Natalie, A
DM5OCM7	DT	Small molecular drug

DMNAJWQ	ID	DMNAJWQ
DMNAJWQ	DN	Piperazine urea derivative 3
DMNAJWQ	HS	Patented
DMNAJWQ	SN	PMID26936077-Compound-18
DMNAJWQ	CP	PROXIMAGEN LTD. BOYD, Joe William MEO, Paul HIGGINBOTTOM, Michael SIMPSON, Iain MOUNTFORD, David Mark SAVORY, Edward Daniel
DMNAJWQ	DT	Small molecular drug
DMNAJWQ	DE	Inflammation; Solid tumour/cancer

DM3K7IM	ID	DM3K7IM
DM3K7IM	DN	Piperazine urea derivative 4
DM3K7IM	HS	Patented
DM3K7IM	SN	PMID26936077-Compound-19
DM3K7IM	CP	PROXIMAGEN LTD. BOYD, Joe William MEO, Paul HIGGINBOTTOM, Michael SIMPSON, Iain MOUNTFORD, David Mark SAVORY, Edward Daniel
DM3K7IM	DT	Small molecular drug
DM3K7IM	PC	60141847
DM3K7IM	MW	350.5
DM3K7IM	FM	C21H26N4O
DM3K7IM	IC	InChI=1S/C21H26N4O/c22-20(23)19-8-6-18(7-9-19)15-24-21(26)25-12-10-17(11-13-25)14-16-4-2-1-3-5-16/h1-9,17H,10-15H2,(H3,22,23)(H,24,26)
DM3K7IM	CS	C1CN(CCC1CC2=CC=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N
DM3K7IM	IK	PPLAJHCOIUEWGN-UHFFFAOYSA-N
DM3K7IM	IU	4-benzyl-N-[(4-carbamimidoylphenyl)methyl]piperidine-1-carboxamide
DM3K7IM	DE	Inflammation; Solid tumour/cancer

DM7WOD9	ID	DM7WOD9
DM7WOD9	DN	Piperazinyl methyl quinazolinone derivative 1
DM7WOD9	HS	Patented
DM7WOD9	SN	PMID30185082-Compound-29
DM7WOD9	CP	WASHINGTON UNIVERSITY
DM7WOD9	DT	Small molecular drug

DM913KS	ID	DM913KS
DM913KS	DN	Piperazinyl methyl quinazolinone derivative 2
DM913KS	HS	Patented
DM913KS	SN	PMID30185082-Compound-30
DM913KS	CP	WASHINGTON UNIVERSITY
DM913KS	DT	Small molecular drug
DM913KS	PC	11214940
DM913KS	MW	547
DM913KS	FM	C30H31ClN4O4
DM913KS	IC	InChI=1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3
DM913KS	CS	CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl
DM913KS	IK	BKQFRNYHFIQEKN-UHFFFAOYSA-N
DM913KS	IU	2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one
DM913KS	CA	CAS 571203-78-6
DM913KS	CB	CHEBI:94287

DMYH4AZ	ID	DMYH4AZ
DMYH4AZ	DN	Piperazinyl methyl quinazolinone derivative 3
DMYH4AZ	HS	Patented
DMYH4AZ	SN	PMID30185082-Compound-31
DMYH4AZ	CP	WASHINGTON UNIVERSITY
DMYH4AZ	DT	Small molecular drug

DM3LKTE	ID	DM3LKTE
DM3LKTE	DN	Piperazinyl norbenzomorphane compound 1
DM3LKTE	HS	Patented
DM3LKTE	SN	PMID30185082-Compound-32
DM3LKTE	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DM3LKTE	DT	Small molecular drug

DMD2CX1	ID	DMD2CX1
DMD2CX1	DN	Piperazinyl norbenzomorphane compound 2
DMD2CX1	HS	Patented
DMD2CX1	SN	PMID30185082-Compound-33
DMD2CX1	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMD2CX1	DT	Small molecular drug
DMD2CX1	PC	129056976
DMD2CX1	MW	419.6
DMD2CX1	FM	C26H33N3O2
DMD2CX1	IC	InChI=1S/C26H33N3O2/c1-2-11-27-13-15-28(16-14-27)22-8-9-23-21-10-12-29(25(17-21)24(23)18-22)26(30)31-19-20-6-4-3-5-7-20/h3-9,18,21,25H,2,10-17,19H2,1H3
DMD2CX1	CS	CCCN1CCN(CC1)C2=CC3=C(C=C2)C4CCN(C3C4)C(=O)OCC5=CC=CC=C5
DMD2CX1	IK	FFCRKESJGXTNRJ-UHFFFAOYSA-N
DMD2CX1	IU	benzyl 5-(4-propylpiperazin-1-yl)-9-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene-9-carboxylate

DMZYJKG	ID	DMZYJKG
DMZYJKG	DN	Piperazinyl norbenzomorphane compound 3
DMZYJKG	HS	Patented
DMZYJKG	SN	PMID30185082-Compound-34
DMZYJKG	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMZYJKG	DT	Small molecular drug
DMZYJKG	PC	44825925
DMZYJKG	MW	391.5
DMZYJKG	FM	C24H29N3O2
DMZYJKG	IC	InChI=1S/C24H29N3O2/c1-25-11-13-26(14-12-25)20-7-8-21-19-9-10-27(23(15-19)22(21)16-20)24(28)29-17-18-5-3-2-4-6-18/h2-8,16,19,23H,9-15,17H2,1H3
DMZYJKG	CS	CN1CCN(CC1)C2=CC3=C(C=C2)C4CCN(C3C4)C(=O)OCC5=CC=CC=C5
DMZYJKG	IK	CQQWIHMDQBNBBE-UHFFFAOYSA-N
DMZYJKG	IU	benzyl 5-(4-methylpiperazin-1-yl)-9-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene-9-carboxylate
DMZYJKG	CA	CAS 1644629-60-6

DMRSCJ7	ID	DMRSCJ7
DMRSCJ7	DN	Piperazinyl norbenzomorphane compound 4
DMRSCJ7	HS	Patented
DMRSCJ7	SN	PMID30185082-Compound-35
DMRSCJ7	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMRSCJ7	DT	Small molecular drug

DMY8QIG	ID	DMY8QIG
DMY8QIG	DN	Piperidine carboxamide derivative 1
DMY8QIG	HS	Patented
DMY8QIG	SN	PMID28627961-Compound-26
DMY8QIG	CP	NOVASAID AB WANNBERG, Johan ALTERMAN, Mathias MALM, Johan STENBERG, Patric WESTMAN, Jacob WALLBERG, Hans
DMY8QIG	DT	Small molecular drug
DMY8QIG	PC	50997187
DMY8QIG	MW	468.6
DMY8QIG	FM	C29H32N4O2
DMY8QIG	IC	InChI=1S/C29H32N4O2/c1-19-15-26-27(16-20(19)2)33(25-8-7-21-5-3-4-6-23(21)17-25)29(31-26)32-12-9-22(10-13-32)28(34)30-24-11-14-35-18-24/h3-8,15-17,22,24H,9-14,18H2,1-2H3,(H,30,34)
DMY8QIG	CS	CC1=CC2=C(C=C1C)N(C(=N2)N3CCC(CC3)C(=O)NC4CCOC4)C5=CC6=CC=CC=C6C=C5
DMY8QIG	IK	CPCIYGHUPLRYBW-UHFFFAOYSA-N
DMY8QIG	IU	1-(5,6-dimethyl-1-naphthalen-2-ylbenzimidazol-2-yl)-N-(oxolan-3-yl)piperidine-4-carboxamide

DMHN5KW	ID	DMHN5KW
DMHN5KW	DN	Piperidine derivative 1
DMHN5KW	HS	Patented
DMHN5KW	SN	PMID29334795-Compound-60
DMHN5KW	DT	Small molecular drug
DMHN5KW	PC	72792768
DMHN5KW	MW	396.5
DMHN5KW	FM	C25H33FN2O
DMHN5KW	IC	InChI=1S/C25H33FN2O/c1-27(2)14-6-13-25(22-8-10-23(26)11-9-22)24-12-7-20(17-21(24)19-29-25)18-28-15-4-3-5-16-28/h7-12,17H,3-6,13-16,18-19H2,1-2H3
DMHN5KW	CS	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)CN3CCCCC3)C4=CC=C(C=C4)F
DMHN5KW	IK	UWNUOIHSSBTGRY-UHFFFAOYSA-N
DMHN5KW	IU	3-[1-(4-fluorophenyl)-5-(piperidin-1-ylmethyl)-3H-2-benzofuran-1-yl]-N,N-dimethylpropan-1-amine

DMHXMB4	ID	DMHXMB4
DMHXMB4	DN	Piperidine derivative 2
DMHXMB4	HS	Patented
DMHXMB4	SN	PMID26936077-Compound-17
DMHXMB4	CP	PROXIMAGEN LTD. BOYD, Joe William MEO, Paul HIGGINBOTTOM, Michael SIMPSON, Iain MOUNTFORD, David Mark SAVORY, Edward Daniel
DMHXMB4	DT	Small molecular drug
DMHXMB4	DE	Inflammation; Solid tumour/cancer

DM80XRM	ID	DM80XRM
DM80XRM	DN	Piperidine derivative 3
DM80XRM	HS	Patented
DM80XRM	SN	PMID26936077-Compound-20
DM80XRM	CP	PROXIMAGEN LTD. BOYD, Joe William MEO, Paul HIGGINBOTTOM, Michael SIMPSON, Iain MOUNTFORD, David Mark SAVORY, Edward Daniel
DM80XRM	DT	Small molecular drug
DM80XRM	DE	Inflammation; Solid tumour/cancer

DM6C5DR	ID	DM6C5DR
DM6C5DR	DN	Piperidine derivative 4
DM6C5DR	HS	Patented
DM6C5DR	SN	PMID28051882-Compound-I
DM6C5DR	CP	Australian Nuclear Science & Technology Organisation
DM6C5DR	DT	Small molecular drug

DMQ0VK4	ID	DMQ0VK4
DMQ0VK4	DN	Piperidine derivative 5
DMQ0VK4	HS	Patented
DMQ0VK4	SN	PMID28051882-Compound-1
DMQ0VK4	CP	Australian Nuclear Science & Technology Organisation
DMQ0VK4	DT	Small molecular drug

DM0GCTY	ID	DM0GCTY
DM0GCTY	DN	Piperidine derivative 6
DM0GCTY	HS	Patented
DM0GCTY	SN	PMID28051882-Compound-XII
DM0GCTY	CP	Merk Patent GMBH
DM0GCTY	DT	Small molecular drug

DMAM50X	ID	DMAM50X
DMAM50X	DN	Piperidinone derivative 1
DMAM50X	HS	Patented
DMAM50X	SN	PMID27724045-Compound-3
DMAM50X	CP	GSK
DMAM50X	DT	Small molecular drug
DMAM50X	PC	25016092
DMAM50X	MW	348.75
DMAM50X	FM	C15H16ClF3N2O2
DMAM50X	IC	InChI=1S/C15H16ClF3N2O2/c1-21-11(6-3-7-12(21)22)14(23)20-8-9-4-2-5-10(13(9)16)15(17,18)19/h2,4-5,11H,3,6-8H2,1H3,(H,20,23)
DMAM50X	CS	CN1C(CCCC1=O)C(=O)NCC2=C(C(=CC=C2)C(F)(F)F)Cl
DMAM50X	IK	YGCMKVHDGGAEFD-UHFFFAOYSA-N
DMAM50X	IU	N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-6-oxopiperidine-2-carboxamide

DMWAYXP	ID	DMWAYXP
DMWAYXP	DN	Piperidinyl pyrazole derivative 1
DMWAYXP	HS	Patented
DMWAYXP	SN	PMID28699813-Compound-10
DMWAYXP	CP	MERCK SHARP &amDOHME CORP. GRAHAM, Thomas, H. SHEN, Dong-Ming SHU, Min
DMWAYXP	DT	Small molecular drug
DMWAYXP	PC	68206832
DMWAYXP	MW	443.5
DMWAYXP	FM	C28H27F2N3
DMWAYXP	IC	InChI=1S/C28H27F2N3/c29-23-10-6-21(7-11-23)26-19-33(16-14-20-4-2-1-3-5-20)17-15-25(26)28-18-27(31-32-28)22-8-12-24(30)13-9-22/h1-13,18,25-26H,14-17,19H2,(H,31,32)/t25-,26+/m1/s1
DMWAYXP	CS	C1CN(C[C@H]([C@@H]1C2=CC(=NN2)C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CCC5=CC=CC=C5
DMWAYXP	IK	HJPVPXYGXWGSIG-FTJBHMTQSA-N
DMWAYXP	IU	(3R,4R)-3-(4-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-5-yl]-1-(2-phenylethyl)piperidine

DM21S5G	ID	DM21S5G
DM21S5G	DN	Piperidinyl pyrazole derivative 2
DM21S5G	HS	Patented
DM21S5G	SN	PMID28699813-Compound-9
DM21S5G	CP	MERCK SHARP &amDOHME CORP. GRAHAM, Thomas, H. SHEN, Dong-Ming SHU, Min
DM21S5G	DT	Small molecular drug
DM21S5G	PC	54576061
DM21S5G	MW	440.6
DM21S5G	FM	C28H29FN4
DM21S5G	IC	InChI=1S/C28H29FN4/c1-32-27(21-25(31-32)23-10-12-24(29)13-11-23)28(26-9-5-6-17-30-26)15-19-33(20-16-28)18-14-22-7-3-2-4-8-22/h2-13,17,21H,14-16,18-20H2,1H3
DM21S5G	CS	CN1C(=CC(=N1)C2=CC=C(C=C2)F)C3(CCN(CC3)CCC4=CC=CC=C4)C5=CC=CC=N5
DM21S5G	IK	KJFTYICXBUEONK-UHFFFAOYSA-N
DM21S5G	IU	2-[4-[5-(4-fluorophenyl)-2-methylpyrazol-3-yl]-1-(2-phenylethyl)piperidin-4-yl]pyridine

DMX2V0W	ID	DMX2V0W
DMX2V0W	DN	Piperidinyl pyrazole derivative 3
DMX2V0W	HS	Patented
DMX2V0W	SN	PMID28699813-Compound-B
DMX2V0W	CP	MERCK SHARP &amDOHME CORP. GRAHAM, Thomas, H. SHEN, Dong-Ming SHU, Min
DMX2V0W	DT	Small molecular drug

DMS8NFJ	ID	DMS8NFJ
DMS8NFJ	DN	Piperidinyl pyrazole derivative 4
DMS8NFJ	HS	Patented
DMS8NFJ	SN	PMID28699813-Compound-c
DMS8NFJ	CP	MERCK SHARP &amDOHME CORP. GRAHAM, Thomas, H. SHEN, Dong-Ming SHU, Min
DMS8NFJ	DT	Small molecular drug

DMTSX7J	ID	DMTSX7J
DMTSX7J	DN	Piperidinyl triazole derivative 1
DMTSX7J	HS	Patented
DMTSX7J	SN	PMID28699813-Compound-11
DMTSX7J	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMTSX7J	DT	Small molecular drug
DMTSX7J	PC	53497458
DMTSX7J	MW	444
DMTSX7J	FM	C26H26ClN5
DMTSX7J	IC	InChI=1S/C26H26ClN5/c27-23-9-7-21(8-10-23)24-19-25(32(30-24)26-28-14-4-15-29-26)22-12-17-31(18-13-22)16-11-20-5-2-1-3-6-20/h1-10,14-15,19,22H,11-13,16-18H2
DMTSX7J	CS	C1CN(CCC1C2=CC(=NN2C3=NC=CC=N3)C4=CC=C(C=C4)Cl)CCC5=CC=CC=C5
DMTSX7J	IK	SVHYVLJAAMPZJM-UHFFFAOYSA-N
DMTSX7J	IU	2-[3-(4-chlorophenyl)-5-[1-(2-phenylethyl)piperidin-4-yl]pyrazol-1-yl]pyrimidine

DM2FZPE	ID	DM2FZPE
DM2FZPE	DN	Piperidinyl triazole derivative 2
DM2FZPE	HS	Patented
DM2FZPE	SN	PMID28699813-Compound-12
DM2FZPE	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DM2FZPE	DT	Small molecular drug
DM2FZPE	PC	68212658
DM2FZPE	MW	485.6
DM2FZPE	FM	C28H28FN5O2
DM2FZPE	IC	InChI=1S/C28H28FN5O2/c1-36-27(35)24(20-6-3-2-4-7-20)19-33-16-12-22(13-17-33)26-18-25(21-8-10-23(29)11-9-21)32-34(26)28-30-14-5-15-31-28/h2-11,14-15,18,22,24H,12-13,16-17,19H2,1H3
DM2FZPE	CS	COC(=O)C(CN1CCC(CC1)C2=CC(=NN2C3=NC=CC=N3)C4=CC=C(C=C4)F)C5=CC=CC=C5
DM2FZPE	IK	SVWGQADPJAOQRT-UHFFFAOYSA-N
DM2FZPE	IU	methyl 3-[4-[5-(4-fluorophenyl)-2-pyrimidin-2-ylpyrazol-3-yl]piperidin-1-yl]-2-phenylpropanoate

DM0J2TE	ID	DM0J2TE
DM0J2TE	DN	Piperidinyl triazole derivative 3
DM0J2TE	HS	Patented
DM0J2TE	SN	PMID28699813-Compound-13
DM0J2TE	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DM0J2TE	DT	Small molecular drug
DM0J2TE	PC	54597250
DM0J2TE	MW	471.5
DM0J2TE	FM	C27H26FN5O2
DM0J2TE	IC	InChI=1S/C27H26FN5O2/c28-22-9-7-20(8-10-22)24-17-25(33(31-24)27-29-13-4-14-30-27)21-11-15-32(16-12-21)18-23(26(34)35)19-5-2-1-3-6-19/h1-10,13-14,17,21,23H,11-12,15-16,18H2,(H,34,35)
DM0J2TE	CS	C1CN(CCC1C2=CC(=NN2C3=NC=CC=N3)C4=CC=C(C=C4)F)CC(C5=CC=CC=C5)C(=O)O
DM0J2TE	IK	ASWVEQWRTMUNCF-UHFFFAOYSA-N
DM0J2TE	IU	3-[4-[5-(4-fluorophenyl)-2-pyrimidin-2-ylpyrazol-3-yl]piperidin-1-yl]-2-phenylpropanoic acid

DMOQJMU	ID	DMOQJMU
DMOQJMU	DN	Piperidinyl triazole derivative 4
DMOQJMU	HS	Patented
DMOQJMU	SN	PMID28699813-Compound-14
DMOQJMU	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMOQJMU	DT	Small molecular drug
DMOQJMU	PC	54597177
DMOQJMU	MW	460
DMOQJMU	FM	C26H26ClN5O
DMOQJMU	IC	InChI=1S/C26H26ClN5O/c27-22-9-7-19(8-10-22)23-17-24(32(30-23)26-28-13-4-14-29-26)20-11-15-31(16-12-20)18-25(33)21-5-2-1-3-6-21/h1-10,13-14,17,20,25,33H,11-12,15-16,18H2
DMOQJMU	CS	C1CN(CCC1C2=CC(=NN2C3=NC=CC=N3)C4=CC=C(C=C4)Cl)CC(C5=CC=CC=C5)O
DMOQJMU	IK	VSNXVFRRZXFFLD-UHFFFAOYSA-N
DMOQJMU	IU	2-[4-[5-(4-chlorophenyl)-2-pyrimidin-2-ylpyrazol-3-yl]piperidin-1-yl]-1-phenylethanol

DM4QVD0	ID	DM4QVD0
DM4QVD0	DN	Piperidinyl triazole derivative 5
DM4QVD0	HS	Patented
DM4QVD0	SN	PMID28699813-Compound-D
DM4QVD0	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DM4QVD0	DT	Small molecular drug

DMG5HI1	ID	DMG5HI1
DMG5HI1	DN	Piperidinyl triazole derivative 6
DMG5HI1	HS	Patented
DMG5HI1	SN	PMID28699813-Compound-E
DMG5HI1	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMG5HI1	DT	Small molecular drug

DME26SY	ID	DME26SY
DME26SY	DN	Piperonal
DME26SY	HS	Patented
DME26SY	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DME26SY	PC	8438
DME26SY	MW	150.13
DME26SY	FM	C8H6O3
DME26SY	IC	InChI=1S/C8H6O3/c9-4-6-1-2-7-8(3-6)11-5-10-7/h1-4H,5H2
DME26SY	CS	C1OC2=C(O1)C=C(C=C2)C=O
DME26SY	IK	SATCULPHIDQDRE-UHFFFAOYSA-N
DME26SY	IU	1,3-benzodioxole-5-carbaldehyde
DME26SY	CA	CAS 120-57-0
DME26SY	CB	CHEBI:8240

DMFZ9Q3	ID	DMFZ9Q3
DMFZ9Q3	DN	Pitavastatin derivative 1
DMFZ9Q3	HS	Patented
DMFZ9Q3	SN	PMID27537201-Compound-Figure12
DMFZ9Q3	CP	the Shanghai Institute of Technology and the Shanghai Ecust Biomedicine Company
DMFZ9Q3	DT	Small molecular drug

DM8OYI4	ID	DM8OYI4
DM8OYI4	DN	Platinum IV complexe 1
DM8OYI4	HS	Patented
DM8OYI4	SN	PMID26394986-Compound-69
DM8OYI4	CP	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE TURKSON, James JOVE, Richard SEBTI, Said
DM8OYI4	DT	Small molecular drug

DMRXKJZ	ID	DMRXKJZ
DMRXKJZ	DN	PMID25399719-Compound-17
DMRXKJZ	HS	Patented
DMRXKJZ	CP	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
DMRXKJZ	DT	Small molecular drug

DM23NEX	ID	DM23NEX
DM23NEX	DN	PMID25399762-Compound-Figure1-Aphanamixoid A
DM23NEX	HS	Patented

DMRHNOY	ID	DMRHNOY
DMRHNOY	DN	PMID25399762-Compound-Figure1-Chukrasone A
DMRHNOY	HS	Patented

DM0K4XE	ID	DM0K4XE
DM0K4XE	DN	PMID25399762-Compound-Figure1-Chukrasone B
DM0K4XE	HS	Patented

DMDX1MK	ID	DMDX1MK
DMDX1MK	DN	PMID25399762-Compound-Figure1-Eryngiolide A
DMDX1MK	HS	Patented

DMSYGHO	ID	DMSYGHO
DMSYGHO	DN	PMID25399762-Compound-Figure1-Neonectrolide A
DMSYGHO	HS	Patented

DMRIEH3	ID	DMRIEH3
DMRIEH3	DN	PMID25399762-Compound-Figure1-Sarcaboside A
DMRIEH3	HS	Patented

DMDL6TG	ID	DMDL6TG
DMDL6TG	DN	PMID25399762-Compound-Figure1-Sarcaboside B
DMDL6TG	HS	Patented

DMG1EKV	ID	DMG1EKV
DMG1EKV	DN	PMID25399762-Compound-Figure2-Artoxanthochromane
DMG1EKV	HS	Patented
DMG1EKV	CP	Changzhou Kelixin Medical Devices CO LTD
DMG1EKV	DT	Small molecular drug

DMYJ0I8	ID	DMYJ0I8
DMYJ0I8	DN	PMID25399762-Compound-Figure2-Spirooliganone B
DMYJ0I8	HS	Patented

DMP5Y19	ID	DMP5Y19
DMP5Y19	DN	PMID25399762-Compound-Figure3-Aspeverin
DMP5Y19	HS	Patented
DMP5Y19	DT	Small molecular drug
DMP5Y19	PC	71712961
DMP5Y19	MW	376.5
DMP5Y19	FM	C22H24N4O2
DMP5Y19	IC	InChI=1S/C22H24N4O2/c1-20(2)16-10-13-6-5-9-26(13)17(11-23)21(16)12-22(28-19(27)25-21)14-7-3-4-8-15(14)24-18(20)22/h3-4,7-8,13,16-17H,5-6,9-10,12H2,1-2H3,(H,25,27)/t13-,16-,17-,21+,22+/m0/s1
DMP5Y19	CS	CC1([C@@H]2C[C@@H]3CCCN3[C@H]([C@@]24C[C@@]5(C1=NC6=CC=CC=C65)OC(=O)N4)C#N)C
DMP5Y19	IK	MJAHQBSZAYUSFL-MKGFCTCPSA-N
DMP5Y19	IU	(1R,11S,13S,18R,19R)-10,10-dimethyl-21-oxo-22-oxa-8,17,20-triazahexacyclo[17.3.1.01,9.02,7.011,19.013,17]tricosa-2,4,6,8-tetraene-18-carbonitrile

DM9KTRA	ID	DM9KTRA
DM9KTRA	DN	PMID25399762-Compound-Figure3-Fluevirosine A
DM9KTRA	HS	Patented

DMBSP1G	ID	DMBSP1G
DMBSP1G	DN	PMID25399762-Compound-Figure3-Lycojaponicumin A
DMBSP1G	HS	Patented
DMBSP1G	CP	Nanjing Guangkangxie Biolog. Medical Technology CO LTD

DMKP64Z	ID	DMKP64Z
DMKP64Z	DN	PMID25399762-Compound-Figure3-Lycojaponicumin B
DMKP64Z	HS	Patented
DMKP64Z	CP	Nanjing Guangkangxie Biolog. Medical Technology CO LTD

DM7NUT2	ID	DM7NUT2
DM7NUT2	DN	PMID25399762-Compound-Figure3-Lycojaponicumin C
DM7NUT2	HS	Patented
DM7NUT2	CP	Nanjing Guangkangxie Biolog. Medical Technology CO LTD

DMLAS7K	ID	DMLAS7K
DMLAS7K	DN	PMID25399762-Compound-Table 5-8
DMLAS7K	HS	Patented
DMLAS7K	CP	Varinel, Inc

DM18FP4	ID	DM18FP4
DM18FP4	DN	PMID25399762-Compound-Table 5-O-methyl-M30
DM18FP4	HS	Patented
DM18FP4	CP	Varinel, Inc

DM4UM03	ID	DM4UM03
DM4UM03	DN	PMID25399762-Compound-Table 6-10
DM4UM03	HS	Patented
DM4UM03	CP	ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos

DMYGTU2	ID	DMYGTU2
DMYGTU2	DN	PMID25399762-Compound-Table 6-11
DMYGTU2	HS	Patented
DMYGTU2	CP	ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos

DMZ07RP	ID	DMZ07RP
DMZ07RP	DN	PMID25399762-Compound-Table 6-12
DMZ07RP	HS	Patented
DMZ07RP	CP	ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos

DM6LR42	ID	DM6LR42
DM6LR42	DN	PMID25399762-Compound-Table 6-13
DM6LR42	HS	Patented
DM6LR42	CP	ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos

DMZHB9Y	ID	DMZHB9Y
DMZHB9Y	DN	PMID25399762-Compound-Table 6-14
DMZHB9Y	HS	Patented
DMZHB9Y	CP	ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos

DMCHWSF	ID	DMCHWSF
DMCHWSF	DN	PMID25399762-Compound-Table 6-15
DMCHWSF	HS	Patented
DMCHWSF	CP	ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos

DMDWIPG	ID	DMDWIPG
DMDWIPG	DN	PMID25399762-Compound-Table 6-9
DMDWIPG	HS	Patented
DMDWIPG	CP	ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos

DMSL3MB	ID	DMSL3MB
DMSL3MB	DN	PMID25399762-Compound-Table 7-Vanillic acid
DMSL3MB	HS	Patented
DMSL3MB	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER

DM759MJ	ID	DM759MJ
DM759MJ	DN	PMID25399762-Compound-Table 7-Vanillyl alcohol
DM759MJ	HS	Patented
DM759MJ	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER

DM4J2SM	ID	DM4J2SM
DM4J2SM	DN	PMID25399762-Compound-Table 7-Veratraldehyde
DM4J2SM	HS	Patented
DM4J2SM	CP	UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER

DMMP7HX	ID	DMMP7HX
DMMP7HX	DN	PMID25399762-Compound-Table1-C1
DMMP7HX	HS	Patented
DMMP7HX	CP	NTZ LAB LTD [BG]
DMMP7HX	DT	Small molecular drug

DMWY5XT	ID	DMWY5XT
DMWY5XT	DN	PMID25399762-Compound-Table1-C10
DMWY5XT	HS	Patented
DMWY5XT	CP	NTZ LAB LTD [BG]
DMWY5XT	DT	Small molecular drug

DMVASXW	ID	DMVASXW
DMVASXW	DN	PMID25399762-Compound-Table1-C11
DMVASXW	HS	Patented
DMVASXW	CP	NTZ LAB LTD [BG]
DMVASXW	DT	Small molecular drug

DMF9X6P	ID	DMF9X6P
DMF9X6P	DN	PMID25399762-Compound-Table1-C12
DMF9X6P	HS	Patented
DMF9X6P	CP	NTZ LAB LTD [BG]
DMF9X6P	DT	Small molecular drug

DMD80Q6	ID	DMD80Q6
DMD80Q6	DN	PMID25399762-Compound-Table1-C13
DMD80Q6	HS	Patented
DMD80Q6	CP	NTZ LAB LTD [BG]
DMD80Q6	DT	Small molecular drug

DM7960M	ID	DM7960M
DM7960M	DN	PMID25399762-Compound-Table1-C14
DM7960M	HS	Patented
DM7960M	CP	NTZ LAB LTD [BG]
DM7960M	DT	Small molecular drug

DMR0P1U	ID	DMR0P1U
DMR0P1U	DN	PMID25399762-Compound-Table1-C15
DMR0P1U	HS	Patented
DMR0P1U	CP	NTZ LAB LTD [BG]
DMR0P1U	DT	Small molecular drug
DMR0P1U	PC	77844717
DMR0P1U	MW	319.2
DMR0P1U	FM	C16H12Cl2N2O
DMR0P1U	IC	InChI=1S/C16H12Cl2N2O/c1-20-7-6-10-8-11(2-5-15(10)20)16(21)19-12-3-4-13(17)14(18)9-12/h2-9H,1H3,(H,19,21)
DMR0P1U	CS	CN1C=CC2=C1C=CC(=C2)C(=O)NC3=CC(=C(C=C3)Cl)Cl
DMR0P1U	IK	XHTKCMHMWMUSIE-UHFFFAOYSA-N
DMR0P1U	IU	N-(3,4-dichlorophenyl)-1-methylindole-5-carboxamide

DMYTEAC	ID	DMYTEAC
DMYTEAC	DN	PMID25399762-Compound-Table1-C16
DMYTEAC	HS	Patented
DMYTEAC	CP	NTZ LAB LTD [BG]
DMYTEAC	DT	Small molecular drug
DMYTEAC	PC	77844718
DMYTEAC	MW	303.72
DMYTEAC	FM	C15H11ClFN3O
DMYTEAC	IC	InChI=1S/C15H11ClFN3O/c1-20-14-5-2-9(6-10(14)8-18-20)15(21)19-11-3-4-13(17)12(16)7-11/h2-8H,1H3,(H,19,21)
DMYTEAC	CS	CN1C2=C(C=C(C=C2)C(=O)NC3=CC(=C(C=C3)F)Cl)C=N1
DMYTEAC	IK	ISZVIYGCASWHFG-UHFFFAOYSA-N
DMYTEAC	IU	N-(3-chloro-4-fluorophenyl)-1-methylindazole-5-carboxamide

DMNMU3R	ID	DMNMU3R
DMNMU3R	DN	PMID25399762-Compound-Table1-C17
DMNMU3R	HS	Patented
DMNMU3R	CP	NTZ LAB LTD [BG]
DMNMU3R	DT	Small molecular drug

DM2ZUVH	ID	DM2ZUVH
DM2ZUVH	DN	PMID25399762-Compound-Table1-C18
DM2ZUVH	HS	Patented
DM2ZUVH	CP	NTZ LAB LTD [BG]
DM2ZUVH	DT	Small molecular drug
DM2ZUVH	PC	77844720
DM2ZUVH	MW	287.26
DM2ZUVH	FM	C15H11F2N3O
DM2ZUVH	IC	InChI=1S/C15H11F2N3O/c1-20-14-5-2-9(6-10(14)8-18-20)15(21)19-11-3-4-12(16)13(17)7-11/h2-8H,1H3,(H,19,21)
DM2ZUVH	CS	CN1C2=C(C=C(C=C2)C(=O)NC3=CC(=C(C=C3)F)F)C=N1
DM2ZUVH	IK	MDOHBHVKAWMFFN-UHFFFAOYSA-N
DM2ZUVH	IU	N-(3,4-difluorophenyl)-1-methylindazole-5-carboxamide

DMMO3F1	ID	DMMO3F1
DMMO3F1	DN	PMID25399762-Compound-Table1-C19
DMMO3F1	HS	Patented
DMMO3F1	CP	NTZ LAB LTD [BG]
DMMO3F1	DT	Small molecular drug

DMPFLGO	ID	DMPFLGO
DMPFLGO	DN	PMID25399762-Compound-Table1-C2
DMPFLGO	HS	Patented
DMPFLGO	CP	NTZ LAB LTD [BG]
DMPFLGO	DT	Small molecular drug
DMPFLGO	PC	77844666
DMPFLGO	MW	307.13
DMPFLGO	FM	C13H8Cl2N4O
DMPFLGO	IC	InChI=1S/C13H8Cl2N4O/c14-10-4-9(6-16-12(10)15)18-13(20)7-1-2-11-8(3-7)5-17-19-11/h1-6H,(H,17,19)(H,18,20)
DMPFLGO	CS	C1=CC2=C(C=C1C(=O)NC3=CC(=C(N=C3)Cl)Cl)C=NN2
DMPFLGO	IK	JLABGNSHSHVIHC-UHFFFAOYSA-N
DMPFLGO	IU	N-(5,6-dichloropyridin-3-yl)-1H-indazole-5-carboxamide

DMITNWZ	ID	DMITNWZ
DMITNWZ	DN	PMID25399762-Compound-Table1-C20
DMITNWZ	HS	Patented
DMITNWZ	CP	NTZ LAB LTD [BG]
DMITNWZ	DT	Small molecular drug
DMITNWZ	PC	77844722
DMITNWZ	MW	364.2
DMITNWZ	FM	C17H15Cl2N3O2
DMITNWZ	IC	InChI=1S/C17H15Cl2N3O2/c1-24-7-6-22-16-5-2-11(8-12(16)10-20-22)17(23)21-13-3-4-14(18)15(19)9-13/h2-5,8-10H,6-7H2,1H3,(H,21,23)
DMITNWZ	CS	COCCN1C2=C(C=C(C=C2)C(=O)NC3=CC(=C(C=C3)Cl)Cl)C=N1
DMITNWZ	IK	CTHLAPNHCMOVBE-UHFFFAOYSA-N
DMITNWZ	IU	N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)indazole-5-carboxamide

DMMFILA	ID	DMMFILA
DMMFILA	DN	PMID25399762-Compound-Table1-C21
DMMFILA	HS	Patented
DMMFILA	CP	NTZ LAB LTD [BG]
DMMFILA	DT	Small molecular drug

DMBE0R2	ID	DMBE0R2
DMBE0R2	DN	PMID25399762-Compound-Table1-C22
DMBE0R2	HS	Patented
DMBE0R2	CP	NTZ LAB LTD [BG]
DMBE0R2	DT	Small molecular drug

DMF89PY	ID	DMF89PY
DMF89PY	DN	PMID25399762-Compound-Table1-C23
DMF89PY	HS	Patented
DMF89PY	CP	NTZ LAB LTD [BG]
DMF89PY	DT	Small molecular drug

DMJK296	ID	DMJK296
DMJK296	DN	PMID25399762-Compound-Table1-C24
DMJK296	HS	Patented
DMJK296	CP	NTZ LAB LTD [BG]
DMJK296	DT	Small molecular drug

DMHT41B	ID	DMHT41B
DMHT41B	DN	PMID25399762-Compound-Table1-C25
DMHT41B	HS	Patented
DMHT41B	CP	NTZ LAB LTD [BG]
DMHT41B	DT	Small molecular drug

DMXAKNH	ID	DMXAKNH
DMXAKNH	DN	PMID25399762-Compound-Table1-C3
DMXAKNH	HS	Patented
DMXAKNH	CP	NTZ LAB LTD [BG]
DMXAKNH	DT	Small molecular drug

DMJCVBM	ID	DMJCVBM
DMJCVBM	DN	PMID25399762-Compound-Table1-C4
DMJCVBM	HS	Patented
DMJCVBM	CP	NTZ LAB LTD [BG]
DMJCVBM	DT	Small molecular drug

DMEJNUG	ID	DMEJNUG
DMEJNUG	DN	PMID25399762-Compound-Table1-C5
DMEJNUG	HS	Patented
DMEJNUG	CP	NTZ LAB LTD [BG]
DMEJNUG	DT	Small molecular drug
DMEJNUG	PC	77844660
DMEJNUG	MW	287.7
DMEJNUG	FM	C14H10ClN3O2
DMEJNUG	IC	InChI=1S/C14H10ClN3O2/c15-11-6-10(2-4-13(11)19)17-14(20)8-1-3-12-9(5-8)7-16-18-12/h1-7,19H,(H,16,18)(H,17,20)
DMEJNUG	CS	C1=CC2=C(C=C1C(=O)NC3=CC(=C(C=C3)O)Cl)C=NN2
DMEJNUG	IK	VNFLUMWXDOMPIE-UHFFFAOYSA-N
DMEJNUG	IU	N-(3-chloro-4-hydroxyphenyl)-1H-indazole-5-carboxamide

DMY3UKC	ID	DMY3UKC
DMY3UKC	DN	PMID25399762-Compound-Table1-C6
DMY3UKC	HS	Patented
DMY3UKC	CP	NTZ LAB LTD [BG]
DMY3UKC	DT	Small molecular drug
DMY3UKC	PC	90281692
DMY3UKC	MW	287.7
DMY3UKC	FM	C14H10ClN3O2
DMY3UKC	IC	InChI=1S/C14H10ClN3O2/c15-11-3-2-10(6-13(11)19)17-14(20)8-1-4-12-9(5-8)7-16-18-12/h1-7,19H,(H,16,18)(H,17,20)
DMY3UKC	CS	C1=CC2=C(C=C1C(=O)NC3=CC(=C(C=C3)Cl)O)C=NN2
DMY3UKC	IK	HSMCXXGJZHHZDS-UHFFFAOYSA-N
DMY3UKC	IU	N-(4-chloro-3-hydroxyphenyl)-1H-indazole-5-carboxamide

DMQJV3L	ID	DMQJV3L
DMQJV3L	DN	PMID25399762-Compound-Table1-C7
DMQJV3L	HS	Patented
DMQJV3L	CP	NTZ LAB LTD [BG]
DMQJV3L	DT	Small molecular drug

DMRCPKV	ID	DMRCPKV
DMRCPKV	DN	PMID25399762-Compound-Table1-C8
DMRCPKV	HS	Patented
DMRCPKV	CP	NTZ LAB LTD [BG]
DMRCPKV	DT	Small molecular drug
DMRCPKV	PC	77844662
DMRCPKV	MW	306.1
DMRCPKV	FM	C14H9Cl2N3O
DMRCPKV	IC	InChI=1S/C14H9Cl2N3O/c15-10-4-11(16)6-12(5-10)18-14(20)8-1-2-13-9(3-8)7-17-19-13/h1-7H,(H,17,19)(H,18,20)
DMRCPKV	CS	C1=CC2=C(C=C1C(=O)NC3=CC(=CC(=C3)Cl)Cl)C=NN2
DMRCPKV	IK	XXLZLPDHTLLSMN-UHFFFAOYSA-N
DMRCPKV	IU	N-(3,5-dichlorophenyl)-1H-indazole-5-carboxamide

DMVMT26	ID	DMVMT26
DMVMT26	DN	PMID25399762-Compound-Table1-C9
DMVMT26	HS	Patented
DMVMT26	CP	NTZ LAB LTD [BG]
DMVMT26	DT	Small molecular drug
DMVMT26	PC	77844663
DMVMT26	MW	289.69
DMVMT26	FM	C14H9ClFN3O
DMVMT26	IC	InChI=1S/C14H9ClFN3O/c15-11-6-10(2-3-12(11)16)18-14(20)8-1-4-13-9(5-8)7-17-19-13/h1-7H,(H,17,19)(H,18,20)
DMVMT26	CS	C1=CC2=C(C=C1C(=O)NC3=CC(=C(C=C3)F)Cl)C=NN2
DMVMT26	IK	IMFUMEKCOMLOPY-UHFFFAOYSA-N
DMVMT26	IU	N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide

DMJETVH	ID	DMJETVH
DMJETVH	DN	PMID25416646-Compound-Figure2-J
DMJETVH	HS	Patented
DMJETVH	CP	METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC TANIS, Steven, P. PARKER, Timothy GADWOOD, Robert, C. ZELLER, James, R. ARTMAN, Gerald, D., III LARSEN, Scott, D
DMJETVH	DT	Small molecular drug

DMNTAYK	ID	DMNTAYK
DMNTAYK	DN	PMID25416646-Compound-Figure2-K
DMNTAYK	HS	Patented
DMNTAYK	CP	INTEKRIN THERAPEUTICS, INC
DMNTAYK	DT	Small molecular drug
DMNTAYK	PC	10229498
DMNTAYK	MW	514.2
DMNTAYK	FM	C21H12Cl4N2O3S
DMNTAYK	IC	InChI=1S/C21H12Cl4N2O3S/c22-13-5-6-20(16(23)8-13)31(28,29)27-14-9-17(24)21(18(25)10-14)30-15-7-12-3-1-2-4-19(12)26-11-15/h1-11,27H
DMNTAYK	CS	C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3Cl)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)Cl
DMNTAYK	IK	NMRWDFUZLLQSBN-UHFFFAOYSA-N
DMNTAYK	IU	2,4-dichloro-N-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide
DMNTAYK	CA	CAS 315224-26-1

DMLDPGY	ID	DMLDPGY
DMLDPGY	DN	PMID25416646-Compound-Figure2-N
DMLDPGY	HS	Patented
DMLDPGY	CP	PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED FINCH, Harry FOX, Craig
DMLDPGY	DT	Small molecular drug

DM9OHAN	ID	DM9OHAN
DM9OHAN	DN	PMID25416646-Compound-Figure5-A
DM9OHAN	HS	Patented
DM9OHAN	CP	THE UNIVERSITY OF SYDNEY HIBBS, David, Edward SALAM, Noeris, Kris ROUBIN, Rebecca MATIN, Azadeh GAVANDE, Navnath, S
DM9OHAN	DT	Small molecular drug

DM17FKL	ID	DM17FKL
DM17FKL	DN	PMID25416646-Compound-Figure5-C
DM17FKL	HS	Patented
DM17FKL	CP	Sanofi-Aventis
DM17FKL	DT	Small molecular drug

DMYO7VH	ID	DMYO7VH
DMYO7VH	DN	PMID25416646-Compound-Figure5-E
DMYO7VH	HS	Patented
DMYO7VH	CP	KOWA COMPANY, LTD.  MIURA, Toru  ONOGI, Kazuhiro  TAGASHIRA, Junya 
DMYO7VH	DT	Small molecular drug

DMCJTU1	ID	DMCJTU1
DMCJTU1	DN	PMID25416646-Compound-Figure5-H
DMCJTU1	HS	Patented
DMCJTU1	CP	PUSAN NAT UNIVERSITY INDUSTRYUNIVERSITY [KR]
DMCJTU1	DT	Small molecular drug

DMMRUVT	ID	DMMRUVT
DMMRUVT	DN	PMID25435179-Compound-EP20142759295NP-1
DMMRUVT	HS	Patented

DMXJT8R	ID	DMXJT8R
DMXJT8R	DN	PMID25435179-Compound-US2012165330(I)
DMXJT8R	HS	Patented

DMMRT0Q	ID	DMMRT0Q
DMMRT0Q	DN	PMID25435179-Compound-WO2012006391H3K9TSu
DMMRT0Q	HS	Patented
DMMRT0Q	CP	CORNELL UNIVERSITY LIN, Hening

DM2F1T0	ID	DM2F1T0
DM2F1T0	DN	PMID25435179-Compound-WO2012106509CAY10602
DM2F1T0	HS	Patented
DM2F1T0	CP	THE TRUSTEES OF PRINCETON UNIVERSITY SHENK, Thomas KOYUNCU, Emre CRISTEA, Ileana

DMLAH39	ID	DMLAH39
DMLAH39	DN	PMID25435179-Compound-WO2012106509Salermide
DMLAH39	HS	Patented
DMLAH39	CP	THE TRUSTEES OF PRINCETON UNIVERSITY SHENK, Thomas KOYUNCU, Emre CRISTEA, Ileana

DMBSOED	ID	DMBSOED
DMBSOED	DN	PMID25435179-Compound-WO2012106509Tenovin-6
DMBSOED	HS	Patented
DMBSOED	CP	THE TRUSTEES OF PRINCETON UNIVERSITY SHENK, Thomas KOYUNCU, Emre CRISTEA, Ileana
DMBSOED	DT	RNA

DM79BFU	ID	DM79BFU
DM79BFU	DN	PMID25435179-Compound-WO2012149608USYDS1
DM79BFU	HS	Patented
DM79BFU	CP	THE UNIVERSITY OF SYDNEY DUKE, Colin Charles TRAN, Van Hoan DUKE, Rujee Kyokajee

DMIHRG4	ID	DMIHRG4
DMIHRG4	DN	PMID25435179-Compound-WO2013059587(V, 1st set)
DMIHRG4	HS	Patented
DMIHRG4	CP	GLAXOSMITHKLINE LLC CASAUBON, Rebecca, L. NARAYAN, Radha OALMANN, Christopher VU, Chi, B

DM7YJ4L	ID	DM7YJ4L
DM7YJ4L	DN	PMID25435179-Compound-WO2013059587(VI, 2nd set)
DM7YJ4L	HS	Patented
DM7YJ4L	CP	GLAXOSMITHKLINE LLC CASAUBON, Rebecca, L. NARAYAN, Radha OALMANN, Christopher VU, Chi, B

DMLUWCD	ID	DMLUWCD
DMLUWCD	DN	PMID25435179-Compound-WO2013059594(III)
DMLUWCD	HS	Patented
DMLUWCD	CP	GLAXOSMITHKLINE LLC BLUM, Charles, A. DISCH, Jeremy, S. SPRINGER, Stephanie, K

DMK90ED	ID	DMK90ED
DMK90ED	DN	PMID25435179-Compound-WO2013059594(IV)
DMK90ED	HS	Patented
DMK90ED	CP	GLAXOSMITHKLINE LLC BLUM, Charles, A. DISCH, Jeremy, S. SPRINGER, Stephanie, K

DMXC3UP	ID	DMXC3UP
DMXC3UP	DN	PMID25435179-Compound-WO2014110399Splitomycin
DMXC3UP	HS	Patented
DMXC3UP	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

DM12QO7	ID	DM12QO7
DM12QO7	DN	PMID25435285-Compound-10
DM12QO7	HS	Patented
DM12QO7	CP	BRAINCELLS, INCBRAINCELLS, INC. BLEICHER, Leo
DM12QO7	DT	Small molecular drug
DM12QO7	PC	11641449
DM12QO7	MW	476.4
DM12QO7	FM	C22H28Cl2FNO5
DM12QO7	IC	InChI=1S/C22H28Cl2FNO5/c1-2-3-4-5-6-9-30-20(29)21(25)14-11-17(22(26,18(14)21)19(27)28)31-12-13-7-8-15(23)16(24)10-13/h7-8,10,14,17-18H,2-6,9,11-12,26H2,1H3,(H,27,28)/t14-,17-,18+,21-,22+/m1/s1
DM12QO7	CS	CCCCCCCOC(=O)[C@]1([C@H]2[C@@H]1[C@@]([C@@H](C2)OCC3=CC(=C(C=C3)Cl)Cl)(C(=O)O)N)F
DM12QO7	IK	SVZJNGHWEHDHLT-OUSKECTQSA-N
DM12QO7	IU	(1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluoro-6-heptoxycarbonylbicyclo[3.1.0]hexane-2-carboxylic acid

DMHBWNS	ID	DMHBWNS
DMHBWNS	DN	PMID25435285-Compound-15
DMHBWNS	HS	Patented
DMHBWNS	CP	ELI LILLY AND COMPANY
DMHBWNS	DT	Small molecular drug
DMHBWNS	PC	57338826
DMHBWNS	MW	376.2
DMHBWNS	FM	C15H15Cl2NO6
DMHBWNS	IC	InChI=1S/C15H15Cl2NO6/c16-6-2-1-5(3-7(6)17)4-24-12-11(19)8-9(13(20)21)10(8)15(12,18)14(22)23/h1-3,8-12,19H,4,18H2,(H,20,21)(H,22,23)/t8-,9-,10-,11-,12+,15+/m0/s1
DMHBWNS	CS	C1=CC(=C(C=C1CO[C@@H]2[C@H]([C@H]3[C@@H]([C@H]3[C@@]2(C(=O)O)N)C(=O)O)O)Cl)Cl
DMHBWNS	IK	WNOZOUHFGZKGNT-ANYOLZDRSA-N
DMHBWNS	IU	(1S,2R,3S,4S,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-4-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid

DMKFX2G	ID	DMKFX2G
DMKFX2G	DN	PMID25435285-Compound-16
DMKFX2G	HS	Patented
DMKFX2G	CP	ELI LILLY AND COMPANY
DMKFX2G	DT	Small molecular drug
DMKFX2G	PC	67705089
DMKFX2G	MW	459.3
DMKFX2G	FM	C17H16Cl2N4O5S
DMKFX2G	IC	InChI=1S/C17H16Cl2N4O5S/c18-7-2-1-6(3-8(7)19)4-28-13-12(29-16-21-5-22-23-16)9-10(14(24)25)11(9)17(13,20)15(26)27/h1-3,5,9-13H,4,20H2,(H,24,25)(H,26,27)(H,21,22,23)/t9-,10-,11-,12-,13+,17+/m0/s1
DMKFX2G	CS	C1=CC(=C(C=C1CO[C@@H]2[C@H]([C@H]3[C@@H]([C@H]3[C@@]2(C(=O)O)N)C(=O)O)SC4=NC=NN4)Cl)Cl
DMKFX2G	IK	QHBLXVIRCXAIGL-WNAOHANSSA-N
DMKFX2G	IU	(1R,2R,3S,4S,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-4-(1H-1,2,4-triazol-5-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid

DMG9FYH	ID	DMG9FYH
DMG9FYH	DN	PMID25435285-Compound-20
DMG9FYH	HS	Patented
DMG9FYH	CP	ELI LILLY AND COMPANY
DMG9FYH	DT	Small molecular drug

DM27U1F	ID	DM27U1F
DM27U1F	DN	PMID25435285-Compound-22
DM27U1F	HS	Patented
DM27U1F	CP	ELI LILLY AND COMPANY
DM27U1F	DT	Small molecular drug

DMIVJMO	ID	DMIVJMO
DMIVJMO	DN	PMID25435285-Compound-25
DMIVJMO	HS	Patented
DMIVJMO	CP	F. HOFFMANN-LA ROCHE AF. Hoffmann-La Roche AG
DMIVJMO	DT	Small molecular drug
DMIVJMO	PC	353213
DMIVJMO	MW	250.29
DMIVJMO	FM	C16H14N2O
DMIVJMO	IC	InChI=1S/C16H14N2O/c1-11-7-8-13-15(9-11)18-16(19)10-14(17-13)12-5-3-2-4-6-12/h2-9H,10H2,1H3,(H,18,19)
DMIVJMO	CS	CC1=CC2=C(C=C1)N=C(CC(=O)N2)C3=CC=CC=C3
DMIVJMO	IK	SCWDIXHHIUWDED-UHFFFAOYSA-N
DMIVJMO	IU	8-methyl-4-phenyl-1,3-dihydro-1,5-benzodiazepin-2-one
DMIVJMO	CA	CAS 64376-00-7

DMTJHAK	ID	DMTJHAK
DMTJHAK	DN	PMID25435285-Compound-26
DMTJHAK	HS	Patented
DMTJHAK	CP	F. HOFFMANN-LA ROCHE AF. Hoffmann-La Roche AG
DMTJHAK	DT	Small molecular drug
DMTJHAK	PC	9820321
DMTJHAK	MW	361.4
DMTJHAK	FM	C24H15N3O
DMTJHAK	IC	InChI=1S/C24H15N3O/c25-16-19-7-4-8-20(13-19)22-15-24(28)27-23-14-18(11-12-21(23)26-22)10-9-17-5-2-1-3-6-17/h1-8,11-14H,15H2,(H,27,28)
DMTJHAK	CS	C1C(=NC2=C(C=C(C=C2)C#CC3=CC=CC=C3)NC1=O)C4=CC=CC(=C4)C#N
DMTJHAK	IK	YQYIKKPJWMTPST-UHFFFAOYSA-N
DMTJHAK	IU	3-[2-oxo-8-(2-phenylethynyl)-1,3-dihydro-1,5-benzodiazepin-4-yl]benzonitrile

DMTYHCU	ID	DMTYHCU
DMTYHCU	DN	PMID25435285-Compound-37
DMTYHCU	HS	Patented
DMTYHCU	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMTYHCU	DT	Small molecular drug
DMTYHCU	PC	57468863
DMTYHCU	MW	473.4
DMTYHCU	FM	C25H17F6N3
DMTYHCU	IC	InChI=1S/C25H17F6N3/c1-14-10-19(11-15(2)32-14)17-4-3-5-18(12-17)23-33-21(13-22(34-23)25(29,30)31)16-6-8-20(9-7-16)24(26,27)28/h3-13H,1-2H3
DMTYHCU	CS	CC1=CC(=CC(=N1)C)C2=CC(=CC=C2)C3=NC(=CC(=N3)C(F)(F)F)C4=CC=C(C=C4)C(F)(F)F
DMTYHCU	IK	UTZMRRRZFDOYFQ-UHFFFAOYSA-N
DMTYHCU	IU	2-[3-(2,6-dimethylpyridin-4-yl)phenyl]-4-(trifluoromethyl)-6-[4-(trifluoromethyl)phenyl]pyrimidine

DMSIKM2	ID	DMSIKM2
DMSIKM2	DN	PMID25435285-Compound-38
DMSIKM2	HS	Patented
DMSIKM2	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMSIKM2	DT	Small molecular drug
DMSIKM2	PC	3415095
DMSIKM2	MW	324.69
DMSIKM2	FM	C14H8ClF3N4
DMSIKM2	IC	InChI=1S/C14H8ClF3N4/c15-10-3-1-9(2-4-10)11-7-12(14(16,17)18)21-13(20-11)22-6-5-19-8-22/h1-8H
DMSIKM2	CS	C1=CC(=CC=C1C2=CC(=NC(=N2)N3C=CN=C3)C(F)(F)F)Cl
DMSIKM2	IK	LXVWPYFCJFOEJE-UHFFFAOYSA-N
DMSIKM2	IU	4-(4-chlorophenyl)-2-imidazol-1-yl-6-(trifluoromethyl)pyrimidine

DMG2ES1	ID	DMG2ES1
DMG2ES1	DN	PMID25435285-Compound-39
DMG2ES1	HS	Patented
DMG2ES1	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMG2ES1	DT	Small molecular drug
DMG2ES1	PC	57468846
DMG2ES1	MW	481.8
DMG2ES1	FM	C19H11ClF3N5O3S
DMG2ES1	IC	InChI=1S/C19H11ClF3N5O3S/c20-12-6-4-10(5-7-12)14-9-15(19(21,22)23)26-16(25-14)17-27-18(31-28-17)11-2-1-3-13(8-11)32(24,29)30/h1-9H,(H2,24,29,30)
DMG2ES1	CS	C1=CC(=CC(=C1)S(=O)(=O)N)C2=NC(=NO2)C3=NC(=CC(=N3)C(F)(F)F)C4=CC=C(C=C4)Cl
DMG2ES1	IK	BODKDPJDJKXVIU-UHFFFAOYSA-N
DMG2ES1	IU	3-[3-[4-(4-chlorophenyl)-6-(trifluoromethyl)pyrimidin-2-yl]-1,2,4-oxadiazol-5-yl]benzenesulfonamide

DMW2C19	ID	DMW2C19
DMW2C19	DN	PMID25435285-Compound-40
DMW2C19	HS	Patented
DMW2C19	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMW2C19	DT	Small molecular drug
DMW2C19	PC	60209409
DMW2C19	MW	559.4
DMW2C19	FM	C24H14F9N5O
DMW2C19	IC	InChI=1S/C24H14F9N5O/c25-22(26,27)11-39-18-7-13(4-5-16(18)23(28,29)30)17-8-19(24(31,32)33)38-20(37-17)14-3-1-2-12(6-14)15-9-35-21(34)36-10-15/h1-10H,11H2,(H2,34,35,36)
DMW2C19	CS	C1=CC(=CC(=C1)C2=NC(=CC(=N2)C(F)(F)F)C3=CC(=C(C=C3)C(F)(F)F)OCC(F)(F)F)C4=CN=C(N=C4)N
DMW2C19	IK	YCJPDEUHPPTQFR-UHFFFAOYSA-N
DMW2C19	IU	5-[3-[4-[3-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-yl]phenyl]pyrimidin-2-amine

DMJ5LGA	ID	DMJ5LGA
DMJ5LGA	DN	PMID25435285-Compound-41
DMJ5LGA	HS	Patented
DMJ5LGA	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMJ5LGA	DT	Small molecular drug

DMTN79G	ID	DMTN79G
DMTN79G	DN	PMID25435285-Compound-42
DMTN79G	HS	Patented
DMTN79G	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMTN79G	DT	Small molecular drug
DMTN79G	PC	60209373
DMTN79G	MW	405.4
DMTN79G	FM	C24H18F3N3
DMTN79G	IC	InChI=1S/C24H18F3N3/c1-15-11-20(16-5-8-21(9-6-16)24(25,26)27)13-22(30-15)18-4-2-3-17(12-18)19-7-10-23(28)29-14-19/h2-14H,1H3,(H2,28,29)
DMTN79G	CS	CC1=CC(=CC(=N1)C2=CC=CC(=C2)C3=CN=C(C=C3)N)C4=CC=C(C=C4)C(F)(F)F
DMTN79G	IK	PGUYKLHAVPKWNB-UHFFFAOYSA-N
DMTN79G	IU	5-[3-[6-methyl-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]phenyl]pyridin-2-amine

DMEGJ73	ID	DMEGJ73
DMEGJ73	DN	PMID25435285-Compound-43
DMEGJ73	HS	Patented
DMEGJ73	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMEGJ73	DT	Small molecular drug
DMEGJ73	PC	60209453
DMEGJ73	MW	459.4
DMEGJ73	FM	C24H15F6N3
DMEGJ73	IC	InChI=1S/C24H15F6N3/c25-23(26,27)19-7-4-14(5-8-19)18-11-20(33-21(12-18)24(28,29)30)16-3-1-2-15(10-16)17-6-9-22(31)32-13-17/h1-13H,(H2,31,32)
DMEGJ73	CS	C1=CC(=CC(=C1)C2=NC(=CC(=C2)C3=CC=C(C=C3)C(F)(F)F)C(F)(F)F)C4=CN=C(C=C4)N
DMEGJ73	IK	VLHFNIFTVTULIS-UHFFFAOYSA-N
DMEGJ73	IU	5-[3-[6-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]phenyl]pyridin-2-amine

DM4K3AU	ID	DM4K3AU
DM4K3AU	DN	PMID25435285-Compound-44
DM4K3AU	HS	Patented
DM4K3AU	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DM4K3AU	DT	Small molecular drug
DM4K3AU	PC	24760659
DM4K3AU	MW	407.4
DM4K3AU	FM	C22H16F3N5
DM4K3AU	IC	InChI=1S/C22H16F3N5/c1-13-10-16(14-2-4-17(5-3-14)22(23,24)25)11-19(29-13)18-7-9-28-21(30-18)15-6-8-27-20(26)12-15/h2-12H,1H3,(H2,26,27)
DM4K3AU	CS	CC1=CC(=CC(=N1)C2=NC(=NC=C2)C3=CC(=NC=C3)N)C4=CC=C(C=C4)C(F)(F)F
DM4K3AU	IK	RODNKGNVQQLSIE-UHFFFAOYSA-N
DM4K3AU	IU	4-[4-[6-methyl-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]pyrimidin-2-yl]pyridin-2-amine

DM74WSJ	ID	DM74WSJ
DM74WSJ	DN	PMID25435285-Compound-45
DM74WSJ	HS	Patented
DM74WSJ	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DM74WSJ	DT	Small molecular drug

DMC6HPV	ID	DMC6HPV
DMC6HPV	DN	PMID25435285-Compound-46
DMC6HPV	HS	Patented
DMC6HPV	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMC6HPV	DT	Small molecular drug
DMC6HPV	PC	24760738
DMC6HPV	MW	469.5
DMC6HPV	FM	C24H18F3N3O2S
DMC6HPV	IC	InChI=1S/C24H18F3N3O2S/c1-15-12-18(16-8-10-19(11-9-16)24(25,26)27)14-23(29-15)22-7-3-6-21(30-22)17-4-2-5-20(13-17)33(28,31)32/h2-14H,1H3,(H2,28,31,32)
DMC6HPV	CS	CC1=CC(=CC(=N1)C2=CC=CC(=N2)C3=CC(=CC=C3)S(=O)(=O)N)C4=CC=C(C=C4)C(F)(F)F
DMC6HPV	IK	DQITWECLUPKXEE-UHFFFAOYSA-N
DMC6HPV	IU	3-[6-[6-methyl-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]pyridin-2-yl]benzenesulfonamide

DM92F1C	ID	DM92F1C
DM92F1C	DN	PMID25435285-Compound-47
DM92F1C	HS	Patented
DM92F1C	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DM92F1C	DT	Small molecular drug
DM92F1C	PC	24760017
DM92F1C	MW	525.5
DM92F1C	FM	C27H22F3N3O3S
DM92F1C	IC	InChI=1S/C27H22F3N3O3S/c1-3-26(34)33-37(35,36)22-7-4-6-19(15-22)23-8-5-9-24(32-23)25-16-20(14-17(2)31-25)18-10-12-21(13-11-18)27(28,29)30/h4-16H,3H2,1-2H3,(H,33,34)
DM92F1C	CS	CCC(=O)NS(=O)(=O)C1=CC=CC(=C1)C2=NC(=CC=C2)C3=NC(=CC(=C3)C4=CC=C(C=C4)C(F)(F)F)C
DM92F1C	IK	OCTDFPIPOMIKKG-UHFFFAOYSA-N
DM92F1C	IU	N-[3-[6-[6-methyl-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]pyridin-2-yl]phenyl]sulfonylpropanamide

DM7G51M	ID	DM7G51M
DM7G51M	DN	PMID25435285-Compound-49
DM7G51M	HS	Patented
DM7G51M	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DM7G51M	DT	Small molecular drug
DM7G51M	PC	25097193
DM7G51M	MW	495.9
DM7G51M	FM	C21H13ClF3N3O2S2
DM7G51M	IC	InChI=1S/C21H13ClF3N3O2S2/c22-19-8-7-17(31-19)16-11-18(21(23,24)25)28-20(27-16)14-5-1-3-12(9-14)13-4-2-6-15(10-13)32(26,29)30/h1-11H,(H2,26,29,30)
DM7G51M	CS	C1=CC(=CC(=C1)C2=NC(=CC(=N2)C(F)(F)F)C3=CC=C(S3)Cl)C4=CC(=CC=C4)S(=O)(=O)N
DM7G51M	IK	PNTBWHIVXJKWAT-UHFFFAOYSA-N
DM7G51M	IU	3-[3-[4-(5-chlorothiophen-2-yl)-6-(trifluoromethyl)pyrimidin-2-yl]phenyl]benzenesulfonamide

DML48NA	ID	DML48NA
DML48NA	DN	PMID25435285-Compound-50
DML48NA	HS	Patented
DML48NA	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DML48NA	DT	Small molecular drug
DML48NA	PC	67393308
DML48NA	MW	496.4
DML48NA	FM	C20H13F5N6O2S
DML48NA	IC	InChI=1S/C20H13F5N6O2S/c21-18(22)15-7-14(12-4-5-17(27-8-12)20(23,24)25)29-19(30-15)31-9-16(28-10-31)11-2-1-3-13(6-11)34(26,32)33/h1-10,18H,(H2,26,32,33)
DML48NA	CS	C1=CC(=CC(=C1)S(=O)(=O)N)C2=CN(C=N2)C3=NC(=CC(=N3)C(F)F)C4=CN=C(C=C4)C(F)(F)F
DML48NA	IK	OGTCWWKKFTYEFV-UHFFFAOYSA-N
DML48NA	IU	3-[1-[4-(difluoromethyl)-6-[6-(trifluoromethyl)pyridin-3-yl]pyrimidin-2-yl]imidazol-4-yl]benzenesulfonamide

DM2VZG6	ID	DM2VZG6
DM2VZG6	DN	PMID25435285-Compound-51
DM2VZG6	HS	Patented
DM2VZG6	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DM2VZG6	DT	Small molecular drug
DM2VZG6	PC	86624638
DM2VZG6	MW	462.3
DM2VZG6	FM	C21H12F6N6
DM2VZG6	IC	InChI=1S/C21H12F6N6/c22-20(23,24)16-3-1-13(9-30-16)15-8-17(21(25,26)27)33-19(32-15)11-5-6-29-14(7-11)12-2-4-18(28)31-10-12/h1-10H,(H2,28,31)
DM2VZG6	CS	C1=CC(=NC=C1C2=CC(=NC(=N2)C3=CC(=NC=C3)C4=CN=C(C=C4)N)C(F)(F)F)C(F)(F)F
DM2VZG6	IK	XWOLECIBHRHRCW-UHFFFAOYSA-N
DM2VZG6	IU	5-[4-[4-(trifluoromethyl)-6-[6-(trifluoromethyl)pyridin-3-yl]pyrimidin-2-yl]pyridin-2-yl]pyridin-2-amine

DMXD8L1	ID	DMXD8L1
DMXD8L1	DN	PMID25435285-Compound-52
DMXD8L1	HS	Patented
DMXD8L1	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DMXD8L1	DT	Small molecular drug
DMXD8L1	PC	25096944
DMXD8L1	MW	461.4
DMXD8L1	FM	C22H13F6N5
DMXD8L1	IC	InChI=1S/C22H13F6N5/c23-21(24,25)17-6-4-15(11-30-17)16-9-18(22(26,27)28)33-20(32-16)13-3-1-2-12(8-13)14-5-7-19(29)31-10-14/h1-11H,(H2,29,31)
DMXD8L1	CS	C1=CC(=CC(=C1)C2=NC(=CC(=N2)C(F)(F)F)C3=CN=C(C=C3)C(F)(F)F)C4=CN=C(C=C4)N
DMXD8L1	IK	RUFVODIMOVLNAI-UHFFFAOYSA-N
DMXD8L1	IU	5-[3-[4-(trifluoromethyl)-6-[6-(trifluoromethyl)pyridin-3-yl]pyrimidin-2-yl]phenyl]pyridin-2-amine

DMSRYIP	ID	DMSRYIP
DMSRYIP	DN	PMID25435285-Compound-53
DMSRYIP	HS	Patented
DMSRYIP	CP	F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DMSRYIP	DT	Small molecular drug
DMSRYIP	PC	67393923
DMSRYIP	MW	470.5
DMSRYIP	FM	C23H17F3N4O2S
DMSRYIP	IC	InChI=1S/C23H17F3N4O2S/c1-14-10-17(16-8-9-22(28-13-16)23(24,25)26)12-21(29-14)20-7-3-6-19(30-20)15-4-2-5-18(11-15)33(27,31)32/h2-13H,1H3,(H2,27,31,32)
DMSRYIP	CS	CC1=CC(=CC(=N1)C2=CC=CC(=N2)C3=CC(=CC=C3)S(=O)(=O)N)C4=CN=C(C=C4)C(F)(F)F
DMSRYIP	IK	SNOQZNIOGMOXDJ-UHFFFAOYSA-N
DMSRYIP	IU	3-[6-[6-methyl-4-[6-(trifluoromethyl)pyridin-3-yl]pyridin-2-yl]pyridin-2-yl]benzenesulfonamide

DMSKCEH	ID	DMSKCEH
DMSKCEH	DN	PMID25468267-Compound-46
DMSKCEH	HS	Patented
DMSKCEH	DT	Small molecular drug
DMSKCEH	PC	53392492
DMSKCEH	MW	491.5
DMSKCEH	FM	C27H29N3O6
DMSKCEH	IC	InChI=1S/C27H29N3O6/c31-25(14-15-26(32)33)30(35)17-4-3-16-28-18-20-10-12-21(13-11-20)19-36-27(34)29-24-9-5-7-22-6-1-2-8-23(22)24/h1-2,5-15,28,35H,3-4,16-19H2,(H,29,34)(H,32,33)/b15-14+
DMSKCEH	CS	C1=CC=C2C(=C1)C=CC=C2NC(=O)OCC3=CC=C(C=C3)CNCCCCN(C(=O)/C=C/C(=O)O)O
DMSKCEH	IK	FOJNYQXAAPCEPX-CCEZHUSRSA-N
DMSKCEH	IU	(E)-4-[hydroxy-[4-[[4-(naphthalen-1-ylcarbamoyloxymethyl)phenyl]methylamino]butyl]amino]-4-oxobut-2-enoic acid

DMG2JEK	ID	DMG2JEK
DMG2JEK	DN	PMID25468267-Compound-47
DMG2JEK	HS	Patented
DMG2JEK	DT	Small molecular drug
DMG2JEK	PC	53392493
DMG2JEK	MW	505.6
DMG2JEK	FM	C28H31N3O6
DMG2JEK	IC	InChI=1S/C28H31N3O6/c1-36-27(33)16-15-26(32)31(35)18-5-4-17-29-19-21-11-13-22(14-12-21)20-37-28(34)30-25-10-6-8-23-7-2-3-9-24(23)25/h2-3,6-16,29,35H,4-5,17-20H2,1H3,(H,30,34)/b16-15+
DMG2JEK	CS	COC(=O)/C=C/C(=O)N(CCCCNCC1=CC=C(C=C1)COC(=O)NC2=CC=CC3=CC=CC=C32)O
DMG2JEK	IK	MUJOCHRZXRZONW-FOCLMDBBSA-N
DMG2JEK	IU	methyl (E)-4-[hydroxy-[4-[[4-(naphthalen-1-ylcarbamoyloxymethyl)phenyl]methylamino]butyl]amino]-4-oxobut-2-enoate
DMG2JEK	CB	CHEBI:95078

DMBPT9Z	ID	DMBPT9Z
DMBPT9Z	DN	PMID25468267-Compound-48
DMBPT9Z	HS	Patented
DMBPT9Z	DT	Small molecular drug
DMBPT9Z	PC	89592590
DMBPT9Z	MW	421.5
DMBPT9Z	FM	C22H35N3O5
DMBPT9Z	IC	InChI=1S/C22H35N3O5/c26-20(24-19-11-5-3-6-12-19)13-7-4-9-17-23-16-8-1-2-10-18-25(30)21(27)14-15-22(28)29/h3,5-6,11-12,23,30H,1-2,4,7-10,13-18H2,(H,24,26)(H,28,29)
DMBPT9Z	CS	C1=CC=C(C=C1)NC(=O)CCCCCNCCCCCCN(C(=O)CCC(=O)O)O
DMBPT9Z	IK	FJNPYJKFIGGTME-UHFFFAOYSA-N
DMBPT9Z	IU	4-[6-[(6-anilino-6-oxohexyl)amino]hexyl-hydroxyamino]-4-oxobutanoic acid

DM2HG9U	ID	DM2HG9U
DM2HG9U	DN	PMID25468267-Compound-49
DM2HG9U	HS	Patented
DM2HG9U	DT	Small molecular drug

DMIVJ2W	ID	DMIVJ2W
DMIVJ2W	DN	PMID25468267-Compound-50
DMIVJ2W	HS	Patented
DMIVJ2W	CP	EPITHERAPEUTICS APS
DMIVJ2W	DT	Small molecular drug
DMIVJ2W	PC	90093815
DMIVJ2W	MW	260.29
DMIVJ2W	FM	C13H16N4O2
DMIVJ2W	IC	InChI=1S/C13H16N4O2/c18-13(19)11-2-4-16-12(8-11)9-14-3-1-6-17-7-5-15-10-17/h2,4-5,7-8,10,14H,1,3,6,9H2,(H,18,19)
DMIVJ2W	CS	C1=CN=C(C=C1C(=O)O)CNCCCN2C=CN=C2
DMIVJ2W	IK	HGXLVPBZRFKRHK-UHFFFAOYSA-N
DMIVJ2W	IU	2-[(3-imidazol-1-ylpropylamino)methyl]pyridine-4-carboxylic acid

DMNPC0H	ID	DMNPC0H
DMNPC0H	DN	PMID25468267-Compound-51
DMNPC0H	HS	Patented
DMNPC0H	CP	EPITHERAPEUTICS APS
DMNPC0H	DT	Small molecular drug
DMNPC0H	PC	73670709
DMNPC0H	MW	223.27
DMNPC0H	FM	C11H17N3O2
DMNPC0H	IC	InChI=1S/C11H17N3O2/c1-14(2)6-5-12-8-10-7-9(11(15)16)3-4-13-10/h3-4,7,12H,5-6,8H2,1-2H3,(H,15,16)
DMNPC0H	CS	CN(C)CCNCC1=NC=CC(=C1)C(=O)O
DMNPC0H	IK	SAAOFVWGGZSWSS-UHFFFAOYSA-N
DMNPC0H	IU	2-[[2-(dimethylamino)ethylamino]methyl]pyridine-4-carboxylic acid

DMAH1G7	ID	DMAH1G7
DMAH1G7	DN	PMID25468267-Compound-52
DMAH1G7	HS	Patented
DMAH1G7	CP	EPITHERAPEUTICS APS
DMAH1G7	DT	Small molecular drug
DMAH1G7	PC	73670714
DMAH1G7	MW	232.23
DMAH1G7	FM	C12H12N2O3
DMAH1G7	IC	InChI=1S/C12H12N2O3/c15-12(16)9-3-4-14-10(6-9)7-13-8-11-2-1-5-17-11/h1-6,13H,7-8H2,(H,15,16)
DMAH1G7	CS	C1=COC(=C1)CNCC2=NC=CC(=C2)C(=O)O
DMAH1G7	IK	WAXTXDDUSDCZNA-UHFFFAOYSA-N
DMAH1G7	IU	2-[(furan-2-ylmethylamino)methyl]pyridine-4-carboxylic acid

DMONWYI	ID	DMONWYI
DMONWYI	DN	PMID25468267-Compound-53
DMONWYI	HS	Patented
DMONWYI	CP	EPITHERAPEUTICS APS
DMONWYI	DT	Small molecular drug
DMONWYI	PC	73670871
DMONWYI	MW	226.3
DMONWYI	FM	C10H14N2O2S
DMONWYI	IC	InChI=1S/C10H14N2O2S/c1-15-5-4-11-7-9-6-8(10(13)14)2-3-12-9/h2-3,6,11H,4-5,7H2,1H3,(H,13,14)
DMONWYI	CS	CSCCNCC1=NC=CC(=C1)C(=O)O
DMONWYI	IK	RTKPPOFYHYGKKG-UHFFFAOYSA-N
DMONWYI	IU	2-[(2-methylsulfanylethylamino)methyl]pyridine-4-carboxylic acid

DMI93AX	ID	DMI93AX
DMI93AX	DN	PMID25468267-Compound-54
DMI93AX	HS	Patented
DMI93AX	CP	EPITHERAPEUTICS APS
DMI93AX	DT	Small molecular drug
DMI93AX	PC	73670872
DMI93AX	MW	279.33
DMI93AX	FM	C14H21N3O3
DMI93AX	IC	InChI=1S/C14H21N3O3/c1-3-4-7-17(2)13(18)10-15-9-12-8-11(14(19)20)5-6-16-12/h5-6,8,15H,3-4,7,9-10H2,1-2H3,(H,19,20)
DMI93AX	CS	CCCCN(C)C(=O)CNCC1=NC=CC(=C1)C(=O)O
DMI93AX	IK	ZASDPPHIPJCPAA-UHFFFAOYSA-N
DMI93AX	IU	2-[[[2-[butyl(methyl)amino]-2-oxoethyl]amino]methyl]pyridine-4-carboxylic acid

DMIXQRY	ID	DMIXQRY
DMIXQRY	DN	PMID25468267-Compound-55
DMIXQRY	HS	Patented
DMIXQRY	CP	EPITHERAPEUTICS APS
DMIXQRY	DT	Small molecular drug

DMAI19Z	ID	DMAI19Z
DMAI19Z	DN	PMID25468267-Compound-56
DMAI19Z	HS	Patented
DMAI19Z	CP	EPITHERAPEUTICS APS
DMAI19Z	DT	Small molecular drug
DMAI19Z	PC	90093146
DMAI19Z	MW	414.5
DMAI19Z	FM	C22H30N4O4
DMAI19Z	IC	InChI=1S/C22H30N4O4/c1-5-26(13-12-25(2)3)21(27)16-23-15-18-14-17(10-11-24-18)22(28)30-20-8-6-19(29-4)7-9-20/h6-11,14,23H,5,12-13,15-16H2,1-4H3
DMAI19Z	CS	CCN(CCN(C)C)C(=O)CNCC1=NC=CC(=C1)C(=O)OC2=CC=C(C=C2)OC
DMAI19Z	IK	VCJMVGNCXKDPNL-UHFFFAOYSA-N
DMAI19Z	IU	(4-methoxyphenyl) 2-[[[2-[2-(dimethylamino)ethyl-ethylamino]-2-oxoethyl]amino]methyl]pyridine-4-carboxylate

DM6EN54	ID	DM6EN54
DM6EN54	DN	PMID25470667-Compound-AZD3988
DM6EN54	HS	Patented
DM6EN54	CP	BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DM6EN54	DT	Small molecular drug

DMY3140	ID	DMY3140
DMY3140	DN	PMID25470667-Compound-BAY744113
DMY3140	HS	Patented
DMY3140	CP	BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DMY3140	DT	Small molecular drug

DMMVQW8	ID	DMMVQW8
DMMVQW8	DN	PMID25470667-Compound-Figure4-1A
DMMVQW8	HS	Patented
DMMVQW8	CP	PFIZER INC
DMMVQW8	DT	Small molecular drug

DME40TS	ID	DME40TS
DME40TS	DN	PMID25470667-Compound-GO-CoA-Tat
DME40TS	HS	Patented
DME40TS	CP	THE JOHNS HOPKINS UNIVERSITY COLE, Philip A. BARNETT, Bradley P. HWANG, Yousang BOEKE, Jef D
DME40TS	DT	Small molecular drug
DME40TS	DE	Type-2 diabetes; Obesity

DMYZ2UA	ID	DMYZ2UA
DMYZ2UA	DN	PMID25470667-Compound-K-604
DMYZ2UA	HS	Patented
DMYZ2UA	CP	KOWA COMPANY, LTD
DMYZ2UA	DT	Small molecular drug
DMYZ2UA	PC	9892288
DMYZ2UA	MW	502.7
DMYZ2UA	FM	C23H30N6OS3
DMYZ2UA	IC	InChI=1S/C23H30N6OS3/c1-16-14-19(31-2)21(22(24-16)32-3)27-20(30)15-29-10-8-28(9-11-29)12-13-33-23-25-17-6-4-5-7-18(17)26-23/h4-7,14H,8-13,15H2,1-3H3,(H,25,26)(H,27,30)
DMYZ2UA	CS	CC1=CC(=C(C(=N1)SC)NC(=O)CN2CCN(CC2)CCSC3=NC4=CC=CC=C4N3)SC
DMYZ2UA	IK	VGGMTOYKEDKFLN-UHFFFAOYSA-N
DMYZ2UA	IU	2-[4-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]piperazin-1-yl]-N-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]acetamide
DMYZ2UA	CA	CAS 561023-90-3

DM0OBAW	ID	DM0OBAW
DM0OBAW	DN	PMID25470667-Compound-PF-04620110
DM0OBAW	HS	Patented
DM0OBAW	CP	BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DM0OBAW	DT	Small molecular drug

DMCF2G7	ID	DMCF2G7
DMCF2G7	DN	PMID25470667-Compound-roselipins
DMCF2G7	HS	Patented
DMCF2G7	CP	KITASATO INST [JPOMURA SATOSHI [JPTOMODA HIROSHI [JPMASUMA ROKURO [JP]
DMCF2G7	DT	Small molecular drug

DMQB4LE	ID	DMQB4LE
DMQB4LE	DN	PMID25482888-Compound-11
DMQB4LE	HS	Patented
DMQB4LE	DT	Small molecular drug
DMQB4LE	PC	24853009
DMQB4LE	MW	354.4
DMQB4LE	FM	C19H26N6O
DMQB4LE	IC	InChI=1S/C19H26N6O/c20-8-16-2-1-3-25(16)17(26)9-22-19-6-14-4-15(19)7-18(5-14,10-19)11-24-13-21-12-23-24/h12-16,22H,1-7,9-11H2/t14?,15?,16-,18?,19?/m0/s1
DMQB4LE	CS	C1C[C@H](N(C1)C(=O)CNC23CC4CC2CC(C4)(C3)CN5C=NC=N5)C#N
DMQB4LE	IK	IGRDXWYZILJAIK-YYSDWXCKSA-N
DMQB4LE	IU	(2S)-1-[2-[[1-(1,2,4-triazol-1-ylmethyl)-3-tricyclo[3.3.1.03,7]nonanyl]amino]acetyl]pyrrolidine-2-carbonitrile

DM8JIDR	ID	DM8JIDR
DM8JIDR	DN	PMID25482888-Compound-12
DM8JIDR	HS	Patented
DM8JIDR	DT	Small molecular drug
DM8JIDR	PC	69163062
DM8JIDR	MW	427.5
DM8JIDR	FM	C25H25N5O2
DM8JIDR	IC	InChI=1S/C25H25N5O2/c26-17-20-4-3-15-30(20)25(31)23(27)16-18-6-10-21(11-7-18)32-22-12-8-19(9-13-22)29-24-5-1-2-14-28-24/h1-2,5-14,20,23H,3-4,15-16,27H2,(H,28,29)/t20?,23-/m0/s1
DM8JIDR	CS	C1CC(N(C1)C(=O)[C@H](CC2=CC=C(C=C2)OC3=CC=C(C=C3)NC4=CC=CC=N4)N)C#N
DM8JIDR	IK	UTSGGYFCIGGJDF-AKRCKQFNSA-N
DM8JIDR	IU	1-[(2S)-2-amino-3-[4-[4-(pyridin-2-ylamino)phenoxy]phenyl]propanoyl]pyrrolidine-2-carbonitrile

DMBS2FT	ID	DMBS2FT
DMBS2FT	DN	PMID25482888-Compound-13
DMBS2FT	HS	Patented
DMBS2FT	CP	MSN LABORATORIES LIMITED THIRUMALAI RAJAN, Srinivasan ESWARAIAH, Sajja VENKAT REDDY, Ghojala
DMBS2FT	DT	Small molecular drug
DMBS2FT	PC	58819012
DMBS2FT	MW	315.4
DMBS2FT	FM	C18H25N3O2
DMBS2FT	IC	InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15?,17?,18?/m1/s1
DMBS2FT	CS	C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
DMBS2FT	IK	QGJUIPDUBHWZPV-UGTKGIOISA-N
DMBS2FT	IU	(1S,3S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

DMC82UR	ID	DMC82UR
DMC82UR	DN	PMID25482888-Compound-14
DMC82UR	HS	Patented
DMC82UR	DT	Small molecular drug

DMO913H	ID	DMO913H
DMO913H	DN	PMID25482888-Compound-15
DMO913H	HS	Patented
DMO913H	DT	Small molecular drug
DMO913H	PC	22387295
DMO913H	MW	235.33
DMO913H	FM	C13H21N3O
DMO913H	IC	InChI=1S/C13H21N3O/c14-9-11-7-4-8-16(11)13(17)12(15)10-5-2-1-3-6-10/h10-12H,1-8,15H2
DMO913H	CS	C1CCC(CC1)C(C(=O)N2CCCC2C#N)N
DMO913H	IK	SXNUNNAPZNTPQV-UHFFFAOYSA-N
DMO913H	IU	1-(2-amino-2-cyclohexylacetyl)pyrrolidine-2-carbonitrile

DMIFVXE	ID	DMIFVXE
DMIFVXE	DN	PMID25482888-Compound-16
DMIFVXE	HS	Patented
DMIFVXE	DT	Small molecular drug

DMY4AJ7	ID	DMY4AJ7
DMY4AJ7	DN	PMID25482888-Compound-17
DMY4AJ7	HS	Patented
DMY4AJ7	CP	Sunshine Lake Pharma Co., Ltd
DMY4AJ7	DT	Small molecular drug

DM0W5UA	ID	DM0W5UA
DM0W5UA	DN	PMID25482888-Compound-18
DM0W5UA	HS	Patented
DM0W5UA	CP	Sunshine Lake Pharma Co., Ltd
DM0W5UA	DT	Small molecular drug

DM2W9AP	ID	DM2W9AP
DM2W9AP	DN	PMID25482888-Compound-21
DM2W9AP	HS	Patented
DM2W9AP	DT	Peptide

DMX5R9N	ID	DMX5R9N
DMX5R9N	DN	PMID25482888-Compound-34
DMX5R9N	HS	Patented
DMX5R9N	DT	Small molecular drug
DMX5R9N	PC	70975627
DMX5R9N	MW	376.5
DMX5R9N	FM	C21H24N6O
DMX5R9N	IC	InChI=1S/C21H24N6O/c1-14-10-18(26-9-5-8-17(23)13-26)19-20(24-14)25(2)21(28)27(19)12-16-7-4-3-6-15(16)11-22/h3-4,6-7,10,17H,5,8-9,12-13,23H2,1-2H3
DMX5R9N	CS	CC1=CC(=C2C(=N1)N(C(=O)N2CC3=CC=CC=C3C#N)C)N4CCCC(C4)N
DMX5R9N	IK	UWSKGQJKQNVRJZ-UHFFFAOYSA-N
DMX5R9N	IU	2-[[7-(3-aminopiperidin-1-yl)-3,5-dimethyl-2-oxoimidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile

DMMZO8Y	ID	DMMZO8Y
DMMZO8Y	DN	PMID25482888-Compound-37
DMMZO8Y	HS	Patented
DMMZO8Y	DT	Small molecular drug

DMJOPEL	ID	DMJOPEL
DMJOPEL	DN	PMID25482888-Compound-38
DMJOPEL	HS	Patented
DMJOPEL	DT	Small molecular drug

DMMLJ5E	ID	DMMLJ5E
DMMLJ5E	DN	PMID25482888-Compound-50
DMMLJ5E	HS	Patented
DMMLJ5E	CP	MERCK SHARP & DOHME CORP. BIFTU, Tesfaye
DMMLJ5E	DT	Small molecular drug

DMDLPB7	ID	DMDLPB7
DMDLPB7	DN	PMID25482888-Compound-52
DMDLPB7	HS	Patented
DMDLPB7	DT	Small molecular drug

DMB3DMR	ID	DMB3DMR
DMB3DMR	DN	PMID25482888-Compound-56
DMB3DMR	HS	Patented
DMB3DMR	DT	Small molecular drug
DMB3DMR	PC	73388310
DMB3DMR	MW	534.6
DMB3DMR	FM	C28H26N10O2
DMB3DMR	IC	InChI=1S/C28H26N10O2/c1-2-3-13-36-24-25(34-27(36)35-12-6-9-21(31)18-35)37(16-19-7-4-10-32-22(19)14-29)28(40)38(26(24)39)17-20-8-5-11-33-23(20)15-30/h4-5,7-8,10-11,21H,6,9,12-13,16-18,31H2,1H3/t21-/m1/s1
DMB3DMR	CS	CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=C(N=CC=C4)C#N)CC5=C(N=CC=C5)C#N
DMB3DMR	IK	BQCBNCZDTPPBMN-OAQYLSRUSA-N
DMB3DMR	IU	3-[[8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-1-[(2-cyanopyridin-3-yl)methyl]-2,6-dioxopurin-3-yl]methyl]pyridine-2-carbonitrile

DM03UK2	ID	DM03UK2
DM03UK2	DN	PMID25482888-Compound-6
DM03UK2	HS	Patented
DM03UK2	CP	CADILA HEALTHCARE LIMITED PANDEY, Bipin DAVE, Mayank, Ghanshyambhai KOTHARI, Himanshu, M. SHUKLA, Bhavin, Shriprasad
DM03UK2	DT	Small molecular drug

DMPY8NU	ID	DMPY8NU
DMPY8NU	DN	PMID25482888-Compound-69
DMPY8NU	HS	Patented
DMPY8NU	DT	Small molecular drug
DMPY8NU	PC	71731242
DMPY8NU	MW	418.5
DMPY8NU	FM	C23H26N6O2
DMPY8NU	IC	InChI=1S/C23H26N6O2/c1-3-4-12-28-21(27-11-7-8-17(24)14-27)13-22(30)29(23(28)31)15-20-25-16(2)18-9-5-6-10-19(18)26-20/h5-6,9-10,13,17H,7-8,11-12,14-15,24H2,1-2H3/t17-/m1/s1
DMPY8NU	CS	CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC=C3C(=N2)C)N4CCC[C@H](C4)N
DMPY8NU	IK	GHHYMLIQMIXJDE-QGZVFWFLSA-N
DMPY8NU	IU	6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-[(4-methylquinazolin-2-yl)methyl]pyrimidine-2,4-dione

DMEYLM2	ID	DMEYLM2
DMEYLM2	DN	PMID25482888-Compound-70
DMEYLM2	HS	Patented
DMEYLM2	DT	Small molecular drug

DMZB140	ID	DMZB140
DMZB140	DN	PMID25482888-Compound-71
DMZB140	HS	Patented
DMZB140	DT	Small molecular drug
DMZB140	PC	77844155
DMZB140	MW	452.9
DMZB140	FM	C23H25ClN6O2
DMZB140	IC	InChI=1S/C23H25ClN6O2/c1-3-4-10-29-21(28-9-5-6-17(25)13-28)12-22(31)30(23(29)32)14-20-26-15(2)18-11-16(24)7-8-19(18)27-20/h7-8,11-12,17H,5-6,9-10,13-14,25H2,1-2H3/t17-/m1/s1
DMZB140	CS	CC#CCN1C(=CC(=O)N(C1=O)CC2=NC(=C3C=C(C=CC3=N2)Cl)C)N4CCC[C@H](C4)N
DMZB140	IK	NESYRYDEOFUJRC-QGZVFWFLSA-N
DMZB140	IU	6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-[(6-chloro-4-methylquinazolin-2-yl)methyl]pyrimidine-2,4-dione

DMQOVKF	ID	DMQOVKF
DMQOVKF	DN	PMID25482888-Compound-72
DMQOVKF	HS	Patented
DMQOVKF	DT	Small molecular drug
DMQOVKF	PC	77844211
DMQOVKF	MW	430.5
DMQOVKF	FM	C24H26N6O2
DMQOVKF	IC	InChI=1S/C24H26N6O2/c1-2-3-12-29-21(28-11-5-7-17(25)14-28)13-22(31)30(24(29)32)15-20-26-18-8-4-6-16-9-10-19(27-20)23(16)18/h4,6,8,13,17H,5,7,9-12,14-15,25H2,1H3/t17-/m1/s1
DMQOVKF	CS	CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC4=C3C(=N2)CC4)N5CCC[C@H](C5)N
DMQOVKF	IK	VRAJXOQRFSNNNZ-QGZVFWFLSA-N
DMQOVKF	IU	6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-(5,7-diazatricyclo[6.3.1.04,12]dodeca-1(12),4,6,8,10-pentaen-6-ylmethyl)pyrimidine-2,4-dione

DME0XS4	ID	DME0XS4
DME0XS4	DN	PMID25514969-Compound-10
DME0XS4	HS	Patented
DME0XS4	CP	Takeda Pharmaceutical Co. Ltd
DME0XS4	DT	Small molecular drug
DME0XS4	PC	118378889
DME0XS4	MW	364.4
DME0XS4	FM	C20H20N4O3
DME0XS4	IC	InChI=1S/C20H20N4O3/c25-20(24-14-3-4-15(24)10-26-9-14)17-6-22-19-16(18-7-21-11-27-18)5-13(8-23(17)19)12-1-2-12/h5-8,11-12,14-15H,1-4,9-10H2
DME0XS4	CS	C1CC1C2=CN3C(=CN=C3C(=C2)C4=CN=CO4)C(=O)N5C6CCC5COC6
DME0XS4	IK	SESFIBLYIKNNRP-UHFFFAOYSA-N
DME0XS4	IU	[6-cyclopropyl-8-(1,3-oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)methanone

DMUPL0W	ID	DMUPL0W
DMUPL0W	DN	PMID25514969-Compound-11
DMUPL0W	HS	Patented
DMUPL0W	CP	Takeda Pharmaceutical Co. Ltd
DMUPL0W	DT	Small molecular drug
DMUPL0W	PC	118379012
DMUPL0W	MW	342.32
DMUPL0W	FM	C17H15FN4O3
DMUPL0W	IC	InChI=1S/C17H15FN4O3/c18-10-3-13(15-5-19-9-25-15)16-20-4-14(21(16)6-10)17(23)22-11-1-2-12(22)8-24-7-11/h3-6,9,11-12H,1-2,7-8H2
DMUPL0W	CS	C1CC2COCC1N2C(=O)C3=CN=C4N3C=C(C=C4C5=CN=CO5)F
DMUPL0W	IK	AVXVHVNSDORSDK-UHFFFAOYSA-N
DMUPL0W	IU	[6-fluoro-8-(1,3-oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)methanone

DMOE5N0	ID	DMOE5N0
DMOE5N0	DN	PMID25514969-Compound-12
DMOE5N0	HS	Patented
DMOE5N0	CP	Takeda Pharmaceutical Co. Ltd
DMOE5N0	DT	Small molecular drug

DMQB03U	ID	DMQB03U
DMQB03U	DN	PMID25514969-Compound-13
DMQB03U	HS	Patented
DMQB03U	CP	Takeda Pharmaceutical Co. Ltd
DMQB03U	DT	Small molecular drug
DMQB03U	PC	118378871
DMQB03U	MW	387.3
DMQB03U	FM	C18H12F3N5O2
DMQB03U	IC	InChI=1S/C18H12F3N5O2/c19-18(20,21)12-6-13(14-8-22-10-28-14)15-24-25-16(26(15)9-12)17(27)23-7-11-4-2-1-3-5-11/h1-6,8-10H,7H2,(H,23,27)
DMQB03U	CS	C1=CC=C(C=C1)CNC(=O)C2=NN=C3N2C=C(C=C3C4=CN=CO4)C(F)(F)F
DMQB03U	IK	QZZRSTUQIGEDKT-UHFFFAOYSA-N
DMQB03U	IU	N-benzyl-8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide

DM2NVLZ	ID	DM2NVLZ
DM2NVLZ	DN	PMID25514969-Compound-8
DM2NVLZ	HS	Patented
DM2NVLZ	CP	Takeda Pharmaceutical Co. Ltd
DM2NVLZ	DT	Small molecular drug
DM2NVLZ	PC	118378988
DM2NVLZ	MW	386.3
DM2NVLZ	FM	C19H13F3N4O2
DM2NVLZ	IC	InChI=1S/C19H13F3N4O2/c20-19(21,22)13-6-14(16-9-23-11-28-16)17-24-8-15(26(17)10-13)18(27)25-7-12-4-2-1-3-5-12/h1-6,8-11H,7H2,(H,25,27)
DM2NVLZ	CS	C1=CC=C(C=C1)CNC(=O)C2=CN=C3N2C=C(C=C3C4=CN=CO4)C(F)(F)F
DM2NVLZ	IK	PSHYVANCPSFWJM-UHFFFAOYSA-N
DM2NVLZ	IU	N-benzyl-8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carboxamide

DMAEZB1	ID	DMAEZB1
DMAEZB1	DN	PMID25514969-Compound-9
DMAEZB1	HS	Patented
DMAEZB1	CP	Takeda Pharmaceutical Co. Ltd
DMAEZB1	DT	Small molecular drug
DMAEZB1	PC	118379029
DMAEZB1	MW	372.3
DMAEZB1	FM	C18H11F3N4O2
DMAEZB1	IC	InChI=1S/C18H11F3N4O2/c19-18(20,21)11-6-13(15-8-22-10-27-15)16-23-7-14(25(16)9-11)17(26)24-12-4-2-1-3-5-12/h1-10H,(H,24,26)
DMAEZB1	CS	C1=CC=C(C=C1)NC(=O)C2=CN=C3N2C=C(C=C3C4=CN=CO4)C(F)(F)F
DMAEZB1	IK	SNIXWKGBBMUCPJ-UHFFFAOYSA-N
DMAEZB1	IU	8-(1,3-oxazol-5-yl)-N-phenyl-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carboxamide

DMC6S0W	ID	DMC6S0W
DMC6S0W	DN	PMID25514969-Compound-Figure2-2
DMC6S0W	HS	Patented
DMC6S0W	CP	Takeda Pharmaceutical Co. Ltd
DMC6S0W	DT	Small molecular drug

DMUYVOP	ID	DMUYVOP
DMUYVOP	DN	PMID25514969-Compound-Figure2-3
DMUYVOP	HS	Patented
DMUYVOP	CP	Takeda Pharmaceutical Co. Ltd
DMUYVOP	DT	Small molecular drug
DMUYVOP	PC	73437845
DMUYVOP	MW	373.4
DMUYVOP	FM	C23H23N3O2
DMUYVOP	IC	InChI=1S/C23H23N3O2/c27-22(20-7-4-12-25-21(20)19-8-13-24-14-9-19)26-15-10-23(28,11-16-26)17-18-5-2-1-3-6-18/h1-9,12-14,28H,10-11,15-17H2
DMUYVOP	CS	C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4
DMUYVOP	IK	XKUZMIUSBMCVPP-UHFFFAOYSA-N
DMUYVOP	IU	(4-benzyl-4-hydroxypiperidin-1-yl)-(2-pyridin-4-ylpyridin-3-yl)methanone
DMUYVOP	CA	CAS 1429505-03-2

DMXSAN7	ID	DMXSAN7
DMXSAN7	DN	PMID25514969-Compound-Figure2-4
DMXSAN7	HS	Patented
DMXSAN7	CP	Takeda Pharmaceutical Co. Ltd
DMXSAN7	DT	Small molecular drug
DMXSAN7	PC	118379001
DMXSAN7	MW	392.3
DMXSAN7	FM	C18H15F3N4O3
DMXSAN7	IC	InChI=1S/C18H15F3N4O3/c19-18(20,21)10-3-13(15-5-22-9-28-15)16-23-4-14(24(16)6-10)17(26)25-11-1-2-12(25)8-27-7-11/h3-6,9,11-12H,1-2,7-8H2
DMXSAN7	CS	C1CC2COCC1N2C(=O)C3=CN=C4N3C=C(C=C4C5=CN=CO5)C(F)(F)F
DMXSAN7	IK	OANZLTUUAVMTHM-UHFFFAOYSA-N
DMXSAN7	IU	3-oxa-8-azabicyclo[3.2.1]octan-8-yl-[8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methanone

DM7D12Y	ID	DM7D12Y
DM7D12Y	DN	PMID25514969-Compound-Figure3
DM7D12Y	HS	Patented
DM7D12Y	CP	Takeda Pharmaceutical Co. Ltd
DM7D12Y	DT	Small molecular drug

DMRJ30G	ID	DMRJ30G
DMRJ30G	DN	PMID25522065-Compound-10
DMRJ30G	HS	Patented
DMRJ30G	DT	Small molecular drug

DM410Z6	ID	DM410Z6
DM410Z6	DN	PMID25522065-Compound-11
DM410Z6	HS	Patented
DM410Z6	CP	ASTRAZENECA AB ASTRAZENECA UK LIMITED JOHANSSON, Lars, Anders, Mikael JUDKINS, Robert, Andrew LI, Lanna LOFBERG, Bjorn, Christian, Ingvar PERSSON, Joachim
DM410Z6	DT	Small molecular drug
DM410Z6	PC	46937295
DM410Z6	MW	466.9
DM410Z6	FM	C24H23ClN4O4
DM410Z6	IC	InChI=1S/C24H23ClN4O4/c25-18-5-3-17(4-6-18)21-26-27-22(33-21)23(30)29-10-20(11-29)32-19-7-1-16(2-8-19)9-28-12-24(13-28)14-31-15-24/h1-8,20H,9-15H2
DM410Z6	CS	C1C(CN1C(=O)C2=NN=C(O2)C3=CC=C(C=C3)Cl)OC4=CC=C(C=C4)CN5CC6(C5)COC6
DM410Z6	IK	OVCNWJXOBLGBEA-UHFFFAOYSA-N
DM410Z6	IU	[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-[3-[4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy]azetidin-1-yl]methanone

DMVKO9C	ID	DMVKO9C
DMVKO9C	DN	PMID25522065-Compound-12
DMVKO9C	HS	Patented
DMVKO9C	CP	ASTRAZENECA AB [SEASTRAZENECA UK LTD [GBBOEKMAN-WINIWARTER SUSANNE DORIS MARGIT [SEFREDENWALL MARLENE [SEHOGNER CARL ANDERS [SEJOHANSSON LARS ANDERS MIKAEL [SEJUDKINS ROBERT ANDREW [SELI LANNA [SELOEFBERG BJOERN CHRISTIAN INGVAR [SEUNGE SVERKER VON [SE]
DMVKO9C	DT	Small molecular drug
DMVKO9C	PC	56597688
DMVKO9C	MW	468.9
DMVKO9C	FM	C24H25ClN4O4
DMVKO9C	IC	InChI=1S/C24H25ClN4O4/c1-16-12-17(13-28-8-10-31-11-9-28)2-7-21(16)32-20-14-29(15-20)24(30)23-27-26-22(33-23)18-3-5-19(25)6-4-18/h2-7,12,20H,8-11,13-15H2,1H3
DMVKO9C	CS	CC1=C(C=CC(=C1)CN2CCOCC2)OC3CN(C3)C(=O)C4=NN=C(O4)C5=CC=C(C=C5)Cl
DMVKO9C	IK	PGIWDCQJRFXKTN-UHFFFAOYSA-N
DMVKO9C	IU	[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-[3-[2-methyl-4-(morpholin-4-ylmethyl)phenoxy]azetidin-1-yl]methanone

DM92HZG	ID	DM92HZG
DM92HZG	DN	PMID25522065-Compound-13
DM92HZG	HS	Patented
DM92HZG	CP	ASTRAZENECA AB ASTRAZENECA UK LIMITED JOHANSSON, Lars, Anders, Mikael
DM92HZG	DT	Small molecular drug
DM92HZG	PC	71226268
DM92HZG	MW	460.5
DM92HZG	FM	C26H28N4O4
DM92HZG	IC	InChI=1S/C26H28N4O4/c1-18-11-21(8-7-20(18)12-29-15-26(16-29)9-10-32-17-26)33-22-13-30(14-22)25(31)24-28-27-23(34-24)19-5-3-2-4-6-19/h2-8,11,22H,9-10,12-17H2,1H3
DM92HZG	CS	CC1=C(C=CC(=C1)OC2CN(C2)C(=O)C3=NN=C(O3)C4=CC=CC=C4)CN5CC6(C5)CCOC6
DM92HZG	IK	FMNDCDNBXCVEBC-UHFFFAOYSA-N
DM92HZG	IU	[3-[3-methyl-4-(6-oxa-2-azaspiro[3.4]octan-2-ylmethyl)phenoxy]azetidin-1-yl]-(5-phenyl-1,3,4-oxadiazol-2-yl)methanone

DMGZER5	ID	DMGZER5
DMGZER5	DN	PMID25522065-Compound-14
DMGZER5	HS	Patented
DMGZER5	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMGZER5	DT	Small molecular drug
DMGZER5	PC	71731806
DMGZER5	MW	390.5
DMGZER5	FM	C24H26N2O3
DMGZER5	IC	InChI=1S/C24H26N2O3/c1-18-13-20(15-25(2)3)9-10-22(18)23(27)16-26-12-11-21(14-24(26)28)29-17-19-7-5-4-6-8-19/h4-14H,15-17H2,1-3H3
DMGZER5	CS	CC1=C(C=CC(=C1)CN(C)C)C(=O)CN2C=CC(=CC2=O)OCC3=CC=CC=C3
DMGZER5	IK	QONJYPHKWHUJOW-UHFFFAOYSA-N
DMGZER5	IU	1-[2-[4-[(dimethylamino)methyl]-2-methylphenyl]-2-oxoethyl]-4-phenylmethoxypyridin-2-one

DMZMQFW	ID	DMZMQFW
DMZMQFW	DN	PMID25522065-Compound-15
DMZMQFW	HS	Patented
DMZMQFW	DT	Small molecular drug
DMZMQFW	PC	25117272
DMZMQFW	MW	456.9
DMZMQFW	FM	C23H21ClN2O4S
DMZMQFW	IC	InChI=1S/C23H21ClN2O4S/c1-23(2,28)13-30-18-9-8-17(11-19(18)29-3)26-22(27)21-15(12-25-26)10-20(31-21)14-4-6-16(24)7-5-14/h4-12,28H,13H2,1-3H3
DMZMQFW	CS	CC(C)(COC1=C(C=C(C=C1)N2C(=O)C3=C(C=C(S3)C4=CC=C(C=C4)Cl)C=N2)OC)O
DMZMQFW	IK	QOXWOBOEWLTLQE-UHFFFAOYSA-N
DMZMQFW	IU	2-(4-chlorophenyl)-6-[4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl]thieno[2,3-d]pyridazin-7-one

DMAN3BT	ID	DMAN3BT
DMAN3BT	DN	PMID25522065-Compound-16
DMAN3BT	HS	Patented
DMAN3BT	CP	BRISTOL-MYERS SQUIBB COMPANY
DMAN3BT	DT	Small molecular drug
DMAN3BT	PC	118282530
DMAN3BT	MW	459.5
DMAN3BT	FM	C28H29NO5
DMAN3BT	IC	InChI=1S/C28H29NO5/c1-32-27-17-22(11-14-25(27)33-18-24(30)21-7-8-21)29-16-15-26(28(29)31)34-23-12-9-20(10-13-23)19-5-3-2-4-6-19/h2-6,9-14,17,21,24,26,30H,7-8,15-16,18H2,1H3/t24-,26+/m0/s1
DMAN3BT	CS	COC1=C(C=CC(=C1)N2CC[C@H](C2=O)OC3=CC=C(C=C3)C4=CC=CC=C4)OC[C@@H](C5CC5)O
DMAN3BT	IK	GLIZEOCMOXBOFJ-AZGAKELHSA-N
DMAN3BT	IU	(3R)-1-[4-[(2R)-2-cyclopropyl-2-hydroxyethoxy]-3-methoxyphenyl]-3-(4-phenylphenoxy)pyrrolidin-2-one

DM7X6HR	ID	DM7X6HR
DM7X6HR	DN	PMID25522065-Compound-17
DM7X6HR	HS	Patented
DM7X6HR	CP	BRISTOL-MYERS SQUIBB COMPANY
DM7X6HR	DT	Small molecular drug
DM7X6HR	PC	89996639
DM7X6HR	MW	465.6
DM7X6HR	FM	C26H27NO5S
DM7X6HR	IC	InChI=1S/C26H27NO5S/c1-19-18-22(10-13-24(19)31-16-17-33(2,29)30)27-15-14-25(26(27)28)32-23-11-8-21(9-12-23)20-6-4-3-5-7-20/h3-13,18,25H,14-17H2,1-2H3/t25-/m1/s1
DM7X6HR	CS	CC1=C(C=CC(=C1)N2CC[C@H](C2=O)OC3=CC=C(C=C3)C4=CC=CC=C4)OCCS(=O)(=O)C
DM7X6HR	IK	FNCUHIWLQCDGMI-RUZDIDTESA-N
DM7X6HR	IU	(3R)-1-[3-methyl-4-(2-methylsulfonylethoxy)phenyl]-3-(4-phenylphenoxy)pyrrolidin-2-one

DMTPJI8	ID	DMTPJI8
DMTPJI8	DN	PMID25522065-Compound-18
DMTPJI8	HS	Patented
DMTPJI8	CP	BRISTOL-MYERS SQUIBB COMPANY
DMTPJI8	DT	Small molecular drug
DMTPJI8	PC	118284274
DMTPJI8	MW	472.6
DMTPJI8	FM	C29H32N2O4
DMTPJI8	IC	InChI=1S/C29H32N2O4/c1-33-28-21-24(11-14-26(28)34-20-19-30-16-5-6-17-30)31-18-15-27(29(31)32)35-25-12-9-23(10-13-25)22-7-3-2-4-8-22/h2-4,7-14,21,27H,5-6,15-20H2,1H3/t27-/m0/s1
DMTPJI8	CS	COC1=C(C=CC(=C1)N2CC[C@@H](C2=O)OC3=CC=C(C=C3)C4=CC=CC=C4)OCCN5CCCC5
DMTPJI8	IK	QXWLILWORIGJCR-MHZLTWQESA-N
DMTPJI8	IU	(3S)-1-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-3-(4-phenylphenoxy)pyrrolidin-2-one

DMP4VYQ	ID	DMP4VYQ
DMP4VYQ	DN	PMID25522065-Compound-19
DMP4VYQ	HS	Patented
DMP4VYQ	CP	BRISTOL-MYERS SQUIBB COMPANY
DMP4VYQ	DT	Small molecular drug
DMP4VYQ	PC	89996843
DMP4VYQ	MW	434.5
DMP4VYQ	FM	C26H30N2O4
DMP4VYQ	IC	InChI=1S/C26H30N2O4/c1-30-25-18-21(8-11-23(25)31-17-16-27-13-2-3-14-27)28-15-12-24(26(28)29)32-22-9-6-20(7-10-22)19-4-5-19/h6-12,18-19H,2-5,13-17H2,1H3
DMP4VYQ	CS	COC1=C(C=CC(=C1)N2CC=C(C2=O)OC3=CC=C(C=C3)C4CC4)OCCN5CCCC5
DMP4VYQ	IK	NDQYSDBXPKTXCY-UHFFFAOYSA-N
DMP4VYQ	IU	4-(4-cyclopropylphenoxy)-1-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-2H-pyrrol-5-one

DM3I6OF	ID	DM3I6OF
DM3I6OF	DN	PMID25522065-Compound-2
DM3I6OF	HS	Patented
DM3I6OF	CP	ALBANY MOLECULAR RESEARCH, INC
DM3I6OF	DT	Small molecular drug
DM3I6OF	PC	49869488
DM3I6OF	MW	399.5
DM3I6OF	FM	C25H25N3O2
DM3I6OF	IC	InChI=1S/C25H25N3O2/c1-27-23-14-19(9-10-22(23)21-8-5-12-26-16-24(21)27)28-13-11-20(15-25(28)29)30-17-18-6-3-2-4-7-18/h2-4,6-7,9-11,13-15,26H,5,8,12,16-17H2,1H3
DM3I6OF	CS	CN1C2=C(CCCNC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5
DM3I6OF	IK	BCAMBGJXPGJPAB-UHFFFAOYSA-N
DM3I6OF	IU	1-(10-methyl-2,3,4,5-tetrahydro-1H-azepino[3,4-b]indol-8-yl)-4-phenylmethoxypyridin-2-one

DMG5J9Z	ID	DMG5J9Z
DMG5J9Z	DN	PMID25522065-Compound-20
DMG5J9Z	HS	Patented
DMG5J9Z	CP	GLAXOSMITHKLINE LLC CHRISTENSEN, Siegfried, Benjamin, IV QIN, Donghui CHEN, Shenglin HUANG, Xing LI, Di LI, Fei LIN, Xiaojuan LU, Shi LV, Maoyun WU, Chengde XU, Weiliang YAN, Gang YUAN, Jianxing ZHANG, Weina ZHANG, Zhiliu
DMG5J9Z	DT	Small molecular drug
DMG5J9Z	PC	49793232
DMG5J9Z	MW	412.9
DMG5J9Z	FM	C21H21ClN4O3
DMG5J9Z	IC	InChI=1S/C21H21ClN4O3/c22-15-3-4-16(23-11-15)14-29-19-7-9-26(21(28)10-19)17-5-6-20(24-12-17)25-8-1-2-18(25)13-27/h3-7,9-12,18,27H,1-2,8,13-14H2/t18-/m1/s1
DMG5J9Z	CS	C1C[C@@H](N(C1)C2=NC=C(C=C2)N3C=CC(=CC3=O)OCC4=NC=C(C=C4)Cl)CO
DMG5J9Z	IK	FLLZLALIXHIFNL-GOSISDBHSA-N
DMG5J9Z	IU	4-[(5-chloropyridin-2-yl)methoxy]-1-[6-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]pyridin-2-one

DMRZMH5	ID	DMRZMH5
DMRZMH5	DN	PMID25522065-Compound-21
DMRZMH5	HS	Patented
DMRZMH5	CP	GLAXOSMITHKLINE LLC CHRISTENSEN, Siegfried, Benjamin, IV QIN, Donghui CHEN, Shenglin HUANG, Xing LI, Di LI, Fei LI, Lei LIN, Xiaojuan LU, Shi LU, Zhen LV, Maoyun WANG, Chuanning WU, Chengde XIAO, Mei YU, Haiyu ZHANG, Weina ZHANG, Zhiliu
DMRZMH5	DT	Small molecular drug
DMRZMH5	PC	49793259
DMRZMH5	MW	427.9
DMRZMH5	FM	C22H26ClN5O2
DMRZMH5	IC	InChI=1S/C22H26ClN5O2/c1-3-27(4-2)12-10-24-21-8-7-19(15-26-21)28-11-9-20(13-22(28)29)30-16-18-6-5-17(23)14-25-18/h5-9,11,13-15H,3-4,10,12,16H2,1-2H3,(H,24,26)
DMRZMH5	CS	CCN(CC)CCNC1=NC=C(C=C1)N2C=CC(=CC2=O)OCC3=NC=C(C=C3)Cl
DMRZMH5	IK	QZSXDTLVUJGVDX-UHFFFAOYSA-N
DMRZMH5	IU	4-[(5-chloropyridin-2-yl)methoxy]-1-[6-[2-(diethylamino)ethylamino]pyridin-3-yl]pyridin-2-one

DM1N5UH	ID	DM1N5UH
DM1N5UH	DN	PMID25522065-Compound-22
DM1N5UH	HS	Patented
DM1N5UH	CP	GLAXOSMITHKLINE LLC CHRISTENSEN, Siegfried, Benjamin, IV QIN, Donghui LU, Shi WEI, Shuai YANG, Nianyong ZHANG, Zhiliu
DM1N5UH	DT	Small molecular drug
DM1N5UH	PC	49793263
DM1N5UH	MW	437.9
DM1N5UH	FM	C23H24ClN5O2
DM1N5UH	IC	InChI=1S/C23H24ClN5O2/c1-22-13-23(22,25-2)15-28(14-22)20-6-5-18(11-27-20)29-8-7-19(9-21(29)30)31-12-17-4-3-16(24)10-26-17/h3-11,25H,12-15H2,1-2H3/t22-,23-/m0/s1
DM1N5UH	CS	C[C@@]12C[C@@]1(CN(C2)C3=NC=C(C=C3)N4C=CC(=CC4=O)OCC5=NC=C(C=C5)Cl)NC
DM1N5UH	IK	KROAARZZGJOXPL-GOTSBHOMSA-N
DM1N5UH	IU	4-[(5-chloropyridin-2-yl)methoxy]-1-[6-[(1S,5R)-1-methyl-5-(methylamino)-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-3-yl]pyridin-2-one

DMHSGPU	ID	DMHSGPU
DMHSGPU	DN	PMID25522065-Compound-23
DMHSGPU	HS	Patented
DMHSGPU	CP	GLAXOSMITHKLINE LLC CHRISTENSEN, Siegfried, Benjamin, IV QIN, Donghui CHEN, Shuhui LU, Shi
DMHSGPU	DT	Small molecular drug
DMHSGPU	PC	49793260
DMHSGPU	MW	451.9
DMHSGPU	FM	C23H22ClN5O3
DMHSGPU	IC	InChI=1S/C23H22ClN5O3/c24-16-1-2-17(26-12-16)14-32-19-5-10-28(21(30)11-19)18-3-4-20(27-13-18)29-15-23(22(29)31)6-8-25-9-7-23/h1-5,10-13,25H,6-9,14-15H2
DMHSGPU	CS	C1CNCCC12CN(C2=O)C3=NC=C(C=C3)N4C=CC(=CC4=O)OCC5=NC=C(C=C5)Cl
DMHSGPU	IK	SIMRWGQXBPBXAH-UHFFFAOYSA-N
DMHSGPU	IU	2-[5-[4-[(5-chloropyridin-2-yl)methoxy]-2-oxopyridin-1-yl]pyridin-2-yl]-2,7-diazaspiro[3.5]nonan-3-one

DM9MLQ6	ID	DM9MLQ6
DM9MLQ6	DN	PMID25522065-Compound-24
DM9MLQ6	HS	Patented
DM9MLQ6	CP	GLAXOSMITHKLINE LLC QIN, Donghui CHRISTENSEN, Sieg WU, Chengde ZHANG, Zhiliu YU, Haiyu YUAN, Jiangxing
DM9MLQ6	DT	Small molecular drug
DM9MLQ6	PC	71745113
DM9MLQ6	MW	511.7
DM9MLQ6	FM	C26H29N3O4S2
DM9MLQ6	IC	InChI=1S/C26H29N3O4S2/c1-18-17-34-25(28-18)16-33-24-6-9-29(26(30)14-24)23-5-4-20-12-19(2-3-21(20)13-23)15-27-22-7-10-35(31,32)11-8-22/h2-3,6,9,12-14,17,22,27H,4-5,7-8,10-11,15-16H2,1H3
DM9MLQ6	CS	CC1=CSC(=N1)COC2=CC(=O)N(C=C2)C3=CC4=C(CC3)C=C(C=C4)CNC5CCS(=O)(=O)CC5
DM9MLQ6	IK	XVQJOVCBLFUQMO-UHFFFAOYSA-N
DM9MLQ6	IU	1-[6-[[(1,1-dioxothian-4-yl)amino]methyl]-3,4-dihydronaphthalen-2-yl]-4-[(4-methyl-1,3-thiazol-2-yl)methoxy]pyridin-2-one

DMUM3YW	ID	DMUM3YW
DMUM3YW	DN	PMID25522065-Compound-25
DMUM3YW	HS	Patented
DMUM3YW	CP	GLAXOSMITHKLINE LLC QIN, Donghui CHRISTENSEN, IV, Siegfried Benjamin WU, Chengde ZHANG, Zhiliu YU, Haiyu YUAN, Jiangxing LIN, Xiaojuan XU, Shanli LV, Maoyun YAO, Chen LI, Lei HUANG, Xing GAO, Min
DMUM3YW	DT	Small molecular drug
DMUM3YW	PC	72195244
DMUM3YW	MW	478
DMUM3YW	FM	C28H32ClN3O2
DMUM3YW	IC	InChI=1S/C28H32ClN3O2/c1-20(2)31-13-12-30-18-22-3-6-24-16-26(10-7-23(24)15-22)32-14-11-27(17-28(32)33)34-19-21-4-8-25(29)9-5-21/h3-6,8-9,11,14-17,20,30-31H,7,10,12-13,18-19H2,1-2H3
DMUM3YW	CS	CC(C)NCCNCC1=CC2=C(C=C1)C=C(CC2)N3C=CC(=CC3=O)OCC4=CC=C(C=C4)Cl
DMUM3YW	IK	SCTPFHKOHPCDLG-UHFFFAOYSA-N
DMUM3YW	IU	4-[(4-chlorophenyl)methoxy]-1-[6-[[2-(propan-2-ylamino)ethylamino]methyl]-3,4-dihydronaphthalen-2-yl]pyridin-2-one

DMY07NA	ID	DMY07NA
DMY07NA	DN	PMID25522065-Compound-26
DMY07NA	HS	Patented
DMY07NA	DT	Small molecular drug

DMXN4KB	ID	DMXN4KB
DMXN4KB	DN	PMID25522065-Compound-27
DMXN4KB	HS	Patented
DMXN4KB	DT	Small molecular drug
DMXN4KB	PC	71483227
DMXN4KB	MW	467.5
DMXN4KB	FM	C23H23F2N7O2
DMXN4KB	IC	InChI=1S/C23H23F2N7O2/c1-34-22-21(28-19-9-16(24)17(25)10-20(19)29-22)30-23(33)27-15-4-6-32(7-5-15)12-13-2-3-14-11-26-31-18(14)8-13/h2-3,8-11,15H,4-7,12H2,1H3,(H,26,31)(H2,27,28,30,33)
DMXN4KB	CS	COC1=NC2=CC(=C(C=C2N=C1NC(=O)NC3CCN(CC3)CC4=CC5=C(C=C4)C=NN5)F)F
DMXN4KB	IK	XSQADOWIAZCVIY-UHFFFAOYSA-N
DMXN4KB	IU	1-(6,7-difluoro-3-methoxyquinoxalin-2-yl)-3-[1-(1H-indazol-6-ylmethyl)piperidin-4-yl]urea

DMB93QU	ID	DMB93QU
DMB93QU	DN	PMID25522065-Compound-28
DMB93QU	HS	Patented
DMB93QU	DT	Small molecular drug
DMB93QU	PC	71496168
DMB93QU	MW	443.9
DMB93QU	FM	C23H26ClN3O4
DMB93QU	IC	InChI=1S/C23H26ClN3O4/c1-28-21-14-18(6-9-20(21)30-13-12-27-10-2-3-11-27)23-25-22(31-26-23)16-29-15-17-4-7-19(24)8-5-17/h4-9,14H,2-3,10-13,15-16H2,1H3
DMB93QU	CS	COC1=C(C=CC(=C1)C2=NOC(=N2)COCC3=CC=C(C=C3)Cl)OCCN4CCCC4
DMB93QU	IK	KTSBQVGVFAEOBK-UHFFFAOYSA-N
DMB93QU	IU	5-[(4-chlorophenyl)methoxymethyl]-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-oxadiazole

DMBNAK9	ID	DMBNAK9
DMBNAK9	DN	PMID25522065-Compound-29
DMBNAK9	HS	Patented
DMBNAK9	DT	Small molecular drug
DMBNAK9	PC	60169095
DMBNAK9	MW	461.6
DMBNAK9	FM	C26H27N3O3S
DMBNAK9	IC	InChI=1S/C26H27N3O3S/c1-31-23-17-20(10-11-22(23)32-16-15-28-13-5-6-14-28)29-18-19-9-12-24(27-25(19)26(29)30)33-21-7-3-2-4-8-21/h2-4,7-12,17H,5-6,13-16,18H2,1H3
DMBNAK9	CS	COC1=C(C=CC(=C1)N2CC3=C(C2=O)N=C(C=C3)SC4=CC=CC=C4)OCCN5CCCC5
DMBNAK9	IK	PULOMQYOCPKDEH-UHFFFAOYSA-N
DMBNAK9	IU	6-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-2-phenylsulfanyl-5H-pyrrolo[3,4-b]pyridin-7-one

DM54DXT	ID	DM54DXT
DM54DXT	DN	PMID25522065-Compound-3
DM54DXT	HS	Patented
DM54DXT	CP	ALBANY MOLECULAR RESEARCH, INC
DM54DXT	DT	Small molecular drug
DM54DXT	PC	49869209
DM54DXT	MW	438.4
DM54DXT	FM	C24H21F3N4O
DM54DXT	IC	InChI=1S/C24H21F3N4O/c1-30-21-3-2-9-28-14-19(21)18-6-5-17(12-22(18)30)31-10-8-15(11-23(31)32)20-7-4-16(13-29-20)24(25,26)27/h4-8,10-13,28H,2-3,9,14H2,1H3
DM54DXT	CS	CN1C2=C(CNCCC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)C5=NC=C(C=C5)C(F)(F)F
DM54DXT	IK	KTVJCRABCWFUNK-UHFFFAOYSA-N
DM54DXT	IU	1-(6-methyl-2,3,4,5-tetrahydro-1H-azepino[4,3-b]indol-8-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]pyridin-2-one

DMMOV67	ID	DMMOV67
DMMOV67	DN	PMID25522065-Compound-30
DMMOV67	HS	Patented
DMMOV67	DT	Small molecular drug
DMMOV67	PC	60169096
DMMOV67	MW	479.6
DMMOV67	FM	C26H26FN3O3S
DMMOV67	IC	InChI=1S/C26H26FN3O3S/c1-32-23-16-20(7-10-22(23)33-15-14-29-12-2-3-13-29)30-17-18-4-11-24(28-25(18)26(30)31)34-21-8-5-19(27)6-9-21/h4-11,16H,2-3,12-15,17H2,1H3
DMMOV67	CS	COC1=C(C=CC(=C1)N2CC3=C(C2=O)N=C(C=C3)SC4=CC=C(C=C4)F)OCCN5CCCC5
DMMOV67	IK	IOVNPTLMMFSPCO-UHFFFAOYSA-N
DMMOV67	IU	2-(4-fluorophenyl)sulfanyl-6-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-5H-pyrrolo[3,4-b]pyridin-7-one

DMEMBOW	ID	DMEMBOW
DMEMBOW	DN	PMID25522065-Compound-31
DMEMBOW	HS	Patented
DMEMBOW	DT	Small molecular drug
DMEMBOW	PC	71719525
DMEMBOW	MW	457.6
DMEMBOW	FM	C28H31N3O3
DMEMBOW	IC	InChI=1S/C28H31N3O3/c1-3-20-6-8-21(9-7-20)24-12-10-22-19-31(28(32)27(22)29-24)23-11-13-25(26(18-23)33-2)34-17-16-30-14-4-5-15-30/h6-13,18H,3-5,14-17,19H2,1-2H3
DMEMBOW	CS	CCC1=CC=C(C=C1)C2=NC3=C(CN(C3=O)C4=CC(=C(C=C4)OCCN5CCCC5)OC)C=C2
DMEMBOW	IK	JRDLEMTYNVKHFV-UHFFFAOYSA-N
DMEMBOW	IU	2-(4-ethylphenyl)-6-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-5H-pyrrolo[3,4-b]pyridin-7-one

DM5H3YA	ID	DM5H3YA
DM5H3YA	DN	PMID25522065-Compound-32
DM5H3YA	HS	Patented
DM5H3YA	DT	Small molecular drug
DM5H3YA	PC	56835134
DM5H3YA	MW	516.6
DM5H3YA	FM	C30H30F2N4O2
DM5H3YA	IC	InChI=1S/C30H30F2N4O2/c1-20(37)33-24-7-4-6-22(18-24)21-12-16-35(17-13-21)14-5-15-36-30(38)26-9-3-2-8-25(26)29(34-36)23-10-11-27(31)28(32)19-23/h2-4,6-11,18-19,21H,5,12-17H2,1H3,(H,33,37)
DM5H3YA	CS	CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCN3C(=O)C4=CC=CC=C4C(=N3)C5=CC(=C(C=C5)F)F
DM5H3YA	IK	YVVMAGRTTSOPEO-UHFFFAOYSA-N
DM5H3YA	IU	N-[3-[1-[3-[4-(3,4-difluorophenyl)-1-oxophthalazin-2-yl]propyl]piperidin-4-yl]phenyl]acetamide

DMYMJIW	ID	DMYMJIW
DMYMJIW	DN	PMID25522065-Compound-33
DMYMJIW	HS	Patented
DMYMJIW	DT	Small molecular drug

DMZDIRQ	ID	DMZDIRQ
DMZDIRQ	DN	PMID25522065-Compound-34
DMZDIRQ	HS	Patented
DMZDIRQ	DT	Small molecular drug
DMZDIRQ	PC	71727344
DMZDIRQ	MW	505.7
DMZDIRQ	FM	C28H35N5O2S
DMZDIRQ	IC	InChI=1S/C28H35N5O2S/c1-21(34)29-24-7-4-6-23(20-24)22-10-14-31(15-11-22)12-5-13-33-28(35)26-9-3-2-8-25(26)27(30-33)32-16-18-36-19-17-32/h2-4,6-9,20,22H,5,10-19H2,1H3,(H,29,34)
DMZDIRQ	CS	CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCN3C(=O)C4=CC=CC=C4C(=N3)N5CCSCC5
DMZDIRQ	IK	XXBGKRFICBGOCH-UHFFFAOYSA-N
DMZDIRQ	IU	N-[3-[1-[3-(1-oxo-4-thiomorpholin-4-ylphthalazin-2-yl)propyl]piperidin-4-yl]phenyl]acetamide

DM1JAFV	ID	DM1JAFV
DM1JAFV	DN	PMID25522065-Compound-35
DM1JAFV	HS	Patented
DM1JAFV	DT	Small molecular drug
DM1JAFV	PC	70675668
DM1JAFV	MW	506.6
DM1JAFV	FM	C31H30N4O3
DM1JAFV	IC	InChI=1S/C31H30N4O3/c1-21(36)34-28-4-2-3-25(18-28)24-11-14-35(15-12-24)16-13-33-31(37)30-19-27-17-26(9-10-29(27)38-30)23-7-5-22(20-32)6-8-23/h2-10,17-19,24H,11-16H2,1H3,(H,33,37)(H,34,36)
DM1JAFV	CS	CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCNC(=O)C3=CC4=C(O3)C=CC(=C4)C5=CC=C(C=C5)C#N
DM1JAFV	IK	FYWPSNHXRLJIKV-UHFFFAOYSA-N
DM1JAFV	IU	N-[2-[4-(3-acetamidophenyl)piperidin-1-yl]ethyl]-5-(4-cyanophenyl)-1-benzofuran-2-carboxamide

DMNISGE	ID	DMNISGE
DMNISGE	DN	PMID25522065-Compound-36
DMNISGE	HS	Patented
DMNISGE	DT	Small molecular drug
DMNISGE	PC	72715352
DMNISGE	MW	532.6
DMNISGE	FM	C33H32N4O3
DMNISGE	IC	InChI=1S/C33H32N4O3/c1-22(38)36-27-6-4-5-25(19-27)23-11-16-37(17-12-23)18-15-35-33(39)31-21-26-20-30(24-9-13-34-14-10-24)28-7-2-3-8-29(28)32(26)40-31/h2-10,13-14,19-21,23H,11-12,15-18H2,1H3,(H,35,39)(H,36,38)
DMNISGE	CS	CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCNC(=O)C3=CC4=C(O3)C5=CC=CC=C5C(=C4)C6=CC=NC=C6
DMNISGE	IK	KFXQNHZULSOCEW-UHFFFAOYSA-N
DMNISGE	IU	N-[2-[4-(3-acetamidophenyl)piperidin-1-yl]ethyl]-5-pyridin-4-ylbenzo[g][1]benzofuran-2-carboxamide

DMH3CK0	ID	DMH3CK0
DMH3CK0	DN	PMID25522065-Compound-37
DMH3CK0	HS	Patented
DMH3CK0	CP	MERCK SHARP &amDOHME CORP. LIN, Linus SOLL, Richard DONG, Jingchao WU, Hao SUZUKI, Takao HU, Bin LIU, Dejun HAO, Jinglai XU, Ming
DMH3CK0	DT	Small molecular drug
DMH3CK0	PC	46911512
DMH3CK0	MW	397.4
DMH3CK0	FM	C23H24FNO4
DMH3CK0	IC	InChI=1S/C23H24FNO4/c1-16-12-19(8-9-21(16)29-15-23(2,3)27)25-11-10-20(13-22(25)26)28-14-17-4-6-18(24)7-5-17/h4-13,27H,14-15H2,1-3H3
DMH3CK0	CS	CC1=C(C=CC(=C1)N2C=CC(=CC2=O)OCC3=CC=C(C=C3)F)OCC(C)(C)O
DMH3CK0	IK	WCMFUWBVIKILDJ-UHFFFAOYSA-N
DMH3CK0	IU	4-[(4-fluorophenyl)methoxy]-1-[4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl]pyridin-2-one

DMQLBAJ	ID	DMQLBAJ
DMQLBAJ	DN	PMID25522065-Compound-38
DMQLBAJ	HS	Patented
DMQLBAJ	CP	MERCK SHARP &amDOHME CORP. LIN, Linus SOLL, Richard DONG, Jingchao WU, Hao SUZUKI, Takao HU, Bin LIU, Dejun HAO, Jinglai XU, Ming
DMQLBAJ	DT	Small molecular drug
DMQLBAJ	PC	53476614
DMQLBAJ	MW	395.4
DMQLBAJ	FM	C23H22FNO4
DMQLBAJ	IC	InChI=1S/C23H22FNO4/c1-16-12-19(6-7-21(16)29-15-23(27)9-10-23)25-11-8-20(13-22(25)26)28-14-17-2-4-18(24)5-3-17/h2-8,11-13,27H,9-10,14-15H2,1H3
DMQLBAJ	CS	CC1=C(C=CC(=C1)N2C=CC(=CC2=O)OCC3=CC=C(C=C3)F)OCC4(CC4)O
DMQLBAJ	IK	DSXGYSJOEHCCMA-UHFFFAOYSA-N
DMQLBAJ	IU	4-[(4-fluorophenyl)methoxy]-1-[4-[(1-hydroxycyclopropyl)methoxy]-3-methylphenyl]pyridin-2-one

DM5YMQH	ID	DM5YMQH
DM5YMQH	DN	PMID25522065-Compound-39
DM5YMQH	HS	Patented
DM5YMQH	CP	MERCK SHARP & DOHME CORP. MSD K.K. LIN, Linus, S. SUZUKI, Takao
DM5YMQH	DT	Small molecular drug

DM84U7F	ID	DM84U7F
DM84U7F	DN	PMID25522065-Compound-4
DM84U7F	HS	Patented
DM84U7F	CP	ALBANY MOLECULAR RESEARCH, INC
DM84U7F	DT	Small molecular drug
DM84U7F	PC	49868803
DM84U7F	MW	439.4
DM84U7F	FM	C23H20F3N5O
DM84U7F	IC	InChI=1S/C23H20F3N5O/c1-30-19-7-10-27-9-6-17(19)16-3-2-15(13-20(16)30)31-11-8-14(12-22(31)32)18-4-5-21(29-28-18)23(24,25)26/h2-5,8,11-13,27H,6-7,9-10H2,1H3
DM84U7F	CS	CN1C2=C(CCNCC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)C5=NN=C(C=C5)C(F)(F)F
DM84U7F	IK	RTHGRJZORFROEE-UHFFFAOYSA-N
DM84U7F	IU	1-(6-methyl-2,3,4,5-tetrahydro-1H-azepino[4,5-b]indol-8-yl)-4-[6-(trifluoromethyl)pyridazin-3-yl]pyridin-2-one

DMCIQ01	ID	DMCIQ01
DMCIQ01	DN	PMID25522065-Compound-40
DMCIQ01	HS	Patented
DMCIQ01	CP	MERCK SHARP & DOHME CORP. MSD K.K. LIN, Linus, S. SUZUKI, Takao
DMCIQ01	DT	Small molecular drug

DMWALOT	ID	DMWALOT
DMWALOT	DN	PMID25522065-Compound-41
DMWALOT	HS	Patented
DMWALOT	CP	RICHTER GEDEON NYRT [HU]
DMWALOT	DT	Small molecular drug
DMWALOT	PC	70982502
DMWALOT	MW	510
DMWALOT	FM	C26H24ClN3O4S
DMWALOT	IC	InChI=1S/C26H24ClN3O4S/c1-32-22-10-19(6-7-21(22)34-9-8-29-12-26(13-29)14-33-15-26)30-16-28-20-11-23(35-24(20)25(30)31)17-2-4-18(27)5-3-17/h2-7,10-11,16H,8-9,12-15H2,1H3
DMWALOT	CS	COC1=C(C=CC(=C1)N2C=NC3=C(C2=O)SC(=C3)C4=CC=C(C=C4)Cl)OCCN5CC6(C5)COC6
DMWALOT	IK	RYWKRAVYOFTFPJ-UHFFFAOYSA-N
DMWALOT	IU	6-(4-chlorophenyl)-3-[3-methoxy-4-[2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethoxy]phenyl]thieno[3,2-d]pyrimidin-4-one

DMAUO6C	ID	DMAUO6C
DMAUO6C	DN	PMID25522065-Compound-42
DMAUO6C	HS	Patented
DMAUO6C	CP	OMORI, Naoki et al
DMAUO6C	DT	Small molecular drug

DMS1FKC	ID	DMS1FKC
DMS1FKC	DN	PMID25522065-Compound-43
DMS1FKC	HS	Patented
DMS1FKC	CP	OMORI, Naoki et al
DMS1FKC	DT	Small molecular drug

DMJKOFB	ID	DMJKOFB
DMJKOFB	DN	PMID25522065-Compound-44
DMJKOFB	HS	Patented
DMJKOFB	CP	TAISHO PHARMACEUTICAL CO., LTD
DMJKOFB	DT	Small molecular drug
DMJKOFB	PC	45255788
DMJKOFB	MW	393.5
DMJKOFB	FM	C23H27N3O3
DMJKOFB	IC	InChI=1S/C23H27N3O3/c1-29-20-4-2-3-18(14-20)23(28)24-19-9-11-26(12-10-19)15-16-5-6-17-7-8-22(27)25-21(17)13-16/h2-6,13-14,19H,7-12,15H2,1H3,(H,24,28)(H,25,27)
DMJKOFB	CS	COC1=CC=CC(=C1)C(=O)NC2CCN(CC2)CC3=CC4=C(CCC(=O)N4)C=C3
DMJKOFB	IK	SWKXQUKCAIDRHK-UHFFFAOYSA-N
DMJKOFB	IU	3-methoxy-N-[1-[(2-oxo-3,4-dihydro-1H-quinolin-7-yl)methyl]piperidin-4-yl]benzamide

DMONJLT	ID	DMONJLT
DMONJLT	DN	PMID25522065-Compound-45
DMONJLT	HS	Patented
DMONJLT	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED  MASADA, Shinichi 
DMONJLT	DT	Small molecular drug
DMONJLT	PC	53303548
DMONJLT	MW	435.6
DMONJLT	FM	C26H33N3O3
DMONJLT	IC	InChI=1S/C26H33N3O3/c1-17-22-13-20(14-27-16-26(2,3)31)29(4)24(22)12-11-23(17)28-25(30)19-7-9-21(10-8-19)32-15-18-5-6-18/h7-13,18,27,31H,5-6,14-16H2,1-4H3,(H,28,30)
DMONJLT	CS	CC1=C(C=CC2=C1C=C(N2C)CNCC(C)(C)O)NC(=O)C3=CC=C(C=C3)OCC4CC4
DMONJLT	IK	LYUFDXWEPKVSLW-UHFFFAOYSA-N
DMONJLT	IU	4-(cyclopropylmethoxy)-N-[2-[[(2-hydroxy-2-methylpropyl)amino]methyl]-1,4-dimethylindol-5-yl]benzamide

DMBH97R	ID	DMBH97R
DMBH97R	DN	PMID25522065-Compound-46
DMBH97R	HS	Patented
DMBH97R	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED  MASADA, Shinichi 
DMBH97R	DT	Small molecular drug
DMBH97R	PC	53303549
DMBH97R	MW	491.6
DMBH97R	FM	C29H37N3O4
DMBH97R	IC	InChI=1S/C29H37N3O4/c1-20-26-16-23(18-30-17-21-11-14-34-15-12-21)32(2)28(26)10-9-27(20)31-29(33)22-5-7-24(8-6-22)36-19-25-4-3-13-35-25/h5-10,16,21,25,30H,3-4,11-15,17-19H2,1-2H3,(H,31,33)/t25-/m0/s1
DMBH97R	CS	CC1=C(C=CC2=C1C=C(N2C)CNCC3CCOCC3)NC(=O)C4=CC=C(C=C4)OC[C@@H]5CCCO5
DMBH97R	IK	ODYOYEADBNGJGQ-VWLOTQADSA-N
DMBH97R	IU	N-[1,4-dimethyl-2-[(oxan-4-ylmethylamino)methyl]indol-5-yl]-4-[[(2S)-oxolan-2-yl]methoxy]benzamide

DMXRI5J	ID	DMXRI5J
DMXRI5J	DN	PMID25522065-Compound-47
DMXRI5J	HS	Patented
DMXRI5J	DT	Small molecular drug
DMXRI5J	PC	72198297
DMXRI5J	MW	446.9
DMXRI5J	FM	C25H19ClN2O4
DMXRI5J	IC	InChI=1S/C25H19ClN2O4/c1-30-23-12-18(6-7-21(23)31-15-25(14-27)9-10-25)28-11-8-20-19(24(28)29)13-22(32-20)16-2-4-17(26)5-3-16/h2-8,11-13H,9-10,15H2,1H3
DMXRI5J	CS	COC1=C(C=CC(=C1)N2C=CC3=C(C2=O)C=C(O3)C4=CC=C(C=C4)Cl)OCC5(CC5)C#N
DMXRI5J	IK	RMJJVTXKEKNHEK-UHFFFAOYSA-N
DMXRI5J	IU	1-[[4-[2-(4-chlorophenyl)-4-oxofuro[3,2-c]pyridin-5-yl]-2-methoxyphenoxy]methyl]cyclopropane-1-carbonitrile

DMHI4L6	ID	DMHI4L6
DMHI4L6	DN	PMID25522065-Compound-48
DMHI4L6	HS	Patented
DMHI4L6	DT	Small molecular drug
DMHI4L6	PC	71816529
DMHI4L6	MW	439.9
DMHI4L6	FM	C24H22ClNO5
DMHI4L6	IC	InChI=1S/C24H22ClNO5/c1-24(2,28)14-30-20-9-8-17(12-22(20)29-3)26-11-10-19-18(23(26)27)13-21(31-19)15-4-6-16(25)7-5-15/h4-13,28H,14H2,1-3H3
DMHI4L6	CS	CC(C)(COC1=C(C=C(C=C1)N2C=CC3=C(C2=O)C=C(O3)C4=CC=C(C=C4)Cl)OC)O
DMHI4L6	IK	UBVMNCOEYQICSI-UHFFFAOYSA-N
DMHI4L6	IU	2-(4-chlorophenyl)-5-[4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl]furo[3,2-c]pyridin-4-one

DMNI03Z	ID	DMNI03Z
DMNI03Z	DN	PMID25522065-Compound-49
DMNI03Z	HS	Patented
DMNI03Z	DT	Small molecular drug
DMNI03Z	PC	71816518
DMNI03Z	MW	415.9
DMNI03Z	FM	C24H18ClN3O2
DMNI03Z	IC	InChI=1S/C24H18ClN3O2/c1-14-23(16-2-3-16)26-22-9-8-18(13-28(14)22)27-11-10-20-19(24(27)29)12-21(30-20)15-4-6-17(25)7-5-15/h4-13,16H,2-3H2,1H3
DMNI03Z	CS	CC1=C(N=C2N1C=C(C=C2)N3C=CC4=C(C3=O)C=C(O4)C5=CC=C(C=C5)Cl)C6CC6
DMNI03Z	IK	FBRSISPMXWGFQN-UHFFFAOYSA-N
DMNI03Z	IU	2-(4-chlorophenyl)-5-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)furo[3,2-c]pyridin-4-one

DMA8G6B	ID	DMA8G6B
DMA8G6B	DN	PMID25522065-Compound-5
DMA8G6B	HS	Patented
DMA8G6B	CP	ALBANY MOLECULAR RESEARCH, INC
DMA8G6B	DT	Small molecular drug
DMA8G6B	PC	50903067
DMA8G6B	MW	430.5
DMA8G6B	FM	C25H23FN4O2
DMA8G6B	IC	InChI=1S/C25H23FN4O2/c1-29-22-11-18(5-6-20(22)25-21-7-4-16(28-21)10-23(25)29)30-9-8-19(12-24(30)31)32-14-17-3-2-15(26)13-27-17/h2-3,5-6,8-9,11-13,16,21,28H,4,7,10,14H2,1H3
DMA8G6B	CS	CN1C2=C(C3CCC(C2)N3)C4=C1C=C(C=C4)N5C=CC(=CC5=O)OCC6=NC=C(C=C6)F
DMA8G6B	IK	WIHBSZQMVJUBGL-UHFFFAOYSA-N
DMA8G6B	IU	4-[(5-fluoropyridin-2-yl)methoxy]-1-(9-methyl-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraen-6-yl)pyridin-2-one

DMBWA0V	ID	DMBWA0V
DMBWA0V	DN	PMID25522065-Compound-50
DMBWA0V	HS	Patented
DMBWA0V	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMBWA0V	DT	Small molecular drug
DMBWA0V	PC	71660914
DMBWA0V	MW	377.4
DMBWA0V	FM	C22H20FN3O2
DMBWA0V	IC	InChI=1S/C22H20FN3O2/c1-3-21-24-19-9-8-17(12-20(19)25(21)2)26-11-10-18(13-22(26)27)28-14-15-4-6-16(23)7-5-15/h4-13H,3,14H2,1-2H3
DMBWA0V	CS	CCC1=NC2=C(N1C)C=C(C=C2)N3C=CC(=CC3=O)OCC4=CC=C(C=C4)F
DMBWA0V	IK	UDLQRAVGQUJISV-UHFFFAOYSA-N
DMBWA0V	IU	1-(2-ethyl-3-methylbenzimidazol-5-yl)-4-[(4-fluorophenyl)methoxy]pyridin-2-one

DMEU48I	ID	DMEU48I
DMEU48I	DN	PMID25522065-Compound-51
DMEU48I	HS	Patented
DMEU48I	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMEU48I	DT	Small molecular drug
DMEU48I	PC	71660917
DMEU48I	MW	363.4
DMEU48I	FM	C21H18FN3O2
DMEU48I	IC	InChI=1S/C21H18FN3O2/c1-14-23-19-8-7-17(11-20(19)24(14)2)25-10-9-18(12-21(25)26)27-13-15-3-5-16(22)6-4-15/h3-12H,13H2,1-2H3
DMEU48I	CS	CC1=NC2=C(N1C)C=C(C=C2)N3C=CC(=CC3=O)OCC4=CC=C(C=C4)F
DMEU48I	IK	WSKXMIQVCMWHGL-UHFFFAOYSA-N
DMEU48I	IU	1-(2,3-dimethylbenzimidazol-5-yl)-4-[(4-fluorophenyl)methoxy]pyridin-2-one

DMU1PEZ	ID	DMU1PEZ
DMU1PEZ	DN	PMID25522065-Compound-6
DMU1PEZ	HS	Patented
DMU1PEZ	CP	ALBANY MOLECULAR RESEARCH, INC
DMU1PEZ	DT	Small molecular drug
DMU1PEZ	PC	50903153
DMU1PEZ	MW	450.5
DMU1PEZ	FM	C25H21F3N4O
DMU1PEZ	IC	InChI=1S/C25H21F3N4O/c1-31-20-12-17(4-5-18(20)24-19-6-3-16(30-19)11-21(24)31)32-9-8-14(10-23(32)33)15-2-7-22(29-13-15)25(26,27)28/h2,4-5,7-10,12-13,16,19,30H,3,6,11H2,1H3
DMU1PEZ	CS	CN1C2=C(C3CCC(C2)N3)C4=C1C=C(C=C4)N5C=CC(=CC5=O)C6=CN=C(C=C6)C(F)(F)F
DMU1PEZ	IK	NAYVWRUHNOMLBF-UHFFFAOYSA-N
DMU1PEZ	IU	1-(9-methyl-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraen-6-yl)-4-[6-(trifluoromethyl)pyridin-3-yl]pyridin-2-one

DMYZMX6	ID	DMYZMX6
DMYZMX6	DN	PMID25522065-Compound-7
DMYZMX6	HS	Patented
DMYZMX6	CP	ALBANY MOLECULAR RESEARCH, INC
DMYZMX6	DT	Small molecular drug
DMYZMX6	PC	58092191
DMYZMX6	MW	414.5
DMYZMX6	FM	C26H30N4O
DMYZMX6	IC	InChI=1S/C26H30N4O/c1-28-23-16-20(8-9-21(23)26-22-10-7-19(27-22)15-24(26)28)30-14-13-29(17-25(30)31)12-11-18-5-3-2-4-6-18/h2-6,8-9,16,19,22,27H,7,10-15,17H2,1H3
DMYZMX6	CS	CN1C2=C(C3CCC(C2)N3)C4=C1C=C(C=C4)N5CCN(CC5=O)CCC6=CC=CC=C6
DMYZMX6	IK	JXBCIEBMTZBYLB-UHFFFAOYSA-N
DMYZMX6	IU	1-(9-methyl-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraen-6-yl)-4-(2-phenylethyl)piperazin-2-one

DMJMCKD	ID	DMJMCKD
DMJMCKD	DN	PMID25522065-Compound-8
DMJMCKD	HS	Patented
DMJMCKD	CP	ALBANY MOLECULAR RESEARCH, INC
DMJMCKD	DT	Small molecular drug
DMJMCKD	PC	49836016
DMJMCKD	MW	411.5
DMJMCKD	FM	C26H25N3O2
DMJMCKD	IC	InChI=1S/C26H25N3O2/c1-27-24-13-20(7-8-22(24)23-16-28-11-9-19(15-28)26(23)27)29-12-10-21(14-25(29)30)31-17-18-5-3-2-4-6-18/h2-8,10,12-14,19H,9,11,15-17H2,1H3
DMJMCKD	CS	CN1C2=C(C=CC(=C2)N3C=CC(=CC3=O)OCC4=CC=CC=C4)C5=C1C6CCN(C6)C5
DMJMCKD	IK	UPOGSKZLDRHZBU-UHFFFAOYSA-N
DMJMCKD	IU	1-(3-methyl-3,12-diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4(9),5,7-tetraen-6-yl)-4-phenylmethoxypyridin-2-one

DMAMRPW	ID	DMAMRPW
DMAMRPW	DN	PMID25522065-Compound-9
DMAMRPW	HS	Patented
DMAMRPW	DT	Small molecular drug
DMAMRPW	PC	57524505
DMAMRPW	MW	386.4
DMAMRPW	FM	C23H22N4O2
DMAMRPW	IC	InChI=1S/C23H22N4O2/c1-26-20-9-11-24-14-19(20)18-7-8-21(25-23(18)26)27-12-10-17(13-22(27)28)29-15-16-5-3-2-4-6-16/h2-8,10,12-13,24H,9,11,14-15H2,1H3
DMAMRPW	CS	CN1C2=C(CNCC2)C3=C1N=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5
DMAMRPW	IK	SXWOYRGICAISET-UHFFFAOYSA-N
DMAMRPW	IU	1-(8-methyl-4,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-11-yl)-4-phenylmethoxypyridin-2-one

DM4GQJH	ID	DM4GQJH
DM4GQJH	DN	PMID25553724-Compound-EP20132578214 2
DM4GQJH	HS	Patented
DM4GQJH	CP	Korea Ocean Research and Development Institute

DMM3QEW	ID	DMM3QEW
DMM3QEW	DN	PMID25553724-Compound-US2011000295210
DMM3QEW	HS	Patented
DMM3QEW	DT	Small molecular drug
DMM3QEW	DE	Immune System disease

DMZCO6J	ID	DMZCO6J
DMZCO6J	DN	PMID25553724-Compound-US2011788838110
DMZCO6J	HS	Patented
DMZCO6J	DT	Small molecular drug
DMZCO6J	DE	Immune System disease

DMH4DMY	ID	DMH4DMY
DMH4DMY	DN	PMID25553724-Compound-US2011796857710
DMH4DMY	HS	Patented
DMH4DMY	DT	Small molecular drug
DMH4DMY	DE	Immune System disease

DMIZ64O	ID	DMIZ64O
DMIZ64O	DN	PMID25553724-Compound-US2011799419010
DMIZ64O	HS	Patented
DMIZ64O	DT	Small molecular drug
DMIZ64O	DE	Immune System disease

DMZ96CG	ID	DMZ96CG
DMZ96CG	DN	PMID25553724-Compound-US2011801300410
DMZ96CG	HS	Patented
DMZ96CG	DT	Small molecular drug
DMZ96CG	DE	Immune System disease

DMCDHZT	ID	DMCDHZT
DMCDHZT	DN	PMID25553724-Compound-US2011803494010
DMCDHZT	HS	Patented
DMCDHZT	DT	Small molecular drug
DMCDHZT	DE	Immune System disease

DMIAV5M	ID	DMIAV5M
DMIAV5M	DN	PMID25553724-Compound-US2011806744710
DMIAV5M	HS	Patented
DMIAV5M	DT	Small molecular drug
DMIAV5M	DE	Immune System disease

DM9KAF1	ID	DM9KAF1
DM9KAF1	DN	PMID25553724-Compound-US2012810604610
DM9KAF1	HS	Patented
DM9KAF1	DT	Small molecular drug
DM9KAF1	DE	Immune System disease

DMS7RYP	ID	DMS7RYP
DMS7RYP	DN	PMID25553724-Compound-US2012819831110
DMS7RYP	HS	Patented
DMS7RYP	DT	Small molecular drug
DMS7RYP	DE	Immune System disease

DMDQ6H7	ID	DMDQ6H7
DMDQ6H7	DN	PMID25553724-Compound-US2012820715110
DMDQ6H7	HS	Patented
DMDQ6H7	DT	Small molecular drug
DMDQ6H7	DE	Immune System disease

DMCUMSV	ID	DMCUMSV
DMCUMSV	DN	PMID25553724-Compound-US2012830453910
DMCUMSV	HS	Patented
DMCUMSV	DT	Small molecular drug
DMCUMSV	DE	Immune System disease

DMFCE51	ID	DMFCE51
DMFCE51	DN	PMID25553724-Compound-US2012832440110
DMFCE51	HS	Patented
DMFCE51	DT	Small molecular drug
DMFCE51	DE	Immune System disease

DMUBZO3	ID	DMUBZO3
DMUBZO3	DN	PMID25553724-Compound-US20130116324 2
DMUBZO3	HS	Patented
DMUBZO3	CP	Korea Ocean Research and Development Institute

DMYGB2O	ID	DMYGB2O
DMYGB2O	DN	PMID25553724-Compound-US20130237529 35
DMYGB2O	HS	Patented

DM9NGDI	ID	DM9NGDI
DM9NGDI	DN	PMID25553724-Compound-US20130237529 36
DM9NGDI	HS	Patented

DMV7SQH	ID	DMV7SQH
DMV7SQH	DN	PMID25553724-Compound-US20138552206 4
DMV7SQH	HS	Patented

DMRVE7Z	ID	DMRVE7Z
DMRVE7Z	DN	PMID25553724-Compound-US20138552206 5
DMRVE7Z	HS	Patented

DM5ATIV	ID	DM5ATIV
DM5ATIV	DN	PMID25553724-Compound-WO2011127048 31
DM5ATIV	HS	Patented
DM5ATIV	CP	VALIDUS BIOPHARMA MCCALL, John, M. HOFFMAN, Eric NAGARAJU, Kanneboyina

DMH3NOZ	ID	DMH3NOZ
DMH3NOZ	DN	PMID25553724-Compound-WO2011127048 32
DMH3NOZ	HS	Patented
DMH3NOZ	CP	VALIDUS BIOPHARMA MCCALL, John, M. HOFFMAN, Eric NAGARAJU, Kanneboyina

DMH7496	ID	DMH7496
DMH7496	DN	PMID25553724-Compound-WO2011127048 33
DMH7496	HS	Patented
DMH7496	CP	VALIDUS BIOPHARMA MCCALL, John, M. HOFFMAN, Eric NAGARAJU, Kanneboyina

DM4YE8W	ID	DM4YE8W
DM4YE8W	DN	PMID25553724-Compound-WO2011127048 34
DM4YE8W	HS	Patented
DM4YE8W	CP	VALIDUS BIOPHARMA MCCALL, John, M. HOFFMAN, Eric NAGARAJU, Kanneboyina

DMPQ175	ID	DMPQ175
DMPQ175	DN	PMID25553724-Compound-WO2011152671 2
DMPQ175	HS	Patented
DMPQ175	CP	KOREA OCEAN RESEARCH AND DEVELOPMENT INSITUTE         YIM, Joung Han     KIM, Il Chan     LEE, Sung Gu     KIM, Doc Kyu     HAN, Se Jong     LEE, Hyoung Seok

DMPFMSJ	ID	DMPFMSJ
DMPFMSJ	DN	PMID25553724-Compound-WO2013082253 31
DMPFMSJ	HS	Patented
DMPFMSJ	CP	REVERAGEN BIOPHARMA, INC

DMXYSO1	ID	DMXYSO1
DMXYSO1	DN	PMID25553724-Compound-WO2013082253 32
DMXYSO1	HS	Patented
DMXYSO1	CP	REVERAGEN BIOPHARMA, INC

DMR1YH9	ID	DMR1YH9
DMR1YH9	DN	PMID25553724-Compound-WO2013082253 33
DMR1YH9	HS	Patented
DMR1YH9	CP	REVERAGEN BIOPHARMA, INC

DML1U69	ID	DML1U69
DML1U69	DN	PMID25553724-Compound-WO2013082253 34
DML1U69	HS	Patented
DML1U69	CP	REVERAGEN BIOPHARMA, INC

DMA2IMQ	ID	DMA2IMQ
DMA2IMQ	DN	PMID25623274-Compound-WO2014132220C1
DMA2IMQ	HS	Patented
DMA2IMQ	CP	NOVARTIS AG BRUCE, Ian CHAMOIN, Sylvie COLLINGWOOD, Stephen Paul FURET, Pascal FURMINGER, Vikki LEWIS, Sarah LOREN, Jon LV, Lin MOLTENI, Valentina SAUNDERS, Alex Michael SHAW, Duncan TURNER, Roy YEH, Vince
DMA2IMQ	DT	Small molecular drug
DMA2IMQ	DE	Pulmonary arterial hypertension

DMXEZWP	ID	DMXEZWP
DMXEZWP	DN	PMID25623274-Compound-WO2014132220C2
DMXEZWP	HS	Patented
DMXEZWP	CP	NOVARTIS AG BRUCE, Ian CHAMOIN, Sylvie COLLINGWOOD, Stephen Paul FURET, Pascal FURMINGER, Vikki LEWIS, Sarah LOREN, Jon LV, Lin MOLTENI, Valentina SAUNDERS, Alex Michael SHAW, Duncan TURNER, Roy YEH, Vince
DMXEZWP	DT	Small molecular drug
DMXEZWP	DE	Pulmonary arterial hypertension

DM8POGS	ID	DM8POGS
DM8POGS	DN	PMID25656651-Compound-10
DM8POGS	HS	Patented
DM8POGS	CP	IRM LLC DING, Qiang SIM, Tae-bo ZHANG, Guobao ADRIAN, Francisco GRAY, Nathanael, S
DM8POGS	DT	Small molecular drug
DM8POGS	PC	44129660
DM8POGS	MW	418.4
DM8POGS	FM	C20H17F3N4O3
DM8POGS	IC	InChI=1S/C20H17F3N4O3/c21-20(22,23)30-16-6-4-15(5-7-16)27-18-11-17(25-12-26-18)13-2-1-3-14(10-13)19(29)24-8-9-28/h1-7,10-12,28H,8-9H2,(H,24,29)(H,25,26,27)
DM8POGS	CS	C1=CC(=CC(=C1)C(=O)NCCO)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F
DM8POGS	IK	IIQUYGWWHIHOCF-UHFFFAOYSA-N
DM8POGS	IU	N-(2-hydroxyethyl)-3-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]benzamide
DM8POGS	CA	CAS 778277-15-9

DM5ECH2	ID	DM5ECH2
DM5ECH2	DN	PMID25656651-Compound-11a
DM5ECH2	HS	Patented
DM5ECH2	CP	CURIS, INC
DM5ECH2	DT	Small molecular drug
DM5ECH2	PC	24756907
DM5ECH2	MW	547.1
DM5ECH2	FM	C24H31ClN8O3S
DM5ECH2	IC	InChI=1S/C24H31ClN8O3S/c1-15-7-6-8-17(25)22(15)32-23(35)18-14-28-24(37-18)31-20-13-19(29-16(2)30-20)27-12-11-26-10-5-3-4-9-21(34)33-36/h6-8,13-14,26,36H,3-5,9-12H2,1-2H3,(H,32,35)(H,33,34)(H2,27,28,29,30,31)
DM5ECH2	CS	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)NCCNCCCCCC(=O)NO)C
DM5ECH2	IK	FVPJJDVBEPNQCD-UHFFFAOYSA-N
DM5ECH2	IU	N-(2-chloro-6-methylphenyl)-2-[[6-[2-[[6-(hydroxyamino)-6-oxohexyl]amino]ethylamino]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DM5ECH2	DE	Chronic myeloid leukaemia

DMP580J	ID	DMP580J
DMP580J	DN	PMID25656651-Compound-11b
DMP580J	HS	Patented
DMP580J	CP	CURIS, INC
DMP580J	DT	Small molecular drug
DMP580J	DE	Chronic myeloid leukaemia

DMAYINQ	ID	DMAYINQ
DMAYINQ	DN	PMID25656651-Compound-11c
DMAYINQ	HS	Patented
DMAYINQ	CP	CURIS, INC
DMAYINQ	DT	Small molecular drug
DMAYINQ	PC	24856901
DMAYINQ	MW	518
DMAYINQ	FM	C23H28ClN7O3S
DMAYINQ	IC	InChI=1S/C23H28ClN7O3S/c1-14-8-7-9-16(24)21(14)30-22(33)17-13-26-23(35-17)29-19-12-18(27-15(2)28-19)25-11-6-4-3-5-10-20(32)31-34/h7-9,12-13,34H,3-6,10-11H2,1-2H3,(H,30,33)(H,31,32)(H2,25,26,27,28,29)
DMAYINQ	CS	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)NCCCCCCC(=O)NO)C
DMAYINQ	IK	UHHSKEMLNIATAI-UHFFFAOYSA-N
DMAYINQ	IU	N-(2-chloro-6-methylphenyl)-2-[[6-[[7-(hydroxyamino)-7-oxoheptyl]amino]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DMAYINQ	DE	Chronic myeloid leukaemia

DM0C9YL	ID	DM0C9YL
DM0C9YL	DN	PMID25656651-Compound-15a
DM0C9YL	HS	Patented
DM0C9YL	DT	Small molecular drug
DM0C9YL	PC	25156740
DM0C9YL	MW	580.6
DM0C9YL	FM	C32H23F3N6O2
DM0C9YL	IC	InChI=1S/C32H23F3N6O2/c1-20-18-41(19-38-20)24-15-22(32(33,34)35)14-23(16-24)39-31(42)28-6-4-5-21-13-25(8-9-27(21)28)43-26-10-12-37-30(17-26)40-29-7-2-3-11-36-29/h2-19H,1H3,(H,39,42)(H,36,37,40)
DM0C9YL	CS	CC1=CN(C=N1)C2=CC(=CC(=C2)NC(=O)C3=CC=CC4=C3C=CC(=C4)OC5=CC(=NC=C5)NC6=CC=CC=N6)C(F)(F)F
DM0C9YL	IK	YLFSQHDNZXYOOB-UHFFFAOYSA-N
DM0C9YL	IU	N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-6-[2-(pyridin-2-ylamino)pyridin-4-yl]oxynaphthalene-1-carboxamide

DMJ4DRI	ID	DMJ4DRI
DMJ4DRI	DN	PMID25656651-Compound-15b
DMJ4DRI	HS	Patented
DMJ4DRI	DT	Small molecular drug
DMJ4DRI	PC	59314436
DMJ4DRI	MW	571.5
DMJ4DRI	FM	C31H24F3N5O3
DMJ4DRI	IC	InChI=1S/C31H24F3N5O3/c1-17-36-16-27(37-17)20-11-21(31(32,33)34)14-22(12-20)38-30(41)26-4-2-3-19-13-23(7-8-25(19)26)42-24-9-10-35-28(15-24)39-29(40)18-5-6-18/h2-4,7-16,18H,5-6H2,1H3,(H,36,37)(H,38,41)(H,35,39,40)
DMJ4DRI	CS	CC1=NC=C(N1)C2=CC(=CC(=C2)NC(=O)C3=CC=CC4=C3C=CC(=C4)OC5=CC(=NC=C5)NC(=O)C6CC6)C(F)(F)F
DMJ4DRI	IK	LFBDVPDAUGENGX-UHFFFAOYSA-N
DMJ4DRI	IU	6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(2-methyl-1H-imidazol-5-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide

DMNK2DQ	ID	DMNK2DQ
DMNK2DQ	DN	PMID25656651-Compound-15c
DMNK2DQ	HS	Patented
DMNK2DQ	DT	Small molecular drug

DM9XRYU	ID	DM9XRYU
DM9XRYU	DN	PMID25656651-Compound-16a
DM9XRYU	HS	Patented
DM9XRYU	CP	NATCO PHARMA LIMITED KOMPELLA, Amala, Kishan RACHAKONDA, Sreenivas ADIBHATLA KALISATYA, Bhujanga, Rao VENKAIAH CHOWDARY, Nannapanen
DM9XRYU	DT	Small molecular drug
DM9XRYU	PC	11562629
DM9XRYU	MW	517.4
DM9XRYU	FM	C25H17F6N5O
DM9XRYU	IC	InChI=1S/C25H17F6N5O/c1-14-4-5-19(12-21(14)36-23-33-8-6-20(35-23)15-3-2-7-32-13-15)34-22(37)16-9-17(24(26,27)28)11-18(10-16)25(29,30)31/h2-13H,1H3,(H,34,37)(H,33,35,36)
DM9XRYU	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)NC3=NC=CC(=N3)C4=CN=CC=C4
DM9XRYU	IK	LCPGCGAJBOWMIP-UHFFFAOYSA-N
DM9XRYU	IU	N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3,5-bis(trifluoromethyl)benzamide
DM9XRYU	CA	CAS 879507-25-2

DM5EHK2	ID	DM5EHK2
DM5EHK2	DN	PMID25656651-Compound-16b
DM5EHK2	HS	Patented
DM5EHK2	CP	NATCO PHARMA LIMITED KOMPELLA, Amala, Kishan RACHAKONDA, Sreenivas ADIBHATLA KALISATYA, Bhujanga, Rao VENKAIAH CHOWDARY, Nannapanen
DM5EHK2	DT	Small molecular drug
DM5EHK2	PC	11548024
DM5EHK2	MW	513.5
DM5EHK2	FM	C24H18F3N5O3S
DM5EHK2	IC	InChI=1S/C24H18F3N5O3S/c1-15-7-8-18(30-22(33)16-4-2-6-19(12-16)36(34,35)24(25,26)27)13-21(15)32-23-29-11-9-20(31-23)17-5-3-10-28-14-17/h2-14H,1H3,(H,30,33)(H,29,31,32)
DM5EHK2	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)S(=O)(=O)C(F)(F)F)NC3=NC=CC(=N3)C4=CN=CC=C4
DM5EHK2	IK	SCDUZEXJWFANOL-UHFFFAOYSA-N
DM5EHK2	IU	N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethylsulfonyl)benzamide

DMAIVEN	ID	DMAIVEN
DMAIVEN	DN	PMID25656651-Compound-18
DMAIVEN	HS	Patented
DMAIVEN	CP	IRM LLC HUANG, Shenlin LIU, Zuosheng ALBAUGH, Pamela, A. WANG, Xing PAN, Shifeng XIE, Yongping ZHANG, Guobao
DMAIVEN	DT	Small molecular drug
DMAIVEN	PC	25110837
DMAIVEN	MW	468.4
DMAIVEN	FM	C22H19F3N8O
DMAIVEN	IC	InChI=1S/C22H19F3N8O/c1-13-6-7-16(31-20(34)14-4-3-5-15(8-14)22(23,24)25)9-17(13)32-21-29-12-30-33(21)19-10-18(26-2)27-11-28-19/h3-12H,1-2H3,(H,31,34)(H,26,27,28)(H,29,30,32)
DMAIVEN	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)NC3=NC=NN3C4=NC=NC(=C4)NC
DMAIVEN	IK	ZHABTPLXVWUNPN-UHFFFAOYSA-N
DMAIVEN	IU	N-[4-methyl-3-[[2-[6-(methylamino)pyrimidin-4-yl]-1,2,4-triazol-3-yl]amino]phenyl]-3-(trifluoromethyl)benzamide

DMSNUVZ	ID	DMSNUVZ
DMSNUVZ	DN	PMID25656651-Compound-19a
DMSNUVZ	HS	Patented
DMSNUVZ	CP	4SC AG [DE]
DMSNUVZ	DT	Small molecular drug
DMSNUVZ	PC	42613483
DMSNUVZ	MW	471.5
DMSNUVZ	FM	C25H21N5O3S
DMSNUVZ	IC	InChI=1S/C25H21N5O3S/c1-16-4-10-20(27-24(32)18-8-5-17(6-9-18)7-11-23(31)30-33)13-21(16)28-25-29-22(15-34-25)19-3-2-12-26-14-19/h2-15,33H,1H3,(H,27,32)(H,28,29)(H,30,31)/b11-7+
DMSNUVZ	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)/C=C/C(=O)NO)NC3=NC(=CS3)C4=CN=CC=C4
DMSNUVZ	IK	OINCRSHJNMRVSX-YRNVUSSQSA-N
DMSNUVZ	IU	4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide

DMI1Z7D	ID	DMI1Z7D
DMI1Z7D	DN	PMID25656651-Compound-19b
DMI1Z7D	HS	Patented
DMI1Z7D	CP	4SC AG [DE]
DMI1Z7D	DT	Small molecular drug
DMI1Z7D	PC	42626200
DMI1Z7D	MW	477.6
DMI1Z7D	FM	C23H19N5O3S2
DMI1Z7D	IC	InChI=1S/C23H19N5O3S2/c1-14-4-5-16(25-22(30)20-8-6-17(33-20)7-9-21(29)28-31)11-18(14)26-23-27-19(13-32-23)15-3-2-10-24-12-15/h2-13,31H,1H3,(H,25,30)(H,26,27)(H,28,29)/b9-7+
DMI1Z7D	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(S2)/C=C/C(=O)NO)NC3=NC(=CS3)C4=CN=CC=C4
DMI1Z7D	IK	DFZFLIGZEDFNOL-VQHVLOKHSA-N
DMI1Z7D	IU	5-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]thiophene-2-carboxamide

DM7R2X0	ID	DM7R2X0
DM7R2X0	DN	PMID25656651-Compound-20a
DM7R2X0	HS	Patented
DM7R2X0	CP	IRM LLC DING, Qiang SIM, Tae-bo ZHANG, Guobao ADRIAN, Francisco GRAY, Nathanael, S
DM7R2X0	DT	Small molecular drug
DM7R2X0	PC	49782106
DM7R2X0	MW	386.3
DM7R2X0	FM	C18H13F3N6O
DM7R2X0	IC	InChI=1S/C18H13F3N6O/c19-18(20,21)28-14-5-3-13(4-6-14)26-16-15-9-25-27(17(15)24-11-23-16)10-12-2-1-7-22-8-12/h1-9,11H,10H2,(H,23,24,26)
DM7R2X0	CS	C1=CC(=CN=C1)CN2C3=NC=NC(=C3C=N2)NC4=CC=C(C=C4)OC(F)(F)F
DM7R2X0	IK	JOLSWPYDQLCFEP-UHFFFAOYSA-N
DM7R2X0	IU	1-(pyridin-3-ylmethyl)-N-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-d]pyrimidin-4-amine

DMLUFB2	ID	DMLUFB2
DMLUFB2	DN	PMID25656651-Compound-20b
DMLUFB2	HS	Patented
DMLUFB2	CP	IRM LLC DING, Qiang SIM, Tae-bo ZHANG, Guobao ADRIAN, Francisco GRAY, Nathanael, S
DMLUFB2	DT	Small molecular drug
DMLUFB2	PC	42628828
DMLUFB2	MW	424.4
DMLUFB2	FM	C18H15F3N4O3S
DMLUFB2	IC	InChI=1S/C18H15F3N4O3S/c1-29(26,27)25-14-4-2-12(3-5-14)16-10-17(23-11-22-16)24-13-6-8-15(9-7-13)28-18(19,20)21/h2-11,25H,1H3,(H,22,23,24)
DMLUFB2	CS	CS(=O)(=O)NC1=CC=C(C=C1)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F
DMLUFB2	IK	IQTSERMRWSERDI-UHFFFAOYSA-N
DMLUFB2	IU	N-[4-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]phenyl]methanesulfonamide

DMCKAON	ID	DMCKAON
DMCKAON	DN	PMID25656651-Compound-21a
DMCKAON	HS	Patented
DMCKAON	CP	SUN PHARMA ADVANCED RESEARCH COMPANY LTD., SENGUPTA, Prabal PURI, Chetan Surjitsingh CHOKSHI, Hemantkumar CHITTURI, Trinadha Rao THENNATI, Rajamannar
DMCKAON	DT	Small molecular drug
DMCKAON	PC	44225624
DMCKAON	MW	472.9
DMCKAON	FM	C25H21ClN6O2
DMCKAON	IC	InChI=1S/C25H21ClN6O2/c1-15-8-9-17(23(33)31-32-24(34)22-16(2)5-3-7-19(22)26)13-21(15)30-25-28-12-10-20(29-25)18-6-4-11-27-14-18/h3-14H,1-2H3,(H,31,33)(H,32,34)(H,28,29,30)
DMCKAON	CS	CC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)NC3=NC=CC(=N3)C4=CN=CC=C4
DMCKAON	IK	RCYQHUIWHIZRQI-UHFFFAOYSA-N
DMCKAON	IU	2-chloro-6-methyl-N'-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzoyl]benzohydrazide

DMVABXI	ID	DMVABXI
DMVABXI	DN	PMID25656651-Compound-21b
DMVABXI	HS	Patented
DMVABXI	CP	SUN PHARMA ADVANCED RESEARCH COMPANY LTD., SENGUPTA, Prabal PURI, Chetan Surjitsingh CHOKSHI, Hemantkumar CHITTURI, Trinadha Rao THENNATI, Rajamannar
DMVABXI	DT	Small molecular drug
DMVABXI	PC	44227512
DMVABXI	MW	564.4
DMVABXI	FM	C25H21IN6O2
DMVABXI	IC	InChI=1S/C25H21IN6O2/c1-15-8-9-17(23(33)31-32-24(34)22-16(2)5-3-7-19(22)26)13-21(15)30-25-28-12-10-20(29-25)18-6-4-11-27-14-18/h3-14H,1-2H3,(H,31,33)(H,32,34)(H,28,29,30)
DMVABXI	CS	CC1=C(C(=CC=C1)I)C(=O)NNC(=O)C2=CC(=C(C=C2)C)NC3=NC=CC(=N3)C4=CN=CC=C4
DMVABXI	IK	KRUFMIXJJSFERC-UHFFFAOYSA-N
DMVABXI	IU	2-iodo-6-methyl-N'-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzoyl]benzohydrazide

DMZUB3D	ID	DMZUB3D
DMZUB3D	DN	PMID25656651-Compound-23a
DMZUB3D	HS	Patented
DMZUB3D	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA DAR, Arvin SHOKAT, Kevan M
DMZUB3D	DT	Small molecular drug
DMZUB3D	PC	25011745
DMZUB3D	MW	455.4
DMZUB3D	FM	C22H20F3N7O
DMZUB3D	IC	InChI=1S/C22H20F3N7O/c1-12(2)32-20-17(19(26)27-11-28-20)18(31-32)13-6-8-15(9-7-13)29-21(33)30-16-5-3-4-14(10-16)22(23,24)25/h3-12H,1-2H3,(H2,26,27,28)(H2,29,30,33)
DMZUB3D	CS	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F)N
DMZUB3D	IK	LEERPLGXOHLQPF-UHFFFAOYSA-N
DMZUB3D	IU	1-[4-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea

DMTOFGH	ID	DMTOFGH
DMTOFGH	DN	PMID25656651-Compound-23b
DMTOFGH	HS	Patented
DMTOFGH	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA DAR, Arvin SHOKAT, Kevan M
DMTOFGH	DT	Small molecular drug
DMTOFGH	PC	45381436
DMTOFGH	MW	523.5
DMTOFGH	FM	C26H24F3N7O2
DMTOFGH	IC	InChI=1S/C26H24F3N7O2/c1-14(2)36-23-20(22(30-13-31-23)34-24(37)16-6-7-16)21(35-36)15-8-10-18(11-9-15)32-25(38)33-19-5-3-4-17(12-19)26(27,28)29/h3-5,8-14,16H,6-7H2,1-2H3,(H2,32,33,38)(H,30,31,34,37)
DMTOFGH	CS	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F)NC(=O)C5CC5
DMTOFGH	IK	UNZJMBBOGIRTFD-UHFFFAOYSA-N
DMTOFGH	IU	N-[1-propan-2-yl-3-[4-[[3-(trifluoromethyl)phenyl]carbamoylamino]phenyl]pyrazolo[3,4-d]pyrimidin-4-yl]cyclopropanecarboxamide

DMLTR9E	ID	DMLTR9E
DMLTR9E	DN	PMID25656651-Compound-23c
DMLTR9E	HS	Patented
DMLTR9E	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA DAR, Arvin SHOKAT, Kevan M
DMLTR9E	DT	Small molecular drug
DMLTR9E	PC	45381323
DMLTR9E	MW	551.6
DMLTR9E	FM	C28H28F3N7O2
DMLTR9E	IC	InChI=1S/C28H28F3N7O2/c1-16(2)38-25-22(24(32-15-33-25)36-26(39)18-6-3-4-7-18)23(37-38)17-10-12-20(13-11-17)34-27(40)35-21-9-5-8-19(14-21)28(29,30)31/h5,8-16,18H,3-4,6-7H2,1-2H3,(H2,34,35,40)(H,32,33,36,39)
DMLTR9E	CS	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F)NC(=O)C5CCCC5
DMLTR9E	IK	HXLONDQXUGAZKS-UHFFFAOYSA-N
DMLTR9E	IU	N-[1-propan-2-yl-3-[4-[[3-(trifluoromethyl)phenyl]carbamoylamino]phenyl]pyrazolo[3,4-d]pyrimidin-4-yl]cyclopentanecarboxamide

DMAYSNQ	ID	DMAYSNQ
DMAYSNQ	DN	PMID25656651-Compound-25
DMAYSNQ	HS	Patented
DMAYSNQ	CP	SYNTECH SOLUTION LLC CHEN, Yongsheng
DMAYSNQ	DT	Small molecular drug
DMAYSNQ	PC	46861598
DMAYSNQ	MW	555.6
DMAYSNQ	FM	C30H24F3N7O
DMAYSNQ	IC	InChI=1S/C30H24F3N7O/c1-18-4-5-20(11-26(18)39-29-35-10-8-25(38-29)21-3-2-9-34-15-21)28(41)37-23-12-22(30(31,32)33)13-24(14-23)40-16-27(36-17-40)19-6-7-19/h2-5,8-17,19H,6-7H2,1H3,(H,37,41)(H,35,38,39)
DMAYSNQ	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C4CC4)NC5=NC=CC(=N5)C6=CN=CC=C6
DMAYSNQ	IK	GKVZSPCAKFODTN-UHFFFAOYSA-N
DMAYSNQ	IU	N-[3-(4-cyclopropylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide

DMXM98J	ID	DMXM98J
DMXM98J	DN	PMID25656651-Compound-26a
DMXM98J	HS	Patented
DMXM98J	DT	Small molecular drug
DMXM98J	PC	46928937
DMXM98J	MW	420.4
DMXM98J	FM	C22H15F3N6
DMXM98J	IC	InChI=1S/C22H15F3N6/c23-22(24,25)14-4-1-3-13(9-14)10-28-21-29-11-17-15-6-8-26-12-18(15)30-20-16(19(17)31-21)5-2-7-27-20/h1-9,11-12H,10H2,(H,27,30)(H,28,29,31)
DMXM98J	CS	C1=CC(=CC(=C1)C(F)(F)F)CNC2=NC=C3C4=C(C=NC=C4)NC5=C(C3=N2)C=CC=N5
DMXM98J	IK	BJNZVGIKBDSXJO-UHFFFAOYSA-N
DMXM98J	IU	N-[[3-(trifluoromethyl)phenyl]methyl]-3,5,11,14,16-pentazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),2,4,6,8(13),9,11,16,18-nonaen-4-amine

DMWG95Z	ID	DMWG95Z
DMWG95Z	DN	PMID25656651-Compound-26b
DMWG95Z	HS	Patented
DMWG95Z	DT	Small molecular drug
DMWG95Z	PC	46929350
DMWG95Z	MW	386.8
DMWG95Z	FM	C21H15ClN6
DMWG95Z	IC	InChI=1S/C21H15ClN6/c22-14-5-3-13(4-6-14)10-25-21-26-11-17-15-7-9-23-12-18(15)27-20-16(19(17)28-21)2-1-8-24-20/h1-9,11-12H,10H2,(H,24,27)(H,25,26,28)
DMWG95Z	CS	C1=CC2=C(NC3=C(C=CN=C3)C4=CN=C(N=C24)NCC5=CC=C(C=C5)Cl)N=C1
DMWG95Z	IK	PBJUHSSYAPBPIB-UHFFFAOYSA-N
DMWG95Z	IU	N-[(4-chlorophenyl)methyl]-3,5,11,14,16-pentazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),2,4,6,8(13),9,11,16,18-nonaen-4-amine

DMR7A58	ID	DMR7A58
DMR7A58	DN	PMID25656651-Compound-26c
DMR7A58	HS	Patented
DMR7A58	DT	Small molecular drug
DMR7A58	PC	46909564
DMR7A58	MW	388.4
DMR7A58	FM	C21H14F2N6
DMR7A58	IC	InChI=1S/C21H14F2N6/c22-16-4-3-12(8-17(16)23)9-26-21-27-10-15-13-5-7-24-11-18(13)28-20-14(19(15)29-21)2-1-6-25-20/h1-8,10-11H,9H2,(H,25,28)(H,26,27,29)
DMR7A58	CS	C1=CC2=C(NC3=C(C=CN=C3)C4=CN=C(N=C24)NCC5=CC(=C(C=C5)F)F)N=C1
DMR7A58	IK	HIVDOLJVFRYLKP-UHFFFAOYSA-N
DMR7A58	IU	N-[(3,4-difluorophenyl)methyl]-3,5,11,14,16-pentazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),2,4,6,8(13),9,11,16,18-nonaen-4-amine

DMXK43O	ID	DMXK43O
DMXK43O	DN	PMID25656651-Compound-27
DMXK43O	HS	Patented
DMXK43O	DT	Small molecular drug

DM06LDV	ID	DM06LDV
DM06LDV	DN	PMID25656651-Compound-28a
DM06LDV	HS	Patented
DM06LDV	CP	ZHANG, Dawei
DM06LDV	DT	Small molecular drug
DM06LDV	PC	49872881
DM06LDV	MW	593.6
DM06LDV	FM	C31H31F4N7O
DM06LDV	IC	InChI=1S/C31H31F4N7O/c1-3-41-11-13-42(14-12-41)19-23-7-6-21(15-25(23)31(33,34)35)29(43)38-24-16-26(32)20(2)28(17-24)40-30-37-10-8-27(39-30)22-5-4-9-36-18-22/h4-10,15-18H,3,11-14,19H2,1-2H3,(H,38,43)(H,37,39,40)
DM06LDV	CS	CCN1CCN(CC1)CC2=C(C=C(C=C2)C(=O)NC3=CC(=C(C(=C3)F)C)NC4=NC=CC(=N4)C5=CN=CC=C5)C(F)(F)F
DM06LDV	IK	CQBGILGFZXYQMT-UHFFFAOYSA-N
DM06LDV	IU	4-[(4-ethylpiperazin-1-yl)methyl]-N-[3-fluoro-4-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide

DMKB7XV	ID	DMKB7XV
DMKB7XV	DN	PMID25656651-Compound-28b
DMKB7XV	HS	Patented
DMKB7XV	CP	ZHANG, Dawei
DMKB7XV	DT	Small molecular drug
DMKB7XV	PC	49872974
DMKB7XV	MW	511.6
DMKB7XV	FM	C29H30FN7O
DMKB7XV	IC	InChI=1S/C29H30FN7O/c1-20-25(30)16-24(17-27(20)35-29-32-11-9-26(34-29)23-4-3-10-31-18-23)33-28(38)22-7-5-21(6-8-22)19-37-14-12-36(2)13-15-37/h3-11,16-18H,12-15,19H2,1-2H3,(H,33,38)(H,32,34,35)
DMKB7XV	CS	CC1=C(C=C(C=C1F)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DMKB7XV	IK	ZRPUCWORBBVKGL-UHFFFAOYSA-N
DMKB7XV	IU	N-[3-fluoro-4-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide

DMCEST4	ID	DMCEST4
DMCEST4	DN	PMID25656651-Compound-29a
DMCEST4	HS	Patented
DMCEST4	CP	HANMI SCIENCE CO., LTD. KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION SON, Jung Beom JUNG, Seung Hyun CHOI, Wha Il JUNG, Young Hee CHOI, Jae Yul SONG, Ji Yeon LEE, Kyu Hang LEE, Jae Chul KIM, Eun Young AHN, Young Gil KIM, Maeng Sup CHOI, Hwan Geun SIM, Tae Bo HAM, Young Jin PARK, Dong-sik KIM, Hwan KIM, Dong-Wook
DMCEST4	DT	Small molecular drug
DMCEST4	PC	53345642
DMCEST4	MW	556.7
DMCEST4	FM	C29H32N8O2S
DMCEST4	IC	InChI=1S/C29H32N8O2S/c1-3-36-10-12-37(13-11-36)24-9-8-21(15-30-24)34-28(38)19-5-4-18(2)23(14-19)35-29(39)22-16-40-26-25(22)31-17-32-27(26)33-20-6-7-20/h4-5,8-9,14-17,20H,3,6-7,10-13H2,1-2H3,(H,34,38)(H,35,39)(H,31,32,33)
DMCEST4	CS	CCN1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)NC(=O)C4=CSC5=C4N=CN=C5NC6CC6
DMCEST4	IK	VVZVKYOPIITGGL-UHFFFAOYSA-N
DMCEST4	IU	4-(cyclopropylamino)-N-[5-[[6-(4-ethylpiperazin-1-yl)pyridin-3-yl]carbamoyl]-2-methylphenyl]thieno[3,2-d]pyrimidine-7-carboxamide

DMBKRY7	ID	DMBKRY7
DMBKRY7	DN	PMID25656651-Compound-29b
DMBKRY7	HS	Patented
DMBKRY7	CP	HANMI SCIENCE CO., LTD. KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION SON, Jung Beom JUNG, Seung Hyun CHOI, Wha Il JUNG, Young Hee CHOI, Jae Yul SONG, Ji Yeon LEE, Kyu Hang LEE, Jae Chul KIM, Eun Young AHN, Young Gil KIM, Maeng Sup CHOI, Hwan Geun SIM, Tae Bo HAM, Young Jin PARK, Dong-sik KIM, Hwan KIM, Dong-Wook
DMBKRY7	DT	Small molecular drug
DMBKRY7	PC	53345434
DMBKRY7	MW	515.6
DMBKRY7	FM	C26H22FN7O2S
DMBKRY7	IC	InChI=1S/C26H22FN7O2S/c1-14-3-8-18(10-20(14)32-25(35)19-12-37-23-22(19)29-13-30-24(23)28)31-26(36)21-9-15(2)33-34(21)11-16-4-6-17(27)7-5-16/h3-10,12-13H,11H2,1-2H3,(H,31,36)(H,32,35)(H2,28,29,30)
DMBKRY7	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=NN2CC3=CC=C(C=C3)F)C)NC(=O)C4=CSC5=C4N=CN=C5N
DMBKRY7	IK	XYZZDCAVPVYIRF-UHFFFAOYSA-N
DMBKRY7	IU	4-amino-N-[5-[[2-[(4-fluorophenyl)methyl]-5-methylpyrazole-3-carbonyl]amino]-2-methylphenyl]thieno[3,2-d]pyrimidine-7-carboxamide

DMVMSQ2	ID	DMVMSQ2
DMVMSQ2	DN	PMID25656651-Compound-30a
DMVMSQ2	HS	Patented
DMVMSQ2	CP	PIRAMAL HEALTHCARE LIMITED SIVAKUMAR, Meenakshi JOSHI, Kalpana Sanjay AWARE, Valmik Sopan SARDE, Ankush Gangaram BAGUL, Sandeep Mukunda MANOHAR, Sonal Mohan
DMVMSQ2	DT	Small molecular drug
DMVMSQ2	PC	135565531
DMVMSQ2	MW	246.26
DMVMSQ2	FM	C13H14N2O3
DMVMSQ2	IC	InChI=1S/C13H14N2O3/c1-2-3-12-14-13(18-15-12)7-5-9-4-6-10(16)11(17)8-9/h4-8,16-17H,2-3H2,1H3/b7-5+
DMVMSQ2	CS	CCCC1=NOC(=N1)/C=C/C2=CC(=C(C=C2)O)O
DMVMSQ2	IK	MAWOOXDYMFRJNN-FNORWQNLSA-N
DMVMSQ2	IU	4-[(E)-2-(3-propyl-1,2,4-oxadiazol-5-yl)ethenyl]benzene-1,2-diol
DMVMSQ2	CA	CAS 1332498-21-1

DMEJMPD	ID	DMEJMPD
DMEJMPD	DN	PMID25656651-Compound-30b
DMEJMPD	HS	Patented
DMEJMPD	CP	PIRAMAL HEALTHCARE LIMITED SIVAKUMAR, Meenakshi JOSHI, Kalpana Sanjay AWARE, Valmik Sopan SARDE, Ankush Gangaram BAGUL, Sandeep Mukunda MANOHAR, Sonal Mohan
DMEJMPD	DT	Small molecular drug
DMEJMPD	PC	136344503
DMEJMPD	MW	294.3
DMEJMPD	FM	C17H14N2O3
DMEJMPD	IC	InChI=1S/C17H14N2O3/c20-14-8-6-13(10-15(14)21)7-9-17-18-16(19-22-17)11-12-4-2-1-3-5-12/h1-10,20-21H,11H2/b9-7+
DMEJMPD	CS	C1=CC=C(C=C1)CC2=NOC(=N2)/C=C/C3=CC(=C(C=C3)O)O
DMEJMPD	IK	BJLAYSATLVCCDW-VQHVLOKHSA-N
DMEJMPD	IU	4-[(E)-2-(3-benzyl-1,2,4-oxadiazol-5-yl)ethenyl]benzene-1,2-diol

DMSVQMO	ID	DMSVQMO
DMSVQMO	DN	PMID25656651-Compound-31a
DMSVQMO	HS	Patented
DMSVQMO	CP	NOVARTIS AG BURGER, Matthew DING, Yu HAN, Wooseok LINDVALL, Mika NISHIGUCHI, Gisele A. RICO, Alice SMITH, Aaron TANNER, Huw WAN, Lifeng
DMSVQMO	DT	Small molecular drug
DMSVQMO	PC	56599744
DMSVQMO	MW	429.5
DMSVQMO	FM	C24H23N5O3
DMSVQMO	IC	InChI=1S/C24H23N5O3/c1-14-19(30)11-20(32-24(14)8-9-24)16-7-10-26-12-18(16)29-23(31)21-22(25)27-13-17(28-21)15-5-3-2-4-6-15/h2-7,10,12-13,19-20,30H,1,8-9,11H2,(H2,25,27)(H,29,31)/t19-,20-/m0/s1
DMSVQMO	CS	C=C1[C@H](C[C@H](OC12CC2)C3=C(C=NC=C3)NC(=O)C4=NC(=CN=C4N)C5=CC=CC=C5)O
DMSVQMO	IK	WHESOVNDWAKAQI-PMACEKPBSA-N
DMSVQMO	IU	3-amino-N-[4-[(5S,7S)-7-hydroxy-8-methylidene-4-oxaspiro[2.5]octan-5-yl]pyridin-3-yl]-6-phenylpyrazine-2-carboxamide

DM6TGUR	ID	DM6TGUR
DM6TGUR	DN	PMID25656651-Compound-31b
DM6TGUR	HS	Patented
DM6TGUR	CP	NOVARTIS AG BURGER, Matthew DING, Yu HAN, Wooseok LINDVALL, Mika NISHIGUCHI, Gisele A. RICO, Alice SMITH, Aaron TANNER, Huw WAN, Lifeng
DM6TGUR	DT	Small molecular drug

DMDJGPC	ID	DMDJGPC
DMDJGPC	DN	PMID25656651-Compound-31c
DMDJGPC	HS	Patented
DMDJGPC	CP	NOVARTIS AG BURGER, Matthew DING, Yu HAN, Wooseok LINDVALL, Mika NISHIGUCHI, Gisele A. RICO, Alice SMITH, Aaron TANNER, Huw WAN, Lifeng
DMDJGPC	DT	Small molecular drug
DMDJGPC	PC	89534789
DMDJGPC	MW	461.5
DMDJGPC	FM	C25H27N5O4
DMDJGPC	IC	InChI=1S/C25H27N5O4/c26-23-22(29-17(14-28-23)15-6-2-1-3-7-15)24(32)30-18-13-27-11-9-16(18)19-12-20(31)25(33)10-5-4-8-21(25)34-19/h1-3,6-7,9,11,13-14,19-21,31,33H,4-5,8,10,12H2,(H2,26,28)(H,30,32)/t19-,20-,21-,25+/m1/s1
DMDJGPC	CS	C1CC[C@]2([C@@H](C1)O[C@H](C[C@H]2O)C3=C(C=NC=C3)NC(=O)C4=NC(=CN=C4N)C5=CC=CC=C5)O
DMDJGPC	IK	MHELWFWYAKEXOQ-YCFYUYSTSA-N
DMDJGPC	IU	N-[4-[(2R,4R,4aS,8aR)-4,4a-dihydroxy-2,3,4,5,6,7,8,8a-octahydrochromen-2-yl]pyridin-3-yl]-3-amino-6-phenylpyrazine-2-carboxamide

DMCRA2U	ID	DMCRA2U
DMCRA2U	DN	PMID25656651-Compound-33a
DMCRA2U	HS	Patented
DMCRA2U	CP	PF MEDICAMENT [FR]
DMCRA2U	DT	Small molecular drug
DMCRA2U	PC	57521300
DMCRA2U	MW	579.7
DMCRA2U	FM	C29H31F2N7O2S
DMCRA2U	IC	InChI=1S/C29H31F2N7O2S/c1-37-6-8-38(9-7-37)21-2-3-24(26(15-21)33-20-4-10-40-11-5-20)29(39)34-28-25-16-23(17-32-27(25)35-36-28)41-22-13-18(30)12-19(31)14-22/h2-3,12-17,20,33H,4-11H2,1H3,(H2,32,34,35,36,39)
DMCRA2U	CS	CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=C4C=C(C=NC4=NN3)SC5=CC(=CC(=C5)F)F)NC6CCOCC6
DMCRA2U	IK	DNSGDBHRFQIANM-UHFFFAOYSA-N
DMCRA2U	IU	N-[5-(3,5-difluorophenyl)sulfanyl-2H-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide

DMU8ZI3	ID	DMU8ZI3
DMU8ZI3	DN	PMID25656651-Compound-33b
DMU8ZI3	HS	Patented
DMU8ZI3	CP	PF MEDICAMENT [FR]
DMU8ZI3	DT	Small molecular drug
DMU8ZI3	PC	60143177
DMU8ZI3	MW	561.6
DMU8ZI3	FM	C30H33F2N7O2
DMU8ZI3	IC	InChI=1S/C30H33F2N7O2/c1-38-6-8-39(9-7-38)24-2-3-25(27(17-24)34-23-4-10-41-11-5-23)30(40)35-29-26-15-20(18-33-28(26)36-37-29)12-19-13-21(31)16-22(32)14-19/h2-3,13-18,23,34H,4-12H2,1H3,(H2,33,35,36,37,40)
DMU8ZI3	CS	CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=C4C=C(C=NC4=NN3)CC5=CC(=CC(=C5)F)F)NC6CCOCC6
DMU8ZI3	IK	HHXDZBJLUOYVEU-UHFFFAOYSA-N
DMU8ZI3	IU	N-[5-[(3,5-difluorophenyl)methyl]-2H-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide

DMWOR8B	ID	DMWOR8B
DMWOR8B	DN	PMID25656651-Compound-34a
DMWOR8B	HS	Patented
DMWOR8B	CP	UNIVERSITA' DEGLI STUDI DI PADOVA CHILIN, Adriana MARZARO, Giovanni GUIOTTO, Adriano CONCONI, Maria Teresa CASTAGLIUOLO, Ignazio
DMWOR8B	DT	Small molecular drug

DMBD706	ID	DMBD706
DMBD706	DN	PMID25656651-Compound-34b
DMBD706	HS	Patented
DMBD706	CP	UNIVERSITA' DEGLI STUDI DI PADOVA CHILIN, Adriana MARZARO, Giovanni GUIOTTO, Adriano CONCONI, Maria Teresa CASTAGLIUOLO, Ignazio
DMBD706	DT	Small molecular drug

DMG5I41	ID	DMG5I41
DMG5I41	DN	PMID25656651-Compound-34c
DMG5I41	HS	Patented
DMG5I41	CP	UNIVERSITA' DEGLI STUDI DI PADOVA CHILIN, Adriana MARZARO, Giovanni GUIOTTO, Adriano CONCONI, Maria Teresa CASTAGLIUOLO, Ignazio
DMG5I41	DT	Small molecular drug

DMNXVY9	ID	DMNXVY9
DMNXVY9	DN	PMID25656651-Compound-36a
DMNXVY9	HS	Patented
DMNXVY9	CP	NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
DMNXVY9	DT	Small molecular drug
DMNXVY9	PC	72203009
DMNXVY9	MW	375.8
DMNXVY9	FM	C18H12ClF2N3O2
DMNXVY9	IC	InChI=1S/C18H12ClF2N3O2/c19-18(20,21)26-16-6-4-15(5-7-16)24-17(25)13-3-1-2-12(8-13)14-9-22-11-23-10-14/h1-11H,(H,24,25)
DMNXVY9	CS	C1=CC(=CC(=C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)Cl)C3=CN=CN=C3
DMNXVY9	IK	IEPKEELESQZYDU-UHFFFAOYSA-N
DMNXVY9	IU	N-[4-[chloro(difluoro)methoxy]phenyl]-3-pyrimidin-5-ylbenzamide

DMHYDM7	ID	DMHYDM7
DMHYDM7	DN	PMID25656651-Compound-36b
DMHYDM7	HS	Patented
DMHYDM7	CP	NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
DMHYDM7	DT	Small molecular drug
DMHYDM7	PC	72203013
DMHYDM7	MW	373.3
DMHYDM7	FM	C19H14F3N3O2
DMHYDM7	IC	InChI=1S/C19H14F3N3O2/c1-12-2-3-13(8-17(12)14-9-23-11-24-10-14)18(26)25-15-4-6-16(7-5-15)27-19(20,21)22/h2-11H,1H3,(H,25,26)
DMHYDM7	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)F)C3=CN=CN=C3
DMHYDM7	IK	CHZIAMJENFGBCI-UHFFFAOYSA-N
DMHYDM7	IU	4-methyl-3-pyrimidin-5-yl-N-[4-(trifluoromethoxy)phenyl]benzamide

DMOGKSW	ID	DMOGKSW
DMOGKSW	DN	PMID25656651-Compound-36c
DMOGKSW	HS	Patented
DMOGKSW	CP	NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
DMOGKSW	DT	Small molecular drug
DMOGKSW	PC	72203014
DMOGKSW	MW	361.3
DMOGKSW	FM	C18H14F3N3O2
DMOGKSW	IC	InChI=1S/C18H14F3N3O2/c1-12-2-3-13(10-16(12)24-9-8-22-11-24)17(25)23-14-4-6-15(7-5-14)26-18(19,20)21/h2-11H,1H3,(H,23,25)
DMOGKSW	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)F)N3C=CN=C3
DMOGKSW	IK	VTOBGTLKLODAIL-UHFFFAOYSA-N
DMOGKSW	IU	3-imidazol-1-yl-4-methyl-N-[4-(trifluoromethoxy)phenyl]benzamide

DMKMY4I	ID	DMKMY4I
DMKMY4I	DN	PMID25656651-Compound-36d
DMKMY4I	HS	Patented
DMKMY4I	CP	NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
DMKMY4I	DT	Small molecular drug
DMKMY4I	PC	89906474
DMKMY4I	MW	411.2
DMKMY4I	FM	C17H10Cl2F2N4O2
DMKMY4I	IC	InChI=1S/C17H10Cl2F2N4O2/c18-15-14(11-6-22-9-23-7-11)5-10(8-24-15)16(26)25-12-1-3-13(4-2-12)27-17(19,20)21/h1-9H,(H,25,26)
DMKMY4I	CS	C1=CC(=CC=C1NC(=O)C2=CC(=C(N=C2)Cl)C3=CN=CN=C3)OC(F)(F)Cl
DMKMY4I	IK	BHFPNMRGSVUFLM-UHFFFAOYSA-N
DMKMY4I	IU	6-chloro-N-[4-[chloro(difluoro)methoxy]phenyl]-5-pyrimidin-5-ylpyridine-3-carboxamide

DM0P4F3	ID	DM0P4F3
DM0P4F3	DN	PMID25656651-Compound-37a
DM0P4F3	HS	Patented
DM0P4F3	CP	NOVARTIS AG DODD, Stephanie Kay FURET, Pascal GROTZFELD, Robert Martin JAHNKE, Wolfgang JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph
DM0P4F3	DT	Small molecular drug
DM0P4F3	PC	72544218
DM0P4F3	MW	466.8
DM0P4F3	FM	C21H18ClF3N4O3
DM0P4F3	IC	InChI=1S/C21H18ClF3N4O3/c22-21(24,25)32-15-4-2-13(3-5-15)27-20(31)12-1-6-18(29-8-7-14(30)11-29)16(9-12)19-17(23)10-26-28-19/h1-6,9-10,14,30H,7-8,11H2,(H,26,28)(H,27,31)/t14-/m1/s1
DM0P4F3	CS	C1CN(C[C@@H]1O)C2=C(C=C(C=C2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=C(C=NN4)F
DM0P4F3	IK	XFHOXKYPYFGBCJ-CQSZACIVSA-N
DM0P4F3	IU	N-[4-[chloro(difluoro)methoxy]phenyl]-3-(4-fluoro-1H-pyrazol-5-yl)-4-[(3R)-3-hydroxypyrrolidin-1-yl]benzamide

DMX98YV	ID	DMX98YV
DMX98YV	DN	PMID25656651-Compound-37b
DMX98YV	HS	Patented
DMX98YV	CP	NOVARTIS AG DODD, Stephanie Kay FURET, Pascal GROTZFELD, Robert Martin JAHNKE, Wolfgang JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph
DMX98YV	DT	Small molecular drug
DMX98YV	PC	72545600
DMX98YV	MW	467.8
DMX98YV	FM	C20H17ClF3N5O3
DMX98YV	IC	InChI=1S/C20H17ClF3N5O3/c21-20(23,24)32-14-3-1-12(2-4-14)27-19(31)11-7-15(17-16(22)9-26-28-17)18(25-8-11)29-6-5-13(30)10-29/h1-4,7-9,13,30H,5-6,10H2,(H,26,28)(H,27,31)/t13-/m1/s1
DMX98YV	CS	C1CN(C[C@@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=C(C=NN4)F
DMX98YV	IK	NAXNSUPRCUTVTP-CYBMUJFWSA-N
DMX98YV	IU	N-[4-[chloro(difluoro)methoxy]phenyl]-5-(4-fluoro-1H-pyrazol-5-yl)-6-[(3R)-3-hydroxypyrrolidin-1-yl]pyridine-3-carboxamide

DM684IK	ID	DM684IK
DM684IK	DN	PMID25656651-Compound-37c
DM684IK	HS	Patented
DM684IK	CP	NOVARTIS AG DODD, Stephanie Kay FURET, Pascal GROTZFELD, Robert Martin JAHNKE, Wolfgang JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph
DM684IK	DT	Small molecular drug
DM684IK	PC	72545851
DM684IK	MW	467.8
DM684IK	FM	C20H17ClF3N5O3
DM684IK	IC	InChI=1S/C20H17ClF3N5O3/c21-20(23,24)32-14-3-1-12(2-4-14)27-19(31)11-7-15(17-16(22)9-26-28-17)18(25-8-11)29-6-5-13(30)10-29/h1-4,7-9,13,30H,5-6,10H2,(H,26,28)(H,27,31)/t13-/m0/s1
DM684IK	CS	C1CN(C[C@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=C(C=NN4)F
DM684IK	IK	NAXNSUPRCUTVTP-ZDUSSCGKSA-N
DM684IK	IU	N-[4-[chloro(difluoro)methoxy]phenyl]-5-(4-fluoro-1H-pyrazol-5-yl)-6-[(3S)-3-hydroxypyrrolidin-1-yl]pyridine-3-carboxamide

DMECOY7	ID	DMECOY7
DMECOY7	DN	PMID25656651-Compound-38
DMECOY7	HS	Patented
DMECOY7	CP	ASTAR BIOTECH LLC HUANG, Haihong YU, Chunrong ZHANG, Dongfeng LI, Peng
DMECOY7	DT	Small molecular drug
DMECOY7	PC	72725269
DMECOY7	MW	526.6
DMECOY7	FM	C30H28F2N6O
DMECOY7	IC	InChI=1S/C30H28F2N6O/c1-20-5-6-22(16-21(20)7-9-24-19-33-28-4-3-11-34-38(24)28)29(39)35-23-8-10-25-26(17-23)30(31,32)18-27(25)37-14-12-36(2)13-15-37/h3-6,8,10-11,16-17,19,27H,12-15,18H2,1-2H3,(H,35,39)
DMECOY7	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC3=C(C=C2)C(CC3(F)F)N4CCN(CC4)C)C#CC5=CN=C6N5N=CC=C6
DMECOY7	IK	BPLVEFPXYUJTQJ-UHFFFAOYSA-N
DMECOY7	IU	N-[3,3-difluoro-1-(4-methylpiperazin-1-yl)-1,2-dihydroinden-5-yl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide

DMLGD52	ID	DMLGD52
DMLGD52	DN	PMID25656651-Compound-40
DMLGD52	HS	Patented
DMLGD52	CP	NANJING SANHOME PHARMACEUTICAL CO LTD [CN]
DMLGD52	DT	Small molecular drug
DMLGD52	PC	136248912
DMLGD52	MW	629.6
DMLGD52	FM	C31H29F6N7O
DMLGD52	IC	InChI=1S/C31H29F6N7O/c1-19-4-5-21(14-20(19)6-9-24-18-43(3)28(39-24)27-38-16-26(41-27)31(35,36)37)29(45)40-23-8-7-22(25(15-23)30(32,33)34)17-44-12-10-42(2)11-13-44/h4-5,7-8,14-16,18H,10-13,17H2,1-3H3,(H,38,41)(H,40,45)
DMLGD52	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN(C(=N4)C5=NC=C(N5)C(F)(F)F)C
DMLGD52	IK	HTQFCQUXHWQFLM-UHFFFAOYSA-N
DMLGD52	IU	4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-[1-methyl-2-[5-(trifluoromethyl)-1H-imidazol-2-yl]imidazol-4-yl]ethynyl]benzamide

DMTUA6E	ID	DMTUA6E
DMTUA6E	DN	PMID25656651-Compound-42
DMTUA6E	HS	Patented
DMTUA6E	CP	AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
DMTUA6E	DT	Small molecular drug
DMTUA6E	PC	76071870
DMTUA6E	MW	498.5
DMTUA6E	FM	C27H29F3N4O2
DMTUA6E	IC	InChI=1S/C27H29F3N4O2/c1-2-33-12-14-34(15-13-33)18-22-5-8-23(16-25(22)27(28,29)30)32-26(35)19-36-24-9-6-20(7-10-24)21-4-3-11-31-17-21/h3-11,16-17H,2,12-15,18-19H2,1H3,(H,32,35)
DMTUA6E	CS	CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)COC3=CC=C(C=C3)C4=CN=CC=C4)C(F)(F)F
DMTUA6E	IK	UXNUQVZRIJPJBL-UHFFFAOYSA-N
DMTUA6E	IU	N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-2-(4-pyridin-3-ylphenoxy)acetamide

DM7XQUT	ID	DM7XQUT
DM7XQUT	DN	PMID25656651-Compound-46
DM7XQUT	HS	Patented
DM7XQUT	CP	TERRABAY PHARMACEUTICALS, INC
DM7XQUT	DT	Small molecular drug
DM7XQUT	PC	76286469
DM7XQUT	MW	605.6
DM7XQUT	FM	C31H24F5N7O
DM7XQUT	IC	InChI=1S/C31H24F5N7O/c1-18-4-5-19(9-26(18)42-29-38-8-6-25(41-29)20-3-2-7-37-15-20)28(44)40-23-10-22(31(34,35)36)11-24(12-23)43-16-27(39-17-43)21-13-30(32,33)14-21/h2-12,15-17,21H,13-14H2,1H3,(H,40,44)(H,38,41,42)
DM7XQUT	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C4CC(C4)(F)F)NC5=NC=CC(=N5)C6=CN=CC=C6
DM7XQUT	IK	FHMNIXSTLJZGDP-UHFFFAOYSA-N
DM7XQUT	IU	N-[3-[4-(3,3-difluorocyclobutyl)imidazol-1-yl]-5-(trifluoromethyl)phenyl]-4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide

DMAI95U	ID	DMAI95U
DMAI95U	DN	PMID25656651-Compound-5
DMAI95U	HS	Patented
DMAI95U	CP	ARIAD PHARMACEUTICALS, INC. HUANG, Wei-sheng RIVERA, Victor, M. CLACKSON, Timothy, P. SHAKESPEARE, William, C. SQUILLACE, Rachel, M. GOZGIT, Joseph, M
DMAI95U	DT	Small molecular drug
DMAI95U	PC	24826799
DMAI95U	MW	532.6
DMAI95U	FM	C29H27F3N6O
DMAI95U	IC	InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
DMAI95U	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
DMAI95U	IK	PHXJVRSECIGDHY-UHFFFAOYSA-N
DMAI95U	IU	3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
DMAI95U	CA	CAS 943319-70-8
DMAI95U	CB	CHEBI:78543
DMAI95U	DE	Chronic myeloid leukaemia

DMK3TMD	ID	DMK3TMD
DMK3TMD	DN	PMID25656651-Compound-7
DMK3TMD	HS	Patented
DMK3TMD	CP	DECIPHERA PHARMACEUTICALS, LLC PETILLO, Peter, A. KAUFMAN, Michael, D. FLYNN, Daniel, L
DMK3TMD	DT	Small molecular drug
DMK3TMD	PC	25066467
DMK3TMD	MW	553.6
DMK3TMD	FM	C30H28FN7O3
DMK3TMD	IC	InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
DMK3TMD	CS	CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5
DMK3TMD	IK	WVXNSAVVKYZVOE-UHFFFAOYSA-N
DMK3TMD	IU	4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
DMK3TMD	CA	CAS 1020172-07-9
DMK3TMD	CB	CHEBI:62166

DMEL1WX	ID	DMEL1WX
DMEL1WX	DN	PMID25666693-Compound-1
DMEL1WX	HS	Patented
DMEL1WX	CP	ABBVIE INC
DMEL1WX	DT	Small molecular drug
DMEL1WX	PC	68313317
DMEL1WX	MW	363.4
DMEL1WX	FM	C22H22FN3O
DMEL1WX	IC	InChI=1S/C22H22FN3O/c1-14-11-19-17(13-24-14)8-10-20(23)21(19)26-22(27)25-18-9-7-16(12-18)15-5-3-2-4-6-15/h2-6,8,10-11,13,16,18H,7,9,12H2,1H3,(H2,25,26,27)/t16-,18+/m0/s1
DMEL1WX	CS	CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@@H](C3)C4=CC=CC=C4)F)C=N1
DMEL1WX	IK	BLFYIBROKHRKEJ-FUHWJXTLSA-N
DMEL1WX	IU	1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3S)-3-phenylcyclopentyl]urea
DMEL1WX	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMQP3TD	ID	DMQP3TD
DMQP3TD	DN	PMID25666693-Compound-10
DMQP3TD	HS	Patented
DMQP3TD	CP	ABBVIE INC
DMQP3TD	DT	Small molecular drug
DMQP3TD	PC	66551086
DMQP3TD	MW	363.4
DMQP3TD	FM	C22H22FN3O
DMQP3TD	IC	InChI=1S/C22H22FN3O/c1-14-11-19-17(13-24-14)8-10-20(23)21(19)26-22(27)25-18-9-7-16(12-18)15-5-3-2-4-6-15/h2-6,8,10-11,13,16,18H,7,9,12H2,1H3,(H2,25,26,27)/t16-,18-/m1/s1
DMQP3TD	CS	CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@H](C3)C4=CC=CC=C4)F)C=N1
DMQP3TD	IK	BLFYIBROKHRKEJ-SJLPKXTDSA-N
DMQP3TD	IU	1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3R)-3-phenylcyclopentyl]urea
DMQP3TD	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMYTZFP	ID	DMYTZFP
DMYTZFP	DN	PMID25666693-Compound-100
DMYTZFP	HS	Patented
DMYTZFP	CP	PURDUE PHARMA LP [USSHIONOGI & CO [JPTAFESSE LAYKEA [USANDO SHIGERU [JPKUROSE NORIYUKI [JP]
DMYTZFP	DT	Small molecular drug
DMYTZFP	PC	71480662
DMYTZFP	MW	449.5
DMYTZFP	FM	C20H21F2N5O3S
DMYTZFP	IC	InChI=1S/C20H21F2N5O3S/c1-11-9-26(18-14(22)6-12(8-23-18)16(29)10-28)4-5-27(11)20(30)25-19-24-15-7-13(21)2-3-17(15)31-19/h2-3,6-8,11,16,28-29H,4-5,9-10H2,1H3,(H,24,25,30)/t11-,16+/m0/s1
DMYTZFP	CS	C[C@H]1CN(CCN1C(=O)NC2=NC3=C(S2)C=CC(=C3)F)C4=C(C=C(C=N4)[C@@H](CO)O)F
DMYTZFP	IK	GVENNMJXQHKHOV-MEDUHNTESA-N
DMYTZFP	IU	(2S)-4-[5-[(1S)-1,2-dihydroxyethyl]-3-fluoropyridin-2-yl]-N-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazine-1-carboxamide
DMYTZFP	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMNOD4A	ID	DMNOD4A
DMNOD4A	DN	PMID25666693-Compound-101
DMNOD4A	HS	Patented
DMNOD4A	CP	PURDUE PHARMA L.P
DMNOD4A	DT	Small molecular drug
DMNOD4A	PC	71609207
DMNOD4A	MW	423.5
DMNOD4A	FM	C22H18FN3O3S
DMNOD4A	IC	InChI=1S/C22H18FN3O3S/c23-17-10-13(9-16(28)12-27)11-24-20(17)14-5-7-15(8-6-14)21(29)26-22-25-18-3-1-2-4-19(18)30-22/h1-8,10-11,16,27-28H,9,12H2,(H,25,26,29)/t16-/m0/s1
DMNOD4A	CS	C1=CC=C2C(=C1)N=C(S2)NC(=O)C3=CC=C(C=C3)C4=C(C=C(C=N4)C[C@@H](CO)O)F
DMNOD4A	IK	AMBUADZXQKAOQQ-INIZCTEOSA-N
DMNOD4A	IU	N-(1,3-benzothiazol-2-yl)-4-[5-[(2S)-2,3-dihydroxypropyl]-3-fluoropyridin-2-yl]benzamide
DMNOD4A	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM0OY5D	ID	DM0OY5D
DM0OY5D	DN	PMID25666693-Compound-102
DM0OY5D	HS	Patented
DM0OY5D	CP	PURDUE PHARMA L.P
DM0OY5D	DT	Small molecular drug
DM0OY5D	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM8DZA6	ID	DM8DZA6
DM8DZA6	DN	PMID25666693-Compound-103
DM8DZA6	HS	Patented
DM8DZA6	CP	PURDUE PHARMA L.P
DM8DZA6	DT	Small molecular drug
DM8DZA6	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMYCT5B	ID	DMYCT5B
DMYCT5B	DN	PMID25666693-Compound-104
DMYCT5B	HS	Patented
DMYCT5B	CP	Purdue Pharma L.P
DMYCT5B	DT	Small molecular drug
DMYCT5B	PC	25104368
DMYCT5B	MW	461.8
DMYCT5B	FM	C20H20ClF4N3O3
DMYCT5B	IC	InChI=1S/C20H20ClF4N3O3/c21-15-9-12(16(30)11-29)10-26-17(15)19(22)5-7-28(8-6-19)18(31)27-14-3-1-13(2-4-14)20(23,24)25/h1-4,9-10,16,29-30H,5-8,11H2,(H,27,31)/t16-/m1/s1
DMYCT5B	CS	C1CN(CCC1(C2=C(C=C(C=N2)[C@@H](CO)O)Cl)F)C(=O)NC3=CC=C(C=C3)C(F)(F)F
DMYCT5B	IK	DSVBUDHKIZVCPH-MRXNPFEDSA-N
DMYCT5B	IU	4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]pyridin-2-yl]-4-fluoro-N-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide
DMYCT5B	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMV509A	ID	DMV509A
DMV509A	DN	PMID25666693-Compound-105
DMV509A	HS	Patented
DMV509A	CP	Purdue Pharma L.P
DMV509A	DT	Small molecular drug
DMV509A	PC	25027804
DMV509A	MW	476.3
DMV509A	FM	C20H18Cl2F3N3O3
DMV509A	IC	InChI=1S/C20H18Cl2F3N3O3/c21-15-8-13(1-2-14(15)20(23,24)25)27-19(31)28-5-3-11(4-6-28)18-16(22)7-12(9-26-18)17(30)10-29/h1-3,7-9,17,29-30H,4-6,10H2,(H,27,31)/t17-/m1/s1
DMV509A	CS	C1CN(CC=C1C2=C(C=C(C=N2)[C@@H](CO)O)Cl)C(=O)NC3=CC(=C(C=C3)C(F)(F)F)Cl
DMV509A	IK	CJDYNMVVGNTWLD-QGZVFWFLSA-N
DMV509A	IU	4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]pyridin-2-yl]-N-[3-chloro-4-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxamide
DMV509A	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMEG8CB	ID	DMEG8CB
DMEG8CB	DN	PMID25666693-Compound-106
DMEG8CB	HS	Patented
DMEG8CB	DT	Small molecular drug
DMEG8CB	PC	51349065
DMEG8CB	MW	389
DMEG8CB	FM	C19H25ClN4OSi
DMEG8CB	IC	InChI=1S/C19H25ClN4OSi/c1-26(2,3)16-8-6-15(7-9-16)22-19(25)24-13-11-23(12-14-24)18-17(20)5-4-10-21-18/h4-10H,11-14H2,1-3H3,(H,22,25)
DMEG8CB	CS	C[Si](C)(C)C1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=C(C=CC=N3)Cl
DMEG8CB	IK	VOWXQOSAQUYVQK-UHFFFAOYSA-N
DMEG8CB	IU	4-(3-chloropyridin-2-yl)-N-(4-trimethylsilylphenyl)piperazine-1-carboxamide
DMEG8CB	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMB2RML	ID	DMB2RML
DMB2RML	DN	PMID25666693-Compound-107
DMB2RML	HS	Patented
DMB2RML	DT	Small molecular drug
DMB2RML	PC	51349201
DMB2RML	MW	414.5
DMB2RML	FM	C22H21F3N2OSi
DMB2RML	IC	InChI=1S/C22H21F3N2OSi/c1-29(2,3)18-12-10-17(11-13-18)27-21(28)16-8-6-15(7-9-16)20-19(22(23,24)25)5-4-14-26-20/h4-14H,1-3H3,(H,27,28)
DMB2RML	CS	C[Si](C)(C)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)C3=C(C=CC=N3)C(F)(F)F
DMB2RML	IK	ATDYJIBFGKJFQE-UHFFFAOYSA-N
DMB2RML	IU	4-[3-(trifluoromethyl)pyridin-2-yl]-N-(4-trimethylsilylphenyl)benzamide
DMB2RML	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMN0FCA	ID	DMN0FCA
DMN0FCA	DN	PMID25666693-Compound-108
DMN0FCA	HS	Patented
DMN0FCA	DT	Small molecular drug
DMN0FCA	PC	51349341
DMN0FCA	MW	386
DMN0FCA	FM	C20H24ClN3OSi
DMN0FCA	IC	InChI=1S/C20H24ClN3OSi/c1-26(2,3)17-8-6-16(7-9-17)23-20(25)15-10-13-24(14-11-15)19-18(21)5-4-12-22-19/h4-10,12H,11,13-14H2,1-3H3,(H,23,25)
DMN0FCA	CS	C[Si](C)(C)C1=CC=C(C=C1)NC(=O)C2=CCN(CC2)C3=C(C=CC=N3)Cl
DMN0FCA	IK	DYKDTFQPEROGHZ-UHFFFAOYSA-N
DMN0FCA	IU	1-(3-chloropyridin-2-yl)-N-(4-trimethylsilylphenyl)-3,6-dihydro-2H-pyridine-4-carboxamide
DMN0FCA	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMWGIS7	ID	DMWGIS7
DMWGIS7	DN	PMID25666693-Compound-109
DMWGIS7	HS	Patented
DMWGIS7	CP	Purdue Pharma L.P
DMWGIS7	DT	Small molecular drug
DMWGIS7	PC	11187857
DMWGIS7	MW	370.9
DMWGIS7	FM	C20H23ClN4O
DMWGIS7	IC	InChI=1S/C20H23ClN4O/c1-20(2,3)15-4-6-16(7-5-15)24-19(26)25-12-8-14(9-13-25)17-18(21)23-11-10-22-17/h4-8,10-11H,9,12-13H2,1-3H3,(H,24,26)
DMWGIS7	CS	CC(C)(C)C1=CC=C(C=C1)NC(=O)N2CCC(=CC2)C3=NC=CN=C3Cl
DMWGIS7	IK	SOOFDEGWVPVUAQ-UHFFFAOYSA-N
DMWGIS7	IU	N-(4-tert-butylphenyl)-4-(3-chloropyrazin-2-yl)-3,6-dihydro-2H-pyridine-1-carboxamide
DMWGIS7	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM9HOM6	ID	DM9HOM6
DM9HOM6	DN	PMID25666693-Compound-11
DM9HOM6	HS	Patented
DM9HOM6	CP	ABBVIE INC
DM9HOM6	DT	Small molecular drug
DM9HOM6	PC	66549650
DM9HOM6	MW	381.4
DM9HOM6	FM	C22H21F2N3O
DM9HOM6	IC	InChI=1S/C22H21F2N3O/c1-13-10-18-15(12-25-13)7-9-20(24)21(18)27-22(28)26-16-8-6-14(11-16)17-4-2-3-5-19(17)23/h2-5,7,9-10,12,14,16H,6,8,11H2,1H3,(H2,26,27,28)/t14-,16-/m1/s1
DM9HOM6	CS	CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@H](C3)C4=CC=CC=C4F)F)C=N1
DM9HOM6	IK	PJVXUKARZNCIRA-GDBMZVCRSA-N
DM9HOM6	IU	1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3R)-3-(2-fluorophenyl)cyclopentyl]urea
DM9HOM6	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMNGD2S	ID	DMNGD2S
DMNGD2S	DN	PMID25666693-Compound-110
DMNGD2S	HS	Patented
DMNGD2S	CP	Shionogi & Co., Ltd. KUROSE, Noriyuki
DMNGD2S	DT	Small molecular drug
DMNGD2S	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMNKW1E	ID	DMNKW1E
DMNKW1E	DN	PMID25666693-Compound-111
DMNKW1E	HS	Patented
DMNKW1E	CP	Shionogi & Co., Ltd. KUROSE, Noriyuki
DMNKW1E	DT	Small molecular drug
DMNKW1E	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMQOSH5	ID	DMQOSH5
DMQOSH5	DN	PMID25666693-Compound-112
DMQOSH5	HS	Patented
DMQOSH5	CP	Shionogi & Co., Ltd. KUROSE, Noriyuki
DMQOSH5	DT	Small molecular drug
DMQOSH5	PC	70652314
DMQOSH5	MW	455.9
DMQOSH5	FM	C21H21ClF3N3O3
DMQOSH5	IC	InChI=1S/C21H21ClF3N3O3/c22-18-10-13(9-17(30)12-29)11-26-19(18)14-5-7-28(8-6-14)20(31)27-16-3-1-15(2-4-16)21(23,24)25/h1-5,10-11,17,29-30H,6-9,12H2,(H,27,31)
DMQOSH5	CS	C1CN(CC=C1C2=C(C=C(C=N2)CC(CO)O)Cl)C(=O)NC3=CC=C(C=C3)C(F)(F)F
DMQOSH5	IK	DMTZGKUBPJHALY-UHFFFAOYSA-N
DMQOSH5	IU	4-[3-chloro-5-(2,3-dihydroxypropyl)pyridin-2-yl]-N-[4-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxamide
DMQOSH5	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM02O5V	ID	DM02O5V
DM02O5V	DN	PMID25666693-Compound-113
DM02O5V	HS	Patented
DM02O5V	CP	Shionogi & Co., Ltd. KUROSE, Noriyuki
DM02O5V	DT	Small molecular drug
DM02O5V	PC	70652315
DM02O5V	MW	490.3
DM02O5V	FM	C21H20Cl2F3N3O3
DM02O5V	IC	InChI=1S/C21H20Cl2F3N3O3/c22-17-9-14(1-2-16(17)21(24,25)26)28-20(32)29-5-3-13(4-6-29)19-18(23)8-12(10-27-19)7-15(31)11-30/h1-3,8-10,15,30-31H,4-7,11H2,(H,28,32)
DM02O5V	CS	C1CN(CC=C1C2=C(C=C(C=N2)CC(CO)O)Cl)C(=O)NC3=CC(=C(C=C3)C(F)(F)F)Cl
DM02O5V	IK	XRTGOKOICCLLQT-UHFFFAOYSA-N
DM02O5V	IU	4-[3-chloro-5-(2,3-dihydroxypropyl)pyridin-2-yl]-N-[3-chloro-4-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxamide
DM02O5V	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMA9YDK	ID	DMA9YDK
DMA9YDK	DN	PMID25666693-Compound-114
DMA9YDK	HS	Patented
DMA9YDK	CP	Shionogi & Co., Ltd. KUROSE, Noriyuki
DMA9YDK	DT	Small molecular drug
DMA9YDK	PC	89556774
DMA9YDK	MW	465.9
DMA9YDK	FM	C20H21ClFN5O3S
DMA9YDK	IC	InChI=1S/C20H21ClFN5O3S/c21-15-8-12(7-14(29)11-28)10-23-18(15)26-3-5-27(6-4-26)20(30)25-19-24-16-2-1-13(22)9-17(16)31-19/h1-2,8-10,14,28-29H,3-7,11H2,(H,24,25,30)/t14-/m1/s1
DMA9YDK	CS	C1CN(CCN1C2=C(C=C(C=N2)C[C@H](CO)O)Cl)C(=O)NC3=NC4=C(S3)C=C(C=C4)F
DMA9YDK	IK	GUCBTAMMWIOHHO-CQSZACIVSA-N
DMA9YDK	IU	4-[3-chloro-5-[(2R)-2,3-dihydroxypropyl]pyridin-2-yl]-N-(6-fluoro-1,3-benzothiazol-2-yl)piperazine-1-carboxamide
DMA9YDK	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMF5ODZ	ID	DMF5ODZ
DMF5ODZ	DN	PMID25666693-Compound-115
DMF5ODZ	HS	Patented
DMF5ODZ	CP	Shionogi & Co., Ltd. KUROSE, Noriyuki
DMF5ODZ	DT	Small molecular drug
DMF5ODZ	PC	88875843
DMF5ODZ	MW	480
DMF5ODZ	FM	C21H23ClFN5O3S
DMF5ODZ	IC	InChI=1S/C21H23ClFN5O3S/c1-12-10-27(19-16(22)7-13(9-24-19)6-15(30)11-29)4-5-28(12)21(31)26-20-25-17-3-2-14(23)8-18(17)32-20/h2-3,7-9,12,15,29-30H,4-6,10-11H2,1H3,(H,25,26,31)/t12-,15-/m1/s1
DMF5ODZ	CS	C[C@@H]1CN(CCN1C(=O)NC2=NC3=C(S2)C=C(C=C3)F)C4=C(C=C(C=N4)C[C@H](CO)O)Cl
DMF5ODZ	IK	SRAUTTLRNBOIMG-IUODEOHRSA-N
DMF5ODZ	IU	(2R)-4-[3-chloro-5-[(2R)-2,3-dihydroxypropyl]pyridin-2-yl]-N-(6-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazine-1-carboxamide
DMF5ODZ	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMNEBXL	ID	DMNEBXL
DMNEBXL	DN	PMID25666693-Compound-116
DMNEBXL	HS	Patented
DMNEBXL	CP	Shionogi & Co., Ltd. KUROSE, Noriyuki
DMNEBXL	DT	Small molecular drug
DMNEBXL	PC	88875796
DMNEBXL	MW	465.9
DMNEBXL	FM	C20H21ClFN5O3S
DMNEBXL	IC	InChI=1S/C20H21ClFN5O3S/c21-13-1-2-16-17(9-13)31-19(24-16)25-20(30)27-5-3-26(4-6-27)18-15(22)8-12(10-23-18)7-14(29)11-28/h1-2,8-10,14,28-29H,3-7,11H2,(H,24,25,30)/t14-/m1/s1
DMNEBXL	CS	C1CN(CCN1C2=C(C=C(C=N2)C[C@H](CO)O)F)C(=O)NC3=NC4=C(S3)C=C(C=C4)Cl
DMNEBXL	IK	STXPENJJMUYCAL-CQSZACIVSA-N
DMNEBXL	IU	N-(6-chloro-1,3-benzothiazol-2-yl)-4-[5-[(2R)-2,3-dihydroxypropyl]-3-fluoropyridin-2-yl]piperazine-1-carboxamide
DMNEBXL	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMN9LDH	ID	DMN9LDH
DMN9LDH	DN	PMID25666693-Compound-117
DMN9LDH	HS	Patented
DMN9LDH	CP	Shionogi & Co., Ltd. KUROSE, Noriyuki
DMN9LDH	DT	Small molecular drug
DMN9LDH	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMBIQMS	ID	DMBIQMS
DMBIQMS	DN	PMID25666693-Compound-118
DMBIQMS	HS	Patented
DMBIQMS	CP	PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMBIQMS	DT	Small molecular drug
DMBIQMS	PC	53386424
DMBIQMS	MW	400.9
DMBIQMS	FM	C20H21ClN4O3
DMBIQMS	IC	InChI=1S/C20H21ClN4O3/c21-14-7-6-13(17(10-14)25-8-1-2-9-25)11-22-20(27)24-16-5-3-4-15-19(16)28-12-18(26)23-15/h3-7,10H,1-2,8-9,11-12H2,(H,23,26)(H2,22,24,27)
DMBIQMS	CS	C1CCN(C1)C2=C(C=CC(=C2)Cl)CNC(=O)NC3=CC=CC4=C3OCC(=O)N4
DMBIQMS	IK	IMKHWDHGNGTOSD-UHFFFAOYSA-N
DMBIQMS	IU	1-[(4-chloro-2-pyrrolidin-1-ylphenyl)methyl]-3-(3-oxo-4H-1,4-benzoxazin-8-yl)urea
DMBIQMS	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMD0WIA	ID	DMD0WIA
DMD0WIA	DN	PMID25666693-Compound-119
DMD0WIA	HS	Patented
DMD0WIA	CP	PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMD0WIA	DT	Small molecular drug
DMD0WIA	PC	53477385
DMD0WIA	MW	393.4
DMD0WIA	FM	C18H18F3N5O2
DMD0WIA	IC	InChI=1S/C18H18F3N5O2/c1-26(2)14-8-11(18(19,20)21)7-6-10(14)9-22-16(27)23-12-4-3-5-13-15(12)25-17(28)24-13/h3-8H,9H2,1-2H3,(H2,22,23,27)(H2,24,25,28)
DMD0WIA	CS	CN(C)C1=C(C=CC(=C1)C(F)(F)F)CNC(=O)NC2=CC=CC3=C2NC(=O)N3
DMD0WIA	IK	GUTYAMHQYWODRM-UHFFFAOYSA-N
DMD0WIA	IU	1-[[2-(dimethylamino)-4-(trifluoromethyl)phenyl]methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea
DMD0WIA	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMVSFNE	ID	DMVSFNE
DMVSFNE	DN	PMID25666693-Compound-12
DMVSFNE	HS	Patented
DMVSFNE	CP	ABBVIE INC
DMVSFNE	DT	Small molecular drug
DMVSFNE	PC	66549652
DMVSFNE	MW	381.4
DMVSFNE	FM	C22H21F2N3O
DMVSFNE	IC	InChI=1S/C22H21F2N3O/c1-13-9-19-16(12-25-13)6-8-20(24)21(19)27-22(28)26-18-7-5-15(11-18)14-3-2-4-17(23)10-14/h2-4,6,8-10,12,15,18H,5,7,11H2,1H3,(H2,26,27,28)/t15-,18-/m1/s1
DMVSFNE	CS	CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@H](C3)C4=CC(=CC=C4)F)F)C=N1
DMVSFNE	IK	PAFRMBKESKKSIA-CRAIPNDOSA-N
DMVSFNE	IU	1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3R)-3-(3-fluorophenyl)cyclopentyl]urea
DMVSFNE	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMVREIM	ID	DMVREIM
DMVREIM	DN	PMID25666693-Compound-120
DMVREIM	HS	Patented
DMVREIM	CP	PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMVREIM	DT	Small molecular drug
DMVREIM	PC	53477386
DMVREIM	MW	419.4
DMVREIM	FM	C20H20F3N5O2
DMVREIM	IC	InChI=1S/C20H20F3N5O2/c21-20(22,23)13-7-6-12(16(10-13)28-8-1-2-9-28)11-24-18(29)25-14-4-3-5-15-17(14)27-19(30)26-15/h3-7,10H,1-2,8-9,11H2,(H2,24,25,29)(H2,26,27,30)
DMVREIM	CS	C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CNC(=O)NC3=CC=CC4=C3NC(=O)N4
DMVREIM	IK	GUWJRCUFOIXCMK-UHFFFAOYSA-N
DMVREIM	IU	1-(2-oxo-1,3-dihydrobenzimidazol-4-yl)-3-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]urea
DMVREIM	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMC1QDB	ID	DMC1QDB
DMC1QDB	DN	PMID25666693-Compound-121
DMC1QDB	HS	Patented
DMC1QDB	CP	PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMC1QDB	DT	Small molecular drug
DMC1QDB	PC	53477387
DMC1QDB	MW	433.4
DMC1QDB	FM	C21H22F3N5O2
DMC1QDB	IC	InChI=1S/C21H22F3N5O2/c22-21(23,24)14-8-7-13(17(11-14)29-9-2-1-3-10-29)12-25-19(30)26-15-5-4-6-16-18(15)28-20(31)27-16/h4-8,11H,1-3,9-10,12H2,(H2,25,26,30)(H2,27,28,31)
DMC1QDB	CS	C1CCN(CC1)C2=C(C=CC(=C2)C(F)(F)F)CNC(=O)NC3=CC=CC4=C3NC(=O)N4
DMC1QDB	IK	ILFYSMXXQODUJS-UHFFFAOYSA-N
DMC1QDB	IU	1-(2-oxo-1,3-dihydrobenzimidazol-4-yl)-3-[[2-piperidin-1-yl-4-(trifluoromethyl)phenyl]methyl]urea
DMC1QDB	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMR63O2	ID	DMR63O2
DMR63O2	DN	PMID25666693-Compound-122
DMR63O2	HS	Patented
DMR63O2	CP	PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMR63O2	DT	Small molecular drug
DMR63O2	PC	53476470
DMR63O2	MW	408.4
DMR63O2	FM	C19H19F3N4O3
DMR63O2	IC	InChI=1S/C19H19F3N4O3/c1-26(2)15-8-12(19(20,21)22)7-6-11(15)9-23-18(28)25-14-5-3-4-13-17(14)29-10-16(27)24-13/h3-8H,9-10H2,1-2H3,(H,24,27)(H2,23,25,28)
DMR63O2	CS	CN(C)C1=C(C=CC(=C1)C(F)(F)F)CNC(=O)NC2=CC=CC3=C2OCC(=O)N3
DMR63O2	IK	NEPJFAHBBJEELA-UHFFFAOYSA-N
DMR63O2	IU	1-[[2-(dimethylamino)-4-(trifluoromethyl)phenyl]methyl]-3-(3-oxo-4H-1,4-benzoxazin-8-yl)urea
DMR63O2	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM9358G	ID	DM9358G
DM9358G	DN	PMID25666693-Compound-123
DM9358G	HS	Patented
DM9358G	CP	PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DM9358G	DT	Small molecular drug
DM9358G	PC	53476471
DM9358G	MW	434.4
DM9358G	FM	C21H21F3N4O3
DM9358G	IC	InChI=1S/C21H21F3N4O3/c22-21(23,24)14-7-6-13(17(10-14)28-8-1-2-9-28)11-25-20(30)27-16-5-3-4-15-19(16)31-12-18(29)26-15/h3-7,10H,1-2,8-9,11-12H2,(H,26,29)(H2,25,27,30)
DM9358G	CS	C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CNC(=O)NC3=CC=CC4=C3OCC(=O)N4
DM9358G	IK	ABNCWKBVNWSWPZ-UHFFFAOYSA-N
DM9358G	IU	1-(3-oxo-4H-1,4-benzoxazin-8-yl)-3-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]urea
DM9358G	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM6ODU7	ID	DM6ODU7
DM6ODU7	DN	PMID25666693-Compound-124
DM6ODU7	HS	Patented
DM6ODU7	CP	PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DM6ODU7	DT	Small molecular drug
DM6ODU7	PC	53476472
DM6ODU7	MW	448.4
DM6ODU7	FM	C22H23F3N4O3
DM6ODU7	IC	InChI=1S/C22H23F3N4O3/c23-22(24,25)15-8-7-14(18(11-15)29-9-2-1-3-10-29)12-26-21(31)28-17-6-4-5-16-20(17)32-13-19(30)27-16/h4-8,11H,1-3,9-10,12-13H2,(H,27,30)(H2,26,28,31)
DM6ODU7	CS	C1CCN(CC1)C2=C(C=CC(=C2)C(F)(F)F)CNC(=O)NC3=CC=CC4=C3OCC(=O)N4
DM6ODU7	IK	FSBAINYERQVPNQ-UHFFFAOYSA-N
DM6ODU7	IU	1-(3-oxo-4H-1,4-benzoxazin-8-yl)-3-[[2-piperidin-1-yl-4-(trifluoromethyl)phenyl]methyl]urea
DM6ODU7	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMR0WM1	ID	DMR0WM1
DMR0WM1	DN	PMID25666693-Compound-125
DMR0WM1	HS	Patented
DMR0WM1	CP	PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMR0WM1	DT	Small molecular drug
DMR0WM1	PC	53475699
DMR0WM1	MW	385.8
DMR0WM1	FM	C19H20ClN5O2
DMR0WM1	IC	InChI=1S/C19H20ClN5O2/c20-13-7-6-12(16(10-13)25-8-1-2-9-25)11-21-18(26)22-14-4-3-5-15-17(14)24-19(27)23-15/h3-7,10H,1-2,8-9,11H2,(H2,21,22,26)(H2,23,24,27)
DMR0WM1	CS	C1CCN(C1)C2=C(C=CC(=C2)Cl)CNC(=O)NC3=CC=CC4=C3NC(=O)N4
DMR0WM1	IK	HZDOWKSLUNQEPU-UHFFFAOYSA-N
DMR0WM1	IU	1-[(4-chloro-2-pyrrolidin-1-ylphenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea
DMR0WM1	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMKN72Y	ID	DMKN72Y
DMKN72Y	DN	PMID25666693-Compound-126
DMKN72Y	HS	Patented
DMKN72Y	CP	PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMKN72Y	DT	Small molecular drug
DMKN72Y	PC	53475700
DMKN72Y	MW	399.9
DMKN72Y	FM	C20H22ClN5O2
DMKN72Y	IC	InChI=1S/C20H22ClN5O2/c21-14-8-7-13(17(11-14)26-9-2-1-3-10-26)12-22-19(27)23-15-5-4-6-16-18(15)25-20(28)24-16/h4-8,11H,1-3,9-10,12H2,(H2,22,23,27)(H2,24,25,28)
DMKN72Y	CS	C1CCN(CC1)C2=C(C=CC(=C2)Cl)CNC(=O)NC3=CC=CC4=C3NC(=O)N4
DMKN72Y	IK	UDSQXLZVIWKXME-UHFFFAOYSA-N
DMKN72Y	IU	1-[(4-chloro-2-piperidin-1-ylphenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea
DMKN72Y	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMCE6MB	ID	DMCE6MB
DMCE6MB	DN	PMID25666693-Compound-127
DMCE6MB	HS	Patented
DMCE6MB	CP	Sanofi-Aventis
DMCE6MB	DT	Small molecular drug
DMCE6MB	PC	24759759
DMCE6MB	MW	439.5
DMCE6MB	FM	C26H22FN5O
DMCE6MB	IC	InChI=1S/C26H22FN5O/c27-19-4-6-22-18(13-19)14-24(32(22)16-17-8-10-28-11-9-17)26(33)29-20-5-7-23-21(15-20)30-25-3-1-2-12-31(23)25/h4-11,13-15H,1-3,12,16H2,(H,29,33)
DMCE6MB	CS	C1CCN2C(=NC3=C2C=CC(=C3)NC(=O)C4=CC5=C(N4CC6=CC=NC=C6)C=CC(=C5)F)C1
DMCE6MB	IK	NFRFMCDNQXJWRI-UHFFFAOYSA-N
DMCE6MB	IU	5-fluoro-1-(pyridin-4-ylmethyl)-N-(1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-7-yl)indole-2-carboxamide
DMCE6MB	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM6QHGV	ID	DM6QHGV
DM6QHGV	DN	PMID25666693-Compound-128
DM6QHGV	HS	Patented
DM6QHGV	CP	Sanofi-Aventis
DM6QHGV	DT	Small molecular drug
DM6QHGV	PC	24758063
DM6QHGV	MW	425.5
DM6QHGV	FM	C25H20FN5O
DM6QHGV	IC	InChI=1S/C25H20FN5O/c26-18-3-5-21-17(12-18)13-23(31(21)15-16-7-9-27-10-8-16)25(32)28-19-4-6-22-20(14-19)29-24-2-1-11-30(22)24/h3-10,12-14H,1-2,11,15H2,(H,28,32)
DM6QHGV	CS	C1CC2=NC3=C(N2C1)C=CC(=C3)NC(=O)C4=CC5=C(N4CC6=CC=NC=C6)C=CC(=C5)F
DM6QHGV	IK	GBRKESHSZHLQFC-UHFFFAOYSA-N
DM6QHGV	IU	N-(2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-6-yl)-5-fluoro-1-(pyridin-4-ylmethyl)indole-2-carboxamide
DM6QHGV	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM74NBY	ID	DM74NBY
DM74NBY	DN	PMID25666693-Compound-129
DM74NBY	HS	Patented
DM74NBY	CP	Sanofi-Aventis
DM74NBY	DT	Small molecular drug
DM74NBY	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMI0YWU	ID	DMI0YWU
DMI0YWU	DN	PMID25666693-Compound-13
DMI0YWU	HS	Patented
DMI0YWU	CP	ABBVIE INC
DMI0YWU	DT	Small molecular drug
DMI0YWU	PC	66549649
DMI0YWU	MW	379.4
DMI0YWU	FM	C22H22FN3O2
DMI0YWU	IC	InChI=1S/C22H22FN3O2/c1-26-20-8-4-7-19(17(20)11-12-21(26)27)25-22(28)24-15-10-9-14(13-15)16-5-2-3-6-18(16)23/h2-8,11-12,14-15H,9-10,13H2,1H3,(H2,24,25,28)/t14-,15-/m1/s1
DMI0YWU	CS	CN1C(=O)C=CC2=C(C=CC=C21)NC(=O)N[C@@H]3CC[C@H](C3)C4=CC=CC=C4F
DMI0YWU	IK	NGJOCHXSRSVEDI-HUUCEWRRSA-N
DMI0YWU	IU	1-[(1R,3R)-3-(2-fluorophenyl)cyclopentyl]-3-(1-methyl-2-oxoquinolin-5-yl)urea
DMI0YWU	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMIX1K0	ID	DMIX1K0
DMIX1K0	DN	PMID25666693-Compound-130
DMIX1K0	HS	Patented
DMIX1K0	CP	Sanofi-Aventis
DMIX1K0	DT	Small molecular drug
DMIX1K0	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DML7SYH	ID	DML7SYH
DML7SYH	DN	PMID25666693-Compound-131
DML7SYH	HS	Patented
DML7SYH	CP	Sanofi
DML7SYH	DT	Small molecular drug
DML7SYH	PC	25094155
DML7SYH	MW	443.4
DML7SYH	FM	C22H17F4N5O
DML7SYH	IC	InChI=1S/C22H17F4N5O/c1-27-19-6-5-17(11-28-19)30-21(32)18-9-14-8-15(22(24,25)26)10-29-20(14)31(18)12-13-3-2-4-16(23)7-13/h2-11H,12H2,1H3,(H,27,28)(H,30,32)
DML7SYH	CS	CNC1=NC=C(C=C1)NC(=O)C2=CC3=CC(=CN=C3N2CC4=CC(=CC=C4)F)C(F)(F)F
DML7SYH	IK	XTNRHSVPOQBJCX-UHFFFAOYSA-N
DML7SYH	IU	1-[(3-fluorophenyl)methyl]-N-[6-(methylamino)pyridin-3-yl]-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-2-carboxamide
DML7SYH	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMHQM8W	ID	DMHQM8W
DMHQM8W	DN	PMID25666693-Compound-132
DMHQM8W	HS	Patented
DMHQM8W	CP	Sanofi
DMHQM8W	DT	Small molecular drug
DMHQM8W	PC	66908117
DMHQM8W	MW	483.5
DMHQM8W	FM	C25H21F4N5O
DMHQM8W	IC	InChI=1S/C25H21F4N5O/c26-19-5-3-4-16(10-19)15-34-21(12-17-11-18(25(27,28)29)13-31-23(17)34)24(35)32-20-6-7-22(30-14-20)33-8-1-2-9-33/h3-7,10-14H,1-2,8-9,15H2,(H,32,35)
DMHQM8W	CS	C1CCN(C1)C2=NC=C(C=C2)NC(=O)C3=CC4=CC(=CN=C4N3CC5=CC(=CC=C5)F)C(F)(F)F
DMHQM8W	IK	IZIWMKBKLZPSFO-UHFFFAOYSA-N
DMHQM8W	IU	1-[(3-fluorophenyl)methyl]-N-(6-pyrrolidin-1-ylpyridin-3-yl)-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-2-carboxamide
DMHQM8W	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMHEPR3	ID	DMHEPR3
DMHEPR3	DN	PMID25666693-Compound-133
DMHEPR3	HS	Patented
DMHEPR3	CP	Sanofi
DMHEPR3	DT	Small molecular drug
DMHEPR3	PC	25094231
DMHEPR3	MW	469.4
DMHEPR3	FM	C24H19F4N5O
DMHEPR3	IC	InChI=1S/C24H19F4N5O/c25-18-4-1-3-15(9-18)14-33-20(11-16-10-17(24(26,27)28)12-30-22(16)33)23(34)31-19-5-6-21(29-13-19)32-7-2-8-32/h1,3-6,9-13H,2,7-8,14H2,(H,31,34)
DMHEPR3	CS	C1CN(C1)C2=NC=C(C=C2)NC(=O)C3=CC4=CC(=CN=C4N3CC5=CC(=CC=C5)F)C(F)(F)F
DMHEPR3	IK	DXPFHQMFHSGNDI-UHFFFAOYSA-N
DMHEPR3	IU	N-[6-(azetidin-1-yl)pyridin-3-yl]-1-[(3-fluorophenyl)methyl]-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-2-carboxamide
DMHEPR3	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM2WJKR	ID	DM2WJKR
DM2WJKR	DN	PMID25666693-Compound-134
DM2WJKR	HS	Patented
DM2WJKR	CP	Novartis AG
DM2WJKR	DT	Small molecular drug
DM2WJKR	PC	11674039
DM2WJKR	MW	313.8
DM2WJKR	FM	C17H16ClN3O
DM2WJKR	IC	InChI=1S/C17H16ClN3O/c1-10(2)16-20-15-9-12(19)5-8-14(15)17(22)21(16)13-6-3-11(18)4-7-13/h3-10H,19H2,1-2H3
DM2WJKR	CS	CC(C)C1=NC2=C(C=CC(=C2)N)C(=O)N1C3=CC=C(C=C3)Cl
DM2WJKR	IK	XBLNKLVBZMWWLK-UHFFFAOYSA-N
DM2WJKR	IU	7-amino-3-(4-chlorophenyl)-2-propan-2-ylquinazolin-4-one
DM2WJKR	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMYZVPD	ID	DMYZVPD
DMYZVPD	DN	PMID25666693-Compound-135
DMYZVPD	HS	Patented
DMYZVPD	CP	Novartis AG
DMYZVPD	DT	Small molecular drug
DMYZVPD	PC	58387673
DMYZVPD	MW	347.3
DMYZVPD	FM	C18H16F3N3O
DMYZVPD	IC	InChI=1S/C18H16F3N3O/c1-10(2)16-23-15-9-12(22)5-8-14(15)17(25)24(16)13-6-3-11(4-7-13)18(19,20)21/h3-10H,22H2,1-2H3
DMYZVPD	CS	CC(C)C1=NC2=C(C=CC(=C2)N)C(=O)N1C3=CC=C(C=C3)C(F)(F)F
DMYZVPD	IK	BRVXMMDZSNVASE-UHFFFAOYSA-N
DMYZVPD	IU	7-amino-2-propan-2-yl-3-[4-(trifluoromethyl)phenyl]quinazolin-4-one
DMYZVPD	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMPY1QC	ID	DMPY1QC
DMPY1QC	DN	PMID25666693-Compound-136
DMPY1QC	HS	Patented
DMPY1QC	CP	Novartis AG
DMPY1QC	DT	Small molecular drug
DMPY1QC	PC	58387639
DMPY1QC	MW	348.2
DMPY1QC	FM	C17H15Cl2N3O
DMPY1QC	IC	InChI=1S/C17H15Cl2N3O/c1-9(2)16-21-15-12(7-8-13(20)14(15)19)17(23)22(16)11-5-3-10(18)4-6-11/h3-9H,20H2,1-2H3
DMPY1QC	CS	CC(C)C1=NC2=C(C=CC(=C2Cl)N)C(=O)N1C3=CC=C(C=C3)Cl
DMPY1QC	IK	KVPDVXGLZNHXJL-UHFFFAOYSA-N
DMPY1QC	IU	7-amino-8-chloro-3-(4-chlorophenyl)-2-propan-2-ylquinazolin-4-one
DMPY1QC	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMZ7LAO	ID	DMZ7LAO
DMZ7LAO	DN	PMID25666693-Compound-137
DMZ7LAO	HS	Patented
DMZ7LAO	CP	Novartis AG
DMZ7LAO	DT	Small molecular drug
DMZ7LAO	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMJLFEN	ID	DMJLFEN
DMJLFEN	DN	PMID25666693-Compound-138
DMJLFEN	HS	Patented
DMJLFEN	CP	Novartis AG
DMJLFEN	DT	Small molecular drug
DMJLFEN	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMLMEPI	ID	DMLMEPI
DMLMEPI	DN	PMID25666693-Compound-139
DMLMEPI	HS	Patented
DMLMEPI	CP	Novartis AG
DMLMEPI	DT	Small molecular drug
DMLMEPI	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM3D4RI	ID	DM3D4RI
DM3D4RI	DN	PMID25666693-Compound-14
DM3D4RI	HS	Patented
DM3D4RI	CP	ABBVIE INC
DM3D4RI	DT	Small molecular drug
DM3D4RI	PC	60202428
DM3D4RI	MW	338.4
DM3D4RI	FM	C19H19FN4O
DM3D4RI	IC	InChI=1S/C19H19FN4O/c20-16-5-2-1-4-14(16)12-8-9-13(10-12)22-19(25)23-17-6-3-7-18-15(17)11-21-24-18/h1-7,11-13H,8-10H2,(H,21,24)(H2,22,23,25)/t12-,13-/m1/s1
DM3D4RI	CS	C1C[C@H](C[C@@H]1C2=CC=CC=C2F)NC(=O)NC3=CC=CC4=C3C=NN4
DM3D4RI	IK	MNXPYZUSFURMKS-CHWSQXEVSA-N
DM3D4RI	IU	1-[(1R,3R)-3-(2-fluorophenyl)cyclopentyl]-3-(1H-indazol-4-yl)urea
DM3D4RI	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMVQU9T	ID	DMVQU9T
DMVQU9T	DN	PMID25666693-Compound-140
DMVQU9T	HS	Patented
DMVQU9T	CP	Novartis AG
DMVQU9T	DT	Small molecular drug
DMVQU9T	PC	23585453
DMVQU9T	MW	314.8
DMVQU9T	FM	C17H15ClN2O2
DMVQU9T	IC	InChI=1S/C17H15ClN2O2/c1-10(2)16-19-15-9-13(21)7-8-14(15)17(22)20(16)12-5-3-11(18)4-6-12/h3-10,21H,1-2H3
DMVQU9T	CS	CC(C)C1=NC2=C(C=CC(=C2)O)C(=O)N1C3=CC=C(C=C3)Cl
DMVQU9T	IK	OJVMSICJWQFIOS-UHFFFAOYSA-N
DMVQU9T	IU	3-(4-chlorophenyl)-7-hydroxy-2-propan-2-ylquinazolin-4-one
DMVQU9T	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMQGTYE	ID	DMQGTYE
DMQGTYE	DN	PMID25666693-Compound-141
DMQGTYE	HS	Patented
DMQGTYE	CP	Novartis AG
DMQGTYE	DT	Small molecular drug
DMQGTYE	PC	53402973
DMQGTYE	MW	348.3
DMQGTYE	FM	C18H15F3N2O2
DMQGTYE	IC	InChI=1S/C18H15F3N2O2/c1-10(2)16-22-15-9-13(24)7-8-14(15)17(25)23(16)12-5-3-11(4-6-12)18(19,20)21/h3-10,24H,1-2H3
DMQGTYE	CS	CC(C)C1=NC2=C(C=CC(=C2)O)C(=O)N1C3=CC=C(C=C3)C(F)(F)F
DMQGTYE	IK	BQCYMHBVGHVCTM-UHFFFAOYSA-N
DMQGTYE	IU	7-hydroxy-2-propan-2-yl-3-[4-(trifluoromethyl)phenyl]quinazolin-4-one
DMQGTYE	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMFKN1O	ID	DMFKN1O
DMFKN1O	DN	PMID25666693-Compound-142
DMFKN1O	HS	Patented
DMFKN1O	CP	Novartis AG
DMFKN1O	DT	Small molecular drug
DMFKN1O	PC	58387658
DMFKN1O	MW	393.7
DMFKN1O	FM	C17H14BrClN2O2
DMFKN1O	IC	InChI=1S/C17H14BrClN2O2/c1-9(2)16-20-15-12(7-8-13(22)14(15)18)17(23)21(16)11-5-3-10(19)4-6-11/h3-9,22H,1-2H3
DMFKN1O	CS	CC(C)C1=NC2=C(C=CC(=C2Br)O)C(=O)N1C3=CC=C(C=C3)Cl
DMFKN1O	IK	RGGBBKIVAZMLNK-UHFFFAOYSA-N
DMFKN1O	IU	8-bromo-3-(4-chlorophenyl)-7-hydroxy-2-propan-2-ylquinazolin-4-one
DMFKN1O	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMJP0NB	ID	DMJP0NB
DMJP0NB	DN	PMID25666693-Compound-143
DMJP0NB	HS	Patented
DMJP0NB	CP	DAEWOONG PHARMACEUTICAL CO., LTD. KIM, Ji Duck YOON, Hong Chul KIM, In Woo CHO, Min Jae LEE, In Young LEE, Sang Ho PARK, Eun Kyung LIM, Kwon Jo NAM, Sang Hyun
DMJP0NB	DT	Small molecular drug
DMJP0NB	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMCXELD	ID	DMCXELD
DMCXELD	DN	PMID25666693-Compound-144
DMCXELD	HS	Patented
DMCXELD	CP	DAEWOONG PHARMACEUTICAL CO., LTD. KIM, Ji Duck YOON, Hong Chul KIM, In Woo CHO, Min Jae LEE, In Young LEE, Sang Ho PARK, Eun Kyung LIM, Kwon Jo NAM, Sang Hyun
DMCXELD	DT	Small molecular drug
DMCXELD	PC	67412556
DMCXELD	MW	440.9
DMCXELD	FM	C22H18ClFN4O3
DMCXELD	IC	InChI=1S/C22H18ClFN4O3/c1-30-13-5-6-20(25-9-13)28-12(10-29)11-31-21-14(3-2-4-19(21)28)22-26-17-7-15(23)16(24)8-18(17)27-22/h2-9,12,29H,10-11H2,1H3,(H,26,27)/t12-/m0/s1
DMCXELD	CS	COC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C4=NC5=CC(=C(C=C5N4)F)Cl)CO
DMCXELD	IK	KALRQYKXWDYSRI-LBPRGKRZSA-N
DMCXELD	IU	[(3S)-8-(5-chloro-6-fluoro-1H-benzimidazol-2-yl)-4-(5-methoxypyridin-2-yl)-2,3-dihydro-1,4-benzoxazin-3-yl]methanol
DMCXELD	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMP89E4	ID	DMP89E4
DMP89E4	DN	PMID25666693-Compound-145
DMP89E4	HS	Patented
DMP89E4	CP	DAEWOONG PHARMACEUTICAL CO., LTD. KIM, Ji Duck YOON, Hong Chul KIM, In Woo CHO, Min Jae LEE, In Young LEE, Sang Ho PARK, Eun Kyung LIM, Kwon Jo NAM, Sang Hyun
DMP89E4	DT	Small molecular drug
DMP89E4	PC	67412506
DMP89E4	MW	490.9
DMP89E4	FM	C23H18ClF3N4O3
DMP89E4	IC	InChI=1S/C23H18ClF3N4O3/c1-33-14-5-6-19(28-9-14)31-13(10-32)11-34-21-15(3-2-4-18(21)31)22-29-17-8-12(23(25,26)27)7-16(24)20(17)30-22/h2-9,13,32H,10-11H2,1H3,(H,29,30)/t13-/m0/s1
DMP89E4	CS	COC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C4=NC5=C(N4)C=C(C=C5Cl)C(F)(F)F)CO
DMP89E4	IK	CKJDUPIYRSXWAL-ZDUSSCGKSA-N
DMP89E4	IU	[(3S)-8-[4-chloro-6-(trifluoromethyl)-1H-benzimidazol-2-yl]-4-(5-methoxypyridin-2-yl)-2,3-dihydro-1,4-benzoxazin-3-yl]methanol
DMP89E4	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMLE5BK	ID	DMLE5BK
DMLE5BK	DN	PMID25666693-Compound-146
DMLE5BK	HS	Patented
DMLE5BK	CP	Xention Ltd
DMLE5BK	DT	Small molecular drug
DMLE5BK	PC	59730981
DMLE5BK	MW	430.5
DMLE5BK	FM	C26H26N2O4
DMLE5BK	IC	InChI=1S/C26H26N2O4/c1-2-32-25(30)19-11-9-17(10-12-19)20-6-3-7-21(15-20)27-26(31)28-24-8-4-5-18-13-14-22(29)16-23(18)24/h3-12,15,22,29H,2,13-14,16H2,1H3,(H2,27,28,31)
DMLE5BK	CS	CCOC(=O)C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)NC3=CC=CC4=C3CC(CC4)O
DMLE5BK	IK	IWMJRJDFRWWJBW-UHFFFAOYSA-N
DMLE5BK	IU	ethyl 4-[3-[(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)carbamoylamino]phenyl]benzoate
DMLE5BK	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMG1SYN	ID	DMG1SYN
DMG1SYN	DN	PMID25666693-Compound-147
DMG1SYN	HS	Patented
DMG1SYN	CP	Xention Ltd
DMG1SYN	DT	Small molecular drug
DMG1SYN	PC	59731029
DMG1SYN	MW	410.9
DMG1SYN	FM	C23H20ClFN2O2
DMG1SYN	IC	InChI=1S/C23H20ClFN2O2/c24-20-10-8-16(12-21(20)25)15-4-1-5-17(11-15)26-23(29)27-22-6-2-3-14-7-9-18(28)13-19(14)22/h1-6,8,10-12,18,28H,7,9,13H2,(H2,26,27,29)
DMG1SYN	CS	C1CC2=C(CC1O)C(=CC=C2)NC(=O)NC3=CC=CC(=C3)C4=CC(=C(C=C4)Cl)F
DMG1SYN	IK	VIQQVXGGWBFLTG-UHFFFAOYSA-N
DMG1SYN	IU	1-[3-(4-chloro-3-fluorophenyl)phenyl]-3-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea
DMG1SYN	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM0EYON	ID	DM0EYON
DM0EYON	DN	PMID25666693-Compound-148
DM0EYON	HS	Patented
DM0EYON	CP	Xention Ltd
DM0EYON	DT	Small molecular drug
DM0EYON	PC	59731038
DM0EYON	MW	379.4
DM0EYON	FM	C23H19F2NO2
DM0EYON	IC	InChI=1S/C23H19F2NO2/c24-20-11-9-17(12-21(20)25)14-4-6-16(7-5-14)23(28)26-22-3-1-2-15-8-10-18(27)13-19(15)22/h1-7,9,11-12,18,27H,8,10,13H2,(H,26,28)
DM0EYON	CS	C1CC2=C(CC1O)C(=CC=C2)NC(=O)C3=CC=C(C=C3)C4=CC(=C(C=C4)F)F
DM0EYON	IK	BBXIMYHEGLSHKN-UHFFFAOYSA-N
DM0EYON	IU	4-(3,4-difluorophenyl)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)benzamide
DM0EYON	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMPU19H	ID	DMPU19H
DMPU19H	DN	PMID25666693-Compound-149
DMPU19H	HS	Patented
DMPU19H	CP	Xention Ltd
DMPU19H	DT	Small molecular drug
DMPU19H	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM1G6AE	ID	DM1G6AE
DM1G6AE	DN	PMID25666693-Compound-15
DM1G6AE	HS	Patented
DM1G6AE	CP	ABBOTT LABORATORIES 
DM1G6AE	DT	Small molecular drug
DM1G6AE	PC	25263680
DM1G6AE	MW	417.4
DM1G6AE	FM	C21H18F3N3O3
DM1G6AE	IC	InChI=1S/C21H18F3N3O3/c1-12-10-15-13(11-25-12)4-2-6-16(15)26-20(28)27-17-8-9-29-19-14(17)5-3-7-18(19)30-21(22,23)24/h2-7,10-11,17H,8-9H2,1H3,(H2,26,27,28)/t17-/m1/s1
DM1G6AE	CS	CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CCOC4=C3C=CC=C4OC(F)(F)F)C=N1
DM1G6AE	IK	JPPAKTWQFHCNDQ-QGZVFWFLSA-N
DM1G6AE	IU	1-(3-methylisoquinolin-5-yl)-3-[(4R)-8-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea
DM1G6AE	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMHMEFY	ID	DMHMEFY
DMHMEFY	DN	PMID25666693-Compound-150
DMHMEFY	HS	Patented
DMHMEFY	CP	Amorepacific Corp
DMHMEFY	DT	Small molecular drug
DMHMEFY	PC	68324561
DMHMEFY	MW	479.6
DMHMEFY	FM	C22H23F2N3O3S2
DMHMEFY	IC	InChI=1S/C22H23F2N3O3S2/c1-12(2)14-6-5-7-15(8-14)22-26-19(11-31-22)21(28)25-13(3)16-9-17(23)20(18(24)10-16)27-32(4,29)30/h5-13,27H,1-4H3,(H,25,28)/t13-/m1/s1
DMHMEFY	CS	C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=CSC(=N2)C3=CC(=CC=C3)C(C)C
DMHMEFY	IK	PCULXRGTXBQRDF-CYBMUJFWSA-N
DMHMEFY	IU	N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-2-(3-propan-2-ylphenyl)-1,3-thiazole-4-carboxamide
DMHMEFY	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM5CY86	ID	DM5CY86
DM5CY86	DN	PMID25666693-Compound-151
DM5CY86	HS	Patented
DM5CY86	CP	Amorepacific Corp
DM5CY86	DT	Small molecular drug
DM5CY86	PC	68324656
DM5CY86	MW	461.5
DM5CY86	FM	C22H21F2N3O4S
DM5CY86	IC	InChI=1S/C22H21F2N3O4S/c1-12(16-9-17(23)20(18(24)10-16)27-32(2,29)30)25-21(28)19-11-31-22(26-19)15-5-3-4-14(8-15)13-6-7-13/h3-5,8-13,27H,6-7H2,1-2H3,(H,25,28)/t12-/m1/s1
DM5CY86	CS	C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=COC(=N2)C3=CC(=CC=C3)C4CC4
DM5CY86	IK	PCQJGNGGTPQUOG-GFCCVEGCSA-N
DM5CY86	IU	2-(3-cyclopropylphenyl)-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-1,3-oxazole-4-carboxamide
DM5CY86	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM27154	ID	DM27154
DM27154	DN	PMID25666693-Compound-152
DM27154	HS	Patented
DM27154	CP	Amorepacific Corp
DM27154	DT	Small molecular drug
DM27154	PC	44548476
DM27154	MW	488.4
DM27154	FM	C21H17F5N2O4S
DM27154	IC	InChI=1S/C21H17F5N2O4S/c1-11(13-9-15(22)19(16(23)10-13)28-33(2,30)31)27-20(29)18-7-6-17(32-18)12-4-3-5-14(8-12)21(24,25)26/h3-11,28H,1-2H3,(H,27,29)/t11-/m1/s1
DM27154	CS	C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=CC=C(O2)C3=CC(=CC=C3)C(F)(F)F
DM27154	IK	UBEWFMQQEXOLKY-LLVKDONJSA-N
DM27154	IU	N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-5-[3-(trifluoromethyl)phenyl]furan-2-carboxamide
DM27154	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM1FTV6	ID	DM1FTV6
DM1FTV6	DN	PMID25666693-Compound-153
DM1FTV6	HS	Patented
DM1FTV6	CP	Amorepacific Corp
DM1FTV6	DT	Small molecular drug
DM1FTV6	PC	88937082
DM1FTV6	MW	556.4
DM1FTV6	FM	C22H16F8N2O4S
DM1FTV6	IC	InChI=1S/C22H16F8N2O4S/c1-10(11-7-15(23)19(16(24)8-11)32-37(2,34)35)31-20(33)18-4-3-17(36-18)12-5-13(21(25,26)27)9-14(6-12)22(28,29)30/h3-10,32H,1-2H3,(H,31,33)/t10-/m1/s1
DM1FTV6	CS	C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=CC=C(O2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DM1FTV6	IK	RGPMLUVMZUYQEJ-SNVBAGLBSA-N
DM1FTV6	IU	5-[3,5-bis(trifluoromethyl)phenyl]-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]furan-2-carboxamide
DM1FTV6	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMKNU0Z	ID	DMKNU0Z
DMKNU0Z	DN	PMID25666693-Compound-154
DMKNU0Z	HS	Patented
DMKNU0Z	CP	Amorepacific Corp
DMKNU0Z	DT	Small molecular drug
DMKNU0Z	PC	88937150
DMKNU0Z	MW	506.4
DMKNU0Z	FM	C21H16F6N2O4S
DMKNU0Z	IC	InChI=1S/C21H16F6N2O4S/c1-10(12-8-15(23)19(16(24)9-12)29-34(2,31)32)28-20(30)18-6-5-17(33-18)11-3-4-14(22)13(7-11)21(25,26)27/h3-10,29H,1-2H3,(H,28,30)/t10-/m1/s1
DMKNU0Z	CS	C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=CC=C(O2)C3=CC(=C(C=C3)F)C(F)(F)F
DMKNU0Z	IK	UERGSQUAPFQUKE-SNVBAGLBSA-N
DMKNU0Z	IU	N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-5-[4-fluoro-3-(trifluoromethyl)phenyl]furan-2-carboxamide
DMKNU0Z	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMZLB07	ID	DMZLB07
DMZLB07	DN	PMID25666693-Compound-155
DMZLB07	HS	Patented
DMZLB07	CP	Janssen Pharmaceutica NV
DMZLB07	DT	Small molecular drug
DMZLB07	PC	24782891
DMZLB07	MW	441.5
DMZLB07	FM	C24H26F3N5
DMZLB07	IC	InChI=1S/C24H26F3N5/c1-23(2,3)16-6-8-17(9-7-16)31-21-18-10-13-32(14-11-20(18)29-15-30-21)22-19(24(25,26)27)5-4-12-28-22/h4-9,12,15H,10-11,13-14H2,1-3H3,(H,29,30,31)
DMZLB07	CS	CC(C)(C)C1=CC=C(C=C1)NC2=NC=NC3=C2CCN(CC3)C4=C(C=CC=N4)C(F)(F)F
DMZLB07	IK	HUWDXCSRDAPMOC-UHFFFAOYSA-N
DMZLB07	IU	N-(4-tert-butylphenyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-5,6,8,9-tetrahydropyrimido[4,5-d]azepin-4-amine
DMZLB07	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMTVAUP	ID	DMTVAUP
DMTVAUP	DN	PMID25666693-Compound-156
DMTVAUP	HS	Patented
DMTVAUP	CP	Janssen Pharmaceutica NV
DMTVAUP	DT	Small molecular drug
DMTVAUP	PC	24783142
DMTVAUP	MW	483.6
DMTVAUP	FM	C27H32F3N5
DMTVAUP	IC	InChI=1S/C27H32F3N5/c1-17(2)23-33-22-13-16-35(25-21(27(28,29)30)7-6-14-31-25)15-12-20(22)24(34-23)32-19-10-8-18(9-11-19)26(3,4)5/h6-11,14,17H,12-13,15-16H2,1-5H3,(H,32,33,34)
DMTVAUP	CS	CC(C)C1=NC2=C(CCN(CC2)C3=C(C=CC=N3)C(F)(F)F)C(=N1)NC4=CC=C(C=C4)C(C)(C)C
DMTVAUP	IK	KJNMKUGTDFIAPJ-UHFFFAOYSA-N
DMTVAUP	IU	N-(4-tert-butylphenyl)-2-propan-2-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-5,6,8,9-tetrahydropyrimido[4,5-d]azepin-4-amine
DMTVAUP	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DME8LUY	ID	DME8LUY
DME8LUY	DN	PMID25666693-Compound-157
DME8LUY	HS	Patented
DME8LUY	CP	Janssen Pharmaceutica NV
DME8LUY	DT	Small molecular drug
DME8LUY	PC	52949700
DME8LUY	MW	496.5
DME8LUY	FM	C23H22F6N6
DME8LUY	IC	InChI=1S/C23H22F6N6/c1-13(2)19-32-17-8-11-35(21-16(23(27,28)29)4-3-9-30-21)10-7-15(17)20(34-19)33-18-6-5-14(12-31-18)22(24,25)26/h3-6,9,12-13H,7-8,10-11H2,1-2H3,(H,31,32,33,34)
DME8LUY	CS	CC(C)C1=NC2=C(CCN(CC2)C3=C(C=CC=N3)C(F)(F)F)C(=N1)NC4=NC=C(C=C4)C(F)(F)F
DME8LUY	IK	NACDTTPBPBGLSZ-UHFFFAOYSA-N
DME8LUY	IU	2-propan-2-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-5,6,8,9-tetrahydropyrimido[4,5-d]azepin-4-amine
DME8LUY	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM2BTCU	ID	DM2BTCU
DM2BTCU	DN	PMID25666693-Compound-158
DM2BTCU	HS	Patented
DM2BTCU	CP	Janssen Pharmaceutica NV
DM2BTCU	DT	Small molecular drug
DM2BTCU	PC	16742146
DM2BTCU	MW	536.5
DM2BTCU	FM	C26H26F6N6
DM2BTCU	IC	InChI=1S/C26H26F6N6/c27-25(28,29)17-6-8-18(9-7-17)34-22-19-10-15-37(23-20(26(30,31)32)5-4-12-33-23)16-11-21(19)35-24(36-22)38-13-2-1-3-14-38/h4-9,12H,1-3,10-11,13-16H2,(H,34,35,36)
DM2BTCU	CS	C1CCN(CC1)C2=NC3=C(CCN(CC3)C4=C(C=CC=N4)C(F)(F)F)C(=N2)NC5=CC=C(C=C5)C(F)(F)F
DM2BTCU	IK	MRHHSXHMRZMNIM-UHFFFAOYSA-N
DM2BTCU	IU	2-piperidin-1-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-5,6,8,9-tetrahydropyrimido[4,5-d]azepin-4-amine
DM2BTCU	CA	CAS 951135-00-5
DM2BTCU	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM74OGS	ID	DM74OGS
DM74OGS	DN	PMID25666693-Compound-159
DM74OGS	HS	Patented
DM74OGS	CP	Janssen Pharmaceutica NV
DM74OGS	DT	Small molecular drug
DM74OGS	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM6SL9D	ID	DM6SL9D
DM6SL9D	DN	PMID25666693-Compound-16
DM6SL9D	HS	Patented
DM6SL9D	CP	ABBOTT LABORATORIES 
DM6SL9D	DT	Small molecular drug
DM6SL9D	PC	46191563
DM6SL9D	MW	481.4
DM6SL9D	FM	C23H20F5N3O3
DM6SL9D	IC	InChI=1S/C23H20F5N3O3/c1-13-8-16-14(10-29-13)4-2-6-17(16)30-21(32)31-18-9-22(11-24,12-25)34-20-15(18)5-3-7-19(20)33-23(26,27)28/h2-8,10,18H,9,11-12H2,1H3,(H2,30,31,32)/t18-/m1/s1
DM6SL9D	CS	CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC=C4OC(F)(F)F)(CF)CF)C=N1
DM6SL9D	IK	NCTHKPLEGMZRNY-GOSISDBHSA-N
DM6SL9D	IU	1-[(4R)-2,2-bis(fluoromethyl)-8-(trifluoromethoxy)-3,4-dihydrochromen-4-yl]-3-(3-methylisoquinolin-5-yl)urea
DM6SL9D	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM2KTAB	ID	DM2KTAB
DM2KTAB	DN	PMID25666693-Compound-160
DM2KTAB	HS	Patented
DM2KTAB	CP	Janssen Pharmaceutica NV
DM2KTAB	DT	Small molecular drug
DM2KTAB	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM06IWA	ID	DM06IWA
DM06IWA	DN	PMID25666693-Compound-161
DM06IWA	HS	Patented
DM06IWA	CP	Janssen Pharmaceutica NV
DM06IWA	DT	Small molecular drug
DM06IWA	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMXS5WY	ID	DMXS5WY
DMXS5WY	DN	PMID25666693-Compound-162
DMXS5WY	HS	Patented
DMXS5WY	CP	Janssen Pharmaceutica NV
DMXS5WY	DT	Small molecular drug
DMXS5WY	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMRK1W7	ID	DMRK1W7
DMRK1W7	DN	PMID25666693-Compound-17
DMRK1W7	HS	Patented
DMRK1W7	CP	ABBOTT LABORATORIES 
DMRK1W7	DT	Small molecular drug
DMRK1W7	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMKU6C3	ID	DMKU6C3
DMKU6C3	DN	PMID25666693-Compound-18
DMKU6C3	HS	Patented
DMKU6C3	CP	ABBOTT LABORATORIES 
DMKU6C3	DT	Small molecular drug
DMKU6C3	PC	25265637
DMKU6C3	MW	407.5
DMKU6C3	FM	C24H26FN3O2
DMKU6C3	IC	InChI=1S/C24H26FN3O2/c1-4-24(5-2)13-21(17-9-7-10-19(25)22(17)30-24)28-23(29)27-20-11-6-8-16-14-26-15(3)12-18(16)20/h6-12,14,21H,4-5,13H2,1-3H3,(H2,27,28,29)/t21-/m1/s1
DMKU6C3	CS	CCC1(C[C@H](C2=C(O1)C(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CC
DMKU6C3	IK	KRCMLCOREROPCP-OAQYLSRUSA-N
DMKU6C3	IU	1-[(4R)-2,2-diethyl-8-fluoro-3,4-dihydrochromen-4-yl]-3-(3-methylisoquinolin-5-yl)urea
DMKU6C3	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM63UM8	ID	DM63UM8
DM63UM8	DN	PMID25666693-Compound-19
DM63UM8	HS	Patented
DM63UM8	CP	ABBOTT LABORATORIES 
DM63UM8	DT	Small molecular drug
DM63UM8	PC	25263543
DM63UM8	MW	423.9
DM63UM8	FM	C24H26ClN3O2
DM63UM8	IC	InChI=1S/C24H26ClN3O2/c1-4-24(5-2)13-21(18-10-9-17(25)12-22(18)30-24)28-23(29)27-20-8-6-7-16-14-26-15(3)11-19(16)20/h6-12,14,21H,4-5,13H2,1-3H3,(H2,27,28,29)/t21-/m1/s1
DM63UM8	CS	CCC1(C[C@H](C2=C(O1)C=C(C=C2)Cl)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CC
DM63UM8	IK	PETMJQMEMLSBKV-OAQYLSRUSA-N
DM63UM8	IU	1-[(4R)-7-chloro-2,2-diethyl-3,4-dihydrochromen-4-yl]-3-(3-methylisoquinolin-5-yl)urea
DM63UM8	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMERD39	ID	DMERD39
DMERD39	DN	PMID25666693-Compound-2
DMERD39	HS	Patented
DMERD39	CP	ABBVIE INC
DMERD39	DT	Small molecular drug
DMERD39	PC	66549276
DMERD39	MW	381.4
DMERD39	FM	C22H21F2N3O
DMERD39	IC	InChI=1S/C22H21F2N3O/c1-13-10-18-15(12-25-13)7-9-20(24)21(18)27-22(28)26-16-8-6-14(11-16)17-4-2-3-5-19(17)23/h2-5,7,9-10,12,14,16H,6,8,11H2,1H3,(H2,26,27,28)/t14-,16+/m0/s1
DMERD39	CS	CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@@H](C3)C4=CC=CC=C4F)F)C=N1
DMERD39	IK	PJVXUKARZNCIRA-GOEBONIOSA-N
DMERD39	IU	1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3S)-3-(2-fluorophenyl)cyclopentyl]urea
DMERD39	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM3I90D	ID	DM3I90D
DM3I90D	DN	PMID25666693-Compound-20
DM3I90D	HS	Patented
DM3I90D	CP	ABBOTT LABORATORIES 
DM3I90D	DT	Small molecular drug
DM3I90D	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMUXO47	ID	DMUXO47
DMUXO47	DN	PMID25666693-Compound-21
DMUXO47	HS	Patented
DMUXO47	CP	ABBOTT LABORATORIES 
DMUXO47	DT	Small molecular drug
DMUXO47	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMHPW3X	ID	DMHPW3X
DMHPW3X	DN	PMID25666693-Compound-22
DMHPW3X	HS	Patented
DMHPW3X	CP	ABBOTT LABORATORIES 
DMHPW3X	DT	Small molecular drug
DMHPW3X	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMJ3YDT	ID	DMJ3YDT
DMJ3YDT	DN	PMID25666693-Compound-23
DMJ3YDT	HS	Patented
DMJ3YDT	CP	ABBOTT LABORATORIES 
DMJ3YDT	DT	Small molecular drug
DMJ3YDT	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMUMYKX	ID	DMUMYKX
DMUMYKX	DN	PMID25666693-Compound-24
DMUMYKX	HS	Patented
DMUMYKX	CP	AbbVie, Inc
DMUMYKX	DT	Small molecular drug
DMUMYKX	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMI8CB3	ID	DMI8CB3
DMI8CB3	DN	PMID25666693-Compound-25
DMI8CB3	HS	Patented
DMI8CB3	CP	ABBVIE INC
DMI8CB3	DT	Small molecular drug
DMI8CB3	PC	71599909
DMI8CB3	MW	404.9
DMI8CB3	FM	C21H22ClFN2O3
DMI8CB3	IC	InChI=1S/C21H22ClFN2O3/c1-21(2)10-17(13-6-7-15(23)18(22)19(13)28-21)25-20(27)24-16-5-3-4-11-8-12(26)9-14(11)16/h3-7,12,17,26H,8-10H2,1-2H3,(H2,24,25,27)/t12-,17-/m1/s1
DMI8CB3	CS	CC1(C[C@H](C2=C(O1)C(=C(C=C2)F)Cl)NC(=O)NC3=CC=CC4=C3C[C@@H](C4)O)C
DMI8CB3	IK	NXZOBNXJGCHNTQ-SJKOYZFVSA-N
DMI8CB3	IU	1-[(4R)-8-chloro-7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DMI8CB3	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMQBFI2	ID	DMQBFI2
DMQBFI2	DN	PMID25666693-Compound-26
DMQBFI2	HS	Patented
DMQBFI2	CP	ABBVIE INC
DMQBFI2	DT	Small molecular drug
DMQBFI2	PC	71599484
DMQBFI2	MW	436.4
DMQBFI2	FM	C22H23F3N2O4
DMQBFI2	IC	InChI=1S/C22H23F3N2O4/c1-21(2)11-17(14-6-4-8-18(19(14)31-21)30-22(23,24)25)27-20(29)26-16-7-3-5-12-9-13(28)10-15(12)16/h3-8,13,17,28H,9-11H2,1-2H3,(H2,26,27,29)/t13-,17+/m0/s1
DMQBFI2	CS	CC1(C[C@H](C2=C(O1)C(=CC=C2)OC(F)(F)F)NC(=O)NC3=CC=CC4=C3C[C@H](C4)O)C
DMQBFI2	IK	VGEBXDOPNDGVPV-SUMWQHHRSA-N
DMQBFI2	IU	1-[(4R)-2,2-dimethyl-8-(trifluoromethoxy)-3,4-dihydrochromen-4-yl]-3-[(2S)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DMQBFI2	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMKHO8T	ID	DMKHO8T
DMKHO8T	DN	PMID25666693-Compound-27
DMKHO8T	HS	Patented
DMKHO8T	CP	ABBVIE INC
DMKHO8T	DT	Small molecular drug
DMKHO8T	PC	71599827
DMKHO8T	MW	422.9
DMKHO8T	FM	C21H21ClF2N2O3
DMKHO8T	IC	InChI=1S/C21H21ClF2N2O3/c22-13-4-5-15-18(9-21(10-23,11-24)29-19(15)7-13)26-20(28)25-17-3-1-2-12-6-14(27)8-16(12)17/h1-5,7,14,18,27H,6,8-11H2,(H2,25,26,28)/t14-,18-/m1/s1
DMKHO8T	CS	C1[C@H](CC2=C1C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)Cl)(CF)CF)O
DMKHO8T	IK	UKGBTQWQSDNAQR-RDTXWAMCSA-N
DMKHO8T	IU	1-[(4R)-7-chloro-2,2-bis(fluoromethyl)-3,4-dihydrochromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DMKHO8T	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM7T962	ID	DM7T962
DM7T962	DN	PMID25666693-Compound-28
DM7T962	HS	Patented
DM7T962	CP	ABBVIE INC
DM7T962	DT	Small molecular drug
DM7T962	PC	71580510
DM7T962	MW	456.4
DM7T962	FM	C22H21F5N2O3
DM7T962	IC	InChI=1S/C22H21F5N2O3/c23-10-21(11-24)9-18(15-5-4-13(22(25,26)27)7-19(15)32-21)29-20(31)28-17-3-1-2-12-6-14(30)8-16(12)17/h1-5,7,14,18,30H,6,8-11H2,(H2,28,29,31)/t14-,18-/m1/s1
DM7T962	CS	C1[C@H](CC2=C1C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)C(F)(F)F)(CF)CF)O
DM7T962	IK	PPTIROVBLCDDBO-RDTXWAMCSA-N
DM7T962	IU	1-[(4R)-2,2-bis(fluoromethyl)-7-(trifluoromethyl)-3,4-dihydrochromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DM7T962	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM02D1B	ID	DM02D1B
DM02D1B	DN	PMID25666693-Compound-29
DM02D1B	HS	Patented
DM02D1B	CP	ABBVIE INC
DM02D1B	DT	Small molecular drug
DM02D1B	PC	71599906
DM02D1B	MW	388.4
DM02D1B	FM	C21H22F2N2O3
DM02D1B	IC	InChI=1S/C21H22F2N2O3/c1-21(2)10-17(13-6-7-15(22)18(23)19(13)28-21)25-20(27)24-16-5-3-4-11-8-12(26)9-14(11)16/h3-7,12,17,26H,8-10H2,1-2H3,(H2,24,25,27)/t12-,17-/m1/s1
DM02D1B	CS	CC1(C[C@H](C2=C(O1)C(=C(C=C2)F)F)NC(=O)NC3=CC=CC4=C3C[C@@H](C4)O)C
DM02D1B	IK	YOPCFYQBNUSQMJ-SJKOYZFVSA-N
DM02D1B	IU	1-[(4R)-7,8-difluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DM02D1B	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMN692C	ID	DMN692C
DMN692C	DN	PMID25666693-Compound-3
DMN692C	HS	Patented
DMN692C	CP	ABBVIE INC
DMN692C	DT	Small molecular drug
DMN692C	PC	66549466
DMN692C	MW	381.4
DMN692C	FM	C22H21F2N3O
DMN692C	IC	InChI=1S/C22H21F2N3O/c1-13-9-19-16(12-25-13)6-8-20(24)21(19)27-22(28)26-18-7-5-15(11-18)14-3-2-4-17(23)10-14/h2-4,6,8-10,12,15,18H,5,7,11H2,1H3,(H2,26,27,28)/t15-,18+/m0/s1
DMN692C	CS	CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@@H](C3)C4=CC(=CC=C4)F)F)C=N1
DMN692C	IK	PAFRMBKESKKSIA-MAUKXSAKSA-N
DMN692C	IU	1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3S)-3-(3-fluorophenyl)cyclopentyl]urea
DMN692C	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMC3DT7	ID	DMC3DT7
DMC3DT7	DN	PMID25666693-Compound-30
DMC3DT7	HS	Patented
DMC3DT7	CP	ABBVIE INC
DMC3DT7	DT	Small molecular drug
DMC3DT7	PC	71598766
DMC3DT7	MW	404.9
DMC3DT7	FM	C21H22ClFN2O3
DMC3DT7	IC	InChI=1S/C21H22ClFN2O3/c1-21(2)10-17(13-6-7-15(23)18(22)19(13)28-21)25-20(27)24-16-5-3-4-11-8-12(26)9-14(11)16/h3-7,12,17,26H,8-10H2,1-2H3,(H2,24,25,27)/t12-,17+/m0/s1
DMC3DT7	CS	CC1(C[C@H](C2=C(O1)C(=C(C=C2)F)Cl)NC(=O)NC3=CC=CC4=C3C[C@H](C4)O)C
DMC3DT7	IK	NXZOBNXJGCHNTQ-YVEFUNNKSA-N
DMC3DT7	IU	1-[(4R)-8-chloro-7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-[(2S)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DMC3DT7	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM853Y7	ID	DM853Y7
DM853Y7	DN	PMID25666693-Compound-31
DM853Y7	HS	Patented
DM853Y7	CP	ABBVIE INC
DM853Y7	DT	Small molecular drug
DM853Y7	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM58Z4M	ID	DM58Z4M
DM58Z4M	DN	PMID25666693-Compound-32
DM58Z4M	HS	Patented
DM58Z4M	CP	ABBVIE INC
DM58Z4M	DT	Small molecular drug
DM58Z4M	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMW7981	ID	DMW7981
DMW7981	DN	PMID25666693-Compound-33
DMW7981	HS	Patented
DMW7981	CP	ABBVIE INC
DMW7981	DT	Small molecular drug
DMW7981	PC	71611619
DMW7981	MW	434.4
DMW7981	FM	C21H21F3N4O3
DMW7981	IC	InChI=1S/C21H21F3N4O3/c1-20(21(22,23)24)10-16(14-5-3-4-6-17(14)31-20)26-18(29)25-13-8-7-12-11-28(2)19(30)27-15(12)9-13/h3-9,16H,10-11H2,1-2H3,(H,27,30)(H2,25,26,29)/t16-,20-/m1/s1
DMW7981	CS	C[C@@]1(C[C@H](C2=CC=CC=C2O1)NC(=O)NC3=CC4=C(CN(C(=O)N4)C)C=C3)C(F)(F)F
DMW7981	IK	OFCQSAHGUNDUTK-OXQOHEQNSA-N
DMW7981	IU	1-(3-methyl-2-oxo-1,4-dihydroquinazolin-7-yl)-3-[(2R,4R)-2-methyl-2-(trifluoromethyl)-3,4-dihydrochromen-4-yl]urea
DMW7981	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMWGAQU	ID	DMWGAQU
DMWGAQU	DN	PMID25666693-Compound-34
DMWGAQU	HS	Patented
DMWGAQU	CP	ABBVIE INC
DMWGAQU	DT	Small molecular drug
DMWGAQU	PC	71611907
DMWGAQU	MW	401.4
DMWGAQU	FM	C21H21F2N3O3
DMWGAQU	IC	InChI=1S/C21H21F2N3O3/c1-21(2)10-16(13-6-7-14(22)18(23)19(13)29-21)26-20(28)24-12-5-3-11-4-8-17(27)25-15(11)9-12/h3,5-7,9,16H,4,8,10H2,1-2H3,(H,25,27)(H2,24,26,28)/t16-/m1/s1
DMWGAQU	CS	CC1(C[C@H](C2=C(O1)C(=C(C=C2)F)F)NC(=O)NC3=CC4=C(CCC(=O)N4)C=C3)C
DMWGAQU	IK	UDVRSQKMFMPYID-MRXNPFEDSA-N
DMWGAQU	IU	1-[(4R)-7,8-difluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-(2-oxo-3,4-dihydro-1H-quinolin-7-yl)urea
DMWGAQU	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMG9CPH	ID	DMG9CPH
DMG9CPH	DN	PMID25666693-Compound-35
DMG9CPH	HS	Patented
DMG9CPH	CP	ABBVIE INC
DMG9CPH	DT	Small molecular drug
DMG9CPH	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMWVR81	ID	DMWVR81
DMWVR81	DN	PMID25666693-Compound-36
DMWVR81	HS	Patented
DMWVR81	CP	ABBVIE INC
DMWVR81	DT	Small molecular drug
DMWVR81	PC	71611910
DMWVR81	MW	385.4
DMWVR81	FM	C20H20FN3O4
DMWVR81	IC	InChI=1S/C20H20FN3O4/c1-20(2)9-15(13-5-3-11(21)7-17(13)28-20)24-19(26)22-12-4-6-16-14(8-12)23-18(25)10-27-16/h3-8,15H,9-10H2,1-2H3,(H,23,25)(H2,22,24,26)/t15-/m1/s1
DMWVR81	CS	CC1(C[C@H](C2=C(O1)C=C(C=C2)F)NC(=O)NC3=CC4=C(C=C3)OCC(=O)N4)C
DMWVR81	IK	GBNGQHMENHKOCY-OAHLLOKOSA-N
DMWVR81	IU	1-[(4R)-7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-(3-oxo-4H-1,4-benzoxazin-6-yl)urea
DMWVR81	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMSR218	ID	DMSR218
DMSR218	DN	PMID25666693-Compound-37
DMSR218	HS	Patented
DMSR218	CP	GRUENENTHAL GMBH [DE]
DMSR218	DT	Small molecular drug
DMSR218	PC	49802515
DMSR218	MW	458.9
DMSR218	FM	C23H18ClF3N4O
DMSR218	IC	InChI=1S/C23H18ClF3N4O/c1-14(19-7-2-4-15-12-28-9-8-20(15)19)22(32)29-13-18-11-21(23(25,26)27)30-31(18)17-6-3-5-16(24)10-17/h2-12,14H,13H2,1H3,(H,29,32)
DMSR218	CS	CC(C1=CC=CC2=C1C=CN=C2)C(=O)NCC3=CC(=NN3C4=CC(=CC=C4)Cl)C(F)(F)F
DMSR218	IK	ZBOCDMVUEHZVGP-UHFFFAOYSA-N
DMSR218	IU	N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-isoquinolin-5-ylpropanamide
DMSR218	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMBW36Y	ID	DMBW36Y
DMBW36Y	DN	PMID25666693-Compound-38
DMBW36Y	HS	Patented
DMBW36Y	CP	GRUENENTHAL GMBH [DE]
DMBW36Y	DT	Small molecular drug
DMBW36Y	PC	87087836
DMBW36Y	MW	493.3
DMBW36Y	FM	C23H17Cl2F3N4O
DMBW36Y	IC	InChI=1S/C23H17Cl2F3N4O/c1-13(18-7-2-4-14-11-29-21(25)10-19(14)18)22(33)30-12-17-9-20(23(26,27)28)31-32(17)16-6-3-5-15(24)8-16/h2-11,13H,12H2,1H3,(H,30,33)
DMBW36Y	CS	CC(C1=CC=CC2=CN=C(C=C21)Cl)C(=O)NCC3=CC(=NN3C4=CC(=CC=C4)Cl)C(F)(F)F
DMBW36Y	IK	IMGRGGRJBGEWLE-UHFFFAOYSA-N
DMBW36Y	IU	2-(3-chloroisoquinolin-5-yl)-N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide
DMBW36Y	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DML3KHF	ID	DML3KHF
DML3KHF	DN	PMID25666693-Compound-39
DML3KHF	HS	Patented
DML3KHF	CP	GRUENENTHAL GMBH [DE]
DML3KHF	DT	Small molecular drug
DML3KHF	PC	57335613
DML3KHF	MW	476.9
DML3KHF	FM	C23H20ClF3N4O2
DML3KHF	IC	InChI=1S/C23H20ClF3N4O2/c1-13(19-12-30(2)20-7-6-17(32)10-18(19)20)22(33)28-11-16-9-21(23(25,26)27)29-31(16)15-5-3-4-14(24)8-15/h3-10,12-13,32H,11H2,1-2H3,(H,28,33)
DML3KHF	CS	CC(C1=CN(C2=C1C=C(C=C2)O)C)C(=O)NCC3=CC(=NN3C4=CC(=CC=C4)Cl)C(F)(F)F
DML3KHF	IK	OSCHEDGPGHRWRA-UHFFFAOYSA-N
DML3KHF	IU	N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(5-hydroxy-1-methylindol-3-yl)propanamide
DML3KHF	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMBD9S5	ID	DMBD9S5
DMBD9S5	DN	PMID25666693-Compound-4
DMBD9S5	HS	Patented
DMBD9S5	CP	ABBVIE INC
DMBD9S5	DT	Small molecular drug
DMBD9S5	PC	66551282
DMBD9S5	MW	320.4
DMBD9S5	FM	C19H20N4O
DMBD9S5	IC	InChI=1S/C19H20N4O/c24-19(22-17-7-4-8-18-16(17)12-20-23-18)21-15-10-9-14(11-15)13-5-2-1-3-6-13/h1-8,12,14-15H,9-11H2,(H,20,23)(H2,21,22,24)/t14-,15+/m1/s1
DMBD9S5	CS	C1C[C@@H](C[C@@H]1C2=CC=CC=C2)NC(=O)NC3=CC=CC4=C3C=NN4
DMBD9S5	IK	JSEHDPNFIUYQLO-CABCVRRESA-N
DMBD9S5	IU	1-(1H-indazol-4-yl)-3-[(1S,3R)-3-phenylcyclopentyl]urea
DMBD9S5	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM58QW1	ID	DM58QW1
DM58QW1	DN	PMID25666693-Compound-40
DM58QW1	HS	Patented
DM58QW1	CP	GRENTHAL GMBH FRANK, Robert BAHRENBERG, Gregor CHRISTOPH, Thomas SCHIENE, Klaus DE VRY, Jean DAMANN, Nils FRORMANN, Sven LESCH, Bernhard LEE, Jeewoo KIM, Yong-Soo KIM, Myeon-Seop
DM58QW1	DT	Small molecular drug
DM58QW1	PC	66644325
DM58QW1	MW	518.9
DM58QW1	FM	C21H19ClF4N4O3S
DM58QW1	IC	InChI=1S/C21H19ClF4N4O3S/c1-12(13-6-7-18(17(23)8-13)29-34(2,32)33)20(31)27-11-16-10-19(21(24,25)26)28-30(16)15-5-3-4-14(22)9-15/h3-10,12,29H,11H2,1-2H3,(H,27,31)/t12-/m0/s1
DM58QW1	CS	C[C@@H](C1=CC(=C(C=C1)NS(=O)(=O)C)F)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(F)(F)F
DM58QW1	IK	REFSKWWRGFCGDO-LBPRGKRZSA-N
DM58QW1	IU	(2S)-N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-[3-fluoro-4-(methanesulfonamido)phenyl]propanamide
DM58QW1	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DML76MF	ID	DML76MF
DML76MF	DN	PMID25666693-Compound-41
DML76MF	HS	Patented
DML76MF	CP	GRENTHAL GMBH FRANK, Robert BAHRENBERG, Gregor CHRISTOPH, Thomas SCHIENE, Klaus DE VRY, Jean DAMANN, Nils FRORMANN, Sven LESCH, Bernhard LEE, Jeewoo KIM, Yong-Soo KIM, Myeon-Seop
DML76MF	DT	Small molecular drug
DML76MF	PC	66644203
DML76MF	MW	507
DML76MF	FM	C24H28ClFN4O3S
DML76MF	IC	InChI=1S/C24H28ClFN4O3S/c1-15(16-9-10-21(20(26)11-16)29-34(5,32)33)23(31)27-14-19-13-22(24(2,3)4)28-30(19)18-8-6-7-17(25)12-18/h6-13,15,29H,14H2,1-5H3,(H,27,31)/t15-/m0/s1
DML76MF	CS	C[C@@H](C1=CC(=C(C=C1)NS(=O)(=O)C)F)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(C)(C)C
DML76MF	IK	WVJARZWJWNGZDX-HNNXBMFYSA-N
DML76MF	IU	(2S)-N-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-2-[3-fluoro-4-(methanesulfonamido)phenyl]propanamide
DML76MF	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM6I49E	ID	DM6I49E
DM6I49E	DN	PMID25666693-Compound-42
DM6I49E	HS	Patented
DM6I49E	CP	GRUENENTHAL GMBH [DE]
DM6I49E	DT	Small molecular drug
DM6I49E	PC	70816270
DM6I49E	MW	504
DM6I49E	FM	C24H30ClN5O3S
DM6I49E	IC	InChI=1S/C24H30ClN5O3S/c1-16(18-10-8-17(9-11-18)14-28-34(26,32)33)23(31)27-15-21-13-22(24(2,3)4)29-30(21)20-7-5-6-19(25)12-20/h5-13,16,28H,14-15H2,1-4H3,(H,27,31)(H2,26,32,33)
DM6I49E	CS	CC(C1=CC=C(C=C1)CNS(=O)(=O)N)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(C)(C)C
DM6I49E	IK	DACXYKBLLKSFLC-UHFFFAOYSA-N
DM6I49E	IU	N-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-2-[4-[(sulfamoylamino)methyl]phenyl]propanamide
DM6I49E	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMTN25V	ID	DMTN25V
DMTN25V	DN	PMID25666693-Compound-43
DMTN25V	HS	Patented
DMTN25V	CP	GRUENENTHAL GMBH [DE]
DMTN25V	DT	Small molecular drug
DMTN25V	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM0I72B	ID	DM0I72B
DM0I72B	DN	PMID25666693-Compound-44
DM0I72B	HS	Patented
DM0I72B	CP	GRUENENTHAL GMBH [DE]
DM0I72B	DT	Small molecular drug
DM0I72B	PC	70816274
DM0I72B	MW	463.5
DM0I72B	FM	C24H25F4N3O2
DM0I72B	IC	InChI=1S/C24H25F4N3O2/c1-14(2)16-5-4-6-19(9-16)31-20(11-22(30-31)24(26,27)28)12-29-23(33)15(3)17-7-8-18(13-32)21(25)10-17/h4-11,14-15,32H,12-13H2,1-3H3,(H,29,33)
DM0I72B	CS	CC(C)C1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)CNC(=O)C(C)C3=CC(=C(C=C3)CO)F
DM0I72B	IK	WEWXHMWEKISRRJ-UHFFFAOYSA-N
DM0I72B	IU	2-[3-fluoro-4-(hydroxymethyl)phenyl]-N-[[2-(3-propan-2-ylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide
DM0I72B	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMVDKXY	ID	DMVDKXY
DMVDKXY	DN	PMID25666693-Compound-45
DMVDKXY	HS	Patented
DMVDKXY	CP	GRUENENTHAL GMBH [DE]
DMVDKXY	DT	Small molecular drug
DMVDKXY	PC	70816331
DMVDKXY	MW	477.5
DMVDKXY	FM	C25H27F4N3O2
DMVDKXY	IC	InChI=1S/C25H27F4N3O2/c1-15(2)18-5-4-6-20(11-18)32-21(13-23(31-32)25(27,28)29)14-30-24(34)16(3)19-8-7-17(9-10-33)22(26)12-19/h4-8,11-13,15-16,33H,9-10,14H2,1-3H3,(H,30,34)
DMVDKXY	CS	CC(C)C1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)CNC(=O)C(C)C3=CC(=C(C=C3)CCO)F
DMVDKXY	IK	VKEXSUFTMBHDFU-UHFFFAOYSA-N
DMVDKXY	IU	2-[3-fluoro-4-(2-hydroxyethyl)phenyl]-N-[[2-(3-propan-2-ylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide
DMVDKXY	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM0MEXT	ID	DM0MEXT
DM0MEXT	DN	PMID25666693-Compound-46
DM0MEXT	HS	Patented
DM0MEXT	CP	GRUENENTHAL GMBH [DE]
DM0MEXT	DT	Small molecular drug
DM0MEXT	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMHBN5M	ID	DMHBN5M
DMHBN5M	DN	PMID25666693-Compound-47
DMHBN5M	HS	Patented
DMHBN5M	CP	GRUENENTHAL GMBH [DE]
DMHBN5M	DT	Small molecular drug
DMHBN5M	PC	88995251
DMHBN5M	MW	562.9
DMHBN5M	FM	C27H20ClF5N4O2
DMHBN5M	IC	InChI=1S/C27H20ClF5N4O2/c1-15(16-5-10-22(23(30)11-16)26(39)35-19-8-6-18(29)7-9-19)25(38)34-14-21-13-24(27(31,32)33)36-37(21)20-4-2-3-17(28)12-20/h2-13,15H,14H2,1H3,(H,34,38)(H,35,39)
DMHBN5M	CS	CC(C1=CC(=C(C=C1)C(=O)NC2=CC=C(C=C2)F)F)C(=O)NCC3=CC(=NN3C4=CC(=CC=C4)Cl)C(F)(F)F
DMHBN5M	IK	SRQSJNYCMNVXTK-UHFFFAOYSA-N
DMHBN5M	IU	4-[1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methylamino]-1-oxopropan-2-yl]-2-fluoro-N-(4-fluorophenyl)benzamide
DMHBN5M	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMEVL0S	ID	DMEVL0S
DMEVL0S	DN	PMID25666693-Compound-48
DMEVL0S	HS	Patented
DMEVL0S	CP	GRUENENTHAL GMBH [DE]
DMEVL0S	DT	Small molecular drug
DMEVL0S	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM67DEG	ID	DM67DEG
DM67DEG	DN	PMID25666693-Compound-49
DM67DEG	HS	Patented
DM67DEG	CP	GRUENENTHAL GMBH [DE]
DM67DEG	DT	Small molecular drug
DM67DEG	PC	71238636
DM67DEG	MW	438.8
DM67DEG	FM	C20H18ClF3N4O2
DM67DEG	IC	InChI=1S/C20H18ClF3N4O2/c1-12(13-5-6-15(11-29)25-9-13)19(30)26-10-17-8-18(20(22,23)24)27-28(17)16-4-2-3-14(21)7-16/h2-9,12,29H,10-11H2,1H3,(H,26,30)
DM67DEG	CS	CC(C1=CN=C(C=C1)CO)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(F)(F)F
DM67DEG	IK	BPOYGEDVQYUUIM-UHFFFAOYSA-N
DM67DEG	IU	N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-[6-(hydroxymethyl)pyridin-3-yl]propanamide
DM67DEG	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM53PBG	ID	DM53PBG
DM53PBG	DN	PMID25666693-Compound-5
DM53PBG	HS	Patented
DM53PBG	CP	ABBVIE INC
DM53PBG	DT	Small molecular drug
DM53PBG	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM4GUZO	ID	DM4GUZO
DM4GUZO	DN	PMID25666693-Compound-50
DM4GUZO	HS	Patented
DM4GUZO	CP	GRUENENTHAL GMBH [DE]
DM4GUZO	DT	Small molecular drug
DM4GUZO	PC	71237925
DM4GUZO	MW	467.9
DM4GUZO	FM	C21H21ClF3N5O2
DM4GUZO	IC	InChI=1S/C21H21ClF3N5O2/c1-13(14-5-6-19(27-11-14)26-7-8-31)20(32)28-12-17-10-18(21(23,24)25)29-30(17)16-4-2-3-15(22)9-16/h2-6,9-11,13,31H,7-8,12H2,1H3,(H,26,27)(H,28,32)
DM4GUZO	CS	CC(C1=CN=C(C=C1)NCCO)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(F)(F)F
DM4GUZO	IK	QZMPZIHZYACLIU-UHFFFAOYSA-N
DM4GUZO	IU	N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-[6-(2-hydroxyethylamino)pyridin-3-yl]propanamide
DM4GUZO	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM3KSV9	ID	DM3KSV9
DM3KSV9	DN	PMID25666693-Compound-51
DM3KSV9	HS	Patented
DM3KSV9	CP	GRUENENTHAL GMBH [DE]
DM3KSV9	DT	Small molecular drug
DM3KSV9	PC	57335038
DM3KSV9	MW	453
DM3KSV9	FM	C25H29ClN4O2
DM3KSV9	IC	InChI=1S/C25H29ClN4O2/c1-25(2,3)23-13-19(30(29-23)18-8-5-7-17(26)12-18)15-27-24(32)28-22-9-4-6-16-10-11-20(31)14-21(16)22/h5,7-8,10-14,22,31H,4,6,9,15H2,1-3H3,(H2,27,28,32)
DM3KSV9	CS	CC(C)(C)C1=NN(C(=C1)CNC(=O)NC2CCCC3=C2C=C(C=C3)O)C4=CC(=CC=C4)Cl
DM3KSV9	IK	RUCBWZCSOLTLOQ-UHFFFAOYSA-N
DM3KSV9	IU	1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(7-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)urea
DM3KSV9	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMQPOGC	ID	DMQPOGC
DMQPOGC	DN	PMID25666693-Compound-52
DMQPOGC	HS	Patented
DMQPOGC	CP	GRUENENTHAL GMBH [DE]
DMQPOGC	DT	Small molecular drug
DMQPOGC	PC	70816169
DMQPOGC	MW	528.5
DMQPOGC	FM	C22H24F4N6O3S
DMQPOGC	IC	InChI=1S/C22H24F4N6O3S/c1-13(2)14-4-3-5-17(8-14)32-18(10-20(31-32)22(24,25)26)12-28-21(33)30-16-7-6-15(19(23)9-16)11-29-36(27,34)35/h3-10,13,29H,11-12H2,1-2H3,(H2,27,34,35)(H2,28,30,33)
DMQPOGC	CS	CC(C)C1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC(=C(C=C3)CNS(=O)(=O)N)F
DMQPOGC	IK	PXYVSPVUKXZTLN-UHFFFAOYSA-N
DMQPOGC	IU	1-[3-fluoro-4-[(sulfamoylamino)methyl]phenyl]-3-[[2-(3-propan-2-ylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea
DMQPOGC	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMKCARH	ID	DMKCARH
DMKCARH	DN	PMID25666693-Compound-53
DMKCARH	HS	Patented
DMKCARH	CP	GRUENENTHAL GMBH [DE]
DMKCARH	DT	Small molecular drug
DMKCARH	PC	70816499
DMKCARH	MW	526.5
DMKCARH	FM	C24H26F4N4O3S
DMKCARH	IC	InChI=1S/C24H26F4N4O3S/c1-15(2)17-5-4-6-19(11-17)32-20(13-22(31-32)24(26,27)28)14-29-23(33)30-18-8-7-16(21(25)12-18)9-10-36(3,34)35/h4-8,11-13,15H,9-10,14H2,1-3H3,(H2,29,30,33)
DMKCARH	CS	CC(C)C1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC(=C(C=C3)CCS(=O)(=O)C)F
DMKCARH	IK	XUFAPWVIHXCCMT-UHFFFAOYSA-N
DMKCARH	IU	1-[3-fluoro-4-(2-methylsulfonylethyl)phenyl]-3-[[2-(3-propan-2-ylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea
DMKCARH	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMLW95Y	ID	DMLW95Y
DMLW95Y	DN	PMID25666693-Compound-54
DMLW95Y	HS	Patented
DMLW95Y	CP	GRUENENTHAL GMBH [DE]
DMLW95Y	DT	Small molecular drug
DMLW95Y	PC	70816505
DMLW95Y	MW	472
DMLW95Y	FM	C24H27ClFN5O2
DMLW95Y	IC	InChI=1S/C24H27ClFN5O2/c1-24(2,3)22-11-18(31(29-22)17-6-4-5-15(25)9-17)12-27-23(33)28-16-7-8-21(20(26)10-16)30-13-19(32)14-30/h4-11,19,32H,12-14H2,1-3H3,(H2,27,28,33)
DMLW95Y	CS	CC(C)(C)C1=NN(C(=C1)CNC(=O)NC2=CC(=C(C=C2)N3CC(C3)O)F)C4=CC(=CC=C4)Cl
DMLW95Y	IK	BLMVABKWVMAQJO-UHFFFAOYSA-N
DMLW95Y	IU	1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-[3-fluoro-4-(3-hydroxyazetidin-1-yl)phenyl]urea
DMLW95Y	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMPE7M8	ID	DMPE7M8
DMPE7M8	DN	PMID25666693-Compound-55
DMPE7M8	HS	Patented
DMPE7M8	CP	GRENTHAL GMBH FRANK, Robert BAHRENBERG, Gregor CHRISTOPH, Thomas SCHIENE, Klaus DE VRY, Jean
DMPE7M8	DT	Small molecular drug
DMPE7M8	PC	56836246
DMPE7M8	MW	487.4
DMPE7M8	FM	C24H28Cl2N6O
DMPE7M8	IC	InChI=1S/C24H28Cl2N6O/c1-24(2,3)21-15-19(32(29-21)18-7-4-6-17(25)14-18)16-28-23(33)31-12-10-30(11-13-31)22-20(26)8-5-9-27-22/h4-9,14-15H,10-13,16H2,1-3H3,(H,28,33)
DMPE7M8	CS	CC(C)(C)C1=NN(C(=C1)CNC(=O)N2CCN(CC2)C3=C(C=CC=N3)Cl)C4=CC(=CC=C4)Cl
DMPE7M8	IK	UGDIRECFVAQSNI-UHFFFAOYSA-N
DMPE7M8	IU	N-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
DMPE7M8	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM82BAM	ID	DM82BAM
DM82BAM	DN	PMID25666693-Compound-56
DM82BAM	HS	Patented
DM82BAM	CP	GRUENENTHAL GMBH [DE]
DM82BAM	DT	Small molecular drug
DM82BAM	PC	71238385
DM82BAM	MW	517.5
DM82BAM	FM	C22H27F4N5O3S
DM82BAM	IC	InChI=1S/C22H27F4N5O3S/c1-13-6-8-31(9-7-13)20-15(4-5-18(29-20)22(24,25)26)11-28-21(32)14(2)16-10-17(23)19(27-12-16)30-35(3,33)34/h4-5,10,12-14H,6-9,11H2,1-3H3,(H,27,30)(H,28,32)
DM82BAM	CS	CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)C(C)C3=CC(=C(N=C3)NS(=O)(=O)C)F
DM82BAM	IK	PZSVFYQEXXZEFT-UHFFFAOYSA-N
DM82BAM	IU	2-[5-fluoro-6-(methanesulfonamido)pyridin-3-yl]-N-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide
DM82BAM	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMQRFXT	ID	DMQRFXT
DMQRFXT	DN	PMID25666693-Compound-57
DMQRFXT	HS	Patented
DMQRFXT	CP	Grunenthal GmbH
DMQRFXT	DT	Small molecular drug
DMQRFXT	PC	71537379
DMQRFXT	MW	516.6
DMQRFXT	FM	C23H28F4N4O3S
DMQRFXT	IC	InChI=1S/C23H28F4N4O3S/c1-15-7-9-31(10-8-15)22-18(5-6-20(30-22)23(25,26)27)13-28-21(32)12-16-3-4-17(19(24)11-16)14-29-35(2,33)34/h3-6,11,15,29H,7-10,12-14H2,1-2H3,(H,28,32)
DMQRFXT	CS	CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)CC3=CC(=C(C=C3)CNS(=O)(=O)C)F
DMQRFXT	IK	DAEWVVDOSOXCOU-UHFFFAOYSA-N
DMQRFXT	IU	2-[3-fluoro-4-(methanesulfonamidomethyl)phenyl]-N-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]acetamide
DMQRFXT	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMJEH0F	ID	DMJEH0F
DMJEH0F	DN	PMID25666693-Compound-58
DMJEH0F	HS	Patented
DMJEH0F	CP	GRUENENTHAL GMBH [DE] 
DMJEH0F	DT	Small molecular drug
DMJEH0F	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMLI1YR	ID	DMLI1YR
DMLI1YR	DN	PMID25666693-Compound-59
DMLI1YR	HS	Patented
DMLI1YR	CP	GRUENENTHAL GMBH [DE]
DMLI1YR	DT	Small molecular drug
DMLI1YR	PC	71539690
DMLI1YR	MW	510.5
DMLI1YR	FM	C23H22F4N4O3S
DMLI1YR	IC	InChI=1S/C23H22F4N4O3S/c1-14-4-3-5-15(10-14)21-17(7-9-20(31-21)23(25,26)27)12-28-22(32)30-18-8-6-16(19(24)11-18)13-29-35(2,33)34/h3-11,29H,12-13H2,1-2H3,(H2,28,30,32)
DMLI1YR	CS	CC1=CC(=CC=C1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC(=C(C=C3)CNS(=O)(=O)C)F
DMLI1YR	IK	RKDUDSFOPJMGMR-UHFFFAOYSA-N
DMLI1YR	IU	1-[3-fluoro-4-(methanesulfonamidomethyl)phenyl]-3-[[2-(3-methylphenyl)-6-(trifluoromethyl)pyridin-3-yl]methyl]urea
DMLI1YR	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMC5W1Y	ID	DMC5W1Y
DMC5W1Y	DN	PMID25666693-Compound-6
DMC5W1Y	HS	Patented
DMC5W1Y	CP	ABBVIE INC
DMC5W1Y	DT	Small molecular drug
DMC5W1Y	PC	66549275
DMC5W1Y	MW	338.4
DMC5W1Y	FM	C19H19FN4O
DMC5W1Y	IC	InChI=1S/C19H19FN4O/c20-14-4-1-3-12(9-14)13-7-8-15(10-13)22-19(25)23-17-5-2-6-18-16(17)11-21-24-18/h1-6,9,11,13,15H,7-8,10H2,(H,21,24)(H2,22,23,25)/t13-,15+/m1/s1
DMC5W1Y	CS	C1C[C@@H](C[C@@H]1C2=CC(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=NN4
DMC5W1Y	IK	ROOFFAWDIFZLQB-HIFRSBDPSA-N
DMC5W1Y	IU	1-[(1S,3R)-3-(3-fluorophenyl)cyclopentyl]-3-(1H-indazol-4-yl)urea
DMC5W1Y	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM2C58A	ID	DM2C58A
DM2C58A	DN	PMID25666693-Compound-60
DM2C58A	HS	Patented
DM2C58A	CP	GRUENENTHAL GMBH [DE]
DM2C58A	DT	Small molecular drug
DM2C58A	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM0B578	ID	DM0B578
DM0B578	DN	PMID25666693-Compound-61
DM0B578	HS	Patented
DM0B578	CP	GRUENENTHAL GMBH [DE]
DM0B578	DT	Small molecular drug
DM0B578	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMDMFJG	ID	DMDMFJG
DMDMFJG	DN	PMID25666693-Compound-62
DMDMFJG	HS	Patented
DMDMFJG	CP	GRUENENTHAL GMBH [DE] 
DMDMFJG	DT	Small molecular drug
DMDMFJG	PC	71506872
DMDMFJG	MW	500.5
DMDMFJG	FM	C21H27F3N6O3S
DMDMFJG	IC	InChI=1S/C21H27F3N6O3S/c1-14-8-10-30(11-9-14)19-16(4-7-18(29-19)21(22,23)24)13-26-20(31)28-17-5-2-15(3-6-17)12-27-34(25,32)33/h2-7,14,27H,8-13H2,1H3,(H2,25,32,33)(H2,26,28,31)
DMDMFJG	CS	CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC=C(C=C3)CNS(=O)(=O)N
DMDMFJG	IK	OTVBHAAUANCTTG-UHFFFAOYSA-N
DMDMFJG	IU	1-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]-3-[4-[(sulfamoylamino)methyl]phenyl]urea
DMDMFJG	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM6DFAK	ID	DM6DFAK
DM6DFAK	DN	PMID25666693-Compound-63
DM6DFAK	HS	Patented
DM6DFAK	CP	GRUENENTHAL GMBH [DE] 
DM6DFAK	DT	Small molecular drug
DM6DFAK	PC	71534837
DM6DFAK	MW	518.5
DM6DFAK	FM	C21H26F4N6O3S
DM6DFAK	IC	InChI=1S/C21H26F4N6O3S/c1-13-6-8-31(9-7-13)19-15(3-5-18(30-19)21(23,24)25)11-27-20(32)29-16-4-2-14(17(22)10-16)12-28-35(26,33)34/h2-5,10,13,28H,6-9,11-12H2,1H3,(H2,26,33,34)(H2,27,29,32)
DM6DFAK	CS	CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC(=C(C=C3)CNS(=O)(=O)N)F
DM6DFAK	IK	ULLMJBDXTPAPKF-UHFFFAOYSA-N
DM6DFAK	IU	1-[3-fluoro-4-[(sulfamoylamino)methyl]phenyl]-3-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]urea
DM6DFAK	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMDWH8T	ID	DMDWH8T
DMDWH8T	DN	PMID25666693-Compound-64
DMDWH8T	HS	Patented
DMDWH8T	CP	GRUENENTHAL GMBH [DE]
DMDWH8T	DT	Small molecular drug
DMDWH8T	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM1A0GT	ID	DM1A0GT
DM1A0GT	DN	PMID25666693-Compound-65
DM1A0GT	HS	Patented
DM1A0GT	CP	GRUENENTHAL GMBH [DE]
DM1A0GT	DT	Small molecular drug
DM1A0GT	PC	71238361
DM1A0GT	MW	452.5
DM1A0GT	FM	C21H27F3N6O2
DM1A0GT	IC	InChI=1S/C21H27F3N6O2/c1-14-6-9-30(10-7-14)19-15(2-4-17(29-19)21(22,23)24)12-27-20(32)28-16-3-5-18(26-13-16)25-8-11-31/h2-5,13-14,31H,6-12H2,1H3,(H,25,26)(H2,27,28,32)
DM1A0GT	CS	CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)NC3=CN=C(C=C3)NCCO
DM1A0GT	IK	YIEBGPCORZIWJQ-UHFFFAOYSA-N
DM1A0GT	IU	1-[6-(2-hydroxyethylamino)pyridin-3-yl]-3-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]urea
DM1A0GT	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMD13OS	ID	DMD13OS
DMD13OS	DN	PMID25666693-Compound-66
DMD13OS	HS	Patented
DMD13OS	CP	Japan Tobacco, Inc
DMD13OS	DT	Small molecular drug
DMD13OS	PC	23627957
DMD13OS	MW	483.5
DMD13OS	FM	C26H27F2N3O4
DMD13OS	IC	InChI=1S/C26H27F2N3O4/c1-15-8-9-22(29-12-15)31-17(13-32)14-34-23-18(6-5-7-21(23)31)25(33)30-16-10-19(27)24(20(28)11-16)35-26(2,3)4/h5-12,17,32H,13-14H2,1-4H3,(H,30,33)/t17-/m0/s1
DMD13OS	CS	CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CC(=C(C(=C4)F)OC(C)(C)C)F)CO
DMD13OS	IK	XZRDDTOOBFNFRB-KRWDZBQOSA-N
DMD13OS	IU	(3S)-N-[3,5-difluoro-4-[(2-methylpropan-2-yl)oxy]phenyl]-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DMD13OS	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMPV9L2	ID	DMPV9L2
DMPV9L2	DN	PMID25666693-Compound-67
DMPV9L2	HS	Patented
DMPV9L2	CP	Japan Tobacco, Inc
DMPV9L2	DT	Small molecular drug
DMPV9L2	PC	23628014
DMPV9L2	MW	469.5
DMPV9L2	FM	C25H25F2N3O4
DMPV9L2	IC	InChI=1S/C25H25F2N3O4/c1-14(2)34-24-19(26)9-16(10-20(24)27)29-25(32)18-5-4-6-21-23(18)33-13-17(12-31)30(21)22-8-7-15(3)11-28-22/h4-11,14,17,31H,12-13H2,1-3H3,(H,29,32)/t17-/m0/s1
DMPV9L2	CS	CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CC(=C(C(=C4)F)OC(C)C)F)CO
DMPV9L2	IK	IUQNHNNDFBOZEL-KRWDZBQOSA-N
DMPV9L2	IU	(3S)-N-(3,5-difluoro-4-propan-2-yloxyphenyl)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DMPV9L2	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM87HTO	ID	DM87HTO
DM87HTO	DN	PMID25666693-Compound-68
DM87HTO	HS	Patented
DM87HTO	CP	Japan Tobacco, Inc
DM87HTO	DT	Small molecular drug
DM87HTO	PC	23628075
DM87HTO	MW	509.4
DM87HTO	FM	C24H20F5N3O4
DM87HTO	IC	InChI=1S/C24H20F5N3O4/c1-13-5-6-20(30-9-13)32-15(10-33)11-35-21-16(3-2-4-19(21)32)23(34)31-14-7-17(25)22(18(26)8-14)36-12-24(27,28)29/h2-9,15,33H,10-12H2,1H3,(H,31,34)/t15-/m0/s1
DM87HTO	CS	CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CC(=C(C(=C4)F)OCC(F)(F)F)F)CO
DM87HTO	IK	RPAMBIQBMQRYLH-HNNXBMFYSA-N
DM87HTO	IU	(3S)-N-[3,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl]-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DM87HTO	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMIPFO3	ID	DMIPFO3
DMIPFO3	DN	PMID25666693-Compound-69
DMIPFO3	HS	Patented
DMIPFO3	CP	Japan Tobacco, Inc
DMIPFO3	DT	Small molecular drug
DMIPFO3	PC	23628077
DMIPFO3	MW	499.5
DMIPFO3	FM	C26H27F2N3O5
DMIPFO3	IC	InChI=1S/C26H27F2N3O5/c1-15-7-8-22(29-11-15)31-17(12-32)13-35-23-18(5-4-6-21(23)31)25(34)30-16-9-19(27)24(20(28)10-16)36-26(2,3)14-33/h4-11,17,32-33H,12-14H2,1-3H3,(H,30,34)/t17-/m0/s1
DMIPFO3	CS	CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CC(=C(C(=C4)F)OC(C)(C)CO)F)CO
DMIPFO3	IK	HVUQTZHOXKBNTC-KRWDZBQOSA-N
DMIPFO3	IU	(3S)-N-[3,5-difluoro-4-(1-hydroxy-2-methylpropan-2-yl)oxyphenyl]-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DMIPFO3	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMNTVFH	ID	DMNTVFH
DMNTVFH	DN	PMID25666693-Compound-7
DMNTVFH	HS	Patented
DMNTVFH	CP	ABBVIE INC
DMNTVFH	DT	Small molecular drug
DMNTVFH	PC	66551085
DMNTVFH	MW	320.4
DMNTVFH	FM	C19H20N4O
DMNTVFH	IC	InChI=1S/C19H20N4O/c24-19(22-17-7-4-8-18-16(17)12-20-23-18)21-15-10-9-14(11-15)13-5-2-1-3-6-13/h1-8,12,14-15H,9-11H2,(H,20,23)(H2,21,22,24)/t14-,15-/m0/s1
DMNTVFH	CS	C1C[C@@H](C[C@H]1C2=CC=CC=C2)NC(=O)NC3=CC=CC4=C3C=NN4
DMNTVFH	IK	JSEHDPNFIUYQLO-GJZGRUSLSA-N
DMNTVFH	IU	1-(1H-indazol-4-yl)-3-[(1S,3S)-3-phenylcyclopentyl]urea
DMNTVFH	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMEPYGQ	ID	DMEPYGQ
DMEPYGQ	DN	PMID25666693-Compound-70
DMEPYGQ	HS	Patented
DMEPYGQ	CP	Japan Tobacco, Inc
DMEPYGQ	DT	Small molecular drug
DMEPYGQ	PC	58416270
DMEPYGQ	MW	462.5
DMEPYGQ	FM	C26H30N4O4
DMEPYGQ	IC	InChI=1S/C26H30N4O4/c1-17-8-10-22(27-12-17)30-19(14-31)15-33-24-20(6-5-7-21(24)30)25(32)29-18-9-11-23(28-13-18)34-16-26(2,3)4/h5-13,19,31H,14-16H2,1-4H3,(H,29,32)/t19-/m0/s1
DMEPYGQ	CS	CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CN=C(C=C4)OCC(C)(C)C)CO
DMEPYGQ	IK	LMURYRLZRMJVEI-IBGZPJMESA-N
DMEPYGQ	IU	(3S)-N-[6-(2,2-dimethylpropoxy)pyridin-3-yl]-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DMEPYGQ	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM4VAQ3	ID	DM4VAQ3
DM4VAQ3	DN	PMID25666693-Compound-71
DM4VAQ3	HS	Patented
DM4VAQ3	CP	Japan Tobacco, Inc
DM4VAQ3	DT	Small molecular drug
DM4VAQ3	PC	23628017
DM4VAQ3	MW	474.4
DM4VAQ3	FM	C23H21F3N4O4
DM4VAQ3	IC	InChI=1S/C23H21F3N4O4/c1-14-5-7-19(27-9-14)30-16(11-31)12-33-21-17(3-2-4-18(21)30)22(32)29-15-6-8-20(28-10-15)34-13-23(24,25)26/h2-10,16,31H,11-13H2,1H3,(H,29,32)/t16-/m0/s1
DM4VAQ3	CS	CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CN=C(C=C4)OCC(F)(F)F)CO
DM4VAQ3	IK	QZUCKCLSVBFSOS-INIZCTEOSA-N
DM4VAQ3	IU	(3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DM4VAQ3	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMW8XD2	ID	DMW8XD2
DMW8XD2	DN	PMID25666693-Compound-72
DMW8XD2	HS	Patented
DMW8XD2	CP	Japan Tobacco, Inc
DMW8XD2	DT	Small molecular drug
DMW8XD2	PC	11582721
DMW8XD2	MW	428.4
DMW8XD2	FM	C23H23Cl2N3O
DMW8XD2	IC	InChI=1S/C23H23Cl2N3O/c1-23(2,3)16-8-10-17(11-9-16)27-22(29)15-7-12-18(24)20(14-15)28(4)21-19(25)6-5-13-26-21/h5-14H,1-4H3,(H,27,29)
DMW8XD2	CS	CC(C)(C)C1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(C)C3=C(C=CC=N3)Cl
DMW8XD2	IK	KDJDFSOSSGWODT-UHFFFAOYSA-N
DMW8XD2	IU	N-(4-tert-butylphenyl)-4-chloro-3-[(3-chloropyridin-2-yl)-methylamino]benzamide
DMW8XD2	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM9LZJ5	ID	DM9LZJ5
DM9LZJ5	DN	PMID25666693-Compound-73
DM9LZJ5	HS	Patented
DM9LZJ5	CP	Japan Tobacco, Inc
DM9LZJ5	DT	Small molecular drug
DM9LZJ5	PC	11532940
DM9LZJ5	MW	472.4
DM9LZJ5	FM	C25H27Cl2N3O2
DM9LZJ5	IC	InChI=1S/C25H27Cl2N3O2/c1-25(2,3)18-8-10-19(11-9-18)29-24(31)17-7-12-20(26)22(16-17)30(14-15-32-4)23-21(27)6-5-13-28-23/h5-13,16H,14-15H2,1-4H3,(H,29,31)
DM9LZJ5	CS	CC(C)(C)C1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(CCOC)C3=C(C=CC=N3)Cl
DM9LZJ5	IK	ZYJYGKAKEUKYMJ-UHFFFAOYSA-N
DM9LZJ5	IU	N-(4-tert-butylphenyl)-4-chloro-3-[(3-chloropyridin-2-yl)-(2-methoxyethyl)amino]benzamide
DM9LZJ5	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM80E3F	ID	DM80E3F
DM80E3F	DN	PMID25666693-Compound-74
DM80E3F	HS	Patented
DM80E3F	CP	Japan Tobacco, Inc
DM80E3F	DT	Small molecular drug
DM80E3F	PC	11676921
DM80E3F	MW	458.4
DM80E3F	FM	C24H25Cl2N3O2
DM80E3F	IC	InChI=1S/C24H25Cl2N3O2/c1-24(2,3)17-7-9-18(10-8-17)28-23(31)16-6-11-19(25)21(15-16)29(13-14-30)22-20(26)5-4-12-27-22/h4-12,15,30H,13-14H2,1-3H3,(H,28,31)
DM80E3F	CS	CC(C)(C)C1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(CCO)C3=C(C=CC=N3)Cl
DM80E3F	IK	PUELSMJKWSTCFR-UHFFFAOYSA-N
DM80E3F	IU	N-(4-tert-butylphenyl)-4-chloro-3-[(3-chloropyridin-2-yl)-(2-hydroxyethyl)amino]benzamide
DM80E3F	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMNATSQ	ID	DMNATSQ
DMNATSQ	DN	PMID25666693-Compound-75
DMNATSQ	HS	Patented
DMNATSQ	CP	Japan Tobacco, Inc
DMNATSQ	DT	Small molecular drug
DMNATSQ	PC	11598064
DMNATSQ	MW	474.4
DMNATSQ	FM	C24H25Cl2N3O3
DMNATSQ	IC	InChI=1S/C24H25Cl2N3O3/c1-16(2)15-32-19-8-6-18(7-9-19)28-24(31)17-5-10-20(25)22(14-17)29(12-13-30)23-21(26)4-3-11-27-23/h3-11,14,16,30H,12-13,15H2,1-2H3,(H,28,31)
DMNATSQ	CS	CC(C)COC1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(CCO)C3=C(C=CC=N3)Cl
DMNATSQ	IK	BQRACGGWLNJTKY-UHFFFAOYSA-N
DMNATSQ	IU	4-chloro-3-[(3-chloropyridin-2-yl)-(2-hydroxyethyl)amino]-N-[4-(2-methylpropoxy)phenyl]benzamide
DMNATSQ	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMYH429	ID	DMYH429
DMYH429	DN	PMID25666693-Compound-76
DMYH429	HS	Patented
DMYH429	CP	Japan Tobacco, Inc
DMYH429	DT	Small molecular drug
DMYH429	PC	11532887
DMYH429	MW	470
DMYH429	FM	C25H28ClN3O4
DMYH429	IC	InChI=1S/C25H28ClN3O4/c1-17(2)16-33-20-9-7-19(8-10-20)28-25(31)18-6-11-23(32-3)22(15-18)29(13-14-30)24-21(26)5-4-12-27-24/h4-12,15,17,30H,13-14,16H2,1-3H3,(H,28,31)
DMYH429	CS	CC(C)COC1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)OC)N(CCO)C3=C(C=CC=N3)Cl
DMYH429	IK	QGYXTXVZRNIAOQ-UHFFFAOYSA-N
DMYH429	IU	3-[(3-chloropyridin-2-yl)-(2-hydroxyethyl)amino]-4-methoxy-N-[4-(2-methylpropoxy)phenyl]benzamide
DMYH429	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM05D48	ID	DM05D48
DM05D48	DN	PMID25666693-Compound-77
DM05D48	HS	Patented
DM05D48	CP	Japan Tobacco, Inc
DM05D48	DT	Small molecular drug
DM05D48	PC	11562798
DM05D48	MW	531.4
DM05D48	FM	C26H28Cl2N4O4
DM05D48	IC	InChI=1S/C26H28Cl2N4O4/c1-16(2)15-36-23-9-7-18(14-19(23)26(35)29-3)31-25(34)17-6-8-20(27)22(13-17)32(11-12-33)24-21(28)5-4-10-30-24/h4-10,13-14,16,33H,11-12,15H2,1-3H3,(H,29,35)(H,31,34)
DM05D48	CS	CC(C)COC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(CCO)C3=C(C=CC=N3)Cl)C(=O)NC
DM05D48	IK	VOVIFBICMYYQQM-UHFFFAOYSA-N
DM05D48	IU	4-chloro-3-[(3-chloropyridin-2-yl)-(2-hydroxyethyl)amino]-N-[3-(methylcarbamoyl)-4-(2-methylpropoxy)phenyl]benzamide
DM05D48	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMQI1YN	ID	DMQI1YN
DMQI1YN	DN	PMID25666693-Compound-78
DMQI1YN	HS	Patented
DMQI1YN	CP	Japan Tobacco, Inc
DMQI1YN	DT	Small molecular drug
DMQI1YN	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMTQ26G	ID	DMTQ26G
DMTQ26G	DN	PMID25666693-Compound-79
DMTQ26G	HS	Patented
DMTQ26G	CP	Japan Tobacco, Inc
DMTQ26G	DT	Small molecular drug
DMTQ26G	PC	11677423
DMTQ26G	MW	483.3
DMTQ26G	FM	C21H15Cl2F3N4O2
DMTQ26G	IC	InChI=1S/C21H15Cl2F3N4O2/c22-15-8-3-12(20(32)29-14-6-4-13(5-7-14)21(24,25)26)10-17(15)30(11-18(27)31)19-16(23)2-1-9-28-19/h1-10H,11H2,(H2,27,31)(H,29,32)
DMTQ26G	CS	C1=CC(=C(N=C1)N(CC(=O)N)C2=C(C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(F)(F)F)Cl)Cl
DMTQ26G	IK	LLVCZHNGUDERCY-UHFFFAOYSA-N
DMTQ26G	IU	3-[(2-amino-2-oxoethyl)-(3-chloropyridin-2-yl)amino]-4-chloro-N-[4-(trifluoromethyl)phenyl]benzamide
DMTQ26G	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMZQ6HC	ID	DMZQ6HC
DMZQ6HC	DN	PMID25666693-Compound-8
DMZQ6HC	HS	Patented
DMZQ6HC	CP	ABBVIE INC
DMZQ6HC	DT	Small molecular drug
DMZQ6HC	PC	66549082
DMZQ6HC	MW	338.4
DMZQ6HC	FM	C19H19FN4O
DMZQ6HC	IC	InChI=1S/C19H19FN4O/c20-16-5-2-1-4-14(16)12-8-9-13(10-12)22-19(25)23-17-6-3-7-18-15(17)11-21-24-18/h1-7,11-13H,8-10H2,(H,21,24)(H2,22,23,25)/t12-,13-/m0/s1
DMZQ6HC	CS	C1C[C@@H](C[C@H]1C2=CC=CC=C2F)NC(=O)NC3=CC=CC4=C3C=NN4
DMZQ6HC	IK	MNXPYZUSFURMKS-STQMWFEESA-N
DMZQ6HC	IU	1-[(1S,3S)-3-(2-fluorophenyl)cyclopentyl]-3-(1H-indazol-4-yl)urea
DMZQ6HC	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMB56LS	ID	DMB56LS
DMB56LS	DN	PMID25666693-Compound-80
DMB56LS	HS	Patented
DMB56LS	CP	Japan Tobacco, Inc
DMB56LS	DT	Small molecular drug
DMB56LS	PC	11656215
DMB56LS	MW	497.3
DMB56LS	FM	C22H17Cl2F3N4O2
DMB56LS	IC	InChI=1S/C22H17Cl2F3N4O2/c1-28-19(32)12-31(20-17(24)3-2-10-29-20)18-11-13(4-9-16(18)23)21(33)30-15-7-5-14(6-8-15)22(25,26)27/h2-11H,12H2,1H3,(H,28,32)(H,30,33)
DMB56LS	CS	CNC(=O)CN(C1=C(C=CC(=C1)C(=O)NC2=CC=C(C=C2)C(F)(F)F)Cl)C3=C(C=CC=N3)Cl
DMB56LS	IK	OGONHQFOPUHELI-UHFFFAOYSA-N
DMB56LS	IU	4-chloro-3-[(3-chloropyridin-2-yl)-[2-(methylamino)-2-oxoethyl]amino]-N-[4-(trifluoromethyl)phenyl]benzamide
DMB56LS	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM5ZELW	ID	DM5ZELW
DM5ZELW	DN	PMID25666693-Compound-81
DM5ZELW	HS	Patented
DM5ZELW	CP	Japan Tobacco, Inc
DM5ZELW	DT	Small molecular drug
DM5ZELW	PC	11706654
DM5ZELW	MW	551.3
DM5ZELW	FM	C22H14Cl2F6N4O2
DM5ZELW	IC	InChI=1S/C22H14Cl2F6N4O2/c23-15-6-1-11(20(36)33-14-4-2-12(3-5-14)21(25,26)27)7-17(15)34(10-18(31)35)19-16(24)8-13(9-32-19)22(28,29)30/h1-9H,10H2,(H2,31,35)(H,33,36)
DM5ZELW	CS	C1=CC(=CC=C1C(F)(F)F)NC(=O)C2=CC(=C(C=C2)Cl)N(CC(=O)N)C3=C(C=C(C=N3)C(F)(F)F)Cl
DM5ZELW	IK	YLOQUQYZKPTZAV-UHFFFAOYSA-N
DM5ZELW	IU	3-[(2-amino-2-oxoethyl)-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]-4-chloro-N-[4-(trifluoromethyl)phenyl]benzamide
DM5ZELW	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM1MZ70	ID	DM1MZ70
DM1MZ70	DN	PMID25666693-Compound-82
DM1MZ70	HS	Patented
DM1MZ70	CP	Japan Tobacco, Inc
DM1MZ70	DT	Small molecular drug
DM1MZ70	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM2ZVXD	ID	DM2ZVXD
DM2ZVXD	DN	PMID25666693-Compound-83
DM2ZVXD	HS	Patented
DM2ZVXD	CP	Japan Tobacco, Inc
DM2ZVXD	DT	Small molecular drug
DM2ZVXD	PC	11720246
DM2ZVXD	MW	499.3
DM2ZVXD	FM	C21H15Cl2F3N4O3
DM2ZVXD	IC	InChI=1S/C21H15Cl2F3N4O3/c22-15-8-3-12(20(32)29-13-4-6-14(7-5-13)33-21(24,25)26)10-17(15)30(11-18(27)31)19-16(23)2-1-9-28-19/h1-10H,11H2,(H2,27,31)(H,29,32)
DM2ZVXD	CS	C1=CC(=C(N=C1)N(CC(=O)N)C2=C(C=CC(=C2)C(=O)NC3=CC=C(C=C3)OC(F)(F)F)Cl)Cl
DM2ZVXD	IK	OHISWWFMRZTNTO-UHFFFAOYSA-N
DM2ZVXD	IU	3-[(2-amino-2-oxoethyl)-(3-chloropyridin-2-yl)amino]-4-chloro-N-[4-(trifluoromethoxy)phenyl]benzamide
DM2ZVXD	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM4QYIJ	ID	DM4QYIJ
DM4QYIJ	DN	PMID25666693-Compound-84
DM4QYIJ	HS	Patented
DM4QYIJ	CP	Japan Tobacco, Inc
DM4QYIJ	DT	Small molecular drug
DM4QYIJ	PC	11613881
DM4QYIJ	MW	567.3
DM4QYIJ	FM	C22H14Cl2F6N4O3
DM4QYIJ	IC	InChI=1S/C22H14Cl2F6N4O3/c23-15-6-1-11(20(36)33-13-2-4-14(5-3-13)37-22(28,29)30)7-17(15)34(10-18(31)35)19-16(24)8-12(9-32-19)21(25,26)27/h1-9H,10H2,(H2,31,35)(H,33,36)
DM4QYIJ	CS	C1=CC(=CC=C1NC(=O)C2=CC(=C(C=C2)Cl)N(CC(=O)N)C3=C(C=C(C=N3)C(F)(F)F)Cl)OC(F)(F)F
DM4QYIJ	IK	FZDJPSLGLZJDRY-UHFFFAOYSA-N
DM4QYIJ	IU	3-[(2-amino-2-oxoethyl)-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]-4-chloro-N-[4-(trifluoromethoxy)phenyl]benzamide
DM4QYIJ	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMGVU7M	ID	DMGVU7M
DMGVU7M	DN	PMID25666693-Compound-85
DMGVU7M	HS	Patented
DMGVU7M	CP	Japan Tobacco, Inc
DMGVU7M	DT	Small molecular drug
DMGVU7M	PC	11671115
DMGVU7M	MW	543.3
DMGVU7M	FM	C23H19Cl2F3N4O4
DMGVU7M	IC	InChI=1S/C23H19Cl2F3N4O4/c1-35-12-13-8-18(25)21(30-10-13)32(11-20(29)33)19-9-14(2-7-17(19)24)22(34)31-15-3-5-16(6-4-15)36-23(26,27)28/h2-10H,11-12H2,1H3,(H2,29,33)(H,31,34)
DMGVU7M	CS	COCC1=CC(=C(N=C1)N(CC(=O)N)C2=C(C=CC(=C2)C(=O)NC3=CC=C(C=C3)OC(F)(F)F)Cl)Cl
DMGVU7M	IK	DQUAXWYLWLLDLL-UHFFFAOYSA-N
DMGVU7M	IU	3-[(2-amino-2-oxoethyl)-[3-chloro-5-(methoxymethyl)pyridin-2-yl]amino]-4-chloro-N-[4-(trifluoromethoxy)phenyl]benzamide
DMGVU7M	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMFZ3S4	ID	DMFZ3S4
DMFZ3S4	DN	PMID25666693-Compound-86
DMFZ3S4	HS	Patented
DMFZ3S4	CP	GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMFZ3S4	DT	Small molecular drug
DMFZ3S4	PC	56949431
DMFZ3S4	MW	373.4
DMFZ3S4	FM	C20H21F2N3O2
DMFZ3S4	IC	InChI=1S/C20H21F2N3O2/c1-20(2,3)18-15(21)10-13(11-16(18)22)27-9-7-23-19(26)14-12-24-25-8-5-4-6-17(14)25/h4-6,8,10-12H,7,9H2,1-3H3,(H,23,26)
DMFZ3S4	CS	CC(C)(C)C1=C(C=C(C=C1F)OCCNC(=O)C2=C3C=CC=CN3N=C2)F
DMFZ3S4	IK	SDAKWMHNXUGINA-UHFFFAOYSA-N
DMFZ3S4	IU	N-[2-(4-tert-butyl-3,5-difluorophenoxy)ethyl]pyrazolo[1,5-a]pyridine-3-carboxamide
DMFZ3S4	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMAV4XY	ID	DMAV4XY
DMAV4XY	DN	PMID25666693-Compound-87
DMAV4XY	HS	Patented
DMAV4XY	CP	GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMAV4XY	DT	Small molecular drug
DMAV4XY	PC	56961050
DMAV4XY	MW	403.4
DMAV4XY	FM	C21H23F2N3O3
DMAV4XY	IC	InChI=1S/C21H23F2N3O3/c1-21(2,3)19-16(22)9-14(10-17(19)23)29-8-7-24-20(28)15-11-25-26-13(12-27)5-4-6-18(15)26/h4-6,9-11,27H,7-8,12H2,1-3H3,(H,24,28)
DMAV4XY	CS	CC(C)(C)C1=C(C=C(C=C1F)OCCNC(=O)C2=C3C=CC=C(N3N=C2)CO)F
DMAV4XY	IK	SNBOLRWYZPETPJ-UHFFFAOYSA-N
DMAV4XY	IU	N-[2-(4-tert-butyl-3,5-difluorophenoxy)ethyl]-7-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxamide
DMAV4XY	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMT9EJL	ID	DMT9EJL
DMT9EJL	DN	PMID25666693-Compound-88
DMT9EJL	HS	Patented
DMT9EJL	CP	SNU R&DB Foundation
DMT9EJL	DT	Small molecular drug
DMT9EJL	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM6RQKH	ID	DM6RQKH
DM6RQKH	DN	PMID25666693-Compound-89
DM6RQKH	HS	Patented
DM6RQKH	CP	SNU R&DB Foundation
DM6RQKH	DT	Small molecular drug
DM6RQKH	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM8A4B5	ID	DM8A4B5
DM8A4B5	DN	PMID25666693-Compound-9
DM8A4B5	HS	Patented
DM8A4B5	CP	ABBVIE INC
DM8A4B5	DT	Small molecular drug
DM8A4B5	PC	66549271
DM8A4B5	MW	338.4
DM8A4B5	FM	C19H19FN4O
DM8A4B5	IC	InChI=1S/C19H19FN4O/c20-14-4-1-3-12(9-14)13-7-8-15(10-13)22-19(25)23-17-5-2-6-18-16(17)11-21-24-18/h1-6,9,11,13,15H,7-8,10H2,(H,21,24)(H2,22,23,25)/t13-,15-/m0/s1
DM8A4B5	CS	C1C[C@@H](C[C@H]1C2=CC(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=NN4
DM8A4B5	IK	ROOFFAWDIFZLQB-ZFWWWQNUSA-N
DM8A4B5	IU	1-[(1S,3S)-3-(3-fluorophenyl)cyclopentyl]-3-(1H-indazol-4-yl)urea
DM8A4B5	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM26NQE	ID	DM26NQE
DM26NQE	DN	PMID25666693-Compound-90
DM26NQE	HS	Patented
DM26NQE	CP	SNU R&DB Foundation
DM26NQE	DT	Small molecular drug
DM26NQE	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMXU3IE	ID	DMXU3IE
DMXU3IE	DN	PMID25666693-Compound-91
DMXU3IE	HS	Patented
DMXU3IE	CP	SNU R&DB Foundation
DMXU3IE	DT	Small molecular drug
DMXU3IE	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMRGOZ8	ID	DMRGOZ8
DMRGOZ8	DN	PMID25666693-Compound-92
DMRGOZ8	HS	Patented
DMRGOZ8	CP	GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMRGOZ8	DT	Small molecular drug
DMRGOZ8	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMM5EI4	ID	DMM5EI4
DMM5EI4	DN	PMID25666693-Compound-93
DMM5EI4	HS	Patented
DMM5EI4	CP	GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMM5EI4	DT	Small molecular drug
DMM5EI4	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMHREX9	ID	DMHREX9
DMHREX9	DN	PMID25666693-Compound-94
DMHREX9	HS	Patented
DMHREX9	CP	GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMHREX9	DT	Small molecular drug
DMHREX9	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMFNB1T	ID	DMFNB1T
DMFNB1T	DN	PMID25666693-Compound-95
DMFNB1T	HS	Patented
DMFNB1T	CP	GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMFNB1T	DT	Small molecular drug
DMFNB1T	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DME3NTB	ID	DME3NTB
DME3NTB	DN	PMID25666693-Compound-96
DME3NTB	HS	Patented
DME3NTB	CP	GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DME3NTB	DT	Small molecular drug
DME3NTB	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMHJOP7	ID	DMHJOP7
DMHJOP7	DN	PMID25666693-Compound-97
DMHJOP7	HS	Patented
DMHJOP7	CP	GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMHJOP7	DT	Small molecular drug
DMHJOP7	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DM2ZR8M	ID	DM2ZR8M
DM2ZR8M	DN	PMID25666693-Compound-98
DM2ZR8M	HS	Patented
DM2ZR8M	CP	PURDUE PHARMA LP [USSHIONOGI & CO [JPTAFESSE LAYKEA [USANDO SHIGERU [JPKUROSE NORIYUKI [JP]
DM2ZR8M	DT	Small molecular drug
DM2ZR8M	PC	71480662
DM2ZR8M	MW	449.5
DM2ZR8M	FM	C20H21F2N5O3S
DM2ZR8M	IC	InChI=1S/C20H21F2N5O3S/c1-11-9-26(18-14(22)6-12(8-23-18)16(29)10-28)4-5-27(11)20(30)25-19-24-15-7-13(21)2-3-17(15)31-19/h2-3,6-8,11,16,28-29H,4-5,9-10H2,1H3,(H,24,25,30)/t11-,16+/m0/s1
DM2ZR8M	CS	C[C@H]1CN(CCN1C(=O)NC2=NC3=C(S2)C=CC(=C3)F)C4=C(C=C(C=N4)[C@@H](CO)O)F
DM2ZR8M	IK	GVENNMJXQHKHOV-MEDUHNTESA-N
DM2ZR8M	IU	(2S)-4-[5-[(1S)-1,2-dihydroxyethyl]-3-fluoropyridin-2-yl]-N-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazine-1-carboxamide
DM2ZR8M	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMOISDH	ID	DMOISDH
DMOISDH	DN	PMID25666693-Compound-99
DMOISDH	HS	Patented
DMOISDH	CP	PURDUE PHARMA LP [USSHIONOGI & CO [JPTAFESSE LAYKEA [USANDO SHIGERU [JPKUROSE NORIYUKI [JP]
DMOISDH	DT	Small molecular drug
DMOISDH	PC	71498842
DMOISDH	MW	445.5
DMOISDH	FM	C21H24FN5O3S
DMOISDH	IC	InChI=1S/C21H24FN5O3S/c1-12-3-4-16-18(7-12)31-20(24-16)25-21(30)27-6-5-26(10-13(27)2)19-15(22)8-14(9-23-19)17(29)11-28/h3-4,7-9,13,17,28-29H,5-6,10-11H2,1-2H3,(H,24,25,30)/t13-,17+/m0/s1
DMOISDH	CS	C[C@H]1CN(CCN1C(=O)NC2=NC3=C(S2)C=C(C=C3)C)C4=C(C=C(C=N4)[C@@H](CO)O)F
DMOISDH	IK	MOYYIRTYGZTKTA-SUMWQHHRSA-N
DMOISDH	IU	(2S)-4-[5-[(1S)-1,2-dihydroxyethyl]-3-fluoropyridin-2-yl]-2-methyl-N-(6-methyl-1,3-benzothiazol-2-yl)piperazine-1-carboxamide
DMOISDH	DE	Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain

DMDZT7Y	ID	DMDZT7Y
DMDZT7Y	DN	PMID25684022-Compound-EP20041486488
DMDZT7Y	HS	Patented
DMDZT7Y	CP	Phosphosites GmbH
DMDZT7Y	DT	Small molecular drug
DMDZT7Y	DE	Solid tumour/cancer; Metastatic cancer

DMR4MSH	ID	DMR4MSH
DMR4MSH	DN	PMID25684022-Compound-US20120277229 39(1.1)
DMR4MSH	HS	Patented
DMR4MSH	DE	Solid tumour/cancer; Metastatic cancer

DMR3J9A	ID	DMR3J9A
DMR3J9A	DN	PMID25684022-Compound-US20120277229 40(1.2)
DMR3J9A	HS	Patented
DMR3J9A	DE	Solid tumour/cancer; Metastatic cancer

DM7V6E0	ID	DM7V6E0
DM7V6E0	DN	PMID25684022-Compound-US20120277229 41(1.3)
DM7V6E0	HS	Patented
DM7V6E0	DE	Solid tumour/cancer; Metastatic cancer

DMUQ04C	ID	DMUQ04C
DMUQ04C	DN	PMID25684022-Compound-US20120277229 44(1.4)
DMUQ04C	HS	Patented
DMUQ04C	DE	Solid tumour/cancer; Metastatic cancer

DMEIA6Y	ID	DMEIA6Y
DMEIA6Y	DN	PMID25684022-Compound-US20120277229 45(1.5)
DMEIA6Y	HS	Patented
DMEIA6Y	DE	Solid tumour/cancer; Metastatic cancer

DMDHJMU	ID	DMDHJMU
DMDHJMU	DN	PMID25684022-Compound-US20130053382 35(1-11)
DMDHJMU	HS	Patented
DMDHJMU	DE	Solid tumour/cancer; Metastatic cancer

DM40FVN	ID	DM40FVN
DM40FVN	DN	PMID25684022-Compound-US20130053382 36(3-5)
DM40FVN	HS	Patented
DM40FVN	DE	Solid tumour/cancer; Metastatic cancer

DMY7Z85	ID	DMY7Z85
DMY7Z85	DN	PMID25684022-Compound-US20130053382 37(4-6)
DMY7Z85	HS	Patented
DMY7Z85	DE	Solid tumour/cancer; Metastatic cancer

DMHLQ2T	ID	DMHLQ2T
DMHLQ2T	DN	PMID25684022-Compound-US20130053382 38(5-7)
DMHLQ2T	HS	Patented
DMHLQ2T	DE	Solid tumour/cancer; Metastatic cancer

DM809AX	ID	DM809AX
DM809AX	DN	PMID25684022-Compound-WO2004087707
DM809AX	HS	Patented
DM809AX	CP	Vernalis Cambridge Ltd
DM809AX	DT	Small molecular drug
DM809AX	DE	Solid tumour/cancer; Metastatic cancer

DMV7PNF	ID	DMV7PNF
DMV7PNF	DN	PMID25684022-Compound-WO2006015124
DMV7PNF	HS	Patented
DMV7PNF	CP	SGX PHARMACEUTICALS, INC. ARNOLD, William, D. GOSBERG, Andreas LI, Zhe STEENSMA, Ruo, W. WILSON, Mark, E
DMV7PNF	DT	Small molecular drug
DMV7PNF	DE	Solid tumour/cancer; Metastatic cancer

DMDMJYL	ID	DMDMJYL
DMDMJYL	DN	PMID25684022-Compound-WO2008005457
DMDMJYL	HS	Patented
DMDMJYL	CP	SUNESIS PHARMACEUTICALS BIOGEN IDEC MA INC. LIND, Kenneth, Egnard CAO, Kathy LIN, Edward, Yin-shiang NGUYEN, Thinh, Ba TANGONAN, Bradley, T. ERLANSON, Daniel, A. GUCKIAN, Kevin SIMMONS, Robert, Lowell LEE, Wen-cherng BIOGEN IDEC, INC. SUN, Lihong HANSEN, Stig PATHAN, Nuzhat ZHANG, Lei
DMDMJYL	DT	Small molecular drug
DMDMJYL	DE	Solid tumour/cancer; Metastatic cancer

DMKJ1HC	ID	DMKJ1HC
DMKJ1HC	DN	PMID25684022-Compound-WO2008079988
DMKJ1HC	HS	Patented
DMKJ1HC	CP	Novartis
DMKJ1HC	DT	Small molecular drug
DMKJ1HC	DE	Solid tumour/cancer; Metastatic cancer

DM8L5JR	ID	DM8L5JR
DM8L5JR	DN	PMID25684022-Compound-WO2008107444
DM8L5JR	HS	Patented
DM8L5JR	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH 
DM8L5JR	DT	Small molecular drug
DM8L5JR	DE	Solid tumour/cancer; Metastatic cancer

DMTP02Q	ID	DMTP02Q
DMTP02Q	DN	PMID25684022-Compound-WO2009153313
DMTP02Q	HS	Patented
DMTP02Q	CP	NOVARTIS AG JAIN, Rama LIN, Xiaodong NG, Simon C. PFISTER, Keith B. RAMURTHY, Savithri RICO, Alice SUBRAMANIAN, Sharadha WANG, Xiaojing Michael
DMTP02Q	DT	Small molecular drug
DMTP02Q	DE	Solid tumour/cancer; Metastatic cancer

DM37FDV	ID	DM37FDV
DM37FDV	DN	PMID25684022-Compound-WO2010127754
DM37FDV	HS	Patented
DM37FDV	CP	MERCK PATENT GMBH DORSCH, Dieter WUCHERER-PLIETKER, Margarita MUELLER, Thomas, J., J. MERKUL, Eugen
DM37FDV	DT	Small molecular drug
DM37FDV	DE	Solid tumour/cancer; Metastatic cancer

DM3IZ0H	ID	DM3IZ0H
DM3IZ0H	DN	PMID25684022-Compound-WO2011137219 35(1-11)
DM3IZ0H	HS	Patented
DM3IZ0H	CP	MERCK SHARP & DOHME CORP. KEENAN, Kevin, A. NORTHRUP, Alan, B
DM3IZ0H	DE	Solid tumour/cancer; Metastatic cancer

DMAQHI5	ID	DMAQHI5
DMAQHI5	DN	PMID25684022-Compound-WO2011137219 36(3-5)
DMAQHI5	HS	Patented
DMAQHI5	CP	MERCK SHARP & DOHME CORP. KEENAN, Kevin, A. NORTHRUP, Alan, B
DMAQHI5	DE	Solid tumour/cancer; Metastatic cancer

DMSQ5J8	ID	DMSQ5J8
DMSQ5J8	DN	PMID25684022-Compound-WO2011137219 37(4-6)
DMSQ5J8	HS	Patented
DMSQ5J8	CP	MERCK SHARP & DOHME CORP. KEENAN, Kevin, A. NORTHRUP, Alan, B
DMSQ5J8	DE	Solid tumour/cancer; Metastatic cancer

DM4NXBK	ID	DM4NXBK
DM4NXBK	DN	PMID25684022-Compound-WO2011137219 38(5-7)
DM4NXBK	HS	Patented
DM4NXBK	CP	MERCK SHARP & DOHME CORP. KEENAN, Kevin, A. NORTHRUP, Alan, B
DM4NXBK	DE	Solid tumour/cancer; Metastatic cancer

DMSDRA4	ID	DMSDRA4
DMSDRA4	DN	PMID25684022-Compound-WO2012135799 42(1.4)
DMSDRA4	HS	Patented
DMSDRA4	CP	UNIVERSITY OF UTAH RESEARCH FOUNDATION BEARSS, David, J. VANKAYALAPATI, Hariprasad SORNA, Venkataswamy WARNER, Steven, L. SHARMA, Sunil
DMSDRA4	DE	Solid tumour/cancer; Metastatic cancer

DMHI3O1	ID	DMHI3O1
DMHI3O1	DN	PMID25684022-Compound-WO2012135799 43(1.5)
DMHI3O1	HS	Patented
DMHI3O1	CP	UNIVERSITY OF UTAH RESEARCH FOUNDATION BEARSS, David, J. VANKAYALAPATI, Hariprasad SORNA, Venkataswamy WARNER, Steven, L. SHARMA, Sunil
DMHI3O1	DE	Solid tumour/cancer; Metastatic cancer

DMZ73D9	ID	DMZ73D9
DMZ73D9	DN	PMID25726713-Compound-10
DMZ73D9	HS	Patented
DMZ73D9	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, H&eacute;l&egrave;ne ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Ang&egrave;le TADDEI, Maurizio MANN, Andr&eacute
DMZ73D9	DT	Small molecular drug

DMN42OT	ID	DMN42OT
DMN42OT	DN	PMID25726713-Compound-11
DMN42OT	HS	Patented
DMN42OT	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, H&eacute;l&egrave;ne ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Ang&egrave;le TADDEI, Maurizio MANN, Andr&eacute
DMN42OT	DT	Small molecular drug

DMD3AHN	ID	DMD3AHN
DMD3AHN	DN	PMID25726713-Compound-12
DMD3AHN	HS	Patented
DMD3AHN	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, H&eacute;l&egrave;ne ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Ang&egrave;le TADDEI, Maurizio MANN, Andr&eacute
DMD3AHN	DT	Small molecular drug

DM8LZ60	ID	DM8LZ60
DM8LZ60	DN	PMID25726713-Compound-13
DM8LZ60	HS	Patented
DM8LZ60	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, H&eacute;l&egrave;ne ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Ang&egrave;le TADDEI, Maurizio MANN, Andr&eacute
DM8LZ60	DT	Small molecular drug

DM6ORB9	ID	DM6ORB9
DM6ORB9	DN	PMID25726713-Compound-14
DM6ORB9	HS	Patented
DM6ORB9	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, H&eacute;l&egrave;ne ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Ang&egrave;le TADDEI, Maurizio MANN, Andr&eacute
DM6ORB9	DT	Small molecular drug

DM67WM4	ID	DM67WM4
DM67WM4	DN	PMID25726713-Compound-15
DM67WM4	HS	Patented
DM67WM4	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, H&eacute;l&egrave;ne ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Ang&egrave;le TADDEI, Maurizio MANN, Andr&eacute
DM67WM4	DT	Small molecular drug

DM3BOZP	ID	DM3BOZP
DM3BOZP	DN	PMID25726713-Compound-16
DM3BOZP	HS	Patented
DM3BOZP	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, H&eacute;l&egrave;ne ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Ang&egrave;le TADDEI, Maurizio MANN, Andr&eacute
DM3BOZP	DT	Small molecular drug

DM9MFUN	ID	DM9MFUN
DM9MFUN	DN	PMID25726713-Compound-17
DM9MFUN	HS	Patented
DM9MFUN	CP	DUKE UNIVERSITY
DM9MFUN	DT	Small molecular drug

DMP7C5L	ID	DMP7C5L
DMP7C5L	DN	PMID25726713-Compound-18
DMP7C5L	HS	Patented
DMP7C5L	CP	DUKE UNIVERSITY
DMP7C5L	DT	Small molecular drug

DMQJZLI	ID	DMQJZLI
DMQJZLI	DN	PMID25726713-Compound-19
DMQJZLI	HS	Patented
DMQJZLI	CP	IMPACT THERAPEUTICS, INC.  CAI, Suixiong  TIAN, Ye Edward  WANG, Xiaozhu  XIE, Kai  LI, Sicun  YU, Zenghui  GU, Chengyun  LIU, Lijun 
DMQJZLI	DT	Small molecular drug

DMZOG9S	ID	DMZOG9S
DMZOG9S	DN	PMID25726713-Compound-20
DMZOG9S	HS	Patented
DMZOG9S	CP	IMPACT THERAPEUTICS, INC.  CAI, Suixiong  TIAN, Ye Edward  WANG, Xiaozhu  XIE, Kai  LI, Sicun  YU, Zenghui  GU, Chengyun  LIU, Lijun 
DMZOG9S	DT	Small molecular drug
DMZOG9S	PC	71484081
DMZOG9S	MW	490
DMZOG9S	FM	C26H24ClN5O3
DMZOG9S	IC	InChI=1S/C26H24ClN5O3/c1-14(2)35-16-6-8-21-22(11-16)32-26(31-21)18-9-15(5-7-20(18)27)30-25-19-10-17(33-3)12-23(34-4)24(19)28-13-29-25/h5-14H,1-4H3,(H,31,32)(H,28,29,30)
DMZOG9S	CS	CC(C)OC1=CC2=C(C=C1)N=C(N2)C3=C(C=CC(=C3)NC4=NC=NC5=C4C=C(C=C5OC)OC)Cl
DMZOG9S	IK	UTABPCPBPRTBQJ-UHFFFAOYSA-N
DMZOG9S	IU	N-[4-chloro-3-(6-propan-2-yloxy-1H-benzimidazol-2-yl)phenyl]-6,8-dimethoxyquinazolin-4-amine

DMB0DS5	ID	DMB0DS5
DMB0DS5	DN	PMID25726713-Compound-21
DMB0DS5	HS	Patented
DMB0DS5	CP	IMPACT THERAPEUTICS, INC.  CAI, Suixiong  TIAN, Ye Edward  WANG, Xiaozhu  XIE, Kai  LI, Sicun  YU, Zenghui  GU, Chengyun  LIU, Lijun 
DMB0DS5	DT	Small molecular drug

DMJUHXB	ID	DMJUHXB
DMJUHXB	DN	PMID25726713-Compound-22
DMJUHXB	HS	Patented
DMJUHXB	CP	IMPACT THERAPEUTICS, INC.  CAI, Suixiong  TIAN, Ye Edward  WANG, Xiaozhu  XIE, Kai  LI, Sicun  YU, Zenghui  GU, Chengyun  LIU, Lijun 
DMJUHXB	DT	Small molecular drug

DMEXNOP	ID	DMEXNOP
DMEXNOP	DN	PMID25726713-Compound-23
DMEXNOP	HS	Patented
DMEXNOP	CP	IMPACT THERAPEUTICS, INC.  CAI, Suixiong  TIAN, Ye Edward  WANG, Xiaozhu  XIE, Kai  LI, Sicun  YU, Zenghui  GU, Chengyun  LIU, Lijun 
DMEXNOP	DT	Small molecular drug

DMMFK2Q	ID	DMMFK2Q
DMMFK2Q	DN	PMID25726713-Compound-24
DMMFK2Q	HS	Patented
DMMFK2Q	CP	IMPACT THERAPEUTICS, INC.  CAI, Suixiong  TIAN, Ye Edward  WANG, Xiaozhu  XIE, Kai  LI, Sicun  YU, Zenghui  GU, Chengyun  LIU, Lijun 
DMMFK2Q	DT	Small molecular drug

DMLCPWT	ID	DMLCPWT
DMLCPWT	DN	PMID25726713-Compound-25
DMLCPWT	HS	Patented
DMLCPWT	CP	IMPACT THERAPEUTICS, INC
DMLCPWT	DT	Small molecular drug

DMJ8MXZ	ID	DMJ8MXZ
DMJ8MXZ	DN	PMID25726713-Compound-26
DMJ8MXZ	HS	Patented
DMJ8MXZ	CP	IMPACT THERAPEUTICS, INC
DMJ8MXZ	DT	Small molecular drug

DMTL73W	ID	DMTL73W
DMTL73W	DN	PMID25726713-Compound-27
DMTL73W	HS	Patented
DMTL73W	CP	IMPACT THERAPEUTICS, INC
DMTL73W	DT	Small molecular drug

DMYM60P	ID	DMYM60P
DMYM60P	DN	PMID25726713-Compound-28
DMYM60P	HS	Patented
DMYM60P	CP	IMPACT THERAPEUTICS, INC
DMYM60P	DT	Small molecular drug

DM3QU80	ID	DM3QU80
DM3QU80	DN	PMID25726713-Compound-29
DM3QU80	HS	Patented
DM3QU80	CP	IMPACT THERAPEUTICS, INC
DM3QU80	DT	Small molecular drug

DMFBHAC	ID	DMFBHAC
DMFBHAC	DN	PMID25726713-Compound-30
DMFBHAC	HS	Patented
DMFBHAC	CP	IMPACT THERAPEUTICS, INC
DMFBHAC	DT	Small molecular drug

DMN13BI	ID	DMN13BI
DMN13BI	DN	PMID25726713-Compound-31
DMN13BI	HS	Patented
DMN13BI	DT	Small molecular drug

DMIFH8T	ID	DMIFH8T
DMIFH8T	DN	PMID25726713-Compound-32
DMIFH8T	HS	Patented
DMIFH8T	DT	Small molecular drug

DMEQ9BN	ID	DMEQ9BN
DMEQ9BN	DN	PMID25726713-Compound-33
DMEQ9BN	HS	Patented
DMEQ9BN	DT	Small molecular drug

DMCXDKS	ID	DMCXDKS
DMCXDKS	DN	PMID25726713-Compound-34
DMCXDKS	HS	Patented
DMCXDKS	DT	Small molecular drug

DMYCABN	ID	DMYCABN
DMYCABN	DN	PMID25726713-Compound-35
DMYCABN	HS	Patented
DMYCABN	DT	Small molecular drug

DMYPT63	ID	DMYPT63
DMYPT63	DN	PMID25726713-Compound-36
DMYPT63	HS	Patented
DMYPT63	DT	Small molecular drug

DMGXOJK	ID	DMGXOJK
DMGXOJK	DN	PMID25726713-Compound-37
DMGXOJK	HS	Patented
DMGXOJK	DT	Small molecular drug

DM4XJST	ID	DM4XJST
DM4XJST	DN	PMID25726713-Compound-38
DM4XJST	HS	Patented
DM4XJST	DT	Small molecular drug
DM4XJST	PC	118706742
DM4XJST	MW	617.6
DM4XJST	FM	C32H30F3N7O3
DM4XJST	IC	InChI=1S/C32H30F3N7O3/c1-20-3-4-21(18-42-13-15-44-16-14-42)17-26(20)38-30(43)23-5-9-24(10-6-23)37-31-39-27(28-29(40-31)41(2)19-36-28)22-7-11-25(12-8-22)45-32(33,34)35/h3-12,17,19H,13-16,18H2,1-2H3,(H,38,43)(H,37,39,40)
DM4XJST	CS	CC1=C(C=C(C=C1)CN2CCOCC2)NC(=O)C3=CC=C(C=C3)NC4=NC(=C5C(=N4)N(C=N5)C)C6=CC=C(C=C6)OC(F)(F)F
DM4XJST	IK	RXPJNNAJKCJKEX-UHFFFAOYSA-N
DM4XJST	IU	N-[2-methyl-5-(morpholin-4-ylmethyl)phenyl]-4-[[9-methyl-6-[4-(trifluoromethoxy)phenyl]purin-2-yl]amino]benzamide

DMVL25C	ID	DMVL25C
DMVL25C	DN	PMID25726713-Compound-39
DMVL25C	HS	Patented
DMVL25C	DT	Small molecular drug

DM5E2B3	ID	DM5E2B3
DM5E2B3	DN	PMID25726713-Compound-42
DM5E2B3	HS	Patented
DM5E2B3	CP	MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DM5E2B3	DT	Small molecular drug

DME9QCM	ID	DME9QCM
DME9QCM	DN	PMID25726713-Compound-43
DME9QCM	HS	Patented
DME9QCM	CP	MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DME9QCM	DT	Small molecular drug

DMEFA20	ID	DMEFA20
DMEFA20	DN	PMID25726713-Compound-44
DMEFA20	HS	Patented
DMEFA20	CP	MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DMEFA20	DT	Small molecular drug

DMR8OVI	ID	DMR8OVI
DMR8OVI	DN	PMID25726713-Compound-45
DMR8OVI	HS	Patented
DMR8OVI	CP	MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DMR8OVI	DT	Small molecular drug

DM27DQP	ID	DM27DQP
DM27DQP	DN	PMID25726713-Compound-46
DM27DQP	HS	Patented
DM27DQP	CP	MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DM27DQP	DT	Small molecular drug

DMXE5KM	ID	DMXE5KM
DMXE5KM	DN	PMID25726713-Compound-47
DMXE5KM	HS	Patented
DMXE5KM	DT	Small molecular drug

DMSIOUA	ID	DMSIOUA
DMSIOUA	DN	PMID25726713-Compound-48
DMSIOUA	HS	Patented
DMSIOUA	DT	Small molecular drug

DM2CT4G	ID	DM2CT4G
DM2CT4G	DN	PMID25726713-Compound-49
DM2CT4G	HS	Patented
DM2CT4G	DT	Small molecular drug

DM3BDFV	ID	DM3BDFV
DM3BDFV	DN	PMID25726713-Compound-50
DM3BDFV	HS	Patented
DM3BDFV	DT	Small molecular drug

DMF0OW4	ID	DMF0OW4
DMF0OW4	DN	PMID25726713-Compound-51
DMF0OW4	HS	Patented
DMF0OW4	DT	Small molecular drug

DMUHEP8	ID	DMUHEP8
DMUHEP8	DN	PMID25726713-Compound-56
DMUHEP8	HS	Patented
DMUHEP8	DT	Small molecular drug

DMMZHB1	ID	DMMZHB1
DMMZHB1	DN	PMID25726713-Compound-57
DMMZHB1	HS	Patented
DMMZHB1	DT	Small molecular drug

DMPDX3L	ID	DMPDX3L
DMPDX3L	DN	PMID25726713-Compound-58
DMPDX3L	HS	Patented
DMPDX3L	DT	Small molecular drug

DMBF1OG	ID	DMBF1OG
DMBF1OG	DN	PMID25726713-Compound-59
DMBF1OG	HS	Patented
DMBF1OG	DT	Small molecular drug

DMR8HSU	ID	DMR8HSU
DMR8HSU	DN	PMID25726713-Compound-60
DMR8HSU	HS	Patented
DMR8HSU	DT	Small molecular drug

DMYXK7I	ID	DMYXK7I
DMYXK7I	DN	PMID25726713-Compound-61
DMYXK7I	HS	Patented
DMYXK7I	DT	Small molecular drug

DMXNLTR	ID	DMXNLTR
DMXNLTR	DN	PMID25726713-Compound-62
DMXNLTR	HS	Patented
DMXNLTR	DT	Small molecular drug

DMT0QLO	ID	DMT0QLO
DMT0QLO	DN	PMID25726713-Compound-63
DMT0QLO	HS	Patented
DMT0QLO	DT	Small molecular drug

DM6A8TS	ID	DM6A8TS
DM6A8TS	DN	PMID25726713-Compound-64
DM6A8TS	HS	Patented
DM6A8TS	DT	Small molecular drug

DM048C1	ID	DM048C1
DM048C1	DN	PMID25747044-Compound-miRNA
DM048C1	HS	Patented
DM048C1	CP	UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
DM048C1	DT	miRNA

DMVWF6I	ID	DMVWF6I
DMVWF6I	DN	PMID25772215-Compound-EP20082149552C9
DMVWF6I	HS	Patented
DMVWF6I	DT	Small molecular drug

DM48YKE	ID	DM48YKE
DM48YKE	DN	PMID25772215-Compound-EP2149552diaminopyrimidines
DM48YKE	HS	Patented
DM48YKE	CP	BAYER SCHERING PHARMA AG [DE]
DM48YKE	DT	Small molecular drug

DM7EKZ6	ID	DM7EKZ6
DM7EKZ6	DN	PMID25772215-Compound-US02014179750M1
DM7EKZ6	HS	Patented
DM7EKZ6	DT	Small molecular drug

DMC50F3	ID	DMC50F3
DMC50F3	DN	PMID25772215-Compound-US02014179750M2
DMC50F3	HS	Patented
DMC50F3	DT	Small molecular drug

DMJA1XC	ID	DMJA1XC
DMJA1XC	DN	PMID25772215-Compound-US02014179750M3
DMJA1XC	HS	Patented
DMJA1XC	DT	Small molecular drug

DMWD1FP	ID	DMWD1FP
DMWD1FP	DN	PMID25772215-Compound-US02014179750TG6-10-1
DMWD1FP	HS	Patented
DMWD1FP	CP	EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMWD1FP	DT	Small molecular drug

DMRLZD2	ID	DMRLZD2
DMRLZD2	DN	PMID25772215-Compound-US02014179750TG6-129
DMRLZD2	HS	Patented
DMRLZD2	CP	EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMRLZD2	DT	Small molecular drug

DMB87WZ	ID	DMB87WZ
DMB87WZ	DN	PMID25772215-Compound-US02014179750TG7-112-2
DMB87WZ	HS	Patented
DMB87WZ	DT	Small molecular drug

DMORK8H	ID	DMORK8H
DMORK8H	DN	PMID25772215-Compound-US02014179750TG7-170
DMORK8H	HS	Patented
DMORK8H	DT	Small molecular drug

DM9I4EV	ID	DM9I4EV
DM9I4EV	DN	PMID25772215-Compound-US02014179750TG7-74
DM9I4EV	HS	Patented
DM9I4EV	DT	Small molecular drug

DMRTZC4	ID	DMRTZC4
DMRTZC4	DN	PMID25772215-Compound-US02014179750TG7-76
DMRTZC4	HS	Patented
DMRTZC4	DT	Small molecular drug

DM8IL6Y	ID	DM8IL6Y
DM8IL6Y	DN	PMID25772215-Compound-US02014179750TG8-15
DM8IL6Y	HS	Patented
DM8IL6Y	DT	Small molecular drug

DMD3CB4	ID	DMD3CB4
DMD3CB4	DN	PMID25772215-Compound-WO2012177618M4
DMD3CB4	HS	Patented
DMD3CB4	CP	EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMD3CB4	DT	Small molecular drug

DMWUK9X	ID	DMWUK9X
DMWUK9X	DN	PMID25772215-Compound-WO2012177618M5
DMWUK9X	HS	Patented
DMWUK9X	CP	EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMWUK9X	DT	Small molecular drug

DMDCZVI	ID	DMDCZVI
DMDCZVI	DN	PMID25772215-Compound-WO2012177618M6
DMDCZVI	HS	Patented
DMDCZVI	CP	EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMDCZVI	DT	Small molecular drug

DMGHSR9	ID	DMGHSR9
DMGHSR9	DN	PMID25776143-Compound-1
DMGHSR9	HS	Patented
DMGHSR9	CP	Ferring BV
DMGHSR9	DT	Small molecular drug

DMTZRFP	ID	DMTZRFP
DMTZRFP	DN	PMID25776143-Compound-2
DMTZRFP	HS	Patented
DMTZRFP	CP	Ferring BV
DMTZRFP	DT	Small molecular drug

DMCULI1	ID	DMCULI1
DMCULI1	DN	PMID25776143-Compound-3
DMCULI1	HS	Patented
DMCULI1	CP	Hoffmann-La Roche Ag
DMCULI1	DT	Small molecular drug

DMMVETJ	ID	DMMVETJ
DMMVETJ	DN	PMID25776143-Compound-4
DMMVETJ	HS	Patented
DMMVETJ	CP	Hoffmann-La Roche Ag
DMMVETJ	DT	Small molecular drug

DM7QIMN	ID	DM7QIMN
DM7QIMN	DN	PMID25776143-Compound-7
DM7QIMN	HS	Patented
DM7QIMN	CP	Vantia Ltd
DM7QIMN	DT	Small molecular drug
DM7QIMN	PC	135468116
DM7QIMN	MW	597.6
DM7QIMN	FM	C31H38Cl2N6O2
DM7QIMN	IC	InChI=1S/C31H38Cl2N6O2/c1-31(2,3)11-14-38-12-9-20(10-13-38)29(40)34-17-22-6-5-21(15-25(22)33)30(41)39-19-23-18-35-37(4)28(23)36-26-16-24(32)7-8-27(26)39/h5-8,15-16,18,20,36H,9-14,17,19H2,1-4H3,(H,34,40)
DM7QIMN	CS	CC(C)(C)CCN1CCC(CC1)C(=O)NCC2=C(C=C(C=C2)C(=O)N3CC4=C(NC5=C3C=CC(=C5)Cl)N(N=C4)C)Cl
DM7QIMN	IK	QYCFYRDBJAXOJI-UHFFFAOYSA-N
DM7QIMN	IU	N-[[2-chloro-4-(8-chloro-1-methyl-4,10-dihydropyrazolo[4,3-c][1,5]benzodiazepine-5-carbonyl)phenyl]methyl]-1-(3,3-dimethylbutyl)piperidine-4-carboxamide

DMUKFJ0	ID	DMUKFJ0
DMUKFJ0	DN	PMID25776143-Compound-8
DMUKFJ0	HS	Patented
DMUKFJ0	CP	Ferring BV
DMUKFJ0	DT	Small molecular drug
DMUKFJ0	PC	136396729
DMUKFJ0	MW	449.9
DMUKFJ0	FM	C24H24ClN5O2
DMUKFJ0	IC	InChI=1S/C24H24ClN5O2/c1-14-9-16(5-6-17(14)11-26-23(31)15-3-4-15)24(32)30-13-18-12-27-29(2)22(18)28-20-10-19(25)7-8-21(20)30/h5-10,12,15,28H,3-4,11,13H2,1-2H3,(H,26,31)
DMUKFJ0	CS	CC1=C(C=CC(=C1)C(=O)N2CC3=C(NC4=C2C=CC(=C4)Cl)N(N=C3)C)CNC(=O)C5CC5
DMUKFJ0	IK	DZLYFDUKRUYUIP-UHFFFAOYSA-N
DMUKFJ0	IU	N-[[4-(8-chloro-1-methyl-4,10-dihydropyrazolo[4,3-c][1,5]benzodiazepine-5-carbonyl)-2-methylphenyl]methyl]cyclopropanecarboxamide

DMEC1TR	ID	DMEC1TR
DMEC1TR	DN	PMID25828189-Compound-19
DMEC1TR	HS	Patented
DMEC1TR	DT	Small molecular drug

DM7D0CT	ID	DM7D0CT
DM7D0CT	DN	PMID25828189-Compound-21
DM7D0CT	HS	Patented
DM7D0CT	DT	Small molecular drug
DM7D0CT	PC	60152347
DM7D0CT	MW	502.5
DM7D0CT	FM	C24H25F3N6O3
DM7D0CT	IC	InChI=1S/C24H25F3N6O3/c25-24(26,27)19-13-33(14-31-19)23-29-11-18(12-30-23)32-21(15-3-1-2-4-15)16-5-7-17(8-6-16)22(36)28-10-9-20(34)35/h5-8,11-15,21,32H,1-4,9-10H2,(H,28,36)(H,34,35)
DM7D0CT	CS	C1CCC(C1)C(C2=CC=C(C=C2)C(=O)NCCC(=O)O)NC3=CN=C(N=C3)N4C=C(N=C4)C(F)(F)F
DM7D0CT	IK	KUIQXXFGGIPRIS-UHFFFAOYSA-N
DM7D0CT	IU	3-[[4-[cyclopentyl-[[2-[4-(trifluoromethyl)imidazol-1-yl]pyrimidin-5-yl]amino]methyl]benzoyl]amino]propanoic acid

DMC2O0Q	ID	DMC2O0Q
DMC2O0Q	DN	PMID25828189-Compound-22
DMC2O0Q	HS	Patented
DMC2O0Q	DT	Small molecular drug
DMC2O0Q	PC	68178614
DMC2O0Q	MW	461.6
DMC2O0Q	FM	C27H31N3O4
DMC2O0Q	IC	InChI=1S/C27H31N3O4/c1-2-5-25(19-8-10-20(11-9-19)27(33)28-17-16-26(31)32)34-23-14-12-22(13-15-23)30-18-21-6-3-4-7-24(21)29-30/h8-15,18,25H,2-7,16-17H2,1H3,(H,28,33)(H,31,32)
DMC2O0Q	CS	CCCC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)OC2=CC=C(C=C2)N3C=C4CCCCC4=N3
DMC2O0Q	IK	BFFBGZWQVKRFRU-UHFFFAOYSA-N
DMC2O0Q	IU	3-[[4-[1-[4-(4,5,6,7-tetrahydroindazol-2-yl)phenoxy]butyl]benzoyl]amino]propanoic acid

DMYPT2H	ID	DMYPT2H
DMYPT2H	DN	PMID25980951-Compound-1
DMYPT2H	HS	Patented
DMYPT2H	CP	PHARMASCIENCE INC. LAURENT, Alain PROULX, Melanie ROSE, Yannick DENISSOVA, Irina DAIRI, Kenza JARVIS, Scott JAQUITH, James, B
DMYPT2H	DT	Small molecular drug
DMYPT2H	PC	68265428
DMYPT2H	MW	565.7
DMYPT2H	FM	C30H40FN7O3
DMYPT2H	IC	InChI=1S/C30H40FN7O3/c1-20(32-5)26(39)35-25(30(2,3)4)28(41)38-16-6-8-23(38)18-36(17-13-21-9-11-22(31)12-10-21)27(40)24-19-37-15-7-14-33-29(37)34-24/h7,9-12,14-15,19-20,23,25,32H,6,8,13,16-18H2,1-5H3,(H,35,39)/t20-,23-,25+/m0/s1
DMYPT2H	CS	C[C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1CN(CCC2=CC=C(C=C2)F)C(=O)C3=CN4C=CC=NC4=N3)C(C)(C)C)NC
DMYPT2H	IK	HWFGTCIBSHAQOY-GRYUFTJMSA-N
DMYPT2H	IU	N-[[(2S)-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-N-[2-(4-fluorophenyl)ethyl]imidazo[1,2-a]pyrimidine-2-carboxamide

DME3ZJO	ID	DME3ZJO
DME3ZJO	DN	PMID25980951-Compound-10
DME3ZJO	HS	Patented
DME3ZJO	CP	GENENTECH, INC. BERGERON, Philippe KOEHLER, Michael, F. T
DME3ZJO	DT	Small molecular drug
DME3ZJO	PC	46175910
DME3ZJO	MW	489.6
DME3ZJO	FM	C28H35N5O3
DME3ZJO	IC	InChI=1S/C28H35N5O3/c1-18(29-2)27(34)32-26(20-11-15-36-16-12-20)28(35)33-14-6-9-23(33)22-17-21-10-13-30-24(25(21)31-22)19-7-4-3-5-8-19/h3-5,7-8,10,13,17-18,20,23,26,29,31H,6,9,11-12,14-16H2,1-2H3,(H,32,34)/t18-,23-,26-/m0/s1
DME3ZJO	CS	C[C@@H](C(=O)N[C@@H](C1CCOCC1)C(=O)N2CCC[C@H]2C3=CC4=C(N3)C(=NC=C4)C5=CC=CC=C5)NC
DME3ZJO	IK	IKVUPSWUHVVHKV-WMDMVVLCSA-N
DME3ZJO	IU	(2S)-2-(methylamino)-N-[(1S)-1-(oxan-4-yl)-2-oxo-2-[(2S)-2-(7-phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl)pyrrolidin-1-yl]ethyl]propanamide

DMZ9LSY	ID	DMZ9LSY
DMZ9LSY	DN	PMID25980951-Compound-11
DMZ9LSY	HS	Patented
DMZ9LSY	CP	HANMI HOLDINGS CO., LTD. BAE, In Hwan JUN, Mi Ae SONG, Ji Young JU, Hae Kyoung SONG, Tae Hun CHO, Ju Hyun KWEON, Eun Kyung AHN, Young Gil KIM, Cheol Kyung KIM, Maeng Sup
DMZ9LSY	DT	Small molecular drug

DMG8K1P	ID	DMG8K1P
DMG8K1P	DN	PMID25980951-Compound-12
DMG8K1P	HS	Patented
DMG8K1P	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMG8K1P	DT	Small molecular drug

DMGHR4D	ID	DMGHR4D
DMGHR4D	DN	PMID25980951-Compound-13
DMGHR4D	HS	Patented
DMGHR4D	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMGHR4D	DT	Small molecular drug
DMGHR4D	PC	73296970
DMGHR4D	MW	472.5
DMGHR4D	FM	C25H30F2N4O3
DMGHR4D	IC	InChI=1S/C25H30F2N4O3/c1-14(28-5)22(32)30-21(25(2,3)4)24(34)31-13-15-9-6-7-10-16(15)20(31)23(33)29-19-17(26)11-8-12-18(19)27/h6-12,14,20-21,28H,13H2,1-5H3,(H,29,33)(H,30,32)/t14-,20-,21+/m0/s1
DMGHR4D	CS	C[C@@H](C(=O)N[C@H](C(=O)N1CC2=CC=CC=C2[C@H]1C(=O)NC3=C(C=CC=C3F)F)C(C)(C)C)NC
DMGHR4D	IK	YVSLGVHZPIUKJU-SZFUDVHCSA-N
DMGHR4D	IU	(1S)-N-(2,6-difluorophenyl)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-1,3-dihydroisoindole-1-carboxamide

DM637IC	ID	DM637IC
DM637IC	DN	PMID25980951-Compound-14
DM637IC	HS	Patented
DM637IC	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM637IC	DT	Small molecular drug

DMB2MIT	ID	DMB2MIT
DMB2MIT	DN	PMID25980951-Compound-15
DMB2MIT	HS	Patented
DMB2MIT	CP	SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
DMB2MIT	DT	Small molecular drug

DM1J3LE	ID	DM1J3LE
DM1J3LE	DN	PMID25980951-Compound-16
DM1J3LE	HS	Patented
DM1J3LE	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED 
DM1J3LE	DT	Small molecular drug
DM1J3LE	PC	50913339
DM1J3LE	MW	605.7
DM1J3LE	FM	C31H45F2N5O5
DM1J3LE	IC	InChI=1S/C31H45F2N5O5/c1-4-42-22-15-21-16-38(30(41)27(36-28(39)19(2)34-3)20-9-12-31(32,33)13-10-20)25(18-37(21)17-22)29(40)35-24-11-14-43-26-8-6-5-7-23(24)26/h5-8,19-22,24-25,27,34H,4,9-18H2,1-3H3,(H,35,40)(H,36,39)/t19-,21+,22+,24+,25-,27-/m0/s1
DM1J3LE	CS	CCO[C@@H]1C[C@@H]2CN([C@@H](CN2C1)C(=O)N[C@@H]3CCOC4=CC=CC=C34)C(=O)[C@H](C5CCC(CC5)(F)F)NC(=O)[C@H](C)NC
DM1J3LE	IK	WQLHYSFOEZZZDD-QAPMSZJWSA-N
DM1J3LE	IU	(3S,7R,8aR)-2-[(2S)-2-(4,4-difluorocyclohexyl)-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(4R)-3,4-dihydro-2H-chromen-4-yl]-7-ethoxy-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine-3-carboxamide

DMSC8B6	ID	DMSC8B6
DMSC8B6	DN	PMID25980951-Compound-17
DMSC8B6	HS	Patented
DMSC8B6	DT	Small molecular drug

DMC3NHJ	ID	DMC3NHJ
DMC3NHJ	DN	PMID25980951-Compound-18
DMC3NHJ	HS	Patented
DMC3NHJ	DT	Small molecular drug

DMGIV0M	ID	DMGIV0M
DMGIV0M	DN	PMID25980951-Compound-19
DMGIV0M	HS	Patented
DMGIV0M	CP	TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. LAPORTE, Matthew, G
DMGIV0M	DT	Small molecular drug

DMM45AC	ID	DMM45AC
DMM45AC	DN	PMID25980951-Compound-20
DMM45AC	HS	Patented
DMM45AC	CP	TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. DENG, Yijun LAPORTE, Matthew, G
DMM45AC	DT	Small molecular drug
DMM45AC	PC	67478013
DMM45AC	MW	558.7
DMM45AC	FM	C27H38N6O5S
DMM45AC	IC	InChI=1S/C27H38N6O5S/c1-16(28-5)24(34)31-23(27(2,3)4)26(36)32-14-12-20-22(32)18(15-33(20)39(6,37)38)25(35)30-19-11-7-9-17-10-8-13-29-21(17)19/h7-11,13,16,18,20,22-23,28H,12,14-15H2,1-6H3,(H,30,35)(H,31,34)/t16-,18-,20+,22+,23+/m0/s1
DMM45AC	CS	C[C@@H](C(=O)N[C@H](C(=O)N1CC[C@@H]2[C@H]1[C@H](CN2S(=O)(=O)C)C(=O)NC3=CC=CC4=C3N=CC=C4)C(C)(C)C)NC
DMM45AC	IK	VDNCJSPAMUEWDC-VBEIARHESA-N
DMM45AC	IU	(3aR,6S,6aR)-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-4-methylsulfonyl-N-quinolin-8-yl-2,3,3a,5,6,6a-hexahydropyrrolo[3,2-b]pyrrole-6-carboxamide

DMIE0MR	ID	DMIE0MR
DMIE0MR	DN	PMID25980951-Compound-21
DMIE0MR	HS	Patented
DMIE0MR	CP	TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. DENG, Yijun ALEXANDER, Matthew, D. LAPORTE, Matthew, G
DMIE0MR	DT	Small molecular drug
DMIE0MR	PC	49818910
DMIE0MR	MW	516.6
DMIE0MR	FM	C23H34F2N4O5S
DMIE0MR	IC	InChI=1S/C23H34F2N4O5S/c1-13(26-5)21(30)27-20(23(2,3)4)22(31)28-10-9-17-19(28)18(12-29(17)35(6,32)33)34-14-7-8-15(24)16(25)11-14/h7-8,11,13,17-20,26H,9-10,12H2,1-6H3,(H,27,30)/t13-,17+,18-,19-,20+/m0/s1
DMIE0MR	CS	C[C@@H](C(=O)N[C@H](C(=O)N1CC[C@@H]2[C@H]1[C@H](CN2S(=O)(=O)C)OC3=CC(=C(C=C3)F)F)C(C)(C)C)NC
DMIE0MR	IK	JFUYRIMMOJAVPX-FOGBYNIYSA-N
DMIE0MR	IU	(2S)-N-[(2S)-1-[(3aR,6S,6aS)-6-(3,4-difluorophenoxy)-4-methylsulfonyl-2,3,3a,5,6,6a-hexahydropyrrolo[3,2-b]pyrrol-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]-2-(methylamino)propanamide

DM6OEHK	ID	DM6OEHK
DM6OEHK	DN	PMID25980951-Compound-22
DM6OEHK	HS	Patented
DM6OEHK	CP	TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen M. LAPORTE, Matthew G. HAIMOWITZ, Thomas
DM6OEHK	DT	Small molecular drug
DM6OEHK	PC	53239649
DM6OEHK	MW	580.7
DM6OEHK	FM	C30H40N6O4S
DM6OEHK	IC	InChI=1S/C30H40N6O4S/c1-19(31-5)28(37)33-26(30(2,3)4)29(38)35-16-14-24-25(35)22(17-36(24)41(6,39)40)23-18-34-15-10-13-21(27(34)32-23)20-11-8-7-9-12-20/h7-13,15,18-19,22,24-26,31H,14,16-17H2,1-6H3,(H,33,37)/t19-,22+,24+,25+,26+/m0/s1
DM6OEHK	CS	C[C@@H](C(=O)N[C@H](C(=O)N1CC[C@@H]2[C@H]1[C@H](CN2S(=O)(=O)C)C3=CN4C=CC=C(C4=N3)C5=CC=CC=C5)C(C)(C)C)NC
DM6OEHK	IK	CDYZPYAGGGZKJG-PFCQFSIYSA-N
DM6OEHK	IU	(2S)-N-[(2S)-1-[(3aR,6S,6aR)-4-methylsulfonyl-6-(8-phenylimidazo[1,2-a]pyridin-2-yl)-2,3,3a,5,6,6a-hexahydropyrrolo[3,2-b]pyrrol-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]-2-(methylamino)propanamide

DMK9DH7	ID	DMK9DH7
DMK9DH7	DN	PMID25980951-Compound-26
DMK9DH7	HS	Patented
DMK9DH7	CP	ENSEMBLE THERAPEUTICS CORPORATION
DMK9DH7	DT	Small molecular drug

DMXAH9F	ID	DMXAH9F
DMXAH9F	DN	PMID25980951-Compound-27
DMXAH9F	HS	Patented
DMXAH9F	CP	ASTRAZENECA AB ASTRAZENECA UK LIMITED AQUILA, Brian HENNESSY, Edward HIRD, Alexander OZA, Vibha SAEH, Jamal Carlos SHA, Li
DMXAH9F	DT	Small molecular drug
DMXAH9F	PC	49847690
DMXAH9F	MW	1015.3
DMXAH9F	FM	C58H78N8O8
DMXAH9F	IC	InChI=1S/C58H78N8O8/c1-37(59-3)53(67)61-49(39-21-9-7-10-22-39)57(71)65-31-19-29-45(65)55(69)63-51-43-27-15-13-25-41(43)35-47(51)73-33-17-5-6-18-34-74-48-36-42-26-14-16-28-44(42)52(48)64-56(70)46-30-20-32-66(46)58(72)50(40-23-11-8-12-24-40)62-54(68)38(2)60-4/h13-16,25-28,37-40,45-52,59-60H,7-12,19-24,29-36H2,1-4H3,(H,61,67)(H,62,68)(H,63,69)(H,64,70)/t37-,38-,45-,46-,47+,48+,49-,50-,51-,52-/m0/s1
DMXAH9F	CS	C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)OCC#CC#CCO[C@@H]5CC6=CC=CC=C6[C@@H]5NC(=O)[C@@H]7CCCN7C(=O)[C@H](C8CCCCC8)NC(=O)[C@H](C)NC)NC
DMXAH9F	IK	WLMCRYCCYXHPQF-ZVMUOSSASA-N
DMXAH9F	IU	(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(1S,2R)-2-[6-[[(1S,2R)-1-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]oxy]hexa-2,4-diynoxy]-2,3-dihydro-1H-inden-1-yl]pyrrolidine-2-carboxamide

DMV0EIA	ID	DMV0EIA
DMV0EIA	DN	PMID25980951-Compound-28
DMV0EIA	HS	Patented
DMV0EIA	DT	Small molecular drug

DM5WIX3	ID	DM5WIX3
DM5WIX3	DN	PMID25980951-Compound-29
DM5WIX3	HS	Patented
DM5WIX3	CP	ENSEMBLE THERAPEUTICS CORPORATION
DM5WIX3	DT	Small molecular drug
DM5WIX3	PC	90155550
DM5WIX3	MW	1505.7
DM5WIX3	FM	C80H96N16O14
DM5WIX3	IC	InChI=1S/C80H96N16O14/c1-45(81-9)69(97)87-67(79(3,4)5)75(103)93-33-31-63-65(93)73(101)83-59(39-49-19-25-51-15-11-13-17-53(51)35-49)71(99)85-61(77(105)106)37-47-23-29-58(30-24-47)110-44-56-42-96(92-90-56)64-32-34-94(76(104)68(80(6,7)8)88-70(98)46(2)82-10)66(64)74(102)84-60(40-50-20-26-52-16-12-14-18-54(52)36-50)72(100)86-62(78(107)108)38-48-21-27-57(28-22-48)109-43-55-41-95(63)91-89-55/h11-30,35-36,41-42,45-46,59-68,81-82H,31-34,37-40,43-44H2,1-10H3,(H,83,101)(H,84,102)(H,85,99)(H,86,100)(H,87,97)(H,88,98)(H,105,106)(H,107,108)/t45-,46-,59-,60-,61-,62-,63+,64+,65-,66-,67+,68+/m0/s1
DM5WIX3	CS	C[C@@H](C(=O)N[C@H](C(=O)N1CC[C@@H]2[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC3=CC=C(C=C3)OCC4=CN([C@@H]5CCN([C@@H]5C(=O)N[C@H](C(=O)N[C@@H](CC6=CC=C(C=C6)OCC7=CN2N=N7)C(=O)O)CC8=CC9=CC=CC=C9C=C8)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C)NC)N=N4)C(=O)O)CC1=CC2=CC=CC=C2C=C1)C(C)(C)C)NC
DM5WIX3	IK	MBKNBOLIPVRUSC-YZMHPAFASA-N
DM5WIX3	IU	(8R,12S,15S,18S,30R,34S,37S,40S)-11,33-bis[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-15,37-bis(naphthalen-2-ylmethyl)-13,16,35,38-tetraoxo-2,24-dioxa-5,6,7,11,14,17,27,28,29,33,36,39-dodecazaheptacyclo[40.2.2.220,23.14,7.126,29.08,12.030,34]pentaconta-1(45),4(50),5,20,22,26(47),27,42(46),43,48-decaene-18,40-dicarboxylic acid

DMPSWXU	ID	DMPSWXU
DMPSWXU	DN	PMID25980951-Compound-3
DMPSWXU	HS	Patented
DMPSWXU	CP	ASTEX THERAPEUTICS LIMITED
DMPSWXU	DT	Small molecular drug
DMPSWXU	PC	90126716
DMPSWXU	MW	541.7
DMPSWXU	FM	C32H36FN5O2
DMPSWXU	IC	InChI=1S/C32H36FN5O2/c1-21-16-36(26(14-34-21)18-37-17-23-6-4-5-7-27(23)31(37)40)19-30(39)38-20-32(2,3)28-15-35-25(13-29(28)38)12-22-8-10-24(33)11-9-22/h4-11,13,15,21,26,34H,12,14,16-20H2,1-3H3/t21-,26-/m1/s1
DMPSWXU	CS	C[C@@H]1CN([C@H](CN1)CN2CC3=CC=CC=C3C2=O)CC(=O)N4CC(C5=C4C=C(N=C5)CC6=CC=C(C=C6)F)(C)C
DMPSWXU	IK	LINGVLYPDLNMKZ-QFQXNSOFSA-N
DMPSWXU	IU	2-[[(2R,5R)-1-[2-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2H-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]-3H-isoindol-1-one

DMXCSHE	ID	DMXCSHE
DMXCSHE	DN	PMID25980951-Compound-30
DMXCSHE	HS	Patented
DMXCSHE	CP	BRISTOL-MYERS SQUIBB COMPANY
DMXCSHE	DT	Small molecular drug
DMXCSHE	PC	73603510
DMXCSHE	MW	1070.3
DMXCSHE	FM	C61H80FN9O7
DMXCSHE	IC	InChI=1S/C61H80FN9O7/c1-36(63-10)53(72)67-51(60(4,5)6)58(77)70-34-43-21-13-12-20-42(43)31-50(70)57(76)69(38(3)45-23-16-17-25-47(45)62)33-39-27-29-41(30-28-39)55(74)65-44-32-49(56(75)66-48-26-18-22-40-19-14-15-24-46(40)48)71(35-44)59(78)52(61(7,8)9)68-54(73)37(2)64-11/h12-17,19-21,23-25,27-30,36-38,44,48-52,63-64H,18,22,26,31-35H2,1-11H3,(H,65,74)(H,66,75)(H,67,72)(H,68,73)/t36-,37-,38+,44-,48+,49-,50-,51+,52+/m0/s1
DMXCSHE	CS	C[C@H](C1=CC=CC=C1F)N(CC2=CC=C(C=C2)C(=O)N[C@H]3C[C@H](N(C3)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C)NC)C(=O)N[C@@H]4CCCC5=CC=CC=C45)C(=O)[C@@H]6CC7=CC=CC=C7CN6C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C)NC
DMXCSHE	IK	SUVGZSPIXFUCLS-NQFXVQPCSA-N
DMXCSHE	IU	(3S)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-N-[[4-[[(3S,5S)-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-5-[[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]pyrrolidin-3-yl]carbamoyl]phenyl]methyl]-N-[(1R)-1-(2-fluorophenyl)ethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide

DMC1Y2T	ID	DMC1Y2T
DMC1Y2T	DN	PMID25980951-Compound-31
DMC1Y2T	HS	Patented
DMC1Y2T	CP	BRISTOL-MYERS SQUIBB COMPANY
DMC1Y2T	DT	Small molecular drug

DMXETA8	ID	DMXETA8
DMXETA8	DN	PMID25980951-Compound-32
DMXETA8	HS	Patented
DMXETA8	CP	BRISTOL-MYERS SQUIBB COMPANY
DMXETA8	DT	Small molecular drug
DMXETA8	PC	72710867
DMXETA8	MW	1028.4
DMXETA8	FM	C57H77N9O7Si
DMXETA8	IC	InChI=1S/C57H77N9O7Si/c1-35(58-6)51(68)63-46(55(72)66-34-74(8,9)33-48(66)54(71)62-45-23-15-19-40-17-11-13-21-43(40)45)30-38-26-24-37(25-27-38)28-29-49(67)60-41-31-47(53(70)61-44-22-14-18-39-16-10-12-20-42(39)44)65(32-41)56(73)50(57(3,4)5)64-52(69)36(2)59-7/h10-13,16-17,20-21,24-27,35-36,41,44-48,50,58-59H,14-15,18-19,22-23,30-34H2,1-9H3,(H,60,67)(H,61,70)(H,62,71)(H,63,68)(H,64,69)/t35-,36-,41-,44+,45+,46-,47-,48-,50+/m0/s1
DMXETA8	CS	C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)C#CC(=O)N[C@H]2C[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C)NC)C(=O)N[C@@H]3CCCC4=CC=CC=C34)C(=O)N5C[Si](C[C@H]5C(=O)N[C@@H]6CCCC7=CC=CC=C67)(C)C)NC
DMXETA8	IK	SOUZAGJRYQSXAP-UZNJVIDBSA-N
DMXETA8	IU	(5R)-1-[(2S)-3-[4-[3-[[(3S,5S)-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-5-[[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]pyrrolidin-3-yl]amino]-3-oxoprop-1-ynyl]phenyl]-2-[[(2S)-2-(methylamino)propanoyl]amino]propanoyl]-3,3-dimethyl-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-azasilolidine-5-carboxamide

DMYO9UD	ID	DMYO9UD
DMYO9UD	DN	PMID25980951-Compound-33
DMYO9UD	HS	Patented
DMYO9UD	CP	BRISTOL-MYERS SQUIBB COMPANY
DMYO9UD	DT	Small molecular drug

DMBD4K9	ID	DMBD4K9
DMBD4K9	DN	PMID25980951-Compound-36
DMBD4K9	HS	Patented
DMBD4K9	CP	NOVARTIS AG STRAUB, Christopher Sean CHEN, Zhuoliang
DMBD4K9	DT	Small molecular drug

DMHP6J2	ID	DMHP6J2
DMHP6J2	DN	PMID25980951-Compound-37
DMHP6J2	HS	Patented
DMHP6J2	CP	NOVARTIS AG STRAUB, Christopher Sean CHEN, Zhuoliang
DMHP6J2	DT	Small molecular drug
DMHP6J2	PC	57389344
DMHP6J2	MW	1197.5
DMHP6J2	FM	C70H82F2N10O6
DMHP6J2	IC	InChI=1S/C70H82F2N10O6/c1-43(73-3)65(83)79-63(47-13-7-5-8-14-47)69(87)81-31-11-17-61(81)55-33-51(37-75-39-55)59-29-27-57(71)35-53(59)41-77-67(85)49-23-19-45(20-24-49)46-21-25-50(26-22-46)68(86)78-42-54-36-58(72)28-30-60(54)52-34-56(40-76-38-52)62-18-12-32-82(62)70(88)64(48-15-9-6-10-16-48)80-66(84)44(2)74-4/h19-30,33-40,43-44,47-48,61-64,73-74H,5-18,31-32,41-42H2,1-4H3,(H,77,85)(H,78,86)(H,79,83)(H,80,84)/t43-,44-,61-,62-,63-,64-/m0/s1
DMHP6J2	CS	C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=CN=CC(=C3)C4=C(C=C(C=C4)F)CNC(=O)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)NCC7=C(C=CC(=C7)F)C8=CC(=CN=C8)[C@@H]9CCCN9C(=O)[C@H](C1CCCCC1)NC(=O)[C@H](C)NC)NC
DMHP6J2	IK	MZOSJSCTFRNVMS-PDAHXLKQSA-N
DMHP6J2	IU	N-[[2-[5-[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidin-2-yl]pyridin-3-yl]-5-fluorophenyl]methyl]-4-[4-[[2-[5-[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidin-2-yl]pyridin-3-yl]-5-fluorophenyl]methylcarbamoyl]phenyl]benzamide

DMEUBDA	ID	DMEUBDA
DMEUBDA	DN	PMID25980951-Compound-38
DMEUBDA	HS	Patented
DMEUBDA	CP	NOVARTIS AG STRAUB, Christopher Sean CHEN, Zhuoliang PALERMO, Mark G
DMEUBDA	DT	Small molecular drug

DMEZ3QV	ID	DMEZ3QV
DMEZ3QV	DN	PMID25980951-Compound-39
DMEZ3QV	HS	Patented
DMEZ3QV	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMEZ3QV	DT	Small molecular drug
DMEZ3QV	PC	76283048
DMEZ3QV	MW	1152.9
DMEZ3QV	FM	C58H56Br2N8O8
DMEZ3QV	IC	InChI=1S/C58H56Br2N8O8/c1-33(61-3)53(69)63-45-31-67(49-13-9-7-11-47(49)65(57(45)73)29-43-41-23-21-39(59)27-37(41)19-25-51(43)75-5)55(71)35-15-17-36(18-16-35)56(72)68-32-46(64-54(70)34(2)62-4)58(74)66(48-12-8-10-14-50(48)68)30-44-42-24-22-40(60)28-38(42)20-26-52(44)76-6/h7-28,33-34,45-46,61-62H,29-32H2,1-6H3,(H,63,69)(H,64,70)/t33-,34-,45-,46-/m0/s1
DMEZ3QV	CS	C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)C(=O)N6C[C@@H](C(=O)N(C7=CC=CC=C76)CC8=C(C=CC9=C8C=CC(=C9)Br)OC)NC(=O)[C@H](C)NC)NC
DMEZ3QV	IK	PBGWEJJBQUBSJN-MLLHAFNLSA-N
DMEZ3QV	IU	(2S)-N-[(3S)-5-[(6-bromo-2-methoxynaphthalen-1-yl)methyl]-1-[4-[(3S)-5-[(6-bromo-2-methoxynaphthalen-1-yl)methyl]-3-[[(2S)-2-(methylamino)propanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzodiazepine-1-carbonyl]benzoyl]-4-oxo-2,3-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide

DM9RZSH	ID	DM9RZSH
DM9RZSH	DN	PMID25980951-Compound-4
DM9RZSH	HS	Patented
DM9RZSH	CP	ASTEX THERAPEUTICS LIMITED
DM9RZSH	DT	Small molecular drug

DMJOD8I	ID	DMJOD8I
DMJOD8I	DN	PMID25980951-Compound-40
DMJOD8I	HS	Patented
DMJOD8I	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMJOD8I	DT	Small molecular drug
DMJOD8I	PC	76282560
DMJOD8I	MW	1125.2
DMJOD8I	FM	C60H70BrN9O8
DMJOD8I	IC	InChI=1S/C60H70BrN9O8/c1-35(62-3)54(71)66-48-34-70(50-21-12-11-20-49(50)69(59(48)76)33-46-44-28-27-42(61)30-41(44)26-29-52(46)78-5)58(75)40-24-22-39(23-25-40)56(73)64-43-31-51(57(74)65-47-19-13-17-37-14-9-10-18-45(37)47)68(32-43)60(77)53(38-15-7-6-8-16-38)67-55(72)36(2)63-4/h9-12,14,18,20-30,35-36,38,43,47-48,51,53,62-63H,6-8,13,15-17,19,31-34H2,1-5H3,(H,64,73)(H,65,74)(H,66,71)(H,67,72)/t35-,36-,43-,47+,48-,51-,53-/m0/s1
DMJOD8I	CS	C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)C(=O)N[C@H]6C[C@H](N(C6)C(=O)[C@H](C7CCCCC7)NC(=O)[C@H](C)NC)C(=O)N[C@@H]8CCCC9=CC=CC=C89)NC
DMJOD8I	IK	OVCDDAXIBKWFRB-SFDZCEMOSA-N
DMJOD8I	IU	(2S,4S)-4-[[4-[(3S)-5-[(6-bromo-2-methoxynaphthalen-1-yl)methyl]-3-[[(2S)-2-(methylamino)propanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzodiazepine-1-carbonyl]benzoyl]amino]-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]pyrrolidine-2-carboxamide

DMNROIP	ID	DMNROIP
DMNROIP	DN	PMID25980951-Compound-41
DMNROIP	HS	Patented
DMNROIP	CP	TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. LAPORTE, Matthew, G
DMNROIP	DT	Small molecular drug

DM8XESD	ID	DM8XESD
DM8XESD	DN	PMID25980951-Compound-42
DM8XESD	HS	Patented
DM8XESD	CP	TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. DENG, Yijun LAPORTE, Matthew, G
DM8XESD	DT	Small molecular drug

DMTJRCS	ID	DMTJRCS
DMTJRCS	DN	PMID25980951-Compound-43
DMTJRCS	HS	Patented
DMTJRCS	CP	THE REGENTS OF THE UNIVERSITY OF MICHIGAN WANG, Shaomeng SUN, Haiying
DMTJRCS	DT	Small molecular drug
DMTJRCS	PC	52919959
DMTJRCS	MW	1103.4
DMTJRCS	FM	C62H78N12O7
DMTJRCS	IC	InChI=1S/C62H78N12O7/c1-39(63-3)59(77)67-49-37-71(33-31-43-27-29-51(73(43)61(49)79)57-65-47-23-15-21-45(55(47)69-57)41-17-7-5-8-18-41)53(75)25-11-13-35-81-36-14-12-26-54(76)72-34-32-44-28-30-52(74(44)62(80)50(38-72)68-60(78)40(2)64-4)58-66-48-24-16-22-46(56(48)70-58)42-19-9-6-10-20-42/h5-10,15-24,39-40,43-44,49-52,63-64H,11-14,25-38H2,1-4H3,(H,65,69)(H,66,70)(H,67,77)(H,68,78)/t39-,40-,43+,44+,49-,50-,51-,52-/m0/s1
DMTJRCS	CS	C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C3=NC4=C(C=CC=C4N3)C5=CC=CC=C5)C(=O)CCCCOCCCCC(=O)N6CC[C@H]7CC[C@H](N7C(=O)[C@H](C6)NC(=O)[C@H](C)NC)C8=NC9=C(C=CC=C9N8)C1=CC=CC=C1)NC
DMTJRCS	IK	ZPYWWTKXCOYJBE-LLUFGHGUSA-N
DMTJRCS	IU	(2S)-N-[(5S,8S,10aR)-3-[5-[5-[(5S,8S,10aR)-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-8-(4-phenyl-1H-benzimidazol-2-yl)-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-3-yl]-5-oxopentoxy]pentanoyl]-6-oxo-8-(4-phenyl-1H-benzimidazol-2-yl)-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-5-yl]-2-(methylamino)propanamide

DMS5896	ID	DMS5896
DMS5896	DN	PMID25980951-Compound-44
DMS5896	HS	Patented
DMS5896	CP	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DMS5896	DT	Small molecular drug
DMS5896	PC	71661892
DMS5896	MW	1115.3
DMS5896	FM	C62H74N12O8
DMS5896	IC	InChI=1S/C62H74N12O8/c1-39(63-3)55(75)67-49-37-71(35-33-47-29-31-51(73(47)59(49)79)57(77)69-53(41-17-9-5-10-18-41)42-19-11-6-12-20-42)61(81)65-45-25-27-46(28-26-45)66-62(82)72-36-34-48-30-32-52(74(48)60(80)50(38-72)68-56(76)40(2)64-4)58(78)70-54(43-21-13-7-14-22-43)44-23-15-8-16-24-44/h5-28,39-40,47-54,63-64H,29-38H2,1-4H3,(H,65,81)(H,66,82)(H,67,75)(H,68,76)(H,69,77)(H,70,78)/t39-,40-,47+,48+,49-,50-,51-,52-/m0/s1
DMS5896	CS	C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)NC5=CC=C(C=C5)NC(=O)N6CC[C@H]7CC[C@H](N7C(=O)[C@H](C6)NC(=O)[C@H](C)NC)C(=O)NC(C8=CC=CC=C8)C9=CC=CC=C9)NC
DMS5896	IK	SGWUDLNUDPDRSR-CEQBHCGOSA-N
DMS5896	IU	(5S,8S,10aR)-3-N-[4-[[(5S,8S,10aR)-8-(benzhydrylcarbamoyl)-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-3-carbonyl]amino]phenyl]-8-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-3,8-dicarboxamide

DM1EU06	ID	DM1EU06
DM1EU06	DN	PMID25980951-Compound-45
DM1EU06	HS	Patented
DM1EU06	CP	HANMI SCIENCE CO., LTD. BAE, In Hwan BYUN, Eun Young JU, Hae Kyoung SONG, Ji Young JUNG, Seung Hyun JUN, Seung Ah KIM, Ho Seok JUNG, Young Hee SHIM, Mi Yon AHN, Young Gil KIM, Maeng Sup
DM1EU06	DT	Small molecular drug
DM1EU06	PC	56924622
DM1EU06	MW	632.1
DM1EU06	FM	C30H36ClF2N7O4
DM1EU06	IC	InChI=1S/C30H36ClF2N7O4/c1-15(34-5)27(41)39-25(30(2,3)4)29(43)40-11-7-8-21(40)28(42)38-20-12-16-19(13-22(20)44-6)35-14-36-26(16)37-18-10-9-17(32)23(31)24(18)33/h9-10,12-15,21,25,34H,7-8,11H2,1-6H3,(H,38,42)(H,39,41)(H,35,36,37)/t15-,21-,25+/m0/s1
DM1EU06	CS	C[C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=C(C=C4)F)Cl)F)OC)C(C)(C)C)NC
DM1EU06	IK	KJLMHHDQQFRBTF-HHCYOLOASA-N
DM1EU06	IU	(2S)-N-[4-(3-chloro-2,4-difluoroanilino)-7-methoxyquinazolin-6-yl]-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidine-2-carboxamide

DMB3IZT	ID	DMB3IZT
DMB3IZT	DN	PMID25980951-Compound-5
DMB3IZT	HS	Patented
DMB3IZT	CP	ASTEX THERAPEUTICS LIMITED
DMB3IZT	DT	Small molecular drug

DMVSW5N	ID	DMVSW5N
DMVSW5N	DN	PMID25980951-Compound-6
DMVSW5N	HS	Patented
DMVSW5N	CP	AVILA THERAPEUTICS, INC. PETTER, Russell C. JEWELL, Charles F. LEE, Kwangho MEDIKONDA, Aravind Prasad NIU, Deqiang QIAO, Lixin SINGH, Juswinder ZHU, Zhendong
DMVSW5N	DT	Small molecular drug
DMVSW5N	PC	58491512
DMVSW5N	MW	469.6
DMVSW5N	FM	C25H35N5O4
DMVSW5N	IC	InChI=1S/C25H35N5O4/c1-4-22(31)28-18-9-7-8-17(14-18)15-27-24(33)21-13-12-19-10-5-6-11-20(25(34)30(19)21)29-23(32)16(2)26-3/h4,7-9,14,16,19-21,26H,1,5-6,10-13,15H2,2-3H3,(H,27,33)(H,28,31)(H,29,32)/t16-,19-,20-,21-/m0/s1
DMVSW5N	CS	C[C@@H](C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)NCC3=CC(=CC=C3)NC(=O)C=C)NC
DMVSW5N	IK	KIYJPROOFKKHPR-FIRPJDEBSA-N
DMVSW5N	IU	(3S,6S,10aS)-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-N-[[3-(prop-2-enoylamino)phenyl]methyl]-2,3,6,7,8,9,10,10a-octahydro-1H-pyrrolo[1,2-a]azocine-3-carboxamide

DMF8V5J	ID	DMF8V5J
DMF8V5J	DN	PMID25980951-Compound-7
DMF8V5J	HS	Patented
DMF8V5J	DT	Small molecular drug

DM89LF0	ID	DM89LF0
DM89LF0	DN	PMID25991433-Compound-A1
DM89LF0	HS	Patented
DM89LF0	CP	F. HOFFMANN-LA ROCHE AG GONG, Leyi JAHANGIR, Alam REUTER, Deborah CaroF. HOFFMANN-LA ROCHE AG GOLDSTEIN, David Michael GONG, Leyi MICHOUD, Christophe PALMER, Wylie Solang SIDDURI, Achyutharao
DM89LF0	DT	Small molecular drug

DM39NBT	ID	DM39NBT
DM39NBT	DN	PMID25991433-Compound-A10
DM39NBT	HS	Patented
DM39NBT	DT	Small molecular drug

DMD59C2	ID	DMD59C2
DMD59C2	DN	PMID25991433-Compound-A11
DMD59C2	HS	Patented
DMD59C2	DT	Small molecular drug

DMX7MHC	ID	DMX7MHC
DMX7MHC	DN	PMID25991433-Compound-A2
DMX7MHC	HS	Patented
DMX7MHC	CP	F. HOFFMANN-LA ROCHE AG GONG, Leyi JAHANGIR, Alam REUTER, Deborah Carol
DMX7MHC	DT	Small molecular drug
DMX7MHC	PC	46834072
DMX7MHC	MW	453.5
DMX7MHC	FM	C20H23N9O2S
DMX7MHC	IC	InChI=1S/C20H23N9O2S/c1-13-16(12-22-25-13)15-4-3-5-17-19(15)26-27-29(17)18-6-9-21-20(24-18)23-14-7-10-28(11-8-14)32(2,30)31/h3-6,9,12,14H,7-8,10-11H2,1-2H3,(H,22,25)(H,21,23,24)
DMX7MHC	CS	CC1=C(C=NN1)C2=C3C(=CC=C2)N(N=N3)C4=NC(=NC=C4)NC5CCN(CC5)S(=O)(=O)C
DMX7MHC	IK	VBKBWWKTPBEGBH-UHFFFAOYSA-N
DMX7MHC	IU	4-[4-(5-methyl-1H-pyrazol-4-yl)benzotriazol-1-yl]-N-(1-methylsulfonylpiperidin-4-yl)pyrimidin-2-amine

DMJ1X53	ID	DMJ1X53
DMJ1X53	DN	PMID25991433-Compound-A3
DMJ1X53	HS	Patented
DMJ1X53	CP	F. HOFFMANN-LA ROCHE AG GONG, Leyi JAHANGIR, Alam REUTER, Deborah Carol
DMJ1X53	DT	Small molecular drug

DM5YD1K	ID	DM5YD1K
DM5YD1K	DN	PMID25991433-Compound-A5
DM5YD1K	HS	Patented
DM5YD1K	CP	F. HOFFMANN-LA ROCHE AG BUETTELMANN, Bernd GOYAL, Bindu PALMER, Wylie Solang
DM5YD1K	DT	Small molecular drug

DMFSB9Y	ID	DMFSB9Y
DMFSB9Y	DN	PMID25991433-Compound-A6
DMFSB9Y	HS	Patented
DMFSB9Y	CP	F. HOFFMANN-LA ROCHE AG BUETTELMANN, Bernd GOYAL, Bindu PALMER, Wylie Solang
DMFSB9Y	DT	Small molecular drug

DM2ISDH	ID	DM2ISDH
DM2ISDH	DN	PMID25991433-Compound-A7
DM2ISDH	HS	Patented
DM2ISDH	CP	F. HOFFMANN-LA ROCHE AG BUETTELMANN, Bernd GOYAL, Bindu PALMER, Wylie Solang
DM2ISDH	DT	Small molecular drug

DMHG4WD	ID	DMHG4WD
DMHG4WD	DN	PMID25991433-Compound-A8
DMHG4WD	HS	Patented
DMHG4WD	DT	Small molecular drug

DMPYCIM	ID	DMPYCIM
DMPYCIM	DN	PMID25991433-Compound-A9
DMPYCIM	HS	Patented
DMPYCIM	DT	Small molecular drug

DMJTO69	ID	DMJTO69
DMJTO69	DN	PMID25991433-Compound-B1
DMJTO69	HS	Patented
DMJTO69	CP	F. HOFFMANN-LA ROCHE AG ARZENO, Humberto, Bartolome FILONOVA, Lubov GOLDSTEIN, David, Michael GONG, Leyi LOE, Bradley, E. O'BRIEN, Erin, M. PALMER, Wylie, Solang ROTSTEIN, David, Mark SILVA, Tania TAN, Yun-chou
DMJTO69	DT	Small molecular drug

DMTYQOF	ID	DMTYQOF
DMTYQOF	DN	PMID25991433-Compound-B2
DMTYQOF	HS	Patented
DMTYQOF	CP	F. HOFFMANN-LA ROCHE AG ARZENO, Humberto, Bartolome FILONOVA, Lubov GOLDSTEIN, David, Michael GONG, Leyi LOE, Bradley, E. O'BRIEN, Erin, M. PALMER, Wylie, Solang ROTSTEIN, David, Mark SILVA, Tania TAN, Yun-chou
DMTYQOF	DT	Small molecular drug

DMWSGV2	ID	DMWSGV2
DMWSGV2	DN	PMID25991433-Compound-B3
DMWSGV2	HS	Patented
DMWSGV2	CP	F. HOFFMANN-LA ROCHE AG ARZENO, Humberto, Bartolome FILONOVA, Lubov GOLDSTEIN, David, Michael GONG, Leyi LOE, Bradley, E. O'BRIEN, Erin, M. PALMER, Wylie, Solang ROTSTEIN, David, Mark SILVA, Tania TAN, Yun-chou
DMWSGV2	DT	Small molecular drug

DM3KWFQ	ID	DM3KWFQ
DM3KWFQ	DN	PMID25991433-Compound-C1
DM3KWFQ	HS	Patented
DM3KWFQ	CP	F. HOFFMANN-LA ROCHE AG GONG, Leyi TAN, Yun-chou
DM3KWFQ	DT	Small molecular drug

DMOAU09	ID	DMOAU09
DMOAU09	DN	PMID25991433-Compound-C2
DMOAU09	HS	Patented
DMOAU09	CP	F. HOFFMANN-LA ROCHE AG GONG, Leyi TAN, Yun-chou
DMOAU09	DT	Small molecular drug

DMSKWBE	ID	DMSKWBE
DMSKWBE	DN	PMID25991433-Compound-C3
DMSKWBE	HS	Patented
DMSKWBE	CP	F. HOFFMANN-LA ROCHE AG GONG, Leyi TAN, Yun-chou
DMSKWBE	DT	Small molecular drug

DMXSK8Y	ID	DMXSK8Y
DMXSK8Y	DN	PMID25991433-Compound-D1
DMXSK8Y	HS	Patented
DMXSK8Y	CP	F. HOFFMANN-LA ROCHE AG BOICE, Genevieve N. GONG, Leyi MCCALEB, Kristen Lynn PALMER, Wylie Solang
DMXSK8Y	DT	Small molecular drug
DMXSK8Y	PC	45257202
DMXSK8Y	MW	316.4
DMXSK8Y	FM	C17H24N4O2
DMXSK8Y	IC	InChI=1S/C17H24N4O2/c1-12(9-10-22)21-15(23)8-7-13-11-18-17(20-16(13)21)19-14-5-3-2-4-6-14/h7-8,11-12,14,22H,2-6,9-10H2,1H3,(H,18,19,20)
DMXSK8Y	CS	CC(CCO)N1C(=O)C=CC2=CN=C(N=C21)NC3CCCCC3
DMXSK8Y	IK	WWOJIYPDCCGHSL-UHFFFAOYSA-N
DMXSK8Y	IU	2-(cyclohexylamino)-8-(4-hydroxybutan-2-yl)pyrido[2,3-d]pyrimidin-7-one

DMLWSNA	ID	DMLWSNA
DMLWSNA	DN	PMID25991433-Compound-D2
DMLWSNA	HS	Patented
DMLWSNA	CP	F. HOFFMANN-LA ROCHE AG BOICE, Genevieve N. GONG, Leyi MCCALEB, Kristen Lynn PALMER, Wylie Solang
DMLWSNA	DT	Small molecular drug

DMKWFVP	ID	DMKWFVP
DMKWFVP	DN	PMID25991433-Compound-E1
DMKWFVP	HS	Patented
DMKWFVP	CP	F. HOFFMANN-LA ROCHE AG 
DMKWFVP	DT	Small molecular drug
DMKWFVP	PC	25104303
DMKWFVP	MW	490.9
DMKWFVP	FM	C27H23ClN2O5
DMKWFVP	IC	InChI=1S/C27H23ClN2O5/c1-35-27(34)24-22(15-17-7-9-18(10-8-17)26(33)29-13-14-31)25(32)21-12-11-19(28)16-23(21)30(24)20-5-3-2-4-6-20/h2-12,16,31H,13-15H2,1H3,(H,29,33)
DMKWFVP	CS	COC(=O)C1=C(C(=O)C2=C(N1C3=CC=CC=C3)C=C(C=C2)Cl)CC4=CC=C(C=C4)C(=O)NCCO
DMKWFVP	IK	STNCBMGTCZRJPA-UHFFFAOYSA-N
DMKWFVP	IU	methyl 7-chloro-3-[[4-(2-hydroxyethylcarbamoyl)phenyl]methyl]-4-oxo-1-phenylquinoline-2-carboxylate

DM8YR1V	ID	DM8YR1V
DM8YR1V	DN	PMID25991433-Compound-E2
DM8YR1V	HS	Patented
DM8YR1V	CP	F. HOFFMANN-LA ROCHE AG 
DM8YR1V	DT	Small molecular drug

DM62XNE	ID	DM62XNE
DM62XNE	DN	PMID25991433-Compound-E3
DM62XNE	HS	Patented
DM62XNE	CP	F. HOFFMANN-LA ROCHE AG 
DM62XNE	DT	Small molecular drug
DM62XNE	PC	71217329
DM62XNE	MW	563
DM62XNE	FM	C32H23ClN4O4
DM62XNE	IC	InChI=1S/C32H23ClN4O4/c33-23-11-12-25-27(18-23)37(24-9-5-2-6-10-24)29(32-34-14-16-41-32)26(30(25)39)19-35-31(40)22-13-15-36(28(38)17-22)20-21-7-3-1-4-8-21/h1-18H,19-20H2,(H,35,40)
DM62XNE	CS	C1=CC=C(C=C1)CN2C=CC(=CC2=O)C(=O)NCC3=C(N(C4=C(C3=O)C=CC(=C4)Cl)C5=CC=CC=C5)C6=NC=CO6
DM62XNE	IK	CDEQUNLOBIAUNN-UHFFFAOYSA-N
DM62XNE	IU	1-benzyl-N-[[7-chloro-2-(1,3-oxazol-2-yl)-4-oxo-1-phenylquinolin-3-yl]methyl]-2-oxopyridine-4-carboxamide

DM1VHYX	ID	DM1VHYX
DM1VHYX	DN	PMID25991433-Compound-E4
DM1VHYX	HS	Patented
DM1VHYX	CP	F. HOFFMANN-LA ROCHE AG 
DM1VHYX	DT	Small molecular drug
DM1VHYX	PC	71208846
DM1VHYX	MW	458.9
DM1VHYX	FM	C26H23ClN4O2
DM1VHYX	IC	InChI=1S/C26H23ClN4O2/c27-20-9-10-22-23(14-20)31(21-6-2-1-3-7-21)17-19(25(22)32)16-29-26(33)18-8-11-24(28-15-18)30-12-4-5-13-30/h1-3,6-11,14-15,17H,4-5,12-13,16H2,(H,29,33)
DM1VHYX	CS	C1CCN(C1)C2=NC=C(C=C2)C(=O)NCC3=CN(C4=C(C3=O)C=CC(=C4)Cl)C5=CC=CC=C5
DM1VHYX	IK	RUQWOHJJIMCQMH-UHFFFAOYSA-N
DM1VHYX	IU	N-[(7-chloro-4-oxo-1-phenylquinolin-3-yl)methyl]-6-pyrrolidin-1-ylpyridine-3-carboxamide

DM2ZCTW	ID	DM2ZCTW
DM2ZCTW	DN	PMID25991433-Compound-E5
DM2ZCTW	HS	Patented
DM2ZCTW	CP	F. HOFFMANN-LA ROCHE AG 
DM2ZCTW	DT	Small molecular drug
DM2ZCTW	PC	71208512
DM2ZCTW	MW	560.5
DM2ZCTW	FM	C25H19F3N4O6S
DM2ZCTW	IC	InChI=1S/C25H19F3N4O6S/c1-38-24(35)20-18(13-30-23(34)14-7-9-16(10-8-14)39(29,36)37)21(33)17-11-12-19(25(26,27)28)31-22(17)32(20)15-5-3-2-4-6-15/h2-12H,13H2,1H3,(H,30,34)(H2,29,36,37)
DM2ZCTW	CS	COC(=O)C1=C(C(=O)C2=C(N1C3=CC=CC=C3)N=C(C=C2)C(F)(F)F)CNC(=O)C4=CC=C(C=C4)S(=O)(=O)N
DM2ZCTW	IK	HRBSYTKTEPLYNB-UHFFFAOYSA-N
DM2ZCTW	IU	methyl 4-oxo-1-phenyl-3-[[(4-sulfamoylbenzoyl)amino]methyl]-7-(trifluoromethyl)-1,8-naphthyridine-2-carboxylate

DM536JN	ID	DM536JN
DM536JN	DN	PMID25991433-Compound-Eb
DM536JN	HS	Patented
DM536JN	CP	F. HOFFMANN-LA ROCHE AG
DM536JN	DT	Small molecular drug

DMFS2YL	ID	DMFS2YL
DMFS2YL	DN	PMID25991433-Compound-F1
DMFS2YL	HS	Patented
DMFS2YL	CP	SIGNAL PHARMACEUTICALS, LLC BEAUCHAMPS, Marie, Georges HARRIS, Louise, Michelle KOTHARE, Mohit, Atul SAINDANE, Manohar, T
DMFS2YL	DT	Small molecular drug
DMFS2YL	PC	11647397
DMFS2YL	MW	418.5
DMFS2YL	FM	C23H23FN6O
DMFS2YL	IC	InChI=1S/C23H23FN6O/c1-31-17-12-10-15(11-13-17)26-22-25-14-20-21(29-22)30(16-6-2-3-7-16)23(28-20)27-19-9-5-4-8-18(19)24/h4-5,8-14,16H,2-3,6-7H2,1H3,(H,27,28)(H,25,26,29)
DMFS2YL	CS	COC1=CC=C(C=C1)NC2=NC=C3C(=N2)N(C(=N3)NC4=CC=CC=C4F)C5CCCC5
DMFS2YL	IK	IMFVPVKPQOQCBY-UHFFFAOYSA-N
DMFS2YL	IU	9-cyclopentyl-8-N-(2-fluorophenyl)-2-N-(4-methoxyphenyl)purine-2,8-diamine
DMFS2YL	CB	CHEBI:90530

DM37VIQ	ID	DM37VIQ
DM37VIQ	DN	PMID25991433-Compound-F2
DM37VIQ	HS	Patented
DM37VIQ	CP	SIGNAL PHARMACEUTICALS, LLC BEAUCHAMPS, Marie, Georges HARRIS, Louise, Michelle KOTHARE, Mohit, Atul SAINDANE, Manohar, T
DM37VIQ	DT	Small molecular drug

DMHS3ZW	ID	DMHS3ZW
DMHS3ZW	DN	PMID25991433-Compound-G1
DMHS3ZW	HS	Patented
DMHS3ZW	CP	SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMHS3ZW	DT	Small molecular drug
DMHS3ZW	PC	71237169
DMHS3ZW	MW	300.36
DMHS3ZW	FM	C15H20N6O
DMHS3ZW	IC	InChI=1S/C15H20N6O/c1-21(2)9-8-17-15-18-10-12(13(16)22)14(20-15)19-11-6-4-3-5-7-11/h3-7,10H,8-9H2,1-2H3,(H2,16,22)(H2,17,18,19,20)
DMHS3ZW	CS	CN(C)CCNC1=NC=C(C(=N1)NC2=CC=CC=C2)C(=O)N
DMHS3ZW	IK	GTNNAVLREWBUPQ-UHFFFAOYSA-N
DMHS3ZW	IU	4-anilino-2-[2-(dimethylamino)ethylamino]pyrimidine-5-carboxamide

DMU3XBH	ID	DMU3XBH
DMU3XBH	DN	PMID25991433-Compound-G2
DMU3XBH	HS	Patented
DMU3XBH	CP	SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMU3XBH	DT	Small molecular drug

DMACWQY	ID	DMACWQY
DMACWQY	DN	PMID25991433-Compound-G4
DMACWQY	HS	Patented
DMACWQY	CP	SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMACWQY	DT	Small molecular drug
DMACWQY	PC	71237626
DMACWQY	MW	340.4
DMACWQY	FM	C17H20N6O2
DMACWQY	IC	InChI=1S/C17H20N6O2/c18-14(24)11-6-8-23(9-7-11)17-20-10-13(15(19)25)16(22-17)21-12-4-2-1-3-5-12/h1-5,10-11H,6-9H2,(H2,18,24)(H2,19,25)(H,20,21,22)
DMACWQY	CS	C1CN(CCC1C(=O)N)C2=NC=C(C(=N2)NC3=CC=CC=C3)C(=O)N
DMACWQY	IK	KEVAFBBLBKUMEB-UHFFFAOYSA-N
DMACWQY	IU	4-anilino-2-(4-carbamoylpiperidin-1-yl)pyrimidine-5-carboxamide

DMRJ1KY	ID	DMRJ1KY
DMRJ1KY	DN	PMID25991433-Compound-G5
DMRJ1KY	HS	Patented
DMRJ1KY	CP	SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMRJ1KY	DT	Small molecular drug
DMRJ1KY	PC	66576636
DMRJ1KY	MW	321.34
DMRJ1KY	FM	C16H15N7O
DMRJ1KY	IC	InChI=1S/C16H15N7O/c1-10-7-8-18-15(20-10)23-16-19-9-12(13(17)24)14(22-16)21-11-5-3-2-4-6-11/h2-9H,1H3,(H2,17,24)(H2,18,19,20,21,22,23)
DMRJ1KY	CS	CC1=NC(=NC=C1)NC2=NC=C(C(=N2)NC3=CC=CC=C3)C(=O)N
DMRJ1KY	IK	YVTIEYHXPXUHLT-UHFFFAOYSA-N
DMRJ1KY	IU	4-anilino-2-[(4-methylpyrimidin-2-yl)amino]pyrimidine-5-carboxamide

DM0Q37R	ID	DM0Q37R
DM0Q37R	DN	PMID25991433-Compound-H1
DM0Q37R	HS	Patented
DM0Q37R	CP	SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DM0Q37R	DT	Small molecular drug
DM0Q37R	PC	71237973
DM0Q37R	MW	293.4
DM0Q37R	FM	C17H19N5
DM0Q37R	IC	InChI=1S/C17H19N5/c18-11-13-12-19-17(21-15-9-5-2-6-10-15)22-16(13)20-14-7-3-1-4-8-14/h1,3-4,7-8,12,15H,2,5-6,9-10H2,(H2,19,20,21,22)
DM0Q37R	CS	C1CCC(CC1)NC2=NC=C(C(=N2)NC3=CC=CC=C3)C#N
DM0Q37R	IK	HKWATPBSDKRVFA-UHFFFAOYSA-N
DM0Q37R	IU	4-anilino-2-(cyclohexylamino)pyrimidine-5-carbonitrile

DMZ9BTN	ID	DMZ9BTN
DMZ9BTN	DN	PMID25991433-Compound-H2
DMZ9BTN	HS	Patented
DMZ9BTN	CP	SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMZ9BTN	DT	Small molecular drug

DMQKLX0	ID	DMQKLX0
DMQKLX0	DN	PMID25991433-Compound-H3
DMQKLX0	HS	Patented
DMQKLX0	CP	SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMQKLX0	DT	Small molecular drug

DMQGUMN	ID	DMQGUMN
DMQGUMN	DN	PMID25991433-Compound-J1
DMQGUMN	HS	Patented
DMQGUMN	CP	DANA-FARBER CANCER INSTITUTE, INC
DMQGUMN	DT	Small molecular drug
DMQGUMN	PC	25123232
DMQGUMN	MW	507.6
DMQGUMN	FM	C29H29N7O2
DMQGUMN	IC	InChI=1S/C29H29N7O2/c1-20-8-11-24(18-26(20)35-29-31-16-14-25(34-29)22-6-4-15-30-19-22)33-28(38)21-9-12-23(13-10-21)32-27(37)7-5-17-36(2)3/h4-16,18-19H,17H2,1-3H3,(H,32,37)(H,33,38)(H,31,34,35)/b7-5+
DMQGUMN	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)NC(=O)/C=C/CN(C)C)NC3=NC=CC(=N3)C4=CN=CC=C4
DMQGUMN	IK	YFRXAAWSVLQGDR-FNORWQNLSA-N
DMQGUMN	IU	4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide

DMZSOCK	ID	DMZSOCK
DMZSOCK	DN	PMID25991433-Compound-J2
DMZSOCK	HS	Patented
DMZSOCK	CP	DANA-FARBER CANCER INSTITUTE, INC
DMZSOCK	DT	Small molecular drug

DM17P3F	ID	DM17P3F
DM17P3F	DN	PMID25991433-Compound-J3
DM17P3F	HS	Patented
DM17P3F	CP	DANA-FARBER CANCER INSTITUTE, INC
DM17P3F	DT	Small molecular drug
DM17P3F	PC	57340683
DM17P3F	MW	436.5
DM17P3F	FM	C25H20N6O2
DM17P3F	IC	InChI=1S/C25H20N6O2/c1-2-23(32)28-21-7-3-5-17(15-21)24(33)29-19-8-10-20(11-9-19)30-25-27-14-12-22(31-25)18-6-4-13-26-16-18/h2-16H,1H2,(H,28,32)(H,29,33)(H,27,30,31)
DM17P3F	CS	C=CC(=O)NC1=CC=CC(=C1)C(=O)NC2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CN=CC=C4
DM17P3F	IK	LUFRTLQRKNBFAZ-UHFFFAOYSA-N
DM17P3F	IU	3-(prop-2-enoylamino)-N-[4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide

DMU75ZX	ID	DMU75ZX
DMU75ZX	DN	PMID25991433-Compound-J5
DMU75ZX	HS	Patented
DMU75ZX	CP	DANA-FARBER CANCER INSTITUTE, INC
DMU75ZX	DT	Small molecular drug
DMU75ZX	PC	57340689
DMU75ZX	MW	608.7
DMU75ZX	FM	C36H32N8O2
DMU75ZX	IC	InChI=1S/C36H32N8O2/c1-43(2)22-9-15-32(45)38-29-13-8-12-26(24-29)35(46)39-27-16-18-28(19-17-27)40-36-37-21-20-30(41-36)33-31-14-6-7-23-44(31)42-34(33)25-10-4-3-5-11-25/h3-21,23-24H,22H2,1-2H3,(H,38,45)(H,39,46)(H,37,40,41)/b15-9+
DMU75ZX	CS	CN(C)C/C=C/C(=O)NC1=CC=CC(=C1)C(=O)NC2=CC=C(C=C2)NC3=NC=CC(=N3)C4=C5C=CC=CN5N=C4C6=CC=CC=C6
DMU75ZX	IK	OCZDPFMSAKKNRH-OQLLNIDSSA-N
DMU75ZX	IU	3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[4-[[4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
DMU75ZX	CB	CHEBI:124926

DMOWULJ	ID	DMOWULJ
DMOWULJ	DN	PMID25991433-Compound-J6
DMOWULJ	HS	Patented
DMOWULJ	CP	DANA-FARBER CANCER INSTITUTE, INC
DMOWULJ	DT	Small molecular drug
DMOWULJ	PC	57340690
DMOWULJ	MW	588.7
DMOWULJ	FM	C32H28N8O2S
DMOWULJ	IC	InChI=1S/C32H28N8O2S/c1-40(2)18-6-11-29(41)35-24-8-5-7-21(19-24)30(42)36-22-12-14-23(15-13-22)37-32-34-17-16-26(39-32)25(20-33)31-38-27-9-3-4-10-28(27)43-31/h3-17,19,38H,18H2,1-2H3,(H,35,41)(H,36,42)(H,34,37,39)/b11-6+,31-25+
DMOWULJ	CS	CN(C)C/C=C/C(=O)NC1=CC=CC(=C1)C(=O)NC2=CC=C(C=C2)NC3=NC=CC(=N3)/C(=C/4\\NC5=CC=CC=C5S4)/C#N
DMOWULJ	IK	HOHLJRLTAVJARA-KCBYSLGISA-N
DMOWULJ	IU	N-[4-[[4-[(Z)-3H-1,3-benzothiazol-2-ylidene(cyano)methyl]pyrimidin-2-yl]amino]phenyl]-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide

DMLT8PA	ID	DMLT8PA
DMLT8PA	DN	PMID25991433-Compound-K1
DMLT8PA	HS	Patented
DMLT8PA	CP	PFIZER PRODUCTS INC. HUANG, Liming LIU, Song LUNNEY, Elizabeth, Ann PLANKEN, Simon, Paul
DMLT8PA	DT	Small molecular drug

DMBS4LE	ID	DMBS4LE
DMBS4LE	DN	PMID25991433-Compound-K2
DMBS4LE	HS	Patented
DMBS4LE	CP	PFIZER PRODUCTS INC. HUANG, Liming LIU, Song LUNNEY, Elizabeth, Ann PLANKEN, Simon, Paul
DMBS4LE	DT	Small molecular drug

DM5U8WT	ID	DM5U8WT
DM5U8WT	DN	PMID25991433-Compound-L
DM5U8WT	HS	Patented
DM5U8WT	CP	SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE PELLECCHIA, Maurizio
DM5U8WT	DT	Small molecular drug

DM2135Y	ID	DM2135Y
DM2135Y	DN	PMID25991433-Compound-L1
DM2135Y	HS	Patented
DM2135Y	CP	SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE PELLECCHIA, Maurizio
DM2135Y	DT	Small molecular drug

DM58UO9	ID	DM58UO9
DM58UO9	DN	PMID25991433-Compound-L2
DM58UO9	HS	Patented
DM58UO9	CP	SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE PELLECCHIA, Maurizio
DM58UO9	DT	Small molecular drug

DM3LWUR	ID	DM3LWUR
DM3LWUR	DN	PMID25991433-Compound-L3
DM3LWUR	HS	Patented
DM3LWUR	CP	SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE PELLECCHIA, Maurizio
DM3LWUR	DT	Small molecular drug

DMN27QB	ID	DMN27QB
DMN27QB	DN	PMID25991433-Compound-N1
DMN27QB	HS	Patented
DMN27QB	CP	VERTEX PHARMACEUTICALS INCORPORATED YANG, Xiaoqing HADIDA RUAH, Sara, S. GROOTENHUIS, Peter, D.J. VAN GOOR, Fredrick, F. BOTFIELD, Martyn, C. ZLOKARNIK, Gregor
DMN27QB	DT	Small molecular drug
DMN27QB	PC	2190145
DMN27QB	MW	338.4
DMN27QB	FM	C19H18N2O2S
DMN27QB	IC	InChI=1S/C19H18N2O2S/c1-11-12(2)24-19(17(11)18(20)23)21-16(22)10-14-8-5-7-13-6-3-4-9-15(13)14/h3-9H,10H2,1-2H3,(H2,20,23)(H,21,22)
DMN27QB	CS	CC1=C(SC(=C1C(=O)N)NC(=O)CC2=CC=CC3=CC=CC=C32)C
DMN27QB	IK	WKFBSIRAGVAYFT-UHFFFAOYSA-N
DMN27QB	IU	4,5-dimethyl-2-[(2-naphthalen-1-ylacetyl)amino]thiophene-3-carboxamide

DMXY4BE	ID	DMXY4BE
DMXY4BE	DN	PMID25991433-Compound-N2
DMXY4BE	HS	Patented
DMXY4BE	CP	VERTEX PHARMACEUTICALS INCORPORATED YANG, Xiaoqing HADIDA RUAH, Sara, S. GROOTENHUIS, Peter, D.J. VAN GOOR, Fredrick, F. BOTFIELD, Martyn, C. ZLOKARNIK, Gregor
DMXY4BE	DT	Small molecular drug
DMXY4BE	PC	46926710
DMXY4BE	MW	288.4
DMXY4BE	FM	C15H16N2O2S
DMXY4BE	IC	InChI=1S/C15H16N2O2S/c1-9-5-10(2)7-11(6-9)8-13(18)17-15-12(14(16)19)3-4-20-15/h3-7H,8H2,1-2H3,(H2,16,19)(H,17,18)
DMXY4BE	CS	CC1=CC(=CC(=C1)CC(=O)NC2=C(C=CS2)C(=O)N)C
DMXY4BE	IK	DXUHHRPREFMGHI-UHFFFAOYSA-N
DMXY4BE	IU	2-[[2-(3,5-dimethylphenyl)acetyl]amino]thiophene-3-carboxamide

DMLHC5V	ID	DMLHC5V
DMLHC5V	DN	PMID25991433-Compound-N3
DMLHC5V	HS	Patented
DMLHC5V	CP	VERTEX PHARMACEUTICALS INCORPORATED YANG, Xiaoqing HADIDA RUAH, Sara, S. GROOTENHUIS, Peter, D.J. VAN GOOR, Fredrick, F. BOTFIELD, Martyn, C. ZLOKARNIK, Gregor
DMLHC5V	DT	Small molecular drug
DMLHC5V	PC	46926788
DMLHC5V	MW	316.4
DMLHC5V	FM	C15H12N2O2S2
DMLHC5V	IC	InChI=1S/C15H12N2O2S2/c16-14(19)11-5-6-20-15(11)17-13(18)7-9-8-21-12-4-2-1-3-10(9)12/h1-6,8H,7H2,(H2,16,19)(H,17,18)
DMLHC5V	CS	C1=CC=C2C(=C1)C(=CS2)CC(=O)NC3=C(C=CS3)C(=O)N
DMLHC5V	IK	ZZKGJVRSUVIYIJ-UHFFFAOYSA-N
DMLHC5V	IU	2-[[2-(1-benzothiophen-3-yl)acetyl]amino]thiophene-3-carboxamide

DMH073T	ID	DMH073T
DMH073T	DN	PMID25991433-Compound-O1
DMH073T	HS	Patented
DMH073T	CP	UNIVERSITY OF LAUSANNE BONNY, Christophe
DMH073T	DT	Peptide
DMH073T	SQ	H2N-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQD-CONH2

DMTROIQ	ID	DMTROIQ
DMTROIQ	DN	PMID25991433-Compound-O2
DMTROIQ	HS	Patented
DMTROIQ	CP	UNIVERSITY OF LAUSANNE BONNY, Christophe
DMTROIQ	DT	Peptide
DMTROIQ	SQ	H2N-dqsrpvqpflnlttprkprpprrrqrrkkrg-CONH2

DMVOWS5	ID	DMVOWS5
DMVOWS5	DN	PMID25991433-Compound-O3
DMVOWS5	HS	Patented
DMVOWS5	CP	XIGEN S.A. COMBETTE, Jean-Marc DELOCHE, Catherine
DMVOWS5	DT	Peptide
DMVOWS5	SQ	H2N-rKKRrQRRrRPkRPaTLNLf-CONH2

DMD8AX6	ID	DMD8AX6
DMD8AX6	DN	PMID25991433-Compound-P1
DMD8AX6	HS	Patented
DMD8AX6	CP	ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMD8AX6	DT	Small molecular drug

DMEGS7U	ID	DMEGS7U
DMEGS7U	DN	PMID25991433-Compound-P2
DMEGS7U	HS	Patented
DMEGS7U	CP	ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMEGS7U	DT	Small molecular drug
DMEGS7U	PC	46869000
DMEGS7U	MW	314.4
DMEGS7U	FM	C16H14N2O3S
DMEGS7U	IC	InChI=1S/C16H14N2O3S/c1-20-12-4-2-11(3-5-12)10-14(19)18-13-6-9-22-15(13)16-17-7-8-21-16/h2-9H,10H2,1H3,(H,18,19)
DMEGS7U	CS	COC1=CC=C(C=C1)CC(=O)NC2=C(SC=C2)C3=NC=CO3
DMEGS7U	IK	KSZHRLGDJPCAID-UHFFFAOYSA-N
DMEGS7U	IU	2-(4-methoxyphenyl)-N-[2-(1,3-oxazol-2-yl)thiophen-3-yl]acetamide

DMAFZLP	ID	DMAFZLP
DMAFZLP	DN	PMID25991433-Compound-P3
DMAFZLP	HS	Patented
DMAFZLP	CP	ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMAFZLP	DT	Small molecular drug

DMVF1D6	ID	DMVF1D6
DMVF1D6	DN	PMID25991433-Compound-P4
DMVF1D6	HS	Patented
DMVF1D6	CP	ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMVF1D6	DT	Small molecular drug

DM6FCS9	ID	DM6FCS9
DM6FCS9	DN	PMID25991433-Compound-P5
DM6FCS9	HS	Patented
DM6FCS9	CP	ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DM6FCS9	DT	Small molecular drug
DM6FCS9	PC	46868926
DM6FCS9	MW	498.3
DM6FCS9	FM	C18H11BrF3N5O2S
DM6FCS9	IC	InChI=1S/C18H11BrF3N5O2S/c19-11-7-30-17(15(11)16-23-8-24-26-16)25-13(28)6-27-12-3-2-10(18(20,21)22)5-9(12)1-4-14(27)29/h1-5,7-8H,6H2,(H,25,28)(H,23,24,26)
DM6FCS9	CS	C1=CC2=C(C=CC(=O)N2CC(=O)NC3=C(C(=CS3)Br)C4=NC=NN4)C=C1C(F)(F)F
DM6FCS9	IK	CRWXJGJNJZPMRW-UHFFFAOYSA-N
DM6FCS9	IU	N-[4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl]-2-[2-oxo-6-(trifluoromethyl)quinolin-1-yl]acetamide

DMNDVC9	ID	DMNDVC9
DMNDVC9	DN	PMID25991433-Compound-P6
DMNDVC9	HS	Patented
DMNDVC9	CP	ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMNDVC9	DT	Small molecular drug
DMNDVC9	PC	45102739
DMNDVC9	MW	369.8
DMNDVC9	FM	C17H12ClN5OS
DMNDVC9	IC	InChI=1S/C17H12ClN5OS/c18-13-8-25-17(15(13)16-20-9-21-23-16)22-14(24)6-10-2-1-3-11-7-19-5-4-12(10)11/h1-5,7-9H,6H2,(H,22,24)(H,20,21,23)
DMNDVC9	CS	C1=CC2=C(C=CN=C2)C(=C1)CC(=O)NC3=C(C(=CS3)Cl)C4=NC=NN4
DMNDVC9	IK	MYLVKAPPYVXQKQ-UHFFFAOYSA-N
DMNDVC9	IU	N-[4-chloro-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl]-2-isoquinolin-5-ylacetamide
DMNDVC9	CA	CAS 1239461-27-8

DMEMSB2	ID	DMEMSB2
DMEMSB2	DN	PMID25991433-Compound-Q1
DMEMSB2	HS	Patented
DMEMSB2	CP	UNIVERSIT DEGLI STUDI DI BARI [IT]
DMEMSB2	DT	Small molecular drug
DMEMSB2	PC	56946834
DMEMSB2	MW	444.4
DMEMSB2	FM	C22H18F2N2O6
DMEMSB2	IC	InChI=1S/C22H18F2N2O6/c1-30-19-9-14(10-20(31-2)21(19)32-3)22(27)25-17-5-4-12(8-18(17)26(28)29)13-6-15(23)11-16(24)7-13/h4-11H,1-3H3,(H,25,27)
DMEMSB2	CS	COC1=CC(=CC(=C1OC)OC)C(=O)NC2=C(C=C(C=C2)C3=CC(=CC(=C3)F)F)[N+](=O)[O-]
DMEMSB2	IK	UCSAAECBPXPZFV-UHFFFAOYSA-N
DMEMSB2	IU	N-[4-(3,5-difluorophenyl)-2-nitrophenyl]-3,4,5-trimethoxybenzamide

DMAIKJV	ID	DMAIKJV
DMAIKJV	DN	PMID25991433-Compound-Q2
DMAIKJV	HS	Patented
DMAIKJV	CP	UNIVERSIT DEGLI STUDI DI BARI [IT]
DMAIKJV	DT	Small molecular drug
DMAIKJV	PC	56946615
DMAIKJV	MW	408.4
DMAIKJV	FM	C22H20N2O6
DMAIKJV	IC	InChI=1S/C22H20N2O6/c1-28-19-12-16(13-20(29-2)21(19)30-3)23-22(25)17-10-9-15(11-18(17)24(26)27)14-7-5-4-6-8-14/h4-13H,1-3H3,(H,23,25)
DMAIKJV	CS	COC1=CC(=CC(=C1OC)OC)NC(=O)C2=C(C=C(C=C2)C3=CC=CC=C3)[N+](=O)[O-]
DMAIKJV	IK	RCEYITFFDFXLHB-UHFFFAOYSA-N
DMAIKJV	IU	2-nitro-4-phenyl-N-(3,4,5-trimethoxyphenyl)benzamide

DM8FQJB	ID	DM8FQJB
DM8FQJB	DN	PMID26004420-Compound-U2014S0288042A
DM8FQJB	HS	Patented
DM8FQJB	CP	Merck Sharp & Dohme Corp
DM8FQJB	DT	Small molecular drug

DM8RJTQ	ID	DM8RJTQ
DM8RJTQ	DN	PMID26004420-Compound-U2014S0288042C
DM8RJTQ	HS	Patented
DM8RJTQ	CP	Merck Sharp & Dohme Corp
DM8RJTQ	DT	Small molecular drug

DMVQSYT	ID	DMVQSYT
DMVQSYT	DN	PMID26004420-Compound-US20140031349A
DMVQSYT	HS	Patented
DMVQSYT	CP	Merck Sharp & Dohme Corp
DMVQSYT	DT	Small molecular drug

DM3M1NB	ID	DM3M1NB
DM3M1NB	DN	PMID26004420-Compound-US20140031349B
DM3M1NB	HS	Patented
DM3M1NB	CP	Merck Sharp & Dohme Corp
DM3M1NB	DT	Small molecular drug

DMDP8J0	ID	DMDP8J0
DMDP8J0	DN	PMID26004420-Compound-US20140031349C
DMDP8J0	HS	Patented
DMDP8J0	CP	Merck Sharp & Dohme Corp
DMDP8J0	DT	Small molecular drug

DMUD7IB	ID	DMUD7IB
DMUD7IB	DN	PMID26004420-Compound-US20140031349D
DMUD7IB	HS	Patented
DMUD7IB	CP	Merck Sharp & Dohme Corp
DMUD7IB	DT	Small molecular drug

DMIXVNQ	ID	DMIXVNQ
DMIXVNQ	DN	PMID26004420-Compound-US20140142115A
DMIXVNQ	HS	Patented
DMIXVNQ	CP	Merck Sharp & Dohme Corp
DMIXVNQ	DT	Small molecular drug

DM07DC6	ID	DM07DC6
DM07DC6	DN	PMID26004420-Compound-US20140142115B
DM07DC6	HS	Patented
DM07DC6	CP	Merck Sharp & Dohme Corp
DM07DC6	DT	Small molecular drug

DMQ7Z5F	ID	DMQ7Z5F
DMQ7Z5F	DN	PMID26004420-Compound-US20140142115C
DMQ7Z5F	HS	Patented
DMQ7Z5F	CP	Merck Sharp & Dohme Corp
DMQ7Z5F	DT	Small molecular drug

DMQ5AIT	ID	DMQ5AIT
DMQ5AIT	DN	PMID26004420-Compound-US20140275020D
DMQ5AIT	HS	Patented
DMQ5AIT	CP	Merck Sharp & Dohme Corp
DMQ5AIT	DT	Small molecular drug

DMH7JKI	ID	DMH7JKI
DMH7JKI	DN	PMID26004420-Compound-US20140275020E
DMH7JKI	HS	Patented
DMH7JKI	CP	Merck Sharp & Dohme Corp
DMH7JKI	DT	Small molecular drug

DMH8M1D	ID	DMH8M1D
DMH8M1D	DN	PMID26004420-Compound-US20140309213A
DMH8M1D	HS	Patented
DMH8M1D	CP	Merck Sharp & Dohme Corp
DMH8M1D	DT	Small molecular drug

DM0P4TA	ID	DM0P4TA
DM0P4TA	DN	PMID26004420-Compound-US20140309213B
DM0P4TA	HS	Patented
DM0P4TA	CP	Merck Sharp & Dohme Corp
DM0P4TA	DT	Small molecular drug

DM4M2TU	ID	DM4M2TU
DM4M2TU	DN	PMID26004420-Compound-US20140336177D
DM4M2TU	HS	Patented
DM4M2TU	CP	Merck Sharp & Dohme Corp
DM4M2TU	DT	Small molecular drug

DMCRJO1	ID	DMCRJO1
DMCRJO1	DN	PMID26004420-Compound-US20140336177E
DMCRJO1	HS	Patented
DMCRJO1	CP	Merck Sharp & Dohme Corp
DMCRJO1	DT	Small molecular drug

DM37GMQ	ID	DM37GMQ
DM37GMQ	DN	PMID26004420-Compound-WO2010129379A
DM37GMQ	HS	Patented
DM37GMQ	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM37GMQ	DT	Small molecular drug

DM62A1H	ID	DM62A1H
DM62A1H	DN	PMID26004420-Compound-WO2010129379B
DM62A1H	HS	Patented
DM62A1H	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM62A1H	DT	Small molecular drug

DMV3X64	ID	DMV3X64
DMV3X64	DN	PMID26004420-Compound-WO2010129379C
DMV3X64	HS	Patented
DMV3X64	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMV3X64	DT	Small molecular drug

DMR9B2D	ID	DMR9B2D
DMR9B2D	DN	PMID26004420-Compound-WO2012058116A
DMR9B2D	HS	Patented
DMR9B2D	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMR9B2D	DT	Small molecular drug

DMD41UF	ID	DMD41UF
DMD41UF	DN	PMID26004420-Compound-WO2012058116B
DMD41UF	HS	Patented
DMD41UF	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMD41UF	DT	Small molecular drug

DM2Y64W	ID	DM2Y64W
DM2Y64W	DN	PMID26004420-Compound-WO2012058116C
DM2Y64W	HS	Patented
DM2Y64W	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM2Y64W	DT	Small molecular drug

DMUX0SG	ID	DMUX0SG
DMUX0SG	DN	PMID26004420-Compound-WO2012058134A
DMUX0SG	HS	Patented
DMUX0SG	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMUX0SG	DT	Small molecular drug

DMGVXCL	ID	DMGVXCL
DMGVXCL	DN	PMID26004420-Compound-WO2012058134B
DMGVXCL	HS	Patented
DMGVXCL	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMGVXCL	DT	Small molecular drug

DM9AJVK	ID	DM9AJVK
DM9AJVK	DN	PMID26004420-Compound-WO2012058134C
DM9AJVK	HS	Patented
DM9AJVK	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM9AJVK	DT	Small molecular drug

DMIV92A	ID	DMIV92A
DMIV92A	DN	PMID26004420-Compound-WO2013028474A
DMIV92A	HS	Patented
DMIV92A	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMIV92A	DT	Small molecular drug

DMCP0WF	ID	DMCP0WF
DMCP0WF	DN	PMID26004420-Compound-WO2013028474B
DMCP0WF	HS	Patented
DMCP0WF	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMCP0WF	DT	Small molecular drug

DMTCPNY	ID	DMTCPNY
DMTCPNY	DN	PMID26004420-Compound-WO2013028474C
DMTCPNY	HS	Patented
DMTCPNY	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMTCPNY	DT	Small molecular drug

DMT7GQ1	ID	DMT7GQ1
DMT7GQ1	DN	PMID26004420-Compound-WO2013039802A
DMT7GQ1	HS	Patented
DMT7GQ1	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMT7GQ1	DT	Small molecular drug

DMP130R	ID	DMP130R
DMP130R	DN	PMID26004420-Compound-WO2013039802B
DMP130R	HS	Patented
DMP130R	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMP130R	DT	Small molecular drug

DMV7ISR	ID	DMV7ISR
DMV7ISR	DN	PMID26004420-Compound-WO2013039802C
DMV7ISR	HS	Patented
DMV7ISR	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMV7ISR	DT	Small molecular drug

DMH7E38	ID	DMH7E38
DMH7E38	DN	PMID26004420-Compound-WO2013062892D
DMH7E38	HS	Patented
DMH7E38	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMH7E38	DT	Small molecular drug

DMMHLA9	ID	DMMHLA9
DMMHLA9	DN	PMID26004420-Compound-WO2013062892E
DMMHLA9	HS	Patented
DMMHLA9	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMMHLA9	DT	Small molecular drug

DM5N9M4	ID	DM5N9M4
DM5N9M4	DN	PMID26004420-Compound-WO2013062900A
DM5N9M4	HS	Patented
DM5N9M4	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM5N9M4	DT	Small molecular drug

DMIM8UF	ID	DMIM8UF
DMIM8UF	DN	PMID26004420-Compound-WO2013062900B
DMIM8UF	HS	Patented
DMIM8UF	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMIM8UF	DT	Small molecular drug

DMDZHAB	ID	DMDZHAB
DMDZHAB	DN	PMID26004420-Compound-WO2013062900C
DMDZHAB	HS	Patented
DMDZHAB	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMDZHAB	DT	Small molecular drug
DMDZHAB	PC	71519588
DMDZHAB	MW	415.5
DMDZHAB	FM	C25H25N3O3
DMDZHAB	IC	InChI=1S/C25H25N3O3/c26-14-18-1-3-20-13-22(5-4-19(20)12-18)28-10-9-27(15-24(28)29)8-7-17-2-6-23-21(11-17)16-31-25(23)30/h1-3,6,11-12,22H,4-5,7-10,13,15-16H2
DMDZHAB	CS	C1CC2=C(CC1N3CCN(CC3=O)CCC4=CC5=C(C=C4)C(=O)OC5)C=CC(=C2)C#N
DMDZHAB	IK	IXHFMRBAJKIWFU-UHFFFAOYSA-N
DMDZHAB	IU	6-[2-oxo-4-[2-(1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]-5,6,7,8-tetrahydronaphthalene-2-carbonitrile

DMRDUS9	ID	DMRDUS9
DMRDUS9	DN	PMID26004420-Compound-WO2014015495A
DMRDUS9	HS	Patented
DMRDUS9	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMRDUS9	DT	Small molecular drug

DMLH637	ID	DMLH637
DMLH637	DN	PMID26004420-Compound-WO2014015495B
DMLH637	HS	Patented
DMLH637	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMLH637	DT	Small molecular drug

DMHA18O	ID	DMHA18O
DMHA18O	DN	PMID26004420-Compound-WO2014015495C
DMHA18O	HS	Patented
DMHA18O	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMHA18O	DT	Small molecular drug

DM3QO5R	ID	DM3QO5R
DM3QO5R	DN	PMID26004420-Compound-WO2014015495D
DM3QO5R	HS	Patented
DM3QO5R	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM3QO5R	DT	Small molecular drug

DMY6JAB	ID	DMY6JAB
DMY6JAB	DN	PMID26004420-Compound-WO2014085210A
DMY6JAB	HS	Patented
DMY6JAB	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMY6JAB	DT	Small molecular drug

DMTD0RK	ID	DMTD0RK
DMTD0RK	DN	PMID26004420-Compound-WO2014085210B
DMTD0RK	HS	Patented
DMTD0RK	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMTD0RK	DT	Small molecular drug

DMKC6SA	ID	DMKC6SA
DMKC6SA	DN	PMID26004420-Compound-WO2014085210C
DMKC6SA	HS	Patented
DMKC6SA	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMKC6SA	DT	Small molecular drug

DMJIZWR	ID	DMJIZWR
DMJIZWR	DN	PMID26004420-Compound-WO2014099633D
DMJIZWR	HS	Patented
DMJIZWR	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMJIZWR	DT	Small molecular drug

DMSPG8Y	ID	DMSPG8Y
DMSPG8Y	DN	PMID26004420-Compound-WO2014099633E
DMSPG8Y	HS	Patented
DMSPG8Y	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMSPG8Y	DT	Small molecular drug

DM59INV	ID	DM59INV
DM59INV	DN	PMID26004420-Compound-WO2014126944A
DM59INV	HS	Patented
DM59INV	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM59INV	DT	Small molecular drug

DMH0LBI	ID	DMH0LBI
DMH0LBI	DN	PMID26004420-Compound-WO2014126944B
DMH0LBI	HS	Patented
DMH0LBI	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMH0LBI	DT	Small molecular drug

DMN1B3F	ID	DMN1B3F
DMN1B3F	DN	PMID26004420-Compound-WO2014150132A
DMN1B3F	HS	Patented
DMN1B3F	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMN1B3F	DT	Small molecular drug

DMJX8WY	ID	DMJX8WY
DMJX8WY	DN	PMID26004420-Compound-WO2014150132B
DMJX8WY	HS	Patented
DMJX8WY	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMJX8WY	DT	Small molecular drug

DM2FDCT	ID	DM2FDCT
DM2FDCT	DN	PMID26004420-Compound-WO2014150132C
DM2FDCT	HS	Patented
DM2FDCT	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM2FDCT	DT	Small molecular drug

DMI30GA	ID	DMI30GA
DMI30GA	DN	PMID26004420-Compound-WO2015017305D
DMI30GA	HS	Patented
DMI30GA	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMI30GA	DT	Small molecular drug

DMV4HQ5	ID	DMV4HQ5
DMV4HQ5	DN	PMID26004420-Compound-WO2015017305E
DMV4HQ5	HS	Patented
DMV4HQ5	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMV4HQ5	DT	Small molecular drug

DMLV6IY	ID	DMLV6IY
DMLV6IY	DN	PMID26004420-Compound-WO2015017305F
DMLV6IY	HS	Patented
DMLV6IY	CP	MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMLV6IY	DT	Small molecular drug

DMENX90	ID	DMENX90
DMENX90	DN	PMID26077642-Compound-Figure3A
DMENX90	HS	Patented
DMENX90	CP	VIVOLUX AB LINDER, Stig LARSSON, Rolf
DMENX90	DT	Small molecular drug

DM9A8PN	ID	DM9A8PN
DM9A8PN	DN	PMID26077642-Compound-Figure3G
DM9A8PN	HS	Patented
DM9A8PN	CP	THE REGENTS OF THE UNIVERSITY OF MICHIGAN DONATO, Nicholas, J. WOBUS, Christiane SHOWALTER, H. D. Hollis TALPAZ, Moshe PERRY, Jeffrey, William SORENSON, Roderick, Joseph O'RIORDAN, Mary, Xuan Dziem JIN, Yafei
DM9A8PN	DT	Small molecular drug

DMQYWBR	ID	DMQYWBR
DMQYWBR	DN	PMID26077642-Compound-Figure3H
DMQYWBR	HS	Patented
DMQYWBR	DT	Small molecular drug

DMS9KCF	ID	DMS9KCF
DMS9KCF	DN	PMID26077642-Compound-Vif1
DMS9KCF	HS	Patented
DMS9KCF	DT	Peptide

DMYXIS7	ID	DMYXIS7
DMYXIS7	DN	PMID26077642-Compound-Vif2
DMYXIS7	HS	Patented
DMYXIS7	DT	Peptide

DM2PUBI	ID	DM2PUBI
DM2PUBI	DN	PMID26099857-Compound-WO2011037610Formula(I)
DM2PUBI	HS	Patented
DM2PUBI	CP	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY SCHUSTER, Victor, L. CHI, Yuling WASMUTH, Andrew, S. POTTORF, Richard, S. OLSON, Gary, L
DM2PUBI	DT	Small molecular drug

DMXVCHZ	ID	DMXVCHZ
DMXVCHZ	DN	PMID26161698-Compound-10
DMXVCHZ	HS	Patented
DMXVCHZ	CP	SCHERING CORPORATION PARUCH, Kamil GUZI, Timothy J. DWYER, Michael P
DMXVCHZ	DT	Small molecular drug

DMB92RA	ID	DMB92RA
DMB92RA	DN	PMID26161698-Compound-17
DMB92RA	HS	Patented
DMB92RA	CP	SENEX BIOTECHNOLOGY, INC
DMB92RA	DT	Small molecular drug
DMB92RA	PC	739323
DMB92RA	MW	229.1
DMB92RA	FM	C10H10Cl2N2
DMB92RA	IC	InChI=1S/C10H10Cl2N2/c11-7-3-8-6(1-2-13)5-14-10(8)9(12)4-7/h3-5,14H,1-2,13H2
DMB92RA	CS	C1=C(C=C(C2=C1C(=CN2)CCN)Cl)Cl
DMB92RA	IK	MOPMGVMKLSZZPB-UHFFFAOYSA-N
DMB92RA	IU	2-(5,7-dichloro-1H-indol-3-yl)ethanamine

DM6JVR5	ID	DM6JVR5
DM6JVR5	DN	PMID26161698-Compound-18
DM6JVR5	HS	Patented
DM6JVR5	CP	NOSCIRA, S.A
DM6JVR5	DT	Small molecular drug
DM6JVR5	PC	136273305
DM6JVR5	MW	260.68
DM6JVR5	FM	C12H9ClN4O
DM6JVR5	IC	InChI=1S/C12H9ClN4O/c13-6-1-2-8-7(5-6)10(11(18)16-8)9-3-4-15-12(14)17-9/h1-5,16,18H,(H2,14,15,17)
DM6JVR5	CS	C1=CC2=C(C=C1Cl)C(=C(N2)O)C3=NC(=NC=C3)N
DM6JVR5	IK	LHICLFBRLYHBGK-UHFFFAOYSA-N
DM6JVR5	IU	3-(2-aminopyrimidin-4-yl)-5-chloro-1H-indol-2-ol

DM4AFHY	ID	DM4AFHY
DM4AFHY	DN	PMID26161698-Compound-25
DM4AFHY	HS	Patented
DM4AFHY	CP	BAYER INTELLECTUAL PROPERTY GMBH
DM4AFHY	DT	Small molecular drug
DM4AFHY	PC	71618654
DM4AFHY	MW	481.5
DM4AFHY	FM	C24H21F2N5O2S
DM4AFHY	IC	InChI=1S/C24H21F2N5O2S/c1-34(27,32)14-17-5-3-7-20(11-17)30-24-29-15-28-23(31-24)21-9-8-19(26)12-22(21)33-13-16-4-2-6-18(25)10-16/h2-12,15,27H,13-14H2,1H3,(H,28,29,30,31)
DM4AFHY	CS	CS(=N)(=O)CC1=CC(=CC=C1)NC2=NC=NC(=N2)C3=C(C=C(C=C3)F)OCC4=CC(=CC=C4)F
DM4AFHY	IK	YPAQXRURXUKFGB-UHFFFAOYSA-N
DM4AFHY	IU	4-[4-fluoro-2-[(3-fluorophenyl)methoxy]phenyl]-N-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine

DMRIWKV	ID	DMRIWKV
DMRIWKV	DN	PMID26161698-Compound-32
DMRIWKV	HS	Patented
DMRIWKV	CP	LEAD DISCOVERY CENTER GMBH MAX-PLANCK-GESELLSCHAFT ZUR FDERUNG DER WISSENSCHAFTEN E.V. CHOIDAS, Axel KLEBL, Bert HABENBERGER, Peter EICKHOFF, Jan THOMAS, Roman HEUCKMANN, Johannes
DMRIWKV	DT	Small molecular drug
DMRIWKV	PC	53491923
DMRIWKV	MW	371.4
DMRIWKV	FM	C17H17N5O3S
DMRIWKV	IC	InChI=1S/C17H17N5O3S/c1-25-15-8-3-2-7-14(15)16-19-11-20-17(22-16)21-13-6-4-5-12(9-13)10-26(18,23)24/h2-9,11H,10H2,1H3,(H2,18,23,24)(H,19,20,21,22)
DMRIWKV	CS	COC1=CC=CC=C1C2=NC(=NC=N2)NC3=CC=CC(=C3)CS(=O)(=O)N
DMRIWKV	IK	BQJUSTFHSZCQFK-UHFFFAOYSA-N
DMRIWKV	IU	[3-[[4-(2-methoxyphenyl)-1,3,5-triazin-2-yl]amino]phenyl]methanesulfonamide

DMTIM1E	ID	DMTIM1E
DMTIM1E	DN	PMID26161698-Compound-34
DMTIM1E	HS	Patented
DMTIM1E	CP	DANA-FARBER CANCER INSTITUTE, INC
DMTIM1E	DT	Small molecular drug

DM8UPO3	ID	DM8UPO3
DM8UPO3	DN	PMID26161698-Compound-44
DM8UPO3	HS	Patented
DM8UPO3	CP	NERVIANO MEDICAL SCIENCES S.R.L. ZAMPIERI, Massimo VANOTTI, Ermes CIVAROLI, Paola FORNARETTO, Maria, Gioia
DM8UPO3	DT	Small molecular drug

DMF9C4I	ID	DMF9C4I
DMF9C4I	DN	PMID26161824-Compound-68
DMF9C4I	HS	Patented
DMF9C4I	DT	Small molecular drug
DMF9C4I	PC	24881103
DMF9C4I	MW	461.8
DMF9C4I	FM	C24H23Cl3N2O
DMF9C4I	IC	InChI=1S/C24H23Cl3N2O/c1-15-23(22(30)13-16-5-3-2-4-6-16)28-29(21-12-11-19(26)14-20(21)27)24(15)17-7-9-18(25)10-8-17/h7-12,14,16H,2-6,13H2,1H3
DMF9C4I	CS	CC1=C(N(N=C1C(=O)CC2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMF9C4I	IK	XMPCPPFFIBUKLW-UHFFFAOYSA-N
DMF9C4I	IU	1-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-2-cyclohexylethanone
DMF9C4I	DE	Obesity

DMKOSN5	ID	DMKOSN5
DMKOSN5	DN	PMID26161824-Compound-69
DMKOSN5	HS	Patented
DMKOSN5	DT	Small molecular drug
DMKOSN5	PC	25003056
DMKOSN5	MW	455.8
DMKOSN5	FM	C24H17Cl3N2O
DMKOSN5	IC	InChI=1S/C24H17Cl3N2O/c1-15-23(22(30)13-16-5-3-2-4-6-16)28-29(21-12-11-19(26)14-20(21)27)24(15)17-7-9-18(25)10-8-17/h2-12,14H,13H2,1H3
DMKOSN5	CS	CC1=C(N(N=C1C(=O)CC2=CC=CC=C2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMKOSN5	IK	GTXRPIMCNZXFIC-UHFFFAOYSA-N
DMKOSN5	IU	1-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-2-phenylethanone
DMKOSN5	DE	Obesity

DMHXT12	ID	DMHXT12
DMHXT12	DN	PMID26293650-Compound-34
DMHXT12	HS	Patented
DMHXT12	CP	DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMHXT12	DT	Small molecular drug
DMHXT12	PC	72950600
DMHXT12	MW	426.5
DMHXT12	FM	C25H26N6O
DMHXT12	IC	InChI=1S/C25H26N6O/c1-17(2)28-24(32)18-5-8-21(9-6-18)29-25-27-12-11-22(30-25)19-7-10-23(20(15-19)16-26)31-13-3-4-14-31/h5-12,15,17H,3-4,13-14H2,1-2H3,(H,28,32)(H,27,29,30)
DMHXT12	CS	CC(C)NC(=O)C1=CC=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)N4CCCC4)C#N
DMHXT12	IK	FJNGYFUMQJIPOQ-UHFFFAOYSA-N
DMHXT12	IU	4-[[4-(3-cyano-4-pyrrolidin-1-ylphenyl)pyrimidin-2-yl]amino]-N-propan-2-ylbenzamide

DMPG8MF	ID	DMPG8MF
DMPG8MF	DN	PMID26293650-Compound-35
DMPG8MF	HS	Patented
DMPG8MF	CP	DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMPG8MF	DT	Small molecular drug

DMP8RQ4	ID	DMP8RQ4
DMP8RQ4	DN	PMID26394986-Compound-10
DMP8RQ4	HS	Patented
DMP8RQ4	CP	H. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMP8RQ4	DT	Small molecular drug
DMP8RQ4	PC	252682
DMP8RQ4	MW	365.4
DMP8RQ4	FM	C16H15NO7S
DMP8RQ4	IC	InChI=1S/C16H15NO7S/c1-10-2-5-12(6-3-10)25(22,23)24-9-15(19)17-11-4-7-13(16(20)21)14(18)8-11/h2-8,18H,9H2,1H3,(H,17,19)(H,20,21)
DMP8RQ4	CS	CC1=CC=C(C=C1)S(=O)(=O)OCC(=O)NC2=CC(=C(C=C2)C(=O)O)O
DMP8RQ4	IK	HWNUSGNZBAISFM-UHFFFAOYSA-N
DMP8RQ4	IU	2-hydroxy-4-[[2-(4-methylphenyl)sulfonyloxyacetyl]amino]benzoic acid
DMP8RQ4	CA	CAS 501919-59-1
DMP8RQ4	CB	CHEBI:91224

DMWMZE4	ID	DMWMZE4
DMWMZE4	DN	PMID26394986-Compound-11
DMWMZE4	HS	Patented
DMWMZE4	CP	H. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMWMZE4	DT	Small molecular drug
DMWMZE4	PC	341
DMWMZE4	MW	322.22
DMWMZE4	FM	C14H10O9
DMWMZE4	IC	InChI=1S/C14H10O9/c15-7-2-6(3-8(16)11(7)18)14(22)23-10-4-5(13(20)21)1-9(17)12(10)19/h1-4,15-19H,(H,20,21)
DMWMZE4	CS	C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)O
DMWMZE4	IK	COVFEVWNJUOYRL-UHFFFAOYSA-N
DMWMZE4	IU	3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoic acid
DMWMZE4	CA	CAS 536-08-3
DMWMZE4	CB	CHEBI:30814

DMTSQXE	ID	DMTSQXE
DMTSQXE	DN	PMID26394986-Compound-12
DMTSQXE	HS	Patented
DMTSQXE	CP	H. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMTSQXE	DT	Small molecular drug
DMTSQXE	PC	237973
DMTSQXE	MW	637.5
DMTSQXE	FM	C25H19NO15S2
DMTSQXE	IC	InChI=1S/C25H19NO15S2/c27-17-4-11(24(32)33)5-19(22(17)30)41-25(34)15-8-18(28)23(31)21(29)16(15)9-26-12-2-1-10-3-13(42(35,36)37)7-20(14(10)6-12)43(38,39)40/h1-8,26-31H,9H2,(H,32,33)(H,35,36,37)(H,38,39,40)
DMTSQXE	CS	C1=CC(=CC2=C(C=C(C=C21)S(=O)(=O)O)S(=O)(=O)O)NCC3=C(C(=C(C=C3C(=O)OC4=CC(=CC(=C4O)O)C(=O)O)O)O)O
DMTSQXE	IK	AIBIWCKHWTUBPW-UHFFFAOYSA-N
DMTSQXE	IU	3-[2-[[(6,8-disulfonaphthalen-2-yl)amino]methyl]-3,4,5-trihydroxybenzoyl]oxy-4,5-dihydroxybenzoic acid
DMTSQXE	CA	CAS 6635-00-3

DMBUZHO	ID	DMBUZHO
DMBUZHO	DN	PMID26394986-Compound-13
DMBUZHO	HS	Patented
DMBUZHO	DT	Small molecular drug
DMBUZHO	PC	24767791
DMBUZHO	MW	550.7
DMBUZHO	FM	C30H34N2O6S
DMBUZHO	IC	InChI=1S/C30H34N2O6S/c1-21-8-15-26(16-9-21)39(37,38)31(2)20-29(34)32(25-14-17-27(30(35)36)28(33)18-25)19-22-10-12-24(13-11-22)23-6-4-3-5-7-23/h8-18,23,33H,3-7,19-20H2,1-2H3,(H,35,36)
DMBUZHO	CS	CC1=CC=C(C=C1)S(=O)(=O)N(C)CC(=O)N(CC2=CC=C(C=C2)C3CCCCC3)C4=CC(=C(C=C4)C(=O)O)O
DMBUZHO	IK	DMZMMAPPHDCECB-UHFFFAOYSA-N
DMBUZHO	IU	4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(4-methylphenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid

DMF9J0Y	ID	DMF9J0Y
DMF9J0Y	DN	PMID26394986-Compound-20
DMF9J0Y	HS	Patented
DMF9J0Y	CP	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INCH. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMF9J0Y	DT	Small molecular drug
DMF9J0Y	PC	76336555
DMF9J0Y	MW	550.7
DMF9J0Y	FM	C30H34N2O6S
DMF9J0Y	IC	InChI=1S/C30H34N2O6S/c1-21-8-15-26(16-9-21)39(37,38)31(2)20-29(34)32(25-14-17-28(33)27(18-25)30(35)36)19-22-10-12-24(13-11-22)23-6-4-3-5-7-23/h8-18,23,33H,3-7,19-20H2,1-2H3,(H,35,36)
DMF9J0Y	CS	CC1=CC=C(C=C1)S(=O)(=O)N(C)CC(=O)N(CC2=CC=C(C=C2)C3CCCCC3)C4=CC(=C(C=C4)O)C(=O)O
DMF9J0Y	IK	PTAQXAOGPHGSTK-UHFFFAOYSA-N
DMF9J0Y	IU	5-[(4-cyclohexylphenyl)methyl-[2-[methyl-(4-methylphenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid

DMLMQD4	ID	DMLMQD4
DMLMQD4	DN	PMID26394986-Compound-21
DMLMQD4	HS	Patented
DMLMQD4	CP	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INCH. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMLMQD4	DT	Small molecular drug
DMLMQD4	PC	73672447
DMLMQD4	MW	521.6
DMLMQD4	FM	C33H31NO5
DMLMQD4	IC	InChI=1S/C33H31NO5/c35-31-20-17-27(21-30(31)33(37)38)34(22-23-11-13-25(14-12-23)24-7-3-1-4-8-24)32(36)26-15-18-29(19-16-26)39-28-9-5-2-6-10-28/h2,5-6,9-21,24,35H,1,3-4,7-8,22H2,(H,37,38)
DMLMQD4	CS	C1CCC(CC1)C2=CC=C(C=C2)CN(C3=CC(=C(C=C3)O)C(=O)O)C(=O)C4=CC=C(C=C4)OC5=CC=CC=C5
DMLMQD4	IK	ZJMHQDKLWUWPDR-UHFFFAOYSA-N
DMLMQD4	IU	5-[(4-cyclohexylphenyl)methyl-(4-phenoxybenzoyl)amino]-2-hydroxybenzoic acid

DM43Z1G	ID	DM43Z1G
DM43Z1G	DN	PMID26394986-Compound-22
DM43Z1G	HS	Patented
DM43Z1G	CP	G. D. SEARLE & CO. GAO, Danchen HLINAK, Anthony, J. MAZHARY, Ahmad, M. TRUELOVE, James, E. VAUGHN, Margaret, B., Woodhull
DM43Z1G	DT	Small molecular drug
DM43Z1G	PC	2662
DM43Z1G	MW	381.4
DM43Z1G	FM	C17H14F3N3O2S
DM43Z1G	IC	InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
DM43Z1G	CS	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
DM43Z1G	IK	RZEKVGVHFLEQIL-UHFFFAOYSA-N
DM43Z1G	IU	4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM43Z1G	CA	CAS 169590-42-5
DM43Z1G	CB	CHEBI:41423

DM2E6M7	ID	DM2E6M7
DM2E6M7	DN	PMID26394986-Compound-42
DM2E6M7	HS	Patented
DM2E6M7	DT	Small molecular drug
DM2E6M7	PC	9799188
DM2E6M7	MW	364.6
DM2E6M7	FM	C24H44O2
DM2E6M7	IC	InChI=1S/C24H44O2/c1-21-22(24(2,3)19-18-23(21)26)17-15-13-11-9-7-5-4-6-8-10-12-14-16-20-25/h25H,4-20H2,1-3H3
DM2E6M7	CS	CC1=C(C(CCC1=O)(C)C)CCCCCCCCCCCCCCCO
DM2E6M7	IK	FGMAOXGOTRUOKJ-UHFFFAOYSA-N
DM2E6M7	IU	3-(15-hydroxypentadecyl)-2,4,4-trimethylcyclohex-2-en-1-one
DM2E6M7	CA	CAS 220757-88-0

DM1HIEZ	ID	DM1HIEZ
DM1HIEZ	DN	PMID26394986-Compound-43
DM1HIEZ	HS	Patented
DM1HIEZ	CP	The Ohio University
DM1HIEZ	DT	Small molecular drug
DM1HIEZ	PC	46911017
DM1HIEZ	MW	303.29
DM1HIEZ	FM	C14H9NO5S
DM1HIEZ	IC	InChI=1S/C14H9NO5S/c15-21(19,20)10-6-2-4-8-12(10)14(18)7-3-1-5-9(16)11(7)13(8)17/h1-6,16H,(H2,15,19,20)
DM1HIEZ	CS	C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C(=CC=C3)S(=O)(=O)N
DM1HIEZ	IK	CQBHSRLUQDYPBU-UHFFFAOYSA-N
DM1HIEZ	IU	5-hydroxy-9,10-dioxoanthracene-1-sulfonamide
DM1HIEZ	CA	CAS 1260247-42-4

DMOJ52P	ID	DMOJ52P
DMOJ52P	DN	PMID26394986-Compound-44
DMOJ52P	HS	Patented
DMOJ52P	DT	Small molecular drug
DMOJ52P	PC	65064
DMOJ52P	MW	458.4
DMOJ52P	FM	C22H18O11
DMOJ52P	IC	InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
DMOJ52P	CS	C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMOJ52P	IK	WMBWREPUVVBILR-WIYYLYMNSA-N
DMOJ52P	IU	[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMOJ52P	CA	CAS 989-51-5
DMOJ52P	CB	CHEBI:4806

DML5I9K	ID	DML5I9K
DML5I9K	DN	PMID26394986-Compound-50
DML5I9K	HS	Patented
DML5I9K	CP	BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DML5I9K	DT	Small molecular drug
DML5I9K	PC	9881541
DML5I9K	MW	256.209
DML5I9K	FM	C14H8O5
DML5I9K	IC	InChI=1S/C14H8O5/c1-6(15)10-5-8-12(17)7-3-2-4-9(16)11(7)13(18)14(8)19-10/h2-5,16H,1H3
DML5I9K	CS	CC(=O)C1=CC2=C(O1)C(=O)C3=C(C2=O)C=CC=C3O
DML5I9K	IK	MYDAXHYLQBNETF-UHFFFAOYSA-N
DML5I9K	IU	2-acetyl-8-hydroxybenzo[f][1]benzofuran-4,9-dione
DML5I9K	CA	CAS 123297-91-6

DMV6GIC	ID	DMV6GIC
DMV6GIC	DN	PMID26394986-Compound-51
DMV6GIC	HS	Patented
DMV6GIC	CP	BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DMV6GIC	DT	Small molecular drug
DMV6GIC	PC	118707758
DMV6GIC	MW	334.3
DMV6GIC	FM	C19H10O4S
DMV6GIC	IC	InChI=1S/C19H10O4S/c20-13-8-4-7-11-15(13)18(23)19-12(17(11)22)9-14(24-19)16(21)10-5-2-1-3-6-10/h1-9,20H
DMV6GIC	CS	C1=CC=C(C=C1)C(=O)C2=CC3=C(S2)C(=O)C4=C(C3=O)C=CC=C4O
DMV6GIC	IK	FLMLYZNKLBTMFK-UHFFFAOYSA-N
DMV6GIC	IU	2-benzoyl-8-hydroxybenzo[f][1]benzothiole-4,9-dione

DMSZWAM	ID	DMSZWAM
DMSZWAM	DN	PMID26394986-Compound-52
DMSZWAM	HS	Patented
DMSZWAM	CP	BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DMSZWAM	DT	Small molecular drug

DMS6EDU	ID	DMS6EDU
DMS6EDU	DN	PMID26394986-Compound-53
DMS6EDU	HS	Patented
DMS6EDU	CP	BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DMS6EDU	DT	Small molecular drug
DMS6EDU	PC	25226944
DMS6EDU	MW	274.65
DMS6EDU	FM	C14H7ClO4
DMS6EDU	IC	InChI=1S/C14H7ClO4/c1-6(16)11-5-10-12(17)8-3-2-7(15)4-9(8)13(18)14(10)19-11/h2-5H,1H3
DMS6EDU	CS	CC(=O)C1=CC2=C(O1)C(=O)C3=C(C2=O)C=CC(=C3)Cl
DMS6EDU	IK	RVIUPSHRLLQFOH-UHFFFAOYSA-N
DMS6EDU	IU	2-acetyl-7-chlorobenzo[f][1]benzofuran-4,9-dione

DMY8FZA	ID	DMY8FZA
DMY8FZA	DN	PMID26394986-Compound-54
DMY8FZA	HS	Patented
DMY8FZA	CP	BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DMY8FZA	DT	Small molecular drug
DMY8FZA	PC	25226945
DMY8FZA	MW	258.2
DMY8FZA	FM	C14H7FO4
DMY8FZA	IC	InChI=1S/C14H7FO4/c1-6(16)11-5-10-12(17)8-3-2-7(15)4-9(8)13(18)14(10)19-11/h2-5H,1H3
DMY8FZA	CS	CC(=O)C1=CC2=C(O1)C(=O)C3=C(C2=O)C=CC(=C3)F
DMY8FZA	IK	RPCXZIRGAHYOKZ-UHFFFAOYSA-N
DMY8FZA	IU	2-acetyl-7-fluorobenzo[f][1]benzofuran-4,9-dione

DMPNJ4X	ID	DMPNJ4X
DMPNJ4X	DN	PMID26394986-Compound-56
DMPNJ4X	HS	Patented
DMPNJ4X	CP	THOMAS JEFFERSON UNIVERSITY
DMPNJ4X	DT	Small molecular drug

DMILUT8	ID	DMILUT8
DMILUT8	DN	PMID26394986-Compound-57
DMILUT8	HS	Patented
DMILUT8	CP	THOMAS JEFFERSON UNIVERSITY
DMILUT8	DT	Small molecular drug

DMNEGA0	ID	DMNEGA0
DMNEGA0	DN	PMID26394986-Compound-Figure16
DMNEGA0	HS	Patented
DMNEGA0	CP	OTSUKA PHARMACEUTICAL CO., LTD. SEKIGUCHI, Kazuo SUZUKI, Takashi OHBUCHI, Yutaka OKUNO, Mitsuhiro OHI, Naoto OHNISHI, Kenji MOTOYAMA, Masaaki YOSHIDA, Kenji KODAMA, Takeshi SUGIYAMA, Kazuhisa AKAMATSU, Seiji KIYONO, Kunihiko YANAGIHARA, Yasuo WATANABE, Takashi HAYASHI, Kazuhiko TANAKA, Hideo SUMIDA, Takumi
DMNEGA0	DT	Small molecular drug

DMEGBHP	ID	DMEGBHP
DMEGBHP	DN	PMID26394986-Compound-Figure17
DMEGBHP	HS	Patented
DMEGBHP	CP	Meiji Dairies Corporation
DMEGBHP	DT	Small molecular drug

DMNOJGW	ID	DMNOJGW
DMNOJGW	DN	PMID26413912-Compound-84
DMNOJGW	HS	Patented
DMNOJGW	CP	BIAL-Portela & Ca., S.A
DMNOJGW	DT	Small molecular drug
DMNOJGW	PC	91008342
DMNOJGW	MW	379.31
DMNOJGW	FM	C17H15F2N3O5
DMNOJGW	IC	InChI=1S/C17H15F2N3O5/c1-24-6-7-25-15-9-11(3-4-13(15)20)22-17(23)27-16(21-22)26-14-5-2-10(18)8-12(14)19/h2-5,8-9H,6-7,20H2,1H3
DMNOJGW	CS	COCCOC1=C(C=CC(=C1)N2C(=O)OC(=N2)OC3=C(C=C(C=C3)F)F)N
DMNOJGW	IK	AYJCMQZJZQQNKN-UHFFFAOYSA-N
DMNOJGW	IU	3-[4-amino-3-(2-methoxyethoxy)phenyl]-5-(2,4-difluorophenoxy)-1,3,4-oxadiazol-2-one

DM9V13U	ID	DM9V13U
DM9V13U	DN	PMID26560362-Compound-90
DM9V13U	HS	Patented
DM9V13U	DT	Small molecular drug
DM9V13U	PC	9948627
DM9V13U	MW	311.2
DM9V13U	FM	C14H12Cl2N2O2
DM9V13U	IC	InChI=1S/C14H12Cl2N2O2/c1-20-13-5-2-8(6-12(13)17)14(19)18-9-3-4-10(15)11(16)7-9/h2-7H,17H2,1H3,(H,18,19)
DM9V13U	CS	COC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)Cl)N
DM9V13U	IK	ZKXFJDCWWSKUHN-UHFFFAOYSA-N
DM9V13U	IU	3-amino-N-(3,4-dichlorophenyl)-4-methoxybenzamide

DMSI7F2	ID	DMSI7F2
DMSI7F2	DN	PMID26560530-Compound-1
DMSI7F2	HS	Patented
DMSI7F2	CP	Syntex, Inc
DMSI7F2	DT	Small molecular drug

DMZ5UST	ID	DMZ5UST
DMZ5UST	DN	PMID26560530-Compound-11
DMZ5UST	HS	Patented
DMZ5UST	CP	N Zyme Biotech GmbH
DMZ5UST	DT	Small molecular drug

DMA8JGP	ID	DMA8JGP
DMA8JGP	DN	PMID26560530-Compound-12
DMA8JGP	HS	Patented
DMA8JGP	CP	N Zyme Biotech GmbH
DMA8JGP	DT	Small molecular drug

DMKF26Z	ID	DMKF26Z
DMKF26Z	DN	PMID26560530-Compound-13
DMKF26Z	HS	Patented
DMKF26Z	CP	Apotex Inc
DMKF26Z	DT	Small molecular drug
DMKF26Z	PC	11202494
DMKF26Z	MW	482.5
DMKF26Z	FM	C18H22N6O6S2
DMKF26Z	IC	InChI=1S/C18H22N6O6S2/c25-16(26)13-22(17-21-31-18-19-10-12-23(17)18)11-6-2-1-5-9-20-32(29,30)15-8-4-3-7-14(15)24(27)28/h3-4,7-8,10,12,20H,1-2,5-6,9,11,13H2,(H,25,26)
DMKF26Z	CS	C1=CC=C(C(=C1)[N+](=O)[O-])S(=O)(=O)NCCCCCCN(CC(=O)O)C2=NSC3=NC=CN23
DMKF26Z	IK	NCXBWLQKBKSTHD-UHFFFAOYSA-N
DMKF26Z	IU	2-[imidazo[1,2-d][1,2,4]thiadiazol-3-yl-[6-[(2-nitrophenyl)sulfonylamino]hexyl]amino]acetic acid

DM52MIK	ID	DM52MIK
DM52MIK	DN	PMID26560530-Compound-14
DM52MIK	HS	Patented
DM52MIK	CP	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. STEIN, Ross, L. CASE, April YEH, Li-An CUNY, Greg DUVAL, Eric
DM52MIK	DT	Small molecular drug
DM52MIK	PC	1150683
DM52MIK	MW	408.5
DM52MIK	FM	C20H16N4O2S2
DM52MIK	IC	InChI=1S/C20H16N4O2S2/c21-23-16(25)12-28-20-22-18-17(15(11-27-18)13-7-3-1-4-8-13)19(26)24(20)14-9-5-2-6-10-14/h1-11H,12,21H2,(H,23,25)
DM52MIK	CS	C1=CC=C(C=C1)C2=CSC3=C2C(=O)N(C(=N3)SCC(=O)NN)C4=CC=CC=C4
DM52MIK	IK	WLBUICQBNZXIDJ-UHFFFAOYSA-N
DM52MIK	IU	2-(4-oxo-3,5-diphenylthieno[2,3-d]pyrimidin-2-yl)sulfanylacetohydrazide

DM1ZSEI	ID	DM1ZSEI
DM1ZSEI	DN	PMID26560530-Compound-15
DM1ZSEI	HS	Patented
DM1ZSEI	CP	ALVINE PHARMACEUTICALS, INC. PHARMIX CORPORATION GRIFFIN, John LANZA, Guido BOARDMAN, Paul SPENCER, Andrew
DM1ZSEI	DT	Small molecular drug
DM1ZSEI	PC	3604365
DM1ZSEI	MW	306.27
DM1ZSEI	FM	C17H10N2O4
DM1ZSEI	IC	InChI=1S/C17H10N2O4/c20-14-10-6-8(1-3-12(10)18-16(14)22)5-9-2-4-13-11(7-9)15(21)17(23)19-13/h1-4,6-7H,5H2,(H,18,20,22)(H,19,21,23)
DM1ZSEI	CS	C1=CC2=C(C=C1CC3=CC4=C(C=C3)NC(=O)C4=O)C(=O)C(=O)N2
DM1ZSEI	IK	ZWPNSXUXJWRFIZ-UHFFFAOYSA-N
DM1ZSEI	IU	5-[(2,3-dioxo-1H-indol-5-yl)methyl]-1H-indole-2,3-dione

DM8UI4Z	ID	DM8UI4Z
DM8UI4Z	DN	PMID26560530-Compound-16
DM8UI4Z	HS	Patented
DM8UI4Z	CP	ALVINE PHARMACEUTICALS, INC. PHARMIX CORPORATION GRIFFIN, John LANZA, Guido BOARDMAN, Paul SPENCER, Andrew
DM8UI4Z	DT	Small molecular drug

DMITU83	ID	DMITU83
DMITU83	DN	PMID26560530-Compound-17
DMITU83	HS	Patented
DMITU83	CP	NATIONAL CANCER CENTER KIM, Soo Youl
DMITU83	DT	Small molecular drug

DMK39S5	ID	DMK39S5
DMK39S5	DN	PMID26560530-Compound-18
DMK39S5	HS	Patented
DMK39S5	CP	Stanford University
DMK39S5	DT	Small molecular drug
DMK39S5	PC	644315
DMK39S5	MW	499.4
DMK39S5	FM	C23H23BrN4O4
DMK39S5	IC	InChI=1S/C23H23BrN4O4/c24-21-11-17(32-28-21)13-26-22(29)20(10-16-12-25-19-9-5-4-8-18(16)19)27-23(30)31-14-15-6-2-1-3-7-15/h1-9,12,17,20,25H,10-11,13-14H2,(H,26,29)(H,27,30)/t17?,20-/m0/s1
DMK39S5	CS	C1C(ON=C1Br)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)OCC4=CC=CC=C4
DMK39S5	IK	MAQVWGRATZCTBU-OZBJMMHXSA-N
DMK39S5	IU	benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamate
DMK39S5	CA	CAS 744198-17-2

DMC7AXQ	ID	DMC7AXQ
DMC7AXQ	DN	PMID26560530-Compound-2
DMC7AXQ	HS	Patented
DMC7AXQ	CP	Syntex, Inc
DMC7AXQ	DT	Small molecular drug

DMDS2CU	ID	DMDS2CU
DMDS2CU	DN	PMID26560530-Compound-23
DMDS2CU	HS	Patented
DMDS2CU	CP	National Cancer Center (S. Korea)
DMDS2CU	DT	Small molecular drug
DMDS2CU	PC	5281767
DMDS2CU	MW	368.4
DMDS2CU	FM	C21H20O6
DMDS2CU	IC	InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13-
DMDS2CU	CS	COC1=C(C=CC(=C1)/C=C/C(=C/C(=O)/C=C/C2=CC(=C(C=C2)O)OC)/O)O
DMDS2CU	IK	ZIUSSTSXXLLKKK-KOBPDPAPSA-N
DMDS2CU	IU	(1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one

DMWCM2I	ID	DMWCM2I
DMWCM2I	DN	PMID26560530-Compound-24
DMWCM2I	HS	Patented
DMWCM2I	CP	NATIONAL CANCER CENTER       KIM, Soo Youl     LEE, Chang Hoon
DMWCM2I	DT	Small molecular drug
DMWCM2I	PC	4534
DMWCM2I	MW	302.4
DMWCM2I	FM	C18H22O4
DMWCM2I	IC	InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3
DMWCM2I	CS	CC(CC1=CC(=C(C=C1)O)O)C(C)CC2=CC(=C(C=C2)O)O
DMWCM2I	IK	HCZKYJDFEPMADG-UHFFFAOYSA-N
DMWCM2I	IU	4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
DMWCM2I	CA	CAS 500-38-9
DMWCM2I	CB	CHEBI:7625

DMZ43OM	ID	DMZ43OM
DMZ43OM	DN	PMID26560530-Compound-25
DMZ43OM	HS	Patented
DMZ43OM	CP	National Cancer Center (S. Korea)
DMZ43OM	DT	Small molecular drug
DMZ43OM	PC	2194
DMZ43OM	MW	240.4
DMZ43OM	FM	C10H8OS3
DMZ43OM	IC	InChI=1S/C10H8OS3/c1-11-8-4-2-7(3-5-8)9-6-10(12)14-13-9/h2-6H,1H3
DMZ43OM	CS	COC1=CC=C(C=C1)C2=CC(=S)SS2
DMZ43OM	IK	KYLIZBIRMBGUOP-UHFFFAOYSA-N
DMZ43OM	IU	5-(4-methoxyphenyl)dithiole-3-thione
DMZ43OM	CA	CAS 532-11-6
DMZ43OM	CB	CHEBI:31221

DMVEQ2P	ID	DMVEQ2P
DMVEQ2P	DN	PMID26560530-Compound-26
DMVEQ2P	HS	Patented
DMVEQ2P	CP	National Cancer Center (S. Korea)
DMVEQ2P	DT	Small molecular drug
DMVEQ2P	PC	65064
DMVEQ2P	MW	458.4
DMVEQ2P	FM	C22H18O11
DMVEQ2P	IC	InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
DMVEQ2P	CS	C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMVEQ2P	IK	WMBWREPUVVBILR-WIYYLYMNSA-N
DMVEQ2P	IU	[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMVEQ2P	CA	CAS 989-51-5
DMVEQ2P	CB	CHEBI:4806

DM8WP3D	ID	DM8WP3D
DM8WP3D	DN	PMID26560530-Compound-27
DM8WP3D	HS	Patented
DM8WP3D	CP	NATIONAL CANCER CENTER       KIM, Soo Youl     LEE, Chang Hoon
DM8WP3D	DT	Small molecular drug

DM92OT0	ID	DM92OT0
DM92OT0	DN	PMID26560530-Compound-3
DM92OT0	HS	Patented
DM92OT0	CP	Merck & Co., Inc
DM92OT0	DT	Small molecular drug

DM74GUB	ID	DM74GUB
DM74GUB	DN	PMID26560530-Compound-31
DM74GUB	HS	Patented
DM74GUB	CP	Aston University
DM74GUB	DT	Small molecular drug
DM74GUB	PC	11433028
DM74GUB	MW	487.6
DM74GUB	FM	C25H31N2O6S+
DM74GUB	IC	InChI=1S/C25H30N2O6S/c1-34(2)17-20(28)13-14-21(24(30)31)26-23(29)22(15-18-9-5-3-6-10-18)27-25(32)33-16-19-11-7-4-8-12-19/h3-12,21-22H,13-17H2,1-2H3,(H2-,26,27,29,30,31,32)/p+1/t21-,22-/m0/s1
DM74GUB	CS	C[S+](C)CC(=O)CC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2
DM74GUB	IK	MQKDBWQFOOQINN-VXKWHMMOSA-O
DM74GUB	IU	[(5S)-5-carboxy-2-oxo-5-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentyl]-dimethylsulfanium

DM2QWXF	ID	DM2QWXF
DM2QWXF	DN	PMID26560530-Compound-32
DM2QWXF	HS	Patented
DM2QWXF	CP	Aston University
DM2QWXF	DT	Small molecular drug
DM2QWXF	PC	16049202
DM2QWXF	MW	437.5
DM2QWXF	FM	C21H29N2O6S+
DM2QWXF	IC	InChI=1S/C21H28N2O6S/c1-30(2)14-16(24)10-11-17(20(26)27)22-19(25)18-9-6-12-23(18)21(28)29-13-15-7-4-3-5-8-15/h3-5,7-8,17-18H,6,9-14H2,1-2H3,(H-,22,25,26,27)/p+1/t17-,18-/m0/s1
DM2QWXF	CS	C[S+](C)CC(=O)CC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)OCC2=CC=CC=C2
DM2QWXF	IK	SKEWALVSEUJDCH-ROUUACIJSA-O
DM2QWXF	IU	[(5S)-5-carboxy-2-oxo-5-[[(2S)-1-phenylmethoxycarbonylpyrrolidine-2-carbonyl]amino]pentyl]-dimethylsulfanium

DMUL84D	ID	DMUL84D
DMUL84D	DN	PMID26560530-Compound-33
DMUL84D	HS	Patented
DMUL84D	CP	National Cancer Center (S. Korea)
DMUL84D	DT	Small molecular drug

DMLGZPO	ID	DMLGZPO
DMLGZPO	DN	PMID26560530-Compound-34
DMLGZPO	HS	Patented
DMLGZPO	CP	National Cancer Center (S. Korea)
DMLGZPO	DT	Small molecular drug
DMLGZPO	PC	47318
DMLGZPO	MW	226.3
DMLGZPO	FM	C8H6N2S3
DMLGZPO	IC	InChI=1S/C8H6N2S3/c1-5-7(12-13-8(5)11)6-4-9-2-3-10-6/h2-4H,1H3
DMLGZPO	CS	CC1=C(SSC1=S)C2=NC=CN=C2
DMLGZPO	IK	CKNAQFVBEHDJQV-UHFFFAOYSA-N
DMLGZPO	IU	4-methyl-5-pyrazin-2-yldithiole-3-thione
DMLGZPO	CA	CAS 64224-21-1
DMLGZPO	CB	CHEBI:77319

DMO36RL	ID	DMO36RL
DMO36RL	DN	PMID26560530-Compound-35
DMO36RL	HS	Patented
DMO36RL	CP	University of Texas
DMO36RL	DT	Small molecular drug
DMO36RL	PC	5281847
DMO36RL	MW	516.5
DMO36RL	FM	C30H28O8
DMO36RL	IC	InChI=1S/C30H28O8/c1-15-24(33)19(27(36)22(16(2)31)25(15)34)14-20-26(35)18-12-13-30(3,4)38-29(18)23(28(20)37)21(32)11-10-17-8-6-5-7-9-17/h5-13,33-37H,14H2,1-4H3/b11-10+
DMO36RL	CS	CC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C(=C3C(=C2O)C=CC(O3)(C)C)C(=O)/C=C/C4=CC=CC=C4)O)O
DMO36RL	IK	DEZFNHCVIZBHBI-ZHACJKMWSA-N
DMO36RL	IU	(E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one
DMO36RL	CA	CAS 82-08-6
DMO36RL	CB	CHEBI:8899

DMEZLBQ	ID	DMEZLBQ
DMEZLBQ	DN	PMID26560530-Compound-4
DMEZLBQ	HS	Patented
DMEZLBQ	CP	Merck & Co., Inc
DMEZLBQ	DT	Small molecular drug

DMTOJCG	ID	DMTOJCG
DMTOJCG	DN	PMID26560530-Compound-46
DMTOJCG	HS	Patented
DMTOJCG	CP	Leland Stanford Junior University
DMTOJCG	DT	Small molecular drug

DMWC1IY	ID	DMWC1IY
DMWC1IY	DN	PMID26560530-Compound-47
DMWC1IY	HS	Patented
DMWC1IY	CP	Leland Stanford Junior University
DMWC1IY	DT	Small molecular drug

DMXV0CK	ID	DMXV0CK
DMXV0CK	DN	PMID26560530-Compound-48
DMXV0CK	HS	Patented
DMXV0CK	CP	Leland Stanford Junior University
DMXV0CK	DT	Small molecular drug

DMST6C2	ID	DMST6C2
DMST6C2	DN	PMID26560530-Compound-49
DMST6C2	HS	Patented
DMST6C2	CP	University of Texas
DMST6C2	DT	Small molecular drug
DMST6C2	PC	2810536
DMST6C2	MW	420.8
DMST6C2	FM	C17H14ClFN6O2S
DMST6C2	IC	InChI=1S/C17H14ClFN6O2S/c1-10(26)20-11-3-2-4-13(7-11)25-23-17(22-24-25)28-9-16(27)21-12-5-6-15(19)14(18)8-12/h2-8H,9H2,1H3,(H,20,26)(H,21,27)
DMST6C2	CS	CC(=O)NC1=CC(=CC=C1)N2N=C(N=N2)SCC(=O)NC3=CC(=C(C=C3)F)Cl
DMST6C2	IK	NIWRZNPQACMKRY-UHFFFAOYSA-N
DMST6C2	IU	2-[2-(3-acetamidophenyl)tetrazol-5-yl]sulfanyl-N-(3-chloro-4-fluorophenyl)acetamide

DM6G2WJ	ID	DM6G2WJ
DM6G2WJ	DN	PMID26560530-Compound-5
DM6G2WJ	HS	Patented
DM6G2WJ	CP	Merck & Co., Inc
DM6G2WJ	DT	Small molecular drug

DMHZ8N1	ID	DMHZ8N1
DMHZ8N1	DN	PMID26560530-Compound-50
DMHZ8N1	HS	Patented
DMHZ8N1	CP	University of Texas
DMHZ8N1	DT	Small molecular drug
DMHZ8N1	PC	2810543
DMHZ8N1	MW	420.4
DMHZ8N1	FM	C20H16N6O3S
DMHZ8N1	IC	InChI=1S/C20H16N6O3S/c1-13(27)21-15-8-5-9-16(10-15)26-23-20(22-25-26)30-12-18(28)19-11-17(24-29-19)14-6-3-2-4-7-14/h2-11H,12H2,1H3,(H,21,27)
DMHZ8N1	CS	CC(=O)NC1=CC(=CC=C1)N2N=C(N=N2)SCC(=O)C3=CC(=NO3)C4=CC=CC=C4
DMHZ8N1	IK	ZSSIYCOJZBCFEO-UHFFFAOYSA-N
DMHZ8N1	IU	N-[3-[5-[2-oxo-2-(3-phenyl-1,2-oxazol-5-yl)ethyl]sulfanyltetrazol-2-yl]phenyl]acetamide

DM2X4R0	ID	DM2X4R0
DM2X4R0	DN	PMID26560530-Compound-54
DM2X4R0	HS	Patented
DM2X4R0	CP	Japan Science and Technology Agency
DM2X4R0	DT	Small molecular drug
DM2X4R0	PC	46231396
DM2X4R0	MW	225.28
DM2X4R0	FM	C12H19NO3
DM2X4R0	IC	InChI=1S/C12H19NO3/c1-10(2)13(7-8-14)6-5-11(15)12-4-3-9-16-12/h3-4,9-10,14H,5-8H2,1-2H3
DM2X4R0	CS	CC(C)N(CCC(=O)C1=CC=CO1)CCO
DM2X4R0	IK	DCZMNFQBOIDRNH-UHFFFAOYSA-N
DM2X4R0	IU	1-(furan-2-yl)-3-[2-hydroxyethyl(propan-2-yl)amino]propan-1-one

DMMHL2C	ID	DMMHL2C
DMMHL2C	DN	PMID26560530-Compound-6
DMMHL2C	HS	Patented
DMMHL2C	CP	Merck & Co., Inc
DMMHL2C	DT	Small molecular drug

DMRAXD1	ID	DMRAXD1
DMRAXD1	DN	PMID26560530-Compound-7
DMRAXD1	HS	Patented
DMRAXD1	CP	Merck & Co., Inc
DMRAXD1	DT	Small molecular drug
DMRAXD1	PC	6193963
DMRAXD1	MW	188.18
DMRAXD1	FM	C10H8N2O2
DMRAXD1	IC	InChI=1S/C10H8N2O2/c13-10(14)6-5-9-11-7-3-1-2-4-8(7)12-9/h1-6H,(H,11,12)(H,13,14)/b6-5+
DMRAXD1	CS	C1=CC=C2C(=C1)NC(=N2)/C=C/C(=O)O
DMRAXD1	IK	FEGNPBYZFFAMCR-AATRIKPKSA-N
DMRAXD1	IU	(E)-3-(1H-benzimidazol-2-yl)prop-2-enoic acid

DMN6TG7	ID	DMN6TG7
DMN6TG7	DN	PMID26560530-Compound-8
DMN6TG7	HS	Patented
DMN6TG7	CP	University of Texas
DMN6TG7	DT	Small molecular drug
DMN6TG7	PC	4247
DMN6TG7	MW	335.5
DMN6TG7	FM	C17H25N3O2S
DMN6TG7	IC	InChI=1S/C17H25N3O2S/c1-20(2)16-10-6-9-15-14(16)8-7-11-17(15)23(21,22)19-13-5-3-4-12-18/h6-11,19H,3-5,12-13,18H2,1-2H3
DMN6TG7	CS	CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCCCN
DMN6TG7	IK	MLEBFEHOJICQQS-UHFFFAOYSA-N
DMN6TG7	IU	N-(5-aminopentyl)-5-(dimethylamino)naphthalene-1-sulfonamide
DMN6TG7	CA	CAS 10121-91-2
DMN6TG7	CB	CHEBI:52007

DMBYTSI	ID	DMBYTSI
DMBYTSI	DN	PMID26609882-Compound-34
DMBYTSI	HS	Patented
DMBYTSI	CP	ARENA PHARMACEUTICALS, INC. TEEGARDEN, Bradley JAYAKUMAR, Honnappa LI, Hongmei STRAH-PLEYNET, Sonja DOSA, Peter, Ian
DMBYTSI	DT	Small molecular drug

DM8OLYQ	ID	DM8OLYQ
DM8OLYQ	DN	PMID26609882-Compound-35
DM8OLYQ	HS	Patented
DM8OLYQ	CP	ARENA PHARMACEUTICALS, INC. TEEGARDEN, Bradley JAYAKUMAR, Honnappa LI, Hongmei STRAH-PLEYNET, Sonja DOSA, Peter, Ian
DM8OLYQ	DT	Small molecular drug

DMFT3RM	ID	DMFT3RM
DMFT3RM	DN	PMID26609882-Compound-36
DMFT3RM	HS	Patented
DMFT3RM	CP	ARENA PHARMACEUTICALS, INC. SELVEY, Lee, Alani CARLOS, Marlon V. MAFFUID, Paul SHAN, Yun BETTS, William, L., III GIVEN, Deam, Windate, III HART, Ryan, M. SHAO, Zezhi, Jesse
DMFT3RM	DT	Small molecular drug
DMFT3RM	PC	11683556
DMFT3RM	MW	437.2
DMFT3RM	FM	C18H15BrF2N4O2
DMFT3RM	IC	InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)
DMFT3RM	CS	CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)F)F)OC
DMFT3RM	IK	COSPVUFTLGQDQL-UHFFFAOYSA-N
DMFT3RM	IU	1-[3-(4-bromo-2-methylpyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
DMFT3RM	CA	CAS 839713-36-9

DMD3T1Q	ID	DMD3T1Q
DMD3T1Q	DN	PMID26609882-Compound-58
DMD3T1Q	HS	Patented
DMD3T1Q	CP	LUNDBECK & CO AS H [DK]
DMD3T1Q	DT	Small molecular drug

DM6C45G	ID	DM6C45G
DM6C45G	DN	PMID26609882-Compound-83
DM6C45G	HS	Patented
DM6C45G	CP	Apotex Pharmachem IncTeva Pharmaceutical Industries LtdSynthon Ip IncU & I Pharmaceuticals, LtdGeneva Pharmaceuticals, IncEli Lilly and CompanLilly Industries LimitedKRKA, Tovarna Zdravil, D.D
DM6C45G	DT	Small molecular drug

DMOJVK6	ID	DMOJVK6
DMOJVK6	DN	PMID26651364-Compound-105
DMOJVK6	HS	Patented
DMOJVK6	CP	WASHINGTON UNIVERSITY
DMOJVK6	DT	Carbohydrates
DMOJVK6	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMQZJDF	ID	DMQZJDF
DMQZJDF	DN	PMID26651364-Compound-106
DMQZJDF	HS	Patented
DMQZJDF	CP	WASHINGTON UNIVERSITY
DMQZJDF	DT	Carbohydrates
DMQZJDF	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMZ1WL	ID	DMMZ1WL
DMMZ1WL	DN	PMID26651364-Compound-107
DMMZ1WL	HS	Patented
DMMZ1WL	CP	WASHINGTON UNIVERSITY
DMMZ1WL	DT	Carbohydrates
DMMZ1WL	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMA7D3K	ID	DMA7D3K
DMA7D3K	DN	PMID26651364-Compound-108
DMA7D3K	HS	Patented
DMA7D3K	CP	UNIVERSITY OF BASEL ERNST, Beat
DMA7D3K	DT	Carbohydrates
DMA7D3K	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM01IWV	ID	DM01IWV
DM01IWV	DN	PMID26651364-Compound-109
DM01IWV	HS	Patented
DM01IWV	CP	UNIVERSITY OF BASEL ERNST, Beat
DM01IWV	DT	Carbohydrates
DM01IWV	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMTPBNY	ID	DMTPBNY
DMTPBNY	DN	PMID26651364-Compound-10a
DMTPBNY	HS	Patented
DMTPBNY	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMTPBNY	DT	Carbohydrates
DMTPBNY	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM16ANH	ID	DM16ANH
DM16ANH	DN	PMID26651364-Compound-10b
DM16ANH	HS	Patented
DM16ANH	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM16ANH	DT	Carbohydrates
DM16ANH	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMCRNWA	ID	DMCRNWA
DMCRNWA	DN	PMID26651364-Compound-10c
DMCRNWA	HS	Patented
DMCRNWA	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMCRNWA	DT	Carbohydrates
DMCRNWA	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMGIV3C	ID	DMGIV3C
DMGIV3C	DN	PMID26651364-Compound-10d
DMGIV3C	HS	Patented
DMGIV3C	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMGIV3C	DT	Carbohydrates
DMGIV3C	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMPA3IX	ID	DMPA3IX
DMPA3IX	DN	PMID26651364-Compound-110
DMPA3IX	HS	Patented
DMPA3IX	CP	UNIVERSITY OF BASEL ERNST, Beat
DMPA3IX	DT	Carbohydrates
DMPA3IX	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMY9R58	ID	DMY9R58
DMY9R58	DN	PMID26651364-Compound-111
DMY9R58	HS	Patented
DMY9R58	CP	UNIVERSITY OF BASEL ERNST, Beat
DMY9R58	DT	Carbohydrates
DMY9R58	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM1LIRP	ID	DM1LIRP
DM1LIRP	DN	PMID26651364-Compound-112
DM1LIRP	HS	Patented
DM1LIRP	CP	UNIVERSITY OF BASEL ERNST, Beat
DM1LIRP	DT	Carbohydrates
DM1LIRP	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM6OQKM	ID	DM6OQKM
DM6OQKM	DN	PMID26651364-Compound-113
DM6OQKM	HS	Patented
DM6OQKM	CP	UNIVERSITY OF BASEL ERNST, Beat
DM6OQKM	DT	Carbohydrates
DM6OQKM	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM5GHJA	ID	DM5GHJA
DM5GHJA	DN	PMID26651364-Compound-114
DM5GHJA	HS	Patented
DM5GHJA	CP	UNIVERSITY OF BASEL ERNST, Beat
DM5GHJA	DT	Carbohydrates
DM5GHJA	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMHIA26	ID	DMHIA26
DMHIA26	DN	PMID26651364-Compound-115
DMHIA26	HS	Patented
DMHIA26	CP	UNIVERSITY OF BASEL ERNST, Beat
DMHIA26	DT	Carbohydrates
DMHIA26	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMJ3201	ID	DMJ3201
DMJ3201	DN	PMID26651364-Compound-116
DMJ3201	HS	Patented
DMJ3201	CP	UNIVERSITY OF BASEL ERNST, Beat
DMJ3201	DT	Carbohydrates
DMJ3201	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM6LXHS	ID	DM6LXHS
DM6LXHS	DN	PMID26651364-Compound-117a
DM6LXHS	HS	Patented
DM6LXHS	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM6LXHS	DT	Carbohydrates
DM6LXHS	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMUQSM1	ID	DMUQSM1
DMUQSM1	DN	PMID26651364-Compound-117b
DMUQSM1	HS	Patented
DMUQSM1	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMUQSM1	DT	Carbohydrates
DMUQSM1	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM6ZRV4	ID	DM6ZRV4
DM6ZRV4	DN	PMID26651364-Compound-118
DM6ZRV4	HS	Patented
DM6ZRV4	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM6ZRV4	DT	Carbohydrates
DM6ZRV4	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMONAZI	ID	DMONAZI
DMONAZI	DN	PMID26651364-Compound-119
DMONAZI	HS	Patented
DMONAZI	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMONAZI	DT	Carbohydrates
DMONAZI	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMGBFK3	ID	DMGBFK3
DMGBFK3	DN	PMID26651364-Compound-11b
DMGBFK3	HS	Patented
DMGBFK3	CP	CENTRE NAT RECH SCIENT [FRUNIV D AUVERGNE [FRUNIV LILLE SCIENCES TECH [FRUNIV NANTES [FRINST NAT SANTE RECH MED [FR]
DMGBFK3	DT	Carbohydrates
DMGBFK3	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM76WBP	ID	DM76WBP
DM76WBP	DN	PMID26651364-Compound-11c
DM76WBP	HS	Patented
DM76WBP	CP	CENTRE NAT RECH SCIENT [FRUNIV D AUVERGNE [FRUNIV LILLE SCIENCES TECH [FRUNIV NANTES [FRINST NAT SANTE RECH MED [FR]
DM76WBP	DT	Carbohydrates
DM76WBP	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMZTBEQ	ID	DMZTBEQ
DMZTBEQ	DN	PMID26651364-Compound-120
DMZTBEQ	HS	Patented
DMZTBEQ	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMZTBEQ	DT	Carbohydrates
DMZTBEQ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM4ZG0Q	ID	DM4ZG0Q
DM4ZG0Q	DN	PMID26651364-Compound-121
DM4ZG0Q	HS	Patented
DM4ZG0Q	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM4ZG0Q	DT	Carbohydrates
DM4ZG0Q	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMVFTIL	ID	DMVFTIL
DMVFTIL	DN	PMID26651364-Compound-122
DMVFTIL	HS	Patented
DMVFTIL	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMVFTIL	DT	Carbohydrates
DMVFTIL	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMR0E5W	ID	DMR0E5W
DMR0E5W	DN	PMID26651364-Compound-123
DMR0E5W	HS	Patented
DMR0E5W	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMR0E5W	DT	Carbohydrates
DMR0E5W	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM6VER5	ID	DM6VER5
DM6VER5	DN	PMID26651364-Compound-124
DM6VER5	HS	Patented
DM6VER5	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM6VER5	DT	Carbohydrates
DM6VER5	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMINUDB	ID	DMINUDB
DMINUDB	DN	PMID26651364-Compound-125
DMINUDB	HS	Patented
DMINUDB	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMINUDB	DT	Carbohydrates
DMINUDB	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMSTKH6	ID	DMSTKH6
DMSTKH6	DN	PMID26651364-Compound-126a
DMSTKH6	HS	Patented
DMSTKH6	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMSTKH6	DT	Carbohydrates
DMSTKH6	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM2I1QZ	ID	DM2I1QZ
DM2I1QZ	DN	PMID26651364-Compound-126b
DM2I1QZ	HS	Patented
DM2I1QZ	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM2I1QZ	DT	Carbohydrates
DM2I1QZ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM80PI1	ID	DM80PI1
DM80PI1	DN	PMID26651364-Compound-126c
DM80PI1	HS	Patented
DM80PI1	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM80PI1	DT	Carbohydrates
DM80PI1	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMEN8RA	ID	DMEN8RA
DMEN8RA	DN	PMID26651364-Compound-127
DMEN8RA	HS	Patented
DMEN8RA	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMEN8RA	DT	Carbohydrates
DMEN8RA	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM4W0BX	ID	DM4W0BX
DM4W0BX	DN	PMID26651364-Compound-128
DM4W0BX	HS	Patented
DM4W0BX	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM4W0BX	DT	Carbohydrates
DM4W0BX	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMY0HP1	ID	DMY0HP1
DMY0HP1	DN	PMID26651364-Compound-4
DMY0HP1	HS	Patented
DMY0HP1	CP	THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMY0HP1	DT	Carbohydrates
DMY0HP1	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMLBZGO	ID	DMLBZGO
DMLBZGO	DN	PMID26651364-Compound-45
DMLBZGO	HS	Patented
DMLBZGO	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMLBZGO	DT	Carbohydrates
DMLBZGO	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMQFDU8	ID	DMQFDU8
DMQFDU8	DN	PMID26651364-Compound-46
DMQFDU8	HS	Patented
DMQFDU8	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMQFDU8	DT	Carbohydrates
DMQFDU8	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM4S5PB	ID	DM4S5PB
DM4S5PB	DN	PMID26651364-Compound-47
DM4S5PB	HS	Patented
DM4S5PB	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM4S5PB	DT	Carbohydrates
DM4S5PB	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMHXFGU	ID	DMHXFGU
DMHXFGU	DN	PMID26651364-Compound-48
DMHXFGU	HS	Patented
DMHXFGU	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMHXFGU	DT	Carbohydrates
DMHXFGU	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMV5A9	ID	DMMV5A9
DMMV5A9	DN	PMID26651364-Compound-49
DMMV5A9	HS	Patented
DMMV5A9	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMMV5A9	DT	Carbohydrates
DMMV5A9	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMH7XL3	ID	DMH7XL3
DMH7XL3	DN	PMID26651364-Compound-5
DMH7XL3	HS	Patented
DMH7XL3	CP	WASHINGTON UNIVERSITY
DMH7XL3	DT	Carbohydrates
DMH7XL3	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM6GFYR	ID	DM6GFYR
DM6GFYR	DN	PMID26651364-Compound-50
DM6GFYR	HS	Patented
DM6GFYR	CP	UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM6GFYR	DT	Carbohydrates
DM6GFYR	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM01GVE	ID	DM01GVE
DM01GVE	DN	PMID26651364-Compound-5a
DM01GVE	HS	Patented
DM01GVE	CP	WASHINGTON UNIVERSITY
DM01GVE	DT	Carbohydrates
DM01GVE	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMLHJ1E	ID	DMLHJ1E
DMLHJ1E	DN	PMID26651364-Compound-5b
DMLHJ1E	HS	Patented
DMLHJ1E	CP	WASHINGTON UNIVERSITY
DMLHJ1E	DT	Carbohydrates
DMLHJ1E	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMDQTA2	ID	DMDQTA2
DMDQTA2	DN	PMID26651364-Compound-5c
DMDQTA2	HS	Patented
DMDQTA2	CP	WASHINGTON UNIVERSITY
DMDQTA2	DT	Carbohydrates
DMDQTA2	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMF6Z5I	ID	DMF6Z5I
DMF6Z5I	DN	PMID26651364-Compound-5d
DMF6Z5I	HS	Patented
DMF6Z5I	CP	WASHINGTON UNIVERSITY
DMF6Z5I	DT	Carbohydrates
DMF6Z5I	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM9TJR5	ID	DM9TJR5
DM9TJR5	DN	PMID26651364-Compound-5e
DM9TJR5	HS	Patented
DM9TJR5	CP	WASHINGTON UNIVERSITY
DM9TJR5	DT	Carbohydrates
DM9TJR5	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMAZIY6	ID	DMAZIY6
DMAZIY6	DN	PMID26651364-Compound-5f
DMAZIY6	HS	Patented
DMAZIY6	CP	WASHINGTON UNIVERSITY
DMAZIY6	DT	Carbohydrates
DMAZIY6	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMSW0HB	ID	DMSW0HB
DMSW0HB	DN	PMID26651364-Compound-5g
DMSW0HB	HS	Patented
DMSW0HB	CP	WASHINGTON UNIVERSITY
DMSW0HB	DT	Carbohydrates
DMSW0HB	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM8HAJ3	ID	DM8HAJ3
DM8HAJ3	DN	PMID26651364-Compound-6a
DM8HAJ3	HS	Patented
DM8HAJ3	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM8HAJ3	DT	Carbohydrates
DM8HAJ3	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMBINOJ	ID	DMBINOJ
DMBINOJ	DN	PMID26651364-Compound-6b
DMBINOJ	HS	Patented
DMBINOJ	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMBINOJ	DT	Carbohydrates
DMBINOJ	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMPF86L	ID	DMPF86L
DMPF86L	DN	PMID26651364-Compound-6c
DMPF86L	HS	Patented
DMPF86L	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMPF86L	DT	Carbohydrates
DMPF86L	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM9J57W	ID	DM9J57W
DM9J57W	DN	PMID26651364-Compound-6d
DM9J57W	HS	Patented
DM9J57W	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM9J57W	DT	Carbohydrates
DM9J57W	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM4LF0X	ID	DM4LF0X
DM4LF0X	DN	PMID26651364-Compound-6e
DM4LF0X	HS	Patented
DM4LF0X	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM4LF0X	DT	Carbohydrates
DM4LF0X	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMQMBY9	ID	DMQMBY9
DMQMBY9	DN	PMID26651364-Compound-7a
DMQMBY9	HS	Patented
DMQMBY9	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMQMBY9	DT	Carbohydrates
DMQMBY9	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM3LCIM	ID	DM3LCIM
DM3LCIM	DN	PMID26651364-Compound-7b
DM3LCIM	HS	Patented
DM3LCIM	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM3LCIM	DT	Carbohydrates
DM3LCIM	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMGCUJB	ID	DMGCUJB
DMGCUJB	DN	PMID26651364-Compound-7c
DMGCUJB	HS	Patented
DMGCUJB	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMGCUJB	DT	Carbohydrates
DMGCUJB	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM89VQT	ID	DM89VQT
DM89VQT	DN	PMID26651364-Compound-7d
DM89VQT	HS	Patented
DM89VQT	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM89VQT	DT	Carbohydrates
DM89VQT	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM2SZ0B	ID	DM2SZ0B
DM2SZ0B	DN	PMID26651364-Compound-7e
DM2SZ0B	HS	Patented
DM2SZ0B	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM2SZ0B	DT	Carbohydrates
DM2SZ0B	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM1M3WF	ID	DM1M3WF
DM1M3WF	DN	PMID26651364-Compound-8a
DM1M3WF	HS	Patented
DM1M3WF	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM1M3WF	DT	Carbohydrates
DM1M3WF	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMYVU36	ID	DMYVU36
DMYVU36	DN	PMID26651364-Compound-8b
DMYVU36	HS	Patented
DMYVU36	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMYVU36	DT	Carbohydrates
DMYVU36	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DME7UNT	ID	DME7UNT
DME7UNT	DN	PMID26651364-Compound-8c
DME7UNT	HS	Patented
DME7UNT	CP	VERTEX PHARMACEUTICALS INCORPORATED
DME7UNT	DT	Carbohydrates
DME7UNT	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMSO2F8	ID	DMSO2F8
DMSO2F8	DN	PMID26651364-Compound-8d
DMSO2F8	HS	Patented
DMSO2F8	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMSO2F8	DT	Carbohydrates
DMSO2F8	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMAXWPS	ID	DMAXWPS
DMAXWPS	DN	PMID26651364-Compound-9a
DMAXWPS	HS	Patented
DMAXWPS	CP	UNIVERSITY OF BASEL ERNST, Beat
DMAXWPS	DT	Carbohydrates
DMAXWPS	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM6HTU0	ID	DM6HTU0
DM6HTU0	DN	PMID26651364-Compound-9b
DM6HTU0	HS	Patented
DM6HTU0	CP	UNIVERSITY OF BASEL ERNST, Beat
DM6HTU0	DT	Carbohydrates
DM6HTU0	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM49V8G	ID	DM49V8G
DM49V8G	DN	PMID26651364-Compound-9c
DM49V8G	HS	Patented
DM49V8G	CP	UNIVERSITY OF BASEL ERNST, Beat
DM49V8G	DT	Carbohydrates
DM49V8G	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMF0L3E	ID	DMF0L3E
DMF0L3E	DN	PMID26651364-Compound-9d
DMF0L3E	HS	Patented
DMF0L3E	CP	UNIVERSITY OF BASEL ERNST, Beat
DMF0L3E	DT	Carbohydrates
DMF0L3E	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DM9FIKD	ID	DM9FIKD
DM9FIKD	DN	PMID26651364-Compound-9e
DM9FIKD	HS	Patented
DM9FIKD	CP	UNIVERSITY OF BASEL ERNST, Beat
DM9FIKD	DT	Carbohydrates
DM9FIKD	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMF1MV6	ID	DMF1MV6
DMF1MV6	DN	PMID26651364-Compound-9f
DMF1MV6	HS	Patented
DMF1MV6	CP	UNIVERSITY OF BASEL ERNST, Beat
DMF1MV6	DT	Carbohydrates
DMF1MV6	DE	Crohn disease; Ulcerative colitis; Urinary tract infection

DMMGQ7Z	ID	DMMGQ7Z
DMMGQ7Z	DN	PMID26666870-Compound-16
DMMGQ7Z	HS	Patented
DMMGQ7Z	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNITHE REGENTS OF THE UNIVERSITY OF CALIFORNIA HE, Biao FUJII, Naoaki YOU, Liang XU, Zhidong JABLONS, David M
DMMGQ7Z	DT	Small molecular drug

DMWJXRO	ID	DMWJXRO
DMWJXRO	DN	PMID26666989-Compound-Figure11Ala down
DMWJXRO	HS	Patented
DMWJXRO	DT	Nucleotide

DMGU914	ID	DMGU914
DMGU914	DN	PMID26666989-Compound-Figure11Ala up
DMGU914	HS	Patented
DMGU914	DT	Nucleotide

DMA59QF	ID	DMA59QF
DMA59QF	DN	PMID26666989-Compound-Figure11topright
DMA59QF	HS	Patented
DMA59QF	DT	Nucleotide

DMGIPDH	ID	DMGIPDH
DMGIPDH	DN	PMID26666989-Compound-Figure12bottommiddle01
DMGIPDH	HS	Patented
DMGIPDH	DT	Nucleotide

DM2VHJ7	ID	DM2VHJ7
DM2VHJ7	DN	PMID26666989-Compound-Figure12bottommiddle02
DM2VHJ7	HS	Patented
DM2VHJ7	DT	Nucleotide

DMDLVXU	ID	DMDLVXU
DMDLVXU	DN	PMID26666989-Compound-Figure12bottomright
DMDLVXU	HS	Patented
DMDLVXU	DT	Nucleotide

DMF5LNK	ID	DMF5LNK
DMF5LNK	DN	PMID26666989-Compound-Figure12left
DMF5LNK	HS	Patented
DMF5LNK	DT	Nucleotide

DMEUSGR	ID	DMEUSGR
DMEUSGR	DN	PMID26666989-Compound-Figure12topmiddile
DMEUSGR	HS	Patented
DMEUSGR	DT	Nucleotide

DMISJDH	ID	DMISJDH
DMISJDH	DN	PMID26666989-Compound-Figure9bottomright
DMISJDH	HS	Patented
DMISJDH	CP	DEBRECENI EGYETEM
DMISJDH	DT	Carbohydrates

DM0NM1Y	ID	DM0NM1Y
DM0NM1Y	DN	PMID26666989-Compound-Figure9left01
DM0NM1Y	HS	Patented
DM0NM1Y	CP	DEBRECENI EGYETEM
DM0NM1Y	DT	Small molecular drug

DM7L6WS	ID	DM7L6WS
DM7L6WS	DN	PMID26666989-Compound-Figure9left02
DM7L6WS	HS	Patented
DM7L6WS	CP	DEBRECENI EGYETEM
DM7L6WS	DT	Small molecular drug

DM4MA2X	ID	DM4MA2X
DM4MA2X	DN	PMID26666989-Compound-Figure9middle01
DM4MA2X	HS	Patented
DM4MA2X	CP	DEBRECENI EGYETEM
DM4MA2X	DT	Small molecular drug

DM2ANJ7	ID	DM2ANJ7
DM2ANJ7	DN	PMID26666989-Compound-Figure9middle02
DM2ANJ7	HS	Patented
DM2ANJ7	CP	DEBRECENI EGYETEM
DM2ANJ7	DT	Carbohydrates

DMOPR7A	ID	DMOPR7A
DMOPR7A	DN	PMID26666989-Compound-Figure9middle03
DMOPR7A	HS	Patented
DMOPR7A	CP	DEBRECENI EGYETEM
DMOPR7A	DT	Carbohydrates

DMNWRA0	ID	DMNWRA0
DMNWRA0	DN	PMID26666989-Compound-Figure9middle04
DMNWRA0	HS	Patented
DMNWRA0	CP	DEBRECENI EGYETEM
DMNWRA0	DT	Carbohydrates

DMN73KO	ID	DMN73KO
DMN73KO	DN	PMID26666989-Compound-Figure9middle05
DMN73KO	HS	Patented
DMN73KO	CP	DEBRECENI EGYETEM
DMN73KO	DT	Carbohydrates

DMYKPHX	ID	DMYKPHX
DMYKPHX	DN	PMID26666989-Compound-Figure9middle06
DMYKPHX	HS	Patented
DMYKPHX	CP	DEBRECENI EGYETEM
DMYKPHX	DT	Carbohydrates

DMA02ED	ID	DMA02ED
DMA02ED	DN	PMID26666989-Compound-Figure9middle07
DMA02ED	HS	Patented
DMA02ED	CP	DEBRECENI EGYETEM
DMA02ED	DT	Carbohydrates

DM8KF15	ID	DM8KF15
DM8KF15	DN	PMID26666989-Compound-Figure9middle08
DM8KF15	HS	Patented
DM8KF15	CP	DEBRECENI EGYETEM
DM8KF15	DT	Carbohydrates

DMB4SH8	ID	DMB4SH8
DMB4SH8	DN	PMID26666989-Compound-Figure9middle10
DMB4SH8	HS	Patented
DMB4SH8	CP	DEBRECENI EGYETEM
DMB4SH8	DT	Carbohydrates

DMT6CNM	ID	DMT6CNM
DMT6CNM	DN	PMID26666989-Compound-Figure9middle11
DMT6CNM	HS	Patented
DMT6CNM	CP	DEBRECENI EGYETEM
DMT6CNM	DT	Carbohydrates

DMX612V	ID	DMX612V
DMX612V	DN	PMID26666989-Compound-Figure9middle12
DMX612V	HS	Patented
DMX612V	CP	DEBRECENI EGYETEM
DMX612V	DT	Carbohydrates

DMKZTVR	ID	DMKZTVR
DMKZTVR	DN	PMID26666989-Compound-Figure9middle13
DMKZTVR	HS	Patented
DMKZTVR	CP	DEBRECENI EGYETEM
DMKZTVR	DT	Carbohydrates

DMVS1TU	ID	DMVS1TU
DMVS1TU	DN	PMID26666989-Compound-Figure9topright01
DMVS1TU	HS	Patented
DMVS1TU	CP	DEBRECENI EGYETEM
DMVS1TU	DT	Carbohydrates

DMJ3GX6	ID	DMJ3GX6
DMJ3GX6	DN	PMID26666989-Compound-Figure9toprightR02
DMJ3GX6	HS	Patented
DMJ3GX6	CP	DEBRECENI EGYETEM
DMJ3GX6	DT	Carbohydrates

DMOJ936	ID	DMOJ936
DMOJ936	DN	PMID26815044-Compound-114
DMOJ936	HS	Patented
DMOJ936	DT	Small molecular drug
DMOJ936	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM8SWHO	ID	DM8SWHO
DM8SWHO	DN	PMID26815044-Compound-115
DM8SWHO	HS	Patented
DM8SWHO	DT	Small molecular drug
DM8SWHO	PC	51036643
DM8SWHO	MW	314.5
DM8SWHO	FM	C17H34N2O3
DM8SWHO	IC	InChI=1S/C17H34N2O3/c1-14(2)19(15(3)4)13-12-18-16(20)10-8-6-5-7-9-11-17(21)22/h14-15H,5-13H2,1-4H3,(H,18,20)(H,21,22)
DM8SWHO	CS	CC(C)N(CCNC(=O)CCCCCCCC(=O)O)C(C)C
DM8SWHO	IK	LAOKJSWBEZVBIK-UHFFFAOYSA-N
DM8SWHO	IU	9-[2-[di(propan-2-yl)amino]ethylamino]-9-oxononanoic acid
DM8SWHO	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMDUXRT	ID	DMDUXRT
DMDUXRT	DN	PMID26815044-Compound-116
DMDUXRT	HS	Patented
DMDUXRT	DT	Small molecular drug
DMDUXRT	PC	51036037
DMDUXRT	MW	272.38
DMDUXRT	FM	C14H28N2O3
DMDUXRT	IC	InChI=1S/C14H28N2O3/c1-16(2)12-8-11-15-13(17)9-6-4-3-5-7-10-14(18)19/h3-12H2,1-2H3,(H,15,17)(H,18,19)
DMDUXRT	CS	CN(C)CCCNC(=O)CCCCCCCC(=O)O
DMDUXRT	IK	GACCFZXBPOHVCL-UHFFFAOYSA-N
DMDUXRT	IU	9-[3-(dimethylamino)propylamino]-9-oxononanoic acid
DMDUXRT	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM2GON6	ID	DM2GON6
DM2GON6	DN	PMID26815044-Compound-117
DM2GON6	HS	Patented
DM2GON6	DT	Small molecular drug
DM2GON6	PC	51038800
DM2GON6	MW	272.38
DM2GON6	FM	C14H28N2O3
DM2GON6	IC	InChI=1S/C14H28N2O3/c1-16(2)12-11-15-13(17)9-7-5-3-4-6-8-10-14(18)19/h3-12H2,1-2H3,(H,15,17)(H,18,19)
DM2GON6	CS	CN(C)CCNC(=O)CCCCCCCCC(=O)O
DM2GON6	IK	RGOJAAXJOLYDHR-UHFFFAOYSA-N
DM2GON6	IU	10-[2-(dimethylamino)ethylamino]-10-oxodecanoic acid
DM2GON6	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMC28VB	ID	DMC28VB
DMC28VB	DN	PMID26815044-Compound-118
DMC28VB	HS	Patented
DMC28VB	DT	Small molecular drug
DMC28VB	PC	51038580
DMC28VB	MW	286.41
DMC28VB	FM	C15H30N2O3
DMC28VB	IC	InChI=1S/C15H30N2O3/c1-17(2)13-9-12-16-14(18)10-7-5-3-4-6-8-11-15(19)20/h3-13H2,1-2H3,(H,16,18)(H,19,20)
DMC28VB	CS	CN(C)CCCNC(=O)CCCCCCCCC(=O)O
DMC28VB	IK	GWKPWGKMVDEOGQ-UHFFFAOYSA-N
DMC28VB	IU	10-[3-(dimethylamino)propylamino]-10-oxodecanoic acid
DMC28VB	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMMNXA1	ID	DMMNXA1
DMMNXA1	DN	PMID26815044-Compound-121
DMMNXA1	HS	Patented
DMMNXA1	DT	Small molecular drug
DMMNXA1	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM1HAGJ	ID	DM1HAGJ
DM1HAGJ	DN	PMID26815044-Compound-122
DM1HAGJ	HS	Patented
DM1HAGJ	DT	Small molecular drug
DM1HAGJ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMFTE3Y	ID	DMFTE3Y
DMFTE3Y	DN	PMID26815044-Compound-123
DMFTE3Y	HS	Patented
DMFTE3Y	DT	Small molecular drug
DMFTE3Y	PC	57094730
DMFTE3Y	MW	301.4
DMFTE3Y	FM	C22H23N
DMFTE3Y	IC	InChI=1S/C22H23N/c23-18-10-17-22(19-11-4-1-5-12-19,20-13-6-2-7-14-20)21-15-8-3-9-16-21/h1-9,11-16H,10,17-18,23H2
DMFTE3Y	CS	C1=CC=C(C=C1)C(CCCN)(C2=CC=CC=C2)C3=CC=CC=C3
DMFTE3Y	IK	PVCHAKQXNCGVFU-UHFFFAOYSA-N
DMFTE3Y	IU	4,4,4-triphenylbutan-1-amine
DMFTE3Y	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM25WGP	ID	DM25WGP
DM25WGP	DN	PMID26815044-Compound-124
DM25WGP	HS	Patented
DM25WGP	DT	Small molecular drug
DM25WGP	PC	15372344
DM25WGP	MW	327.5
DM25WGP	FM	C24H25N
DM25WGP	IC	InChI=1S/C24H25N/c1-5-13-21(14-6-1)24(22-15-7-2-8-16-22,23-17-9-3-10-18-23)25-19-11-4-12-20-25/h1-3,5-10,13-18H,4,11-12,19-20H2
DM25WGP	CS	C1CCN(CC1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DM25WGP	IK	ZDTBBCYZMFEIHU-UHFFFAOYSA-N
DM25WGP	IU	1-tritylpiperidine
DM25WGP	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM6EFIN	ID	DM6EFIN
DM6EFIN	DN	PMID26815044-Compound-125
DM6EFIN	HS	Patented
DM6EFIN	DT	Small molecular drug
DM6EFIN	PC	15372343
DM6EFIN	MW	313.4
DM6EFIN	FM	C23H23N
DM6EFIN	IC	InChI=1S/C23H23N/c1-4-12-20(13-5-1)23(24-18-10-11-19-24,21-14-6-2-7-15-21)22-16-8-3-9-17-22/h1-9,12-17H,10-11,18-19H2
DM6EFIN	CS	C1CCN(C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DM6EFIN	IK	DVFDHIZVAQOEMX-UHFFFAOYSA-N
DM6EFIN	IU	1-tritylpyrrolidine
DM6EFIN	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMMJK0L	ID	DMMJK0L
DMMJK0L	DN	PMID26815044-Compound-126
DMMJK0L	HS	Patented
DMMJK0L	DT	Small molecular drug
DMMJK0L	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMO97LR	ID	DMO97LR
DMO97LR	DN	PMID26815044-Compound-127
DMO97LR	HS	Patented
DMO97LR	DT	Small molecular drug
DMO97LR	PC	67427052
DMO97LR	MW	334.4
DMO97LR	FM	C22H22O3
DMO97LR	IC	InChI=1S/C22H22O3/c1-24-21-14-12-20(13-15-21)22(25-17-16-23,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-15,23H,16-17H2,1H3
DMO97LR	CS	COC1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCCO
DMO97LR	IK	JOXFVFZKGOUGOT-UHFFFAOYSA-N
DMO97LR	IU	2-[(4-methoxyphenyl)-diphenylmethoxy]ethanol
DMO97LR	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMH8E7S	ID	DMH8E7S
DMH8E7S	DN	PMID26815044-Compound-30
DMH8E7S	HS	Patented
DMH8E7S	DT	Small molecular drug
DMH8E7S	PC	46207833
DMH8E7S	MW	194.23
DMH8E7S	FM	C11H14O3
DMH8E7S	IC	InChI=1S/C11H14O3/c12-9-1-2-10(11(13)7-9)8-3-5-14-6-4-8/h1-2,7-8,12-13H,3-6H2
DMH8E7S	CS	C1COCCC1C2=C(C=C(C=C2)O)O
DMH8E7S	IK	YVJHGULPEXKTIJ-UHFFFAOYSA-N
DMH8E7S	IU	4-(oxan-4-yl)benzene-1,3-diol
DMH8E7S	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMBINQ9	ID	DMBINQ9
DMBINQ9	DN	PMID26815044-Compound-31
DMBINQ9	HS	Patented
DMBINQ9	DT	Small molecular drug
DMBINQ9	PC	46218697
DMBINQ9	MW	210.29
DMBINQ9	FM	C11H14O2S
DMBINQ9	IC	InChI=1S/C11H14O2S/c12-9-1-2-10(11(13)7-9)8-3-5-14-6-4-8/h1-2,7-8,12-13H,3-6H2
DMBINQ9	CS	C1CSCCC1C2=C(C=C(C=C2)O)O
DMBINQ9	IK	OLWFCALCIRMVMM-UHFFFAOYSA-N
DMBINQ9	IU	4-(thian-4-yl)benzene-1,3-diol
DMBINQ9	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMN5H3C	ID	DMN5H3C
DMN5H3C	DN	PMID26815044-Compound-32
DMN5H3C	HS	Patented
DMN5H3C	DT	Small molecular drug
DMN5H3C	PC	88936412
DMN5H3C	MW	323.4
DMN5H3C	FM	C16H21NO4S
DMN5H3C	IC	InChI=1S/C16H21NO4S/c1-3-12(2)11-22(20,21)17-8-6-13(7-9-17)15-5-4-14(18)10-16(15)19/h3-5,10,13,18-19H,1-2,6-9,11H2
DMN5H3C	CS	C=CC(=C)CS(=O)(=O)N1CCC(CC1)C2=C(C=C(C=C2)O)O
DMN5H3C	IK	JCJFASCAOSDZDC-UHFFFAOYSA-N
DMN5H3C	IU	4-[1-(2-methylidenebut-3-enylsulfonyl)piperidin-4-yl]benzene-1,3-diol
DMN5H3C	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMM3FJO	ID	DMM3FJO
DMM3FJO	DN	PMID26815044-Compound-47
DMM3FJO	HS	Patented
DMM3FJO	CP	Boiteau JG, Barbuis CM, Bouquet K
DMM3FJO	DT	Small molecular drug
DMM3FJO	PC	25142954
DMM3FJO	MW	196.3
DMM3FJO	FM	C8H8N2S2
DMM3FJO	IC	InChI=1S/C8H8N2S2/c1-5-2-7(12-4-5)6-3-9-8(11)10-6/h2-4H,1H3,(H2,9,10,11)
DMM3FJO	CS	CC1=CSC(=C1)C2=CNC(=S)N2
DMM3FJO	IK	KEJRMOMLDKMMDC-UHFFFAOYSA-N
DMM3FJO	IU	4-(4-methylthiophen-2-yl)-1,3-dihydroimidazole-2-thione
DMM3FJO	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMJ1Z7U	ID	DMJ1Z7U
DMJ1Z7U	DN	PMID26815044-Compound-48
DMJ1Z7U	HS	Patented
DMJ1Z7U	CP	Boiteau JG, Barbuis CM, Bouquet K
DMJ1Z7U	DT	Small molecular drug
DMJ1Z7U	PC	25142950
DMJ1Z7U	MW	196.3
DMJ1Z7U	FM	C8H8N2S2
DMJ1Z7U	IC	InChI=1S/C8H8N2S2/c1-5-2-3-7(12-5)6-4-9-8(11)10-6/h2-4H,1H3,(H2,9,10,11)
DMJ1Z7U	CS	CC1=CC=C(S1)C2=CNC(=S)N2
DMJ1Z7U	IK	VLDBRCXNFRGTRR-UHFFFAOYSA-N
DMJ1Z7U	IU	4-(5-methylthiophen-2-yl)-1,3-dihydroimidazole-2-thione
DMJ1Z7U	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMD9WRS	ID	DMD9WRS
DMD9WRS	DN	PMID26815044-Compound-49
DMD9WRS	HS	Patented
DMD9WRS	CP	Boiteau JG, Barbuis CM, Bouquet K
DMD9WRS	DT	Small molecular drug
DMD9WRS	PC	25124260
DMD9WRS	MW	220.25
DMD9WRS	FM	C10H8N2O2S
DMD9WRS	IC	InChI=1S/C10H8N2O2S/c13-9(14)7-3-1-6(2-4-7)8-5-11-10(15)12-8/h1-5H,(H,13,14)(H2,11,12,15)
DMD9WRS	CS	C1=CC(=CC=C1C2=CNC(=S)N2)C(=O)O
DMD9WRS	IK	RUEHTYRZLLKGKE-UHFFFAOYSA-N
DMD9WRS	IU	4-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)benzoic acid
DMD9WRS	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMYI1SX	ID	DMYI1SX
DMYI1SX	DN	PMID26815044-Compound-50
DMYI1SX	HS	Patented
DMYI1SX	CP	Boiteau J-G, Barbuis CM, Talano S
DMYI1SX	DT	Small molecular drug
DMYI1SX	PC	25124264
DMYI1SX	MW	206.27
DMYI1SX	FM	C10H10N2OS
DMYI1SX	IC	InChI=1S/C10H10N2OS/c13-6-7-1-3-8(4-2-7)9-5-11-10(14)12-9/h1-5,13H,6H2,(H2,11,12,14)
DMYI1SX	CS	C1=CC(=CC=C1CO)C2=CNC(=S)N2
DMYI1SX	IK	BTFQSXRRGYWCHB-UHFFFAOYSA-N
DMYI1SX	IU	4-[4-(hydroxymethyl)phenyl]-1,3-dihydroimidazole-2-thione
DMYI1SX	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMQGTJ5	ID	DMQGTJ5
DMQGTJ5	DN	PMID26815044-Compound-51
DMQGTJ5	HS	Patented
DMQGTJ5	CP	Boiteau J-G, Barbuis CM, Talano S
DMQGTJ5	DT	Small molecular drug
DMQGTJ5	PC	25124267
DMQGTJ5	MW	242.25
DMQGTJ5	FM	C10H8F2N2OS
DMQGTJ5	IC	InChI=1S/C10H8F2N2OS/c11-9(12)15-7-3-1-6(2-4-7)8-5-13-10(16)14-8/h1-5,9H,(H2,13,14,16)
DMQGTJ5	CS	C1=CC(=CC=C1C2=CNC(=S)N2)OC(F)F
DMQGTJ5	IK	RSUPNTVGCZRJCF-UHFFFAOYSA-N
DMQGTJ5	IU	4-[4-(difluoromethoxy)phenyl]-1,3-dihydroimidazole-2-thione
DMQGTJ5	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMN4C2O	ID	DMN4C2O
DMN4C2O	DN	PMID26815044-Compound-52
DMN4C2O	HS	Patented
DMN4C2O	CP	Boiteau J-G, Barbuis CM, Talano S
DMN4C2O	DT	Small molecular drug
DMN4C2O	PC	25124592
DMN4C2O	MW	206.27
DMN4C2O	FM	C10H10N2OS
DMN4C2O	IC	InChI=1S/C10H10N2OS/c1-13-8-4-2-3-7(5-8)9-6-11-10(14)12-9/h2-6H,1H3,(H2,11,12,14)
DMN4C2O	CS	COC1=CC=CC(=C1)C2=CNC(=S)N2
DMN4C2O	IK	NAHCKRAVJDCJKM-UHFFFAOYSA-N
DMN4C2O	IU	4-(3-methoxyphenyl)-1,3-dihydroimidazole-2-thione
DMN4C2O	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMEKBOG	ID	DMEKBOG
DMEKBOG	DN	PMID26815044-Compound-64
DMEKBOG	HS	Patented
DMEKBOG	CP	JOHNSON & JOHNSON CONSUMER COMPANIES, INC
DMEKBOG	DT	Small molecular drug
DMEKBOG	PC	44594137
DMEKBOG	MW	330.4
DMEKBOG	FM	C22H18O3
DMEKBOG	IC	InChI=1S/C22H18O3/c23-20-9-5-16(6-10-20)1-3-18-13-19(15-22(25)14-18)4-2-17-7-11-21(24)12-8-17/h1-15,23-25H/b3-1+,4-2+
DMEKBOG	CS	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)/C=C/C3=CC=C(C=C3)O)O
DMEKBOG	IK	ICUPUOLNNGGWKO-ZPUQHVIOSA-N
DMEKBOG	IU	3,5-bis[(E)-2-(4-hydroxyphenyl)ethenyl]phenol
DMEKBOG	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMV46DG	ID	DMV46DG
DMV46DG	DN	PMID26815044-Compound-93
DMV46DG	HS	Patented
DMV46DG	DT	Small molecular drug
DMV46DG	PC	71079964
DMV46DG	MW	306.26
DMV46DG	FM	C13H16F2O6
DMV46DG	IC	InChI=1S/C13H16F2O6/c14-13(15)8(5-16)9(18)10(19)11(20)12(13)21-7-3-1-6(17)2-4-7/h1-4,8-12,16-20H,5H2/t8-,9-,10+,11-,12+/m1/s1
DMV46DG	CS	C1=CC(=CC=C1O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](C2(F)F)CO)O)O)O
DMV46DG	IK	PIRSYSBZACJVMC-ZIQFBCGOSA-N
DMV46DG	IU	(1R,2S,3R,4R,6S)-5,5-difluoro-4-(hydroxymethyl)-6-(4-hydroxyphenoxy)cyclohexane-1,2,3-triol
DMV46DG	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMI3QLT	ID	DMI3QLT
DMI3QLT	DN	PMID26815044-Compound-H
DMI3QLT	HS	Patented
DMI3QLT	DT	Small molecular drug
DMI3QLT	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMZISDR	ID	DMZISDR
DMZISDR	DN	PMID26815044-Compound-I
DMZISDR	HS	Patented
DMZISDR	DT	Small molecular drug
DMZISDR	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMPAE8N	ID	DMPAE8N
DMPAE8N	DN	PMID26882240-Compound-1
DMPAE8N	HS	Patented
DMPAE8N	CP	YUNG SHIN PHARM. IND. CO., LTD
DMPAE8N	DT	Small molecular drug
DMPAE8N	PC	5712
DMPAE8N	MW	304.3
DMPAE8N	FM	C19H16N2O2
DMPAE8N	IC	InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2
DMPAE8N	CS	C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)C4=CC=C(O4)CO
DMPAE8N	IK	OQQVFCKUDYMWGV-UHFFFAOYSA-N
DMPAE8N	IU	[5-(1-benzylindazol-3-yl)furan-2-yl]methanol
DMPAE8N	CA	CAS 170632-47-0
DMPAE8N	CB	CHEBI:93060

DMQVZ01	ID	DMQVZ01
DMQVZ01	DN	PMID26882240-Compound-14
DMQVZ01	HS	Patented
DMQVZ01	CP	ELARA PHARMACEUTICALS GMBH [DE]
DMQVZ01	DT	Small molecular drug
DMQVZ01	PC	66563603
DMQVZ01	MW	419.5
DMQVZ01	FM	C23H21N3O3S
DMQVZ01	IC	InChI=1S/C23H21N3O3S/c1-16-3-4-19(15-24-16)17-5-8-23-22(14-17)26(11-12-29-23)30(27,28)20-6-7-21-18(13-20)9-10-25(21)2/h3-10,13-15H,11-12H2,1-2H3
DMQVZ01	CS	CC1=NC=C(C=C1)C2=CC3=C(C=C2)OCCN3S(=O)(=O)C4=CC5=C(C=C4)N(C=C5)C
DMQVZ01	IK	FPMLAMSVUUIGOG-UHFFFAOYSA-N
DMQVZ01	IU	4-(1-methylindol-5-yl)sulfonyl-6-(6-methylpyridin-3-yl)-2,3-dihydro-1,4-benzoxazine

DMZ12V4	ID	DMZ12V4
DMZ12V4	DN	PMID26882240-Compound-15
DMZ12V4	HS	Patented
DMZ12V4	CP	ELARA PHARMACEUTICALS GMBH [DE]
DMZ12V4	DT	Small molecular drug
DMZ12V4	PC	52934476
DMZ12V4	MW	396.5
DMZ12V4	FM	C20H16N2O3S2
DMZ12V4	IC	InChI=1S/C20H16N2O3S2/c1-14-2-6-17(7-3-14)27(23,24)22-10-11-25-19-8-4-15(12-18(19)22)20-9-5-16(13-21)26-20/h2-9,12H,10-11H2,1H3
DMZ12V4	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCOC3=C2C=C(C=C3)C4=CC=C(S4)C#N
DMZ12V4	IK	VIWNRKLYEZMKCY-UHFFFAOYSA-N
DMZ12V4	IU	5-[4-(4-methylphenyl)sulfonyl-2,3-dihydro-1,4-benzoxazin-6-yl]thiophene-2-carbonitrile

DMX7Y52	ID	DMX7Y52
DMX7Y52	DN	PMID26882240-Compound-2
DMX7Y52	HS	Patented
DMX7Y52	CP	CASE WESTERN RESERVE UNIVERSITY
DMX7Y52	DT	Small molecular drug
DMX7Y52	PC	219104
DMX7Y52	MW	188.3
DMX7Y52	FM	C7H12N2S2
DMX7Y52	IC	InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)
DMX7Y52	CS	CCC(C)SSC1=NC=CN1
DMX7Y52	IK	BPBPYQWMFCTCNG-UHFFFAOYSA-N
DMX7Y52	IU	2-(butan-2-yldisulfanyl)-1H-imidazole
DMX7Y52	CA	CAS 141400-58-0
DMX7Y52	CB	CHEBI:94291

DMFZM3X	ID	DMFZM3X
DMFZM3X	DN	PMID26882240-Compound-3
DMFZM3X	HS	Patented
DMFZM3X	CP	NORTHWESTERN UNIVERSITY ONCOTHYREON INC. GORDON, Leo I. EVENS, Andrew PESTANO, Linda FOWLER, Kerry PETERSON, Scott
DMFZM3X	DT	Small molecular drug

DMJS4RP	ID	DMJS4RP
DMJS4RP	DN	PMID26882240-Compound-32
DMJS4RP	HS	Patented
DMJS4RP	CP	MEDICAL RESEARCH COUNCIL CHEESEMAN, Michael, T BROWN, Steve. D. M
DMJS4RP	DT	Small molecular drug
DMJS4RP	PC	5288674
DMJS4RP	MW	616.7
DMJS4RP	FM	C32H48N4O8
DMJS4RP	IC	InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1
DMJS4RP	CS	C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)\\C)C)O)OC
DMJS4RP	IK	KUFRQPKVAWMTJO-LMZWQJSESA-N
DMJS4RP	IU	[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[2-(dimethylamino)ethylamino]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DMJS4RP	CA	CAS 467214-20-6
DMJS4RP	CB	CHEBI:65324

DMS4RLZ	ID	DMS4RLZ
DMS4RLZ	DN	PMID26882240-Compound-4
DMS4RLZ	HS	Patented
DMS4RLZ	CP	ONCOTHYREON INC. PETERSON, Scott PESTANO, Linda FOWLER, Kerry VO, Cong, Hung
DMS4RLZ	DT	Small molecular drug
DMS4RLZ	PC	67516319
DMS4RLZ	MW	198.69
DMS4RLZ	FM	C10H15ClN2
DMS4RLZ	IC	InChI=1S/C10H15ClN2/c11-6-8-13-10-3-1-9(2-4-10)5-7-12/h1-4,13H,5-8,12H2
DMS4RLZ	CS	C1=CC(=CC=C1CCN)NCCCl
DMS4RLZ	IK	CPOKZPJUSOYUNW-UHFFFAOYSA-N
DMS4RLZ	IU	4-(2-aminoethyl)-N-(2-chloroethyl)aniline

DM61NOP	ID	DM61NOP
DM61NOP	DN	PMID26882240-Compound-6
DM61NOP	HS	Patented
DM61NOP	CP	Korea Research Institute of Bioscience and Biotechnology Dongguk University Industry-Academic Cooperation Foundation WON, Mi-Sun KIM, Hwan-Mook LEE, Kyeong PARK, Song-Kyu LEE, Ki-Ho LEE, Chang-Woo LEE, Jung-Joon CHUNG, Kyung-Sook KIM, Bo-Kyung JIN, Ying-Lan
DM61NOP	DT	Small molecular drug
DM61NOP	PC	16124726
DM61NOP	MW	435.5
DM61NOP	FM	C26H29NO5
DM61NOP	IC	InChI=1S/C26H29NO5/c1-31-25(30)19-2-7-23(28)22(11-19)27-24(29)15-32-21-5-3-20(4-6-21)26-12-16-8-17(13-26)10-18(9-16)14-26/h2-7,11,16-18,28H,8-10,12-15H2,1H3,(H,27,29)
DM61NOP	CS	COC(=O)C1=CC(=C(C=C1)O)NC(=O)COC2=CC=C(C=C2)C34CC5CC(C3)CC(C5)C4
DM61NOP	IK	BJRPPNOJYFZSLY-UHFFFAOYSA-N
DM61NOP	IU	methyl 3-[[2-[4-(1-adamantyl)phenoxy]acetyl]amino]-4-hydroxybenzoate

DMOX8E3	ID	DMOX8E3
DMOX8E3	DN	PMID26882240-Compound-7
DMOX8E3	HS	Patented
DMOX8E3	CP	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
DMOX8E3	DT	Small molecular drug
DMOX8E3	PC	118364731
DMOX8E3	MW	543.6
DMOX8E3	FM	C32H33NO7
DMOX8E3	IC	InChI=1S/C32H33NO7/c1-37-29(35)23-4-2-5-25(13-23)33-28(34)19-39-26-9-7-24(8-10-26)31-14-21-12-22(15-31)17-32(16-21,20-31)30(36)40-18-27-6-3-11-38-27/h2-11,13,21-22H,12,14-20H2,1H3,(H,33,34)
DMOX8E3	CS	COC(=O)C1=CC(=CC=C1)NC(=O)COC2=CC=C(C=C2)C34CC5CC(C3)CC(C5)(C4)C(=O)OCC6=CC=CO6
DMOX8E3	IK	GQISNYKUWPQVDL-UHFFFAOYSA-N
DMOX8E3	IU	furan-2-ylmethyl 3-[4-[2-(3-methoxycarbonylanilino)-2-oxoethoxy]phenyl]adamantane-1-carboxylate

DMWJRY7	ID	DMWJRY7
DMWJRY7	DN	PMID26882240-Compound-8
DMWJRY7	HS	Patented
DMWJRY7	CP	Ildong Pharmaceutical Co., Ltd., S. Korea
DMWJRY7	DT	Small molecular drug
DMWJRY7	PC	625381
DMWJRY7	MW	286.4
DMWJRY7	FM	C18H22O3
DMWJRY7	IC	InChI=1S/C18H22O3/c19-17(20)11-21-16-3-1-15(2-4-16)18-8-12-5-13(9-18)7-14(6-12)10-18/h1-4,12-14H,5-11H2,(H,19,20)
DMWJRY7	CS	C1C2CC3CC1CC(C2)(C3)C4=CC=C(C=C4)OCC(=O)O
DMWJRY7	IK	WIWCHWGNONICJI-UHFFFAOYSA-N
DMWJRY7	IU	2-[4-(1-adamantyl)phenoxy]acetic acid
DMWJRY7	CA	CAS 52804-26-9

DMEJ107	ID	DMEJ107
DMEJ107	DN	PMID26924192-Compound-102
DMEJ107	HS	Patented
DMEJ107	CP	MEDIVATION TECHNOLOGIES, INC
DMEJ107	DT	Small molecular drug
DMEJ107	PC	102004282
DMEJ107	MW	367.4
DMEJ107	FM	C22H25NO4
DMEJ107	IC	InChI=1S/C22H25NO4/c1-6-19(24)23(5)17-12-16(20(25)15-10-8-7-9-11-15)13-18(14-17)27-21(26)22(2,3)4/h6-14,20,25H,1H2,2-5H3
DMEJ107	CS	CC(C)(C)C(=O)OC1=CC(=CC(=C1)N(C)C(=O)C=C)C(C2=CC=CC=C2)O
DMEJ107	IK	ZPLXDAHNNDDTEM-UHFFFAOYSA-N
DMEJ107	IU	[3-[hydroxy(phenyl)methyl]-5-[methyl(prop-2-enoyl)amino]phenyl] 2,2-dimethylpropanoate

DMWOCP7	ID	DMWOCP7
DMWOCP7	DN	PMID26924192-Compound-103
DMWOCP7	HS	Patented
DMWOCP7	CP	MEDIVATION TECHNOLOGIES, INC
DMWOCP7	DT	Small molecular drug
DMWOCP7	PC	118542373
DMWOCP7	MW	283.32
DMWOCP7	FM	C17H17NO3
DMWOCP7	IC	InChI=1S/C17H17NO3/c1-3-16(20)18(2)14-9-13(10-15(19)11-14)17(21)12-7-5-4-6-8-12/h3-11,17,19,21H,1H2,2H3
DMWOCP7	CS	CN(C1=CC(=CC(=C1)C(C2=CC=CC=C2)O)O)C(=O)C=C
DMWOCP7	IK	ISTAOAGDLRWZMS-UHFFFAOYSA-N
DMWOCP7	IU	N-[3-hydroxy-5-[hydroxy(phenyl)methyl]phenyl]-N-methylprop-2-enamide

DM346EU	ID	DM346EU
DM346EU	DN	PMID26924192-Compound-104
DM346EU	HS	Patented
DM346EU	CP	MEDIVATION TECHNOLOGIES, INC
DM346EU	DT	Small molecular drug
DM346EU	PC	118548317
DM346EU	MW	283.32
DM346EU	FM	C17H17NO3
DM346EU	IC	InChI=1S/C17H17NO3/c1-3-16(20)18(2)14-9-13(10-15(19)11-14)17(21)12-7-5-4-6-8-12/h3-11,17,19,21H,1H2,2H3/t17-/m1/s1
DM346EU	CS	CN(C1=CC(=CC(=C1)[C@@H](C2=CC=CC=C2)O)O)C(=O)C=C
DM346EU	IK	ISTAOAGDLRWZMS-QGZVFWFLSA-N
DM346EU	IU	N-[3-hydroxy-5-[(R)-hydroxy(phenyl)methyl]phenyl]-N-methylprop-2-enamide

DMAWLGI	ID	DMAWLGI
DMAWLGI	DN	PMID26924192-Compound-105
DMAWLGI	HS	Patented
DMAWLGI	CP	MEDIVATION TECHNOLOGIES, INC
DMAWLGI	DT	Small molecular drug
DMAWLGI	PC	118548311
DMAWLGI	MW	283.32
DMAWLGI	FM	C17H17NO3
DMAWLGI	IC	InChI=1S/C17H17NO3/c1-3-16(20)18(2)14-9-13(10-15(19)11-14)17(21)12-7-5-4-6-8-12/h3-11,17,19,21H,1H2,2H3/t17-/m0/s1
DMAWLGI	CS	CN(C1=CC(=CC(=C1)[C@H](C2=CC=CC=C2)O)O)C(=O)C=C
DMAWLGI	IK	ISTAOAGDLRWZMS-KRWDZBQOSA-N
DMAWLGI	IU	N-[3-hydroxy-5-[(S)-hydroxy(phenyl)methyl]phenyl]-N-methylprop-2-enamide

DM9HRZJ	ID	DM9HRZJ
DM9HRZJ	DN	PMID26924192-Compound-106
DM9HRZJ	HS	Patented
DM9HRZJ	CP	UNIVERSITY OF DUNDEE CAMBRIDGE ENTERPRISE LIMITED
DM9HRZJ	DT	Small molecular drug
DM9HRZJ	PC	86277842
DM9HRZJ	MW	424.9
DM9HRZJ	FM	C22H21ClN4O3
DM9HRZJ	IC	InChI=1S/C22H21ClN4O3/c1-12(22(28)30-4)19-21-26-25-13(2)27(21)18-10-9-16(29-3)11-17(18)20(24-19)14-5-7-15(23)8-6-14/h5-12,19H,1-4H3/t12-,19+/m1/s1
DM9HRZJ	CS	CC1=NN=C2N1C3=C(C=C(C=C3)OC)C(=N[C@H]2[C@@H](C)C(=O)OC)C4=CC=C(C=C4)Cl
DM9HRZJ	IK	FENXDXHDXYVGRJ-BLVKFPJESA-N
DM9HRZJ	IU	methyl (2R)-2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]propanoate

DMHAOF1	ID	DMHAOF1
DMHAOF1	DN	PMID26924192-Compound-20
DMHAOF1	HS	Patented
DMHAOF1	CP	KAINOS MEDICINE, INC
DMHAOF1	DT	Small molecular drug
DMHAOF1	PC	118437927
DMHAOF1	MW	497
DMHAOF1	FM	C23H21ClN6O3S
DMHAOF1	IC	InChI=1S/C23H21ClN6O3S/c1-14-27-28-23-20(13-33-34(3,31)32)26-22(15-4-7-18(24)8-5-15)19-10-16(6-9-21(19)30(14)23)17-11-25-29(2)12-17/h4-12,20H,13H2,1-3H3/t20-/m0/s1
DMHAOF1	CS	CC1=NN=C2N1C3=C(C=C(C=C3)C4=CN(N=C4)C)C(=N[C@H]2COS(=O)(=O)C)C5=CC=C(C=C5)Cl
DMHAOF1	IK	YAFLYAXZAFQVAT-FQEVSTJZSA-N
DMHAOF1	IU	[(4R)-6-(4-chlorophenyl)-1-methyl-8-(1-methylpyrazol-4-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl methanesulfonate

DM4MZ29	ID	DM4MZ29
DM4MZ29	DN	PMID26924192-Compound-21
DM4MZ29	HS	Patented
DM4MZ29	CP	KAINOS MEDICINE, INC
DM4MZ29	DT	Small molecular drug
DM4MZ29	PC	118437931
DM4MZ29	MW	540
DM4MZ29	FM	C24H22ClN7O4S
DM4MZ29	IC	InChI=1S/C24H22ClN7O4S/c1-14-29-30-24-20(13-36-37(2,34)35)28-23(15-3-6-18(25)7-4-15)19-9-16(5-8-21(19)32(14)24)17-10-27-31(11-17)12-22(26)33/h3-11,20H,12-13H2,1-2H3,(H2,26,33)/t20-/m0/s1
DM4MZ29	CS	CC1=NN=C2N1C3=C(C=C(C=C3)C4=CN(N=C4)CC(=O)N)C(=N[C@H]2COS(=O)(=O)C)C5=CC=C(C=C5)Cl
DM4MZ29	IK	ZZJJMUOPZJGNMG-FQEVSTJZSA-N
DM4MZ29	IU	[(4R)-8-[1-(2-amino-2-oxoethyl)pyrazol-4-yl]-6-(4-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl methanesulfonate

DMX964E	ID	DMX964E
DMX964E	DN	PMID26924192-Compound-22
DMX964E	HS	Patented
DMX964E	CP	KAINOS MEDICINE, INC
DMX964E	DT	Small molecular drug
DMX964E	PC	118437971
DMX964E	MW	568
DMX964E	FM	C26H26ClN7O4S
DMX964E	IC	InChI=1S/C26H26ClN7O4S/c1-16-30-31-26-22(15-38-39(4,36)37)29-25(17-5-8-20(27)9-6-17)21-11-18(7-10-23(21)34(16)26)19-12-28-33(13-19)14-24(35)32(2)3/h5-13,22H,14-15H2,1-4H3/t22-/m0/s1
DMX964E	CS	CC1=NN=C2N1C3=C(C=C(C=C3)C4=CN(N=C4)CC(=O)N(C)C)C(=N[C@H]2COS(=O)(=O)C)C5=CC=C(C=C5)Cl
DMX964E	IK	FLSJIUPJVTYGIO-QFIPXVFZSA-N
DMX964E	IU	[(4R)-6-(4-chlorophenyl)-8-[1-[2-(dimethylamino)-2-oxoethyl]pyrazol-4-yl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl methanesulfonate

DME60LY	ID	DME60LY
DME60LY	DN	PMID26924192-Compound-23
DME60LY	HS	Patented
DME60LY	CP	KAINOS MEDICINE, INC
DME60LY	DT	Small molecular drug
DME60LY	PC	118437924
DME60LY	MW	472.9
DME60LY	FM	C22H21ClN4O4S
DME60LY	IC	InChI=1S/C22H21ClN4O4S/c1-13-25-26-22-19(12-31-32(28,29)17-8-9-17)24-21(14-3-5-15(23)6-4-14)18-11-16(30-2)7-10-20(18)27(13)22/h3-7,10-11,17,19H,8-9,12H2,1-2H3/t19-/m0/s1
DME60LY	CS	CC1=NN=C2N1C3=C(C=C(C=C3)OC)C(=N[C@H]2COS(=O)(=O)C4CC4)C5=CC=C(C=C5)Cl
DME60LY	IK	BTVRKLXZFWPBGV-IBGZPJMESA-N
DME60LY	IU	[(4R)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl cyclopropanesulfonate

DMDN5Q4	ID	DMDN5Q4
DMDN5Q4	DN	PMID26924192-Compound-24
DMDN5Q4	HS	Patented
DMDN5Q4	CP	KAINOS MEDICINE, INC
DMDN5Q4	DT	Small molecular drug
DMDN5Q4	PC	91971319
DMDN5Q4	MW	446.9
DMDN5Q4	FM	C20H19ClN4O4S
DMDN5Q4	IC	InChI=1S/C20H19ClN4O4S/c1-12-23-24-20-17(11-29-30(3,26)27)22-19(13-4-6-14(21)7-5-13)16-10-15(28-2)8-9-18(16)25(12)20/h4-10,17H,11H2,1-3H3/t17-/m0/s1
DMDN5Q4	CS	CC1=NN=C2N1C3=C(C=C(C=C3)OC)C(=N[C@H]2COS(=O)(=O)C)C4=CC=C(C=C4)Cl
DMDN5Q4	IK	LELNYTXQJUOJKQ-KRWDZBQOSA-N
DMDN5Q4	IU	[(4R)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl methanesulfonate

DMEL7XA	ID	DMEL7XA
DMEL7XA	DN	PMID26924192-Compound-25
DMEL7XA	HS	Patented
DMEL7XA	CP	KAINOS MEDICINE, INC
DMEL7XA	DT	Small molecular drug
DMEL7XA	PC	118437925
DMEL7XA	MW	460.9
DMEL7XA	FM	C21H21ClN4O4S
DMEL7XA	IC	InChI=1S/C21H21ClN4O4S/c1-4-31(27,28)30-12-18-21-25-24-13(2)26(21)19-10-9-16(29-3)11-17(19)20(23-18)14-5-7-15(22)8-6-14/h5-11,18H,4,12H2,1-3H3/t18-/m0/s1
DMEL7XA	CS	CCS(=O)(=O)OC[C@H]1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C
DMEL7XA	IK	YVHHEUZAFNGTKI-SFHVURJKSA-N
DMEL7XA	IU	[(4R)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl ethanesulfonate

DMWXNIJ	ID	DMWXNIJ
DMWXNIJ	DN	PMID26924192-Compound-30
DMWXNIJ	HS	Patented
DMWXNIJ	CP	KYORIN PHARMACEUTICAL CO., LTD
DMWXNIJ	DT	Small molecular drug
DMWXNIJ	PC	124182286
DMWXNIJ	MW	583.7
DMWXNIJ	FM	C33H41N7O3
DMWXNIJ	IC	InChI=1S/C33H41N7O3/c1-5-43-30-18-22(32(41)40-17-14-24(21-40)35-23-12-15-37(2)16-13-23)10-11-26(30)36-31-19-28-29(20-34-31)39(4)33(42)25-8-6-7-9-27(25)38(28)3/h6-11,18-20,23-24,35H,5,12-17,21H2,1-4H3,(H,34,36)/t24-/m0/s1
DMWXNIJ	CS	CCOC1=C(C=CC(=C1)C(=O)N2CC[C@@H](C2)NC3CCN(CC3)C)NC4=NC=C5C(=C4)N(C6=CC=CC=C6C(=O)N5C)C
DMWXNIJ	IK	SXKDARBSSREUSH-DEOSSOPVSA-N
DMWXNIJ	IU	2-[2-ethoxy-4-[(3S)-3-[(1-methylpiperidin-4-yl)amino]pyrrolidine-1-carbonyl]anilino]-5,11-dimethylpyrido[4,3-b][1,4]benzodiazepin-6-one

DMIFV58	ID	DMIFV58
DMIFV58	DN	PMID26924192-Compound-31
DMIFV58	HS	Patented
DMIFV58	CP	KYORIN PHARMACEUTICAL CO., LTD
DMIFV58	DT	Small molecular drug
DMIFV58	PC	124182114
DMIFV58	MW	530.6
DMIFV58	FM	C29H34N6O4
DMIFV58	IC	InChI=1S/C29H34N6O4/c1-4-38-25-15-19(28(36)35-13-9-20(18-35)34-11-5-6-12-34)7-8-21(25)31-26-16-23-24(17-30-26)33(3)29(37)27-22(32(23)2)10-14-39-27/h7-8,10,14-17,20H,4-6,9,11-13,18H2,1-3H3,(H,30,31)
DMIFV58	CS	CCOC1=C(C=CC(=C1)C(=O)N2CCC(C2)N3CCCC3)NC4=NC=C5C(=C4)N(C6=C(C(=O)N5C)OC=C6)C
DMIFV58	IK	MABJPFUJXNIKGP-UHFFFAOYSA-N
DMIFV58	IU	13-[2-ethoxy-4-(3-pyrrolidin-1-ylpyrrolidine-1-carbonyl)anilino]-2,9-dimethyl-6-oxa-2,9,12-triazatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one

DM0JSOZ	ID	DM0JSOZ
DM0JSOZ	DN	PMID26924192-Compound-32
DM0JSOZ	HS	Patented
DM0JSOZ	CP	KYORIN PHARMACEUTICAL CO., LTD
DM0JSOZ	DT	Small molecular drug
DM0JSOZ	PC	91864635
DM0JSOZ	MW	554.7
DM0JSOZ	FM	C32H38N6O3
DM0JSOZ	IC	InChI=1S/C32H38N6O3/c1-4-41-29-19-22(31(39)38-17-13-23(14-18-38)37-15-7-8-16-37)11-12-25(29)34-30-20-27-28(21-33-30)36(3)32(40)24-9-5-6-10-26(24)35(27)2/h5-6,9-12,19-21,23H,4,7-8,13-18H2,1-3H3,(H,33,34)
DM0JSOZ	CS	CCOC1=C(C=CC(=C1)C(=O)N2CCC(CC2)N3CCCC3)NC4=NC=C5C(=C4)N(C6=CC=CC=C6C(=O)N5C)C
DM0JSOZ	IK	CBWCJYFVVHOTAZ-UHFFFAOYSA-N
DM0JSOZ	IU	2-[2-ethoxy-4-(4-pyrrolidin-1-ylpiperidine-1-carbonyl)anilino]-5,11-dimethylpyrido[4,3-b][1,4]benzodiazepin-6-one

DM9NWXM	ID	DM9NWXM
DM9NWXM	DN	PMID26924192-Compound-33
DM9NWXM	HS	Patented
DM9NWXM	CP	KYORIN PHARMACEUTICAL CO., LTD
DM9NWXM	DT	Small molecular drug
DM9NWXM	PC	124182231
DM9NWXM	MW	597.7
DM9NWXM	FM	C34H43N7O3
DM9NWXM	IC	InChI=1S/C34H43N7O3/c1-5-44-31-21-24(33(42)41-17-13-25(14-18-41)40-16-8-15-37(2)19-20-40)11-12-27(31)36-32-22-29-30(23-35-32)39(4)34(43)26-9-6-7-10-28(26)38(29)3/h6-7,9-12,21-23,25H,5,8,13-20H2,1-4H3,(H,35,36)
DM9NWXM	CS	CCOC1=C(C=CC(=C1)C(=O)N2CCC(CC2)N3CCCN(CC3)C)NC4=NC=C5C(=C4)N(C6=CC=CC=C6C(=O)N5C)C
DM9NWXM	IK	YZJHEYIGGRFZOH-UHFFFAOYSA-N
DM9NWXM	IU	2-[2-ethoxy-4-[4-(4-methyl-1,4-diazepan-1-yl)piperidine-1-carbonyl]anilino]-5,11-dimethylpyrido[4,3-b][1,4]benzodiazepin-6-one

DMTVZWM	ID	DMTVZWM
DMTVZWM	DN	PMID26924192-Compound-50
DMTVZWM	HS	Patented
DMTVZWM	CP	INCYTE CORPORATIOIncyte Corporation
DMTVZWM	DT	Small molecular drug
DMTVZWM	PC	118467688
DMTVZWM	MW	371.4
DMTVZWM	FM	C22H17N3O3
DMTVZWM	IC	InChI=1S/C22H17N3O3/c1-25-12-16(14-10-11-23-18(14)22(25)27)15-8-5-9-17-20(15)28-19(21(26)24-17)13-6-3-2-4-7-13/h2-12,19,23H,1H3,(H,24,26)
DMTVZWM	CS	CN1C=C(C2=C(C1=O)NC=C2)C3=C4C(=CC=C3)NC(=O)C(O4)C5=CC=CC=C5
DMTVZWM	IK	DWZVOOLKEMMANA-UHFFFAOYSA-N
DMTVZWM	IU	8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-phenyl-4H-1,4-benzoxazin-3-one

DMB2MH3	ID	DMB2MH3
DMB2MH3	DN	PMID26924192-Compound-51
DMB2MH3	HS	Patented
DMB2MH3	CP	INCYTE CORPORATIOIncyte Corporation
DMB2MH3	DT	Small molecular drug
DMB2MH3	PC	118467741
DMB2MH3	MW	353.4
DMB2MH3	FM	C19H19N3O4
DMB2MH3	IC	InChI=1S/C19H19N3O4/c1-19(2)18(24)21-14-8-10(25-4)7-12(16(14)26-19)13-9-22(3)17(23)15-11(13)5-6-20-15/h5-9,20H,1-4H3,(H,21,24)
DMB2MH3	CS	CC1(C(=O)NC2=CC(=CC(=C2O1)C3=CN(C(=O)C4=C3C=CN4)C)OC)C
DMB2MH3	IK	YAGDWXZVBYSOAH-UHFFFAOYSA-N
DMB2MH3	IU	6-methoxy-2,2-dimethyl-8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-4H-1,4-benzoxazin-3-one

DMFU6JR	ID	DMFU6JR
DMFU6JR	DN	PMID26924192-Compound-52
DMFU6JR	HS	Patented
DMFU6JR	CP	INCYTE CORPORATIOIncyte Corporation
DMFU6JR	DT	Small molecular drug
DMFU6JR	PC	118467707
DMFU6JR	MW	393.4
DMFU6JR	FM	C22H23N3O4
DMFU6JR	IC	InChI=1S/C22H23N3O4/c1-25-11-16(14-7-8-23-18(14)22(25)27)15-9-13(28-2)10-17-20(15)29-19(21(26)24-17)12-5-3-4-6-12/h7-12,19,23H,3-6H2,1-2H3,(H,24,26)
DMFU6JR	CS	CN1C=C(C2=C(C1=O)NC=C2)C3=C4C(=CC(=C3)OC)NC(=O)C(O4)C5CCCC5
DMFU6JR	IK	APVTWFGLNNDNFT-UHFFFAOYSA-N
DMFU6JR	IU	2-cyclopentyl-6-methoxy-8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-4H-1,4-benzoxazin-3-one

DMFN1AR	ID	DMFN1AR
DMFN1AR	DN	PMID26924192-Compound-53
DMFN1AR	HS	Patented
DMFN1AR	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMFN1AR	DT	Small molecular drug
DMFN1AR	PC	121412319
DMFN1AR	MW	459.6
DMFN1AR	FM	C22H29N5O4S
DMFN1AR	IC	InChI=1S/C22H29N5O4S/c1-4-23-32(29,30)18-7-5-6-16(14-18)24-20-9-8-19-21(25-20)27(15(2)22(28)26(19)3)17-10-12-31-13-11-17/h5-9,14-15,17,23H,4,10-13H2,1-3H3,(H,24,25)/t15-/m1/s1
DMFN1AR	CS	CCNS(=O)(=O)C1=CC=CC(=C1)NC2=NC3=C(C=C2)N(C(=O)[C@H](N3C4CCOCC4)C)C
DMFN1AR	IK	IVGZHVCCAQPDME-OAHLLOKOSA-N
DMFN1AR	IU	3-[[(3R)-1,3-dimethyl-4-(oxan-4-yl)-2-oxo-3H-pyrido[2,3-b]pyrazin-6-yl]amino]-N-ethylbenzenesulfonamide

DMODT8F	ID	DMODT8F
DMODT8F	DN	PMID26924192-Compound-54
DMODT8F	HS	Patented
DMODT8F	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMODT8F	DT	Small molecular drug
DMODT8F	PC	86582981
DMODT8F	MW	582.6
DMODT8F	FM	C26H33F3N6O4S
DMODT8F	IC	InChI=1S/C26H33F3N6O4S/c1-18-25(36)32(2)22-6-7-23(31-24(22)35(18)20-8-14-39-15-9-20)30-19-4-3-5-21(16-19)40(37,38)34-12-10-33(11-13-34)17-26(27,28)29/h3-7,16,18,20H,8-15,17H2,1-2H3,(H,30,31)/t18-/m1/s1
DMODT8F	CS	C[C@@H]1C(=O)N(C2=C(N1C3CCOCC3)N=C(C=C2)NC4=CC(=CC=C4)S(=O)(=O)N5CCN(CC5)CC(F)(F)F)C
DMODT8F	IK	DRCMYKRSYNVVMM-GOSISDBHSA-N
DMODT8F	IU	(3R)-1,3-dimethyl-4-(oxan-4-yl)-6-[3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]sulfonylanilino]-3H-pyrido[2,3-b]pyrazin-2-one

DMGWQVT	ID	DMGWQVT
DMGWQVT	DN	PMID26924192-Compound-55
DMGWQVT	HS	Patented
DMGWQVT	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DMGWQVT	DT	Small molecular drug
DMGWQVT	PC	87055858
DMGWQVT	MW	528.7
DMGWQVT	FM	C26H36N6O4S
DMGWQVT	IC	InChI=1S/C26H36N6O4S/c1-18-26(33)31(3)23-7-8-24(28-25(23)32(18)21-11-15-36-16-12-21)27-20-5-4-6-22(17-20)37(34,35)29-19-9-13-30(2)14-10-19/h4-8,17-19,21,29H,9-16H2,1-3H3,(H,27,28)/t18-/m1/s1
DMGWQVT	CS	C[C@@H]1C(=O)N(C2=C(N1C3CCOCC3)N=C(C=C2)NC4=CC(=CC=C4)S(=O)(=O)NC5CCN(CC5)C)C
DMGWQVT	IK	NYFZHTKDUXWZDU-GOSISDBHSA-N
DMGWQVT	IU	3-[[(3R)-1,3-dimethyl-4-(oxan-4-yl)-2-oxo-3H-pyrido[2,3-b]pyrazin-6-yl]amino]-N-(1-methylpiperidin-4-yl)benzenesulfonamide

DM6YGLT	ID	DM6YGLT
DM6YGLT	DN	PMID26924192-Compound-56
DM6YGLT	HS	Patented
DM6YGLT	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DM6YGLT	DT	Small molecular drug
DM6YGLT	PC	87055861
DM6YGLT	MW	498.6
DM6YGLT	FM	C25H34N6O3S
DM6YGLT	IC	InChI=1S/C25H34N6O3S/c1-18-25(32)29(3)22-9-10-23(27-24(22)31(18)20-11-15-28(2)16-12-20)26-19-7-6-8-21(17-19)35(33,34)30-13-4-5-14-30/h6-10,17-18,20H,4-5,11-16H2,1-3H3,(H,26,27)/t18-/m1/s1
DM6YGLT	CS	C[C@@H]1C(=O)N(C2=C(N1C3CCN(CC3)C)N=C(C=C2)NC4=CC(=CC=C4)S(=O)(=O)N5CCCC5)C
DM6YGLT	IK	IIDSCXUAKMUCPQ-GOSISDBHSA-N
DM6YGLT	IU	(3R)-1,3-dimethyl-4-(1-methylpiperidin-4-yl)-6-(3-pyrrolidin-1-ylsulfonylanilino)-3H-pyrido[2,3-b]pyrazin-2-one

DM3NXP8	ID	DM3NXP8
DM3NXP8	DN	PMID26924192-Compound-57
DM3NXP8	HS	Patented
DM3NXP8	CP	BAYER PHARMA AKTIENGESELLSCHAFT
DM3NXP8	DT	Small molecular drug
DM3NXP8	PC	87055862
DM3NXP8	MW	471.6
DM3NXP8	FM	C23H29N5O4S
DM3NXP8	IC	InChI=1S/C23H29N5O4S/c1-15-23(29)27(2)20-8-9-21(25-22(20)28(15)18-10-12-32-13-11-18)24-17-4-3-5-19(14-17)33(30,31)26-16-6-7-16/h3-5,8-9,14-16,18,26H,6-7,10-13H2,1-2H3,(H,24,25)/t15-/m1/s1
DM3NXP8	CS	C[C@@H]1C(=O)N(C2=C(N1C3CCOCC3)N=C(C=C2)NC4=CC(=CC=C4)S(=O)(=O)NC5CC5)C
DM3NXP8	IK	XMBSYBXAJSVFRE-OAHLLOKOSA-N
DM3NXP8	IU	N-cyclopropyl-3-[[(3R)-1,3-dimethyl-4-(oxan-4-yl)-2-oxo-3H-pyrido[2,3-b]pyrazin-6-yl]amino]benzenesulfonamide

DMXK6LV	ID	DMXK6LV
DMXK6LV	DN	PMID26936077-Compound-13
DMXK6LV	HS	Patented
DMXK6LV	CP	THE UNIVERSITY OF QUEENSLAND FAIRLIE, David Paul LIU, Ligong YAU, Mei-Kwan SUEN, Jacky Yung REID, Robert LOHMAN, Rink-Jan IYER, Abishek Venkatasubramanian LIM, Junxian BROWN, Lindsay CharleThe University of Queensland
DMXK6LV	DT	Small molecular drug
DMXK6LV	DE	Type-2 diabetes; Metabolic disorder; Gastric ulcer

DMIZL8D	ID	DMIZL8D
DMIZL8D	DN	PMID26936077-Compound-34
DMIZL8D	HS	Patented
DMIZL8D	CP	THE UNIVERSITY OF QUEENSLAND FAIRLIE, David Paul LIU, Ligong YAU, Mei-Kwan SUEN, Jacky Yung REID, Robert LOHMAN, Rink-Jan IYER, Abishek Venkatasubramanian LIM, Junxian BROWN, Lindsay CharleThe University of Queensland
DMIZL8D	DT	Small molecular drug
DMIZL8D	DE	Type-2 diabetes; Metabolic disorder; Gastric ulcer

DMD0HAT	ID	DMD0HAT
DMD0HAT	DN	PMID27019002-Compound-13
DMD0HAT	HS	Patented
DMD0HAT	CP	NEVADA CANCER INSTITUTE SHENZHEN GRADUATE SCHOOL OF PEKING UNIVERSITY ZHANG, Hui YE, Tao QUAN, Junmin WANG, Jing
DMD0HAT	DT	Small molecular drug

DMZ9T8H	ID	DMZ9T8H
DMZ9T8H	DN	PMID27019002-Compound-16
DMZ9T8H	HS	Patented
DMZ9T8H	CP	MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
DMZ9T8H	DT	Small molecular drug

DM7JASU	ID	DM7JASU
DM7JASU	DN	PMID27019002-Compound-17
DM7JASU	HS	Patented
DM7JASU	CP	UNIVERSITY OF UTAUNIVERSITY OF UTAH RESEARCH FOUNDATIOUNIVERSITY OF UTAH RESEARCH FOUNDATION VANKAYALAPATI, Hariprasad SORNA, Venkataswamy WARNER, Steve, L. BEARSS, David, J. SHARMA, Sunil STEPHENS, BreUniversity of Utah, USA
DM7JASU	DT	Small molecular drug

DMRX748	ID	DMRX748
DMRX748	DN	PMID27019002-Compound-20a
DMRX748	HS	Patented
DMRX748	CP	ORYZON GENOMICS SA [ES]
DMRX748	DT	Small molecular drug

DMYRV8I	ID	DMYRV8I
DMYRV8I	DN	PMID27019002-Compound-20b
DMYRV8I	HS	Patented
DMYRV8I	CP	ORYZON GENOMICS SA [ES]
DMYRV8I	DT	Small molecular drug

DMC6AF2	ID	DMC6AF2
DMC6AF2	DN	PMID27019002-Compound-21a
DMC6AF2	HS	Patented
DMC6AF2	CP	ORYZON GENOMICS, S.A. BAKER, Jonathan, A. FYFE, Matthew, Colin, ThoORYZON GENOMICS, S.A. BAKER, Jonathan, Alleman FYFE, Matthew, Colin Thor
DMC6AF2	DT	Small molecular drug

DMMC31N	ID	DMMC31N
DMMC31N	DN	PMID27019002-Compound-21b
DMMC31N	HS	Patented
DMMC31N	CP	ORYZON GENOMICS SA [ESORYZON GENOMICS S.A. BAKER, Jonathan, Alleman CASTRO PALOMINO, Julio FYFE, Matthew, Colin, Thor MAES, Tamara MARTINELL PEDEMONTE, MarORYZON GENOMICS, S.A. BAKER, Jonathan, Alleman FYFE, Matthew, Colin Thor
DMMC31N	DT	Small molecular drug

DMWZOKP	ID	DMWZOKP
DMWZOKP	DN	PMID27019002-Compound-21c
DMWZOKP	HS	Patented
DMWZOKP	CP	ORYZON GENOMICS SA [ESORYZON GENOMICS S.A. BAKER, Jonathan, Alleman CASTRO PALOMINO, Julio FYFE, Matthew, Colin, Thor MAES, Tamara MARTINELL PEDEMONTE, MarORYZON GENOMICS, S.A. BAKER, Jonathan, Alleman FYFE, Matthew, Colin Thor
DMWZOKP	DT	Small molecular drug

DM1R6GA	ID	DM1R6GA
DM1R6GA	DN	PMID27019002-Compound-28
DM1R6GA	HS	Patented
DM1R6GA	CP	IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L
DM1R6GA	DT	Small molecular drug

DM954C8	ID	DM954C8
DM954C8	DN	PMID27019002-Compound-28a
DM954C8	HS	Patented
DM954C8	CP	IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L
DM954C8	DT	Small molecular drug

DMRWGHN	ID	DMRWGHN
DMRWGHN	DN	PMID27019002-Compound-31a
DMRWGHN	HS	Patented
DMRWGHN	CP	THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF NEVADA, LAS VEGAS
DMRWGHN	DT	Small molecular drug

DMJ1K4Y	ID	DMJ1K4Y
DMJ1K4Y	DN	PMID27019002-Compound-31b
DMJ1K4Y	HS	Patented
DMJ1K4Y	CP	THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF NEVADA, LAS VEGAS
DMJ1K4Y	DT	Small molecular drug

DMMB6XC	ID	DMMB6XC
DMMB6XC	DN	PMID27019002-Compound-37a
DMMB6XC	HS	Patented
DMMB6XC	CP	NEVADA CANCER INSTITUTE SHENZHEN GRADUATE SCHOOL OF PEKING UNIVERSITY ZHANG, Hui YE, Tao QUAN, Junmin WANG, Jing
DMMB6XC	DT	Small molecular drug

DMCIT5A	ID	DMCIT5A
DMCIT5A	DN	PMID27019002-Compound-37b
DMCIT5A	HS	Patented
DMCIT5A	CP	NEVADA CANCER INSTITUTE SHENZHEN GRADUATE SCHOOL OF PEKING UNIVERSITY ZHANG, Hui YE, Tao QUAN, Junmin WANG, Jing
DMCIT5A	DT	Small molecular drug

DMVLXRB	ID	DMVLXRB
DMVLXRB	DN	PMID27019002-Compound-41
DMVLXRB	HS	Patented
DMVLXRB	CP	UNIVERSITY OF UTAUNIVERSITY OF UTAH RESEARCH FOUNDATIOUNIVERSITY OF UTAH RESEARCH FOUNDATION VANKAYALAPATI, Hariprasad SORNA, Venkataswamy WARNER, Steve, L. BEARSS, David, J. SHARMA, Sunil STEPHENS, BreUniversity of Utah, USA
DMVLXRB	DT	Small molecular drug

DM42VUQ	ID	DM42VUQ
DM42VUQ	DN	PMID27019002-Compound-42a
DM42VUQ	HS	Patented
DM42VUQ	CP	UNIVERSITY OF UTAH RESEARCH FOUNDATIOUniversity of Utah, USA
DM42VUQ	DT	Small molecular drug

DMHJBRO	ID	DMHJBRO
DMHJBRO	DN	PMID27019002-Compound-42b
DMHJBRO	HS	Patented
DMHJBRO	CP	UNIVERSITY OF UTAH RESEARCH FOUNDATIOUniversity of Utah, USA
DMHJBRO	DT	Small molecular drug

DMMOVGU	ID	DMMOVGU
DMMOVGU	DN	PMID27019002-Compound-43a
DMMOVGU	HS	Patented
DMMOVGU	CP	UNIVERSITY OF UTAH
DMMOVGU	DT	Small molecular drug

DMIMFND	ID	DMIMFND
DMIMFND	DN	PMID27019002-Compound-43b
DMIMFND	HS	Patented
DMIMFND	CP	UNIVERSITY OF UTAH
DMIMFND	DT	Small molecular drug

DM72TBJ	ID	DM72TBJ
DM72TBJ	DN	PMID27019002-Compound-43c
DM72TBJ	HS	Patented
DM72TBJ	CP	UNIVERSITY OF UTAH
DM72TBJ	DT	Small molecular drug

DM5HUCR	ID	DM5HUCR
DM5HUCR	DN	PMID27019002-Compound-44
DM5HUCR	HS	Patented
DM5HUCR	CP	MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
DM5HUCR	DT	Small molecular drug

DM3G6YV	ID	DM3G6YV
DM3G6YV	DN	PMID27019002-Compound-45
DM3G6YV	HS	Patented
DM3G6YV	CP	UNIVERSITY OF CANBERRKYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY EDUCATIONAL CORPORATION KANSAI BUNRI SOUGOUGAKUEN FRONTIER PHARMA INC. KYOTO UNIVERSITY
DM3G6YV	DT	Small molecular drug

DMQPU7K	ID	DMQPU7K
DMQPU7K	DN	PMID27019002-Compound-46
DMQPU7K	HS	Patented
DMQPU7K	CP	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. SHI, Yujiang Geno LIAN, Christine Guo
DMQPU7K	DT	Small molecular drug

DMRLWP9	ID	DMRLWP9
DMRLWP9	DN	PMID27019002-Compound-47
DMRLWP9	HS	Patented
DMRLWP9	CP	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. SHI, Yujiang Geno LIAN, Christine Guo
DMRLWP9	DT	Small molecular drug

DMIO8J3	ID	DMIO8J3
DMIO8J3	DN	PMID27019002-Compound-48
DMIO8J3	HS	Patented
DMIO8J3	CP	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. SHI, Yujiang Geno LIAN, Christine Guo
DMIO8J3	DT	Small molecular drug

DMP6WCX	ID	DMP6WCX
DMP6WCX	DN	PMID27019002-Compound-49
DMP6WCX	HS	Patented
DMP6WCX	CP	MCCORD, Darlene E. KARAGIANNIS, Thomas
DMP6WCX	DT	Small molecular drug

DM4D75L	ID	DM4D75L
DM4D75L	DN	PMID27019002-Compound-50
DM4D75L	HS	Patented
DM4D75L	CP	MCCORD, Darlene E. KARAGIANNIS, Thomas
DM4D75L	DT	Small molecular drug

DMB0S52	ID	DMB0S52
DMB0S52	DN	PMID27019002-Compound-7
DMB0S52	HS	Patented
DMB0S52	CP	THE JOHNS HOPKINS UNIVERSITY INTONATION RESEARCH LABORATORIES
DMB0S52	DT	Small molecular drug

DMW2N5D	ID	DMW2N5D
DMW2N5D	DN	PMID27109571-Compound-1
DMW2N5D	HS	Patented
DMW2N5D	DT	Small molecular drug
DMW2N5D	PC	68053067
DMW2N5D	MW	236.27
DMW2N5D	FM	C12H16N2O3
DMW2N5D	IC	InChI=1S/C12H16N2O3/c15-12(16)10-1-2-11(13-9-10)3-4-14-5-7-17-8-6-14/h1-2,9H,3-8H2,(H,15,16)
DMW2N5D	CS	C1COCCN1CCC2=NC=C(C=C2)C(=O)O
DMW2N5D	IK	IAYFDTNYXBOKKE-UHFFFAOYSA-N
DMW2N5D	IU	6-(2-morpholin-4-ylethyl)pyridine-3-carboxylic acid

DMW60HU	ID	DMW60HU
DMW60HU	DN	PMID27109571-Compound-10
DMW60HU	HS	Patented
DMW60HU	DT	Small molecular drug

DMMI4KQ	ID	DMMI4KQ
DMMI4KQ	DN	PMID27109571-Compound-11
DMMI4KQ	HS	Patented
DMMI4KQ	DT	Small molecular drug

DM6HWBK	ID	DM6HWBK
DM6HWBK	DN	PMID27109571-Compound-12
DM6HWBK	HS	Patented
DM6HWBK	DT	Small molecular drug
DM6HWBK	PC	71556165
DM6HWBK	MW	323.8
DM6HWBK	FM	C19H14ClNO2
DM6HWBK	IC	InChI=1S/C19H14ClNO2/c20-13-8-9-15-14(10-13)16(11-4-2-1-3-5-11)17(19(22)23)18(21-15)12-6-7-12/h1-5,8-10,12H,6-7H2,(H,22,23)
DM6HWBK	CS	C1CC1C2=NC3=C(C=C(C=C3)Cl)C(=C2C(=O)O)C4=CC=CC=C4
DM6HWBK	IK	OKOHKZNRTKWMBM-UHFFFAOYSA-N
DM6HWBK	IU	6-chloro-2-cyclopropyl-4-phenylquinoline-3-carboxylic acid

DMUKOGJ	ID	DMUKOGJ
DMUKOGJ	DN	PMID27109571-Compound-13
DMUKOGJ	HS	Patented
DMUKOGJ	DT	Small molecular drug
DMUKOGJ	PC	71556619
DMUKOGJ	MW	375.2
DMUKOGJ	FM	C19H16Cl2N2O2
DMUKOGJ	IC	InChI=1S/C19H16Cl2N2O2/c1-3-23(2)18-16(19(24)25)15(11-7-5-4-6-8-11)13-9-12(20)10-14(21)17(13)22-18/h4-10H,3H2,1-2H3,(H,24,25)
DMUKOGJ	CS	CCN(C)C1=C(C(=C2C=C(C=C(C2=N1)Cl)Cl)C3=CC=CC=C3)C(=O)O
DMUKOGJ	IK	RNRWKMXASDHXSW-UHFFFAOYSA-N
DMUKOGJ	IU	6,8-dichloro-2-[ethyl(methyl)amino]-4-phenylquinoline-3-carboxylic acid

DMVY6B9	ID	DMVY6B9
DMVY6B9	DN	PMID27109571-Compound-14
DMVY6B9	HS	Patented
DMVY6B9	DT	Small molecular drug
DMVY6B9	PC	89542132
DMVY6B9	MW	364.8
DMVY6B9	FM	C19H17ClN6
DMVY6B9	IC	InChI=1S/C19H17ClN6/c1-3-26(2)19-17(18-22-24-25-23-18)16(12-7-5-4-6-8-12)14-11-13(20)9-10-15(14)21-19/h4-11H,3H2,1-2H3,(H,22,23,24,25)
DMVY6B9	CS	CCN(C)C1=NC2=C(C=C(C=C2)Cl)C(=C1C3=NNN=N3)C4=CC=CC=C4
DMVY6B9	IK	DNKGOGCNEVPJAB-UHFFFAOYSA-N
DMVY6B9	IU	6-chloro-N-ethyl-N-methyl-4-phenyl-3-(2H-tetrazol-5-yl)quinolin-2-amine

DMUR3FY	ID	DMUR3FY
DMUR3FY	DN	PMID27109571-Compound-15
DMUR3FY	HS	Patented
DMUR3FY	DT	Small molecular drug
DMUR3FY	PC	71555922
DMUR3FY	MW	422.9
DMUR3FY	FM	C22H19ClN4OS
DMUR3FY	IC	InChI=1S/C22H19ClN4OS/c23-15-9-10-17-16(13-15)18(14-7-3-1-4-8-14)19(21-25-26-22(29)28-21)20(24-17)27-11-5-2-6-12-27/h1,3-4,7-10,13H,2,5-6,11-12H2,(H,26,29)
DMUR3FY	CS	C1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)C(=C2C4=NNC(=S)O4)C5=CC=CC=C5
DMUR3FY	IK	QNSIEZUINFOQFH-UHFFFAOYSA-N
DMUR3FY	IU	5-(6-chloro-4-phenyl-2-piperidin-1-ylquinolin-3-yl)-3H-1,3,4-oxadiazole-2-thione

DMZI25U	ID	DMZI25U
DMZI25U	DN	PMID27109571-Compound-16
DMZI25U	HS	Patented
DMZI25U	DT	Small molecular drug
DMZI25U	PC	86683056
DMZI25U	MW	424.4
DMZI25U	FM	C22H19F3N6
DMZI25U	IC	InChI=1S/C22H19F3N6/c23-22(24,25)15-9-10-17-16(13-15)18(14-7-3-1-4-8-14)19(20-27-29-30-28-20)21(26-17)31-11-5-2-6-12-31/h1,3-4,7-10,13H,2,5-6,11-12H2,(H,27,28,29,30)
DMZI25U	CS	C1CCN(CC1)C2=NC3=C(C=C(C=C3)C(F)(F)F)C(=C2C4=NNN=N4)C5=CC=CC=C5
DMZI25U	IK	SUXQAVNHOCPUSH-UHFFFAOYSA-N
DMZI25U	IU	4-phenyl-2-piperidin-1-yl-3-(2H-tetrazol-5-yl)-6-(trifluoromethyl)quinoline

DMBETU6	ID	DMBETU6
DMBETU6	DN	PMID27109571-Compound-17
DMBETU6	HS	Patented
DMBETU6	DT	Small molecular drug
DMBETU6	PC	86683057
DMBETU6	MW	412.4
DMBETU6	FM	C21H19F3N6
DMBETU6	IC	InChI=1S/C21H19F3N6/c1-3-30(4-2)20-18(19-26-28-29-27-19)17(13-8-6-5-7-9-13)15-12-14(21(22,23)24)10-11-16(15)25-20/h5-12H,3-4H2,1-2H3,(H,26,27,28,29)
DMBETU6	CS	CCN(CC)C1=NC2=C(C=C(C=C2)C(F)(F)F)C(=C1C3=NNN=N3)C4=CC=CC=C4
DMBETU6	IK	RVTWZFXKPCJMAI-UHFFFAOYSA-N
DMBETU6	IU	N,N-diethyl-4-phenyl-3-(2H-tetrazol-5-yl)-6-(trifluoromethyl)quinolin-2-amine

DM4S5ME	ID	DM4S5ME
DM4S5ME	DN	PMID27109571-Compound-18
DM4S5ME	HS	Patented
DM4S5ME	DT	Small molecular drug
DM4S5ME	PC	89542341
DM4S5ME	MW	395.9
DM4S5ME	FM	C21H19ClFN5
DM4S5ME	IC	InChI=1S/C21H19ClFN5/c1-3-12(4-2)20-19(21-25-27-28-26-21)18(13-8-6-5-7-9-13)14-10-15(22)16(23)11-17(14)24-20/h5-12H,3-4H2,1-2H3,(H,25,26,27,28)
DM4S5ME	CS	CCC(CC)C1=NC2=CC(=C(C=C2C(=C1C3=NNN=N3)C4=CC=CC=C4)Cl)F
DM4S5ME	IK	OTAAEQZYEFGHGG-UHFFFAOYSA-N
DM4S5ME	IU	6-chloro-7-fluoro-2-pentan-3-yl-4-phenyl-3-(2H-tetrazol-5-yl)quinoline

DMIJGLB	ID	DMIJGLB
DMIJGLB	DN	PMID27109571-Compound-19
DMIJGLB	HS	Patented
DMIJGLB	DT	Small molecular drug
DMIJGLB	PC	86683063
DMIJGLB	MW	408.9
DMIJGLB	FM	C21H18ClFN6
DMIJGLB	IC	InChI=1S/C21H18ClFN6/c22-15-11-14-17(12-16(15)23)24-21(29-9-5-2-6-10-29)19(20-25-27-28-26-20)18(14)13-7-3-1-4-8-13/h1,3-4,7-8,11-12H,2,5-6,9-10H2,(H,25,26,27,28)
DMIJGLB	CS	C1CCN(CC1)C2=NC3=CC(=C(C=C3C(=C2C4=NNN=N4)C5=CC=CC=C5)Cl)F
DMIJGLB	IK	APFHIGYPDALGOX-UHFFFAOYSA-N
DMIJGLB	IU	6-chloro-7-fluoro-4-phenyl-2-piperidin-1-yl-3-(2H-tetrazol-5-yl)quinoline

DMTD1X8	ID	DMTD1X8
DMTD1X8	DN	PMID27109571-Compound-2
DMTD1X8	HS	Patented
DMTD1X8	DT	Small molecular drug
DMTD1X8	PC	56592602
DMTD1X8	MW	264.32
DMTD1X8	FM	C14H20N2O3
DMTD1X8	IC	InChI=1S/C14H20N2O3/c1-2-19-14(17)12-3-4-13(15-11-12)5-6-16-7-9-18-10-8-16/h3-4,11H,2,5-10H2,1H3
DMTD1X8	CS	CCOC(=O)C1=CN=C(C=C1)CCN2CCOCC2
DMTD1X8	IK	XIDYSJNRQHEJQG-UHFFFAOYSA-N
DMTD1X8	IU	ethyl 6-(2-morpholin-4-ylethyl)pyridine-3-carboxylate

DMQU9XP	ID	DMQU9XP
DMQU9XP	DN	PMID27109571-Compound-20
DMQU9XP	HS	Patented
DMQU9XP	DT	Small molecular drug
DMQU9XP	PC	86683065
DMQU9XP	MW	396.8
DMQU9XP	FM	C20H18ClFN6
DMQU9XP	IC	InChI=1S/C20H18ClFN6/c1-3-28(4-2)20-18(19-24-26-27-25-19)17(12-8-6-5-7-9-12)13-10-14(21)15(22)11-16(13)23-20/h5-11H,3-4H2,1-2H3,(H,24,25,26,27)
DMQU9XP	CS	CCN(CC)C1=NC2=CC(=C(C=C2C(=C1C3=NNN=N3)C4=CC=CC=C4)Cl)F
DMQU9XP	IK	CVFVCWWTTQCZRK-UHFFFAOYSA-N
DMQU9XP	IU	6-chloro-N,N-diethyl-7-fluoro-4-phenyl-3-(2H-tetrazol-5-yl)quinolin-2-amine

DM0R5Y8	ID	DM0R5Y8
DM0R5Y8	DN	PMID27109571-Compound-21
DM0R5Y8	HS	Patented
DM0R5Y8	DT	Small molecular drug
DM0R5Y8	PC	118589228
DM0R5Y8	MW	374.5
DM0R5Y8	FM	C22H26N6
DM0R5Y8	IC	InChI=1S/C22H26N6/c1-3-7-16(8-4-1)21-20(22-25-27-28-26-22)19(15-11-13-23-14-12-15)17-9-5-2-6-10-18(17)24-21/h11-14,16H,1-10H2,(H,25,26,27,28)
DM0R5Y8	CS	C1CCC(CC1)C2=NC3=C(CCCCC3)C(=C2C4=NNN=N4)C5=CC=NC=C5
DM0R5Y8	IK	FMTDJMYDWZGVPK-UHFFFAOYSA-N
DM0R5Y8	IU	2-cyclohexyl-4-pyridin-4-yl-3-(2H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

DMC52VP	ID	DMC52VP
DMC52VP	DN	PMID27109571-Compound-22
DMC52VP	HS	Patented
DMC52VP	DT	Small molecular drug
DMC52VP	PC	118589197
DMC52VP	MW	442.5
DMC52VP	FM	C23H25F3N6
DMC52VP	IC	InChI=1S/C23H25F3N6/c1-13-11-15(9-10-27-13)19-17-12-16(23(24,25)26)7-8-18(17)28-21(14-5-3-2-4-6-14)20(19)22-29-31-32-30-22/h9-11,14,16H,2-8,12H2,1H3,(H,29,30,31,32)
DMC52VP	CS	CC1=NC=CC(=C1)C2=C(C(=NC3=C2CC(CC3)C(F)(F)F)C4CCCCC4)C5=NNN=N5
DMC52VP	IK	ALFQKPZYXQRVDU-UHFFFAOYSA-N
DMC52VP	IU	2-cyclohexyl-4-(2-methylpyridin-4-yl)-3-(2H-tetrazol-5-yl)-6-(trifluoromethyl)-5,6,7,8-tetrahydroquinoline

DML49UI	ID	DML49UI
DML49UI	DN	PMID27109571-Compound-23
DML49UI	HS	Patented
DML49UI	DT	Small molecular drug
DML49UI	PC	73295099
DML49UI	MW	374.5
DML49UI	FM	C22H26N6
DML49UI	IC	InChI=1S/C22H26N6/c1-13-7-8-18-17(11-13)19(16-9-10-23-14(2)12-16)20(22-25-27-28-26-22)21(24-18)15-5-3-4-6-15/h9-10,12-13,15H,3-8,11H2,1-2H3,(H,25,26,27,28)
DML49UI	CS	CC1CCC2=C(C1)C(=C(C(=N2)C3CCCC3)C4=NNN=N4)C5=CC(=NC=C5)C
DML49UI	IK	LSPFDXQDUWKIKF-UHFFFAOYSA-N
DML49UI	IU	2-cyclopentyl-6-methyl-4-(2-methylpyridin-4-yl)-3-(2H-tetrazol-5-yl)-5,6,7,8-tetrahydroquinoline

DMPHTC0	ID	DMPHTC0
DMPHTC0	DN	PMID27109571-Compound-24
DMPHTC0	HS	Patented
DMPHTC0	DT	Small molecular drug

DM435GR	ID	DM435GR
DM435GR	DN	PMID27109571-Compound-25
DM435GR	HS	Patented
DM435GR	DT	Small molecular drug
DM435GR	PC	90043846
DM435GR	MW	404.5
DM435GR	FM	C23H28N6O
DM435GR	IC	InChI=1S/C23H28N6O/c1-15-13-16(9-12-24-15)19-17-7-3-2-4-8-18(17)25-21(20(19)22-26-28-29-27-22)23(14-30)10-5-6-11-23/h9,12-13,30H,2-8,10-11,14H2,1H3,(H,26,27,28,29)
DM435GR	CS	CC1=NC=CC(=C1)C2=C(C(=NC3=C2CCCCC3)C4(CCCC4)CO)C5=NNN=N5
DM435GR	IK	JDONBBWFRSZVOY-UHFFFAOYSA-N
DM435GR	IU	[1-[4-(2-methylpyridin-4-yl)-3-(2H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-yl]cyclopentyl]methanol

DMJCL53	ID	DMJCL53
DMJCL53	DN	PMID27109571-Compound-26
DMJCL53	HS	Patented
DMJCL53	DT	Small molecular drug
DMJCL53	PC	118589084
DMJCL53	MW	459.6
DMJCL53	FM	C28H37N5O
DMJCL53	IC	InChI=1S/C28H37N5O/c1-3-4-6-11-20-14-15-23-22(18-20)24(21-12-7-5-8-13-21)25(27-30-32-33-31-27)26(29-23)28(19-34-2)16-9-10-17-28/h5,7-8,12-13,20H,3-4,6,9-11,14-19H2,1-2H3,(H,30,31,32,33)
DMJCL53	CS	CCCCCC1CCC2=C(C1)C(=C(C(=N2)C3(CCCC3)COC)C4=NNN=N4)C5=CC=CC=C5
DMJCL53	IK	OGYHUAQNUJEKHA-UHFFFAOYSA-N
DMJCL53	IU	2-[1-(methoxymethyl)cyclopentyl]-6-pentyl-4-phenyl-3-(2H-tetrazol-5-yl)-5,6,7,8-tetrahydroquinoline

DMXRTH4	ID	DMXRTH4
DMXRTH4	DN	PMID27109571-Compound-27
DMXRTH4	HS	Patented
DMXRTH4	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMXRTH4	DT	Small molecular drug
DMXRTH4	PC	86270841
DMXRTH4	MW	358.8
DMXRTH4	FM	C19H19ClN2O3
DMXRTH4	IC	InChI=1S/C19H19ClN2O3/c20-14-8-9-15(13-6-2-1-3-7-13)16(12-14)21-18(25)22-19(17(23)24)10-4-5-11-19/h1-3,6-9,12H,4-5,10-11H2,(H,23,24)(H2,21,22,25)
DMXRTH4	CS	C1CCC(C1)(C(=O)O)NC(=O)NC2=C(C=CC(=C2)Cl)C3=CC=CC=C3
DMXRTH4	IK	YBQHFZNBCISVBS-UHFFFAOYSA-N
DMXRTH4	IU	1-[(5-chloro-2-phenylphenyl)carbamoylamino]cyclopentane-1-carboxylic acid

DMTZVY3	ID	DMTZVY3
DMTZVY3	DN	PMID27109571-Compound-28
DMTZVY3	HS	Patented
DMTZVY3	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMTZVY3	DT	Small molecular drug
DMTZVY3	PC	86270934
DMTZVY3	MW	376.8
DMTZVY3	FM	C19H18ClFN2O3
DMTZVY3	IC	InChI=1S/C19H18ClFN2O3/c20-13-5-8-15(12-3-6-14(21)7-4-12)16(11-13)22-18(26)23-19(17(24)25)9-1-2-10-19/h3-8,11H,1-2,9-10H2,(H,24,25)(H2,22,23,26)
DMTZVY3	CS	C1CCC(C1)(C(=O)O)NC(=O)NC2=C(C=CC(=C2)Cl)C3=CC=C(C=C3)F
DMTZVY3	IK	PDTYXZFDMKYTCF-UHFFFAOYSA-N
DMTZVY3	IU	1-[[5-chloro-2-(4-fluorophenyl)phenyl]carbamoylamino]cyclopentane-1-carboxylic acid

DMDMEHQ	ID	DMDMEHQ
DMDMEHQ	DN	PMID27109571-Compound-29
DMDMEHQ	HS	Patented
DMDMEHQ	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMDMEHQ	DT	Small molecular drug
DMDMEHQ	PC	86270939
DMDMEHQ	MW	376.8
DMDMEHQ	FM	C19H18ClFN2O3
DMDMEHQ	IC	InChI=1S/C19H18ClFN2O3/c20-14-11-16(13(10-15(14)21)12-6-2-1-3-7-12)22-18(26)23-19(17(24)25)8-4-5-9-19/h1-3,6-7,10-11H,4-5,8-9H2,(H,24,25)(H2,22,23,26)
DMDMEHQ	CS	C1CCC(C1)(C(=O)O)NC(=O)NC2=CC(=C(C=C2C3=CC=CC=C3)F)Cl
DMDMEHQ	IK	OZCRNUIWAXZIST-UHFFFAOYSA-N
DMDMEHQ	IU	1-[(5-chloro-4-fluoro-2-phenylphenyl)carbamoylamino]cyclopentane-1-carboxylic acid

DMDXMH9	ID	DMDXMH9
DMDXMH9	DN	PMID27109571-Compound-3
DMDXMH9	HS	Patented
DMDXMH9	DT	Small molecular drug
DMDXMH9	PC	56592603
DMDXMH9	MW	352.4
DMDXMH9	FM	C21H24N2O3
DMDXMH9	IC	InChI=1S/C21H24N2O3/c24-21(26-20-7-5-16-2-1-3-17(16)14-20)18-4-6-19(22-15-18)8-9-23-10-12-25-13-11-23/h4-7,14-15H,1-3,8-13H2
DMDXMH9	CS	C1CC2=C(C1)C=C(C=C2)OC(=O)C3=CN=C(C=C3)CCN4CCOCC4
DMDXMH9	IK	YBXFSMTZUPPQRJ-UHFFFAOYSA-N
DMDXMH9	IU	2,3-dihydro-1H-inden-5-yl 6-(2-morpholin-4-ylethyl)pyridine-3-carboxylate

DM24FSP	ID	DM24FSP
DM24FSP	DN	PMID27109571-Compound-30
DM24FSP	HS	Patented
DM24FSP	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM24FSP	DT	Small molecular drug
DM24FSP	PC	78319116
DM24FSP	MW	393.3
DM24FSP	FM	C19H18Cl2N2O3
DM24FSP	IC	InChI=1S/C19H18Cl2N2O3/c20-13-10-14(21)16(12-6-2-1-3-7-12)15(11-13)22-18(26)23-19(17(24)25)8-4-5-9-19/h1-3,6-7,10-11H,4-5,8-9H2,(H,24,25)(H2,22,23,26)
DM24FSP	CS	C1CCC(C1)(C(=O)O)NC(=O)NC2=C(C(=CC(=C2)Cl)Cl)C3=CC=CC=C3
DM24FSP	IK	XKZSVPIUPDFCIQ-UHFFFAOYSA-N
DM24FSP	IU	1-[(3,5-dichloro-2-phenylphenyl)carbamoylamino]cyclopentane-1-carboxylic acid

DMU690T	ID	DMU690T
DMU690T	DN	PMID27109571-Compound-31
DMU690T	HS	Patented
DMU690T	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMU690T	DT	Small molecular drug
DMU690T	PC	86271032
DMU690T	MW	392.4
DMU690T	FM	C20H19F3N2O3
DMU690T	IC	InChI=1S/C20H19F3N2O3/c21-20(22,23)14-8-9-15(13-6-2-1-3-7-13)16(12-14)24-18(28)25-19(17(26)27)10-4-5-11-19/h1-3,6-9,12H,4-5,10-11H2,(H,26,27)(H2,24,25,28)
DMU690T	CS	C1CCC(C1)(C(=O)O)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)C3=CC=CC=C3
DMU690T	IK	LZSZOARSNJNBDV-UHFFFAOYSA-N
DMU690T	IU	1-[[2-phenyl-5-(trifluoromethyl)phenyl]carbamoylamino]cyclopentane-1-carboxylic acid

DM4IS6Q	ID	DM4IS6Q
DM4IS6Q	DN	PMID27109571-Compound-32
DM4IS6Q	HS	Patented
DM4IS6Q	DT	Small molecular drug

DMGR2JC	ID	DMGR2JC
DMGR2JC	DN	PMID27109571-Compound-33
DMGR2JC	HS	Patented
DMGR2JC	DT	Small molecular drug

DM5OXUK	ID	DM5OXUK
DM5OXUK	DN	PMID27109571-Compound-34
DM5OXUK	HS	Patented
DM5OXUK	DT	Small molecular drug

DMGV4PT	ID	DMGV4PT
DMGV4PT	DN	PMID27109571-Compound-35
DMGV4PT	HS	Patented
DMGV4PT	DT	Small molecular drug
DMGV4PT	PC	58448012
DMGV4PT	MW	366.8
DMGV4PT	FM	C19H15ClN4O2
DMGV4PT	IC	InChI=1S/C19H15ClN4O2/c1-12-15(20)8-5-9-16(12)26-11-14-10-17(25)24-19(21-14)22-18(23-24)13-6-3-2-4-7-13/h2-10H,11H2,1H3,(H,21,22,23)
DMGV4PT	CS	CC1=C(C=CC=C1Cl)OCC2=CC(=O)N3C(=N2)N=C(N3)C4=CC=CC=C4
DMGV4PT	IK	DHVPJCVPOZYDTH-UHFFFAOYSA-N
DMGV4PT	IU	5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl-1H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one

DMCJ48G	ID	DMCJ48G
DMCJ48G	DN	PMID27109571-Compound-36
DMCJ48G	HS	Patented
DMCJ48G	DT	Small molecular drug
DMCJ48G	PC	73442005
DMCJ48G	MW	389.5
DMCJ48G	FM	C18H19N3O3S2
DMCJ48G	IC	InChI=1S/C18H19N3O3S2/c1-8-13(17-19-9(2)21-26-17)16(25-14(8)10-6-7-10)20-15(22)11-4-3-5-12(11)18(23)24/h10H,3-7H2,1-2H3,(H,20,22)(H,23,24)
DMCJ48G	CS	CC1=C(SC(=C1C2=NC(=NS2)C)NC(=O)C3=C(CCC3)C(=O)O)C4CC4
DMCJ48G	IK	PPVLCUXVOGWJMY-UHFFFAOYSA-N
DMCJ48G	IU	2-[[5-cyclopropyl-4-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)thiophen-2-yl]carbamoyl]cyclopentene-1-carboxylic acid

DMJCAOD	ID	DMJCAOD
DMJCAOD	DN	PMID27109571-Compound-37
DMJCAOD	HS	Patented
DMJCAOD	DT	Small molecular drug
DMJCAOD	PC	73442653
DMJCAOD	MW	467.5
DMJCAOD	FM	C21H20F3N3O4S
DMJCAOD	IC	InChI=1S/C21H20F3N3O4S/c1-8-12(9-2-3-9)15(17-26-20(27-31-17)21(22,23)24)18(32-8)25-16(28)13-10-4-6-11(7-5-10)14(13)19(29)30/h9-11H,2-7H2,1H3,(H,25,28)(H,29,30)
DMJCAOD	CS	CC1=C(C(=C(S1)NC(=O)C2=C(C3CCC2CC3)C(=O)O)C4=NC(=NO4)C(F)(F)F)C5CC5
DMJCAOD	IK	HXCOCQVXJUKVAX-UHFFFAOYSA-N
DMJCAOD	IU	3-[[4-cyclopropyl-5-methyl-3-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]thiophen-2-yl]carbamoyl]bicyclo[2.2.2]oct-2-ene-2-carboxylic acid

DMRQHDF	ID	DMRQHDF
DMRQHDF	DN	PMID27109571-Compound-38
DMRQHDF	HS	Patented
DMRQHDF	DT	Small molecular drug
DMRQHDF	PC	73442650
DMRQHDF	MW	313.4
DMRQHDF	FM	C17H15NO3S
DMRQHDF	IC	InChI=1S/C17H15NO3S/c19-15(13-7-4-8-14(13)17(20)21)18-16-12(9-10-22-16)11-5-2-1-3-6-11/h1-3,5-6,9-10H,4,7-8H2,(H,18,19)(H,20,21)
DMRQHDF	CS	C1CC(=C(C1)C(=O)O)C(=O)NC2=C(C=CS2)C3=CC=CC=C3
DMRQHDF	IK	WTIMMZFOZTXDOY-UHFFFAOYSA-N
DMRQHDF	IU	2-[(3-phenylthiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid

DMBHJDR	ID	DMBHJDR
DMBHJDR	DN	PMID27109571-Compound-39
DMBHJDR	HS	Patented
DMBHJDR	CP	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 
DMBHJDR	DT	Small molecular drug

DMYRG0Q	ID	DMYRG0Q
DMYRG0Q	DN	PMID27109571-Compound-4
DMYRG0Q	HS	Patented
DMYRG0Q	DT	Small molecular drug
DMYRG0Q	PC	68060544
DMYRG0Q	MW	248.32
DMYRG0Q	FM	C14H20N2O2
DMYRG0Q	IC	InChI=1S/C14H20N2O2/c1-2-18-14(17)12-5-6-13(15-11-12)7-10-16-8-3-4-9-16/h5-6,11H,2-4,7-10H2,1H3
DMYRG0Q	CS	CCOC(=O)C1=CN=C(C=C1)CCN2CCCC2
DMYRG0Q	IK	MBNVMBKJYZXTNI-UHFFFAOYSA-N
DMYRG0Q	IU	ethyl 6-(2-pyrrolidin-1-ylethyl)pyridine-3-carboxylate

DMQ83EV	ID	DMQ83EV
DMQ83EV	DN	PMID27109571-Compound-40
DMQ83EV	HS	Patented
DMQ83EV	CP	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 
DMQ83EV	DT	Small molecular drug

DMY4IAV	ID	DMY4IAV
DMY4IAV	DN	PMID27109571-Compound-41
DMY4IAV	HS	Patented
DMY4IAV	CP	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 
DMY4IAV	DT	Small molecular drug

DMZOI3K	ID	DMZOI3K
DMZOI3K	DN	PMID27109571-Compound-42
DMZOI3K	HS	Patented
DMZOI3K	CP	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 
DMZOI3K	DT	Small molecular drug

DMYZ42W	ID	DMYZ42W
DMYZ42W	DN	PMID27109571-Compound-43
DMYZ42W	HS	Patented
DMYZ42W	CP	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 
DMYZ42W	DT	Small molecular drug

DM3AUZS	ID	DM3AUZS
DM3AUZS	DN	PMID27109571-Compound-44
DM3AUZS	HS	Patented
DM3AUZS	CP	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 
DM3AUZS	DT	Small molecular drug

DMOZKAH	ID	DMOZKAH
DMOZKAH	DN	PMID27109571-Compound-5
DMOZKAH	HS	Patented
DMOZKAH	DT	Small molecular drug
DMOZKAH	PC	23728673
DMOZKAH	MW	260.329
DMOZKAH	FM	C15H20N2O2
DMOZKAH	IC	InChI=1S/C15H20N2O2/c18-15(19)5-3-4-13-6-7-14(16-12-13)8-11-17-9-1-2-10-17/h3-4,6-7,12H,1-2,5,8-11H2,(H,18,19)/b4-3+
DMOZKAH	CS	C1CCN(C1)CCC2=NC=C(C=C2)/C=C/CC(=O)O
DMOZKAH	IK	YAJGYOKZMAZQGT-ONEGZZNKSA-N
DMOZKAH	IU	(E)-4-[6-(2-pyrrolidin-1-ylethyl)pyridin-3-yl]but-3-enoic acid

DMPHMTR	ID	DMPHMTR
DMPHMTR	DN	PMID27109571-Compound-6
DMPHMTR	HS	Patented
DMPHMTR	DT	Small molecular drug

DM8GYCD	ID	DM8GYCD
DM8GYCD	DN	PMID27109571-Compound-7
DM8GYCD	HS	Patented
DM8GYCD	DT	Small molecular drug

DMTKFX7	ID	DMTKFX7
DMTKFX7	DN	PMID27109571-Compound-8
DMTKFX7	HS	Patented
DMTKFX7	DT	Small molecular drug
DMTKFX7	PC	68749983
DMTKFX7	MW	383.8
DMTKFX7	FM	C20H18ClN3O3
DMTKFX7	IC	InChI=1S/C20H18ClN3O3/c21-13-6-3-5-12(11-13)18(25)16-9-4-10-24(16)20(27)17-19(26)23-15-8-2-1-7-14(15)22-17/h1-3,5-8,11,16,18,25H,4,9-10H2,(H,23,26)
DMTKFX7	CS	C1CC(N(C1)C(=O)C2=NC3=CC=CC=C3NC2=O)C(C4=CC(=CC=C4)Cl)O
DMTKFX7	IK	FORQANAYPSMAGB-UHFFFAOYSA-N
DMTKFX7	IU	3-[2-[(3-chlorophenyl)-hydroxymethyl]pyrrolidine-1-carbonyl]-1H-quinoxalin-2-one

DMWM03O	ID	DMWM03O
DMWM03O	DN	PMID27109571-Compound-9
DMWM03O	HS	Patented
DMWM03O	DT	Small molecular drug

DMBWLSA	ID	DMBWLSA
DMBWLSA	DN	PMID27172114-Compound-30
DMBWLSA	HS	Patented
DMBWLSA	CP	CURADEV PHARMA PRIVATE LTDCuradev Pharma Private Ltd
DMBWLSA	DT	Small molecular drug

DMTIQYD	ID	DMTIQYD
DMTIQYD	DN	PMID27172114-Compound-47
DMTIQYD	HS	Patented
DMTIQYD	CP	DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia, M. COURTNEY, Stephen, Martin PRIME, Michael MITCHELL, William BROWN, Christopher, John DE AGUIAR PENA, Paula, C. JOHNSON, Peter
DMTIQYD	DT	Small molecular drug

DMSXJVY	ID	DMSXJVY
DMSXJVY	DN	PMID27172114-Compound-49
DMSXJVY	HS	Patented
DMSXJVY	CP	DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia, M. COURTNEY, Stephen, Martin PRIME, Michael MITCHELL, William BROWN, Christopher, John DE AGUIAR PENA, Paula, C. JOHNSON, Peter
DMSXJVY	DT	Small molecular drug

DM84RES	ID	DM84RES
DM84RES	DN	PMID27215781-Compound-1
DM84RES	HS	Patented
DM84RES	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM84RES	DT	Small molecular drug
DM84RES	PC	78428089
DM84RES	MW	314.4
DM84RES	FM	C19H26N2O2
DM84RES	IC	InChI=1S/C19H26N2O2/c1-3-19(4-2)12-23-18(21-19)16-9-17(22-11-13-5-6-13)15(10-20-16)14-7-8-14/h9-10,13-14H,3-8,11-12H2,1-2H3
DM84RES	CS	CCC1(COC(=N1)C2=NC=C(C(=C2)OCC3CC3)C4CC4)CC
DM84RES	IK	NMHFZCVAQZPHOP-UHFFFAOYSA-N
DM84RES	IU	2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole

DMIX90M	ID	DMIX90M
DMIX90M	DN	PMID27215781-Compound-11
DMIX90M	HS	Patented
DMIX90M	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH HICKEY, Eugene Richard RIETHER, Doris ERMANN, Monika
DMIX90M	DT	Small molecular drug
DMIX90M	PC	59662643
DMIX90M	MW	448.5
DMIX90M	FM	C19H23F3N2O3S2
DMIX90M	IC	InChI=1S/C19H23F3N2O3S2/c1-11-14(17(2,3)4)28-16(23-11)24-15(25)18(5,6)29(26,27)13-9-7-12(8-10-13)19(20,21)22/h7-10H,1-6H3,(H,23,24,25)
DMIX90M	CS	CC1=C(SC(=N1)NC(=O)C(C)(C)S(=O)(=O)C2=CC=C(C=C2)C(F)(F)F)C(C)(C)C
DMIX90M	IK	GQVUAMKUPFMNNE-UHFFFAOYSA-N
DMIX90M	IU	N-(5-tert-butyl-4-methyl-1,3-thiazol-2-yl)-2-methyl-2-[4-(trifluoromethyl)phenyl]sulfonylpropanamide

DMR9GLW	ID	DMR9GLW
DMR9GLW	DN	PMID27215781-Compound-12
DMR9GLW	HS	Patented
DMR9GLW	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH HICKEY, Eugene Richard RIETHER, Doris ERMANN, Monika
DMR9GLW	DT	Small molecular drug
DMR9GLW	PC	56639654
DMR9GLW	MW	389.5
DMR9GLW	FM	C16H27N3O4S2
DMR9GLW	IC	InChI=1S/C16H27N3O4S2/c1-15(2,3)13-18-19-14(24-13)17-12(20)16(4,5)10-25(21,22)11-6-8-23-9-7-11/h11H,6-10H2,1-5H3,(H,17,19,20)
DMR9GLW	CS	CC(C)(C)C1=NN=C(S1)NC(=O)C(C)(C)CS(=O)(=O)C2CCOCC2
DMR9GLW	IK	YNOMXHGERFXVDK-UHFFFAOYSA-N
DMR9GLW	IU	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-2,2-dimethyl-3-(oxan-4-ylsulfonyl)propanamide

DMNKH07	ID	DMNKH07
DMNKH07	DN	PMID27215781-Compound-13
DMNKH07	HS	Patented
DMNKH07	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH HICKEY, Eugene Richard RIETHER, Doris ERMANN, Monika
DMNKH07	DT	Small molecular drug

DMYMTSL	ID	DMYMTSL
DMYMTSL	DN	PMID27215781-Compound-19
DMYMTSL	HS	Patented
DMYMTSL	CP	ARENA PHARMACEUTICALS, INC. BLACKBURN, Anthony C. HAN, Sangdon JONES, Robert M. MONTALBAN, Anthony Garrido PAL, Biman B. RUETER, Jaimie Karyn
DMYMTSL	DT	Small molecular drug

DMBOX0K	ID	DMBOX0K
DMBOX0K	DN	PMID27215781-Compound-2
DMBOX0K	HS	Patented
DMBOX0K	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMBOX0K	DT	Small molecular drug
DMBOX0K	PC	76283339
DMBOX0K	MW	365.4
DMBOX0K	FM	C19H25F2N3O2
DMBOX0K	IC	InChI=1S/C19H25F2N3O2/c1-18(2)8-3-9-24(18)17(25)14-6-7-15(23-11-19(20,21)12-23)16(22-14)26-10-13-4-5-13/h6-7,13H,3-5,8-12H2,1-2H3
DMBOX0K	CS	CC1(CCCN1C(=O)C2=NC(=C(C=C2)N3CC(C3)(F)F)OCC4CC4)C
DMBOX0K	IK	AOQJVECXJNNKAZ-UHFFFAOYSA-N
DMBOX0K	IU	[6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyridin-2-yl]-(2,2-dimethylpyrrolidin-1-yl)methanone

DMKZF8E	ID	DMKZF8E
DMKZF8E	DN	PMID27215781-Compound-25
DMKZF8E	HS	Patented
DMKZF8E	CP	ISIS INNOVATION LIMITED
DMKZF8E	DT	Small molecular drug
DMKZF8E	PC	5752181
DMKZF8E	MW	258.339
DMKZF8E	FM	C13H14N4S
DMKZF8E	IC	InChI=1S/C13H14N4S/c1-2-3-8-18-13-15-12-11(16-17-13)9-6-4-5-7-10(9)14-12/h4-7H,2-3,8H2,1H3,(H,14,15,17)
DMKZF8E	CS	CCCCSC1=NC2=C(C3=CC=CC=C3N2)N=N1
DMKZF8E	IK	JLINGBANGFPKNS-UHFFFAOYSA-N
DMKZF8E	IU	3-butylsulfanyl-5H-[1,2,4]triazino[5,6-b]indole

DMTJHC2	ID	DMTJHC2
DMTJHC2	DN	PMID27215781-Compound-27
DMTJHC2	HS	Patented
DMTJHC2	CP	ISIS INNOVATION LIMITED
DMTJHC2	DT	Small molecular drug
DMTJHC2	PC	71539748
DMTJHC2	MW	412.4
DMTJHC2	FM	C21H12N6O2S
DMTJHC2	IC	InChI=1S/C21H12N6O2S/c22-11-13-5-1-2-6-14(13)12-30-21-24-19-18(25-26-21)15-7-3-4-8-16(15)27(19)20(28)17-9-10-23-29-17/h1-10H,12H2
DMTJHC2	CS	C1=CC=C(C(=C1)CSC2=NC3=C(C4=CC=CC=C4N3C(=O)C5=CC=NO5)N=N2)C#N
DMTJHC2	IK	DRIBOKZNLIGADO-UHFFFAOYSA-N
DMTJHC2	IU	2-[[5-(1,2-oxazole-5-carbonyl)-[1,2,4]triazino[5,6-b]indol-3-yl]sulfanylmethyl]benzonitrile

DM9ZF3P	ID	DM9ZF3P
DM9ZF3P	DN	PMID27215781-Compound-28
DM9ZF3P	HS	Patented
DM9ZF3P	CP	BAYER INTELLECTUAL PROPERTY GMBH KOCH, Markus WOLF, Siegmund BUCHMANN, Bernd FUHRMANN, Ulrike DROESCHER, Peter ZOLLNER, Thomas
DM9ZF3P	DT	Small molecular drug
DM9ZF3P	DE	Endometriosis

DMDJM1Y	ID	DMDJM1Y
DMDJM1Y	DN	PMID27215781-Compound-29
DMDJM1Y	HS	Patented
DMDJM1Y	DT	Small molecular drug
DMDJM1Y	PC	89597397
DMDJM1Y	MW	468.4
DMDJM1Y	FM	C18H14F6N2O4S
DMDJM1Y	IC	InChI=1S/C18H14F6N2O4S/c19-17(20,21)29-12-3-1-2-11(7-12)26-13-8-25-16(30-31(27,28)18(22,23)24)15-10-5-4-9(6-10)14(13)15/h1-3,7-10,26H,4-6H2
DMDJM1Y	CS	C1CC2CC1C3=C2C(=NC=C3NC4=CC(=CC=C4)OC(F)(F)F)OS(=O)(=O)C(F)(F)F
DMDJM1Y	IK	DQBACBSLAAPBLG-UHFFFAOYSA-N
DMDJM1Y	IU	[6-[3-(trifluoromethoxy)anilino]-4-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-3-yl] trifluoromethanesulfonate

DM7USO9	ID	DM7USO9
DM7USO9	DN	PMID27215781-Compound-30
DM7USO9	HS	Patented
DM7USO9	DT	Small molecular drug
DM7USO9	PC	89608962
DM7USO9	MW	360.4
DM7USO9	FM	C21H26F2N2O
DM7USO9	IC	InChI=1S/C21H26F2N2O/c1-26-18-17-14-3-2-13(4-14)16(17)15(8-24-18)25-21-7-12-5-19(22,10-21)9-20(23,6-12)11-21/h8,12-14,25H,2-7,9-11H2,1H3
DM7USO9	CS	COC1=NC=C(C2=C1C3CCC2C3)NC45CC6CC(C4)(CC(C6)(C5)F)F
DM7USO9	IK	YKIONNFZUQIKPS-UHFFFAOYSA-N
DM7USO9	IU	N-(3,5-difluoro-1-adamantyl)-3-methoxy-4-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-6-amine

DMJMO72	ID	DMJMO72
DMJMO72	DN	PMID27215781-Compound-31
DMJMO72	HS	Patented
DMJMO72	DT	Small molecular drug

DM7IYRM	ID	DM7IYRM
DM7IYRM	DN	PMID27215781-Compound-32
DM7IYRM	HS	Patented
DM7IYRM	CP	C4T S.C. A.R.L
DM7IYRM	DT	Small molecular drug
DM7IYRM	PC	76285830
DM7IYRM	MW	469.6
DM7IYRM	FM	C24H23NO5S2
DM7IYRM	IC	InChI=1S/C24H23NO5S2/c26-23-20-12-11-19(30-32(27,28)22-10-7-15-31-22)16-21(20)29-24(13-5-2-6-14-24)25(23)17-18-8-3-1-4-9-18/h1,3-4,7-12,15-16H,2,5-6,13-14,17H2
DM7IYRM	CS	C1CCC2(CC1)N(C(=O)C3=C(O2)C=C(C=C3)OS(=O)(=O)C4=CC=CS4)CC5=CC=CC=C5
DM7IYRM	IK	XBCSLRKNSRBEMJ-UHFFFAOYSA-N
DM7IYRM	IU	(3-benzyl-4-oxospiro[1,3-benzoxazine-2,1'-cyclohexane]-7-yl) thiophene-2-sulfonate

DMX4W2R	ID	DMX4W2R
DMX4W2R	DN	PMID27215781-Compound-33
DMX4W2R	HS	Patented
DMX4W2R	CP	C4T S.C. A.R.L
DMX4W2R	DT	Small molecular drug
DMX4W2R	PC	75593310
DMX4W2R	MW	455.5
DMX4W2R	FM	C24H22FNO5S
DMX4W2R	IC	InChI=1S/C24H22FNO5S/c1-16-4-11-20(12-5-16)32(28,29)31-19-10-13-21-22(14-19)30-24(2,3)26(23(21)27)15-17-6-8-18(25)9-7-17/h4-14H,15H2,1-3H3
DMX4W2R	CS	CC1=CC=C(C=C1)S(=O)(=O)OC2=CC3=C(C=C2)C(=O)N(C(O3)(C)C)CC4=CC=C(C=C4)F
DMX4W2R	IK	RDCDFXNTJYTRNH-UHFFFAOYSA-N
DMX4W2R	IU	[3-[(4-fluorophenyl)methyl]-2,2-dimethyl-4-oxo-1,3-benzoxazin-7-yl] 4-methylbenzenesulfonate

DMTAZBC	ID	DMTAZBC
DMTAZBC	DN	PMID27215781-Compound-34
DMTAZBC	HS	Patented
DMTAZBC	CP	C4T S.C. A.R.L
DMTAZBC	DT	Small molecular drug

DM0L68P	ID	DM0L68P
DM0L68P	DN	PMID27215781-Compound-37
DM0L68P	HS	Patented
DM0L68P	CP	CONSEJO SUPERIOR DE INVESTIGACIONES CIENTICAS (CSIC) UNIVERSIDAD DE ALCAL DE HENARES UNIVERSIDAD COMPLUTENSE DE MADRID
DM0L68P	DT	Small molecular drug
DM0L68P	PC	60148509
DM0L68P	MW	356.5
DM0L68P	FM	C21H28N2O3
DM0L68P	IC	InChI=1S/C21H28N2O3/c1-6-7-8-9-10-20(2,3)13-11-15(24)16-17-14(12-22-23-17)21(4,5)26-19(16)18(13)25/h11-12H,6-10H2,1-5H3,(H,22,23)
DM0L68P	CS	CCCCCCC(C)(C)C1=CC(=O)C2=C(C1=O)OC(C3=C2NN=C3)(C)C
DM0L68P	IK	XRDIITMVNDBOHN-UHFFFAOYSA-N
DM0L68P	IU	4,4-dimethyl-7-(2-methyloctan-2-yl)-1H-chromeno[4,3-c]pyrazole-6,9-dione
DM0L68P	DE	Prostate cancer

DMRU0BL	ID	DMRU0BL
DMRU0BL	DN	PMID27215781-Compound-4
DMRU0BL	HS	Patented
DMRU0BL	CP	F. HOFFMANN-LA ROCHE AG BISSANTZ, Caterina DHURWASULU, Baledi GRETHER, Uwe HAZRA, Anindya HEBEISEN, Paul ROEVER, Stephan ROGERS-EVANS, Mark
DMRU0BL	DT	Small molecular drug
DMRU0BL	PC	71526408
DMRU0BL	MW	410.4
DMRU0BL	FM	C19H24F2N4O4
DMRU0BL	IC	InChI=1S/C19H24F2N4O4/c1-18(12-5-6-12,17(27)28-2)24-15(26)13-7-22-14(25-9-19(20,21)10-25)16(23-13)29-8-11-3-4-11/h7,11-12H,3-6,8-10H2,1-2H3,(H,24,26)
DMRU0BL	CS	CC(C1CC1)(C(=O)OC)NC(=O)C2=CN=C(C(=N2)OCC3CC3)N4CC(C4)(F)F
DMRU0BL	IK	ZVGNNTZBRRKTHH-UHFFFAOYSA-N
DMRU0BL	IU	methyl 2-cyclopropyl-2-[[6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyrazine-2-carbonyl]amino]propanoate

DM0NYK3	ID	DM0NYK3
DM0NYK3	DN	PMID27321640-Compound-58
DM0NYK3	HS	Patented
DM0NYK3	CP	LUNDBECK & CO AS H [DK]
DM0NYK3	DT	Small molecular drug

DM41B5O	ID	DM41B5O
DM41B5O	DN	PMID27321640-Compound-59
DM41B5O	HS	Patented
DM41B5O	CP	LUNDBECK & CO AS H [DK]
DM41B5O	DT	Small molecular drug

DMHWV67	ID	DMHWV67
DMHWV67	DN	PMID27321640-Compound-74
DMHWV67	HS	Patented
DMHWV67	DT	Small molecular drug

DM2P5J9	ID	DM2P5J9
DM2P5J9	DN	PMID27321640-Compound-75
DM2P5J9	HS	Patented
DM2P5J9	DT	Small molecular drug

DM40LIN	ID	DM40LIN
DM40LIN	DN	PMID27321640-Compound-76
DM40LIN	HS	Patented
DM40LIN	DT	Small molecular drug

DMYUP6G	ID	DMYUP6G
DMYUP6G	DN	PMID27336223-Compound-10
DMYUP6G	HS	Patented
DMYUP6G	DT	Small molecular drug
DMYUP6G	PC	5381
DMYUP6G	MW	351.5
DMYUP6G	FM	C21H21NO2S
DMYUP6G	IC	InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3
DMYUP6G	CS	CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
DMYUP6G	IK	OGQICQVSFDPSEI-UHFFFAOYSA-N
DMYUP6G	IU	ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
DMYUP6G	CA	CAS 118292-40-3
DMYUP6G	CB	CHEBI:32184

DMBN6KU	ID	DMBN6KU
DMBN6KU	DN	PMID27336223-Compound-11
DMBN6KU	HS	Patented
DMBN6KU	DT	Small molecular drug
DMBN6KU	PC	60164
DMBN6KU	MW	412.5
DMBN6KU	FM	C28H28O3
DMBN6KU	IC	InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)
DMBN6KU	CS	COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5
DMBN6KU	IK	LZCDAPDGXCYOEH-UHFFFAOYSA-N
DMBN6KU	IU	6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
DMBN6KU	CA	CAS 106685-40-9
DMBN6KU	CB	CHEBI:31174

DMT4P7K	ID	DMT4P7K
DMT4P7K	DN	PMID27336223-Compound-12
DMT4P7K	HS	Patented
DMT4P7K	DT	Small molecular drug
DMT4P7K	PC	135411
DMT4P7K	MW	398.5
DMT4P7K	FM	C27H26O3
DMT4P7K	IC	InChI=1S/C27H26O3/c28-25-6-5-22(20-1-2-21-11-23(26(29)30)4-3-19(21)10-20)12-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)
DMT4P7K	CS	C1C2CC3CC1CC(C2)(C3)C4=C(C=CC(=C4)C5=CC6=C(C=C5)C=C(C=C6)C(=O)O)O
DMT4P7K	IK	LDGIHZJOIQSHPB-UHFFFAOYSA-N
DMT4P7K	IU	6-[3-(1-adamantyl)-4-hydroxyphenyl]naphthalene-2-carboxylic acid
DMT4P7K	CA	CAS 125316-60-1
DMT4P7K	CB	CHEBI:88334

DMSZLYD	ID	DMSZLYD
DMSZLYD	DN	PMID27336223-Compound-13
DMSZLYD	HS	Patented
DMSZLYD	DT	Small molecular drug

DMC41MA	ID	DMC41MA
DMC41MA	DN	PMID27336223-Compound-14
DMC41MA	HS	Patented
DMC41MA	DT	Small molecular drug
DMC41MA	PC	445455
DMC41MA	MW	399.5
DMC41MA	FM	C23H26FNO4
DMC41MA	IC	InChI=1S/C23H26FNO4/c1-22(2)9-10-23(3,4)16-11-13(5-7-15(16)22)19(26)20(27)25-18-8-6-14(21(28)29)12-17(18)24/h5-8,11-12,19,26H,9-10H2,1-4H3,(H,25,27)(H,28,29)/t19-/m1/s1
DMC41MA	CS	CC1(CCC(C2=C1C=CC(=C2)[C@H](C(=O)NC3=C(C=C(C=C3)C(=O)O)F)O)(C)C)C
DMC41MA	IK	AANFHDFOMFRLLR-LJQANCHMSA-N
DMC41MA	IU	3-fluoro-4-[[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid

DMIYCFE	ID	DMIYCFE
DMIYCFE	DN	PMID27336223-Compound-15
DMIYCFE	HS	Patented
DMIYCFE	DT	Small molecular drug
DMIYCFE	PC	445455
DMIYCFE	MW	399.5
DMIYCFE	FM	C23H26FNO4
DMIYCFE	IC	InChI=1S/C23H26FNO4/c1-22(2)9-10-23(3,4)16-11-13(5-7-15(16)22)19(26)20(27)25-18-8-6-14(21(28)29)12-17(18)24/h5-8,11-12,19,26H,9-10H2,1-4H3,(H,25,27)(H,28,29)/t19-/m1/s1
DMIYCFE	CS	CC1(CCC(C2=C1C=CC(=C2)[C@H](C(=O)NC3=C(C=C(C=C3)C(=O)O)F)O)(C)C)C
DMIYCFE	IK	AANFHDFOMFRLLR-LJQANCHMSA-N
DMIYCFE	IU	3-fluoro-4-[[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid

DMJFSOM	ID	DMJFSOM
DMJFSOM	DN	PMID27336223-Compound-4
DMJFSOM	HS	Patented
DMJFSOM	CP	KEMPHYS LTD
DMJFSOM	DT	Small molecular drug
DMJFSOM	PC	108143
DMJFSOM	MW	351.4
DMJFSOM	FM	C22H25NO3
DMJFSOM	IC	InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)
DMJFSOM	CS	CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C
DMJFSOM	IK	MUTNCGKQJGXKEM-UHFFFAOYSA-N
DMJFSOM	IU	4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid
DMJFSOM	CA	CAS 94497-51-5
DMJFSOM	CB	CHEBI:32181

DM6E50A	ID	DM6E50A
DM6E50A	DN	PMID27336223-Compound-5
DM6E50A	HS	Patented
DM6E50A	CP	CORNELL UNIVERSITY
DM6E50A	DT	Small molecular drug
DM6E50A	PC	2126
DM6E50A	MW	351.4
DM6E50A	FM	C22H25NO3
DM6E50A	IC	InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-15(7-10-17(18)21)19(24)23-16-8-5-14(6-9-16)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)
DM6E50A	CS	CC1(CCC(C2=C1C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)(C)C)C
DM6E50A	IK	SZWKGOZKRMMLAJ-UHFFFAOYSA-N
DM6E50A	IU	4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]benzoic acid
DM6E50A	CA	CAS 102121-60-8
DM6E50A	CB	CHEBI:64210

DM9QM6I	ID	DM9QM6I
DM9QM6I	DN	PMID27336223-Compound-7
DM9QM6I	HS	Patented
DM9QM6I	CP	CORNELL UNIVERSITY
DM9QM6I	DT	Small molecular drug

DM460D1	ID	DM460D1
DM460D1	DN	PMID27336223-Compound-8
DM460D1	HS	Patented
DM460D1	CP	CORNELL UNIVERSITY
DM460D1	DT	Small molecular drug
DM460D1	PC	1714884
DM460D1	MW	310.4
DM460D1	FM	C21H26O2
DM460D1	IC	InChI=1S/C21H26O2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)19-13-15-20(16-14-19)21(22)23/h9-16H,2-8H2,1H3,(H,22,23)
DM460D1	CS	CCCCCCCCC1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)O
DM460D1	IK	HXBKPYIEQLLNBK-UHFFFAOYSA-N
DM460D1	IU	4-(4-octylphenyl)benzoic acid
DM460D1	CA	CAS 59662-49-6
DM460D1	CB	CHEBI:95048

DM6V13W	ID	DM6V13W
DM6V13W	DN	PMID27336223-Compound-9
DM6V13W	HS	Patented
DM6V13W	CP	CORNELL UNIVERSITY GUDAS, Lorraine J TANG, Xiao-Han OSEI-SARFO, Kwame URVALEK, Aliso
DM6V13W	DT	Small molecular drug
DM6V13W	PC	9952709
DM6V13W	MW	398.5
DM6V13W	FM	C27H26O3
DM6V13W	IC	InChI=1S/C27H26O3/c28-25-12-22-6-5-21(19-1-3-20(4-2-19)26(29)30)10-23(22)11-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)
DM6V13W	CS	C1C2CC3CC1CC(C2)(C3)C4=C(C=C5C=CC(=CC5=C4)C6=CC=C(C=C6)C(=O)O)O
DM6V13W	IK	VCQGNUWOMLYNNG-UHFFFAOYSA-N
DM6V13W	IU	4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid
DM6V13W	CA	CAS 107430-66-0

DMTQRVC	ID	DMTQRVC
DMTQRVC	DN	PMID27376512-Compound-asCEBP-1
DMTQRVC	HS	Patented
DMTQRVC	CP	NEW ENGLAND BIOLABS INC
DMTQRVC	DT	Nucleotide
DMTQRVC	SQ	CCGGGACGCAGGCGGCGUCAGGC

DMLAY8B	ID	DMLAY8B
DMLAY8B	DN	PMID27376512-Compound-asCEBP-1HPE
DMLAY8B	HS	Patented
DMLAY8B	CP	NEW ENGLAND BIOLABS INC
DMLAY8B	DT	Nucleotide
DMLAY8B	SQ	CCGGGAAGCAGGCGGCGUCAGGC

DMJUL1A	ID	DMJUL1A
DMJUL1A	DN	PMID27376512-Compound-asCEBP-2
DMJUL1A	HS	Patented
DMJUL1A	CP	NEW ENGLAND BIOLABS INC
DMJUL1A	DT	Nucleotide
DMJUL1A	SQ	GCCAGUGGCGAGGGGCGGCGCGG

DM9QEIV	ID	DM9QEIV
DM9QEIV	DN	PMID27376512-Compound-asCEBP-2HPE
DM9QEIV	HS	Patented
DM9QEIV	CP	NEW ENGLAND BIOLABS INC
DM9QEIV	DT	Nucleotide
DM9QEIV	SQ	GACAGUGGAGAGGGGCGGAGCGG

DMBFUTL	ID	DMBFUTL
DMBFUTL	DN	PMID27376512-Compound-CROs
DMBFUTL	HS	Patented
DMBFUTL	CP	BETH ISRAEL DEACONESS MEDICAL CENTER, INC. DIRUSCIO, Annalisa EBRALIDZE, Alexander, K. TENEN, Daniel, G. LEONE, Giuseppe UNIVERSITA CATTOLICA DEL SACRO CUOR
DMBFUTL	DT	siRNA drug

DMP59OX	ID	DMP59OX
DMP59OX	DN	PMID27376512-Compound-Figure2aExample1
DMP59OX	HS	Patented
DMP59OX	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED HENDRICKSON, Thomas, Francis HO, Koc-Kan SAUNDERS, Michael, David STEVENS, Brian, John SWIERCZEK, Krzysztof WRIGHT, Kevin, Bret
DMP59OX	DT	Small molecular drug
DMP59OX	PC	71521835
DMP59OX	MW	438.9
DMP59OX	FM	C16H19ClN8O3S
DMP59OX	IC	InChI=1S/C16H19ClN8O3S/c17-9-1-2-19-16(24-9)20-3-4-29-5-8-11(26)12(27)15(28-8)25-7-23-10-13(18)21-6-22-14(10)25/h1-2,6-8,11-12,15,26-27H,3-5H2,(H2,18,21,22)(H,19,20,24)/t8-,11-,12-,15-/m0/s1
DMP59OX	CS	C1=CN=C(N=C1Cl)NCCSC[C@H]2[C@@H]([C@@H]([C@H](O2)N3C=NC4=C(N=CN=C43)N)O)O
DMP59OX	IK	ZWBSJRQJKXXDKA-REXDEQPNSA-N
DMP59OX	IU	(2S,3S,4R,5R)-2-(6-aminopurin-9-yl)-5-[2-[(4-chloropyrimidin-2-yl)amino]ethylsulfanylmethyl]oxolane-3,4-diol

DMZIKN6	ID	DMZIKN6
DMZIKN6	DN	PMID27376512-Compound-Figure3CG
DMZIKN6	HS	Patented
DMZIKN6	CP	PIERRE FABRE MEDICAMENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
DMZIKN6	DT	Small molecular drug
DMZIKN6	PC	117967861
DMZIKN6	MW	546.7
DMZIKN6	FM	C34H38N6O
DMZIKN6	IC	InChI=1S/C34H38N6O/c1-2-7-26(8-3-1)9-6-17-37-34-30-13-12-28(23-33(30)38-25-39-34)41-24-27-15-20-40(21-16-27)22-19-36-32-14-18-35-31-11-5-4-10-29(31)32/h1-5,7-8,10-14,18,23,25,27H,6,9,15-17,19-22,24H2,(H,35,36)(H,37,38,39)
DMZIKN6	CS	C1CN(CCC1COC2=CC3=C(C=C2)C(=NC=N3)NCCCC4=CC=CC=C4)CCNC5=CC=NC6=CC=CC=C65
DMZIKN6	IK	DPNGRMNVFKZZSM-UHFFFAOYSA-N
DMZIKN6	IU	N-(3-phenylpropyl)-7-[[1-[2-(quinolin-4-ylamino)ethyl]piperidin-4-yl]methoxy]quinazolin-4-amine

DMIS4H0	ID	DMIS4H0
DMIS4H0	DN	PMID27376512-Compound-Figure3CM
DMIS4H0	HS	Patented
DMIS4H0	CP	PIERRE FABRE MEDICAMENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
DMIS4H0	DT	Small molecular drug
DMIS4H0	PC	117976053
DMIS4H0	MW	599.7
DMIS4H0	FM	C36H37N7O2
DMIS4H0	IC	InChI=1S/C36H37N7O2/c44-36-30-10-9-27(23-35(30)41-25-43(36)22-18-40-34-12-16-38-32-8-4-2-6-29(32)34)45-24-26-13-19-42(20-14-26)21-17-39-33-11-15-37-31-7-3-1-5-28(31)33/h1-12,15-16,23,25-26H,13-14,17-22,24H2,(H,37,39)(H,38,40)
DMIS4H0	CS	C1CN(CCC1COC2=CC3=C(C=C2)C(=O)N(C=N3)CCNC4=CC=NC5=CC=CC=C54)CCNC6=CC=NC7=CC=CC=C76
DMIS4H0	IK	ZJSGNMNKODEYPA-UHFFFAOYSA-N
DMIS4H0	IU	3-[2-(quinolin-4-ylamino)ethyl]-7-[[1-[2-(quinolin-4-ylamino)ethyl]piperidin-4-yl]methoxy]quinazolin-4-one

DMP7DL6	ID	DMP7DL6
DMP7DL6	DN	PMID27376512-Compound-Figure3CN
DMP7DL6	HS	Patented
DMP7DL6	CP	PIERRE FABRE MEDICAMENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
DMP7DL6	DT	Small molecular drug
DMP7DL6	PC	117968550
DMP7DL6	MW	594.7
DMP7DL6	FM	C38H38N6O
DMP7DL6	IC	InChI=1S/C38H38N6O/c1-2-6-30(7-3-1)31-12-10-28(11-13-31)25-41-38-34-15-14-32(24-37(34)42-27-43-38)45-26-29-17-21-44(22-18-29)23-20-40-36-16-19-39-35-9-5-4-8-33(35)36/h1-16,19,24,27,29H,17-18,20-23,25-26H2,(H,39,40)(H,41,42,43)
DMP7DL6	CS	C1CN(CCC1COC2=CC3=C(C=C2)C(=NC=N3)NCC4=CC=C(C=C4)C5=CC=CC=C5)CCNC6=CC=NC7=CC=CC=C76
DMP7DL6	IK	GPQPTJSUKRSGBL-UHFFFAOYSA-N
DMP7DL6	IU	N-[(4-phenylphenyl)methyl]-7-[[1-[2-(quinolin-4-ylamino)ethyl]piperidin-4-yl]methoxy]quinazolin-4-amine

DM67VNW	ID	DM67VNW
DM67VNW	DN	PMID27376512-Compound-miR-155-5p
DM67VNW	HS	Patented
DM67VNW	CP	NEW ENGLAND BIOLABS INC
DM67VNW	DT	Nucleotide
DM67VNW	SQ	UUAAUGCUAAUCGUGAUAGGGGU

DM1MVQD	ID	DM1MVQD
DM1MVQD	DN	PMID27376512-Compound-MTC-422 
DM1MVQD	HS	Patented
DM1MVQD	CP	METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DM1MVQD	DT	Nucleotide

DM9RSDX	ID	DM9RSDX
DM9RSDX	DN	PMID27376512-Compound-MTC-423
DM9RSDX	HS	Patented
DM9RSDX	CP	METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DM9RSDX	DT	Nucleotide
DM9RSDX	SQ	5CCTATGCGATCGAGTTTTCT[zebularine (pyrimidin-2-one ribonucleoside)]GAT[zebularine (pyrimidin-2-one ribonucleoside)]GCATAGG3

DMGNRZU	ID	DMGNRZU
DMGNRZU	DN	PMID27376512-Compound-MTC-424
DMGNRZU	HS	Patented
DMGNRZU	CP	METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DMGNRZU	DT	Nucleotide
DMGNRZU	SQ	5GTACATG[X]GCTCCAGA3 

DMWXEZD	ID	DMWXEZD
DMWXEZD	DN	PMID27376512-Compound-MTC-427
DMWXEZD	HS	Patented
DMWXEZD	CP	METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DMWXEZD	DT	Nucleotide
DMWXEZD	SQ	5CCTATG[methylcytosine]GAT[methylcytosine]GAGTTTTCT[zebularine]GCATAGG3

DM7OS5E	ID	DM7OS5E
DM7OS5E	DN	PMID27376512-Compound-MTC-433
DM7OS5E	HS	Patented
DM7OS5E	CP	METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DM7OS5E	DT	Nucleotide
DM7OS5E	SQ	5CCTATG[5-methylcytosine]GAT[5-methylcytosine]GAGTTTTCT[deoxyzebularine]GAT[deoxyzebularine]GCATAGG3 

DM70CTE	ID	DM70CTE
DM70CTE	DN	PMID27376512-Compound-MTC-434
DM70CTE	HS	Patented
DM70CTE	CP	METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DM70CTE	DT	Nucleotide
DM70CTE	SQ	5CCTATGGCATGCAGTTTTCTGCATGCCATAGG3 

DM5K4YF	ID	DM5K4YF
DM5K4YF	DN	PMID27376512-Compound-PG-11047
DM5K4YF	HS	Patented
DM5K4YF	DT	Small molecular drug
DM5K4YF	PC	6475492
DM5K4YF	MW	256.43
DM5K4YF	FM	C14H32N4
DM5K4YF	IC	InChI=1S/C14H32N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h5-6,15-18H,3-4,7-14H2,1-2H3/b6-5-
DM5K4YF	CS	CCNCCCNC/C=C\\CNCCCNCC
DM5K4YF	IK	XFWLTFZLLXVKDY-WAYWQWQTSA-N
DM5K4YF	IU	(Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine
DM5K4YF	CA	CAS 308145-19-9

DM3U7RN	ID	DM3U7RN
DM3U7RN	DN	PMID27376512-Compound-PG-11048
DM3U7RN	HS	Patented
DM3U7RN	DT	Small molecular drug
DM3U7RN	PC	6532281
DM3U7RN	MW	256.43
DM3U7RN	FM	C14H32N4
DM3U7RN	IC	InChI=1S/C14H32N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h5-6,15-18H,3-4,7-14H2,1-2H3/b6-5+
DM3U7RN	CS	CCNCCCNC/C=C/CNCCCNCC
DM3U7RN	IK	XFWLTFZLLXVKDY-AATRIKPKSA-N
DM3U7RN	IU	(E)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine
DM3U7RN	CB	CHEBI:93760

DMIFTUN	ID	DMIFTUN
DMIFTUN	DN	PMID27376512-Compound-Table1Example11
DMIFTUN	HS	Patented
DMIFTUN	CP	IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DMIFTUN	DT	Small molecular drug
DMIFTUN	PC	75201485
DMIFTUN	MW	467.4
DMIFTUN	FM	C24H21NO9
DMIFTUN	IC	InChI=1S/C24H21NO9/c1-33-11-7-15-20(19(8-11)34-2)14(12-3-5-16(26)23(31)21(12)29)9-25(15)10-18(28)13-4-6-17(27)24(32)22(13)30/h3-9,26-27,29-32H,10H2,1-2H3
DMIFTUN	CS	COC1=CC2=C(C(=C1)OC)C(=CN2CC(=O)C3=C(C(=C(C=C3)O)O)O)C4=C(C(=C(C=C4)O)O)O
DMIFTUN	IK	GBDRNHMXDAEPNN-UHFFFAOYSA-N
DMIFTUN	IU	2-[4,6-dimethoxy-3-(2,3,4-trihydroxyphenyl)indol-1-yl]-1-(2,3,4-trihydroxyphenyl)ethanone

DMM3VA8	ID	DMM3VA8
DMM3VA8	DN	PMID27376512-Compound-Table1Example16
DMM3VA8	HS	Patented
DMM3VA8	CP	IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DMM3VA8	DT	Small molecular drug
DMM3VA8	PC	75201537
DMM3VA8	MW	379.4
DMM3VA8	FM	C22H15F2NO3
DMM3VA8	IC	InChI=1S/C22H15F2NO3/c23-15-9-19(24)22-18(13-1-5-16(26)6-2-13)11-25(20(22)10-15)12-21(28)14-3-7-17(27)8-4-14/h1-11,26-27H,12H2
DMM3VA8	CS	C1=CC(=CC=C1C2=CN(C3=C2C(=CC(=C3)F)F)CC(=O)C4=CC=C(C=C4)O)O
DMM3VA8	IK	ZSLQOKAZOXSRMM-UHFFFAOYSA-N
DMM3VA8	IU	2-[4,6-difluoro-3-(4-hydroxyphenyl)indol-1-yl]-1-(4-hydroxyphenyl)ethanone

DM5RX9D	ID	DM5RX9D
DM5RX9D	DN	PMID27376512-Compound-Table1Example30
DM5RX9D	HS	Patented
DM5RX9D	CP	IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DM5RX9D	DT	Small molecular drug
DM5RX9D	PC	75201638
DM5RX9D	MW	603.6
DM5RX9D	FM	C32H29NO11
DM5RX9D	IC	InChI=1S/C32H29NO11/c1-17(34)41-27-9-7-21(11-29(27)43-19(3)36)24-15-33(25-13-23(39-5)14-31(40-6)32(24)25)16-26(38)22-8-10-28(42-18(2)35)30(12-22)44-20(4)37/h7-15H,16H2,1-6H3
DM5RX9D	CS	CC(=O)OC1=C(C=C(C=C1)C2=CN(C3=C2C(=CC(=C3)OC)OC)CC(=O)C4=CC(=C(C=C4)OC(=O)C)OC(=O)C)OC(=O)C
DM5RX9D	IK	NMWWCTXMWYUUNT-UHFFFAOYSA-N
DM5RX9D	IU	[2-acetyloxy-4-[1-[2-(3,4-diacetyloxyphenyl)-2-oxoethyl]-4,6-dimethoxyindol-3-yl]phenyl] acetate

DMFJG7P	ID	DMFJG7P
DMFJG7P	DN	PMID27376512-Compound-Table1Example4
DMFJG7P	HS	Patented
DMFJG7P	CP	IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DMFJG7P	DT	Small molecular drug
DMFJG7P	PC	75201432
DMFJG7P	MW	405.4
DMFJG7P	FM	C23H19NO6
DMFJG7P	IC	InChI=1S/C23H19NO6/c1-30-15-4-5-16-17(13-2-6-19(25)21(27)8-13)11-24(18(16)10-15)12-23(29)14-3-7-20(26)22(28)9-14/h2-11,25-28H,12H2,1H3
DMFJG7P	CS	COC1=CC2=C(C=C1)C(=CN2CC(=O)C3=CC(=C(C=C3)O)O)C4=CC(=C(C=C4)O)O
DMFJG7P	IK	YPZMHCJTRFQAIG-UHFFFAOYSA-N
DMFJG7P	IU	1-(3,4-dihydroxyphenyl)-2-[3-(3,4-dihydroxyphenyl)-6-methoxyindol-1-yl]ethanone

DM4Q6XZ	ID	DM4Q6XZ
DM4Q6XZ	DN	PMID27376512-Compound-Table1Example5
DM4Q6XZ	HS	Patented
DM4Q6XZ	CP	IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DM4Q6XZ	DT	Small molecular drug
DM4Q6XZ	PC	73774653
DM4Q6XZ	MW	437.4
DM4Q6XZ	FM	C23H19NO8
DM4Q6XZ	IC	InChI=1S/C23H19NO8/c1-32-11-2-3-12-15(13-4-6-17(25)22(30)20(13)28)9-24(16(12)8-11)10-19(27)14-5-7-18(26)23(31)21(14)29/h2-9,25-26,28-31H,10H2,1H3
DM4Q6XZ	CS	COC1=CC2=C(C=C1)C(=CN2CC(=O)C3=C(C(=C(C=C3)O)O)O)C4=C(C(=C(C=C4)O)O)O
DM4Q6XZ	IK	SFHIQZITSGPFGB-UHFFFAOYSA-N
DM4Q6XZ	IU	2-[6-methoxy-3-(2,3,4-trihydroxyphenyl)indol-1-yl]-1-(2,3,4-trihydroxyphenyl)ethanone

DMKU7GD	ID	DMKU7GD
DMKU7GD	DN	PMID27376512-Compound-Table1Example8
DMKU7GD	HS	Patented
DMKU7GD	CP	IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DMKU7GD	DT	Small molecular drug
DMKU7GD	PC	75201482
DMKU7GD	MW	435.4
DMKU7GD	FM	C24H21NO7
DMKU7GD	IC	InChI=1S/C24H21NO7/c1-31-15-9-17-24(23(10-15)32-2)16(13-3-5-18(26)20(28)7-13)11-25(17)12-22(30)14-4-6-19(27)21(29)8-14/h3-11,26-29H,12H2,1-2H3
DMKU7GD	CS	COC1=CC2=C(C(=C1)OC)C(=CN2CC(=O)C3=CC(=C(C=C3)O)O)C4=CC(=C(C=C4)O)O
DMKU7GD	IK	VZIMIRNNOGRJFC-UHFFFAOYSA-N
DMKU7GD	IU	1-(3,4-dihydroxyphenyl)-2-[3-(3,4-dihydroxyphenyl)-4,6-dimethoxyindol-1-yl]ethanone

DMD4CIU	ID	DMD4CIU
DMD4CIU	DN	PMID27387065-Compound-6
DMD4CIU	HS	Patented
DMD4CIU	DT	Small molecular drug
DMD4CIU	PC	3154
DMD4CIU	MW	324.4
DMD4CIU	FM	C10H16N2O4S3
DMD4CIU	IC	InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)
DMD4CIU	CS	CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
DMD4CIU	IK	IAVUPMFITXYVAF-UHFFFAOYSA-N
DMD4CIU	IU	4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
DMD4CIU	CA	CAS 120280-13-9

DMDQMZT	ID	DMDQMZT
DMDQMZT	DN	PMID27410995-Compound-Figure3c
DMDQMZT	HS	Patented
DMDQMZT	DT	Small molecular drug

DMJRZLB	ID	DMJRZLB
DMJRZLB	DN	PMID27410995-Compound-Figure3j
DMJRZLB	HS	Patented
DMJRZLB	DT	Small molecular drug

DMJ0QLB	ID	DMJ0QLB
DMJ0QLB	DN	PMID27410995-Compound-Figure3k
DMJ0QLB	HS	Patented
DMJ0QLB	DT	Small molecular drug

DMUG9X0	ID	DMUG9X0
DMUG9X0	DN	PMID27414413-Compound-Figure6right
DMUG9X0	HS	Patented
DMUG9X0	CP	J-PHARMA CO., LTD. WEMPE, Michael, F. ENDOU, Hitoshi
DMUG9X0	DT	Small molecular drug
DMUG9X0	PC	2333
DMUG9X0	MW	424.1
DMUG9X0	FM	C17H12Br2O3
DMUG9X0	IC	InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3
DMUG9X0	CS	CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br
DMUG9X0	IK	WHQCHUCQKNIQEC-UHFFFAOYSA-N
DMUG9X0	IU	(3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone
DMUG9X0	CA	CAS 3562-84-3
DMUG9X0	CB	CHEBI:3023

DMTZNSM	ID	DMTZNSM
DMTZNSM	DN	PMID27414413-Compound-Figure8right
DMTZNSM	HS	Patented
DMTZNSM	DT	Small molecular drug
DMTZNSM	PC	71532153
DMTZNSM	MW	298.3
DMTZNSM	FM	C15H10N2O3S
DMTZNSM	IC	InChI=1S/C15H10N2O3S/c1-8-4-12-14(21-8)9(6-16)7-17(12)10-2-3-11(15(19)20)13(18)5-10/h2-5,7,18H,1H3,(H,19,20)
DMTZNSM	CS	CC1=CC2=C(S1)C(=CN2C3=CC(=C(C=C3)C(=O)O)O)C#N
DMTZNSM	IK	CBQIUEMJMYALSV-UHFFFAOYSA-N
DMTZNSM	IU	4-(6-cyano-2-methylthieno[3,2-b]pyrrol-4-yl)-2-hydroxybenzoic acid

DM5LOST	ID	DM5LOST
DM5LOST	DN	PMID27454349-Compound-100
DM5LOST	HS	Patented
DM5LOST	CP	Nanjing-University-of-Science-and-Technology
DM5LOST	DT	Small molecular drug

DMQIYM6	ID	DMQIYM6
DMQIYM6	DN	PMID27454349-Compound-101
DMQIYM6	HS	Patented
DMQIYM6	CP	UNIV SANTIAGO COMPOSTELA [ESUNIV DA CORU A [ESSERVIZO GALEGO DE SAUDE SERGAS [ES]
DMQIYM6	DT	Small molecular drug

DMEGRMX	ID	DMEGRMX
DMEGRMX	DN	PMID27454349-Compound-102
DMEGRMX	HS	Patented
DMEGRMX	CP	UNIV SANTIAGO COMPOSTELA [ESUNIV DA CORU A [ESSERVIZO GALEGO DE SAUDE SERGAS [ES]
DMEGRMX	DT	Small molecular drug

DMAN7CG	ID	DMAN7CG
DMAN7CG	DN	PMID27454349-Compound-91
DMAN7CG	HS	Patented
DMAN7CG	CP	Wisconsin-Alumni-Research-Foundation
DMAN7CG	DT	Small molecular drug
DMAN7CG	PC	11366080
DMAN7CG	MW	416.6
DMAN7CG	FM	C27H44O3
DMAN7CG	IC	InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)22-12-13-23-21(9-7-15-27(22,23)5)11-10-20-16-24(28)19(2)25(29)17-20/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b21-11+/t18-,22?,23-,24+,25+,27+/m0/s1
DMAN7CG	CS	C[C@@H](CCCC(C)(C)O)C1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C(=C)[C@@H](C3)O)O)C
DMAN7CG	IK	UHMPCVGLSKFXHR-NFZXMVPNSA-N
DMAN7CG	IU	(1R,3R)-5-[(2E)-2-[(3aS,7aR)-1-[(2S)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol
DMAN7CG	CA	CAS 213250-70-5

DMOEYVT	ID	DMOEYVT
DMOEYVT	DN	PMID27454349-Compound-92
DMOEYVT	HS	Patented
DMOEYVT	CP	Wisconsin-Alumni-Research-Foundation
DMOEYVT	DT	Small molecular drug

DMCTMB1	ID	DMCTMB1
DMCTMB1	DN	PMID27454349-Compound-93
DMCTMB1	HS	Patented
DMCTMB1	CP	Wisconsin-Alumni-Research-Foundation
DMCTMB1	DT	Small molecular drug

DMK0SIM	ID	DMK0SIM
DMK0SIM	DN	PMID27454349-Compound-94
DMK0SIM	HS	Patented
DMK0SIM	CP	Wisconsin-Alumni-Research-Foundation
DMK0SIM	DT	Small molecular drug

DM17KL2	ID	DM17KL2
DM17KL2	DN	PMID27454349-Compound-95
DM17KL2	HS	Patented
DM17KL2	CP	CYTOCHROMA INC. JOHNS HOPKINS UNIVERSITY POSNER, Gary, H. HESS, Lindsey, C. KALINDA, Alvin, S. SLACK, Rachel, D. SAHA, Uttam PETKOVICH, P., Martin
DM17KL2	DT	Small molecular drug

DMW0TM1	ID	DMW0TM1
DMW0TM1	DN	PMID27454349-Compound-96
DMW0TM1	HS	Patented
DMW0TM1	CP	CYTOCHROMA INC. JOHNS HOPKINS UNIVERSITY POSNER, Gary, H. HESS, Lindsey, C. KALINDA, Alvin, S. SLACK, Rachel, D. SAHA, Uttam PETKOVICH, P., Martin
DMW0TM1	DT	Small molecular drug

DMEXV6L	ID	DMEXV6L
DMEXV6L	DN	PMID27454349-Compound-97
DMEXV6L	HS	Patented
DMEXV6L	CP	CYTOCHROMA INC. JOHNS HOPKINS UNIVERSITY POSNER, Gary, H. HESS, Lindsey, C. KALINDA, Alvin, S. SLACK, Rachel, D. SAHA, Uttam PETKOVICH, P., Martin
DMEXV6L	DT	Small molecular drug

DMZKYMI	ID	DMZKYMI
DMZKYMI	DN	PMID27454349-Compound-98
DMZKYMI	HS	Patented
DMZKYMI	CP	Celus-Pharmaceuticals
DMZKYMI	DT	Small molecular drug
DMZKYMI	PC	11396600
DMZKYMI	MW	442.6
DMZKYMI	FM	C29H43FO2
DMZKYMI	IC	InChI=1S/C29H43FO2/c1-6-29(32,7-2)17-8-10-20(3)25-14-15-26-22(11-9-16-28(25,26)5)12-13-23-18-24(31)19-27(30)21(23)4/h8,12-14,17,20,24,26-27,31-32H,4,6-7,9-11,15-16,18-19H2,1-3,5H3/b17-8+,22-12+,23-13-/t20-,24+,26-,27-,28+/m0/s1
DMZKYMI	CS	CCC(CC)(/C=C/C[C@H](C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)F)O)C)O
DMZKYMI	IK	LRLWXBHFPGSUOX-GJQYOBCGSA-N
DMZKYMI	IU	(1R,3Z,5S)-3-[(2E)-2-[(3aS,7aS)-1-[(E,2S)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol
DMZKYMI	CA	CAS 199798-84-0

DMH0CQU	ID	DMH0CQU
DMH0CQU	DN	PMID27454349-Compound-99
DMH0CQU	HS	Patented
DMH0CQU	CP	Nanjing-University-of-Science-and-Technology
DMH0CQU	DT	Small molecular drug

DM9C4XH	ID	DM9C4XH
DM9C4XH	DN	PMID27537201-Compound-Figure11
DM9C4XH	HS	Patented
DM9C4XH	DT	Small molecular drug

DMPDTHQ	ID	DMPDTHQ
DMPDTHQ	DN	PMID27537201-Compound-Figure13b
DMPDTHQ	HS	Patented
DMPDTHQ	CP	the Shanghai Institute of Pharmaceutical Industry
DMPDTHQ	DT	Small molecular drug

DMWZ1PD	ID	DMWZ1PD
DMWZ1PD	DN	PMID27537201-Compound-Figure13c
DMWZ1PD	HS	Patented
DMWZ1PD	CP	the Shanghai Institute of Pharmaceutical Industry
DMWZ1PD	DT	Small molecular drug

DMVBJKH	ID	DMVBJKH
DMVBJKH	DN	PMID27537201-Compound-Figure15a
DMVBJKH	HS	Patented
DMVBJKH	CP	the Shanghai Institute of Technology together with the East China University of Science and Technology
DMVBJKH	DT	Small molecular drug

DMZ6N2J	ID	DMZ6N2J
DMZ6N2J	DN	PMID27537201-Compound-Figure15b
DMZ6N2J	HS	Patented
DMZ6N2J	CP	the Shanghai Institute of Technology
DMZ6N2J	DT	Small molecular drug

DMWKVZD	ID	DMWKVZD
DMWKVZD	DN	PMID27537201-Compound-Figure17
DMWKVZD	HS	Patented
DMWKVZD	CP	HANS JOACHIM [DEGROTHE TORSTEN [DEWOEHRLE INGO [DEMOLDENHAUER JANA [DEKOEPCKE BAERBEL [DEKUEPER THOMAS [DEBITZER JENS [DEREINHARDT KATHRIN [DE
DMWKVZD	DT	Small molecular drug

DM61SR0	ID	DM61SR0
DM61SR0	DN	PMID27539678-Compound-10
DM61SR0	HS	Patented
DM61SR0	CP	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK UNIVERSITY OF STRATHCLYDE BITTMAN, Robert PYNE, Nigel J. PYNE, Susan BAEK, Dong Jae LIU, Zheng BYUN, Hoe Sup
DM61SR0	DT	Small molecular drug
DM61SR0	PC	72735621
DM61SR0	MW	373.6
DM61SR0	FM	C25H43NO
DM61SR0	IC	InChI=1S/C25H43NO/c1-2-3-4-5-6-7-8-9-10-11-13-23-15-17-24(18-16-23)19-21-26-20-12-14-25(26)22-27/h15-18,25,27H,2-14,19-22H2,1H3/t25-/m1/s1
DM61SR0	CS	CCCCCCCCCCCCC1=CC=C(C=C1)CCN2CCC[C@@H]2CO
DM61SR0	IK	PNEOFQRNMJSTMT-RUZDIDTESA-N
DM61SR0	IU	[(2R)-1-[2-(4-dodecylphenyl)ethyl]pyrrolidin-2-yl]methanol

DMIKAJC	ID	DMIKAJC
DMIKAJC	DN	PMID27539678-Compound-11
DMIKAJC	HS	Patented
DMIKAJC	CP	AJINOMOTO CO., INC
DMIKAJC	DT	Small molecular drug
DMIKAJC	PC	78426051
DMIKAJC	MW	362.5
DMIKAJC	FM	C24H30N2O
DMIKAJC	IC	InChI=1S/C24H30N2O/c1-24(2,3)20-7-4-6-17(13-20)18-9-10-23-19(12-18)14-21(25-23)15-26-11-5-8-22(26)16-27/h4,6-7,9-10,12-14,22,25,27H,5,8,11,15-16H2,1-3H3/t22-/m1/s1
DMIKAJC	CS	CC(C)(C)C1=CC=CC(=C1)C2=CC3=C(C=C2)NC(=C3)CN4CCC[C@@H]4CO
DMIKAJC	IK	WJXINPLKVRUVDV-JOCHJYFZSA-N
DMIKAJC	IU	[(2R)-1-[[5-(3-tert-butylphenyl)-1H-indol-2-yl]methyl]pyrrolidin-2-yl]methanol

DMNIKTA	ID	DMNIKTA
DMNIKTA	DN	PMID27539678-Compound-12
DMNIKTA	HS	Patented
DMNIKTA	CP	AJINOMOTO CO., INC
DMNIKTA	DT	Small molecular drug
DMNIKTA	PC	86274705
DMNIKTA	MW	404.5
DMNIKTA	FM	C26H32N2O2
DMNIKTA	IC	InChI=1S/C26H32N2O2/c29-17-24-7-4-12-28(24)16-23-15-22-14-21(10-11-26(22)27-23)20-6-3-5-19(13-20)18-30-25-8-1-2-9-25/h3,5-6,10-11,13-15,24-25,27,29H,1-2,4,7-9,12,16-18H2/t24-/m1/s1
DMNIKTA	CS	C1CCC(C1)OCC2=CC(=CC=C2)C3=CC4=C(C=C3)NC(=C4)CN5CCC[C@@H]5CO
DMNIKTA	IK	GCKSLJXLYRTNCV-XMMPIXPASA-N
DMNIKTA	IU	[(2R)-1-[[5-[3-(cyclopentyloxymethyl)phenyl]-1H-indol-2-yl]methyl]pyrrolidin-2-yl]methanol

DM1J2V8	ID	DM1J2V8
DM1J2V8	DN	PMID27539678-Compound-13
DM1J2V8	HS	Patented
DM1J2V8	CP	AJINOMOTO CO., INC
DM1J2V8	DT	Small molecular drug
DM1J2V8	PC	86275654
DM1J2V8	MW	386.5
DM1J2V8	FM	C26H30N2O
DM1J2V8	IC	InChI=1S/C26H30N2O/c29-18-25-10-5-13-28(25)17-24-16-23-15-22(11-12-26(23)27-24)21-9-4-8-20(14-21)19-6-2-1-3-7-19/h4,6,8-9,11-12,14-16,25,27,29H,1-3,5,7,10,13,17-18H2/t25-/m1/s1
DM1J2V8	CS	C1CCC(=CC1)C2=CC=CC(=C2)C3=CC4=C(C=C3)NC(=C4)CN5CCC[C@@H]5CO
DM1J2V8	IK	VGAFMTJLEJHSLL-RUZDIDTESA-N
DM1J2V8	IU	[(2R)-1-[[5-[3-(cyclohexen-1-yl)phenyl]-1H-indol-2-yl]methyl]pyrrolidin-2-yl]methanol

DMZ02LA	ID	DMZ02LA
DMZ02LA	DN	PMID27539678-Compound-14
DMZ02LA	HS	Patented
DMZ02LA	CP	AJINOMOTO CO., INC
DMZ02LA	DT	Small molecular drug
DMZ02LA	PC	117626498
DMZ02LA	MW	428.6
DMZ02LA	FM	C28H32N2O2
DMZ02LA	IC	InChI=1S/C28H32N2O2/c1-28(2)11-10-27(32)25(16-28)21-6-3-5-19(13-21)20-8-9-26-22(14-20)15-23(29-26)17-30-12-4-7-24(30)18-31/h3,5-6,8-9,13-16,24,29,31H,4,7,10-12,17-18H2,1-2H3/t24-/m1/s1
DMZ02LA	CS	CC1(CCC(=O)C(=C1)C2=CC=CC(=C2)C3=CC4=C(C=C3)NC(=C4)CN5CCC[C@@H]5CO)C
DMZ02LA	IK	PNODTUCQTPQANY-XMMPIXPASA-N
DMZ02LA	IU	2-[3-[2-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl]-1H-indol-5-yl]phenyl]-4,4-dimethylcyclohex-2-en-1-one

DMMDJH8	ID	DMMDJH8
DMMDJH8	DN	PMID27539678-Compound-16
DMMDJH8	HS	Patented
DMMDJH8	CP	GENZYME CORPORATION XIANG, Yibin HIRTH, Bradford KANE, John, L. LIAO, Junkai NOSON, Kevin YEE, Christopher
DMMDJH8	DT	Small molecular drug
DMMDJH8	PC	46911228
DMMDJH8	MW	398.5
DMMDJH8	FM	C22H30N4O3
DMMDJH8	IC	InChI=1S/C22H30N4O3/c1-14(24-22(28)20-18(27)12-13-23-20)16-7-9-17(10-8-16)21-25-19(29-26-21)11-6-15-4-2-3-5-15/h7-10,14-15,18,20,23,27H,2-6,11-13H2,1H3,(H,24,28)/t14-,18-,20-/m0/s1
DMMDJH8	CS	C[C@@H](C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCC3)NC(=O)[C@@H]4[C@H](CCN4)O
DMMDJH8	IK	GDJANRNMFHNVOW-DCPHZVHLSA-N
DMMDJH8	IU	(2S,3S)-N-[(1S)-1-[4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-3-hydroxypyrrolidine-2-carboxamide

DMVG7A5	ID	DMVG7A5
DMVG7A5	DN	PMID27539678-Compound-17
DMVG7A5	HS	Patented
DMVG7A5	CP	GENZYME CORPORATION XIANG, Yibin HIRTH, Bradford KANE, John, L. LIAO, Junkai NOSON, Kevin YEE, Christopher
DMVG7A5	DT	Small molecular drug
DMVG7A5	PC	45256914
DMVG7A5	MW	386.5
DMVG7A5	FM	C21H30N4O3
DMVG7A5	IC	InChI=1S/C21H30N4O3/c1-2-3-4-5-6-7-18-24-20(25-28-18)16-10-8-15(9-11-16)14-23-21(27)19-17(26)12-13-22-19/h8-11,17,19,22,26H,2-7,12-14H2,1H3,(H,23,27)/t17-,19-/m0/s1
DMVG7A5	CS	CCCCCCCC1=NC(=NO1)C2=CC=C(C=C2)CNC(=O)[C@@H]3[C@H](CCN3)O
DMVG7A5	IK	CMLALAZUOVTKKV-HKUYNNGSSA-N
DMVG7A5	IU	(2S,3S)-N-[[4-(5-heptyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]-3-hydroxypyrrolidine-2-carboxamide

DMRNBP3	ID	DMRNBP3
DMRNBP3	DN	PMID27539678-Compound-3
DMRNBP3	HS	Patented
DMRNBP3	CP	Merck Patent GmBH
DMRNBP3	DT	Small molecular drug
DMRNBP3	PC	53250556
DMRNBP3	MW	421.6
DMRNBP3	FM	C27H39N3O
DMRNBP3	IC	InChI=1S/C27H39N3O/c1-26(2)12-13-27(3,4)23-20-21(10-11-22(23)26)24-8-7-9-25(28-24)30-17-15-29(16-18-30)14-5-6-19-31/h7-11,20,31H,5-6,12-19H2,1-4H3
DMRNBP3	CS	CC1(CCC(C2=C1C=CC(=C2)C3=NC(=CC=C3)N4CCN(CC4)CCCCO)(C)C)C
DMRNBP3	IK	NSOIVUTZXMNIJX-UHFFFAOYSA-N
DMRNBP3	IU	4-[4-[6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)pyridin-2-yl]piperazin-1-yl]butan-1-ol

DMJ8BAS	ID	DMJ8BAS
DMJ8BAS	DN	PMID27539678-Compound-4
DMJ8BAS	HS	Patented
DMJ8BAS	CP	University of Virginia Patent Foundation
DMJ8BAS	DT	Small molecular drug
DMJ8BAS	PC	50916701
DMJ8BAS	MW	379.6
DMJ8BAS	FM	C22H41N3O2
DMJ8BAS	IC	InChI=1S/C22H41N3O2/c23-20(24)22(14-15-22)21(26)25-16-10-5-3-1-2-4-6-11-17-27-18-19-12-8-7-9-13-19/h19H,1-18H2,(H3,23,24)(H,25,26)
DMJ8BAS	CS	C1CCC(CC1)COCCCCCCCCCCNC(=O)C2(CC2)C(=N)N
DMJ8BAS	IK	DCHHZPQOGYUREG-UHFFFAOYSA-N
DMJ8BAS	IU	1-carbamimidoyl-N-[10-(cyclohexylmethoxy)decyl]cyclopropane-1-carboxamide

DMBKNDE	ID	DMBKNDE
DMBKNDE	DN	PMID27539678-Compound-6
DMBKNDE	HS	Patented
DMBKNDE	CP	ALMAC DISCOVERY LIMITED HARRISON, Timothy BURKAMP, Frank JORDAN, Linda BELL, Mark JANSSEN, Dominic MIEL, Hugues MCFARLAND, Mary
DMBKNDE	DT	Small molecular drug
DMBKNDE	PC	53250711
DMBKNDE	MW	407.6
DMBKNDE	FM	C26H37N3O
DMBKNDE	IC	InChI=1S/C26H37N3O/c1-25(2)11-12-26(3,4)22-19-20(9-10-21(22)25)23-7-5-8-24(27-23)29-16-14-28(15-17-29)13-6-18-30/h5,7-10,19,30H,6,11-18H2,1-4H3
DMBKNDE	CS	CC1(CCC(C2=C1C=CC(=C2)C3=NC(=CC=C3)N4CCN(CC4)CCCO)(C)C)C
DMBKNDE	IK	ITCPVAVDRJPVOV-UHFFFAOYSA-N
DMBKNDE	IU	3-[4-[6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)pyridin-2-yl]piperazin-1-yl]propan-1-ol

DMQAC4K	ID	DMQAC4K
DMQAC4K	DN	PMID27539678-Compound-7
DMQAC4K	HS	Patented
DMQAC4K	CP	ALMAC DISCOVERY LIMITED HARRISON, Timothy BURKAMP, Frank JORDAN, Linda BELL, Mark JANSSEN, Dominic MIEL, Hugues MCFARLAND, Mary
DMQAC4K	DT	Small molecular drug
DMQAC4K	PC	67609351
DMQAC4K	MW	384.5
DMQAC4K	FM	C25H28N4
DMQAC4K	IC	InChI=1S/C25H28N4/c1-24(2)12-13-25(3,4)20-15-18(9-10-19(20)24)21-11-14-28-23(29-21)17-7-5-16(6-8-17)22(26)27/h5-11,14-15H,12-13H2,1-4H3,(H3,26,27)
DMQAC4K	CS	CC1(CCC(C2=C1C=CC(=C2)C3=NC(=NC=C3)C4=CC=C(C=C4)C(=N)N)(C)C)C
DMQAC4K	IK	HBVOXJWWSHTROQ-UHFFFAOYSA-N
DMQAC4K	IU	4-[4-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)pyrimidin-2-yl]benzenecarboximidamide

DMHWUEV	ID	DMHWUEV
DMHWUEV	DN	PMID27539678-Compound-8
DMHWUEV	HS	Patented
DMHWUEV	CP	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK UNIVERSITY OF STRATHCLYDE BITTMAN, Robert PYNE, Nigel J. PYNE, Susan BAEK, Dong Jae LIU, Zheng BYUN, Hoe Sup
DMHWUEV	DT	Small molecular drug
DMHWUEV	PC	42611957
DMHWUEV	MW	383.5
DMHWUEV	FM	C20H34NO4P
DMHWUEV	IC	InChI=1S/C20H34NO4P/c1-2-3-4-5-6-7-8-18-9-11-19(12-10-18)13-14-20(21,17-22)15-16-26(23,24)25/h9-12,15-16,22H,2-8,13-14,17,21H2,1H3,(H2,23,24,25)/b16-15+/t20-/m0/s1
DMHWUEV	CS	CCCCCCCCC1=CC=C(C=C1)CC[C@@](CO)(/C=C/P(=O)(O)O)N
DMHWUEV	IK	YWQUROWPKWKDNA-APHAIJBRSA-N
DMHWUEV	IU	[(E,3S)-3-amino-3-(hydroxymethyl)-5-(4-octylphenyl)pent-1-enyl]phosphonic acid

DM0Y5NU	ID	DM0Y5NU
DM0Y5NU	DN	PMID27539678-Compound-9
DM0Y5NU	HS	Patented
DM0Y5NU	CP	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK UNIVERSITY OF STRATHCLYDE BITTMAN, Robert PYNE, Nigel J. PYNE, Susan BAEK, Dong Jae LIU, Zheng BYUN, Hoe Sup
DM0Y5NU	DT	Small molecular drug
DM0Y5NU	PC	72735440
DM0Y5NU	MW	316.5
DM0Y5NU	FM	C21H36N2
DM0Y5NU	IC	InChI=1S/C21H36N2/c1-2-3-4-5-6-7-8-19-9-11-20(12-10-19)13-16-23-17-14-21(22)15-18-23/h9-12,21H,2-8,13-18,22H2,1H3
DM0Y5NU	CS	CCCCCCCCC1=CC=C(C=C1)CCN2CCC(CC2)N
DM0Y5NU	IK	ILDHJXNNCSUCMI-UHFFFAOYSA-N
DM0Y5NU	IU	1-[2-(4-octylphenyl)ethyl]piperidin-4-amine

DM5OQBR	ID	DM5OQBR
DM5OQBR	DN	PMID27551786-Compound-106
DM5OQBR	HS	Patented
DM5OQBR	CP	Merck Sharp & Dohme
DM5OQBR	DT	Small molecular drug

DM4IZUH	ID	DM4IZUH
DM4IZUH	DN	PMID27551786-Compound-138
DM4IZUH	HS	Patented
DM4IZUH	CP	Merck Sharp & Dohme
DM4IZUH	DT	Small molecular drug

DMA7H63	ID	DMA7H63
DMA7H63	DN	PMID27551786-Compound-I
DMA7H63	HS	Patented
DMA7H63	CP	Merck Sharp & DohmeMerck Sharp & Dohme
DMA7H63	DT	Small molecular drug

DMJADXV	ID	DMJADXV
DMJADXV	DN	PMID27551786-Compound-II
DMJADXV	HS	Patented
DMJADXV	CP	Merck Sharp & Dohme
DMJADXV	DT	Small molecular drug

DMBQ981	ID	DMBQ981
DMBQ981	DN	PMID27551786-Compound-III
DMBQ981	HS	Patented
DMBQ981	CP	Merck Sharp & Dohme
DMBQ981	DT	Small molecular drug

DM7IB8L	ID	DM7IB8L
DM7IB8L	DN	PMID27551786-Compound-IV
DM7IB8L	HS	Patented
DM7IB8L	CP	Merck Sharp & DohmMerck Sharp & Dohme
DM7IB8L	DT	Small molecular drug

DM5KARO	ID	DM5KARO
DM5KARO	DN	PMID27599163-Compound-52
DM5KARO	HS	Patented
DM5KARO	CP	GE HEALTHCARE LIMITED WADSWORTH, Harry, John SHAN, Bo O'SHEA, Dennis PASSMORE, Joanna, Marie TRIGG, William, John
DM5KARO	DT	Small molecular drug

DMYCQR4	ID	DMYCQR4
DMYCQR4	DN	PMID27599163-Compound-75
DMYCQR4	HS	Patented
DMYCQR4	CP	Verleye M, Guern MEL, Girard P, et alMsn Laboratories Limited, India
DMYCQR4	DT	Small molecular drug

DMODPFU	ID	DMODPFU
DMODPFU	DN	PMID27599163-Compound-76
DMODPFU	HS	Patented
DMODPFU	CP	Verleye M, Guern MEL, Girard P, et al
DMODPFU	DT	Small molecular drug

DM2TNH4	ID	DM2TNH4
DM2TNH4	DN	PMID27599163-Compound-77
DM2TNH4	HS	Patented
DM2TNH4	CP	BIOCODEX
DM2TNH4	DT	Small molecular drug

DMZC58R	ID	DMZC58R
DMZC58R	DN	PMID27599163-Compound-78
DMZC58R	HS	Patented
DMZC58R	CP	BIOCODEX
DMZC58R	DT	Small molecular drug

DMVUWYB	ID	DMVUWYB
DMVUWYB	DN	PMID27599163-Compound-79
DMVUWYB	HS	Patented
DMVUWYB	CP	Owen D, Wilkins M
DMVUWYB	DT	Small molecular drug

DMZ5QC4	ID	DMZ5QC4
DMZ5QC4	DN	PMID27599163-Compound-81
DMZ5QC4	HS	Patented
DMZ5QC4	CP	RICHTER GEDEON NYRT
DMZ5QC4	DT	Small molecular drug

DMO74I9	ID	DMO74I9
DMO74I9	DN	PMID27599163-Compound-82
DMO74I9	HS	Patented
DMO74I9	DT	Small molecular drug

DM5RBFC	ID	DM5RBFC
DM5RBFC	DN	PMID27607364-Compound-10
DM5RBFC	HS	Patented
DM5RBFC	DT	Small molecular drug
DM5RBFC	PC	9841240
DM5RBFC	MW	348.4
DM5RBFC	FM	C21H20N2O3
DM5RBFC	IC	InChI=1S/C21H20N2O3/c1-16(24)23(15-17-8-6-7-11-20(17)25-2)19-14-22-13-12-21(19)26-18-9-4-3-5-10-18/h3-14H,15H2,1-2H3
DM5RBFC	CS	CC(=O)N(CC1=CC=CC=C1OC)C2=C(C=CN=C2)OC3=CC=CC=C3
DM5RBFC	IK	DHZBNHMEIOBPAE-UHFFFAOYSA-N
DM5RBFC	IU	N-[(2-methoxyphenyl)methyl]-N-(4-phenoxypyridin-3-yl)acetamide

DMMF4XO	ID	DMMF4XO
DMMF4XO	DN	PMID27607364-Compound-141
DMMF4XO	HS	Patented
DMMF4XO	DT	Small molecular drug
DMMF4XO	PC	45108357
DMMF4XO	MW	490.4
DMMF4XO	FM	C21H25IN4O2
DMMF4XO	IC	InChI=1S/C21H25IN4O2/c1-6-25(7-2)19(27)12-16-20(15-8-9-18(28-5)17(22)11-15)24-26-14(4)10-13(3)23-21(16)26/h8-11H,6-7,12H2,1-5H3/i22-2
DMMF4XO	CS	CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC(=C(C=C3)OC)[125I])C)C
DMMF4XO	IK	TYBYEGAEDKDDES-ONBQKKEBSA-N
DMMF4XO	IU	N,N-diethyl-2-[2-(3-(125I)iodanyl-4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide
DMMF4XO	CA	CAS 1192559-24-2

DM0F6VU	ID	DM0F6VU
DM0F6VU	DN	PMID27607364-Compound-162
DM0F6VU	HS	Patented
DM0F6VU	CP	Dainippon Pharmaceutical Co., Ltd
DM0F6VU	DT	Small molecular drug

DMKBZDP	ID	DMKBZDP
DMKBZDP	DN	PMID27607364-Compound-4
DMKBZDP	HS	Patented
DMKBZDP	CP	COCENSYS, INC
DMKBZDP	DT	Small molecular drug
DMKBZDP	PC	3016
DMKBZDP	MW	284.74
DMKBZDP	FM	C16H13ClN2O
DMKBZDP	IC	InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
DMKBZDP	CS	CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DMKBZDP	IK	AAOVKJBEBIDNHE-UHFFFAOYSA-N
DMKBZDP	IU	7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DMKBZDP	CA	CAS 439-14-5
DMKBZDP	CB	CHEBI:49575

DMXJVW4	ID	DMXJVW4
DMXJVW4	DN	PMID27607364-Compound-58
DMXJVW4	HS	Patented
DMXJVW4	DT	Small molecular drug

DMLY7I3	ID	DMLY7I3
DMLY7I3	DN	PMID27607364-Compound-59
DMLY7I3	HS	Patented
DMLY7I3	CP	BIO IMAGING KOREA CO., LTD
DMLY7I3	DT	Small molecular drug

DM584EP	ID	DM584EP
DM584EP	DN	PMID27607364-Compound-60
DM584EP	HS	Patented
DM584EP	CP	BAYER SCHERING PHARMA AKTIENGESELLSCHAFT LEHMANN, Lutz THIELE, Andrea HEINRICH, Tobias VOLLMER, Sonja
DM584EP	DT	Small molecular drug
DM584EP	PC	44632752
DM584EP	MW	439.5
DM584EP	FM	C24H25FN2O5
DM584EP	IC	InChI=1S/C24H25FN2O5/c1-17(28)27(16-18-15-21(30-3)10-11-23(18)31-14-12-25)22-5-4-13-26-24(22)32-20-8-6-19(29-2)7-9-20/h4-11,13,15H,12,14,16H2,1-3H3/i25-1
DM584EP	CS	CC(=O)N(CC1=C(C=CC(=C1)OC)OCC[18F])C2=C(N=CC=C2)OC3=CC=C(C=C3)OC
DM584EP	IK	WDCDJYGFOQXTQD-FNNGWQQSSA-N
DM584EP	IU	N-[[2-(2-(18F)fluoranylethoxy)-5-methoxyphenyl]methyl]-N-[2-(4-methoxyphenoxy)pyridin-3-yl]acetamide
DM584EP	CA	CAS 1207345-42-3

DMWE6NZ	ID	DMWE6NZ
DMWE6NZ	DN	PMID27607364-Compound-61
DMWE6NZ	HS	Patented
DMWE6NZ	CP	BAYER SCHERING PHARMA AKTIENGESELLSCHAFT LEHMANN, Lutz THIELE, Andrea HEINRICH, Tobias VOLLMER, Sonja
DMWE6NZ	DT	Small molecular drug
DMWE6NZ	PC	44622012
DMWE6NZ	MW	437.5
DMWE6NZ	FM	C25H27FN2O4
DMWE6NZ	IC	InChI=1S/C25H27FN2O4/c1-17-7-5-9-23(18(17)2)32-25-22(8-6-13-27-25)28(19(3)29)16-20-15-21(30-4)10-11-24(20)31-14-12-26/h5-11,13,15H,12,14,16H2,1-4H3/i26-1
DMWE6NZ	CS	CC1=C(C(=CC=C1)OC2=C(C=CC=N2)N(CC3=C(C=CC(=C3)OC)OCC[18F])C(=O)C)C
DMWE6NZ	IK	JBDICOKSGXRRSY-KPVNRNJOSA-N
DMWE6NZ	IU	N-[2-(2,3-dimethylphenoxy)pyridin-3-yl]-N-[[2-(2-(18F)fluoranylethoxy)-5-methoxyphenyl]methyl]acetamide

DMXGT2A	ID	DMXGT2A
DMXGT2A	DN	PMID27607364-Compound-62
DMXGT2A	HS	Patented
DMXGT2A	CP	BAYER SCHERING PHARMA AKTIENGESELLSCHAFT LEHMANN, Lutz THIELE, Andrea HEINRICH, Tobias VOLLMER, Sonja
DMXGT2A	DT	Small molecular drug

DMVTPHY	ID	DMVTPHY
DMVTPHY	DN	PMID27607364-Compound-63
DMVTPHY	HS	Patented
DMVTPHY	DT	Small molecular drug
DMVTPHY	PC	53245866
DMVTPHY	MW	376.4
DMVTPHY	FM	C23H20FNO3
DMVTPHY	IC	InChI=1S/C23H20FNO3/c24-15-22(26)25(16-18-8-6-7-17-13-14-27-23(17)18)20-11-4-5-12-21(20)28-19-9-2-1-3-10-19/h1-12H,13-16H2/i24-1
DMVTPHY	CS	C1COC2=C1C=CC=C2CN(C3=CC=CC=C3OC4=CC=CC=C4)C(=O)C[18F]
DMVTPHY	IK	RDJNEDDYELAPBM-MIGPCILRSA-N
DMVTPHY	IU	N-(2,3-dihydro-1-benzofuran-7-ylmethyl)-2-(18F)fluoranyl-N-(2-phenoxyphenyl)acetamide

DMZSI15	ID	DMZSI15
DMZSI15	DN	PMID27607364-Compound-64
DMZSI15	HS	Patented
DMZSI15	DT	Small molecular drug
DMZSI15	PC	53245982
DMZSI15	MW	378.4
DMZSI15	FM	C22H18FNO4
DMZSI15	IC	InChI=1S/C22H18FNO4/c23-13-21(25)24(14-16-7-6-12-20-22(16)27-15-26-20)18-10-4-5-11-19(18)28-17-8-2-1-3-9-17/h1-12H,13-15H2/i23-1
DMZSI15	CS	C1OC2=CC=CC(=C2O1)CN(C3=CC=CC=C3OC4=CC=CC=C4)C(=O)C[18F]
DMZSI15	IK	JHMUPOREYLLSRB-VNRZBHCFSA-N
DMZSI15	IU	N-(1,3-benzodioxol-4-ylmethyl)-2-(18F)fluoranyl-N-(2-phenoxyphenyl)acetamide

DM9NEFG	ID	DM9NEFG
DM9NEFG	DN	PMID27607364-Compound-65
DM9NEFG	HS	Patented
DM9NEFG	DT	Small molecular drug
DM9NEFG	PC	53245983
DM9NEFG	MW	392.4
DM9NEFG	FM	C23H20FNO4
DM9NEFG	IC	InChI=1S/C23H20FNO4/c24-15-22(26)25(16-17-7-6-12-21-23(17)28-14-13-27-21)19-10-4-5-11-20(19)29-18-8-2-1-3-9-18/h1-12H,13-16H2/i24-1
DM9NEFG	CS	C1COC2=C(C=CC=C2O1)CN(C3=CC=CC=C3OC4=CC=CC=C4)C(=O)C[18F]
DM9NEFG	IK	UDPFMHCLCUMIOF-MIGPCILRSA-N
DM9NEFG	IU	N-(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)-2-(18F)fluoranyl-N-(2-phenoxyphenyl)acetamide

DMTJ0LB	ID	DMTJ0LB
DMTJ0LB	DN	PMID27724045-Compound-14
DMTJ0LB	HS	Patented
DMTJ0LB	CP	Janssen Pharmaceutica
DMTJ0LB	DT	Small molecular drug
DMTJ0LB	PC	90414893
DMTJ0LB	MW	466.8
DMTJ0LB	FM	C20H15ClF4N6O
DMTJ0LB	IC	InChI=1S/C20H15ClF4N6O/c21-15-12(4-2-5-13(15)20(23,24)25)19(32)31-11-3-1-6-14(31)17-28-29-18(30(17)9-11)16-26-7-10(22)8-27-16/h2,4-5,7-8,11,14H,1,3,6,9H2/t11-,14+/m1/s1
DMTJ0LB	CS	C1C[C@@H]2CN3C(=NN=C3C4=NC=C(C=N4)F)[C@H](C1)N2C(=O)C5=C(C(=CC=C5)C(F)(F)F)Cl
DMTJ0LB	IK	OKEUHBTYCIUVSL-RISCZKNCSA-N
DMTJ0LB	IU	[2-chloro-3-(trifluoromethyl)phenyl]-[(1S,8R)-5-(5-fluoropyrimidin-2-yl)-3,4,6,12-tetrazatricyclo[6.3.1.02,6]dodeca-2,4-dien-12-yl]methanone

DMVN5BD	ID	DMVN5BD
DMVN5BD	DN	PMID27724045-Compound-15
DMVN5BD	HS	Patented
DMVN5BD	CP	Janssen Pharmaceutica
DMVN5BD	DT	Small molecular drug
DMVN5BD	PC	86281295
DMVN5BD	MW	421.8
DMVN5BD	FM	C19H15ClF3N5O
DMVN5BD	IC	InChI=1S/C19H15ClF3N5O/c1-10-16-12(17(25-9-24-16)14-5-7-26-27-14)6-8-28(10)18(29)11-3-2-4-13(15(11)20)19(21,22)23/h2-5,7,9-10H,6,8H2,1H3,(H,26,27)/t10-/m1/s1
DMVN5BD	CS	C[C@@H]1C2=NC=NC(=C2CCN1C(=O)C3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=NN4
DMVN5BD	IK	CJGMJEYIRWOWHA-SNVBAGLBSA-N
DMVN5BD	IU	[2-chloro-3-(trifluoromethyl)phenyl]-[(8R)-8-methyl-4-(1H-pyrazol-5-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]methanone

DM4W72V	ID	DM4W72V
DM4W72V	DN	PMID27724045-Compound-17
DM4W72V	HS	Patented
DM4W72V	CP	Janssen Pharmaceutica
DM4W72V	DT	Small molecular drug
DM4W72V	PC	86278949
DM4W72V	MW	436.8
DM4W72V	FM	C19H16ClF3N6O
DM4W72V	IC	InChI=1S/C19H16ClF3N6O/c1-2-12-10-29-16(14-8-24-6-7-25-14)26-27-17(29)18(30)28(12)9-11-4-3-5-13(15(11)20)19(21,22)23/h3-8,12H,2,9-10H2,1H3/t12-/m0/s1
DM4W72V	CS	CC[C@H]1CN2C(=NN=C2C(=O)N1CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=NC=CN=C4
DM4W72V	IK	XOUUTQMOXWSZSL-LBPRGKRZSA-N
DM4W72V	IU	(6S)-7-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-6-ethyl-3-pyrazin-2-yl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8-one

DMVDBHT	ID	DMVDBHT
DMVDBHT	DN	PMID27724045-Compound-19
DMVDBHT	HS	Patented
DMVDBHT	CP	Actelion pharmaceuticals Ltd
DMVDBHT	DT	Small molecular drug

DMKTQX8	ID	DMKTQX8
DMKTQX8	DN	PMID27724045-Compound-29
DMKTQX8	HS	Patented
DMKTQX8	CP	Evotec
DMKTQX8	DT	Small molecular drug

DMOS7ZP	ID	DMOS7ZP
DMOS7ZP	DN	PMID27724045-Compound-33
DMOS7ZP	HS	Patented
DMOS7ZP	CP	Aventis Pharmaceuticals, Inc
DMOS7ZP	DT	Small molecular drug

DMFKS2P	ID	DMFKS2P
DMFKS2P	DN	PMID27744724-Compound-10
DMFKS2P	HS	Patented
DMFKS2P	CP	VANDERBILT UNIVERSITY
DMFKS2P	DT	Small molecular drug

DMCFOXP	ID	DMCFOXP
DMCFOXP	DN	PMID27744724-Compound-13
DMCFOXP	HS	Patented
DMCFOXP	CP	VANDERBILT UNIVERSITY
DMCFOXP	DT	Small molecular drug

DM73S2C	ID	DM73S2C
DM73S2C	DN	PMID27744724-Compound-18
DM73S2C	HS	Patented
DM73S2C	CP	THE REGENTS OF THE UNIVERSITY OF MICHGIAN NIKOLOVSKA-COLESKA, Zaneta SHOWALTER, Hollis D. LIAO, Chenzhong MOHAMMAD, Ramzi ABULWERDI, Fardokht WAYNE STATE UNIVERSITY
DM73S2C	DT	Small molecular drug

DM214WA	ID	DM214WA
DM214WA	DN	PMID27744724-Compound-19
DM214WA	HS	Patented
DM214WA	CP	THE REGENTS OF THE UNIVERSITY OF MICHGIAN NIKOLOVSKA-COLESKA, Zaneta SHOWALTER, Hollis D. LIAO, Chenzhong MOHAMMAD, Ramzi ABULWERDI, Fardokht WAYNE STATE UNIVERSITY
DM214WA	DT	Small molecular drug

DMD0T6S	ID	DMD0T6S
DMD0T6S	DN	PMID27744724-Compound-20
DMD0T6S	HS	Patented
DMD0T6S	CP	THE REGENTS OF THE UNIVERSITY OF MICHIGAN NIKOLOVSKA-COLESKA, Zaneta BAJWA, Naval LIAO, Chenzhong MIAO, Lei
DMD0T6S	DT	Small molecular drug

DM18UA5	ID	DM18UA5
DM18UA5	DN	PMID27744724-Compound-21
DM18UA5	HS	Patented
DM18UA5	CP	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DM18UA5	DT	Small molecular drug

DMM6FOW	ID	DMM6FOW
DMM6FOW	DN	PMID27744724-Compound-22
DMM6FOW	HS	Patented
DMM6FOW	CP	DANA FARBER CANCER INSTITUTE, INCDANA-FARBER CANCER INSTITUTE, INC WALENSKY, Loren, D. STEWART, Michelle, L. COHEN, Nicole
DMM6FOW	DT	Small molecular drug

DMXA70C	ID	DMXA70C
DMXA70C	DN	PMID27744724-Compound-23
DMXA70C	HS	Patented
DMXA70C	CP	DANA FARBER CANCER INSTITUTE, INCDANA-FARBER CANCER INSTITUTE, INC WALENSKY, Loren, D. STEWART, Michelle, L. COHEN, Nicole
DMXA70C	DT	Small molecular drug

DM8GOH3	ID	DM8GOH3
DM8GOH3	DN	PMID27744724-Compound-26
DM8GOH3	HS	Patented
DM8GOH3	CP	AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH NATIONAL UNIVERSITY OF SINGAPORE CHAI, Christina, L., L. BERNARDO, Paul, H. XU, Jin YU, Victor, C. WAN, Kah-Fei MOK, Henry, Y., K. SIVARAMAN, Thirunavukkarasu KJRISHNAMOORTHY, Janarthanan
DM8GOH3	DT	Small molecular drug

DMV6MLC	ID	DMV6MLC
DMV6MLC	DN	PMID27744724-Compound-27
DMV6MLC	HS	Patented
DMV6MLC	CP	AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH NATIONAL UNIVERSITY OF SINGAPORE CHAI, Christina, L., L. BERNARDO, Paul, H. XU, Jin YU, Victor, C. WAN, Kah-Fei MOK, Henry, Y., K. SIVARAMAN, Thirunavukkarasu KJRISHNAMOORTHY, Janarthanan
DMV6MLC	DT	Small molecular drug

DMB018S	ID	DMB018S
DMB018S	DN	PMID27744724-Compound-28
DMB018S	HS	Patented
DMB018S	CP	SERVIER LAB [FRVERNALIS R & D LTD [GB]
DMB018S	DT	Small molecular drug

DM2GDXH	ID	DM2GDXH
DM2GDXH	DN	PMID27744724-Compound-29
DM2GDXH	HS	Patented
DM2GDXH	CP	AMGEN INC
DM2GDXH	DT	Small molecular drug

DMWKYU4	ID	DMWKYU4
DMWKYU4	DN	PMID27744724-Compound-3
DMWKYU4	HS	Patented
DMWKYU4	CP	ABBOTT LABORATORIES 
DMWKYU4	DT	Small molecular drug

DMV1WND	ID	DMV1WND
DMV1WND	DN	PMID27744724-Compound-4
DMV1WND	HS	Patented
DMV1WND	CP	ABBOTT LABORATORIES 
DMV1WND	DT	Small molecular drug

DM6UTAQ	ID	DM6UTAQ
DM6UTAQ	DN	PMID27744724-Compound-5
DM6UTAQ	HS	Patented
DM6UTAQ	CP	ABBOTT LABORATORIES 
DM6UTAQ	DT	Small molecular drug

DMV7P4N	ID	DMV7P4N
DMV7P4N	DN	PMID27744724-Compound-6
DMV7P4N	HS	Patented
DMV7P4N	CP	ABBOTT LABORATORIES
DMV7P4N	DT	Small molecular drug

DMT2W97	ID	DMT2W97
DMT2W97	DN	PMID27744724-Compound-Fomula2
DMT2W97	HS	Patented
DMT2W97	CP	ABBOTT LABORATORIES 
DMT2W97	DT	Small molecular drug

DMFAGOZ	ID	DMFAGOZ
DMFAGOZ	DN	PMID27774822-Compound-Figure10Compound12
DMFAGOZ	HS	Patented
DMFAGOZ	CP	TOLERO PHARMACEUTICALS, INC
DMFAGOZ	DT	Small molecular drug

DMMJVTW	ID	DMMJVTW
DMMJVTW	DN	PMID27774822-Compound-Figure10Compound4
DMMJVTW	HS	Patented
DMMJVTW	CP	TOLERO PHARMACEUTICALS, INC
DMMJVTW	DT	Small molecular drug

DM3M6SE	ID	DM3M6SE
DM3M6SE	DN	PMID27774822-Compound-Figure10CompoundA
DM3M6SE	HS	Patented
DM3M6SE	CP	SUPERGEN, INC. VANKAYALAPATI, Hariprasad LIU, Xiao-hui BEARSS, David, J
DM3M6SE	DT	Small molecular drug

DMCTXPQ	ID	DMCTXPQ
DMCTXPQ	DN	PMID27774822-Compound-Figure10Example1
DMCTXPQ	HS	Patented
DMCTXPQ	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMCTXPQ	DT	Small molecular drug

DMNXYZP	ID	DMNXYZP
DMNXYZP	DN	PMID27774822-Compound-Figure10Example19
DMNXYZP	HS	Patented
DMNXYZP	CP	VERTEX PHARMACEUTICALS INCORPORATED
DMNXYZP	DT	Small molecular drug

DMAHFXV	ID	DMAHFXV
DMAHFXV	DN	PMID27774822-Compound-Figure11Example5
DMAHFXV	HS	Patented
DMAHFXV	CP	YM BIOSCIENCES AUSTRALIA PTY LTD
DMAHFXV	DT	Small molecular drug

DMCL19N	ID	DMCL19N
DMCL19N	DN	PMID27774822-Compound-Figure1Example20
DMCL19N	HS	Patented
DMCL19N	CP	JIANGSU CAREFREE PHARMACEUTICAL CO., LTD
DMCL19N	DT	Small molecular drug

DM86M7D	ID	DM86M7D
DM86M7D	DN	PMID27774822-Compound-Figure2Example1-1left
DM86M7D	HS	Patented
DM86M7D	CP	MERCK SHARP &amDOHME CORP. AHEARN, Sean, P. CHRISTOPHER, Matthew JUNG, Joon PU, Qinglin RIVKIN, Alexey SCOTT, Mark, E. WITTER, David, J. WOO, Hyun Chong CASH, Brandon DINSMORE, Christopher GUERIN, David
DM86M7D	DT	Small molecular drug

DM2YPLF	ID	DM2YPLF
DM2YPLF	DN	PMID27774822-Compound-Figure2Example1-1right
DM2YPLF	HS	Patented
DM2YPLF	CP	MERCK SHARP & DOHME CORP. BUTCHER, John, W. WITTER, David DINSMORE, Christopher KIM, June HENDRIX, John ARCHARYA, Raksha AHEARN, Sean, P. JUNG, Joon RIVKIN, Alexey JONES, Philip
DM2YPLF	DT	Small molecular drug

DMEHIS4	ID	DMEHIS4
DMEHIS4	DN	PMID27774822-Compound-Figure2Example4-3
DMEHIS4	HS	Patented
DMEHIS4	CP	MERCK SHARP &amDOHME CORP. AHEARN, Sean, P. CHRISTOPHER, Matthew JUNG, Joon PU, Qinglin RIVKIN, Alexey SCOTT, Mark, E. WITTER, David, J. WOO, Hyun Chong CASH, Brandon DINSMORE, Christopher GUERIN, David
DMEHIS4	DT	Small molecular drug

DMOENP4	ID	DMOENP4
DMOENP4	DN	PMID27774822-Compound-Figure3CompoundI-165
DMOENP4	HS	Patented
DMOENP4	CP	NIMBUS LAKSHMI, INC
DMOENP4	DT	Small molecular drug

DMCD19T	ID	DMCD19T
DMCD19T	DN	PMID27774822-Compound-Figure6Example2
DMCD19T	HS	Patented
DMCD19T	CP	PRINCIPIA BIOPHARMA INC
DMCD19T	DT	Small molecular drug

DM3FY85	ID	DM3FY85
DM3FY85	DN	PMID27774822-Compound-Figure6Example3
DM3FY85	HS	Patented
DM3FY85	CP	PRINCIPIA BIOPHARMA INC
DM3FY85	DT	Small molecular drug

DMF5IWB	ID	DMF5IWB
DMF5IWB	DN	PMID27774822-Compound-Figure7Example63
DMF5IWB	HS	Patented
DMF5IWB	CP	F. HOFFMANN-LA ROCHE AG GENENTECH, INC
DMF5IWB	DT	Small molecular drug

DMRHZF3	ID	DMRHZF3
DMRHZF3	DN	PMID27774822-Compound-Figure8Example5
DMRHZF3	HS	Patented
DMRHZF3	CP	INCYTE CORPORATION
DMRHZF3	DT	Small molecular drug

DMSHIT2	ID	DMSHIT2
DMSHIT2	DN	PMID27774822-Compound-Figure9Example15
DMSHIT2	HS	Patented
DMSHIT2	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMSHIT2	DT	Small molecular drug

DMH1W8F	ID	DMH1W8F
DMH1W8F	DN	PMID27774824-Compound-Figure11Example1up
DMH1W8F	HS	Patented
DMH1W8F	CP	GALAPAGOS NV
DMH1W8F	DT	Small molecular drug

DMAGKNJ	ID	DMAGKNJ
DMAGKNJ	DN	PMID27774824-Compound-Figure12Example1
DMAGKNJ	HS	Patented
DMAGKNJ	CP	HANMI PHARM CO., LTD
DMAGKNJ	DT	Small molecular drug

DMYOSIA	ID	DMYOSIA
DMYOSIA	DN	PMID27774824-Compound-Figure12Example10
DMYOSIA	HS	Patented
DMYOSIA	CP	BEIJING HANMI PHARMACEUTICAL CO., LTD
DMYOSIA	DT	Small molecular drug

DMNIZD7	ID	DMNIZD7
DMNIZD7	DN	PMID27774824-Compound-Figure12Example61
DMNIZD7	HS	Patented
DMNIZD7	CP	BEIJING HANMI PHARMACEUTICAL CO., LTD
DMNIZD7	DT	Small molecular drug

DMQHYMJ	ID	DMQHYMJ
DMQHYMJ	DN	PMID27774824-Compound-Figure2Example4
DMQHYMJ	HS	Patented
DMQHYMJ	CP	ALMIRALL SA [ESEASTWOOD PAUL ROBERT [ESBACH TANA JORDI [ESPAGES SANTACANA LLUIS MIQUEL [ES]
DMQHYMJ	DT	Small molecular drug

DMYZ6XQ	ID	DMYZ6XQ
DMYZ6XQ	DN	PMID27774824-Compound-Figure3Example18
DMYZ6XQ	HS	Patented
DMYZ6XQ	CP	ARRAY BIOPHARMA INC
DMYZ6XQ	DT	Small molecular drug

DMXDOGK	ID	DMXDOGK
DMXDOGK	DN	PMID27774824-Compound-Figure3Example7
DMXDOGK	HS	Patented
DMXDOGK	CP	ARRIEN PHARMACEUTICALS LLC
DMXDOGK	DT	Small molecular drug

DMDZKXC	ID	DMDZKXC
DMDZKXC	DN	PMID27774824-Compound-Figure5Example13
DMDZKXC	HS	Patented
DMDZKXC	CP	CADILA HEALTHCARE LIMITED THOMBARE, Pravin, S. ARGADE, Anil JAIN, Mukul, R. GITE, Sanjay
DMDZKXC	DT	Small molecular drug

DM1CM7S	ID	DM1CM7S
DM1CM7S	DN	PMID27774824-Compound-Figure6Example12
DM1CM7S	HS	Patented
DM1CM7S	CP	CALITOR SCIENCES, LLC SUNSHINE LAKE PHARMA CO., LTD
DM1CM7S	DT	Small molecular drug

DMB18V5	ID	DMB18V5
DMB18V5	DN	PMID27774824-Compound-Figure6Example6
DMB18V5	HS	Patented
DMB18V5	CP	CALITOR SCIENCES, LLC SUNSHINE LAKE PHARMA CO., LTD
DMB18V5	DT	Small molecular drug

DMT85AH	ID	DMT85AH
DMT85AH	DN	PMID27774824-Compound-Figure7Example10
DMT85AH	HS	Patented
DMT85AH	CP	CALITOR SCIENCES, LLC SUNSHINE LAKE PHARMA CO., LTD

DM6OCSJ	ID	DM6OCSJ
DM6OCSJ	DN	PMID27774824-Compound-Figure8Example22
DM6OCSJ	HS	Patented
DM6OCSJ	CP	CELON PHARMA S.A
DM6OCSJ	DT	Small molecular drug

DM1VOPH	ID	DM1VOPH
DM1VOPH	DN	PMID27774824-Compound-Figure8Example99
DM1VOPH	HS	Patented
DM1VOPH	CP	CELON PHARMA S.A
DM1VOPH	DT	Small molecular drug

DMXAV42	ID	DMXAV42
DMXAV42	DN	PMID27774824-Compound-Figure9Example2down
DMXAV42	HS	Patented
DMXAV42	CP	DANA-FARBER CANCER INSTITUTE, INC
DMXAV42	DT	Small molecular drug

DME3TMS	ID	DME3TMS
DME3TMS	DN	PMID27774824-Compound-Figure9Example2up
DME3TMS	HS	Patented
DME3TMS	CP	DANA-FARBER CANCER INSTITUTE, INC
DME3TMS	DT	Small molecular drug

DMHPK31	ID	DMHPK31
DMHPK31	DN	PMID27788040-Compound-5
DMHPK31	HS	Patented
DMHPK31	CP	MERCK SHARP & DOHME CORP. BARROW, James, C. BILODEAU, Mark, T. COX, Christopher, D. HARTNETT, John, C. KETT, Nathan, R. LI, Yiwei MANLEY, Peter MELAMED, Jeffrey SHIPE, William, D. TROTTER, B. Wesley ZARTMAN, Amy, E
DMHPK31	DT	Small molecular drug

DMW3X1I	ID	DMW3X1I
DMW3X1I	DN	PMID27788040-Compound-5a
DMW3X1I	HS	Patented
DMW3X1I	CP	MERCK SHARP & DOHME CORP. BARROW, James, C. BILODEAU, Mark, T. COX, Christopher, D. HARTNETT, John, C. KETT, Nathan, R. LI, Yiwei MANLEY, Peter MELAMED, Jeffrey SHIPE, William, D. TROTTER, B. Wesley ZARTMAN, Amy, E
DMW3X1I	DT	Small molecular drug
DMW3X1I	PC	46208464
DMW3X1I	MW	492.7
DMW3X1I	FM	C30H44N4O2
DMW3X1I	IC	InChI=1S/C30H44N4O2/c1-31-17-19-34(20-18-31)30(15-9-4-10-16-30)23-33(29(36)24-11-5-3-6-12-24)22-26-21-25-13-7-8-14-27(25)32(2)28(26)35/h7-8,13-14,21,24H,3-6,9-12,15-20,22-23H2,1-2H3
DMW3X1I	CS	CN1CCN(CC1)C2(CCCCC2)CN(CC3=CC4=CC=CC=C4N(C3=O)C)C(=O)C5CCCCC5
DMW3X1I	IK	PJVMTTZJMVQBDL-UHFFFAOYSA-N
DMW3X1I	IU	N-[(1-methyl-2-oxoquinolin-3-yl)methyl]-N-[[1-(4-methylpiperazin-1-yl)cyclohexyl]methyl]cyclohexanecarboxamide

DMPQKXR	ID	DMPQKXR
DMPQKXR	DN	PMID27788040-Compound-5b
DMPQKXR	HS	Patented
DMPQKXR	CP	MERCK SHARP & DOHME CORP. BARROW, James, C. BILODEAU, Mark, T. COX, Christopher, D. HARTNETT, John, C. KETT, Nathan, R. LI, Yiwei MANLEY, Peter MELAMED, Jeffrey SHIPE, William, D. TROTTER, B. Wesley ZARTMAN, Amy, E
DMPQKXR	DT	Small molecular drug
DMPQKXR	PC	49862986
DMPQKXR	MW	465.7
DMPQKXR	FM	C29H43N3O2
DMPQKXR	IC	InChI=1S/C29H43N3O2/c1-4-29(2,17-20-31-18-11-6-12-19-31)32(28(34)23-13-7-5-8-14-23)22-25-21-24-15-9-10-16-26(24)30(3)27(25)33/h9-10,15-16,21,23H,4-8,11-14,17-20,22H2,1-3H3
DMPQKXR	CS	CCC(C)(CCN1CCCCC1)N(CC2=CC3=CC=CC=C3N(C2=O)C)C(=O)C4CCCCC4
DMPQKXR	IK	LQTUVTFQPOMQHL-UHFFFAOYSA-N
DMPQKXR	IU	N-[(1-methyl-2-oxoquinolin-3-yl)methyl]-N-(3-methyl-1-piperidin-1-ylpentan-3-yl)cyclohexanecarboxamide

DMK72JS	ID	DMK72JS
DMK72JS	DN	PMID27788040-Compound-5c
DMK72JS	HS	Patented
DMK72JS	CP	MERCK SHARP & DOHME CORP. BARROW, James, C. BILODEAU, Mark, T. COX, Christopher, D. HARTNETT, John, C. KETT, Nathan, R. LI, Yiwei MANLEY, Peter MELAMED, Jeffrey SHIPE, William, D. TROTTER, B. Wesley ZARTMAN, Amy, E
DMK72JS	DT	Small molecular drug
DMK72JS	PC	44156964
DMK72JS	MW	467.6
DMK72JS	FM	C28H41N3O3
DMK72JS	IC	InChI=1S/C28H41N3O3/c1-4-28(2,14-15-30-16-18-34-19-17-30)31(27(33)22-10-6-5-7-11-22)21-24-20-23-12-8-9-13-25(23)29(3)26(24)32/h8-9,12-13,20,22H,4-7,10-11,14-19,21H2,1-3H3
DMK72JS	CS	CCC(C)(CCN1CCOCC1)N(CC2=CC3=CC=CC=C3N(C2=O)C)C(=O)C4CCCCC4
DMK72JS	IK	FWHNGUFKFXDMER-UHFFFAOYSA-N
DMK72JS	IU	N-(3-methyl-1-morpholin-4-ylpentan-3-yl)-N-[(1-methyl-2-oxoquinolin-3-yl)methyl]cyclohexanecarboxamide

DMHX8OF	ID	DMHX8OF
DMHX8OF	DN	PMID27788040-Compound-6
DMHX8OF	HS	Patented
DMHX8OF	CP	MERCK SHARP & DOHME CORP. MANLEY, Peter, J. NANDA, Kausik, K. TROTTER, B. Wesley
DMHX8OF	DT	Small molecular drug

DM4QA6X	ID	DM4QA6X
DM4QA6X	DN	PMID27788040-Compound-6a
DM4QA6X	HS	Patented
DM4QA6X	CP	MERCK SHARP & DOHME CORP. MANLEY, Peter, J. NANDA, Kausik, K. TROTTER, B. Wesley
DM4QA6X	DT	Small molecular drug

DMD3U96	ID	DMD3U96
DMD3U96	DN	PMID27788040-Compound-6b
DMD3U96	HS	Patented
DMD3U96	CP	MERCK SHARP & DOHME CORP. MANLEY, Peter, J. NANDA, Kausik, K. TROTTER, B. Wesley
DMD3U96	DT	Small molecular drug
DMD3U96	PC	46202376
DMD3U96	MW	394.9
DMD3U96	FM	C23H23ClN2O2
DMD3U96	IC	InChI=1S/C23H23ClN2O2/c1-27-19-6-7-20-21(14-19)23(26-11-10-25-22(20)26,15-16-8-12-28-13-9-16)17-2-4-18(24)5-3-17/h2-7,10-11,14,16H,8-9,12-13,15H2,1H3
DMD3U96	CS	COC1=CC2=C(C=C1)C3=NC=CN3C2(CC4CCOCC4)C5=CC=C(C=C5)Cl
DMD3U96	IK	XRZGTQYRLUSRHL-UHFFFAOYSA-N
DMD3U96	IU	5-(4-chlorophenyl)-7-methoxy-5-(oxan-4-ylmethyl)imidazo[2,1-a]isoindole

DMNRU35	ID	DMNRU35
DMNRU35	DN	PMID27788040-Compound-6c
DMNRU35	HS	Patented
DMNRU35	CP	MERCK SHARP & DOHME CORP. MANLEY, Peter, J. NANDA, Kausik, K. TROTTER, B. Wesley
DMNRU35	DT	Small molecular drug
DMNRU35	PC	58415473
DMNRU35	MW	423.9
DMNRU35	FM	C24H26ClN3O2
DMNRU35	IC	InChI=1S/C24H26ClN3O2/c1-4-27(5-2)22(29)12-13-24(17-6-8-18(25)9-7-17)21-16-19(30-3)10-11-20(21)23-26-14-15-28(23)24/h6-11,14-16H,4-5,12-13H2,1-3H3
DMNRU35	CS	CCN(CC)C(=O)CCC1(C2=C(C=CC(=C2)OC)C3=NC=CN31)C4=CC=C(C=C4)Cl
DMNRU35	IK	YBMSTCJKQQMCAW-UHFFFAOYSA-N
DMNRU35	IU	3-[5-(4-chlorophenyl)-7-methoxyimidazo[1,2-b]isoindol-5-yl]-N,N-diethylpropanamide

DM3G21F	ID	DM3G21F
DM3G21F	DN	PMID27828716-Compound-15
DM3G21F	HS	Patented
DM3G21F	DT	Small molecular drug

DM9VXY7	ID	DM9VXY7
DM9VXY7	DN	PMID27828716-Compound-16
DM9VXY7	HS	Patented
DM9VXY7	DT	Small molecular drug
DM9VXY7	PC	23122113
DM9VXY7	MW	443.7
DM9VXY7	FM	C14H8Cl3F3N4OS
DM9VXY7	IC	InChI=1S/C14H8Cl3F3N4OS/c15-6-1-4-26-11(6)9-7(16)8-10(12(17)23-5-22-8)24(9)3-2-21-13(25)14(18,19)20/h1,4-5H,2-3H2,(H,21,25)
DM9VXY7	CS	C1=CSC(=C1Cl)C2=C(C3=C(N2CCNC(=O)C(F)(F)F)C(=NC=N3)Cl)Cl
DM9VXY7	IK	OHSATPMXJJAETD-UHFFFAOYSA-N
DM9VXY7	IU	N-[2-[4,7-dichloro-6-(3-chlorothiophen-2-yl)pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-2,2,2-trifluoroacetamide

DMR7V9E	ID	DMR7V9E
DMR7V9E	DN	PMID27828716-Compound-17
DMR7V9E	HS	Patented
DMR7V9E	DT	Small molecular drug
DMR7V9E	PC	10065515
DMR7V9E	MW	335.32
DMR7V9E	FM	C16H13N7O2
DMR7V9E	IC	InChI=1S/C16H13N7O2/c1-25-11-5-3-10(4-6-11)23-13(24)9-12-14(22-23)15(21-20-12)19-16-17-7-2-8-18-16/h2-9,20H,1H3,(H,17,18,19,21)
DMR7V9E	CS	COC1=CC=C(C=C1)N2C(=O)C=C3C(=N2)C(=NN3)NC4=NC=CC=N4
DMR7V9E	IK	SSEXHPVKWUREDI-UHFFFAOYSA-N
DMR7V9E	IU	5-(4-methoxyphenyl)-3-(pyrimidin-2-ylamino)-1H-pyrazolo[4,3-c]pyridazin-6-one

DMNR6KL	ID	DMNR6KL
DMNR6KL	DN	PMID27828716-Compound-18
DMNR6KL	HS	Patented
DMNR6KL	DT	Small molecular drug
DMNR6KL	PC	9944655
DMNR6KL	MW	313.78
DMNR6KL	FM	C16H16ClN5
DMNR6KL	IC	InChI=1S/C16H16ClN5/c1-9-8-14(22-21-9)19-15-10(2)11(3)18-16(20-15)12-6-4-5-7-13(12)17/h4-8H,1-3H3,(H2,18,19,20,21,22)
DMNR6KL	CS	CC1=CC(=NN1)NC2=NC(=NC(=C2C)C)C3=CC=CC=C3Cl
DMNR6KL	IK	ONBXAMQNBSFIQS-UHFFFAOYSA-N
DMNR6KL	IU	2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

DM8V7QH	ID	DM8V7QH
DM8V7QH	DN	PMID27828716-Compound-19
DM8V7QH	HS	Patented
DM8V7QH	DT	Small molecular drug
DM8V7QH	PC	9800945
DM8V7QH	MW	397.4
DM8V7QH	FM	C21H19N9
DM8V7QH	IC	InChI=1S/C21H19N9/c1-13-9-19(30-28-13)26-21-25-18(10-14-5-3-2-4-6-14)24-20(27-21)23-16-8-7-15-12-22-29-17(15)11-16/h2-9,11-12H,10H2,1H3,(H,22,29)(H3,23,24,25,26,27,28,30)
DM8V7QH	CS	CC1=CC(=NN1)NC2=NC(=NC(=N2)NC3=CC4=C(C=C3)C=NN4)CC5=CC=CC=C5
DM8V7QH	IK	OKPNIPFZIIYESG-UHFFFAOYSA-N
DM8V7QH	IU	6-benzyl-4-N-(1H-indazol-6-yl)-2-N-(5-methyl-1H-pyrazol-3-yl)-1,3,5-triazine-2,4-diamine

DMDA3PN	ID	DMDA3PN
DMDA3PN	DN	PMID27828716-Compound-20
DMDA3PN	HS	Patented
DMDA3PN	DT	Small molecular drug
DMDA3PN	PC	57521263
DMDA3PN	MW	364.4
DMDA3PN	FM	C20H17FN4O2
DMDA3PN	IC	InChI=1S/C20H17FN4O2/c21-15-4-1-3-14-17(7-10-22-19(14)15)24-20(26)25-18-6-2-5-16(23-18)13-8-11-27-12-9-13/h1-8,10H,9,11-12H2,(H2,22,23,24,25,26)
DMDA3PN	CS	C1COCC=C1C2=NC(=CC=C2)NC(=O)NC3=C4C=CC=C(C4=NC=C3)F
DMDA3PN	IK	BYKSEVADXIBXTH-UHFFFAOYSA-N
DMDA3PN	IU	1-[6-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yl]-3-(8-fluoroquinolin-4-yl)urea
DMDA3PN	CA	CAS 1384424-60-5

DMO1NAR	ID	DMO1NAR
DMO1NAR	DN	PMID27828716-Compound-21
DMO1NAR	HS	Patented
DMO1NAR	DT	Small molecular drug
DMO1NAR	PC	49831011
DMO1NAR	MW	305.3
DMO1NAR	FM	C18H15N3O2
DMO1NAR	IC	InChI=1S/C18H15N3O2/c19-9-10-4-6-14-12(8-10)17(18(23)21-14)15-7-5-11-13(20-15)2-1-3-16(11)22/h4-8,16-17,22H,1-3H2,(H,21,23)
DMO1NAR	CS	C1CC(C2=C(C1)N=C(C=C2)C3C4=C(C=CC(=C4)C#N)NC3=O)O
DMO1NAR	IK	XZWVOUQIYLZUCJ-UHFFFAOYSA-N
DMO1NAR	IU	3-(5-hydroxy-5,6,7,8-tetrahydroquinolin-2-yl)-2-oxo-1,3-dihydroindole-5-carbonitrile

DMUM5L6	ID	DMUM5L6
DMUM5L6	DN	PMID27828716-Compound-BIO-acetoxime
DMUM5L6	HS	Patented
DMUM5L6	CP	UNIVERSITAET BASEL
DMUM5L6	DT	Small molecular drug
DMUM5L6	DE	Malignant glioma

DMY9WHZ	ID	DMY9WHZ
DMY9WHZ	DN	PMID27841036-Compound-23
DMY9WHZ	HS	Patented
DMY9WHZ	CP	Janssen Pharmaceutica NV
DMY9WHZ	DT	Small molecular drug
DMY9WHZ	PC	44514723
DMY9WHZ	MW	404.5
DMY9WHZ	FM	C23H24N4O3
DMY9WHZ	IC	InChI=1S/C23H24N4O3/c1-23(13-24,12-19-26-20(29-2)11-21(27-19)30-3)14-8-9-16-15-6-4-5-7-17(15)22(28)25-18(16)10-14/h8-11H,4-7,12H2,1-3H3,(H,25,28)
DMY9WHZ	CS	CC(CC1=NC(=CC(=N1)OC)OC)(C#N)C2=CC3=C(C=C2)C4=C(CCCC4)C(=O)N3
DMY9WHZ	IK	FITDTEZFVLDGBX-UHFFFAOYSA-N
DMY9WHZ	IU	3-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-2-(6-oxo-7,8,9,10-tetrahydro-5H-phenanthridin-3-yl)propanenitrile

DM9VMJ3	ID	DM9VMJ3
DM9VMJ3	DN	PMID27841036-Compound-24
DM9VMJ3	HS	Patented
DM9VMJ3	CP	Janssen Pharmaceutica NV
DM9VMJ3	DT	Small molecular drug
DM9VMJ3	PC	44515029
DM9VMJ3	MW	368.4
DM9VMJ3	FM	C23H20N4O
DM9VMJ3	IC	InChI=1S/C23H20N4O/c1-23(14-25,12-16-5-4-6-17(13-24)26-16)15-9-10-19-18-7-2-3-8-20(18)22(28)27-21(19)11-15/h4-6,9-11H,2-3,7-8,12H2,1H3,(H,27,28)
DM9VMJ3	CS	CC(CC1=NC(=CC=C1)C#N)(C#N)C2=CC3=C(C=C2)C4=C(CCCC4)C(=O)N3
DM9VMJ3	IK	WVGLSASLDWFLFS-UHFFFAOYSA-N
DM9VMJ3	IU	6-[2-cyano-2-(6-oxo-7,8,9,10-tetrahydro-5H-phenanthridin-3-yl)propyl]pyridine-2-carbonitrile

DMGXI95	ID	DMGXI95
DMGXI95	DN	PMID27841036-Compound-33
DMGXI95	HS	Patented
DMGXI95	CP	SHANGHAI HENGRUI PHARM CO LTD [CNJIANGSU HENGRUI MEDICINE CO [CNTANG PENGCHO [CNLI XIN [CNLI XIANGQIN [CNCHEN YANG [CNWANG BIN [CNZHU ZHE [CN] 
DMGXI95	DT	Small molecular drug
DMGXI95	PC	56649297
DMGXI95	MW	472.4
DMGXI95	FM	C22H16F4N6O2
DMGXI95	IC	InChI=1S/C22H16F4N6O2/c23-16-6-5-12(10-17-13-3-1-2-4-14(13)19(33)29-28-17)9-15(16)20(34)31-7-8-32-18(11-31)27-21(30-32)22(24,25)26/h1-6,9H,7-8,10-11H2,(H,29,33)
DMGXI95	CS	C1CN2C(=NC(=N2)C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
DMGXI95	IK	XJGXCBHXFWBOTN-UHFFFAOYSA-N
DMGXI95	IU	4-[[4-fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2H-phthalazin-1-one
DMGXI95	CA	CAS 1358715-18-0

DMHIV2L	ID	DMHIV2L
DMHIV2L	DN	PMID27841036-Compound-36
DMHIV2L	HS	Patented
DMHIV2L	CP	MGI GP, INC. XU, Weizheng DELAHANTY, Greg ZHANG, Jie
DMHIV2L	DT	Small molecular drug
DMHIV2L	PC	11660296
DMHIV2L	MW	349.4
DMHIV2L	FM	C20H19N3O3
DMHIV2L	IC	InChI=1S/C20H19N3O3/c24-13-6-8-23(9-7-13)11-12-4-5-16-15(10-12)19-18-14(20(25)22-21-19)2-1-3-17(18)26-16/h1-5,10,13,24H,6-9,11H2,(H,22,25)
DMHIV2L	CS	C1CN(CCC1O)CC2=CC3=C(C=C2)OC4=CC=CC5=C4C3=NNC5=O
DMHIV2L	IK	HAVFFEMDLROBGI-UHFFFAOYSA-N
DMHIV2L	IU	4-[(4-hydroxypiperidin-1-yl)methyl]-8-oxa-15,16-diazatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17)-heptaen-14-one
DMHIV2L	CA	CAS 902128-92-1

DM1KJAQ	ID	DM1KJAQ
DM1KJAQ	DN	PMID27841036-Compound-38
DM1KJAQ	HS	Patented
DM1KJAQ	CP	CEPHALON, INC. BIERLMAIER, Stephen CHRISTIE, Michael COURVOISIER, Laurent FIELD, R. Scott HALTIWANGER, R. Curtis HE, Linli JACOBS, Martin J. KRESS, Michael MCKEAN, Robert E. MOWREY, Dale R. PETRAITIS, Joseph YAZDANIAN, MehraCEPHALON, INC. DIEBOLD, James, L. HUDKINS, Robert, L. MIKNYOCZKI, Sheila, J. RUGGERI, BrucTEVA(Cephalon,Inc.)
DM1KJAQ	DT	Small molecular drug
DM1KJAQ	PC	24780387
DM1KJAQ	MW	418.5
DM1KJAQ	FM	C24H26N4O3
DM1KJAQ	IC	InChI=1S/C24H26N4O3/c1-26-9-11-27(12-10-26)13-28-23(29)18-14-5-3-6-15(14)22-20(21(18)24(28)30)19-16(25-22)7-4-8-17(19)31-2/h4,7-8,25H,3,5-6,9-13H2,1-2H3
DM1KJAQ	CS	CN1CCN(CC1)CN2C(=O)C3=C(C2=O)C4=C(C5=C3CCC5)NC6=C4C(=CC=C6)OC
DM1KJAQ	IK	CTLOSZHDGZLOQE-UHFFFAOYSA-N
DM1KJAQ	IU	14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione
DM1KJAQ	CA	CAS 916574-83-9

DM3FAIS	ID	DM3FAIS
DM3FAIS	DN	PMID27841036-Compound-V
DM3FAIS	HS	Patented
DM3FAIS	CP	Medshine Discovery Inc
DM3FAIS	DT	Small molecular drug

DM1HPY7	ID	DM1HPY7
DM1HPY7	DN	PMID27841036-Compound-XI
DM1HPY7	HS	Patented
DM1HPY7	CP	Janssen Pharmaceutica NV
DM1HPY7	DT	Small molecular drug

DM9K5BZ	ID	DM9K5BZ
DM9K5BZ	DN	PMID27841036-Compound-XVII
DM9K5BZ	HS	Patented
DM9K5BZ	CP	Santen Pharmaceutical Co
DM9K5BZ	DT	Small molecular drug

DME2IHD	ID	DME2IHD
DME2IHD	DN	PMID27841045-Compound-129
DME2IHD	HS	Patented
DME2IHD	CP	Korea Bio Health Co. Ltd
DME2IHD	DT	Small molecular drug
DME2IHD	PC	442126
DME2IHD	MW	328.4
DME2IHD	FM	C19H20O5
DME2IHD	IC	InChI=1S/C19H20O5/c1-11(2)7-18(21)23-16-9-13-8-12-5-6-17(20)22-14(12)10-15(13)24-19(16,3)4/h5-8,10,16H,9H2,1-4H3/t16-/m0/s1
DME2IHD	CS	CC(=CC(=O)O[C@H]1CC2=C(C=C3C(=C2)C=CC(=O)O3)OC1(C)C)C
DME2IHD	IK	CUKSFECWKQBVED-INIZCTEOSA-N
DME2IHD	IU	[(3S)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] 3-methylbut-2-enoate
DME2IHD	CA	CAS 5928-25-6
DME2IHD	CB	CHEBI:4353

DM2AVEG	ID	DM2AVEG
DM2AVEG	DN	PMID27841045-Compound-130
DM2AVEG	HS	Patented
DM2AVEG	CP	Korea Bio Health Co. Ltd
DM2AVEG	DT	Small molecular drug
DM2AVEG	PC	776126
DM2AVEG	MW	328.4
DM2AVEG	FM	C19H20O5
DM2AVEG	IC	InChI=1S/C19H20O5/c1-5-11(2)18(21)23-16-9-13-8-12-6-7-17(20)22-14(12)10-15(13)24-19(16,3)4/h5-8,10,16H,9H2,1-4H3/b11-5-/t16-/m1/s1
DM2AVEG	CS	C/C=C(/C)\\C(=O)O[C@@H]1CC2=C(C=C3C(=C2)C=CC(=O)O3)OC1(C)C
DM2AVEG	IK	AGABNGOXUSXQDD-YLBKJFSISA-N
DM2AVEG	IU	[(3R)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] (Z)-2-methylbut-2-enoate

DMIKTVL	ID	DMIKTVL
DMIKTVL	DN	PMID27841045-Compound-131
DMIKTVL	HS	Patented
DMIKTVL	CP	Astellas Pharma Inc
DMIKTVL	DT	Small molecular drug

DMCQB93	ID	DMCQB93
DMCQB93	DN	PMID27841045-Compound-132
DMCQB93	HS	Patented
DMCQB93	CP	Kissei Pharmaceutical Co. Ltd
DMCQB93	DT	Small molecular drug
DMCQB93	PC	59478131
DMCQB93	MW	294.26
DMCQB93	FM	C16H10N2O4
DMCQB93	IC	InChI=1S/C16H10N2O4/c17-7-10-8-18(9-13(10)15-2-1-5-22-15)11-3-4-12(16(20)21)14(19)6-11/h1-6,8-9,19H,(H,20,21)
DMCQB93	CS	C1=COC(=C1)C2=CN(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O
DMCQB93	IK	ZWZQFNSOFGQISH-UHFFFAOYSA-N
DMCQB93	IU	4-[3-cyano-4-(furan-2-yl)pyrrol-1-yl]-2-hydroxybenzoic acid

DMXPO6T	ID	DMXPO6T
DMXPO6T	DN	PMID27841045-Compound-133
DMXPO6T	HS	Patented
DMXPO6T	CP	Kissei Pharmaceutical Co. Ltd
DMXPO6T	DT	Small molecular drug
DMXPO6T	PC	25052195
DMXPO6T	MW	289.29
DMXPO6T	FM	C17H11N3O2
DMXPO6T	IC	InChI=1S/C17H11N3O2/c18-9-14-10-20(11-15(14)12-4-2-1-3-5-12)16-8-13(17(21)22)6-7-19-16/h1-8,10-11H,(H,21,22)
DMXPO6T	CS	C1=CC=C(C=C1)C2=CN(C=C2C#N)C3=NC=CC(=C3)C(=O)O
DMXPO6T	IK	XMNOTSLRNISRFW-UHFFFAOYSA-N
DMXPO6T	IU	2-(3-cyano-4-phenylpyrrol-1-yl)pyridine-4-carboxylic acid

DMY3U7N	ID	DMY3U7N
DMY3U7N	DN	PMID27841045-Compound-134
DMY3U7N	HS	Patented
DMY3U7N	CP	Kissei Pharmaceutical Co. Ltd
DMY3U7N	DT	Small molecular drug
DMY3U7N	PC	59478031
DMY3U7N	MW	310.3
DMY3U7N	FM	C16H10N2O3S
DMY3U7N	IC	InChI=1S/C16H10N2O3S/c17-7-10-8-18(9-13(10)15-2-1-5-22-15)11-3-4-12(16(20)21)14(19)6-11/h1-6,8-9,19H,(H,20,21)
DMY3U7N	CS	C1=CSC(=C1)C2=CN(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O
DMY3U7N	IK	DWSLFJUREKSUNF-UHFFFAOYSA-N
DMY3U7N	IU	4-(3-cyano-4-thiophen-2-ylpyrrol-1-yl)-2-hydroxybenzoic acid

DMVR9TJ	ID	DMVR9TJ
DMVR9TJ	DN	PMID27841045-Compound-135
DMVR9TJ	HS	Patented
DMVR9TJ	CP	Kissei Pharmaceutical Co. Ltd
DMVR9TJ	DT	Small molecular drug
DMVR9TJ	PC	59477845
DMVR9TJ	MW	284.31
DMVR9TJ	FM	C16H16N2O3
DMVR9TJ	IC	InChI=1S/C16H16N2O3/c1-2-3-4-11-9-18(10-12(11)8-17)13-5-6-14(16(20)21)15(19)7-13/h5-7,9-10,19H,2-4H2,1H3,(H,20,21)
DMVR9TJ	CS	CCCCC1=CN(C=C1C#N)C2=CC(=C(C=C2)C(=O)O)O
DMVR9TJ	IK	IFZIPYWLVUUWDL-UHFFFAOYSA-N
DMVR9TJ	IU	4-(3-butyl-4-cyanopyrrol-1-yl)-2-hydroxybenzoic acid

DM0KR8E	ID	DM0KR8E
DM0KR8E	DN	PMID27841045-Compound-136
DM0KR8E	HS	Patented
DM0KR8E	CP	Kissei Pharmaceutical Co. Ltd
DM0KR8E	DT	Small molecular drug
DM0KR8E	PC	59477789
DM0KR8E	MW	304.3
DM0KR8E	FM	C18H12N2O3
DM0KR8E	IC	InChI=1S/C18H12N2O3/c19-9-13-10-20(11-16(13)12-4-2-1-3-5-12)14-6-7-15(18(22)23)17(21)8-14/h1-8,10-11,21H,(H,22,23)
DM0KR8E	CS	C1=CC=C(C=C1)C2=CN(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O
DM0KR8E	IK	KTIOENPGGRVZED-UHFFFAOYSA-N
DM0KR8E	IU	4-(3-cyano-4-phenylpyrrol-1-yl)-2-hydroxybenzoic acid

DML25WY	ID	DML25WY
DML25WY	DN	PMID27841045-Compound-137
DML25WY	HS	Patented
DML25WY	CP	Kissei Pharmaceutical Co. Ltd
DML25WY	DT	Small molecular drug
DML25WY	PC	59477603
DML25WY	MW	310.3
DML25WY	FM	C16H10N2O3S
DML25WY	IC	InChI=1S/C16H10N2O3S/c17-6-11-7-18(8-14(11)10-3-4-22-9-10)12-1-2-13(16(20)21)15(19)5-12/h1-5,7-9,19H,(H,20,21)
DML25WY	CS	C1=CC(=C(C=C1N2C=C(C(=C2)C3=CSC=C3)C#N)O)C(=O)O
DML25WY	IK	ZWWRXUXPUSYNGI-UHFFFAOYSA-N
DML25WY	IU	4-(3-cyano-4-thiophen-3-ylpyrrol-1-yl)-2-hydroxybenzoic acid

DMR7MBY	ID	DMR7MBY
DMR7MBY	DN	PMID27841045-Compound-143
DMR7MBY	HS	Patented
DMR7MBY	CP	LG Life Sciences Ltd
DMR7MBY	DT	Small molecular drug
DMR7MBY	PC	51353128
DMR7MBY	MW	317.3
DMR7MBY	FM	C19H15N3O2
DMR7MBY	IC	InChI=1S/C19H15N3O2/c20-9-15-11-22(10-12-1-2-12)18-4-3-13(7-16(15)18)17-8-14(19(23)24)5-6-21-17/h3-8,11-12H,1-2,10H2,(H,23,24)
DMR7MBY	CS	C1CC1CN2C=C(C3=C2C=CC(=C3)C4=NC=CC(=C4)C(=O)O)C#N
DMR7MBY	IK	MHJSHOXSYFENTO-UHFFFAOYSA-N
DMR7MBY	IU	2-[3-cyano-1-(cyclopropylmethyl)indol-5-yl]pyridine-4-carboxylic acid

DMR43JE	ID	DMR43JE
DMR43JE	DN	PMID27841045-Compound-144
DMR43JE	HS	Patented
DMR43JE	CP	LG Life Sciences Ltd
DMR43JE	DT	Small molecular drug
DMR43JE	PC	51352995
DMR43JE	MW	306.32
DMR43JE	FM	C17H14N4O2
DMR43JE	IC	InChI=1S/C17H14N4O2/c18-6-12-9-20(8-11-1-2-11)16-4-3-14(5-15(12)16)21-10-13(7-19-21)17(22)23/h3-5,7,9-11H,1-2,8H2,(H,22,23)
DMR43JE	CS	C1CC1CN2C=C(C3=C2C=CC(=C3)N4C=C(C=N4)C(=O)O)C#N
DMR43JE	IK	MHZLIWHOFCJYKU-UHFFFAOYSA-N
DMR43JE	IU	1-[3-cyano-1-(cyclopropylmethyl)indol-5-yl]pyrazole-4-carboxylic acid

DMAJRP1	ID	DMAJRP1
DMAJRP1	DN	PMID27841045-Compound-145
DMAJRP1	HS	Patented
DMAJRP1	CP	LG Life Sciences Ltd
DMAJRP1	DT	Small molecular drug
DMAJRP1	PC	51039100
DMAJRP1	MW	294.31
DMAJRP1	FM	C16H14N4O2
DMAJRP1	IC	InChI=1S/C16H14N4O2/c1-10(2)19-8-11(6-17)14-5-13(3-4-15(14)19)20-9-12(7-18-20)16(21)22/h3-5,7-10H,1-2H3,(H,21,22)
DMAJRP1	CS	CC(C)N1C=C(C2=C1C=CC(=C2)N3C=C(C=N3)C(=O)O)C#N
DMAJRP1	IK	JLQQRYOWGCIMMZ-UHFFFAOYSA-N
DMAJRP1	IU	1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid

DM675SX	ID	DM675SX
DM675SX	DN	PMID27841045-Compound-155
DM675SX	HS	Patented
DM675SX	CP	National Taiwan University
DM675SX	DT	Small molecular drug
DM675SX	PC	15560442
DM675SX	MW	302.23
DM675SX	FM	C15H10O7
DM675SX	IC	InChI=1S/C15H10O7/c16-8-3-1-6(5-10(8)18)14-13(21)11(19)7-2-4-9(17)12(20)15(7)22-14/h1-5,16-18,20-21H
DM675SX	CS	C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C(=C(C=C3)O)O)O)O)O
DM675SX	IK	RHTZDFORBKRGQU-UHFFFAOYSA-N
DM675SX	IU	2-(3,4-dihydroxyphenyl)-3,7,8-trihydroxychromen-4-one

DML4AVX	ID	DML4AVX
DML4AVX	DN	PMID27841045-Compound-156
DML4AVX	HS	Patented
DML4AVX	CP	National Taiwan University
DML4AVX	DT	Small molecular drug
DML4AVX	PC	5281294
DML4AVX	MW	288.25
DML4AVX	FM	C15H12O6
DML4AVX	IC	InChI=1S/C15H12O6/c16-10(9-3-6-12(18)15(21)14(9)20)4-1-8-2-5-11(17)13(19)7-8/h1-7,17-21H/b4-1+
DML4AVX	CS	C1=CC(=C(C=C1/C=C/C(=O)C2=C(C(=C(C=C2)O)O)O)O)O
DML4AVX	IK	GSBNFGRTUCCBTK-DAFODLJHSA-N
DML4AVX	IU	(E)-3-(3,4-dihydroxyphenyl)-1-(2,3,4-trihydroxyphenyl)prop-2-en-1-one
DML4AVX	CA	CAS 484-76-4
DML4AVX	CB	CHEBI:7734

DM7EXNI	ID	DM7EXNI
DM7EXNI	DN	PMID27841045-Compound-157
DM7EXNI	HS	Patented
DM7EXNI	CP	Baylor College of Medicine
DM7EXNI	DT	Small molecular drug
DM7EXNI	PC	5748957
DM7EXNI	MW	183.12
DM7EXNI	FM	C7H5NO5
DM7EXNI	IC	InChI=1S/C7H5NO5/c9-3-4-1-5(8(12)13)7(11)6(10)2-4/h1-3,10-11H
DM7EXNI	CS	C1=C(C=C(C(=C1[N+](=O)[O-])O)O)C=O
DM7EXNI	IK	BBFJODMCHICIAA-UHFFFAOYSA-N
DM7EXNI	IU	3,4-dihydroxy-5-nitrobenzaldehyde
DM7EXNI	CA	CAS 116313-85-0

DMBNHI7	ID	DMBNHI7
DMBNHI7	DN	PMID27967267-Compound-12
DMBNHI7	HS	Patented
DMBNHI7	CP	Centrum Medyczne
DMBNHI7	DT	Small molecular drug

DMY5UB8	ID	DMY5UB8
DMY5UB8	DN	PMID27967267-Compound-13
DMY5UB8	HS	Patented
DMY5UB8	CP	Centrum Medyczne
DMY5UB8	DT	Small molecular drug

DMGI5Z8	ID	DMGI5Z8
DMGI5Z8	DN	PMID27967267-Compound-14
DMGI5Z8	HS	Patented
DMGI5Z8	CP	Centrum Medyczne
DMGI5Z8	DT	Small molecular drug

DMEW46T	ID	DMEW46T
DMEW46T	DN	PMID27967267-Compound-15
DMEW46T	HS	Patented
DMEW46T	CP	Centrum Medyczne
DMEW46T	DT	Small molecular drug

DMO0QME	ID	DMO0QME
DMO0QME	DN	PMID27967267-Compound-27
DMO0QME	HS	Patented
DMO0QME	DT	Small molecular drug

DMVM31E	ID	DMVM31E
DMVM31E	DN	PMID27967267-Compound-28
DMVM31E	HS	Patented
DMVM31E	CP	JIANGSU SIMCERE PHARMACEUTICAL CO., LTD
DMVM31E	DT	Small molecular drug

DM7JIF0	ID	DM7JIF0
DM7JIF0	DN	PMID27967267-Compound-3
DM7JIF0	HS	Patented
DM7JIF0	CP	INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUS) DE ROUEN CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) UNIVERSITE DE ROUEN VFP THAPIES
DM7JIF0	DT	Small molecular drug

DM7CWZ4	ID	DM7CWZ4
DM7CWZ4	DN	PMID27967267-Compound-36
DM7CWZ4	HS	Patented
DM7CWZ4	CP	Zhejiang University
DM7CWZ4	DT	Small molecular drug

DMQOAJP	ID	DMQOAJP
DMQOAJP	DN	PMID27967267-Compound-39
DMQOAJP	HS	Patented
DMQOAJP	CP	Kunming Inst Botany CN ACAD
DMQOAJP	DT	Small molecular drug

DM68KPS	ID	DM68KPS
DM68KPS	DN	PMID27967267-Compound-42
DM68KPS	HS	Patented
DM68KPS	CP	Univ Shenyang Chemical Tech
DM68KPS	DT	Small molecular drug

DM12X0P	ID	DM12X0P
DM12X0P	DN	PMID27967267-Compound-43
DM12X0P	HS	Patented
DM12X0P	CP	Univ Shenyang Chemical Tech
DM12X0P	DT	Small molecular drug

DMEXATH	ID	DMEXATH
DMEXATH	DN	PMID27967267-Compound-47
DMEXATH	HS	Patented
DMEXATH	CP	Southwest Res Inst
DMEXATH	DT	Small molecular drug

DM81A50	ID	DM81A50
DM81A50	DN	PMID27967267-Compound-48
DM81A50	HS	Patented
DM81A50	CP	Southwest Res Inst
DM81A50	DT	Small molecular drug

DMQTRFX	ID	DMQTRFX
DMQTRFX	DN	PMID27967267-Compound-49
DMQTRFX	HS	Patented
DMQTRFX	CP	Univ California, Scripps Research Inst
DMQTRFX	DT	Small molecular drug

DMNH891	ID	DMNH891
DMNH891	DN	PMID27967267-Compound-51
DMNH891	HS	Patented
DMNH891	CP	UNIVERSITE DE STRASBOURG COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE ROUEN L'ETAT (MINISTE DE LA DENSE), REPRENT PAR LE DIRECTEUR CENTRAL DU SERVICE DE SANT DES ARMS
DMNH891	DT	Small molecular drug

DMRH7ZY	ID	DMRH7ZY
DMRH7ZY	DN	PMID27967267-Compound-52
DMRH7ZY	HS	Patented
DMRH7ZY	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
DMRH7ZY	DT	Small molecular drug

DMAN71J	ID	DMAN71J
DMAN71J	DN	PMID27967267-Compound-7
DMAN71J	HS	Patented
DMAN71J	CP	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
DMAN71J	DT	Small molecular drug

DM7TLDW	ID	DM7TLDW
DM7TLDW	DN	PMID27967267-Compound-neostenine
DM7TLDW	HS	Patented
DM7TLDW	CP	Univ Lanzhou Tech
DM7TLDW	DT	Small molecular drug

DM3CPJQ	ID	DM3CPJQ
DM3CPJQ	DN	PMID27967267-Compound-neotuberostemonine
DM3CPJQ	HS	Patented
DM3CPJQ	CP	Univ Lanzhou Tech
DM3CPJQ	DT	Small molecular drug

DM2K54D	ID	DM2K54D
DM2K54D	DN	PMID27967267-Compound-stenine
DM2K54D	HS	Patented
DM2K54D	CP	Univ Lanzhou Tech
DM2K54D	DT	Small molecular drug

DMTI5E3	ID	DMTI5E3
DMTI5E3	DN	PMID27977313-Compound-17
DMTI5E3	HS	Patented
DMTI5E3	CP	THE UNIVERSITY OF HONG KON
DMTI5E3	DT	Small molecular drug

DMIA3GH	ID	DMIA3GH
DMIA3GH	DN	PMID27977313-Compound-18
DMIA3GH	HS	Patented
DMIA3GH	CP	THE UNIVERSITY OF HONG KON
DMIA3GH	DT	Small molecular drug

DM5JSI3	ID	DM5JSI3
DM5JSI3	DN	PMID27977313-Compound-19
DM5JSI3	HS	Patented
DM5JSI3	CP	THE UNIVERSITY OF HONG KON
DM5JSI3	DT	Small molecular drug

DMVYO09	ID	DMVYO09
DMVYO09	DN	PMID27977313-Compound-27
DMVYO09	HS	Patented
DMVYO09	DT	Small molecular drug
DMVYO09	PC	387473
DMVYO09	MW	245.19
DMVYO09	FM	C10H7N5O3
DMVYO09	IC	InChI=1S/C10H7N5O3/c1-14-7-5-3-2-4-6(7)8(12-13-11)9(10(14)16)15(17)18/h2-5H,1H3
DMVYO09	CS	CN1C2=CC=CC=C2C(=C(C1=O)[N+](=O)[O-])N=[N+]=[N-]
DMVYO09	IK	PVHDZPYQHVOXSW-UHFFFAOYSA-N
DMVYO09	IU	4-azido-1-methyl-3-nitroquinolin-2-one

DM67NBI	ID	DM67NBI
DM67NBI	DN	PMID27977313-Compound-28
DM67NBI	HS	Patented
DM67NBI	DT	Small molecular drug

DMIF7KG	ID	DMIF7KG
DMIF7KG	DN	PMID27977313-Compound-29
DMIF7KG	HS	Patented
DMIF7KG	DT	Small molecular drug
DMIF7KG	PC	436058
DMIF7KG	MW	217.31
DMIF7KG	FM	C14H19NO
DMIF7KG	IC	InChI=1S/C14H19NO/c1-10-6-7-13(11(2)8-10)14(16)12(3)9-15(4)5/h6-8H,3,9H2,1-2,4-5H3
DMIF7KG	CS	CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C
DMIF7KG	IK	QXLQZLBNPTZMRK-UHFFFAOYSA-N
DMIF7KG	IU	2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one
DMIF7KG	CA	CAS 116218-49-6

DMWHAKG	ID	DMWHAKG
DMWHAKG	DN	PMID27977313-Compound-30
DMWHAKG	HS	Patented
DMWHAKG	DT	Small molecular drug
DMWHAKG	PC	99298
DMWHAKG	MW	374.3
DMWHAKG	FM	C22H14O6
DMWHAKG	IC	InChI=1S/C22H14O6/c1-9-7-11-12(23)3-4-13(24)19(11)22(28)18(9)17-10(2)8-16(27)20-14(25)5-6-15(26)21(17)20/h3-8,27-28H,1-2H3
DMWHAKG	CS	CC1=CC2=C(C(=O)C=CC2=O)C(=C1C3=C4C(=O)C=CC(=O)C4=C(C=C3C)O)O
DMWHAKG	IK	OEEOHKZVBKYMBA-UHFFFAOYSA-N
DMWHAKG	IU	5-hydroxy-6-(4-hydroxy-2-methyl-5,8-dioxonaphthalen-1-yl)-7-methylnaphthalene-1,4-dione
DMWHAKG	CA	CAS 20175-84-2
DMWHAKG	CB	CHEBI:6002

DMBL5J9	ID	DMBL5J9
DMBL5J9	DN	PMID27977313-Compound-31
DMBL5J9	HS	Patented
DMBL5J9	DT	Small molecular drug
DMBL5J9	PC	2781092
DMBL5J9	MW	316.2
DMBL5J9	FM	C14H15Cl2NO3
DMBL5J9	IC	InChI=1S/C14H15Cl2NO3/c1-3-8-6-5-7-9(4-2)12(8)17-13(18)10(15)11(16)14(19)20/h5-7H,3-4H2,1-2H3,(H,17,18)(H,19,20)/b11-10+
DMBL5J9	CS	CCC1=C(C(=CC=C1)CC)NC(=O)/C(=C(/C(=O)O)\\Cl)/Cl
DMBL5J9	IK	JDSFJBVJTZVNIT-ZHACJKMWSA-N
DMBL5J9	IU	(E)-2,3-dichloro-4-(2,6-diethylanilino)-4-oxobut-2-enoic acid

DMZNM52	ID	DMZNM52
DMZNM52	DN	PMID27977313-Compound-32
DMZNM52	HS	Patented
DMZNM52	DT	Small molecular drug
DMZNM52	PC	3004002
DMZNM52	MW	274.1
DMZNM52	FM	C11H9Cl2NO3
DMZNM52	IC	InChI=1S/C11H9Cl2NO3/c1-6-2-4-7(5-3-6)14-10(15)8(12)9(13)11(16)17/h2-5H,1H3,(H,14,15)(H,16,17)/b9-8+
DMZNM52	CS	CC1=CC=C(C=C1)NC(=O)/C(=C(/C(=O)O)\\Cl)/Cl
DMZNM52	IK	LYXYEAXSHFSVNI-CMDGGOBGSA-N
DMZNM52	IU	(E)-2,3-dichloro-4-(4-methylanilino)-4-oxobut-2-enoic acid

DM0LB21	ID	DM0LB21
DM0LB21	DN	PMID27977313-Compound-39
DM0LB21	HS	Patented
DM0LB21	DT	Small molecular drug
DM0LB21	PC	123132501
DM0LB21	MW	328.4
DM0LB21	FM	C4H10Na2O6S4+2
DM0LB21	IC	InChI=1S/C4H10O6S4.2Na/c5-13(6,7)3-1-11-12-2-4-14(8,9)10;;/h1-4H2,(H,5,6,7)(H,8,9,10);;/q;2*+1
DM0LB21	CS	C(CS(=O)(=O)O)SSCCS(=O)(=O)O.[Na+].[Na+]
DM0LB21	IK	KQYGMURBTJPBPQ-UHFFFAOYSA-N
DM0LB21	IU	disodium;2-(2-sulfoethyldisulfanyl)ethanesulfonic acid

DML4C6D	ID	DML4C6D
DML4C6D	DN	PMID27977313-Compound-42
DML4C6D	HS	Patented
DML4C6D	DT	Small molecular drug

DMTFLVN	ID	DMTFLVN
DMTFLVN	DN	PMID27977313-Compound-43
DMTFLVN	HS	Patented
DMTFLVN	DT	Small molecular drug

DM9S2UP	ID	DM9S2UP
DM9S2UP	DN	PMID27977313-Compound-44
DM9S2UP	HS	Patented
DM9S2UP	DT	Small molecular drug

DMSZ0GE	ID	DMSZ0GE
DMSZ0GE	DN	PMID27977313-Compound-45
DMSZ0GE	HS	Patented
DMSZ0GE	DT	Small molecular drug

DMGF04T	ID	DMGF04T
DMGF04T	DN	PMID27977313-Compound-46
DMGF04T	HS	Patented
DMGF04T	DT	Small molecular drug
DMGF04T	PC	140895
DMGF04T	MW	259.92
DMGF04T	FM	C5H8Br2O2
DMGF04T	IC	InChI=1S/C5H8Br2O2/c1-9-5(8)4(2-6)3-7/h4H,2-3H2,1H3
DMGF04T	CS	COC(=O)C(CBr)CBr
DMGF04T	IK	USXVPPOARMSYGY-UHFFFAOYSA-N
DMGF04T	IU	methyl 3-bromo-2-(bromomethyl)propanoate
DMGF04T	CA	CAS 22262-60-8

DMI61KF	ID	DMI61KF
DMI61KF	DN	PMID27977313-Compound-47
DMI61KF	HS	Patented
DMI61KF	CP	TRUSTEES OF BOSTON UNIVERSITY SCHAUS, Scott, E. EASTWOOD, Erin, L
DMI61KF	DT	Small molecular drug
DMI61KF	PC	53261455
DMI61KF	MW	266.32
DMI61KF	FM	C11H14N4O2S
DMI61KF	IC	InChI=1S/C11H14N4O2S/c1-2-3-9-18(16,17)11-12-13-14-15(11)10-7-5-4-6-8-10/h4-8H,2-3,9H2,1H3
DMI61KF	CS	CCCCS(=O)(=O)C1=NN=NN1C2=CC=CC=C2
DMI61KF	IK	FSUGWNZPOPKNAK-UHFFFAOYSA-N
DMI61KF	IU	5-butylsulfonyl-1-phenyltetrazole

DM4EFRL	ID	DM4EFRL
DM4EFRL	DN	PMID27977313-Compound-48
DM4EFRL	HS	Patented
DM4EFRL	CP	RIGAS, Basil
DM4EFRL	DT	Small molecular drug
DM4EFRL	PC	25193001
DM4EFRL	MW	526.4
DM4EFRL	FM	C20H32O12P2
DM4EFRL	IC	InChI=1S/C20H32O12P2/c1-6-26-33(23,27-7-2)30-15-17(32-34(24,28-8-3)29-9-4)14-25-20(22)18-12-10-11-13-19(18)31-16(5)21/h10-13,17H,6-9,14-15H2,1-5H3
DM4EFRL	CS	CCOP(=O)(OCC)OCC(COC(=O)C1=CC=CC=C1OC(=O)C)OP(=O)(OCC)OCC
DM4EFRL	IK	UISLTGPOZYGIOG-UHFFFAOYSA-N
DM4EFRL	IU	2,3-bis(diethoxyphosphoryloxy)propyl 2-acetyloxybenzoate

DMTUNW4	ID	DMTUNW4
DMTUNW4	DN	PMID27977313-Compound-5
DMTUNW4	HS	Patented
DMTUNW4	CP	CENTRE NAT RECH SCIENT [FR
DMTUNW4	DT	Small molecular drug

DMCUAO9	ID	DMCUAO9
DMCUAO9	DN	PMID27977313-Compound-6
DMCUAO9	HS	Patented
DMCUAO9	CP	CENTRE NAT RECH SCIENT [FR
DMCUAO9	DT	Small molecular drug

DMWIMN9	ID	DMWIMN9
DMWIMN9	DN	PMID27977313-Compound-7
DMWIMN9	HS	Patented
DMWIMN9	CP	CENTRE NAT RECH SCIENT [FR
DMWIMN9	DT	Small molecular drug

DMYFV3D	ID	DMYFV3D
DMYFV3D	DN	PMID27977313-Compound-8
DMYFV3D	HS	Patented
DMYFV3D	CP	CENTRE NAT RECH SCIENT [FR
DMYFV3D	DT	Small molecular drug

DMJ6CI5	ID	DMJ6CI5
DMJ6CI5	DN	PMID27977313-Compound-Figure4b
DMJ6CI5	HS	Patented
DMJ6CI5	CP	CENTRE NAT RECH SCIENT [FR
DMJ6CI5	DT	Small molecular drug

DMICBFK	ID	DMICBFK
DMICBFK	DN	PMID27977313-Compound-Figure6C
DMICBFK	HS	Patented
DMICBFK	DT	Small molecular drug

DM5QH4C	ID	DM5QH4C
DM5QH4C	DN	PMID27998201-Compound-1
DM5QH4C	HS	Patented
DM5QH4C	CP	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS PRABHAKAR, Bellur, S. ELSHABRAWY, Hatem, A
DM5QH4C	DT	Small molecular drug
DM5QH4C	PC	826236
DM5QH4C	MW	307.35
DM5QH4C	FM	C13H21N7O2
DM5QH4C	IC	InChI=1S/C13H21N7O2/c1-8(2)15-11-17-12(16-9(3)4)19-13(18-11)20(7-14)6-10(21)22-5/h8-9H,6H2,1-5H3,(H2,15,16,17,18,19)
DM5QH4C	CS	CC(C)NC1=NC(=NC(=N1)N(CC(=O)OC)C#N)NC(C)C
DM5QH4C	IK	QYAYANIDXCPTDU-UHFFFAOYSA-N
DM5QH4C	IU	methyl 2-[[4,6-bis(propan-2-ylamino)-1,3,5-triazin-2-yl]-cyanoamino]acetate
DM5QH4C	DE	Coronavirus infection; Henipavirus Encephalitis

DMVXTIL	ID	DMVXTIL
DMVXTIL	DN	PMID27998201-Compound-10
DMVXTIL	HS	Patented
DMVXTIL	DT	Small molecular drug
DMVXTIL	PC	71813529
DMVXTIL	MW	411.5
DMVXTIL	FM	C27H29N3O
DMVXTIL	IC	InChI=1S/C27H29N3O/c1-20(2)17-26(27(31)30(4)29(3)19-28)25-12-8-11-24(18-25)23-15-13-22(14-16-23)21-9-6-5-7-10-21/h5-16,18,20,26H,17H2,1-4H3
DMVXTIL	CS	CC(C)CC(C1=CC=CC(=C1)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)N(C)N(C)C#N
DMVXTIL	IK	VUAQQIIYDSXRAP-UHFFFAOYSA-N
DMVXTIL	IU	methyl-[methyl-[4-methyl-2-[3-(4-phenylphenyl)phenyl]pentanoyl]amino]cyanamide
DMVXTIL	DE	Osteoporosis

DMTV5NU	ID	DMTV5NU
DMTV5NU	DN	PMID27998201-Compound-11
DMTV5NU	HS	Patented
DMTV5NU	CP	VIROBAY, INC
DMTV5NU	DT	Small molecular drug
DMTV5NU	PC	77846164
DMTV5NU	MW	578.4
DMTV5NU	FM	C25H25Cl2F4N3O4
DMTV5NU	IC	InChI=1S/C25H25Cl2F4N3O4/c1-2-18(21(36)24(38)32-15-7-8-15)34-23(37)19(11-12-9-16(26)20(35)17(27)10-12)33-22(25(29,30)31)13-3-5-14(28)6-4-13/h3-6,9-10,15,18-19,22,33,35H,2,7-8,11H2,1H3,(H,32,38)(H,34,37)/t18-,19-,22-/m0/s1
DMTV5NU	CS	CC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@H](CC2=CC(=C(C(=C2)Cl)O)Cl)N[C@@H](C3=CC=C(C=C3)F)C(F)(F)F
DMTV5NU	IK	HNEZRIRYWXIOJA-IPJJNNNSSA-N
DMTV5NU	IU	(3S)-N-cyclopropyl-3-[[(2S)-3-(3,5-dichloro-4-hydroxyphenyl)-2-[[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]amino]propanoyl]amino]-2-oxopentanamide
DMTV5NU	DE	Metastatic cancer

DM8QZNC	ID	DM8QZNC
DM8QZNC	DN	PMID27998201-Compound-12
DM8QZNC	HS	Patented
DM8QZNC	CP	VIROBAY, INC. BOOTH, Rober
DM8QZNC	DT	Small molecular drug
DM8QZNC	DE	Cancer related pain; Bone cancer

DMZHIM8	ID	DMZHIM8
DMZHIM8	DN	PMID27998201-Compound-13
DMZHIM8	HS	Patented
DMZHIM8	CP	VIROBAY, INC. HOLSINGER, Lesli
DMZHIM8	DT	Small molecular drug
DMZHIM8	PC	25233001
DMZHIM8	MW	758.9
DMZHIM8	FM	C40H54N8O7
DMZHIM8	IC	InChI=1S/C40H54N8O7/c1-39(2,3)34(45-38(53)46-40(4,5)6)37(52)47-22-26(55-31-21-32(48-17-9-16-41-48)43-28-19-25(54-7)14-15-27(28)31)20-30(47)35(50)44-29(18-23-10-8-11-23)33(49)36(51)42-24-12-13-24/h9,14-17,19,21,23-24,26,29-30,34H,8,10-13,18,20,22H2,1-7H3,(H,42,51)(H,44,50)(H2,45,46,53)/t26-,29+,30+,34-/m1/s1
DMZHIM8	CS	CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@H](CC2CCC2)C(=O)C(=O)NC3CC3)OC4=CC(=NC5=C4C=CC(=C5)OC)N6C=CC=N6)NC(=O)NC(C)(C)C
DMZHIM8	IK	YOTPWZLVXAMQNL-GUXYKIAJSA-N
DMZHIM8	IU	(2S,4R)-1-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-N-[(2S)-1-cyclobutyl-4-(cyclopropylamino)-3,4-dioxobutan-2-yl]-4-(7-methoxy-2-pyrazol-1-ylquinolin-4-yl)oxypyrrolidine-2-carboxamide
DMZHIM8	DE	Hepatic fibrosis

DMOB8LU	ID	DMOB8LU
DMOB8LU	DN	PMID27998201-Compound-15
DMOB8LU	HS	Patented
DMOB8LU	CP	GRUENENTHAL GMBH [DE
DMOB8LU	DT	Small molecular drug
DMOB8LU	DE	Pain

DMAZVHJ	ID	DMAZVHJ
DMAZVHJ	DN	PMID27998201-Compound-17
DMAZVHJ	HS	Patented
DMAZVHJ	CP	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA DIAMOND, Scott, L. BEAVERS, Mary, Pat HURYN, Donna MYERS, Michael, C. SMITH, Amos, B. SHAH, Parag, P. LIU, Zhuqin
DMAZVHJ	DT	Small molecular drug
DMAZVHJ	DE	Hair loss

DM67RMX	ID	DM67RMX
DM67RMX	DN	PMID27998201-Compound-19
DM67RMX	HS	Patented
DM67RMX	DT	Small molecular drug
DM67RMX	PC	100951597
DM67RMX	MW	629.6
DM67RMX	FM	C30H33BrN2O6S
DM67RMX	IC	InChI=1S/C30H33BrN2O6S/c1-22(2)19-26(17-18-40(36,37)39-27-15-13-25(31)14-16-27)32-29(34)28(20-23-9-5-3-6-10-23)33-30(35)38-21-24-11-7-4-8-12-24/h3-18,22,26,28H,19-21H2,1-2H3,(H,32,34)(H,33,35)/b18-17+/t26-,28+/m1/s1
DM67RMX	CS	CC(C)C[C@@H](/C=C/S(=O)(=O)OC1=CC=C(C=C1)Br)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3
DM67RMX	IK	FMZWJWZKFKZMSS-FMPLDUIVSA-N
DM67RMX	IU	(4-bromophenyl) (E,3S)-5-methyl-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]hex-1-ene-1-sulfonate
DM67RMX	DE	Solid tumour/cancer

DMMAE3C	ID	DMMAE3C
DMMAE3C	DN	PMID27998201-Compound-2
DMMAE3C	HS	Patented
DMMAE3C	CP	MERCK FROSST CANADA LTD. GAUTHIER, Jacques-Yves TRUONG, Vouy-Lin
DMMAE3C	DT	Small molecular drug
DMMAE3C	DE	Alzheimer disease

DMS9QA7	ID	DMS9QA7
DMS9QA7	DN	PMID27998201-Compound-22
DMS9QA7	HS	Patented
DMS9QA7	DT	Small molecular drug
DMS9QA7	PC	19910
DMS9QA7	MW	190.16
DMS9QA7	FM	C9H6N2O3
DMS9QA7	IC	InChI=1S/C9H6N2O3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12H
DMS9QA7	CS	C1=CC2=C(C=CC(=C2N=C1)O)[N+](=O)[O-]
DMS9QA7	IK	RJIWZDNTCBHXAL-UHFFFAOYSA-N
DMS9QA7	IU	5-nitroquinolin-8-ol
DMS9QA7	CA	CAS 4008-48-4
DMS9QA7	CB	CHEBI:67121
DMS9QA7	DE	Neurodegenerative disorder; Pancreatitis; Alzheimer disease; Osteoarthritis

DM25BNZ	ID	DM25BNZ
DM25BNZ	DN	PMID27998201-Compound-24
DM25BNZ	HS	Patented
DM25BNZ	DT	Small molecular drug
DM25BNZ	PC	6431125
DM25BNZ	MW	272.5
DM25BNZ	FM	C20H32
DM25BNZ	IC	InChI=1S/C20H32/c1-14(2)15-7-9-17-16(13-15)8-10-18-19(3,4)11-6-12-20(17,18)5/h7,14,18H,6,8-13H2,1-5H3/t18?,20-/m1/s1
DM25BNZ	CS	CC(C)C1=CCC2=C(C1)CCC3[C@@]2(CCCC3(C)C)C
DM25BNZ	IK	BGVUIJDZTQIJIO-ROPPNANJSA-N
DM25BNZ	IU	(4bS)-4b,8,8-trimethyl-2-propan-2-yl-1,4,5,6,7,8a,9,10-octahydrophenanthrene
DM25BNZ	DE	Meningioma tumour; Glioma

DMVZ0ND	ID	DMVZ0ND
DMVZ0ND	DN	PMID27998201-Compound-5
DMVZ0ND	HS	Patented
DMVZ0ND	DT	Small molecular drug
DMVZ0ND	PC	46202117
DMVZ0ND	MW	479.6
DMVZ0ND	FM	C23H27F2N3O2S2
DMVZ0ND	IC	InChI=1S/C23H27F2N3O2S2/c1-3-4-20(23(24,25)30-17-7-9-18(31-2)10-8-17)27-19(14-32-13-16-5-6-16)21(29)28-22(15-26)11-12-22/h7-10,16,19-20,27H,5-6,11-14H2,1-2H3,(H,28,29)/t19-,20-/m0/s1
DMVZ0ND	CS	CC#C[C@@H](C(OC1=CC=C(C=C1)SC)(F)F)N[C@@H](CSCC2CC2)C(=O)NC3(CC3)C#N
DMVZ0ND	IK	UKRDTRXIEUADJU-PMACEKPBSA-N
DMVZ0ND	IU	(2R)-N-(1-cyanocyclopropyl)-3-(cyclopropylmethylsulfanyl)-2-[[(2S)-1,1-difluoro-1-(4-methylsulfanylphenoxy)pent-3-yn-2-yl]amino]propanamide
DMVZ0ND	DE	Cirrhosis; Chronic obstructive pulmonary disease; Psoriasis vulgaris; Multiple sclerosis; Gastrointestinal disease

DM0LGTY	ID	DM0LGTY
DM0LGTY	DN	PMID27998201-Compound-6
DM0LGTY	HS	Patented
DM0LGTY	CP	F. HOFFMANN-LA ROCHE AG ALVAREZ SANCHEZ, Ruben BANNER, David CECCARELLI, Simona M. GRETHER, Uwe HAAP, Wolfgang HARTMAN, Peter HARTMANN, Guido HILPERT, Hans KUEHNE, Holger MAUSER, Harald PLANCHER, Jean-Mar
DM0LGTY	DT	Small molecular drug

DMU4QYR	ID	DMU4QYR
DMU4QYR	DN	PMID27998201-Compound-7
DMU4QYR	HS	Patented
DMU4QYR	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMU4QYR	DT	Small molecular drug
DMU4QYR	PC	73294953
DMU4QYR	MW	626.4
DMU4QYR	FM	C24H21F2IN4O4S
DMU4QYR	IC	InChI=1S/C24H21F2IN4O4S/c25-16-3-1-2-4-19(16)36(34,35)15-10-18(21(32)30-23(13-28)5-6-23)31(12-15)22(33)24(7-8-24)20-17(26)9-14(27)11-29-20/h1-4,9,11,15,18H,5-8,10,12H2,(H,30,32)/t15-,18+/m1/s1
DMU4QYR	CS	C1CC1(C#N)NC(=O)[C@@H]2C[C@H](CN2C(=O)C3(CC3)C4=C(C=C(C=N4)I)F)S(=O)(=O)C5=CC=CC=C5F
DMU4QYR	IK	ZEFHIBBPLAGQMT-QAPCUYQASA-N
DMU4QYR	IU	(2S,4R)-N-(1-cyanocyclopropyl)-1-[1-(3-fluoro-5-iodopyridin-2-yl)cyclopropanecarbonyl]-4-(2-fluorophenyl)sulfonylpyrrolidine-2-carboxamide
DMU4QYR	DE	Abdominal aortic aneurysm

DMZK0SY	ID	DMZK0SY
DMZK0SY	DN	PMID27998201-Compound-8
DMZK0SY	HS	Patented
DMZK0SY	CP	F. HOFFMANN-LA ROCHE AG BANNER, David CECCARELLI, Simona M. GRETHER, Uwe HAAP, Wolfgang HILPERT, Hans KUEHNE, Holger MAUSER, Harald PLANCHER, Jean-Marc SANCHEZ, Rub Alvare
DMZK0SY	DT	Small molecular drug

DM1JOZN	ID	DM1JOZN
DM1JOZN	DN	PMID27998201-Compound-9
DM1JOZN	HS	Patented
DM1JOZN	DT	Small molecular drug
DM1JOZN	PC	78108715
DM1JOZN	MW	454.6
DM1JOZN	FM	C28H30N4O2
DM1JOZN	IC	InChI=1S/C28H30N4O2/c1-20(2)17-26(28(34)32(4)31(3)19-29)30-27(33)25-12-8-11-24(18-25)23-15-13-22(14-16-23)21-9-6-5-7-10-21/h5-16,18,20,26H,17H2,1-4H3,(H,30,33)
DM1JOZN	CS	CC(C)CC(C(=O)N(C)N(C)C#N)NC(=O)C1=CC=CC(=C1)C2=CC=C(C=C2)C3=CC=CC=C3
DM1JOZN	IK	PYEQDWCBKMTPFO-UHFFFAOYSA-N
DM1JOZN	IU	N-[1-[[cyano(methyl)amino]-methylamino]-4-methyl-1-oxopentan-2-yl]-3-(4-phenylphenyl)benzamide
DM1JOZN	DE	Rheumatoid arthritis

DMQ6WEN	ID	DMQ6WEN
DMQ6WEN	DN	PMID28048944-Compound-11
DMQ6WEN	HS	Patented
DMQ6WEN	CP	AMAKEM NV
DMQ6WEN	DT	Small molecular drug
DMQ6WEN	PC	76955629
DMQ6WEN	MW	556.6
DMQ6WEN	FM	C30H25FN4O4S
DMQ6WEN	IC	InChI=1S/C30H25FN4O4S/c31-25-17-33-12-10-26(25)35-29(37)20-4-5-21(16-32)24(15-20)19-2-1-3-22(14-19)34-28(36)18-6-8-23(9-7-18)40-27-11-13-39-30(27)38/h1-10,12,14-15,17,27H,11,13,16,32H2,(H,34,36)(H,33,35,37)
DMQ6WEN	CS	C1COC(=O)C1SC2=CC=C(C=C2)C(=O)NC3=CC=CC(=C3)C4=C(C=CC(=C4)C(=O)NC5=C(C=NC=C5)F)CN
DMQ6WEN	IK	QKLHHIYLYLZRFM-UHFFFAOYSA-N
DMQ6WEN	IU	4-(aminomethyl)-N-(3-fluoropyridin-4-yl)-3-[3-[[4-(2-oxooxolan-3-yl)sulfanylbenzoyl]amino]phenyl]benzamide

DMPT3V9	ID	DMPT3V9
DMPT3V9	DN	PMID28048944-Compound-19
DMPT3V9	HS	Patented
DMPT3V9	CP	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC
DMPT3V9	DT	Small molecular drug
DMPT3V9	PC	56596554
DMPT3V9	MW	280.32
DMPT3V9	FM	C16H16N4O
DMPT3V9	IC	InChI=1S/C16H16N4O/c21-16(17-9-8-12-4-2-1-3-5-12)19-14-6-7-15-13(10-14)11-18-20-15/h1-7,10-11H,8-9H2,(H,18,20)(H2,17,19,21)
DMPT3V9	CS	C1=CC=C(C=C1)CCNC(=O)NC2=CC3=C(C=C2)NN=C3
DMPT3V9	IK	XEZOXLSEWZHMQY-UHFFFAOYSA-N
DMPT3V9	IU	1-(1H-indazol-5-yl)-3-(2-phenylethyl)urea

DM9ZXOP	ID	DM9ZXOP
DM9ZXOP	DN	PMID28048944-Compound-2
DM9ZXOP	HS	Patented
DM9ZXOP	CP	KADMON CORPORATION, LLC
DM9ZXOP	DT	Small molecular drug
DM9ZXOP	PC	90096055
DM9ZXOP	MW	388.5
DM9ZXOP	FM	C22H24N6O
DM9ZXOP	IC	InChI=1S/C22H24N6O/c1-15(2)23-10-11-29-19-5-3-4-16(13-19)22-24-9-8-21(27-22)26-18-6-7-20-17(12-18)14-25-28-20/h3-9,12-15,23H,10-11H2,1-2H3,(H,25,28)(H,24,26,27)
DM9ZXOP	CS	CC(C)NCCOC1=CC=CC(=C1)C2=NC=CC(=N2)NC3=CC4=C(C=C3)NN=C4
DM9ZXOP	IK	CBUNAFRZRCOJEX-UHFFFAOYSA-N
DM9ZXOP	IU	N-[2-[3-[2-(propan-2-ylamino)ethoxy]phenyl]pyrimidin-4-yl]-1H-indazol-5-amine

DM19BQ6	ID	DM19BQ6
DM19BQ6	DN	PMID28048944-Compound-20
DM19BQ6	HS	Patented
DM19BQ6	CP	LES LABORATOIRES SERVIER
DM19BQ6	DT	Small molecular drug
DM19BQ6	PC	129114209
DM19BQ6	MW	312.3
DM19BQ6	FM	C18H14F2N2O
DM19BQ6	IC	InChI=1S/C18H14F2N2O/c1-10(21)12-7-15(19)17(16(20)8-12)18(23)14-4-2-3-11-9-22-6-5-13(11)14/h2-10H,21H2,1H3
DM19BQ6	CS	CC(C1=CC(=C(C(=C1)F)C(=O)C2=CC=CC3=C2C=CN=C3)F)N
DM19BQ6	IK	MZQREGYHCORZLY-UHFFFAOYSA-N
DM19BQ6	IU	[4-(1-aminoethyl)-2,6-difluorophenyl]-isoquinolin-5-ylmethanone

DMPNG9C	ID	DMPNG9C
DMPNG9C	DN	PMID28048944-Compound-21
DMPNG9C	HS	Patented
DMPNG9C	CP	LES LABORATOIRES SERVIER
DMPNG9C	DT	Small molecular drug
DMPNG9C	PC	118326165
DMPNG9C	MW	342.3
DMPNG9C	FM	C19H16F2N2O2
DMPNG9C	IC	InChI=1S/C19H16F2N2O2/c1-19(2,22)10-8-14(20)16(15(21)9-10)17(24)12-4-3-5-13-11(12)6-7-23-18(13)25/h3-9H,22H2,1-2H3,(H,23,25)
DMPNG9C	CS	CC(C)(C1=CC(=C(C(=C1)F)C(=O)C2=CC=CC3=C2C=CNC3=O)F)N
DMPNG9C	IK	FBSSVAIINOQLST-UHFFFAOYSA-N
DMPNG9C	IU	5-[4-(2-aminopropan-2-yl)-2,6-difluorobenzoyl]-2H-isoquinolin-1-one

DM1BN74	ID	DM1BN74
DM1BN74	DN	PMID28048944-Compound-3
DM1BN74	HS	Patented
DM1BN74	CP	KADMON CORPORATION, LLC
DM1BN74	DT	Small molecular drug
DM1BN74	PC	73603819
DM1BN74	MW	442.5
DM1BN74	FM	C25H26N6O2
DM1BN74	IC	InChI=1S/C25H26N6O2/c1-15-16(2)27-25(30-24(15)29-20-9-10-22-18(11-20)13-26-31-22)17-5-3-8-21(12-17)33-14-23(32)28-19-6-4-7-19/h3,5,8-13,19H,4,6-7,14H2,1-2H3,(H,26,31)(H,28,32)(H,27,29,30)
DM1BN74	CS	CC1=C(N=C(N=C1NC2=CC3=C(C=C2)NN=C3)C4=CC(=CC=C4)OCC(=O)NC5CCC5)C
DM1BN74	IK	FFIBTGFOEVIJLU-UHFFFAOYSA-N
DM1BN74	IU	N-cyclobutyl-2-[3-[4-(1H-indazol-5-ylamino)-5,6-dimethylpyrimidin-2-yl]phenoxy]acetamide

DMJAUWG	ID	DMJAUWG
DMJAUWG	DN	PMID28048944-Compound-4
DMJAUWG	HS	Patented
DMJAUWG	CP	KADMON CORPORATION, LLC
DMJAUWG	DT	Small molecular drug

DMAB987	ID	DMAB987
DMAB987	DN	PMID28048944-Compound-5
DMAB987	HS	Patented
DMAB987	CP	KADMON CORPORATION, LLC
DMAB987	DT	Small molecular drug
DMAB987	PC	91669217
DMAB987	MW	358.4
DMAB987	FM	C20H18N6O
DMAB987	IC	InChI=1S/C20H18N6O/c1-27-17-4-2-13-11-26(12-15(13)9-17)20-21-7-6-19(24-20)23-16-3-5-18-14(8-16)10-22-25-18/h2-10H,11-12H2,1H3,(H,22,25)(H,21,23,24)
DMAB987	CS	COC1=CC2=C(CN(C2)C3=NC=CC(=N3)NC4=CC5=C(C=C4)NN=C5)C=C1
DMAB987	IK	SWHUIIODYNUMNO-UHFFFAOYSA-N
DMAB987	IU	N-[2-(5-methoxy-1,3-dihydroisoindol-2-yl)pyrimidin-4-yl]-1H-indazol-5-amine

DM5RCBV	ID	DM5RCBV
DM5RCBV	DN	PMID28048944-Compound-6
DM5RCBV	HS	Patented
DM5RCBV	CP	KADMON CORPORATION, LLC
DM5RCBV	DT	Small molecular drug
DM5RCBV	PC	118010994
DM5RCBV	MW	384.4
DM5RCBV	FM	C22H20N6O
DM5RCBV	IC	InChI=1S/C22H20N6O/c1-29-20-7-4-16-13-28(14-17(16)10-20)22-23-9-8-21(27-22)26-19-5-2-15(3-6-19)18-11-24-25-12-18/h2-12H,13-14H2,1H3,(H,24,25)(H,23,26,27)
DM5RCBV	CS	COC1=CC2=C(CN(C2)C3=NC=CC(=N3)NC4=CC=C(C=C4)C5=CNN=C5)C=C1
DM5RCBV	IK	QWVKCTINPBKQMS-UHFFFAOYSA-N
DM5RCBV	IU	2-(5-methoxy-1,3-dihydroisoindol-2-yl)-N-[4-(1H-pyrazol-4-yl)phenyl]pyrimidin-4-amine

DMXZ368	ID	DMXZ368
DMXZ368	DN	PMID28048944-Compound-7
DMXZ368	HS	Patented
DMXZ368	CP	THE REGENTS OF THE UNIVERSITY OF MICHIGAN GLICK, Gary D
DMXZ368	DT	Small molecular drug

DMRANS2	ID	DMRANS2
DMRANS2	DN	PMID28051882-Compound-Figure9
DMRANS2	HS	Patented
DMRANS2	CP	WASHINGTON UNIVERSITY
DMRANS2	DT	Small molecular drug
DMRANS2	PC	124197470
DMRANS2	MW	914.1
DMRANS2	FM	C53H67N7O7
DMRANS2	IC	InChI=1S/C53H67N7O7/c1-4-65-49-19-10-9-18-47(49)60-50(55-45-17-8-7-16-44(45)52(60)62)36-57-28-30-58(31-29-57)51(61)37-66-42-23-21-39(22-24-42)35-54-26-11-5-6-12-27-59-40-14-13-15-41(59)34-43(33-40)67-53(63)56-46-32-38(2)20-25-48(46)64-3/h7-10,16-25,32,40-41,43,54H,4-6,11-15,26-31,33-37H2,1-3H3,(H,56,63)
DMRANS2	CS	CCOC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)CN4CCN(CC4)C(=O)COC5=CC=C(C=C5)CNCCCCCCN6C7CCCC6CC(C7)OC(=O)NC8=C(C=CC(=C8)C)OC
DMRANS2	IK	NMJRVPZKOISERX-UHFFFAOYSA-N
DMRANS2	IU	[9-[6-[[4-[2-[4-[[3-(2-ethoxyphenyl)-4-oxoquinazolin-2-yl]methyl]piperazin-1-yl]-2-oxoethoxy]phenyl]methylamino]hexyl]-9-azabicyclo[3.3.1]nonan-3-yl] N-(2-methoxy-5-methylphenyl)carbamate

DMLNA8P	ID	DMLNA8P
DMLNA8P	DN	PMID28051882-Compound-XI
DMLNA8P	HS	Patented
DMLNA8P	CP	WASHINGTON UNIVERSITY
DMLNA8P	DT	Small molecular drug

DM1RN89	ID	DM1RN89
DM1RN89	DN	PMID28051882-Compound-XIV
DM1RN89	HS	Patented
DM1RN89	CP	VAMVAKIDES, Alexandre
DM1RN89	DT	Small molecular drug

DMG2PCZ	ID	DMG2PCZ
DMG2PCZ	DN	PMID28067079-Compound-95
DMG2PCZ	HS	Patented
DMG2PCZ	CP	HEPTARES THERAPEUTICS LIMITED
DMG2PCZ	DT	Small molecular drug

DMCUX42	ID	DMCUX42
DMCUX42	DN	PMID28067079-Compound-97
DMCUX42	HS	Patented
DMCUX42	CP	HEPTARES THERAPEUTICS LIMITED
DMCUX42	DT	Small molecular drug

DMLKP1O	ID	DMLKP1O
DMLKP1O	DN	PMID28067079-Compound-98
DMLKP1O	HS	Patented
DMLKP1O	CP	HEPTARES THERAPEUTICS LIMITED
DMLKP1O	DT	Small molecular drug
DMLKP1O	PC	90646678
DMLKP1O	MW	281.7
DMLKP1O	FM	C14H8ClN5
DMLKP1O	IC	InChI=1S/C14H8ClN5/c15-12-5-10(8-16)4-11(6-12)13-7-14(18-9-17-13)20-3-1-2-19-20/h1-7,9H
DMLKP1O	CS	C1=CN(N=C1)C2=NC=NC(=C2)C3=CC(=CC(=C3)C#N)Cl
DMLKP1O	IK	RDPNIWXBEYDORQ-UHFFFAOYSA-N
DMLKP1O	IU	3-chloro-5-(6-pyrazol-1-ylpyrimidin-4-yl)benzonitrile

DMQW470	ID	DMQW470
DMQW470	DN	PMID28074661-Compound-US20100022547C80
DMQW470	HS	Patented
DMQW470	CP	Brandeis University and University of Georgia Research Foundation, Inc
DMQW470	DT	Small molecular drug

DMM9E1U	ID	DMM9E1U
DMM9E1U	DN	PMID28074661-Compound-US20100022547C81
DMM9E1U	HS	Patented
DMM9E1U	CP	Brandeis University and University of Georgia Research Foundation, Inc
DMM9E1U	DT	Small molecular drug

DM94MT3	ID	DM94MT3
DM94MT3	DN	PMID28074661-Compound-US20100022547C82
DM94MT3	HS	Patented
DM94MT3	CP	Brandeis University and University of Georgia Research Foundation, Inc
DM94MT3	DT	Small molecular drug

DM18LO7	ID	DM18LO7
DM18LO7	DN	PMID28074661-Compound-US20100022547C83
DM18LO7	HS	Patented
DM18LO7	CP	Brandeis University and University of Georgia Research Foundation, Inc
DM18LO7	DT	Small molecular drug

DMONEJ4	ID	DMONEJ4
DMONEJ4	DN	PMID28074661-Compound-US20100022547C86
DMONEJ4	HS	Patented
DMONEJ4	CP	Brandeis University and University of Georgia Research Foundation, Inc
DMONEJ4	DT	Small molecular drug

DM8E702	ID	DM8E702
DM8E702	DN	PMID28074661-Compound-US20100022547C87
DM8E702	HS	Patented
DM8E702	CP	Brandeis University and University of Georgia Research Foundation, Inc
DM8E702	DT	Small molecular drug

DMNUR8E	ID	DMNUR8E
DMNUR8E	DN	PMID28074661-Compound-US20100022547C88
DMNUR8E	HS	Patented
DMNUR8E	CP	Brandeis University and University of Georgia Research Foundation, Inc
DMNUR8E	DT	Small molecular drug

DM75QVW	ID	DM75QVW
DM75QVW	DN	PMID28074661-Compound-US20120264760C80
DM75QVW	HS	Patented
DM75QVW	CP	Brandeis University and University of Georgia Research Foundation, Inc
DM75QVW	DT	Small molecular drug

DMH249S	ID	DMH249S
DMH249S	DN	PMID28074661-Compound-US20120264760C81
DMH249S	HS	Patented
DMH249S	CP	Brandeis University and University of Georgia Research Foundation, Inc
DMH249S	DT	Small molecular drug

DM18PRU	ID	DM18PRU
DM18PRU	DN	PMID28074661-Compound-US20120264760C82
DM18PRU	HS	Patented
DM18PRU	CP	Brandeis University and University of Georgia Research Foundation, Inc
DM18PRU	DT	Small molecular drug

DMD7AU3	ID	DMD7AU3
DMD7AU3	DN	PMID28074661-Compound-US20120264760C83
DMD7AU3	HS	Patented
DMD7AU3	CP	Brandeis University and University of Georgia Research Foundation, Inc
DMD7AU3	DT	Small molecular drug

DMKFEO4	ID	DMKFEO4
DMKFEO4	DN	PMID28074661-Compound-US20120264760C86
DMKFEO4	HS	Patented
DMKFEO4	CP	Brandeis University and University of Georgia Research Foundation, Inc
DMKFEO4	DT	Small molecular drug

DM85XKT	ID	DM85XKT
DM85XKT	DN	PMID28074661-Compound-US20120264760C87
DM85XKT	HS	Patented
DM85XKT	CP	Brandeis University and University of Georgia Research Foundation, Inc
DM85XKT	DT	Small molecular drug

DMIKRCM	ID	DMIKRCM
DMIKRCM	DN	PMID28074661-Compound-US20120264760C88
DMIKRCM	HS	Patented
DMIKRCM	CP	Brandeis University and University of Georgia Research Foundation, Inc
DMIKRCM	DT	Small molecular drug

DMEJ4LW	ID	DMEJ4LW
DMEJ4LW	DN	PMID28074661-Compound-US20128202889C90
DMEJ4LW	HS	Patented
DMEJ4LW	CP	Vertex Pharmaceuticals Inc
DMEJ4LW	DT	Small molecular drug

DM1QUN0	ID	DM1QUN0
DM1QUN0	DN	PMID28074661-Compound-US20158969342C84
DM1QUN0	HS	Patented
DM1QUN0	CP	Brandeis University, University of Georgia Research Foundation, Inc., and The Brigham and Womens Hospital, Inc
DM1QUN0	DT	Small molecular drug

DMMYH82	ID	DMMYH82
DMMYH82	DN	PMID28074661-Compound-US20169447134C85
DMMYH82	HS	Patented
DMMYH82	CP	Brandeis University and The Brigham and Womens Hospital, Inc
DMMYH82	DT	Small molecular drug

DMFORUW	ID	DMFORUW
DMFORUW	DN	PMID28074661-Compound-WO2009018344C78
DMFORUW	HS	Patented
DMFORUW	CP	REGENTS OF THE UNIVERSITY OF MINNESOTA PANKIEWICZ, Krzysztof CHEN, Liqiang VINCE, Robert
DMFORUW	DT	Small molecular drug

DM64QNL	ID	DM64QNL
DM64QNL	DN	PMID28074661-Compound-WO2009018344C79
DM64QNL	HS	Patented
DM64QNL	CP	REGENTS OF THE UNIVERSITY OF MINNESOTA PANKIEWICZ, Krzysztof CHEN, Liqiang VINCE, Robert
DM64QNL	DT	Small molecular drug

DMC4TQL	ID	DMC4TQL
DMC4TQL	DN	PMID28092474-Compound-32
DMC4TQL	HS	Patented
DMC4TQL	CP	KARUS THERAPEUTICS LTD
DMC4TQL	DT	Small molecular drug

DMGZ61E	ID	DMGZ61E
DMGZ61E	DN	PMID28092474-Compound-32a
DMGZ61E	HS	Patented
DMGZ61E	CP	KARUS THERAPEUTICS LTD
DMGZ61E	DT	Small molecular drug

DMT2B5A	ID	DMT2B5A
DMT2B5A	DN	PMID28092474-Compound-32b
DMT2B5A	HS	Patented
DMT2B5A	CP	KARUS THERAPEUTICS LTD
DMT2B5A	DT	Small molecular drug
DMT2B5A	PC	86282589
DMT2B5A	MW	325.32
DMT2B5A	FM	C16H15N5O3
DMT2B5A	IC	InChI=1S/C16H15N5O3/c1-11-18-16(24-20-11)21(14-4-2-3-9-17-14)10-12-5-7-13(8-6-12)15(22)19-23/h2-9,23H,10H2,1H3,(H,19,22)
DMT2B5A	CS	CC1=NOC(=N1)N(CC2=CC=C(C=C2)C(=O)NO)C3=CC=CC=N3
DMT2B5A	IK	DUVRIRNTROCZMI-UHFFFAOYSA-N
DMT2B5A	IU	N-hydroxy-4-[[(3-methyl-1,2,4-oxadiazol-5-yl)-pyridin-2-ylamino]methyl]benzamide

DMGA3XL	ID	DMGA3XL
DMGA3XL	DN	PMID28092474-Compound-32c
DMGA3XL	HS	Patented
DMGA3XL	CP	KARUS THERAPEUTICS LTD
DMGA3XL	DT	Small molecular drug

DMW21U4	ID	DMW21U4
DMW21U4	DN	PMID28092474-Compound-32d
DMW21U4	HS	Patented
DMW21U4	CP	KARUS THERAPEUTICS LTD
DMW21U4	DT	Small molecular drug
DMW21U4	PC	86282452
DMW21U4	MW	327.4
DMW21U4	FM	C15H13N5O2S
DMW21U4	IC	InChI=1S/C15H13N5O2S/c21-14(19-22)12-6-4-11(5-7-12)9-20(15-18-17-10-23-15)13-3-1-2-8-16-13/h1-8,10,22H,9H2,(H,19,21)
DMW21U4	CS	C1=CC=NC(=C1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NN=CS3
DMW21U4	IK	BQMQOALHRWIFDX-UHFFFAOYSA-N
DMW21U4	IU	N-hydroxy-4-[[pyridin-2-yl(1,3,4-thiadiazol-2-yl)amino]methyl]benzamide

DM8NHQS	ID	DM8NHQS
DM8NHQS	DN	PMID28092474-Compound-32e
DM8NHQS	HS	Patented
DM8NHQS	CP	KARUS THERAPEUTICS LTD
DM8NHQS	DT	Small molecular drug

DMEIZ6Y	ID	DMEIZ6Y
DMEIZ6Y	DN	PMID28092474-Compound-32f
DMEIZ6Y	HS	Patented
DMEIZ6Y	CP	KARUS THERAPEUTICS LTD
DMEIZ6Y	DT	Small molecular drug

DMTKLEP	ID	DMTKLEP
DMTKLEP	DN	PMID28092474-Compound-32g
DMTKLEP	HS	Patented
DMTKLEP	CP	KARUS THERAPEUTICS LTD
DMTKLEP	DT	Small molecular drug

DME1WHT	ID	DME1WHT
DME1WHT	DN	PMID28092474-Compound-32h
DME1WHT	HS	Patented
DME1WHT	CP	KARUS THERAPEUTICS LTD
DME1WHT	DT	Small molecular drug

DMN3ZEF	ID	DMN3ZEF
DMN3ZEF	DN	PMID28092474-Compound-32i
DMN3ZEF	HS	Patented
DMN3ZEF	CP	KARUS THERAPEUTICS LTD
DMN3ZEF	DT	Small molecular drug

DMSGWTX	ID	DMSGWTX
DMSGWTX	DN	PMID28092474-Compound-32j
DMSGWTX	HS	Patented
DMSGWTX	CP	KARUS THERAPEUTICS LTD
DMSGWTX	DT	Small molecular drug

DMHSJ65	ID	DMHSJ65
DMHSJ65	DN	PMID28092474-Compound-32k
DMHSJ65	HS	Patented
DMHSJ65	CP	KARUS THERAPEUTICS LTD
DMHSJ65	DT	Small molecular drug

DMSP5IA	ID	DMSP5IA
DMSP5IA	DN	PMID28092474-Compound-32l
DMSP5IA	HS	Patented
DMSP5IA	CP	KARUS THERAPEUTICS LTD
DMSP5IA	DT	Small molecular drug

DMADMWB	ID	DMADMWB
DMADMWB	DN	PMID28092474-Compound-32m
DMADMWB	HS	Patented
DMADMWB	CP	KARUS THERAPEUTICS LTD
DMADMWB	DT	Small molecular drug
DMADMWB	PC	117703481
DMADMWB	MW	339.32
DMADMWB	FM	C17H14FN5O2
DMADMWB	IC	InChI=1S/C17H14FN5O2/c18-14-5-6-15(21-9-14)23(16-10-19-7-8-20-16)11-12-1-3-13(4-2-12)17(24)22-25/h1-10,25H,11H2,(H,22,24)
DMADMWB	CS	C1=CC(=CC=C1CN(C2=NC=C(C=C2)F)C3=NC=CN=C3)C(=O)NO
DMADMWB	IK	GEFHLXDMZNZOPQ-UHFFFAOYSA-N
DMADMWB	IU	4-[[(5-fluoropyridin-2-yl)-pyrazin-2-ylamino]methyl]-N-hydroxybenzamide

DMJO3RW	ID	DMJO3RW
DMJO3RW	DN	PMID28092474-Compound-32n
DMJO3RW	HS	Patented
DMJO3RW	CP	KARUS THERAPEUTICS LTD
DMJO3RW	DT	Small molecular drug
DMJO3RW	PC	86282455
DMJO3RW	MW	343.31
DMJO3RW	FM	C16H14FN5O3
DMJO3RW	IC	InChI=1S/C16H14FN5O3/c1-10-19-16(25-21-10)22(14-7-6-13(17)8-18-14)9-11-2-4-12(5-3-11)15(23)20-24/h2-8,24H,9H2,1H3,(H,20,23)
DMJO3RW	CS	CC1=NOC(=N1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NC=C(C=C3)F
DMJO3RW	IK	YHMSVHVCVQHZRX-UHFFFAOYSA-N
DMJO3RW	IU	4-[[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-oxadiazol-5-yl)amino]methyl]-N-hydroxybenzamide

DMV9BQN	ID	DMV9BQN
DMV9BQN	DN	PMID28092474-Compound-32o
DMV9BQN	HS	Patented
DMV9BQN	CP	KARUS THERAPEUTICS LTD
DMV9BQN	DT	Small molecular drug
DMV9BQN	PC	86282321
DMV9BQN	MW	341.34
DMV9BQN	FM	C17H16FN5O2
DMV9BQN	IC	InChI=1S/C17H16FN5O2/c1-22-9-8-16(20-22)23(15-7-6-14(18)10-19-15)11-12-2-4-13(5-3-12)17(24)21-25/h2-10,25H,11H2,1H3,(H,21,24)
DMV9BQN	CS	CN1C=CC(=N1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NC=C(C=C3)F
DMV9BQN	IK	YBRKYFUMBLZQCO-UHFFFAOYSA-N
DMV9BQN	IU	4-[[(5-fluoropyridin-2-yl)-(1-methylpyrazol-3-yl)amino]methyl]-N-hydroxybenzamide

DM4ZO21	ID	DM4ZO21
DM4ZO21	DN	PMID28092474-Compound-32p
DM4ZO21	HS	Patented
DM4ZO21	CP	KARUS THERAPEUTICS LTD
DM4ZO21	DT	Small molecular drug
DM4ZO21	PC	86282322
DM4ZO21	MW	359.4
DM4ZO21	FM	C16H14FN5O2S
DM4ZO21	IC	InChI=1S/C16H14FN5O2S/c1-10-19-16(25-21-10)22(14-7-6-13(17)8-18-14)9-11-2-4-12(5-3-11)15(23)20-24/h2-8,24H,9H2,1H3,(H,20,23)
DM4ZO21	CS	CC1=NSC(=N1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NC=C(C=C3)F
DM4ZO21	IK	RBFLOFRQBMMVRY-UHFFFAOYSA-N
DM4ZO21	IU	4-[[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-thiadiazol-5-yl)amino]methyl]-N-hydroxybenzamide

DMEASZY	ID	DMEASZY
DMEASZY	DN	PMID28092474-Compound-32q
DMEASZY	HS	Patented
DMEASZY	CP	KARUS THERAPEUTICS LTD
DMEASZY	DT	Small molecular drug
DMEASZY	PC	86282451
DMEASZY	MW	413.4
DMEASZY	FM	C16H11F4N5O2S
DMEASZY	IC	InChI=1S/C16H11F4N5O2S/c17-11-5-6-12(21-7-11)25(15-22-14(24-28-15)16(18,19)20)8-9-1-3-10(4-2-9)13(26)23-27/h1-7,27H,8H2,(H,23,26)
DMEASZY	CS	C1=CC(=CC=C1CN(C2=NC=C(C=C2)F)C3=NC(=NS3)C(F)(F)F)C(=O)NO
DMEASZY	IK	XGHLBDLYNQPBIS-UHFFFAOYSA-N
DMEASZY	IU	4-[[(5-fluoropyridin-2-yl)-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]methyl]-N-hydroxybenzamide

DMLTKMS	ID	DMLTKMS
DMLTKMS	DN	PMID28092474-Compound-32r
DMLTKMS	HS	Patented
DMLTKMS	CP	KARUS THERAPEUTICS LTD
DMLTKMS	DT	Small molecular drug
DMLTKMS	PC	86282178
DMLTKMS	MW	391.4
DMLTKMS	FM	C21H18FN5O2
DMLTKMS	IC	InChI=1S/C21H18FN5O2/c1-26-18-5-3-2-4-17(18)24-21(26)27(19-11-10-16(22)12-23-19)13-14-6-8-15(9-7-14)20(28)25-29/h2-12,29H,13H2,1H3,(H,25,28)
DMLTKMS	CS	CN1C2=CC=CC=C2N=C1N(CC3=CC=C(C=C3)C(=O)NO)C4=NC=C(C=C4)F
DMLTKMS	IK	DTDCFCPAKQGZSU-UHFFFAOYSA-N
DMLTKMS	IU	4-[[(5-fluoropyridin-2-yl)-(1-methylbenzimidazol-2-yl)amino]methyl]-N-hydroxybenzamide

DMS103B	ID	DMS103B
DMS103B	DN	PMID28092474-Compound-32s
DMS103B	HS	Patented
DMS103B	CP	KARUS THERAPEUTICS LTD
DMS103B	DT	Small molecular drug
DMS103B	PC	117703493
DMS103B	MW	378.4
DMS103B	FM	C20H15FN4O3
DMS103B	IC	InChI=1S/C20H15FN4O3/c21-15-9-10-18(22-11-15)25(20-23-16-3-1-2-4-17(16)28-20)12-13-5-7-14(8-6-13)19(26)24-27/h1-11,27H,12H2,(H,24,26)
DMS103B	CS	C1=CC=C2C(=C1)N=C(O2)N(CC3=CC=C(C=C3)C(=O)NO)C4=NC=C(C=C4)F
DMS103B	IK	CJXJBYDELMRNKR-UHFFFAOYSA-N
DMS103B	IU	4-[[1,3-benzoxazol-2-yl-(5-fluoropyridin-2-yl)amino]methyl]-N-hydroxybenzamide

DM2JF0T	ID	DM2JF0T
DM2JF0T	DN	PMID28092474-Compound-32t
DM2JF0T	HS	Patented
DM2JF0T	CP	KARUS THERAPEUTICS LTD
DM2JF0T	DT	Small molecular drug
DM2JF0T	PC	86282179
DM2JF0T	MW	364.4
DM2JF0T	FM	C20H20N4O3
DM2JF0T	IC	InChI=1S/C20H20N4O3/c1-14-5-10-18(22-12-14)24(19-17(27-2)4-3-11-21-19)13-15-6-8-16(9-7-15)20(25)23-26/h3-12,26H,13H2,1-2H3,(H,23,25)
DM2JF0T	CS	CC1=CN=C(C=C1)N(CC2=CC=C(C=C2)C(=O)NO)C3=C(C=CC=N3)OC
DM2JF0T	IK	JGXHNVLWEATQAQ-UHFFFAOYSA-N
DM2JF0T	IU	N-hydroxy-4-[[(3-methoxypyridin-2-yl)-(5-methylpyridin-2-yl)amino]methyl]benzamide

DM805ZN	ID	DM805ZN
DM805ZN	DN	PMID28092474-Compound-32u
DM805ZN	HS	Patented
DM805ZN	CP	KARUS THERAPEUTICS LTD
DM805ZN	DT	Small molecular drug

DMHV3ES	ID	DMHV3ES
DMHV3ES	DN	PMID28092474-Compound-32v
DMHV3ES	HS	Patented
DMHV3ES	CP	KARUS THERAPEUTICS LTD
DMHV3ES	DT	Small molecular drug

DML79XQ	ID	DML79XQ
DML79XQ	DN	PMID28092474-Compound-32x
DML79XQ	HS	Patented
DML79XQ	CP	KARUS THERAPEUTICS LTD
DML79XQ	DT	Small molecular drug
DML79XQ	PC	117703583
DML79XQ	MW	435.5
DML79XQ	FM	C23H25N5O4
DML79XQ	IC	InChI=1S/C23H25N5O4/c1-31-20-7-9-22(25-15-20)28(16-17-2-4-18(5-3-17)23(29)26-30)21-8-6-19(14-24-21)27-10-12-32-13-11-27/h2-9,14-15,30H,10-13,16H2,1H3,(H,26,29)
DML79XQ	CS	COC1=CN=C(C=C1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NC=C(C=C3)N4CCOCC4
DML79XQ	IK	ATEJVBHLZROGEX-UHFFFAOYSA-N
DML79XQ	IU	N-hydroxy-4-[[(5-methoxypyridin-2-yl)-(5-morpholin-4-ylpyridin-2-yl)amino]methyl]benzamide

DMLR03U	ID	DMLR03U
DMLR03U	DN	PMID28092474-Compound-32y
DMLR03U	HS	Patented
DMLR03U	CP	KARUS THERAPEUTICS LTD
DMLR03U	DT	Small molecular drug

DMEPWGH	ID	DMEPWGH
DMEPWGH	DN	PMID28092474-Compound-32z
DMEPWGH	HS	Patented
DMEPWGH	CP	KARUS THERAPEUTICS LTD
DMEPWGH	DT	Small molecular drug

DMRE6GP	ID	DMRE6GP
DMRE6GP	DN	PMID28092474-Compound-33
DMRE6GP	HS	Patented
DMRE6GP	CP	KARUS THERAPEUTICS LTD
DMRE6GP	DT	Small molecular drug

DM7GH4Y	ID	DM7GH4Y
DM7GH4Y	DN	PMID28092474-Compound-33a
DM7GH4Y	HS	Patented
DM7GH4Y	CP	KARUS THERAPEUTICS LTD
DM7GH4Y	DT	Small molecular drug

DMIJQZV	ID	DMIJQZV
DMIJQZV	DN	PMID28092474-Compound-33b
DMIJQZV	HS	Patented
DMIJQZV	CP	KARUS THERAPEUTICS LTD
DMIJQZV	DT	Small molecular drug

DM51JP6	ID	DM51JP6
DM51JP6	DN	PMID28092474-Compound-33c
DM51JP6	HS	Patented
DM51JP6	CP	KARUS THERAPEUTICS LTD
DM51JP6	DT	Small molecular drug

DMW38MK	ID	DMW38MK
DMW38MK	DN	PMID28092474-Compound-33d
DMW38MK	HS	Patented
DMW38MK	CP	KARUS THERAPEUTICS LTD
DMW38MK	DT	Small molecular drug
DMW38MK	PC	117703486
DMW38MK	MW	340.31
DMW38MK	FM	C16H13FN6O2
DMW38MK	IC	InChI=1S/C16H13FN6O2/c17-13-7-11(16(24)22-25)1-2-12(13)10-23(14-8-18-3-5-20-14)15-9-19-4-6-21-15/h1-9,25H,10H2,(H,22,24)
DMW38MK	CS	C1=CC(=C(C=C1C(=O)NO)F)CN(C2=NC=CN=C2)C3=NC=CN=C3
DMW38MK	IK	PLETUCDALFTIQN-UHFFFAOYSA-N
DMW38MK	IU	4-[[di(pyrazin-2-yl)amino]methyl]-3-fluoro-N-hydroxybenzamide

DMGTSXL	ID	DMGTSXL
DMGTSXL	DN	PMID28092474-Compound-33e
DMGTSXL	HS	Patented
DMGTSXL	CP	KARUS THERAPEUTICS LTD
DMGTSXL	DT	Small molecular drug

DMA360M	ID	DMA360M
DMA360M	DN	PMID28092474-Compound-33f
DMA360M	HS	Patented
DMA360M	CP	KARUS THERAPEUTICS LTD
DMA360M	DT	Small molecular drug

DM18DY6	ID	DM18DY6
DM18DY6	DN	PMID28092474-Compound-33g
DM18DY6	HS	Patented
DM18DY6	CP	KARUS THERAPEUTICS LTD
DM18DY6	DT	Small molecular drug
DM18DY6	PC	117703541
DM18DY6	MW	369.3
DM18DY6	FM	C18H16FN5O3
DM18DY6	IC	InChI=1S/C18H16FN5O3/c1-27-15-3-2-6-22-17(15)24(16-10-20-7-8-21-16)11-13-5-4-12(9-14(13)19)18(25)23-26/h2-10,26H,11H2,1H3,(H,23,25)
DM18DY6	CS	COC1=C(N=CC=C1)N(CC2=C(C=C(C=C2)C(=O)NO)F)C3=NC=CN=C3
DM18DY6	IK	APGUTSIVBNKJKQ-UHFFFAOYSA-N
DM18DY6	IU	3-fluoro-N-hydroxy-4-[[(3-methoxypyridin-2-yl)-pyrazin-2-ylamino]methyl]benzamide

DM1DN6V	ID	DM1DN6V
DM1DN6V	DN	PMID28092474-Compound-33h
DM1DN6V	HS	Patented
DM1DN6V	CP	KARUS THERAPEUTICS LTD
DM1DN6V	DT	Small molecular drug

DM16E95	ID	DM16E95
DM16E95	DN	PMID28092474-Compound-33i
DM16E95	HS	Patented
DM16E95	CP	KARUS THERAPEUTICS LTD
DM16E95	DT	Small molecular drug

DMNTRIZ	ID	DMNTRIZ
DMNTRIZ	DN	PMID28092474-Compound-33j
DMNTRIZ	HS	Patented
DMNTRIZ	CP	KARUS THERAPEUTICS LTD
DMNTRIZ	DT	Small molecular drug
DMNTRIZ	PC	117703439
DMNTRIZ	MW	340.31
DMNTRIZ	FM	C16H13FN6O2
DMNTRIZ	IC	InChI=1S/C16H13FN6O2/c17-13-8-11(16(24)22-25)3-4-12(13)10-23(14-2-1-5-20-21-14)15-9-18-6-7-19-15/h1-9,25H,10H2,(H,22,24)
DMNTRIZ	CS	C1=CC(=NN=C1)N(CC2=C(C=C(C=C2)C(=O)NO)F)C3=NC=CN=C3
DMNTRIZ	IK	JRLWVTOAMRASSS-UHFFFAOYSA-N
DMNTRIZ	IU	3-fluoro-N-hydroxy-4-[[pyrazin-2-yl(pyridazin-3-yl)amino]methyl]benzamide

DMF2ZNT	ID	DMF2ZNT
DMF2ZNT	DN	PMID28092474-Compound-33k
DMF2ZNT	HS	Patented
DMF2ZNT	CP	KARUS THERAPEUTICS LTD
DMF2ZNT	DT	Small molecular drug

DMPJSB2	ID	DMPJSB2
DMPJSB2	DN	PMID28092474-Compound-33l
DMPJSB2	HS	Patented
DMPJSB2	CP	KARUS THERAPEUTICS LTD
DMPJSB2	DT	Small molecular drug

DMXSPT9	ID	DMXSPT9
DMXSPT9	DN	PMID28092474-Compound-33m
DMXSPT9	HS	Patented
DMXSPT9	CP	KARUS THERAPEUTICS LTD
DMXSPT9	DT	Small molecular drug

DM6DJZ7	ID	DM6DJZ7
DM6DJZ7	DN	PMID28092474-Compound-33o
DM6DJZ7	HS	Patented
DM6DJZ7	CP	KARUS THERAPEUTICS LTD
DM6DJZ7	DT	Small molecular drug

DMI8ZBK	ID	DMI8ZBK
DMI8ZBK	DN	PMID28092474-Compound-33p
DMI8ZBK	HS	Patented
DMI8ZBK	CP	KARUS THERAPEUTICS LTD
DMI8ZBK	DT	Small molecular drug

DM6JRCW	ID	DM6JRCW
DM6JRCW	DN	PMID28092474-Compound-34
DM6JRCW	HS	Patented
DM6JRCW	CP	KARUS THERAPEUTICS LTD
DM6JRCW	DT	Small molecular drug

DMXQE7C	ID	DMXQE7C
DMXQE7C	DN	PMID28092474-Compound-34a
DMXQE7C	HS	Patented
DMXQE7C	CP	KARUS THERAPEUTICS LTD
DMXQE7C	DT	Small molecular drug

DM6X2CO	ID	DM6X2CO
DM6X2CO	DN	PMID28092474-Compound-34b
DM6X2CO	HS	Patented
DM6X2CO	CP	KARUS THERAPEUTICS LTD
DM6X2CO	DT	Small molecular drug

DMMI7DY	ID	DMMI7DY
DMMI7DY	DN	PMID28092474-Compound-34c
DMMI7DY	HS	Patented
DMMI7DY	CP	KARUS THERAPEUTICS LTD
DMMI7DY	DT	Small molecular drug

DMAXS57	ID	DMAXS57
DMAXS57	DN	PMID28117607-Compound-20
DMAXS57	HS	Patented
DMAXS57	CP	IPSEN PHARMA S.A.S. ONCODESIGN S.A
DMAXS57	DT	Small molecular drug

DMS8OTG	ID	DMS8OTG
DMS8OTG	DN	PMID28117607-Compound-21
DMS8OTG	HS	Patented
DMS8OTG	CP	ONCODESIGN S.A. IPSEN PHARMA S.A.S
DMS8OTG	DT	Small molecular drug

DMVIY73	ID	DMVIY73
DMVIY73	DN	PMID28117607-Compound-4
DMVIY73	HS	Patented
DMVIY73	CP	ORIGENIS GMBH
DMVIY73	DT	Small molecular drug

DMPBNFM	ID	DMPBNFM
DMPBNFM	DN	PMID28117607-Compound-5
DMPBNFM	HS	Patented
DMPBNFM	CP	ORIGENIS GMBH
DMPBNFM	DT	Small molecular drug

DM68B1R	ID	DM68B1R
DM68B1R	DN	PMID28117607-Compound-6
DM68B1R	HS	Patented
DM68B1R	CP	ORIGENIS GMBH
DM68B1R	DT	Small molecular drug

DMJZREU	ID	DMJZREU
DMJZREU	DN	PMID28117607-Compound-7
DMJZREU	HS	Patented
DMJZREU	CP	ORIGENIS GMBH
DMJZREU	DT	Small molecular drug

DMBHRUP	ID	DMBHRUP
DMBHRUP	DN	PMID28270010-Compound-Figure16-a
DMBHRUP	HS	Patented
DMBHRUP	CP	ARRAY BIOPHARMA INC
DMBHRUP	DT	Small molecular drug
DMBHRUP	PC	74220979
DMBHRUP	MW	513.4
DMBHRUP	FM	C25H26Cl2N6O2
DMBHRUP	IC	InChI=1S/C25H26Cl2N6O2/c1-16-23(18-14-28-32(2)15-18)31-33(19-9-5-4-6-10-19)24(16)30-25(34)29-22-13-21(27)20(26)12-17(22)8-7-11-35-3/h4-6,9-10,12-15H,7-8,11H2,1-3H3,(H2,29,30,34)
DMBHRUP	CS	CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)NC4=CC(=C(C=C4CCCOC)Cl)Cl
DMBHRUP	IK	UZWKONVGWZDEMU-UHFFFAOYSA-N
DMBHRUP	IU	1-[4,5-dichloro-2-(3-methoxypropyl)phenyl]-3-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]urea

DMAIRL2	ID	DMAIRL2
DMAIRL2	DN	PMID28270010-Compound-Figure16-b-1
DMAIRL2	HS	Patented
DMAIRL2	CP	ARRAY BIOPHARMA INC
DMAIRL2	DT	Small molecular drug

DM6YLMB	ID	DM6YLMB
DM6YLMB	DN	PMID28270010-Compound-Figure16-b-2
DM6YLMB	HS	Patented
DM6YLMB	CP	ARRAY BIOPHARMA INC
DM6YLMB	DT	Small molecular drug
DM6YLMB	PC	76071100
DM6YLMB	MW	498.5
DM6YLMB	FM	C25H25F3N6O2
DM6YLMB	IC	InChI=1S/C25H25F3N6O2/c1-16-22(19-13-30-33(2)14-19)32-34(20-7-5-4-6-8-20)23(16)31-24(35)29-12-18-11-17(15-36-3)9-10-21(18)25(26,27)28/h4-11,13-14H,12,15H2,1-3H3,(H2,29,31,35)
DM6YLMB	CS	CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)NCC4=C(C=CC(=C4)COC)C(F)(F)F
DM6YLMB	IK	SBSBZPNKXQZAIG-UHFFFAOYSA-N
DM6YLMB	IU	1-[[5-(methoxymethyl)-2-(trifluoromethyl)phenyl]methyl]-3-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]urea

DMPOI27	ID	DMPOI27
DMPOI27	DN	PMID28270010-Compound-Figure17-1
DMPOI27	HS	Patented
DMPOI27	CP	ARRAY BIOPHARMA INC
DMPOI27	DT	Small molecular drug
DMPOI27	PC	92135967
DMPOI27	MW	529.6
DMPOI27	FM	C29H32FN7O2
DMPOI27	IC	InChI=1S/C29H32FN7O2/c1-19-27(22-15-31-20(2)32-16-22)35-37(24-10-5-4-6-11-24)28(19)34-29(38)33-26-18-36(12-13-39-3)17-25(26)21-8-7-9-23(30)14-21/h4-11,14-16,25-26H,12-13,17-18H2,1-3H3,(H2,33,34,38)/t25-,26+/m0/s1
DMPOI27	CS	CC1=C(N(N=C1C2=CN=C(N=C2)C)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=CC=C5)F)CCOC
DMPOI27	IK	BGKSBHPSVMJTFL-IZZNHLLZSA-N
DMPOI27	IU	1-[(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[4-methyl-5-(2-methylpyrimidin-5-yl)-2-phenylpyrazol-3-yl]urea

DM7QLX8	ID	DM7QLX8
DM7QLX8	DN	PMID28270010-Compound-Figure17-2
DM7QLX8	HS	Patented
DM7QLX8	CP	ARRAY BIOPHARMA INC
DM7QLX8	DT	Small molecular drug
DM7QLX8	PC	71041449
DM7QLX8	MW	547.6
DM7QLX8	FM	C29H31F2N7O2
DM7QLX8	IC	InChI=1S/C29H31F2N7O2/c1-18-27(21-14-32-19(2)33-15-21)36-38(22-7-5-4-6-8-22)28(18)35-29(39)34-26-17-37(11-12-40-3)16-23(26)20-9-10-24(30)25(31)13-20/h4-10,13-15,23,26H,11-12,16-17H2,1-3H3,(H2,34,35,39)/t23-,26+/m0/s1
DM7QLX8	CS	CC1=C(N(N=C1C2=CN=C(N=C2)C)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DM7QLX8	IK	HMZMJVUIFWVPPL-JYFHCDHNSA-N
DM7QLX8	IU	1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[4-methyl-5-(2-methylpyrimidin-5-yl)-2-phenylpyrazol-3-yl]urea

DME0TUJ	ID	DME0TUJ
DME0TUJ	DN	PMID28270010-Compound-Figure17-3
DME0TUJ	HS	Patented
DME0TUJ	CP	ARRAY BIOPHARMA INC
DME0TUJ	DT	Small molecular drug
DME0TUJ	PC	71041443
DME0TUJ	MW	517.6
DME0TUJ	FM	C28H32FN7O2
DME0TUJ	IC	InChI=1S/C28H32FN7O2/c1-19-26(21-15-30-34(2)16-21)33-36(23-7-5-4-6-8-23)27(19)32-28(37)31-25-18-35(13-14-38-3)17-24(25)20-9-11-22(29)12-10-20/h4-12,15-16,24-25H,13-14,17-18H2,1-3H3,(H2,31,32,37)/t24-,25+/m0/s1
DME0TUJ	CS	CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC=C(C=C5)F)CCOC
DME0TUJ	IK	JNTHQYPNOWOSDA-LOSJGSFVSA-N
DME0TUJ	IU	1-[(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]urea

DM6IYAT	ID	DM6IYAT
DM6IYAT	DN	PMID28270010-Compound-Figure21-b
DM6IYAT	HS	Patented
DM6IYAT	CP	PFIZER INC
DM6IYAT	DT	Small molecular drug
DM6IYAT	PC	71731823
DM6IYAT	MW	406.4
DM6IYAT	FM	C21H19FN6O2
DM6IYAT	IC	InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
DM6IYAT	CS	C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
DM6IYAT	IK	IIXWYSCJSQVBQM-LLVKDONJSA-N
DM6IYAT	IU	(16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
DM6IYAT	CA	CAS 1454846-35-5
DM6IYAT	CB	CHEBI:143117
DM6IYAT	DE	Brain metastases

DMNTQL5	ID	DMNTQL5
DMNTQL5	DN	PMID28270010-Compound-Figure24-a
DMNTQL5	HS	Patented
DMNTQL5	DT	Small molecular drug
DMNTQL5	PC	11617559
DMNTQL5	MW	366.4
DMNTQL5	FM	C20H22N4O3
DMNTQL5	IC	InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)
DMNTQL5	CS	COC1=CC=C(C=C1)COC2=C(C=C(C=C2)CC3=CN=C(N=C3N)N)OC
DMNTQL5	IK	MYQAUKPBNJWPIE-UHFFFAOYSA-N
DMNTQL5	IU	5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine
DMNTQL5	CA	CAS 870483-87-7

DM0QHLK	ID	DM0QHLK
DM0QHLK	DN	PMID28270010-Compound-Figure24-b
DM0QHLK	HS	Patented
DM0QHLK	CP	GENZYME CORPORATION
DM0QHLK	DT	Small molecular drug
DM0QHLK	PC	118009787
DM0QHLK	MW	470.5
DM0QHLK	FM	C26H26N6O3
DM0QHLK	IC	InChI=1S/C26H26N6O3/c1-31-15-20(13-29-31)19-11-22-25(28-12-19)32(26(27)30-22)14-18-6-9-23(24(10-18)34-3)35-16-17-4-7-21(33-2)8-5-17/h4-13,15H,14,16H2,1-3H3,(H2,27,30)
DM0QHLK	CS	CN1C=C(C=N1)C2=CC3=C(N=C2)N(C(=N3)N)CC4=CC(=C(C=C4)OCC5=CC=C(C=C5)OC)OC
DM0QHLK	IK	HVRWZFQFSQUILC-UHFFFAOYSA-N
DM0QHLK	IU	3-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]-6-(1-methylpyrazol-4-yl)imidazo[4,5-b]pyridin-2-amine
DM0QHLK	CA	CAS 1788906-96-6

DM2YAPJ	ID	DM2YAPJ
DM2YAPJ	DN	PMID28270010-Compound-Figure5-1
DM2YAPJ	HS	Patented
DM2YAPJ	CP	ABBVIE INC
DM2YAPJ	DT	Small molecular drug
DM2YAPJ	PC	118256282
DM2YAPJ	MW	512.6
DM2YAPJ	FM	C29H32N6O3
DM2YAPJ	IC	InChI=1S/C29H32N6O3/c30-28-27-24(32-33-28)16-20(18-26(27)38-22-8-14-37-15-9-22)19-6-7-23(29(31)36)25(17-19)35-12-10-34(11-13-35)21-4-2-1-3-5-21/h1-7,16-18,22H,8-15H2,(H2,31,36)(H3,30,32,33)
DM2YAPJ	CS	C1COCCC1OC2=CC(=CC3=C2C(=NN3)N)C4=CC(=C(C=C4)C(=O)N)N5CCN(CC5)C6=CC=CC=C6
DM2YAPJ	IK	UDESEJHYZQLNDD-UHFFFAOYSA-N
DM2YAPJ	IU	4-[3-amino-4-(oxan-4-yloxy)-1H-indazol-6-yl]-2-(4-phenylpiperazin-1-yl)benzamide

DMK3GRZ	ID	DMK3GRZ
DMK3GRZ	DN	PMID28270010-Compound-Figure5-2
DMK3GRZ	HS	Patented
DMK3GRZ	CP	ABBVIE INC
DMK3GRZ	DT	Small molecular drug
DMK3GRZ	PC	118256311
DMK3GRZ	MW	524.5
DMK3GRZ	FM	C27H27F3N6O2
DMK3GRZ	IC	InChI=1S/C27H27F3N6O2/c1-16(27(28,29)30)38-23-15-18(13-21-24(23)25(31)34-33-21)17-7-8-20(26(32)37)22(14-17)36-11-9-35(10-12-36)19-5-3-2-4-6-19/h2-8,13-16H,9-12H2,1H3,(H2,32,37)(H3,31,33,34)
DMK3GRZ	CS	CC(C(F)(F)F)OC1=CC(=CC2=C1C(=NN2)N)C3=CC(=C(C=C3)C(=O)N)N4CCN(CC4)C5=CC=CC=C5
DMK3GRZ	IK	NRNLAILVLWFKCG-UHFFFAOYSA-N
DMK3GRZ	IU	4-[3-amino-4-(1,1,1-trifluoropropan-2-yloxy)-1H-indazol-6-yl]-2-(4-phenylpiperazin-1-yl)benzamide

DMSOT1R	ID	DMSOT1R
DMSOT1R	DN	PMID28270010-Compound-Figure5-3
DMSOT1R	HS	Patented
DMSOT1R	CP	ABBVIE INC
DMSOT1R	DT	Small molecular drug
DMSOT1R	PC	118256189
DMSOT1R	MW	532.7
DMSOT1R	FM	C30H40N6O3
DMSOT1R	IC	InChI=1S/C30H40N6O3/c1-32-30(37)24-8-7-20(18-26(24)36-13-11-35(12-14-36)22-5-3-2-4-6-22)21-17-25-28(29(31)34-33-25)27(19-21)39-23-9-15-38-16-10-23/h7-8,17-19,22-23H,2-6,9-16H2,1H3,(H,32,37)(H3,31,33,34)
DMSOT1R	CS	CNC(=O)C1=C(C=C(C=C1)C2=CC3=C(C(=C2)OC4CCOCC4)C(=NN3)N)N5CCN(CC5)C6CCCCC6
DMSOT1R	IK	QLRPXVWKEWQCQV-UHFFFAOYSA-N
DMSOT1R	IU	4-[3-amino-4-(oxan-4-yloxy)-1H-indazol-6-yl]-2-(4-cyclohexylpiperazin-1-yl)-N-methylbenzamide

DM437ZC	ID	DM437ZC
DM437ZC	DN	PMID28270021-Compound-WO2010077680 103
DM437ZC	HS	Patented
DM437ZC	CP	VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DM437ZC	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMNUA21	ID	DMNUA21
DMNUA21	DN	PMID28270021-Compound-WO2010077680 109
DMNUA21	HS	Patented
DMNUA21	CP	VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DMNUA21	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMQAZMC	ID	DMQAZMC
DMQAZMC	DN	PMID28270021-Compound-WO2010077680 201
DMQAZMC	HS	Patented
DMQAZMC	CP	VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DMQAZMC	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM6VAS2	ID	DM6VAS2
DM6VAS2	DN	PMID28270021-Compound-WO2010077680 481
DM6VAS2	HS	Patented
DM6VAS2	CP	VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DM6VAS2	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMQ9CBS	ID	DMQ9CBS
DMQ9CBS	DN	PMID28270021-Compound-WO2010077680 495
DMQ9CBS	HS	Patented
DMQ9CBS	CP	VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DMQ9CBS	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM6TJU0	ID	DM6TJU0
DM6TJU0	DN	PMID28270021-Compound-WO2010077680 803
DM6TJU0	HS	Patented
DM6TJU0	CP	VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DM6TJU0	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM47FNS	ID	DM47FNS
DM47FNS	DN	PMID28270021-Compound-WO2010077680 811
DM47FNS	HS	Patented
DM47FNS	CP	VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DM47FNS	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMVS7CJ	ID	DMVS7CJ
DMVS7CJ	DN	PMID28270021-Compound-WO2013009582Example16
DMVS7CJ	HS	Patented
DMVS7CJ	CP	MERCK SHARP & DOHME CORP
DMVS7CJ	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMQK4IX	ID	DMQK4IX
DMQK4IX	DN	PMID28270021-Compound-WO2013009582Example76
DMQK4IX	HS	Patented
DMQK4IX	CP	MERCK SHARP & DOHME CORP
DMQK4IX	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM2XKTB	ID	DM2XKTB
DM2XKTB	DN	PMID28270021-Compound-WO2013161919Example85-117
DM2XKTB	HS	Patented
DM2XKTB	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMO02EL	ID	DMO02EL
DMO02EL	DN	PMID28270021-Compound-WO2014078408Example1
DMO02EL	HS	Patented
DMO02EL	CP	ARRAY BIOPHARMA INC
DMO02EL	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMVCBSK	ID	DMVCBSK
DMVCBSK	DN	PMID28270021-Compound-WO2014078408Example26
DMVCBSK	HS	Patented
DMVCBSK	CP	ARRAY BIOPHARMA INC
DMVCBSK	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMKO4ZH	ID	DMKO4ZH
DMKO4ZH	DN	PMID28270021-Compound-WO2014129431Example8-1
DMKO4ZH	HS	Patented
DMKO4ZH	CP	ONO PHARMACEUTICAL CO., LTD
DMKO4ZH	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMA04P6	ID	DMA04P6
DMA04P6	DN	PMID28270021-Compound-WO2014152663 701
DMA04P6	HS	Patented
DMA04P6	CP	MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED
DMA04P6	DE	Osteoarthritis pain; Pruritus; Chronic pain; Neuropathic pain; Thymic cancer

DM16URY	ID	DM16URY
DM16URY	DN	PMID28270021-Compound-WO2015042088Example11
DM16URY	HS	Patented
DM16URY	CP	MERCK SHARP & DOHME CORP
DM16URY	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMOZHGU	ID	DMOZHGU
DMOZHGU	DN	PMID28270021-Compound-WO2015042088Example12
DMOZHGU	HS	Patented
DMOZHGU	CP	MERCK SHARP & DOHME CORP
DMOZHGU	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM6KXOQ	ID	DM6KXOQ
DM6KXOQ	DN	PMID28270021-Compound-WO2015042088Example4
DM6KXOQ	HS	Patented
DM6KXOQ	CP	MERCK SHARP & DOHME CORP
DM6KXOQ	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMD5QEL	ID	DMD5QEL
DMD5QEL	DN	PMID28270021-Compound-WO2016054807Example1
DMD5QEL	HS	Patented
DMD5QEL	CP	MERCK SHARP & DOHME CORP
DMD5QEL	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMW2ZRM	ID	DMW2ZRM
DMW2ZRM	DN	PMID28270021-Compound-WO2016054807Example112
DMW2ZRM	HS	Patented
DMW2ZRM	CP	MERCK SHARP & DOHME CORP
DMW2ZRM	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMREZ9I	ID	DMREZ9I
DMREZ9I	DN	PMID28270021-Compound-WO2016054807Example71
DMREZ9I	HS	Patented
DMREZ9I	CP	MERCK SHARP & DOHME CORP
DMREZ9I	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMPI86D	ID	DMPI86D
DMPI86D	DN	PMID28270021-Compound-WO2016054807Example80
DMPI86D	HS	Patented
DMPI86D	CP	MERCK SHARP & DOHME CORP
DMPI86D	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM9ADSN	ID	DM9ADSN
DM9ADSN	DN	PMID28270021-Compound-WO2016054807Example82
DM9ADSN	HS	Patented
DM9ADSN	CP	MERCK SHARP & DOHME CORP
DM9ADSN	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMSEIL0	ID	DMSEIL0
DMSEIL0	DN	PMID28350212-Compound-1
DMSEIL0	HS	Patented
DMSEIL0	CP	WONKWANG UNIVERSITY CENTER FOR INDUSTRY-ACADEMY COOPERATION
DMSEIL0	DT	Small molecular drug

DME72ZH	ID	DME72ZH
DME72ZH	DN	PMID28350212-Compound-12
DME72ZH	HS	Patented
DME72ZH	CP	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. WOLFE, Michael, S
DME72ZH	DT	Peptide
DME72ZH	SQ	Boc-D-Val-Gly-Aib-D-Val-D-Val-D-IIe-Aib-D-Thr(OBn)-D-Val-Aib-D-Val-D-IIe-Aib-Ome

DMPWYL8	ID	DMPWYL8
DMPWYL8	DN	PMID28350212-Compound-13
DMPWYL8	HS	Patented
DMPWYL8	DT	Small molecular drug

DMSFL5B	ID	DMSFL5B
DMSFL5B	DN	PMID28350212-Compound-15
DMSFL5B	HS	Patented
DMSFL5B	DT	Small molecular drug

DMA1RP9	ID	DMA1RP9
DMA1RP9	DN	PMID28350212-Compound-16
DMA1RP9	HS	Patented
DMA1RP9	CP	PFIZER PRODUCTS INC. BRODNEY, Michael, Aaron CHEN, Yuhpyng, Liang COFFMAN, Karen, Jean KLEINMAN, Edward, Fox O'NEILL, Brian, Thomas
DMA1RP9	DT	Small molecular drug

DMH8GC6	ID	DMH8GC6
DMH8GC6	DN	PMID28350212-Compound-18
DMH8GC6	HS	Patented
DMH8GC6	DT	Small molecular drug
DMH8GC6	DE	Alzheimer disease

DMI4US6	ID	DMI4US6
DMI4US6	DN	PMID28350212-Compound-19
DMI4US6	HS	Patented
DMI4US6	CP	PFIZER PRODUCTS INC. BRODNEY, Michael, Aaron CHEN, Yuhpyng, Liang COFFMAN, Karen, Jean KLEINMAN, Edward, Fox O'NEILL, Brian, Thomas
DMI4US6	DT	Small molecular drug
DMI4US6	DE	Alzheimer disease

DMM5G7S	ID	DMM5G7S
DMM5G7S	DN	PMID28350212-Compound-20
DMM5G7S	HS	Patented
DMM5G7S	DT	Small molecular drug
DMM5G7S	DE	Alzheimer disease

DMFTGZC	ID	DMFTGZC
DMFTGZC	DN	PMID28350212-Compound-21
DMFTGZC	HS	Patented
DMFTGZC	CP	WYETH KREFT, Anthony, Frank RESNICK, Lynn MAYER, Scott, Christian DIAMANTIDIS, George COLE, Derek, Cecil WANG, Tingzhong GALANTE, Rocco, John HOKE, Molly HARRISON, Boyd, Lynn ZHANG, Minshen
DMFTGZC	DT	Small molecular drug

DMKXZYC	ID	DMKXZYC
DMKXZYC	DN	PMID28350212-Compound-22
DMKXZYC	HS	Patented
DMKXZYC	CP	WYETH KREFT, Anthony, Frank RESNICK, Lynn MAYER, Scott, Christian DIAMANTIDIS, George COLE, Derek, Cecil WANG, Tingzhong GALANTE, Rocco, John HOKE, Molly HARRISON, Boyd, Lynn ZHANG, Minsheng
DMKXZYC	DT	Small molecular drug
DMKXZYC	PC	25159185
DMKXZYC	MW	391.7
DMKXZYC	FM	C9H8ClF6NO3S2
DMKXZYC	IC	InChI=1S/C9H8ClF6NO3S2/c10-5-1-2-6(21-5)22(19,20)17-4(3-18)7(8(11,12)13)9(14,15)16/h1-2,4,7,17-18H,3H2/t4-/m0/s1
DMKXZYC	CS	C1=C(SC(=C1)Cl)S(=O)(=O)N[C@@H](CO)C(C(F)(F)F)C(F)(F)F
DMKXZYC	IK	PSXOKXJMVRSARX-BYPYZUCNSA-N
DMKXZYC	IU	5-chloro-N-[(2R)-4,4,4-trifluoro-1-hydroxy-3-(trifluoromethyl)butan-2-yl]thiophene-2-sulfonamide

DM3MVW1	ID	DM3MVW1
DM3MVW1	DN	PMID28350212-Compound-23
DM3MVW1	HS	Patented
DM3MVW1	CP	WYETH KREFT, Anthony, Frank RESNICK, Lynn MAYER, Scott, Christian DIAMANTIDIS, George COLE, Derek, Cecil WANG, Tingzhong GALANTE, Rocco, John HOKE, Molly HARRISON, Boyd, Lynn ZHANG, Minsheng
DM3MVW1	DT	Small molecular drug

DMPJH6L	ID	DMPJH6L
DMPJH6L	DN	PMID28350212-Compound-24
DMPJH6L	HS	Patented
DMPJH6L	CP	BRISTOL-MYERS SQUIBB COMPANY
DMPJH6L	DT	Small molecular drug

DML2VUC	ID	DML2VUC
DML2VUC	DN	PMID28350212-Compound-25
DML2VUC	HS	Patented
DML2VUC	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-EMERY, Fabienne JAKOB-ROETNE, Rolan
DML2VUC	DT	Small molecular drug

DMF1ZJ3	ID	DMF1ZJ3
DMF1ZJ3	DN	PMID28350212-Compound-30
DMF1ZJ3	HS	Patented
DMF1ZJ3	CP	MERCK SHARP &amDOHME LIMITED CHURCHER, Ian HARRISON, Timothy KERRAD, Sonia NADIN, Alan, John OWENS, Andrew, Pate SHAW, Duncan, Edward THOMSON, Joanne WILLIAMS, Susannah
DMF1ZJ3	DT	Small molecular drug

DMSKE2O	ID	DMSKE2O
DMSKE2O	DN	PMID28350212-Compound-35
DMSKE2O	HS	Patented
DMSKE2O	CP	MERCK SHARP &amDOHME CORP. PISSARNITSKI, Dmitri ZHAO, Zhiqiang
DMSKE2O	DT	Small molecular drug

DM7ULWD	ID	DM7ULWD
DM7ULWD	DN	PMID28350212-Compound-36
DM7ULWD	HS	Patented
DM7ULWD	CP	MERCK SHARP & DOHME CORP. WU, Wen-Lian BURNETT, Duane, A
DM7ULWD	DT	Small molecular drug

DMUBSFV	ID	DMUBSFV
DMUBSFV	DN	PMID28350212-Compound-7
DMUBSFV	HS	Patented
DMUBSFV	CP	WONKWANG UNIVERSITY CENTER FOR INDUSTRY-ACADEMY COOPERATION
DMUBSFV	DT	Small molecular drug
DMUBSFV	DE	Herpes simplex virus infection

DMR0PUA	ID	DMR0PUA
DMR0PUA	DN	PMID28394193-Compound-10
DMR0PUA	HS	Patented
DMR0PUA	DT	Small molecular drug

DMJ23AL	ID	DMJ23AL
DMJ23AL	DN	PMID28394193-Compound-11
DMJ23AL	HS	Patented
DMJ23AL	DT	Small molecular drug

DMA7H9T	ID	DMA7H9T
DMA7H9T	DN	PMID28394193-Compound-12
DMA7H9T	HS	Patented
DMA7H9T	DT	Small molecular drug

DMGZ9MW	ID	DMGZ9MW
DMGZ9MW	DN	PMID28394193-Compound-13
DMGZ9MW	HS	Patented
DMGZ9MW	CP	EPIZYME, INC
DMGZ9MW	DT	Small molecular drug
DMGZ9MW	PC	86765324
DMGZ9MW	MW	529.7
DMGZ9MW	FM	C30H39N7O2
DMGZ9MW	IC	InChI=1S/C30H39N7O2/c1-6-20(4)36-18-19(3)28-24(29(38)33-17-25-21(5)37(7-2)34-30(25)39)14-23(15-26(28)36)22-8-9-27(32-16-22)35-12-10-31-11-13-35/h8-9,14-16,18,20,31H,6-7,10-13,17H2,1-5H3,(H,33,38)(H,34,39)
DMGZ9MW	CS	CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(N(NC5=O)CC)C)C
DMGZ9MW	IK	MQDSSXUQHUNJLJ-UHFFFAOYSA-N
DMGZ9MW	IU	1-butan-2-yl-N-[(2-ethyl-3-methyl-5-oxo-1H-pyrazol-4-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide

DM6T2FM	ID	DM6T2FM
DM6T2FM	DN	PMID28394193-Compound-14
DM6T2FM	HS	Patented
DM6T2FM	CP	EPIZYME, INC
DM6T2FM	DT	Small molecular drug
DM6T2FM	PC	90467336
DM6T2FM	MW	543.7
DM6T2FM	FM	C31H41N7O2
DM6T2FM	IC	InChI=1S/C31H41N7O2/c1-7-21(4)37-19-20(3)29-25(30(39)34-18-26-22(5)38(8-2)35-31(26)40-6)15-24(16-27(29)37)23-9-10-28(33-17-23)36-13-11-32-12-14-36/h9-10,15-17,19,21,32H,7-8,11-14,18H2,1-6H3,(H,34,39)
DM6T2FM	CS	CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(N(N=C5OC)CC)C)C
DM6T2FM	IK	NMLLGPWQRDDVGB-UHFFFAOYSA-N
DM6T2FM	IU	1-butan-2-yl-N-[(1-ethyl-3-methoxy-5-methylpyrazol-4-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide

DMXMP92	ID	DMXMP92
DMXMP92	DN	PMID28394193-Compound-15
DMXMP92	HS	Patented
DMXMP92	CP	EPIZYME, INC
DMXMP92	DT	Small molecular drug

DMQDRUT	ID	DMQDRUT
DMQDRUT	DN	PMID28394193-Compound-16
DMQDRUT	HS	Patented
DMQDRUT	CP	EPIZYME, INC
DMQDRUT	DT	Small molecular drug

DMPR9GA	ID	DMPR9GA
DMPR9GA	DN	PMID28394193-Compound-17
DMPR9GA	HS	Patented
DMPR9GA	CP	EPIZYME, INC
DMPR9GA	DT	Small molecular drug

DMIBZ2H	ID	DMIBZ2H
DMIBZ2H	DN	PMID28394193-Compound-18
DMIBZ2H	HS	Patented
DMIBZ2H	CP	EPIZYME, INC
DMIBZ2H	DT	Small molecular drug

DM4ZAE8	ID	DM4ZAE8
DM4ZAE8	DN	PMID28394193-Compound-19
DM4ZAE8	HS	Patented
DM4ZAE8	CP	EPIZYME, INC
DM4ZAE8	DT	Small molecular drug

DMC5NR0	ID	DMC5NR0
DMC5NR0	DN	PMID28394193-Compound-20
DMC5NR0	HS	Patented
DMC5NR0	CP	EPIZYME, INC
DMC5NR0	DT	Small molecular drug

DMLD8K3	ID	DMLD8K3
DMLD8K3	DN	PMID28394193-Compound-21
DMLD8K3	HS	Patented
DMLD8K3	CP	EPIZYME, INC
DMLD8K3	DT	Small molecular drug

DM8PJ3F	ID	DM8PJ3F
DM8PJ3F	DN	PMID28394193-Compound-22
DM8PJ3F	HS	Patented
DM8PJ3F	CP	EPIZYME, INC
DM8PJ3F	DT	Small molecular drug

DMNHCMY	ID	DMNHCMY
DMNHCMY	DN	PMID28394193-Compound-23
DMNHCMY	HS	Patented
DMNHCMY	CP	EPIZYME, INC
DMNHCMY	DT	Small molecular drug
DMNHCMY	PC	117807623
DMNHCMY	MW	421.5
DMNHCMY	FM	C25H31N3O3
DMNHCMY	IC	InChI=1S/C25H31N3O3/c1-15-13-16(2)27-24(29)21(15)14-26-25(30)23-18(4)28(22-8-6-5-7-20(22)23)17(3)19-9-11-31-12-10-19/h5-8,13,17,19H,9-12,14H2,1-4H3,(H,26,30)(H,27,29)
DMNHCMY	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCOCC4)C)C
DMNHCMY	IK	HFMSKVHOEPULNV-UHFFFAOYSA-N
DMNHCMY	IU	N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[1-(oxan-4-yl)ethyl]indole-3-carboxamide

DMYCVWZ	ID	DMYCVWZ
DMYCVWZ	DN	PMID28394193-Compound-24
DMYCVWZ	HS	Patented
DMYCVWZ	CP	EPIZYME, INC
DMYCVWZ	DT	Small molecular drug
DMYCVWZ	PC	117807842
DMYCVWZ	MW	437.5
DMYCVWZ	FM	C25H31N3O4
DMYCVWZ	IC	InChI=1S/C25H31N3O4/c1-15-13-22(31-4)20(24(29)27-15)14-26-25(30)23-17(3)28(21-8-6-5-7-19(21)23)16(2)18-9-11-32-12-10-18/h5-8,13,16,18H,9-12,14H2,1-4H3,(H,26,30)(H,27,29)
DMYCVWZ	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCOCC4)C)OC
DMYCVWZ	IK	PFPSFENQCNMITC-UHFFFAOYSA-N
DMYCVWZ	IU	N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[1-(oxan-4-yl)ethyl]indole-3-carboxamide

DMPIXAO	ID	DMPIXAO
DMPIXAO	DN	PMID28394193-Compound-25
DMPIXAO	HS	Patented
DMPIXAO	CP	EPIZYME, INC
DMPIXAO	DT	Small molecular drug
DMPIXAO	PC	117807842
DMPIXAO	MW	437.5
DMPIXAO	FM	C25H31N3O4
DMPIXAO	IC	InChI=1S/C25H31N3O4/c1-15-13-22(31-4)20(24(29)27-15)14-26-25(30)23-17(3)28(21-8-6-5-7-19(21)23)16(2)18-9-11-32-12-10-18/h5-8,13,16,18H,9-12,14H2,1-4H3,(H,26,30)(H,27,29)
DMPIXAO	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCOCC4)C)OC
DMPIXAO	IK	PFPSFENQCNMITC-UHFFFAOYSA-N
DMPIXAO	IU	N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[1-(oxan-4-yl)ethyl]indole-3-carboxamide

DMNWCUJ	ID	DMNWCUJ
DMNWCUJ	DN	PMID28394193-Compound-26
DMNWCUJ	HS	Patented
DMNWCUJ	CP	EPIZYME, INC
DMNWCUJ	DT	Small molecular drug
DMNWCUJ	PC	75203283
DMNWCUJ	MW	526.7
DMNWCUJ	FM	C31H38N6O2
DMNWCUJ	IC	InChI=1S/C31H38N6O2/c1-6-21(4)37-18-19(2)30-25(31(39)34-17-26-22(5)35-20(3)13-28(26)38)14-24(15-27(30)37)23-7-8-29(33-16-23)36-11-9-32-10-12-36/h7-8,13-16,18,21,32H,6,9-12,17H2,1-5H3,(H,34,39)(H,35,38)
DMNWCUJ	CS	CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(NC(=CC5=O)C)C)C
DMNWCUJ	IK	GSJUSSJURDTFPS-UHFFFAOYSA-N
DMNWCUJ	IU	1-butan-2-yl-N-[(2,6-dimethyl-4-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide

DM2KVDH	ID	DM2KVDH
DM2KVDH	DN	PMID28394193-Compound-27
DM2KVDH	HS	Patented
DM2KVDH	CP	EPIZYME, INC
DM2KVDH	DT	Small molecular drug
DM2KVDH	PC	76684269
DM2KVDH	MW	542.7
DM2KVDH	FM	C31H38N6O3
DM2KVDH	IC	InChI=1S/C31H38N6O3/c1-6-21(4)37-18-19(2)29-24(30(39)34-17-25-27(38)13-20(3)35-31(25)40-5)14-23(15-26(29)37)22-7-8-28(33-16-22)36-11-9-32-10-12-36/h7-8,13-16,18,21,32H,6,9-12,17H2,1-5H3,(H,34,39)(H,35,38)
DM2KVDH	CS	CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(NC(=CC5=O)C)OC)C
DM2KVDH	IK	RKSMELDENOCZPF-UHFFFAOYSA-N
DM2KVDH	IU	1-butan-2-yl-N-[(2-methoxy-6-methyl-4-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide

DMC24OL	ID	DMC24OL
DMC24OL	DN	PMID28394193-Compound-28
DMC24OL	HS	Patented
DMC24OL	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMC24OL	DT	Small molecular drug
DMC24OL	PC	91884579
DMC24OL	MW	550.7
DMC24OL	FM	C33H38N6O2
DMC24OL	IC	InChI=1S/C33H38N6O2/c1-21(2)39-20-25-8-6-4-5-7-23-15-22(3)37-33(41)28(23)19-36-32(40)27-16-26(17-29(39)31(25)27)24-9-10-30(35-18-24)38-13-11-34-12-14-38/h4,6,9-10,15-18,20-21,34H,5,7-8,11-14,19H2,1-3H3,(H,36,40)(H,37,41)/b6-4+
DMC24OL	CS	CC1=CC2=C(CNC(=O)C3=C4C(=CN(C4=CC(=C3)C5=CN=C(C=C5)N6CCNCC6)C(C)C)C/C=C/CC2)C(=O)N1
DMC24OL	IK	GMAFAVDEQFGQCC-GQCTYLIASA-N
DMC24OL	IU	(13E)-8-methyl-21-(6-piperazin-1-ylpyridin-3-yl)-18-propan-2-yl-3,7,18-triazatetracyclo[14.6.1.05,10.019,23]tricosa-1(23),5(10),8,13,16,19,21-heptaene-2,6-dione

DMBVI7L	ID	DMBVI7L
DMBVI7L	DN	PMID28394193-Compound-29
DMBVI7L	HS	Patented
DMBVI7L	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMBVI7L	DT	Small molecular drug

DMGEZT8	ID	DMGEZT8
DMGEZT8	DN	PMID28394193-Compound-30
DMGEZT8	HS	Patented
DMGEZT8	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMGEZT8	DT	Small molecular drug

DMJ02N1	ID	DMJ02N1
DMJ02N1	DN	PMID28394193-Compound-31
DMJ02N1	HS	Patented
DMJ02N1	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMJ02N1	DT	Small molecular drug

DM628MP	ID	DM628MP
DM628MP	DN	PMID28394193-Compound-32
DM628MP	HS	Patented
DM628MP	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DM628MP	DT	Small molecular drug

DMEOHX2	ID	DMEOHX2
DMEOHX2	DN	PMID28394193-Compound-33
DMEOHX2	HS	Patented
DMEOHX2	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMEOHX2	DT	Small molecular drug
DMEOHX2	PC	121305270
DMEOHX2	MW	517.7
DMEOHX2	FM	C31H39N3O2S
DMEOHX2	IC	InChI=1S/C31H39N3O2S/c1-5-25(24-11-14-32-15-12-24)29-22(4)28-27(37-29)13-16-34(31(28)35)18-26-20(2)17-21(3)33-30(26)36-19-23-9-7-6-8-10-23/h6-10,17,24-25,32H,5,11-16,18-19H2,1-4H3
DMEOHX2	CS	CCC(C1CCNCC1)C2=C(C3=C(S2)CCN(C3=O)CC4=C(N=C(C=C4C)C)OCC5=CC=CC=C5)C
DMEOHX2	IK	SJBPGCIWHCAKKL-UHFFFAOYSA-N
DMEOHX2	IU	5-[(4,6-dimethyl-2-phenylmethoxypyridin-3-yl)methyl]-3-methyl-2-(1-piperidin-4-ylpropyl)-6,7-dihydrothieno[3,2-c]pyridin-4-one

DMB7WNP	ID	DMB7WNP
DMB7WNP	DN	PMID28394193-Compound-34
DMB7WNP	HS	Patented
DMB7WNP	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMB7WNP	DT	Small molecular drug

DMV1AGC	ID	DMV1AGC
DMV1AGC	DN	PMID28394193-Compound-35
DMV1AGC	HS	Patented
DMV1AGC	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMV1AGC	DT	Small molecular drug

DM658HJ	ID	DM658HJ
DM658HJ	DN	PMID28394193-Compound-36
DM658HJ	HS	Patented
DM658HJ	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DM658HJ	DT	Small molecular drug

DM73CA5	ID	DM73CA5
DM73CA5	DN	PMID28394193-Compound-37
DM73CA5	HS	Patented
DM73CA5	DT	Small molecular drug
DM73CA5	PC	78320107
DM73CA5	MW	500.6
DM73CA5	FM	C27H34F2N4O3
DM73CA5	IC	InChI=1S/C27H34F2N4O3/c1-16-13-23(36-4)21(26(34)31-16)14-30-27(35)25-18(3)33(22-8-6-5-7-20(22)25)17(2)19-9-11-32(12-10-19)15-24(28)29/h5-8,13,17,19,24H,9-12,14-15H2,1-4H3,(H,30,35)(H,31,34)
DM73CA5	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCN(CC4)CC(F)F)C)OC
DM73CA5	IK	RQOXQFWLPWTPPB-UHFFFAOYSA-N
DM73CA5	IU	1-[1-[1-(2,2-difluoroethyl)piperidin-4-yl]ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methylindole-3-carboxamide

DM25PMQ	ID	DM25PMQ
DM25PMQ	DN	PMID28394193-Compound-38
DM25PMQ	HS	Patented
DM25PMQ	DT	Small molecular drug
DM25PMQ	PC	78320108
DM25PMQ	MW	518.6
DM25PMQ	FM	C27H33F3N4O3
DM25PMQ	IC	InChI=1S/C27H33F3N4O3/c1-16-13-23(37-4)21(25(35)32-16)14-31-26(36)24-18(3)34(22-8-6-5-7-20(22)24)17(2)19-9-11-33(12-10-19)15-27(28,29)30/h5-8,13,17,19H,9-12,14-15H2,1-4H3,(H,31,36)(H,32,35)
DM25PMQ	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCN(CC4)CC(F)(F)F)C)OC
DM25PMQ	IK	HPODOLXTMDHLLC-UHFFFAOYSA-N
DM25PMQ	IU	N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide

DM2NS5T	ID	DM2NS5T
DM2NS5T	DN	PMID28394193-Compound-39
DM2NS5T	HS	Patented
DM2NS5T	CP	CONSTELLATION PHARMACEUTICALS, INC
DM2NS5T	DT	Small molecular drug

DMO5479	ID	DMO5479
DMO5479	DN	PMID28394193-Compound-40
DMO5479	HS	Patented
DMO5479	CP	BRISTOL-MYERS SQUIBB COMPANY
DMO5479	DT	Small molecular drug
DMO5479	PC	118095598
DMO5479	MW	628.8
DMO5479	FM	C37H45FN4O4
DMO5479	IC	InChI=1S/C37H45FN4O4/c1-4-42(29-12-16-45-17-13-29)34-21-28(27-10-8-26(9-11-27)23-41-14-18-46-19-15-41)20-31(24(34)2)36(43)39-22-32-35-30(6-5-7-33(35)38)25(3)40-37(32)44/h5-11,20-21,25,29,32H,4,12-19,22-23H2,1-3H3,(H,39,43)(H,40,44)
DMO5479	CS	CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3C4=C(C=CC=C4F)C(NC3=O)C)C5=CC=C(C=C5)CN6CCOCC6
DMO5479	IK	FUYGRYVZMCQDEP-UHFFFAOYSA-N
DMO5479	IU	3-[ethyl(oxan-4-yl)amino]-N-[(5-fluoro-1-methyl-3-oxo-2,4-dihydro-1H-isoquinolin-4-yl)methyl]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide

DMYLVTQ	ID	DMYLVTQ
DMYLVTQ	DN	PMID28394193-Compound-41
DMYLVTQ	HS	Patented
DMYLVTQ	CP	BRISTOL-MYERS SQUIBB COMPANY
DMYLVTQ	DT	Small molecular drug
DMYLVTQ	PC	118101320
DMYLVTQ	MW	662.8
DMYLVTQ	FM	C39H46N6O4
DMYLVTQ	IC	InChI=1S/C39H46N6O4/c1-8-25(3)45-23-24(2)35-31(36(46)41-22-32-30-12-10-9-11-29(30)26(4)42-37(32)47)19-28(20-33(35)45)27-13-14-34(40-21-27)43-15-17-44(18-16-43)38(48)49-39(5,6)7/h9-14,19-21,23,25H,8,15-18,22H2,1-7H3,(H,41,46)(H,42,47)
DMYLVTQ	CS	CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCN(CC4)C(=O)OC(C)(C)C)C(=O)NCC5=C6C=CC=CC6=C(NC5=O)C)C
DMYLVTQ	IK	LTHICEHOVQKREU-UHFFFAOYSA-N
DMYLVTQ	IU	tert-butyl 4-[5-[1-butan-2-yl-3-methyl-4-[(1-methyl-3-oxo-2H-isoquinolin-4-yl)methylcarbamoyl]indol-6-yl]pyridin-2-yl]piperazine-1-carboxylate

DMLI7TG	ID	DMLI7TG
DMLI7TG	DN	PMID28394193-Compound-42
DMLI7TG	HS	Patented
DMLI7TG	CP	BRISTOL-MYERS SQUIBB COMPANY
DMLI7TG	DT	Small molecular drug
DMLI7TG	PC	118096643
DMLI7TG	MW	405.3
DMLI7TG	FM	C19H21BrN2O3
DMLI7TG	IC	InChI=1S/C19H21BrN2O3/c1-10-5-11(2)22-18(24)14(10)9-21-17(23)12-6-13-8-19(3,4)25-16(13)15(20)7-12/h5-7H,8-9H2,1-4H3,(H,21,23)(H,22,24)
DMLI7TG	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC3=C(C(=C2)Br)OC(C3)(C)C)C
DMLI7TG	IK	HDXJPZKHNBTZOX-UHFFFAOYSA-N
DMLI7TG	IU	7-bromo-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,2-dimethyl-3H-1-benzofuran-5-carboxamide

DMASV8I	ID	DMASV8I
DMASV8I	DN	PMID28394193-Compound-43
DMASV8I	HS	Patented
DMASV8I	CP	BRISTOL-MYERS SQUIBB COMPANY
DMASV8I	DT	Small molecular drug
DMASV8I	PC	118096796
DMASV8I	MW	486.6
DMASV8I	FM	C29H34N4O3
DMASV8I	IC	InChI=1S/C29H34N4O3/c1-18-13-19(2)32-28(35)25(18)17-31-27(34)21-14-22-16-29(3,4)36-26(22)24(15-21)20-5-7-23(8-6-20)33-11-9-30-10-12-33/h5-8,13-15,30H,9-12,16-17H2,1-4H3,(H,31,34)(H,32,35)
DMASV8I	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC3=C(C(=C2)C4=CC=C(C=C4)N5CCNCC5)OC(C3)(C)C)C
DMASV8I	IK	ZIIBOHIVIFEGAI-UHFFFAOYSA-N
DMASV8I	IU	N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,2-dimethyl-7-(4-piperazin-1-ylphenyl)-3H-1-benzofuran-5-carboxamide

DME6FWY	ID	DME6FWY
DME6FWY	DN	PMID28394193-Compound-44
DME6FWY	HS	Patented
DME6FWY	CP	BRISTOL-MYERS SQUIBB COMPANY
DME6FWY	DT	Small molecular drug
DME6FWY	PC	118096614
DME6FWY	MW	417.3
DME6FWY	FM	C20H21BrN2O3
DME6FWY	IC	InChI=1S/C20H21BrN2O3/c1-11-4-5-26-18-14(6-11)8-15(9-17(18)21)19(24)22-10-16-12(2)7-13(3)23-20(16)25/h4,7-9H,5-6,10H2,1-3H3,(H,22,24)(H,23,25)
DME6FWY	CS	CC1=CCOC2=C(C1)C=C(C=C2Br)C(=O)NCC3=C(C=C(NC3=O)C)C
DME6FWY	IK	FKDNRFGIZCNPMK-UHFFFAOYSA-N
DME6FWY	IU	9-bromo-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methyl-2,5-dihydro-1-benzoxepine-7-carboxamide

DMZJXPF	ID	DMZJXPF
DMZJXPF	DN	PMID28394193-Compound-45
DMZJXPF	HS	Patented
DMZJXPF	CP	PFIZER INC
DMZJXPF	DT	Small molecular drug
DMZJXPF	PC	118607675
DMZJXPF	MW	337.4
DMZJXPF	FM	C19H19N3O3
DMZJXPF	IC	InChI=1S/C19H19N3O3/c1-11-8-12(2)21-18(23)15(11)10-22-7-6-13-4-5-16(25-3)14(9-20)17(13)19(22)24/h4-5,8H,6-7,10H2,1-3H3,(H,21,23)
DMZJXPF	CS	CC1=CC(=C(C(=O)N1)CN2CCC3=C(C2=O)C(=C(C=C3)OC)C#N)C
DMZJXPF	IK	SJAPTZBKLVFZLU-UHFFFAOYSA-N
DMZJXPF	IU	2-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-7-methoxy-1-oxo-3,4-dihydroisoquinoline-8-carbonitrile

DMYMPNA	ID	DMYMPNA
DMYMPNA	DN	PMID28394193-Compound-46
DMYMPNA	HS	Patented
DMYMPNA	CP	PFIZER INC
DMYMPNA	DT	Small molecular drug
DMYMPNA	PC	102593999
DMYMPNA	MW	462.3
DMYMPNA	FM	C22H21Cl2N3O4
DMYMPNA	IC	InChI=1S/C22H21Cl2N3O4/c1-10-6-11(2)25-21(29)15(10)8-27-5-4-13-16(23)7-14(20(24)19(13)22(27)30)18-12(3)31-26-17(18)9-28/h6-7,28H,4-5,8-9H2,1-3H3,(H,25,29)
DMYMPNA	CS	CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C4=C(ON=C4CO)C)Cl)C
DMYMPNA	IK	WZHICSHLNWIANY-UHFFFAOYSA-N
DMYMPNA	IU	5,8-dichloro-2-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[3-(hydroxymethyl)-5-methyl-1,2-oxazol-4-yl]-3,4-dihydroisoquinolin-1-one

DM7UDIM	ID	DM7UDIM
DM7UDIM	DN	PMID28394193-Compound-47
DM7UDIM	HS	Patented
DM7UDIM	CP	PFIZER INC
DM7UDIM	DT	Small molecular drug
DM7UDIM	PC	118616529
DM7UDIM	MW	462.3
DM7UDIM	FM	C22H21Cl2N3O4
DM7UDIM	IC	InChI=1S/C22H21Cl2N3O4/c1-10-7-17(30-4)15(21(28)25-10)9-27-6-5-13-16(23)8-14(20(24)19(13)22(27)29)18-11(2)26-31-12(18)3/h7-8H,5-6,9H2,1-4H3,(H,25,28)
DM7UDIM	CS	CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C4=C(ON=C4C)C)Cl)OC
DM7UDIM	IK	HCXPMZKLLCLZQX-UHFFFAOYSA-N
DM7UDIM	IU	5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1-one

DMEU4Y1	ID	DMEU4Y1
DMEU4Y1	DN	PMID28394193-Compound-49
DMEU4Y1	HS	Patented
DMEU4Y1	CP	BRISTOL-MYERS SQUIBB COMPANY
DMEU4Y1	DT	Small molecular drug
DMEU4Y1	PC	118572078
DMEU4Y1	MW	464.4
DMEU4Y1	FM	C23H27Cl2N3O3
DMEU4Y1	IC	InChI=1S/C23H27Cl2N3O3/c1-12-7-19(31-4)17(22(29)26-12)11-28-6-5-15-18(24)8-16(21(25)20(15)23(28)30)13(2)14-9-27(3)10-14/h7-8,13-14H,5-6,9-11H2,1-4H3,(H,26,29)
DMEU4Y1	CS	CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C(C)C4CN(C4)C)Cl)OC
DMEU4Y1	IK	YSHFYFJAQGEFJV-UHFFFAOYSA-N
DMEU4Y1	IU	5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[1-(1-methylazetidin-3-yl)ethyl]-3,4-dihydroisoquinolin-1-one

DM4NVTB	ID	DM4NVTB
DM4NVTB	DN	PMID28394193-Compound-50
DM4NVTB	HS	Patented
DM4NVTB	CP	BRISTOL-MYERS SQUIBB COMPANY
DM4NVTB	DT	Small molecular drug
DM4NVTB	PC	118580552
DM4NVTB	MW	430.9
DM4NVTB	FM	C23H27ClN2O4
DM4NVTB	IC	InChI=1S/C23H27ClN2O4/c1-12-7-17(14(3)15-10-30-11-15)21(24)20-16(12)5-6-26(23(20)28)9-18-19(29-4)8-13(2)25-22(18)27/h7-8,14-15H,5-6,9-11H2,1-4H3,(H,25,27)
DM4NVTB	CS	CC1=CC(=C(C2=C1CCN(C2=O)CC3=C(C=C(NC3=O)C)OC)Cl)C(C)C4COC4
DM4NVTB	IK	ZUDMACKBEPQTPV-UHFFFAOYSA-N
DM4NVTB	IU	8-chloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-5-methyl-7-[1-(oxetan-3-yl)ethyl]-3,4-dihydroisoquinolin-1-one

DM0KPQ9	ID	DM0KPQ9
DM0KPQ9	DN	PMID28394193-Compound-51
DM0KPQ9	HS	Patented
DM0KPQ9	CP	BRISTOL-MYERS SQUIBB COMPANY
DM0KPQ9	DT	Small molecular drug
DM0KPQ9	PC	118580509
DM0KPQ9	MW	520.4
DM0KPQ9	FM	C26H31Cl2N3O4
DM0KPQ9	IC	InChI=1S/C26H31Cl2N3O4/c1-14-11-15(2)29-25(33)20(14)13-31-10-7-18-21(27)12-19(23(28)22(18)26(31)34)24(35-4)17-5-8-30(9-6-17)16(3)32/h11-12,17,24H,5-10,13H2,1-4H3,(H,29,33)
DM0KPQ9	CS	CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C(C4CCN(CC4)C(=O)C)OC)Cl)C
DM0KPQ9	IK	PCBQYEOJXRGLFI-UHFFFAOYSA-N
DM0KPQ9	IU	7-[(1-acetylpiperidin-4-yl)-methoxymethyl]-5,8-dichloro-2-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1-one

DM2I9HY	ID	DM2I9HY
DM2I9HY	DN	PMID28394193-Compound-52
DM2I9HY	HS	Patented
DM2I9HY	CP	BRISTOL-MYERS SQUIBB COMPANY
DM2I9HY	DT	Small molecular drug
DM2I9HY	PC	118580510
DM2I9HY	MW	552.4
DM2I9HY	FM	C26H31Cl2N3O6
DM2I9HY	IC	InChI=1S/C26H31Cl2N3O6/c1-14-10-20(36-2)18(25(34)29-14)12-31-9-6-16-19(27)11-17(23(28)22(16)26(31)35)24(37-3)15-4-7-30(8-5-15)21(33)13-32/h10-11,15,24,32H,4-9,12-13H2,1-3H3,(H,29,34)
DM2I9HY	CS	CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C(C4CCN(CC4)C(=O)CO)OC)Cl)OC
DM2I9HY	IK	AARGZKBSIZRPJQ-UHFFFAOYSA-N
DM2I9HY	IU	5,8-dichloro-7-[[1-(2-hydroxyacetyl)piperidin-4-yl]-methoxymethyl]-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1-one

DMXMRQP	ID	DMXMRQP
DMXMRQP	DN	PMID28394193-Compound-53
DMXMRQP	HS	Patented
DMXMRQP	CP	DANA-FARBER CANCER INSTITUTE, INC
DMXMRQP	DT	Small molecular drug
DMXMRQP	PC	121322599
DMXMRQP	MW	542.7
DMXMRQP	FM	C30H38N8O2
DMXMRQP	IC	InChI=1S/C30H38N8O2/c1-6-7-21-14-20(4)34-30(40)24(21)17-32-29(39)23-15-26(35-28-25(23)18-33-38(28)19(2)3)22-8-9-27(31-16-22)37-12-10-36(5)11-13-37/h8-9,14-16,18-19H,6-7,10-13,17H2,1-5H3,(H,32,39)(H,34,40)
DMXMRQP	CS	CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=CC(=NC3=C2C=NN3C(C)C)C4=CN=C(C=C4)N5CCN(CC5)C
DMXMRQP	IK	LQTWDAYNGMMHLV-UHFFFAOYSA-N
DMXMRQP	IU	N-[(6-methyl-2-oxo-4-propyl-1H-pyridin-3-yl)methyl]-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide

DMMQ3UG	ID	DMMQ3UG
DMMQ3UG	DN	PMID28394193-Compound-54
DMMQ3UG	HS	Patented
DMMQ3UG	CP	DANA-FARBER CANCER INSTITUTE, INC
DMMQ3UG	DT	Small molecular drug

DM2FPHZ	ID	DM2FPHZ
DM2FPHZ	DN	PMID28394193-Compound-55
DM2FPHZ	HS	Patented
DM2FPHZ	CP	BAYER PHARMA AKTIENGESELLSCHAFT THE BROAD INSTITUTE INC
DM2FPHZ	DT	Small molecular drug

DMQRFZK	ID	DMQRFZK
DMQRFZK	DN	PMID28394193-Compound-56
DMQRFZK	HS	Patented
DMQRFZK	CP	ELI LILLY AND COMPANY
DMQRFZK	DT	Small molecular drug

DM4Y3US	ID	DM4Y3US
DM4Y3US	DN	PMID28394193-Compound-57
DM4Y3US	HS	Patented
DM4Y3US	CP	ELI LILLY AND COMPANY
DM4Y3US	DT	Small molecular drug

DMXK2GA	ID	DMXK2GA
DMXK2GA	DN	PMID28394193-Compound-Figure3bI
DMXK2GA	HS	Patented
DMXK2GA	CP	EPIZYME, INC
DMXK2GA	DT	Small molecular drug

DML6PE0	ID	DML6PE0
DML6PE0	DN	PMID28394193-Compound-Figure3bII
DML6PE0	HS	Patented
DML6PE0	CP	EPIZYME, INC
DML6PE0	DT	Small molecular drug

DMUI385	ID	DMUI385
DMUI385	DN	PMID28394193-Compound-Figure3bIII
DMUI385	HS	Patented
DMUI385	CP	EPIZYME, INC
DMUI385	DT	Small molecular drug

DMKVRTM	ID	DMKVRTM
DMKVRTM	DN	PMID28394193-Compound-Figure5aVIII
DMKVRTM	HS	Patented
DMKVRTM	DT	Small molecular drug

DMA7OEF	ID	DMA7OEF
DMA7OEF	DN	PMID28447479-Compound-10
DMA7OEF	HS	Patented
DMA7OEF	CP	BIOGEN IDEC MA INC
DMA7OEF	DT	Small molecular drug

DMOYMWZ	ID	DMOYMWZ
DMOYMWZ	DN	PMID28447479-Compound-11
DMOYMWZ	HS	Patented
DMOYMWZ	CP	BIOGEN IDEC MA INC
DMOYMWZ	DT	Small molecular drug

DMA91X2	ID	DMA91X2
DMA91X2	DN	PMID28447479-Compound-14
DMA91X2	HS	Patented
DMA91X2	CP	PHARMAKEA, INC
DMA91X2	DT	Small molecular drug
DMA91X2	PC	118103593
DMA91X2	MW	478.5
DMA91X2	FM	C26H27FN4O4
DMA91X2	IC	InChI=1S/C26H27FN4O4/c1-25(2,23(33)34)14-31-22(32)20-26(3,4)19-17-6-5-11-28-21(17)29(18(19)13-30(20)24(31)35)12-15-7-9-16(27)10-8-15/h5-11,20H,12-14H2,1-4H3,(H,33,34)
DMA91X2	CS	CC1(C2C(=O)N(C(=O)N2CC3=C1C4=C(N3CC5=CC=C(C=C5)F)N=CC=C4)CC(C)(C)C(=O)O)C
DMA91X2	IK	PZDULKFJLQEMQQ-UHFFFAOYSA-N
DMA91X2	IU	3-[8-[(4-fluorophenyl)methyl]-16,16-dimethyl-12,14-dioxo-6,8,11,13-tetrazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2(7),3,5-tetraen-13-yl]-2,2-dimethylpropanoic acid

DMWSL5G	ID	DMWSL5G
DMWSL5G	DN	PMID28447479-Compound-20
DMWSL5G	HS	Patented
DMWSL5G	CP	BIOGEN MA INC
DMWSL5G	DT	Small molecular drug
DMWSL5G	PC	78425825
DMWSL5G	MW	479.4
DMWSL5G	FM	C20H19F6N3O4
DMWSL5G	IC	InChI=1S/C20H19F6N3O4/c1-2-32-17(30)16-9-15-10-28(4-3-5-29(15)27-16)18(31)33-11-12-6-13(19(21,22)23)8-14(7-12)20(24,25)26/h6-9H,2-5,10-11H2,1H3
DMWSL5G	CS	CCOC(=O)C1=NN2CCCN(CC2=C1)C(=O)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMWSL5G	IK	UVKJSSLAVQPIDP-UHFFFAOYSA-N
DMWSL5G	IU	5-O-[[3,5-bis(trifluoromethyl)phenyl]methyl] 2-O-ethyl 4,6,7,8-tetrahydropyrazolo[1,5-a][1,4]diazepine-2,5-dicarboxylate

DM8PET6	ID	DM8PET6
DM8PET6	DN	PMID28447479-Compound-21
DM8PET6	HS	Patented
DM8PET6	CP	BIOGEN MA INC
DM8PET6	DT	Small molecular drug

DMRCM1O	ID	DMRCM1O
DMRCM1O	DN	PMID28447479-Compound-22
DMRCM1O	HS	Patented
DMRCM1O	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMRCM1O	DT	Small molecular drug

DMM0BVE	ID	DMM0BVE
DMM0BVE	DN	PMID28447479-Compound-23
DMM0BVE	HS	Patented
DMM0BVE	CP	X-RX, INC
DMM0BVE	DT	Small molecular drug
DMM0BVE	PC	118417827
DMM0BVE	MW	632.5
DMM0BVE	FM	C28H27F7N4O5
DMM0BVE	IC	InChI=1S/C28H27F7N4O5/c1-15(2)21(36-22(40)19-14-16(27(30,31)32)4-9-20(19)29)23(41)38-12-10-26(11-13-38)24(42)37(3)25(43)39(26)17-5-7-18(8-6-17)44-28(33,34)35/h4-9,14-15,21H,10-13H2,1-3H3,(H,36,40)/t21-/m1/s1
DMM0BVE	CS	CC(C)[C@H](C(=O)N1CCC2(CC1)C(=O)N(C(=O)N2C3=CC=C(C=C3)OC(F)(F)F)C)NC(=O)C4=C(C=CC(=C4)C(F)(F)F)F
DMM0BVE	IK	BYITUQUWMVRENA-OAQYLSRUSA-N
DMM0BVE	IU	2-fluoro-N-[(2R)-3-methyl-1-[3-methyl-2,4-dioxo-1-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]decan-8-yl]-1-oxobutan-2-yl]-5-(trifluoromethyl)benzamide

DMDOVIZ	ID	DMDOVIZ
DMDOVIZ	DN	PMID28447479-Compound-24
DMDOVIZ	HS	Patented
DMDOVIZ	CP	X-RX DISCOVERY, INC
DMDOVIZ	DT	Small molecular drug

DMJZSWF	ID	DMJZSWF
DMJZSWF	DN	PMID28447479-Compound-26
DMJZSWF	HS	Patented
DMJZSWF	CP	BIOGEN MA INC
DMJZSWF	DT	Small molecular drug

DMVZPIO	ID	DMVZPIO
DMVZPIO	DN	PMID28447479-Compound-27
DMVZPIO	HS	Patented
DMVZPIO	CP	BIOGEN MA INC
DMVZPIO	DT	Small molecular drug

DMUBM1Y	ID	DMUBM1Y
DMUBM1Y	DN	PMID28447479-Compound-4
DMUBM1Y	HS	Patented
DMUBM1Y	DT	Small molecular drug

DMD9W6H	ID	DMD9W6H
DMD9W6H	DN	PMID28454500-Compound-10
DMD9W6H	HS	Patented
DMD9W6H	CP	REATA PHARMACEUTICALS, INC
DMD9W6H	DT	Small molecular drug
DMD9W6H	PC	68066062
DMD9W6H	MW	518.7
DMD9W6H	FM	C33H46N2O3
DMD9W6H	IC	InChI=1S/C33H46N2O3/c1-9-25(37)35-33-14-12-28(2,3)18-21(33)26-22(36)16-24-30(6)17-20(19-34)27(38)29(4,5)23(30)10-11-31(24,7)32(26,8)13-15-33/h16-17,21,23,26H,9-15,18H2,1-8H3,(H,35,37)/t21?,23-,26?,30-,31+,32+,33-/m0/s1
DMD9W6H	CS	CCC(=O)N[C@@]12CC[C@@]3(C(C1CC(CC2)(C)C)C(=O)C=C4[C@]3(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)C
DMD9W6H	IK	GTBWGDPMQABIQD-RYMYCHIXSA-N
DMD9W6H	IU	N-[(4aS,6aR,6bS,8aR,12aS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]propanamide

DM1ZFC9	ID	DM1ZFC9
DM1ZFC9	DN	PMID28454500-Compound-11
DM1ZFC9	HS	Patented
DM1ZFC9	CP	REATA PHARMACEUTICALS, INC
DM1ZFC9	DT	Small molecular drug
DM1ZFC9	PC	68066028
DM1ZFC9	MW	504.7
DM1ZFC9	FM	C32H44N2O3
DM1ZFC9	IC	InChI=1S/C32H44N2O3/c1-19(35)34-32-13-11-27(2,3)17-21(32)25-22(36)15-24-29(6)16-20(18-33)26(37)28(4,5)23(29)9-10-30(24,7)31(25,8)12-14-32/h15-16,21,23,25H,9-14,17H2,1-8H3,(H,34,35)/t21?,23-,25?,29-,30+,31+,32-/m0/s1
DM1ZFC9	CS	CC(=O)N[C@@]12CC[C@@]3(C(C1CC(CC2)(C)C)C(=O)C=C4[C@]3(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)C
DM1ZFC9	IK	MXZQJSKPUZWONN-CCCNGEJOSA-N
DM1ZFC9	IU	N-[(4aS,6aR,6bS,8aR,12aS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]acetamide

DMUY4LS	ID	DMUY4LS
DMUY4LS	DN	PMID28454500-Compound-12
DMUY4LS	HS	Patented
DMUY4LS	CP	REATA PHARMACEUTICALS, INC
DMUY4LS	DT	Small molecular drug

DM7SIVA	ID	DM7SIVA
DM7SIVA	DN	PMID28454500-Compound-13
DM7SIVA	HS	Patented
DM7SIVA	CP	REATA PHARMACEUTICALS, INC
DM7SIVA	DT	Small molecular drug
DM7SIVA	PC	73335601
DM7SIVA	MW	521.7
DM7SIVA	FM	C32H43NO5
DM7SIVA	IC	InChI=1S/C32H43NO5/c1-26(2)11-13-31(25(36)38-8)14-12-30(7)29(6)10-9-20-27(3,4)24(35)19(18-33)16-28(20,5)21(29)15-23(34)32(30,37)22(31)17-26/h15-16,20,22,37H,9-14,17H2,1-8H3/t20-,22?,28-,29+,30-,31-,32+/m0/s1
DM7SIVA	CS	C[C@@]12CC[C@@H]3[C@@](C1=CC(=O)[C@]4([C@]2(CC[C@@]5(C4CC(CC5)(C)C)C(=O)OC)C)O)(C=C(C(=O)C3(C)C)C#N)C
DM7SIVA	IK	QBHNHKNDTFTWNV-BTIYJVALSA-N
DM7SIVA	IU	methyl (4aS,6aS,6bR,8aR,12aS,14aS)-11-cyano-14a-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-3,4,5,6,7,8,8a,14b-octahydro-1H-picene-4a-carboxylate

DMAGVHX	ID	DMAGVHX
DMAGVHX	DN	PMID28454500-Compound-3
DMAGVHX	HS	Patented
DMAGVHX	CP	Chengdu Sourcebio Limited Liability Company, Peop. Rep. China.Zhenjiang Shengan Pharmaceutical Co., Ltd., Peop. Rep. China
DMAGVHX	DT	Small molecular drug

DMAIGJP	ID	DMAIGJP
DMAIGJP	DN	PMID28454500-Compound-32
DMAIGJP	HS	Patented
DMAIGJP	CP	FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DMAIGJP	DT	Small molecular drug
DMAIGJP	PC	121289291
DMAIGJP	MW	286.33
DMAIGJP	FM	C16H18N2O3
DMAIGJP	IC	InChI=1S/C16H18N2O3/c1-3-4-16(20)21-13-5-6-15-14(9-13)12(10-18-15)7-8-17-11(2)19/h3-6,9-10,18H,7-8H2,1-2H3,(H,17,19)/b4-3+
DMAIGJP	CS	C/C=C/C(=O)OC1=CC2=C(C=C1)NC=C2CCNC(=O)C
DMAIGJP	IK	YKWJUNJYDNSFHV-ONEGZZNKSA-N
DMAIGJP	IU	[3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-but-2-enoate

DMYXQU3	ID	DMYXQU3
DMYXQU3	DN	PMID28454500-Compound-33
DMYXQU3	HS	Patented
DMYXQU3	CP	FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DMYXQU3	DT	Small molecular drug
DMYXQU3	PC	121289344
DMYXQU3	MW	348.4
DMYXQU3	FM	C21H20N2O3
DMYXQU3	IC	InChI=1S/C21H20N2O3/c1-15(24)22-12-11-17-14-23-20-9-8-18(13-19(17)20)26-21(25)10-7-16-5-3-2-4-6-16/h2-10,13-14,23H,11-12H2,1H3,(H,22,24)/b10-7+
DMYXQU3	CS	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC(=O)/C=C/C3=CC=CC=C3
DMYXQU3	IK	NDJABQJCUZPRSD-JXMROGBWSA-N
DMYXQU3	IU	[3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-phenylprop-2-enoate

DMN2910	ID	DMN2910
DMN2910	DN	PMID28454500-Compound-34
DMN2910	HS	Patented
DMN2910	CP	FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DMN2910	DT	Small molecular drug
DMN2910	PC	121289250
DMN2910	MW	362.4
DMN2910	FM	C22H22N2O3
DMN2910	IC	InChI=1S/C22H22N2O3/c1-15-3-5-17(6-4-15)7-10-22(26)27-19-8-9-21-20(13-19)18(14-24-21)11-12-23-16(2)25/h3-10,13-14,24H,11-12H2,1-2H3,(H,23,25)/b10-7+
DMN2910	CS	CC1=CC=C(C=C1)/C=C/C(=O)OC2=CC3=C(C=C2)NC=C3CCNC(=O)C
DMN2910	IK	FKXPVWWTKVQISE-JXMROGBWSA-N
DMN2910	IU	[3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-(4-methylphenyl)prop-2-enoate

DM2OM4Z	ID	DM2OM4Z
DM2OM4Z	DN	PMID28454500-Compound-35
DM2OM4Z	HS	Patented
DM2OM4Z	CP	FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DM2OM4Z	DT	Small molecular drug
DM2OM4Z	PC	121289348
DM2OM4Z	MW	378.4
DM2OM4Z	FM	C22H22N2O4
DM2OM4Z	IC	InChI=1S/C22H22N2O4/c1-15(25)23-12-11-17-14-24-21-9-8-19(13-20(17)21)28-22(26)10-5-16-3-6-18(27-2)7-4-16/h3-10,13-14,24H,11-12H2,1-2H3,(H,23,25)/b10-5+
DM2OM4Z	CS	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC(=O)/C=C/C3=CC=C(C=C3)OC
DM2OM4Z	IK	XTKZTJVFEUTPPV-BJMVGYQFSA-N
DM2OM4Z	IU	[3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-(4-methoxyphenyl)prop-2-enoate

DM5RZWG	ID	DM5RZWG
DM5RZWG	DN	PMID28454500-Compound-36
DM5RZWG	HS	Patented
DM5RZWG	CP	FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DM5RZWG	DT	Small molecular drug
DM5RZWG	PC	121289252
DM5RZWG	MW	366.4
DM5RZWG	FM	C21H19FN2O3
DM5RZWG	IC	InChI=1S/C21H19FN2O3/c1-14(25)23-11-10-16-13-24-20-8-7-18(12-19(16)20)27-21(26)9-4-15-2-5-17(22)6-3-15/h2-9,12-13,24H,10-11H2,1H3,(H,23,25)/b9-4+
DM5RZWG	CS	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC(=O)/C=C/C3=CC=C(C=C3)F
DM5RZWG	IK	SAMHXGDYEAOVQC-RUDMXATFSA-N
DM5RZWG	IU	[3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-(4-fluorophenyl)prop-2-enoate

DM83P6H	ID	DM83P6H
DM83P6H	DN	PMID28454500-Compound-37
DM83P6H	HS	Patented
DM83P6H	CP	FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DM83P6H	DT	Small molecular drug
DM83P6H	PC	121289347
DM83P6H	MW	393.4
DM83P6H	FM	C21H19N3O5
DM83P6H	IC	InChI=1S/C21H19N3O5/c1-14(25)22-11-10-16-13-23-20-8-7-18(12-19(16)20)29-21(26)9-4-15-2-5-17(6-3-15)24(27)28/h2-9,12-13,23H,10-11H2,1H3,(H,22,25)/b9-4+
DM83P6H	CS	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC(=O)/C=C/C3=CC=C(C=C3)[N+](=O)[O-]
DM83P6H	IK	HAJBAZSPWITWPC-RUDMXATFSA-N
DM83P6H	IU	[3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-(4-nitrophenyl)prop-2-enoate

DM9TVWJ	ID	DM9TVWJ
DM9TVWJ	DN	PMID28454500-Compound-40
DM9TVWJ	HS	Patented
DM9TVWJ	CP	China Pharmaceutical University
DM9TVWJ	DT	Small molecular drug
DM9TVWJ	PC	5316743
DM9TVWJ	MW	278.3
DM9TVWJ	FM	C18H14O3
DM9TVWJ	IC	InChI=1S/C18H14O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-7,10H,8H2,1-2H3
DM9TVWJ	CS	CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C(C=CC=C43)C
DM9TVWJ	IK	HARGZZNYNSYSGJ-UHFFFAOYSA-N
DM9TVWJ	IU	1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione
DM9TVWJ	CA	CAS 87205-99-0

DMGAW81	ID	DMGAW81
DMGAW81	DN	PMID28454500-Compound-41
DMGAW81	HS	Patented
DMGAW81	CP	Guangdong Hospital of Traditional Chinese Medicine
DMGAW81	DT	Small molecular drug
DMGAW81	PC	11000442
DMGAW81	MW	280.32
DMGAW81	FM	C15H20O5
DMGAW81	IC	InChI=1S/C15H20O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8,10-11,13H,2,4-7H2,1,3H3/t8-,10+,11+,13-,14-,15-/m1/s1
DMGAW81	CS	C[C@@H]1CC[C@H]2C(=C)C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C
DMGAW81	IK	IGEBZMMCKFUABB-KPHNHPKPSA-N
DMGAW81	IU	(1R,4S,5R,8S,12S,13R)-1,5-dimethyl-9-methylidene-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one

DM5NJDK	ID	DM5NJDK
DM5NJDK	DN	PMID28454500-Compound-49
DM5NJDK	HS	Patented
DM5NJDK	CP	China Medical University
DM5NJDK	DT	Small molecular drug

DMQPKCD	ID	DMQPKCD
DMQPKCD	DN	PMID28454500-Compound-50
DMQPKCD	HS	Patented
DMQPKCD	CP	Tsukuba University, JapaKyorin Pharmaceutical Co., Ltd
DMQPKCD	DT	Small molecular drug
DMQPKCD	PC	193653
DMQPKCD	MW	179.2
DMQPKCD	FM	C5H9NO4S
DMQPKCD	IC	InChI=1S/C5H9NO4S/c6-3(5(9)10)1-11-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
DMQPKCD	CS	C([C@@H](C(=O)O)N)SCC(=O)O
DMQPKCD	IK	GBFLZEXEOZUWRN-VKHMYHEASA-N
DMQPKCD	IU	(2R)-2-amino-3-(carboxymethylsulfanyl)propanoic acid
DMQPKCD	CA	CAS 638-23-3
DMQPKCD	CB	CHEBI:16163

DMTK9M6	ID	DMTK9M6
DMTK9M6	DN	PMID28454500-Compound-57
DMTK9M6	HS	Patented
DMTK9M6	CP	China Pharmaceutical University
DMTK9M6	DT	Small molecular drug
DMTK9M6	PC	135315519
DMTK9M6	MW	577.6
DMTK9M6	FM	C31H31NO8S
DMTK9M6	IC	InChI=1S/C31H31NO8S/c1-19-15-20(2)31(21(3)16-19)41(37,38)32(18-30(35)36)26-13-14-27(25-8-6-5-7-24(25)26)40-28(17-29(33)34)22-9-11-23(39-4)12-10-22/h5-16,28H,17-18H2,1-4H3,(H,33,34)(H,35,36)
DMTK9M6	CS	CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC(=O)O)C2=CC=C(C3=CC=CC=C32)OC(CC(=O)O)C4=CC=C(C=C4)OC)C
DMTK9M6	IK	PSPVUIANHULZSQ-UHFFFAOYSA-N
DMTK9M6	IU	3-[4-[carboxymethyl-(2,4,6-trimethylphenyl)sulfonylamino]naphthalen-1-yl]oxy-3-(4-methoxyphenyl)propanoic acid

DMDEHYR	ID	DMDEHYR
DMDEHYR	DN	PMID28454500-Compound-58
DMDEHYR	HS	Patented
DMDEHYR	CP	China Pharmaceutical University
DMDEHYR	DT	Small molecular drug

DMQWPSF	ID	DMQWPSF
DMQWPSF	DN	PMID28454500-Compound-59
DMQWPSF	HS	Patented
DMQWPSF	CP	China Pharmaceutical University
DMQWPSF	DT	Small molecular drug

DM1I9JC	ID	DM1I9JC
DM1I9JC	DN	PMID28454500-Compound-60
DM1I9JC	HS	Patented
DM1I9JC	CP	China Pharmaceutical University
DM1I9JC	DT	Small molecular drug

DM6BQFA	ID	DM6BQFA
DM6BQFA	DN	PMID28454500-Compound-8
DM6BQFA	HS	Patented
DM6BQFA	CP	REATA PHARMACEUTICALS, INC. ANDERSON, Eric JIANG, Xin VISNICK, Melean BENDER, Christopher, F. LIU, Xiaofeng
DM6BQFA	DT	Small molecular drug
DM6BQFA	PC	66546002
DM6BQFA	MW	491.7
DM6BQFA	FM	C31H41NO4
DM6BQFA	IC	InChI=1S/C31H41NO4/c1-18-20-8-9-29(5)23(28(20,4)15-19(17-32)25(18)34)14-22(33)24-21-16-27(2,3)10-12-31(21,26(35)36-7)13-11-30(24,29)6/h14-15,18,20-21,24H,8-13,16H2,1-7H3/t18-,20-,21?,24?,28-,29+,30+,31-/m0/s1
DM6BQFA	CS	C[C@H]1[C@@H]2CC[C@@]3(C(=CC(=O)C4[C@]3(CC[C@@]5(C4CC(CC5)(C)C)C(=O)OC)C)[C@]2(C=C(C1=O)C#N)C)C
DM6BQFA	IK	MAOZWESYDBKVCY-HZCQYKMZSA-N
DM6BQFA	IU	methyl (4aS,6aR,6bS,8aS,9S,12aR)-11-cyano-2,2,6a,6b,9,12a-hexamethyl-10,14-dioxo-3,4,5,6,7,8,8a,9,14a,14b-decahydro-1H-picene-4a-carboxylate

DM3HR7F	ID	DM3HR7F
DM3HR7F	DN	PMID28454500-Compound-9
DM3HR7F	HS	Patented
DM3HR7F	CP	REATA PHARMACEUTICALS, INC. ANDERSON, Eric JIANG, Xin VISNICK, Melean BENDER, Christopher, F. LIU, Xiaofeng
DM3HR7F	DT	Small molecular drug
DM3HR7F	PC	66546189
DM3HR7F	MW	463.7
DM3HR7F	FM	C30H41NO3
DM3HR7F	IC	InChI=1S/C30H41NO3/c1-18-20-7-8-28(5)23(27(20,4)14-19(16-31)25(18)34)13-22(33)24-21-15-26(2,3)9-11-30(21,17-32)12-10-29(24,28)6/h13-14,18,20-21,24,32H,7-12,15,17H2,1-6H3/t18-,20-,21?,24?,27-,28+,29+,30+/m0/s1
DM3HR7F	CS	C[C@H]1[C@@H]2CC[C@@]3(C(=CC(=O)C4[C@]3(CC[C@@]5(C4CC(CC5)(C)C)CO)C)[C@]2(C=C(C1=O)C#N)C)C
DM3HR7F	IK	UHGNLMUWOYPXQG-WDPAWIMBSA-N
DM3HR7F	IU	(4S,4aS,6aS,6bR,8aS,14bR)-8a-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-3,13-dioxo-4a,5,6,6a,7,8,9,10,12,12a-decahydro-4H-picene-2-carbonitrile

DMJ1KFO	ID	DMJ1KFO
DMJ1KFO	DN	PMID28454500-Compound-91
DMJ1KFO	HS	Patented
DMJ1KFO	CP	THE HAMNER INSTITUTES
DMJ1KFO	DT	Small molecular drug

DM1RS4X	ID	DM1RS4X
DM1RS4X	DN	PMID28454500-Compound-92
DM1RS4X	HS	Patented
DM1RS4X	CP	THE HAMNER INSTITUTES
DM1RS4X	DT	Small molecular drug

DMMDK6B	ID	DMMDK6B
DMMDK6B	DN	PMID28454500-Compound-93
DMMDK6B	HS	Patented
DMMDK6B	CP	THE HAMNER INSTITUTES
DMMDK6B	DT	Small molecular drug
DMMDK6B	PC	77174
DMMDK6B	MW	150.18
DMMDK6B	FM	C8H10N2O
DMMDK6B	IC	InChI=1S/C8H10N2O/c1-6-2-4-7(5-3-6)8(11)10-9/h2-5H,9H2,1H3,(H,10,11)
DMMDK6B	CS	CC1=CC=C(C=C1)C(=O)NN
DMMDK6B	IK	MFFVZXOPRXMVET-UHFFFAOYSA-N
DMMDK6B	IU	4-methylbenzohydrazide
DMMDK6B	CA	CAS 3619-22-5

DM5Q962	ID	DM5Q962
DM5Q962	DN	PMID28454500-Compound-94
DM5Q962	HS	Patented
DM5Q962	CP	THE HAMNER INSTITUTES
DM5Q962	DT	Small molecular drug
DM5Q962	PC	23527
DM5Q962	MW	114.19
DM5Q962	FM	C6H14N2
DM5Q962	IC	InChI=1S/C6H14N2/c7-5-6-1-3-8-4-2-6/h6,8H,1-5,7H2
DM5Q962	CS	C1CNCCC1CN
DM5Q962	IK	LTEKQAPRXFBRNN-UHFFFAOYSA-N
DM5Q962	IU	piperidin-4-ylmethanamine
DM5Q962	CA	CAS 7144-05-0

DM9L2VR	ID	DM9L2VR
DM9L2VR	DN	PMID28454500-Compound-95
DM9L2VR	HS	Patented
DM9L2VR	CP	THE HAMNER INSTITUTES
DM9L2VR	DT	Small molecular drug
DM9L2VR	PC	21450
DM9L2VR	MW	151.17
DM9L2VR	FM	C7H9N3O
DM9L2VR	IC	InChI=1S/C7H9N3O/c8-6-3-1-5(2-4-6)7(11)10-9/h1-4H,8-9H2,(H,10,11)
DM9L2VR	CS	C1=CC(=CC=C1C(=O)NN)N
DM9L2VR	IK	WPBZMCGPFHZRHJ-UHFFFAOYSA-N
DM9L2VR	IU	4-aminobenzohydrazide
DM9L2VR	CA	CAS 5351-17-7

DM2A75P	ID	DM2A75P
DM2A75P	DN	PMID28454500-Compound-96
DM2A75P	HS	Patented
DM2A75P	CP	THE HAMNER INSTITUTES
DM2A75P	DT	Small molecular drug
DM2A75P	PC	2761171
DM2A75P	MW	166.25
DM2A75P	FM	C8H10N2S
DM2A75P	IC	InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)
DM2A75P	CS	CCC1=NC=CC(=C1)C(=S)N
DM2A75P	IK	AEOCXXJPGCBFJA-UHFFFAOYSA-N
DM2A75P	IU	2-ethylpyridine-4-carbothioamide
DM2A75P	CA	CAS 536-33-4
DM2A75P	CB	CHEBI:4885

DMHV75N	ID	DMHV75N
DMHV75N	DN	PMID28460551-Compound-1
DMHV75N	HS	Patented
DMHV75N	CP	BOSTON BIOMEDICAL, INC
DMHV75N	DT	Small molecular drug
DMHV75N	PC	25190990
DMHV75N	MW	539.7
DMHV75N	FM	C31H33N5O2S
DMHV75N	IC	InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-
DMHV75N	CS	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)C4=CSC(=N4)C5=CC=CC=C5)NC2=O)C
DMHV75N	IK	QDWKGEFGLQMDAM-ULJHMMPZSA-N
DMHV75N	IU	N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[(Z)-[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide
DMHV75N	CA	CAS 1129403-56-0
DMHV75N	DE	Breast cancer; Pancreatic cancer; Lung cancer; Gastric adenocarcinoma; Colon cancer; Colorectal cancer; Prostate cancer

DM4DOUB	ID	DM4DOUB
DM4DOUB	DN	PMID28460551-Compound-2
DM4DOUB	HS	Patented
DM4DOUB	DT	Small molecular drug
DM4DOUB	PC	5329102
DM4DOUB	MW	398.5
DM4DOUB	FM	C22H27FN4O2
DM4DOUB	IC	InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
DM4DOUB	CS	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C
DM4DOUB	IK	WINHZLLDWRZWRT-ATVHPVEESA-N
DM4DOUB	IU	N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DM4DOUB	CA	CAS 557795-19-4
DM4DOUB	CB	CHEBI:38940

DMA1FRM	ID	DMA1FRM
DMA1FRM	DN	PMID28460551-Compound-3
DMA1FRM	HS	Patented
DMA1FRM	CP	Whitehead Institute for Biomedical Research
DMA1FRM	DT	Small molecular drug
DMA1FRM	PC	5083
DMA1FRM	MW	457.5
DMA1FRM	FM	C25H23N5O2S
DMA1FRM	IC	InChI=1S/C25H23N5O2S/c1-29-13-17(15-7-2-4-9-19(15)29)21-22(24(32)28-23(21)31)18-14-30(11-6-12-33-25(26)27)20-10-5-3-8-16(18)20/h2-5,7-10,13-14H,6,11-12H2,1H3,(H3,26,27)(H,28,31,32)
DMA1FRM	CS	CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CCCSC(=N)N
DMA1FRM	IK	DSXXEELGXBCYNQ-UHFFFAOYSA-N
DMA1FRM	IU	3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate
DMA1FRM	CA	CAS 125314-64-9
DMA1FRM	CB	CHEBI:38912

DMT7U1O	ID	DMT7U1O
DMT7U1O	DN	PMID28460551-Compound-6
DMT7U1O	HS	Patented
DMT7U1O	DT	Small molecular drug

DMLZV70	ID	DMLZV70
DMLZV70	DN	PMID28594589-Compound-TABLE3C1
DMLZV70	HS	Patented
DMLZV70	CP	Novartis
DMLZV70	DT	Small molecular drug

DMPK7IU	ID	DMPK7IU
DMPK7IU	DN	PMID28594589-Compound-TABLE3C12
DMPK7IU	HS	Patented
DMPK7IU	CP	Allomek Therapeutics
DMPK7IU	DT	Small molecular drug

DM4KWVF	ID	DM4KWVF
DM4KWVF	DN	PMID28594589-Compound-TABLE3C14
DM4KWVF	HS	Patented
DM4KWVF	CP	The Regents of the University of Michigan
DM4KWVF	DT	Small molecular drug

DMVYG0U	ID	DMVYG0U
DMVYG0U	DN	PMID28594589-Compound-TABLE3C2
DMVYG0U	HS	Patented
DMVYG0U	CP	Novartis
DMVYG0U	DT	Small molecular drug

DMBTZ8I	ID	DMBTZ8I
DMBTZ8I	DN	PMID28621580-Compound-WO2013036866C66
DMBTZ8I	HS	Patented
DMBTZ8I	CP	THE JOHNS HOPKINS UNIVERSITY LIU, Jun, O. SHI, Wei PASUNOOTI, Kalyan, Kumar
DMBTZ8I	DT	Small molecular drug
DMBTZ8I	DE	Solid tumour/cancer

DM15OKA	ID	DM15OKA
DM15OKA	DN	PMID28621580-Compound-WO2013112959C68
DM15OKA	HS	Patented
DM15OKA	CP	ANGION BIOMEDICA CORP
DM15OKA	DT	Small molecular drug
DM15OKA	DE	Fibrosis

DMR58TX	ID	DMR58TX
DMR58TX	DN	PMID28621580-Compound-WO2014079545C69
DMR58TX	HS	Patented
DMR58TX	CP	KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
DMR58TX	DT	Small molecular drug

DMX96FI	ID	DMX96FI
DMX96FI	DN	PMID28621580-Compound-WO2015089220C70
DMX96FI	HS	Patented
DMX96FI	CP	ALLERGAN, INC
DMX96FI	DT	Small molecular drug
DMX96FI	DE	Retinopathy; Age-related macular degeneration

DM36P7T	ID	DM36P7T
DM36P7T	DN	PMID28627961-Compound-22
DM36P7T	HS	Patented
DM36P7T	CP	Glenmark Pharmaceuticals S.A
DM36P7T	DT	Small molecular drug
DM36P7T	PC	86692276
DM36P7T	MW	574
DM36P7T	FM	C28H24ClF4N5O2
DM36P7T	IC	InChI=1S/C28H24ClF4N5O2/c1-27(2,3)26(40)34-13-15-10-11-19(29)21(22(15)30)25(39)38-20-9-5-8-18-23(20)35-14-36-24(18)37-17-7-4-6-16(12-17)28(31,32)33/h4-12,14H,13H2,1-3H3,(H,34,40)(H,38,39)(H,35,36,37)
DM36P7T	CS	CC(C)(C)C(=O)NCC1=C(C(=C(C=C1)Cl)C(=O)NC2=CC=CC3=C2N=CN=C3NC4=CC=CC(=C4)C(F)(F)F)F
DM36P7T	IK	NPMRJEGXUPKUTE-UHFFFAOYSA-N
DM36P7T	IU	6-chloro-3-[(2,2-dimethylpropanoylamino)methyl]-2-fluoro-N-[4-[3-(trifluoromethyl)anilino]quinazolin-8-yl]benzamide

DMRLU8I	ID	DMRLU8I
DMRLU8I	DN	PMID28627961-Compound-30
DMRLU8I	HS	Patented
DMRLU8I	CP	GLENMARK PHARMACEUTICALS S.A
DMRLU8I	DT	Small molecular drug

DMLGYXW	ID	DMLGYXW
DMLGYXW	DN	PMID28627961-Compound-31
DMLGYXW	HS	Patented
DMLGYXW	CP	GLENMARK PHARMACEUTICALS S.A
DMLGYXW	DT	Small molecular drug
DMLGYXW	PC	71766655
DMLGYXW	MW	520.9
DMLGYXW	FM	C27H19ClF2N4O3
DMLGYXW	IC	InChI=1S/C27H19ClF2N4O3/c28-18-2-1-3-19(29)22(18)33-27-32-21-13-17(24-25(23(21)34-27)37-11-10-36-24)26(35)31-16-9-8-15(20(30)12-16)7-6-14-4-5-14/h1-3,8-9,12-14H,4-5,10-11H2,(H,31,35)(H2,32,33,34)
DMLGYXW	CS	C1CC1C#CC2=C(C=C(C=C2)NC(=O)C3=CC4=C(C5=C3OCCO5)N=C(N4)NC6=C(C=CC=C6Cl)F)F
DMLGYXW	IK	CSOLVYOAIFCMHY-UHFFFAOYSA-N
DMLGYXW	IU	2-(2-chloro-6-fluoroanilino)-N-[4-(2-cyclopropylethynyl)-3-fluorophenyl]-7,8-dihydro-3H-[1,4]dioxino[2,3-e]benzimidazole-5-carboxamide

DM5IZKD	ID	DM5IZKD
DM5IZKD	DN	PMID28627961-Compound-32
DM5IZKD	HS	Patented
DM5IZKD	CP	NOVASAID AB [SE]
DM5IZKD	DT	Small molecular drug

DMWV4YE	ID	DMWV4YE
DMWV4YE	DN	PMID28627961-Compound-33
DMWV4YE	HS	Patented
DMWV4YE	CP	GLENMARK PHARMACEUTICALS S.A
DMWV4YE	DT	Small molecular drug

DMODL3P	ID	DMODL3P
DMODL3P	DN	PMID28627961-Compound-41
DMODL3P	HS	Patented
DMODL3P	CP	Astra Zeneca AB 
DMODL3P	DT	Small molecular drug
DMODL3P	PC	42630323
DMODL3P	MW	453.9
DMODL3P	FM	C18H16ClN3O5S2
DMODL3P	IC	InChI=1S/C18H16ClN3O5S2/c1-27-18-15(19)10-13(11-21-18)12-5-4-6-14(9-12)29(25,26)22-16-7-2-3-8-17(16)28(20,23)24/h2-11,22H,1H3,(H2,20,23,24)
DMODL3P	CS	COC1=C(C=C(C=N1)C2=CC(=CC=C2)S(=O)(=O)NC3=CC=CC=C3S(=O)(=O)N)Cl
DMODL3P	IK	WVXMZKAIOMLXRH-UHFFFAOYSA-N
DMODL3P	IU	2-[[3-(5-chloro-6-methoxypyridin-3-yl)phenyl]sulfonylamino]benzenesulfonamide

DM7ATLP	ID	DM7ATLP
DM7ATLP	DN	PMID28627961-Compound-44
DM7ATLP	HS	Patented
DM7ATLP	CP	EBERHARD KARLS UNIVERSIT TINGEN WERZ, Oliver KOEBERLE, Andreas
DM7ATLP	DT	Small molecular drug
DM7ATLP	PC	10327116
DM7ATLP	MW	668.8
DM7ATLP	FM	C38H52O10
DM7ATLP	IC	InChI=1S/C38H52O10/c1-15(2)18(22-29(43)35(7,8)33(47)36(9,10)30(22)44)20-26(40)21(28(42)24(27(20)41)25(39)17(5)6)19(16(3)4)23-31(45)37(11,12)34(48)38(13,14)32(23)46/h15-19,40-43,45H,1-14H3
DM7ATLP	CS	CC(C)C(C1=C(C(=C(C(=C1O)C(=O)C(C)C)O)C(C2=C(C(C(=O)C(C2=O)(C)C)(C)C)O)C(C)C)O)C3=C(C(C(=O)C(C3=O)(C)C)(C)C)O
DM7ATLP	IK	BIHONVMOJSPPFL-UHFFFAOYSA-N
DM7ATLP	IU	5-hydroxy-2,2,6,6-tetramethyl-4-[2-methyl-1-[2,4,6-trihydroxy-3-[1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohexen-1-yl)-2-methylpropyl]-5-(2-methylpropanoyl)phenyl]propyl]cyclohex-4-ene-1,3-dione

DMBN3X4	ID	DMBN3X4
DMBN3X4	DN	PMID28766366-Compound-Scheme11
DMBN3X4	HS	Patented
DMBN3X4	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE UNIVERSITE PARIS DIDEROT PARIS 7
DMBN3X4	DT	Small molecular drug
DMBN3X4	PC	72792831
DMBN3X4	MW	318.3
DMBN3X4	FM	C19H14N2O3
DMBN3X4	IC	InChI=1S/C19H14N2O3/c22-14-4-1-11(2-5-14)16-10-21-19-15(16)7-13(9-20-19)12-3-6-17(23)18(24)8-12/h1-10,22-24H,(H,20,21)
DMBN3X4	CS	C1=CC(=CC=C1C2=CNC3=C2C=C(C=N3)C4=CC(=C(C=C4)O)O)O
DMBN3X4	IK	HBCKPNCVCXUSEU-UHFFFAOYSA-N
DMBN3X4	IU	4-[3-(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]benzene-1,2-diol

DMMJ5SN	ID	DMMJ5SN
DMMJ5SN	DN	PMID28766366-Compound-Scheme12-1
DMMJ5SN	HS	Patented
DMMJ5SN	CP	SAMUMED, LLC
DMMJ5SN	DT	Small molecular drug
DMMJ5SN	PC	89450758
DMMJ5SN	MW	412.5
DMMJ5SN	FM	C24H24N6O
DMMJ5SN	IC	InChI=1S/C24H24N6O/c31-24(27-20-5-4-8-25-15-20)23-21-12-18(6-7-22(21)28-29-23)19-11-17(13-26-14-19)16-30-9-2-1-3-10-30/h4-8,11-15H,1-3,9-10,16H2,(H,27,31)(H,28,29)
DMMJ5SN	CS	C1CCN(CC1)CC2=CC(=CN=C2)C3=CC4=C(C=C3)NN=C4C(=O)NC5=CN=CC=C5
DMMJ5SN	IK	VCNIUYPAMGFBLR-UHFFFAOYSA-N
DMMJ5SN	IU	5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-N-pyridin-3-yl-1H-indazole-3-carboxamide

DM3BA1L	ID	DM3BA1L
DM3BA1L	DN	PMID28766366-Compound-Scheme12-2
DM3BA1L	HS	Patented
DM3BA1L	CP	SAMUMED, LLC
DM3BA1L	DT	Small molecular drug
DM3BA1L	PC	118381061
DM3BA1L	MW	426.5
DM3BA1L	FM	C25H26N6O
DM3BA1L	IC	InChI=1S/C25H26N6O/c1-17-9-21(15-26-12-17)28-25(32)24-22-11-19(5-6-23(22)29-30-24)20-10-18(13-27-14-20)16-31-7-3-2-4-8-31/h5-6,9-15H,2-4,7-8,16H2,1H3,(H,28,32)(H,29,30)
DM3BA1L	CS	CC1=CC(=CN=C1)NC(=O)C2=NNC3=C2C=C(C=C3)C4=CN=CC(=C4)CN5CCCCC5
DM3BA1L	IK	LIXXQBRPVXEVJX-UHFFFAOYSA-N
DM3BA1L	IU	N-(5-methylpyridin-3-yl)-5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide

DM4V3AY	ID	DM4V3AY
DM4V3AY	DN	PMID28766366-Compound-Scheme12-3
DM4V3AY	HS	Patented
DM4V3AY	CP	SAMUMED, LLC
DM4V3AY	DT	Small molecular drug
DM4V3AY	PC	89458694
DM4V3AY	MW	426.5
DM4V3AY	FM	C25H26N6O
DM4V3AY	IC	InChI=1S/C25H26N6O/c1-17-5-7-21(15-27-17)28-25(32)24-22-12-19(6-8-23(22)29-30-24)20-11-18(13-26-14-20)16-31-9-3-2-4-10-31/h5-8,11-15H,2-4,9-10,16H2,1H3,(H,28,32)(H,29,30)
DM4V3AY	CS	CC1=NC=C(C=C1)NC(=O)C2=NNC3=C2C=C(C=C3)C4=CN=CC(=C4)CN5CCCCC5
DM4V3AY	IK	HVEOEVJLUUUHNZ-UHFFFAOYSA-N
DM4V3AY	IU	N-(6-methylpyridin-3-yl)-5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide

DM5BG6L	ID	DM5BG6L
DM5BG6L	DN	PMID28766366-Compound-Scheme12-4
DM5BG6L	HS	Patented
DM5BG6L	CP	SAMUMED, LLC
DM5BG6L	DT	Small molecular drug
DM5BG6L	PC	118381715
DM5BG6L	MW	470.6
DM5BG6L	FM	C27H30N6O2
DM5BG6L	IC	InChI=1S/C27H30N6O2/c1-18(2)35-25-9-7-22(16-29-25)30-27(34)26-23-13-20(6-8-24(23)31-32-26)21-12-19(14-28-15-21)17-33-10-4-3-5-11-33/h6-9,12-16,18H,3-5,10-11,17H2,1-2H3,(H,30,34)(H,31,32)
DM5BG6L	CS	CC(C)OC1=NC=C(C=C1)NC(=O)C2=NNC3=C2C=C(C=C3)C4=CN=CC(=C4)CN5CCCCC5
DM5BG6L	IK	QWXGMMPJHDIFKI-UHFFFAOYSA-N
DM5BG6L	IU	5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-N-(6-propan-2-yloxypyridin-3-yl)-1H-indazole-3-carboxamide

DMLQCYV	ID	DMLQCYV
DMLQCYV	DN	PMID28766366-Compound-Scheme13INDY
DMLQCYV	HS	Patented
DMLQCYV	CP	SIRTRIS PHARMACEUTICALS, INC. PERNI, Robert, B. BEMIS, Jean NUNES, Joseph, J. SZCZEPANKIEWICZ, Bruce, G
DMLQCYV	DT	Small molecular drug
DMLQCYV	PC	44136031
DMLQCYV	MW	235.3
DMLQCYV	FM	C12H13NO2S
DMLQCYV	IC	InChI=1S/C12H13NO2S/c1-3-13-10-7-9(15)4-5-11(10)16-12(13)6-8(2)14/h4-7,15H,3H2,1-2H3/b12-6-
DMLQCYV	CS	CCN\\1C2=C(C=CC(=C2)O)S/C1=C\\C(=O)C
DMLQCYV	IK	GCSZJMUFYOAHFY-SDQBBNPISA-N
DMLQCYV	IU	(1Z)-1-(3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene)propan-2-one

DMBQ0RN	ID	DMBQ0RN
DMBQ0RN	DN	PMID28766366-Compound-Scheme14BINDY
DMBQ0RN	HS	Patented
DMBQ0RN	CP	KYOTO UNIVERSITY
DMBQ0RN	DT	Small molecular drug

DMVG275	ID	DMVG275
DMVG275	DN	PMID28766366-Compound-Scheme15-1
DMVG275	HS	Patented
DMVG275	CP	LYTIX BIOPHARMA AS
DMVG275	DT	Small molecular drug
DMVG275	PC	655817
DMVG275	MW	222.27
DMVG275	FM	C10H10N2O2S
DMVG275	IC	InChI=1S/C10H10N2O2S/c1-6(13)11-10-12-8-5-7(14-2)3-4-9(8)15-10/h3-5H,1-2H3,(H,11,12,13)
DMVG275	CS	CC(=O)NC1=NC2=C(S1)C=CC(=C2)OC
DMVG275	IK	ZKNFVQNHIHCHEW-UHFFFAOYSA-N
DMVG275	IU	N-(5-methoxy-1,3-benzothiazol-2-yl)acetamide

DMU8ENF	ID	DMU8ENF
DMU8ENF	DN	PMID28766366-Compound-Scheme15-2
DMU8ENF	HS	Patented
DMU8ENF	CP	LYTIX BIOPHARMA AS
DMU8ENF	DT	Small molecular drug
DMU8ENF	PC	118295558
DMU8ENF	MW	208.24
DMU8ENF	FM	C9H8N2O2S
DMU8ENF	IC	InChI=1S/C9H8N2O2S/c1-5(12)10-9-11-7-4-6(13)2-3-8(7)14-9/h2-4,13H,1H3,(H,10,11,12)
DMU8ENF	CS	CC(=O)NC1=NC2=C(S1)C=CC(=C2)O
DMU8ENF	IK	YOMAHEQEXVNJNF-UHFFFAOYSA-N
DMU8ENF	IU	N-(5-hydroxy-1,3-benzothiazol-2-yl)acetamide

DMA423P	ID	DMA423P
DMA423P	DN	PMID28766366-Compound-Scheme15-3
DMA423P	HS	Patented
DMA423P	CP	LYTIX BIOPHARMA AS
DMA423P	DT	Small molecular drug
DMA423P	PC	731719
DMA423P	MW	237.24
DMA423P	FM	C9H7N3O3S
DMA423P	IC	InChI=1S/C9H7N3O3S/c1-5(13)10-9-11-7-3-2-6(12(14)15)4-8(7)16-9/h2-4H,1H3,(H,10,11,13)
DMA423P	CS	CC(=O)NC1=NC2=C(S1)C=C(C=C2)[N+](=O)[O-]
DMA423P	IK	XARDSBCDZPSYTN-UHFFFAOYSA-N
DMA423P	IU	N-(6-nitro-1,3-benzothiazol-2-yl)acetamide
DMA423P	CA	CAS 80395-50-2

DMQ5UEA	ID	DMQ5UEA
DMQ5UEA	DN	PMID28766366-Compound-Scheme16DMAT
DMQ5UEA	HS	Patented
DMQ5UEA	CP	SELVITA S.A
DMQ5UEA	DT	Small molecular drug
DMQ5UEA	PC	5326976
DMQ5UEA	MW	476.79
DMQ5UEA	FM	C9H7Br4N3
DMQ5UEA	IC	InChI=1S/C9H7Br4N3/c1-16(2)9-14-7-5(12)3(10)4(11)6(13)8(7)15-9/h1-2H3,(H,14,15)
DMQ5UEA	CS	CN(C)C1=NC2=C(N1)C(=C(C(=C2Br)Br)Br)Br
DMQ5UEA	IK	SLPJGDQJLTYWCI-UHFFFAOYSA-N
DMQ5UEA	IU	4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine
DMQ5UEA	CA	CAS 749234-11-5

DMBQ21J	ID	DMBQ21J
DMBQ21J	DN	PMID28766366-Compound-Scheme18
DMBQ21J	HS	Patented
DMBQ21J	CP	SERVIER LAB [FRVERNALIS (R&D) LTD [GB]
DMBQ21J	DT	Small molecular drug

DMHIUWX	ID	DMHIUWX
DMHIUWX	DN	PMID28766366-Compound-Scheme1WO2011135259
DMHIUWX	HS	Patented
DMHIUWX	CP	CENTRE NAT RECH SCIENT [FRUNIV ORLEANS [FRROUTIER SYLVAIN [FRGUILLAUMET GERALD [FRTIKAD ABDELLATIF [BEDEHBI OUSSAMA [FR]
DMHIUWX	DT	Small molecular drug
DMHIUWX	PC	136335012
DMHIUWX	MW	320.3
DMHIUWX	FM	C18H16N4O2
DMHIUWX	IC	InChI=1S/C18H16N4O2/c23-14-6-4-12(5-7-14)18-20-11-16-15(21-18)9-13(10-19-16)22-8-2-1-3-17(22)24/h4-7,9-11,23H,1-3,8H2
DMHIUWX	CS	C1CCN(C(=O)C1)C2=CC3=NC(=NC=C3N=C2)C4=CC=C(C=C4)O
DMHIUWX	IK	GIUNPBXEXJKOFE-UHFFFAOYSA-N
DMHIUWX	IU	1-[2-(4-hydroxyphenyl)pyrido[3,2-d]pyrimidin-7-yl]piperidin-2-one

DMWTRUK	ID	DMWTRUK
DMWTRUK	DN	PMID28766366-Compound-Scheme21Left
DMWTRUK	HS	Patented
DMWTRUK	CP	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. HIGGINS, Jonathan PATNAIK, Debasis ULYANOVA, Natalia STEIN, Ross L. XIAN, Jun GLICKSMAN, Marcie CUNY, Gregory D
DMWTRUK	DT	Small molecular drug

DMF3X40	ID	DMF3X40
DMF3X40	DN	PMID28766366-Compound-Scheme21Right
DMF3X40	HS	Patented
DMF3X40	CP	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. PRESIDENT AND FELLOWS OF HARVARD COLLEGE UNIVERSITY PAUL CEZANNE MARSEILLE III/AIX 
DMF3X40	DT	Small molecular drug
DMF3X40	PC	53390843
DMF3X40	MW	328.4
DMF3X40	FM	C18H20N2O2S
DMF3X40	IC	InChI=1S/C18H20N2O2S/c1-21-12-4-6-16-14(10-12)18(23-9-3-8-19)15-11-13(22-2)5-7-17(15)20-16/h4-7,10-11H,3,8-9,19H2,1-2H3
DMF3X40	CS	COC1=CC2=C(C=C1)N=C3C=CC(=CC3=C2SCCCN)OC
DMF3X40	IK	ZFOMCSNUEHMROO-UHFFFAOYSA-N
DMF3X40	IU	3-(2,7-dimethoxyacridin-9-yl)sulfanylpropan-1-amine

DMD8N5O	ID	DMD8N5O
DMD8N5O	DN	PMID28766366-Compound-Scheme22Middle
DMD8N5O	HS	Patented
DMD8N5O	CP	TRANSLATIONAL GENOMICS RESEARCH INSTITUTE DUNCKLEY, Travis
DMD8N5O	DT	Small molecular drug

DMRLSKV	ID	DMRLSKV
DMRLSKV	DN	PMID28766366-Compound-Scheme23MPPDerivatives
DMRLSKV	HS	Patented
DMRLSKV	CP	MEDIPROPHARMA, INC. SHCHERBAKOVA, Irina NIKOLICH, Karoly NIKOLYUKIN, Yuri
DMRLSKV	DT	Small molecular drug

DMBWAV7	ID	DMBWAV7
DMBWAV7	DN	PMID28766366-Compound-Scheme24-11H-pyrido[4,3-a]carbazole
DMBWAV7	HS	Patented
DMBWAV7	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DMBWAV7	DT	Small molecular drug
DMBWAV7	PC	12248893
DMBWAV7	MW	243.26
DMBWAV7	FM	C16H9N3
DMBWAV7	IC	InChI=1S/C16H9N3/c17-8-10-7-11-9-18-6-5-12(11)16-15(10)13-3-1-2-4-14(13)19-16/h1-7,9,19H
DMBWAV7	CS	C1=CC=C2C(=C1)C3=C(C=C4C=NC=CC4=C3N2)C#N
DMBWAV7	IK	DCPBIOSSTDLFHO-UHFFFAOYSA-N
DMBWAV7	IU	11H-pyrido[4,3-a]carbazole-6-carbonitrile

DMNKRSZ	ID	DMNKRSZ
DMNKRSZ	DN	PMID28766366-Compound-Scheme24Paprotrain
DMNKRSZ	HS	Patented
DMNKRSZ	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DMNKRSZ	DT	Small molecular drug
DMNKRSZ	PC	12248889
DMNKRSZ	MW	245.28
DMNKRSZ	FM	C16H11N3
DMNKRSZ	IC	InChI=1S/C16H11N3/c17-9-13(8-12-4-3-7-18-10-12)15-11-19-16-6-2-1-5-14(15)16/h1-8,10-11,19H/b13-8+
DMNKRSZ	CS	C1=CC=C2C(=C1)C(=CN2)/C(=C/C3=CN=CC=C3)/C#N
DMNKRSZ	IK	YMYYQRZCCKBFBE-MDWZMJQESA-N
DMNKRSZ	IU	(Z)-2-(1H-indol-3-yl)-3-pyridin-3-ylprop-2-enenitrile

DM7OGWH	ID	DM7OGWH
DM7OGWH	DN	PMID28766366-Compound-Scheme25-2
DM7OGWH	HS	Patented
DM7OGWH	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DM7OGWH	DT	Small molecular drug
DM7OGWH	PC	77105816
DM7OGWH	MW	273.29
DM7OGWH	FM	C17H11N3O
DM7OGWH	IC	InChI=1S/C17H11N3O/c1-21-12-2-3-14-15(7-12)20-17-13-4-5-19-9-11(13)6-10(8-18)16(14)17/h2-7,9,20H,1H3
DM7OGWH	CS	COC1=CC2=C(C=C1)C3=C(C=C4C=NC=CC4=C3N2)C#N
DM7OGWH	IK	UVJQEKJPAVSBTA-UHFFFAOYSA-N
DM7OGWH	IU	9-methoxy-11H-pyrido[4,3-a]carbazole-6-carbonitrile

DMGVT5Y	ID	DMGVT5Y
DMGVT5Y	DN	PMID28766366-Compound-Scheme25-3
DMGVT5Y	HS	Patented
DMGVT5Y	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DMGVT5Y	DT	Small molecular drug
DMGVT5Y	PC	77105818
DMGVT5Y	MW	303.3
DMGVT5Y	FM	C18H13N3O2
DMGVT5Y	IC	InChI=1S/C18H13N3O2/c1-22-12-3-4-13-14(6-12)21-18-16(13)10(7-19)5-11-8-20-9-15(23-2)17(11)18/h3-6,8-9,21H,1-2H3
DMGVT5Y	CS	COC1=CC2=C(C=C1)C3=C(C=C4C=NC=C(C4=C3N2)OC)C#N
DMGVT5Y	IK	WAJNOEPHTZIWTO-UHFFFAOYSA-N
DMGVT5Y	IU	1,9-dimethoxy-11H-pyrido[4,3-a]carbazole-6-carbonitrile

DMOD9BY	ID	DMOD9BY
DMOD9BY	DN	PMID28766366-Compound-Scheme25-4
DMOD9BY	HS	Patented
DMOD9BY	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DMOD9BY	DT	Small molecular drug

DM3Q1FT	ID	DM3Q1FT
DM3Q1FT	DN	PMID28766366-Compound-Scheme27LeucettamineB
DM3Q1FT	HS	Patented
DM3Q1FT	CP	GAMBRO LUNDIA AB [SEJOENSSON LENNART [SENILSSON EDDIE [SESTERNBY JAN [SE]
DM3Q1FT	DT	Small molecular drug
DM3Q1FT	PC	10037501
DM3Q1FT	MW	245.23
DM3Q1FT	FM	C12H11N3O3
DM3Q1FT	IC	InChI=1S/C12H11N3O3/c1-15-11(16)8(14-12(15)13)4-7-2-3-9-10(5-7)18-6-17-9/h2-5H,6H2,1H3,(H2,13,14)/b8-4-
DM3Q1FT	CS	CN1C(=O)/C(=C/C2=CC3=C(C=C2)OCO3)/N=C1N
DM3Q1FT	IK	PKEDBIGNILOTHW-YWEYNIOJSA-N
DM3Q1FT	IU	(5Z)-2-amino-5-(1,3-benzodioxol-5-ylmethylidene)-3-methylimidazol-4-one

DMLX26R	ID	DMLX26R
DMLX26R	DN	PMID28766366-Compound-Scheme27LeucettineL41
DMLX26R	HS	Patented
DMLX26R	CP	GAMBRO LUNDIA AB [SEJOENSSON LENNART [SENILSSON EDDIE [SESTERNBY JAN [SE]
DMLX26R	DT	Small molecular drug
DMLX26R	PC	135398522
DMLX26R	MW	307.3
DMLX26R	FM	C17H13N3O3
DMLX26R	IC	InChI=1S/C17H13N3O3/c21-16-13(8-11-6-7-14-15(9-11)23-10-22-14)19-17(20-16)18-12-4-2-1-3-5-12/h1-9H,10H2,(H2,18,19,20,21)/b13-8-
DMLX26R	CS	C1OC2=C(O1)C=C(C=C2)/C=C\\3/C(=O)NC(=N3)NC4=CC=CC=C4
DMLX26R	IK	PGPHHJBZEGSUNE-JYRVWZFOSA-N
DMLX26R	IU	(4Z)-2-anilino-4-(1,3-benzodioxol-5-ylmethylidene)-1H-imidazol-5-one

DMPVZ6W	ID	DMPVZ6W
DMPVZ6W	DN	PMID28766366-Compound-Scheme27LeucettineL41derivatives
DMPVZ6W	HS	Patented
DMPVZ6W	CP	GAMBRO LUNDIA AB [SEJOENSSON LENNART [SENILSSON EDDIE [SESTERNBY JAN [SE]
DMPVZ6W	DT	Small molecular drug

DMO4Q95	ID	DMO4Q95
DMO4Q95	DN	PMID28766366-Compound-Scheme2WO2012/098065bottom
DMO4Q95	HS	Patented
DMO4Q95	CP	F. HOFFMANN-LA ROCHE AG ANDERSON, Kevin William CHEN, Yi CHEN, Zhi LUK, Kin-Chun Thomas ROSSMAN, Pamela Loreen SUN, Hongmao WOVKULICH, Peter Michael

DMVJDRI	ID	DMVJDRI
DMVJDRI	DN	PMID28766366-Compound-Scheme2WO2012/098065upper
DMVJDRI	HS	Patented
DMVJDRI	CP	F. HOFFMANN-LA ROCHE AG ANDERSON, Kevin William CHEN, Yi CHEN, Zhi LUK, Kin-Chun Thomas ROSSMAN, Pamela Loreen SUN, Hongmao WOVKULICH, Peter Michael

DMDXIU9	ID	DMDXIU9
DMDXIU9	DN	PMID28766366-Compound-Scheme4Bottom
DMDXIU9	HS	Patented
DMDXIU9	CP	F. HOFFMANN-LA ROCHE AG LUK, Kin-Chun Thomas
DMDXIU9	DT	Small molecular drug

DMPH4JV	ID	DMPH4JV
DMPH4JV	DN	PMID28766366-Compound-Scheme4Upper
DMPH4JV	HS	Patented
DMPH4JV	CP	F. HOFFMANN-LA ROCHE AG LUK, Kin-Chun Thomas
DMPH4JV	DT	Small molecular drug

DMO6KZ5	ID	DMO6KZ5
DMO6KZ5	DN	PMID28766366-Compound-Scheme5
DMO6KZ5	HS	Patented
DMO6KZ5	CP	F. HOFFMANN-LA ROCHE AG LIU, Wenjian LUK, Kin-Chun Thomas ZHANG, Xiaoh
DMO6KZ5	DT	Small molecular drug

DMJOG3W	ID	DMJOG3W
DMJOG3W	DN	PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines
DMJOG3W	HS	Patented
DMJOG3W	CP	SERVIER LAB [FRVERNALIS (R&D) LTD [GB]
DMJOG3W	DT	Small molecular drug

DMQV6R0	ID	DMQV6R0
DMQV6R0	DN	PMID28766366-Compound-Scheme7WO2012/098070bottom
DMQV6R0	HS	Patented
DMQV6R0	CP	F. HOFFMANN-LA ROCHE AG DOMINIQUE, Romyr LUK, Kin-Chun Thomas QIAO, Qi ROSSMAN, Pamela Loreen

DMGAQR5	ID	DMGAQR5
DMGAQR5	DN	PMID28766366-Compound-Scheme7WO2012/098070upper
DMGAQR5	HS	Patented
DMGAQR5	CP	F. HOFFMANN-LA ROCHE AG DOMINIQUE, Romyr LUK, Kin-Chun Thomas QIAO, Qi ROSSMAN, Pamela Loreen

DMSX09A	ID	DMSX09A
DMSX09A	DN	PMID28766366-Compound-Scheme8NCGC-00010037
DMSX09A	HS	Patented
DMSX09A	CP	Department of Health and Human Services (NIH, Bethesda, US)
DMSX09A	DT	Small molecular drug
DMSX09A	PC	3232621
DMSX09A	MW	361.4
DMSX09A	FM	C20H15N3O2S
DMSX09A	IC	InChI=1S/C20H15N3O2S/c1-2-15(26-7-1)10-21-20-16-8-13(3-5-17(16)22-11-23-20)14-4-6-18-19(9-14)25-12-24-18/h1-9,11H,10,12H2,(H,21,22,23)
DMSX09A	CS	C1OC2=C(O1)C=C(C=C2)C3=CC4=C(C=C3)N=CN=C4NCC5=CC=CS5
DMSX09A	IK	QFBOPHGXTBOQRN-UHFFFAOYSA-N
DMSX09A	IU	6-(1,3-benzodioxol-5-yl)-N-(thiophen-2-ylmethyl)quinazolin-4-amine
DMSX09A	CB	CHEBI:93238

DMDUSN5	ID	DMDUSN5
DMDUSN5	DN	PMID28766366-Compound-Scheme8NCGC-00185981
DMDUSN5	HS	Patented
DMDUSN5	CP	Department of Health and Human Services (NIH, Bethesda, US)
DMDUSN5	DT	Small molecular drug

DMUWZD9	ID	DMUWZD9
DMUWZD9	DN	PMID28766366-Compound-Scheme8NCGC-00189310
DMUWZD9	HS	Patented
DMUWZD9	CP	Department of Health and Human Services (NIH, Bethesda, US)
DMUWZD9	DT	Small molecular drug
DMUWZD9	PC	46916176
DMUWZD9	MW	335.4
DMUWZD9	FM	C20H21N3O2
DMUWZD9	IC	InChI=1S/C20H21N3O2/c1-20(2,3)10-21-19-15-8-13(4-6-16(15)22-11-23-19)14-5-7-17-18(9-14)25-12-24-17/h4-9,11H,10,12H2,1-3H3,(H,21,22,23)
DMUWZD9	CS	CC(C)(C)CNC1=NC=NC2=C1C=C(C=C2)C3=CC4=C(C=C3)OCO4
DMUWZD9	IK	OSWHZHVVVZAPRN-UHFFFAOYSA-N
DMUWZD9	IU	6-(1,3-benzodioxol-5-yl)-N-(2,2-dimethylpropyl)quinazolin-4-amine

DMMZGC8	ID	DMMZGC8
DMMZGC8	DN	PMID28766366-Compound-Scheme9EHT1610
DMMZGC8	HS	Patented
DMMZGC8	CP	DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DMMZGC8	DT	Small molecular drug
DMMZGC8	PC	71529602
DMMZGC8	MW	383.4
DMMZGC8	FM	C18H14FN5O2S
DMMZGC8	IC	InChI=1S/C18H14FN5O2S/c1-25-9-3-4-11(10(19)7-9)23-17-14-12(21-8-22-17)5-6-13-15(14)27-18(24-13)16(20)26-2/h3-8,20H,1-2H3,(H,21,22,23)
DMMZGC8	CS	COC1=CC(=C(C=C1)NC2=NC=NC3=C2C4=C(C=C3)N=C(S4)C(=N)OC)F
DMMZGC8	IK	RYBNARZBIXTFJS-UHFFFAOYSA-N
DMMZGC8	IU	methyl 9-(2-fluoro-4-methoxyanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate

DMVBPML	ID	DMVBPML
DMVBPML	DN	PMID28766366-Compound-Scheme9EHT3356
DMVBPML	HS	Patented
DMVBPML	CP	DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DMVBPML	DT	Small molecular drug
DMVBPML	PC	71529599
DMVBPML	MW	349.4
DMVBPML	FM	C18H15N5OS
DMVBPML	IC	InChI=1S/C18H15N5OS/c1-10-3-5-11(6-4-10)22-17-14-12(20-9-21-17)7-8-13-15(14)25-18(23-13)16(19)24-2/h3-9,19H,1-2H3,(H,20,21,22)
DMVBPML	CS	CC1=CC=C(C=C1)NC2=NC=NC3=C2C4=C(C=C3)N=C(S4)C(=N)OC
DMVBPML	IK	AVKKQBJQERVCTD-UHFFFAOYSA-N
DMVBPML	IU	methyl 9-(4-methylanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate

DM0O18N	ID	DM0O18N
DM0O18N	DN	PMID28766366-Compound-Scheme9EHT5372
DM0O18N	HS	Patented
DM0O18N	CP	DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DM0O18N	DT	Small molecular drug
DM0O18N	PC	71529610
DM0O18N	MW	404.3
DM0O18N	FM	C17H11Cl2N5OS
DM0O18N	IC	InChI=1S/C17H11Cl2N5OS/c1-25-15(20)17-24-12-5-4-11-13(14(12)26-17)16(22-7-21-11)23-10-3-2-8(18)6-9(10)19/h2-7,20H,1H3,(H,21,22,23)
DM0O18N	CS	COC(=N)C1=NC2=C(S1)C3=C(C=C2)N=CN=C3NC4=C(C=C(C=C4)Cl)Cl
DM0O18N	IK	QSGKPYRFWJINEH-UHFFFAOYSA-N
DM0O18N	IU	methyl 9-(2,4-dichloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate

DMVY6PX	ID	DMVY6PX
DMVY6PX	DN	PMID28766366-Compound-Scheme9EHT6840
DMVY6PX	HS	Patented
DMVY6PX	CP	DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DMVY6PX	DT	Small molecular drug
DMVY6PX	PC	71529609
DMVY6PX	MW	387.8
DMVY6PX	FM	C17H11ClFN5OS
DMVY6PX	IC	InChI=1S/C17H11ClFN5OS/c1-25-15(20)17-24-12-5-4-11-13(14(12)26-17)16(22-7-21-11)23-10-3-2-8(18)6-9(10)19/h2-7,20H,1H3,(H,21,22,23)
DMVY6PX	CS	COC(=N)C1=NC2=C(S1)C3=C(C=C2)N=CN=C3NC4=C(C=C(C=C4)Cl)F
DMVY6PX	IK	RFRICXRVXVFZMF-UHFFFAOYSA-N
DMVY6PX	IU	methyl 9-(4-chloro-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate

DM7RPKM	ID	DM7RPKM
DM7RPKM	DN	PMID28766366-Compound-Scheme9EHT9851
DM7RPKM	HS	Patented
DM7RPKM	CP	DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DM7RPKM	DT	Small molecular drug
DM7RPKM	PC	71529622
DM7RPKM	MW	371.4
DM7RPKM	FM	C17H11F2N5OS
DM7RPKM	IC	InChI=1S/C17H11F2N5OS/c1-25-15(20)17-24-12-5-4-11-13(14(12)26-17)16(22-7-21-11)23-10-3-2-8(18)6-9(10)19/h2-7,20H,1H3,(H,21,22,23)
DM7RPKM	CS	COC(=N)C1=NC2=C(S1)C3=C(C=C2)N=CN=C3NC4=C(C=C(C=C4)F)F
DM7RPKM	IK	VONVAHFLRYRXSJ-UHFFFAOYSA-N
DM7RPKM	IU	methyl 9-(2,4-difluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate

DMQJF15	ID	DMQJF15
DMQJF15	DN	PMID28870136-Compound-36
DMQJF15	HS	Patented
DMQJF15	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMQJF15	DT	Small molecular drug
DMQJF15	PC	64115
DMQJF15	MW	208.22
DMQJF15	FM	C9H12N4O2
DMQJF15	IC	InChI=1S/C9H12N4O2/c1-5-10-7-6(11(5)2)8(14)13(4)9(15)12(7)3/h1-4H3
DMQJF15	CS	CC1=NC2=C(N1C)C(=O)N(C(=O)N2C)C
DMQJF15	IK	LFHHOHMIVKIHMG-UHFFFAOYSA-N
DMQJF15	IU	1,3,7,8-tetramethylpurine-2,6-dione
DMQJF15	CA	CAS 832-66-6

DMAPMG2	ID	DMAPMG2
DMAPMG2	DN	PMID28870136-Compound-37
DMAPMG2	HS	Patented
DMAPMG2	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMAPMG2	DT	Small molecular drug
DMAPMG2	PC	134222455
DMAPMG2	MW	383.5
DMAPMG2	FM	C21H29N5O2
DMAPMG2	IC	InChI=1S/C21H29N5O2/c1-5-12-25(6-2)13-14-26-17(15-16-10-8-7-9-11-16)22-19-18(26)20(27)24(4)21(28)23(19)3/h7-11H,5-6,12-15H2,1-4H3
DMAPMG2	CS	CCCN(CC)CCN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=CC=C3
DMAPMG2	IK	PKUZGRWGAWHGEF-UHFFFAOYSA-N
DMAPMG2	IU	8-benzyl-7-[2-[ethyl(propyl)amino]ethyl]-1,3-dimethylpurine-2,6-dione

DM67XSL	ID	DM67XSL
DM67XSL	DN	PMID28870136-Compound-38
DM67XSL	HS	Patented
DM67XSL	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM67XSL	DT	Small molecular drug
DM67XSL	PC	1329
DM67XSL	MW	304.39
DM67XSL	FM	C16H24N4O2
DM67XSL	IC	InChI=1S/C16H24N4O2/c1-3-9-19-14-12(15(21)20(10-4-2)16(19)22)17-13(18-14)11-7-5-6-8-11/h11H,3-10H2,1-2H3,(H,17,18)
DM67XSL	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3CCCC3
DM67XSL	IK	FFBDFADSZUINTG-UHFFFAOYSA-N
DM67XSL	IU	8-cyclopentyl-1,3-dipropyl-7H-purine-2,6-dione
DM67XSL	CA	CAS 102146-07-6
DM67XSL	CB	CHEBI:73282

DMU18W6	ID	DMU18W6
DMU18W6	DN	PMID28870136-Compound-39
DMU18W6	HS	Patented
DMU18W6	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMU18W6	DT	Small molecular drug

DMJP0AG	ID	DMJP0AG
DMJP0AG	DN	PMID28870136-Compound-40
DMJP0AG	HS	Patented
DMJP0AG	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMJP0AG	DT	Small molecular drug

DMSWM9Q	ID	DMSWM9Q
DMSWM9Q	DN	PMID28870136-Compound-41
DMSWM9Q	HS	Patented
DMSWM9Q	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMSWM9Q	DT	Small molecular drug
DMSWM9Q	PC	95030
DMSWM9Q	MW	194.19
DMSWM9Q	FM	C8H10N4O2
DMSWM9Q	IC	InChI=1S/C8H10N4O2/c1-4-9-5-6(10-4)11(2)8(14)12(3)7(5)13/h1-3H3,(H,9,10)
DMSWM9Q	CS	CC1=NC2=C(N1)C(=O)N(C(=O)N2C)C
DMSWM9Q	IK	WZBKGWBHAPBSBF-UHFFFAOYSA-N
DMSWM9Q	IU	1,3,8-trimethyl-7H-purine-2,6-dione
DMSWM9Q	CA	CAS 830-65-9

DMV0R2X	ID	DMV0R2X
DMV0R2X	DN	PMID28870136-Compound-42
DMV0R2X	HS	Patented
DMV0R2X	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMV0R2X	DT	Small molecular drug

DMWGV8N	ID	DMWGV8N
DMWGV8N	DN	PMID28870136-Compound-43
DMWGV8N	HS	Patented
DMWGV8N	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMWGV8N	DT	Small molecular drug
DMWGV8N	PC	3182
DMWGV8N	MW	254.24
DMWGV8N	FM	C10H14N4O4
DMWGV8N	IC	InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3
DMWGV8N	CS	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O
DMWGV8N	IK	KSCFJBIXMNOVSH-UHFFFAOYSA-N
DMWGV8N	IU	7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione
DMWGV8N	CA	CAS 479-18-5
DMWGV8N	CB	CHEBI:4728

DMNOAQB	ID	DMNOAQB
DMNOAQB	DN	PMID28870136-Compound-44
DMNOAQB	HS	Patented
DMNOAQB	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMNOAQB	DT	Small molecular drug
DMNOAQB	PC	128784
DMNOAQB	MW	312.37
DMNOAQB	FM	C17H20N4O2
DMNOAQB	IC	InChI=1S/C17H20N4O2/c1-3-10-20-15-13(16(22)21(11-4-2)17(20)23)18-14(19-15)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3,(H,18,19)
DMNOAQB	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=CC=C3
DMNOAQB	IK	CLIGSMOZKDCDRZ-UHFFFAOYSA-N
DMNOAQB	IU	8-phenyl-1,3-dipropyl-7H-purine-2,6-dione
DMNOAQB	CA	CAS 85872-53-3
DMNOAQB	CB	CHEBI:107631

DM1QHV0	ID	DM1QHV0
DM1QHV0	DN	PMID28870136-Compound-45
DM1QHV0	HS	Patented
DM1QHV0	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM1QHV0	DT	Small molecular drug

DM4FD7C	ID	DM4FD7C
DM4FD7C	DN	PMID28870136-Compound-46
DM4FD7C	HS	Patented
DM4FD7C	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM4FD7C	DT	Small molecular drug

DMYWBRX	ID	DMYWBRX
DMYWBRX	DN	PMID28870136-Compound-47
DMYWBRX	HS	Patented
DMYWBRX	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMYWBRX	DT	Small molecular drug
DMYWBRX	PC	1676
DMYWBRX	MW	194.19
DMYWBRX	FM	C8H10N4O2
DMYWBRX	IC	InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)
DMYWBRX	CS	CCCN1C2=C(C(=O)NC1=O)NC=N2
DMYWBRX	IK	SIQPXVQCUCHWDI-UHFFFAOYSA-N
DMYWBRX	IU	3-propyl-7H-purine-2,6-dione
DMYWBRX	CA	CAS 41078-02-8
DMYWBRX	CB	CHEBI:126237

DMPIM9L	ID	DMPIM9L
DMPIM9L	DN	PMID28870136-Compound-48
DMPIM9L	HS	Patented
DMPIM9L	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMPIM9L	DT	Small molecular drug
DMPIM9L	PC	2153
DMPIM9L	MW	180.16
DMPIM9L	FM	C7H8N4O2
DMPIM9L	IC	InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)
DMPIM9L	CS	CN1C2=C(C(=O)N(C1=O)C)NC=N2
DMPIM9L	IK	ZFXYFBGIUFBOJW-UHFFFAOYSA-N
DMPIM9L	IU	1,3-dimethyl-7H-purine-2,6-dione
DMPIM9L	CA	CAS 58-55-9
DMPIM9L	CB	CHEBI:28177

DMTUC9E	ID	DMTUC9E
DMTUC9E	DN	PMID28870136-Compound-49
DMTUC9E	HS	Patented
DMTUC9E	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMTUC9E	DT	Small molecular drug
DMTUC9E	PC	4740
DMTUC9E	MW	278.31
DMTUC9E	FM	C13H18N4O3
DMTUC9E	IC	InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
DMTUC9E	CS	CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
DMTUC9E	IK	BYPFEZZEUUWMEJ-UHFFFAOYSA-N
DMTUC9E	IU	3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
DMTUC9E	CA	CAS 6493-05-6
DMTUC9E	CB	CHEBI:7986

DM42OYU	ID	DM42OYU
DM42OYU	DN	PMID28870136-Compound-50
DM42OYU	HS	Patented
DM42OYU	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM42OYU	DT	Small molecular drug
DM42OYU	PC	5429
DM42OYU	MW	180.16
DM42OYU	FM	C7H8N4O2
DM42OYU	IC	InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13)
DM42OYU	CS	CN1C=NC2=C1C(=O)NC(=O)N2C
DM42OYU	IK	YAPQBXQYLJRXSA-UHFFFAOYSA-N
DM42OYU	IU	3,7-dimethylpurine-2,6-dione
DM42OYU	CA	CAS 83-67-0
DM42OYU	CB	CHEBI:28946

DMU3MQB	ID	DMU3MQB
DMU3MQB	DN	PMID28870136-Compound-51
DMU3MQB	HS	Patented
DMU3MQB	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMU3MQB	DT	Small molecular drug

DMFDERP	ID	DMFDERP
DMFDERP	DN	PMID28870136-Compound-52
DMFDERP	HS	Patented
DMFDERP	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMFDERP	DT	Small molecular drug
DMFDERP	PC	2519
DMFDERP	MW	194.19
DMFDERP	FM	C8H10N4O2
DMFDERP	IC	InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
DMFDERP	CS	CN1C=NC2=C1C(=O)N(C(=O)N2C)C
DMFDERP	IK	RYYVLZVUVIJVGH-UHFFFAOYSA-N
DMFDERP	IU	1,3,7-trimethylpurine-2,6-dione
DMFDERP	CA	CAS 58-08-2
DMFDERP	CB	CHEBI:27732

DMLEWY6	ID	DMLEWY6
DMLEWY6	DN	PMID28870136-Compound-53
DMLEWY6	HS	Patented
DMLEWY6	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMLEWY6	DT	Small molecular drug
DMLEWY6	PC	67565716
DMLEWY6	MW	292.4
DMLEWY6	FM	C18H20N4
DMLEWY6	IC	InChI=1S/C18H20N4/c1-3-7-13(8-4-1)16-21-17-15(11-12-19-17)18(22-16)20-14-9-5-2-6-10-14/h1,3-4,7-8,11-12,14H,2,5-6,9-10H2,(H2,19,20,21,22)
DMLEWY6	CS	C1CCC(CC1)NC2=NC(=NC3=C2C=CN3)C4=CC=CC=C4
DMLEWY6	IK	QWRCXRFAIZINSM-UHFFFAOYSA-N
DMLEWY6	IU	N-cyclohexyl-2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

DM6HOES	ID	DM6HOES
DM6HOES	DN	PMID28870136-Compound-54
DM6HOES	HS	Patented
DM6HOES	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM6HOES	DT	Small molecular drug

DMVRJZX	ID	DMVRJZX
DMVRJZX	DN	PMID28870136-Compound-55
DMVRJZX	HS	Patented
DMVRJZX	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMVRJZX	DT	Small molecular drug
DMVRJZX	PC	3007918
DMVRJZX	MW	266.25
DMVRJZX	FM	C11H14N4O4
DMVRJZX	IC	InChI=1S/C11H14N4O4/c12-9-5-1-2-15(10(5)14-4-13-9)11-8(18)7(17)6(3-16)19-11/h1-2,4,6-8,11,16-18H,3H2,(H2,12,13,14)/t6-,7-,8+,11-/m1/s1
DMVRJZX	CS	C1=CN(C2=NC=NC(=C21)N)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O
DMVRJZX	IK	HDZZVAMISRMYHH-HGIWHZBTSA-N
DMVRJZX	IU	(2R,3S,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMVRJZX	CA	CAS 64526-34-7

DMK0RTV	ID	DMK0RTV
DMK0RTV	DN	PMID28870136-Compound-56
DMK0RTV	HS	Patented
DMK0RTV	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMK0RTV	DT	Small molecular drug

DME3HLC	ID	DME3HLC
DME3HLC	DN	PMID28870136-Compound-57
DME3HLC	HS	Patented
DME3HLC	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DME3HLC	DT	Small molecular drug
DME3HLC	PC	135156846
DME3HLC	MW	302.69
DME3HLC	FM	C11H12ClFN4O3
DME3HLC	IC	InChI=1S/C11H12ClFN4O3/c12-11-15-8(14)4-1-2-17(9(4)16-11)10-6(13)7(19)5(3-18)20-10/h1-2,5-7,10,18-19H,3H2,(H2,14,15,16)/t5-,6+,7-,10-/m1/s1
DME3HLC	CS	C1=CN(C2=NC(=NC(=C21)N)Cl)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F
DME3HLC	IK	VLXMLGCQJSJFSY-JTGULSINSA-N
DME3HLC	IU	(2R,3R,4S,5R)-5-(4-amino-2-chloropyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol

DMQIUD9	ID	DMQIUD9
DMQIUD9	DN	PMID28870136-Compound-58
DMQIUD9	HS	Patented
DMQIUD9	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMQIUD9	DT	Small molecular drug

DMHP90Q	ID	DMHP90Q
DMHP90Q	DN	PMID28870136-Compound-59
DMHP90Q	HS	Patented
DMHP90Q	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMHP90Q	DT	Small molecular drug
DMHP90Q	PC	3035594
DMHP90Q	MW	374.4
DMHP90Q	FM	C21H18N4O3
DMHP90Q	IC	InChI=1S/C21H18N4O3/c26-18-12-11-16(22-25(18)14-6-10-19(27)28)20-17-9-4-5-13-24(17)23-21(20)15-7-2-1-3-8-15/h1-5,7-9,11-13H,6,10,14H2,(H,27,28)
DMHP90Q	CS	C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=NN(C(=O)C=C4)CCCC(=O)O
DMHP90Q	IK	FKJPZJACCBMNKZ-UHFFFAOYSA-N
DMHP90Q	IU	4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-1-yl]butanoic acid
DMHP90Q	CA	CAS 131185-37-0

DM39QU8	ID	DM39QU8
DM39QU8	DN	PMID28870136-Compound-60
DM39QU8	HS	Patented
DM39QU8	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM39QU8	DT	Small molecular drug
DM39QU8	PC	11110698
DM39QU8	MW	344.4
DM39QU8	FM	C20H16N4O2
DM39QU8	IC	InChI=1S/C20H16N4O2/c1-14(25)13-24-18(26)11-10-16(21-24)19-17-9-5-6-12-23(17)22-20(19)15-7-3-2-4-8-15/h2-12H,13H2,1H3
DM39QU8	CS	CC(=O)CN1C(=O)C=CC(=N1)C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DM39QU8	IK	QATXIDMQXCGKIY-UHFFFAOYSA-N
DM39QU8	IU	2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one

DMFNU9D	ID	DMFNU9D
DMFNU9D	DN	PMID28870136-Compound-61
DMFNU9D	HS	Patented
DMFNU9D	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMFNU9D	DT	Small molecular drug
DMFNU9D	PC	134222456
DMFNU9D	MW	358.4
DMFNU9D	FM	C22H22N4O
DMFNU9D	IC	InChI=1S/C22H22N4O/c1-22(2,3)15-26-19(27)13-12-17(23-26)20-18-11-7-8-14-25(18)24-21(20)16-9-5-4-6-10-16/h4-14H,15H2,1-3H3
DMFNU9D	CS	CC(C)(C)CN1C(=O)C=CC(=N1)C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DMFNU9D	IK	XGZUBYNARGEPRB-UHFFFAOYSA-N
DMFNU9D	IU	2-(2,2-dimethylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one

DMNKXJ2	ID	DMNKXJ2
DMNKXJ2	DN	PMID28870136-Compound-62
DMNKXJ2	HS	Patented
DMNKXJ2	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMNKXJ2	DT	Small molecular drug
DMNKXJ2	PC	11110698
DMNKXJ2	MW	344.4
DMNKXJ2	FM	C20H16N4O2
DMNKXJ2	IC	InChI=1S/C20H16N4O2/c1-14(25)13-24-18(26)11-10-16(21-24)19-17-9-5-6-12-23(17)22-20(19)15-7-3-2-4-8-15/h2-12H,13H2,1H3
DMNKXJ2	CS	CC(=O)CN1C(=O)C=CC(=N1)C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DMNKXJ2	IK	QATXIDMQXCGKIY-UHFFFAOYSA-N
DMNKXJ2	IU	2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one

DM26WNY	ID	DM26WNY
DM26WNY	DN	PMID28870136-Compound-63
DM26WNY	HS	Patented
DM26WNY	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM26WNY	DT	Small molecular drug
DM26WNY	PC	10544406
DM26WNY	MW	330.4
DM26WNY	FM	C20H18N4O
DM26WNY	IC	InChI=1S/C20H18N4O/c1-2-13-24-18(25)12-11-16(21-24)19-17-10-6-7-14-23(17)22-20(19)15-8-4-3-5-9-15/h3-12,14H,2,13H2,1H3
DM26WNY	CS	CCCN1C(=O)C=CC(=N1)C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DM26WNY	IK	ATTQDJZYFIDUQX-UHFFFAOYSA-N
DM26WNY	IU	6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propylpyridazin-3-one

DMBKSVH	ID	DMBKSVH
DMBKSVH	DN	PMID28870136-Compound-64
DMBKSVH	HS	Patented
DMBKSVH	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMBKSVH	DT	Small molecular drug
DMBKSVH	PC	9821511
DMBKSVH	MW	385.5
DMBKSVH	FM	C23H23N5O
DMBKSVH	IC	InChI=1S/C23H23N5O/c1-26-15-12-18(13-16-26)28-21(29)11-10-19(24-28)22-20-9-5-6-14-27(20)25-23(22)17-7-3-2-4-8-17/h2-11,14,18H,12-13,15-16H2,1H3
DMBKSVH	CS	CN1CCC(CC1)N2C(=O)C=CC(=N2)C3=C4C=CC=CN4N=C3C5=CC=CC=C5
DMBKSVH	IK	YHDRUTMZCJZJAL-UHFFFAOYSA-N
DMBKSVH	IU	2-(1-methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one
DMBKSVH	CA	CAS 202646-80-8

DMF5K9J	ID	DMF5K9J
DMF5K9J	DN	PMID28870136-Compound-65
DMF5K9J	HS	Patented
DMF5K9J	CP	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMF5K9J	DT	Small molecular drug
DMF5K9J	PC	9821511
DMF5K9J	MW	385.5
DMF5K9J	FM	C23H23N5O
DMF5K9J	IC	InChI=1S/C23H23N5O/c1-26-15-12-18(13-16-26)28-21(29)11-10-19(24-28)22-20-9-5-6-14-27(20)25-23(22)17-7-3-2-4-8-17/h2-11,14,18H,12-13,15-16H2,1H3
DMF5K9J	CS	CN1CCC(CC1)N2C(=O)C=CC(=N2)C3=C4C=CC=CN4N=C3C5=CC=CC=C5
DMF5K9J	IK	YHDRUTMZCJZJAL-UHFFFAOYSA-N
DMF5K9J	IU	2-(1-methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one
DMF5K9J	CA	CAS 202646-80-8

DME3YRI	ID	DME3YRI
DME3YRI	DN	PMID28870136-Compound-67
DME3YRI	HS	Patented
DME3YRI	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -,HOSPICES CIVILS DE LYON,ECOLE NORMALE SUPERIEURE DE LYON,UNIVERSITE CLAUDE BERNARD LYON 1,UNIVERSITE DE MONTPELLIER 
DME3YRI	DT	Small molecular drug

DMFTM8X	ID	DMFTM8X
DMFTM8X	DN	PMID28870136-Compound-68
DMFTM8X	HS	Patented
DMFTM8X	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -,HOSPICES CIVILS DE LYON,ECOLE NORMALE SUPERIEURE DE LYON,UNIVERSITE CLAUDE BERNARD LYON 1,UNIVERSITE DE MONTPELLIER 
DMFTM8X	DT	Small molecular drug

DMVCQKB	ID	DMVCQKB
DMVCQKB	DN	PMID28870136-Compound-69
DMVCQKB	HS	Patented
DMVCQKB	CP	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -,HOSPICES CIVILS DE LYON,ECOLE NORMALE SUPERIEURE DE LYON,UNIVERSITE CLAUDE BERNARD LYON 1,UNIVERSITE DE MONTPELLIER 
DMVCQKB	DT	Small molecular drug

DMECU90	ID	DMECU90
DMECU90	DN	PMID28906174-Compound-figure1g
DMECU90	HS	Patented
DMECU90	CP	Ixchelsis Ltd
DMECU90	DT	Small molecular drug

DMLMHR5	ID	DMLMHR5
DMLMHR5	DN	PMID29053063-Compound-11c
DMLMHR5	HS	Patented
DMLMHR5	CP	ABIDE THERAPEUTICS, INC
DMLMHR5	DT	Small molecular drug
DMLMHR5	PC	90467446
DMLMHR5	MW	472.4
DMLMHR5	FM	C23H22F6N2O2
DMLMHR5	IC	InChI=1S/C23H22F6N2O2/c24-22(25,26)20(23(27,28)29)33-21(32)31-13-18-11-30(12-19(18)14-31)10-15-6-8-17(9-7-15)16-4-2-1-3-5-16/h1-9,18-20H,10-14H2
DMLMHR5	CS	C1C2CN(CC2CN1CC3=CC=C(C=C3)C4=CC=CC=C4)C(=O)OC(C(F)(F)F)C(F)(F)F
DMLMHR5	IK	YPFURSFOBNHDRO-UHFFFAOYSA-N
DMLMHR5	IU	1,1,1,3,3,3-hexafluoropropan-2-yl 2-[(4-phenylphenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate

DMDRK68	ID	DMDRK68
DMDRK68	DN	PMID29053063-Compound-11d
DMDRK68	HS	Patented
DMDRK68	CP	ABIDE THERAPEUTICS, INC
DMDRK68	DT	Small molecular drug

DMBR72X	ID	DMBR72X
DMBR72X	DN	PMID29053063-Compound-14
DMBR72X	HS	Patented
DMBR72X	CP	DR. AUGUST WOLFF GMBH &amCO. KG ARZNEIMITTEL
DMBR72X	DT	Small molecular drug

DM07U5R	ID	DM07U5R
DM07U5R	DN	PMID29053063-Compound-15
DM07U5R	HS	Patented
DM07U5R	CP	NORTHEASTERN UNIVERSITY
DM07U5R	DT	Small molecular drug

DMRHPN0	ID	DMRHPN0
DMRHPN0	DN	PMID29053063-Compound-17
DMRHPN0	HS	Patented
DMRHPN0	CP	INFINITY PHARMACEUTICALS, INC
DMRHPN0	DT	Small molecular drug

DM8RAK0	ID	DM8RAK0
DM8RAK0	DN	PMID29053063-Compound-4
DM8RAK0	HS	Patented
DM8RAK0	CP	INSERM INST NAT DE LA SANT  ET DE LA RECH M DICALE [FRUNIVERSIT  PARIS DIDEROT PARIS 7 [FRCENTRE NAT RECH SCIENT [FR]
DM8RAK0	DT	Small molecular drug

DM2P05S	ID	DM2P05S
DM2P05S	DN	PMID29053063-Compound-5
DM2P05S	HS	Patented
DM2P05S	CP	INSERM INST NAT DE LA SANT  ET DE LA RECH M DICALE [FRUNIVERSIT  PARIS DIDEROT PARIS 7 [FRCENTRE NAT RECH SCIENT [FR]
DM2P05S	DT	Small molecular drug

DMTOHNQ	ID	DMTOHNQ
DMTOHNQ	DN	PMID29053063-Compound-7a
DMTOHNQ	HS	Patented
DMTOHNQ	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMTOHNQ	DT	Small molecular drug

DMDJ6O8	ID	DMDJ6O8
DMDJ6O8	DN	PMID29053063-Compound-7b
DMDJ6O8	HS	Patented
DMDJ6O8	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMDJ6O8	DT	Small molecular drug

DMNZO7V	ID	DMNZO7V
DMNZO7V	DN	PMID29053063-Compound-7c
DMNZO7V	HS	Patented
DMNZO7V	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMNZO7V	DT	Small molecular drug

DMUNXAR	ID	DMUNXAR
DMUNXAR	DN	PMID29053063-Compound-7d
DMUNXAR	HS	Patented
DMUNXAR	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMUNXAR	DT	Small molecular drug

DM6XYFB	ID	DM6XYFB
DM6XYFB	DN	PMID29053063-Compound-7e
DM6XYFB	HS	Patented
DM6XYFB	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM6XYFB	DT	Small molecular drug
DM6XYFB	PC	118196736
DM6XYFB	MW	539.6
DM6XYFB	FM	C27H24F3N5O2S
DM6XYFB	IC	InChI=1S/C27H24F3N5O2S/c28-27(29,30)19-1-3-20(4-2-19)34-8-7-18-13-21(5-6-24(18)34)35-15-22(14-25(35)36)32-9-11-33(12-10-32)26(37)23-16-38-17-31-23/h1-8,13,16-17,22H,9-12,14-15H2/t22-/m1/s1
DM6XYFB	CS	C1CN(CCN1[C@@H]2CC(=O)N(C2)C3=CC4=C(C=C3)N(C=C4)C5=CC=C(C=C5)C(F)(F)F)C(=O)C6=CSC=N6
DM6XYFB	IK	ACWGPXVJPMRMHD-JOCHJYFZSA-N
DM6XYFB	IU	(4R)-4-[4-(1,3-thiazole-4-carbonyl)piperazin-1-yl]-1-[1-[4-(trifluoromethyl)phenyl]indol-5-yl]pyrrolidin-2-one

DMIQ263	ID	DMIQ263
DMIQ263	DN	PMID29053063-Compound-7f
DMIQ263	HS	Patented
DMIQ263	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMIQ263	DT	Small molecular drug

DMFWXPS	ID	DMFWXPS
DMFWXPS	DN	PMID29130358-Compound-Figure10(2a)
DMFWXPS	HS	Patented
DMFWXPS	DT	Small molecular drug

DMSME2B	ID	DMSME2B
DMSME2B	DN	PMID29130358-Compound-Figure11(3)
DMSME2B	HS	Patented
DMSME2B	DT	Small molecular drug

DMDFPIO	ID	DMDFPIO
DMDFPIO	DN	PMID29130358-Compound-Figure13(4)
DMDFPIO	HS	Patented
DMDFPIO	DT	Small molecular drug

DMB6KS9	ID	DMB6KS9
DMB6KS9	DN	PMID29130358-Compound-Figure14(5)
DMB6KS9	HS	Patented
DMB6KS9	CP	UNIVERSITY OF NOTRE DAME DU LAC CHANG, Mayland MOBASHERY, Shahriar LEE, Mijoon
DMB6KS9	DT	Small molecular drug

DMFMJIN	ID	DMFMJIN
DMFMJIN	DN	PMID29130358-Compound-Figure14(6)
DMFMJIN	HS	Patented
DMFMJIN	CP	UNIVERSITY OF NOTRE DAME DU LAC
DMFMJIN	DT	Small molecular drug

DM85ETX	ID	DM85ETX
DM85ETX	DN	PMID29130358-Compound-Figure15(7)
DM85ETX	HS	Patented
DM85ETX	DT	Small molecular drug

DML8FUD	ID	DML8FUD
DML8FUD	DN	PMID29130358-Compound-Figure15(8)
DML8FUD	HS	Patented
DML8FUD	DT	Small molecular drug

DMKX5R8	ID	DMKX5R8
DMKX5R8	DN	PMID29130358-Compound-Figure16(9a)
DMKX5R8	HS	Patented
DMKX5R8	DT	Small molecular drug
DMKX5R8	PC	58107501
DMKX5R8	MW	388.7
DMKX5R8	FM	C14H11BrClNO3S
DMKX5R8	IC	InChI=1S/C14H11BrClNO3S/c1-8-2-4-10(11(15)6-8)14(18)9-3-5-12(16)13(7-9)21(17,19)20/h2-7H,1H3,(H2,17,19,20)
DMKX5R8	CS	CC1=CC(=C(C=C1)C(=O)C2=CC(=C(C=C2)Cl)S(=O)(=O)N)Br
DMKX5R8	IK	IWYFDCPQQNBMTJ-UHFFFAOYSA-N
DMKX5R8	IU	5-(2-bromo-4-methylbenzoyl)-2-chlorobenzenesulfonamide

DMPAQLZ	ID	DMPAQLZ
DMPAQLZ	DN	PMID29130358-Compound-Figure16(9b)
DMPAQLZ	HS	Patented
DMPAQLZ	DT	Small molecular drug

DM0ZRI9	ID	DM0ZRI9
DM0ZRI9	DN	PMID29130358-Compound-Figure16(9c)
DM0ZRI9	HS	Patented
DM0ZRI9	DT	Small molecular drug

DMVA15O	ID	DMVA15O
DMVA15O	DN	PMID29130358-Compound-Figure17(10)
DMVA15O	HS	Patented
DMVA15O	CP	RANBAXY LABORATORIES LIMITED KHERA, Manoj, Kumar SATTIGERI, Jitendra SATTIGERI, Viswajanani YADAV, Neeraj, Kumar KUMAR, Kewal RAUF, Abdul, Rehman, Abdul CLIFFE, Ian, A. BHATNAGAR, Pradip, Kumar RAY, Abhijit SRIVASTAVA, Punit DASTIDAR, Sunanda, Ghosh
DMVA15O	DT	Small molecular drug

DMSZA9L	ID	DMSZA9L
DMSZA9L	DN	PMID29130358-Compound-Figure17(11)
DMSZA9L	HS	Patented
DMSZA9L	CP	RANBAXY LABORATORIES LIMITED KHERA, Manoj Kumar SONI, Ajay SATTIGERI, Jitendra SATTIGERI, Viswajanani DAS, Biswajit CLIFFE, Ian A. BHATNAGAR, Pradip Kumar RAUF, Abdul Rehman Abdul MUSIB, Arpita SAHA, Subham YADAV, Neeraj Kumar AHAMMED, Sabir REDDY, Ranadheer R. RAY, Abhijit SRIVASTAVA, Punit DASTIDAR, Sunanda Ghosh
DMSZA9L	DT	Small molecular drug

DMML4PA	ID	DMML4PA
DMML4PA	DN	PMID29130358-Compound-Figure17(12)
DMML4PA	HS	Patented
DMML4PA	CP	RANBAXY LABORATORIES LIMITED KHERA, Manoj Kumar PALLE, Venkata P. SATTIGERI, Viswajanani SATTIGERI, Jitendra SONI, Ajay RAUF, Abdul Rehman Abdul SIVAKUMAR, R. REDDY, Ranadheer R. MUSIB, Arpita CLIFFE, Ian A. BHATNAGAR, Pradip Kumar RAY, Abhijit SRIVASTAVA, Punit DASTIDAR, Sunanda Ghosh
DMML4PA	DT	Small molecular drug

DM2QRIW	ID	DM2QRIW
DM2QRIW	DN	PMID29130358-Compound-Figure17(13)
DM2QRIW	HS	Patented
DM2QRIW	CP	RANBAXY LABORATORIES LIMITED KHERA, Manoj Kumar SATTIGERI, Jitendra YADAV, Neeraj Kumar RAUF, Abdul Rehman Abdul CLIFFE, Ian A. BHATNAGAR, Pradip Kumar RAY, Abhijit SRIVASTAVA, Punit DASTIDAR, Sunanda Ghosh
DM2QRIW	DT	Small molecular drug

DM7WXJ9	ID	DM7WXJ9
DM7WXJ9	DN	PMID29130358-Compound-Figure18(14)
DM7WXJ9	HS	Patented
DM7WXJ9	CP	PHARMAHUNGARY 2000 KFT [HUINFARMATIK KFT [HUTARGETEX KFT [HU]
DM7WXJ9	DT	Small molecular drug

DMHIBTZ	ID	DMHIBTZ
DMHIBTZ	DN	PMID29130358-Compound-Figure18(14a)
DMHIBTZ	HS	Patented
DMHIBTZ	CP	PHARMAHUNGARY 2000 KFT [HUINFARMATIK KFT [HUTARGETEX KFT [HU]
DMHIBTZ	DT	Small molecular drug

DMMX5I6	ID	DMMX5I6
DMMX5I6	DN	PMID29130358-Compound-Figure9(1)
DMMX5I6	HS	Patented
DMMX5I6	DT	Small molecular drug

DMTJEU5	ID	DMTJEU5
DMTJEU5	DN	PMID29130358-Compound-LonimacranthoideVI
DMTJEU5	HS	Patented
DMTJEU5	DT	Small molecular drug

DMOGIAU	ID	DMOGIAU
DMOGIAU	DN	PMID29130358-Compound-LonimacranthoideVII
DMOGIAU	HS	Patented
DMOGIAU	DT	Small molecular drug

DMC64XQ	ID	DMC64XQ
DMC64XQ	DN	PMID29130358-Compound-SB-3CT
DMC64XQ	HS	Patented
DMC64XQ	DT	Small molecular drug

DMDN4KP	ID	DMDN4KP
DMDN4KP	DN	PMID29166791-Compound-AMPCP
DMDN4KP	HS	Patented
DMDN4KP	CP	ARCUS BIOSCIENCES, INCVITAE PHARMACEUTICALS, INC
DMDN4KP	DT	Small molecular drug

DM0DAR1	ID	DM0DAR1
DM0DAR1	DN	PMID29324067-Compound-25
DM0DAR1	HS	Patented
DM0DAR1	DT	Small molecular drug

DMPXZYN	ID	DMPXZYN
DMPXZYN	DN	PMID29324067-Compound-38
DMPXZYN	HS	Patented
DMPXZYN	DT	Small molecular drug

DM69A05	ID	DM69A05
DM69A05	DN	PMID29324067-Compound-40
DM69A05	HS	Patented
DM69A05	DT	Small molecular drug

DMTOA1Q	ID	DMTOA1Q
DMTOA1Q	DN	PMID29334795-Compound-21
DMTOA1Q	HS	Patented
DMTOA1Q	CP	SANOFSANOFI LANGEVIN, Beverly C. FARR, Robert Allan SHAH, Dinubhai H. SHERER, DanieSANOFI-AVENTIS DIAZ MARTIN, Juan Antonio JIMENEZ BARGUENO, Maria Dolores
DMTOA1Q	DT	Small molecular drug
DMTOA1Q	DE	Progressive supranuclear palsy; Corticobasal degeneration

DM8N10A	ID	DM8N10A
DM8N10A	DN	PMID29334795-Compound-22
DM8N10A	HS	Patented
DM8N10A	CP	LES LABORATOIRES SERVIELES LABORATOIRES SERVIER ROBERT, Nicolas LERESTIF, Jean-Michel LECOUVE, Jean-Pierre GAILLARD, Marina DELCROIX - MEUNIER, Julie LETELLIER, Philippe BOIRET, MathieLES LABORATOIRES SERVIER TROCME-THIBIERGE, Caryn SORS, Aurore KEIME GUIBERT, FlorencLES LABORATOIRES SERVIER CASARA, Patrick CHOLLET, Anne-Marie DHAINAUT, Alain BERT, Lionel LESTAGE, Pierre LOCKHART, Brian
DM8N10A	DT	Small molecular drug
DM8N10A	DE	Neuropathic pain; Alzheimer disease

DM3VL64	ID	DM3VL64
DM3VL64	DN	PMID29334795-Compound-23
DM3VL64	HS	Patented
DM3VL64	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, HongtaGLAXO GROUP LIMITED BAMFORD, Mark, James DEAN, David, Kenneth SEHMI, Sanjeet, Singh WILSON, David, Matthew WITHERINGTON, Jason
DM3VL64	DT	Small molecular drug
DM3VL64	PC	9976892
DM3VL64	MW	377.5
DM3VL64	FM	C23H27N3O2
DM3VL64	IC	InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2
DM3VL64	CS	C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O
DM3VL64	IK	YFRBKEVUUCQYOW-UHFFFAOYSA-N
DM3VL64	IU	1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one
DM3VL64	CA	CAS 720691-69-0
DM3VL64	DE	Schizophrenia

DMTUQV0	ID	DMTUQV0
DMTUQV0	DN	PMID29334795-Compound-24
DMTUQV0	HS	Patented
DMTUQV0	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, HongtaGLAXO GROUP LIMITED BAILEY, James, Matthew BRUTON, Gordon HUXLEY, Anthony MILNER, Peter, Henry ORLEK, Barry, Sidney
DMTUQV0	DT	Small molecular drug
DMTUQV0	PC	69354506
DMTUQV0	MW	327.5
DMTUQV0	FM	C20H29N3O
DMTUQV0	IC	InChI=1S/C20H29N3O/c1-16(2)22-11-7-19(8-12-22)24-20-9-13-23(14-10-20)18-5-3-17(15-21)4-6-18/h3-6,16,19-20H,7-14H2,1-2H3
DMTUQV0	CS	CC(C)N1CCC(CC1)OC2CCN(CC2)C3=CC=C(C=C3)C#N
DMTUQV0	IK	RIRWRSQXDDJXDS-UHFFFAOYSA-N
DMTUQV0	IU	4-[4-(1-propan-2-ylpiperidin-4-yl)oxypiperidin-1-yl]benzonitrile

DMGEWVP	ID	DMGEWVP
DMGEWVP	DN	PMID29334795-Compound-25
DMGEWVP	HS	Patented
DMGEWVP	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, Hongtao
DMGEWVP	DT	Small molecular drug
DMGEWVP	PC	71664257
DMGEWVP	MW	341.4
DMGEWVP	FM	C19H23N3O3
DMGEWVP	IC	InChI=1S/C19H23N3O3/c1-2-15(3-1)22-8-6-13(7-9-22)10-18-20-19(21-25-18)14-4-5-16-17(11-14)24-12-23-16/h4-5,11,13,15H,1-3,6-10,12H2
DMGEWVP	CS	C1CC(C1)N2CCC(CC2)CC3=NC(=NO3)C4=CC5=C(C=C4)OCO5
DMGEWVP	IK	ATGQONNRRWKPGJ-UHFFFAOYSA-N
DMGEWVP	IU	3-(1,3-benzodioxol-5-yl)-5-[(1-cyclobutylpiperidin-4-yl)methyl]-1,2,4-oxadiazole

DM1SWYU	ID	DM1SWYU
DM1SWYU	DN	PMID29334795-Compound-28
DM1SWYU	HS	Patented
DM1SWYU	CP	ARENA PHARMACEUTICALS, INC
DM1SWYU	DT	Small molecular drug
DM1SWYU	DE	Histamine H3-associated disorder

DMM30LJ	ID	DMM30LJ
DMM30LJ	DN	PMID29334795-Compound-55
DMM30LJ	HS	Patented
DMM30LJ	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMM30LJ	DT	Small molecular drug
DMM30LJ	PC	71271072
DMM30LJ	MW	369.5
DMM30LJ	FM	C24H35NO2
DMM30LJ	IC	InChI=1S/C24H35NO2/c1-27-23-11-14-24(26,15-12-23)21-9-7-20(8-10-21)18-19-4-3-16-25(17-13-19)22-5-2-6-22/h7-10,18,22-23,26H,2-6,11-17H2,1H3/b19-18+
DMM30LJ	CS	COC1CCC(CC1)(C2=CC=C(C=C2)/C=C/3\\CCCN(CC3)C4CCC4)O
DMM30LJ	IK	CVCLZBKTZVQEGU-VHEBQXMUSA-N
DMM30LJ	IU	1-[4-[(E)-(1-cyclobutylazepan-4-ylidene)methyl]phenyl]-4-methoxycyclohexan-1-ol

DMS9Q3U	ID	DMS9Q3U
DMS9Q3U	DN	PMID29334795-Compound-56
DMS9Q3U	HS	Patented
DMS9Q3U	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMS9Q3U	DT	Small molecular drug
DMS9Q3U	PC	71271008
DMS9Q3U	MW	355.5
DMS9Q3U	FM	C23H33NO2
DMS9Q3U	IC	InChI=1S/C23H33NO2/c1-26-22-9-13-23(25,14-10-22)20-7-5-18(6-8-20)17-19-11-15-24(16-12-19)21-3-2-4-21/h5-8,17,21-22,25H,2-4,9-16H2,1H3
DMS9Q3U	CS	COC1CCC(CC1)(C2=CC=C(C=C2)C=C3CCN(CC3)C4CCC4)O
DMS9Q3U	IK	PTJSNMGOBXREIH-UHFFFAOYSA-N
DMS9Q3U	IU	1-[4-[(1-cyclobutylpiperidin-4-ylidene)methyl]phenyl]-4-methoxycyclohexan-1-ol

DMGO1PA	ID	DMGO1PA
DMGO1PA	DN	PMID29334795-Compound-57
DMGO1PA	HS	Patented
DMGO1PA	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMGO1PA	DT	Small molecular drug
DMGO1PA	PC	71271826
DMGO1PA	MW	307.4
DMGO1PA	FM	C20H25N3
DMGO1PA	IC	InChI=1S/C20H25N3/c1-22-15-19(14-21-22)18-7-5-16(6-8-18)13-17-9-11-23(12-10-17)20-3-2-4-20/h5-8,13-15,20H,2-4,9-12H2,1H3
DMGO1PA	CS	CN1C=C(C=N1)C2=CC=C(C=C2)C=C3CCN(CC3)C4CCC4
DMGO1PA	IK	JKRRUTHXHYUIML-UHFFFAOYSA-N
DMGO1PA	IU	1-cyclobutyl-4-[[4-(1-methylpyrazol-4-yl)phenyl]methylidene]piperidine

DMB8GHJ	ID	DMB8GHJ
DMB8GHJ	DN	PMID29334795-Compound-58
DMB8GHJ	HS	Patented
DMB8GHJ	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMB8GHJ	DT	Small molecular drug
DMB8GHJ	PC	71271057
DMB8GHJ	MW	325.5
DMB8GHJ	FM	C22H31NO
DMB8GHJ	IC	InChI=1S/C22H31NO/c24-22(19-4-1-2-5-19)20-10-8-17(9-11-20)16-18-12-14-23(15-13-18)21-6-3-7-21/h8-11,16,19,21-22,24H,1-7,12-15H2
DMB8GHJ	CS	C1CCC(C1)C(C2=CC=C(C=C2)C=C3CCN(CC3)C4CCC4)O
DMB8GHJ	IK	UWSZCEKCJNGAAH-UHFFFAOYSA-N
DMB8GHJ	IU	[4-[(1-cyclobutylpiperidin-4-ylidene)methyl]phenyl]-cyclopentylmethanol

DM9H3LI	ID	DM9H3LI
DM9H3LI	DN	PMID29334795-Compound-61
DM9H3LI	HS	Patented
DM9H3LI	DT	Small molecular drug
DM9H3LI	PC	122460116
DM9H3LI	MW	411.6
DM9H3LI	FM	C25H34FN3O
DM9H3LI	IC	InChI=1S/C25H34FN3O/c1-27(2)12-4-11-25(22-6-8-23(26)9-7-22)24-10-5-20(17-21(24)19-30-25)18-29-15-13-28(3)14-16-29/h5-10,17H,4,11-16,18-19H2,1-3H3
DM9H3LI	CS	CN1CCN(CC1)CC2=CC3=C(C=C2)C(OC3)(CCCN(C)C)C4=CC=C(C=C4)F
DM9H3LI	IK	SJDALWQXTPZZQB-UHFFFAOYSA-N
DM9H3LI	IU	3-[1-(4-fluorophenyl)-5-[(4-methylpiperazin-1-yl)methyl]-3H-2-benzofuran-1-yl]-N,N-dimethylpropan-1-amine

DMKAFPC	ID	DMKAFPC
DMKAFPC	DN	PMID29334795-Compound-62
DMKAFPC	HS	Patented
DMKAFPC	CP	AAPA B.V
DMKAFPC	DT	Small molecular drug
DMKAFPC	PC	71819442
DMKAFPC	MW	452.5
DMKAFPC	FM	C25H32N4O4
DMKAFPC	IC	InChI=1S/C25H32N4O4/c30-25-26-22-3-1-4-23(24(22)33-25)29-12-10-27(11-13-29)9-2-16-32-21-7-5-20(6-8-21)19-28-14-17-31-18-15-28/h1,3-8H,2,9-19H2,(H,26,30)
DMKAFPC	CS	C1CN(CCN1CCCOC2=CC=C(C=C2)CN3CCOCC3)C4=CC=CC5=C4OC(=O)N5
DMKAFPC	IK	JHTDAMZJAOPBAK-UHFFFAOYSA-N
DMKAFPC	IU	7-[4-[3-[4-(morpholin-4-ylmethyl)phenoxy]propyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one

DMQOF53	ID	DMQOF53
DMQOF53	DN	PMID29334795-Compound-66
DMQOF53	HS	Patented
DMQOF53	CP	AAPA B.V
DMQOF53	DT	Small molecular drug
DMQOF53	PC	118063527
DMQOF53	MW	462.6
DMQOF53	FM	C27H34N4O3
DMQOF53	IC	InChI=1S/C27H34N4O3/c32-27-28-24-5-2-6-25(26(24)34-27)31-17-15-29(16-18-31)19-20-7-9-22(10-8-20)33-23-11-13-30(14-12-23)21-3-1-4-21/h2,5-10,21,23H,1,3-4,11-19H2,(H,28,32)
DMQOF53	CS	C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)CN4CCN(CC4)C5=CC=CC6=C5OC(=O)N6
DMQOF53	IK	MCJUAFCGICUNIN-UHFFFAOYSA-N
DMQOF53	IU	7-[4-[[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one

DMC95N7	ID	DMC95N7
DMC95N7	DN	PMID29334795-Compound-67
DMC95N7	HS	Patented
DMC95N7	CP	AAPA B.V
DMC95N7	DT	Small molecular drug
DMC95N7	PC	118064808
DMC95N7	MW	504.7
DMC95N7	FM	C30H40N4O3
DMC95N7	IC	InChI=1S/C30H40N4O3/c1-22-30(35)31(2)27-7-4-8-28(29(27)36-22)34-19-17-32(18-20-34)21-23-9-11-25(12-10-23)37-26-13-15-33(16-14-26)24-5-3-6-24/h4,7-12,22,24,26H,3,5-6,13-21H2,1-2H3
DMC95N7	CS	CC1C(=O)N(C2=C(O1)C(=CC=C2)N3CCN(CC3)CC4=CC=C(C=C4)OC5CCN(CC5)C6CCC6)C
DMC95N7	IK	FPIGKLIJDSBXLG-UHFFFAOYSA-N
DMC95N7	IU	8-[4-[[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]methyl]piperazin-1-yl]-2,4-dimethyl-1,4-benzoxazin-3-one

DMDJFUX	ID	DMDJFUX
DMDJFUX	DN	PMID29338548-Compound-13
DMDJFUX	HS	Patented
DMDJFUX	CP	GLAXO GROUP LIMITED BRADLEY, Daniel, Marcus BRANCH, Clive, Leslie CHAN, Wai, Ngor COULTON, Steven GILPIN, Martin, Leonard HARRIS, Andrew, Jonathan JAXA-CHAMIEC, Albert, Andrzej LAI, Justine, Yeun, Quai MARSHALL, Howard, Robert MACRITCHIE, Jacqueline, Anne NASH, David, John PORTER, Roderick, Alan SPADA, Simone THEWLIS, Kevin, Michael WARD, Simon, Edward
DMDJFUX	DT	Small molecular drug
DMDJFUX	DE	Schizophrenia

DMXIO9A	ID	DMXIO9A
DMXIO9A	DN	PMID29338548-Compound-14
DMXIO9A	HS	Patented
DMXIO9A	DT	Small molecular drug

DM6J0Z8	ID	DM6J0Z8
DM6J0Z8	DN	PMID29338548-Compound-15
DM6J0Z8	HS	Patented
DM6J0Z8	DT	Small molecular drug

DMQNVUB	ID	DMQNVUB
DMQNVUB	DN	PMID29338548-Compound-16
DMQNVUB	HS	Patented
DMQNVUB	CP	F. HOFFMANN-LA ROCHE AG KOLCZEWSKI, Sabine PINARD, Emmanuel
DMQNVUB	DT	Small molecular drug
DMQNVUB	PC	58567900
DMQNVUB	MW	478.6
DMQNVUB	FM	C25H29F3N2O2S
DMQNVUB	IC	InChI=1S/C25H29F3N2O2S/c1-32-19-15-18(25(26,27)28)16-20(33-2)22(19)23(31)29-24(17-9-4-3-5-10-17)12-8-14-30-13-7-6-11-21(24)30/h3-5,9-10,15-16,21H,6-8,11-14H2,1-2H3,(H,29,31)/t21-,24+/m1/s1
DMQNVUB	CS	COC1=C(C(=CC(=C1)C(F)(F)F)SC)C(=O)N[C@@]2(CCCN3[C@@H]2CCCC3)C4=CC=CC=C4
DMQNVUB	IK	VEQWRPXCFYIVLR-QPPBQGQZSA-N
DMQNVUB	IU	N-[(1S,9aR)-1-phenyl-2,3,4,6,7,8,9,9a-octahydroquinolizin-1-yl]-2-methoxy-6-methylsulfanyl-4-(trifluoromethyl)benzamide

DMFXCPQ	ID	DMFXCPQ
DMFXCPQ	DN	PMID29338548-Compound-17
DMFXCPQ	HS	Patented
DMFXCPQ	CP	F. HOFFMANN-LA ROCHE AG
DMFXCPQ	DT	Small molecular drug

DM0XA3D	ID	DM0XA3D
DM0XA3D	DN	PMID29338548-Compound-18
DM0XA3D	HS	Patented
DM0XA3D	CP	F. HOFFMANN-LA ROCHE AG 
DM0XA3D	DT	Small molecular drug

DMKHTE1	ID	DMKHTE1
DMKHTE1	DN	PMID29338548-Compound-19
DMKHTE1	HS	Patented
DMKHTE1	CP	F. HOFFMANN-LA ROCHE AG KOLCZEWSKI, Sabine PINARD, Emmanuel
DMKHTE1	DT	Small molecular drug

DMZ3EHV	ID	DMZ3EHV
DMZ3EHV	DN	PMID29338548-Compound-20
DMZ3EHV	HS	Patented
DMZ3EHV	DT	Small molecular drug

DMRTBKC	ID	DMRTBKC
DMRTBKC	DN	PMID29338548-Compound-21
DMRTBKC	HS	Patented
DMRTBKC	CP	ALBANY MOLECULAR RESEARCH, INC. CIOFFI, Christopher, L. WOLF, Mark, A. GUZZO, Peter, R. LIU, Shuang SADALAPURE, Kashinath PARTHASARATHY, Visweswaren MAENG, Jun-ho
DMRTBKC	DT	Small molecular drug
DMRTBKC	DE	Schizophrenia

DMT3AL5	ID	DMT3AL5
DMT3AL5	DN	PMID29338548-Compound-22
DMT3AL5	HS	Patented
DMT3AL5	CP	ALBANY MOLECULAR RESEARCH, INC. CIOFFI, Christopher, L. WOLF, Mark, A. GUZZO, Peter, R. LIU, Shuang SADALAPURE, Kashinath PARTHASARATHY, Visweswaren MAENG, Jun-ho
DMT3AL5	DT	Small molecular drug

DMTA3D8	ID	DMTA3D8
DMTA3D8	DN	PMID29338548-Compound-23
DMTA3D8	HS	Patented
DMTA3D8	CP	ALBANY MOLECULAR RESEARCH, INC. CIOFFI, Christopher, L. WOLF, Mark, A. GUZZO, Peter, R. LIU, Shuang SADALAPURE, Kashinath PARTHASARATHY, Visweswaren MAENG, Jun-ho
DMTA3D8	DT	Small molecular drug

DMWRGOX	ID	DMWRGOX
DMWRGOX	DN	PMID29338548-Compound-24
DMWRGOX	HS	Patented
DMWRGOX	CP	ABBOTT GMBH &amCO. KG ABBOTT LABORATORIES AMBERG, Wilhelm OCHSE, Michael LANGE, Udo BEHL, Berthold HORNBERGER, Wilfried MEZLER, Mario POHLKI, Frauke TURNER, Sean HUTCHINS, Charles
DMWRGOX	DT	Small molecular drug

DM83LWC	ID	DM83LWC
DM83LWC	DN	PMID29338548-Compound-25
DM83LWC	HS	Patented
DM83LWC	DT	Small molecular drug

DMT2D5H	ID	DMT2D5H
DMT2D5H	DN	PMID29338548-Compound-26
DMT2D5H	HS	Patented
DMT2D5H	CP	ABBVIE DEUTSCHLAND [DEABBVIE INC [US] 
DMT2D5H	DT	Small molecular drug

DMNW37Y	ID	DMNW37Y
DMNW37Y	DN	PMID29338548-Compound-27
DMNW37Y	HS	Patented
DMNW37Y	CP	ABBVIE DEUTSCHLAND GMBH &amCO. KG ABBVIE INC. AMBERG, Wilhelm LANGE, Udo OCHSE, Michael POHLKI, Frauke BEHL, Berthold MEZLER, Mario HORNBERGER, Wilfried HUTCHINS, Charles W
DMNW37Y	DT	Small molecular drug

DMNBT3K	ID	DMNBT3K
DMNBT3K	DN	PMID29338548-Compound-28
DMNBT3K	HS	Patented
DMNBT3K	CP	ABBOTT GMBH & CO. KG LANGE, Udo HEUTLING, Andreas AMBERG, Wilhelm OCHSE, Michael BEHL, Berthold HORNBERGER, Wilfried MEZLER, Mario
DMNBT3K	DT	Small molecular drug

DMUGC53	ID	DMUGC53
DMUGC53	DN	PMID29338548-Compound-29
DMUGC53	HS	Patented
DMUGC53	CP	ABBVIE DEUTSCHLAND GMBH &amCO. KG ABBVIE INC
DMUGC53	DT	Small molecular drug

DM8JK2D	ID	DM8JK2D
DM8JK2D	DN	PMID29338548-Compound-30
DM8JK2D	HS	Patented
DM8JK2D	DT	Small molecular drug

DMWMPE2	ID	DMWMPE2
DMWMPE2	DN	PMID29338548-Compound-31
DMWMPE2	HS	Patented
DMWMPE2	CP	ABBVIE DEUTSCHLAND GMBH & CO. KG ABBVIE INC
DMWMPE2	DT	Small molecular drug

DM4Q5SW	ID	DM4Q5SW
DM4Q5SW	DN	PMID29338548-Compound-33
DM4Q5SW	HS	Patented
DM4Q5SW	CP	TAISHO PHARMACEUTICAL CO., LTD. YASUHARA, Akito SAKAGAMI, Kazunari OHTA, Hiroshi HAYASHI, Masato SHIRASAKI, Yoshihisa YAMAMOTO, Shuji SHIMAZAKI, Youichi ARAKI, Yuko ABE, Kumi SUN, Xiang-Min
DM4Q5SW	DT	Small molecular drug

DM839NQ	ID	DM839NQ
DM839NQ	DN	PMID29338548-Compound-34
DM839NQ	HS	Patented
DM839NQ	DT	Small molecular drug

DMG675B	ID	DMG675B
DMG675B	DN	PMID29338548-Compound-36
DMG675B	HS	Patented
DMG675B	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH GIOVANNINI, Riccardo BERTANI, Barbara FERRARA, Marco LINGARD, Iain MAZZAFERRO, Rocco ROSENBROCK, Holger
DMG675B	DT	Small molecular drug

DMAM0US	ID	DMAM0US
DMAM0US	DN	PMID29338548-Compound-37
DMAM0US	HS	Patented
DMAM0US	CP	DART NEUROSCIENCE (CAYMAN) LTD
DMAM0US	DT	Small molecular drug

DM6BKQ8	ID	DM6BKQ8
DM6BKQ8	DN	PMID29338548-Compound-38
DM6BKQ8	HS	Patented
DM6BKQ8	CP	DART NEUROSCIENCE (CAYMAN) LTD
DM6BKQ8	DT	Small molecular drug

DM69Y7R	ID	DM69Y7R
DM69Y7R	DN	PMID29338548-Compound-39
DM69Y7R	HS	Patented
DM69Y7R	DT	Small molecular drug

DMLAHC1	ID	DMLAHC1
DMLAHC1	DN	PMID29338548-Compound-40
DMLAHC1	HS	Patented
DMLAHC1	DT	Small molecular drug

DM2L7ES	ID	DM2L7ES
DM2L7ES	DN	PMID29338548-Compound-41
DM2L7ES	HS	Patented
DM2L7ES	DT	Small molecular drug

DMJYQLC	ID	DMJYQLC
DMJYQLC	DN	PMID29338548-Compound-44
DMJYQLC	HS	Patented
DMJYQLC	DT	Small molecular drug

DMO4JYK	ID	DMO4JYK
DMO4JYK	DN	PMID29338548-Compound-45
DMO4JYK	HS	Patented
DMO4JYK	CP	TAISHO PHARMA CO LTD [JP]
DMO4JYK	DT	Small molecular drug

DMRKIA1	ID	DMRKIA1
DMRKIA1	DN	PMID29338548-Compound-46
DMRKIA1	HS	Patented
DMRKIA1	CP	TAISHO PHARMA CO LTD [JP]
DMRKIA1	DT	Small molecular drug

DMHBOK6	ID	DMHBOK6
DMHBOK6	DN	PMID29338548-Compound-47
DMHBOK6	HS	Patented
DMHBOK6	CP	TAISHO PHARMA CO LTD [JP]
DMHBOK6	DT	Small molecular drug

DMDRJHO	ID	DMDRJHO
DMDRJHO	DN	PMID29338548-Compound-48
DMDRJHO	HS	Patented
DMDRJHO	CP	GLAXO GROUP LIMITED BLUNT, Richard EATHERTON, Andrew John GARZYA, Vincenzo HEALY, Mark Patrick MYATT, James PORTER, Roderick Alan
DMDRJHO	DT	Small molecular drug

DM1NJ3U	ID	DM1NJ3U
DM1NJ3U	DN	PMID29338548-Compound-49
DM1NJ3U	HS	Patented
DM1NJ3U	DT	Small molecular drug

DM7EW5U	ID	DM7EW5U
DM7EW5U	DN	PMID29473428-Compound-10
DM7EW5U	HS	Patented
DM7EW5U	CP	IOMET PHARMA LTD. MERCK SHARP & DOHME CORP. COWLEY, Phillip, M. WISE, Alan BROWN, Thomas, J. MCGOWAN, Meredeth, A. ZHOU, Hua HAN, Yongxin
DM7EW5U	DT	Small molecular drug
DM7EW5U	PC	124189844
DM7EW5U	MW	387.3
DM7EW5U	FM	C14H19BrN4O2S
DM7EW5U	IC	InChI=1S/C14H19BrN4O2S/c1-14(2)9-17(4-5-19(14)22(3,20)21)13-7-11(15)6-12-8-16-10-18(12)13/h6-8,10H,4-5,9H2,1-3H3
DM7EW5U	CS	CC1(CN(CCN1S(=O)(=O)C)C2=CC(=CC3=CN=CN23)Br)C
DM7EW5U	IK	MJEJSWKBPXDOCH-UHFFFAOYSA-N
DM7EW5U	IU	7-bromo-5-(3,3-dimethyl-4-methylsulfonylpiperazin-1-yl)imidazo[1,5-a]pyridine

DM5MXFK	ID	DM5MXFK
DM5MXFK	DN	PMID29473428-Compound-11
DM5MXFK	HS	Patented
DM5MXFK	CP	IOMET PHARMA LTD. MERCK SHARP & DOHME CORP. COWLEY, Phillip, M. WISE, Alan BROWN, Thomas, J. MCGOWAN, Meredeth, A. ZHOU, Hua HAN, Yongxin
DM5MXFK	DT	Small molecular drug

DMCB0D6	ID	DMCB0D6
DMCB0D6	DN	PMID29473428-Compound-14
DMCB0D6	HS	Patented
DMCB0D6	CP	AUCKLAND UNISERVICES LIMITED
DMCB0D6	DT	Small molecular drug
DMCB0D6	PC	5305899
DMCB0D6	MW	197.62
DMCB0D6	FM	C8H8ClN3O
DMCB0D6	IC	InChI=1S/C8H8ClN3O/c1-3-5-7(10)12-13-8(5)11-4(2)6(3)9/h1-2H3,(H2,10,12)
DMCB0D6	CS	CC1=C2C(=NOC2=NC(=C1Cl)C)N
DMCB0D6	IK	XEYWCHKONZUDGB-UHFFFAOYSA-N
DMCB0D6	IU	5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-amine

DM571JP	ID	DM571JP
DM571JP	DN	PMID29473428-Compound-15
DM571JP	HS	Patented
DM571JP	CP	AUCKLAND UNISERVICES LIMITED
DM571JP	DT	Small molecular drug
DM571JP	PC	126640018
DM571JP	MW	317.72
DM571JP	FM	C15H12ClN3O3
DM571JP	IC	InChI=1S/C15H12ClN3O3/c1-8-11-13(19-22-14(11)17-9(2)12(8)16)18-15(20)21-10-6-4-3-5-7-10/h3-7H,1-2H3,(H,18,19,20)
DM571JP	CS	CC1=C2C(=NOC2=NC(=C1Cl)C)NC(=O)OC3=CC=CC=C3
DM571JP	IK	WUNZBHVIWUQNNS-UHFFFAOYSA-N
DM571JP	IU	phenyl N-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)carbamate

DM21QCE	ID	DM21QCE
DM21QCE	DN	PMID29473428-Compound-16
DM21QCE	HS	Patented
DM21QCE	CP	AUCKLAND UNISERVICES LIMITED
DM21QCE	DT	Small molecular drug
DM21QCE	PC	118867679
DM21QCE	MW	183.59
DM21QCE	FM	C7H6ClN3O
DM21QCE	IC	InChI=1S/C7H6ClN3O/c1-3-2-4(8)10-7-5(3)6(9)11-12-7/h2H,1H3,(H2,9,11)
DM21QCE	CS	CC1=CC(=NC2=C1C(=NO2)N)Cl
DM21QCE	IK	FQUKGVSRJVUOPA-UHFFFAOYSA-N
DM21QCE	IU	6-chloro-4-methyl-[1,2]oxazolo[5,4-b]pyridin-3-amine

DMI04GC	ID	DMI04GC
DMI04GC	DN	PMID29473428-Compound-17
DMI04GC	HS	Patented
DMI04GC	CP	AUCKLAND UNISERVICES LIMITED
DMI04GC	DT	Small molecular drug
DMI04GC	PC	118867629
DMI04GC	MW	187.56
DMI04GC	FM	C6H3ClFN3O
DMI04GC	IC	InChI=1S/C6H3ClFN3O/c7-4-3(8)1-2-5(9)11-12-6(2)10-4/h1H,(H2,9,11)
DMI04GC	CS	C1=C2C(=NOC2=NC(=C1F)Cl)N
DMI04GC	IK	MTIDNIWREKNKHM-UHFFFAOYSA-N
DMI04GC	IU	6-chloro-5-fluoro-[1,2]oxazolo[5,4-b]pyridin-3-amine

DMZGNWO	ID	DMZGNWO
DMZGNWO	DN	PMID29473428-Compound-21
DMZGNWO	HS	Patented
DMZGNWO	CP	MERCK SHARP &amDOHME CORP. HAN, Yongxin ACHAB, Abdelghani BIJU, Purakkattle DENG, Yongqi FRADERA, Xavier GUO, Liangqin HE, Shuwen KOZLOWSKI, Joseph KURUKULASURIYA, Ravi LIU, Kun MCGOWAN, Meredeth, A. PU, Qinglin SCIAMMETTA, Nunzio ZHANG, Hongjun ZHOU, Hua
DMZGNWO	DT	Small molecular drug

DMCNSZD	ID	DMCNSZD
DMCNSZD	DN	PMID29473428-Compound-22
DMCNSZD	HS	Patented
DMCNSZD	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
DMCNSZD	DT	Small molecular drug

DMBMTUV	ID	DMBMTUV
DMBMTUV	DN	PMID29473428-Compound-29
DMBMTUV	HS	Patented
DMBMTUV	CP	NEWLINK GENETICS CORPORATION MAUTINO, Mario KUMAR, Sanjeev WALDO, Jesse JAIPURI, Firoz KESHARWANI, Tanay ZHANG, Xiaoxia
DMBMTUV	DT	Small molecular drug

DMZA3FL	ID	DMZA3FL
DMZA3FL	DN	PMID29473428-Compound-33
DMZA3FL	HS	Patented
DMZA3FL	DT	Small molecular drug
DMZA3FL	PC	78426054
DMZA3FL	MW	282.4
DMZA3FL	FM	C18H22N2O
DMZA3FL	IC	InChI=1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-15-14-8-4-5-9-16(14)20-12-19-11-17(15)20/h4-5,8-9,11-13,15,18,21H,1-3,6-7,10H2
DMZA3FL	CS	C1CCC(CC1)C(CC2C3=CC=CC=C3N4C2=CN=C4)O
DMZA3FL	IK	MENMLCRHDMAGQE-UHFFFAOYSA-N
DMZA3FL	IU	1-cyclohexyl-2-(4H-imidazo[1,5-a]indol-4-yl)ethanol

DM7BRPI	ID	DM7BRPI
DM7BRPI	DN	PMID29473428-Compound-34
DM7BRPI	HS	Patented
DM7BRPI	CP	REDX PHARMA PLC
DM7BRPI	DT	Small molecular drug
DM7BRPI	PC	121254849
DM7BRPI	MW	262.3
DM7BRPI	FM	C17H14N2O
DM7BRPI	IC	InChI=1S/C17H14N2O/c1-12-6-2-5-9-16(12)20-17-13-7-3-4-8-14(13)19-11-18-10-15(17)19/h2-11,17H,1H3
DM7BRPI	CS	CC1=CC=CC=C1OC2C3=CC=CC=C3N4C2=CN=C4
DM7BRPI	IK	OZIYVKPSWZBCSG-UHFFFAOYSA-N
DM7BRPI	IU	4-(2-methylphenoxy)-4H-imidazo[1,5-a]indole

DMKRUPW	ID	DMKRUPW
DMKRUPW	DN	PMID29473428-Compound-39
DMKRUPW	HS	Patented
DMKRUPW	CP	MERCK PATENT GMBH SHERER, Brian A
DMKRUPW	DT	Small molecular drug
DMKRUPW	PC	118916909
DMKRUPW	MW	302.4
DMKRUPW	FM	C18H20F2N2
DMKRUPW	IC	InChI=1S/C18H20F2N2/c19-14-8-4-7-13-17-10-21-11-22(17)16(18(13)14)9-15(20)12-5-2-1-3-6-12/h4,7-8,10-12,15-16H,1-3,5-6,9H2
DMKRUPW	CS	C1CCC(CC1)C(CC2C3=C(C=CC=C3F)C4=CN=CN24)F
DMKRUPW	IK	OHWIXLJBJCDWBA-UHFFFAOYSA-N
DMKRUPW	IU	5-(2-cyclohexyl-2-fluoroethyl)-6-fluoro-5H-imidazo[5,1-a]isoindole

DM9KVOD	ID	DM9KVOD
DM9KVOD	DN	PMID29473428-Compound-4
DM9KVOD	HS	Patented
DM9KVOD	DT	Small molecular drug
DM9KVOD	PC	71941441
DM9KVOD	MW	295.33
DM9KVOD	FM	C13H14FN3O2S
DM9KVOD	IC	InChI=1S/C13H14FN3O2S/c14-10-1-2-11-12(8-16-13(11)7-10)9-3-5-17(6-4-9)20(15,18)19/h1-3,7-8,16H,4-6H2,(H2,15,18,19)
DM9KVOD	CS	C1CN(CC=C1C2=CNC3=C2C=CC(=C3)F)S(=O)(=O)N
DM9KVOD	IK	JQVNNQIVDXRAAV-UHFFFAOYSA-N
DM9KVOD	IU	4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridine-1-sulfonamide

DM4AOIR	ID	DM4AOIR
DM4AOIR	DN	PMID29473428-Compound-41
DM4AOIR	HS	Patented
DM4AOIR	CP	MERCK PATENT GMBH SHERER, Brian A
DM4AOIR	DT	Small molecular drug
DM4AOIR	PC	118917121
DM4AOIR	MW	301.36
DM4AOIR	FM	C17H20FN3O
DM4AOIR	IC	InChI=1S/C17H20FN3O/c18-17-6-12-13(8-20-17)15-9-19-10-21(15)14(12)7-16(22)11-4-2-1-3-5-11/h6,8-11,14,16,22H,1-5,7H2
DM4AOIR	CS	C1CCC(CC1)C(CC2C3=CC(=NC=C3C4=CN=CN24)F)O
DM4AOIR	IK	QUDWXPLDIKCCKW-UHFFFAOYSA-N
DM4AOIR	IU	1-cyclohexyl-2-(10-fluoro-4,6,11-triazatricyclo[6.4.0.02,6]dodeca-1(12),2,4,8,10-pentaen-7-yl)ethanol

DMQ8EYV	ID	DMQ8EYV
DMQ8EYV	DN	PMID29473428-Compound-43
DMQ8EYV	HS	Patented
DMQ8EYV	CP	REDX PHARMA PLC
DMQ8EYV	DT	Small molecular drug
DMQ8EYV	PC	121288667
DMQ8EYV	MW	390.7
DMQ8EYV	FM	C17H13BrClN3O
DMQ8EYV	IC	InChI=1S/C17H13BrClN3O/c18-10-1-2-12(14(19)5-10)17(23)6-15-11-3-4-20-7-13(11)16-8-21-9-22(15)16/h1-5,7-9,15,17,23H,6H2
DMQ8EYV	CS	C1=CC(=C(C=C1Br)Cl)C(CC2C3=C(C=NC=C3)C4=CN=CN24)O
DMQ8EYV	IK	FULOIPPDAZMZJS-UHFFFAOYSA-N
DMQ8EYV	IU	1-(4-bromo-2-chlorophenyl)-2-(4,6,11-triazatricyclo[6.4.0.02,6]dodeca-1(8),2,4,9,11-pentaen-7-yl)ethanol

DMCLJ0M	ID	DMCLJ0M
DMCLJ0M	DN	PMID29473428-Compound-47
DMCLJ0M	HS	Patented
DMCLJ0M	CP	SCIFLUOR LIFE SCIENCES, INC
DMCLJ0M	DT	Small molecular drug
DMCLJ0M	PC	129072590
DMCLJ0M	MW	298.4
DMCLJ0M	FM	C19H23FN2
DMCLJ0M	IC	InChI=1S/C19H23FN2/c20-18(14-6-2-1-3-7-14)11-16-10-15-8-4-5-9-17(15)19-12-21-13-22(16)19/h4-5,8-9,12-14,16,18H,1-3,6-7,10-11H2
DMCLJ0M	CS	C1CCC(CC1)C(CC2CC3=CC=CC=C3C4=CN=CN24)F
DMCLJ0M	IK	MCRCDKJVHBJTQP-UHFFFAOYSA-N
DMCLJ0M	IU	5-(2-cyclohexyl-2-fluoroethyl)-5,6-dihydroimidazo[5,1-a]isoquinoline

DMAYT2E	ID	DMAYT2E
DMAYT2E	DN	PMID29473428-Compound-48
DMAYT2E	HS	Patented
DMAYT2E	CP	EMCURE PHARMACEUTICALS LIMITED
DMAYT2E	DT	Small molecular drug

DMXUVDH	ID	DMXUVDH
DMXUVDH	DN	PMID29473428-Compound-50
DMXUVDH	HS	Patented
DMXUVDH	CP	EMCURE PHARMACEUTICALS LIMITED
DMXUVDH	DT	Small molecular drug
DMXUVDH	PC	130300332
DMXUVDH	MW	427.5
DMXUVDH	FM	C27H29N3O2
DMXUVDH	IC	InChI=1S/C27H29N3O2/c1-19-24-17-28-18-30(24)23(26(19)21-8-4-2-5-9-21)16-25(31)20-12-14-29(15-13-20)27(32)22-10-6-3-7-11-22/h2-11,17-18,20,23,25,31H,12-16H2,1H3
DMXUVDH	CS	CC1=C(C(N2C1=CN=C2)CC(C3CCN(CC3)C(=O)C4=CC=CC=C4)O)C5=CC=CC=C5
DMXUVDH	IK	AJSXKLLHMGVTFL-UHFFFAOYSA-N
DMXUVDH	IU	[4-[1-hydroxy-2-(7-methyl-6-phenyl-5H-pyrrolo[1,2-c]imidazol-5-yl)ethyl]piperidin-1-yl]-phenylmethanone

DMSXKP6	ID	DMSXKP6
DMSXKP6	DN	PMID29473428-Compound-52
DMSXKP6	HS	Patented
DMSXKP6	CP	KYOWA HAKKO KIRIN CO., LTD
DMSXKP6	DT	Small molecular drug

DMOASLQ	ID	DMOASLQ
DMOASLQ	DN	PMID29473428-Compound-53
DMOASLQ	HS	Patented
DMOASLQ	CP	BRISTOL-MYERS SQUIBB COMPANY
DMOASLQ	DT	Small molecular drug
DMOASLQ	PC	121339539
DMOASLQ	MW	500.6
DMOASLQ	FM	C28H29FN6O2
DMOASLQ	IC	InChI=1S/C28H29FN6O2/c1-3-5-6-11-19-17-20(21-12-7-8-13-22(21)27-32-34-35-33-27)18-25(26(19)37-16-4-2)31-28(36)30-24-15-10-9-14-23(24)29/h5-10,12-15,17-18H,3-4,11,16H2,1-2H3,(H2,30,31,36)(H,32,33,34,35)/b6-5+
DMOASLQ	CS	CCCOC1=C(C=C(C=C1NC(=O)NC2=CC=CC=C2F)C3=CC=CC=C3C4=NNN=N4)C/C=C/CC
DMOASLQ	IK	KTJPMWGPZICNCM-AATRIKPKSA-N
DMOASLQ	IU	1-(2-fluorophenyl)-3-[3-[(E)-pent-2-enyl]-2-propoxy-5-[2-(2H-tetrazol-5-yl)phenyl]phenyl]urea

DMKIS26	ID	DMKIS26
DMKIS26	DN	PMID29473428-Compound-54
DMKIS26	HS	Patented
DMKIS26	CP	BRISTOL-MYERS SQUIBB COMPANY
DMKIS26	DT	Small molecular drug
DMKIS26	PC	121339537
DMKIS26	MW	567.5
DMKIS26	FM	C27H28BrFN6O2
DMKIS26	IC	InChI=1S/C27H28BrFN6O2/c1-3-9-18(10-4-2)37-25-21(28)15-17(19-11-5-6-12-20(19)26-32-34-35-33-26)16-24(25)31-27(36)30-23-14-8-7-13-22(23)29/h5-8,11-16,18H,3-4,9-10H2,1-2H3,(H2,30,31,36)(H,32,33,34,35)
DMKIS26	CS	CCCC(CCC)OC1=C(C=C(C=C1Br)C2=CC=CC=C2C3=NNN=N3)NC(=O)NC4=CC=CC=C4F
DMKIS26	IK	RCDIDCDPBBVKLP-UHFFFAOYSA-N
DMKIS26	IU	1-[3-bromo-2-heptan-4-yloxy-5-[2-(2H-tetrazol-5-yl)phenyl]phenyl]-3-(2-fluorophenyl)urea

DMVP7DL	ID	DMVP7DL
DMVP7DL	DN	PMID29473428-Compound-58
DMVP7DL	HS	Patented
DMVP7DL	CP	BRISTOL-MYERS SQUIBB COMPANY
DMVP7DL	DT	Small molecular drug
DMVP7DL	PC	118898844
DMVP7DL	MW	515.5
DMVP7DL	FM	C25H30F5N3O3
DMVP7DL	IC	InChI=1S/C25H30F5N3O3/c1-14(2)12-33(13-15(3)4)22-8-5-16(18(11-23(34)35)25(28,29)30)9-21(22)32-24(36)31-20-7-6-17(26)10-19(20)27/h5-10,14-15,18H,11-13H2,1-4H3,(H,34,35)(H2,31,32,36)
DMVP7DL	CS	CC(C)CN(CC(C)C)C1=C(C=C(C=C1)C(CC(=O)O)C(F)(F)F)NC(=O)NC2=C(C=C(C=C2)F)F
DMVP7DL	IK	LLRWXYAXYSABOE-UHFFFAOYSA-N
DMVP7DL	IU	3-[4-[bis(2-methylpropyl)amino]-3-[(2,4-difluorophenyl)carbamoylamino]phenyl]-4,4,4-trifluorobutanoic acid

DMJYUN2	ID	DMJYUN2
DMJYUN2	DN	PMID29473428-Compound-59
DMJYUN2	HS	Patented
DMJYUN2	CP	BRISTOL-MYERS SQUIBB COMPANY
DMJYUN2	DT	Small molecular drug
DMJYUN2	PC	117614378
DMJYUN2	MW	454.6
DMJYUN2	FM	C25H34N4O4
DMJYUN2	IC	InChI=1S/C25H34N4O4/c1-15(2)14-29(18-7-5-4-6-8-18)22-10-9-17(19-13-20(19)24(30)31)12-21(22)26-25(32)27-23-11-16(3)28-33-23/h9-12,15,18-20H,4-8,13-14H2,1-3H3,(H,30,31)(H2,26,27,32)/t19-,20-/m0/s1
DMJYUN2	CS	CC1=NOC(=C1)NC(=O)NC2=C(C=CC(=C2)[C@@H]3C[C@@H]3C(=O)O)N(CC(C)C)C4CCCCC4
DMJYUN2	IK	JFOVWQVFKHJGRN-PMACEKPBSA-N
DMJYUN2	IU	(1S,2R)-2-[4-[cyclohexyl(2-methylpropyl)amino]-3-[(3-methyl-1,2-oxazol-5-yl)carbamoylamino]phenyl]cyclopropane-1-carboxylic acid

DMOVPWD	ID	DMOVPWD
DMOVPWD	DN	PMID29473428-Compound-6
DMOVPWD	HS	Patented
DMOVPWD	CP	IOMET PHARMA LTD
DMOVPWD	DT	Small molecular drug
DMOVPWD	PC	7323927
DMOVPWD	MW	298.8
DMOVPWD	FM	C17H15ClN2O
DMOVPWD	IC	InChI=1S/C17H15ClN2O/c1-11(12-5-3-2-4-6-12)19-17(21)16-10-13-9-14(18)7-8-15(13)20-16/h2-11,20H,1H3,(H,19,21)/t11-/m0/s1
DMOVPWD	CS	C[C@@H](C1=CC=CC=C1)NC(=O)C2=CC3=C(N2)C=CC(=C3)Cl
DMOVPWD	IK	KNBUEFQZZKXGIC-NSHDSACASA-N
DMOVPWD	IU	5-chloro-N-[(1S)-1-phenylethyl]-1H-indole-2-carboxamide

DMRKWPQ	ID	DMRKWPQ
DMRKWPQ	DN	PMID29473428-Compound-60
DMRKWPQ	HS	Patented
DMRKWPQ	CP	BRISTOL-MYERS SQUIBB COMPANY
DMRKWPQ	DT	Small molecular drug
DMRKWPQ	PC	124158753
DMRKWPQ	MW	492
DMRKWPQ	FM	C25H31ClFN3O4
DMRKWPQ	IC	InChI=1S/C25H31ClFN3O4/c1-16(2)14-30(18-6-4-3-5-7-18)23-11-9-19(34-15-24(31)32)13-22(23)29-25(33)28-21-10-8-17(26)12-20(21)27/h8-13,16,18H,3-7,14-15H2,1-2H3,(H,31,32)(H2,28,29,33)
DMRKWPQ	CS	CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)OCC(=O)O)NC(=O)NC3=C(C=C(C=C3)Cl)F
DMRKWPQ	IK	TVQUEBMGNJZEOT-UHFFFAOYSA-N
DMRKWPQ	IU	2-[3-[(4-chloro-2-fluorophenyl)carbamoylamino]-4-[cyclohexyl(2-methylpropyl)amino]phenoxy]acetic acid

DMMV5KI	ID	DMMV5KI
DMMV5KI	DN	PMID29473428-Compound-70
DMMV5KI	HS	Patented
DMMV5KI	CP	FLEXUS BIOSCIENCES, INC
DMMV5KI	DT	Small molecular drug
DMMV5KI	PC	121318124
DMMV5KI	MW	427.9
DMMV5KI	FM	C23H23ClFN3O2
DMMV5KI	IC	InChI=1S/C23H23ClFN3O2/c1-15(23(29)27-18-5-2-16(24)3-6-18)28-12-9-19(10-13-28)30-22-8-11-26-21-7-4-17(25)14-20(21)22/h2-8,11,14-15,19H,9-10,12-13H2,1H3,(H,27,29)
DMMV5KI	CS	CC(C(=O)NC1=CC=C(C=C1)Cl)N2CCC(CC2)OC3=C4C=C(C=CC4=NC=C3)F
DMMV5KI	IK	JOMPEBQANPZAPO-UHFFFAOYSA-N
DMMV5KI	IU	N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)oxypiperidin-1-yl]propanamide

DML5G6D	ID	DML5G6D
DML5G6D	DN	PMID29473428-Compound-71
DML5G6D	HS	Patented
DML5G6D	CP	FLEXUS BIOSCIENCES, INC
DML5G6D	DT	Small molecular drug
DML5G6D	PC	138490227
DML5G6D	MW	410.9
DML5G6D	FM	C21H22ClF3N2O
DML5G6D	IC	InChI=1S/C21H22ClF3N2O/c1-13(20(28)27-18-8-6-17(22)7-9-18)14-2-4-15(5-3-14)16-10-11-26-19(12-16)21(23,24)25/h6-15H,2-5H2,1H3,(H,27,28)
DML5G6D	CS	CC(C1CCC(CC1)C2=CC(=NC=C2)C(F)(F)F)C(=O)NC3=CC=C(C=C3)Cl
DML5G6D	IK	WSWKMGSCQQQPBU-UHFFFAOYSA-N
DML5G6D	IU	N-(4-chlorophenyl)-2-[4-[2-(trifluoromethyl)pyridin-4-yl]cyclohexyl]propanamide

DMJOBUZ	ID	DMJOBUZ
DMJOBUZ	DN	PMID29473428-Compound-72
DMJOBUZ	HS	Patented
DMJOBUZ	CP	FLEXUS BIOSCIENCES, INC
DMJOBUZ	DT	Small molecular drug

DM8PZ46	ID	DM8PZ46
DM8PZ46	DN	PMID29473428-Compound-76
DM8PZ46	HS	Patented
DM8PZ46	CP	IOMET PHARMA LTD
DM8PZ46	DT	Small molecular drug
DM8PZ46	PC	121325256
DM8PZ46	MW	342.4
DM8PZ46	FM	C17H14N2O4S
DM8PZ46	IC	InChI=1S/C17H14N2O4S/c20-24(21,13-4-5-16-17(10-13)23-9-8-22-16)19-15-3-1-2-12-11-18-7-6-14(12)15/h1-7,10-11,19H,8-9H2
DM8PZ46	CS	C1COC2=C(O1)C=CC(=C2)S(=O)(=O)NC3=CC=CC4=C3C=CN=C4
DM8PZ46	IK	QYTGSNGNCQHITP-UHFFFAOYSA-N
DM8PZ46	IU	N-isoquinolin-5-yl-2,3-dihydro-1,4-benzodioxine-6-sulfonamide

DM8VBU2	ID	DM8VBU2
DM8VBU2	DN	PMID29473428-Compound-80
DM8VBU2	HS	Patented
DM8VBU2	CP	VERTEX PHARMACEUTICALS INCORPORATED
DM8VBU2	DT	Small molecular drug
DM8VBU2	PC	75202660
DM8VBU2	MW	252.7
DM8VBU2	FM	C11H13ClN4O
DM8VBU2	IC	InChI=1S/C11H13ClN4O/c1-17-5-4-8-6-9(12)2-3-10(8)14-11-7-13-16-15-11/h2-3,6-7H,4-5H2,1H3,(H2,13,14,15,16)
DM8VBU2	CS	COCCC1=C(C=CC(=C1)Cl)NC2=NNN=C2
DM8VBU2	IK	ZVGDDDHHESZRQT-UHFFFAOYSA-N
DM8VBU2	IU	N-[4-chloro-2-(2-methoxyethyl)phenyl]-2H-triazol-4-amine

DMDKT9X	ID	DMDKT9X
DMDKT9X	DN	PMID29649907-Compound-1
DMDKT9X	HS	Patented
DMDKT9X	CP	INTERCEPT PHARMACEUTICALS, INC
DMDKT9X	DT	Small molecular drug
DMDKT9X	PC	126582691
DMDKT9X	MW	420.6
DMDKT9X	FM	C26H44O4
DMDKT9X	IC	InChI=1S/C26H44O4/c1-5-16-18-8-6-7-13-25(18,3)23-20(27)14-26(4)17(15(2)9-12-21(28)29)10-11-19(26)22(23)24(16)30/h15-20,22-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18+,19?,20+,22?,23?,24-,25+,26-/m1/s1
DMDKT9X	CS	CC[C@@H]1[C@@H]2CCCC[C@@]2(C3[C@H](C[C@@]4([C@H](CCC4C3[C@@H]1O)[C@H](C)CCC(=O)O)C)O)C
DMDKT9X	IK	IMDDBKRWRHUMNT-QAUCXMOESA-N
DMDKT9X	IU	(4R)-4-[(5S,6R,7R,10S,11S,13R,17R)-6-ethyl-7,11-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

DMNE9AX	ID	DMNE9AX
DMNE9AX	DN	PMID29649907-Compound-10
DMNE9AX	HS	Patented
DMNE9AX	CP	ENANTA PHARMACEUTICALS, INC
DMNE9AX	DT	Small molecular drug

DMSC9MH	ID	DMSC9MH
DMSC9MH	DN	PMID29649907-Compound-11
DMSC9MH	HS	Patented
DMSC9MH	CP	ENANTA PHARMACEUTICALS, INC
DMSC9MH	DT	Small molecular drug

DMBHT2E	ID	DMBHT2E
DMBHT2E	DN	PMID29649907-Compound-12
DMBHT2E	HS	Patented
DMBHT2E	CP	ENANTA PHARMACEUTICALS, INC
DMBHT2E	DT	Small molecular drug

DMLBQUS	ID	DMLBQUS
DMLBQUS	DN	PMID29649907-Compound-13
DMLBQUS	HS	Patented
DMLBQUS	CP	ENANTA PHARMACEUTICALS, INC
DMLBQUS	DT	Small molecular drug

DMQAV30	ID	DMQAV30
DMQAV30	DN	PMID29649907-Compound-14
DMQAV30	HS	Patented
DMQAV30	CP	ENANTA PHARMACEUTICALS, INC
DMQAV30	DT	Small molecular drug

DMMIKFU	ID	DMMIKFU
DMMIKFU	DN	PMID29649907-Compound-15
DMMIKFU	HS	Patented
DMMIKFU	CP	ENANTA PHARMACEUTICALS, INC
DMMIKFU	DT	Small molecular drug

DMBVOZK	ID	DMBVOZK
DMBVOZK	DN	PMID29649907-Compound-18
DMBVOZK	HS	Patented
DMBVOZK	CP	GILEAD SCIENCES, INC
DMBVOZK	DT	Small molecular drug
DMBVOZK	PC	121414040
DMBVOZK	MW	600.9
DMBVOZK	FM	C29H24Cl3N3O5
DMBVOZK	IC	InChI=1S/C29H24Cl3N3O5/c30-21-2-1-3-22(31)25(21)26-19(27(40-34-26)16-4-5-16)14-39-18-7-8-20(23(32)12-18)29(38)10-11-35(15-29)24-9-6-17(13-33-24)28(36)37/h1-3,6-9,12-13,16,38H,4-5,10-11,14-15H2,(H,36,37)
DMBVOZK	CS	C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5(CCN(C5)C6=NC=C(C=C6)C(=O)O)O)Cl
DMBVOZK	IK	YGRGAPWBPFVISR-UHFFFAOYSA-N
DMBVOZK	IU	6-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxypyrrolidin-1-yl]pyridine-3-carboxylic acid

DMFL38V	ID	DMFL38V
DMFL38V	DN	PMID29649907-Compound-19
DMFL38V	HS	Patented
DMFL38V	CP	SUNSHINE LAKE PHARMA CO., LTD
DMFL38V	DT	Small molecular drug
DMFL38V	PC	122491783
DMFL38V	MW	572.4
DMFL38V	FM	C27H19Cl2NO7S
DMFL38V	IC	InChI=1S/C27H19Cl2NO7S/c28-19-2-1-3-20(29)24(19)25-18(26(37-30-25)14-4-5-14)12-35-17-8-9-21-23(11-17)38(33,34)13-16-7-6-15(27(31)32)10-22(16)36-21/h1-3,6-11,14H,4-5,12-13H2,(H,31,32)
DMFL38V	CS	C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC5=C(C=C4)OC6=C(CS5(=O)=O)C=CC(=C6)C(=O)O
DMFL38V	IK	LTDMSLKNDBRACZ-UHFFFAOYSA-N
DMFL38V	IU	3-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-5,5-dioxo-6H-benzo[b][1,5]benzoxathiepine-9-carboxylic acid

DMM4TBH	ID	DMM4TBH
DMM4TBH	DN	PMID29649907-Compound-2
DMM4TBH	HS	Patented
DMM4TBH	CP	INTERCEPT PHARMACEUTICALS, INC
DMM4TBH	DT	Small molecular drug

DMGNW34	ID	DMGNW34
DMGNW34	DN	PMID29649907-Compound-20
DMGNW34	HS	Patented
DMGNW34	CP	SUNSHINE LAKE PHARMA CO., LTD
DMGNW34	DT	Small molecular drug
DMGNW34	PC	122491785
DMGNW34	MW	600.5
DMGNW34	FM	C28H23Cl2N3O6S
DMGNW34	IC	InChI=1S/C28H23Cl2N3O6S/c1-40(35,36)33-28(34)17-8-5-15-9-10-21-22(38-23(15)13-17)11-12-24(31-21)37-14-18-26(32-39-27(18)16-6-7-16)25-19(29)3-2-4-20(25)30/h2-5,8,11-13,16H,6-7,9-10,14H2,1H3,(H,33,34)
DMGNW34	CS	CS(=O)(=O)NC(=O)C1=CC2=C(CCC3=C(O2)C=CC(=N3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6)C=C1
DMGNW34	IK	ADZBYRFCADJPGB-UHFFFAOYSA-N
DMGNW34	IU	3-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-N-methylsulfonyl-5,6-dihydro-[1]benzoxepino[3,2-b]pyridine-9-carboxamide

DMES0UY	ID	DMES0UY
DMES0UY	DN	PMID29649907-Compound-21
DMES0UY	HS	Patented
DMES0UY	CP	ALIOS BIOPHARMA, INC
DMES0UY	DT	Small molecular drug
DMES0UY	PC	130366919
DMES0UY	MW	570.8
DMES0UY	FM	C29H22Cl3NO5
DMES0UY	IC	InChI=1S/C29H22Cl3NO5/c30-21-5-2-6-22(31)25(21)26-20(27(38-33-26)15-7-8-15)14-36-19-12-17-9-10-24(37-28(17)23(32)13-19)16-3-1-4-18(11-16)29(34)35/h1-6,11-13,15,24H,7-10,14H2,(H,34,35)
DMES0UY	CS	C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC5=C(C(=C4)Cl)OC(CC5)C6=CC(=CC=C6)C(=O)O
DMES0UY	IK	KCNYPNKMQPDXHA-UHFFFAOYSA-N
DMES0UY	IU	3-[8-chloro-6-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-3,4-dihydro-2H-chromen-2-yl]benzoic acid

DMXW108	ID	DMXW108
DMXW108	DN	PMID29649907-Compound-22
DMXW108	HS	Patented
DMXW108	CP	ALIOS BIOPHARMA, INC
DMXW108	DT	Small molecular drug
DMXW108	PC	130366935
DMXW108	MW	549.4
DMXW108	FM	C30H26Cl2N2O4
DMXW108	IC	InChI=1S/C30H26Cl2N2O4/c1-34-25(18-4-2-5-20(14-18)30(35)36)12-10-19-15-21(11-13-26(19)34)37-16-22-28(33-38-29(22)17-8-9-17)27-23(31)6-3-7-24(27)32/h2-7,11,13-15,17,25H,8-10,12,16H2,1H3,(H,35,36)
DMXW108	CS	CN1C(CCC2=C1C=CC(=C2)OCC3=C(ON=C3C4=C(C=CC=C4Cl)Cl)C5CC5)C6=CC(=CC=C6)C(=O)O
DMXW108	IK	WROIATMBIYLPMI-UHFFFAOYSA-N
DMXW108	IU	3-[6-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-1-methyl-3,4-dihydro-2H-quinolin-2-yl]benzoic acid

DMW7T45	ID	DMW7T45
DMW7T45	DN	PMID29649907-Compound-23
DMW7T45	HS	Patented
DMW7T45	CP	Gilead Sciences
DMW7T45	DT	Small molecular drug

DMUHNS7	ID	DMUHNS7
DMUHNS7	DN	PMID29649907-Compound-24
DMUHNS7	HS	Patented
DMUHNS7	CP	Gilead Sciences
DMUHNS7	DT	Small molecular drug

DMALOEW	ID	DMALOEW
DMALOEW	DN	PMID29649907-Compound-25
DMALOEW	HS	Patented
DMALOEW	CP	ENANTA PHARMACEUTICALS, INC
DMALOEW	DT	Small molecular drug
DMALOEW	PC	132042402
DMALOEW	MW	650.6
DMALOEW	FM	C28H29Cl2N5O5S2
DMALOEW	IC	InChI=1S/C28H29Cl2N5O5S2/c1-34(2)42(37,38)33-27(36)17-8-9-22-23(14-17)41-28(31-22)35-12-10-18(11-13-35)39-15-19-25(32-40-26(19)16-6-7-16)24-20(29)4-3-5-21(24)30/h3-5,8-9,14,16,18H,6-7,10-13,15H2,1-2H3,(H,33,36)
DMALOEW	CS	CN(C)S(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(S2)N3CCC(CC3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6
DMALOEW	IK	FJNHJIMGAHRBKJ-UHFFFAOYSA-N
DMALOEW	IU	2-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-N-(dimethylsulfamoyl)-1,3-benzothiazole-6-carboxamide

DM6O78C	ID	DM6O78C
DM6O78C	DN	PMID29649907-Compound-26
DM6O78C	HS	Patented
DM6O78C	CP	ENANTA PHARMACEUTICALS, INC
DM6O78C	DT	Small molecular drug

DMQDGZL	ID	DMQDGZL
DMQDGZL	DN	PMID29649907-Compound-27
DMQDGZL	HS	Patented
DMQDGZL	CP	SALK INSTITUTE FOR BIOLOGICAL STUDIE
DMQDGZL	DT	Small molecular drug
DMQDGZL	PC	126652833
DMQDGZL	MW	515.6
DMQDGZL	FM	C32H35FN2O3
DMQDGZL	IC	InChI=1S/C32H35FN2O3/c1-34(2)28-17-15-24(16-18-28)26-13-14-27(30(33)21-26)22-35(32(37)25-9-5-4-6-10-25)29-11-7-8-23(20-29)12-19-31(36)38-3/h7-8,11-21,25H,4-6,9-10,22H2,1-3H3/b19-12+/i22D
DMQDGZL	CS	[2H]C(C1=C(C=C(C=C1)C2=CC=C(C=C2)N(C)C)F)N(C3=CC=CC(=C3)/C=C/C(=O)OC)C(=O)C4CCCCC4
DMQDGZL	IK	BRNNEWSVEXDLGK-OFSGRHOTSA-N
DMQDGZL	IU	methyl (E)-3-[3-[cyclohexanecarbonyl-[deuterio-[4-[4-(dimethylamino)phenyl]-2-fluorophenyl]methyl]amino]phenyl]prop-2-enoate

DMYMKZC	ID	DMYMKZC
DMYMKZC	DN	PMID29649907-Compound-28
DMYMKZC	HS	Patented
DMYMKZC	CP	SALK INSTITUTE FOR BIOLOGICAL STUDIE
DMYMKZC	DT	Small molecular drug
DMYMKZC	PC	126652917
DMYMKZC	MW	527.6
DMYMKZC	FM	C33H35FN2O3
DMYMKZC	IC	InChI=1S/C33H35FN2O3/c1-35(2)29-13-11-26(12-14-29)25-8-4-22(5-9-25)21-36(33(38)31-19-23-6-10-27(31)16-23)30-18-24(17-28(34)20-30)7-15-32(37)39-3/h4-5,7-9,11-15,17-18,20,23,27,31H,6,10,16,19,21H2,1-3H3/b15-7+/t23-,27+,31?/m0/s1/i21D/t21?,23-,27+,31?
DMYMKZC	CS	[2H]C(C1=CC=C(C=C1)C2=CC=C(C=C2)N(C)C)N(C3=CC(=CC(=C3)/C=C/C(=O)OC)F)C(=O)C4C[C@H]5CC[C@@H]4C5
DMYMKZC	IK	OQLFJJIBJUSVIK-YNEPWPPESA-N
DMYMKZC	IU	methyl (E)-3-[3-[[(1R,4S)-bicyclo[2.2.1]heptane-2-carbonyl]-[deuterio-[4-[4-(dimethylamino)phenyl]phenyl]methyl]amino]-5-fluorophenyl]prop-2-enoate

DMEVZIK	ID	DMEVZIK
DMEVZIK	DN	PMID29649907-Compound-29
DMEVZIK	HS	Patented
DMEVZIK	CP	SALK INSTITUTE FOR BIOLOGICAL STUDIE
DMEVZIK	DT	Small molecular drug
DMEVZIK	PC	91885586
DMEVZIK	MW	545.6
DMEVZIK	FM	C33H34F2N2O3
DMEVZIK	IC	InChI=1S/C33H34F2N2O3/c1-36(2)28-11-9-23(10-12-28)24-7-8-26(31(35)18-24)20-37(33(39)30-17-21-4-6-25(30)14-21)29-16-22(15-27(34)19-29)5-13-32(38)40-3/h5,7-13,15-16,18-19,21,25,30H,4,6,14,17,20H2,1-3H3/b13-5+/t21-,25+,30?/m0/s1/i20D/t20?,21-,25+,30?
DMEVZIK	CS	[2H]C(C1=C(C=C(C=C1)C2=CC=C(C=C2)N(C)C)F)N(C3=CC(=CC(=C3)/C=C/C(=O)OC)F)C(=O)C4C[C@H]5CC[C@@H]4C5
DMEVZIK	IK	AYPFTLSDFVNKEW-TZCKJPFISA-N
DMEVZIK	IU	methyl (E)-3-[3-[[(1R,4S)-bicyclo[2.2.1]heptane-2-carbonyl]-[deuterio-[4-[4-(dimethylamino)phenyl]-2-fluorophenyl]methyl]amino]-5-fluorophenyl]prop-2-enoate

DMPVSG9	ID	DMPVSG9
DMPVSG9	DN	PMID29649907-Compound-3
DMPVSG9	HS	Patented
DMPVSG9	CP	INTERCEPT PHARMACEUTICALS, INC
DMPVSG9	DT	Small molecular drug

DM0SY7Q	ID	DM0SY7Q
DM0SY7Q	DN	PMID29649907-Compound-30
DM0SY7Q	HS	Patented
DM0SY7Q	CP	SALK INSTITUTE FOR BIOLOGICAL STUDIE
DM0SY7Q	DT	Small molecular drug
DM0SY7Q	PC	126652862
DM0SY7Q	MW	526.6
DM0SY7Q	FM	C32H32FN3O3
DM0SY7Q	IC	InChI=1S/C32H32FN3O3/c1-35-30-15-14-24(18-27(30)20-34-35)25-12-13-26(29(33)19-25)21-36(32(38)23-8-4-3-5-9-23)28-10-6-7-22(17-28)11-16-31(37)39-2/h6-7,10-20,23H,3-5,8-9,21H2,1-2H3/b16-11+/i21D
DM0SY7Q	CS	[2H]C(C1=C(C=C(C=C1)C2=CC3=C(C=C2)N(N=C3)C)F)N(C4=CC=CC(=C4)/C=C/C(=O)OC)C(=O)C5CCCCC5
DM0SY7Q	IK	NOJHCAUXLPQOOD-STTMTRHISA-N
DM0SY7Q	IU	methyl (E)-3-[3-[cyclohexanecarbonyl-[deuterio-[2-fluoro-4-(1-methylindazol-5-yl)phenyl]methyl]amino]phenyl]prop-2-enoate

DME6H8Q	ID	DME6H8Q
DME6H8Q	DN	PMID29649907-Compound-31
DME6H8Q	HS	Patented
DME6H8Q	CP	SALK INSTITUTE FOR BIOLOGICAL STUDIE
DME6H8Q	DT	Small molecular drug
DME6H8Q	PC	126652837
DME6H8Q	MW	544.6
DME6H8Q	FM	C32H31F2N3O3
DME6H8Q	IC	InChI=1S/C32H31F2N3O3/c1-36-30-12-11-23(16-26(30)19-35-36)24-9-10-25(29(34)17-24)20-37(32(39)22-6-4-3-5-7-22)28-15-21(14-27(33)18-28)8-13-31(38)40-2/h8-19,22H,3-7,20H2,1-2H3/b13-8+/i20D
DME6H8Q	CS	[2H]C(C1=C(C=C(C=C1)C2=CC3=C(C=C2)N(N=C3)C)F)N(C4=CC(=CC(=C4)/C=C/C(=O)OC)F)C(=O)C5CCCCC5
DME6H8Q	IK	FCAAOLBKZMXHIT-CPVMVVEOSA-N
DME6H8Q	IU	methyl (E)-3-[3-[cyclohexanecarbonyl-[deuterio-[2-fluoro-4-(1-methylindazol-5-yl)phenyl]methyl]amino]-5-fluorophenyl]prop-2-enoate

DM7E9HA	ID	DM7E9HA
DM7E9HA	DN	PMID29649907-Compound-32
DM7E9HA	HS	Patented
DM7E9HA	CP	METACRINE, INC
DM7E9HA	DT	Small molecular drug
DM7E9HA	PC	126696931
DM7E9HA	MW	470.6
DM7E9HA	FM	C30H34N2O3
DM7E9HA	IC	InChI=1S/C30H34N2O3/c1-30(2,3)29(34)32(27-9-7-8-22(20-27)12-19-28(33)35-6)21-23-10-13-24(14-11-23)25-15-17-26(18-16-25)31(4)5/h7-20H,21H2,1-6H3/b19-12+
DM7E9HA	CS	CC(C)(C)C(=O)N(CC1=CC=C(C=C1)C2=CC=C(C=C2)N(C)C)C3=CC=CC(=C3)/C=C/C(=O)OC
DM7E9HA	IK	CROILKLCCCWJNU-XDHOZWIPSA-N
DM7E9HA	IU	methyl (E)-3-[3-[[4-[4-(dimethylamino)phenyl]phenyl]methyl-(2,2-dimethylpropanoyl)amino]phenyl]prop-2-enoate

DM39HCU	ID	DM39HCU
DM39HCU	DN	PMID29649907-Compound-33
DM39HCU	HS	Patented
DM39HCU	CP	METACRINE, INC
DM39HCU	DT	Small molecular drug
DM39HCU	PC	126696428
DM39HCU	MW	519.7
DM39HCU	FM	C34H37N3O2
DM39HCU	IC	InChI=1S/C34H37N3O2/c1-36(2)31-18-16-27(17-19-31)26-14-12-25(13-15-26)24-37(34(38)28-8-5-4-6-9-28)32-11-7-10-29(20-32)30-21-33(39-3)23-35-22-30/h7,10-23,28H,4-6,8-9,24H2,1-3H3
DM39HCU	CS	CN(C)C1=CC=C(C=C1)C2=CC=C(C=C2)CN(C3=CC=CC(=C3)C4=CC(=CN=C4)OC)C(=O)C5CCCCC5
DM39HCU	IK	GNROXEVONXEHCJ-UHFFFAOYSA-N
DM39HCU	IU	N-[[4-[4-(dimethylamino)phenyl]phenyl]methyl]-N-[3-(5-methoxypyridin-3-yl)phenyl]cyclohexanecarboxamide

DMUDKE0	ID	DMUDKE0
DMUDKE0	DN	PMID29649907-Compound-34
DMUDKE0	HS	Patented
DMUDKE0	CP	METACRINE, INC
DMUDKE0	DT	Small molecular drug

DMSWJPO	ID	DMSWJPO
DMSWJPO	DN	PMID29649907-Compound-35
DMSWJPO	HS	Patented
DMSWJPO	CP	METACRINE, INC
DMSWJPO	DT	Small molecular drug

DMP5KEW	ID	DMP5KEW
DMP5KEW	DN	PMID29649907-Compound-36
DMP5KEW	HS	Patented
DMP5KEW	CP	ALIOS BIOPHARMA, INC
DMP5KEW	DT	Small molecular drug
DMP5KEW	PC	121439420
DMP5KEW	MW	439.5
DMP5KEW	FM	C24H23F2N3O3
DMP5KEW	IC	InChI=1S/C24H23F2N3O3/c1-13(2)32-23(31)16-11-29(22(30)14-7-8-17(25)18(26)10-14)12-24(3,4)19-15-6-5-9-27-21(15)28-20(16)19/h5-11,13H,12H2,1-4H3,(H,27,28)
DMP5KEW	CS	CC(C)OC(=O)C1=CN(CC(C2=C1NC3=C2C=CC=N3)(C)C)C(=O)C4=CC(=C(C=C4)F)F
DMP5KEW	IK	PKWPSFIXOLFFPB-UHFFFAOYSA-N
DMP5KEW	IU	propan-2-yl 12-(3,4-difluorobenzoyl)-14,14-dimethyl-6,8,12-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5,10-pentaene-10-carboxylate

DM8WKYT	ID	DM8WKYT
DM8WKYT	DN	PMID29649907-Compound-37
DM8WKYT	HS	Patented
DM8WKYT	CP	ALIOS BIOPHARMA, INC
DM8WKYT	DT	Small molecular drug
DM8WKYT	PC	121439394
DM8WKYT	MW	439.5
DM8WKYT	FM	C24H23F2N3O3
DM8WKYT	IC	InChI=1S/C24H23F2N3O3/c1-13(2)32-23(31)15-11-29(22(30)14-7-8-16(25)17(26)10-14)12-24(3,4)19-20(15)28-18-6-5-9-27-21(18)19/h5-11,13,28H,12H2,1-4H3
DM8WKYT	CS	CC(C)OC(=O)C1=CN(CC(C2=C1NC3=C2N=CC=C3)(C)C)C(=O)C4=CC(=C(C=C4)F)F
DM8WKYT	IK	LHMOWNHVOCSXKQ-UHFFFAOYSA-N
DM8WKYT	IU	propan-2-yl 12-(3,4-difluorobenzoyl)-14,14-dimethyl-3,8,12-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5,10-pentaene-10-carboxylate

DMMP09F	ID	DMMP09F
DMMP09F	DN	PMID29649907-Compound-38
DMMP09F	HS	Patented
DMMP09F	CP	AKARNA THERAPEUTICS, LTDAKARNA THERAPEUTICS, LTD. PRATT, Benjamin Anthony
DMMP09F	DT	Small molecular drug

DMI3ELU	ID	DMI3ELU
DMI3ELU	DN	PMID29649907-Compound-39
DMI3ELU	HS	Patented
DMI3ELU	CP	AKARNA THERAPEUTICS, LTD
DMI3ELU	DT	Small molecular drug
DMI3ELU	PC	134472051
DMI3ELU	MW	511.6
DMI3ELU	FM	C28H39N4O5+
DMI3ELU	IC	InChI=1S/C28H39N4O5/c1-19(2)37-27(34)23-17-31(18-28(4,5)24-20(3)29-30-25(23)24)26(33)21-7-9-22(10-8-21)36-16-13-32(6)11-14-35-15-12-32/h7-10,17,19H,11-16,18H2,1-6H3,(H,29,30)/q+1
DMI3ELU	CS	CC1=C2C(=NN1)C(=CN(CC2(C)C)C(=O)C3=CC=C(C=C3)OCC[N+]4(CCOCC4)C)C(=O)OC(C)C
DMI3ELU	IK	BFMZLOKFIVIHGO-UHFFFAOYSA-N
DMI3ELU	IU	propan-2-yl 3,4,4-trimethyl-6-[4-[2-(4-methylmorpholin-4-ium-4-yl)ethoxy]benzoyl]-2,5-dihydropyrazolo[3,4-d]azepine-8-carboxylate

DMO45VP	ID	DMO45VP
DMO45VP	DN	PMID29649907-Compound-4
DMO45VP	HS	Patented
DMO45VP	CP	INTERCEPT PHARMACEUTICALS, INC
DMO45VP	DT	Small molecular drug

DMS6UD2	ID	DMS6UD2
DMS6UD2	DN	PMID29649907-Compound-40
DMS6UD2	HS	Patented
DMS6UD2	CP	AKARNA THERAPEUTICS, LTD
DMS6UD2	DT	Small molecular drug

DM26IRH	ID	DM26IRH
DM26IRH	DN	PMID29649907-Compound-41
DM26IRH	HS	Patented
DM26IRH	CP	NOVARTIS AG CHIANELLI, Donatella LIU, Xiaodong MOLTENI, Valentina NELSON, John ROLAND, Jason RUCKER, Paul TULLY, David
DM26IRH	DT	Small molecular drug
DM26IRH	PC	91758306
DM26IRH	MW	566.9
DM26IRH	FM	C28H21ClF2N4O5
DM26IRH	IC	InChI=1S/C28H21ClF2N4O5/c1-34-26-19-11-17(29)6-8-23(19)40-14-20(26)25(33-34)27(37)35(12-15-3-2-4-18(30)9-15)13-24(36)32-22-10-16(28(38)39)5-7-21(22)31/h2-11H,12-14H2,1H3,(H,32,36)(H,38,39)
DM26IRH	CS	CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC(=CC=C4)F)CC(=O)NC5=C(C=CC(=C5)C(=O)O)F
DM26IRH	IK	VJLVLEHRWCLRBO-UHFFFAOYSA-N
DM26IRH	IU	3-[[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]acetyl]amino]-4-fluorobenzoic acid

DMSAD9B	ID	DMSAD9B
DMSAD9B	DN	PMID29649907-Compound-42
DMSAD9B	HS	Patented
DMSAD9B	CP	NOVARTIS AG CHIANELLI, Donatella LIU, Xiaodong MOLTENI, Valentina NELSON, John ROLAND, Jason RUCKER, Paul Vincent TULLY, David Charles
DMSAD9B	DT	Small molecular drug
DMSAD9B	PC	122657506
DMSAD9B	MW	482.9
DMSAD9B	FM	C25H24ClFN4O3
DMSAD9B	IC	InChI=1S/C25H24ClFN4O3/c1-30-24-18-10-17(26)8-9-21(18)34-14-19(24)23(29-30)25(33)31(12-16-4-2-3-5-20(16)27)13-22(32)28-11-15-6-7-15/h2-5,8-10,15H,6-7,11-14H2,1H3,(H,28,32)
DMSAD9B	CS	CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4F)CC(=O)NCC5CC5
DMSAD9B	IK	CQPYMJNUAFOXPI-UHFFFAOYSA-N
DMSAD9B	IU	8-chloro-N-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-[(2-fluorophenyl)methyl]-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carboxamide

DMBA2S3	ID	DMBA2S3
DMBA2S3	DN	PMID29649907-Compound-44
DMBA2S3	HS	Patented
DMBA2S3	CP	CITY OF HOPE FOREMAN, Barry
DMBA2S3	DT	Small molecular drug

DMDWSIE	ID	DMDWSIE
DMDWSIE	DN	PMID29649907-Compound-5
DMDWSIE	HS	Patented
DMDWSIE	CP	INTERCEPT PHARMACEUTICALS, INC
DMDWSIE	DT	Small molecular drug

DMV2D5M	ID	DMV2D5M
DMV2D5M	DN	PMID29649907-Compound-8
DMV2D5M	HS	Patented
DMV2D5M	CP	INTERCEPT PHARMACEUTICALS, INC
DMV2D5M	DT	Small molecular drug

DMA6H4W	ID	DMA6H4W
DMA6H4W	DN	PMID29649907-Compound-9
DMA6H4W	HS	Patented
DMA6H4W	CP	ENANTA PHARMACEUTICALS, INC
DMA6H4W	DT	Small molecular drug
DMA6H4W	PC	121355122
DMA6H4W	MW	444.7
DMA6H4W	FM	C26H44N4O2
DMA6H4W	IC	InChI=1S/C26H44N4O2/c1-5-17-21-14-16(31)10-12-26(21,4)20-11-13-25(3)18(7-8-19(25)23(20)24(17)32)15(2)6-9-22-27-29-30-28-22/h15-21,23-24,31-32H,5-14H2,1-4H3,(H,27,28,29,30)/t15-,16-,17-,18-,19?,20?,21+,23?,24-,25-,26-/m1/s1
DMA6H4W	CS	CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2(C3CC[C@@]4([C@H](CCC4C3[C@@H]1O)[C@H](C)CCC5=NNN=N5)C)C)O
DMA6H4W	IK	NGMMYLUHCOHSOR-AMGBFIHRSA-N
DMA6H4W	IU	(3R,5S,6R,7R,10S,13R,17R)-6-ethyl-10,13-dimethyl-17-[(2R)-4-(2H-tetrazol-5-yl)butan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol

DMA0RI8	ID	DMA0RI8
DMA0RI8	DN	PMID29649907-Compound-INT767
DMA0RI8	HS	Patented
DMA0RI8	CP	INTERCEPT PHARMACEUTICALS, INC. PELLICCIARI, Roberto FIORUCCI, Stefano PRUZANSKI, Mark
DMA0RI8	DT	Small molecular drug

DMNKABH	ID	DMNKABH
DMNKABH	DN	PMID29671355-Compound-11
DMNKABH	HS	Patented
DMNKABH	CP	ACETYLON PHARMACEUTICALS, INC
DMNKABH	DT	Small molecular drug
DMNKABH	PC	118005782
DMNKABH	MW	462.5
DMNKABH	FM	C24H26N6O4
DMNKABH	IC	InChI=1S/C24H26N6O4/c1-34-20-9-7-19(8-10-20)27-23(32)30-13-11-24(12-14-30,18-5-3-2-4-6-18)28-22-25-15-17(16-26-22)21(31)29-33/h2-10,15-16,33H,11-14H2,1H3,(H,27,32)(H,29,31)(H,25,26,28)
DMNKABH	CS	COC1=CC=C(C=C1)NC(=O)N2CCC(CC2)(C3=CC=CC=C3)NC4=NC=C(C=N4)C(=O)NO
DMNKABH	IK	LFKIEMRCUDLUJN-UHFFFAOYSA-N
DMNKABH	IU	N-hydroxy-2-[[1-[(4-methoxyphenyl)carbamoyl]-4-phenylpiperidin-4-yl]amino]pyrimidine-5-carboxamide

DMBQOW4	ID	DMBQOW4
DMBQOW4	DN	PMID29671355-Compound-12
DMBQOW4	HS	Patented
DMBQOW4	CP	CHDI FOUNDATION, INC
DMBQOW4	DT	Small molecular drug
DMBQOW4	PC	78425879
DMBQOW4	MW	335.4
DMBQOW4	FM	C18H13N3O2S
DMBQOW4	IC	InChI=1S/C18H13N3O2S/c22-18(20-23)16-11-15(19-21(16)13-6-2-1-3-7-13)14-8-4-5-12-9-10-24-17(12)14/h1-11,23H,(H,20,22)
DMBQOW4	CS	C1=CC=C(C=C1)N2C(=CC(=N2)C3=CC=CC4=C3SC=C4)C(=O)NO
DMBQOW4	IK	OYRFBDZKQFEJSC-UHFFFAOYSA-N
DMBQOW4	IU	5-(1-benzothiophen-7-yl)-N-hydroxy-2-phenylpyrazole-3-carboxamide

DMALXYR	ID	DMALXYR
DMALXYR	DN	PMID29671355-Compound-13
DMALXYR	HS	Patented
DMALXYR	DT	Small molecular drug
DMALXYR	PC	71811260
DMALXYR	MW	427.5
DMALXYR	FM	C26H25N3O3
DMALXYR	IC	InChI=1S/C26H25N3O3/c1-2-24-27-23-13-10-20(16-19-8-11-21(12-9-19)25(30)28-32)17-22(23)26(31)29(24)15-14-18-6-4-3-5-7-18/h3-13,17,32H,2,14-16H2,1H3,(H,28,30)
DMALXYR	CS	CCC1=NC2=C(C=C(C=C2)CC3=CC=C(C=C3)C(=O)NO)C(=O)N1CCC4=CC=CC=C4
DMALXYR	IK	VLBQAJZSHGGUBQ-UHFFFAOYSA-N
DMALXYR	IU	4-[[2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-6-yl]methyl]-N-hydroxybenzamide

DM8UMQH	ID	DM8UMQH
DM8UMQH	DN	PMID29671355-Compound-14
DM8UMQH	HS	Patented
DM8UMQH	DT	Small molecular drug

DMAEPD4	ID	DMAEPD4
DMAEPD4	DN	PMID29671355-Compound-15
DMAEPD4	HS	Patented
DMAEPD4	DT	Small molecular drug
DMAEPD4	PC	122439227
DMAEPD4	MW	334.4
DMAEPD4	FM	C17H22N2O5
DMAEPD4	IC	InChI=1S/C17H22N2O5/c20-16(18-22)13-2-3-14-11-19(6-1-7-24-15(14)10-13)17(21)12-4-8-23-9-5-12/h2-3,10,12,22H,1,4-9,11H2,(H,18,20)
DMAEPD4	CS	C1CN(CC2=C(C=C(C=C2)C(=O)NO)OC1)C(=O)C3CCOCC3
DMAEPD4	IK	UIDRHDHNNBIRIS-UHFFFAOYSA-N
DMAEPD4	IU	N-hydroxy-5-(oxane-4-carbonyl)-2,3,4,6-tetrahydro-1,5-benzoxazocine-9-carboxamide

DM2C6ZF	ID	DM2C6ZF
DM2C6ZF	DN	PMID29671355-Compound-16
DM2C6ZF	HS	Patented
DM2C6ZF	CP	FORMA THERAPEUTICS, INC
DM2C6ZF	DT	Small molecular drug
DM2C6ZF	PC	122616384
DM2C6ZF	MW	364.4
DM2C6ZF	FM	C22H24N2O3
DM2C6ZF	IC	InChI=1S/C22H24N2O3/c25-20(23-27)18-7-8-19-14-22(11-9-17(19)13-18)10-4-12-24(21(22)26)15-16-5-2-1-3-6-16/h1-3,5-8,13,27H,4,9-12,14-15H2,(H,23,25)
DM2C6ZF	CS	C1CC2(CCC3=C(C2)C=CC(=C3)C(=O)NO)C(=O)N(C1)CC4=CC=CC=C4
DM2C6ZF	IK	PRTQLYSHPNDHIG-UHFFFAOYSA-N
DM2C6ZF	IU	1'-benzyl-N-hydroxy-2'-oxospiro[7,8-dihydro-5H-naphthalene-6,3'-piperidine]-2-carboxamide

DMUY53P	ID	DMUY53P
DMUY53P	DN	PMID29671355-Compound-18
DMUY53P	HS	Patented
DMUY53P	CP	KARUS THERAPEUTICS LTD
DMUY53P	DT	Small molecular drug
DMUY53P	PC	86302675
DMUY53P	MW	320.3
DMUY53P	FM	C18H16N4O2
DMUY53P	IC	InChI=1S/C18H16N4O2/c23-18(21-24)15-9-7-14(8-10-15)13-22(16-5-1-3-11-19-16)17-6-2-4-12-20-17/h1-12,24H,13H2,(H,21,23)
DMUY53P	CS	C1=CC=NC(=C1)N(CC2=CC=C(C=C2)C(=O)NO)C3=CC=CC=N3
DMUY53P	IK	FWQCLQYFYHSYHY-UHFFFAOYSA-N
DMUY53P	IU	4-[(dipyridin-2-ylamino)methyl]-N-hydroxybenzamide

DM9LMNB	ID	DM9LMNB
DM9LMNB	DN	PMID29671355-Compound-19
DM9LMNB	HS	Patented
DM9LMNB	CP	KARUS THERAPEUTICS LTD
DM9LMNB	DT	Small molecular drug

DMPJN0M	ID	DMPJN0M
DMPJN0M	DN	PMID29671355-Compound-21
DMPJN0M	HS	Patented
DMPJN0M	CP	CHONG KUN DANG PHARMACEUTICAL CORP
DMPJN0M	DT	Small molecular drug
DMPJN0M	PC	86295624
DMPJN0M	MW	423.4
DMPJN0M	FM	C20H20F3N3O4
DMPJN0M	IC	InChI=1S/C20H20F3N3O4/c21-20(22,23)16-2-1-3-17(12-16)26(19(28)25-8-10-30-11-9-25)13-14-4-6-15(7-5-14)18(27)24-29/h1-7,12,29H,8-11,13H2,(H,24,27)
DMPJN0M	CS	C1COCCN1C(=O)N(CC2=CC=C(C=C2)C(=O)NO)C3=CC=CC(=C3)C(F)(F)F
DMPJN0M	IK	SOEPWATUUFBVRJ-UHFFFAOYSA-N
DMPJN0M	IU	N-[[4-(hydroxycarbamoyl)phenyl]methyl]-N-[3-(trifluoromethyl)phenyl]morpholine-4-carboxamide

DMRGV83	ID	DMRGV83
DMRGV83	DN	PMID29671355-Compound-22
DMRGV83	HS	Patented
DMRGV83	CP	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH BRESLOW, Ronald MARKS, Paul, A
DMRGV83	DT	Small molecular drug
DMRGV83	PC	71532921
DMRGV83	MW	314.34
DMRGV83	FM	C17H18N2O4
DMRGV83	IC	InChI=1S/C17H18N2O4/c20-11-10-19(15-4-2-1-3-5-15)16(21)12-13-6-8-14(9-7-13)17(22)18-23/h1-9,20,23H,10-12H2,(H,18,22)
DMRGV83	CS	C1=CC=C(C=C1)N(CCO)C(=O)CC2=CC=C(C=C2)C(=O)NO
DMRGV83	IK	RFAZNTABYJYOAR-UHFFFAOYSA-N
DMRGV83	IU	N-hydroxy-4-[2-[N-(2-hydroxyethyl)anilino]-2-oxoethyl]benzamide

DMUBOEX	ID	DMUBOEX
DMUBOEX	DN	PMID29671355-Compound-23
DMUBOEX	HS	Patented
DMUBOEX	CP	UNIVERSIT T REGENSBURG [DEFRIEDRICH SCHILLER UNIVERSIT T JENA [DEUNIVERSIT TSKLINIKUM JENA [DE]
DMUBOEX	DT	Small molecular drug
DMUBOEX	PC	118884610
DMUBOEX	MW	404.4
DMUBOEX	FM	C22H20N4O4
DMUBOEX	IC	InChI=1S/C22H20N4O4/c1-24-21(28)16-11-25(22(24)29)12-18-19(16)15-4-2-3-5-17(15)26(18)10-13-6-8-14(9-7-13)20(27)23-30/h2-9,16,30H,10-12H2,1H3,(H,23,27)
DMUBOEX	CS	CN1C(=O)C2CN(C1=O)CC3=C2C4=CC=CC=C4N3CC5=CC=C(C=C5)C(=O)NO
DMUBOEX	IK	ZCAIUGLOTHAUQX-UHFFFAOYSA-N
DMUBOEX	IU	N-hydroxy-4-[(14-methyl-13,15-dioxo-9,12,14-triazatetracyclo[10.3.1.02,10.03,8]hexadeca-2(10),3,5,7-tetraen-9-yl)methyl]benzamide

DMCIGJ1	ID	DMCIGJ1
DMCIGJ1	DN	PMID29671355-Compound-24
DMCIGJ1	HS	Patented
DMCIGJ1	CP	CHONG KUN DANG PHARMACEUTICAL CORP
DMCIGJ1	DT	Small molecular drug

DMPV0KZ	ID	DMPV0KZ
DMPV0KZ	DN	PMID29671355-Compound-25
DMPV0KZ	HS	Patented
DMPV0KZ	DT	Small molecular drug
DMPV0KZ	PC	126569528
DMPV0KZ	MW	301.32
DMPV0KZ	FM	C14H11N3O3S
DMPV0KZ	IC	InChI=1S/C14H11N3O3S/c18-12(16-20)10-5-3-9(4-6-10)8-17-14(19)11-2-1-7-15-13(11)21-17/h1-7,20H,8H2,(H,16,18)
DMPV0KZ	CS	C1=CC2=C(N=C1)SN(C2=O)CC3=CC=C(C=C3)C(=O)NO
DMPV0KZ	IK	VLJAVCKTTLIBDT-UHFFFAOYSA-N
DMPV0KZ	IU	N-hydroxy-4-[(3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)methyl]benzamide

DM5K6MG	ID	DM5K6MG
DM5K6MG	DN	PMID29671355-Compound-26
DM5K6MG	HS	Patented
DM5K6MG	CP	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DM5K6MG	DT	Small molecular drug
DM5K6MG	PC	130361892
DM5K6MG	MW	283.32
DM5K6MG	FM	C16H17N3O2
DM5K6MG	IC	InChI=1S/C16H17N3O2/c20-16(18-21)13-7-5-12(6-8-13)11-19-10-9-17-14-3-1-2-4-15(14)19/h1-8,17,21H,9-11H2,(H,18,20)
DM5K6MG	CS	C1CN(C2=CC=CC=C2N1)CC3=CC=C(C=C3)C(=O)NO
DM5K6MG	IK	RGVWNOQFULPCMK-UHFFFAOYSA-N
DM5K6MG	IU	4-(3,4-dihydro-2H-quinoxalin-1-ylmethyl)-N-hydroxybenzamide

DMP7S9E	ID	DMP7S9E
DMP7S9E	DN	PMID29671355-Compound-27
DMP7S9E	HS	Patented
DMP7S9E	CP	CHARIT  UNIVERSIT TSMEDIZIN BERLIN [DEUNIVERSIT T BAYREUTH [DE]
DMP7S9E	DT	Small molecular drug
DMP7S9E	PC	130227480
DMP7S9E	MW	363.4
DMP7S9E	FM	C21H21N3O3
DMP7S9E	IC	InChI=1S/C21H21N3O3/c1-3-24-14-22-20(16-9-11-18(27-2)12-10-16)21(24)17-7-4-15(5-8-17)6-13-19(25)23-26/h4-14,26H,3H2,1-2H3,(H,23,25)/b13-6+
DMP7S9E	CS	CCN1C=NC(=C1C2=CC=C(C=C2)/C=C/C(=O)NO)C3=CC=C(C=C3)OC
DMP7S9E	IK	JRABOCDIAYUFQB-AWNIVKPZSA-N
DMP7S9E	IU	(E)-3-[4-[3-ethyl-5-(4-methoxyphenyl)imidazol-4-yl]phenyl]-N-hydroxyprop-2-enamide

DMLXSHW	ID	DMLXSHW
DMLXSHW	DN	PMID29671355-Compound-28
DMLXSHW	HS	Patented
DMLXSHW	CP	CHARIT  UNIVERSIT TSMEDIZIN BERLIN [DEUNIVERSIT T BAYREUTH [DE]
DMLXSHW	DT	Small molecular drug

DM3H78D	ID	DM3H78D
DM3H78D	DN	PMID29671355-Compound-31
DM3H78D	HS	Patented
DM3H78D	CP	THE GENERAL HOSPITAL CORPORATION
DM3H78D	DT	Small molecular drug
DM3H78D	PC	90479372
DM3H78D	MW	354.5
DM3H78D	FM	C22H30N2O2
DM3H78D	IC	InChI=1S/C22H30N2O2/c1-24(14-17-4-2-16(3-5-17)6-7-21(25)23-26)15-22-11-18-8-19(12-22)10-20(9-18)13-22/h2-7,18-20,26H,8-15H2,1H3,(H,23,25)/b7-6+
DM3H78D	CS	CN(CC1=CC=C(C=C1)/C=C/C(=O)NO)CC23CC4CC(C2)CC(C4)C3
DM3H78D	IK	WNIDBXBLQFPAJA-VOTSOKGWSA-N
DM3H78D	IU	(E)-3-[4-[[1-adamantylmethyl(methyl)amino]methyl]phenyl]-N-hydroxyprop-2-enamide
DM3H78D	CA	CAS 1629052-58-9

DMQJ3TC	ID	DMQJ3TC
DMQJ3TC	DN	PMID29671355-Compound-36
DMQJ3TC	HS	Patented
DMQJ3TC	CP	UNIVERSITE PARIS-SUD CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
DMQJ3TC	DT	Small molecular drug

DMJ1O5R	ID	DMJ1O5R
DMJ1O5R	DN	PMID29671355-Compound-37
DMJ1O5R	HS	Patented
DMJ1O5R	CP	INCYTE CORPORATION
DMJ1O5R	DT	Small molecular drug

DMYATB5	ID	DMYATB5
DMYATB5	DN	PMID29671355-Compound-38a
DMYATB5	HS	Patented
DMYATB5	CP	KARUS THERAPEUTICS LTD
DMYATB5	DT	Small molecular drug
DMYATB5	PC	121304883
DMYATB5	MW	316.36
DMYATB5	FM	C15H20N6O2
DMYATB5	IC	InChI=1S/C15H20N6O2/c22-15(20-23)5-3-1-2-4-8-21(13-9-17-12-18-10-13)14-11-16-6-7-19-14/h6-7,9-12,23H,1-5,8H2,(H,20,22)
DMYATB5	CS	C1=CN=C(C=N1)N(CCCCCCC(=O)NO)C2=CN=CN=C2
DMYATB5	IK	SQFSXNZGZJNPJZ-UHFFFAOYSA-N
DMYATB5	IU	N-hydroxy-7-[pyrazin-2-yl(pyrimidin-5-yl)amino]heptanamide

DMYXE4J	ID	DMYXE4J
DMYXE4J	DN	PMID29671355-Compound-38b
DMYXE4J	HS	Patented
DMYXE4J	CP	KARUS THERAPEUTICS LTD
DMYXE4J	DT	Small molecular drug
DMYXE4J	PC	73774655
DMYXE4J	MW	335.4
DMYXE4J	FM	C15H21N5O2S
DMYXE4J	IC	InChI=1S/C15H21N5O2S/c1-12-17-15(23-19-12)20(13-8-5-6-10-16-13)11-7-3-2-4-9-14(21)18-22/h5-6,8,10,22H,2-4,7,9,11H2,1H3,(H,18,21)
DMYXE4J	CS	CC1=NSC(=N1)N(CCCCCCC(=O)NO)C2=CC=CC=N2
DMYXE4J	IK	OMIWXFMPPYEWJD-UHFFFAOYSA-N
DMYXE4J	IU	N-hydroxy-7-[(3-methyl-1,2,4-thiadiazol-5-yl)-pyridin-2-ylamino]heptanamide

DM6EJ93	ID	DM6EJ93
DM6EJ93	DN	PMID29671355-Compound-39
DM6EJ93	HS	Patented
DM6EJ93	CP	CHONG KUN DANG PHARMACEUTICAL CORP
DM6EJ93	DT	Small molecular drug
DM6EJ93	PC	124093354
DM6EJ93	MW	438.6
DM6EJ93	FM	C25H34N4O3
DM6EJ93	IC	InChI=1S/C25H34N4O3/c30-23(27-32)15-9-1-2-10-16-26-25(31)29-19-17-28(18-20-29)24(21-11-5-3-6-12-21)22-13-7-4-8-14-22/h3-8,11-14,24,32H,1-2,9-10,15-20H2,(H,26,31)(H,27,30)
DM6EJ93	CS	C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCCCCCCC(=O)NO
DM6EJ93	IK	GFDQSOACLIFRIQ-UHFFFAOYSA-N
DM6EJ93	IU	4-benzhydryl-N-[7-(hydroxyamino)-7-oxoheptyl]piperazine-1-carboxamide

DMXY103	ID	DMXY103
DMXY103	DN	PMID29671355-Compound-42
DMXY103	HS	Patented
DMXY103	CP	AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
DMXY103	DT	Small molecular drug
DMXY103	PC	118366974
DMXY103	MW	509.6
DMXY103	FM	C26H35N7O4
DMXY103	IC	InChI=1S/C26H35N7O4/c1-18(2)33-17-27-24-23(29-26(30-25(24)33)32-12-14-37-15-13-32)19-8-7-9-20(16-19)28-21(34)10-5-3-4-6-11-22(35)31-36/h7-9,16-18,36H,3-6,10-15H2,1-2H3,(H,28,34)(H,31,35)
DMXY103	CS	CC(C)N1C=NC2=C(N=C(N=C21)N3CCOCC3)C4=CC(=CC=C4)NC(=O)CCCCCCC(=O)NO
DMXY103	IK	QWBHGNUFZYWTSG-UHFFFAOYSA-N
DMXY103	IU	N'-hydroxy-N-[3-(2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)phenyl]octanediamide

DMVPMWJ	ID	DMVPMWJ
DMVPMWJ	DN	PMID29671355-Compound-43
DMVPMWJ	HS	Patented
DMVPMWJ	CP	THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
DMVPMWJ	DT	Small molecular drug
DMVPMWJ	PC	118515590
DMVPMWJ	MW	481.6
DMVPMWJ	FM	C25H35N7O3
DMVPMWJ	IC	InChI=1S/C25H35N7O3/c1-32-17-26-23-22(32)24(27-18-9-5-4-6-10-18)30-25(29-23)28-19-12-14-20(15-13-19)35-16-8-3-2-7-11-21(33)31-34/h12-15,17-18,34H,2-11,16H2,1H3,(H,31,33)(H2,27,28,29,30)
DMVPMWJ	CS	CN1C=NC2=C1C(=NC(=N2)NC3=CC=C(C=C3)OCCCCCCC(=O)NO)NC4CCCCC4
DMVPMWJ	IK	RYYJQDSPRGRHMH-UHFFFAOYSA-N
DMVPMWJ	IU	7-[4-[[6-(cyclohexylamino)-7-methylpurin-2-yl]amino]phenoxy]-N-hydroxyheptanamide

DM80A3V	ID	DM80A3V
DM80A3V	DN	PMID29671355-Compound-44
DM80A3V	HS	Patented
DM80A3V	CP	SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A
DM80A3V	DT	Small molecular drug
DM80A3V	PC	72710871
DM80A3V	MW	458.4
DM80A3V	FM	C20H25F3N4O5
DM80A3V	IC	InChI=1S/C20H25F3N4O5/c21-20(22,23)12-5-4-6-13(11-12)24-18(30)14(7-2-1-3-8-17(29)27-32)26-19(31)15-9-10-16(28)25-15/h4-6,11,14-15,32H,1-3,7-10H2,(H,24,30)(H,25,28)(H,26,31)(H,27,29)/t14-,15+/m0/s1
DM80A3V	CS	C1CC(=O)N[C@H]1C(=O)N[C@@H](CCCCCC(=O)NO)C(=O)NC2=CC=CC(=C2)C(F)(F)F
DM80A3V	IK	XVGBJXUAVWXLJX-LSDHHAIUSA-N
DM80A3V	IU	(2S)-N'-hydroxy-2-[[(2R)-5-oxopyrrolidine-2-carbonyl]amino]-N-[3-(trifluoromethyl)phenyl]octanediamide

DM5LYKR	ID	DM5LYKR
DM5LYKR	DN	PMID29671355-Compound-45a
DM5LYKR	HS	Patented
DM5LYKR	CP	CHDI FOUNDATION, INC
DM5LYKR	DT	Small molecular drug
DM5LYKR	PC	86302836
DM5LYKR	MW	337.3
DM5LYKR	FM	C19H16FN3O2
DM5LYKR	IC	InChI=1S/C19H16FN3O2/c1-12-21-10-15(11-22-12)13-6-8-14(9-7-13)18(19(24)23-25)16-4-2-3-5-17(16)20/h2-11,18,25H,1H3,(H,23,24)
DM5LYKR	CS	CC1=NC=C(C=N1)C2=CC=C(C=C2)C(C3=CC=CC=C3F)C(=O)NO
DM5LYKR	IK	SFXMVIQZYOMYOF-UHFFFAOYSA-N
DM5LYKR	IU	2-(2-fluorophenyl)-N-hydroxy-2-[4-(2-methylpyrimidin-5-yl)phenyl]acetamide

DM5I1QV	ID	DM5I1QV
DM5I1QV	DN	PMID29671355-Compound-47a
DM5I1QV	HS	Patented
DM5I1QV	CP	CHDI FOUNDATION, INC
DM5I1QV	DT	Small molecular drug
DM5I1QV	PC	72722126
DM5I1QV	MW	367.3
DM5I1QV	FM	C20H15F2N3O2
DM5I1QV	IC	InChI=1S/C20H15F2N3O2/c21-15-10-23-18(24-11-15)14-8-6-13(7-9-14)17-16(12-4-2-1-3-5-12)20(17,22)19(26)25-27/h1-11,16-17,27H,(H,25,26)/t16-,17-,20+/m1/s1
DM5I1QV	CS	C1=CC=C(C=C1)[C@@H]2[C@H]([C@@]2(C(=O)NO)F)C3=CC=C(C=C3)C4=NC=C(C=N4)F
DM5I1QV	IK	MREATSZIGJDNKB-HLIPFELVSA-N
DM5I1QV	IU	(1S,2S,3S)-1-fluoro-2-[4-(5-fluoropyrimidin-2-yl)phenyl]-N-hydroxy-3-phenylcyclopropane-1-carboxamide

DMBUJ39	ID	DMBUJ39
DMBUJ39	DN	PMID29671355-Compound-47b
DMBUJ39	HS	Patented
DMBUJ39	CP	CHDI FOUNDATION, INC
DMBUJ39	DT	Small molecular drug
DMBUJ39	PC	72950863
DMBUJ39	MW	363.4
DMBUJ39	FM	C21H18FN3O2
DMBUJ39	IC	InChI=1S/C21H18FN3O2/c1-13-11-23-19(24-12-13)16-9-7-15(8-10-16)18-17(14-5-3-2-4-6-14)21(18,22)20(26)25-27/h2-12,17-18,27H,1H3,(H,25,26)/t17-,18-,21+/m1/s1
DMBUJ39	CS	CC1=CN=C(N=C1)C2=CC=C(C=C2)[C@@H]3[C@H]([C@]3(C(=O)NO)F)C4=CC=CC=C4
DMBUJ39	IK	LERFWXLGVNOQCJ-OPYAIIAOSA-N
DMBUJ39	IU	(1S,2S,3S)-1-fluoro-N-hydroxy-2-[4-(5-methylpyrimidin-2-yl)phenyl]-3-phenylcyclopropane-1-carboxamide

DMAH982	ID	DMAH982
DMAH982	DN	PMID29671355-Compound-47c
DMAH982	HS	Patented
DMAH982	CP	CHDI FOUNDATION, INC
DMAH982	DT	Small molecular drug
DMAH982	PC	72948227
DMAH982	MW	415.4
DMAH982	FM	C21H16F3N3O3
DMAH982	IC	InChI=1S/C21H16F3N3O3/c22-20(23)30-15-10-25-18(26-11-15)14-8-6-13(7-9-14)17-16(12-4-2-1-3-5-12)21(17,24)19(28)27-29/h1-11,16-17,20,29H,(H,27,28)/t16-,17-,21+/m1/s1
DMAH982	CS	C1=CC=C(C=C1)[C@@H]2[C@H]([C@@]2(C(=O)NO)F)C3=CC=C(C=C3)C4=NC=C(C=N4)OC(F)F
DMAH982	IK	RUTGGTYDBCHEPE-LZJOCLMNSA-N
DMAH982	IU	(1S,2S,3S)-2-[4-[5-(difluoromethoxy)pyrimidin-2-yl]phenyl]-1-fluoro-N-hydroxy-3-phenylcyclopropane-1-carboxamide

DMPA9OY	ID	DMPA9OY
DMPA9OY	DN	PMID29671355-Compound-47d
DMPA9OY	HS	Patented
DMPA9OY	CP	CHDI FOUNDATION, INC
DMPA9OY	DT	Small molecular drug
DMPA9OY	PC	72948224
DMPA9OY	MW	417.4
DMPA9OY	FM	C21H15F4N3O2
DMPA9OY	IC	InChI=1S/C21H15F4N3O2/c22-20(19(29)28-30)16(12-4-2-1-3-5-12)17(20)13-6-8-14(9-7-13)18-26-11-10-15(27-18)21(23,24)25/h1-11,16-17,30H,(H,28,29)/t16-,17-,20+/m1/s1
DMPA9OY	CS	C1=CC=C(C=C1)[C@@H]2[C@H]([C@@]2(C(=O)NO)F)C3=CC=C(C=C3)C4=NC=CC(=N4)C(F)(F)F
DMPA9OY	IK	DDTXYXHMSVMLET-HLIPFELVSA-N
DMPA9OY	IU	(1S,2S,3S)-1-fluoro-N-hydroxy-2-phenyl-3-[4-[4-(trifluoromethyl)pyrimidin-2-yl]phenyl]cyclopropane-1-carboxamide

DMLDFVN	ID	DMLDFVN
DMLDFVN	DN	PMID29671355-Compound-50
DMLDFVN	HS	Patented
DMLDFVN	CP	CHDI FOUNDATION, INC
DMLDFVN	DT	Small molecular drug

DMEUZM3	ID	DMEUZM3
DMEUZM3	DN	PMID29671355-Compound-52
DMEUZM3	HS	Patented
DMEUZM3	CP	CHDI FOUNDATION, INC
DMEUZM3	DT	Small molecular drug
DMEUZM3	PC	117603070
DMEUZM3	MW	385.4
DMEUZM3	FM	C21H21F2N3O2
DMEUZM3	IC	InChI=1S/C21H21F2N3O2/c1-12-16(4-3-5-17(12)22)21(20(27)25-28)9-8-13(10-21)15-7-6-14-11-24-26(2)19(14)18(15)23/h3-7,11,13,28H,8-10H2,1-2H3,(H,25,27)
DMEUZM3	CS	CC1=C(C=CC=C1F)C2(CCC(C2)C3=C(C4=C(C=C3)C=NN4C)F)C(=O)NO
DMEUZM3	IK	CFMBAUBXRNMZPH-UHFFFAOYSA-N
DMEUZM3	IU	3-(7-fluoro-1-methylindazol-6-yl)-1-(3-fluoro-2-methylphenyl)-N-hydroxycyclopentane-1-carboxamide

DMCRWV3	ID	DMCRWV3
DMCRWV3	DN	PMID29671355-Compound-53
DMCRWV3	HS	Patented
DMCRWV3	CP	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
DMCRWV3	DT	Small molecular drug
DMCRWV3	PC	97324
DMCRWV3	MW	196.27
DMCRWV3	FM	C10H12O2S
DMCRWV3	IC	InChI=1S/C10H12O2S/c11-10(12)7-4-8-13-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)
DMCRWV3	CS	C1=CC=C(C=C1)SCCCC(=O)O
DMCRWV3	IK	HHZVQLOVHIDMBD-UHFFFAOYSA-N
DMCRWV3	IU	4-phenylsulfanylbutanoic acid
DMCRWV3	CA	CAS 17742-51-7

DMJV1SY	ID	DMJV1SY
DMJV1SY	DN	PMID29671355-Compound-55
DMJV1SY	HS	Patented
DMJV1SY	CP	BIOMARIN PHARMACEUTICAL INC
DMJV1SY	DT	Small molecular drug
DMJV1SY	PC	60198673
DMJV1SY	MW	408.5
DMJV1SY	FM	C26H24N4O
DMJV1SY	IC	InChI=1S/C26H24N4O/c27-23-3-1-2-4-24(23)29-26(31)22-9-5-18(6-10-22)13-20-16-30(17-20)15-19-7-8-21-11-12-28-25(21)14-19/h1-14,28H,15-17,27H2,(H,29,31)
DMJV1SY	CS	C1C(=CC2=CC=C(C=C2)C(=O)NC3=CC=CC=C3N)CN1CC4=CC5=C(C=C4)C=CN5
DMJV1SY	IK	YLZQVWHBPTVEHO-UHFFFAOYSA-N
DMJV1SY	IU	N-(2-aminophenyl)-4-[[1-(1H-indol-6-ylmethyl)azetidin-3-ylidene]methyl]benzamide

DM0VBMI	ID	DM0VBMI
DM0VBMI	DN	PMID29671355-Compound-56
DM0VBMI	HS	Patented
DM0VBMI	CP	CANCER RESEARCH TECHNOLOGY LIMITED GRIGG, Ronald Ernest INMAN, Martyn PACKHAM, Graham
DM0VBMI	DT	Small molecular drug
DM0VBMI	PC	56965342
DM0VBMI	MW	383.4
DM0VBMI	FM	C24H21N3O2
DM0VBMI	IC	InChI=1S/C24H21N3O2/c1-16-14-27(24(29)20-7-3-2-6-19(16)20)15-17-10-12-18(13-11-17)23(28)26-22-9-5-4-8-21(22)25/h2-13H,1,14-15,25H2,(H,26,28)
DM0VBMI	CS	C=C1CN(C(=O)C2=CC=CC=C12)CC3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N
DM0VBMI	IK	GTLTXEIKQVWSRF-UHFFFAOYSA-N
DM0VBMI	IU	N-(2-aminophenyl)-4-[(4-methylidene-1-oxo-3H-isoquinolin-2-yl)methyl]benzamide

DM57N3Y	ID	DM57N3Y
DM57N3Y	DN	PMID29671355-Compound-57
DM57N3Y	HS	Patented
DM57N3Y	CP	BIOMARIN PHARMACEUTICAL INC
DM57N3Y	DT	Small molecular drug

DM2F0CQ	ID	DM2F0CQ
DM2F0CQ	DN	PMID29671355-Compound-59
DM2F0CQ	HS	Patented
DM2F0CQ	CP	REGENACY PHARMACEUTICALS, LLC
DM2F0CQ	DT	Small molecular drug
DM2F0CQ	PC	130319551
DM2F0CQ	MW	429.5
DM2F0CQ	FM	C24H23N5OS
DM2F0CQ	IC	InChI=1S/C24H23N5OS/c25-20-6-4-17(23-2-1-11-31-23)14-21(20)28-24(30)22-13-16-3-5-19(12-18(16)15-27-22)29-9-7-26-8-10-29/h1-6,11-15,26H,7-10,25H2,(H,28,30)
DM2F0CQ	CS	C1CN(CCN1)C2=CC3=CN=C(C=C3C=C2)C(=O)NC4=C(C=CC(=C4)C5=CC=CS5)N
DM2F0CQ	IK	SRWKZCCXNJSFMX-UHFFFAOYSA-N
DM2F0CQ	IU	N-(2-amino-5-thiophen-2-ylphenyl)-7-piperazin-1-ylisoquinoline-3-carboxamide

DMXH1G3	ID	DMXH1G3
DMXH1G3	DN	PMID29671355-Compound-61
DMXH1G3	HS	Patented
DMXH1G3	CP	UWM RESEARCH FOUNDATION, INC
DMXH1G3	DT	Small molecular drug

DMWRS34	ID	DMWRS34
DMWRS34	DN	PMID29671355-Compound-62
DMWRS34	HS	Patented
DMWRS34	CP	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A
DMWRS34	DT	Small molecular drug

DMY3Q58	ID	DMY3Q58
DMY3Q58	DN	PMID29671355-Compound-65a
DMY3Q58	HS	Patented
DMY3Q58	CP	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMY3Q58	DT	Small molecular drug
DMY3Q58	PC	126720707
DMY3Q58	MW	303.4
DMY3Q58	FM	C16H21N3OS
DMY3Q58	IC	InChI=1S/C16H21N3OS/c20-15(12-21)18-10-3-1-2-9-17-14-8-4-6-13-7-5-11-19-16(13)14/h4-8,11,17,21H,1-3,9-10,12H2,(H,18,20)
DMY3Q58	CS	C1=CC2=C(C(=C1)NCCCCCNC(=O)CS)N=CC=C2
DMY3Q58	IK	WCTPLVYFIGGBJC-UHFFFAOYSA-N
DMY3Q58	IU	N-[5-(quinolin-8-ylamino)pentyl]-2-sulfanylacetamide

DM1RPL4	ID	DM1RPL4
DM1RPL4	DN	PMID29671355-Compound-67
DM1RPL4	HS	Patented
DM1RPL4	CP	HOCHSCHULE DARMSTADT
DM1RPL4	DT	Small molecular drug
DM1RPL4	PC	60201048
DM1RPL4	MW	235.28
DM1RPL4	FM	C11H10FN3S
DM1RPL4	IC	InChI=1S/C11H10FN3S/c12-7-2-3-8-9(6-7)16-11(13)15-5-1-4-14-10(8)15/h2-3,6,13H,1,4-5H2
DM1RPL4	CS	C1CN=C2C3=C(C=C(C=C3)F)SC(=N)N2C1
DM1RPL4	IK	QEVWRCSULVKULZ-UHFFFAOYSA-N
DM1RPL4	IU	9-fluoro-3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine

DMLGBR6	ID	DMLGBR6
DMLGBR6	DN	PMID29671355-Compound-68b
DMLGBR6	HS	Patented
DMLGBR6	CP	UNIVERSITY OF CONNECTICUT
DMLGBR6	DT	Small molecular drug

DMU61XP	ID	DMU61XP
DMU61XP	DN	PMID29671355-Compound-69
DMU61XP	HS	Patented
DMU61XP	CP	IRBM - SCIENCE PARK S.P.A. C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
DMU61XP	DT	Small molecular drug
DMU61XP	PC	72793856
DMU61XP	MW	478.6
DMU61XP	FM	C27H34N4O4
DMU61XP	IC	InChI=1S/C27H34N4O4/c1-4-20(32)11-6-5-7-13-23(29-25(33)19-16-31(2)17-19)27-28-15-24(35-27)21-14-18-10-8-9-12-22(18)30-26(21)34-3/h8-10,12,14-15,19,23H,4-7,11,13,16-17H2,1-3H3,(H,29,33)/t23-/m0/s1
DMU61XP	CS	CCC(=O)CCCCC[C@@H](C1=NC=C(O1)C2=CC3=CC=CC=C3N=C2OC)NC(=O)C4CN(C4)C
DMU61XP	IK	YOCBGMVQRJHNRU-QHCPKHFHSA-N
DMU61XP	IU	N-[(1S)-1-[5-(2-methoxyquinolin-3-yl)-1,3-oxazol-2-yl]-7-oxononyl]-1-methylazetidine-3-carboxamide

DM394WH	ID	DM394WH
DM394WH	DN	PMID29671355-Compound-70
DM394WH	HS	Patented
DM394WH	CP	CHDI FOUNDATION, INC
DM394WH	DT	Small molecular drug
DM394WH	PC	122669618
DM394WH	MW	408.4
DM394WH	FM	C20H23F3N4O2
DM394WH	IC	InChI=1S/C20H23F3N4O2/c1-13(11-27-10-2-7-19(12-27)8-9-19)24-17(28)15-5-3-14(4-6-15)16-25-18(29-26-16)20(21,22)23/h3-6,13H,2,7-12H2,1H3,(H,24,28)/t13-/m1/s1
DM394WH	CS	C[C@H](CN1CCCC2(C1)CC2)NC(=O)C3=CC=C(C=C3)C4=NOC(=N4)C(F)(F)F
DM394WH	IK	DPJWEPTZTQMWTC-CYBMUJFWSA-N
DM394WH	IU	N-[(2R)-1-(5-azaspiro[2.5]octan-5-yl)propan-2-yl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

DMUAC1T	ID	DMUAC1T
DMUAC1T	DN	PMID29671355-Compound-71a
DMUAC1T	HS	Patented
DMUAC1T	CP	CHDI FOUNDATION, INC
DMUAC1T	DT	Small molecular drug

DM8VG4Q	ID	DM8VG4Q
DM8VG4Q	DN	PMID29671355-Compound-71b
DM8VG4Q	HS	Patented
DM8VG4Q	CP	CHDI FOUNDATION, INC
DM8VG4Q	DT	Small molecular drug

DMICDV6	ID	DMICDV6
DMICDV6	DN	PMID29671355-Compound-72a
DMICDV6	HS	Patented
DMICDV6	CP	CHDI FOUNDATION, INC
DMICDV6	DT	Small molecular drug

DM08OV7	ID	DM08OV7
DM08OV7	DN	PMID29671355-Compound-72b
DM08OV7	HS	Patented
DM08OV7	CP	CHDI FOUNDATION, INC
DM08OV7	DT	Small molecular drug

DMCNF36	ID	DMCNF36
DMCNF36	DN	PMID29671355-Compound-73
DMCNF36	HS	Patented
DMCNF36	DT	Small molecular drug
DMCNF36	PC	124194015
DMCNF36	MW	345.27
DMCNF36	FM	C17H10F3N3O2
DMCNF36	IC	InChI=1S/C17H10F3N3O2/c18-17(19,20)16-21-14(22-25-16)10-6-7-13-11(8-10)9-23(15(13)24)12-4-2-1-3-5-12/h1-8H,9H2
DMCNF36	CS	C1C2=C(C=CC(=C2)C3=NOC(=N3)C(F)(F)F)C(=O)N1C4=CC=CC=C4
DMCNF36	IK	FROSXYATWLHDNN-UHFFFAOYSA-N
DMCNF36	IU	2-phenyl-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-3H-isoindol-1-one

DM49YTU	ID	DM49YTU
DM49YTU	DN	PMID29671355-Compound-74
DM49YTU	HS	Patented
DM49YTU	CP	UNIVERSITY OF CONNECTICUT
DM49YTU	DT	Small molecular drug
DM49YTU	PC	72946782
DM49YTU	MW	278.35
DM49YTU	FM	C15H22N2O3
DM49YTU	IC	InChI=1S/C15H22N2O3/c1-2-20-15(19)17-11-6-9-14(18)16-12-10-13-7-4-3-5-8-13/h3-5,7-8H,2,6,9-12H2,1H3,(H,16,18)(H,17,19)
DM49YTU	CS	CCOC(=O)NCCCC(=O)NCCC1=CC=CC=C1
DM49YTU	IK	HTOYBIILVCHURC-UHFFFAOYSA-N
DM49YTU	IU	ethyl N-[4-oxo-4-(2-phenylethylamino)butyl]carbamate

DM7YQJK	ID	DM7YQJK
DM7YQJK	DN	PMID29671355-Compound-8
DM7YQJK	HS	Patented
DM7YQJK	CP	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DM7YQJK	DT	Small molecular drug

DMXL96M	ID	DMXL96M
DMXL96M	DN	PMID29671355-Compound-9
DMXL96M	HS	Patented
DMXL96M	CP	ACETYLON PHARMACEUTICALS, INC. VIB VZW KATHOLIEKE UNVERSITEIT LEUVEN LIFE SCIENCES RESEARCH PARTNERS VZW
DMXL96M	DT	Small molecular drug
DMXL96M	PC	57381425
DMXL96M	MW	270.29
DMXL96M	FM	C14H14N4O2
DMXL96M	IC	InChI=1S/C14H14N4O2/c19-12(18-20)10-8-15-13(16-9-10)17-14(6-7-14)11-4-2-1-3-5-11/h1-5,8-9,20H,6-7H2,(H,18,19)(H,15,16,17)
DMXL96M	CS	C1CC1(C2=CC=CC=C2)NC3=NC=C(C=N3)C(=O)NO
DMXL96M	IK	LIIWIMDSZVNYHY-UHFFFAOYSA-N
DMXL96M	IU	N-hydroxy-2-[(1-phenylcyclopropyl)amino]pyrimidine-5-carboxamide

DMZBHR9	ID	DMZBHR9
DMZBHR9	DN	PMID29757691-Compound-10
DMZBHR9	HS	Patented
DMZBHR9	CP	FARGEM FARMAS T K ARA TIRMA GEL  T RME MERKEZ  SANAY  VE T&Id [TR]
DMZBHR9	DT	Small molecular drug

DMEUC04	ID	DMEUC04
DMEUC04	DN	PMID29757691-Compound-2a
DMEUC04	HS	Patented
DMEUC04	CP	UNIV WARSZAWSKI [PLCT MEDYCZNE KSZTALCENIA PODYPLOMOWEGO [PL]
DMEUC04	DT	Small molecular drug

DMBRQP1	ID	DMBRQP1
DMBRQP1	DN	PMID29757691-Compound-2a-i
DMBRQP1	HS	Patented
DMBRQP1	CP	UNIV WARSZAWSKI [PLCT MEDYCZNE KSZTALCENIA PODYPLOMOWEGO [PL]
DMBRQP1	DT	Small molecular drug
DMBRQP1	PC	71078245
DMBRQP1	MW	555.7
DMBRQP1	FM	C33H41N5O3
DMBRQP1	IC	InChI=1S/C33H41N5O3/c1-22(39)35-18-15-23(20-31(41-33(34)40)25-13-14-28-24(21-25)16-19-36-28)8-6-7-17-37-32-26-9-2-4-11-29(26)38-30-12-5-3-10-27(30)32/h2,4,9,11,13-14,16,19,21,23,31,36H,3,5-8,10,12,15,17-18,20H2,1H3,(H2,34,40)(H,35,39)(H,37,38)
DMBRQP1	CS	CC(=O)NCCC(CCCCNC1=C2CCCCC2=NC3=CC=CC=C31)CC(C4=CC5=C(C=C4)NC=C5)OC(=O)N
DMBRQP1	IK	YSPYIIMVNQAFBG-UHFFFAOYSA-N
DMBRQP1	IU	[3-(2-acetamidoethyl)-1-(1H-indol-5-yl)-7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptyl] carbamate

DMFD9UZ	ID	DMFD9UZ
DMFD9UZ	DN	PMID29757691-Compound-4
DMFD9UZ	HS	Patented
DMFD9UZ	DT	Small molecular drug

DM7TPBF	ID	DM7TPBF
DM7TPBF	DN	PMID29757691-Compound-7
DM7TPBF	HS	Patented
DM7TPBF	DT	Small molecular drug
DM7TPBF	PC	71451207
DM7TPBF	MW	494
DM7TPBF	FM	C28H32ClN3O3
DM7TPBF	IC	InChI=1S/C28H32ClN3O3/c29-20-11-12-22-24(18-20)32-23-8-4-3-7-21(23)28(22)31-16-6-2-1-5-15-30-27(35)14-10-19-9-13-25(33)26(34)17-19/h9-14,17-18,33-34H,1-8,15-16H2,(H,30,35)(H,31,32)/b14-10+
DM7TPBF	CS	C1CCC2=NC3=C(C=CC(=C3)Cl)C(=C2C1)NCCCCCCNC(=O)/C=C/C4=CC(=C(C=C4)O)O
DM7TPBF	IK	PBISLIYZMJMPKF-GXDHUFHOSA-N
DM7TPBF	IU	(E)-N-[6-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]hexyl]-3-(3,4-dihydroxyphenyl)prop-2-enamide

DM5IFBV	ID	DM5IFBV
DM5IFBV	DN	PMID29757691-Compound-8a
DM5IFBV	HS	Patented
DM5IFBV	DT	Small molecular drug
DM5IFBV	PC	42602188
DM5IFBV	MW	432.6
DM5IFBV	FM	C28H36N2O2
DM5IFBV	IC	InChI=1S/C28H36N2O2/c31-27(15-21-29-17-3-1-4-18-29)25-11-7-23(8-12-25)24-9-13-26(14-10-24)28(32)16-22-30-19-5-2-6-20-30/h7-14H,1-6,15-22H2
DM5IFBV	CS	C1CCN(CC1)CCC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)CCN4CCCCC4
DM5IFBV	IK	OEJCMWCXCHXDOS-UHFFFAOYSA-N
DM5IFBV	IU	3-piperidin-1-yl-1-[4-[4-(3-piperidin-1-ylpropanoyl)phenyl]phenyl]propan-1-one
DM5IFBV	CA	CAS 1092934-23-0

DMEOZKF	ID	DMEOZKF
DMEOZKF	DN	PMID29757691-Compound-8b
DMEOZKF	HS	Patented
DMEOZKF	DT	Small molecular drug
DMEOZKF	PC	42602271
DMEOZKF	MW	436.5
DMEOZKF	FM	C26H32N2O4
DMEOZKF	IC	InChI=1S/C26H32N2O4/c29-25(9-11-27-13-17-31-18-14-27)23-5-1-21(2-6-23)22-3-7-24(8-4-22)26(30)10-12-28-15-19-32-20-16-28/h1-8H,9-20H2
DMEOZKF	CS	C1COCCN1CCC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)CCN4CCOCC4
DMEOZKF	IK	UKUXOYHUMOANRU-UHFFFAOYSA-N
DMEOZKF	IU	3-morpholin-4-yl-1-[4-[4-(3-morpholin-4-ylpropanoyl)phenyl]phenyl]propan-1-one

DMHL7SW	ID	DMHL7SW
DMHL7SW	DN	PMID29757691-Compound-8c
DMHL7SW	HS	Patented
DMHL7SW	DT	Small molecular drug
DMHL7SW	PC	42602187
DMHL7SW	MW	408.6
DMHL7SW	FM	C26H36N2O2
DMHL7SW	IC	InChI=1S/C26H36N2O2/c1-5-27(6-2)19-17-25(29)23-13-9-21(10-14-23)22-11-15-24(16-12-22)26(30)18-20-28(7-3)8-4/h9-16H,5-8,17-20H2,1-4H3
DMHL7SW	CS	CCN(CC)CCC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCN(CC)CC
DMHL7SW	IK	BFCHHHLQSJIBJK-UHFFFAOYSA-N
DMHL7SW	IU	3-(diethylamino)-1-[4-[4-[3-(diethylamino)propanoyl]phenyl]phenyl]propan-1-one

DM6PDEH	ID	DM6PDEH
DM6PDEH	DN	PMID29757691-Compound-8d
DM6PDEH	HS	Patented
DM6PDEH	DT	Small molecular drug
DM6PDEH	PC	42602272
DM6PDEH	MW	352.5
DM6PDEH	FM	C22H28N2O2
DM6PDEH	IC	InChI=1S/C22H28N2O2/c1-23(2)15-13-21(25)19-9-5-17(6-10-19)18-7-11-20(12-8-18)22(26)14-16-24(3)4/h5-12H,13-16H2,1-4H3
DM6PDEH	CS	CN(C)CCC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCN(C)C
DM6PDEH	IK	KDKCLSBOSGNKSF-UHFFFAOYSA-N
DM6PDEH	IU	3-(dimethylamino)-1-[4-[4-[3-(dimethylamino)propanoyl]phenyl]phenyl]propan-1-one

DMCZ3SH	ID	DMCZ3SH
DMCZ3SH	DN	PMID29865878-Compound-38
DMCZ3SH	HS	Patented
DMCZ3SH	CP	University of Kentucky Research Foundation
DMCZ3SH	DT	Small molecular drug

DMSCWZF	ID	DMSCWZF
DMSCWZF	DN	PMID29865878-Compound-39
DMSCWZF	HS	Patented
DMSCWZF	CP	University of Kentucky Research Foundation
DMSCWZF	DT	Small molecular drug

DMGXUNA	ID	DMGXUNA
DMGXUNA	DN	PMID29865878-Compound-40
DMGXUNA	HS	Patented
DMGXUNA	CP	University of Kentucky Research Foundation
DMGXUNA	DT	Small molecular drug

DMSAO52	ID	DMSAO52
DMSAO52	DN	PMID29865878-Compound-41
DMSAO52	HS	Patented
DMSAO52	CP	University of Kentucky Research Foundation
DMSAO52	DT	Small molecular drug

DMY2PTU	ID	DMY2PTU
DMY2PTU	DN	PMID29865878-Compound-42
DMY2PTU	HS	Patented
DMY2PTU	CP	ARES TRADING S.A
DMY2PTU	DT	Small molecular drug

DMQUE6D	ID	DMQUE6D
DMQUE6D	DN	PMID29865878-Compound-43
DMQUE6D	HS	Patented
DMQUE6D	CP	ARES TRADING S.A
DMQUE6D	DT	Small molecular drug

DMRTQ4I	ID	DMRTQ4I
DMRTQ4I	DN	PMID29865878-Compound-44
DMRTQ4I	HS	Patented
DMRTQ4I	CP	ARES TRADING S.A
DMRTQ4I	DT	Small molecular drug

DM462XZ	ID	DM462XZ
DM462XZ	DN	PMID29865878-Compound-45
DM462XZ	HS	Patented
DM462XZ	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM462XZ	DT	Small molecular drug

DMP3MXK	ID	DMP3MXK
DMP3MXK	DN	PMID29865878-Compound-46
DMP3MXK	HS	Patented
DMP3MXK	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMP3MXK	DT	Small molecular drug

DMX31I2	ID	DMX31I2
DMX31I2	DN	PMID29865878-Compound-47
DMX31I2	HS	Patented
DMX31I2	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMX31I2	DT	Small molecular drug

DMVQTR2	ID	DMVQTR2
DMVQTR2	DN	PMID29865878-Compound-48
DMVQTR2	HS	Patented
DMVQTR2	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMVQTR2	DT	Small molecular drug

DMK0GTV	ID	DMK0GTV
DMK0GTV	DN	PMID29865878-Compound-49
DMK0GTV	HS	Patented
DMK0GTV	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMK0GTV	DT	Small molecular drug

DMZ8BJX	ID	DMZ8BJX
DMZ8BJX	DN	PMID29865878-Compound-50
DMZ8BJX	HS	Patented
DMZ8BJX	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMZ8BJX	DT	Small molecular drug

DM0LXT2	ID	DM0LXT2
DM0LXT2	DN	PMID29865878-Compound-51
DM0LXT2	HS	Patented
DM0LXT2	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM0LXT2	DT	Small molecular drug

DM47M2U	ID	DM47M2U
DM47M2U	DN	PMID29865878-Compound-52
DM47M2U	HS	Patented
DM47M2U	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM47M2U	DT	Small molecular drug

DM6JV1W	ID	DM6JV1W
DM6JV1W	DN	PMID29865878-Compound-53
DM6JV1W	HS	Patented
DM6JV1W	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM6JV1W	DT	Small molecular drug

DMED71P	ID	DMED71P
DMED71P	DN	PMID29865878-Compound-54
DMED71P	HS	Patented
DMED71P	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMED71P	DT	Small molecular drug

DMY52ZB	ID	DMY52ZB
DMY52ZB	DN	PMID29865878-Compound-55
DMY52ZB	HS	Patented
DMY52ZB	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMY52ZB	DT	Small molecular drug

DM45QW1	ID	DM45QW1
DM45QW1	DN	PMID29865878-Compound-56
DM45QW1	HS	Patented
DM45QW1	CP	UNIVERZA V LJUBLJANI
DM45QW1	DT	Small molecular drug

DM3VQ1Y	ID	DM3VQ1Y
DM3VQ1Y	DN	PMID29865878-Compound-57
DM3VQ1Y	HS	Patented
DM3VQ1Y	CP	UNIVERZA V LJUBLJANI
DM3VQ1Y	DT	Small molecular drug

DMO108N	ID	DMO108N
DMO108N	DN	PMID29865878-Compound-58
DMO108N	HS	Patented
DMO108N	CP	UNIVERZA V LJUBLJANI
DMO108N	DT	Small molecular drug

DMM73VG	ID	DMM73VG
DMM73VG	DN	PMID29865878-Compound-59
DMM73VG	HS	Patented
DMM73VG	CP	UNIVERZA V LJUBLJANI
DMM73VG	DT	Small molecular drug

DMPQX8R	ID	DMPQX8R
DMPQX8R	DN	PMID29865878-Compound-60
DMPQX8R	HS	Patented
DMPQX8R	CP	MERCK PATENT GMBH
DMPQX8R	DT	Small molecular drug

DMG7VF1	ID	DMG7VF1
DMG7VF1	DN	PMID29865878-Compound-61
DMG7VF1	HS	Patented
DMG7VF1	CP	MERCK PATENT GMBH
DMG7VF1	DT	Small molecular drug

DML47KS	ID	DML47KS
DML47KS	DN	PMID29865878-Compound-62
DML47KS	HS	Patented
DML47KS	CP	MERCK PATENT GMBH
DML47KS	DT	Small molecular drug

DMEM2I8	ID	DMEM2I8
DMEM2I8	DN	PMID29865878-Compound-63
DMEM2I8	HS	Patented
DMEM2I8	CP	MERCK PATENT GMBH
DMEM2I8	DT	Small molecular drug

DM1U6H2	ID	DM1U6H2
DM1U6H2	DN	PMID29865878-Compound-64
DM1U6H2	HS	Patented
DM1U6H2	CP	MERCK PATENT GMBH
DM1U6H2	DT	Small molecular drug

DMX1E6O	ID	DMX1E6O
DMX1E6O	DN	PMID29865878-Compound-8
DMX1E6O	HS	Patented
DMX1E6O	CP	PROTEOLIX, INC. SHENK, Kevin, D. PARLATI, Francesco ZHOU, Han-jie SYLVAIN, Catherine SMYTH, Mark, S. BENNETT, Mark, K. LAIDIG, Guy, J
DMX1E6O	DT	Small molecular drug

DM7K3A0	ID	DM7K3A0
DM7K3A0	DN	PMID30074415-Compound-12
DM7K3A0	HS	Patented
DM7K3A0	DT	Small molecular drug

DM06PX4	ID	DM06PX4
DM06PX4	DN	PMID30074415-Compound-19
DM06PX4	HS	Patented
DM06PX4	CP	METASIGNAL THERAPEUTICS INC. SUPURAN, Claudiu DEDHAR, Shoukat CARTA, Fabrizio WINUM, Jean-Yves MCDONALD, Paul C UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES CNRS - DIRE
DM06PX4	DT	Small molecular drug

DMX9LGW	ID	DMX9LGW
DMX9LGW	DN	PMID30074415-Compound-20
DMX9LGW	HS	Patented
DMX9LGW	CP	METASIGNAL THERAPEUTICS INC. SUPURAN, Claudiu DEDHAR, Shoukat CARTA, Fabrizio WINUM, Jean-Yves MCDONALD, Paul C UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES CNRS - DIRE
DMX9LGW	DT	Small molecular drug
DMX9LGW	PC	19890
DMX9LGW	MW	162.21
DMX9LGW	FM	C9H6OS
DMX9LGW	IC	InChI=1S/C9H6OS/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-6H
DMX9LGW	CS	C1=CC=C2C(=C1)C=CC(=S)O2
DMX9LGW	IK	FRZDLTCXOSFHJC-UHFFFAOYSA-N
DMX9LGW	IU	chromene-2-thione
DMX9LGW	CA	CAS 3986-98-9

DM3NPOU	ID	DM3NPOU
DM3NPOU	DN	PMID30074415-Compound-21
DM3NPOU	HS	Patented
DM3NPOU	CP	METASIGNAL THERAPEUTICS INC. SUPURAN, Claudiu DEDHAR, Shoukat CARTA, Fabrizio WINUM, Jean-Yves MCDONALD, Paul C UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES CNRS - DIRE
DM3NPOU	DT	Small molecular drug

DM2G8DN	ID	DM2G8DN
DM2G8DN	DN	PMID30074415-Compound-GS3
DM2G8DN	HS	Patented
DM2G8DN	DT	Small molecular drug

DMY37VQ	ID	DMY37VQ
DMY37VQ	DN	PMID30107136-Compound-Example1
DMY37VQ	HS	Patented
DMY37VQ	CP	BRISTOL-MYERS SQUIBB COMPANY
DMY37VQ	DT	Small molecule immunotherapy 
DMY37VQ	PC	117951478
DMY37VQ	MW	419.5
DMY37VQ	FM	C25H29N3O3
DMY37VQ	IC	InChI=1S/C25H29N3O3/c1-18-22(10-7-11-23(18)20-8-5-4-6-9-20)17-31-24-13-12-21(25(28-24)30-3)16-26-14-15-27-19(2)29/h4-13,26H,14-17H2,1-3H3,(H,27,29)
DMY37VQ	CS	CC1=C(C=CC=C1C2=CC=CC=C2)COC3=NC(=C(C=C3)CNCCNC(=O)C)OC
DMY37VQ	IK	JEDPSOYOYVELLZ-UHFFFAOYSA-N
DMY37VQ	IU	N-[2-[[2-methoxy-6-[(2-methyl-3-phenylphenyl)methoxy]pyridin-3-yl]methylamino]ethyl]acetamide
DMY37VQ	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMD65GU	ID	DMD65GU
DMD65GU	DN	PMID30107136-Compound-Example11
DMD65GU	HS	Patented
DMD65GU	CP	ARISING INTERNATIONAL, INC
DMD65GU	DT	Small molecule immunotherapy 
DMD65GU	PC	134230940
DMD65GU	MW	568.7
DMD65GU	FM	C36H44N2O4
DMD65GU	IC	InChI=1S/C36H44N2O4/c1-25-19-29(21-37-15-17-39)11-13-35(25)41-23-31-7-5-9-33(27(31)3)34-10-6-8-32(28(34)4)24-42-36-14-12-30(20-26(36)2)22-38-16-18-40/h5-14,19-20,37-40H,15-18,21-24H2,1-4H3
DMD65GU	CS	CC1=C(C=CC(=C1)CNCCO)OCC2=C(C(=CC=C2)C3=CC=CC(=C3C)COC4=C(C=C(C=C4)CNCCO)C)C
DMD65GU	IK	OXBVQSJSNDTUEX-UHFFFAOYSA-N
DMD65GU	IU	2-[[4-[[3-[3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylphenyl]methylamino]ethanol
DMD65GU	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMN2K10	ID	DMN2K10
DMN2K10	DN	PMID30107136-Compound-Example12
DMN2K10	HS	Patented
DMN2K10	CP	ARISING INTERNATIONAL, INC
DMN2K10	DT	Small molecule immunotherapy 
DMN2K10	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM4CN9K	ID	DM4CN9K
DM4CN9K	DN	PMID30107136-Compound-Example13
DM4CN9K	HS	Patented
DM4CN9K	CP	POLARIS PHARMACEUTICALS, INC
DM4CN9K	DT	Small molecule immunotherapy 
DM4CN9K	PC	134305040
DM4CN9K	MW	834.6
DM4CN9K	FM	C42H46Br2N2O6
DM4CN9K	IC	InChI=1S/C42H46Br2N2O6/c1-27-31(25-51-39-17-15-29(21-35(39)43)23-45-19-5-3-13-37(45)41(47)48)9-7-11-33(27)34-12-8-10-32(28(34)2)26-52-40-18-16-30(22-36(40)44)24-46-20-6-4-14-38(46)42(49)50/h7-12,15-18,21-22,37-38H,3-6,13-14,19-20,23-26H2,1-2H3,(H,47,48)(H,49,50)/t37-,38-/m0/s1
DM4CN9K	CS	CC1=C(C=CC=C1C2=CC=CC(=C2C)COC3=C(C=C(C=C3)CN4CCCC[C@H]4C(=O)O)Br)COC5=C(C=C(C=C5)CN6CCCC[C@H]6C(=O)O)Br
DM4CN9K	IK	SDCCYXRWWJGRKC-UWXQCODUSA-N
DM4CN9K	IU	(2S)-1-[[3-bromo-4-[[3-[3-[[2-bromo-4-[[(2S)-2-carboxypiperidin-1-yl]methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]phenyl]methyl]piperidine-2-carboxylic acid
DM4CN9K	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMAUFS7	ID	DMAUFS7
DMAUFS7	DN	PMID30107136-Compound-Example14
DMAUFS7	HS	Patented
DMAUFS7	CP	POLARIS PHARMACEUTICALS, INC
DMAUFS7	DT	Small molecule immunotherapy 
DMAUFS7	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMYHQ0S	ID	DMYHQ0S
DMYHQ0S	DN	PMID30107136-Compound-Example15
DMYHQ0S	HS	Patented
DMYHQ0S	CP	CHEMOCENTRYX, INC
DMYHQ0S	DT	Small molecule immunotherapy 
DMYHQ0S	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM6EKIV	ID	DM6EKIV
DM6EKIV	DN	PMID30107136-Compound-Example16
DM6EKIV	HS	Patented
DM6EKIV	CP	CHEMOCENTRYX, INC
DM6EKIV	DT	Small molecule immunotherapy 
DM6EKIV	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM9HMB4	ID	DM9HMB4
DM9HMB4	DN	PMID30107136-Compound-Example2
DM9HMB4	HS	Patented
DM9HMB4	CP	BRISTOL-MYERS SQUIBB COMPANY
DM9HMB4	DT	Small molecule immunotherapy 
DM9HMB4	PC	117941742
DM9HMB4	MW	494.4
DM9HMB4	FM	C27H28BrNO3
DM9HMB4	IC	InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)
DM9HMB4	CS	CC1=C(C=CC=C1C2=CC=CC=C2)COC3=C(C=C(C=C3)CN4CCCCC4C(=O)O)Br
DM9HMB4	IK	QRXBPPWUGITQLE-UHFFFAOYSA-N
DM9HMB4	IU	1-[[3-bromo-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid
DM9HMB4	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMDCN43	ID	DMDCN43
DMDCN43	DN	PMID30107136-Compound-Example3
DMDCN43	HS	Patented
DMDCN43	CP	BRISTOL-MYERS SQUIBB COMPANY
DMDCN43	DT	Small molecule immunotherapy 
DMDCN43	PC	118434705
DMDCN43	MW	594.7
DMDCN43	FM	C35H34N2O7
DMDCN43	IC	InChI=1S/C35H34N2O7/c1-22-13-28(18-37-30(19-38)35(39)40)33(43-20-25-6-3-5-24(14-25)17-36)16-32(22)44-21-27-7-4-8-29(23(27)2)26-9-10-31-34(15-26)42-12-11-41-31/h3-10,13-16,30,37-38H,11-12,18-21H2,1-2H3,(H,39,40)
DMDCN43	CS	CC1=CC(=C(C=C1OCC2=C(C(=CC=C2)C3=CC4=C(C=C3)OCCO4)C)OCC5=CC(=CC=C5)C#N)CNC(CO)C(=O)O
DMDCN43	IK	UWNXGZKSIKQKAH-UHFFFAOYSA-N
DMDCN43	IU	2-[[2-[(3-cyanophenyl)methoxy]-4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-5-methylphenyl]methylamino]-3-hydroxypropanoic acid
DMDCN43	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMRKLTE	ID	DMRKLTE
DMRKLTE	DN	PMID30107136-Compound-Example4
DMRKLTE	HS	Patented
DMRKLTE	CP	BRISTOL-MYERS SQUIBB COMPANY
DMRKLTE	DT	Small molecule immunotherapy 
DMRKLTE	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMQPIK4	ID	DMQPIK4
DMQPIK4	DN	PMID30107136-Compound-Example41
DMQPIK4	HS	Patented
DMQPIK4	CP	INCYTE CORPORATION
DMQPIK4	DT	Small molecule immunotherapy 
DMQPIK4	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM95FIN	ID	DM95FIN
DM95FIN	DN	PMID30107136-Compound-Example42
DM95FIN	HS	Patented
DM95FIN	CP	INCYTE CORPORATION
DM95FIN	DT	Small molecule immunotherapy 
DM95FIN	PC	132166412
DM95FIN	MW	443.5
DM95FIN	FM	C26H29N5O2
DM95FIN	IC	InChI=1S/C26H29N5O2/c1-30-18-19(17-29-30)7-10-28-21-8-11-31(12-9-21)24-4-2-3-22(23(24)16-27)20-5-6-25-26(15-20)33-14-13-32-25/h2-6,15,17-18,21,28H,7-14H2,1H3
DM95FIN	CS	CN1C=C(C=N1)CCNC2CCN(CC2)C3=CC=CC(=C3C#N)C4=CC5=C(C=C4)OCCO5
DM95FIN	IK	YIQQKUGTBUPKTJ-UHFFFAOYSA-N
DM95FIN	IU	2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-[4-[2-(1-methylpyrazol-4-yl)ethylamino]piperidin-1-yl]benzonitrile
DM95FIN	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMJSH0F	ID	DMJSH0F
DMJSH0F	DN	PMID30107136-Compound-Example43
DMJSH0F	HS	Patented
DMJSH0F	CP	Incyte Corporation
DMJSH0F	DT	Small molecule immunotherapy 
DMJSH0F	PC	129019494
DMJSH0F	MW	359.4
DMJSH0F	FM	C21H21N5O
DMJSH0F	IC	InChI=1S/C21H21N5O/c1-15-18(16-6-3-2-4-7-16)8-5-9-19(15)20-14-26-21(24-20)23-13-17(25-26)12-22-10-11-27/h2-9,13-14,22,27H,10-12H2,1H3
DMJSH0F	CS	CC1=C(C=CC=C1C2=CN3C(=N2)N=CC(=N3)CNCCO)C4=CC=CC=C4
DMJSH0F	IK	SIYAOZFRXTVXSP-UHFFFAOYSA-N
DMJSH0F	IU	2-[[6-(2-methyl-3-phenylphenyl)imidazo[1,2-b][1,2,4]triazin-2-yl]methylamino]ethanol
DMJSH0F	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM8KAIY	ID	DM8KAIY
DM8KAIY	DN	PMID30107136-Compound-Example44
DM8KAIY	HS	Patented
DM8KAIY	CP	Incyte Corporation
DM8KAIY	DT	Small molecule immunotherapy 
DM8KAIY	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMC075A	ID	DMC075A
DMC075A	DN	PMID30107136-Compound-Example45
DMC075A	HS	Patented
DMC075A	CP	INCYTE CORPORATION
DMC075A	DT	Small molecule immunotherapy 
DMC075A	PC	132085809
DMC075A	MW	306.4
DMC075A	FM	C19H18N2S
DMC075A	IC	InChI=1S/C19H18N2S/c1-13-15(14-6-3-2-4-7-14)8-5-9-16(13)19-21-17-10-11-20-12-18(17)22-19/h2-9,20H,10-12H2,1H3
DMC075A	CS	CC1=C(C=CC=C1C2=NC3=C(S2)CNCC3)C4=CC=CC=C4
DMC075A	IK	DISXBCWMOVBSKF-UHFFFAOYSA-N
DMC075A	IU	2-(2-methyl-3-phenylphenyl)-4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridine
DMC075A	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMYFSAD	ID	DMYFSAD
DMYFSAD	DN	PMID30107136-Compound-Example46
DMYFSAD	HS	Patented
DMYFSAD	CP	INCYTE CORPORATION
DMYFSAD	DT	Small molecule immunotherapy 
DMYFSAD	PC	132085903
DMYFSAD	MW	364.5
DMYFSAD	FM	C22H24N2OS
DMYFSAD	IC	InChI=1S/C22H24N2OS/c1-15(25)13-24-12-11-20-21(14-24)26-22(23-20)19-10-6-9-18(16(19)2)17-7-4-3-5-8-17/h3-10,15,25H,11-14H2,1-2H3/t15-/m0/s1
DMYFSAD	CS	CC1=C(C=CC=C1C2=NC3=C(S2)CN(CC3)C[C@H](C)O)C4=CC=CC=C4
DMYFSAD	IK	HABSDVBVXAIOBF-HNNXBMFYSA-N
DMYFSAD	IU	(2S)-1-[2-(2-methyl-3-phenylphenyl)-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-2-ol
DMYFSAD	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM1TCBQ	ID	DM1TCBQ
DM1TCBQ	DN	PMID30107136-Compound-Example47
DM1TCBQ	HS	Patented
DM1TCBQ	CP	Incyte Corporation
DM1TCBQ	DT	Small molecule immunotherapy 
DM1TCBQ	PC	134282250
DM1TCBQ	MW	435.5
DM1TCBQ	FM	C24H25N3O3S
DM1TCBQ	IC	InChI=1S/C24H25N3O3S/c1-16-19(17-8-3-2-4-9-17)10-7-11-20(16)26-22(28)23-25-14-18(31-23)15-27-13-6-5-12-21(27)24(29)30/h2-4,7-11,14,21H,5-6,12-13,15H2,1H3,(H,26,28)(H,29,30)/t21-/m0/s1
DM1TCBQ	CS	CC1=C(C=CC=C1NC(=O)C2=NC=C(S2)CN3CCCC[C@H]3C(=O)O)C4=CC=CC=C4
DM1TCBQ	IK	UBENHLQYILNMML-NRFANRHFSA-N
DM1TCBQ	IU	(2S)-1-[[2-[(2-methyl-3-phenylphenyl)carbamoyl]-1,3-thiazol-5-yl]methyl]piperidine-2-carboxylic acid
DM1TCBQ	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMH57FG	ID	DMH57FG
DMH57FG	DN	PMID30107136-Compound-Example48
DMH57FG	HS	Patented
DMH57FG	CP	Incyte Corporation
DMH57FG	DT	Small molecule immunotherapy 
DMH57FG	PC	134282238
DMH57FG	MW	364.4
DMH57FG	FM	C21H24N4O2
DMH57FG	IC	InChI=1S/C21H24N4O2/c1-15-18(16-7-4-3-5-8-16)9-6-10-19(15)24-21(27)20-23-14-17(25(20)2)13-22-11-12-26/h3-10,14,22,26H,11-13H2,1-2H3,(H,24,27)
DMH57FG	CS	CC1=C(C=CC=C1NC(=O)C2=NC=C(N2C)CNCCO)C3=CC=CC=C3
DMH57FG	IK	NMRCIXCIRVZQNY-UHFFFAOYSA-N
DMH57FG	IU	5-[(2-hydroxyethylamino)methyl]-1-methyl-N-(2-methyl-3-phenylphenyl)imidazole-2-carboxamide
DMH57FG	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM4D1WK	ID	DM4D1WK
DM4D1WK	DN	PMID30107136-Compound-Example49
DM4D1WK	HS	Patented
DM4D1WK	CP	INCYTE CORPORATION
DM4D1WK	DT	Small molecule immunotherapy 
DM4D1WK	PC	134177894
DM4D1WK	MW	459.5
DM4D1WK	FM	C27H29N3O4
DM4D1WK	IC	InChI=1S/C27H29N3O4/c1-18-21(20-9-4-3-5-10-20)11-8-12-23(18)28-25(31)22-15-19(16-29(2)26(22)32)17-30-14-7-6-13-24(30)27(33)34/h3-5,8-12,15-16,24H,6-7,13-14,17H2,1-2H3,(H,28,31)(H,33,34)/t24-/m0/s1
DM4D1WK	CS	CC1=C(C=CC=C1NC(=O)C2=CC(=CN(C2=O)C)CN3CCCC[C@H]3C(=O)O)C4=CC=CC=C4
DM4D1WK	IK	DNPQQJGPLXEEDA-DEOSSOPVSA-N
DM4D1WK	IU	(2S)-1-[[1-methyl-5-[(2-methyl-3-phenylphenyl)carbamoyl]-6-oxopyridin-3-yl]methyl]piperidine-2-carboxylic acid
DM4D1WK	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMV15GM	ID	DMV15GM
DMV15GM	DN	PMID30107136-Compound-Example50
DMV15GM	HS	Patented
DMV15GM	CP	INCYTE CORPORATION
DMV15GM	DT	Small molecule immunotherapy 
DMV15GM	PC	134178079
DMV15GM	MW	460.5
DMV15GM	FM	C25H24N4O5
DMV15GM	IC	InChI=1S/C25H24N4O5/c1-29-15-16(14-27-7-8-30)11-19(25(29)32)24(31)28-21-4-2-3-18(20(21)13-26)17-5-6-22-23(12-17)34-10-9-33-22/h2-6,11-12,15,27,30H,7-10,14H2,1H3,(H,28,31)
DMV15GM	CS	CN1C=C(C=C(C1=O)C(=O)NC2=CC=CC(=C2C#N)C3=CC4=C(C=C3)OCCO4)CNCCO
DMV15GM	IK	CAWQORGXRONNAU-UHFFFAOYSA-N
DMV15GM	IU	N-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-5-[(2-hydroxyethylamino)methyl]-1-methyl-2-oxopyridine-3-carboxamide
DMV15GM	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM08CBJ	ID	DM08CBJ
DM08CBJ	DN	PMID30107136-Compound-Example51
DM08CBJ	HS	Patented
DM08CBJ	CP	Incyte Corporation
DM08CBJ	DT	Small molecule immunotherapy 
DM08CBJ	PC	132229919
DM08CBJ	MW	418.5
DM08CBJ	FM	C22H18N4O3S
DM08CBJ	IC	InChI=1S/C22H18N4O3S/c23-11-15-14(13-4-5-18-19(10-13)29-9-8-28-18)2-1-3-16(15)25-21(27)22-26-17-6-7-24-12-20(17)30-22/h1-5,10,24H,6-9,12H2,(H,25,27)
DM08CBJ	CS	C1CNCC2=C1N=C(S2)C(=O)NC3=CC=CC(=C3C#N)C4=CC5=C(C=C4)OCCO5
DM08CBJ	IK	CJCNMXQYXKRQRK-UHFFFAOYSA-N
DM08CBJ	IU	N-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridine-2-carboxamide
DM08CBJ	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMJ1C0A	ID	DMJ1C0A
DMJ1C0A	DN	PMID30107136-Compound-Example52
DMJ1C0A	HS	Patented
DMJ1C0A	CP	Incyte Corporation
DMJ1C0A	DT	Small molecule immunotherapy 
DMJ1C0A	PC	132229917
DMJ1C0A	MW	414.5
DMJ1C0A	FM	C22H18N6OS
DMJ1C0A	IC	InChI=1S/C22H18N6OS/c1-28-19-7-3-5-14(16(19)11-25-28)13-4-2-6-17(15(13)10-23)26-21(29)22-27-18-8-9-24-12-20(18)30-22/h2-7,11,24H,8-9,12H2,1H3,(H,26,29)
DMJ1C0A	CS	CN1C2=CC=CC(=C2C=N1)C3=C(C(=CC=C3)NC(=O)C4=NC5=C(S4)CNCC5)C#N
DMJ1C0A	IK	UPRJKKJMZSATGW-UHFFFAOYSA-N
DMJ1C0A	IU	N-[2-cyano-3-(1-methylindazol-4-yl)phenyl]-4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridine-2-carboxamide
DMJ1C0A	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM39FDV	ID	DM39FDV
DM39FDV	DN	PMID30107136-Compound-Example53
DM39FDV	HS	Patented
DM39FDV	CP	INCYTE CORPORATION
DM39FDV	DT	Small molecule immunotherapy 
DM39FDV	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM9DL1E	ID	DM9DL1E
DM9DL1E	DN	PMID30107136-Compound-Example54
DM9DL1E	HS	Patented
DM9DL1E	CP	INCYTE CORPORATION
DM9DL1E	DT	Small molecule immunotherapy 
DM9DL1E	PC	129138000
DM9DL1E	MW	440.5
DM9DL1E	FM	C28H28N2O3
DM9DL1E	IC	InChI=1S/C28H28N2O3/c1-18-15-20(17-30-14-7-6-13-25(30)28(31)32)16-24-26(18)33-27(29-24)23-12-8-11-22(19(23)2)21-9-4-3-5-10-21/h3-5,8-12,15-16,25H,6-7,13-14,17H2,1-2H3,(H,31,32)/t25-/m0/s1
DM9DL1E	CS	CC1=CC(=CC2=C1OC(=N2)C3=CC=CC(=C3C)C4=CC=CC=C4)CN5CCCC[C@H]5C(=O)O
DM9DL1E	IK	UWWIGOJLOPXCJZ-VWLOTQADSA-N
DM9DL1E	IU	(2S)-1-[[7-methyl-2-(2-methyl-3-phenylphenyl)-1,3-benzoxazol-5-yl]methyl]piperidine-2-carboxylic acid
DM9DL1E	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMZXC0D	ID	DMZXC0D
DMZXC0D	DN	PMID30107136-Compound-Example57
DMZXC0D	HS	Patented
DMZXC0D	CP	Incyte Corporation
DMZXC0D	DT	Small molecule immunotherapy 
DMZXC0D	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM3AY9K	ID	DM3AY9K
DM3AY9K	DN	PMID30107136-Compound-Example58
DM3AY9K	HS	Patented
DM3AY9K	CP	Incyte Corporation
DM3AY9K	DT	Small molecule immunotherapy 
DM3AY9K	PC	129244901
DM3AY9K	MW	452.5
DM3AY9K	FM	C28H28N4O2
DM3AY9K	IC	InChI=1S/C28H28N4O2/c1-19-22(20-8-3-2-4-9-20)10-7-11-24(19)31-27-26-23(14-16-30-27)21(13-15-29-26)18-32-17-6-5-12-25(32)28(33)34/h2-4,7-11,13-16,25H,5-6,12,17-18H2,1H3,(H,30,31)(H,33,34)
DM3AY9K	CS	CC1=C(C=CC=C1NC2=NC=CC3=C(C=CN=C32)CN4CCCCC4C(=O)O)C5=CC=CC=C5
DM3AY9K	IK	PDWPVFMFNAKOIU-UHFFFAOYSA-N
DM3AY9K	IU	1-[[8-(2-methyl-3-phenylanilino)-1,7-naphthyridin-4-yl]methyl]piperidine-2-carboxylic acid
DM3AY9K	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DM6XWL9	ID	DM6XWL9
DM6XWL9	DN	PMID30107136-Compound-Example59
DM6XWL9	HS	Patented
DM6XWL9	CP	RIJKSUNIVERSITEIT GRONINGEN
DM6XWL9	DT	Small molecule immunotherapy 
DM6XWL9	PC	130219614
DM6XWL9	MW	571.7
DM6XWL9	FM	C35H33N5O3
DM6XWL9	IC	InChI=1S/C35H33N5O3/c36-23-31-30(28-9-5-2-6-10-28)15-16-38-35(31)42-25-33-39-34(29-13-11-27(12-14-29)26-7-3-1-4-8-26)32(43-33)24-37-17-18-40-19-21-41-22-20-40/h1-16,37H,17-22,24-25H2
DM6XWL9	CS	C1COCCN1CCNCC2=C(N=C(O2)COC3=NC=CC(=C3C#N)C4=CC=CC=C4)C5=CC=C(C=C5)C6=CC=CC=C6
DM6XWL9	IK	LEMZNPCBMGJIOU-UHFFFAOYSA-N
DM6XWL9	IU	2-[[5-[(2-morpholin-4-ylethylamino)methyl]-4-(4-phenylphenyl)-1,3-oxazol-2-yl]methoxy]-4-phenylpyridine-3-carbonitrile
DM6XWL9	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMUZ85A	ID	DMUZ85A
DMUZ85A	DN	PMID30107136-Compound-Example60
DMUZ85A	HS	Patented
DMUZ85A	CP	RIJKSUNIVERSITEIT GRONINGEN
DMUZ85A	DT	Small molecule immunotherapy 
DMUZ85A	PC	130220023
DMUZ85A	MW	478.5
DMUZ85A	FM	C25H30N6O4
DMUZ85A	IC	InChI=1S/C25H30N6O4/c1-17-21(15-28-8-7-27-2)31(9-10-32)24(30-17)16-35-25-20(14-26)19(5-6-29-25)18-3-4-22-23(13-18)34-12-11-33-22/h3-6,13,27-28,32H,7-12,15-16H2,1-2H3
DMUZ85A	CS	CC1=C(N(C(=N1)COC2=NC=CC(=C2C#N)C3=CC4=C(C=C3)OCCO4)CCO)CNCCNC
DMUZ85A	IK	WQHRKWCRQIAXRG-UHFFFAOYSA-N
DMUZ85A	IU	4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[1-(2-hydroxyethyl)-4-methyl-5-[[2-(methylamino)ethylamino]methyl]imidazol-2-yl]methoxy]pyridine-3-carbonitrile
DMUZ85A	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMS42KH	ID	DMS42KH
DMS42KH	DN	PMID30107136-Compound-Example7
DMS42KH	HS	Patented
DMS42KH	CP	BRISTOL-MYERS SQUIBB COMPANY
DMS42KH	DT	Small molecule immunotherapy 
DMS42KH	PC	129019915
DMS42KH	MW	753.3
DMS42KH	FM	C43H49ClN4O6
DMS42KH	IC	InChI=1S/C43H49ClN4O6/c1-29-33(8-5-9-36(29)37-10-6-12-40(30(37)2)52-19-7-15-47-17-13-35(49)14-18-47)28-54-42-22-41(53-27-32-20-31(23-45)24-46-25-32)34(21-38(42)44)26-48-16-4-3-11-39(48)43(50)51/h5-6,8-10,12,20-22,24-25,35,39,49H,3-4,7,11,13-19,26-28H2,1-2H3,(H,50,51)
DMS42KH	CS	CC1=C(C=CC=C1C2=C(C(=CC=C2)OCCCN3CCC(CC3)O)C)COC4=C(C=C(C(=C4)OCC5=CC(=CN=C5)C#N)CN6CCCCC6C(=O)O)Cl
DMS42KH	IK	VDKPFVAEXSRQOY-UHFFFAOYSA-N
DMS42KH	IU	1-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[[3-[3-[3-(4-hydroxypiperidin-1-yl)propoxy]-2-methylphenyl]-2-methylphenyl]methoxy]phenyl]methyl]piperidine-2-carboxylic acid
DMS42KH	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMBIK28	ID	DMBIK28
DMBIK28	DN	PMID30107136-Compound-Example8
DMBIK28	HS	Patented
DMBIK28	CP	BRISTOL-MYERS SQUIBB COMPANY
DMBIK28	DT	Small molecule immunotherapy 
DMBIK28	PC	129019689
DMBIK28	MW	765.3
DMBIK28	FM	C41H47ClF2N4O6
DMBIK28	IC	InChI=1S/C41H47ClF2N4O6/c1-28-32(7-4-8-34(28)35-9-5-10-37(29(35)2)52-14-6-12-48-13-11-41(43,44)24-48)23-54-39-17-38(53-22-31-15-30(18-45)19-46-20-31)33(16-36(39)42)21-47(3)40(25-49,26-50)27-51/h4-5,7-10,15-17,19-20,49-51H,6,11-14,21-27H2,1-3H3
DMBIK28	CS	CC1=C(C=CC=C1C2=C(C(=CC=C2)OCCCN3CCC(C3)(F)F)C)COC4=C(C=C(C(=C4)OCC5=CC(=CN=C5)C#N)CN(C)C(CO)(CO)CO)Cl
DMBIK28	IK	KNCHTQJZTIPCIA-UHFFFAOYSA-N
DMBIK28	IU	5-[[4-chloro-5-[[3-[3-[3-(3,3-difluoropyrrolidin-1-yl)propoxy]-2-methylphenyl]-2-methylphenyl]methoxy]-2-[[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]-methylamino]methyl]phenoxy]methyl]pyridine-3-carbonitrile
DMBIK28	DE	Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis

DMHTJVA	ID	DMHTJVA
DMHTJVA	DN	PMID30124346-Compound-13TABLE4
DMHTJVA	HS	Patented
DMHTJVA	CP	INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK,UNIWERSYTET JAGIELLO SKI
DMHTJVA	DT	Small molecular drug
DMHTJVA	DE	Attention deficit hyperactivity disorder

DM2G3VE	ID	DM2G3VE
DM2G3VE	DN	PMID30124346-Compound-34TABLE4
DM2G3VE	HS	Patented
DM2G3VE	CP	INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK,UNIWERSYTET JAGIELLO SKI
DM2G3VE	DT	Small molecular drug
DM2G3VE	DE	Attention deficit hyperactivity disorder

DM3QX0R	ID	DM3QX0R
DM3QX0R	DN	PMID30124346-Compound-60TABLE5
DM3QX0R	HS	Patented
DM3QX0R	CP	NEUROLIXIS UNIVERSITE JAGELLONNE
DM3QX0R	DT	Small molecular drug
DM3QX0R	DE	Parkinson disease; Dyskinesia

DMJMTNL	ID	DMJMTNL
DMJMTNL	DN	PMID30124346-Compound-LDT66
DMJMTNL	HS	Patented
DMJMTNL	CP	LAUNIER, Benoi
DMJMTNL	DT	Small molecular drug
DMJMTNL	PC	11778231
DMJMTNL	MW	276.4
DMJMTNL	FM	C17H28N2O
DMJMTNL	IC	InChI=1S/C17H28N2O/c1-3-4-5-8-11-18-12-14-19(15-13-18)16-9-6-7-10-17(16)20-2/h6-7,9-10H,3-5,8,11-15H2,1-2H3
DMJMTNL	CS	CCCCCCN1CCN(CC1)C2=CC=CC=C2OC
DMJMTNL	IK	QLLNEODTUOCQKR-UHFFFAOYSA-N
DMJMTNL	IU	1-hexyl-4-(2-methoxyphenyl)piperazine
DMJMTNL	DE	Benign prostatic hyperplasia

DM5MUNG	ID	DM5MUNG
DM5MUNG	DN	PMID30124346-Compound-LDT8
DM5MUNG	HS	Patented
DM5MUNG	CP	UNIV RIO DE JANEIRO [BRUNIAO BRASILIENSE DE EDUCACAO E CULTURA UBEC [BR
DM5MUNG	DT	Small molecular drug
DM5MUNG	DE	Benign prostatic hyperplasia

DMQU10C	ID	DMQU10C
DMQU10C	DN	PMID30185082-Compound-14
DMQU10C	HS	Patented
DMQU10C	DT	Small molecular drug
DMQU10C	PC	16737780
DMQU10C	MW	443.5
DMQU10C	FM	C25H33FN2O4
DMQU10C	IC	InChI=1S/C25H33FN2O4/c1-18-6-7-22(32-13-9-26)21(14-18)25(29)27-10-4-5-11-28-12-8-19-15-23(30-2)24(31-3)16-20(19)17-28/h6-7,14-16H,4-5,8-13,17H2,1-3H3,(H,27,29)/i26-1
DMQU10C	CS	CC1=CC(=C(C=C1)OCC[18F])C(=O)NCCCCN2CCC3=CC(=C(C=C3C2)OC)OC
DMQU10C	IK	QVRVXSZKCXFBTE-KPVNRNJOSA-N
DMQU10C	IU	N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)butyl]-2-(2-(18F)fluoranylethoxy)-5-methylbenzamide
DMQU10C	CA	CAS 945992-47-2

DMYFLT1	ID	DMYFLT1
DMYFLT1	DN	PMID30185082-Compound-27
DMYFLT1	HS	Patented
DMYFLT1	CP	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
DMYFLT1	DT	Small molecular drug

DMI0WHE	ID	DMI0WHE
DMI0WHE	DN	PMID30185082-Compound-28
DMI0WHE	HS	Patented
DMI0WHE	CP	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
DMI0WHE	DT	Small molecular drug

DM9GX0F	ID	DM9GX0F
DM9GX0F	DN	PMID30185082-Compound-53
DM9GX0F	HS	Patented
DM9GX0F	CP	THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DM9GX0F	DT	Small molecular drug

DMKP14O	ID	DMKP14O
DMKP14O	DN	PMID30185082-Compound-54
DMKP14O	HS	Patented
DMKP14O	CP	THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMKP14O	DT	Small molecular drug
DMKP14O	PC	24807084
DMKP14O	MW	373.6
DMKP14O	FM	C21H31N3OS
DMKP14O	IC	InChI=1S/C21H31N3OS/c25-21-24(19-10-4-5-11-20(19)26-21)13-7-6-12-22-14-16-23(17-15-22)18-8-2-1-3-9-18/h4-5,10-11,18H,1-3,6-9,12-17H2
DMKP14O	CS	C1CCC(CC1)N2CCN(CC2)CCCCN3C4=CC=CC=C4SC3=O
DMKP14O	IK	ZACKDLLCPUTVQK-UHFFFAOYSA-N
DMKP14O	IU	3-[4-(4-cyclohexylpiperazin-1-yl)butyl]-1,3-benzothiazol-2-one

DMW8V4R	ID	DMW8V4R
DMW8V4R	DN	PMID30185082-Compound-55
DMW8V4R	HS	Patented
DMW8V4R	CP	THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMW8V4R	DT	Small molecular drug
DMW8V4R	PC	24763643
DMW8V4R	MW	411.5
DMW8V4R	FM	C23H26FN3O3
DMW8V4R	IC	InChI=1S/C23H26FN3O3/c1-17(28)18-4-9-21-22(16-18)30-23(29)27(21)11-3-2-10-25-12-14-26(15-13-25)20-7-5-19(24)6-8-20/h4-9,16H,2-3,10-15H2,1H3
DMW8V4R	CS	CC(=O)C1=CC2=C(C=C1)N(C(=O)O2)CCCCN3CCN(CC3)C4=CC=C(C=C4)F
DMW8V4R	IK	VGDFDVKDWFJQHD-UHFFFAOYSA-N
DMW8V4R	IU	6-acetyl-3-[4-[4-(4-fluorophenyl)piperazin-1-yl]butyl]-1,3-benzoxazol-2-one

DMLGKYI	ID	DMLGKYI
DMLGKYI	DN	PMID30185082-Compound-56
DMLGKYI	HS	Patented
DMLGKYI	CP	THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMLGKYI	DT	Small molecular drug
DMLGKYI	PC	17756659
DMLGKYI	MW	389.6
DMLGKYI	FM	C21H31N3S2
DMLGKYI	IC	InChI=1S/C21H31N3S2/c25-21-24(19-10-4-5-11-20(19)26-21)13-7-6-12-22-14-16-23(17-15-22)18-8-2-1-3-9-18/h4-5,10-11,18H,1-3,6-9,12-17H2
DMLGKYI	CS	C1CCC(CC1)N2CCN(CC2)CCCCN3C4=CC=CC=C4SC3=S
DMLGKYI	IK	FJGOTAJCEJCFEV-UHFFFAOYSA-N
DMLGKYI	IU	3-[4-(4-cyclohexylpiperazin-1-yl)butyl]-1,3-benzothiazole-2-thione

DMNDF1Z	ID	DMNDF1Z
DMNDF1Z	DN	PMID30185082-Compound-57
DMNDF1Z	HS	Patented
DMNDF1Z	CP	THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMNDF1Z	DT	Small molecular drug
DMNDF1Z	PC	58511957
DMNDF1Z	MW	336.5
DMNDF1Z	FM	C18H25FN2OS
DMNDF1Z	IC	InChI=1S/C18H25FN2OS/c19-9-5-6-15-7-8-16-17(14-15)23-18(22)21(16)13-12-20-10-3-1-2-4-11-20/h7-8,14H,1-6,9-13H2
DMNDF1Z	CS	C1CCCN(CC1)CCN2C3=C(C=C(C=C3)CCCF)SC2=O
DMNDF1Z	IK	DNGYIBDXSUNKMV-UHFFFAOYSA-N
DMNDF1Z	IU	3-[2-(azepan-1-yl)ethyl]-6-(3-fluoropropyl)-1,3-benzothiazol-2-one
DMNDF1Z	CA	CAS 1350296-21-7

DMW2S0J	ID	DMW2S0J
DMW2S0J	DN	PMID30185082-Compound-63
DMW2S0J	HS	Patented
DMW2S0J	CP	COGNITION THERAPEUTICS, INC. CATALANO, Susan, M. RISHTON, Gilbert IZZO, Nicholas, J
DMW2S0J	DT	Small molecular drug

DMKD470	ID	DMKD470
DMKD470	DN	PMID30185082-Compound-64
DMKD470	HS	Patented
DMKD470	CP	COGNITION THERAPEUTICS, INC. CATALANO, Susan, M. RISHTON, Gilbert IZZO, Nicholas, J
DMKD470	DT	Small molecular drug
DMKD470	PC	66731659
DMKD470	MW	353.4
DMKD470	FM	C19H22F3NO2
DMKD470	IC	InChI=1S/C19H22F3NO2/c1-13(3-4-14-7-10-17(24)18(11-14)25-2)23-12-15-5-8-16(9-6-15)19(20,21)22/h5-11,13,23-24H,3-4,12H2,1-2H3
DMKD470	CS	CC(CCC1=CC(=C(C=C1)O)OC)NCC2=CC=C(C=C2)C(F)(F)F
DMKD470	IK	JWMMMNZRBWMHKZ-UHFFFAOYSA-N
DMKD470	IU	2-methoxy-4-[3-[[4-(trifluoromethyl)phenyl]methylamino]butyl]phenol

DME0RJ2	ID	DME0RJ2
DME0RJ2	DN	PMID30259754-Compound-INT-767
DME0RJ2	HS	Patented
DME0RJ2	CP	INTERCEPT PHARMACEUTICALS, INC. PELLICCIARI, Roberto FIORUCCI, Stefano PRUZANSKI, Mark
DME0RJ2	DT	Small molecular drug
DME0RJ2	PC	121356085
DME0RJ2	MW	470.7
DME0RJ2	FM	C26H46O5S
DME0RJ2	IC	InChI=1S/C26H46O5S/c1-5-18-22-15-17(27)10-12-26(22,4)21-11-13-25(3)19(8-9-20(25)23(21)24(18)28)16(2)7-6-14-32(29,30)31/h16-24,27-28H,5-15H2,1-4H3,(H,29,30,31)/t16-,17-,18-,19-,20+,21+,22+,23+,24-,25-,26-/m1/s1
DME0RJ2	CS	CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCCS(=O)(=O)O)C)C)O
DME0RJ2	IK	VJHHZJYLJUGVGO-JDCMAIOWSA-N
DME0RJ2	IU	(4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentane-1-sulfonic acid

DMZ5CDY	ID	DMZ5CDY
DMZ5CDY	DN	PMID30259754-Compound-LY2562175
DMZ5CDY	HS	Patented
DMZ5CDY	CP	ELI LILLY AND COMPANY GENIN, Michael, James AGEJAS-CHICHARRO, Francisco, Javier BUENO MELENDO, Ana, Belen MANNINEN, Peter, Rudolph WARSHAWSKY, Alan, M
DMZ5CDY	DT	Small molecular drug
DMZ5CDY	PC	25204767
DMZ5CDY	MW	540.4
DMZ5CDY	FM	C28H27Cl2N3O4
DMZ5CDY	IC	InChI=1S/C28H27Cl2N3O4/c1-32-14-20(28(34)35)19-8-7-17(13-24(19)32)33-11-9-18(10-12-33)36-15-21-26(31-37-27(21)16-5-6-16)25-22(29)3-2-4-23(25)30/h2-4,7-8,13-14,16,18H,5-6,9-12,15H2,1H3,(H,34,35)
DMZ5CDY	CS	CN1C=C(C2=C1C=C(C=C2)N3CCC(CC3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6)C(=O)O
DMZ5CDY	IK	RPVDFHPBGBMWID-UHFFFAOYSA-N
DMZ5CDY	IU	6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylic acid
DMZ5CDY	CA	CAS 1103500-20-4

DM78IN5	ID	DM78IN5
DM78IN5	DN	PMID30259754-Compound-Px-102
DM78IN5	HS	Patented
DM78IN5	CP	PHENEX PHARMACEUTICALS AG KREMOSER, Claus ABEL, Ulrich STEENECK, Christoph KINZEL, Olaf
DM78IN5	DT	Small molecular drug
DM78IN5	PC	50943003
DM78IN5	MW	554.8
DM78IN5	FM	C29H22Cl3NO4
DM78IN5	IC	InChI=1S/C29H22Cl3NO4/c30-23-2-1-3-24(31)26(23)27-22(28(37-33-27)16-6-7-16)14-36-18-10-11-19(25(32)12-18)21-13-20(21)15-4-8-17(9-5-15)29(34)35/h1-5,8-12,16,20-21H,6-7,13-14H2,(H,34,35)
DM78IN5	CS	C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5CC5C6=CC=C(C=C6)C(=O)O)Cl
DM78IN5	IK	XBUXXJUEBFDQHD-UHFFFAOYSA-N
DM78IN5	IU	4-[2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]cyclopropyl]benzoic acid

DMVP16K	ID	DMVP16K
DMVP16K	DN	PMID30259754-Compound-pyrrole[2,3-d]azepines
DMVP16K	HS	Patented
DMVP16K	DT	Small molecular drug
DMVP16K	PC	42601440
DMVP16K	MW	415.4
DMVP16K	FM	C22H23F2N3O3
DMVP16K	IC	InChI=1S/C22H23F2N3O3/c1-12(2)30-21(29)15-10-27(20(28)13-5-6-17(23)18(24)7-13)11-22(3,4)16-8-14(9-25)26-19(15)16/h5-8,12,15,26H,10-11H2,1-4H3
DMVP16K	CS	CC(C)OC(=O)C1CN(CC(C2=C1NC(=C2)C#N)(C)C)C(=O)C3=CC(=C(C=C3)F)F
DMVP16K	IK	JTWLRQHGXNKRJB-UHFFFAOYSA-N
DMVP16K	IU	propan-2-yl 2-cyano-6-(3,4-difluorobenzoyl)-4,4-dimethyl-1,5,7,8-tetrahydropyrrolo[2,3-d]azepine-8-carboxylate

DMDKSJQ	ID	DMDKSJQ
DMDKSJQ	DN	PMID30259754-Compound-WAY-362450
DMDKSJQ	HS	Patented
DMDKSJQ	DT	Small molecular drug
DMDKSJQ	PC	10026128
DMDKSJQ	MW	438.5
DMDKSJQ	FM	C25H24F2N2O3
DMDKSJQ	IC	InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3
DMDKSJQ	CS	CC(C)OC(=O)C1=CN(CC(C2=C1NC3=CC=CC=C32)(C)C)C(=O)C4=CC(=C(C=C4)F)F
DMDKSJQ	IK	INASOKQDNHHMRE-UHFFFAOYSA-N
DMDKSJQ	IU	propan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-2,6-dihydroazepino[4,5-b]indole-5-carboxylate
DMDKSJQ	CA	CAS 629664-81-9

DM52MKV	ID	DM52MKV
DM52MKV	DN	PMID30273516-Compound-1
DM52MKV	HS	Patented
DM52MKV	DT	Small molecular drug

DMIWEZH	ID	DMIWEZH
DMIWEZH	DN	PMID30273516-Compound-12
DMIWEZH	HS	Patented
DMIWEZH	CP	CALITHERA BIOSCIENCES, INC
DMIWEZH	DT	Small molecular drug

DMK9TJP	ID	DMK9TJP
DMK9TJP	DN	PMID30273516-Compound-13
DMK9TJP	HS	Patented
DMK9TJP	CP	CORNELL UNIVERSITY ITHACA COLLEGE
DMK9TJP	DT	Small molecular drug

DMURZHA	ID	DMURZHA
DMURZHA	DN	PMID30273516-Compound-14
DMURZHA	HS	Patented
DMURZHA	CP	CORNELL UNIVERSITY ITHACA COLLEGE
DMURZHA	DT	Small molecular drug

DMSD647	ID	DMSD647
DMSD647	DN	PMID30273516-Compound-15
DMSD647	HS	Patented
DMSD647	CP	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION CORNELL UNIVERSITY
DMSD647	DT	Small molecular drug

DMVZA0U	ID	DMVZA0U
DMVZA0U	DN	PMID30273516-Compound-22a
DMVZA0U	HS	Patented
DMVZA0U	CP	ASTRAZENECA AB CANCER RESEARCH TECHNOLOGY LIMITED
DMVZA0U	DT	Small molecular drug

DMZ5O3K	ID	DMZ5O3K
DMZ5O3K	DN	PMID30273516-Compound-22b
DMZ5O3K	HS	Patented
DMZ5O3K	CP	ASTRAZENECA AB CANCER RESEARCH TECHNOLOGY LIMITED
DMZ5O3K	DT	Small molecular drug

DM8NBJV	ID	DM8NBJV
DM8NBJV	DN	PMID30273516-Compound-37
DM8NBJV	HS	Patented
DM8NBJV	CP	HANGZHOU GAMMA BIOTECH CO., LTD
DM8NBJV	DT	Small molecular drug

DMRPJBF	ID	DMRPJBF
DMRPJBF	DN	PMID30273516-Compound-38
DMRPJBF	HS	Patented
DMRPJBF	CP	HANGZHOU GAMMA BIOTECH CO., LTD
DMRPJBF	DT	Small molecular drug

DMBF3ZE	ID	DMBF3ZE
DMBF3ZE	DN	PMID30273516-Compound-39
DMBF3ZE	HS	Patented
DMBF3ZE	DT	Small molecular drug

DM5N8YJ	ID	DM5N8YJ
DM5N8YJ	DN	PMID30273516-Compound-40
DM5N8YJ	HS	Patented
DM5N8YJ	DT	Small molecular drug

DM5UBMJ	ID	DM5UBMJ
DM5UBMJ	DN	PMID30273516-Compound-41
DM5UBMJ	HS	Patented
DM5UBMJ	CP	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DM5UBMJ	DT	Small molecular drug

DMM83WL	ID	DMM83WL
DMM83WL	DN	PMID30280939-Compound-US20170128558
DMM83WL	HS	Patented
DMM83WL	DT	Vaccine
DMM83WL	DE	Malaria

DMPVW2Q	ID	DMPVW2Q
DMPVW2Q	DN	PMID30280939-Compound-US20179642901
DMPVW2Q	HS	Patented
DMPVW2Q	DT	Vaccine
DMPVW2Q	DE	Malaria

DM6VP5K	ID	DM6VP5K
DM6VP5K	DN	PMID30280939-Compound-WO2005070959
DM6VP5K	HS	Patented
DM6VP5K	CP	VIEVAX CORP. MAHAIRAS, Gregory, G
DM6VP5K	DT	Vaccine

DMLVSEK	ID	DMLVSEK
DMLVSEK	DN	PMID30280939-Compound-WO200606195
DMLVSEK	HS	Patented
DMLVSEK	DT	Vaccine

DM7DG0M	ID	DM7DG0M
DM7DG0M	DN	PMID30280939-Compound-WO2008009652
DM7DG0M	HS	Patented
DM7DG0M	CP	GLAXOSMITHKLINE BIOLOGICALS S.A. THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY COHEN, Joseph D MARCHAND, Martine OCKENHOUSE, Christian F YADAVA, Anjali
DM7DG0M	DT	Vaccine
DM7DG0M	DE	Malaria

DMXRHCJ	ID	DMXRHCJ
DMXRHCJ	DN	PMID30280939-Compound-WO2009082440
DMXRHCJ	HS	Patented
DMXRHCJ	CP	VAXINNATE CORPORATION NEW YORK UNIVERSITY POWELL, Thomas, J. NAKAAR, Valerian MCDONALD, William, F. NARDIN, Elizabeth, H
DMXRHCJ	DT	Vaccine

DMRB7LI	ID	DMRB7LI
DMRB7LI	DN	PMID30280939-Compound-WO2013119856
DMRB7LI	HS	Patented
DMRB7LI	CP	INFECTIOUS DISEASE RESEARCH INSTITUTE
DMRB7LI	DT	Vaccine

DMUKIEJ	ID	DMUKIEJ
DMUKIEJ	DN	PMID30280939-Compound-WO2013148426
DMUKIEJ	HS	Patented
DMUKIEJ	CP	ARTIFICIAL CELL TECHNOLOGIES, INC
DMUKIEJ	DT	Vaccine
DMUKIEJ	DE	Malaria

DM4Z2KY	ID	DM4Z2KY
DM4Z2KY	DN	PMID30280939-Compound-WO2013148427
DM4Z2KY	HS	Patented
DM4Z2KY	CP	ARTIFICIAL CELL TECHNOLOGIES, INC
DM4Z2KY	DT	Vaccine

DM4ILAK	ID	DM4ILAK
DM4ILAK	DN	PMID30280939-Compound-WO2015035128
DM4ILAK	HS	Patented
DM4ILAK	CP	ALTIMMUNE INC
DM4ILAK	DT	Vaccine

DM5K3DF	ID	DM5K3DF
DM5K3DF	DN	PMID30280939-Compound-WO2015091734
DM5K3DF	HS	Patented
DM5K3DF	CP	GLAXOSMITHKLINE BIOLOGICALS S.A. UNITED STATES DEPARTMENT OF THE ARMY, AS REPRESENTED BY THE SECRETARY OF THE US ARMY
DM5K3DF	DT	Vaccine
DM5K3DF	DE	Malaria

DMGCE3Z	ID	DMGCE3Z
DMGCE3Z	DN	PMID30280939-Compound-WO2015150568
DMGCE3Z	HS	Patented
DMGCE3Z	CP	GLAXOSMITHKLINE BIOLOGICALS S.A
DMGCE3Z	DT	Vaccine

DMSWI67	ID	DMSWI67
DMSWI67	DN	Polycyclic compound 1
DMSWI67	HS	Patented
DMSWI67	SN	PMID28627961-Compound-29
DMSWI67	CP	GLENMARK PHARMACEUTICALS S.A. GHARAT, Laxmikant Atmaram GAJERA, Jitendra Maganbhai NARAYANA, Lakshminarayana KHAIRATKAR-JOSHI, Neelima KATTIGE, Vidya Ganapati
DMSWI67	DT	Small molecular drug

DMPHCJ5	ID	DMPHCJ5
DMPHCJ5	DN	Polyhydroxy benzamide derivative 1
DMPHCJ5	HS	Patented
DMPHCJ5	SN	PMID26815044-Compound-53
DMPHCJ5	DT	Small molecular drug
DMPHCJ5	PC	70681015
DMPHCJ5	MW	409.5
DMPHCJ5	FM	C24H27NO5
DMPHCJ5	IC	InChI=1S/C24H27NO5/c26-17-2-1-16(20(27)6-17)12-25-23(30)18-7-19(22(29)8-21(18)28)24-9-13-3-14(10-24)5-15(4-13)11-24/h1-2,6-8,13-15,26-29H,3-5,9-12H2,(H,25,30)
DMPHCJ5	CS	C1C2CC3CC1CC(C2)(C3)C4=C(C=C(C(=C4)C(=O)NCC5=C(C=C(C=C5)O)O)O)O
DMPHCJ5	IK	DHXXJPGHCYCRET-UHFFFAOYSA-N
DMPHCJ5	IU	5-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-2,4-dihydroxybenzamide
DMPHCJ5	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM0BRNU	ID	DM0BRNU
DM0BRNU	DN	Polyhydroxy benzamide derivative 2
DM0BRNU	HS	Patented
DM0BRNU	SN	PMID26815044-Compound-54
DM0BRNU	DT	Small molecular drug
DM0BRNU	PC	57328616
DM0BRNU	MW	423.5
DM0BRNU	FM	C25H29NO5
DM0BRNU	IC	InChI=1S/C25H29NO5/c1-31-23-9-22(29)19(24(30)26-13-17-2-3-18(27)7-21(17)28)8-20(23)25-10-14-4-15(11-25)6-16(5-14)12-25/h2-3,7-9,14-16,27-29H,4-6,10-13H2,1H3,(H,26,30)
DM0BRNU	CS	COC1=C(C=C(C(=C1)O)C(=O)NCC2=C(C=C(C=C2)O)O)C34CC5CC(C3)CC(C5)C4
DM0BRNU	IK	SQCLSKGGXIWWPU-UHFFFAOYSA-N
DM0BRNU	IU	5-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-2-hydroxy-4-methoxybenzamide
DM0BRNU	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMCLZWS	ID	DMCLZWS
DMCLZWS	DN	Polyhydroxy benzamide derivative 3
DMCLZWS	HS	Patented
DMCLZWS	SN	PMID26815044-Compound-55
DMCLZWS	DT	Small molecular drug
DMCLZWS	PC	57328615
DMCLZWS	MW	437.5
DMCLZWS	FM	C26H31NO5
DMCLZWS	IC	InChI=1S/C26H31NO5/c1-31-23-10-24(32-2)21(26-11-15-5-16(12-26)7-17(6-15)13-26)9-20(23)25(30)27-14-18-3-4-19(28)8-22(18)29/h3-4,8-10,15-17,28-29H,5-7,11-14H2,1-2H3,(H,27,30)
DMCLZWS	CS	COC1=CC(=C(C=C1C(=O)NCC2=C(C=C(C=C2)O)O)C34CC5CC(C3)CC(C5)C4)OC
DMCLZWS	IK	WDLDXQVTSRCDMN-UHFFFAOYSA-N
DMCLZWS	IU	5-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-2,4-dimethoxybenzamide
DMCLZWS	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM6QBV2	ID	DM6QBV2
DM6QBV2	DN	Polyhydroxy benzamide derivative 4
DM6QBV2	HS	Patented
DM6QBV2	SN	PMID26815044-Compound-56
DM6QBV2	DT	Small molecular drug
DM6QBV2	PC	70681016
DM6QBV2	MW	393.5
DM6QBV2	FM	C24H27NO4
DM6QBV2	IC	InChI=1S/C24H27NO4/c26-19-3-1-18(22(28)9-19)13-25-23(29)17-2-4-21(27)20(8-17)24-10-14-5-15(11-24)7-16(6-14)12-24/h1-4,8-9,14-16,26-28H,5-7,10-13H2,(H,25,29)
DM6QBV2	CS	C1C2CC3CC1CC(C2)(C3)C4=C(C=CC(=C4)C(=O)NCC5=C(C=C(C=C5)O)O)O
DM6QBV2	IK	FXWMRZHJFYXBFU-UHFFFAOYSA-N
DM6QBV2	IU	3-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-4-hydroxybenzamide
DM6QBV2	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMZC6AI	ID	DMZC6AI
DMZC6AI	DN	Polyhydroxy benzamide derivative 5
DMZC6AI	HS	Patented
DMZC6AI	SN	PMID26815044-Compound-57
DMZC6AI	DT	Small molecular drug
DMZC6AI	PC	70685217
DMZC6AI	MW	407.5
DMZC6AI	FM	C25H29NO4
DMZC6AI	IC	InChI=1S/C25H29NO4/c1-30-23-5-3-18(24(29)26-14-19-2-4-20(27)10-22(19)28)9-21(23)25-11-15-6-16(12-25)8-17(7-15)13-25/h2-5,9-10,15-17,27-28H,6-8,11-14H2,1H3,(H,26,29)
DMZC6AI	CS	COC1=C(C=C(C=C1)C(=O)NCC2=C(C=C(C=C2)O)O)C34CC5CC(C3)CC(C5)C4
DMZC6AI	IK	MZAJLDVRKVEVKU-UHFFFAOYSA-N
DMZC6AI	IU	3-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-4-methoxybenzamide
DMZC6AI	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMDLS54	ID	DMDLS54
DMDLS54	DN	Poly-substituted azoles statin lactone derivative 1
DMDLS54	HS	Patented
DMDLS54	SN	PMID27537201-Compound-Figure15c
DMDLS54	CP	the Shanghai Institute of Technology and the Shanghai Ecust Biomedicine Company
DMDLS54	DT	Small molecular drug

DM5G3CN	ID	DM5G3CN
DM5G3CN	DN	Poly-substituted azoles statin lactone derivative 2
DM5G3CN	HS	Patented
DM5G3CN	SN	PMID27537201-Compound-Figure4
DM5G3CN	DT	Small molecular drug

DMQJ38W	ID	DMQJ38W
DMQJ38W	DN	Poly-substituted miazine derivative 1
DMQJ38W	HS	Patented
DMQJ38W	SN	PMID27537201-Compound-Figure7
DMQJ38W	DT	Small molecular drug

DMH2AYV	ID	DMH2AYV
DMH2AYV	DN	Proline amide derivative 1
DMH2AYV	HS	Patented
DMH2AYV	SN	PMID28699813-Compound-21
DMH2AYV	CP	THE UNIVERSITY OF MISSISSIPPI SHARIAT-MADAR, Ziaeddin RIMOLDI, John, Matthew GADEPALLI, Rama Sarma, Venkata SubbarahmanyUniversity of Mississippi
DMH2AYV	DT	Small molecular drug
DMH2AYV	PC	57325416
DMH2AYV	MW	379.6
DMH2AYV	FM	C22H41N3O2
DMH2AYV	IC	InChI=1S/C22H41N3O2/c1-2-3-4-5-6-7-8-9-10-11-16-24-21(26)20-15-13-18-25(20)22(27)19-14-12-17-23-19/h19-20,23H,2-18H2,1H3,(H,24,26)/t19-,20-/m0/s1
DMH2AYV	CS	CCCCCCCCCCCCNC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CCCN2
DMH2AYV	IK	VWPVALOPPKNSFP-PMACEKPBSA-N
DMH2AYV	IU	(2S)-N-dodecyl-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide

DME57SJ	ID	DME57SJ
DME57SJ	DN	P-toluenesulfonate derivative 1
DME57SJ	HS	Patented
DME57SJ	SN	PMID28594589-Compound-TABLE3c4
DME57SJ	CP	JIANGSU HENGRUI MEDICINE CO., LTD
DME57SJ	DT	Small molecular drug

DM92SWJ	ID	DM92SWJ
DM92SWJ	DN	Purin-6-one derivative 1
DM92SWJ	HS	Patented
DM92SWJ	SN	PMID27321640-Compound-13
DM92SWJ	CP	ALTANA PHARMA AG TENOR, Hermann BAER, Thomas HATZELMANN, Armin
DM92SWJ	DT	Small molecular drug

DMB65Z4	ID	DMB65Z4
DMB65Z4	DN	Purine derivative 1
DMB65Z4	HS	Patented
DMB65Z4	SN	PMID26161824-Compound-147
DMB65Z4	DT	Small molecular drug
DMB65Z4	DE	Obesity

DMNRG0P	ID	DMNRG0P
DMNRG0P	DN	Purine derivative 2
DMNRG0P	HS	Patented
DMNRG0P	SN	PMID26161824-Compound-148
DMNRG0P	DT	Small molecular drug
DMNRG0P	DE	Obesity

DMPI2S9	ID	DMPI2S9
DMPI2S9	DN	Purine derivative 3
DMPI2S9	HS	Patented
DMPI2S9	SN	PMID26161824-Compound-149
DMPI2S9	DT	Small molecular drug
DMPI2S9	DE	Obesity

DMYD5SQ	ID	DMYD5SQ
DMYD5SQ	DN	Purine derivative 4
DMYD5SQ	HS	Patented
DMYD5SQ	SN	PMID26161698-Compound-9
DMYD5SQ	CP	GEORGETOWN UNIVERSITY YENUGONDA, Venkata, Mahidhar BROWN, Milton, L
DMYD5SQ	DT	Small molecular drug
DMYD5SQ	PC	44626421
DMYD5SQ	MW	708.3
DMYD5SQ	FM	C34H42ClN9O4S
DMYD5SQ	IC	InChI=1S/C34H42ClN9O4S/c1-20(2)27(18-45)40-34-41-31(30-32(42-34)44(19-37-30)21(3)4)39-22-13-14-25(26(35)17-22)33(46)36-15-16-38-49(47,48)29-12-8-9-23-24(29)10-7-11-28(23)43(5)6/h7-14,17,19-21,27,38,45H,15-16,18H2,1-6H3,(H,36,46)(H2,39,40,41,42)/t27-/m0/s1
DMYD5SQ	CS	CC(C)[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=C(C=C3)C(=O)NCCNS(=O)(=O)C4=CC=CC5=C4C=CC=C5N(C)C)Cl
DMYD5SQ	IK	NJNQGMFCZFMREY-MHZLTWQESA-N
DMYD5SQ	IU	2-chloro-N-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]ethyl]-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzamide

DMMVG2O	ID	DMMVG2O
DMMVG2O	DN	Pyrano[2,3-b]pyridine derivative 1
DMMVG2O	HS	Patented
DMMVG2O	SN	PMID26161824-Compound-122
DMMVG2O	CP	MERCK & CO., INC. DEBENHAM, John, S. HALE, Jeffrey, J. HUO, Pei MADSEN-DUGGAN, Christina, B. WALSH, Thomas, F. YAN, Li
DMMVG2O	DT	Small molecular drug
DMMVG2O	DE	Obesity

DMOJ8P1	ID	DMOJ8P1
DMOJ8P1	DN	Pyrano[2,3-b]pyridine derivative 2
DMOJ8P1	HS	Patented
DMOJ8P1	SN	PMID26161824-Compound-123
DMOJ8P1	CP	MERCK & CO., INC. DEBENHAM, John, S. HALE, Jeffrey, J. HUO, Pei MADSEN-DUGGAN, Christina, B. WALSH, Thomas, F. YAN, Li
DMOJ8P1	DT	Small molecular drug
DMOJ8P1	DE	Obesity

DM3RAU4	ID	DM3RAU4
DM3RAU4	DN	Pyrazine carboxamide derivative 1
DM3RAU4	HS	Patented
DM3RAU4	SN	PMID25470667-Compound-Figure5-12
DM3RAU4	CP	ASTRAZENECA AB ASTRAZENECA UK LIMITED BIRCH, Alan Martin BUTLIN, Roger John CAMPBELL, Leonie GREEN, Clive LEACH, Andrew MURRAY, Paul Michael RYBERG, Per Olof WARING, Michael James
DM3RAU4	DT	Small molecular drug
DM3RAU4	PC	49817370
DM3RAU4	MW	480.9
DM3RAU4	FM	C25H25ClN4O4
DM3RAU4	IC	InChI=1S/C25H25ClN4O4/c1-13-21(29-22(23(27)32)14(2)28-13)17-8-6-16(7-9-17)18-10-5-15(11-19(18)26)12-20(31)30-25(3,4)24(33)34/h5-11H,12H2,1-4H3,(H2,27,32)(H,30,31)(H,33,34)
DM3RAU4	CS	CC1=C(N=C(C(=N1)C)C(=O)N)C2=CC=C(C=C2)C3=C(C=C(C=C3)CC(=O)NC(C)(C)C(=O)O)Cl
DM3RAU4	IK	XXCQLRBQKLTUDU-UHFFFAOYSA-N
DM3RAU4	IU	2-[[2-[4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]-3-chlorophenyl]acetyl]amino]-2-methylpropanoic acid

DMP1MDV	ID	DMP1MDV
DMP1MDV	DN	Pyrazino[2,1-a]isoquinolin derivative 1
DMP1MDV	HS	Patented
DMP1MDV	SN	PMID28454500-Compound-28
DMP1MDV	CP	China Pharmaceutical University
DMP1MDV	DT	Small molecular drug

DMYXKQ3	ID	DMYXKQ3
DMYXKQ3	DN	Pyrazino[2,1-a]isoquinolin derivative 2
DMYXKQ3	HS	Patented
DMYXKQ3	SN	PMID28454500-Compound-29
DMYXKQ3	CP	China Pharmaceutical University
DMYXKQ3	DT	Small molecular drug

DMXYU3I	ID	DMXYU3I
DMXYU3I	DN	Pyrazino[2,1-a]isoquinolin derivative 3
DMXYU3I	HS	Patented
DMXYU3I	SN	PMID28454500-Compound-30
DMXYU3I	CP	China Pharmaceutical University
DMXYU3I	DT	Small molecular drug

DMKTNBC	ID	DMKTNBC
DMKTNBC	DN	Pyrazino[2,1-a]isoquinolin derivative 4
DMKTNBC	HS	Patented
DMKTNBC	SN	PMID28454500-Compound-31
DMKTNBC	CP	China Pharmaceutical University
DMKTNBC	DT	Small molecular drug

DMUXQST	ID	DMUXQST
DMUXQST	DN	Pyrazinylpyridine derivative 1
DMUXQST	HS	Patented
DMUXQST	SN	PMID26161698-Compound-38
DMUXQST	CP	NOVARTIS AG BARSANTI, Paul A. HU, Cheng PFISTER, Keith B. SENDZIK, Martin SUTTON, James
DMUXQST	DT	Small molecular drug

DM05S2X	ID	DM05S2X
DM05S2X	DN	Pyrazole and benzimidazole derivative 1
DM05S2X	HS	Patented
DM05S2X	SN	PMID27828716-Compound-14
DM05S2X	DT	Small molecular drug

DMKTFJ2	ID	DMKTFJ2
DMKTFJ2	DN	Pyrazole and thiophene derivative 1
DMKTFJ2	HS	Patented
DMKTFJ2	SN	PMID26924192-Compound-89
DMKTFJ2	CP	SignalRx Pharmaceuticals, Inc
DMKTFJ2	DT	Small molecular drug
DMKTFJ2	PC	92045047
DMKTFJ2	MW	310.31
DMKTFJ2	FM	C16H14N4O3
DMKTFJ2	IC	InChI=1S/C16H14N4O3/c21-13-8-4-5-9-19(13)16-18-14(22)12-10-17-20(15(12)23-16)11-6-2-1-3-7-11/h1-3,6-7,10H,4-5,8-9H2
DMKTFJ2	CS	C1CCN(C(=O)C1)C2=NC(=O)C3=C(O2)N(N=C3)C4=CC=CC=C4
DMKTFJ2	IK	GHCGOVANSHYUTA-UHFFFAOYSA-N
DMKTFJ2	IU	6-(2-oxopiperidin-1-yl)-1-phenylpyrazolo[4,3-e][1,3]oxazin-4-one

DMD51HM	ID	DMD51HM
DMD51HM	DN	Pyrazole and thiophene derivative 2
DMD51HM	HS	Patented
DMD51HM	SN	PMID26924192-Compound-90
DMD51HM	CP	SignalRx Pharmaceuticals, Inc
DMD51HM	DT	Small molecular drug
DMD51HM	PC	118487503
DMD51HM	MW	296.32
DMD51HM	FM	C16H16N4O2
DMD51HM	IC	InChI=1S/C16H16N4O2/c21-14-13-11-17-20(12-7-3-1-4-8-12)15(13)22-16(18-14)19-9-5-2-6-10-19/h1,3-4,7-8,11H,2,5-6,9-10H2
DMD51HM	CS	C1CCN(CC1)C2=NC(=O)C3=C(O2)N(N=C3)C4=CC=CC=C4
DMD51HM	IK	FXNLCONPKYSXSM-UHFFFAOYSA-N
DMD51HM	IU	1-phenyl-6-piperidin-1-ylpyrazolo[4,3-e][1,3]oxazin-4-one

DMIKUN9	ID	DMIKUN9
DMIKUN9	DN	Pyrazole and thiophene derivative 3
DMIKUN9	HS	Patented
DMIKUN9	SN	PMID26924192-Compound-91
DMIKUN9	CP	SignalRx Pharmaceuticals, Inc
DMIKUN9	DT	Small molecular drug
DMIKUN9	PC	136991243
DMIKUN9	MW	295.34
DMIKUN9	FM	C16H17N5O
DMIKUN9	IC	InChI=1S/C16H17N5O/c22-15-13-11-17-21(12-7-3-1-4-8-12)14(13)18-16(19-15)20-9-5-2-6-10-20/h1,3-4,7-8,11H,2,5-6,9-10H2,(H,18,19,22)
DMIKUN9	CS	C1CCN(CC1)C2=NC3=C(C=NN3C4=CC=CC=C4)C(=O)N2
DMIKUN9	IK	ULYRISNPZZRBFO-UHFFFAOYSA-N
DMIKUN9	IU	1-phenyl-6-piperidin-1-yl-5H-pyrazolo[3,4-d]pyrimidin-4-one

DMDETKY	ID	DMDETKY
DMDETKY	DN	Pyrazole and thiophene derivative 4
DMDETKY	HS	Patented
DMDETKY	SN	PMID26924192-Compound-92
DMDETKY	CP	SignalRx Pharmaceuticals, Inc
DMDETKY	DT	Small molecular drug
DMDETKY	PC	118487470
DMDETKY	MW	372.4
DMDETKY	FM	C18H16N2O5S
DMDETKY	IC	InChI=1S/C18H16N2O5S/c21-17-16-15(25-18(19-17)20-3-5-22-6-4-20)12(10-26-16)11-1-2-13-14(9-11)24-8-7-23-13/h1-2,9-10H,3-8H2
DMDETKY	CS	C1COCCN1C2=NC(=O)C3=C(O2)C(=CS3)C4=CC5=C(C=C4)OCCO5
DMDETKY	IK	RQLXBUCYHIVDGH-UHFFFAOYSA-N
DMDETKY	IU	7-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-morpholin-4-ylthieno[2,3-e][1,3]oxazin-4-one

DM3R9PL	ID	DM3R9PL
DM3R9PL	DN	Pyrazole derivative 1
DM3R9PL	HS	Patented
DM3R9PL	SN	PMID26161824-Compound-11
DM3R9PL	CP	SOLVAY PHARMACEUTICALS B.V. LANGE, Josephus H.M. KRUSE, Cornelis G. VAN VLIET, Bernard J
DM3R9PL	DT	Small molecular drug
DM3R9PL	PC	23624319
DM3R9PL	MW	495.8
DM3R9PL	FM	C22H21Cl3N4OS
DM3R9PL	IC	InChI=1S/C22H21Cl3N4OS/c1-31-21-19(22(30)27-28-11-3-2-4-12-28)26-29(18-10-9-16(24)13-17(18)25)20(21)14-5-7-15(23)8-6-14/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DM3R9PL	CS	CSC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DM3R9PL	IK	MDNGVPOVESSODT-UHFFFAOYSA-N
DM3R9PL	IU	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylsulfanyl-N-piperidin-1-ylpyrazole-3-carboxamide
DM3R9PL	DE	Obesity

DMH7PGU	ID	DMH7PGU
DMH7PGU	DN	Pyrazole derivative 11
DMH7PGU	HS	Patented
DMH7PGU	SN	PMID26161824-Compound-23
DMH7PGU	CP	7TM PHARMA A/S COOPER, Martin RECEVEUR, Jean-Marie HOEGBERG, Thomas NIELSEN, Peter, Aadal LINGET, Jean-Michel NOEREGAARD, Pia, Karina
DMH7PGU	DT	Small molecular drug
DMH7PGU	PC	25157097
DMH7PGU	MW	468.3
DMH7PGU	FM	C22H15Cl2N5O3
DMH7PGU	IC	InChI=1S/C22H15Cl2N5O3/c23-14-7-5-13(6-8-14)20-16(11-18(30)31)19(22(32)27-15-3-1-9-25-12-15)28-29(20)21-17(24)4-2-10-26-21/h1-10,12H,11H2,(H,27,32)(H,30,31)
DMH7PGU	CS	C1=CC(=CN=C1)NC(=O)C2=NN(C(=C2CC(=O)O)C3=CC=C(C=C3)Cl)C4=C(C=CC=N4)Cl
DMH7PGU	IK	RHWMIURMWNGDKU-UHFFFAOYSA-N
DMH7PGU	IU	2-[5-(4-chlorophenyl)-1-(3-chloropyridin-2-yl)-3-(pyridin-3-ylcarbamoyl)pyrazol-4-yl]acetic acid
DMH7PGU	DE	Obesity

DM7LFNG	ID	DM7LFNG
DM7LFNG	DN	Pyrazole derivative 12
DM7LFNG	HS	Patented
DM7LFNG	SN	PMID26161824-Compound-24
DM7LFNG	CP	7TM PHARMA A/S COOPER, Martin RECEVEUR, Jean-Marie HOEGBERG, Thomas NIELSEN, Peter, Aadal LINGET, Jean-Michel NOEREGAARD, Pia, Karina
DM7LFNG	DT	Small molecular drug
DM7LFNG	DE	Obesity

DM5S3L0	ID	DM5S3L0
DM5S3L0	DN	Pyrazole derivative 13
DM5S3L0	HS	Patented
DM5S3L0	SN	PMID26161824-Compound-25
DM5S3L0	CP	7TM PHARMA A/S COOPER, Martin RECEVEUR, Jean-Marie HOEGBERG, Thomas NIELSEN, Peter, Aadal LINGET, Jean-Michel NOEREGAARD, Pia, Karina
DM5S3L0	DT	Small molecular drug
DM5S3L0	PC	24824727
DM5S3L0	MW	573.4
DM5S3L0	FM	C25H17Cl2F3N8O
DM5S3L0	IC	InChI=1S/C25H17Cl2F3N8O/c26-17-9-5-15(6-10-17)22-18(12-20-33-36-37-34-20)21(35-38(22)23-19(27)2-1-11-31-23)24(39)32-13-14-3-7-16(8-4-14)25(28,29)30/h1-11H,12-13H2,(H,32,39)(H,33,34,36,37)
DM5S3L0	CS	C1=CC(=C(N=C1)N2C(=C(C(=N2)C(=O)NCC3=CC=C(C=C3)C(F)(F)F)CC4=NNN=N4)C5=CC=C(C=C5)Cl)Cl
DM5S3L0	IK	FXZYLULQTVQTLV-UHFFFAOYSA-N
DM5S3L0	IU	5-(4-chlorophenyl)-1-(3-chloropyridin-2-yl)-4-(2H-tetrazol-5-ylmethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]pyrazole-3-carboxamide
DM5S3L0	DE	Obesity

DMEDXW9	ID	DMEDXW9
DMEDXW9	DN	Pyrazole derivative 14
DMEDXW9	HS	Patented
DMEDXW9	SN	PMID26161824-Compound-26
DMEDXW9	CP	7TM PHARMA A/S COOPER, Martin RECEVEUR, Jean-Marie HOEGBERG, Thomas NIELSEN, Peter, Aadal LINGET, Jean-Michel NOEREGAARD, Pia, Karina
DMEDXW9	DT	Small molecular drug
DMEDXW9	DE	Obesity

DMJCX8M	ID	DMJCX8M
DMJCX8M	DN	Pyrazole derivative 15
DMJCX8M	HS	Patented
DMJCX8M	SN	PMID26161824-Compound-27
DMJCX8M	DT	Small molecular drug
DMJCX8M	PC	59146323
DMJCX8M	MW	526.4
DMJCX8M	FM	C27H22Cl2FN3O3
DMJCX8M	IC	InChI=1S/C27H22Cl2FN3O3/c1-27(2,17-9-13-19(30)14-10-17)31-26(36)24-20(15-23(34)35)25(16-7-11-18(28)12-8-16)33(32-24)22-6-4-3-5-21(22)29/h3-14H,15H2,1-2H3,(H,31,36)(H,34,35)
DMJCX8M	CS	CC(C)(C1=CC=C(C=C1)F)NC(=O)C2=NN(C(=C2CC(=O)O)C3=CC=C(C=C3)Cl)C4=CC=CC=C4Cl
DMJCX8M	IK	YBFWRMNFSYACJD-UHFFFAOYSA-N
DMJCX8M	IU	2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-[2-(4-fluorophenyl)propan-2-ylcarbamoyl]pyrazol-4-yl]acetic acid
DMJCX8M	DE	Obesity

DM5A8F3	ID	DM5A8F3
DM5A8F3	DN	Pyrazole derivative 16
DM5A8F3	HS	Patented
DM5A8F3	SN	PMID26161824-Compound-28
DM5A8F3	DT	Small molecular drug
DM5A8F3	DE	Obesity

DM7F9V4	ID	DM7F9V4
DM7F9V4	DN	Pyrazole derivative 17
DM7F9V4	HS	Patented
DM7F9V4	SN	PMID26161824-Compound-29
DM7F9V4	DT	Small molecular drug
DM7F9V4	DE	Obesity

DMVZ8KD	ID	DMVZ8KD
DMVZ8KD	DN	Pyrazole derivative 18
DMVZ8KD	HS	Patented
DMVZ8KD	SN	PMID26161824-Compound-30
DMVZ8KD	DT	Small molecular drug
DMVZ8KD	DE	Obesity

DMM7OR3	ID	DMM7OR3
DMM7OR3	DN	Pyrazole derivative 19
DMM7OR3	HS	Patented
DMM7OR3	SN	PMID26161824-Compound-31
DMM7OR3	DT	Small molecular drug
DMM7OR3	PC	24984175
DMM7OR3	MW	468.8
DMM7OR3	FM	C21H20Cl3N3OS
DMM7OR3	IC	InChI=1S/C21H20Cl3N3OS/c1-12-16(11-25-21(28)13-4-2-3-5-13)26-27(17-7-6-14(22)10-15(17)23)20(12)18-8-9-19(24)29-18/h6-10,13H,2-5,11H2,1H3,(H,25,28)
DMM7OR3	CS	CC1=C(N(N=C1CNC(=O)C2CCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(S4)Cl
DMM7OR3	IK	WBIDOYNZOLUBQY-UHFFFAOYSA-N
DMM7OR3	IU	N-[[5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]methyl]cyclopentanecarboxamide
DMM7OR3	DE	Obesity

DMIS97T	ID	DMIS97T
DMIS97T	DN	Pyrazole derivative 2
DMIS97T	HS	Patented
DMIS97T	SN	PMID26161824-Compound-12
DMIS97T	CP	SOLVAY PHARMACEUTICALS B.V. LANGE, Josephus H.M. KRUSE, Cornelis G. VAN VLIET, Bernard J
DMIS97T	DT	Small molecular drug
DMIS97T	PC	24863732
DMIS97T	MW	511.8
DMIS97T	FM	C22H21Cl3N4O2S
DMIS97T	IC	InChI=1S/C22H21Cl3N4O2S/c1-32(31)21-19(22(30)27-28-11-3-2-4-12-28)26-29(18-10-9-16(24)13-17(18)25)20(21)14-5-7-15(23)8-6-14/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMIS97T	CS	CS(=O)C1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMIS97T	IK	LMXGOWNIGCDDEQ-UHFFFAOYSA-N
DMIS97T	IU	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylsulfinyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMIS97T	DE	Obesity

DM2HO1S	ID	DM2HO1S
DM2HO1S	DN	Pyrazole derivative 20
DM2HO1S	HS	Patented
DM2HO1S	SN	PMID26161824-Compound-32
DM2HO1S	DT	Small molecular drug
DM2HO1S	PC	24857045
DM2HO1S	MW	503.5
DM2HO1S	FM	C25H28Cl2N4OS
DM2HO1S	IC	InChI=1S/C25H28Cl2N4OS/c1-3-4-6-9-19-11-13-22(33-19)24-17(2)23(25(32)29-30-14-7-5-8-15-30)28-31(24)21-12-10-18(26)16-20(21)27/h6,9-13,16H,3-5,7-8,14-15H2,1-2H3,(H,29,32)/b9-6+
DM2HO1S	CS	CCC/C=C/C1=CC=C(S1)C2=C(C(=NN2C3=C(C=C(C=C3)Cl)Cl)C(=O)NN4CCCCC4)C
DM2HO1S	IK	IHFQVFSRVQQXSC-RMKNXTFCSA-N
DM2HO1S	IU	1-(2,4-dichlorophenyl)-4-methyl-5-[5-[(E)-pent-1-enyl]thiophen-2-yl]-N-piperidin-1-ylpyrazole-3-carboxamide
DM2HO1S	DE	Obesity

DMUPNHA	ID	DMUPNHA
DMUPNHA	DN	Pyrazole derivative 21
DMUPNHA	HS	Patented
DMUPNHA	SN	PMID26161824-Compound-33
DMUPNHA	DT	Small molecular drug
DMUPNHA	PC	24805936
DMUPNHA	MW	531.5
DMUPNHA	FM	C27H32Cl2N4OS
DMUPNHA	IC	InChI=1S/C27H32Cl2N4OS/c1-3-4-6-11-21-13-15-25(35-21)26-18(2)23(17-30-27(34)31-20-9-7-5-8-10-20)32-33(26)24-14-12-19(28)16-22(24)29/h6,11-16,20H,3-5,7-10,17H2,1-2H3,(H2,30,31,34)/b11-6+
DMUPNHA	CS	CCC/C=C/C1=CC=C(S1)C2=C(C(=NN2C3=C(C=C(C=C3)Cl)Cl)CNC(=O)NC4CCCCC4)C
DMUPNHA	IK	RKQZPZUIJRISOY-IZZDOVSWSA-N
DMUPNHA	IU	1-cyclohexyl-3-[[1-(2,4-dichlorophenyl)-4-methyl-5-[5-[(E)-pent-1-enyl]thiophen-2-yl]pyrazol-3-yl]methyl]urea
DMUPNHA	DE	Obesity

DMCS08K	ID	DMCS08K
DMCS08K	DN	Pyrazole derivative 22
DMCS08K	HS	Patented
DMCS08K	SN	PMID26161824-Compound-34
DMCS08K	DT	Small molecular drug
DMCS08K	DE	Obesity

DMH2LFS	ID	DMH2LFS
DMH2LFS	DN	Pyrazole derivative 23
DMH2LFS	HS	Patented
DMH2LFS	SN	PMID26161824-Compound-35
DMH2LFS	DT	Small molecular drug
DMH2LFS	PC	24983527
DMH2LFS	MW	559.2
DMH2LFS	FM	C20H17BrCl2N4OSe
DMH2LFS	IC	InChI=1S/C20H17BrCl2N4OSe/c1-10-16(18-24-19(26-28-18)20(2,3)4)25-27(13-6-5-11(22)9-12(13)23)17(10)14-7-8-15(21)29-14/h5-9H,1-4H3
DMH2LFS	CS	CC1=C(N(N=C1C2=NC(=NO2)C(C)(C)C)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C([Se]4)Br
DMH2LFS	IK	YUVJAEGOFXSXNJ-UHFFFAOYSA-N
DMH2LFS	IU	5-[5-(5-bromoselenophen-2-yl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-3-tert-butyl-1,2,4-oxadiazole
DMH2LFS	DE	Obesity

DMVX2D0	ID	DMVX2D0
DMVX2D0	DN	Pyrazole derivative 24
DMVX2D0	HS	Patented
DMVX2D0	SN	PMID26161824-Compound-36
DMVX2D0	DT	Small molecular drug
DMVX2D0	PC	25051295
DMVX2D0	MW	459.4
DMVX2D0	FM	C22H20Cl2N4OS
DMVX2D0	IC	InChI=1S/C22H20Cl2N4OS/c1-5-6-15-8-10-18(30-15)20-13(4)19(22-25-21(12(2)3)27-29-22)26-28(20)17-9-7-14(23)11-16(17)24/h5-12H,1-4H3/b6-5+
DMVX2D0	CS	C/C=C/C1=CC=C(S1)C2=C(C(=NN2C3=C(C=C(C=C3)Cl)Cl)C4=NC(=NO4)C(C)C)C
DMVX2D0	IK	WDHLKRONMIKUBC-AATRIKPKSA-N
DMVX2D0	IU	5-[1-(2,4-dichlorophenyl)-4-methyl-5-[5-[(E)-prop-1-enyl]thiophen-2-yl]pyrazol-3-yl]-3-propan-2-yl-1,2,4-oxadiazole
DMVX2D0	DE	Obesity

DMM2RYG	ID	DMM2RYG
DMM2RYG	DN	Pyrazole derivative 25
DMM2RYG	HS	Patented
DMM2RYG	SN	PMID26161824-Compound-37
DMM2RYG	DT	Small molecular drug
DMM2RYG	PC	25051779
DMM2RYG	MW	497.4
DMM2RYG	FM	C25H22Cl2N4OS
DMM2RYG	IC	InChI=1S/C25H22Cl2N4OS/c1-3-22-28-25(32-30-22)23-15(2)24(31(29-23)20-12-9-17(26)14-19(20)27)21-13-11-18(33-21)10-8-16-6-4-5-7-16/h9,11-14,16H,3-7H2,1-2H3
DMM2RYG	CS	CCC1=NOC(=N1)C2=NN(C(=C2C)C3=CC=C(S3)C#CC4CCCC4)C5=C(C=C(C=C5)Cl)Cl
DMM2RYG	IK	NIKGOEACQPFNCK-UHFFFAOYSA-N
DMM2RYG	IU	5-[5-[5-(2-cyclopentylethynyl)thiophen-2-yl]-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-3-ethyl-1,2,4-oxadiazole
DMM2RYG	DE	Obesity

DMX92ZK	ID	DMX92ZK
DMX92ZK	DN	Pyrazole derivative 26
DMX92ZK	HS	Patented
DMX92ZK	SN	PMID26161824-Compound-38
DMX92ZK	CP	GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DMX92ZK	DT	Small molecular drug
DMX92ZK	PC	87176790
DMX92ZK	MW	594.8
DMX92ZK	FM	C25H17Cl3F3N7O
DMX92ZK	IC	InChI=1S/C25H17Cl3F3N7O/c26-15-4-2-14(3-5-15)21-17(11-37-13-32-12-33-37)20(36-38(21)19-7-6-16(27)10-18(19)28)22-34-35-23(39-22)24(8-1-9-24)25(29,30)31/h2-7,10,12-13H,1,8-9,11H2
DMX92ZK	CS	C1CC(C1)(C2=NN=C(O2)C3=NN(C(=C3CN4C=NC=N4)C5=CC=C(C=C5)Cl)C6=C(C=C(C=C6)Cl)Cl)C(F)(F)F
DMX92ZK	IK	MXDYVLWGDAKEMQ-UHFFFAOYSA-N
DMX92ZK	IU	2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1,2,4-triazol-1-ylmethyl)pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]-1,3,4-oxadiazole
DMX92ZK	DE	Obesity

DMDB5FH	ID	DMDB5FH
DMDB5FH	DN	Pyrazole derivative 27
DMDB5FH	HS	Patented
DMDB5FH	SN	PMID26161824-Compound-39
DMDB5FH	CP	GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DMDB5FH	DT	Small molecular drug
DMDB5FH	PC	49865188
DMDB5FH	MW	604.9
DMDB5FH	FM	C29H20Cl3N7S
DMDB5FH	IC	InChI=1S/C29H20Cl3N7S/c30-20-8-6-18(7-9-20)26-22(15-38-17-33-16-34-38)25(37-39(26)24-11-10-21(31)14-23(24)32)27-35-36-28(40-27)29(12-13-29)19-4-2-1-3-5-19/h1-11,14,16-17H,12-13,15H2
DMDB5FH	CS	C1CC1(C2=CC=CC=C2)C3=NN=C(S3)C4=NN(C(=C4CN5C=NC=N5)C6=CC=C(C=C6)Cl)C7=C(C=C(C=C7)Cl)Cl
DMDB5FH	IK	IYLHAOFOPKLWMF-UHFFFAOYSA-N
DMDB5FH	IU	2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1,2,4-triazol-1-ylmethyl)pyrazol-3-yl]-5-(1-phenylcyclopropyl)-1,3,4-thiadiazole
DMDB5FH	DE	Obesity

DMYEFW1	ID	DMYEFW1
DMYEFW1	DN	Pyrazole derivative 28
DMYEFW1	HS	Patented
DMYEFW1	SN	PMID26161824-Compound-40
DMYEFW1	CP	GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DMYEFW1	DT	Small molecular drug
DMYEFW1	DE	Obesity

DM7DTYS	ID	DM7DTYS
DM7DTYS	DN	Pyrazole derivative 29
DM7DTYS	HS	Patented
DM7DTYS	SN	PMID26161824-Compound-41
DM7DTYS	CP	GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DM7DTYS	DT	Small molecular drug
DM7DTYS	PC	24810743
DM7DTYS	MW	502.9
DM7DTYS	FM	C25H26Cl3N5
DM7DTYS	IC	InChI=1S/C25H26Cl3N5/c1-6-15(4)25-29-24(31-32(25)14(2)3)22-16(5)23(17-7-9-18(26)10-8-17)33(30-22)21-12-11-19(27)13-20(21)28/h7-15H,6H2,1-5H3
DM7DTYS	CS	CCC(C)C1=NC(=NN1C(C)C)C2=NN(C(=C2C)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl
DM7DTYS	IK	WWSDQOOUHRYSSK-UHFFFAOYSA-N
DM7DTYS	IU	5-butan-2-yl-3-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-1-propan-2-yl-1,2,4-triazole
DM7DTYS	DE	Obesity

DMX2NQW	ID	DMX2NQW
DMX2NQW	DN	Pyrazole derivative 3
DMX2NQW	HS	Patented
DMX2NQW	SN	PMID26161824-Compound-13
DMX2NQW	CP	SOLVAY PHARMACEUTICALS B.V. LANGE, Josephus H.M. KRUSE, Cornelis G. VAN VLIET, Bernard J
DMX2NQW	DT	Small molecular drug
DMX2NQW	PC	24863731
DMX2NQW	MW	527.8
DMX2NQW	FM	C22H21Cl3N4O3S
DMX2NQW	IC	InChI=1S/C22H21Cl3N4O3S/c1-33(31,32)21-19(22(30)27-28-11-3-2-4-12-28)26-29(18-10-9-16(24)13-17(18)25)20(21)14-5-7-15(23)8-6-14/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMX2NQW	CS	CS(=O)(=O)C1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMX2NQW	IK	WUMRQUSTSNHTOT-UHFFFAOYSA-N
DMX2NQW	IU	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylsulfonyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMX2NQW	DE	Obesity

DMT1DJP	ID	DMT1DJP
DMT1DJP	DN	Pyrazole derivative 30
DMT1DJP	HS	Patented
DMT1DJP	SN	PMID26161824-Compound-42
DMT1DJP	CP	GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DMT1DJP	DT	Small molecular drug
DMT1DJP	PC	66844441
DMT1DJP	MW	460.8
DMT1DJP	FM	C23H20Cl3N3O
DMT1DJP	IC	InChI=1S/C23H20Cl3N3O/c1-13-20(22-27-12-19(30-22)23(2,3)4)28-29(18-10-9-16(25)11-17(18)26)21(13)14-5-7-15(24)8-6-14/h5-12H,1-4H3
DMT1DJP	CS	CC1=C(N(N=C1C2=NC=C(O2)C(C)(C)C)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMT1DJP	IK	ILTATKGFTNWDTG-UHFFFAOYSA-N
DMT1DJP	IU	5-tert-butyl-2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-1,3-oxazole
DMT1DJP	DE	Obesity

DMDTQCG	ID	DMDTQCG
DMDTQCG	DN	Pyrazole derivative 31
DMDTQCG	HS	Patented
DMDTQCG	SN	PMID26161824-Compound-45
DMDTQCG	CP	GREEN CROSS CORPORATION LEE, Sung-Han SEO, Hee Jeong LEE, Jinhwa KIM, Min-ah KIM, Jeong Min KANG, Suk Youn AHN, Kwang-Woo LEE, Suk Ho
DMDTQCG	DT	Small molecular drug
DMDTQCG	PC	44247611
DMDTQCG	MW	567.8
DMDTQCG	FM	C27H21Cl3N6O2
DMDTQCG	IC	InChI=1S/C27H21Cl3N6O2/c1-27(2,3)26-34-33-25(38-26)22-21(24(37)32-20-6-4-5-13-31-20)23(15-7-9-16(28)10-8-15)36(35-22)19-12-11-17(29)14-18(19)30/h4-14H,1-3H3,(H,31,32,37)
DMDTQCG	CS	CC(C)(C)C1=NN=C(O1)C2=NN(C(=C2C(=O)NC3=CC=CC=N3)C4=CC=C(C=C4)Cl)C5=C(C=C(C=C5)Cl)Cl
DMDTQCG	IK	UGTKDMCWCRRUHZ-UHFFFAOYSA-N
DMDTQCG	IU	3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-pyridin-2-ylpyrazole-4-carboxamide
DMDTQCG	DE	Obesity

DMU59IJ	ID	DMU59IJ
DMU59IJ	DN	Pyrazole derivative 32
DMU59IJ	HS	Patented
DMU59IJ	SN	PMID26161824-Compound-46
DMU59IJ	CP	GREEN CROSS CORPORATION LEE, Sung-Han SEO, Hee Jeong LEE, Jinhwa KIM, Min-ah KIM, Jeong Min KANG, Suk Youn AHN, Kwang-Woo LEE, Suk Ho
DMU59IJ	DT	Small molecular drug
DMU59IJ	PC	44247650
DMU59IJ	MW	591.3
DMU59IJ	FM	C25H22BrCl2N5OS
DMU59IJ	IC	InChI=1S/C25H22BrCl2N5OS/c1-25(2,3)24-31-30-23(35-24)20-19(22(34)29-16-9-10-16)21(13-4-6-14(26)7-5-13)33(32-20)18-11-8-15(27)12-17(18)28/h4-8,11-12,16H,9-10H2,1-3H3,(H,29,34)
DMU59IJ	CS	CC(C)(C)C1=NN=C(S1)C2=NN(C(=C2C(=O)NC3CC3)C4=CC=C(C=C4)Br)C5=C(C=C(C=C5)Cl)Cl
DMU59IJ	IK	GBQKLVGYQWGQEF-UHFFFAOYSA-N
DMU59IJ	IU	5-(4-bromophenyl)-3-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyl-1-(2,4-dichlorophenyl)pyrazole-4-carboxamide
DMU59IJ	DE	Obesity

DMUNLK8	ID	DMUNLK8
DMUNLK8	DN	Pyrazole derivative 33
DMUNLK8	HS	Patented
DMUNLK8	SN	PMID26161824-Compound-47
DMUNLK8	CP	GREEN CROSS CORPORATION LEE, Jinhwa SEO, Hee Jeong KIM, Min-Ah KIM, Jeongmin LEE, Sung-Han JUNG, Myung Eun KIM, Mi-Soo
DMUNLK8	DT	Small molecular drug
DMUNLK8	DE	Obesity

DMRH2EJ	ID	DMRH2EJ
DMRH2EJ	DN	Pyrazole derivative 34
DMRH2EJ	HS	Patented
DMRH2EJ	SN	PMID26161824-Compound-48
DMRH2EJ	CP	GREEN CROSS CORPORATION LEE, Jinhwa SEO, Hee Jeong KIM, Min-Ah KIM, Jeongmin LEE, Sung-Han JUNG, Myung Eun KIM, Mi-Soo
DMRH2EJ	DT	Small molecular drug
DMRH2EJ	PC	45102594
DMRH2EJ	MW	573.4
DMRH2EJ	FM	C23H17Cl2F3N4O2S2
DMRH2EJ	IC	InChI=1S/C23H17Cl2F3N4O2S2/c1-36(33,34)19-17(20-29-30-21(35-20)22(11-4-12-22)23(26,27)28)31-32(16-6-3-2-5-15(16)25)18(19)13-7-9-14(24)10-8-13/h2-3,5-10H,4,11-12H2,1H3
DMRH2EJ	CS	CS(=O)(=O)C1=C(N(N=C1C2=NN=C(S2)C3(CCC3)C(F)(F)F)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl
DMRH2EJ	IK	JEHNKOMECQRUIV-UHFFFAOYSA-N
DMRH2EJ	IU	2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylsulfonylpyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]-1,3,4-thiadiazole
DMRH2EJ	DE	Obesity

DM6KROX	ID	DM6KROX
DM6KROX	DN	Pyrazole derivative 35
DM6KROX	HS	Patented
DM6KROX	SN	PMID26161824-Compound-49
DM6KROX	CP	7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DM6KROX	DT	Small molecular drug
DM6KROX	DE	Obesity

DMSDVI1	ID	DMSDVI1
DMSDVI1	DN	Pyrazole derivative 36
DMSDVI1	HS	Patented
DMSDVI1	SN	PMID26161824-Compound-50
DMSDVI1	CP	7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DMSDVI1	DT	Small molecular drug
DMSDVI1	DE	Obesity

DMZJ5FN	ID	DMZJ5FN
DMZJ5FN	DN	Pyrazole derivative 37
DMZJ5FN	HS	Patented
DMZJ5FN	SN	PMID26161824-Compound-51
DMZJ5FN	CP	7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DMZJ5FN	DT	Small molecular drug
DMZJ5FN	DE	Obesity

DMPVDSC	ID	DMPVDSC
DMPVDSC	DN	Pyrazole derivative 38
DMPVDSC	HS	Patented
DMPVDSC	SN	PMID26161824-Compound-52
DMPVDSC	CP	7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DMPVDSC	DT	Small molecular drug
DMPVDSC	PC	71101125
DMPVDSC	MW	504.4
DMPVDSC	FM	C26H19Cl2N5O2
DMPVDSC	IC	InChI=1S/C26H19Cl2N5O2/c27-19-11-9-18(10-12-19)25-20(13-23(30)34)24(32-33(25)22-4-2-1-3-21(22)28)26(35)31-15-17-7-5-16(14-29)6-8-17/h1-12H,13,15H2,(H2,30,34)(H,31,35)
DMPVDSC	CS	C1=CC=C(C(=C1)N2C(=C(C(=N2)C(=O)NCC3=CC=C(C=C3)C#N)CC(=O)N)C4=CC=C(C=C4)Cl)Cl
DMPVDSC	IK	XBSLPZFPNMDPEG-UHFFFAOYSA-N
DMPVDSC	IU	4-(2-amino-2-oxoethyl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-[(4-cyanophenyl)methyl]pyrazole-3-carboxamide
DMPVDSC	DE	Obesity

DMMGWKE	ID	DMMGWKE
DMMGWKE	DN	Pyrazole derivative 39
DMMGWKE	HS	Patented
DMMGWKE	SN	PMID26161824-Compound-53
DMMGWKE	CP	7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DMMGWKE	DT	Small molecular drug
DMMGWKE	PC	25027058
DMMGWKE	MW	482.3
DMMGWKE	FM	C24H18Cl2FN5O
DMMGWKE	IC	InChI=1S/C24H18Cl2FN5O/c25-15-7-5-14(6-8-15)23-18(13-21(28)29)22(24(33)30-17-11-9-16(27)10-12-17)31-32(23)20-4-2-1-3-19(20)26/h1-12H,13H2,(H3,28,29)(H,30,33)
DMMGWKE	CS	C1=CC=C(C(=C1)N2C(=C(C(=N2)C(=O)NC3=CC=C(C=C3)F)CC(=N)N)C4=CC=C(C=C4)Cl)Cl
DMMGWKE	IK	QWOVGBHZFLBBHN-UHFFFAOYSA-N
DMMGWKE	IU	4-(2-amino-2-iminoethyl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(4-fluorophenyl)pyrazole-3-carboxamide
DMMGWKE	DE	Obesity

DM2DK1E	ID	DM2DK1E
DM2DK1E	DN	Pyrazole derivative 4
DM2DK1E	HS	Patented
DM2DK1E	SN	PMID26161824-Compound-14
DM2DK1E	CP	Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DM2DK1E	DT	Small molecular drug
DM2DK1E	PC	66863165
DM2DK1E	MW	531.4
DM2DK1E	FM	C25H28Cl2N6O3
DM2DK1E	IC	InChI=1S/C25H28Cl2N6O3/c1-2-28-25(35)29-13-16-36-23-21(24(34)31-32-14-5-6-15-32)30-33(20-8-4-3-7-19(20)27)22(23)17-9-11-18(26)12-10-17/h3-4,7-12H,2,5-6,13-16H2,1H3,(H,31,34)(H2,28,29,35)
DM2DK1E	CS	CCNC(=O)NCCOC1=C(N(N=C1C(=O)NN2CCCC2)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl
DM2DK1E	IK	ZDSBVGULFYUNNF-UHFFFAOYSA-N
DM2DK1E	IU	1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-[2-(ethylcarbamoylamino)ethoxy]-N-pyrrolidin-1-ylpyrazole-3-carboxamide
DM2DK1E	DE	Obesity

DM7CMV6	ID	DM7CMV6
DM7CMV6	DN	Pyrazole derivative 40
DM7CMV6	HS	Patented
DM7CMV6	SN	PMID26161824-Compound-54
DM7CMV6	CP	7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DM7CMV6	DT	Small molecular drug
DM7CMV6	DE	Obesity

DMDGSKH	ID	DMDGSKH
DMDGSKH	DN	Pyrazole derivative 5
DMDGSKH	HS	Patented
DMDGSKH	SN	PMID26161824-Compound-15
DMDGSKH	CP	Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DMDGSKH	DT	Small molecular drug
DMDGSKH	DE	Obesity

DMMIOZ5	ID	DMMIOZ5
DMMIOZ5	DN	Pyrazole derivative 53
DMMIOZ5	HS	Patented
DMMIOZ5	SN	PMID26161824-Compound-67
DMMIOZ5	DT	Small molecular drug
DMMIOZ5	DE	Obesity

DM9PNTF	ID	DM9PNTF
DM9PNTF	DN	Pyrazole derivative 54
DM9PNTF	HS	Patented
DM9PNTF	SN	PMID26161824-Compound-70
DM9PNTF	CP	UNIVERSITY OF CONNECTICUT MAKRIYANNIS, Alexandros VEMURI, Venkata, Kiran THOTAPALLY, Rajesh OLSZEWSKA, Teresa
DM9PNTF	DT	Small molecular drug
DM9PNTF	PC	46894021
DM9PNTF	MW	524.4
DM9PNTF	FM	C26H23Cl2N5O3
DM9PNTF	IC	InChI=1S/C26H23Cl2N5O3/c27-20-9-10-23(22(28)16-20)33-25(19-7-5-18(6-8-19)4-2-1-3-11-29)21(17-34)24(30-33)26(35)31-32-12-14-36-15-13-32/h5-10,16,34H,1,3,12-15,17H2,(H,31,35)
DM9PNTF	CS	C1COCCN1NC(=O)C2=NN(C(=C2CO)C3=CC=C(C=C3)C#CCCC#N)C4=C(C=C(C=C4)Cl)Cl
DM9PNTF	IK	VQXIVPLXEIZJTH-UHFFFAOYSA-N
DM9PNTF	IU	5-[4-(4-cyanobut-1-ynyl)phenyl]-1-(2,4-dichlorophenyl)-4-(hydroxymethyl)-N-morpholin-4-ylpyrazole-3-carboxamide
DM9PNTF	DE	Obesity

DMZ3J78	ID	DMZ3J78
DMZ3J78	DN	Pyrazole derivative 57
DMZ3J78	HS	Patented
DMZ3J78	SN	PMID26161824-Compound-77
DMZ3J78	CP	RESEARCH TRIANGLE INSTITUTE FULP, Alan Bradley MAITRA, Rangan ZHANG, Yanan SELTZMAN, Herbert H
DMZ3J78	DT	Small molecular drug
DMZ3J78	DE	Obesity

DMZIOW0	ID	DMZIOW0
DMZIOW0	DN	Pyrazole derivative 58
DMZIOW0	HS	Patented
DMZIOW0	SN	PMID26161824-Compound-78
DMZIOW0	CP	RESEARCH TRIANGLE INSTITUTE FULP, Alan Bradley MAITRA, Rangan ZHANG, Yanan SELTZMAN, Herbert H
DMZIOW0	DT	Small molecular drug
DMZIOW0	DE	Obesity

DMXZC8K	ID	DMXZC8K
DMXZC8K	DN	Pyrazole derivative 59
DMXZC8K	HS	Patented
DMXZC8K	SN	PMID26161824-Compound-79
DMXZC8K	CP	RESEARCH TRIANGLE INSTITUTE FULP, Alan Bradley MAITRA, Rangan ZHANG, Yanan SELTZMAN, Herbert H
DMXZC8K	DT	Small molecular drug
DMXZC8K	DE	Obesity

DMIDN6T	ID	DMIDN6T
DMIDN6T	DN	Pyrazole derivative 6
DMIDN6T	HS	Patented
DMIDN6T	SN	PMID26161824-Compound-16
DMIDN6T	CP	Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DMIDN6T	DT	Small molecular drug
DMIDN6T	PC	16718290
DMIDN6T	MW	444.2
DMIDN6T	FM	C19H14Cl2F3N3O2
DMIDN6T	IC	InChI=1S/C19H14Cl2F3N3O2/c1-29-17-15(18(28)25-10-19(22,23)24)26-27(14-5-3-2-4-13(14)21)16(17)11-6-8-12(20)9-7-11/h2-9H,10H2,1H3,(H,25,28)
DMIDN6T	CS	COC1=C(N(N=C1C(=O)NCC(F)(F)F)C2=CC=CC=C2Cl)C3=CC=C(C=C3)Cl
DMIDN6T	IK	SOPUIDIJDHHXJF-UHFFFAOYSA-N
DMIDN6T	IU	1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methoxy-N-(2,2,2-trifluoroethyl)pyrazole-3-carboxamide
DMIDN6T	DE	Obesity

DMQ08BM	ID	DMQ08BM
DMQ08BM	DN	Pyrazole derivative 60
DMQ08BM	HS	Patented
DMQ08BM	SN	PMID26161824-Compound-80
DMQ08BM	CP	RESEARCH TRIANGLE INSTITUTE FULP, Alan Bradley MAITRA, Rangan ZHANG, Yanan SELTZMAN, Herbert H
DMQ08BM	DT	Small molecular drug
DMQ08BM	DE	Obesity

DMO6M1Q	ID	DMO6M1Q
DMO6M1Q	DN	Pyrazole derivative 61
DMO6M1Q	HS	Patented
DMO6M1Q	SN	PMID25684022-Compound-US20090111799
DMO6M1Q	CP	The Ohio State University Research Foundation
DMO6M1Q	DT	Small molecular drug
DMO6M1Q	DE	Solid tumour/cancer; Metastatic cancer

DMN53R0	ID	DMN53R0
DMN53R0	DN	Pyrazole derivative 62
DMN53R0	HS	Patented
DMN53R0	SN	PMID26394986-Compound-23
DMN53R0	CP	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMN53R0	DT	Small molecular drug
DMN53R0	PC	72543768
DMN53R0	MW	612.5
DMN53R0	FM	C27H26BrN5O5S
DMN53R0	IC	InChI=1S/C27H26BrN5O5S/c1-30-26(34)16-38-17-27(35)31-21-8-2-18(3-9-21)14-22-15-25(19-4-6-20(28)7-5-19)33(32-22)23-10-12-24(13-11-23)39(29,36)37/h2-13,15H,14,16-17H2,1H3,(H,30,34)(H,31,35)(H2,29,36,37)
DMN53R0	CS	CNC(=O)COCC(=O)NC1=CC=C(C=C1)CC2=NN(C(=C2)C3=CC=C(C=C3)Br)C4=CC=C(C=C4)S(=O)(=O)N
DMN53R0	IK	WRRXKPVOAFTNLS-UHFFFAOYSA-N
DMN53R0	IU	2-[2-[4-[[5-(4-bromophenyl)-1-(4-sulfamoylphenyl)pyrazol-3-yl]methyl]anilino]-2-oxoethoxy]-N-methylacetamide

DMTVAJ0	ID	DMTVAJ0
DMTVAJ0	DN	Pyrazole derivative 63
DMTVAJ0	HS	Patented
DMTVAJ0	SN	PMID26394986-Compound-24
DMTVAJ0	CP	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMTVAJ0	DT	Small molecular drug
DMTVAJ0	PC	72705159
DMTVAJ0	MW	525.4
DMTVAJ0	FM	C24H21BrN4O3S
DMTVAJ0	IC	InChI=1S/C24H21BrN4O3S/c1-16(30)27-20-8-2-17(3-9-20)14-21-15-24(18-4-6-19(25)7-5-18)29(28-21)22-10-12-23(13-11-22)33(26,31)32/h2-13,15H,14H2,1H3,(H,27,30)(H2,26,31,32)
DMTVAJ0	CS	CC(=O)NC1=CC=C(C=C1)CC2=NN(C(=C2)C3=CC=C(C=C3)Br)C4=CC=C(C=C4)S(=O)(=O)N
DMTVAJ0	IK	RPELRWHDWCPVAL-UHFFFAOYSA-N
DMTVAJ0	IU	N-[4-[[5-(4-bromophenyl)-1-(4-sulfamoylphenyl)pyrazol-3-yl]methyl]phenyl]acetamide

DMXAURE	ID	DMXAURE
DMXAURE	DN	Pyrazole derivative 64
DMXAURE	HS	Patented
DMXAURE	SN	PMID26394986-Compound-25
DMXAURE	CP	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMXAURE	DT	Small molecular drug
DMXAURE	PC	72705347
DMXAURE	MW	587.5
DMXAURE	FM	C29H23BrN4O3S
DMXAURE	IC	InChI=1S/C29H23BrN4O3S/c30-23-10-8-21(9-11-23)28-19-25(33-34(28)26-14-16-27(17-15-26)38(31,36)37)18-20-6-12-24(13-7-20)32-29(35)22-4-2-1-3-5-22/h1-17,19H,18H2,(H,32,35)(H2,31,36,37)
DMXAURE	CS	C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)CC3=NN(C(=C3)C4=CC=C(C=C4)Br)C5=CC=C(C=C5)S(=O)(=O)N
DMXAURE	IK	BOVRIAJBTGLLDC-UHFFFAOYSA-N
DMXAURE	IU	N-[4-[[5-(4-bromophenyl)-1-(4-sulfamoylphenyl)pyrazol-3-yl]methyl]phenyl]benzamide

DMYTLRJ	ID	DMYTLRJ
DMYTLRJ	DN	Pyrazole derivative 65
DMYTLRJ	HS	Patented
DMYTLRJ	SN	PMID26394986-Compound-26
DMYTLRJ	CP	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMYTLRJ	DT	Small molecular drug
DMYTLRJ	PC	72705348
DMYTLRJ	MW	448.4
DMYTLRJ	FM	C20H22BrN3O2S
DMYTLRJ	IC	InChI=1S/C20H22BrN3O2S/c1-14(2)3-8-17-13-20(15-4-6-16(21)7-5-15)24(23-17)18-9-11-19(12-10-18)27(22,25)26/h4-7,9-14H,3,8H2,1-2H3,(H2,22,25,26)
DMYTLRJ	CS	CC(C)CCC1=NN(C(=C1)C2=CC=C(C=C2)Br)C3=CC=C(C=C3)S(=O)(=O)N
DMYTLRJ	IK	BDSMHQBMCUYDCT-UHFFFAOYSA-N
DMYTLRJ	IU	4-[5-(4-bromophenyl)-3-(3-methylbutyl)pyrazol-1-yl]benzenesulfonamide

DMBYWJI	ID	DMBYWJI
DMBYWJI	DN	Pyrazole derivative 66
DMBYWJI	HS	Patented
DMBYWJI	SN	PMID26394986-Compound-27
DMBYWJI	CP	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMBYWJI	DT	Small molecular drug

DMNZUHX	ID	DMNZUHX
DMNZUHX	DN	Pyrazole derivative 67
DMNZUHX	HS	Patented
DMNZUHX	SN	PMID26609882-Compound-24
DMNZUHX	CP	ARENA PHARMACEUTICALS, INC. XIONG, Yifeng CHERRIER, Martin, C. CHOI, Jin Sun, Karoline DOSA, Peter, I. SMITH, Brian, M. STRAH-PLEYNET, Sonja ULLMAN, Bret TEEGARDEN, Bradley
DMNZUHX	DT	Small molecular drug

DMVY0JT	ID	DMVY0JT
DMVY0JT	DN	Pyrazole derivative 68
DMVY0JT	HS	Patented
DMVY0JT	SN	PMID26609882-Compound-25
DMVY0JT	CP	ARENA PHARMACEUTICALS, INC. XIONG, Yifeng CHERRIER, Martin, C. CHOI, Jin Sun, Karoline DOSA, Peter, I. SMITH, Brian, M. STRAH-PLEYNET, Sonja ULLMAN, Bret TEEGARDEN, Bradley
DMVY0JT	DT	Small molecular drug

DMKCJE1	ID	DMKCJE1
DMKCJE1	DN	Pyrazole derivative 69
DMKCJE1	HS	Patented
DMKCJE1	SN	PMID26609882-Compound-26
DMKCJE1	CP	Arena Pharmaceuticals, Inc
DMKCJE1	DT	Small molecular drug

DMYKU0T	ID	DMYKU0T
DMYKU0T	DN	Pyrazole derivative 7
DMYKU0T	HS	Patented
DMYKU0T	SN	PMID26161824-Compound-17
DMYKU0T	CP	Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DMYKU0T	DT	Small molecular drug
DMYKU0T	PC	16717804
DMYKU0T	MW	586.4
DMYKU0T	FM	C28H23Cl2F2N5O3
DMYKU0T	IC	InChI=1S/C28H23Cl2F2N5O3/c1-40-26-24(33-37(23-5-3-2-4-21(23)30)25(26)17-6-8-18(29)9-7-17)27(38)34-36-14-12-35(13-15-36)28(39)20-11-10-19(31)16-22(20)32/h2-11,16H,12-15H2,1H3,(H,34,38)
DMYKU0T	CS	COC1=C(N(N=C1C(=O)NN2CCN(CC2)C(=O)C3=C(C=C(C=C3)F)F)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl
DMYKU0T	IK	RXXJWLVGDKFAMN-UHFFFAOYSA-N
DMYKU0T	IU	1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-[4-(2,4-difluorobenzoyl)piperazin-1-yl]-4-methoxypyrazole-3-carboxamide
DMYKU0T	DE	Obesity

DMR6VIG	ID	DMR6VIG
DMR6VIG	DN	Pyrazole derivative 70
DMR6VIG	HS	Patented
DMR6VIG	SN	PMID26609882-Compound-27
DMR6VIG	CP	Arena Pharmaceuticals, Inc
DMR6VIG	DT	Small molecular drug

DMSNY3W	ID	DMSNY3W
DMSNY3W	DN	Pyrazole derivative 71
DMSNY3W	HS	Patented
DMSNY3W	SN	PMID26609882-Compound-28
DMSNY3W	CP	Arena Pharmaceuticals, Inc
DMSNY3W	DT	Small molecular drug

DMWFTCN	ID	DMWFTCN
DMWFTCN	DN	Pyrazole derivative 72
DMWFTCN	HS	Patented
DMWFTCN	SN	PMID26609882-Compound-29
DMWFTCN	CP	Arena Pharmaceuticals, Inc
DMWFTCN	DT	Small molecular drug

DMFARIK	ID	DMFARIK
DMFARIK	DN	Pyrazole derivative 73
DMFARIK	HS	Patented
DMFARIK	SN	PMID26609882-Compound-30
DMFARIK	CP	Arena Pharmaceuticals, Inc
DMFARIK	DT	Small molecular drug

DM70QPF	ID	DM70QPF
DM70QPF	DN	Pyrazole derivative 74
DM70QPF	HS	Patented
DM70QPF	SN	PMID26609882-Compound-31
DM70QPF	CP	Arena Pharmaceuticals, Inc
DM70QPF	DT	Small molecular drug

DMAB2EN	ID	DMAB2EN
DMAB2EN	DN	Pyrazole derivative 75
DMAB2EN	HS	Patented
DMAB2EN	SN	PMID26609882-Compound-32
DMAB2EN	CP	Arena Pharmaceuticals, Inc
DMAB2EN	DT	Small molecular drug

DM6Y27J	ID	DM6Y27J
DM6Y27J	DN	Pyrazole derivative 76
DM6Y27J	HS	Patented
DM6Y27J	SN	PMID25435285-Compound-70
DM6Y27J	CP	TAISHO PHARMACEUTICAL CO., LTD.  MASUDA Seiji  MATSUDA Yohei  SAKAGAMI Kazunari  KONISHI Kazuhide  URABE Hiroki  SHIMONO Rie  OKADA Kumiko
DM6Y27J	DT	Small molecular drug

DM5E1ZJ	ID	DM5E1ZJ
DM5E1ZJ	DN	Pyrazole derivative 77
DM5E1ZJ	HS	Patented
DM5E1ZJ	SN	PMID25435285-Compound-76
DM5E1ZJ	CP	TAISHO PHARMACEUTICAL CO., LTD.  MASUDA Seiji  MATSUDA Yohei  SAKAGAMI Kazunari  KONISHI Kazuhide  URABE Hiroki  SHIMONO Rie  OKADA Kumiko
DM5E1ZJ	DT	Small molecular drug
DM5E1ZJ	PC	57520392
DM5E1ZJ	MW	458.4
DM5E1ZJ	FM	C21H17F3N6O3
DM5E1ZJ	IC	InChI=1S/C21H17F3N6O3/c1-11-7-12(18(25)31)3-5-14(11)19-28-20(33-29-19)15-9-27-30(2)16(15)10-32-17-6-4-13(8-26-17)21(22,23)24/h3-9H,10H2,1-2H3,(H2,25,31)
DM5E1ZJ	CS	CC1=C(C=CC(=C1)C(=O)N)C2=NOC(=N2)C3=C(N(N=C3)C)COC4=NC=C(C=C4)C(F)(F)F
DM5E1ZJ	IK	QBSSBYCWTIBHGM-UHFFFAOYSA-N
DM5E1ZJ	IU	3-methyl-4-[5-[1-methyl-5-[[5-(trifluoromethyl)pyridin-2-yl]oxymethyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]benzamide

DMMCHOW	ID	DMMCHOW
DMMCHOW	DN	Pyrazole derivative 78
DMMCHOW	HS	Patented
DMMCHOW	SN	PMID25435285-Compound-77
DMMCHOW	CP	TAISHO PHARMACEUTICAL CO., LTD.  MASUDA Seiji  MATSUDA Yohei  SAKAGAMI Kazunari  KONISHI Kazuhide  URABE Hiroki  SHIMONO Rie  OKADA Kumiko
DMMCHOW	DT	Small molecular drug

DM9JHYL	ID	DM9JHYL
DM9JHYL	DN	Pyrazole derivative 79
DM9JHYL	HS	Patented
DM9JHYL	SN	PMID25435285-Compound-78
DM9JHYL	CP	TAISHO PHARMACEUTICAL CO., LTD.  MASUDA Seiji  MATSUDA Yohei  SAKAGAMI Kazunari  KONISHI Kazuhide  URABE Hiroki  SHIMONO Rie  OKADA Kumiko
DM9JHYL	DT	Small molecular drug

DMMRTAL	ID	DMMRTAL
DMMRTAL	DN	Pyrazole derivative 8
DMMRTAL	HS	Patented
DMMRTAL	SN	PMID26161824-Compound-18
DMMRTAL	CP	Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DMMRTAL	DT	Small molecular drug
DMMRTAL	PC	16049863
DMMRTAL	MW	517.299
DMMRTAL	FM	C22H18Cl2F4N4O2
DMMRTAL	IC	InChI=1S/C22H18Cl2F4N4O2/c23-14-7-5-13(6-8-14)18-19(34-21(25)26)17(29-32(18)16-4-2-1-3-15(16)24)20(33)30-31-11-9-22(27,28)10-12-31/h1-8,21H,9-12H2,(H,30,33)
DMMRTAL	CS	C1CN(CCC1(F)F)NC(=O)C2=NN(C(=C2OC(F)F)C3=CC=C(C=C3)Cl)C4=CC=CC=C4Cl
DMMRTAL	IK	UTHOXBJQLSAVTJ-UHFFFAOYSA-N
DMMRTAL	IU	1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(difluoromethoxy)-N-(4,4-difluoropiperidin-1-yl)pyrazole-3-carboxamide
DMMRTAL	DE	Obesity

DMQ3TGM	ID	DMQ3TGM
DMQ3TGM	DN	Pyrazole derivative 80
DMQ3TGM	HS	Patented
DMQ3TGM	SN	PMID29053063-Compound-13a
DMQ3TGM	CP	ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMQ3TGM	DT	Small molecular drug

DMWT437	ID	DMWT437
DMWT437	DN	Pyrazole derivative 81
DMWT437	HS	Patented
DMWT437	SN	PMID29053063-Compound-13b
DMWT437	CP	ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMWT437	DT	Small molecular drug

DMETCI3	ID	DMETCI3
DMETCI3	DN	Pyrazole derivative 82
DMETCI3	HS	Patented
DMETCI3	SN	PMID29053063-Compound-13c
DMETCI3	CP	ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMETCI3	DT	Small molecular drug

DMMGLOA	ID	DMMGLOA
DMMGLOA	DN	Pyrazole derivative 83
DMMGLOA	HS	Patented
DMMGLOA	SN	PMID29053063-Compound-13d
DMMGLOA	CP	ABIDE THERAPEUTICS, INC
DMMGLOA	DT	Small molecular drug

DME8Q0F	ID	DME8Q0F
DME8Q0F	DN	Pyrazole derivative 84
DME8Q0F	HS	Patented
DME8Q0F	SN	PMID29053063-Compound-13e
DME8Q0F	CP	ABIDE THERAPEUTICS, INC
DME8Q0F	DT	Small molecular drug

DMNBCKI	ID	DMNBCKI
DMNBCKI	DN	Pyrazole derivative 85
DMNBCKI	HS	Patented
DMNBCKI	SN	PMID29053063-Compound-13f
DMNBCKI	CP	ABIDE THERAPEUTICS, INC
DMNBCKI	DT	Small molecular drug

DMW3PJV	ID	DMW3PJV
DMW3PJV	DN	Pyrazole derivative 86
DMW3PJV	HS	Patented
DMW3PJV	SN	PMID28051882-Compound-III
DMW3PJV	CP	ESTEVE LABOR DR [ES]
DMW3PJV	DT	Small molecular drug

DMGZUAY	ID	DMGZUAY
DMGZUAY	DN	Pyrazole derivative 87
DMGZUAY	HS	Patented
DMGZUAY	SN	PMID28447479-Compound-9
DMGZUAY	DT	Small molecular drug
DMGZUAY	PC	124165109
DMGZUAY	MW	451.5
DMGZUAY	FM	C22H22FN7O3
DMGZUAY	IC	InChI=1S/C22H22FN7O3/c1-14-12-29(13-21(32)28(2)7-3-6-24)22(33)19-9-18(27-30(14)19)16-5-4-15(11-25)8-17(16)26-20(31)10-23/h4-5,8-9,14H,3,7,10,12-13H2,1-2H3,(H,26,31)/t14-/m0/s1
DMGZUAY	CS	C[C@H]1CN(C(=O)C2=CC(=NN12)C3=C(C=C(C=C3)C#N)NC(=O)CF)CC(=O)N(C)CCC#N
DMGZUAY	IK	TXOZRELGSIJTEA-AWEZNQCLSA-N
DMGZUAY	IU	N-(2-cyanoethyl)-2-[(7S)-2-[4-cyano-2-[(2-fluoroacetyl)amino]phenyl]-7-methyl-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazin-5-yl]-N-methylacetamide

DMVX7YT	ID	DMVX7YT
DMVX7YT	DN	Pyrazole N-1 aryl and heteroaryl derivative 1
DMVX7YT	HS	Patented
DMVX7YT	SN	PMID27310003-Compound-39
DMVX7YT	CP	MERCK SHARP & DOHME [US]
DMVX7YT	DT	Small molecular drug

DMVQXZJ	ID	DMVQXZJ
DMVQXZJ	DN	Pyrazole-3-carboxamide derivative 1
DMVQXZJ	HS	Patented
DMVQXZJ	SN	PMID26609882-Compound-63
DMVQXZJ	DT	Small molecular drug

DMGS2ET	ID	DMGS2ET
DMGS2ET	DN	Pyrazoline derivative 1
DMGS2ET	HS	Patented
DMGS2ET	SN	PMID26161824-Compound-103
DMGS2ET	CP	JENRIN DISCOVERY MCELROY, John CHORVAT, Rober
DMGS2ET	DT	Small molecular drug
DMGS2ET	DE	Obesity

DMCZORA	ID	DMCZORA
DMCZORA	DN	Pyrazoline derivative 10
DMCZORA	HS	Patented
DMCZORA	SN	PMID26161824-Compound-98
DMCZORA	DT	Small molecular drug
DMCZORA	DE	Obesity

DMAB3YG	ID	DMAB3YG
DMAB3YG	DN	Pyrazoline derivative 11
DMAB3YG	HS	Patented
DMAB3YG	SN	PMID26161824-Compound-99
DMAB3YG	DT	Small molecular drug
DMAB3YG	DE	Obesity

DMOA8E4	ID	DMOA8E4
DMOA8E4	DN	Pyrazoline derivative 2
DMOA8E4	HS	Patented
DMOA8E4	SN	PMID26161824-Compound-104
DMOA8E4	CP	JENRIN DISCOVERY MCELROY, John CHORVAT, Rober
DMOA8E4	DT	Small molecular drug
DMOA8E4	DE	Obesity

DMGH0LQ	ID	DMGH0LQ
DMGH0LQ	DN	Pyrazoline derivative 3
DMGH0LQ	HS	Patented
DMGH0LQ	SN	PMID26161824-Compound-105
DMGH0LQ	CP	JENRIN DISCOVERY MCELROY, John CHORVAT, Robert
DMGH0LQ	DT	Small molecular drug
DMGH0LQ	DE	Obesity

DMRT7I8	ID	DMRT7I8
DMRT7I8	DN	Pyrazoline derivative 4
DMRT7I8	HS	Patented
DMRT7I8	SN	PMID26161824-Compound-106
DMRT7I8	CP	JENRIN DISCOVERY MCELROY, John CHORVAT, Robert
DMRT7I8	DT	Small molecular drug
DMRT7I8	DE	Obesity

DMEGS9U	ID	DMEGS9U
DMEGS9U	DN	Pyrazoline derivative 5
DMEGS9U	HS	Patented
DMEGS9U	SN	PMID26161824-Compound-107
DMEGS9U	CP	JENRIN DISCOVERY MCELROY, John CHORVAT, Robert
DMEGS9U	DT	Small molecular drug
DMEGS9U	DE	Obesity

DMOK7CW	ID	DMOK7CW
DMOK7CW	DN	Pyrazolo[1,5-a]-1,3,5-triazine derivative 1
DMOK7CW	HS	Patented
DMOK7CW	SN	PMID26161698-Compound-12
DMOK7CW	CP	CENTRE NAT RECH SCIENT [FR
DMOK7CW	DT	Small molecular drug

DMH1W89	ID	DMH1W89
DMH1W89	DN	Pyrazolo[1,5-a]pyridine derivative 1
DMH1W89	HS	Patented
DMH1W89	SN	PMID28270021-Compound-WO2013088256Example59
DMH1W89	CP	DR. REDDY'S LABORATORIES LTD
DMH1W89	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMLS827	ID	DMLS827
DMLS827	DN	Pyrazolo[1,5-a]pyridine derivative 2
DMLS827	HS	Patented
DMLS827	SN	PMID28270021-Compound-WO2013088257Example240
DMLS827	CP	DR. REDDY'S LABORATORIES LTD
DMLS827	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM0FPMV	ID	DM0FPMV
DM0FPMV	DN	Pyrazolo[1,5-a]pyrimidine derivative 1
DM0FPMV	HS	Patented
DM0FPMV	SN	PMID26161824-Compound-131
DM0FPMV	CP	Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
DM0FPMV	DT	Small molecular drug
DM0FPMV	PC	16049464
DM0FPMV	MW	465.4
DM0FPMV	FM	C25H22Cl2N4O
DM0FPMV	IC	InChI=1S/C25H22Cl2N4O/c26-17-12-10-16(11-13-17)23-20(19-8-4-5-9-22(19)27)14-28-24-21(15-29-31(23)24)25(32)30-18-6-2-1-3-7-18/h4-5,8-15,18H,1-3,6-7H2,(H,30,32)
DM0FPMV	CS	C1CCC(CC1)NC(=O)C2=C3N=CC(=C(N3N=C2)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DM0FPMV	IK	ZZBARLOXOSWJIH-UHFFFAOYSA-N
DM0FPMV	IU	6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-cyclohexylpyrazolo[1,5-a]pyrimidine-3-carboxamide
DM0FPMV	DE	Obesity

DM07GEK	ID	DM07GEK
DM07GEK	DN	Pyrazolo[1,5-a]pyrimidine derivative 10
DM07GEK	HS	Patented
DM07GEK	SN	PMID26161824-Compound-140
DM07GEK	CP	MITSUBISHI TANABE PHARMA CORPORATION TANIMOTO, Koichi OI, Mariko TSUBOI, Yasunori MORITANI, Yasunor
DM07GEK	DT	Small molecular drug
DM07GEK	DE	Obesity

DM0O4WR	ID	DM0O4WR
DM0O4WR	DN	Pyrazolo[1,5-a]pyrimidine derivative 11
DM0O4WR	HS	Patented
DM0O4WR	SN	PMID26161824-Compound-141
DM0O4WR	CP	MITSUBISHI TANABE PHARMA CORPORATION TANIMOTO, Koichi OI, Mariko TSUBOI, Yasunori MORITANI, Yasunor
DM0O4WR	DT	Small molecular drug
DM0O4WR	PC	24772341
DM0O4WR	MW	575.5
DM0O4WR	FM	C26H24Cl2N4O5S
DM0O4WR	IC	InChI=1S/C26H24Cl2N4O5S/c1-26(10-13-38(35,36)15-26)30-24(34)21-23-29-14-19(18-4-2-3-5-20(18)28)22(16-6-8-17(27)9-7-16)32(23)31-25(21)37-12-11-33/h2-9,14,33H,10-13,15H2,1H3,(H,30,34)
DM0O4WR	CS	CC1(CCS(=O)(=O)C1)NC(=O)C2=C3N=CC(=C(N3N=C2OCCO)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DM0O4WR	IK	UNFBOPQOKSVPNI-UHFFFAOYSA-N
DM0O4WR	IU	6-(2-chlorophenyl)-7-(4-chlorophenyl)-2-(2-hydroxyethoxy)-N-(3-methyl-1,1-dioxothiolan-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
DM0O4WR	DE	Obesity

DMMLDUI	ID	DMMLDUI
DMMLDUI	DN	Pyrazolo[1,5-a]pyrimidine derivative 12
DMMLDUI	HS	Patented
DMMLDUI	SN	PMID26161824-Compound-177
DMMLDUI	CP	AMOREPACIFIC CORPORATION ( )       SHIN, Song Seok     HONG, Yong Deog     BYOUN, Kyoung Hee     PARK, Mi Young     CHOI, Jin Ky
DMMLDUI	DT	Small molecular drug
DMMLDUI	PC	89620957
DMMLDUI	MW	466.9
DMMLDUI	FM	C25H24ClFN4O2
DMMLDUI	IC	InChI=1S/C25H24ClFN4O2/c1-33-15-21-24(16-7-9-18(26)10-8-16)25-28-23(30-11-3-6-20(30)14-32)13-22(31(25)29-21)17-4-2-5-19(27)12-17/h2,4-5,7-10,12-13,20,32H,3,6,11,14-15H2,1H3/t20-/m0/s1
DMMLDUI	CS	COCC1=NN2C(=CC(=NC2=C1C3=CC=C(C=C3)Cl)N4CCC[C@H]4CO)C5=CC(=CC=C5)F
DMMLDUI	IK	USQDDAWNOFWURT-FQEVSTJZSA-N
DMMLDUI	IU	[(2S)-1-[3-(4-chlorophenyl)-7-(3-fluorophenyl)-2-(methoxymethyl)pyrazolo[1,5-a]pyrimidin-5-yl]pyrrolidin-2-yl]methanol
DMMLDUI	DE	Obesity

DMR5O7T	ID	DMR5O7T
DMR5O7T	DN	Pyrazolo[1,5-a]pyrimidine derivative 13
DMR5O7T	HS	Patented
DMR5O7T	SN	PMID26161824-Compound-178
DMR5O7T	CP	AMOREPACIFIC CORPORATION ( )       SHIN, Song Seok     HONG, Yong Deog     BYOUN, Kyoung Hee     PARK, Mi Young     CHOI, Jin Ky
DMR5O7T	DT	Small molecular drug
DMR5O7T	PC	89620917
DMR5O7T	MW	454.9
DMR5O7T	FM	C24H24ClFN4O2
DMR5O7T	IC	InChI=1S/C24H24ClFN4O2/c1-3-32-15-20-23(16-7-9-18(25)10-8-16)24-27-22(29(2)11-12-31)14-21(30(24)28-20)17-5-4-6-19(26)13-17/h4-10,13-14,31H,3,11-12,15H2,1-2H3
DMR5O7T	CS	CCOCC1=NN2C(=CC(=NC2=C1C3=CC=C(C=C3)Cl)N(C)CCO)C4=CC(=CC=C4)F
DMR5O7T	IK	HYBHLUDFJVRRSM-UHFFFAOYSA-N
DMR5O7T	IU	2-[[3-(4-chlorophenyl)-2-(ethoxymethyl)-7-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidin-5-yl]-methylamino]ethanol
DMR5O7T	DE	Obesity

DMB6EFV	ID	DMB6EFV
DMB6EFV	DN	Pyrazolo[1,5-a]pyrimidine derivative 14
DMB6EFV	HS	Patented
DMB6EFV	SN	PMID28270010-Compound-Figure10a-1
DMB6EFV	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven S. CONDROSKI, Kevin Ronald HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy SEO, Jeongbeob
DMB6EFV	DT	Small molecular drug
DMB6EFV	PC	67501573
DMB6EFV	MW	381.4
DMB6EFV	FM	C20H20FN5O2
DMB6EFV	IC	InChI=1S/C20H20FN5O2/c21-13-3-1-2-12(8-13)17-9-15(27)11-25(17)18-6-7-26-19(24-18)16(10-22-26)20(28)23-14-4-5-14/h1-3,6-8,10,14-15,17,27H,4-5,9,11H2,(H,23,28)/t15-,17-/m1/s1
DMB6EFV	CS	C1CC1NC(=O)C2=C3N=C(C=CN3N=C2)N4C[C@@H](C[C@@H]4C5=CC(=CC=C5)F)O
DMB6EFV	IK	DHEFBJXZYSKWIF-NVXWUHKLSA-N
DMB6EFV	IU	N-cyclopropyl-5-[(2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

DMAZI3D	ID	DMAZI3D
DMAZI3D	DN	Pyrazolo[1,5-a]pyrimidine derivative 15
DMAZI3D	HS	Patented
DMAZI3D	SN	PMID28270010-Compound-Figure10a-2
DMAZI3D	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven S. CONDROSKI, Kevin Ronald HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy SEO, Jeongbeob
DMAZI3D	DT	Small molecular drug

DMTYN2D	ID	DMTYN2D
DMTYN2D	DN	Pyrazolo[1,5-a]pyrimidine derivative 16
DMTYN2D	HS	Patented
DMTYN2D	SN	PMID28270010-Compound-Figure10a-3
DMTYN2D	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven S. CONDROSKI, Kevin Ronald HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy SEO, Jeongbeob
DMTYN2D	DT	Small molecular drug
DMTYN2D	PC	67500657
DMTYN2D	MW	494.6
DMTYN2D	FM	C26H31FN6O3
DMTYN2D	IC	InChI=1S/C26H31FN6O3/c27-18-3-6-23(36-15-12-31-10-13-35-14-11-31)20(16-18)22-2-1-8-32(22)24-7-9-33-25(30-24)21(17-28-33)26(34)29-19-4-5-19/h3,6-7,9,16-17,19,22H,1-2,4-5,8,10-15H2,(H,29,34)/t22-/m1/s1
DMTYN2D	CS	C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)C(=O)NC4CC4)C5=C(C=CC(=C5)F)OCCN6CCOCC6
DMTYN2D	IK	DXRCURBJOZPWHE-JOCHJYFZSA-N
DMTYN2D	IU	N-cyclopropyl-5-[(2R)-2-[5-fluoro-2-(2-morpholin-4-ylethoxy)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

DMNIER3	ID	DMNIER3
DMNIER3	DN	Pyrazolo[1,5-a]pyrimidine derivative 17
DMNIER3	HS	Patented
DMNIER3	SN	PMID28270010-Compound-Figure10a-4
DMNIER3	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven S. CONDROSKI, Kevin Ronald HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy SEO, Jeongbeob
DMNIER3	DT	Small molecular drug
DMNIER3	PC	66853176
DMNIER3	MW	455.5
DMNIER3	FM	C23H26FN5O4
DMNIER3	IC	InChI=1S/C23H26FN5O4/c24-15-8-14(9-18(10-15)33-13-17(31)12-30)20-2-1-6-28(20)21-5-7-29-22(27-21)19(11-25-29)23(32)26-16-3-4-16/h5,7-11,16-17,20,30-31H,1-4,6,12-13H2,(H,26,32)/t17?,20-/m1/s1
DMNIER3	CS	C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)C(=O)NC4CC4)C5=CC(=CC(=C5)F)OCC(CO)O
DMNIER3	IK	YDZSAJWQPHVDHL-UUSAFJCLSA-N
DMNIER3	IU	N-cyclopropyl-5-[(2R)-2-[3-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

DMVEP6Y	ID	DMVEP6Y
DMVEP6Y	DN	Pyrazolo[1,5-a]pyrimidine derivative 18
DMVEP6Y	HS	Patented
DMVEP6Y	SN	PMID28270010-Compound-Figure11-1
DMVEP6Y	CP	ARRAY BIOPHARMA INC. ANDREWS, Steven, Wade CONDROSKI, Kevin, Ronald HAAS, Julia JIANG, Yutong KOLAKOWSKI, Gabrielle, R. SEO, Jeongbeob YANG, Hong-Woon ZHAO, Qian
DMVEP6Y	DT	Small molecular drug
DMVEP6Y	PC	70169989
DMVEP6Y	MW	398.4
DMVEP6Y	FM	C19H19FN6O3
DMVEP6Y	IC	InChI=1S/C19H19FN6O3/c20-11-6-13-15-2-1-4-25(15)16-3-5-26-17(23-16)14(8-22-26)18(28)21-7-12(27)10-24(9-11)19(13)29/h3,5-6,8-9,12,15,27H,1-2,4,7,10H2,(H,21,28)/t12-,15+/m0/s1
DMVEP6Y	CS	C1C[C@@H]2C3=CC(=CN(C3=O)C[C@H](CNC(=O)C4=C5N=C(N2C1)C=CN5N=C4)O)F
DMVEP6Y	IK	UHWGZELMUUQSBI-SWLSCSKDSA-N
DMVEP6Y	IU	(6R,13S)-9-fluoro-13-hydroxy-2,11,15,19,20,23-hexazapentacyclo[15.5.2.17,11.02,6.020,24]pentacosa-1(23),7,9,17(24),18,21-hexaene-16,25-dione

DMFV36A	ID	DMFV36A
DMFV36A	DN	Pyrazolo[1,5-a]pyrimidine derivative 19
DMFV36A	HS	Patented
DMFV36A	SN	PMID28270010-Compound-Figure11-2
DMFV36A	CP	ARRAY BIOPHARMA INC. ANDREWS, Steven, Wade CONDROSKI, Kevin, Ronald HAAS, Julia JIANG, Yutong KOLAKOWSKI, Gabrielle, R. SEO, Jeongbeob YANG, Hong-Woon ZHAO, Qian
DMFV36A	DT	Small molecular drug

DMO3MJ7	ID	DMO3MJ7
DMO3MJ7	DN	Pyrazolo[1,5-a]pyrimidine derivative 2
DMO3MJ7	HS	Patented
DMO3MJ7	SN	PMID26161824-Compound-132
DMO3MJ7	CP	Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
DMO3MJ7	DT	Small molecular drug
DMO3MJ7	DE	Obesity

DMJLU8R	ID	DMJLU8R
DMJLU8R	DN	Pyrazolo[1,5-a]pyrimidine derivative 20
DMJLU8R	HS	Patented
DMJLU8R	SN	PMID28270010-Compound-Figure11-3
DMJLU8R	CP	ARRAY BIOPHARMA INC. ANDREWS, Steven, Wade CONDROSKI, Kevin, Ronald HAAS, Julia JIANG, Yutong KOLAKOWSKI, Gabrielle, R. SEO, Jeongbeob YANG, Hong-Woon ZHAO, Qian
DMJLU8R	DT	Small molecular drug

DMWNZTI	ID	DMWNZTI
DMWNZTI	DN	Pyrazolo[1,5-a]pyrimidine derivative 21
DMWNZTI	HS	Patented
DMWNZTI	SN	PMID28270010-Compound-Figure19-1
DMWNZTI	CP	CMG PHARMACEUTICAL CO., LTD. HANDOK INC
DMWNZTI	DT	Small molecular drug
DMWNZTI	PC	121395260
DMWNZTI	MW	440.5
DMWNZTI	FM	C22H22F2N6S
DMWNZTI	IC	InChI=1S/C22H22F2N6S/c1-22(2,3)21-28-27-20(31-21)15-12-25-30-10-8-18(26-19(15)30)29-9-4-5-17(29)14-11-13(23)6-7-16(14)24/h6-8,10-12,17H,4-5,9H2,1-3H3
DMWNZTI	CS	CC(C)(C)C1=NN=C(S1)C2=C3N=C(C=CN3N=C2)N4CCCC4C5=C(C=CC(=C5)F)F
DMWNZTI	IK	ZSOVHNMIBOQEED-UHFFFAOYSA-N
DMWNZTI	IU	2-tert-butyl-5-[5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-1,3,4-thiadiazole

DMG5CXB	ID	DMG5CXB
DMG5CXB	DN	Pyrazolo[1,5-a]pyrimidine derivative 22
DMG5CXB	HS	Patented
DMG5CXB	SN	PMID28270010-Compound-Figure19-2
DMG5CXB	CP	CMG PHARMACEUTICAL CO., LTD. HANDOK INC
DMG5CXB	DT	Small molecular drug

DMQVLP8	ID	DMQVLP8
DMQVLP8	DN	Pyrazolo[1,5-a]pyrimidine derivative 23
DMQVLP8	HS	Patented
DMQVLP8	SN	PMID28270010-Compound-Figure19-3
DMQVLP8	CP	CMG PHARMACEUTICAL CO., LTD. HANDOK INC
DMQVLP8	DT	Small molecular drug
DMQVLP8	PC	121395204
DMQVLP8	MW	439.5
DMQVLP8	FM	C23H23F2N5O2
DMQVLP8	IC	InChI=1S/C23H23F2N5O2/c24-17-4-5-19(25)18(14-17)20-2-1-8-29(20)21-7-9-30-23(27-21)16(15-26-30)3-6-22(31)28-10-12-32-13-11-28/h3-7,9,14-15,20H,1-2,8,10-13H2/b6-3+/t20-/m1/s1
DMQVLP8	CS	C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)/C=C/C(=O)N4CCOCC4)C5=C(C=CC(=C5)F)F
DMQVLP8	IK	FFDHOZJDUKYFPJ-SQZHUTIHSA-N
DMQVLP8	IU	(E)-3-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-1-morpholin-4-ylprop-2-en-1-one

DMT4ZP9	ID	DMT4ZP9
DMT4ZP9	DN	Pyrazolo[1,5-a]pyrimidine derivative 24
DMT4ZP9	HS	Patented
DMT4ZP9	SN	PMID28270010-Compound-Figure9-1
DMT4ZP9	CP	ARRAY BIOPHARMA INC. HAAS, Julia ANDREWS, Steven, W. JIANG, Yutong ZHANG, Gan
DMT4ZP9	DT	Small molecular drug

DMKE7YO	ID	DMKE7YO
DMKE7YO	DN	Pyrazolo[1,5-a]pyrimidine derivative 25
DMKE7YO	HS	Patented
DMKE7YO	SN	PMID28270010-Compound-Figure9-2
DMKE7YO	CP	ARRAY BIOPHARMA INC. HAAS, Julia ANDREWS, Steven, W. JIANG, Yutong ZHANG, Gan
DMKE7YO	DT	Small molecular drug
DMKE7YO	PC	58386283
DMKE7YO	MW	408.4
DMKE7YO	FM	C21H18F2N6O
DMKE7YO	IC	InChI=1S/C21H18F2N6O/c22-13-3-4-15(23)14(10-13)17-2-1-8-28(17)18-5-9-29-19(27-18)16(11-25-29)26-20(30)21(12-24)6-7-21/h3-5,9-11,17H,1-2,6-8H2,(H,26,30)/t17-/m1/s1
DMKE7YO	CS	C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)C4(CC4)C#N)C5=C(C=CC(=C5)F)F
DMKE7YO	IK	XFKSYGFIGZCVDN-QGZVFWFLSA-N
DMKE7YO	IU	1-cyano-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]cyclopropane-1-carboxamide

DMGZ59Q	ID	DMGZ59Q
DMGZ59Q	DN	Pyrazolo[1,5-a]pyrimidine derivative 26
DMGZ59Q	HS	Patented
DMGZ59Q	SN	PMID28270010-Compound-Figure9-3
DMGZ59Q	CP	ARRAY BIOPHARMA INC. HAAS, Julia ANDREWS, Steven, W. JIANG, Yutong ZHANG, Gan
DMGZ59Q	DT	Small molecular drug
DMGZ59Q	PC	58386265
DMGZ59Q	MW	454.5
DMGZ59Q	FM	C23H27FN6O3
DMGZ59Q	IC	InChI=1S/C23H27FN6O3/c1-33-20-7-6-15(24)12-17(20)19-5-3-10-29(19)21-8-11-30-22(27-21)18(13-25-30)26-23(32)28-9-2-4-16(31)14-28/h6-8,11-13,16,19,31H,2-5,9-10,14H2,1H3,(H,26,32)/t16-,19+/m0/s1
DMGZ59Q	CS	COC1=C(C=C(C=C1)F)[C@H]2CCCN2C3=NC4=C(C=NN4C=C3)NC(=O)N5CCC[C@@H](C5)O
DMGZ59Q	IK	RGIQATAASXNYCK-QFBILLFUSA-N
DMGZ59Q	IU	(3S)-N-[5-[(2R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypiperidine-1-carboxamide

DM9OXAB	ID	DM9OXAB
DM9OXAB	DN	Pyrazolo[1,5-a]pyrimidine derivative 27
DM9OXAB	HS	Patented
DM9OXAB	SN	PMID28270010-Compound-Figure9-4
DM9OXAB	CP	ARRAY BIOPHARMA INC. HAAS, Julia ANDREWS, Steven, W. JIANG, Yutong ZHANG, Gan
DM9OXAB	DT	Small molecular drug
DM9OXAB	PC	58386288
DM9OXAB	MW	428.4
DM9OXAB	FM	C21H22F2N6O2
DM9OXAB	IC	InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18-/m1/s1
DM9OXAB	CS	C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@H](C4)O)C5=C(C=CC(=C5)F)F
DM9OXAB	IK	NYNZQNWKBKUAII-RDTXWAMCSA-N
DM9OXAB	IU	(3R)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide

DMG1RNL	ID	DMG1RNL
DMG1RNL	DN	Pyrazolo[1,5-a]pyrimidine derivative 28
DMG1RNL	HS	Patented
DMG1RNL	SN	PMID25470667-Compound-Figure5-17
DMG1RNL	CP	GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMG1RNL	DT	Small molecular drug

DMCT6QW	ID	DMCT6QW
DMCT6QW	DN	Pyrazolo[1,5-a]pyrimidine derivative 29
DMCT6QW	HS	Patented
DMCT6QW	SN	PMID25470667-Compound-Figure5-18
DMCT6QW	CP	GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMCT6QW	DT	Small molecular drug
DMCT6QW	PC	74221584
DMCT6QW	MW	291.35
DMCT6QW	FM	C17H17N5
DMCT6QW	IC	InChI=1S/C17H17N5/c1-2-8-21-9-6-13-10-12(3-4-15(13)21)14-11-19-16-5-7-20-22(16)17(14)18/h3-7,9-11H,2,8,18H2,1H3
DMCT6QW	CS	CCCN1C=CC2=C1C=CC(=C2)C3=C(N4C(=CC=N4)N=C3)N
DMCT6QW	IK	WYJQPMFWZLKCBR-UHFFFAOYSA-N
DMCT6QW	IU	6-(1-propylindol-5-yl)pyrazolo[1,5-a]pyrimidin-7-amine

DMHTV47	ID	DMHTV47
DMHTV47	DN	Pyrazolo[1,5-a]pyrimidine derivative 3
DMHTV47	HS	Patented
DMHTV47	SN	PMID26161824-Compound-133
DMHTV47	CP	Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
DMHTV47	DT	Small molecular drug
DMHTV47	PC	16722441
DMHTV47	MW	522.799
DMHTV47	FM	C26H18Cl3N5O
DMHTV47	IC	InChI=1S/C26H18Cl3N5O/c1-33(19-6-4-5-18(28)13-19)32-26(35)22-15-31-34-24(16-9-11-17(27)12-10-16)21(14-30-25(22)34)20-7-2-3-8-23(20)29/h2-15H,1H3,(H,32,35)
DMHTV47	CS	CN(C1=CC(=CC=C1)Cl)NC(=O)C2=C3N=CC(=C(N3N=C2)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMHTV47	IK	VZJOGKVKWHCJNG-UHFFFAOYSA-N
DMHTV47	IU	6-(2-chlorophenyl)-N'-(3-chlorophenyl)-7-(4-chlorophenyl)-N'-methylpyrazolo[1,5-a]pyrimidine-3-carbohydrazide
DMHTV47	DE	Obesity

DMCAVF0	ID	DMCAVF0
DMCAVF0	DN	Pyrazolo[1,5-a]pyrimidine derivative 4
DMCAVF0	HS	Patented
DMCAVF0	SN	PMID26161824-Compound-134
DMCAVF0	CP	Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
DMCAVF0	DT	Small molecular drug
DMCAVF0	PC	68920883
DMCAVF0	MW	557.3
DMCAVF0	FM	C26H17Cl2F3N6O
DMCAVF0	IC	InChI=1S/C26H17Cl2F3N6O/c1-36(20-8-4-5-13-32-20)35-25(38)21-23(26(29,30)31)34-37-22(15-9-11-16(27)12-10-15)18(14-33-24(21)37)17-6-2-3-7-19(17)28/h2-14H,1H3,(H,35,38)
DMCAVF0	CS	CN(C1=CC=CC=N1)NC(=O)C2=C3N=CC(=C(N3N=C2C(F)(F)F)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMCAVF0	IK	BOANGAFVCNVTRF-UHFFFAOYSA-N
DMCAVF0	IU	6-(2-chlorophenyl)-7-(4-chlorophenyl)-N'-methyl-N'-pyridin-2-yl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carbohydrazide
DMCAVF0	DE	Obesity

DM3UBG2	ID	DM3UBG2
DM3UBG2	DN	Pyrazolo[1,5-a]pyrimidine derivative 5
DM3UBG2	HS	Patented
DM3UBG2	SN	PMID26161824-Compound-135
DM3UBG2	DT	Small molecular drug
DM3UBG2	PC	24772732
DM3UBG2	MW	479.4
DM3UBG2	FM	C26H24Cl2N4O
DM3UBG2	IC	InChI=1S/C26H24Cl2N4O/c1-26(13-5-2-6-14-26)31-25(33)21-16-30-32-23(17-9-11-18(27)12-10-17)20(15-29-24(21)32)19-7-3-4-8-22(19)28/h3-4,7-12,15-16H,2,5-6,13-14H2,1H3,(H,31,33)
DM3UBG2	CS	CC1(CCCCC1)NC(=O)C2=C3N=CC(=C(N3N=C2)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DM3UBG2	IK	UVMYGLSWIQQBTO-UHFFFAOYSA-N
DM3UBG2	IU	6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-(1-methylcyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
DM3UBG2	DE	Obesity

DM5E1KS	ID	DM5E1KS
DM5E1KS	DN	Pyrazolo[1,5-a]pyrimidine derivative 6
DM5E1KS	HS	Patented
DM5E1KS	SN	PMID26161824-Compound-136
DM5E1KS	DT	Small molecular drug
DM5E1KS	PC	67272017
DM5E1KS	MW	594.5
DM5E1KS	FM	C24H21Cl2N5O5S2
DM5E1KS	IC	InChI=1S/C24H21Cl2N5O5S2/c1-27-38(35,36)24-20(23(32)29-16-10-11-37(33,34)13-16)22-28-12-18(17-4-2-3-5-19(17)26)21(31(22)30-24)14-6-8-15(25)9-7-14/h2-9,12,16,27H,10-11,13H2,1H3,(H,29,32)
DM5E1KS	CS	CNS(=O)(=O)C1=NN2C(=C(C=NC2=C1C(=O)NC3CCS(=O)(=O)C3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl
DM5E1KS	IK	OGXPEWYKDODYIH-UHFFFAOYSA-N
DM5E1KS	IU	6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-(1,1-dioxothiolan-3-yl)-2-(methylsulfamoyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
DM5E1KS	DE	Obesity

DMFUSPR	ID	DMFUSPR
DMFUSPR	DN	Pyrazolo[1,5-a]pyrimidine derivative 7
DMFUSPR	HS	Patented
DMFUSPR	SN	PMID26161824-Compound-137
DMFUSPR	DT	Small molecular drug
DMFUSPR	PC	67272029
DMFUSPR	MW	587.5
DMFUSPR	FM	C26H24Cl2N6O4S
DMFUSPR	IC	InChI=1S/C26H24Cl2N6O4S/c27-16-11-9-15(10-12-16)23-19(18-7-3-4-8-20(18)28)13-30-24-22(25(36)32-17-5-1-2-6-17)26(33-34(23)24)39(37,38)31-14-21(29)35/h3-4,7-13,17,31H,1-2,5-6,14H2,(H2,29,35)(H,32,36)
DMFUSPR	CS	C1CCC(C1)NC(=O)C2=C3N=CC(=C(N3N=C2S(=O)(=O)NCC(=O)N)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMFUSPR	IK	XUKGKEPVXJSMGH-UHFFFAOYSA-N
DMFUSPR	IU	2-[(2-amino-2-oxoethyl)sulfamoyl]-6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-cyclopentylpyrazolo[1,5-a]pyrimidine-3-carboxamide
DMFUSPR	DE	Obesity

DMTQNYZ	ID	DMTQNYZ
DMTQNYZ	DN	Pyrazolo[1,5-a]pyrimidine derivative 8
DMTQNYZ	HS	Patented
DMTQNYZ	SN	PMID26161824-Compound-138
DMTQNYZ	DT	Small molecular drug
DMTQNYZ	PC	67149150
DMTQNYZ	MW	531.4
DMTQNYZ	FM	C23H20Cl2N6O3S
DMTQNYZ	IC	InChI=1S/C23H20Cl2N6O3S/c24-15-9-7-14(8-10-15)20-17(16-5-1-2-6-18(16)25)13-27-21-19(22(32)28-30-11-3-4-12-30)23(29-31(20)21)35(26,33)34/h1-2,5-10,13H,3-4,11-12H2,(H,28,32)(H2,26,33,34)
DMTQNYZ	CS	C1CCN(C1)NC(=O)C2=C3N=CC(=C(N3N=C2S(=O)(=O)N)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMTQNYZ	IK	WHAZINAXCQYHKF-UHFFFAOYSA-N
DMTQNYZ	IU	6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-pyrrolidin-1-yl-2-sulfamoylpyrazolo[1,5-a]pyrimidine-3-carboxamide
DMTQNYZ	DE	Obesity

DMXAW2S	ID	DMXAW2S
DMXAW2S	DN	Pyrazolo[1,5-a]pyrimidine derivative 9
DMXAW2S	HS	Patented
DMXAW2S	SN	PMID26161824-Compound-139
DMXAW2S	DT	Small molecular drug
DMXAW2S	PC	67273458
DMXAW2S	MW	568.4
DMXAW2S	FM	C25H19Cl2N7O3S
DMXAW2S	IC	InChI=1S/C25H19Cl2N7O3S/c1-33(20-8-4-5-13-29-20)31-24(35)21-23-30-14-18(17-6-2-3-7-19(17)27)22(15-9-11-16(26)12-10-15)34(23)32-25(21)38(28,36)37/h2-14H,1H3,(H,31,35)(H2,28,36,37)
DMXAW2S	CS	CN(C1=CC=CC=N1)NC(=O)C2=C3N=CC(=C(N3N=C2S(=O)(=O)N)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMXAW2S	IK	SIHKCQZRSPKPIN-UHFFFAOYSA-N
DMXAW2S	IU	6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[methyl(pyridin-2-yl)amino]carbamoyl]pyrazolo[1,5-a]pyrimidine-2-sulfonamide
DMXAW2S	DE	Obesity

DMQHCDZ	ID	DMQHCDZ
DMQHCDZ	DN	Pyrazolo[3,4-c]pyridine derivative 1
DMQHCDZ	HS	Patented
DMQHCDZ	SN	PMID28447479-Compound-8
DMQHCDZ	CP	BIOGEN MA INC
DMQHCDZ	DT	Small molecular drug

DMT57C4	ID	DMT57C4
DMT57C4	DN	Pyrazolo[3,4-d]pyrimidine derivative 1
DMT57C4	HS	Patented
DMT57C4	SN	PMID27321640-Compound-70
DMT57C4	CP	PFIZER INC. HELAL, Christopher J. CHAPPIE, Thomas Allen HUMPHREY, John M
DMT57C4	DT	Small molecular drug

DMO054V	ID	DMO054V
DMO054V	DN	Pyrazolo[3,4-d]pyrimidine derivative 2
DMO054V	HS	Patented
DMO054V	SN	PMID27321640-Compound-71
DMO054V	CP	PFIZER INC. HELAL, Christopher J. CHAPPIE, Thomas Allen HUMPHREY, John M
DMO054V	DT	Small molecular drug

DMRKVP9	ID	DMRKVP9
DMRKVP9	DN	Pyrazolo[3,4-d]pyrimidine derivative 3
DMRKVP9	HS	Patented
DMRKVP9	SN	PMID27321640-Compound-72
DMRKVP9	CP	PFIZER INC. HELAL, Christopher J. CHAPPIE, Thomas Allen HUMPHREY, John M
DMRKVP9	DT	Small molecular drug

DMGFAS6	ID	DMGFAS6
DMGFAS6	DN	Pyrazolo[3,4-d]pyrimidine derivative 4
DMGFAS6	HS	Patented
DMGFAS6	SN	PMID27321640-Compound-73
DMGFAS6	CP	PFIZER INC. HELAL, Christopher J. CHAPPIE, Thomas Allen HUMPHREY, John M
DMGFAS6	DT	Small molecular drug

DMIH0F4	ID	DMIH0F4
DMIH0F4	DN	Pyrazolo[3,4-d]pyrimidine derivative 5
DMIH0F4	HS	Patented
DMIH0F4	SN	PMID27646564-Compound-9
DMIH0F4	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA MOUNT SINAI SCHOOL OF MEDICINE DAR, Arvin, C. DAS, Tirtha, K. SOS, Martin BIVONA, Trever, G. SHOKAT, Kevan, M. CAGAN, Ross, LUniversity of California and Icahn School of Medicine at Mount Sinai
DMIH0F4	DT	Small molecular drug

DMCTWVY	ID	DMCTWVY
DMCTWVY	DN	Pyrazolo[3,4-d]pyrimidine derivative 6
DMCTWVY	HS	Patented
DMCTWVY	SN	PMID27646564-Compound-9-1
DMCTWVY	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA MOUNT SINAI SCHOOL OF MEDICINE DAR, Arvin, C. DAS, Tirtha, K. SOS, Martin BIVONA, Trever, G. SHOKAT, Kevan, M. CAGAN, Ross, LUniversity of California and Icahn School of Medicine at Mount Sinai
DMCTWVY	DT	Small molecular drug

DM4GF58	ID	DM4GF58
DM4GF58	DN	Pyrazolo[3,4-d]pyrimidine derivative 7
DM4GF58	HS	Patented
DM4GF58	SN	PMID27646564-Compound-9-2
DM4GF58	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA MOUNT SINAI SCHOOL OF MEDICINE DAR, Arvin, C. DAS, Tirtha, K. SOS, Martin BIVONA, Trever, G. SHOKAT, Kevan, M. CAGAN, Ross, LUniversity of California and Icahn School of Medicine at Mount Sinai
DM4GF58	DT	Small molecular drug

DM89GKE	ID	DM89GKE
DM89GKE	DN	Pyrazolo[3,4-d]pyrimidine derivative 8
DM89GKE	HS	Patented
DM89GKE	SN	PMID27646564-Compound-9-3
DM89GKE	CP	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA MOUNT SINAI SCHOOL OF MEDICINE DAR, Arvin, C. DAS, Tirtha, K. SOS, Martin BIVONA, Trever, G. SHOKAT, Kevan, M. CAGAN, Ross, LUniversity of California and Icahn School of Medicine at Mount Sinai
DM89GKE	DT	Small molecular drug

DMHRUIZ	ID	DMHRUIZ
DMHRUIZ	DN	Pyrazolo[4,3-c]pyridine derivative 1
DMHRUIZ	HS	Patented
DMHRUIZ	SN	PMID28270021-Compound-WO2014053965Example3
DMHRUIZ	CP	PFIZER LIMITED
DMHRUIZ	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMCDFLQ	ID	DMCDFLQ
DMCDFLQ	DN	Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ	HS	Patented
DMCDFLQ	SN	PMID27774824-Compound-Figure7compound1
DMCDFLQ	CP	CELLZOME LIMITED RAMSDEN, Nigel DAGOSTIN, Claudio

DMTM82B	ID	DMTM82B
DMTM82B	DN	Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1
DMTM82B	HS	Patented
DMTM82B	SN	PMID28270021-Compound-WO2010106028Milciclib (PHA-848125)
DMTM82B	CP	NERVIANO MEDICAL 
DMTM82B	DE	Malignant thymoma; Pruritus; Chronic pain; Neuropathic pain; Thymic cancer

DMRN2QI	ID	DMRN2QI
DMRN2QI	DN	Pyrazolodiazepine derivative 1
DMRN2QI	HS	Patented
DMRN2QI	SN	PMID26560530-Compound-28
DMRN2QI	CP	NATIONAL CANCER CENTER ANYGEN CO., LTD. KIM, Young-Chul LEE, Ju-Yeon KIM, Soo Youl LEE, Byung Il
DMRN2QI	DT	Small molecular drug
DMRN2QI	PC	46236234
DMRN2QI	MW	351.6
DMRN2QI	FM	C18H33N5S
DMRN2QI	IC	InChI=1S/C18H33N5S/c1-13(2)9-22-11-15(7-5-6-8-19)20-18(24)17-16(22)12-23(21-17)10-14(3)4/h12-15H,5-11,19H2,1-4H3,(H,20,24)/t15-/m0/s1
DMRN2QI	CS	CC(C)CN1C[C@@H](NC(=S)C2=NN(C=C21)CC(C)C)CCCCN
DMRN2QI	IK	SRDGVWFRHBVJPL-HNNXBMFYSA-N
DMRN2QI	IU	(6S)-6-(4-aminobutyl)-2,4-bis(2-methylpropyl)-6,7-dihydro-5H-pyrazolo[4,3-e][1,4]diazepine-8-thione

DMKYX7J	ID	DMKYX7J
DMKYX7J	DN	Pyrazolodihydropyridine derivative 1
DMKYX7J	HS	Patented
DMKYX7J	SN	PMID27828716-Compound-13
DMKYX7J	CP	THE BROAD INSTITUTE, INC. DANA-FARBER CANCER INSTITUE, INC. THE GENERAL HOSPITAL CORPORATION D/B/A
DMKYX7J	DT	Small molecular drug
DMKYX7J	PC	1478036
DMKYX7J	MW	337.4
DMKYX7J	FM	C20H23N3O2
DMKYX7J	IC	InChI=1S/C20H23N3O2/c1-11-16-17(12-7-5-6-8-15(12)25-4)18-13(21-19(16)23-22-11)9-20(2,3)10-14(18)24/h5-8,17H,9-10H2,1-4H3,(H2,21,22,23)/t17-/m0/s1
DMKYX7J	CS	CC1=C2[C@@H](C3=C(CC(CC3=O)(C)C)NC2=NN1)C4=CC=CC=C4OC
DMKYX7J	IK	KYFJPYWXCUCRPE-KRWDZBQOSA-N
DMKYX7J	IU	(4R)-4-(2-methoxyphenyl)-3,7,7-trimethyl-4,6,8,9-tetrahydro-2H-pyrazolo[3,4-b]quinolin-5-one

DMY03RZ	ID	DMY03RZ
DMY03RZ	DN	Pyrazolopyridine derivative 1
DMY03RZ	HS	Patented
DMY03RZ	SN	PMID27774822-Compound-Figure1Example38compound1138
DMY03RZ	CP	LIGAND PHARMACEUTICALS INCORPORATED COLE, Andrew, G. JAMES, Ray, A. SHAO, Yuefei LETOURNEAU, Jeffrey, J. QUINTERO, Jorge, G. RIVIELLO, Christopher, Mark ZHI, Lin

DMCJVLR	ID	DMCJVLR
DMCJVLR	DN	Pyrazolopyridine derivative 2
DMCJVLR	HS	Patented
DMCJVLR	SN	PMID27774822-Compound-Figure1Example53compound153
DMCJVLR	CP	LIGAND PHARMACEUTICALS INCORPORATED COLE, Andrew, G. JAMES, Ray, A. SHAO, Yuefei LETOURNEAU, Jeffrey, J. QUINTERO, Jorge, G. RIVIELLO, Christopher, Mark ZHI, Lin

DM2VQ4P	ID	DM2VQ4P
DM2VQ4P	DN	Pyrazolopyridine derivative 3
DM2VQ4P	HS	Patented
DM2VQ4P	SN	PMID27774822-Compound-Figure5Example131
DM2VQ4P	CP	PFIZER INC
DM2VQ4P	DT	Small molecular drug

DMX7RWV	ID	DMX7RWV
DMX7RWV	DN	Pyrazolopyridine derivative 4
DMX7RWV	HS	Patented
DMX7RWV	SN	PMID27774822-Compound-Figure9Example1
DMX7RWV	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED

DMTZCLG	ID	DMTZCLG
DMTZCLG	DN	Pyrazolopyridine derivative 5
DMTZCLG	HS	Patented
DMTZCLG	SN	PMID27774822-Compound-Figure9Example1topleft
DMTZCLG	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMTZCLG	DT	Small molecular drug

DM5OH8D	ID	DM5OH8D
DM5OH8D	DN	Pyrazolopyridine derivative 6
DM5OH8D	HS	Patented
DM5OH8D	SN	PMID27774824-Compound-Figure7compoud10
DM5OH8D	CP	CELLZOME LIMITED OXENFORD, Sally HOBSON, Andrew OLIVER, Kathryn RATCLIFFE, Andrew RAMSDEN, Nigel
DM5OH8D	DT	Small molecular drug

DMCTQ9O	ID	DMCTQ9O
DMCTQ9O	DN	Pyrazolopyridine derivative 7
DMCTQ9O	HS	Patented
DMCTQ9O	SN	PMID27774824-Compound-Figure7compoud18
DMCTQ9O	CP	CELLZOME LIMITED OXENFORD, Sally HOBSON, Andrew OLIVER, Kathryn RATCLIFFE, Andrew RAMSDEN, Nigel
DMCTQ9O	DT	Small molecular drug

DMSR5FO	ID	DMSR5FO
DMSR5FO	DN	Pyrazolopyridines and imidazopyridine derivative 1
DMSR5FO	HS	Patented
DMSR5FO	SN	PMID25684022-Compound-WO2010017047
DMSR5FO	CP	MERCK SHARP & DOHME CORP. MSD K.K. KATZ, Jason JEWELL, James JUNG, Joon KATTAR, Solomon HOU, Yongquan MACCOSS, Rachel ITO, Satoru
DMSR5FO	DT	Small molecular drug
DMSR5FO	DE	Solid tumour/cancer; Metastatic cancer

DMRAS8L	ID	DMRAS8L
DMRAS8L	DN	Pyrazolopyrimidine acetamide analog 1
DMRAS8L	HS	Patented
DMRAS8L	SN	PMID27607364-Compound-116
DMRAS8L	DT	Small molecular drug
DMRAS8L	PC	11595759
DMRAS8L	MW	366.5
DMRAS8L	FM	C21H26N4O2
DMRAS8L	IC	InChI=1S/C21H26N4O2/c1-6-24(7-2)19(26)13-18-20(16-8-10-17(27-5)11-9-16)23-25-15(4)12-14(3)22-21(18)25/h8-12H,6-7,13H2,1-5H3
DMRAS8L	CS	CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC=C(C=C3)OC)C)C
DMRAS8L	IK	ILZWUAWCTNWSFZ-UHFFFAOYSA-N
DMRAS8L	IU	N,N-diethyl-2-[2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide
DMRAS8L	CA	CAS 386297-97-8

DMK7F3A	ID	DMK7F3A
DMK7F3A	DN	Pyrazolopyrimidine acetamide analog 2
DMK7F3A	HS	Patented
DMK7F3A	SN	PMID27607364-Compound-117
DMK7F3A	DT	Small molecular drug
DMK7F3A	PC	24895172
DMK7F3A	MW	398.5
DMK7F3A	FM	C22H27FN4O2
DMK7F3A	IC	InChI=1S/C22H27FN4O2/c1-5-26(6-2)20(28)14-19-21(17-7-9-18(10-8-17)29-12-11-23)25-27-16(4)13-15(3)24-22(19)27/h7-10,13H,5-6,11-12,14H2,1-4H3
DMK7F3A	CS	CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC=C(C=C3)OCCF)C)C
DMK7F3A	IK	FLZZFWBNYJNHMY-UHFFFAOYSA-N
DMK7F3A	IU	N,N-diethyl-2-[2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide
DMK7F3A	CA	CAS 958233-07-3

DM6TB4Z	ID	DM6TB4Z
DM6TB4Z	DN	Pyrazolopyrimidine and thienopyrimidine amide derivative 1
DM6TB4Z	HS	Patented
DM6TB4Z	SN	PMID27310003-Compound-30
DM6TB4Z	CP	F. HOFFMANN-LA ROCHE AG ARORA, Nidhi CHEN, Shaoqing HERMANN, Johannes, Cornelius KUGLSTATTER, Andreas LABADIE, Sharada, Shenvi LIN, Clara Jeou Jen LUCAS, Matthew, C. MOORE, Amy, Geraldine PAPP, Eva TALAMAS, Francisco, Xavier WANNER, Jutta ZHAI, Yansheng
DM6TB4Z	DT	Small molecular drug

DMFUNH4	ID	DMFUNH4
DMFUNH4	DN	Pyrazolopyrimidine and thienopyrimidine amide derivative 2
DMFUNH4	HS	Patented
DMFUNH4	SN	PMID27310003-Compound-31
DMFUNH4	CP	F. HOFFMANN-LA ROCHE AG ARORA, Nidhi CHEN, Shaoqing HERMANN, Johannes, Cornelius KUGLSTATTER, Andreas LABADIE, Sharada, Shenvi LIN, Clara Jeou Jen LUCAS, Matthew, C. MOORE, Amy, Geraldine PAPP, Eva TALAMAS, Francisco, Xavier WANNER, Jutta ZHAI, Yansheng
DMFUNH4	DT	Small molecular drug

DMHO3NB	ID	DMHO3NB
DMHO3NB	DN	Pyrazolopyrimidine derivative 1
DMHO3NB	HS	Patented
DMHO3NB	SN	PMID28067079-Compound-78
DMHO3NB	CP	MERZ PHARMA GMBH & CO. KGAA RUSS, Hermann BORTA, Andreas HEERS, Cara HAUPTMEIER, Bernhard BODERKE, Peter PURMANN, Brigitte TARDT, AxeMERZ PHARMA GMBH & CO. KGAA DANYSZ, Wojciech DEKUNDY, Andrzej HECHENBERGER, Mirko HENRICH, Markus JATZKE, Claudia NAGEL, Jens PARSONS, Christopher Graham Raphael WEIL, Tanja MLER, Sibylle FOTINS, Juris GUTCAITS, Aleksandra ZEMRIBO, Ronalds KAUSS, Valerjans KAULINA, Larisa ERDMANE, Elina
DMHO3NB	DT	Small molecular drug
DMHO3NB	PC	24810684
DMHO3NB	MW	371.2
DMHO3NB	FM	C17H15BrN4O
DMHO3NB	IC	InChI=1S/C17H15BrN4O/c1-11-14-5-3-2-4-12(14)6-7-21(11)17(23)15-8-16-19-9-13(18)10-22(16)20-15/h2-5,8-11H,6-7H2,1H3/t11-/m1/s1
DMHO3NB	CS	C[C@@H]1C2=CC=CC=C2CCN1C(=O)C3=NN4C=C(C=NC4=C3)Br
DMHO3NB	IK	TUYZYSNXXSTKQX-LLVKDONJSA-N
DMHO3NB	IU	(6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[(1R)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]methanone
DMHO3NB	CA	CAS 1309783-00-3

DMZEP5X	ID	DMZEP5X
DMZEP5X	DN	Pyrazolopyrimidine derivative 2
DMZEP5X	HS	Patented
DMZEP5X	SN	PMID28067079-Compound-79
DMZEP5X	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMZEP5X	DT	Small molecular drug
DMZEP5X	PC	71739469
DMZEP5X	MW	406.3
DMZEP5X	FM	C16H16BrN5OS
DMZEP5X	IC	InChI=1S/C16H16BrN5OS/c1-2-15-19-11-3-5-21(6-4-13(11)24-15)16(23)12-7-14-18-8-10(17)9-22(14)20-12/h7-9H,2-6H2,1H3
DMZEP5X	CS	CCC1=NC2=C(S1)CCN(CC2)C(=O)C3=NN4C=C(C=NC4=C3)Br
DMZEP5X	IK	OEYKQCOFIDDHKA-UHFFFAOYSA-N
DMZEP5X	IU	(6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(2-ethyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-6-yl)methanone

DMI0J7D	ID	DMI0J7D
DMI0J7D	DN	Pyrazolopyrimidine derivative 3
DMI0J7D	HS	Patented
DMI0J7D	SN	PMID28067079-Compound-80
DMI0J7D	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMI0J7D	DT	Small molecular drug
DMI0J7D	PC	71748062
DMI0J7D	MW	333.8
DMI0J7D	FM	C14H12ClN5OS
DMI0J7D	IC	InChI=1S/C14H12ClN5OS/c15-9-6-16-13-5-11(18-20(13)7-9)14(21)19-3-1-10-12(2-4-19)22-8-17-10/h5-8H,1-4H2
DMI0J7D	CS	C1CN(CCC2=C1N=CS2)C(=O)C3=NN4C=C(C=NC4=C3)Cl
DMI0J7D	IK	UNBIVDPTRGTTPR-UHFFFAOYSA-N
DMI0J7D	IU	(6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-6-yl)methanone

DM7XSHK	ID	DM7XSHK
DM7XSHK	DN	Pyrazolopyrimidine derivative 4
DM7XSHK	HS	Patented
DM7XSHK	SN	PMID28067079-Compound-81
DM7XSHK	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DM7XSHK	DT	Small molecular drug
DM7XSHK	PC	71748065
DM7XSHK	MW	347.8
DM7XSHK	FM	C15H14ClN5OS
DM7XSHK	IC	InChI=1S/C15H14ClN5OS/c1-9-18-11-2-4-20(5-3-13(11)23-9)15(22)12-6-14-17-7-10(16)8-21(14)19-12/h6-8H,2-5H2,1H3
DM7XSHK	CS	CC1=NC2=C(S1)CCN(CC2)C(=O)C3=NN4C=C(C=NC4=C3)Cl
DM7XSHK	IK	WOOXFLPCMNOANB-UHFFFAOYSA-N
DM7XSHK	IU	(6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(2-methyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-6-yl)methanone

DMVUSF3	ID	DMVUSF3
DMVUSF3	DN	Pyrazolopyrimidine derivative 5
DMVUSF3	HS	Patented
DMVUSF3	SN	PMID28067079-Compound-82
DMVUSF3	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMVUSF3	DT	Small molecular drug
DMVUSF3	PC	71748080
DMVUSF3	MW	392.3
DMVUSF3	FM	C15H14BrN5OS
DMVUSF3	IC	InChI=1S/C15H14BrN5OS/c1-9-18-11-2-4-20(5-3-13(11)23-9)15(22)12-6-14-17-7-10(16)8-21(14)19-12/h6-8H,2-5H2,1H3
DMVUSF3	CS	CC1=NC2=C(S1)CCN(CC2)C(=O)C3=NN4C=C(C=NC4=C3)Br
DMVUSF3	IK	PPBYGUATKIHBBC-UHFFFAOYSA-N
DMVUSF3	IU	(6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(2-methyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-6-yl)methanone

DMG8V31	ID	DMG8V31
DMG8V31	DN	Pyrazolopyrimidine derivative 6
DMG8V31	HS	Patented
DMG8V31	SN	PMID28067079-Compound-83
DMG8V31	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMG8V31	DT	Small molecular drug
DMG8V31	PC	71748063
DMG8V31	MW	394.25
DMG8V31	FM	C14H12BrN5O2S
DMG8V31	IC	InChI=1S/C14H12BrN5O2S/c15-8-6-16-12-5-10(18-20(12)7-8)13(21)19-3-1-9-11(2-4-19)23-14(22)17-9/h5-7H,1-4H2,(H,17,22)
DMG8V31	CS	C1CN(CCC2=C1NC(=O)S2)C(=O)C3=NN4C=C(C=NC4=C3)Br
DMG8V31	IK	NFUGEPSHTBCNFR-UHFFFAOYSA-N
DMG8V31	IU	6-(6-bromopyrazolo[1,5-a]pyrimidine-2-carbonyl)-4,5,7,8-tetrahydro-3H-[1,3]thiazolo[4,5-d]azepin-2-one

DMTD3C1	ID	DMTD3C1
DMTD3C1	DN	Pyrazolo-triazine derivative 1
DMTD3C1	HS	Patented
DMTD3C1	SN	PMID26161698-Compound-13
DMTD3C1	CP	LEAD DISCOVERY CENTER GMBH
DMTD3C1	DT	Small molecular drug
DMTD3C1	PC	89778898
DMTD3C1	MW	380.5
DMTD3C1	FM	C21H28N6O
DMTD3C1	IC	InChI=1S/C21H28N6O/c1-14(2)18-13-23-27-19(18)25-21(28-17-10-7-11-22-12-17)26-20(27)24-15(3)16-8-5-4-6-9-16/h4-6,8-9,13-15,17,22H,7,10-12H2,1-3H3,(H,24,25,26)/t15-,17?/m0/s1
DMTD3C1	CS	C[C@@H](C1=CC=CC=C1)NC2=NC(=NC3=C(C=NN32)C(C)C)OC4CCCNC4
DMTD3C1	IK	GTZAVJAMAXSTOG-MYJWUSKBSA-N
DMTD3C1	IU	N-[(1S)-1-phenylethyl]-2-piperidin-3-yloxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine

DML6V78	ID	DML6V78
DML6V78	DN	Pyrazolo-triazine derivative 2
DML6V78	HS	Patented
DML6V78	SN	PMID26161698-Compound-14
DML6V78	CP	LEAD DISCOVERY CENTER GMBH
DML6V78	DT	Small molecular drug
DML6V78	PC	71731909
DML6V78	MW	446.5
DML6V78	FM	C24H30N8O
DML6V78	IC	InChI=1S/C24H30N8O/c1-17(2)20-15-27-32-22(20)28-24(33-19-8-11-30(3)12-9-19)29-23(32)26-14-18-6-4-5-7-21(18)31-13-10-25-16-31/h4-7,10,13,15-17,19H,8-9,11-12,14H2,1-3H3,(H,26,28,29)
DML6V78	CS	CC(C)C1=C2N=C(N=C(N2N=C1)NCC3=CC=CC=C3N4C=CN=C4)OC5CCN(CC5)C
DML6V78	IK	KLTSWTPLJGXFTH-UHFFFAOYSA-N
DML6V78	IU	N-[(2-imidazol-1-ylphenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine

DMKJ3PC	ID	DMKJ3PC
DMKJ3PC	DN	Pyridazin-3(2H)-one derivative 1
DMKJ3PC	HS	Patented
DMKJ3PC	SN	PMID29334795-Compound-20
DMKJ3PC	CP	CEPHALON, INC. BIERLMAIER, Stephen HALTIWANGER, Ralph, Curtis JACOBS, Martin, JCEPHALON, INC. HUDKINS, Robert, L. JOSEF, Kurt, A. TAO, Ming BECKNELL, Nadine, C. HOSTETLER, Greg KNUTSON, Lars, J., S. ZULLI, Allison, L
DMKJ3PC	DT	Small molecular drug

DMF7MEB	ID	DMF7MEB
DMF7MEB	DN	Pyridazinone derivative 1
DMF7MEB	HS	Patented
DMF7MEB	SN	PMID27724045-Compound-32
DMF7MEB	CP	Nissan chemical industries, Ltd
DMF7MEB	DT	Small molecular drug

DM3GU7K	ID	DM3GU7K
DM3GU7K	DN	Pyridic ketone derivative 1
DM3GU7K	HS	Patented
DM3GU7K	SN	PMID28594589-Compound-TABLE3c3
DM3GU7K	CP	Shanghai Hengrui Pharm
DM3GU7K	DT	Small molecular drug
DM3GU7K	PC	118041703
DM3GU7K	MW	618.4
DM3GU7K	FM	C22H21F2IN4O5S
DM3GU7K	IC	InChI=1S/C22H21F2IN4O5S/c1-4-35(32,33)28-14-6-5-7-16(11(14)2)34-19-17(20(26)30)21(29(3)22(31)18(19)24)27-15-9-8-12(25)10-13(15)23/h5-10,27-28H,4H2,1-3H3,(H2,26,30)
DM3GU7K	CS	CCS(=O)(=O)NC1=C(C(=CC=C1)OC2=C(C(=O)N(C(=C2C(=O)N)NC3=C(C=C(C=C3)I)F)C)F)C
DM3GU7K	IK	ABFMVRPVXUKQEQ-UHFFFAOYSA-N
DM3GU7K	IU	4-[3-(ethylsulfonylamino)-2-methylphenoxy]-5-fluoro-2-(2-fluoro-4-iodoanilino)-1-methyl-6-oxopyridine-3-carboxamide

DMGEYJW	ID	DMGEYJW
DMGEYJW	DN	Pyridine and pyrimidine derivative 1
DMGEYJW	HS	Patented
DMGEYJW	SN	PMID28447479-Compound-1
DMGEYJW	CP	INHIBITAXIN LIMITED
DMGEYJW	DT	Small molecular drug
DMGEYJW	PC	71543359
DMGEYJW	MW	432.5
DMGEYJW	FM	C24H21FN4OS
DMGEYJW	IC	InChI=1S/C24H21FN4OS/c25-17-7-5-16(6-8-17)13-21-18-14-29(12-11-19(18)26-15-27-21)24(30)10-9-23-28-20-3-1-2-4-22(20)31-23/h1-8,15H,9-14H2
DMGEYJW	CS	C1CN(CC2=C1N=CN=C2CC3=CC=C(C=C3)F)C(=O)CCC4=NC5=CC=CC=C5S4
DMGEYJW	IK	JGNVAVQZDSOAGO-UHFFFAOYSA-N
DMGEYJW	IU	3-(1,3-benzothiazol-2-yl)-1-[4-[(4-fluorophenyl)methyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]propan-1-one
DMGEYJW	DE	Fibrosis; Pain; Solid tumour/cancer

DMSGF8T	ID	DMSGF8T
DMSGF8T	DN	Pyridine derivative 1
DMSGF8T	HS	Patented
DMSGF8T	SN	PMID29473428-Compound-27
DMSGF8T	CP	CURADEV PHARMA PVT. LTD
DMSGF8T	DT	Small molecular drug

DMVL2G3	ID	DMVL2G3
DMVL2G3	DN	Pyridine derivative 10
DMVL2G3	HS	Patented
DMVL2G3	SN	PMID28621580-Compound-WO2014040242c47
DMVL2G3	CP	HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD. ZHANG, Shixi
DMVL2G3	DT	Small molecular drug

DMF9VMW	ID	DMF9VMW
DMF9VMW	DN	Pyridine derivative 11
DMF9VMW	HS	Patented
DMF9VMW	SN	PMID28621580-Compound-WO2015075483c49
DMF9VMW	CP	CANCER RESEARCH TECHNOLOGY LIMITED INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)
DMF9VMW	DT	Small molecular drug

DM8KBHX	ID	DM8KBHX
DM8KBHX	DN	Pyridine derivative 12
DM8KBHX	HS	Patented
DM8KBHX	SN	PMID28067079-Compound-72
DM8KBHX	DT	Small molecular drug
DM8KBHX	PC	118205502
DM8KBHX	MW	321.3
DM8KBHX	FM	C19H16FN3O
DM8KBHX	IC	InChI=1S/C19H16FN3O/c20-19-15(7-4-10-22-19)16-11-18(23-17-8-3-6-14(16)17)24-12-13-5-1-2-9-21-13/h1-2,4-5,7,9-11H,3,6,8,12H2
DM8KBHX	CS	C1CC2=C(C1)N=C(C=C2C3=C(N=CC=C3)F)OCC4=CC=CC=N4
DM8KBHX	IK	NKDIYHWBHMMBTN-UHFFFAOYSA-N
DM8KBHX	IU	4-(2-fluoropyridin-3-yl)-2-(pyridin-2-ylmethoxy)-6,7-dihydro-5H-cyclopenta[b]pyridine

DMX8RGH	ID	DMX8RGH
DMX8RGH	DN	Pyridine derivative 13
DMX8RGH	HS	Patented
DMX8RGH	SN	PMID28067079-Compound-73
DMX8RGH	DT	Small molecular drug
DMX8RGH	PC	73213414
DMX8RGH	MW	322.3
DMX8RGH	FM	C18H15FN4O
DMX8RGH	IC	InChI=1S/C18H15FN4O/c19-15-4-2-6-22-17(15)10-24-18-7-14(12-8-20-11-21-9-12)13-3-1-5-16(13)23-18/h2,4,6-9,11H,1,3,5,10H2
DMX8RGH	CS	C1CC2=C(C1)N=C(C=C2C3=CN=CN=C3)OCC4=C(C=CC=N4)F
DMX8RGH	IK	JQPYBOWMLVSYFJ-UHFFFAOYSA-N
DMX8RGH	IU	2-[(3-fluoropyridin-2-yl)methoxy]-4-pyrimidin-5-yl-6,7-dihydro-5H-cyclopenta[b]pyridine

DM7JCM6	ID	DM7JCM6
DM7JCM6	DN	Pyridine derivative 14
DM7JCM6	HS	Patented
DM7JCM6	SN	PMID28067079-Compound-74
DM7JCM6	DT	Small molecular drug
DM7JCM6	PC	73335671
DM7JCM6	MW	328.4
DM7JCM6	FM	C20H16N4O
DM7JCM6	IC	InChI=1S/C20H16N4O/c21-9-14-4-6-15(7-5-14)12-25-20-8-18(16-10-22-13-23-11-16)17-2-1-3-19(17)24-20/h4-8,10-11,13H,1-3,12H2
DM7JCM6	CS	C1CC2=C(C1)N=C(C=C2C3=CN=CN=C3)OCC4=CC=C(C=C4)C#N
DM7JCM6	IK	CZFKXGVEBISLMB-UHFFFAOYSA-N
DM7JCM6	IU	4-[(4-pyrimidin-5-yl-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)oxymethyl]benzonitrile

DMGBR43	ID	DMGBR43
DMGBR43	DN	Pyridine derivative 15
DMGBR43	HS	Patented
DMGBR43	SN	PMID28067079-Compound-75
DMGBR43	DT	Small molecular drug
DMGBR43	PC	73335272
DMGBR43	MW	343.4
DMGBR43	FM	C20H17N5O
DMGBR43	IC	InChI=1S/C20H17N5O/c21-10-19-23-11-14(12-24-19)17-9-20(25-18-7-2-1-6-16(17)18)26-13-15-5-3-4-8-22-15/h3-5,8-9,11-12H,1-2,6-7,13H2
DMGBR43	CS	C1CCC2=C(C1)C(=CC(=N2)OCC3=CC=CC=N3)C4=CN=C(N=C4)C#N
DMGBR43	IK	SBDHHIXJPZSGIC-UHFFFAOYSA-N
DMGBR43	IU	5-[2-(pyridin-2-ylmethoxy)-5,6,7,8-tetrahydroquinolin-4-yl]pyrimidine-2-carbonitrile

DMICZLS	ID	DMICZLS
DMICZLS	DN	Pyridine derivative 16
DMICZLS	HS	Patented
DMICZLS	SN	PMID28067079-Compound-76
DMICZLS	DT	Small molecular drug
DMICZLS	PC	73335373
DMICZLS	MW	350.4
DMICZLS	FM	C20H19FN4O
DMICZLS	IC	InChI=1S/C20H19FN4O/c1-13-23-10-14(11-24-13)16-9-20(25-18-7-3-2-5-15(16)18)26-12-19-17(21)6-4-8-22-19/h4,6,8-11H,2-3,5,7,12H2,1H3
DMICZLS	CS	CC1=NC=C(C=N1)C2=CC(=NC3=C2CCCC3)OCC4=C(C=CC=N4)F
DMICZLS	IK	SPNLLZYJQZRTPY-UHFFFAOYSA-N
DMICZLS	IU	2-[(3-fluoropyridin-2-yl)methoxy]-4-(2-methylpyrimidin-5-yl)-5,6,7,8-tetrahydroquinoline

DMLC5WA	ID	DMLC5WA
DMLC5WA	DN	Pyridine derivative 17
DMLC5WA	HS	Patented
DMLC5WA	SN	PMID28067079-Compound-77
DMLC5WA	DT	Small molecular drug
DMLC5WA	PC	118205314
DMLC5WA	MW	350.4
DMLC5WA	FM	C20H19FN4O
DMLC5WA	IC	InChI=1S/C20H19FN4O/c1-13-10-22-11-18(24-13)15-9-20(25-17-7-3-2-5-14(15)17)26-12-19-16(21)6-4-8-23-19/h4,6,8-11H,2-3,5,7,12H2,1H3
DMLC5WA	CS	CC1=CN=CC(=N1)C2=CC(=NC3=C2CCCC3)OCC4=C(C=CC=N4)F
DMLC5WA	IK	NVOTVOBVLQBYNP-UHFFFAOYSA-N
DMLC5WA	IU	2-[(3-fluoropyridin-2-yl)methoxy]-4-(6-methylpyrazin-2-yl)-5,6,7,8-tetrahydroquinoline

DMBZMYT	ID	DMBZMYT
DMBZMYT	DN	Pyridine derivative 18
DMBZMYT	HS	Patented
DMBZMYT	SN	PMID27646564-Compound-5
DMBZMYT	CP	YM BIOSCIENCES AUSTRALIA PTY [AU]
DMBZMYT	DT	Small molecular drug

DMXYT40	ID	DMXYT40
DMXYT40	DN	Pyridine derivative 19
DMXYT40	HS	Patented
DMXYT40	SN	PMID27646564-Compound-5-1
DMXYT40	CP	YM BIOSCIENCES AUSTRALIA PTY [AU]
DMXYT40	DT	Small molecular drug

DMGSUIV	ID	DMGSUIV
DMGSUIV	DN	Pyridine derivative 2
DMGSUIV	HS	Patented
DMGSUIV	SN	PMID28621580-Compound-US20130096136c42
DMGSUIV	CP	MethylGene Inc
DMGSUIV	DT	Small molecular drug
DMGSUIV	PC	71522446
DMGSUIV	MW	563.6
DMGSUIV	FM	C31H25N5O4S
DMGSUIV	IC	InChI=1S/C31H25N5O4S/c1-38-21-7-5-20(6-8-21)34-31-35-24-15-22(9-11-26(24)40-31)39-27-12-13-32-25-16-28(41-30(25)27)23-10-4-19(17-33-23)18-36-14-2-3-29(36)37/h4-13,15-17H,2-3,14,18H2,1H3,(H,34,35)
DMGSUIV	CS	COC1=CC=C(C=C1)NC2=NC3=C(O2)C=CC(=C3)OC4=C5C(=NC=C4)C=C(S5)C6=NC=C(C=C6)CN7CCCC7=O
DMGSUIV	IK	NMDJVUTXFINSAW-UHFFFAOYSA-N
DMGSUIV	IU	1-[[6-[7-[[2-(4-methoxyanilino)-1,3-benzoxazol-5-yl]oxy]thieno[3,2-b]pyridin-2-yl]pyridin-3-yl]methyl]pyrrolidin-2-one

DMAOF0W	ID	DMAOF0W
DMAOF0W	DN	Pyridine derivative 20
DMAOF0W	HS	Patented
DMAOF0W	SN	PMID27646564-Compound-5-2
DMAOF0W	CP	YM BIOSCIENCES AUSTRALIA PTY [AU]
DMAOF0W	DT	Small molecular drug

DMF3907	ID	DMF3907
DMF3907	DN	Pyridine derivative 21
DMF3907	HS	Patented
DMF3907	SN	PMID27646564-Compound-5-3
DMF3907	CP	YM BIOSCIENCES AUSTRALIA PTY [AU]
DMF3907	DT	Small molecular drug

DMSIERF	ID	DMSIERF
DMSIERF	DN	Pyridine derivative 22
DMSIERF	HS	Patented
DMSIERF	SN	PMID27646564-Compound-5-4
DMSIERF	CP	YM BIOSCIENCES AUSTRALIA PTY [AU]
DMSIERF	DT	Small molecular drug

DMFALQN	ID	DMFALQN
DMFALQN	DN	Pyridine derivative 3
DMFALQN	HS	Patented
DMFALQN	SN	PMID28621580-Compound-US20140336108c48
DMFALQN	CP	Allergan, Inc
DMFALQN	DT	Small molecular drug

DM6N8T3	ID	DM6N8T3
DM6N8T3	DN	Pyridine derivative 4
DM6N8T3	HS	Patented
DM6N8T3	SN	PMID28621580-Compound-WO2012169934c40
DM6N8T3	CP	ASINEX LTD [RUKAZULKIN DENIS NIKOLAEVICH [RUKOCHUBEY VALERIY SERGEEVICH [RU]
DM6N8T3	DT	Small molecular drug
DM6N8T3	DE	Solid tumour/cancer

DMXP6W1	ID	DMXP6W1
DMXP6W1	DN	Pyridine derivative 5
DMXP6W1	HS	Patented
DMXP6W1	SN	PMID28621580-Compound-WO2013015657c41
DMXP6W1	CP	BORYUNG PHARMACEUTICAL CO., LTD.           KIM, Ji Han     KIM, Je Hak     LEE, Joon Kwang     JUNG, Hahn-Sun     HAN, Nam Seok     PARK, Yong   
DMXP6W1	DT	Small molecular drug

DM8NBM0	ID	DM8NBM0
DM8NBM0	DN	Pyridine derivative 6
DM8NBM0	HS	Patented
DM8NBM0	SN	PMID28621580-Compound-WO2013044361c43
DM8NBM0	CP	METHYLGENE INC
DM8NBM0	DT	Small molecular drug

DMYT1QN	ID	DMYT1QN
DMYT1QN	DN	Pyridine derivative 7
DMYT1QN	HS	Patented
DMYT1QN	SN	PMID28621580-Compound-WO2013044362c44
DMYT1QN	CP	METHYLGENE INC
DMYT1QN	DT	Small molecular drug

DMITVUY	ID	DMITVUY
DMITVUY	DN	Pyridine derivative 8
DMITVUY	HS	Patented
DMITVUY	SN	PMID28621580-Compound-WO2014029250c45
DMITVUY	CP	CISEN PHARMACEUTICAL CO., LTD. SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
DMITVUY	DT	Small molecular drug

DMVF1BI	ID	DMVF1BI
DMVF1BI	DN	Pyridine derivative 9
DMVF1BI	HS	Patented
DMVF1BI	SN	PMID28621580-Compound-WO2014029251c46
DMVF1BI	CP	CISEN PHARMACEUTICAL CO., LTD. SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
DMVF1BI	DT	Small molecular drug

DMJNE4V	ID	DMJNE4V
DMJNE4V	DN	Pyridine-2,4-dicarboxylic acid analog 1
DMJNE4V	HS	Patented
DMJNE4V	SN	PMID25468267-Compound-22
DMJNE4V	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMJNE4V	DT	Small molecular drug

DMCNWPI	ID	DMCNWPI
DMCNWPI	DN	Pyridine-2,4-dicarboxylic acid analog 2
DMCNWPI	HS	Patented
DMCNWPI	SN	PMID25468267-Compound-23
DMCNWPI	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMCNWPI	DT	Small molecular drug

DM4XAGS	ID	DM4XAGS
DM4XAGS	DN	Pyridine-2,4-dicarboxylic acid analog 3
DM4XAGS	HS	Patented
DM4XAGS	SN	PMID25468267-Compound-24
DM4XAGS	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM4XAGS	DT	Small molecular drug

DMGPCSR	ID	DMGPCSR
DMGPCSR	DN	Pyridine-2,4-dicarboxylic acid analog 4
DMGPCSR	HS	Patented
DMGPCSR	SN	PMID25468267-Compound-25
DMGPCSR	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMGPCSR	DT	Small molecular drug

DMZSTCQ	ID	DMZSTCQ
DMZSTCQ	DN	Pyridine-2,4-dicarboxylic acid derivative 1
DMZSTCQ	HS	Patented
DMZSTCQ	SN	PMID25468267-Compound-5
DMZSTCQ	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMZSTCQ	DT	Small molecular drug

DMGCMF5	ID	DMGCMF5
DMGCMF5	DN	Pyridine-2,4-dicarboxylic acid derivative 2
DMGCMF5	HS	Patented
DMGCMF5	SN	PMID25468267-Compound-6
DMGCMF5	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMGCMF5	DT	Small molecular drug

DMCUP4L	ID	DMCUP4L
DMCUP4L	DN	Pyridine-2,4-dicarboxylic acid derivative 3
DMCUP4L	HS	Patented
DMCUP4L	SN	PMID25468267-Compound-7
DMCUP4L	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMCUP4L	DT	Small molecular drug

DM9KOYX	ID	DM9KOYX
DM9KOYX	DN	Pyridine-amide derivative 1
DM9KOYX	HS	Patented
DM9KOYX	SN	PMID25470667-Compound-Figure5-4
DM9KOYX	CP	BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DM9KOYX	DT	Small molecular drug
DM9KOYX	PC	16757107
DM9KOYX	MW	420.4
DM9KOYX	FM	C20H19F3N4O3
DM9KOYX	IC	InChI=1S/C20H19F3N4O3/c1-27(10-11-29-2)15-9-8-14(12-24-15)25-18(28)16-17(20(21,22)23)30-19(26-16)13-6-4-3-5-7-13/h3-9,12H,10-11H2,1-2H3,(H,25,28)
DM9KOYX	CS	CN(CCOC)C1=NC=C(C=C1)NC(=O)C2=C(OC(=N2)C3=CC=CC=C3)C(F)(F)F
DM9KOYX	IK	QEZWDFXCTTZZRI-UHFFFAOYSA-N
DM9KOYX	IU	N-[6-[2-methoxyethyl(methyl)amino]pyridin-3-yl]-2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carboxamide

DM25M8D	ID	DM25M8D
DM25M8D	DN	Pyridine-carboximide derivative 1
DM25M8D	HS	Patented
DM25M8D	SN	PMID25470667-Compound-Figure5-5
DM25M8D	CP	SCHERING CORPORATION TING, Pauline, C. LEE, Joe, F. ASLANIAN, Robert, G
DM25M8D	DT	Small molecular drug
DM25M8D	PC	52917274
DM25M8D	MW	521.6
DM25M8D	FM	C31H27N3O5
DM25M8D	IC	InChI=1S/C31H27N3O5/c1-19-24-15-21(20-7-5-4-6-8-20)9-13-26(24)39-28(19)29(35)34-23-11-12-25(32-17-23)22-10-14-27(33-16-22)38-18-31(2,3)30(36)37/h4-17H,18H2,1-3H3,(H,34,35)(H,36,37)
DM25M8D	CS	CC1=C(OC2=C1C=C(C=C2)C3=CC=CC=C3)C(=O)NC4=CN=C(C=C4)C5=CN=C(C=C5)OCC(C)(C)C(=O)O
DM25M8D	IK	WBSJFAVPZLMOLD-UHFFFAOYSA-N
DM25M8D	IU	2,2-dimethyl-3-[5-[5-[(3-methyl-5-phenyl-1-benzofuran-2-carbonyl)amino]pyridin-2-yl]pyridin-2-yl]oxypropanoic acid

DMHXWZB	ID	DMHXWZB
DMHXWZB	DN	Pyridine-carboximide derivative 2
DMHXWZB	HS	Patented
DMHXWZB	SN	PMID25470667-Compound-Figure5-6
DMHXWZB	CP	MERCK SHARP & DOHME CORP. TING, Pauline, C. ASLANIAN, Robert CAO, Jianhua KIM, David ZORN, Nicolas
DMHXWZB	DT	Small molecular drug
DMHXWZB	PC	56837993
DMHXWZB	MW	497.5
DMHXWZB	FM	C29H27N3O5
DMHXWZB	IC	InChI=1S/C29H27N3O5/c33-28(26-11-10-25(37-26)21-5-2-1-3-6-21)31-23-9-12-27(30-18-23)32-15-13-20(14-16-32)19-36-24-8-4-7-22(17-24)29(34)35/h1-12,17-18,20H,13-16,19H2,(H,31,33)(H,34,35)
DMHXWZB	CS	C1CN(CCC1COC2=CC=CC(=C2)C(=O)O)C3=NC=C(C=C3)NC(=O)C4=CC=C(O4)C5=CC=CC=C5
DMHXWZB	IK	FQDLXNVBCMMHLG-UHFFFAOYSA-N
DMHXWZB	IU	3-[[1-[5-[(5-phenylfuran-2-carbonyl)amino]pyridin-2-yl]piperidin-4-yl]methoxy]benzoic acid

DMKQFTY	ID	DMKQFTY
DMKQFTY	DN	Pyridino tricyclic compound 1
DMKQFTY	HS	Patented
DMKQFTY	SN	PMID29473428-Compound-42
DMKQFTY	CP	REDX PHARMA PLC
DMKQFTY	DT	Small molecular drug
DMKQFTY	PC	121288581
DMKQFTY	MW	283.37
DMKQFTY	FM	C17H21N3O
DMKQFTY	IC	InChI=1S/C17H21N3O/c21-17(12-4-2-1-3-5-12)8-15-13-6-7-18-9-14(13)16-10-19-11-20(15)16/h6-7,9-12,15,17,21H,1-5,8H2
DMKQFTY	CS	C1CCC(CC1)C(CC2C3=C(C=NC=C3)C4=CN=CN24)O
DMKQFTY	IK	PCYLWVWPFZLSAJ-UHFFFAOYSA-N
DMKQFTY	IU	1-cyclohexyl-2-(4,6,11-triazatricyclo[6.4.0.02,6]dodeca-1(8),2,4,9,11-pentaen-7-yl)ethanol

DM3F4KS	ID	DM3F4KS
DM3F4KS	DN	Pyridinone carboxamide derivative 1
DM3F4KS	HS	Patented
DM3F4KS	SN	PMID25684022-Compound-WO2010007116
DM3F4KS	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH ENGELHARDT, Harald BOEHMELT, Guido KOFINK, Christiane KUHN, Daniel MCCONNELL, Darryl STADTMUELLER, Heinz
DM3F4KS	DT	Small molecular drug
DM3F4KS	DE	Solid tumour/cancer; Metastatic cancer

DM2GR5Q	ID	DM2GR5Q
DM2GR5Q	DN	Pyridinone compound 1
DM2GR5Q	HS	Patented
DM2GR5Q	SN	PMID28594589-Compound-TABLE3c9
DM2GR5Q	CP	Asan Foundation
DM2GR5Q	DT	Small molecular drug
DM2GR5Q	PC	86582134
DM2GR5Q	MW	515.299
DM2GR5Q	FM	C20H23FIN3O4
DM2GR5Q	IC	InChI=1S/C20H23FIN3O4/c1-20(2,28)10-29-24-18(26)16-12-5-4-6-13(12)19(27)25(3)17(16)23-15-8-7-11(22)9-14(15)21/h7-9,23,28H,4-6,10H2,1-3H3,(H,24,26)
DM2GR5Q	CS	CC(C)(CONC(=O)C1=C(N(C(=O)C2=C1CCC2)C)NC3=C(C=C(C=C3)I)F)O
DM2GR5Q	IK	WMBPVWDVQRPCQY-UHFFFAOYSA-N
DM2GR5Q	IU	3-(2-fluoro-4-iodoanilino)-N-(2-hydroxy-2-methylpropoxy)-2-methyl-1-oxo-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carboxamide

DMK5YJI	ID	DMK5YJI
DMK5YJI	DN	Pyrido/pyrrolo-fused pyrimidine derivative 1
DMK5YJI	HS	Patented
DMK5YJI	SN	PMID28447479-Compound-2
DMK5YJI	CP	ELI LILLY AND COMPANY
DMK5YJI	DT	Small molecular drug
DMK5YJI	PC	76285327
DMK5YJI	MW	405.5
DMK5YJI	FM	C21H23N7O2
DMK5YJI	IC	InChI=1S/C21H23N7O2/c29-20(13-30-6-5-17-10-23-27-26-17)28-11-16-9-22-21(25-19(16)12-28)24-18-7-14-3-1-2-4-15(14)8-18/h1-4,9-10,18H,5-8,11-13H2,(H,22,24,25)(H,23,26,27)
DMK5YJI	CS	C1C(CC2=CC=CC=C21)NC3=NC=C4CN(CC4=N3)C(=O)COCCC5=NNN=C5
DMK5YJI	IK	ILOFWCAZDNILKY-UHFFFAOYSA-N
DMK5YJI	IU	1-[2-(2,3-dihydro-1H-inden-2-ylamino)-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]-2-[2-(2H-triazol-4-yl)ethoxy]ethanone
DMK5YJI	DE	Pain

DMHKRVL	ID	DMHKRVL
DMHKRVL	DN	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1
DMHKRVL	HS	Patented
DMHKRVL	SN	PMID27321640-Compound-54
DMHKRVL	CP	LUNDBECK & CO AS H [DKJOERGENSEN MORTEN [DKBRUUN ANNE TECHAU [DKRASMUSSEN LARS KYHN [DK]
DMHKRVL	DT	Small molecular drug
DMHKRVL	PC	71295288
DMHKRVL	MW	309.75
DMHKRVL	FM	C16H12ClN5
DMHKRVL	IC	InChI=1S/C16H12ClN5/c1-9-5-3-6-11(17)13(9)16-21-20-15-10(2)19-14-12(22(15)16)7-4-8-18-14/h3-8H,1-2H3
DMHKRVL	CS	CC1=C(C(=CC=C1)Cl)C2=NN=C3N2C4=C(N=CC=C4)N=C3C
DMHKRVL	IK	GBABEYRPJLOPCN-UHFFFAOYSA-N
DMHKRVL	IU	3-(2-chloro-6-methylphenyl)-7-methyl-2,4,5,8,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene

DMUO25Y	ID	DMUO25Y
DMUO25Y	DN	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2
DMUO25Y	HS	Patented
DMUO25Y	SN	PMID27321640-Compound-55
DMUO25Y	CP	LUNDBECK & CO AS H [DKJOERGENSEN MORTEN [DKBRUUN ANNE TECHAU [DKRASMUSSEN LARS KYHN [DK]
DMUO25Y	DT	Small molecular drug
DMUO25Y	PC	71295314
DMUO25Y	MW	295.72
DMUO25Y	FM	C15H10ClN5
DMUO25Y	IC	InChI=1S/C15H10ClN5/c1-9-14-19-20-15(10-4-2-3-5-11(10)16)21(14)13-6-7-17-8-12(13)18-9/h2-8H,1H3
DMUO25Y	CS	CC1=NC2=C(C=CN=C2)N3C1=NN=C3C4=CC=CC=C4Cl
DMUO25Y	IK	NUACZBDSBLGPGS-UHFFFAOYSA-N
DMUO25Y	IU	3-(2-chlorophenyl)-7-methyl-2,4,5,8,11-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene

DMAEYNT	ID	DMAEYNT
DMAEYNT	DN	Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3
DMAEYNT	HS	Patented
DMAEYNT	SN	PMID27321640-Compound-56
DMAEYNT	CP	LUNDBECK & CO AS H [DKJOERGENSEN MORTEN [DKBRUUN ANNE TECHAU [DKRASMUSSEN LARS KYHN [DK]
DMAEYNT	DT	Small molecular drug

DMF0XI3	ID	DMF0XI3
DMF0XI3	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 1
DMF0XI3	HS	Patented
DMF0XI3	SN	PMID25468267-Compound-34
DMF0XI3	CP	EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John VILE, Julia GELMAN, Danny M. GAI, Xinjie BARKER, Oliver Robin DEBOVES, Herv Jean Claude EAST, Stephen Peter BOESEN, Thomas
DMF0XI3	DT	Small molecular drug
DMF0XI3	PC	56589666
DMF0XI3	MW	355.4
DMF0XI3	FM	C19H21N3O4
DMF0XI3	IC	InChI=1S/C19H21N3O4/c1-21(2)10-11-26-19(24)17-14-8-7-13(18(23)20-25-3)12-16(14)22-9-5-4-6-15(17)22/h4-9,12H,10-11H2,1-3H3,(H,20,23)
DMF0XI3	CS	CN(C)CCOC(=O)C1=C2C=CC=CN2C3=C1C=CC(=C3)C(=O)NOC
DMF0XI3	IK	ZZDUDEMXVPDTNG-UHFFFAOYSA-N
DMF0XI3	IU	2-(dimethylamino)ethyl 3-(methoxycarbamoyl)pyrido[1,2-a]indole-10-carboxylate

DMWMV48	ID	DMWMV48
DMWMV48	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 2
DMWMV48	HS	Patented
DMWMV48	SN	PMID25468267-Compound-35
DMWMV48	CP	EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John VILE, Julia GELMAN, Danny M. GAI, Xinjie BARKER, Oliver Robin DEBOVES, Herv Jean Claude EAST, Stephen Peter BOESEN, Thomas
DMWMV48	DT	Small molecular drug

DMCLKBY	ID	DMCLKBY
DMCLKBY	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 3
DMCLKBY	HS	Patented
DMCLKBY	SN	PMID25468267-Compound-36
DMCLKBY	CP	EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John VILE, Julia GELMAN, Danny M. GAI, Xinjie BARKER, Oliver Robin DEBOVES, Herv Jean Claude EAST, Stephen Peter BOESEN, Thomas
DMCLKBY	DT	Small molecular drug
DMCLKBY	PC	66666946
DMCLKBY	MW	381.5
DMCLKBY	FM	C22H27N3O3
DMCLKBY	IC	InChI=1S/C22H27N3O3/c1-23(2)12-10-20(26)16-8-9-17-19(15-16)25-11-6-5-7-18(25)21(17)22(27)28-14-13-24(3)4/h5-9,11,15H,10,12-14H2,1-4H3
DMCLKBY	CS	CN(C)CCC(=O)C1=CC2=C(C=C1)C(=C3N2C=CC=C3)C(=O)OCCN(C)C
DMCLKBY	IK	HQWDSOCFKBELNH-UHFFFAOYSA-N
DMCLKBY	IU	2-(dimethylamino)ethyl 3-[3-(dimethylamino)propanoyl]pyrido[1,2-a]indole-10-carboxylate

DM09FOQ	ID	DM09FOQ
DM09FOQ	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 4
DM09FOQ	HS	Patented
DM09FOQ	SN	PMID25468267-Compound-37
DM09FOQ	CP	EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John VILE, Julia GELMAN, Danny M. GAI, Xinjie BARKER, Oliver Robin DEBOVES, Herv Jean Claude EAST, Stephen Peter BOESEN, Thomas
DM09FOQ	DT	Small molecular drug
DM09FOQ	PC	66667765
DM09FOQ	MW	294.3
DM09FOQ	FM	C18H18N2O2
DM09FOQ	IC	InChI=1S/C18H18N2O2/c1-12(21)13-7-8-14-16(10-13)20-9-5-4-6-15(20)18(14)17(22)11-19(2)3/h4-10H,11H2,1-3H3
DM09FOQ	CS	CC(=O)C1=CC2=C(C=C1)C(=C3N2C=CC=C3)C(=O)CN(C)C
DM09FOQ	IK	QISRGBAMCCXAKB-UHFFFAOYSA-N
DM09FOQ	IU	1-(3-acetylpyrido[1,2-a]indol-10-yl)-2-(dimethylamino)ethanone

DMO3QDW	ID	DMO3QDW
DMO3QDW	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 5
DMO3QDW	HS	Patented
DMO3QDW	SN	PMID25468267-Compound-38
DMO3QDW	CP	EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John
DMO3QDW	DT	Small molecular drug
DMO3QDW	PC	56589667
DMO3QDW	MW	325.4
DMO3QDW	FM	C18H19N3O3
DMO3QDW	IC	InChI=1S/C18H19N3O3/c1-20(2)10-8-19-17(22)12-6-7-13-15(11-12)21-9-4-3-5-14(21)16(13)18(23)24/h3-7,9,11H,8,10H2,1-2H3,(H,19,22)(H,23,24)
DMO3QDW	CS	CN(C)CCNC(=O)C1=CC2=C(C=C1)C(=C3N2C=CC=C3)C(=O)O
DMO3QDW	IK	OMVKEKNQENTGRO-UHFFFAOYSA-N
DMO3QDW	IU	3-[2-(dimethylamino)ethylcarbamoyl]pyrido[1,2-a]indole-10-carboxylic acid

DMRQ1ZB	ID	DMRQ1ZB
DMRQ1ZB	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 6
DMRQ1ZB	HS	Patented
DMRQ1ZB	SN	PMID25468267-Compound-39
DMRQ1ZB	CP	EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John
DMRQ1ZB	DT	Small molecular drug
DMRQ1ZB	PC	66667268
DMRQ1ZB	MW	312.32
DMRQ1ZB	FM	C17H16N2O4
DMRQ1ZB	IC	InChI=1S/C17H16N2O4/c1-23-9-7-18-16(20)11-5-6-12-14(10-11)19-8-3-2-4-13(19)15(12)17(21)22/h2-6,8,10H,7,9H2,1H3,(H,18,20)(H,21,22)
DMRQ1ZB	CS	COCCNC(=O)C1=CC2=C(C=C1)C(=C3N2C=CC=C3)C(=O)O
DMRQ1ZB	IK	HHIORJMMUBJBIN-UHFFFAOYSA-N
DMRQ1ZB	IU	3-(2-methoxyethylcarbamoyl)pyrido[1,2-a]indole-10-carboxylic acid

DMXY3F0	ID	DMXY3F0
DMXY3F0	DN	Pyrido[1,2-a]indole-1.-carboxylic acid analog 7
DMXY3F0	HS	Patented
DMXY3F0	SN	PMID25468267-Compound-40
DMXY3F0	CP	EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John
DMXY3F0	DT	Small molecular drug
DMXY3F0	PC	56643890
DMXY3F0	MW	298.29
DMXY3F0	FM	C16H14N2O4
DMXY3F0	IC	InChI=1S/C16H14N2O4/c19-8-6-17-15(20)10-4-5-11-13(9-10)18-7-2-1-3-12(18)14(11)16(21)22/h1-5,7,9,19H,6,8H2,(H,17,20)(H,21,22)
DMXY3F0	CS	C1=CC2=C(C3=C(N2C=C1)C=C(C=C3)C(=O)NCCO)C(=O)O
DMXY3F0	IK	OVCGCJPQKMNJNJ-UHFFFAOYSA-N
DMXY3F0	IU	3-(2-hydroxyethylcarbamoyl)pyrido[1,2-a]indole-10-carboxylic acid

DMHZLSO	ID	DMHZLSO
DMHZLSO	DN	Pyrido[2,3-d]pyrimidine derivative 1
DMHZLSO	HS	Patented
DMHZLSO	SN	PMID26161824-Compound-142
DMHZLSO	DT	Small molecular drug
DMHZLSO	PC	25098114
DMHZLSO	MW	457.8
DMHZLSO	FM	C23H19Cl3N4
DMHZLSO	IC	InChI=1S/C23H19Cl3N4/c1-23(2,3)22-29-20(27)17-11-16(12-4-6-13(24)7-5-12)19(28-21(17)30-22)15-9-8-14(25)10-18(15)26/h4-11H,1-3H3,(H2,27,28,29,30)
DMHZLSO	CS	CC(C)(C)C1=NC2=NC(=C(C=C2C(=N1)N)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl
DMHZLSO	IK	QVFUKBUINZLPLW-UHFFFAOYSA-N
DMHZLSO	IU	2-tert-butyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)pyrido[2,3-d]pyrimidin-4-amine
DMHZLSO	DE	Obesity

DMSM53I	ID	DMSM53I
DMSM53I	DN	Pyrido[2,3-d]pyrimidine derivative 2
DMSM53I	HS	Patented
DMSM53I	SN	PMID26161824-Compound-143
DMSM53I	DT	Small molecular drug
DMSM53I	DE	Obesity

DMM8CL4	ID	DMM8CL4
DMM8CL4	DN	Pyrido[2,3-d]pyrimidine-2,4-diamine derivative 1
DMM8CL4	HS	Patented
DMM8CL4	SN	PMID27321640-Compound-18
DMM8CL4	CP	PFIZER PRODUCTS INC. BEYER, Thomas, Arthur CHAMBERS, Robert, James LAM, Kelvin LI, Mei MORRELL, Andrew, Ian THOMPSON, David, Duane
DMM8CL4	DT	Small molecular drug

DMRHAU4	ID	DMRHAU4
DMRHAU4	DN	Pyrido[3,2-d]pyrimidine derivative 2
DMRHAU4	HS	Patented
DMRHAU4	SN	PMID28270021-Compound-WO2012125668Example12
DMRHAU4	CP	MERCK SHARP & DOHME CORP
DMRHAU4	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM6D1XR	ID	DM6D1XR
DM6D1XR	DN	Pyrido[3,2-d]pyrimidine derivative 3
DM6D1XR	HS	Patented
DM6D1XR	SN	PMID28270021-Compound-WO2012125668Example27
DM6D1XR	CP	MERCK SHARP & DOHME CORP
DM6D1XR	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMC8935	ID	DMC8935
DMC8935	DN	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1
DMC8935	HS	Patented
DMC8935	SN	PMID27321640-Compound-37
DMC8935	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMC8935	DT	Small molecular drug

DM4CSBD	ID	DM4CSBD
DM4CSBD	DN	Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2
DM4CSBD	HS	Patented
DM4CSBD	SN	PMID27321640-Compound-38
DM4CSBD	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DM4CSBD	DT	Small molecular drug

DMOTGEK	ID	DMOTGEK
DMOTGEK	DN	Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1
DMOTGEK	HS	Patented
DMOTGEK	SN	PMID25684022-Compound-WO2010019637
DMOTGEK	CP	GLAXOSMITHKLINE LLC ATKINSON, Francis, Louis AXTEN, Jeffrey, Michael CICHY-KNIGHT, Maria MOORE, Michael, Lee PATEI, Vipulkumar, Kantibhai TIAN, Xinrong WELLAWAY, Christopher, Roland DUNN, Allison, K
DMOTGEK	DT	Small molecular drug
DMOTGEK	DE	Solid tumour/cancer; Metastatic cancer

DMP6TUQ	ID	DMP6TUQ
DMP6TUQ	DN	Pyridoindole derivative 1
DMP6TUQ	HS	Patented
DMP6TUQ	SN	PMID25656651-Compound-22a
DMP6TUQ	CP	UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA UNIVERSITE DE GENEVE UNIVERSITE CLAUDE BERNARD LYON 1
DMP6TUQ	DT	Small molecular drug
DMP6TUQ	PC	46183444
DMP6TUQ	MW	432.5
DMP6TUQ	FM	C28H24N4O
DMP6TUQ	IC	InChI=1S/C28H24N4O/c1-2-4-20(5-3-1)6-7-21-16-25-24-17-22(8-10-27(24)31-28(25)30-18-21)26-11-9-23(19-29-26)32-12-14-33-15-13-32/h1-11,16-19H,12-15H2,(H,30,31)/b7-6+
DMP6TUQ	CS	C1COCCN1C2=CN=C(C=C2)C3=CC4=C(C=C3)NC5=C4C=C(C=N5)/C=C/C6=CC=CC=C6
DMP6TUQ	IK	RPPRUVFNILNTHG-VOTSOKGWSA-N
DMP6TUQ	IU	4-[6-[3-[(E)-2-phenylethenyl]-9H-pyrido[2,3-b]indol-6-yl]pyridin-3-yl]morpholine

DMIXK7Y	ID	DMIXK7Y
DMIXK7Y	DN	Pyridoindole derivative 2
DMIXK7Y	HS	Patented
DMIXK7Y	SN	PMID25656651-Compound-22b
DMIXK7Y	CP	UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA UNIVERSITE DE GENEVE UNIVERSITE CLAUDE BERNARD LYON 1 
DMIXK7Y	DT	Small molecular drug
DMIXK7Y	PC	58514479
DMIXK7Y	MW	270.3
DMIXK7Y	FM	C19H14N2
DMIXK7Y	IC	InChI=1S/C19H14N2/c1-2-6-14(7-3-1)10-11-15-12-17-16-8-4-5-9-18(16)21-19(17)20-13-15/h1-13H,(H,20,21)/b11-10+
DMIXK7Y	CS	C1=CC=C(C=C1)/C=C/C2=CC3=C(NC4=CC=CC=C43)N=C2
DMIXK7Y	IK	UNSLEGIUCMXDGG-ZHACJKMWSA-N
DMIXK7Y	IU	3-[(E)-2-phenylethenyl]-9H-pyrido[2,3-b]indole

DMONCT1	ID	DMONCT1
DMONCT1	DN	Pyridoindole derivative 3
DMONCT1	HS	Patented
DMONCT1	SN	PMID25656651-Compound-22c
DMONCT1	CP	UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA UNIVERSITE DE GENEVE UNIVERSITE CLAUDE BERNARD LYON 1 
DMONCT1	DT	Small molecular drug
DMONCT1	PC	66765887
DMONCT1	MW	274.3
DMONCT1	FM	C18H14N2O
DMONCT1	IC	InChI=1S/C18H14N2O/c1-21-13-8-6-12(7-9-13)14-10-11-19-18-17(14)15-4-2-3-5-16(15)20-18/h2-11H,1H3,(H,19,20)
DMONCT1	CS	COC1=CC=C(C=C1)C2=C3C4=CC=CC=C4NC3=NC=C2
DMONCT1	IK	PJJCQNCRSXRPLV-UHFFFAOYSA-N
DMONCT1	IU	4-(4-methoxyphenyl)-9H-pyrido[2,3-b]indole

DMTZK6V	ID	DMTZK6V
DMTZK6V	DN	Pyridopyrimidine derivative 1
DMTZK6V	HS	Patented
DMTZK6V	SN	PMID28594589-Compound-TABLE3c10
DMTZK6V	CP	LUPIN LIMITED
DMTZK6V	DT	Small molecular drug
DMTZK6V	PC	118918608
DMTZK6V	MW	604.4
DMTZK6V	FM	C24H22FIN6O4
DMTZK6V	IC	InChI=1S/C24H22FIN6O4/c1-12-20-19(21(30(2)22(12)34)29-17-8-7-13(26)9-16(17)25)23(35)31(3)24(36)32(20)15-6-4-5-14(10-15)28-11-18(27)33/h4-10,28-29H,11H2,1-3H3,(H2,27,33)
DMTZK6V	CS	CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NCC(=O)N)C
DMTZK6V	IK	KAVFKXKOUQPGQL-UHFFFAOYSA-N
DMTZK6V	IU	2-[3-[5-(2-fluoro-4-iodoanilino)-3,6,8-trimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]anilino]acetamide

DMZ6TSD	ID	DMZ6TSD
DMZ6TSD	DN	Pyridopyrimidinone derivative 1
DMZ6TSD	HS	Patented
DMZ6TSD	SN	PMID28117607-Compound-45
DMZ6TSD	CP	Oscotec, Inc., S. Korea. assignee
DMZ6TSD	DT	Small molecular drug

DMUF63N	ID	DMUF63N
DMUF63N	DN	Pyridopyrimidinone derivative 2
DMUF63N	HS	Patented
DMUF63N	SN	PMID28117607-Compound-46
DMUF63N	CP	Oscotec, Inc., S. Korea. assignee
DMUF63N	DT	Small molecular drug

DMHSDUR	ID	DMHSDUR
DMHSDUR	DN	Pyridopyrimidinone derivative 3
DMHSDUR	HS	Patented
DMHSDUR	SN	PMID28117607-Compound-47
DMHSDUR	CP	Oscotec, Inc., S. Korea. assignee
DMHSDUR	DT	Small molecular drug

DM71UYI	ID	DM71UYI
DM71UYI	DN	Pyridotriazolopyrimidine derivative 1
DM71UYI	HS	Patented
DM71UYI	SN	PMID26161824-Compound-144
DM71UYI	DT	Small molecular drug
DM71UYI	PC	25095251
DM71UYI	MW	497.9
DM71UYI	FM	C26H20ClN7O2
DM71UYI	IC	InChI=1S/C26H20ClN7O2/c1-26(2,3)24-30-22-18(23-31-32-25(35)34(23)24)12-17(20(29-22)16-6-4-5-7-19(16)27)14-8-10-15(11-9-14)21-28-13-36-33-21/h4-13H,1-3H3,(H,32,35)
DM71UYI	CS	CC(C)(C)C1=NC2=NC(=C(C=C2C3=NNC(=O)N31)C4=CC=C(C=C4)C5=NOC=N5)C6=CC=CC=C6Cl
DM71UYI	IK	CHQLSHSXSIIVFC-UHFFFAOYSA-N
DM71UYI	IU	7-tert-butyl-11-(2-chlorophenyl)-12-[4-(1,2,4-oxadiazol-3-yl)phenyl]-3,4,6,8,10-pentazatricyclo[7.4.0.02,6]trideca-1(13),2,7,9,11-pentaen-5-one
DM71UYI	DE	Obesity

DM0VOY9	ID	DM0VOY9
DM0VOY9	DN	Pyridotriazolopyrimidine derivative 2
DM0VOY9	HS	Patented
DM0VOY9	SN	PMID26161824-Compound-145
DM0VOY9	DT	Small molecular drug
DM0VOY9	PC	25098092
DM0VOY9	MW	464.3
DM0VOY9	FM	C24H19Cl2N5O
DM0VOY9	IC	InChI=1S/C24H19Cl2N5O/c1-24(2,3)22-28-20-17(21-29-30-23(32)31(21)22)12-16(13-8-10-14(25)11-9-13)19(27-20)15-6-4-5-7-18(15)26/h4-12H,1-3H3,(H,30,32)
DM0VOY9	CS	CC(C)(C)C1=NC2=NC(=C(C=C2C3=NNC(=O)N31)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DM0VOY9	IK	RCDDRZOJAVJMCL-UHFFFAOYSA-N
DM0VOY9	IU	7-tert-butyl-11-(2-chlorophenyl)-12-(4-chlorophenyl)-3,4,6,8,10-pentazatricyclo[7.4.0.02,6]trideca-1(13),2,7,9,11-pentaen-5-one
DM0VOY9	DE	Obesity

DMYVCTD	ID	DMYVCTD
DMYVCTD	DN	Pyridotriazolopyrimidine derivative 3
DMYVCTD	HS	Patented
DMYVCTD	SN	PMID26161824-Compound-146
DMYVCTD	DT	Small molecular drug
DMYVCTD	PC	24944528
DMYVCTD	MW	489.4
DMYVCTD	FM	C25H18Cl2N6O
DMYVCTD	IC	InChI=1S/C25H18Cl2N6O/c1-25(2,3)23-30-21-18(22-31-32-24(34)33(22)23)11-17(14-5-7-15(26)8-6-14)20(29-21)16-9-4-13(12-28)10-19(16)27/h4-11H,1-3H3,(H,32,34)
DMYVCTD	CS	CC(C)(C)C1=NC2=NC(=C(C=C2C3=NNC(=O)N31)C4=CC=C(C=C4)Cl)C5=C(C=C(C=C5)C#N)Cl
DMYVCTD	IK	CSEQBOCMDXHKIF-UHFFFAOYSA-N
DMYVCTD	IU	4-[7-tert-butyl-12-(4-chlorophenyl)-5-oxo-3,4,6,8,10-pentazatricyclo[7.4.0.02,6]trideca-1(13),2,7,9,11-pentaen-11-yl]-3-chlorobenzonitrile
DMYVCTD	DE	Obesity

DMUTE5S	ID	DMUTE5S
DMUTE5S	DN	Pyridyl compound 1
DMUTE5S	HS	Patented
DMUTE5S	SN	PMID28454500-Compound-15
DMUTE5S	CP	TRUSTEES OF DARTMOUTH COLLEGE
DMUTE5S	DT	Small molecular drug

DMD6GNO	ID	DMD6GNO
DMD6GNO	DN	Pyrimidine benzenesulfonamide derivative 1
DMD6GNO	HS	Patented
DMD6GNO	SN	PMID27172114-Compound-62
DMD6GNO	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMD6GNO	DT	Small molecular drug
DMD6GNO	PC	71282692
DMD6GNO	MW	401.9
DMD6GNO	FM	C19H16ClN3O3S
DMD6GNO	IC	InChI=1S/C19H16ClN3O3S/c20-16-10-13(6-9-18(16)26-14-7-8-14)17-11-19(22-12-21-17)23-27(24,25)15-4-2-1-3-5-15/h1-6,9-12,14H,7-8H2,(H,21,22,23)
DMD6GNO	CS	C1CC1OC2=C(C=C(C=C2)C3=CC(=NC=N3)NS(=O)(=O)C4=CC=CC=C4)Cl
DMD6GNO	IK	AJZPXSIAEFVSBW-UHFFFAOYSA-N
DMD6GNO	IU	N-[6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidin-4-yl]benzenesulfonamide

DMVQ4NS	ID	DMVQ4NS
DMVQ4NS	DN	Pyrimidine benzenesulfonamide derivative 2
DMVQ4NS	HS	Patented
DMVQ4NS	SN	PMID27172114-Compound-63
DMVQ4NS	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMVQ4NS	DT	Small molecular drug
DMVQ4NS	PC	71285521
DMVQ4NS	MW	419.9
DMVQ4NS	FM	C19H15ClFN3O3S
DMVQ4NS	IC	InChI=1S/C19H15ClFN3O3S/c20-16-9-12(1-8-18(16)27-14-4-5-14)17-10-19(23-11-22-17)24-28(25,26)15-6-2-13(21)3-7-15/h1-3,6-11,14H,4-5H2,(H,22,23,24)
DMVQ4NS	CS	C1CC1OC2=C(C=C(C=C2)C3=CC(=NC=N3)NS(=O)(=O)C4=CC=C(C=C4)F)Cl
DMVQ4NS	IK	NHNNNQMEILXDMV-UHFFFAOYSA-N
DMVQ4NS	IU	N-[6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidin-4-yl]-4-fluorobenzenesulfonamide

DMJ71Q0	ID	DMJ71Q0
DMJ71Q0	DN	Pyrimidine benzenesulfonamide derivative 3
DMJ71Q0	HS	Patented
DMJ71Q0	SN	PMID27172114-Compound-64
DMJ71Q0	CP	COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMJ71Q0	DT	Small molecular drug

DMN9VQM	ID	DMN9VQM
DMN9VQM	DN	Pyrimidine derivative 1
DMN9VQM	HS	Patented
DMN9VQM	SN	PMID25539043-Compound-WO2012020567Example17
DMN9VQM	CP	RAQUALIA PHARMA INC
DMN9VQM	DT	Small molecular drug

DMBEZUY	ID	DMBEZUY
DMBEZUY	DN	Pyrimidine derivative 10
DMBEZUY	HS	Patented
DMBEZUY	SN	PMID28621580-Compound-WO2014000686c53
DMBEZUY	CP	CISEN PHARMACEUTICAL CO., LTD. SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY LI, Jianqi WANG, Wenya ZHOU, Bin XIE, Peng DU, Zhenxin LU, Xiulian WENG, Zhijie ZHANG, Qingwei HUANG, Daowei
DMBEZUY	DT	Small molecular drug

DMJ4QD5	ID	DMJ4QD5
DMJ4QD5	DN	Pyrimidine derivative 11
DMJ4QD5	HS	Patented
DMJ4QD5	SN	PMID28621580-Compound-WO2014139458c54
DMJ4QD5	CP	CISEN PHARMACEUTICAL CO., LTD. SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
DMJ4QD5	DT	Small molecular drug

DMMBFQH	ID	DMMBFQH
DMMBFQH	DN	Pyrimidine derivative 12
DMMBFQH	HS	Patented
DMMBFQH	SN	PMID28621580-Compound-WO2014184778c56
DMMBFQH	CP	NOVARTIS AG GLAENZEL, Ulrike NUFER, Robert
DMMBFQH	DT	Small molecular drug

DMASGR1	ID	DMASGR1
DMASGR1	DN	Pyrimidine derivative 13
DMASGR1	HS	Patented
DMASGR1	SN	PMID28621580-Compound-WO2014184778c57
DMASGR1	CP	NOVARTIS AG GLAENZEL, Ulrike NUFER, Robert
DMASGR1	DT	Small molecular drug

DM7B2XG	ID	DM7B2XG
DM7B2XG	DN	Pyrimidine derivative 14
DM7B2XG	HS	Patented
DM7B2XG	SN	PMID28621580-Compound-WO2014197313c51
DM7B2XG	CP	KALA PHARMACEUTICALS, INC
DM7B2XG	DT	Small molecular drug

DMV2Y84	ID	DMV2Y84
DMV2Y84	DN	Pyrimidine derivative 15
DMV2Y84	HS	Patented
DMV2Y84	SN	PMID28621580-Compound-WO2015123722c58
DMV2Y84	CP	BIONOMICS LIMITED
DMV2Y84	DT	Small molecular drug

DM3GYPD	ID	DM3GYPD
DM3GYPD	DN	Pyrimidine derivative 16
DM3GYPD	HS	Patented
DM3GYPD	SN	PMID27019002-Compound-38
DM3GYPD	CP	CELGENE QUANTICEL RESEARCH, INC
DM3GYPD	DT	Small molecular drug

DM7YA9Z	ID	DM7YA9Z
DM7YA9Z	DN	Pyrimidine derivative 17
DM7YA9Z	HS	Patented
DM7YA9Z	SN	PMID27019002-Compound-39
DM7YA9Z	CP	CELGENE QUANTICEL RESEARCH, INC
DM7YA9Z	DT	Small molecular drug

DMIZTKS	ID	DMIZTKS
DMIZTKS	DN	Pyrimidine derivative 18
DMIZTKS	HS	Patented
DMIZTKS	SN	PMID27019002-Compound-40
DMIZTKS	CP	CELGENE QUANTICEL RESEARCH, INC
DMIZTKS	DT	Small molecular drug

DMLPO0K	ID	DMLPO0K
DMLPO0K	DN	Pyrimidine derivative 19
DMLPO0K	HS	Patented
DMLPO0K	SN	PMID25726713-Compound-67
DMLPO0K	DT	Small molecular drug

DMS8OR3	ID	DMS8OR3
DMS8OR3	DN	Pyrimidine derivative 2
DMS8OR3	HS	Patented
DMS8OR3	SN	PMID28627961-Compound-34
DMS8OR3	CP	GLENMARK PHARMACEUTICALS S.A
DMS8OR3	DT	Small molecular drug
DMS8OR3	PC	118038559
DMS8OR3	MW	482.9
DMS8OR3	FM	C22H19ClF4N4O2
DMS8OR3	IC	InChI=1S/C22H19ClF4N4O2/c1-21(2,3)19(32)29-10-12-4-6-13(23)17(18(12)24)15-8-14(30-20(33)31-15)11-5-7-16(28-9-11)22(25,26)27/h4-9H,10H2,1-3H3,(H,29,32)(H,30,31,33)
DMS8OR3	CS	CC(C)(C)C(=O)NCC1=C(C(=C(C=C1)Cl)C2=CC(=NC(=O)N2)C3=CN=C(C=C3)C(F)(F)F)F
DMS8OR3	IK	CHFIXQQTHCXPKE-UHFFFAOYSA-N
DMS8OR3	IU	N-[[4-chloro-2-fluoro-3-[2-oxo-4-[6-(trifluoromethyl)pyridin-3-yl]-1H-pyrimidin-6-yl]phenyl]methyl]-2,2-dimethylpropanamide

DMQUEDK	ID	DMQUEDK
DMQUEDK	DN	Pyrimidine derivative 20
DMQUEDK	HS	Patented
DMQUEDK	SN	PMID25726713-Compound-68
DMQUEDK	DT	Small molecular drug

DMELA2F	ID	DMELA2F
DMELA2F	DN	Pyrimidine derivative 21
DMELA2F	HS	Patented
DMELA2F	SN	PMID25726713-Compound-69
DMELA2F	DT	Small molecular drug

DMN64AK	ID	DMN64AK
DMN64AK	DN	Pyrimidine derivative 22
DMN64AK	HS	Patented
DMN64AK	SN	PMID25726713-Compound-70
DMN64AK	CP	ZHANG, Xiaohu
DMN64AK	DT	Small molecular drug

DM5MLQU	ID	DM5MLQU
DM5MLQU	DN	Pyrimidine derivative 23
DM5MLQU	HS	Patented
DM5MLQU	SN	PMID26609882-Compound-50
DM5MLQU	CP	JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DM5MLQU	DT	Small molecular drug

DMOQ726	ID	DMOQ726
DMOQ726	DN	Pyrimidine derivative 24
DMOQ726	HS	Patented
DMOQ726	SN	PMID26609882-Compound-51
DMOQ726	CP	JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DMOQ726	DT	Small molecular drug

DM51MFS	ID	DM51MFS
DM51MFS	DN	Pyrimidine derivative 25
DM51MFS	HS	Patented
DM51MFS	SN	PMID26609882-Compound-52
DM51MFS	CP	JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DM51MFS	DT	Small molecular drug

DM90WKN	ID	DM90WKN
DM90WKN	DN	Pyrimidine derivative 26
DM90WKN	HS	Patented
DM90WKN	SN	PMID26609882-Compound-53
DM90WKN	CP	JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DM90WKN	DT	Small molecular drug

DMIQSDW	ID	DMIQSDW
DMIQSDW	DN	Pyrimidine derivative 27
DMIQSDW	HS	Patented
DMIQSDW	SN	PMID26609882-Compound-54
DMIQSDW	CP	JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DMIQSDW	DT	Small molecular drug

DM1D2AS	ID	DM1D2AS
DM1D2AS	DN	Pyrimidine derivative 28
DM1D2AS	HS	Patented
DM1D2AS	SN	PMID26609882-Compound-55
DM1D2AS	CP	JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DM1D2AS	DT	Small molecular drug

DMVOYJ8	ID	DMVOYJ8
DMVOYJ8	DN	Pyrimidine derivative 29
DMVOYJ8	HS	Patented
DMVOYJ8	SN	PMID26609882-Compound-56
DMVOYJ8	CP	JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DMVOYJ8	DT	Small molecular drug

DMC3E8M	ID	DMC3E8M
DMC3E8M	DN	Pyrimidine derivative 3
DMC3E8M	HS	Patented
DMC3E8M	SN	PMID25684022-Compound-WO2011076327
DMC3E8M	CP	MERCK PATENT GMBH WUCHERER-PLIETKER, Margarita ESDAR, Christina
DMC3E8M	DT	Small molecular drug
DMC3E8M	DE	Solid tumour/cancer; Metastatic cancer

DMTQBUD	ID	DMTQBUD
DMTQBUD	DN	Pyrimidine derivative 30
DMTQBUD	HS	Patented
DMTQBUD	SN	PMID25482888-Compound-32
DMTQBUD	DT	Small molecular drug

DMOJTLU	ID	DMOJTLU
DMOJTLU	DN	Pyrimidine derivative 31
DMOJTLU	HS	Patented
DMOJTLU	SN	PMID25482888-Compound-33
DMOJTLU	DT	Small molecular drug

DMCUQFG	ID	DMCUQFG
DMCUQFG	DN	Pyrimidine derivative 32
DMCUQFG	HS	Patented
DMCUQFG	SN	PMID25482888-Compound-66
DMCUQFG	DT	Small molecular drug
DMCUQFG	PC	71731242
DMCUQFG	MW	418.5
DMCUQFG	FM	C23H26N6O2
DMCUQFG	IC	InChI=1S/C23H26N6O2/c1-3-4-12-28-21(27-11-7-8-17(24)14-27)13-22(30)29(23(28)31)15-20-25-16(2)18-9-5-6-10-19(18)26-20/h5-6,9-10,13,17H,7-8,11-12,14-15,24H2,1-2H3/t17-/m1/s1
DMCUQFG	CS	CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC=C3C(=N2)C)N4CCC[C@H](C4)N
DMCUQFG	IK	GHHYMLIQMIXJDE-QGZVFWFLSA-N
DMCUQFG	IU	6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-[(4-methylquinazolin-2-yl)methyl]pyrimidine-2,4-dione

DMWL5V0	ID	DMWL5V0
DMWL5V0	DN	Pyrimidine derivative 33
DMWL5V0	HS	Patented
DMWL5V0	SN	PMID25482888-Compound-67
DMWL5V0	DT	Small molecular drug
DMWL5V0	PC	71731606
DMWL5V0	MW	437.9
DMWL5V0	FM	C23H24ClN5O2
DMWL5V0	IC	InChI=1S/C23H24ClN5O2/c1-2-3-11-28-21(27-10-4-5-18(25)14-27)13-22(30)29(23(28)31)15-19-9-7-16-6-8-17(24)12-20(16)26-19/h6-9,12-13,18H,4-5,10-11,14-15,25H2,1H3/t18-/m1/s1
DMWL5V0	CS	CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=CC(=C3)Cl)C=C2)N4CCC[C@H](C4)N
DMWL5V0	IK	MRWKTDPDQXVRSA-GOSISDBHSA-N
DMWL5V0	IU	6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-[(7-chloroquinolin-2-yl)methyl]pyrimidine-2,4-dione

DM4192V	ID	DM4192V
DM4192V	DN	Pyrimidine derivative 34
DM4192V	HS	Patented
DM4192V	SN	PMID26118988-Compound-27
DM4192V	CP	CHIESI FARMACEUTICI S.p.A. EDWARDS, Christine KULAGOWSKI, Janusz FINCH, Harry
DM4192V	DT	Small molecular drug

DM8K6IS	ID	DM8K6IS
DM8K6IS	DN	Pyrimidine derivative 4
DM8K6IS	HS	Patented
DM8K6IS	SN	PMID28621580-Compound-US20080255172c50
DM8K6IS	CP	Hutchison MediPharma Enterprises Limited, Bahamas
DM8K6IS	DT	Small molecular drug

DMNET19	ID	DMNET19
DMNET19	DN	Pyrimidine derivative 5
DMNET19	HS	Patented
DMNET19	SN	PMID28621580-Compound-US20160096832c60
DMNET19	CP	Allergan, Inc
DMNET19	DT	Small molecular drug
DMNET19	DE	Neurodegenerative disorder; Fibrosis; Blood vessel proliferative disorder

DMBAHYO	ID	DMBAHYO
DMBAHYO	DN	Pyrimidine derivative 6
DMBAHYO	HS	Patented
DMBAHYO	SN	PMID28621580-Compound-US20160096837c61
DMBAHYO	CP	Allergan, Inc
DMBAHYO	DT	Small molecular drug
DMBAHYO	DE	Neurodegenerative disorder; Fibrosis; Blood vessel proliferative disorder

DMF6DUT	ID	DMF6DUT
DMF6DUT	DN	Pyrimidine derivative 7
DMF6DUT	HS	Patented
DMF6DUT	SN	PMID28621580-Compound-US20169233968c59
DMF6DUT	CP	Allergan, Inc
DMF6DUT	DT	Small molecular drug
DMF6DUT	DE	Neurodegenerative disorder; Fibrosis; Blood vessel proliferative disorder

DMVW25O	ID	DMVW25O
DMVW25O	DN	Pyrimidine derivative 8
DMVW25O	HS	Patented
DMVW25O	SN	PMID28621580-Compound-US20169296747c52
DMVW25O	CP	Allergan, Inc
DMVW25O	DT	Small molecular drug

DMV6U9Y	ID	DMV6U9Y
DMV6U9Y	DN	Pyrimidine derivative 9
DMV6U9Y	HS	Patented
DMV6U9Y	SN	PMID28621580-Compound-WO2010066684c55
DMV6U9Y	CP	NOVARTIS AG ARTMAN III, Gerald David ELLIOTT, Jason Matthew JI, Nan LIU, Donglei MA, Fupeng MAINOLFI, Nello MEREDITH, Erik MIRANDA, Karl POWERS, James J. RAO, Chang
DMV6U9Y	DT	Small molecular drug

DMT6O1N	ID	DMT6O1N
DMT6O1N	DN	Pyrimidine-4(3H)-one derivative 1
DMT6O1N	HS	Patented
DMT6O1N	SN	PMID25470667-Compound-Figure6-20
DMT6O1N	CP	MSD K.K. ARAKAWA, Keisuke ITO, Yoshiki KAWAMOTO, Hiroshi SAKAKI, Junichi SHIMAMURA, Tadashi
DMT6O1N	DT	Small molecular drug

DML4OYQ	ID	DML4OYQ
DML4OYQ	DN	Pyrimidinedione derivative 1
DML4OYQ	HS	Patented
DML4OYQ	SN	PMID25482888-Compound-45
DML4OYQ	DT	Small molecular drug

DM1I7Z6	ID	DM1I7Z6
DM1I7Z6	DN	Pyrimidinone derivative 1
DM1I7Z6	HS	Patented
DM1I7Z6	SN	PMID25684022-Compound-WO2010007114
DM1I7Z6	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH ENGELHARDT, Harald BOEHMELT, Guido KOFINK, Christiane KUHN, Daniel McCONNELL, Darryl STADTMUELLER, Heinz
DM1I7Z6	DT	Small molecular drug
DM1I7Z6	DE	Solid tumour/cancer; Metastatic cancer

DMDQNKW	ID	DMDQNKW
DMDQNKW	DN	Pyrimidinone derivative 4
DMDQNKW	HS	Patented
DMDQNKW	SN	PMID26118988-Compound-23
DMDQNKW	DT	Small molecular drug
DMDQNKW	PC	24752875
DMDQNKW	MW	982.9
DMDQNKW	FM	C51H36F6N10O5
DMDQNKW	IC	InChI=1S/C51H36F6N10O5/c1-29-40(44-17-19-62-66(44)35-13-9-31(25-58)10-14-35)23-42(48(71)64(29)37-7-3-5-33(21-37)50(52,53)54)46(69)60-27-39(68)28-61-47(70)43-24-41(45-18-20-63-67(45)36-15-11-32(26-59)12-16-36)30(2)65(49(43)72)38-8-4-6-34(22-38)51(55,56)57/h3-24,39,68H,27-28H2,1-2H3,(H,60,69)(H,61,70)
DMDQNKW	CS	CC1=C(C=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)NCC(CNC(=O)C3=CC(=C(N(C3=O)C4=CC=CC(=C4)C(F)(F)F)C)C5=CC=NN5C6=CC=C(C=C6)C#N)O)C7=CC=NN7C8=CC=C(C=C8)C#N
DMDQNKW	IK	KYPHYLQIJUHQAO-UHFFFAOYSA-N
DMDQNKW	IU	5-[2-(4-cyanophenyl)pyrazol-3-yl]-N-[3-[[5-[2-(4-cyanophenyl)pyrazol-3-yl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carbonyl]amino]-2-hydroxypropyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide

DMLFY57	ID	DMLFY57
DMLFY57	DN	Pyrimidinone derivative 5
DMLFY57	HS	Patented
DMLFY57	SN	PMID28447479-Compound-6
DMLFY57	DT	Small molecular drug
DMLFY57	PC	137426105
DMLFY57	MW	419.9
DMLFY57	FM	C21H26ClN3O4
DMLFY57	IC	InChI=1S/C21H26ClN3O4/c1-2-3-4-6-18-24-17(15-8-10-16(22)11-9-15)13-20(27)25(18)14-19(26)23-12-5-7-21(28)29/h8-11,13H,2-7,12,14H2,1H3,(H,23,26)(H,28,29)
DMLFY57	CS	CCCCCC1=NC(=CC(=O)N1CC(=O)NCCCC(=O)O)C2=CC=C(C=C2)Cl
DMLFY57	IK	GMCBZWCKSMXZFV-UHFFFAOYSA-N
DMLFY57	IU	4-[[2-[4-(4-chlorophenyl)-6-oxo-2-pentylpyrimidin-1-yl]acetyl]amino]butanoic acid

DMYKHQ8	ID	DMYKHQ8
DMYKHQ8	DN	Pyrimidinyl compound 1
DMYKHQ8	HS	Patented
DMYKHQ8	SN	PMID26293650-Compound-36
DMYKHQ8	CP	DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMYKHQ8	DT	Small molecular drug
DMYKHQ8	PC	56646025
DMYKHQ8	MW	384.4
DMYKHQ8	FM	C22H20N6O
DMYKHQ8	IC	InChI=1S/C22H20N6O/c23-14-17-12-15(6-7-20(17)28-10-1-2-11-28)19-8-9-25-22(27-19)26-18-5-3-4-16(13-18)21(24)29/h3-9,12-13H,1-2,10-11H2,(H2,24,29)(H,25,26,27)
DMYKHQ8	CS	C1CCN(C1)C2=C(C=C(C=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C(=O)N)C#N
DMYKHQ8	IK	KPMCSBDURLKXIY-UHFFFAOYSA-N
DMYKHQ8	IU	3-[[4-(3-cyano-4-pyrrolidin-1-ylphenyl)pyrimidin-2-yl]amino]benzamide

DM9TW5O	ID	DM9TW5O
DM9TW5O	DN	Pyrimidinyl compound 2
DM9TW5O	HS	Patented
DM9TW5O	SN	PMID26293650-Compound-37
DM9TW5O	CP	DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DM9TW5O	DT	Small molecular drug

DMOE2FZ	ID	DMOE2FZ
DMOE2FZ	DN	Pyrimidinyl compound 3
DMOE2FZ	HS	Patented
DMOE2FZ	SN	PMID26293650-Compound-38
DMOE2FZ	CP	DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMOE2FZ	DT	Small molecular drug

DM53O9Y	ID	DM53O9Y
DM53O9Y	DN	Pyrimidinyl compound 4
DM53O9Y	HS	Patented
DM53O9Y	SN	PMID26293650-Compound-39
DM53O9Y	CP	DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DM53O9Y	DT	Small molecular drug
DM53O9Y	PC	56646218
DM53O9Y	MW	396.4
DM53O9Y	FM	C23H20N6O
DM53O9Y	IC	InChI=1S/C23H20N6O/c24-14-17-11-15(3-6-21(17)29-9-1-2-10-29)20-7-8-25-23(28-20)26-18-4-5-19-16(12-18)13-22(30)27-19/h3-8,11-12H,1-2,9-10,13H2,(H,27,30)(H,25,26,28)
DM53O9Y	CS	C1CCN(C1)C2=C(C=C(C=C2)C3=NC(=NC=C3)NC4=CC5=C(C=C4)NC(=O)C5)C#N
DM53O9Y	IK	DHPSFJYFPJRCTN-UHFFFAOYSA-N
DM53O9Y	IU	5-[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile

DMCKBGM	ID	DMCKBGM
DMCKBGM	DN	Pyrimidinyl compound 5
DMCKBGM	HS	Patented
DMCKBGM	SN	PMID26293650-Compound-40
DMCKBGM	CP	DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMCKBGM	DT	Small molecular drug
DMCKBGM	PC	56593541
DMCKBGM	MW	427.5
DMCKBGM	FM	C24H25N7O
DMCKBGM	IC	InChI=1S/C24H25N7O/c25-16-19-15-18(3-5-22(19)30-9-1-2-10-30)21-7-8-26-24(29-21)28-20-4-6-23(27-17-20)31-11-13-32-14-12-31/h3-8,15,17H,1-2,9-14H2,(H,26,28,29)
DMCKBGM	CS	C1CCN(C1)C2=C(C=C(C=C2)C3=NC(=NC=C3)NC4=CN=C(C=C4)N5CCOCC5)C#N
DMCKBGM	IK	BEWCKABPPSBSRH-UHFFFAOYSA-N
DMCKBGM	IU	5-[2-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile

DML2E8S	ID	DML2E8S
DML2E8S	DN	Pyrimidinyl compound 6
DML2E8S	HS	Patented
DML2E8S	SN	PMID26293650-Compound-41
DML2E8S	CP	DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DML2E8S	DT	Small molecular drug
DML2E8S	PC	66685711
DML2E8S	MW	401.4
DML2E8S	FM	C21H19N7O2
DML2E8S	IC	InChI=1S/C21H19N7O2/c1-13(29)25-20-5-3-16(10-24-20)26-21-23-7-6-18(27-21)14-2-4-19(15(8-14)9-22)28-11-17(30)12-28/h2-8,10,17,30H,11-12H2,1H3,(H,23,26,27)(H,24,25,29)
DML2E8S	CS	CC(=O)NC1=NC=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)N4CC(C4)O)C#N
DML2E8S	IK	ULOABNKVPRZZBK-UHFFFAOYSA-N
DML2E8S	IU	N-[5-[[4-[3-cyano-4-(3-hydroxyazetidin-1-yl)phenyl]pyrimidin-2-yl]amino]pyridin-2-yl]acetamide

DMMYW2L	ID	DMMYW2L
DMMYW2L	DN	Pyrimidinyl compound 7
DMMYW2L	HS	Patented
DMMYW2L	SN	PMID26293650-Compound-42
DMMYW2L	CP	DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMMYW2L	DT	Small molecular drug
DMMYW2L	PC	89837438
DMMYW2L	MW	446.5
DMMYW2L	FM	C24H27FN8
DMMYW2L	IC	InChI=1S/C24H27FN8/c1-32(2)12-10-27-23-6-4-20(15-29-23)30-24-28-9-7-21(31-24)17-3-5-22(18(13-17)14-26)33-11-8-19(25)16-33/h3-7,9,13,15,19H,8,10-12,16H2,1-2H3,(H,27,29)(H,28,30,31)
DMMYW2L	CS	CN(C)CCNC1=NC=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)N4CCC(C4)F)C#N
DMMYW2L	IK	NGQHJZXAWIBXQH-UHFFFAOYSA-N
DMMYW2L	IU	5-[2-[[6-[2-(dimethylamino)ethylamino]pyridin-3-yl]amino]pyrimidin-4-yl]-2-(3-fluoropyrrolidin-1-yl)benzonitrile

DMZ83P1	ID	DMZ83P1
DMZ83P1	DN	Pyrimidinyl ethylenediamine derivative 1
DMZ83P1	HS	Patented
DMZ83P1	SN	PMID26413912-Compound-79
DMZ83P1	CP	JANSSEN PHARMACEUTICA NV HAWRYLUK, Natalie, A. BREITENBUCHER, J., Guy JONES, William, M. CHAMBERS, Alison, L. KEITH, John, M. SEIERSTAD, Mark
DMZ83P1	DT	Small molecular drug
DMZ83P1	PC	51037025
DMZ83P1	MW	428.8
DMZ83P1	FM	C19H14ClF5N4
DMZ83P1	IC	InChI=1S/C19H14ClF5N4/c20-13-5-11(1-3-12(13)19(23,24)25)17-7-18(29-9-28-17)27-8-16(26)10-2-4-14(21)15(22)6-10/h1-7,9,16H,8,26H2,(H,27,28,29)/t16-/m0/s1
DMZ83P1	CS	C1=CC(=C(C=C1C2=CC(=NC=N2)NC[C@@H](C3=CC(=C(C=C3)F)F)N)Cl)C(F)(F)F
DMZ83P1	IK	WKWUCPXAFUCNHR-INIZCTEOSA-N
DMZ83P1	IU	(1R)-N'-[6-[3-chloro-4-(trifluoromethyl)phenyl]pyrimidin-4-yl]-1-(3,4-difluorophenyl)ethane-1,2-diamine

DM72T58	ID	DM72T58
DM72T58	DN	Pyrimidinyl pyrazolamine derivative 1
DM72T58	HS	Patented
DM72T58	SN	PMID25656651-Compound-14
DM72T58	CP	IRM LLC NOVARTIS AG ALBAUGH, Pamela CHOPIUK, Gregory S. DING, Qiang HUANG, Shenlin LIU, Zuosheng PAN, Shifeng REN, Pingda WANG, Xia WANG, Xing XIE, Yongping ZHANG, Chengzhi ZHANG, Qiong ZHANG, Guobao POON, Daniel RENHOWE, Paul SENDZIK, Martin
DM72T58	DT	Small molecular drug
DM72T58	PC	59173275
DM72T58	MW	552.6
DM72T58	FM	C28H31F3N8O
DM72T58	IC	InChI=1S/C28H31F3N8O/c1-16(2)33-14-19-9-20(11-21(10-19)28(29,30)31)27(40)36-22-7-6-17(3)23(12-22)37-26-8-18(4)38-39(26)25-13-24(32-5)34-15-35-25/h6-13,15-16,33,37H,14H2,1-5H3,(H,36,40)(H,32,34,35)
DM72T58	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)CNC(C)C)C(F)(F)F)NC3=CC(=NN3C4=NC=NC(=C4)NC)C
DM72T58	IK	ZBUIYGDQZSKXHD-UHFFFAOYSA-N
DM72T58	IU	N-[4-methyl-3-[[5-methyl-2-[6-(methylamino)pyrimidin-4-yl]pyrazol-3-yl]amino]phenyl]-3-[(propan-2-ylamino)methyl]-5-(trifluoromethyl)benzamide

DM6O2Q9	ID	DM6O2Q9
DM6O2Q9	DN	Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1
DM6O2Q9	HS	Patented
DM6O2Q9	SN	PMID27410995-Compound-Figure3d
DM6O2Q9	DT	Small molecular drug

DMB5UF7	ID	DMB5UF7
DMB5UF7	DN	Pyrimido-indole derivative 1
DMB5UF7	HS	Patented
DMB5UF7	SN	PMID26924192-Compound-80
DMB5UF7	CP	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DMB5UF7	DT	Small molecular drug
DMB5UF7	PC	118340554
DMB5UF7	MW	443.5
DMB5UF7	FM	C24H25N7O2
DMB5UF7	IC	InChI=1S/C24H25N7O2/c1-11-21(12(2)33-30-11)16-8-18-15(9-19(16)32-5)22-23(27-18)25-13(3)26-24(22)28-20-10-17(14-6-7-14)29-31(20)4/h8-10,14H,6-7H2,1-5H3,(H2,25,26,27,28)
DMB5UF7	CS	CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)NC4=C3C(=NC(=N4)C)NC5=CC(=NN5C)C6CC6)OC
DMB5UF7	IK	JIYPVUCBRQNICX-UHFFFAOYSA-N
DMB5UF7	IU	N-(5-cyclopropyl-2-methylpyrazol-3-yl)-7-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine

DM3REN5	ID	DM3REN5
DM3REN5	DN	Pyrimido-indole derivative 2
DM3REN5	HS	Patented
DM3REN5	SN	PMID26924192-Compound-81
DM3REN5	CP	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DM3REN5	DT	Small molecular drug
DM3REN5	PC	91864675
DM3REN5	MW	471.6
DM3REN5	FM	C26H29N7O2
DM3REN5	IC	InChI=1S/C26H29N7O2/c1-6-33-26(16-9-7-8-10-19(16)31-33)30-25-23-17-12-21(34-5)18(22-13(2)32-35-14(22)3)11-20(17)29-24(23)27-15(4)28-25/h11-12H,6-10H2,1-5H3,(H2,27,28,29,30)
DM3REN5	CS	CCN1C(=C2CCCCC2=N1)NC3=NC(=NC4=C3C5=CC(=C(C=C5N4)C6=C(ON=C6C)C)OC)C
DM3REN5	IK	PKOGGTPBCXRZNX-UHFFFAOYSA-N
DM3REN5	IU	7-(3,5-dimethyl-1,2-oxazol-4-yl)-N-(2-ethyl-4,5,6,7-tetrahydroindazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine

DM53LGD	ID	DM53LGD
DM53LGD	DN	Pyrimido-indole derivative 3
DM53LGD	HS	Patented
DM53LGD	SN	PMID26924192-Compound-82
DM53LGD	CP	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DM53LGD	DT	Small molecular drug
DM53LGD	PC	118340734
DM53LGD	MW	451.5
DM53LGD	FM	C26H21N5O3
DM53LGD	IC	InChI=1S/C26H21N5O3/c1-13-23(14(2)34-31-13)18-11-20-17(12-22(18)32-4)24-25(30-20)28-15(3)29-26(24)33-21-9-10-27-19-8-6-5-7-16(19)21/h5-12H,1-4H3,(H,28,29,30)
DM53LGD	CS	CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)NC4=C3C(=NC(=N4)C)OC5=CC=NC6=CC=CC=C65)OC
DM53LGD	IK	RYLREOMADHRZEY-UHFFFAOYSA-N
DM53LGD	IU	4-(6-methoxy-2-methyl-4-quinolin-4-yloxy-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethyl-1,2-oxazole

DM32N7D	ID	DM32N7D
DM32N7D	DN	Pyrimidopyridazinone derivative 1
DM32N7D	HS	Patented
DM32N7D	SN	PMID27774824-Compound-Figure10Example191
DM32N7D	CP	ENDO PHARMACEUTICALS INC. VENKATESAN, Aranapakam SMITH, Roger, Astbury HOSAHALLI, Subramanya POTLURI, Vijay PANIGRAHI, Sunil, Kumar BASETTI, Vishnu KUNTU, Karunasree
DM32N7D	DT	Small molecular drug

DMD1RT0	ID	DMD1RT0
DMD1RT0	DN	Pyrimidopyridazinone derivative 2
DMD1RT0	HS	Patented
DMD1RT0	SN	PMID27774824-Compound-Figure10Example7
DMD1RT0	CP	ELI LILLY AND COMPANENDO PHARMACEUTICALS INC. VENKATESAN, Aranapakam SMITH, Roger, Astbury HOSAHALLI, Subramanya POTLURI, Vijay PANIGRAHI, Sunil, Kumar BASETTI, Vishnu KUNTU, Karunasree
DMD1RT0	DT	Small molecular drug

DM0RC1Z	ID	DM0RC1Z
DM0RC1Z	DN	Pyrrole derivative 1
DM0RC1Z	HS	Patented
DM0RC1Z	SN	PMID26161824-Compound-10
DM0RC1Z	CP	SANOFI-AVENTIS BARTH, Francis BICHON, Daniel CONGY, Christian RINALDI-CARMONA, Muriell
DM0RC1Z	DT	Small molecular drug
DM0RC1Z	PC	44481280
DM0RC1Z	MW	625
DM0RC1Z	FM	C33H32Cl3N3O3
DM0RC1Z	IC	InChI=1S/C33H32Cl3N3O3/c34-23-9-12-25(13-10-23)39-29(8-4-5-19-40)27(21-30(39)26-14-11-24(35)20-28(26)36)31(41)38-17-15-33(16-18-38,32(37)42)22-6-2-1-3-7-22/h1-3,6-7,9-14,20-21,40H,4-5,8,15-19H2,(H2,37,42)
DM0RC1Z	CS	C1CN(CCC1(C2=CC=CC=C2)C(=O)N)C(=O)C3=C(N(C(=C3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)CCCCO
DM0RC1Z	IK	JVBKCVQNRQUJHM-UHFFFAOYSA-N
DM0RC1Z	IU	1-[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-(4-hydroxybutyl)pyrrole-3-carbonyl]-4-phenylpiperidine-4-carboxamide
DM0RC1Z	DE	Obesity

DMMNKFX	ID	DMMNKFX
DMMNKFX	DN	Pyrrole derivative 2
DMMNKFX	HS	Patented
DMMNKFX	SN	PMID26161824-Compound-5
DMMNKFX	CP	SANOFI-AVENTIS BARTH, Francis CONGY, Christian DUCOUX, Jean-Philippe RINALDI-CARMONA, Murielle
DMMNKFX	DT	Small molecular drug
DMMNKFX	PC	44626131
DMMNKFX	MW	609.6
DMMNKFX	FM	C32H30Cl2N2O4S
DMMNKFX	IC	InChI=1S/C32H30Cl2N2O4S/c33-23-9-12-25(27(34)19-23)29-26(21-7-10-24(11-8-21)40-18-4-17-37)20-28(41-29)30(38)36-15-13-32(14-16-36,31(35)39)22-5-2-1-3-6-22/h1-3,5-12,19-20,37H,4,13-18H2,(H2,35,39)
DMMNKFX	CS	C1CN(CCC1(C2=CC=CC=C2)C(=O)N)C(=O)C3=CC(=C(S3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)OCCCO
DMMNKFX	IK	WHNYDESPWWLRBM-UHFFFAOYSA-N
DMMNKFX	IU	1-[5-(2,4-dichlorophenyl)-4-[4-(3-hydroxypropoxy)phenyl]thiophene-2-carbonyl]-4-phenylpiperidine-4-carboxamide
DMMNKFX	DE	Obesity

DMFV64B	ID	DMFV64B
DMFV64B	DN	Pyrrole derivative 3
DMFV64B	HS	Patented
DMFV64B	SN	PMID26161824-Compound-6
DMFV64B	DT	Small molecular drug
DMFV64B	PC	58367580
DMFV64B	MW	575.1
DMFV64B	FM	C32H31ClN2O4S
DMFV64B	IC	InChI=1S/C32H31ClN2O4S/c33-27-10-5-4-9-25(27)29-26(22-11-13-24(14-12-22)39-20-6-19-36)21-28(40-29)30(37)35-17-15-32(16-18-35,31(34)38)23-7-2-1-3-8-23/h1-5,7-14,21,36H,6,15-20H2,(H2,34,38)
DMFV64B	CS	C1CN(CCC1(C2=CC=CC=C2)C(=O)N)C(=O)C3=CC(=C(S3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)OCCCO
DMFV64B	IK	MWPKIBLLWUZVNJ-UHFFFAOYSA-N
DMFV64B	IU	1-[5-(2-chlorophenyl)-4-[4-(3-hydroxypropoxy)phenyl]thiophene-2-carbonyl]-4-phenylpiperidine-4-carboxamide
DMFV64B	DE	Obesity

DMQDL43	ID	DMQDL43
DMQDL43	DN	Pyrrole derivative 4
DMQDL43	HS	Patented
DMQDL43	SN	PMID26161824-Compound-7
DMQDL43	CP	SANOFI-AVENTIS BARTH, Francis CONGY, Christian JEANJEAN, Audrey RINALDI-CARMONA, Muriell
DMQDL43	DT	Small molecular drug
DMQDL43	PC	58307112
DMQDL43	MW	605.5
DMQDL43	FM	C32H30Cl2N4O4
DMQDL43	IC	InChI=1S/C32H30Cl2N4O4/c1-37-27(30(40)38-15-13-32(14-16-38,31(36)41)21-5-3-2-4-6-21)18-25(24-12-9-22(33)17-26(24)34)29(37)20-7-10-23(11-8-20)42-19-28(35)39/h2-12,17-18H,13-16,19H2,1H3,(H2,35,39)(H2,36,41)
DMQDL43	CS	CN1C(=CC(=C1C2=CC=C(C=C2)OCC(=O)N)C3=C(C=C(C=C3)Cl)Cl)C(=O)N4CCC(CC4)(C5=CC=CC=C5)C(=O)N
DMQDL43	IK	LTDLMCVMMICHRM-UHFFFAOYSA-N
DMQDL43	IU	1-[5-[4-(2-amino-2-oxoethoxy)phenyl]-4-(2,4-dichlorophenyl)-1-methylpyrrole-2-carbonyl]-4-phenylpiperidine-4-carboxamide
DMQDL43	DE	Obesity

DMJUMC6	ID	DMJUMC6
DMJUMC6	DN	Pyrrole derivative 5
DMJUMC6	HS	Patented
DMJUMC6	SN	PMID26161824-Compound-8
DMJUMC6	CP	SANOFI-AVENTIS BARTH, Francis CONGY, Christian JEANJEAN, Audrey RINALDI-CARMONA, Muriell
DMJUMC6	DT	Small molecular drug
DMJUMC6	PC	44511396
DMJUMC6	MW	619.1
DMJUMC6	FM	C34H36ClFN4O4
DMJUMC6	IC	InChI=1S/C34H36ClFN4O4/c1-39-30(32(42)40-17-15-34(16-18-40,33(37)43)38-22-23-7-11-25(36)12-8-23)21-28(27-5-2-3-6-29(27)35)31(39)24-9-13-26(14-10-24)44-20-4-19-41/h2-3,5-14,21,38,41H,4,15-20,22H2,1H3,(H2,37,43)
DMJUMC6	CS	CN1C(=CC(=C1C2=CC=C(C=C2)OCCCO)C3=CC=CC=C3Cl)C(=O)N4CCC(CC4)(C(=O)N)NCC5=CC=C(C=C5)F
DMJUMC6	IK	QZKLHVGMMWBLEQ-UHFFFAOYSA-N
DMJUMC6	IU	1-[4-(2-chlorophenyl)-5-[4-(3-hydroxypropoxy)phenyl]-1-methylpyrrole-2-carbonyl]-4-[(4-fluorophenyl)methylamino]piperidine-4-carboxamide
DMJUMC6	DE	Obesity

DM875RE	ID	DM875RE
DM875RE	DN	Pyrrole derivative 6
DM875RE	HS	Patented
DM875RE	SN	PMID26161824-Compound-9
DM875RE	CP	SANOFI-AVENTIS BARTH, Francis BICHON, Daniel CONGY, Christian RINALDI-CARMONA, Muriell
DM875RE	DT	Small molecular drug
DM875RE	PC	58319355
DM875RE	MW	645.4
DM875RE	FM	C32H29Cl4N3O3
DM875RE	IC	InChI=1S/C32H29Cl4N3O3/c33-21-5-3-20(4-6-21)32(31(37)42)13-15-38(16-14-32)30(41)26-19-29(25-12-9-23(35)18-27(25)36)39(28(26)2-1-17-40)24-10-7-22(34)8-11-24/h3-12,18-19,40H,1-2,13-17H2,(H2,37,42)
DM875RE	CS	C1CN(CCC1(C2=CC=C(C=C2)Cl)C(=O)N)C(=O)C3=C(N(C(=C3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)CCCO
DM875RE	IK	VICABLXDCCBPMT-UHFFFAOYSA-N
DM875RE	IU	4-(4-chlorophenyl)-1-[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-(3-hydroxypropyl)pyrrole-3-carbonyl]piperidine-4-carboxamide
DM875RE	DE	Obesity

DMZCERW	ID	DMZCERW
DMZCERW	DN	Pyrrole derivative 7
DMZCERW	HS	Patented
DMZCERW	SN	PMID27774822-Compound-Figure3compound229
DMZCERW	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMZCERW	DT	Small molecular drug

DM1A0VB	ID	DM1A0VB
DM1A0VB	DN	Pyrrole six-membered heteroaryl ring derivative 1
DM1A0VB	HS	Patented
DM1A0VB	SN	PMID27774822-Compound-Figure1Example6
DM1A0VB	CP	JIANGSU HENGRUI MEDICINE CO [CNSHANGHAI HENGRUI PHARM CO LTD [CN]
DM1A0VB	DT	Small molecular drug

DMJK98Z	ID	DMJK98Z
DMJK98Z	DN	Pyrrolidine carboxamide derivative 1
DMJK98Z	HS	Patented
DMJK98Z	SN	PMID26882240-Compound-22
DMJK98Z	CP	YALE UNIVERSITY GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED CAMBRIDGE ENTERPRISE LIMITED UNIVERSITY OF CAMBRIDGE
DMJK98Z	DT	Small molecular drug
DMJK98Z	PC	56684144
DMJK98Z	MW	410.4
DMJK98Z	FM	C21H22N4O5
DMJK98Z	IC	InChI=1S/C21H22N4O5/c1-13-6-17(30-24-13)8-20(27)25-11-16(26)7-18(25)21(28)23-9-14-2-4-15(5-3-14)19-10-22-12-29-19/h2-6,10,12,16,18,26H,7-9,11H2,1H3,(H,23,28)/t16-,18+/m1/s1
DMJK98Z	CS	CC1=NOC(=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)NCC3=CC=C(C=C3)C4=CN=CO4)O
DMJK98Z	IK	HFCLIEBJTGJKSV-AEFFLSMTSA-N
DMJK98Z	IU	(2S,4R)-4-hydroxy-1-[2-(3-methyl-1,2-oxazol-5-yl)acetyl]-N-[[4-(1,3-oxazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide

DMKDX6W	ID	DMKDX6W
DMKDX6W	DN	Pyrrolidine carboxamide derivative 2
DMKDX6W	HS	Patented
DMKDX6W	SN	PMID28699813-Compound-19
DMKDX6W	CP	MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMKDX6W	DT	Small molecular drug
DMKDX6W	PC	54670732
DMKDX6W	MW	559.1
DMKDX6W	FM	C30H34ClF3N4O
DMKDX6W	IC	InChI=1S/C30H34ClF3N4O/c1-18-13-28(38(35-18)21-6-8-26(33)25(31)15-21)19-9-11-36(12-10-19)29(39)24-17-37(30(2,3)4)16-23(24)22-7-5-20(32)14-27(22)34/h5-8,13-15,19,23-24H,9-12,16-17H2,1-4H3/t23-,24+/m0/s1
DMKDX6W	CS	CC1=NN(C(=C1)C2CCN(CC2)C(=O)[C@@H]3CN(C[C@H]3C4=C(C=C(C=C4)F)F)C(C)(C)C)C5=CC(=C(C=C5)F)Cl
DMKDX6W	IK	UGINLDOCQNRWSG-BJKOFHAPSA-N
DMKDX6W	IU	[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]-[4-[2-(3-chloro-4-fluorophenyl)-5-methylpyrazol-3-yl]piperidin-1-yl]methanone

DMXALJE	ID	DMXALJE
DMXALJE	DN	Pyrrolidine derivative 1
DMXALJE	HS	Patented
DMXALJE	SN	PMID28067079-Compound-29
DMXALJE	CP	HUA MEDICINE (SHANGHAI) LTD
DMXALJE	DT	Small molecular drug
DMXALJE	PC	86291149
DMXALJE	MW	300.8
DMXALJE	FM	C17H14ClFN2
DMXALJE	IC	InChI=1S/C17H14ClFN2/c18-14-4-3-6-16(12-14)21-11-9-17(19,13-21)8-7-15-5-1-2-10-20-15/h1-6,10,12H,9,11,13H2
DMXALJE	CS	C1CN(CC1(C#CC2=CC=CC=N2)F)C3=CC(=CC=C3)Cl
DMXALJE	IK	AHSZAMGYMLYSLL-UHFFFAOYSA-N
DMXALJE	IU	2-[2-[1-(3-chlorophenyl)-3-fluoropyrrolidin-3-yl]ethynyl]pyridine

DMCQN5M	ID	DMCQN5M
DMCQN5M	DN	Pyrrolidine derivative 10
DMCQN5M	HS	Patented
DMCQN5M	SN	PMID28906174-Compound-Figure1c
DMCQN5M	CP	Obseva SA
DMCQN5M	DT	Small molecular drug

DMIHRV9	ID	DMIHRV9
DMIHRV9	DN	Pyrrolidine derivative 11
DMIHRV9	HS	Patented
DMIHRV9	SN	PMID28906174-Compound-Figure1d
DMIHRV9	CP	Obseva SA
DMIHRV9	DT	Small molecular drug

DMXO8R5	ID	DMXO8R5
DMXO8R5	DN	Pyrrolidine derivative 12
DMXO8R5	HS	Patented
DMXO8R5	SN	PMID28906174-Compound-Figure1e
DMXO8R5	CP	Obseva SA
DMXO8R5	DT	Small molecular drug

DM3VA8P	ID	DM3VA8P
DM3VA8P	DN	Pyrrolidine derivative 13
DM3VA8P	HS	Patented
DM3VA8P	SN	PMID28906174-Compound-Figure1f
DM3VA8P	CP	Obseva SA
DM3VA8P	DT	Small molecular drug

DM5WA29	ID	DM5WA29
DM5WA29	DN	Pyrrolidine derivative 2
DM5WA29	HS	Patented
DM5WA29	SN	PMID28067079-Compound-30
DM5WA29	CP	HUA MEDICINE (SHANGHAI) LTD
DM5WA29	DT	Small molecular drug
DM5WA29	PC	86291200
DM5WA29	MW	291.3
DM5WA29	FM	C18H14FN3
DM5WA29	IC	InChI=1S/C18H14FN3/c19-18(8-7-16-5-1-2-10-21-16)9-11-22(14-18)17-6-3-4-15(12-17)13-20/h1-6,10,12H,9,11,14H2
DM5WA29	CS	C1CN(CC1(C#CC2=CC=CC=N2)F)C3=CC=CC(=C3)C#N
DM5WA29	IK	NHUYADGCDLCNRQ-UHFFFAOYSA-N
DM5WA29	IU	3-[3-fluoro-3-(2-pyridin-2-ylethynyl)pyrrolidin-1-yl]benzonitrile

DMHM8WJ	ID	DMHM8WJ
DMHM8WJ	DN	Pyrrolidine derivative 3
DMHM8WJ	HS	Patented
DMHM8WJ	SN	PMID28067079-Compound-31
DMHM8WJ	CP	HUA MEDICINE (SHANGHAI) LTD
DMHM8WJ	DT	Small molecular drug
DMHM8WJ	PC	90352795
DMHM8WJ	MW	344.4
DMHM8WJ	FM	C18H17FN2O2S
DMHM8WJ	IC	InChI=1S/C18H17FN2O2S/c1-24(22,23)17-7-4-6-16(13-17)21-12-10-18(19,14-21)9-8-15-5-2-3-11-20-15/h2-7,11,13H,10,12,14H2,1H3
DMHM8WJ	CS	CS(=O)(=O)C1=CC=CC(=C1)N2CCC(C2)(C#CC3=CC=CC=N3)F
DMHM8WJ	IK	FBIPFOUWZKBKQR-UHFFFAOYSA-N
DMHM8WJ	IU	2-[2-[3-fluoro-1-(3-methylsulfonylphenyl)pyrrolidin-3-yl]ethynyl]pyridine

DMZ2HBL	ID	DMZ2HBL
DMZ2HBL	DN	Pyrrolidine derivative 4
DMZ2HBL	HS	Patented
DMZ2HBL	SN	PMID28067079-Compound-32
DMZ2HBL	CP	HUA MEDICINE (SHANGHAI) LTD
DMZ2HBL	DT	Small molecular drug
DMZ2HBL	PC	86291361
DMZ2HBL	MW	274.33
DMZ2HBL	FM	C16H19FN2O
DMZ2HBL	IC	InChI=1S/C16H19FN2O/c1-2-3-7-15(20)19-12-10-16(17,13-19)9-8-14-6-4-5-11-18-14/h4-6,11H,2-3,7,10,12-13H2,1H3
DMZ2HBL	CS	CCCCC(=O)N1CCC(C1)(C#CC2=CC=CC=N2)F
DMZ2HBL	IK	HKFZZVZBEQGITN-UHFFFAOYSA-N
DMZ2HBL	IU	1-[3-fluoro-3-(2-pyridin-2-ylethynyl)pyrrolidin-1-yl]pentan-1-one

DM5NKXO	ID	DM5NKXO
DM5NKXO	DN	Pyrrolidine derivative 5
DM5NKXO	HS	Patented
DM5NKXO	SN	PMID28067079-Compound-33
DM5NKXO	CP	HUA MEDICINE (SHANGHAI) LTD
DM5NKXO	DT	Small molecular drug
DM5NKXO	PC	86291332
DM5NKXO	MW	290.33
DM5NKXO	FM	C16H19FN2O2
DM5NKXO	IC	InChI=1S/C16H19FN2O2/c1-2-3-12-21-15(20)19-11-9-16(17,13-19)8-7-14-6-4-5-10-18-14/h4-6,10H,2-3,9,11-13H2,1H3
DM5NKXO	CS	CCCCOC(=O)N1CCC(C1)(C#CC2=CC=CC=N2)F
DM5NKXO	IK	NCBPLEITPLWATL-UHFFFAOYSA-N
DM5NKXO	IU	butyl 3-fluoro-3-(2-pyridin-2-ylethynyl)pyrrolidine-1-carboxylate

DMJ3ZP2	ID	DMJ3ZP2
DMJ3ZP2	DN	Pyrrolidine derivative 6
DMJ3ZP2	HS	Patented
DMJ3ZP2	SN	PMID25828189-Compound-25
DMJ3ZP2	CP	SCHERING CORPORATION GILBERT, Eric, J. MILLER, Michael, W. DEMONG, Duane Eugene STAMFORD, Andrew, W. GREENLEE, William, J
DMJ3ZP2	DT	Small molecular drug

DMIOJD6	ID	DMIOJD6
DMIOJD6	DN	Pyrrolidine derivative 7
DMIOJD6	HS	Patented
DMIOJD6	SN	PMID25828189-Compound-26
DMIOJD6	CP	SCHERING CORPORATION GILBERT, Eric, J. MILLER, Michael, W. DEMONG, Duane Eugene STAMFORD, Andrew, W. GREENLEE, William, J
DMIOJD6	DT	Small molecular drug
DMIOJD6	PC	51042268
DMIOJD6	MW	591.5
DMIOJD6	FM	C33H32Cl2N2O4
DMIOJD6	IC	InChI=1S/C33H32Cl2N2O4/c1-20(21-3-5-22(6-4-21)33(40)36-12-11-32(38)39)37-19-27(26-14-28(34)18-29(35)15-26)17-31(37)25-8-7-24-16-30(41-2)10-9-23(24)13-25/h3-10,13-16,18,20,27,31H,11-12,17,19H2,1-2H3,(H,36,40)(H,38,39)/t20?,27-,31-/m1/s1
DMIOJD6	CS	CC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)N2C[C@@H](C[C@@H]2C3=CC4=C(C=C3)C=C(C=C4)OC)C5=CC(=CC(=C5)Cl)Cl
DMIOJD6	IK	MKGXNUKACRIFNF-JOPCKLHNSA-N
DMIOJD6	IU	3-[[4-[1-[(2R,4S)-4-(3,5-dichlorophenyl)-2-(6-methoxynaphthalen-2-yl)pyrrolidin-1-yl]ethyl]benzoyl]amino]propanoic acid

DMWPXJ5	ID	DMWPXJ5
DMWPXJ5	DN	Pyrrolidine derivative 8
DMWPXJ5	HS	Patented
DMWPXJ5	SN	PMID25828189-Compound-27
DMWPXJ5	CP	SCHERING CORPORATION GILBERT, Eric, J. MILLER, Michael, W. DEMONG, Duane Eugene STAMFORD, Andrew, W. GREENLEE, William, J
DMWPXJ5	DT	Small molecular drug
DMWPXJ5	PC	51042475
DMWPXJ5	MW	627.5
DMWPXJ5	FM	C31H28Cl2N2O6S
DMWPXJ5	IC	InChI=1S/C31H28Cl2N2O6S/c1-41-27-7-4-20-12-22(3-2-21(20)15-27)29-16-24(23-13-25(32)17-26(33)14-23)18-35(29)42(39,40)28-8-5-19(6-9-28)31(38)34-11-10-30(36)37/h2-9,12-15,17,24,29H,10-11,16,18H2,1H3,(H,34,38)(H,36,37)/t24-,29-/m1/s1
DMWPXJ5	CS	COC1=CC2=C(C=C1)C=C(C=C2)[C@H]3C[C@H](CN3S(=O)(=O)C4=CC=C(C=C4)C(=O)NCCC(=O)O)C5=CC(=CC(=C5)Cl)Cl
DMWPXJ5	IK	DOKNZWNPLZNQJB-FUFSCUOVSA-N
DMWPXJ5	IU	3-[[4-[(2R,4S)-4-(3,5-dichlorophenyl)-2-(6-methoxynaphthalen-2-yl)pyrrolidin-1-yl]sulfonylbenzoyl]amino]propanoic acid

DMZK658	ID	DMZK658
DMZK658	DN	Pyrrolidine derivative 9
DMZK658	HS	Patented
DMZK658	SN	PMID28906174-Compound-Figure1b
DMZK658	CP	Obseva SA
DMZK658	DT	Small molecular drug

DM7DF6Z	ID	DM7DF6Z
DM7DF6Z	DN	Pyrrolidinyl urea derivative 1
DM7DF6Z	HS	Patented
DM7DF6Z	SN	PMID26413912-Compound-52
DM7DF6Z	CP	JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. TICHENOR, Mark, S. MERIT, Jeffrey, E. HAWRYLUK, Natalie, A. CHAMBERS, Alison, L. KEITH, John, M
DM7DF6Z	DT	Small molecular drug
DM7DF6Z	PC	49839185
DM7DF6Z	MW	405.5
DM7DF6Z	FM	C24H24FN3O2
DM7DF6Z	IC	InChI=1S/C24H24FN3O2/c25-20-8-10-22(11-9-20)30-23-5-1-3-18(15-23)6-7-19-12-14-28(17-19)24(29)27-21-4-2-13-26-16-21/h1-5,8-11,13,15-16,19H,6-7,12,14,17H2,(H,27,29)
DM7DF6Z	CS	C1CN(CC1CCC2=CC(=CC=C2)OC3=CC=C(C=C3)F)C(=O)NC4=CN=CC=C4
DM7DF6Z	IK	BDZREAHMWOSTKO-UHFFFAOYSA-N
DM7DF6Z	IU	3-[2-[3-(4-fluorophenoxy)phenyl]ethyl]-N-pyridin-3-ylpyrrolidine-1-carboxamide

DMV6YXJ	ID	DMV6YXJ
DMV6YXJ	DN	Pyrrolidinyl urea derivative 10
DMV6YXJ	HS	Patented
DMV6YXJ	SN	PMID28270010-Compound-Figure12-6
DMV6YXJ	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMV6YXJ	DT	Small molecular drug
DMV6YXJ	PC	71041571
DMV6YXJ	MW	489.5
DMV6YXJ	FM	C24H26F3N5O3
DMV6YXJ	IC	InChI=1S/C24H26F3N5O3/c1-14-22(32(30-23(14)33)16-6-4-3-5-7-16)29-24(34)28-20-13-31(8-9-35-2)12-17(20)15-10-18(25)21(27)19(26)11-15/h3-7,10-11,17,20H,8-9,12-13H2,1-2H3,(H,30,33)(H2,28,29,34)/t17-,20+/m0/s1
DMV6YXJ	CS	CC1=C(N(NC1=O)C2=CC=CC=C2)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=C(C(=C4)F)F)F)CCOC
DMV6YXJ	IK	YWWGXKZIBWIKLW-FXAWDEMLSA-N
DMV6YXJ	IU	1-[(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl]-3-(4-methyl-5-oxo-2-phenyl-1H-pyrazol-3-yl)urea

DMWKSF3	ID	DMWKSF3
DMWKSF3	DN	Pyrrolidinyl urea derivative 11
DMWKSF3	HS	Patented
DMWKSF3	SN	PMID28270010-Compound-Figure12-7
DMWKSF3	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMWKSF3	DT	Small molecular drug
DMWKSF3	PC	118128775
DMWKSF3	MW	471.5
DMWKSF3	FM	C23H27F2N7O2
DMWKSF3	IC	InChI=1S/C23H27F2N7O2/c1-14-10-27-20(11-26-14)19-9-22(31(2)30-19)29-23(33)28-21-13-32(6-7-34-3)12-16(21)15-4-5-17(24)18(25)8-15/h4-5,8-11,16,21H,6-7,12-13H2,1-3H3,(H2,28,29,33)/t16-,21+/m0/s1
DMWKSF3	CS	CC1=CN=C(C=N1)C2=NN(C(=C2)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=C(C=C4)F)F)CCOC)C
DMWKSF3	IK	NPZQKAJVRDLUTI-HRAATJIYSA-N
DMWKSF3	IU	1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[2-methyl-5-(5-methylpyrazin-2-yl)pyrazol-3-yl]urea

DMJ6IE5	ID	DMJ6IE5
DMJ6IE5	DN	Pyrrolidinyl urea derivative 12
DMJ6IE5	HS	Patented
DMJ6IE5	SN	PMID28270010-Compound-Figure12-8
DMJ6IE5	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMJ6IE5	DT	Small molecular drug
DMJ6IE5	PC	71041077
DMJ6IE5	MW	529.6
DMJ6IE5	FM	C27H33F2N5O4
DMJ6IE5	IC	InChI=1S/C27H33F2N5O4/c1-33-26(15-24(32-33)18-4-7-20(8-5-18)38-13-12-37-3)31-27(35)30-25-17-34(10-11-36-2)16-21(25)19-6-9-22(28)23(29)14-19/h4-9,14-15,21,25H,10-13,16-17H2,1-3H3,(H2,30,31,35)/t21-,25+/m0/s1
DMJ6IE5	CS	CN1C(=CC(=N1)C2=CC=C(C=C2)OCCOC)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=C(C=C4)F)F)CCOC
DMJ6IE5	IK	JNRIBRHEHFYMHN-SQJMNOBHSA-N
DMJ6IE5	IU	1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[5-[4-(2-methoxyethoxy)phenyl]-2-methylpyrazol-3-yl]urea

DM3VL82	ID	DM3VL82
DM3VL82	DN	Pyrrolidinyl urea derivative 13
DM3VL82	HS	Patented
DM3VL82	SN	PMID28270010-Compound-Figure12-9
DM3VL82	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DM3VL82	DT	Small molecular drug
DM3VL82	PC	71471488
DM3VL82	MW	495.5
DM3VL82	FM	C25H27F2N7O2
DM3VL82	IC	InChI=1S/C25H27F2N7O2/c1-32-24(13-20(31-32)22-4-3-5-23-28-8-9-34(22)23)30-25(35)29-21-15-33(10-11-36-2)14-17(21)16-6-7-18(26)19(27)12-16/h3-9,12-13,17,21H,10-11,14-15H2,1-2H3,(H2,29,30,35)/t17-,21+/m0/s1
DM3VL82	CS	CN1C(=CC(=N1)C2=CC=CC3=NC=CN32)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DM3VL82	IK	SRPJIAHTEPDSEX-LAUBAEHRSA-N
DM3VL82	IU	1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-(5-imidazo[1,2-a]pyridin-5-yl-2-methylpyrazol-3-yl)urea

DMYFP95	ID	DMYFP95
DMYFP95	DN	Pyrrolidinyl urea derivative 2
DMYFP95	HS	Patented
DMYFP95	SN	PMID28270010-Compound-Figure12-1
DMYFP95	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMYFP95	DT	Small molecular drug
DMYFP95	PC	118129006
DMYFP95	MW	503.6
DMYFP95	FM	C28H33N5O4
DMYFP95	IC	InChI=1S/C28H33N5O4/c1-36-18-25(27(34)37-2)32-16-22(19-10-5-3-6-11-19)24(17-32)29-28(35)30-26-21-14-9-15-23(21)31-33(26)20-12-7-4-8-13-20/h3-8,10-13,22,24-25H,9,14-18H2,1-2H3,(H2,29,30,35)/t22-,24+,25?/m0/s1
DMYFP95	CS	COCC(C(=O)OC)N1C[C@H]([C@@H](C1)NC(=O)NC2=C3CCCC3=NN2C4=CC=CC=C4)C5=CC=CC=C5
DMYFP95	IK	JOOGNXILJRJIEZ-LNJIZIIWSA-N
DMYFP95	IU	methyl 3-methoxy-2-[(3R,4S)-3-phenyl-4-[(2-phenyl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)carbamoylamino]pyrrolidin-1-yl]propanoate

DMFDLHN	ID	DMFDLHN
DMFDLHN	DN	Pyrrolidinyl urea derivative 3
DMFDLHN	HS	Patented
DMFDLHN	SN	PMID28270010-Compound-Figure12-10
DMFDLHN	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMFDLHN	DT	Small molecular drug
DMFDLHN	PC	71040977
DMFDLHN	MW	553.6
DMFDLHN	FM	C28H30F3N7O2
DMFDLHN	IC	InChI=1S/C28H30F3N7O2/c1-17-26(19-13-32-36(2)14-19)35-38(21-7-5-20(29)6-8-21)27(17)34-28(39)33-25-16-37(10-11-40-3)15-22(25)18-4-9-23(30)24(31)12-18/h4-9,12-14,22,25H,10-11,15-16H2,1-3H3,(H2,33,34,39)/t22-,25+/m0/s1
DMFDLHN	CS	CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=C(C=C3)F)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DMFDLHN	IK	XWJMJPIDPZSDIR-WIOPSUGQSA-N
DMFDLHN	IU	1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[2-(4-fluorophenyl)-4-methyl-5-(1-methylpyrazol-4-yl)pyrazol-3-yl]urea

DM8SZKU	ID	DM8SZKU
DM8SZKU	DN	Pyrrolidinyl urea derivative 4
DM8SZKU	HS	Patented
DM8SZKU	SN	PMID28270010-Compound-Figure12-11
DM8SZKU	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DM8SZKU	DT	Small molecular drug
DM8SZKU	PC	71041118
DM8SZKU	MW	588
DM8SZKU	FM	C28H29ClF3N7O2
DM8SZKU	IC	InChI=1S/C28H29ClF3N7O2/c1-16-26(18-12-33-37(2)13-18)36-39(24-6-4-5-20(29)25(24)32)27(16)35-28(40)34-23-15-38(9-10-41-3)14-19(23)17-7-8-21(30)22(31)11-17/h4-8,11-13,19,23H,9-10,14-15H2,1-3H3,(H2,34,35,40)/t19-,23+/m0/s1
DM8SZKU	CS	CC1=C(N(N=C1C2=CN(N=C2)C)C3=C(C(=CC=C3)Cl)F)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DM8SZKU	IK	RFVRMWNCZARMFM-WMZHIEFXSA-N
DM8SZKU	IU	1-[2-(3-chloro-2-fluorophenyl)-4-methyl-5-(1-methylpyrazol-4-yl)pyrazol-3-yl]-3-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]urea

DMU51T4	ID	DMU51T4
DMU51T4	DN	Pyrrolidinyl urea derivative 5
DMU51T4	HS	Patented
DMU51T4	SN	PMID28270010-Compound-Figure12-12
DMU51T4	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMU51T4	DT	Small molecular drug
DMU51T4	PC	71041284
DMU51T4	MW	554.6
DMU51T4	FM	C27H29F3N8O2
DMU51T4	IC	InChI=1S/C27H29F3N8O2/c1-16-25(18-10-32-36(2)13-18)35-38(20-9-19(28)11-31-12-20)26(16)34-27(39)33-24-15-37(6-7-40-3)14-21(24)17-4-5-22(29)23(30)8-17/h4-5,8-13,21,24H,6-7,14-15H2,1-3H3,(H2,33,34,39)/t21-,24+/m0/s1
DMU51T4	CS	CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC(=CN=C3)F)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DMU51T4	IK	UNGZVJKZTCHIBB-XUZZJYLKSA-N
DMU51T4	IU	1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[2-(5-fluoropyridin-3-yl)-4-methyl-5-(1-methylpyrazol-4-yl)pyrazol-3-yl]urea

DM01GEB	ID	DM01GEB
DM01GEB	DN	Pyrrolidinyl urea derivative 6
DM01GEB	HS	Patented
DM01GEB	SN	PMID28270010-Compound-Figure12-2
DM01GEB	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DM01GEB	DT	Small molecular drug
DM01GEB	PC	118128873
DM01GEB	MW	499.5
DM01GEB	FM	C26H28F3N5O2
DM01GEB	IC	InChI=1S/C26H28F3N5O2/c27-26(28,29)36-15-14-33-16-21(18-8-3-1-4-9-18)23(17-33)30-25(35)31-24-20-12-7-13-22(20)32-34(24)19-10-5-2-6-11-19/h1-6,8-11,21,23H,7,12-17H2,(H2,30,31,35)/t21-,23+/m0/s1
DM01GEB	CS	C1CC2=C(N(N=C2C1)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC=CC=C5)CCOC(F)(F)F
DM01GEB	IK	AMRJQXCVKABTNA-JTHBVZDNSA-N
DM01GEB	IU	1-(2-phenyl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)-3-[(3S,4R)-4-phenyl-1-[2-(trifluoromethoxy)ethyl]pyrrolidin-3-yl]urea

DMYADJP	ID	DMYADJP
DMYADJP	DN	Pyrrolidinyl urea derivative 7
DMYADJP	HS	Patented
DMYADJP	SN	PMID28270010-Compound-Figure12-3
DMYADJP	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMYADJP	DT	Small molecular drug
DMYADJP	PC	118128612
DMYADJP	MW	469.5
DMYADJP	FM	C25H26F3N5O
DMYADJP	IC	InChI=1S/C25H26F3N5O/c26-25(27,28)16-32-14-20(17-8-3-1-4-9-17)22(15-32)29-24(34)30-23-19-12-7-13-21(19)31-33(23)18-10-5-2-6-11-18/h1-6,8-11,20,22H,7,12-16H2,(H2,29,30,34)/t20-,22+/m0/s1
DMYADJP	CS	C1CC2=C(N(N=C2C1)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC=CC=C5)CC(F)(F)F
DMYADJP	IK	AFWYYOYVHRLTSQ-RBBKRZOGSA-N
DMYADJP	IU	1-(2-phenyl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)-3-[(3S,4R)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]urea

DMW2JG8	ID	DMW2JG8
DMW2JG8	DN	Pyrrolidinyl urea derivative 8
DMW2JG8	HS	Patented
DMW2JG8	SN	PMID28270010-Compound-Figure12-4
DMW2JG8	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMW2JG8	DT	Small molecular drug
DMW2JG8	PC	71041580
DMW2JG8	MW	453.5
DMW2JG8	FM	C24H28FN5O3
DMW2JG8	IC	InChI=1S/C24H28FN5O3/c1-16-22(30(28-23(16)31)19-9-4-3-5-10-19)27-24(32)26-21-15-29(11-12-33-2)14-20(21)17-7-6-8-18(25)13-17/h3-10,13,20-21H,11-12,14-15H2,1-2H3,(H,28,31)(H2,26,27,32)/t20-,21+/m0/s1
DMW2JG8	CS	CC1=C(N(NC1=O)C2=CC=CC=C2)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=CC=C4)F)CCOC
DMW2JG8	IK	HIHSIUUJZCQIBY-LEWJYISDSA-N
DMW2JG8	IU	1-[(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-(4-methyl-5-oxo-2-phenyl-1H-pyrazol-3-yl)urea

DMO1I4W	ID	DMO1I4W
DMO1I4W	DN	Pyrrolidinyl urea derivative 9
DMO1I4W	HS	Patented
DMO1I4W	SN	PMID28270010-Compound-Figure12-5
DMO1I4W	CP	ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMO1I4W	DT	Small molecular drug
DMO1I4W	PC	118128691
DMO1I4W	MW	488
DMO1I4W	FM	C24H27ClFN5O3
DMO1I4W	IC	InChI=1S/C24H27ClFN5O3/c1-15-22(31(29-23(15)32)17-6-4-3-5-7-17)28-24(33)27-21-14-30(10-11-34-2)13-18(21)16-8-9-20(26)19(25)12-16/h3-9,12,18,21H,10-11,13-14H2,1-2H3,(H,29,32)(H2,27,28,33)/t18-,21+/m0/s1
DMO1I4W	CS	CC1=C(N(NC1=O)C2=CC=CC=C2)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=C(C=C4)F)Cl)CCOC
DMO1I4W	IK	GIFBEFSILNFYRM-GHTZIAJQSA-N
DMO1I4W	IU	1-[(3S,4R)-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-(4-methyl-5-oxo-2-phenyl-1H-pyrazol-3-yl)urea

DM5RCW8	ID	DM5RCW8
DM5RCW8	DN	Pyrrolo[1,2-c]pyrazole derivative 1
DM5RCW8	HS	Patented
DM5RCW8	SN	PMID29473428-Compound-49
DM5RCW8	CP	EMCURE PHARMACEUTICALS LIMITED
DM5RCW8	DT	Small molecular drug

DMI0AW7	ID	DMI0AW7
DMI0AW7	DN	Pyrrolo[1,2-f]triazine derivative 1
DMI0AW7	HS	Patented
DMI0AW7	SN	PMID25482888-Compound-62
DMI0AW7	DT	Small molecular drug

DM7DU9P	ID	DM7DU9P
DM7DU9P	DN	Pyrrolo[1,2-f]triazine derivative 2
DM7DU9P	HS	Patented
DM7DU9P	SN	PMID25482888-Compound-63
DM7DU9P	DT	Small molecular drug
DM7DU9P	PC	86301498
DM7DU9P	MW	517.6
DM7DU9P	FM	C26H27N7O3S
DM7DU9P	IC	InChI=1S/C26H27N7O3S/c1-18-8-10-23(11-9-18)37(35,36)30-22-13-24-25(34)32(15-20-6-3-2-5-19(20)14-27)26(29-33(24)17-22)31-12-4-7-21(28)16-31/h2-3,5-6,8-11,13,17,21,30H,4,7,12,15-16,28H2,1H3/t21-/m1/s1
DM7DU9P	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=CN3C(=C2)C(=O)N(C(=N3)N4CCC[C@H](C4)N)CC5=CC=CC=C5C#N
DM7DU9P	IK	ZYJICIOJMGMKDZ-OAQYLSRUSA-N
DM7DU9P	IU	N-[2-[(3R)-3-aminopiperidin-1-yl]-3-[(2-cyanophenyl)methyl]-4-oxopyrrolo[2,1-f][1,2,4]triazin-6-yl]-4-methylbenzenesulfonamide

DMWXZBF	ID	DMWXZBF
DMWXZBF	DN	Pyrrolo[2,3-b]pyridine carboxamide derivative 1
DMWXZBF	HS	Patented
DMWXZBF	SN	PMID25656651-Compound-17
DMWXZBF	CP	IRM LLC REN, Pingda WANG, Xia JIANG, Songchun NAGLE, Advait OKRAM, Barun HE, Yun XIE, Yongping WANG, Xing HUANG, Shenlin WANG, Xiaodong LIU, Yi ALBAUGH, Pamela, A. GRAY, Nathanael, S. ZHANG, Guobao
DMWXZBF	DT	Small molecular drug
DMWXZBF	PC	25123000
DMWXZBF	MW	424.4
DMWXZBF	FM	C22H15F3N4O2
DMWXZBF	IC	InChI=1S/C22H15F3N4O2/c23-22(24,25)14-4-1-3-13(11-14)20(30)28-15-5-2-6-16(12-15)29-21(31)18-8-10-27-19-17(18)7-9-26-19/h1-12H,(H,26,27)(H,28,30)(H,29,31)
DMWXZBF	CS	C1=CC(=CC(=C1)C(F)(F)F)C(=O)NC2=CC(=CC=C2)NC(=O)C3=C4C=CNC4=NC=C3
DMWXZBF	IK	NFUORXLZMPSICI-UHFFFAOYSA-N
DMWXZBF	IU	N-[3-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-1H-pyrrolo[2,3-b]pyridine-4-carboxamide

DMVKCQU	ID	DMVKCQU
DMVKCQU	DN	Pyrrolo[2,3-b]pyridine derivative 1
DMVKCQU	HS	Patented
DMVKCQU	SN	PMID28270021-Compound-WO2008063888P-0171
DMVKCQU	CP	PLEXXIKON, INC. ZHANG, Chao ZHANG, Jiazhong IBRAHIM, Prabha N. ARTIS, Dean R. BREMER, Ryan WU, Guoxian ZHU, Hongyao NESPI, Marika
DMVKCQU	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM7IPWB	ID	DM7IPWB
DM7IPWB	DN	Pyrrolo[2,3-b]pyridine derivative 2
DM7IPWB	HS	Patented
DM7IPWB	SN	PMID28270021-Compound-WO2008063888P-0180
DM7IPWB	CP	PLEXXIKON, INC. ZHANG, Chao ZHANG, Jiazhong IBRAHIM, Prabha N. ARTIS, Dean R. BREMER, Ryan WU, Guoxian ZHU, Hongyao NESPI, Marika
DM7IPWB	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMCYOL7	ID	DMCYOL7
DMCYOL7	DN	Pyrrolo[2,3-b]pyridine derivative 3
DMCYOL7	HS	Patented
DMCYOL7	SN	PMID28270021-Compound-WO2010129570P-2061
DMCYOL7	CP	PLEXXIKON, INC. VISOR, Gary Conard IBRAHIM, Prabha N. SPEVAK, Wayne CHO, Hanna SHI, Songyuan WU, Guoxian
DMCYOL7	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMJBTZG	ID	DMJBTZG
DMJBTZG	DN	Pyrrolo[2,3-b]pyridine derivative 4
DMJBTZG	HS	Patented
DMJBTZG	SN	PMID25656651-Compound-24
DMJBTZG	CP	NOVA DECISION [FRAZASYNTH [FR]
DMJBTZG	DT	Small molecular drug
DMJBTZG	PC	89899422
DMJBTZG	MW	349.31
DMJBTZG	FM	C17H14F3N3O2
DMJBTZG	IC	InChI=1S/C17H14F3N3O2/c1-25-16(24)14-7-11-6-12(9-22-15(11)23-14)21-8-10-4-2-3-5-13(10)17(18,19)20/h2-7,9,21H,8H2,1H3,(H,22,23)
DMJBTZG	CS	COC(=O)C1=CC2=CC(=CN=C2N1)NCC3=CC=CC=C3C(F)(F)F
DMJBTZG	IK	MFAPLYWBOUSVJJ-UHFFFAOYSA-N
DMJBTZG	IU	methyl 5-[[2-(trifluoromethyl)phenyl]methylamino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate

DMYUEA6	ID	DMYUEA6
DMYUEA6	DN	Pyrrolo[2,3-d]pyrimidine derivative 1
DMYUEA6	HS	Patented
DMYUEA6	SN	PMID27410995-Compound-Figure3i
DMYUEA6	DT	Small molecular drug

DMRWG2E	ID	DMRWG2E
DMRWG2E	DN	Pyrrolo[2,3-d]pyrimidine derivative 10
DMRWG2E	HS	Patented
DMRWG2E	SN	PMID26161698-Compound-2
DMRWG2E	CP	NOVARTIS AG BRAIN, Christopher, Thomas CHO, Young Shin GIRALDES, John, William LAGU, Bharat LEVELL, Julian LUZZIO, Michael PEREZ, Lawrence, Blas WANG, Yaping YANG, Fan
DMRWG2E	DT	Small molecular drug
DMRWG2E	PC	53378895
DMRWG2E	MW	552.7
DMRWG2E	FM	C31H36N8O2
DMRWG2E	IC	InChI=1S/C31H36N8O2/c1-31(2,3)21-7-11-24(12-8-21)39-25(29(41)37(4)5)14-20-16-33-30(36-27(20)39)35-26-13-6-19(15-32-26)28(40)38-17-22-9-10-23(18-38)34-22/h6-8,11-16,22-23,34H,9-10,17-18H2,1-5H3,(H,32,33,35,36)
DMRWG2E	CS	CC(C)(C)C1=CC=C(C=C1)N2C(=CC3=CN=C(N=C32)NC4=NC=C(C=C4)C(=O)N5CC6CCC(C5)N6)C(=O)N(C)C
DMRWG2E	IK	VTSDFHMWTKRCAL-UHFFFAOYSA-N
DMRWG2E	IU	7-(4-tert-butylphenyl)-2-[[5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-yl]amino]-N,N-dimethylpyrrolo[2,3-d]pyrimidine-6-carboxamide

DM983CY	ID	DM983CY
DM983CY	DN	Pyrrolo[2,3-d]pyrimidine derivative 11
DM983CY	HS	Patented
DM983CY	SN	PMID27774824-Compound-Figure13Example25
DM983CY	CP	INCYTE CORPORATION
DM983CY	DT	Small molecular drug

DMYTV49	ID	DMYTV49
DMYTV49	DN	Pyrrolo[2,3-d]pyrimidine derivative 12
DMYTV49	HS	Patented
DMYTV49	SN	PMID28705083-Compound-10
DMYTV49	CP	PHARMACYCLICS, INC. CHEN, Wei LOURY, David, J. MODY, Tarak, D. WANG, Longcheng
DMYTV49	DT	Small molecular drug
DMYTV49	PC	71217672
DMYTV49	MW	544.6
DMYTV49	FM	C33H32N6O2
DMYTV49	IC	InChI=1S/C33H32N6O2/c1-37(24-15-16-24)19-7-12-30(40)38(2)25-8-6-9-26(20-25)39-21-29(31-32(34)35-22-36-33(31)39)23-13-17-28(18-14-23)41-27-10-4-3-5-11-27/h3-14,17-18,20-22,24H,15-16,19H2,1-2H3,(H2,34,35,36)/b12-7+
DMYTV49	CS	CN(C/C=C/C(=O)N(C)C1=CC=CC(=C1)N2C=C(C3=C(N=CN=C32)N)C4=CC=C(C=C4)OC5=CC=CC=C5)C6CC6
DMYTV49	IK	NARJNVJAUDCMNV-KPKJPENVSA-N
DMYTV49	IU	(E)-N-[3-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]-4-[cyclopropyl(methyl)amino]-N-methylbut-2-enamide

DMTGELI	ID	DMTGELI
DMTGELI	DN	Pyrrolo[2,3-d]pyrimidine derivative 13
DMTGELI	HS	Patented
DMTGELI	SN	PMID28705083-Compound-11
DMTGELI	CP	PHARMACYCLICS, INC. CHEN, Wei LOURY, David, J. MODY, Tarak, D. WANG, Longcheng
DMTGELI	DT	Small molecular drug
DMTGELI	PC	71208697
DMTGELI	MW	482.6
DMTGELI	FM	C28H30N6O2
DMTGELI	IC	InChI=1S/C28H30N6O2/c1-32(2)15-6-9-25(35)33-16-14-21(17-33)34-18-24(26-27(29)30-19-31-28(26)34)20-10-12-23(13-11-20)36-22-7-4-3-5-8-22/h3-13,18-19,21H,14-17H2,1-2H3,(H2,29,30,31)/b9-6+
DMTGELI	CS	CN(C)C/C=C/C(=O)N1CCC(C1)N2C=C(C3=C(N=CN=C32)N)C4=CC=C(C=C4)OC5=CC=CC=C5
DMTGELI	IK	QKYMWVAQZSLTKG-RMKNXTFCSA-N
DMTGELI	IU	(E)-1-[3-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]pyrrolidin-1-yl]-4-(dimethylamino)but-2-en-1-one

DMK4LOH	ID	DMK4LOH
DMK4LOH	DN	Pyrrolo[2,3-d]pyrimidine derivative 14
DMK4LOH	HS	Patented
DMK4LOH	SN	PMID28705083-Compound-12
DMK4LOH	CP	PHARMACYCLICS, INC
DMK4LOH	DT	Small molecular drug
DMK4LOH	PC	71263162
DMK4LOH	MW	470.6
DMK4LOH	FM	C27H30N6O2
DMK4LOH	IC	InChI=1S/C27H30N6O2/c1-18-11-12-19(14-23(18)35-5)22-16-33(27-25(22)26(28)29-17-30-27)21-9-6-8-20(15-21)32(4)24(34)10-7-13-31(2)3/h6-12,14-17H,13H2,1-5H3,(H2,28,29,30)/b10-7+
DMK4LOH	CS	CC1=C(C=C(C=C1)C2=CN(C3=NC=NC(=C23)N)C4=CC(=CC=C4)N(C)C(=O)/C=C/CN(C)C)OC
DMK4LOH	IK	XIEVUMXHZAXKDT-JXMROGBWSA-N
DMK4LOH	IU	(E)-N-[3-[4-amino-5-(3-methoxy-4-methylphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]-4-(dimethylamino)-N-methylbut-2-enamide

DMZ4PLC	ID	DMZ4PLC
DMZ4PLC	DN	Pyrrolo[2,3-d]pyrimidine derivative 15
DMZ4PLC	HS	Patented
DMZ4PLC	SN	PMID28705083-Compound-13
DMZ4PLC	CP	PHARMACYCLICS, INC
DMZ4PLC	DT	Small molecular drug

DM1GYZQ	ID	DM1GYZQ
DM1GYZQ	DN	Pyrrolo[2,3-d]pyrimidine derivative 16
DM1GYZQ	HS	Patented
DM1GYZQ	SN	PMID28705083-Compound-14
DM1GYZQ	CP	PRINCIPIA BIOPHARMA INCPRINCIPIA BIOPHARMA INC. GOLDSTEIN, David Michael BRAMELD, Kenneth Albert
DM1GYZQ	DT	Small molecular drug
DM1GYZQ	PC	89188538
DM1GYZQ	MW	504.6
DM1GYZQ	FM	C30H28N6O2
DM1GYZQ	IC	InChI=1S/C30H28N6O2/c31-16-22(15-20-8-9-20)30(37)35-14-4-5-23(17-35)36-18-26(27-28(32)33-19-34-29(27)36)21-10-12-25(13-11-21)38-24-6-2-1-3-7-24/h1-3,6-7,10-13,15,18-20,23H,4-5,8-9,14,17H2,(H2,32,33,34)/b22-15-
DM1GYZQ	CS	C1CC(CN(C1)C(=O)/C(=C\\C2CC2)/C#N)N3C=C(C4=C(N=CN=C43)N)C5=CC=C(C=C5)OC6=CC=CC=C6
DM1GYZQ	IK	QBWDAFICRCELKK-JCMHNJIXSA-N
DM1GYZQ	IU	(Z)-2-[3-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carbonyl]-3-cyclopropylprop-2-enenitrile
DM1GYZQ	DE	Solid tumour/cancer; Autoimmune disease

DMXWVN2	ID	DMXWVN2
DMXWVN2	DN	Pyrrolo[2,3-d]pyrimidine derivative 17
DMXWVN2	HS	Patented
DMXWVN2	SN	PMID28705083-Compound-15
DMXWVN2	CP	PRINCIPIA BIOPHARMA INCPRINCIPIA BIOPHARMA INC. GOLDSTEIN, David Michael BRAMELD, Kenneth Albert
DMXWVN2	DT	Small molecular drug
DMXWVN2	PC	90002026
DMXWVN2	MW	549.7
DMXWVN2	FM	C32H35N7O2
DMXWVN2	IC	InChI=1S/C32H35N7O2/c1-32(2,37(3)4)17-23(18-33)31(40)39-16-8-9-24(39)19-38-20-27(28-29(34)35-21-36-30(28)38)22-12-14-26(15-13-22)41-25-10-6-5-7-11-25/h5-7,10-15,17,20-21,24H,8-9,16,19H2,1-4H3,(H2,34,35,36)/b23-17+
DMXWVN2	CS	CC(C)(/C=C(\\C#N)/C(=O)N1CCCC1CN2C=C(C3=C(N=CN=C32)N)C4=CC=C(C=C4)OC5=CC=CC=C5)N(C)C
DMXWVN2	IK	BJBBMHJDZCVALB-HAVVHWLPSA-N
DMXWVN2	IU	(E)-2-[2-[[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]methyl]pyrrolidine-1-carbonyl]-4-(dimethylamino)-4-methylpent-2-enenitrile
DMXWVN2	DE	Solid tumour/cancer; Autoimmune disease

DMSXH8K	ID	DMSXH8K
DMSXH8K	DN	Pyrrolo[2,3-d]pyrimidine derivative 18
DMSXH8K	HS	Patented
DMSXH8K	SN	PMID28705083-Compound-16
DMSXH8K	CP	ADVINUS THERAPEUTICS LIMITED
DMSXH8K	DT	Small molecular drug
DMSXH8K	PC	71760910
DMSXH8K	MW	556.7
DMSXH8K	FM	C34H32N6O2
DMSXH8K	IC	InChI=1S/C34H32N6O2/c1-21-27(3-2-4-29(21)39-33(41)25-11-7-23(8-12-25)22-5-6-22)31-28-19-30(38-32(28)37-20-36-31)24-9-13-26(14-10-24)34(42)40-17-15-35-16-18-40/h2-4,7-14,19-20,22,35H,5-6,15-18H2,1H3,(H,39,41)(H,36,37,38)
DMSXH8K	CS	CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C3CC3)C4=C5C=C(NC5=NC=N4)C6=CC=C(C=C6)C(=O)N7CCNCC7
DMSXH8K	IK	JIGUYYJYCISLMS-UHFFFAOYSA-N
DMSXH8K	IU	4-cyclopropyl-N-[2-methyl-3-[6-[4-(piperazine-1-carbonyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]benzamide

DMC9TGM	ID	DMC9TGM
DMC9TGM	DN	Pyrrolo[2,3-d]pyrimidine derivative 19
DMC9TGM	HS	Patented
DMC9TGM	SN	PMID28705083-Compound-17
DMC9TGM	CP	ADVINUS THERAPEUTICS LIMITED
DMC9TGM	DT	Small molecular drug
DMC9TGM	PC	72193305
DMC9TGM	MW	597.7
DMC9TGM	FM	C36H35N7O2
DMC9TGM	IC	InChI=1S/C36H35N7O2/c1-41-13-15-42(16-14-41)20-23-5-7-25(8-6-23)32-18-30-34(37-22-38-35(30)40-32)29-3-2-4-33(31(29)21-44)43-36(45)28-12-11-26(24-9-10-24)17-27(28)19-39-43/h2-8,11-12,17-19,22,24,44H,9-10,13-16,20-21H2,1H3,(H,37,38,40)
DMC9TGM	CS	CN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(N=CN=C4N3)C5=C(C(=CC=C5)N6C(=O)C7=C(C=C(C=C7)C8CC8)C=N6)CO
DMC9TGM	IK	HPYIZQVYHGPMDT-UHFFFAOYSA-N
DMC9TGM	IU	6-cyclopropyl-2-[2-(hydroxymethyl)-3-[6-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]phthalazin-1-one

DMJFYK1	ID	DMJFYK1
DMJFYK1	DN	Pyrrolo[2,3-d]pyrimidine derivative 2
DMJFYK1	HS	Patented
DMJFYK1	SN	PMID27410995-Compound-Figure3g
DMJFYK1	DT	Small molecular drug

DM2E7DJ	ID	DM2E7DJ
DM2E7DJ	DN	Pyrrolo[2,3-d]pyrimidine derivative 20
DM2E7DJ	HS	Patented
DM2E7DJ	SN	PMID28705083-Compound-18
DM2E7DJ	CP	ADVINUS THERAPEUTICS LIMITED
DM2E7DJ	DT	Small molecular drug
DM2E7DJ	PC	72188716
DM2E7DJ	MW	614.7
DM2E7DJ	FM	C37H38N6O3
DM2E7DJ	IC	InChI=1S/C37H38N6O3/c1-41-13-15-42(16-14-41)21-24-5-7-26(8-6-24)32-20-30-35(38-23-39-36(30)40-32)28-3-2-4-33(31(28)22-44)43-17-18-46-34-19-27(25-9-10-25)11-12-29(34)37(43)45/h2-8,11-12,19-20,23,25,44H,9-10,13-18,21-22H2,1H3,(H,38,39,40)
DM2E7DJ	CS	CN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(N=CN=C4N3)C5=C(C(=CC=C5)N6CCOC7=C(C6=O)C=CC(=C7)C8CC8)CO
DM2E7DJ	IK	AYQKNTPWCXIAQQ-UHFFFAOYSA-N
DM2E7DJ	IU	8-cyclopropyl-4-[2-(hydroxymethyl)-3-[6-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one

DM9S07A	ID	DM9S07A
DM9S07A	DN	Pyrrolo[2,3-d]pyrimidine derivative 21
DM9S07A	HS	Patented
DM9S07A	SN	PMID28705083-Compound-19
DM9S07A	DT	Small molecular drug
DM9S07A	PC	117934513
DM9S07A	MW	647.7
DM9S07A	FM	C36H34FN7O4
DM9S07A	IC	InChI=1S/C36H34FN7O4/c1-2-32(46)42-10-4-5-24(18-42)44-17-23(16-40-44)29-15-26-34(38-20-39-35(26)41-29)25-6-3-7-30(27(25)19-45)43-11-12-48-31-14-22(21-8-9-21)13-28(37)33(31)36(43)47/h2-3,6-7,13-17,20-21,24,45H,1,4-5,8-12,18-19H2,(H,38,39,41)
DM9S07A	CS	C=CC(=O)N1CCCC(C1)N2C=C(C=N2)C3=CC4=C(N=CN=C4N3)C5=C(C(=CC=C5)N6CCOC7=C(C6=O)C(=CC(=C7)C8CC8)F)CO
DM9S07A	IK	SGCPAQMSTLOCLE-UHFFFAOYSA-N
DM9S07A	IU	8-cyclopropyl-6-fluoro-4-[2-(hydroxymethyl)-3-[6-[1-(1-prop-2-enoylpiperidin-3-yl)pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one

DMHWNSD	ID	DMHWNSD
DMHWNSD	DN	Pyrrolo[2,3-d]pyrimidine derivative 22
DMHWNSD	HS	Patented
DMHWNSD	SN	PMID28705083-Compound-20
DMHWNSD	DT	Small molecular drug
DMHWNSD	PC	117926799
DMHWNSD	MW	719.7
DMHWNSD	FM	C37H34F5N7O3
DMHWNSD	IC	InChI=1S/C37H34F5N7O3/c38-24-13-25(27(18-50)31(14-24)49-9-10-52-32-12-23(22-2-3-22)11-28(39)33(32)36(49)51)34-26-15-30(46-35(26)45-20-44-34)29-4-1-21(16-43-29)17-47-5-7-48(8-6-47)19-37(40,41)42/h1,4,11-16,20,22,50H,2-3,5-10,17-19H2,(H,44,45,46)
DMHWNSD	CS	C1CC1C2=CC3=C(C(=C2)F)C(=O)N(CCO3)C4=CC(=CC(=C4CO)C5=C6C=C(NC6=NC=N5)C7=NC=C(C=C7)CN8CCN(CC8)CC(F)(F)F)F
DMHWNSD	IK	TYFKEORPONMRPY-UHFFFAOYSA-N
DMHWNSD	IU	8-cyclopropyl-6-fluoro-4-[5-fluoro-2-(hydroxymethyl)-3-[6-[5-[[4-(2,2,2-trifluoroethyl)piperazin-1-yl]methyl]pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one

DMTMWKX	ID	DMTMWKX
DMTMWKX	DN	Pyrrolo[2,3-d]pyrimidine derivative 23
DMTMWKX	HS	Patented
DMTMWKX	SN	PMID28705083-Compound-21
DMTMWKX	CP	ACEA BIOSCIENCES INC
DMTMWKX	DT	Small molecular drug
DMTMWKX	PC	72734520
DMTMWKX	MW	487.5
DMTMWKX	FM	C26H26FN7O2
DMTMWKX	IC	InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
DMTMWKX	CS	CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F
DMTMWKX	IK	UOFYSRZSLXWIQB-UHFFFAOYSA-N
DMTMWKX	IU	N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide
DMTMWKX	CA	CAS 1557267-42-1

DMZQF9R	ID	DMZQF9R
DMZQF9R	DN	Pyrrolo[2,3-d]pyrimidine derivative 24
DMZQF9R	HS	Patented
DMZQF9R	SN	PMID28705083-Compound-22
DMZQF9R	DT	Small molecular drug
DMZQF9R	PC	90468938
DMZQF9R	MW	445.5
DMZQF9R	FM	C24H23N5O4
DMZQF9R	IC	InChI=1S/C24H23N5O4/c1-3-21(30)26-17-5-4-6-19(15-17)33-23-20-11-12-25-22(20)28-24(29-23)27-16-7-9-18(10-8-16)32-14-13-31-2/h3-12,15H,1,13-14H2,2H3,(H,26,30)(H2,25,27,28,29)
DMZQF9R	CS	COCCOC1=CC=C(C=C1)NC2=NC3=C(C=CN3)C(=N2)OC4=CC=CC(=C4)NC(=O)C=C
DMZQF9R	IK	GVVINAQSLGCCRZ-UHFFFAOYSA-N
DMZQF9R	IU	N-[3-[[2-[4-(2-methoxyethoxy)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide

DMWU3O4	ID	DMWU3O4
DMWU3O4	DN	Pyrrolo[2,3-d]pyrimidine derivative 25
DMWU3O4	HS	Patented
DMWU3O4	SN	PMID28705083-Compound-23
DMWU3O4	CP	MERCK SHARP & DOHME CORP. MERCK SHARP &amDOHME B.V. DE MAN, Adrianus P.A. STERRENBURG, Jan-Gerard RAAIJMAKERS, Hans C.A. KAPTEIN, Allard OUBRIE, Arthur REWINKEL, Johannes B.M. JANS, Christiaan G.J.M. WIJKMANS, Jacobus C.H.M BARF, Tjeerd A. COOPER, Alan B. KIM, Ronald M. BOGA, Sobhana Babu ZHU, Hugh Y. GAO, Xiaolei YAO, Xin ANAND, Rajan WU, Hao LIU, Shilan YANG, Chundao ALHASSAN, Abdul-Basit WANG, James YU, Younong LIU, Jian VACCARO, Henry M
DMWU3O4	DT	Small molecular drug

DMX1ANB	ID	DMX1ANB
DMX1ANB	DN	Pyrrolo[2,3-d]pyrimidine derivative 26
DMX1ANB	HS	Patented
DMX1ANB	SN	PMID28705083-Compound-24
DMX1ANB	CP	TAIHO PHARMACEUTICAL CO., LTD
DMX1ANB	DT	Small molecular drug
DMX1ANB	PC	118519862
DMX1ANB	MW	451.9
DMX1ANB	FM	C21H18ClN7O3
DMX1ANB	IC	InChI=1S/C21H18ClN7O3/c1-2-16(30)28-6-5-12(8-28)29-9-13(17-18(23)24-10-25-19(17)29)20(31)27-21-26-14-7-11(22)3-4-15(14)32-21/h2-4,7,9-10,12H,1,5-6,8H2,(H2,23,24,25)(H,26,27,31)
DMX1ANB	CS	C=CC(=O)N1CCC(C1)N2C=C(C3=C(N=CN=C32)N)C(=O)NC4=NC5=C(O4)C=CC(=C5)Cl
DMX1ANB	IK	HDJGAVFAWSMJSN-UHFFFAOYSA-N
DMX1ANB	IU	4-amino-N-(5-chloro-1,3-benzoxazol-2-yl)-7-(1-prop-2-enoylpyrrolidin-3-yl)pyrrolo[2,3-d]pyrimidine-5-carboxamide

DMCZJ1W	ID	DMCZJ1W
DMCZJ1W	DN	Pyrrolo[2,3-d]pyrimidine derivative 27
DMCZJ1W	HS	Patented
DMCZJ1W	SN	PMID28705083-Compound-25
DMCZJ1W	CP	PHARMASCIENCE INC
DMCZJ1W	DT	Small molecular drug
DMCZJ1W	PC	118119806
DMCZJ1W	MW	484.5
DMCZJ1W	FM	C27H25FN6O2
DMCZJ1W	IC	InChI=1S/C27H25FN6O2/c1-16(2)34-13-21(24-26(29)32-15-33-27(24)34)19-7-9-20(10-8-19)36-23-6-4-5-22(25(23)28)35-14-18-11-30-17(3)31-12-18/h4-13,15-16H,14H2,1-3H3,(H2,29,32,33)
DMCZJ1W	CS	CC1=NC=C(C=N1)COC2=C(C(=CC=C2)OC3=CC=C(C=C3)C4=CN(C5=NC=NC(=C45)N)C(C)C)F
DMCZJ1W	IK	HVHZPWHNJSXHGP-UHFFFAOYSA-N
DMCZJ1W	IU	5-[4-[2-fluoro-3-[(2-methylpyrimidin-5-yl)methoxy]phenoxy]phenyl]-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-4-amine

DMXRJI2	ID	DMXRJI2
DMXRJI2	DN	Pyrrolo[2,3-d]pyrimidine derivative 28
DMXRJI2	HS	Patented
DMXRJI2	SN	PMID28705083-Compound-26
DMXRJI2	CP	MEDIVATION TECHNOLOGIES, INC
DMXRJI2	DT	Small molecular drug
DMXRJI2	PC	118025736
DMXRJI2	MW	360.4
DMXRJI2	FM	C21H17FN4O
DMXRJI2	IC	InChI=1S/C21H17FN4O/c22-15-5-14(8-17(27)9-15)18-10-26(21-19(18)20(23)24-11-25-21)16-6-12-3-1-2-4-13(12)7-16/h1-5,8-11,16,27H,6-7H2,(H2,23,24,25)
DMXRJI2	CS	C1C(CC2=CC=CC=C21)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC(=C5)F)O
DMXRJI2	IK	FOYDQEHGCZAQII-UHFFFAOYSA-N
DMXRJI2	IU	3-[4-amino-7-(2,3-dihydro-1H-inden-2-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-5-fluorophenol

DM6IJRG	ID	DM6IJRG
DM6IJRG	DN	Pyrrolo[2,3-d]pyrimidine derivative 29
DM6IJRG	HS	Patented
DM6IJRG	SN	PMID28705083-Compound-27
DM6IJRG	CP	F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM6IJRG	DT	Small molecular drug
DM6IJRG	PC	90125978
DM6IJRG	MW	474.5
DM6IJRG	FM	C24H23FN8O2
DM6IJRG	IC	InChI=1S/C24H23FN8O2/c1-24(2,3)23-31-21(32-35-23)22(34)26-9-14-6-5-13(7-17(14)25)19-16-8-18(15-10-29-33(4)11-15)30-20(16)28-12-27-19/h5-8,10-12H,9H2,1-4H3,(H,26,34)(H,27,28,30)
DM6IJRG	CS	CC(C)(C)C1=NC(=NO1)C(=O)NCC2=C(C=C(C=C2)C3=C4C=C(NC4=NC=N3)C5=CN(N=C5)C)F
DM6IJRG	IK	XRNHJQXCSOAXLV-UHFFFAOYSA-N
DM6IJRG	IU	5-tert-butyl-N-[[2-fluoro-4-[6-(1-methylpyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]methyl]-1,2,4-oxadiazole-3-carboxamide

DMTX1G4	ID	DMTX1G4
DMTX1G4	DN	Pyrrolo[2,3-d]pyrimidine derivative 3
DMTX1G4	HS	Patented
DMTX1G4	SN	PMID28270021-Compound-WO2012137089cE-245677
DMTX1G4	CP	PFIZER LIMITED ANDREWS, Mark David BAGAL, Sharanjeet Kaur GIBSON, Karl Richard OMOTO, Kiyoyuki RYCKMANS, Thomas SKERRATT, Sarah Elizabeth STUPPLE, Paul Anthony
DMTX1G4	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM57W29	ID	DM57W29
DM57W29	DN	Pyrrolo[2,3-d]pyrimidine derivative 30
DM57W29	HS	Patented
DM57W29	SN	PMID28705083-Compound-28
DM57W29	CP	NOVARTIS AG HENG, Richard HOEGENAUER, Elizabeth, Kate KOCH, Guido PULZ, Robert, Alexander VULPETTI, Anna WAELCHLI, Rudolf
DM57W29	DT	Small molecular drug
DM57W29	PC	71230726
DM57W29	MW	572.7
DM57W29	FM	C31H33FN6O2S
DM57W29	IC	InChI=1S/C31H33FN6O2S/c1-17-5-6-26-20(11-17)12-27(41-26)30(39)36-24-14-21(32)13-22(18(24)2)28-23-15-25(35-29(23)34-16-33-28)19-7-9-38(10-8-19)31(40)37(3)4/h7,12-17H,5-6,8-11H2,1-4H3,(H,36,39)(H,33,34,35)
DM57W29	CS	CC1CCC2=C(C1)C=C(S2)C(=O)NC3=CC(=CC(=C3C)C4=C5C=C(NC5=NC=N4)C6=CCN(CC6)C(=O)N(C)C)F
DM57W29	IK	AFEUSBPUCPEXMI-UHFFFAOYSA-N
DM57W29	IU	4-[4-[5-fluoro-2-methyl-3-[(5-methyl-4,5,6,7-tetrahydro-1-benzothiophene-2-carbonyl)amino]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl-3,6-dihydro-2H-pyridine-1-carboxamide

DMA9PM4	ID	DMA9PM4
DMA9PM4	DN	Pyrrolo[2,3-d]pyrimidine derivative 31
DMA9PM4	HS	Patented
DMA9PM4	SN	PMID28705083-Compound-29
DMA9PM4	CP	BIOGEN MA INC. SUNESIS PHARMACEUTICALS, INC
DMA9PM4	DT	Small molecular drug
DMA9PM4	PC	122662718
DMA9PM4	MW	594.7
DMA9PM4	FM	C33H34N6O3S
DMA9PM4	IC	InChI=1S/C33H34N6O3S/c1-20-15-23(9-10-24(20)17-34-30(40)31-35-18-27(43-31)33(2,3)4)28-25-16-26(38-29(25)37-19-36-28)21-5-7-22(8-6-21)32(41)39-11-13-42-14-12-39/h5-10,15-16,18-19H,11-14,17H2,1-4H3,(H,34,40)(H,36,37,38)
DMA9PM4	CS	CC1=C(C=CC(=C1)C2=C3C=C(NC3=NC=N2)C4=CC=C(C=C4)C(=O)N5CCOCC5)CNC(=O)C6=NC=C(S6)C(C)(C)C
DMA9PM4	IK	HVNCDYSVQHLXPA-UHFFFAOYSA-N
DMA9PM4	IU	5-tert-butyl-N-[[2-methyl-4-[6-[4-(morpholine-4-carbonyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]methyl]-1,3-thiazole-2-carboxamide

DMQGI0R	ID	DMQGI0R
DMQGI0R	DN	Pyrrolo[2,3-d]pyrimidine derivative 32
DMQGI0R	HS	Patented
DMQGI0R	SN	PMID28705083-Compound-30
DMQGI0R	DT	Small molecular drug
DMQGI0R	PC	86764737
DMQGI0R	MW	427.5
DMQGI0R	FM	C24H25N7O
DMQGI0R	IC	InChI=1S/C24H25N7O/c1-2-21(32)30-10-6-9-19(15-30)29-24-22-20(12-25-23(22)26-16-27-24)18-11-28-31(14-18)13-17-7-4-3-5-8-17/h2-5,7-8,11-12,14,16,19H,1,6,9-10,13,15H2,(H2,25,26,27,29)
DMQGI0R	CS	C=CC(=O)N1CCCC(C1)NC2=NC=NC3=C2C(=CN3)C4=CN(N=C4)CC5=CC=CC=C5
DMQGI0R	IK	KOFRBWGSVPRLLQ-UHFFFAOYSA-N
DMQGI0R	IU	1-[3-[[5-(1-benzylpyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]prop-2-en-1-one

DM6BTMX	ID	DM6BTMX
DM6BTMX	DN	Pyrrolo[2,3-d]pyrimidine derivative 33
DM6BTMX	HS	Patented
DM6BTMX	SN	PMID28705083-Compound-31
DM6BTMX	CP	UNIVERSITY OF UTAH RESEARCH FOUNDATION
DM6BTMX	DT	Small molecular drug
DM6BTMX	PC	73669702
DM6BTMX	MW	474.9
DM6BTMX	FM	C25H23ClN6O2
DM6BTMX	IC	InChI=1S/C25H23ClN6O2/c1-2-21(33)28-17-6-3-5-16(13-17)23-22-20(26)15-27-24(22)31-25(30-23)29-18-7-4-8-19(14-18)32-9-11-34-12-10-32/h2-8,13-15H,1,9-12H2,(H,28,33)(H2,27,29,30,31)
DM6BTMX	CS	C=CC(=O)NC1=CC=CC(=C1)C2=C3C(=CNC3=NC(=N2)NC4=CC(=CC=C4)N5CCOCC5)Cl
DM6BTMX	IK	OQGHSORLLAGPRT-UHFFFAOYSA-N
DM6BTMX	IU	N-[3-[5-chloro-2-(3-morpholin-4-ylanilino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]prop-2-enamide

DMXU08A	ID	DMXU08A
DMXU08A	DN	Pyrrolo[2,3-d]pyrimidine derivative 35
DMXU08A	HS	Patented
DMXU08A	SN	PMID27410995-Compound-Figure3b
DMXU08A	DT	Small molecular drug

DME0WSR	ID	DME0WSR
DME0WSR	DN	Pyrrolo[2,3-d]pyrimidine derivative 4
DME0WSR	HS	Patented
DME0WSR	SN	PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)
DME0WSR	CP	PFIZER LIMITED ANDREWS, Mark David BAGAL, Sharanjeet Kaur GIBSON, Karl Richard OMOTO, Kiyoyuki RYCKMANS, Thomas SKERRATT, Sarah Elizabeth STUPPLE, Paul Anthony
DME0WSR	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM3D1L6	ID	DM3D1L6
DM3D1L6	DN	Pyrrolo[2,3-d]pyrimidine derivative 6
DM3D1L6	HS	Patented
DM3D1L6	SN	PMID27774822-Compound-Figure5Example10
DM3D1L6	CP	PFIZER INC
DM3D1L6	DT	Small molecular drug

DM30Y8M	ID	DM30Y8M
DM30Y8M	DN	Pyrrolo[2,3-d]pyrimidine derivative 7
DM30Y8M	HS	Patented
DM30Y8M	SN	PMID27774822-Compound-Figure5Example14
DM30Y8M	CP	PFIZER INC
DM30Y8M	DT	Small molecular drug

DMAW6KU	ID	DMAW6KU
DMAW6KU	DN	Pyrrolo[2,3-d]pyrimidine derivative 8
DMAW6KU	HS	Patented
DMAW6KU	SN	PMID27774822-Compound-Figure5Example2
DMAW6KU	CP	PFIZER INC
DMAW6KU	DT	Small molecular drug

DM0HU5O	ID	DM0HU5O
DM0HU5O	DN	Pyrrolo[2,3-d]pyrimidine derivative 9
DM0HU5O	HS	Patented
DM0HU5O	SN	PMID26161698-Compound-1
DM0HU5O	CP	NOVARTIS AG ASTEX THERAPEUTICS LTD. BESONG, Gilbert BRAIN, Christopher Thomas BROOKS, Clinton A. CONGREVE, Miles Stuart DAGOSTIN, Claudio HE, Guo HOU, Ying HOWARD, Steven LI, Yue LU, Yipin MORTENSON, Paul SMITH, Troy SUNG, Moo WOODHEAD, Steven WRONA, Wojciech
DM0HU5O	DT	Small molecular drug
DM0HU5O	PC	44818950
DM0HU5O	MW	476.6
DM0HU5O	FM	C26H36N8O
DM0HU5O	IC	InChI=1S/C26H36N8O/c1-18(2)32-11-13-33(14-12-32)21-9-10-23(27-17-21)29-26-28-16-19-15-22(25(35)31(3)4)34(24(19)30-26)20-7-5-6-8-20/h9-10,15-18,20H,5-8,11-14H2,1-4H3,(H,27,28,29,30)
DM0HU5O	CS	CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C(N(C4=N3)C5CCCC5)C(=O)N(C)C
DM0HU5O	IK	XVVBHKGQHJECBA-UHFFFAOYSA-N
DM0HU5O	IU	7-cyclopentyl-N,N-dimethyl-2-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide

DMKF8HI	ID	DMKF8HI
DMKF8HI	DN	Pyrrolo[3,2-c]pyridine derivative 1
DMKF8HI	HS	Patented
DMKF8HI	SN	PMID28270021-Compound-WO2014053968Example5
DMKF8HI	CP	PFIZER LIMITED
DMKF8HI	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMS4I6B	ID	DMS4I6B
DMS4I6B	DN	Pyrrolo-benzo-diazine derivative 1
DMS4I6B	HS	Patented
DMS4I6B	SN	PMID25539043-Compound-WO2010151597Example35
DMS4I6B	CP	SCHERING CORPORATION HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R. EARLEY, William, G. COURNEYA, Brandy
DMS4I6B	DT	Small molecular drug

DMP8I02	ID	DMP8I02
DMP8I02	DN	Pyrrolo-pyrazine derivative 1
DMP8I02	HS	Patented
DMP8I02	SN	PMID27774822-Compound-Figure5Example168
DMP8I02	CP	PFIZER INC
DMP8I02	DT	Small molecular drug

DMO9Q8J	ID	DMO9Q8J
DMO9Q8J	DN	Pyrrolo-pyrazine derivative 2
DMO9Q8J	HS	Patented
DMO9Q8J	SN	PMID27774822-Compound-Figure6Example1
DMO9Q8J	CP	PRINCIPIA BIOPHARMA INC
DMO9Q8J	DT	Small molecular drug
DMO9Q8J	PC	74223673
DMO9Q8J	MW	363.4
DMO9Q8J	FM	C20H21N5O2
DMO9Q8J	IC	InChI=1S/C20H21N5O2/c1-5-16(26)23-13-8-6-7-12(9-13)15-11-22-18-17(24-15)14(10-21-18)19(27)25-20(2,3)4/h5-11H,1H2,2-4H3,(H,21,22)(H,23,26)(H,25,27)
DMO9Q8J	CS	CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=CC(=CC=C3)NC(=O)C=C
DMO9Q8J	IK	RGYYZLGXRYSDRO-UHFFFAOYSA-N
DMO9Q8J	IU	N-tert-butyl-2-[3-(prop-2-enoylamino)phenyl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide

DMLM6DT	ID	DMLM6DT
DMLM6DT	DN	Pyrrolo-pyrazine derivative 3
DMLM6DT	HS	Patented
DMLM6DT	SN	PMID27774822-Compound-Figure7ExampleI-29
DMLM6DT	CP	F. HOFFMANN-LA ROCHE AG CHEN, Shaoqing DE VICENTE FIDALGO, Javier HAMILTON, Matthew Michael HERMANN, Johannes Cornelius KENNEDY-SMITH, Joshua LI, Hongju LOVEY, Allen John LUCAS, Matthew C. LUK, Kin-Chun Thomas LYNCH, Stephen M. O'YANG, Counde PADILLA, Fernando SCHOENFELD, Ryan Craig SIDDURI, Achyutharao SOTH, Michael WANG, Ce WOVKULICH, Peter Michael ZHANG, Xiaohu
DMLM6DT	DT	Small molecular drug

DMD1S92	ID	DMD1S92
DMD1S92	DN	Pyrrolo-pyrazine derivative 4
DMD1S92	HS	Patented
DMD1S92	SN	PMID27774822-Compound-Figure7ExampleI-4
DMD1S92	CP	F. HOFFMANN-LA ROCHE AG CHEN, Shaoqing DE VICENTE FIDALGO, Javier HAMILTON, Matthew Michael HERMANN, Johannes Cornelius KENNEDY-SMITH, Joshua LI, Hongju LOVEY, Allen John LUCAS, Matthew C. LUK, Kin-Chun Thomas LYNCH, Stephen M. O'YANG, Counde PADILLA, Fernando SCHOENFELD, Ryan Craig SIDDURI, Achyutharao SOTH, Michael WANG, Ce WOVKULICH, Peter Michael ZHANG, Xiaohu
DMD1S92	DT	Small molecular drug

DMQ2U54	ID	DMQ2U54
DMQ2U54	DN	Pyrrolo-pyridazine derivative 1
DMQ2U54	HS	Patented
DMQ2U54	SN	PMID28117607-Compound-2
DMQ2U54	CP	PFIZER INC
DMQ2U54	DT	Small molecular drug

DM9K5CI	ID	DM9K5CI
DM9K5CI	DN	Pyrrolo-pyridine derivative 1
DM9K5CI	HS	Patented
DM9K5CI	SN	PMID28117607-Compound-10
DM9K5CI	CP	H. LUNDBECK A/S VERNALIS (R&D) LTD
DM9K5CI	DT	Small molecular drug

DMVNY5I	ID	DMVNY5I
DMVNY5I	DN	Pyrrolo-pyridine derivative 2
DMVNY5I	HS	Patented
DMVNY5I	SN	PMID28117607-Compound-11
DMVNY5I	CP	H. LUNDBECK A/S VERNALIS (R&D) LTD
DMVNY5I	DT	Small molecular drug

DMSNQEJ	ID	DMSNQEJ
DMSNQEJ	DN	Pyrrolo-pyridine derivative 3
DMSNQEJ	HS	Patented
DMSNQEJ	SN	PMID27774822-Compound-Figure8Example55
DMSNQEJ	DT	Small molecular drug

DMK820T	ID	DMK820T
DMK820T	DN	Pyrrolo-pyridinone derivative 1
DMK820T	HS	Patented
DMK820T	SN	PMID27646564-Compound-8
DMK820T	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMK820T	DT	Small molecular drug

DM5G67X	ID	DM5G67X
DM5G67X	DN	Pyrrolo-pyridinone derivative 2
DM5G67X	HS	Patented
DM5G67X	SN	PMID27646564-Compound-8-1
DM5G67X	CP	NERVIANO MEDICAL SCIENCES S.R.L
DM5G67X	DT	Small molecular drug

DME1Q3W	ID	DME1Q3W
DME1Q3W	DN	Pyrrolo-pyridinone derivative 3
DME1Q3W	HS	Patented
DME1Q3W	SN	PMID27646564-Compound-8-2
DME1Q3W	CP	NERVIANO MEDICAL SCIENCES S.R.L
DME1Q3W	DT	Small molecular drug

DM2EVJR	ID	DM2EVJR
DM2EVJR	DN	Pyrrolo-pyridinone derivative 4
DM2EVJR	HS	Patented
DM2EVJR	SN	PMID27646564-Compound-8-3
DM2EVJR	CP	NERVIANO MEDICAL SCIENCES S.R.L
DM2EVJR	DT	Small molecular drug

DMK2FSY	ID	DMK2FSY
DMK2FSY	DN	Pyrrolo-pyridinone derivative 5
DMK2FSY	HS	Patented
DMK2FSY	SN	PMID25539043-Compound-WO2013161312Example15
DMK2FSY	CP	RAQUALIA PHARMA INC
DMK2FSY	DT	Small molecular drug

DMXGNP8	ID	DMXGNP8
DMXGNP8	DN	Pyrrolo-pyridinone derivative 6
DMXGNP8	HS	Patented
DMXGNP8	SN	PMID25539043-Compound-WO2013161312Example16
DMXGNP8	CP	RAQUALIA PHARMA INC
DMXGNP8	DT	Small molecular drug

DMR6QCE	ID	DMR6QCE
DMR6QCE	DN	Pyrrolo-pyridone derivative 1
DMR6QCE	HS	Patented
DMR6QCE	SN	PMID27774822-Compound-Figure2Example1-19
DMR6QCE	CP	MERCK SHARP & DOHME CORP. DINSMORE, Christopher FULLER, Peter GUERIN, David THOMPSON, Christopher F. PU, Qinglin SCOTT, Mark E. KATZ, Jason David KURUKULASURIYA, Ravi CLOSE, Joshua T. FALCONE, Danielle BRUBAKER, Jason ZENG, Hongbo BAI, Yunfeng FU, Jianmin KONG, Norman LIU, Yumei ZHENG, Zhixiang
DMR6QCE	DT	Small molecular drug

DMCZ8UV	ID	DMCZ8UV
DMCZ8UV	DN	Pyrrolo-pyridone derivative 2
DMCZ8UV	HS	Patented
DMCZ8UV	SN	PMID27774822-Compound-Figure2ExampleII-92
DMCZ8UV	CP	MERCK SHARP & DOHME [US]
DMCZ8UV	DT	Small molecular drug

DMUIK3W	ID	DMUIK3W
DMUIK3W	DN	Pyrrolo-pyridone derivative 3
DMUIK3W	HS	Patented
DMUIK3W	SN	PMID27774822-Compound-Figure9Example4
DMUIK3W	CP	TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMUIK3W	DT	Small molecular drug

DMEVXT0	ID	DMEVXT0
DMEVXT0	DN	Pyrrolo-pyrimidine derivative 1
DMEVXT0	HS	Patented
DMEVXT0	SN	PMID28117607-Compound-1
DMEVXT0	CP	Pfizer Inc., USA. Assignee
DMEVXT0	DT	Small molecular drug

DMR0ZU6	ID	DMR0ZU6
DMR0ZU6	DN	Pyrrolo-pyrimidine derivative 10
DMR0ZU6	HS	Patented
DMR0ZU6	SN	PMID28117607-Compound-43
DMR0ZU6	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED GLAXOSMITHKLINE (CHINA) R&amp;D COMPANY LIMITED
DMR0ZU6	DT	Small molecular drug

DMEIDC0	ID	DMEIDC0
DMEIDC0	DN	Pyrrolo-pyrimidine derivative 11
DMEIDC0	HS	Patented
DMEIDC0	SN	PMID28117607-Compound-44
DMEIDC0	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED GLAXOSMITHKLINE (CHINA) R&amp;D COMPANY LIMITED
DMEIDC0	DT	Small molecular drug

DMEHYBJ	ID	DMEHYBJ
DMEHYBJ	DN	Pyrrolo-pyrimidine derivative 2
DMEHYBJ	HS	Patented
DMEHYBJ	SN	PMID27646564-Compound-7
DMEHYBJ	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMEHYBJ	DT	Small molecular drug

DMKHWN9	ID	DMKHWN9
DMKHWN9	DN	Pyrrolo-pyrimidine derivative 3
DMKHWN9	HS	Patented
DMKHWN9	SN	PMID27646564-Compound-7-1
DMKHWN9	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMKHWN9	DT	Small molecular drug

DMITK03	ID	DMITK03
DMITK03	DN	Pyrrolo-pyrimidine derivative 4
DMITK03	HS	Patented
DMITK03	SN	PMID27646564-Compound-7-2
DMITK03	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMITK03	DT	Small molecular drug

DMVA95G	ID	DMVA95G
DMVA95G	DN	Pyrrolo-pyrimidine derivative 5
DMVA95G	HS	Patented
DMVA95G	SN	PMID27646564-Compound-7-3
DMVA95G	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMVA95G	DT	Small molecular drug
DMVA95G	PC	86292773
DMVA95G	MW	417.4
DMVA95G	FM	C20H15F4N5O
DMVA95G	IC	InChI=1S/C20H15F4N5O/c21-15-6-3-12(19(30)28-14-4-5-14)7-11(15)1-2-13-8-29(9-20(22,23)24)18-16(13)17(25)26-10-27-18/h3,6-8,10,14H,4-5,9H2,(H,28,30)(H2,25,26,27)
DMVA95G	CS	C1CC1NC(=O)C2=CC(=C(C=C2)F)C#CC3=CN(C4=NC=NC(=C34)N)CC(F)(F)F
DMVA95G	IK	SHIKADMSFNHXTC-UHFFFAOYSA-N
DMVA95G	IU	3-[2-[4-amino-7-(2,2,2-trifluoroethyl)pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-N-cyclopropyl-4-fluorobenzamide

DMGYT81	ID	DMGYT81
DMGYT81	DN	Pyrrolo-pyrimidine derivative 6
DMGYT81	HS	Patented
DMGYT81	SN	PMID27646564-Compound-7-4
DMGYT81	CP	NERVIANO MEDICAL SCIENCES S.R.L
DMGYT81	DT	Small molecular drug

DMZH27I	ID	DMZH27I
DMZH27I	DN	Pyrrolo-pyrimidine derivative 8
DMZH27I	HS	Patented
DMZH27I	SN	PMID28117607-Compound-41
DMZH27I	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED GLAXOSMITHKLINE (CHINA) R&amp;D COMPANY LIMITED
DMZH27I	DT	Small molecular drug

DMJEV86	ID	DMJEV86
DMJEV86	DN	Pyrrolo-pyrimidine derivative 9
DMJEV86	HS	Patented
DMJEV86	SN	PMID28117607-Compound-42
DMJEV86	CP	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED GLAXOSMITHKLINE (CHINA) R&amp;D COMPANY LIMITED
DMJEV86	DT	Small molecular drug

DMN4SE5	ID	DMN4SE5
DMN4SE5	DN	Pyrrolo-pyrrolone derivative 1
DMN4SE5	HS	Patented
DMN4SE5	SN	PMID26924192-Compound-34
DMN4SE5	CP	NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMN4SE5	DT	Small molecular drug
DMN4SE5	PC	122553486
DMN4SE5	MW	515
DMN4SE5	FM	C28H27ClN6O2
DMN4SE5	IC	InChI=1S/C28H27ClN6O2/c1-15-10-21(13-33-16(2)30-31-27(15)33)35-25(19-6-8-20(29)9-7-19)26-24(28(35)37)23(18-4-5-18)14-34(26)22-11-32(12-22)17(3)36/h6-10,13-14,18,22,25H,4-5,11-12H2,1-3H3
DMN4SE5	CS	CC1=CC(=CN2C1=NN=C2C)N3C(C4=C(C3=O)C(=CN4C5CN(C5)C(=O)C)C6CC6)C7=CC=C(C=C7)Cl
DMN4SE5	IK	CASINEGODQBEAL-UHFFFAOYSA-N
DMN4SE5	IU	1-(1-acetylazetidin-3-yl)-6-(4-chlorophenyl)-3-cyclopropyl-5-(3,8-dimethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-6H-pyrrolo[3,4-b]pyrrol-4-one

DM8VYMA	ID	DM8VYMA
DM8VYMA	DN	Pyrrolo-pyrrolone derivative 2
DM8VYMA	HS	Patented
DM8VYMA	SN	PMID26924192-Compound-35
DM8VYMA	CP	NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DM8VYMA	DT	Small molecular drug
DM8VYMA	PC	118095207
DM8VYMA	MW	448.9
DM8VYMA	FM	C23H21ClN6O2
DM8VYMA	IC	InChI=1S/C23H21ClN6O2/c1-12-9-15(10-17-19(12)26-27-29(17)4)30-20(13-5-7-14(24)8-6-13)21-18(23(30)32)16(11-28(21)3)22(31)25-2/h5-11,20H,1-4H3,(H,25,31)
DM8VYMA	CS	CC1=CC(=CC2=C1N=NN2C)N3C(C4=C(C3=O)C(=CN4C)C(=O)NC)C5=CC=C(C=C5)Cl
DM8VYMA	IK	VQZKOWOEYPJMPU-UHFFFAOYSA-N
DM8VYMA	IU	6-(4-chlorophenyl)-5-(3,7-dimethylbenzotriazol-5-yl)-N,1-dimethyl-4-oxo-6H-pyrrolo[3,4-b]pyrrole-3-carboxamide

DMHGPU1	ID	DMHGPU1
DMHGPU1	DN	Pyrrolo-pyrrolone derivative 3
DMHGPU1	HS	Patented
DMHGPU1	SN	PMID26924192-Compound-36
DMHGPU1	CP	NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMHGPU1	DT	Small molecular drug
DMHGPU1	PC	122553422
DMHGPU1	MW	516
DMHGPU1	FM	C27H26ClN7O2
DMHGPU1	IC	InChI=1S/C27H26ClN7O2/c1-14-10-21(29-26-23(14)30-31-32(26)3)35-24(17-6-8-18(28)9-7-17)25-22(27(35)37)20(16-4-5-16)13-34(25)19-11-33(12-19)15(2)36/h6-10,13,16,19,24H,4-5,11-12H2,1-3H3
DMHGPU1	CS	CC1=CC(=NC2=C1N=NN2C)N3C(C4=C(C3=O)C(=CN4C5CN(C5)C(=O)C)C6CC6)C7=CC=C(C=C7)Cl
DMHGPU1	IK	NBJPFMDWXKYTQF-UHFFFAOYSA-N
DMHGPU1	IU	1-(1-acetylazetidin-3-yl)-6-(4-chlorophenyl)-3-cyclopropyl-5-(3,7-dimethyltriazolo[4,5-b]pyridin-5-yl)-6H-pyrrolo[3,4-b]pyrrol-4-one

DMFJBZI	ID	DMFJBZI
DMFJBZI	DN	Pyrrolo-pyrrolone derivative 4
DMFJBZI	HS	Patented
DMFJBZI	SN	PMID26924192-Compound-37
DMFJBZI	CP	NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMFJBZI	DT	Small molecular drug
DMFJBZI	PC	118095161
DMFJBZI	MW	500.9
DMFJBZI	FM	C22H19ClF2N8O2
DMFJBZI	IC	InChI=1S/C22H19ClF2N8O2/c1-10-8-14(30-33-19(10)28-29-20(33)18(24)25)32-16(11-4-6-12(23)7-5-11)17-15(21(32)34)13(9-31(17)3)27-22(35)26-2/h4-9,16,18H,1-3H3,(H2,26,27,35)
DMFJBZI	CS	CC1=CC(=NN2C1=NN=C2C(F)F)N3C(C4=C(C3=O)C(=CN4C)NC(=O)NC)C5=CC=C(C=C5)Cl
DMFJBZI	IK	RNLAJPMWXHNSOJ-UHFFFAOYSA-N
DMFJBZI	IU	1-[6-(4-chlorophenyl)-5-[3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]-1-methyl-4-oxo-6H-pyrrolo[3,4-b]pyrrol-3-yl]-3-methylurea

DMMX0N5	ID	DMMX0N5
DMMX0N5	DN	Pyrrolo-pyrrolone derivative 5
DMMX0N5	HS	Patented
DMMX0N5	SN	PMID26924192-Compound-38
DMMX0N5	CP	NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMMX0N5	DT	Small molecular drug
DMMX0N5	PC	118095173
DMMX0N5	MW	546
DMMX0N5	FM	C29H28ClN5O4
DMMX0N5	IC	InChI=1S/C29H28ClN5O4/c1-5-39-29(37)35-24(20-10-12-38-13-11-20)17(3)23-26(35)25(19-6-8-21(30)9-7-19)34(28(23)36)22-14-16(2)27-32-31-18(4)33(27)15-22/h6-10,14-15,25H,5,11-13H2,1-4H3
DMMX0N5	CS	CCOC(=O)N1C2=C(C(=C1C3=CCOCC3)C)C(=O)N(C2C4=CC=C(C=C4)Cl)C5=CN6C(=NN=C6C(=C5)C)C
DMMX0N5	IK	XQCLLKJYKDIUDW-UHFFFAOYSA-N
DMMX0N5	IU	ethyl 6-(4-chlorophenyl)-2-(3,6-dihydro-2H-pyran-4-yl)-5-(3,8-dimethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methyl-4-oxo-6H-pyrrolo[3,4-b]pyrrole-1-carboxylate

DMBW208	ID	DMBW208
DMBW208	DN	Pyrrolo-pyrrolone derivative 6
DMBW208	HS	Patented
DMBW208	SN	PMID26924192-Compound-39
DMBW208	CP	NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMBW208	DT	Small molecular drug
DMBW208	PC	122553484
DMBW208	MW	506
DMBW208	FM	C26H24ClN5O4
DMBW208	IC	InChI=1S/C26H24ClN5O4/c1-14-10-17(13-30(2)24(14)33)32-21(15-6-8-16(27)9-7-15)22-18(25(32)34)11-20(31(22)3)19-12-28-26(36-5)29-23(19)35-4/h6-13,21H,1-5H3/t21-/m1/s1
DMBW208	CS	CC1=CC(=CN(C1=O)C)N2[C@@H](C3=C(C2=O)C=C(N3C)C4=CN=C(N=C4OC)OC)C5=CC=C(C=C5)Cl
DMBW208	IK	QLRYSHYUZMZZPY-OAQYLSRUSA-N
DMBW208	IU	(6R)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-5-(1,5-dimethyl-6-oxopyridin-3-yl)-1-methyl-6H-pyrrolo[3,4-b]pyrrol-4-one

DM4DJA7	ID	DM4DJA7
DM4DJA7	DN	QCPOIDRINIAUKU-SRBBEKPSSA-N
DM4DJA7	HS	Patented
DM4DJA7	SN	((1R,2R,3S,4R)-2,3-dihydroxy-4-([2-(1-naphthyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino)cyclopentyl)methyl sulfamate; ((1R,2R,3S,4R)-2,3-dihydroxy-4-{[2-(1-naphthyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino}cyclopentyl)methyl sulfamate; SCHEMBL15192059; QCPOIDRINIAUKU-SRBBEKPSSA-N
DM4DJA7	DT	Small molecular drug
DM4DJA7	PC	71666343
DM4DJA7	MW	469.5
DM4DJA7	FM	C22H23N5O5S
DM4DJA7	IC	InChI=1S/C22H23N5O5S/c23-33(30,31)32-12-14-10-18(22(29)21(14)28)25-19-8-9-24-20-11-17(26-27(19)20)16-7-3-5-13-4-1-2-6-15(13)16/h1-9,11,14,18,21-22,25,28-29H,10,12H2,(H2,23,30,31)/t14-,18-,21-,22+/m1/s1
DM4DJA7	CS	C1[C@@H]([C@H]([C@H]([C@@H]1NC2=CC=NC3=CC(=NN23)C4=CC=CC5=CC=CC=C54)O)O)COS(=O)(=O)N
DM4DJA7	IK	QCPOIDRINIAUKU-SRBBEKPSSA-N
DM4DJA7	IU	[(1R,2R,3S,4R)-2,3-dihydroxy-4-[(2-naphthalen-1-ylpyrazolo[1,5-a]pyrimidin-7-yl)amino]cyclopentyl]methyl sulfamate

DMH86F2	ID	DMH86F2
DMH86F2	DN	Quinazoline alkaloid derivative 1
DMH86F2	HS	Patented
DMH86F2	SN	PMID29757691-Compound-11
DMH86F2	DT	Small molecular drug
DMH86F2	PC	442929
DMH86F2	MW	188.23
DMH86F2	FM	C11H12N2O
DMH86F2	IC	InChI=1S/C11H12N2O/c14-10-5-6-13-7-8-3-1-2-4-9(8)12-11(10)13/h1-4,10,14H,5-7H2/t10-/m1/s1
DMH86F2	CS	C1CN2CC3=CC=CC=C3N=C2[C@@H]1O
DMH86F2	IK	YIICVSCAKJMMDJ-SNVBAGLBSA-N
DMH86F2	IU	(3R)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-3-ol
DMH86F2	CA	CAS 18549-38-7
DMH86F2	CB	CHEBI:7949

DMOBFAU	ID	DMOBFAU
DMOBFAU	DN	Quinazoline derivative 1
DMOBFAU	HS	Patented
DMOBFAU	SN	PMID25482888-Compound-68
DMOBFAU	CP	BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFRENGLE, Waldemar FRANK, Markus KLEIN, Thomas
DMOBFAU	DT	Small molecular drug
DMOBFAU	PC	71487629
DMOBFAU	MW	945.1
DMOBFAU	FM	C50H56N16O4
DMOBFAU	IC	InChI=1S/C50H56N16O4/c1-6-8-24-63-40-42(56-46(63)61-22-14-16-31(51)27-61)59(4)48(69)65(44(40)67)29-38-53-35-20-12-10-18-33(35)37(55-38)26-50(3)34-19-11-13-21-36(34)54-39(58-50)30-66-45(68)41-43(60(5)49(66)70)57-47(64(41)25-9-7-2)62-23-15-17-32(52)28-62/h10-13,18-21,31-32H,14-17,22-30,51-52H2,1-5H3,(H,54,58)/t31-,32-,50?/m1/s1
DMOBFAU	CS	CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC(C5=CC=CC=C5N4)(C)CC6=NC(=NC7=CC=CC=C76)CN8C(=O)C9=C(N=C(N9CC#CC)N1CCC[C@H](C1)N)N(C8=O)C)C
DMOBFAU	IK	CEWRYIAJQLCIAT-BZDWUGKRSA-N
DMOBFAU	IU	8-[(3R)-3-aminopiperidin-1-yl]-1-[[4-[[2-[[8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-2,6-dioxopurin-1-yl]methyl]quinazolin-4-yl]methyl]-4-methyl-1H-quinazolin-2-yl]methyl]-7-but-2-ynyl-3-methylpurine-2,6-dione

DMZ3ORT	ID	DMZ3ORT
DMZ3ORT	DN	Quinazoline derivative 10
DMZ3ORT	HS	Patented
DMZ3ORT	SN	PMID26936077-Compound-21
DMZ3ORT	CP	NeoPharm Co. Ltd
DMZ3ORT	DT	Small molecular drug
DMZ3ORT	PC	6737869
DMZ3ORT	MW	468.3
DMZ3ORT	FM	C22H15BrFN3O3
DMZ3ORT	IC	InChI=1S/C22H15BrFN3O3/c1-30-15-10-11-18(23)17(12-15)21(28)26-27-20(13-6-8-14(24)9-7-13)25-19-5-3-2-4-16(19)22(27)29/h2-12H,1H3,(H,26,28)
DMZ3ORT	CS	COC1=CC(=C(C=C1)Br)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4=CC=C(C=C4)F
DMZ3ORT	IK	NCDCVFJWCCFMHL-UHFFFAOYSA-N
DMZ3ORT	IU	2-bromo-N-[2-(4-fluorophenyl)-4-oxoquinazolin-3-yl]-5-methoxybenzamide
DMZ3ORT	DE	Cirrhosis; Chronic obstructive pulmonary disease; Psoriasis vulgaris; Multiple sclerosis

DMAH435	ID	DMAH435
DMAH435	DN	Quinazoline derivative 11
DMAH435	HS	Patented
DMAH435	SN	PMID26936077-Compound-22
DMAH435	CP	NeoPharm Co. Ltd
DMAH435	DT	Small molecular drug
DMAH435	PC	60163203
DMAH435	MW	456.3
DMAH435	FM	C20H14BrN3O3S
DMAH435	IC	InChI=1S/C20H14BrN3O3S/c1-27-12-8-9-15(21)14(11-12)19(25)23-24-18(17-7-4-10-28-17)22-16-6-3-2-5-13(16)20(24)26/h2-11H,1H3,(H,23,25)
DMAH435	CS	COC1=CC(=C(C=C1)Br)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4=CC=CS4
DMAH435	IK	SIPGYZVTRHQPRD-UHFFFAOYSA-N
DMAH435	IU	2-bromo-5-methoxy-N-(4-oxo-2-thiophen-2-ylquinazolin-3-yl)benzamide
DMAH435	DE	Cirrhosis; Chronic obstructive pulmonary disease; Psoriasis vulgaris; Multiple sclerosis; Gastrointestinal disease

DMVKZU2	ID	DMVKZU2
DMVKZU2	DN	Quinazoline derivative 12
DMVKZU2	HS	Patented
DMVKZU2	SN	PMID26936077-Compound-23
DMVKZU2	CP	NeoPharm Co. Ltd
DMVKZU2	DT	Small molecular drug
DMVKZU2	PC	60163336
DMVKZU2	MW	414.3
DMVKZU2	FM	C19H16BrN3O3
DMVKZU2	IC	InChI=1S/C19H16BrN3O3/c1-26-12-8-9-15(20)14(10-12)18(24)22-23-17(11-6-7-11)21-16-5-3-2-4-13(16)19(23)25/h2-5,8-11H,6-7H2,1H3,(H,22,24)
DMVKZU2	CS	COC1=CC(=C(C=C1)Br)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4CC4
DMVKZU2	IK	OWJRZOOAIAWSHE-UHFFFAOYSA-N
DMVKZU2	IU	2-bromo-N-(2-cyclopropyl-4-oxoquinazolin-3-yl)-5-methoxybenzamide
DMVKZU2	DE	Cirrhosis; Chronic obstructive pulmonary disease; Psoriasis vulgaris; Multiple sclerosis; Gastrointestinal disease

DMFU6OD	ID	DMFU6OD
DMFU6OD	DN	Quinazoline derivative 13
DMFU6OD	HS	Patented
DMFU6OD	SN	PMID26936077-Compound-24
DMFU6OD	CP	NeoPharm Co. Ltd
DMFU6OD	DT	Small molecular drug
DMFU6OD	PC	60161489
DMFU6OD	MW	369.8
DMFU6OD	FM	C19H16ClN3O3
DMFU6OD	IC	InChI=1S/C19H16ClN3O3/c1-26-12-8-9-15(20)14(10-12)18(24)22-23-17(11-6-7-11)21-16-5-3-2-4-13(16)19(23)25/h2-5,8-11H,6-7H2,1H3,(H,22,24)
DMFU6OD	CS	COC1=CC(=C(C=C1)Cl)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4CC4
DMFU6OD	IK	PHWRMNPWLIXVPO-UHFFFAOYSA-N
DMFU6OD	IU	2-chloro-N-(2-cyclopropyl-4-oxoquinazolin-3-yl)-5-methoxybenzamide
DMFU6OD	DE	Multiple sclerosis; Gastrointestinal disease; Atopic dermatitis; Arteriosclerosis

DMHLJA7	ID	DMHLJA7
DMHLJA7	DN	Quinazoline derivative 14
DMHLJA7	HS	Patented
DMHLJA7	SN	PMID27646564-Compound-12
DMHLJA7	CP	CANCER RESEARCH TECHNOLOGY LIMITED
DMHLJA7	DT	Small molecular drug

DMD965S	ID	DMD965S
DMD965S	DN	Quinazoline derivative 15
DMD965S	HS	Patented
DMD965S	SN	PMID27646564-Compound-12-1
DMD965S	CP	CANCER RESEARCH TECHNOLOGY LIMITED
DMD965S	DT	Small molecular drug

DMQ704Z	ID	DMQ704Z
DMQ704Z	DN	Quinazoline derivative 16
DMQ704Z	HS	Patented
DMQ704Z	SN	PMID27646564-Compound-12-2
DMQ704Z	CP	CANCER RESEARCH TECHNOLOGY LIMITED
DMQ704Z	DT	Small molecular drug

DMGECO2	ID	DMGECO2
DMGECO2	DN	Quinazoline derivative 2
DMGECO2	HS	Patented
DMGECO2	SN	PMID27607364-Compound-46
DMGECO2	DT	Small molecular drug
DMGECO2	PC	24956250
DMGECO2	MW	293.32
DMGECO2	FM	C17H15N3O2
DMGECO2	IC	InChI=1S/C17H15N3O2/c1-20(2)17(21)22-16-13-10-6-7-11-14(13)18-15(19-16)12-8-4-3-5-9-12/h3-11H,1-2H3
DMGECO2	CS	CN(C)C(=O)OC1=NC(=NC2=CC=CC=C21)C3=CC=CC=C3
DMGECO2	IK	NAXSAPGEPBKPDD-UHFFFAOYSA-N
DMGECO2	IU	(2-phenylquinazolin-4-yl) N,N-dimethylcarbamate

DMF05GL	ID	DMF05GL
DMF05GL	DN	Quinazoline derivative 3
DMF05GL	HS	Patented
DMF05GL	SN	PMID27607364-Compound-47
DMF05GL	CP	TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMF05GL	DT	Small molecular drug

DMJIDLU	ID	DMJIDLU
DMJIDLU	DN	Quinazoline derivative 4
DMJIDLU	HS	Patented
DMJIDLU	SN	PMID27607364-Compound-48
DMJIDLU	CP	TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMJIDLU	DT	Small molecular drug
DMJIDLU	PC	13769184
DMJIDLU	MW	321.4
DMJIDLU	FM	C19H19N3O2
DMJIDLU	IC	InChI=1S/C19H19N3O2/c1-3-22(4-2)19(23)24-18-15-12-8-9-13-16(15)20-17(21-18)14-10-6-5-7-11-14/h5-13H,3-4H2,1-2H3
DMJIDLU	CS	CCN(CC)C(=O)OC1=NC(=NC2=CC=CC=C21)C3=CC=CC=C3
DMJIDLU	IK	VZRHWILGJDZNKG-UHFFFAOYSA-N
DMJIDLU	IU	(2-phenylquinazolin-4-yl) N,N-diethylcarbamate

DMEIH73	ID	DMEIH73
DMEIH73	DN	Quinazoline derivative 5
DMEIH73	HS	Patented
DMEIH73	SN	PMID27607364-Compound-49
DMEIH73	CP	TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMEIH73	DT	Small molecular drug
DMEIH73	PC	118479984
DMEIH73	MW	327.8
DMEIH73	FM	C17H14ClN3O2
DMEIH73	IC	InChI=1S/C17H14ClN3O2/c1-21(2)17(22)23-16-12-8-4-6-10-14(12)19-15(20-16)11-7-3-5-9-13(11)18/h3-10H,1-2H3
DMEIH73	CS	CN(C)C(=O)OC1=NC(=NC2=CC=CC=C21)C3=CC=CC=C3Cl
DMEIH73	IK	IKJKKLDPZAPXOQ-UHFFFAOYSA-N
DMEIH73	IU	[2-(2-chlorophenyl)quinazolin-4-yl] N,N-dimethylcarbamate

DMKZ6MD	ID	DMKZ6MD
DMKZ6MD	DN	Quinazoline derivative 6
DMKZ6MD	HS	Patented
DMKZ6MD	SN	PMID27607364-Compound-50
DMKZ6MD	CP	TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMKZ6MD	DT	Small molecular drug

DMIBRE5	ID	DMIBRE5
DMIBRE5	DN	Quinazoline derivative 7
DMIBRE5	HS	Patented
DMIBRE5	SN	PMID27607364-Compound-51
DMIBRE5	CP	TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMIBRE5	DT	Small molecular drug
DMIBRE5	PC	118472700
DMIBRE5	MW	341.8
DMIBRE5	FM	C18H16ClN3O2
DMIBRE5	IC	InChI=1S/C18H16ClN3O2/c1-3-22(2)18(23)24-17-13-9-5-7-11-15(13)20-16(21-17)12-8-4-6-10-14(12)19/h4-11H,3H2,1-2H3
DMIBRE5	CS	CCN(C)C(=O)OC1=NC(=NC2=CC=CC=C21)C3=CC=CC=C3Cl
DMIBRE5	IK	PBHDUERHMVFHLD-UHFFFAOYSA-N
DMIBRE5	IU	[2-(2-chlorophenyl)quinazolin-4-yl] N-ethyl-N-methylcarbamate

DMSD04W	ID	DMSD04W
DMSD04W	DN	Quinazolinedione derivative 1
DMSD04W	HS	Patented
DMSD04W	SN	PMID27841036-Compound-11
DMSD04W	CP	Impact Therapeutics Inc
DMSD04W	DT	Small molecular drug
DMSD04W	PC	66546486
DMSD04W	MW	460.5
DMSD04W	FM	C24H21FN6O3
DMSD04W	IC	InChI=1S/C24H21FN6O3/c25-19-7-6-16(15-31-20-5-2-1-4-17(20)21(32)28-24(31)34)14-18(19)22(33)29-10-12-30(13-11-29)23-26-8-3-9-27-23/h1-9,14H,10-13,15H2,(H,28,32,34)
DMSD04W	CS	C1CN(CCN1C2=NC=CC=N2)C(=O)C3=C(C=CC(=C3)CN4C5=CC=CC=C5C(=O)NC4=O)F
DMSD04W	IK	LYSWZKKQEGTMEA-UHFFFAOYSA-N
DMSD04W	IU	1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione

DM3TVI6	ID	DM3TVI6
DM3TVI6	DN	Quinazolinedione derivative 2
DM3TVI6	HS	Patented
DM3TVI6	SN	PMID27841036-Compound-12
DM3TVI6	CP	Impact Therapeutics Inc
DM3TVI6	DT	Small molecular drug
DM3TVI6	PC	68388735
DM3TVI6	MW	460.5
DM3TVI6	FM	C24H21FN6O3
DM3TVI6	IC	InChI=1S/C24H21FN6O3/c25-18-6-2-7-19-20(18)21(32)28-24(34)31(19)15-16-4-1-5-17(14-16)22(33)29-10-12-30(13-11-29)23-26-8-3-9-27-23/h1-9,14H,10-13,15H2,(H,28,32,34)
DM3TVI6	CS	C1CN(CCN1C2=NC=CC=N2)C(=O)C3=CC=CC(=C3)CN4C5=C(C(=CC=C5)F)C(=O)NC4=O
DM3TVI6	IK	QUTRGYJIPOIOGH-UHFFFAOYSA-N
DM3TVI6	IU	5-fluoro-1-[[3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione

DMZ5GIH	ID	DMZ5GIH
DMZ5GIH	DN	Quinazolinedione derivative 3
DMZ5GIH	HS	Patented
DMZ5GIH	SN	PMID27841036-Compound-13
DMZ5GIH	CP	Janssen Pharmaceutica NV 
DMZ5GIH	DT	Small molecular drug
DMZ5GIH	PC	59663666
DMZ5GIH	MW	402.5
DMZ5GIH	FM	C24H26N4O2
DMZ5GIH	IC	InChI=1S/C24H26N4O2/c29-23-19-7-2-4-9-22(19)28(24(30)26-23)13-5-12-27-14-10-17(11-15-27)20-16-25-21-8-3-1-6-18(20)21/h1-4,6-9,16-17,25H,5,10-15H2,(H,26,29,30)
DMZ5GIH	CS	C1CN(CCC1C2=CNC3=CC=CC=C32)CCCN4C5=CC=CC=C5C(=O)NC4=O
DMZ5GIH	IK	MAJCEXQEEGYUCA-UHFFFAOYSA-N
DMZ5GIH	IU	1-[3-[4-(1H-indol-3-yl)piperidin-1-yl]propyl]quinazoline-2,4-dione

DME24BI	ID	DME24BI
DME24BI	DN	Quinazolines and azaquinazoline derivative 1
DME24BI	HS	Patented
DME24BI	SN	PMID28594589-Compound-TABLE3c13
DME24BI	CP	Asana Biosciences
DME24BI	DT	Small molecular drug

DMSU1PC	ID	DMSU1PC
DMSU1PC	DN	Quinazolinone derivative 1
DMSU1PC	HS	Patented
DMSU1PC	SN	PMID28074661-Compound-WO2004022554c47
DMSU1PC	CP	CELLTECH R&D LIMITED HAUGHAN, Alan, Findlay BUCKLEY, George, Martin DAVIES, Natasha DYKE, Hazel, Joan HANNAH, Duncan, Robert MORGAN, Trevor RICHARD, Marianna, Dilani SHARPE, Andrew WILLIAMS, Sophie, Caroline
DMSU1PC	DT	Small molecular drug

DM0XVQY	ID	DM0XVQY
DM0XVQY	DN	Quinazolinone derivative 2
DM0XVQY	HS	Patented
DM0XVQY	SN	PMID28074661-Compound-WO2004022554c48
DM0XVQY	CP	CELLTECH R&D LIMITED HAUGHAN, Alan, Findlay BUCKLEY, George, Martin DAVIES, Natasha DYKE, Hazel, Joan HANNAH, Duncan, Robert MORGAN, Trevor RICHARD, Marianna, Dilani SHARPE, Andrew WILLIAMS, Sophie, Caroline
DM0XVQY	DT	Small molecular drug

DMDRIZF	ID	DMDRIZF
DMDRIZF	DN	Quinazolinone derivative 3
DMDRIZF	HS	Patented
DMDRIZF	SN	PMID26924192-Compound-86
DMDRIZF	CP	ZENITH EPIGENETICS CORP
DMDRIZF	DT	Small molecular drug
DMDRIZF	PC	137051728
DMDRIZF	MW	424.5
DMDRIZF	FM	C23H28N4O4
DMDRIZF	IC	InChI=1S/C23H28N4O4/c1-27-9-7-14(8-10-27)24-18-11-15(29-2)5-6-17(18)22-25-19-12-16(30-3)13-20(31-4)21(19)23(28)26-22/h5-6,11-14,24H,7-10H2,1-4H3,(H,25,26,28)
DMDRIZF	CS	CN1CCC(CC1)NC2=C(C=CC(=C2)OC)C3=NC4=C(C(=CC(=C4)OC)OC)C(=O)N3
DMDRIZF	IK	FRAHQMXXLOFANF-UHFFFAOYSA-N
DMDRIZF	IU	5,7-dimethoxy-2-[4-methoxy-2-[(1-methylpiperidin-4-yl)amino]phenyl]-3H-quinazolin-4-one

DM8WH97	ID	DM8WH97
DM8WH97	DN	Quinazolinone derivative 4
DM8WH97	HS	Patented
DM8WH97	SN	PMID26924192-Compound-87
DM8WH97	CP	ZENITH EPIGENETICS CORP
DM8WH97	DT	Small molecular drug
DM8WH97	PC	137051771
DM8WH97	MW	424.5
DM8WH97	FM	C23H28N4O4
DM8WH97	IC	InChI=1S/C23H28N4O4/c1-27-8-7-14(13-27)12-24-18-9-15(29-2)5-6-17(18)22-25-19-10-16(30-3)11-20(31-4)21(19)23(28)26-22/h5-6,9-11,14,24H,7-8,12-13H2,1-4H3,(H,25,26,28)
DM8WH97	CS	CN1CCC(C1)CNC2=C(C=CC(=C2)OC)C3=NC4=C(C(=CC(=C4)OC)OC)C(=O)N3
DM8WH97	IK	PRDGUEJBCFBYCA-UHFFFAOYSA-N
DM8WH97	IU	5,7-dimethoxy-2-[4-methoxy-2-[(1-methylpyrrolidin-3-yl)methylamino]phenyl]-3H-quinazolin-4-one

DMXOKH3	ID	DMXOKH3
DMXOKH3	DN	Quinazolinone derivative 5
DMXOKH3	HS	Patented
DMXOKH3	SN	PMID26924192-Compound-88
DMXOKH3	CP	ZENITH EPIGENETICS CORP
DMXOKH3	DT	Small molecular drug

DMKDTO4	ID	DMKDTO4
DMKDTO4	DN	Quinoline and quinazoline derivative 1
DMKDTO4	HS	Patented
DMKDTO4	SN	PMID28621580-Compound-US20120219522c30
DMKDTO4	CP	Sunshine Lake Pharma Co., LtdCalitor Sciences, LLC
DMKDTO4	DT	Small molecular drug

DM6E1N4	ID	DM6E1N4
DM6E1N4	DN	Quinoline and quinazoline derivative 10
DM6E1N4	HS	Patented
DM6E1N4	SN	PMID28621580-Compound-WO2014127335c34
DM6E1N4	CP	KALA PHARMACEUTICALS, INC
DM6E1N4	DT	Small molecular drug

DM9PSI3	ID	DM9PSI3
DM9PSI3	DN	Quinoline and quinazoline derivative 2
DM9PSI3	HS	Patented
DM9PSI3	SN	PMID28621580-Compound-US20130165458c38
DM9PSI3	CP	Development Center for Biotechnology
DM9PSI3	DT	Small molecular drug

DMGY4WO	ID	DMGY4WO
DMGY4WO	DN	Quinoline and quinazoline derivative 3
DMGY4WO	HS	Patented
DMGY4WO	SN	PMID28621580-Compound-US20150158854c39
DMGY4WO	CP	Development Center for Biotechnology
DMGY4WO	DT	Small molecular drug

DM5VCQP	ID	DM5VCQP
DM5VCQP	DN	Quinoline and quinazoline derivative 4
DM5VCQP	HS	Patented
DM5VCQP	SN	PMID28621580-Compound-WO2012127012c31
DM5VCQP	CP	UNIVERSITA' DEGLI STUDI DI PADOVA CHILIN, Adriana MARZARO, Giovanni GUIOTTO, Adriano CONCONI, Maria Teresa CASTAGLIUOLO, Ignazio
DM5VCQP	DT	Small molecular drug

DM7RQ2G	ID	DM7RQ2G
DM7RQ2G	DN	Quinoline and quinazoline derivative 5
DM7RQ2G	HS	Patented
DM7RQ2G	SN	PMID28621580-Compound-WO2012171487c32
DM7RQ2G	CP	TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD
DM7RQ2G	DT	Small molecular drug

DMZ2TB5	ID	DMZ2TB5
DMZ2TB5	DN	Quinoline and quinazoline derivative 6
DMZ2TB5	HS	Patented
DMZ2TB5	SN	PMID28621580-Compound-WO2013040515c36
DMZ2TB5	CP	NEUPHARMA, INC. QIAN, Xiangping ZHU, Yong-liang
DMZ2TB5	DT	Small molecular drug

DMMJEWB	ID	DMMJEWB
DMMJEWB	DN	Quinoline and quinazoline derivative 7
DMMJEWB	HS	Patented
DMMJEWB	SN	PMID28621580-Compound-WO2013112950c37
DMMJEWB	CP	NEUPHARMA, INC. ZHU, Yong-liang QIAN, Xiangping
DMMJEWB	DT	Small molecular drug

DMW3JH0	ID	DMW3JH0
DMW3JH0	DN	Quinoline and quinazoline derivative 8
DMW3JH0	HS	Patented
DMW3JH0	SN	PMID28621580-Compound-WO2014113859c33
DMW3JH0	CP	UNIVERSIDADE FEDERAL DO RIO DE JANEIRO
DMW3JH0	DT	Small molecular drug

DMBL86O	ID	DMBL86O
DMBL86O	DN	Quinoline and quinazoline derivative 9
DMBL86O	HS	Patented
DMBL86O	SN	PMID28621580-Compound-WO2014127214c35
DMBL86O	CP	KALA PHARMACEUTICALS, INC
DMBL86O	DT	Small molecular drug

DMW5YJB	ID	DMW5YJB
DMW5YJB	DN	Quinoline carboxamide derivative 1
DMW5YJB	HS	Patented
DMW5YJB	SN	PMID26394986-Compound-28
DMW5YJB	CP	Pharma. Ip. General, Inc. Mamoto Health Science University
DMW5YJB	DT	Small molecular drug
DMW5YJB	PC	4253236
DMW5YJB	MW	382.4
DMW5YJB	FM	C22H14N4O3
DMW5YJB	IC	InChI=1S/C22H14N4O3/c27-20(24-22-26-25-21(29-22)19-11-6-12-28-19)16-13-18(14-7-2-1-3-8-14)23-17-10-5-4-9-15(16)17/h1-13H,(H,24,26,27)
DMW5YJB	CS	C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2)C(=O)NC4=NN=C(O4)C5=CC=CO5
DMW5YJB	IK	MNPXTRXFUMGQLK-UHFFFAOYSA-N
DMW5YJB	IU	N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenylquinoline-4-carboxamide

DMZTQVF	ID	DMZTQVF
DMZTQVF	DN	Quinoline carboxamide derivative 10
DMZTQVF	HS	Patented
DMZTQVF	SN	PMID27607364-Compound-20
DMZTQVF	CP	COCENSYS, INC
DMZTQVF	DT	Small molecular drug

DM9XQBG	ID	DM9XQBG
DM9XQBG	DN	Quinoline carboxamide derivative 2
DM9XQBG	HS	Patented
DM9XQBG	SN	PMID26394986-Compound-29
DM9XQBG	CP	Pharma. Ip. General, Inc. Mamoto Health Science University
DM9XQBG	DT	Small molecular drug
DM9XQBG	PC	67206397
DM9XQBG	MW	416.8
DM9XQBG	FM	C22H13ClN4O3
DM9XQBG	IC	InChI=1S/C22H13ClN4O3/c23-14-8-9-17-15(11-14)16(12-18(24-17)13-5-2-1-3-6-13)20(28)25-22-27-26-21(30-22)19-7-4-10-29-19/h1-12H,(H,25,27,28)
DM9XQBG	CS	C1=CC=C(C=C1)C2=NC3=C(C=C(C=C3)Cl)C(=C2)C(=O)NC4=NN=C(O4)C5=CC=CO5
DM9XQBG	IK	GMIGNWBMEJMRDV-UHFFFAOYSA-N
DM9XQBG	IU	6-chloro-N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenylquinoline-4-carboxamide

DMCAS85	ID	DMCAS85
DMCAS85	DN	Quinoline carboxamide derivative 3
DMCAS85	HS	Patented
DMCAS85	SN	PMID26394986-Compound-30
DMCAS85	CP	Pharma. Ip. General, Inc. Mamoto Health Science University
DMCAS85	DT	Small molecular drug
DMCAS85	PC	67204713
DMCAS85	MW	466.4
DMCAS85	FM	C23H13F3N4O4
DMCAS85	IC	InChI=1S/C23H13F3N4O4/c24-23(25,26)34-14-8-9-17-15(11-14)16(12-18(27-17)13-5-2-1-3-6-13)20(31)28-22-30-29-21(33-22)19-7-4-10-32-19/h1-12H,(H,28,30,31)
DMCAS85	CS	C1=CC=C(C=C1)C2=NC3=C(C=C(C=C3)OC(F)(F)F)C(=C2)C(=O)NC4=NN=C(O4)C5=CC=CO5
DMCAS85	IK	OGCHQJNHUGTSIR-UHFFFAOYSA-N
DMCAS85	IU	N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenyl-6-(trifluoromethoxy)quinoline-4-carboxamide

DMVUNYD	ID	DMVUNYD
DMVUNYD	DN	Quinoline carboxamide derivative 4
DMVUNYD	HS	Patented
DMVUNYD	SN	PMID27607364-Compound-14
DMVUNYD	CP	COCENSYS, INC
DMVUNYD	DT	Small molecular drug

DM14029	ID	DM14029
DM14029	DN	Quinoline carboxamide derivative 5
DM14029	HS	Patented
DM14029	SN	PMID27607364-Compound-15
DM14029	CP	COCENSYS, INC
DM14029	DT	Small molecular drug

DMQ9ATN	ID	DMQ9ATN
DMQ9ATN	DN	Quinoline carboxamide derivative 6
DMQ9ATN	HS	Patented
DMQ9ATN	SN	PMID27607364-Compound-16
DMQ9ATN	CP	COCENSYS, INC
DMQ9ATN	DT	Small molecular drug

DM8AG0Z	ID	DM8AG0Z
DM8AG0Z	DN	Quinoline carboxamide derivative 7
DM8AG0Z	HS	Patented
DM8AG0Z	SN	PMID27607364-Compound-17
DM8AG0Z	CP	COCENSYS, INC
DM8AG0Z	DT	Small molecular drug

DM3IXYL	ID	DM3IXYL
DM3IXYL	DN	Quinoline carboxamide derivative 8
DM3IXYL	HS	Patented
DM3IXYL	SN	PMID27607364-Compound-18
DM3IXYL	CP	COCENSYS, INC
DM3IXYL	DT	Small molecular drug

DM7YFBT	ID	DM7YFBT
DM7YFBT	DN	Quinoline carboxamide derivative 9
DM7YFBT	HS	Patented
DM7YFBT	SN	PMID27607364-Compound-19
DM7YFBT	CP	COCENSYS, INC
DM7YFBT	DT	Small molecular drug

DMRY2HL	ID	DMRY2HL
DMRY2HL	DN	Quinoline derivative 1
DMRY2HL	HS	Patented
DMRY2HL	SN	PMID27537201-Compound-Figure13f
DMRY2HL	CP	the Shanghai Institute of Pharmaceutical Industry
DMRY2HL	DT	Small molecular drug

DM6GSCV	ID	DM6GSCV
DM6GSCV	DN	Quinoline derivative 10
DM6GSCV	HS	Patented
DM6GSCV	SN	PMID27724045-Compound-13
DM6GSCV	CP	Janssen Pharmaceutica
DM6GSCV	DT	Small molecular drug
DM6GSCV	PC	44247634
DM6GSCV	MW	550
DM6GSCV	FM	C25H27ClF3N7O2
DM6GSCV	IC	InChI=1S/C25H27ClF3N7O2/c26-18-2-3-19-17(1-4-21(34-19)36-6-5-16(30)14-36)22(18)23(37)31-13-20(35-7-9-38-10-8-35)15-11-32-24(33-12-15)25(27,28)29/h1-4,11-12,16,20H,5-10,13-14,30H2,(H,31,37)/t16-,20?/m0/s1
DM6GSCV	CS	C1CN(C[C@H]1N)C2=NC3=C(C=C2)C(=C(C=C3)Cl)C(=O)NCC(C4=CN=C(N=C4)C(F)(F)F)N5CCOCC5
DM6GSCV	IK	WVZNREBVNBJZKF-DJZRFWRSSA-N
DM6GSCV	IU	2-[(3S)-3-aminopyrrolidin-1-yl]-6-chloro-N-[2-morpholin-4-yl-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]quinoline-5-carboxamide

DMH02JL	ID	DMH02JL
DMH02JL	DN	Quinoline derivative 11
DMH02JL	HS	Patented
DMH02JL	SN	PMID27724045-Compound-6
DMH02JL	CP	AstraZeneca
DMH02JL	DT	Small molecular drug

DM9FXE7	ID	DM9FXE7
DM9FXE7	DN	Quinoline derivative 12
DM9FXE7	HS	Patented
DM9FXE7	SN	PMID27724045-Compound-7
DM9FXE7	CP	AstraZeneca
DM9FXE7	DT	Small molecular drug
DM9FXE7	PC	25015092
DM9FXE7	MW	417.9
DM9FXE7	FM	C22H28ClN3O3
DM9FXE7	IC	InChI=1S/C22H28ClN3O3/c1-14-3-2-9-22(29,11-14)13-24-21(28)20-16-4-7-19(26-10-8-15(27)12-26)25-18(16)6-5-17(20)23/h4-7,14-15,27,29H,2-3,8-13H2,1H3,(H,24,28)/t14-,15+,22-/m0/s1
DM9FXE7	CS	C[C@H]1CCC[C@](C1)(CNC(=O)C2=C(C=CC3=C2C=CC(=N3)N4CC[C@H](C4)O)Cl)O
DM9FXE7	IK	GTFTZKPCYSYNOU-KIMHZCHSSA-N
DM9FXE7	IU	6-chloro-N-[[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl]-2-[(3R)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide

DMAH4P8	ID	DMAH4P8
DMAH4P8	DN	Quinoline derivative 13
DMAH4P8	HS	Patented
DMAH4P8	SN	PMID27724045-Compound-8
DMAH4P8	CP	AstraZeneca
DMAH4P8	DT	Small molecular drug
DMAH4P8	PC	25015093
DMAH4P8	MW	432
DMAH4P8	FM	C23H30ClN3O3
DMAH4P8	IC	InChI=1S/C23H30ClN3O3/c1-15-3-2-10-23(30,13-15)14-25-22(29)21-17-4-7-20(26-19(17)6-5-18(21)24)27-11-8-16(28)9-12-27/h4-7,15-16,28,30H,2-3,8-14H2,1H3,(H,25,29)/t15-,23-/m0/s1
DMAH4P8	CS	C[C@H]1CCC[C@](C1)(CNC(=O)C2=C(C=CC3=C2C=CC(=N3)N4CCC(CC4)O)Cl)O
DMAH4P8	IK	BAHOQKHEWZJWME-WNSKOXEYSA-N
DMAH4P8	IU	6-chloro-N-[[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl]-2-(4-hydroxypiperidin-1-yl)quinoline-5-carboxamide

DMSRB8M	ID	DMSRB8M
DMSRB8M	DN	Quinoline derivative 14
DMSRB8M	HS	Patented
DMSRB8M	SN	PMID27828716-Compound-7
DMSRB8M	DT	Small molecular drug

DM7HD0T	ID	DM7HD0T
DM7HD0T	DN	Quinoline derivative 15
DM7HD0T	HS	Patented
DM7HD0T	SN	PMID27828716-Compound-VP0.7
DM7HD0T	DT	Small molecular drug

DMTHG87	ID	DMTHG87
DMTHG87	DN	Quinoline derivative 16
DMTHG87	HS	Patented
DMTHG87	SN	PMID27537201-Compound-Figure13a
DMTHG87	CP	SHANGHAI INST PHARM INDUSTRY [CNCAI ZHENGYAN [CNZHOU WEICHENG [CNHAO QUN [CN]the Shanghai Institute of Pharmaceutical Industry
DMTHG87	DT	Small molecular drug

DMKULV8	ID	DMKULV8
DMKULV8	DN	Quinoline derivative 17
DMKULV8	HS	Patented
DMKULV8	SN	PMID27537201-Compound-Figure13d
DMKULV8	CP	the Shanghai Institute of Pharmaceutical Industry
DMKULV8	DT	Small molecular drug

DMSG71Z	ID	DMSG71Z
DMSG71Z	DN	Quinoline derivative 18
DMSG71Z	HS	Patented
DMSG71Z	SN	PMID25435179-Compound-US20148685970(IX)

DM0MLI9	ID	DM0MLI9
DM0MLI9	DN	Quinoline derivative 19
DM0MLI9	HS	Patented
DM0MLI9	SN	PMID25435179-Compound-US20148685970(VII)

DMNO2BP	ID	DMNO2BP
DMNO2BP	DN	Quinoline derivative 2
DMNO2BP	HS	Patented
DMNO2BP	SN	PMID26609882-Compound-84
DMNO2BP	CP	WYETH RAMAMOORTHY, Sivaramakrishnan, P
DMNO2BP	DT	Small molecular drug

DMNXCZT	ID	DMNXCZT
DMNXCZT	DN	Quinoline derivative 20
DMNXCZT	HS	Patented
DMNXCZT	SN	PMID25435179-Compound-US20148685970(VIII)

DMDV6EY	ID	DMDV6EY
DMDV6EY	DN	Quinoline derivative 3
DMDV6EY	HS	Patented
DMDV6EY	SN	PMID25435285-Compound-100
DMDV6EY	CP	MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMDV6EY	DT	Small molecular drug
DMDV6EY	PC	89554768
DMDV6EY	MW	397.5
DMDV6EY	FM	C25H23N3O2
DMDV6EY	IC	InChI=1S/C25H23N3O2/c1-16(12-17-4-3-11-27-15-17)19-7-10-21-22(18-5-8-20(30-2)9-6-18)14-24(25(26)29)28-23(21)13-19/h3-11,13-16H,12H2,1-2H3,(H2,26,29)
DMDV6EY	CS	CC(CC1=CN=CC=C1)C2=CC3=C(C=C2)C(=CC(=N3)C(=O)N)C4=CC=C(C=C4)OC
DMDV6EY	IK	SLSRIELIUCLTJB-UHFFFAOYSA-N
DMDV6EY	IU	4-(4-methoxyphenyl)-7-(1-pyridin-3-ylpropan-2-yl)quinoline-2-carboxamide

DMPB4L6	ID	DMPB4L6
DMPB4L6	DN	Quinoline derivative 4
DMPB4L6	HS	Patented
DMPB4L6	SN	PMID25435285-Compound-101
DMPB4L6	CP	MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMPB4L6	DT	Small molecular drug
DMPB4L6	PC	89554759
DMPB4L6	MW	474.4
DMPB4L6	FM	C22H18F4N6O2
DMPB4L6	IC	InChI=1S/C22H18F4N6O2/c1-2-21(34,22(24,25)26)19-11-32(31-30-19)10-12-3-5-14-15(16-6-4-13(23)9-28-16)8-18(20(27)33)29-17(14)7-12/h3-9,11,34H,2,10H2,1H3,(H2,27,33)/t21-/m1/s1
DMPB4L6	CS	CC[C@@](C1=CN(N=N1)CC2=CC3=C(C=C2)C(=CC(=N3)C(=O)N)C4=NC=C(C=C4)F)(C(F)(F)F)O
DMPB4L6	IK	HPUYYHXUYOZNBL-OAQYLSRUSA-N
DMPB4L6	IU	4-(5-fluoropyridin-2-yl)-7-[[4-[(2R)-1,1,1-trifluoro-2-hydroxybutan-2-yl]triazol-1-yl]methyl]quinoline-2-carboxamide

DMS1TOX	ID	DMS1TOX
DMS1TOX	DN	Quinoline derivative 5
DMS1TOX	HS	Patented
DMS1TOX	SN	PMID25435285-Compound-102
DMS1TOX	CP	MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMS1TOX	DT	Small molecular drug
DMS1TOX	PC	89554809
DMS1TOX	MW	436.5
DMS1TOX	FM	C20H19F3N4O2S
DMS1TOX	IC	InChI=1S/C20H19F3N4O2S/c1-11-25-8-17(30-11)14-7-16(19(24)28)26-15-6-12(2-3-13(14)15)9-27-4-5-29-18(10-27)20(21,22)23/h2-3,6-8,18H,4-5,9-10H2,1H3,(H2,24,28)
DMS1TOX	CS	CC1=NC=C(S1)C2=CC(=NC3=C2C=CC(=C3)CN4CCOC(C4)C(F)(F)F)C(=O)N
DMS1TOX	IK	QYGZQJAQOQLFSQ-UHFFFAOYSA-N
DMS1TOX	IU	4-(2-methyl-1,3-thiazol-5-yl)-7-[[2-(trifluoromethyl)morpholin-4-yl]methyl]quinoline-2-carboxamide

DMVBPGI	ID	DMVBPGI
DMVBPGI	DN	Quinoline derivative 6
DMVBPGI	HS	Patented
DMVBPGI	SN	PMID25435285-Compound-103
DMVBPGI	CP	MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMVBPGI	DT	Small molecular drug
DMVBPGI	PC	89554734
DMVBPGI	MW	419.4
DMVBPGI	FM	C20H20F3N5O2
DMVBPGI	IC	InChI=1S/C20H20F3N5O2/c1-27-10-13(8-25-27)15-7-17(19(24)29)26-16-6-12(2-3-14(15)16)9-28-4-5-30-18(11-28)20(21,22)23/h2-3,6-8,10,18H,4-5,9,11H2,1H3,(H2,24,29)/t18-/m1/s1
DMVBPGI	CS	CN1C=C(C=N1)C2=CC(=NC3=C2C=CC(=C3)CN4CCO[C@H](C4)C(F)(F)F)C(=O)N
DMVBPGI	IK	PUIAIYDBFPDZPF-GOSISDBHSA-N
DMVBPGI	IU	4-(1-methylpyrazol-4-yl)-7-[[(2R)-2-(trifluoromethyl)morpholin-4-yl]methyl]quinoline-2-carboxamide

DM56I8H	ID	DM56I8H
DM56I8H	DN	Quinoline derivative 7
DM56I8H	HS	Patented
DM56I8H	SN	PMID25435285-Compound-104
DM56I8H	CP	MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DM56I8H	DT	Small molecular drug
DM56I8H	PC	89554814
DM56I8H	MW	469.4
DM56I8H	FM	C24H19F4N5O
DM56I8H	IC	InChI=1S/C24H19F4N5O/c25-16-4-2-15(3-5-16)18-10-20(23(29)34)30-19-9-14(1-6-17(18)19)11-32-7-8-33-12-21(24(26,27)28)31-22(33)13-32/h1-6,9-10,12H,7-8,11,13H2,(H2,29,34)
DM56I8H	CS	C1CN2C=C(N=C2CN1CC3=CC4=C(C=C3)C(=CC(=N4)C(=O)N)C5=CC=C(C=C5)F)C(F)(F)F
DM56I8H	IK	CGZZSGTWUICICQ-UHFFFAOYSA-N
DM56I8H	IU	4-(4-fluorophenyl)-7-[[2-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,2-a]pyrazin-7-yl]methyl]quinoline-2-carboxamide

DMLIW1X	ID	DMLIW1X
DMLIW1X	DN	Quinoline derivative 8
DMLIW1X	HS	Patented
DMLIW1X	SN	PMID25435285-Compound-98
DMLIW1X	CP	MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMLIW1X	DT	Small molecular drug
DMLIW1X	PC	89545211
DMLIW1X	MW	437.4
DMLIW1X	FM	C20H19F4N5O2
DMLIW1X	IC	InChI=1S/C20H19F4N5O2/c1-28-8-12(7-26-28)14-6-15(19(25)30)27-18-13(14)3-2-11(17(18)21)9-29-4-5-31-16(10-29)20(22,23)24/h2-3,6-8,16H,4-5,9-10H2,1H3,(H2,25,30)/t16-/m0/s1
DMLIW1X	CS	CN1C=C(C=N1)C2=CC(=NC3=C2C=CC(=C3F)CN4CCO[C@@H](C4)C(F)(F)F)C(=O)N
DMLIW1X	IK	GTJVIXLYXAAAKE-INIZCTEOSA-N
DMLIW1X	IU	8-fluoro-4-(1-methylpyrazol-4-yl)-7-[[(2S)-2-(trifluoromethyl)morpholin-4-yl]methyl]quinoline-2-carboxamide

DMIC86N	ID	DMIC86N
DMIC86N	DN	Quinoline derivative 9
DMIC86N	HS	Patented
DMIC86N	SN	PMID25435285-Compound-99
DMIC86N	CP	MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMIC86N	DT	Small molecular drug
DMIC86N	PC	89554776
DMIC86N	MW	478.4
DMIC86N	FM	C26H18F4N4O
DMIC86N	IC	InChI=1S/C26H18F4N4O/c27-17-8-6-16(7-9-17)19-12-22(25(31)35)32-21-11-15(5-10-18(19)21)14-34-23-4-2-1-3-20(23)33-24(34)13-26(28,29)30/h1-12H,13-14H2,(H2,31,35)
DMIC86N	CS	C1=CC=C2C(=C1)N=C(N2CC3=CC4=C(C=C3)C(=CC(=N4)C(=O)N)C5=CC=C(C=C5)F)CC(F)(F)F
DMIC86N	IK	OOWXUDJNUOKLDH-UHFFFAOYSA-N
DMIC86N	IU	4-(4-fluorophenyl)-7-[[2-(2,2,2-trifluoroethyl)benzimidazol-1-yl]methyl]quinoline-2-carboxamide

DMENZPR	ID	DMENZPR
DMENZPR	DN	Quinolinyl compound 1
DMENZPR	HS	Patented
DMENZPR	SN	PMID25828189-Compound-23
DMENZPR	CP	PFIZER INC. DIDIUK, Mary FILIPSKI, Kevin J. GUZMAN-PEREZ, Angel LEE, Esther C. PFEFFERKORN, Jeffrey A. STEVENS, Benjamin TU, Meihua
DMENZPR	DT	Small molecular drug

DMGLK92	ID	DMGLK92
DMGLK92	DN	Quinolinyl compound 2
DMGLK92	HS	Patented
DMGLK92	SN	PMID25828189-Compound-24
DMGLK92	CP	PFIZER INC. DIDIUK, Mary FILIPSKI, Kevin J. GUZMAN-PEREZ, Angel LEE, Esther C. PFEFFERKORN, Jeffrey A. STEVENS, Benjamin TU, Meihua
DMGLK92	DT	Small molecular drug
DMGLK92	PC	71239286
DMGLK92	MW	405.5
DMGLK92	FM	C24H27N3O3
DMGLK92	IC	InChI=1S/C24H27N3O3/c1-3-6-20(26-23-16(2)15-19-7-4-5-8-21(19)27-23)17-9-11-18(12-10-17)24(30)25-14-13-22(28)29/h4-5,7-12,15,20H,3,6,13-14H2,1-2H3,(H,25,30)(H,26,27)(H,28,29)
DMGLK92	CS	CCCC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)NC2=NC3=CC=CC=C3C=C2C
DMGLK92	IK	KQBQZWBDDOVGRD-UHFFFAOYSA-N
DMGLK92	IU	3-[[4-[1-[(3-methylquinolin-2-yl)amino]butyl]benzoyl]amino]propanoic acid

DMCIKR3	ID	DMCIKR3
DMCIKR3	DN	Quinolinyl pyrazinyl urea derivative 1
DMCIKR3	HS	Patented
DMCIKR3	SN	PMID27828716-Compound-2
DMCIKR3	DT	Small molecular drug
DMCIKR3	PC	24772168
DMCIKR3	MW	265.27
DMCIKR3	FM	C14H11N5O
DMCIKR3	IC	InChI=1S/C14H11N5O/c20-14(19-13-9-15-7-8-17-13)18-12-5-6-16-11-4-2-1-3-10(11)12/h1-9H,(H2,16,17,18,19,20)
DMCIKR3	CS	C1=CC=C2C(=C1)C(=CC=N2)NC(=O)NC3=NC=CN=C3
DMCIKR3	IK	LNIDFQVRZCDVBI-UHFFFAOYSA-N
DMCIKR3	IU	1-pyrazin-2-yl-3-quinolin-4-ylurea

DMKJN9G	ID	DMKJN9G
DMKJN9G	DN	Quinolinyl pyrazinyl urea derivative 2
DMKJN9G	HS	Patented
DMKJN9G	SN	PMID27828716-Compound-3
DMKJN9G	DT	Small molecular drug
DMKJN9G	PC	24858859
DMKJN9G	MW	333.27
DMKJN9G	FM	C15H10F3N5O
DMKJN9G	IC	InChI=1S/C15H10F3N5O/c16-15(17,18)9-1-2-11-10(7-9)12(3-4-20-11)22-14(24)23-13-8-19-5-6-21-13/h1-8H,(H2,20,21,22,23,24)
DMKJN9G	CS	C1=CC2=NC=CC(=C2C=C1C(F)(F)F)NC(=O)NC3=NC=CN=C3
DMKJN9G	IK	GHAZVJQMLWOQLP-UHFFFAOYSA-N
DMKJN9G	IU	1-pyrazin-2-yl-3-[6-(trifluoromethyl)quinolin-4-yl]urea

DME6P7T	ID	DME6P7T
DME6P7T	DN	Quinolone derivative 1
DME6P7T	HS	Patented
DME6P7T	SN	PMID28074661-Compound-US20030105073c44
DME6P7T	CP	Celltech R&D Ltd
DME6P7T	DT	Small molecular drug

DMENQ5O	ID	DMENQ5O
DMENQ5O	DN	Quinoxaline derivative 1
DMENQ5O	HS	Patented
DMENQ5O	SN	PMID25553724-Compound-US20130289041 14

DM031YW	ID	DM031YW
DM031YW	DN	Quinoxaline derivative 2
DM031YW	HS	Patented
DM031YW	SN	PMID25553724-Compound-US20130289041 15

DMLZRAI	ID	DMLZRAI
DMLZRAI	DN	Quinoxaline derivative 3
DMLZRAI	HS	Patented
DMLZRAI	SN	PMID25553724-Compound-US20130289041 16

DMS3PRT	ID	DMS3PRT
DMS3PRT	DN	Quinoxaline derivative 4
DMS3PRT	HS	Patented
DMS3PRT	SN	PMID25553724-Compound-WO2012071414 14
DMS3PRT	CP	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA NATARAJAN, Amarnath CHEN, Qianyi BRYANT, Vashti, C. RAJULE, Rajkumar

DM8EY2G	ID	DM8EY2G
DM8EY2G	DN	Quinoxaline derivative 5
DM8EY2G	HS	Patented
DM8EY2G	SN	PMID25553724-Compound-WO2012071414 15
DM8EY2G	CP	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA NATARAJAN, Amarnath CHEN, Qianyi BRYANT, Vashti, C. RAJULE, Rajkumar

DMBRX8D	ID	DMBRX8D
DMBRX8D	DN	Quinoxaline derivative 6
DMBRX8D	HS	Patented
DMBRX8D	SN	PMID25553724-Compound-WO2012071414 16
DMBRX8D	CP	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA NATARAJAN, Amarnath CHEN, Qianyi BRYANT, Vashti, C. RAJULE, Rajkumar

DMG4FYP	ID	DMG4FYP
DMG4FYP	DN	Resorcinol compound 1
DMG4FYP	HS	Patented
DMG4FYP	SN	PMID26815044-Compound-1
DMG4FYP	DT	Small molecular drug
DMG4FYP	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMPA26U	ID	DMPA26U
DMPA26U	DN	Resorcinol compound 10
DMPA26U	HS	Patented
DMPA26U	SN	PMID26815044-Compound-18
DMPA26U	DT	Small molecular drug
DMPA26U	PC	44611571
DMPA26U	MW	231.25
DMPA26U	FM	C13H13NO3
DMPA26U	IC	InChI=1S/C13H13NO3/c1-17-13-10(3-2-6-14-13)7-9-4-5-11(15)8-12(9)16/h2-6,8,15-16H,7H2,1H3
DMPA26U	CS	COC1=C(C=CC=N1)CC2=C(C=C(C=C2)O)O
DMPA26U	IK	DRCOSVLHATXBGT-UHFFFAOYSA-N
DMPA26U	IU	4-[(2-methoxypyridin-3-yl)methyl]benzene-1,3-diol
DMPA26U	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMGDLPZ	ID	DMGDLPZ
DMGDLPZ	DN	Resorcinol compound 11
DMGDLPZ	HS	Patented
DMGDLPZ	SN	PMID26815044-Compound-19
DMGDLPZ	DT	Small molecular drug
DMGDLPZ	PC	44611840
DMGDLPZ	MW	204.22
DMGDLPZ	FM	C12H12O3
DMGDLPZ	IC	InChI=1S/C12H12O3/c13-10-5-3-9(12(14)8-10)4-6-11-2-1-7-15-11/h1-3,5,7-8,13-14H,4,6H2
DMGDLPZ	CS	C1=COC(=C1)CCC2=C(C=C(C=C2)O)O
DMGDLPZ	IK	DRPCFXFFIMCRRN-UHFFFAOYSA-N
DMGDLPZ	IU	4-[2-(furan-2-yl)ethyl]benzene-1,3-diol
DMGDLPZ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMEMT3I	ID	DMEMT3I
DMEMT3I	DN	Resorcinol compound 12
DMEMT3I	HS	Patented
DMEMT3I	SN	PMID26815044-Compound-2
DMEMT3I	DT	Small molecular drug
DMEMT3I	PC	85471319
DMEMT3I	MW	156.15
DMEMT3I	FM	C8H9FO2
DMEMT3I	IC	InChI=1S/C8H9FO2/c1-2-6-7(9)3-5(10)4-8(6)11/h3-4,10-11H,2H2,1H3
DMEMT3I	CS	CCC1=C(C=C(C=C1F)O)O
DMEMT3I	IK	GJVVTWQXSOPPFB-UHFFFAOYSA-N
DMEMT3I	IU	4-ethyl-5-fluorobenzene-1,3-diol
DMEMT3I	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMVARUE	ID	DMVARUE
DMVARUE	DN	Resorcinol compound 13
DMVARUE	HS	Patented
DMVARUE	SN	PMID26815044-Compound-20
DMVARUE	DT	Small molecular drug
DMVARUE	PC	44611708
DMVARUE	MW	258.269
DMVARUE	FM	C15H14O4
DMVARUE	IC	InChI=1S/C15H14O4/c16-12-5-4-11(13(17)8-12)3-1-10-2-6-14-15(7-10)19-9-18-14/h2,4-8,16-17H,1,3,9H2
DMVARUE	CS	C1OC2=C(O1)C=C(C=C2)CCC3=C(C=C(C=C3)O)O
DMVARUE	IK	WYCYXIGYEQHUEJ-UHFFFAOYSA-N
DMVARUE	IU	4-[2-(1,3-benzodioxol-5-yl)ethyl]benzene-1,3-diol
DMVARUE	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM6XFA5	ID	DM6XFA5
DM6XFA5	DN	Resorcinol compound 14
DM6XFA5	HS	Patented
DM6XFA5	SN	PMID26815044-Compound-21
DM6XFA5	DT	Small molecular drug
DM6XFA5	PC	24849532
DM6XFA5	MW	246.26
DM6XFA5	FM	C14H14O4
DM6XFA5	IC	InChI=1S/C14H14O4/c15-11-5-3-9(13(17)7-11)1-2-10-4-6-12(16)8-14(10)18/h3-8,15-18H,1-2H2
DM6XFA5	CS	C1=CC(=C(C=C1O)O)CCC2=C(C=C(C=C2)O)O
DM6XFA5	IK	WKIFTWPZTZUMRN-UHFFFAOYSA-N
DM6XFA5	IU	4-[2-(2,4-dihydroxyphenyl)ethyl]benzene-1,3-diol
DM6XFA5	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMSLYVT	ID	DMSLYVT
DMSLYVT	DN	Resorcinol compound 15
DMSLYVT	HS	Patented
DMSLYVT	SN	PMID26815044-Compound-22
DMSLYVT	DT	Small molecular drug
DMSLYVT	PC	44611713
DMSLYVT	MW	288.34
DMSLYVT	FM	C17H20O4
DMSLYVT	IC	InChI=1S/C17H20O4/c1-11-16(20-2)9-7-13(17(11)21-3)5-4-12-6-8-14(18)10-15(12)19/h6-10,18-19H,4-5H2,1-3H3
DMSLYVT	CS	CC1=C(C=CC(=C1OC)CCC2=C(C=C(C=C2)O)O)OC
DMSLYVT	IK	IUYGPVSGZMZJPS-UHFFFAOYSA-N
DMSLYVT	IU	4-[2-(2,4-dimethoxy-3-methylphenyl)ethyl]benzene-1,3-diol
DMSLYVT	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMFDXBJ	ID	DMFDXBJ
DMFDXBJ	DN	Resorcinol compound 16
DMFDXBJ	HS	Patented
DMFDXBJ	SN	PMID26815044-Compound-23
DMFDXBJ	DT	Small molecular drug
DMFDXBJ	PC	44611835
DMFDXBJ	MW	232.27
DMFDXBJ	FM	C14H16O3
DMFDXBJ	IC	InChI=1S/C14H16O3/c1-2-12-7-8-13(17-12)6-4-10-3-5-11(15)9-14(10)16/h3,5,7-9,15-16H,2,4,6H2,1H3
DMFDXBJ	CS	CCC1=CC=C(O1)CCC2=C(C=C(C=C2)O)O
DMFDXBJ	IK	UPOWUYPZHMWQPH-UHFFFAOYSA-N
DMFDXBJ	IU	4-[2-(5-ethylfuran-2-yl)ethyl]benzene-1,3-diol
DMFDXBJ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMFR4S0	ID	DMFR4S0
DMFR4S0	DN	Resorcinol compound 17
DMFR4S0	HS	Patented
DMFR4S0	SN	PMID26815044-Compound-24
DMFR4S0	DT	Small molecular drug
DMFR4S0	PC	18459633
DMFR4S0	MW	228.29
DMFR4S0	FM	C15H16O2
DMFR4S0	IC	InChI=1S/C15H16O2/c1-11(9-12-5-3-2-4-6-12)14-8-7-13(16)10-15(14)17/h2-8,10-11,16-17H,9H2,1H3
DMFR4S0	CS	CC(CC1=CC=CC=C1)C2=C(C=C(C=C2)O)O
DMFR4S0	IK	NGQMLDWNBTVAAC-UHFFFAOYSA-N
DMFR4S0	IU	4-(1-phenylpropan-2-yl)benzene-1,3-diol
DMFR4S0	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM64R2K	ID	DM64R2K
DM64R2K	DN	Resorcinol compound 18
DM64R2K	HS	Patented
DM64R2K	SN	PMID26815044-Compound-25
DM64R2K	DT	Small molecular drug
DM64R2K	PC	44611843
DM64R2K	MW	318.4
DM64R2K	FM	C18H22O5
DM64R2K	IC	InChI=1S/C18H22O5/c1-21-14-10-17(22-2)15(18(11-14)23-3)6-4-5-12-7-8-13(19)9-16(12)20/h7-11,19-20H,4-6H2,1-3H3
DM64R2K	CS	COC1=CC(=C(C(=C1)OC)CCCC2=C(C=C(C=C2)O)O)OC
DM64R2K	IK	BLSIHFDETVSCHH-UHFFFAOYSA-N
DM64R2K	IU	4-[3-(2,4,6-trimethoxyphenyl)propyl]benzene-1,3-diol
DM64R2K	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMJIZPQ	ID	DMJIZPQ
DMJIZPQ	DN	Resorcinol compound 19
DMJIZPQ	HS	Patented
DMJIZPQ	SN	PMID26815044-Compound-26
DMJIZPQ	DT	Small molecular drug
DMJIZPQ	PC	44611837
DMJIZPQ	MW	260.279
DMJIZPQ	FM	C15H16O4
DMJIZPQ	IC	InChI=1S/C15H16O4/c16-12-5-4-11(15(19)9-12)3-1-2-10-6-13(17)8-14(18)7-10/h4-9,16-19H,1-3H2
DMJIZPQ	CS	C1=CC(=C(C=C1O)O)CCCC2=CC(=CC(=C2)O)O
DMJIZPQ	IK	NQTJPTOXNAMXIJ-UHFFFAOYSA-N
DMJIZPQ	IU	4-[3-(3,5-dihydroxyphenyl)propyl]benzene-1,3-diol
DMJIZPQ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMGDQYW	ID	DMGDQYW
DMGDQYW	DN	Resorcinol compound 2
DMGDQYW	HS	Patented
DMGDQYW	SN	PMID26815044-Compound-10
DMGDQYW	DT	Small molecular drug
DMGDQYW	PC	85471347
DMGDQYW	MW	166.22
DMGDQYW	FM	C10H14O2
DMGDQYW	IC	InChI=1S/C10H14O2/c1-6(2)10-7(3)4-8(11)5-9(10)12/h4-6,11-12H,1-3H3
DMGDQYW	CS	CC1=CC(=CC(=C1C(C)C)O)O
DMGDQYW	IK	FBSIDCYWGKQYRW-UHFFFAOYSA-N
DMGDQYW	IU	5-methyl-4-propan-2-ylbenzene-1,3-diol
DMGDQYW	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DME4OGJ	ID	DME4OGJ
DME4OGJ	DN	Resorcinol compound 20
DME4OGJ	HS	Patented
DME4OGJ	SN	PMID26815044-Compound-27
DME4OGJ	DT	Small molecular drug
DME4OGJ	PC	44611842
DME4OGJ	MW	196.24
DME4OGJ	FM	C11H16O3
DME4OGJ	IC	InChI=1S/C11H16O3/c12-7-3-1-2-4-9-5-6-10(13)8-11(9)14/h5-6,8,12-14H,1-4,7H2
DME4OGJ	CS	C1=CC(=C(C=C1O)O)CCCCCO
DME4OGJ	IK	ZZBHJCFPTVMPAC-UHFFFAOYSA-N
DME4OGJ	IU	4-(5-hydroxypentyl)benzene-1,3-diol
DME4OGJ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM8EQPJ	ID	DM8EQPJ
DM8EQPJ	DN	Resorcinol compound 21
DM8EQPJ	HS	Patented
DM8EQPJ	SN	PMID26815044-Compound-28
DM8EQPJ	DT	Small molecular drug
DM8EQPJ	PC	44611711
DM8EQPJ	MW	288.34
DM8EQPJ	FM	C17H20O4
DM8EQPJ	IC	InChI=1S/C17H20O4/c1-20-15-8-12(9-16(11-15)21-2)4-3-5-13-6-7-14(18)10-17(13)19/h6-11,18-19H,3-5H2,1-2H3
DM8EQPJ	CS	COC1=CC(=CC(=C1)CCCC2=C(C=C(C=C2)O)O)OC
DM8EQPJ	IK	FKEXLBVQKBTEJO-UHFFFAOYSA-N
DM8EQPJ	IU	4-[3-(3,5-dimethoxyphenyl)propyl]benzene-1,3-diol
DM8EQPJ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMSW3GB	ID	DMSW3GB
DMSW3GB	DN	Resorcinol compound 22
DMSW3GB	HS	Patented
DMSW3GB	SN	PMID26815044-Compound-29
DMSW3GB	DT	Small molecular drug
DMSW3GB	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMU3APC	ID	DMU3APC
DMU3APC	DN	Resorcinol compound 23
DMU3APC	HS	Patented
DMU3APC	SN	PMID26815044-Compound-3
DMU3APC	DT	Small molecular drug
DMU3APC	PC	85471348
DMU3APC	MW	180.24
DMU3APC	FM	C11H16O2
DMU3APC	IC	InChI=1S/C11H16O2/c1-3-4-5-10-8(2)6-9(12)7-11(10)13/h6-7,12-13H,3-5H2,1-2H3
DMU3APC	CS	CCCCC1=C(C=C(C=C1C)O)O
DMU3APC	IK	IYOQFZBJNROXMO-UHFFFAOYSA-N
DMU3APC	IU	4-butyl-5-methylbenzene-1,3-diol
DMU3APC	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM2IKDL	ID	DM2IKDL
DM2IKDL	DN	Resorcinol compound 24
DM2IKDL	HS	Patented
DM2IKDL	SN	PMID26815044-Compound-4
DM2IKDL	DT	Small molecular drug
DM2IKDL	PC	45097120
DM2IKDL	MW	208.3
DM2IKDL	FM	C13H20O2
DM2IKDL	IC	InChI=1S/C13H20O2/c1-3-4-5-6-7-12-10(2)8-11(14)9-13(12)15/h8-9,14-15H,3-7H2,1-2H3
DM2IKDL	CS	CCCCCCC1=C(C=C(C=C1C)O)O
DM2IKDL	IK	VCKRCCNBIYKEFP-UHFFFAOYSA-N
DM2IKDL	IU	4-hexyl-5-methylbenzene-1,3-diol
DM2IKDL	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMEZUN7	ID	DMEZUN7
DMEZUN7	DN	Resorcinol compound 25
DMEZUN7	HS	Patented
DMEZUN7	SN	PMID26815044-Compound-5
DMEZUN7	DT	Small molecular drug
DMEZUN7	PC	85471349
DMEZUN7	MW	206.28
DMEZUN7	FM	C13H18O2
DMEZUN7	IC	InChI=1S/C13H18O2/c1-9-7-11(14)8-12(15)13(9)10-5-3-2-4-6-10/h7-8,10,14-15H,2-6H2,1H3
DMEZUN7	CS	CC1=CC(=CC(=C1C2CCCCC2)O)O
DMEZUN7	IK	NZLWYNBRWDATJO-UHFFFAOYSA-N
DMEZUN7	IU	4-cyclohexyl-5-methylbenzene-1,3-diol
DMEZUN7	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMT21JG	ID	DMT21JG
DMT21JG	DN	Resorcinol compound 26
DMT21JG	HS	Patented
DMT21JG	SN	PMID26815044-Compound-6
DMT21JG	DT	Small molecular drug
DMT21JG	PC	85471322
DMT21JG	MW	260.25
DMT21JG	FM	C13H15F3O2
DMT21JG	IC	InChI=1S/C13H15F3O2/c14-13(15,16)10-6-9(17)7-11(18)12(10)8-4-2-1-3-5-8/h6-8,17-18H,1-5H2
DMT21JG	CS	C1CCC(CC1)C2=C(C=C(C=C2O)O)C(F)(F)F
DMT21JG	IK	BYAFHGYCRSXCQR-UHFFFAOYSA-N
DMT21JG	IU	4-cyclohexyl-5-(trifluoromethyl)benzene-1,3-diol
DMT21JG	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM71R3T	ID	DM71R3T
DM71R3T	DN	Resorcinol compound 27
DM71R3T	HS	Patented
DM71R3T	SN	PMID26815044-Compound-7
DM71R3T	DT	Small molecular drug
DM71R3T	PC	85471321
DM71R3T	MW	206.16
DM71R3T	FM	C9H9F3O2
DM71R3T	IC	InChI=1S/C9H9F3O2/c1-2-6-7(9(10,11)12)3-5(13)4-8(6)14/h3-4,13-14H,2H2,1H3
DM71R3T	CS	CCC1=C(C=C(C=C1O)O)C(F)(F)F
DM71R3T	IK	KNSOMAAWMTUOTF-UHFFFAOYSA-N
DM71R3T	IU	4-ethyl-5-(trifluoromethyl)benzene-1,3-diol
DM71R3T	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMCHLAN	ID	DMCHLAN
DMCHLAN	DN	Resorcinol compound 28
DMCHLAN	HS	Patented
DMCHLAN	SN	PMID26815044-Compound-8
DMCHLAN	DT	Small molecular drug
DMCHLAN	PC	85471350
DMCHLAN	MW	206.16
DMCHLAN	FM	C9H9F3O2
DMCHLAN	IC	InChI=1S/C9H9F3O2/c1-5-2-6(13)3-8(14)7(5)4-9(10,11)12/h2-3,13-14H,4H2,1H3
DMCHLAN	CS	CC1=CC(=CC(=C1CC(F)(F)F)O)O
DMCHLAN	IK	JMBGLSBPUYZWGE-UHFFFAOYSA-N
DMCHLAN	IU	5-methyl-4-(2,2,2-trifluoroethyl)benzene-1,3-diol
DMCHLAN	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DML7ONU	ID	DML7ONU
DML7ONU	DN	Resorcinol compound 29
DML7ONU	HS	Patented
DML7ONU	SN	PMID26815044-Compound-9
DML7ONU	DT	Small molecular drug
DML7ONU	PC	10560580
DML7ONU	MW	214.26
DML7ONU	FM	C14H14O2
DML7ONU	IC	InChI=1S/C14H14O2/c1-10-7-12(15)9-14(16)13(10)8-11-5-3-2-4-6-11/h2-7,9,15-16H,8H2,1H3
DML7ONU	CS	CC1=CC(=CC(=C1CC2=CC=CC=C2)O)O
DML7ONU	IK	VPHJXVVCNGTIMH-UHFFFAOYSA-N
DML7ONU	IU	4-benzyl-5-methylbenzene-1,3-diol
DML7ONU	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMPTK0G	ID	DMPTK0G
DMPTK0G	DN	Resorcinol compound 3
DMPTK0G	HS	Patented
DMPTK0G	SN	PMID26815044-Compound-11
DMPTK0G	DT	Small molecular drug
DMPTK0G	PC	22001174
DMPTK0G	MW	187.19
DMPTK0G	FM	C11H9NO2
DMPTK0G	IC	InChI=1S/C11H9NO2/c13-9-3-4-10(11(14)6-9)8-2-1-5-12-7-8/h1-7,13-14H
DMPTK0G	CS	C1=CC(=CN=C1)C2=C(C=C(C=C2)O)O
DMPTK0G	IK	QGIIUQKOKJXLED-UHFFFAOYSA-N
DMPTK0G	IU	4-pyridin-3-ylbenzene-1,3-diol
DMPTK0G	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMMTVN4	ID	DMMTVN4
DMMTVN4	DN	Resorcinol compound 30
DMMTVN4	HS	Patented
DMMTVN4	SN	PMID26815044-Compound-A
DMMTVN4	DT	Small molecular drug
DMMTVN4	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMSPCLD	ID	DMSPCLD
DMSPCLD	DN	Resorcinol compound 31
DMSPCLD	HS	Patented
DMSPCLD	SN	PMID26815044-Compound-B
DMSPCLD	DT	Small molecular drug
DMSPCLD	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM2RPYB	ID	DM2RPYB
DM2RPYB	DN	Resorcinol compound 32
DM2RPYB	HS	Patented
DM2RPYB	SN	PMID26815044-Compound-c
DM2RPYB	DT	Small molecular drug
DM2RPYB	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMLJYS1	ID	DMLJYS1
DMLJYS1	DN	Resorcinol compound 33
DMLJYS1	HS	Patented
DMLJYS1	SN	PMID26815044-Compound-D
DMLJYS1	DT	Small molecular drug
DMLJYS1	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMQF90E	ID	DMQF90E
DMQF90E	DN	Resorcinol compound 34
DMQF90E	HS	Patented
DMQF90E	SN	PMID26815044-Compound-E
DMQF90E	DT	Small molecular drug
DMQF90E	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMIM9EY	ID	DMIM9EY
DMIM9EY	DN	Resorcinol compound 4
DMIM9EY	HS	Patented
DMIM9EY	SN	PMID26815044-Compound-12
DMIM9EY	DT	Small molecular drug
DMIM9EY	PC	44611437
DMIM9EY	MW	216.23
DMIM9EY	FM	C13H12O3
DMIM9EY	IC	InChI=1S/C13H12O3/c1-16-11-5-2-9(3-6-11)12-7-4-10(14)8-13(12)15/h2-8,14-15H,1H3
DMIM9EY	CS	COC1=CC=C(C=C1)C2=C(C=C(C=C2)O)O
DMIM9EY	IK	QYQMHWNFXIXZGS-UHFFFAOYSA-N
DMIM9EY	IU	4-(4-methoxyphenyl)benzene-1,3-diol
DMIM9EY	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMQ5TYK	ID	DMQ5TYK
DMQ5TYK	DN	Resorcinol compound 5
DMQ5TYK	HS	Patented
DMQ5TYK	SN	PMID26815044-Compound-13
DMQ5TYK	DT	Small molecular drug
DMQ5TYK	PC	20387
DMQ5TYK	MW	218.2
DMQ5TYK	FM	C12H10O4
DMQ5TYK	IC	InChI=1S/C12H10O4/c13-7-1-3-9(11(15)5-7)10-4-2-8(14)6-12(10)16/h1-6,13-16H
DMQ5TYK	CS	C1=CC(=C(C=C1O)O)C2=C(C=C(C=C2)O)O
DMQ5TYK	IK	CFGDTWRKBRQUFB-UHFFFAOYSA-N
DMQ5TYK	IU	4-(2,4-dihydroxyphenyl)benzene-1,3-diol
DMQ5TYK	CA	CAS 4371-31-7
DMQ5TYK	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM809YH	ID	DM809YH
DM809YH	DN	Resorcinol compound 6
DM809YH	HS	Patented
DM809YH	SN	PMID26815044-Compound-14
DM809YH	DT	Small molecular drug
DM809YH	PC	13035019
DM809YH	MW	244.24
DM809YH	FM	C14H12O4
DM809YH	IC	InChI=1S/C14H12O4/c15-11-3-2-10(12(16)7-11)5-9-1-4-13-14(6-9)18-8-17-13/h1-4,6-7,15-16H,5,8H2
DM809YH	CS	C1OC2=C(O1)C=C(C=C2)CC3=C(C=C(C=C3)O)O
DM809YH	IK	KUMBCKZCFIONIT-UHFFFAOYSA-N
DM809YH	IU	4-(1,3-benzodioxol-5-ylmethyl)benzene-1,3-diol
DM809YH	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM031RU	ID	DM031RU
DM031RU	DN	Resorcinol compound 7
DM031RU	HS	Patented
DM031RU	SN	PMID26815044-Compound-15
DM031RU	DT	Small molecular drug
DM031RU	PC	44611569
DM031RU	MW	190.19
DM031RU	FM	C11H10O3
DM031RU	IC	InChI=1S/C11H10O3/c12-9-4-3-8(11(13)7-9)6-10-2-1-5-14-10/h1-5,7,12-13H,6H2
DM031RU	CS	C1=COC(=C1)CC2=C(C=C(C=C2)O)O
DM031RU	IK	UGOKFADRDRUFRJ-UHFFFAOYSA-N
DM031RU	IU	4-(furan-2-ylmethyl)benzene-1,3-diol
DM031RU	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMLF53V	ID	DMLF53V
DMLF53V	DN	Resorcinol compound 8
DMLF53V	HS	Patented
DMLF53V	SN	PMID26815044-Compound-16
DMLF53V	DT	Small molecular drug
DMLF53V	PC	59152424
DMLF53V	MW	201.22
DMLF53V	FM	C12H11NO2
DMLF53V	IC	InChI=1S/C12H11NO2/c14-11-4-3-10(12(15)7-11)6-9-2-1-5-13-8-9/h1-5,7-8,14-15H,6H2
DMLF53V	CS	C1=CC(=CN=C1)CC2=C(C=C(C=C2)O)O
DMLF53V	IK	ZWKHYPPKPLXBIY-UHFFFAOYSA-N
DMLF53V	IU	4-(pyridin-3-ylmethyl)benzene-1,3-diol
DMLF53V	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMCJO0R	ID	DMCJO0R
DMCJO0R	DN	Resorcinol compound 9
DMCJO0R	HS	Patented
DMCJO0R	SN	PMID26815044-Compound-17
DMCJO0R	DT	Small molecular drug
DMCJO0R	PC	44611570
DMCJO0R	MW	190.19
DMCJO0R	FM	C11H10O3
DMCJO0R	IC	InChI=1S/C11H10O3/c12-10-2-1-9(11(13)6-10)5-8-3-4-14-7-8/h1-4,6-7,12-13H,5H2
DMCJO0R	CS	C1=CC(=C(C=C1O)O)CC2=COC=C2
DMCJO0R	IK	LOAGBHXAWVQEGF-UHFFFAOYSA-N
DMCJO0R	IU	4-(furan-3-ylmethyl)benzene-1,3-diol
DMCJO0R	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMUB7RV	ID	DMUB7RV
DMUB7RV	DN	Ring-fused compound 1
DMUB7RV	HS	Patented
DMUB7RV	SN	PMID27414413-Compound-Figure5left
DMUB7RV	DT	Small molecular drug

DMD1G3Z	ID	DMD1G3Z
DMD1G3Z	DN	Roscovitine derivative 1
DMD1G3Z	HS	Patented
DMD1G3Z	SN	PMID26161698-Compound-8
DMD1G3Z	CP	UNIVERZITA PALACKEHO V OLOMOUCI BIOPATTERNS S.R.O
DMD1G3Z	DT	Small molecular drug
DMD1G3Z	PC	73353575
DMD1G3Z	MW	472.6
DMD1G3Z	FM	C26H32N8O
DMD1G3Z	IC	InChI=1S/C26H32N8O/c27-18-8-10-19(11-9-18)31-26-32-24(23-25(33-26)34(16-30-23)20-4-1-2-5-20)29-15-17-7-12-21(28-14-17)22-6-3-13-35-22/h3,6-7,12-14,16,18-20H,1-2,4-5,8-11,15,27H2,(H2,29,31,32,33)
DMD1G3Z	CS	C1CCC(C1)N2C=NC3=C(N=C(N=C32)NC4CCC(CC4)N)NCC5=CN=C(C=C5)C6=CC=CO6
DMD1G3Z	IK	MDEXMDFOZRJJIN-UHFFFAOYSA-N
DMD1G3Z	IU	2-N-(4-aminocyclohexyl)-9-cyclopentyl-6-N-[[6-(furan-2-yl)pyridin-3-yl]methyl]purine-2,6-diamine

DM41ZW9	ID	DM41ZW9
DM41ZW9	DN	Ruxolitinib derivative 1
DM41ZW9	HS	Patented
DM41ZW9	SN	PMID27774824-Compound-Figure9Example3
DM41ZW9	CP	CONCERT PHARMACEUTICALS, INC
DM41ZW9	DT	Small molecular drug

DMSJWZ3	ID	DMSJWZ3
DMSJWZ3	DN	Ruxolitinib derivative 2
DMSJWZ3	HS	Patented
DMSJWZ3	SN	PMID27774824-Compound-Figure4Example4
DMSJWZ3	CP	JIN, Bohan
DMSJWZ3	DT	Small molecular drug

DMB79QJ	ID	DMB79QJ
DMB79QJ	DN	Salicylic acid derivative 1
DMB79QJ	HS	Patented
DMB79QJ	SN	PMID26394986-Compound-13a
DMB79QJ	CP	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DMB79QJ	DT	Small molecular drug
DMB79QJ	PC	68075823
DMB79QJ	MW	694.8
DMB79QJ	FM	C37H37F3N2O6S
DMB79QJ	IC	InChI=1S/C37H37F3N2O6S/c1-25-11-18-31(19-12-25)49(47,48)41(23-29-9-5-6-10-33(29)37(38,39)40)24-35(44)42(30-17-20-32(36(45)46)34(43)21-30)22-26-13-15-28(16-14-26)27-7-3-2-4-8-27/h5-6,9-21,27,43H,2-4,7-8,22-24H2,1H3,(H,45,46)
DMB79QJ	CS	CC1=CC=C(C=C1)S(=O)(=O)N(CC2=CC=CC=C2C(F)(F)F)CC(=O)N(CC3=CC=C(C=C3)C4CCCCC4)C5=CC(=C(C=C5)C(=O)O)O
DMB79QJ	IK	GFASCHAWPQEYTQ-UHFFFAOYSA-N
DMB79QJ	IU	4-[(4-cyclohexylphenyl)methyl-[2-[(4-methylphenyl)sulfonyl-[[2-(trifluoromethyl)phenyl]methyl]amino]acetyl]amino]-2-hydroxybenzoic acid

DMD8C9S	ID	DMD8C9S
DMD8C9S	DN	Salicylic acid derivative 2
DMD8C9S	HS	Patented
DMD8C9S	SN	PMID26394986-Compound-14
DMD8C9S	CP	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DMD8C9S	DT	Small molecular drug
DMD8C9S	PC	53388144
DMD8C9S	MW	626.6
DMD8C9S	FM	C29H27F5N2O6S
DMD8C9S	IC	InChI=1S/C29H27F5N2O6S/c1-35(43(41,42)28-26(33)24(31)23(30)25(32)27(28)34)15-22(38)36(19-11-12-20(29(39)40)21(37)13-19)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h7-13,17,37H,2-6,14-15H2,1H3,(H,39,40)
DMD8C9S	CS	CN(CC(=O)N(CC1=CC=C(C=C1)C2CCCCC2)C3=CC(=C(C=C3)C(=O)O)O)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F
DMD8C9S	IK	WNVSFFVDMUSXSX-UHFFFAOYSA-N
DMD8C9S	IU	4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid

DM4OGKH	ID	DM4OGKH
DM4OGKH	DN	Salicylic acid derivative 3
DM4OGKH	HS	Patented
DM4OGKH	SN	PMID26394986-Compound-14a
DM4OGKH	CP	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DM4OGKH	DT	Small molecular drug
DM4OGKH	PC	73333953
DM4OGKH	MW	770.7
DM4OGKH	FM	C36H30F8N2O6S
DM4OGKH	IC	InChI=1S/C36H30F8N2O6S/c37-29-30(38)32(40)34(33(41)31(29)39)53(51,52)45(18-23-8-4-5-9-26(23)36(42,43)44)19-28(48)46(24-14-15-25(35(49)50)27(47)16-24)17-20-10-12-22(13-11-20)21-6-2-1-3-7-21/h4-5,8-16,21,47H,1-3,6-7,17-19H2,(H,49,50)
DM4OGKH	CS	C1CCC(CC1)C2=CC=C(C=C2)CN(C3=CC(=C(C=C3)C(=O)O)O)C(=O)CN(CC4=CC=CC=C4C(F)(F)F)S(=O)(=O)C5=C(C(=C(C(=C5F)F)F)F)F
DM4OGKH	IK	UEUVIKQOEXBPOQ-UHFFFAOYSA-N
DM4OGKH	IU	4-[(4-cyclohexylphenyl)methyl-[2-[(2,3,4,5,6-pentafluorophenyl)sulfonyl-[[2-(trifluoromethyl)phenyl]methyl]amino]acetyl]amino]-2-hydroxybenzoic acid

DM4MAHK	ID	DM4MAHK
DM4MAHK	DN	Salicylic acid derivative 4
DM4MAHK	HS	Patented
DM4MAHK	SN	PMID26394986-Compound-16
DM4MAHK	CP	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DM4MAHK	DT	Small molecular drug
DM4MAHK	PC	72545583
DM4MAHK	MW	668.6
DM4MAHK	FM	C31H29F5N2O7S
DM4MAHK	IC	InChI=1S/C31H29F5N2O7S/c1-17(39)45-23-14-21(12-13-22(23)31(41)42)38(15-18-8-10-20(11-9-18)19-6-4-3-5-7-19)24(40)16-37(2)46(43,44)30-28(35)26(33)25(32)27(34)29(30)36/h8-14,19H,3-7,15-16H2,1-2H3,(H,41,42)
DM4MAHK	CS	CC(=O)OC1=C(C=CC(=C1)N(CC2=CC=C(C=C2)C3CCCCC3)C(=O)CN(C)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F)C(=O)O
DM4MAHK	IK	MXLQNCLPTUVOQV-UHFFFAOYSA-N
DM4MAHK	IU	2-acetyloxy-4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]benzoic acid

DM3OZ0F	ID	DM3OZ0F
DM3OZ0F	DN	Salicylic acid derivative 5
DM3OZ0F	HS	Patented
DM3OZ0F	SN	PMID26394986-Compound-17
DM3OZ0F	CP	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DM3OZ0F	DT	Small molecular drug
DM3OZ0F	PC	72188643
DM3OZ0F	MW	610.6
DM3OZ0F	FM	C29H27F5N2O5S
DM3OZ0F	IC	InChI=1S/C29H27F5N2O5S/c1-35(42(40,41)28-26(33)24(31)23(30)25(32)27(28)34)16-22(37)36(21-13-11-20(12-14-21)29(38)39)15-17-7-9-19(10-8-17)18-5-3-2-4-6-18/h7-14,18H,2-6,15-16H2,1H3,(H,38,39)
DM3OZ0F	CS	CN(CC(=O)N(CC1=CC=C(C=C1)C2CCCCC2)C3=CC=C(C=C3)C(=O)O)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F
DM3OZ0F	IK	VFPYGNNOSJWBHF-UHFFFAOYSA-N
DM3OZ0F	IU	4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]benzoic acid

DMLBEPW	ID	DMLBEPW
DMLBEPW	DN	Salicylic acid derivative 6
DMLBEPW	HS	Patented
DMLBEPW	SN	PMID26394986-Compound-18
DMLBEPW	CP	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DMLBEPW	DT	Small molecular drug
DMLBEPW	PC	72550504
DMLBEPW	MW	625.6
DMLBEPW	FM	C29H28F5N3O5S
DMLBEPW	IC	InChI=1S/C29H28F5N3O5S/c1-36(43(41,42)28-26(33)24(31)23(30)25(32)27(28)34)16-22(38)37(21-13-11-20(12-14-21)29(39)35-40)15-17-7-9-19(10-8-17)18-5-3-2-4-6-18/h7-14,18,40H,2-6,15-16H2,1H3,(H,35,39)
DMLBEPW	CS	CN(CC(=O)N(CC1=CC=C(C=C1)C2CCCCC2)C3=CC=C(C=C3)C(=O)NO)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F
DMLBEPW	IK	QPSUYVALAOXFGL-UHFFFAOYSA-N
DMLBEPW	IU	4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]-N-hydroxybenzamide
DMLBEPW	CA	CAS 1456632-41-9

DMJFHVN	ID	DMJFHVN
DMJFHVN	DN	Salicylic acid derivative 7
DMJFHVN	HS	Patented
DMJFHVN	SN	PMID26394986-Compound-19
DMJFHVN	CP	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DMJFHVN	DT	Small molecular drug
DMJFHVN	PC	72545832
DMJFHVN	MW	628.6
DMJFHVN	FM	C29H26F6N2O5S
DMJFHVN	IC	InChI=1S/C29H26F6N2O5S/c1-36(43(41,42)28-26(34)24(32)23(31)25(33)27(28)35)15-22(38)37(19-11-12-20(29(39)40)21(30)13-19)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h7-13,17H,2-6,14-15H2,1H3,(H,39,40)
DMJFHVN	CS	CN(CC(=O)N(CC1=CC=C(C=C1)C2CCCCC2)C3=CC(=C(C=C3)C(=O)O)F)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F
DMJFHVN	IK	PSOITMRLZWEHSO-UHFFFAOYSA-N
DMJFHVN	IU	4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]-2-fluorobenzoic acid

DM2MQD0	ID	DM2MQD0
DM2MQD0	DN	SB19065
DM2MQD0	HS	Patented
DM2MQD0	SN	CHEMBL2336005; SCHEMBL14777163; ZINC95587687; BDBM50430875; SB19065; 3-(2-(3-(morpholinomethyl)phenyl)thieno[3,2-b]pyridin-7-ylamino)phenol; 3-({2-[3-(morpholin-4-ylmethyl)phenyl]thieno[3,2-b]pyridin-7-yl}amino)phenol; 1228102-01-9
DM2MQD0	DT	Small molecular drug
DM2MQD0	PC	71577234
DM2MQD0	MW	417.5
DM2MQD0	FM	C24H23N3O2S
DM2MQD0	IC	InChI=1S/C24H23N3O2S/c28-20-6-2-5-19(14-20)26-21-7-8-25-22-15-23(30-24(21)22)18-4-1-3-17(13-18)16-27-9-11-29-12-10-27/h1-8,13-15,28H,9-12,16H2,(H,25,26)
DM2MQD0	CS	C1COCCN1CC2=CC(=CC=C2)C3=CC4=NC=CC(=C4S3)NC5=CC(=CC=C5)O
DM2MQD0	IK	ZCWXCBKGPJOAFQ-UHFFFAOYSA-N
DM2MQD0	IU	3-[[2-[3-(morpholin-4-ylmethyl)phenyl]thieno[3,2-b]pyridin-7-yl]amino]phenol

DMKQ0GE	ID	DMKQ0GE
DMKQ0GE	DN	SCHEMBL15198145
DMKQ0GE	HS	Patented
DMKQ0GE	SN	SCHEMBL15198145
DMKQ0GE	DT	Small molecular drug
DMKQ0GE	PC	71715083
DMKQ0GE	MW	495.6
DMKQ0GE	FM	C24H25N5O5S
DMKQ0GE	IC	InChI=1S/C24H25N5O5S/c25-35(32,33)34-14-18-12-20(24(31)23(18)30)27-21-9-10-26-22-13-19(28-29(21)22)17-8-4-7-16(11-17)15-5-2-1-3-6-15/h1-11,13,18,20,23-24,27,30-31H,12,14H2,(H2,25,32,33)/t18-,20-,23-,24+/m1/s1
DMKQ0GE	CS	C1[C@@H]([C@H]([C@H]([C@@H]1NC2=CC=NC3=CC(=NN23)C4=CC=CC(=C4)C5=CC=CC=C5)O)O)COS(=O)(=O)N
DMKQ0GE	IK	OHUBWOCZKZLWIV-ILEGPTGMSA-N
DMKQ0GE	IU	[(1R,2R,3S,4R)-2,3-dihydroxy-4-[[2-(3-phenylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]cyclopentyl]methyl sulfamate

DMHPQI2	ID	DMHPQI2
DMHPQI2	DN	SCHEMBL15198146
DMHPQI2	HS	Patented
DMHPQI2	SN	SCHEMBL15198146
DMHPQI2	DT	Small molecular drug
DMHPQI2	PC	71715084
DMHPQI2	MW	433.5
DMHPQI2	FM	C19H23N5O5S
DMHPQI2	IC	InChI=1S/C19H23N5O5S/c1-11-7-16(22-15-8-13(18(25)19(15)26)10-29-30(20,27)28)24-17(21-11)9-14(23-24)12-5-3-2-4-6-12/h2-7,9,13,15,18-19,22,25-26H,8,10H2,1H3,(H2,20,27,28)/t13-,15-,18-,19+/m1/s1
DMHPQI2	CS	CC1=NC2=CC(=NN2C(=C1)N[C@@H]3C[C@@H]([C@H]([C@H]3O)O)COS(=O)(=O)N)C4=CC=CC=C4
DMHPQI2	IK	LFVBSFKFKWBKIB-LRHNDGHRSA-N
DMHPQI2	IU	[(1R,2R,3S,4R)-2,3-dihydroxy-4-[(5-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]cyclopentyl]methyl sulfamate

DMK0T9E	ID	DMK0T9E
DMK0T9E	DN	SCHEMBL15295829
DMK0T9E	HS	Patented
DMK0T9E	SN	SCHEMBL15295829
DMK0T9E	DT	Small molecular drug
DMK0T9E	PC	71738918
DMK0T9E	MW	435.3
DMK0T9E	FM	C19H20Cl2N6O2
DMK0T9E	IC	InChI=1S/C19H20Cl2N6O2/c1-5-6-27-18-17(11(4)25-27)13(10(2)3)9-16(24-18)29-26-19(28)22-12-7-14(20)23-15(21)8-12/h5,7-10H,1,6H2,2-4H3,(H2,22,23,26,28)
DMK0T9E	CS	CC1=NN(C2=C1C(=CC(=N2)ONC(=O)NC3=CC(=NC(=C3)Cl)Cl)C(C)C)CC=C
DMK0T9E	IK	GSDSPSURUKLGBL-UHFFFAOYSA-N
DMK0T9E	IU	1-(2,6-dichloropyridin-4-yl)-3-(3-methyl-4-propan-2-yl-1-prop-2-enylpyrazolo[3,4-b]pyridin-6-yl)oxyurea

DM3OB4T	ID	DM3OB4T
DM3OB4T	DN	SCHEMBL16322760
DM3OB4T	HS	Patented
DM3OB4T	SN	SCHEMBL16322760
DM3OB4T	DT	Small molecular drug
DM3OB4T	PC	86580570
DM3OB4T	MW	477.5
DM3OB4T	FM	C24H21F2N7O2
DM3OB4T	IC	InChI=1S/C24H21F2N7O2/c1-4-35-16-9-19(25)18(20(26)10-16)13-33-14(2)17(11-27)22(32-33)24-29-12-21(34-3)23(31-24)30-15-5-7-28-8-6-15/h5-10,12H,4,13H2,1-3H3,(H,28,29,30,31)
DM3OB4T	CS	CCOC1=CC(=C(C(=C1)F)CN2C(=C(C(=N2)C3=NC=C(C(=N3)NC4=CC=NC=C4)OC)C#N)C)F
DM3OB4T	IK	VNVLBWOVSDGPGB-UHFFFAOYSA-N
DM3OB4T	IU	1-[(4-ethoxy-2,6-difluorophenyl)methyl]-3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-5-methylpyrazole-4-carbonitrile

DMQARW2	ID	DMQARW2
DMQARW2	DN	SCHEMBL16365841
DMQARW2	HS	Patented
DMQARW2	SN	SCHEMBL16365841
DMQARW2	DT	Small molecular drug
DMQARW2	PC	86580571
DMQARW2	MW	542.5
DMQARW2	FM	C26H25F3N6O4
DMQARW2	IC	InChI=1S/C26H25F3N6O4/c1-5-38-15-9-18(27)17(19(28)10-15)13-35-14(3)22(29)23(34-35)25-31-12-21(37-4)24(33-25)32-20-7-8-30-11-16(20)26(36)39-6-2/h7-12H,5-6,13H2,1-4H3,(H,30,31,32,33)
DMQARW2	CS	CCOC1=CC(=C(C(=C1)F)CN2C(=C(C(=N2)C3=NC=C(C(=N3)NC4=C(C=NC=C4)C(=O)OCC)OC)F)C)F
DMQARW2	IK	GCVMXSOKVYMCOA-UHFFFAOYSA-N
DMQARW2	IU	ethyl 4-[[2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-4-fluoro-5-methylpyrazol-3-yl]-5-methoxypyrimidin-4-yl]amino]pyridine-3-carboxylate

DMC7PTY	ID	DMC7PTY
DMC7PTY	DN	SCHEMBL17766424
DMC7PTY	HS	Patented
DMC7PTY	SN	SCHEMBL17766424
DMC7PTY	DT	Small molecular drug
DMC7PTY	PC	86580572
DMC7PTY	MW	481.5
DMC7PTY	FM	C24H25F2N7O2
DMC7PTY	IC	InChI=1S/C24H25F2N7O2/c1-5-35-16-10-18(25)17(19(26)11-16)13-33-14-20(32(2)3)22(31-33)24-28-12-21(34-4)23(30-24)29-15-6-8-27-9-7-15/h6-12,14H,5,13H2,1-4H3,(H,27,28,29,30)
DMC7PTY	CS	CCOC1=CC(=C(C(=C1)F)CN2C=C(C(=N2)C3=NC=C(C(=N3)NC4=CC=NC=C4)OC)N(C)C)F
DMC7PTY	IK	TYXHNCNKIXBYQD-UHFFFAOYSA-N
DMC7PTY	IU	2-[4-(dimethylamino)-1-[(4-ethoxy-2,6-difluorophenyl)methyl]pyrazol-3-yl]-5-methoxy-N-pyridin-4-ylpyrimidin-4-amine

DMQD6IL	ID	DMQD6IL
DMQD6IL	DN	Schiff base compound 1
DMQD6IL	HS	Patented
DMQD6IL	SN	PMID29324067-Compound-43
DMQD6IL	CP	University China Pharma
DMQD6IL	DT	Small molecular drug
DMQD6IL	DE	Alzheimer disease

DMWD20L	ID	DMWD20L
DMWD20L	DN	Schiff base compound 2
DMWD20L	HS	Patented
DMWD20L	SN	PMID29324067-Compound-53
DMWD20L	CP	University China Pharma
DMWD20L	DT	Small molecular drug
DMWD20L	DE	Alzheimer disease

DMEDNTJ	ID	DMEDNTJ
DMEDNTJ	DN	Secondary and tertiary (hetero)arylamide derivative 1
DMEDNTJ	HS	Patented
DMEDNTJ	SN	PMID29324067-Compound-1
DMEDNTJ	CP	University Zhejiang Technology
DMEDNTJ	DT	Small molecular drug

DMIES9B	ID	DMIES9B
DMIES9B	DN	Secondary and tertiary (hetero)arylamide derivative 2
DMIES9B	HS	Patented
DMIES9B	SN	PMID29324067-Compound-12
DMIES9B	CP	University Zhejiang Technology
DMIES9B	DT	Small molecular drug

DM9C5Z8	ID	DM9C5Z8
DM9C5Z8	DN	Selenium compound 1
DM9C5Z8	HS	Patented
DM9C5Z8	SN	PMID25468267-Compound-28
DM9C5Z8	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DM9C5Z8	DT	Small molecular drug
DM9C5Z8	PC	23427
DM9C5Z8	MW	189.08
DM9C5Z8	FM	C6H6O2Se
DM9C5Z8	IC	InChI=1S/C6H6O2Se/c7-9(8)6-4-2-1-3-5-6/h1-5H,(H,7,8)
DM9C5Z8	CS	C1=CC=C(C=C1)[Se](=O)O
DM9C5Z8	IK	WIHKGDVGLJJAMC-UHFFFAOYSA-N
DM9C5Z8	IU	benzeneseleninic acid
DM9C5Z8	CA	CAS 6996-92-5

DMLWIJ7	ID	DMLWIJ7
DMLWIJ7	DN	Selenium compound 2
DMLWIJ7	HS	Patented
DMLWIJ7	SN	PMID25468267-Compound-29
DMLWIJ7	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DMLWIJ7	DT	Small molecular drug
DMLWIJ7	PC	21928
DMLWIJ7	MW	191.53
DMLWIJ7	FM	C6H5ClSe
DMLWIJ7	IC	InChI=1S/C6H5ClSe/c7-8-6-4-2-1-3-5-6/h1-5H
DMLWIJ7	CS	C1=CC=C(C=C1)[Se]Cl
DMLWIJ7	IK	WJCXADMLESSGRI-UHFFFAOYSA-N
DMLWIJ7	IU	phenyl selenohypochlorite
DMLWIJ7	CA	CAS 5707-04-0

DMQ5AJ6	ID	DMQ5AJ6
DMQ5AJ6	DN	Selenium compound 3
DMQ5AJ6	HS	Patented
DMQ5AJ6	SN	PMID25468267-Compound-30
DMQ5AJ6	CP	ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DMQ5AJ6	DT	Small molecular drug
DMQ5AJ6	PC	3194
DMQ5AJ6	MW	274.19
DMQ5AJ6	FM	C13H9NOSe
DMQ5AJ6	IC	InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
DMQ5AJ6	CS	C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
DMQ5AJ6	IK	DYEFUKCXAQOFHX-UHFFFAOYSA-N
DMQ5AJ6	IU	2-phenyl-1,2-benzoselenazol-3-one
DMQ5AJ6	CA	CAS 60940-34-3
DMQ5AJ6	CB	CHEBI:77543

DMYFK85	ID	DMYFK85
DMYFK85	DN	Six-membered heterocyclic benzamide derivative 1
DMYFK85	HS	Patented
DMYFK85	SN	PMID28270021-Compound-WO2015143654Example29
DMYFK85	CP	MERCK SHARP & DOHME CORP
DMYFK85	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMX6AKV	ID	DMX6AKV
DMX6AKV	DN	Six-membered heterocyclic benzamide derivative 2
DMX6AKV	HS	Patented
DMX6AKV	SN	PMID28270021-Compound-WO2015143654Example41
DMX6AKV	CP	MERCK SHARP & DOHME CORP
DMX6AKV	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMEGVD4	ID	DMEGVD4
DMEGVD4	DN	Six-membered heterocyclic benzamide derivative 3
DMEGVD4	HS	Patented
DMEGVD4	SN	PMID28270021-Compound-WO2015143654Example60
DMEGVD4	CP	MERCK SHARP & DOHME CORP
DMEGVD4	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMB0D1H	ID	DMB0D1H
DMB0D1H	DN	Six-membered heterocyclic benzamide derivative 4
DMB0D1H	HS	Patented
DMB0D1H	SN	PMID28270021-Compound-WO2015143654Example62
DMB0D1H	CP	MERCK SHARP & DOHME CORP
DMB0D1H	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM0GTUH	ID	DM0GTUH
DM0GTUH	DN	Six-membered heterocyclic benzamide derivative 5
DM0GTUH	HS	Patented
DM0GTUH	SN	PMID28270021-Compound-WO2015148344Example152
DM0GTUH	CP	MERCK SHARP & DOHME CORP
DM0GTUH	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMZU96C	ID	DMZU96C
DMZU96C	DN	Six-membered heterocyclic benzamide derivative 6
DMZU96C	HS	Patented
DMZU96C	SN	PMID28270021-Compound-WO2015148344Example59
DMZU96C	CP	MERCK SHARP & DOHME CORP
DMZU96C	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM15AFI	ID	DM15AFI
DM15AFI	DN	Six-membered heterocyclic benzamide derivative 7
DM15AFI	HS	Patented
DM15AFI	SN	PMID28270021-Compound-WO2015148344Example96
DM15AFI	CP	MERCK SHARP & DOHME CORP
DM15AFI	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMJF6S0	ID	DMJF6S0
DMJF6S0	DN	Sphinx
DMJF6S0	HS	Patented
DMJF6S0	SN	SPHINX; AC1NI3K3; SCHEMBL15648757; US9695160, SPHINX; BDBM221070; ZINC6790230; AKOS001099848; MCULE-7133870197; 5-methyl-N-[2-morpholin-4-yl-5-(trifluoromethyl)phenyl]furan-2-carboxamide; 5-methyl-N-(2-morpholino-5-(trifluoromethyl)phenyl)furan-2-carboxamide; 5-methyl-N-[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]furan-2-carboxamide; 848057-98-7
DMJF6S0	DT	Small molecular drug
DMJF6S0	PC	4799939
DMJF6S0	MW	354.32
DMJF6S0	FM	C17H17F3N2O3
DMJF6S0	IC	InChI=1S/C17H17F3N2O3/c1-11-2-5-15(25-11)16(23)21-13-10-12(17(18,19)20)3-4-14(13)22-6-8-24-9-7-22/h2-5,10H,6-9H2,1H3,(H,21,23)
DMJF6S0	CS	CC1=CC=C(O1)C(=O)NC2=C(C=CC(=C2)C(F)(F)F)N3CCOCC3
DMJF6S0	IK	FZCPNRVICXFZJR-UHFFFAOYSA-N
DMJF6S0	IU	5-methyl-N-[2-morpholin-4-yl-5-(trifluoromethyl)phenyl]furan-2-carboxamide

DM8XJTH	ID	DM8XJTH
DM8XJTH	DN	SPHINX scaffold, 3
DM8XJTH	HS	Patented
DM8XJTH	SN	SPHINX scaffold, 3; SCHEMBL18538650; BDBM221073; US9695160, SPHINX7
DM8XJTH	DT	Small molecular drug
DM8XJTH	PC	73672854
DM8XJTH	MW	487.5
DM8XJTH	FM	C25H28F3N5O2
DM8XJTH	IC	InChI=1S/C25H28F3N5O2/c1-31(2)11-12-32-13-15-33(16-14-32)21-4-3-19(25(26,27)28)17-20(21)30-24(34)23-6-5-22(35-23)18-7-9-29-10-8-18/h3-10,17H,11-16H2,1-2H3,(H,30,34)
DM8XJTH	CS	CN(C)CCN1CCN(CC1)C2=C(C=C(C=C2)C(F)(F)F)NC(=O)C3=CC=C(O3)C4=CC=NC=C4
DM8XJTH	IK	ALLIMXLDTJFWHR-UHFFFAOYSA-N
DM8XJTH	IU	N-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-(trifluoromethyl)phenyl]-5-pyridin-4-ylfuran-2-carboxamide

DM4R7OQ	ID	DM4R7OQ
DM4R7OQ	DN	Spirocyclic diamine urea derivative 1
DM4R7OQ	HS	Patented
DM4R7OQ	SN	PMID26413912-Compound-46
DM4R7OQ	CP	JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. KEITH, John, M. JONES, William, M
DM4R7OQ	DT	Small molecular drug

DMH5N78	ID	DMH5N78
DMH5N78	DN	Spirocyclic diamine urea derivative 2
DMH5N78	HS	Patented
DMH5N78	SN	PMID26413912-Compound-47
DMH5N78	CP	JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. KEITH, John, M. JONES, William, M
DMH5N78	DT	Small molecular drug
DMH5N78	PC	49822348
DMH5N78	MW	497.4
DMH5N78	FM	C26H26Cl2N4O2
DMH5N78	IC	InChI=1S/C26H26Cl2N4O2/c27-20-4-6-23(7-5-20)34-24-3-1-2-19(12-24)16-31-10-8-26(9-11-31)17-32(18-26)25(33)30-22-13-21(28)14-29-15-22/h1-7,12-15H,8-11,16-18H2,(H,30,33)
DMH5N78	CS	C1CN(CCC12CN(C2)C(=O)NC3=CC(=CN=C3)Cl)CC4=CC(=CC=C4)OC5=CC=C(C=C5)Cl
DMH5N78	IK	UNZBUFAASDCGFU-UHFFFAOYSA-N
DMH5N78	IU	7-[[3-(4-chlorophenoxy)phenyl]methyl]-N-(5-chloropyridin-3-yl)-2,7-diazaspiro[3.5]nonane-2-carboxamide

DMCPVRU	ID	DMCPVRU
DMCPVRU	DN	Spiroimidazolone derivative 1
DMCPVRU	HS	Patented
DMCPVRU	SN	PMID25828189-Compound-28
DMCPVRU	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DMCPVRU	DT	Small molecular drug

DM3EAHB	ID	DM3EAHB
DM3EAHB	DN	Spiroimidazolone derivative 2
DM3EAHB	HS	Patented
DM3EAHB	SN	PMID25828189-Compound-29
DM3EAHB	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DM3EAHB	DT	Small molecular drug
DM3EAHB	PC	53472814
DM3EAHB	MW	644.9
DM3EAHB	FM	C37H56N8O2
DM3EAHB	IC	InChI=1S/C37H56N8O2/c1-35(2,3)19-17-30(26-11-13-27(14-12-26)33(46)38-23-31-40-42-43-41-31)45-34(47)32(44-22-18-25-9-7-8-10-28(25)24-44)39-37(45)20-15-29(16-21-37)36(4,5)6/h11-14,25,28-30H,7-10,15-24H2,1-6H3,(H,38,46)(H,40,41,42,43)/t25?,28?,29?,30-,37?/m1/s1
DM3EAHB	CS	CC(C)(C)CC[C@H](C1=CC=C(C=C1)C(=O)NCC2=NNN=N2)N3C(=O)C(=NC34CCC(CC4)C(C)(C)C)N5CCC6CCCCC6C5
DM3EAHB	IK	QRNMPSNUYHYWGG-RLLJVHIDSA-N
DM3EAHB	IU	4-[(1R)-1-[2-(3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl)-8-tert-butyl-3-oxo-1,4-diazaspiro[4.5]dec-1-en-4-yl]-4,4-dimethylpentyl]-N-(2H-tetrazol-5-ylmethyl)benzamide

DM02J8N	ID	DM02J8N
DM02J8N	DN	Spiroimidazolone derivative 3
DM02J8N	HS	Patented
DM02J8N	SN	PMID25828189-Compound-30
DM02J8N	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DM02J8N	DT	Small molecular drug
DM02J8N	PC	53377590
DM02J8N	MW	524.7
DM02J8N	FM	C30H44N4O4
DM02J8N	IC	InChI=1S/C30H44N4O4/c1-5-24(21-9-11-22(12-10-21)27(37)31-18-15-25(35)36)34-28(38)26(33-19-7-6-8-20-33)32-30(34)16-13-23(14-17-30)29(2,3)4/h9-12,23-24H,5-8,13-20H2,1-4H3,(H,31,37)(H,35,36)/t23?,24-,30?/m1/s1
DM02J8N	CS	CC[C@H](C1=CC=C(C=C1)C(=O)NCCC(=O)O)N2C(=O)C(=NC23CCC(CC3)C(C)(C)C)N4CCCCC4
DM02J8N	IK	RSTWUMARZLVIKV-OLYGOTPTSA-N
DM02J8N	IU	3-[[4-[(1R)-1-(8-tert-butyl-3-oxo-2-piperidin-1-yl-1,4-diazaspiro[4.5]dec-1-en-4-yl)propyl]benzoyl]amino]propanoic acid

DMXIHPT	ID	DMXIHPT
DMXIHPT	DN	Spiroimidazolone derivative 4
DMXIHPT	HS	Patented
DMXIHPT	SN	PMID25828189-Compound-31
DMXIHPT	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DMXIHPT	DT	Small molecular drug
DMXIHPT	PC	71202253
DMXIHPT	MW	589.8
DMXIHPT	FM	C34H51N7O2
DMXIHPT	IC	InChI=1S/C34H51N7O2/c1-32(2,3)19-18-27(23-12-14-25(15-13-23)30(42)35-22-28-37-39-40-38-28)41-31(43)29(24-10-8-7-9-11-24)36-34(41)20-16-26(17-21-34)33(4,5)6/h12-15,24,26-27H,7-11,16-22H2,1-6H3,(H,35,42)(H,37,38,39,40)/t26?,27-,34?/m1/s1
DMXIHPT	CS	CC(C)(C)CC[C@H](C1=CC=C(C=C1)C(=O)NCC2=NNN=N2)N3C(=O)C(=NC34CCC(CC4)C(C)(C)C)C5CCCCC5
DMXIHPT	IK	PTRTYSISBCSORS-XSUYSUAISA-N
DMXIHPT	IU	4-[(1R)-1-(8-tert-butyl-2-cyclohexyl-3-oxo-1,4-diazaspiro[4.5]dec-1-en-4-yl)-4,4-dimethylpentyl]-N-(2H-tetrazol-5-ylmethyl)benzamide

DM5A62X	ID	DM5A62X
DM5A62X	DN	Spiroimidazolone derivative 5
DM5A62X	HS	Patented
DM5A62X	SN	PMID25828189-Compound-32
DM5A62X	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DM5A62X	DT	Small molecular drug

DMJN5CI	ID	DMJN5CI
DMJN5CI	DN	Spiroimidazolone derivative 6
DMJN5CI	HS	Patented
DMJN5CI	SN	PMID25828189-Compound-33
DMJN5CI	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DMJN5CI	DT	Small molecular drug
DMJN5CI	PC	53377591
DMJN5CI	MW	683.9
DMJN5CI	FM	C40H57N7O3
DMJN5CI	IC	InChI=1S/C40H57N7O3/c1-37(2,3)20-19-32(27-13-15-28(16-14-27)35(48)41-26-33-43-45-46-44-33)47-36(49)34(42-40(47)21-17-30(18-22-40)39(7,8)9)29-11-10-12-31(25-29)50-24-23-38(4,5)6/h10-16,25,30,32H,17-24,26H2,1-9H3,(H,41,48)(H,43,44,45,46)/t30?,32-,40?/m1/s1
DMJN5CI	CS	CC(C)(C)CC[C@H](C1=CC=C(C=C1)C(=O)NCC2=NNN=N2)N3C(=O)C(=NC34CCC(CC4)C(C)(C)C)C5=CC(=CC=C5)OCCC(C)(C)C
DMJN5CI	IK	BKPCTAJENJTTAU-WHPMNUFOSA-N
DMJN5CI	IU	4-[(1R)-1-[8-tert-butyl-2-[3-(3,3-dimethylbutoxy)phenyl]-3-oxo-1,4-diazaspiro[4.5]dec-1-en-4-yl]-4,4-dimethylpentyl]-N-(2H-tetrazol-5-ylmethyl)benzamide

DM5A4TP	ID	DM5A4TP
DM5A4TP	DN	Spiroimidazolone derivative 7
DM5A4TP	HS	Patented
DM5A4TP	SN	PMID25828189-Compound-34
DM5A4TP	CP	MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DM5A4TP	DT	Small molecular drug
DM5A4TP	PC	53467170
DM5A4TP	MW	607.8
DM5A4TP	FM	C34H46FN3O4Si
DM5A4TP	IC	InChI=1S/C34H46FN3O4Si/c1-33(2,3)18-16-28(23-10-12-24(13-11-23)31(41)36-21-17-29(39)40)38-32(42)30(25-8-7-9-26(35)22-25)37-34(38)19-14-27(15-20-34)43(4,5)6/h7-13,22,27-28H,14-21H2,1-6H3,(H,36,41)(H,39,40)/t27?,28-,34?/m1/s1
DM5A4TP	CS	CC(C)(C)CC[C@H](C1=CC=C(C=C1)C(=O)NCCC(=O)O)N2C(=O)C(=NC23CCC(CC3)[Si](C)(C)C)C4=CC(=CC=C4)F
DM5A4TP	IK	RBMROQXTXSWPGO-IXDCWVCYSA-N
DM5A4TP	IU	3-[[4-[(1R)-1-[2-(3-fluorophenyl)-3-oxo-8-trimethylsilyl-1,4-diazaspiro[4.5]dec-1-en-4-yl]-4,4-dimethylpentyl]benzoyl]amino]propanoic acid

DMK5G7D	ID	DMK5G7D
DMK5G7D	DN	Spirolaxine derivative 1
DMK5G7D	HS	Patented
DMK5G7D	SN	PMID25416646-Compound-Figure2-L
DMK5G7D	CP	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. CALVANI, Menotti D'IDDIO, Stefania BENATTI, Paola
DMK5G7D	DT	Small molecular drug

DMYJL2Z	ID	DMYJL2Z
DMYJL2Z	DN	Spiroquinolone derivative 1
DMYJL2Z	HS	Patented
DMYJL2Z	SN	PMID27828716-Compound-8
DMYJL2Z	DT	Small molecular drug
DMYJL2Z	PC	25253820
DMYJL2Z	MW	453.5
DMYJL2Z	FM	C23H24FN5O4
DMYJL2Z	IC	InChI=1S/C23H24FN5O4/c24-16-17(25)15-19-21(18(16)28-10-9-27-14-4-1-2-8-26-14)33-11-7-23(5-3-6-23)29(19)12-13(20(15)30)22(31)32/h1-2,4,8,12,28H,3,5-7,9-11,25H2,(H,26,27)(H,31,32)
DMYJL2Z	CS	C1CC2(C1)CCOC3=C4N2C=C(C(=O)C4=C(C(=C3NCCNC5=CC=CC=N5)F)N)C(=O)O
DMYJL2Z	IK	FBGUGRUHZTVCSL-UHFFFAOYSA-N
DMYJL2Z	IU	6-amino-7-fluoro-4-oxo-8-[2-(pyridin-2-ylamino)ethylamino]spiro[10-oxa-1-azatricyclo[7.4.1.05,14]tetradeca-2,5,7,9(14)-tetraene-13,1'-cyclobutane]-3-carboxylic acid

DMB0NVQ	ID	DMB0NVQ
DMB0NVQ	DN	Steroid derivative 1
DMB0NVQ	HS	Patented
DMB0NVQ	SN	PMID26882240-Compound-23
DMB0NVQ	DT	Small molecular drug
DMB0NVQ	PC	66414
DMB0NVQ	MW	302.4
DMB0NVQ	FM	C19H26O3
DMB0NVQ	IC	InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1
DMB0NVQ	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)OC)O
DMB0NVQ	IK	CQOQDQWUFQDJMK-SSTWWWIQSA-N
DMB0NVQ	IU	(8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMB0NVQ	CA	CAS 362-07-2
DMB0NVQ	CB	CHEBI:28955

DMQ0RGB	ID	DMQ0RGB
DMQ0RGB	DN	Steroid derivative 2
DMQ0RGB	HS	Patented
DMQ0RGB	SN	PMID26882240-Compound-25
DMQ0RGB	CP	Macau University of Science and Technology, Macau
DMQ0RGB	DT	Small molecular drug
DMQ0RGB	PC	11261800
DMQ0RGB	MW	587.7
DMQ0RGB	FM	C31H41NO8S
DMQ0RGB	IC	InChI=1S/C31H41NO8S/c1-17-13-30(32-9-10-41-30)31(36)26(38-17)39-23-12-19-3-4-22-21(28(19,16-33)14-24(23)40-31)5-7-27(2)20(6-8-29(22,27)35)18-11-25(34)37-15-18/h9,11,16-17,19-24,26,35-36H,3-8,10,12-15H2,1-2H3/t17-,19+,20-,21+,22-,23-,24-,26+,27-,28-,29+,30+,31-/m1/s1
DMQ0RGB	CS	C[C@@H]1C[C@]2([C@]3([C@@H](O1)O[C@@H]4C[C@@H]5CC[C@@H]6[C@@H]([C@]5(C[C@H]4O3)C=O)CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)N=CCS2
DMQ0RGB	IK	DONIPVCAKBPJLH-IGACXKNBSA-N
DMQ0RGB	IU	(1S,3R,5S,7R,9S,10R,12R,14R,15S,18R,19R,22S,23R)-10,22-dihydroxy-7,18-dimethyl-19-(5-oxo-2H-furan-3-yl)spiro[4,6,11-trioxahexacyclo[12.11.0.03,12.05,10.015,23.018,22]pentacosane-9,2'-5H-1,3-thiazole]-14-carbaldehyde
DMQ0RGB	CA	CAS 24211-81-2

DMETIKC	ID	DMETIKC
DMETIKC	DN	Steroid derivative 3
DMETIKC	HS	Patented
DMETIKC	SN	PMID26882240-Compound-26
DMETIKC	CP	Macau University of Science and Technology, Macau
DMETIKC	DT	Small molecular drug
DMETIKC	PC	86301250
DMETIKC	MW	587.7
DMETIKC	FM	C31H41NO8S
DMETIKC	IC	InChI=1S/C31H41NO8S/c1-17-13-30(32-9-10-41-30)31(36)26(38-17)39-23-12-19-3-4-22-21(28(19,16-33)14-24(23)40-31)5-7-27(2)20(6-8-29(22,27)35)18-11-25(34)37-15-18/h9,11,16-17,19-24,26,35-36H,3-8,10,12-15H2,1-2H3/t17-,19+,20-,21+,22-,23-,24-,26+,27-,28-,29+,30+,31+/m1/s1
DMETIKC	CS	C[C@@H]1C[C@]2([C@@]3([C@@H](O1)O[C@@H]4C[C@@H]5CC[C@@H]6[C@@H]([C@]5(C[C@H]4O3)C=O)CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)N=CCS2
DMETIKC	IK	DONIPVCAKBPJLH-NCSQWUIOSA-N
DMETIKC	IU	(1S,3R,5S,7R,9S,10S,12R,14R,15S,18R,19R,22S,23R)-10,22-dihydroxy-7,18-dimethyl-19-(5-oxo-2H-furan-3-yl)spiro[4,6,11-trioxahexacyclo[12.11.0.03,12.05,10.015,23.018,22]pentacosane-9,2'-5H-1,3-thiazole]-14-carbaldehyde

DMJPYVS	ID	DMJPYVS
DMJPYVS	DN	Steroid derivative 4
DMJPYVS	HS	Patented
DMJPYVS	SN	PMID26882240-Compound-27
DMJPYVS	CP	SRI INTERNATIONAL ZHOU, Wei SAMBUCETTI, LidiSRI International, USA
DMJPYVS	DT	Small molecular drug

DMHLA5V	ID	DMHLA5V
DMHLA5V	DN	Steroidal carboxamide derivative 1
DMHLA5V	HS	Patented
DMHLA5V	SN	PMID29334795-Compound-34
DMHLA5V	CP	RICHTER GEDEON NYRT [HU]
DMHLA5V	DT	Small molecular drug

DM5U36G	ID	DM5U36G
DM5U36G	DN	Sterol derivative 1
DM5U36G	HS	Patented
DM5U36G	SN	PMID27537201-Compound-Figure16a
DM5U36G	CP	UNIV BEIJING PEKING WBL BIOTECH CO LTD [CN]
DM5U36G	DT	Small molecular drug

DME1B23	ID	DME1B23
DME1B23	DN	Sterol derivative 2
DME1B23	HS	Patented
DME1B23	SN	PMID27537201-Compound-Figure16b
DME1B23	CP	BEIJING PEKING UNIVERSITY WBL BIOTECH CO., LTD.  DUAN, ZhenwenUNIV BEIJING PEKING WBL BIOTECH CO LTD [CN]
DME1B23	DT	Small molecular drug

DMOT1FQ	ID	DMOT1FQ
DMOT1FQ	DN	Sterol derivative 3
DMOT1FQ	HS	Patented
DMOT1FQ	SN	PMID27537201-Compound-Figure16c
DMOT1FQ	CP	BEIJING WBL PEKING UNIV BIOTEC
DMOT1FQ	DT	Small molecular drug

DM6KPYL	ID	DM6KPYL
DM6KPYL	DN	STK296197
DM6KPYL	HS	Patented
DM6KPYL	SN	2-(2,4-dimethoxyphenyl)-6,7-dimethoxy-4H-3,1-benzoxazin-4-one; SCHEMBL18352860; BDBM113301; ZINC8906265; STK296197; AKOS003369098; MCULE-2502072969; 847572-11-6; US9695194, 17; Z223457118
DM6KPYL	DT	Small molecular drug
DM6KPYL	PC	17018602
DM6KPYL	MW	343.3
DM6KPYL	FM	C18H17NO6
DM6KPYL	IC	InChI=1S/C18H17NO6/c1-21-10-5-6-11(14(7-10)22-2)17-19-13-9-16(24-4)15(23-3)8-12(13)18(20)25-17/h5-9H,1-4H3
DM6KPYL	CS	COC1=CC(=C(C=C1)C2=NC3=CC(=C(C=C3C(=O)O2)OC)OC)OC
DM6KPYL	IK	JCFSQIOFMQLSPV-UHFFFAOYSA-N
DM6KPYL	IU	2-(2,4-dimethoxyphenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one

DM19GAY	ID	DM19GAY
DM19GAY	DN	STK696827
DM19GAY	HS	Patented
DM19GAY	SN	CHEMBL1084866; 4-[2-(Anthracen-9-Ylmethylidene)hydrazino]-N-(3-Chlorophenyl)-4-Oxobutanamide; 4-[(2E)-2-(anthracen-9-ylmethylidene)hydrazinyl]-N-(3-chlorophenyl)-4-oxobutanamide; NadD inhibitor 1_02; SCHEMBL11887958; A0640/0029695; STK696827; BDBM50318652; AKOS001707409; US8785499, 1_02; 4-{2-[(E)-1-(9-anthryl)methylidene]hydrazino}-N-(3-chlorophenyl)-4-oxobutanamide; (E)-4-(2-(anthracen-9-ylmethylene)hydrazinyl)-N-(3-chlorophenyl)-4-oxobutanamide
DM19GAY	DT	Small molecular drug
DM19GAY	PC	9597188
DM19GAY	MW	429.9
DM19GAY	FM	C25H20ClN3O2
DM19GAY	IC	InChI=1S/C25H20ClN3O2/c26-19-8-5-9-20(15-19)28-24(30)12-13-25(31)29-27-16-23-21-10-3-1-6-17(21)14-18-7-2-4-11-22(18)23/h1-11,14-16H,12-13H2,(H,28,30)(H,29,31)/b27-16+
DM19GAY	CS	C1=CC=C2C(=C1)C=C3C=CC=CC3=C2/C=N/NC(=O)CCC(=O)NC4=CC(=CC=C4)Cl
DM19GAY	IK	OJLFRDWWYAPUAJ-JVWAILMASA-N
DM19GAY	IU	N'-[(E)-anthracen-9-ylmethylideneamino]-N-(3-chlorophenyl)butanediamide

DMTXDSG	ID	DMTXDSG
DMTXDSG	DN	Succinamide derivative 1
DMTXDSG	HS	Patented
DMTXDSG	SN	PMID27414413-Compound-Figure11upright
DMTXDSG	CP	Yuanqiang Z
DMTXDSG	DT	Small molecular drug

DMQ0VK9	ID	DMQ0VK9
DMQ0VK9	DN	Sulfamic acid ester derivative 1
DMQ0VK9	HS	Patented
DMQ0VK9	SN	PMID29473428-Compound-20
DMQ0VK9	DT	Small molecular drug

DMO7ZRW	ID	DMO7ZRW
DMO7ZRW	DN	Sulfamoylamide derivative 1
DMO7ZRW	HS	Patented
DMO7ZRW	SN	PMID29473428-Compound-61
DMO7ZRW	CP	BRISTOL-MYERS SQUIBB COMPANY
DMO7ZRW	DT	Small molecular drug
DMO7ZRW	PC	124158767
DMO7ZRW	MW	598.1
DMO7ZRW	FM	C27H37ClFN5O5S
DMO7ZRW	IC	InChI=1S/C27H37ClFN5O5S/c1-18(2)16-34(20-8-6-5-7-9-20)25-13-11-21(39-17-26(35)32-40(37,38)33(3)4)15-24(25)31-27(36)30-23-12-10-19(28)14-22(23)29/h10-15,18,20H,5-9,16-17H2,1-4H3,(H,32,35)(H2,30,31,36)
DMO7ZRW	CS	CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)OCC(=O)NS(=O)(=O)N(C)C)NC(=O)NC3=C(C=C(C=C3)Cl)F
DMO7ZRW	IK	GXQLSHAYKCFGCU-UHFFFAOYSA-N
DMO7ZRW	IU	2-[3-[(4-chloro-2-fluorophenyl)carbamoylamino]-4-[cyclohexyl(2-methylpropyl)amino]phenoxy]-N-(dimethylsulfamoyl)acetamide

DMTX21L	ID	DMTX21L
DMTX21L	DN	Sulfonamide derivative 1
DMTX21L	HS	Patented
DMTX21L	SN	PMID26161824-Compound-95
DMTX21L	DT	Small molecular drug
DMTX21L	DE	Obesity

DMA32GJ	ID	DMA32GJ
DMA32GJ	DN	Sulfonamide derivative 10
DMA32GJ	HS	Patented
DMA32GJ	SN	PMID27414413-Compound-Figure3bottomleft
DMA32GJ	CP	PFIZER LIMITED
DMA32GJ	DT	Small molecular drug
DMA32GJ	PC	86294663
DMA32GJ	MW	428.8
DMA32GJ	FM	C19H10ClFN4O3S
DMA32GJ	IC	InChI=1S/C19H10ClFN4O3S/c20-17-8-15(3-1-12(17)9-22)28-18-5-4-16(7-13(18)10-23)29(26,27)25-19-6-2-14(21)11-24-19/h1-8,11H,(H,24,25)
DMA32GJ	CS	C1=CC(=C(C=C1OC2=C(C=C(C=C2)S(=O)(=O)NC3=NC=C(C=C3)F)C#N)Cl)C#N
DMA32GJ	IK	ABKCBHGHCYFDNT-UHFFFAOYSA-N
DMA32GJ	IU	4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide

DMJBR86	ID	DMJBR86
DMJBR86	DN	Sulfonamide derivative 11
DMJBR86	HS	Patented
DMJBR86	SN	PMID27414413-Compound-Figure3bottomright
DMJBR86	CP	PFIZER LIMITED
DMJBR86	DT	Small molecular drug
DMJBR86	PC	86282507
DMJBR86	MW	416.9
DMJBR86	FM	C17H9ClN4O3S2
DMJBR86	IC	InChI=1S/C17H9ClN4O3S2/c18-15-8-13(2-1-11(15)9-19)25-16-4-3-14(7-12(16)10-20)27(23,24)22-17-21-5-6-26-17/h1-8H,(H,21,22)
DMJBR86	CS	C1=CC(=C(C=C1OC2=C(C=C(C=C2)S(=O)(=O)NC3=NC=CS3)C#N)Cl)C#N
DMJBR86	IK	JONVMVCPXBMHHN-UHFFFAOYSA-N
DMJBR86	IU	4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(1,3-thiazol-2-yl)benzenesulfonamide

DMXEL56	ID	DMXEL56
DMXEL56	DN	Sulfonamide derivative 12
DMXEL56	HS	Patented
DMXEL56	SN	PMID30074415-Compound-16
DMXEL56	DT	Small molecular drug
DMXEL56	PC	71607911
DMXEL56	MW	444.4
DMXEL56	FM	C21H15F3N4O2S
DMXEL56	IC	InChI=1S/C21H15F3N4O2S/c22-21(23,24)14-7-5-13(6-8-14)19-17-3-1-2-4-18(17)20(28-27-19)26-15-9-11-16(12-10-15)31(25,29)30/h1-12H,(H,26,28)(H2,25,29,30)
DMXEL56	CS	C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)S(=O)(=O)N)C4=CC=C(C=C4)C(F)(F)F
DMXEL56	IK	DXRJQXFJLLMHKO-UHFFFAOYSA-N
DMXEL56	IU	4-[[4-[4-(trifluoromethyl)phenyl]phthalazin-1-yl]amino]benzenesulfonamide

DM5CUSJ	ID	DM5CUSJ
DM5CUSJ	DN	Sulfonamide derivative 15
DM5CUSJ	HS	Patented
DM5CUSJ	SN	PMID28460551-Compound-7
DM5CUSJ	DT	Small molecular drug
DM5CUSJ	PC	11964527
DM5CUSJ	MW	333.5
DM5CUSJ	FM	C17H19NO2S2
DM5CUSJ	IC	InChI=1S/C17H19NO2S2/c19-22(20,16-6-3-9-21-16)18-17-14-7-8-15(17)11-13-5-2-1-4-12(13)10-14/h1-6,9,14-15,17-18H,7-8,10-11H2
DM5CUSJ	CS	C1CC2CC3=CC=CC=C3CC1C2NS(=O)(=O)C4=CC=CS4
DM5CUSJ	IK	IFPBWXNUXWIDSN-UHFFFAOYSA-N
DM5CUSJ	IU	N-(13-tricyclo[8.2.1.03,8]trideca-3,5,7-trienyl)thiophene-2-sulfonamide

DMTFNGM	ID	DMTFNGM
DMTFNGM	DN	Sulfonamide derivative 16
DMTFNGM	HS	Patented
DMTFNGM	SN	PMID29886770-Compound-Figure6
DMTFNGM	CP	Chong Kun Dang Pharmaceutical Corp
DMTFNGM	DT	Small molecular drug

DMIQ1PL	ID	DMIQ1PL
DMIQ1PL	DN	Sulfonamide derivative 17
DMIQ1PL	HS	Patented
DMIQ1PL	SN	PMID29886770-Compound-Figure7
DMIQ1PL	CP	UNIVERSITY OF SOUTH AUSTRALIA CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC
DMIQ1PL	DT	Small molecular drug

DMHTJ7N	ID	DMHTJ7N
DMHTJ7N	DN	Sulfonamide derivative 18
DMHTJ7N	HS	Patented
DMHTJ7N	SN	PMID25416646-Compound-Figure2-M
DMHTJ7N	CP	PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED RAMDAS, Vidya FINCH, Harry FOX, Craig
DMHTJ7N	DT	Small molecular drug

DMD51AV	ID	DMD51AV
DMD51AV	DN	Sulfonamide derivative 6
DMD51AV	HS	Patented
DMD51AV	SN	PMID29473428-Compound-75
DMD51AV	CP	FLEXUS BIOSCIENCES, INC
DMD51AV	DT	Small molecular drug

DMN5YUK	ID	DMN5YUK
DMN5YUK	DN	Sulfonamide derivative 7
DMN5YUK	HS	Patented
DMN5YUK	SN	PMID29473428-Compound-78
DMN5YUK	CP	IOMET PHARMA LTD
DMN5YUK	DT	Small molecular drug
DMN5YUK	PC	110402129
DMN5YUK	MW	300.3
DMN5YUK	FM	C15H12N2O3S
DMN5YUK	IC	InChI=1S/C15H12N2O3S/c18-21(19,13-9-5-2-6-10-13)17-15-14(11-16-20-15)12-7-3-1-4-8-12/h1-11,17H
DMN5YUK	CS	C1=CC=C(C=C1)C2=C(ON=C2)NS(=O)(=O)C3=CC=CC=C3
DMN5YUK	IK	KJPWMAIBFGUKIA-UHFFFAOYSA-N
DMN5YUK	IU	N-(4-phenyl-1,2-oxazol-5-yl)benzenesulfonamide

DMOXIZC	ID	DMOXIZC
DMOXIZC	DN	Sulfonamide derivative 8
DMOXIZC	HS	Patented
DMOXIZC	SN	PMID29473428-Compound-79
DMOXIZC	CP	IOMET PHARMA LTD
DMOXIZC	DT	Small molecular drug
DMOXIZC	PC	118895401
DMOXIZC	MW	280.34
DMOXIZC	FM	C13H16N2O3S
DMOXIZC	IC	InChI=1S/C13H16N2O3S/c1-10(2)9-19(16,17)15-12-8-14-18-13(12)11-6-4-3-5-7-11/h3-8,10,15H,9H2,1-2H3
DMOXIZC	CS	CC(C)CS(=O)(=O)NC1=C(ON=C1)C2=CC=CC=C2
DMOXIZC	IK	PNZONOIXJUOMIU-UHFFFAOYSA-N
DMOXIZC	IU	2-methyl-N-(5-phenyl-1,2-oxazol-4-yl)propane-1-sulfonamide

DM2RZL8	ID	DM2RZL8
DM2RZL8	DN	Sulfonamide derivative 9
DM2RZL8	HS	Patented
DM2RZL8	SN	PMID26560530-Compound-55
DM2RZL8	CP	CHDI Foundation, Inc
DM2RZL8	DT	Small molecular drug

DMP9Z34	ID	DMP9Z34
DMP9Z34	DN	Sulfonamide-thiadiazole derivative 1
DMP9Z34	HS	Patented
DMP9Z34	SN	PMID30074415-Compound-17
DMP9Z34	DT	Small molecular drug

DMZAE78	ID	DMZAE78
DMZAE78	DN	Sulfonamide-thiadiazole derivative 2
DMZAE78	HS	Patented
DMZAE78	SN	PMID30074415-Compound-18
DMZAE78	DT	Small molecular drug

DMCO8JD	ID	DMCO8JD
DMCO8JD	DN	Sulfonylated piperazine derivative 1
DMCO8JD	HS	Patented
DMCO8JD	SN	PMID26161824-Compound-181
DMCO8JD	DT	Small molecular drug
DMCO8JD	PC	24945152
DMCO8JD	MW	387.5
DMCO8JD	FM	C20H25N3O3S
DMCO8JD	IC	InChI=1S/C20H25N3O3S/c24-20(21-11-4-1-5-12-21)22-13-15-23(16-14-22)27(25,26)19-10-6-8-17-7-2-3-9-18(17)19/h2-3,6-10H,1,4-5,11-16H2
DMCO8JD	CS	C1CCN(CC1)C(=O)N2CCN(CC2)S(=O)(=O)C3=CC=CC4=CC=CC=C43
DMCO8JD	IK	FVGJQXBVEVXXEH-UHFFFAOYSA-N
DMCO8JD	IU	(4-naphthalen-1-ylsulfonylpiperazin-1-yl)-piperidin-1-ylmethanone
DMCO8JD	DE	Obesity

DMZYPV3	ID	DMZYPV3
DMZYPV3	DN	Sulfonylated piperazine derivative 2
DMZYPV3	HS	Patented
DMZYPV3	SN	PMID26161824-Compound-182
DMZYPV3	DT	Small molecular drug
DMZYPV3	PC	44582884
DMZYPV3	MW	412.5
DMZYPV3	FM	C23H28N2O3S
DMZYPV3	IC	InChI=1S/C23H28N2O3S/c26-23(18-8-2-1-3-9-18)25-19-13-14-20(25)16-24(15-19)29(27,28)22-12-6-10-17-7-4-5-11-21(17)22/h4-7,10-12,18-20H,1-3,8-9,13-16H2
DMZYPV3	CS	C1CCC(CC1)C(=O)N2C3CCC2CN(C3)S(=O)(=O)C4=CC=CC5=CC=CC=C54
DMZYPV3	IK	REHIEVFQRQVSNB-UHFFFAOYSA-N
DMZYPV3	IU	cyclohexyl-(3-naphthalen-1-ylsulfonyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone
DMZYPV3	DE	Obesity

DMOJAZ9	ID	DMOJAZ9
DMOJAZ9	DN	Sulfonylated piperazine derivative 3
DMOJAZ9	HS	Patented
DMOJAZ9	SN	PMID26161824-Compound-183
DMOJAZ9	DT	Small molecular drug
DMOJAZ9	PC	13458368
DMOJAZ9	MW	466.4
DMOJAZ9	FM	C19H16F6N2O3S
DMOJAZ9	IC	InChI=1S/C19H16F6N2O3S/c20-18(21,22)14-10-15(19(23,24)25)12-16(11-14)31(29,30)27-8-6-26(7-9-27)17(28)13-4-2-1-3-5-13/h1-5,10-12H,6-9H2
DMOJAZ9	CS	C1CN(CCN1C(=O)C2=CC=CC=C2)S(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMOJAZ9	IK	PIYWKJKVVMSCGG-UHFFFAOYSA-N
DMOJAZ9	IU	[4-[3,5-bis(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-phenylmethanone
DMOJAZ9	DE	Obesity

DMZW2XP	ID	DMZW2XP
DMZW2XP	DN	Sulfonylated piperazine derivative 4
DMZW2XP	HS	Patented
DMZW2XP	SN	PMID26161824-Compound-184
DMZW2XP	DT	Small molecular drug
DMZW2XP	PC	24945235
DMZW2XP	MW	538.5
DMZW2XP	FM	C22H20F6N2O5S
DMZW2XP	IC	InChI=1S/C22H20F6N2O5S/c1-35-20(32)15-11-17(22(26,27)28)13-18(12-15)36(33,34)30-8-6-29(7-9-30)19(31)10-14-2-4-16(5-3-14)21(23,24)25/h2-5,11-13H,6-10H2,1H3
DMZW2XP	CS	COC(=O)C1=CC(=CC(=C1)S(=O)(=O)N2CCN(CC2)C(=O)CC3=CC=C(C=C3)C(F)(F)F)C(F)(F)F
DMZW2XP	IK	GJGRAMGTQURCNW-UHFFFAOYSA-N
DMZW2XP	IU	methyl 3-(trifluoromethyl)-5-[4-[2-[4-(trifluoromethyl)phenyl]acetyl]piperazin-1-yl]sulfonylbenzoate
DMZW2XP	DE	Obesity

DM65NBS	ID	DM65NBS
DM65NBS	DN	Sulfonylated piperazine derivative 5
DM65NBS	HS	Patented
DM65NBS	SN	PMID26161824-Compound-185
DM65NBS	DT	Small molecular drug
DM65NBS	PC	24744027
DM65NBS	MW	520.5
DM65NBS	FM	C23H22F6N2O3S
DM65NBS	IC	InChI=1S/C23H22F6N2O3S/c24-22(25,26)18-5-1-15(2-6-18)11-21(32)30-7-9-31(10-8-30)35(33,34)20-13-17(16-3-4-16)12-19(14-20)23(27,28)29/h1-2,5-6,12-14,16H,3-4,7-11H2
DM65NBS	CS	C1CC1C2=CC(=CC(=C2)S(=O)(=O)N3CCN(CC3)C(=O)CC4=CC=C(C=C4)C(F)(F)F)C(F)(F)F
DM65NBS	IK	DVPAFQJRBKXLSG-UHFFFAOYSA-N
DM65NBS	IU	1-[4-[3-cyclopropyl-5-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-2-[4-(trifluoromethyl)phenyl]ethanone
DM65NBS	DE	Obesity

DMHO29Y	ID	DMHO29Y
DMHO29Y	DN	T83193
DMHO29Y	HS	Patented
DMHO29Y	SN	vanillin; 4-Hydroxy-3-methoxybenzaldehyde; 121-33-5; Vanillaldehyde; Vanillic aldehyde; Vanilla; p-Vanillin; 2-Methoxy-4-formylphenol; Vanilline; Lioxin; 4-Hydroxy-m-anisaldehyde; 3-Methoxy-4-hydroxybenzaldehyde; Zimco; Benzaldehyde, 4-hydroxy-3-methoxy-; 4-Hydroxy-3-methoxy-benzaldehyde; Vanilin; p-Hydroxy-m-methoxybenzaldehyde; 4-Formyl-2-methoxyphenol; Methylprotocatechuic aldehyde; Vanillin (natural); 4-Hydroxy-5-methoxybenzaldehyde; m-Anisaldehyde, 4-hydroxy-; Protocatechualdehyde, methyl-; Vanillin [USAN]; Vanillin (NF)
DMHO29Y	DT	Small molecular drug
DMHO29Y	PC	1183
DMHO29Y	MW	152.15
DMHO29Y	FM	C8H8O3
DMHO29Y	IC	InChI=1S/C8H8O3/c1-11-8-4-6(5-9)2-3-7(8)10/h2-5,10H,1H3
DMHO29Y	CS	COC1=C(C=CC(=C1)C=O)O
DMHO29Y	IK	MWOOGOJBHIARFG-UHFFFAOYSA-N
DMHO29Y	IU	4-hydroxy-3-methoxybenzaldehyde
DMHO29Y	CA	CAS 121-33-5
DMHO29Y	CB	CHEBI:18346
DMHO29Y	DE	Discovery agent

DM86BDS	ID	DM86BDS
DM86BDS	DN	T8361
DM86BDS	HS	Patented
DM86BDS	SN	2,3-dibromo-6-hydroxy-5-methoxybenzaldehyde; 20035-42-1; 2,3-Dibromo-6-hydroxy-5-methoxy-benzaldehyde; AC1NN9L0; SCHEMBL12767437; CHEMBL3660308; CTK6J5070; BDBM110970; ZINC2168927; STK037780; MFCD00046151; BBL023774; AKOS000288884; MCULE-3295227366; BB 0244040; T8361; 2,3-Dibromo-6-hydroxy-5-methoxy-benzalde hyde; US8614253, .3-1
DM86BDS	DT	Small molecular drug
DM86BDS	PC	5039109
DM86BDS	MW	309.94
DM86BDS	FM	C8H6Br2O3
DM86BDS	IC	InChI=1S/C8H6Br2O3/c1-13-6-2-5(9)7(10)4(3-11)8(6)12/h2-3,12H,1H3
DM86BDS	CS	COC1=CC(=C(C(=C1O)C=O)Br)Br
DM86BDS	IK	NEQRDPRMCZPVJM-UHFFFAOYSA-N
DM86BDS	IU	2,3-dibromo-6-hydroxy-5-methoxybenzaldehyde
DM86BDS	CA	CAS 20035-42-1

DMX41ZF	ID	DMX41ZF
DMX41ZF	DN	T863
DMX41ZF	HS	Patented
DMX41ZF	SN	701232-20-4; DGAT-3; T863; DGAT-1 inhibitor; UNII-OF68Z8HK6V; OF68Z8HK6V; trans-4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexaneacetic acid; T-863; 2-(4-(4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid; trans-4-(4-(4-amino-7,7-dimethyl-7h-pyrimido(4,5-b)(1,4)oxazin-6-yl)phenyl)cyclohexaneacetic acid; Cyclohexaneacetic acid, 4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]-, trans-; Cyclohexaneacetic acid, 4-(4-(4-amino-7,7-di
DMX41ZF	DT	Small molecular drug
DMX41ZF	PC	9865421
DMX41ZF	MW	394.5
DMX41ZF	FM	C22H26N4O3
DMX41ZF	IC	InChI=1S/C22H26N4O3/c1-22(2)19(26-18-20(23)24-12-25-21(18)29-22)16-9-7-15(8-10-16)14-5-3-13(4-6-14)11-17(27)28/h7-10,12-14H,3-6,11H2,1-2H3,(H,27,28)(H2,23,24,25)
DMX41ZF	CS	CC1(C(=NC2=C(N=CN=C2O1)N)C3=CC=C(C=C3)C4CCC(CC4)CC(=O)O)C
DMX41ZF	IK	FUIYMYNYUHVDPT-UHFFFAOYSA-N
DMX41ZF	IU	2-[4-[4-(4-amino-7,7-dimethylpyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]acetic acid
DMX41ZF	CA	CAS 701232-20-4
DMX41ZF	DE	Discovery agent

DMFOKRW	ID	DMFOKRW
DMFOKRW	DN	Tacrine heterodimer derivative 1
DMFOKRW	HS	Patented
DMFOKRW	SN	PMID29757691-Compound-6
DMFOKRW	DT	Small molecular drug

DMJ04RQ	ID	DMJ04RQ
DMJ04RQ	DN	Tacrine-caffeic acid hybrid derivative 1
DMJ04RQ	HS	Patented
DMJ04RQ	SN	PMID27967267-Compound-19
DMJ04RQ	CP	Univ Sun Yat Sen
DMJ04RQ	DT	Small molecular drug

DMMVPSY	ID	DMMVPSY
DMMVPSY	DN	Tacrine-caffeic acid hybrid derivative 2
DMMVPSY	HS	Patented
DMMVPSY	SN	PMID27967267-Compound-20
DMMVPSY	CP	Univ Sun Yat Sen
DMMVPSY	DT	Small molecular drug

DM6YBTR	ID	DM6YBTR
DM6YBTR	DN	Tacrine-coumarin hybrid derivative 1
DM6YBTR	HS	Patented
DM6YBTR	SN	PMID29324067-Compound-96
DM6YBTR	CP	University Guangdong Technology
DM6YBTR	DT	Small molecular drug

DMK0S4I	ID	DMK0S4I
DMK0S4I	DN	Tacrine-dihydropyridine hybrid derivative 1
DMK0S4I	HS	Patented
DMK0S4I	SN	PMID27967267-Compound-29
DMK0S4I	CP	JIANGSU SIMCERE PHARMACEUTICAL R&amp;D CO., LTD  CHEN, Rong  LIU, Fei  CONG, Xin
DMK0S4I	DT	Small molecular drug

DMQ3K5B	ID	DMQ3K5B
DMQ3K5B	DN	Tacrine-indole hybrid derivative 1
DMQ3K5B	HS	Patented
DMQ3K5B	SN	PMID27967267-Compound-16
DMQ3K5B	CP	Univ China Pharma
DMQ3K5B	DT	Small molecular drug
DMQ3K5B	PC	118717433
DMQ3K5B	MW	483.6
DMQ3K5B	FM	C30H37N5O
DMQ3K5B	IC	InChI=1S/C30H37N5O/c31-25(19-21-20-34-26-14-6-3-11-22(21)26)30(36)33-18-10-2-1-9-17-32-29-23-12-4-7-15-27(23)35-28-16-8-5-13-24(28)29/h3-4,6-7,11-12,14-15,20,25,34H,1-2,5,8-10,13,16-19,31H2,(H,32,35)(H,33,36)/t25-/m0/s1
DMQ3K5B	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCNC(=O)[C@H](CC4=CNC5=CC=CC=C54)N
DMQ3K5B	IK	KADKUQSSIRPDHT-VWLOTQADSA-N
DMQ3K5B	IU	(2S)-2-amino-3-(1H-indol-3-yl)-N-[6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyl]propanamide

DMH9N2T	ID	DMH9N2T
DMH9N2T	DN	Tacrine-indole hybrid derivative 2
DMH9N2T	HS	Patented
DMH9N2T	SN	PMID27967267-Compound-17
DMH9N2T	CP	Univ China Pharma
DMH9N2T	DT	Small molecular drug
DMH9N2T	PC	118717425
DMH9N2T	MW	491.6
DMH9N2T	FM	C31H33N5O
DMH9N2T	IC	InChI=1S/C31H33N5O/c37-31(28-19-24-21-11-3-6-14-25(21)36-29(24)20-34-28)33-18-10-2-1-9-17-32-30-22-12-4-7-15-26(22)35-27-16-8-5-13-23(27)30/h3-4,6-7,11-12,14-15,19-20,36H,1-2,5,8-10,13,16-18H2,(H,32,35)(H,33,37)
DMH9N2T	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCNC(=O)C4=NC=C5C(=C4)C6=CC=CC=C6N5
DMH9N2T	IK	OLKLOVAJULLISR-UHFFFAOYSA-N
DMH9N2T	IU	N-[6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyl]-9H-pyrido[3,4-b]indole-3-carboxamide

DMUTKNW	ID	DMUTKNW
DMUTKNW	DN	Tacrine-indole hybrid derivative 3
DMUTKNW	HS	Patented
DMUTKNW	SN	PMID27967267-Compound-18
DMUTKNW	CP	Univ China Pharma
DMUTKNW	DT	Small molecular drug

DMNGY8R	ID	DMNGY8R
DMNGY8R	DN	Tacrine-phenothiazine hybrid derivative 1
DMNGY8R	HS	Patented
DMNGY8R	SN	PMID27967267-Compound-21
DMNGY8R	CP	Univ Hefei Technology
DMNGY8R	DT	Small molecular drug

DMK5HAC	ID	DMK5HAC
DMK5HAC	DN	Tarizine derivative 1
DMK5HAC	HS	Patented
DMK5HAC	SN	PMID25539043-Compound-WO2010022055Example25
DMK5HAC	CP	Amgen, Inc
DMK5HAC	DT	Small molecular drug

DMQKOMR	ID	DMQKOMR
DMQKOMR	DN	Tarnylcypromine derivative 1
DMQKOMR	HS	Patented
DMQKOMR	SN	PMID27019002-Compound-18
DMQKOMR	CP	UNIV ROMA [ITFOND IEO [ITUNIV PAVIA [ITUNIV DEGLI STUDI MILANO [ITMINUCCI SAVERIO [ITMAI ANTONELLO [ITMATTEVI ANDREA [IT]
DMQKOMR	DT	Small molecular drug

DMEJR2F	ID	DMEJR2F
DMEJR2F	DN	Tarnylcypromine derivative 2
DMEJR2F	HS	Patented
DMEJR2F	SN	PMID27019002-Compound-26a-h
DMEJR2F	CP	UNIV ROMA [ITFOND IEO [ITUNIV PAVIA [ITUNIV DEGLI STUDI MILANO [ITMINUCCI SAVERIO [ITMAI ANTONELLO [ITMATTEVI ANDREA [IT]
DMEJR2F	DT	Small molecular drug

DMKJOMC	ID	DMKJOMC
DMKJOMC	DN	Tarnylcypromine derivative 3
DMKJOMC	HS	Patented
DMKJOMC	SN	PMID27019002-Compound-27a-m
DMKJOMC	CP	UNIV ROMA [ITFOND IEO [ITUNIV PAVIA [ITUNIV DEGLI STUDI MILANO [ITMINUCCI SAVERIO [ITMAI ANTONELLO [ITMATTEVI ANDREA [IT]
DMKJOMC	DT	Small molecular drug

DMG6Q45	ID	DMG6Q45
DMG6Q45	DN	TDZD-8
DMG6Q45	HS	Patented
DMG6Q45	SN	327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3   Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8
DMG6Q45	DT	Small molecular drug
DMG6Q45	PC	4124851
DMG6Q45	MW	222.27
DMG6Q45	FM	C10H10N2O2S
DMG6Q45	IC	InChI=1S/C10H10N2O2S/c1-11-9(13)12(10(14)15-11)7-8-5-3-2-4-6-8/h2-6H,7H2,1H3
DMG6Q45	CS	CN1C(=O)N(C(=O)S1)CC2=CC=CC=C2
DMG6Q45	IK	JDSJDASOXWCHPN-UHFFFAOYSA-N
DMG6Q45	IU	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
DMG6Q45	CA	CAS 327036-89-5
DMG6Q45	CB	CHEBI:147411
DMG6Q45	DE	Malignant glioma

DMFMZCW	ID	DMFMZCW
DMFMZCW	DN	Terpyridineplatinum(II) complexe 1
DMFMZCW	HS	Patented
DMFMZCW	SN	PMID27977313-Compound-1
DMFMZCW	CP	ISIS INNOVATION LIMITED LOWE, Gordon
DMFMZCW	DT	Small molecular drug

DMLUYR0	ID	DMLUYR0
DMLUYR0	DN	Terpyridineplatinum(II) complexe 2
DMLUYR0	HS	Patented
DMLUYR0	SN	PMID27977313-Compound-2
DMLUYR0	CP	ISIS INNOVATION LIMITED LOWE, Gordon
DMLUYR0	DT	Small molecular drug

DM54EFD	ID	DM54EFD
DM54EFD	DN	Terpyridineplatinum(II) complexe 3
DM54EFD	HS	Patented
DM54EFD	SN	PMID27977313-Compound-3
DM54EFD	CP	ISIS INNOVATION LIMITED LOWE, Gordon
DM54EFD	DT	Small molecular drug

DMOV86T	ID	DMOV86T
DMOV86T	DN	Terpyridineplatinum(II) complexe 4
DMOV86T	HS	Patented
DMOV86T	SN	PMID27977313-Compound-4
DMOV86T	CP	ISIS INNOVATION LIMITED LOWE, Gordon
DMOV86T	DT	Small molecular drug

DMI4MJ2	ID	DMI4MJ2
DMI4MJ2	DN	Terpyridineplatinum(II) complexe 5
DMI4MJ2	HS	Patented
DMI4MJ2	SN	PMID27977313-Compound-Figure4a
DMI4MJ2	CP	ISIS INNOVATION LIMITED LOWE, Gordon
DMI4MJ2	DT	Small molecular drug

DMS3YPJ	ID	DMS3YPJ
DMS3YPJ	DN	Tetra/penta-cyclic pyridophthalazinone derivative 1
DMS3YPJ	HS	Patented
DMS3YPJ	SN	PMID27841036-Compound-XIII
DMS3YPJ	CP	BeiGene Ltd
DMS3YPJ	DT	Small molecular drug

DMLRY53	ID	DMLRY53
DMLRY53	DN	Tetra-azabenzo[e]azulene derivative 1
DMLRY53	HS	Patented
DMLRY53	SN	PMID25776143-Compound-5
DMLRY53	CP	Hoffmann-La Roche, Inc
DMLRY53	DT	Small molecular drug

DMUEI4N	ID	DMUEI4N
DMUEI4N	DN	Tetra-azabenzo[e]azulene derivative 2
DMUEI4N	HS	Patented
DMUEI4N	SN	PMID25776143-Compound-6
DMUEI4N	CP	Hoffmann-La Roche, Inc
DMUEI4N	DT	Small molecular drug

DMS1GJD	ID	DMS1GJD
DMS1GJD	DN	Tetra-cyclic compound 1
DMS1GJD	HS	Patented
DMS1GJD	SN	PMID27774824-Compound-Figure4compound22j
DMS1GJD	CP	BIOCRYST PHARMACEUTICALS, INC. BABU, Yarlagadda, S. KOTIAN, Pravin, L. CHINTAREDDY, Venkat, R
DMS1GJD	DT	Small molecular drug
DMS1GJD	PC	46224913
DMS1GJD	MW	332.3
DMS1GJD	FM	C19H13FN4O
DMS1GJD	IC	InChI=1S/C19H13FN4O/c20-14-7-10(25)5-6-11(14)17-13-8-21-19-16(13)18(22-9-23-19)12-3-1-2-4-15(12)24-17/h1-9,17,24-25H,(H,21,22,23)
DMS1GJD	CS	C1=CC=C2C(=C1)C3=C4C(=CNC4=NC=N3)C(N2)C5=C(C=C(C=C5)O)F
DMS1GJD	IK	IROWCEJAOYOCFJ-UHFFFAOYSA-N
DMS1GJD	IU	3-fluoro-4-(8,12,14,16-tetrazatetracyclo[8.6.1.02,7.013,17]heptadeca-1(17),2,4,6,10,13,15-heptaen-9-yl)phenol

DMX2EFL	ID	DMX2EFL
DMX2EFL	DN	Tetra-cyclic pyridophthalazinone derivative 1
DMX2EFL	HS	Patented
DMX2EFL	SN	PMID27841036-Compound-25
DMX2EFL	CP	BeiGene Ltd
DMX2EFL	DT	Small molecular drug

DMUXNKG	ID	DMUXNKG
DMUXNKG	DN	Tetra-hydro-1H-1,2,6-triazaazulene derivative 1
DMUXNKG	HS	Patented
DMUXNKG	SN	PMID26161824-Compound-155
DMUXNKG	DT	Small molecular drug
DMUXNKG	DE	Obesity

DMVTZ6S	ID	DMVTZ6S
DMVTZ6S	DN	Tetra-hydro-1H-1,2,6-triazaazulene derivative 2
DMVTZ6S	HS	Patented
DMVTZ6S	SN	PMID26161824-Compound-156
DMVTZ6S	DT	Small molecular drug
DMVTZ6S	DE	Obesity

DM5MVLG	ID	DM5MVLG
DM5MVLG	DN	Tetra-hydro-carboline derivative 1
DM5MVLG	HS	Patented
DM5MVLG	SN	PMID28447479-Compound-28
DM5MVLG	DT	Small molecular drug

DMXTL7V	ID	DMXTL7V
DMXTL7V	DN	Tetra-hydro-carboline derivative 2
DMXTL7V	HS	Patented
DMXTL7V	SN	PMID28447479-Compound-29
DMXTL7V	DT	Small molecular drug
DMXTL7V	PC	66548941
DMXTL7V	MW	471.6
DMXTL7V	FM	C29H33N3O3
DMXTL7V	IC	InChI=1S/C29H33N3O3/c1-2-20-5-3-6-21(15-20)17-32-24-18-31(14-8-22(24)23-7-4-13-30-26(23)32)25(33)16-28-9-11-29(19-28,12-10-28)27(34)35/h3-7,13,15H,2,8-12,14,16-19H2,1H3,(H,34,35)
DMXTL7V	CS	CCC1=CC(=CC=C1)CN2C3=C(CCN(C3)C(=O)CC45CCC(C4)(CC5)C(=O)O)C6=C2N=CC=C6
DMXTL7V	IK	KFNXYFDWAKJOGZ-UHFFFAOYSA-N
DMXTL7V	IU	4-[2-[8-[(3-ethylphenyl)methyl]-5,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-5-yl]-2-oxoethyl]bicyclo[2.2.1]heptane-1-carboxylic acid

DM3W5SM	ID	DM3W5SM
DM3W5SM	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 1
DM3W5SM	HS	Patented
DM3W5SM	SN	PMID25435285-Compound-91
DM3W5SM	CP	EISAI R&amp;D MANAGEMENT CO., LTD
DM3W5SM	DT	Small molecular drug
DM3W5SM	PC	131636309
DM3W5SM	MW	445.5
DM3W5SM	FM	C24H26F3N3O2
DM3W5SM	IC	InChI=1S/C24H26F3N3O2/c1-5-31-21-12-17(6-7-19(21)24(25,26)27)23-29-22(18-10-14(2)28-15(3)11-18)20-8-9-32-16(4)13-30(20)23/h6-7,10-12,16H,5,8-9,13H2,1-4H3/t16-/m1/s1
DM3W5SM	CS	CCOC1=C(C=CC(=C1)C2=NC(=C3N2C[C@H](OCC3)C)C4=CC(=NC(=C4)C)C)C(F)(F)F
DM3W5SM	IK	NVGWTIMTJOAYSJ-MRXNPFEDSA-N
DM3W5SM	IU	(6R)-1-(2,6-dimethylpyridin-4-yl)-3-[3-ethoxy-4-(trifluoromethyl)phenyl]-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine

DMB1T6S	ID	DMB1T6S
DMB1T6S	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 2
DMB1T6S	HS	Patented
DMB1T6S	SN	PMID25435285-Compound-92
DMB1T6S	CP	EISAI R&amp;D MANAGEMENT CO., LTD
DMB1T6S	DT	Small molecular drug

DM71LVY	ID	DM71LVY
DM71LVY	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 3
DM71LVY	HS	Patented
DM71LVY	SN	PMID25435285-Compound-93
DM71LVY	CP	EISAI R&amp;D MANAGEMENT CO., LTD
DM71LVY	DT	Small molecular drug
DM71LVY	PC	78324632
DM71LVY	MW	397.9
DM71LVY	FM	C22H24ClN3O2
DM71LVY	IC	InChI=1S/C22H24ClN3O2/c1-13-9-17(10-14(2)24-13)21-19-7-8-28-15(3)12-26(19)22(25-21)16-5-6-18(23)20(11-16)27-4/h5-6,9-11,15H,7-8,12H2,1-4H3/t15-/m1/s1
DM71LVY	CS	C[C@@H]1CN2C(=C(N=C2C3=CC(=C(C=C3)Cl)OC)C4=CC(=NC(=C4)C)C)CCO1
DM71LVY	IK	MPBPPCNVMAZSGS-OAHLLOKOSA-N
DM71LVY	IU	(6R)-3-(4-chloro-3-methoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine

DMLMXT6	ID	DMLMXT6
DMLMXT6	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 4
DMLMXT6	HS	Patented
DMLMXT6	SN	PMID25435285-Compound-94
DMLMXT6	CP	EISAI R&amp;D MANAGEMENT CO., LTD
DMLMXT6	DT	Small molecular drug
DMLMXT6	PC	90354590
DMLMXT6	MW	443.5
DMLMXT6	FM	C27H26FN3O2
DMLMXT6	IC	InChI=1S/C27H26FN3O2/c1-18-14-22(15-19(2)29-18)26-24-10-12-32-13-11-31(24)27(30-26)21-8-9-25(23(28)16-21)33-17-20-6-4-3-5-7-20/h3-9,14-16H,10-13,17H2,1-2H3
DMLMXT6	CS	CC1=CC(=CC(=N1)C)C2=C3CCOCCN3C(=N2)C4=CC(=C(C=C4)OCC5=CC=CC=C5)F
DMLMXT6	IK	DNUJOEZUOUPUCH-UHFFFAOYSA-N
DMLMXT6	IU	1-(2,6-dimethylpyridin-4-yl)-3-(3-fluoro-4-phenylmethoxyphenyl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine

DM7C0R8	ID	DM7C0R8
DM7C0R8	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 5
DM7C0R8	HS	Patented
DM7C0R8	SN	PMID25435285-Compound-95
DM7C0R8	CP	EISAI R&amp;D MANAGEMENT CO., LTD
DM7C0R8	DT	Small molecular drug
DM7C0R8	PC	131636429
DM7C0R8	MW	421.5
DM7C0R8	FM	C25H28FN3O2
DM7C0R8	IC	InChI=1S/C25H28FN3O2/c1-15-10-18(4-7-23(15)31-21-5-6-21)25-28-24(19-11-16(2)27-20(12-19)13-26)22-8-9-30-17(3)14-29(22)25/h4,7,10-12,17,21H,5-6,8-9,13-14H2,1-3H3/t17-/m1/s1
DM7C0R8	CS	C[C@@H]1CN2C(=C(N=C2C3=CC(=C(C=C3)OC4CC4)C)C5=CC(=NC(=C5)C)CF)CCO1
DM7C0R8	IK	AOKFYLVAJDLEJH-QGZVFWFLSA-N
DM7C0R8	IU	(6R)-3-(4-cyclopropyloxy-3-methylphenyl)-1-[2-(fluoromethyl)-6-methylpyridin-4-yl]-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine

DMCE3J0	ID	DMCE3J0
DMCE3J0	DN	Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 6
DMCE3J0	HS	Patented
DMCE3J0	SN	PMID25435285-Compound-96
DMCE3J0	CP	EISAI R&amp;D MANAGEMENT CO., LTD
DMCE3J0	DT	Small molecular drug
DMCE3J0	PC	131636416
DMCE3J0	MW	460.4
DMCE3J0	FM	C23H20F4N4O2
DMCE3J0	IC	InChI=1S/C23H20F4N4O2/c1-13-7-16(8-14(2)29-13)21-19-5-6-32-18(10-24)12-31(19)22(30-21)15-3-4-20(17(9-15)11-28)33-23(25,26)27/h3-4,7-9,18H,5-6,10,12H2,1-2H3/t18-/m1/s1
DMCE3J0	CS	CC1=CC(=CC(=N1)C)C2=C3CCO[C@@H](CN3C(=N2)C4=CC(=C(C=C4)OC(F)(F)F)C#N)CF
DMCE3J0	IK	XEHQUSUNPCVWGP-GOSISDBHSA-N
DMCE3J0	IU	5-[(6S)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepin-3-yl]-2-(trifluoromethoxy)benzonitrile

DML86IO	ID	DML86IO
DML86IO	DN	Tetra-hydro-isoquinoline derivative 1
DML86IO	HS	Patented
DML86IO	SN	PMID29757691-Compound-5a
DML86IO	DT	Small molecular drug
DML86IO	PC	46829776
DML86IO	MW	336.4
DML86IO	FM	C21H24N2O2
DML86IO	IC	InChI=1S/C21H24N2O2/c24-21-9-7-17-6-8-19(14-20(17)22-21)25-13-3-11-23-12-10-16-4-1-2-5-18(16)15-23/h1-2,4-6,8,14H,3,7,9-13,15H2,(H,22,24)
DML86IO	CS	C1CC(=O)NC2=C1C=CC(=C2)OCCCN3CCC4=CC=CC=C4C3
DML86IO	IK	VUVLHXICIKCCTI-UHFFFAOYSA-N
DML86IO	IU	7-[3-(3,4-dihydro-1H-isoquinolin-2-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one

DM5CKVF	ID	DM5CKVF
DM5CKVF	DN	Tetra-hydro-isoquinoline derivative 2
DM5CKVF	HS	Patented
DM5CKVF	SN	PMID29757691-Compound-5b
DM5CKVF	DT	Small molecular drug
DM5CKVF	PC	46829772
DM5CKVF	MW	350.5
DM5CKVF	FM	C22H26N2O2
DM5CKVF	IC	InChI=1S/C22H26N2O2/c25-22-10-8-18-7-9-20(15-21(18)23-22)26-14-4-3-12-24-13-11-17-5-1-2-6-19(17)16-24/h1-2,5-7,9,15H,3-4,8,10-14,16H2,(H,23,25)
DM5CKVF	CS	C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCC4=CC=CC=C4C3
DM5CKVF	IK	WKRADRDLWGKBQG-UHFFFAOYSA-N
DM5CKVF	IU	7-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one

DMCZA45	ID	DMCZA45
DMCZA45	DN	Tetra-hydro-isoquinoline derivative 3
DMCZA45	HS	Patented
DMCZA45	SN	PMID29757691-Compound-5c
DMCZA45	DT	Small molecular drug
DMCZA45	PC	137653313
DMCZA45	MW	364.5
DMCZA45	FM	C23H28N2O2
DMCZA45	IC	InChI=1S/C23H28N2O2/c26-23-11-9-19-8-10-21(16-22(19)24-23)27-15-5-1-4-13-25-14-12-18-6-2-3-7-20(18)17-25/h2-3,6-8,10,16H,1,4-5,9,11-15,17H2,(H,24,26)
DMCZA45	CS	C1CC(=O)NC2=C1C=CC(=C2)OCCCCCN3CCC4=CC=CC=C4C3
DMCZA45	IK	MANGBYSAGCIUHY-UHFFFAOYSA-N
DMCZA45	IU	7-[5-(3,4-dihydro-1H-isoquinolin-2-yl)pentoxy]-3,4-dihydro-1H-quinolin-2-one

DMDV0MP	ID	DMDV0MP
DMDV0MP	DN	Tetra-hydro-isoquinoline derivative 4
DMDV0MP	HS	Patented
DMDV0MP	SN	PMID29757691-Compound-5d
DMDV0MP	DT	Small molecular drug
DMDV0MP	PC	137652717
DMDV0MP	MW	378.5
DMDV0MP	FM	C24H30N2O2
DMDV0MP	IC	InChI=1S/C24H30N2O2/c27-24-12-10-20-9-11-22(17-23(20)25-24)28-16-6-2-1-5-14-26-15-13-19-7-3-4-8-21(19)18-26/h3-4,7-9,11,17H,1-2,5-6,10,12-16,18H2,(H,25,27)
DMDV0MP	CS	C1CC(=O)NC2=C1C=CC(=C2)OCCCCCCN3CCC4=CC=CC=C4C3
DMDV0MP	IK	BIIFFVLUGVJJJX-UHFFFAOYSA-N
DMDV0MP	IU	7-[6-(3,4-dihydro-1H-isoquinolin-2-yl)hexoxy]-3,4-dihydro-1H-quinolin-2-one

DMURYO0	ID	DMURYO0
DMURYO0	DN	Tetra-hydro-naphthalene derivative 1
DMURYO0	HS	Patented
DMURYO0	SN	PMID26413912-Compound-19
DMURYO0	CP	THE SCRIPPS RESEARCH INSTITUTE
DMURYO0	DT	Small molecular drug

DMEBGZJ	ID	DMEBGZJ
DMEBGZJ	DN	Tetra-hydro-naphthalene derivative 2
DMEBGZJ	HS	Patented
DMEBGZJ	SN	PMID26413912-Compound-20
DMEBGZJ	CP	THE SCRIPPS RESEARCH INSTITUTE
DMEBGZJ	DT	Small molecular drug

DMVBZKF	ID	DMVBZKF
DMVBZKF	DN	Tetra-hydro-naphthalene derivative 3
DMVBZKF	HS	Patented
DMVBZKF	SN	PMID26413912-Compound-21
DMVBZKF	CP	THE SCRIPPS RESEARCH INSTITUTE
DMVBZKF	DT	Small molecular drug

DM5YSTU	ID	DM5YSTU
DM5YSTU	DN	Tetra-hydro-naphthyridine derivative 1
DM5YSTU	HS	Patented
DM5YSTU	SN	PMID26413912-Compound-80
DM5YSTU	CP	RENOVIS, INC. KELLY, Michael, G. KINCAID, John GOWLUGARI, Sumithra KAUB, Carl
DM5YSTU	DT	Small molecular drug
DM5YSTU	PC	25138302
DM5YSTU	MW	366.5
DM5YSTU	FM	C24H22N4
DM5YSTU	IC	InChI=1S/C24H22N4/c1-2-6-18(7-3-1)16-28-13-11-22-20(17-28)10-12-25-24(22)27-21-14-19-8-4-5-9-23(19)26-15-21/h1-10,12,14-15H,11,13,16-17H2,(H,25,27)
DM5YSTU	CS	C1CN(CC2=C1C(=NC=C2)NC3=CC4=CC=CC=C4N=C3)CC5=CC=CC=C5
DM5YSTU	IK	WVIVDSQVVHCZNX-UHFFFAOYSA-N
DM5YSTU	IU	6-benzyl-N-quinolin-3-yl-7,8-dihydro-5H-2,6-naphthyridin-1-amine

DM72MDA	ID	DM72MDA
DM72MDA	DN	Tetra-hydro-oxazolopyridine derivative 1
DM72MDA	HS	Patented
DM72MDA	SN	PMID28067079-Compound-59
DM72MDA	CP	Dainippon Sumitomo Pharma Co Ltd
DM72MDA	DT	Small molecular drug

DMP65Z4	ID	DMP65Z4
DMP65Z4	DN	Tetra-hydro-oxazolopyridine derivative 2
DMP65Z4	HS	Patented
DMP65Z4	SN	PMID28067079-Compound-60
DMP65Z4	CP	Dainippon Sumitomo Pharma Co Ltd
DMP65Z4	DT	Small molecular drug
DMP65Z4	PC	86275459
DMP65Z4	MW	330.74
DMP65Z4	FM	C16H12ClFN4O
DMP65Z4	IC	InChI=1S/C16H12ClFN4O/c17-10-5-12(8-19-6-10)22-4-3-15-14(9-22)21-16(23-15)13-2-1-11(18)7-20-13/h1-2,5-8H,3-4,9H2
DMP65Z4	CS	C1CN(CC2=C1OC(=N2)C3=NC=C(C=C3)F)C4=CC(=CN=C4)Cl
DMP65Z4	IK	OEQFRGKRTUFWNP-UHFFFAOYSA-N
DMP65Z4	IU	5-(5-chloropyridin-3-yl)-2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridine

DMQYKT2	ID	DMQYKT2
DMQYKT2	DN	Tetra-hydro-oxazolopyridine derivative 3
DMQYKT2	HS	Patented
DMQYKT2	SN	PMID28067079-Compound-63
DMQYKT2	CP	DAINIPPON SUMITOMO PHARMA CO., LTD
DMQYKT2	DT	Small molecular drug
DMQYKT2	PC	74221950
DMQYKT2	MW	375.8
DMQYKT2	FM	C18H12ClF2N3O2
DMQYKT2	IC	InChI=1S/C18H12ClF2N3O2/c19-11-5-10(6-13(21)7-11)18(25)24-4-3-16-15(9-24)23-17(26-16)14-2-1-12(20)8-22-14/h1-2,5-8H,3-4,9H2
DMQYKT2	CS	C1CN(CC2=C1OC(=N2)C3=NC=C(C=C3)F)C(=O)C4=CC(=CC(=C4)Cl)F
DMQYKT2	IK	CHAFCAFCZBTARK-UHFFFAOYSA-N
DMQYKT2	IU	(3-chloro-5-fluorophenyl)-[2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridin-5-yl]methanone

DM21J83	ID	DM21J83
DM21J83	DN	Tetra-hydro-oxazolopyridine derivative 4
DM21J83	HS	Patented
DM21J83	SN	PMID28067079-Compound-64
DM21J83	CP	DAINIPPON SUMITOMO PHARMA CO., LTD
DM21J83	DT	Small molecular drug
DM21J83	PC	137639643
DM21J83	MW	339.8
DM21J83	FM	C18H14ClN3O2
DM21J83	IC	InChI=1S/C18H14ClN3O2/c19-13-6-7-14(20-10-13)17-21-15-11-22(9-8-16(15)24-17)18(23)12-4-2-1-3-5-12/h1-7,10H,8-9,11H2
DM21J83	CS	C1CN(CC2=C1OC(=N2)C3=NC=C(C=C3)Cl)C(=O)C4=CC=CC=C4
DM21J83	IK	NUNJYRYJNBEYPH-UHFFFAOYSA-N
DM21J83	IU	[2-(5-chloropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridin-5-yl]-phenylmethanone

DMQGA1I	ID	DMQGA1I
DMQGA1I	DN	Tetra-hydro-oxazolopyridine derivative 5
DMQGA1I	HS	Patented
DMQGA1I	SN	PMID28067079-Compound-65
DMQGA1I	CP	DAINIPPON SUMITOMO PHARMA CO., LTD
DMQGA1I	DT	Small molecular drug
DMQGA1I	PC	74222037
DMQGA1I	MW	357.8
DMQGA1I	FM	C18H13ClFN3O2
DMQGA1I	IC	InChI=1S/C18H13ClFN3O2/c19-12-3-1-2-11(8-12)18(24)23-7-6-16-15(10-23)22-17(25-16)14-5-4-13(20)9-21-14/h1-5,8-9H,6-7,10H2
DMQGA1I	CS	C1CN(CC2=C1OC(=N2)C3=NC=C(C=C3)F)C(=O)C4=CC(=CC=C4)Cl
DMQGA1I	IK	NZJPQHNBSVEQFL-UHFFFAOYSA-N
DMQGA1I	IU	(3-chlorophenyl)-[2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridin-5-yl]methanone

DMLW7YO	ID	DMLW7YO
DMLW7YO	DN	Tetra-hydro-oxazolopyridine derivative 6
DMLW7YO	HS	Patented
DMLW7YO	SN	PMID28067079-Compound-66
DMLW7YO	CP	DAINIPPON SUMITOMO PHARMA CO., LTD
DMLW7YO	DT	Small molecular drug
DMLW7YO	PC	137637236
DMLW7YO	MW	371.8
DMLW7YO	FM	C19H15ClFN3O2
DMLW7YO	IC	InChI=1S/C19H15ClFN3O2/c1-11-6-12(8-13(20)7-11)19(25)24-5-4-17-16(10-24)23-18(26-17)15-3-2-14(21)9-22-15/h2-3,6-9H,4-5,10H2,1H3
DMLW7YO	CS	CC1=CC(=CC(=C1)Cl)C(=O)N2CCC3=C(C2)N=C(O3)C4=NC=C(C=C4)F
DMLW7YO	IK	NMKCKZQPMUTSIC-UHFFFAOYSA-N
DMLW7YO	IU	(3-chloro-5-methylphenyl)-[2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridin-5-yl]methanone

DM3HVCZ	ID	DM3HVCZ
DM3HVCZ	DN	Tetra-hydro-pyrazolopyrazine derivative 1
DM3HVCZ	HS	Patented
DM3HVCZ	SN	PMID28067079-Compound-67
DM3HVCZ	CP	Dainippon Sumitomo Pharma Co Ltd
DM3HVCZ	DT	Small molecular drug

DMQ027F	ID	DMQ027F
DMQ027F	DN	Tetra-hydro-pyrazolopyrazine derivative 2
DMQ027F	HS	Patented
DMQ027F	SN	PMID28067079-Compound-68
DMQ027F	CP	Dainippon Sumitomo Pharma Co Ltd
DMQ027F	DT	Small molecular drug
DMQ027F	PC	137662068
DMQ027F	MW	374.8
DMQ027F	FM	C18H13ClF2N4O
DMQ027F	IC	InChI=1S/C18H13ClF2N4O/c19-12-5-11(6-14(21)7-12)18(26)24-3-4-25-15(10-24)8-17(23-25)16-2-1-13(20)9-22-16/h1-2,5-9H,3-4,10H2
DMQ027F	CS	C1CN2C(=CC(=N2)C3=NC=C(C=C3)F)CN1C(=O)C4=CC(=CC(=C4)Cl)F
DMQ027F	IK	PAVOURBCAONWKJ-UHFFFAOYSA-N
DMQ027F	IU	(3-chloro-5-fluorophenyl)-[2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-5-yl]methanone

DMKGJ1S	ID	DMKGJ1S
DMKGJ1S	DN	Tetra-hydro-pyrazolopyrazine derivative 3
DMKGJ1S	HS	Patented
DMKGJ1S	SN	PMID28067079-Compound-69
DMKGJ1S	CP	Dainippon Sumitomo Pharma Co Ltd
DMKGJ1S	DT	Small molecular drug

DMRMTF6	ID	DMRMTF6
DMRMTF6	DN	Tetra-hydro-pyrazolopyrazine derivative 4
DMRMTF6	HS	Patented
DMRMTF6	SN	PMID28067079-Compound-70
DMRMTF6	CP	Dainippon Sumitomo Pharma Co Ltd
DMRMTF6	DT	Small molecular drug

DMAM7Y2	ID	DMAM7Y2
DMAM7Y2	DN	Tetra-hydro-pyrazolopyrazine derivative 5
DMAM7Y2	HS	Patented
DMAM7Y2	SN	PMID28067079-Compound-71
DMAM7Y2	CP	Dainippon Sumitomo Pharma Co Ltd
DMAM7Y2	DT	Small molecular drug

DMM06K5	ID	DMM06K5
DMM06K5	DN	Tetra-hydro-pyrrolopyrimidinedione derivative 1
DMM06K5	HS	Patented
DMM06K5	SN	PMID26118988-Compound-24
DMM06K5	DT	Small molecular drug

DMM92KW	ID	DMM92KW
DMM92KW	DN	Tetra-hydro-quinoline derivative 1
DMM92KW	HS	Patented
DMM92KW	SN	PMID27841036-Compound-VIII
DMM92KW	CP	LUPIN LIMITED
DMM92KW	DT	Small molecular drug

DMEKO71	ID	DMEKO71
DMEKO71	DN	Tetra-hydro-quinoline derivative 2
DMEKO71	HS	Patented
DMEKO71	SN	PMID26924192-Compound-83
DMEKO71	CP	FORMA THERAPEUTICS INC
DMEKO71	DT	Small molecular drug

DMAWY4L	ID	DMAWY4L
DMAWY4L	DN	Tetra-hydro-quinoline derivative 3
DMAWY4L	HS	Patented
DMAWY4L	SN	PMID26924192-Compound-84
DMAWY4L	CP	FORMA THERAPEUTICS INC
DMAWY4L	DT	Small molecular drug
DMAWY4L	PC	118076120
DMAWY4L	MW	373.4
DMAWY4L	FM	C20H24FN3O3
DMAWY4L	IC	InChI=1S/C20H24FN3O3/c1-13-3-6-17-18(24(13)20(25)26-2)8-7-16(19(17)27-10-9-21)14-11-22-23(12-14)15-4-5-15/h7-8,11-13,15H,3-6,9-10H2,1-2H3/t13-/m0/s1
DMAWY4L	CS	C[C@H]1CCC2=C(N1C(=O)OC)C=CC(=C2OCCF)C3=CN(N=C3)C4CC4
DMAWY4L	IK	LVOBMWBVNYYGFM-ZDUSSCGKSA-N
DMAWY4L	IU	methyl (2S)-6-(1-cyclopropylpyrazol-4-yl)-5-(2-fluoroethoxy)-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylate

DMMC3AG	ID	DMMC3AG
DMMC3AG	DN	Tetra-hydro-quinoline derivative 4
DMMC3AG	HS	Patented
DMMC3AG	SN	PMID26924192-Compound-85
DMMC3AG	CP	FORMA THERAPEUTICS INC
DMMC3AG	DT	Small molecular drug
DMMC3AG	PC	118076127
DMMC3AG	MW	357.4
DMMC3AG	FM	C20H27N3O3
DMMC3AG	IC	InChI=1S/C20H27N3O3/c1-4-11-26-20-17(16-12-21-22(13-16)9-10-24)7-8-19-18(20)6-5-14(2)23(19)15(3)25/h7-8,12-14,24H,4-6,9-11H2,1-3H3/t14-/m0/s1
DMMC3AG	CS	CCCOC1=C(C=CC2=C1CC[C@@H](N2C(=O)C)C)C3=CN(N=C3)CCO
DMMC3AG	IK	LCUMODKDHNQTRE-AWEZNQCLSA-N
DMMC3AG	IU	1-[(2S)-6-[1-(2-hydroxyethyl)pyrazol-4-yl]-2-methyl-5-propoxy-3,4-dihydro-2H-quinolin-1-yl]ethanone

DMI6VG9	ID	DMI6VG9
DMI6VG9	DN	Tetra-hydro-triazolopyrimidine derivative 2
DMI6VG9	HS	Patented
DMI6VG9	SN	PMID29171765-Compound-Figure4
DMI6VG9	CP	CHIESI FARMACEUTICI S.p.A. BLENCH, Toby Jonathan EDWARDS, Christine HEALD, Robert Andrew KULAGOWSKI, Janusz Jozef SUTTON, Jonathan Mark CAPALDI, CarmelidBoehringer Ingelheim International GmbBayer Intellectual Property GmbH

DMEG5YO	ID	DMEG5YO
DMEG5YO	DN	Tetra-substituted urea derivative 1
DMEG5YO	HS	Patented
DMEG5YO	SN	PMID26413912-Compound-53
DMEG5YO	CP	BIAL PORTELA & CA SA [PT]
DMEG5YO	DT	Small molecular drug
DMEG5YO	PC	66681741
DMEG5YO	MW	258.32
DMEG5YO	FM	C14H18N4O
DMEG5YO	IC	InChI=1S/C14H18N4O/c1-17(11-7-3-2-4-8-11)14(19)18-13-10-6-5-9-12(13)15-16-18/h5-6,9-11H,2-4,7-8H2,1H3
DMEG5YO	CS	CN(C1CCCCC1)C(=O)N2C3=CC=CC=C3N=N2
DMEG5YO	IK	ATPCFTJMZOBYDC-UHFFFAOYSA-N
DMEG5YO	IU	N-cyclohexyl-N-methylbenzotriazole-1-carboxamide

DMKXZUA	ID	DMKXZUA
DMKXZUA	DN	Tetra-substituted urea derivative 2
DMKXZUA	HS	Patented
DMKXZUA	SN	PMID26413912-Compound-54
DMKXZUA	CP	BIAL PORTELA & CA SA [PT]
DMKXZUA	DT	Small molecular drug
DMKXZUA	PC	66683059
DMKXZUA	MW	303.33
DMKXZUA	FM	C16H18FN3O2
DMKXZUA	IC	InChI=1S/C16H18FN3O2/c1-19(12-4-2-3-5-12)16(22)20-9-14(18-10-20)11-6-7-15(21)13(17)8-11/h6-10,12,21H,2-5H2,1H3
DMKXZUA	CS	CN(C1CCCC1)C(=O)N2C=C(N=C2)C3=CC(=C(C=C3)O)F
DMKXZUA	IK	IWRLZEZXDCIMHJ-UHFFFAOYSA-N
DMKXZUA	IU	N-cyclopentyl-4-(3-fluoro-4-hydroxyphenyl)-N-methylimidazole-1-carboxamide

DM52683	ID	DM52683
DM52683	DN	Tetrazole acetic acid derivative 1
DM52683	HS	Patented
DM52683	SN	PMID27414413-Compound-Figure11upleft
DM52683	CP	Yuanqiang Z
DM52683	DT	Small molecular drug

DM1AGSD	ID	DM1AGSD
DM1AGSD	DN	Tetrazole derivative 1
DM1AGSD	HS	Patented
DM1AGSD	SN	PMID27724045-Compound-31
DM1AGSD	CP	Abbott
DM1AGSD	DT	Small molecular drug
DM1AGSD	PC	68678249
DM1AGSD	MW	507.4
DM1AGSD	FM	C23H29Cl2FN8
DM1AGSD	IC	InChI=1S/C23H29Cl2FN8/c1-23(2,3)15-32-10-5-11-33(13-12-32)21-16(6-4-9-27-21)14-28-22-29-30-31-34(22)18-8-7-17(26)19(24)20(18)25/h4,6-9H,5,10-15H2,1-3H3,(H,28,29,31)
DM1AGSD	CS	CC(C)(C)CN1CCCN(CC1)C2=C(C=CC=N2)CNC3=NN=NN3C4=C(C(=C(C=C4)F)Cl)Cl
DM1AGSD	IK	JYRXOWVYFHHKEV-UHFFFAOYSA-N
DM1AGSD	IU	1-(2,3-dichloro-4-fluorophenyl)-N-[[2-[4-(2,2-dimethylpropyl)-1,4-diazepan-1-yl]pyridin-3-yl]methyl]tetrazol-5-amine

DM2D4WQ	ID	DM2D4WQ
DM2D4WQ	DN	Tetrazolyl urea derivative 1
DM2D4WQ	HS	Patented
DM2D4WQ	SN	PMID26413912-Compound-55
DM2D4WQ	CP	NORTHEASTERN UNIVERSITY MAKRIYANNIS, Alexandros PANDARINATHAN, Lakshimpathi ZVONOK, Nikolai PARKKARI, Teija CHAPMAN, Lauren
DM2D4WQ	DT	Small molecular drug
DM2D4WQ	PC	44232540
DM2D4WQ	MW	376.7
DM2D4WQ	FM	C14H16Cl3N5O
DM2D4WQ	IC	InChI=1S/C14H16Cl3N5O/c1-21(7-3-2-6-15)14(23)22-19-13(18-20-22)8-10-4-5-11(16)9-12(10)17/h4-5,9H,2-3,6-8H2,1H3
DM2D4WQ	CS	CN(CCCCCl)C(=O)N1N=C(N=N1)CC2=C(C=C(C=C2)Cl)Cl
DM2D4WQ	IK	OQUPYXJFXDHGPX-UHFFFAOYSA-N
DM2D4WQ	IU	N-(4-chlorobutyl)-5-[(2,4-dichlorophenyl)methyl]-N-methyltetrazole-2-carboxamide

DMP4HR2	ID	DMP4HR2
DMP4HR2	DN	TG003
DMP4HR2	HS	Patented
DMP4HR2	SN	Clk inhibitor; TG 003; TG-003
DMP4HR2	DT	Small molecular drug
DMP4HR2	PC	1893668
DMP4HR2	MW	249.33
DMP4HR2	FM	C13H15NO2S
DMP4HR2	IC	InChI=1S/C13H15NO2S/c1-4-14-11-8-10(16-3)5-6-12(11)17-13(14)7-9(2)15/h5-8H,4H2,1-3H3/b13-7-
DMP4HR2	CS	CCN\\1C2=C(C=CC(=C2)OC)S/C1=C\\C(=O)C
DMP4HR2	IK	BGVLELSCIHASRV-QPEQYQDCSA-N
DMP4HR2	IU	(1Z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one
DMP4HR2	DE	Discovery agent

DM1L3ZA	ID	DM1L3ZA
DM1L3ZA	DN	Thiadiazolidindione derivative 1
DM1L3ZA	HS	Patented
DM1L3ZA	SN	PMID27828716-Compound-4
DM1L3ZA	DT	Small molecular drug

DM5AUL0	ID	DM5AUL0
DM5AUL0	DN	Thiadiazolidindione derivative 2
DM5AUL0	HS	Patented
DM5AUL0	SN	PMID27828716-Compound-5
DM5AUL0	DT	Small molecular drug
DM5AUL0	PC	71715288
DM5AUL0	MW	292.36
DM5AUL0	FM	C14H16N2O3S
DM5AUL0	IC	InChI=1S/C14H16N2O3S/c17-13-15(10-12-7-4-8-19-12)14(18)20-16(13)9-11-5-2-1-3-6-11/h1-3,5-6,12H,4,7-10H2
DM5AUL0	CS	C1CC(OC1)CN2C(=O)N(SC2=O)CC3=CC=CC=C3
DM5AUL0	IK	AGFKNYDGTJNEDN-UHFFFAOYSA-N
DM5AUL0	IU	2-benzyl-4-(oxolan-2-ylmethyl)-1,2,4-thiadiazolidine-3,5-dione

DMNTZ93	ID	DMNTZ93
DMNTZ93	DN	Thiadiazolidindione derivative 3
DMNTZ93	HS	Patented
DMNTZ93	SN	PMID27828716-Compound-6
DMNTZ93	DT	Small molecular drug
DMNTZ93	PC	71715287
DMNTZ93	MW	252.29
DMNTZ93	FM	C11H12N2O3S
DMNTZ93	IC	InChI=1S/C11H12N2O3S/c14-7-6-12-10(15)13(17-11(12)16)8-9-4-2-1-3-5-9/h1-5,14H,6-8H2
DMNTZ93	CS	C1=CC=C(C=C1)CN2C(=O)N(C(=O)S2)CCO
DMNTZ93	IK	DDYFMVMCMQSWNI-UHFFFAOYSA-N
DMNTZ93	IU	2-benzyl-4-(2-hydroxyethyl)-1,2,4-thiadiazolidine-3,5-dione

DMX93AI	ID	DMX93AI
DMX93AI	DN	Thiadiazolyl carboxamide derivative 1
DMX93AI	HS	Patented
DMX93AI	SN	PMID28270010-Compound-Figure18-1
DMX93AI	CP	BUCK INSTITUTE FOR RESEARCH ON AGING JOHN, Varghese ZHANG, Qiang BREDESEN, Dale, E
DMX93AI	DT	Small molecular drug
DMX93AI	PC	71263688
DMX93AI	MW	366.5
DMX93AI	FM	C20H22N4OS
DMX93AI	IC	InChI=1S/C20H22N4OS/c1-5-24(18(25)15-7-6-12-21-13-15)19-23-22-17(26-19)14-8-10-16(11-9-14)20(2,3)4/h6-13H,5H2,1-4H3
DMX93AI	CS	CCN(C1=NN=C(S1)C2=CC=C(C=C2)C(C)(C)C)C(=O)C3=CN=CC=C3
DMX93AI	IK	XMRKDXZDAAFZDU-UHFFFAOYSA-N
DMX93AI	IU	N-[5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-yl]-N-ethylpyridine-3-carboxamide
DMX93AI	DE	Alzheimer disease

DMW62LX	ID	DMW62LX
DMW62LX	DN	Thiazole carboxamide derivative 1
DMW62LX	HS	Patented
DMW62LX	SN	PMID25684022-Compound-US20130165450 10(4)
DMW62LX	CP	Schering Corp
DMW62LX	DE	Solid tumour/cancer; Metastatic cancer

DMWKI89	ID	DMWKI89
DMWKI89	DN	Thiazole carboxamide derivative 10
DMWKI89	HS	Patented
DMWKI89	SN	PMID25684022-Compound-US20130165450 19(36)
DMWKI89	CP	Schering Corp
DMWKI89	DE	Solid tumour/cancer; Metastatic cancer

DM0Q3HF	ID	DM0Q3HF
DM0Q3HF	DN	Thiazole carboxamide derivative 11
DM0Q3HF	HS	Patented
DM0Q3HF	SN	PMID25684022-Compound-US20130165450 20(38)
DM0Q3HF	CP	Schering Corp
DM0Q3HF	DE	Solid tumour/cancer; Metastatic cancer

DMG0H73	ID	DMG0H73
DMG0H73	DN	Thiazole carboxamide derivative 12
DMG0H73	HS	Patented
DMG0H73	SN	PMID25684022-Compound-US20130165450 21(40)
DMG0H73	CP	Schering Corp
DMG0H73	DE	Solid tumour/cancer; Metastatic cancer

DMHQCEJ	ID	DMHQCEJ
DMHQCEJ	DN	Thiazole carboxamide derivative 13
DMHQCEJ	HS	Patented
DMHQCEJ	SN	PMID25684022-Compound-US20130165450 23(41)
DMHQCEJ	CP	Schering Corp
DMHQCEJ	DE	Solid tumour/cancer; Metastatic cancer

DMMKNP7	ID	DMMKNP7
DMMKNP7	DN	Thiazole carboxamide derivative 14
DMMKNP7	HS	Patented
DMMKNP7	SN	PMID25684022-Compound-US20130165450 24(45)
DMMKNP7	CP	Schering Corp
DMMKNP7	DE	Solid tumour/cancer; Metastatic cancer

DMCH1DL	ID	DMCH1DL
DMCH1DL	DN	Thiazole carboxamide derivative 15
DMCH1DL	HS	Patented
DMCH1DL	SN	PMID25684022-Compound-US20130165450 9(2)
DMCH1DL	CP	Schering Corp
DMCH1DL	DE	Solid tumour/cancer; Metastatic cancer

DMJQBVH	ID	DMJQBVH
DMJQBVH	DN	Thiazole carboxamide derivative 16
DMJQBVH	HS	Patented
DMJQBVH	SN	PMID25684022-Compound-WO2012036974 10(4)
DMJQBVH	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMJQBVH	DE	Solid tumour/cancer; Metastatic cancer

DMPMN92	ID	DMPMN92
DMPMN92	DN	Thiazole carboxamide derivative 17
DMPMN92	HS	Patented
DMPMN92	SN	PMID25684022-Compound-WO2012036974 11(5)
DMPMN92	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMPMN92	DE	Solid tumour/cancer; Metastatic cancer

DM987MK	ID	DM987MK
DM987MK	DN	Thiazole carboxamide derivative 18
DM987MK	HS	Patented
DM987MK	SN	PMID25684022-Compound-WO2012036974 12(12)
DM987MK	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DM987MK	DE	Solid tumour/cancer; Metastatic cancer

DMW59Q4	ID	DMW59Q4
DMW59Q4	DN	Thiazole carboxamide derivative 19
DMW59Q4	HS	Patented
DMW59Q4	SN	PMID25684022-Compound-WO2012036974 13(13)
DMW59Q4	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMW59Q4	DE	Solid tumour/cancer; Metastatic cancer

DMLIRGM	ID	DMLIRGM
DMLIRGM	DN	Thiazole carboxamide derivative 2
DMLIRGM	HS	Patented
DMLIRGM	SN	PMID25684022-Compound-US20130165450 11(5)
DMLIRGM	CP	Schering Corp
DMLIRGM	DE	Solid tumour/cancer; Metastatic cancer

DMORSH9	ID	DMORSH9
DMORSH9	DN	Thiazole carboxamide derivative 20
DMORSH9	HS	Patented
DMORSH9	SN	PMID25684022-Compound-WO2012036974 14(14)
DMORSH9	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMORSH9	DE	Solid tumour/cancer; Metastatic cancer

DMTJBCG	ID	DMTJBCG
DMTJBCG	DN	Thiazole carboxamide derivative 21
DMTJBCG	HS	Patented
DMTJBCG	SN	PMID25684022-Compound-WO2012036974 15(15)
DMTJBCG	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMTJBCG	DE	Solid tumour/cancer; Metastatic cancer

DM6WTR2	ID	DM6WTR2
DM6WTR2	DN	Thiazole carboxamide derivative 22
DM6WTR2	HS	Patented
DM6WTR2	SN	PMID25684022-Compound-WO2012036974 16(16)
DM6WTR2	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DM6WTR2	DE	Solid tumour/cancer; Metastatic cancer

DMMO6JY	ID	DMMO6JY
DMMO6JY	DN	Thiazole carboxamide derivative 23
DMMO6JY	HS	Patented
DMMO6JY	SN	PMID25684022-Compound-WO2012036974 17(23)
DMMO6JY	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMMO6JY	DE	Solid tumour/cancer; Metastatic cancer

DMZ6YB0	ID	DMZ6YB0
DMZ6YB0	DN	Thiazole carboxamide derivative 24
DMZ6YB0	HS	Patented
DMZ6YB0	SN	PMID25684022-Compound-WO2012036974 18(27)
DMZ6YB0	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMZ6YB0	DE	Solid tumour/cancer; Metastatic cancer

DMLRTFX	ID	DMLRTFX
DMLRTFX	DN	Thiazole carboxamide derivative 25
DMLRTFX	HS	Patented
DMLRTFX	SN	PMID25684022-Compound-WO2012036974 19(36)
DMLRTFX	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMLRTFX	DE	Solid tumour/cancer; Metastatic cancer

DM8DHZ4	ID	DM8DHZ4
DM8DHZ4	DN	Thiazole carboxamide derivative 26
DM8DHZ4	HS	Patented
DM8DHZ4	SN	PMID25684022-Compound-WO2012036974 20(38)
DM8DHZ4	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DM8DHZ4	DE	Solid tumour/cancer; Metastatic cancer

DMV30QO	ID	DMV30QO
DMV30QO	DN	Thiazole carboxamide derivative 27
DMV30QO	HS	Patented
DMV30QO	SN	PMID25684022-Compound-WO2012036974 21(40)
DMV30QO	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMV30QO	DE	Solid tumour/cancer; Metastatic cancer

DMGEIZV	ID	DMGEIZV
DMGEIZV	DN	Thiazole carboxamide derivative 28
DMGEIZV	HS	Patented
DMGEIZV	SN	PMID25684022-Compound-WO2012036974 23(41)
DMGEIZV	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMGEIZV	DE	Solid tumour/cancer; Metastatic cancer

DMCRVO5	ID	DMCRVO5
DMCRVO5	DN	Thiazole carboxamide derivative 29
DMCRVO5	HS	Patented
DMCRVO5	SN	PMID25684022-Compound-WO2012036974 24(45)
DMCRVO5	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMCRVO5	DE	Solid tumour/cancer; Metastatic cancer

DMLRA3C	ID	DMLRA3C
DMLRA3C	DN	Thiazole carboxamide derivative 3
DMLRA3C	HS	Patented
DMLRA3C	SN	PMID25684022-Compound-US20130165450 12(12)
DMLRA3C	CP	Schering Corp
DMLRA3C	DE	Solid tumour/cancer; Metastatic cancer

DMEOKCB	ID	DMEOKCB
DMEOKCB	DN	Thiazole carboxamide derivative 30
DMEOKCB	HS	Patented
DMEOKCB	SN	PMID25684022-Compound-WO2012036974 9(2)
DMEOKCB	CP	MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMEOKCB	DE	Solid tumour/cancer; Metastatic cancer

DMI3X14	ID	DMI3X14
DMI3X14	DN	Thiazole carboxamide derivative 4
DMI3X14	HS	Patented
DMI3X14	SN	PMID25684022-Compound-US20130165450 13(13)
DMI3X14	CP	Schering Corp
DMI3X14	DE	Solid tumour/cancer; Metastatic cancer

DM2H95E	ID	DM2H95E
DM2H95E	DN	Thiazole carboxamide derivative 5
DM2H95E	HS	Patented
DM2H95E	SN	PMID25684022-Compound-US20130165450 14(14)
DM2H95E	CP	Schering Corp
DM2H95E	DE	Solid tumour/cancer; Metastatic cancer

DMWHCOE	ID	DMWHCOE
DMWHCOE	DN	Thiazole carboxamide derivative 6
DMWHCOE	HS	Patented
DMWHCOE	SN	PMID25684022-Compound-US20130165450 15(15)
DMWHCOE	CP	Schering Corp
DMWHCOE	DE	Solid tumour/cancer; Metastatic cancer

DMLBK8V	ID	DMLBK8V
DMLBK8V	DN	Thiazole carboxamide derivative 7
DMLBK8V	HS	Patented
DMLBK8V	SN	PMID25684022-Compound-US20130165450 16(16)
DMLBK8V	CP	Schering Corp
DMLBK8V	DE	Solid tumour/cancer; Metastatic cancer

DMVOTKN	ID	DMVOTKN
DMVOTKN	DN	Thiazole carboxamide derivative 8
DMVOTKN	HS	Patented
DMVOTKN	SN	PMID25684022-Compound-US20130165450 17(23)
DMVOTKN	CP	Schering Corp
DMVOTKN	DE	Solid tumour/cancer; Metastatic cancer

DM5P04R	ID	DM5P04R
DM5P04R	DN	Thiazole carboxamide derivative 9
DM5P04R	HS	Patented
DM5P04R	SN	PMID25684022-Compound-US20130165450 18(27)
DM5P04R	CP	Schering Corp
DM5P04R	DE	Solid tumour/cancer; Metastatic cancer

DM2WDXV	ID	DM2WDXV
DM2WDXV	DN	Thiazole derivative 1
DM2WDXV	HS	Patented
DM2WDXV	SN	PMID26815044-Compound-44
DM2WDXV	DT	Small molecular drug
DM2WDXV	PC	136183501
DM2WDXV	MW	237.23
DM2WDXV	FM	C10H7NO4S
DM2WDXV	IC	InChI=1S/C10H7NO4S/c12-5-1-2-6(8(13)3-5)9-11-7(4-16-9)10(14)15/h1-4,12-13H,(H,14,15)
DM2WDXV	CS	C1=CC(=C(C=C1O)O)C2=NC(=CS2)C(=O)O
DM2WDXV	IK	ANYJSBBMNGTYRM-UHFFFAOYSA-N
DM2WDXV	IU	2-(2,4-dihydroxyphenyl)-1,3-thiazole-4-carboxylic acid
DM2WDXV	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM8ZXBS	ID	DM8ZXBS
DM8ZXBS	DN	Thiazole derivative 2
DM8ZXBS	HS	Patented
DM8ZXBS	SN	PMID28454500-Compound-83
DM8ZXBS	CP	THE JOHNS HOPKINS UNIVERSITY The National Institutes of Health
DM8ZXBS	DT	Small molecular drug
DM8ZXBS	PC	1298265
DM8ZXBS	MW	473.4
DM8ZXBS	FM	C22H14F3N3O4S
DM8ZXBS	IC	InChI=1S/C22H14F3N3O4S/c23-22(24,25)15-6-4-13(5-7-15)10-17-12-26-21(33-17)27-20(29)19-9-8-18(32-19)14-2-1-3-16(11-14)28(30)31/h1-9,11-12H,10H2,(H,26,27,29)
DM8ZXBS	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC=C(O2)C(=O)NC3=NC=C(S3)CC4=CC=C(C=C4)C(F)(F)F
DM8ZXBS	IK	GIUVRWFYNOIRLR-UHFFFAOYSA-N
DM8ZXBS	IU	5-(3-nitrophenyl)-N-[5-[[4-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]furan-2-carboxamide

DMKU51G	ID	DMKU51G
DMKU51G	DN	Thiazole derivative 3
DMKU51G	HS	Patented
DMKU51G	SN	PMID28454500-Compound-84
DMKU51G	CP	THE JOHNS HOPKINS UNIVERSITY The National Institutes of Health
DMKU51G	DT	Small molecular drug
DMKU51G	PC	1383822
DMKU51G	MW	511.6
DMKU51G	FM	C29H25N3O4S
DMKU51G	IC	InChI=1S/C29H25N3O4S/c1-17-5-3-4-6-22(17)28(34)32-12-11-20-15-21(8-9-23(20)32)27-18(2)37-29(31-27)30-26(33)14-19-7-10-24-25(13-19)36-16-35-24/h3-10,13,15H,11-12,14,16H2,1-2H3,(H,30,31,33)
DMKU51G	CS	CC1=CC=CC=C1C(=O)N2CCC3=C2C=CC(=C3)C4=C(SC(=N4)NC(=O)CC5=CC6=C(C=C5)OCO6)C
DMKU51G	IK	LINHYWKZVCNAMQ-UHFFFAOYSA-N
DMKU51G	IU	2-(1,3-benzodioxol-5-yl)-N-[5-methyl-4-[1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl]-1,3-thiazol-2-yl]acetamide

DM5UQK6	ID	DM5UQK6
DM5UQK6	DN	Thiazole derivative 4
DM5UQK6	HS	Patented
DM5UQK6	SN	PMID28270010-Compound-Figure15-b
DM5UQK6	CP	ARRAY BIOPHARMA INC
DM5UQK6	DT	Small molecular drug
DM5UQK6	PC	73891136
DM5UQK6	MW	523.5
DM5UQK6	FM	C25H20F3N7OS
DM5UQK6	IC	InChI=1S/C25H20F3N7OS/c1-15-19(17-13-29-34(2)14-17)33-35(18-11-7-4-8-12-18)21(15)31-24(36)32-22-20(16-9-5-3-6-10-16)30-23(37-22)25(26,27)28/h3-14H,1-2H3,(H2,31,32,36)
DM5UQK6	CS	CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)NC4=C(N=C(S4)C(F)(F)F)C5=CC=CC=C5
DM5UQK6	IK	OKQYVMVRBRSVES-UHFFFAOYSA-N
DM5UQK6	IU	1-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]-3-[4-phenyl-2-(trifluoromethyl)-1,3-thiazol-5-yl]urea

DMESAUL	ID	DMESAUL
DMESAUL	DN	Thiazole derivative 5
DMESAUL	HS	Patented
DMESAUL	SN	PMID27724045-Compound-36
DMESAUL	CP	AXXAM S.P.A
DMESAUL	DT	Small molecular drug
DMESAUL	PC	91827420
DMESAUL	MW	399.9
DMESAUL	FM	C18H20ClF2N3OS
DMESAUL	IC	InChI=1S/C18H20ClF2N3OS/c1-12-3-2-4-13(19)16(12)17(25)23-9-14(15-10-22-11-26-15)24-7-5-18(20,21)6-8-24/h2-4,10-11,14H,5-9H2,1H3,(H,23,25)
DMESAUL	CS	CC1=C(C(=CC=C1)Cl)C(=O)NCC(C2=CN=CS2)N3CCC(CC3)(F)F
DMESAUL	IK	WADLCIPMWTXETG-UHFFFAOYSA-N
DMESAUL	IU	2-chloro-N-[2-(4,4-difluoropiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]-6-methylbenzamide

DMCPV0D	ID	DMCPV0D
DMCPV0D	DN	Thiazole-fused cycloalkyl carboxamide derivative 1
DMCPV0D	HS	Patented
DMCPV0D	SN	PMID27724045-Compound-20
DMCPV0D	CP	Actelion pharmaceuticals Ltd
DMCPV0D	DT	Small molecular drug
DMCPV0D	PC	71239321
DMCPV0D	MW	337.2
DMCPV0D	FM	C16H14Cl2N2O2
DMCPV0D	IC	InChI=1S/C16H14Cl2N2O2/c1-9-4-10(17)5-13(18)12(9)6-16(21)20-14-8-22-15-7-19-3-2-11(14)15/h2-5,7,14H,6,8H2,1H3,(H,20,21)
DMCPV0D	CS	CC1=CC(=CC(=C1CC(=O)NC2COC3=C2C=CN=C3)Cl)Cl
DMCPV0D	IK	CPLYQTQQYXUOCX-UHFFFAOYSA-N
DMCPV0D	IU	2-(2,4-dichloro-6-methylphenyl)-N-(2,3-dihydrofuro[2,3-c]pyridin-3-yl)acetamide

DM05VO6	ID	DM05VO6
DM05VO6	DN	Thiazolidine derivative 1
DM05VO6	HS	Patented
DM05VO6	SN	PMID26815044-Compound-33
DM05VO6	DT	Small molecular drug
DM05VO6	PC	13946769
DM05VO6	MW	225.27
DM05VO6	FM	C10H11NO3S
DM05VO6	IC	InChI=1S/C10H11NO3S/c12-7-3-1-6(2-4-7)9-11-8(5-15-9)10(13)14/h1-4,8-9,11-12H,5H2,(H,13,14)/t8-,9?/m0/s1
DM05VO6	CS	C1[C@H](NC(S1)C2=CC=C(C=C2)O)C(=O)O
DM05VO6	IK	TWPYJYQNZHPNGQ-IENPIDJESA-N
DM05VO6	IU	(4R)-2-(4-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
DM05VO6	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DM73GNJ	ID	DM73GNJ
DM73GNJ	DN	Thiazolidine derivative 2
DM73GNJ	HS	Patented
DM73GNJ	SN	PMID26815044-Compound-34
DM73GNJ	DT	Small molecular drug
DM73GNJ	PC	60194536
DM73GNJ	MW	241.27
DM73GNJ	FM	C10H11NO4S
DM73GNJ	IC	InChI=1S/C10H11NO4S/c12-5-1-2-6(8(13)3-5)9-11-7(4-16-9)10(14)15/h1-3,7,9,11-13H,4H2,(H,14,15)/t7-,9?/m0/s1
DM73GNJ	CS	C1[C@H](NC(S1)C2=C(C=C(C=C2)O)O)C(=O)O
DM73GNJ	IK	GYBITJROHWLVSE-JAVCKPHESA-N
DM73GNJ	IU	(4R)-2-(2,4-dihydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
DM73GNJ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMXFGTZ	ID	DMXFGTZ
DMXFGTZ	DN	Thiazolidine derivative 3
DMXFGTZ	HS	Patented
DMXFGTZ	SN	PMID26815044-Compound-35
DMXFGTZ	DT	Small molecular drug
DMXFGTZ	PC	6610557
DMXFGTZ	MW	269.32
DMXFGTZ	FM	C12H15NO4S
DMXFGTZ	IC	InChI=1S/C12H15NO4S/c1-16-7-3-4-8(10(5-7)17-2)11-13-9(6-18-11)12(14)15/h3-5,9,11,13H,6H2,1-2H3,(H,14,15)/t9-,11?/m0/s1
DMXFGTZ	CS	COC1=CC(=C(C=C1)C2N[C@@H](CS2)C(=O)O)OC
DMXFGTZ	IK	GXPHSEXJDZAWQX-FTNKSUMCSA-N
DMXFGTZ	IU	(4R)-2-(2,4-dimethoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
DMXFGTZ	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMLBA4D	ID	DMLBA4D
DMLBA4D	DN	Thiazolidine dione crystalline derivative 1
DMLBA4D	HS	Patented
DMLBA4D	SN	PMID25416646-Compound-Figure2-I
DMLBA4D	CP	Daiichi Sankyo Co., Ltd
DMLBA4D	DT	Small molecular drug
DMLBA4D	PC	9832447
DMLBA4D	MW	502.6
DMLBA4D	FM	C27H26N4O4S
DMLBA4D	IC	InChI=1S/C27H26N4O4S/c1-15-10-20(11-16(2)25(15)28)35-19-8-9-21-22(13-19)31(3)24(29-21)14-34-18-6-4-17(5-7-18)12-23-26(32)30-27(33)36-23/h4-11,13,23H,12,14,28H2,1-3H3,(H,30,32,33)
DMLBA4D	CS	CC1=CC(=CC(=C1N)C)OC2=CC3=C(C=C2)N=C(N3C)COC4=CC=C(C=C4)CC5C(=O)NC(=O)S5
DMLBA4D	IK	JCYNMRJCUYVDBC-UHFFFAOYSA-N
DMLBA4D	IU	5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methylbenzimidazol-2-yl]methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMLBA4D	CA	CAS 223132-37-4

DM86HU3	ID	DM86HU3
DM86HU3	DN	Thiazoline derivative 1
DM86HU3	HS	Patented
DM86HU3	SN	PMID26815044-Compound-45
DM86HU3	DT	Small molecular drug
DM86HU3	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMXRE1V	ID	DMXRE1V
DMXRE1V	DN	Thiazoline derivative 2
DMXRE1V	HS	Patented
DMXRE1V	SN	PMID26815044-Compound-46
DMXRE1V	DT	Small molecular drug
DMXRE1V	DE	Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma

DMAFE5R	ID	DMAFE5R
DMAFE5R	DN	Thiazolopyridine derivative 1
DMAFE5R	HS	Patented
DMAFE5R	SN	PMID27774822-Compound-Figure7Example20
DMAFE5R	CP	F. HOFFMANN-LA ROCHE AG GENENTECH, INC
DMAFE5R	DT	Small molecular drug

DMLUPV1	ID	DMLUPV1
DMLUPV1	DN	Thieno[2,3-c]pyridine derivative 1
DMLUPV1	HS	Patented
DMLUPV1	SN	PMID29473428-Compound-68
DMLUPV1	CP	CURADEV PHARMA PRIVATE LTD
DMLUPV1	DT	Small molecular drug
DMLUPV1	PC	86581712
DMLUPV1	MW	277.68
DMLUPV1	FM	C13H9ClFN3O
DMLUPV1	IC	InChI=1S/C13H9ClFN3O/c14-9-5-7(1-2-10(9)15)18-12-8-3-4-17-6-11(8)19-13(12)16/h1-6,18H,16H2
DMLUPV1	CS	C1=CC(=C(C=C1NC2=C(OC3=C2C=CN=C3)N)Cl)F
DMLUPV1	IK	MAFDXEXXQIAQTR-UHFFFAOYSA-N
DMLUPV1	IU	3-N-(3-chloro-4-fluorophenyl)furo[2,3-c]pyridine-2,3-diamine

DM1C8MA	ID	DM1C8MA
DM1C8MA	DN	Thieno[3,2-c]pyridine-7-carboxamide derivative 1
DM1C8MA	HS	Patented
DM1C8MA	SN	PMID25684022-Compound-WO2006106326c1
DM1C8MA	CP	ASTRAZENECA AB ASTRAZENECA UK LIMITED DALY, Kevin HERON, Nicola HIRD, Alexander IOANNIDIS, Stephanos JANETKA, James, Walter LYNE, Paul SCOTT, Jamie TOADER, Dorin VASBINDER, Melissa YU, Dingwei YU, Yan
DM1C8MA	DT	Small molecular drug
DM1C8MA	DE	Solid tumour/cancer; Metastatic cancer

DMOWFA5	ID	DMOWFA5
DMOWFA5	DN	Thieno[3,2-c]pyridine-7-carboxamide derivative 2
DMOWFA5	HS	Patented
DMOWFA5	SN	PMID25684022-Compound-WO2006106326c2
DMOWFA5	CP	ASTRAZENECA AB ASTRAZENECA UK LIMITED DALY, Kevin HERON, Nicola HIRD, Alexander IOANNIDIS, Stephanos JANETKA, James, Walter LYNE, Paul SCOTT, Jamie TOADER, Dorin VASBINDER, Melissa YU, Dingwei YU, Yan
DMOWFA5	DT	Small molecular drug
DMOWFA5	DE	Solid tumour/cancer; Metastatic cancer

DMZP6KR	ID	DMZP6KR
DMZP6KR	DN	Thiomorpholine derivative 1
DMZP6KR	HS	Patented
DMZP6KR	SN	PMID25482888-Compound-19
DMZP6KR	DT	Small molecular drug

DMWOK1D	ID	DMWOK1D
DMWOK1D	DN	Thiomorpholine derivative 2
DMWOK1D	HS	Patented
DMWOK1D	SN	PMID25482888-Compound-20
DMWOK1D	DT	Small molecular drug

DM6QHO0	ID	DM6QHO0
DM6QHO0	DN	Tihoacetate derivative 1
DM6QHO0	HS	Patented
DM6QHO0	SN	PMID27414413-Compound-Figure2left
DM6QHO0	CP	ARDEA BIOSCIENCES, INC. OUK, Samedy VERNIER, Jean-michel GUNIC, Esmir CHEN, Chixu
DM6QHO0	DT	Small molecular drug

DM5UI73	ID	DM5UI73
DM5UI73	DN	Tihotungstate derivative 1
DM5UI73	HS	Patented
DM5UI73	SN	PMID25553724-Compound-US2011015102237
DM5UI73	DT	Small molecular drug
DM5UI73	DE	Nervous system disease; Neurodegenerative disorder; Copper metabolism disorder; Aberrant vascularization

DMGR6IJ	ID	DMGR6IJ
DMGR6IJ	DN	Tihourea derivative 1
DMGR6IJ	HS	Patented
DMGR6IJ	SN	PMID25553724-Compound-WO2012060594 1
DMGR6IJ	CP	SOOKMYUNG WOMEN&#039;S UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION              CHONBUK NATIONAL UNIVERSITY INDUSTRIAL COOPERATION FOUNDATION            JEON, Raok    

DMHR43K	ID	DMHR43K
DMHR43K	DN	Tlouidine sulfonamide derivative 1
DMHR43K	HS	Patented
DMHR43K	SN	PMID26882240-Compound-16
DMHR43K	CP	ELARA PHARMACEUTICALS GMBH MCLAUGHLIN, Fiona LEWIS, Joe
DMHR43K	DT	Small molecular drug

DM6KJLG	ID	DM6KJLG
DM6KJLG	DN	Trepenoid derivative 1
DM6KJLG	HS	Patented
DM6KJLG	SN	PMID28454500-Compound-14
DM6KJLG	DT	Small molecular drug

DM9QB2S	ID	DM9QB2S
DM9QB2S	DN	Triazole derivative 1
DM9QB2S	HS	Patented
DM9QB2S	SN	PMID26560530-Compound-42
DM9QB2S	CP	Universit de Montral
DM9QB2S	DT	Small molecular drug
DM9QB2S	PC	25015312
DM9QB2S	MW	379.3
DM9QB2S	FM	C18H13N5O5
DM9QB2S	IC	InChI=1S/C18H13N5O5/c24-18(10-5-13-1-6-15(7-2-13)22(25)26)17-12-21(20-19-17)11-14-3-8-16(9-4-14)23(27)28/h1-10,12H,11H2/b10-5+
DM9QB2S	CS	C1=CC(=CC=C1CN2C=C(N=N2)C(=O)/C=C/C3=CC=C(C=C3)[N+](=O)[O-])[N+](=O)[O-]
DM9QB2S	IK	CVKOJPBBOPIMAL-BJMVGYQFSA-N
DM9QB2S	IU	(E)-3-(4-nitrophenyl)-1-[1-[(4-nitrophenyl)methyl]triazol-4-yl]prop-2-en-1-one

DM7KNXH	ID	DM7KNXH
DM7KNXH	DN	Triazole derivative 2
DM7KNXH	HS	Patented
DM7KNXH	SN	PMID27724045-Compound-30
DM7KNXH	CP	Abbott
DM7KNXH	DT	Small molecular drug
DM7KNXH	PC	16679492
DM7KNXH	MW	416.3
DM7KNXH	FM	C19H15Cl2N5S
DM7KNXH	IC	InChI=1S/C19H15Cl2N5S/c1-12-24-25-19(26(12)16-6-2-5-15(20)17(16)21)23-10-13-4-3-8-22-18(13)14-7-9-27-11-14/h2-9,11H,10H2,1H3,(H,23,25)
DM7KNXH	CS	CC1=NN=C(N1C2=C(C(=CC=C2)Cl)Cl)NCC3=C(N=CC=C3)C4=CSC=C4
DM7KNXH	IK	SMJNWZUHIGQMEW-UHFFFAOYSA-N
DM7KNXH	IU	4-(2,3-dichlorophenyl)-5-methyl-N-[(2-thiophen-3-ylpyridin-3-yl)methyl]-1,2,4-triazol-3-amine

DMZR0TH	ID	DMZR0TH
DMZR0TH	DN	Triazole derivative 3
DMZR0TH	HS	Patented
DMZR0TH	SN	PMID26560362-Compound-32
DMZR0TH	DT	Small molecular drug
DMZR0TH	PC	16663189
DMZR0TH	MW	223.62
DMZR0TH	FM	C8H6ClN5O
DMZR0TH	IC	InChI=1S/C8H6ClN5O/c9-5-1-2-7(10-3-5)12-8(15)6-4-11-14-13-6/h1-4H,(H,10,12,15)(H,11,13,14)
DMZR0TH	CS	C1=CC(=NC=C1Cl)NC(=O)C2=NNN=C2
DMZR0TH	IK	RVQBIGKKUXHYRZ-UHFFFAOYSA-N
DMZR0TH	IU	N-(5-chloropyridin-2-yl)-2H-triazole-4-carboxamide

DMCFEAS	ID	DMCFEAS
DMCFEAS	DN	Triazole derivative 4
DMCFEAS	HS	Patented
DMCFEAS	SN	PMID28906174-Compound-Figure1h
DMCFEAS	CP	Ixchelsis Limited
DMCFEAS	DT	Small molecular drug

DMA83QK	ID	DMA83QK
DMA83QK	DN	Triazole derivative 5
DMA83QK	HS	Patented
DMA83QK	SN	PMID28906174-Compound-Figure1i
DMA83QK	CP	Ixchelsis Limited
DMA83QK	DT	Small molecular drug

DMU15FW	ID	DMU15FW
DMU15FW	DN	Triazole derivative 6
DMU15FW	HS	Patented
DMU15FW	SN	PMID28906174-Compound-Figure1j
DMU15FW	CP	Ixchelsis Limited
DMU15FW	DT	Small molecular drug

DMRK4AT	ID	DMRK4AT
DMRK4AT	DN	Triazole derivative 7
DMRK4AT	HS	Patented
DMRK4AT	SN	PMID28906174-Compound-Figure1k
DMRK4AT	CP	Ixchelsis Limited
DMRK4AT	DT	Small molecular drug

DMCWES7	ID	DMCWES7
DMCWES7	DN	Triazole gold complexe 1
DMCWES7	HS	Patented
DMCWES7	SN	PMID27977313-Compound-10
DMCWES7	DT	Small molecular drug

DMJON7D	ID	DMJON7D
DMJON7D	DN	Triazole gold complexe 2
DMJON7D	HS	Patented
DMJON7D	SN	PMID27977313-Compound-9
DMJON7D	DT	Small molecular drug

DM5TILQ	ID	DM5TILQ
DM5TILQ	DN	Triazole gold complexe 3
DM5TILQ	HS	Patented
DM5TILQ	SN	PMID27977313-Compound-Figure4c
DM5TILQ	DT	Small molecular drug

DMPRGLZ	ID	DMPRGLZ
DMPRGLZ	DN	Triazole piperazine derivative 1
DMPRGLZ	HS	Patented
DMPRGLZ	SN	PMID25482888-Compound-36
DMPRGLZ	DT	Small molecular drug

DM8LFGS	ID	DM8LFGS
DM8LFGS	DN	Triazole propanedioic acid derivative 1
DM8LFGS	HS	Patented
DM8LFGS	SN	PMID27414413-Compound-Figure11down
DM8LFGS	CP	Yuanqiang Z
DM8LFGS	DT	Small molecular drug

DM34MCP	ID	DM34MCP
DM34MCP	DN	Triazolo[4,3-b]pyridazine derivative 1
DM34MCP	HS	Patented
DM34MCP	SN	PMID25435179-Compound-WO2013059589(II)
DM34MCP	CP	GLAXOSMITHKLINE LLC BLUM, Charles, A. SPRINGER, Stephanie, K. VU, Chi, B

DMMJ1FN	ID	DMMJ1FN
DMMJ1FN	DN	Triazolo[4,3-b]pyridazine derivative 2
DMMJ1FN	HS	Patented
DMMJ1FN	SN	PMID28270021-Compound-WO2012125667Example24
DMMJ1FN	CP	MERCK SHARP & DOHME CORP
DMMJ1FN	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DM79KEX	ID	DM79KEX
DM79KEX	DN	Triazolo-benzodiazepine derivative 1
DM79KEX	HS	Patented
DM79KEX	SN	PMID29334795-Compound-26
DM79KEX	DT	Small molecular drug
DM79KEX	PC	71254559
DM79KEX	MW	433.6
DM79KEX	FM	C26H31N3OS
DM79KEX	IC	InChI=1S/C26H31N3OS/c1-20-25(31-26-27-18-22-8-3-4-9-23(22)19-29(20)26)21-10-12-24(13-11-21)30-17-7-16-28-14-5-2-6-15-28/h3-4,8-13H,2,5-7,14-19H2,1H3
DM79KEX	CS	CC1=C(SC2=NCC3=CC=CC=C3CN12)C4=CC=C(C=C4)OCCCN5CCCCC5
DM79KEX	IK	RUTOALHMLUQLAH-UHFFFAOYSA-N
DM79KEX	IU	1-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-5,10-dihydro-[1,3]thiazolo[3,2-b][2,4]benzodiazepine

DMQSCHA	ID	DMQSCHA
DMQSCHA	DN	Triazolo-benzodiazepine derivative 2
DMQSCHA	HS	Patented
DMQSCHA	SN	PMID29334795-Compound-27
DMQSCHA	DT	Small molecular drug

DMU9A7V	ID	DMU9A7V
DMU9A7V	DN	Triazolo-phthalazine derivative 1
DMU9A7V	HS	Patented
DMU9A7V	SN	PMID27321640-Compound-14
DMU9A7V	CP	ALTANA PHARMA AG [DEALTANA PHARMA AG SCHMIDT, Beate WEINBRENNER, Steffen FLOCKERZI, Dieter KUELZER, Raimund TENOR, Hermann KLEY, Hans-Peter
DMU9A7V	DT	Small molecular drug

DM1KHGY	ID	DM1KHGY
DM1KHGY	DN	Triazolo-pyrazinone derivative 1
DM1KHGY	HS	Patented
DM1KHGY	SN	PMID27724045-Compound-35
DM1KHGY	CP	MERCK SHARP &amDOHME CORP. LABROLI, Marc CZARNIECKI, Michael, F. POKER, Cory Seth
DM1KHGY	DT	Small molecular drug
DM1KHGY	PC	56944547
DM1KHGY	MW	559
DM1KHGY	FM	C26H18ClF3N4O3S
DM1KHGY	IC	InChI=1S/C26H18ClF3N4O3S/c1-16-21(26(28,29)30)7-4-8-22(16)33-13-14-34-23(24(33)35)31-32-25(34)38(36,37)15-18-5-2-3-6-20(18)17-9-11-19(27)12-10-17/h2-14H,15H2,1H3
DM1KHGY	CS	CC1=C(C=CC=C1N2C=CN3C(=NN=C3S(=O)(=O)CC4=CC=CC=C4C5=CC=C(C=C5)Cl)C2=O)C(F)(F)F
DM1KHGY	IK	BEOJDRXHECGYFM-UHFFFAOYSA-N
DM1KHGY	IU	3-[[2-(4-chlorophenyl)phenyl]methylsulfonyl]-7-[2-methyl-3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyrazin-8-one

DM0Q9VY	ID	DM0Q9VY
DM0Q9VY	DN	Triazolo-pyridine derivative 1
DM0Q9VY	HS	Patented
DM0Q9VY	SN	PMID27774822-Compound-Figure7ExampleI-286
DM0Q9VY	CP	F.HOFFMANN-LA ROCHE AG GENENTECH, INC LI, Wei
DM0Q9VY	DT	Small molecular drug

DMXPQ24	ID	DMXPQ24
DMXPQ24	DN	Triazolo-pyridine derivative 2
DMXPQ24	HS	Patented
DMXPQ24	SN	PMID27321640-Compound-49
DMXPQ24	CP	LUNDBECK & CO AS H [DK]
DMXPQ24	DT	Small molecular drug

DMQL1TV	ID	DMQL1TV
DMQL1TV	DN	Triazolo-pyridine derivative 3
DMQL1TV	HS	Patented
DMQL1TV	SN	PMID27321640-Compound-50
DMQL1TV	CP	LUNDBECK & CO AS H [DK]
DMQL1TV	DT	Small molecular drug

DM5ZQKS	ID	DM5ZQKS
DM5ZQKS	DN	Triazolo-pyridine derivative 4
DM5ZQKS	HS	Patented
DM5ZQKS	SN	PMID27321640-Compound-51
DM5ZQKS	CP	LUNDBECK & CO AS H [DK]
DM5ZQKS	DT	Small molecular drug
DM5ZQKS	PC	71295299
DM5ZQKS	MW	295.72
DM5ZQKS	FM	C15H10ClN5
DM5ZQKS	IC	InChI=1S/C15H10ClN5/c1-9-14-19-20-15(10-4-2-3-5-11(10)16)21(14)13-8-17-7-6-12(13)18-9/h2-8H,1H3
DM5ZQKS	CS	CC1=NC2=C(C=NC=C2)N3C1=NN=C3C4=CC=CC=C4Cl
DM5ZQKS	IK	SNQXTEAQGLZIDL-UHFFFAOYSA-N
DM5ZQKS	IU	3-(2-chlorophenyl)-7-methyl-2,4,5,8,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene

DM1R205	ID	DM1R205
DM1R205	DN	Triazolo-pyridine derivative 5
DM1R205	HS	Patented
DM1R205	SN	PMID27321640-Compound-52
DM1R205	CP	LUNDBECK & CO AS H [DK]
DM1R205	DT	Small molecular drug
DM1R205	PC	71295652
DM1R205	MW	324.8
DM1R205	FM	C17H13ClN4O
DM1R205	IC	InChI=1S/C17H13ClN4O/c1-10-16-20-21-17(11-6-3-4-7-12(11)18)22(16)15-13(19-10)8-5-9-14(15)23-2/h3-9H,1-2H3
DM1R205	CS	CC1=NC2=C(C(=CC=C2)OC)N3C1=NN=C3C4=CC=CC=C4Cl
DM1R205	IK	MGVXODADYYKJPQ-UHFFFAOYSA-N
DM1R205	IU	1-(2-chlorophenyl)-9-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline

DMX4WFP	ID	DMX4WFP
DMX4WFP	DN	Triazolo-pyridine derivative 6
DMX4WFP	HS	Patented
DMX4WFP	SN	PMID27321640-Compound-53
DMX4WFP	CP	LUNDBECK & CO AS H [DK]
DMX4WFP	DT	Small molecular drug
DMX4WFP	PC	71295624
DMX4WFP	MW	312.73
DMX4WFP	FM	C16H10ClFN4
DMX4WFP	IC	InChI=1S/C16H10ClFN4/c1-9-15-20-21-16(10-5-2-3-6-11(10)17)22(15)14-12(18)7-4-8-13(14)19-9/h2-8H,1H3
DMX4WFP	CS	CC1=NC2=C(C(=CC=C2)F)N3C1=NN=C3C4=CC=CC=C4Cl
DMX4WFP	IK	ZXWSCYGUZHTXLO-UHFFFAOYSA-N
DMX4WFP	IU	1-(2-chlorophenyl)-9-fluoro-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline

DMJN72E	ID	DMJN72E
DMJN72E	DN	Triazolo-pyrimidinedione derivative 1
DMJN72E	HS	Patented
DMJN72E	SN	PMID25482888-Compound-64
DMJN72E	CP	SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong YUAN, Quan LIU, Caiping LUO, Lian SHI, Hailong ZOU, Chunlan YAN, Chengyi
DMJN72E	DT	Small molecular drug

DMLGNB2	ID	DMLGNB2
DMLGNB2	DN	Triazolo-pyrimidinedione derivative 2
DMLGNB2	HS	Patented
DMLGNB2	SN	PMID25482888-Compound-65
DMLGNB2	CP	SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong YUAN, Quan LIU, Caiping LUO, Lian SHI, Hailong ZOU, Chunlan YAN, Chengyi
DMLGNB2	DT	Small molecular drug

DMYEDJI	ID	DMYEDJI
DMYEDJI	DN	Tricyclic 5-quinolone derivative 1
DMYEDJI	HS	Patented
DMYEDJI	SN	PMID27828716-Compound-9
DMYEDJI	CP	DAIICHI SANKYO CO LTD [JP]
DMYEDJI	DT	Small molecular drug
DMYEDJI	PC	72695231
DMYEDJI	MW	447.5
DMYEDJI	FM	C22H27F2N5O3
DMYEDJI	IC	InChI=1S/C22H27F2N5O3/c1-10(30)28-8-5-11(6-9-28)27-18-15(23)17(25)14-19(16(18)24)29-12(4-7-22(29,2)3)13(20(14)31)21(26)32/h11,27H,4-9,25H2,1-3H3,(H2,26,32)
DMYEDJI	CS	CC(=O)N1CCC(CC1)NC2=C(C(=C3C(=C2F)N4C(=C(C3=O)C(=O)N)CCC4(C)C)N)F
DMYEDJI	IK	KPYGNCXHNQMYPD-UHFFFAOYSA-N
DMYEDJI	IU	8-[(1-acetylpiperidin-4-yl)amino]-6-amino-7,9-difluoro-1,1-dimethyl-5-oxo-2,3-dihydropyrrolo[1,2-a]quinoline-4-carboxamide

DM5SD9E	ID	DM5SD9E
DM5SD9E	DN	Tricyclic benzimidazole derivative 1
DM5SD9E	HS	Patented
DM5SD9E	SN	PMID26161698-Compound-21
DM5SD9E	CP	SELVITA SA
DM5SD9E	DT	Small molecular drug
DM5SD9E	PC	75201489
DM5SD9E	MW	479.01
DM5SD9E	FM	C14H15Br3N4
DM5SD9E	IC	InChI=1S/C14H15Br3N4/c15-9-8-2-1-5-21-13(8)12(11(17)10(9)16)19-14(21)20-6-3-18-4-7-20/h18H,1-7H2
DM5SD9E	CS	C1CC2=C3C(=C(C(=C2Br)Br)Br)N=C(N3C1)N4CCNCC4
DM5SD9E	IK	FUOROZXAYONUGD-UHFFFAOYSA-N
DM5SD9E	IU	5,6,7-tribromo-2-piperazin-1-yl-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene

DMLBR4F	ID	DMLBR4F
DMLBR4F	DN	Tricyclic compound 1
DMLBR4F	HS	Patented
DMLBR4F	SN	PMID27774824-Compound-Figure1Example1
DMLBR4F	CP	ALMIRALL, S.AABBVIE INC
DMLBR4F	DT	Small molecular drug

DMV1RQX	ID	DMV1RQX
DMV1RQX	DN	Tricyclic compound 10
DMV1RQX	HS	Patented
DMV1RQX	SN	PMID27568917-Compound-Figure7(d)
DMV1RQX	DT	Small molecular drug
DMV1RQX	PC	66546795
DMV1RQX	MW	322.4
DMV1RQX	FM	C20H19FN2O
DMV1RQX	IC	InChI=1S/C20H19FN2O/c1-12-3-4-14-7-10-17-19(18(14)11-12)22-23(13(2)24)20(17)15-5-8-16(21)9-6-15/h3-6,8-9,11,17,20H,7,10H2,1-2H3
DMV1RQX	CS	CC1=CC2=C(CCC3C2=NN(C3C4=CC=C(C=C4)F)C(=O)C)C=C1
DMV1RQX	IK	KSFRHQFENHYLGG-UHFFFAOYSA-N
DMV1RQX	IU	1-[3-(4-fluorophenyl)-8-methyl-3,3a,4,5-tetrahydrobenzo[g]indazol-2-yl]ethanone

DMJAZ7D	ID	DMJAZ7D
DMJAZ7D	DN	Tricyclic compound 11
DMJAZ7D	HS	Patented
DMJAZ7D	SN	PMID27774822-Compound-Figure7Example34
DMJAZ7D	CP	F. HOFFMANN-LA ROCHE AG BERGERON, Philippe BODIL VAN NIEL, Monique DRAGOVICH, Peter HURLEY, Christopher KULAGOWSKI, Janusz LABADIE, Sharada MCLEAN, Neville James MENDONCA, Rohan PULK, Rebecca ZAK, Mark
DMJAZ7D	DT	Small molecular drug

DMJAWOI	ID	DMJAWOI
DMJAWOI	DN	Tricyclic compound 2
DMJAWOI	HS	Patented
DMJAWOI	SN	PMID27774824-Compound-Figure1Example68
DMJAWOI	CP	ABBVIE INC. WISHART, Neil BONAFOUX, Dominique F. FRANK, Kristine E. HOBSON, Adrian D. KONOPACKI, Donald B, MARTINEZ, Gloria Y. WANG, Lu
DMJAWOI	DT	Small molecular drug

DM9K7P0	ID	DM9K7P0
DM9K7P0	DN	Tricyclic compound 3
DM9K7P0	HS	Patented
DM9K7P0	SN	PMID27774824-Compound-Figure13Example20
DM9K7P0	CP	INCYTE CORPORATION
DM9K7P0	DT	Small molecular drug

DMEIG16	ID	DMEIG16
DMEIG16	DN	Tricyclic compound 4
DMEIG16	HS	Patented
DMEIG16	SN	PMID28048944-Compound-23
DMEIG16	CP	BRISTOL-MYERS SQUIBB COMPANY
DMEIG16	DT	Small molecular drug
DMEIG16	PC	129159093
DMEIG16	MW	387.4
DMEIG16	FM	C23H21N3O3
DMEIG16	IC	InChI=1S/C23H21N3O3/c1-2-25-22(27)16-5-3-4-15(10-16)12-26-23(28)17-6-7-19-18(11-17)14-29-21-13-24-9-8-20(19)21/h3-11,13H,2,12,14H2,1H3,(H,25,27)(H,26,28)
DMEIG16	CS	CCNC(=O)C1=CC=CC(=C1)CNC(=O)C2=CC3=C(C=C2)C4=C(C=NC=C4)OC3
DMEIG16	IK	YKJXZODWOQJHCQ-UHFFFAOYSA-N
DMEIG16	IU	N-[[3-(ethylcarbamoyl)phenyl]methyl]-6H-isochromeno[3,4-c]pyridine-8-carboxamide

DMLPMS7	ID	DMLPMS7
DMLPMS7	DN	Tricyclic compound 5
DMLPMS7	HS	Patented
DMLPMS7	SN	PMID28048944-Compound-24
DMLPMS7	CP	BRISTOL-MYERS SQUIBB COMPANY
DMLPMS7	DT	Small molecular drug
DMLPMS7	PC	129159126
DMLPMS7	MW	470.6
DMLPMS7	FM	C28H30N4O3
DMLPMS7	IC	InChI=1S/C28H30N4O3/c1-2-32-12-4-7-23(32)16-31-27(33)20-6-3-5-19(13-20)15-30-28(34)21-8-9-24-22(14-21)18-35-26-17-29-11-10-25(24)26/h3,5-6,8-11,13-14,17,23H,2,4,7,12,15-16,18H2,1H3,(H,30,34)(H,31,33)
DMLPMS7	CS	CCN1CCCC1CNC(=O)C2=CC=CC(=C2)CNC(=O)C3=CC4=C(C=C3)C5=C(C=NC=C5)OC4
DMLPMS7	IK	PMNRRBVQSVNKLM-UHFFFAOYSA-N
DMLPMS7	IU	N-[[3-[(1-ethylpyrrolidin-2-yl)methylcarbamoyl]phenyl]methyl]-6H-isochromeno[3,4-c]pyridine-8-carboxamide

DMMJ81G	ID	DMMJ81G
DMMJ81G	DN	Tricyclic compound 6
DMMJ81G	HS	Patented
DMMJ81G	SN	PMID28048944-Compound-25
DMMJ81G	CP	BRISTOL-MYERS SQUIBB COMPANY
DMMJ81G	DT	Small molecular drug
DMMJ81G	PC	91895903
DMMJ81G	MW	333.4
DMMJ81G	FM	C20H19N3O2
DMMJ81G	IC	InChI=1S/C20H19N3O2/c1-3-23-18-8-6-5-7-16(18)17-11-15(9-10-19(17)23)22-13-14(12-21)20(24)25-4-2/h5-11,13-14H,3-4H2,1-2H3
DMMJ81G	CS	CCN1C2=C(C=C(C=C2)N=CC(C#N)C(=O)OCC)C3=CC=CC=C31
DMMJ81G	IK	ZCSFFBZXCQGHRG-UHFFFAOYSA-N
DMMJ81G	IU	ethyl 2-cyano-3-(9-ethylcarbazol-3-yl)iminopropanoate

DME84S5	ID	DME84S5
DME84S5	DN	Tricyclic compound 7
DME84S5	HS	Patented
DME84S5	SN	PMID28048944-Compound-26
DME84S5	CP	BRISTOL-MYERS SQUIBB COMPANY
DME84S5	DT	Small molecular drug

DMZI8GK	ID	DMZI8GK
DMZI8GK	DN	Tricyclic compound 8
DMZI8GK	HS	Patented
DMZI8GK	SN	PMID27568917-Compound-Figure1(a)
DMZI8GK	DT	Small molecular drug
DMZI8GK	PC	194580
DMZI8GK	MW	243.26
DMZI8GK	FM	C13H13N3O2
DMZI8GK	IC	InChI=1S/C13H13N3O2/c1-16-12(17)11(15-13(16)18)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,11,14H,6H2,1H3,(H,15,18)
DMZI8GK	CS	CN1C(=O)C(NC1=O)CC2=CNC3=CC=CC=C32
DMZI8GK	IK	PANAMPMZPUJRLL-UHFFFAOYSA-N
DMZI8GK	IU	5-(1H-indol-3-ylmethyl)-3-methylimidazolidine-2,4-dione
DMZI8GK	CA	CAS 74311-00-5

DMF5E6U	ID	DMF5E6U
DMF5E6U	DN	Tricyclic compound 9
DMF5E6U	HS	Patented
DMF5E6U	SN	PMID27568917-Compound-Figure7(c)
DMF5E6U	DT	Small molecular drug
DMF5E6U	PC	135444572
DMF5E6U	MW	317.25
DMF5E6U	FM	C15H11NO7
DMF5E6U	IC	InChI=1S/C15H11NO7/c1-8-6-13(19)14(15(20)23-8)12(18)5-3-9-2-4-11(17)10(7-9)16(21)22/h2-7,17,19H,1H3/b5-3+
DMF5E6U	CS	CC1=CC(=C(C(=O)O1)C(=O)/C=C/C2=CC(=C(C=C2)O)[N+](=O)[O-])O
DMF5E6U	IK	QYYBACCETRXSEX-HWKANZROSA-N
DMF5E6U	IU	4-hydroxy-3-[(E)-3-(4-hydroxy-3-nitrophenyl)prop-2-enoyl]-6-methylpyran-2-one

DMXLJH4	ID	DMXLJH4
DMXLJH4	DN	Tricyclic heterocycle derivative 1
DMXLJH4	HS	Patented
DMXLJH4	SN	PMID27774822-Compound-Figure3Example81
DMXLJH4	CP	NISSAN CHEMICAL INDUSTRIES, LTD. HAYASHI, Keishi WATANABE, Tsuneo TOYAMA, Koji KAMON, Junji MINAMI, Masataka UNI, Miyuki NASU, Mariko
DMXLJH4	DT	Small molecular drug

DM1W02D	ID	DM1W02D
DM1W02D	DN	Tricyclic heterocycle derivative 2
DM1W02D	HS	Patented
DM1W02D	SN	PMID27774824-Compound-Figure4compound118
DM1W02D	CP	VERTEX PHARMACEUTICALS INCORPORATED BENNANI, Yousseff WANG, Tiansheng SALITURO, Francesco DUFFY, John
DM1W02D	DT	Small molecular drug

DMJNCD6	ID	DMJNCD6
DMJNCD6	DN	Tricyclic heterocycle derivative 3
DMJNCD6	HS	Patented
DMJNCD6	SN	PMID26077642-Compound-Figure3c
DMJNCD6	CP	PRESIDENT AND FELLOWS OF HARVARD COLLEGE FINLEY, Daniel KING, Randall, W. LEE, Byung-Hoon LEE, Min, Jae GAHMAN, Timothy, C
DMJNCD6	DT	Small molecular drug

DM9XBL4	ID	DM9XBL4
DM9XBL4	DN	Tricyclic heterocycle derivative 4
DM9XBL4	HS	Patented
DM9XBL4	SN	PMID26077642-Compound-Figure3D
DM9XBL4	CP	PRESIDENT AND FELLOWS OF HARVARD COLLEGE FINLEY, Daniel KING, Randall, W. LEE, Byung-Hoon LEE, Min, Jae GAHMAN, Timothy, C
DM9XBL4	DT	Small molecular drug
DM9XBL4	PC	56644389
DM9XBL4	MW	259.37
DM9XBL4	FM	C14H17N3S
DM9XBL4	IC	InChI=1S/C14H17N3S/c1-17(9-6-7-9)13-12-10-4-2-3-5-11(10)18-14(12)16-8-15-13/h8-9H,2-7H2,1H3
DM9XBL4	CS	CN(C1CC1)C2=C3C4=C(CCCC4)SC3=NC=N2
DM9XBL4	IK	PGGINYVNLNKQRD-UHFFFAOYSA-N
DM9XBL4	IU	N-cyclopropyl-N-methyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-amine

DMG1ESV	ID	DMG1ESV
DMG1ESV	DN	Tricyclic heterocycle derivative 5
DMG1ESV	HS	Patented
DMG1ESV	SN	PMID27774822-Compound-Figure7Example4
DMG1ESV	CP	F. HOFFMANN-LA ROCHE AG HURLEY, Christopher KULAGOWSKI, Janusz ZAK, Mark
DMG1ESV	DT	Small molecular drug

DMQJK70	ID	DMQJK70
DMQJK70	DN	Tricyclic heterocycle derivative 6
DMQJK70	HS	Patented
DMQJK70	SN	PMID25482888-Compound-55
DMQJK70	CP	MERCK SHARP & DOHME CORP. BURNETT, Duane, A. ZHAO, Zhiqiang COLE, David JOSIEN, Hubert PISSARNITSKI, Dmitri, A. SASIKUMAR, Thavalakulamgar WU, Wen-Lian DOMALSKI, Martin
DMQJK70	DT	Small molecular drug
DMQJK70	PC	90129657
DMQJK70	MW	455.5
DMQJK70	FM	C22H29N7O4
DMQJK70	IC	InChI=1S/C22H29N7O4/c1-6-7-11-28-16-17(24-19-26(5)15(30)13-29(19)18(16)31)25-20(28)27-10-8-9-14(12-27)23-21(32)33-22(2,3)4/h14H,8-13H2,1-5H3,(H,23,32)/t14-/m1/s1
DMQJK70	CS	CC#CCN1C2=C(N=C3N(C(=O)CN3C2=O)C)N=C1N4CCC[C@H](C4)NC(=O)OC(C)(C)C
DMQJK70	IK	CBLPHWVBNDVSJU-CQSZACIVSA-N
DMQJK70	IU	tert-butyl N-[(3R)-1-(1-but-2-ynyl-5-methyl-6,9-dioxo-7H-imidazo[1,2-a]purin-2-yl)piperidin-3-yl]carbamate

DM4HBWU	ID	DM4HBWU
DM4HBWU	DN	Tricyclic indole compound 1
DM4HBWU	HS	Patented
DM4HBWU	SN	PMID27599163-Compound-(R)-2
DM4HBWU	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DM4HBWU	DT	Small molecular drug

DMK1QTH	ID	DMK1QTH
DMK1QTH	DN	Tricyclic indole compound 10
DMK1QTH	HS	Patented
DMK1QTH	SN	PMID27599163-Compound-67
DMK1QTH	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMK1QTH	DT	Small molecular drug

DML724H	ID	DML724H
DML724H	DN	Tricyclic indole compound 11
DML724H	HS	Patented
DML724H	SN	PMID27599163-Compound-68
DML724H	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DML724H	DT	Small molecular drug

DMEZQ29	ID	DMEZQ29
DMEZQ29	DN	Tricyclic indole compound 12
DMEZQ29	HS	Patented
DMEZQ29	SN	PMID27599163-Compound-69
DMEZQ29	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMEZQ29	DT	Small molecular drug

DMS6XT4	ID	DMS6XT4
DMS6XT4	DN	Tricyclic indole compound 13
DMS6XT4	HS	Patented
DMS6XT4	SN	PMID27841036-Compound-XVI
DMS6XT4	CP	China Pharmaceutical University
DMS6XT4	DT	Small molecular drug

DMXVNSR	ID	DMXVNSR
DMXVNSR	DN	Tricyclic indole compound 14
DMXVNSR	HS	Patented
DMXVNSR	SN	PMID27599163-Compound-2
DMXVNSR	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMXVNSR	DT	Small molecular drug

DMHRY63	ID	DMHRY63
DMHRY63	DN	Tricyclic indole compound 2
DMHRY63	HS	Patented
DMHRY63	SN	PMID27599163-Compound-(S)-2
DMHRY63	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexande
DMHRY63	DT	Small molecular drug

DM5B92W	ID	DM5B92W
DM5B92W	DN	Tricyclic indole compound 3
DM5B92W	HS	Patented
DM5B92W	SN	PMID27599163-Compound-60
DM5B92W	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DM5B92W	DT	Small molecular drug

DMUZ4L3	ID	DMUZ4L3
DMUZ4L3	DN	Tricyclic indole compound 4
DMUZ4L3	HS	Patented
DMUZ4L3	SN	PMID27599163-Compound-61
DMUZ4L3	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMUZ4L3	DT	Small molecular drug

DMX5YG9	ID	DMX5YG9
DMX5YG9	DN	Tricyclic indole compound 5
DMX5YG9	HS	Patented
DMX5YG9	SN	PMID27599163-Compound-62
DMX5YG9	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMX5YG9	DT	Small molecular drug

DMXAS8P	ID	DMXAS8P
DMXAS8P	DN	Tricyclic indole compound 6
DMXAS8P	HS	Patented
DMXAS8P	SN	PMID27599163-Compound-63
DMXAS8P	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMXAS8P	DT	Small molecular drug

DMFQSU8	ID	DMFQSU8
DMFQSU8	DN	Tricyclic indole compound 7
DMFQSU8	HS	Patented
DMFQSU8	SN	PMID27599163-Compound-64
DMFQSU8	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMFQSU8	DT	Small molecular drug

DMYAUVM	ID	DMYAUVM
DMYAUVM	DN	Tricyclic indole compound 8
DMYAUVM	HS	Patented
DMYAUVM	SN	PMID27599163-Compound-65
DMYAUVM	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMYAUVM	DT	Small molecular drug

DMVA7BC	ID	DMVA7BC
DMVA7BC	DN	Tricyclic indole compound 9
DMVA7BC	HS	Patented
DMVA7BC	SN	PMID27599163-Compound-66
DMVA7BC	CP	GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMVA7BC	DT	Small molecular drug

DM6QSND	ID	DM6QSND
DM6QSND	DN	Tricyclic isoxazoloquinazoline derivative 1
DM6QSND	HS	Patented
DM6QSND	SN	PMID27646439-Compound-11
DM6QSND	CP	NERVIANO MEDICAL SCIENCES S.R.L. CALDARELLI, Marina BERIA, Italo COLOMBO, Nicoletta PIUTTI, Claudia SALSA, Matteo TRAQUANDI, Gabriella
DM6QSND	DT	Small molecular drug

DMH4TY1	ID	DMH4TY1
DMH4TY1	DN	Tricyclic isoxazoloquinazoline derivative 2
DMH4TY1	HS	Patented
DMH4TY1	SN	PMID27646439-Compound-12
DMH4TY1	CP	NERVIANO MEDICAL SCIENCES S.R.L. CALDARELLI, Marina BERIA, Italo COLOMBO, Nicoletta PIUTTI, Claudia SALSA, Matteo TRAQUANDI, Gabriella
DMH4TY1	DT	Small molecular drug
DMH4TY1	PC	66713957
DMH4TY1	MW	406.4
DMH4TY1	FM	C21H22N6O3
DMH4TY1	IC	InChI=1S/C21H22N6O3/c1-26-8-10-27(11-9-26)14-3-5-15(6-4-14)29-21-23-12-13-2-7-16-18(17(13)24-21)25-30-19(16)20(22)28/h3-6,12H,2,7-11H2,1H3,(H2,22,28)
DMH4TY1	CS	CN1CCN(CC1)C2=CC=C(C=C2)OC3=NC=C4CCC5=C(ON=C5C4=N3)C(=O)N
DMH4TY1	IK	CMFVPEXDTAEYSG-UHFFFAOYSA-N
DMH4TY1	IU	8-[4-(4-methylpiperazin-1-yl)phenoxy]-4,5-dihydro-[1,2]oxazolo[4,3-h]quinazoline-3-carboxamide

DML2PWF	ID	DML2PWF
DML2PWF	DN	Tricyclic isoxazoloquinazoline derivative 3
DML2PWF	HS	Patented
DML2PWF	SN	PMID27646439-Compound-13
DML2PWF	CP	NERVIANO MEDICAL SCIENCES S.R.L. CALDARELLI, Marina BERIA, Italo COLOMBO, Nicoletta PIUTTI, Claudia SALSA, Matteo TRAQUANDI, Gabriella
DML2PWF	DT	Small molecular drug

DM8VIM4	ID	DM8VIM4
DM8VIM4	DN	Tricyclic isoxazoloquinazoline derivative 4
DM8VIM4	HS	Patented
DM8VIM4	SN	PMID27646439-Compound-14
DM8VIM4	CP	NERVIANO MEDICAL SCIENCES S.R.L. CALDARELLI, Marina BERIA, Italo COLOMBO, Nicoletta PIUTTI, Claudia SALSA, Matteo TRAQUANDI, Gabriella
DM8VIM4	DT	Small molecular drug

DM94NZF	ID	DM94NZF
DM94NZF	DN	Tricyclic phytocannabinoid derivative 1
DM94NZF	HS	Patented
DM94NZF	SN	PMID27215781-Compound-41
DM94NZF	CP	NORTHEASTERN UNIVERSITY MAKRIYANNIS, Alexandros THAKUR, Ganesh, A. SHARMA, Rishi
DM94NZF	DT	Small molecular drug
DM94NZF	PC	73330476
DM94NZF	MW	402.5
DM94NZF	FM	C24H34O5
DM94NZF	IC	InChI=1S/C24H34O5/c1-6-7-10-28-22(27)23(2,3)16-12-19(26)21-17-11-15(14-25)8-9-18(17)24(4,5)29-20(21)13-16/h8,12-13,17-18,25-26H,6-7,9-11,14H2,1-5H3/t17-,18-/m1/s1
DM94NZF	CS	CCCCOC(=O)C(C)(C)C1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)CO)O
DM94NZF	IK	AUMCYBWLZBTQLN-QZTJIDSGSA-N
DM94NZF	IU	butyl 2-[(6aR,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-3-yl]-2-methylpropanoate
DM94NZF	DE	Neuropathic pain

DM7YVQL	ID	DM7YVQL
DM7YVQL	DN	Tricyclic phytocannabinoid derivative 2
DM7YVQL	HS	Patented
DM7YVQL	SN	PMID27215781-Compound-42
DM7YVQL	CP	NORTHEASTERN UNIVERSITY MAKRIYANNIS, Alexandros THAKUR, Ganesh, A. SHARMA, Rishi
DM7YVQL	DT	Small molecular drug
DM7YVQL	PC	121231416
DM7YVQL	MW	404.5
DM7YVQL	FM	C24H36O5
DM7YVQL	IC	InChI=1S/C24H36O5/c1-6-7-10-28-22(27)23(2,3)16-12-19(26)21-17-11-15(14-25)8-9-18(17)24(4,5)29-20(21)13-16/h12-13,15,17-18,25-26H,6-11,14H2,1-5H3/t15-,17-,18-/m1/s1
DM7YVQL	CS	CCCCOC(=O)C(C)(C)C1=CC(=C2[C@@H]3C[C@@H](CC[C@H]3C(OC2=C1)(C)C)CO)O
DM7YVQL	IK	OSVHLUXLWQLPIY-KBAYOESNSA-N
DM7YVQL	IU	butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate
DM7YVQL	DE	Neuropathic pain

DMGY3OR	ID	DMGY3OR
DMGY3OR	DN	Tricyclic pyrrolidine derivative 1
DMGY3OR	HS	Patented
DMGY3OR	SN	PMID26609882-Compound-79
DMGY3OR	CP	ATHERSYS, INC.ATHERSYS, INC. BENNANI, Youssef, L. BOM, David, C. ROBARGE, Michael, J
DMGY3OR	DT	Small molecular drug

DMRD1XJ	ID	DMRD1XJ
DMRD1XJ	DN	Tricyclic pyrrolidine derivative 2
DMRD1XJ	HS	Patented
DMRD1XJ	SN	PMID26609882-Compound-80
DMRD1XJ	CP	ATHERSYS, INC.ATHERSYS, INC. BENNANI, Youssef, L. BOM, David, C. ROBARGE, Michael, J
DMRD1XJ	DT	Small molecular drug

DMK2V6H	ID	DMK2V6H
DMK2V6H	DN	Tricyclic pyrrolidine derivative 3
DMK2V6H	HS	Patented
DMK2V6H	SN	PMID26609882-Compound-81
DMK2V6H	CP	ATHERSYS, INC.ATHERSYS, INC. BENNANI, Youssef, L. BOM, David, C. ROBARGE, Michael, J
DMK2V6H	DT	Small molecular drug

DM0JYWT	ID	DM0JYWT
DM0JYWT	DN	Tricyclic pyrrolidine derivative 4
DM0JYWT	HS	Patented
DM0JYWT	SN	PMID26609882-Compound-82
DM0JYWT	CP	ATHERSYS, INC.ATHERSYS, INC. BENNANI, Youssef, L. BOM, David, C. ROBARGE, Michael, J
DM0JYWT	DT	Small molecular drug

DMFIXW4	ID	DMFIXW4
DMFIXW4	DN	Tricyclic pyrrolopyridine compound 1
DMFIXW4	HS	Patented
DMFIXW4	SN	PMID27774822-Compound-Figure3Example45
DMFIXW4	DT	Small molecular drug

DMZTPUA	ID	DMZTPUA
DMZTPUA	DN	Triptolidenol analog 1
DMZTPUA	HS	Patented
DMZTPUA	SN	PMID26882240-Compound-38
DMZTPUA	CP	Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China
DMZTPUA	DT	Small molecular drug
DMZTPUA	PC	122377866
DMZTPUA	MW	524.5
DMZTPUA	FM	C29H29FO8
DMZTPUA	IC	InChI=1S/C29H29FO8/c1-25(2,33)28-21(37-28)22-29(38-22)26(3)11-10-16-17(13-34-23(16)32)18(26)12-19-27(29,36-19)24(28)35-20(31)9-6-14-4-7-15(30)8-5-14/h4-9,18-19,21-22,24,33H,10-13H2,1-3H3/b9-6+/t18-,19-,21-,22-,24-,26-,27+,28-,29+/m0/s1
DMZTPUA	CS	C[C@]12CCC3=C([C@@H]1C[C@H]4[C@@]5([C@@]26[C@@H](O6)[C@H]7[C@@]([C@H]5OC(=O)/C=C/C8=CC=C(C=C8)F)(O7)C(C)(C)O)O4)COC3=O
DMZTPUA	IK	FVQHGGQECDTHSW-YZAYWNIQSA-N
DMZTPUA	IU	[(1S,2S,4S,5S,7S,8R,9R,11S,13S)-7-(2-hydroxypropan-2-yl)-1-methyl-17-oxo-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-8-yl] (E)-3-(4-fluorophenyl)prop-2-enoate

DMEQ3RD	ID	DMEQ3RD
DMEQ3RD	DN	Tri-substituted benzene derivative 1
DMEQ3RD	HS	Patented
DMEQ3RD	SN	PMID26560362-Compound-91
DMEQ3RD	DT	Small molecular drug
DMEQ3RD	PC	10113381
DMEQ3RD	MW	428.4
DMEQ3RD	FM	C17H18F2N4O5S
DMEQ3RD	IC	InChI=1S/C17H18F2N4O5S/c1-23(2)29(26,27)22-17(25)21-14-8-10(4-7-15(14)28-3)16(24)20-11-5-6-12(18)13(19)9-11/h4-9H,1-3H3,(H,20,24)(H2,21,22,25)
DMEQ3RD	CS	CN(C)S(=O)(=O)NC(=O)NC1=C(C=CC(=C1)C(=O)NC2=CC(=C(C=C2)F)F)OC
DMEQ3RD	IK	VUAXXZRGLYBYPO-UHFFFAOYSA-N
DMEQ3RD	IU	N-(3,4-difluorophenyl)-3-(dimethylsulfamoylcarbamoylamino)-4-methoxybenzamide

DM7NTO9	ID	DM7NTO9
DM7NTO9	DN	Tri-substituted purine derivative 1
DM7NTO9	HS	Patented
DM7NTO9	SN	PMID26394986-Compound-9
DM7NTO9	CP	UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. UNIVERSITY OF TORONTO MISSISSAUGA TURKSON, James GUNNING, Patrick
DM7NTO9	DT	Small molecular drug
DM7NTO9	PC	71770709
DM7NTO9	MW	539.6
DM7NTO9	FM	C26H30FN7O3S
DM7NTO9	IC	InChI=1S/C26H30FN7O3S/c27-21-10-12-22(13-11-21)31-24-23-25(34(17-30-23)14-15-37-38(28,35)36)33-26(32-24)29-16-18-6-8-20(9-7-18)19-4-2-1-3-5-19/h6-13,17,19H,1-5,14-16H2,(H2,28,35,36)(H2,29,31,32,33)
DM7NTO9	CS	C1CCC(CC1)C2=CC=C(C=C2)CNC3=NC(=C4C(=N3)N(C=N4)CCOS(=O)(=O)N)NC5=CC=C(C=C5)F
DM7NTO9	IK	SDEPDOGWVAMEDD-UHFFFAOYSA-N
DM7NTO9	IU	2-[2-[(4-cyclohexylphenyl)methylamino]-6-(4-fluoroanilino)purin-9-yl]ethyl sulfamate

DMHGRTX	ID	DMHGRTX
DMHGRTX	DN	Tri-substituted urea derivative 1
DMHGRTX	HS	Patented
DMHGRTX	SN	PMID28270021-Compound-WO2013176970Example1
DMHGRTX	CP	MERCK SHARP & DOHME CORP
DMHGRTX	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMUVPR8	ID	DMUVPR8
DMUVPR8	DN	Tri-substituted urea derivative 2
DMUVPR8	HS	Patented
DMUVPR8	SN	PMID28270021-Compound-WO2013176970Example2
DMUVPR8	CP	MERCK SHARP & DOHME CORP
DMUVPR8	DE	Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer

DMLJ2HE	ID	DMLJ2HE
DMLJ2HE	DN	Undecylenic acid derivative 1
DMLJ2HE	HS	Patented
DMLJ2HE	SN	PMID25399719-Compound-61
DMLJ2HE	CP	EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION               KWON, Young Joo
DMLJ2HE	DT	Small molecular drug
DMLJ2HE	PC	5634
DMLJ2HE	MW	184.27
DMLJ2HE	FM	C11H20O2
DMLJ2HE	IC	InChI=1S/C11H20O2/c1-2-3-4-5-6-7-8-9-10-11(12)13/h2H,1,3-10H2,(H,12,13)
DMLJ2HE	CS	C=CCCCCCCCCC(=O)O
DMLJ2HE	IK	FRPZMMHWLSIFAZ-UHFFFAOYSA-N
DMLJ2HE	IU	undec-10-enoic acid
DMLJ2HE	CA	CAS 112-38-9
DMLJ2HE	CB	CHEBI:35045

DMUD7H8	ID	DMUD7H8
DMUD7H8	DN	Unii-I92MU0V408
DMUD7H8	HS	Patented
DMUD7H8	SN	UNII-I92MU0V408; I92MU0V408; SCHEMBL1695326; CHEMBL3695568; RTDCVLCTBQDLBW-UHFFFAOYSA-N; BDBM142597; RV568; US8933228, Ref 1; RV-568; JNJ-49095397; N-(4-(((4-((((3-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)amino)carbonyl)amino)-1-naphthalenyl)oxy)methyl)-2-pyridinyl)-2-methoxyacetamide; Acetamide, N-(4-(((4-((((3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)amino)carbonyl)amino)-1-naphthalenyl)oxy)methyl)-2-pyridinyl)-2-methoxy-; 1220626-82-3; N-[4-({4-[3-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)ur
DMUD7H8	DT	Small molecular drug
DMUD7H8	PC	45109868
DMUD7H8	MW	592.7
DMUD7H8	FM	C34H36N6O4
DMUD7H8	IC	InChI=1S/C34H36N6O4/c1-22-10-12-24(13-11-22)40-31(19-29(39-40)34(2,3)4)38-33(42)36-27-14-15-28(26-9-7-6-8-25(26)27)44-20-23-16-17-35-30(18-23)37-32(41)21-43-5/h6-19H,20-21H2,1-5H3,(H,35,37,41)(H2,36,38,42)
DMUD7H8	CS	CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCC5=CC(=NC=C5)NC(=O)COC
DMUD7H8	IK	RTDCVLCTBQDLBW-UHFFFAOYSA-N
DMUD7H8	IU	N-[4-[[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxymethyl]pyridin-2-yl]-2-methoxyacetamide
DMUD7H8	CA	CAS 1220626-82-3

DMUHSAZ	ID	DMUHSAZ
DMUHSAZ	DN	Unii-R228S06soh
DMUHSAZ	HS	Patented
DMUHSAZ	SN	UNII-R228S06SOH; R228S06SOH; AB-22; 1463913-43-0; SCHEMBL15295885; SB19630; N-(2-Chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo(3,4-b)pyridin-6-yl)hydrazinecarboxamide; Hydrazinecarboxamide, N-(2-chloro-6-propoxy-4-pyridinyl)-2-(1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo(3,4-b)pyridin-6-yl)-2-(2-hydroxyethyl); 
DMUHSAZ	DT	Small molecular drug
DMUHSAZ	PC	81689736
DMUHSAZ	MW	476
DMUHSAZ	FM	C22H30ClN7O3
DMUHSAZ	IC	InChI=1S/C22H30ClN7O3/c1-6-9-33-19-11-15(10-17(23)25-19)24-22(32)28-30(7-8-31)18-12-16(13(2)3)20-14(4)27-29(5)21(20)26-18/h10-13,31H,6-9H2,1-5H3,(H2,24,25,28,32)
DMUHSAZ	CS	CCCOC1=NC(=CC(=C1)NC(=O)NN(CCO)C2=NC3=C(C(=NN3C)C)C(=C2)C(C)C)Cl
DMUHSAZ	IK	GOQBSVFOBGVWTA-UHFFFAOYSA-N
DMUHSAZ	IU	1-(2-chloro-6-propoxypyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)-(2-hydroxyethyl)amino]urea
DMUHSAZ	CA	CAS 1463913-43-0

DM5SX8T	ID	DM5SX8T
DM5SX8T	DN	Uracil derivative 1
DM5SX8T	HS	Patented
DM5SX8T	SN	PMID26118988-Compound-41
DM5SX8T	CP	D2 BIOSCIENCE GROUP LTD. BAYERL, Thoma
DM5SX8T	DT	Small molecular drug

DMEQFXZ	ID	DMEQFXZ
DMEQFXZ	DN	Urea and carbamate bioisostere derivative 1
DMEQFXZ	HS	Patented
DMEQFXZ	SN	PMID28074661-Compound-US20026399773BMS-337197
DMEQFXZ	CP	Bristol-Myers Squibb Co
DMEQFXZ	DT	Small molecular drug

DMWNR8I	ID	DMWNR8I
DMWNR8I	DN	Urea and carbamate bioisostere derivative 10
DMWNR8I	HS	Patented
DMWNR8I	SN	PMID28074661-Compound-US20036617323c29
DMWNR8I	CP	Bristol-Myers Squibb Co
DMWNR8I	DT	Small molecular drug

DMAP6YS	ID	DMAP6YS
DMAP6YS	DN	Urea and carbamate bioisostere derivative 11
DMAP6YS	HS	Patented
DMAP6YS	SN	PMID28074661-Compound-US20036624184c31
DMAP6YS	CP	Bristol-Myers Squibb Co
DMAP6YS	DT	Small molecular drug

DM6BJEW	ID	DM6BJEW
DM6BJEW	DN	Urea and carbamate bioisostere derivative 13
DM6BJEW	HS	Patented
DM6BJEW	SN	PMID28074661-Compound-US20056867299c40
DM6BJEW	CP	Hoffmann-La Roche Inc
DM6BJEW	DT	Small molecular drug

DMDP09N	ID	DMDP09N
DMDP09N	DN	Urea and carbamate bioisostere derivative 14
DMDP09N	HS	Patented
DMDP09N	SN	PMID28074661-Compound-US20067053111c32
DMDP09N	CP	Bristol-Myers Squibb Co
DMDP09N	DT	Small molecular drug

DM3SQUD	ID	DM3SQUD
DM3SQUD	DN	Urea and carbamate bioisostere derivative 15
DM3SQUD	HS	Patented
DM3SQUD	SN	PMID28074661-Compound-US20067060720c32
DM3SQUD	CP	Bristol-Myers Squibb Co
DM3SQUD	DT	Small molecular drug

DMRLC4X	ID	DMRLC4X
DMRLC4X	DN	Urea and carbamate bioisostere derivative 16
DMRLC4X	HS	Patented
DMRLC4X	SN	PMID28074661-Compound-US20077205324c32
DMRLC4X	CP	Bristol-Myers Squibb Co
DMRLC4X	DT	Small molecular drug

DM7PSB1	ID	DM7PSB1
DM7PSB1	DN	Urea and carbamate bioisostere derivative 18
DM7PSB1	HS	Patented
DM7PSB1	SN	PMID28074661-Compound-WO2003045901c30
DM7PSB1	CP	CELLTECH R & D LIMITED DYKE, Hazel, Joan BUCKLEY, George, Martin
DM7PSB1	DT	Small molecular drug

DMRTJSC	ID	DMRTJSC
DMRTJSC	DN	Urea and carbamate bioisostere derivative 2
DMRTJSC	HS	Patented
DMRTJSC	SN	PMID28074661-Compound-US20026399773c21
DMRTJSC	CP	Bristol-Myers Squibb Co
DMRTJSC	DT	Small molecular drug

DMPXVWE	ID	DMPXVWE
DMPXVWE	DN	Urea and carbamate bioisostere derivative 3
DMPXVWE	HS	Patented
DMPXVWE	SN	PMID28074661-Compound-US20026399773c22
DMPXVWE	CP	Bristol-Myers Squibb Co
DMPXVWE	DT	Small molecular drug

DM5GZNS	ID	DM5GZNS
DM5GZNS	DN	Urea and carbamate bioisostere derivative 4
DM5GZNS	HS	Patented
DM5GZNS	SN	PMID28074661-Compound-US20026420403c26
DM5GZNS	CP	Bristol-Myers Squibb Co
DM5GZNS	DT	Small molecular drug

DM02ZM4	ID	DM02ZM4
DM02ZM4	DN	Urea and carbamate bioisostere derivative 5
DM02ZM4	HS	Patented
DM02ZM4	SN	PMID28074661-Compound-US20026420403c27
DM02ZM4	CP	Bristol-Myers Squibb Co
DM02ZM4	DT	Small molecular drug

DMP29I0	ID	DMP29I0
DMP29I0	DN	Urea and carbamate bioisostere derivative 6
DMP29I0	HS	Patented
DMP29I0	SN	PMID28074661-Compound-US20036518291c24
DMP29I0	CP	Vertex Pharmaceuticals, Inc
DMP29I0	DT	Small molecular drug

DM2GPLQ	ID	DM2GPLQ
DM2GPLQ	DN	Urea and carbamate bioisostere derivative 7
DM2GPLQ	HS	Patented
DM2GPLQ	SN	PMID28074661-Compound-US20036518291c25
DM2GPLQ	CP	Vertex Pharmaceuticals, Inc
DM2GPLQ	DT	Small molecular drug

DMIYD41	ID	DMIYD41
DMIYD41	DN	Urea and carbamate bioisostere derivative 9
DMIYD41	HS	Patented
DMIYD41	SN	PMID28074661-Compound-US20036617323c28
DMIYD41	CP	Bristol-Myers Squibb Co
DMIYD41	DT	Small molecular drug

DMN51XF	ID	DMN51XF
DMN51XF	DN	Ureido-phenyl-substituted triazine derivative 1
DMN51XF	HS	Patented
DMN51XF	SN	PMID28270010-Compound-Figure6-1
DMN51XF	CP	ABRAXIS BIOSCIENCE, LLC 
DMN51XF	DT	Small molecular drug
DMN51XF	PC	88588864
DMN51XF	MW	414.6
DMN51XF	FM	C18H22N8S2
DMN51XF	IC	InChI=1S/C18H22N8S2/c1-12-11-20-17(27-12)22-15-21-16(26-9-7-25(2)8-10-26)24-18(23-15)28-14-5-3-13(19)4-6-14/h3-6,11H,7-10,19H2,1-2H3,(H,20,21,22,23,24)
DMN51XF	CS	CC1=CN=C(S1)NC2=NC(=NC(=N2)SC3=CC=C(C=C3)N)N4CCN(CC4)C
DMN51XF	IK	WLWGUMHFVGHNRD-UHFFFAOYSA-N
DMN51XF	IU	N-[4-(4-aminophenyl)sulfanyl-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl]-5-methyl-1,3-thiazol-2-amine

DMR0JDW	ID	DMR0JDW
DMR0JDW	DN	Ureido-phenyl-substituted triazine derivative 2
DMR0JDW	HS	Patented
DMR0JDW	SN	PMID28270010-Compound-Figure6-2
DMR0JDW	CP	ABRAXIS BIOSCIENCE, LLC 
DMR0JDW	DT	Small molecular drug
DMR0JDW	PC	49800205
DMR0JDW	MW	533.7
DMR0JDW	FM	C25H27N9OS2
DMR0JDW	IC	InChI=1S/C25H27N9OS2/c1-17-16-26-24(36-17)30-21-29-22(34-14-12-33(2)13-15-34)32-25(31-21)37-20-10-8-19(9-11-20)28-23(35)27-18-6-4-3-5-7-18/h3-11,16H,12-15H2,1-2H3,(H2,27,28,35)(H,26,29,30,31,32)
DMR0JDW	CS	CC1=CN=C(S1)NC2=NC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)NC4=CC=CC=C4)N5CCN(CC5)C
DMR0JDW	IK	RZAWEAWFWJQMTD-UHFFFAOYSA-N
DMR0JDW	IU	1-[4-[[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1,3-thiazol-2-yl)amino]-1,3,5-triazin-2-yl]sulfanyl]phenyl]-3-phenylurea

DMVCWXD	ID	DMVCWXD
DMVCWXD	DN	US10022354, Example 151
DMVCWXD	HS	Patented
DMVCWXD	SN	SCHEMBL19513974; CHEMBL4060968; BDBM281211; US10022354, Example 151
DMVCWXD	DT	Small molecular drug
DMVCWXD	PC	132054530
DMVCWXD	MW	290.36
DMVCWXD	FM	C15H22N4O2
DMVCWXD	IC	InChI=1S/C15H22N4O2/c1-9(2)12-7-13(18-17-12)15(21)19-6-5-11(8-19)16-14(20)10-3-4-10/h7,9-11H,3-6,8H2,1-2H3,(H,16,20)(H,17,18)
DMVCWXD	CS	CC(C)C1=CC(=NN1)C(=O)N2CCC(C2)NC(=O)C3CC3
DMVCWXD	IK	CXEXTVGTDZRKJS-UHFFFAOYSA-N
DMVCWXD	IU	N-[1-(5-propan-2-yl-1H-pyrazole-3-carbonyl)pyrrolidin-3-yl]cyclopropanecarboxamide

DMGDZLP	ID	DMGDZLP
DMGDZLP	DN	US10022354, Example 152
DMGDZLP	HS	Patented
DMGDZLP	SN	CHEMBL4059597; SCHEMBL17682668; BDBM281212; US10022354, Example 152
DMGDZLP	DT	Small molecular drug
DMGDZLP	PC	121279737
DMGDZLP	MW	304.39
DMGDZLP	FM	C16H24N4O2
DMGDZLP	IC	InChI=1S/C16H24N4O2/c1-10(2)13-8-14(19-18-13)16(22)20-7-6-12(9-20)17-15(21)11-4-3-5-11/h8,10-12H,3-7,9H2,1-2H3,(H,17,21)(H,18,19)
DMGDZLP	CS	CC(C)C1=CC(=NN1)C(=O)N2CCC(C2)NC(=O)C3CCC3
DMGDZLP	IK	WFZQSICPYNAMNU-UHFFFAOYSA-N
DMGDZLP	IU	N-[1-(5-propan-2-yl-1H-pyrazole-3-carbonyl)pyrrolidin-3-yl]cyclobutanecarboxamide

DMIAGPX	ID	DMIAGPX
DMIAGPX	DN	US10022354, Example 5
DMIAGPX	HS	Patented
DMIAGPX	SN	SCHEMBL17682496; CHEMBL4062756; US10022354, Example 5; BDBM281065
DMIAGPX	DT	Small molecular drug
DMIAGPX	PC	121279569
DMIAGPX	MW	369.5
DMIAGPX	FM	C20H27N5O2
DMIAGPX	IC	InChI=1S/C20H27N5O2/c1-12(2)16-10-18(23-22-16)20(27)25-7-6-14(11-25)17-9-15(8-13(3)21-17)19(26)24(4)5/h8-10,12,14H,6-7,11H2,1-5H3,(H,22,23)
DMIAGPX	CS	CC1=CC(=CC(=N1)C2CCN(C2)C(=O)C3=NNC(=C3)C(C)C)C(=O)N(C)C
DMIAGPX	IK	YAVZAMCCDJRPBX-UHFFFAOYSA-N
DMIAGPX	IU	N,N,2-trimethyl-6-[1-(5-propan-2-yl-1H-pyrazole-3-carbonyl)pyrrolidin-3-yl]pyridine-4-carboxamide

DMU21PD	ID	DMU21PD
DMU21PD	DN	US10023583, Example 13
DMU21PD	HS	Patented
DMU21PD	SN	SCHEMBL19774049; BDBM284941; US10023583, Example 13
DMU21PD	DT	Small molecular drug
DMU21PD	PC	134172650
DMU21PD	MW	392.5
DMU21PD	FM	C20H28N2O4S
DMU21PD	IC	InChI=1S/C20H28N2O4S/c1-2-9-27-12-18(21)20(25,19(23)24)11-16-15-10-14(6-5-13-3-4-13)26-17(15)7-8-22-16/h7-8,10,13,18,25H,2-6,9,11-12,21H2,1H3,(H,23,24)/t18-,20+/m0/s1
DMU21PD	CS	CCCSC[C@@H]([C@](CC1=NC=CC2=C1C=C(O2)CCC3CC3)(C(=O)O)O)N
DMU21PD	IK	ZJHMLTXEBYSRTJ-AZUAARDMSA-N
DMU21PD	IU	(2R,3R)-3-amino-2-[[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl]-2-hydroxy-4-propylsulfanylbutanoic acid

DM5LK6O	ID	DM5LK6O
DM5LK6O	DN	US10023583, Example 24
DM5LK6O	HS	Patented
DM5LK6O	SN	SCHEMBL19774043; BDBM284952; US10023583, Example 24
DM5LK6O	DT	Small molecular drug
DM5LK6O	PC	134172644
DM5LK6O	MW	406.5
DM5LK6O	FM	C21H30N2O4S
DM5LK6O	IC	InChI=1S/C21H30N2O4S/c1-13(2)11-28-12-19(22)21(26,20(24)25)10-17-16-9-15(6-5-14-3-4-14)27-18(16)7-8-23-17/h7-9,13-14,19,26H,3-6,10-12,22H2,1-2H3,(H,24,25)/t19-,21+/m0/s1
DM5LK6O	CS	CC(C)CSC[C@@H]([C@](CC1=NC=CC2=C1C=C(O2)CCC3CC3)(C(=O)O)O)N
DM5LK6O	IK	HMDRAHWGUKKPQA-PZJWPPBQSA-N
DM5LK6O	IU	(2R,3R)-3-amino-2-[[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl]-2-hydroxy-4-(2-methylpropylsulfanyl)butanoic acid

DMZR10T	ID	DMZR10T
DMZR10T	DN	US10023583, Example 5
DMZR10T	HS	Patented
DMZR10T	SN	SCHEMBL19774051; US10023583, Example 5; BDBM284932
DMZR10T	DT	Small molecular drug
DMZR10T	PC	134172652
DMZR10T	MW	378.5
DMZR10T	FM	C19H26N2O4S
DMZR10T	IC	InChI=1S/C19H26N2O4S/c1-24-18(22)19(23,17(20)11-26-2)10-15-14-9-13(6-5-12-3-4-12)25-16(14)7-8-21-15/h7-9,12,17,23H,3-6,10-11,20H2,1-2H3/t17-,19+/m0/s1
DMZR10T	CS	COC(=O)[C@@](CC1=NC=CC2=C1C=C(O2)CCC3CC3)([C@H](CSC)N)O
DMZR10T	IK	GTBZNNHYIZEBEO-PKOBYXMFSA-N
DMZR10T	IU	methyl (2R,3R)-3-amino-2-[[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl]-2-hydroxy-4-methylsulfanylbutanoate

DM40KU8	ID	DM40KU8
DM40KU8	DN	US10023583, Example 8
DM40KU8	HS	Patented
DM40KU8	SN	SCHEMBL19774240; US10023583, Example 8; BDBM284936
DM40KU8	DT	Small molecular drug
DM40KU8	PC	134172826
DM40KU8	MW	368.5
DM40KU8	FM	C17H24N2O3S2
DM40KU8	IC	InChI=1S/C17H24N2O3S2/c1-3-4-5-11-8-12-13(19-7-6-14(12)24-11)9-17(22,16(20)21)15(18)10-23-2/h6-8,15,22H,3-5,9-10,18H2,1-2H3,(H,20,21)/t15-,17+/m0/s1
DM40KU8	CS	CCCCC1=CC2=C(S1)C=CN=C2C[C@@]([C@H](CSC)N)(C(=O)O)O
DM40KU8	IK	DBCFIUMQYJLFBC-DOTOQJQBSA-N
DM40KU8	IU	(2R,3R)-3-amino-2-[(2-butylthieno[3,2-c]pyridin-4-yl)methyl]-2-hydroxy-4-methylsulfanylbutanoic acid

DMG4T13	ID	DMG4T13
DMG4T13	DN	US10030004, Compound 11a
DMG4T13	HS	Patented
DMG4T13	SN	SCHEMBL18205771; BDBM280344; US10030004, Compound 11a; Synthesis of (S)-4-(2-(5-chloro-2-fluorophenyl)-5-ethylpyridin-4-ylamino)-N-(2-hydroxy propyl)nicotinamide
DMG4T13	DT	Small molecular drug
DMG4T13	PC	91820701
DMG4T13	MW	428.9
DMG4T13	FM	C22H22ClFN4O2
DMG4T13	IC	InChI=1S/C22H22ClFN4O2/c1-3-14-11-26-21(16-8-15(23)4-5-18(16)24)9-20(14)28-19-6-7-25-12-17(19)22(30)27-10-13(2)29/h4-9,11-13,29H,3,10H2,1-2H3,(H,27,30)(H,25,26,28)/t13-/m0/s1
DMG4T13	CS	CCC1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NC[C@H](C)O)C3=C(C=CC(=C3)Cl)F
DMG4T13	IK	OGPVQKHTKOAKDQ-ZDUSSCGKSA-N
DMG4T13	IU	4-[[2-(5-chloro-2-fluorophenyl)-5-ethylpyridin-4-yl]amino]-N-[(2S)-2-hydroxypropyl]pyridine-3-carboxamide

DM0RAPC	ID	DM0RAPC
DM0RAPC	DN	US10030004, Compound 19
DM0RAPC	HS	Patented
DM0RAPC	SN	SCHEMBL16879133; BDBM280352; US10030004, Compound 19; Synthesis of N-(2-aminoethyl)-4-[[2-(5-chloro-2-fluoro-phenyl)-5-isopropyl-4-pyridyl]amino]pyridine-3-carboxamide
DM0RAPC	DT	Small molecular drug
DM0RAPC	PC	118211014
DM0RAPC	MW	528
DM0RAPC	FM	C27H31ClFN5O3
DM0RAPC	IC	InChI=1S/C27H31ClFN5O3/c1-16(2)19-15-33-23(18-12-17(28)6-7-21(18)29)13-24(19)34-22-8-9-30-14-20(22)25(35)31-10-11-32-26(36)37-27(3,4)5/h6-9,12-16H,10-11H2,1-5H3,(H,31,35)(H,32,36)(H,30,33,34)
DM0RAPC	CS	CC(C)C1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NCCNC(=O)OC(C)(C)C)C3=C(C=CC(=C3)Cl)F
DM0RAPC	IK	NUVPAWNZKYSCFY-UHFFFAOYSA-N
DM0RAPC	IU	tert-butyl N-[2-[[4-[[2-(5-chloro-2-fluorophenyl)-5-propan-2-ylpyridin-4-yl]amino]pyridine-3-carbonyl]amino]ethyl]carbamate

DMD0GN6	ID	DMD0GN6
DMD0GN6	DN	US10030004, Compound 33
DMD0GN6	HS	Patented
DMD0GN6	SN	SCHEMBL16879197; BDBM280367; US10030004, Compound 33; Synthesis of 4-{[2-(5-chloro-2-fluorophenyl)-5-(pyrrolidin-1-yl)pyridin-4-yl]amino}-N-(1,3-dihydroxypropan-2-yl)pyridine-3-carboxamide
DMD0GN6	DT	Small molecular drug
DMD0GN6	PC	118211070
DMD0GN6	MW	485.9
DMD0GN6	FM	C24H25ClFN5O3
DMD0GN6	IC	InChI=1S/C24H25ClFN5O3/c25-15-3-4-19(26)17(9-15)21-10-22(23(12-28-21)31-7-1-2-8-31)30-20-5-6-27-11-18(20)24(34)29-16(13-32)14-33/h3-6,9-12,16,32-33H,1-2,7-8,13-14H2,(H,29,34)(H,27,28,30)
DMD0GN6	CS	C1CCN(C1)C2=CN=C(C=C2NC3=C(C=NC=C3)C(=O)NC(CO)CO)C4=C(C=CC(=C4)Cl)F
DMD0GN6	IK	FDMRIXRWLAMVEF-UHFFFAOYSA-N
DMD0GN6	IU	4-[[2-(5-chloro-2-fluorophenyl)-5-pyrrolidin-1-ylpyridin-4-yl]amino]-N-(1,3-dihydroxypropan-2-yl)pyridine-3-carboxamide

DMLJV01	ID	DMLJV01
DMLJV01	DN	US10034861, Example 1
DMLJV01	HS	Patented
DMLJV01	SN	SCHEMBL19762512; US10034861, Example 1; BDBM278971; 5-(2-ethoxy-3-pyridyl)-1-isopropyl-3-methyl-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]pyrazolo[4,3-b]pyridin-7-amine
DMLJV01	DT	Small molecular drug
DMLJV01	PC	132273299
DMLJV01	MW	407.5
DMLJV01	FM	C21H25N7O2
DMLJV01	IC	InChI=1S/C21H25N7O2/c1-6-29-21-15(8-7-9-22-21)16-10-17(23-11-18-26-25-14(5)30-18)20-19(24-16)13(4)27-28(20)12(2)3/h7-10,12H,6,11H2,1-5H3,(H,23,24)
DMLJV01	CS	CCOC1=C(C=CC=N1)C2=NC3=C(C(=C2)NCC4=NN=C(O4)C)N(N=C3C)C(C)C
DMLJV01	IK	XEBJMVLHZBRKST-UHFFFAOYSA-N
DMLJV01	IU	5-(2-ethoxypyridin-3-yl)-3-methyl-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-1-propan-2-ylpyrazolo[4,3-b]pyridin-7-amine

DM27SFD	ID	DM27SFD
DM27SFD	DN	US10034861, Example 164
DM27SFD	HS	Patented
DM27SFD	SN	SCHEMBL19762485; BDBM279133; US10034861, Example 164; 5-(2-ethoxy-3-pyridyl)-1-isopropyl-3-methyl-7-[(1-methylpyrazol-4-yl)methylsulfanyl]pyrazolo[4,3-b]pyridine
DM27SFD	DT	Small molecular drug
DM27SFD	PC	132273278
DM27SFD	MW	456.6
DM27SFD	FM	C24H32N4O3S
DM27SFD	IC	InChI=1S/C24H32N4O3S/c1-7-30-24-18(9-8-11-25-24)19-13-20(32-12-10-21(29)31-14-15(2)3)23-22(26-19)17(6)27-28(23)16(4)5/h8-9,11,13,15-16H,7,10,12,14H2,1-6H3
DM27SFD	CS	CCOC1=C(C=CC=N1)C2=NC3=C(C(=C2)SCCC(=O)OCC(C)C)N(N=C3C)C(C)C
DM27SFD	IK	HVDCJFCTBUPVCE-UHFFFAOYSA-N
DM27SFD	IU	2-methylpropyl 3-[5-(2-ethoxypyridin-3-yl)-3-methyl-1-propan-2-ylpyrazolo[4,3-b]pyridin-7-yl]sulfanylpropanoate

DMD8FS5	ID	DMD8FS5
DMD8FS5	DN	US10034861, Example 165
DMD8FS5	HS	Patented
DMD8FS5	SN	SCHEMBL19762492; BDBM279134; US10034861, Example 165; N-[[1-(difluoromethyl)pyrazol-4-yl]methyl]-5-(2-ethoxy-3-pyridyl)-1-isopropyl-3-methyl-pyrazolo[4,3-b]pyridin-7-amine
DMD8FS5	DT	Small molecular drug
DMD8FS5	PC	132273284
DMD8FS5	MW	561.6
DMD8FS5	FM	C30H33F2N7O2
DMD8FS5	IC	InChI=1S/C30H33F2N7O2/c1-6-41-29-24(8-7-13-33-29)25-14-26(28-27(35-25)20(4)36-39(28)19(2)3)37(16-21-9-11-23(40-5)12-10-21)17-22-15-34-38(18-22)30(31)32/h7-15,18-19,30H,6,16-17H2,1-5H3
DMD8FS5	CS	CCOC1=C(C=CC=N1)C2=NC3=C(C(=C2)N(CC4=CC=C(C=C4)OC)CC5=CN(N=C5)C(F)F)N(N=C3C)C(C)C
DMD8FS5	IK	UXTFTMXAFOTATJ-UHFFFAOYSA-N
DMD8FS5	IU	N-[[1-(difluoromethyl)pyrazol-4-yl]methyl]-5-(2-ethoxypyridin-3-yl)-N-[(4-methoxyphenyl)methyl]-3-methyl-1-propan-2-ylpyrazolo[4,3-b]pyridin-7-amine

DM28XHN	ID	DM28XHN
DM28XHN	DN	US10035778, Example 1
DM28XHN	HS	Patented
DM28XHN	SN	SCHEMBL19067133; US10035778, Example 1; BDBM279560; Preparation of (3S)-3-(3,5-dibromophenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid
DM28XHN	DT	Small molecular drug
DM28XHN	PC	130177146
DM28XHN	MW	613.3
DM28XHN	FM	C22H23Br2N5O6
DM28XHN	IC	InChI=1S/C22H23Br2N5O6/c23-13-1-11(2-14(24)5-13)18(7-20(33)34)29-19(32)10-25-21(35)12-3-15(6-16(30)4-12)28-22-26-8-17(31)9-27-22/h1-6,17-18,30-31H,7-10H2,(H,25,35)(H,29,32)(H,33,34)(H2,26,27,28)/t18-/m0/s1
DM28XHN	CS	C1C(CN=C(N1)NC2=CC(=CC(=C2)C(=O)NCC(=O)N[C@@H](CC(=O)O)C3=CC(=CC(=C3)Br)Br)O)O
DM28XHN	IK	BWAUVRFZNDRMLY-SFHVURJKSA-N
DM28XHN	IU	(3S)-3-(3,5-dibromophenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid

DMBN6W2	ID	DMBN6W2
DMBN6W2	DN	US10035778, Example 12
DMBN6W2	HS	Patented
DMBN6W2	SN	SCHEMBL19067109; BDBM279571; US10035778, Example 12; Preparation of (3S)-3-[3-chloro-5-methyl-phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid
DMBN6W2	DT	Small molecular drug
DMBN6W2	PC	130177126
DMBN6W2	MW	503.9
DMBN6W2	FM	C23H26ClN5O6
DMBN6W2	IC	InChI=1S/C23H26ClN5O6/c1-12-2-13(4-15(24)3-12)19(8-21(33)34)29-20(32)11-25-22(35)14-5-16(7-17(30)6-14)28-23-26-9-18(31)10-27-23/h2-7,18-19,30-31H,8-11H2,1H3,(H,25,35)(H,29,32)(H,33,34)(H2,26,27,28)/t19-/m0/s1
DMBN6W2	CS	CC1=CC(=CC(=C1)Cl)[C@H](CC(=O)O)NC(=O)CNC(=O)C2=CC(=CC(=C2)O)NC3=NCC(CN3)O
DMBN6W2	IK	UCBYYQWMMNUSGH-IBGZPJMESA-N
DMBN6W2	IU	(3S)-3-(3-chloro-5-methylphenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid

DMJ53DR	ID	DMJ53DR
DMJ53DR	DN	US10035778, Example 16
DMJ53DR	HS	Patented
DMJ53DR	SN	SCHEMBL19067135; BDBM279575; US10035778, Example 16; Preparation of (3S)-3-[3-chloro-5-(trifluoromethoxy)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid
DMJ53DR	DT	Small molecular drug
DMJ53DR	PC	130177149
DMJ53DR	MW	573.9
DMJ53DR	FM	C23H23ClF3N5O7
DMJ53DR	IC	InChI=1S/C23H23ClF3N5O7/c24-13-1-11(4-17(5-13)39-23(25,26)27)18(7-20(36)37)32-19(35)10-28-21(38)12-2-14(6-15(33)3-12)31-22-29-8-16(34)9-30-22/h1-6,16,18,33-34H,7-10H2,(H,28,38)(H,32,35)(H,36,37)(H2,29,30,31)/t18-/m0/s1
DMJ53DR	CS	C1C(CN=C(N1)NC2=CC(=CC(=C2)C(=O)NCC(=O)N[C@@H](CC(=O)O)C3=CC(=CC(=C3)Cl)OC(F)(F)F)O)O
DMJ53DR	IK	BQYBIJDRTDZCAJ-SFHVURJKSA-N
DMJ53DR	IU	(3S)-3-[3-chloro-5-(trifluoromethoxy)phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid

DMLMV1Y	ID	DMLMV1Y
DMLMV1Y	DN	US10040779, Example 1
DMLMV1Y	HS	Patented
DMLMV1Y	SN	SCHEMBL15792304; US10040779, Example 1; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid
DMLMV1Y	DT	Small molecular drug
DMLMV1Y	PC	76282043
DMLMV1Y	MW	268.27
DMLMV1Y	FM	C14H12N4O2
DMLMV1Y	IC	InChI=1S/C14H12N4O2/c1-18-12-5-3-2-4-10(12)13(17-18)16-11-8-15-7-6-9(11)14(19)20/h2-8H,1H3,(H,16,17)(H,19,20)
DMLMV1Y	CS	CN1C2=CC=CC=C2C(=N1)NC3=C(C=CN=C3)C(=O)O
DMLMV1Y	IK	CPZUCKVTDNNRCJ-UHFFFAOYSA-N
DMLMV1Y	IU	3-[(1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid

DMWDGCH	ID	DMWDGCH
DMWDGCH	DN	US10040779, Example 4
DMWDGCH	HS	Patented
DMWDGCH	SN	SCHEMBL15792083; US10040779, Example 4; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid
DMWDGCH	DT	Small molecular drug
DMWDGCH	PC	75202257
DMWDGCH	MW	302.71
DMWDGCH	FM	C14H11ClN4O2
DMWDGCH	IC	InChI=1S/C14H11ClN4O2/c1-19-12-3-2-8(15)6-10(12)13(18-19)17-11-7-16-5-4-9(11)14(20)21/h2-7H,1H3,(H,17,18)(H,20,21)
DMWDGCH	CS	CN1C2=C(C=C(C=C2)Cl)C(=N1)NC3=C(C=CN=C3)C(=O)O
DMWDGCH	IK	TXMBUJQSVXBAFZ-UHFFFAOYSA-N
DMWDGCH	IU	3-[(5-chloro-1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid

DMPM8VB	ID	DMPM8VB
DMPM8VB	DN	US10053465, 12
DMPM8VB	HS	Patented
DMPM8VB	SN	SCHEMBL9894097; SCHEMBL9927070; SCHEMBL9894098; BDBM246873; US10053465, 12; {trans-3-(4-{[4- {[(2S)-2- (hydroxymethyl) pyrrolidin-1-yl] methyl}-6- (trifluoromethyl) pyridin-2- yl]oxy}piperidin-1- yl)-1-[4-(7H- pyrrolo[2,3- d]pyrimidin-4-yl)- 1H-pyrazol-1- yl]cyclobutyl} acetonitrile
DMPM8VB	DT	Small molecular drug
DMPM8VB	PC	67954458
DMPM8VB	MW	635.7
DMPM8VB	FM	C32H36F3N9O2
DMPM8VB	IC	InChI=1S/C32H36F3N9O2/c33-32(34,35)27-12-21(17-43-9-1-2-23(43)19-45)13-28(41-27)46-25-4-10-42(11-5-25)24-14-31(15-24,6-7-36)44-18-22(16-40-44)29-26-3-8-37-30(26)39-20-38-29/h3,8,12-13,16,18,20,23-25,45H,1-2,4-6,9-11,14-15,17,19H2,(H,37,38,39)/t23-,24?,31?/m0/s1
DMPM8VB	CS	C1C[C@H](N(C1)CC2=CC(=NC(=C2)OC3CCN(CC3)C4CC(C4)(CC#N)N5C=C(C=N5)C6=C7C=CNC7=NC=N6)C(F)(F)F)CO
DMPM8VB	IK	WQXUGBZSZWSUTM-VVTYCJQISA-N
DMPM8VB	IU	2-[3-[4-[4-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl]-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]cyclobutyl]acetonitrile

DMV7BF2	ID	DMV7BF2
DMV7BF2	DN	US10053465, 5
DMV7BF2	HS	Patented
DMV7BF2	SN	SCHEMBL12780151; BDBM246866; US10053465, 5; 4-[(4-{3-cyano-2-[4- (7H-pyrrolo[2,3- d]pyrimidin-4-yl)- 1H-pyrazol-1- yl]propyl}piperazin- 1-yl)carbonyl]-3- fluorobenzonitrile
DMV7BF2	DT	Small molecular drug
DMV7BF2	PC	58180930
DMV7BF2	MW	483.5
DMV7BF2	FM	C25H22FN9O
DMV7BF2	IC	InChI=1S/C25H22FN9O/c1-28-18-2-3-20(22(26)12-18)25(36)34-10-8-33(9-11-34)15-19(4-6-27)35-14-17(13-32-35)23-21-5-7-29-24(21)31-16-30-23/h2-3,5,7,12-14,16,19H,4,8-11,15H2,(H,29,30,31)
DMV7BF2	CS	[C-]#[N+]C1=CC(=C(C=C1)C(=O)N2CCN(CC2)CC(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)F
DMV7BF2	IK	VCJFOLMEZCAWFO-UHFFFAOYSA-N
DMV7BF2	IU	4-[4-(2-fluoro-4-isocyanobenzoyl)piperazin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanenitrile

DM42XWO	ID	DM42XWO
DM42XWO	DN	US10053465, 8
DM42XWO	HS	Patented
DM42XWO	SN	SCHEMBL2395720; CHEMBL3911726; RZUCZMLSGAQMJN-UHFFFAOYSA-N; BDBM246869; US10053465, 8; 4-{3-(Cyanomethyl)- 3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)- 1H-pyrazol-1- yl]azetidin-1-yl}-N- [4-fluoro-2- (trifluoromethyl) phenyl]piperidine-1- carboxamide; 4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}-N-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide
DM42XWO	DT	Small molecular drug
DM42XWO	PC	58431300
DM42XWO	MW	567.5
DM42XWO	FM	C27H25F4N9O
DM42XWO	IC	InChI=1S/C27H25F4N9O/c28-18-1-2-22(21(11-18)27(29,30)31)37-25(41)38-9-4-19(5-10-38)39-14-26(15-39,6-7-32)40-13-17(12-36-40)23-20-3-8-33-24(20)35-16-34-23/h1-3,8,11-13,16,19H,4-6,9-10,14-15H2,(H,37,41)(H,33,34,35)
DM42XWO	CS	C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)NC6=C(C=C(C=C6)F)C(F)(F)F
DM42XWO	IK	RZUCZMLSGAQMJN-UHFFFAOYSA-N
DM42XWO	IU	4-[3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide

DMBD95S	ID	DMBD95S
DMBD95S	DN	US10059720, Example 80
DMBD95S	HS	Patented
DMBD95S	SN	SCHEMBL17303615; BDBM271265; US10059720, Example 80
DMBD95S	DT	Small molecular drug
DMBD95S	PC	118549471
DMBD95S	MW	416.5
DMBD95S	FM	C21H28N4O5
DMBD95S	IC	InChI=1S/C21H28N4O5/c1-14-2-4-16(5-3-14)30-17-6-7-24-15(10-17)11-21(28,20(26)27)18(22)13-29-19-12-23-8-9-25-19/h6-10,12,14,16,18,28H,2-5,11,13,22H2,1H3,(H,26,27)/t14?,16?,18-,21+/m0/s1
DMBD95S	CS	CC1CCC(CC1)OC2=CC(=NC=C2)C[C@@]([C@H](COC3=NC=CN=C3)N)(C(=O)O)O
DMBD95S	IK	GDORSLXMLRLKBT-MAQYLPRKSA-N
DMBD95S	IU	(2R,3S)-3-amino-2-hydroxy-2-[[4-(4-methylcyclohexyl)oxypyridin-2-yl]methyl]-4-pyrazin-2-yloxybutanoic acid

DMJ6GU9	ID	DMJ6GU9
DMJ6GU9	DN	US10059720, Example 82
DMJ6GU9	HS	Patented
DMJ6GU9	SN	SCHEMBL17303611; BDBM271267; US10059720, Example 82
DMJ6GU9	DT	Small molecular drug
DMJ6GU9	PC	118549467
DMJ6GU9	MW	350.5
DMJ6GU9	FM	C19H30N2O4
DMJ6GU9	IC	InChI=1S/C19H30N2O4/c1-12(2)8-17(20)19(24,18(22)23)11-15-10-16(6-7-21-15)25-13(3)9-14-4-5-14/h6-7,10,12-14,17,24H,4-5,8-9,11,20H2,1-3H3,(H,22,23)/t13-,17+,19-/m1/s1
DMJ6GU9	CS	C[C@H](CC1CC1)OC2=CC(=NC=C2)C[C@@]([C@H](CC(C)C)N)(C(=O)O)O
DMJ6GU9	IK	YLKHAUHZCVMCJX-XVGQJIODSA-N
DMJ6GU9	IU	(2R,3S)-3-amino-2-[[4-[(2R)-1-cyclopropylpropan-2-yl]oxypyridin-2-yl]methyl]-2-hydroxy-5-methylhexanoic acid

DMKLVE4	ID	DMKLVE4
DMKLVE4	DN	US10059720, Example 84
DMKLVE4	HS	Patented
DMKLVE4	SN	SCHEMBL17303614; BDBM271269; US10059720, Example 84
DMKLVE4	DT	Small molecular drug
DMKLVE4	PC	118549470
DMKLVE4	MW	433.5
DMKLVE4	FM	C22H28FN3O5
DMKLVE4	IC	InChI=1S/C22H28FN3O5/c1-14-2-5-17(6-3-14)31-18-8-9-25-16(10-18)11-22(29,21(27)28)19(24)13-30-20-7-4-15(23)12-26-20/h4,7-10,12,14,17,19,29H,2-3,5-6,11,13,24H2,1H3,(H,27,28)/t14?,17?,19-,22+/m0/s1
DMKLVE4	CS	CC1CCC(CC1)OC2=CC(=NC=C2)C[C@@]([C@H](COC3=NC=C(C=C3)F)N)(C(=O)O)O
DMKLVE4	IK	AOFAGXGTSSPBTM-UCQMRJNNSA-N
DMKLVE4	IU	(2R,3S)-3-amino-4-(5-fluoropyridin-2-yl)oxy-2-hydroxy-2-[[4-(4-methylcyclohexyl)oxypyridin-2-yl]methyl]butanoic acid

DMBWJK4	ID	DMBWJK4
DMBWJK4	DN	US10065972, Example 281
DMBWJK4	HS	Patented
DMBWJK4	SN	SCHEMBL18335781; BDBM273097; US10065972, Example 281; (R)-N-benzyl-1-(5-difluoromethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide
DMBWJK4	DT	Small molecular drug
DMBWJK4	PC	124152707
DMBWJK4	MW	419.5
DMBWJK4	FM	C19H19F2N5O2S
DMBWJK4	IC	InChI=1S/C19H19F2N5O2S/c1-25-15(14(20)21)24-17-13(18(25)28)23-19(29-17)26-9-5-8-12(26)16(27)22-10-11-6-3-2-4-7-11/h2-4,6-7,12,14H,5,8-10H2,1H3,(H,22,27)/t12-/m1/s1
DMBWJK4	CS	CN1C(=O)C2=C(N=C1C(F)F)SC(=N2)N3CCC[C@@H]3C(=O)NCC4=CC=CC=C4
DMBWJK4	IK	VIBFDLHDQBMSOA-GFCCVEGCSA-N
DMBWJK4	IU	(2R)-N-benzyl-1-[5-(difluoromethyl)-6-methyl-7-oxo-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

DMT8WVZ	ID	DMT8WVZ
DMT8WVZ	DN	US10065972, Example 396
DMT8WVZ	HS	Patented
DMT8WVZ	SN	SCHEMBL18335771; BDBM273125; US10065972, Example 396; (R)-N-benzyl-1-[6-(2-hydroxyethyl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide
DMT8WVZ	DT	Small molecular drug
DMT8WVZ	PC	124152697
DMT8WVZ	MW	467.5
DMT8WVZ	FM	C20H20F3N5O3S
DMT8WVZ	IC	InChI=1S/C20H20F3N5O3S/c21-20(22,23)18-26-16-14(17(31)28(18)9-10-29)25-19(32-16)27-8-4-7-13(27)15(30)24-11-12-5-2-1-3-6-12/h1-3,5-6,13,29H,4,7-11H2,(H,24,30)/t13-/m1/s1
DMT8WVZ	CS	C1C[C@@H](N(C1)C2=NC3=C(S2)N=C(N(C3=O)CCO)C(F)(F)F)C(=O)NCC4=CC=CC=C4
DMT8WVZ	IK	SXQHHSSAGQUGBT-CYBMUJFWSA-N
DMT8WVZ	IU	(2R)-N-benzyl-1-[6-(2-hydroxyethyl)-7-oxo-5-(trifluoromethyl)-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide

DM9QCTJ	ID	DM9QCTJ
DM9QCTJ	DN	US10065972, Example 560
DM9QCTJ	HS	Patented
DM9QCTJ	SN	SCHEMBL18336240; BDBM273119; BDBM273144; BDBM273143; BDBM273093; BDBM273070; US10065972, Example 560; US10065972, Example 265; US10065972, Example 559; US10065972, Example 178; US10065972, Example 347; N-[dideuterio(phenyl)methyl]-1-[7-oxo-5-phenyl-6-(trideuteriomethyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[6-methyl-7-oxo-5-(2,3,4,5,6-pentadeuteriophenyl)-6,7
DM9QCTJ	DT	Small molecular drug
DM9QCTJ	PC	92045015
DM9QCTJ	MW	445.5
DM9QCTJ	FM	C24H23N5O2S
DM9QCTJ	IC	InChI=1S/C24H23N5O2S/c1-28-20(17-11-6-3-7-12-17)27-22-19(23(28)31)26-24(32-22)29-14-8-13-18(29)21(30)25-15-16-9-4-2-5-10-16/h2-7,9-12,18H,8,13-15H2,1H3,(H,25,30)/t18-/m1/s1
DM9QCTJ	CS	CN1C(=NC2=C(C1=O)N=C(S2)N3CCC[C@@H]3C(=O)NCC4=CC=CC=C4)C5=CC=CC=C5
DM9QCTJ	IK	LYGQOCVESZDBMV-GOSISDBHSA-N
DM9QCTJ	IU	(2R)-N-benzyl-1-(6-methyl-7-oxo-5-phenyl-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide

DM95YLX	ID	DM95YLX
DM95YLX	DN	US10071110, Compound cCDV
DM95YLX	HS	Patented
DM95YLX	SN	SCHEMBL2380283; BDBM275768; US10071110, Compound cCDV; US10071110, Compound Cyclic Cidofovir (cDCV)
DM95YLX	DT	Small molecular drug
DM95YLX	PC	18914028
DM95YLX	MW	261.17
DM95YLX	FM	C8H12N3O5P
DM95YLX	IC	InChI=1S/C8H12N3O5P/c9-7-1-2-11(8(12)10-7)3-6-4-16-17(13,14)5-15-6/h1-2,6H,3-5H2,(H,13,14)(H2,9,10,12)
DM95YLX	CS	C1C(OCP(=O)(O1)O)CN2C=CC(=NC2=O)N
DM95YLX	IK	YXQUGSXUDFTPLL-UHFFFAOYSA-N
DM95YLX	IU	4-amino-1-[(2-hydroxy-2-oxo-1,4,2lambda5-dioxaphosphinan-5-yl)methyl]pyrimidin-2-one

DMOZ84C	ID	DMOZ84C
DMOZ84C	DN	US10077269, Example 6
DMOZ84C	HS	Patented
DMOZ84C	SN	SCHEMBL17492361; US10077269, Example 6; KZFDLYSKEWBCTB-UHFFFAOYSA-N; BDBM285533; N-Cyclopropyl-3-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazo[1,2-b]pyridazine-2-carboxamide (6); N-Cyclopropyl-3-([1,2,4]triazolo[1,5-a]pyridin-6-yl )imidazo[1,2-b]pyridazine-2-carboxamide
DMOZ84C	DT	Small molecular drug
DMOZ84C	PC	118863057
DMOZ84C	MW	319.32
DMOZ84C	FM	C16H13N7O
DMOZ84C	IC	InChI=1S/C16H13N7O/c24-16(20-11-4-5-11)14-15(23-13(21-14)2-1-7-18-23)10-3-6-12-17-9-19-22(12)8-10/h1-3,6-9,11H,4-5H2,(H,20,24)
DMOZ84C	CS	C1CC1NC(=O)C2=C(N3C(=N2)C=CC=N3)C4=CN5C(=NC=N5)C=C4
DMOZ84C	IK	KZFDLYSKEWBCTB-UHFFFAOYSA-N
DMOZ84C	IU	N-cyclopropyl-3-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazo[1,2-b]pyridazine-2-carboxamide

DM3BDHN	ID	DM3BDHN
DM3BDHN	DN	US10081632, Compound 25
DM3BDHN	HS	Patented
DM3BDHN	SN	SCHEMBL19252896; BDBM286094; US10081632, Compound 25; Synthesis of (R) inverted question markN-(1-(4-aminobenzyl)-1H-pyrazol-4-yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide hydrochloride salt
DM3BDHN	DT	Small molecular drug
DM3BDHN	PC	130338820
DM3BDHN	MW	415.4
DM3BDHN	FM	C22H21N7O2
DM3BDHN	IC	InChI=1S/C22H21N7O2/c1-13-9-24-22(31)19-8-15-4-7-18(27-20(15)29(13)19)21(30)26-17-10-25-28(12-17)11-14-2-5-16(23)6-3-14/h2-8,10,12-13H,9,11,23H2,1H3,(H,24,31)(H,26,30)/t13-/m1/s1
DM3BDHN	CS	C[C@@H]1CNC(=O)C2=CC3=C(N12)N=C(C=C3)C(=O)NC4=CN(N=C4)CC5=CC=C(C=C5)N
DM3BDHN	IK	IBOJVZMIACTCIV-CYBMUJFWSA-N
DM3BDHN	IU	(13R)-N-[1-[(4-aminophenyl)methyl]pyrazol-4-yl]-13-methyl-10-oxo-1,3,11-triazatricyclo[7.4.0.02,7]trideca-2(7),3,5,8-tetraene-4-carboxamide

DMM6WAB	ID	DMM6WAB
DMM6WAB	DN	US10087167, Compound 3002
DMM6WAB	HS	Patented
DMM6WAB	SN	SCHEMBL18034174; BDBM287988; US10087167, Compound 3002
DMM6WAB	DT	Small molecular drug
DMM6WAB	PC	122503924
DMM6WAB	MW	703.8
DMM6WAB	FM	C36H38FN5O7S
DMM6WAB	IC	InChI=1S/C36H38FN5O7S/c1-7-42(50(6,46)47)29-19-30-28(31(33(43)39-5)32(48-30)22-11-13-25(37)14-12-22)18-27(29)23-9-8-10-24(17-23)34(44)41-16-15-40(21-26(41)20-38)35(45)49-36(2,3)4/h8-14,17-19,26H,7,15-16,21H2,1-6H3,(H,39,43)/t26-/m1/s1
DMM6WAB	CS	CCN(C1=C(C=C2C(=C1)OC(=C2C(=O)NC)C3=CC=C(C=C3)F)C4=CC(=CC=C4)C(=O)N5CCN(C[C@H]5C#N)C(=O)OC(C)(C)C)S(=O)(=O)C
DMM6WAB	IK	MBGMGMOYLOFWNU-AREMUKBSSA-N
DMM6WAB	IU	tert-butyl (3S)-3-cyano-4-[3-[6-[ethyl(methylsulfonyl)amino]-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-5-yl]benzoyl]piperazine-1-carboxylate

DMITOY6	ID	DMITOY6
DMITOY6	DN	US10087167, Compound 3003
DMITOY6	HS	Patented
DMITOY6	SN	SCHEMBL18034173; BDBM287989; US10087167, Compound 3003
DMITOY6	DT	Small molecular drug
DMITOY6	PC	122503923
DMITOY6	MW	681.8
DMITOY6	FM	C32H32FN5O7S2
DMITOY6	IC	InChI=1S/C32H32FN5O7S2/c1-5-37(46(3,41)42)27-17-28-26(29(31(39)35-2)30(45-28)20-9-11-23(33)12-10-20)16-25(27)21-7-6-8-22(15-21)32(40)36-13-14-38(47(4,43)44)24(18-34)19-36/h6-12,15-17,24H,5,13-14,19H2,1-4H3,(H,35,39)
DMITOY6	CS	CCN(C1=C(C=C2C(=C1)OC(=C2C(=O)NC)C3=CC=C(C=C3)F)C4=CC(=CC=C4)C(=O)N5CCN(C(C5)C#N)S(=O)(=O)C)S(=O)(=O)C
DMITOY6	IK	WEBAERCGMUCGLL-UHFFFAOYSA-N
DMITOY6	IU	5-[3-(3-cyano-4-methylsulfonylpiperazine-1-carbonyl)phenyl]-6-[ethyl(methylsulfonyl)amino]-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide

DMAP1DN	ID	DMAP1DN
DMAP1DN	DN	US10087167, Compound 4001
DMAP1DN	HS	Patented
DMAP1DN	SN	SCHEMBL18034175; BDBM287990; US10087167, Compound 4001
DMAP1DN	DT	Small molecular drug
DMAP1DN	PC	122503925
DMAP1DN	MW	692.7
DMAP1DN	FM	C32H29F5N4O6S
DMAP1DN	IC	InChI=1S/C32H29F5N4O6S/c1-38-29(42)27-24-17-23(20-4-3-5-21(16-20)30(43)39-12-14-40(15-13-39)31(44)32(35,36)37)25(41(11-10-33)48(2,45)46)18-26(24)47-28(27)19-6-8-22(34)9-7-19/h3-9,16-18H,10-15H2,1-2H3,(H,38,42)
DMAP1DN	CS	CNC(=O)C1=C(OC2=CC(=C(C=C21)C3=CC(=CC=C3)C(=O)N4CCN(CC4)C(=O)C(F)(F)F)N(CCF)S(=O)(=O)C)C5=CC=C(C=C5)F
DMAP1DN	IK	QALVUUHEMYLFBN-UHFFFAOYSA-N
DMAP1DN	IU	6-[2-fluoroethyl(methylsulfonyl)amino]-2-(4-fluorophenyl)-N-methyl-5-[3-[4-(2,2,2-trifluoroacetyl)piperazine-1-carbonyl]phenyl]-1-benzofuran-3-carboxamide

DMU8CAD	ID	DMU8CAD
DMU8CAD	DN	US10092575, Example 101
DMU8CAD	HS	Patented
DMU8CAD	SN	SCHEMBL17225595; CHEMBL4068450; AXPVGJNPJSMCLA-UHFFFAOYSA-N; BDBM289613; US10092575, Example 101; 6-(4-Chlorobenzyl)-9-methyl-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one; 6-(4-Chlorobenzyl)-9-methyl-8,9,10,11-tetrahydropyrido[4'',3'':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one
DMU8CAD	DT	Small molecular drug
DMU8CAD	PC	118485599
DMU8CAD	MW	385.9
DMU8CAD	FM	C18H16ClN5OS
DMU8CAD	IC	InChI=1S/C18H16ClN5OS/c1-22-7-6-13-14(9-22)26-17-15(13)16-20-10-21-24(16)18(25)23(17)8-11-2-4-12(19)5-3-11/h2-5,10H,6-9H2,1H3
DMU8CAD	CS	CN1CCC2=C(C1)SC3=C2C4=NC=NN4C(=O)N3CC5=CC=C(C=C5)Cl
DMU8CAD	IK	AXPVGJNPJSMCLA-UHFFFAOYSA-N
DMU8CAD	IU	8-[(4-chlorophenyl)methyl]-13-methyl-10-thia-3,5,6,8,13-pentazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),2,4,11(16)-tetraen-7-one

DMT47DF	ID	DMT47DF
DMT47DF	DN	US10092575, Example 141
DMT47DF	HS	Patented
DMT47DF	SN	CHEMBL4067682; SCHEMBL17225636; BDBM289653; US10092575, Example 141; 6-(2-fluoro-4-methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one; 6-(2-Fluoro-4-methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4'',3'':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5 (6H)-one
DMT47DF	DT	Small molecular drug
DMT47DF	PC	72706254
DMT47DF	MW	483.6
DMT47DF	FM	C24H26FN5O3S
DMT47DF	IC	InChI=1S/C24H26FN5O3S/c1-32-17-3-2-16(19(25)10-17)12-29-23-21(22-26-14-27-30(22)24(29)31)18-4-7-28(13-20(18)34-23)11-15-5-8-33-9-6-15/h2-3,10,14-15H,4-9,11-13H2,1H3
DMT47DF	CS	COC1=CC(=C(C=C1)CN2C3=C(C4=C(S3)CN(CC4)CC5CCOCC5)C6=NC=NN6C2=O)F
DMT47DF	IK	FOZFBBKUKXGMND-UHFFFAOYSA-N
DMT47DF	IU	8-[(2-fluoro-4-methoxyphenyl)methyl]-13-(oxan-4-ylmethyl)-10-thia-3,5,6,8,13-pentazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),2,4,11(16)-tetraen-7-one

DM7MNE2	ID	DM7MNE2
DM7MNE2	DN	US10092575, Example 158
DM7MNE2	HS	Patented
DM7MNE2	SN	CHEMBL4074038; SCHEMBL17225654; BDBM289669; US10092575, Example 158; 6-(4-Chlorobenzyl)-9-(cyclopropanecarbonyl)-8,9,10,11-tetrahydropyrido[4'',3'':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one
DM7MNE2	DT	Small molecular drug
DM7MNE2	PC	118485649
DM7MNE2	MW	439.9
DM7MNE2	FM	C21H18ClN5O2S
DM7MNE2	IC	InChI=1S/C21H18ClN5O2S/c22-14-5-1-12(2-6-14)9-26-20-17(18-23-11-24-27(18)21(26)29)15-7-8-25(10-16(15)30-20)19(28)13-3-4-13/h1-2,5-6,11,13H,3-4,7-10H2
DM7MNE2	CS	C1CC1C(=O)N2CCC3=C(C2)SC4=C3C5=NC=NN5C(=O)N4CC6=CC=C(C=C6)Cl
DM7MNE2	IK	FYTZTJBBBNSPSE-UHFFFAOYSA-N
DM7MNE2	IU	8-[(4-chlorophenyl)methyl]-13-(cyclopropanecarbonyl)-10-thia-3,5,6,8,13-pentazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),2,4,11(16)-tetraen-7-one

DMJKS4X	ID	DMJKS4X
DMJKS4X	DN	US10100051, Compound 1
DMJKS4X	HS	Patented
DMJKS4X	SN	SCHEMBL18122067; US10100051, Compound 1; BDBM292132; 2-(5-hydroxy-8-methyl-2-phenoxy-1,7-naphthyridine-6-formamido) acetic acid
DMJKS4X	DT	Small molecular drug
DMJKS4X	PC	137094888
DMJKS4X	MW	353.3
DMJKS4X	FM	C18H15N3O5
DMJKS4X	IC	InChI=1S/C18H15N3O5/c1-10-15-12(17(24)16(20-10)18(25)19-9-14(22)23)7-8-13(21-15)26-11-5-3-2-4-6-11/h2-8,24H,9H2,1H3,(H,19,25)(H,22,23)
DMJKS4X	CS	CC1=C2C(=C(C(=N1)C(=O)NCC(=O)O)O)C=CC(=N2)OC3=CC=CC=C3
DMJKS4X	IK	FMQZRTFVSFAASE-UHFFFAOYSA-N
DMJKS4X	IU	2-[(5-hydroxy-8-methyl-2-phenoxy-1,7-naphthyridine-6-carbonyl)amino]acetic acid

DMQ7ODW	ID	DMQ7ODW
DMQ7ODW	DN	US10100051, Compound 10
DMQ7ODW	HS	Patented
DMQ7ODW	SN	SCHEMBL18122066; BDBM292141; US10100051, Compound 10; (2-(2-(4-bromophenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-formamido) acetic acid
DMQ7ODW	DT	Small molecular drug
DMQ7ODW	PC	137094887
DMQ7ODW	MW	432.2
DMQ7ODW	FM	C18H14BrN3O5
DMQ7ODW	IC	InChI=1S/C18H14BrN3O5/c1-9-15-12(17(25)16(21-9)18(26)20-8-14(23)24)6-7-13(22-15)27-11-4-2-10(19)3-5-11/h2-7,25H,8H2,1H3,(H,20,26)(H,23,24)
DMQ7ODW	CS	CC1=C2C(=C(C(=N1)C(=O)NCC(=O)O)O)C=CC(=N2)OC3=CC=C(C=C3)Br
DMQ7ODW	IK	PKTKHEQNIDLMBW-UHFFFAOYSA-N
DMQ7ODW	IU	2-[[2-(4-bromophenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-carbonyl]amino]acetic acid

DM2DEOA	ID	DM2DEOA
DM2DEOA	DN	US10100051, Compound 11
DM2DEOA	HS	Patented
DM2DEOA	SN	SCHEMBL18122076; BDBM292142; US10100051, Compound 11; 2-(2-(3-(tert-butyl)phenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-formamido) acetic acid
DM2DEOA	DT	Small molecular drug
DM2DEOA	PC	137094889
DM2DEOA	MW	409.4
DM2DEOA	FM	C22H23N3O5
DM2DEOA	IC	InChI=1S/C22H23N3O5/c1-12-18-15(20(28)19(24-12)21(29)23-11-17(26)27)8-9-16(25-18)30-14-7-5-6-13(10-14)22(2,3)4/h5-10,28H,11H2,1-4H3,(H,23,29)(H,26,27)
DM2DEOA	CS	CC1=C2C(=C(C(=N1)C(=O)NCC(=O)O)O)C=CC(=N2)OC3=CC=CC(=C3)C(C)(C)C
DM2DEOA	IK	NYGCHYPUCCYURU-UHFFFAOYSA-N
DM2DEOA	IU	2-[[2-(3-tert-butylphenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-carbonyl]amino]acetic acid

DMWESZ1	ID	DMWESZ1
DMWESZ1	DN	US10100051, Compound 2
DMWESZ1	HS	Patented
DMWESZ1	SN	SCHEMBL18122063; US10100051, Compound 2; BDBM292133; (2-(2-(4-fluorophenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-formamido) acetic acid
DMWESZ1	DT	Small molecular drug
DMWESZ1	PC	137094886
DMWESZ1	MW	371.3
DMWESZ1	FM	C18H14FN3O5
DMWESZ1	IC	InChI=1S/C18H14FN3O5/c1-9-15-12(17(25)16(21-9)18(26)20-8-14(23)24)6-7-13(22-15)27-11-4-2-10(19)3-5-11/h2-7,25H,8H2,1H3,(H,20,26)(H,23,24)
DMWESZ1	CS	CC1=C2C(=C(C(=N1)C(=O)NCC(=O)O)O)C=CC(=N2)OC3=CC=C(C=C3)F
DMWESZ1	IK	ZGAARGWNIMGZMM-UHFFFAOYSA-N
DMWESZ1	IU	2-[[2-(4-fluorophenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-carbonyl]amino]acetic acid

DMEVGR6	ID	DMEVGR6
DMEVGR6	DN	US10149841, Compound 1
DMEVGR6	HS	Patented
DMEVGR6	SN	SCHEMBL19808953; US10149841, Compound 1; BDBM306795
DMEVGR6	DT	Small molecular drug
DMEVGR6	PC	134204800
DMEVGR6	MW	288.25
DMEVGR6	FM	C14H12N2O5
DMEVGR6	IC	InChI=1S/C14H12N2O5/c17-11-6-10(21-9-4-2-1-3-5-9)7-15-13(11)14(20)16-8-12(18)19/h1-7,17H,8H2,(H,16,20)(H,18,19)
DMEVGR6	CS	C1=CC=C(C=C1)OC2=CC(=C(N=C2)C(=O)NCC(=O)O)O
DMEVGR6	IK	SUWPOWJCFOLJFD-UHFFFAOYSA-N
DMEVGR6	IU	2-[(3-hydroxy-5-phenoxypyridine-2-carbonyl)amino]acetic acid

DMYSI9J	ID	DMYSI9J
DMYSI9J	DN	US10149841, Compound 19
DMYSI9J	HS	Patented
DMYSI9J	SN	SCHEMBL19808937; BDBM306799; US10149841, Compound 19
DMYSI9J	DT	Small molecular drug
DMYSI9J	PC	134204785
DMYSI9J	MW	316.31
DMYSI9J	FM	C16H16N2O5
DMYSI9J	IC	InChI=1S/C16H16N2O5/c1-9-3-4-13(10(2)5-9)23-11-6-12(19)15(17-7-11)16(22)18-8-14(20)21/h3-7,19H,8H2,1-2H3,(H,18,22)(H,20,21)
DMYSI9J	CS	CC1=CC(=C(C=C1)OC2=CC(=C(N=C2)C(=O)NCC(=O)O)O)C
DMYSI9J	IK	NRYBEIHDIVNLGM-UHFFFAOYSA-N
DMYSI9J	IU	2-[[5-(2,4-dimethylphenoxy)-3-hydroxypyridine-2-carbonyl]amino]acetic acid

DMBS50K	ID	DMBS50K
DMBS50K	DN	US10149841, Compound 5
DMBS50K	HS	Patented
DMBS50K	SN	SCHEMBL19808950; US10149841, Compound 5; BDBM306796
DMBS50K	DT	Small molecular drug
DMBS50K	PC	134204798
DMBS50K	MW	316.31
DMBS50K	FM	C16H16N2O5
DMBS50K	IC	InChI=1S/C16H16N2O5/c1-9-4-3-5-13(10(9)2)23-11-6-12(19)15(17-7-11)16(22)18-8-14(20)21/h3-7,19H,8H2,1-2H3,(H,18,22)(H,20,21)
DMBS50K	CS	CC1=C(C(=CC=C1)OC2=CC(=C(N=C2)C(=O)NCC(=O)O)O)C
DMBS50K	IK	FSLSXJQWQVETMM-UHFFFAOYSA-N
DMBS50K	IU	2-[[5-(2,3-dimethylphenoxy)-3-hydroxypyridine-2-carbonyl]amino]acetic acid

DMS415A	ID	DMS415A
DMS415A	DN	US10149841, Compound 9
DMS415A	HS	Patented
DMS415A	SN	SCHEMBL19808943; US10149841, Compound 9; BDBM306798
DMS415A	DT	Small molecular drug
DMS415A	PC	134204791
DMS415A	MW	324.24
DMS415A	FM	C14H10F2N2O5
DMS415A	IC	InChI=1S/C14H10F2N2O5/c15-8-2-1-3-10(12(8)16)23-7-4-9(19)13(17-5-7)14(22)18-6-11(20)21/h1-5,19H,6H2,(H,18,22)(H,20,21)
DMS415A	CS	C1=CC(=C(C(=C1)F)F)OC2=CC(=C(N=C2)C(=O)NCC(=O)O)O
DMS415A	IK	CTRIOCMSHSAPNW-UHFFFAOYSA-N
DMS415A	IU	2-[[5-(2,3-difluorophenoxy)-3-hydroxypyridine-2-carbonyl]amino]acetic acid

DME2AZG	ID	DME2AZG
DME2AZG	DN	US10150740, Example 1
DME2AZG	HS	Patented
DME2AZG	SN	SCHEMBL18425452; US10150740, Example 1; BDBM307505
DME2AZG	DT	Small molecular drug
DME2AZG	PC	126508802
DME2AZG	MW	302.28
DME2AZG	FM	C15H14N2O5
DME2AZG	IC	InChI=1S/C15H14N2O5/c1-21-13-3-8-6-16-17-7-10(15(19)20)12(18)5-11(17)9(8)4-14(13)22-2/h3-5,7,16H,6H2,1-2H3,(H,19,20)
DME2AZG	CS	COC1=C(C=C2C(=C1)CNN3C2=CC(=O)C(=C3)C(=O)O)OC
DME2AZG	IK	BPBHVSAWZGGVPZ-UHFFFAOYSA-N
DME2AZG	IU	9,10-dimethoxy-2-oxo-6,7-dihydropyrido[2,1-a]phthalazine-3-carboxylic acid

DMKM93Q	ID	DMKM93Q
DMKM93Q	DN	US10150740, Example 4
DMKM93Q	HS	Patented
DMKM93Q	SN	SCHEMBL18426560; US10150740, Example 4; BDBM307508
DMKM93Q	DT	Small molecular drug
DMKM93Q	PC	126509775
DMKM93Q	MW	344.4
DMKM93Q	FM	C18H20N2O5
DMKM93Q	IC	InChI=1S/C18H20N2O5/c1-10(2)19-8-11-5-16(24-3)17(25-4)6-12(11)14-7-15(21)13(18(22)23)9-20(14)19/h5-7,9-10H,8H2,1-4H3,(H,22,23)
DMKM93Q	CS	CC(C)N1CC2=CC(=C(C=C2C3=CC(=O)C(=CN31)C(=O)O)OC)OC
DMKM93Q	IK	PURJTKDWCZADSM-UHFFFAOYSA-N
DMKM93Q	IU	9,10-dimethoxy-2-oxo-6-propan-2-yl-7H-pyrido[2,1-a]phthalazine-3-carboxylic acid

DM1VPLU	ID	DM1VPLU
DM1VPLU	DN	US10150740, Example 9
DM1VPLU	HS	Patented
DM1VPLU	SN	SCHEMBL18425902; US10150740, Example 9; BDBM307513
DM1VPLU	DT	Small molecular drug
DM1VPLU	PC	126509196
DM1VPLU	MW	464.5
DM1VPLU	FM	C22H28N2O7S
DM1VPLU	IC	InChI=1S/C22H28N2O7S/c1-14(2)11-23-12-15-8-21(31-6-5-7-32(4,28)29)20(30-3)9-16(15)18-10-19(25)17(22(26)27)13-24(18)23/h8-10,13-14H,5-7,11-12H2,1-4H3,(H,26,27)
DM1VPLU	CS	CC(C)CN1CC2=CC(=C(C=C2C3=CC(=O)C(=CN31)C(=O)O)OC)OCCCS(=O)(=O)C
DM1VPLU	IK	RECMZXKLBVQDRN-UHFFFAOYSA-N
DM1VPLU	IU	10-methoxy-6-(2-methylpropyl)-9-(3-methylsulfonylpropoxy)-2-oxo-7H-pyrido[2,1-a]phthalazine-3-carboxylic acid

DMVMNP1	ID	DMVMNP1
DMVMNP1	DN	US10166249, Example 695
DMVMNP1	HS	Patented
DMVMNP1	SN	SCHEMBL17511437; BDBM313178; US10166249, Example 695
DMVMNP1	DT	Small molecular drug
DMVMNP1	PC	118877315
DMVMNP1	MW	411.5
DMVMNP1	FM	C21H34NO5P
DMVMNP1	IC	InChI=1S/C21H34NO5P/c1-2-26-11-3-4-16-5-6-18-13-19(8-7-17(18)12-16)20-9-10-21(22,14-20)15-27-28(23,24)25/h7-8,13,16,20H,2-6,9-12,14-15,22H2,1H3,(H2,23,24,25)/t16?,20-,21+/m0/s1
DMVMNP1	CS	CCOCCCC1CCC2=C(C1)C=CC(=C2)[C@H]3CC[C@@](C3)(COP(=O)(O)O)N
DMVMNP1	IK	VHKORLDZIRFKDI-KCECWRNFSA-N
DMVMNP1	IU	[(1R,3S)-1-amino-3-[6-(3-ethoxypropyl)-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methyl dihydrogen phosphate

DMSYRI3	ID	DMSYRI3
DMSYRI3	DN	US10174026, Example 2
DMSYRI3	HS	Patented
DMSYRI3	SN	SCHEMBL16149258; US10174026, Example 2; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid
DMSYRI3	DT	Small molecular drug
DMSYRI3	PC	86280871
DMSYRI3	MW	238.24
DMSYRI3	FM	C14H10N2O2
DMSYRI3	IC	InChI=1S/C14H10N2O2/c17-14(18)10-6-7-15-12-8-11(16-13(10)12)9-4-2-1-3-5-9/h1-8,16H,(H,17,18)
DMSYRI3	CS	C1=CC=C(C=C1)C2=CC3=NC=CC(=C3N2)C(=O)O
DMSYRI3	IK	FEZIKLVLFANZBD-UHFFFAOYSA-N
DMSYRI3	IU	2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid

DMJKTYW	ID	DMJKTYW
DMJKTYW	DN	US10174026, Example 99
DMJKTYW	HS	Patented
DMJKTYW	SN	SCHEMBL16157351; BDBM320432; US10174026, Example 99; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid
DMJKTYW	DT	Small molecular drug
DMJKTYW	PC	85469291
DMJKTYW	MW	259.26
DMJKTYW	FM	C13H13N3O3
DMJKTYW	IC	InChI=1S/C13H13N3O3/c17-12(16-5-1-2-6-16)10-7-9-11(15-10)8(13(18)19)3-4-14-9/h3-4,7,15H,1-2,5-6H2,(H,18,19)
DMJKTYW	CS	C1CCN(C1)C(=O)C2=CC3=NC=CC(=C3N2)C(=O)O
DMJKTYW	IK	YVSBFLGSNJSZJQ-UHFFFAOYSA-N
DMJKTYW	IU	2-(pyrrolidine-1-carbonyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid

DMGTBO3	ID	DMGTBO3
DMGTBO3	DN	US10179791, Compound 171
DMGTBO3	HS	Patented
DMGTBO3	SN	SCHEMBL10268794; BDBM321321; US10179791, Compound 171
DMGTBO3	DT	Small molecular drug
DMGTBO3	PC	56599384
DMGTBO3	MW	381.4
DMGTBO3	FM	C23H24FNO3
DMGTBO3	IC	InChI=1S/C23H24FNO3/c24-20-4-2-1-3-18(20)7-5-17-6-8-19-21(15-17)28-16-23(19)10-13-25(14-11-23)12-9-22(26)27/h1-8,15H,9-14,16H2,(H,26,27)/b7-5+
DMGTBO3	CS	C1CN(CCC12COC3=C2C=CC(=C3)/C=C/C4=CC=CC=C4F)CCC(=O)O
DMGTBO3	IK	SWXZUILIRNOBES-FNORWQNLSA-N
DMGTBO3	IU	3-[6-[(E)-2-(2-fluorophenyl)ethenyl]spiro[2H-1-benzofuran-3,4'-piperidine]-1'-yl]propanoic acid

DMRHQLF	ID	DMRHQLF
DMRHQLF	DN	US10179791, Compound 176
DMRHQLF	HS	Patented
DMRHQLF	SN	SCHEMBL327072; BDBM321322; US10179791, Compound 176
DMRHQLF	DT	Small molecular drug
DMRHQLF	PC	56599386
DMRHQLF	MW	432.3
DMRHQLF	FM	C23H23Cl2NO3
DMRHQLF	IC	InChI=1S/C23H23Cl2NO3/c24-18-2-1-3-19(25)22(18)16-11-15(16)14-4-5-17-20(10-14)29-13-23(17)6-8-26(9-7-23)12-21(27)28/h1-5,10,15-16H,6-9,11-13H2,(H,27,28)
DMRHQLF	CS	C1CN(CCC12COC3=C2C=CC(=C3)C4CC4C5=C(C=CC=C5Cl)Cl)CC(=O)O
DMRHQLF	IK	UTYPIEPGWJMTNG-UHFFFAOYSA-N
DMRHQLF	IU	2-[6-[2-(2,6-dichlorophenyl)cyclopropyl]spiro[2H-1-benzofuran-3,4'-piperidine]-1'-yl]acetic acid

DMLZBRM	ID	DMLZBRM
DMLZBRM	DN	US10179791, Compound 296
DMLZBRM	HS	Patented
DMLZBRM	SN	SCHEMBL10265363; BDBM321333; US10179791, Compound 296
DMLZBRM	DT	Small molecular drug
DMLZBRM	PC	56599299
DMLZBRM	MW	464
DMLZBRM	FM	C24H27ClFNO3S
DMLZBRM	IC	InChI=1S/C24H27ClFNO3S/c1-2-16-4-3-5-19(25)17(16)14-31-20-7-6-18-23(22(20)26)30-15-24(18)9-12-27(13-10-24)11-8-21(28)29/h3-7H,2,8-15H2,1H3,(H,28,29)
DMLZBRM	CS	CCC1=C(C(=CC=C1)Cl)CSC2=C(C3=C(C=C2)C4(CCN(CC4)CCC(=O)O)CO3)F
DMLZBRM	IK	QTCUMVXBAZTPSZ-UHFFFAOYSA-N
DMLZBRM	IU	3-[6-[(2-chloro-6-ethylphenyl)methylsulfanyl]-7-fluorospiro[2H-1-benzofuran-3,4'-piperidine]-1'-yl]propanoic acid

DMAE6CK	ID	DMAE6CK
DMAE6CK	DN	US20160326143, 28
DMAE6CK	HS	Patented
DMAE6CK	SN	CHEMBL3898699; SCHEMBL18205901; BDBM223253; US20160326143, 28; 2-(5-((Cyclopropylmethyl)(2,3-dimethylbenzyl)amino)-3-methoxypicolinoyl)cyclopropanecarboxylic acid
DMAE6CK	DT	Small molecular drug
DMAE6CK	PC	122670152
DMAE6CK	MW	408.5
DMAE6CK	FM	C24H28N2O4
DMAE6CK	IC	InChI=1S/C24H28N2O4/c1-14-5-4-6-17(15(14)2)13-26(12-16-7-8-16)18-9-21(30-3)22(25-11-18)23(27)19-10-20(19)24(28)29/h4-6,9,11,16,19-20H,7-8,10,12-13H2,1-3H3,(H,28,29)
DMAE6CK	CS	CC1=C(C(=CC=C1)CN(CC2CC2)C3=CC(=C(N=C3)C(=O)C4CC4C(=O)O)OC)C
DMAE6CK	IK	LRXJWJPKMGAWTD-UHFFFAOYSA-N
DMAE6CK	IU	2-[5-[cyclopropylmethyl-[(2,3-dimethylphenyl)methyl]amino]-3-methoxypyridine-2-carbonyl]cyclopropane-1-carboxylic acid

DML5KXB	ID	DML5KXB
DML5KXB	DN	US20160326143, 3
DML5KXB	HS	Patented
DML5KXB	SN	CHEMBL3899164; BDBM223228; US20160326143, 3; 2-(5-((4-Chlorophenyl)((1-(trifluoromethyl)cyclopropyl)methyl)amino)-3-methoxypicolinoyl)cyclopropanecarboxylic acid
DML5KXB	DT	Small molecular drug
DML5KXB	PC	126961660
DML5KXB	MW	468.9
DML5KXB	FM	C22H20ClF3N2O4
DML5KXB	IC	InChI=1S/C22H20ClF3N2O4/c1-32-17-8-14(10-27-18(17)19(29)15-9-16(15)21(30)31)28(13-6-4-12(23)5-7-13)20(11-2-3-11)22(24,25)26/h4-8,10-11,15-16,20H,2-3,9H2,1H3,(H,30,31)
DML5KXB	CS	COC1=C(N=CC(=C1)N(C2=CC=C(C=C2)Cl)C(C3CC3)C(F)(F)F)C(=O)C4CC4C(=O)O
DML5KXB	IK	LWAUMGSKFOFDCB-UHFFFAOYSA-N
DML5KXB	IU	2-[5-(4-chloro-N-(1-cyclopropyl-2,2,2-trifluoroethyl)anilino)-3-methoxypyridine-2-carbonyl]cyclopropane-1-carboxylic acid

DMUDE89	ID	DMUDE89
DMUDE89	DN	US20160326143, 38
DMUDE89	HS	Patented
DMUDE89	SN	CHEMBL3901235; SCHEMBL18205890; BDBM223263; US20160326143, 38; 2-(5-((Cyclopropylmethyl)(1,2-dihydroacenaphthylen-3-yl)amino)-3-methoxypicolinoyl)cyclopropanecarboxylic acid
DMUDE89	DT	Small molecular drug
DMUDE89	PC	122670142
DMUDE89	MW	442.5
DMUDE89	FM	C27H26N2O4
DMUDE89	IC	InChI=1S/C27H26N2O4/c1-33-23-11-18(13-28-25(23)26(30)20-12-21(20)27(31)32)29(14-15-5-6-15)22-10-8-17-4-2-3-16-7-9-19(22)24(16)17/h2-4,8,10-11,13,15,20-21H,5-7,9,12,14H2,1H3,(H,31,32)
DMUDE89	CS	COC1=C(N=CC(=C1)N(CC2CC2)C3=C4CCC5=CC=CC(=C54)C=C3)C(=O)C6CC6C(=O)O
DMUDE89	IK	VUVDRPVJLHQYMJ-UHFFFAOYSA-N
DMUDE89	IU	2-[5-[cyclopropylmethyl(1,2-dihydroacenaphthylen-3-yl)amino]-3-methoxypyridine-2-carbonyl]cyclopropane-1-carboxylic acid

DM2DU7R	ID	DM2DU7R
DM2DU7R	DN	US20160326143, 50
DM2DU7R	HS	Patented
DM2DU7R	SN	SCHEMBL18205873; CHEMBL3894959; BDBM223275; US20160326143, 50; 2-(4-((Cyclopropylmethyl)(3,4-dimethylphenyl)amino)-2-methoxybenzoyl)cyclopropanecarboxylic acid
DM2DU7R	DT	Small molecular drug
DM2DU7R	PC	122670126
DM2DU7R	MW	393.5
DM2DU7R	FM	C24H27NO4
DM2DU7R	IC	InChI=1S/C24H27NO4/c1-14-4-7-17(10-15(14)2)25(13-16-5-6-16)18-8-9-19(22(11-18)29-3)23(26)20-12-21(20)24(27)28/h4,7-11,16,20-21H,5-6,12-13H2,1-3H3,(H,27,28)
DM2DU7R	CS	CC1=C(C=C(C=C1)N(CC2CC2)C3=CC(=C(C=C3)C(=O)C4CC4C(=O)O)OC)C
DM2DU7R	IK	HYAQXBPDSJIQND-UHFFFAOYSA-N
DM2DU7R	IU	2-[4-[N-(cyclopropylmethyl)-3,4-dimethylanilino]-2-methoxybenzoyl]cyclopropane-1-carboxylic acid

DMH7JVA	ID	DMH7JVA
DMH7JVA	DN	US8470836, 2
DMH7JVA	HS	Patented
DMH7JVA	SN	SCHEMBL3101345; CHEMBL3644783; BDBM97575; US8470836, 2
DMH7JVA	DT	Small molecular drug
DMH7JVA	PC	42635875
DMH7JVA	MW	505.4
DMH7JVA	FM	C18H19F8N5O3
DMH7JVA	IC	InChI=1S/C18H19F8N5O3/c19-16(20)3-1-11(32)31(15(16)34)6-8(27)5-12(33)30-4-2-9-10(7-30)28-14(18(24,25)26)29-13(9)17(21,22)23/h8,15,34H,1-7,27H2/t8-,15-/m0/s1
DMH7JVA	CS	C1CC([C@@H](N(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)O)(F)F
DMH7JVA	IK	DMXWXVXGQLCKOY-AYVTZFPOSA-N
DMH7JVA	IU	(6S)-1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoro-6-hydroxypiperidin-2-one
DMH7JVA	CA	CAS 1173174-99-6

DMYR10P	ID	DMYR10P
DMYR10P	DN	US8470836, 5
DMYR10P	HS	Patented
DMYR10P	SN	SCHEMBL3111337; CHEMBL3644786; BDBM97578; US8470836, 5
DMYR10P	DT	Small molecular drug
DMYR10P	PC	44126186
DMYR10P	MW	491.5
DMYR10P	FM	C21H26F5N5O3
DMYR10P	IC	InChI=1S/C21H26F5N5O3/c22-20(23)6-4-15(32)31(19(20)34)9-12(27)8-16(33)30-7-5-13-14(10-30)28-18(11-2-1-3-11)29-17(13)21(24,25)26/h11-12,19,34H,1-10,27H2/t12-,19?/m0/s1
DMYR10P	CS	C1CC(C1)C2=NC3=C(CCN(C3)C(=O)C[C@@H](CN4C(C(CCC4=O)(F)F)O)N)C(=N2)C(F)(F)F
DMYR10P	IK	OPWLXRFLOSHBNJ-HSLMYDHPSA-N
DMYR10P	IU	1-[(2S)-2-amino-4-[2-cyclobutyl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoro-6-hydroxypiperidin-2-one

DMVYQXH	ID	DMVYQXH
DMVYQXH	DN	US8470836, 6
DMVYQXH	HS	Patented
DMVYQXH	SN	SCHEMBL13099347; CHEMBL3644787; BDBM97579; US8470836, 6
DMVYQXH	DT	Small molecular drug
DMVYQXH	PC	44126288
DMVYQXH	MW	514.4
DMVYQXH	FM	C22H23F5N6O3
DMVYQXH	IC	InChI=1S/C22H23F5N6O3/c23-21(24)5-1-16(34)33(20(21)36)10-13(28)9-17(35)32-8-4-14-15(11-32)30-19(12-2-6-29-7-3-12)31-18(14)22(25,26)27/h2-3,6-7,13,20,36H,1,4-5,8-11,28H2/t13-,20-/m0/s1
DMVYQXH	CS	C1CC([C@@H](N(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C4=CC=NC=C4)N)O)(F)F
DMVYQXH	IK	JLAXABGHGCBAGV-RBZFPXEDSA-N
DMVYQXH	IU	(6S)-1-[(2S)-2-amino-4-oxo-4-[2-pyridin-4-yl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5,5-difluoro-6-hydroxypiperidin-2-one

DMM4GLH	ID	DMM4GLH
DMM4GLH	DN	US8470836, 8
DMM4GLH	HS	Patented
DMM4GLH	SN	SCHEMBL13099353; CHEMBL3644788; BDBM97581; US8470836, 8
DMM4GLH	DT	Small molecular drug
DMM4GLH	PC	59550092
DMM4GLH	MW	503.4
DMM4GLH	FM	C21H22F5N5O4
DMM4GLH	IC	InChI=1S/C21H22F5N5O4/c22-20(23)5-3-15(32)31(19(20)34)9-11(27)8-16(33)30-6-4-12-13(10-30)28-18(14-2-1-7-35-14)29-17(12)21(24,25)26/h1-2,7,11,19,34H,3-6,8-10,27H2/t11-,19-/m0/s1
DMM4GLH	CS	C1CC([C@@H](N(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C4=CC=CO4)N)O)(F)F
DMM4GLH	IK	QGMCXZMURXFXMP-WLRWDXFRSA-N
DMM4GLH	IU	(6S)-1-[(2S)-2-amino-4-[2-(furan-2-yl)-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoro-6-hydroxypiperidin-2-one

DMFEUMZ	ID	DMFEUMZ
DMFEUMZ	DN	US8481586, 15
DMFEUMZ	HS	Patented
DMFEUMZ	SN	CHEMBL575336; SCHEMBL844646; BDBM50299246; 7-Bromo-1,10-dihydropyrrolo[2,3-a]carbazole; US8481586, 15
DMFEUMZ	DT	Small molecular drug
DMFEUMZ	PC	44479463
DMFEUMZ	MW	285.14
DMFEUMZ	FM	C14H9BrN2
DMFEUMZ	IC	InChI=1S/C14H9BrN2/c15-9-2-4-12-11(7-9)10-3-1-8-5-6-16-13(8)14(10)17-12/h1-7,16-17H
DMFEUMZ	CS	C1=CC2=C(C3=C1C=CN3)NC4=C2C=C(C=C4)Br
DMFEUMZ	IK	JRPUZUBQJFQSQO-UHFFFAOYSA-N
DMFEUMZ	IU	7-bromo-1,10-dihydropyrrolo[2,3-a]carbazole

DM6U3ZR	ID	DM6U3ZR
DM6U3ZR	DN	US8481586, 40
DM6U3ZR	HS	Patented
DM6U3ZR	SN	CHEMBL575739; SCHEMBL844464; BDBM50299250; US8481586, 40; 7-(2,4-Difluorophenyl)-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde
DM6U3ZR	DT	Small molecular drug
DM6U3ZR	PC	44480198
DM6U3ZR	MW	346.3
DM6U3ZR	FM	C21H12F2N2O
DM6U3ZR	IC	InChI=1S/C21H12F2N2O/c22-13-2-3-14(18(23)8-13)11-1-6-19-17(7-11)16-5-4-15-12(10-26)9-24-20(15)21(16)25-19/h1-10,24-25H
DM6U3ZR	CS	C1=CC2=C(C=C1C3=C(C=C(C=C3)F)F)C4=C(N2)C5=C(C=C4)C(=CN5)C=O
DM6U3ZR	IK	BFWHRHJPPAUSLJ-UHFFFAOYSA-N
DM6U3ZR	IU	7-(2,4-difluorophenyl)-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde

DM5W0A2	ID	DM5W0A2
DM5W0A2	DN	US8481586, 5
DM5W0A2	HS	Patented
DM5W0A2	SN	CHEMBL573176; SCHEMBL844935; BDBM50299248; US8481586, 5; 1,10-Dihydropyrrolo[2,3-a]carbazole-3-carboxamide
DM5W0A2	DT	Small molecular drug
DM5W0A2	PC	44479711
DM5W0A2	MW	249.27
DM5W0A2	FM	C15H11N3O
DM5W0A2	IC	InChI=1S/C15H11N3O/c16-15(19)11-7-17-13-10(11)6-5-9-8-3-1-2-4-12(8)18-14(9)13/h1-7,17-18H,(H2,16,19)
DM5W0A2	CS	C1=CC=C2C(=C1)C3=C(N2)C4=C(C=C3)C(=CN4)C(=O)N
DM5W0A2	IK	MXZKCOUOYWSEKW-UHFFFAOYSA-N
DM5W0A2	IU	1,10-dihydropyrrolo[2,3-a]carbazole-3-carboxamide

DMV6FL8	ID	DMV6FL8
DMV6FL8	DN	US8481733, 106
DMV6FL8	HS	Patented
DMV6FL8	SN	SCHEMBL1128749; SCHEMBL1128751; CHEMBL2325938; BDBM98294; US8481733, 106
DMV6FL8	DT	Small molecular drug
DMV6FL8	PC	44468332
DMV6FL8	MW	414.5
DMV6FL8	FM	C25H26N4O2
DMV6FL8	IC	InChI=1S/C25H26N4O2/c1-24(30)14-17(15-24)23-28-20(21-22(26)27-12-13-29(21)23)16-8-10-19(11-9-16)25(2,31)18-6-4-3-5-7-18/h3-13,17,30-31H,14-15H2,1-2H3,(H2,26,27)
DMV6FL8	CS	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(C)(C5=CC=CC=C5)O)O
DMV6FL8	IK	MUKLAWDKMYGQSN-UHFFFAOYSA-N
DMV6FL8	IU	3-[8-amino-1-[4-(1-hydroxy-1-phenylethyl)phenyl]imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol

DMZQIKL	ID	DMZQIKL
DMZQIKL	DN	US8481733, 118
DMZQIKL	HS	Patented
DMZQIKL	SN	SCHEMBL1129553; SCHEMBL1129554; CHEMBL2325937; BDBM98306; US8481733, 118
DMZQIKL	DT	Small molecular drug
DMZQIKL	PC	44538590
DMZQIKL	MW	420.5
DMZQIKL	FM	C24H22F2N4O
DMZQIKL	IC	InChI=1S/C24H22F2N4O/c1-23(31)13-16(14-23)22-29-19(20-21(27)28-11-12-30(20)22)15-7-9-18(10-8-15)24(25,26)17-5-3-2-4-6-17/h2-12,16,31H,13-14H2,1H3,(H2,27,28)
DMZQIKL	CS	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(C5=CC=CC=C5)(F)F)O
DMZQIKL	IK	QXYZHRYXSNHAFM-UHFFFAOYSA-N
DMZQIKL	IU	3-[8-amino-1-[4-[difluoro(phenyl)methyl]phenyl]imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol

DM36R21	ID	DM36R21
DM36R21	DN	US8481733, 95
DM36R21	HS	Patented
DM36R21	SN	SCHEMBL4356213; SCHEMBL4356209; CHEMBL2325936; BDBM98283; US8481733, 95
DM36R21	DT	Small molecular drug
DM36R21	PC	57961044
DM36R21	MW	384.5
DM36R21	FM	C24H24N4O
DM36R21	IC	InChI=1S/C24H24N4O/c1-24(29)14-19(15-24)23-27-20(21-22(25)26-11-12-28(21)23)18-9-7-17(8-10-18)13-16-5-3-2-4-6-16/h2-12,19,29H,13-15H2,1H3,(H2,25,26)
DM36R21	CS	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)CC5=CC=CC=C5)O
DM36R21	IK	ZSKAHJMMVVSPKI-UHFFFAOYSA-N
DM36R21	IU	3-[8-amino-1-(4-benzylphenyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol

DMCJH4F	ID	DMCJH4F
DMCJH4F	DN	US8524917, 10
DMCJH4F	HS	Patented
DMCJH4F	SN	SCHEMBL291250; CHEMBL3651713; HYKLZEZGHJEJET-UHFFFAOYSA-N; BDBM101037; US8524917, 10; US8563594, 168; 1-benzyl-N-(3,4-difluorobenzyl)-6-ethoxy-2-isopropyl-1H-indole-3-carboxamide
DMCJH4F	DT	Small molecular drug
DMCJH4F	PC	25059487
DMCJH4F	MW	462.5
DMCJH4F	FM	C28H28F2N2O2
DMCJH4F	IC	InChI=1S/C28H28F2N2O2/c1-4-34-21-11-12-22-25(15-21)32(17-19-8-6-5-7-9-19)27(18(2)3)26(22)28(33)31-16-20-10-13-23(29)24(30)14-20/h5-15,18H,4,16-17H2,1-3H3,(H,31,33)
DMCJH4F	CS	CCOC1=CC2=C(C=C1)C(=C(N2CC3=CC=CC=C3)C(C)C)C(=O)NCC4=CC(=C(C=C4)F)F
DMCJH4F	IK	HYKLZEZGHJEJET-UHFFFAOYSA-N
DMCJH4F	IU	1-benzyl-N-[(3,4-difluorophenyl)methyl]-6-ethoxy-2-propan-2-ylindole-3-carboxamide

DMETY0U	ID	DMETY0U
DMETY0U	DN	US8524917, 11
DMETY0U	HS	Patented
DMETY0U	SN	SCHEMBL289923; CHEMBL3651714; AFDUGVKJXKJJMO-UHFFFAOYSA-N; BDBM101038; US8524917, 11; US8563594, 169; 1-Benzyl-N-(3,4-difluorobenzyl)-2-isopropyl-6-propoxy-1H-indole-3-carboxamide
DMETY0U	DT	Small molecular drug
DMETY0U	PC	25059488
DMETY0U	MW	476.6
DMETY0U	FM	C29H30F2N2O2
DMETY0U	IC	InChI=1S/C29H30F2N2O2/c1-4-14-35-22-11-12-23-26(16-22)33(18-20-8-6-5-7-9-20)28(19(2)3)27(23)29(34)32-17-21-10-13-24(30)25(31)15-21/h5-13,15-16,19H,4,14,17-18H2,1-3H3,(H,32,34)
DMETY0U	CS	CCCOC1=CC2=C(C=C1)C(=C(N2CC3=CC=CC=C3)C(C)C)C(=O)NCC4=CC(=C(C=C4)F)F
DMETY0U	IK	AFDUGVKJXKJJMO-UHFFFAOYSA-N
DMETY0U	IU	1-benzyl-N-[(3,4-difluorophenyl)methyl]-2-propan-2-yl-6-propoxyindole-3-carboxamide

DMZ2ECB	ID	DMZ2ECB
DMZ2ECB	DN	US8524917, 12
DMZ2ECB	HS	Patented
DMZ2ECB	SN	SCHEMBL786644; CHEMBL3651715; UJUPJZYUKBFHHO-UHFFFAOYSA-N; BDBM101039; US8524917, 12; US8563594, 170; 1-Benzyl-N-(3,4-difluorobenzyl)-6-isopropoxy-2-isopropyl-1H-indole-3-carboxamide
DMZ2ECB	DT	Small molecular drug
DMZ2ECB	PC	25059745
DMZ2ECB	MW	476.6
DMZ2ECB	FM	C29H30F2N2O2
DMZ2ECB	IC	InChI=1S/C29H30F2N2O2/c1-18(2)28-27(29(34)32-16-21-10-13-24(30)25(31)14-21)23-12-11-22(35-19(3)4)15-26(23)33(28)17-20-8-6-5-7-9-20/h5-15,18-19H,16-17H2,1-4H3,(H,32,34)
DMZ2ECB	CS	CC(C)C1=C(C2=C(N1CC3=CC=CC=C3)C=C(C=C2)OC(C)C)C(=O)NCC4=CC(=C(C=C4)F)F
DMZ2ECB	IK	UJUPJZYUKBFHHO-UHFFFAOYSA-N
DMZ2ECB	IU	1-benzyl-N-[(3,4-difluorophenyl)methyl]-2-propan-2-yl-6-propan-2-yloxyindole-3-carboxamide

DMRPD8U	ID	DMRPD8U
DMRPD8U	DN	US8524917, 60
DMRPD8U	HS	Patented
DMRPD8U	SN	SCHEMBL4885528; CHEMBL3639543; JRPPHTCHABUGFY-UHFFFAOYSA-N; BDBM101087; US8524917, 60; 1-Benzyl-N-(3,4-difluorobenzyl)-2-isopropyl-6-(1,3,4-oxadiazol-2-yl)-1H-indole-3-carboxamide
DMRPD8U	DT	Small molecular drug
DMRPD8U	PC	59762338
DMRPD8U	MW	486.5
DMRPD8U	FM	C28H24F2N4O2
DMRPD8U	IC	InChI=1S/C28H24F2N4O2/c1-17(2)26-25(27(35)31-14-19-8-11-22(29)23(30)12-19)21-10-9-20(28-33-32-16-36-28)13-24(21)34(26)15-18-6-4-3-5-7-18/h3-13,16-17H,14-15H2,1-2H3,(H,31,35)
DMRPD8U	CS	CC(C)C1=C(C2=C(N1CC3=CC=CC=C3)C=C(C=C2)C4=NN=CO4)C(=O)NCC5=CC(=C(C=C5)F)F
DMRPD8U	IK	JRPPHTCHABUGFY-UHFFFAOYSA-N
DMRPD8U	IU	1-benzyl-N-[(3,4-difluorophenyl)methyl]-6-(1,3,4-oxadiazol-2-yl)-2-propan-2-ylindole-3-carboxamide

DMF9LNO	ID	DMF9LNO
DMF9LNO	DN	US8536181, A41
DMF9LNO	HS	Patented
DMF9LNO	SN	SCHEMBL1770480; CHEMBL3115298; UPJZLOCUUOIMNC-UHFFFAOYSA-N; BDBM102348; US8536181, A41; tert-butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate
DMF9LNO	DT	Small molecular drug
DMF9LNO	PC	52912218
DMF9LNO	MW	433.9
DMF9LNO	FM	C22H28ClN3O4
DMF9LNO	IC	InChI=1S/C22H28ClN3O4/c1-22(2,3)30-21(29)25-12-10-24(11-13-25)15-17-8-9-26(20(28)19(17)27)14-16-4-6-18(23)7-5-16/h4-9,27H,10-15H2,1-3H3
DMF9LNO	CS	CC(C)(C)OC(=O)N1CCN(CC1)CC2=C(C(=O)N(C=C2)CC3=CC=C(C=C3)Cl)O
DMF9LNO	IK	UPJZLOCUUOIMNC-UHFFFAOYSA-N
DMF9LNO	IU	tert-butyl 4-[[1-[(4-chlorophenyl)methyl]-3-hydroxy-2-oxopyridin-4-yl]methyl]piperazine-1-carboxylate

DMZNF59	ID	DMZNF59
DMZNF59	DN	US8536181, C14
DMZNF59	HS	Patented
DMZNF59	SN	SCHEMBL271606; CHEMBL3649594; BDBM102338; US8536181, C14
DMZNF59	DT	Small molecular drug
DMZNF59	PC	9997015
DMZNF59	MW	334.4
DMZNF59	FM	C21H22N2O2
DMZNF59	IC	InChI=1S/C21H22N2O2/c1-16(18-10-6-3-7-11-18)22-14-19-12-13-23(21(25)20(19)24)15-17-8-4-2-5-9-17/h2-13,16,22,24H,14-15H2,1H3
DMZNF59	CS	CC(C1=CC=CC=C1)NCC2=C(C(=O)N(C=C2)CC3=CC=CC=C3)O
DMZNF59	IK	VGDRCKOTQHHWTA-UHFFFAOYSA-N
DMZNF59	IU	1-benzyl-3-hydroxy-4-[(1-phenylethylamino)methyl]pyridin-2-one

DMRTL63	ID	DMRTL63
DMRTL63	DN	US8536181, C17
DMRTL63	HS	Patented
DMRTL63	SN	SCHEMBL272935; CHEMBL3649592; BDBM102336; US8536181, C17
DMRTL63	DT	Small molecular drug
DMRTL63	PC	10042063
DMRTL63	MW	326.4
DMRTL63	FM	C20H26N2O2
DMRTL63	IC	InChI=1S/C20H26N2O2/c1-15-7-9-18(10-8-15)21-13-17-11-12-22(20(24)19(17)23)14-16-5-3-2-4-6-16/h2-6,11-12,15,18,21,23H,7-10,13-14H2,1H3
DMRTL63	CS	CC1CCC(CC1)NCC2=C(C(=O)N(C=C2)CC3=CC=CC=C3)O
DMRTL63	IK	VJHCNYYTYSQTGD-UHFFFAOYSA-N
DMRTL63	IU	1-benzyl-3-hydroxy-4-[[(4-methylcyclohexyl)amino]methyl]pyridin-2-one

DMAM51Z	ID	DMAM51Z
DMAM51Z	DN	US8536181, C35
DMAM51Z	HS	Patented
DMAM51Z	SN	SCHEMBL5240905; CHEMBL3649593; BDBM102337; US8536181, C35
DMAM51Z	DT	Small molecular drug
DMAM51Z	PC	10449798
DMAM51Z	MW	338.4
DMAM51Z	FM	C19H22N4O2
DMAM51Z	IC	InChI=1S/C19H22N4O2/c24-18-17(13-20-8-4-10-22-12-9-21-15-22)7-11-23(19(18)25)14-16-5-2-1-3-6-16/h1-3,5-7,9,11-12,15,20,24H,4,8,10,13-14H2
DMAM51Z	CS	C1=CC=C(C=C1)CN2C=CC(=C(C2=O)O)CNCCCN3C=CN=C3
DMAM51Z	IK	VKLSJRDNBKOSAR-UHFFFAOYSA-N
DMAM51Z	IU	1-benzyl-3-hydroxy-4-[(3-imidazol-1-ylpropylamino)methyl]pyridin-2-one

DMQRO6G	ID	DMQRO6G
DMQRO6G	DN	US8546370, 102
DMQRO6G	HS	Patented
DMQRO6G	SN	SCHEMBL1043246; CHEMBL3639414; BDBM103514; US8546370, 102
DMQRO6G	DT	Small molecular drug
DMQRO6G	PC	58094043
DMQRO6G	MW	432.9
DMQRO6G	FM	C24H21ClN4O2
DMQRO6G	IC	InChI=1S/C24H21ClN4O2/c25-20-4-2-1-3-19(20)21-15-16-9-10-26-24(30)22(16)23(28-21)27-17-5-7-18(8-6-17)29-11-13-31-14-12-29/h1-10,15H,11-14H2,(H,26,30)(H,27,28)
DMQRO6G	CS	C1COCCN1C2=CC=C(C=C2)NC3=C4C(=CC(=N3)C5=CC=CC=C5Cl)C=CNC4=O
DMQRO6G	IK	BMPOWIIBXCMAFL-UHFFFAOYSA-N
DMQRO6G	IU	6-(2-chlorophenyl)-8-(4-morpholin-4-ylanilino)-2H-2,7-naphthyridin-1-one

DM2K6YU	ID	DM2K6YU
DM2K6YU	DN	US8546370, 11
DM2K6YU	HS	Patented
DM2K6YU	SN	SCHEMBL1044792; CHEMBL3642577; BDBM103510; US8546370, 11
DM2K6YU	DT	Small molecular drug
DM2K6YU	PC	44193817
DM2K6YU	MW	398.5
DM2K6YU	FM	C24H22N4O2
DM2K6YU	IC	InChI=1S/C24H22N4O2/c29-24-22-18(10-11-25-24)16-21(17-4-2-1-3-5-17)27-23(22)26-19-6-8-20(9-7-19)28-12-14-30-15-13-28/h1-11,16H,12-15H2,(H,25,29)(H,26,27)
DM2K6YU	CS	C1COCCN1C2=CC=C(C=C2)NC3=C4C(=CC(=N3)C5=CC=CC=C5)C=CNC4=O
DM2K6YU	IK	UNLNOESEDGPPCS-UHFFFAOYSA-N
DM2K6YU	IU	8-(4-morpholin-4-ylanilino)-6-phenyl-2H-2,7-naphthyridin-1-one

DMGIJZA	ID	DMGIJZA
DMGIJZA	DN	US8546370, 17
DMGIJZA	HS	Patented
DMGIJZA	SN	SCHEMBL1048459; CHEMBL3642578; BDBM103511; US8546370, 17
DMGIJZA	DT	Small molecular drug
DMGIJZA	PC	44180013
DMGIJZA	MW	379.5
DMGIJZA	FM	C21H25N5O2
DMGIJZA	IC	InChI=1S/C21H25N5O2/c22-8-1-2-17-14-15-7-9-23-21(27)19(15)20(25-17)24-16-3-5-18(6-4-16)26-10-12-28-13-11-26/h3-7,9,14H,1-2,8,10-13,22H2,(H,23,27)(H,24,25)
DMGIJZA	CS	C1COCCN1C2=CC=C(C=C2)NC3=C4C(=CC(=N3)CCCN)C=CNC4=O
DMGIJZA	IK	MKILIVUEQNFIIU-UHFFFAOYSA-N
DMGIJZA	IU	6-(3-aminopropyl)-8-(4-morpholin-4-ylanilino)-2H-2,7-naphthyridin-1-one

DMDP87V	ID	DMDP87V
DMDP87V	DN	US8563594, 152
DMDP87V	HS	Patented
DMDP87V	SN	SCHEMBL805680; CHEMBL3651716; PKIXUSGPPGWLFE-UHFFFAOYSA-N; BDBM103603; US8563594, 152; {3-[(5,6-Diphenylpyridin-2-ylmethyl)-amino]-propyl}-phosphonic Acid
DMDP87V	DT	Small molecular drug
DMDP87V	PC	44234513
DMDP87V	MW	382.4
DMDP87V	FM	C21H23N2O3P
DMDP87V	IC	InChI=1S/C21H23N2O3P/c24-27(25,26)15-7-14-22-16-19-12-13-20(17-8-3-1-4-9-17)21(23-19)18-10-5-2-6-11-18/h1-6,8-13,22H,7,14-16H2,(H2,24,25,26)
DMDP87V	CS	C1=CC=C(C=C1)C2=C(N=C(C=C2)CNCCCP(=O)(O)O)C3=CC=CC=C3
DMDP87V	IK	PKIXUSGPPGWLFE-UHFFFAOYSA-N
DMDP87V	IU	3-[(5,6-diphenylpyridin-2-yl)methylamino]propylphosphonic acid

DMZV6YT	ID	DMZV6YT
DMZV6YT	DN	US8569313, Inhibitor 14
DMZV6YT	HS	Patented
DMZV6YT	SN	SCHEMBL8197672; SCHEMBL19309547; CHEMBL3655685; US8569313, Inhibitor 14; BDBM104906
DMZV6YT	DT	Small molecular drug
DMZV6YT	PC	59603780
DMZV6YT	MW	549.7
DMZV6YT	FM	C28H35N7O3S
DMZV6YT	IC	InChI=1S/C28H35N7O3S/c29-12-9-19-10-13-35(14-11-19)28(36)25(16-20-3-1-5-22(15-20)27(31)32)34-39(37,38)24-6-2-4-21(17-24)23-7-8-26(30)33-18-23/h1-8,15,17-19,25,34H,9-14,16,29H2,(H2,30,33)(H3,31,32)
DMZV6YT	CS	C1CN(CCC1CCN)C(=O)C(CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC=CC(=C3)C4=CN=C(C=C4)N
DMZV6YT	IK	YXXOMQLSCCTIBA-UHFFFAOYSA-N
DMZV6YT	IU	3-[3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[3-(6-aminopyridin-3-yl)phenyl]sulfonylamino]-3-oxopropyl]benzenecarboximidamide

DMTMG02	ID	DMTMG02
DMTMG02	DN	US8569313, Inhibitor 15
DMTMG02	HS	Patented
DMTMG02	SN	CHEMBL3655686; SCHEMBL19309680; SCHEMBL12998675; US8569313, Inhibitor 15; BDBM104907
DMTMG02	DT	Small molecular drug
DMTMG02	PC	25181492
DMTMG02	MW	553.7
DMTMG02	FM	C28H39N7O3S
DMTMG02	IC	InChI=1S/C28H39N7O3S/c29-12-9-19-10-13-35(14-11-19)28(36)25(16-20-3-1-5-22(15-20)27(31)32)34-39(37,38)24-6-2-4-21(17-24)23-7-8-26(30)33-18-23/h1-6,15,17,19,23,25,34H,7-14,16,18,29H2,(H2,30,33)(H3,31,32)
DMTMG02	CS	C1CC(=NCC1C2=CC(=CC=C2)S(=O)(=O)NC(CC3=CC(=CC=C3)C(=N)N)C(=O)N4CCC(CC4)CCN)N
DMTMG02	IK	JLKDEEFFWQESQM-UHFFFAOYSA-N
DMTMG02	IU	3-[3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[3-(6-amino-2,3,4,5-tetrahydropyridin-3-yl)phenyl]sulfonylamino]-3-oxopropyl]benzenecarboximidamide

DMXTCGM	ID	DMXTCGM
DMXTCGM	DN	US8569313, Inhibitor 18
DMXTCGM	HS	Patented
DMXTCGM	SN	SCHEMBL8201065; CHEMBL3655687; US8569313, Inhibitor 18; BDBM104909
DMXTCGM	DT	Small molecular drug
DMXTCGM	PC	25031016
DMXTCGM	MW	633.8
DMXTCGM	FM	C34H43N5O5S
DMXTCGM	IC	InChI=1S/C34H43N5O5S/c1-3-44-29-15-13-26(14-16-29)27-9-6-11-30(23-27)45(42,43)38-31(22-25-8-4-10-28(21-25)33(35)36)34(41)39-19-17-24(18-20-39)7-5-12-32(40)37-2/h4,6,8-11,13-16,21,23-24,31,38H,3,5,7,12,17-20,22H2,1-2H3,(H3,35,36)(H,37,40)/t31-/m0/s1
DMXTCGM	CS	CCOC1=CC=C(C=C1)C2=CC(=CC=C2)S(=O)(=O)N[C@@H](CC3=CC(=CC=C3)C(=N)N)C(=O)N4CCC(CC4)CCCC(=O)NC
DMXTCGM	IK	XXQHDBAWRGBXGY-HKBQPEDESA-N
DMXTCGM	IU	4-[1-[(2S)-3-(3-carbamimidoylphenyl)-2-[[3-(4-ethoxyphenyl)phenyl]sulfonylamino]propanoyl]piperidin-4-yl]-N-methylbutanamide

DMLXG43	ID	DMLXG43
DMLXG43	DN	US8569313, Inhibitor 19
DMLXG43	HS	Patented
DMLXG43	SN	SCHEMBL8203194; CHEMBL3655688; US8569313, Inhibitor 19; BDBM104910
DMLXG43	DT	Small molecular drug
DMLXG43	PC	25031103
DMLXG43	MW	617.8
DMLXG43	FM	C34H43N5O4S
DMLXG43	IC	InChI=1S/C34H43N5O4S/c1-3-24-13-15-27(16-14-24)28-9-6-11-30(23-28)44(42,43)38-31(22-26-8-4-10-29(21-26)33(35)36)34(41)39-19-17-25(18-20-39)7-5-12-32(40)37-2/h4,6,8-11,13-16,21,23,25,31,38H,3,5,7,12,17-20,22H2,1-2H3,(H3,35,36)(H,37,40)/t31-/m0/s1
DMLXG43	CS	CCC1=CC=C(C=C1)C2=CC(=CC=C2)S(=O)(=O)N[C@@H](CC3=CC(=CC=C3)C(=N)N)C(=O)N4CCC(CC4)CCCC(=O)NC
DMLXG43	IK	CGNCDGWBKGYOAP-HKBQPEDESA-N
DMLXG43	IU	4-[1-[(2S)-3-(3-carbamimidoylphenyl)-2-[[3-(4-ethylphenyl)phenyl]sulfonylamino]propanoyl]piperidin-4-yl]-N-methylbutanamide

DMKLJ6O	ID	DMKLJ6O
DMKLJ6O	DN	US8586571, 12
DMKLJ6O	HS	Patented
DMKLJ6O	SN	4-(3-(2-tert-butylphenoxy)azetidin-1-yl)-4-oxobutanoic acid; 4-[3-(2-tert-butylphenoxy)azetidin-1-yl]-4-oxobutanoic acid; SCHEMBL3104804; CHEMBL3642667; PSHYFYJKCNFREU-UHFFFAOYSA-N; BDBM106683; US8586571, 12
DMKLJ6O	DT	Small molecular drug
DMKLJ6O	PC	25242543
DMKLJ6O	MW	305.4
DMKLJ6O	FM	C17H23NO4
DMKLJ6O	IC	InChI=1S/C17H23NO4/c1-17(2,3)13-6-4-5-7-14(13)22-12-10-18(11-12)15(19)8-9-16(20)21/h4-7,12H,8-11H2,1-3H3,(H,20,21)
DMKLJ6O	CS	CC(C)(C)C1=CC=CC=C1OC2CN(C2)C(=O)CCC(=O)O
DMKLJ6O	IK	PSHYFYJKCNFREU-UHFFFAOYSA-N
DMKLJ6O	IU	4-[3-(2-tert-butylphenoxy)azetidin-1-yl]-4-oxobutanoic acid

DMX3A0O	ID	DMX3A0O
DMX3A0O	DN	US8586571, 36
DMX3A0O	HS	Patented
DMX3A0O	SN	SCHEMBL3105846; CHEMBL3642666; VZDYQTRPYQHMNA-UHFFFAOYSA-N; BDBM106682; US8586571, 36; 3-(3-(2-tert-butylphenoxy)azetidin-1-yl)-3-oxopropanoic acid
DMX3A0O	DT	Small molecular drug
DMX3A0O	PC	59577090
DMX3A0O	MW	291.34
DMX3A0O	FM	C16H21NO4
DMX3A0O	IC	InChI=1S/C16H21NO4/c1-16(2,3)12-6-4-5-7-13(12)21-11-9-17(10-11)14(18)8-15(19)20/h4-7,11H,8-10H2,1-3H3,(H,19,20)
DMX3A0O	CS	CC(C)(C)C1=CC=CC=C1OC2CN(C2)C(=O)CC(=O)O
DMX3A0O	IK	VZDYQTRPYQHMNA-UHFFFAOYSA-N
DMX3A0O	IU	3-[3-(2-tert-butylphenoxy)azetidin-1-yl]-3-oxopropanoic acid

DM1N74R	ID	DM1N74R
DM1N74R	DN	US8586571, 6
DM1N74R	HS	Patented
DM1N74R	SN	SCHEMBL3108837; CHEMBL3642665; BDBM106681; US8586571, 6
DM1N74R	DT	Small molecular drug
DM1N74R	PC	59577179
DM1N74R	MW	328.4
DM1N74R	FM	C19H21FN2O2
DM1N74R	IC	InChI=1S/C19H21FN2O2/c1-19(2,3)15-10-13(20)7-8-17(15)24-14-11-22(12-14)18(23)16-6-4-5-9-21-16/h4-10,14H,11-12H2,1-3H3
DM1N74R	CS	CC(C)(C)C1=C(C=CC(=C1)F)OC2CN(C2)C(=O)C3=CC=CC=N3
DM1N74R	IK	NKBTZZMPHFITPK-UHFFFAOYSA-N
DM1N74R	IU	[3-(2-tert-butyl-4-fluorophenoxy)azetidin-1-yl]-pyridin-2-ylmethanone

DM29KS1	ID	DM29KS1
DM29KS1	DN	US8592431, 181
DM29KS1	HS	Patented
DM29KS1	SN	SCHEMBL1371832; CHEMBL3648562; QMZXPLFRIAZTAV-UHFFFAOYSA-N; BDBM107374; US8592431, 181; 7-propyl-4-(2,2,3,3-tetramethyl-1,4-dioxaspiro[4.5]dec-8-yl)-6-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one
DM29KS1	DT	Small molecular drug
DM29KS1	PC	59437703
DM29KS1	MW	608.7
DM29KS1	FM	C34H40N8O3
DM29KS1	IC	InChI=1S/C34H40N8O3/c1-6-9-28-27(20-22-12-14-23(15-13-22)25-10-7-8-11-26(25)29-37-39-40-38-29)30(43)41(31-35-21-36-42(28)31)24-16-18-34(19-17-24)44-32(2,3)33(4,5)45-34/h7-8,10-15,21,24H,6,9,16-20H2,1-5H3,(H,37,38,39,40)
DM29KS1	CS	CCCC1=C(C(=O)N(C2=NC=NN12)C3CCC4(CC3)OC(C(O4)(C)C)(C)C)CC5=CC=C(C=C5)C6=CC=CC=C6C7=NNN=N7
DM29KS1	IK	QMZXPLFRIAZTAV-UHFFFAOYSA-N
DM29KS1	IU	7-propyl-4-(2,2,3,3-tetramethyl-1,4-dioxaspiro[4.5]decan-8-yl)-6-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-[1,2,4]triazolo[1,5-a]pyrimidin-5-one

DM1K5HS	ID	DM1K5HS
DM1K5HS	DN	US8592431, 185
DM1K5HS	HS	Patented
DM1K5HS	SN	SCHEMBL1373214; SCHEMBL1373217; CHEMBL3648565; IFFXJMQHLNIFIO-YHBQERECSA-N; BDBM107377; US8592431, 185; 4-[trans-4-(1,3-oxazol-5-yl)cyclohexyl]-7-propyl-6-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one
DM1K5HS	DT	Small molecular drug
DM1K5HS	PC	59437597
DM1K5HS	MW	561.6
DM1K5HS	FM	C31H31N9O2
DM1K5HS	IC	InChI=1S/C31H31N9O2/c1-2-5-27-26(16-20-8-10-21(11-9-20)24-6-3-4-7-25(24)29-35-37-38-36-29)30(41)39(31-33-18-34-40(27)31)23-14-12-22(13-15-23)28-17-32-19-42-28/h3-4,6-11,17-19,22-23H,2,5,12-16H2,1H3,(H,35,36,37,38)
DM1K5HS	CS	CCCC1=C(C(=O)N(C2=NC=NN12)C3CCC(CC3)C4=CN=CO4)CC5=CC=C(C=C5)C6=CC=CC=C6C7=NNN=N7
DM1K5HS	IK	IFFXJMQHLNIFIO-UHFFFAOYSA-N
DM1K5HS	IU	4-[4-(1,3-oxazol-5-yl)cyclohexyl]-7-propyl-6-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-[1,2,4]triazolo[1,5-a]pyrimidin-5-one

DMAPGBF	ID	DMAPGBF
DMAPGBF	DN	US8592431, 457
DMAPGBF	HS	Patented
DMAPGBF	SN	SCHEMBL1374524; SCHEMBL1374521; CHEMBL3651823; LXXPRMLBRPJLIY-RQNOJGIXSA-N; BDBM107466; US8592431, 457; 7-butyl-6-{[3-fluoro-2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-4-[trans-4-(2-hydroxy-2-methylpropoxy)cyclohexyl][1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one
DMAPGBF	DT	Small molecular drug
DMAPGBF	PC	59437811
DMAPGBF	MW	614.7
DMAPGBF	FM	C33H39FN8O3
DMAPGBF	IC	InChI=1S/C33H39FN8O3/c1-4-5-10-29-27(17-22-12-11-21(18-28(22)34)25-8-6-7-9-26(25)30-37-39-40-38-30)31(43)41(32-35-20-36-42(29)32)23-13-15-24(16-14-23)45-19-33(2,3)44/h6-9,11-12,18,20,23-24,44H,4-5,10,13-17,19H2,1-3H3,(H,37,38,39,40)
DMAPGBF	CS	CCCCC1=C(C(=O)N(C2=NC=NN12)C3CCC(CC3)OCC(C)(C)O)CC4=C(C=C(C=C4)C5=CC=CC=C5C6=NNN=N6)F
DMAPGBF	IK	LXXPRMLBRPJLIY-UHFFFAOYSA-N
DMAPGBF	IU	7-butyl-6-[[2-fluoro-4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-[4-(2-hydroxy-2-methylpropoxy)cyclohexyl]-[1,2,4]triazolo[1,5-a]pyrimidin-5-one

DMY8U6J	ID	DMY8U6J
DMY8U6J	DN	US8592455, 3
DMY8U6J	HS	Patented
DMY8U6J	SN	CHEMBL3105021; SCHEMBL1711372; BDBM106803; US8592455, 3
DMY8U6J	DT	Small molecular drug
DMY8U6J	PC	59226518
DMY8U6J	MW	472.5
DMY8U6J	FM	C23H23F3N6O2
DMY8U6J	IC	InChI=1S/C23H23F3N6O2/c1-11-9-32(10-16(28)22(11)33)18-5-6-29-8-17(18)30-23(34)21-15(27)7-14(26)20(31-21)19-12(24)3-2-4-13(19)25/h2-8,11,16,22,33H,9-10,27-28H2,1H3,(H,30,34)/t11-,16+,22+/m0/s1
DMY8U6J	CS	C[C@H]1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3N)F)C4=C(C=CC=C4F)F
DMY8U6J	IK	QJWGSVNGDURFSA-CNUNAPQTSA-N
DMY8U6J	IU	3-amino-N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide

DMTE8QO	ID	DMTE8QO
DMTE8QO	DN	US8592455, 90
DMTE8QO	HS	Patented
DMTE8QO	SN	SCHEMBL9608645; CHEMBL3639508; BDBM106890; US8592455, 90
DMTE8QO	DT	Small molecular drug
DMTE8QO	PC	46179670
DMTE8QO	MW	423.6
DMTE8QO	FM	C24H33N5O2
DMTE8QO	IC	InChI=1S/C24H33N5O2/c1-14-11-16(12-19(26)23(14)30)17-9-10-27-13-21(17)29-24(31)22-18(25)7-8-20(28-22)15-5-3-2-4-6-15/h7-10,13-16,19,23,30H,2-6,11-12,25-26H2,1H3,(H,29,31)/t14-,16+,19+,23+/m0/s1
DMTE8QO	CS	C[C@H]1C[C@H](C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=C(C=CC(=N3)C4CCCCC4)N
DMTE8QO	IK	JMHGWOVBMIFUIZ-CBAWVIOQSA-N
DMTE8QO	IU	3-amino-N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-cyclohexylpyridine-2-carboxamide

DM0YD3Z	ID	DM0YD3Z
DM0YD3Z	DN	US8598172, 1
DM0YD3Z	HS	Patented
DM0YD3Z	SN	SCHEMBL1527199; CHEMBL3660143; BDBM108214; US8598172, 1
DM0YD3Z	DT	Small molecular drug
DM0YD3Z	PC	42611166
DM0YD3Z	MW	533.6
DM0YD3Z	FM	C26H34F3N7O2
DM0YD3Z	IC	InChI=1S/C26H34F3N7O2/c1-4-20-24(37)34(3)21-16-30-25(32-23(21)36(20)17-7-5-6-8-17)31-19-15-18(35-13-11-33(2)12-14-35)9-10-22(19)38-26(27,28)29/h9-10,15-17,20H,4-8,11-14H2,1-3H3,(H,30,31,32)/t20-/m1/s1
DM0YD3Z	CS	CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=CC(=C4)N5CCN(CC5)C)OC(F)(F)F)C
DM0YD3Z	IK	UKDYPCZCLRCOMP-HXUWFJFHSA-N
DM0YD3Z	IU	(7R)-8-cyclopentyl-7-ethyl-5-methyl-2-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-7H-pteridin-6-one

DM9YI3K	ID	DM9YI3K
DM9YI3K	DN	US8598210, Table XV, 1
DM9YI3K	HS	Patented
DM9YI3K	SN	US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyridine-2- carbonyl]-amino}-acetic acid methyl ester; SCHEMBL1921387; CHEMBL3646212; LQWXMRRGVHUWEN-UHFFFAOYSA-N; BDBM107695; US8598210, Table XV, 1; {[5-(3-chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester
DM9YI3K	DT	Small molecular drug
DM9YI3K	PC	24891582
DM9YI3K	MW	320.73
DM9YI3K	FM	C15H13ClN2O4
DM9YI3K	IC	InChI=1S/C15H13ClN2O4/c1-22-13(20)8-18-15(21)14-12(19)6-10(7-17-14)9-3-2-4-11(16)5-9/h2-7,19H,8H2,1H3,(H,18,21)
DM9YI3K	CS	COC(=O)CNC(=O)C1=C(C=C(C=N1)C2=CC(=CC=C2)Cl)O
DM9YI3K	IK	LQWXMRRGVHUWEN-UHFFFAOYSA-N
DM9YI3K	IU	methyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate

DMDK98P	ID	DMDK98P
DMDK98P	DN	US8598210, Table XV, 2
DMDK98P	HS	Patented
DMDK98P	SN	US8722895, 2: {[5-(4-Chloro-phenyl)-3-hydroxy-pyridine- 2-carbonyl]-amino}-acetic acid methyl ester; SCHEMBL1921358; CHEMBL3646213; BDBM107696; US8598210, Table XV, 2
DMDK98P	DT	Small molecular drug
DMDK98P	PC	24891583
DMDK98P	MW	320.73
DMDK98P	FM	C15H13ClN2O4
DMDK98P	IC	InChI=1S/C15H13ClN2O4/c1-22-13(20)8-18-15(21)14-12(19)6-10(7-17-14)9-2-4-11(16)5-3-9/h2-7,19H,8H2,1H3,(H,18,21)
DMDK98P	CS	COC(=O)CNC(=O)C1=C(C=C(C=N1)C2=CC=C(C=C2)Cl)O
DMDK98P	IK	BYGKIXAXITXFDW-UHFFFAOYSA-N
DMDK98P	IU	methyl 2-[[5-(4-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate

DM3XWMO	ID	DM3XWMO
DM3XWMO	DN	US8598210, Table XV, 4
DM3XWMO	HS	Patented
DM3XWMO	SN	US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridine-2- carbonyl)amino]-acetic acid; SCHEMBL1923034; CHEMBL3646215; BDBM107698; US8598210, Table XV, 4
DM3XWMO	DT	Small molecular drug
DM3XWMO	PC	24891734
DM3XWMO	MW	286.28
DM3XWMO	FM	C15H14N2O4
DM3XWMO	IC	InChI=1S/C15H14N2O4/c1-9-2-4-10(5-3-9)11-6-12(18)14(16-7-11)15(21)17-8-13(19)20/h2-7,18H,8H2,1H3,(H,17,21)(H,19,20)
DM3XWMO	CS	CC1=CC=C(C=C1)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
DM3XWMO	IK	VBNCAZJDNCXKIO-UHFFFAOYSA-N
DM3XWMO	IU	2-[[3-hydroxy-5-(4-methylphenyl)pyridine-2-carbonyl]amino]acetic acid

DMEU5ST	ID	DMEU5ST
DMEU5ST	DN	US8598210, Table XV, 5
DMEU5ST	HS	Patented
DMEU5ST	SN	US8722895, 5: [(3-Hydroxy-4'-methyl-biphenyl-4- carbonyl)-amino]-acetic acid; SCHEMBL1921403; CHEMBL3646216; BDBM107699; US8598210, Table XV, 5
DMEU5ST	DT	Small molecular drug
DMEU5ST	PC	24891042
DMEU5ST	MW	285.29
DMEU5ST	FM	C16H15NO4
DMEU5ST	IC	InChI=1S/C16H15NO4/c1-10-2-4-11(5-3-10)12-6-7-13(14(18)8-12)16(21)17-9-15(19)20/h2-8,18H,9H2,1H3,(H,17,21)(H,19,20)
DMEU5ST	CS	CC1=CC=C(C=C1)C2=CC(=C(C=C2)C(=O)NCC(=O)O)O
DMEU5ST	IK	POKDHYRFSOQLCV-UHFFFAOYSA-N
DMEU5ST	IU	2-[[2-hydroxy-4-(4-methylphenyl)benzoyl]amino]acetic acid

DM5CULA	ID	DM5CULA
DM5CULA	DN	US8609715, A-1
DM5CULA	HS	Patented
DM5CULA	SN	CHEMBL3642856; SCHEMBL13641235; BDBM109582; US8609715, A-1
DM5CULA	DT	Small molecular drug
DM5CULA	PC	74982902
DM5CULA	MW	401.4
DM5CULA	FM	C19H19N3O7
DM5CULA	IC	InChI=1S/C19H19N3O7/c1-10(17(24)22-14(9-23)18(25)26)8-13-6-7-15(28-13)19(27)29-12-4-2-11(3-5-12)16(20)21/h2-8,14,23H,9H2,1H3,(H3,20,21)(H,22,24)(H,25,26)/b10-8+/t14-/m0/s1
DM5CULA	CS	C/C(=C\\C1=CC=C(O1)C(=O)OC2=CC=C(C=C2)C(=N)N)/C(=O)N[C@@H](CO)C(=O)O
DM5CULA	IK	NRFIREHTDRUARE-PLWJUESGSA-N
DM5CULA	IU	(2S)-2-[[(E)-3-[5-(4-carbamimidoylphenoxy)carbonylfuran-2-yl]-2-methylprop-2-enoyl]amino]-3-hydroxypropanoic acid

DMY9SFE	ID	DMY9SFE
DMY9SFE	DN	US8609715, A-26
DMY9SFE	HS	Patented
DMY9SFE	SN	SCHEMBL12581314; CHEMBL3639417; BDBM109604; US8609715, A-26
DMY9SFE	DT	Small molecular drug
DMY9SFE	PC	53242150
DMY9SFE	MW	431.4
DMY9SFE	FM	C20H21N3O8
DMY9SFE	IC	InChI=1S/C20H21N3O8/c1-11(19(28)23(9-16(24)25)10-17(26)27)8-14-6-7-15(30-14)20(29)31-13-4-2-12(3-5-13)18(21)22/h2-7,11H,8-10H2,1H3,(H3,21,22)(H,24,25)(H,26,27)
DMY9SFE	CS	CC(CC1=CC=C(O1)C(=O)OC2=CC=C(C=C2)C(=N)N)C(=O)N(CC(=O)O)CC(=O)O
DMY9SFE	IK	GTJNXXKNXAEKAD-UHFFFAOYSA-N
DMY9SFE	IU	2-[[3-[5-(4-carbamimidoylphenoxy)carbonylfuran-2-yl]-2-methylpropanoyl]-(carboxymethyl)amino]acetic acid

DMU26R7	ID	DMU26R7
DMU26R7	DN	US8609715, B-61
DMU26R7	HS	Patented
DMU26R7	SN	CHEMBL3639418; SCHEMBL12581324; BDBM109704; US8609715, B-61
DMU26R7	DT	Small molecular drug
DMU26R7	PC	53242141
DMU26R7	MW	465.5
DMU26R7	FM	C20H20FN3O7S
DMU26R7	IC	InChI=1S/C20H20FN3O7S/c1-9-6-15(20(30)31-13-3-2-10(18(22)23)7-11(13)21)32-14(9)4-5-16(25)24-12(19(28)29)8-17(26)27/h2-3,6-7,12H,4-5,8H2,1H3,(H3,22,23)(H,24,25)(H,26,27)(H,28,29)/t12-/m0/s1
DMU26R7	CS	CC1=C(SC(=C1)C(=O)OC2=C(C=C(C=C2)C(=N)N)F)CCC(=O)N[C@@H](CC(=O)O)C(=O)O
DMU26R7	IK	KUFWXCZSAUGMIW-LBPRGKRZSA-N
DMU26R7	IU	(2S)-2-[3-[5-(4-carbamimidoyl-2-fluorophenoxy)carbonyl-3-methylthiophen-2-yl]propanoylamino]butanedioic acid

DMJKFVU	ID	DMJKFVU
DMJKFVU	DN	US8614253, 29-1
DMJKFVU	HS	Patented
DMJKFVU	SN	CHEMBL3265258; SCHEMBL12767127; WXSWAZIIQXYJAM-UHFFFAOYSA-N; BDBM111341; US8614253, 29-1; methyl 3-(5-formyl-6-hydroxynaphthalen-2-yl)benzoate
DMJKFVU	DT	Small molecular drug
DMJKFVU	PC	25160990
DMJKFVU	MW	306.3
DMJKFVU	FM	C19H14O4
DMJKFVU	IC	InChI=1S/C19H14O4/c1-23-19(22)15-4-2-3-12(10-15)13-5-7-16-14(9-13)6-8-18(21)17(16)11-20/h2-11,21H,1H3
DMJKFVU	CS	COC(=O)C1=CC=CC(=C1)C2=CC3=C(C=C2)C(=C(C=C3)O)C=O
DMJKFVU	IK	WXSWAZIIQXYJAM-UHFFFAOYSA-N
DMJKFVU	IU	methyl 3-(5-formyl-6-hydroxynaphthalen-2-yl)benzoate

DMVI83P	ID	DMVI83P
DMVI83P	DN	US8614253, 29-19
DMVI83P	HS	Patented
DMVI83P	SN	SCHEMBL12674915; CHEMBL3665044; BDBM111359; US8614253, 29-19
DMVI83P	DT	Small molecular drug
DMVI83P	PC	59599768
DMVI83P	MW	319.4
DMVI83P	FM	C20H17NO3
DMVI83P	IC	InChI=1S/C20H17NO3/c1-21(2)20(24)16-5-3-4-13(11-16)14-6-8-17-15(10-14)7-9-19(23)18(17)12-22/h3-12,23H,1-2H3
DMVI83P	CS	CN(C)C(=O)C1=CC=CC(=C1)C2=CC3=C(C=C2)C(=C(C=C3)O)C=O
DMVI83P	IK	NWWPDKVVFKCCIV-UHFFFAOYSA-N
DMVI83P	IU	3-(5-formyl-6-hydroxynaphthalen-2-yl)-N,N-dimethylbenzamide

DMRSP2M	ID	DMRSP2M
DMRSP2M	DN	US8614253, 32-4
DMRSP2M	HS	Patented
DMRSP2M	SN	SCHEMBL12674916; CHEMBL3665053; BDBM111368; US8614253, 32-4
DMRSP2M	DT	Small molecular drug
DMRSP2M	PC	59599904
DMRSP2M	MW	333.4
DMRSP2M	FM	C21H19NO3
DMRSP2M	IC	InChI=1S/C21H19NO3/c1-13(2)22-21(25)17-5-3-4-14(11-17)15-6-8-18-16(10-15)7-9-20(24)19(18)12-23/h3-13,24H,1-2H3,(H,22,25)
DMRSP2M	CS	CC(C)NC(=O)C1=CC=CC(=C1)C2=CC3=C(C=C2)C(=C(C=C3)O)C=O
DMRSP2M	IK	LCESLTUVSXEGCC-UHFFFAOYSA-N
DMRSP2M	IU	3-(5-formyl-6-hydroxynaphthalen-2-yl)-N-propan-2-ylbenzamide

DMSQODK	ID	DMSQODK
DMSQODK	DN	US8614253, 32-5
DMSQODK	HS	Patented
DMSQODK	SN	SCHEMBL12767163; CHEMBL3639639; BDBM111369; US8614253, 32-5
DMSQODK	DT	Small molecular drug
DMSQODK	PC	59599919
DMSQODK	MW	395.4
DMSQODK	FM	C26H21NO3
DMSQODK	IC	InChI=1S/C26H21NO3/c1-27(16-18-5-3-2-4-6-18)26(30)20-9-7-19(8-10-20)21-11-13-23-22(15-21)12-14-25(29)24(23)17-28/h2-15,17,29H,16H2,1H3
DMSQODK	CS	CN(CC1=CC=CC=C1)C(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=C(C=C4)O)C=O
DMSQODK	IK	VYGZNGAQJYQSJI-UHFFFAOYSA-N
DMSQODK	IU	N-benzyl-4-(5-formyl-6-hydroxynaphthalen-2-yl)-N-methylbenzamide

DM4G3OC	ID	DM4G3OC
DM4G3OC	DN	US8669361, 102
DM4G3OC	HS	Patented
DM4G3OC	SN	SCHEMBL2521818; CHEMBL3652620; NJUKVCLHVLPDAP-UHFFFAOYSA-N; BDBM119380; US8669361, 102; 5-amino-2-(2,6-difluorophenyl)-N-(1-methyl-1H-pyrazol-4-yl)thiazole-4-carboxamide
DM4G3OC	DT	Small molecular drug
DM4G3OC	PC	58464924
DM4G3OC	MW	335.33
DM4G3OC	FM	C14H11F2N5OS
DM4G3OC	IC	InChI=1S/C14H11F2N5OS/c1-21-6-7(5-18-21)19-13(22)11-12(17)23-14(20-11)10-8(15)3-2-4-9(10)16/h2-6H,17H2,1H3,(H,19,22)
DM4G3OC	CS	CN1C=C(C=N1)NC(=O)C2=C(SC(=N2)C3=C(C=CC=C3F)F)N
DM4G3OC	IK	NJUKVCLHVLPDAP-UHFFFAOYSA-N
DM4G3OC	IU	5-amino-2-(2,6-difluorophenyl)-N-(1-methylpyrazol-4-yl)-1,3-thiazole-4-carboxamide

DMC67G4	ID	DMC67G4
DMC67G4	DN	US8669361, 103
DMC67G4	HS	Patented
DMC67G4	SN	SCHEMBL2525678; CHEMBL3652621; NVTPYRCDKQXUGU-VIFPVBQESA-N; BDBM119381; US8669361, 103; (S)-5-amino-N-(5-(3-aminopiperidin-1-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide
DMC67G4	DT	Small molecular drug
DMC67G4	PC	53482276
DMC67G4	MW	419.5
DMC67G4	FM	C18H19F2N7OS
DMC67G4	IC	InChI=1S/C18H19F2N7OS/c19-10-4-1-5-11(20)13(10)18-25-14(15(22)29-18)17(28)24-12-7-23-26-16(12)27-6-2-3-9(21)8-27/h1,4-5,7,9H,2-3,6,8,21-22H2,(H,23,26)(H,24,28)/t9-/m0/s1
DMC67G4	CS	C1C[C@@H](CN(C1)C2=C(C=NN2)NC(=O)C3=C(SC(=N3)C4=C(C=CC=C4F)F)N)N
DMC67G4	IK	NVTPYRCDKQXUGU-VIFPVBQESA-N
DMC67G4	IU	5-amino-N-[5-[(3S)-3-aminopiperidin-1-yl]-1H-pyrazol-4-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide

DMIZWM6	ID	DMIZWM6
DMIZWM6	DN	US8669361, 105
DMIZWM6	HS	Patented
DMIZWM6	SN	SCHEMBL2523114; CHEMBL3652622; QVHWRVHLJFUJKP-UHFFFAOYSA-N; BDBM119382; US8669361, 105; 5-amino-2-(2,6-difluorophenyl)-N-(1-methyl-5-(piperidin-4-ylmethylamino)-1H-pyrazol-4-yl)thiazole-4-carboxamide
DMIZWM6	DT	Small molecular drug
DMIZWM6	PC	53482278
DMIZWM6	MW	447.5
DMIZWM6	FM	C20H23F2N7OS
DMIZWM6	IC	InChI=1S/C20H23F2N7OS/c1-29-18(25-9-11-5-7-24-8-6-11)14(10-26-29)27-19(30)16-17(23)31-20(28-16)15-12(21)3-2-4-13(15)22/h2-4,10-11,24-25H,5-9,23H2,1H3,(H,27,30)
DMIZWM6	CS	CN1C(=C(C=N1)NC(=O)C2=C(SC(=N2)C3=C(C=CC=C3F)F)N)NCC4CCNCC4
DMIZWM6	IK	QVHWRVHLJFUJKP-UHFFFAOYSA-N
DMIZWM6	IU	5-amino-2-(2,6-difluorophenyl)-N-[1-methyl-5-(piperidin-4-ylmethylamino)pyrazol-4-yl]-1,3-thiazole-4-carboxamide

DMF8MIB	ID	DMF8MIB
DMF8MIB	DN	US8669361, 107
DMF8MIB	HS	Patented
DMF8MIB	SN	SCHEMBL2517841; CHEMBL3652623; OEPCHHARAQRIEP-NSHDSACASA-N; BDBM119383; US8669361, 107; (S)-5-amino-N-(5-(3-aminopiperidin-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2-fluorophenyl)thiazole-4-carboxamide
DMF8MIB	DT	Small molecular drug
DMF8MIB	PC	53482332
DMF8MIB	MW	415.5
DMF8MIB	FM	C19H22FN7OS
DMF8MIB	IC	InChI=1S/C19H22FN7OS/c1-26-19(27-8-4-5-11(21)10-27)14(9-23-26)24-17(28)15-16(22)29-18(25-15)12-6-2-3-7-13(12)20/h2-3,6-7,9,11H,4-5,8,10,21-22H2,1H3,(H,24,28)/t11-/m0/s1
DMF8MIB	CS	CN1C(=C(C=N1)NC(=O)C2=C(SC(=N2)C3=CC=CC=C3F)N)N4CCC[C@@H](C4)N
DMF8MIB	IK	OEPCHHARAQRIEP-NSHDSACASA-N
DMF8MIB	IU	5-amino-N-[5-[(3S)-3-aminopiperidin-1-yl]-1-methylpyrazol-4-yl]-2-(2-fluorophenyl)-1,3-thiazole-4-carboxamide

DMKYNB0	ID	DMKYNB0
DMKYNB0	DN	US8703720, 15
DMKYNB0	HS	Patented
DMKYNB0	SN	SCHEMBL10036913; CHEMBL3680811; BDBM120771; US8703720, 15
DMKYNB0	DT	Small molecular drug
DMKYNB0	PC	68014110
DMKYNB0	MW	600.6
DMKYNB0	FM	C28H30F2N6O5S
DMKYNB0	IC	InChI=1S/C28H30F2N6O5S/c29-17-8-3-1-6-15(17)19-12-35(33-31-19)21-10-5-11-23(25(21)38)42-28-27(40)24(26(39)22(14-37)41-28)36-13-20(32-34-36)16-7-2-4-9-18(16)30/h1-4,6-9,12-13,21-28,37-40H,5,10-11,14H2/t21?,22?,23-,24+,25?,26+,27?,28+/m1/s1
DMKYNB0	CS	C1C[C@H](C(C(C1)N2C=C(N=N2)C3=CC=CC=C3F)O)S[C@H]4C([C@H]([C@H](C(O4)CO)O)N5C=C(N=N5)C6=CC=CC=C6F)O
DMKYNB0	IK	BJVVNEYHVCHMBX-NJCBQTTNSA-N
DMKYNB0	IU	(2S,4S,5R)-4-[4-(2-fluorophenyl)triazol-1-yl]-2-[(1R)-3-[4-(2-fluorophenyl)triazol-1-yl]-2-hydroxycyclohexyl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol

DMFGIPR	ID	DMFGIPR
DMFGIPR	DN	US8703720, Reference Compound 1
DMFGIPR	HS	Patented
DMFGIPR	SN	SCHEMBL10036902; CHEMBL3680808; BDBM120768; US8703720, Reference Compound 1
DMFGIPR	DT	Small molecular drug
DMFGIPR	PC	58805972
DMFGIPR	MW	194.18
DMFGIPR	FM	C7H14O6
DMFGIPR	IC	InChI=1S/C7H14O6/c1-12-7-6(11)5(10)4(9)3(2-8)13-7/h3-11H,2H2,1H3/t3?,4-,5-,6?,7+/m0/s1
DMFGIPR	CS	CO[C@H]1C([C@H]([C@H](C(O1)CO)O)O)O
DMFGIPR	IK	HOVAGTYPODGVJG-FSUQTPNVSA-N
DMFGIPR	IU	(3R,4S,6R)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol

DM536FO	ID	DM536FO
DM536FO	DN	US8703720, Reference Compound 2
DM536FO	HS	Patented
DM536FO	SN	SCHEMBL17678835; CHEMBL3680809; BDBM120769; US8703720, Reference Compound 2
DM536FO	DT	Small molecular drug
DM536FO	PC	84973162
DM536FO	MW	397.37
DM536FO	FM	C15H27NO11
DM536FO	IC	InChI=1S/C15H27NO11/c1-5(19)16-8-10(21)13(7(4-18)26-14(8)24-2)27-15-12(23)11(22)9(20)6(3-17)25-15/h6-15,17-18,20-23H,3-4H2,1-2H3,(H,16,19)/t6?,7?,8?,9-,10+,11-,12?,13+,14+,15-/m0/s1
DM536FO	CS	CC(=O)NC1[C@H]([C@@H](C(O[C@H]1OC)CO)O[C@H]2C([C@H]([C@H](C(O2)CO)O)O)O)O
DM536FO	IK	PKPZITUQXLANSE-IFUIUTNGSA-N
DM536FO	IU	N-[(2R,4R,5S)-4-hydroxy-6-(hydroxymethyl)-2-methoxy-5-[(2S,4S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide

DMCNAM9	ID	DMCNAM9
DMCNAM9	DN	US8710232, 1
DMCNAM9	HS	Patented
DMCNAM9	SN	SCHEMBL4942017; CHEMBL3694266; BDBM120781; US8710232, 1
DMCNAM9	DT	Small molecular drug
DMCNAM9	PC	11702405
DMCNAM9	MW	314.4
DMCNAM9	FM	C17H22N4O2
DMCNAM9	IC	InChI=1S/C17H22N4O2/c18-16-7-6-12(9-19-16)8-14(17(22)23)15-10-21(11-20-15)13-4-2-1-3-5-13/h6-7,9-11,13-14H,1-5,8H2,(H2,18,19)(H,22,23)
DMCNAM9	CS	C1CCC(CC1)N2C=C(N=C2)C(CC3=CN=C(C=C3)N)C(=O)O
DMCNAM9	IK	XHKJBNCTUYFLDC-UHFFFAOYSA-N
DMCNAM9	IU	3-(6-aminopyridin-3-yl)-2-(1-cyclohexylimidazol-4-yl)propanoic acid

DMCNS9T	ID	DMCNS9T
DMCNS9T	DN	US8710232, 7
DMCNS9T	HS	Patented
DMCNS9T	SN	SCHEMBL4947561; CHEMBL3694267; IQZKZQSOVLMDRA-UHFFFAOYSA-N; BDBM120782; US8710232, 7; 3-(6-Aminopyridin-3-yl)-2-(1-cyclopentyl-1H-imidazol-4-yl)propionic acid
DMCNS9T	DT	Small molecular drug
DMCNS9T	PC	69252172
DMCNS9T	MW	300.36
DMCNS9T	FM	C16H20N4O2
DMCNS9T	IC	InChI=1S/C16H20N4O2/c17-15-6-5-11(8-18-15)7-13(16(21)22)14-9-20(10-19-14)12-3-1-2-4-12/h5-6,8-10,12-13H,1-4,7H2,(H2,17,18)(H,21,22)
DMCNS9T	CS	C1CCC(C1)N2C=C(N=C2)C(CC3=CN=C(C=C3)N)C(=O)O
DMCNS9T	IK	IQZKZQSOVLMDRA-UHFFFAOYSA-N
DMCNS9T	IU	3-(6-aminopyridin-3-yl)-2-(1-cyclopentylimidazol-4-yl)propanoic acid

DM1MQ7J	ID	DM1MQ7J
DM1MQ7J	DN	US8710232, 8
DM1MQ7J	HS	Patented
DM1MQ7J	SN	SCHEMBL5148920; CHEMBL3694268; BDBM120783; US8710232, 8
DM1MQ7J	DT	Small molecular drug
DM1MQ7J	PC	11500637
DM1MQ7J	MW	315.37
DM1MQ7J	FM	C16H21N5O2
DM1MQ7J	IC	InChI=1S/C16H21N5O2/c17-15-2-1-11(8-19-15)7-13(16(22)23)14-9-21(10-20-14)12-3-5-18-6-4-12/h1-2,8-10,12-13,18H,3-7H2,(H2,17,19)(H,22,23)
DM1MQ7J	CS	C1CNCCC1N2C=C(N=C2)C(CC3=CN=C(C=C3)N)C(=O)O
DM1MQ7J	IK	ZPMPWZIJWOLMHZ-UHFFFAOYSA-N
DM1MQ7J	IU	3-(6-aminopyridin-3-yl)-2-(1-piperidin-4-ylimidazol-4-yl)propanoic acid

DMU9YPV	ID	DMU9YPV
DMU9YPV	DN	US8741907-compound-3
DMU9YPV	HS	Patented
DMU9YPV	DT	Small molecular drug
DMU9YPV	PC	135422930
DMU9YPV	MW	302.4
DMU9YPV	FM	C17H26N4O
DMU9YPV	IC	InChI=1S/C17H26N4O/c1-3-13(4-2)21-16-14(11-18-21)17(22)20-15(19-16)10-12-8-6-5-7-9-12/h11-13H,3-10H2,1-2H3,(H,19,20,22)
DMU9YPV	CS	CCC(CC)N1C2=C(C=N1)C(=O)NC(=N2)CC3CCCCC3
DMU9YPV	IK	GXWSVMJGLJNVHK-UHFFFAOYSA-N
DMU9YPV	IU	6-(cyclohexylmethyl)-1-pentan-3-yl-5H-pyrazolo[3,4-d]pyrimidin-4-one

DMSYD3X	ID	DMSYD3X
DMSYD3X	DN	US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine
DMSYD3X	HS	Patented
DMSYD3X	SN	SCHEMBL686607; CHEMBL3680986; BDBM123923; US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine
DMSYD3X	DT	Small molecular drug
DMSYD3X	PC	66768033
DMSYD3X	MW	310.4
DMSYD3X	FM	C15H14N6S
DMSYD3X	IC	InChI=1S/C15H14N6S/c1-2-4-13-12(3-1)20-15(22-13)11-8-19-21-14(11)17-6-5-10-7-16-9-18-10/h1-4,7-9H,5-6H2,(H,16,18)(H2,17,19,21)
DMSYD3X	CS	C1=CC=C2C(=C1)N=C(S2)C3=C(NN=C3)NCCC4=CN=CN4
DMSYD3X	IK	SKFIGKZRFZMUKR-UHFFFAOYSA-N
DMSYD3X	IU	4-(1,3-benzothiazol-2-yl)-N-[2-(1H-imidazol-5-yl)ethyl]-1H-pyrazol-5-amine

DMJPQNH	ID	DMJPQNH
DMJPQNH	DN	US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide
DMJPQNH	HS	Patented
DMJPQNH	SN	SCHEMBL687220; CHEMBL3639798; BDBM123930; US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide
DMJPQNH	DT	Small molecular drug
DMJPQNH	PC	66768275
DMJPQNH	MW	313.3
DMJPQNH	FM	C10H8FN5O2S2
DMJPQNH	IC	InChI=1S/C10H8FN5O2S2/c11-5-1-6-7(2-8(5)20(13,17)18)19-10(15-6)4-3-14-16-9(4)12/h1-3H,(H3,12,14,16)(H2,13,17,18)
DMJPQNH	CS	C1=C2C(=CC(=C1F)S(=O)(=O)N)SC(=N2)C3=C(NN=C3)N
DMJPQNH	IK	MJSWBRWBMZMVTH-UHFFFAOYSA-N
DMJPQNH	IU	2-(5-amino-1H-pyrazol-4-yl)-5-fluoro-1,3-benzothiazole-6-sulfonamide

DMJY0CD	ID	DMJY0CD
DMJY0CD	DN	US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine
DMJY0CD	HS	Patented
DMJY0CD	SN	SCHEMBL686446; CHEMBL3639845; BDBM123985; US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine
DMJY0CD	DT	Small molecular drug
DMJY0CD	PC	66767960
DMJY0CD	MW	358.4
DMJY0CD	FM	C17H12F2N4OS
DMJY0CD	IC	InChI=1S/C17H12F2N4OS/c1-24-12-7-13-11(6-10(12)19)21-17(25-13)14-15(22-23-16(14)20)8-4-2-3-5-9(8)18/h2-7H,1H3,(H3,20,22,23)
DMJY0CD	CS	COC1=C(C=C2C(=C1)SC(=N2)C3=C(NN=C3N)C4=CC=CC=C4F)F
DMJY0CD	IK	YMZGLBIKIDCVFV-UHFFFAOYSA-N
DMJY0CD	IU	4-(5-fluoro-6-methoxy-1,3-benzothiazol-2-yl)-5-(2-fluorophenyl)-1H-pyrazol-3-amine

DMRHNIL	ID	DMRHNIL
DMRHNIL	DN	US8759338, 1
DMRHNIL	HS	Patented
DMRHNIL	SN	SCHEMBL1710320; CHEMBL3685734; BDBM124897; US8759338, 1
DMRHNIL	DT	Small molecular drug
DMRHNIL	PC	46186002
DMRHNIL	MW	429.5
DMRHNIL	FM	C25H21F2N5
DMRHNIL	IC	InChI=1S/C25H21F2N5/c26-19-7-3-8-20(27)23(19)25-30-13-16-5-2-9-21(24(16)32-25)31-22-14-29-11-10-18(22)15-4-1-6-17(28)12-15/h2-3,5,7-14,17,31H,1,4,6,28H2
DMRHNIL	CS	C1CC(C=C(C1)C2=C(C=NC=C2)NC3=CC=CC4=CN=C(N=C43)C5=C(C=CC=C5F)F)N
DMRHNIL	IK	VWDOGNVHWKGFOS-UHFFFAOYSA-N
DMRHNIL	IU	N-[4-(3-aminocyclohexen-1-yl)pyridin-3-yl]-2-(2,6-difluorophenyl)quinazolin-8-amine

DMXHN1V	ID	DMXHN1V
DMXHN1V	DN	US8759338, 12
DMXHN1V	HS	Patented
DMXHN1V	SN	SCHEMBL1710271; CHEMBL3639846; BDBM124908; US8759338, 12
DMXHN1V	DT	Small molecular drug
DMXHN1V	PC	46182813
DMXHN1V	MW	433.5
DMXHN1V	FM	C23H21F2N7
DMXHN1V	IC	InChI=1S/C23H21F2N7/c24-16-6-2-7-17(25)20(16)22-28-10-14-4-1-8-18(21(14)31-22)30-19-11-27-13-29-23(19)32-9-3-5-15(26)12-32/h1-2,4,6-8,10-11,13,15,30H,3,5,9,12,26H2/t15-/m0/s1
DMXHN1V	CS	C1C[C@@H](CN(C1)C2=NC=NC=C2NC3=CC=CC4=CN=C(N=C43)C5=C(C=CC=C5F)F)N
DMXHN1V	IK	XPBFQTIASOFUJQ-HNNXBMFYSA-N
DMXHN1V	IU	N-[4-[(3S)-3-aminopiperidin-1-yl]pyrimidin-5-yl]-2-(2,6-difluorophenyl)quinazolin-8-amine

DMSBRHJ	ID	DMSBRHJ
DMSBRHJ	DN	US8759338, 2
DMSBRHJ	HS	Patented
DMSBRHJ	SN	SCHEMBL1710174; CHEMBL3685735; BDBM124898; US8759338, 2
DMSBRHJ	DT	Small molecular drug
DMSBRHJ	PC	46186003
DMSBRHJ	MW	448.5
DMSBRHJ	FM	C24H22F2N6O
DMSBRHJ	IC	InChI=1S/C24H22F2N6O/c25-15-4-2-5-16(26)22(15)24-29-11-14-3-1-6-18(23(14)31-24)30-19-12-28-9-7-20(19)32-10-8-21(33)17(27)13-32/h1-7,9,11-12,17,21,30,33H,8,10,13,27H2/t17-,21+/m1/s1
DMSBRHJ	CS	C1CN(C[C@H]([C@H]1O)N)C2=C(C=NC=C2)NC3=CC=CC4=CN=C(N=C43)C5=C(C=CC=C5F)F
DMSBRHJ	IK	WAISNUDWNYJNMT-UTKZUKDTSA-N
DMSBRHJ	IU	(3R,4S)-3-amino-1-[3-[[2-(2,6-difluorophenyl)quinazolin-8-yl]amino]pyridin-4-yl]piperidin-4-ol

DM2J8IS	ID	DM2J8IS
DM2J8IS	DN	US8772478, 1
DM2J8IS	HS	Patented
DM2J8IS	SN	SCHEMBL996444; CHEMBL3643908; MVDTXPPSDKEWJP-FQEVSTJZSA-N; BDBM125917; US8772478, 1; (S)-3-(4-benzyloxybenzenesulfonylamino)-N-hydroxy-2-piperidin-1-ylpropionamide
DM2J8IS	DT	Small molecular drug
DM2J8IS	PC	49854306
DM2J8IS	MW	433.5
DM2J8IS	FM	C21H27N3O5S
DM2J8IS	IC	InChI=1S/C21H27N3O5S/c25-21(23-26)20(24-13-5-2-6-14-24)15-22-30(27,28)19-11-9-18(10-12-19)29-16-17-7-3-1-4-8-17/h1,3-4,7-12,20,22,26H,2,5-6,13-16H2,(H,23,25)/t20-/m0/s1
DM2J8IS	CS	C1CCN(CC1)[C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC3=CC=CC=C3)C(=O)NO
DM2J8IS	IK	MVDTXPPSDKEWJP-FQEVSTJZSA-N
DM2J8IS	IU	(2S)-N-hydroxy-3-[(4-phenylmethoxyphenyl)sulfonylamino]-2-piperidin-1-ylpropanamide

DMFJD5L	ID	DMFJD5L
DMFJD5L	DN	US8772478, 2
DMFJD5L	HS	Patented
DMFJD5L	SN	SCHEMBL997565; CHEMBL3643909; BDBM125918; US8772478, 2
DMFJD5L	DT	Small molecular drug
DMFJD5L	PC	49854307
DMFJD5L	MW	419.5
DMFJD5L	FM	C20H25N3O5S
DMFJD5L	IC	InChI=1S/C20H25N3O5S/c24-20(22-25)19(23-12-4-5-13-23)14-21-29(26,27)18-10-8-17(9-11-18)28-15-16-6-2-1-3-7-16/h1-3,6-11,19,21,25H,4-5,12-15H2,(H,22,24)/t19-/m0/s1
DMFJD5L	CS	C1CCN(C1)[C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC3=CC=CC=C3)C(=O)NO
DMFJD5L	IK	NOUZHOVZVQEFTM-IBGZPJMESA-N
DMFJD5L	IU	(2S)-N-hydroxy-3-[(4-phenylmethoxyphenyl)sulfonylamino]-2-pyrrolidin-1-ylpropanamide

DMN4FRE	ID	DMN4FRE
DMN4FRE	DN	US8772478, 3
DMN4FRE	HS	Patented
DMN4FRE	SN	SCHEMBL998690; CHEMBL3643910; BDBM125919; US8772478, 3
DMN4FRE	DT	Small molecular drug
DMN4FRE	PC	49854406
DMN4FRE	MW	451.5
DMN4FRE	FM	C21H26FN3O5S
DMN4FRE	IC	InChI=1S/C21H26FN3O5S/c22-17-6-4-16(5-7-17)15-30-18-8-10-19(11-9-18)31(28,29)23-14-20(21(26)24-27)25-12-2-1-3-13-25/h4-11,20,23,27H,1-3,12-15H2,(H,24,26)/t20-/m0/s1
DMN4FRE	CS	C1CCN(CC1)[C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC3=CC=C(C=C3)F)C(=O)NO
DMN4FRE	IK	PDOPZKWZZGOMJC-FQEVSTJZSA-N
DMN4FRE	IU	(2S)-3-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonylamino]-N-hydroxy-2-piperidin-1-ylpropanamide

DMHI6RZ	ID	DMHI6RZ
DMHI6RZ	DN	US8772478, 5
DMHI6RZ	HS	Patented
DMHI6RZ	SN	SCHEMBL996082; CHEMBL3643911; BDBM125920; US8772478, 5
DMHI6RZ	DT	Small molecular drug
DMHI6RZ	PC	49854408
DMHI6RZ	MW	483.6
DMHI6RZ	FM	C25H29N3O5S
DMHI6RZ	IC	InChI=1S/C25H29N3O5S/c29-25(27-30)24(28-14-4-1-5-15-28)17-26-34(31,32)23-12-10-22(11-13-23)33-18-19-8-9-20-6-2-3-7-21(20)16-19/h2-3,6-13,16,24,26,30H,1,4-5,14-15,17-18H2,(H,27,29)/t24-/m0/s1
DMHI6RZ	CS	C1CCN(CC1)[C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC3=CC4=CC=CC=C4C=C3)C(=O)NO
DMHI6RZ	IK	OPHJLUDAYHJCPN-DEOSSOPVSA-N
DMHI6RZ	IU	(2S)-N-hydroxy-3-[[4-(naphthalen-2-ylmethoxy)phenyl]sulfonylamino]-2-piperidin-1-ylpropanamide

DMUPRX2	ID	DMUPRX2
DMUPRX2	DN	US8791257, 17
DMUPRX2	HS	Patented
DMUPRX2	SN	CHEMBL3681194; SCHEMBL12285791; BDBM127319; US8791257, 17
DMUPRX2	DT	Small molecular drug
DMUPRX2	PC	68231238
DMUPRX2	MW	453.5
DMUPRX2	FM	C22H27N7O4
DMUPRX2	IC	InChI=1S/C22H27N7O4/c1-3-33-22(31)28-15-6-4-14(5-7-15)27-21(30)16-11-17(13-8-9-24-18(10-13)32-2)29-19(16)20(23)25-12-26-29/h8-12,14-15H,3-7H2,1-2H3,(H,27,30)(H,28,31)(H2,23,25,26)
DMUPRX2	CS	CCOC(=O)NC1CCC(CC1)NC(=O)C2=C3C(=NC=NN3C(=C2)C4=CC(=NC=C4)OC)N
DMUPRX2	IK	UOUCFNDSPAGXJQ-UHFFFAOYSA-N
DMUPRX2	IU	ethyl N-[4-[[4-amino-7-(2-methoxypyridin-4-yl)pyrrolo[2,1-f][1,2,4]triazine-5-carbonyl]amino]cyclohexyl]carbamate

DMAEHCP	ID	DMAEHCP
DMAEHCP	DN	US8791257, 38
DMAEHCP	HS	Patented
DMAEHCP	SN	CHEMBL3681195; BDBM127320; US8791257, 38
DMAEHCP	DT	Small molecular drug
DMAEHCP	PC	86766696
DMAEHCP	MW	423.5
DMAEHCP	FM	C21H25N7O3
DMAEHCP	IC	InChI=1S/C21H25N7O3/c1-2-31-21(30)27-15-5-3-14(4-6-15)26-20(29)16-11-17(13-7-9-23-10-8-13)28-18(16)19(22)24-12-25-28/h7-12,14-15H,2-6H2,1H3,(H,26,29)(H,27,30)(H2,22,24,25)
DMAEHCP	CS	CCOC(=O)NC1CCC(CC1)NC(=O)C2=C3C(=NC=NN3C(=C2)C4=CC=NC=C4)N
DMAEHCP	IK	JJHBNGJYDQCBGI-UHFFFAOYSA-N
DMAEHCP	IU	ethyl N-[4-[(4-amino-7-pyridin-4-ylpyrrolo[2,1-f][1,2,4]triazine-5-carbonyl)amino]cyclohexyl]carbamate

DMIQO8N	ID	DMIQO8N
DMIQO8N	DN	US8791257, 4
DMIQO8N	HS	Patented
DMIQO8N	SN	SCHEMBL14634987; SCHEMBL12284249; CHEMBL3681193; DZUXIHIXWCKJDW-HAQNSBGRSA-N; BDBM127318; US8791257, 4; 4-Amino-N-(trans-4-hydroxycyclohexyl)-7-(2-fluoro-4-pyridinyl)pyrrolo[2,1-f][1,2,4]triazine-5-carboxamide
DMIQO8N	DT	Small molecular drug
DMIQO8N	PC	68230695
DMIQO8N	MW	370.4
DMIQO8N	FM	C18H19FN6O2
DMIQO8N	IC	InChI=1S/C18H19FN6O2/c19-15-7-10(5-6-21-15)14-8-13(16-17(20)22-9-23-25(14)16)18(27)24-11-1-3-12(26)4-2-11/h5-9,11-12,26H,1-4H2,(H,24,27)(H2,20,22,23)
DMIQO8N	CS	C1CC(CCC1NC(=O)C2=C3C(=NC=NN3C(=C2)C4=CC(=NC=C4)F)N)O
DMIQO8N	IK	DZUXIHIXWCKJDW-UHFFFAOYSA-N
DMIQO8N	IU	4-amino-7-(2-fluoropyridin-4-yl)-N-(4-hydroxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazine-5-carboxamide

DMWKDET	ID	DMWKDET
DMWKDET	DN	US8829193, 1
DMWKDET	HS	Patented
DMWKDET	SN	SCHEMBL2691319; CHEMBL3676258; BDBM131728; US8829193, 1
DMWKDET	DT	Small molecular drug
DMWKDET	PC	51002052
DMWKDET	MW	415.5
DMWKDET	FM	C20H19F2N5OS
DMWKDET	IC	InChI=1S/C20H19F2N5OS/c21-13-4-1-5-14(22)18(13)20-26-16(11-29-20)19(28)25-15-9-24-7-6-17(15)27-8-2-3-12(23)10-27/h1,4-7,9,11-12H,2-3,8,10,23H2,(H,25,28)/t12-/m0/s1
DMWKDET	CS	C1C[C@@H](CN(C1)C2=C(C=NC=C2)NC(=O)C3=CSC(=N3)C4=C(C=CC=C4F)F)N
DMWKDET	IK	DRSGGAHSPDXOOW-LBPRGKRZSA-N
DMWKDET	IU	N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide

DMBIAQD	ID	DMBIAQD
DMBIAQD	DN	US8829193, 2
DMBIAQD	HS	Patented
DMBIAQD	SN	SCHEMBL2693373; CHEMBL3676259; BDBM131729; US8829193, 2
DMBIAQD	DT	Small molecular drug
DMBIAQD	PC	59455648
DMBIAQD	MW	431.5
DMBIAQD	FM	C20H19F2N5O2S
DMBIAQD	IC	InChI=1S/C20H19F2N5O2S/c21-11-2-1-3-12(22)18(11)20-26-15(10-30-20)19(29)25-14-8-24-6-4-16(14)27-7-5-17(28)13(23)9-27/h1-4,6,8,10,13,17,28H,5,7,9,23H2,(H,25,29)/t13-,17-/m1/s1
DMBIAQD	CS	C1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=CSC(=N3)C4=C(C=CC=C4F)F
DMBIAQD	IK	LQASHUDUJOBHMP-CXAGYDPISA-N
DMBIAQD	IU	N-[4-[(3R,4R)-3-amino-4-hydroxypiperidin-1-yl]pyridin-3-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide

DM5ZGK3	ID	DM5ZGK3
DM5ZGK3	DN	US8829193, 3
DM5ZGK3	HS	Patented
DM5ZGK3	SN	SCHEMBL2693572; CHEMBL3676260; BDBM131730; US8829193, 3
DM5ZGK3	DT	Small molecular drug
DM5ZGK3	PC	59455638
DM5ZGK3	MW	433.5
DM5ZGK3	FM	C20H18F3N5OS
DM5ZGK3	IC	InChI=1S/C20H18F3N5OS/c21-11-5-7-28(9-14(11)24)17-4-6-25-8-15(17)26-19(29)16-10-30-20(27-16)18-12(22)2-1-3-13(18)23/h1-4,6,8,10-11,14H,5,7,9,24H2,(H,26,29)/t11-,14-/m1/s1
DM5ZGK3	CS	C1CN(C[C@H]([C@@H]1F)N)C2=C(C=NC=C2)NC(=O)C3=CSC(=N3)C4=C(C=CC=C4F)F
DM5ZGK3	IK	QQRNXNZMTIFVNK-BXUZGUMPSA-N
DM5ZGK3	IU	N-[4-[(3R,4R)-3-amino-4-fluoropiperidin-1-yl]pyridin-3-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide

DMRUTJZ	ID	DMRUTJZ
DMRUTJZ	DN	US8846654, 11
DMRUTJZ	HS	Patented
DMRUTJZ	SN	BDBM135577; US8846654, 11
DMRUTJZ	DT	Small molecular drug
DMRUTJZ	PC	74434786
DMRUTJZ	MW	523.6
DMRUTJZ	FM	C26H35F2N3O6
DMRUTJZ	IC	InChI=1S/C26H35F2N3O6/c1-35-23-6-3-17(11-24(23)36-2)15-30-25(33)21-12-19(37-20(13-27)14-28)4-5-22(21)31(26(30)34)18-7-9-29(16-32)10-8-18/h3,6,11,16,18-22H,4-5,7-10,12-15H2,1-2H3
DMRUTJZ	CS	COC1=C(C=C(C=C1)CN2C(=O)C3CC(CCC3N(C2=O)C4CCN(CC4)C=O)OC(CF)CF)OC
DMRUTJZ	IK	QZWWBGKSFBRQGT-UHFFFAOYSA-N
DMRUTJZ	IU	4-[6-(1,3-difluoropropan-2-yloxy)-3-[(3,4-dimethoxyphenyl)methyl]-2,4-dioxo-4a,5,6,7,8,8a-hexahydroquinazolin-1-yl]piperidine-1-carbaldehyde

DMML258	ID	DMML258
DMML258	DN	US8846654, 251
DMML258	HS	Patented
DMML258	SN	BDBM135583; US8846654, 251
DMML258	DT	Small molecular drug
DMML258	PC	75240056
DMML258	MW	634.7
DMML258	FM	C32H44F2N4O7
DMML258	IC	InChI=1S/C32H44F2N4O7/c1-43-29-15-22(5-8-28(29)44-20-30(40)36-11-3-2-4-12-36)19-37-31(41)26-16-24(45-25(17-33)18-34)6-7-27(26)38(32(37)42)23-9-13-35(21-39)14-10-23/h5,8,15,21,23-27H,2-4,6-7,9-14,16-20H2,1H3
DMML258	CS	COC1=C(C=CC(=C1)CN2C(=O)C3CC(CCC3N(C2=O)C4CCN(CC4)C=O)OC(CF)CF)OCC(=O)N5CCCCC5
DMML258	IK	NIQRJBGTHGXCJU-UHFFFAOYSA-N
DMML258	IU	4-[6-(1,3-difluoropropan-2-yloxy)-3-[[3-methoxy-4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]methyl]-2,4-dioxo-4a,5,6,7,8,8a-hexahydroquinazolin-1-yl]piperidine-1-carbaldehyde

DMP3RCH	ID	DMP3RCH
DMP3RCH	DN	US8846654, 294
DMP3RCH	HS	Patented
DMP3RCH	SN	BDBM135584; US8846654, 294
DMP3RCH	DT	Small molecular drug
DMP3RCH	PC	72333047
DMP3RCH	MW	564.6
DMP3RCH	FM	C31H34F2N4O4
DMP3RCH	IC	InChI=1S/C31H34F2N4O4/c32-16-26(17-33)41-25-7-9-29-28(15-25)30(39)36(31(40)37(29)24-10-12-35(20-38)13-11-24)19-21-6-8-27(23(14-21)18-34)22-4-2-1-3-5-22/h1-6,8,14,20,24-26,28-29H,7,9-13,15-17,19H2
DMP3RCH	CS	C1CC2C(CC1OC(CF)CF)C(=O)N(C(=O)N2C3CCN(CC3)C=O)CC4=CC(=C(C=C4)C5=CC=CC=C5)C#N
DMP3RCH	IK	FDTVWOHILNTAPC-UHFFFAOYSA-N
DMP3RCH	IU	5-[[6-(1,3-difluoropropan-2-yloxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-4a,5,6,7,8,8a-hexahydroquinazolin-3-yl]methyl]-2-phenylbenzonitrile

DMX8NLB	ID	DMX8NLB
DMX8NLB	DN	US8853215, 3
DMX8NLB	HS	Patented
DMX8NLB	SN	SCHEMBL631179; CHEMBL3644466; DISALCDEOIPUGE-UHFFFAOYSA-N; BDBM135825; US8853215, 3; 1-(2-tert-Butylphenyl)-4-(1H-imidazol-4-ylcarbonyl)piperazine
DMX8NLB	DT	Small molecular drug
DMX8NLB	PC	66751133
DMX8NLB	MW	312.4
DMX8NLB	FM	C18H24N4O
DMX8NLB	IC	InChI=1S/C18H24N4O/c1-18(2,3)14-6-4-5-7-16(14)21-8-10-22(11-9-21)17(23)15-12-19-13-20-15/h4-7,12-13H,8-11H2,1-3H3,(H,19,20)
DMX8NLB	CS	CC(C)(C)C1=CC=CC=C1N2CCN(CC2)C(=O)C3=CN=CN3
DMX8NLB	IK	DISALCDEOIPUGE-UHFFFAOYSA-N
DMX8NLB	IU	[4-(2-tert-butylphenyl)piperazin-1-yl]-(1H-imidazol-5-yl)methanone

DMDN8P1	ID	DMDN8P1
DMDN8P1	DN	US8877733, 27
DMDN8P1	HS	Patented
DMDN8P1	SN	BDBM139220; US8877733, 27
DMDN8P1	DT	Small molecular drug
DMDN8P1	PC	91669038
DMDN8P1	MW	525.19
DMDN8P1	FM	C11H18N3O15P3
DMDN8P1	IC	InChI=1S/C11H18N3O15P3/c1-10(18)8(16)6(4-26-31(22,23)29-32(24,25)28-30(19,20)21)27-11(10,5-12)14-3-2-7(15)13-9(14)17/h6,8,16,18H,2-4H2,1H3,(H,22,23)(H,24,25)(H,13,15,17)(H2,19,20,21)/t6-,8-,10-,11-/m0/s1
DMDN8P1	CS	C[C@@]1([C@H]([C@@H](O[C@]1(C#N)N2CCC(=O)NC2=O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMDN8P1	IK	OIFHDPSGRVTKRS-SEZOGAINSA-N
DMDN8P1	IU	[[(2S,3S,4S,5S)-5-cyano-5-(2,4-dioxo-1,3-diazinan-1-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

DMLY3RE	ID	DMLY3RE
DMLY3RE	DN	US8877733, 28
DMLY3RE	HS	Patented
DMLY3RE	SN	CHEMBL3686494; BDBM139221; US8877733, 28
DMLY3RE	DT	Small molecular drug
DMLY3RE	PC	91669039
DMLY3RE	MW	522.19
DMLY3RE	FM	C11H17N4O14P3
DMLY3RE	IC	InChI=1S/C11H17N4O14P3/c1-10(18)8(16)6(4-26-31(22,23)29-32(24,25)28-30(19,20)21)27-11(10,5-12)15-3-2-7(13)14-9(15)17/h2-3,6,8,16,18H,4H2,1H3,(H,22,23)(H,24,25)(H2,13,14,17)(H2,19,20,21)/t6-,8-,10-,11-/m0/s1
DMLY3RE	CS	C[C@@]1([C@H]([C@@H](O[C@]1(C#N)N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMLY3RE	IK	KAONGDYMRWWDBJ-SEZOGAINSA-N
DMLY3RE	IU	[[(2S,3S,4S,5S)-5-(4-amino-2-oxopyrimidin-1-yl)-5-cyano-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

DM8B1Q4	ID	DM8B1Q4
DM8B1Q4	DN	US8889672, 252-036-001
DM8B1Q4	HS	Patented
DM8B1Q4	SN	SCHEMBL13837647; CHEMBL2393427; BDBM139472; US8889672, 252-036-001
DM8B1Q4	DT	Small molecular drug
DM8B1Q4	PC	71009752
DM8B1Q4	MW	369.4
DM8B1Q4	FM	C20H19NO4S
DM8B1Q4	IC	InChI=1S/C20H19NO4S/c1-23-16-9-8-14(10-17(16)24-2)15-12-26-19(21)18(15)20(22)25-11-13-6-4-3-5-7-13/h3-10,12H,11,21H2,1-2H3
DM8B1Q4	CS	COC1=C(C=C(C=C1)C2=CSC(=C2C(=O)OCC3=CC=CC=C3)N)OC
DM8B1Q4	IK	DXFCCKZJJXVRFH-UHFFFAOYSA-N
DM8B1Q4	IU	benzyl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate

DMKXRJ4	ID	DMKXRJ4
DMKXRJ4	DN	US8889696, 39
DMKXRJ4	HS	Patented
DMKXRJ4	SN	CHEMBL3702566; SCHEMBL13385799; BDBM139539; US8889696, 39
DMKXRJ4	DT	Small molecular drug
DMKXRJ4	PC	70895719
DMKXRJ4	MW	417.5
DMKXRJ4	FM	C22H16FN5OS
DMKXRJ4	IC	InChI=1S/C22H16FN5OS/c1-28-20-14(11-19(21(28)29)30-17-5-2-15(23)3-6-17)12-25-22(27-20)26-16-4-7-18-13(10-16)8-9-24-18/h2-12,24H,1H3,(H,25,26,27)
DMKXRJ4	CS	CN1C2=NC(=NC=C2C=C(C1=O)SC3=CC=C(C=C3)F)NC4=CC5=C(C=C4)NC=C5
DMKXRJ4	IK	FJECSOOLAWUZAB-UHFFFAOYSA-N
DMKXRJ4	IU	6-(4-fluorophenyl)sulfanyl-2-(1H-indol-5-ylamino)-8-methylpyrido[2,3-d]pyrimidin-7-one

DMSYUHK	ID	DMSYUHK
DMSYUHK	DN	US8889696, Staurosporine
DMSYUHK	HS	Patented
DMSYUHK	SN	US8889696, Staurosporine; CHEMBL3683258; BDBM139540
DMSYUHK	DT	Small molecular drug
DMSYUHK	PC	91669270
DMSYUHK	MW	452.5
DMSYUHK	FM	C27H24N4O3
DMSYUHK	IC	InChI=1S/C27H24N4O3/c1-28-16-11-19-30-17-9-5-4-8-14(17)21-22-15(12-29-26(22)32)20-13-7-3-6-10-18(13)31(23(20)24(21)30)27(34-19)25(16)33-2/h3-10,16,19,25,27-28H,11-12H2,1-2H3,(H,29,32)/t16-,19?,25-,27?/m1/s1
DMSYUHK	CS	CN[C@@H]1CC2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N(C7=C53)C([C@@H]1OC)O2)CNC6=O
DMSYUHK	IK	YISMQBFJYDFMAL-AESIHLKFSA-N
DMSYUHK	IU	(3R,4R)-3-methoxy-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one

DMEAUJT	ID	DMEAUJT
DMEAUJT	DN	US8901295, F609
DMEAUJT	HS	Patented
DMEAUJT	SN	SCHEMBL2039766; CHEMBL3647430; BDBM140001; US8901295, F609
DMEAUJT	DT	Small molecular drug
DMEAUJT	PC	67257644
DMEAUJT	MW	382.5
DMEAUJT	FM	C21H26N4O3
DMEAUJT	IC	InChI=1S/C21H26N4O3/c1-28-19-7-3-2-5-17(19)18-6-4-12-25(18)20(26)14-24-21(27)23-13-15-8-10-16(22)11-9-15/h2-3,5,7-11,18H,4,6,12-14,22H2,1H3,(H2,23,24,27)
DMEAUJT	CS	COC1=CC=CC=C1C2CCCN2C(=O)CNC(=O)NCC3=CC=C(C=C3)N
DMEAUJT	IK	VJEMAKQKNYWEFQ-UHFFFAOYSA-N
DMEAUJT	IU	1-[(4-aminophenyl)methyl]-3-[2-[2-(2-methoxyphenyl)pyrrolidin-1-yl]-2-oxoethyl]urea

DMPICE1	ID	DMPICE1
DMPICE1	DN	US8901295, F673
DMPICE1	HS	Patented
DMPICE1	SN	SCHEMBL2039389; CHEMBL3639462; BDBM140003; US8901295, F673
DMPICE1	DT	Small molecular drug
DMPICE1	PC	67257505
DMPICE1	MW	386.9
DMPICE1	FM	C20H23ClN4O2
DMPICE1	IC	InChI=1S/C20H23ClN4O2/c21-17-5-2-1-4-16(17)18-6-3-11-25(18)19(26)13-24-20(27)23-12-14-7-9-15(22)10-8-14/h1-2,4-5,7-10,18H,3,6,11-13,22H2,(H2,23,24,27)
DMPICE1	CS	C1CC(N(C1)C(=O)CNC(=O)NCC2=CC=C(C=C2)N)C3=CC=CC=C3Cl
DMPICE1	IK	HPUOXERGZUDYRB-UHFFFAOYSA-N
DMPICE1	IU	1-[(4-aminophenyl)methyl]-3-[2-[2-(2-chlorophenyl)pyrrolidin-1-yl]-2-oxoethyl]urea

DM34KXF	ID	DM34KXF
DM34KXF	DN	US8921389, 1
DM34KXF	HS	Patented
DM34KXF	SN	CHEMBL3671864; SCHEMBL12503126; RKTAODJRDMTRFE-UHFFFAOYSA-N; BDBM141545; US8921389, 1; [(1-Benzyl-5-hydroxy-2-oxo-1,2,3,4-tetrahydro-[1,7]naphthyridine-6-carbonyl)-amino]-acetic acid; [(1-Benzyl-5-hydroxy-2-oxo-1,2,3,4-tetrahydro-[1,7]naphthyridine-6-carbonyl)-amino]acetic acid
DM34KXF	DT	Small molecular drug
DM34KXF	PC	60152762
DM34KXF	MW	355.3
DM34KXF	FM	C18H17N3O5
DM34KXF	IC	InChI=1S/C18H17N3O5/c22-14-7-6-12-13(21(14)10-11-4-2-1-3-5-11)8-19-16(17(12)25)18(26)20-9-15(23)24/h1-5,8,25H,6-7,9-10H2,(H,20,26)(H,23,24)
DM34KXF	CS	C1CC(=O)N(C2=CN=C(C(=C21)O)C(=O)NCC(=O)O)CC3=CC=CC=C3
DM34KXF	IK	RKTAODJRDMTRFE-UHFFFAOYSA-N
DM34KXF	IU	2-[(1-benzyl-5-hydroxy-2-oxo-3,4-dihydro-1,7-naphthyridine-6-carbonyl)amino]acetic acid

DM8NE12	ID	DM8NE12
DM8NE12	DN	US8921389, 123
DM8NE12	HS	Patented
DM8NE12	SN	SCHEMBL12502342; CHEMBL3639708; CJDQJFHCXLGXOK-UHFFFAOYSA-N; BDBM141666; US8921389, 123; 3-[(1-Benzyl-5-hydroxy-2-oxo-3-phenethyl-1,2-dihydro-[1,7]naphthyridine-6-carbonyl)-amino]-propionic acid
DM8NE12	DT	Small molecular drug
DM8NE12	PC	60151541
DM8NE12	MW	471.5
DM8NE12	FM	C27H25N3O5
DM8NE12	IC	InChI=1S/C27H25N3O5/c31-23(32)13-14-28-26(34)24-25(33)21-15-20(12-11-18-7-3-1-4-8-18)27(35)30(22(21)16-29-24)17-19-9-5-2-6-10-19/h1-10,15-16,33H,11-14,17H2,(H,28,34)(H,31,32)
DM8NE12	CS	C1=CC=C(C=C1)CCC2=CC3=C(C(=NC=C3N(C2=O)CC4=CC=CC=C4)C(=O)NCCC(=O)O)O
DM8NE12	IK	CJDQJFHCXLGXOK-UHFFFAOYSA-N
DM8NE12	IU	3-[[1-benzyl-5-hydroxy-2-oxo-3-(2-phenylethyl)-1,7-naphthyridine-6-carbonyl]amino]propanoic acid

DMX7KDR	ID	DMX7KDR
DMX7KDR	DN	US8921389, 2
DMX7KDR	HS	Patented
DMX7KDR	SN	SCHEMBL12502926; CHEMBL3671865; WGLKJEAEYYHYAM-UHFFFAOYSA-N; BDBM141546; US8921389, 2; [(1-Benzyl-5-hydroxy-3-methyl-2-oxo-1,2-dihydro-[1,7]naphthyridine-6-carbonyl)-amino]-acetic acid
DMX7KDR	DT	Small molecular drug
DMX7KDR	PC	60152763
DMX7KDR	MW	367.4
DMX7KDR	FM	C19H17N3O5
DMX7KDR	IC	InChI=1S/C19H17N3O5/c1-11-7-13-14(22(19(11)27)10-12-5-3-2-4-6-12)8-20-16(17(13)25)18(26)21-9-15(23)24/h2-8,25H,9-10H2,1H3,(H,21,26)(H,23,24)
DMX7KDR	CS	CC1=CC2=C(C(=NC=C2N(C1=O)CC3=CC=CC=C3)C(=O)NCC(=O)O)O
DMX7KDR	IK	WGLKJEAEYYHYAM-UHFFFAOYSA-N
DMX7KDR	IU	2-[(1-benzyl-5-hydroxy-3-methyl-2-oxo-1,7-naphthyridine-6-carbonyl)amino]acetic acid

DME1A80	ID	DME1A80
DME1A80	DN	US8921389, 210
DME1A80	HS	Patented
DME1A80	SN	SCHEMBL12502343; CHEMBL3639757; VSKYLKKDQYXUIH-UHFFFAOYSA-N; BDBM141750; US8921389, 210; 3-{[1-Benzyl-5-hydroxy-2-oxo-3-(2-trifluoromethyl-phenyl)-1,2-dihydro-[1,7]naphthyridine-6-carbonyl]-amino}-propionic acid
DME1A80	DT	Small molecular drug
DME1A80	PC	60152500
DME1A80	MW	511.4
DME1A80	FM	C26H20F3N3O5
DME1A80	IC	InChI=1S/C26H20F3N3O5/c27-26(28,29)19-9-5-4-8-16(19)17-12-18-20(32(25(17)37)14-15-6-2-1-3-7-15)13-31-22(23(18)35)24(36)30-11-10-21(33)34/h1-9,12-13,35H,10-11,14H2,(H,30,36)(H,33,34)
DME1A80	CS	C1=CC=C(C=C1)CN2C3=CN=C(C(=C3C=C(C2=O)C4=CC=CC=C4C(F)(F)F)O)C(=O)NCCC(=O)O
DME1A80	IK	VSKYLKKDQYXUIH-UHFFFAOYSA-N
DME1A80	IU	3-[[1-benzyl-5-hydroxy-2-oxo-3-[2-(trifluoromethyl)phenyl]-1,7-naphthyridine-6-carbonyl]amino]propanoic acid

DMIY68N	ID	DMIY68N
DMIY68N	DN	US8921389, 22
DMIY68N	HS	Patented
DMIY68N	SN	CHEMBL3639707; SCHEMBL12503102; DKTMWXXXKCITJR-UHFFFAOYSA-N; BDBM141566; US8921389, 22; 3-[(1,3-Dibenzyl-5-hydroxy-2-oxo-8-pyridin-3-yl-1,2-dihydro-[1,7]naphthyridine-6-carbonyl)-amino]-propionic acid
DMIY68N	DT	Small molecular drug
DMIY68N	PC	60152635
DMIY68N	MW	534.6
DMIY68N	FM	C31H26N4O5
DMIY68N	IC	InChI=1S/C31H26N4O5/c36-25(37)13-15-33-30(39)27-29(38)24-17-23(16-20-8-3-1-4-9-20)31(40)35(19-21-10-5-2-6-11-21)28(24)26(34-27)22-12-7-14-32-18-22/h1-12,14,17-18,38H,13,15-16,19H2,(H,33,39)(H,36,37)
DMIY68N	CS	C1=CC=C(C=C1)CC2=CC3=C(C(=NC(=C3O)C(=O)NCCC(=O)O)C4=CN=CC=C4)N(C2=O)CC5=CC=CC=C5
DMIY68N	IK	DKTMWXXXKCITJR-UHFFFAOYSA-N
DMIY68N	IU	3-[(1,3-dibenzyl-5-hydroxy-2-oxo-8-pyridin-3-yl-1,7-naphthyridine-6-carbonyl)amino]propanoic acid

DMG3T7E	ID	DMG3T7E
DMG3T7E	DN	US8933095, 1
DMG3T7E	HS	Patented
DMG3T7E	SN	CHEMBL2347107; SCHEMBL9912514; BDBM107746; US8933095, 1
DMG3T7E	DT	Small molecular drug
DMG3T7E	PC	67962992
DMG3T7E	MW	258.279
DMG3T7E	FM	C13H14N4O2
DMG3T7E	IC	InChI=1S/C13H14N4O2/c14-11-6-10-8-16(7-9-4-2-1-3-5-9)15-12(10)17(19)13(11)18/h1-5,8,11,19H,6-7,14H2/t11-/m0/s1
DMG3T7E	CS	C1[C@@H](C(=O)N(C2=NN(C=C21)CC3=CC=CC=C3)O)N
DMG3T7E	IK	YEHNWRNMGIYLAL-NSHDSACASA-N
DMG3T7E	IU	(5S)-5-amino-2-benzyl-7-hydroxy-4,5-dihydropyrazolo[3,4-b]pyridin-6-one

DMZUNJ4	ID	DMZUNJ4
DMZUNJ4	DN	US8933095, 14
DMZUNJ4	HS	Patented
DMZUNJ4	SN	CHEMBL2347108; SCHEMBL9280114; BDBM107730; US8933095, 14
DMZUNJ4	DT	Small molecular drug
DMZUNJ4	PC	67813781
DMZUNJ4	MW	244.25
DMZUNJ4	FM	C12H12N4O2
DMZUNJ4	IC	InChI=1S/C12H12N4O2/c13-10-6-8-7-15(9-4-2-1-3-5-9)14-11(8)16(18)12(10)17/h1-5,7,10,18H,6,13H2/t10-/m0/s1
DMZUNJ4	CS	C1[C@@H](C(=O)N(C2=NN(C=C21)C3=CC=CC=C3)O)N
DMZUNJ4	IK	AUAOKUNOKVGYJP-JTQLQIEISA-N
DMZUNJ4	IU	(5S)-5-amino-7-hydroxy-2-phenyl-4,5-dihydropyrazolo[3,4-b]pyridin-6-one

DMRN5F4	ID	DMRN5F4
DMRN5F4	DN	US8933095, 16
DMRN5F4	HS	Patented
DMRN5F4	SN	CHEMBL2347109; SCHEMBL15493583; BDBM50432200; US8933095, 16
DMRN5F4	DT	Small molecular drug
DMRN5F4	PC	71717745
DMRN5F4	MW	244.25
DMRN5F4	FM	C12H12N4O2
DMRN5F4	IC	InChI=1S/C12H12N4O2/c13-9-6-10-11(16(18)12(9)17)7-15(14-10)8-4-2-1-3-5-8/h1-5,7,9,18H,6,13H2/t9-/m0/s1
DMRN5F4	CS	C1[C@@H](C(=O)N(C2=CN(N=C21)C3=CC=CC=C3)O)N
DMRN5F4	IK	LHLQHHDRLPOVCF-VIFPVBQESA-N
DMRN5F4	IU	(6S)-6-amino-4-hydroxy-2-phenyl-6,7-dihydropyrazolo[4,3-b]pyridin-5-one

DMOZ4FS	ID	DMOZ4FS
DMOZ4FS	DN	US8933095, 18
DMOZ4FS	HS	Patented
DMOZ4FS	SN	CHEMBL2347111; SCHEMBL9912531; BDBM107734; US8933095, 18
DMOZ4FS	DT	Small molecular drug
DMOZ4FS	PC	67963001
DMOZ4FS	MW	182.18
DMOZ4FS	FM	C7H10N4O2
DMOZ4FS	IC	InChI=1S/C7H10N4O2/c1-10-6-4(3-9-10)2-5(8)7(12)11(6)13/h3,5,13H,2,8H2,1H3/t5-/m0/s1
DMOZ4FS	CS	CN1C2=C(C[C@@H](C(=O)N2O)N)C=N1
DMOZ4FS	IK	OETBHDOEBPITJA-YFKPBYRVSA-N
DMOZ4FS	IU	(5S)-5-amino-7-hydroxy-1-methyl-4,5-dihydropyrazolo[3,4-b]pyridin-6-one

DMPNCOL	ID	DMPNCOL
DMPNCOL	DN	US8933228, 3
DMPNCOL	HS	Patented
DMPNCOL	SN	SCHEMBL12434738; CHEMBL1090979; BDBM142601; US8933228, 3
DMPNCOL	DT	Small molecular drug
DMPNCOL	PC	46198319
DMPNCOL	MW	561.6
DMPNCOL	FM	C32H31N7O3
DMPNCOL	IC	InChI=1S/C32H31N7O3/c1-19-10-12-20(13-11-19)39-27(18-26(37-39)32(2,3)4)35-30(40)34-23-14-15-24(22-9-7-6-8-21(22)23)42-25-16-17-33-29-28(25)38(5)31(41)36-29/h6-18H,1-5H3,(H,33,36,41)(H2,34,35,40)
DMPNCOL	CS	CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OC5=C6C(=NC=C5)NC(=O)N6C
DMPNCOL	IK	JIFZZVZROIFPKB-UHFFFAOYSA-N
DMPNCOL	IU	1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[(1-methyl-2-oxo-3H-imidazo[4,5-b]pyridin-7-yl)oxy]naphthalen-1-yl]urea

DMKEX51	ID	DMKEX51
DMKEX51	DN	US8933228, Ref 2
DMKEX51	HS	Patented
DMKEX51	SN	SCHEMBL2531614; CHEMBL3695569; AVUUHIYJPTWYNX-UHFFFAOYSA-N; BDBM142598; US8933228, Ref 2; N-(4-(4-(3-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)pyridin-2-yl)-2-methoxyacetamide
DMKEX51	DT	Small molecular drug
DMKEX51	PC	46218331
DMKEX51	MW	578.7
DMKEX51	FM	C33H34N6O4
DMKEX51	IC	InChI=1S/C33H34N6O4/c1-21-10-12-22(13-11-21)39-30(19-28(38-39)33(2,3)4)37-32(41)35-26-14-15-27(25-9-7-6-8-24(25)26)43-23-16-17-34-29(18-23)36-31(40)20-42-5/h6-19H,20H2,1-5H3,(H,34,36,40)(H2,35,37,41)
DMKEX51	CS	CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OC5=CC(=NC=C5)NC(=O)COC
DMKEX51	IK	AVUUHIYJPTWYNX-UHFFFAOYSA-N
DMKEX51	IU	N-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyridin-2-yl]-2-methoxyacetamide

DM6EMYB	ID	DM6EMYB
DM6EMYB	DN	US8937193-compound-6b
DM6EMYB	HS	Patented
DM6EMYB	DT	Small molecular drug
DM6EMYB	PC	136183441
DM6EMYB	MW	518.6
DM6EMYB	FM	C30H30O8
DM6EMYB	IC	InChI=1S/C30H30O8/c1-11(2)7-15-23-17(9-19(31)27(15)35)29(37)21(13(5)25(23)33)22-14(6)26(34)24-16(8-12(3)4)28(36)20(32)10-18(24)30(22)38/h9-12,31,33,35,37H,7-8H2,1-6H3
DM6EMYB	CS	CC1=C(C(=O)C2=CC(=O)C(=O)C(=C2C1=O)CC(C)C)C3=C(C4=CC(=C(C(=C4C(=C3C)O)CC(C)C)O)O)O
DM6EMYB	IK	WDQZGCJOCKBUQY-UHFFFAOYSA-N
DM6EMYB	IU	3-methyl-5-(2-methylpropyl)-2-[1,4,6,7-tetrahydroxy-3-methyl-5-(2-methylpropyl)naphthalen-2-yl]naphthalene-1,4,6,7-tetrone

DMHZJEA	ID	DMHZJEA
DMHZJEA	DN	US8937193-compound-7
DMHZJEA	HS	Patented
DMHZJEA	SN	CHEMBL1269072
DMHZJEA	DT	Small molecular drug
DMHZJEA	PC	136002683
DMHZJEA	MW	642.6
DMHZJEA	FM	C38H26O10
DMHZJEA	IC	InChI=1S/C38H26O10/c1-17-27(35(45)21-15-25(41)37(47)31(29(21)33(17)43)23(39)13-19-9-5-3-6-10-19)28-18(2)34(44)30-22(36(28)46)16-26(42)38(48)32(30)24(40)14-20-11-7-4-8-12-20/h3-12,15-16,41,43,45,47H,13-14H2,1-2H3
DMHZJEA	CS	CC1=C(C(=O)C2=CC(=O)C(=O)C(=C2C1=O)C(=O)CC3=CC=CC=C3)C4=C(C5=CC(=C(C(=C5C(=C4C)O)C(=O)CC6=CC=CC=C6)O)O)O
DMHZJEA	IK	SAXRAWJDCMFHQD-UHFFFAOYSA-N
DMHZJEA	IU	3-methyl-5-(2-phenylacetyl)-2-[1,4,6,7-tetrahydroxy-3-methyl-5-(2-phenylacetyl)naphthalen-2-yl]naphthalene-1,4,6,7-tetrone

DM3PU57	ID	DM3PU57
DM3PU57	DN	US8940736, 23
DM3PU57	HS	Patented
DM3PU57	SN	CHEMBL3699236; SCHEMBL15425350; BDBM142776; US8940736, 23
DM3PU57	DT	Small molecular drug
DM3PU57	PC	72948498
DM3PU57	MW	460.9
DM3PU57	FM	C22H21ClN10
DM3PU57	IC	InChI=1S/C22H21ClN10/c1-31-9-22(10-31)11-32(12-22)17-5-13(6-24)4-16(18(17)23)28-21-29-19(27-14-2-3-14)20-26-8-15(7-25)33(20)30-21/h4-5,8,14H,2-3,9-12H2,1H3,(H2,27,28,29,30)
DM3PU57	CS	CN1CC2(C1)CN(C2)C3=CC(=CC(=C3Cl)NC4=NN5C(=CN=C5C(=N4)NC6CC6)C#N)C#N
DM3PU57	IK	UGYSMTLFOSQOTN-UHFFFAOYSA-N
DM3PU57	IU	2-[2-chloro-5-cyano-3-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile

DMXY4SP	ID	DMXY4SP
DMXY4SP	DN	US8940736, 6
DMXY4SP	HS	Patented
DMXY4SP	SN	SCHEMBL15408873; CHEMBL3699234; BDBM142774; US8940736, 6
DMXY4SP	DT	Small molecular drug
DMXY4SP	PC	89919749
DMXY4SP	MW	370.4
DMXY4SP	FM	C18H14N10
DMXY4SP	IC	InChI=1S/C18H14N10/c1-27-15-5-4-11(6-13(15)14(8-20)25-27)23-18-24-16(22-10-2-3-10)17-21-9-12(7-19)28(17)26-18/h4-6,9-10H,2-3H2,1H3,(H2,22,23,24,26)
DMXY4SP	CS	CN1C2=C(C=C(C=C2)NC3=NN4C(=CN=C4C(=N3)NC5CC5)C#N)C(=N1)C#N
DMXY4SP	IK	JAQNOWSPKHFMOW-UHFFFAOYSA-N
DMXY4SP	IU	2-[(3-cyano-1-methylindazol-5-yl)amino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile

DM9KSVI	ID	DM9KSVI
DM9KSVI	DN	US8940736, 7
DM9KSVI	HS	Patented
DM9KSVI	SN	CHEMBL3699235; SCHEMBL15408805; BDBM142775; US8940736, 7
DM9KSVI	DT	Small molecular drug
DM9KSVI	PC	89919708
DM9KSVI	MW	435.9
DM9KSVI	FM	C20H18ClN9O
DM9KSVI	IC	InChI=1S/C20H18ClN9O/c21-17-15(5-11(7-22)6-16(17)29-4-3-14(31)10-29)26-20-27-18(25-12-1-2-12)19-24-9-13(8-23)30(19)28-20/h5-6,9,12,14,31H,1-4,10H2,(H2,25,26,27,28)
DM9KSVI	CS	C1CC1NC2=NC(=NN3C2=NC=C3C#N)NC4=C(C(=CC(=C4)C#N)N5CCC(C5)O)Cl
DM9KSVI	IK	XMYPWCUEOAYOMV-UHFFFAOYSA-N
DM9KSVI	IU	2-[2-chloro-5-cyano-3-(3-hydroxypyrrolidin-1-yl)anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile

DM4S5DF	ID	DM4S5DF
DM4S5DF	DN	US8975409, Comparative compound B
DM4S5DF	HS	Patented
DM4S5DF	SN	SCHEMBL5912478; CHEMBL3401375; BDBM149711; US8975409, Comparative compound B
DM4S5DF	DT	Small molecular drug
DM4S5DF	PC	23071856
DM4S5DF	MW	414.5
DM4S5DF	FM	C24H31FN2O3
DM4S5DF	IC	InChI=1S/C24H31FN2O3/c1-3-18(4-2)17-24(29)12-14-27(15-13-24)23(28)26-20-6-5-7-22(16-20)30-21-10-8-19(25)9-11-21/h5-11,16,18,29H,3-4,12-15,17H2,1-2H3,(H,26,28)
DM4S5DF	CS	CCC(CC)CC1(CCN(CC1)C(=O)NC2=CC(=CC=C2)OC3=CC=C(C=C3)F)O
DM4S5DF	IK	QDTNDGDKXXSUJU-UHFFFAOYSA-N
DM4S5DF	IU	4-(2-ethylbutyl)-N-[3-(4-fluorophenoxy)phenyl]-4-hydroxypiperidine-1-carboxamide

DMVB42P	ID	DMVB42P
DMVB42P	DN	US8975409, Example 13
DMVB42P	HS	Patented
DMVB42P	SN	SCHEMBL14839321; CHEMBL3703198; US8975409, Example 13; BDBM149706
DMVB42P	DT	Small molecular drug
DMVB42P	PC	89484778
DMVB42P	MW	590.7
DMVB42P	FM	C34H39FN2O6
DMVB42P	IC	InChI=1S/C34H39FN2O6/c1-3-23(4-2)22-33(41)15-17-37(18-16-33)32(40)36-26-19-29(21-30(20-26)43-28-11-7-25(35)8-12-28)42-27-9-5-24(6-10-27)34(13-14-34)31(38)39/h5-12,19-21,23,41H,3-4,13-18,22H2,1-2H3,(H,36,40)(H,38,39)
DMVB42P	CS	CCC(CC)CC1(CCN(CC1)C(=O)NC2=CC(=CC(=C2)OC3=CC=C(C=C3)F)OC4=CC=C(C=C4)C5(CC5)C(=O)O)O
DMVB42P	IK	UZPSRIVFHKJDOL-UHFFFAOYSA-N
DMVB42P	IU	1-[4-[3-[[4-(2-ethylbutyl)-4-hydroxypiperidine-1-carbonyl]amino]-5-(4-fluorophenoxy)phenoxy]phenyl]cyclopropane-1-carboxylic acid

DMJQOAE	ID	DMJQOAE
DMJQOAE	DN	US8975409, Example 9(3)
DMJQOAE	HS	Patented
DMJQOAE	SN	SCHEMBL14839451; CHEMBL3618201; BDBM149705; US8975409, Example 9(3)
DMJQOAE	DT	Small molecular drug
DMJQOAE	PC	71547555
DMJQOAE	MW	560.5
DMJQOAE	FM	C31H26F2N2O6
DMJQOAE	IC	InChI=1S/C31H26F2N2O6/c32-22-5-3-21(4-6-22)31(39)13-15-35(16-14-31)30(38)34-24-17-27(40-25-9-1-20(2-10-25)29(36)37)19-28(18-24)41-26-11-7-23(33)8-12-26/h1-12,17-19,39H,13-16H2,(H,34,38)(H,36,37)
DMJQOAE	CS	C1CN(CCC1(C2=CC=C(C=C2)F)O)C(=O)NC3=CC(=CC(=C3)OC4=CC=C(C=C4)F)OC5=CC=C(C=C5)C(=O)O
DMJQOAE	IK	PZFBUIYFAFMDBM-UHFFFAOYSA-N
DMJQOAE	IU	4-[3-(4-fluorophenoxy)-5-[[4-(4-fluorophenyl)-4-hydroxypiperidine-1-carbonyl]amino]phenoxy]benzoic acid

DM4MRP9	ID	DM4MRP9
DM4MRP9	DN	US8987457, 117
DM4MRP9	HS	Patented
DM4MRP9	SN	CHEMBL3639863; SCHEMBL16579588; BDBM151923; US8987457, 117
DM4MRP9	DT	Small molecular drug
DM4MRP9	PC	91937577
DM4MRP9	MW	570.6
DM4MRP9	FM	C30H33F3N4O4
DM4MRP9	IC	InChI=1S/C30H33F3N4O4/c1-16-11-17(12-23(34)28(16)40-2)19-5-8-35-15-25(19)37-29(38)24-4-3-20(31)27(36-24)26-21(32)13-18(14-22(26)33)30(39)6-9-41-10-7-30/h3-5,8,13-17,23,28,39H,6-7,9-12,34H2,1-2H3,(H,37,38)/t16-,17+,23+,28+/m0/s1
DM4MRP9	CS	C[C@H]1C[C@H](C[C@H]([C@@H]1OC)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=C(C=C4F)C5(CCOCC5)O)F
DM4MRP9	IK	KRXHIAQHNCEJEE-XCPDJCNPSA-N
DM4MRP9	IU	N-[4-[(1R,3R,4R,5S)-3-amino-4-methoxy-5-methylcyclohexyl]pyridin-3-yl]-6-[2,6-difluoro-4-(4-hydroxyoxan-4-yl)phenyl]-5-fluoropyridine-2-carboxamide

DMAGNEH	ID	DMAGNEH
DMAGNEH	DN	US8987457, 15
DMAGNEH	HS	Patented
DMAGNEH	SN	CHEMBL3639862; SCHEMBL15588795; XQMOXTIXSKOQJT-LCNIEQOASA-N; BDBM151821; US8987457, 15; N-(4-((1R,3R,4S,5S)-3-amino-4-(2-hydroxyethylsulfonyl)-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide
DMAGNEH	DT	Small molecular drug
DMAGNEH	PC	90055863
DMAGNEH	MW	548.6
DMAGNEH	FM	C26H27F3N4O4S
DMAGNEH	IC	InChI=1S/C26H27F3N4O4S/c1-14-11-15(12-20(30)25(14)38(36,37)10-9-34)16-7-8-31-13-22(16)33-26(35)21-6-5-19(29)24(32-21)23-17(27)3-2-4-18(23)28/h2-8,13-15,20,25,34H,9-12,30H2,1H3,(H,33,35)/t14-,15+,20+,25-/m0/s1
DMAGNEH	CS	C[C@H]1C[C@H](C[C@H]([C@H]1S(=O)(=O)CCO)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=CC=C4F)F
DMAGNEH	IK	XQMOXTIXSKOQJT-LCNIEQOASA-N
DMAGNEH	IU	N-[4-[(1R,3R,4S,5S)-3-amino-4-(2-hydroxyethylsulfonyl)-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide

DM0O8WS	ID	DM0O8WS
DM0O8WS	DN	US8987457, 198
DM0O8WS	HS	Patented
DM0O8WS	SN	SCHEMBL16588183; CHEMBL3639908; BDBM152004; US8987457, 198
DM0O8WS	DT	Small molecular drug
DM0O8WS	PC	91937649
DM0O8WS	MW	578.6
DM0O8WS	FM	C29H35FN8O4
DM0O8WS	IC	InChI=1S/C29H35FN8O4/c1-15(2)34-27(39)17-5-6-19(30)18(11-17)22-8-7-20(31)26(35-22)28(40)36-23-12-33-10-9-24(23)38-13-16(3)25(21(32)14-38)37-29(41)42-4/h5-12,15-16,21,25H,13-14,31-32H2,1-4H3,(H,34,39)(H,36,40)(H,37,41)/t16-,21+,25-/m0/s1
DM0O8WS	CS	C[C@H]1CN(C[C@H]([C@H]1NC(=O)OC)N)C2=C(C=NC=C2)NC(=O)C3=C(C=CC(=N3)C4=C(C=CC(=C4)C(=O)NC(C)C)F)N
DM0O8WS	IK	FGLBTUNMAVXKMV-LMNXFLSBSA-N
DM0O8WS	IU	methyl N-[(3R,4S,5S)-3-amino-1-[3-[[3-amino-6-[2-fluoro-5-(propan-2-ylcarbamoyl)phenyl]pyridine-2-carbonyl]amino]pyridin-4-yl]-5-methylpiperidin-4-yl]carbamate

DMBF1C0	ID	DMBF1C0
DMBF1C0	DN	US9006244, E1
DMBF1C0	HS	Patented
DMBF1C0	SN	CHEMBL3672843; SCHEMBL15273081; SEQLXXRHDQNPMX-UHFFFAOYSA-N; US9006244, E1; 1-isopropyl-7-(methylsulfonyl)-2-(4-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyrazine
DMBF1C0	DT	Small molecular drug
DMBF1C0	PC	89815984
DMBF1C0	MW	439.5
DMBF1C0	FM	C19H20F3N5O2S
DMBF1C0	IC	InChI=1S/C19H20F3N5O2S/c1-11(2)16-17-24-13-5-4-12(30(3,28)29)10-14(13)26(17)8-9-27(16)18-23-7-6-15(25-18)19(20,21)22/h4-7,10-11,16H,8-9H2,1-3H3
DMBF1C0	CS	CC(C)C1C2=NC3=C(N2CCN1C4=NC=CC(=N4)C(F)(F)F)C=C(C=C3)S(=O)(=O)C
DMBF1C0	IK	SEQLXXRHDQNPMX-UHFFFAOYSA-N
DMBF1C0	IU	7-methylsulfonyl-1-propan-2-yl-2-[4-(trifluoromethyl)pyrimidin-2-yl]-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazole

DMPDF9B	ID	DMPDF9B
DMPDF9B	DN	US9006244, E2a
DMPDF9B	HS	Patented
DMPDF9B	SN	SCHEMBL15272683; CHEMBL3672844; US9006244, E2a
DMPDF9B	DT	Small molecular drug
DMPDF9B	PC	71735263
DMPDF9B	MW	469.5
DMPDF9B	FM	C20H22F3N5O3S
DMPDF9B	IC	InChI=1S/C20H22F3N5O3S/c1-11(2)17-18-25-13-8-12(10-29)15(32(3,30)31)9-14(13)27(18)6-7-28(17)19-24-5-4-16(26-19)20(21,22)23/h4-5,8-9,11,17,29H,6-7,10H2,1-3H3/t17-/m1/s1
DMPDF9B	CS	CC(C)[C@@H]1C2=NC3=C(N2CCN1C4=NC=CC(=N4)C(F)(F)F)C=C(C(=C3)CO)S(=O)(=O)C
DMPDF9B	IK	CABUZECPUSGGRX-QGZVFWFLSA-N
DMPDF9B	IU	[(1R)-7-methylsulfonyl-1-propan-2-yl-2-[4-(trifluoromethyl)pyrimidin-2-yl]-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]methanol

DMP0TBO	ID	DMP0TBO
DMP0TBO	DN	US9006244, E2b
DMP0TBO	HS	Patented
DMP0TBO	SN	CHEMBL3672845; SCHEMBL15273196; US9006244, E2b
DMP0TBO	DT	Small molecular drug
DMP0TBO	PC	71735264
DMP0TBO	MW	469.5
DMP0TBO	FM	C20H22F3N5O3S
DMP0TBO	IC	InChI=1S/C20H22F3N5O3S/c1-11(2)17-18-25-13-8-12(10-29)15(32(3,30)31)9-14(13)27(18)6-7-28(17)19-24-5-4-16(26-19)20(21,22)23/h4-5,8-9,11,17,29H,6-7,10H2,1-3H3/t17-/m0/s1
DMP0TBO	CS	CC(C)[C@H]1C2=NC3=C(N2CCN1C4=NC=CC(=N4)C(F)(F)F)C=C(C(=C3)CO)S(=O)(=O)C
DMP0TBO	IK	CABUZECPUSGGRX-KRWDZBQOSA-N
DMP0TBO	IU	[(1S)-7-methylsulfonyl-1-propan-2-yl-2-[4-(trifluoromethyl)pyrimidin-2-yl]-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]methanol

DMPGY0M	ID	DMPGY0M
DMPGY0M	DN	US9024044, 1
DMPGY0M	HS	Patented
DMPGY0M	SN	CHEMBL3667879; SCHEMBL15605530; BDBM158073; US9024044, 1
DMPGY0M	DT	Small molecular drug
DMPGY0M	PC	72699917
DMPGY0M	MW	491.5
DMPGY0M	FM	C22H22FN3O7S
DMPGY0M	IC	InChI=1S/C22H22FN3O7S/c23-13-8-11(18(24)25)2-4-15(13)33-20(31)16-5-3-12(34-16)10-22(6-1-7-22)21(32)26-14(19(29)30)9-17(27)28/h2-5,8,14H,1,6-7,9-10H2,(H3,24,25)(H,26,32)(H,27,28)(H,29,30)/t14-/m0/s1
DMPGY0M	CS	C1CC(C1)(CC2=CC=C(S2)C(=O)OC3=C(C=C(C=C3)C(=N)N)F)C(=O)N[C@@H](CC(=O)O)C(=O)O
DMPGY0M	IK	CHAXFLSDNLDWPP-AWEZNQCLSA-N
DMPGY0M	IU	(2S)-2-[[1-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]cyclobutanecarbonyl]amino]butanedioic acid

DMWRXS8	ID	DMWRXS8
DMWRXS8	DN	US9024044, 2
DMWRXS8	HS	Patented
DMWRXS8	SN	SCHEMBL16623616; CHEMBL3667880; BDBM158074; US9024044, 2
DMWRXS8	DT	Small molecular drug
DMWRXS8	PC	90019132
DMWRXS8	MW	505.5
DMWRXS8	FM	C23H24FN3O7S
DMWRXS8	IC	InChI=1S/C23H24FN3O7S/c24-14-9-12(19(25)26)3-5-16(14)34-21(32)17-6-4-13(35-17)11-23(7-1-2-8-23)22(33)27-15(20(30)31)10-18(28)29/h3-6,9,15H,1-2,7-8,10-11H2,(H3,25,26)(H,27,33)(H,28,29)(H,30,31)/t15-/m0/s1
DMWRXS8	CS	C1CCC(C1)(CC2=CC=C(S2)C(=O)OC3=C(C=C(C=C3)C(=N)N)F)C(=O)N[C@@H](CC(=O)O)C(=O)O
DMWRXS8	IK	HXDKJHJAMFQXBA-HNNXBMFYSA-N
DMWRXS8	IU	(2S)-2-[[1-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]cyclopentanecarbonyl]amino]butanedioic acid

DMKNDMB	ID	DMKNDMB
DMKNDMB	DN	US9024044, 3
DMKNDMB	HS	Patented
DMKNDMB	SN	SCHEMBL15605631; CHEMBL3667881; BDBM158075; US9024044, 3
DMKNDMB	DT	Small molecular drug
DMKNDMB	PC	72699918
DMKNDMB	MW	421.4
DMKNDMB	FM	C19H20FN3O5S
DMKNDMB	IC	InChI=1S/C19H20FN3O5S/c1-19(2,18(27)23-9-15(24)25)8-11-4-6-14(29-11)17(26)28-13-5-3-10(16(21)22)7-12(13)20/h3-7H,8-9H2,1-2H3,(H3,21,22)(H,23,27)(H,24,25)
DMKNDMB	CS	CC(C)(CC1=CC=C(S1)C(=O)OC2=C(C=C(C=C2)C(=N)N)F)C(=O)NCC(=O)O
DMKNDMB	IK	FBFZNZYSXBOYCU-UHFFFAOYSA-N
DMKNDMB	IU	2-[[3-[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]-2,2-dimethylpropanoyl]amino]acetic acid

DMANFK8	ID	DMANFK8
DMANFK8	DN	US9024044, 4
DMANFK8	HS	Patented
DMANFK8	SN	SCHEMBL15605510; CHEMBL3667882; BDBM158076; US9024044, 4
DMANFK8	DT	Small molecular drug
DMANFK8	PC	72699919
DMANFK8	MW	451.5
DMANFK8	FM	C20H22FN3O6S
DMANFK8	IC	InChI=1S/C20H22FN3O6S/c1-20(2,19(29)24-13(9-25)17(26)27)8-11-4-6-15(31-11)18(28)30-14-5-3-10(16(22)23)7-12(14)21/h3-7,13,25H,8-9H2,1-2H3,(H3,22,23)(H,24,29)(H,26,27)/t13-/m0/s1
DMANFK8	CS	CC(C)(CC1=CC=C(S1)C(=O)OC2=C(C=C(C=C2)C(=N)N)F)C(=O)N[C@@H](CO)C(=O)O
DMANFK8	IK	PGOXWLZRNRRTHV-ZDUSSCGKSA-N
DMANFK8	IU	(2S)-2-[[3-[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]-2,2-dimethylpropanoyl]amino]-3-hydroxypropanoic acid

DMZKGOX	ID	DMZKGOX
DMZKGOX	DN	US9024044, 62
DMZKGOX	HS	Patented
DMZKGOX	SN	SCHEMBL16623655; CHEMBL3639717; BDBM158134; US9024044, 62
DMZKGOX	DT	Small molecular drug
DMZKGOX	PC	92044970
DMZKGOX	MW	491.6
DMZKGOX	FM	C24H30FN3O5S
DMZKGOX	IC	InChI=1S/C24H30FN3O5S/c1-3-24(4-2,23(32)28-12-6-5-7-20(29)30)14-16-9-11-19(34-16)22(31)33-18-10-8-15(21(26)27)13-17(18)25/h8-11,13H,3-7,12,14H2,1-2H3,(H3,26,27)(H,28,32)(H,29,30)
DMZKGOX	CS	CCC(CC)(CC1=CC=C(S1)C(=O)OC2=C(C=C(C=C2)C(=N)N)F)C(=O)NCCCCC(=O)O
DMZKGOX	IK	JBHHRVQRHSBNTN-UHFFFAOYSA-N
DMZKGOX	IU	5-[[2-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]-2-ethylbutanoyl]amino]pentanoic acid

DMDELNU	ID	DMDELNU
DMDELNU	DN	US9040714, 155
DMDELNU	HS	Patented
DMDELNU	SN	SCHEMBL14916256; CHEMBL3639669; BDBM160441; US9040714, 155
DMDELNU	DT	Small molecular drug
DMDELNU	PC	89541971
DMDELNU	MW	377.4
DMDELNU	FM	C19H23NO7
DMDELNU	IC	InChI=1S/C19H23NO7/c1-4-20-16(23)6-5-12-11(2)17-15(26-8-7-25-3)9-14(22)13(10-21)18(17)27-19(12)24/h9-10,22H,4-8H2,1-3H3,(H,20,23)
DMDELNU	CS	CCNC(=O)CCC1=C(C2=C(C=C(C(=C2OC1=O)C=O)O)OCCOC)C
DMDELNU	IK	LPHJXGTWAKQUGZ-UHFFFAOYSA-N
DMDELNU	IU	N-ethyl-3-[8-formyl-7-hydroxy-5-(2-methoxyethoxy)-4-methyl-2-oxochromen-3-yl]propanamide

DM53Z4I	ID	DM53Z4I
DM53Z4I	DN	US9040714, 7
DM53Z4I	HS	Patented
DM53Z4I	SN	SCHEMBL14924888; CHEMBL3639668; BDBM160340; US9040714, 7
DM53Z4I	DT	Small molecular drug
DM53Z4I	PC	89548086
DM53Z4I	MW	345.14
DM53Z4I	FM	C16H9BrO4
DM53Z4I	IC	InChI=1S/C16H9BrO4/c17-11-4-1-9(2-5-11)12-7-10-3-6-14(19)13(8-18)15(10)21-16(12)20/h1-8,19H
DM53Z4I	CS	C1=CC(=CC=C1C2=CC3=C(C(=C(C=C3)O)C=O)OC2=O)Br
DM53Z4I	IK	DJSPMRZGTUKARX-UHFFFAOYSA-N
DM53Z4I	IU	3-(4-bromophenyl)-7-hydroxy-2-oxochromene-8-carbaldehyde

DM2Z43I	ID	DM2Z43I
DM2Z43I	DN	US9073931, E1
DM2Z43I	HS	Patented
DM2Z43I	SN	CHEMBL3673668; SCHEMBL15273071; UVRFHLLVIGMMMM-UHFFFAOYSA-N; BDBM168072; US9073931, E1; 1-(2-(1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)ethanone
DM2Z43I	DT	Small molecular drug
DM2Z43I	PC	71735986
DM2Z43I	MW	481.5
DM2Z43I	FM	C21H22F3N5O3S
DM2Z43I	IC	InChI=1S/C21H22F3N5O3S/c1-11(2)17-19-26-15-6-5-13(33(4,31)32)9-16(15)28(19)7-8-29(17)20-25-10-14(12(3)30)18(27-20)21(22,23)24/h5-6,9-11,17H,7-8H2,1-4H3
DM2Z43I	CS	CC(C)C1C2=NC3=C(N2CCN1C4=NC=C(C(=N4)C(F)(F)F)C(=O)C)C=C(C=C3)S(=O)(=O)C
DM2Z43I	IK	UVRFHLLVIGMMMM-UHFFFAOYSA-N
DM2Z43I	IU	1-[2-(7-methylsulfonyl-1-propan-2-yl-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-2-yl)-4-(trifluoromethyl)pyrimidin-5-yl]ethanone

DMK9FJG	ID	DMK9FJG
DMK9FJG	DN	US9073931, E2
DMK9FJG	HS	Patented
DMK9FJG	SN	SCHEMBL15273082; CHEMBL3673669; LOFRRPNYSLDHRM-UHFFFAOYSA-N; BDBM168073; US9073931, E2; 2-(2-(1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)propan-2-ol
DMK9FJG	DT	Small molecular drug
DMK9FJG	PC	71735987
DMK9FJG	MW	497.5
DMK9FJG	FM	C22H26F3N5O3S
DMK9FJG	IC	InChI=1S/C22H26F3N5O3S/c1-12(2)17-19-27-15-7-6-13(34(5,32)33)10-16(15)29(19)8-9-30(17)20-26-11-14(21(3,4)31)18(28-20)22(23,24)25/h6-7,10-12,17,31H,8-9H2,1-5H3
DMK9FJG	CS	CC(C)C1C2=NC3=C(N2CCN1C4=NC=C(C(=N4)C(F)(F)F)C(C)(C)O)C=C(C=C3)S(=O)(=O)C
DMK9FJG	IK	LOFRRPNYSLDHRM-UHFFFAOYSA-N
DMK9FJG	IU	2-[2-(7-methylsulfonyl-1-propan-2-yl-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-2-yl)-4-(trifluoromethyl)pyrimidin-5-yl]propan-2-ol

DMCYM8P	ID	DMCYM8P
DMCYM8P	DN	US9073931, E3
DMCYM8P	HS	Patented
DMCYM8P	SN	SCHEMBL15273343; CHEMBL3673670; VWVWWPZPLJBDBN-UHFFFAOYSA-N; BDBM168074; US9073931, E3; ethyl 2-(1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2 (1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylate; ethyl 2-(1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylate
DMCYM8P	DT	Small molecular drug
DMCYM8P	PC	71735988
DMCYM8P	MW	511.5
DMCYM8P	FM	C22H24F3N5O4S
DMCYM8P	IC	InChI=1S/C22H24F3N5O4S/c1-5-34-20(31)14-11-26-21(28-18(14)22(23,24)25)30-9-8-29-16-10-13(35(4,32)33)6-7-15(16)27-19(29)17(30)12(2)3/h6-7,10-12,17H,5,8-9H2,1-4H3
DMCYM8P	CS	CCOC(=O)C1=CN=C(N=C1C(F)(F)F)N2CCN3C4=C(C=CC(=C4)S(=O)(=O)C)N=C3C2C(C)C
DMCYM8P	IK	VWVWWPZPLJBDBN-UHFFFAOYSA-N
DMCYM8P	IU	ethyl 2-(7-methylsulfonyl-1-propan-2-yl-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-2-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylate

DMZD1L5	ID	DMZD1L5
DMZD1L5	DN	US9073936, 1
DMZD1L5	HS	Patented
DMZD1L5	SN	SCHEMBL16036074; CHEMBL3678504; RKEUHNQOPBPRQD-UHFFFAOYSA-N; BDBM168126; US9073936, 1; 7,8-Dihydro-2-(4-acetylbenzyl)-3-(4-fluorophenylamino)-5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one
DMZD1L5	DT	Small molecular drug
DMZD1L5	PC	90409046
DMZD1L5	MW	460.5
DMZD1L5	FM	C25H25FN6O2
DMZD1L5	IC	InChI=1S/C25H25FN6O2/c1-15(33)17-7-5-16(6-8-17)13-32-21(27-19-11-9-18(26)10-12-19)20-22(29-32)31-14-25(2,3)28-24(31)30(4)23(20)34/h5-12,27H,13-14H2,1-4H3
DMZD1L5	CS	CC(=O)C1=CC=C(C=C1)CN2C(=C3C(=N2)N4CC(N=C4N(C3=O)C)(C)C)NC5=CC=C(C=C5)F
DMZD1L5	IK	RKEUHNQOPBPRQD-UHFFFAOYSA-N
DMZD1L5	IU	4-[(4-acetylphenyl)methyl]-5-(4-fluoroanilino)-8,11,11-trimethyl-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2,5,9-trien-7-one

DMZH3MX	ID	DMZH3MX
DMZH3MX	DN	US9073936, 2
DMZH3MX	HS	Patented
DMZH3MX	SN	CHEMBL3678505; SCHEMBL16036012; BDBM168127; US9073936, 2
DMZH3MX	DT	Small molecular drug
DMZH3MX	PC	86279224
DMZH3MX	MW	462.5
DMZH3MX	FM	C25H27FN6O2
DMZH3MX	IC	InChI=1S/C25H27FN6O2/c1-15(33)17-7-5-16(6-8-17)13-32-21(27-19-11-9-18(26)10-12-19)20-22(29-32)31-14-25(2,3)28-24(31)30(4)23(20)34/h5-12,15,27,33H,13-14H2,1-4H3
DMZH3MX	CS	CC(C1=CC=C(C=C1)CN2C(=C3C(=N2)N4CC(N=C4N(C3=O)C)(C)C)NC5=CC=C(C=C5)F)O
DMZH3MX	IK	PSUHAEXBWCRQED-UHFFFAOYSA-N
DMZH3MX	IU	5-(4-fluoroanilino)-4-[[4-(1-hydroxyethyl)phenyl]methyl]-8,11,11-trimethyl-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2,5,9-trien-7-one

DMS9W6O	ID	DMS9W6O
DMS9W6O	DN	US9073936, 3
DMS9W6O	HS	Patented
DMS9W6O	SN	CHEMBL3678506; SCHEMBL16035729; BDBM168128; US9073936, 3
DMS9W6O	DT	Small molecular drug
DMS9W6O	PC	86279223
DMS9W6O	MW	478.5
DMS9W6O	FM	C25H24F2N6O2
DMS9W6O	IC	InChI=1S/C25H24F2N6O2/c1-14(34)16-7-5-15(6-8-16)12-33-21(28-17-9-10-18(26)19(27)11-17)20-22(30-33)32-13-25(2,3)29-24(32)31(4)23(20)35/h5-11,28H,12-13H2,1-4H3
DMS9W6O	CS	CC(=O)C1=CC=C(C=C1)CN2C(=C3C(=N2)N4CC(N=C4N(C3=O)C)(C)C)NC5=CC(=C(C=C5)F)F
DMS9W6O	IK	ITYGOFCAYSOSFS-UHFFFAOYSA-N
DMS9W6O	IU	4-[(4-acetylphenyl)methyl]-5-(3,4-difluoroanilino)-8,11,11-trimethyl-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2,5,9-trien-7-one

DM8UOKE	ID	DM8UOKE
DM8UOKE	DN	US9096594, 3
DM8UOKE	HS	Patented
DM8UOKE	SN	BDBM173195; US9096594, 3
DM8UOKE	DT	Small molecular drug
DM8UOKE	PC	118797815
DM8UOKE	MW	311.4
DM8UOKE	FM	C19H25N3O
DM8UOKE	IC	InChI=1S/C19H25N3O/c1-11-15-16(12-7-5-4-6-8-12)17-13(20-18(15)22-21-11)9-19(2,3)10-14(17)23/h4-8,11,15-16,18,20-22H,9-10H2,1-3H3/t11?,15?,16-,18?/m0/s1
DM8UOKE	CS	CC1C2[C@@H](C3=C(CC(CC3=O)(C)C)NC2NN1)C4=CC=CC=C4
DM8UOKE	IK	RWOOXYWACRLYJU-RQWZRZRSSA-N
DM8UOKE	IU	(4R)-3,7,7-trimethyl-4-phenyl-2,3,3a,4,6,8,9,9a-octahydro-1H-pyrazolo[3,4-b]quinolin-5-one

DMPT2ZS	ID	DMPT2ZS
DMPT2ZS	DN	US9108950, 1
DMPT2ZS	HS	Patented
DMPT2ZS	SN	CHEMBL3701217; SCHEMBL14837075; BDBM161376; US9108950, 1
DMPT2ZS	DT	Small molecular drug
DMPT2ZS	PC	71547929
DMPT2ZS	MW	583.7
DMPT2ZS	FM	C35H33N7O2
DMPT2ZS	IC	InChI=1S/C35H33N7O2/c1-23-14-16-25(17-15-23)42-31(22-30(41-42)35(2,3)4)39-34(43)38-28-18-19-29(27-13-9-8-12-26(27)28)44-32-20-21-36-33(40-32)37-24-10-6-5-7-11-24/h5-22H,1-4H3,(H,36,37,40)(H2,38,39,43)
DMPT2ZS	CS	CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OC5=NC(=NC=C5)NC6=CC=CC=C6
DMPT2ZS	IK	DBXJNQABFNNKPN-UHFFFAOYSA-N
DMPT2ZS	IU	1-[4-(2-anilinopyrimidin-4-yl)oxynaphthalen-1-yl]-3-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]urea

DMKLYCV	ID	DMKLYCV
DMKLYCV	DN	US9127005, P0L
DMKLYCV	HS	Patented
DMKLYCV	SN	CHEMBL3902347; SCHEMBL11991856; BDBM179736; US9127005, P0L
DMKLYCV	DT	Small molecular drug
DMKLYCV	PC	50902705
DMKLYCV	MW	460.5
DMKLYCV	FM	C27H29FN4O2
DMKLYCV	IC	InChI=1S/C27H29FN4O2/c1-18(31-25(33)21-14-20-4-2-3-5-24(20)29-15-21)17-32-12-10-27(11-13-32)23(16-30-26(27)34)19-6-8-22(28)9-7-19/h2-9,14-15,18,23H,10-13,16-17H2,1H3,(H,30,34)(H,31,33)/t18-,23+/m0/s1
DMKLYCV	CS	C[C@@H](CN1CCC2(CC1)[C@H](CNC2=O)C3=CC=C(C=C3)F)NC(=O)C4=CC5=CC=CC=C5N=C4
DMKLYCV	IK	VALMDDHRZJXVOR-FDDCHVKYSA-N
DMKLYCV	IU	N-[(2S)-1-[(4R)-4-(4-fluorophenyl)-1-oxo-2,8-diazaspiro[4.5]decan-8-yl]propan-2-yl]quinoline-3-carboxamide

DM3R7BT	ID	DM3R7BT
DM3R7BT	DN	US9127005, P2B
DM3R7BT	HS	Patented
DM3R7BT	SN	SCHEMBL12965084; CHEMBL3910701; BDBM179743; US9127005, P2B
DM3R7BT	DT	Small molecular drug
DM3R7BT	PC	50902792
DM3R7BT	MW	427.5
DM3R7BT	FM	C24H27F2N3O2
DM3R7BT	IC	InChI=1S/C24H27F2N3O2/c1-16(28-22(30)18-4-8-20(26)9-5-18)15-29-12-10-24(11-13-29)21(14-27-23(24)31)17-2-6-19(25)7-3-17/h2-9,16,21H,10-15H2,1H3,(H,27,31)(H,28,30)/t16-,21?/m0/s1
DM3R7BT	CS	C[C@@H](CN1CCC2(CC1)C(CNC2=O)C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)F
DM3R7BT	IK	ZRRZCDIHCHFDRR-BJQOMGFOSA-N
DM3R7BT	IU	4-fluoro-N-[(2S)-1-[4-(4-fluorophenyl)-1-oxo-2,8-diazaspiro[4.5]decan-8-yl]propan-2-yl]benzamide

DMMT98V	ID	DMMT98V
DMMT98V	DN	US9127005, P2C
DMMT98V	HS	Patented
DMMT98V	SN	CHEMBL3892578; BDBM179751; US9127005, P2C
DMMT98V	DT	Small molecular drug
DMMT98V	PC	68182802
DMMT98V	MW	413.5
DMMT98V	FM	C23H25F2N3O2
DMMT98V	IC	InChI=1S/C23H25F2N3O2/c24-18-5-1-16(2-6-18)20-15-27-22(30)23(20)9-12-28(13-10-23)14-11-26-21(29)17-3-7-19(25)8-4-17/h1-8,20H,9-15H2,(H,26,29)(H,27,30)
DMMT98V	CS	C1CN(CCC12C(CNC2=O)C3=CC=C(C=C3)F)CCNC(=O)C4=CC=C(C=C4)F
DMMT98V	IK	BPCQYJWHRHUHQC-UHFFFAOYSA-N
DMMT98V	IU	4-fluoro-N-[2-[4-(4-fluorophenyl)-1-oxo-2,8-diazaspiro[4.5]decan-8-yl]ethyl]benzamide

DM9RIF4	ID	DM9RIF4
DM9RIF4	DN	US9132129, Cpd002
DM9RIF4	HS	Patented
DM9RIF4	SN	SCHEMBL6122927; CHEMBL3964350; NWMYEMJIPIXUNW-UHFFFAOYSA-N; BDBM179821; US9132129, Cpd002; 2-tert-butoxy-2-[2-methyl-4-(p-tolyl)-6,7,8,9-tetrahydrobenzo[g]quinolin-3-yl]acetic acid; tert-butoxy-(2-methyl-4-p-tolyl-6,7,8,9-tetrahydro-benzo[g]quinolin-3-yl)-acetic acid
DM9RIF4	DT	Small molecular drug
DM9RIF4	PC	69673878
DM9RIF4	MW	417.5
DM9RIF4	FM	C27H31NO3
DM9RIF4	IC	InChI=1S/C27H31NO3/c1-16-10-12-18(13-11-16)24-21-14-19-8-6-7-9-20(19)15-22(21)28-17(2)23(24)25(26(29)30)31-27(3,4)5/h10-15,25H,6-9H2,1-5H3,(H,29,30)
DM9RIF4	CS	CC1=CC=C(C=C1)C2=C3C=C4CCCCC4=CC3=NC(=C2C(C(=O)O)OC(C)(C)C)C
DM9RIF4	IK	NWMYEMJIPIXUNW-UHFFFAOYSA-N
DM9RIF4	IU	2-[2-methyl-4-(4-methylphenyl)-6,7,8,9-tetrahydrobenzo[g]quinolin-3-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid

DMG18XH	ID	DMG18XH
DMG18XH	DN	US9132129, Cpd023
DMG18XH	HS	Patented
DMG18XH	SN	SCHEMBL6122208; CHEMBL3941519; MNMDSGXKGOEYSF-UHFFFAOYSA-N; BDBM179842; US9132129, Cpd023; 2-(3-methyl-1-p-tolyl-8,9-dihydro-7H-cyclopenta[f]quinolin-2-yl)pentanoic acid; 2-[3-methyl-1-(p-tolyl)-8,9-dihydro-7H-cyclopenta[f]quinolin-2-yl]pentanoic acid
DMG18XH	DT	Small molecular drug
DMG18XH	PC	69673439
DMG18XH	MW	373.5
DMG18XH	FM	C25H27NO2
DMG18XH	IC	InChI=1S/C25H27NO2/c1-4-6-20(25(27)28)22-16(3)26-21-14-13-17-7-5-8-19(17)24(21)23(22)18-11-9-15(2)10-12-18/h9-14,20H,4-8H2,1-3H3,(H,27,28)
DMG18XH	CS	CCCC(C1=C(N=C2C=CC3=C(C2=C1C4=CC=C(C=C4)C)CCC3)C)C(=O)O
DMG18XH	IK	MNMDSGXKGOEYSF-UHFFFAOYSA-N
DMG18XH	IU	2-[3-methyl-1-(4-methylphenyl)-8,9-dihydro-7H-cyclopenta[f]quinolin-2-yl]pentanoic acid

DM17YHP	ID	DM17YHP
DM17YHP	DN	US9132129, Cpd047
DM17YHP	HS	Patented
DM17YHP	SN	SCHEMBL6122355; CHEMBL3910801; ZCHVIKJTLWPNBL-UHFFFAOYSA-N; BDBM179866; US9132129, Cpd047; 2-(2-methyl-4-p-tolylpyrimido[1,2-b]indazol-3-yl)pentanoic acid
DM17YHP	DT	Small molecular drug
DM17YHP	PC	69673524
DM17YHP	MW	373.4
DM17YHP	FM	C23H23N3O2
DM17YHP	IC	InChI=1S/C23H23N3O2/c1-4-7-18(23(27)28)20-15(3)24-22-17-8-5-6-9-19(17)25-26(22)21(20)16-12-10-14(2)11-13-16/h5-6,8-13,18H,4,7H2,1-3H3,(H,27,28)
DM17YHP	CS	CCCC(C1=C(N2C(=C3C=CC=CC3=N2)N=C1C)C4=CC=C(C=C4)C)C(=O)O
DM17YHP	IK	ZCHVIKJTLWPNBL-UHFFFAOYSA-N
DM17YHP	IU	2-[2-methyl-4-(4-methylphenyl)pyrimido[1,2-b]indazol-3-yl]pentanoic acid

DMT6HXB	ID	DMT6HXB
DMT6HXB	DN	US9156852, 1
DMT6HXB	HS	Patented
DMT6HXB	SN	CHEMBL3969260; SCHEMBL15066998; BDBM185584; US9156852, 1
DMT6HXB	DT	Small molecular drug
DMT6HXB	PC	71622578
DMT6HXB	MW	460.9
DMT6HXB	FM	C23H17ClN6OS
DMT6HXB	IC	InChI=1S/C23H17ClN6OS/c1-12-2-7-16-15(8-9-26-22(16)29-14-5-3-13(24)4-6-14)18(12)30-23(31)17-10-32-20-19(17)27-11-28-21(20)25/h2-11H,1H3,(H,26,29)(H,30,31)(H2,25,27,28)
DMT6HXB	CS	CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC=C(C=C3)Cl)NC(=O)C4=CSC5=C4N=CN=C5N
DMT6HXB	IK	FHPTWZJZWOYCKG-UHFFFAOYSA-N
DMT6HXB	IU	4-amino-N-[1-(4-chloroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide

DMZ1RMA	ID	DMZ1RMA
DMZ1RMA	DN	US9156852, 105
DMZ1RMA	HS	Patented
DMZ1RMA	SN	SCHEMBL15066797; CHEMBL3915720; BDBM185590; US9156852, 105
DMZ1RMA	DT	Small molecular drug
DMZ1RMA	PC	71622865
DMZ1RMA	MW	478.9
DMZ1RMA	FM	C23H16ClFN6OS
DMZ1RMA	IC	InChI=1S/C23H16ClFN6OS/c1-11-2-4-14-13(6-7-27-22(14)30-12-3-5-17(25)16(24)8-12)18(11)31-23(32)15-9-33-20-19(15)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)
DMZ1RMA	CS	CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC(=C(C=C3)F)Cl)NC(=O)C4=CSC5=C4N=CN=C5N
DMZ1RMA	IK	GNDBDDNLWIOKDN-UHFFFAOYSA-N
DMZ1RMA	IU	4-amino-N-[1-(3-chloro-4-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide

DMFSOQY	ID	DMFSOQY
DMFSOQY	DN	US9156852, 38
DMFSOQY	HS	Patented
DMFSOQY	SN	SCHEMBL15065881; CHEMBL3954810; BDBM185586; US9156852, 38
DMFSOQY	DT	Small molecular drug
DMFSOQY	PC	89655060
DMFSOQY	MW	460.9
DMFSOQY	FM	C23H17ClN6OS
DMFSOQY	IC	InChI=1S/C23H17ClN6OS/c1-12-5-6-16-15(7-8-26-22(16)29-14-4-2-3-13(24)9-14)18(12)30-23(31)17-10-32-20-19(17)27-11-28-21(20)25/h2-11H,1H3,(H,26,29)(H,30,31)(H2,25,27,28)
DMFSOQY	CS	CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC(=CC=C3)Cl)NC(=O)C4=CSC5=C4N=CN=C5N
DMFSOQY	IK	RFEWCQAWLXXDQI-UHFFFAOYSA-N
DMFSOQY	IU	4-amino-N-[1-(3-chloroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide

DM1K5T0	ID	DM1K5T0
DM1K5T0	DN	US9156852, 83
DM1K5T0	HS	Patented
DM1K5T0	SN	SCHEMBL15067512; CHEMBL3944137; BDBM185589; US9156852, 83
DM1K5T0	DT	Small molecular drug
DM1K5T0	PC	71622312
DM1K5T0	MW	468.5
DM1K5T0	FM	C25H20N6O2S
DM1K5T0	IC	InChI=1S/C25H20N6O2S/c1-13-3-8-18-17(9-10-27-24(18)30-16-6-4-15(5-7-16)14(2)32)20(13)31-25(33)19-11-34-22-21(19)28-12-29-23(22)26/h3-12H,1-2H3,(H,27,30)(H,31,33)(H2,26,28,29)
DM1K5T0	CS	CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC=C(C=C3)C(=O)C)NC(=O)C4=CSC5=C4N=CN=C5N
DM1K5T0	IK	VDPIYNSZQSYYGQ-UHFFFAOYSA-N
DM1K5T0	IU	N-[1-(4-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide

DMOKG3Q	ID	DMOKG3Q
DMOKG3Q	DN	US9181182, 34
DMOKG3Q	HS	Patented
DMOKG3Q	SN	SCHEMBL565019; CHEMBL3941765; KBLICPOFCCULHE-UHFFFAOYSA-N; BDBM190503; US9181182, 34; 2-Amino-2-((4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)indolin-1-yl)methyl)propane-1,3-diol
DMOKG3Q	DT	Small molecular drug
DMOKG3Q	PC	45255648
DMOKG3Q	MW	454.5
DMOKG3Q	FM	C24H30N4O5
DMOKG3Q	IC	InChI=1S/C24H30N4O5/c1-3-31-20-9-8-16(12-21(20)32-4-2)23-26-22(27-33-23)18-6-5-7-19-17(18)10-11-28(19)13-24(25,14-29)15-30/h5-9,12,29-30H,3-4,10-11,13-15,25H2,1-2H3
DMOKG3Q	CS	CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCN(C4=CC=C3)CC(CO)(CO)N)OCC
DMOKG3Q	IK	KBLICPOFCCULHE-UHFFFAOYSA-N
DMOKG3Q	IU	2-amino-2-[[4-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydroindol-1-yl]methyl]propane-1,3-diol

DM3QIF4	ID	DM3QIF4
DM3QIF4	DN	US9181182, 40
DM3QIF4	HS	Patented
DM3QIF4	SN	SCHEMBL566013; CHEMBL3896342; ARJYSAJMGKMECN-UHFFFAOYSA-N; BDBM190507; US9181182, 40; 2-Amino-2-((5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)indolin-1-yl)methyl)propane-1,3-diol
DM3QIF4	DT	Small molecular drug
DM3QIF4	PC	46195170
DM3QIF4	MW	454.5
DM3QIF4	FM	C24H30N4O5
DM3QIF4	IC	InChI=1S/C24H30N4O5/c1-3-31-20-8-6-18(12-21(20)32-4-2)23-26-22(27-33-23)17-5-7-19-16(11-17)9-10-28(19)13-24(25,14-29)15-30/h5-8,11-12,29-30H,3-4,9-10,13-15,25H2,1-2H3
DM3QIF4	CS	CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC4=C(C=C3)N(CC4)CC(CO)(CO)N)OCC
DM3QIF4	IK	ARJYSAJMGKMECN-UHFFFAOYSA-N
DM3QIF4	IU	2-amino-2-[[5-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydroindol-1-yl]methyl]propane-1,3-diol

DM4OHB5	ID	DM4OHB5
DM4OHB5	DN	US9181182, 47
DM4OHB5	HS	Patented
DM4OHB5	SN	SCHEMBL566158; CHEMBL3944892; KVXIWHRSUIQTTC-UHFFFAOYSA-N; BDBM190520; US9181182, 47; 2-Amino-2-((4-(5-(3,4-dipropylphenyl)-1,2,4-oxadiazol-3-yl)indolin-1-yl)methyl)propane-1,3-diol
DM4OHB5	DT	Small molecular drug
DM4OHB5	PC	46195606
DM4OHB5	MW	450.6
DM4OHB5	FM	C26H34N4O3
DM4OHB5	IC	InChI=1S/C26H34N4O3/c1-3-6-18-10-11-20(14-19(18)7-4-2)25-28-24(29-33-25)22-8-5-9-23-21(22)12-13-30(23)15-26(27,16-31)17-32/h5,8-11,14,31-32H,3-4,6-7,12-13,15-17,27H2,1-2H3
DM4OHB5	CS	CCCC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCN(C4=CC=C3)CC(CO)(CO)N)CCC
DM4OHB5	IK	KVXIWHRSUIQTTC-UHFFFAOYSA-N
DM4OHB5	IU	2-amino-2-[[4-[5-(3,4-dipropylphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydroindol-1-yl]methyl]propane-1,3-diol

DMVFBHD	ID	DMVFBHD
DMVFBHD	DN	US9187437, 24
DMVFBHD	HS	Patented
DMVFBHD	SN	SCHEMBL876114; CHEMBL3909228; BDBM192144; US9187437, 24
DMVFBHD	DT	Small molecular drug
DMVFBHD	PC	56949017
DMVFBHD	MW	481.4
DMVFBHD	FM	C26H26Cl2N4O
DMVFBHD	IC	InChI=1S/C26H26Cl2N4O/c27-23-24(28)32(18-29-23)17-19-8-7-9-20(16-19)25-30-22(33-31-25)12-15-26(13-5-2-6-14-26)21-10-3-1-4-11-21/h1,3-4,7-11,16,18H,2,5-6,12-15,17H2
DMVFBHD	CS	C1CCC(CC1)(CCC2=NC(=NO2)C3=CC=CC(=C3)CN4C=NC(=C4Cl)Cl)C5=CC=CC=C5
DMVFBHD	IK	TVHRMMKSOSXQRC-UHFFFAOYSA-N
DMVFBHD	IU	3-[3-[(4,5-dichloroimidazol-1-yl)methyl]phenyl]-5-[2-(1-phenylcyclohexyl)ethyl]-1,2,4-oxadiazole

DM2ULB8	ID	DM2ULB8
DM2ULB8	DN	US9187437, 38
DM2ULB8	HS	Patented
DM2ULB8	SN	SCHEMBL876090; CHEMBL3906369; BDBM192146; US9187437, 38
DM2ULB8	DT	Small molecular drug
DM2ULB8	PC	56949269
DM2ULB8	MW	333.4
DM2ULB8	FM	C21H23N3O
DM2ULB8	IC	InChI=1S/C21H23N3O/c1-3-9-18(10-4-1)21(12-5-2-6-13-21)14-11-19-23-20(24-25-19)17-8-7-15-22-16-17/h1,3-4,7-10,15-16H,2,5-6,11-14H2
DM2ULB8	CS	C1CCC(CC1)(CCC2=NC(=NO2)C3=CN=CC=C3)C4=CC=CC=C4
DM2ULB8	IK	UAUQCABEJBRLRC-UHFFFAOYSA-N
DM2ULB8	IU	5-[2-(1-phenylcyclohexyl)ethyl]-3-pyridin-3-yl-1,2,4-oxadiazole

DMEHSR7	ID	DMEHSR7
DMEHSR7	DN	US9187437, 8
DMEHSR7	HS	Patented
DMEHSR7	SN	SCHEMBL877139; CHEMBL3911469; BDBM192127; US9187437, 8
DMEHSR7	DT	Small molecular drug
DMEHSR7	PC	56948777
DMEHSR7	MW	400.4
DMEHSR7	FM	C23H23F3N2O
DMEHSR7	IC	InChI=1S/C23H23F3N2O/c24-23(25,26)19-11-7-8-17(16-19)21-27-20(29-28-21)12-15-22(13-5-2-6-14-22)18-9-3-1-4-10-18/h1,3-4,7-11,16H,2,5-6,12-15H2
DMEHSR7	CS	C1CCC(CC1)(CCC2=NC(=NO2)C3=CC(=CC=C3)C(F)(F)F)C4=CC=CC=C4
DMEHSR7	IK	QEEBNTVAPQWKOQ-UHFFFAOYSA-N
DMEHSR7	IU	5-[2-(1-phenylcyclohexyl)ethyl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole

DMCLHX5	ID	DMCLHX5
DMCLHX5	DN	US9200020, Table 3 compound 8
DMCLHX5	HS	Patented
DMCLHX5	SN	BDBM194499; US9200020, Table 3 compound 8
DMCLHX5	DT	Small molecular drug
DMCLHX5	PC	72671667
DMCLHX5	MW	374.29
DMCLHX5	FM	C12H19N6O6P
DMCLHX5	IC	InChI=1S/C12H19N6O6P/c13-12-15-10-9(11(21)16-12)14-7-18(10)4-3-17(2-1-8(19)20)5-6-25(22,23)24/h7,9H,1-6H2,(H,19,20)(H2,13,16,21)(H2,22,23,24)
DMCLHX5	CS	C1=NC2C(=NC(=NC2=O)N)N1CCN(CCC(=O)O)CCP(=O)(O)O
DMCLHX5	IK	LUBVDKAUBOMGNH-UHFFFAOYSA-N
DMCLHX5	IU	3-[2-(2-amino-6-oxo-5H-purin-9-yl)ethyl-(2-phosphonoethyl)amino]propanoic acid

DMEARS2	ID	DMEARS2
DMEARS2	DN	US9200020, Table 3, Compound 1B
DMEARS2	HS	Patented
DMEARS2	SN	BDBM60886; US9200020, Table 3, Compound 1B
DMEARS2	DT	Small molecular drug
DMEARS2	PC	72672374
DMEARS2	MW	373.3
DMEARS2	FM	C13H20N5O6P
DMEARS2	IC	InChI=1S/C13H20N5O6P/c1-2-24-10(19)7-17(5-6-25(21,22)23)3-4-18-9-16-11-12(18)14-8-15-13(11)20/h8-9,11H,2-7H2,1H3,(H2,21,22,23)
DMEARS2	CS	CCOC(=O)CN(CCN1C=NC2C1=NC=NC2=O)CCP(=O)(O)O
DMEARS2	IK	ISSPDMWVBYSPCQ-UHFFFAOYSA-N
DMEARS2	IU	2-[(2-ethoxy-2-oxoethyl)-[2-(6-oxo-5H-purin-9-yl)ethyl]amino]ethylphosphonic acid

DMXFB5Z	ID	DMXFB5Z
DMXFB5Z	DN	US9200020, Table 3, Compound 2B
DMXFB5Z	HS	Patented
DMXFB5Z	SN	BDBM60887; US9200020, Table 3, Compound 2B
DMXFB5Z	DT	Small molecular drug
DMXFB5Z	PC	72671666
DMXFB5Z	MW	373.3
DMXFB5Z	FM	C13H20N5O6P
DMXFB5Z	IC	InChI=1S/C13H20N5O6P/c1-24-10(19)2-3-17(6-7-25(21,22)23)4-5-18-9-16-11-12(18)14-8-15-13(11)20/h8-9,11H,2-7H2,1H3,(H2,21,22,23)
DMXFB5Z	CS	COC(=O)CCN(CCN1C=NC2C1=NC=NC2=O)CCP(=O)(O)O
DMXFB5Z	IK	VXLAMFCNIGSKKO-UHFFFAOYSA-N
DMXFB5Z	IU	2-[(3-methoxy-3-oxopropyl)-[2-(6-oxo-5H-purin-9-yl)ethyl]amino]ethylphosphonic acid

DM3NE8J	ID	DM3NE8J
DM3NE8J	DN	US9206139, 4
DM3NE8J	HS	Patented
DM3NE8J	SN	CHEMBL3955404; SCHEMBL15692527; BDBM194645; US9206139, 4
DM3NE8J	DT	Small molecular drug
DM3NE8J	PC	74221131
DM3NE8J	MW	411.4
DM3NE8J	FM	C20H24F3N3O3
DM3NE8J	IC	InChI=1S/C20H24F3N3O3/c1-11(2)15(9-12-3-5-14(6-4-12)20(21,22)23)16(27)24-10-19(13-7-8-13)17(28)25-18(29)26-19/h3-6,11,13,15H,7-10H2,1-2H3,(H,24,27)(H2,25,26,28,29)/t15-,19-/m0/s1
DM3NE8J	CS	CC(C)[C@H](CC1=CC=C(C=C1)C(F)(F)F)C(=O)NC[C@@]2(C(=O)NC(=O)N2)C3CC3
DM3NE8J	IK	VXXYNKXMRXANKX-KXBFYZLASA-N
DM3NE8J	IU	(2S)-N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-3-methyl-2-[[4-(trifluoromethyl)phenyl]methyl]butanamide

DMB4JS7	ID	DMB4JS7
DMB4JS7	DN	US9206139, 5
DMB4JS7	HS	Patented
DMB4JS7	SN	SCHEMBL15692518; CHEMBL3972836; BDBM194646; US9206139, 5
DMB4JS7	DT	Small molecular drug
DMB4JS7	PC	74221070
DMB4JS7	MW	397.4
DMB4JS7	FM	C19H22F3N3O3
DMB4JS7	IC	InChI=1S/C19H22F3N3O3/c1-17(2,9-11-3-5-13(6-4-11)19(20,21)22)14(26)23-10-18(12-7-8-12)15(27)24-16(28)25-18/h3-6,12H,7-10H2,1-2H3,(H,23,26)(H2,24,25,27,28)/t18-/m0/s1
DMB4JS7	CS	CC(C)(CC1=CC=C(C=C1)C(F)(F)F)C(=O)NC[C@@]2(C(=O)NC(=O)N2)C3CC3
DMB4JS7	IK	FJEJHTFPLBTMLO-SFHVURJKSA-N
DMB4JS7	IU	N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2,2-dimethyl-3-[4-(trifluoromethyl)phenyl]propanamide

DMD803F	ID	DMD803F
DMD803F	DN	US9216972, 132
DMD803F	HS	Patented
DMD803F	SN	SCHEMBL1807765; CHEMBL3909064; XVGCLGONKUIZED-UHFFFAOYSA-N; BDBM197672; US9216972, 132; N-(1-cyanocyclopropyl)-2-hydroxy-2-(3-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-4,5-dihydronaphtho[1,2-c]isoxazol-7-yl)acetamide
DMD803F	DT	Small molecular drug
DMD803F	PC	67168742
DMD803F	MW	520.5
DMD803F	FM	C27H19F3N4O4
DMD803F	IC	InChI=1S/C27H19F3N4O4/c28-27(29,30)19-21(34-37-23(19)14-4-2-1-3-5-14)24-18-9-6-15-12-16(7-8-17(15)20(18)33-38-24)22(35)25(36)32-26(13-31)10-11-26/h1-5,7-8,12,22,35H,6,9-11H2,(H,32,36)
DMD803F	CS	C1CC2=C(ON=C2C3=C1C=C(C=C3)C(C(=O)NC4(CC4)C#N)O)C5=NOC(=C5C(F)(F)F)C6=CC=CC=C6
DMD803F	IK	XVGCLGONKUIZED-UHFFFAOYSA-N
DMD803F	IU	N-(1-cyanocyclopropyl)-2-hydroxy-2-[3-[5-phenyl-4-(trifluoromethyl)-1,2-oxazol-3-yl]-4,5-dihydrobenzo[g][2,1]benzoxazol-7-yl]acetamide

DM7AHQE	ID	DM7AHQE
DM7AHQE	DN	US9216972, 61
DM7AHQE	HS	Patented
DM7AHQE	SN	SCHEMBL1806497; CHEMBL3908750; BDBM197666; US9216972, 61
DM7AHQE	DT	Small molecular drug
DM7AHQE	PC	67168136
DM7AHQE	MW	497.4
DM7AHQE	FM	C25H18F3N3O5
DM7AHQE	IC	InChI=1S/C25H18F3N3O5/c26-25(27,28)19-20(14-4-2-1-3-5-14)29-36-23(19)22-17-12-34-18-8-13(6-7-16(18)21(17)30-35-22)9-31-10-15(11-31)24(32)33/h1-8,15H,9-12H2,(H,32,33)
DM7AHQE	CS	C1C(CN1CC2=CC3=C(C=C2)C4=NOC(=C4CO3)C5=C(C(=NO5)C6=CC=CC=C6)C(F)(F)F)C(=O)O
DM7AHQE	IK	QUYMGOJIHUGBPQ-UHFFFAOYSA-N
DM7AHQE	IU	1-[[3-[3-phenyl-4-(trifluoromethyl)-1,2-oxazol-5-yl]-4H-chromeno[4,3-c][1,2]oxazol-7-yl]methyl]azetidine-3-carboxylic acid

DMXR5SZ	ID	DMXR5SZ
DMXR5SZ	DN	US9216972, 67
DMXR5SZ	HS	Patented
DMXR5SZ	SN	SCHEMBL1810811; CHEMBL3900885; BDBM197667; US9216972, 67
DMXR5SZ	DT	Small molecular drug
DMXR5SZ	PC	67170110
DMXR5SZ	MW	499.4
DMXR5SZ	FM	C25H17F4N3O4
DMXR5SZ	IC	InChI=1S/C25H17F4N3O4/c26-17-9-16-13(8-18(17)32-10-14(11-32)24(33)34)6-7-15-21(16)31-35-22(15)23-19(25(27,28)29)20(30-36-23)12-4-2-1-3-5-12/h1-5,8-9,14H,6-7,10-11H2,(H,33,34)
DMXR5SZ	CS	C1CC2=C(ON=C2C3=CC(=C(C=C31)N4CC(C4)C(=O)O)F)C5=C(C(=NO5)C6=CC=CC=C6)C(F)(F)F
DMXR5SZ	IK	TTXDTJUDJNHFLR-UHFFFAOYSA-N
DMXR5SZ	IU	1-[8-fluoro-3-[3-phenyl-4-(trifluoromethyl)-1,2-oxazol-5-yl]-4,5-dihydrobenzo[g][2,1]benzoxazol-7-yl]azetidine-3-carboxylic acid

DMKLCZF	ID	DMKLCZF
DMKLCZF	DN	US9216972, 94
DMKLCZF	HS	Patented
DMKLCZF	SN	SCHEMBL1815648; CHEMBL3893505; HJNGPEXUUTVSJW-UHFFFAOYSA-N; BDBM197671; US9216972, 94; 2-amino-2-methyl-4-(3-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-4,5-dihydronaphtho[1,2-c]isoxazol-7-yl)butanoic acid
DMKLCZF	DT	Small molecular drug
DMKLCZF	PC	67172159
DMKLCZF	MW	497.5
DMKLCZF	FM	C26H22F3N3O4
DMKLCZF	IC	InChI=1S/C26H22F3N3O4/c1-25(30,24(33)34)12-11-14-7-9-17-16(13-14)8-10-18-20(17)31-36-23(18)21-19(26(27,28)29)22(35-32-21)15-5-3-2-4-6-15/h2-7,9,13H,8,10-12,30H2,1H3,(H,33,34)
DMKLCZF	CS	CC(CCC1=CC2=C(C=C1)C3=NOC(=C3CC2)C4=NOC(=C4C(F)(F)F)C5=CC=CC=C5)(C(=O)O)N
DMKLCZF	IK	HJNGPEXUUTVSJW-UHFFFAOYSA-N
DMKLCZF	IU	2-amino-2-methyl-4-[3-[5-phenyl-4-(trifluoromethyl)-1,2-oxazol-3-yl]-4,5-dihydrobenzo[g][2,1]benzoxazol-7-yl]butanoic acid

DMSXG78	ID	DMSXG78
DMSXG78	DN	US9217012, 10
DMSXG78	HS	Patented
DMSXG78	SN	SCHEMBL19222783; CHEMBL3969776; BDBM199180; US9217012, 10
DMSXG78	DT	Small molecular drug
DMSXG78	PC	122198705
DMSXG78	MW	898
DMSXG78	FM	C46H62F2N5O9P
DMSXG78	IC	InChI=1S/C46H62F2N5O9P/c1-5-31-15-19-34(20-16-31)43(56)50-24-10-9-13-37(42(49)55)52-45(58)39(27-33-17-21-35(22-18-33)46(47,48)63(59,60)61)53-44(57)38(26-32-11-7-6-8-12-32)51-41(54)28-62-40-25-30(4)14-23-36(40)29(2)3/h6-8,11-12,15-22,29-30,36-40H,5,9-10,13-14,23-28H2,1-4H3,(H2,49,55)(H,50,56)(H,51,54)(H,52,58)(H,53,57)(H2,59,60,61)
DMSXG78	CS	CCC1=CC=C(C=C1)C(=O)NCCCCC(C(=O)N)NC(=O)C(CC2=CC=C(C=C2)C(F)(F)P(=O)(O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)COC4CC(CCC4C(C)C)C
DMSXG78	IK	DZZMIHDOJVEPRL-UHFFFAOYSA-N
DMSXG78	IU	[[4-[3-[[1-amino-6-[(4-ethylbenzoyl)amino]-1-oxohexan-2-yl]amino]-2-[[2-[[2-(5-methyl-2-propan-2-ylcyclohexyl)oxyacetyl]amino]-3-phenylpropanoyl]amino]-3-oxopropyl]phenyl]-difluoromethyl]phosphonic acid

DM8GW54	ID	DM8GW54
DM8GW54	DN	US9241942, 32-12
DM8GW54	HS	Patented
DM8GW54	SN	CHEMBL3917195; SCHEMBL12674880; BDBM202540; US9241942, 32-12
DM8GW54	DT	Small molecular drug
DM8GW54	PC	88947020
DM8GW54	MW	364.4
DM8GW54	FM	C21H20N2O4
DM8GW54	IC	InChI=1S/C21H20N2O4/c1-22-8-10-23(11-9-22)21(26)20-7-6-19(27-20)15-2-4-16-14(12-15)3-5-18(25)17(16)13-24/h2-7,12-13,25H,8-11H2,1H3
DM8GW54	CS	CN1CCN(CC1)C(=O)C2=CC=C(O2)C3=CC4=C(C=C3)C(=C(C=C4)O)C=O
DM8GW54	IK	XYOMDLUIYINLEM-UHFFFAOYSA-N
DM8GW54	IU	2-hydroxy-6-[5-(4-methylpiperazine-1-carbonyl)furan-2-yl]naphthalene-1-carbaldehyde

DMYUDCE	ID	DMYUDCE
DMYUDCE	DN	US9266828, B
DMYUDCE	HS	Patented
DMYUDCE	SN	SCHEMBL15289220; CHEMBL3902107; BDBM207839; US9266828, B
DMYUDCE	DT	Small molecular drug
DMYUDCE	PC	71735825
DMYUDCE	MW	668.8
DMYUDCE	FM	C31H45FN12O4
DMYUDCE	IC	InChI=1S/C31H45FN12O4/c1-16(2)25(44-28(47)23(41-17(3)45)5-4-12-39-30(35)36)29(48)43-24(14-18-6-9-20(10-7-18)42-31(37)38)27(46)40-15-19-8-11-21(26(33)34)22(32)13-19/h6-11,13,16,23-25H,4-5,12,14-15H2,1-3H3,(H3,33,34)(H,40,46)(H,41,45)(H,43,48)(H,44,47)(H4,35,36,39)(H4,37,38,42)/t23-,24-,25-/m0/s1
DMYUDCE	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)N=C(N)N)C(=O)NCC2=CC(=C(C=C2)C(=N)N)F)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DMYUDCE	IK	STWIQLJAZUCKRU-SDHOMARFSA-N
DMYUDCE	IU	(2S)-2-acetamido-N-[(2S)-1-[[(2S)-1-[(4-carbamimidoyl-3-fluorophenyl)methylamino]-3-[4-(diaminomethylideneamino)phenyl]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-5-(diaminomethylideneamino)pentanamide

DMQEL1W	ID	DMQEL1W
DMQEL1W	DN	US9266828, C
DMQEL1W	HS	Patented
DMQEL1W	SN	CHEMBL3951979; SCHEMBL15289221; BDBM207840; US9266828, C
DMQEL1W	DT	Small molecular drug
DMQEL1W	PC	71735826
DMQEL1W	MW	668.8
DMQEL1W	FM	C31H45FN12O4
DMQEL1W	IC	InChI=1S/C31H45FN12O4/c1-16(2)25(44-28(47)23(41-17(3)45)5-4-12-39-30(35)36)29(48)43-24(13-18-6-10-21(11-7-18)42-31(37)38)27(46)40-15-20-9-8-19(26(33)34)14-22(20)32/h6-11,14,16,23-25H,4-5,12-13,15H2,1-3H3,(H3,33,34)(H,40,46)(H,41,45)(H,43,48)(H,44,47)(H4,35,36,39)(H4,37,38,42)/t23-,24-,25-/m0/s1
DMQEL1W	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)N=C(N)N)C(=O)NCC2=C(C=C(C=C2)C(=N)N)F)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DMQEL1W	IK	HYFZTDZJLMLSBP-SDHOMARFSA-N
DMQEL1W	IU	(2S)-2-acetamido-N-[(2S)-1-[[(2S)-1-[(4-carbamimidoyl-2-fluorophenyl)methylamino]-3-[4-(diaminomethylideneamino)phenyl]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-5-(diaminomethylideneamino)pentanamide

DMYUL2X	ID	DMYUL2X
DMYUL2X	DN	US9266828, E
DMYUL2X	HS	Patented
DMYUL2X	SN	SCHEMBL15289761; CHEMBL3936612; BDBM207842; US9266828, E
DMYUL2X	DT	Small molecular drug
DMYUL2X	PC	71722448
DMYUL2X	MW	600.7
DMYUL2X	FM	C27H40N10O4S
DMYUL2X	IC	InChI=1S/C27H40N10O4S/c1-16(2)22(37-42(40,41)15-18-7-11-20(12-8-18)24(30)31)26(39)36-21(4-3-13-34-27(32)33)25(38)35-14-17-5-9-19(10-6-17)23(28)29/h5-12,16,21-22,37H,3-4,13-15H2,1-2H3,(H3,28,29)(H3,30,31)(H,35,38)(H,36,39)(H4,32,33,34)/t21-,22-/m0/s1
DMYUL2X	CS	CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC1=CC=C(C=C1)C(=N)N)NS(=O)(=O)CC2=CC=C(C=C2)C(=N)N
DMYUL2X	IK	PRSVXIFOXDFBKT-VXKWHMMOSA-N
DMYUL2X	IU	(2S)-N-[(4-carbamimidoylphenyl)methyl]-2-[[(2S)-2-[(4-carbamimidoylphenyl)methylsulfonylamino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanamide

DM0GOCZ	ID	DM0GOCZ
DM0GOCZ	DN	US9340511, 2
DM0GOCZ	HS	Patented
DM0GOCZ	SN	SCHEMBL522741; CHEMBL3962368; ZLDYCVXVGXUSBB-UHFFFAOYSA-N; BDBM227554; US9340511, 2; 2-(4-hydroxy-1-methyl-6-phenoxyisoquinoline-3-carboxamido)acetic acid
DM0GOCZ	DT	Small molecular drug
DM0GOCZ	PC	11462288
DM0GOCZ	MW	352.3
DM0GOCZ	FM	C19H16N2O5
DM0GOCZ	IC	InChI=1S/C19H16N2O5/c1-11-14-8-7-13(26-12-5-3-2-4-6-12)9-15(14)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
DM0GOCZ	CS	CC1=C2C=CC(=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3
DM0GOCZ	IK	ZLDYCVXVGXUSBB-UHFFFAOYSA-N
DM0GOCZ	IU	2-[(4-hydroxy-1-methyl-6-phenoxyisoquinoline-3-carbonyl)amino]acetic acid

DMFQERG	ID	DMFQERG
DMFQERG	DN	US9340511, 5
DMFQERG	HS	Patented
DMFQERG	SN	SCHEMBL523724; CHEMBL3970151; JPXYINYXIDIDQY-UHFFFAOYSA-N; BDBM227556; US9340511, 5; 2-[4-hydroxy-1-methyl-7-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid
DMFQERG	DT	Small molecular drug
DMFQERG	PC	11440448
DMFQERG	MW	382.4
DMFQERG	FM	C20H18N2O6
DMFQERG	IC	InChI=1S/C20H18N2O6/c1-11-16-9-14(28-13-5-3-12(27-2)4-6-13)7-8-15(16)19(25)18(22-11)20(26)21-10-17(23)24/h3-9,25H,10H2,1-2H3,(H,21,26)(H,23,24)
DMFQERG	CS	CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=C(C=C3)OC
DMFQERG	IK	JPXYINYXIDIDQY-UHFFFAOYSA-N
DMFQERG	IU	2-[[4-hydroxy-7-(4-methoxyphenoxy)-1-methylisoquinoline-3-carbonyl]amino]acetic acid

DMRL0WA	ID	DMRL0WA
DMRL0WA	DN	US9340511, 6
DMRL0WA	HS	Patented
DMRL0WA	SN	SCHEMBL522900; CHEMBL3902458; MHMUTVWPLKKCIN-UHFFFAOYSA-N; BDBM227557; US9340511, 6; 2-[4-hydroxy-1-methyl-6-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid
DMRL0WA	DT	Small molecular drug
DMRL0WA	PC	57423255
DMRL0WA	MW	382.4
DMRL0WA	FM	C20H18N2O6
DMRL0WA	IC	InChI=1S/C20H18N2O6/c1-11-15-8-7-14(28-13-5-3-12(27-2)4-6-13)9-16(15)19(25)18(22-11)20(26)21-10-17(23)24/h3-9,25H,10H2,1-2H3,(H,21,26)(H,23,24)
DMRL0WA	CS	CC1=C2C=CC(=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=C(C=C3)OC
DMRL0WA	IK	MHMUTVWPLKKCIN-UHFFFAOYSA-N
DMRL0WA	IU	2-[[4-hydroxy-6-(4-methoxyphenoxy)-1-methylisoquinoline-3-carbonyl]amino]acetic acid

DMC0PUI	ID	DMC0PUI
DMC0PUI	DN	US9340511, 7
DMC0PUI	HS	Patented
DMC0PUI	SN	SCHEMBL522957; CHEMBL3960288; AWHJVFRHVNXXDF-UHFFFAOYSA-N; BDBM227558; US9340511, 7; 2-[4-hydroxy-1-methyl-7-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido]acetic acid
DMC0PUI	DT	Small molecular drug
DMC0PUI	PC	11176709
DMC0PUI	MW	388.3
DMC0PUI	FM	C19H14F2N2O5
DMC0PUI	IC	InChI=1S/C19H14F2N2O5/c1-9-15-7-12(28-13-5-10(20)4-11(21)6-13)2-3-14(15)18(26)17(23-9)19(27)22-8-16(24)25/h2-7,26H,8H2,1H3,(H,22,27)(H,24,25)
DMC0PUI	CS	CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC(=CC(=C3)F)F
DMC0PUI	IK	AWHJVFRHVNXXDF-UHFFFAOYSA-N
DMC0PUI	IU	2-[[7-(3,5-difluorophenoxy)-4-hydroxy-1-methylisoquinoline-3-carbonyl]amino]acetic acid

DM5E9RH	ID	DM5E9RH
DM5E9RH	DN	US9340574, 7
DM5E9RH	HS	Patented
DM5E9RH	SN	CHEMBL3978384; BDBM231167; US9340574, 7
DM5E9RH	DT	Small molecular drug
DM5E9RH	PC	71494947
DM5E9RH	MW	1085.6
DM5E9RH	FM	C42H45BrF2IN6O11P
DM5E9RH	IC	InChI=1S/C42H45BrF2IN6O11P/c1-23-8-12-27(21-30(23)43)39(57)51-32(17-24-9-13-28(14-10-24)42(44,45)64(60,61)62)41(59)50-31(7-4-16-48-38(56)26-5-3-6-29(46)20-26)40(58)52-33(37(47)55)22-49-36(54)19-25-11-15-34(53)35(18-25)63-2/h3,5-6,8-15,18,20-21,31-33,53H,4,7,16-17,19,22H2,1-2H3,(H2,47,55)(H,48,56)(H,49,54)(H,50,59)(H,51,57)(H,52,58)(H2,60,61,62)
DM5E9RH	CS	CC1=C(C=C(C=C1)C(=O)NC(CC2=CC=C(C=C2)C(F)(F)P(=O)(O)O)C(=O)NC(CCCNC(=O)C3=CC(=CC=C3)I)C(=O)NC(CNC(=O)CC4=CC(=C(C=C4)O)OC)C(=O)N)Br
DM5E9RH	IK	PXNYEUGGRMYQLD-UHFFFAOYSA-N
DM5E9RH	IU	[[4-[3-[[1-[[1-amino-3-[[2-(4-hydroxy-3-methoxyphenyl)acetyl]amino]-1-oxopropan-2-yl]amino]-5-[(3-iodobenzoyl)amino]-1-oxopentan-2-yl]amino]-2-[(3-bromo-4-methylbenzoyl)amino]-3-oxopropyl]phenyl]-difluoromethyl]phosphonic acid

DMSLBT3	ID	DMSLBT3
DMSLBT3	DN	US9346821, A-20
DMSLBT3	HS	Patented
DMSLBT3	SN	CHEMBL3891228; SCHEMBL17770900; BDBM234241; US9346821, A-20
DMSLBT3	DT	Small molecular drug
DMSLBT3	PC	71491786
DMSLBT3	MW	432.4
DMSLBT3	FM	C19H20N4O8
DMSLBT3	IC	InChI=1S/C19H20N4O8/c1-23(19(29)22-13(17(26)27)8-15(24)25)9-12-6-7-14(30-12)18(28)31-11-4-2-10(3-5-11)16(20)21/h2-7,13H,8-9H2,1H3,(H3,20,21)(H,22,29)(H,24,25)(H,26,27)/t13-/m0/s1
DMSLBT3	CS	CN(CC1=CC=C(O1)C(=O)OC2=CC=C(C=C2)C(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O
DMSLBT3	IK	IPAMUZPOGLKECI-ZDUSSCGKSA-N
DMSLBT3	IU	(2S)-2-[[[5-(4-carbamimidoylphenoxy)carbonylfuran-2-yl]methyl-methylcarbamoyl]amino]butanedioic acid

DMR6P8T	ID	DMR6P8T
DMR6P8T	DN	US9346821, B-13
DMR6P8T	HS	Patented
DMR6P8T	SN	CHEMBL3890156; SCHEMBL17771462; BDBM234246; US9346821, B-13
DMR6P8T	DT	Small molecular drug
DMR6P8T	PC	71491842
DMR6P8T	MW	506.5
DMR6P8T	FM	C22H23FN4O7S
DMR6P8T	IC	InChI=1S/C22H23FN4O7S/c23-13-8-11(19(24)25)3-5-16(13)34-22(33)17-6-4-12(35-17)10-27-7-1-2-15(27)20(30)26-14(21(31)32)9-18(28)29/h3-6,8,14-15H,1-2,7,9-10H2,(H3,24,25)(H,26,30)(H,28,29)(H,31,32)/t14-,15+/m0/s1
DMR6P8T	CS	C1C[C@@H](N(C1)CC2=CC=C(S2)C(=O)OC3=C(C=C(C=C3)C(=N)N)F)C(=O)N[C@@H](CC(=O)O)C(=O)O
DMR6P8T	IK	CEBSLTBKCPYKRD-LSDHHAIUSA-N
DMR6P8T	IU	(2S)-2-[[(2R)-1-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]pyrrolidine-2-carbonyl]amino]butanedioic acid

DMQ1LGV	ID	DMQ1LGV
DMQ1LGV	DN	US9346821, B-42
DMQ1LGV	HS	Patented
DMQ1LGV	SN	SCHEMBL17770908; CHEMBL3897108; BDBM234261; US9346821, B-42
DMQ1LGV	DT	Small molecular drug
DMQ1LGV	PC	71491117
DMQ1LGV	MW	387.4
DMQ1LGV	FM	C18H14FN3O4S
DMQ1LGV	IC	InChI=1S/C18H14FN3O4S/c19-12-8-10(16(20)21)3-5-14(12)26-18(25)15-6-4-11(27-15)9-22-7-1-2-13(22)17(23)24/h1-8H,9H2,(H3,20,21)(H,23,24)
DMQ1LGV	CS	C1=CN(C(=C1)C(=O)O)CC2=CC=C(S2)C(=O)OC3=C(C=C(C=C3)C(=N)N)F
DMQ1LGV	IK	FIQOBFTVRYSLKW-UHFFFAOYSA-N
DMQ1LGV	IU	1-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]pyrrole-2-carboxylic acid

DMWG98Z	ID	DMWG98Z
DMWG98Z	DN	US9353089, 135
DMWG98Z	HS	Patented
DMWG98Z	SN	CHEMBL2011974; SCHEMBL4232691; BDBM234502; BDBM50379890; US9353089, 135
DMWG98Z	DT	Small molecular drug
DMWG98Z	PC	11359820
DMWG98Z	MW	342.4
DMWG98Z	FM	C21H18N4O
DMWG98Z	IC	InChI=1S/C21H18N4O/c1-25-19(26)21(24-20(25)22,17-9-3-2-4-10-17)18-11-5-7-15(13-18)16-8-6-12-23-14-16/h2-14H,1H3,(H2,22,24)
DMWG98Z	CS	CN1C(=O)C(N=C1N)(C2=CC=CC=C2)C3=CC=CC(=C3)C4=CN=CC=C4
DMWG98Z	IK	PNSQCPQDRVOKMA-UHFFFAOYSA-N
DMWG98Z	IU	2-amino-3-methyl-5-phenyl-5-(3-pyridin-3-ylphenyl)imidazol-4-one

DMB4MJ0	ID	DMB4MJ0
DMB4MJ0	DN	US9353089, 327
DMB4MJ0	HS	Patented
DMB4MJ0	SN	CHEMBL2011967; SCHEMBL7536669; SCHEMBL8237937; BDBM234554; BDBM50379882; US9353089, 327
DMB4MJ0	DT	Small molecular drug
DMB4MJ0	PC	11581511
DMB4MJ0	MW	371.4
DMB4MJ0	FM	C23H21N3O2
DMB4MJ0	IC	InChI=1S/C23H21N3O2/c1-26-21(27)23(25-22(26)24,18-10-4-3-5-11-18)19-12-6-8-16(14-19)17-9-7-13-20(15-17)28-2/h3-15H,1-2H3,(H2,24,25)
DMB4MJ0	CS	CN1C(=O)C(N=C1N)(C2=CC=CC=C2)C3=CC=CC(=C3)C4=CC(=CC=C4)OC
DMB4MJ0	IK	LRYKHTDVFXMHEH-UHFFFAOYSA-N
DMB4MJ0	IU	2-amino-5-[3-(3-methoxyphenyl)phenyl]-3-methyl-5-phenylimidazol-4-one

DMK02LS	ID	DMK02LS
DMK02LS	DN	US9353089, 330
DMK02LS	HS	Patented
DMK02LS	SN	CHEMBL2012001; SCHEMBL7539510; BDBM234557; BDBM50379880; US9353089, 330
DMK02LS	DT	Small molecular drug
DMK02LS	PC	59262421
DMK02LS	MW	335.4
DMK02LS	FM	C20H21N3O2
DMK02LS	IC	InChI=1S/C20H21N3O2/c1-23-18(24)20(15-9-10-15,22-19(23)21)16-7-3-5-13(11-16)14-6-4-8-17(12-14)25-2/h3-8,11-12,15H,9-10H2,1-2H3,(H2,21,22)
DMK02LS	CS	CN1C(=O)C(N=C1N)(C2CC2)C3=CC=CC(=C3)C4=CC(=CC=C4)OC
DMK02LS	IK	NCNMSGOJBLVCOM-UHFFFAOYSA-N
DMK02LS	IU	2-amino-5-cyclopropyl-5-[3-(3-methoxyphenyl)phenyl]-3-methylimidazol-4-one

DMA3OI4	ID	DMA3OI4
DMA3OI4	DN	US9359293, TA
DMA3OI4	HS	Patented
DMA3OI4	SN	SCHEMBL18103200; CHEMBL3892393; BDBM234205; US9359293, TA
DMA3OI4	DT	Small molecular drug
DMA3OI4	PC	122580129
DMA3OI4	MW	399.5
DMA3OI4	FM	C21H25N3O3S
DMA3OI4	IC	InChI=1S/C21H25N3O3S/c1-16(28)22-15-9-8-14-19(20(25)23-17-10-4-2-5-11-17)24-21(26)27-18-12-6-3-7-13-18/h2-7,10-13,19H,8-9,14-15H2,1H3,(H,22,28)(H,23,25)(H,24,26)
DMA3OI4	CS	CC(=S)NCCCCC(C(=O)NC1=CC=CC=C1)NC(=O)OC2=CC=CC=C2
DMA3OI4	IK	KPDAUKDFHIWNQM-UHFFFAOYSA-N
DMA3OI4	IU	phenyl N-[1-anilino-6-(ethanethioylamino)-1-oxohexan-2-yl]carbamate

DMRQ2G4	ID	DMRQ2G4
DMRQ2G4	DN	US9359293, TB
DMRQ2G4	HS	Patented
DMRQ2G4	SN	SCHEMBL18103198; CHEMBL3968962; BDBM234206; US9359293, TB
DMRQ2G4	DT	Small molecular drug
DMRQ2G4	PC	122580127
DMRQ2G4	MW	427.6
DMRQ2G4	FM	C23H29N3O3S
DMRQ2G4	IC	InChI=1S/C23H29N3O3S/c1-2-11-21(30)24-17-10-9-16-20(22(27)25-18-12-5-3-6-13-18)26-23(28)29-19-14-7-4-8-15-19/h3-8,12-15,20H,2,9-11,16-17H2,1H3,(H,24,30)(H,25,27)(H,26,28)
DMRQ2G4	CS	CCCC(=S)NCCCCC(C(=O)NC1=CC=CC=C1)NC(=O)OC2=CC=CC=C2
DMRQ2G4	IK	WGKXXIZEWYTERA-UHFFFAOYSA-N
DMRQ2G4	IU	phenyl N-[1-anilino-6-(butanethioylamino)-1-oxohexan-2-yl]carbamate

DM0NIB5	ID	DM0NIB5
DM0NIB5	DN	US9359293, TM
DM0NIB5	HS	Patented
DM0NIB5	SN	SCHEMBL18103197; CHEMBL3940508; BDBM234208; US9359293, TM
DM0NIB5	DT	Small molecular drug
DM0NIB5	PC	71533676
DM0NIB5	MW	567.8
DM0NIB5	FM	C33H49N3O3S
DM0NIB5	IC	InChI=1S/C33H49N3O3S/c1-2-3-4-5-6-7-8-9-10-11-18-26-31(40)34-27-20-19-25-30(32(37)35-28-21-14-12-15-22-28)36-33(38)39-29-23-16-13-17-24-29/h12-17,21-24,30H,2-11,18-20,25-27H2,1H3,(H,34,40)(H,35,37)(H,36,38)
DM0NIB5	CS	CCCCCCCCCCCCCC(=S)NCCCCC(C(=O)NC1=CC=CC=C1)NC(=O)OC2=CC=CC=C2
DM0NIB5	IK	KNGBKXOOWUXHDK-UHFFFAOYSA-N
DM0NIB5	IU	phenyl N-[1-anilino-1-oxo-6-(tetradecanethioylamino)hexan-2-yl]carbamate

DMSA86Y	ID	DMSA86Y
DMSA86Y	DN	US9365572, 5
DMSA86Y	HS	Patented
DMSA86Y	SN	BDBM236557; US9365572, 5
DMSA86Y	DT	Small molecular drug
DMSA86Y	PC	129012341
DMSA86Y	MW	460.5
DMSA86Y	FM	C22H23F3N6O2
DMSA86Y	IC	InChI=1S/C22H23F3N6O2/c23-22(24,25)12-2-1-3-13(8-12)31-19-14(20(32)30-21(31)33)10-27-16-6-5-15(29-18(16)19)11-4-7-17(26)28-9-11/h1-4,7-9,14-16,18-19,27,29H,5-6,10H2,(H2,26,28)(H,30,32,33)
DMSA86Y	CS	C1CC(NC2C1NCC3C2N(C(=O)NC3=O)C4=CC=CC(=C4)C(F)(F)F)C5=CN=C(C=C5)N
DMSA86Y	IK	PPLLDCXSMMXDPV-UHFFFAOYSA-N
DMSA86Y	IU	9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]-4a,5,6,6a,7,8,9,10,10a,10b-decahydropyrimido[5,4-c][1,5]naphthyridine-2,4-dione

DMVL57U	ID	DMVL57U
DMVL57U	DN	US9388139, 12
DMVL57U	HS	Patented
DMVL57U	SN	SCHEMBL12493454; CHEMBL3899621; BDBM236643; US9388139, 12
DMVL57U	DT	Small molecular drug
DMVL57U	PC	60194756
DMVL57U	MW	391.3
DMVL57U	FM	C20H20Cl2N2O2
DMVL57U	IC	InChI=1S/C20H20Cl2N2O2/c1-20(2,3)18-11-17(15-9-6-13(21)10-16(15)22)24(23-18)14-7-4-12(5-8-14)19(25)26/h4-10,17H,11H2,1-3H3,(H,25,26)
DMVL57U	CS	CC(C)(C)C1=NN(C(C1)C2=C(C=C(C=C2)Cl)Cl)C3=CC=C(C=C3)C(=O)O
DMVL57U	IK	DIZHQHRVPINGBC-UHFFFAOYSA-N
DMVL57U	IU	4-[5-tert-butyl-3-(2,4-dichlorophenyl)-3,4-dihydropyrazol-2-yl]benzoic acid

DMMFC0V	ID	DMMFC0V
DMMFC0V	DN	US9409892, 136
DMMFC0V	HS	Patented
DMMFC0V	SN	SCHEMBL15268512; CHEMBL3893046; WTLXLQBMAJRSSQ-UHFFFAOYSA-N; BDBM241041; US9409892, 136; 3-{[1-(5-Fluoro-pyridin-3-yl)-4-hydroxy-7-phenoxy-isoquinoline-3-carbonyl]amino}-2,2-dimethyl-propionic acid
DMMFC0V	DT	Small molecular drug
DMMFC0V	PC	71735619
DMMFC0V	MW	475.5
DMMFC0V	FM	C26H22FN3O5
DMMFC0V	IC	InChI=1S/C26H22FN3O5/c1-26(2,25(33)34)14-29-24(32)22-23(31)19-9-8-18(35-17-6-4-3-5-7-17)11-20(19)21(30-22)15-10-16(27)13-28-12-15/h3-13,31H,14H2,1-2H3,(H,29,32)(H,33,34)
DMMFC0V	CS	CC(C)(CNC(=O)C1=C(C2=C(C=C(C=C2)OC3=CC=CC=C3)C(=N1)C4=CC(=CN=C4)F)O)C(=O)O
DMMFC0V	IK	WTLXLQBMAJRSSQ-UHFFFAOYSA-N
DMMFC0V	IU	3-[[1-(5-fluoropyridin-3-yl)-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl]amino]-2,2-dimethylpropanoic acid

DMZJTSP	ID	DMZJTSP
DMZJTSP	DN	US9409892, 148
DMZJTSP	HS	Patented
DMZJTSP	SN	CHEMBL3893184; SCHEMBL15268628; BDBM241053; US9409892, 148
DMZJTSP	DT	Small molecular drug
DMZJTSP	PC	71736440
DMZJTSP	MW	368.4
DMZJTSP	FM	C20H17FN2O4
DMZJTSP	IC	InChI=1S/C20H17FN2O4/c21-15-6-3-12(4-7-15)13-5-8-16-14(10-13)11-23-18(19(16)26)20(27)22-9-1-2-17(24)25/h3-8,10-11,26H,1-2,9H2,(H,22,27)(H,24,25)
DMZJTSP	CS	C1=CC(=CC=C1C2=CC3=CN=C(C(=C3C=C2)O)C(=O)NCCCC(=O)O)F
DMZJTSP	IK	ZCPXHSRUGVQBOS-UHFFFAOYSA-N
DMZJTSP	IU	4-[[7-(4-fluorophenyl)-4-hydroxyisoquinoline-3-carbonyl]amino]butanoic acid

DMHF2OX	ID	DMHF2OX
DMHF2OX	DN	US9409892, 19
DMHF2OX	HS	Patented
DMHF2OX	SN	SCHEMBL15268580; CHEMBL3889830; JSYWJICQZNCWHF-UHFFFAOYSA-N; BDBM240924; US9409892, 19; 1-{[(1-Cyano-4-hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-methyl}-cyclopentanecarboxylic acid
DMHF2OX	DT	Small molecular drug
DMHF2OX	PC	89812932
DMHF2OX	MW	431.4
DMHF2OX	FM	C24H21N3O5
DMHF2OX	IC	InChI=1S/C24H21N3O5/c25-13-19-18-12-16(32-15-6-2-1-3-7-15)8-9-17(18)21(28)20(27-19)22(29)26-14-24(23(30)31)10-4-5-11-24/h1-3,6-9,12,28H,4-5,10-11,14H2,(H,26,29)(H,30,31)
DMHF2OX	CS	C1CCC(C1)(CNC(=O)C2=C(C3=C(C=C(C=C3)OC4=CC=CC=C4)C(=N2)C#N)O)C(=O)O
DMHF2OX	IK	JSYWJICQZNCWHF-UHFFFAOYSA-N
DMHF2OX	IU	1-[[(1-cyano-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)amino]methyl]cyclopentane-1-carboxylic acid

DMWAL5Q	ID	DMWAL5Q
DMWAL5Q	DN	US9409892, 59
DMWAL5Q	HS	Patented
DMWAL5Q	SN	SCHEMBL15268697; CHEMBL3893917; QBSUFMQXFVGWJT-UHFFFAOYSA-N; BDBM240964; US9409892, 59; 3-{[1-Cyano-4-hydroxy-7-(naphthalen-2-yloxy)-isoquinoline-3-carbonyl]-amino}-2,2-dimethyl-propionic acid
DMWAL5Q	DT	Small molecular drug
DMWAL5Q	PC	89813011
DMWAL5Q	MW	455.5
DMWAL5Q	FM	C26H21N3O5
DMWAL5Q	IC	InChI=1S/C26H21N3O5/c1-26(2,25(32)33)14-28-24(31)22-23(30)19-10-9-18(12-20(19)21(13-27)29-22)34-17-8-7-15-5-3-4-6-16(15)11-17/h3-12,30H,14H2,1-2H3,(H,28,31)(H,32,33)
DMWAL5Q	CS	CC(C)(CNC(=O)C1=C(C2=C(C=C(C=C2)OC3=CC4=CC=CC=C4C=C3)C(=N1)C#N)O)C(=O)O
DMWAL5Q	IK	QBSUFMQXFVGWJT-UHFFFAOYSA-N
DMWAL5Q	IU	3-[(1-cyano-4-hydroxy-7-naphthalen-2-yloxyisoquinoline-3-carbonyl)amino]-2,2-dimethylpropanoic acid

DMV4AHL	ID	DMV4AHL
DMV4AHL	DN	US9422240, 1-282
DMV4AHL	HS	Patented
DMV4AHL	SN	SCHEMBL16762172; CHEMBL3896281; BDBM242546; US9422240, 1-282
DMV4AHL	DT	Small molecular drug
DMV4AHL	PC	73053164
DMV4AHL	MW	414.4
DMV4AHL	FM	C21H19FN2O6
DMV4AHL	IC	InChI=1S/C21H19FN2O6/c22-15-3-1-2-4-17(15)30-14-7-5-13(6-8-14)12-24-10-9-16(25)19(21(24)29)20(28)23-11-18(26)27/h1-8,25H,9-12H2,(H,23,28)(H,26,27)
DMV4AHL	CS	C1CN(C(=O)C(=C1O)C(=O)NCC(=O)O)CC2=CC=C(C=C2)OC3=CC=CC=C3F
DMV4AHL	IK	FFAFLVNMXIWUFY-UHFFFAOYSA-N
DMV4AHL	IU	2-[[1-[[4-(2-fluorophenoxy)phenyl]methyl]-4-hydroxy-6-oxo-2,3-dihydropyridine-5-carbonyl]amino]acetic acid

DM0S2UK	ID	DM0S2UK
DM0S2UK	DN	US9422240, 1-286
DM0S2UK	HS	Patented
DM0S2UK	SN	CHEMBL3899803; SCHEMBL16761915; BDBM242550; US9422240, 1-286
DM0S2UK	DT	Small molecular drug
DM0S2UK	PC	73053305
DM0S2UK	MW	426.4
DM0S2UK	FM	C22H22N2O7
DM0S2UK	IC	InChI=1S/C22H22N2O7/c1-30-16-3-2-4-17(11-16)31-15-7-5-14(6-8-15)13-24-10-9-18(25)20(22(24)29)21(28)23-12-19(26)27/h2-8,11,25H,9-10,12-13H2,1H3,(H,23,28)(H,26,27)
DM0S2UK	CS	COC1=CC(=CC=C1)OC2=CC=C(C=C2)CN3CCC(=C(C3=O)C(=O)NCC(=O)O)O
DM0S2UK	IK	ZKPWKTAYUOZETR-UHFFFAOYSA-N
DM0S2UK	IU	2-[[4-hydroxy-1-[[4-(3-methoxyphenoxy)phenyl]methyl]-6-oxo-2,3-dihydropyridine-5-carbonyl]amino]acetic acid

DMST6IF	ID	DMST6IF
DMST6IF	DN	US9422240, 1-297
DMST6IF	HS	Patented
DMST6IF	SN	SCHEMBL16761684; CHEMBL3900473; BDBM242555; US9422240, 1-297
DMST6IF	DT	Small molecular drug
DMST6IF	PC	73050968
DMST6IF	MW	411.4
DMST6IF	FM	C21H21N3O6
DMST6IF	IC	InChI=1S/C21H21N3O6/c1-13-2-7-17(22-10-13)30-15-5-3-14(4-6-15)12-24-9-8-16(25)19(21(24)29)20(28)23-11-18(26)27/h2-7,10,25H,8-9,11-12H2,1H3,(H,23,28)(H,26,27)
DMST6IF	CS	CC1=CN=C(C=C1)OC2=CC=C(C=C2)CN3CCC(=C(C3=O)C(=O)NCC(=O)O)O
DMST6IF	IK	FHMUUXWOUSOEJQ-UHFFFAOYSA-N
DMST6IF	IU	2-[[4-hydroxy-1-[[4-(5-methylpyridin-2-yl)oxyphenyl]methyl]-6-oxo-2,3-dihydropyridine-5-carbonyl]amino]acetic acid

DMH7DL5	ID	DMH7DL5
DMH7DL5	DN	US9422240, 1-298
DMH7DL5	HS	Patented
DMH7DL5	SN	SCHEMBL16761969; CHEMBL3899583; BDBM242556; US9422240, 1-298
DMH7DL5	DT	Small molecular drug
DMH7DL5	PC	73050969
DMH7DL5	MW	465.4
DMH7DL5	FM	C21H18F3N3O6
DMH7DL5	IC	InChI=1S/C21H18F3N3O6/c22-21(23,24)13-3-6-16(25-9-13)33-14-4-1-12(2-5-14)11-27-8-7-15(28)18(20(27)32)19(31)26-10-17(29)30/h1-6,9,28H,7-8,10-11H2,(H,26,31)(H,29,30)
DMH7DL5	CS	C1CN(C(=O)C(=C1O)C(=O)NCC(=O)O)CC2=CC=C(C=C2)OC3=NC=C(C=C3)C(F)(F)F
DMH7DL5	IK	OAYSSFWXQZDVKQ-UHFFFAOYSA-N
DMH7DL5	IU	2-[[4-hydroxy-6-oxo-1-[[4-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]-2,3-dihydropyridine-5-carbonyl]amino]acetic acid

DMS842X	ID	DMS842X
DMS842X	DN	US9434725, 113
DMS842X	HS	Patented
DMS842X	SN	SCHEMBL15401435; CHEMBL3890745; AWEQRQAMCRCOJY-INIZCTEOSA-N; BDBM248882; US9434725, 113; (S)-1-(6-(3-methylpiperazin-1-yl)pyridin-2-yl)-6-(5-(oxetan-3-yl)pyridin-3-yl)-1H-pyrazolo[4,3-c]pyridine
DMS842X	DT	Small molecular drug
DMS842X	PC	72715135
DMS842X	MW	427.5
DMS842X	FM	C24H25N7O
DMS842X	IC	InChI=1S/C24H25N7O/c1-16-13-30(6-5-26-16)23-3-2-4-24(29-23)31-22-8-21(27-11-19(22)12-28-31)18-7-17(9-25-10-18)20-14-32-15-20/h2-4,7-12,16,20,26H,5-6,13-15H2,1H3/t16-/m0/s1
DMS842X	CS	C[C@H]1CN(CCN1)C2=CC=CC(=N2)N3C4=CC(=NC=C4C=N3)C5=CC(=CN=C5)C6COC6
DMS842X	IK	AWEQRQAMCRCOJY-INIZCTEOSA-N
DMS842X	IU	1-[6-[(3S)-3-methylpiperazin-1-yl]pyridin-2-yl]-6-[5-(oxetan-3-yl)pyridin-3-yl]pyrazolo[4,3-c]pyridine

DM6Z01B	ID	DM6Z01B
DM6Z01B	DN	US9434725, 285
DM6Z01B	HS	Patented
DM6Z01B	SN	SCHEMBL15400185; CHEMBL3891387; BDBM249054; US9434725, 285
DM6Z01B	DT	Small molecular drug
DM6Z01B	PC	89914090
DM6Z01B	MW	401.5
DM6Z01B	FM	C21H23N9
DM6Z01B	IC	InChI=1S/C21H23N9/c1-2-24-19-14-23-13-17(27-19)16-10-18-15(11-25-16)12-26-30(18)21-5-3-4-20(28-21)29-8-6-22-7-9-29/h3-5,10-14,22H,2,6-9H2,1H3,(H,24,27)
DM6Z01B	CS	CCNC1=NC(=CN=C1)C2=NC=C3C=NN(C3=C2)C4=NC(=CC=C4)N5CCNCC5
DM6Z01B	IK	XXIAOEADCPRWAT-UHFFFAOYSA-N
DM6Z01B	IU	N-ethyl-6-[1-(6-piperazin-1-ylpyridin-2-yl)pyrazolo[4,3-c]pyridin-6-yl]pyrazin-2-amine

DM316FB	ID	DM316FB
DM316FB	DN	US9434725, 315
DM316FB	HS	Patented
DM316FB	SN	SCHEMBL15400195; CHEMBL3890953; BDBM249084; US9434725, 315
DM316FB	DT	Small molecular drug
DM316FB	PC	89914096
DM316FB	MW	382.4
DM316FB	FM	C21H18N8
DM316FB	IC	InChI=1S/C21H18N8/c1-2-16-13-23-14-18(26-16)17-10-19-15(11-24-17)12-25-29(19)21-5-3-4-20(27-21)28-8-6-22-7-9-28/h1,3-5,10-14,22H,6-9H2
DM316FB	CS	C#CC1=CN=CC(=N1)C2=NC=C3C=NN(C3=C2)C4=NC(=CC=C4)N5CCNCC5
DM316FB	IK	LBSWUVMKCABART-UHFFFAOYSA-N
DM316FB	IU	6-(6-ethynylpyrazin-2-yl)-1-(6-piperazin-1-ylpyridin-2-yl)pyrazolo[4,3-c]pyridine

DMIT0H3	ID	DMIT0H3
DMIT0H3	DN	US9434727, 120
DMIT0H3	HS	Patented
DMIT0H3	SN	SCHEMBL17222950; CHEMBL3890586; BDBM249522; US9434727, 120
DMIT0H3	DT	Small molecular drug
DMIT0H3	PC	118483425
DMIT0H3	MW	439.4
DMIT0H3	FM	C20H18F5N5O
DMIT0H3	IC	InChI=1S/C20H18F5N5O/c21-14-2-1-12(16(17(14)22)20(23,24)25)11-3-7-30(8-4-11)19(31)18-13-5-6-29(10-26)9-15(13)27-28-18/h1-2,11H,3-9H2,(H,27,28)
DMIT0H3	CS	C1CN(CCC1C2=C(C(=C(C=C2)F)F)C(F)(F)F)C(=O)C3=NNC4=C3CCN(C4)C#N
DMIT0H3	IK	TXJTYIKCTGYLBH-UHFFFAOYSA-N
DMIT0H3	IU	3-[4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl]-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carbonitrile

DMC812I	ID	DMC812I
DMC812I	DN	US9434727, 153
DMC812I	HS	Patented
DMC812I	SN	SCHEMBL17223023; CHEMBL3892497; BDBM249555; US9434727, 153
DMC812I	DT	Small molecular drug
DMC812I	PC	118483501
DMC812I	MW	488.4
DMC812I	FM	C22H22F6N4O2
DMC812I	IC	InChI=1S/C22H22F6N4O2/c1-12(33)32-7-4-17-18(11-32)29-30-19(17)20(34)31-5-2-13(3-6-31)14-8-15(21(23,24)25)10-16(9-14)22(26,27)28/h8-10,13H,2-7,11H2,1H3,(H,29,30)
DMC812I	CS	CC(=O)N1CCC2=C(C1)NN=C2C(=O)N3CCC(CC3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMC812I	IK	UYJQGBUMNGFPIF-UHFFFAOYSA-N
DMC812I	IU	1-[3-[4-[3,5-bis(trifluoromethyl)phenyl]piperidine-1-carbonyl]-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]ethanone

DMLPWK3	ID	DMLPWK3
DMLPWK3	DN	US9434727, 40
DMLPWK3	HS	Patented
DMLPWK3	SN	SCHEMBL17229884; CHEMBL3981399; BDBM249462; US9434727, 40
DMLPWK3	DT	Small molecular drug
DMLPWK3	PC	118483372
DMLPWK3	MW	362.8
DMLPWK3	FM	C18H20ClFN4O
DMLPWK3	IC	InChI=1S/C18H20ClFN4O/c19-16-12(2-1-3-14(16)20)11-5-8-24(9-6-11)18(25)17-13-4-7-21-10-15(13)22-23-17/h1-3,11,21H,4-10H2,(H,22,23)
DMLPWK3	CS	C1CN(CCC1C2=C(C(=CC=C2)F)Cl)C(=O)C3=NNC4=C3CCNC4
DMLPWK3	IK	PJUXIWWOLCCJBG-UHFFFAOYSA-N
DMLPWK3	IU	[4-(2-chloro-3-fluorophenyl)piperidin-1-yl]-(4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-yl)methanone

DM9HQXC	ID	DM9HQXC
DM9HQXC	DN	US9434727, 63
DM9HQXC	HS	Patented
DM9HQXC	SN	CHEMBL3892353; SCHEMBL17223067; BDBM249464; US9434727, 63
DM9HQXC	DT	Small molecular drug
DM9HQXC	PC	118483546
DM9HQXC	MW	438.4
DM9HQXC	FM	C21H22F4N4O2
DM9HQXC	IC	InChI=1S/C21H22F4N4O2/c1-12(30)29-10-7-15-17(11-29)26-27-19(15)20(31)28-8-5-13(6-9-28)14-3-2-4-16(22)18(14)21(23,24)25/h2-4,13H,5-11H2,1H3,(H,26,27)
DM9HQXC	CS	CC(=O)N1CCC2=C(C1)NN=C2C(=O)N3CCC(CC3)C4=C(C(=CC=C4)F)C(F)(F)F
DM9HQXC	IK	VICXOPXLVAUSNR-UHFFFAOYSA-N
DM9HQXC	IU	1-[3-[4-[3-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl]-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]ethanone

DMCJG8Z	ID	DMCJG8Z
DMCJG8Z	DN	US9434727, 93
DMCJG8Z	HS	Patented
DMCJG8Z	SN	SCHEMBL17222937; CHEMBL3890367; BDBM249495; US9434727, 93
DMCJG8Z	DT	Small molecular drug
DMCJG8Z	PC	118483410
DMCJG8Z	MW	510.4
DMCJG8Z	FM	C22H22F8N4O
DMCJG8Z	IC	InChI=1S/C22H22F8N4O/c23-15-2-1-13(17(18(15)24)22(28,29)30)12-3-8-34(9-4-12)20(35)19-14-11-33(10-6-21(25,26)27)7-5-16(14)31-32-19/h1-2,12H,3-11H2,(H,31,32)
DMCJG8Z	CS	C1CN(CCC1C2=C(C(=C(C=C2)F)F)C(F)(F)F)C(=O)C3=NNC4=C3CN(CC4)CCC(F)(F)F
DMCJG8Z	IK	GUCHXVVEHJYGON-UHFFFAOYSA-N
DMCJG8Z	IU	[4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]-[5-(3,3,3-trifluoropropyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-3-yl]methanone

DMVQ3IX	ID	DMVQ3IX
DMVQ3IX	DN	US9453017, 1
DMVQ3IX	HS	Patented
DMVQ3IX	SN	CHEMBL3925090; BDBM247409; US9453017, 1
DMVQ3IX	DT	Small molecular drug
DMVQ3IX	PC	131635533
DMVQ3IX	MW	446.5
DMVQ3IX	FM	C26H27FN4O2
DMVQ3IX	IC	InChI=1S/C26H27FN4O2/c27-22-6-3-7-23(17-22)31-25(33)29-18-26(31)10-13-30(14-11-26)15-12-28-24(32)21-9-8-19-4-1-2-5-20(19)16-21/h1-9,16-17H,10-15,18H2,(H,28,32)(H,29,33)
DMVQ3IX	CS	C1CN(CCC12CNC(=O)N2C3=CC(=CC=C3)F)CCNC(=O)C4=CC5=CC=CC=C5C=C4
DMVQ3IX	IK	BYFCBILNFVVIKQ-UHFFFAOYSA-N
DMVQ3IX	IU	N-[2-[1-(3-fluorophenyl)-2-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]ethyl]naphthalene-2-carboxamide

DMPH05Y	ID	DMPH05Y
DMPH05Y	DN	US9453017, 2
DMPH05Y	HS	Patented
DMPH05Y	SN	SCHEMBL14833317; CHEMBL3947795; BDBM247410; US9453017, 2
DMPH05Y	DT	Small molecular drug
DMPH05Y	PC	74763829
DMPH05Y	MW	497.4
DMPH05Y	FM	C25H29BrN4O2
DMPH05Y	IC	InChI=1S/C25H29BrN4O2/c1-16(27-24(31)21-14-20(21)17-5-3-2-4-6-17)15-29-11-9-19(10-12-29)30-23-8-7-18(26)13-22(23)28-25(30)32/h2-8,13,16,19-21H,9-12,14-15H2,1H3,(H,27,31)(H,28,32)/t16-,20+,21+/m0/s1
DMPH05Y	CS	C[C@@H](CN1CCC(CC1)N2C3=C(C=C(C=C3)Br)NC2=O)NC(=O)[C@@H]4C[C@@H]4C5=CC=CC=C5
DMPH05Y	IK	JSVNNLRZCJAYTQ-ZLGUVYLKSA-N
DMPH05Y	IU	(1R,2S)-N-[(2S)-1-[4-(5-bromo-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]propan-2-yl]-2-phenylcyclopropane-1-carboxamide

DMGPDEF	ID	DMGPDEF
DMGPDEF	DN	US9475795, 19
DMGPDEF	HS	Patented
DMGPDEF	SN	CHEMBL3891428; SCHEMBL15549092; UOPFZPMEKNDBSU-UHFFFAOYSA-N; BDBM250540; US9475795, 19; 4-Phenoxy-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]piperidine
DMGPDEF	DT	Small molecular drug
DMGPDEF	PC	72549319
DMGPDEF	MW	349.4
DMGPDEF	FM	C17H23N3O3S
DMGPDEF	IC	InChI=1S/C17H23N3O3S/c1-13-17(14(2)19(3)18-13)24(21,22)20-11-9-16(10-12-20)23-15-7-5-4-6-8-15/h4-8,16H,9-12H2,1-3H3
DMGPDEF	CS	CC1=C(C(=NN1C)C)S(=O)(=O)N2CCC(CC2)OC3=CC=CC=C3
DMGPDEF	IK	UOPFZPMEKNDBSU-UHFFFAOYSA-N
DMGPDEF	IU	4-phenoxy-1-(1,3,5-trimethylpyrazol-4-yl)sulfonylpiperidine

DM0ZDL3	ID	DM0ZDL3
DM0ZDL3	DN	US9475795, 80
DM0ZDL3	HS	Patented
DM0ZDL3	SN	SCHEMBL15548679; CHEMBL3891242; RXIULEDXXPGKEE-UHFFFAOYSA-N; BDBM250601; US9475795, 80; 4-(4-Chloro-2-fluorobenzyl)-1-((3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl)-4-fluoropiperidine
DM0ZDL3	DT	Small molecular drug
DM0ZDL3	PC	72550891
DM0ZDL3	MW	403.9
DM0ZDL3	FM	C17H20ClF2N3O2S
DM0ZDL3	IC	InChI=1S/C17H20ClF2N3O2S/c1-11-16(12(2)22-21-11)26(24,25)23-7-5-17(20,6-8-23)10-13-3-4-14(18)9-15(13)19/h3-4,9H,5-8,10H2,1-2H3,(H,21,22)
DM0ZDL3	CS	CC1=C(C(=NN1)C)S(=O)(=O)N2CCC(CC2)(CC3=C(C=C(C=C3)Cl)F)F
DM0ZDL3	IK	RXIULEDXXPGKEE-UHFFFAOYSA-N
DM0ZDL3	IU	4-[(4-chloro-2-fluorophenyl)methyl]-1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-fluoropiperidine

DMR6ODL	ID	DMR6ODL
DMR6ODL	DN	US9475795, 89
DMR6ODL	HS	Patented
DMR6ODL	SN	CHEMBL3889563; SCHEMBL15549096; JDTHPTFPMSSAJL-UHFFFAOYSA-N; BDBM250610; US9475795, 89; 4-(4-Chloro-2-methoxybenzyl)-1-((3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-ol
DMR6ODL	DT	Small molecular drug
DMR6ODL	PC	72551112
DMR6ODL	MW	413.9
DMR6ODL	FM	C18H24ClN3O4S
DMR6ODL	IC	InChI=1S/C18H24ClN3O4S/c1-12-17(13(2)21-20-12)27(24,25)22-8-6-18(23,7-9-22)11-14-4-5-15(19)10-16(14)26-3/h4-5,10,23H,6-9,11H2,1-3H3,(H,20,21)
DMR6ODL	CS	CC1=C(C(=NN1)C)S(=O)(=O)N2CCC(CC2)(CC3=C(C=C(C=C3)Cl)OC)O
DMR6ODL	IK	JDTHPTFPMSSAJL-UHFFFAOYSA-N
DMR6ODL	IU	4-[(4-chloro-2-methoxyphenyl)methyl]-1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]piperidin-4-ol

DM4MJ3U	ID	DM4MJ3U
DM4MJ3U	DN	US9493447, 1001
DM4MJ3U	HS	Patented
DM4MJ3U	SN	SCHEMBL2388915; CHEMBL3964627; BDBM253042; US9493447, 1001
DM4MJ3U	DT	Small molecular drug
DM4MJ3U	PC	53378118
DM4MJ3U	MW	499
DM4MJ3U	FM	C25H23ClN2O5S
DM4MJ3U	IC	InChI=1S/C25H23ClN2O5S/c1-5-32-24(15-6-8-16(9-7-15)25-28-27-14(2)34-25)23(29)19-11-10-18(33-19)17-12-20(30-3)22(26)21(13-17)31-4/h6-13,24H,5H2,1-4H3
DM4MJ3U	CS	CCOC(C1=CC=C(C=C1)C2=NN=C(S2)C)C(=O)C3=CC=C(O3)C4=CC(=C(C(=C4)OC)Cl)OC
DM4MJ3U	IK	QQHJRLKSCSRMEM-UHFFFAOYSA-N
DM4MJ3U	IU	1-[5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl]-2-ethoxy-2-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]ethanone

DMC1YR5	ID	DMC1YR5
DMC1YR5	DN	US9493490, C
DMC1YR5	HS	Patented
DMC1YR5	SN	US9493490, Example 3; BDBM258594; US9493490, C; US9493490, 6-(4-(1-aminoethyl)-2-fluorophenoxy)benzo[c][1,2]oxaborol-1(3H)-ol
DMC1YR5	DT	Small molecular drug
DMC1YR5	PC	90646682
DMC1YR5	MW	287.1
DMC1YR5	FM	C15H15BFNO3
DMC1YR5	IC	InChI=1S/C15H15BFNO3/c1-9(18)10-3-5-15(14(17)6-10)21-12-4-2-11-8-20-16(19)13(11)7-12/h2-7,9,19H,8,18H2,1H3
DMC1YR5	CS	B1(C2=C(CO1)C=CC(=C2)OC3=C(C=C(C=C3)C(C)N)F)O
DMC1YR5	IK	AKFFDQJZYBSJJA-UHFFFAOYSA-N
DMC1YR5	IU	1-[3-fluoro-4-[(1-hydroxy-3H-2,1-benzoxaborol-6-yl)oxy]phenyl]ethanamine

DMUVC25	ID	DMUVC25
DMUVC25	DN	US9493490, D
DMUVC25	HS	Patented
DMUVC25	SN	US9493490, Example 4; BDBM258595; US9493490, D; US9493490, 6-(4-(aminomethyl)-2-fluorophenoxy)-7-methylbenzo[c][1,2]oxaborol-1(3H)-ol
DMUVC25	DT	Small molecular drug
DMUVC25	PC	90646684
DMUVC25	MW	287.1
DMUVC25	FM	C15H15BFNO3
DMUVC25	IC	InChI=1S/C15H15BFNO3/c1-9-13(5-3-11-8-20-16(19)15(9)11)21-14-4-2-10(7-18)6-12(14)17/h2-6,19H,7-8,18H2,1H3
DMUVC25	CS	B1(C2=C(CO1)C=CC(=C2C)OC3=C(C=C(C=C3)CN)F)O
DMUVC25	IK	ZCITXZXBLWIHHP-UHFFFAOYSA-N
DMUVC25	IU	[3-fluoro-4-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-6-yl)oxy]phenyl]methanamine

DMFCIGE	ID	DMFCIGE
DMFCIGE	DN	US9493490, E
DMFCIGE	HS	Patented
DMFCIGE	SN	US9493490, Example 5; BDBM258596; US9493490, E; US9493490, 6-(4-(1-aminoethyl)-2-fluorophenoxy)-7-methylbenzo[c][1,2]oxaborol-1(3H)-ol
DMFCIGE	DT	Small molecular drug
DMFCIGE	PC	87056186
DMFCIGE	MW	301.1
DMFCIGE	FM	C16H17BFNO3
DMFCIGE	IC	InChI=1S/C16H17BFNO3/c1-9-14(5-4-12-8-21-17(20)16(9)12)22-15-6-3-11(10(2)19)7-13(15)18/h3-7,10,20H,8,19H2,1-2H3
DMFCIGE	CS	B1(C2=C(CO1)C=CC(=C2C)OC3=C(C=C(C=C3)C(C)N)F)O
DMFCIGE	IK	LKHWQSZVOZRQIZ-UHFFFAOYSA-N
DMFCIGE	IU	1-[3-fluoro-4-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-6-yl)oxy]phenyl]ethanamine

DMJDTSN	ID	DMJDTSN
DMJDTSN	DN	US9493490, L
DMJDTSN	HS	Patented
DMJDTSN	SN	US9493490, Example 11; BDBM258599; US9493490, L; US9493490, tert-butyl 2-fluoro-3-(1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborol-6-yloxy)benzylcarbamate
DMJDTSN	DT	Small molecular drug
DMJDTSN	PC	90646685
DMJDTSN	MW	387.2
DMJDTSN	FM	C20H23BFNO5
DMJDTSN	IC	InChI=1S/C20H23BFNO5/c1-12-15(9-8-14-11-26-21(25)17(12)14)27-16-7-5-6-13(18(16)22)10-23-19(24)28-20(2,3)4/h5-9,25H,10-11H2,1-4H3,(H,23,24)
DMJDTSN	CS	B1(C2=C(CO1)C=CC(=C2C)OC3=CC=CC(=C3F)CNC(=O)OC(C)(C)C)O
DMJDTSN	IK	LHNSCZROXVKHFK-UHFFFAOYSA-N
DMJDTSN	IU	tert-butyl N-[[2-fluoro-3-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-6-yl)oxy]phenyl]methyl]carbamate

DMR1Z3I	ID	DMR1Z3I
DMR1Z3I	DN	US9522888, 412
DMR1Z3I	HS	Patented
DMR1Z3I	SN	SCHEMBL17511423; BDBM65041; XFNWLBLKUWRFPE-SQGPQFPESA-N; US9522888, 412; ((1R,3S)-1-amino-3-((R)-2-((pentyloxy)methyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)cyclopentyl)methyl dihydrogen phosphate
DMR1Z3I	DT	Small molecular drug
DMR1Z3I	PC	118877302
DMR1Z3I	MW	429.4
DMR1Z3I	FM	C20H32NO7P
DMR1Z3I	IC	InChI=1S/C20H32NO7P/c1-2-3-4-9-25-12-17-13-26-19-10-15(5-6-18(19)28-17)16-7-8-20(21,11-16)14-27-29(22,23)24/h5-6,10,16-17H,2-4,7-9,11-14,21H2,1H3,(H2,22,23,24)/t16-,17+,20+/m0/s1
DMR1Z3I	CS	CCCCCOC[C@@H]1COC2=C(O1)C=CC(=C2)[C@H]3CC[C@@](C3)(COP(=O)(O)O)N
DMR1Z3I	IK	XFNWLBLKUWRFPE-SQGPQFPESA-N
DMR1Z3I	IU	[(1R,3S)-1-amino-3-[(2R)-2-(pentoxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]cyclopentyl]methyl dihydrogen phosphate

DM6UXZK	ID	DM6UXZK
DM6UXZK	DN	US9522888, 575
DM6UXZK	HS	Patented
DM6UXZK	SN	SCHEMBL15953589; BDBM65249; US9522888, 575
DM6UXZK	DT	Small molecular drug
DM6UXZK	PC	90342772
DM6UXZK	MW	409.5
DM6UXZK	FM	C22H36NO4P
DM6UXZK	IC	InChI=1S/C22H36NO4P/c1-2-3-4-5-6-17-7-8-19-14-20(10-9-18(19)13-17)21-11-12-22(23,15-21)16-27-28(24,25)26/h9-10,14,17,21H,2-8,11-13,15-16,23H2,1H3,(H2,24,25,26)/t17-,21-,22+/m1/s1
DM6UXZK	CS	CCCCCC[C@@H]1CCC2=C(C1)C=CC(=C2)[C@@H]3CC[C@](C3)(COP(=O)(O)O)N
DM6UXZK	IK	BWKSEIHXZRSETR-YHYVQYDKSA-N
DM6UXZK	IU	[(1S,3R)-1-amino-3-[(6R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methyl dihydrogen phosphate

DMG0QZ1	ID	DMG0QZ1
DMG0QZ1	DN	US9522888, 618
DMG0QZ1	HS	Patented
DMG0QZ1	SN	SCHEMBL17511478; BDBM65302; US9522888, 618
DMG0QZ1	DT	Small molecular drug
DMG0QZ1	PC	118877354
DMG0QZ1	MW	479.5
DMG0QZ1	FM	C23H30NO6PS
DMG0QZ1	IC	InChI=1S/C23H30NO6PS/c24-23(16-30-31(25,26)27)11-10-21(14-23)20-9-8-18-12-17(6-7-19(18)13-20)15-32(28,29)22-4-2-1-3-5-22/h1-5,8-9,13,17,21H,6-7,10-12,14-16,24H2,(H2,25,26,27)/t17-,21-,23+/m0/s1
DMG0QZ1	CS	C1CC2=C(C[C@H]1CS(=O)(=O)C3=CC=CC=C3)C=CC(=C2)[C@H]4CC[C@@](C4)(COP(=O)(O)O)N
DMG0QZ1	IK	UIXJBOOFWQSQAS-JWNTYJGQSA-N
DMG0QZ1	IU	[(1R,3S)-1-amino-3-[(6S)-6-(benzenesulfonylmethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methyl dihydrogen phosphate

DMTRZI7	ID	DMTRZI7
DMTRZI7	DN	US9522888, 695
DMTRZI7	HS	Patented
DMTRZI7	SN	SCHEMBL17511431; BDBM258469; US9522888, 695
DMTRZI7	DT	Small molecular drug
DMTRZI7	PC	118877309
DMTRZI7	MW	411.5
DMTRZI7	FM	C21H34NO5P
DMTRZI7	IC	InChI=1S/C21H34NO5P/c1-2-26-11-3-4-16-5-6-18-13-19(8-7-17(18)12-16)20-9-10-21(22,14-20)15-27-28(23,24)25/h7-8,13,16,20H,2-6,9-12,14-15,22H2,1H3,(H2,23,24,25)/t16-,20+,21-/m1/s1
DMTRZI7	CS	CCOCCC[C@@H]1CCC2=C(C1)C=CC(=C2)[C@H]3CC[C@@](C3)(COP(=O)(O)O)N
DMTRZI7	IK	VHKORLDZIRFKDI-TYCQWZJGSA-N
DMTRZI7	IU	[(1R,3S)-1-amino-3-[(6S)-6-(3-ethoxypropyl)-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methyl dihydrogen phosphate

DM81MV6	ID	DM81MV6
DM81MV6	DN	US9567304, Compound F-54
DM81MV6	HS	Patented
DM81MV6	SN	SCHEMBL16529160; ASAFNJMZLYOBFG-OAHLLOKOSA-N; BDBM286586; US9567304, Compound F-54; 7-[[(3R)-3-aminopiperidin-1-yl]methyl]-8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-6-(trifluoromethyl)-1H-quinazoline-2,4-dione; 7-((R)-3-Amino-piperidin-1-ylmethyl)-8-chloro-3-(5-chloro-2-ethanesulfonyl-benzyl)-6-trifluoromethyl-1H-quinazoline-2,4-dione
DM81MV6	DT	Small molecular drug
DM81MV6	PC	72195492
DM81MV6	MW	593.4
DM81MV6	FM	C24H25Cl2F3N4O4S
DM81MV6	IC	InChI=1S/C24H25Cl2F3N4O4S/c1-2-38(36,37)19-6-5-14(25)8-13(19)10-33-22(34)16-9-18(24(27,28)29)17(20(26)21(16)31-23(33)35)12-32-7-3-4-15(30)11-32/h5-6,8-9,15H,2-4,7,10-12,30H2,1H3,(H,31,35)/t15-/m1/s1
DM81MV6	CS	CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CN2C(=O)C3=CC(=C(C(=C3NC2=O)Cl)CN4CCC[C@H](C4)N)C(F)(F)F
DM81MV6	IK	ASAFNJMZLYOBFG-OAHLLOKOSA-N
DM81MV6	IU	7-[[(3R)-3-aminopiperidin-1-yl]methyl]-8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-6-(trifluoromethyl)-1H-quinazoline-2,4-dione

DMCGUNB	ID	DMCGUNB
DMCGUNB	DN	US9567304, Compound N-9
DMCGUNB	HS	Patented
DMCGUNB	SN	8-Chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-7-[[(3S)-3-(2-hydroxyethylamino)piperidin-1-yl]methyl]-6-(trifluoromethyl)-1H-quinazoline-2,4-dione; SCHEMBL15363305; YWUVDJQWNVIFHU-KRWDZBQOSA-N; US9567304, Compound N-9; BDBM286969
DMCGUNB	DT	Small molecular drug
DMCGUNB	PC	72195490
DMCGUNB	MW	637.5
DMCGUNB	FM	C26H29Cl2F3N4O5S
DMCGUNB	IC	InChI=1S/C26H29Cl2F3N4O5S/c1-2-41(39,40)21-6-5-16(27)10-15(21)12-35-24(37)18-11-20(26(29,30)31)19(22(28)23(18)33-25(35)38)14-34-8-3-4-17(13-34)32-7-9-36/h5-6,10-11,17,32,36H,2-4,7-9,12-14H2,1H3,(H,33,38)/t17-/m0/s1
DMCGUNB	CS	CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CN2C(=O)C3=CC(=C(C(=C3NC2=O)Cl)CN4CCC[C@@H](C4)NCCO)C(F)(F)F
DMCGUNB	IK	YWUVDJQWNVIFHU-KRWDZBQOSA-N
DMCGUNB	IU	8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-7-[[(3S)-3-(2-hydroxyethylamino)piperidin-1-yl]methyl]-6-(trifluoromethyl)-1H-quinazoline-2,4-dione

DMJ76RC	ID	DMJ76RC
DMJ76RC	DN	US9580418, Example 11
DMJ76RC	HS	Patented
DMJ76RC	SN	N-{4-[(3R,4R,5S)-3-Amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl}-7-(tetrahydro-2H-pyran-4-yl)quinoline-2-carboxamide; SCHEMBL17420248; ZCIAXCLJCAUHGJ-CQSIOLINSA-N; US9580418, Example 11; BDBM291190
DMJ76RC	DT	Small molecular drug
DMJ76RC	PC	118646830
DMJ76RC	MW	461.6
DMJ76RC	FM	C26H31N5O3
DMJ76RC	IC	InChI=1S/C26H31N5O3/c1-16-14-31(15-20(27)25(16)32)24-6-9-28-13-23(24)30-26(33)21-5-4-18-2-3-19(12-22(18)29-21)17-7-10-34-11-8-17/h2-6,9,12-13,16-17,20,25,32H,7-8,10-11,14-15,27H2,1H3,(H,30,33)/t16-,20+,25+/m0/s1
DMJ76RC	CS	C[C@H]1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=NC4=C(C=CC(=C4)C5CCOCC5)C=C3
DMJ76RC	IK	ZCIAXCLJCAUHGJ-CQSIOLINSA-N
DMJ76RC	IU	N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-7-(oxan-4-yl)quinoline-2-carboxamide

DMGH9B3	ID	DMGH9B3
DMGH9B3	DN	US9580418, Example 8
DMGH9B3	HS	Patented
DMGH9B3	SN	N-{4-[(3R,4R,5S)-3-Amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl}-7-morpholin-4-yl-1,5-naphthyridine-2-carboxamide; SCHEMBL17420252; US9580418, Example 8; SSNIKHVUFVVWIH-XSSDXNQZSA-N; BDBM291186
DMGH9B3	DT	Small molecular drug
DMGH9B3	PC	118646834
DMGH9B3	MW	463.5
DMGH9B3	FM	C24H29N7O3
DMGH9B3	IC	InChI=1S/C24H29N7O3/c1-15-13-31(14-17(25)23(15)32)22-4-5-26-12-21(22)29-24(33)19-3-2-18-20(28-19)10-16(11-27-18)30-6-8-34-9-7-30/h2-5,10-12,15,17,23,32H,6-9,13-14,25H2,1H3,(H,29,33)/t15-,17+,23+/m0/s1
DMGH9B3	CS	C[C@H]1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=NC4=C(C=C3)N=CC(=C4)N5CCOCC5
DMGH9B3	IK	SSNIKHVUFVVWIH-XSSDXNQZSA-N
DMGH9B3	IU	N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-7-morpholin-4-yl-1,5-naphthyridine-2-carboxamide

DMERWUQ	ID	DMERWUQ
DMERWUQ	DN	US9586942, 16
DMERWUQ	HS	Patented
DMERWUQ	SN	SCHEMBL16651983; BDBM294242; US9586942, 16; N-(1-((7S,8R)-8-benzyl-7-(3-azabicyclo[3.1.0]hexan-3-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)azetidin-3-yl)-1-methyl-1H-1,2,3-triazole-4-sulfonamide
DMERWUQ	DT	Small molecular drug
DMERWUQ	PC	118022753
DMERWUQ	MW	518.7
DMERWUQ	FM	C28H34N6O2S
DMERWUQ	IC	InChI=1S/C28H34N6O2S/c1-32-18-28(29-31-32)37(35,36)30-23-16-33(17-23)24-9-7-20-8-10-27(34-14-21-12-22(21)15-34)26(25(20)13-24)11-19-5-3-2-4-6-19/h2-7,9,13,18,21-23,26-27,30H,8,10-12,14-17H2,1H3/t21?,22?,26-,27+/m1/s1
DMERWUQ	CS	CN1C=C(N=N1)S(=O)(=O)NC2CN(C2)C3=CC4=C(CC[C@@H]([C@@H]4CC5=CC=CC=C5)N6CC7CC7C6)C=C3
DMERWUQ	IK	RWNRNSRLIFLPBC-PGJSQRTPSA-N
DMERWUQ	IU	N-[1-[(7S,8R)-7-(3-azabicyclo[3.1.0]hexan-3-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]azetidin-3-yl]-1-methyltriazole-4-sulfonamide

DMZ745J	ID	DMZ745J
DMZ745J	DN	US9586942, 2
DMZ745J	HS	Patented
DMZ745J	SN	SCHEMBL16652919; OLRHCKCMIVFULU-FTJBHMTQSA-N; BDBM294228; BDBM294227; US9586942, 2; US9586942, 1; N-(1-((7S,8R)-7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)azetidin-3-yl)-1-methyl-1H-imidazole-4-sulfonamide; N-(1-((7S,8R)-7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)azetidin-3-yl)-1-methyl-1H-pyrazole-4-sulfonamide
DMZ745J	DT	Small molecular drug
DMZ745J	PC	91754447
DMZ745J	MW	491.6
DMZ745J	FM	C27H33N5O2S
DMZ745J	IC	InChI=1S/C27H33N5O2S/c1-30-18-27(28-19-30)35(33,34)29-22-16-32(17-22)23-10-8-21-9-11-26(31-12-5-13-31)25(24(21)15-23)14-20-6-3-2-4-7-20/h2-4,6-8,10,15,18-19,22,25-26,29H,5,9,11-14,16-17H2,1H3/t25-,26+/m1/s1
DMZ745J	CS	CN1C=C(N=C1)S(=O)(=O)NC2CN(C2)C3=CC4=C(CC[C@@H]([C@@H]4CC5=CC=CC=C5)N6CCC6)C=C3
DMZ745J	IK	OLRHCKCMIVFULU-FTJBHMTQSA-N
DMZ745J	IU	N-[1-[(7S,8R)-7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]azetidin-3-yl]-1-methylimidazole-4-sulfonamide

DMRXCYF	ID	DMRXCYF
DMRXCYF	DN	US9586942, 3*
DMRXCYF	HS	Patented
DMRXCYF	SN	SCHEMBL16651324; BDBM294229; US9586942, 3*
DMRXCYF	DT	Small molecular drug
DMRXCYF	PC	118022168
DMRXCYF	MW	425.6
DMRXCYF	FM	C24H31N3O2S
DMRXCYF	IC	InChI=1S/C24H31N3O2S/c1-30(28,29)25-20-16-27(17-20)21-10-8-19-9-11-24(26-12-5-13-26)23(22(19)15-21)14-18-6-3-2-4-7-18/h2-4,6-8,10,15,20,23-25H,5,9,11-14,16-17H2,1H3/t23-,24+/m1/s1
DMRXCYF	CS	CS(=O)(=O)NC1CN(C1)C2=CC3=C(CC[C@@H]([C@@H]3CC4=CC=CC=C4)N5CCC5)C=C2
DMRXCYF	IK	DTCYWONIILSWPE-RPWUZVMVSA-N
DMRXCYF	IU	N-[1-[(7S,8R)-7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]azetidin-3-yl]methanesulfonamide

DM2RE91	ID	DM2RE91
DM2RE91	DN	US9586945, 1
DM2RE91	HS	Patented
DM2RE91	SN	SCHEMBL16652550; BDBM294244; US9586945, 1; N-[1-[3-(azetidin-1-yl)-4-benzyl-chroman-6-yl]azetidin-3-yl]-1-methyl-imidazole-4-sulfonamide
DM2RE91	DT	Small molecular drug
DM2RE91	PC	91754453
DM2RE91	MW	493.6
DM2RE91	FM	C26H31N5O3S
DM2RE91	IC	InChI=1S/C26H31N5O3S/c1-29-16-26(27-18-29)35(32,33)28-20-14-31(15-20)21-8-9-25-23(13-21)22(12-19-6-3-2-4-7-19)24(17-34-25)30-10-5-11-30/h2-4,6-9,13,16,18,20,22,24,28H,5,10-12,14-15,17H2,1H3
DM2RE91	CS	CN1C=C(N=C1)S(=O)(=O)NC2CN(C2)C3=CC4=C(C=C3)OCC(C4CC5=CC=CC=C5)N6CCC6
DM2RE91	IK	LMBGMNQXZDWDDD-UHFFFAOYSA-N
DM2RE91	IU	N-[1-[3-(azetidin-1-yl)-4-benzyl-3,4-dihydro-2H-chromen-6-yl]azetidin-3-yl]-1-methylimidazole-4-sulfonamide

DMKZC4V	ID	DMKZC4V
DMKZC4V	DN	US9586945, 19a
DMKZC4V	HS	Patented
DMKZC4V	SN	SCHEMBL16651999; BDBM294267; US9586945, 19a; Cis-N-(1-(4-benzyl-7-fluoro-3-(methylamino)chroman-6-yl)azetidin-3-yl)-1-cyclopropylmethanesulfonamide
DMKZC4V	DT	Small molecular drug
DMKZC4V	PC	118022766
DMKZC4V	MW	459.6
DMKZC4V	FM	C24H30FN3O3S
DMKZC4V	IC	InChI=1S/C24H30FN3O3S/c1-26-22-14-31-24-11-21(25)23(10-20(24)19(22)9-16-5-3-2-4-6-16)28-12-18(13-28)27-32(29,30)15-17-7-8-17/h2-6,10-11,17-19,22,26-27H,7-9,12-15H2,1H3/t19-,22+/m0/s1
DMKZC4V	CS	CN[C@@H]1COC2=CC(=C(C=C2[C@@H]1CC3=CC=CC=C3)N4CC(C4)NS(=O)(=O)CC5CC5)F
DMKZC4V	IK	BOABKZGNZKTRFI-SIKLNZKXSA-N
DMKZC4V	IU	N-[1-[(3S,4S)-4-benzyl-7-fluoro-3-(methylamino)-3,4-dihydro-2H-chromen-6-yl]azetidin-3-yl]-1-cyclopropylmethanesulfonamide

DM6A8XJ	ID	DM6A8XJ
DM6A8XJ	DN	US9586945, 5
DM6A8XJ	HS	Patented
DM6A8XJ	SN	SCHEMBL16651786; BDBM294248; US9586945, 5; Cis-N-(1-(3-(azetidin-1-yl)-4-benzylchroman-6-yl)azetidin-3-yl)-1-methyl-1H-pyrazole-4-sulfonamide
DM6A8XJ	DT	Small molecular drug
DM6A8XJ	PC	118022572
DM6A8XJ	MW	493.6
DM6A8XJ	FM	C26H31N5O3S
DM6A8XJ	IC	InChI=1S/C26H31N5O3S/c1-29-17-22(14-27-29)35(32,33)28-20-15-31(16-20)21-8-9-26-24(13-21)23(12-19-6-3-2-4-7-19)25(18-34-26)30-10-5-11-30/h2-4,6-9,13-14,17,20,23,25,28H,5,10-12,15-16,18H2,1H3
DM6A8XJ	CS	CN1C=C(C=N1)S(=O)(=O)NC2CN(C2)C3=CC4=C(C=C3)OCC(C4CC5=CC=CC=C5)N6CCC6
DM6A8XJ	IK	WCDMIBGCPCYAHS-UHFFFAOYSA-N
DM6A8XJ	IU	N-[1-[3-(azetidin-1-yl)-4-benzyl-3,4-dihydro-2H-chromen-6-yl]azetidin-3-yl]-1-methylpyrazole-4-sulfonamide

DMRVQ5Z	ID	DMRVQ5Z
DMRVQ5Z	DN	US9598431, 1
DMRVQ5Z	HS	Patented
DMRVQ5Z	SN	SCHEMBL18579631; BDBM302858; US9598431, 1; (S)-N-((5-(ETHYLSULFONYL)PYRIDIN-2-YL)METHYL)-5'-METHYL-1-((R)-1-(2-(TRIFLUOROMETHYL)PYRIMIDIN-5-YL)ETHYL)-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN]-2'-CARBOXAMIDE; N-{[5-(Ethylsulfonyl)pyridine-2-yl]methyl}-5'-methyl-1-{1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-4',5'-dihydrospiro[piperidine-4,7'thieno[2,3-C]pyran]-2'-carboxamide
DMRVQ5Z	DT	Small molecular drug
DMRVQ5Z	PC	126644142
DMRVQ5Z	MW	623.7
DMRVQ5Z	FM	C28H32F3N5O4S2
DMRVQ5Z	IC	InChI=1S/C28H32F3N5O4S2/c1-4-42(38,39)22-6-5-21(32-16-22)15-33-25(37)23-12-19-11-17(2)40-27(24(19)41-23)7-9-36(10-8-27)18(3)20-13-34-26(35-14-20)28(29,30)31/h5-6,12-14,16-18H,4,7-11,15H2,1-3H3,(H,33,37)
DMRVQ5Z	CS	CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C(S2)C4(CCN(CC4)C(C)C5=CN=C(N=C5)C(F)(F)F)OC(C3)C
DMRVQ5Z	IK	ILXLMNLDODDHOQ-UHFFFAOYSA-N
DMRVQ5Z	IU	N-[(5-ethylsulfonylpyridin-2-yl)methyl]-5-methyl-1'-[1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-2-carboxamide

DMILY1P	ID	DMILY1P
DMILY1P	DN	US9598431, 2
DMILY1P	HS	Patented
DMILY1P	SN	SCHEMBL18609672; BDBM302859; US9598431, 2; (5S') inverted question markN-{[5-(Ethylsulfonyl)pyridine-2-yl]methyl}-5'-methyl-1-{(1S)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-4',5'-dihydrospiro[piperidine-4,7'thieno[2,3-C]pyran]-2'-carboxamide
DMILY1P	DT	Small molecular drug
DMILY1P	PC	126669595
DMILY1P	MW	623.7
DMILY1P	FM	C28H32F3N5O4S2
DMILY1P	IC	InChI=1S/C28H32F3N5O4S2/c1-4-42(38,39)22-6-5-21(32-16-22)15-33-25(37)23-12-19-11-17(2)40-27(24(19)41-23)7-9-36(10-8-27)18(3)20-13-34-26(35-14-20)28(29,30)31/h5-6,12-14,16-18H,4,7-11,15H2,1-3H3,(H,33,37)/t17-,18-/m0/s1
DMILY1P	CS	CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C(S2)C4(CCN(CC4)[C@@H](C)C5=CN=C(N=C5)C(F)(F)F)O[C@H](C3)C
DMILY1P	IK	ILXLMNLDODDHOQ-ROUUACIJSA-N
DMILY1P	IU	(5S)-N-[(5-ethylsulfonylpyridin-2-yl)methyl]-5-methyl-1'-[(1S)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-2-carboxamide

DMRC4O7	ID	DMRC4O7
DMRC4O7	DN	US9598431, 3
DMRC4O7	HS	Patented
DMRC4O7	SN	SCHEMBL18580158; BDBM302860; (2S)-1-(3-Thienyl)propan-2-ol; US9598431, 3
DMRC4O7	DT	Small molecular drug
DMRC4O7	PC	126644564
DMRC4O7	MW	623.7
DMRC4O7	FM	C28H32F3N5O4S2
DMRC4O7	IC	InChI=1S/C28H32F3N5O4S2/c1-4-42(38,39)22-6-5-21(32-16-22)15-33-25(37)23-12-19-11-17(2)40-27(24(19)41-23)7-9-36(10-8-27)18(3)20-13-34-26(35-14-20)28(29,30)31/h5-6,12-14,16-18H,4,7-11,15H2,1-3H3,(H,33,37)/t17-,18+/m0/s1
DMRC4O7	CS	CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C(S2)C4(CCN(CC4)[C@H](C)C5=CN=C(N=C5)C(F)(F)F)O[C@H](C3)C
DMRC4O7	IK	ILXLMNLDODDHOQ-ZWKOTPCHSA-N
DMRC4O7	IU	(5S)-N-[(5-ethylsulfonylpyridin-2-yl)methyl]-5-methyl-1'-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-2-carboxamide

DMXGF56	ID	DMXGF56
DMXGF56	DN	US9598431, 5
DMXGF56	HS	Patented
DMXGF56	SN	SCHEMBL18609480; BDBM302861; BDBM302862; US9598431, 5; US9598431, 4; (5'S)-5-Methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]; tert-Butyl (5'S)-5'-methyl-4',5'-dihydro-1H-spiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-carboxylate
DMXGF56	DT	Small molecular drug
DMXGF56	PC	126669412
DMXGF56	MW	623.7
DMXGF56	FM	C28H32F3N5O4S2
DMXGF56	IC	InChI=1S/C28H32F3N5O4S2/c1-4-42(38,39)22-6-5-21(32-16-22)15-33-25(37)23-12-19-11-17(2)40-27(24(19)41-23)7-9-36(10-8-27)18(3)20-13-34-26(35-14-20)28(29,30)31/h5-6,12-14,16-18H,4,7-11,15H2,1-3H3,(H,33,37)/t17-,18?/m1/s1
DMXGF56	CS	CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C(S2)C4(CCN(CC4)C(C)C5=CN=C(N=C5)C(F)(F)F)O[C@@H](C3)C
DMXGF56	IK	ILXLMNLDODDHOQ-QNSVNVJESA-N
DMXGF56	IU	(5R)-N-[(5-ethylsulfonylpyridin-2-yl)methyl]-5-methyl-1'-[1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-2-carboxamide

DMSD354	ID	DMSD354
DMSD354	DN	US9611221, Example 9
DMSD354	HS	Patented
DMSD354	SN	3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; US9611221, Example 9; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105
DMSD354	DT	Small molecular drug
DMSD354	PC	71766727
DMSD354	MW	304.3
DMSD354	FM	C19H16N2O2
DMSD354	IC	InChI=1S/C19H16N2O2/c22-19(23)17-10-11-20-13-18(17)21-12-14-6-8-16(9-7-14)15-4-2-1-3-5-15/h1-11,13,21H,12H2,(H,22,23)
DMSD354	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CNC3=C(C=CN=C3)C(=O)O
DMSD354	IK	RNBCOBWQQCESLL-UHFFFAOYSA-N
DMSD354	IU	3-[(4-phenylphenyl)methylamino]pyridine-4-carboxylic acid

DM89LKQ	ID	DM89LKQ
DM89LKQ	DN	US9617250, Example 1 Example 204 of D1
DM89LKQ	HS	Patented
DM89LKQ	SN	CHEMBL3124957; BDBM50165434; SCHEMBL3214485; BDBM317453; US9617250, Example 1 Example 204 of D1
DM89LKQ	DT	Small molecular drug
DM89LKQ	PC	25031140
DM89LKQ	MW	496.6
DM89LKQ	FM	C27H36N4O5
DM89LKQ	IC	InChI=1S/C27H36N4O5/c1-6-18(7-2)23-12-21(10-17(5)29-23)27-30-26(31-36-27)20-9-16(4)25(19(8-3)11-20)35-15-22(33)13-28-24(34)14-32/h9-12,18,22,32-33H,6-8,13-15H2,1-5H3,(H,28,34)/t22-/m0/s1
DM89LKQ	CS	CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)C)C(CC)CC)C)OC[C@H](CNC(=O)CO)O
DM89LKQ	IK	CHIUPZSZKBJIHD-QFIPXVFZSA-N
DM89LKQ	IU	N-[(2S)-3-[2-ethyl-6-methyl-4-[5-(2-methyl-6-pentan-3-ylpyridin-4-yl)-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide

DM6F7M2	ID	DM6F7M2
DM6F7M2	DN	US9623028, Compound 101
DM6F7M2	HS	Patented
DM6F7M2	SN	SCHEMBL15880506; CHEMBL4099734; BDBM317468; US9623028, Compound 101; 4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxyethyl)-3- methoxybenzamide
DM6F7M2	DT	Small molecular drug
DM6F7M2	PC	90285039
DM6F7M2	MW	542.6
DM6F7M2	FM	C29H30N6O5
DM6F7M2	IC	InChI=1S/C29H30N6O5/c1-16-32-22-9-7-17(13-24(22)39-16)20-15-31-26-25(20)28(40-19-5-3-4-6-19)35-29(34-26)33-21-10-8-18(14-23(21)38-2)27(37)30-11-12-36/h7-10,13-15,19,36H,3-6,11-12H2,1-2H3,(H,30,37)(H2,31,33,34,35)
DM6F7M2	CS	CC1=NC2=C(O1)C=C(C=C2)C3=CNC4=C3C(=NC(=N4)NC5=C(C=C(C=C5)C(=O)NCCO)OC)OC6CCCC6
DM6F7M2	IK	DUZMKFLMNMTYDM-UHFFFAOYSA-N
DM6F7M2	IU	4-[[4-cyclopentyloxy-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)-3-methoxybenzamide

DMMSHX4	ID	DMMSHX4
DMMSHX4	DN	US9623028, Compound 79
DMMSHX4	HS	Patented
DMMSHX4	SN	SCHEMBL15882853; CHEMBL4093026; US9623028, Compound 79; BDBM317465; 4-(4-(cyclopentyloxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide
DMMSHX4	DT	Small molecular drug
DMMSHX4	PC	77846902
DMMSHX4	MW	514.6
DMMSHX4	FM	C28H30N6O4
DMMSHX4	IC	InChI=1S/C28H30N6O4/c1-29-25(35)17-10-8-16(9-11-17)20-15-31-24-23(20)27(38-19-6-4-5-7-19)34-28(33-24)32-21-13-12-18(26(36)30-2)14-22(21)37-3/h8-15,19H,4-7H2,1-3H3,(H,29,35)(H,30,36)(H2,31,32,33,34)
DMMSHX4	CS	CNC(=O)C1=CC=C(C=C1)C2=CNC3=C2C(=NC(=N3)NC4=C(C=C(C=C4)C(=O)NC)OC)OC5CCCC5
DMMSHX4	IK	YMYOREROCXXANC-UHFFFAOYSA-N
DMMSHX4	IU	4-[[4-cyclopentyloxy-5-[4-(methylcarbamoyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxy-N-methylbenzamide

DMR3Z49	ID	DMR3Z49
DMR3Z49	DN	US9650366, 12
DMR3Z49	HS	Patented
DMR3Z49	SN	SCHEMBL17669987; BDBM308061; US9650366, 12
DMR3Z49	DT	Small molecular drug
DMR3Z49	PC	121268883
DMR3Z49	MW	525.5
DMR3Z49	FM	C25H19F4N7O2
DMR3Z49	IC	InChI=1S/C25H19F4N7O2/c26-21-9-6-19(25(27,28)29)13-22(21)32-24(38)31-20-7-4-16(5-8-20)2-3-17-12-18(15-30-14-17)23-33-35-36(34-23)10-1-11-37/h4-9,12-15,37H,1,10-11H2,(H2,31,32,38)
DMR3Z49	CS	C1=CC(=CC=C1C#CC2=CC(=CN=C2)C3=NN(N=N3)CCCO)NC(=O)NC4=C(C=CC(=C4)C(F)(F)F)F
DMR3Z49	IK	LOBSULBGQKFHGX-UHFFFAOYSA-N
DMR3Z49	IU	1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-[4-[2-[5-[2-(3-hydroxypropyl)tetrazol-5-yl]pyridin-3-yl]ethynyl]phenyl]urea

DM9HZ03	ID	DM9HZ03
DM9HZ03	DN	US9650366, 2
DM9HZ03	HS	Patented
DM9HZ03	SN	SCHEMBL17669993; LHUVPYZTQHNXRU-UHFFFAOYSA-N; BDBM308050; US9650366, 2; 1-{2-[2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl]-1-benzothien-5-yl}-3-[4-chloro-3-(trifluoromethyl)phenyl]urea; 1-(2-(2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl)benzo[b]thiophen-5-yl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea
DM9HZ03	DT	Small molecular drug
DM9HZ03	PC	121268887
DM9HZ03	MW	530.9
DM9HZ03	FM	C22H14ClF3N8OS
DM9HZ03	IC	InChI=1S/C22H14ClF3N8OS/c23-16-3-1-13(8-15(16)22(24,25)26)30-21(35)29-12-2-4-17-10(5-12)7-18(36-17)14-6-11(9-28-19(14)27)20-31-33-34-32-20/h1-9H,(H2,27,28)(H2,29,30,35)(H,31,32,33,34)
DM9HZ03	CS	C1=CC2=C(C=C1NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)C=C(S2)C4=C(N=CC(=C4)C5=NNN=N5)N
DM9HZ03	IK	LHUVPYZTQHNXRU-UHFFFAOYSA-N
DM9HZ03	IU	1-[2-[2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl]-1-benzothiophen-5-yl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea

DMUCIPE	ID	DMUCIPE
DMUCIPE	DN	US9650366, 9
DMUCIPE	HS	Patented
DMUCIPE	SN	SCHEMBL17670002; OGVARLFWIBVKET-UHFFFAOYSA-N; BDBM308058; US9650366, 9; N-[3-({5-[2-(3-hydroxypropyl)-2H-tetrazol-5-yl]pyridin-3-yl}ethynyl)phenyl]-3-methyl-2-furamide
DMUCIPE	DT	Small molecular drug
DMUCIPE	PC	121268893
DMUCIPE	MW	428.4
DMUCIPE	FM	C23H20N6O3
DMUCIPE	IC	InChI=1S/C23H20N6O3/c1-16-8-11-32-21(16)23(31)25-20-5-2-4-17(13-20)6-7-18-12-19(15-24-14-18)22-26-28-29(27-22)9-3-10-30/h2,4-5,8,11-15,30H,3,9-10H2,1H3,(H,25,31)
DMUCIPE	CS	CC1=C(OC=C1)C(=O)NC2=CC=CC(=C2)C#CC3=CC(=CN=C3)C4=NN(N=N4)CCCO
DMUCIPE	IK	OGVARLFWIBVKET-UHFFFAOYSA-N
DMUCIPE	IU	N-[3-[2-[5-[2-(3-hydroxypropyl)tetrazol-5-yl]pyridin-3-yl]ethynyl]phenyl]-3-methylfuran-2-carboxamide

DMXU8DI	ID	DMXU8DI
DMXU8DI	DN	US9656955, Example 351
DMXU8DI	HS	Patented
DMXU8DI	SN	SCHEMBL16032164; BDBM308837; US9656955, Example 351; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine
DMXU8DI	DT	Small molecular drug
DMXU8DI	PC	86295652
DMXU8DI	MW	469.5
DMXU8DI	FM	C20H19F4N5O2S
DMXU8DI	IC	InChI=1S/C20H19F4N5O2S/c1-28-11-19(25-12-28)32(30,31)29-9-15(13-5-7-14(21)8-6-13)16(10-29)26-18-4-2-3-17(27-18)20(22,23)24/h2-8,11-12,15-16H,9-10H2,1H3,(H,26,27)/t15-,16+/m1/s1
DMXU8DI	CS	CN1C=C(N=C1)S(=O)(=O)N2C[C@@H]([C@H](C2)NC3=CC=CC(=N3)C(F)(F)F)C4=CC=C(C=C4)F
DMXU8DI	IK	QHPPCJNRRPMMDC-CVEARBPZSA-N
DMXU8DI	IU	N-[(3R,4S)-4-(4-fluorophenyl)-1-(1-methylimidazol-4-yl)sulfonylpyrrolidin-3-yl]-6-(trifluoromethyl)pyridin-2-amine

DMC3Q9O	ID	DMC3Q9O
DMC3Q9O	DN	US9656955, Example 540
DMC3Q9O	HS	Patented
DMC3Q9O	SN	SCHEMBL16032646; BDBM309019; US9656955, Example 540; (3R,4S)-N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine
DMC3Q9O	DT	Small molecular drug
DMC3Q9O	PC	86295651
DMC3Q9O	MW	502.9
DMC3Q9O	FM	C21H19ClF4N4O2S
DMC3Q9O	IC	InChI=1S/C21H19ClF4N4O2S/c1-29-11-20(27-12-29)33(31,32)30-9-16(13-2-4-14(23)5-3-13)19(10-30)28-15-6-7-18(22)17(8-15)21(24,25)26/h2-8,11-12,16,19,28H,9-10H2,1H3/t16-,19+/m1/s1
DMC3Q9O	CS	CN1C=C(N=C1)S(=O)(=O)N2C[C@@H]([C@H](C2)NC3=CC(=C(C=C3)Cl)C(F)(F)F)C4=CC=C(C=C4)F
DMC3Q9O	IK	VSJNRQGUSYDZJE-APWZRJJASA-N
DMC3Q9O	IU	(3R,4S)-N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-(1-methylimidazol-4-yl)sulfonylpyrrolidin-3-amine

DMKS7D9	ID	DMKS7D9
DMKS7D9	DN	US9656955, Example 652
DMKS7D9	HS	Patented
DMKS7D9	SN	SCHEMBL16031609; BDBM309130; US9656955, Example 652; (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine
DMKS7D9	DT	Small molecular drug
DMKS7D9	PC	86295441
DMKS7D9	MW	486.5
DMKS7D9	FM	C21H19F5N4O2S
DMKS7D9	IC	InChI=1S/C21H19F5N4O2S/c1-29-11-20(27-12-29)33(31,32)30-9-16(13-2-4-14(22)5-3-13)19(10-30)28-15-6-7-18(23)17(8-15)21(24,25)26/h2-8,11-12,16,19,28H,9-10H2,1H3/t16-,19+/m1/s1
DMKS7D9	CS	CN1C=C(N=C1)S(=O)(=O)N2C[C@@H]([C@H](C2)NC3=CC(=C(C=C3)F)C(F)(F)F)C4=CC=C(C=C4)F
DMKS7D9	IK	QHYIYIVWHBQJLT-APWZRJJASA-N
DMKS7D9	IU	(3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-(1-methylimidazol-4-yl)sulfonylpyrrolidin-3-amine

DM9JCL2	ID	DM9JCL2
DM9JCL2	DN	US9670220, 33
DM9JCL2	HS	Patented
DM9JCL2	SN	SCHEMBL322452; BDBM195889; US9670220, 33
DM9JCL2	DT	Small molecular drug
DM9JCL2	PC	56597913
DM9JCL2	MW	395.4
DM9JCL2	FM	C23H22FNO4
DM9JCL2	IC	InChI=1S/C23H22FNO4/c24-20-4-2-1-3-17(20)15-28-19-7-5-16(6-8-19)22-13-18-14-25(12-10-23(26)27)11-9-21(18)29-22/h1-8,13H,9-12,14-15H2,(H,26,27)
DM9JCL2	CS	C1CN(CC2=C1OC(=C2)C3=CC=C(C=C3)OCC4=CC=CC=C4F)CCC(=O)O
DM9JCL2	IK	TUHBOROWRALEDS-UHFFFAOYSA-N
DM9JCL2	IU	3-[2-[4-[(2-fluorophenyl)methoxy]phenyl]-6,7-dihydro-4H-furo[3,2-c]pyridin-5-yl]propanoic acid

DMNZD8T	ID	DMNZD8T
DMNZD8T	DN	US9670220, 76
DMNZD8T	HS	Patented
DMNZD8T	SN	SCHEMBL321039; BDBM195896; US9670220, 76
DMNZD8T	DT	Small molecular drug
DMNZD8T	PC	56598044
DMNZD8T	MW	391.5
DMNZD8T	FM	C24H25NO4
DMNZD8T	IC	InChI=1S/C24H25NO4/c1-17(13-24(26)27)25-12-11-22-20(15-25)14-23(29-22)19-7-9-21(10-8-19)28-16-18-5-3-2-4-6-18/h2-10,14,17H,11-13,15-16H2,1H3,(H,26,27)
DMNZD8T	CS	CC(CC(=O)O)N1CCC2=C(C1)C=C(O2)C3=CC=C(C=C3)OCC4=CC=CC=C4
DMNZD8T	IK	OBUYLWCGRDYKEQ-UHFFFAOYSA-N
DMNZD8T	IU	3-[2-(4-phenylmethoxyphenyl)-6,7-dihydro-4H-furo[3,2-c]pyridin-5-yl]butanoic acid

DMZG1HO	ID	DMZG1HO
DMZG1HO	DN	US9670220, 77
DMZG1HO	HS	Patented
DMZG1HO	SN	SCHEMBL320491; BDBM195897; US9670220, 77
DMZG1HO	DT	Small molecular drug
DMZG1HO	PC	56598043
DMZG1HO	MW	425.9
DMZG1HO	FM	C24H24ClNO4
DMZG1HO	IC	InChI=1S/C24H24ClNO4/c1-16(24(27)28)13-26-11-10-22-19(14-26)12-23(30-22)18-4-8-21(9-5-18)29-15-17-2-6-20(25)7-3-17/h2-9,12,16H,10-11,13-15H2,1H3,(H,27,28)
DMZG1HO	CS	CC(CN1CCC2=C(C1)C=C(O2)C3=CC=C(C=C3)OCC4=CC=C(C=C4)Cl)C(=O)O
DMZG1HO	IK	YVXSDYLDIVRURS-UHFFFAOYSA-N
DMZG1HO	IU	3-[2-[4-[(4-chlorophenyl)methoxy]phenyl]-6,7-dihydro-4H-furo[3,2-c]pyridin-5-yl]-2-methylpropanoic acid

DM6EQVT	ID	DM6EQVT
DM6EQVT	DN	US9682983, 1
DM6EQVT	HS	Patented
DM6EQVT	SN	SCHEMBL16112697; YTUZELSDHUVEFM-UHFFFAOYSA-N; BDBM111122; US9682983, 1; US9682983, 17; 4-(6-(6-(piperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline
DM6EQVT	DT	Small molecular drug
DM6EQVT	PC	86275005
DM6EQVT	MW	407.5
DM6EQVT	FM	C24H21N7
DM6EQVT	IC	InChI=1S/C24H21N7/c1-2-4-22-20(3-1)19(7-8-26-22)21-15-29-31-16-18(14-28-24(21)31)17-5-6-23(27-13-17)30-11-9-25-10-12-30/h1-8,13-16,25H,9-12H2
DM6EQVT	CS	C1CN(CCN1)C2=NC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3
DM6EQVT	IK	YTUZELSDHUVEFM-UHFFFAOYSA-N
DM6EQVT	IU	4-[6-(6-piperazin-1-ylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline

DM6R1YP	ID	DM6R1YP
DM6R1YP	DN	US9682983, 33
DM6R1YP	HS	Patented
DM6R1YP	SN	SCHEMBL16134982; BDBM148372; US9682983, 33
DM6R1YP	DT	Small molecular drug
DM6R1YP	PC	86275006
DM6R1YP	MW	435.5
DM6R1YP	FM	C26H25N7
DM6R1YP	IC	InChI=1S/C26H25N7/c1-17-11-27-12-18(2)33(17)25-8-7-19(13-29-25)20-14-30-26-23(15-31-32(26)16-20)21-9-10-28-24-6-4-3-5-22(21)24/h3-10,13-18,27H,11-12H2,1-2H3/t17-,18+
DM6R1YP	CS	C[C@@H]1CNC[C@@H](N1C2=NC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3)C
DM6R1YP	IK	OVXMCCQKIOSDGE-HDICACEKSA-N
DM6R1YP	IU	4-[6-[6-[(2S,6R)-2,6-dimethylpiperazin-1-yl]pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline

DMVGQXK	ID	DMVGQXK
DMVGQXK	DN	US9682991, 2
DMVGQXK	HS	Patented
DMVGQXK	SN	SCHEMBL12498787; BDBM161938; US9682991, 2
DMVGQXK	DT	Small molecular drug
DMVGQXK	PC	53311212
DMVGQXK	MW	463.5
DMVGQXK	FM	C21H24F3N7O2
DMVGQXK	IC	InChI=1S/C21H24F3N7O2/c1-29-8-6-14(7-9-29)25-18-16-17(32-11-10-30(16)2)20-27-26-19(31(20)28-18)13-4-3-5-15(12-13)33-21(22,23)24/h3-5,12,14H,6-11H2,1-2H3,(H,25,28)
DMVGQXK	CS	CN1CCC(CC1)NC2=NN3C(=NN=C3C4=C2N(CCO4)C)C5=CC(=CC=C5)OC(F)(F)F
DMVGQXK	IK	OIOYUXMGVUEQPH-UHFFFAOYSA-N
DMVGQXK	IU	10-methyl-N-(1-methylpiperidin-4-yl)-5-[3-(trifluoromethoxy)phenyl]-13-oxa-3,4,6,7,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7-tetraen-8-amine

DMGTIP6	ID	DMGTIP6
DMGTIP6	DN	US9682991, 23
DMGTIP6	HS	Patented
DMGTIP6	SN	SCHEMBL2177395; BDBM161974; US9682991, 23
DMGTIP6	DT	Small molecular drug
DMGTIP6	PC	53252518
DMGTIP6	MW	450.4
DMGTIP6	FM	C20H21F3N6O3
DMGTIP6	IC	InChI=1S/C20H21F3N6O3/c1-28-7-10-31-16-15(28)17(24-13-5-8-30-9-6-13)27-29-18(25-26-19(16)29)12-3-2-4-14(11-12)32-20(21,22)23/h2-4,11,13H,5-10H2,1H3,(H,24,27)
DMGTIP6	CS	CN1CCOC2=C1C(=NN3C2=NN=C3C4=CC(=CC=C4)OC(F)(F)F)NC5CCOCC5
DMGTIP6	IK	DKFWOQOORFAKNT-UHFFFAOYSA-N
DMGTIP6	IU	10-methyl-N-(oxan-4-yl)-5-[3-(trifluoromethoxy)phenyl]-13-oxa-3,4,6,7,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7-tetraen-8-amine

DM7SQKD	ID	DM7SQKD
DM7SQKD	DN	US9682991, 7
DM7SQKD	HS	Patented
DM7SQKD	SN	SCHEMBL2222299; BDBM161946; US9682991, 7
DM7SQKD	DT	Small molecular drug
DM7SQKD	PC	53311131
DM7SQKD	MW	420.4
DM7SQKD	FM	C19H19F3N6O2
DM7SQKD	IC	InChI=1S/C19H19F3N6O2/c1-27-7-8-29-15-14(27)16(23-10-11-5-6-11)26-28-17(24-25-18(15)28)12-3-2-4-13(9-12)30-19(20,21)22/h2-4,9,11H,5-8,10H2,1H3,(H,23,26)
DM7SQKD	CS	CN1CCOC2=C1C(=NN3C2=NN=C3C4=CC(=CC=C4)OC(F)(F)F)NCC5CC5
DM7SQKD	IK	RTBZFULAXSZFTC-UHFFFAOYSA-N
DM7SQKD	IU	N-(cyclopropylmethyl)-10-methyl-5-[3-(trifluoromethoxy)phenyl]-13-oxa-3,4,6,7,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7-tetraen-8-amine

DMMCNVO	ID	DMMCNVO
DMMCNVO	DN	US9694002, 129
DMMCNVO	HS	Patented
DMMCNVO	SN	SCHEMBL15535910; BDBM70974; US9694002, 129
DMMCNVO	DT	Small molecular drug
DMMCNVO	PC	90015925
DMMCNVO	MW	482.5
DMMCNVO	FM	C21H23FN2O6S2
DMMCNVO	IC	InChI=1S/C21H23FN2O6S2/c1-31(26,27)23-21(25)18-9-17(15-7-8-15)20(10-19(18)22)30-13-14-11-24(12-14)32(28,29)16-5-3-2-4-6-16/h2-6,9-10,14-15H,7-8,11-13H2,1H3,(H,23,25)
DMMCNVO	CS	CS(=O)(=O)NC(=O)C1=C(C=C(C(=C1)C2CC2)OCC3CN(C3)S(=O)(=O)C4=CC=CC=C4)F
DMMCNVO	IK	SPEKXWKFVSKSOS-UHFFFAOYSA-N
DMMCNVO	IU	4-[[1-(benzenesulfonyl)azetidin-3-yl]methoxy]-5-cyclopropyl-2-fluoro-N-methylsulfonylbenzamide

DMV1OR0	ID	DMV1OR0
DMV1OR0	DN	US9694002, 495
DMV1OR0	HS	Patented
DMV1OR0	SN	SCHEMBL16770932; BDBM71464; US9694002, 495
DMV1OR0	DT	Small molecular drug
DMV1OR0	PC	91799679
DMV1OR0	MW	569.5
DMV1OR0	FM	C27H31Cl2FN2O4S
DMV1OR0	IC	InChI=1S/C27H31Cl2FN2O4S/c1-27(2,17-10-18(28)12-19(29)11-17)32-9-3-4-20(15-32)36-25-14-24(30)23(13-22(25)16-5-6-16)26(33)31-37(34,35)21-7-8-21/h10-14,16,20-21H,3-9,15H2,1-2H3,(H,31,33)/t20-/m1/s1
DMV1OR0	CS	CC(C)(C1=CC(=CC(=C1)Cl)Cl)N2CCC[C@H](C2)OC3=CC(=C(C=C3C4CC4)C(=O)NS(=O)(=O)C5CC5)F
DMV1OR0	IK	OCNOGKDYKRVBCZ-HXUWFJFHSA-N
DMV1OR0	IU	5-cyclopropyl-N-cyclopropylsulfonyl-4-[(3R)-1-[2-(3,5-dichlorophenyl)propan-2-yl]piperidin-3-yl]oxy-2-fluorobenzamide

DM804T5	ID	DM804T5
DM804T5	DN	US9694002, 59
DM804T5	HS	Patented
DM804T5	SN	SCHEMBL15535893; BDBM70886; YUDSOPSBYJDZMS-UHFFFAOYSA-N; US9694002, 59; 4-((1-benzhydrylazetidin-3-yl)methoxy)-5-chloro-2-fluoro-N-(methylsulfonyl)benzamide
DM804T5	DT	Small molecular drug
DM804T5	PC	86703776
DM804T5	MW	503
DM804T5	FM	C25H24ClFN2O4S
DM804T5	IC	InChI=1S/C25H24ClFN2O4S/c1-34(31,32)28-25(30)20-12-21(26)23(13-22(20)27)33-16-17-14-29(15-17)24(18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-13,17,24H,14-16H2,1H3,(H,28,30)
DM804T5	CS	CS(=O)(=O)NC(=O)C1=CC(=C(C=C1F)OCC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)Cl
DM804T5	IK	YUDSOPSBYJDZMS-UHFFFAOYSA-N
DM804T5	IU	4-[(1-benzhydrylazetidin-3-yl)methoxy]-5-chloro-2-fluoro-N-methylsulfonylbenzamide

DMZF3AQ	ID	DMZF3AQ
DMZF3AQ	DN	US9695118, 4
DMZF3AQ	HS	Patented
DMZF3AQ	SN	SCHEMBL16528736; BDBM77146; US9695118, 4; US9695118, 13
DMZF3AQ	DT	Small molecular drug
DMZF3AQ	PC	72195070
DMZF3AQ	MW	484.7
DMZF3AQ	FM	C17H14BrClF3NO3S
DMZF3AQ	IC	InChI=1S/C17H14BrClF3NO3S/c1-2-27(25,26)15-4-3-14(19)7-11(15)9-23-16(24)10-5-12(17(20,21)22)8-13(18)6-10/h3-8H,2,9H2,1H3,(H,23,24)
DMZF3AQ	CS	CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CNC(=O)C2=CC(=CC(=C2)Br)C(F)(F)F
DMZF3AQ	IK	ZJRYMLPPVADAGI-UHFFFAOYSA-N
DMZF3AQ	IU	3-bromo-N-[(5-chloro-2-ethylsulfonylphenyl)methyl]-5-(trifluoromethyl)benzamide

DMAD3VL	ID	DMAD3VL
DMAD3VL	DN	US9695118, 8
DMAD3VL	HS	Patented
DMAD3VL	SN	SCHEMBL16528302; BDBM77168; YHSRDHPSFFNXQB-UHFFFAOYSA-N; US9695118, 8; N-(5-Chloro-2-ethanesulfonyl-benzyl)-3-trifluoromethyl-benzamide
DMAD3VL	DT	Small molecular drug
DMAD3VL	PC	72195071
DMAD3VL	MW	405.8
DMAD3VL	FM	C17H15ClF3NO3S
DMAD3VL	IC	InChI=1S/C17H15ClF3NO3S/c1-2-26(24,25)15-7-6-14(18)9-12(15)10-22-16(23)11-4-3-5-13(8-11)17(19,20)21/h3-9H,2,10H2,1H3,(H,22,23)
DMAD3VL	CS	CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CNC(=O)C2=CC(=CC=C2)C(F)(F)F
DMAD3VL	IK	YHSRDHPSFFNXQB-UHFFFAOYSA-N
DMAD3VL	IU	N-[(5-chloro-2-ethylsulfonylphenyl)methyl]-3-(trifluoromethyl)benzamide

DMSI09Y	ID	DMSI09Y
DMSI09Y	DN	US9707205, 40
DMSI09Y	HS	Patented
DMSI09Y	SN	SCHEMBL176871; BDBM255789; US9707205, 40; 2-amino-2-(5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol
DMSI09Y	DT	Small molecular drug
DMSI09Y	PC	45255647
DMSI09Y	MW	439.5
DMSI09Y	FM	C23H25N3O6
DMSI09Y	IC	InChI=1S/C23H25N3O6/c1-3-29-18-8-6-15(10-19(18)30-4-2)22-25-21(26-32-22)14-5-7-17-16(9-14)11-20(31-17)23(24,12-27)13-28/h5-11,27-28H,3-4,12-13,24H2,1-2H3
DMSI09Y	CS	CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC4=C(C=C3)OC(=C4)C(CO)(CO)N)OCC
DMSI09Y	IK	YPBZKICXUPGWLN-UHFFFAOYSA-N
DMSI09Y	IU	2-amino-2-[5-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-1-benzofuran-2-yl]propane-1,3-diol

DMEB59T	ID	DMEB59T
DMEB59T	DN	US9714230, 12
DMEB59T	HS	Patented
DMEB59T	SN	SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; US9714230, 12; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid
DMEB59T	DT	Small molecular drug
DMEB59T	PC	76901247
DMEB59T	MW	279.29
DMEB59T	FM	C16H13N3O2
DMEB59T	IC	InChI=1S/C16H13N3O2/c1-11-2-4-12(5-3-11)14-7-9-18-19(14)15-10-13(16(20)21)6-8-17-15/h2-10H,1H3,(H,20,21)
DMEB59T	CS	CC1=CC=C(C=C1)C2=CC=NN2C3=NC=CC(=C3)C(=O)O
DMEB59T	IK	LKBZHRSAENXIOI-UHFFFAOYSA-N
DMEB59T	IU	2-[5-(4-methylphenyl)pyrazol-1-yl]pyridine-4-carboxylic acid

DMPZS16	ID	DMPZS16
DMPZS16	DN	US9714230, 46
DMPZS16	HS	Patented
DMPZS16	SN	SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; US9714230, 46; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid
DMPZS16	DT	Small molecular drug
DMPZS16	PC	86725517
DMPZS16	MW	344.16
DMPZS16	FM	C15H10BrN3O2
DMPZS16	IC	InChI=1S/C15H10BrN3O2/c16-12-3-1-10(2-4-12)13-6-8-18-19(13)14-9-11(15(20)21)5-7-17-14/h1-9H,(H,20,21)
DMPZS16	CS	C1=CC(=CC=C1C2=CC=NN2C3=NC=CC(=C3)C(=O)O)Br
DMPZS16	IK	MITOFELVTHNBGA-UHFFFAOYSA-N
DMPZS16	IU	2-[5-(4-bromophenyl)pyrazol-1-yl]pyridine-4-carboxylic acid

DMOVEZF	ID	DMOVEZF
DMOVEZF	DN	VAPBGCRAUJRZPO-UHFFFAOYSA-N
DMOVEZF	HS	Patented
DMOVEZF	SN	CHEMBL3422020; SCHEMBL16528756; VAPBGCRAUJRZPO-UHFFFAOYSA-N; BDBM50080409; N-(5-Chloro-2-ethanesulfonyl-benzyl)-4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-benzamide
DMOVEZF	DT	Small molecular drug
DMOVEZF	PC	71768628
DMOVEZF	MW	518
DMOVEZF	FM	C23H27ClF3N3O3S
DMOVEZF	IC	InChI=1S/C23H27ClF3N3O3S/c1-3-34(32,33)21-7-6-19(24)12-18(21)14-28-22(31)16-4-5-17(20(13-16)23(25,26)27)15-30-10-8-29(2)9-11-30/h4-7,12-13H,3,8-11,14-15H2,1-2H3,(H,28,31)
DMOVEZF	CS	CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CNC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F
DMOVEZF	IK	VAPBGCRAUJRZPO-UHFFFAOYSA-N
DMOVEZF	IU	N-[(5-chloro-2-ethylsulfonylphenyl)methyl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide

DMH9ION	ID	DMH9ION
DMH9ION	DN	VFEDEOUBYBLDKN-AAFJCEBUSA-N
DMH9ION	HS	Patented
DMH9ION	SN	CHEMBL1922120; SCHEMBL3853662; VFEDEOUBYBLDKN-AAFJCEBUSA-N; BDBM50358221; (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-hexan-3-ol; (3RS, 4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-hexan-3-ol; US8846696, (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-hexan-3-ol
DMH9ION	DT	Small molecular drug
DMH9ION	PC	12111409
DMH9ION	MW	383.5
DMH9ION	FM	C20H29N7O
DMH9ION	IC	InChI=1S/C20H29N7O/c1-5-15(16(28)6-2)24-20-25-18(22-11-14-8-7-9-21-10-14)17-19(26-20)27(12-23-17)13(3)4/h7-10,12-13,15-16,28H,5-6,11H2,1-4H3,(H2,22,24,25,26)/t15-,16?/m1/s1
DMH9ION	CS	CC[C@H](C(CC)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=CC=C3
DMH9ION	IK	VFEDEOUBYBLDKN-AAFJCEBUSA-N
DMH9ION	IU	(4R)-4-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]hexan-3-ol

DMTMFNK	ID	DMTMFNK
DMTMFNK	DN	Vinyl sulfone derivative 1
DMTMFNK	HS	Patented
DMTMFNK	SN	PMID28454500-Compound-20
DMTMFNK	CP	KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
DMTMFNK	DT	Small molecular drug
DMTMFNK	PC	73053707
DMTMFNK	MW	308.8
DMTMFNK	FM	C15H13ClO3S
DMTMFNK	IC	InChI=1S/C15H13ClO3S/c1-19-14-8-4-5-9-15(14)20(17,18)11-10-12-6-2-3-7-13(12)16/h2-11H,1H3/b11-10+
DMTMFNK	CS	COC1=CC=CC=C1S(=O)(=O)/C=C/C2=CC=CC=C2Cl
DMTMFNK	IK	KVDYSDOWSIXKPB-ZHACJKMWSA-N
DMTMFNK	IU	1-chloro-2-[(E)-2-(2-methoxyphenyl)sulfonylethenyl]benzene

DML32R8	ID	DML32R8
DML32R8	DN	VX-148
DML32R8	HS	Patented
DML32R8	SN	VX-148; SCHEMBL12343182; BDBM248095; VX-148 (3)
DML32R8	DT	Small molecular drug
DML32R8	PC	56603796
DML32R8	MW	435.5
DML32R8	FM	C23H25N5O4
DML32R8	IC	InChI=1S/C23H25N5O4/c1-4-20(10-11-24)32-23(30)26-15(2)16-6-5-7-18(12-16)27-22(29)28-19-9-8-17(14-25)21(13-19)31-3/h5-9,12-13,15,20H,4,10H2,1-3H3,(H,26,30)(H2,27,28,29)/t15-,20?/m0/s1
DML32R8	CS	CCC(CC#N)OC(=O)N[C@@H](C)C1=CC(=CC=C1)NC(=O)NC2=CC(=C(C=C2)C#N)OC
DML32R8	IK	PJFQWSNOXLEDDZ-OOJLDXBWSA-N
DML32R8	IU	1-cyanobutan-2-yl N-[(1S)-1-[3-[(4-cyano-3-methoxyphenyl)carbamoylamino]phenyl]ethyl]carbamate
DML32R8	DE	Psoriasis vulgaris

DMIULVJ	ID	DMIULVJ
DMIULVJ	DN	Xanthine derivative 1
DMIULVJ	HS	Patented
DMIULVJ	SN	PMID25482888-Compound-57
DMIULVJ	DT	Small molecular drug

DMNXJ8G	ID	DMNXJ8G
DMNXJ8G	DN	Xanthine/amino piperidine compound 1
DMNXJ8G	HS	Patented
DMNXJ8G	SN	PMID25482888-Compound-53
DMNXJ8G	CP	MERCK SHARP & DOHME CORP. BURNETT, Duane, A. ZHAO, Zhiqiang COLE, David JOSIEN, Hubert PISSARNITSKI, Dmitri, A. SASIKUMAR, Thavalakulamgar WU, Wen-Lian DOMALSKI, Martin
DMNXJ8G	DT	Small molecular drug
DMNXJ8G	PC	57378228
DMNXJ8G	MW	483.6
DMNXJ8G	FM	C26H29N9O
DMNXJ8G	IC	InChI=1S/C26H29N9O/c1-3-4-13-33-22-23(31-26(33)32-12-7-8-18(27)15-32)34-14-11-28-25(34)35(24(22)36)16-21-29-17(2)19-9-5-6-10-20(19)30-21/h5-6,9-10,18H,7-8,11-16,27H2,1-2H3/t18-/m1/s1
DMNXJ8G	CS	CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N4CCN=C4N(C2=O)CC5=NC6=CC=CC=C6C(=N5)C
DMNXJ8G	IK	WDWDEKNARRTAAI-GOSISDBHSA-N
DMNXJ8G	IU	2-[(3R)-3-aminopiperidin-1-yl]-3-but-2-ynyl-5-[(4-methylquinazolin-2-yl)methyl]-7,8-dihydroimidazo[2,1-b]purin-4-one

DM5Q93Y	ID	DM5Q93Y
DM5Q93Y	DN	XHPNYYOUZWOWNT-PYUWXLGESA-N
DM5Q93Y	HS	Patented
DM5Q93Y	SN	CHEMBL1922122; SCHEMBL3855548; XHPNYYOUZWOWNT-PYUWXLGESA-N; BDBM50358223; US8846696, (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2,2-dimethyl-hexan-3-ol; (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2,2-dimethyl-hexan-3-ol; (3RS, 4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2,2-dimethyl-hexan-3-ol
DM5Q93Y	DT	Small molecular drug
DM5Q93Y	PC	12111413
DM5Q93Y	MW	411.5
DM5Q93Y	FM	C22H33N7O
DM5Q93Y	IC	InChI=1S/C22H33N7O/c1-7-16(18(30)22(4,5)6)26-21-27-19(24-12-15-9-8-10-23-11-15)17-20(28-21)29(13-25-17)14(2)3/h8-11,13-14,16,18,30H,7,12H2,1-6H3,(H2,24,26,27,28)/t16-,18?/m1/s1
DM5Q93Y	CS	CC[C@H](C(C(C)(C)C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=CC=C3
DM5Q93Y	IK	XHPNYYOUZWOWNT-PYUWXLGESA-N
DM5Q93Y	IU	(4R)-2,2-dimethyl-4-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]hexan-3-ol

DMHAVYS	ID	DMHAVYS
DMHAVYS	DN	Y-9680
DMHAVYS	HS	Patented
DMHAVYS	SN	isopropyl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate; 350997-33-0; ISOPROPYL 2-AMINO-4-(3,4-DIMETHOXYPHENYL)-THIOPHENE-3-CARBOXYLATE; propan-2-yl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate; AC1LI5BZ; CBMicro_031058; MixCom6_001362; Oprea1_764229; SCHEMBL12632700; CHEMBL2393423; CTK6J7310; US8889672, PKCzI-diMeO; ZINC442750; BDBM139464; ZX-AN001734; ALBB-001750; MFCD01923453; STK348738; BBL016154; AKOS000304253; MCULE-6167327602; BIM-0031131.P001; TR-051961; Y-9680; SR-01000228616; SR-01000228616-1
DMHAVYS	DT	Small molecular drug
DMHAVYS	PC	874670
DMHAVYS	MW	321.4
DMHAVYS	FM	C16H19NO4S
DMHAVYS	IC	InChI=1S/C16H19NO4S/c1-9(2)21-16(18)14-11(8-22-15(14)17)10-5-6-12(19-3)13(7-10)20-4/h5-9H,17H2,1-4H3
DMHAVYS	CS	CC(C)OC(=O)C1=C(SC=C1C2=CC(=C(C=C2)OC)OC)N
DMHAVYS	IK	WEHPOCNINSGWET-UHFFFAOYSA-N
DMHAVYS	IU	propan-2-yl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate

DMA91FM	ID	DMA91FM
DMA91FM	DN	YYDJCLCSBYCSCO-UHFFFAOYSA-N
DMA91FM	HS	Patented
DMA91FM	SN	CHEMBL1080382; 6-[cyclohexyl(cyclopropylmethyl)amino]-N-(6-methyl-1H-indazol-5-yl)pyrimidine-4-carboxamide; 6-(cyclohexyl(cyclopropylmethyl)amino)-N-(6-methyl-1H-indazol-5-yl)pyrimidine-4-carboxamide; SCHEMBL3025879; YYDJCLCSBYCSCO-UHFFFAOYSA-N; BDBM50313353
DMA91FM	DT	Small molecular drug
DMA91FM	PC	25182901
DMA91FM	MW	404.5
DMA91FM	FM	C23H28N6O
DMA91FM	IC	InChI=1S/C23H28N6O/c1-15-9-20-17(12-26-28-20)10-19(15)27-23(30)21-11-22(25-14-24-21)29(13-16-7-8-16)18-5-3-2-4-6-18/h9-12,14,16,18H,2-8,13H2,1H3,(H,26,28)(H,27,30)
DMA91FM	CS	CC1=CC2=C(C=C1NC(=O)C3=CC(=NC=N3)N(CC4CC4)C5CCCCC5)C=NN2
DMA91FM	IK	YYDJCLCSBYCSCO-UHFFFAOYSA-N
DMA91FM	IU	6-[cyclohexyl(cyclopropylmethyl)amino]-N-(6-methyl-1H-indazol-5-yl)pyrimidine-4-carboxamide

DMUOZEJ	ID	DMUOZEJ
DMUOZEJ	DN	Z223457004
DMUOZEJ	HS	Patented
DMUOZEJ	SN	SCHEMBL18352896; BDBM113297; ZINC12619614; AKOS033814184; MCULE-3787435099; US9695194, 14; Z223457004; 5-(2-methanesulfonylphenyl)-6,11,14-trioxa-4-azatricyclo[8.4.0.0^{3,8}]tetradeca-1,3(8),4,9-tetraen-7-one; 1000928-10-8
DMUOZEJ	DT	Small molecular drug
DMUOZEJ	PC	25400536
DMUOZEJ	MW	359.4
DMUOZEJ	FM	C17H13NO6S
DMUOZEJ	IC	InChI=1S/C17H13NO6S/c1-25(20,21)15-5-3-2-4-10(15)16-18-12-9-14-13(22-6-7-23-14)8-11(12)17(19)24-16/h2-5,8-9H,6-7H2,1H3
DMUOZEJ	CS	CS(=O)(=O)C1=CC=CC=C1C2=NC3=CC4=C(C=C3C(=O)O2)OCCO4
DMUOZEJ	IK	NYGGGQOBPHOCIJ-UHFFFAOYSA-N
DMUOZEJ	IU	2-(2-methylsulfonylphenyl)-7,8-dihydro-[1,4]dioxino[2,3-g][3,1]benzoxazin-4-one

DMRBFUA	ID	DMRBFUA
DMRBFUA	DN	Z90308237
DMRBFUA	HS	Patented
DMRBFUA	SN	SCHEMBL18352966; BDBM113300; ZINC12619607; AKOS034677493; MCULE-1271453362; US9695194, 16; Z90308237; 1000928-01-7; 5-(2-chlorophenyl)-6,11,14-trioxa-4-azatricyclo[8.4.0.0^{3,8}]tetradeca-1,3(8),4,9-tetraen-7-one
DMRBFUA	DT	Small molecular drug
DMRBFUA	PC	25400532
DMRBFUA	MW	315.71
DMRBFUA	FM	C16H10ClNO4
DMRBFUA	IC	InChI=1S/C16H10ClNO4/c17-11-4-2-1-3-9(11)15-18-12-8-14-13(20-5-6-21-14)7-10(12)16(19)22-15/h1-4,7-8H,5-6H2
DMRBFUA	CS	C1COC2=C(O1)C=C3C(=C2)N=C(OC3=O)C4=CC=CC=C4Cl
DMRBFUA	IK	RMEUFAVEIHZTRM-UHFFFAOYSA-N
DMRBFUA	IU	2-(2-chlorophenyl)-7,8-dihydro-[1,4]dioxino[2,3-g][3,1]benzoxazin-4-one

DMLZDAK	ID	DMLZDAK
DMLZDAK	DN	ZINC19658740
DMLZDAK	HS	Patented
DMLZDAK	SN	SCHEMBL15548184; CHEMBL3448261; LSJGWMPNBWLCRK-UHFFFAOYSA-N; BDBM250597; ZINC19658740; AKOS030474436; US9475795, 76; 1-((3,5-Dimethyl-1H-pyrazol-4-yl)sulfonyl)-4-(2-fluorophenoxyl)piperidine; 1-((3,5-Dimethyl-1H-pyrazol-4-yl)sulfonyl)-4-(2-fluorophenoxy)piperidine
DMLZDAK	DT	Small molecular drug
DMLZDAK	PC	46981204
DMLZDAK	MW	353.4
DMLZDAK	FM	C16H20FN3O3S
DMLZDAK	IC	InChI=1S/C16H20FN3O3S/c1-11-16(12(2)19-18-11)24(21,22)20-9-7-13(8-10-20)23-15-6-4-3-5-14(15)17/h3-6,13H,7-10H2,1-2H3,(H,18,19)
DMLZDAK	CS	CC1=C(C(=NN1)C)S(=O)(=O)N2CCC(CC2)OC3=CC=CC=C3F
DMLZDAK	IK	LSJGWMPNBWLCRK-UHFFFAOYSA-N
DMLZDAK	IU	1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-(2-fluorophenoxy)piperidine

DMYCH0G	ID	DMYCH0G
DMYCH0G	DN	ZINC584606052
DMYCH0G	HS	Patented
DMYCH0G	SN	SCHEMBL17492363; YDADFGXXCHDXFC-UHFFFAOYSA-N; US10077269, Example 5; BDBM285532; ZINC584606052; 3-(6-cyanopyridin-3-yl)-N-cyclopropylimidazo[1,2-b]pyridazine-2-carboxamide; 3-(6-Cyanopyridin-3-yl)-N-cyclopropylimidazo[1,2-b]pyridazine-2-carboxamide (5)
DMYCH0G	DT	Small molecular drug
DMYCH0G	PC	118863059
DMYCH0G	MW	304.31
DMYCH0G	FM	C16H12N6O
DMYCH0G	IC	InChI=1S/C16H12N6O/c17-8-12-4-3-10(9-18-12)15-14(16(23)20-11-5-6-11)21-13-2-1-7-19-22(13)15/h1-4,7,9,11H,5-6H2,(H,20,23)
DMYCH0G	CS	C1CC1NC(=O)C2=C(N3C(=N2)C=CC=N3)C4=CN=C(C=C4)C#N
DMYCH0G	IK	YDADFGXXCHDXFC-UHFFFAOYSA-N
DMYCH0G	IU	3-(6-cyanopyridin-3-yl)-N-cyclopropylimidazo[1,2-b]pyridazine-2-carboxamide

DMW9P6U	ID	DMW9P6U
DMW9P6U	DN	ZINC915379
DMW9P6U	HS	Patented
DMW9P6U	SN	CHEMBL2315467; BAS 02073268; SCHEMBL16409978; ZINC915379; BDBM50424850; AKOS000586084; MCULE-1228568202; 3-Benzylsulfanyl-5-phenoxymethyl-4-phenyl-4H-[1,2,4]triazole
DMW9P6U	DT	Small molecular drug
DMW9P6U	PC	1162727
DMW9P6U	MW	373.5
DMW9P6U	FM	C22H19N3OS
DMW9P6U	IC	InChI=1S/C22H19N3OS/c1-4-10-18(11-5-1)17-27-22-24-23-21(16-26-20-14-8-3-9-15-20)25(22)19-12-6-2-7-13-19/h1-15H,16-17H2
DMW9P6U	CS	C1=CC=C(C=C1)CSC2=NN=C(N2C3=CC=CC=C3)COC4=CC=CC=C4
DMW9P6U	IK	SSZGXGUFAAHHAF-UHFFFAOYSA-N
DMW9P6U	IU	3-benzylsulfanyl-5-(phenoxymethyl)-4-phenyl-1,2,4-triazole

DMR0F4H	ID	DMR0F4H
DMR0F4H	DN	ZINC959121
DMR0F4H	HS	Patented
DMR0F4H	SN	SCHEMBL18538657; ZINC959121; BDBM101826; AKOS001379122; MCULE-5667109528; US9695160, 40
DMR0F4H	DT	Small molecular drug
DMR0F4H	PC	1194266
DMR0F4H	MW	369.4
DMR0F4H	FM	C17H18F3N3OS
DMR0F4H	IC	InChI=1S/C17H18F3N3OS/c1-22-6-8-23(9-7-22)14-5-4-12(17(18,19)20)11-13(14)21-16(24)15-3-2-10-25-15/h2-5,10-11H,6-9H2,1H3,(H,21,24)
DMR0F4H	CS	CN1CCN(CC1)C2=C(C=C(C=C2)C(F)(F)F)NC(=O)C3=CC=CS3
DMR0F4H	IK	ZMQGTVWBYJXOLY-UHFFFAOYSA-N
DMR0F4H	IU	N-[2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]thiophene-2-carboxamide

DM3OPBR	ID	DM3OPBR
DM3OPBR	DN	ZNFTXQFGUIKQQE-UHFFFAOYSA-N
DM3OPBR	HS	Patented
DM3OPBR	SN	CHEMBL1076708; 6-[cyclohexyl(ethyl)amino]-N-(4-hydroxy-2-methylphenyl)pyrimidine-4-carboxamide; 6-(cyclohexyl(ethyl)amino)-N-(4-hydroxy-2-methylphenyl)pyrimidine-4-carboxamide; SCHEMBL3029985; ZNFTXQFGUIKQQE-UHFFFAOYSA-N; BDBM50313322
DM3OPBR	DT	Small molecular drug
DM3OPBR	PC	25182763
DM3OPBR	MW	354.4
DM3OPBR	FM	C20H26N4O2
DM3OPBR	IC	InChI=1S/C20H26N4O2/c1-3-24(15-7-5-4-6-8-15)19-12-18(21-13-22-19)20(26)23-17-10-9-16(25)11-14(17)2/h9-13,15,25H,3-8H2,1-2H3,(H,23,26)
DM3OPBR	CS	CCN(C1CCCCC1)C2=NC=NC(=C2)C(=O)NC3=C(C=C(C=C3)O)C
DM3OPBR	IK	ZNFTXQFGUIKQQE-UHFFFAOYSA-N
DM3OPBR	IU	6-[cyclohexyl(ethyl)amino]-N-(4-hydroxy-2-methylphenyl)pyrimidine-4-carboxamide

DMXYA5K	ID	DMXYA5K
DMXYA5K	DN	Agomelatine
DMXYA5K	HS	Withdrawn from market
DMXYA5K	SN	Thymanax; Valdoxan; Agomelatine [INN]; AGO 178; AGO178; S 20098; S20098; AGO-178; Agomelatine(INN); S-20098; Valdoxan (TN); Valdoxan, Melitor, Thymanax, Agomelatine; N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide; N-(2-(7-Methoxy-1-naphthalenyl)ethyl)acetamide; N-(2-(7-Methoxynaphth-1-yl)ethyl)acetamide; N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide
DMXYA5K	CP	Servier
DMXYA5K	DT	Small molecular drug
DMXYA5K	PC	82148
DMXYA5K	MW	243.3
DMXYA5K	FM	C15H17NO2
DMXYA5K	IC	InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
DMXYA5K	CS	CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC
DMXYA5K	IK	YJYPHIXNFHFHND-UHFFFAOYSA-N
DMXYA5K	IU	N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
DMXYA5K	CA	CAS 138112-76-2
DMXYA5K	CB	CHEBI:134990
DMXYA5K	DE	Major depressive disorder

DMYJ8Z3	ID	DMYJ8Z3
DMYJ8Z3	DN	Alprenolol
DMYJ8Z3	HS	Withdrawn from market
DMYJ8Z3	SN	Alfeprol; Alpheprol; Alprenololum; Yobir; Alfeprol [Russian]; Alprenolol (INN); Alprenolol [INN:BAN]; Alprenololum [INN-Latin]; Apllobal (TN); Aptine (TN); Aptol (TN); Duriles (TN); Gubernal (TN); Regletin (TN); Yobir (TN); H-56-28; 1-(2-Allylphenoxy)-3-isopropylamino-2-propanol; 1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol; 1-(o-Allylphenoxy)-3-isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol; 1-[2-(propen-2-ylphenoxy)]-3-(isopropylamino)propan-2-ol
DMYJ8Z3	CP	AstraZeneca
DMYJ8Z3	TC	Antiarrhythmic Agents
DMYJ8Z3	DT	Small molecular drug
DMYJ8Z3	PC	2119
DMYJ8Z3	MW	249.35
DMYJ8Z3	FM	C15H23NO2
DMYJ8Z3	IC	InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3
DMYJ8Z3	CS	CC(C)NCC(COC1=CC=CC=C1CC=C)O
DMYJ8Z3	IK	PAZJSJFMUHDSTF-UHFFFAOYSA-N
DMYJ8Z3	IU	1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol
DMYJ8Z3	CA	CAS 13655-52-2
DMYJ8Z3	CB	CHEBI:51211
DMYJ8Z3	DE	Hypertension

DMGVNJ7	ID	DMGVNJ7
DMGVNJ7	DN	Amineptine
DMGVNJ7	HS	Withdrawn from market
DMGVNJ7	SN	Amineptin; Amineptino; Amineptinum; Amineptine [INN]; S 1694; Amineptine (INN); Amineptino [INN-Spanish]; Amineptinum [INN-Latin]; Survector (TN); 10,11-dihydrodibenzo(a,d)cyclohept-5-enyl-7-aminoheptanoic acid; 7-((10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)amino)heptanoic acid; 7-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)heptanoic acid
DMGVNJ7	CP	Roche
DMGVNJ7	DT	Small molecular drug
DMGVNJ7	PC	34870
DMGVNJ7	MW	337.5
DMGVNJ7	FM	C22H27NO2
DMGVNJ7	IC	InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25)
DMGVNJ7	CS	C1CC2=CC=CC=C2C(C3=CC=CC=C31)NCCCCCCC(=O)O
DMGVNJ7	IK	ONNOFKFOZAJDHT-UHFFFAOYSA-N
DMGVNJ7	IU	7-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylamino)heptanoic acid
DMGVNJ7	CA	CAS 57574-09-1
DMGVNJ7	CB	CHEBI:32499
DMGVNJ7	DE	Major depressive disorder

DMQ9RBV	ID	DMQ9RBV
DMQ9RBV	DN	Aminopterin
DMQ9RBV	HS	Withdrawn from market
DMQ9RBV	SN	APGA; Aminopteridine; Aminopterine; Aminopterinum; Aminotrexate; Pteramina; Pteramina [Czech]; A 1784; A-7170;A-Ninopterin; ENT-26079; Kyselina 4-aminolistova; Kyselina 4-aminolistova [Czech]; Kyselina 4-aminopteroylglutamova; Kyselina 4-aminopteroylglutamova [Czech]; L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]; N-(1-((2,4-Diamino-6-pteridinylmethyl)amino)benzoyl)glutaminsaeure; N-[(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}phenyl)carbonyl]glutamic acid; N-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid; N-(4-(((2,4-Diamino-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; Kyselina N-(p-((2,4-diamino-6-pteridinyl)methyl)benzoyl)-L(+)-glutamova; Kyselina N-(p-((2,4-diamino-6-pteridinyl)methyl)benzoyl)-L(+)-glutamova [Czech]; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)amino)benzoyl)-L(+)-glutamova; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)amino)benzoyl)-L(+)-glutamova [Czech]; N-(4-(((2,4-Diamino-6-pteridyl)-methyl)amino)benzoyl)-L-glutamic acid; (2R)-2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 4'-Amino-folsaeure; 4'-Desoxy-4'-aminofolsaeure; 4-Amino pteroylglutamic acid; 4-Amino-4-deoxypteroylglutamate; 4-Amino-4-desoxy-pteroylglutaminsaeure; 4-Amino-PGA; 4-Aminofolic acid; 4-Aminopteroyl-<R>glutamic acid; 4-Aminopteroyl-L-glutamic acid; 4-Aminopteroyl-glutamic acid; 4-Aminopteroylglutamic acid
DMQ9RBV	CP	Lederle Laboratories 
DMQ9RBV	TC	Anticancer Agents
DMQ9RBV	DT	Small molecular drug
DMQ9RBV	PC	169371
DMQ9RBV	MW	440.4
DMQ9RBV	FM	C19H20N8O5
DMQ9RBV	IC	InChI=1S/C19H20N8O5/c20-15-14-16(27-19(21)26-15)23-8-11(24-14)7-22-10-3-1-9(2-4-10)17(30)25-12(18(31)32)5-6-13(28)29/h1-4,8,12,22H,5-7H2,(H,25,30)(H,28,29)(H,31,32)(H4,20,21,23,26,27)/t12-/m0/s1
DMQ9RBV	CS	C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N
DMQ9RBV	IK	TVZGACDUOSZQKY-LBPRGKRZSA-N
DMQ9RBV	IU	(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMQ9RBV	CA	CAS 54-62-6
DMQ9RBV	CB	CHEBI:22526
DMQ9RBV	DE	leukaemia

DM2HN6Q	ID	DM2HN6Q
DM2HN6Q	DN	Astemizole
DM2HN6Q	HS	Withdrawn from market
DM2HN6Q	SN	Alermizol; Astemina; Astemisan; Astemisol; Astemison; Astemizol; Astemizolum; Astesen; Emdar; Esmacen; Fustermizol; Hestazol; Hismanal; Histamen; Histaminos; Histazol; Hubermizol; Kelp; Laridal; Metodih; Metodik; Paralergin; Retolen; Rifedot; Rimbol; Romadin; Simprox; Urdrim; Wareezol; Waruzol; AlacanBrand of Astemizole; Alonga Brand of Astemizole; Astemizol Alonga; Astemizol [German]; Astemizol ratiopharm; Astemizole Alacan Brand; Astemizole Alonga Brand; Astemizole Byk Brand; Astemizole Diba Brand; Astemizole Elfar Brand; Astemizole Esteve Brand; Astemizole Fustery Brand; Astemizole ICN Brand; Astemizole Janssen Brand; Astemizole Lesvi Brand; Astemizole McNeil Brand; Astemizole Medinsa Brand; Astemizole Merck Brand; Astemizole Senosiain Brand; Astemizole Septa Brand; Astemizole Smaller Brand; Astemizole Urbion Brand; Astemizole Vita Brand; Astemizole ratiopharm Brand; Byk Brand of Astemizole; Diba Brand of Astemizole; Elfar Brand of Astemizole; Esteve Brand of Astemizole; Fustery Brand of Astemizole; ICN Brand of Astemizole; Janssen Brand of Astemizole; Lesvi Brand of Astemizole; McNeil Brand of Astemizole; Medinsa Brand of Astemizole; Merck Brand of Astemizole; Ratiopharm Brand of Astemizole; Reig Jofre Brand of Astemizole; Senosiain Brand of Astemizole; Septa Brand of Astemizole; Smaller Brand of Astemizole; Urbion Brand of Astemizole; Vita Brand of Astemizole; R 42512; [3H]Astemizole; Alonga, Astemizol; Astemizol [INN-Spanish]; Astemizolum [INN-Latin]; HISMANAL (TN); Hismanal (TN); MJD-30; Nono-Nastizol A; Novo-mastizol A; Ratiopharm, Astemizol; Astemizole [USAN:BAN:INN]; GNF-PF-2461; Astemizole (JAN/USP/INN); Hestazol, Kelp, Laridal, Retolen, Wareezol, HSBD 6799, BRN 4830190; 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole
DM2HN6Q	CP	Janssen Pharmaceutica
DM2HN6Q	TC	Antiallergic Agents
DM2HN6Q	DT	Small molecular drug
DM2HN6Q	PC	2247
DM2HN6Q	MW	458.6
DM2HN6Q	FM	C28H31FN4O
DM2HN6Q	IC	InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)
DM2HN6Q	CS	COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
DM2HN6Q	IK	GXDALQBWZGODGZ-UHFFFAOYSA-N
DM2HN6Q	IU	1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]benzimidazol-2-amine
DM2HN6Q	CA	CAS 68844-77-9
DM2HN6Q	CB	CHEBI:2896
DM2HN6Q	DE	Allergic rhinitis

DM0J92L	ID	DM0J92L
DM0J92L	DN	Benactyzine
DM0J92L	HS	Withdrawn from market
DM0J92L	SN	BENACTYZINE; Benactyzin; Benzactyzine; 302-40-9; Diethylaminoethyl benzilate; Benactizina; Benactizina [DCIT]; Benactizina [Italian]; 2-(Diethylamino)ethyl benzilate; Benactyzine [INN:BAN]; Benactyzinum [INN-Latin]; Benacticina [INN-Spanish]; 2-Diethylaminoethyl benzilate; UNII-595EG71R3F; 2-(Diethylamino)ethyl diphenylglycolate; HSDB 3292; Benzilic acid, 2-(diethylamino)ethyl ester; EINECS 206-123-8; Diphenylglycolic acid 2-(diethylamino)ethyl ester; BRN 2156821; Benzilic acid beta-diethylaminoethyl ester; CHEMBL70352
DM0J92L	DT	Small molecular drug
DM0J92L	PC	9330
DM0J92L	MW	327.4
DM0J92L	FM	C20H25NO3
DM0J92L	IC	InChI=1S/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3
DM0J92L	CS	CCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O
DM0J92L	IK	IVQOFBKHQCTVQV-UHFFFAOYSA-N
DM0J92L	IU	2-(diethylamino)ethyl 2-hydroxy-2,2-diphenylacetate
DM0J92L	CA	CAS 302-40-9
DM0J92L	CB	CHEBI:94775
DM0J92L	DE	Depression

DM5ZOX8	ID	DM5ZOX8
DM5ZOX8	DN	Benoxaprofen
DM5ZOX8	HS	Withdrawn from market
DM5ZOX8	SN	Benoxaprofene; Benoxaprofeno; Benoxaprofenum; Coxigon; Inflamid; Opren; Oraflex; Uniprofen; LRCL3794; Lilly 90459; Benoxaprofene [INN-French]; Benoxaprofeno [INN-Spanish]; Benoxaprofenum [INN-Latin]; Dl-Benoxaprofen; Oraflex (TN); Benoxaprofen (USAN/INN); Benoxaprofen [USAN:INN:BAN]; (+-)-2-(p-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; (-)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; (-)-Benoxaprofen; (1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid; 2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid; 2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; 2-(p-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid; 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
DM5ZOX8	CP	Eli Lilly
DM5ZOX8	DT	Small molecular drug
DM5ZOX8	PC	39941
DM5ZOX8	MW	301.72
DM5ZOX8	FM	C16H12ClNO3
DM5ZOX8	IC	InChI=1S/C16H12ClNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20)
DM5ZOX8	CS	CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O
DM5ZOX8	IK	MITFXPHMIHQXPI-UHFFFAOYSA-N
DM5ZOX8	IU	2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
DM5ZOX8	CA	CAS 51234-28-7
DM5ZOX8	CB	CHEBI:76114
DM5ZOX8	DE	Inflammation

DMJMHNL	ID	DMJMHNL
DMJMHNL	DN	Bethanidine
DMJMHNL	HS	Withdrawn from market
DMJMHNL	SN	Betanidina; Betanidine; Betanidinum; Betanidole; Bethanid; Esbatal; Regulin; Tenathan; Bethanidine hemisulfate; Bethanidinesulfate; BW 467C60; BW467C60; Betanidina [INN-Spanish]; Betanidine [INN:BAN]; Betanidinum [INN-Latin]; Esbatal (TN); Regulin (TN); Tenathan (TN); Bethanidine Sulfate (2:1); Ulfate (2:1); BW-467-C-60;Bethanidine Sulfate (2:1) (USAN); Bethanidine, Sulfate (2:1); Guanidine, 1-benzyl-2,3-dimethyl-(8CI); Guanidine, 1-benzyl-2,3-dimethyl-, s; N-Benzyl-N',N''-dimethylguanidine sulfate; N,N'-dimethyl-N''-(phenylmethyl)-guanidine; Sulfuric acid compound with N''-benzyl-N,N'-dimethylguanidine (1:1); Guanidine, N, N'-dimethyl-N''-(phenylmethyl)-, sulfate (2:1); 1,2-dimethyl-3-(phenylmethyl)guanidine; 1-BENZYL-2,3-DIMETHYLGUANIDINE; 1-Benzyl-2,3-dimethylguanidine sulfate; 1-Benzyl-2,3-dimethylguanidine sulfate (1:1/2); 1-Benzyl-2,3-dimethylguanidinium sulfate; 2-Benzyl-1,3-dimethylguanidine
DMJMHNL	TC	Antihypertensive Agents
DMJMHNL	DT	Small molecular drug
DMJMHNL	PC	2368
DMJMHNL	MW	177.25
DMJMHNL	FM	C10H15N3
DMJMHNL	IC	InChI=1S/C10H15N3/c1-11-10(12-2)13-8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3,(H2,11,12,13)
DMJMHNL	CS	CNC(=NC)NCC1=CC=CC=C1
DMJMHNL	IK	NIVZHWNOUVJHKV-UHFFFAOYSA-N
DMJMHNL	IU	1-benzyl-2,3-dimethylguanidine
DMJMHNL	CA	CAS 55-73-2
DMJMHNL	CB	CHEBI:37937
DMJMHNL	DE	Heart arrhythmia

DMPJKRL	ID	DMPJKRL
DMPJKRL	DN	Bithionol
DMPJKRL	HS	Withdrawn from market
DMPJKRL	SN	bithionol; 97-18-7; Actamer; Bithin; 2,2'-Thiobis(4,6-dichlorophenol); Lorothidol; Bitionol; Bithionol sulfide; Bisoxyphen; Bidiphen; Lorothiodol; Bitin; Nobacter; Bithionolate; Neopellis; Vancide BL; Usaf B-22; Bithional; Bithionolum; 2-Hydroxy-3,5-dichlorophenyl sulfide; TKhsd; Bis(2-hydroxy-3,5-dichlorophenyl) sulfide; Bis(3,5-dichloro-2-hydroxyphenyl) sulfide; 2,2'-sulfanediylbis(4,6-dichlorophenol); Caswell No. 852; Bitionol [INN-Spanish]; XL 7; Bithionolum [INN-Latin]; 2,2'-Dihydroxy-3,3',5,5'-tetrachlorodiphenyl sulfide
DMPJKRL	DT	Small molecular drug
DMPJKRL	PC	2406
DMPJKRL	MW	356
DMPJKRL	FM	C12H6Cl4O2S
DMPJKRL	IC	InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H
DMPJKRL	CS	C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl
DMPJKRL	IK	JFIOVJDNOJYLKP-UHFFFAOYSA-N
DMPJKRL	IU	2,4-dichloro-6-(3,5-dichloro-2-hydroxyphenyl)sulfanylphenol
DMPJKRL	CA	CAS 97-18-7
DMPJKRL	CB	CHEBI:3131
DMPJKRL	DE	Trematode infection

DMBQYO0	ID	DMBQYO0
DMBQYO0	DN	Casopitant
DMBQYO0	HS	Withdrawn from market
DMBQYO0	SN	Rezonic; Zunrisa; GW 679769; GW679769
DMBQYO0	CP	GlaxoSmithKline
DMBQYO0	DT	Small molecular drug
DMBQYO0	PC	9917021
DMBQYO0	MW	616.6
DMBQYO0	FM	C30H35F7N4O2
DMBQYO0	IC	InChI=1S/C30H35F7N4O2/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37/h5-6,13-16,19,25,27H,7-12,17H2,1-4H3/t19-,25+,27-/m1/s1
DMBQYO0	CS	CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C
DMBQYO0	IK	XGGTZCKQRWXCHW-WMTVXVAQSA-N
DMBQYO0	IU	(2R,4S)-4-(4-acetylpiperazin-1-yl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide
DMBQYO0	CA	CAS 414910-27-3
DMBQYO0	CB	CHEBI:135967
DMBQYO0	DE	Chemotherapy-induced nausea

DM4Y95F	ID	DM4Y95F
DM4Y95F	DN	Cephaloridine
DM4Y95F	HS	Withdrawn from market
DM4Y95F	SN	cephaloridine; cefaloridine; Cefaloridin; Cephaloridin; Cephaloridinum; Cepaloridin; Cefalorizin; Cephalomycine; Cefaloridinum; Cepalorin; Cefaloridina; Loridine; Ceflorin; 50-59-9; Kefloridin; Glaxoridin; Ceporin; Vioviantine; Intrasporin; Sefacin; Keflordin; Deflorin; Cilifor; Ceporan; Sasperin; Faredina; Ceporine; Keflodin; Verolgin; Lloncefal; Kefspor; Ampligram; Betaine cephaloridine; CHEBI:3537; UNII-LVZ1VC61HB; Cefaloridinum [INN-Latin]; Cefaloridina [INN-Spanish]; N-(7-(2'-Thienylacetamidoceph-3-ylmethyl))-pyridinium-2-carboxylate; SCH 
DM4Y95F	DT	Small molecular drug
DM4Y95F	PC	5773
DM4Y95F	MW	415.5
DM4Y95F	FM	C19H17N3O4S2
DM4Y95F	IC	InChI=1S/C19H17N3O4S2/c23-14(9-13-5-4-8-27-13)20-15-17(24)22-16(19(25)26)12(11-28-18(15)22)10-21-6-2-1-3-7-21/h1-8,15,18H,9-11H2,(H-,20,23,25,26)/t15-,18-/m1/s1
DM4Y95F	CS	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CS3)C(=O)[O-])C[N+]4=CC=CC=C4
DM4Y95F	IK	CZTQZXZIADLWOZ-CRAIPNDOSA-N
DM4Y95F	IU	(6R,7R)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM4Y95F	CA	CAS 50-59-9
DM4Y95F	CB	CHEBI:3537
DM4Y95F	DE	Gram-positive bacterial infection

DMSV2WZ	ID	DMSV2WZ
DMSV2WZ	DN	Chlorotrianisene
DMSV2WZ	HS	Withdrawn from market
DMSV2WZ	SN	Anisene; Chloortrianisestrol; Chlorestrolo; Chlorotrianisenum; Chlorotrianisestrol; Chlorotrianisine; Chlorotrianizen; Chlorotrisin; Chlortrianisen; Chlortrianisene; Chlortrianisenum; Chlortrianisestrol; Chlortrianisoestrolum; Chlortrianizen; Clorestrolo; Clorotrianisene; Clorotrianiseno; Clorotrisin; Hormonisene; Khlortrianizen; Merbentul; Metace; Rianil; TACE; Triagen; Trianisestrol; Chlorotrianisene [Nonsteroidal oestrogens]; Clorotrianisene [DCIT]; Chlorotrianisene (INN); Chlorotrianisene [BAN:INN]; Chlorotrianisene [INN:BAN]; Chlorotrianisenum [INN-Latin]; Clorotrianiseno [INN-Spanish]; TACE (TN); Tace (pharmaceutical); Tace-fn; Chlorotris(p-methoxyphenyl)ethylene; Tri-p-anisylchloroethylene; Tris(p-methoxyphenyl)chloroethylene; 1,1',1''-(1-Chloro-1-ethenyl-2-ylidene)-tris(4-methoxybenzene); 1,1',1''-(2-chloroethene-1,1,2-triyl)tris(4-methoxybenzene); 1,1',1''-(2-chloroethene-1,1,2-triyl)tris[4-(methyloxy)benzene]; 1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
DMSV2WZ	TC	Anticancer Agents
DMSV2WZ	DT	Small molecular drug
DMSV2WZ	PC	11289
DMSV2WZ	MW	380.9
DMSV2WZ	FM	C23H21ClO3
DMSV2WZ	IC	InChI=1S/C23H21ClO3/c1-25-19-10-4-16(5-11-19)22(17-6-12-20(26-2)13-7-17)23(24)18-8-14-21(27-3)15-9-18/h4-15H,1-3H3
DMSV2WZ	CS	COC1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)OC)Cl)C3=CC=C(C=C3)OC
DMSV2WZ	IK	BFPSDSIWYFKGBC-UHFFFAOYSA-N
DMSV2WZ	IU	1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
DMSV2WZ	CA	CAS 569-57-3
DMSV2WZ	CB	CHEBI:3641
DMSV2WZ	DE	Menopause symptom

DM746BZ	ID	DM746BZ
DM746BZ	DN	Clioquinol
DM746BZ	HS	Withdrawn from market
DM746BZ	SN	clioquinol; 130-26-7; 5-Chloro-7-iodoquinolin-8-ol; Iodochlorhydroxyquin; Chinoform; Chloroiodoquin; Chloroiodoquine; 5-Chloro-8-hydroxy-7-iodoquinoline; Iodochloroxyquinoline; Cliquinol; Vioform; Iodochlorohydroxyquinoline; Chlorojodochin; Iodochloroxine; Iodochloroquine; Enteroquinol; Iodoenterol; 7-Iodo-5-chloroxine; Entero-Vioform; 5-Chloro-7-iodo-8-quinolinol; Iodochlorhydroxyquinoline; Iodoxyquinoline; Rheaform; Quinoform; Quinambicide; Lekosept; Dioquinol; Dermaform; Iodenterol; Entrokin; Enteroseptol; Domeform; Barquinol
DM746BZ	DT	Small molecular drug
DM746BZ	PC	2788
DM746BZ	MW	305.5
DM746BZ	FM	C9H5ClINO
DM746BZ	IC	InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
DM746BZ	CS	C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1
DM746BZ	IK	QCDFBFJGMNKBDO-UHFFFAOYSA-N
DM746BZ	IU	5-chloro-7-iodoquinolin-8-ol
DM746BZ	CA	CAS 130-26-7
DM746BZ	CB	CHEBI:74460

DMJ7YDS	ID	DMJ7YDS
DMJ7YDS	DN	Dexfenfluramine
DMJ7YDS	HS	Withdrawn from market
DMJ7YDS	SN	DEXFENFLURAN; Dexfenfluramine (INN); Redux (TN); (2S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; (S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DMJ7YDS	CP	Wyeth Pharmaceuticals
DMJ7YDS	TC	Appetite Depressants
DMJ7YDS	DT	Small molecular drug
DMJ7YDS	PC	66265
DMJ7YDS	MW	231.26
DMJ7YDS	FM	C12H16F3N
DMJ7YDS	IC	InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3/t9-/m0/s1
DMJ7YDS	CS	CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
DMJ7YDS	IK	DBGIVFWFUFKIQN-VIFPVBQESA-N
DMJ7YDS	IU	(2S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DMJ7YDS	CA	CAS 3239-44-9
DMJ7YDS	CB	CHEBI:439329
DMJ7YDS	DE	Obesity

DMRZ5D7	ID	DMRZ5D7
DMRZ5D7	DN	Droxicam
DMRZ5D7	HS	Withdrawn from market
DMRZ5D7	SN	Dobenam; Drogelon; Droxar; Ferpan; Ombolan; Precam; E-3128; E-318
DMRZ5D7	CP	Esteve
DMRZ5D7	DT	Small molecular drug
DMRZ5D7	PC	65679
DMRZ5D7	MW	357.3
DMRZ5D7	FM	C16H11N3O5S
DMRZ5D7	IC	InChI=1S/C16H11N3O5S/c1-18-13-14(10-6-2-3-7-11(10)25(18,22)23)24-16(21)19(15(13)20)12-8-4-5-9-17-12/h2-9H,1H3
DMRZ5D7	CS	CN1C2=C(C3=CC=CC=C3S1(=O)=O)OC(=O)N(C2=O)C4=CC=CC=N4
DMRZ5D7	IK	OEHFRZLKGRKFAS-UHFFFAOYSA-N
DMRZ5D7	IU	5-methyl-6,6-dioxo-3-pyridin-2-yl-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4-dione
DMRZ5D7	CA	CAS 90101-16-9
DMRZ5D7	CB	CHEBI:76133
DMRZ5D7	DE	Inflammation

DMV5KR3	ID	DMV5KR3
DMV5KR3	DN	Ebrotidine
DMV5KR3	HS	Withdrawn from market
DMV5KR3	SN	Ebrocit; FI-3542
DMV5KR3	CP	Ferrer Internacional SA
DMV5KR3	DT	Small molecular drug
DMV5KR3	PC	65869
DMV5KR3	MW	477.4
DMV5KR3	FM	C14H17BrN6O2S3
DMV5KR3	IC	InChI=1S/C14H17BrN6O2S3/c15-10-1-3-12(4-2-10)26(22,23)19-9-18-5-6-24-7-11-8-25-14(20-11)21-13(16)17/h1-4,8-9H,5-7H2,(H,18,19)(H4,16,17,20,21)
DMV5KR3	CS	C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br
DMV5KR3	IK	ZQHFZHPUZXNPMF-UHFFFAOYSA-N
DMV5KR3	IU	N-(4-bromophenyl)sulfonyl-N'-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]methanimidamide
DMV5KR3	CA	CAS 100981-43-9
DMV5KR3	CB	CHEBI:135774
DMV5KR3	DE	Duodenal ulcer

DMK0GHV	ID	DMK0GHV
DMK0GHV	DN	Encainide
DMK0GHV	HS	Withdrawn from market
DMK0GHV	SN	Encainida; Encainidum; Enkaid; Encainida [Spanish]; Encainide [French]; Encainidum [Latin]; No stereochem; MJ 9067; Encainide (INN); Encainide [INN:BAN]; MJ-9067; MJ-9067-1; Encainide Hydrochloride, (+-)-Isomer; (+-)-2'-[2-(1-methyl-2-piperidyl)ethyl]-p-anisanilide; (+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide; (+/-)-4-Methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide; 4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide; 4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide; 4-methoxy-N-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide
DMK0GHV	TC	Antiarrhythmic Agents
DMK0GHV	DT	Small molecular drug
DMK0GHV	PC	48041
DMK0GHV	MW	352.5
DMK0GHV	FM	C22H28N2O2
DMK0GHV	IC	InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)
DMK0GHV	CS	CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC
DMK0GHV	IK	PJWPNDMDCLXCOM-UHFFFAOYSA-N
DMK0GHV	IU	4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide
DMK0GHV	CA	CAS 66778-36-7
DMK0GHV	CB	CHEBI:4788
DMK0GHV	DE	Heart arrhythmia

DM67PWD	ID	DM67PWD
DM67PWD	DN	Etilefrine
DM67PWD	HS	Withdrawn from market
DM67PWD	SN	etilefrine hydrochloride; 943-17-9; Etilefrine HCl; Circupon; Kertasin; Effontil; 534-87-2; 3-[2-(ethylamino)-1-hydroxyethyl]phenol hydrochloride; Effortilvet; Phetasin; Updormin; Pulsamin; Apocretin; Phetanol; Funasol; Ethyl adrianol; Tonus-Forte; Etilefrin Hydrochloride; Eti-Puren; 3-(2-(Ethylamino)-1-hydroxyethyl)phenol hydrochloride; 2-Ethylamino-1-(3-hydroxyphenyl)ethanol Hydrochloride; Etilefrine hydrochloride (TN); dl-Effortil hydrochloride; Ethylephrine hydrochloride; dl-Etilefrin hydrochloride; dl-N-Ethylnorphenylephrine h
DM67PWD	DT	Small molecular drug
DM67PWD	PC	3306
DM67PWD	MW	181.23
DM67PWD	FM	C10H15NO2
DM67PWD	IC	InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
DM67PWD	CS	CCNCC(C1=CC(=CC=C1)O)O
DM67PWD	IK	SQVIAVUSQAWMKL-UHFFFAOYSA-N
DM67PWD	IU	3-[2-(ethylamino)-1-hydroxyethyl]phenol
DM67PWD	CA	CAS 709-55-7
DM67PWD	CB	CHEBI:91518
DM67PWD	DE	Cardiovascular disease

DMVG9YN	ID	DMVG9YN
DMVG9YN	DN	Fencamfamine
DMVG9YN	HS	Withdrawn from market
DMVG9YN	SN	Euvitol; Fenacamfamin; Fencamfamin; Fencamfamina; Fencamfaminum; Fencanfamina; Reactivan; Fencamfamina [DCIT]; Fencamfamin (INN); Fencamfamin [INN:BAN]; Fencamfamine [INN-French]; Fencamfaminum [INN-Latin]; Fencanfamina [INN-Spanish]; Glucoenergan (TN); Reactivan (TN); N-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine; N-ethyl-3-phenylbicyclo(2.2.1)heptan-2-amine; 2-Ethylamino-3-phenylnorbornane; 2-Phenyl-3-ethylaminobicyclo(2.2.1)heptane; 2-ethylamino-3-phenylnorcamphane; 3-Phenyl-N-ethyl-2-norbornanamine
DMVG9YN	TC	Central Nervous System Stimulants
DMVG9YN	DT	Small molecular drug
DMVG9YN	PC	14584
DMVG9YN	MW	215.33
DMVG9YN	FM	C15H21N
DMVG9YN	IC	InChI=1S/C15H21N/c1-2-16-15-13-9-8-12(10-13)14(15)11-6-4-3-5-7-11/h3-7,12-16H,2,8-10H2,1H3
DMVG9YN	CS	CCNC1C2CCC(C2)C1C3=CC=CC=C3
DMVG9YN	IK	IKFBPFGUINLYQI-UHFFFAOYSA-N
DMVG9YN	IU	N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine
DMVG9YN	CA	CAS 1209-98-9
DMVG9YN	CB	CHEBI:134895
DMVG9YN	DE	Depressive fatigue

DMH6NG5	ID	DMH6NG5
DMH6NG5	DN	Fendiline
DMH6NG5	HS	Withdrawn from market
DMH6NG5	SN	fendiline; Fendilin; 13042-18-7; Fendilinum; Fendilinum [INN-Latin]; Fendilina [INN-Spanish]; Fendiline [INN]; EINECS 235-915-6; CHEMBL254832; Fendiline (INN); Benzenepropanamine, gamma-phenyl-N-(1-phenylethyl)-; Benzenepropanamine, .gamma.-phenyl-N-(1-phenylethyl)-; 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine; Phendilin; Fendilina; Senzit; NCGC00018223-06; SPBio_001131; Spectrum_000443; AC1L1FPB; Spectrum5_001302; Spectrum2_001006; Prestwick1_000270; Spectrum4_000417; Prestwick3_000270; Spectrum3_001436; Prestwick2_000270
DMH6NG5	DT	Small molecular drug
DMH6NG5	PC	3336
DMH6NG5	MW	315.5
DMH6NG5	FM	C23H25N
DMH6NG5	IC	InChI=1S/C23H25N/c1-19(20-11-5-2-6-12-20)24-18-17-23(21-13-7-3-8-14-21)22-15-9-4-10-16-22/h2-16,19,23-24H,17-18H2,1H3
DMH6NG5	CS	CC(C1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
DMH6NG5	IK	NMKSAYKQLCHXDK-UHFFFAOYSA-N
DMH6NG5	IU	3,3-diphenyl-N-(1-phenylethyl)propan-1-amine
DMH6NG5	CA	CAS 13042-18-7
DMH6NG5	CB	CHEBI:94434
DMH6NG5	DE	Coronary artery disease

DMY9P37	ID	DMY9P37
DMY9P37	DN	Flupenthixol
DMY9P37	HS	Withdrawn from market
DMY9P37	SN	Depixol; Emergil; Fluanxol; Fluxanxol; Siplaril; Siplarol; LC 44; N 7009; ALPHA-FLUPENTHIXOL; Cis(Z)Flupenthixol; Cis-Flupenthixol; Cis-Flupentixol; Depixol (TN); Fluanxol (TN); Flupentixol (INN); Flupentixol [INN:DCF]; Flupentixolum [INN-Latin]; Cis-(Z)-Flupenthixol; (Z)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; (Z)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)piperazine-1-ethanol; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-(9CI); 2-Trifluoromethyl-9-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propylidene)thioxanthene; 2-Trifluoromethyl-9-(3-(4-(beta-hydroxyethyl)-1-piperazinyl)propylidene)thioxanthene; 2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol
DMY9P37	CP	Lundbeck Inc
DMY9P37	TC	Antipsychotic Agents
DMY9P37	DT	Small molecular drug
DMY9P37	PC	5281881
DMY9P37	MW	434.5
DMY9P37	FM	C23H25F3N2OS
DMY9P37	IC	InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
DMY9P37	CS	C1CN(CCN1CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DMY9P37	IK	NJMYODHXAKYRHW-DVZOWYKESA-N
DMY9P37	IU	2-[4-[(3Z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DMY9P37	CA	CAS 53772-82-0
DMY9P37	CB	CHEBI:10454
DMY9P37	DE	Schizophrenia

DMWIDJK	ID	DMWIDJK
DMWIDJK	DN	FORMESTANE
DMWIDJK	HS	Withdrawn from market
DMWIDJK	SN	formestane; 566-48-3; 4-Hydroxyandrost-4-ene-3,17-dione; 4-Hydroxyandrostenedione; Lentaron; CGP-32349; Lentaron(R); 4-OH-A; B, Aromatase inhibitor; 4-Hydroxy-4-androstene-3,17-dione; NSC 282175; 17-dione; 4-OHA; CGP 32349; Formestane [INN:BAN]; UNII-PUB9T8T355; CCRIS 7483; ANDROST-4-ENE-3,17-DIONE, 4-HYDROXY-; 4-Hydroxy-delta(sub 4)-androstenedione; BRN 1889793; MLS002153359; MLS000028826; PUB9T8T355; CHEBI:75172
DMWIDJK	DT	Small molecular drug
DMWIDJK	PC	11273
DMWIDJK	MW	302.4
DMWIDJK	FM	C19H26O3
DMWIDJK	IC	InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
DMWIDJK	CS	C[C@]12CCC(=O)C(=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DMWIDJK	IK	OSVMTWJCGUFAOD-KZQROQTASA-N
DMWIDJK	IU	(8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMWIDJK	CA	CAS 566-48-3
DMWIDJK	CB	CHEBI:75172
DMWIDJK	DE	Breast cancer

DM9AGWQ	ID	DM9AGWQ
DM9AGWQ	DN	HEXESTROL
DM9AGWQ	HS	Withdrawn from market
DM9AGWQ	SN	hexestrol; Dihydrodiethylstilbestrol; Vitestrol; Hexoestrolum; Exestrol; 5635-50-7; Stilbestrol, dihydro-; 4,4'-(1,2-Diethylethylene)diphenol; 4,4'-(hexane-3,4-diyl)diphenol; Synoestrolum; Hexanestrol; Cycloestrol; Esestrolo [DCIT]; Phenol, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-; Hexestrolum [INN-Latin]; Hexane, 3,4-bis(4-hydroxyphenyl)-; EINECS 227-082-2; 3,4-Bis(p-hydroxyphenyl)hexane; Hormoestrol; Syntrogene; Synthovo; Phenol, 4,4'-(1,2-diethylethylene)di-; CHEBI:31669; PBBGSZCBWVPOOL-UHFFFAOYSA-N; Hexestrol [INN]
DM9AGWQ	DT	Small molecular drug
DM9AGWQ	PC	3606
DM9AGWQ	MW	270.4
DM9AGWQ	FM	C18H22O2
DM9AGWQ	IC	InChI=1S/C18H22O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,17-20H,3-4H2,1-2H3
DM9AGWQ	CS	CCC(C1=CC=C(C=C1)O)C(CC)C2=CC=C(C=C2)O
DM9AGWQ	IK	PBBGSZCBWVPOOL-UHFFFAOYSA-N
DM9AGWQ	IU	4-[4-(4-hydroxyphenyl)hexan-3-yl]phenol
DM9AGWQ	CA	CAS 5635-50-7
DM9AGWQ	CB	CHEBI:31669
DM9AGWQ	DE	Irregularities

DMSO2T9	ID	DMSO2T9
DMSO2T9	DN	Ibuproxam
DMSO2T9	HS	Withdrawn from market
DMSO2T9	SN	Ibuproxam; Ibudros; Ibuproxamum; 53648-05-8; Ibuproxam [INN]; n-hydroxy-2-(4-isobutylphenyl)propanamide; G-277; BRN 2267673; CHEMBL292707; CHEBI:76160; D,L-2-(4-Isobutylphenyl)propiohydroxamic acid; p-Isobutylhydratropohydroxamic acid; Ibuproxam (INN); D,L-N-Hydroxy-alpha-methyl-4-(2-methylpropyl)benzeneacetamide; N-hydroxy-2-[4-(2-methylpropyl)phenyl]propanamide; Propionohydroxamic acid, 2-(p-isobutylphenyl)-, D,L-; Deflogon; Ibuproxamum [INN-Latin]; (S)-Ibuproxam; 73826-33-2; Ibudros (TN); EINECS 258-683-8; NSC 305528
DMSO2T9	DT	Small molecular drug
DMSO2T9	PC	68704
DMSO2T9	MW	221.29
DMSO2T9	FM	C13H19NO2
DMSO2T9	IC	InChI=1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)
DMSO2T9	CS	CC(C)CC1=CC=C(C=C1)C(C)C(=O)NO
DMSO2T9	IK	BYPIURIATSUHDW-UHFFFAOYSA-N
DMSO2T9	IU	N-hydroxy-2-[4-(2-methylpropyl)phenyl]propanamide
DMSO2T9	CA	CAS 53648-05-8
DMSO2T9	CB	CHEBI:76160
DMSO2T9	DE	Respiratory disease

DM5QSKN	ID	DM5QSKN
DM5QSKN	DN	INDOPROFEN
DM5QSKN	HS	Withdrawn from market
DM5QSKN	SN	Dexindoprofen; UNII-004T8726AU; 53086-13-8; 004T8726AU; (+)-indoprofen; Dexindoprofenum; Dexindoprofene; Dexindoprofeno; Dexindoprofen [INN]; Dexindoprofenum [INN-Latin]; Dexindoprofene [INN-French]; Dexindoprofeno [INN-Spanish]; Indoprofen (+)-; EINECS 258-351-2; AC1Q5QZO; AC1L2A9M; ZINC391; SCHEMBL286896; (+)-(S)-4-(1-Oxo-2-isoindolinyl)hydratropasaeure; CHEMBL2106252; AJ-07888; (+)-(S)-p-(1-Oxo-2-isoindolinyl)hydratropic acid; UNII-CPE46ZU14N component RJMIEHBSYVWVIN-NSHDSACASA-N
DM5QSKN	DT	Small molecular drug
DM5QSKN	PC	3718
DM5QSKN	MW	281.3
DM5QSKN	FM	C17H15NO3
DM5QSKN	IC	InChI=1S/C17H15NO3/c1-11(17(20)21)12-6-8-14(9-7-12)18-10-13-4-2-3-5-15(13)16(18)19/h2-9,11H,10H2,1H3,(H,20,21)
DM5QSKN	CS	CC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O
DM5QSKN	IK	RJMIEHBSYVWVIN-UHFFFAOYSA-N
DM5QSKN	IU	2-[4-(3-oxo-1H-isoindol-2-yl)phenyl]propanoic acid
DM5QSKN	CA	CAS 31842-01-0
DM5QSKN	CB	CHEBI:76162
DM5QSKN	DE	Gout

DMNSJFD	ID	DMNSJFD
DMNSJFD	DN	Indoramin
DMNSJFD	HS	Withdrawn from market
DMNSJFD	SN	INDORAMIN; Indoramine; 26844-12-2; Indoramina; Wy-21901; Indoraminum [INN-Latin]; Indoramine [INN-French]; Indoramina [INN-Spanish]; UNII-0Z802HMY7H; Baratol; EINECS 248-041-5; BRN 0494035; WY 21901; 0Z802HMY7H; CHEMBL279516; C22H25N3O; Benzamide, N-(1-(2-(1H-indol-3-yl)ethyl)-4-piperidinyl)-; 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole; JXZZEXZZKAWDSP-UHFFFAOYSA-N; N-(1-(2-Indol-3-ylethyl)-4-piperidyl)benzamide; N-(1-(2-(1H-Indol-3-yl)ethyl)-4-piperidinyl)benzamide; Benzamide, N-(1-(2-indol-3-ylethyl)-4-piperidyl)-; Benzamide, N
DMNSJFD	DT	Small molecular drug
DMNSJFD	PC	33625
DMNSJFD	MW	347.5
DMNSJFD	FM	C22H25N3O
DMNSJFD	IC	InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
DMNSJFD	CS	C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43
DMNSJFD	IK	JXZZEXZZKAWDSP-UHFFFAOYSA-N
DMNSJFD	IU	N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide
DMNSJFD	CA	CAS 26844-12-2
DMNSJFD	CB	CHEBI:135470
DMNSJFD	DE	Hypertension

DMGTBC7	ID	DMGTBC7
DMGTBC7	DN	ISIS 2922
DMGTBC7	HS	Withdrawn from market
DMGTBC7	SN	Formivirsen sodium; 5'-d[G*C*G*T*T*T*G*C*T*C*T*T*C*T*T*C*T*T*G*C*G*]-3'; 5-SpG SpC SpG SpT spT SpT spG spC spT spC spT spT spC spT spT spC spT spT spG spC spG-3'
DMGTBC7	CP	Isis Pharmaceuticals
DMGTBC7	DT	Antisense drug
DMGTBC7	SQ	GCGTTTGCTCTTCTTCTTGCG
DMGTBC7	DE	Cytomegalovirus infection

DMMS2J5	ID	DMMS2J5
DMMS2J5	DN	Isoxicam
DMMS2J5	HS	Withdrawn from market
DMMS2J5	SN	isoxicam; 34552-84-6; Maxicam; Isoxicamo; Isoxicamum; UNII-8XU734C4NG; Pacyl (antiinflammatory); Isoxicamum [INN-Latin]; Isoxicamo [INN-Spanish]; EINECS 252-084-5; W 8495; BRN 0577221; 8XU734C4NG; CHEBI:76163; C14H13N3O5S; NCGC00016829-05; CAS-34552-84-6; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; DSSTox_CID_25462; DSSTox_RID_80893; DSSTox_GSID_45462
DMMS2J5	DT	Small molecular drug
DMMS2J5	PC	54677972
DMMS2J5	MW	335.34
DMMS2J5	FM	C14H13N3O5S
DMMS2J5	IC	InChI=1S/C14H13N3O5S/c1-8-7-11(16-22-8)15-14(19)12-13(18)9-5-3-4-6-10(9)23(20,21)17(12)2/h3-7,18H,1-2H3,(H,15,16,19)
DMMS2J5	CS	CC1=CC(=NO1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
DMMS2J5	IK	YYUAYBYLJSNDCX-UHFFFAOYSA-N
DMMS2J5	IU	4-hydroxy-2-methyl-N-(5-methyl-1,2-oxazol-3-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
DMMS2J5	CA	CAS 34552-84-6
DMMS2J5	CB	CHEBI:76163
DMMS2J5	DE	Osteoarthritis

DMACMLO	ID	DMACMLO
DMACMLO	DN	LYSERGIC ACID DIETHYLAMIDE
DMACMLO	HS	Withdrawn from market
DMACMLO	SN	Lysergide; D-Lysergic acid diethylamide; Delysid; D-Lsd; N,N-Diethyllysergamide; Lysergamid; 50-37-3; Lysergsaeurediaethylamid; Cubes; Pearly gates; Heavenly Blue; Lysergaure diethylamid; Royal blue; N,N-Diethyl-D-lysergamide; LSD (alkaloid); Lysergidum; Wedding bells; Lysergsauerediaethylamid; Lysergic acid diethylamide-25; LSD 25; Lysergidum [INN-Latin]; LSD-25; Lisergide [DCIT]; Lysergamide, N,N-diethyl-; Ubergluben; Clearlight; Sunshine; Cupcakes; Greenies; Barrels; Yellows; Trippers; Microdots; Spoonies
DMACMLO	DT	Small molecular drug
DMACMLO	PC	5761
DMACMLO	MW	323.4
DMACMLO	FM	C20H25N3O
DMACMLO	IC	InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1
DMACMLO	CS	CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMACMLO	IK	VAYOSLLFUXYJDT-RDTXWAMCSA-N
DMACMLO	IU	(6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMACMLO	CA	CAS 50-37-3
DMACMLO	CB	CHEBI:6605
DMACMLO	DE	Addictive disorder

DM79GRO	ID	DM79GRO
DM79GRO	DN	Metamizole
DM79GRO	HS	Withdrawn from market
DM79GRO	SN	Dipyrone; dipyrone; Analgin; Metamizole sodium; Methampyrone; Novalgin; sulpyrine; 68-89-3; Neomelurbrin; Methylmelubrin; Algocalmin; Optalgin; Novalgetol; Sulpyrin; Pyralgin; Narone; Novaminsulfone; Novamidazophen; Nevralgina; Pharmalgine; Algopyrine; Farmolisina; Pyretin; Keypyrone; Analgine; Noveltex; Fevonil; Diprofarn; Dimethone; Alginodia; Pyrojec; Paralgin; Metilon; Metapyrin; Gifaril; Bonpyrin; Sulpin; Conmel; Barone; Neo-melubrine; Di-podil; Aminopyrine sodium sulfonate; Novaminsulfonum; Novaminsulfon; Metamizolum natricum
DM79GRO	CP	Aventis SA
DM79GRO	DT	Small molecular drug
DM79GRO	PC	3111
DM79GRO	MW	311.36
DM79GRO	FM	C13H17N3O4S
DM79GRO	IC	InChI=1S/C13H17N3O4S/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11/h4-8H,9H2,1-3H3,(H,18,19,20)
DM79GRO	CS	CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)O
DM79GRO	IK	LVWZTYCIRDMTEY-UHFFFAOYSA-N
DM79GRO	IU	[(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonic acid
DM79GRO	CA	CAS 50567-35-6
DM79GRO	CB	CHEBI:62088
DM79GRO	DE	Pain; Fever

DMW9NY0	ID	DMW9NY0
DMW9NY0	DN	Methaqualone
DMW9NY0	HS	Withdrawn from market
DMW9NY0	SN	Methaqualone hydrochloride; Melsedin; Somnofac; Optimil; Parest; Mequal; Melsed HCl; MTQ hydrochloride; Sopor hydrochloride; Somnafac; Quaalude hydrochloride; Methaqualone HCl; Hyminal monohydrochloride; TR 495 monohydrochloride; Mozambin hydrochloride; Methylquinazolone hydrochloride; UNII-RJQ4G25ZRH; 340-56-7; EINECS 206-431-2; NSC 75892; RJQ4G25ZRH; 2-Methyl-3-(o-tolyl)-4-quinazolone hydrochloride; CHI 38; 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)-, monohydrochloride; 2-Methyl-3-tolylchinazolon-4 hydrochloride [German]
DMW9NY0	DT	Small molecular drug
DMW9NY0	PC	6292
DMW9NY0	MW	250.29
DMW9NY0	FM	C16H14N2O
DMW9NY0	IC	InChI=1S/C16H14N2O/c1-11-7-3-6-10-15(11)18-12(2)17-14-9-5-4-8-13(14)16(18)19/h3-10H,1-2H3
DMW9NY0	CS	CC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)C
DMW9NY0	IK	JEYCTXHKTXCGPB-UHFFFAOYSA-N
DMW9NY0	IU	2-methyl-3-(2-methylphenyl)quinazolin-4-one
DMW9NY0	CA	CAS 72-44-6
DMW9NY0	CB	CHEBI:6821
DMW9NY0	DE	Insomnia

DMCP2TS	ID	DMCP2TS
DMCP2TS	DN	Nomifensine
DMCP2TS	HS	Withdrawn from market
DMCP2TS	SN	Linamiphen; Nomifenison; Nomifensin; Nomifensina; Nomifensinum; Nomiphensine; Nomifensina [INN-Spanish]; Nomifensine [INN:BAN]; Nomifensine maleate(USAN); Nomifensinum [INN-Latin]; D,L-nomifensine; Nomifensine Maleate (1:1); R/S-nomifensine; (+)-Nomifensine; (+)-Nomiphensine; (+-)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine; (+-)-Nomifensin; (+-)-Nomifensine; (R)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine 2-butenedioate; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine; 2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine; 2-methyl-4-phenyl-3,4-dihydro-1H-isoquinolin-8-amine; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisochinolin; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline maleate (1:1); 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-(9CI)
DMCP2TS	CP	Uihlein
DMCP2TS	DT	Small molecular drug
DMCP2TS	PC	4528
DMCP2TS	MW	238.33
DMCP2TS	FM	C16H18N2
DMCP2TS	IC	InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3
DMCP2TS	CS	CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3
DMCP2TS	IK	XXPANQJNYNUNES-UHFFFAOYSA-N
DMCP2TS	IU	2-methyl-4-phenyl-3,4-dihydro-1H-isoquinolin-8-amine
DMCP2TS	CA	CAS 24526-64-5
DMCP2TS	CB	CHEBI:116225
DMCP2TS	DE	Breast cancer

DMDKXYC	ID	DMDKXYC
DMDKXYC	DN	Parabis
DMDKXYC	HS	Withdrawn from market
DMDKXYC	SN	Dichlorophen; dichlorophene; Dichlorofen; Dichlorphen; 2,2'-Methylenebis(4-chlorophenol); Didroxane; Didroxan; Trivex; Difentan; Dicestal; Antiphen; Vermithana; Teniatol; Prevental; Teniotol; Embephen; Anthiphen; Teniathane; Taeniatol; Panacide; Cordocel; Palacel; Halenol; Parabis; Korium; Hyosan; Antifen; Dichlorophen B; Dichlorophene 10; Dichloorfeen; Gingivit; Wespuril; Gefir; Fungicide M; Plath-Lyse; DDDM; Bis(5-chloro-2-hydroxyphenyl)methane; Preventol GD; Fungicide GM; Preventol GDC; Diphenthane 70; Sandocide; Super mosstox
DMDKXYC	PC	3037
DMDKXYC	MW	269.12
DMDKXYC	FM	C13H10Cl2O2
DMDKXYC	IC	InChI=1S/C13H10Cl2O2/c14-10-1-3-12(16)8(6-10)5-9-7-11(15)2-4-13(9)17/h1-4,6-7,16-17H,5H2
DMDKXYC	CS	C1=CC(=C(C=C1Cl)CC2=C(C=CC(=C2)Cl)O)O
DMDKXYC	IK	MDNWOSOZYLHTCG-UHFFFAOYSA-N
DMDKXYC	IU	4-chloro-2-[(5-chloro-2-hydroxyphenyl)methyl]phenol
DMDKXYC	CA	CAS 97-23-4
DMDKXYC	CB	CHEBI:34689
DMDKXYC	DE	Tapeworm infestation

DMRQAM0	ID	DMRQAM0
DMRQAM0	DN	Phenacetin
DMRQAM0	HS	Withdrawn from market
DMRQAM0	SN	phenacetin; 62-44-2; Acetophenetidin; N-(4-Ethoxyphenyl)acetamide; Acetphenetidin; Acetophenetidine; Acetophenetin; Phenacetine; p-Acetophenetidide; Contradouleur; Commotional; Achrocidin; Phenazetin; Contradol; Codempiral; 4'-Ethoxyacetanilide; 4-Ethoxyacetanilide; Acetamide, N-(4-ethoxyphenyl)-; p-Acetophenetidine; Fenacetina; Phenidin; Pyraphen; Phenacitin; Phenacetinum; Fenidina; Phenedina; Phenacet; Pertonal; Fenina; Phenin; Kalmin; p-Acetphenetidin; p-Acetophenetide; Phenazetina; Tetracydin; p-Ethoxyacetanilide; Stellacyl; Phenodyne; Imidazo[4,5-e][1,4]diazapine nucleotide (I)
DMRQAM0	DT	Small molecular drug
DMRQAM0	PC	4754
DMRQAM0	MW	179.22
DMRQAM0	FM	C10H13NO2
DMRQAM0	IC	InChI=1S/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)
DMRQAM0	CS	CCOC1=CC=C(C=C1)NC(=O)C
DMRQAM0	IK	CPJSUEIXXCENMM-UHFFFAOYSA-N
DMRQAM0	IU	N-(4-ethoxyphenyl)acetamide
DMRQAM0	CA	CAS 62-44-2
DMRQAM0	CB	CHEBI:8050
DMRQAM0	DE	Analgesia

DMQ52JG	ID	DMQ52JG
DMQ52JG	DN	Phenformin
DMQ52JG	HS	Withdrawn from market
DMQ52JG	SN	Azucaps; Cronoformin; DBI; Debeone; Debinyl; Diabis; Dibein; Dibiraf; Dibotin; Dipar; Feguanide; Fenfoduron; Fenformin; Fenformina; Fenormin; Glukopostin; Glyphen; Insoral; Lentobetic; Meltrol; Normoglucina; Pedg; Phenethyldiguanide; Phenformine; Phenforminum; Phenformix; Phenylethylbiguanide; Retardo; D Bretard; DB Comb; DBI monohydrochloride; Phenformine HCl; Phenoformine hydrochloride; W 32; Beta-PEBG; Beta-Phenethybiguanide; Beta-Phenethylbiguanide; Db-retard; Debeone (TN); Fenformina [INN-Spanish]; Meltrol-50; N-Phenethylbiguanide hydrochloride; Phenformin (BAN); Phenformin [INN:BAN]; Phenformine [INN-French]; Phenforminum [INN-Latin]; N'-beta-Fenetilformamidiniliminourea; N'-beta-Fenetilformamidiniliminourea [Italian]; N'-beta-Phenethylformamidinylliminourea; N-(2-Phenylethyl)imidodicarbonimidic diamide; PHENFORMIN (SEE ALSO PHENFORMIN HYDROCHLORIDE 834-28-6); 1-(diaminomethylidene)-2-phenethylguanidine; 1-Phenethylbiguanide
DMQ52JG	CP	Eli Lilly
DMQ52JG	TC	Hypoglycemic Agents
DMQ52JG	DT	Small molecular drug
DMQ52JG	PC	8249
DMQ52JG	MW	205.26
DMQ52JG	FM	C10H15N5
DMQ52JG	IC	InChI=1S/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)
DMQ52JG	CS	C1=CC=C(C=C1)CCN=C(N)N=C(N)N
DMQ52JG	IK	ICFJFFQQTFMIBG-UHFFFAOYSA-N
DMQ52JG	IU	1-(diaminomethylidene)-2-(2-phenylethyl)guanidine
DMQ52JG	CA	CAS 114-86-3
DMQ52JG	CB	CHEBI:8064
DMQ52JG	DE	Diabetic complication

DM5SICT	ID	DM5SICT
DM5SICT	DN	Phenolphthalein
DM5SICT	HS	Withdrawn from market
DM5SICT	SN	phenolphthalein; 77-09-8; Phthalimetten; Phthalin; Euchessina; Phenolax; Purgophen; Espotabs; Koprol; Trilax; Laxogen; Purga; Lilo; Spulmako-lax; Feen-A-Mint Gum; Chocolax; Purgen; 3,3-Bis(4-hydroxyphenyl)phthalide; Ex-Lax; Fenolftalein; Correctol; Alophen; Medilax; Doxidan; Colax; Laxin; FemiLax; Dihydroxyphthalophenone; Phillips Gelcaps; 3,3-Bis(4-hydroxyphenyl)-1(3H)-isobenzofuranone; Lax-Pills; Evac-Q-Tabs; Evac-Q-Kwik; Evac-U-Gen; Evac-Q-Kit; 1(3H)-Isobenzofuranone, 3,3-bis(4-hydroxyphenyl)-; Phenolphtaleine; Fenolftaleina; Phenophthalein
DM5SICT	DT	Small molecular drug
DM5SICT	PC	4764
DM5SICT	MW	318.3
DM5SICT	FM	C20H14O4
DM5SICT	IC	InChI=1S/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22H
DM5SICT	CS	C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
DM5SICT	IK	KJFMBFZCATUALV-UHFFFAOYSA-N
DM5SICT	IU	3,3-bis(4-hydroxyphenyl)-2-benzofuran-1-one
DM5SICT	CA	CAS 77-09-8
DM5SICT	CB	CHEBI:34914
DM5SICT	DE	Constipation

DMTFK3O	ID	DMTFK3O
DMTFK3O	DN	Phenylpropanolamine
DMTFK3O	HS	Withdrawn from market
DMTFK3O	SN	Norephedrine; phenylpropanolamine; Rhindecon; dl-Norephedrine; (+)-Norephedrine; Propagest; Dexatrim; Mucron; d-Norephedrine; Propadrine; 1r,2s-phenylpropylamine; Super Odrinex; 14838-15-4; (1S,2R)-2-amino-1-phenylpropan-1-ol; Fenilpropanolamina; dl-1-Phenyl-2-aminopropanol-1; UNII-7875H6443P; Phenylpropanolaminum; (+-)-Norephedrin; dl-Phenylpropanolamine; dl-2-Amino-1-hydroxy-1-phenylpropane; CHEBI:36; Naldecon; Cathinum [INN-Latin]; (+-)-Phenylpropanolamine; NSC9920; DLNKOYKMWOXYQA-VXNVDRBHSA-N; 37577-28-9; Cathina [INN-Spanish];  Acutrim; Cathina; Cathine; Cathinum; Codimal; Conex; Contuss; Despec; Exponcit; Fansia; Fugoa; Gentab; Guaipax; Katine; Minusine; Mydriatin; Myminic; Nolex; Norpseudoephedrine; Partuss; Phenoxine; Phenyldrine; Phenylfenesin; Phenylpropanolamina; Pseudonorephedrine; Rhymed; Snaplets; ULR; Vanex; Cathine [INN]; Fugoa Depot; Ami-Tex; D-Norpseudoephedrine; Dl-Norephedrine; Dura-Vent; Fansia (TN); L-Norephedrine; Proin (TN); Propalin (TN); Psi-Norephedrine; TAVIST-D; USAF CS-6; D-Nor-psi-ephedrine; L-Nor-psi-ephedrin; L-Nor-psi-ephedrine; D-(+)-Norephedrine; L-(-)-Norephedrine; (+-)-Norephedrine; (+/-)-Norephedrin; (+/-)-Norephedrine; (-)-Norephedrin; (-)-Norephedrine; (1R,2S)-Norephedrine
DMTFK3O	CP	Cipla phamaceuticals
DMTFK3O	TC	Appetite Depressants
DMTFK3O	DT	Small molecular drug
DMTFK3O	PC	26934
DMTFK3O	MW	151.21
DMTFK3O	FM	C9H13NO
DMTFK3O	IC	InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m1/s1
DMTFK3O	CS	C[C@H]([C@H](C1=CC=CC=C1)O)N
DMTFK3O	IK	DLNKOYKMWOXYQA-VXNVDRBHSA-N
DMTFK3O	IU	(1S,2R)-2-amino-1-phenylpropan-1-ol
DMTFK3O	CA	CAS 37577-28-9
DMTFK3O	CB	CHEBI:36
DMTFK3O	DE	Obesity

DMGQF3R	ID	DMGQF3R
DMGQF3R	DN	Remoxipride
DMGQF3R	HS	Withdrawn from market
DMGQF3R	SN	Remoxiprida; Remoxipridum; Romoxipride; A 33547; FLA 731; A-33547; FLA-731; Remoxiprida [INN-Spanish]; Remoxipride (USAN); Remoxipridum [INN-Latin]; Remoxipride [USAN:BAN:INN]; (-)-(S)-3-Brom-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamid; (-)-(S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; (-)-n-ethyl-2-(3-bromo-2,6-dimethoxybenzamidomethyl)pyrrolidine; (S)-3-Bromo-2,6-dimethoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; (S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
DMGQF3R	TC	Antipsychotic Agents
DMGQF3R	DT	Small molecular drug
DMGQF3R	PC	54477
DMGQF3R	MW	371.27
DMGQF3R	FM	C16H23BrN2O3
DMGQF3R	IC	InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
DMGQF3R	CS	CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC
DMGQF3R	IK	GUJRSXAPGDDABA-NSHDSACASA-N
DMGQF3R	IU	3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
DMGQF3R	CA	CAS 80125-14-0
DMGQF3R	CB	CHEBI:92948
DMGQF3R	DE	Schizophrenia

DMVMIK2	ID	DMVMIK2
DMVMIK2	DN	Roxithromycin
DMVMIK2	HS	Withdrawn from market
DMVMIK2	SN	Assoral; Overall; RXM; Rossitrol; Roxithromycine; Roxithromycinum; Roxitromicina; Rulid; Rulide; Surlid; Roxithromycine [French]; Roxithromycinum [Latin]; Roxitromicina [Spanish]; RC2952; RU 28965; RU 965; Biaxsig (TN); Coroxin (TN); RU-28965; RU-965; Roxar (TN); Roximycin (TN); Roxithromycin & Tumor Necrosis Factor; Roxo (TN); Rulide (TN); Surlid (TN); Tirabicin (TN); Roxithromycin [USAN:INN:JAN]; Roxl-150 (TN); Roxithromycin (JP15/USAN/INN); Erythromycin 9-(-O-[2-methoxyethoxy]methyloxime);Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime); 9-(O-((2-Methoxyethoxy)methyl)oxime)erythromycin; 9-[O-(2-methoxyethoxymethyl)-oxime] of erythromycin
DMVMIK2	CP	Sanofi-Aventis
DMVMIK2	TC	Antibiotics
DMVMIK2	DT	Small molecular drug
DMVMIK2	PC	6915744
DMVMIK2	MW	837
DMVMIK2	FM	C41H76N2O15
DMVMIK2	IC	InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1
DMVMIK2	CS	CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
DMVMIK2	IK	RXZBMPWDPOLZGW-XMRMVWPWSA-N
DMVMIK2	IU	(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
DMVMIK2	CA	CAS 80214-83-1
DMVMIK2	CB	CHEBI:48935
DMVMIK2	DE	Bacterial infection

DMMP65N	ID	DMMP65N
DMMP65N	DN	Sertindole
DMMP65N	HS	Withdrawn from market
DMMP65N	SN	SerLect; Serdolect; Sertindol; Sertindolum; Sertindole hydrochloride; Lu 23-174; S-1991; SerLect (TN); Serdolect (TN); Serlect (TN); Sertindol [INN-Spanish]; Sertindole [USAN:INN]; Sertindolum [INN-Latin]; Lu-23-174; Sertindole (USAN/INN); 1-(2-(4-(5-Chloro-1-(4-fluorophenyl)-1H-indole-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone; 1-(2-(4-(5-Chloro-1-(p-fluorophenyl)indol-3-yl)piperidino)ethyl)-2-imidazolidinone; 1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone; 1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one; 1-[2-[4-[5-Chloro-1-(p-fluorophenyl)indol-3-yl]piperidino]ethyl]-2-imidazolidinone; 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one; 1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one
DMMP65N	TC	Antipsychotic Agents
DMMP65N	DT	Small molecular drug
DMMP65N	PC	60149
DMMP65N	MW	440.9
DMMP65N	FM	C24H26ClFN4O
DMMP65N	IC	InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)
DMMP65N	CS	C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O
DMMP65N	IK	GZKLJWGUPQBVJQ-UHFFFAOYSA-N
DMMP65N	IU	1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one
DMMP65N	CA	CAS 106516-24-9
DMMP65N	CB	CHEBI:9122
DMMP65N	DE	Schizophrenia

DMKM5HB	ID	DMKM5HB
DMKM5HB	DN	Sitaxsentan
DMKM5HB	HS	Withdrawn from market
DMKM5HB	SN	Sitaxentan; IPI 1040; TBC 11251; TBC11251; Sitaxentan (INN); TBC-11251; N-(4-Chloro-3-methyl-5-isoxazolyl)-2-((2-methyl-4,5-methylenedioxyphenyl)acetyl)thiophene-3-sulfonamide; N-(4-Chloro-3-methyl-5-isoxazolyl)-2-((3,4-(methylenedioxy)-6-methylphenyl)acetyl)-3-thiophenesulfonamide; N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
DMKM5HB	CP	Encysive
DMKM5HB	DT	Small molecular drug
DMKM5HB	PC	216235
DMKM5HB	MW	454.9
DMKM5HB	FM	C18H15ClN2O6S2
DMKM5HB	IC	InChI=1S/C18H15ClN2O6S2/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18/h3-5,7,21H,6,8H2,1-2H3
DMKM5HB	CS	CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2
DMKM5HB	IK	PHWXUGHIIBDVKD-UHFFFAOYSA-N
DMKM5HB	IU	N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
DMKM5HB	CA	CAS 184036-34-8
DMKM5HB	CB	CHEBI:135736
DMKM5HB	DE	Pulmonary arterial hypertension

DMBCK2S	ID	DMBCK2S
DMBCK2S	DN	Sulfametopyrazine
DMBCK2S	HS	Withdrawn from market
DMBCK2S	SN	Dalysep; Kelfizin; Kelfizina; Kelfizine; Longum; Polycidal; SMP; SULFALENE; Solfametopirazina; Sulfalen; Sulfaleno; Sulfalenum; Sulfamethopyrazine; Sulfamethoxypyrazine; Sulfamethoxysuccinate; Sulfametoxypyridazin; Sulfapyrazinemethoxine; Sulfapyrazinemethoxyine; Sulfapyrazinemethoxyne; Sulfapyrazinmethoxine; Sulphalene; Sulphametopyrazine; Kelfizine W; Solfametopirazina [DCIT]; AS 18908; CBMicro_013257; FI 5978; WR 4629; Farmitalia 204/122; Kelfizina (TN); Sulfalene (USAN); Sulfalene [USAN:INN]; Sulfaleno [INN-Spanish]; Sulfalenum [INN-Latin]; Sulfamethopyrazine (JAN); N1-(3-Methoxypyrazinyl)sulfanilamide; N(sup 1)-(3-Methoxypyrazinyl)sulfanilamide; N(sup1)-(3-Methoxypyrazinyl)sulfanilamide; N(sup 1)-(3-Methoxy-2-pyrazinyl)sulfanilamide; N(sup1)-(3-Methoxy-2-pyrazinyl)sulfanilamide; Sulfanilamide, N1-(3-methoxypyrazinyl)-(8CI); 2-(p-Aminobenzenesulfanamide)-3-methoxypyrazine; 2-(p-Aminobenzenesulfonamido)-3-methoxypyrazine; 2-Methoxy-3-sulfanilamidopyrazine; 2-Sulfanilamide 3-methoxy-pyrazine; 2-Sulfanilamido-3-methoxypyrazine; 3-Methoxy-2-sulfanilamidopyrazine; 3-Methoxy-2-sulfapyrazine; 3-Methoxypyrazine sulfanilamide; 4-Amino-N-(3-methoxy-pyrazin-2-yl)-benzenesulfonamide; 4-Amino-N-(3-methoxypyrazinyl)-benzenesulfonamide; 4-Amino-N-(3-methoxypyrazinyl)benzenesulfonamide; 4-amino-N-(3-methoxypyrazin-2-yl)benzenesulfonamide
DMBCK2S	TC	Antiinfective Agents
DMBCK2S	DT	Small molecular drug
DMBCK2S	PC	9047
DMBCK2S	MW	280.31
DMBCK2S	FM	C11H12N4O3S
DMBCK2S	IC	InChI=1S/C11H12N4O3S/c1-18-11-10(13-6-7-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,15)
DMBCK2S	CS	COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(C=C2)N
DMBCK2S	IK	KXRZBTAEDBELFD-UHFFFAOYSA-N
DMBCK2S	IU	4-amino-N-(3-methoxypyrazin-2-yl)benzenesulfonamide
DMBCK2S	CA	CAS 152-47-6
DMBCK2S	CB	CHEBI:32162
DMBCK2S	DE	Urinary tract infection

DMFR79T	ID	DMFR79T
DMFR79T	DN	TBC 11251 (TBC)
DMFR79T	HS	Withdrawn from market
DMFR79T	DT	Small molecular drug
DMFR79T	PC	9867934
DMFR79T	MW	441.5
DMFR79T	FM	C24H31N3O5
DMFR79T	IC	InChI=1S/C20H27N3O.C4H4O4/c1-3-24-19-10-7-13-21-20(19)22(2)18-11-14-23(15-12-18)16-17-8-5-4-6-9-17;5-3(6)1-2-4(7)8/h4-10,13,18H,3,11-12,14-16H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMFR79T	CS	CCOC1=C(N=CC=C1)N(C)C2CCN(CC2)CC3=CC=CC=C3.C(=C\\C(=O)O)\\C(=O)O
DMFR79T	IK	ADAMULBLHXHVFN-BTJKTKAUSA-N
DMFR79T	IU	N-(1-benzylpiperidin-4-yl)-3-ethoxy-N-methylpyridin-2-amine;(Z)-but-2-enedioic acid
DMFR79T	DE	Pulmonary arterial hypertension

DM3TON2	ID	DM3TON2
DM3TON2	DN	Temafloxacin
DM3TON2	HS	Withdrawn from market
DM3TON2	SN	Omniflox; Temabiotic; Temac; Temadie; Temaflox; Temafloxacin hydrochloride; A-62254; A-63004; T-30036; TA-167
DM3TON2	CP	Abbott Laboratories
DM3TON2	DT	Small molecular drug
DM3TON2	PC	60021
DM3TON2	MW	417.4
DM3TON2	FM	C21H18F3N3O3
DM3TON2	IC	InChI=1S/C21H18F3N3O3/c1-11-9-26(5-4-25-11)19-8-18-13(7-16(19)24)20(28)14(21(29)30)10-27(18)17-3-2-12(22)6-15(17)23/h2-3,6-8,10-11,25H,4-5,9H2,1H3,(H,29,30)
DM3TON2	CS	CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F
DM3TON2	IK	QKDHBVNJCZBTMR-UHFFFAOYSA-N
DM3TON2	IU	1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DM3TON2	CA	CAS 108319-06-8
DM3TON2	CB	CHEBI:77796
DM3TON2	DE	Bacterial infection

DM4KLPT	ID	DM4KLPT
DM4KLPT	DN	Terfenadine
DM4KLPT	HS	Withdrawn from market
DM4KLPT	SN	Aldaban; Allerplus; Cyater; Hisfedin; Rapidal; Seldane; Teldane; Teldanex; Terdin; Terfedura; Terfemundin; Terfen; Terfenadina; Terfenadinum; Terfenidine; Terfex; Ternadin; Triludan; Aliud Brand of Terfenadine; Balkis Saft Spezial; Bial Brand of Terfenadine; Cantabria Brand of Terfenadine; Ct Arzneimittel Brand of Terfenadine; Dolorgiet Brand of Terfenadine; Heumann Brand of Terfenadine; Hoechst Brand of Terfenadine; Merck dura Brand of Terfenadine; Mundipharma Brand of Terfenadine; Ratiopharm Brand of Terfenadine; Sigma Tau Brand of Terfenadine; Stadapharm Brand of Terfenadine; Terfenadin AL; Terfenadin Heumann; Terfenadin Stada; Terfenadin von ct; Wolff Brand of Terfenadine; MDL 9918; RMI 9918; RMI9918; T 9652; Ct-Arzneimittel Brand of Terfenadine; MDL-9918; RMI-9918; Seldane (TN); Sigma-Tau Brand of Terfenadine; Teldane (TN); Terfenadin-ratiopharm; Terfenadina [INN-Spanish]; Terfenadinum [INN-Latin]; Triludan (TN); Terfenadine (JAN/USAN/INN); Terfenadine [USAN:BAN:INN:JAN]; Alpha-(4-[1,1-Dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol; Alpha-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol; 1-(4-tert-Butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol; 1-(p-tert-Butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol; 1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol
DM4KLPT	CP	Marion Merrell. Dow, Inc.
DM4KLPT	TC	Antihistamines
DM4KLPT	DT	Small molecular drug
DM4KLPT	PC	5405
DM4KLPT	MW	471.7
DM4KLPT	FM	C32H41NO2
DM4KLPT	IC	InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3
DM4KLPT	CS	CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
DM4KLPT	IK	GUGOEEXESWIERI-UHFFFAOYSA-N
DM4KLPT	IU	1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol
DM4KLPT	CA	CAS 50679-08-8
DM4KLPT	CB	CHEBI:9453
DM4KLPT	DE	Allergy

DMLFSTR	ID	DMLFSTR
DMLFSTR	DN	Ticrynafen
DMLFSTR	HS	Withdrawn from market
DMLFSTR	SN	Ticrynafen; Tienilic acid; 40180-04-9; Thienylic acid; Selacryn; Diflurex; Ticrex; Acido tienilico; Acide tienilique; Acidum tienilicum; Tienilico acido; Tienilico acido [Spanish]; Ticrynafen [USAN]; Acido tienilico [INN-Spanish]; Acide tienilique [INN-French]; Acidum tienilicum [INN-Latin]; ANP 3624; C13H8Cl2O4S; SKF 62698; UNII-HC95205SY4; 2-(2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-thenoyl)phenoxy)acetic acid; CCRIS 5489; 4-(2-Thienylketo)-2,3-dichlorophenoxyacetic acid
DMLFSTR	DT	Small molecular drug
DMLFSTR	PC	38409
DMLFSTR	MW	331.2
DMLFSTR	FM	C13H8Cl2O4S
DMLFSTR	IC	InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)
DMLFSTR	CS	C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl
DMLFSTR	IK	AGHANLSBXUWXTB-UHFFFAOYSA-N
DMLFSTR	IU	2-[2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy]acetic acid
DMLFSTR	CA	CAS 40180-04-9
DMLFSTR	CB	CHEBI:9590
DMLFSTR	DE	Congestive heart failure

DMABRJL	ID	DMABRJL
DMABRJL	DN	Ximelagatran
DMABRJL	HS	Withdrawn from market
DMABRJL	SN	Exanta; Exarta; H 376/95; Ximelagatran [USAN:INN]; 192939-46-1; H 376-95; H 37695; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-, ethyl ester; NCGC00183598-01; Ethyl (((1R)-1-cyclohexyl-2-((2S)-2-((4-(hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl-2-oxoethyl)amino)acetate; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ethyl ester; H 376 95; Exanta (TN); Exarta (TN); Xi-melagatran; H-376/95; Ximelagatran (JAN/USAN/INN); Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-((hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ester ester; H376/95
DMABRJL	CP	AstraZeneca
DMABRJL	TC	Anticoagulants
DMABRJL	DT	Small molecular drug
DMABRJL	PC	9574101
DMABRJL	MW	473.6
DMABRJL	FM	C24H35N5O5
DMABRJL	IC	InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1
DMABRJL	CS	CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)/C(=N/O)/N
DMABRJL	IK	ZXIBCJHYVWYIKI-PZJWPPBQSA-N
DMABRJL	IU	ethyl 2-[[(1R)-1-cyclohexyl-2-[(2S)-2-[[4-[(Z)-N'-hydroxycarbamimidoyl]phenyl]methylcarbamoyl]azetidin-1-yl]-2-oxoethyl]amino]acetate
DMABRJL	CA	CAS 192939-46-1
DMABRJL	CB	CHEBI:136702
DMABRJL	DE	Coagulation defect

DMNI3U2	ID	DMNI3U2
DMNI3U2	DN	ZIMELIDINE
DMNI3U2	HS	Withdrawn from market
DMNI3U2	SN	Prestwick0_000092; Prestwick1_000092; 56775-88-3; AC1L26VA; NCIStruc1_001846; NCIStruc2_001359; SPBio_001983; 2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-; CTK1F3832; OYPPVKRFBIWMSX-UHFFFAOYSA-N; DB04832; NCI60_002580; FT-0675907; N,N-dimethyl-3-(4-bromophenyl)-3-(pyrid-3-yl)allylamine; N,N-dimethyl-3-(4-bromophenyl)-3-(3-pyridyl)-allylamine; (Z)-3-[1-(p-Bromophenyl)-3-(dimethylamino)propenyl]pyridine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine
DMNI3U2	DT	Small molecular drug
DMNI3U2	PC	5365247
DMNI3U2	MW	317.22
DMNI3U2	FM	C16H17BrN2
DMNI3U2	IC	InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9-
DMNI3U2	CS	CN(C)C/C=C(/C1=CC=C(C=C1)Br)\\C2=CN=CC=C2
DMNI3U2	IK	OYPPVKRFBIWMSX-SXGWCWSVSA-N
DMNI3U2	IU	(Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine
DMNI3U2	CA	CAS 56775-88-3
DMNI3U2	CB	CHEBI:92824
DMNI3U2	DE	Major depressive disorder; Depression

DM7APNJ	ID	DM7APNJ
DM7APNJ	DN	Zomepirac
DM7APNJ	HS	Withdrawn from market
DM7APNJ	SN	ZOMEPIRAC SODIUM; Zomepirac sodium [USAN:USP]; UNII-Y0185WZ209; McN-2783-21-98; Y0185WZ209; 64092-49-5; Zomepirac sodium dihydrate; 1H-Pyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethyl-, sodium salt, dihydrate; Zomepirac sodium (USAN); CHEMBL3989403; DTXSID60214282; ZJXLSCXDGPDZOL-UHFFFAOYSA-M; D06382; Sodium 5-(p-chlorobenzoyl)-1,4-dimethylpyrrole-2-acetate dihydrate; Sodium 5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetate Dihydrate
DM7APNJ	DT	Small molecular drug
DM7APNJ	PC	5733
DM7APNJ	MW	291.73
DM7APNJ	FM	C15H14ClNO3
DM7APNJ	IC	InChI=1S/C15H14ClNO3/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10/h3-7H,8H2,1-2H3,(H,18,19)
DM7APNJ	CS	CC1=C(N(C(=C1)CC(=O)O)C)C(=O)C2=CC=C(C=C2)Cl
DM7APNJ	IK	ZXVNMYWKKDOREA-UHFFFAOYSA-N
DM7APNJ	IU	2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetic acid
DM7APNJ	CA	CAS 33369-31-2
DM7APNJ	CB	CHEBI:35859
DM7APNJ	DE	Pain

DMEQ3IW	ID	DMEQ3IW
DMEQ3IW	DN	(S)-amisulpride
DMEQ3IW	HS	Discontinued in Phase 4
DMEQ3IW	SN	UNII-ES3TWM82E8; ES3TWM82E8; 71675-92-8; Amisulpride, (S)-; AC1MHORM; SCHEMBL675545; NTJOBXMMWNYJFB-LBPRGKRZSA-N; ZINC1846088; Benzamide, 4-amino-N-(((2S)-1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-; LS-25533; UNII-8110R61I4U component NTJOBXMMWNYJFB-LBPRGKRZSA-N; 4-amino-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMEQ3IW	CP	Sanofi-Aventis
DMEQ3IW	DT	Small molecular drug
DMEQ3IW	PC	3055076
DMEQ3IW	MW	369.5
DMEQ3IW	FM	C17H27N3O4S
DMEQ3IW	IC	InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)/t12-/m0/s1
DMEQ3IW	CS	CCN1CCC[C@H]1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
DMEQ3IW	IK	NTJOBXMMWNYJFB-LBPRGKRZSA-N
DMEQ3IW	IU	4-amino-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMEQ3IW	CA	CAS 71675-92-8
DMEQ3IW	DE	Schizophrenia

DMPL2KM	ID	DMPL2KM
DMPL2KM	DN	GW-501516
DMPL2KM	HS	Discontinued in Phase 4
DMPL2KM	SN	317318-70-0; GW501516; GW 501516; Endurobol; GW-501516; GSK-516; UNII-7I2HA1NU22; GW1516; GW 1516; 2-(2-Methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)thio)phenoxy)acetic acid; GW-516; GW-1516; CHEMBL38943; 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy)acetic acid; 2-(4-((2-(4-(Trifluoromethyl)phenyl)-4-methylthiazol-5-yl)methylthio)-2-methylphenoxy)acetic acid; 7I2HA1NU22
DMPL2KM	DT	Small molecular drug
DMPL2KM	PC	9803963
DMPL2KM	MW	453.5
DMPL2KM	FM	C21H18F3NO3S2
DMPL2KM	IC	InChI=1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)
DMPL2KM	CS	CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O
DMPL2KM	IK	YDBLKRPLXZNVNB-UHFFFAOYSA-N
DMPL2KM	IU	2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid
DMPL2KM	CA	CAS 317318-70-0
DMPL2KM	CB	CHEBI:73726
DMPL2KM	DE	Type-1 diabetes

DMTF9YV	ID	DMTF9YV
DMTF9YV	DN	AE-0047
DMTF9YV	HS	Discontinued in Preregistration
DMTF9YV	SN	Calbren; Vatanidipine; Watanidipine hydrochloride; GJ-0956; (R)-(-)-AE 0047; (S)-(+)-AE 0047
DMTF9YV	CP	Mitsubishi Pharma Corp
DMTF9YV	DT	Small molecular drug
DMTF9YV	PC	101588922
DMTF9YV	MW	686.8
DMTF9YV	FM	C41H42N4O6
DMTF9YV	IC	InChI=1S/C41H42N4O6/c1-28-36(40(46)50-3)38(33-15-10-16-35(27-33)45(48)49)37(29(2)42-28)41(47)51-26-21-30-17-19-34(20-18-30)43-22-24-44(25-23-43)39(31-11-6-4-7-12-31)32-13-8-5-9-14-32/h4-20,27,38-39,46H,21-26H2,1-3H3
DMTF9YV	CS	CC1=C(C(C(=C([O-])OC)C(=N1)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCC3=CC=C(C=C3)[NH+]4CCN(CC4)C(C5=CC=CC=C5)C6=CC=CC=C6
DMTF9YV	IK	VPQACPHDDSSGPL-UHFFFAOYSA-N
DMTF9YV	IU	[5-[2-[4-(4-benzhydrylpiperazin-1-ium-1-yl)phenyl]ethoxycarbonyl]-2,6-dimethyl-4-(3-nitrophenyl)-4H-pyridin-3-ylidene]-methoxymethanolate
DMTF9YV	DE	Hypertension

DM7BN1A	ID	DM7BN1A
DM7BN1A	DN	Bermoprofen
DM7BN1A	HS	Discontinued in Preregistration
DM7BN1A	SN	Dibenon; Bermoprofen potasium salt; AD-1590; AJ-1590
DM7BN1A	CP	Dainippon Pharmaceutical Co Ltd
DM7BN1A	DT	Small molecular drug
DM7BN1A	PC	54204
DM7BN1A	MW	296.3
DM7BN1A	FM	C18H16O4
DM7BN1A	IC	InChI=1S/C18H16O4/c1-10-3-5-16-13(7-10)9-15(19)14-8-12(11(2)18(20)21)4-6-17(14)22-16/h3-8,11H,9H2,1-2H3,(H,20,21)
DM7BN1A	CS	CC1=CC2=C(C=C1)OC3=C(C=C(C=C3)C(C)C(=O)O)C(=O)C2
DM7BN1A	IK	REHLODZXMGOGQP-UHFFFAOYSA-N
DM7BN1A	IU	2-(8-methyl-5-oxo-6H-benzo[b][1]benzoxepin-3-yl)propanoic acid
DM7BN1A	CA	CAS 78499-27-1
DM7BN1A	CB	CHEBI:135248
DM7BN1A	DE	Inflammation

DM6E5VA	ID	DM6E5VA
DM6E5VA	DN	Clinprost
DM6E5VA	HS	Discontinued in Preregistration
DM6E5VA	SN	Arteon; Isocarbacyclin methyl ester; TEI-9090; TTC-909; Clinprost (liposomal), Taisho; Clinprost (liposomal), Teijin
DM6E5VA	CP	Teijin Ltd
DM6E5VA	DT	Small molecular drug
DM6E5VA	PC	6436040
DM6E5VA	MW	364.5
DM6E5VA	FM	C22H36O4
DM6E5VA	IC	InChI=1S/C22H36O4/c1-3-4-5-9-18(23)11-12-19-20-14-16(13-17(20)15-21(19)24)8-6-7-10-22(25)26-2/h11-13,17-21,23-24H,3-10,14-15H2,1-2H3/b12-11+/t17-,18-,19+,20-,21+/m0/s1
DM6E5VA	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=C2)CCCCC(=O)OC)O)O
DM6E5VA	IK	QIGRQPVOWVHYBT-KABTVRTISA-N
DM6E5VA	IU	methyl 5-[(3aS,5R,6R,6aS)-5-hydroxy-6-[(E,3S)-3-hydroxyoct-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoate
DM6E5VA	CA	CAS 88931-51-5
DM6E5VA	DE	Asthma

DM3OUWC	ID	DM3OUWC
DM3OUWC	DN	Domitroban
DM3OUWC	HS	Discontinued in Preregistration
DM3OUWC	SN	S-145; UNII-742F5K270Q; 5,7-(3-Phenylsulfonylamino(221)bicyclohept-2-yl)heptenoic acid; Calcium 5,7-(3-phenylsulfonylaminobicyclo(221)hept-2-yl)-5-heptenoate hydrate; 742F5K270Q; 112966-96-8; S-1452; (+)-S-145; (+)-(Z)-7-((1R,2S,3S,4S)-3-Benzenesulfonamido-2-norbornyl)-5-heptenoic acid; 5-Heptenoic acid, 7-(3-((phenylsulfonyl)amino)bicyclo(221)hept-2-yl)-, (1R-(1alpha,2alpha(Z),3beta,4alpha))-; Domitroban [INN]; 5-Heptenoic acid, 7-((1R,2S,3S,4S)-3-((phenylsulfonyl)amino)bicyclo(221)hept-2-yl)-,;  Amboxan; Anboxan; [3H]S-145
DM3OUWC	CP	Shionogi & Co Ltd
DM3OUWC	DT	Small molecular drug
DM3OUWC	PC	5312138
DM3OUWC	MW	377.5
DM3OUWC	FM	C20H27NO4S
DM3OUWC	IC	InChI=1S/C20H27NO4S/c22-19(23)11-7-2-1-6-10-18-15-12-13-16(14-15)20(18)21-26(24,25)17-8-4-3-5-9-17/h1,3-6,8-9,15-16,18,20-21H,2,7,10-14H2,(H,22,23)/b6-1-/t15-,16+,18+,20+/m1/s1
DM3OUWC	CS	C1C[C@H]2C[C@@H]1[C@@H]([C@H]2NS(=O)(=O)C3=CC=CC=C3)C/C=C\\CCCC(=O)O
DM3OUWC	IK	PWTCIBWRMQFJBC-ZEMKZVSASA-N
DM3OUWC	IU	(Z)-7-[(1R,2S,3S,4S)-3-(benzenesulfonamido)-2-bicyclo[2.2.1]heptanyl]hept-5-enoic acid
DM3OUWC	CA	CAS 112966-96-8
DM3OUWC	CB	CHEBI:135586
DM3OUWC	DE	Thrombosis

DMFOEVQ	ID	DMFOEVQ
DMFOEVQ	DN	Ecabapide
DMFOEVQ	HS	Discontinued in Preregistration
DMFOEVQ	SN	Ecabamide; Muralis; DQ-2511
DMFOEVQ	CP	Daiichi Seiyaku Co Ltd
DMFOEVQ	DT	Small molecular drug
DMFOEVQ	PC	65885
DMFOEVQ	MW	371.4
DMFOEVQ	FM	C20H25N3O4
DMFOEVQ	IC	InChI=1S/C20H25N3O4/c1-21-20(25)15-5-4-6-16(12-15)23-13-19(24)22-10-9-14-7-8-17(26-2)18(11-14)27-3/h4-8,11-12,23H,9-10,13H2,1-3H3,(H,21,25)(H,22,24)
DMFOEVQ	CS	CNC(=O)C1=CC(=CC=C1)NCC(=O)NCCC2=CC(=C(C=C2)OC)OC
DMFOEVQ	IK	JTAGHJPZEDNHHA-UHFFFAOYSA-N
DMFOEVQ	IU	3-[[2-[2-(3,4-dimethoxyphenyl)ethylamino]-2-oxoethyl]amino]-N-methylbenzamide
DMFOEVQ	CA	CAS 104775-36-2
DMFOEVQ	DE	Peptic ulcer

DMKQI7S	ID	DMKQI7S
DMKQI7S	DN	EMITEFUR
DMKQI7S	HS	Discontinued in Preregistration
DMKQI7S	SN	BOF-A2; Emitefur; Last-F (Otsuka, JP, US, US, US); 3-[3-(6-Benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl]-1-(ethoxymethyl)-5-fluorouracil
DMKQI7S	DT	Small molecular drug
DMKQI7S	PC	65910
DMKQI7S	MW	558.5
DMKQI7S	FM	C28H19FN4O8
DMKQI7S	IC	InChI=1S/C28H19FN4O8/c1-2-39-16-32-15-21(29)25(35)33(28(32)38)24(34)18-9-6-10-19(13-18)27(37)41-23-20(14-30)11-12-22(31-23)40-26(36)17-7-4-3-5-8-17/h3-13,15H,2,16H2,1H3
DMKQI7S	CS	CCOCN1C=C(C(=O)N(C1=O)C(=O)C2=CC(=CC=C2)C(=O)OC3=C(C=CC(=N3)OC(=O)C4=CC=CC=C4)C#N)F
DMKQI7S	IK	WTSKMKRYHATLLL-UHFFFAOYSA-N
DMKQI7S	IU	(6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate
DMKQI7S	CA	CAS 110690-43-2
DMKQI7S	DE	Solid tumour/cancer

DML1Y49	ID	DML1Y49
DML1Y49	DN	Epanolol
DML1Y49	HS	Discontinued in Preregistration
DML1Y49	SN	Visacor; TS-704
DML1Y49	CP	Imperial Chemical Industries Plc
DML1Y49	DT	Small molecular drug
DML1Y49	PC	72014
DML1Y49	MW	369.4
DML1Y49	FM	C20H23N3O4
DML1Y49	IC	InChI=1S/C20H23N3O4/c21-12-16-3-1-2-4-19(16)27-14-18(25)13-22-9-10-23-20(26)11-15-5-7-17(24)8-6-15/h1-8,18,22,24-25H,9-11,13-14H2,(H,23,26)
DML1Y49	CS	C1=CC=C(C(=C1)C#N)OCC(CNCCNC(=O)CC2=CC=C(C=C2)O)O
DML1Y49	IK	YARKMNAWFIMDKV-UHFFFAOYSA-N
DML1Y49	IU	N-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-2-(4-hydroxyphenyl)acetamide
DML1Y49	CA	CAS 86880-51-5
DML1Y49	CB	CHEBI:4800
DML1Y49	DE	Angina pectoris

DM05MCO	ID	DM05MCO
DM05MCO	DN	Inaperisone
DM05MCO	HS	Discontinued in Preregistration
DM05MCO	SN	Inapen; Inapene; Rilan; Riran; Inaperison HCl; Inaperisone hydrochloride; HN-770; HSR-770; HY-770; YM-170; YM-18170; 118230-97-]]]
DM05MCO	CP	Hokuriku Seiyaku KK
DM05MCO	DT	Small molecular drug
DM05MCO	PC	65860
DM05MCO	MW	245.36
DM05MCO	FM	C16H23NO
DM05MCO	IC	InChI=1S/C16H23NO/c1-3-14-6-8-15(9-7-14)16(18)13(2)12-17-10-4-5-11-17/h6-9,13H,3-5,10-12H2,1-2H3
DM05MCO	CS	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCC2
DM05MCO	IK	VNFAARJCGSAROU-UHFFFAOYSA-N
DM05MCO	IU	1-(4-ethylphenyl)-2-methyl-3-pyrrolidin-1-ylpropan-1-one
DM05MCO	CA	CAS 99323-21-4
DM05MCO	CB	CHEBI:134999
DM05MCO	DE	Pollakiuria

DM1B8NU	ID	DM1B8NU
DM1B8NU	DN	Isbogrel
DM1B8NU	HS	Discontinued in Preregistration
DM1B8NU	SN	Antexan; A-66900; CV-4151
DM1B8NU	CP	Takeda Pharmaceutical Co Ltd
DM1B8NU	DT	Small molecular drug
DM1B8NU	PC	5284442
DM1B8NU	MW	281.3
DM1B8NU	FM	C18H19NO2
DM1B8NU	IC	InChI=1S/C18H19NO2/c20-18(21)12-6-2-5-11-17(15-8-3-1-4-9-15)16-10-7-13-19-14-16/h1,3-4,7-11,13-14H,2,5-6,12H2,(H,20,21)/b17-11+
DM1B8NU	CS	C1=CC=C(C=C1)/C(=C\\CCCCC(=O)O)/C2=CN=CC=C2
DM1B8NU	IK	UWPBQLKEHGGKKD-GZTJUZNOSA-N
DM1B8NU	IU	(E)-7-phenyl-7-pyridin-3-ylhept-6-enoic acid
DM1B8NU	CA	CAS 89667-40-3
DM1B8NU	DE	Angina pectoris

DMXZ4BK	ID	DMXZ4BK
DMXZ4BK	DN	LAS-41001
DMXZ4BK	HS	Discontinued in Preregistration
DMXZ4BK	SN	Anti-inflammatory doxycycline derivative (rosacea), Almirall
DMXZ4BK	CP	Almirall Prodesfarma SA
DMXZ4BK	DE	Rosacea

DMBKNJT	ID	DMBKNJT
DMBKNJT	DN	LEMINOPRAZOLE
DMBKNJT	HS	Discontinued in Preregistration
DMBKNJT	SN	Leminon; Leminoprazole; NC-1300-O-3; Rac-2-[2-(N-Isobutyl-N-methylamino)benzylsulfinyl]benzimidazole
DMBKNJT	DT	Small molecular drug
DMBKNJT	PC	65881
DMBKNJT	MW	341.5
DMBKNJT	FM	C19H23N3OS
DMBKNJT	IC	InChI=1S/C19H23N3OS/c1-14(2)12-22(3)18-11-7-4-8-15(18)13-24(23)19-20-16-9-5-6-10-17(16)21-19/h4-11,14H,12-13H2,1-3H3,(H,20,21)
DMBKNJT	CS	CC(C)CN(C)C1=CC=CC=C1CS(=O)C2=NC3=CC=CC=C3N2
DMBKNJT	IK	PSIREIZGKQBEEO-UHFFFAOYSA-N
DMBKNJT	IU	2-(1H-benzimidazol-2-ylsulfinylmethyl)-N-methyl-N-(2-methylpropyl)aniline
DMBKNJT	CA	CAS 104340-86-5
DMBKNJT	DE	Ulcerative colitis

DMNS4TK	ID	DMNS4TK
DMNS4TK	DN	Levcromakalim
DMNS4TK	HS	Discontinued in Preregistration
DMNS4TK	SN	Levcromakalim; Lemakalim; Cromakalim; (-)-Cromakalim; 94535-50-9; Levcromakelim; BRL 38227; BRL-38227; UNII-RW7PN4BLDJ; RW7PN4BLDJ; CHEMBL100; BRN 3622889; MLS000069770; CHEBI:6436; Cromakalime [French]; Cromakalimum [Latin]; Cromakalim, (3S-trans)-Isomer; SMR000058880; (3S,4R)-3-Hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-chromancarbonitrile; DSSTox_RID_81051; DSSTox_CID_25677; DSSTox_GSID_45677; 94470-67-4; Cromakalimum; Cromakalime; BRL-34915; BRL 34915; 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-o
DMNS4TK	DT	Small molecular drug
DMNS4TK	PC	93504
DMNS4TK	MW	286.33
DMNS4TK	FM	C16H18N2O3
DMNS4TK	IC	InChI=1S/C16H18N2O3/c1-16(2)15(20)14(18-7-3-4-13(18)19)11-8-10(9-17)5-6-12(11)21-16/h5-6,8,14-15,20H,3-4,7H2,1-2H3/t14-,15+/m1/s1
DMNS4TK	CS	CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N3CCCC3=O)O)C
DMNS4TK	IK	TVZCRIROJQEVOT-CABCVRRESA-N
DMNS4TK	IU	(3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydrochromene-6-carbonitrile
DMNS4TK	CA	CAS 94535-50-9
DMNS4TK	CB	CHEBI:6436
DMNS4TK	DE	Chronic obstructive pulmonary disease

DMFGMD9	ID	DMFGMD9
DMFGMD9	DN	LUBELUZOLE
DMFGMD9	HS	Discontinued in Preregistration
DMFGMD9	SN	Lubeluzole; Prosynap; 144665-07-6; UNII-V2SIB71583; CHEMBL281724; V2SIB71583; R 87926; R-87926; (2S)-1-[4-[1,3-benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol; (+)-(S)-4-(2-Benzothiazolylmethylamino)-alpha-((3,4-difluorophenoxy)methyl)-1-piperidineethanol; 1-Piperidineethanol, 4-(2-benzothiazolylmethylamino)-alpha-((3,4-difluorophenoxy)methyl)-, (S)-; Lubeluzol; Lubeluzole [USAN:INN:BAN]; C22H25F2N3O2S; Prosynap (TN); R-91154; AC1Q4ONU; Lubeluzole (USAN/INN); SCHEMBL159725; Lubeluzole [USAN:B
DMFGMD9	DT	Small molecular drug
DMFGMD9	PC	65998
DMFGMD9	MW	433.5
DMFGMD9	FM	C22H25F2N3O2S
DMFGMD9	IC	InChI=1S/C22H25F2N3O2S/c1-26(22-25-20-4-2-3-5-21(20)30-22)15-8-10-27(11-9-15)13-16(28)14-29-17-6-7-18(23)19(24)12-17/h2-7,12,15-16,28H,8-11,13-14H2,1H3/t16-/m0/s1
DMFGMD9	CS	CN(C1CCN(CC1)C[C@@H](COC2=CC(=C(C=C2)F)F)O)C3=NC4=CC=CC=C4S3
DMFGMD9	IK	OZFSWVOEXHGDES-INIZCTEOSA-N
DMFGMD9	IU	(2S)-1-[4-[1,3-benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol
DMFGMD9	CA	CAS 144665-07-6
DMFGMD9	CB	CHEBI:135703
DMFGMD9	DE	Neurological disorder

DMEQDHP	ID	DMEQDHP
DMEQDHP	DN	Meluadrine
DMEQDHP	HS	Discontinued in Preregistration
DMEQDHP	SN	Meluadrine tartrate; HSR-81
DMEQDHP	CP	Hokuriku Seiyaku KK
DMEQDHP	DT	Small molecular drug
DMEQDHP	PC	3045414
DMEQDHP	MW	243.73
DMEQDHP	FM	C12H18ClNO2
DMEQDHP	IC	InChI=1S/C12H18ClNO2/c1-12(2,3)14-7-11(16)9-5-4-8(15)6-10(9)13/h4-6,11,14-16H,7H2,1-3H3/t11-/m0/s1
DMEQDHP	CS	CC(C)(C)NC[C@@H](C1=C(C=C(C=C1)O)Cl)O
DMEQDHP	IK	LIXBJWRFCNRAPA-NSHDSACASA-N
DMEQDHP	IU	4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol
DMEQDHP	CA	CAS 134865-33-1
DMEQDHP	DE	Premature ejaculation

DM9ADLQ	ID	DM9ADLQ
DM9ADLQ	DN	Monatepil maleate
DM9ADLQ	HS	Discontinued in Preregistration
DM9ADLQ	SN	AD-2615; AJ-2615
DM9ADLQ	CP	Dainippon Pharmaceutical Co Ltd
DM9ADLQ	DT	Small molecular drug
DM9ADLQ	PC	5282401
DM9ADLQ	MW	591.7
DM9ADLQ	FM	C32H34FN3O5S
DM9ADLQ	IC	InChI=1S/C28H30FN3OS.C4H4O4/c29-22-11-13-23(14-12-22)32-18-16-31(17-19-32)15-5-10-27(33)30-28-24-7-2-1-6-21(24)20-34-26-9-4-3-8-25(26)28;5-3(6)1-2-4(7)8/h1-4,6-9,11-14,28H,5,10,15-20H2,(H,30,33);1-2H,(H,5,6)(H,7,8)/b;2-1-
DM9ADLQ	CS	C1CN(CCN1CCCC(=O)NC2C3=CC=CC=C3CSC4=CC=CC=C24)C5=CC=C(C=C5)F.C(=C\\C(=O)O)\\C(=O)O
DM9ADLQ	IK	ZDZXCYHMVFLGMT-BTJKTKAUSA-N
DM9ADLQ	IU	(Z)-but-2-enedioic acid;N-(6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-4-[4-(4-fluorophenyl)piperazin-1-yl]butanamide
DM9ADLQ	CA	CAS 103379-03-9
DM9ADLQ	CB	CHEBI:31862
DM9ADLQ	DE	Angina pectoris

DM31OGZ	ID	DM31OGZ
DM31OGZ	DN	MONTIRELIN TETRAHYDRATE
DM31OGZ	HS	Discontinued in Preregistration
DM31OGZ	SN	NS-3; Montirelin tetrahydrate; Remnos (Nippon Shinyaku, JP); (2R,5R)-N-(2-Methyl-3-oxothiomorpholin-5-ylcarbonyl)-L-histidyl-L-prolinamide tetrahydrate
DM31OGZ	DT	Small molecular drug
DM31OGZ	PC	53297483
DM31OGZ	MW	480.5
DM31OGZ	FM	C17H32N6O8S
DM31OGZ	IC	InChI=1S/C17H24N6O4S.4H2O/c1-9-15(25)22-12(7-28-9)16(26)21-11(5-10-6-19-8-20-10)17(27)23-4-2-3-13(23)14(18)24;;;;/h6,8-9,11-13H,2-5,7H2,1H3,(H2,18,24)(H,19,20)(H,21,26)(H,22,25);4*1H2/t9-,11+,12+,13+;;;;/m1..../s1
DM31OGZ	CS	C[C@@H]1C(=O)N[C@@H](CS1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N.O.O.O.O
DM31OGZ	IK	LYTHVCBIYIODIA-UVZXXTSMSA-N
DM31OGZ	IU	(3R,6R)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-6-methyl-5-oxothiomorpholine-3-carboxamide;tetrahydrate
DM31OGZ	DE	Pain

DMXF0NS	ID	DMXF0NS
DMXF0NS	DN	Norastemizole
DMXF0NS	HS	Discontinued in Preregistration
DMXF0NS	SN	Tecastemizole; Soltara; UNII-W5DCO14M05; 75970-99-9; CHEMBL61301; W5DCO14M05; T 1348; 1-((4-Flurophenyl)methyl)-N-4-piperidinyl-1H-benzimidazol-2-amine; 1-(-Fluorobenzyl)-N-(piperidin-4-yl)-1H-benzimidazol-2-amine; 1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-piperidinyl-; Tecastemizole[USAN]; 75970-64-8; Tecastemizole [USAN:INN]; 1-(4-fluorobenzyl)-n-(piperidin-4-yl)-1h-benzimidazol-2-amine; AC1Q4NSA; AC1L3WZJ; Tecastemizole (USAN/INN); SCHEMBL18200; ZINC2303; DTXSID30226877
DMXF0NS	DT	Small molecular drug
DMXF0NS	PC	123618
DMXF0NS	MW	324.4
DMXF0NS	FM	C19H21FN4
DMXF0NS	IC	InChI=1S/C19H21FN4/c20-15-7-5-14(6-8-15)13-24-18-4-2-1-3-17(18)23-19(24)22-16-9-11-21-12-10-16/h1-8,16,21H,9-13H2,(H,22,23)
DMXF0NS	CS	C1CNCCC1NC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
DMXF0NS	IK	SFOVDSLXFUGAIV-UHFFFAOYSA-N
DMXF0NS	IU	1-[(4-fluorophenyl)methyl]-N-piperidin-4-ylbenzimidazol-2-amine
DMXF0NS	CA	CAS 75970-99-9

DMUH0KO	ID	DMUH0KO
DMUH0KO	DN	Palonidipine hydrochloride
DMUH0KO	HS	Discontinued in Preregistration
DMUH0KO	SN	Palonidipine; TC-81
DMUH0KO	CP	Teijin Ltd
DMUH0KO	DT	Small molecular drug
DMUH0KO	PC	119153
DMUH0KO	MW	576.1
DMUH0KO	FM	C29H35ClFN3O6
DMUH0KO	IC	InChI=1S/C29H34FN3O6.ClH/c1-18-24(27(34)38-6)26(22-14-21(33(36)37)12-13-23(22)30)25(19(2)31-18)28(35)39-17-29(3,4)16-32(5)15-20-10-8-7-9-11-20;/h7-14,26,31H,15-17H2,1-6H3;1H
DMUH0KO	CS	CC1=C(C(C(=C(N1)C)C(=O)OCC(C)(C)CN(C)CC2=CC=CC=C2)C3=C(C=CC(=C3)[N+](=O)[O-])F)C(=O)OC.Cl
DMUH0KO	IK	OQHXRVQARZHYGQ-UHFFFAOYSA-N
DMUH0KO	IU	5-O-[3-[benzyl(methyl)amino]-2,2-dimethylpropyl] 3-O-methyl 4-(2-fluoro-5-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride
DMUH0KO	CA	CAS 96515-74-1
DMUH0KO	DE	Hypertension

DMP6BG4	ID	DMP6BG4
DMP6BG4	DN	Pirazolac
DMP6BG4	HS	Discontinued in Preregistration
DMP6BG4	SN	MY-309; ZK-76604
DMP6BG4	CP	Bayer Schering Pharma AG
DMP6BG4	DT	Small molecular drug
DMP6BG4	PC	51222
DMP6BG4	MW	330.7
DMP6BG4	FM	C17H12ClFN2O2
DMP6BG4	IC	InChI=1S/C17H12ClFN2O2/c18-12-3-1-11(2-4-12)15-10-21(20-16(15)9-17(22)23)14-7-5-13(19)6-8-14/h1-8,10H,9H2,(H,22,23)
DMP6BG4	CS	C1=CC(=CC=C1C2=CN(N=C2CC(=O)O)C3=CC=C(C=C3)F)Cl
DMP6BG4	IK	YAMFWQIVVMITPG-UHFFFAOYSA-N
DMP6BG4	IU	2-[4-(4-chlorophenyl)-1-(4-fluorophenyl)pyrazol-3-yl]acetic acid
DMP6BG4	CA	CAS 71002-09-0
DMP6BG4	DE	Inflammation

DMD8K3B	ID	DMD8K3B
DMD8K3B	DN	PW-2101
DMD8K3B	HS	Discontinued in Preregistration
DMD8K3B	SN	Antihypertensive (oral once-daily, TIMERx), Penwest
DMD8K3B	CP	Penwest Pharmaceuticals
DMD8K3B	DE	Angina pectoris

DM4LSJ2	ID	DM4LSJ2
DM4LSJ2	DN	Satigrel
DM4LSJ2	HS	Discontinued in Preregistration
DM4LSJ2	SN	E-5510
DM4LSJ2	CP	Eisai Co Ltd
DM4LSJ2	DT	Small molecular drug
DM4LSJ2	PC	65913
DM4LSJ2	MW	337.4
DM4LSJ2	FM	C20H19NO4
DM4LSJ2	IC	InChI=1S/C20H19NO4/c1-24-17-8-3-14(4-9-17)20(16(13-21)7-12-19(22)23)15-5-10-18(25-2)11-6-15/h3-6,8-11H,7,12H2,1-2H3,(H,22,23)
DM4LSJ2	CS	COC1=CC=C(C=C1)C(=C(CCC(=O)O)C#N)C2=CC=C(C=C2)OC
DM4LSJ2	IK	GRVCTHTXJDYIHB-UHFFFAOYSA-N
DM4LSJ2	IU	4-cyano-5,5-bis(4-methoxyphenyl)pent-4-enoic acid
DM4LSJ2	CA	CAS 111753-73-2
DM4LSJ2	DE	Thrombosis

DMYBPJ1	ID	DMYBPJ1
DMYBPJ1	DN	Semotiadil
DMYBPJ1	HS	Discontinued in Preregistration
DMYBPJ1	SN	Semotiadil fumarate; Sesamodil fumarate; DQ-4823; DS-4823; SD-3211
DMYBPJ1	CP	Santen Pharmaceutical Co Ltd
DMYBPJ1	DT	Small molecular drug
DMYBPJ1	PC	65929
DMYBPJ1	MW	536.6
DMYBPJ1	FM	C29H32N2O6S
DMYBPJ1	IC	InChI=1S/C29H32N2O6S/c1-30(14-16-34-21-10-12-25-26(18-21)37-19-36-25)13-6-15-35-24-11-9-20(33-3)17-22(24)28-29(32)31(2)23-7-4-5-8-27(23)38-28/h4-5,7-12,17-18,28H,6,13-16,19H2,1-3H3/t28-/m1/s1
DMYBPJ1	CS	CN1C2=CC=CC=C2S[C@@H](C1=O)C3=C(C=CC(=C3)OC)OCCCN(C)CCOC4=CC5=C(C=C4)OCO5
DMYBPJ1	IK	RKXVEXUAWGRFNP-MUUNZHRXSA-N
DMYBPJ1	IU	(2R)-2-[2-[3-[2-(1,3-benzodioxol-5-yloxy)ethyl-methylamino]propoxy]-5-methoxyphenyl]-4-methyl-1,4-benzothiazin-3-one
DMYBPJ1	CA	CAS 116476-13-2
DMYBPJ1	DE	Hypertension

DMC14HL	ID	DMC14HL
DMC14HL	DN	Suriclone
DMC14HL	HS	Discontinued in Preregistration
DMC14HL	SN	Suril; RP-31264
DMC14HL	CP	Rhone-Poulenc SA
DMC14HL	DT	Small molecular drug
DMC14HL	PC	40903
DMC14HL	MW	478
DMC14HL	FM	C20H20ClN5O3S2
DMC14HL	IC	InChI=1S/C20H20ClN5O3S2/c1-24-6-8-25(9-7-24)20(28)29-19-16-15(30-10-11-31-16)18(27)26(19)14-5-3-12-2-4-13(21)22-17(12)23-14/h2-5,19H,6-11H2,1H3
DMC14HL	CS	CN1CCN(CC1)C(=O)OC2C3=C(C(=O)N2C4=NC5=C(C=C4)C=CC(=N5)Cl)SCCS3
DMC14HL	IK	RMXOUBDDDQUBKD-UHFFFAOYSA-N
DMC14HL	IU	[6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7-dihydro-2H-[1,4]dithiino[2,3-c]pyrrol-7-yl] 4-methylpiperazine-1-carboxylate
DMC14HL	CA	CAS 53813-83-5
DMC14HL	DE	Anxiety disorder

DM6PVWS	ID	DM6PVWS
DM6PVWS	DN	Telenzepine
DM6PVWS	HS	Discontinued in Preregistration
DM6PVWS	SN	Telenzepine [INN]; Telenzepinum [Latin]; Telenzepino [Spanish]; 80880-90-6; UNII-0990EG3K10; 0990EG3K10; NCGC00015987-05; DSSTox_RID_80752; DSSTox_CID_25209; 1-methyl-10-[2-(4-methylpiperazin-1-yl)acetyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one; DSSTox_GSID_45209; 4,9-Dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl)-10H-thieno(3,4-b)(1,5)benzodiazepin-10-one; Telenzepine hydrochloride; Telenzepine dihydrochloide; C19H22N4O2S; Telenzepino; Telenzepinum; Telenzepine dihydrochloride hydrate;  BY-802; [3H](+)telenzepine
DM6PVWS	CP	ALTANA Pharma AG
DM6PVWS	DT	Small molecular drug
DM6PVWS	PC	5387
DM6PVWS	MW	370.5
DM6PVWS	FM	C19H22N4O2S
DM6PVWS	IC	InChI=1S/C19H22N4O2S/c1-13-18-14(12-26-13)19(25)20-15-5-3-4-6-16(15)23(18)17(24)11-22-9-7-21(2)8-10-22/h3-6,12H,7-11H2,1-2H3,(H,20,25)
DM6PVWS	CS	CC1=C2C(=CS1)C(=O)NC3=CC=CC=C3N2C(=O)CN4CCN(CC4)C
DM6PVWS	IK	VSWPGAIWKHPTKX-UHFFFAOYSA-N
DM6PVWS	IU	1-methyl-10-[2-(4-methylpiperazin-1-yl)acetyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one
DM6PVWS	CA	CAS 80880-90-6
DM6PVWS	CB	CHEBI:92110
DM6PVWS	DE	Chronic obstructive pulmonary disease

DMUM3CP	ID	DMUM3CP
DMUM3CP	DN	15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon
DMUM3CP	HS	Discontinued in Phase 3
DMUM3CP	SN	PROCALYX; 15(S)-HETE; 15(S)-Hydroxyeicosatetraenoic acid
DMUM3CP	CP	Alcon Inc
DMUM3CP	DT	Small molecular drug
DMUM3CP	PC	5280724
DMUM3CP	MW	320.5
DMUM3CP	FM	C20H32O3
DMUM3CP	IC	InChI=1S/C20H32O3/c1-2-3-13-16-19(21)17-14-11-9-7-5-4-6-8-10-12-15-18-20(22)23/h4-5,8-11,14,17,19,21H,2-3,6-7,12-13,15-16,18H2,1H3,(H,22,23)/b5-4-,10-8-,11-9-,17-14+/t19-/m0/s1
DMUM3CP	CS	CCCCC[C@@H](/C=C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O)O
DMUM3CP	IK	JSFATNQSLKRBCI-VAEKSGALSA-N
DMUM3CP	IU	(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoic acid
DMUM3CP	CA	CAS 54845-95-3
DMUM3CP	CB	CHEBI:15558
DMUM3CP	DE	Ocular disease

DM0GMJ6	ID	DM0GMJ6
DM0GMJ6	DN	2085-P
DM0GMJ6	HS	Discontinued in Phase 3
DM0GMJ6	SN	VD-2085
DM0GMJ6	CP	LEO Pharma A/S
DM0GMJ6	DT	Small molecular drug
DM0GMJ6	PC	6917705
DM0GMJ6	MW	743.7
DM0GMJ6	FM	C30H39BrN4O9S2
DM0GMJ6	IC	InChI=1S/C22H29N3O6S.C8H10BrNO3S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12;1-8(2)4(7(12)13)10-5(11)3(9)6(10)14-8/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26);3-4,6H,1-2H3,(H,12,13)/t13-,14+,15-,18+;3-,4+,6-/m01/s1
DM0GMJ6	CS	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)Br)C(=O)[O-])C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@H](C3=CC=CC=C3)[NH3+])C(=O)OCOC(=O)C(C)(C)C)C
DM0GMJ6	IK	NSZOIZOWOWUYKG-VKICDOHCSA-N
DM0GMJ6	IU	(2S,5R,6R)-6-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;[(1S)-2-[[(2S,5R,6R)-2-(2,2-dimethylpropanoyloxymethoxycarbonyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-6-yl]amino]-2-oxo-1-phenylethyl]azanium
DM0GMJ6	DE	Otitis media

DM09GSW	ID	DM09GSW
DM09GSW	DN	Abafungin
DM09GSW	HS	Discontinued in Phase 3
DM09GSW	SN	Abasol; W-634; YP-006; YP-007; Abafungin (gel formulation), York Pharma; Abafungin (cream, dermatomycosis), York Pharma; Abafungin (gel formulation, onychomycosis), York Pharma; Abafungin (pessary, vaginal candidiasis), York Pharma
DM09GSW	CP	York Pharma
DM09GSW	DT	Small molecular drug
DM09GSW	PC	159326
DM09GSW	MW	378.5
DM09GSW	FM	C21H22N4OS
DM09GSW	IC	InChI=1S/C21H22N4OS/c1-14-8-9-18(15(2)12-14)26-19-7-4-3-6-16(19)17-13-27-21(24-17)25-20-22-10-5-11-23-20/h3-4,6-9,12-13H,5,10-11H2,1-2H3,(H2,22,23,24,25)
DM09GSW	CS	CC1=CC(=C(C=C1)OC2=CC=CC=C2C3=CSC(=N3)NC4=NCCCN4)C
DM09GSW	IK	TYBHXIFFPVFXQW-UHFFFAOYSA-N
DM09GSW	IU	4-[2-(2,4-dimethylphenoxy)phenyl]-N-(1,4,5,6-tetrahydropyrimidin-2-yl)-1,3-thiazol-2-amine
DM09GSW	CA	CAS 129639-79-8
DM09GSW	CB	CHEBI:76005
DM09GSW	DE	Fungal infection

DMAENDF	ID	DMAENDF
DMAENDF	DN	Abetimus sodium
DMAENDF	HS	Discontinued in Phase 3
DMAENDF	SN	Abetimus sodium (USAN); Riquent (TN)
DMAENDF	CP	La Jolla Pharmaceutical
DMAENDF	DE	Lupus

DMNKZ61	ID	DMNKZ61
DMNKZ61	DN	Ablukast
DMNKZ61	HS	Discontinued in Phase 3
DMNKZ61	SN	Ablukast sodium; RO-23-3544
DMNKZ61	CP	Roche Holding AG
DMNKZ61	DT	Small molecular drug
DMNKZ61	PC	57109
DMNKZ61	MW	498.6
DMNKZ61	FM	C28H34O8
DMNKZ61	IC	InChI=1S/C28H34O8/c1-4-8-21-23(12-10-20(17(2)29)27(21)31)34-13-6-5-7-14-35-26-16-25-19(15-22(26)18(3)30)9-11-24(36-25)28(32)33/h10,12,15-16,24,31H,4-9,11,13-14H2,1-3H3,(H,32,33)
DMNKZ61	CS	CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCCOC2=C(C=C3CCC(OC3=C2)C(=O)O)C(=O)C
DMNKZ61	IK	FGGYJWZYDAROFF-UHFFFAOYSA-N
DMNKZ61	IU	6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid
DMNKZ61	CA	CAS 96566-25-5
DMNKZ61	DE	Asthma

DMKM543	ID	DMKM543
DMKM543	DN	Acecainide
DMKM543	HS	Discontinued in Phase 3
DMKM543	SN	N-Acetylprocainamide; Acekainid; 32795-44-1; Acecainida; Acecainidum; NAPA; N-Acetyloprokainamid; Acecainide [INN]; Acekainid [Polish]; 4'-((2-(Diethylamino)ethyl)carbamoyl)acetanilide; Acecainidum [INN-Latin]; Acecainida [INN-Spanish]; N-Acetyloprokainamid [Polish]; UNII-910Q707V6F; CHEBI:60728; Benzamide, 4-(acetylamino)-N-(2-(diethylamino)ethyl)-; BRN 2868559; CHEMBL1097; MLS000069490; KEECCEWTUVWFCV-UHFFFAOYSA-N; 4-acetamido-N-[2-(diethylamino)ethyl]benzamide; 910Q707V6F; SMR000059070; ACETANILIDE,;  NAPA; Acecainide hydrochloride; ASL-601; Acetylprocainamide
DMKM543	CP	King Pharmaceuticals R&D Inc
DMKM543	DT	Small molecular drug
DMKM543	PC	4342
DMKM543	MW	277.36
DMKM543	FM	C15H23N3O2
DMKM543	IC	InChI=1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)
DMKM543	CS	CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C
DMKM543	IK	KEECCEWTUVWFCV-UHFFFAOYSA-N
DMKM543	IU	4-acetamido-N-[2-(diethylamino)ethyl]benzamide
DMKM543	CA	CAS 32795-44-1
DMKM543	CB	CHEBI:60728
DMKM543	DE	Solid tumour/cancer

DMPQZ80	ID	DMPQZ80
DMPQZ80	DN	Acivicin
DMPQZ80	HS	Discontinued in Phase 3
DMPQZ80	SN	acivicin; 42228-92-2; Antibiotic AT 125; Acivicinum; Acivicino; Acivicine; AT-125; AT 125; NSC-163501; NSC 163501; NSC163501; UNII-O0X60K76I6; ACIA; U 42126; CHEBI:74545; O0X60K76I6; U-42,126; Acivicin [USAN:INN]; (alphaS,5S)-alpha-Amino-3-chloro-2-isoxazoline-5-acetic acid; Acivicinum [INN-Latin]; Acivicine [INN-French]; Acivicino [INN-Spanish]; (alpha-S,5S)-alpha-Amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid; C5H7ClN2O3; (2S)-2-Amino-2-[(5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl]acetic acid; U-42126
DMPQZ80	DT	Small molecular drug
DMPQZ80	PC	294641
DMPQZ80	MW	178.57
DMPQZ80	FM	C5H7ClN2O3
DMPQZ80	IC	InChI=1S/C5H7ClN2O3/c6-3-1-2(11-8-3)4(7)5(9)10/h2,4H,1,7H2,(H,9,10)/t2-,4-/m0/s1
DMPQZ80	CS	C1[C@H](ON=C1Cl)[C@@H](C(=O)O)N
DMPQZ80	IK	QAWIHIJWNYOLBE-OKKQSCSOSA-N
DMPQZ80	IU	(2S)-2-amino-2-[(5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl]acetic acid
DMPQZ80	CA	CAS 42228-92-2
DMPQZ80	CB	CHEBI:74545

DMTG18I	ID	DMTG18I
DMTG18I	DN	Aleglitazar
DMTG18I	HS	Discontinued in Phase 3
DMTG18I	SN	RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid
DMTG18I	CP	Roche
DMTG18I	DT	Small molecular drug
DMTG18I	PC	10274777
DMTG18I	MW	437.5
DMTG18I	FM	C24H23NO5S
DMTG18I	IC	InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1
DMTG18I	CS	CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)C[C@@H](C(=O)O)OC
DMTG18I	IK	DAYKLWSKQJBGCS-NRFANRHFSA-N
DMTG18I	IU	(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]propanoic acid
DMTG18I	CA	CAS 475479-34-6
DMTG18I	DE	Type-2 diabetes

DMV2Y6L	ID	DMV2Y6L
DMV2Y6L	DN	Alinidine
DMV2Y6L	HS	Discontinued in Phase 3
DMV2Y6L	SN	ST-567
DMV2Y6L	CP	Boehringer Ingelheim Corp
DMV2Y6L	DT	Small molecular drug
DMV2Y6L	PC	36354
DMV2Y6L	MW	270.15
DMV2Y6L	FM	C12H13Cl2N3
DMV2Y6L	IC	InChI=1S/C12H13Cl2N3/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14/h2-5H,1,6-8H2,(H,15,16)
DMV2Y6L	CS	C=CCN(C1=C(C=CC=C1Cl)Cl)C2=NCCN2
DMV2Y6L	IK	OXTYVEUAQHPPMV-UHFFFAOYSA-N
DMV2Y6L	IU	N-(2,6-dichlorophenyl)-N-prop-2-enyl-4,5-dihydro-1H-imidazol-2-amine
DMV2Y6L	CA	CAS 33178-86-8
DMV2Y6L	DE	Angina pectoris

DMV3PEA	ID	DMV3PEA
DMV3PEA	DN	Almokalant
DMV3PEA	HS	Discontinued in Phase 3
DMV3PEA	SN	Almokalant; 123955-10-2; Almokalantum; CHEMBL362103; Almokalant [INN]; 4-(3-(Ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)benzonitrile; Almokalantum [INN-Latin]; Almoklant; Benzonitrile, 4-(3-(ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)-; (+-)-p-(3-(Ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)benzonitrile; AC1MHWND; SCHEMBL247121; H 234-09; ZMHOBBKJBYLXFR-UHFFFAOYSA-N; BDBM50151869; LS-38713; HY-106855; CS-0026741; 4-[3-[ethyl[3-(propylsulfinyl)propyl]amino]-2-hydroxypropoxy]-benzonitrile
DMV3PEA	DT	Small molecular drug
DMV3PEA	PC	3033962
DMV3PEA	MW	352.5
DMV3PEA	FM	C18H28N2O3S
DMV3PEA	IC	InChI=1S/C18H28N2O3S/c1-3-11-24(22)12-5-10-20(4-2)14-17(21)15-23-18-8-6-16(13-19)7-9-18/h6-9,17,21H,3-5,10-12,14-15H2,1-2H3
DMV3PEA	CS	CCCS(=O)CCCN(CC)CC(COC1=CC=C(C=C1)C#N)O
DMV3PEA	IK	ZMHOBBKJBYLXFR-UHFFFAOYSA-N
DMV3PEA	IU	4-[3-[ethyl(3-propylsulfinylpropyl)amino]-2-hydroxypropoxy]benzonitrile
DMV3PEA	CA	CAS 123955-10-2
DMV3PEA	DE	Cardiac arrhythmias

DMFE3CT	ID	DMFE3CT
DMFE3CT	DN	Alniditan
DMFE3CT	HS	Discontinued in Phase 3
DMFE3CT	SN	UNII-B57Z82EOGE; B57Z82EOGE; 152317-89-0; [3H]alniditan; Alniditan [INN:BAN]; N-[[(2R)-chroman-2-yl]methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine; AC1Q4UFC; AC1L24EQ; GTPL117; GTPL120; SCHEMBL717887; CHEMBL88240; ZINC1536693; PDSP2_001383; PDSP1_001399; BDBM50403503; CS-6739; HY-101698; 2-((3-(((R)-2-Chromanylmethyl)amino)propyl)amino)-1,4,5,6-tetrahydropyrimidine;  Pasmigren; R-091274
DMFE3CT	CP	Janssen-Cilag Ltd
DMFE3CT	DT	Small molecular drug
DMFE3CT	PC	66004
DMFE3CT	MW	302.4
DMFE3CT	FM	C17H26N4O
DMFE3CT	IC	InChI=1S/C17H26N4O/c1-2-6-16-14(5-1)7-8-15(22-16)13-18-9-3-10-19-17-20-11-4-12-21-17/h1-2,5-6,15,18H,3-4,7-13H2,(H2,19,20,21)/t15-/m1/s1
DMFE3CT	CS	C1CNC(=NC1)NCCCNC[C@H]2CCC3=CC=CC=C3O2
DMFE3CT	IK	QVSXOXCYXPQXMF-OAHLLOKOSA-N
DMFE3CT	IU	N-[[(2R)-3,4-dihydro-2H-chromen-2-yl]methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine
DMFE3CT	CA	CAS 152317-89-0
DMFE3CT	DE	Migraine

DMGW07M	ID	DMGW07M
DMGW07M	DN	Aloxistatin
DMGW07M	HS	Discontinued in Phase 3
DMGW07M	SN	NSC694281; AC1L95AQ; SCHEMBL254426; CHEMBL1978255; CTK8C9289; ethyl(2s,3s)-3-[[1-(isopentylcarbamoyl)-3-methyl-butyl]carbamoyl]oxirane-2-carboxylate; NSC-694281; VC30685; NCI60_033765; ethyl (2S,3S)-3-[[4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate; 2-Oxiranecarboxylicacid,3-[[[(1S)-3-methyl-1-[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-,ethyl ester, (2S,3S)-
DMGW07M	DT	Small molecular drug
DMGW07M	PC	65663
DMGW07M	MW	342.4
DMGW07M	FM	C17H30N2O5
DMGW07M	IC	InChI=1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)/t12-,13-,14-/m0/s1
DMGW07M	CS	CCOC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C
DMGW07M	IK	SRVFFFJZQVENJC-IHRRRGAJSA-N
DMGW07M	IU	ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
DMGW07M	CA	CAS 88321-09-9
DMGW07M	CB	CHEBI:101381
DMGW07M	DE	Neurological disorder; Coronavirus infection

DMPS14M	ID	DMPS14M
DMPS14M	DN	Amibegron
DMPS14M	HS	Discontinued in Phase 3
DMPS14M	SN	SR 58611; Amibegron (USAN/INN); Ethyl 2-[[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate
DMPS14M	CP	Sanofi-Aventis; Eli Lilly
DMPS14M	DT	Small molecular drug
DMPS14M	PC	3035442
DMPS14M	MW	403.9
DMPS14M	FM	C22H26ClNO4
DMPS14M	IC	InChI=1S/C22H26ClNO4/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3/t19-,21-/m0/s1
DMPS14M	CS	CCOC(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=CC=C3)Cl)O)C=C1
DMPS14M	IK	RDJQCOBTKKAQAH-FPOVZHCZSA-N
DMPS14M	IU	ethyl 2-[[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate
DMPS14M	CA	CAS 121524-08-1
DMPS14M	DE	Type-2 diabetes; Obesity; Major depressive disorder; Mood disorder

DMNEM2C	ID	DMNEM2C
DMNEM2C	DN	Anipamil
DMNEM2C	HS	Discontinued in Phase 3
DMNEM2C	SN	LU-42668
DMNEM2C	CP	Knoll GmbH
DMNEM2C	DT	Small molecular drug
DMNEM2C	PC	54966
DMNEM2C	MW	520.799
DMNEM2C	FM	C34H52N2O2
DMNEM2C	IC	InChI=1S/C34H52N2O2/c1-5-6-7-8-9-10-11-12-13-14-23-34(29-35,31-19-16-21-33(28-31)38-4)24-17-25-36(2)26-22-30-18-15-20-32(27-30)37-3/h15-16,18-21,27-28H,5-14,17,22-26H2,1-4H3
DMNEM2C	CS	CCCCCCCCCCCCC(CCCN(C)CCC1=CC(=CC=C1)OC)(C#N)C2=CC(=CC=C2)OC
DMNEM2C	IK	PHFDAOXXIZOUIX-UHFFFAOYSA-N
DMNEM2C	IU	2-(3-methoxyphenyl)-2-[3-[2-(3-methoxyphenyl)ethyl-methylamino]propyl]tetradecanenitrile
DMNEM2C	CA	CAS 83200-10-6
DMNEM2C	DE	Hypertension

DM8XO3B	ID	DM8XO3B
DM8XO3B	DN	ARANOSE
DM8XO3B	HS	Discontinued in Phase 3
DM8XO3B	SN	Aranoza; CRC-0510375; 3-(alpha-L-Arabinopyranosyl)-1-methyl-1-nitrosourea
DM8XO3B	DT	Small molecular drug
DM8XO3B	PC	208900
DM8XO3B	MW	235.19
DM8XO3B	FM	C7H13N3O6
DM8XO3B	IC	InChI=1S/C7H13N3O6/c1-10(9-15)7(14)8-6-5(13)4(12)3(11)2-16-6/h3-6,11-13H,2H2,1H3,(H,8,14)/t3-,4-,5+,6+/m0/s1
DM8XO3B	CS	CN(C(=O)N[C@H]1[C@@H]([C@H]([C@H](CO1)O)O)O)N=O
DM8XO3B	IK	BADMGRJDJPQBLS-UNTFVMJOSA-N
DM8XO3B	IU	1-methyl-1-nitroso-3-[(2R,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]urea
DM8XO3B	CA	CAS 167396-23-8
DM8XO3B	DE	Solid tumour/cancer

DM4BV2W	ID	DM4BV2W
DM4BV2W	DN	Asoprisnil
DM4BV2W	HS	Discontinued in Phase 3
DM4BV2W	SN	J867; J-867; Asoprisnil (USAN/INN); 11beta-(4-((E)-(Hydroxyimino)methyl)phenyl)-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one
DM4BV2W	CP	Bayer
DM4BV2W	DT	Small molecular drug
DM4BV2W	PC	9577221
DM4BV2W	MW	449.6
DM4BV2W	FM	C28H35NO4
DM4BV2W	IC	InChI=1S/C28H35NO4/c1-27-15-24(19-6-4-18(5-7-19)16-29-31)26-22-11-9-21(30)14-20(22)8-10-23(26)25(27)12-13-28(27,33-3)17-32-2/h4-7,14,16,23-25,31H,8-13,15,17H2,1-3H3/b29-16+/t23-,24+,25-,27-,28+/m0/s1
DM4BV2W	CS	C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(COC)OC)C5=CC=C(C=C5)/C=N/O
DM4BV2W	IK	GJMNAFGEUJBOCE-MEQIQULJSA-N
DM4BV2W	IU	(8S,11R,13S,14S,17S)-11-[4-[(E)-hydroxyiminomethyl]phenyl]-17-methoxy-17-(methoxymethyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DM4BV2W	CA	CAS 199396-76-4
DM4BV2W	DE	Endometriosis

DMPTG39	ID	DMPTG39
DMPTG39	DN	Ataprost
DMPTG39	HS	Discontinued in Phase 3
DMPTG39	SN	ONO-41483; OP-41483
DMPTG39	CP	Ono Pharmaceutical Co Ltd
DMPTG39	DT	Small molecular drug
DMPTG39	PC	6436122
DMPTG39	MW	348.5
DMPTG39	FM	C21H32O4
DMPTG39	IC	InChI=1S/C21H32O4/c22-19(15-6-2-3-7-15)10-9-17-18-12-14(5-1-4-8-21(24)25)11-16(18)13-20(17)23/h5,9-10,15-20,22-23H,1-4,6-8,11-13H2,(H,24,25)/b10-9+,14-5+/t16-,17+,18-,19+,20+/m0/s1
DMPTG39	CS	C1CCC(C1)[C@@H](/C=C/[C@H]2[C@@H](C[C@H]3[C@@H]2C/C(=C/CCCC(=O)O)/C3)O)O
DMPTG39	IK	DKLGLHQHLFISGJ-YLBFUXKPSA-N
DMPTG39	IU	(5E)-5-[(3aS,4R,5R,6aS)-4-[(E,3S)-3-cyclopentyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
DMPTG39	CA	CAS 83997-19-7
DMPTG39	DE	Asthma

DMFG4OM	ID	DMFG4OM
DMFG4OM	DN	Avasimibe
DMFG4OM	HS	Discontinued in Phase 3
DMFG4OM	SN	Avasimibe; 166518-60-1; CI-1011; Avasimibe(CI-1011); UNII-28LQ20T5RC; CI 1011; Avasimibe (CI-1011); PD 148515; CHEMBL101309; 28LQ20T5RC; 2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)acetyl)sulfamate; 2,6-diisopropylphenyl 2-(2,4,6-triisopropylphenyl)acetylsulfamate; 2,6-Diisopropylphenyl ((2,4,6-triisopropylphenyl)acetyl)sulfamate; 2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)-acetyl)sulfamate; ((2,4,6-Tris(1-methylethyl)phenyl)acetyl)sulfamic acid 2,6-bis(1-methylethyl)phenyl ester
DMFG4OM	DT	Small molecular drug
DMFG4OM	PC	166558
DMFG4OM	MW	501.7
DMFG4OM	FM	C29H43NO4S
DMFG4OM	IC	InChI=1S/C29H43NO4S/c1-17(2)22-14-25(20(7)8)27(26(15-22)21(9)10)16-28(31)30-35(32,33)34-29-23(18(3)4)12-11-13-24(29)19(5)6/h11-15,17-21H,16H2,1-10H3,(H,30,31)
DMFG4OM	CS	CC(C)C1=C(C(=CC=C1)C(C)C)OS(=O)(=O)NC(=O)CC2=C(C=C(C=C2C(C)C)C(C)C)C(C)C
DMFG4OM	IK	PTQXTEKSNBVPQJ-UHFFFAOYSA-N
DMFG4OM	IU	[2,6-di(propan-2-yl)phenyl] N-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate
DMFG4OM	CA	CAS 166518-60-1
DMFG4OM	DE	Peripheral vascular disease

DM3SE2N	ID	DM3SE2N
DM3SE2N	DN	Avitriptan
DM3SE2N	HS	Discontinued in Phase 3
DM3SE2N	SN	Avitriptan fumarate; BMS-180048
DM3SE2N	CP	Bristol-Myers Squibb Co
DM3SE2N	DT	Small molecular drug
DM3SE2N	PC	133081
DM3SE2N	MW	458.6
DM3SE2N	FM	C22H30N6O3S
DM3SE2N	IC	InChI=1S/C22H30N6O3S/c1-23-32(29,30)15-17-5-6-20-19(12-17)18(13-25-20)4-3-7-27-8-10-28(11-9-27)22-21(31-2)14-24-16-26-22/h5-6,12-14,16,23,25H,3-4,7-11,15H2,1-2H3
DM3SE2N	CS	CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCCN3CCN(CC3)C4=NC=NC=C4OC
DM3SE2N	IK	WRZVGHXUPBWIOO-UHFFFAOYSA-N
DM3SE2N	IU	1-[3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
DM3SE2N	CA	CAS 151140-96-4
DM3SE2N	DE	Migraine

DMT5O8I	ID	DMT5O8I
DMT5O8I	DN	Axokine
DMT5O8I	HS	Discontinued in Phase 3
DMT5O8I	DE	Obesity

DM7G8T0	ID	DM7G8T0
DM7G8T0	DN	Azithromycin/chloroquine
DM7G8T0	HS	Discontinued in Phase 3
DM7G8T0	SN	Chloroquine (TN)
DM7G8T0	CP	Pfizer
DM7G8T0	DE	Bacterial infection

DMAMFXC	ID	DMAMFXC
DMAMFXC	DN	BCG65-E7
DMAMFXC	HS	Discontinued in Phase 3
DMAMFXC	CP	Nventa BioPharma
DMAMFXC	DE	Human papillomavirus infection; Anal intraepithelial neoplasia

DMRQV8I	ID	DMRQV8I
DMRQV8I	DN	Becatecarin
DMRQV8I	HS	Discontinued in Phase 3
DMRQV8I	SN	BMS-181176; Becatecarin < USAN; DEAE-Rebeccamycin; XL-119; BMY-27557-01 (HCl); BMY-27557-14 (tartrate); 1,11-Dichloro-6-[2-(diethylamino)ethyl]-12-(4-O-methyl-beta-D-glucopyranosyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
DMRQV8I	CP	Exelixis
DMRQV8I	DT	Small molecular drug
DMRQV8I	PC	101524
DMRQV8I	MW	669.5
DMRQV8I	FM	C33H34Cl2N4O7
DMRQV8I	IC	InChI=1S/C33H34Cl2N4O7/c1-4-37(5-2)12-13-38-31(43)22-20-15-8-6-10-17(34)24(15)36-25(20)27-21(23(22)32(38)44)16-9-7-11-18(35)26(16)39(27)33-29(42)28(41)30(45-3)19(14-40)46-33/h6-11,19,28-30,33,36,40-42H,4-5,12-14H2,1-3H3/t19-,28-,29-,30-,33-/m1/s1
DMRQV8I	CS	CCN(CC)CCN1C(=O)C2=C3C4=C(C(=CC=C4)Cl)NC3=C5C(=C2C1=O)C6=C(N5[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)OC)O)O)C(=CC=C6)Cl
DMRQV8I	IK	JSKFWUPVIZYJMR-UDOAKELVSA-N
DMRQV8I	IU	5,21-dichloro-13-[2-(diethylamino)ethyl]-3-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
DMRQV8I	CA	CAS 119673-08-4
DMRQV8I	DE	Solid tumour/cancer

DMZIV6D	ID	DMZIV6D
DMZIV6D	DN	Befloxatone
DMZIV6D	HS	Discontinued in Phase 3
DMZIV6D	SN	MD-370503
DMZIV6D	CP	Sanofi-Synthelabo
DMZIV6D	DT	Small molecular drug
DMZIV6D	PC	60824
DMZIV6D	MW	349.3
DMZIV6D	FM	C15H18F3NO5
DMZIV6D	IC	InChI=1S/C15H18F3NO5/c1-22-9-12-8-19(14(21)24-12)10-2-4-11(5-3-10)23-7-6-13(20)15(16,17)18/h2-5,12-13,20H,6-9H2,1H3/t12-,13-/m1/s1
DMZIV6D	CS	COC[C@H]1CN(C(=O)O1)C2=CC=C(C=C2)OCC[C@H](C(F)(F)F)O
DMZIV6D	IK	IALVDLPLCLFBCF-CHWSQXEVSA-N
DMZIV6D	IU	(5R)-5-(methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-1,3-oxazolidin-2-one
DMZIV6D	CA	CAS 134564-82-2
DMZIV6D	DE	Major depressive disorder

DMSPJX9	ID	DMSPJX9
DMSPJX9	DN	BEMESETRON
DMSPJX9	HS	Discontinued in Phase 3
DMSPJX9	SN	3-Tropanyl-3,5-dichlorobenzoate; MDL 72222; MDL-72222; C15H17Cl2NO2; CHEMBL376379; 40796-97-2; Tropyl 3,5-dichlorobenzoate; 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3,5-dichlorobenzoate; Bemesetron [USAN:INN]; Bemesetronum [INN-Latin]; 3,5-Dichloro-benzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester; SR-01000075587; Tropanyl 3,5-dichlorobenzoate; 1alphaH,5alphaH-Tropan-3alpha-yl 3,5-dichlorobenzoate; endo-8-Methyl-8-azabicyclo(3.2.1)oct-3-yl 3,5-dichlorobenzoate; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3,5-dichlorobenzo
DMSPJX9	DT	Small molecular drug
DMSPJX9	PC	671690
DMSPJX9	MW	314.2
DMSPJX9	FM	C15H17Cl2NO2
DMSPJX9	IC	InChI=1S/C15H17Cl2NO2/c1-18-12-2-3-13(18)8-14(7-12)20-15(19)9-4-10(16)6-11(17)5-9/h4-6,12-14H,2-3,7-8H2,1H3/t12-,13+,14?
DMSPJX9	CS	CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CC(=CC(=C3)Cl)Cl
DMSPJX9	IK	MNJNPLVXBISNSX-PBWFPOADSA-N
DMSPJX9	IU	[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3,5-dichlorobenzoate
DMSPJX9	CA	CAS 40796-97-2

DMIEB8Y	ID	DMIEB8Y
DMIEB8Y	DN	Bevasiranib
DMIEB8Y	HS	Discontinued in Phase 3
DMIEB8Y	CP	Opko Health
DMIEB8Y	TC	siRNA
DMIEB8Y	DT	siRNA drug
DMIEB8Y	DE	Exudative age-related macular degeneration

DM47ZHW	ID	DM47ZHW
DM47ZHW	DN	Bidisomide
DM47ZHW	HS	Discontinued in Phase 3
DM47ZHW	SN	Butanamide; SC-40230
DM47ZHW	CP	GD Searle & Co
DM47ZHW	DT	Small molecular drug
DM47ZHW	PC	59798
DM47ZHW	MW	408
DM47ZHW	FM	C22H34ClN3O2
DM47ZHW	IC	InChI=1S/C22H34ClN3O2/c1-17(2)26(18(3)27)16-12-22(21(24)28,19-9-5-6-10-20(19)23)11-15-25-13-7-4-8-14-25/h5-6,9-10,17H,4,7-8,11-16H2,1-3H3,(H2,24,28)
DM47ZHW	CS	CC(C)N(CCC(CCN1CCCCC1)(C2=CC=CC=C2Cl)C(=O)N)C(=O)C
DM47ZHW	IK	GTEPPJFJSNSNIH-UHFFFAOYSA-N
DM47ZHW	IU	2-[2-[acetyl(propan-2-yl)amino]ethyl]-2-(2-chlorophenyl)-4-piperidin-1-ylbutanamide
DM47ZHW	CA	CAS 116078-65-0
DM47ZHW	CB	CHEBI:135658
DM47ZHW	DE	Heart arrhythmia

DMOQIMS	ID	DMOQIMS
DMOQIMS	DN	Bifeprunox
DMOQIMS	HS	Discontinued in Phase 3
DMOQIMS	SN	Bifeprunoxum; Bifeprunox [INN]; DU 127090; DU127090; Bifeprunoxum [INN-Latin]; Bifeprunox (USAN/INN); 7-(4-(Biphenyl-3-ylmethyl)piperazin-1-yl)benzoxazol-2(3H)-one; 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
DMOQIMS	CP	Solvay
DMOQIMS	DT	Small molecular drug
DMOQIMS	PC	208951
DMOQIMS	MW	385.5
DMOQIMS	FM	C24H23N3O2
DMOQIMS	IC	InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28)
DMOQIMS	CS	C1CN(CCN1CC2=CC(=CC=C2)C3=CC=CC=C3)C4=CC=CC5=C4OC(=O)N5
DMOQIMS	IK	CYGODHVAJQTCBG-UHFFFAOYSA-N
DMOQIMS	IU	7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
DMOQIMS	CA	CAS 350992-10-8
DMOQIMS	DE	Schizophrenia

DMLXHZR	ID	DMLXHZR
DMLXHZR	DN	BL-1832
DMLXHZR	HS	Discontinued in Phase 3
DMLXHZR	CP	Bioglan Labs Ltd
DMLXHZR	DE	Pain

DMKSFPE	ID	DMKSFPE
DMKSFPE	DN	BMS 275291
DMKSFPE	HS	Discontinued in Phase 3
DMKSFPE	SN	D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide
DMKSFPE	CP	Bristol Myers Squibb; Celltech Group
DMKSFPE	TC	Anticancer Agents
DMKSFPE	DT	Small molecular drug
DMKSFPE	PC	148203
DMKSFPE	MW	499.7
DMKSFPE	FM	C23H41N5O5S
DMKSFPE	IC	InChI=1S/C23H41N5O5S/c1-13(2)12-14(17(29)26-19(31)16(24-8)22(3,4)5)25-18(30)15(34)10-11-28-20(32)23(6,7)27(9)21(28)33/h13-16,24,34H,10-12H2,1-9H3,(H,25,30)(H,26,29,31)/t14-,15-,16+/m0/s1
DMKSFPE	CS	CC(C)C[C@@H](C(=O)NC(=O)[C@H](C(C)(C)C)NC)NC(=O)[C@H](CCN1C(=O)C(N(C1=O)C)(C)C)S
DMKSFPE	IK	BWLOJMZLTBBDHA-HRCADAONSA-N
DMKSFPE	IU	(2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide
DMKSFPE	DE	Kaposi sarcoma; Prostate cancer; Non-small-cell lung cancer

DM0HR5W	ID	DM0HR5W
DM0HR5W	DN	BMS-181100
DM0HR5W	HS	Discontinued in Phase 3
DM0HR5W	SN	BMY-14786; BMY-14802; BMY-14802 hydrochloride; MJ-14676; MJ-14786; MJ-14802; BMY-14802, Skybridge; BMY-14802-1; BMY-14802 (dyskinesia), Skybridge; 5-HT 1a receptor agonist (dyskinesia), Skybridge
DM0HR5W	CP	Bristol-Myers Squibb Co; Skybridge Pharmaceuticals Inc
DM0HR5W	DT	Small molecular drug
DM0HR5W	PC	108046
DM0HR5W	MW	348.4
DM0HR5W	FM	C18H22F2N4O
DM0HR5W	IC	InChI=1S/C18H22F2N4O/c19-15-5-3-14(4-6-15)17(25)2-1-7-23-8-10-24(11-9-23)18-21-12-16(20)13-22-18/h3-6,12-13,17,25H,1-2,7-11H2
DM0HR5W	CS	C1CN(CCN1CCCC(C2=CC=C(C=C2)F)O)C3=NC=C(C=N3)F
DM0HR5W	IK	ZXUYYZPJUGQHLQ-UHFFFAOYSA-N
DM0HR5W	IU	1-(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butan-1-ol
DM0HR5W	CA	CAS 105565-56-8
DM0HR5W	CB	CHEBI:91549
DM0HR5W	DE	Psychotic disorder

DMFZNLH	ID	DMFZNLH
DMFZNLH	DN	BMS-204352
DMFZNLH	HS	Discontinued in Phase 3
DMFZNLH	SN	Flindokalner; MaxiPost; BMS-204352; 187523-35-9; Flindokalner [USAN:INN]; UNII-J57O328W4W; (3S)-3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1,3-dihydro-2H-indol-2-one; BMS 204352; J57O328W4W; 2H-Indol-2-one, 3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-, (3S)-; Maxipost (TN); (s)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one; (3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1H-indol-2-one; Bms204352; Flindokalner (USAN/INN); AC1Q4JQL; AC1L4WO7
DMFZNLH	DT	Small molecular drug
DMFZNLH	PC	214350
DMFZNLH	MW	359.7
DMFZNLH	FM	C16H10ClF4NO2
DMFZNLH	IC	InChI=1S/C16H10ClF4NO2/c1-24-13-5-3-9(17)7-11(13)15(18)10-4-2-8(16(19,20)21)6-12(10)22-14(15)23/h2-7H,1H3,(H,22,23)/t15-/m0/s1
DMFZNLH	CS	COC1=C(C=C(C=C1)Cl)[C@]2(C3=C(C=C(C=C3)C(F)(F)F)NC2=O)F
DMFZNLH	IK	ULYONBAOIMCNEH-HNNXBMFYSA-N
DMFZNLH	IU	(3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1H-indol-2-one
DMFZNLH	CA	CAS 187523-35-9
DMFZNLH	DE	Nerve injury

DMZK70E	ID	DMZK70E
DMZK70E	DN	BN 50730
DMZK70E	HS	Discontinued in Phase 3
DMZK70E	SN	Rocepafant; BN 50730; UNII-4KGX1STY2N; BN-50730; 4KGX1STY2N; 132579-32-9; BN50730; 132418-36-1; 6-(2-Chlorophenyl)-9-((4-methoxyphenyl)thiocarbamoyl)-1-methyl-7,8,9,10-tetrahydro-4H-pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 4H-Pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8H)-carbothioamide, 6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-; Rocepafant [INN]; LAU8080; LAU-8080; LAU 8080; AC1MHWNG; C27H25ClN6OS; SCHEMBL1065775; CHEMBL2105298; ZINC1481916; LS-172840
DMZK70E	DT	Small molecular drug
DMZK70E	PC	3033963
DMZK70E	MW	535.1
DMZK70E	FM	C26H23ClN6OS2
DMZK70E	IC	InChI=1S/C26H23ClN6OS2/c1-15-30-31-22-13-28-24(18-5-3-4-6-20(18)27)23-19-11-12-32(14-21(19)36-25(23)33(15)22)26(35)29-16-7-9-17(34-2)10-8-16/h3-10H,11-14H2,1-2H3,(H,29,35)
DMZK70E	CS	CC1=NN=C2N1C3=C(C4=C(S3)CN(CC4)C(=S)NC5=CC=C(C=C5)OC)C(=NC2)C6=CC=CC=C6Cl
DMZK70E	IK	WBGAFGNZNGJVNW-UHFFFAOYSA-N
DMZK70E	IU	9-(2-chlorophenyl)-N-(4-methoxyphenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaene-14-carbothioamide
DMZK70E	CA	CAS 132579-32-9
DMZK70E	DE	Asthma

DMMT1YQ	ID	DMMT1YQ
DMMT1YQ	DN	Bropirimine
DMMT1YQ	HS	Discontinued in Phase 3
DMMT1YQ	SN	56741-95-8; 2-Amino-5-bromo-4-hydroxy-6-phenylpyrimidine; ABPP; 2-AMINO-5-BROMO-6-PHENYLPYRIMIDIN-4-OL; Bropiriminum [Latin]; 2-Amino-5-bromo-6-phenyl-4(3H)-pyrimidinone; 2-amino-5-bromo-6-phenylpyrimidin-4(3H)-one; U-54461; Bropirimina [Spanish]; UNII-J57CTF25XJ; C10H8BrN3O; CCRIS 3730; 2-amino-5-bromo-6-phenyl-1H-pyrimidin-4-one; 2-Amino-5-bromo-6-phenyl-4(1H)-pyrimidinone; 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-phenyl-; BRN 0651807; J57CTF25XJ; 5-Bromo-6-phenylisocytosine; CHEBI:31307; 2-Amino-5-Bromo-6-Phenylpyrimidin-4-Ol
DMMT1YQ	CP	Pharmacia & Upjohn Inc
DMMT1YQ	DT	Small molecular drug
DMMT1YQ	PC	135413497
DMMT1YQ	MW	266.09
DMMT1YQ	FM	C10H8BrN3O
DMMT1YQ	IC	InChI=1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)
DMMT1YQ	CS	C1=CC=C(C=C1)C2=C(C(=O)NC(=N2)N)Br
DMMT1YQ	IK	CIUUIPMOFZIWIZ-UHFFFAOYSA-N
DMMT1YQ	IU	2-amino-5-bromo-4-phenyl-1H-pyrimidin-6-one
DMMT1YQ	CA	CAS 56741-95-8
DMMT1YQ	CB	CHEBI:31307
DMMT1YQ	DE	Virus infection

DMRA6H5	ID	DMRA6H5
DMRA6H5	DN	Broxaterol
DMRA6H5	HS	Discontinued in Phase 3
DMRA6H5	SN	Summair; Z-1170
DMRA6H5	CP	Zambon Co SpA
DMRA6H5	DT	Small molecular drug
DMRA6H5	PC	71149
DMRA6H5	MW	263.13
DMRA6H5	FM	C9H15BrN2O2
DMRA6H5	IC	InChI=1S/C9H15BrN2O2/c1-9(2,3)11-5-6(13)7-4-8(10)12-14-7/h4,6,11,13H,5H2,1-3H3
DMRA6H5	CS	CC(C)(C)NCC(C1=CC(=NO1)Br)O
DMRA6H5	IK	JBRBWHCVRGURBA-UHFFFAOYSA-N
DMRA6H5	IU	1-(3-bromo-1,2-oxazol-5-yl)-2-(tert-butylamino)ethanol
DMRA6H5	CA	CAS 76596-57-1
DMRA6H5	DE	Asthma

DM4HGMX	ID	DM4HGMX
DM4HGMX	DN	CDP571
DM4HGMX	HS	Discontinued in Phase 3
DM4HGMX	DE	Crohn disease

DMANMXZ	ID	DMANMXZ
DMANMXZ	DN	CEFCANEL DALOXATE HYDROCHLORIDE
DMANMXZ	HS	Discontinued in Phase 3
DMANMXZ	SN	Loride; Onohydrochloride; Enylethyl ester monohydrochloride; KY-109; Cefcanel daloxate hydrochloride; (5-Methyl-1,3-dioxolen-2-on-4-ylmethyl) 7-[D-O-(L-alanyl)mandelamido]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl]-3-cephem-4-carboxylate hydrochloride; (5-Methyl-2-oxo-1,3-dioxo-4-yl)methyl (6R,7R)-7-[(R)-2-[(S)-alanyloxy]-2-phenylacetamido]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydroch; (6R,7R)-7beta-[2(R)-(S-Alanyloxy)-2-phenylacetamido]-3-(5-methyl-1,3,4-thiadiazol-2-ylthiomethyl)-3-cephem-4-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; L-Alanine [6R-[6alpha,7beta(R*)]]-2-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-ph; 2,3-Dihydroxy-2-butenyl (6R,7R)-7-[(R)-mandelamido]-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate,cyclic-2,3-carbonate,ester with L-alanine m
DMANMXZ	DT	Small molecular drug
DMANMXZ	PC	179696
DMANMXZ	MW	698.2
DMANMXZ	FM	C27H28ClN5O9S3
DMANMXZ	IC	InChI=1S/C27H27N5O9S3.ClH/c1-12(28)24(35)41-20(15-7-5-4-6-8-15)21(33)29-18-22(34)32-19(25(36)38-9-17-13(2)39-27(37)40-17)16(10-42-23(18)32)11-43-26-31-30-14(3)44-26;/h4-8,12,18,20,23H,9-11,28H2,1-3H3,(H,29,33);1H/t12-,18+,20+,23+;/m0./s1
DMANMXZ	CS	CC1=C(OC(=O)O1)COC(=O)C2=C(CS[C@H]3N2C(=O)[C@H]3NC(=O)[C@@H](C4=CC=CC=C4)OC(=O)[C@H](C)N)CSC5=NN=C(S5)C.Cl
DMANMXZ	IK	HFVATKYQUGKLGL-PCQLZLFJSA-N
DMANMXZ	IU	(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (6R,7R)-7-[[(2R)-2-[(2S)-2-aminopropanoyl]oxy-2-phenylacetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydrochloride
DMANMXZ	CA	CAS 92602-21-6
DMANMXZ	DE	Bacterial infection

DMEMUQP	ID	DMEMUQP
DMEMUQP	DN	CEFETECOL
DMEMUQP	HS	Discontinued in Phase 3
DMEMUQP	SN	Cefetecol < Rec INN; GR-69153; GR-69153E (diNa salt); GR-69153X (as tetrahydrate); (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 7(2)-(Z)-[O-[(S)-alpha-carboxy-3,4-dihydroxybenzyl]oxime]; (6R,7R,2'Z,S)-7beta-[2-(2-Aminothiazol-4-yl)-2-[(carboxy)(3,4-dihydroxyphenyl)methoxyimino]acetamido]-3-cephem-4-carboxylic acid
DMEMUQP	DT	Small molecular drug
DMEMUQP	PC	71719688
DMEMUQP	MW	535.5
DMEMUQP	FM	C20H17N5O9S2
DMEMUQP	IC	InChI=1S/C20H17N5O9S2/c21-20-22-8(6-36-20)12(24-34-14(19(32)33)7-1-2-10(26)11(27)5-7)15(28)23-13-16(29)25-9(18(30)31)3-4-35-17(13)25/h1-3,5-6,13-14,17,26-27H,4H2,(H2,21,22)(H,23,28)(H,30,31)(H,32,33)/b24-12+/t13-,14+,17-/m1/s1
DMEMUQP	CS	C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=N/O[C@@H](C3=CC(=C(C=C3)O)O)C(=O)O)/C4=CSC(=N4)N)C(=O)O
DMEMUQP	IK	ILZCDOYRDFDUPN-UITOYEBDSA-N
DMEMUQP	IU	(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-[(S)-carboxy-(3,4-dihydroxyphenyl)methoxy]iminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMEMUQP	CA	CAS 117211-03-7
DMEMUQP	DE	Bacterial infection

DMRYC08	ID	DMRYC08
DMRYC08	DN	CGP71683A
DMRYC08	HS	Discontinued in Phase 3
DMRYC08	SN	CGP-71683A; N-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide
DMRYC08	CP	Servier
DMRYC08	DT	Small molecular drug
DMRYC08	PC	9849276
DMRYC08	MW	512.1
DMRYC08	FM	C26H30ClN5O2S
DMRYC08	IC	InChI=1S/C26H29N5O2S.ClH/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24;/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31);1H
DMRYC08	CS	C1CC(CCC1CNC2=NC3=CC=CC=C3C(=N2)N)CNS(=O)(=O)C4=CC=CC5=CC=CC=C54.Cl
DMRYC08	IK	DIQDKUNCSVFGHH-UHFFFAOYSA-N
DMRYC08	IU	N-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide;hydrochloride
DMRYC08	CA	CAS 192322-50-2
DMRYC08	DE	Obesity

DMHSM7I	ID	DMHSM7I
DMHSM7I	DN	Cilomilast
DMHSM7I	HS	Discontinued in Phase 3
DMHSM7I	SN	Ariflo; CIO; SB 207499; SB207499; Ariflo (TN); Cilomilast [USAN:INN]; SB-207499; Ariflo, SB-207499,Cilomilast; Cilomilast (JAN/USAN/INN); CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; Cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid
DMHSM7I	CP	GlaxoSmithKline
DMHSM7I	DT	Small molecular drug
DMHSM7I	PC	151170
DMHSM7I	MW	343.4
DMHSM7I	FM	C20H25NO4
DMHSM7I	IC	InChI=1S/C20H25NO4/c1-24-17-7-6-15(12-18(17)25-16-4-2-3-5-16)20(13-21)10-8-14(9-11-20)19(22)23/h6-7,12,14,16H,2-5,8-11H2,1H3,(H,22,23)
DMHSM7I	CS	COC1=C(C=C(C=C1)C2(CCC(CC2)C(=O)O)C#N)OC3CCCC3
DMHSM7I	IK	CFBUZOUXXHZCFB-UHFFFAOYSA-N
DMHSM7I	IU	4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid
DMHSM7I	CA	CAS 153259-65-5
DMHSM7I	CB	CHEBI:94683
DMHSM7I	DE	Chronic obstructive pulmonary disease; Bronchitis; Emphysema

DMOU173	ID	DMOU173
DMOU173	DN	CP-945598
DMOU173	HS	Discontinued in Phase 3
DMOU173	SN	Otenabant; Otenabant hydrochloride; CP 945598; Otenabant hydrochloride (USAN); CP-945,598; Otenabant (USAN/INN); 1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide monohydrochloride; 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-ethylamino-piperidine-4-carboxamide
DMOU173	CP	Pfizer
DMOU173	DT	Small molecular drug
DMOU173	PC	10052040
DMOU173	MW	510.4
DMOU173	FM	C25H25Cl2N7O
DMOU173	IC	InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35)
DMOU173	CS	CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N
DMOU173	IK	UNAZAADNBYXMIV-UHFFFAOYSA-N
DMOU173	IU	1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-(ethylamino)piperidine-4-carboxamide
DMOU173	CA	CAS 686344-29-6
DMOU173	DE	Obesity

DM753RT	ID	DM753RT
DM753RT	DN	CVT-124
DM753RT	HS	Discontinued in Phase 3
DM753RT	SN	Adentri; Naxifylline; ENX cpd; BG 9719; BG9719; CVT 124; BG-9719; 1,3-ENX; 1,3-dipropyl-8-(2-(5,6-epoxy)norbornyl)xanthine; 8-((2S,5,6-Exo)-5,6-epoxy-2-norbonyl)-1,3-dipropylxanthine
DM753RT	CP	CV Therapeutics
DM753RT	DT	Small molecular drug
DM753RT	PC	9841075
DM753RT	MW	344.4
DM753RT	FM	C18H24N4O3
DM753RT	IC	InChI=1S/C18H24N4O3/c1-3-5-21-16-12(17(23)22(6-4-2)18(21)24)19-15(20-16)11-8-9-7-10(11)14-13(9)25-14/h9-11,13-14H,3-8H2,1-2H3,(H,19,20)/t9-,10+,11+,13-,14+/m1/s1
DM753RT	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)[C@H]3C[C@H]4C[C@@H]3[C@H]5[C@@H]4O5
DM753RT	IK	OQCJPFYWFGUHIN-GJKBLCTNSA-N
DM753RT	IU	8-[(1S,2R,4S,5S,6S)-3-oxatricyclo[3.2.1.02,4]octan-6-yl]-1,3-dipropyl-7H-purine-2,6-dione
DM753RT	CA	CAS 166374-49-8
DM753RT	DE	Autoimmune diabetes

DMHSLVO	ID	DMHSLVO
DMHSLVO	DN	DA-7101
DMHSLVO	HS	Discontinued in Phase 3
DMHSLVO	CP	Dong-A 
DMHSLVO	DE	Gram-positive bacterial infection

DMNQIKV	ID	DMNQIKV
DMNQIKV	DN	DALTROBAN
DMNQIKV	HS	Discontinued in Phase 3
DMNQIKV	SN	79094-20-5; BM-13505; Daltrobanum; SKF 96148; BM 13505; UNII-S25VDY08ZC; BM 13.505; C16H16ClNO4S; SKF-96148; F 96148; S25VDY08ZC; CHEMBL71685; 4-(2-(4-Chlorophenylsulfonylamino)ethyl)phenylacetic acid; 4-(2-(4-Chlorobenzenesulfonylamino)ethyl)benzeneacetic acid; F-96148; NCGC00165787-02; 2-(4-(2-(4-chlorophenylsulfonamido)ethyl)phenyl)acetic acid; 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]acetic acid; DSSTox_RID_81670; DSSTox_CID_26501; DSSTox_GSID_46501; 105218-03-9; Benzeneacetic acid, 4-(2-((
DMNQIKV	DT	Small molecular drug
DMNQIKV	PC	54343
DMNQIKV	MW	353.8
DMNQIKV	FM	C16H16ClNO4S
DMNQIKV	IC	InChI=1S/C16H16ClNO4S/c17-14-5-7-15(8-6-14)23(21,22)18-10-9-12-1-3-13(4-2-12)11-16(19)20/h1-8,18H,9-11H2,(H,19,20)
DMNQIKV	CS	C1=CC(=CC=C1CCNS(=O)(=O)C2=CC=C(C=C2)Cl)CC(=O)O
DMNQIKV	IK	IULOBWFWYDMECP-UHFFFAOYSA-N
DMNQIKV	IU	2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]acetic acid
DMNQIKV	CA	CAS 79094-20-5

DMZ38EN	ID	DMZ38EN
DMZ38EN	DN	Dalvastatin
DMZ38EN	HS	Discontinued in Phase 3
DMZ38EN	SN	RG-12561
DMZ38EN	CP	Rhone-Poulenc SA
DMZ38EN	DT	Small molecular drug
DMZ38EN	PC	6436002
DMZ38EN	MW	386.5
DMZ38EN	FM	C24H31FO3
DMZ38EN	IC	InChI=1S/C24H31FO3/c1-15-10-16(6-9-21(15)25)19-13-23(2,3)14-24(4,5)20(19)8-7-18-11-17(26)12-22(27)28-18/h6-10,17-18,26H,11-14H2,1-5H3/b8-7+/t17-,18-/m0/s1
DMZ38EN	CS	CC1=C(C=CC(=C1)C2=C(C(CC(C2)(C)C)(C)C)/C=C/[C@H]3C[C@@H](CC(=O)O3)O)F
DMZ38EN	IK	VDSBXXDKCUBMQC-VUOWKATKSA-N
DMZ38EN	IU	(4S,6R)-6-[(E)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one
DMZ38EN	DE	Hyperlipidaemia

DMSWLA3	ID	DMSWLA3
DMSWLA3	DN	Darapladib
DMSWLA3	HS	Discontinued in Phase 3
DMSWLA3	SN	SB 480848; Darapladib (USAN)
DMSWLA3	CP	GlaxoSmithKline
DMSWLA3	DT	Small molecular drug
DMSWLA3	PC	9939609
DMSWLA3	MW	666.8
DMSWLA3	FM	C36H38F4N4O2S
DMSWLA3	IC	InChI=1S/C36H38F4N4O2S/c1-3-42(4-2)20-21-43(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-44-32-7-5-6-31(32)34(46)41-35(44)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3
DMSWLA3	CS	CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F
DMSWLA3	IK	WDPFJWLDPVQCAJ-UHFFFAOYSA-N
DMSWLA3	IU	N-[2-(diethylamino)ethyl]-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-1-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
DMSWLA3	CA	CAS 356057-34-6
DMSWLA3	DE	Arteriosclerosis

DMC40SD	ID	DMC40SD
DMC40SD	DN	Darexaban maleate
DMC40SD	HS	Discontinued in Phase 3
DMC40SD	SN	Darexaban maleate; UNII-03RTP2436R; 365462-24-4; 03RTP2436R; YM150; Darexaban maleate (JAN); SCHEMBL5406349; CHEMBL1922345; D09817; N-[2-[[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxybenzamide (2Z)-2-Butenedioate
DMC40SD	CP	Astellas Pharma
DMC40SD	DT	Small molecular drug
DMC40SD	PC	49843900
DMC40SD	MW	590.6
DMC40SD	FM	C31H34N4O8
DMC40SD	IC	InChI=1S/C27H30N4O4.C4H4O4/c1-30-15-4-16-31(18-17-30)21-11-7-19(8-12-21)27(34)29-25-23(5-3-6-24(25)32)28-26(33)20-9-13-22(35-2)14-10-20;5-3(6)1-2-4(7)8/h3,5-14,32H,4,15-18H2,1-2H3,(H,28,33)(H,29,34);1-2H,(H,5,6)(H,7,8)/b;2-1-
DMC40SD	CS	CN1CCCN(CC1)C2=CC=C(C=C2)C(=O)NC3=C(C=CC=C3O)NC(=O)C4=CC=C(C=C4)OC.C(=C\\C(=O)O)\\C(=O)O
DMC40SD	IK	WHMPMUVISXATBH-BTJKTKAUSA-N
DMC40SD	IU	(Z)-but-2-enedioic acid;N-[2-hydroxy-6-[(4-methoxybenzoyl)amino]phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide
DMC40SD	CA	CAS 365462-24-4
DMC40SD	DE	Acute coronary syndrome

DMEMF60	ID	DMEMF60
DMEMF60	DN	Delequamine hydrochloride
DMEMF60	HS	Discontinued in Phase 3
DMEMF60	SN	Delquamine; RS-15385-197; RS-15385-FP; RS-15385-FPh
DMEMF60	CP	Roche Bioscience
DMEMF60	DT	Small molecular drug
DMEMF60	PC	168898
DMEMF60	MW	386.9
DMEMF60	FM	C18H27ClN2O3S
DMEMF60	IC	InChI=1S/C18H26N2O3S.ClH/c1-23-15-5-6-16-13(10-15)7-9-19-12-14-4-3-8-20(24(2,21)22)17(14)11-18(16)19;/h5-6,10,14,17-18H,3-4,7-9,11-12H2,1-2H3;1H/t14-,17+,18+;/m1./s1
DMEMF60	CS	COC1=CC2=C(C=C1)[C@@H]3C[C@H]4[C@H](CCCN4S(=O)(=O)C)CN3CC2.Cl
DMEMF60	IK	ITJOISLXCMAIOC-CVLULELNSA-N
DMEMF60	IU	(8aR,12aS,13aS)-3-methoxy-12-methylsulfonyl-5,6,8,8a,9,10,11,12a,13,13a-decahydroisoquinolino[2,1-g][1,6]naphthyridine;hydrochloride
DMEMF60	CA	CAS 119942-75-5
DMEMF60	DE	Male sexual disorder

DMXKWAL	ID	DMXKWAL
DMXKWAL	DN	Deligoparin sodium
DMXKWAL	HS	Discontinued in Phase 3
DMXKWAL	SN	Ultra low molecular weight heparin
DMXKWAL	CP	Aeolus Pharmaceuticals
DMXKWAL	DE	Ulcerative colitis

DM8DUZT	ID	DM8DUZT
DM8DUZT	DN	Deramciclane
DM8DUZT	HS	Discontinued in Phase 3
DM8DUZT	SN	EGIS-3886; EGIS-7056; EGYT-3886
DM8DUZT	CP	EGIS Gyogyszergyar RT
DM8DUZT	DT	Small molecular drug
DM8DUZT	PC	119590
DM8DUZT	MW	301.5
DM8DUZT	FM	C20H31NO
DM8DUZT	IC	InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1
DM8DUZT	CS	C[C@@]12CC[C@@H](C1(C)C)C[C@@]2(C3=CC=CC=C3)OCCN(C)C
DM8DUZT	IK	QOBGWWQAMAPULA-RLLQIKCJSA-N
DM8DUZT	IU	N,N-dimethyl-2-[[(1R,2S,4R)-1,7,7-trimethyl-2-phenyl-2-bicyclo[2.2.1]heptanyl]oxy]ethanamine
DM8DUZT	CA	CAS 120444-71-5
DM8DUZT	DE	Anxiety disorder

DMO3AJS	ID	DMO3AJS
DMO3AJS	DN	DG031
DMO3AJS	HS	Discontinued in Phase 3
DMO3AJS	SN	Veliflapon; 128253-31-6; Bay-x-1005; Bay X 1005; DG-031; Bayx-1005; Bay X1005; UNII-JXH6X663L0; Bay-X1005; BAY 1005; DG 031; CHEMBL88712; JXH6X663L0; 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; Benzeneacetic acid, alpha-cyclopentyl-4-(2-quinolinylmethoxy)-, (R)-; C23H23NO3; BAY-X 1005; (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid; Veliflapon [USAN:INN]; Velifapon; Veliflapon (USAN/INN); AC1L3X6M; MLS006010705; Benzeneacetic acid, a-cyclopentyl-4-(2-quinolinylmethoxy)-,(aR)-; GTPL5148
DMO3AJS	CP	DeCODE genetics
DMO3AJS	DT	Small molecular drug
DMO3AJS	PC	123723
DMO3AJS	MW	361.4
DMO3AJS	FM	C23H23NO3
DMO3AJS	IC	InChI=1S/C23H23NO3/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26)/t22-/m1/s1
DMO3AJS	CS	C1CCC(C1)[C@H](C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O
DMO3AJS	IK	ZEYYDOLCHFETHQ-JOCHJYFZSA-N
DMO3AJS	IU	(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid
DMO3AJS	CA	CAS 128253-31-6
DMO3AJS	DE	Asthma

DMX2SHT	ID	DMX2SHT
DMX2SHT	DN	Dianicline
DMX2SHT	HS	Discontinued in Phase 3
DMX2SHT	SN	SSR591813; SSR591813L; 5a,6,9,10-Tetrahydro-7H,11H-8,10a-methanopyrido(2',3'-5,6)pyrano(2,3-d)azepine
DMX2SHT	CP	Sanofi-Aventis
DMX2SHT	DT	Small molecular drug
DMX2SHT	PC	10176764
DMX2SHT	MW	216.28
DMX2SHT	FM	C13H16N2O
DMX2SHT	IC	InChI=1S/C13H16N2O/c1-2-11-10(14-5-1)8-13-4-7-15(9-13)6-3-12(13)16-11/h1-2,5,12H,3-4,6-9H2/t12-,13+/m0/s1
DMX2SHT	CS	C1CN2CC[C@@]3(C2)[C@H]1OC4=C(C3)N=CC=C4
DMX2SHT	IK	SUPRUPHAEXPGPF-QWHCGFSZSA-N
DMX2SHT	IU	(1R,10S)-9-oxa-4,13-diazatetracyclo[11.2.1.01,10.03,8]hexadeca-3(8),4,6-triene
DMX2SHT	CA	CAS 292634-27-6
DMX2SHT	DE	Tobacco dependence

DMWMHU7	ID	DMWMHU7
DMWMHU7	DN	Dofequidar fumarate
DMWMHU7	HS	Discontinued in Phase 3
DMWMHU7	SN	MS-209; Dofequidar fumarate; 1-(Diphenylacetyl)-4-[(2RS)-2-hydroxy-3-(5-quinolyloxy)propyl]piperazine sesquifumarate; 1-[4-(2,2-Diphenylacetyl)piperazin-1-yl]-3-(quinoliln-5-yloxy)-2-propanol sesquifumarate; 5-[3-[4-(2,2-Diphenylacetyl)piperazin-1-yl]-2-hydroxypropoxy]quinoline sesquifumarate
DMWMHU7	DT	Small molecular drug
DMWMHU7	PC	9960287
DMWMHU7	MW	597.7
DMWMHU7	FM	C34H35N3O7
DMWMHU7	IC	InChI=1S/C30H31N3O3.C4H4O4/c34-25(22-36-28-15-7-14-27-26(28)13-8-16-31-27)21-32-17-19-33(20-18-32)30(35)29(23-9-3-1-4-10-23)24-11-5-2-6-12-24;5-3(6)1-2-4(7)8/h1-16,25,29,34H,17-22H2;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMWMHU7	CS	C1CN(CCN1CC(COC2=CC=CC3=C2C=CC=N3)O)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5.C(=C/C(=O)O)\\C(=O)O
DMWMHU7	IK	QIAVTDQTRFYXSD-WLHGVMLRSA-N
DMWMHU7	IU	(E)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone
DMWMHU7	DE	Solid tumour/cancer

DMJOM31	ID	DMJOM31
DMJOM31	DN	ELGODIPINE HYDROCHLORIDE
DMJOM31	HS	Discontinued in Phase 3
DMJOM31	SN	IQB-875; Elgodipine hydrochloride; Rac-2,6-Dimethyl-4-(2,3-methylenedioxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-isopropyl 5-[2-[N-(4-fluorobenzyl)-N-methylamino]ethyl] diester monohydrochloride
DMJOM31	DT	Small molecular drug
DMJOM31	PC	3078492
DMJOM31	MW	561
DMJOM31	FM	C29H34ClFN2O6
DMJOM31	IC	InChI=1S/C29H33FN2O6.ClH/c1-17(2)38-29(34)25-19(4)31-18(3)24(26(25)22-7-6-8-23-27(22)37-16-36-23)28(33)35-14-13-32(5)15-20-9-11-21(30)12-10-20;/h6-12,17,26,31H,13-16H2,1-5H3;1H
DMJOM31	CS	CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=C3C(=CC=C2)OCO3)C(=O)OCCN(C)CC4=CC=C(C=C4)F.Cl
DMJOM31	IK	JBKDMKOYLBVOOR-UHFFFAOYSA-N
DMJOM31	IU	3-O-[2-[(4-fluorophenyl)methyl-methylamino]ethyl] 5-O-propan-2-yl 4-(1,3-benzodioxol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride
DMJOM31	CA	CAS 121489-04-1
DMJOM31	DE	Angina pectoris

DM38CIV	ID	DM38CIV
DM38CIV	DN	ELTANOLONE
DM38CIV	HS	Discontinued in Phase 3
DM38CIV	SN	Pregnanolone; 3alpha-Hydroxy-5beta-pregnan-20-one; 128-20-1; Pregnanolone II; Pregnan-3alpha-ol-20-one; Eltanolona; Eltanolonum; 5beta-Pregnan-3alpha-ol-20-one; Eltanolone [INN]; SKF 6455; NSC 82867; UNII-BXO86P3XXW; Eltanolonum [INN-Latin]; Eltanolona [INN-Spanish]; Allopregnan-3 beta-ol-20-one; (3alpha,5beta)-3-hydroxypregnan-20-one; 3alpha-Hydroxy-5beta-tetrahydroprogesterone; 3alpha,5beta-Epimeric pregnanolone; Pregnanolone, (3alpha,5beta)-isomer; BXO86P3XXW
DM38CIV	DT	Small molecular drug
DM38CIV	PC	31402
DM38CIV	MW	318.5
DM38CIV	FM	C21H34O2
DM38CIV	IC	InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16+,17-,18+,19+,20+,21-/m1/s1
DM38CIV	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C
DM38CIV	IK	AURFZBICLPNKBZ-YZRLXODZSA-N
DM38CIV	IU	1-[(3R,5R,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DM38CIV	CA	CAS 128-20-1
DM38CIV	CB	CHEBI:1712
DM38CIV	DE	Premenstrual syndrome

DM5JUW0	ID	DM5JUW0
DM5JUW0	DN	EM-800
DM5JUW0	HS	Discontinued in Phase 3
DM5JUW0	SN	EM-800; UNII-XCR716LECP; XCR716LECP; 182167-03-9; Em 800; SCH 57050; BIDD:ER0061; SCHEMBL1821303; CHEMBL308234; 189021-25-8; (s)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-meth-yl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2h-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate
DM5JUW0	DT	Small molecular drug
DM5JUW0	PC	9873952
DM5JUW0	MW	625.8
DM5JUW0	FM	C39H47NO6
DM5JUW0	IC	InChI=1S/C39H47NO6/c1-26-32-20-19-31(45-37(42)39(5,6)7)25-33(32)46-35(34(26)27-11-17-30(18-12-27)44-36(41)38(2,3)4)28-13-15-29(16-14-28)43-24-23-40-21-9-8-10-22-40/h11-20,25,35H,8-10,21-24H2,1-7H3/t35-/m0/s1
DM5JUW0	CS	CC1=C([C@@H](OC2=C1C=CC(=C2)OC(=O)C(C)(C)C)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)OC(=O)C(C)(C)C
DM5JUW0	IK	OEKMGABCSLYWOP-DHUJRADRSA-N
DM5JUW0	IU	[4-[(2S)-7-(2,2-dimethylpropanoyloxy)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-3-yl]phenyl] 2,2-dimethylpropanoate
DM5JUW0	CA	CAS 182167-03-9
DM5JUW0	DE	Estrogen deficiency

DMCU1WO	ID	DMCU1WO
DMCU1WO	DN	Eperezolid
DMCU1WO	HS	Discontinued in Phase 3
DMCU1WO	SN	PNU-100592; U-100592
DMCU1WO	CP	Pharmacia & Upjohn Co
DMCU1WO	DT	Small molecular drug
DMCU1WO	PC	73214
DMCU1WO	MW	394.4
DMCU1WO	FM	C18H23FN4O5
DMCU1WO	IC	InChI=1S/C18H23FN4O5/c1-12(25)20-9-14-10-23(18(27)28-14)13-2-3-16(15(19)8-13)21-4-6-22(7-5-21)17(26)11-24/h2-3,8,14,24H,4-7,9-11H2,1H3,(H,20,25)/t14-/m0/s1
DMCU1WO	CS	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCN(CC3)C(=O)CO)F
DMCU1WO	IK	SIMWTRCFFSTNMG-AWEZNQCLSA-N
DMCU1WO	IU	N-[[(5S)-3-[3-fluoro-4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
DMCU1WO	CA	CAS 165800-04-4
DMCU1WO	DE	Bacterial infection

DMM5ZX6	ID	DMM5ZX6
DMM5ZX6	DN	Epothilone B
DMM5ZX6	HS	Discontinued in Phase 3
DMM5ZX6	SN	Epothilone B; Patupilone; 152044-54-7; (-)-Epothilone B; Epo B; EpoB; EPO906; EPO 906; UNII-UEC0H0URSE; EPO 906A; GNF-PF-193; CHEBI:31550; UEC0H0URSE; AK163080; Epothilone B (EPO906, Patupilone); 7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-[1-METHYL-2-(2-METHYL-THIAZOL-4-YL)VINYL]-4,17-DIOXABICYCLO[14.1.0]HEPTADECANE-5,9-DIONE; Epothilon B; Patupilone [INN]; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMM5ZX6	DT	Small molecular drug
DMM5ZX6	PC	448013
DMM5ZX6	MW	507.7
DMM5ZX6	FM	C27H41NO6S
DMM5ZX6	IC	InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1
DMM5ZX6	CS	C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C
DMM5ZX6	IK	QXRSDHAAWVKZLJ-PVYNADRNSA-N
DMM5ZX6	IU	(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMM5ZX6	CA	CAS 152044-54-7
DMM5ZX6	CB	CHEBI:31550
DMM5ZX6	DE	Solid tumour/cancer

DM3OUT0	ID	DM3OUT0
DM3OUT0	DN	Etarotene
DM3OUT0	HS	Discontinued in Phase 3
DM3OUT0	SN	Ro-15-1570; Ro-15-1570/000
DM3OUT0	CP	Roche Holding AG
DM3OUT0	DT	Small molecular drug
DM3OUT0	PC	6435463
DM3OUT0	MW	396.6
DM3OUT0	FM	C25H32O2S
DM3OUT0	IC	InChI=1S/C25H32O2S/c1-7-28(26,27)21-11-8-19(9-12-21)16-18(2)20-10-13-22-23(17-20)25(5,6)15-14-24(22,3)4/h8-13,16-17H,7,14-15H2,1-6H3/b18-16+
DM3OUT0	CS	CCS(=O)(=O)C1=CC=C(C=C1)/C=C(\\C)/C2=CC3=C(C=C2)C(CCC3(C)C)(C)C
DM3OUT0	IK	UDAZCXVIYSIEFX-FBMGVBCBSA-N
DM3OUT0	IU	6-[(E)-1-(4-ethylsulfonylphenyl)prop-1-en-2-yl]-1,1,4,4-tetramethyl-2,3-dihydronaphthalene
DM3OUT0	CA	CAS 87719-32-2
DM3OUT0	DE	Psoriasis vulgaris

DMF93U1	ID	DMF93U1
DMF93U1	DN	Etilevodopa
DMF93U1	HS	Discontinued in Phase 3
DMF93U1	SN	LDEE; ND-0601; TV-1203; Levodopa-ethyl-ester; Levodopa prodrug (transdermal, Parkinson's disease); Levodopa prodrug (transdermal, Parkinson's disease), NeuroDerm; L-DOPA prodrug (transdermal, Parkinson's disease), NeuroDerm; Levodopa ester, (transdermal, Parkinson's disease), NeuroDerm
DMF93U1	CP	Hebrew University of Jerusalem; NeuroDerm Ltd
DMF93U1	DT	Small molecular drug
DMF93U1	PC	170345
DMF93U1	MW	225.24
DMF93U1	FM	C11H15NO4
DMF93U1	IC	InChI=1S/C11H15NO4/c1-2-16-11(15)8(12)5-7-3-4-9(13)10(14)6-7/h3-4,6,8,13-14H,2,5,12H2,1H3/t8-/m0/s1
DMF93U1	CS	CCOC(=O)[C@H](CC1=CC(=C(C=C1)O)O)N
DMF93U1	IK	NULMGOSOSZBEQL-QMMMGPOBSA-N
DMF93U1	IU	ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
DMF93U1	CA	CAS 37178-37-3
DMF93U1	CB	CHEBI:135971
DMF93U1	DE	Parkinson disease

DM159U2	ID	DM159U2
DM159U2	DN	Evernimicin
DM159U2	HS	Discontinued in Phase 3
DM159U2	SN	Everninomicin; Everninomycin; Everninomycins; Ziracin; Evernimicin [USAN:INN]; Sch-27899; Antibiotic 13-384-1
DM159U2	CP	Schering-Plough
DM159U2	DT	Small molecular drug
DM159U2	PC	6917933
DM159U2	MW	1631.4
DM159U2	FM	C70H97Cl2NO38
DM159U2	IC	InChI=1S/C70H97Cl2NO38/c1-24-15-31(74)16-32(75)40(24)61(82)100-36-22-94-70(60-53(36)92-23-93-60)108-37-21-91-63(46(79)52(37)109-70)106-65-56(89-13)45(78)51(35(101-65)20-86-10)104-64-47(80)55(50(87-11)27(4)97-64)105-66-57(81)68(9)59(30(7)98-66)110-69(111-68)18-33(76)48(28(5)107-69)102-38-17-34(99-39-19-67(8,73(84)85)58(90-14)29(6)96-39)49(26(3)95-38)103-62(83)41-25(2)42(71)44(77)43(72)54(41)88-12/h15-16,26-30,33-39,45-53,55-60,63-66,74-81H,17-23H2,1-14H3/t26-,27-,28-,29+,30-,33-,34-,35-,36-,37+,38+,39+,45+,46-,47-,48-,49-,50+,51-,52-,53+,55-,56+,57-,58+,59-,60-,63+,64+,65+,66+,67+,68-,69-,70-/m1/s1
DM159U2	CS	C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@]3(C[C@H]2O)O[C@@H]4[C@H](O[C@H]([C@H]([C@]4(O3)C)O)O[C@@H]5[C@H]([C@@H](O[C@@H]([C@@H]5OC)C)O[C@@H]6[C@H](O[C@H]([C@H]([C@H]6O)OC)O[C@H]7[C@@H]([C@H]8[C@H](CO7)O[C@@]9(O8)[C@H]1[C@H]([C@@H](CO9)OC(=O)C2=C(C=C(C=C2C)O)O)OCO1)O)COC)O)C)C)O[C@H]1C[C@]([C@H]([C@@H](O1)C)OC)(C)[N+](=O)[O-])OC(=O)C1=C(C(=C(C(=C1OC)Cl)O)Cl)C
DM159U2	IK	UPADRKHAIMTUCC-OWALTSPQSA-N
DM159U2	IU	[(2R,3R,4R,6S)-6-[(2R,2'R,3'S,3aR,4R,4'R,6S,7S,7aR)-6-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5S,6S)-6-[(3aR,3'aS,4R,6'S,7R,7'R,7aS,7'aS)-7-(2,4-dihydroxy-6-methylbenzoyl)oxy-7'-hydroxyspiro[3a,6,7,7a-tetrahydro-[1,3]dioxolo[4,5-c]pyran-4,2'-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran]-6'-yl]oxy-4-hydroxy-5-methoxy-2-(methoxymethyl)oxan-3-yl]oxy-3-hydroxy-5-methoxy-6-methyloxan-4-yl]oxy-4',7-dihydroxy-2',4,7a-trimethylspiro[3a,4,6,7-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2,6'-oxane]-3'-yl]oxy-4-[(2S,4S,5R,6S)-5-methoxy-4,6-dimethyl-4-nitrooxan-2-yl]oxy-2-methyloxan-3-yl] 3,5-dichloro-4-hydroxy-2-methoxy-6-methylbenzoate
DM159U2	CA	CAS 109545-84-8
DM159U2	DE	Bacterial infection

DMOIP7R	ID	DMOIP7R
DMOIP7R	DN	Flesinoxan
DMOIP7R	HS	Discontinued in Phase 3
DMOIP7R	SN	Flesinoxan hydrochloride; DU-29373
DMOIP7R	CP	Solvay Pharmaceuticals BV
DMOIP7R	DT	Small molecular drug
DMOIP7R	PC	57347
DMOIP7R	MW	415.5
DMOIP7R	FM	C22H26FN3O4
DMOIP7R	IC	InChI=1S/C22H26FN3O4/c23-17-6-4-16(5-7-17)22(28)24-8-9-25-10-12-26(13-11-25)19-2-1-3-20-21(19)29-15-18(14-27)30-20/h1-7,18,27H,8-15H2,(H,24,28)/t18-/m0/s1
DMOIP7R	CS	C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)F)C3=C4C(=CC=C3)O[C@H](CO4)CO
DMOIP7R	IK	NYSDRDDQELAVKP-SFHVURJKSA-N
DMOIP7R	IU	4-fluoro-N-[2-[4-[(2S)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl]ethyl]benzamide
DMOIP7R	CA	CAS 98206-10-1
DMOIP7R	DE	Anxiety disorder

DMN1O7E	ID	DMN1O7E
DMN1O7E	DN	FLUPAROXAN
DMN1O7E	HS	Discontinued in Phase 3
DMN1O7E	SN	Fluparoxan < Rec INN; GR-50360A (HCl); (3aS,9aS)-5-Fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]benzodioxino[2,3-c]pyrrole
DMN1O7E	DT	Small molecular drug
DMN1O7E	PC	72036
DMN1O7E	MW	195.19
DMN1O7E	FM	C10H10FNO2
DMN1O7E	IC	InChI=1S/C10H10FNO2/c11-6-2-1-3-7-10(6)14-9-5-12-4-8(9)13-7/h1-3,8-9,12H,4-5H2/t8-,9-/m0/s1
DMN1O7E	CS	C1[C@H]2[C@H](CN1)OC3=C(O2)C=CC=C3F
DMN1O7E	IK	XSOUHEXVEOQRKJ-IUCAKERBSA-N
DMN1O7E	IU	(3aS,9aS)-5-fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]benzodioxino[2,3-c]pyrrole
DMN1O7E	CA	CAS 105182-45-4
DMN1O7E	DE	Depression

DML1DGP	ID	DML1DGP
DML1DGP	DN	FOROPAFANT
DML1DGP	HS	Discontinued in Phase 3
DML1DGP	SN	SR-27417; Foropafant; 2-[N-[2-(Dimethylamino)ethyl]-N-(3-pyridylmethyl)amino]-4-(2,4,6-triisopropylphenyl)thiazole
DML1DGP	DT	Small molecular drug
DML1DGP	PC	119368
DML1DGP	MW	464.7
DML1DGP	FM	C28H40N4S
DML1DGP	IC	InChI=1S/C28H40N4S/c1-19(2)23-14-24(20(3)4)27(25(15-23)21(5)6)26-18-33-28(30-26)32(13-12-31(7)8)17-22-10-9-11-29-16-22/h9-11,14-16,18-21H,12-13,17H2,1-8H3
DML1DGP	CS	CC(C)C1=CC(=C(C(=C1)C(C)C)C2=CSC(=N2)N(CCN(C)C)CC3=CN=CC=C3)C(C)C
DML1DGP	IK	VVBFISAUNSXQGZ-UHFFFAOYSA-N
DML1DGP	IU	N,N-dimethyl-N'-(pyridin-3-ylmethyl)-N'-[4-[2,4,6-tri(propan-2-yl)phenyl]-1,3-thiazol-2-yl]ethane-1,2-diamine
DML1DGP	CA	CAS 136468-36-5
DML1DGP	DE	Asthma

DME94QF	ID	DME94QF
DME94QF	DN	Furnidipine
DME94QF	HS	Discontinued in Phase 3
DME94QF	SN	Furaldipine; CRE-319
DME94QF	CP	Cermol SA
DME94QF	DT	Small molecular drug
DME94QF	PC	65988
DME94QF	MW	416.4
DME94QF	FM	C21H24N2O7
DME94QF	IC	InChI=1S/C21H24N2O7/c1-12-17(20(24)28-3)19(15-8-4-5-9-16(15)23(26)27)18(13(2)22-12)21(25)30-11-14-7-6-10-29-14/h4-5,8-9,14,19,22H,6-7,10-11H2,1-3H3
DME94QF	CS	CC1=C(C(C(=C(N1)C)C(=O)OCC2CCCO2)C3=CC=CC=C3[N+](=O)[O-])C(=O)OC
DME94QF	IK	GGVUNNUOJDGCBK-UHFFFAOYSA-N
DME94QF	IU	3-O-methyl 5-O-(oxolan-2-ylmethyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DME94QF	CA	CAS 138661-03-7
DME94QF	DE	Nerve injury

DMNSE2I	ID	DMNSE2I
DMNSE2I	DN	Galocitabine
DMNSE2I	HS	Discontinued in Phase 3
DMNSE2I	SN	Galocitabine; Ro-09-1390; N-[1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydro-4-pyrimidinyl]-3,4,5-trimethoxybenzamide; 5'-Deoxy-5-fluoro-N4-(3,4,5-trimethoxybenzoyl)cytidine
DMNSE2I	DT	Small molecular drug
DMNSE2I	PC	65950
DMNSE2I	MW	439.4
DMNSE2I	FM	C19H22FN3O8
DMNSE2I	IC	InChI=1S/C19H22FN3O8/c1-8-13(24)14(25)18(31-8)23-7-10(20)16(22-19(23)27)21-17(26)9-5-11(28-2)15(30-4)12(6-9)29-3/h5-8,13-14,18,24-25H,1-4H3,(H,21,22,26,27)/t8-,13-,14-,18-/m1/s1
DMNSE2I	CS	C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=NC2=O)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC)F)O)O
DMNSE2I	IK	TVYPSLDUBVTDIS-FUOMVGGVSA-N
DMNSE2I	IU	N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide
DMNSE2I	CA	CAS 124012-42-6
DMNSE2I	DE	Solid tumour/cancer

DMJ4KQS	ID	DMJ4KQS
DMJ4KQS	DN	GW-406381
DMJ4KQS	HS	Discontinued in Phase 3
DMJ4KQS	SN	GW 406381; GW406381; 8-(4-ethoxyphenyl)-7-(4-methylsulfonylphenyl)-1,2,9-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene
DMJ4KQS	CP	GlaxoSmithKline
DMJ4KQS	TC	Analgesics
DMJ4KQS	DT	Small molecular drug
DMJ4KQS	PC	9832687
DMJ4KQS	MW	393.5
DMJ4KQS	FM	C21H19N3O3S
DMJ4KQS	IC	InChI=1S/C21H19N3O3S/c1-3-27-17-10-6-16(7-11-17)21-20(19-5-4-14-22-24(19)23-21)15-8-12-18(13-9-15)28(2,25)26/h4-14H,3H2,1-2H3
DMJ4KQS	CS	CCOC1=CC=C(C=C1)C2=NN3C(=C2C4=CC=C(C=C4)S(=O)(=O)C)C=CC=N3
DMJ4KQS	IK	NXMZBNYLCVTRGB-UHFFFAOYSA-N
DMJ4KQS	IU	2-(4-ethoxyphenyl)-3-(4-methylsulfonylphenyl)pyrazolo[1,5-b]pyridazine
DMJ4KQS	CA	CAS 221148-46-5
DMJ4KQS	DE	Neuropathic pain; Osteoarthritis

DMG6TS2	ID	DMG6TS2
DMG6TS2	DN	GW873140
DMG6TS2	HS	Discontinued in Phase 3
DMG6TS2	SN	Aplaviroc; Aplaviroc HCl; Aplaviroc hydrochloride; AK 602; AK602; GSK873140; GW 873140; ONO 4128; AK-602; Aplaviroc hydrochloride (USAN); GW-873140; ONO-4128; Benzoic acid, 4-[4-[[1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-& Soluble CD4; 4-[4-[[(9R)-11-butyl-9-[(R)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid; 4-[4-[[(9R)-11-butyl-9-[(R)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid hydrochloride; 873140 Compound
DMG6TS2	CP	GlaxoSmithKline
DMG6TS2	DT	Small molecular drug
DMG6TS2	PC	3001322
DMG6TS2	MW	577.7
DMG6TS2	FM	C33H43N3O6
DMG6TS2	IC	InChI=1S/C33H43N3O6/c1-2-3-19-36-30(38)28(29(37)24-7-5-4-6-8-24)34-32(41)33(36)17-20-35(21-18-33)22-23-9-13-26(14-10-23)42-27-15-11-25(12-16-27)31(39)40/h9-16,24,28-29,37H,2-8,17-22H2,1H3,(H,34,41)(H,39,40)/t28-,29-/m1/s1
DMG6TS2	CS	CCCCN1C(=O)[C@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@@H](C5CCCCC5)O
DMG6TS2	IK	GWNOTCOIYUNTQP-FQLXRVMXSA-N
DMG6TS2	IU	4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid
DMG6TS2	CA	CAS 461443-59-4
DMG6TS2	DE	Human immunodeficiency virus-1 infection

DMWB23S	ID	DMWB23S
DMWB23S	DN	H1N1 influenza vaccine
DMWB23S	HS	Discontinued in Phase 3
DMWB23S	SN	GC-1116; Greenflu-S Plus; H1N1 influenza vaccine (MF59-adjuvanted); H1N1 influenza vaccine (MF59-adjuvanted), Korea Green Cross
DMWB23S	CP	Green Cross Corp
DMWB23S	DT	Vaccine
DMWB23S	DE	Influenza virus infection

DMX3IRE	ID	DMX3IRE
DMX3IRE	DN	HBP-347
DMX3IRE	HS	Discontinued in Phase 3
DMX3IRE	SN	HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University
DMX3IRE	CP	Weizmann Institute of Science
DMX3IRE	DE	Autoimmune diabetes

DMGYKDN	ID	DMGYKDN
DMGYKDN	DN	Hemoximer
DMGYKDN	HS	Discontinued in Phase 3
DMGYKDN	SN	PHP-CT; PHP-HT; PHP-OC; Pyridoxalated hemoglobin polyoxyethylene-CT; Pyridoxalated hemoglobin polyoxyethylene-HT; Pyridoxalated hemoglobin polyoxyethylene-OC; VTR-PHP
DMGYKDN	CP	Ajinomoto Co Inc
DMGYKDN	DE	Hypotension

DMRXUY7	ID	DMRXUY7
DMRXUY7	DN	Idoxifene
DMRXUY7	HS	Discontinued in Phase 3
DMRXUY7	SN	CB-7432; SB-223030
DMRXUY7	CP	Institute of Cancer Research UK
DMRXUY7	DT	Small molecular drug
DMRXUY7	PC	3034011
DMRXUY7	MW	523.4
DMRXUY7	FM	C28H30INO
DMRXUY7	IC	InChI=1S/C28H30INO/c1-2-27(22-8-4-3-5-9-22)28(23-10-14-25(29)15-11-23)24-12-16-26(17-13-24)31-21-20-30-18-6-7-19-30/h3-5,8-17H,2,6-7,18-21H2,1H3/b28-27-
DMRXUY7	CS	CC/C(=C(/C1=CC=C(C=C1)OCCN2CCCC2)\\C3=CC=C(C=C3)I)/C4=CC=CC=C4
DMRXUY7	IK	JJKOTMDDZAJTGQ-DQSJHHFOSA-N
DMRXUY7	IU	1-[2-[4-[(E)-1-(4-iodophenyl)-2-phenylbut-1-enyl]phenoxy]ethyl]pyrrolidine
DMRXUY7	CA	CAS 116057-75-1
DMRXUY7	DE	Breast cancer

DM3SKAC	ID	DM3SKAC
DM3SKAC	DN	Idraparinux
DM3SKAC	HS	Discontinued in Phase 3
DM3SKAC	SN	SR 34006; SR-34006
DM3SKAC	CP	Sanofi-Aventis
DM3SKAC	DT	Small molecular drug
DM3SKAC	PC	3083445
DM3SKAC	MW	1529.4
DM3SKAC	FM	C38H64O49S7
DM3SKAC	IC	InChI=1S/C38H64O49S7/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-/m1/s1
DM3SKAC	CS	CO[C@@H]1[C@H](O[C@@H]([C@@H]([C@H]1OC)OC)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]4[C@@H]([C@H]([C@@H](O[C@H]4C(=O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5OS(=O)(=O)O)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O
DM3SKAC	IK	AJBMORBNKXNZSF-COSHMZDQSA-N
DM3SKAC	IU	(2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxyoxane-2-carboxylic acid
DM3SKAC	CA	CAS 162610-17-5
DM3SKAC	DE	Thrombosis

DMDEL2W	ID	DMDEL2W
DMDEL2W	DN	Iferanserin-Ventrus
DMDEL2W	HS	Discontinued in Phase 3
DMDEL2W	SN	VEN 309; VEN-309
DMDEL2W	CP	Ventrus Biosciences
DMDEL2W	DE	Hemorrhoids

DM8KSMX	ID	DM8KSMX
DM8KSMX	DN	IMIRESTAT
DM8KSMX	HS	Discontinued in Phase 3
DM8KSMX	SN	Imirestat; 89391-50-4; Imirestat [INN]; Alcon 1576; HOE 843; Imirestatum [INN-Latin]; Hoe-843; UNII-0PM69S95UQ; AL 1576; C15H8F2N2O2; AL-1576; 0PM69S95UQ; CHEMBL269455; 2,7-Difluorospiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione; Imirestatum; 2,7-Difluorospiro(fluorene-9,4'-imidazolidine)-2',5'-dione; Spiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione, 2,7-difluoro-; Spiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione, 2,7-difluoro-; AL-theta-1576; ALO1576; AL1576; SCHEMBL49034; ZINC3724; AC1L23Q8; DTXSID80237635
DM8KSMX	DT	Small molecular drug
DM8KSMX	PC	65673
DM8KSMX	MW	286.23
DM8KSMX	FM	C15H8F2N2O2
DM8KSMX	IC	InChI=1S/C15H8F2N2O2/c16-7-1-3-9-10-4-2-8(17)6-12(10)15(11(9)5-7)13(20)18-14(21)19-15/h1-6H,(H2,18,19,20,21)
DM8KSMX	CS	C1=CC2=C(C=C1F)C3(C4=C2C=CC(=C4)F)C(=O)NC(=O)N3
DM8KSMX	IK	QCCHBHSAIQIQGO-UHFFFAOYSA-N
DM8KSMX	IU	2,7-difluorospiro[fluorene-9,5'-imidazolidine]-2',4'-dione
DM8KSMX	CA	CAS 89391-50-4
DM8KSMX	DE	Diabetic complication

DMTHMEI	ID	DMTHMEI
DMTHMEI	DN	INS 316
DMTHMEI	HS	Discontinued in Phase 3
DMTHMEI	SN	Uridine 5'-triphosphate; uridine 5'-triphosphate; uridine triphosphate; 63-39-8; Uteplex; UTP; Uridine 5'-(tetrahydrogen triphosphate); 5'-UTP; Uridine 5'-triphosphoric acid; H4utp; UNII-UT0S826Z60; BRN 0071520; INS316; EINECS 200-558-7; uridine-5'-triphosphate; CHEMBL336296; CHEBI:15713; UT0S826Z60; Uridine5'-(tetrahydrogen triphosphate); [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate; uridine5'-triphosphate; uridintriphosphat; uridine tetrahydrogen
DMTHMEI	CP	Inspire Pharmaceuticals
DMTHMEI	DT	Small molecular drug
DMTHMEI	PC	6133
DMTHMEI	MW	484.14
DMTHMEI	FM	C9H15N2O15P3
DMTHMEI	IC	InChI=1S/C9H15N2O15P3/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DMTHMEI	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMTHMEI	IK	PGAVKCOVUIYSFO-XVFCMESISA-N
DMTHMEI	IU	[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMTHMEI	CA	CAS 63-39-8
DMTHMEI	CB	CHEBI:15713
DMTHMEI	DE	Lung cancer

DMVL8PB	ID	DMVL8PB
DMVL8PB	DN	IoGen
DMVL8PB	HS	Discontinued in Phase 3
DMVL8PB	SN	Oral iodine-based therapy (fibrocystic breast disease), Symbollon; Oral iodine-based therapy (fibrocystic breast disease), Symbollon/Gardant
DMVL8PB	CP	Symbollon Pharmaceuticals
DMVL8PB	DE	Pain

DM7SA9J	ID	DM7SA9J
DM7SA9J	DN	IR-103
DM7SA9J	HS	Discontinued in Phase 3
DM7SA9J	SN	HIV vaccine + Amplivax, IRC; HIV vaccine + Amplivax, Immune Response Corp; HIV vaccine + HYB-2055, IRC; HIV vaccine + HYB-2055, Immune Response Corp; Vaccine (HIV) + Amplivax, IRC; Vaccine (HIV) + Amplivax, Immune Response Corp; Vaccine (HIV) + HYB-2055, IRC; Vaccine (HIV) + HYB-2055, Immune Response Corp
DM7SA9J	CP	Immune Response BioPharma Inc
DM7SA9J	DT	Vaccine
DM7SA9J	DE	Human immunodeficiency virus infection

DMUYQH8	ID	DMUYQH8
DMUYQH8	DN	IRX-4310
DMUYQH8	HS	Discontinued in Phase 3
DMUYQH8	SN	AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310; RARa antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics; Retinoic acid receptor alpha antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics
DMUYQH8	CP	Io Therapeutics Inc
DMUYQH8	DE	Psoriasis vulgaris

DM1AFPW	ID	DM1AFPW
DM1AFPW	DN	KC-764
DM1AFPW	HS	Discontinued in Phase 3
DM1AFPW	SN	(2-Methylpyrazolo[1,5-a]pyridin-3-yl)(1,4,5,6-tetrahydro-3-pyridyl)methanone; 2-Methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine; 2-Methyl-3-(1,4,5,6-tetrahydropyridin-3-ylcarbonyl)pyrazolo[1,5-a]pyridine; 94457-09-7
DM1AFPW	DT	Small molecular drug
DM1AFPW	PC	146826
DM1AFPW	MW	241.29
DM1AFPW	FM	C14H15N3O
DM1AFPW	IC	InChI=1S/C14H15N3O/c1-10-13(12-6-2-3-8-17(12)16-10)14(18)11-5-4-7-15-9-11/h2-3,6,8-9,15H,4-5,7H2,1H3
DM1AFPW	CS	CC1=NN2C=CC=CC2=C1C(=O)C3=CNCCC3
DM1AFPW	IK	SLMUMPSLUWOXAO-UHFFFAOYSA-N
DM1AFPW	IU	(2-methylpyrazolo[1,5-a]pyridin-3-yl)-(1,2,3,4-tetrahydropyridin-5-yl)methanone
DM1AFPW	CA	CAS 94457-09-7
DM1AFPW	DE	Platelet aggregation disorder

DMZMFX6	ID	DMZMFX6
DMZMFX6	DN	KU-1257
DMZMFX6	HS	Discontinued in Phase 3
DMZMFX6	SN	Dalcotidine; 120958-90-9; UNII-9968S2UKFJ; KU-1257; KU 1257; 9968S2UKFJ; NCGC00182982-01; Dalcotidine [INN]; Dalcotidine (JAN/INN); AC1L2VE9; DSSTox_RID_83001; DSSTox_CID_28732; DSSTox_GSID_48806; CHEMBL311206; SCHEMBL1815082; N-Ethyl-N'-(3-(3-(piperidinomethyl)phenoxy)propyl)urea; DTXSID4048806; CHEBI:31454; 1-ethyl-3-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]urea; ZINC1889603; Tox21_113283; BDBM50406670; CAS-120958-90-9; D01698; L002431; A1-04840; 1-Ethyl-3-(3-((alpha-piperidino-m-tolyl)oxy)propyl)urea; Urea, N-ethyl-N'-(3-(3-(1-p
DMZMFX6	CP	Kyorin Pharmaceutical Co Ltd
DMZMFX6	DT	Small molecular drug
DMZMFX6	PC	129319
DMZMFX6	MW	319.4
DMZMFX6	FM	C18H29N3O2
DMZMFX6	IC	InChI=1S/C18H29N3O2/c1-2-19-18(22)20-10-7-13-23-17-9-6-8-16(14-17)15-21-11-4-3-5-12-21/h6,8-9,14H,2-5,7,10-13,15H2,1H3,(H2,19,20,22)
DMZMFX6	CS	CCNC(=O)NCCCOC1=CC=CC(=C1)CN2CCCCC2
DMZMFX6	IK	SVCQBXMFONNZHX-UHFFFAOYSA-N
DMZMFX6	IU	1-ethyl-3-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]urea
DMZMFX6	CA	CAS 120958-90-9
DMZMFX6	CB	CHEBI:31454
DMZMFX6	DE	Duodenal ulcer

DMQZ6SE	ID	DMQZ6SE
DMQZ6SE	DN	KW-2149
DMQZ6SE	HS	Discontinued in Phase 3
DMQZ6SE	SN	KT-6149; E-90/007; Mitomycin C derivatives (cancer), Kyowa
DMQZ6SE	CP	Kyowa Hakko Kogyo Co Ltd
DMQZ6SE	DT	Small molecular drug
DMQZ6SE	PC	108151
DMQZ6SE	MW	598.7
DMQZ6SE	FM	C24H34N6O8S2
DMQZ6SE	IC	InChI=1S/C24H34N6O8S2/c1-11-17(28-6-8-40-39-7-5-27-15(31)4-3-13(25)22(34)35)20(33)16-12(10-38-23(26)36)24(37-2)21-14(29-21)9-30(24)18(16)19(11)32/h12-14,21,28-29H,3-10,25H2,1-2H3,(H2,26,36)(H,27,31)(H,34,35)/t12-,13+,14+,21+,24-/m1/s1
DMQZ6SE	CS	CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)NCCSSCCNC(=O)CC[C@@H](C(=O)O)N
DMQZ6SE	IK	BIOSTZMAOGCGSC-CYUGEGSCSA-N
DMQZ6SE	IU	(2S)-2-amino-5-[2-[2-[[(4S,6S,7R,8S)-8-(carbamoyloxymethyl)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-11-yl]amino]ethyldisulfanyl]ethylamino]-5-oxopentanoic acid
DMQZ6SE	CA	CAS 118359-59-4
DMQZ6SE	DE	Solid tumour/cancer

DMXWRGF	ID	DMXWRGF
DMXWRGF	DN	L-759274
DMXWRGF	HS	Discontinued in Phase 3
DMXWRGF	CP	Merck
DMXWRGF	DE	Depression; Mood disorder

DM7RGFW	ID	DM7RGFW
DM7RGFW	DN	Lamectacin
DM7RGFW	HS	Discontinued in Phase 3
DM7RGFW	CP	AstraZeneca & NewBiotics
DM7RGFW	DT	Small molecular drug
DM7RGFW	PC	9873954
DM7RGFW	MW	625.9
DM7RGFW	FM	C26H19Cl3N2O6S2
DM7RGFW	IC	InChI=1S/C26H19Cl3N2O6S2/c27-14-3-5-18(17(29)8-14)37-19-6-4-15(28)9-20(19)36-11-13-12-39-25-22(24(33)31(25)23(13)26(34)35)30-21(32)10-16-2-1-7-38-16/h1-9,22,25H,10-12H2,(H,30,32)(H,34,35)/t22-,25-/m1/s1
DM7RGFW	CS	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CS3)C(=O)O)COC4=C(C=CC(=C4)Cl)OC5=C(C=C(C=C5)Cl)Cl
DM7RGFW	IK	XKYWDADJBIQZBT-RCZVLFRGSA-N
DM7RGFW	IU	(6R,7R)-3-[[5-chloro-2-(2,4-dichlorophenoxy)phenoxy]methyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7RGFW	DE	Bacterial infection

DMHR1A7	ID	DMHR1A7
DMHR1A7	DN	LAMIFIBAN
DMHR1A7	HS	Discontinued in Phase 3
DMHR1A7	SN	Lamifiban; UNII-9XOE28082S; Ro-44-9883; CHEMBL108111; 144412-49-7; 9XOE28082S; Lamifiban [USAN:INN]; Ro 44-9883/000; Lamstat; AC1MI4XF; SCHEMBL4683; ((1-(N-(p-Amidinobenzoyl)-L-tyrosyl)-4-piperidyl)oxy)acetic acid; FPKOGTAFKSLZLD-FQEVSTJZSA-N; 2-[1-[2-[(4-carbamimidoylbenzoyl)amino]-3-(4-hydroxyphenyl)propanoyl]piperidin-4-yl]oxyacetic acid; Acetic acid, ((1-(2-((4-(aminoiminomethyl)benzoyl)amino)-3-(4-hydroxyphenyl)-1-oxopropyl)-4-piperidinyl)oxy)-, (S)-; Acetic acid, ((1-(2-((4-aminoiminomethyl)benzoyl)amino)-3-(4-hydro
DMHR1A7	DT	Small molecular drug
DMHR1A7	PC	3038484
DMHR1A7	MW	468.5
DMHR1A7	FM	C24H28N4O6
DMHR1A7	IC	InChI=1S/C24H28N4O6/c25-22(26)16-3-5-17(6-4-16)23(32)27-20(13-15-1-7-18(29)8-2-15)24(33)28-11-9-19(10-12-28)34-14-21(30)31/h1-8,19-20,29H,9-14H2,(H3,25,26)(H,27,32)(H,30,31)/t20-/m0/s1
DMHR1A7	CS	C1CN(CCC1OCC(=O)O)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)C3=CC=C(C=C3)C(=N)N
DMHR1A7	IK	FPKOGTAFKSLZLD-FQEVSTJZSA-N
DMHR1A7	IU	2-[1-[(2S)-2-[(4-carbamimidoylbenzoyl)amino]-3-(4-hydroxyphenyl)propanoyl]piperidin-4-yl]oxyacetic acid
DMHR1A7	CA	CAS 144412-49-7
DMHR1A7	DE	Angina pectoris

DMJY9CW	ID	DMJY9CW
DMJY9CW	DN	Lapaquistat acetate
DMJY9CW	HS	Discontinued in Phase 3
DMJY9CW	SN	Lapaquistat acetate (USAN); TAK-475; 1-((1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid
DMJY9CW	CP	Takeda Chemical Industries
DMJY9CW	DT	Small molecular drug
DMJY9CW	PC	9874248
DMJY9CW	MW	645.1
DMJY9CW	FM	C33H41ClN2O9
DMJY9CW	IC	InChI=1S/C33H41ClN2O9/c1-20(37)44-19-33(2,3)18-36-25-10-9-22(34)16-24(25)30(23-7-6-8-26(42-4)31(23)43-5)45-27(32(36)41)17-28(38)35-13-11-21(12-14-35)15-29(39)40/h6-10,16,21,27,30H,11-15,17-19H2,1-5H3,(H,39,40)/t27-,30-/m1/s1
DMJY9CW	CS	CC(=O)OCC(C)(C)CN1C2=C(C=C(C=C2)Cl)[C@H](O[C@@H](C1=O)CC(=O)N3CCC(CC3)CC(=O)O)C4=C(C(=CC=C4)OC)OC
DMJY9CW	IK	CMLUGNQVANVZHY-POURPWNDSA-N
DMJY9CW	IU	2-[1-[2-[(3R,5S)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid
DMJY9CW	CA	CAS 189060-13-7
DMJY9CW	DE	Hyperlipidaemia

DM8CEDR	ID	DM8CEDR
DM8CEDR	DN	Laropiprant+niacin
DM8CEDR	HS	Discontinued in Phase 3
DM8CEDR	SN	Tredaptive (TN)
DM8CEDR	CP	Merck
DM8CEDR	DT	Small molecular drug
DM8CEDR	PC	11948701
DM8CEDR	MW	559
DM8CEDR	FM	C27H24ClFN2O6S
DM8CEDR	IC	InChI=1S/C21H19ClFNO4S.C6H5NO2/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12;8-6(9)5-2-1-3-7-4-5/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26);1-4H,(H,8,9)/t13-;/m1./s1
DM8CEDR	CS	CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F.C1=CC(=CN=C1)C(=O)O
DM8CEDR	IK	ZZRFQBQNZLFESZ-BTQNPOSSSA-N
DM8CEDR	IU	2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid;pyridine-3-carboxylic acid
DM8CEDR	CA	CAS 1046050-73-0
DM8CEDR	DE	Dyslipidemia

DMCM239	ID	DMCM239
DMCM239	DN	Larotaxel
DMCM239	HS	Discontinued in Phase 3
DMCM239	SN	Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881
DMCM239	CP	Sanofi-Aventis
DMCM239	DT	Small molecular drug
DMCM239	PC	6918260
DMCM239	MW	831.9
DMCM239	FM	C45H53NO14
DMCM239	IC	InChI=1S/C45H53NO14/c1-23-29(57-39(52)33(49)32(26-15-11-9-12-16-26)46-40(53)60-41(4,5)6)21-45(54)37(58-38(51)27-17-13-10-14-18-27)35-43(36(50)34(56-24(2)47)31(23)42(45,7)8)20-28(43)19-30-44(35,22-55-30)59-25(3)48/h9-18,28-30,32-35,37,49,54H,19-22H2,1-8H3,(H,46,53)/t28-,29+,30-,32+,33-,34-,35+,37+,43-,44+,45-/m1/s1
DMCM239	CS	CC1=C2[C@H](C(=O)[C@]34C[C@H]3C[C@@H]5[C@]([C@H]4[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C6=CC=CC=C6)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)OC(=O)C
DMCM239	IK	DXOJIXGRFSHVKA-BZVZGCBYSA-N
DMCM239	IU	[(1S,2S,3R,4S,7R,9S,11R,13R,16S)-4,13-diacetyloxy-1-hydroxy-16-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-15,18,18-trimethyl-12-oxo-6-oxapentacyclo[12.3.1.03,11.04,7.09,11]octadec-14-en-2-yl] benzoate
DMCM239	CA	CAS 156294-36-9
DMCM239	DE	Bladder cancer; Pancreatic cancer

DMKMTR7	ID	DMKMTR7
DMKMTR7	DN	LDI-200
DMKMTR7	HS	Discontinued in Phase 3
DMKMTR7	SN	Chorionic gonadotropin, Milkhaus; HCG, Milkhaus; Oncology therapeutics, Milkhaus
DMKMTR7	CP	Milkhaus Laboratory Inc
DMKMTR7	DE	leukaemia

DMN9KJ2	ID	DMN9KJ2
DMN9KJ2	DN	Lenercept
DMN9KJ2	HS	Discontinued in Phase 3
DMN9KJ2	SN	Tenefuse; RsTNFR-IgG1; Ro-45-2081; TNF receptor-Ig, Roche; TNFR-IgG1 fusion protein, Roche
DMN9KJ2	CP	Roche Holding AG
DMN9KJ2	DE	Asthma

DMWUS8N	ID	DMWUS8N
DMWUS8N	DN	Licarbazepine
DMWUS8N	HS	Discontinued in Phase 3
DMWUS8N	SN	GP 47779; GP-47779; (-)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-hydroxycarbamazepine; 10-HYDROXY-CARBAMAZEPINE; 10-Hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide; 10-Hydroxy-10,11-dihydrocarbamazepine; 10-Hydroxycarbamazepine; 10-Hydroxycarbazepine; 10-OH-Carbazepine; 5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMWUS8N	CP	Novartis
DMWUS8N	DT	Small molecular drug
DMWUS8N	PC	114709
DMWUS8N	MW	254.28
DMWUS8N	FM	C15H14N2O2
DMWUS8N	IC	InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)
DMWUS8N	CS	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
DMWUS8N	IK	BMPDWHIDQYTSHX-UHFFFAOYSA-N
DMWUS8N	IU	5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMWUS8N	CA	CAS 29331-92-8
DMWUS8N	CB	CHEBI:701
DMWUS8N	DE	Bipolar disorder

DM8OMI6	ID	DM8OMI6
DM8OMI6	DN	Lobucavir
DM8OMI6	HS	Discontinued in Phase 3
DM8OMI6	SN	LOBUCAVIR; 127759-89-1; Cyclobut-G; C-Oxetanocin-G; C-Oxt-G; BMS-180194; Cygalovir; (+)-Cyclobut G; 2-Amino-9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)-1H-purin-6(9H)-one; Lobucavir [USAN:INN]; SQ 33054; UNII-8U5PYQ1R2E; SQ 34,514; DRG-0235; 126062-18-8; 8U5PYQ1R2E; SQ-34514; Bms 180194; 9-((1R,2R,3S)-2,3-Bis(hydroxymethyl)cyclobutyl)guanine; C11H15N5O3; Carbocyclic oxetanocin G; A-69992; 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-3H-purin-6-one
DM8OMI6	CP	Bristol-Myers Squibb
DM8OMI6	DT	Small molecular drug
DM8OMI6	PC	135413519
DM8OMI6	MW	265.27
DM8OMI6	FM	C11H15N5O3
DM8OMI6	IC	InChI=1S/C11H15N5O3/c12-11-14-9-8(10(19)15-11)13-4-16(9)7-1-5(2-17)6(7)3-18/h4-7,17-18H,1-3H2,(H3,12,14,15,19)/t5-,6-,7-/m1/s1
DM8OMI6	CS	C1[C@@H]([C@H]([C@@H]1N2C=NC3=C2N=C(NC3=O)N)CO)CO
DM8OMI6	IK	GWFOVSGRNGAGDL-FSDSQADBSA-N
DM8OMI6	IU	2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-1H-purin-6-one
DM8OMI6	CA	CAS 127759-89-1
DM8OMI6	DE	Virus infection

DMHE804	ID	DMHE804
DMHE804	DN	LOTRAFIBAN
DMHE804	HS	Discontinued in Phase 3
DMHE804	SN	Lotrafiban; SB 214857; UNII-KLQ306I83X; 171049-14-2; SB-214857; CHEMBL356301; KLQ306I83X; DSSTox_CID_31391; R-Lotrafiban; Lotrafiban [INN]; AC1L2Z4G; DSSTox_RID_97278; DSSTox_RID_97279; DSSTox_GSID_57602; DSSTox_GSID_57603; SCHEMBL29596; CAS-NOCAS_57603; DTXSID7057602; ZINC3812598; Tox21_113990; Tox21_113989; BDBM50054825; SB-214857A; NCGC00319023-02; NCGC00319023-01; (2S)-7-((4,4'-Bipiperidin)-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid; KB-80491; SB-214134; CAS-171049-14-2
DMHE804	DT	Small molecular drug
DMHE804	PC	80274
DMHE804	MW	428.5
DMHE804	FM	C23H32N4O4
DMHE804	IC	InChI=1S/C23H32N4O4/c1-26-14-18-12-17(2-3-19(18)25-20(23(26)31)13-21(28)29)22(30)27-10-6-16(7-11-27)15-4-8-24-9-5-15/h2-3,12,15-16,20,24-25H,4-11,13-14H2,1H3,(H,28,29)/t20-/m0/s1
DMHE804	CS	CN1CC2=C(C=CC(=C2)C(=O)N3CCC(CC3)C4CCNCC4)N[C@H](C1=O)CC(=O)O
DMHE804	IK	PYZOVVQJTLOHDG-FQEVSTJZSA-N
DMHE804	IU	2-[(2S)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1H-1,4-benzodiazepin-2-yl]acetic acid
DMHE804	CA	CAS 171049-14-2
DMHE804	DE	Cardiovascular disease

DM2KITF	ID	DM2KITF
DM2KITF	DN	LY335979
DM2KITF	HS	Discontinued in Phase 3
DM2KITF	SN	Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride
DM2KITF	CP	Eli Lilly
DM2KITF	TC	Anticancer Agents
DM2KITF	DT	Small molecular drug
DM2KITF	PC	153997
DM2KITF	MW	637
DM2KITF	FM	C32H34Cl3F2N3O2
DM2KITF	IC	InChI=1S/C32H31F2N3O2.3ClH/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27;;;/h1-14,21,29-31,38H,15-20H2;3*1H/t21-,29-,30+,31?;;;/m1.../s1
DM2KITF	CS	C1CN(CCN1C[C@H](COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5[C@H]6[C@H](C6(F)F)C7=CC=CC=C47.Cl.Cl.Cl
DM2KITF	IK	ZPFVQKPWGDRLHL-ZLYBXYBFSA-N
DM2KITF	IU	(2R)-1-[4-[(2R,4S)-3,3-difluoro-11-tetracyclo[10.4.0.02,4.05,10]hexadeca-1(16),5,7,9,12,14-hexaenyl]piperazin-1-yl]-3-quinolin-5-yloxypropan-2-ol;trihydrochloride
DM2KITF	CA	CAS 167465-36-3
DM2KITF	DE	Acute myeloid leukaemia

DMSC4K1	ID	DMSC4K1
DMSC4K1	DN	LY-544344
DMSC4K1	HS	Discontinued in Phase 3
DMSC4K1	CP	Eli Lilly
DMSC4K1	TC	Psychiatric
DMSC4K1	DT	Small molecular drug
DMSC4K1	PC	9857256
DMSC4K1	MW	256.25
DMSC4K1	FM	C11H16N2O5
DMSC4K1	IC	InChI=1S/C11H16N2O5/c1-4(12)8(14)13-11(10(17)18)3-2-5-6(7(5)11)9(15)16/h4-7H,2-3,12H2,1H3,(H,13,14)(H,15,16)(H,17,18)/t4-,5-,6-,7-,11-/m0/s1
DMSC4K1	CS	C[C@@H](C(=O)N[C@]1(CC[C@@H]2[C@H]1[C@H]2C(=O)O)C(=O)O)N
DMSC4K1	IK	UPSXYNJDCKOCFD-QIMCWZKGSA-N
DMSC4K1	IU	(1S,2S,5R,6S)-2-[[(2S)-2-aminopropanoyl]amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DMSC4K1	CA	CAS 441765-98-6
DMSC4K1	DE	Anxiety disorder

DMUR3VP	ID	DMUR3VP
DMUR3VP	DN	MDL-11939
DMUR3VP	HS	Discontinued in Phase 3
DMUR3VP	SN	Glemanserin; 107703-78-6; alpha-Phenyl-1-(2-phenylethyl)-4-piperidinemethanol; MDL 11,939; Mdl 11939; Mdl-11,939; MDL-11939; Glemanserin [USAN:INN]; CHEMBL18972; 132553-86-7; 4-Piperidinemethanol, alpha-phenyl-1-(2-phenylethyl)-; 4-Piperidinemethanol, alpha-phenyl-1-(2-phenylethyl)-, (+-)-; (+-)-1-Phenethyl-alpha-phenyl-4-piperidinemethanol; AC1L2GSP; Glemanserin (USAN/INN); ( inverted exclamation markA)-1-phenethyl-a-phenyl-4-piperidinemethanol; GTPL186; SCHEMBL120012; AC1Q771C; DTXSID4042624; CTK8D3348; CHEBI:91790
DMUR3VP	DT	Small molecular drug
DMUR3VP	PC	71781
DMUR3VP	MW	295.4
DMUR3VP	FM	C20H25NO
DMUR3VP	IC	InChI=1S/C20H25NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19-20,22H,11-16H2
DMUR3VP	CS	C1CN(CCC1C(C2=CC=CC=C2)O)CCC3=CC=CC=C3
DMUR3VP	IK	AXNGJCOYCMDPQG-UHFFFAOYSA-N
DMUR3VP	IU	phenyl-[1-(2-phenylethyl)piperidin-4-yl]methanol
DMUR3VP	CA	CAS 107703-78-6
DMUR3VP	CB	CHEBI:91790
DMUR3VP	DE	Anxiety disorder

DMAZ28C	ID	DMAZ28C
DMAZ28C	DN	Metazosin
DMAZ28C	HS	Discontinued in Phase 3
DMAZ28C	SN	Metazosin; Kenosin; VUFB15111; 116728-65-5; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine; (+-)-4-Amino-2-(4-(2-methoxypropionyl)piperazino)-6,7-dimethoxyquinazoline; (+-)-1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxypropionyl)piperazine; 95549-92-1; 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-methoxypropan-1-one; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)-
DMAZ28C	DT	Small molecular drug
DMAZ28C	PC	93514
DMAZ28C	MW	375.4
DMAZ28C	FM	C18H25N5O4
DMAZ28C	IC	InChI=1S/C18H25N5O4/c1-11(25-2)17(24)22-5-7-23(8-6-22)18-20-13-10-15(27-4)14(26-3)9-12(13)16(19)21-18/h9-11H,5-8H2,1-4H3,(H2,19,20,21)
DMAZ28C	CS	CC(C(=O)N1CCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC)OC
DMAZ28C	IK	YEOTYALSMRNXLJ-UHFFFAOYSA-N
DMAZ28C	IU	1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-methoxypropan-1-one
DMAZ28C	CA	CAS 95549-92-1
DMAZ28C	DE	Cardiac disease

DM9FJ7N	ID	DM9FJ7N
DM9FJ7N	DN	Midafotel
DM9FJ7N	HS	Discontinued in Phase 3
DM9FJ7N	SN	EAA-494
DM9FJ7N	CP	BTG plc
DM9FJ7N	DT	Small molecular drug
DM9FJ7N	PC	6435801
DM9FJ7N	MW	250.19
DM9FJ7N	FM	C8H15N2O5P
DM9FJ7N	IC	InChI=1S/C8H15N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h1,5,7,9H,2-4,6H2,(H,11,12)(H2,13,14,15)/b5-1+/t7-/m1/s1
DM9FJ7N	CS	C1CN(C[C@@H](N1)C(=O)O)C/C=C/P(=O)(O)O
DM9FJ7N	IK	VZXMZMJSGLFKQI-ABVWVHJUSA-N
DM9FJ7N	IU	(2R)-4-[(E)-3-phosphonoprop-2-enyl]piperazine-2-carboxylic acid
DM9FJ7N	CA	CAS 117414-74-1
DM9FJ7N	DE	Cognitive impairment

DMPCY8K	ID	DMPCY8K
DMPCY8K	DN	Milameline
DMPCY8K	HS	Discontinued in Phase 3
DMPCY8K	SN	Miramelin; Mirameline; Milameline hydrochloride; PD-129409; RU-35926
DMPCY8K	CP	Pfizer Inc
DMPCY8K	DT	Small molecular drug
DMPCY8K	PC	9571002
DMPCY8K	MW	154.21
DMPCY8K	FM	C8H14N2O
DMPCY8K	IC	InChI=1S/C8H14N2O/c1-10-5-3-4-8(7-10)6-9-11-2/h4,6H,3,5,7H2,1-2H3/b9-6+
DMPCY8K	CS	CN1CCC=C(C1)/C=N/OC
DMPCY8K	IK	YMMXHEYLRHNXAB-RMKNXTFCSA-N
DMPCY8K	IU	(E)-N-methoxy-1-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)methanimine
DMPCY8K	CA	CAS 139886-32-1
DMPCY8K	DE	Cognitive impairment

DM86XJG	ID	DM86XJG
DM86XJG	DN	MINALRESTAT
DM86XJG	HS	Discontinued in Phase 3
DM86XJG	SN	Minalrestat; WAY-ARI-509; 129688-50-2; Minalrestat [USAN:INN]; Spiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone, 2-((4-bromo-2-fluorophenyl)-methyl)-6-fluoro-;; 2-(4-Bromo-2-fluorobenzyl)-6-fluorospiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone; Spiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone, 2-((4-Bromo-2-fluorophenyl)methyl)-6-fluoro-; Bffipt; Minalrestat (2); AC1L4RBZ; Minalrestat (USAN/INN); SCHEMBL49649; CHEMBL273910; BDBM228819; AKOS022180622; SB19712; API0013644
DM86XJG	DT	Small molecular drug
DM86XJG	PC	190816
DM86XJG	MW	449.2
DM86XJG	FM	C19H11BrF2N2O4
DM86XJG	IC	InChI=1S/C19H11BrF2N2O4/c20-10-2-1-9(14(22)5-10)8-24-16(26)12-4-3-11(21)6-13(12)19(18(24)28)7-15(25)23-17(19)27/h1-6H,7-8H2,(H,23,25,27)
DM86XJG	CS	C1C(=O)NC(=O)C12C3=C(C=CC(=C3)F)C(=O)N(C2=O)CC4=C(C=C(C=C4)Br)F
DM86XJG	IK	BMHZAHGTGIZZCT-UHFFFAOYSA-N
DM86XJG	IU	2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4,3'-pyrrolidine]-1,2',3,5'-tetrone
DM86XJG	CA	CAS 129688-50-2
DM86XJG	DE	Diabetic complication

DMMZO8X	ID	DMMZO8X
DMMZO8X	DN	Miproxifene
DMMZO8X	HS	Discontinued in Phase 3
DMMZO8X	SN	Miproxifene phosphate; TAT-59
DMMZO8X	CP	Taiho Pharmaceutical Co Ltd
DMMZO8X	DT	Small molecular drug
DMMZO8X	PC	3037015
DMMZO8X	MW	429.6
DMMZO8X	FM	C29H35NO2
DMMZO8X	IC	InChI=1S/C29H35NO2/c1-6-28(23-9-7-22(8-10-23)21(2)3)29(24-11-15-26(31)16-12-24)25-13-17-27(18-14-25)32-20-19-30(4)5/h7-18,21,31H,6,19-20H2,1-5H3/b29-28-
DMMZO8X	CS	CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=C(C=C3)C(C)C
DMMZO8X	IK	FVVPWVFWOOMXEZ-ZIADKAODSA-N
DMMZO8X	IU	4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-(4-propan-2-ylphenyl)but-1-enyl]phenol
DMMZO8X	CA	CAS 129612-87-9
DMMZO8X	DE	Solid tumour/cancer

DMXT36M	ID	DMXT36M
DMXT36M	DN	Mivazerol
DMXT36M	HS	Discontinued in Phase 3
DMXT36M	SN	125472-02-8; Mivazerol [INN]; UNII-W5P1SSA8KD; Mivazerolum [INN-Latin]; alpha-Imidazol-4-yl-2,3-cresotamide; 2-HYDROXY-3-(1H-IMIDAZOL-4-YLMETHYL)-BENZAMIDE; W5P1SSA8KD; 3-((1H-Imidazol-4-yl)methyl)-2-hydroxybenzamide; Benzamide,2-hydroxy-3-(1H-imidazol-5-ylmethyl)-; Mivazerolum; ucb 22073; mivazerol[inn]; ACMC-20mrix; AC1L1TX2; 2-hydroxy-3-(1H-imidazol-5-ylmethyl)benzamide; SCHEMBL593707; SCHEMBL8097939; AC1Q5D40; CHEMBL2105189; CTK4B4380; DTXSID30154782; ZINC4674535; 3-((1H-imidazol-4-yl)methyl)-2-hydroxybenzamide; Closantel 6
DMXT36M	DT	Small molecular drug
DMXT36M	PC	60784
DMXT36M	MW	217.22
DMXT36M	FM	C11H11N3O2
DMXT36M	IC	InChI=1S/C11H11N3O2/c12-11(16)9-3-1-2-7(10(9)15)4-8-5-13-6-14-8/h1-3,5-6,15H,4H2,(H2,12,16)(H,13,14)
DMXT36M	CS	C1=CC(=C(C(=C1)C(=O)N)O)CC2=CN=CN2
DMXT36M	IK	RLHGFJMGWQXPBW-UHFFFAOYSA-N
DMXT36M	IU	2-hydroxy-3-(1H-imidazol-5-ylmethyl)benzamide
DMXT36M	CA	CAS 125472-02-8
DMXT36M	DE	Angina pectoris

DMJ59A4	ID	DMJ59A4
DMJ59A4	DN	MOFEGILINE
DMJ59A4	HS	Discontinued in Phase 3
DMJ59A4	SN	Mofegiline; Mofegiline (free base); UNII-1FMJ6D8Y1B; MDL 72974; 119386-96-8; MDL-72,974; 1FMJ6D8Y1B; CHEMBL489079; C11H13F2N; (E)-2-(Fluoromethylene)-4-(p-fluorophenyl)butylamine; Benzenebutanamine, 4-fluoro-beta-(fluoromethylene)-, (E)-; (2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine; Mofegiline [INN]; AC1O5OIU; 4-fluoro-beta-(fluoromethylene)benzenebutanamine; SCHEMBL1295041; GTPL9754; VXLBSYHAEKDUSU-JXMROGBWSA-N; ZINC1542534; Mofegiline Hydrochloride (free base); MDL-72974; BDBM50246766; AKOS006271451; LS-172413
DMJ59A4	DT	Small molecular drug
DMJ59A4	PC	6437850
DMJ59A4	MW	197.22
DMJ59A4	FM	C11H13F2N
DMJ59A4	IC	InChI=1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+
DMJ59A4	CS	C1=CC(=CC=C1CC/C(=C\\F)/CN)F
DMJ59A4	IK	VXLBSYHAEKDUSU-JXMROGBWSA-N
DMJ59A4	IU	(2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine
DMJ59A4	CA	CAS 119386-96-8
DMJ59A4	DE	Cognitive impairment

DMZAL8C	ID	DMZAL8C
DMZAL8C	DN	Motesanib
DMZAL8C	HS	Discontinued in Phase 3
DMZAL8C	SN	N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide
DMZAL8C	CP	Amgen
DMZAL8C	DT	Small molecular drug
DMZAL8C	PC	11667893
DMZAL8C	MW	373.5
DMZAL8C	FM	C22H23N5O
DMZAL8C	IC	InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
DMZAL8C	CS	CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C
DMZAL8C	IK	RAHBGWKEPAQNFF-UHFFFAOYSA-N
DMZAL8C	IU	N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
DMZAL8C	CA	CAS 453562-69-1
DMZAL8C	CB	CHEBI:51098
DMZAL8C	DE	Non-small-cell lung cancer

DMYQZBT	ID	DMYQZBT
DMYQZBT	DN	MR-889
DMYQZBT	HS	Discontinued in Phase 3
DMYQZBT	SN	Midesteine; Midesteine [INN]; Midesteinum [INN-Latin]; Midesteina [INN-Spanish]; MR-889; 94149-41-4; MR 889; CHEMBL1808549; 2-(Thiophen-2-ylcarbonylthio)-N-(2-oxo-2,3,4,5-tetrahydrothiophen-3-yl)propionamide; 2-Thiophenecarbothioic acid, S-(1-methyl-2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl) ester; C12H13NO3S3; Midesteinum; Midesteina; 2-Thiophenecarbothioic acid, S-ester with (+-)-2-mercapto-N-(tetrahydro-2-oxo-3-thienyl)propionamide; SCHEMBL724755; AC1L242H; CTK3I7550; MR889; BDBM50349435; SB19618; LS-152918
DMYQZBT	DT	Small molecular drug
DMYQZBT	PC	65837
DMYQZBT	MW	315.4
DMYQZBT	FM	C12H13NO3S3
DMYQZBT	IC	InChI=1S/C12H13NO3S3/c1-7(19-12(16)9-3-2-5-17-9)10(14)13-8-4-6-18-11(8)15/h2-3,5,7-8H,4,6H2,1H3,(H,13,14)
DMYQZBT	CS	CC(C(=O)NC1CCSC1=O)SC(=O)C2=CC=CS2
DMYQZBT	IK	MKTVMEMIKNBVHI-UHFFFAOYSA-N
DMYQZBT	IU	S-[1-oxo-1-[(2-oxothiolan-3-yl)amino]propan-2-yl] thiophene-2-carbothioate
DMYQZBT	CA	CAS 94149-41-4
DMYQZBT	DE	Phlegmy cough

DMNX0JH	ID	DMNX0JH
DMNX0JH	DN	N-0861
DMNX0JH	HS	Discontinued in Phase 3
DMNX0JH	SN	WRC-0006; WRC-0007
DMNX0JH	CP	Aderis Pharmaceuticals Inc
DMNX0JH	DT	Small molecular drug
DMNX0JH	PC	126615
DMNX0JH	MW	243.31
DMNX0JH	FM	C13H17N5
DMNX0JH	IC	InChI=1S/C13H17N5/c1-18-7-16-11-12(14-6-15-13(11)18)17-10-5-8-2-3-9(10)4-8/h6-10H,2-5H2,1H3,(H,14,15,17)/t8-,9+,10-/m1/s1
DMNX0JH	CS	CN1C=NC2=C(N=CN=C21)N[C@@H]3C[C@@H]4CC[C@H]3C4
DMNX0JH	IK	MTQYIGCUBBMQCJ-KXUCPTDWSA-N
DMNX0JH	IU	N-[(1S,2R,4R)-2-bicyclo[2.2.1]heptanyl]-9-methylpurin-6-amine
DMNX0JH	CA	CAS 141696-90-4
DMNX0JH	DE	Cardiac disease

DMXHWK6	ID	DMXHWK6
DMXHWK6	DN	Neutralase
DMXHWK6	HS	Discontinued in Phase 3
DMXHWK6	SN	Heparinase I, IBEX
DMXHWK6	CP	IBEX Technologies Inc
DMXHWK6	DE	Angiogenesis disorder

DMJL5TR	ID	DMJL5TR
DMJL5TR	DN	NOLOMIROLE HYDROCHLORIDE
DMJL5TR	HS	Discontinued in Phase 3
DMJL5TR	SN	CHF-1035; Nolomirole hydrochloride; Rac-5,6-Diisobutyryloxy-2-(methylamino)-1,2,3,4-tetrahydronaphthalene hydrochloride
DMJL5TR	DT	Small molecular drug
DMJL5TR	PC	219049
DMJL5TR	MW	369.9
DMJL5TR	FM	C19H28ClNO4
DMJL5TR	IC	InChI=1S/C19H27NO4.ClH/c1-11(2)18(21)23-16-9-6-13-10-14(20-5)7-8-15(13)17(16)24-19(22)12(3)4;/h6,9,11-12,14,20H,7-8,10H2,1-5H3;1H
DMJL5TR	CS	CC(C)C(=O)OC1=C(C2=C(CC(CC2)NC)C=C1)OC(=O)C(C)C.Cl
DMJL5TR	IK	TWTMQRXNAZGSCE-UHFFFAOYSA-N
DMJL5TR	IU	[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;hydrochloride
DMJL5TR	CA	CAS 138531-51-8
DMJL5TR	DE	Heart failure

DMMDY27	ID	DMMDY27
DMMDY27	DN	Nuleusin
DMMDY27	HS	Discontinued in Phase 3
DMMDY27	SN	IL-2 (subcutaneous formulation, RCC/MM), 3SBio
DMMDY27	CP	3SBio Inc
DMMDY27	DE	Melanoma

DMQN3JX	ID	DMQN3JX
DMQN3JX	DN	Ocinaplon
DMQN3JX	HS	Discontinued in Phase 3
DMQN3JX	SN	CL 273547; Ocinaplon [USAN:INN]; Ocinaplon (USAN/INN); Pyridin-2-yl-(7-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)methanone; Methanone, 2-pyri(dinyl(7-(4-pyridinyl)pyrazolo(1,5-a)pyrimidin-3-yl); 2-Pyridinyl(7-(4-pyridinyl)pyrazolo(1,5-a)pyrimidin-3-yl)methanone; 2-Pyridyl 7-(4-pyridyl)pyrazolo(1,5-a)pyrimidin-3-yl ketone
DMQN3JX	CP	Dov Pharmaceutical
DMQN3JX	TC	Psychiatric
DMQN3JX	DT	Small molecular drug
DMQN3JX	PC	216456
DMQN3JX	MW	301.3
DMQN3JX	FM	C17H11N5O
DMQN3JX	IC	InChI=1S/C17H11N5O/c23-16(14-3-1-2-7-19-14)13-11-21-22-15(6-10-20-17(13)22)12-4-8-18-9-5-12/h1-11H
DMQN3JX	CS	C1=CC=NC(=C1)C(=O)C2=C3N=CC=C(N3N=C2)C4=CC=NC=C4
DMQN3JX	IK	OQJFBUOFGHPMSR-UHFFFAOYSA-N
DMQN3JX	IU	pyridin-2-yl-(7-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)methanone
DMQN3JX	CA	CAS 96604-21-6
DMQN3JX	DE	Generalized anxiety disorder

DM0O2HP	ID	DM0O2HP
DM0O2HP	DN	OLAMUFLOXACIN MESILATE
DM0O2HP	HS	Discontinued in Phase 3
DM0O2HP	SN	HSR-903; Olamufloxacin mesilate; (-)-5-Amino-7-[7(S)-amino-5-azaspiro[2.4]hept-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid methanesulfonate
DM0O2HP	DT	Small molecular drug
DM0O2HP	PC	9826542
DM0O2HP	MW	482.5
DM0O2HP	FM	C21H27FN4O6S
DM0O2HP	IC	InChI=1S/C20H23FN4O3.CH4O3S/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20;1-5(2,3)4/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28);1H3,(H,2,3,4)/t12-;/m1./s1
DM0O2HP	CS	CC1=C2C(=C(C(=C1N3C[C@H](C4(C3)CC4)N)F)N)C(=O)C(=CN2C5CC5)C(=O)O.CS(=O)(=O)O
DM0O2HP	IK	QCRMQMNCFYYEFX-UTONKHPSSA-N
DM0O2HP	IU	5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid
DM0O2HP	CA	CAS 167888-07-5
DM0O2HP	DE	Bacterial infection

DM1RKWV	ID	DM1RKWV
DM1RKWV	DN	ONO-3805
DM1RKWV	HS	Discontinued in Phase 3
DM1RKWV	SN	ONO-3805; CHEMBL24470; BDBM50057482; 4-(2-{4-[1-(4-Isobutyl-phenyl)-ethoxy]-2,3-dimethyl-benzoylamino}-phenoxy)-butyric acid; 4-(2-{4-[(S)-1-(4-Isobutyl-phenyl)-ethoxy]-2,3-dimethyl-benzoylamino}-phenoxy)-butyric acid
DM1RKWV	DT	Small molecular drug
DM1RKWV	PC	11504627
DM1RKWV	MW	503.6
DM1RKWV	FM	C31H37NO5
DM1RKWV	IC	InChI=1S/C31H37NO5/c1-20(2)19-24-12-14-25(15-13-24)23(5)37-28-17-16-26(21(3)22(28)4)31(35)32-27-9-6-7-10-29(27)36-18-8-11-30(33)34/h6-7,9-10,12-17,20,23H,8,11,18-19H2,1-5H3,(H,32,35)(H,33,34)/t23-/m0/s1
DM1RKWV	CS	CC1=C(C=CC(=C1C)O[C@@H](C)C2=CC=C(C=C2)CC(C)C)C(=O)NC3=CC=CC=C3OCCCC(=O)O
DM1RKWV	IK	XWNSOVPLENXWNU-QHCPKHFHSA-N
DM1RKWV	IU	4-[2-[[2,3-dimethyl-4-[(1S)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl]amino]phenoxy]butanoic acid
DM1RKWV	DE	Prostate disease

DMEDLXJ	ID	DMEDLXJ
DMEDLXJ	DN	ORBOFIBAN
DMEDLXJ	HS	Discontinued in Phase 3
DMEDLXJ	SN	Orbofiban; UNII-FGJ53JS7PT; 163250-90-6; FGJ53JS7PT; CHEMBL64706; SC-57099B; Orbofiban [INN]; AC1L435J; SCHEMBL7854981; DTXSID20167543; ZINC3951736; BDBM50092109; AKOS022181223; AJ-47472; ethyl 3-[[(3S)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate; 3-{(S)-3-[1-(4-Carbamimidoyl-phenyl)-2-oxo-pyrrolidin-3-yl]-ureido}-propionic acid ethyl ester; beta-Alanine, N-((((3S)-1-(4-(aminoiminomethyl)phenyl)-2-oxo-3- pyrrolidinyl)amino)carbonyl)-, ethyl ester
DMEDLXJ	DT	Small molecular drug
DMEDLXJ	PC	178080
DMEDLXJ	MW	361.4
DMEDLXJ	FM	C17H23N5O4
DMEDLXJ	IC	InChI=1S/C17H23N5O4/c1-2-26-14(23)7-9-20-17(25)21-13-8-10-22(16(13)24)12-5-3-11(4-6-12)15(18)19/h3-6,13H,2,7-10H2,1H3,(H3,18,19)(H2,20,21,25)/t13-/m0/s1
DMEDLXJ	CS	CCOC(=O)CCNC(=O)N[C@H]1CCN(C1=O)C2=CC=C(C=C2)C(=N)N
DMEDLXJ	IK	VJDOPFARMOLELX-ZDUSSCGKSA-N
DMEDLXJ	IU	ethyl 3-[[(3S)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate
DMEDLXJ	CA	CAS 163250-90-6
DMEDLXJ	DE	Angina pectoris; Cardiovascular disease

DMVRA8N	ID	DMVRA8N
DMVRA8N	DN	Org-2766
DMVRA8N	HS	Discontinued in Phase 3
DMVRA8N	SN	Org-2766; H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH; UNII-OP1H5I4TBQ; OP1H5I4TBQ; 50913-82-1; AC1OCEIT; (4S)-5-[[(2S)-1-[[(2S)-1-[[(2R)-6-amino-1-[[(2S)-1-hydroxy-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid
DMVRA8N	CP	Organon BioSciences
DMVRA8N	DT	Small molecular drug
DMVRA8N	PC	6917685
DMVRA8N	MW	870
DMVRA8N	FM	C40H55N9O11S
DMVRA8N	IC	InChI=1S/C40H55N9O11S/c1-61(59,60)19-17-28(42)35(52)45-30(15-16-34(50)51)37(54)48-32(22-27-23-43-24-44-27)39(56)47-31(20-25-10-4-2-5-11-25)38(55)46-29(14-8-9-18-41)36(53)49-33(40(57)58)21-26-12-6-3-7-13-26/h2-7,10-13,23-24,28-33H,8-9,14-22,41-42H2,1H3,(H,43,44)(H,45,52)(H,46,55)(H,47,56)(H,48,54)(H,49,53)(H,50,51)(H,57,58)/t28-,29+,30-,31-,32-,33-/m0/s1
DMVRA8N	CS	CS(=O)(=O)CC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N
DMVRA8N	IK	QUCFVNGGGFLOES-ACQYNFKHSA-N
DMVRA8N	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2R)-6-amino-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid
DMVRA8N	CA	CAS 50913-82-1
DMVRA8N	DE	Cognitive impairment

DMN7TL8	ID	DMN7TL8
DMN7TL8	DN	Osutidine
DMN7TL8	HS	Discontinued in Phase 3
DMN7TL8	SN	T-593
DMN7TL8	CP	Toyama Chemical Co Ltd
DMN7TL8	DT	Small molecular drug
DMN7TL8	PC	132303
DMN7TL8	MW	456.6
DMN7TL8	FM	C19H28N4O5S2
DMN7TL8	IC	InChI=1S/C19H28N4O5S2/c1-20-11-16-7-8-17(28-16)13-29-10-9-21-19(23-30(2,26)27)22-12-18(25)14-3-5-15(24)6-4-14/h3-8,18,20,24-25H,9-13H2,1-2H3,(H2,21,22,23)
DMN7TL8	CS	CNCC1=CC=C(O1)CSCCNC(=NCC(C2=CC=C(C=C2)O)O)NS(=O)(=O)C
DMN7TL8	IK	GZPOYVTZKHVRHE-UHFFFAOYSA-N
DMN7TL8	IU	2-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-1-[2-[[5-(methylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-3-methylsulfonylguanidine
DMN7TL8	CA	CAS 140695-21-2
DMN7TL8	DE	Duodenal ulcer

DMGOPMK	ID	DMGOPMK
DMGOPMK	DN	Otamixaban
DMGOPMK	HS	Discontinued in Phase 3
DMGOPMK	SN	Methyl 2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-4-yl)benzoyl]amino]butanoate; Methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate; 2-(3-Carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester
DMGOPMK	CP	Sanofi-Aventis
DMGOPMK	DT	Small molecular drug
DMGOPMK	PC	5496659
DMGOPMK	MW	446.5
DMGOPMK	FM	C25H26N4O4
DMGOPMK	IC	InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1
DMGOPMK	CS	C[C@H]([C@@H](CC1=CC(=CC=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-]
DMGOPMK	IK	PFGVNLZDWRZPJW-OPAMFIHVSA-N
DMGOPMK	IU	methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate
DMGOPMK	CA	CAS 193153-04-7
DMGOPMK	DE	Angina pectoris

DMWPT8J	ID	DMWPT8J
DMWPT8J	DN	Oxibendazole
DMWPT8J	HS	Discontinued in Phase 3
DMWPT8J	SN	Oxibendazole, GlaxoSmithKline
DMWPT8J	CP	GlaxoSmithKline
DMWPT8J	DT	Small molecular drug
DMWPT8J	PC	4622
DMWPT8J	MW	249.27
DMWPT8J	FM	C12H15N3O3
DMWPT8J	IC	InChI=1S/C12H15N3O3/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
DMWPT8J	CS	CCCOC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
DMWPT8J	IK	RAOCRURYZCVHMG-UHFFFAOYSA-N
DMWPT8J	IU	methyl N-(6-propoxy-1H-benzimidazol-2-yl)carbamate
DMWPT8J	CA	CAS 20559-55-1
DMWPT8J	CB	CHEBI:92907
DMWPT8J	DE	Pediatric cancer

DMPEHBJ	ID	DMPEHBJ
DMPEHBJ	DN	OX-NLA
DMPEHBJ	HS	Discontinued in Phase 3
DMPEHBJ	SN	NLA; BLX-NLA; NCX-1510; NO-donating therapeutics, Biolipox; Anti-allergy drug, NicOx/Biolipox; NO-donating allergy therapeutics, Biolipox/Nicox; NO-donating respiratory therapeutics, NicOx/Biolipox; NO-donating therapeutics, Biolipox/Nicox; Liposomal nitric oxide-donating cetirizine derivative (nasal, rhinitis), Biolipox; Nitric oxide-donating cetirizine derivative (liposomal, intranasal, rhinitis), Orexo; OX-NLA (nasal/liposomal formulation, allergic rhinitis/rhinitis); OX-NLA (nasal/liposomal formulation, allergic rhinitis/rhinitis), Meda
DMPEHBJ	CP	NicOx SA
DMPEHBJ	DT	Small molecular drug
DMPEHBJ	PC	55182
DMPEHBJ	MW	461.8
DMPEHBJ	FM	C21H27Cl3N2O3
DMPEHBJ	IC	InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H
DMPEHBJ	CS	C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl
DMPEHBJ	IK	PGLIUCLTXOYQMV-UHFFFAOYSA-N
DMPEHBJ	IU	2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
DMPEHBJ	CA	CAS 83881-52-1
DMPEHBJ	CB	CHEBI:3562
DMPEHBJ	DE	Allergic rhinitis

DMFNLDY	ID	DMFNLDY
DMFNLDY	DN	P-1
DMFNLDY	HS	Discontinued in Phase 3
DMFNLDY	SN	Zemaphyte; Zemaphyte (P1)
DMFNLDY	CP	Phytopharm plc
DMFNLDY	DT	Small molecular drug
DMFNLDY	PC	200882
DMFNLDY	MW	287.78
DMFNLDY	FM	C14H22ClNO3
DMFNLDY	IC	InChI=1S/C14H21NO3.ClH/c1-3-15(4-2)8-9-16-12-6-5-7-13-14(12)18-11-10-17-13;/h5-7H,3-4,8-11H2,1-2H3;1H
DMFNLDY	CS	CCN(CC)CCOC1=CC=CC2=C1OCCO2.Cl
DMFNLDY	IK	ACLBTXLOASZGRX-UHFFFAOYSA-N
DMFNLDY	IU	2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-N,N-diethylethanamine;hydrochloride
DMFNLDY	CA	CAS 2906-73-2
DMFNLDY	DE	Atopic dermatitis

DM1FST8	ID	DM1FST8
DM1FST8	DN	Pazinaclone
DM1FST8	HS	Discontinued in Phase 3
DM1FST8	SN	A-77000; DN-2327; Pazinaclone < Rec INN; Rac-8-[[2-(7-Chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-1,4-dioxa-8-azaspiro[4.5]decane
DM1FST8	DT	Small molecular drug
DM1FST8	PC	59743
DM1FST8	MW	478.9
DM1FST8	FM	C25H23ClN4O4
DM1FST8	IC	InChI=1S/C25H23ClN4O4/c26-20-7-5-16-6-8-21(28-23(16)27-20)30-19(17-3-1-2-4-18(17)24(30)32)15-22(31)29-11-9-25(10-12-29)33-13-14-34-25/h1-8,19H,9-15H2
DM1FST8	CS	C1CN(CCC12OCCO2)C(=O)CC3C4=CC=CC=C4C(=O)N3C5=NC6=C(C=C5)C=CC(=N6)Cl
DM1FST8	IK	DPGKFACWOCLTCA-UHFFFAOYSA-N
DM1FST8	IU	2-(7-chloro-1,8-naphthyridin-2-yl)-3-[2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3H-isoindol-1-one
DM1FST8	CA	CAS 103255-66-9
DM1FST8	DE	Anxiety disorder

DM4IM0G	ID	DM4IM0G
DM4IM0G	DN	Pexelizumab
DM4IM0G	HS	Discontinued in Phase 3
DM4IM0G	CP	Alexion Pharmaceuticals
DM4IM0G	DT	Antibody
DM4IM0G	SQ	h5g1.1 scFv: MADIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQRKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIKRTGGGGSGGGGSGGGGSQVQLVQSGAEVEKPGASVKKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYAQKFQGRVTMTADTSTSTAYMELSSLRSEDTAVYYCARYFFGSSPNYWYFDVWGQGTLVTVSS</sequence>    <sequence format="FASTA">&gt;h5g1.1VHC + F | Heavy Chain Variable RegionQVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYAQKFQGRVTMTADTSTSTAYMELSSLRSEDTAVYYCARYFFGSSPNWYFVWGQGT</sequence>    <sequence format="FASTA">&gt;h5g1.1VHC + F | Light Chain Variable RegionDIQMTQSPSLSASVGDRVTITCGASENIYGALNWYQRKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK
DM4IM0G	DE	Cardiovascular disease

DMXEU14	ID	DMXEU14
DMXEU14	DN	PF-1913539
DMXEU14	HS	Discontinued in Phase 3
DMXEU14	SN	Sch-58261; Sch 58261; 160098-96-4; Sch58261; 2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; UNII-4309023MAH; CHEMBL17127; 4309023MAH; 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; [3H]SCH 58261; SCH58261
DMXEU14	CP	Pfizer
DMXEU14	DT	Small molecular drug
DMXEU14	PC	176408
DMXEU14	MW	345.4
DMXEU14	FM	C18H15N7O
DMXEU14	IC	InChI=1S/C18H15N7O/c19-18-22-16-13(11-20-24(16)9-8-12-5-2-1-3-6-12)17-21-15(23-25(17)18)14-7-4-10-26-14/h1-7,10-11H,8-9H2,(H2,19,22)
DMXEU14	CS	C1=CC=C(C=C1)CCN2C3=C(C=N2)C4=NC(=NN4C(=N3)N)C5=CC=CO5
DMXEU14	IK	UTLPKQYUXOEJIL-UHFFFAOYSA-N
DMXEU14	IU	4-(furan-2-yl)-10-(2-phenylethyl)-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
DMXEU14	CA	CAS 160098-96-4
DMXEU14	CB	CHEBI:93424
DMXEU14	DE	Alzheimer disease

DMXSTRM	ID	DMXSTRM
DMXSTRM	DN	Pibutidine
DMXSTRM	HS	Discontinued in Phase 3
DMXSTRM	SN	Alex; Pibutidine hydrochloride; IT-066
DMXSTRM	CP	Ikeda Mohando Co Ltd
DMXSTRM	DT	Small molecular drug
DMXSTRM	PC	5282450
DMXSTRM	MW	356.4
DMXSTRM	FM	C19H24N4O3
DMXSTRM	IC	InChI=1S/C19H24N4O3/c20-16-17(19(25)18(16)24)22-7-2-5-11-26-15-12-14(6-8-21-15)13-23-9-3-1-4-10-23/h2,5-6,8,12,22H,1,3-4,7,9-11,13,20H2/b5-2-
DMXSTRM	CS	C1CCN(CC1)CC2=CC(=NC=C2)OC/C=C\\CNC3=C(C(=O)C3=O)N
DMXSTRM	IK	XMDYZASWLGWIPL-DJWKRKHSSA-N
DMXSTRM	IU	3-amino-4-[[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]amino]cyclobut-3-ene-1,2-dione
DMXSTRM	CA	CAS 103922-33-4
DMXSTRM	CB	CHEBI:145662
DMXSTRM	DE	Ulcerative colitis

DMQXJDM	ID	DMQXJDM
DMQXJDM	DN	Piroximone
DMQXJDM	HS	Discontinued in Phase 3
DMQXJDM	SN	MDL-19205
DMQXJDM	CP	Hoechst Marion Roussel Inc
DMQXJDM	DT	Small molecular drug
DMQXJDM	PC	55263
DMQXJDM	MW	217.22
DMQXJDM	FM	C11H11N3O2
DMQXJDM	IC	InChI=1S/C11H11N3O2/c1-2-8-9(14-11(16)13-8)10(15)7-3-5-12-6-4-7/h3-6H,2H2,1H3,(H2,13,14,16)
DMQXJDM	CS	CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2
DMQXJDM	IK	OQGWJZOWLHWFME-UHFFFAOYSA-N
DMQXJDM	IU	4-ethyl-5-(pyridine-4-carbonyl)-1,3-dihydroimidazol-2-one
DMQXJDM	CA	CAS 84490-12-0
DMQXJDM	DE	Cardiac failure

DMDZBIQ	ID	DMDZBIQ
DMDZBIQ	DN	PMI-001
DMDZBIQ	HS	Discontinued in Phase 3
DMDZBIQ	CP	Phytomedics
DMDZBIQ	DE	Lupus

DM04ZUW	ID	DM04ZUW
DM04ZUW	DN	Ponalrestat
DM04ZUW	HS	Discontinued in Phase 3
DM04ZUW	SN	PONALRESTAT; statil; 72702-95-5; Ponalrestatum [Latin]; UNII-2CV0A5G64E; ICI-128436; ICI 128,436; CHEMBL7679; C17H12BrFN2O3; 2CV0A5G64E; 2-(3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid; NCGC00024824-01; 3-(4-Bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid; 1-Phthalazineaceticacid, 3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-; Ponalrestatum; 1-Phthalazineacetic acid, 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-; Prodiax; Ponalrestat [USAN:BAN:INN]; ISIS-5GLT2rx
DM04ZUW	DT	Small molecular drug
DM04ZUW	PC	5278
DM04ZUW	MW	391.2
DM04ZUW	FM	C17H12BrFN2O3
DM04ZUW	IC	InChI=1S/C17H12BrFN2O3/c18-11-6-5-10(14(19)7-11)9-21-17(24)13-4-2-1-3-12(13)15(20-21)8-16(22)23/h1-7H,8-9H2,(H,22,23)
DM04ZUW	CS	C1=CC=C2C(=C1)C(=NN(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
DM04ZUW	IK	LKBFFDOJUKLQNY-UHFFFAOYSA-N
DM04ZUW	IU	2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid
DM04ZUW	CA	CAS 72702-95-5
DM04ZUW	CB	CHEBI:93199
DM04ZUW	DE	Gout; Diabetic complication

DML6EWH	ID	DML6EWH
DML6EWH	DN	Posatirelin
DML6EWH	HS	Discontinued in Phase 3
DML6EWH	SN	Esotirelin; Pyladox; RGH-2202
DML6EWH	CP	Gedeon Richter Ltd
DML6EWH	DT	Small molecular drug
DML6EWH	PC	71230
DML6EWH	MW	352.4
DML6EWH	FM	C17H28N4O4
DML6EWH	IC	InChI=1S/C17H28N4O4/c1-10(2)9-12(17(25)21-8-4-6-13(21)15(18)23)20-16(24)11-5-3-7-14(22)19-11/h10-13H,3-9H2,1-2H3,(H2,18,23)(H,19,22)(H,20,24)/t11-,12-,13-/m0/s1
DML6EWH	CS	CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@@H]2CCCC(=O)N2
DML6EWH	IK	DPNGIIPSQYKWQA-AVGNSLFASA-N
DML6EWH	IU	(2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]-6-oxopiperidine-2-carboxamide
DML6EWH	CA	CAS 78664-73-0
DML6EWH	CB	CHEBI:135486
DML6EWH	DE	Neurodegenerative disorder

DMI02PF	ID	DMI02PF
DMI02PF	DN	PRINOMIDE TROMETHAMINE
DMI02PF	HS	Discontinued in Phase 3
DMI02PF	SN	3-(1-Methylpyrrol-2-yl)-3-oxo-2-(N-phenylcarbamoyl)propionitrile tromethamine salt
DMI02PF	DT	Small molecular drug
DMI02PF	PC	3033812
DMI02PF	MW	388.4
DMI02PF	FM	C19H24N4O5
DMI02PF	IC	InChI=1S/C15H13N3O2.C4H11NO3/c1-18-9-5-8-13(18)14(19)12(10-16)15(20)17-11-6-3-2-4-7-11;5-4(1-6,2-7)3-8/h2-9,12H,1H3,(H,17,20);6-8H,1-3,5H2
DMI02PF	CS	CN1C=CC=C1C(=O)C(C#N)C(=O)NC2=CC=CC=C2.C(C(CO)(CO)N)O
DMI02PF	IK	CPUJDORGQAJDCT-UHFFFAOYSA-N
DMI02PF	IU	2-amino-2-(hydroxymethyl)propane-1,3-diol;2-cyano-3-(1-methylpyrrol-2-yl)-3-oxo-N-phenylpropanamide
DMI02PF	CA	CAS 109636-76-2
DMI02PF	DE	Inflammation

DMW9H7M	ID	DMW9H7M
DMW9H7M	DN	Propiram fumarate
DMW9H7M	HS	Discontinued in Phase 3
DMW9H7M	SN	Algeril; Diramax; Dirame; Diramine; Diratab; Propiram; FBA-4503
DMW9H7M	CP	Bayer AG
DMW9H7M	DT	Small molecular drug
DMW9H7M	PC	6433584
DMW9H7M	MW	391.5
DMW9H7M	FM	C20H29N3O5
DMW9H7M	IC	InChI=1S/C16H25N3O.C4H4O4/c1-3-16(20)19(15-9-5-6-10-17-15)14(2)13-18-11-7-4-8-12-18;5-3(6)1-2-4(7)8/h5-6,9-10,14H,3-4,7-8,11-13H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMW9H7M	CS	CCC(=O)N(C1=CC=CC=N1)C(C)CN2CCCCC2.C(=C/C(=O)O)\\C(=O)O
DMW9H7M	IK	WQTLOZFMTGYQDX-WLHGVMLRSA-N
DMW9H7M	IU	(E)-but-2-enedioic acid;N-(1-piperidin-1-ylpropan-2-yl)-N-pyridin-2-ylpropanamide
DMW9H7M	CA	CAS 13717-04-9
DMW9H7M	DE	Cancer related pain

DMB069L	ID	DMB069L
DMB069L	DN	PUMAPRAZOLE
DMB069L	HS	Discontinued in Phase 3
DMB069L	SN	BY-841; Pumaprazole; N-[2-(2,3-Dimethylimidazol[1,2-a]pyridin-8-ylaminomethyl)-3-methylphenyl]carbamic acid methyl ester
DMB069L	DT	Small molecular drug
DMB069L	PC	3052764
DMB069L	MW	338.4
DMB069L	FM	C19H22N4O2
DMB069L	IC	InChI=1S/C19H22N4O2/c1-12-7-5-8-16(22-19(24)25-4)15(12)11-20-17-9-6-10-23-14(3)13(2)21-18(17)23/h5-10,20H,11H2,1-4H3,(H,22,24)
DMB069L	CS	CC1=C(C(=CC=C1)NC(=O)OC)CNC2=CC=CN3C2=NC(=C3C)C
DMB069L	IK	NZQTVUWEPPDOKK-UHFFFAOYSA-N
DMB069L	IU	methyl N-[2-[[(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino]methyl]-3-methylphenyl]carbamate
DMB069L	CA	CAS 158364-59-1
DMB069L	DE	Duodenal ulcer

DMO9XTJ	ID	DMO9XTJ
DMO9XTJ	DN	Quinelorane
DMO9XTJ	HS	Discontinued in Phase 3
DMO9XTJ	SN	Quinelorane; Quinelorane [INN:BAN]; Quineloranum [INN-Latin]; UNII-Z0X4VT3Y1Q; Quinelorano [INN-Spanish]; 97466-90-5; Z0X4VT3Y1Q; LY 163502; LY 137157; LY 175877; CHEMBL155731; (5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine; (5aR-trans)-5,5a,6,7,8,9,9a,10-Octahydro-6-propylpyrido(2,3-g)quinazolin-2-amine; Pyrido(2,3-g)quinazolin-2-amine, 5,5a,6,7,8,9,9a,10-octahydro-6-propyl-, (5aR-trans)-; DSSTox_RID_81533; DSSTox_CID_26315; DSSTox_GSID_46315; Quineloranum; Quinelorano; CAS-97466-90-5
DMO9XTJ	DT	Small molecular drug
DMO9XTJ	PC	57242
DMO9XTJ	MW	246.35
DMO9XTJ	FM	C14H22N4
DMO9XTJ	IC	InChI=1S/C14H22N4/c1-2-5-18-6-3-4-10-7-12-11(8-13(10)18)9-16-14(15)17-12/h9-10,13H,2-8H2,1H3,(H2,15,16,17)/t10-,13-/m1/s1
DMO9XTJ	CS	CCCN1CCC[C@H]2[C@H]1CC3=CN=C(N=C3C2)N
DMO9XTJ	IK	TUFADSGTJUOBEH-ZWNOBZJWSA-N
DMO9XTJ	IU	(5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine
DMO9XTJ	CA	CAS 97466-90-5
DMO9XTJ	CB	CHEBI:92230
DMO9XTJ	DE	Male sexual disorder

DMNTURD	ID	DMNTURD
DMNTURD	DN	Ranagengliotucel-T
DMNTURD	HS	Discontinued in Phase 3
DMNTURD	SN	Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx
DMNTURD	CP	NovaRx Corp
DMNTURD	DT	Vaccine
DMNTURD	DE	Brain cancer

DMAINU1	ID	DMAINU1
DMAINU1	DN	RB-006
DMAINU1	HS	Discontinued in Phase 3
DMAINU1	CP	Regado Biosci
DMAINU1	PC	86278324
DMAINU1	MW	551.5
DMAINU1	FM	C20H39N3NaO11P
DMAINU1	IC	InChI=1S/C20H40N3O11P.Na/c1-30-13-15-32-19(25)22-11-7-5-9-17(23-20(26)33-16-14-31-2)18(24)21-10-6-3-4-8-12-34-35(27,28)29;/h17H,3-16H2,1-2H3,(H,21,24)(H,22,25)(H,23,26)(H2,27,28,29);/q;+1/p-1
DMAINU1	CS	COCCOC(=O)NCCCCC(C(=O)NCCCCCCOP(=O)(O)[O-])NC(=O)OCCOC.[Na+]
DMAINU1	IK	AYPFBAOWSFOSKF-UHFFFAOYSA-M
DMAINU1	IU	sodium;6-[2,6-bis(2-methoxyethoxycarbonylamino)hexanoylamino]hexyl hydrogen phosphate
DMAINU1	CA	CAS 959716-32-6
DMAINU1	DE	Vascular disease; Coronary artery disease; Thrombosis

DMXV28I	ID	DMXV28I
DMXV28I	DN	RG-12915
DMXV28I	HS	Discontinued in Phase 3
DMXV28I	SN	RG 12915; CHEMBL171393; RG-12915; (5aS-(4(R*),5aalpha,9aalpha))-N-1-Azabicyclo(2.2.2)oct-3-yl-2-chloro-5a,6,7,8,9,9a-hexahydro-4-dibenzofurancarboxamide; 4-dibenzofurancarboxamide, N-(3S)-1-azabicyclo(2.2.2)oct-3-yl-2-chloro-5a,6,7,8,9,9a-hexahydro-, (5aS,9aS)-; N-(1-Azabicyclo(2.2.2)octan-3-yl)-2-chloro-5a,6,7,8,9,9a-hexahydrodibenzofuran-4-carboxamide; 4-Dibenzofurancarboxamide, N-1-azabicyclo(2.2.2)oct-3-yl-2-chloro-5a,6,7,8,9,9a-hexahydro-, (5aS-(4(R*),5aalpha,9aalpha))-; UNII-533O919MKO; 533O919MKO
DMXV28I	CP	Rhone-Poulenc SA
DMXV28I	DT	Small molecular drug
DMXV28I	PC	130427
DMXV28I	MW	360.9
DMXV28I	FM	C20H25ClN2O2
DMXV28I	IC	InChI=1S/C20H25ClN2O2/c21-13-9-15-14-3-1-2-4-18(14)25-19(15)16(10-13)20(24)22-17-11-23-7-5-12(17)6-8-23/h9-10,12,14,17-18H,1-8,11H2,(H,22,24)
DMXV28I	CS	C1CCC2C(C1)C3=C(O2)C(=CC(=C3)Cl)C(=O)NC4CN5CCC4CC5
DMXV28I	IK	LDYMIBZOCSHLBG-UHFFFAOYSA-N
DMXV28I	IU	N-(1-azabicyclo[2.2.2]octan-3-yl)-2-chloro-5a,6,7,8,9,9a-hexahydrodibenzofuran-4-carboxamide
DMXV28I	CA	CAS 125363-06-6
DMXV28I	DE	Nausea

DMCV0BZ	ID	DMCV0BZ
DMCV0BZ	DN	RhTPO
DMCV0BZ	HS	Discontinued in Phase 3
DMCV0BZ	SN	TPIAO (TN)
DMCV0BZ	CP	Pharmacia; Pfizer
DMCV0BZ	DE	Idiopathic thrombocytopenic purpura

DMBKN4P	ID	DMBKN4P
DMBKN4P	DN	Riferminogene pecaplasmid
DMBKN4P	HS	Discontinued in Phase 3
DMBKN4P	SN	Temusi (TN)
DMBKN4P	CP	Sanofi-aventis
DMBKN4P	DE	Critical limb ischemia

DM0X36Y	ID	DM0X36Y
DM0X36Y	DN	Ritanserin
DM0X36Y	HS	Discontinued in Phase 3
DM0X36Y	SN	ritanserin; 87051-43-2; Tiserton; Ritanserine; Ritanserinum; Ritanserina; R-55667; Ritanserinum [Latin]; Ritanserine [French]; Ritanserina [Spanish]; UNII-145TFV465S; C27H25F2N3OS; R 55,667; 6-(2-(4-(bis(4-fluorophenyl)methylene)piperidin-1-yl)ethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; MLS000069360; CHEMBL267777; 6-(2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl)-7-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one; N,N-dialkyl-dipeptidylamines
DM0X36Y	DT	Small molecular drug
DM0X36Y	PC	5074
DM0X36Y	MW	477.6
DM0X36Y	FM	C27H25F2N3OS
DM0X36Y	IC	InChI=1S/C27H25F2N3OS/c1-18-24(26(33)32-16-17-34-27(32)30-18)12-15-31-13-10-21(11-14-31)25(19-2-6-22(28)7-3-19)20-4-8-23(29)9-5-20/h2-9,16-17H,10-15H2,1H3
DM0X36Y	CS	CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3
DM0X36Y	IK	JUQLTPCYUFPYKE-UHFFFAOYSA-N
DM0X36Y	IU	6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one
DM0X36Y	CA	CAS 87051-43-2
DM0X36Y	CB	CHEBI:64195
DM0X36Y	DE	Anxiety disorder

DM8M1X0	ID	DM8M1X0
DM8M1X0	DN	Ro-16-6028
DM8M1X0	HS	Discontinued in Phase 3
DM8M1X0	SN	Bretazenil; 84379-13-5; Ro 16-6028; UNII-OSZ0E9DGOJ; Bretazenil [USAN:INN]; 1-Bretazenil; Bretazenilum [INN-Latin]; Ro-16-6028; OSZ0E9DGOJ; BRN 4765855; C19H20BrN3O3; CHEMBL366947; NCGC00160640-01; DSSTox_RID_81493; DSSTox_CID_26266; DSSTox_GSID_46266; tert-Butyl (S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo(1,5-a)pyrrolo(2,1-c)(1,4)benzodiazepine-1-carboxylate; Bretazenilum; 9H-Imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid; 9H-Imidazo(1,5-a)pyrrolo(2,1-c)(1,4)benzodiazepine-1-carboxylic acid, 8-bro
DM8M1X0	DT	Small molecular drug
DM8M1X0	PC	107926
DM8M1X0	MW	418.3
DM8M1X0	FM	C19H20BrN3O3
DM8M1X0	IC	InChI=1S/C19H20BrN3O3/c1-19(2,3)26-18(25)15-16-13-8-5-9-22(13)17(24)14-11(20)6-4-7-12(14)23(16)10-21-15/h4,6-7,10,13H,5,8-9H2,1-3H3/t13-/m0/s1
DM8M1X0	CS	CC(C)(C)OC(=O)C1=C2[C@@H]3CCCN3C(=O)C4=C(N2C=N1)C=CC=C4Br
DM8M1X0	IK	LWUDDYHYYNNIQI-ZDUSSCGKSA-N
DM8M1X0	IU	tert-butyl (7S)-14-bromo-12-oxo-2,4,11-triazatetracyclo[11.4.0.02,6.07,11]heptadeca-1(17),3,5,13,15-pentaene-5-carboxylate
DM8M1X0	CA	CAS 84379-13-5
DM8M1X0	DE	Anxiety disorder

DMOVJ60	ID	DMOVJ60
DMOVJ60	DN	RPAF-AH
DMOVJ60	HS	Discontinued in Phase 3
DMOVJ60	CP	ICOS Corp
DMOVJ60	DE	Sepsis

DMPUED3	ID	DMPUED3
DMPUED3	DN	S-12968
DMPUED3	HS	Discontinued in Phase 3
DMPUED3	SN	Olradipine; Pranedipine; (-)-S 12968
DMPUED3	CP	Servier
DMPUED3	DT	Small molecular drug
DMPUED3	PC	6918192
DMPUED3	MW	637.5
DMPUED3	FM	C26H34Cl2N2O12
DMPUED3	IC	InChI=1S/C22H28Cl2N2O6.C4H6O6/c1-4-32-22(28)19-16(12-31-11-10-30-9-8-25)26-13(2)17(21(27)29-3)18(19)14-6-5-7-15(23)20(14)24;5-1(3(7)8)2(6)4(9)10/h5-7,18,26H,4,8-12,25H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
DMPUED3	CS	CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)COCCOCCN.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMPUED3	IK	LKFLYCNXQSCXIV-LREBCSMRSA-N
DMPUED3	IU	(2R,3R)-2,3-dihydroxybutanedioic acid;3-O-ethyl 5-O-methyl 2-[2-(2-aminoethoxy)ethoxymethyl]-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMPUED3	DE	Hypertension

DMSW051	ID	DMSW051
DMSW051	DN	Sabeluzole
DMSW051	HS	Discontinued in Phase 3
DMSW051	SN	Arbetuzole; R-58735
DMSW051	CP	Janssen Pharmaceutica NV
DMSW051	DT	Small molecular drug
DMSW051	PC	59823
DMSW051	MW	415.5
DMSW051	FM	C22H26FN3O2S
DMSW051	IC	InChI=1S/C22H26FN3O2S/c1-25(22-24-20-4-2-3-5-21(20)29-22)17-10-12-26(13-11-17)14-18(27)15-28-19-8-6-16(23)7-9-19/h2-9,17-18,27H,10-15H2,1H3
DMSW051	CS	CN(C1CCN(CC1)CC(COC2=CC=C(C=C2)F)O)C3=NC4=CC=CC=C4S3
DMSW051	IK	IGMKTIJBFUMVIN-UHFFFAOYSA-N
DMSW051	IU	1-[4-[1,3-benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(4-fluorophenoxy)propan-2-ol
DMSW051	CA	CAS 104383-17-7
DMSW051	DE	Cerebrovascular ischaemia

DM3KC81	ID	DM3KC81
DM3KC81	DN	Sanfetrinem
DM3KC81	HS	Discontinued in Phase 3
DM3KC81	SN	Sanfetrinem sodium; GV-104326; GV-104326B; GV-104326X; GV-326; LK-176
DM3KC81	CP	Glaxo Wellcome plc
DM3KC81	DT	Small molecular drug
DM3KC81	PC	71452
DM3KC81	MW	281.3
DM3KC81	FM	C14H19NO5
DM3KC81	IC	InChI=1S/C14H19NO5/c1-6(16)9-11-7-4-3-5-8(20-2)10(7)12(14(18)19)15(11)13(9)17/h6-9,11,16H,3-5H2,1-2H3,(H,18,19)/t6-,7+,8+,9-,11-/m1/s1
DM3KC81	CS	C[C@H]([C@@H]1[C@H]2[C@H]3CCC[C@@H](C3=C(N2C1=O)C(=O)O)OC)O
DM3KC81	IK	ICFDDEJRXZSWTA-KJFVXYAMSA-N
DM3KC81	IU	(1S,5S,8aS,8bR)-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-5,6,7,8,8a,8b-hexahydro-1H-azeto[1,2-b]isoindole-4-carboxylic acid
DM3KC81	CA	CAS 156769-21-0
DM3KC81	DE	Bacterial infection

DMSRJY3	ID	DMSRJY3
DMSRJY3	DN	Saredutant
DMSRJY3	HS	Discontinued in Phase 3
DMSRJY3	SN	SR-48968; 142001-63-6; SR 48968; SR48968; UNII-720U2QK8I5; (S)-N-Methyl-N(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl)benzamide; CHEMBL308148; SR48968C; 720U2QK8I5; N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide; N-((S)-beta-(2-(4-Acetamido-4-phenylpiperidino)ethyl)-3,4-dichlorophenethyl)-N-methylbenzamide; [3H]saredutant; SR 48968C; Benzamide, N-((2S)-4-(4-(acetylamino)-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl)-N-methyl-;  SR 48965; SR-48965; SR-489686; SR-48968C
DMSRJY3	CP	Sanofi-aventis
DMSRJY3	DT	Small molecular drug
DMSRJY3	PC	104974
DMSRJY3	MW	552.5
DMSRJY3	FM	C31H35Cl2N3O2
DMSRJY3	IC	InChI=1S/C31H35Cl2N3O2/c1-23(37)34-31(27-11-7-4-8-12-27)16-19-36(20-17-31)18-15-26(25-13-14-28(32)29(33)21-25)22-35(2)30(38)24-9-5-3-6-10-24/h3-14,21,26H,15-20,22H2,1-2H3,(H,34,37)/t26-/m1/s1
DMSRJY3	CS	CC(=O)NC1(CCN(CC1)CC[C@H](CN(C)C(=O)C2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4
DMSRJY3	IK	PGKXDIMONUAMFR-AREMUKBSSA-N
DMSRJY3	IU	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide
DMSRJY3	CA	CAS 142001-63-6
DMSRJY3	DE	Anxiety disorder; Depression

DMCJLD1	ID	DMCJLD1
DMCJLD1	DN	SCH 727965
DMCJLD1	HS	Discontinued in Phase 3
DMCJLD1	SN	Dinaciclib; SCH-727965
DMCJLD1	CP	Schering-Plough
DMCJLD1	DT	Small molecular drug
DMCJLD1	PC	46926350
DMCJLD1	MW	396.5
DMCJLD1	FM	C21H28N6O2
DMCJLD1	IC	InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1
DMCJLD1	CS	CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO
DMCJLD1	IK	PIMQWRZWLQKKBJ-SFHVURJKSA-N
DMCJLD1	IU	2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol
DMCJLD1	CA	CAS 779353-01-4
DMCJLD1	CB	CHEBI:95060
DMCJLD1	DE	Acute lymphoblastic leukaemia

DMIHQZ8	ID	DMIHQZ8
DMIHQZ8	DN	Segard
DMIHQZ8	HS	Discontinued in Phase 3
DMIHQZ8	SN	Afelimomab
DMIHQZ8	CP	Abbott Laboratories
DMIHQZ8	DT	Antibody
DMIHQZ8	DE	Sepsis

DM3IJMN	ID	DM3IJMN
DM3IJMN	DN	Seletracetam
DM3IJMN	HS	Discontinued in Phase 3
DM3IJMN	SN	UCB 44212; UCB-44212; 2-[4-(2,2-difluoroethenyl)-2-oxo-pyrrolidin-1-yl]butanamide
DM3IJMN	CP	UCB Pharma
DM3IJMN	DT	Small molecular drug
DM3IJMN	PC	9942725
DM3IJMN	MW	232.23
DM3IJMN	FM	C10H14F2N2O2
DM3IJMN	IC	InChI=1S/C10H14F2N2O2/c1-2-7(10(13)16)14-5-6(3-8(11)12)4-9(14)15/h3,6-7H,2,4-5H2,1H3,(H2,13,16)/t6-,7+/m1/s1
DM3IJMN	CS	CC[C@@H](C(=O)N)N1C[C@@H](CC1=O)C=C(F)F
DM3IJMN	IK	ANWPENAPCIFDSZ-RQJHMYQMSA-N
DM3IJMN	IU	(2S)-2-[(4S)-4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl]butanamide
DM3IJMN	CA	CAS 357336-74-4
DM3IJMN	DE	Epilepsy

DM3FLIX	ID	DM3FLIX
DM3FLIX	DN	Selfotel
DM3FLIX	HS	Discontinued in Phase 3
DM3FLIX	SN	Selfotel; 110347-85-8; CGS 19755; CGS-19755; Selfotel [USAN:INN]; CPDD 0027; (2S,4R)-4-(phosphonomethyl)piperidine-2-carboxylic acid; UNII-N0905W44Y3; H-4-Pal-OH.2HCl; cis-4-(Phosphonomethyl)pipecolic acid; CHEMBL39664; 2-Piperidinecarboxylic acid, 4-(phosphonomethyl)-, cis-; CIS-4-[PHOSPHONOMETHYL]-PIPERIDINE-2-CARBOXYLIC ACID; CHEBI:34973; 2-Piperidinecarboxylic acid, 4-(phosphonomethyl)-, (2S,4R)-; N0905W44Y3; 113229-62-2; cis-4-(phosphonomethyl)piperidine-2-carboxylic acid; Selfotel, (+)-
DM3FLIX	DT	Small molecular drug
DM3FLIX	PC	68736
DM3FLIX	MW	223.16
DM3FLIX	FM	C7H14NO5P
DM3FLIX	IC	InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1
DM3FLIX	CS	C1CN[C@@H](C[C@@H]1CP(=O)(O)O)C(=O)O
DM3FLIX	IK	LPMRCCNDNGONCD-RITPCOANSA-N
DM3FLIX	IU	(2S,4R)-4-(phosphonomethyl)piperidine-2-carboxylic acid
DM3FLIX	CA	CAS 110347-85-8
DM3FLIX	CB	CHEBI:34973
DM3FLIX	DE	Cerebrovascular ischaemia

DMRBYH8	ID	DMRBYH8
DMRBYH8	DN	Sepimostat mesylate
DMRBYH8	HS	Discontinued in Phase 3
DMRBYH8	SN	Renofuthan; FUT-187; TO-187
DMRBYH8	CP	Taiho Pharmaceutical Co Ltd
DMRBYH8	DT	Small molecular drug
DMRBYH8	PC	108040
DMRBYH8	MW	469.5
DMRBYH8	FM	C22H23N5O5S
DMRBYH8	IC	InChI=1S/C21H19N5O2.CH4O3S/c22-19(23)16-2-1-15-12-18(8-5-14(15)11-16)28-20(27)13-3-6-17(7-4-13)26-21-24-9-10-25-21;1-5(2,3)4/h1-8,11-12H,9-10H2,(H3,22,23)(H2,24,25,26);1H3,(H,2,3,4)
DMRBYH8	CS	CS(=O)(=O)O.C1CN=C(N1)NC2=CC=C(C=C2)C(=O)OC3=CC4=C(C=C3)C=C(C=C4)C(=N)N
DMRBYH8	IK	NAMGRNXMZHEICS-UHFFFAOYSA-N
DMRBYH8	IU	(6-carbamimidoylnaphthalen-2-yl) 4-(4,5-dihydro-1H-imidazol-2-ylamino)benzoate;methanesulfonic acid
DMRBYH8	CA	CAS 103926-82-5
DMRBYH8	DE	Solid tumour/cancer

DMPNTDL	ID	DMPNTDL
DMPNTDL	DN	Seratrodast
DMPNTDL	HS	Discontinued in Phase 3
DMPNTDL	SN	Bronica; A 73001; AA 2414; ABT 001; Abbott 73001; A-73001; AA-2414; ABT-001; Abbott-73001; Bronica (TN); Seratrodast [USAN:INN]; Seratrodast (JAN/USAN/INN); (+-)-2,4,5-Trimethyl-3,6-dioxo-zeta-phenyl-1,4-cyclohexadiene-1-heptanoic acid; (+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
DMPNTDL	CP	Takeda Pharma
DMPNTDL	DT	Small molecular drug
DMPNTDL	PC	2449
DMPNTDL	MW	354.4
DMPNTDL	FM	C22H26O4
DMPNTDL	IC	InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
DMPNTDL	CS	CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C
DMPNTDL	IK	ZBVKEHDGYSLCCC-UHFFFAOYSA-N
DMPNTDL	IU	7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
DMPNTDL	CA	CAS 112665-43-7
DMPNTDL	CB	CHEBI:32126
DMPNTDL	DE	Allergic asthma

DMYQT2V	ID	DMYQT2V
DMYQT2V	DN	Sibenadet
DMYQT2V	HS	Discontinued in Phase 3
DMYQT2V	SN	UNII-N32934RHGW; 154189-40-9; CHEMBL82663; N32934RHGW; Sibenadet [INN:BAN]; AC1L4DOB; SCHEMBL48983; DTXSID50165552; AR-C 68397XX; ZINC36268680; ARC-68397; BDBM50128690; AR-C 68397; 4-Hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-1,3-benzothiazol-2(3H)-one; SB-07499; 2(3H)-Benzothiazolone, 4-hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-; FT-0674579; L001485; 4-Hydroxy-7-{2-[2-(3-phenethyloxy-propane-1-sulfonyl)-ethylamino]-ethyl}-3H-benzothiazol-2-one
DMYQT2V	CP	AstraZeneca
DMYQT2V	DT	Small molecular drug
DMYQT2V	PC	183812
DMYQT2V	MW	464.6
DMYQT2V	FM	C22H28N2O5S2
DMYQT2V	IC	InChI=1S/C22H28N2O5S2/c25-19-8-7-18(21-20(19)24-22(26)30-21)9-11-23-12-16-31(27,28)15-4-13-29-14-10-17-5-2-1-3-6-17/h1-3,5-8,23,25H,4,9-16H2,(H,24,26)
DMYQT2V	CS	C1=CC=C(C=C1)CCOCCCS(=O)(=O)CCNCCC2=C3C(=C(C=C2)O)NC(=O)S3
DMYQT2V	IK	DBCKRBGYGMVSTI-UHFFFAOYSA-N
DMYQT2V	IU	4-hydroxy-7-[2-[2-[3-(2-phenylethoxy)propylsulfonyl]ethylamino]ethyl]-3H-1,3-benzothiazol-2-one
DMYQT2V	CA	CAS 154189-40-9
DMYQT2V	DE	Chronic obstructive pulmonary disease

DMZU1TV	ID	DMZU1TV
DMZU1TV	DN	SIBRAFIBAN
DMZU1TV	HS	Discontinued in Phase 3
DMZU1TV	SN	Sibrafiban; UNII-YUE443B0NF; Sibrafiban [USAN:INN:BAN]; YUE443B0NF; Ro 48-3657; 172927-65-0; Ro 48-3657/001; Ethyl (Z)-((1-(N-((p-hydroxyamidino)benzoyl)-L-alanyl)-4-piperidyl)oxy)acetate; Ro-48-3657; ((1-(2-((4-(amino(hydroxyimino)methyl)benzoyl)amino)-1-oxopropyl)-4-piperidinyl)oxy)acetic acid ethyl ester; Sibrafiban [INN]; Acetic acid, ((1-(2-((4-(amino(hydroxyimino)methyl)benzoyl)amino)-1-oxopropyl)-4-piperidinyl)oxy)-, ethyl ester, (S-(Z))-; Sibrafiban [USAN]; Sibrafiban [MART.]; Sibrafiban [WHO-DD]; Xubix
DMZU1TV	DT	Small molecular drug
DMZU1TV	PC	5491394
DMZU1TV	MW	420.5
DMZU1TV	FM	C20H28N4O6
DMZU1TV	IC	InChI=1S/C20H28N4O6/c1-3-29-17(25)12-30-16-8-10-24(11-9-16)20(27)13(2)22-19(26)15-6-4-14(5-7-15)18(21)23-28/h4-7,13,16,28H,3,8-12H2,1-2H3,(H2,21,23)(H,22,26)/t13-/m0/s1
DMZU1TV	CS	CCOC(=O)COC1CCN(CC1)C(=O)[C@H](C)NC(=O)C2=CC=C(C=C2)/C(=N\\O)/N
DMZU1TV	IK	WBNUCLPUOSXSNJ-ZDUSSCGKSA-N
DMZU1TV	IU	ethyl 2-[1-[(2S)-2-[[4-[(E)-N'-hydroxycarbamimidoyl]benzoyl]amino]propanoyl]piperidin-4-yl]oxyacetate
DMZU1TV	CA	CAS 170094-62-9
DMZU1TV	DE	Angina pectoris; Cardiovascular disease

DM0T2QV	ID	DM0T2QV
DM0T2QV	DN	Sitimagene ceradenovec
DM0T2QV	HS	Discontinued in Phase 3
DM0T2QV	SN	Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark
DM0T2QV	CP	Ark Therapeutics
DM0T2QV	DE	Brain cancer

DMXW1Y3	ID	DMXW1Y3
DMXW1Y3	DN	SKF-96067
DMXW1Y3	HS	Discontinued in Phase 3
DMXW1Y3	SN	115607-61-9; Skf-96067; F-96067; SKF96067; 3-Butyryl-4-(2-methylphenylamino)-8-methoxyquinoline; CHEMBL327717; SK-96067; 1-Butanone,1-[8-methoxy-4-[(2-methylphenyl)amino]-3-quinolinyl]-; 1-Butanone, 1-[8-methoxy-4-[(2-methylphenyl)amino]-3-quinolinyl]-; 1-Butanone, 1-(8-methoxy-4-((2-methylphenyl)amino)-3-quinolinyl)-; MAVJDLHBPIXVJL-UHFFFAOYSA-N; AC1MIWAF; ACMC-1BTM4; SCHEMBL451221; ZINC3665; CTK4A9399; DTXSID40151146; BDBM50001254; HY-U00042; 1-[8-METHOXY-4-[(2-METHYLPHENYL)AMINO]-3-QUINOLINYL]-1-BUTANONE
DMXW1Y3	CP	SmithKline Beecham plc
DMXW1Y3	DT	Small molecular drug
DMXW1Y3	PC	3081087
DMXW1Y3	MW	334.4
DMXW1Y3	FM	C21H22N2O2
DMXW1Y3	IC	InChI=1S/C21H22N2O2/c1-4-8-18(24)16-13-22-21-15(10-7-12-19(21)25-3)20(16)23-17-11-6-5-9-14(17)2/h5-7,9-13H,4,8H2,1-3H3,(H,22,23)
DMXW1Y3	CS	CCCC(=O)C1=CN=C2C(=C1NC3=CC=CC=C3C)C=CC=C2OC
DMXW1Y3	IK	MAVJDLHBPIXVJL-UHFFFAOYSA-N
DMXW1Y3	IU	1-[8-methoxy-4-(2-methylanilino)quinolin-3-yl]butan-1-one
DMXW1Y3	CA	CAS 115607-61-9
DMXW1Y3	DE	Peptic ulcer

DMMG47P	ID	DMMG47P
DMMG47P	DN	SUN-09
DMMG47P	HS	Discontinued in Phase 3
DMMG47P	SN	SUN-B09; Prodrug (muscle spasticity), Sun Pharmaceutical
DMMG47P	CP	Sun pharma advanced research
DMMG47P	DE	Hypertonia

DM6M8ZX	ID	DM6M8ZX
DM6M8ZX	DN	Sunepitron
DM6M8ZX	HS	Discontinued in Phase 3
DM6M8ZX	SN	Sunepitron hydrochloride; SUNEPITRON HYDROCHLORIDE; (7S,9aS)-7-(2,5-Dioxopyrrolidin-1-ylmethyl)-2-(2-pyrimidinyl)octahydro-1H-pyrido[1,2-a]pyrazine hydrochloride; (7S,9aS)-1-[2-(2-Pyrimidinyl)perhydropyrido[1,2-a]pyrazin-7-ylmethyl]pyrrolidine-2,5-dione hydrochloride; Sunepitron hydrochloride; CP-93393 (free base); CP-93393-1; 131831-03-3
DM6M8ZX	DT	Small molecular drug
DM6M8ZX	PC	183092
DM6M8ZX	MW	329.4
DM6M8ZX	FM	C17H23N5O2
DM6M8ZX	IC	InChI=1S/C17H23N5O2/c23-15-4-5-16(24)22(15)11-13-2-3-14-12-21(9-8-20(14)10-13)17-18-6-1-7-19-17/h1,6-7,13-14H,2-5,8-12H2/t13-,14-/m0/s1
DM6M8ZX	CS	C1C[C@H]2CN(CCN2C[C@H]1CN3C(=O)CCC3=O)C4=NC=CC=N4
DM6M8ZX	IK	UXWBIYCPUVWKHP-KBPBESRZSA-N
DM6M8ZX	IU	1-[[(7S,9aS)-2-pyrimidin-2-yl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-yl]methyl]pyrrolidine-2,5-dione
DM6M8ZX	CA	CAS 131831-03-3

DMVB9XC	ID	DMVB9XC
DMVB9XC	DN	Tanomastat
DMVB9XC	HS	Discontinued in Phase 3
DMVB9XC	SN	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
DMVB9XC	CP	Bayer
DMVB9XC	TC	Anticancer Agents
DMVB9XC	DT	Small molecular drug
DMVB9XC	PC	6918336
DMVB9XC	MW	410.9
DMVB9XC	FM	C23H19ClO3S
DMVB9XC	IC	InChI=1S/C23H19ClO3S/c24-20-12-10-17(11-13-20)16-6-8-18(9-7-16)22(25)14-19(23(26)27)15-28-21-4-2-1-3-5-21/h1-13,19H,14-15H2,(H,26,27)/t19-/m1/s1
DMVB9XC	CS	C1=CC=C(C=C1)SC[C@@H](CC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)Cl)C(=O)O
DMVB9XC	IK	JXAGDPXECXQWBC-LJQANCHMSA-N
DMVB9XC	IU	(2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
DMVB9XC	CA	CAS 179545-77-8
DMVB9XC	DE	Osteoarthritis; Ovarian cancer; Lung cancer; Pancreatic cancer

DMA4WY5	ID	DMA4WY5
DMA4WY5	DN	Taprostene
DMA4WY5	HS	Discontinued in Phase 3
DMA4WY5	SN	CG-4203
DMA4WY5	CP	Grunenthal GmbH
DMA4WY5	DT	Small molecular drug
DMA4WY5	PC	5311243
DMA4WY5	MW	398.5
DMA4WY5	FM	C24H30O5
DMA4WY5	IC	InChI=1S/C24H30O5/c25-21(16-6-2-1-3-7-16)10-9-19-20-13-18(29-23(20)14-22(19)26)12-15-5-4-8-17(11-15)24(27)28/h4-5,8-12,16,19-23,25-26H,1-3,6-7,13-14H2,(H,27,28)/b10-9+,18-12-/t19-,20-,21-,22-,23+/m1/s1
DMA4WY5	CS	C1CCC(CC1)[C@@H](/C=C/[C@H]2[C@@H](C[C@H]3[C@@H]2C/C(=C/C4=CC(=CC=C4)C(=O)O)/O3)O)O
DMA4WY5	IK	ZLJOKYGJNOQXDP-OZUBPDBUSA-N
DMA4WY5	IU	3-[(Z)-[(3aR,4R,5R,6aS)-4-[(E,3S)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]methyl]benzoic acid
DMA4WY5	CA	CAS 108945-35-3
DMA4WY5	DE	Thrombosis

DM5G9W0	ID	DM5G9W0
DM5G9W0	DN	Taranabant
DM5G9W0	HS	Discontinued in Phase 3
DM5G9W0	SN	Taranabant [USAN]; MK 0364; MK0364; MK-0364; MK-0634; Taranabant (INN/USAN); L]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide; N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropy; N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide; N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide; N-((1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
DM5G9W0	CP	Merck
DM5G9W0	DT	Small molecular drug
DM5G9W0	PC	11226090
DM5G9W0	MW	516
DM5G9W0	FM	C27H25ClF3N3O2
DM5G9W0	IC	InChI=1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1
DM5G9W0	CS	C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F
DM5G9W0	IK	QLYKJCMUNUWAGO-GAJHUEQPSA-N
DM5G9W0	IU	N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide
DM5G9W0	CA	CAS 701977-09-5
DM5G9W0	DE	Obesity

DM9T6MS	ID	DM9T6MS
DM9T6MS	DN	Tecadenoson
DM9T6MS	HS	Discontinued in Phase 3
DM9T6MS	SN	CVT-510; 204512-90-3; UNII-GZ1X96601Z; CHEMBL392149; GZ1X96601Z; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol; BDBM50224766; Tecadenoson [USAN:INN]; Tecadenoson (USAN/INN); AC1L4KMO; SCHEMBL246787; GTPL5592; CHEMBL356254; DTXSID80174415; BDBM50138530; DB04954; N6-[3-(R)-tetrahydrofuranyl]adenosine; HY-19661; Adenosine, N-(3R)-tetrahydro-3-furanyl-; LS-190860; Adenosine, N-(3R)-tetrahydro-3-furanyl)-; CS-0016174; D06019;  CVT-510; N-(3-Tetrahydrofuranyl)-6-aminopurine riboside; Selenocompounds
DM9T6MS	CP	CV Therapeutics
DM9T6MS	DT	Small molecular drug
DM9T6MS	PC	158795
DM9T6MS	MW	337.33
DM9T6MS	FM	C14H19N5O5
DM9T6MS	IC	InChI=1S/C14H19N5O5/c20-3-8-10(21)11(22)14(24-8)19-6-17-9-12(15-5-16-13(9)19)18-7-1-2-23-4-7/h5-8,10-11,14,20-22H,1-4H2,(H,15,16,18)/t7-,8-,10-,11-,14-/m1/s1
DM9T6MS	CS	C1COC[C@@H]1NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DM9T6MS	IK	OESBDSFYJMDRJY-BAYCTPFLSA-N
DM9T6MS	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol
DM9T6MS	CA	CAS 204512-90-3
DM9T6MS	DE	Cardiac arrhythmias; Atrial fibrillation

DMYF1DN	ID	DMYF1DN
DMYF1DN	DN	Terutroban sodium
DMYF1DN	HS	Discontinued in Phase 3
DMYF1DN	SN	S-18886; Terutroban sodium salt; 609340-89-8; 1-Naphthalenepropanoic acid, 6-(((4-chlorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydro-2-methyl-, monosodium salt,
DMYF1DN	CP	Servier
DMYF1DN	DT	Small molecular drug
DMYF1DN	PC	23674098
DMYF1DN	MW	429.9
DMYF1DN	FM	C20H21ClNNaO4S
DMYF1DN	IC	InChI=1S/C20H22ClNO4S.Na/c1-13-2-3-14-12-16(6-9-19(14)18(13)10-11-20(23)24)22-27(25,26)17-7-4-15(21)5-8-17;/h2-5,7-8,16,22H,6,9-12H2,1H3,(H,23,24);/q;+1/p-1/t16-;/m1./s1
DMYF1DN	CS	CC1=C(C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(C=C3)Cl)C=C1)CCC(=O)[O-].[Na+]
DMYF1DN	IK	BQMSKINGUUUIHE-PKLMIRHRSA-M
DMYF1DN	IU	sodium;3-[(6R)-6-[(4-chlorophenyl)sulfonylamino]-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoate
DMYF1DN	CA	CAS 609340-89-8
DMYF1DN	DE	Thrombosis

DMWNXES	ID	DMWNXES
DMWNXES	DN	Thrombomodulin
DMWNXES	HS	Discontinued in Phase 3
DMWNXES	SN	THRODULIN Inj; MB-015; MR-33; Thrombomodulin, Mochida/JCR
DMWNXES	CP	Mochida Pharmaceutical Co Ltd
DMWNXES	DE	Disseminated intravascular coagulation

DME5QDP	ID	DME5QDP
DME5QDP	DN	TIOSPIRONE
DME5QDP	HS	Discontinued in Phase 3
DME5QDP	SN	TIOSPIRONE; tiaspirone; Tiospirone [INN]; Tiospironum [Latin]; Tiospirona [Spanish]; 87691-91-6; UNII-35C6UMO5SR; 35C6UMO5SR; CHEMBL35057; BMY-13859; Tiospironum; Tiospirona; 8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-Azaspiro(4,5)decane-7,9-dione, 8-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-; BMY-13859-1; tiospyrone; TIOSPERONE; AC1L1JPQ; 8-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-8-azaspiro(4.5)decane-7,9-dione hydrochloride; SCHEMBL78696; GTPL101
DME5QDP	DT	Small molecular drug
DME5QDP	PC	55752
DME5QDP	MW	440.6
DME5QDP	FM	C24H32N4O2S
DME5QDP	IC	InChI=1S/C24H32N4O2S/c29-21-17-24(9-3-4-10-24)18-22(30)28(21)12-6-5-11-26-13-15-27(16-14-26)23-19-7-1-2-8-20(19)31-25-23/h1-2,7-8H,3-6,9-18H2
DME5QDP	CS	C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54
DME5QDP	IK	ZFZPJDFBJFHYIV-UHFFFAOYSA-N
DME5QDP	IU	8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione
DME5QDP	CA	CAS 87691-91-6

DM7RNPJ	ID	DM7RNPJ
DM7RNPJ	DN	Trenonacog alfa
DM7RNPJ	HS	Discontinued in Phase 3
DM7RNPJ	SN	IB-1001; IXinity; Nonacog-alfa biosimilar - Emergent BioSolutions; Nonacog-alfa biosimilar - Inspiration; Recombinant factor IX biosimilar - Emergent BioSolutions; Recombinant factor IX biosimilar - Inspiration
DM7RNPJ	DE	Discovery agent

DMOVBSF	ID	DMOVBSF
DMOVBSF	DN	Tresperimus
DMOVBSF	HS	Discontinued in Phase 3
DMOVBSF	SN	LF-08-0299
DMOVBSF	CP	Fournier Pharma
DMOVBSF	DT	Small molecular drug
DMOVBSF	PC	3086680
DMOVBSF	MW	387.5
DMOVBSF	FM	C17H37N7O3
DMOVBSF	IC	InChI=1S/C17H37N7O3/c18-8-7-10-21-9-5-6-13-24-17(26)27-14-15(25)22-11-3-1-2-4-12-23-16(19)20/h21H,1-14,18H2,(H,22,25)(H,24,26)(H4,19,20,23)
DMOVBSF	CS	C(CCCN=C(N)N)CCNC(=O)COC(=O)NCCCCNCCCN
DMOVBSF	IK	LVBMFPUTQOHXQE-UHFFFAOYSA-N
DMOVBSF	IU	[2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] N-[4-(3-aminopropylamino)butyl]carbamate
DMOVBSF	CA	CAS 160677-67-8
DMOVBSF	DE	Autoimmune diabetes

DMXRU9M	ID	DMXRU9M
DMXRU9M	DN	Valspodar
DMXRU9M	HS	Discontinued in Phase 3
DMXRU9M	CP	Novartis
DMXRU9M	DT	Small molecular drug
DMXRU9M	PC	5281884
DMXRU9M	MW	1214.6
DMXRU9M	FM	C63H111N11O12
DMXRU9M	IC	InChI=1S/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)/b27-26+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52+/m1/s1
DMXRU9M	CS	C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C
DMXRU9M	IK	YJDYDFNKCBANTM-QCWCSKBGSA-N
DMXRU9M	IU	(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(E,2R)-2-methylhex-4-enoyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMXRU9M	CA	CAS 121584-18-7
DMXRU9M	CB	CHEBI:8985
DMXRU9M	DE	Acute myeloid leukaemia

DMUB0EC	ID	DMUB0EC
DMUB0EC	DN	VELNACRINE
DMUB0EC	HS	Discontinued in Phase 3
DMUB0EC	SN	Velnacrine; 124027-47-0; 1-hydroxytacrine; 9-amino-1,2,3,4-tetrahydroacridin-1-ol; Velnacrine [INN:BAN]; Velnacrinum [INN-Latin]; Velnacrina [INN-Spanish]; 1-Acridinol,9-amino-1,2,3,4-tetrahydro-; 104675-29-8; 1-Acridinol, 9-amino-1,2,3,4-tetrahydro-; UNII-JFN3Z63E2C; UNII-OQL6V4U301; JFN3Z63E2C; CHEMBL51934; OQL6V4U301; HLVVITIHAZBPKB-UHFFFAOYSA-N; AK160411; Velnacrinum; Velnacrina; 112964-98-4; Velnacrine, (+)-; 9-ATHCO; 1-hydroxy-tacrine; 1-Hydroxy Tacrine; 121445-17-8; ACMC-20ddjc; Velnacrine, (-)-; Spectrum_000073; AC1Q7AWG
DMUB0EC	DT	Small molecular drug
DMUB0EC	PC	3655
DMUB0EC	MW	214.26
DMUB0EC	FM	C13H14N2O
DMUB0EC	IC	InChI=1S/C13H14N2O/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15)
DMUB0EC	CS	C1CC(C2=C(C3=CC=CC=C3N=C2C1)N)O
DMUB0EC	IK	HLVVITIHAZBPKB-UHFFFAOYSA-N
DMUB0EC	IU	9-amino-1,2,3,4-tetrahydroacridin-1-ol
DMUB0EC	CA	CAS 124027-47-0
DMUB0EC	CB	CHEBI:91990
DMUB0EC	DE	Cognitive impairment

DMFJORV	ID	DMFJORV
DMFJORV	DN	Verpasep caltespen
DMFJORV	HS	Discontinued in Phase 3
DMFJORV	CP	Akela Pharma
DMFJORV	DT	Vaccine
DMFJORV	DE	Cervical Intraepithelial neoplasia

DMBRYT8	ID	DMBRYT8
DMBRYT8	DN	XEMILOFIBAN
DMBRYT8	HS	Discontinued in Phase 3
DMBRYT8	SN	Xemilofiban; Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate
DMBRYT8	DT	Small molecular drug
DMBRYT8	PC	60957
DMBRYT8	MW	358.4
DMBRYT8	FM	C18H22N4O4
DMBRYT8	IC	InChI=1S/C18H22N4O4/c1-3-13(11-17(25)26-4-2)21-15(23)9-10-16(24)22-14-7-5-12(6-8-14)18(19)20/h1,5-8,13H,4,9-11H2,2H3,(H3,19,20)(H,21,23)(H,22,24)/t13-/m1/s1
DMBRYT8	CS	CCOC(=O)C[C@@H](C#C)NC(=O)CCC(=O)NC1=CC=C(C=C1)C(=N)N
DMBRYT8	IK	ZHCINJQZDFCSEL-CYBMUJFWSA-N
DMBRYT8	IU	ethyl (3S)-3-[[4-(4-carbamimidoylanilino)-4-oxobutanoyl]amino]pent-4-ynoate
DMBRYT8	CA	CAS 149820-74-6
DMBRYT8	DE	Peripheral vascular disease; Cardiovascular disease

DM3EZ68	ID	DM3EZ68
DM3EZ68	DN	Y-23684
DM3EZ68	HS	Discontinued in Phase 3
DM3EZ68	SN	2-(4-Chlorophenyl)-2,3,5,6-tetrahydro[1]benzothiepino[5,4-c]pyridazin-3-one 7-oxide
DM3EZ68	DT	Small molecular drug
DM3EZ68	PC	195253
DM3EZ68	MW	356.8
DM3EZ68	FM	C18H13ClN2O2S
DM3EZ68	IC	InChI=1S/C18H13ClN2O2S/c19-13-5-7-14(8-6-13)21-17(22)11-12-9-10-24(23)16-4-2-1-3-15(16)18(12)20-21/h1-8,11H,9-10H2
DM3EZ68	CS	C1CS(=O)C2=CC=CC=C2C3=NN(C(=O)C=C31)C4=CC=C(C=C4)Cl
DM3EZ68	IK	WHMCSFWQVGJBGM-UHFFFAOYSA-N
DM3EZ68	IU	2-(4-chlorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one
DM3EZ68	CA	CAS 118288-67-8
DM3EZ68	CB	CHEBI:79404
DM3EZ68	DE	Anxiety disorder

DMFEN6T	ID	DMFEN6T
DMFEN6T	DN	YM533
DMFEN6T	HS	Discontinued in Phase 3
DMFEN6T	SN	Beraprost sodium
DMFEN6T	CP	Astellas
DMFEN6T	DT	Small molecular drug
DMFEN6T	PC	23676207
DMFEN6T	MW	420.5
DMFEN6T	FM	C24H29NaO5
DMFEN6T	IC	InChI=1S/C24H30O5.Na/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28;/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28);/q;+1/p-1/b13-12+;
DMFEN6T	CS	CC#CCC(C)C(/C=C/C1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)[O-])O)O.[Na+]
DMFEN6T	IK	YTCZZXIRLARSET-UEIGIMKUSA-M
DMFEN6T	IU	sodium;4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
DMFEN6T	CA	CAS 88475-69-8
DMFEN6T	DE	Chronic renal failure

DM51FVE	ID	DM51FVE
DM51FVE	DN	Zamifenacin
DM51FVE	HS	Discontinued in Phase 3
DM51FVE	SN	Zamifenacin; 127308-82-1; UNII-Y88Q418Y7M; Y88Q418Y7M; Zamifenacin [INN]; 127263-13-2; AC1MJ6I5; DSSTox_RID_82215; DSSTox_CID_27257; DSSTox_GSID_47257; SCHEMBL311829; CHEMBL27507; DTXSID9047257; UK-766542 [As Fumarate]; CHEBI:93417; ZINC3802222; BCP28100; Tox21_300210; AKOS022182209; SB19711; API0007427; UK-76654-2 [AS FUMARATE]; NCGC00247932-01; NCGC00254011-01; AJ-45652; CAS-127308-82-1; BRD-K80451230-051-01-8; (R)-3-(Diphenylmethoxy)-1-(3,4-(methylenedioxy)phenetyl)piperidene
DM51FVE	DT	Small molecular drug
DM51FVE	PC	3086618
DM51FVE	MW	415.5
DM51FVE	FM	C27H29NO3
DM51FVE	IC	InChI=1S/C27H29NO3/c1-3-8-22(9-4-1)27(23-10-5-2-6-11-23)31-24-12-7-16-28(19-24)17-15-21-13-14-25-26(18-21)30-20-29-25/h1-6,8-11,13-14,18,24,27H,7,12,15-17,19-20H2/t24-/m1/s1
DM51FVE	CS	C1C[C@H](CN(C1)CCC2=CC3=C(C=C2)OCO3)OC(C4=CC=CC=C4)C5=CC=CC=C5
DM51FVE	IK	BDNFQGRSKSQXRI-XMMPIXPASA-N
DM51FVE	IU	(3R)-3-benzhydryloxy-1-[2-(1,3-benzodioxol-5-yl)ethyl]piperidine
DM51FVE	CA	CAS 127308-82-1
DM51FVE	CB	CHEBI:93417
DM51FVE	DE	Urinary incontinence

DMTCP8H	ID	DMTCP8H
DMTCP8H	DN	Zanapezil
DMTCP8H	HS	Discontinued in Phase 3
DMTCP8H	SN	TAK-147
DMTCP8H	CP	Takeda Pharmaceutical Co Ltd
DMTCP8H	DT	Small molecular drug
DMTCP8H	PC	198752
DMTCP8H	MW	376.5
DMTCP8H	FM	C25H32N2O
DMTCP8H	IC	InChI=1S/C25H32N2O/c28-25(23-11-10-22-8-4-5-15-26-24(22)18-23)12-9-20-13-16-27(17-14-20)19-21-6-2-1-3-7-21/h1-3,6-7,10-11,18,20,26H,4-5,8-9,12-17,19H2
DMTCP8H	CS	C1CCNC2=C(C1)C=CC(=C2)C(=O)CCC3CCN(CC3)CC4=CC=CC=C4
DMTCP8H	IK	PMBLXLOXUGVTGB-UHFFFAOYSA-N
DMTCP8H	IU	3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)propan-1-one
DMTCP8H	CA	CAS 142852-50-4
DMTCP8H	DE	Alzheimer disease

DMIK6C9	ID	DMIK6C9
DMIK6C9	DN	Zibotentan
DMIK6C9	HS	Discontinued in Phase 3
DMIK6C9	SN	ZD4054; ZD-4054; ZD4054, Zibotentan; Zibotentan (JAN/INN); Trans,trans-2(4-methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic acid; N-(3-methoxy-5-methyl-pyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
DMIK6C9	CP	AstraZeneca
DMIK6C9	DT	Small molecular drug
DMIK6C9	PC	9910224
DMIK6C9	MW	424.4
DMIK6C9	FM	C19H16N6O4S
DMIK6C9	IC	InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25)
DMIK6C9	CS	CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4
DMIK6C9	IK	FJHHZXWJVIEFGJ-UHFFFAOYSA-N
DMIK6C9	IU	N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
DMIK6C9	CA	CAS 186497-07-4
DMIK6C9	CB	CHEBI:94573
DMIK6C9	DE	Prostate cancer

DM6R3WC	ID	DM6R3WC
DM6R3WC	DN	BAY 86-6150
DM6R3WC	HS	Discontinued in Phase 2/3
DM6R3WC	SN	Peg rFVIIa
DM6R3WC	CP	Bayer HealthCare Pharmaceuticals
DM6R3WC	DE	Hemophilia

DMTR50E	ID	DMTR50E
DMTR50E	DN	Ilepatril
DMTR50E	HS	Discontinued in Phase 2/3
DMTR50E	CP	Sanofi-Aventis
DMTR50E	PC	9824131
DMTR50E	MW	432.5
DMTR50E	FM	C22H28N2O5S
DMTR50E	IC	InChI=1S/C22H28N2O5S/c1-12(2)19(30-13(3)25)20(26)23-16-11-14-7-4-5-8-15(14)17-9-6-10-18(22(28)29)24(17)21(16)27/h4-5,7-8,12,16-19H,6,9-11H2,1-3H3,(H,23,26)(H,28,29)/t16-,17+,18-,19-/m0/s1
DMTR50E	CS	CC(C)[C@@H](C(=O)N[C@H]1CC2=CC=CC=C2[C@H]3CCC[C@H](N3C1=O)C(=O)O)SC(=O)C
DMTR50E	IK	FXKFFTMLFPWYFH-RDGPPVDQSA-N
DMTR50E	IU	(4S,7S,12bR)-7-[[(2S)-2-acetylsulfanyl-3-methylbutanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid
DMTR50E	CA	CAS 473289-62-2
DMTR50E	DE	Diabetic nephropathy; Heart failure; Renal failure; Hypertension

DMMT4PB	ID	DMMT4PB
DMMT4PB	DN	Osanetant
DMMT4PB	HS	Discontinued in Phase 2b
DMMT4PB	SN	Osanetant [INN]; SR-142801; UNII-K7G81N94DT; SB-236984; SR-142806; SR142801; SR-14280; K7G81N94DT; CHEMBL346178; 160492-56-8; SR 142801; N-(1-(3-((R)-1-Benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl)propyl)-4-phenyl-4-piperidyl)-N-methylacetamide; n-(1-{3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-n-methylacetamide; N-(1-(3-((3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl)propyl)-4-phenyl-4-piperidinyl)-N-methylacetamide; [3H]osanetant;  Osanetant [INN]; N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N-methylacetamide; N-(1-{3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-n-methylacetamide
DMMT4PB	CP	Sanofi-aventis
DMMT4PB	DT	Small molecular drug
DMMT4PB	PC	219077
DMMT4PB	MW	606.6
DMMT4PB	FM	C35H41Cl2N3O2
DMMT4PB	IC	InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1
DMMT4PB	CS	CC(=O)N(C)C1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
DMMT4PB	IK	DZOJBGLFWINFBF-UMSFTDKQSA-N
DMMT4PB	IU	N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N-methylacetamide
DMMT4PB	CA	CAS 160492-56-8
DMMT4PB	DE	Schizoaffective disorder; Schizophrenia; Depression

DMLQVTJ	ID	DMLQVTJ
DMLQVTJ	DN	Octopamine
DMLQVTJ	HS	Discontinued in Phase 2a
DMLQVTJ	SN	Analet; Norden; Norfen; Norphen; Norsympathol; Norsympatol; Norsynephrine; Octapamine; Octopamin; Octopamina; Octopaminum; Octopamina [Spanish]; Octopamine [INN]; Octopamine hydrochloride; Octopaminum [Latin]; Paraoxyphenyl aminoethanol; ND 50; TBB066518; WIN 5512; WV 569; Beta-hydroxytyramine; Octopamina [INN-Spanish]; Octopaminum [INN-Latin]; P-Hydroxyphenylethanolamine; P-Norsynephrin; P-Octopamine; Para-Octopamine; Alpha-Aminoethyl-4-hydroxybenzylalkohol; Alpha-(Aminoethyl)-4-hydroxybenzenemethanol; Alpha-(Aminoethyl)-p-hydroxybenzyl alcohol; Alpha-(Aminomethyl)-p-hydroxybenzyl alcohol; Alpha-(aminomethyl)-4-hydroxybenzenemethanol; 1-(p-Hydroxyphenyl)-2-aminoethanol; 4-(2-Amino-1-hydroxyethyl)phenol; 4-Octopamine
DMLQVTJ	CP	Sanofi-aventis
DMLQVTJ	DT	Small molecular drug
DMLQVTJ	PC	4581
DMLQVTJ	MW	153.18
DMLQVTJ	FM	C8H11NO2
DMLQVTJ	IC	InChI=1S/C8H11NO2/c9-5-8(11)6-1-3-7(10)4-2-6/h1-4,8,10-11H,5,9H2
DMLQVTJ	CS	C1=CC(=CC=C1C(CN)O)O
DMLQVTJ	IK	QHGUCRYDKWKLMG-UHFFFAOYSA-N
DMLQVTJ	IU	4-(2-amino-1-hydroxyethyl)phenol
DMLQVTJ	CA	CAS 104-14-3
DMLQVTJ	CB	CHEBI:17134
DMLQVTJ	DE	Thrombosis

DMQV4C3	ID	DMQV4C3
DMQV4C3	DN	4030W92
DMQV4C3	HS	Discontinued in Phase 2
DMQV4C3	SN	BW-4030W92; 5-(2,3-Dichlorophenyl)-6-(fluoromethyl)pyrimidine-2,4-diamine
DMQV4C3	DT	Small molecular drug
DMQV4C3	PC	9860692
DMQV4C3	MW	287.12
DMQV4C3	FM	C11H9Cl2FN4
DMQV4C3	IC	InChI=1S/C11H9Cl2FN4/c12-6-3-1-2-5(9(6)13)8-7(4-14)17-11(16)18-10(8)15/h1-3H,4H2,(H4,15,16,17,18)
DMQV4C3	CS	C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=C2N)N)CF
DMQV4C3	IK	GKBLWFDYSYTVEA-UHFFFAOYSA-N
DMQV4C3	IU	5-(2,3-dichlorophenyl)-6-(fluoromethyl)pyrimidine-2,4-diamine
DMQV4C3	CA	CAS 130801-33-1
DMQV4C3	DE	Pain

DMUXMGN	ID	DMUXMGN
DMUXMGN	DN	4991W93
DMUXMGN	HS	Discontinued in Phase 2
DMUXMGN	SN	UNII-EP9X802T0C; EP9X802T0C; 171549-56-7; SCHEMBL7838123; SCHEMBL7838126; 2-Oxazolidinone, 4-((3-(trans-3-(dimethylamino)cyclobutyl)-1H-indol-5-yl)methyl)-, (4S)-; LS-192216; 4991-W-93
DMUXMGN	CP	Glaxo Wellcome plc
DMUXMGN	DT	Small molecular drug
DMUXMGN	PC	9818279
DMUXMGN	MW	313.4
DMUXMGN	FM	C18H23N3O2
DMUXMGN	IC	InChI=1S/C18H23N3O2/c1-21(2)14-7-12(8-14)16-9-19-17-4-3-11(6-15(16)17)5-13-10-23-18(22)20-13/h3-4,6,9,12-14,19H,5,7-8,10H2,1-2H3,(H,20,22)/t12?,13-,14?/m0/s1
DMUXMGN	CS	CN(C)C1CC(C1)C2=CNC3=C2C=C(C=C3)C[C@H]4COC(=O)N4
DMUXMGN	IK	JLDUTSKKXXJGGG-MOKVOYLWSA-N
DMUXMGN	IU	(4S)-4-[[3-[3-(dimethylamino)cyclobutyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
DMUXMGN	CA	CAS 171549-56-7
DMUXMGN	DE	Migraine

DMYOG98	ID	DMYOG98
DMYOG98	DN	534U87
DMYOG98	HS	Discontinued in Phase 2
DMYOG98	SN	Anticonvulsant, Glaxo Wellcome; BW-534U87
DMYOG98	CP	Burroughs Wellcome Inc
DMYOG98	PC	22149400
DMYOG98	MW	297.69
DMYOG98	FM	C12H10ClF2N5
DMYOG98	IC	InChI=1S/C12H9F2N5.ClH/c13-8-2-1-3-9(14)7(8)6-19-10-4-5-16-12(15)11(10)17-18-19;/h1-5H,6H2,(H2,15,16);1H
DMYOG98	CS	C1=CC(=C(C(=C1)F)CN2C3=C(C(=NC=C3)N)N=N2)F.Cl
DMYOG98	IK	JKXUBXRPDZPXOD-UHFFFAOYSA-N
DMYOG98	IU	1-[(2,6-difluorophenyl)methyl]triazolo[4,5-c]pyridin-4-amine;hydrochloride
DMYOG98	CA	CAS 143153-93-9
DMYOG98	DE	Epileptic seizures

DMG0I6L	ID	DMG0I6L
DMG0I6L	DN	97-139
DMG0I6L	HS	Discontinued in Phase 2
DMG0I6L	SN	S-0139; SB-737004; 737004; [4aS-(4abeta,6aalpha,6bbeta,12abeta,14bbeta]-6a-[3-[2-(3-Carboxy-2(E)-propenamido)-5-hydroxyphenyl]-2(E)-propenoyloxymethyl]-2,2,6b,9,9.12a-hexamethyl-10-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a
DMG0I6L	DE	Cerebrovascular disease

DMSGY5M	ID	DMSGY5M
DMSGY5M	DN	99mTc-ciprofloxacin
DMSGY5M	HS	Discontinued in Phase 2
DMSGY5M	SN	INFECTON; Technetium-99m-ciprofloxacin; 99mTc-ciprofloxacin
DMSGY5M	CP	Draxis
DMSGY5M	DE	Infectious disease

DMEG240	ID	DMEG240
DMEG240	DN	A-437203
DMEG240	HS	Discontinued in Phase 2
DMEG240	SN	ABT-925 anhydrous free base; A-437203; 220519-06-2; UNII-E6CKI5C54O; E6CKI5C54O; CHEMBL439338; 2-((3-(4-(2-(tert-Butyl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)propyl)thio)pyrimidin-4(3H)-one; ABT-925 free base; SCHEMBL1043144; DTXSID70176529; BDBM50177354; HY-U00185; AKOS027334456; CS-7258; LU-201640; LU 201640; A 37203; A-37203; L018707; 4(3H)-Pyrimidinone, 2-((3-(4-(2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl)-1-piperazinyl)propyl)thio)-
DMEG240	DT	Small molecular drug
DMEG240	PC	9916104
DMEG240	MW	456.5
DMEG240	FM	C20H27F3N6OS
DMEG240	IC	InChI=1S/C20H27F3N6OS/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30)
DMEG240	CS	CC(C)(C)C1=NC(=CC(=N1)N2CCN(CC2)CCCSC3=NC=CC(=O)N3)C(F)(F)F
DMEG240	IK	KXVAICSRMHXLJN-UHFFFAOYSA-N
DMEG240	IU	2-[3-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]propylsulfanyl]-1H-pyrimidin-6-one
DMEG240	CA	CAS 220519-06-2
DMEG240	DE	Psychotic disorder

DMX56G4	ID	DMX56G4
DMX56G4	DN	A-5021
DMX56G4	HS	Discontinued in Phase 2
DMX56G4	SN	(-)-9-[1(S),2(R)-Bis(hydroxymethyl)cyclopropan-1-ylmethyl]guanine; 145512-85-2
DMX56G4	DT	Small molecular drug
DMX56G4	PC	484557
DMX56G4	DE	Virus infection

DMF4MRD	ID	DMF4MRD
DMF4MRD	DN	A-75925
DMF4MRD	HS	Discontinued in Phase 2
DMF4MRD	SN	A-74704; A-76928; A-77003; Protease inhibitors, Abbott
DMF4MRD	CP	Abbott Laboratories
DMF4MRD	DT	Small molecular drug
DMF4MRD	PC	72290
DMF4MRD	MW	766.9
DMF4MRD	FM	C44H54N4O8
DMF4MRD	IC	InChI=1S/C44H54N4O8/c1-29(2)37(47-43(53)55-27-33-21-13-7-14-22-33)41(51)45-35(25-31-17-9-5-10-18-31)39(49)40(50)36(26-32-19-11-6-12-20-32)46-42(52)38(30(3)4)48-44(54)56-28-34-23-15-8-16-24-34/h5-24,29-30,35-40,49-50H,25-28H2,1-4H3,(H,45,51)(H,46,52)(H,47,53)(H,48,54)/t35-,36-,37-,38-,39+,40+/m0/s1
DMF4MRD	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H]([C@@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)C)NC(=O)OCC3=CC=CC=C3)O)O)NC(=O)OCC4=CC=CC=C4
DMF4MRD	IK	TZRRVSCDIPHXHN-RRUVMKMCSA-N
DMF4MRD	IU	benzyl N-[(2S)-1-[[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
DMF4MRD	CA	CAS 129467-48-7
DMF4MRD	DE	Virus infection

DM7VSBH	ID	DM7VSBH
DM7VSBH	DN	A-86719.1
DM7VSBH	HS	Discontinued in Phase 2
DM7VSBH	SN	ABT-719; AC1OCF8N; A-86719.1; 8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid hydrate hydrochloride
DM7VSBH	CP	Abbott Laboratories
DM7VSBH	DT	Small molecular drug
DM7VSBH	PC	6918280
DM7VSBH	MW	399.8
DM7VSBH	FM	C18H23ClFN3O4
DM7VSBH	IC	InChI=1S/C18H20FN3O3.ClH.H2O/c1-9-15-12(10-2-3-10)6-13(18(24)25)17(23)22(15)8-14(19)16(9)21-5-4-11(20)7-21;;/h6,8,10-11H,2-5,7,20H2,1H3,(H,24,25);1H;1H2/t11-;;/m0../s1
DM7VSBH	CS	CC1=C(C(=CN2C1=C(C=C(C2=O)C(=O)O)C3CC3)F)N4CC[C@@H](C4)N.O.Cl
DM7VSBH	IK	HOXFHPNUPIUHBB-IDMXKUIJSA-N
DM7VSBH	IU	8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid;hydrate;hydrochloride
DM7VSBH	DE	Bacterial infection

DMB5TH3	ID	DMB5TH3
DMB5TH3	DN	AA-193
DMB5TH3	HS	Discontinued in Phase 2
DMB5TH3	SN	AA-193; 107804-48-8; Furo[2,3-g]-1,2-benzisoxazole-7-carboxylicacid, 5-chloro-7,8-dihydro-3-phenyl-; AC1OCEWV; ACMC-20mb6x; CHEMBL93997; SCHEMBL10512834; CTK0H6407; AKOS030601198; 5-chloro-3-phenyl-7,8-dihydrofuro[2,3-g][1,2]benzoxazole-7-carboxylic acid
DMB5TH3	CP	Chugai Pharmaceutical Co Ltd
DMB5TH3	DT	Small molecular drug
DMB5TH3	PC	6918012
DMB5TH3	MW	315.71
DMB5TH3	FM	C16H10ClNO4
DMB5TH3	IC	InChI=1S/C16H10ClNO4/c17-11-6-9-13(8-4-2-1-3-5-8)18-22-14(9)10-7-12(16(19)20)21-15(10)11/h1-6,12H,7H2,(H,19,20)
DMB5TH3	CS	C1C(OC2=C(C=C3C(=C21)ON=C3C4=CC=CC=C4)Cl)C(=O)O
DMB5TH3	IK	RVKIPRIYUGLRFF-UHFFFAOYSA-N
DMB5TH3	IU	5-chloro-3-phenyl-7,8-dihydrofuro[2,3-g][1,2]benzoxazole-7-carboxylic acid
DMB5TH3	DE	Hyperuricaemia

DM78623	ID	DM78623
DM78623	DN	AA-2379
DM78623	HS	Discontinued in Phase 2
DM78623	SN	7-Butyl-3-(methylamino)-4,6-dioxo-5-propyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidine-2-carboxylic acid methyl ester
DM78623	DT	Small molecular drug
DM78623	PC	128390
DM78623	MW	337.37
DM78623	FM	C15H23N5O4
DM78623	IC	InChI=1S/C15H23N5O4/c1-5-7-9-18-12-10(13(21)19(8-6-2)14(18)22)11(16-3)20(17-12)15(23)24-4/h16H,5-9H2,1-4H3
DM78623	CS	CCCCN1C2=NN(C(=C2C(=O)N(C1=O)CCC)NC)C(=O)OC
DM78623	IK	AKJPAUXGPOUISG-UHFFFAOYSA-N
DM78623	IU	methyl 7-butyl-3-(methylamino)-4,6-dioxo-5-propylpyrazolo[3,4-d]pyrimidine-2-carboxylate
DM78623	CA	CAS 103446-98-6
DM78623	DE	Inflammation

DM8DT7U	ID	DM8DT7U
DM8DT7U	DN	ABT-089
DM8DT7U	HS	Discontinued in Phase 2
DM8DT7U	SN	Pozanicline; A 94224; ABT 089; Pozanicline (USAN); (R)-2-Methyl-3-(2-pyrrolidinylmethoxy)pyridine; 2-Methyl-3-(2-pyrrolidinylmethoxy)pyridine; 2-Methyl-3-(2S-pyrrolidinylmethoxy)pyridine; 2-methyl-3-[[(2R)-pyrrolidin-2-yl]methoxy]pyridine; 2-methyl-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine
DM8DT7U	CP	Abbott Laboratories
DM8DT7U	DT	Small molecular drug
DM8DT7U	PC	178052
DM8DT7U	MW	192.26
DM8DT7U	FM	C11H16N2O
DM8DT7U	IC	InChI=1S/C11H16N2O/c1-9-11(5-3-6-12-9)14-8-10-4-2-7-13-10/h3,5-6,10,13H,2,4,7-8H2,1H3/t10-/m0/s1
DM8DT7U	CS	CC1=C(C=CC=N1)OC[C@@H]2CCCN2
DM8DT7U	IK	YRVIKLBSVVNSHF-JTQLQIEISA-N
DM8DT7U	IU	2-methyl-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine
DM8DT7U	CA	CAS 161417-03-4
DM8DT7U	DE	Dementia; Anxiety disorder; Schizophrenia; Attention deficit hyperactivity disorder

DMNP72I	ID	DMNP72I
DMNP72I	DN	ABT-418
DMNP72I	HS	Discontinued in Phase 2
DMNP72I	SN	Abt-418; Abt 418; 147402-53-7; 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; CHEMBL274525; (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)isoxazole; C9H14N2O; Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-; Isoxazole, 3-methyl-5-(1-methyl-2-pyrrolidinyl)-, (S)-; Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-; 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole; AC1L3OPH; SCHEMBL194161; DTXSID10163711; ILLGYRJAYAAAEW-QMMMGPOBSA-N; ZINC3786099; BDBM50035398
DMNP72I	DT	Small molecular drug
DMNP72I	PC	119380
DMNP72I	MW	166.22
DMNP72I	FM	C9H14N2O
DMNP72I	IC	InChI=1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1
DMNP72I	CS	CC1=NOC(=C1)[C@@H]2CCCN2C
DMNP72I	IK	ILLGYRJAYAAAEW-QMMMGPOBSA-N
DMNP72I	IU	3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
DMNP72I	CA	CAS 147402-53-7
DMNP72I	DE	Alzheimer disease

DMGMBCW	ID	DMGMBCW
DMGMBCW	DN	ABT-594
DMGMBCW	HS	Discontinued in Phase 2
DMGMBCW	SN	Tebanicline; ABT-594; 198283-73-7; Tebanicline [INN]; UNII-9KX8NKV538; CHEMBL430497; ABT594; 9KX8NKV538; (R)-5-(2-Azetidnylmethoxy)-2-chloropyridine; 5-((2R)-Azetidinylmethoxy)-2-chloropyridine; Pyridine, 5-(2-azetidnylmethoxy)-2-chloro-, (R)-; (R)-5-(azetidin-2-ylmethoxy)-2-chloropyridine; 5-[[(2R)-azetidin-2-yl]methoxy]-2-chloropyridine; Ebanicline; TEBENICILINE; AC1MIP4S; Tebanicline(ABT-594); SCHEMBL120178; GTPL3989; DTXSID90173555; MolPort-044-727-781; MKTAGSRKQIGEBH-SSDOTTSWSA-N; EX-A2483; BCP19181; ZINC3959783; BDBM50062641
DMGMBCW	DT	Small molecular drug
DMGMBCW	PC	3075702
DMGMBCW	MW	198.65
DMGMBCW	FM	C9H11ClN2O
DMGMBCW	IC	InChI=1S/C9H11ClN2O/c10-9-2-1-8(5-12-9)13-6-7-3-4-11-7/h1-2,5,7,11H,3-4,6H2/t7-/m1/s1
DMGMBCW	CS	C1CN[C@H]1COC2=CN=C(C=C2)Cl
DMGMBCW	IK	MKTAGSRKQIGEBH-SSDOTTSWSA-N
DMGMBCW	IU	5-[[(2R)-azetidin-2-yl]methoxy]-2-chloropyridine
DMGMBCW	CA	CAS 198283-73-7

DMDQVY4	ID	DMDQVY4
DMDQVY4	DN	ABT-724
DMDQVY4	HS	Discontinued in Phase 2
DMDQVY4	SN	2-[4-(2-Pyridyl)piperazin-1-ylmethyl]-1H-benzimidazole maleate
DMDQVY4	DT	Small molecular drug
DMDQVY4	PC	5025739
DMDQVY4	MW	293.4
DMDQVY4	FM	C17H19N5
DMDQVY4	IC	InChI=1S/C17H19N5/c1-2-6-15-14(5-1)19-16(20-15)13-21-9-11-22(12-10-21)17-7-3-4-8-18-17/h1-8H,9-13H2,(H,19,20)
DMDQVY4	CS	C1CN(CCN1CC2=NC3=CC=CC=C3N2)C4=CC=CC=N4
DMDQVY4	IK	FRPJGTNLZNXQEX-UHFFFAOYSA-N
DMDQVY4	IU	2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole
DMDQVY4	CA	CAS 70006-24-5
DMDQVY4	CB	CHEBI:104134
DMDQVY4	DE	Erectile dysfunction

DMM02XV	ID	DMM02XV
DMM02XV	DN	AD-5467
DMM02XV	HS	Discontinued in Phase 2
DMM02XV	SN	Rac-2,8-Bis(1-methylethyl)-3-thioxo-2,3-dihydro-4H-1,4-benzoxazine-4-acetic acid
DMM02XV	DT	Small molecular drug
DMM02XV	PC	197383
DMM02XV	MW	307.4
DMM02XV	FM	C16H21NO3S
DMM02XV	IC	InChI=1S/C16H21NO3S/c1-9(2)11-6-5-7-12-15(11)20-14(10(3)4)16(21)17(12)8-13(18)19/h5-7,9-10,14H,8H2,1-4H3,(H,18,19)
DMM02XV	CS	CC(C)C1C(=S)N(C2=CC=CC(=C2O1)C(C)C)CC(=O)O
DMM02XV	IK	CLDJCRWXLDLJLO-UHFFFAOYSA-N
DMM02XV	IU	2-[2,8-di(propan-2-yl)-3-sulfanylidene-1,4-benzoxazin-4-yl]acetic acid
DMM02XV	CA	CAS 112808-22-7
DMM02XV	DE	Diabetic complication

DMTOCV7	ID	DMTOCV7
DMTOCV7	DN	Adaprolol maleate-SME
DMTOCV7	HS	Discontinued in Phase 2
DMTOCV7	SN	Adaprolol; Adaprolol maleate; CDDD-2803; HGP-2; Submicron Emulsion, Pharmos; Adaprolol maleate-SME, Pharmos
DMTOCV7	CP	Pharmos Corp
DMTOCV7	DE	Glaucoma/ocular hypertension

DMMKFUP	ID	DMMKFUP
DMMKFUP	DN	Adatanserin
DMMKFUP	HS	Discontinued in Phase 2
DMMKFUP	SN	Adatanserin [INN]; WY 50324; N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide
DMMKFUP	CP	Wyeth
DMMKFUP	DT	Small molecular drug
DMMKFUP	PC	130918
DMMKFUP	MW	369.5
DMMKFUP	FM	C21H31N5O
DMMKFUP	IC	InChI=1S/C21H31N5O/c27-19(21-13-16-10-17(14-21)12-18(11-16)15-21)22-4-5-25-6-8-26(9-7-25)20-23-2-1-3-24-20/h1-3,16-18H,4-15H2,(H,22,27)
DMMKFUP	CS	C1CN(CCN1CCNC(=O)C23CC4CC(C2)CC(C4)C3)C5=NC=CC=N5
DMMKFUP	IK	HPFLVTSWRFCPCV-UHFFFAOYSA-N
DMMKFUP	IU	N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide
DMMKFUP	CA	CAS 127266-56-2
DMMKFUP	DE	Mood disorder

DMPFQLX	ID	DMPFQLX
DMPFQLX	DN	ADL 10-0101
DMPFQLX	HS	Discontinued in Phase 2
DMPFQLX	CP	Adolor
DMPFQLX	DE	Pain

DMQM54P	ID	DMQM54P
DMQM54P	DN	ADL-5945
DMQM54P	HS	Discontinued in Phase 2
DMQM54P	SN	OpRA III
DMQM54P	CP	Eli Lilly & Co
DMQM54P	DE	Constipation

DMJ8ZFR	ID	DMJ8ZFR
DMJ8ZFR	DN	ADOZELESIN
DMJ8ZFR	HS	Discontinued in Phase 2
DMJ8ZFR	SN	Adosar; Adozelesin < Rec INN; U-73975; (7bR,8aS)-N-[2-[(1,2,4,5,8,8a-Hexahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2-yl)carbonyl]-1H-indol-5-yl]-2-benzofurancarboxamide
DMJ8ZFR	DT	Small molecular drug
DMJ8ZFR	PC	6917987
DMJ8ZFR	MW	502.5
DMJ8ZFR	FM	C30H22N4O4
DMJ8ZFR	IC	InChI=1S/C30H22N4O4/c1-15-13-31-27-22(35)11-25-30(26(15)27)12-18(30)14-34(25)29(37)21-9-17-8-19(6-7-20(17)33-21)32-28(36)24-10-16-4-2-3-5-23(16)38-24/h2-11,13,18,31,33H,12,14H2,1H3,(H,32,36)/t18-,30+/m1/s1
DMJ8ZFR	CS	CC1=CNC2=C1[C@@]34C[C@@H]3CN(C4=CC2=O)C(=O)C5=CC6=C(N5)C=CC(=C6)NC(=O)C7=CC8=CC=CC=C8O7
DMJ8ZFR	IK	BYRVKDUQDLJUBX-JJCDCTGGSA-N
DMJ8ZFR	IU	N-[2-[(1R,12S)-3-methyl-7-oxo-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),3,8-triene-10-carbonyl]-1H-indol-5-yl]-1-benzofuran-2-carboxamide
DMJ8ZFR	CA	CAS 110314-48-2
DMJ8ZFR	DE	Solid tumour/cancer

DMS8JIU	ID	DMS8JIU
DMS8JIU	DN	ADROGOLIDE HYDROCHLORIDE
DMS8JIU	HS	Discontinued in Phase 2
DMS8JIU	SN	ABT-431; Adrogolide hydrochloride < USAN; DAS-431; A-93431.1; 9,10-Diacetoxy-2-propyl-4,5,5a(R),6,7,11b(S)-hexahydrobenzo[f]thieno[2,3-c]quinoline hydrochloride
DMS8JIU	DT	Small molecular drug
DMS8JIU	PC	6918298
DMS8JIU	MW	436
DMS8JIU	FM	C22H26ClNO4S
DMS8JIU	IC	InChI=1S/C22H25NO4S.ClH/c1-4-5-15-9-17-21(28-15)11-23-18-7-6-14-8-19(26-12(2)24)20(27-13(3)25)10-16(14)22(17)18;/h8-10,18,22-23H,4-7,11H2,1-3H3;1H/t18-,22+;/m1./s1
DMS8JIU	CS	CCCC1=CC2=C(S1)CN[C@H]3[C@H]2C4=CC(=C(C=C4CC3)OC(=O)C)OC(=O)C.Cl
DMS8JIU	IK	NPEZSCRKHFTLPE-MYXGOWFTSA-N
DMS8JIU	IU	[(1S,10R)-4-acetyloxy-15-propyl-14-thia-11-azatetracyclo[8.7.0.02,7.013,17]heptadeca-2,4,6,13(17),15-pentaen-5-yl] acetate;hydrochloride
DMS8JIU	CA	CAS 166591-11-3
DMS8JIU	DE	Cognitive impairment

DMZS2M4	ID	DMZS2M4
DMZS2M4	DN	ADX-10061
DMZS2M4	HS	Discontinued in Phase 2
DMZS2M4	SN	CEE-310; NNC-687; NO-687; CEE-03-310; NNC-01-0687; NNC-01-687
DMZS2M4	CP	Addex Pharmaceuticals; Novo Nordisk A/S
DMZS2M4	DE	Psychotic disorder

DMZ7WKN	ID	DMZ7WKN
DMZ7WKN	DN	Adyvia
DMZ7WKN	HS	Discontinued in Phase 2
DMZ7WKN	SN	ID 1101
DMZ7WKN	CP	Innodia
DMZ7WKN	DT	Small molecular drug
DMZ7WKN	PC	6918732
DMZ7WKN	MW	147.17
DMZ7WKN	FM	C6H13NO3
DMZ7WKN	IC	InChI=1S/C6H13NO3/c1-3(4(2)8)5(7)6(9)10/h3-5,8H,7H2,1-2H3,(H,9,10)/t3-,4-,5-/m0/s1
DMZ7WKN	CS	C[C@@H]([C@H](C)O)[C@@H](C(=O)O)N
DMZ7WKN	IK	OSCCDBFHNMXNME-YUPRTTJUSA-N
DMZ7WKN	IU	(2S,3R,4S)-2-amino-4-hydroxy-3-methylpentanoic acid
DMZ7WKN	CA	CAS 55399-93-4
DMZ7WKN	CB	CHEBI:78247
DMZ7WKN	DE	Type-2 diabetes

DMRWSKX	ID	DMRWSKX
DMRWSKX	DN	Afegostat
DMRWSKX	HS	Discontinued in Phase 2
DMRWSKX	SN	Isofagomine; (3R,4R,5R)-5-(HYDROXYMETHYL)PIPERIDINE-3,4-DIOL; 169105-89-9; iso-Fagomine; D-Isofagomine; UNII-G23AP190YS; 5-HYDROXYMETHYL-3,4-DIHYDROXYPIPERIDINE; CHEMBL206468; G23AP190YS; IFM; 5-Hydroxymethyl-3,4-piperidinediol; (3R,4R,5R)-5-(HYDROXYMETHYL)PIPERIDINE-3,4-DIOL HYDROCHLORIDE; Afegostat [USAN:INN]; 1oif; Afegostat (USAN/INN); SCHEMBL581577; GTPL7410; 3,4-piperidinediol, 5-(hydroxymethyl)-, (3R,4R,5R)-; DTXSID20168651; 5-Hydroxymethylpiperidine-3,4-diol; ZINC3813668; BDBM50182801; AKOS006348872; DB04545; HY-14829; CS-0003581; D09576; Q21396373; (3R,4R,5R)-5-(Hydroxymethyl)piperidine-3,4-diol, 8; Afegostat; isofagomine; (3R,4R,5R)-5-(HYDROXYMETHYL)PIPERIDINE-3,4-DIOL
DMRWSKX	CP	Amicus Therapeutics
DMRWSKX	DT	Small molecular drug
DMRWSKX	PC	447607
DMRWSKX	MW	147.17
DMRWSKX	FM	C6H13NO3
DMRWSKX	IC	InChI=1S/C6H13NO3/c8-3-4-1-7-2-5(9)6(4)10/h4-10H,1-3H2/t4-,5-,6-/m1/s1
DMRWSKX	CS	C1[C@@H]([C@H]([C@@H](CN1)O)O)CO
DMRWSKX	IK	QPYJXFZUIJOGNX-HSUXUTPPSA-N
DMRWSKX	IU	(3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol
DMRWSKX	CA	CAS 169105-89-9
DMRWSKX	DE	Gaucher disease

DMSF5VK	ID	DMSF5VK
DMSF5VK	DN	Affitope AD-02
DMSF5VK	HS	Discontinued in Phase 2
DMSF5VK	SN	Alzheimer's disease vaccine 2 (AFFITOPE), AFFiRiS; Alzheimer's disease vaccine 2 (AFFITOPE), GlaxoSmithKline Biologicals
DMSF5VK	CP	AFFiRiS AG
DMSF5VK	DT	Vaccine
DMSF5VK	DE	Alzheimer disease

DM497SK	ID	DM497SK
DM497SK	DN	Agatolimod
DM497SK	HS	Discontinued in Phase 2
DM497SK	CP	Pfizer
DM497SK	DE	Lung cancer

DMZRW5E	ID	DMZRW5E
DMZRW5E	DN	AGN211745
DMZRW5E	HS	Discontinued in Phase 2
DMZRW5E	CP	Allergan
DMZRW5E	TC	siRNA
DMZRW5E	DT	siRNA drug
DMZRW5E	DE	Choroidal neovascularization

DME6OXB	ID	DME6OXB
DME6OXB	DN	AKL-0707
DME6OXB	HS	Discontinued in Phase 2
DME6OXB	SN	Akela GHRH; LAB GHRH; GHRH analog, Akela; Malnutrition therapy, LAB International
DME6OXB	CP	Akela Pharma Inc
DME6OXB	DE	Lipodystrophy

DM6IPWN	ID	DM6IPWN
DM6IPWN	DN	AKP-020
DM6IPWN	HS	Discontinued in Phase 2
DM6IPWN	SN	BEOV; Bis(ethylmaltolato)oxovanadium IV; Insulin enhancer (oral, type 2 diabetes), Akesis Pharmaceuticals
DM6IPWN	CP	Akesis Pharmaceuticals
DM6IPWN	DE	Type-2 diabetes

DMT5KBF	ID	DMT5KBF
DMT5KBF	DN	ALNESPIRONE
DMT5KBF	HS	Discontinued in Phase 2
DMT5KBF	SN	S-20499; Alnespirone; (+)-(S)-N-[4-[(5-Methoxy-3-chromanyl)propylamino]butyl]-1,1-cyclopentanediacetimide; (S)-(+)-8-[4-[N-(5-Methoxy-3,4-dihydro-2H-benzo[b]pyran-3-yl)-N-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione
DMT5KBF	DT	Small molecular drug
DMT5KBF	PC	178132
DMT5KBF	MW	442.6
DMT5KBF	FM	C26H38N2O4
DMT5KBF	IC	InChI=1S/C26H38N2O4/c1-3-13-27(20-16-21-22(31-2)9-8-10-23(21)32-19-20)14-6-7-15-28-24(29)17-26(18-25(28)30)11-4-5-12-26/h8-10,20H,3-7,11-19H2,1-2H3/t20-/m0/s1
DMT5KBF	CS	CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@H]3CC4=C(C=CC=C4OC)OC3
DMT5KBF	IK	DLLULNTXJPATBC-FQEVSTJZSA-N
DMT5KBF	IU	8-[4-[[(3S)-5-methoxy-3,4-dihydro-2H-chromen-3-yl]-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione
DMT5KBF	CA	CAS 138298-79-0
DMT5KBF	DE	Anxiety disorder

DMIKLRN	ID	DMIKLRN
DMIKLRN	DN	ALPRENOXIME HYDROCHLORIDE
DMIKLRN	HS	Discontinued in Phase 2
DMIKLRN	SN	CDDD-1815; HGP-5; Alprenoxime hydrochloride; 1-(2-Allylphenoxy)-3-(isopropylamino)-2-propanone oxime monohydrochloride; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyl)phenoxy]-2-propanone oxime monohydrochloride
DMIKLRN	DT	Small molecular drug
DMIKLRN	PC	60729
DMIKLRN	MW	298.81
DMIKLRN	FM	C15H23ClN2O2
DMIKLRN	IC	InChI=1S/C15H22N2O2.ClH/c1-4-7-13-8-5-6-9-15(13)19-11-14(17-18)10-16-12(2)3;/h4-6,8-9,12,16,18H,1,7,10-11H2,2-3H3;1H
DMIKLRN	CS	CC(C)NCC(=NO)COC1=CC=CC=C1CC=C.Cl
DMIKLRN	IK	ZFLRDGZJSCQDSR-UHFFFAOYSA-N
DMIKLRN	IU	N-[1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ylidene]hydroxylamine;hydrochloride
DMIKLRN	CA	CAS 121009-30-1
DMIKLRN	DE	Glaucoma/ocular hypertension

DMIAXCZ	ID	DMIAXCZ
DMIAXCZ	DN	Alrestatin
DMIAXCZ	HS	Discontinued in Phase 2
DMIAXCZ	SN	alrestatin; 51411-04-2; Alrestatine; Alrestatin [INN]; Alrestatinum [INN-Latin]; Alrestatine [INN-French]; Alrestatino [INN-Spanish]; UNII-515DHK15LG; Spectrum_001449; Tocris-0485; (1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-acetic acid; (1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)acetic acid; NSC 299132; BRN 0244370; AY 22284; CHEMBL63055; 515DHK15LG; NSC299132; 1,3-Dioxo-1H-benz(de)isoquinoline-2(3H)-acetic acid; 1H-Benz[de]isoquinoline-2(3H)-aceticacid, 1,3-dioxo-; NCGC00024613-01
DMIAXCZ	DT	Small molecular drug
DMIAXCZ	PC	2120
DMIAXCZ	MW	255.22
DMIAXCZ	FM	C14H9NO4
DMIAXCZ	IC	InChI=1S/C14H9NO4/c16-11(17)7-15-13(18)9-5-1-3-8-4-2-6-10(12(8)9)14(15)19/h1-6H,7H2,(H,16,17)
DMIAXCZ	CS	C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CC(=O)O
DMIAXCZ	IK	GCUCIFQCGJIRNT-UHFFFAOYSA-N
DMIAXCZ	IU	2-(1,3-dioxobenzo[de]isoquinolin-2-yl)acetic acid
DMIAXCZ	CA	CAS 51411-04-2

DMEKHX0	ID	DMEKHX0
DMEKHX0	DN	ALS 2-0426
DMEKHX0	HS	Discontinued in Phase 2
DMEKHX0	CP	Alantos Pharmaceuticals
DMEKHX0	DE	Type-2 diabetes

DMAQNBW	ID	DMAQNBW
DMAQNBW	DN	AM103
DMAQNBW	HS	Discontinued in Phase 2
DMAQNBW	CP	Amira Pharma.
DMAQNBW	DT	Small molecular drug
DMAQNBW	PC	56603665
DMAQNBW	DE	Cardiovascular disease

DMF8KH7	ID	DMF8KH7
DMF8KH7	DN	AM336
DMF8KH7	HS	Discontinued in Phase 2
DMF8KH7	SN	Leconotide; Leconotide [INN]; Omega conotoxin CVID; Omega-conopeptide CVID; UNII-2P1P5JB93S; 2P1P5JB93S; 247207-64-3; 247207-83-6
DMF8KH7	TC	Analgesics
DMF8KH7	DT	Small molecular drug
DMF8KH7	PC	16132255
DMF8KH7	MW	2756.3
DMF8KH7	FM	C107H179N35O36S7
DMF8KH7	IC	InChI=1S/C107H179N35O36S7/c1-51(2)33-64(129-91(163)62(20-11-15-30-111)127-100(172)71(44-147)135-103(175)73(47-181)137-93(165)60(18-9-13-28-109)124-85(157)53(5)121-77(150)36-117-87(159)58(17-8-12-27-108)126-99(171)70(43-146)134-92(164)61(19-10-14-29-110)125-86(158)57(112)45-179)95(167)128-63(26-32-185-7)94(166)130-65(34-55-22-24-56(149)25-23-55)96(168)131-66(35-81(154)155)97(169)138-76(50-184)104(176)140-75(49-183)102(174)133-67(40-143)88(160)118-37-79(152)123-69(42-145)98(170)139-74(48-182)101(173)132-68(41-144)89(161)119-39-80(153)141-83(54(6)148)106(178)142-82(52(3)4)105(177)120-38-78(151)122-59(21-16-31-116-107(114)115)90(162)136-72(46-180)84(113)156/h22-25,46,48-49,51-54,57-76,82-83,143-149,179,181,184H,8-21,26-45,47,50,108-112H2,1-7H3,(H2,113,156)(H,117,159)(H,118,160)(H,119,161)(H,120,177)(H,121,150)(H,122,151)(H,123,152)(H,124,157)(H,125,158)(H,126,171)(H,127,172)(H,128,167)(H,129,163)(H,130,166)(H,131,168)(H,132,173)(H,133,174)(H,134,164)(H,135,175)(H,136,162)(H,137,165)(H,138,169)(H,139,170)(H,140,176)(H,141,153)(H,142,178)(H,154,155)(H4,114,115,116)/t53-,54+,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,82-,83-/m0/s1
DMF8KH7	CS	C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C=S)C(=O)N)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C=S)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C=S)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)O
DMF8KH7	IK	HBMCYCKNGADUQP-CFIKXUEXSA-N
DMF8KH7	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[2-[[(2S,3R)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylidenepropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylidenepropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylidenepropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-oxobutanoic acid
DMF8KH7	CA	CAS 247207-64-3
DMF8KH7	DE	Pain

DMA57O4	ID	DMA57O4
DMA57O4	DN	Ambasilide
DMA57O4	HS	Discontinued in Phase 2
DMA57O4	SN	LU-47110
DMA57O4	CP	BASF AG
DMA57O4	DT	Small molecular drug
DMA57O4	PC	71270
DMA57O4	MW	335.4
DMA57O4	FM	C21H25N3O
DMA57O4	IC	InChI=1S/C21H25N3O/c22-20-8-6-19(7-9-20)21(25)24-14-17-10-18(15-24)13-23(12-17)11-16-4-2-1-3-5-16/h1-9,17-18H,10-15,22H2
DMA57O4	CS	C1C2CN(CC1CN(C2)C(=O)C3=CC=C(C=C3)N)CC4=CC=CC=C4
DMA57O4	IK	DLNAKYFPFYUBDR-UHFFFAOYSA-N
DMA57O4	IU	(4-aminophenyl)-(7-benzyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone
DMA57O4	CA	CAS 83991-25-7
DMA57O4	DE	Cardiac arrhythmias

DMRY9V8	ID	DMRY9V8
DMRY9V8	DN	AMESERGIDE
DMRY9V8	HS	Discontinued in Phase 2
DMRY9V8	SN	Amesergide < Rec INN; LY-237733; N-Cyclohexyl-1-isopropyl-6-methylergoline-8beta-carboxamide; N-Cyclohexyl-4-isopropyl-7-methyl-4,6,6abeta,7,8,9,10,10aalpha-octahydroindolo[4,3-fg]quinoline-9beta-carboxamide
DMRY9V8	DT	Small molecular drug
DMRY9V8	PC	9821951
DMRY9V8	MW	393.6
DMRY9V8	FM	C25H35N3O
DMRY9V8	IC	InChI=1S/C25H35N3O/c1-16(2)28-15-17-13-23-21(20-10-7-11-22(28)24(17)20)12-18(14-27(23)3)25(29)26-19-8-5-4-6-9-19/h7,10-11,15-16,18-19,21,23H,4-6,8-9,12-14H2,1-3H3,(H,26,29)/t18-,21-,23-/m1/s1
DMRY9V8	CS	CC(C)N1C=C2C[C@@H]3[C@H](C[C@H](CN3C)C(=O)NC4CCCCC4)C5=C2C1=CC=C5
DMRY9V8	IK	KEMOOQHMCGCZKH-JMUQELJHSA-N
DMRY9V8	IU	(6aR,9R,10aR)-N-cyclohexyl-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
DMRY9V8	CA	CAS 121588-75-8
DMRY9V8	DE	Mood disorder

DMMUS8X	ID	DMMUS8X
DMMUS8X	DN	AMG 108
DMMUS8X	HS	Discontinued in Phase 2
DMMUS8X	CP	Amgen
DMMUS8X	DT	Small molecular drug
DMMUS8X	PC	444499
DMMUS8X	DE	Rheumatoid arthritis

DM4RFT8	ID	DM4RFT8
DM4RFT8	DN	Amifloxacin
DM4RFT8	HS	Discontinued in Phase 2
DM4RFT8	SN	AMIFLOXACIN; 86393-37-5; UNII-5TU5227KYQ; Win49375; WIN-49375; 5TU5227KYQ; 6-Fluoro-1,4-dihydro-1-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Amifloxacino; Amifloxacine; Amifloxacinum; Win-493753; Amifloxacinum [Latin]; Amifloxacine [French]; Amifloxacino [Spanish]; Amifloxacin [USAN:INN:BAN]; Win 49375; EINECS 289-231-8; Amifloxacin (USAN/INN); CHEMBL6231; SCHEMBL48001; ZINC917; AC1L1J77; CTK3E8601; DTXSID20235519; Win 49,375; RUXPNBWPIRDVTH-UHFFFAOYSA-N; HY-U00221; AKOS030530713; CS-7366; FT-0711169
DM4RFT8	DT	Small molecular drug
DM4RFT8	PC	55492
DM4RFT8	MW	334.35
DM4RFT8	FM	C16H19FN4O3
DM4RFT8	IC	InChI=1S/C16H19FN4O3/c1-18-21-9-11(16(23)24)15(22)10-7-12(17)14(8-13(10)21)20-5-3-19(2)4-6-20/h7-9,18H,3-6H2,1-2H3,(H,23,24)
DM4RFT8	CS	CNN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O
DM4RFT8	IK	RUXPNBWPIRDVTH-UHFFFAOYSA-N
DM4RFT8	IU	6-fluoro-1-(methylamino)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DM4RFT8	CA	CAS 86393-37-5

DMGL0Q2	ID	DMGL0Q2
DMGL0Q2	DN	AN-9
DMGL0Q2	HS	Discontinued in Phase 2
DMGL0Q2	SN	Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE
DMGL0Q2	CP	Anacor Pharma.
DMGL0Q2	DT	Small molecular drug
DMGL0Q2	PC	60748
DMGL0Q2	MW	202.25
DMGL0Q2	FM	C10H18O4
DMGL0Q2	IC	InChI=1S/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3
DMGL0Q2	CS	CCCC(=O)OCOC(=O)C(C)(C)C
DMGL0Q2	IK	GYKLFBYWXZYSOW-UHFFFAOYSA-N
DMGL0Q2	IU	butanoyloxymethyl 2,2-dimethylpropanoate
DMGL0Q2	CA	CAS 122110-53-6
DMGL0Q2	DE	Melanoma

DMBQLS5	ID	DMBQLS5
DMBQLS5	DN	Angiozyme
DMBQLS5	HS	Discontinued in Phase 2
DMBQLS5	SN	RPI-4610; Ribozyme (VEGFr), Ribozyme/Chiron; Ribozyme (VEGFr), Sirna/Chiron
DMBQLS5	CP	Sirna Therapeutics Inc
DMBQLS5	DE	Solid tumour/cancer

DMEO6PR	ID	DMEO6PR
DMEO6PR	DN	Antide
DMEO6PR	HS	Discontinued in Phase 2
DMEO6PR	SN	GnRH antagonist, Serono; GnRHA, Serono; Iturelix nanospheres, Serono; ORF-23541; Iturelix (nanospheres encapsulated), Serono; Nal-Lys-GnRH
DMEO6PR	CP	Merck Serono SA
DMEO6PR	DT	Small molecular drug
DMEO6PR	PC	16130938
DMEO6PR	MW	1591.3
DMEO6PR	FM	C82H108ClN17O14
DMEO6PR	IC	InChI=1S/C82H108ClN17O14/c1-50(2)41-65(76(108)95-64(26-11-12-37-88-51(3)4)82(114)100-40-18-27-70(100)81(113)91-52(5)71(84)103)96-75(107)63(25-10-14-39-90-73(105)60-23-17-36-87-48-60)93-74(106)62(24-9-13-38-89-72(104)59-22-16-35-86-47-59)94-80(112)69(49-101)99-79(111)68(45-56-19-15-34-85-46-56)98-78(110)67(43-54-29-32-61(83)33-30-54)97-77(109)66(92-53(6)102)44-55-28-31-57-20-7-8-21-58(57)42-55/h7-8,15-17,19-23,28-36,42,46-48,50-52,62-70,88,101H,9-14,18,24-27,37-41,43-45,49H2,1-6H3,(H2,84,103)(H,89,104)(H,90,105)(H,91,113)(H,92,102)(H,93,106)(H,94,112)(H,95,108)(H,96,107)(H,97,109)(H,98,110)(H,99,111)/t52-,62+,63-,64+,65+,66-,67-,68-,69+,70+/m1/s1
DMEO6PR	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCNC(=O)C2=CN=CC=C2)NC(=O)[C@H](CCCCNC(=O)C3=CN=CC=C3)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMEO6PR	IK	QRYFGTULTGLGHU-NBERXCRTSA-N
DMEO6PR	IU	N-[(5R)-5-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-(pyridine-3-carbonylamino)hexanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-6-oxohexyl]pyridine-3-carboxamide
DMEO6PR	CA	CAS 112568-12-4
DMEO6PR	DE	Prostate hyperplasia

DMGDPSI	ID	DMGDPSI
DMGDPSI	DN	AOD-9604
DMGDPSI	HS	Discontinued in Phase 2
DMGDPSI	SN	AOD 9604; AOD9604; Human GH (hGH) lipolytic fragment; Tyr-somatostatin (177-191)
DMGDPSI	CP	Monash University/Metabolic Pharmaceuticals
DMGDPSI	DT	Small molecular drug
DMGDPSI	PC	16131447
DMGDPSI	MW	1817.1
DMGDPSI	FM	C78H125N23O23S2
DMGDPSI	IC	InChI=1S/C78H125N23O23S2/c1-9-41(8)62(101-68(115)47(18-14-28-86-78(83)84)91-63(110)45(79)29-38(2)3)75(122)100-61(40(6)7)74(121)94-49(23-25-56(80)105)67(114)98-55(37-126)72(119)92-46(17-13-27-85-77(81)82)66(113)96-53(35-103)71(118)99-60(39(4)5)73(120)93-48(24-26-59(108)109)64(111)87-33-58(107)90-52(34-102)70(117)97-54(36-125)65(112)88-32-57(106)89-50(30-42-15-11-10-12-16-42)69(116)95-51(76(123)124)31-43-19-21-44(104)22-20-43/h10-12,15-16,19-22,38-41,45-55,60-62,102-104,125-126H,9,13-14,17-18,23-37,79H2,1-8H3,(H2,80,105)(H,87,111)(H,88,112)(H,89,106)(H,90,107)(H,91,110)(H,92,119)(H,93,120)(H,94,121)(H,95,116)(H,96,113)(H,97,117)(H,98,114)(H,99,118)(H,100,122)(H,101,115)(H,108,109)(H,123,124)(H4,81,82,85)(H4,83,84,86)/t41-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,60-,61-,62-/m0/s1
DMGDPSI	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)N
DMGDPSI	IK	GNOVCDMBTHSXBH-BPXGDYAESA-N
DMGDPSI	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-5-[[2-[[(2S)-1-[[(2R)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid
DMGDPSI	DE	Obesity

DMWDCG7	ID	DMWDCG7
DMWDCG7	DN	AP-521
DMWDCG7	HS	Discontinued in Phase 2
DMWDCG7	SN	N-(1,3-Benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine-3(R)-carboxamide hydrochloride
DMWDCG7	DE	Anxiety disorder

DMWKJCB	ID	DMWKJCB
DMWKJCB	DN	AP-5346
DMWKJCB	HS	Discontinued in Phase 2
DMWKJCB	SN	ProLindac; AP-5286; DACH polymer platinate, Access; DACH-Pt; DACH-Pt prodrug
DMWKJCB	CP	Access Pharmaceuticals Inc
DMWKJCB	DE	Head and neck cancer

DM8IB6K	ID	DM8IB6K
DM8IB6K	DN	APC-2059
DM8IB6K	HS	Discontinued in Phase 2
DM8IB6K	SN	BAY-44-3965
DM8IB6K	CP	Celera South San Francisco
DM8IB6K	DE	Inflammatory bowel disease

DM02DNQ	ID	DM02DNQ
DM02DNQ	DN	APC-366
DM02DNQ	HS	Discontinued in Phase 2
DM02DNQ	SN	APC-366; UNII-TGP1HP0WBC; TGP1HP0WBC; APC 366; 178925-65-0; apc366; N-(1-Hydroxy-2-naphthoyl)-L-arginyl-L-prolinamide hydrochloride; APC-366 hydrochloride; AC1L42OQ; SCHEMBL15659721; APC-366-C; APC-366-A; APC-366-R; L-Prolinamide, N2-((1-hydroxy-2-naphthalenyl)carbonyl)-L-arginyl-, monohydrochloride; (2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[(1-hydroxynaphthalene-2-carbonyl)amino]pentanoyl]pyrrolidine-2-carboxamide hydrochloride
DM02DNQ	DT	Small molecular drug
DM02DNQ	PC	177339
DM02DNQ	MW	477
DM02DNQ	FM	C22H29ClN6O4
DM02DNQ	IC	InChI=1S/C22H28N6O4.ClH/c23-19(30)17-8-4-12-28(17)21(32)16(7-3-11-26-22(24)25)27-20(31)15-10-9-13-5-1-2-6-14(13)18(15)29;/h1-2,5-6,9-10,16-17,29H,3-4,7-8,11-12H2,(H2,23,30)(H,27,31)(H4,24,25,26);1H/t16-,17-;/m0./s1
DM02DNQ	CS	C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)C2=C(C3=CC=CC=C3C=C2)O)C(=O)N.Cl
DM02DNQ	IK	IZLPTTJTHFFFJF-QJHJCNPRSA-N
DM02DNQ	IU	(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[(1-hydroxynaphthalene-2-carbonyl)amino]pentanoyl]pyrrolidine-2-carboxamide;hydrochloride
DM02DNQ	CA	CAS 178925-65-0
DM02DNQ	DE	Asthma

DMR3Q82	ID	DMR3Q82
DMR3Q82	DN	Apricoxib
DMR3Q82	HS	Discontinued in Phase 2
DMR3Q82	SN	TG01
DMR3Q82	CP	Tragara Pharmaceuticals
DMR3Q82	DT	Small molecular drug
DMR3Q82	PC	9820073
DMR3Q82	MW	356.4
DMR3Q82	FM	C19H20N2O3S
DMR3Q82	IC	InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)
DMR3Q82	CS	CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
DMR3Q82	IK	JTMITOKKUMVWRT-UHFFFAOYSA-N
DMR3Q82	IU	4-[2-(4-ethoxyphenyl)-4-methylpyrrol-1-yl]benzenesulfonamide
DMR3Q82	CA	CAS 197904-84-0
DMR3Q82	DE	Rheumatoid arthritis; Pancreatic cancer; Non-small-cell lung cancer

DMML5WB	ID	DMML5WB
DMML5WB	DN	AR-D-111421
DMML5WB	HS	Discontinued in Phase 2
DMML5WB	CP	AstraZeneca plc
DMML5WB	DE	Asthma

DMBTG8J	ID	DMBTG8J
DMBTG8J	DN	AR-H047108
DMBTG8J	HS	Discontinued in Phase 2
DMBTG8J	SN	RAPID, AstraZeneca; Reversible acid pump inhibitor, AstraZeneca
DMBTG8J	CP	AstraZeneca plc
DMBTG8J	PC	9864291
DMBTG8J	MW	336.4
DMBTG8J	FM	C20H24N4O
DMBTG8J	IC	InChI=1S/C20H24N4O/c1-5-15-8-6-7-12(2)17(15)10-22-18-9-16(19(21)25)11-24-14(4)13(3)23-20(18)24/h6-9,11,22H,5,10H2,1-4H3,(H2,21,25)
DMBTG8J	CS	CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C
DMBTG8J	IK	IDSZXCFCCNVXER-UHFFFAOYSA-N
DMBTG8J	IU	8-[(2-ethyl-6-methylphenyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide
DMBTG8J	CA	CAS 248281-68-7
DMBTG8J	DE	Duodenal ulcer

DMNGQM0	ID	DMNGQM0
DMNGQM0	DN	Arm036
DMNGQM0	HS	Discontinued in Phase 2
DMNGQM0	SN	ALADORIAN; UNII-PJ5KSA836G; PJ5KSA836G; 865433-00-7; ARM036; Aladorian [USAN:INN]; Aladorian (USAN/INN); S44121-1; SCHEMBL3423110; CHEMBL2104951; DTXSID40235657; FPWBHFYYVSNIFZ-UHFFFAOYSA-N; s44121; D10304; (7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)oxoacetic acid; 1,4-Benzothiazepine-4(5H)-acetic acid, 2,3-dihydro-7-methoxy-alpha-oxo-; 2-(7-Methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)-2-oxoacetic acid
DMNGQM0	CP	Armgo pharma
DMNGQM0	DT	Small molecular drug
DMNGQM0	PC	11161474
DMNGQM0	MW	267.3
DMNGQM0	FM	C12H13NO4S
DMNGQM0	IC	InChI=1S/C12H13NO4S/c1-17-9-2-3-10-8(6-9)7-13(4-5-18-10)11(14)12(15)16/h2-3,6H,4-5,7H2,1H3,(H,15,16)
DMNGQM0	CS	COC1=CC2=C(C=C1)SCCN(C2)C(=O)C(=O)O
DMNGQM0	IK	FPWBHFYYVSNIFZ-UHFFFAOYSA-N
DMNGQM0	IU	2-(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)-2-oxoacetic acid
DMNGQM0	CA	CAS 865433-00-7
DMNGQM0	DE	Heart failure

DMS0LCZ	ID	DMS0LCZ
DMS0LCZ	DN	ARX-201
DMS0LCZ	HS	Discontinued in Phase 2
DMS0LCZ	SN	PEG-ahGH; PEG-hGH variants (growth disorders), Ambrx; PEG-human growth hormone variants (ReCODE, growth disorders), Ambrx; 30KPEG-N1-pAFhGH; 30PEG-N4-pAFhGH
DMS0LCZ	CP	Ambrx Inc
DMS0LCZ	DE	Growth failure

DMC2WI7	ID	DMC2WI7
DMC2WI7	DN	AS-35
DMC2WI7	HS	Discontinued in Phase 2
DMC2WI7	SN	AS-35; AS 35; 108427-72-1; 9-((4-Acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; C21H20N6O4; 4H-Pyrido[1,2-a]pyrimidin-4-one,9-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(2H-tetrazol-5-yl)-; 4H-Pyrido(1,2-a)pyrimidin-4-one, 9-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-; RVRGDCZGEKSIRW-UHFFFAOYSA-N; ACMC-20mbio; as35; AC1L2WU8; SCHEMBL159227; CTK4A6033; DTXSID90148546; CS-7624; LS-134160; HY-101946; L003846
DMC2WI7	CP	Mitsubishi-Tokyo Pharmaceuticals Inc
DMC2WI7	DT	Small molecular drug
DMC2WI7	PC	130135
DMC2WI7	MW	420.4
DMC2WI7	FM	C21H20N6O4
DMC2WI7	IC	InChI=1S/C21H20N6O4/c1-3-5-15-17(8-7-14(12(2)28)18(15)29)31-11-13-6-4-9-27-20(13)22-10-16(21(27)30)19-23-25-26-24-19/h4,6-10,29H,3,5,11H2,1-2H3,(H,23,24,25,26)
DMC2WI7	CS	CCCC1=C(C=CC(=C1O)C(=O)C)OCC2=CC=CN3C2=NC=C(C3=O)C4=NNN=N4
DMC2WI7	IK	RVRGDCZGEKSIRW-UHFFFAOYSA-N
DMC2WI7	IU	9-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
DMC2WI7	CA	CAS 108427-72-1
DMC2WI7	DE	Asthma

DM10XWU	ID	DM10XWU
DM10XWU	DN	Atipamezole
DM10XWU	HS	Discontinued in Phase 2
DM10XWU	SN	Atipamezole; 104054-27-5; Antisedan; MPV-1248; MPV 1248; 4-(2-Ethyl-2-indanyl)imidazole; 4-(2-ethyl-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; Atipamezolum [Latin]; Atipamezol [Spanish]; UNII-03N9U5JAF6; 1H-Imidazole, 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-; 03N9U5JAF6; 5-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole; NCGC00182707-01; Zeolite, type: ZSM-5; DSSTox_CID_29061; DSSTox_RID_83274; DSSTox_GSID_49135; 5-(2-ethyl-1,3-dihydroinden-2-yl)-1H-imidazole; antipamezole; Atipamezolum; Atipamezol; C14H16N2
DM10XWU	DT	Small molecular drug
DM10XWU	PC	71310
DM10XWU	MW	212.29
DM10XWU	FM	C14H16N2
DM10XWU	IC	InChI=1S/C14H16N2/c1-2-14(13-9-15-10-16-13)7-11-5-3-4-6-12(11)8-14/h3-6,9-10H,2,7-8H2,1H3,(H,15,16)
DM10XWU	CS	CCC1(CC2=CC=CC=C2C1)C3=CN=CN3
DM10XWU	IK	HSWPZIDYAHLZDD-UHFFFAOYSA-N
DM10XWU	IU	5-(2-ethyl-1,3-dihydroinden-2-yl)-1H-imidazole
DM10XWU	CA	CAS 104054-27-5
DM10XWU	DE	Male sexual disorder

DMZEMG6	ID	DMZEMG6
DMZEMG6	DN	Atiratecan
DMZEMG6	HS	Discontinued in Phase 2
DMZEMG6	SN	CH-0793011; CH-0793076; CH-4556300; TP-300
DMZEMG6	CP	Chugai Pharmaceutical Co Ltd
DMZEMG6	DT	Small molecular drug
DMZEMG6	PC	11592352
DMZEMG6	MW	586.6
DMZEMG6	FM	C31H34N6O6
DMZEMG6	IC	InChI=1S/C31H34N6O6/c1-4-6-7-11-36-17-33-21-9-8-10-22-26(21)28(36)18-14-37-23(27(18)34-22)12-20-19(29(37)40)16-42-30(41)31(20,5-2)43-25(39)15-35(3)24(38)13-32/h8-10,12,17H,4-7,11,13-16,32H2,1-3H3/t31-/m0/s1
DMZEMG6	CS	CCCCCN1C=NC2=CC=CC3=C2C1=C4CN5C(=CC6=C(C5=O)COC(=O)[C@@]6(CC)OC(=O)CN(C)C(=O)CN)C4=N3
DMZEMG6	IK	CWJSAEZZZABNRI-HKBQPEDESA-N
DMZEMG6	IU	[(10S)-10-ethyl-5,9-dioxo-23-pentyl-8-oxa-4,15,21,23-tetrazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16(24),17,19,21-octaen-10-yl] 2-[(2-aminoacetyl)-methylamino]acetate
DMZEMG6	CA	CAS 867063-97-6
DMZEMG6	DE	Colorectal cancer

DM7OE9F	ID	DM7OE9F
DM7OE9F	DN	Atocalcitol
DM7OE9F	HS	Discontinued in Phase 2
DM7OE9F	SN	KH-1650
DM7OE9F	CP	LEO Pharma A/S
DM7OE9F	DT	Small molecular drug
DM7OE9F	PC	6445225
DM7OE9F	MW	494.7
DM7OE9F	FM	C32H46O4
DM7OE9F	IC	InChI=1S/C32H46O4/c1-21(19-36-20-23-8-6-10-26(16-23)31(3,4)35)28-13-14-29-24(9-7-15-32(28,29)5)11-12-25-17-27(33)18-30(34)22(25)2/h6,8,10-12,16,21,27-30,33-35H,2,7,9,13-15,17-20H2,1,3-5H3/b24-11+,25-12-/t21-,27+,28+,29-,30-,32+/m0/s1
DM7OE9F	CS	C[C@@H](COCC1=CC(=CC=C1)C(C)(C)O)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DM7OE9F	IK	CFIFSLBCJAXYTC-FJLAUVHZSA-N
DM7OE9F	IU	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-1-[[3-(2-hydroxypropan-2-yl)phenyl]methoxy]propan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM7OE9F	CA	CAS 302904-82-1
DM7OE9F	DE	Psoriasis vulgaris

DMWJ245	ID	DMWJ245
DMWJ245	DN	ATX-201
DMWJ245	HS	Discontinued in Phase 2
DMWJ245	CP	Kythera Biopharmaceuticals
DMWJ245	DE	Actinic keratosis

DMWA957	ID	DMWA957
DMWA957	DN	Avarofloxacin
DMWA957	HS	Discontinued in Phase 2
DMWA957	SN	JNJ-Q2
DMWA957	CP	Furiex pharmaceuticals
DMWA957	DT	Small molecular drug
DMWA957	PC	11546234
DMWA957	MW	419.4
DMWA957	FM	C21H23F2N3O4
DMWA957	IC	InChI=1S/C21H23F2N3O4/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29)/b16-11+
DMWA957	CS	COC1=C2C(=CC(=C1N3CCC/C(=C(/CN)\\F)/C3)F)C(=O)C(=CN2C4CC4)C(=O)O
DMWA957	IK	VMKVDAAFMQKZJS-LFIBNONCSA-N
DMWA957	IU	7-[(3E)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMWA957	CA	CAS 878592-87-1
DMWA957	DE	Bacterial pneumonia

DMRYK1C	ID	DMRYK1C
DMRYK1C	DN	AVE-0847
DMRYK1C	HS	Discontinued in Phase 2
DMRYK1C	SN	PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis
DMRYK1C	CP	Genfit SA
DMRYK1C	DE	Hyperlipidaemia

DMXNK0J	ID	DMXNK0J
DMXNK0J	DN	AVE1625
DMXNK0J	HS	Discontinued in Phase 2
DMXNK0J	SN	Drinabant; 358970-97-5; AVE-1625; AVE1625; UNII-61S98RLL5I; 61S98RLL5I; Drinabant [INN]; SCHEMBL684143; C23H20Cl2F2N2O2S; CHEMBL3545166; CTK8E8263; DTXSID50189455; MolPort-009-019-211; ZINC59299699; 1745AH; RT-011348; 970D975; Methanesulfonamide, N-(1-(bis(4-chlorophenyl)methyl)-3-azetidinyl)-N-(3,5-difluorophenyl)-
DMXNK0J	CP	Sanofi-Aventis
DMXNK0J	DT	Small molecular drug
DMXNK0J	PC	10278470
DMXNK0J	MW	497.4
DMXNK0J	FM	C23H20Cl2F2N2O2S
DMXNK0J	IC	InChI=1S/C23H20Cl2F2N2O2S/c1-32(30,31)29(21-11-19(26)10-20(27)12-21)22-13-28(14-22)23(15-2-6-17(24)7-3-15)16-4-8-18(25)9-5-16/h2-12,22-23H,13-14H2,1H3
DMXNK0J	CS	CS(=O)(=O)N(C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)F)F
DMXNK0J	IK	IQQBRKLVEALROM-UHFFFAOYSA-N
DMXNK0J	IU	N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide
DMXNK0J	CA	CAS 358970-97-5
DMXNK0J	DE	Psychotic disorder

DMUQ6IL	ID	DMUQ6IL
DMUQ6IL	DN	AVE-1642
DMUQ6IL	HS	Discontinued in Phase 2
DMUQ6IL	SN	EM-164; Anti-IGF-1 receptor antibody (cancer), Aventis; Anti-IGF-1 receptor antibody (cancer), ImmunoGen; Anti-insulin-like growth factor-1 receptor antibody, Aventis; Anti-insulin-like growth factor-1 receptor antibody, ImmunoGen; Anti-IGF-1 receptor antibody (cancer), sanofi-aventis; Anti-insulin-like growthfactor-1 receptor antibody, sanofi-aventis
DMUQ6IL	CP	ImmunoGen Inc
DMUQ6IL	DT	Antibody
DMUQ6IL	DE	Breast cancer

DMCX6MD	ID	DMCX6MD
DMCX6MD	DN	AVE-8134
DMCX6MD	HS	Discontinued in Phase 2
DMCX6MD	SN	PPAR alpha agonist, Genfit
DMCX6MD	CP	Genfit SA
DMCX6MD	PC	11625114
DMCX6MD	MW	381.4
DMCX6MD	FM	C22H23NO5
DMCX6MD	IC	InChI=1S/C22H23NO5/c1-16-7-5-10-18(20(16)22(24)25)13-26-11-6-12-27-14-19-15-28-21(23-19)17-8-3-2-4-9-17/h2-5,7-10,15H,6,11-14H2,1H3,(H,24,25)
DMCX6MD	CS	CC1=C(C(=CC=C1)COCCCOCC2=COC(=N2)C3=CC=CC=C3)C(=O)O
DMCX6MD	IK	WLHOBCUVPMOXAT-UHFFFAOYSA-N
DMCX6MD	IU	2-methyl-6-[3-[(2-phenyl-1,3-oxazol-4-yl)methoxy]propoxymethyl]benzoic acid
DMCX6MD	CA	CAS 304025-09-0
DMCX6MD	DE	Heart failure

DMFCOZL	ID	DMFCOZL
DMFCOZL	DN	AVN 397
DMFCOZL	HS	Discontinued in Phase 2
DMFCOZL	CP	Avineuro Pharmaceuticals
DMFCOZL	DE	Anxiety disorder; Alzheimer disease

DM2I8NT	ID	DM2I8NT
DM2I8NT	DN	Avosentan
DM2I8NT	HS	Discontinued in Phase 2
DM2I8NT	SN	SPP 301; SPP301; Ro 67-0565; N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-5-methyl-pyridine-2-sulfonamide; 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide
DM2I8NT	CP	Speedel
DM2I8NT	DT	Small molecular drug
DM2I8NT	PC	9912992
DM2I8NT	MW	479.5
DM2I8NT	FM	C23H21N5O5S
DM2I8NT	IC	InChI=1S/C23H21N5O5S/c1-15-8-9-19(25-14-15)34(29,30)28-22-20(33-18-7-5-4-6-17(18)31-2)23(32-3)27-21(26-22)16-10-12-24-13-11-16/h4-14H,1-3H3,(H,26,27,28)
DM2I8NT	CS	CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC=NC=C3)OC)OC4=CC=CC=C4OC
DM2I8NT	IK	YBWLTKFZAOSWSM-UHFFFAOYSA-N
DM2I8NT	IU	N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
DM2I8NT	CA	CAS 290815-26-8
DM2I8NT	DE	Diabetic nephropathy

DM8NA4M	ID	DM8NA4M
DM8NA4M	DN	AVT-02 UE
DM8NA4M	HS	Discontinued in Phase 2
DM8NA4M	CP	Avontec GmbH
DM8NA4M	DE	Skin infection

DMV1ES3	ID	DMV1ES3
DMV1ES3	DN	AZALANSTAT
DMV1ES3	HS	Discontinued in Phase 2
DMV1ES3	SN	Azalanstat; RS-21607; UNII-2NL79NI1WS; 143393-27-5; 2NL79NI1WS; CHEMBL70611; 1-(((2S,4S)-4-(((p-Aminophenyl)thio)methyl)-2-(p-chlorophenethyl)-1,3-dioxolan-2-yl)methyl)imidazole; 4-[[(2S,4S)-2-[2-(4-chlorophenyl)ethyl]-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]aniline; Azalanstat [INN]; RS-21607197; RS 21607; AC1Q3NQV; AC1L1U3F; SCHEMBL1230519; GTPL8799; 4-{2-[2-(4-Chloro-phenyl)-ethyl]-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethylsulfanyl}-phenylamine; BDBM50044424; compound 1 [PMID: 8340925]; Benzenamine, 4
DMV1ES3	DT	Small molecular drug
DMV1ES3	PC	60876
DMV1ES3	MW	430
DMV1ES3	FM	C22H24ClN3O2S
DMV1ES3	IC	InChI=1S/C22H24ClN3O2S/c23-18-3-1-17(2-4-18)9-10-22(15-26-12-11-25-16-26)27-13-20(28-22)14-29-21-7-5-19(24)6-8-21/h1-8,11-12,16,20H,9-10,13-15,24H2/t20-,22-/m0/s1
DMV1ES3	CS	C1[C@H](O[C@@](O1)(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)CSC4=CC=C(C=C4)N
DMV1ES3	IK	VYNIUBZKEWJOJP-UNMCSNQZSA-N
DMV1ES3	IU	4-[[(2S,4S)-2-[2-(4-chlorophenyl)ethyl]-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]aniline
DMV1ES3	CA	CAS 143393-27-5
DMV1ES3	DE	Hyperlipidaemia

DM4B7CM	ID	DM4B7CM
DM4B7CM	DN	AZD0328
DM4B7CM	HS	Discontinued in Phase 2
DM4B7CM	SN	AR-R23465XX; AZD-0328; Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]
DM4B7CM	CP	AstraZeneca
DM4B7CM	DT	Small molecular drug
DM4B7CM	PC	9794392
DM4B7CM	MW	216.28
DM4B7CM	FM	C13H16N2O
DM4B7CM	IC	InChI=1S/C13H16N2O/c1-2-10-8-13(16-12(10)14-5-1)9-15-6-3-11(13)4-7-15/h1-2,5,11H,3-4,6-9H2/t13-/m0/s1
DM4B7CM	CS	C1CN2CCC1[C@@]3(C2)CC4=C(O3)N=CC=C4
DM4B7CM	IK	OCKIPDMKGPYYJS-ZDUSSCGKSA-N
DM4B7CM	IU	(3R)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3H-furo[2,3-b]pyridine]
DM4B7CM	CA	CAS 220099-91-2
DM4B7CM	DE	Alzheimer disease

DMA9Q2V	ID	DMA9Q2V
DMA9Q2V	DN	AZD0837
DMA9Q2V	HS	Discontinued in Phase 2
DMA9Q2V	SN	Atecegatran metoxil; Atecegatran fexenetil; UNII-4GU1D587JV; 4GU1D587JV; AZD0837; AZD 0837; 433937-93-0; Atecegatran metoxil [INN]; Atecegatran fexenetil [INN]; SCHEMBL9914214; DB12507; 2-Azetidinecarboxamide, 1-((2R)-(3-chloro-5-  (difluoromethoxy)phenyl)hydroxyacetyl)-N-((4-(imino(methoxyamino)methyl)phenyl)methyl)-, (2S)-
DMA9Q2V	CP	AstraZeneca
DMA9Q2V	DT	Small molecular drug
DMA9Q2V	PC	9961205
DMA9Q2V	MW	496.9
DMA9Q2V	FM	C22H23ClF2N4O5
DMA9Q2V	IC	InChI=1S/C22H23ClF2N4O5/c1-33-28-19(26)13-4-2-12(3-5-13)11-27-20(31)17-6-7-29(17)21(32)18(30)14-8-15(23)10-16(9-14)34-22(24)25/h2-5,8-10,17-18,22,30H,6-7,11H2,1H3,(H2,26,28)(H,27,31)/t17-,18+/m0/s1
DMA9Q2V	CS	CO/N=C(/C1=CC=C(C=C1)CNC(=O)[C@@H]2CCN2C(=O)[C@@H](C3=CC(=CC(=C3)Cl)OC(F)F)O)\\N
DMA9Q2V	IK	XSNMGLZVFNDDPW-ZWKOTPCHSA-N
DMA9Q2V	IU	(2S)-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(Z)-N'-methoxycarbamimidoyl]phenyl]methyl]azetidine-2-carboxamide
DMA9Q2V	CA	CAS 433937-93-0
DMA9Q2V	DE	Thrombosis; Nonvalvular atrial fibrillation

DML3RSF	ID	DML3RSF
DML3RSF	DN	AZD1236
DML3RSF	HS	Discontinued in Phase 2
DML3RSF	SN	(S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; 459814-90-5; AZD1236; AZD-1236; UNII-B4OQY51WZS; B4OQY51WZS; (S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)-sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; SCHEMBL942315; GTPL7844; DTXSID30647184; SFJFBTPHDHUUPU-OAHLLOKOSA-N; AZD 1236; 6326AB; ZINC59688588; AKOS016011525; DB11961; AX8246058; KB-211575; AJ-113592; Piperidine, 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl)
DML3RSF	CP	AstraZeneca
DML3RSF	DT	Small molecular drug
DML3RSF	PC	24751752
DML3RSF	MW	402.9
DML3RSF	FM	C15H19ClN4O5S
DML3RSF	IC	InChI=1S/C15H19ClN4O5S/c1-15(13(21)18-14(22)19-15)9-26(23,24)20-6-4-11(5-7-20)25-12-3-2-10(16)8-17-12/h2-3,8,11H,4-7,9H2,1H3,(H2,18,19,21,22)/t15-/m1/s1
DML3RSF	CS	C[C@]1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCC(CC2)OC3=NC=C(C=C3)Cl
DML3RSF	IK	SFJFBTPHDHUUPU-OAHLLOKOSA-N
DML3RSF	IU	(5S)-5-[[4-(5-chloropyridin-2-yl)oxypiperidin-1-yl]sulfonylmethyl]-5-methylimidazolidine-2,4-dione
DML3RSF	CA	CAS 459814-89-2
DML3RSF	DE	Chronic obstructive pulmonary disease

DMFAG8W	ID	DMFAG8W
DMFAG8W	DN	AZD1386
DMFAG8W	HS	Discontinued in Phase 2
DMFAG8W	SN	azd1386; 946080-23-5; AZD-1386; KB-270807; AZD 1386; SCHEMBL4257077; GTPL7820; CHEMBL3545039; AZ12457709
DMFAG8W	CP	AstraZeneca
DMFAG8W	TC	Analgesics
DMFAG8W	DT	Small molecular drug
DMFAG8W	PC	24752296
DMFAG8W	MW	423.8
DMFAG8W	FM	C19H13ClF3N3O3
DMFAG8W	IC	InChI=1S/C19H13ClF3N3O3/c1-9-5-12(20)7-13-14(9)26(16(28)18(13)15(27)24-17(29)25-18)8-10-3-2-4-11(6-10)19(21,22)23/h2-7H,8H2,1H3,(H2,24,25,27,29)
DMFAG8W	CS	CC1=CC(=CC2=C1N(C(=O)C23C(=O)NC(=O)N3)CC4=CC(=CC=C4)C(F)(F)F)Cl
DMFAG8W	IK	DXDVSYALLVVBOV-UHFFFAOYSA-N
DMFAG8W	IU	5'-chloro-7'-methyl-1'-[[3-(trifluoromethyl)phenyl]methyl]spiro[imidazolidine-5,3'-indole]-2,2',4-trione
DMFAG8W	DE	Gastroesophageal reflux disease; Esophagus sensitivity

DMHP6OY	ID	DMHP6OY
DMHP6OY	DN	AZD2066
DMHP6OY	HS	Discontinued in Phase 2
DMHP6OY	SN	AZD-2066; UNII-MQ908Y1ZB2; MQ908Y1ZB2; 934282-55-0; AZD 2066; AZD2066; SXWHYTICXCLKDG-GFCCVEGCSA-N; SCHEMBL1848325; CHEMBL3545164; MolPort-042-624-538; ZINC34885049; AKOS027470229; DB12644; Pyridine, 4-(5-((1R)-1-(5-(3-chlorophenyl)-3-isoxazolyl)ethoxy)-4-methyl-4H-1,2,4-triazol-3-yl)-; J3.560.339E; 5-(3-chlorophenyl)-3-[(1r)-1-[[4-methyl-5-(4-pyridyl)-1,2,4-triazol-3-yl]oxy]ethyl]isoxazole; 4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine
DMHP6OY	CP	AstraZeneca
DMHP6OY	TC	Analgesics
DMHP6OY	DT	Small molecular drug
DMHP6OY	PC	16041426
DMHP6OY	MW	381.8
DMHP6OY	FM	C19H16ClN5O2
DMHP6OY	IC	InChI=1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1
DMHP6OY	CS	C[C@H](C1=NOC(=C1)C2=CC(=CC=C2)Cl)OC3=NN=C(N3C)C4=CC=NC=C4
DMHP6OY	IK	SXWHYTICXCLKDG-GFCCVEGCSA-N
DMHP6OY	IU	5-(3-chlorophenyl)-3-[(1R)-1-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)oxy]ethyl]-1,2-oxazole
DMHP6OY	CA	CAS 934282-55-0
DMHP6OY	DE	Chronic neuropathic pain; Gastroesophageal reflux disease; Major depressive disorder

DM1TDWI	ID	DM1TDWI
DM1TDWI	DN	AZD2207
DM1TDWI	HS	Discontinued in Phase 2
DM1TDWI	SN	AC1O4QIO; CHEMBL3545289
DM1TDWI	CP	AstraZeneca
DM1TDWI	DT	Small molecular drug
DM1TDWI	PC	6398473
DM1TDWI	MW	499.3
DM1TDWI	FM	C22H22Cl2F2N4O3+2
DM1TDWI	IC	InChI=1S/C22H20Cl2F2N4O3/c1-14(15-5-4-6-16(23)11-15)28-21(31)12-18-17(24)8-9-20(30(18)33)27-13-22(25,26)19-7-2-3-10-29(19)32/h2-11,14,33H,12-13H2,1H3,(H-,28,31,32)/p+2/t14-/m1/s1
DM1TDWI	CS	C[C@H](C1=CC(=CC=C1)Cl)NC(=O)CC2=C(C=CC(=[N+]2O)NCC(C3=CC=CC=[N+]3O)(F)F)Cl
DM1TDWI	IK	GNYWBETUYIZBHL-CQSZACIVSA-P
DM1TDWI	IU	2-[3-chloro-6-[[2,2-difluoro-2-(1-hydroxypyridin-1-ium-2-yl)ethyl]amino]-1-hydroxypyridin-1-ium-2-yl]-N-[(1R)-1-(3-chlorophenyl)ethyl]acetamide
DM1TDWI	DE	Obesity; Diabetic complication

DM9OPDE	ID	DM9OPDE
DM9OPDE	DN	AZD2516
DM9OPDE	HS	Discontinued in Phase 2
DM9OPDE	CP	AstraZeneca
DM9OPDE	TC	Analgesics
DM9OPDE	DE	Chronic neuropathic pain

DMT5ZK3	ID	DMT5ZK3
DMT5ZK3	DN	AZD3355
DMT5ZK3	HS	Discontinued in Phase 2
DMT5ZK3	CP	AstraZeneca
DMT5ZK3	DT	Small molecular drug
DMT5ZK3	PC	9833984
DMT5ZK3	MW	140.07
DMT5ZK3	FM	C3H8FNO2P+
DMT5ZK3	IC	InChI=1S/C3H7FNO2P/c4-3(1-5)2-8(6)7/h3H,1-2,5H2/p+1/t3-/m1/s1
DMT5ZK3	CS	C([C@H](C[P+](=O)O)F)N
DMT5ZK3	IK	WVTGPBOMAQLPCP-GSVOUGTGSA-O
DMT5ZK3	IU	[(2R)-3-amino-2-fluoropropyl]-hydroxy-oxophosphanium
DMT5ZK3	CA	CAS 344413-67-8
DMT5ZK3	DE	Gastroesophageal reflux disease

DM4K085	ID	DM4K085
DM4K085	DN	AZD-3778
DM4K085	HS	Discontinued in Phase 2
DM4K085	SN	AZD-3778; CHEMBL2158814; SCHEMBL5418656; GTPL7679; AZD3778; QVLZVRFIGXNZMN-UHFFFAOYSA-N; AZD 3778; BDBM50394155; N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide
DM4K085	CP	AstraZeneca plc
DM4K085	DT	Small molecular drug
DM4K085	PC	11753159
DM4K085	MW	526.5
DM4K085	FM	C24H29Cl2N3O4S
DM4K085	IC	InChI=1S/C24H29Cl2N3O4S/c1-17-2-5-21(6-3-17)34(31,32)27-24(30)29-12-8-18(9-13-29)28-14-10-19(11-15-28)33-20-4-7-22(25)23(26)16-20/h2-7,16,18-19H,8-15H2,1H3,(H,27,30)
DM4K085	CS	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
DM4K085	IK	QVLZVRFIGXNZMN-UHFFFAOYSA-N
DM4K085	IU	4-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-N-(4-methylphenyl)sulfonylpiperidine-1-carboxamide
DM4K085	DE	Asthma

DM3VFKM	ID	DM3VFKM
DM3VFKM	DN	AZD4818
DM3VFKM	HS	Discontinued in Phase 2
DM3VFKM	SN	18-HYDROXYASCOMYCIN; AC1L9IBR; SCHEMBL14434002
DM3VFKM	CP	AstraZeneca
DM3VFKM	DT	Small molecular drug
DM3VFKM	DE	Chronic obstructive pulmonary disease

DME8KQW	ID	DME8KQW
DME8KQW	DN	AZD-5423
DME8KQW	HS	Discontinued in Phase 2
DME8KQW	SN	AZD-5423; 1034148-04-3; UNII-641H0Q518W; 641H0Q518W; 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide; 2,2,2-Tris(Fluoranyl)-~{n}-[(1~{r},2~{s})-1-[1-(4-Fluorophenyl)indazol-5-Yl]oxy-1-(3-Methoxyphenyl)propan-2-Yl]ethanamide; Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-;Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-
DME8KQW	CP	AstraZeneca plc
DME8KQW	DT	Small molecular drug
DME8KQW	PC	24825740
DME8KQW	MW	487.4
DME8KQW	FM	C25H21F4N3O3
DME8KQW	IC	InChI=1S/C25H21F4N3O3/c1-15(31-24(33)25(27,28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15,23H,1-2H3,(H,31,33)/t15-,23-/m0/s1
DME8KQW	CS	C[C@@H]([C@@H](C1=CC(=CC=C1)OC)OC2=CC3=C(C=C2)N(N=C3)C4=CC=C(C=C4)F)NC(=O)C(F)(F)F
DME8KQW	IK	FCNQMDSJHADDFT-WNSKOXEYSA-N
DME8KQW	IU	2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide
DME8KQW	CA	CAS 1034148-04-3
DME8KQW	DE	Chronic obstructive pulmonary disease

DMVZSRG	ID	DMVZSRG
DMVZSRG	DN	AZD6370
DMVZSRG	HS	Discontinued in Phase 2
DMVZSRG	CP	AstraZeneca
DMVZSRG	DE	Type-2 diabetes

DMHZ3DE	ID	DMHZ3DE
DMHZ3DE	DN	AZD6765
DMHZ3DE	HS	Discontinued in Phase 2
DMHZ3DE	SN	Lanicemine; 153322-05-5; AZD6765; UNII-9TMU325RK3; AR-R15896AR; ARL 15896; 9TMU325RK3; AZD-6765; (1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-amine; Lanicemine [INN]; FPL 15896; AR-R 15896; GTPL7681; CHEMBL467084; SCHEMBL1422817; ZINC6163; AR-R-15896AR; MolPort-030-004-688; AKOS026744074; DB11889; AJ-08269; (1S)-1-phenyl-2-pyridin-2-ylethanamine; (+)-2-((S)-beta-Aminophenethyl)pyridine; ( )-2-(S)-beta-Aminophenethyl-pyridine.; Z2286637868
DMHZ3DE	CP	AstraZeneca
DMHZ3DE	DT	Small molecular drug
DMHZ3DE	PC	9794203
DMHZ3DE	MW	198.26
DMHZ3DE	FM	C13H14N2
DMHZ3DE	IC	InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1
DMHZ3DE	CS	C1=CC=C(C=C1)[C@H](CC2=CC=CC=N2)N
DMHZ3DE	IK	FWUQWDCOOWEXRY-ZDUSSCGKSA-N
DMHZ3DE	IU	(1S)-1-phenyl-2-pyridin-2-ylethanamine
DMHZ3DE	CA	CAS 153322-05-5
DMHZ3DE	DE	Major depressive disorder

DMEQ2N1	ID	DMEQ2N1
DMEQ2N1	DN	AZD8529
DMEQ2N1	HS	Discontinued in Phase 2
DMEQ2N1	SN	AZD-8529; UNII-6H81G454I7; CHEMBL3937907; 6H81G454I7; AZD8529; 7-Methyl-5-(3-piperazin-1-ylmethyl-(1,2,4)oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one; 7-methyl-5-(3-piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one; GTPL7678; SCHEMBL2124540; AZD 8529; ZINC43201296; BDBM50194618; HY-107457; CS-0028525; 1092453-15-0; 7-methyl-5-[3-(piperazin-1-ylmethyl)-1,2,4-oxadiazol-5-yl]-2-[[4-(trifluoromethoxy)phenyl]methyl]-3H-isoindol-1-one
DMEQ2N1	CP	AstraZeneca
DMEQ2N1	DT	Small molecular drug
DMEQ2N1	PC	25125217
DMEQ2N1	MW	487.5
DMEQ2N1	FM	C24H24F3N5O3
DMEQ2N1	IC	InChI=1S/C24H24F3N5O3/c1-15-10-17(22-29-20(30-35-22)14-31-8-6-28-7-9-31)11-18-13-32(23(33)21(15)18)12-16-2-4-19(5-3-16)34-24(25,26)27/h2-5,10-11,28H,6-9,12-14H2,1H3
DMEQ2N1	CS	CC1=CC(=CC2=C1C(=O)N(C2)CC3=CC=C(C=C3)OC(F)(F)F)C4=NC(=NO4)CN5CCNCC5
DMEQ2N1	IK	IPCYZQQFECEHLI-UHFFFAOYSA-N
DMEQ2N1	IU	7-methyl-5-[3-(piperazin-1-ylmethyl)-1,2,4-oxadiazol-5-yl]-2-[[4-(trifluoromethoxy)phenyl]methyl]-3H-isoindol-1-one
DMEQ2N1	CA	CAS 1092453-15-0
DMEQ2N1	DE	Schizophrenia

DMHA5ME	ID	DMHA5ME
DMHA5ME	DN	AZD-9684
DMHA5ME	HS	Discontinued in Phase 2
DMHA5ME	SN	Laudanosine; DL-Laudanosine; 1699-51-0; (+-)-Laudanosine; Laudanosine (R,S); (R,S)-Laudanosine; EINECS 216-923-9; NSC 94267; AI3-61890; 20412-65-1; NSC35045; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline; (+-)-1,2,3,4-Tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinoline; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline; ISOQUINOLINE, 1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-1-VERATRYL-, (+-)-
DMHA5ME	CP	AstraZeneca
DMHA5ME	DT	Small molecular drug
DMHA5ME	PC	87609775
DMHA5ME	MW	226.3
DMHA5ME	FM	C10H14N2O2S
DMHA5ME	IC	InChI=1S/C10H14N2O2S/c1-6(15)8(10(13)14)4-7-2-3-9(11)12-5-7/h2-3,5-6,8,15H,4H2,1H3,(H2,11,12)(H,13,14)/t6-,8-/m1/s1
DMHA5ME	CS	C[C@H]([C@@H](CC1=CN=C(C=C1)N)C(=O)O)S
DMHA5ME	IK	GYIYAOUGKJSCCG-HTRCEHHLSA-N
DMHA5ME	IU	(2S,3R)-2-[(6-aminopyridin-3-yl)methyl]-3-sulfanylbutanoic acid
DMHA5ME	DE	Thrombosis

DM04CIK	ID	DM04CIK
DM04CIK	DN	AZT-P-DDI
DM04CIK	HS	Discontinued in Phase 2
DM04CIK	SN	Scriptene; IVX-E-59; 3'-Azido-3'-deoxythymidylyl-(5',5')-2',3'-dideoxy-5'-inosinic acid; 3'-Azido-3'-deoxythymidylyl-(5'-5')-2',3'-dideoxyinosine
DM04CIK	DT	Small molecular drug
DM04CIK	PC	135462914
DM04CIK	MW	565.4
DM04CIK	FM	C20H24N9O9P
DM04CIK	IC	InChI=1S/C20H24N9O9P/c1-10-5-28(20(32)25-18(10)30)15-4-12(26-27-21)13(38-15)7-36-39(33,34)35-6-11-2-3-14(37-11)29-9-24-16-17(29)22-8-23-19(16)31/h5,8-9,11-15H,2-4,6-7H2,1H3,(H,33,34)(H,22,23,31)(H,25,30,32)/t11-,12-,13+,14+,15+/m0/s1
DM04CIK	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OC[C@@H]3CC[C@@H](O3)N4C=NC5=C4N=CNC5=O)N=[N+]=[N-]
DM04CIK	IK	XURFYCWNUGWGDL-VQJWOFKYSA-N
DM04CIK	IU	[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl [(2S,5R)-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl hydrogen phosphate
DM04CIK	CA	CAS 121135-53-3
DM04CIK	DE	Human immunodeficiency virus infection

DM06JTL	ID	DM06JTL
DM06JTL	DN	Balicatib
DM06JTL	HS	Discontinued in Phase 2
DM06JTL	SN	N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide
DM06JTL	CP	Novartis
DM06JTL	DT	Small molecular drug
DM06JTL	PC	10201696
DM06JTL	MW	411.5
DM06JTL	FM	C23H33N5O2
DM06JTL	IC	InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)
DM06JTL	CS	CCCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3(CCCCC3)C(=O)NCC#N
DM06JTL	IK	LLCRBOWRJOUJAE-UHFFFAOYSA-N
DM06JTL	IU	N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide
DM06JTL	CA	CAS 354813-19-7
DM06JTL	DE	Osteoporosis

DMPMKUF	ID	DMPMKUF
DMPMKUF	DN	BAM-1110
DMPMKUF	HS	Discontinued in Phase 2
DMPMKUF	SN	(6aR,9R,10aR)-7-Methyl-9-(1,2,4-triazol-1-ylmethyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolinemaleate
DMPMKUF	DT	Small molecular drug
DMPMKUF	PC	3064755
DMPMKUF	MW	307.4
DMPMKUF	FM	C18H21N5
DMPMKUF	IC	InChI=1S/C18H21N5/c1-22-8-12(9-23-11-19-10-21-23)5-15-14-3-2-4-16-18(14)13(7-20-16)6-17(15)22/h2-4,7,10-12,15,17,20H,5-6,8-9H2,1H3/t12-,15?,17-/m1/s1
DMPMKUF	CS	CN1C[C@@H](CC2[C@H]1CC3=CNC4=CC=CC2=C34)CN5C=NC=N5
DMPMKUF	IK	AIBHLZVVPXCTKY-XURPUJGUSA-N
DMPMKUF	IU	(6aR,9R)-7-methyl-9-(1,2,4-triazol-1-ylmethyl)-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
DMPMKUF	CA	CAS 105579-47-3
DMPMKUF	DE	Parkinson disease

DMV2DIW	ID	DMV2DIW
DMV2DIW	DN	BAY 10-00394
DMV2DIW	HS	Discontinued in Phase 2
DMV2DIW	SN	roniciclib; BAY 1000394; BAY 10-00394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874
DMV2DIW	CP	Bayer healthcare pharmaceuticals
DMV2DIW	DT	Small molecular drug
DMV2DIW	PC	45380979
DMV2DIW	MW	430.4
DMV2DIW	FM	C18H21F3N4O3S
DMV2DIW	IC	InChI=1S/C18H21F3N4O3S/c1-10(26)11(2)28-16-15(18(19,20)21)9-23-17(25-16)24-12-3-5-13(6-4-12)29(22,27)14-7-8-14/h3-6,9-11,14,22,26H,7-8H2,1-2H3,(H,23,24,25)/t10-,11-,29?/m1/s1
DMV2DIW	CS	C[C@H]([C@@H](C)OC1=NC(=NC=C1C(F)(F)F)NC2=CC=C(C=C2)S(=N)(=O)C3CC3)O
DMV2DIW	IK	UELYDGOOJPRWGF-MFOHZAOFSA-N
DMV2DIW	IU	(2R,3R)-3-[2-[4-(cyclopropylsulfonimidoyl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]oxybutan-2-ol
DMV2DIW	DE	Small-cell lung cancer

DMCZKG0	ID	DMCZKG0
DMCZKG0	DN	BAY-Y-3118
DMCZKG0	HS	Discontinued in Phase 2
DMCZKG0	SN	UNII-08VLU38WTI; BAY-Y-3118 free base; Bay-Y 3118; 08VLU38WTI; 151213-16-0; 144194-96-7; AC1L3OP2; SCHEMBL7502039; CHEMBL107544; DTXSID40164736; VRXORHRXNRJZCQ-ZUZCIYMTSA-N; BAY-Y-3118; HY-U00092; CS-7127; LS-194353; 8-Chloro-1-cyclopropyl-7-[(S,S)-2,8- diazobicyclo(4.3.0)-non-8-yl]-6-fluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acid, hydrochloride; 8-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[[(4aalpha,7aalpha)-octahydro-1H-pyrrolo[3,4-b]pyridin]-6-yl]quinoline-3-carboxylic acid
DMCZKG0	CP	Bayer AG
DMCZKG0	DT	Small molecular drug
DMCZKG0	PC	119375
DMCZKG0	MW	405.8
DMCZKG0	FM	C20H21ClFN3O3
DMCZKG0	IC	InChI=1S/C20H21ClFN3O3/c21-16-17-12(19(26)13(20(27)28)8-25(17)11-3-4-11)6-14(22)18(16)24-7-10-2-1-5-23-15(10)9-24/h6,8,10-11,15,23H,1-5,7,9H2,(H,27,28)/t10-,15+/m0/s1
DMCZKG0	CS	C1C[C@H]2CN(C[C@H]2NC1)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5CC5)F
DMCZKG0	IK	VRXORHRXNRJZCQ-ZUZCIYMTSA-N
DMCZKG0	IU	7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMCZKG0	CA	CAS 151213-51-3
DMCZKG0	DE	Bacterial infection

DMR569L	ID	DMR569L
DMR569L	DN	BBR-3438
DMR569L	HS	Discontinued in Phase 2
DMR569L	SN	Nortopixantrone; UNII-PH2639TAB4; BBR-3438; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438
DMR569L	CP	Roche Holding AG
DMR569L	DT	Small molecular drug
DMR569L	PC	3038512
DMR569L	MW	380.4
DMR569L	FM	C20H24N6O2
DMR569L	IC	InChI=1S/C20H24N6O2/c1-21-6-7-24-15-2-3-16-18-17(15)20(28)13-4-5-23-12-14(13)19(18)25-26(16)10-8-22-9-11-27/h2-5,12,21-22,24,27H,6-11H2,1H3
DMR569L	CS	CNCCNC1=C2C3=C(C=C1)N(N=C3C4=C(C2=O)C=CN=C4)CCNCCO
DMR569L	IK	PMGQHDIXCJMHRO-UHFFFAOYSA-N
DMR569L	IU	14-[2-(2-hydroxyethylamino)ethyl]-10-[2-(methylamino)ethylamino]-4,14,15-triazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one
DMR569L	CA	CAS 156090-17-4
DMR569L	DE	Gastric adenocarcinoma

DM6ANFC	ID	DM6ANFC
DM6ANFC	DN	BCH-2687
DM6ANFC	HS	Discontinued in Phase 2
DM6ANFC	CP	Shire BioChem Inc
DM6ANFC	DE	Pain

DMPIJE7	ID	DMPIJE7
DMPIJE7	DN	Becampanel
DMPIJE7	HS	Discontinued in Phase 2
DMPIJE7	SN	AMP397; AMP-397; AMP-397A; [(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methylamino]methylphosphonic acid
DMPIJE7	CP	Novartis
DMPIJE7	DT	Small molecular drug
DMPIJE7	PC	5491960
DMPIJE7	MW	330.19
DMPIJE7	FM	C10H11N4O7P
DMPIJE7	IC	InChI=1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21)
DMPIJE7	CS	C1=C(C=C2C(=C1CNCP(=O)(O)O)NC(=O)C(=O)N2)[N+](=O)[O-]
DMPIJE7	IK	ABFMMCZFKUIJGQ-UHFFFAOYSA-N
DMPIJE7	IU	[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methylamino]methylphosphonic acid
DMPIJE7	CA	CAS 188696-80-2
DMPIJE7	DE	Epilepsy

DMEQL9U	ID	DMEQL9U
DMEQL9U	DN	Benzydamine
DMEQL9U	HS	Discontinued in Phase 2
DMEQL9U	SN	Bencidamina; Benzidamina; Benzidamine; Benzindamine; Benzydaminum; Benzidamina [DCIT]; Benzydamine Monohydrochoride; C 1523; Apo-Benzydamine; Bencidamina [INN-Spanish]; Benzydamine (INN); Benzydamine [INN:BAN]; Benzydaminum [INN-Latin]; Apo-Benzydamine (TN); {3-[(1-benzyl-1H-indazol-3-yl)oxy]propyl}dimethylamine; 1-Benzyl-3-(3-(dimethylamino)propoxy)-1H-indazole; 3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine; 3-[(1-benzyl-1H-indazol-3-yl)oxy]-N,N-dimethylpropan-1-amine
DMEQL9U	CP	Camurus
DMEQL9U	TC	Analgesics
DMEQL9U	DT	Small molecular drug
DMEQL9U	PC	12555
DMEQL9U	MW	309.4
DMEQL9U	FM	C19H23N3O
DMEQL9U	IC	InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3
DMEQL9U	CS	CN(C)CCCOC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3
DMEQL9U	IK	CNBGNNVCVSKAQZ-UHFFFAOYSA-N
DMEQL9U	IU	3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine
DMEQL9U	CA	CAS 642-72-8
DMEQL9U	CB	CHEBI:94563
DMEQL9U	DE	Chemotherapy or radiotherapy-induced mucositis

DMEK6J0	ID	DMEK6J0
DMEK6J0	DN	Bervastatin
DMEK6J0	HS	Discontinued in Phase 2
DMEK6J0	SN	LS-2904
DMEK6J0	CP	Merck Sante SA
DMEK6J0	DT	Small molecular drug
DMEK6J0	PC	6436003
DMEK6J0	MW	466.5
DMEK6J0	FM	C28H31FO5
DMEK6J0	IC	InChI=1S/C28H31FO5/c1-2-33-26(32)18-22(31)17-21(30)13-14-24-27(19-9-11-20(29)12-10-19)23-7-3-4-8-25(23)34-28(24)15-5-6-16-28/h3-4,7-14,21-22,30-31H,2,5-6,15-18H2,1H3/b14-13+/t21-,22-/m0/s1
DMEK6J0	CS	CCOC(=O)C[C@H](C[C@H](/C=C/C1=C(C2=CC=CC=C2OC13CCCC3)C4=CC=C(C=C4)F)O)O
DMEK6J0	IK	ZADJRRFMOOACHL-WQICJITCSA-N
DMEK6J0	IU	ethyl (E,3S,5R)-7-[4-(4-fluorophenyl)spiro[chromene-2,1'-cyclopentane]-3-yl]-3,5-dihydroxyhept-6-enoate
DMEK6J0	CA	CAS 132017-01-7
DMEK6J0	DE	Thrombosis

DMTE3UV	ID	DMTE3UV
DMTE3UV	DN	BI 1467335
DMTE3UV	HS	Discontinued in Phase 2
DMTE3UV	SN	PXS-4728A; 1478364-68-9; BI-1467335 HCl; UNII-6W2049SJPH; 6W2049SJPH; PXS 4728A; 1478364-68-9 (HCl); (E)-4-((2-(Aminomethyl)-3-fluoroallyl)oxy)-N-(tert-butyl)benzamide hydrochloride; PXS 4728 HCl; BI-1467335 hydrochloride; CHEMBL3897599; SCHEMBL16766775; EX-A4639; AC-31510; Benzamide, 4-(((2E)-2-(aminomethyl)-3-fluoro-2-propen-1-yl)oxy)-N-(1,1-dimethylethyl)-, hydrochloride (1:1); HY-112726; CS-0062985; Q27265609; (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride
DMTE3UV	CP	Boehringer Ingelheim
DMTE3UV	DT	Small molecular drug
DMTE3UV	PC	71812246
DMTE3UV	MW	316.8
DMTE3UV	FM	C15H22ClFN2O2
DMTE3UV	IC	InChI=1S/C15H21FN2O2.ClH/c1-15(2,3)18-14(19)12-4-6-13(7-5-12)20-10-11(8-16)9-17;/h4-8H,9-10,17H2,1-3H3,(H,18,19);1H/b11-8+;
DMTE3UV	CS	CC(C)(C)NC(=O)C1=CC=C(C=C1)OC/C(=C/F)/CN.Cl
DMTE3UV	IK	AEMZEDNMNLIDSL-YGCVIUNWSA-N
DMTE3UV	IU	4-[(E)-2-(aminomethyl)-3-fluoroprop-2-enoxy]-N-tert-butylbenzamide;hydrochloride
DMTE3UV	CA	CAS 1478364-68-9
DMTE3UV	DE	Diabetic retinopathy

DMGWFZJ	ID	DMGWFZJ
DMGWFZJ	DN	BIBR-363
DMGWFZJ	HS	Discontinued in Phase 2
DMGWFZJ	SN	BIBR 363 CL2
DMGWFZJ	CP	Boehringer Ingelheim Corp
DMGWFZJ	DE	Hypertension

DMIZ59O	ID	DMIZ59O
DMIZ59O	DN	BIM-23268
DMIZ59O	HS	Discontinued in Phase 2
DMIZ59O	SN	BIM-23268D; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-phenylalanyl-L-cysteinamide cyclic-(1-8)-disulfide
DMIZ59O	DT	Small molecular drug
DMIZ59O	PC	5311026
DMIZ59O	MW	1078.3
DMIZ59O	FM	C54H67N11O9S2
DMIZ59O	IC	InChI=1S/C54H67N11O9S2/c1-32(66)46-54(74)63-43(27-35-19-9-4-10-20-35)52(72)64-45(47(57)67)31-76-75-30-38(56)48(68)60-41(25-33-15-5-2-6-16-33)50(70)61-42(26-34-17-7-3-8-18-34)51(71)62-44(28-36-29-58-39-22-12-11-21-37(36)39)53(73)59-40(49(69)65-46)23-13-14-24-55/h2-12,15-22,29,32,38,40-46,58,66H,13-14,23-28,30-31,55-56H2,1H3,(H2,57,67)(H,59,73)(H,60,68)(H,61,70)(H,62,71)(H,63,74)(H,64,72)(H,65,69)/t32-,38+,40+,41+,42+,43+,44-,45+,46+/m1/s1
DMIZ59O	CS	C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)N)CC6=CC=CC=C6)O
DMIZ59O	IK	JNMPZUZCPFIJGJ-OCZUONHDSA-N
DMIZ59O	IU	(4R,7S,10S,13S,16R,19S,22S,25R)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carboxamide
DMIZ59O	DE	Acromegaly

DMOP95G	ID	DMOP95G
DMOP95G	DN	Bimoclomol
DMOP95G	HS	Discontinued in Phase 2
DMOP95G	SN	ABT-822; BRLP-42; BRX-211
DMOP95G	CP	CytRx; Biorex Research and Development Co
DMOP95G	DT	Small molecular drug
DMOP95G	PC	9576891
DMOP95G	MW	297.78
DMOP95G	FM	C14H20ClN3O2
DMOP95G	IC	InChI=1S/C14H20ClN3O2/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18/h4-6,9,13,19H,1-3,7-8,10-11H2/b17-14-
DMOP95G	CS	C1CCN(CC1)CC(CO/N=C(/C2=CN=CC=C2)\\Cl)O
DMOP95G	IK	NMOVJBAGBXIKCG-VKAVYKQESA-N
DMOP95G	IU	(3Z)-N-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidoyl chloride
DMOP95G	CA	CAS 130493-03-7
DMOP95G	DE	Diabetic complication

DM65JCM	ID	DM65JCM
DM65JCM	DN	Biricodar
DM65JCM	HS	Discontinued in Phase 2
DM65JCM	SN	Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
DM65JCM	CP	Vertex Pharmaceuticals
DM65JCM	TC	Anticancer Agents
DM65JCM	DT	Small molecular drug
DM65JCM	PC	3037617
DM65JCM	MW	603.7
DM65JCM	FM	C34H41N3O7
DM65JCM	IC	InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1
DM65JCM	CS	COC1=CC(=CC(=C1OC)OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)OC(CCCC3=CN=CC=C3)CCCC4=CN=CC=C4
DM65JCM	IK	CGVWPQOFHSAKRR-NDEPHWFRSA-N
DM65JCM	IU	1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
DM65JCM	CA	CAS 159997-94-1
DM65JCM	CB	CHEBI:135847
DM65JCM	DE	Ovarian cancer

DMBIQL2	ID	DMBIQL2
DMBIQL2	DN	BISNAFIDE MESILATE
DMBIQL2	HS	Discontinued in Phase 2
DMBIQL2	SN	DMP-840; Bisnafide mesilate; Bisnafide mesylate; (R,R)-2,2'-(Ethane-1,2-diyl)bis[imino(1-methylethane-2,1-diyl)]bis(5-nitro-2,3-dihydro-1H-benzo[de]isoquinoline-1,3-dione) dimethanesulfonate; (R,R)-2,2'-(Ethylenediimino)bis(1-methyl-2,1-ethanediyl)bis(5-nitro-2,3-dihydro-1H-benzo[de]isoquinoline-1,3-dione) dimethanesulfonate
DMBIQL2	DT	Small molecular drug
DMBIQL2	PC	60916
DMBIQL2	MW	816.8
DMBIQL2	FM	C34H36N6O14S2
DMBIQL2	IC	InChI=1S/C32H28N6O8.2CH4O3S/c1-17(35-29(39)23-7-3-5-19-11-21(37(43)44)13-25(27(19)23)31(35)41)15-33-9-10-34-16-18(2)36-30(40)24-8-4-6-20-12-22(38(45)46)14-26(28(20)24)32(36)42;2*1-5(2,3)4/h3-8,11-14,17-18,33-34H,9-10,15-16H2,1-2H3;2*1H3,(H,2,3,4)/t17-,18-;;/m1../s1
DMBIQL2	CS	C[C@H](CNCCNC[C@@H](C)N1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)[N+](=O)[O-])N4C(=O)C5=CC=CC6=CC(=CC(=C65)C4=O)[N+](=O)[O-].CS(=O)(=O)O.CS(=O)(=O)O
DMBIQL2	IK	KPQJSSLKKBKWEW-RKDOVGOJSA-N
DMBIQL2	IU	methanesulfonic acid;5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione
DMBIQL2	CA	CAS 145124-30-7
DMBIQL2	DE	Solid tumour/cancer

DMQ6CYE	ID	DMQ6CYE
DMQ6CYE	DN	BIWB-1
DMQ6CYE	HS	Discontinued in Phase 2
DMQ6CYE	SN	Melanoma vaccine (autologous), Boehringer Ingelheim/Bender; IL-2 gene therapy (autologous), Boehringer Ingelheim/Bender
DMQ6CYE	CP	Boehringer Ingelheim Corp
DMQ6CYE	DT	Vaccine
DMQ6CYE	DE	Melanoma

DM7ZI8A	ID	DM7ZI8A
DM7ZI8A	DN	BM-17.0744
DM7ZI8A	HS	Discontinued in Phase 2
DM7ZI8A	SN	K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid
DM7ZI8A	DT	Small molecular drug
DM7ZI8A	PC	9929731
DM7ZI8A	MW	379.7
DM7ZI8A	FM	C18H25Cl3O2
DM7ZI8A	IC	InChI=1S/C18H25Cl3O2/c19-16-12-10-15(11-13-16)9-7-5-3-1-2-4-6-8-14-18(20,21)17(22)23/h10-13H,1-9,14H2,(H,22,23)
DM7ZI8A	CS	C1=CC(=CC=C1CCCCCCCCCCC(C(=O)O)(Cl)Cl)Cl
DM7ZI8A	IK	GPCJDSXBRMKASP-UHFFFAOYSA-N
DM7ZI8A	IU	2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
DM7ZI8A	CA	CAS 221564-97-2
DM7ZI8A	DE	Type-1 diabetes

DMVBGIT	ID	DMVBGIT
DMVBGIT	DN	BMS-180448
DMVBGIT	HS	Discontinued in Phase 2
DMVBGIT	SN	C20H18ClN5O2; BMS 180448; CHEMBL11802; 144264-47-1; BMS-180448; trans-N-(4-Chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)guanidine; Guanidine, N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-, trans-; Bms 180426; AC1L3TUP; DTXSID90162661; BDBM50409908; BMS-180426; LS-173206; 1-(4-chlorophenyl)-3-cyano-2-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]guanidine
DMVBGIT	CP	Bristol-Myers Squibb Co
DMVBGIT	DT	Small molecular drug
DMVBGIT	PC	60880
DMVBGIT	MW	395.8
DMVBGIT	FM	C20H18ClN5O2
DMVBGIT	IC	InChI=1S/C20H18ClN5O2/c1-20(2)18(27)17(15-9-12(10-22)3-8-16(15)28-20)26-19(24-11-23)25-14-6-4-13(21)5-7-14/h3-9,17-18,27H,1-2H3,(H2,24,25,26)/t17-,18+/m1/s1
DMVBGIT	CS	CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N=C(NC#N)NC3=CC=C(C=C3)Cl)O)C
DMVBGIT	IK	VLICJSLDCJXZBG-MSOLQXFVSA-N
DMVBGIT	IU	1-(4-chlorophenyl)-3-cyano-2-[(3S,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]guanidine
DMVBGIT	CA	CAS 144301-94-0
DMVBGIT	DE	Angina pectoris

DMT4VSE	ID	DMT4VSE
DMT4VSE	DN	BMS-181101
DMT4VSE	HS	Discontinued in Phase 2
DMT4VSE	SN	1H-Indole
DMT4VSE	CP	Bristol-Myers Squibb Co
DMT4VSE	DT	Small molecular drug
DMT4VSE	PC	177836
DMT4VSE	MW	369.4
DMT4VSE	FM	C20H24FN5O
DMT4VSE	IC	InChI=1S/C20H24FN5O/c1-27-19-13-22-14-24-20(19)26-9-7-25(8-10-26)6-2-3-15-12-23-18-5-4-16(21)11-17(15)18/h4-5,11-14,23H,2-3,6-10H2,1H3
DMT4VSE	CS	COC1=CN=CN=C1N2CCN(CC2)CCCC3=CNC4=C3C=C(C=C4)F
DMT4VSE	IK	NRLXAYBZNVHRFL-UHFFFAOYSA-N
DMT4VSE	IU	5-fluoro-3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indole
DMT4VSE	CA	CAS 141071-67-2
DMT4VSE	DE	Mood disorder

DMGPHTJ	ID	DMGPHTJ
DMGPHTJ	DN	BMS-181168
DMGPHTJ	HS	Discontinued in Phase 2
DMGPHTJ	SN	BMY-21502
DMGPHTJ	CP	Bristol-Myers Squibb Co
DMGPHTJ	DT	Small molecular drug
DMGPHTJ	PC	129930
DMGPHTJ	MW	328.33
DMGPHTJ	FM	C15H19F3N4O
DMGPHTJ	IC	InChI=1S/C15H19F3N4O/c16-15(17,18)14-19-6-3-12(20-14)21-8-4-11(5-9-21)10-22-7-1-2-13(22)23/h3,6,11H,1-2,4-5,7-10H2
DMGPHTJ	CS	C1CC(=O)N(C1)CC2CCN(CC2)C3=NC(=NC=C3)C(F)(F)F
DMGPHTJ	IK	KEWFMWJJMGQBAN-UHFFFAOYSA-N
DMGPHTJ	IU	1-[[1-[2-(trifluoromethyl)pyrimidin-4-yl]piperidin-4-yl]methyl]pyrrolidin-2-one
DMGPHTJ	CA	CAS 123259-91-6
DMGPHTJ	DE	Cognitive impairment

DMP8SIV	ID	DMP8SIV
DMP8SIV	DN	BMS-187745
DMP8SIV	HS	Discontinued in Phase 2
DMP8SIV	SN	157124-84-0; CHEMBL351151
DMP8SIV	DT	Small molecular drug
DMP8SIV	PC	153978
DMP8SIV	MW	386.4
DMP8SIV	FM	C16H19O7PS
DMP8SIV	IC	InChI=1S/C16H19O7PS/c17-24(18,19)16(25(20,21)22)11-5-7-13-6-4-10-15(12-13)23-14-8-2-1-3-9-14/h1-4,6,8-10,12,16H,5,7,11H2,(H2,17,18,19)(H,20,21,22)/t16-/m0/s1
DMP8SIV	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)CCC[C@@H](P(=O)(O)O)S(=O)(=O)O
DMP8SIV	IK	RCGCZPXSRLLKCK-INIZCTEOSA-N
DMP8SIV	IU	(1S)-4-(3-phenoxyphenyl)-1-phosphonobutane-1-sulfonic acid
DMP8SIV	CA	CAS 157126-18-6
DMP8SIV	DE	Hyperlipidaemia

DMODK2J	ID	DMODK2J
DMODK2J	DN	BMS-193884
DMODK2J	HS	Discontinued in Phase 2
DMODK2J	SN	BMS-193884; UNII-7ON53PV45J; CHEMBL24461; 7ON53PV45J; 176960-47-7; SCHEMBL4204130; BDBM50091105; (1,1'-Biphenyl)-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-; LS-44539; L001532; 4''-Oxazol-2-yl-biphenyl-2-sulfonicacid(3,4-dimethyl-isoxazol-5-yl)-amide; 4''-Oxazol-2-yl-biphenyl-2-sulfonic acid (3,4-dimethyl-isoxazol-5-yl)-amide; 4''''-Oxazol-2-yl-biphenyl-2-sulfonic acid (3,4-dimethyl-isoxazol-5-yl)-amide
DMODK2J	DT	Small molecular drug
DMODK2J	PC	9843631
DMODK2J	MW	395.4
DMODK2J	FM	C20H17N3O4S
DMODK2J	IC	InChI=1S/C20H17N3O4S/c1-13-14(2)22-27-19(13)23-28(24,25)18-6-4-3-5-17(18)15-7-9-16(10-8-15)20-21-11-12-26-20/h3-12,23H,1-2H3
DMODK2J	CS	CC1=C(ON=C1C)NS(=O)(=O)C2=CC=CC=C2C3=CC=C(C=C3)C4=NC=CO4
DMODK2J	IK	LJGUZUROJOJEMI-UHFFFAOYSA-N
DMODK2J	IU	N-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(1,3-oxazol-2-yl)phenyl]benzenesulfonamide
DMODK2J	CA	CAS 176960-47-7
DMODK2J	DE	Pulmonary arterial hypertension

DMRPU10	ID	DMRPU10
DMRPU10	DN	BMS-488043
DMRPU10	HS	Discontinued in Phase 2
DMRPU10	SN	AIDS171276; BMS043; BMS488043; BMS-043; 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione
DMRPU10	CP	Bristol-Myers Squibb
DMRPU10	DT	Small molecular drug
DMRPU10	PC	507806
DMRPU10	MW	422.4
DMRPU10	FM	C22H22N4O5
DMRPU10	IC	InChI=1S/C22H22N4O5/c1-30-16-13-24-20(31-2)18-17(16)15(12-23-18)19(27)22(29)26-10-8-25(9-11-26)21(28)14-6-4-3-5-7-14/h3-7,12-13,23H,8-11H2,1-2H3
DMRPU10	CS	COC1=CN=C(C2=C1C(=CN2)C(=O)C(=O)N3CCN(CC3)C(=O)C4=CC=CC=C4)OC
DMRPU10	IK	DBPMWRYLTBNCCE-UHFFFAOYSA-N
DMRPU10	IU	1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione
DMRPU10	CA	CAS 452296-83-2
DMRPU10	DE	Human immunodeficiency virus infection

DMS2IC9	ID	DMS2IC9
DMS2IC9	DN	BMS-587101
DMS2IC9	HS	Discontinued in Phase 2
DMS2IC9	SN	BMS-688521
DMS2IC9	CP	Bristol Myers Squibb
DMS2IC9	PC	11635371
DMS2IC9	MW	555.4
DMS2IC9	FM	C26H20Cl2N4O4S
DMS2IC9	IC	InChI=1S/C26H20Cl2N4O4S/c1-30-25(36)32(20-8-18(27)7-19(28)9-20)24(35)26(30)14-31(11-21-6-17(13-37-21)23(33)34)12-22(26)16-4-2-15(10-29)3-5-16/h2-9,13,22H,11-12,14H2,1H3,(H,33,34)/t22-,26+/m0/s1
DMS2IC9	CS	CN1C(=O)N(C(=O)[C@]12CN(C[C@H]2C3=CC=C(C=C3)C#N)CC4=CC(=CS4)C(=O)O)C5=CC(=CC(=C5)Cl)Cl
DMS2IC9	IK	NXNKJLOEGWSJGI-BKMJKUGQSA-N
DMS2IC9	IU	5-[[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl]methyl]thiophene-3-carboxylic acid
DMS2IC9	CA	CAS 509083-77-6
DMS2IC9	DE	Psoriasis vulgaris

DM2NBXR	ID	DM2NBXR
DM2NBXR	DN	BMY-21950
DM2NBXR	HS	Discontinued in Phase 2
DM2NBXR	SN	Rac-erythro-9,9-Bis(4-fluorophenyl)-3,5-dihydroxy-8-(1-methyl-1H-tetrazol-5-yl)-6,8-nonadienoic acid sodium salt
DM2NBXR	DT	Small molecular drug
DM2NBXR	PC	23665941
DM2NBXR	MW	478.4
DM2NBXR	FM	C23H21F2N4NaO4
DM2NBXR	IC	InChI=1S/C23H22F2N4O4.Na/c1-29-23(26-27-28-29)20(11-10-18(30)12-19(31)13-21(32)33)22(14-2-6-16(24)7-3-14)15-4-8-17(25)9-5-15;/h2-11,18-19,30-31H,12-13H2,1H3,(H,32,33);/q;+1/p-1/b11-10+;/t18-,19-;/m0./s1
DM2NBXR	CS	CN1C(=NN=N1)C(=C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O.[Na+]
DM2NBXR	IK	NTDIRNUKAZNMSW-IYVGUKHKSA-M
DM2NBXR	IU	sodium;(3S,5R,6E)-9,9-bis(4-fluorophenyl)-3,5-dihydroxy-8-(1-methyltetrazol-5-yl)nona-6,8-dienoate
DM2NBXR	CA	CAS 131177-45-2
DM2NBXR	DE	Hyperlipidaemia

DMMJDYI	ID	DMMJDYI
DMMJDYI	DN	BMY-30123
DMMJDYI	HS	Discontinued in Phase 2
DMMJDYI	SN	Retinoic acid 4-acetamidophenyl ester; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2(E),4(E),6(E),8(E)-nonatetraenoic acid 4-acetamidophenyl ester
DMMJDYI	DT	Small molecular drug
DMMJDYI	PC	6505275
DMMJDYI	MW	433.6
DMMJDYI	FM	C28H35NO3
DMMJDYI	IC	InChI=1S/C28H35NO3/c1-20(12-17-26-22(3)11-8-18-28(26,5)6)9-7-10-21(2)19-27(31)32-25-15-13-24(14-16-25)29-23(4)30/h7,9-10,12-17,19H,8,11,18H2,1-6H3,(H,29,30)/b10-7+,17-12+,20-9+,21-19+
DMMJDYI	CS	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)OC2=CC=C(C=C2)NC(=O)C)/C)/C
DMMJDYI	IK	LQBHPDDJEMOJQA-ABRSJASVSA-N
DMMJDYI	IU	(4-acetamidophenyl) (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
DMMJDYI	CA	CAS 1959588-74-9
DMMJDYI	DE	Acne vulgaris

DMA4UCP	ID	DMA4UCP
DMA4UCP	DN	BMY-30129
DMA4UCP	HS	Discontinued in Phase 2
DMA4UCP	SN	BMS-181162; 4-(3-Carboxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2(Z),4(E),6(E),8(E)-nonatetraenoicacid
DMA4UCP	DE	Pruritus

DMC35T1	ID	DMC35T1
DMC35T1	DN	BN50727
DMC35T1	HS	Discontinued in Phase 2
DMC35T1	SN	Setipafant; Setipafant [INN]; UNII-UFN2Q54HS6; UFN2Q54HS6; 132418-35-0; BN 50727; 6-(o-Chlorophenyl)-7,10-dihydro-1-methyl-4H-pyrido(4',3':4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8H)-carbox-p-anisidide; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8H)-carboxamide, 7,10-dihydro-6-(2-chlorophenyl)-N-(4-methoxyphenyl)-1-methyl-; BN50727; AC1L24CK; AC1Q3P7H; SCHEMBL2110462; CHEMBL2107078; DTXSID90157552; ZINC1481922; CS-6678; BN-50727; LS-134347; HY-101675
DMC35T1	DT	Small molecular drug
DMC35T1	PC	65968
DMC35T1	MW	519
DMC35T1	FM	C26H23ClN6O2S
DMC35T1	IC	InChI=1S/C26H23ClN6O2S/c1-15-30-31-22-13-28-24(18-5-3-4-6-20(18)27)23-19-11-12-32(14-21(19)36-25(23)33(15)22)26(34)29-16-7-9-17(35-2)10-8-16/h3-10H,11-14H2,1-2H3,(H,29,34)
DMC35T1	CS	CC1=NN=C2N1C3=C(C4=C(S3)CN(CC4)C(=O)NC5=CC=C(C=C5)OC)C(=NC2)C6=CC=CC=C6Cl
DMC35T1	IK	DDJKTQDAEYPACV-UHFFFAOYSA-N
DMC35T1	IU	9-(2-chlorophenyl)-N-(4-methoxyphenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaene-14-carboxamide
DMC35T1	CA	CAS 132418-35-0
DMC35T1	DE	Inflammatory bowel disease

DMK0PVC	ID	DMK0PVC
DMK0PVC	DN	BOF-4272
DMK0PVC	HS	Discontinued in Phase 2
DMK0PVC	SN	Rac-8-[3-Methoxy-4-(phenylsulfinyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazin-4-ol sodium salt hydrate
DMK0PVC	DT	Small molecular drug
DMK0PVC	PC	23698229
DMK0PVC	MW	388.4
DMK0PVC	FM	C18H13N4NaO3S
DMK0PVC	IC	InChI=1S/C18H14N4O3S.Na/c1-25-15-9-12(14-10-21-22-17(14)19-11-20-18(22)23)7-8-16(15)26(24)13-5-3-2-4-6-13;/h2-11H,1H3,(H,19,20,21,23);/q;+1/p-1
DMK0PVC	CS	COC1=C(C=CC(=C1)C2=C3[N-]C=NC(=O)N3N=C2)S(=O)C4=CC=CC=C4.[Na+]
DMK0PVC	IK	FRSOALVXQKHLLF-UHFFFAOYSA-M
DMK0PVC	IU	sodium;7-[4-(benzenesulfinyl)-3-methoxyphenyl]-1,3,9-triaza-5-azanidabicyclo[4.3.0]nona-3,6,8-trien-2-one
DMK0PVC	CA	CAS 142181-44-0
DMK0PVC	DE	Gout

DMI3T64	ID	DMI3T64
DMI3T64	DN	BP-2.94
DMI3T64	HS	Discontinued in Phase 2
DMI3T64	SN	FUB-94; (-)-2-[1-[2-(4-Imidazolyl)-1(R)-methylethylimino]-1-phenylmethyl]phenol
DMI3T64	DT	Small molecular drug
DMI3T64	PC	5487462
DMI3T64	DE	Pain

DMAQ6DS	ID	DMAQ6DS
DMAQ6DS	DN	BP-897
DMAQ6DS	HS	Discontinued in Phase 2
DMAQ6DS	SN	BP 897; BP-897; BP897; UNII-2FVL90IM8I; 2FVL90IM8I; CHEMBL25236; 314776-92-6; N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide; N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide; BP-897 free base; SPBio_002558; SR-01000075725; DO-687; Prestwick-07H10; Prestwick3_000559; Prestwick2_000559; Prestwick1_000559; Prestwick0_000559; Lopac-B-9308; 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-; AC1MI4Y9; Lopac0_000165; BSPBio_000637; SCHEMBL2125882; GTPL7625; BPBio1_000701
DMAQ6DS	DT	Small molecular drug
DMAQ6DS	PC	3038495
DMAQ6DS	MW	417.5
DMAQ6DS	FM	C26H31N3O2
DMAQ6DS	IC	InChI=1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30)
DMAQ6DS	CS	COC1=CC=CC=C1N2CCN(CC2)CCCCNC(=O)C3=CC4=CC=CC=C4C=C3
DMAQ6DS	IK	MNHDKMDLOJSCGN-UHFFFAOYSA-N
DMAQ6DS	IU	N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide
DMAQ6DS	CA	CAS 192384-87-5
DMAQ6DS	CB	CHEBI:92310
DMAQ6DS	DE	Cocaine addiction

DMFN1WI	ID	DMFN1WI
DMFN1WI	DN	BR3-Fc
DMFN1WI	HS	Discontinued in Phase 2
DMFN1WI	CP	Genentech; Biogen Idec
DMFN1WI	DE	Idiopathic thrombocytopenic purpura; Rheumatoid arthritis

DMRVH2S	ID	DMRVH2S
DMRVH2S	DN	Brecanavir
DMRVH2S	HS	Discontinued in Phase 2
DMRVH2S	SN	Brecanavir; 313682-08-5; UNII-E367I8C7FI; GW64085X; GW640385; E367I8C7FI; CHEMBL206031; VX-385; GW0385; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL [(1S,2R)-3-[(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO]-2-HYDROXY-1-{4-[(2-METHYL-1,3-THIAZOL-4-YL)METHOXY]BENZYL}PROPYL]CARBAMATE; [3H]GW0385; Brecanavir [USAN:INN]; Proteinase inhibitor 640385; 2fde; 2fdd; Brecanavir (USAN); GSK 640385; GW 0385; AC1NX470; SCHEMBL1533991; BDBM4685; DTXSID10185296; JORVRJNILJXMMG-OLNQLETPSA-N; ZINC3994828; VX 385; AKOS005145761; DB04887; D03253
DMRVH2S	DT	Small molecular drug
DMRVH2S	PC	5743186
DMRVH2S	MW	703.8
DMRVH2S	FM	C33H41N3O10S2
DMRVH2S	IC	InChI=1S/C33H41N3O10S2/c1-20(2)14-36(48(39,40)25-8-9-29-30(13-25)45-19-44-29)15-28(37)27(35-33(38)46-31-17-43-32-26(31)10-11-41-32)12-22-4-6-24(7-5-22)42-16-23-18-47-21(3)34-23/h4-9,13,18,20,26-28,31-32,37H,10-12,14-17,19H2,1-3H3,(H,35,38)/t26-,27-,28+,31-,32+/m0/s1
DMRVH2S	CS	CC1=NC(=CS1)COC2=CC=C(C=C2)C[C@@H]([C@@H](CN(CC(C)C)S(=O)(=O)C3=CC4=C(C=C3)OCO4)O)NC(=O)O[C@H]5CO[C@@H]6[C@H]5CCO6
DMRVH2S	IK	JORVRJNILJXMMG-OLNQLETPSA-N
DMRVH2S	IU	[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[1,3-benzodioxol-5-ylsulfonyl(2-methylpropyl)amino]-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]carbamate
DMRVH2S	CA	CAS 313682-08-5
DMRVH2S	DE	Human immunodeficiency virus infection

DMRKBIU	ID	DMRKBIU
DMRKBIU	DN	BRL-32872A
DMRKBIU	HS	Discontinued in Phase 2
DMRKBIU	SN	BRL-32872 (free base); N-(3,4-Dimethoxyphenyl)-N-[3-[N'-methyl-N'-[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride
DMRKBIU	DT	Small molecular drug
DMRKBIU	PC	656770
DMRKBIU	MW	574.1
DMRKBIU	FM	C29H36ClN3O7
DMRKBIU	IC	InChI=1S/C29H35N3O7.ClH/c1-30(18-15-21-7-13-25(36-2)27(19-21)38-4)16-6-17-31(24-12-14-26(37-3)28(20-24)39-5)29(33)22-8-10-23(11-9-22)32(34)35;/h7-14,19-20H,6,15-18H2,1-5H3;1H
DMRKBIU	CS	CN(CCCN(C1=CC(=C(C=C1)OC)OC)C(=O)C2=CC=C(C=C2)[N+](=O)[O-])CCC3=CC(=C(C=C3)OC)OC.Cl
DMRKBIU	IK	CMKVOHIRMCFVBJ-UHFFFAOYSA-N
DMRKBIU	IU	N-(3,4-dimethoxyphenyl)-N-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-4-nitrobenzamide;hydrochloride
DMRKBIU	CA	CAS 113241-47-7
DMRKBIU	CB	CHEBI:34551
DMRKBIU	DE	Cardiac arrhythmias

DMIHSOG	ID	DMIHSOG
DMIHSOG	DN	BRL-46470
DMIHSOG	HS	Discontinued in Phase 2
DMIHSOG	SN	CHEMBL285999; BRL-46470; SCHEMBL634827; BDBM50060257; BC600835; N-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-3,3-dimethyl-1H-indole-1-carboxamide; 3,3-Dimethyl-2,3-dihydro-indole-1-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide; endo-N-(8-methyl-8-azabicyclo [3.2.1]oct-3-yl)2,3-dihydro-3,3 dimethyl-indole-1-carboxamide
DMIHSOG	DT	Small molecular drug
DMIHSOG	PC	71785
DMIHSOG	MW	313.4
DMIHSOG	FM	C19H27N3O
DMIHSOG	IC	InChI=1S/C19H27N3O/c1-19(2)12-22(17-7-5-4-6-16(17)19)18(23)20-13-10-14-8-9-15(11-13)21(14)3/h4-7,13-15H,8-12H2,1-3H3,(H,20,23)/t13?,14-,15+
DMIHSOG	CS	CC1(CN(C2=CC=CC=C21)C(=O)NC3C[C@H]4CC[C@@H](C3)N4C)C
DMIHSOG	IK	ILXWRFDRNAKTDD-GOOCMWNKSA-N
DMIHSOG	IU	3,3-dimethyl-N-[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2H-indole-1-carboxamide
DMIHSOG	CA	CAS 117086-68-7
DMIHSOG	DE	Anxiety disorder

DM0WG4U	ID	DM0WG4U
DM0WG4U	DN	BRL-55834
DM0WG4U	HS	Discontinued in Phase 2
DM0WG4U	SN	Brl-55834; Brl 55834; 131899-25-7; brl55834; SCHEMBL6369898; AC1L2Z70; DTXSID80157243; 3,4-Dihydro-2,2-dimethyl-4-(oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol; 2-Piperidinone, 1-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(pentafluoroethyl)-2H-1-benzopyran-4-yl)-, (3S-trans)-
DM0WG4U	CP	SmithKline Beecham plc
DM0WG4U	DT	Small molecular drug
DM0WG4U	PC	131442
DM0WG4U	MW	393.3
DM0WG4U	FM	C18H20F5NO3
DM0WG4U	IC	InChI=1S/C18H20F5NO3/c1-16(2)15(26)14(24-8-4-3-5-13(24)25)11-9-10(6-7-12(11)27-16)17(19,20)18(21,22)23/h6-7,9,14-15,26H,3-5,8H2,1-2H3/t14-,15+/m1/s1
DM0WG4U	CS	CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C(C(F)(F)F)(F)F)N3CCCCC3=O)O)C
DM0WG4U	IK	ZSUFQZNGDIXQAD-CABCVRRESA-N
DM0WG4U	IU	1-[(3S,4R)-3-hydroxy-2,2-dimethyl-6-(1,1,2,2,2-pentafluoroethyl)-3,4-dihydrochromen-4-yl]piperidin-2-one
DM0WG4U	CA	CAS 131899-25-7
DM0WG4U	DE	Chronic obstructive pulmonary disease

DMV3Y8R	ID	DMV3Y8R
DMV3Y8R	DN	BRL-61063
DMV3Y8R	HS	Discontinued in Phase 2
DMV3Y8R	SN	Cipamfylline; 132210-43-6; UNII-AFP56R140L; AFP56R140L; CHEMBL356323; Cipamfylline [USAN:INN]; Cipamfyllinum; AC1Q6LCD; 8-Amino-1,3-bis(cyclopropylmethyl)xanthine; Cipamfylline (USAN/INN); AC1L2G0B; SCHEMBL26990; MLS006010682; SCHEMBL8327157; Brl 61063; 8-amino-1,3-bis(cyclopropylmethyl)-7H-purine-2,6-dione; DTXSID50157437; Cipamfylline, &gt; KSPYMJJKQMWWNB-UHFFFAOYSA-N; ZINC3781835; BDBM50040348; 1,3-dicyclopropylmethyl-8-amino xanthine; SMR004701664; 8-Amino-1,3-di(cyclopropylmethyl)xanthine; D03516
DMV3Y8R	DT	Small molecular drug
DMV3Y8R	PC	71356
DMV3Y8R	MW	275.31
DMV3Y8R	FM	C13H17N5O2
DMV3Y8R	IC	InChI=1S/C13H17N5O2/c14-12-15-9-10(16-12)17(5-7-1-2-7)13(20)18(11(9)19)6-8-3-4-8/h7-8H,1-6H2,(H3,14,15,16)
DMV3Y8R	CS	C1CC1CN2C3=C(C(=O)N(C2=O)CC4CC4)NC(=N3)N
DMV3Y8R	IK	KSPYMJJKQMWWNB-UHFFFAOYSA-N
DMV3Y8R	IU	8-amino-1,3-bis(cyclopropylmethyl)-7H-purine-2,6-dione
DMV3Y8R	CA	CAS 132210-43-6
DMV3Y8R	DE	Allergy

DMTEQ0G	ID	DMTEQ0G
DMTEQ0G	DN	Brofaromine
DMTEQ0G	HS	Discontinued in Phase 2
DMTEQ0G	SN	Brofaremine; Consonar; Consonev; Brofaromine hydrochloride; CGP-11305A
DMTEQ0G	CP	Novartis AG
DMTEQ0G	DT	Small molecular drug
DMTEQ0G	PC	44571
DMTEQ0G	MW	310.19
DMTEQ0G	FM	C14H16BrNO2
DMTEQ0G	IC	InChI=1S/C14H16BrNO2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16H,2-5H2,1H3
DMTEQ0G	CS	COC1=CC(=C2C(=C1)C=C(O2)C3CCNCC3)Br
DMTEQ0G	IK	WZXHSWVDAYOFPE-UHFFFAOYSA-N
DMTEQ0G	IU	4-(7-bromo-5-methoxy-1-benzofuran-2-yl)piperidine
DMTEQ0G	CA	CAS 63638-91-5
DMTEQ0G	DE	Anxiety disorder

DM54K2P	ID	DM54K2P
DM54K2P	DN	BTS-67582
DM54K2P	HS	Discontinued in Phase 2
DM54K2P	SN	1,1-Dimethyl-2-(2-morpholinophenyl)guanidine fumarate
DM54K2P	PC	9885406
DM54K2P	MW	364.4
DM54K2P	FM	C17H24N4O5
DM54K2P	IC	InChI=1S/C13H20N4O.C4H4O4/c1-16(2)13(14)15-11-5-3-4-6-12(11)17-7-9-18-10-8-17;5-3(6)1-2-4(7)8/h3-6H,7-10H2,1-2H3,(H2,14,15);1-2H,(H,5,6)(H,7,8)/b;2-1+
DM54K2P	CS	CN(C)C(=NC1=CC=CC=C1N2CCOCC2)N.C(=C/C(=O)O)\\C(=O)O
DM54K2P	IK	FFEKJBVVAJTQST-WLHGVMLRSA-N
DM54K2P	IU	(E)-but-2-enedioic acid;1,1-dimethyl-2-(2-morpholin-4-ylphenyl)guanidine
DM54K2P	CA	CAS 161748-40-9
DM54K2P	DE	Diabetic complication

DM43JK0	ID	DM43JK0
DM43JK0	DN	BVT-115959
DM43JK0	HS	Discontinued in Phase 2
DM43JK0	SN	Adenosine A2a agonists, Biovitrum; CBT-1008; Pain therapy, Cambridge Biotechnology
DM43JK0	CP	Biovitrum
DM43JK0	DE	Pain

DMI2LFG	ID	DMI2LFG
DMI2LFG	DN	BW-773U82
DMI2LFG	HS	Discontinued in Phase 2
DMI2LFG	SN	BW-A773U; 2-(3-Fluoranthenylmethylamino)-2-methyl-1,3-propanediol hydrochloride; 3-[2-Hydroxy-1-(hydroxymethyl)-1-methylethylaminomethyl]fluoranthene hydrochloride; 773U82.HCl
DMI2LFG	DT	Small molecular drug
DMI2LFG	PC	3024572
DMI2LFG	MW	355.9
DMI2LFG	FM	C21H22ClNO2
DMI2LFG	IC	InChI=1S/C21H21NO2.ClH/c1-21(12-23,13-24)22-11-14-9-10-19-17-6-3-2-5-16(17)18-8-4-7-15(14)20(18)19;/h2-10,22-24H,11-13H2,1H3;1H
DMI2LFG	CS	CC(CO)(CO)NCC1=C2C=CC=C3C2=C(C=C1)C4=CC=CC=C43.Cl
DMI2LFG	IK	XPSPHVAGYMFPFA-UHFFFAOYSA-N
DMI2LFG	IU	2-(fluoranthen-3-ylmethylamino)-2-methylpropane-1,3-diol;hydrochloride
DMI2LFG	CA	CAS 96404-51-2
DMI2LFG	DE	Solid tumour/cancer

DM8ZFS3	ID	DM8ZFS3
DM8ZFS3	DN	BY-1949
DM8ZFS3	HS	Discontinued in Phase 2
DM8ZFS3	SN	BY-1949; 90158-59-1; 3-Methoxy-11-methyldibenz(b,f)oxazepine-8-carboxylate; AC1L3SM5; SCHEMBL194184; DTXSID60238049; JTZGDJSJVQONAV-UHFFFAOYSA-N; 11-methyl-3-methoxydibenz[b,f][1,4]oxazepine-8-carboxylic acid; Dibenz(b,f)(1,4)oxazepine-8-carboxylic acid, 3-methoxy-11-methyl-; 9-methoxy-6-methylbenzo[b][1,4]benzoxazepine-3-carboxylic acid; 3-methoxy-11-methyldibenzo[b,f][1,4]oxazepin-8-carboxylic acid
DM8ZFS3	CP	Chugai Pharmaceutical Co Ltd
DM8ZFS3	DT	Small molecular drug
DM8ZFS3	PC	146138
DM8ZFS3	MW	283.28
DM8ZFS3	FM	C16H13NO4
DM8ZFS3	IC	InChI=1S/C16H13NO4/c1-9-12-5-4-11(20-2)8-15(12)21-14-6-3-10(16(18)19)7-13(14)17-9/h3-8H,1-2H3,(H,18,19)
DM8ZFS3	CS	CC1=NC2=C(C=CC(=C2)C(=O)O)OC3=C1C=CC(=C3)OC
DM8ZFS3	IK	JTZGDJSJVQONAV-UHFFFAOYSA-N
DM8ZFS3	IU	9-methoxy-6-methylbenzo[b][1,4]benzoxazepine-3-carboxylic acid
DM8ZFS3	CA	CAS 90158-59-1
DM8ZFS3	DE	Cognitive impairment

DMHJ3SN	ID	DMHJ3SN
DMHJ3SN	DN	Cadrofloxacin
DMHJ3SN	HS	Discontinued in Phase 2
DMHJ3SN	SN	Caderofloxacin; CS-940
DMHJ3SN	CP	Sankyo Co Ltd
DMHJ3SN	DT	Small molecular drug
DMHJ3SN	PC	189912
DMHJ3SN	MW	411.4
DMHJ3SN	FM	C19H20F3N3O4
DMHJ3SN	IC	InChI=1S/C19H20F3N3O4/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28)/t9-/m0/s1
DMHJ3SN	CS	C[C@H]1CN(CCN1)C2=C(C=C3C(=C2OC(F)F)N(C=C(C3=O)C(=O)O)C4CC4)F
DMHJ3SN	IK	QBDBUKJBJJWZMG-VIFPVBQESA-N
DMHJ3SN	IU	1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-7-[(3S)-3-methylpiperazin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMHJ3SN	CA	CAS 153808-85-6
DMHJ3SN	DE	Bacterial infection

DMS3ECJ	ID	DMS3ECJ
DMS3ECJ	DN	Camobucol
DMS3ECJ	HS	Discontinued in Phase 2
DMS3ECJ	SN	AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics
DMS3ECJ	CP	AtheroGenics Inc
DMS3ECJ	DT	Small molecular drug
DMS3ECJ	PC	9875498
DMS3ECJ	MW	574.9
DMS3ECJ	FM	C33H50O4S2
DMS3ECJ	IC	InChI=1S/C33H50O4S2/c1-29(2,3)22-15-20(16-23(27(22)36)30(4,5)6)38-33(13,14)39-21-17-24(31(7,8)9)28(37-19-26(34)35)25(18-21)32(10,11)12/h15-18,36H,19H2,1-14H3,(H,34,35)
DMS3ECJ	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)OCC(=O)O)C(C)(C)C
DMS3ECJ	IK	FGBGXESDYFKUFX-UHFFFAOYSA-N
DMS3ECJ	IU	2-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]acetic acid
DMS3ECJ	CA	CAS 216167-92-9
DMS3ECJ	DE	Rheumatoid arthritis

DMNOLHT	ID	DMNOLHT
DMNOLHT	DN	Caracemide
DMNOLHT	HS	Discontinued in Phase 2
DMNOLHT	SN	NSC-253272
DMNOLHT	CP	Hoechst Marion Roussel Inc
DMNOLHT	DT	Small molecular drug
DMNOLHT	PC	54747
DMNOLHT	MW	189.17
DMNOLHT	FM	C6H11N3O4
DMNOLHT	IC	InChI=1S/C6H11N3O4/c1-4(10)9(5(11)7-2)13-6(12)8-3/h1-3H3,(H,7,11)(H,8,12)
DMNOLHT	CS	CC(=O)N(C(=O)NC)OC(=O)NC
DMNOLHT	IK	JURAJLFHWXNPHG-UHFFFAOYSA-N
DMNOLHT	IU	[acetyl(methylcarbamoyl)amino] N-methylcarbamate
DMNOLHT	CA	CAS 81424-67-1
DMNOLHT	DE	Solid tumour/cancer

DMV2DY3	ID	DMV2DY3
DMV2DY3	DN	CARIPORIDE
DMV2DY3	HS	Discontinued in Phase 2
DMV2DY3	SN	Cariporide mesylate; UNII-0543W2JFRZ; 159138-81-5; Cariporide mesylate [USAN]; CHEMBL462831; 0543W2JFRZ; Cariporide mesylate (USAN); Cariporide mesilate; N-(4-Isopropyl-3-methanesulfonyl-benzoyl)-guanidine; DSSTox_RID_82284; DSSTox_CID_27344; DSSTox_GSID_47344; SCHEMBL221094; DTXSID3047344; AC1L4343; Tox21_300231; NCGC00254230-01; CAS-159138-81-5; D03406; (4-isopropyl-3-methanesulfonyl-benzoyl) guanidine methanesulfonate; Benzamide, N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)-, monomethanesulfonate
DMV2DY3	DT	Small molecular drug
DMV2DY3	PC	151172
DMV2DY3	MW	283.35
DMV2DY3	FM	C12H17N3O3S
DMV2DY3	IC	InChI=1S/C12H17N3O3S/c1-7(2)9-5-4-8(11(16)15-12(13)14)6-10(9)19(3,17)18/h4-7H,1-3H3,(H4,13,14,15,16)
DMV2DY3	CS	CC(C)C1=C(C=C(C=C1)C(=O)N=C(N)N)S(=O)(=O)C
DMV2DY3	IK	IWXNYAIICFKCTM-UHFFFAOYSA-N
DMV2DY3	IU	N-(diaminomethylidene)-3-methylsulfonyl-4-propan-2-ylbenzamide
DMV2DY3	CA	CAS 159138-80-4
DMV2DY3	DE	Angina pectoris

DM5DI1G	ID	DM5DI1G
DM5DI1G	DN	CARZELESIN
DM5DI1G	HS	Discontinued in Phase 2
DM5DI1G	SN	Carzelesin < Rec INN; U-80244; (S)-N-[2-[1-(Chloromethyl)-8-methyl-5-(N-phenylcarbamoyloxy)-1,2,3,6-tetrahydrobenzo[1,2-b:4,3-b']dipyrrol-3-ylcarbonyl]-1H-indol-5-yl]-6-(diethylamino)benzofuran-2-carboxamide
DM5DI1G	DT	Small molecular drug
DM5DI1G	PC	3034013
DM5DI1G	MW	729.2
DM5DI1G	FM	C41H37ClN6O5
DM5DI1G	IC	InChI=1S/C41H37ClN6O5/c1-4-47(5-2)29-13-11-24-17-35(52-33(24)18-29)39(49)44-28-12-14-30-25(15-28)16-31(46-30)40(50)48-22-26(20-42)37-32(48)19-34(38-36(37)23(3)21-43-38)53-41(51)45-27-9-7-6-8-10-27/h6-19,21,26,43,46H,4-5,20,22H2,1-3H3,(H,44,49)(H,45,51)/t26-/m1/s1
DM5DI1G	CS	CCN(CC)C1=CC2=C(C=C1)C=C(O2)C(=O)NC3=CC4=C(C=C3)NC(=C4)C(=O)N5C[C@H](C6=C7C(=CNC7=C(C=C65)OC(=O)NC8=CC=CC=C8)C)CCl
DM5DI1G	IK	BBZDXMBRAFTCAA-AREMUKBSSA-N
DM5DI1G	IU	[(8S)-8-(chloromethyl)-6-[5-[[6-(diethylamino)-1-benzofuran-2-carbonyl]amino]-1H-indole-2-carbonyl]-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indol-4-yl] N-phenylcarbamate
DM5DI1G	CA	CAS 119813-10-4
DM5DI1G	DE	Solid tumour/cancer

DMPZFDE	ID	DMPZFDE
DMPZFDE	DN	CASTANOSPERMINE
DMPZFDE	HS	Discontinued in Phase 2
DMPZFDE	SN	MDL-26190; (1S,6S,7R,8R,8aR)-1,6,7,8-Tetrahydroxyoctahydroindolizine
DMPZFDE	DT	Small molecular drug
DMPZFDE	PC	54445
DMPZFDE	MW	189.21
DMPZFDE	FM	C8H15NO4
DMPZFDE	IC	InChI=1S/C8H15NO4/c10-4-1-2-9-3-5(11)7(12)8(13)6(4)9/h4-8,10-13H,1-3H2/t4-,5-,6+,7+,8+/m0/s1
DMPZFDE	CS	C1CN2C[C@@H]([C@H]([C@@H]([C@H]2[C@H]1O)O)O)O
DMPZFDE	IK	JDVVGAQPNNXQDW-TVNFTVLESA-N
DMPZFDE	IU	(1S,6S,7R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,6,7,8-tetrol
DMPZFDE	CA	CAS 79831-76-8
DMPZFDE	CB	CHEBI:27860
DMPZFDE	DE	Diabetic complication

DMVP4YK	ID	DMVP4YK
DMVP4YK	DN	CB1954
DMVP4YK	HS	Discontinued in Phase 2
DMVP4YK	SN	Tretazicar; CB 1954; 21919-05-1; CB1954; 5-(1-Aziridinyl)-2,4-dinitrobenzamide; 5-Aziridino-2,4-dinitrobenzamide; CB-1954; 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE; 5-Aziridinyl-2,4-dinitrobenzamide; Tretazicar [INN]; 2,4-Dinitroethyleneiminobenzamide; 2,4-Dinitro-5-ethyleneiminobenzamide; CHEMBL23330; CCRIS 1631; UNII-7865D5D01M; NSC 115829; 7865D5D01M; BRN 5825582; Benzamide,5-(1-aziridinyl)-2,4-dinitro-; Benzamide, 5-(1-aziridinyl)-2,4-dinitro-; CB1; C9H8N4O5; SMR000326847; aziridine dinitrobenzamide; CB1954(Tretazicar); AC1Q1YAR
DMVP4YK	DT	Small molecular drug
DMVP4YK	PC	89105
DMVP4YK	MW	252.18
DMVP4YK	FM	C9H8N4O5
DMVP4YK	IC	InChI=1S/C9H8N4O5/c10-9(14)5-3-7(11-1-2-11)8(13(17)18)4-6(5)12(15)16/h3-4H,1-2H2,(H2,10,14)
DMVP4YK	CS	C1CN1C2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-]
DMVP4YK	IK	WOCXQMCIOTUMJV-UHFFFAOYSA-N
DMVP4YK	IU	5-(aziridin-1-yl)-2,4-dinitrobenzamide
DMVP4YK	CA	CAS 21919-05-1
DMVP4YK	DE	Solid tumour/cancer

DM2FAH0	ID	DM2FAH0
DM2FAH0	DN	CBF-BS2
DM2FAH0	HS	Discontinued in Phase 2
DM2FAH0	SN	KSB-302
DM2FAH0	CP	KS Biomedix Ltd
DM2FAH0	DE	Rheumatoid arthritis

DM9P7Z2	ID	DM9P7Z2
DM9P7Z2	DN	CD-349
DM9P7Z2	HS	Discontinued in Phase 2
DM9P7Z2	SN	CD-349; CD 349; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(nitrooxy)propyl 3-(nitrooxy)propyl ester; 2-Nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; AC1L3OLK; SCHEMBL7376581; AC1Q63B2; 2-(nitrooxy)propyl 3-(nitrooxy)propyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; LS-186864; LS-187520; 5-O-(2-nitrooxypropyl) 3-O-(3-nitrooxypropyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM9P7Z2	CP	Taisho Pharmaceutical Co Ltd
DM9P7Z2	DT	Small molecular drug
DM9P7Z2	PC	119325
DM9P7Z2	MW	524.4
DM9P7Z2	FM	C21H24N4O12
DM9P7Z2	IC	InChI=1S/C21H24N4O12/c1-12(37-25(32)33)11-35-21(27)18-14(3)22-13(2)17(20(26)34-8-5-9-36-24(30)31)19(18)15-6-4-7-16(10-15)23(28)29/h4,6-7,10,12,19,22H,5,8-9,11H2,1-3H3
DM9P7Z2	CS	CC1=C(C(C(=C(N1)C)C(=O)OCC(C)O[N+](=O)[O-])C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCCO[N+](=O)[O-]
DM9P7Z2	IK	QSTCLWROWBZZLA-UHFFFAOYSA-N
DM9P7Z2	IU	5-O-(2-nitrooxypropyl) 3-O-(3-nitrooxypropyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM9P7Z2	CA	CAS 88594-08-5
DM9P7Z2	DE	Hypertension

DMUPJW4	ID	DMUPJW4
DMUPJW4	DN	CDP840
DMUPJW4	HS	Discontinued in Phase 2
DMUPJW4	SN	Cdp-840; Cdp 840; CDP840; CHEMBL32442; 4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; (R)-4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; 4-[(2R)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine; Pyridine, 4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)-, (R)-; 162542-90-7; AC1L2SW5; SCHEMBL84490; 4-[2-(3-Cyclopentyloxy-4-methoxy-phenyl)-2-phenyl-ethyl]-pyridine; GTPL9330; UTUUPXBCDMQYRR-HSZRJFAPSA-N; ZINC599006; PDSP2_001272; BDBM50064858; PDSP1_001288
DMUPJW4	DT	Small molecular drug
DMUPJW4	PC	127928
DMUPJW4	MW	373.5
DMUPJW4	FM	C25H27NO2
DMUPJW4	IC	InChI=1S/C25H27NO2/c1-27-24-12-11-21(18-25(24)28-22-9-5-6-10-22)23(20-7-3-2-4-8-20)17-19-13-15-26-16-14-19/h2-4,7-8,11-16,18,22-23H,5-6,9-10,17H2,1H3/t23-/m1/s1
DMUPJW4	CS	COC1=C(C=C(C=C1)[C@H](CC2=CC=NC=C2)C3=CC=CC=C3)OC4CCCC4
DMUPJW4	IK	UTUUPXBCDMQYRR-HSZRJFAPSA-N
DMUPJW4	IU	4-[(2R)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine
DMUPJW4	CA	CAS 162542-90-7
DMUPJW4	DE	Chronic obstructive pulmonary disease

DMWHQM3	ID	DMWHQM3
DMWHQM3	DN	CDP-850
DMWHQM3	HS	Discontinued in Phase 2
DMWHQM3	SN	VLA-4, Celltech; Anti-E-selectin antibody, Celltech
DMWHQM3	CP	UCB Celltech
DMWHQM3	DT	Antibody
DMWHQM3	DE	Solid tumour/cancer

DMEI0LJ	ID	DMEI0LJ
DMEI0LJ	DN	CDP-860
DMEI0LJ	HS	Discontinued in Phase 2
DMEI0LJ	SN	MAb, PDGFr, Celltech
DMEI0LJ	CP	ZymoGenetics Inc
DMEI0LJ	DE	Solid tumour/cancer

DM746L8	ID	DM746L8
DM746L8	DN	CE-1037
DM746L8	HS	Discontinued in Phase 2
DM746L8	SN	SPWHS19WTL; UNII-SPWHS19WTL; CHEMBL56605; Mdl 201404YA; Mdl 201,404YA; CE 1037; 150493-09-7; ce1037; SCHEMBL8974527; BDBM50058491; Bis(4-(2'-(carboxy-2'-methylpropylsulfonyl)phenyl)2,2'-(1,4-phenylene))diisobutyrate; 3-{4-[2-(4-{1-[4-(2-Carboxy-2-methyl-propane-1-sulfonyl)-phenoxycarbonyl]-1-methyl-ethyl}-phenyl)-2-methyl-propionyloxy]-benzenesulfonyl}-2,2-dimethyl-propionic acid(CE-1037)
DM746L8	DT	Small molecular drug
DM746L8	PC	131801066
DM746L8	MW	774.8
DM746L8	FM	C36H40Na2O12S2
DM746L8	IC	InChI=1S/C36H42O12S2.2Na/c1-33(2,29(37)38)21-49(43,44)27-17-13-25(14-18-27)47-31(41)35(5,6)23-9-11-24(12-10-23)36(7,8)32(42)48-26-15-19-28(20-16-26)50(45,46)22-34(3,4)30(39)40;;/h9-20H,21-22H2,1-8H3,(H,37,38)(H,39,40);;/q;2*+1/p-2
DM746L8	CS	CC(C)(CS(=O)(=O)C1=CC=C(C=C1)OC(=O)C(C)(C)C2=CC=C(C=C2)C(C)(C)C(=O)OC3=CC=C(C=C3)S(=O)(=O)CC(C)(C)C(=O)[O-])C(=O)[O-].[Na+].[Na+]
DM746L8	IK	HTARXGMNANKUGQ-UHFFFAOYSA-L
DM746L8	IU	disodium;3-[4-[2-[4-[1-[4-(2-carboxylato-2-methylpropyl)sulfonylphenoxy]-2-methyl-1-oxopropan-2-yl]phenyl]-2-methylpropanoyl]oxyphenyl]sulfonyl-2,2-dimethylpropanoate
DM746L8	CA	CAS 155947-72-1
DM746L8	DE	Chronic obstructive pulmonary disease

DMXO49B	ID	DMXO49B
DMXO49B	DN	CE-326597
DMXO49B	HS	Discontinued in Phase 2
DMXO49B	SN	CE-326597; UNII-1FGZ6L9SF2; 1FGZ6L9SF2; CHEMBL1269258; CE 326597; CE-326,597; GTPL9055; BDBM50329179; DB12694; compound 4a [PMID: 20851601]; 6H-(1,2,4)Triazolo(4,3-a)(1,5)benzodiazepine-6-acetamide, 4,5-dihydro-4-(1H-indol-3-ylmethyl)-N-(1-methylethyl)-5-oxo-1-phenyl-N-(phenylmethyl)-, (-)-; 6H-(1,2,4)Triazolo(4,3-a)(1,5)benzodiazepine-6-acetamide, 4,5-dihydro-4-(1H-indol-3-ylmethyl)-N-(1-methylethyl)-5-oxo-1-phenyl-N-(phenylmethyl)-, (S)-; J3.552.307C
DMXO49B	CP	Pfizer Inc
DMXO49B	DT	Small molecular drug
DMXO49B	PC	52949124
DMXO49B	MW	594.7
DMXO49B	FM	C37H34N6O2
DMXO49B	IC	InChI=1S/C37H34N6O2/c1-25(2)41(23-26-13-5-3-6-14-26)34(44)24-42-32-19-11-12-20-33(32)43-35(27-15-7-4-8-16-27)39-40-36(43)30(37(42)45)21-28-22-38-31-18-10-9-17-29(28)31/h3-20,22,25,30,38H,21,23-24H2,1-2H3/t30-/m0/s1
DMXO49B	CS	CC(C)N(CC1=CC=CC=C1)C(=O)CN2C3=CC=CC=C3N4C(=NN=C4C5=CC=CC=C5)[C@@H](C2=O)CC6=CNC7=CC=CC=C76
DMXO49B	IK	UBNMGTSDHSQBEL-PMERELPUSA-N
DMXO49B	IU	N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4H-[1,2,4]triazolo[3,4-d][1,5]benzodiazepin-6-yl]-N-propan-2-ylacetamide
DMXO49B	CA	CAS 870615-40-0
DMXO49B	DE	Obesity

DMIR4FB	ID	DMIR4FB
DMIR4FB	DN	CEMADOTIN HYDROCHLORIDE
DMIR4FB	HS	Discontinued in Phase 2
DMIR4FB	SN	LU-103793; Cemadotin hydrochloride; N,N-Dimethyl-L-valyl-L-valyl-L-(N-methyl)-valyl-L-prolyl-L-proline benzylamide hydrochloride
DMIR4FB	DT	Small molecular drug
DMIR4FB	PC	21143092
DMIR4FB	MW	677.3
DMIR4FB	FM	C35H57ClN6O5
DMIR4FB	IC	InChI=1S/C35H56N6O5.ClH/c1-22(2)28(37-32(43)29(23(3)4)38(7)8)34(45)39(9)30(24(5)6)35(46)41-20-14-18-27(41)33(44)40-19-13-17-26(40)31(42)36-21-25-15-11-10-12-16-25;/h10-12,15-16,22-24,26-30H,13-14,17-21H2,1-9H3,(H,36,42)(H,37,43);1H/t26-,27-,28-,29-,30-;/m0./s1
DMIR4FB	CS	CC(C)[C@@H](C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N(C)C.Cl
DMIR4FB	IK	MRJQTLJSMQOFTP-JGTKTWDESA-N
DMIR4FB	IU	(2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride
DMIR4FB	CA	CAS 172837-41-1
DMIR4FB	DE	Solid tumour/cancer

DMG62H1	ID	DMG62H1
DMG62H1	DN	CereCRIB
DMG62H1	HS	Discontinued in Phase 2
DMG62H1	SN	ACTID; Drug implant (analgesic), CytoTherapeutics; Bovine cell impant (pain, ECT), CytoTherapeutics; Bovine cell implant (pain, CRIB), CytoTherapeutics; Bovine cell impant (pain, ECT), CytoTherapeutics, AstraZeneca; Bovine cell implant (pain, CRIB), CytoTherapeutics, AstraZeneca
DMG62H1	CP	StemCells Inc
DMG62H1	DT	Small molecular drug
DMG62H1	PC	16129718
DMG62H1	MW	3305.8
DMG62H1	FM	C150H230N44O39S
DMG62H1	IC	InChI=1S/C150H230N44O39S/c1-80(2)120(190-139(224)112-40-26-62-192(112)144(229)101(35-17-21-58-154)173-115(200)75-168-125(210)106(69-87-72-166-93-31-13-12-30-91(87)93)184-129(214)98(37-23-60-164-149(158)159)177-134(219)105(66-84-28-10-9-11-29-84)183-136(221)107(70-88-73-162-79-170-88)185-130(215)99(50-52-117(202)203)178-131(216)100(54-65-234-8)179-137(222)110(78-196)188-135(220)104(182-124(209)92(155)77-195)67-85-42-46-89(197)47-43-85)141(226)169-76-114(199)172-94(32-14-18-55-151)126(211)175-95(33-15-19-56-152)127(212)176-97(36-22-59-163-148(156)157)128(213)181-102(38-24-61-165-150(160)161)145(230)193-63-27-41-113(193)140(225)191-122(82(5)6)142(227)180-96(34-16-20-57-153)132(217)189-121(81(3)4)143(228)187-109(68-86-44-48-90(198)49-45-86)146(231)194-64-25-39-111(194)138(223)186-108(71-119(206)207)133(218)171-83(7)123(208)167-74-116(201)174-103(147(232)233)51-53-118(204)205/h9-13,28-31,42-49,72-73,79-83,92,94-113,120-122,166,195-198H,14-27,32-41,50-71,74-78,151-155H2,1-8H3,(H,162,170)(H,167,208)(H,168,210)(H,169,226)(H,171,218)(H,172,199)(H,173,200)(H,174,201)(H,175,211)(H,176,212)(H,177,219)(H,178,216)(H,179,222)(H,180,227)(H,181,213)(H,182,209)(H,183,221)(H,184,214)(H,185,215)(H,186,223)(H,187,228)(H,188,220)(H,189,217)(H,190,224)(H,191,225)(H,202,203)(H,204,205)(H,206,207)(H,232,233)(H4,156,157,163)(H4,158,159,164)(H4,160,161,165)/t83-,92-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,120-,121-,122-/m0/s1
DMG62H1	CS	C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CO)N
DMG62H1	IK	VDBFSWDFTQMVDA-GDNBNFDOSA-N
DMG62H1	IU	(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]acetyl]amino]pentanedioic acid
DMG62H1	DE	Pain

DMFBNI6	ID	DMFBNI6
DMFBNI6	DN	Ceronapril
DMFBNI6	HS	Discontinued in Phase 2
DMFBNI6	SN	Ceranapril; SQ-29852
DMFBNI6	CP	Bristol-Myers Squibb Co
DMFBNI6	DT	Small molecular drug
DMFBNI6	PC	189729
DMFBNI6	MW	440.5
DMFBNI6	FM	C21H33N2O6P
DMFBNI6	IC	InChI=1S/C21H33N2O6P/c22-14-6-4-13-19(20(24)23-15-8-12-18(23)21(25)26)29-30(27,28)16-7-5-11-17-9-2-1-3-10-17/h1-3,9-10,18-19H,4-8,11-16,22H2,(H,25,26)(H,27,28)/t18-,19-/m0/s1
DMFBNI6	CS	C1C[C@H](N(C1)C(=O)[C@H](CCCCN)OP(=O)(CCCCC2=CC=CC=C2)O)C(=O)O
DMFBNI6	IK	IFYLTXNCFVRALQ-OALUTQOASA-N
DMFBNI6	IU	(2S)-1-[(2S)-6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]pyrrolidine-2-carboxylic acid
DMFBNI6	CA	CAS 111223-26-8
DMFBNI6	DE	Major depressive disorder

DMUG5OB	ID	DMUG5OB
DMUG5OB	DN	CETi-1
DMUG5OB	HS	Discontinued in Phase 2
DMUG5OB	SN	Cholesteryl Ester Transfer Protein Vaccine; CETP vaccine, T Cell Sciences; Vaccine (CETP), AVANT; Vaccine (CETP), T Cell Sciences; Vaccine (atherosclerosis), T Cell Sciences
DMUG5OB	CP	Celldex Therapeutics Inc
DMUG5OB	DT	Vaccine
DMUG5OB	DE	Arteriosclerosis

DMHK8IM	ID	DMHK8IM
DMHK8IM	DN	CFC-222
DMHK8IM	HS	Discontinued in Phase 2
DMHK8IM	SN	Ecenofloxacin
DMHK8IM	CP	CJ Corp
DMHK8IM	DT	Small molecular drug
DMHK8IM	PC	178065
DMHK8IM	MW	408.9
DMHK8IM	FM	C19H22ClFN4O3
DMHK8IM	IC	InChI=1S/C19H21FN4O3.ClH/c1-19-5-14(21)12(19)7-23(8-19)17-13(20)4-10-15(25)11(18(26)27)6-24(9-2-3-9)16(10)22-17;/h4,6,9,12,14H,2-3,5,7-8,21H2,1H3,(H,26,27);1H/t12-,14-,19-;/m0./s1
DMHK8IM	CS	C[C@@]12C[C@@H]([C@@H]1CN(C2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F)N.Cl
DMHK8IM	IK	OTJVJUVCWOCNQA-ZJKXRWPCSA-N
DMHK8IM	IU	7-[(1R,5S,6S)-6-amino-1-methyl-3-azabicyclo[3.2.0]heptan-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;hydrochloride
DMHK8IM	CA	CAS 162424-67-1
DMHK8IM	DE	Bacterial infection

DMBJQU6	ID	DMBJQU6
DMBJQU6	DN	CGP-49823
DMBJQU6	HS	Discontinued in Phase 2
DMBJQU6	SN	CGP-49823; CHEMBL290364; cgp49823; SCHEMBL6904655; BDBM50287397; {(R)-2-Benzyl-4-[(quinolin-4-ylmethyl)-amino]-piperidin-1-yl}-(3,5-dimethyl-phenyl)-methanone
DMBJQU6	CP	Novartis AG
DMBJQU6	DT	Small molecular drug
DMBJQU6	PC	9869033
DMBJQU6	MW	463.6
DMBJQU6	FM	C31H33N3O
DMBJQU6	IC	InChI=1S/C31H33N3O/c1-22-16-23(2)18-26(17-22)31(35)34-15-13-27(20-28(34)19-24-8-4-3-5-9-24)33-21-25-12-14-32-30-11-7-6-10-29(25)30/h3-12,14,16-18,27-28,33H,13,15,19-21H2,1-2H3/t27-,28+/m0/s1
DMBJQU6	CS	CC1=CC(=CC(=C1)C(=O)N2CC[C@@H](C[C@H]2CC3=CC=CC=C3)NCC4=CC=NC5=CC=CC=C45)C
DMBJQU6	IK	WQZUOBIIPDZRJP-WUFINQPMSA-N
DMBJQU6	IU	[(2R,4S)-2-benzyl-4-(quinolin-4-ylmethylamino)piperidin-1-yl]-(3,5-dimethylphenyl)methanone
DMBJQU6	CA	CAS 150705-88-7
DMBJQU6	DE	Pain

DMCRPKS	ID	DMCRPKS
DMCRPKS	DN	CGRP
DMCRPKS	HS	Discontinued in Phase 2
DMCRPKS	SN	Calcitonin gene related peptide; LAB CGRP; CGRP (inhaled, asthma); CGRP (inhaled, asthma), Akela Pharma; Calcitonin gene-related peptide (inhaled, asthma), LAB International
DMCRPKS	CP	Akela Pharma
DMCRPKS	DT	Small molecular drug
DMCRPKS	PC	44134599
DMCRPKS	MW	3795.4
DMCRPKS	FM	C163H273N51O49S2
DMCRPKS	IC	InChI=1S/C163H273N51O49S2/c1-73(2)52-97(186-116(226)65-179-131(233)82(18)183-139(241)98(53-74(3)4)193-137(239)94(44-35-49-176-162(171)172)188-142(244)101(57-91-62-175-72-182-91)199-159(261)128(88(24)221)213-156(258)123(79(13)14)207-151(253)110(71-265)204-160(262)126(86(22)219)210-133(235)84(20)185-157(259)125(85(21)218)211-147(249)105(61-119(229)230)198-150(252)109(70-264)203-130(232)81(17)166)140(242)194-99(54-75(5)6)141(243)202-108(69-217)149(251)190-95(45-36-50-177-163(173)174)138(240)201-106(67-215)134(236)180-63-115(225)178-64-118(228)205-121(77(9)10)155(257)208-122(78(11)12)154(256)191-93(43-32-34-48-165)136(238)196-102(58-112(167)222)144(246)197-103(59-113(168)223)143(245)195-100(56-90-40-29-26-30-41-90)145(247)209-124(80(15)16)161(263)214-51-37-46-111(214)152(254)212-127(87(23)220)158(260)200-104(60-114(169)224)146(248)206-120(76(7)8)153(255)181-66-117(227)187-107(68-216)148(250)189-92(42-31-33-47-164)135(237)184-83(19)132(234)192-96(129(170)231)55-89-38-27-25-28-39-89/h25-30,38-41,73-88,91-111,120-128,175,182,215-221,264-265H,31-37,42-72,164-166H2,1-24H3,(H2,167,222)(H2,168,223)(H2,169,224)(H2,170,231)(H,178,225)(H,179,233)(H,180,236)(H,181,255)(H,183,241)(H,184,237)(H,185,259)(H,186,226)(H,187,227)(H,188,244)(H,189,250)(H,190,251)(H,191,256)(H,192,234)(H,193,239)(H,194,242)(H,195,245)(H,196,238)(H,197,246)(H,198,252)(H,199,261)(H,200,260)(H,201,240)(H,202,243)(H,203,232)(H,204,262)(H,205,228)(H,206,248)(H,207,253)(H,208,257)(H,209,247)(H,210,235)(H,211,249)(H,212,254)(H,213,258)(H,229,230)(H4,171,172,176)(H4,173,174,177)
DMCRPKS	CS	CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CO)C(=O)NCC(=O)NCC(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC3=CC=CC=C3)C(=O)N)NC(=O)CNC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC4CNCN4)NC(=O)C(C(C)O)NC(=O)C(C(C)C)NC(=O)C(CS)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(CS)NC(=O)C(C)N
DMCRPKS	IK	JAPBQZADVRUIIO-UHFFFAOYSA-N
DMCRPKS	IU	4-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[2-[[1-[[1-[[1-[[1-[[1-[[2-[[2-[[1-[[1-[[6-amino-1-[[4-amino-1-[[4-amino-1-[[1-[[1-[2-[[1-[[4-amino-1-[[1-[[2-[[1-[[6-amino-1-[[1-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-imidazolidin-4-yl-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-[[2-(2-aminopropanoylamino)-3-sulfanylpropanoyl]amino]-4-oxobutanoic acid
DMCRPKS	DE	Asthma

DM2OWCV	ID	DM2OWCV
DM2OWCV	DN	CGS-25462
DM2OWCV	HS	Discontinued in Phase 2
DM2OWCV	SN	Cgs-25462; UNII-UP2R15WBF4; UP2R15WBF4; Cgs 25462; 147862-03-1; AC1L31LU; SCHEMBL7312208; CHEMBL147342; JTQWXNZXTRVPHN-LJAQVGFWSA-N; beta-Alanine, N-(3-(1,1'-biphenyl)-4-yl-N-((diphenoxyphosphinyl)methyl)-L-alanyl)-; 3-(N-(2-(((Diphenylphosphono)methyl)amino)-3-(4-biphenylyl)propionyl)amino)propionic acid; (S)-N-[2-(diphenylphosphonomethylamino)-3-(4-biphenylyl)-propionyl]-3-aminopropionic acid; (S)-N-[2-(diphenylphosphonomethylamino)-3-(4-biphenylyl)propionyl]-3-aminopropionic acid
DM2OWCV	CP	Novartis AG
DM2OWCV	DT	Small molecular drug
DM2OWCV	PC	132812
DM2OWCV	MW	558.6
DM2OWCV	FM	C31H31N2O6P
DM2OWCV	IC	InChI=1S/C31H31N2O6P/c34-30(35)20-21-32-31(36)29(22-24-16-18-26(19-17-24)25-10-4-1-5-11-25)33-23-40(37,38-27-12-6-2-7-13-27)39-28-14-8-3-9-15-28/h1-19,29,33H,20-23H2,(H,32,36)(H,34,35)/t29-/m0/s1
DM2OWCV	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C[C@@H](C(=O)NCCC(=O)O)NCP(=O)(OC3=CC=CC=C3)OC4=CC=CC=C4
DM2OWCV	IK	JTQWXNZXTRVPHN-LJAQVGFWSA-N
DM2OWCV	IU	3-[[(2S)-2-(diphenoxyphosphorylmethylamino)-3-(4-phenylphenyl)propanoyl]amino]propanoic acid
DM2OWCV	CA	CAS 147862-03-1
DM2OWCV	DE	Hypertension

DM03XVA	ID	DM03XVA
DM03XVA	DN	CI-1018
DM03XVA	HS	Discontinued in Phase 2
DM03XVA	SN	CI-1018; UNII-Y4O6325SYW; Y4O6325SYW; CHEMBL111925; DSSTox_CID_27248; DSSTox_RID_82208; DSSTox_GSID_47248; SCHEMBL185627; CAS-NOCAS_47248; DTXSID0047248; NOCAS_47248; Tox21_300203; BDBM50217550; NCGC00254191-01; NCGC00247925-01; 179024-48-7; PD-168787; (+)-CI-1018; CI-1018, (+)-; UNII-05127JZ9KQ component KYFWUBJMTHVBIF-QFIPXVFZSA-N; 4-Pyridinecarboxamide, N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (R)-; 4-Pyridinecarboxamide, N-((3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrol
DM03XVA	DT	Small molecular drug
DM03XVA	PC	9865514
DM03XVA	MW	396.4
DM03XVA	FM	C24H20N4O2
DM03XVA	IC	InChI=1S/C24H20N4O2/c1-15-13-18-9-12-28-21(18)19(14-15)20(16-5-3-2-4-6-16)26-22(24(28)30)27-23(29)17-7-10-25-11-8-17/h2-8,10-11,13-14,22H,9,12H2,1H3,(H,27,29)/t22-/m0/s1
DM03XVA	CS	CC1=CC2=C3C(=C1)C(=N[C@H](C(=O)N3CC2)NC(=O)C4=CC=NC=C4)C5=CC=CC=C5
DM03XVA	IK	KYFWUBJMTHVBIF-QFIPXVFZSA-N
DM03XVA	IU	N-[(11R)-6-methyl-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl]pyridine-4-carboxamide
DM03XVA	CA	CAS 179024-48-7
DM03XVA	DE	Asthma

DMADPQX	ID	DMADPQX
DMADPQX	DN	CI-930
DMADPQX	HS	Discontinued in Phase 2
DMADPQX	SN	CI-930; CI 930; 86798-59-6; 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone; 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-5-methyl-; AC1MIBTH; CHEMBL440593; SCHEMBL6052113; CTK5F7194; BDBM14362; AEZZPAQOEUQNBB-UHFFFAOYSA-N; 90791-23-4 (hydrochloride); BDBM50225945; LS-187480; LS-186812; 6-[4-(1-Imidazolyl)phenyl]-5-methyl-3-oxo-2,3,4,5-tetrahydropyridazine; 3-(4-imidazol-1-ylphenyl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one
DMADPQX	DT	Small molecular drug
DMADPQX	PC	3021729
DMADPQX	MW	254.29
DMADPQX	FM	C14H14N4O
DMADPQX	IC	InChI=1S/C14H14N4O/c1-10-8-13(19)16-17-14(10)11-2-4-12(5-3-11)18-7-6-15-9-18/h2-7,9-10H,8H2,1H3,(H,16,19)
DMADPQX	CS	CC1CC(=O)NN=C1C2=CC=C(C=C2)N3C=CN=C3
DMADPQX	IK	AEZZPAQOEUQNBB-UHFFFAOYSA-N
DMADPQX	IU	3-(4-imidazol-1-ylphenyl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one
DMADPQX	CA	CAS 86798-59-6

DMN4QSW	ID	DMN4QSW
DMN4QSW	DN	CI-949
DMN4QSW	HS	Discontinued in Phase 2
DMN4QSW	SN	CI 949; UNII-EM1J51043X; EM1J51043X; L-Arginine, compd. with 5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide (1:1); OHOCQQJBKBVAFF-VWMHFEHESA-N; AC1L4M1L; AC1Q5G9U; 121530-58-3; SCHEMBL17041896; n5-(diaminomethylidene)-l-ornithine- 5-methoxy-1-phenyl-3-(propan-2-yloxy)-n-(2h-tetrazol-5-yl)-1h-indole-2-carboxamide(1:1); LS-21607; 5-Methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide L-arginate salt; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
DMN4QSW	CP	Dura Pharmaceuticals Inc
DMN4QSW	DT	Small molecular drug
DMN4QSW	PC	159563
DMN4QSW	MW	392.4
DMN4QSW	FM	C20H20N6O3
DMN4QSW	IC	InChI=1S/C20H20N6O3/c1-12(2)29-18-15-11-14(28-3)9-10-16(15)26(13-7-5-4-6-8-13)17(18)19(27)21-20-22-24-25-23-20/h4-12H,1-3H3,(H2,21,22,23,24,25,27)
DMN4QSW	CS	CC(C)OC1=C(N(C2=C1C=C(C=C2)OC)C3=CC=CC=C3)C(=O)NC4=NNN=N4
DMN4QSW	IK	JPTSIWRGXIZEOO-UHFFFAOYSA-N
DMN4QSW	IU	5-methoxy-1-phenyl-3-propan-2-yloxy-N-(2H-tetrazol-5-yl)indole-2-carboxamide
DMN4QSW	CA	CAS 104961-19-5
DMN4QSW	DE	Asthma

DMBO28J	ID	DMBO28J
DMBO28J	DN	CI-976
DMBO28J	HS	Discontinued in Phase 2
DMBO28J	SN	CI 976; 114289-47-3; 2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide; CI-976; PD 128042; BRN 5831010; CHEMBL22373; UNII-8653IQ20EA; 8653IQ20EA; Dodecanamide,2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)-; Dodecanamide, 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)-; 2,2-Dimethyl-dodecanoic acid (2,4,6-trimethoxy-phenyl)-amide; C23H39NO4; ACMC-1CUXF; AC1L3UE4; SCHEMBL691688; CTK4A8660; CHEBI:95040; DTXSID00150690; MolPort-002-018-232; HMS3268D10; HMS3262L19; ZINC8022586; Tox21_500859; BN0150; BDBM50005944; AKOS022180044; LP00859; CCG-222163
DMBO28J	DT	Small molecular drug
DMBO28J	PC	122327
DMBO28J	MW	393.6
DMBO28J	FM	C23H39NO4
DMBO28J	IC	InChI=1S/C23H39NO4/c1-7-8-9-10-11-12-13-14-15-23(2,3)22(25)24-21-19(27-5)16-18(26-4)17-20(21)28-6/h16-17H,7-15H2,1-6H3,(H,24,25)
DMBO28J	CS	CCCCCCCCCCC(C)(C)C(=O)NC1=C(C=C(C=C1OC)OC)OC
DMBO28J	IK	WAFNZAURAWBNDZ-UHFFFAOYSA-N
DMBO28J	IU	2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide
DMBO28J	CA	CAS 114289-47-3
DMBO28J	CB	CHEBI:95040
DMBO28J	DE	Hyperlipidaemia

DMTAKNF	ID	DMTAKNF
DMTAKNF	DN	Cipralisant
DMTAKNF	HS	Discontinued in Phase 2
DMTAKNF	SN	Cipralisant [INN]; 5-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole
DMTAKNF	CP	Gliatech
DMTAKNF	DT	Small molecular drug
DMTAKNF	PC	6450823
DMTAKNF	MW	216.32
DMTAKNF	FM	C14H20N2
DMTAKNF	IC	InChI=1S/C14H20N2/c1-14(2,3)7-5-4-6-11-8-12(11)13-9-15-10-16-13/h9-12H,5,7-8H2,1-3H3,(H,15,16)/t11-,12-/m1/s1
DMTAKNF	CS	CC(C)(C)CCC#C[C@@H]1C[C@H]1C2=CN=CN2
DMTAKNF	IK	CVKJAXCQPFOAIN-VXGBXAGGSA-N
DMTAKNF	IU	5-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole
DMTAKNF	CA	CAS 213027-19-1
DMTAKNF	DE	Attention deficit hyperactivity disorder

DM1CDNS	ID	DM1CDNS
DM1CDNS	DN	CJ-13610
DM1CDNS	HS	Discontinued in Phase 2
DM1CDNS	SN	CJ 13610; CJ-13,610
DM1CDNS	CP	Pfizer
DM1CDNS	DT	Small molecular drug
DM1CDNS	PC	9821945
DM1CDNS	MW	393.5
DM1CDNS	FM	C22H23N3O2S
DM1CDNS	IC	InChI=1S/C22H23N3O2S/c1-16-24-11-12-25(16)18-5-7-19(8-6-18)28-20-4-2-3-17(15-20)22(21(23)26)9-13-27-14-10-22/h2-8,11-12,15H,9-10,13-14H2,1H3,(H2,23,26)
DM1CDNS	CS	CC1=NC=CN1C2=CC=C(C=C2)SC3=CC=CC(=C3)C4(CCOCC4)C(=O)N
DM1CDNS	IK	VPTONMHDLLMOOV-UHFFFAOYSA-N
DM1CDNS	IU	4-[3-[4-(2-methylimidazol-1-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide
DM1CDNS	CA	CAS 179420-17-8
DM1CDNS	DE	Asthma

DMQD2LS	ID	DMQD2LS
DMQD2LS	DN	CJC-1131
DMQD2LS	HS	Discontinued in Phase 2
DMQD2LS	SN	CJC-1131-albumin bioconjugate; DAC:GLP-1; Glucagon-like peptide 1, ConjuChem
DMQD2LS	CP	ConjuChem Biotechnologies Inc
DMQD2LS	DT	Small molecular drug
DMQD2LS	PC	72941834
DMQD2LS	MW	3722
DMQD2LS	FM	C168H254N44O52
DMQD2LS	IC	InChI=1S/C168H254N44O52/c1-17-89(10)137(165(260)188-93(14)144(239)197-118(72-99-75-180-104-38-25-24-37-102(99)104)155(250)199-114(68-86(4)5)156(251)208-135(87(6)7)163(258)196-106(40-26-29-58-169)146(241)181-77-125(221)189-107(42-32-61-179-168(174)175)150(245)191-105(140(173)235)39-28-31-60-177-128(224)83-264-66-65-263-64-62-178-124(220)57-63-212-129(225)52-53-130(212)226)210-157(252)116(69-96-33-20-18-21-34-96)200-152(247)112(50-56-133(231)232)195-151(246)108(41-27-30-59-170)192-142(237)91(12)185-141(236)90(11)187-149(244)111(47-51-123(172)219)190-126(222)78-182-148(243)110(49-55-132(229)230)194-153(248)113(67-85(2)3)198-154(249)115(71-98-43-45-101(218)46-44-98)201-160(255)120(80-213)204-162(257)122(82-215)205-164(259)136(88(8)9)209-159(254)119(74-134(233)234)202-161(256)121(81-214)206-167(262)139(95(16)217)211-158(253)117(70-97-35-22-19-23-36-97)203-166(261)138(94(15)216)207-127(223)79-183-147(242)109(48-54-131(227)228)193-143(238)92(13)186-145(240)103(171)73-100-76-176-84-184-100/h18-25,33-38,43-46,52-53,75-76,84-95,103,105-122,135-139,180,213-218H,17,26-32,39-42,47-51,54-74,77-83,169-171H2,1-16H3,(H2,172,219)(H2,173,235)(H,176,184)(H,177,224)(H,178,220)(H,181,241)(H,182,243)(H,183,242)(H,185,236)(H,186,240)(H,187,244)(H,188,260)(H,189,221)(H,190,222)(H,191,245)(H,192,237)(H,193,238)(H,194,248)(H,195,246)(H,196,258)(H,197,239)(H,198,249)(H,199,250)(H,200,247)(H,201,255)(H,202,256)(H,203,261)(H,204,257)(H,205,259)(H,206,262)(H,207,223)(H,208,251)(H,209,254)(H,210,252)(H,211,253)(H,227,228)(H,229,230)(H,231,232)(H,233,234)(H4,174,175,179)/t89-,90-,91-,92+,93-,94+,95+,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,135-,136-,137-,138-,139-/m0/s1
DMQD2LS	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN3C(=O)C=CC3=O)C(=O)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC7=CNC=N7)N
DMQD2LS	IK	AIWAEWBZDJARBJ-PXUUZXDZSA-N
DMQD2LS	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[[(2S)-1-amino-6-[[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]acetyl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMQD2LS	CA	CAS 532951-64-7
DMQD2LS	DE	Type-1 diabetes

DM7LIDT	ID	DM7LIDT
DM7LIDT	DN	CL-283796
DM7LIDT	HS	Discontinued in Phase 2
DM7LIDT	SN	ACB-796; N-(4-Chloro-2,6-dimethylphenyl)-N'-heptyl-N'-[4-(3-methylbutyl)benzyl]urea
DM7LIDT	PC	9955733
DM7LIDT	MW	457.1
DM7LIDT	FM	C28H41ClN2O
DM7LIDT	IC	InChI=1S/C28H41ClN2O/c1-6-7-8-9-10-17-31(20-25-15-13-24(14-16-25)12-11-21(2)3)28(32)30-27-22(4)18-26(29)19-23(27)5/h13-16,18-19,21H,6-12,17,20H2,1-5H3,(H,30,32)
DM7LIDT	CS	CCCCCCCN(CC1=CC=C(C=C1)CCC(C)C)C(=O)NC2=C(C=C(C=C2C)Cl)C
DM7LIDT	IK	YQFGILAFZYCULR-UHFFFAOYSA-N
DM7LIDT	IU	3-(4-chloro-2,6-dimethylphenyl)-1-heptyl-1-[[4-(3-methylbutyl)phenyl]methyl]urea
DM7LIDT	DE	Hyperlipidaemia

DMKFMYR	ID	DMKFMYR
DMKFMYR	DN	CLOTURIN
DMKFMYR	HS	Discontinued in Phase 2
DMKFMYR	SN	VUFB-15686; N-(2-Chloroethyl)thiocarbamic acid 6-purinyl ester; (2-Chloroethyl)carbamothioic acid S-1H-purin-6-yl ester; 6-[N-(2-Chloroethyl)carbamoyl]thiopurine
DMKFMYR	DT	Small molecular drug
DMKFMYR	PC	128676
DMKFMYR	MW	257.7
DMKFMYR	FM	C8H8ClN5OS
DMKFMYR	IC	InChI=1S/C8H8ClN5OS/c9-1-2-10-8(15)16-7-5-6(12-3-11-5)13-4-14-7/h3-4H,1-2H2,(H,10,15)(H,11,12,13,14)
DMKFMYR	CS	C1=NC2=C(N1)C(=NC=N2)SC(=O)NCCCl
DMKFMYR	IK	OQBORDVFGPUGDV-UHFFFAOYSA-N
DMKFMYR	IU	S-(7H-purin-6-yl) N-(2-chloroethyl)carbamothioate
DMKFMYR	CA	CAS 104789-46-0
DMKFMYR	DE	Solid tumour/cancer

DMRVJ1A	ID	DMRVJ1A
DMRVJ1A	DN	Corus 1030
DMRVJ1A	HS	Discontinued in Phase 2
DMRVJ1A	SN	Inhaled Lidocaine
DMRVJ1A	CP	Gilead Sciences
DMRVJ1A	DE	Asthma

DMNJD9H	ID	DMNJD9H
DMNJD9H	DN	CP-118
DMNJD9H	HS	Discontinued in Phase 2
DMNJD9H	SN	Antihistamine combination
DMNJD9H	CP	Collegium Pharmaceuticals
DMNJD9H	DE	Allergic rhinitis

DM3OJP0	ID	DM3OJP0
DM3OJP0	DN	CP-122288
DM3OJP0	HS	Discontinued in Phase 2
DM3OJP0	SN	N-Methyl-3-[1-methylpyrrolidin-2(R)-ylmethyl]-1H-indol-5-ylmethylsulfonamide; 5-(Methylaminosulfonylmethyl)-3-[1-methylpyrrolidin-2(R)-ylmethyl]-1H-indole
DM3OJP0	DT	Small molecular drug
DM3OJP0	PC	132552
DM3OJP0	MW	321.4
DM3OJP0	FM	C16H23N3O2S
DM3OJP0	IC	InChI=1S/C16H23N3O2S/c1-17-22(20,21)11-12-5-6-16-15(8-12)13(10-18-16)9-14-4-3-7-19(14)2/h5-6,8,10,14,17-18H,3-4,7,9,11H2,1-2H3/t14-/m1/s1
DM3OJP0	CS	CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2C[C@H]3CCCN3C
DM3OJP0	IK	BWQZTHPHLITOOZ-CQSZACIVSA-N
DM3OJP0	IU	N-methyl-1-[3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indol-5-yl]methanesulfonamide
DM3OJP0	CA	CAS 143321-74-8
DM3OJP0	DE	Migraine

DM1OSUR	ID	DM1OSUR
DM1OSUR	DN	CP-195543
DM1OSUR	HS	Discontinued in Phase 2
DM1OSUR	SN	LB4 antagonist (RA), Pfizer; LB4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (rheumatoid arthritis), Pfizer
DM1OSUR	CP	Pfizer Inc
DM1OSUR	DT	Small molecular drug
DM1OSUR	PC	9823886
DM1OSUR	MW	428.4
DM1OSUR	FM	C24H19F3O4
DM1OSUR	IC	InChI=1S/C24H19F3O4/c25-24(26,27)17-7-9-18(23(29)30)20(12-17)15-6-8-19-21(11-15)31-13-16(22(19)28)10-14-4-2-1-3-5-14/h1-9,11-12,16,22,28H,10,13H2,(H,29,30)/t16-,22+/m0/s1
DM1OSUR	CS	C1[C@@H]([C@H](C2=C(O1)C=C(C=C2)C3=C(C=CC(=C3)C(F)(F)F)C(=O)O)O)CC4=CC=CC=C4
DM1OSUR	IK	NZQDWKCNBOELAI-KSFYIVLOSA-N
DM1OSUR	IU	2-[(3S,4R)-3-benzyl-4-hydroxy-3,4-dihydro-2H-chromen-7-yl]-4-(trifluoromethyl)benzoic acid
DM1OSUR	CA	CAS 204981-48-6
DM1OSUR	DE	Rheumatoid arthritis

DMZ76EM	ID	DMZ76EM
DMZ76EM	DN	CP-316,311
DMZ76EM	HS	Discontinued in Phase 2
DMZ76EM	SN	CP-316311
DMZ76EM	CP	Pfizer
DMZ76EM	DT	Small molecular drug
DMZ76EM	PC	9818802
DMZ76EM	MW	327.5
DMZ76EM	FM	C21H29NO2
DMZ76EM	IC	InChI=1S/C21H29NO2/c1-8-18(9-2)23-19-12-16(6)22-21(17(19)7)24-20-14(4)10-13(3)11-15(20)5/h10-12,18H,8-9H2,1-7H3
DMZ76EM	CS	CCC(CC)OC1=C(C(=NC(=C1)C)OC2=C(C=C(C=C2C)C)C)C
DMZ76EM	IK	ZSEJGVQTBLJRCQ-UHFFFAOYSA-N
DMZ76EM	IU	3,6-dimethyl-4-pentan-3-yloxy-2-(2,4,6-trimethylphenoxy)pyridine
DMZ76EM	CA	CAS 175139-41-0
DMZ76EM	DE	Mood disorder; Major depressive disorder

DMH5LKS	ID	DMH5LKS
DMH5LKS	DN	CPA-926
DMH5LKS	HS	Discontinued in Phase 2
DMH5LKS	SN	6-(2-Acetamido-2-deoxy-beta-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one
DMH5LKS	PC	9800054
DMH5LKS	MW	381.3
DMH5LKS	FM	C17H19NO9
DMH5LKS	IC	InChI=1S/C17H19NO9/c1-7(20)18-14-16(24)15(23)12(6-19)27-17(14)26-11-4-8-2-3-13(22)25-10(8)5-9(11)21/h2-5,12,14-17,19,21,23-24H,6H2,1H3,(H,18,20)/t12-,14-,15-,16-,17-/m1/s1
DMH5LKS	CS	CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C(C=C3C(=C2)C=CC(=O)O3)O)CO)O)O
DMH5LKS	IK	OTXAWKXSJDFGID-LMHBHQSJSA-N
DMH5LKS	IU	N-[(2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(7-hydroxy-2-oxochromen-6-yl)oxyoxan-3-yl]acetamide
DMH5LKS	DE	Arthritis

DMVU4A5	ID	DMVU4A5
DMVU4A5	DN	CRD-5
DMVU4A5	HS	Discontinued in Phase 2
DMVU4A5	SN	Charge-regulating drugs (dyslipidemia/heart disease), Liponex
DMVU4A5	CP	Liponex Inc
DMVU4A5	DE	Hyperlipidaemia

DMZLIUQ	ID	DMZLIUQ
DMZLIUQ	DN	Cromafiban
DMZLIUQ	HS	Discontinued in Phase 2
DMZLIUQ	CP	Millennium Pharmaceuticals
DMZLIUQ	DE	Coronary artery disease

DMB9QSJ	ID	DMB9QSJ
DMB9QSJ	DN	CRx-191
DMB9QSJ	HS	Discontinued in Phase 2
DMB9QSJ	CP	CombinatoRx
DMB9QSJ	DE	Psoriatic disorder

DM39N7W	ID	DM39N7W
DM39N7W	DN	CRx-401
DM39N7W	HS	Discontinued in Phase 2
DM39N7W	CP	CombinatoRx
DM39N7W	DE	Type-2 diabetes

DM73C4K	ID	DM73C4K
DM73C4K	DN	Cryptophycin
DM73C4K	HS	Discontinued in Phase 2
DM73C4K	SN	Cryptophycin 1; cryptophycin; UNII-XO974V2M5T; 124689-65-2; XO974V2M5T; 10-((3-Chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone; CRYPTOPHYCIN A; 1,4-Dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone, 10-((3-chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-; C35H43ClN2O8; AC1O5PMQ; CHEMBL441018; SCHEMBL1346966; PSNOPSMXOBPNNV-VVCTWANISA-N; LS-172597; C16877
DM73C4K	DT	Small molecular drug
DM73C4K	PC	6438401
DM73C4K	MW	655.2
DM73C4K	FM	C35H43ClN2O8
DM73C4K	IC	InChI=1S/C35H43ClN2O8/c1-20(2)16-29-35(42)44-27(22(4)31-32(46-31)24-10-7-6-8-11-24)12-9-13-30(39)38-26(33(40)37-19-21(3)34(41)45-29)18-23-14-15-28(43-5)25(36)17-23/h6-11,13-15,17,20-22,26-27,29,31-32H,12,16,18-19H2,1-5H3,(H,37,40)(H,38,39)/b13-9+/t21-,22+,26-,27+,29+,31-,32-/m1/s1
DM73C4K	CS	C[C@@H]1CNC(=O)[C@H](NC(=O)/C=C/C[C@H](OC(=O)[C@@H](OC1=O)CC(C)C)[C@H](C)[C@@H]2[C@H](O2)C3=CC=CC=C3)CC4=CC(=C(C=C4)OC)Cl
DM73C4K	IK	PSNOPSMXOBPNNV-VVCTWANISA-N
DM73C4K	IU	(3S,6R,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
DM73C4K	CA	CAS 124689-65-2

DM1AEVT	ID	DM1AEVT
DM1AEVT	DN	CS-003
DM1AEVT	HS	Discontinued in Phase 2
DM1AEVT	CP	Sankyo
DM1AEVT	DT	Small molecular drug
DM1AEVT	PC	9831640
DM1AEVT	MW	710.1
DM1AEVT	FM	C34H39Cl3N2O6S
DM1AEVT	IC	InChI=1S/C34H38Cl2N2O6S.ClH/c1-41-29-18-24(19-30(42-2)31(29)43-3)32(39)38-16-17-44-33(22-38,25-8-9-27(35)28(36)20-25)10-13-37-14-11-34(12-15-37)26-7-5-4-6-23(26)21-45(34)40;/h4-9,18-20H,10-17,21-22H2,1-3H3;1H/t33-,45-;/m0./s1
DM1AEVT	CS	COC1=CC(=CC(=C1OC)OC)C(=O)N2CCO[C@](C2)(CCN3CCC4(CC3)C5=CC=CC=C5C[S@@]4=O)C6=CC(=C(C=C6)Cl)Cl.Cl
DM1AEVT	IK	IHDDYKNRVLPVEV-FFKPOUSOSA-N
DM1AEVT	IU	[(2R)-2-(3,4-dichlorophenyl)-2-[2-[(2S)-2-oxospiro[1H-2-benzothiophene-3,4'-piperidine]-1'-yl]ethyl]morpholin-4-yl]-(3,4,5-trimethoxyphenyl)methanone;hydrochloride
DM1AEVT	DE	Chronic obstructive pulmonary disease

DMGYXA4	ID	DMGYXA4
DMGYXA4	DN	CS-722
DMGYXA4	HS	Discontinued in Phase 2
DMGYXA4	SN	RS-722
DMGYXA4	CP	Sankyo Co Ltd
DMGYXA4	DT	Small molecular drug
DMGYXA4	PC	132659
DMGYXA4	MW	375.2
DMGYXA4	FM	C16H20Cl2N2O4
DMGYXA4	IC	InChI=1S/C16H19ClN2O4.ClH/c17-14-15(12-4-2-1-3-5-12)23-19(16(14)21)11-13(20)10-18-6-8-22-9-7-18;/h1-5,13,20H,6-11H2;1H/t13-;/m1./s1
DMGYXA4	CS	C1COCCN1C[C@H](CN2C(=O)C(=C(O2)C3=CC=CC=C3)Cl)O.Cl
DMGYXA4	IK	KIWUOCZHZROUNT-BTQNPOSSSA-N
DMGYXA4	IU	4-chloro-2-[(2R)-2-hydroxy-3-morpholin-4-ylpropyl]-5-phenyl-1,2-oxazol-3-one;hydrochloride
DMGYXA4	CA	CAS 144886-17-9
DMGYXA4	DE	Epilepsy

DM17I8O	ID	DM17I8O
DM17I8O	DN	CS-891B
DM17I8O	HS	Discontinued in Phase 2
DM17I8O	CP	Sankyo Co Ltd
DM17I8O	DE	Alopecia

DM09CUO	ID	DM09CUO
DM09CUO	DN	CTL-102-GDEPT
DM09CUO	HS	Discontinued in Phase 2
DM09CUO	SN	CTL-102; NTR-GDEPT; GDEPT (CTL-102), ML Laboratories; Gene directed chemotherapy (CTL-102), ML Laboratories; Ad-NTR + CB-1954 GDEPT, ML Labs; Human adenovirus (hAdV5) GDEPT (E coli nitroreductase (NTR)/CB-1954, aseptic prosthetic implant loosening), Broadvector
DM09CUO	CP	Cobra Biomanufacturing plc
DM09CUO	DE	Head and neck cancer

DMG3HX2	ID	DMG3HX2
DMG3HX2	DN	CV-6504
DMG3HX2	HS	Discontinued in Phase 2
DMG3HX2	SN	CV-6504; 117574-40-0; CV 6504; 2,3,5-Trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone; 2,5-Cyclohexadiene-1,4-dione,2,3,5-trimethyl-6-(3-pyridinylmethyl)-; ACMC-20mn9v; AC1L3QEW; ZINC4541; SCHEMBL2715544; CTK4B0337; DTXSID80151827; IPGAFOVEIIWXFR-UHFFFAOYSA-N; EX-A2681; 6-(3-pyridylmethyl)-2,3,5-trimethyl-1,4-benzoquinone; 2,5-Cyclohexadiene-1,4-dione, 2,3,5-trimethyl-6-(3-pyridinylmethyl)-
DMG3HX2	DT	Small molecular drug
DMG3HX2	PC	93543
DMG3HX2	MW	241.28
DMG3HX2	FM	C15H15NO2
DMG3HX2	IC	InChI=1S/C15H15NO2/c1-9-10(2)15(18)13(11(3)14(9)17)7-12-5-4-6-16-8-12/h4-6,8H,7H2,1-3H3
DMG3HX2	CS	CC1=C(C(=O)C(=C(C1=O)C)CC2=CN=CC=C2)C
DMG3HX2	IK	IPGAFOVEIIWXFR-UHFFFAOYSA-N
DMG3HX2	IU	2,3,5-trimethyl-6-(pyridin-3-ylmethyl)cyclohexa-2,5-diene-1,4-dione
DMG3HX2	CA	CAS 117574-40-0

DMP8TKA	ID	DMP8TKA
DMP8TKA	DN	CY-208243
DMP8TKA	HS	Discontinued in Phase 2
DMP8TKA	SN	Indolophenanthridine; CY 208-243; 100999-26-6; CY-208-243; 4,6,6a,7,8,12b-Hexahydro-7-methylindolo(4,3-ab)-phenanthridine; Indolo(4,3-ab)phenanthridine, 4,6,6a,7,8,12b-hexahydro-7-methyl-, trans-(-)-; (6aR,12bR)-7-methyl-4,6,6a,7,8,12b-hexahydroindolo[4,3-ab]phenanthridine; Tocris-1249; AC1L1ODE; Biomol-NT_000032; AC1Q1IN1; CHEMBL313737; BPBio1_001225; SCHEMBL9364562; DTXSID9042598; CHEBI:93399; MolPort-003-983-825; HMS3267H13; ZINC26501186; AKOS024456489; API0009347; NCGC00025078-01; NCGC00025078-02; LS-183405
DMP8TKA	CP	Novartis AG
DMP8TKA	DT	Small molecular drug
DMP8TKA	PC	58144
DMP8TKA	MW	274.4
DMP8TKA	FM	C19H18N2
DMP8TKA	IC	InChI=1S/C19H18N2/c1-21-11-12-5-2-3-6-14(12)19-15-7-4-8-16-18(15)13(10-20-16)9-17(19)21/h2-8,10,17,19-20H,9,11H2,1H3/t17-,19-/m1/s1
DMP8TKA	CS	CN1CC2=CC=CC=C2[C@H]3[C@H]1CC4=CNC5=CC=CC3=C45
DMP8TKA	IK	WRNKIDLXXXIELU-IEBWSBKVSA-N
DMP8TKA	IU	(2R,11R)-10-methyl-10,15-diazapentacyclo[11.6.1.02,11.03,8.016,20]icosa-1(20),3,5,7,13,16,18-heptaene
DMP8TKA	CA	CAS 100999-26-6
DMP8TKA	CB	CHEBI:93399
DMP8TKA	DE	Pain

DMO9HWU	ID	DMO9HWU
DMO9HWU	DN	D-7193
DMO9HWU	HS	Discontinued in Phase 2
DMO9HWU	SN	D-7042
DMO9HWU	CP	Astra AB
DMO9HWU	DE	Immune System disease

DM48ECA	ID	DM48ECA
DM48ECA	DN	DA-5018
DM48ECA	HS	Discontinued in Phase 2
DM48ECA	SN	Capsavanil; Davasaicin; Da 5018; KR-25018; Benzeneacetamide, 4-(2-aminoethoxy)-N-(3-(3,4-dimethylphenyl)propyl)-3-methoxy-, monohydrochloride; 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide; 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide hydrochloride
DM48ECA	CP	Dong-A
DM48ECA	DT	Small molecular drug
DM48ECA	PC	177286
DM48ECA	MW	406.9
DM48ECA	FM	C22H31ClN2O3
DM48ECA	IC	InChI=1S/C22H30N2O3.ClH/c1-16-6-7-18(13-17(16)2)5-4-11-24-22(25)15-19-8-9-20(27-12-10-23)21(14-19)26-3;/h6-9,13-14H,4-5,10-12,15,23H2,1-3H3,(H,24,25);1H
DM48ECA	CS	CC1=C(C=C(C=C1)CCCNC(=O)CC2=CC(=C(C=C2)OCCN)OC)C.Cl
DM48ECA	IK	OUEKLNJUMVZULZ-UHFFFAOYSA-N
DM48ECA	IU	2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide;hydrochloride
DM48ECA	CA	CAS 174661-97-3
DM48ECA	DE	Postherpetic neuralgia; Diabetic neuropathy

DMDQH5E	ID	DMDQH5E
DMDQH5E	DN	Dabuzalgron
DMDQH5E	HS	Discontinued in Phase 2
DMDQH5E	SN	R-450; Alpha-1 adrenoceptor agonist, Roche; Ro-115-1240
DMDQH5E	CP	Roche
DMDQH5E	DT	Small molecular drug
DMDQH5E	PC	216249
DMDQH5E	MW	317.79
DMDQH5E	FM	C12H16ClN3O3S
DMDQH5E	IC	InChI=1S/C12H16ClN3O3S/c1-8-10(19-7-11-14-5-6-15-11)4-3-9(13)12(8)16-20(2,17)18/h3-4,16H,5-7H2,1-2H3,(H,14,15)
DMDQH5E	CS	CC1=C(C=CC(=C1NS(=O)(=O)C)Cl)OCC2=NCCN2
DMDQH5E	IK	FOYWMEJSRSBQGB-UHFFFAOYSA-N
DMDQH5E	IU	N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methylphenyl]methanesulfonamide
DMDQH5E	CA	CAS 219311-44-1
DMDQH5E	CB	CHEBI:142452
DMDQH5E	DE	Urinary incontinence

DMF3E51	ID	DMF3E51
DMF3E51	DN	DANOFLOXACIN
DMF3E51	HS	Discontinued in Phase 2
DMF3E51	SN	CP-76136; Danofloxacin < Rec INN; CP-76136-27 (mesylate); 1-Cyclopropyl-6-fluoro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
DMF3E51	DT	Small molecular drug
DMF3E51	PC	71335
DMF3E51	MW	357.4
DMF3E51	FM	C19H20FN3O3
DMF3E51	IC	InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1
DMF3E51	CS	CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F
DMF3E51	IK	QMLVECGLEOSESV-RYUDHWBXSA-N
DMF3E51	IU	1-cyclopropyl-6-fluoro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-oxoquinoline-3-carboxylic acid
DMF3E51	CA	CAS 112398-08-0
DMF3E51	DE	Bacterial infection

DMJ4WR6	ID	DMJ4WR6
DMJ4WR6	DN	Darotropium
DMJ4WR6	HS	Discontinued in Phase 2
DMJ4WR6	CP	GSK
DMJ4WR6	PC	25195533
DMJ4WR6	MW	345.5
DMJ4WR6	FM	C24H29N2+
DMJ4WR6	IC	InChI=1S/C24H29N2/c1-26(2)22-13-14-23(26)16-19(15-22)17-24(18-25,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,19,22-23H,13-17H2,1-2H3/q+1/t19?,22-,23+
DMJ4WR6	CS	C[N+]1([C@@H]2CC[C@H]1CC(C2)CC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4)C
DMJ4WR6	IK	BKLAJZNVMHLXAP-VKGMXUHCSA-N
DMJ4WR6	IU	3-[(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl]-2,2-diphenylpropanenitrile
DMJ4WR6	CA	CAS 850689-51-9
DMJ4WR6	DE	Chronic obstructive pulmonary disease

DMOWIGC	ID	DMOWIGC
DMOWIGC	DN	DASANTAFIL
DMOWIGC	HS	Discontinued in Phase 2
DMOWIGC	SN	Dasantafil < USAN; SCH-446132; 7-(3-Bromo-4-methoxybenzyl)-1-ethyl-8-[2(R)-hydroxycyclopent-1(R)-ylamino]-3-(2-hydroxyethyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(3-Bromo-4-methoxybenzyl)-1-ethyl-8-[2(R)-hydroxycyclopent-1(R)-ylamino]-3-(2-hydroxyethyl)xanthine
DMOWIGC	DT	Small molecular drug
DMOWIGC	PC	9871410
DMOWIGC	MW	522.4
DMOWIGC	FM	C22H28BrN5O5
DMOWIGC	IC	InChI=1S/C22H28BrN5O5/c1-3-26-20(31)18-19(27(9-10-29)22(26)32)25-21(24-15-5-4-6-16(15)30)28(18)12-13-7-8-17(33-2)14(23)11-13/h7-8,11,15-16,29-30H,3-6,9-10,12H2,1-2H3,(H,24,25)/t15-,16-/m1/s1
DMOWIGC	CS	CCN1C(=O)C2=C(N=C(N2CC3=CC(=C(C=C3)OC)Br)N[C@@H]4CCC[C@H]4O)N(C1=O)CCO
DMOWIGC	IK	RCJYGWGQCPDYSL-HZPDHXFCSA-N
DMOWIGC	IU	7-[(3-bromo-4-methoxyphenyl)methyl]-1-ethyl-8-[[(1R,2R)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)purine-2,6-dione
DMOWIGC	CA	CAS 569351-91-3
DMOWIGC	DE	Erectile dysfunction

DMY3M0J	ID	DMY3M0J
DMY3M0J	DN	DAT-582
DMY3M0J	HS	Discontinued in Phase 2
DMY3M0J	SN	AS-5820
DMY3M0J	CP	Dainippon Pharmaceutical Co Ltd
DMY3M0J	DT	Small molecular drug
DMY3M0J	PC	132326
DMY3M0J	MW	450.4
DMY3M0J	FM	C22H29Cl2N5O
DMY3M0J	IC	InChI=1S/C22H27N5O.2ClH/c1-16-6-5-7-17(12-16)13-27-11-10-26(2)14-18(15-27)23-22(28)21-19-8-3-4-9-20(19)24-25-21;;/h3-9,12,18H,10-11,13-15H2,1-2H3,(H,23,28)(H,24,25);2*1H/t18-;;/m1../s1
DMY3M0J	CS	CC1=CC(=CC=C1)CN2CCN(C[C@H](C2)NC(=O)C3=NNC4=CC=CC=C43)C.Cl.Cl
DMY3M0J	IK	BDHAPQXDDJQQBI-JPKZNVRTSA-N
DMY3M0J	IU	N-[(6R)-1-methyl-4-[(3-methylphenyl)methyl]-1,4-diazepan-6-yl]-1H-indazole-3-carboxamide;dihydrochloride
DMY3M0J	CA	CAS 141034-42-6
DMY3M0J	DE	Nausea

DM9S3R8	ID	DM9S3R8
DM9S3R8	DN	Davalintide
DM9S3R8	HS	Discontinued in Phase 2
DM9S3R8	SN	Davalintide acetate; Second-generation amylinomimetics (obesity), Amylin
DM9S3R8	CP	Amylin Pharmaceuticals Inc
DM9S3R8	PC	71587842
DM9S3R8	MW	3624
DM9S3R8	FM	C152H248N50O49S2
DM9S3R8	IC	InChI=1S/C152H248N50O49S2/c1-66(2)48-91(189-143(245)113(70(9)10)195-140(242)103-64-253-252-63-102(193-122(224)83(154)24-18-19-43-153)139(241)188-97(56-108(158)216)135(237)200-115(73(13)206)144(246)174-71(11)121(223)196-116(74(14)207)148(250)194-103)123(225)171-59-110(218)175-84(25-20-44-168-150(161)162)124(226)183-94(51-69(7)8)132(234)192-101(62-204)138(240)180-87(37-40-105(155)213)126(228)178-89(39-42-112(220)221)127(229)185-93(50-68(5)6)131(233)186-95(54-80-58-167-65-173-80)133(235)177-85(26-21-45-169-151(163)164)125(227)184-92(49-67(3)4)130(232)179-88(38-41-106(156)214)129(231)199-119(77(17)210)147(249)191-99(53-79-31-35-82(212)36-32-79)149(251)202-47-23-28-104(202)141(243)181-86(27-22-46-170-152(165)166)128(230)198-118(76(16)209)146(248)190-98(57-109(159)217)136(238)197-114(72(12)205)142(244)172-60-111(219)176-100(61-203)137(239)187-96(55-107(157)215)134(236)201-117(75(15)208)145(247)182-90(120(160)222)52-78-29-33-81(211)34-30-78/h29-36,58,65-77,83-104,113-119,203-212H,18-28,37-57,59-64,153-154H2,1-17H3,(H2,155,213)(H2,156,214)(H2,157,215)(H2,158,216)(H2,159,217)(H2,160,222)(H,167,173)(H,171,225)(H,172,244)(H,174,246)(H,175,218)(H,176,219)(H,177,235)(H,178,228)(H,179,232)(H,180,240)(H,181,243)(H,182,247)(H,183,226)(H,184,227)(H,185,229)(H,186,233)(H,187,239)(H,188,241)(H,189,245)(H,190,248)(H,191,249)(H,192,234)(H,193,224)(H,194,250)(H,195,242)(H,196,223)(H,197,238)(H,198,230)(H,199,231)(H,200,237)(H,201,236)(H,220,221)(H4,161,162,168)(H4,163,164,169)(H4,165,166,170)/t71-,72+,73+,74+,75+,76+,77+,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,113-,114-,115-,116-,117-,118-,119-/m0/s1
DM9S3R8	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N)[C@@H](C)O
DM9S3R8	IK	SLYFITHISHUGLZ-QPMCIWSFSA-N
DM9S3R8	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoic acid
DM9S3R8	CA	CAS 863919-85-1
DM9S3R8	DE	Obesity

DMXO9BQ	ID	DMXO9BQ
DMXO9BQ	DN	Daxalipram
DMXO9BQ	HS	Discontinued in Phase 2
DMXO9BQ	SN	PDE 4 inhibitor (multiple sclerosis), Schering AG
DMXO9BQ	CP	Bayer Schering Pharma AG
DMXO9BQ	PC	449190
DMXO9BQ	MW	265.3
DMXO9BQ	FM	C14H19NO4
DMXO9BQ	IC	InChI=1S/C14H19NO4/c1-4-7-18-12-8-10(5-6-11(12)17-3)14(2)9-15-13(16)19-14/h5-6,8H,4,7,9H2,1-3H3,(H,15,16)/t14-/m0/s1
DMXO9BQ	CS	CCCOC1=C(C=CC(=C1)[C@@]2(CNC(=O)O2)C)OC
DMXO9BQ	IK	PCCPERGCFKIYIS-AWEZNQCLSA-N
DMXO9BQ	IU	(5R)-5-(4-methoxy-3-propoxyphenyl)-5-methyl-1,3-oxazolidin-2-one
DMXO9BQ	CA	CAS 189940-24-7
DMXO9BQ	DE	Multiple sclerosis

DMGM2HY	ID	DMGM2HY
DMGM2HY	DN	DCDT-2980S
DMGM2HY	HS	Discontinued in Phase 2
DMGM2HY	CP	Genentech
DMGM2HY	DT	Antibody
DMGM2HY	DE	Diffuse large B-cell lymphoma; Non-hodgkin lymphoma

DMMV6RK	ID	DMMV6RK
DMMV6RK	DN	DDP-200
DMMV6RK	HS	Discontinued in Phase 2
DMMV6RK	SN	Overactive bladder therapeutics, Dynogen
DMMV6RK	CP	Dynogen
DMMV6RK	DE	Urinary incontinence

DM3AVO1	ID	DM3AVO1
DM3AVO1	DN	DE-081
DM3AVO1	HS	Discontinued in Phase 2
DM3AVO1	SN	Apafant; 105219-56-5; WEB-2086; Web 2086; Apafant [USAN:INN]; Apafantum [INN-Latin]; Apafanto [INN-Spanish]; WEB 2086BS; WEB2086; UNII-J613NI05SV; WEB 2086 BS; BRN 4302553; C22H22ClN5O2S; J613NI05SV; CHEMBL280164; NCGC00092377-03; NCGC00092377-02; Apafantum; Apafanto; DSSTox_CID_28900; DSSTox_RID_83168; DSSTox_GSID_48974; 4-(3-(4-(o-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine; [3H]apafant; Morpholine; Apafant (ophthalmic formulation), Santen
DM3AVO1	CP	Santen Pharmaceutical Co Ltd
DM3AVO1	DT	Small molecular drug
DM3AVO1	PC	65889
DM3AVO1	MW	456
DM3AVO1	FM	C22H22ClN5O2S
DM3AVO1	IC	InChI=1S/C22H22ClN5O2S/c1-14-25-26-19-13-24-21(16-4-2-3-5-18(16)23)17-12-15(31-22(17)28(14)19)6-7-20(29)27-8-10-30-11-9-27/h2-5,12H,6-11,13H2,1H3
DM3AVO1	CS	CC1=NN=C2N1C3=C(C=C(S3)CCC(=O)N4CCOCC4)C(=NC2)C5=CC=CC=C5Cl
DM3AVO1	IK	JGPJQFOROWSRRS-UHFFFAOYSA-N
DM3AVO1	IU	3-[7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-4-yl]-1-morpholin-4-ylpropan-1-one
DM3AVO1	CA	CAS 105219-56-5
DM3AVO1	CB	CHEBI:92490
DM3AVO1	DE	Conjunctivitis; Ocular allergy

DM5QFT4	ID	DM5QFT4
DM5QFT4	DN	Declopramide
DM5QFT4	HS	Discontinued in Phase 2
DM5QFT4	SN	IBD therapy, Active Biotech; Inflammatory bowel disease therapy, Active Biotech; OXi-104; IMO-B project, Active Biotech; 3-CPA; 3-chloroprocainamide
DM5QFT4	CP	OXiGENE Inc
DM5QFT4	DT	Small molecular drug
DM5QFT4	PC	70177
DM5QFT4	MW	269.77
DM5QFT4	FM	C13H20ClN3O
DM5QFT4	IC	InChI=1S/C13H20ClN3O/c1-3-17(4-2)8-7-16-13(18)10-5-6-12(15)11(14)9-10/h5-6,9H,3-4,7-8,15H2,1-2H3,(H,16,18)
DM5QFT4	CS	CCN(CC)CCNC(=O)C1=CC(=C(C=C1)N)Cl
DM5QFT4	IK	YEYAKZXEBSVURO-UHFFFAOYSA-N
DM5QFT4	IU	4-amino-3-chloro-N-[2-(diethylamino)ethyl]benzamide
DM5QFT4	CA	CAS 891-60-1
DM5QFT4	DE	Inflammatory bowel disease

DMYJ28R	ID	DMYJ28R
DMYJ28R	DN	Deriglidole
DMYJ28R	HS	Discontinued in Phase 2
DMYJ28R	SN	SL-84.0418; SL-84.0714; SL-84.0715
DMYJ28R	CP	Synthelabo
DMYJ28R	DT	Small molecular drug
DMYJ28R	PC	65945
DMYJ28R	MW	255.36
DMYJ28R	FM	C16H21N3
DMYJ28R	IC	InChI=1S/C16H21N3/c1-2-7-16(15-17-8-9-18-15)11-13-5-3-4-12-6-10-19(16)14(12)13/h3-5H,2,6-11H2,1H3,(H,17,18)
DMYJ28R	CS	CCCC1(CC2=CC=CC3=C2N1CC3)C4=NCCN4
DMYJ28R	IK	BADQRNHAZHSOKC-UHFFFAOYSA-N
DMYJ28R	IU	3-(4,5-dihydro-1H-imidazol-2-yl)-3-propyl-4-azatricyclo[5.3.1.04,11]undeca-1(10),7(11),8-triene
DMYJ28R	CA	CAS 122830-14-2
DMYJ28R	DE	Diabetic complication

DM6WSU2	ID	DM6WSU2
DM6WSU2	DN	Dermolastin
DM6WSU2	HS	Discontinued in Phase 2
DM6WSU2	SN	Dermolastin
DM6WSU2	CP	Arriva Pharma
DM6WSU2	DT	Small molecular drug
DM6WSU2	PC	188403
DM6WSU2	MW	449.7
DM6WSU2	FM	C27H31NOS2
DM6WSU2	IC	InChI=1S/C27H31NOS2/c1-5-28(14-8-6-7-13-27(2,3)4)18-22-10-9-11-25(16-22)29-19-26-17-24(21-31-26)23-12-15-30-20-23/h6,8-12,15-17,20-21H,5,14,18-19H2,1-4H3
DM6WSU2	CS	CCN(CC=CC#CC(C)(C)C)CC1=CC(=CC=C1)OCC2=CC(=CS2)C3=CSC=C3
DM6WSU2	IK	KIRGLCXNEVICOG-UHFFFAOYSA-N
DM6WSU2	IU	N-ethyl-6,6-dimethyl-N-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine
DM6WSU2	DE	Atopic dermatitis

DMLZIT2	ID	DMLZIT2
DMLZIT2	DN	Dexniguldipine
DMLZIT2	HS	Discontinued in Phase 2
DMLZIT2	SN	Dexniguldipine hydrochloride; BY-935; B-8509-035; B-859-35
DMLZIT2	CP	ALTANA Pharma AG
DMLZIT2	DT	Small molecular drug
DMLZIT2	PC	6918097
DMLZIT2	MW	609.7
DMLZIT2	FM	C36H39N3O6
DMLZIT2	IC	InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3/t33-/m1/s1
DMLZIT2	CS	CC1=C([C@H](C(=C(N1)C)C(=O)OCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC
DMLZIT2	IK	SVJMLYUFVDMUHP-MGBGTMOVSA-N
DMLZIT2	IU	5-O-[3-(4,4-diphenylpiperidin-1-yl)propyl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMLZIT2	CA	CAS 120054-86-6
DMLZIT2	CB	CHEBI:103932
DMLZIT2	DE	Solid tumour/cancer

DMJT8Q0	ID	DMJT8Q0
DMJT8Q0	DN	Dezinamide
DMJT8Q0	HS	Discontinued in Phase 2
DMJT8Q0	SN	ADD-94057; ADDR-84116; AHR-11748; AN-051
DMJT8Q0	CP	A H Robins Co Inc
DMJT8Q0	DT	Small molecular drug
DMJT8Q0	PC	146291
DMJT8Q0	MW	260.209
DMJT8Q0	FM	C11H11F3N2O2
DMJT8Q0	IC	InChI=1S/C11H11F3N2O2/c12-11(13,14)7-2-1-3-8(4-7)18-9-5-16(6-9)10(15)17/h1-4,9H,5-6H2,(H2,15,17)
DMJT8Q0	CS	C1C(CN1C(=O)N)OC2=CC=CC(=C2)C(F)(F)F
DMJT8Q0	IK	LIAILJLSVRAGSM-UHFFFAOYSA-N
DMJT8Q0	IU	3-[3-(trifluoromethyl)phenoxy]azetidine-1-carboxamide
DMJT8Q0	CA	CAS 91077-32-6
DMJT8Q0	DE	Epileptic seizures

DMVO9WM	ID	DMVO9WM
DMVO9WM	DN	DG041
DMVO9WM	HS	Discontinued in Phase 2
DMVO9WM	SN	DTSI; D-000151746; DG-041
DMVO9WM	CP	DeCODE genetics
DMVO9WM	DT	Small molecular drug
DMVO9WM	PC	11296282
DMVO9WM	MW	592.3
DMVO9WM	FM	C23H15Cl4FN2O3S2
DMVO9WM	IC	InChI=1S/C23H15Cl4FN2O3S2/c1-12-10-30(11-14-2-4-15(24)7-18(14)25)22-13(6-16(28)8-17(12)22)3-5-20(31)29-35(32,33)21-9-19(26)23(27)34-21/h2-10H,11H2,1H3,(H,29,31)/b5-3+
DMVO9WM	CS	CC1=CN(C2=C(C=C(C=C12)F)/C=C/C(=O)NS(=O)(=O)C3=CC(=C(S3)Cl)Cl)CC4=C(C=C(C=C4)Cl)Cl
DMVO9WM	IK	BFBTVZNKWXWKNZ-HWKANZROSA-N
DMVO9WM	IU	(E)-3-[1-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methylindol-7-yl]-N-(4,5-dichlorothiophen-2-yl)sulfonylprop-2-enamide
DMVO9WM	CA	CAS 861238-35-9
DMVO9WM	DE	Peripheral vascular disease

DM3I0GS	ID	DM3I0GS
DM3I0GS	DN	DG051
DM3I0GS	HS	Discontinued in Phase 2
DM3I0GS	SN	929916-05-2; DG-051; (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid; CHEMBL565789; 4-[(2s)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}pyrrolidin-1-Yl]butanoate; compound 20 [PMID: 19950900]; SCHEMBL989668; GTPL6548; PVCTYSQBVIGZRU-KRWDZBQOSA-N; BDBM50303649; ZINC34884331; AKOS030525381; 4-[(2S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl]butanoic acid; 4-{(S)-2-[4-(4-Chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl}-butyric Acid
DM3I0GS	CP	DeCODE genetics
DM3I0GS	DT	Small molecular drug
DM3I0GS	PC	44818987
DM3I0GS	MW	426.3
DM3I0GS	FM	C21H25Cl2NO4
DM3I0GS	IC	InChI=1S/C21H24ClNO4.ClH/c22-16-5-7-19(8-6-16)27-20-11-9-18(10-12-20)26-15-17-3-1-13-23(17)14-2-4-21(24)25;/h5-12,17H,1-4,13-15H2,(H,24,25);1H/t17-;/m0./s1
DM3I0GS	CS	C1C[C@H](N(C1)CCCC(=O)O)COC2=CC=C(C=C2)OC3=CC=C(C=C3)Cl.Cl
DM3I0GS	IK	UCPVOTSNNAVKNE-LMOVPXPDSA-N
DM3I0GS	IU	4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid;hydrochloride
DM3I0GS	CA	CAS 929915-58-2
DM3I0GS	DE	Myocardial infarction

DM64CAS	ID	DM64CAS
DM64CAS	DN	Didox
DM64CAS	HS	Discontinued in Phase 2
DM64CAS	SN	69839-83-4; N,3,4-Trihydroxybenzamide; 3,4-Dihydroxybenzohydroxamic acid; NSC-324360; Benzamide, N,3,4-trihydroxy-; 3,4-Dihydroxyphenylhydroxamic acid; UNII-L106XFV0RQ; VF 147; NSC 324360; DIDO; CCRIS 7909; BRN 2096682; L106XFV0RQ; C7H7NO4; NSC324360; AC1L1F1T; Benzamide,3,4-trihydroxy-; AC1Q5DI9; N-3,4-Tridhydroxybenzamide; SCHEMBL171446; CHEMBL367788; SCHEMBL18732059; Didox, &gt; SCHEMBL18346609; CTK8F9165; DTXSID90220134; QJMCKEPOKRERLN-UHFFFAOYSA-N; MolPort-009-019-216; KS-00001DF2; BCP16846; ZINC3872288; 1716AH
DM64CAS	DT	Small molecular drug
DM64CAS	PC	3045
DM64CAS	MW	169.13
DM64CAS	FM	C7H7NO4
DM64CAS	IC	InChI=1S/C7H7NO4/c9-5-2-1-4(3-6(5)10)7(11)8-12/h1-3,9-10,12H,(H,8,11)
DM64CAS	CS	C1=CC(=C(C=C1C(=O)NO)O)O
DM64CAS	IK	QJMCKEPOKRERLN-UHFFFAOYSA-N
DM64CAS	IU	N,3,4-trihydroxybenzamide
DM64CAS	CA	CAS 69839-83-4
DM64CAS	DE	Solid tumour/cancer

DMIP3EC	ID	DMIP3EC
DMIP3EC	DN	DM-83
DMIP3EC	HS	Discontinued in Phase 2
DMIP3EC	CP	DiaMedica Inc
DMIP3EC	DE	Type-2 diabetes

DMCNEOZ	ID	DMCNEOZ
DMCNEOZ	DN	DMP-543
DMCNEOZ	HS	Discontinued in Phase 2
DMCNEOZ	SN	XR-543
DMCNEOZ	CP	Bristol-Myers Squibb Pharma Co
DMCNEOZ	DT	Small molecular drug
DMCNEOZ	PC	9887884
DMCNEOZ	MW	412.4
DMCNEOZ	FM	C26H18F2N2O
DMCNEOZ	IC	InChI=1S/C26H18F2N2O/c27-23-13-17(9-11-29-23)15-26(16-18-10-12-30-24(28)14-18)21-7-3-1-5-19(21)25(31)20-6-2-4-8-22(20)26/h1-14H,15-16H2
DMCNEOZ	CS	C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2(CC4=CC(=NC=C4)F)CC5=CC(=NC=C5)F
DMCNEOZ	IK	MUJBUUDUXGDXLW-UHFFFAOYSA-N
DMCNEOZ	IU	10,10-bis[(2-fluoropyridin-4-yl)methyl]anthracen-9-one
DMCNEOZ	CA	CAS 160588-45-4
DMCNEOZ	CB	CHEBI:93560
DMCNEOZ	DE	Parkinson disease

DMI5XKC	ID	DMI5XKC
DMI5XKC	DN	DMP-961
DMI5XKC	HS	Discontinued in Phase 2
DMI5XKC	SN	DPC-961; (-)-6-Chloro-4(S)-(2-cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one
DMI5XKC	DT	Small molecular drug
DMI5XKC	PC	474120
DMI5XKC	MW	314.69
DMI5XKC	FM	C14H10ClF3N2O
DMI5XKC	IC	InChI=1S/C14H10ClF3N2O/c15-9-3-4-11-10(7-9)13(14(16,17)18,20-12(21)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H2,19,20,21)/t13-/m0/s1
DMI5XKC	CS	C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)N2)C(F)(F)F
DMI5XKC	IK	JJWJSIAJLBEMEN-ZDUSSCGKSA-N
DMI5XKC	IU	(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one
DMI5XKC	CA	CAS 214287-88-4
DMI5XKC	DE	Human immunodeficiency virus infection

DM4ZO01	ID	DM4ZO01
DM4ZO01	DN	DNK-333
DM4ZO01	HS	Discontinued in Phase 2
DM4ZO01	SN	DNK 333; DNK333; N-((R,R)-(E)-1-(3,4-Dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl)allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide
DM4ZO01	CP	Novartis
DM4ZO01	DT	Small molecular drug
DM4ZO01	PC	9939040
DM4ZO01	MW	624.4
DM4ZO01	FM	C27H25Cl2F6N3O3
DM4ZO01	IC	InChI=1S/C27H25Cl2F6N3O3/c1-38(25(41)16-12-17(26(30,31)32)14-18(13-16)27(33,34)35)19(10-15-5-7-20(28)21(29)11-15)6-8-23(39)37-22-4-2-3-9-36-24(22)40/h5-8,11-14,19,22H,2-4,9-10H2,1H3,(H,36,40)(H,37,39)/b8-6+/t19-,22+/m0/s1
DM4ZO01	CS	CN([C@H](CC1=CC(=C(C=C1)Cl)Cl)/C=C/C(=O)N[C@@H]2CCCCNC2=O)C(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DM4ZO01	IK	BHCJHYIMNHXLOM-WVDRJWPYSA-N
DM4ZO01	IU	N-[(E,2R)-1-(3,4-dichlorophenyl)-5-oxo-5-[[(3R)-2-oxoazepan-3-yl]amino]pent-3-en-2-yl]-N-methyl-3,5-bis(trifluoromethyl)benzamide
DM4ZO01	CA	CAS 398507-81-8
DM4ZO01	DE	Irritable bowel syndrome

DMMC6H7	ID	DMMC6H7
DMMC6H7	DN	Dopropidil
DMMC6H7	HS	Discontinued in Phase 2
DMMC6H7	SN	CERM-4205
DMMC6H7	CP	Riom Laboratories
DMMC6H7	DT	Small molecular drug
DMMC6H7	PC	71236
DMMC6H7	MW	321.5
DMMC6H7	FM	C20H35NO2
DMMC6H7	IC	InChI=1S/C20H35NO2/c1-4-10-20(11-6-5-7-12-20)23-17-19(16-22-15-18(2)3)21-13-8-9-14-21/h18-19H,5-9,11-17H2,1-3H3
DMMC6H7	CS	CC#CC1(CCCCC1)OCC(COCC(C)C)N2CCCC2
DMMC6H7	IK	FITWYAUFKJXWPL-UHFFFAOYSA-N
DMMC6H7	IU	1-[1-(2-methylpropoxy)-3-(1-prop-1-ynylcyclohexyl)oxypropan-2-yl]pyrrolidine
DMMC6H7	CA	CAS 79700-61-1
DMMC6H7	DE	Angina pectoris

DMTE14H	ID	DMTE14H
DMTE14H	DN	DOV-216303
DMTE14H	HS	Discontinued in Phase 2
DMTE14H	SN	66504-40-3; CHEMBL528995; 3-Azabicyclo[3.1.0]hexane, 1-(3,4-dichlorophenyl)-; SCHEMBL79279; SCHEMBL9604846; CTK1J4675; MolPort-035-942-269; BSMNRYCSBFHEMQ-UHFFFAOYSA-N; DOV-2947; BDBM50243895; AKOS025396236; FCH1601649; SB10890; KB-50426; AS-51627; AK173863; CS-0052898; KS-00000461
DMTE14H	CP	DOV
DMTE14H	DT	Small molecular drug
DMTE14H	PC	9795276
DMTE14H	MW	228.11
DMTE14H	FM	C11H11Cl2N
DMTE14H	IC	InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2
DMTE14H	CS	C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl
DMTE14H	IK	BSMNRYCSBFHEMQ-UHFFFAOYSA-N
DMTE14H	IU	1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
DMTE14H	DE	Mood disorder

DMKGXT2	ID	DMKGXT2
DMKGXT2	DN	DPI-3290
DMKGXT2	HS	Discontinued in Phase 2
DMKGXT2	SN	DPI-3290W93; (+)-3-[1(R)-[4-Allyl-2(S),5(R)-dimethylpiperazin-1-yl]-1-(3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide; 3290W93
DMKGXT2	CP	Enhance Biotech
DMKGXT2	DT	Small molecular drug
DMKGXT2	PC	9826770
DMKGXT2	MW	487.6
DMKGXT2	FM	C30H34FN3O2
DMKGXT2	IC	InChI=1S/C30H34FN3O2/c1-5-15-33-19-22(3)34(20-21(33)2)29(24-10-7-14-28(35)17-24)23-9-6-11-25(16-23)30(36)32(4)27-13-8-12-26(31)18-27/h5-14,16-18,21-22,29,35H,1,15,19-20H2,2-4H3/t21-,22+,29-/m1/s1
DMKGXT2	CS	C[C@H]1CN([C@@H](CN1[C@H](C2=CC(=CC=C2)C(=O)N(C)C3=CC(=CC=C3)F)C4=CC(=CC=C4)O)C)CC=C
DMKGXT2	IK	LZXRQLIIMYJZDA-UETOGOEVSA-N
DMKGXT2	IU	3-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide
DMKGXT2	CA	CAS 182417-73-8
DMKGXT2	DE	Pain

DMCZ75T	ID	DMCZ75T
DMCZ75T	DN	DRAFLAZINE
DMCZ75T	HS	Discontinued in Phase 2
DMCZ75T	SN	Draflazine < Rec INN; R-70380; R-75231; Rac-N-(4-Amino-2,6-dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-2-carbamoylpiperazine-1-acetamide; Rac-2-(Aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-1-piperazineacetamide; Rac-4'-Amino-4-[5,5-bis(p-fluorophenyl)pentyl]-2-carbamoyl-2',6'-dichloro-1-piperazineacetanilide
DMCZ75T	DT	Small molecular drug
DMCZ75T	PC	60849
DMCZ75T	MW	604.5
DMCZ75T	FM	C30H33Cl2F2N5O2
DMCZ75T	IC	InChI=1S/C30H33Cl2F2N5O2/c31-25-15-23(35)16-26(32)29(25)37-28(40)18-39-14-13-38(17-27(39)30(36)41)12-2-1-3-24(19-4-8-21(33)9-5-19)20-6-10-22(34)11-7-20/h4-11,15-16,24,27H,1-3,12-14,17-18,35H2,(H2,36,41)(H,37,40)
DMCZ75T	CS	C1CN(C(CN1CCCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)N)CC(=O)NC4=C(C=C(C=C4Cl)N)Cl
DMCZ75T	IK	IWMYIWLIESDFRZ-UHFFFAOYSA-N
DMCZ75T	IU	1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide
DMCZ75T	CA	CAS 120770-34-5
DMCZ75T	DE	Cardiac arrhythmias

DM9JPUD	ID	DM9JPUD
DM9JPUD	DN	Droloxifene
DM9JPUD	HS	Discontinued in Phase 2
DM9JPUD	SN	E-droloxifene; FK-435; K-060; K-060E; RP-60850; K-21.060E; 3-hydroxytamoxifen
DM9JPUD	CP	Klinge Pharma GmbH
DM9JPUD	DT	Small molecular drug
DM9JPUD	PC	3033767
DM9JPUD	MW	387.5
DM9JPUD	FM	C26H29NO2
DM9JPUD	IC	InChI=1S/C26H29NO2/c1-4-25(20-9-6-5-7-10-20)26(22-11-8-12-23(28)19-22)21-13-15-24(16-14-21)29-18-17-27(2)3/h5-16,19,28H,4,17-18H2,1-3H3/b26-25+
DM9JPUD	CS	CC/C(=C(/C1=CC=C(C=C1)OCCN(C)C)\\C2=CC(=CC=C2)O)/C3=CC=CC=C3
DM9JPUD	IK	ZQZFYGIXNQKOAV-OCEACIFDSA-N
DM9JPUD	IU	3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DM9JPUD	CA	CAS 82413-20-5
DM9JPUD	CB	CHEBI:34731
DM9JPUD	DE	Breast cancer

DM8GZWC	ID	DM8GZWC
DM8GZWC	DN	DS-4574
DM8GZWC	HS	Discontinued in Phase 2
DM8GZWC	SN	DS 4574; DS-4574; 118314-35-5; 6-(2-Cyclohexylethyl)-(1,3,4)thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one; (1,3,4)Thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one, 6-(2-cyclohexylethyl)-; [1,3,4]Thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyrimidin-9(3H)-one,6-(2-cyclohexylethyl)-; AC1L4LXR; ACMC-20c9t1; AC1Q6E9S; SCHEMBL156066; CTK4B0638; DTXSID80152096; AKOS030534249; 6-(2-cyclohexylethyl)[1,3,4]thiadiazolo[3,2-a][1,2,3]triazolo[4,5-d]pyrimidin-9(2h)-one; LS-150402
DM8GZWC	CP	Daiichi Seiyaku Co Ltd
DM8GZWC	DT	Small molecular drug
DM8GZWC	PC	159491
DM8GZWC	MW	304.37
DM8GZWC	FM	C13H16N6OS
DM8GZWC	IC	InChI=1S/C13H16N6OS/c20-12-10-11(16-18-15-10)14-13-19(12)17-9(21-13)7-6-8-4-2-1-3-5-8/h8H,1-7H2,(H,15,16,18)
DM8GZWC	CS	C1CCC(CC1)CCC2=NN3C(=O)C4=NNN=C4N=C3S2
DM8GZWC	IK	ASIFEXZWAKYMRM-UHFFFAOYSA-N
DM8GZWC	IU	11-(2-cyclohexylethyl)-10-thia-1,4,5,6,8,12-hexazatricyclo[7.3.0.03,7]dodeca-3,6,8,11-tetraen-2-one
DM8GZWC	CA	CAS 118314-35-5
DM8GZWC	DE	Asthma

DM63UA9	ID	DM63UA9
DM63UA9	DN	DU 125530
DM63UA9	HS	Discontinued in Phase 2
DM63UA9	SN	DU 125530; UNII-ZB05V621UD; CHEMBL79261; DU-125530; ZB05V621UD; 161611-99-0; DU125530; SCHEMBL1082516; BDBM85079; DTXSID00167208; MolPort-044-830-638; PDSP1_000932; PDSP2_000918; 1,2-Benzisothiazol-3(2H)-one, 2-(4-(4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl)butyl)-, 1,1-dioxide; L001571; 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]-butyl]-1,2-benzisothiazol-3(2h)-one-1,1-dioxide; 2-[4-[4-[(7-Chloro-2,3-dihydro-1,4-benzodioxin)-5-yl]-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,
DM63UA9	DT	Small molecular drug
DM63UA9	PC	9848499
DM63UA9	MW	492
DM63UA9	FM	C23H26ClN3O5S
DM63UA9	IC	InChI=1S/C23H26ClN3O5S/c24-17-15-19(22-20(16-17)31-13-14-32-22)26-11-9-25(10-12-26)7-3-4-8-27-23(28)18-5-1-2-6-21(18)33(27,29)30/h1-2,5-6,15-16H,3-4,7-14H2
DM63UA9	CS	C1CN(CCN1CCCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C4=C5C(=CC(=C4)Cl)OCCO5
DM63UA9	IK	LYXKFNHUJJDTIA-UHFFFAOYSA-N
DM63UA9	IU	2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,1-dioxo-1,2-benzothiazol-3-one
DM63UA9	CA	CAS 161611-99-0
DM63UA9	DE	Mood disorder

DMQ9IO0	ID	DMQ9IO0
DMQ9IO0	DN	DuP-654
DMQ9IO0	HS	Discontinued in Phase 2
DMQ9IO0	SN	DUP-654; 2-benzylnaphthalen-1-ol; 2-Benzyl-1-naphthol; Dup 654; 36441-32-4; DuP654; 2-(phenylmethyl)-1-naphthol; UNII-96251IH9OJ; 2-Benzyl-1-hydroxynaphthalene; 2-(Phenylmethyl)-1-naphthalenol; BRN 1965326; CHEMBL85000; 96251IH9OJ; 1-Naphthalenol, 2-(phenylmethyl)-; AC1L4NCB; AC1Q7AVK; 2-phenylmethyl1-naphthol; 2-phenylmethyl-1-naphthol; 2-Benzyl-naphthalen-1-ol; 4-06-00-04990 (Beilstein Handbook Reference); SCHEMBL664782; DTXSID00189965; CZTSOXCSVFEFIK-UHFFFAOYSA-N; ZINC1485058; BDBM50004679; 2-Benzyl-naphthalen-1-ol(DuP 654)
DMQ9IO0	CP	Bristol-Myers Squibb Pharma Co
DMQ9IO0	DT	Small molecular drug
DMQ9IO0	PC	160268
DMQ9IO0	MW	234.29
DMQ9IO0	FM	C17H14O
DMQ9IO0	IC	InChI=1S/C17H14O/c18-17-15(12-13-6-2-1-3-7-13)11-10-14-8-4-5-9-16(14)17/h1-11,18H,12H2
DMQ9IO0	CS	C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3C=C2)O
DMQ9IO0	IK	CZTSOXCSVFEFIK-UHFFFAOYSA-N
DMQ9IO0	IU	2-benzylnaphthalen-1-ol
DMQ9IO0	CA	CAS 36441-32-4
DMQ9IO0	DE	Pruritus

DMSTA5L	ID	DMSTA5L
DMSTA5L	DN	DX-619
DMSTA5L	HS	Discontinued in Phase 2
DMSTA5L	SN	Quinolone derivative (injectable, bacterial infection), Daiichi Sankyo
DMSTA5L	CP	Daiichi Seiyaku Co Ltd
DMSTA5L	DT	Small molecular drug
DMSTA5L	PC	9865774
DMSTA5L	MW	401.4
DMSTA5L	FM	C21H24FN3O4
DMSTA5L	IC	InChI=1S/C21H24FN3O4/c1-29-19-15(24-7-4-11(9-24)21(23)5-6-21)3-2-12-17(19)25(16-8-14(16)22)10-13(18(12)26)20(27)28/h2-3,10-11,14,16H,4-9,23H2,1H3,(H,27,28)/t11-,14+,16-/m1/s1
DMSTA5L	CS	COC1=C(C=CC2=C1N(C=C(C2=O)C(=O)O)[C@@H]3C[C@@H]3F)N4CC[C@H](C4)C5(CC5)N
DMSTA5L	IK	ZLICIITZJTYKAQ-DIOULYMOSA-N
DMSTA5L	IU	7-[(3R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl]-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMSTA5L	CA	CAS 431058-65-0
DMSTA5L	DE	Bacterial infection

DMEQLC4	ID	DMEQLC4
DMEQLC4	DN	DX-9065
DMEQLC4	HS	Discontinued in Phase 2
DMEQLC4	SN	DX-9065 (enteric-coated tablet)
DMEQLC4	CP	Daiichi Sankyo Co Ltd
DMEQLC4	DE	Coagulation defect

DMIXUMZ	ID	DMIXUMZ
DMIXUMZ	DN	DX-9065a
DMIXUMZ	HS	Discontinued in Phase 2
DMIXUMZ	SN	dx-9065a; QXQVEPEVI2; UNII-QXQVEPEVI2; 155204-81-2; 2-(4-((1-Acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphthyl)propanoic acid hydrocloride pentahydrate; DX 9065a; (S-(R*,R*))-7-(Aminoiminomethyl)-alpha-(4-((1-(1-iminoethyl)-3-pyrrolidinyl)oxy)phenyl)-2-naphthalenepropanoic acid monohydrochloride, pentahydrate; 2-Naphthalenepropanoic acid, 7-(aminoiminomethyl)-alpha-(4-((1-(1-iminoethyl)-3-pyrrolidinyl)oxy)phenyl)-, monohydrochloride, pentahydrate, (S-(R*,R*))-; AC1L3U17; X-9065a; C26H28N4O3.5H2O.HCl
DMIXUMZ	DT	Small molecular drug
DMIXUMZ	PC	122128
DMIXUMZ	MW	571.1
DMIXUMZ	FM	C26H39ClN4O8
DMIXUMZ	IC	InChI=1S/C26H28N4O3.ClH.5H2O/c1-16(27)30-11-10-23(15-30)33-22-8-6-19(7-9-22)24(26(31)32)13-17-2-3-18-4-5-20(25(28)29)14-21(18)12-17;;;;;;/h2-9,12,14,23-24,27H,10-11,13,15H2,1H3,(H3,28,29)(H,31,32);1H;5*1H2/t23-,24-;;;;;;/m0....../s1
DMIXUMZ	CS	CC(=N)N1CC[C@@H](C1)OC2=CC=C(C=C2)[C@H](CC3=CC4=C(C=C3)C=CC(=C4)C(=N)N)C(=O)O.O.O.O.O.O.Cl
DMIXUMZ	IK	LJCBAPRMNYSDOP-LVCYMWGESA-N
DMIXUMZ	IU	(2S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3S)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;pentahydrate;hydrochloride
DMIXUMZ	CA	CAS 155204-81-2
DMIXUMZ	DE	Angina pectoris

DMT2WVP	ID	DMT2WVP
DMT2WVP	DN	Dynorphin A
DMT2WVP	HS	Discontinued in Phase 2
DMT2WVP	SN	Dynorphin A; 80448-90-4; Dynorphin A porcine; Dynorphin-(1-17); UNII-9M18T0TD14; 9M18T0TD14; MFCD00076351; Dynorphin A1-17; Dynorphin A (swine); Dynorphin acetate; Dynorphin A (1-17), porcine; JMNJYGMAUMANNW-FIXZTSJVSA-N; BDBM50096785; AKOS024457469; Dynorphin A porcine, &gt; NCGC00167144-01
DMT2WVP	DT	Small molecular drug
DMT2WVP	PC	16133805
DMT2WVP	MW	2147.5
DMT2WVP	FM	C99H155N31O23
DMT2WVP	IC	InChI=1S/C99H155N31O23/c1-7-55(6)81(129-86(142)66(28-18-40-112-98(107)108)118-83(139)65(27-17-39-111-97(105)106)120-88(144)70(44-54(4)5)125-89(145)71(46-56-21-9-8-10-22-56)117-79(135)52-115-78(134)51-116-82(138)61(102)45-57-31-33-59(131)34-32-57)94(150)122-67(29-19-41-113-99(109)110)95(151)130-42-20-30-75(130)93(149)121-64(26-14-16-38-101)85(141)124-69(43-53(2)3)87(143)119-63(25-13-15-37-100)84(140)126-72(47-58-50-114-62-24-12-11-23-60(58)62)90(146)128-74(49-80(136)137)92(148)127-73(48-77(104)133)91(147)123-68(96(152)153)35-36-76(103)132/h8-12,21-24,31-34,50,53-55,61,63-75,81,114,131H,7,13-20,25-30,35-49,51-52,100-102H2,1-6H3,(H2,103,132)(H2,104,133)(H,115,134)(H,116,138)(H,117,135)(H,118,139)(H,119,143)(H,120,144)(H,121,149)(H,122,150)(H,123,147)(H,124,141)(H,125,145)(H,126,140)(H,127,148)(H,128,146)(H,129,142)(H,136,137)(H,152,153)(H4,105,106,111)(H4,107,108,112)(H4,109,110,113)/t55-,61-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,81-/m0/s1
DMT2WVP	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)CNC(=O)[C@H](CC5=CC=C(C=C5)O)N
DMT2WVP	IK	JMNJYGMAUMANNW-FIXZTSJVSA-N
DMT2WVP	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMT2WVP	CA	CAS 80448-90-4

DMHEW40	ID	DMHEW40
DMHEW40	DN	E-2078
DMHEW40	HS	Discontinued in Phase 2
DMHEW40	SN	66A-078
DMHEW40	CP	Eisai Co Ltd
DMHEW40	DT	Small molecular drug
DMHEW40	PC	122220
DMHEW40	MW	1036.3
DMHEW40	FM	C50H81N15O9
DMHEW40	IC	InChI=1S/C50H81N15O9/c1-8-56-44(70)37(24-30(2)3)64-47(73)40(17-13-23-58-50(53)54)65(7)48(74)35(16-12-22-57-49(51)52)62-45(71)38(25-31(4)5)63-46(72)39(27-32-14-10-9-11-15-32)61-42(68)29-59-41(67)28-60-43(69)36(55-6)26-33-18-20-34(66)21-19-33/h9-11,14-15,18-21,30-31,35-40,55,66H,8,12-13,16-17,22-29H2,1-7H3,(H,56,70)(H,59,67)(H,60,69)(H,61,68)(H,62,71)(H,63,72)(H,64,73)(H4,51,52,57)(H4,53,54,58)/t35-,36-,37+,38-,39-,40-/m0/s1
DMHEW40	CS	CCNC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)N(C)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC
DMHEW40	IK	JENWDDCMEATQSR-ONSKYXJOSA-N
DMHEW40	IU	(2R)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-3-(4-hydroxyphenyl)-2-(methylamino)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]-methylamino]pentanoyl]amino]-N-ethyl-4-methylpentanamide
DMHEW40	CA	CAS 103613-84-9
DMHEW40	DE	Pain

DM35KZG	ID	DM35KZG
DM35KZG	DN	E-3040
DM35KZG	HS	Discontinued in Phase 2
DM35KZG	SN	E-3040; E 3040; CHEMBL105139; 145096-30-6; E3040; AC1L9EDQ; CHEBI:4732; 6-Hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole; SCHEMBL6009376; DTXSID80162877; CHEBI:271098; 5,7-Dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-6-benzothiazolol; BDBM50037037; 6-Benzothiazolol, 5,7-dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-; C11593; L001447; 5,7-Dimethyl-2-methylamino-4-pyridin-3-ylmethyl-benzothiazol-6-ol; 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole
DM35KZG	CP	Eisai Co Ltd
DM35KZG	DT	Small molecular drug
DM35KZG	PC	443292
DM35KZG	MW	299.4
DM35KZG	FM	C16H17N3OS
DM35KZG	IC	InChI=1S/C16H17N3OS/c1-9-12(7-11-5-4-6-18-8-11)13-15(10(2)14(9)20)21-16(17-3)19-13/h4-6,8,20H,7H2,1-3H3,(H,17,19)
DM35KZG	CS	CC1=C(C2=C(C(=C1O)C)SC(=N2)NC)CC3=CN=CC=C3
DM35KZG	IK	IONAQTGMWFXHIX-UHFFFAOYSA-N
DM35KZG	IU	5,7-dimethyl-2-(methylamino)-4-(pyridin-3-ylmethyl)-1,3-benzothiazol-6-ol
DM35KZG	CA	CAS 145096-30-6
DM35KZG	CB	CHEBI:4732
DM35KZG	DE	Thrombosis

DMWF95G	ID	DMWF95G
DMWF95G	DN	E-3620
DMWF95G	HS	Discontinued in Phase 2
DMWF95G	CP	Eisai Co Ltd
DMWF95G	PC	11281359
DMWF95G	MW	412.3
DMWF95G	FM	C20H27Cl2N3O2
DMWF95G	IC	InChI=1S/C20H26ClN3O2.ClH/c1-4-5-12(2)26-19-11-18(22)17(21)10-16(19)20(25)23-13-8-14-6-7-15(9-13)24(14)3;/h10-15H,6-9,22H2,1-3H3,(H,23,25);1H/t12-,13?,14-,15+;/m0./s1
DMWF95G	CS	CC#C[C@H](C)OC1=CC(=C(C=C1C(=O)NC2C[C@H]3CC[C@@H](C2)N3C)Cl)N.Cl
DMWF95G	IK	GMHMNKHDLXRRGF-LZMJSSQSSA-N
DMWF95G	IU	4-amino-5-chloro-N-[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-[(2S)-pent-3-yn-2-yl]oxybenzamide;hydrochloride
DMWF95G	CA	CAS 151213-86-4
DMWF95G	DE	Gastric motility disorder

DMWIA56	ID	DMWIA56
DMWIA56	DN	E-4021
DMWIA56	HS	Discontinued in Phase 2
DMWIA56	SN	E-4021; CHEMBL25616; E4021
DMWIA56	CP	Eisai Co Ltd
DMWIA56	DT	Small molecular drug
DMWIA56	PC	23665864
DMWIA56	MW	462.9
DMWIA56	FM	C22H20ClN4NaO4
DMWIA56	IC	InChI=1S/C22H21ClN4O4.Na/c23-15-2-3-17-16(10-15)20(24-11-13-1-4-18-19(9-13)31-12-30-18)26-22(25-17)27-7-5-14(6-8-27)21(28)29;/h1-4,9-10,14H,5-8,11-12H2,(H,28,29)(H,24,25,26);/q;+1/p-1
DMWIA56	CS	C1CN(CCC1C(=O)[O-])C2=NC3=C(C=C(C=C3)Cl)C(=N2)NCC4=CC5=C(C=C4)OCO5.[Na+]
DMWIA56	IK	LDYABEHPDDRNAF-UHFFFAOYSA-M
DMWIA56	IU	sodium;1-[4-(1,3-benzodioxol-5-ylmethylamino)-6-chloroquinazolin-2-yl]piperidine-4-carboxylate
DMWIA56	DE	Cardiovascular disease

DMU872N	ID	DMU872N
DMU872N	DN	E-4031
DMU872N	HS	Discontinued in Phase 2
DMU872N	SN	E-4031; E 4031; 113558-89-7; CHEMBL327980; CHEBI:34732; 2-Methyl-6-(2-(4-(4-methylsulfonylamino)benzoylpiperidin-1-yl)ethyl)pyridine; Methanesulfonamide, N-(4-((1-(2-(6-methyl-2-pyridinyl)ethyl)-4-piperidinyl)carbonyl)phenyl)-; N-(4-((1-(2-(6-Methyl-2-pyridinyl)ethyl)-4-piperidinyl)carbonyl)phenyl)methanesulfonamide; N-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide; E4031; N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide; Tocris-1808; AC1Q6VTV
DMU872N	DT	Small molecular drug
DMU872N	PC	3087190
DMU872N	MW	474.4
DMU872N	FM	C21H29Cl2N3O3S
DMU872N	IC	InChI=1S/C21H27N3O3S.2ClH/c1-16-4-3-5-19(22-16)12-15-24-13-10-18(11-14-24)21(25)17-6-8-20(9-7-17)23-28(2,26)27;;/h3-9,18,23H,10-15H2,1-2H3;2*1H
DMU872N	CS	CC1=NC(=CC=C1)CCN2CCC(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C.Cl.Cl
DMU872N	IK	ZQBNWMFBOSOOLX-UHFFFAOYSA-N
DMU872N	IU	N-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide;dihydrochloride
DMU872N	CA	CAS 113559-13-0
DMU872N	DE	Cardiac arrhythmias

DM2G7IP	ID	DM2G7IP
DM2G7IP	DN	E-4177
DM2G7IP	HS	Discontinued in Phase 2
DM2G7IP	SN	E-4177; 135070-05-2; CHEMBL71162; 2-[4-[(8-cyclopropyl-5-methyl-2,7,9-triazabicyclo[4.3.0]nona-1,3,5,7-tetraen-9-yl)methyl]phenyl]benzoic acid; E4177; VWWMGPCUZVOLLK-UHFFFAOYSA-N; ACMC-20mvn4; AC1L2ZXE; E 4177; SCHEMBL685515; CTK0I0030; DTXSID50159239; BDBM50049212; 3-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine; L004970; 4''-(2-Cyclopropyl-7-methyl-imidazo[4,5-b]pyridin-3-ylmethyl)-biphenyl-2-carboxylic acid
DM2G7IP	CP	Eisai Co Ltd
DM2G7IP	DT	Small molecular drug
DM2G7IP	PC	131857
DM2G7IP	MW	383.4
DM2G7IP	FM	C24H21N3O2
DM2G7IP	IC	InChI=1S/C24H21N3O2/c1-15-12-13-25-23-21(15)26-22(18-10-11-18)27(23)14-16-6-8-17(9-7-16)19-4-2-3-5-20(19)24(28)29/h2-9,12-13,18H,10-11,14H2,1H3,(H,28,29)
DM2G7IP	CS	CC1=C2C(=NC=C1)N(C(=N2)C3CC3)CC4=CC=C(C=C4)C5=CC=CC=C5C(=O)O
DM2G7IP	IK	VWWMGPCUZVOLLK-UHFFFAOYSA-N
DM2G7IP	IU	2-[4-[(2-cyclopropyl-7-methylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]benzoic acid
DM2G7IP	CA	CAS 135070-05-2
DM2G7IP	DE	Hypertension

DM562BM	ID	DM562BM
DM562BM	DN	E-5324
DM562BM	HS	Discontinued in Phase 2
DM562BM	SN	E-5324; 141799-76-0; CHEMBL47095; E 5324; E5324; AC1L30VJ; SCHEMBL692563; DTXSID20161824; BDBM50047557; n-Butyl-N'-(2-(3-(5-ethyl-4-phenyl-1H-imidazol-1-yl)propoxy)-6-methylphenyl)urea; HY-19183; CS-0014924; Urea, N-butyl-N'-(2-(3-(5-ethyl-4-phenyl-1H-imidazol-1-yl)propoxy)-6-methylphenyl)-; 1-butyl-3-[2-[3-(5-ethyl-4-phenylimidazol-1-yl)propoxy]-6-methylphenyl]urea
DM562BM	CP	Eisai Co Ltd
DM562BM	DT	Small molecular drug
DM562BM	PC	132377
DM562BM	MW	434.6
DM562BM	FM	C26H34N4O2
DM562BM	IC	InChI=1S/C26H34N4O2/c1-4-6-16-27-26(31)29-24-20(3)12-10-15-23(24)32-18-11-17-30-19-28-25(22(30)5-2)21-13-8-7-9-14-21/h7-10,12-15,19H,4-6,11,16-18H2,1-3H3,(H2,27,29,31)
DM562BM	CS	CCCCNC(=O)NC1=C(C=CC=C1OCCCN2C=NC(=C2CC)C3=CC=CC=C3)C
DM562BM	IK	NQZTZGNLFLQHKG-UHFFFAOYSA-N
DM562BM	IU	1-butyl-3-[2-[3-(5-ethyl-4-phenylimidazol-1-yl)propoxy]-6-methylphenyl]urea
DM562BM	CA	CAS 141799-76-0
DM562BM	DE	Hyperlipidaemia

DMBFYWU	ID	DMBFYWU
DMBFYWU	DN	E-5531
DMBFYWU	HS	Discontinued in Phase 2
DMBFYWU	SN	E-1-O-phosphate; 2-Deoxy-6-O-[2-deoxy-3-O-[3(R)-[5(Z)-dodecenoyloxy]decyl]-6-O-methyl-2-(3-oxotetradecanamido)-4-O-phosphono-beta-D-glucopyranosyl]-3-O-[3(R)-hydroxydecyl]-2-(3-oxotetradecanamido)-alpha-D-glucopyranos
DMBFYWU	PC	6442269
DMBFYWU	MW	1455.8
DMBFYWU	FM	C73H136N2O22P2
DMBFYWU	IC	InChI=1S/C73H136N2O22P2/c1-7-12-17-22-25-28-31-36-40-45-58(77)53-63(79)74-66-70(90-51-49-57(76)44-39-34-20-15-10-4)68(82)61(94-73(66)97-99(86,87)88)56-92-72-67(75-64(80)54-59(78)46-41-37-32-29-26-23-18-13-8-2)71(69(96-98(83,84)85)62(95-72)55-89-6)91-52-50-60(47-42-35-21-16-11-5)93-65(81)48-43-38-33-30-27-24-19-14-9-3/h30,33,57,60-62,66-73,76,82H,7-29,31-32,34-56H2,1-6H3,(H,74,79)(H,75,80)(H2,83,84,85)(H2,86,87,88)/b33-30-/t57-,60-,61-,62-,66-,67-,68-,69-,70-,71-,72-,73-/m1/s1
DMBFYWU	CS	CCCCCCCCCCCC(=O)CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC)OP(=O)(O)O)OCC[C@@H](CCCCCCC)OC(=O)CCC/C=C\\CCCCCC)NC(=O)CC(=O)CCCCCCCCCCC)O)OCC[C@@H](CCCCCCC)O
DMBFYWU	IK	GDODKYPBSZCPOO-XFMGTHRKSA-N
DMBFYWU	IU	[(3R)-1-[(2R,3R,4R,5S,6R)-2-[[(2R,3S,4R,5R,6R)-3-hydroxy-4-[(3R)-3-hydroxydecoxy]-5-(3-oxotetradecanoylamino)-6-phosphonooxyoxan-2-yl]methoxy]-6-(methoxymethyl)-3-(3-oxotetradecanoylamino)-5-phosphonooxyoxan-4-yl]oxydecan-3-yl] (Z)-dodec-5-enoate
DMBFYWU	CA	CAS 162679-36-9
DMBFYWU	DE	Sepsis

DM296V7	ID	DM296V7
DM296V7	DN	E-6080
DM296V7	HS	Discontinued in Phase 2
DM296V7	SN	E-6080; E 6080; 120164-49-0; E6080; AC1L2UXT; SCHEMBL3053845; DTXSID10152706; 6-Hydroxy-2-(4-sulfamoylbenzylamine)-4,5,7-trimethylbenzothiazole hcl; 6-hydroxy-2-(4-sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazole hydrochloride; Benzenesulfonamide, 4-(((6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)amino)methyl)-, monohydrochloride; 4-[[(6-hydroxy-4,5,7-trimethyl-1,3-benzothiazol-2-yl)amino]methyl]benzenesulfonamide hydrochloride
DM296V7	CP	Eisai Co Ltd
DM296V7	DT	Small molecular drug
DM296V7	PC	129064
DM296V7	MW	413.9
DM296V7	FM	C17H20ClN3O3S2
DM296V7	IC	InChI=1S/C17H19N3O3S2.ClH/c1-9-10(2)15(21)11(3)16-14(9)20-17(24-16)19-8-12-4-6-13(7-5-12)25(18,22)23;/h4-7,21H,8H2,1-3H3,(H,19,20)(H2,18,22,23);1H
DM296V7	CS	CC1=C(C(=C(C2=C1N=C(S2)NCC3=CC=C(C=C3)S(=O)(=O)N)C)O)C.Cl
DM296V7	IK	WLODMDLNSQYBMG-UHFFFAOYSA-N
DM296V7	IU	4-[[(6-hydroxy-4,5,7-trimethyl-1,3-benzothiazol-2-yl)amino]methyl]benzenesulfonamide;hydrochloride
DM296V7	CA	CAS 120164-49-0
DM296V7	DE	Asthma

DMUW6QX	ID	DMUW6QX
DMUW6QX	DN	E-6123
DMUW6QX	HS	Discontinued in Phase 2
DMUW6QX	SN	E 6123; 131614-02-3; E-6123; BRN 4280434; E- 6123; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolol(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-7,8,9,10-tetrahydro-1,4-dimethyl-, (S)-; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 7,8,9,10-tetrahydro-6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-1,4-dimethyl-, (S)-; AC1MHYY4; CHEMBL114014; DTXSID20157146; API0009208; HY-10164; LS-134356
DMUW6QX	DT	Small molecular drug
DMUW6QX	PC	3035214
DMUW6QX	MW	452
DMUW6QX	FM	C23H22ClN5OS
DMUW6QX	IC	InChI=1S/C23H22ClN5OS/c1-12-21-27-26-13(2)29(21)23-19(20(25-12)15-5-3-4-6-17(15)24)16-9-10-28(11-18(16)31-23)22(30)14-7-8-14/h3-6,12,14H,7-11H2,1-2H3/t12-/m0/s1
DMUW6QX	CS	C[C@H]1C2=NN=C(N2C3=C(C4=C(S3)CN(CC4)C(=O)C5CC5)C(=N1)C6=CC=CC=C6Cl)C
DMUW6QX	IK	JEQVYSUCZLYBRQ-LBPRGKRZSA-N
DMUW6QX	IU	[(7S)-9-(2-chlorophenyl)-3,7-dimethyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaen-14-yl]-cyclopropylmethanone
DMUW6QX	CA	CAS 131614-02-3
DMUW6QX	DE	Asthma

DMC28Y4	ID	DMC28Y4
DMC28Y4	DN	EAA-090
DMC28Y4	HS	Discontinued in Phase 2
DMC28Y4	SN	Perzinfotel; EAA 090; Way 126090; WAY-126090; Perzinfotel (USAN/INN); 2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-6-yl)ethylphosphonic acid
DMC28Y4	CP	Wyeth
DMC28Y4	DT	Small molecular drug
DMC28Y4	PC	6918236
DMC28Y4	MW	260.18
DMC28Y4	FM	C9H13N2O5P
DMC28Y4	IC	InChI=1S/C9H13N2O5P/c12-8-6-7(9(8)13)11(3-1-2-10-6)4-5-17(14,15)16/h10H,1-5H2,(H2,14,15,16)
DMC28Y4	CS	C1CNC2=C(C(=O)C2=O)N(C1)CCP(=O)(O)O
DMC28Y4	IK	BDABGOLMYNHHTR-UHFFFAOYSA-N
DMC28Y4	IU	2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethylphosphonic acid
DMC28Y4	CA	CAS 144912-63-0
DMC28Y4	DE	Diabetic neuropathy

DMJ2ZFV	ID	DMJ2ZFV
DMJ2ZFV	DN	EB-1053
DMJ2ZFV	HS	Discontinued in Phase 2
DMJ2ZFV	SN	EB 1053; 125946-92-1; Disodium 1-hydroxy-3-(1-pyrrolidinyl)propylidene-1,1-bisphosphonate; AC1L2Y2V; SCHEMBL3067217; DTXSID20154998; Phosphonic acid, (1-hydroxy-3-(1-pyrrolidinyl)propylidene)bis-, disodium salt; disodium (1-hydroxy-1-phosphonato-3-pyrrolidin-1-ylpropyl)phosphonic acid
DMJ2ZFV	CP	LEO Pharma A/S
DMJ2ZFV	DT	Small molecular drug
DMJ2ZFV	PC	130822
DMJ2ZFV	MW	289.16
DMJ2ZFV	FM	C7H17NO7P2
DMJ2ZFV	IC	InChI=1S/C7H17NO7P2/c9-7(16(10,11)12,17(13,14)15)3-6-8-4-1-2-5-8/h9H,1-6H2,(H2,10,11,12)(H2,13,14,15)
DMJ2ZFV	CS	C1CCN(C1)CCC(O)(P(=O)(O)O)P(=O)(O)O
DMJ2ZFV	IK	PMXAPNNYCFBALB-UHFFFAOYSA-N
DMJ2ZFV	IU	(1-hydroxy-1-phosphono-3-pyrrolidin-1-ylpropyl)phosphonic acid
DMJ2ZFV	CA	CAS 125946-92-1
DMJ2ZFV	DE	Osteoporosis

DMRPUEC	ID	DMRPUEC
DMRPUEC	DN	EDONENTAN HYDRATE
DMRPUEC	HS	Discontinued in Phase 2
DMRPUEC	SN	Edonentan hydrate < USAN; BMS-207940 (anhydrous); BMS-207940-02; N-[2'-(4,5-Dimethylisoxazol-3-ylsulfamoyl)-4-(2-oxazolyl)biphenyl-2-ylmethyl]-N,3,3-trimethylbutyramide hydrate
DMRPUEC	PC	156689
DMRPUEC	MW	554.7
DMRPUEC	FM	C28H34N4O6S
DMRPUEC	IC	InChI=1S/C28H32N4O5S.H2O/c1-18-19(2)37-30-26(18)31-38(34,35)24-10-8-7-9-23(24)22-12-11-20(27-29-13-14-36-27)15-21(22)17-32(6)25(33)16-28(3,4)5;/h7-15H,16-17H2,1-6H3,(H,30,31);1H2
DMRPUEC	CS	CC1=C(ON=C1NS(=O)(=O)C2=CC=CC=C2C3=C(C=C(C=C3)C4=NC=CO4)CN(C)C(=O)CC(C)(C)C)C.O
DMRPUEC	IK	VRUJTPHFVRXEPB-UHFFFAOYSA-N
DMRPUEC	IU	N-[[2-[2-[(4,5-dimethyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]-5-(1,3-oxazol-2-yl)phenyl]methyl]-N,3,3-trimethylbutanamide;hydrate
DMRPUEC	CA	CAS 264609-13-4
DMRPUEC	DE	Pulmonary arterial hypertension

DMZXRF2	ID	DMZXRF2
DMZXRF2	DN	Eflucimibe
DMZXRF2	HS	Discontinued in Phase 2
DMZXRF2	SN	F-12511
DMZXRF2	CP	Pierre Fabre SA
DMZXRF2	DT	Small molecular drug
DMZXRF2	PC	9804740
DMZXRF2	MW	469.7
DMZXRF2	FM	C29H43NO2S
DMZXRF2	IC	InChI=1S/C29H43NO2S/c1-5-6-7-8-9-10-11-12-13-17-20-33-28(25-18-15-14-16-19-25)29(32)30-26-21-22(2)27(31)24(4)23(26)3/h14-16,18-19,21,28,31H,5-13,17,20H2,1-4H3,(H,30,32)/t28-/m0/s1
DMZXRF2	CS	CCCCCCCCCCCCS[C@@H](C1=CC=CC=C1)C(=O)NC2=C(C(=C(C(=C2)C)O)C)C
DMZXRF2	IK	ZXEIEKDGPVTZLD-NDEPHWFRSA-N
DMZXRF2	IU	(2S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide
DMZXRF2	CA	CAS 202340-45-2
DMZXRF2	DE	Hyperlipidaemia

DM7TM91	ID	DM7TM91
DM7TM91	DN	ELAROFIBAN
DM7TM91	HS	Discontinued in Phase 2
DM7TM91	SN	Elarofiban; RWJ-53308; UNII-T9YH5NSL8U; T9YH5NSL8U; 198958-88-2; CHEMBL87728; (3s)-3-[({(3r)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]-3-(pyridin-3-yl)propanoic acid; Elarofiban [INN]; AC1L50BO; AC1Q5T2G; SCHEMBL1650115; CTK4E2665; BDBM50104600; AKOS027326865; (S)-beta-((R)-1-(3-(4-Piperidyl)propionyl)nipecotamido)-3-pyridinepropionic acid; (S)-3-{[(R)-1-(3-Piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-3-pyridin-3-yl-propionic acid
DM7TM91	DT	Small molecular drug
DM7TM91	PC	216230
DM7TM91	MW	416.5
DM7TM91	FM	C22H32N4O4
DM7TM91	IC	InChI=1S/C22H32N4O4/c27-20(6-5-16-7-10-23-11-8-16)26-12-2-4-18(15-26)22(30)25-19(13-21(28)29)17-3-1-9-24-14-17/h1,3,9,14,16,18-19,23H,2,4-8,10-13,15H2,(H,25,30)(H,28,29)/t18-,19+/m1/s1
DM7TM91	CS	C1C[C@H](CN(C1)C(=O)CCC2CCNCC2)C(=O)N[C@@H](CC(=O)O)C3=CN=CC=C3
DM7TM91	IK	ABNXKGFLZFSILK-MOPGFXCFSA-N
DM7TM91	IU	(3S)-3-[[(3R)-1-(3-piperidin-4-ylpropanoyl)piperidine-3-carbonyl]amino]-3-pyridin-3-ylpropanoic acid
DM7TM91	CA	CAS 198958-88-2
DM7TM91	DE	Thrombosis

DM0B23J	ID	DM0B23J
DM0B23J	DN	ELB-139
DM0B23J	HS	Discontinued in Phase 2
DM0B23J	CP	Elbion AG; 4AZA Bioscience
DM0B23J	TC	Psychiatric
DM0B23J	DT	Small molecular drug
DM0B23J	PC	11277418
DM0B23J	MW	277.75
DM0B23J	FM	C14H16ClN3O
DM0B23J	IC	InChI=1S/C14H16ClN3O/c15-11-4-6-12(7-5-11)18-10-13(16-14(18)19)17-8-2-1-3-9-17/h4-7H,1-3,8-10H2
DM0B23J	CS	C1CCN(CC1)C2=NC(=O)N(C2)C3=CC=C(C=C3)Cl
DM0B23J	IK	YGXIELIREXEJQN-UHFFFAOYSA-N
DM0B23J	IU	3-(4-chlorophenyl)-5-piperidin-1-yl-4H-imidazol-2-one
DM0B23J	CA	CAS 188116-08-7
DM0B23J	DE	Anxiety disorder

DMBCYRG	ID	DMBCYRG
DMBCYRG	DN	ELINAFIDE MESILATE
DMBCYRG	HS	Discontinued in Phase 2
DMBCYRG	SN	LU-79553; Elinafide mesilate; 2,2'-Propane-1,3-diylbis(iminoethylene)bis(2,3-dihydro-1H-benz[de]isoquinoline-1,3-dione)dimethanesulfonate
DMBCYRG	DE	Solid tumour/cancer

DM0XF8J	ID	DM0XF8J
DM0XF8J	DN	Elisartan potassium
DM0XF8J	HS	Discontinued in Phase 2
DM0XF8J	SN	HN-65021
DM0XF8J	CP	GE Healthcare
DM0XF8J	DT	Small molecular drug
DM0XF8J	PC	23663417
DM0XF8J	MW	591.1
DM0XF8J	FM	C27H28ClKN6O5
DM0XF8J	IC	InChI=1S/C27H28ClN6O5.K/c1-4-6-11-22-29-24(28)23(26(35)38-17(3)39-27(36)37-5-2)34(22)16-18-12-14-19(15-13-18)20-9-7-8-10-21(20)25-30-32-33-31-25;/h7-10,12-15,17H,4-6,11,16H2,1-3H3;/q-1;+1
DM0XF8J	CS	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)C(=O)OC(C)OC(=O)OCC)Cl.[K+]
DM0XF8J	IK	LWBGIHXLGBYBNG-UHFFFAOYSA-N
DM0XF8J	IU	potassium;1-ethoxycarbonyloxyethyl 2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
DM0XF8J	CA	CAS 154568-18-0
DM0XF8J	DE	Hypertension

DMM5WQL	ID	DMM5WQL
DMM5WQL	DN	Elvucitabine
DMM5WQL	HS	Discontinued in Phase 2
DMM5WQL	SN	Elvucitabine; beta-L-Fd4C; 181785-84-2; UNII-M09BUF90C0; L-F-D4C; L-D4FC; ACH-126443; ACH-126,443; M09BUF90C0; 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one; ACH 126443; 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1h)-one; L-Fd4C; Elvucitabine [USAN:INN]; 4-amino-5-fluoro-1-((2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1H)-one; ACH 126,443; AC1LAJSF; AC1Q4HKY; Elvucitabine (USAN/INN); CHEMBL38700; ZINC7048; SCHEMBL1649928; CTK4D7977
DMM5WQL	DT	Small molecular drug
DMM5WQL	PC	469717
DMM5WQL	MW	227.19
DMM5WQL	FM	C9H10FN3O3
DMM5WQL	IC	InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m1/s1
DMM5WQL	CS	C1=C[C@H](O[C@H]1CO)N2C=C(C(=NC2=O)N)F
DMM5WQL	IK	HSBKFSPNDWWPSL-VDTYLAMSSA-N
DMM5WQL	IU	4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
DMM5WQL	CA	CAS 181785-84-2
DMM5WQL	DE	Human immunodeficiency virus infection

DM1EOC3	ID	DM1EOC3
DM1EOC3	DN	Elzasonan hydrochloride
DM1EOC3	HS	Discontinued in Phase 2
DM1EOC3	SN	Elzasonan HCl; CP 448187-01; Elzasonan hydrochloride (USAN); (2E)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one hydrochloride; (2Z)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one hydrochloride
DM1EOC3	CP	Pfizer
DM1EOC3	DT	Small molecular drug
DM1EOC3	PC	6506051
DM1EOC3	MW	484.9
DM1EOC3	FM	C22H24Cl3N3OS
DM1EOC3	IC	InChI=1S/C22H23Cl2N3OS.ClH/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17;/h2-7,14-15H,8-13H2,1H3;1H/b21-14-;
DM1EOC3	CS	CN1CCN(CC1)C2=CC=CC=C2/C=C\\3/C(=O)N(CCS3)C4=CC(=C(C=C4)Cl)Cl.Cl
DM1EOC3	IK	NMTRXBJYASHMND-UXTSPRGOSA-N
DM1EOC3	IU	(2Z)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one;hydrochloride
DM1EOC3	CA	CAS 220322-05-4
DM1EOC3	DE	Mood disorder

DM0RXCK	ID	DM0RXCK
DM0RXCK	DN	Emapunil
DM0RXCK	HS	Discontinued in Phase 2
DM0RXCK	SN	Emapunil; 226954-04-7; AC-5216; AC 5216; UNII-OG837L732J; XBD173; CHEMBL513922; XBD-173; OG837L732J; N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenyl-7H-purin-9(8H)-yl)acetamide; AC5216; Emapunil [INN]; N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenylpurin-9-yl)acetamide; N-Benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenyl-7,8-dihydro-9H-purin-9-yl)acetamide; Emapunil(AC-5216); AC1O5FL9; GTPL8704; SCHEMBL4757030; CTK4E9959; SYN5155; DTXSID40177220; AOB3568; MolPort-005-943-292; NBMBIEOUVBHEBM-UHFFFAOYSA-N; ZINC602486; EX-A1040; BCP14398; BDBM50266889
DM0RXCK	CP	Dainippon; Novartis
DM0RXCK	DT	Small molecular drug
DM0RXCK	PC	6433109
DM0RXCK	MW	401.5
DM0RXCK	FM	C23H23N5O2
DM0RXCK	IC	InChI=1S/C23H23N5O2/c1-3-27(15-17-10-6-4-7-11-17)20(29)16-28-22-19(26(2)23(28)30)14-24-21(25-22)18-12-8-5-9-13-18/h4-14H,3,15-16H2,1-2H3
DM0RXCK	CS	CCN(CC1=CC=CC=C1)C(=O)CN2C3=NC(=NC=C3N(C2=O)C)C4=CC=CC=C4
DM0RXCK	IK	NBMBIEOUVBHEBM-UHFFFAOYSA-N
DM0RXCK	IU	N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenylpurin-9-yl)acetamide
DM0RXCK	CA	CAS 226954-04-7
DM0RXCK	DE	Anxiety disorder

DMML2PX	ID	DMML2PX
DMML2PX	DN	EML-336
DMML2PX	HS	Discontinued in Phase 2
DMML2PX	SN	CRE-16336; EML-16336; ONO-5816
DMML2PX	CP	Merck Sante SA
DMML2PX	DE	Type-2 diabetes

DMIQRJW	ID	DMIQRJW
DMIQRJW	DN	EMR-62203
DMIQRJW	HS	Discontinued in Phase 2
DMIQRJW	SN	EMR-6203; PDE 5 inhibitor, Merck KGaA
DMIQRJW	CP	Merck KGaA
DMIQRJW	DE	Erectile dysfunction

DMDAS5B	ID	DMDAS5B
DMDAS5B	DN	Enalkiren
DMDAS5B	HS	Discontinued in Phase 2
DMDAS5B	SN	ENALKIREN; Enalquireno; 113082-98-7; Abbott-64662; Enalkirenum [INN-Latin]; Enalkirene [INN-French]; Enalquireno [INN-Spanish]; Abbott 64662; Enalkiren [USAN:INN]; UNII-0U7YZ42Z47; A-64662; CHEMBL300337; CHEBI:4787; 0U7YZ42Z47; A 64662; (alphaS)-alpha-((alphaS)-alpha-(3-Amino-3-methylbutyramido)-p-methoxyhydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)imidazole-4-propionamide; Enalkirenum; Enalkirene
DMDAS5B	DT	Small molecular drug
DMDAS5B	PC	60594
DMDAS5B	MW	656.9
DMDAS5B	FM	C35H56N6O6
DMDAS5B	IC	InChI=1S/C35H56N6O6/c1-22(2)15-30(42)32(44)27(16-23-9-7-6-8-10-23)40-34(46)29(18-25-20-37-21-38-25)41-33(45)28(39-31(43)19-35(3,4)36)17-24-11-13-26(47-5)14-12-24/h11-14,20-23,27-30,32,42,44H,6-10,15-19,36H2,1-5H3,(H,37,38)(H,39,43)(H,40,46)(H,41,45)/t27-,28-,29-,30-,32+/m0/s1
DMDAS5B	CS	CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CC=C(C=C3)OC)NC(=O)CC(C)(C)N)O)O
DMDAS5B	IK	KQXVERRYBYGQJZ-WRPDIKACSA-N
DMDAS5B	IU	3-amino-N-[(2S)-1-[[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-methylbutanamide
DMDAS5B	CA	CAS 113082-98-7
DMDAS5B	CB	CHEBI:4787
DMDAS5B	DE	Glaucoma/ocular hypertension

DME7OCX	ID	DME7OCX
DME7OCX	DN	ENIPORIDE
DME7OCX	HS	Discontinued in Phase 2
DME7OCX	SN	Eniporide; 176644-21-6; N-(diaminomethylene)-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzamide; N-Carbamimidoyl-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzamide; EMD-96785; UNII-7IGF9182QU; CHEMBL64360; 7IGF9182QU; Eniporide [INN]; C14H16N4O3S; N-(Diaminomethylene); AC1O5FJV; Eniporide(EMD96785); SCHEMBL6619621; CTK8C4436; UADMBZFZZOBWBB-UHFFFAOYSA-N; MolPort-035-675-643; KS-00000IZ2; EX-A1476; CZC25146; BCP09780; BDBM50058715; ANW-71932; 9260AA; ZINC13555902; AKOS024262733; AKOS016007503; DS-16493; AK-61121; AJ-64172
DME7OCX	DT	Small molecular drug
DME7OCX	PC	6433092
DME7OCX	MW	320.37
DME7OCX	FM	C14H16N4O3S
DME7OCX	IC	InChI=1S/C14H16N4O3S/c1-9-7-11(18-5-3-4-6-18)12(22(2,20)21)8-10(9)13(19)17-14(15)16/h3-8H,1-2H3,(H4,15,16,17,19)
DME7OCX	CS	CC1=CC(=C(C=C1C(=O)N=C(N)N)S(=O)(=O)C)N2C=CC=C2
DME7OCX	IK	UADMBZFZZOBWBB-UHFFFAOYSA-N
DME7OCX	IU	N-(diaminomethylidene)-2-methyl-5-methylsulfonyl-4-pyrrol-1-ylbenzamide
DME7OCX	CA	CAS 176644-21-6
DME7OCX	DE	Cardiac arrhythmias

DM05F1Z	ID	DM05F1Z
DM05F1Z	DN	ENRASENTAN
DM05F1Z	HS	Discontinued in Phase 2
DM05F1Z	SN	SB-217242; Enrasentan; (+)-(1S,2R,3S)-3-[2-(2-Hydroxyethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid
DM05F1Z	CP	GlaxoSmithKline
DM05F1Z	DT	Small molecular drug
DM05F1Z	PC	178103
DM05F1Z	MW	506.5
DM05F1Z	FM	C29H30O8
DM05F1Z	IC	InChI=1S/C29H30O8/c1-3-11-34-19-6-7-20-22(14-19)27(21-8-5-18(33-2)15-24(21)35-12-10-30)28(29(31)32)26(20)17-4-9-23-25(13-17)37-16-36-23/h4-9,13-15,26-28,30H,3,10-12,16H2,1-2H3,(H,31,32)/t26-,27+,28+/m0/s1
DM05F1Z	CS	CCCOC1=CC2=C(C=C1)[C@@H]([C@H]([C@@H]2C3=C(C=C(C=C3)OC)OCCO)C(=O)O)C4=CC5=C(C=C4)OCO5
DM05F1Z	IK	GLCKXJLCYIJMRB-UPRLRBBYSA-N
DM05F1Z	IU	(1S,2R,3S)-1-(1,3-benzodioxol-5-yl)-3-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-5-propoxy-2,3-dihydro-1H-indene-2-carboxylic acid
DM05F1Z	CA	CAS 167256-08-8
DM05F1Z	CB	CHEBI:156258
DM05F1Z	DE	Pulmonary arterial hypertension

DMG3R14	ID	DMG3R14
DMG3R14	DN	EP-2104R
DMG3R14	HS	Discontinued in Phase 2
DMG3R14	SN	Gadolinium labeled fibrin-binding peptide, EPIX Medical
DMG3R14	CP	Epix Pharmaceutical
DMG3R14	DE	Cardiovascular disease

DMZKBU9	ID	DMZKBU9
DMZKBU9	DN	EPC-K1
DMZKBU9	HS	Discontinued in Phase 2
DMZKBU9	SN	CHX-3107; Phosphoric acid 2-L-ascorbyl D,L-alpha-tocopheryl diester potassium salt; 2-O-[Hydroxy[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydro-2H-1-benzopyran-6-yloxy]phosphoryl]-L-ascorbic acid potassium salt
DMZKBU9	DT	Small molecular drug
DMZKBU9	PC	54715165
DMZKBU9	MW	706.9
DMZKBU9	FM	C35H56KO10P
DMZKBU9	IC	InChI=1S/C35H57O10P.K/c1-21(2)12-9-13-22(3)14-10-15-23(4)16-11-18-35(8)19-17-27-26(7)30(24(5)25(6)31(27)43-35)44-46(40,41)45-33-29(38)32(28(37)20-36)42-34(33)39;/h21-23,28,32,36-38H,9-20H2,1-8H3,(H,40,41);/q;+1/p-1/t22-,23-,28+,32-,35-;/m1./s1
DMZKBU9	CS	CC1=C(C(=C(C2=C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OP(=O)([O-])OC3=C([C@H](OC3=O)[C@H](CO)O)O)C.[K+]
DMZKBU9	IK	VIHIKSJKXIMMLV-FZTHFCCHSA-M
DMZKBU9	IU	potassium;[(2R)-2-[(1S)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2H-furan-4-yl] [(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] phosphate
DMZKBU9	CA	CAS 127061-56-7
DMZKBU9	DE	Nerve injury

DMJ52FZ	ID	DMJ52FZ
DMJ52FZ	DN	EPI-2010
DMJ52FZ	HS	Discontinued in Phase 2
DMJ52FZ	TC	Antisense
DMJ52FZ	DT	Antisense drug
DMJ52FZ	DE	Asthma

DM1WGUT	ID	DM1WGUT
DM1WGUT	DN	Epothilone D
DM1WGUT	HS	Discontinued in Phase 2
DM1WGUT	SN	Epothilone D; Desoxyepothilone b; (-)-Desoxyepothilone B; 189453-10-9; KOS-862; 12,13-Desoxyepothilone B; KOS 862; UNII-T0358E0YUF; (-)-Epothilone D; NSC-703147; T0358E0YUF; CHEBI:29579; 12,13-Deoxyepothilone B; NSC 703147; Epo D; EPD; (4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)oxacyclohexadec-13-ene-2,6-dione; (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-methyl-2-(2-methylthiazol-4-yl)vinyl]-1-oxacyclohexadec-13-ene-2,6-dione; dEpoB
DM1WGUT	DT	Small molecular drug
DM1WGUT	PC	447865
DM1WGUT	MW	491.7
DM1WGUT	FM	C27H41NO5S
DM1WGUT	IC	InChI=1S/C27H41NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h11,13,15,17,19,22-23,25,29,31H,8-10,12,14H2,1-7H3/b16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1
DM1WGUT	CS	C[C@H]1CCC/C(=C\\C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C2=CSC(=N2)C)/C)/C
DM1WGUT	IK	XOZIUKBZLSUILX-GIQCAXHBSA-N
DM1WGUT	IU	(4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
DM1WGUT	CA	CAS 189453-10-9
DM1WGUT	CB	CHEBI:29579
DM1WGUT	DE	Breast cancer

DM6NTAS	ID	DM6NTAS
DM6NTAS	DN	ERA-923
DM6NTAS	HS	Discontinued in Phase 2
DM6NTAS	SN	Pipendoxifene; UNII-TPC5Q8496G; 198480-55-6; CHEMBL44426; TPC5Q8496G; Pipendoxifene [INN]; ERA 923; AC1O5FKF; SCHEMBL134583; JICOGKJOQXTAIP-UHFFFAOYSA-N; ZINC602799; BDBM50099587; AKOS030631784; DB05414; 2-(4-hydroxyphenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-1H-indol-5-ol; US8815934, No 97; US8815934, No 107; 2-(p-Hydroxyphenyl)-3-methyl-1-(p-(2-piperidinoethoxy)benzyl)indol-5-ol; 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol
DM6NTAS	CP	Wyeth
DM6NTAS	DT	Small molecular drug
DM6NTAS	PC	6433099
DM6NTAS	MW	456.6
DM6NTAS	FM	C29H32N2O3
DM6NTAS	IC	InChI=1S/C29H32N2O3/c1-21-27-19-25(33)11-14-28(27)31(29(21)23-7-9-24(32)10-8-23)20-22-5-12-26(13-6-22)34-18-17-30-15-3-2-4-16-30/h5-14,19,32-33H,2-4,15-18,20H2,1H3
DM6NTAS	CS	CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
DM6NTAS	IK	JICOGKJOQXTAIP-UHFFFAOYSA-N
DM6NTAS	IU	2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol
DM6NTAS	CA	CAS 198480-55-6
DM6NTAS	DE	Breast cancer

DM03I7V	ID	DM03I7V
DM03I7V	DN	ERBULOZOLE
DM03I7V	HS	Discontinued in Phase 2
DM03I7V	SN	Erbulozole < Rec INN; R-55104; Ethyl rac-cis-p-[[[2-(Imidazol-1-ylmethyl)-2-(p-methoxyphenyl)-1,3-dioxolan-4-yl]methyl]thio]carbanilate; Rac-cis-[4-[[2-((1H-Imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methylthio]phenyl]carbamic acid ethyl ester
DM03I7V	DT	Small molecular drug
DM03I7V	PC	9934372
DM03I7V	MW	469.6
DM03I7V	FM	C24H27N3O5S
DM03I7V	IC	InChI=1S/C24H27N3O5S/c1-3-30-23(28)26-19-6-10-22(11-7-19)33-15-21-14-31-24(32-21,16-27-13-12-25-17-27)18-4-8-20(29-2)9-5-18/h4-13,17,21H,3,14-16H2,1-2H3,(H,26,28)/t21-,24+/m1/s1
DM03I7V	CS	CCOC(=O)NC1=CC=C(C=C1)SC[C@H]2CO[C@](O2)(CN3C=CN=C3)C4=CC=C(C=C4)OC
DM03I7V	IK	KLEPCGBEXOCIGS-QPPBQGQZSA-N
DM03I7V	IU	ethyl N-[4-[[(2R,4R)-2-(imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate
DM03I7V	CA	CAS 124784-31-2
DM03I7V	DE	Solid tumour/cancer

DMYR5OX	ID	DMYR5OX
DMYR5OX	DN	EREMOMYCIN
DMYR5OX	HS	Discontinued in Phase 2
DMYR5OX	SN	Hexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid; (4"R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-19-dechlorovancomycin; Etrahydroxy-6-(N2-methylleucylamido)-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-1H,22H-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno[1,6,9]oxadiazacyclo; 22-(3-Amino-2,3,6-trideoxy-3-C-methyl-L-arabinohexopyranosyloxy)-44-[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-L-arabinohexopyranosyl)-beta-D-glucopyranosyloxy]-3-(carbamoylmethyl)-10-chloro-7,28,30,32-t; 3-(Carbamoylmethyl)-10-chloro-7,28,30,32-tetrahydroxy-6-(N2-methylleucylamido)-2,5,24,38,39-pentaoxo-22-(4-epi-vancosaminyloxy)-44-[2-O-(4-epi-vancosaminyl)-beta-D-glucopyranosyloxy]-2,3,4,5,6,7,23,24; 35-dimetheno[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid
DMYR5OX	PC	122131
DMYR5OX	MW	1558
DMYR5OX	FM	C73H89ClN10O26
DMYR5OX	IC	InChI=1S/C73H89ClN10O26/c1-27(2)16-39(78-7)64(95)83-54-56(90)32-11-15-43(38(74)18-32)106-45-20-33-19-44(60(45)110-71-61(58(92)57(91)46(26-85)107-71)109-49-25-73(6,77)63(94)29(4)104-49)105-35-12-8-30(9-13-35)59(108-48-24-72(5,76)62(93)28(3)103-48)55-69(100)82-53(70(101)102)37-21-34(86)22-42(88)50(37)36-17-31(10-14-41(36)87)51(66(97)84-55)81-67(98)52(33)80-65(96)40(23-47(75)89)79-68(54)99/h8-15,17-22,27-29,39-40,46,48-49,51-59,61-63,71,78,85-88,90-94H,16,23-26,76-77H2,1-7H3,(H2,75,89)(H,79,99)(H,80,96)(H,81,98)(H,82,100)(H,83,95)(H,84,97)(H,101,102)/t28-,29-,39+,40-,46+,48-,49-,51+,52+,53-,54+,55-,56+,57+,58-,59+,61+,62-,63-,71-,72-,73-/m0/s1
DMYR5OX	CS	C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC=C(O4)C=C1)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)N)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
DMYR5OX	IK	UECIPBUIMXSXEI-BNSVOVDNSA-N
DMYR5OX	IU	(1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-48-[(2S,3R,4S,5S,6R)-3-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-15-chloro-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3(50),4,6(49),8(48),9,11,14,16,29(45),30,32,34(39),35,37,46-pentadecaene-40-carboxylic acid
DMYR5OX	CA	CAS 110865-90-2
DMYR5OX	DE	Bacterial infection

DMTUHWM	ID	DMTUHWM
DMTUHWM	DN	Esreboxetine
DMTUHWM	HS	Discontinued in Phase 2
DMTUHWM	SN	(S,S)-reboxetine; 98819-76-2; UNII-L8S50ZY490; PNU-165442G; L8S50ZY490; Norebox; Davedax; Solvex; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; (2S)-2-[(S)-2-ethoxyphenoxy(phenyl)methyl]morpholine; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenyl-methyl]morpholine; Prolift; Esreboxetine [USAN:INN]; Esreboxetine (USAN/INN); (S,S)-( )-Reboxetine; S-Reboxetine; PNU 165442g; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate; Tocris-1982; NCGC00025335-01; SCHEMBL34534; Reboxetine mesylate; (+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine; (S,S)-Reboxetine
DMTUHWM	CP	Pfizer
DMTUHWM	DT	Small molecular drug
DMTUHWM	PC	65856
DMTUHWM	MW	313.4
DMTUHWM	FM	C19H23NO3
DMTUHWM	IC	InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1
DMTUHWM	CS	CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3
DMTUHWM	IK	CBQGYUDMJHNJBX-OALUTQOASA-N
DMTUHWM	IU	(2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
DMTUHWM	CA	CAS 98819-76-2
DMTUHWM	CB	CHEBI:125535
DMTUHWM	DE	Fibromyalgia

DM1DHOT	ID	DM1DHOT
DM1DHOT	DN	Esuprone
DM1DHOT	HS	Discontinued in Phase 2
DM1DHOT	SN	LU-43839; Esuprone; 7-Hydroxy-3,4-dimethyl-2H-1-benzopyran-2-one ethanesulfonate; 7-Hydroxy-3,4-dimethylcoumarin ethanesulfonate
DM1DHOT	DT	Small molecular drug
DM1DHOT	PC	65827
DM1DHOT	MW	282.31
DM1DHOT	FM	C13H14O5S
DM1DHOT	IC	InChI=1S/C13H14O5S/c1-4-19(15,16)18-10-5-6-11-8(2)9(3)13(14)17-12(11)7-10/h5-7H,4H2,1-3H3
DM1DHOT	CS	CCS(=O)(=O)OC1=CC2=C(C=C1)C(=C(C(=O)O2)C)C
DM1DHOT	IK	CHDGAVDQRSPBTA-UHFFFAOYSA-N
DM1DHOT	IU	(3,4-dimethyl-2-oxochromen-7-yl) ethanesulfonate
DM1DHOT	CA	CAS 91406-11-0
DM1DHOT	DE	Major depressive disorder

DMEGMA2	ID	DMEGMA2
DMEGMA2	DN	ETH615
DMEGMA2	HS	Discontinued in Phase 2
DMEGMA2	SN	Eth 615; Eth-615; 133430-69-0; CHEMBL310584; AC1L2ZIP; SCHEMBL7749388; DTXSID50158106; BDBM50006807; 4-({(3-Fluoro-benzyl)-[4-(quinolin-2-ylmethoxy)-phenyl]-amino}-methyl)-benzoic acid; Benzoic acid, 4-((((3-fluorophenyl)methyl)(4-(2-quinolinylmethoxy)phenyl)amino)methyl)-; 4-[[N-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid
DMEGMA2	DT	Small molecular drug
DMEGMA2	PC	131627
DMEGMA2	MW	492.5
DMEGMA2	FM	C31H25FN2O3
DMEGMA2	IC	InChI=1S/C31H25FN2O3/c32-26-6-3-4-23(18-26)20-34(19-22-8-10-25(11-9-22)31(35)36)28-14-16-29(17-15-28)37-21-27-13-12-24-5-1-2-7-30(24)33-27/h1-18H,19-21H2,(H,35,36)
DMEGMA2	CS	C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)N(CC4=CC=C(C=C4)C(=O)O)CC5=CC(=CC=C5)F
DMEGMA2	IK	KRCUWCAUDKTMPB-UHFFFAOYSA-N
DMEGMA2	IU	4-[[N-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid
DMEGMA2	CA	CAS 133430-69-0
DMEGMA2	DE	Dermatitis

DMRB23N	ID	DMRB23N
DMRB23N	DN	ETRX-101
DMRB23N	HS	Discontinued in Phase 2
DMRB23N	SN	MARstem; Angiotensin analog, Essential; Angiotensin analog, Maret
DMRB23N	CP	Maret Pharmaceuticals Inc
DMRB23N	DE	Anemia

DMOYMGV	ID	DMOYMGV
DMOYMGV	DN	EVT-101
DMOYMGV	HS	Discontinued in Phase 2
DMOYMGV	SN	EVT-101; UNII-B55T45AA8F; B55T45AA8F; CHEMBL3545349
DMOYMGV	CP	Roche
DMOYMGV	TC	Neurodegenerative
DMOYMGV	DT	Small molecular drug
DMOYMGV	PC	72941990
DMOYMGV	MW	391.2
DMOYMGV	FM	C16H15Cl2F3N4
DMOYMGV	IC	InChI=1S/C16H13F3N4.2ClH/c1-10-20-4-5-23(10)9-13-6-12(8-21-22-13)11-2-3-15(17)14(7-11)16(18)19;;/h2-8,16H,9H2,1H3;2*1H
DMOYMGV	CS	CC1=NC=CN1CC2=NN=CC(=C2)C3=CC(=C(C=C3)F)C(F)F.Cl.Cl
DMOYMGV	IK	OJBLXSPBJMGZDN-UHFFFAOYSA-N
DMOYMGV	IU	5-[3-(difluoromethyl)-4-fluorophenyl]-3-[(2-methylimidazol-1-yl)methyl]pyridazine;dihydrochloride
DMOYMGV	CA	CAS 1189088-41-2
DMOYMGV	DE	Neuropathic pain

DMGJMQH	ID	DMGJMQH
DMGJMQH	DN	Examorelin
DMGJMQH	HS	Discontinued in Phase 2
DMGJMQH	SN	Hexarelin; EP-23905; MF-6003
DMGJMQH	CP	Mediolanum Farmaceutici SpA
DMGJMQH	DT	Small molecular drug
DMGJMQH	PC	6918297
DMGJMQH	MW	887
DMGJMQH	FM	C47H58N12O6
DMGJMQH	IC	InChI=1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)/t28-,35-,38-,39+,40-,41+/m0/s1
DMGJMQH	CS	CC1=C(C2=CC=CC=C2N1)C[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CN=CN6)N
DMGJMQH	IK	RVWNMGKSNGWLOL-GIIHNPQRSA-N
DMGJMQH	IU	(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
DMGJMQH	CA	CAS 140703-51-1
DMGJMQH	DE	Growth hormone deficiency

DMTUPZ2	ID	DMTUPZ2
DMTUPZ2	DN	Ezlopitant
DMTUPZ2	HS	Discontinued in Phase 2
DMTUPZ2	SN	UNII-3L098A8MPY; 147116-64-1; CJ-11974; CHEMBL515966; 3L098A8MPY; Ezlopitant [USAN:INN]; Ezlopitant (USAN/INN); (2s,3s)-2-(diphenylmethyl)-n-(5-isopropyl-2-methoxybenzyl)quinuclidin-3-amine; AC1L4NQ6; SCHEMBL383011; AC1Q573W; SCHEMBL9069731; GTPL5751; BDBM50262567; CJ11974; (2S,3S)-2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[222]octan-3-amine; CJ 11974; CJ-11, 974; D04122; 2beta-(Diphenylmethyl)-3beta-(2-methoxy-5-isopropylbenzylamino)-1beta,4beta-ethanopiperidine;  Ezlopitant (USAN/INN); 2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[222]octan-3-amine; CJ 11,974-01
DMTUPZ2	CP	Pfizer
DMTUPZ2	DT	Small molecular drug
DMTUPZ2	PC	188927
DMTUPZ2	MW	454.6
DMTUPZ2	FM	C31H38N2O
DMTUPZ2	IC	InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1
DMTUPZ2	CS	CC(C)C1=CC(=C(C=C1)OC)CN[C@@H]2[C@@H](N3CCC2CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
DMTUPZ2	IK	XPNMCDYOYIKVGB-CONSDPRKSA-N
DMTUPZ2	IU	(2S,3S)-2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
DMTUPZ2	CA	CAS 147116-64-1
DMTUPZ2	DE	Irritable bowel syndrome; Vomiting; Pain

DMMSFK0	ID	DMMSFK0
DMMSFK0	DN	Fabesetron
DMMSFK0	HS	Discontinued in Phase 2
DMMSFK0	SN	FK-1052
DMMSFK0	CP	Fujisawa Pharmaceutical Co Ltd
DMMSFK0	DT	Small molecular drug
DMMSFK0	PC	208947
DMMSFK0	MW	293.4
DMMSFK0	FM	C18H19N3O
DMMSFK0	IC	InChI=1S/C18H19N3O/c1-11-14-5-3-4-6-17(14)21-16(11)8-7-13(18(21)22)9-15-12(2)19-10-20-15/h3-6,10,13H,7-9H2,1-2H3,(H,19,20)/t13-/m1/s1
DMMSFK0	CS	CC1=C2CC[C@@H](C(=O)N2C3=CC=CC=C13)CC4=C(NC=N4)C
DMMSFK0	IK	AEKQMJRJRAHOAP-CYBMUJFWSA-N
DMMSFK0	IU	(7R)-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]-8,9-dihydro-7H-pyrido[1,2-a]indol-6-one
DMMSFK0	CA	CAS 129300-27-2
DMMSFK0	CB	CHEBI:31588
DMMSFK0	DE	Irritable bowel syndrome

DM8UC0K	ID	DM8UC0K
DM8UC0K	DN	FANDOFLOXACIN HYDROCHLORIDE
DM8UC0K	HS	Discontinued in Phase 2
DM8UC0K	SN	DW-116; Fandofloxacin hydrochloride; 6-Fluoro-1-(5-fluoropyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
DM8UC0K	DT	Small molecular drug
DM8UC0K	PC	178086
DM8UC0K	MW	436.8
DM8UC0K	FM	C20H19ClF2N4O3
DM8UC0K	IC	InChI=1S/C20H18F2N4O3.ClH/c1-24-4-6-25(7-5-24)17-9-16-13(8-15(17)22)19(27)14(20(28)29)11-26(16)18-3-2-12(21)10-23-18;/h2-3,8-11H,4-7H2,1H3,(H,28,29);1H
DM8UC0K	CS	CN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=NC=C(C=C4)F)F.Cl
DM8UC0K	IK	UPCHGBDAUCFDMW-UHFFFAOYSA-N
DM8UC0K	IU	6-fluoro-1-(5-fluoropyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride
DM8UC0K	CA	CAS 164150-85-0
DM8UC0K	DE	Bacterial infection

DMRU1KT	ID	DMRU1KT
DMRU1KT	DN	Fasidotril
DMRU1KT	HS	Discontinued in Phase 2
DMRU1KT	SN	Fasidotril; Alatriopril; 135038-57-2; AC1NSKG8; SCHEMBL49006; GTPL6501; CHEMBL325695; ZINC1545064; BP-1137; BP1.137; phenylmethyl (2S)-2-[[(2S)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate; benzyl (2S)-2-[[(2S)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate
DMRU1KT	DT	Small molecular drug
DMRU1KT	PC	5311337
DMRU1KT	MW	443.5
DMRU1KT	FM	C23H25NO6S
DMRU1KT	IC	InChI=1S/C23H25NO6S/c1-15(23(27)28-12-17-6-4-3-5-7-17)24-22(26)19(13-31-16(2)25)10-18-8-9-20-21(11-18)30-14-29-20/h3-9,11,15,19H,10,12-14H2,1-2H3,(H,24,26)/t15-,19+/m0/s1
DMRU1KT	CS	C[C@@H](C(=O)OCC1=CC=CC=C1)NC(=O)[C@H](CC2=CC3=C(C=C2)OCO3)CSC(=O)C
DMRU1KT	IK	KKBIUAUSZKGNOA-HNAYVOBHSA-N
DMRU1KT	IU	benzyl (2S)-2-[[(2S)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate
DMRU1KT	CA	CAS 135038-57-2
DMRU1KT	DE	Hypotension

DMT2Z1L	ID	DMT2Z1L
DMT2Z1L	DN	FCE-22716
DMT2Z1L	HS	Discontinued in Phase 2
DMT2Z1L	SN	1-(6-Methylergolin-8beta-yl)hydantoin; 1-[[(8beta)-6-Methylergolin-8-yl]methyl]-2,4-imidazolidinedione; 7beta-(2,4,-Dioxo-1-imidazolidinylmethyl)-9-methyl-2,5balpha,6,7,8,9,9abeta,10-octahydroindolo[4,3a,3-f,g]quinoline; 8beta-(2,4-Dioxo-1-imidazolidinylmethyl)-6-methylergoline
DMT2Z1L	DT	Small molecular drug
DMT2Z1L	PC	125720
DMT2Z1L	MW	338.4
DMT2Z1L	FM	C19H22N4O2
DMT2Z1L	IC	InChI=1S/C19H22N4O2/c1-22-8-11(9-23-10-17(24)21-19(23)25)5-14-13-3-2-4-15-18(13)12(7-20-15)6-16(14)22/h2-4,7,11,14,16,20H,5-6,8-10H2,1H3,(H,21,24,25)/t11-,14-,16-/m1/s1
DMT2Z1L	CS	CN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CN5CC(=O)NC5=O
DMT2Z1L	IK	VXIHQTMCLKWCBN-DJSGYFEHSA-N
DMT2Z1L	IU	1-[[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]methyl]imidazolidine-2,4-dione
DMT2Z1L	CA	CAS 95688-34-9
DMT2Z1L	DE	Hypertension

DMTQLIJ	ID	DMTQLIJ
DMTQLIJ	DN	FCP-3P1
DMTQLIJ	HS	Discontinued in Phase 2
DMTQLIJ	SN	CardioRex; Antihyperlipidemic, Forbes Medi-Tech
DMTQLIJ	CP	Forbes Medi-Tech Inc
DMTQLIJ	DT	Small molecular drug
DMTQLIJ	PC	60496
DMTQLIJ	MW	567.1
DMTQLIJ	FM	C26H31ClN2O8S
DMTQLIJ	IC	InChI=1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)
DMTQLIJ	CS	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.C1=CC=C(C=C1)S(=O)(=O)O
DMTQLIJ	IK	ZPBWCRDSRKPIDG-UHFFFAOYSA-N
DMTQLIJ	IU	benzenesulfonic acid;3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMTQLIJ	CA	CAS 111470-99-6
DMTQLIJ	CB	CHEBI:2669
DMTQLIJ	DE	Arteriosclerosis

DMJRF5G	ID	DMJRF5G
DMJRF5G	DN	FIDUXOSIN HYDROCHLORIDE
DMJRF5G	HS	Discontinued in Phase 2
DMJRF5G	SN	ABT-980; Fiduxosin hydrochloride < USAN; A-185980.1; (3aR,9bR)-cis-3-[4-(9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenylpyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride
DMJRF5G	DT	Small molecular drug
DMJRF5G	PC	172306
DMJRF5G	MW	592.1
DMJRF5G	FM	C30H30ClN5O4S
DMJRF5G	IC	InChI=1S/C30H29N5O4S.ClH/c1-38-22-10-7-11-23-24(22)20-16-34(15-19(20)17-39-23)12-5-6-13-35-29(36)27-25(33-30(35)37)26-28(40-27)31-14-21(32-26)18-8-3-2-4-9-18;/h2-4,7-11,14,19-20H,5-6,12-13,15-17H2,1H3,(H,33,37);1H/t19-,20-;/m1./s1
DMJRF5G	CS	COC1=CC=CC2=C1[C@@H]3CN(C[C@@H]3CO2)CCCCN4C(=O)C5=C(C6=NC(=CN=C6S5)C7=CC=CC=C7)NC4=O.Cl
DMJRF5G	IK	OFPMGRPQOZABPO-GZJHNZOKSA-N
DMJRF5G	IU	5-[4-[(3aR,9bR)-9-methoxy-3,3a,4,9b-tetrahydro-1H-chromeno[3,4-c]pyrrol-2-yl]butyl]-12-phenyl-8-thia-3,5,10,13-tetrazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11-tetraene-4,6-dione;hydrochloride
DMJRF5G	CA	CAS 208992-74-9
DMJRF5G	DE	Prostate disease

DMGD5QN	ID	DMGD5QN
DMGD5QN	DN	Filaminast
DMGD5QN	HS	Discontinued in Phase 2
DMGD5QN	SN	FILAMINAST; Way-pda-641; UNII-CDD69JC61J; 141184-34-1; CDD69JC61J; (1E)-1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]ETHANONE O-(AMINOCARBONYL)OXIME; FIL; Filaminast [USAN:INN]; Filaminast (USAN/INN); SCHEMBL73844; SCHEMBL73843; CHEMBL590754; BDBM14771; 1-(3-(Cyclopentyloxy)-4-methoxyphenyl)ethanone-(E)-O-(aminocarbonyl)oxime; DB02660; D04185; 3'-(Cyclopentyloxy)-4'-methoxyacetophenone (E)-O-carbamoyloxime; [1-(3-cyclopentyloxy-4-methoxy-phenyl)ethylideneamino] carbamate; (E)-{1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethylidene}amino 
DMGD5QN	DT	Small molecular drug
DMGD5QN	PC	9578243
DMGD5QN	MW	292.33
DMGD5QN	FM	C15H20N2O4
DMGD5QN	IC	InChI=1S/C15H20N2O4/c1-10(17-21-15(16)18)11-7-8-13(19-2)14(9-11)20-12-5-3-4-6-12/h7-9,12H,3-6H2,1-2H3,(H2,16,18)/b17-10+
DMGD5QN	CS	C/C(=N\\OC(=O)N)/C1=CC(=C(C=C1)OC)OC2CCCC2
DMGD5QN	IK	STTRYQAGHGJXJJ-LICLKQGHSA-N
DMGD5QN	IU	[(E)-1-(3-cyclopentyloxy-4-methoxyphenyl)ethylideneamino] carbamate
DMGD5QN	CA	CAS 141184-34-1
DMGD5QN	DE	Chronic obstructive pulmonary disease

DM06SC9	ID	DM06SC9
DM06SC9	DN	FINROZOLE
DM06SC9	HS	Discontinued in Phase 2
DM06SC9	SN	MPV-2213ad; Finrozole; Rac-(R*,S*)-4-[3-(4-Fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzonitrile
DM06SC9	DT	Small molecular drug
DM06SC9	PC	6918277
DM06SC9	MW	322.3
DM06SC9	FM	C18H15FN4O
DM06SC9	IC	InChI=1S/C18H15FN4O/c19-16-7-3-13(4-8-16)9-17(24)18(23-12-21-11-22-23)15-5-1-14(10-20)2-6-15/h1-8,11-12,17-18,24H,9H2/t17-,18+/m0/s1
DM06SC9	CS	C1=CC(=CC=C1C[C@@H]([C@@H](C2=CC=C(C=C2)C#N)N3C=NC=N3)O)F
DM06SC9	IK	SLJZVZKQYSKYNV-ZWKOTPCHSA-N
DM06SC9	IU	4-[(1R,2S)-3-(4-fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzonitrile
DM06SC9	CA	CAS 160146-17-8
DM06SC9	DE	Prostate disease

DMCINOE	ID	DMCINOE
DMCINOE	DN	FK-011
DMCINOE	HS	Discontinued in Phase 2
DMCINOE	CP	Fujisawa Pharmaceutical Co Ltd
DMCINOE	DE	Asthma

DM1JUS0	ID	DM1JUS0
DM1JUS0	DN	FK-224
DM1JUS0	HS	Discontinued in Phase 2
DM1JUS0	SN	FR-115224
DM1JUS0	CP	Fujisawa Pharmaceutical Co Ltd
DM1JUS0	DT	Small molecular drug
DM1JUS0	PC	6437864
DM1JUS0	MW	1041.2
DM1JUS0	FM	C54H72N8O13
DM1JUS0	IC	InChI=1S/C54H72N8O13/c1-7-8-10-17-36-18-13-14-19-37(36)22-25-45(67)60-47-33(5)75-54(74)42(30-63)59-49(69)41(29-44(55)66)58-52(72)46(32(4)64)61-50(70)40(27-34-15-11-9-12-16-34)56-48(68)39(26-31(2)3)57-51(71)43(62(6)53(47)73)28-35-20-23-38(65)24-21-35/h9,11-16,18-21,23-24,28,31-33,39-42,46-47,63-65H,7-8,10,17,22,25-27,29-30H2,1-6H3,(H2,55,66)(H,56,68)(H,57,71)(H,58,72)(H,59,69)(H,60,67)(H,61,70)/b43-28-
DM1JUS0	CS	CCCCCC1=CC=CC=C1CCC(=O)NC2C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)/C(=C/C3=CC=C(C=C3)O)/N(C2=O)C)CC(C)C)CC4=CC=CC=C4)C(C)O)CC(=O)N)CO)C
DM1JUS0	IK	BEWCDVTWUFJSSM-MBMPTNJISA-N
DM1JUS0	IU	N-[(18Z)-6-(2-amino-2-oxoethyl)-12-benzyl-9-(1-hydroxyethyl)-3-(hydroxymethyl)-18-[(4-hydroxyphenyl)methylidene]-19,22-dimethyl-15-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1-oxa-4,7,10,13,16,19-hexazacyclodocos-21-yl]-3-(2-pentylphenyl)propanamide
DM1JUS0	CA	CAS 125787-94-2
DM1JUS0	DE	Asthma

DMHIUGT	ID	DMHIUGT
DMHIUGT	DN	FK-352
DMHIUGT	HS	Discontinued in Phase 2
DMHIUGT	SN	FK-325B; FK-352B
DMHIUGT	CP	Fujisawa Pharmaceutical Co Ltd
DMHIUGT	DT	Small molecular drug
DMHIUGT	PC	6442241
DMHIUGT	MW	389.4
DMHIUGT	FM	C23H23N3O3
DMHIUGT	IC	InChI=1S/C23H23N3O3/c27-21(25-14-6-4-10-18(25)16-22(28)29)13-12-19-20-11-5-7-15-26(20)24-23(19)17-8-2-1-3-9-17/h1-3,5,7-9,11-13,15,18H,4,6,10,14,16H2,(H,28,29)/b13-12+/t18-/m1/s1
DMHIUGT	CS	C1CCN([C@H](C1)CC(=O)O)C(=O)/C=C/C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DMHIUGT	IK	UWTYIJJJSYDUQM-QFQMRYFISA-N
DMHIUGT	IU	2-[(2R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)prop-2-enoyl]piperidin-2-yl]acetic acid
DMHIUGT	CA	CAS 143881-08-7
DMHIUGT	DE	Hypertension

DMH3DXY	ID	DMH3DXY
DMH3DXY	DN	FK-453
DMH3DXY	HS	Discontinued in Phase 2
DMH3DXY	SN	FK-453; FK 453; CHEMBL440115; 121524-18-3; (+)-(R)-((E)-3-(2-Phenylpyrazolo(1,5-a)pyridin-3-yl)acryloyl)-2-piperidineethanol; (R-(E))-1-(1-Oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-2-propenyl)-2-piperidineethanol; C23H25N3O2; 2-Piperidineethanol, 1-(1-oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-2-propenyl)-, (R-(E))-; (E)-1-[(2R)-2-(2-hydroxyethyl)piperidin-1-yl]-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)prop-2-en-1-one; AC1O5QYH; SCHEMBL2826910; GTPL5606; SCHEMBL3074643; FK453; ZINC1486608; FR-453; BDBM50079652; FR113453
DMH3DXY	DT	Small molecular drug
DMH3DXY	PC	6439091
DMH3DXY	MW	375.5
DMH3DXY	FM	C23H25N3O2
DMH3DXY	IC	InChI=1S/C23H25N3O2/c27-17-14-19-10-4-6-15-25(19)22(28)13-12-20-21-11-5-7-16-26(21)24-23(20)18-8-2-1-3-9-18/h1-3,5,7-9,11-13,16,19,27H,4,6,10,14-15,17H2/b13-12+/t19-/m1/s1
DMH3DXY	CS	C1CCN([C@H](C1)CCO)C(=O)/C=C/C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DMH3DXY	IK	OPLOPFHUHFGKMJ-JXOMPUQVSA-N
DMH3DXY	IU	(E)-1-[(2R)-2-(2-hydroxyethyl)piperidin-1-yl]-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)prop-2-en-1-one
DMH3DXY	CA	CAS 121524-18-3
DMH3DXY	DE	Renal failure

DMR2FPO	ID	DMR2FPO
DMR2FPO	DN	FK-584
DMR2FPO	HS	Discontinued in Phase 2
DMR2FPO	SN	4,4-Diphenylcyclopentenylamine hydrochloride; 2-Cyclopenten-1-amine, 4,4-diphenyl-, hydrochloride; 4,4-diphenyl-2-cyclopentenylamine; FK 584; 56740-43-3; AC1L57OZ; LS-58284; 4,4-diphenylcyclopent-2-en-1-amine hydrochloride
DMR2FPO	CP	Fujisawa Pharmaceutical Co Ltd
DMR2FPO	DT	Small molecular drug
DMR2FPO	PC	9947991
DMR2FPO	MW	291.4
DMR2FPO	FM	C21H25N
DMR2FPO	IC	InChI=1S/C21H25N/c1-20(2,3)22-19-14-15-21(16-19,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-15,19,22H,16H2,1-3H3/t19-/m1/s1
DMR2FPO	CS	CC(C)(C)N[C@H]1CC(C=C1)(C2=CC=CC=C2)C3=CC=CC=C3
DMR2FPO	IK	QMTVTICJRCJOFZ-LJQANCHMSA-N
DMR2FPO	IU	(1S)-N-tert-butyl-4,4-diphenylcyclopent-2-en-1-amine
DMR2FPO	DE	Central and peripheral nervous disease

DMQ3O4C	ID	DMQ3O4C
DMQ3O4C	DN	FK-633
DMQ3O4C	HS	Discontinued in Phase 2
DMQ3O4C	SN	FK-633; Dryofragin; ((4-(4-Amidinophenoxy)butanoyl)aspartyl)valine; 147865-49-4; CHEMBL34901; FK 633; AC1L31M0; SCHEMBL1710973; DTXSID00163821; ZINC3918297; BDBM50092111; LS-161294; FR-144633; 4-(4-amidinophenoxy)butanoyl-aspartyl-valine; 2-{2-[4-(4-Carbamimidoyl-phenoxy)-butyrylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (FK633); (2S)-2-[[(2S)-2-[4-(4-carbamimidoylphenoxy)butanoylamino]-4-hydroxy-4-oxobutanoyl]amino]-3-methylbutanoic acid
DMQ3O4C	DT	Small molecular drug
DMQ3O4C	PC	132814
DMQ3O4C	MW	436.5
DMQ3O4C	FM	C20H28N4O7
DMQ3O4C	IC	InChI=1S/C20H28N4O7/c1-11(2)17(20(29)30)24-19(28)14(10-16(26)27)23-15(25)4-3-9-31-13-7-5-12(6-8-13)18(21)22/h5-8,11,14,17H,3-4,9-10H2,1-2H3,(H3,21,22)(H,23,25)(H,24,28)(H,26,27)(H,29,30)/t14-,17-/m0/s1
DMQ3O4C	CS	CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCOC1=CC=C(C=C1)C(=N)N
DMQ3O4C	IK	JFCXCBBSUORTNS-YOEHRIQHSA-N
DMQ3O4C	IU	(2S)-2-[[(2S)-2-[4-(4-carbamimidoylphenoxy)butanoylamino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid
DMQ3O4C	CA	CAS 147865-49-4
DMQ3O4C	DE	Artery stenosis

DMFGJNW	ID	DMFGJNW
DMFGJNW	DN	FK-664
DMFGJNW	HS	Discontinued in Phase 2
DMFGJNW	SN	1-Ethyl-6-(3,4-dimethoxyphenyl)-3-methyl-4-(2,4,6-trimethylphenylimino)-1,2,3,4-tetrahydropyrimidin-2-one
DMFGJNW	DT	Small molecular drug
DMFGJNW	PC	146868
DMFGJNW	MW	407.5
DMFGJNW	FM	C24H29N3O3
DMFGJNW	IC	InChI=1S/C24H29N3O3/c1-8-27-19(18-9-10-20(29-6)21(13-18)30-7)14-22(26(5)24(27)28)25-23-16(3)11-15(2)12-17(23)4/h9-14H,8H2,1-7H3
DMFGJNW	CS	CCN1C(=CC(=NC2=C(C=C(C=C2C)C)C)N(C1=O)C)C3=CC(=C(C=C3)OC)OC
DMFGJNW	IK	OYGHXRNCHYRYRR-UHFFFAOYSA-N
DMFGJNW	IU	6-(3,4-dimethoxyphenyl)-1-ethyl-3-methyl-4-(2,4,6-trimethylphenyl)iminopyrimidin-2-one
DMFGJNW	CA	CAS 94936-90-0
DMFGJNW	DE	Cardiac disease

DM524J3	ID	DM524J3
DM524J3	DN	FK-706
DM524J3	HS	Discontinued in Phase 2
DM524J3	DT	Small molecular drug
DM524J3	PC	23690296
DM524J3	MW	592.5
DM524J3	FM	C26H32F3N4NaO7
DM524J3	IC	InChI=1S/C26H33F3N4O7.Na/c1-13(2)19(21(36)26(27,28)29)31-24(39)17-6-5-11-33(17)25(40)20(14(3)4)32-23(38)16-9-7-15(8-10-16)22(37)30-12-18(34)35;/h7-10,13-14,17,19-20H,5-6,11-12H2,1-4H3,(H,30,37)(H,31,39)(H,32,38)(H,34,35);/q;+1/p-1/t17-,19?,20-;/m0./s1
DM524J3	CS	CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC(C(C)C)C(=O)C(F)(F)F)NC(=O)C2=CC=C(C=C2)C(=O)NCC(=O)[O-].[Na+]
DM524J3	IK	DNTYCMNNMGACPR-JSAITXCESA-M
DM524J3	IU	sodium;2-[[4-[[(2S)-3-methyl-1-oxo-1-[(2S)-2-[(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl]pyrrolidin-1-yl]butan-2-yl]carbamoyl]benzoyl]amino]acetate
DM524J3	DE	Pulmonary emphysema

DM7TLF6	ID	DM7TLF6
DM7TLF6	DN	FK-739
DM7TLF6	HS	Discontinued in Phase 2
DM7TLF6	SN	FR-130739
DM7TLF6	CP	Fujisawa Pharmaceutical Co Ltd
DM7TLF6	DT	Small molecular drug
DM7TLF6	PC	23668568
DM7TLF6	MW	431.5
DM7TLF6	FM	C24H22N7Na
DM7TLF6	IC	InChI=1S/C24H22N7.Na/c1-2-3-10-22-26-21-9-6-15-25-24(21)31(22)16-17-11-13-18(14-12-17)19-7-4-5-8-20(19)23-27-29-30-28-23;/h4-9,11-15H,2-3,10,16H2,1H3;/q-1;+1
DM7TLF6	CS	CCCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=N[N-]5)N=CC=C2.[Na+]
DM7TLF6	IK	YFABTKCYNBWJHS-UHFFFAOYSA-N
DM7TLF6	IU	sodium;2-butyl-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine
DM7TLF6	CA	CAS 136042-19-8
DM7TLF6	DE	Hypertension

DMH6QAI	ID	DMH6QAI
DMH6QAI	DN	FK778
DMH6QAI	HS	Discontinued in Phase 2
DMH6QAI	SN	Manitimus; FK 778; HMR 1715; MNA 715; Malononitrilamide 715; X 920715; FK-778; HMR-1715; MNA-715; MNA-X 920715; Malononitrilamide-715; X-920715; (2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxohept-6-ynenitrile; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynoic acid
DMH6QAI	CP	Astellas
DMH6QAI	DT	Small molecular drug
DMH6QAI	PC	70683056
DMH6QAI	MW	309.24
DMH6QAI	FM	C14H10F3N3O2
DMH6QAI	IC	InChI=1S/C14H10F3N3O2/c15-14(16,17)9-3-5-10(6-4-9)20-13(22)11(8-19)12(21)2-1-7-18/h3-6,21H,1-2H2,(H,20,22)/b12-11-
DMH6QAI	CS	C1=CC(=CC=C1C(F)(F)F)NC(=O)/C(=C(/CCC#N)\\O)/C#N
DMH6QAI	IK	OQUXVPJVBSENGK-QXMHVHEDSA-N
DMH6QAI	IU	(Z)-2,5-dicyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]pent-2-enamide
DMH6QAI	DE	Kidney/heart transplant rejection

DMS87T9	ID	DMS87T9
DMS87T9	DN	FK-838
DMS87T9	HS	Discontinued in Phase 2
DMS87T9	SN	FK-838; FK 838; 131185-37-0; CHEMBL292917; 6-Oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-1(6H)-pyridazinebutyric acid; 6-Oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-1(6H)-pyridazineboutanoic acid; C21H18N4O3; 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-; 1(6H)-Pyridazinebutanoicacid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-; FKJPZJACCBMNKZ-UHFFFAOYSA-N; AC1MHZMV; ACMC-20mtz5; SCHEMBL2641189; CTK0H8748; DTXSID60156936; BDBM50079654; AKOS030617923; LS-172794; L004106
DMS87T9	DT	Small molecular drug
DMS87T9	PC	3035594
DMS87T9	MW	374.4
DMS87T9	FM	C21H18N4O3
DMS87T9	IC	InChI=1S/C21H18N4O3/c26-18-12-11-16(22-25(18)14-6-10-19(27)28)20-17-9-4-5-13-24(17)23-21(20)15-7-2-1-3-8-15/h1-5,7-9,11-13H,6,10,14H2,(H,27,28)
DMS87T9	CS	C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=NN(C(=O)C=C4)CCCC(=O)O
DMS87T9	IK	FKJPZJACCBMNKZ-UHFFFAOYSA-N
DMS87T9	IU	4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-1-yl]butanoic acid
DMS87T9	CA	CAS 131185-37-0
DMS87T9	DE	Hypertension

DM457B1	ID	DM457B1
DM457B1	DN	FK-888
DM457B1	HS	Discontinued in Phase 2
DM457B1	SN	FK 888; FK-888; 138449-07-7; FK888; N(2)-(4-Hydroxy-1-(1-methyl-1H-indol-3-yl)carbonyl-L-prolyl)-N-methyl-N-phenylmethyl-3-(2-naphthyl)-L-alaninamide; SCHEMBL8079679; GTPL2114; AC1L332N; CHEMBL1416993; CHEBI:93463; DTXSID70160680; MolPort-023-276-412; HMS3269A13; ZINC3926844; PDSP2_000648; AKOS024457076; NCGC00159560-01; L-Alaninamide, trans-4-hydroxy-1-((1-methyl-1H-indol-3-yl)carbonyl)-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-; LS-193299; BRD-K83508485-001-01-9
DM457B1	CP	Fujisawa Pharmaceutical Co Ltd
DM457B1	DT	Small molecular drug
DM457B1	PC	107967
DM457B1	MW	588.7
DM457B1	FM	C36H36N4O4
DM457B1	IC	InChI=1S/C36H36N4O4/c1-38-23-30(29-14-8-9-15-32(29)38)35(43)40-22-28(41)20-33(40)34(42)37-31(36(44)39(2)21-24-10-4-3-5-11-24)19-25-16-17-26-12-6-7-13-27(26)18-25/h3-18,23,28,31,33,41H,19-22H2,1-2H3,(H,37,42)/t28-,31+,33+/m1/s1
DM457B1	CS	CN1C=C(C2=CC=CC=C21)C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@H](CC4=CC5=CC=CC=C5C=C4)C(=O)N(C)CC6=CC=CC=C6)O
DM457B1	IK	BFNKQTIJVFGCKQ-PDJGWCFMSA-N
DM457B1	IU	(2S,4R)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-4-hydroxy-1-(1-methylindole-3-carbonyl)pyrrolidine-2-carboxamide
DM457B1	CA	CAS 138449-07-7
DM457B1	CB	CHEBI:93463
DM457B1	DE	Migraine

DMTEW80	ID	DMTEW80
DMTEW80	DN	FK-906
DMTEW80	HS	Discontinued in Phase 2
DMTEW80	SN	FR-115906
DMTEW80	CP	Fujisawa Pharmaceutical Co Ltd
DMTEW80	DT	Small molecular drug
DMTEW80	PC	6918227
DMTEW80	MW	790.4
DMTEW80	FM	C40H64ClN7O7
DMTEW80	IC	InChI=1S/C40H63N7O7.ClH/c1-29(2)16-17-35(48)33(24-30-12-8-6-9-13-30)43-37(49)34(26-32-27-41-28-42-32)46(5)38(50)36(25-31-14-10-7-11-15-31)54-40(52)45(4)19-18-44(3)39(51)47-20-22-53-23-21-47;/h7,10-11,14-15,27-30,33-36,48H,6,8-9,12-13,16-26H2,1-5H3,(H,41,42)(H,43,49);1H/t33-,34-,35-,36-;/m0./s1
DMTEW80	CS	CC(C)CC[C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC2=CN=CN2)N(C)C(=O)[C@H](CC3=CC=CC=C3)OC(=O)N(C)CCN(C)C(=O)N4CCOCC4)O.Cl
DMTEW80	IK	MBTHCNKHNNGZGE-GIOOZNHKSA-N
DMTEW80	IU	[(2S)-1-[[(2S)-1-[[(2S,3S)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl] N-methyl-N-[2-[methyl(morpholine-4-carbonyl)amino]ethyl]carbamate;hydrochloride
DMTEW80	DE	Hypertension

DMPD8O2	ID	DMPD8O2
DMPD8O2	DN	FK-960
DMPD8O2	HS	Discontinued in Phase 2
DMPD8O2	SN	UNII-2GB92V6H2O; 2GB92V6H2O; FK-960; FK-960 hydrate; FK-960 monohydrate; AC1OCFBG; SCHEMBL3089403; FR-59960; LS-25245; N-(4-acetylpiperazin-1-yl)-4-fluorobenzamide hydrate; Benzamide, N-(4-acetyl-1-piperazinyl)-4-fluoro-, hydrate (1:1)
DMPD8O2	CP	Fujisawa Pharmaceutical Co Ltd
DMPD8O2	DT	Small molecular drug
DMPD8O2	PC	181428
DMPD8O2	MW	265.28
DMPD8O2	FM	C13H16FN3O2
DMPD8O2	IC	InChI=1S/C13H16FN3O2/c1-10(18)16-6-8-17(9-7-16)15-13(19)11-2-4-12(14)5-3-11/h2-5H,6-9H2,1H3,(H,15,19)
DMPD8O2	CS	CC(=O)N1CCN(CC1)NC(=O)C2=CC=C(C=C2)F
DMPD8O2	IK	XTOKQKWTUYYVAO-UHFFFAOYSA-N
DMPD8O2	IU	N-(4-acetylpiperazin-1-yl)-4-fluorobenzamide
DMPD8O2	CA	CAS 133920-70-4
DMPD8O2	DE	Cognitive impairment

DMUQN83	ID	DMUQN83
DMUQN83	DN	FL-386
DMUQN83	HS	Discontinued in Phase 2
DMUQN83	SN	Benzene sulfonic acid 2-(trans-4-isobutylcyclohexyl)-2-oxoethyl ester
DMUQN83	DT	Small molecular drug
DMUQN83	PC	134847
DMUQN83	MW	338.5
DMUQN83	FM	C18H26O4S
DMUQN83	IC	InChI=1S/C18H26O4S/c1-14(2)12-15-8-10-16(11-9-15)18(19)13-22-23(20,21)17-6-4-3-5-7-17/h3-7,14-16H,8-13H2,1-2H3
DMUQN83	CS	CC(C)CC1CCC(CC1)C(=O)COS(=O)(=O)C2=CC=CC=C2
DMUQN83	IK	RLVLLBHWAQWLKL-UHFFFAOYSA-N
DMUQN83	IU	[2-[4-(2-methylpropyl)cyclohexyl]-2-oxoethyl] benzenesulfonate
DMUQN83	CA	CAS 84856-18-8
DMUQN83	DE	Hyperlipidaemia

DMOCMXH	ID	DMOCMXH
DMOCMXH	DN	FLOSATIDIL
DMOCMXH	HS	Discontinued in Phase 2
DMOCMXH	SN	Flosatidil; SL-85.1016-08; N-[2-(Dimethylamino)ethyl]-N-[2-[N-[2-(methylthio)phenyl]-N-(3-trifluoromethylbenzyl)amino]-2-oxoethyl]carbamic acid 2-methylpropyl ester
DMOCMXH	DT	Small molecular drug
DMOCMXH	PC	216223
DMOCMXH	MW	525.6
DMOCMXH	FM	C26H34F3N3O3S
DMOCMXH	IC	InChI=1S/C26H34F3N3O3S/c1-19(2)18-35-25(34)31(14-13-30(3)4)17-24(33)32(22-11-6-7-12-23(22)36-5)16-20-9-8-10-21(15-20)26(27,28)29/h6-12,15,19H,13-14,16-18H2,1-5H3
DMOCMXH	CS	CC(C)COC(=O)N(CCN(C)C)CC(=O)N(CC1=CC(=CC=C1)C(F)(F)F)C2=CC=CC=C2SC
DMOCMXH	IK	MJOGWNMYQLVUOU-UHFFFAOYSA-N
DMOCMXH	IU	2-methylpropyl N-[2-(dimethylamino)ethyl]-N-[2-[2-methylsulfanyl-N-[[3-(trifluoromethyl)phenyl]methyl]anilino]-2-oxoethyl]carbamate
DMOCMXH	CA	CAS 113593-34-3
DMOCMXH	DE	Angina pectoris

DM3PXLZ	ID	DM3PXLZ
DM3PXLZ	DN	FO-152
DM3PXLZ	HS	Discontinued in Phase 2
DM3PXLZ	SN	AC1OCEZ1; FO-152; [(2R,3S,4R,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate hydrochloride
DM3PXLZ	CP	Daiichi Fine Chemicals Co Ltd
DM3PXLZ	DT	Small molecular drug
DM3PXLZ	PC	6918058
DM3PXLZ	MW	397.78
DM3PXLZ	FM	C14H21ClFN3O7
DM3PXLZ	IC	InChI=1S/C14H20FN3O7.ClH/c1-5(2)8(16)13(22)24-4-7-9(19)10(20)12(25-7)18-3-6(15)11(21)17-14(18)23;/h3,5,7-10,12,19-20H,4,16H2,1-2H3,(H,17,21,23);1H/t7-,8+,9-,10-,12-;/m1./s1
DM3PXLZ	CS	CC(C)[C@@H](C(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O)N.Cl
DM3PXLZ	IK	HMYHLEZOXXVLBU-LNKDGEPZSA-N
DM3PXLZ	IU	[(2R,3S,4R,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DM3PXLZ	DE	Solid tumour/cancer

DM15LAP	ID	DM15LAP
DM15LAP	DN	Fonsartan
DM15LAP	HS	Discontinued in Phase 2
DM15LAP	SN	HR-720; Hoe-720
DM15LAP	CP	Hoechst Marion Roussel Inc; Hoechst AG
DM15LAP	PC	11585346
DM15LAP	MW	620.9
DM15LAP	FM	C26H30K2N4O5S2
DM15LAP	IC	InChI=1S/C26H32N4O5S2.2K/c1-4-6-11-22-28-24(36-3)23(25(31)32)30(22)17-18-12-14-19(15-13-18)20-9-7-8-10-21(20)37(34,35)29-26(33)27-16-5-2;;/h7-10,12-15H,4-6,11,16-17H2,1-3H3,(H,31,32)(H2,27,29,33);;/q;2*+1/p-2
DM15LAP	CS	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3S(=O)(=O)NC(=NCCC)[O-])C(=O)[O-])SC.[K+].[K+]
DM15LAP	IK	WGZNJDWXOFLZKQ-UHFFFAOYSA-L
DM15LAP	IU	dipotassium;2-butyl-5-methylsulfanyl-3-[[4-[2-[(C-oxido-N-propylcarbonimidoyl)sulfamoyl]phenyl]phenyl]methyl]imidazole-4-carboxylate
DM15LAP	DE	Hypertension

DMEH6LV	ID	DMEH6LV
DMEH6LV	DN	Fontolizumab
DMEH6LV	HS	Discontinued in Phase 2
DMEH6LV	SN	Fontolizumab (USAN/INN)
DMEH6LV	CP	PDL Biopharma
DMEH6LV	DT	Antibody
DMEH6LV	DE	Rheumatoid arthritis; Inflammatory bowel disease

DMTYHK4	ID	DMTYHK4
DMTYHK4	DN	FOSOPAMINE
DMTYHK4	HS	Discontinued in Phase 2
DMTYHK4	SN	S-2055; SIM-2055; Fosopamine; N-Methyldopamine 4-O-phosphate; 4-[2-(Methylamino)ethyl]-1,2-benzenediol 1-(dihydrogen phosphate)
DMTYHK4	DT	Small molecular drug
DMTYHK4	PC	65878
DMTYHK4	MW	247.18
DMTYHK4	FM	C9H14NO5P
DMTYHK4	IC	InChI=1S/C9H14NO5P/c1-10-5-4-7-2-3-9(8(11)6-7)15-16(12,13)14/h2-3,6,10-11H,4-5H2,1H3,(H2,12,13,14)
DMTYHK4	CS	CNCCC1=CC(=C(C=C1)OP(=O)(O)O)O
DMTYHK4	IK	WHEGQKBWPSOMHG-UHFFFAOYSA-N
DMTYHK4	IU	[2-hydroxy-4-[2-(methylamino)ethyl]phenyl] dihydrogen phosphate
DMTYHK4	CA	CAS 103878-96-2
DMTYHK4	DE	Hypertension

DMUD0IN	ID	DMUD0IN
DMUD0IN	DN	FOZIVUDINE TIDOXIL
DMUD0IN	HS	Discontinued in Phase 2
DMUD0IN	SN	HDP-990002; BM-21.1290; Fozivudine tidoxil; 3'-Azido-3'-deoxy-5'-O-[2-decyloxy-3-(dodecylthio)propoxy-hydroxyphosphoryl]thymidine
DMUD0IN	DT	Small molecular drug
DMUD0IN	PC	64140
DMUD0IN	MW	746
DMUD0IN	FM	C35H64N5O8PS
DMUD0IN	IC	InChI=1S/C35H64N5O8PS/c1-4-6-8-10-12-14-15-17-19-21-23-50-28-30(45-22-20-18-16-13-11-9-7-5-2)26-46-49(43,44)47-27-32-31(38-39-36)24-33(48-32)40-25-29(3)34(41)37-35(40)42/h25,30-33H,4-24,26-28H2,1-3H3,(H,43,44)(H,37,41,42)/t30?,31-,32+,33+/m0/s1
DMUD0IN	CS	CCCCCCCCCCCCSCC(COP(=O)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)N=[N+]=[N-])OCCCCCCCCCC
DMUD0IN	IK	IBHARWXWOCPXCR-WELGVCPWSA-N
DMUD0IN	IU	[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate
DMUD0IN	CA	CAS 141790-23-0
DMUD0IN	DE	Human immunodeficiency virus infection

DML6MVP	ID	DML6MVP
DML6MVP	DN	FPL-64170
DML6MVP	HS	Discontinued in Phase 2
DML6MVP	CP	Fisons plc
DML6MVP	DE	Psoriasis vulgaris

DMTRBU4	ID	DMTRBU4
DMTRBU4	DN	Frakefamide
DMTRBU4	HS	Discontinued in Phase 2
DMTRBU4	SN	BCH-3963; LEF-553; LEF-576; SPD-759; LEF, AstraZeneca/BioChem Pharma
DMTRBU4	CP	Shire plc
DMTRBU4	DT	Small molecular drug
DMTRBU4	PC	9829352
DMTRBU4	MW	563.6
DMTRBU4	FM	C30H34FN5O5
DMTRBU4	IC	InChI=1S/C30H34FN5O5/c1-18(34-29(40)24(32)15-20-9-13-23(37)14-10-20)28(39)36-26(17-21-7-11-22(31)12-8-21)30(41)35-25(27(33)38)16-19-5-3-2-4-6-19/h2-14,18,24-26,37H,15-17,32H2,1H3,(H2,33,38)(H,34,40)(H,35,41)(H,36,39)/t18-,24+,25+,26+/m1/s1
DMTRBU4	CS	C[C@H](C(=O)N[C@@H](CC1=CC=C(C=C1)F)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMTRBU4	IK	GTPHQORJKFJIRB-JTQLPTLWSA-N
DMTRBU4	IU	(2S)-2-amino-N-[(2R)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-fluorophenyl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
DMTRBU4	CA	CAS 188196-22-7
DMTRBU4	DE	Pain

DMJLEV7	ID	DMJLEV7
DMJLEV7	DN	FS-205-397
DMJLEV7	HS	Discontinued in Phase 2
DMJLEV7	SN	6-Ethoxy-3,3-dimethyl-2,3-dihydro-1H-indole methanesulfonate; 6-Ethoxy-3,3-dimethylindoline methanesulfonate
DMJLEV7	DT	Small molecular drug
DMJLEV7	PC	164014
DMJLEV7	MW	287.38
DMJLEV7	FM	C13H21NO4S
DMJLEV7	IC	InChI=1S/C12H17NO.CH4O3S/c1-4-14-9-5-6-10-11(7-9)13-8-12(10,2)3;1-5(2,3)4/h5-7,13H,4,8H2,1-3H3;1H3,(H,2,3,4)
DMJLEV7	CS	CCOC1=CC2=C(C=C1)C(CN2)(C)C.CS(=O)(=O)O
DMJLEV7	IK	QZTLHRAONHZQNK-UHFFFAOYSA-N
DMJLEV7	IU	6-ethoxy-3,3-dimethyl-1,2-dihydroindole;methanesulfonic acid
DMJLEV7	CA	CAS 116861-51-9
DMJLEV7	DE	Pain

DMHOMFK	ID	DMHOMFK
DMHOMFK	DN	G-1128
DMHOMFK	HS	Discontinued in Phase 2
DMHOMFK	SN	MATAGEN oligonucleotides; Antisense [cancer], Genta/Chugai; Anti-bcr-abl, Genta/Chugai
DMHOMFK	CP	Genta Inc
DMHOMFK	DT	Antisense drug
DMHOMFK	DE	Chronic myelogenous leukaemia

DMTNYSF	ID	DMTNYSF
DMTNYSF	DN	Galarubicin
DMTNYSF	HS	Discontinued in Phase 2
DMTNYSF	SN	DA-125; Metalloprotease inhibitors (cancer), Dong-A
DMTNYSF	CP	Dong-A Pharmaceutical Co Ltd
DMTNYSF	DT	Small molecular drug
DMTNYSF	PC	114759
DMTNYSF	MW	633.6
DMTNYSF	FM	C30H32FNO13
DMTNYSF	IC	InChI=1S/C30H32FNO13/c1-11-23(35)28(40)22(31)29(44-11)45-15-9-30(41,16(33)10-43-17(34)6-7-32)8-13-19(15)27(39)21-20(25(13)37)24(36)12-4-3-5-14(42-2)18(12)26(21)38/h3-5,11,15,22-23,28-29,35,37,39-41H,6-10,32H2,1-2H3/t11-,15-,22+,23+,28-,29-,30-/m0/s1
DMTNYSF	CS	C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCN)O)F)O)O
DMTNYSF	IK	CKXIPXAIFMTQCS-LRDUUELOSA-N
DMTNYSF	IU	[2-[(2S,4S)-4-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 3-aminopropanoate
DMTNYSF	CA	CAS 195612-80-7
DMTNYSF	DE	Solid tumour/cancer

DMX0Z51	ID	DMX0Z51
DMX0Z51	DN	Gallium maltolate
DMX0Z51	HS	Discontinued in Phase 2
DMX0Z51	SN	GaM
DMX0Z51	CP	Titan Pharmaceuticals; Geomed Inc
DMX0Z51	DT	Small molecular drug
DMX0Z51	PC	9846339
DMX0Z51	MW	445
DMX0Z51	FM	C18H15GaO9
DMX0Z51	IC	InChI=1S/3C6H6O3.Ga/c3*1-4-6(8)5(7)2-3-9-4;/h3*2-3,8H,1H3;/q;;;+3/p-3
DMX0Z51	CS	CC1=C(C(=O)C=CO1)[O-].CC1=C(C(=O)C=CO1)[O-].CC1=C(C(=O)C=CO1)[O-].[Ga+3]
DMX0Z51	IK	ASYYOZSDALANRF-UHFFFAOYSA-K
DMX0Z51	IU	gallium;2-methyl-4-oxopyran-3-olate
DMX0Z51	CA	CAS 108560-70-9
DMX0Z51	DE	Human immunodeficiency virus infection

DMHAM2J	ID	DMHAM2J
DMHAM2J	DN	Gantofiban
DMHAM2J	HS	Discontinued in Phase 2
DMHAM2J	SN	Gantofiban; CHEMBL78871; BDBM50092103; (4-{3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester(EMD-122347); (4-{(R)-3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester
DMHAM2J	DT	Small molecular drug
DMHAM2J	PC	135565976
DMHAM2J	MW	447.5
DMHAM2J	FM	C21H29N5O6
DMHAM2J	IC	InChI=1S/C21H29N5O6/c1-3-31-18(27)14-25-10-8-24(9-11-25)12-17-13-26(21(29)32-17)16-6-4-15(5-7-16)19(22)23-20(28)30-2/h4-7,17H,3,8-14H2,1-2H3,(H2,22,23,28)/t17-/m1/s1
DMHAM2J	CS	CCOC(=O)CN1CCN(CC1)C[C@@H]2CN(C(=O)O2)C3=CC=C(C=C3)C(=N)NC(=O)OC
DMHAM2J	IK	YNBHAPKHWDNTMZ-QGZVFWFLSA-N
DMHAM2J	IU	ethyl 2-[4-[[(5R)-3-[4-(N-methoxycarbonylcarbamimidoyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]piperazin-1-yl]acetate
DMHAM2J	CA	CAS 183547-57-1
DMHAM2J	DE	Arteriosclerosis

DM8IL1U	ID	DM8IL1U
DM8IL1U	DN	Gavestinel
DM8IL1U	HS	Discontinued in Phase 2
DM8IL1U	SN	UNII-318X4QY113; 153436-22-7; GV 150526X; GV-150526X; 318X4QY113; 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-(3-oxo-3-(phenylamino)-1-propenyl)-, (E)-; 4,6-Dichloro-3-((E)-2-(phenylcarbamoyl)vinyl)indole-2-carboxylic acid; 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-((1E)-3-oxo-3-(phenylamino)-1-propenyl)-; (E)-4,6-Dichloro-3-(3-oxo-3-(phenylamino)-1-propenyl)-1H-indole-2-carboxylic acid; GV 150526; Gavestinel (USAN/INN); AC1O51WR; Gavestinel [USAN:INN:BAN]; CHEMBL44793; SCHEMBL678632; SCHEMBL1721070
DM8IL1U	DT	Small molecular drug
DM8IL1U	PC	6450546
DM8IL1U	MW	375.2
DM8IL1U	FM	C18H12Cl2N2O3
DM8IL1U	IC	InChI=1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)/b7-6+
DM8IL1U	CS	C1=CC=C(C=C1)NC(=O)/C=C/C2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O
DM8IL1U	IK	WZBNEZWCNKUOSM-VOTSOKGWSA-N
DM8IL1U	IU	3-[(E)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-1H-indole-2-carboxylic acid
DM8IL1U	CA	CAS 153436-22-7
DM8IL1U	CB	CHEBI:92867
DM8IL1U	DE	Nerve injury

DMS7TC5	ID	DMS7TC5
DMS7TC5	DN	Geldanamycin
DMS7TC5	HS	Discontinued in Phase 2
DMS7TC5	SN	GDM; GMY; Geldanamicin; Geldanomycin; Geldaramycin; Antibiotic U 29135; BODIPY-labeled Geldanamycin; Geldanamycin (9CI); Geldanamycin, Streptomyces hygroscopicus; U-29135; Antibiotic (U-29,135); [(8E,12E,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8E,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8Z,12Z,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10S,11S)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10R,11S,12Z,14E)-6-Hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; (6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate; [8S-(4E,6Z,8R*,9R*,10E,12R*,13S*,14R*,16S*)]-9-[(Aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione; 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9,13-dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, 9-carbamate (8CI); 2-Azabicyclo[16.3.1]docosane, geldanamycin deriv.
DMS7TC5	CP	Fermentek
DMS7TC5	DT	Small molecular drug
DMS7TC5	PC	5288382
DMS7TC5	MW	560.6
DMS7TC5	FM	C29H40N2O9
DMS7TC5	IC	InChI=1S/C29H40N2O9/c1-15-11-19-25(34)20(14-21(32)27(19)39-7)31-28(35)16(2)9-8-10-22(37-5)26(40-29(30)36)18(4)13-17(3)24(33)23(12-15)38-6/h8-10,13-15,17,22-24,26,33H,11-12H2,1-7H3,(H2,30,36)(H,31,35)/b10-8-,16-9+,18-13+/t15-,17+,22+,23+,24-,26+/m1/s1
DMS7TC5	CS	C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)OC)/C)OC)OC(=O)N)\\C)C)O)OC
DMS7TC5	IK	QTQAWLPCGQOSGP-KSRBKZBZSA-N
DMS7TC5	IU	[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DMS7TC5	CA	CAS 30562-34-6
DMS7TC5	CB	CHEBI:5292
DMS7TC5	DE	Peripheral nerve damage; Kidney cancer

DMLMT5O	ID	DMLMT5O
DMLMT5O	DN	Gemopatrilat
DMLMT5O	HS	Discontinued in Phase 2
DMLMT5O	SN	AC1L58XI; 2-[(6S)-2,2-dimethyl-7-oxo-6-[(3-phenyl-2-sulfanylpropanoyl)amino]azepan-1-yl]acetic acid
DMLMT5O	DT	Small molecular drug
DMLMT5O	PC	9886079
DMLMT5O	MW	378.5
DMLMT5O	FM	C19H26N2O4S
DMLMT5O	IC	InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1
DMLMT5O	CS	CC1(CCC[C@@H](C(=O)N1CC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)S)C
DMLMT5O	IK	YRSVDSQRGBYVIY-GJZGRUSLSA-N
DMLMT5O	IU	2-[(6S)-2,2-dimethyl-7-oxo-6-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]azepan-1-yl]acetic acid
DMLMT5O	CA	CAS 160135-92-2
DMLMT5O	DE	Hypotension

DMIUFS4	ID	DMIUFS4
DMIUFS4	DN	GI 181771
DMIUFS4	HS	Discontinued in Phase 2
DMIUFS4	SN	GI 181771; GI-181771X; UNII-6YF0SHR37T; 305366-98-7; 6YF0SHR37T; CHEMBL1269257; GSKI181771X; GSKI 181771X; DTXSID60184613; BDBM50329178; DB12309; SB18866; HY-11076; GI-181771; CS-0003036; J3.552.309J; (S)-3-(3-(1-(2-(isopropyl(phenyl)amino)-2-oxoethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)ureido)benzoic acid; 782482-04-6
DMIUFS4	CP	GlaxoSmithKline
DMIUFS4	DT	Small molecular drug
DMIUFS4	PC	51353551
DMIUFS4	MW	605.6
DMIUFS4	FM	C34H31N5O6
DMIUFS4	IC	InChI=1S/C34H31N5O6/c1-22(2)38(25-14-5-3-6-15-25)29(40)21-37-27-18-9-10-19-28(27)39(26-16-7-4-8-17-26)32(42)30(31(37)41)36-34(45)35-24-13-11-12-23(20-24)33(43)44/h3-20,22,30H,21H2,1-2H3,(H,43,44)(H2,35,36,45)/t30-/m0/s1
DMIUFS4	CS	CC(C)N(C1=CC=CC=C1)C(=O)CN2C3=CC=CC=C3N(C(=O)[C@H](C2=O)NC(=O)NC4=CC=CC(=C4)C(=O)O)C5=CC=CC=C5
DMIUFS4	IK	CABBMMXFOOZVMS-PMERELPUSA-N
DMIUFS4	IU	3-[[(3S)-2,4-dioxo-1-[2-oxo-2-(N-propan-2-ylanilino)ethyl]-5-phenyl-1,5-benzodiazepin-3-yl]carbamoylamino]benzoic acid
DMIUFS4	CA	CAS 305366-98-7
DMIUFS4	DE	Obesity

DM10CBF	ID	DM10CBF
DM10CBF	DN	GL-331
DM10CBF	HS	Discontinued in Phase 2
DM10CBF	SN	GL-331; UNII-0I81858VSZ; 127882-73-9; 0I81858VSZ; NSC628672; NSC 628672; AC1L3WEV; CHEMBL283631; SCHEMBL5953587; DTXSID40155689; ZINC8652994; 5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4-nitrophenyl)amino)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, (5R-(5alpha,5abeta,8aalpha,9beta))-; (5R-(5alpha,5abeta,8aalpha,9beta))-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4-nitrophenyl)amino)furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one
DM10CBF	CP	University of North Carolina
DM10CBF	DT	Small molecular drug
DM10CBF	PC	148091
DM10CBF	MW	520.5
DM10CBF	FM	C27H24N2O9
DM10CBF	IC	InChI=1S/C27H24N2O9/c1-34-21-7-13(8-22(35-2)26(21)30)23-16-9-19-20(38-12-37-19)10-17(16)25(18-11-36-27(31)24(18)23)28-14-3-5-15(6-4-14)29(32)33/h3-10,18,23-25,28,30H,11-12H2,1-2H3/t18-,23+,24-,25+/m0/s1
DM10CBF	CS	COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)NC6=CC=C(C=C6)[N+](=O)[O-]
DM10CBF	IK	DLROLUIVVKTFPW-LVEBQJTPSA-N
DM10CBF	IU	(5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5-(4-nitroanilino)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DM10CBF	CA	CAS 127882-73-9
DM10CBF	DE	Colorectal cancer

DMT1LQS	ID	DMT1LQS
DMT1LQS	DN	GLENVASTATIN
DMT1LQS	HS	Discontinued in Phase 2
DMT1LQS	SN	HR-780; Glenvastatin; [4(R),6(S),(E)]-6-[2-[4-(4-Fluorophenyl)-2-isopropyl-6-phenyl-3-pyridyl]vinyl]-4-hydroxytetrahydropyran-2-one
DMT1LQS	DT	Small molecular drug
DMT1LQS	PC	5281970
DMT1LQS	MW	431.5
DMT1LQS	FM	C27H26FNO3
DMT1LQS	IC	InChI=1S/C27H26FNO3/c1-17(2)27-23(13-12-22-14-21(30)15-26(31)32-22)24(18-8-10-20(28)11-9-18)16-25(29-27)19-6-4-3-5-7-19/h3-13,16-17,21-22,30H,14-15H2,1-2H3/b13-12+/t21-,22-/m1/s1
DMT1LQS	CS	CC(C)C1=C(C(=CC(=N1)C2=CC=CC=C2)C3=CC=C(C=C3)F)/C=C/[C@@H]4C[C@H](CC(=O)O4)O
DMT1LQS	IK	LJIZUXQINHXGAO-ITWZMISCSA-N
DMT1LQS	IU	(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one
DMT1LQS	CA	CAS 122254-45-9
DMT1LQS	CB	CHEBI:5597
DMT1LQS	DE	Hyperlipidaemia

DMC87DR	ID	DMC87DR
DMC87DR	DN	GLPG-0259
DMC87DR	HS	Discontinued in Phase 2
DMC87DR	SN	G-13919, GT-146, GT-1498, GT-1704, GT-314, GT-416, GT-514, GT-562
DMC87DR	CP	Johnson&Johnson
DMC87DR	PC	44462738
DMC87DR	MW	458.5
DMC87DR	FM	C24H26N8O2
DMC87DR	IC	InChI=1S/C24H26N8O2/c1-14(2)30-10-19-8-18(30)11-31(19)17-5-3-16(4-6-17)29-23-24-27-13-28-32(24)20(9-26-23)15-7-21(22(25)33)34-12-15/h3-7,9,12-14,18-19H,8,10-11H2,1-2H3,(H2,25,33)(H,26,29)/t18-,19-/m0/s1
DMC87DR	CS	CC(C)N1C[C@@H]2C[C@H]1CN2C3=CC=C(C=C3)NC4=NC=C(N5C4=NC=N5)C6=COC(=C6)C(=O)N
DMC87DR	IK	YBFGSJUVEOYPIS-OALUTQOASA-N
DMC87DR	IU	4-[8-[4-[(1S,4S)-5-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-2-yl]anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide
DMC87DR	CA	CAS 1195065-29-2
DMC87DR	DE	Rheumatoid arthritis

DM5JKCL	ID	DM5JKCL
DM5JKCL	DN	GlycoPEGylated erythropoietin
DM5JKCL	HS	Discontinued in Phase 2
DM5JKCL	SN	GlycoPEGylated EPO, Neose; GlycoPEGylated erythropoietin, Neose; GlycoPeg-EPO; NE-180
DM5JKCL	CP	Neose Technologies
DM5JKCL	DE	Solid tumour/cancer

DM07VBW	ID	DM07VBW
DM07VBW	DN	Glypromate
DM07VBW	HS	Discontinued in Phase 2
DM07VBW	SN	Glycine-proline-glutamate (neuroprotectant), Neuren
DM07VBW	CP	Neuren Pharmaceuticals
DM07VBW	DE	Neurological disorder

DM7V9CT	ID	DM7V9CT
DM7V9CT	DN	GM6001
DM7V9CT	HS	Discontinued in Phase 2
DM7V9CT	SN	Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup; ILOMASTAT
DM7V9CT	DT	Small molecular drug
DM7V9CT	PC	132519
DM7V9CT	MW	388.5
DM7V9CT	FM	C20H28N4O4
DM7V9CT	IC	InChI=1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1
DM7V9CT	CS	CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NC
DM7V9CT	IK	NITYDPDXAAFEIT-DYVFJYSZSA-N
DM7V9CT	IU	(2R)-N'-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide
DM7V9CT	CA	CAS 142880-36-2
DM7V9CT	CB	CHEBI:137236
DM7V9CT	DE	Corneal ulcer

DM9MEAY	ID	DM9MEAY
DM9MEAY	DN	Gonadimmune
DM9MEAY	HS	Discontinued in Phase 2
DM9MEAY	SN	GnRH pharmaccine, Aphton/GlaxoSmithKline
DM9MEAY	CP	Aphton
DM9MEAY	DE	Prostate cancer

DMCXLIK	ID	DMCXLIK
DMCXLIK	DN	GR-213487
DMCXLIK	HS	Discontinued in Phase 2
DMCXLIK	SN	GR-213487B; MB-121; Gene therapy (CFTR), GW; Gene therapy (CFTR), Valentis; MB-121:CFTR
DMCXLIK	CP	Glaxo Wellcome plc
DMCXLIK	DE	Cystic fibrosis

DMSV6KP	ID	DMSV6KP
DMSV6KP	DN	GSK 679769
DMSV6KP	HS	Discontinued in Phase 2
DMSV6KP	CP	GlaxoSmithKline
DMSV6KP	DE	Major depressive disorder; Chemotherapy-induced nausea; Anxiety disorder; Incontinence

DMTZBXQ	ID	DMTZBXQ
DMTZBXQ	DN	GSK-159797
DMTZBXQ	HS	Discontinued in Phase 2
DMTZBXQ	SN	Milveterol hydrochloride; UNII-1D1MD355SJ; 1D1MD355SJ; 804518-03-4; Milveterol hydrochloride [USAN]; Milveterol hydrochloride (USAN); GSK159797C; Milveterol HCl; SCHEMBL2014099; CHEMBL2107356; DTXSID50230335; QQPHRRSYJMOQOC-DKIIUIKKSA-N; D08945; N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine; 2-5A-anti-hTR
DMTZBXQ	CP	GlaxoSmithKline
DMTZBXQ	DT	Small molecular drug
DMTZBXQ	PC	11225217
DMTZBXQ	MW	472
DMTZBXQ	FM	C25H30ClN3O4
DMTZBXQ	IC	InChI=1S/C25H29N3O4.ClH/c29-17-28-22-14-20(8-11-23(22)30)24(31)15-26-13-12-18-6-9-21(10-7-18)27-16-25(32)19-4-2-1-3-5-19;/h1-11,14,17,24-27,30-32H,12-13,15-16H2,(H,28,29);1H/t24-,25-;/m0./s1
DMTZBXQ	CS	C1=CC=C(C=C1)[C@H](CNC2=CC=C(C=C2)CCNC[C@@H](C3=CC(=C(C=C3)O)NC=O)O)O.Cl
DMTZBXQ	IK	QQPHRRSYJMOQOC-DKIIUIKKSA-N
DMTZBXQ	IU	N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[2-[4-[[(2R)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide;hydrochloride
DMTZBXQ	CA	CAS 804518-03-4
DMTZBXQ	DE	Chronic obstructive pulmonary disease

DM8J2AV	ID	DM8J2AV
DM8J2AV	DN	GSK159802
DM8J2AV	HS	Discontinued in Phase 2
DM8J2AV	CP	GSK
DM8J2AV	DE	Asthma

DMX7DVH	ID	DMX7DVH
DMX7DVH	DN	GSK163090
DMX7DVH	HS	Discontinued in Phase 2
DMX7DVH	SN	844903-58-8; GSK-163090; UNII-7XI927X82B; CHEMBL1631540; 7XI927X82B; 1-(3-(2-(4-(2-Methyl-5-quinolinyl)-1-piperazinyl)ethyl)phenyl)-2-imidazolidinone; 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone; 1-[3-[2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl]phenyl]-2-imidazolidinone; ANGUXJDGJCHGOG-UHFFFAOYSA-N; GSK 163090; SCHEMBL2881345; DTXSID30233480; EX-A1027; BCP16941; ZINC34451922; BDBM50333015; AKOS030526918; CS-5315; HY-14348
DMX7DVH	CP	GSK
DMX7DVH	DT	Small molecular drug
DMX7DVH	PC	11292933
DMX7DVH	MW	415.5
DMX7DVH	FM	C25H29N5O
DMX7DVH	IC	InChI=1S/C25H29N5O/c1-19-8-9-22-23(27-19)6-3-7-24(22)29-16-14-28(15-17-29)12-10-20-4-2-5-21(18-20)30-13-11-26-25(30)31/h2-9,18H,10-17H2,1H3,(H,26,31)
DMX7DVH	CS	CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O
DMX7DVH	IK	ANGUXJDGJCHGOG-UHFFFAOYSA-N
DMX7DVH	IU	1-[3-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]phenyl]imidazolidin-2-one
DMX7DVH	CA	CAS 844903-58-8
DMX7DVH	DE	Anxiety disorder; Episode; Major depressive disorder

DMMIR1K	ID	DMMIR1K
DMMIR1K	DN	GSK184072
DMMIR1K	HS	Discontinued in Phase 2
DMMIR1K	SN	Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione
DMMIR1K	CP	GSK
DMMIR1K	DT	Small molecular drug
DMMIR1K	PC	6443207
DMMIR1K	MW	238.28
DMMIR1K	FM	C12H18N2O3
DMMIR1K	IC	InChI=1S/C12H18N2O3/c1-7(2)5-9-11(15)14(17)12(16)10(13-9)6-8(3)4/h5,7-8,17H,6H2,1-4H3/b9-5-
DMMIR1K	CS	CC(C)CC1=N/C(=C\\C(C)C)/C(=O)N(C1=O)O
DMMIR1K	IK	SIXHCCPAJIVTOY-UITAMQMPSA-N
DMMIR1K	IU	(5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione
DMMIR1K	CA	CAS 162666-34-4
DMMIR1K	DE	Type-2 diabetes; Hematologic tumour; Colon cancer

DMHZQ0T	ID	DMHZQ0T
DMHZQ0T	DN	GSK2190914
DMHZQ0T	HS	Discontinued in Phase 2
DMHZQ0T	CP	GlaxoSmithKline
DMHZQ0T	DE	Asthma

DM89AV2	ID	DM89AV2
DM89AV2	DN	GSK2190915
DM89AV2	HS	Discontinued in Phase 2
DM89AV2	SN	1093403-33-8; sirtuin modulator; SRT 2104; SRT2104 (GSK2245840); SRT2104; SRT-2104; UNII-4521NR0J09; 4521NR0J09; 5-Thiazolecarboxamide, 4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)-; C26H24N6O2S2; 4-Methyl-N-(2-{3-[(morpholin-4-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)-2-(pyridin-3-yl)-1,3-thiazole-5-carboxamide; 4-methyl-n-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide
DM89AV2	CP	GSK
DM89AV2	DT	Small molecular drug
DM89AV2	PC	44473151
DM89AV2	MW	637.8
DM89AV2	FM	C38H43N3O4S
DM89AV2	IC	InChI=1S/C38H43N3O4S/c1-8-44-34-18-14-28(22-40-34)27-12-10-26(11-13-27)23-41-32-17-16-30(45-24-29-15-9-25(2)21-39-29)19-31(32)35(46-37(3,4)5)33(41)20-38(6,7)36(42)43/h9-19,21-22H,8,20,23-24H2,1-7H3,(H,42,43)
DM89AV2	CS	CCOC1=NC=C(C=C1)C2=CC=C(C=C2)CN3C4=C(C=C(C=C4)OCC5=NC=C(C=C5)C)C(=C3CC(C)(C)C(=O)O)SC(C)(C)C
DM89AV2	IK	DFQGDHBGRSTTHX-UHFFFAOYSA-N
DM89AV2	IU	3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoic acid
DM89AV2	CA	CAS 936350-00-4
DM89AV2	DE	Asthma

DMBYQJH	ID	DMBYQJH
DMBYQJH	DN	GSK256066
DMBYQJH	HS	Discontinued in Phase 2
DMBYQJH	SN	GSK-256066
DMBYQJH	CP	GSK
DMBYQJH	DT	Small molecular drug
DMBYQJH	PC	9827968
DMBYQJH	MW	518.6
DMBYQJH	FM	C27H26N4O5S
DMBYQJH	IC	InChI=1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)
DMBYQJH	CS	CC1=CC(=CC2=C(C(=CN=C12)C(=O)N)NC3=CC(=CC=C3)OC)S(=O)(=O)C4=CC=CC(=C4)C(=O)N(C)C
DMBYQJH	IK	JFHROPTYMMSOLG-UHFFFAOYSA-N
DMBYQJH	IU	6-[3-(dimethylcarbamoyl)phenyl]sulfonyl-4-(3-methoxyanilino)-8-methylquinoline-3-carboxamide
DMBYQJH	CA	CAS 13122-87-7
DMBYQJH	DE	Asthma

DMUC9OS	ID	DMUC9OS
DMUC9OS	DN	GSK-644784
DMUC9OS	HS	Discontinued in Phase 2
DMUC9OS	SN	AC1NQWGT
DMUC9OS	CP	GlaxoSmithKline
DMUC9OS	TC	Analgesics
DMUC9OS	DT	Small molecular drug
DMUC9OS	PC	5280119
DMUC9OS	MW	563.6
DMUC9OS	FM	C24H36F3N5O7
DMUC9OS	IC	InChI=1S/C14H12F3N3O5.C10H24N2O2/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11;1-3-9(7-13)11-5-6-12-10(4-2)8-14/h1-4,6,11H,5,7-8H2;9-14H,3-8H2,1-2H3/t11-;9-,10-/m00/s1
DMUC9OS	CS	CC[C@@H](CO)NCCN[C@@H](CC)CO.C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
DMUC9OS	IK	CSKKOIQIXPTXLB-MZEPSHEKSA-N
DMUC9OS	IU	(2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol;(6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
DMUC9OS	DE	Neuropathic pain

DM5WRJX	ID	DM5WRJX
DM5WRJX	DN	GSK-677954
DM5WRJX	HS	Discontinued in Phase 2
DM5WRJX	SN	SCHEMBL2065429
DM5WRJX	CP	GSK
DM5WRJX	DT	Small molecular drug
DM5WRJX	PC	56603715
DM5WRJX	MW	671.8
DM5WRJX	FM	C34H36F3N3O4S2
DM5WRJX	IC	InChI=1S/C34H36F3N3O4S2/c1-4-33(5-2,32(41)42)44-27-14-16-28(17-15-27)45-22-29-30(38-31(46-29)23-6-8-24(9-7-23)34(35,36)37)40-20-18-39(19-21-40)25-10-12-26(43-3)13-11-25/h6-17H,4-5,18-22H2,1-3H3,(H,41,42)
DM5WRJX	CS	CCC(CC)(C(=O)O)OC1=CC=C(C=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)N4CCN(CC4)C5=CC=C(C=C5)OC
DM5WRJX	IK	COHCTXOFKQXTRQ-UHFFFAOYSA-N
DM5WRJX	IU	2-ethyl-2-[4-[[4-[4-(4-methoxyphenyl)piperazin-1-yl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]butanoic acid
DM5WRJX	DE	Non-alcoholic fatty liver disease

DMJ0ZB6	ID	DMJ0ZB6
DMJ0ZB6	DN	GSK-732461
DMJ0ZB6	HS	Discontinued in Phase 2
DMJ0ZB6	SN	HIV vaccine (gag, pol, nef), GSK; HIV vaccine (gag, pol, nef), GlaxoSmithKline; 732461; 732462
DMJ0ZB6	CP	GlaxoSmithKline plc
DMJ0ZB6	DT	Vaccine
DMJ0ZB6	DE	Human immunodeficiency virus infection

DMRNJPY	ID	DMRNJPY
DMRNJPY	DN	GSK835726
DMRNJPY	HS	Discontinued in Phase 2
DMRNJPY	SN	Galnon trifluoroacetate salt; Galnon trifluoroacetate salt, &gt; 7-((9-Fluorenylmethoxycarbonyl)cyclohexylalanyllysyl) amino-4-methylcoumarin trifluoroacetate salt
DMRNJPY	CP	GSK
DMRNJPY	DT	Small molecular drug
DMRNJPY	PC	16219413
DMRNJPY	MW	792.8
DMRNJPY	FM	C42H47F3N4O8
DMRNJPY	IC	InChI=1S/C40H46N4O6.C2HF3O2/c1-25-21-37(45)50-36-23-27(18-19-28(25)36)42-38(46)34(17-9-10-20-41)43-39(47)35(22-26-11-3-2-4-12-26)44-40(48)49-24-33-31-15-7-5-13-29(31)30-14-6-8-16-32(30)33;3-2(4,5)1(6)7/h5-8,13-16,18-19,21,23,26,33-35H,2-4,9-12,17,20,22,24,41H2,1H3,(H,42,46)(H,43,47)(H,44,48);(H,6,7)/t34-,35-;/m0./s1
DMRNJPY	CS	CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3CCCCC3)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46.C(=O)(C(F)(F)F)O
DMRNJPY	IK	NLKOPSMADZXEPE-WDAFUDAASA-N
DMRNJPY	IU	9H-fluoren-9-ylmethyl N-[(2S)-1-[[(2S)-6-amino-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]carbamate;2,2,2-trifluoroacetic acid
DMRNJPY	DE	Allergic rhinitis

DM8J30W	ID	DM8J30W
DM8J30W	DN	GSK870086
DM8J30W	HS	Discontinued in Phase 2
DM8J30W	CP	GlaxoSmithKline
DM8J30W	DE	Asthma

DMLFCNY	ID	DMLFCNY
DMLFCNY	DN	GT-389255
DMLFCNY	HS	Discontinued in Phase 2
DMLFCNY	CP	Peptimmune
DMLFCNY	DE	Obesity

DMZD023	ID	DMZD023
DMZD023	DN	GV-150013
DMZD023	HS	Discontinued in Phase 2
DMZD023	SN	WSFVPEEMNO; UNII-WSFVPEEMNO; CHEBI:79615; gv 150013; GV 150013X; GV-150013; CHEMBL329305; 167355-22-8; GV150013; 1-[(3R)-1-(1-adamantylmethyl)-2,4-dioxo-5-phenyl-1,5-benzodiazepin-3-yl]-3-phenylurea; AC1NSK32; GTPL3503; BDBM50214395; C15096; N-(1-(Adamantyl-1-methyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-N'-phenylurea,(R)-(-); Urea, N-phenyl-N'-(2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl)-, (R)-; Urea, N-phenyl-N'-((3R)-2,3,4,5-tetrahydr
DMZD023	DT	Small molecular drug
DMZD023	PC	5311147
DMZD023	MW	534.6
DMZD023	FM	C33H34N4O3
DMZD023	IC	InChI=1S/C33H34N4O3/c38-30-29(35-32(40)34-25-9-3-1-4-10-25)31(39)37(26-11-5-2-6-12-26)28-14-8-7-13-27(28)36(30)21-33-18-22-15-23(19-33)17-24(16-22)20-33/h1-14,22-24,29H,15-21H2,(H2,34,35,40)/t22?,23?,24?,29-,33?/m1/s1
DMZD023	CS	C1C2CC3CC1CC(C2)(C3)CN4C5=CC=CC=C5N(C(=O)[C@@H](C4=O)NC(=O)NC6=CC=CC=C6)C7=CC=CC=C7
DMZD023	IK	RZERRLOTRSJIAW-NEPGVILWSA-N
DMZD023	IU	1-[(3R)-1-(1-adamantylmethyl)-2,4-dioxo-5-phenyl-1,5-benzodiazepin-3-yl]-3-phenylurea
DMZD023	CA	CAS 167355-22-8
DMZD023	CB	CHEBI:79615
DMZD023	DE	Anxiety disorder

DMFN21T	ID	DMFN21T
DMFN21T	DN	GV-196771
DMFN21T	HS	Discontinued in Phase 2
DMFN21T	SN	GR-196771; GV-196771A
DMFN21T	CP	Glaxo Wellcome plc
DMFN21T	DT	Small molecular drug
DMFN21T	PC	6913185
DMFN21T	MW	401.2
DMFN21T	FM	C20H14Cl2N2O3
DMFN21T	IC	InChI=1S/C20H14Cl2N2O3/c21-12-9-15(22)17-14(18(20(26)27)23-16(17)10-12)8-11-6-7-24(19(11)25)13-4-2-1-3-5-13/h1-5,8-10,23H,6-7H2,(H,26,27)/b11-8+
DMFN21T	CS	C\\1CN(C(=O)/C1=C/C2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O)C4=CC=CC=C4
DMFN21T	IK	VDIRQCDDCGAGET-DHZHZOJOSA-N
DMFN21T	IU	4,6-dichloro-3-[(E)-(2-oxo-1-phenylpyrrolidin-3-ylidene)methyl]-1H-indole-2-carboxylic acid
DMFN21T	CA	CAS 166974-22-7
DMFN21T	DE	Migraine

DMQ92WF	ID	DMQ92WF
DMQ92WF	DN	GW 468816
DMQ92WF	HS	Discontinued in Phase 2
DMQ92WF	SN	GW468816; SCHEMBL5750612; CHEMBL1207366; (4e)-7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid
DMQ92WF	CP	GlaxoSmithKline
DMQ92WF	DT	Small molecular drug
DMQ92WF	PC	10303232
DMQ92WF	MW	368.8
DMQ92WF	FM	C20H17ClN2O3
DMQ92WF	IC	InChI=1S/C20H17ClN2O3/c21-12-6-7-14-16(11-18(20(25)26)22-17(14)10-12)15-8-9-23(19(15)24)13-4-2-1-3-5-13/h1-7,10,18,22H,8-9,11H2,(H,25,26)/b16-15+
DMQ92WF	CS	C\\1CN(C(=O)/C1=C/2\\CC(NC3=C2C=CC(=C3)Cl)C(=O)O)C4=CC=CC=C4
DMQ92WF	IK	XDKRVNKVAKCFGW-FOCLMDBBSA-N
DMQ92WF	IU	(4E)-7-chloro-4-(2-oxo-1-phenylpyrrolidin-3-ylidene)-2,3-dihydro-1H-quinoline-2-carboxylic acid
DMQ92WF	DE	Tobacco dependence

DMOIL29	ID	DMOIL29
DMOIL29	DN	GW-275919
DMOIL29	HS	Discontinued in Phase 2
DMOIL29	CP	Glaxo Wellcome plc
DMOIL29	DE	Pain

DMZ2OBD	ID	DMZ2OBD
DMZ2OBD	DN	GW-493838
DMZ2OBD	HS	Discontinued in Phase 2
DMZ2OBD	CP	GlaxoSmithKline
DMZ2OBD	TC	Analgesics
DMZ2OBD	DT	Small molecular drug
DMZ2OBD	PC	9810927
DMZ2OBD	MW	489.9
DMZ2OBD	FM	C21H21ClFN7O4
DMZ2OBD	IC	InChI=1S/C21H21ClFN7O4/c1-21(2,3)20-29-28-18(34-20)15-13(31)14(32)19(33-15)30-8-26-12-16(24-7-25-17(12)30)27-11-5-4-9(22)6-10(11)23/h4-8,13-15,19,31-32H,1-3H3,(H,24,25,27)/t13-,14+,15-,19+/m0/s1
DMZ2OBD	CS	CC(C)(C)C1=NN=C(O1)[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)NC5=C(C=C(C=C5)Cl)F)O)O
DMZ2OBD	IK	ZQYJPMPXQLNTPQ-QCUYGVNKSA-N
DMZ2OBD	IU	(2S,3S,4R,5R)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluoroanilino)purin-9-yl]oxolane-3,4-diol
DMZ2OBD	CA	CAS 253124-46-8
DMZ2OBD	DE	Neuropathic pain

DM1FIN9	ID	DM1FIN9
DM1FIN9	DN	GW-559090
DM1FIN9	HS	Discontinued in Phase 2
DM1FIN9	SN	Alpha-4 integrin antagonist (inhaled), GlaxoSmithKline
DM1FIN9	CP	GlaxoSmithKline plc
DM1FIN9	PC	9809516
DM1FIN9	MW	596.7
DM1FIN9	FM	C31H40N4O8
DM1FIN9	IC	InChI=1S/C31H40N4O8/c1-19(2)16-24(33-27(36)18-42-26-7-5-4-6-20(26)3)29(38)34-25(30(39)40)17-21-8-10-23(11-9-21)43-31(41)35-14-12-22(13-15-35)28(32)37/h4-11,19,22,24-25H,12-18H2,1-3H3,(H2,32,37)(H,33,36)(H,34,38)(H,39,40)/t24-,25-/m0/s1
DM1FIN9	CS	CC1=CC=CC=C1OCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)OC(=O)N3CCC(CC3)C(=O)N)C(=O)O
DM1FIN9	IK	RZMCXMNNXGCFQG-DQEYMECFSA-N
DM1FIN9	IU	(2S)-3-[4-(4-carbamoylpiperidine-1-carbonyl)oxyphenyl]-2-[[(2S)-4-methyl-2-[[2-(2-methylphenoxy)acetyl]amino]pentanoyl]amino]propanoic acid
DM1FIN9	CA	CAS 278598-52-0
DM1FIN9	DE	Allergic rhinitis

DMKC0J5	ID	DMKC0J5
DMKC0J5	DN	GW-766994
DMKC0J5	HS	Discontinued in Phase 2
DMKC0J5	SN	CCR3 antagonists, GSK; CCR3 antagonists, GlaxoSmithKline; Chemokine receptor 3 antagonist, GlaxoSmithKline; GW-633647; GW-633647X; GW-701877; GW-701897; GW-701897X; GW-782415X; SB-297006; SB-328437
DMKC0J5	CP	GlaxoSmithKline plc
DMKC0J5	DT	Small molecular drug
DMKC0J5	PC	10218765
DMKC0J5	MW	451.3
DMKC0J5	FM	C21H24Cl2N4O3
DMKC0J5	IC	InChI=1S/C21H24Cl2N4O3/c22-18-6-3-15(9-19(18)23)12-27-7-8-30-17(13-27)11-26-21(29)25-10-14-1-4-16(5-2-14)20(24)28/h1-6,9,17H,7-8,10-13H2,(H2,24,28)(H2,25,26,29)/t17-/m0/s1
DMKC0J5	CS	C1CO[C@H](CN1CC2=CC(=C(C=C2)Cl)Cl)CNC(=O)NCC3=CC=C(C=C3)C(=O)N
DMKC0J5	IK	GPLUUMAKBFSDIE-KRWDZBQOSA-N
DMKC0J5	IU	4-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylcarbamoylamino]methyl]benzamide
DMKC0J5	CA	CAS 408303-43-5
DMKC0J5	DE	Asthma

DMLC154	ID	DMLC154
DMLC154	DN	GW842470X
DMLC154	HS	Discontinued in Phase 2
DMLC154	CP	GSK; Elbion
DMLC154	DE	Atopic dermatitis

DMAXRBI	ID	DMAXRBI
DMAXRBI	DN	GW876008
DMAXRBI	HS	Discontinued in Phase 2
DMAXRBI	SN	GW-876008
DMAXRBI	CP	GSK
DMAXRBI	DT	Small molecular drug
DMAXRBI	PC	11223423
DMAXRBI	MW	404.5
DMAXRBI	FM	C22H24N6O2
DMAXRBI	IC	InChI=1S/C22H24N6O2/c1-14-12-16(30-3)4-5-18(14)26-9-6-17-19(13-15(2)24-21(17)26)28-10-7-20(25-28)27-11-8-23-22(27)29/h4-5,7,10,12-13H,6,8-9,11H2,1-3H3,(H,23,29)
DMAXRBI	CS	CC1=CC(=C2CCN(C2=N1)C3=C(C=C(C=C3)OC)C)N4C=CC(=N4)N5CCNC5=O
DMAXRBI	IK	JFHJGXQFESYQGY-UHFFFAOYSA-N
DMAXRBI	IU	1-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]imidazolidin-2-one
DMAXRBI	CA	CAS 786701-13-1
DMAXRBI	DE	Irritable bowel syndrome

DMMZQVS	ID	DMMZQVS
DMMZQVS	DN	GYKI-16084
DMMZQVS	HS	Discontinued in Phase 2
DMMZQVS	SN	Uroflux; IDR-16084; (+)-(R)-2-[3-(Benzo-1,4-dioxan-2-ylmethylamino)propyl]pyridazin-3(2H)-one hydrochloride
DMMZQVS	DT	Small molecular drug
DMMZQVS	PC	154069
DMMZQVS	MW	301.34
DMMZQVS	FM	C16H19N3O3
DMMZQVS	IC	InChI=1S/C16H19N3O3/c20-16-7-3-9-18-19(16)10-4-8-17-11-13-12-21-14-5-1-2-6-15(14)22-13/h1-3,5-7,9,13,17H,4,8,10-12H2/t13-/m1/s1
DMMZQVS	CS	C1[C@H](OC2=CC=CC=C2O1)CNCCCN3C(=O)C=CC=N3
DMMZQVS	IK	FJNRJBQUOQLUNQ-CYBMUJFWSA-N
DMMZQVS	IU	2-[3-[[(3R)-2,3-dihydro-1,4-benzodioxin-3-yl]methylamino]propyl]pyridazin-3-one
DMMZQVS	CA	CAS 185739-21-3
DMMZQVS	DE	Prostate disease

DMYJ9CF	ID	DMYJ9CF
DMYJ9CF	DN	H-409/22
DMYJ9CF	HS	Discontinued in Phase 2
DMYJ9CF	SN	Y1 receptor antagonist 1; AC1NSKN0; H-409/22; H 409-22; SCHEMBL1593464; CS-7270; HY-101704
DMYJ9CF	CP	AstraZeneca plc
DMYJ9CF	DT	Small molecular drug
DMYJ9CF	PC	5311439
DMYJ9CF	MW	487.6
DMYJ9CF	FM	C28H33N5O3
DMYJ9CF	IC	InChI=1S/C28H33N5O3/c1-19(20-14-16-23(34)17-15-20)32-26(35)24(13-8-18-31-28(29)30)33-27(36)25(21-9-4-2-5-10-21)22-11-6-3-7-12-22/h2-7,9-12,14-17,19,24-25,34H,8,13,18H2,1H3,(H,32,35)(H,33,36)(H4,29,30,31)/t19-,24-/m1/s1
DMYJ9CF	CS	C[C@H](C1=CC=C(C=C1)O)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3
DMYJ9CF	IK	AOUQZUZEYSDMEZ-NTKDMRAZSA-N
DMYJ9CF	IU	(2R)-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]-N-[(1R)-1-(4-hydroxyphenyl)ethyl]pentanamide
DMYJ9CF	DE	Cardiovascular disease

DMPQSE4	ID	DMPQSE4
DMPQSE4	DN	HCV-796
DMPQSE4	HS	Discontinued in Phase 2
DMPQSE4	SN	Nesbuvir; Nesbuvir (USAN); 79Z
DMPQSE4	CP	ViroPharma; Wyeth
DMPQSE4	DT	Small molecular drug
DMPQSE4	PC	11561383
DMPQSE4	MW	446.5
DMPQSE4	FM	C22H23FN2O5S
DMPQSE4	IC	InChI=1S/C22H23FN2O5S/c1-24-22(27)20-17-11-16(13-3-4-13)18(25(9-10-26)31(2,28)29)12-19(17)30-21(20)14-5-7-15(23)8-6-14/h5-8,11-13,26H,3-4,9-10H2,1-2H3,(H,24,27)
DMPQSE4	CS	CNC(=O)C1=C(OC2=CC(=C(C=C21)C3CC3)N(CCO)S(=O)(=O)C)C4=CC=C(C=C4)F
DMPQSE4	IK	WTDWVLJJJOTABN-UHFFFAOYSA-N
DMPQSE4	IU	5-cyclopropyl-2-(4-fluorophenyl)-6-[2-hydroxyethyl(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide
DMPQSE4	CA	CAS 691852-58-1
DMPQSE4	DE	Hepatitis C virus infection

DMWH4CY	ID	DMWH4CY
DMWH4CY	DN	HE-2000
DMWH4CY	HS	Discontinued in Phase 2
DMWH4CY	SN	Immunitin; Inactivin; Bromoepiandrosterone, Hollis-Eden; DHEA analogs, Hollis-Eden; Dehydroepiandrosterone, Hollis-Eden
DMWH4CY	CP	Colthurst Ltd
DMWH4CY	DT	Small molecular drug
DMWH4CY	PC	71613
DMWH4CY	MW	369.3
DMWH4CY	FM	C19H29BrO2
DMWH4CY	IC	InChI=1S/C19H29BrO2/c1-18-7-5-12(21)9-11(18)3-4-13-14(18)6-8-19(2)15(13)10-16(20)17(19)22/h11-16,21H,3-10H2,1-2H3/t11-,12-,13+,14-,15-,16+,18-,19-/m0/s1
DMWH4CY	CS	C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3C[C@H](C4=O)Br)C)O
DMWH4CY	IK	CWVMWSZEMZOUPC-JUAXIXHSSA-N
DMWH4CY	IU	(3S,5S,8R,9S,10S,13S,14S,16R)-16-bromo-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMWH4CY	CA	CAS 28507-02-0
DMWH4CY	DE	Cystic fibrosis

DM5JZW2	ID	DM5JZW2
DM5JZW2	DN	Her-2-Bi-armed ATC
DM5JZW2	HS	Discontinued in Phase 2
DM5JZW2	SN	Her-2Bi-armed ATC (cancer), Roger Williams Medical Center; Anti-CD3 + anti-Her2/neu bispecific antibody armed T-cells (cancer), Roger Williams Medical Center; T-cells plus anti-CD3 + anti-Her2/neu antibody (cancer), Roger Williams Medical Center
DM5JZW2	CP	Roger Williams Medical Center
DM5JZW2	DT	Antibody
DM5JZW2	DE	Breast cancer

DMIJSB3	ID	DMIJSB3
DMIJSB3	DN	HMR-1426
DMIJSB3	HS	Discontinued in Phase 2
DMIJSB3	SN	6-Chloro-2-phenyl-8,8a-dihydro-3aH-indeno[1,2-d]thiazol-3a-ol
DMIJSB3	DE	Obesity

DMYJ1ZB	ID	DMYJ1ZB
DMYJ1ZB	DN	HN-10200
DMYJ1ZB	HS	Discontinued in Phase 2
DMYJ1ZB	CP	Nycomed AS
DMYJ1ZB	PC	101656410
DMYJ1ZB	MW	293.4
DMYJ1ZB	FM	C12H11N3O2S2
DMYJ1ZB	IC	InChI=1S/C12H11N3O2S2/c1-17-9-8(19(2)16)6-18-10(9)12-14-7-4-3-5-13-11(7)15-12/h3-6H,1-2H3,(H,13,14,15)
DMYJ1ZB	CS	COC1=C(SC=C1S(=O)C)C2=NC3=C(N2)C=CC=N3
DMYJ1ZB	IK	WUXLGRPRVSOZPL-UHFFFAOYSA-N
DMYJ1ZB	IU	2-(3-methoxy-4-methylsulfinylthiophen-2-yl)-1H-imidazo[4,5-b]pyridine
DMYJ1ZB	DE	Cardiac failure

DMUMGCY	ID	DMUMGCY
DMUMGCY	DN	HP-290
DMUMGCY	HS	Discontinued in Phase 2
DMUMGCY	SN	Quilostigmine; NXX-066; UNII-2L1YNO4SQJ; 2L1YNO4SQJ; 139314-01-5; CHEMBL1243298; Quilostigmine [USAN:INN]; NXX 066; HP 290; AC1L30LY; Quilostigmine (USAN/INN); SCHEMBL28872; IIFRKALDATVOJE-GGAORHGYSA-N; BDBM50326265; (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl 3,4-dihydro-2(1H)-isoquinolinecarboxylate; D03823; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)-;  NXX-066; QUILOSTIGMINE
DMUMGCY	CP	Astra AB; Hoechst AG
DMUMGCY	DT	Small molecular drug
DMUMGCY	PC	132228
DMUMGCY	MW	377.5
DMUMGCY	FM	C23H27N3O2
DMUMGCY	IC	InChI=1S/C23H27N3O2/c1-23-11-13-24(2)21(23)25(3)20-9-8-18(14-19(20)23)28-22(27)26-12-10-16-6-4-5-7-17(16)15-26/h4-9,14,21H,10-13,15H2,1-3H3/t21-,23+/m1/s1
DMUMGCY	CS	C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)N4CCC5=CC=CC=C5C4)C)C
DMUMGCY	IK	IIFRKALDATVOJE-GGAORHGYSA-N
DMUMGCY	IU	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] 3,4-dihydro-1H-isoquinoline-2-carboxylate
DMUMGCY	CA	CAS 139314-01-5
DMUMGCY	DE	Parkinson disease

DM51GZS	ID	DM51GZS
DM51GZS	DN	HR325
DM51GZS	HS	Discontinued in Phase 2
DM51GZS	DT	Small molecular drug
DM51GZS	PC	66583751
DM51GZS	MW	310.27
DM51GZS	FM	C15H13F3N2O2
DM51GZS	IC	InChI=1S/C15H13F3N2O2/c1-8-6-10(4-5-12(8)15(16,17)18)20-14(22)11(7-19)13(21)9-2-3-9/h4-6,9,21H,2-3H2,1H3,(H,20,22)
DM51GZS	CS	CC1=C(C=CC(=C1)NC(=O)C(=C(C2CC2)O)C#N)C(F)(F)F
DM51GZS	IK	GDHFOVCRYCPOTK-UHFFFAOYSA-N
DM51GZS	IU	2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]prop-2-enamide
DM51GZS	DE	Rheumatoid arthritis

DM1PJ0V	ID	DM1PJ0V
DM1PJ0V	DN	HSR-609
DM1PJ0V	HS	Discontinued in Phase 2
DM1PJ0V	SN	FY-609; 3-[4-(8-Fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propionic acid dihydrate
DM1PJ0V	DT	Small molecular drug
DM1PJ0V	PC	3081352
DM1PJ0V	MW	404.4
DM1PJ0V	FM	C21H25FN2O5
DM1PJ0V	IC	InChI=1S/C21H21FN2O3.2H2O/c22-16-3-4-17-18(12-16)27-13-15-2-1-8-23-21(15)20(17)14-5-9-24(10-6-14)11-7-19(25)26;;/h1-4,8,12H,5-7,9-11,13H2,(H,25,26);2*1H2
DM1PJ0V	CS	C1CN(CCC1=C2C3=C(C=C(C=C3)F)OCC4=C2N=CC=C4)CCC(=O)O.O.O
DM1PJ0V	IK	CWNCDQYLHMXURI-UHFFFAOYSA-N
DM1PJ0V	IU	3-[4-(8-fluoro-5H-[1]benzoxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propanoic acid;dihydrate
DM1PJ0V	CA	CAS 188199-97-5
DM1PJ0V	DE	Rhinitis

DM1LVRP	ID	DM1LVRP
DM1LVRP	DN	IC-747
DM1LVRP	HS	Discontinued in Phase 2
DM1LVRP	SN	LFA-1 antagonists, ICOS/Biogen
DM1LVRP	CP	ICOS Corp
DM1LVRP	DE	Psoriasis vulgaris

DMKUVZO	ID	DMKUVZO
DMKUVZO	DN	ICI-170809
DMKUVZO	HS	Discontinued in Phase 2
DMKUVZO	SN	ZM-170809
DMKUVZO	CP	Zeneca Group plc
DMKUVZO	DT	Small molecular drug
DMKUVZO	PC	9885848
DMKUVZO	MW	373
DMKUVZO	FM	C21H25ClN2S
DMKUVZO	IC	InChI=1S/C21H24N2S.ClH/c1-21(2,23(3)4)15-24-20-18(16-10-6-5-7-11-16)14-17-12-8-9-13-19(17)22-20;/h5-14H,15H2,1-4H3;1H
DMKUVZO	CS	CC(C)(CSC1=NC2=CC=CC=C2C=C1C3=CC=CC=C3)N(C)C.Cl
DMKUVZO	IK	HVIXPSLXHVWFAU-UHFFFAOYSA-N
DMKUVZO	IU	N,N,2-trimethyl-1-(3-phenylquinolin-2-yl)sulfanylpropan-2-amine;hydrochloride
DMKUVZO	CA	CAS 85275-49-6
DMKUVZO	DE	Anxiety disorder

DMY8X6Q	ID	DMY8X6Q
DMY8X6Q	DN	ICI-192605
DMY8X6Q	HS	Discontinued in Phase 2
DMY8X6Q	SN	ICI 192,605; SCHEMBL2939361; SCHEMBL3103318; GTPL6072; 6-[2beta-(2-Chlorophenyl)-6beta-(2-hydroxyphenyl)-1,3-dioxan-5beta-yl]-4-hexenoic acid; (E)-6-[(2S,4S,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid
DMY8X6Q	CP	Zeneca Group plc
DMY8X6Q	DT	Small molecular drug
DMY8X6Q	PC	6438399
DMY8X6Q	MW	402.9
DMY8X6Q	FM	C22H23ClO5
DMY8X6Q	IC	InChI=1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m0/s1
DMY8X6Q	CS	C1[C@@H]([C@@H](O[C@@H](O1)C2=CC=CC=C2Cl)C3=CC=CC=C3O)C/C=C\\CCC(=O)O
DMY8X6Q	IK	WHUIENZXNGAHQI-YGPRPMEGSA-N
DMY8X6Q	IU	(Z)-6-[(2R,4R,5S)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid
DMY8X6Q	CA	CAS 117621-64-4
DMY8X6Q	DE	Thrombosis

DM3R8TX	ID	DM3R8TX
DM3R8TX	DN	ICI-D-8731
DM3R8TX	HS	Discontinued in Phase 2
DM3R8TX	SN	D-8731; ZD-8731
DM3R8TX	CP	Zeneca Group plc
DM3R8TX	PC	132562
DM3R8TX	MW	407.5
DM3R8TX	FM	C25H21N5O
DM3R8TX	IC	InChI=1S/C25H21N5O/c1-2-19-15-24(22-9-5-6-10-23(22)26-19)31-16-17-11-13-18(14-12-17)20-7-3-4-8-21(20)25-27-29-30-28-25/h3-15H,2,16H2,1H3,(H,27,28,29,30)
DM3R8TX	CS	CCC1=NC2=CC=CC=C2C(=C1)OCC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DM3R8TX	IK	FSJCYXPMWQPVOS-UHFFFAOYSA-N
DM3R8TX	IU	2-ethyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methoxy]quinoline
DM3R8TX	CA	CAS 143494-72-8
DM3R8TX	DE	Hypertension

DM5WUK9	ID	DM5WUK9
DM5WUK9	DN	Icopezil maleate
DM5WUK9	HS	Discontinued in Phase 2
DM5WUK9	DT	Small molecular drug
DM5WUK9	PC	135462830
DM5WUK9	MW	491.5
DM5WUK9	FM	C27H29N3O6
DM5WUK9	IC	InChI=1S/C23H25N3O2.C4H4O4/c27-23-13-18-12-19-20(25-28-22(19)14-21(18)24-23)7-6-16-8-10-26(11-9-16)15-17-4-2-1-3-5-17;5-3(6)1-2-4(7)8/h1-5,12,14,16H,6-11,13,15H2,(H,24,27);1-2H,(H,5,6)(H,7,8)/b;2-1-
DM5WUK9	CS	C1CN(CCC1CCC2=NOC3=C2C=C4CC(=O)NC4=C3)CC5=CC=CC=C5.C(=C\\C(=O)O)\\C(=O)O
DM5WUK9	IK	CTYSKGVFLJLGGX-BTJKTKAUSA-N
DM5WUK9	IU	3-[2-(1-benzylpiperidin-4-yl)ethyl]-5,7-dihydropyrrolo[3,2-f][1,2]benzoxazol-6-one;(Z)-but-2-enedioic acid
DM5WUK9	CA	CAS 145815-98-1
DM5WUK9	DE	Cognitive impairment

DMILUHA	ID	DMILUHA
DMILUHA	DN	IDEC-151
DMILUHA	HS	Discontinued in Phase 2
DMILUHA	SN	Clenoliximab
DMILUHA	CP	Biogen Idec
DMILUHA	DT	Antibody
DMILUHA	DE	Rheumatoid arthritis

DM7O0UR	ID	DM7O0UR
DM7O0UR	DN	Idrapril
DM7O0UR	HS	Discontinued in Phase 2
DM7O0UR	SN	LG-32001
DM7O0UR	CP	Laboratorio Guidotti SpA
DM7O0UR	DT	Small molecular drug
DM7O0UR	PC	65960
DM7O0UR	MW	258.269
DM7O0UR	FM	C11H18N2O5
DM7O0UR	IC	InChI=1S/C11H18N2O5/c1-13(6-9(14)12-18)10(15)7-4-2-3-5-8(7)11(16)17/h7-8,18H,2-6H2,1H3,(H,12,14)(H,16,17)/t7-,8+/m1/s1
DM7O0UR	CS	CN(CC(=O)NO)C(=O)[C@@H]1CCCC[C@@H]1C(=O)O
DM7O0UR	IK	QKIVRALZQSUWHH-SFYZADRCSA-N
DM7O0UR	IU	(1S,2R)-2-[[2-(hydroxyamino)-2-oxoethyl]-methylcarbamoyl]cyclohexane-1-carboxylic acid
DM7O0UR	CA	CAS 127420-24-0
DM7O0UR	DE	Hypertension

DMRPBJW	ID	DMRPBJW
DMRPBJW	DN	IDX375
DMRPBJW	HS	Discontinued in Phase 2
DMRPBJW	CP	Idenix
DMRPBJW	PC	135566716
DMRPBJW	MW	540.6
DMRPBJW	FM	C24H37N4O6PS
DMRPBJW	IC	InChI=1S/C24H37N4O6PS/c1-9-34-35(31)17-14-15(27-36(8,32)33)10-11-16(17)25-21(26-35)18-19(29)20(24(5,6)7)28(22(18)30)13-12-23(2,3)4/h10-11,14,20,27,29H,9,12-13H2,1-8H3,(H,25,26,31)/t20-,35+/m1/s1
DMRPBJW	CS	CCO[P@@]1(=O)C2=C(C=CC(=C2)NS(=O)(=O)C)NC(=N1)C3=C([C@@H](N(C3=O)CCC(C)(C)C)C(C)(C)C)O
DMRPBJW	IK	FKLYVKZFUGOUQH-GOKJBEJGSA-N
DMRPBJW	IU	N-[(1S)-3-[(2S)-2-tert-butyl-1-(3,3-dimethylbutyl)-3-hydroxy-5-oxo-2H-pyrrol-4-yl]-1-ethoxy-1-oxo-4H-2,4,1lambda5-benzodiazaphosphinin-7-yl]methanesulfonamide
DMRPBJW	DE	Hepatitis C virus infection

DMOG1LX	ID	DMOG1LX
DMOG1LX	DN	IGN-101
DMOG1LX	HS	Discontinued in Phase 2
DMOG1LX	SN	Cancer vaccine, Igeneon; Anti-EpCam murine monoclonal antibody 17-A carcinoma vaccine; Aluminum-adsorbed murine monoclonal antibody 17-1A (edrecolomab) vaccine antigen (cancer), Igeneon
DMOG1LX	CP	Igeneon GmbH
DMOG1LX	DT	Vaccine
DMOG1LX	DE	Colorectal cancer

DMU4N1O	ID	DMU4N1O
DMU4N1O	DN	IGN-2098
DMU4N1O	HS	Discontinued in Phase 2
DMU4N1O	CP	Ikeda Mohando Co Ltd
DMU4N1O	DT	Small molecular drug
DMU4N1O	PC	135483992
DMU4N1O	MW	455.4
DMU4N1O	FM	C22H32Cl2N4O2
DMU4N1O	IC	InChI=1S/C22H30N4O2.2ClH/c1-17-18(2)24-22(25-21(17)27)23-11-4-7-14-28-20-10-8-9-19(15-20)16-26-12-5-3-6-13-26;;/h4,7-10,15H,3,5-6,11-14,16H2,1-2H3,(H2,23,24,25,27);2*1H/b7-4-;;
DMU4N1O	CS	CC1=C(N=C(NC1=O)NC/C=C\\COC2=CC=CC(=C2)CN3CCCCC3)C.Cl.Cl
DMU4N1O	IK	NTLKFRQIRDDXCH-XIFWRFGDSA-N
DMU4N1O	IU	4,5-dimethyl-2-[[(Z)-4-[3-(piperidin-1-ylmethyl)phenoxy]but-2-enyl]amino]-1H-pyrimidin-6-one;dihydrochloride
DMU4N1O	CA	CAS 126869-04-3
DMU4N1O	DE	Duodenal ulcer

DMQ2ULV	ID	DMQ2ULV
DMQ2ULV	DN	Imitrodast
DMQ2ULV	HS	Discontinued in Phase 2
DMQ2ULV	SN	Logran; CS-518; RS-5186
DMQ2ULV	CP	Sankyo Co Ltd
DMQ2ULV	DT	Small molecular drug
DMQ2ULV	PC	65922
DMQ2ULV	MW	260.31
DMQ2ULV	FM	C13H12N2O2S
DMQ2ULV	IC	InChI=1S/C13H12N2O2S/c16-13(17)10-2-1-9-5-11(18-12(9)6-10)7-15-4-3-14-8-15/h3-6,8H,1-2,7H2,(H,16,17)
DMQ2ULV	CS	C1CC2=C(C=C1C(=O)O)SC(=C2)CN3C=CN=C3
DMQ2ULV	IK	KRBSZXUPPSXPAN-UHFFFAOYSA-N
DMQ2ULV	IU	2-(imidazol-1-ylmethyl)-4,5-dihydro-1-benzothiophene-6-carboxylic acid
DMQ2ULV	CA	CAS 114686-12-3
DMQ2ULV	DE	Asthma

DMRHZBD	ID	DMRHZBD
DMRHZBD	DN	INCB19602
DMRHZBD	HS	Discontinued in Phase 2
DMRHZBD	CP	Incyte
DMRHZBD	DE	Type-2 diabetes

DMNRQA9	ID	DMNRQA9
DMNRQA9	DN	INCB47986
DMNRQA9	HS	Discontinued in Phase 2
DMNRQA9	CP	Incyte
DMNRQA9	DE	Rheumatoid arthritis

DMS56UD	ID	DMS56UD
DMS56UD	DN	Indeglitazar
DMS56UD	HS	Discontinued in Phase 2
DMS56UD	SN	PLX-204
DMS56UD	CP	Plexxikon
DMS56UD	DT	Small molecular drug
DMS56UD	PC	11395145
DMS56UD	MW	389.4
DMS56UD	FM	C19H19NO6S
DMS56UD	IC	InChI=1S/C19H19NO6S/c1-25-14-4-7-16(8-5-14)27(23,24)20-12-13(3-10-19(21)22)17-11-15(26-2)6-9-18(17)20/h4-9,11-12H,3,10H2,1-2H3,(H,21,22)
DMS56UD	CS	COC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=C2C=CC(=C3)OC)CCC(=O)O
DMS56UD	IK	YMPALHOKRBVHOJ-UHFFFAOYSA-N
DMS56UD	IU	3-[5-methoxy-1-(4-methoxyphenyl)sulfonylindol-3-yl]propanoic acid
DMS56UD	CA	CAS 835619-41-5
DMS56UD	DE	Type-2 diabetes

DMJM38Q	ID	DMJM38Q
DMJM38Q	DN	INGN-234
DMJM38Q	HS	Discontinued in Phase 2
DMJM38Q	SN	P53 tumor suppressor (topical formulation), Introgen
DMJM38Q	CP	Introgen Therapeutics Inc
DMJM38Q	DE	Oral cancer

DM6HDO3	ID	DM6HDO3
DM6HDO3	DN	INOGATRAN
DM6HDO3	HS	Discontinued in Phase 2
DM6HDO3	SN	Inogatran; Inogatran [INN]; UNII-428409I84L; CHEMBL114715; 155415-08-0; INOGATRAN (ASTRA-ZENECA); {[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)-1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID; 428409I84L; N-((1R)-2-Cyclohexyl-1-(((2S)-2-((3-guanidinopropyl)carbamoyl)piperidino)carbonyl)ethyl)glycine; 2-[[(2R)-3-cyclohexyl-1-[(2S)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid; IGN; AC1Q5JWR; AC1L24ET; SCHEMBL22745; SCHEMBL22747
DM6HDO3	DT	Small molecular drug
DM6HDO3	PC	66005
DM6HDO3	MW	438.6
DM6HDO3	FM	C21H38N6O4
DM6HDO3	IC	InChI=1S/C21H38N6O4/c22-21(23)25-11-6-10-24-19(30)17-9-4-5-12-27(17)20(31)16(26-14-18(28)29)13-15-7-2-1-3-8-15/h15-17,26H,1-14H2,(H,24,30)(H,28,29)(H4,22,23,25)/t16-,17+/m1/s1
DM6HDO3	CS	C1CCC(CC1)C[C@H](C(=O)N2CCCC[C@H]2C(=O)NCCCN=C(N)N)NCC(=O)O
DM6HDO3	IK	CDPROXZBMHOBTQ-SJORKVTESA-N
DM6HDO3	IU	2-[[(2R)-3-cyclohexyl-1-[(2S)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid
DM6HDO3	CA	CAS 155415-08-0
DM6HDO3	DE	Myocardial infarction

DMSATO0	ID	DMSATO0
DMSATO0	DN	IO-21
DMSATO0	HS	Discontinued in Phase 2
DMSATO0	CP	Nissin Foods Holdings Co Ltd
DMSATO0	DE	Ulcer

DM4WJDK	ID	DM4WJDK
DM4WJDK	DN	IPENOXAZONE
DM4WJDK	HS	Discontinued in Phase 2
DM4WJDK	SN	MLV-6976; NC-1200; Ipenoxazone; (+)-(4S,5R)-4-(2-Methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3-oxazolidin-2-one
DM4WJDK	DT	Small molecular drug
DM4WJDK	PC	65882
DM4WJDK	MW	358.5
DM4WJDK	FM	C22H34N2O2
DM4WJDK	IC	InChI=1S/C22H34N2O2/c1-18(2)17-20-21(19-11-6-5-7-12-19)26-22(25)24(20)16-10-15-23-13-8-3-4-9-14-23/h5-7,11-12,18,20-21H,3-4,8-10,13-17H2,1-2H3/t20-,21+/m0/s1
DM4WJDK	CS	CC(C)C[C@H]1[C@H](OC(=O)N1CCCN2CCCCCC2)C3=CC=CC=C3
DM4WJDK	IK	DQNMZSIJHFEYTM-LEWJYISDSA-N
DM4WJDK	IU	(4S,5R)-3-[3-(azepan-1-yl)propyl]-4-(2-methylpropyl)-5-phenyl-1,3-oxazolidin-2-one
DM4WJDK	CA	CAS 104454-71-9
DM4WJDK	DE	Alzheimer disease

DMLQWFA	ID	DMLQWFA
DMLQWFA	DN	IS-159
DMLQWFA	HS	Discontinued in Phase 2
DMLQWFA	SN	133790-13-3; 2-(3-(2-aminoethyl)-1h-indol-5-yloxy)acetyl-l-tyrosyl-glycinamide; 2-[3-(2-aminoethyl)-1h-indol-5-yloxy]acetyl-l-tyrosyl-glycinamide; SCHEMBL6905927; AC1L52G2; CTK4B8797; Glycinamide,N-[[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]-L-tyrosyl- (9CI); AKOS030608101
DMLQWFA	CP	Immunotech SA
DMLQWFA	DT	Small molecular drug
DMLQWFA	PC	154730670
DMLQWFA	DE	Migraine

DMURWPH	ID	DMURWPH
DMURWPH	DN	ISIS 104838
DMURWPH	HS	Discontinued in Phase 2
DMURWPH	CP	Isis Pharmaceuticals
DMURWPH	TC	Antisense
DMURWPH	DT	Antisense drug
DMURWPH	DE	Rheumatoid arthritis; Crohn disease

DMGZV7U	ID	DMGZV7U
DMGZV7U	DN	ISIS 14803
DMGZV7U	HS	Discontinued in Phase 2
DMGZV7U	CP	Isis Pharmaceuticals
DMGZV7U	TC	Antisense
DMGZV7U	DT	Antisense drug
DMGZV7U	DE	Hepatitis C virus infection

DMR2STB	ID	DMR2STB
DMR2STB	DN	ISIS 2105
DMR2STB	HS	Discontinued in Phase 2
DMR2STB	SN	UNII-7EL4K2K27P; Afovirsen sodium; 7EL4K2K27P; ISIS 2105; Afovirsen sodium [USAN]; IP 2105; I 2105; 138330-98-0; ISIS-2105; IP-2105; I-2105; Thymidine, 2'-deoxy-P-thiocytidylyl-(5'-3')-P-thiothymidylyl-(5'-3')-2'-deoxy-P-thioguanylyl-(5'-3')-2'-deoxy-P-thiocytidylyl-(5'-3')-P-thiothymidylyl-(5'-3')-2'-deoxy-P-thiocytidylyl-(5'-3')-2'-deoxy-P-thiocytidy
DMR2STB	CP	Isis Pharmaceuticals
DMR2STB	DT	Antisense drug
DMR2STB	SQ	TTGCTTCCATCTTCCTCGTC
DMR2STB	PC	71587499
DMR2STB	MW	6684
DMR2STB	FM	C192H231N57Na19O107P19S19
DMR2STB	IC	InChI=1S/C192H250N57O107P19S19.19Na/c1-79-46-238(184(271)221-163(79)252)144-27-89(108(55-250)318-144)338-358(281,377)300-64-117-98(36-146(327-117)240-48-81(3)165(254)223-186(240)273)353-372(295,391)317-74-127-106(44-154(337-127)248-77-207-157-161(248)217-174(202)219-172(157)261)355-373(296,392)307-63-116-94(32-141(326-116)235-23-15-133(198)214-181(235)268)343-363(286,382)310-68-121-104(42-152(331-121)246-54-87(9)171(260)229-192(246)279)352-371(294,390)312-70-123-101(39-149(333-123)243-51-84(6)168(257)226-189(243)276)349-368(291,387)304-60-113-91(29-138(323-113)232-20-12-130(195)211-178(232)265)340-360(283,379)302-58-111-95(33-142(321-111)236-24-16-134(199)215-182(236)269)344-364(287,383)315-72-125-105(43-153(335-125)247-76-206-156-159(201)204-75-205-160(156)247)354-374(297,393)313-71-124-102(40-150(334-124)244-52-85(7)169(258)227-190(244)277)350-369(292,388)305-61-114-93(31-140(324-114)234-22-14-132(197)213-180(234)267)342-362(285,381)309-67-120-103(41-151(330-120)245-53-86(8)170(259)228-191(245)278)351-370(293,389)311-69-122-100(38-148(332-122)242-50-83(5)167(256)225-188(242)275)348-367(290,386)303-59-112-90(28-137(322-112)231-19-11-129(194)210-177(231)264)339-359(282,378)301-57-110-92(30-139(320-110)233-21-13-131(196)212-179(233)266)341-361(284,380)308-66-119-99(37-147(329-119)241-49-82(4)166(255)224-187(241)274)347-366(289,385)306-62-115-96(34-143(325-115)237-25-17-135(200)216-183(237)270)345-365(288,384)316-73-126-107(45-155(336-126)249-78-208-158-162(249)218-175(203)220-173(158)262)356-375(298,394)314-65-118-97(35-145(328-118)239-47-80(2)164(253)222-185(239)272)346-357(280,376)299-56-109-88(251)26-136(319-109)230-18-10-128(193)209-176(230)263;;;;;;;;;;;;;;;;;;;/h10-25,46-54,75-78,88-127,136-155,250-251H,26-45,55-74H2,1-9H3,(H,280,376)(H,281,377)(H,282,378)(H,283,379)(H,284,380)(H,285,381)(H,286,382)(H,287,383)(H,288,384)(H,289,385)(H,290,386)(H,291,387)(H,292,388)(H,293,389)(H,294,390)(H,295,391)(H,296,392)(H,297,393)(H,298,394)(H2,193,209,263)(H2,194,210,264)(H2,195,211,265)(H2,196,212,266)(H2,197,213,267)(H2,198,214,268)(H2,199,215,269)(H2,200,216,270)(H2,201,204,205)(H,221,252,271)(H,222,253,272)(H,223,254,273)(H,224,255,274)(H,225,256,275)(H,226,257,276)(H,227,258,277)(H,228,259,278)(H,229,260,279)(H3,202,217,219,261)(H3,203,218,220,262);;;;;;;;;;;;;;;;;;;/q;19*+1/p-19/t88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,357?,358?,359?,360?,361?,362?,363?,364?,365?,366?,367?,368?,369?,370?,371?,372?,373?,374?,375?;;;;;;;;;;;;;;;;;;;/m0.................../s1
DMR2STB	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)OP(=S)([O-])OC[C@@H]3[C@H](C[C@@H](O3)N4C=C(C(=O)NC4=O)C)OP(=S)([O-])OC[C@@H]5[C@H](C[C@@H](O5)N6C=NC7=C6N=C(NC7=O)N)OP(=S)([O-])OC[C@@H]8[C@H](C[C@@H](O8)N9C=CC(=NC9=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)O)[S-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMR2STB	IK	ZWXNIBJNMPZZKZ-JILWZBBZSA-A
DMR2STB	IU	nonadecasodium;1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-sulfidophosphoryl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR2STB	CA	CAS 138330-98-0
DMR2STB	DE	Human papillomavirus infection

DMEMKIS	ID	DMEMKIS
DMEMKIS	DN	ISIS 2503
DMEMKIS	HS	Discontinued in Phase 2
DMEMKIS	DT	Antisense drug
DMEMKIS	SQ	TCCGTCATCGCTCCTCAGGG

DMZFS69	ID	DMZFS69
DMZFS69	DN	ISIS 3521
DMZFS69	HS	Discontinued in Phase 2
DMZFS69	TC	Antisense
DMZFS69	DT	Antisense drug
DMZFS69	SQ	AAAACGTCAGCCATGGTCCC

DMKY2UE	ID	DMKY2UE
DMKY2UE	DN	Ispronicline
DMKY2UE	HS	Discontinued in Phase 2
DMKY2UE	SN	RJR 1734; TC 01734; AZD-3480; RJR-1734; Ispronicline (INN/USAN); (E)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine
DMKY2UE	CP	AstraZeneca
DMKY2UE	DT	Small molecular drug
DMKY2UE	PC	9824145
DMKY2UE	MW	234.34
DMKY2UE	FM	C14H22N2O
DMKY2UE	IC	InChI=1S/C14H22N2O/c1-11(2)17-14-8-13(9-16-10-14)7-5-6-12(3)15-4/h5,7-12,15H,6H2,1-4H3/b7-5+/t12-/m0/s1
DMKY2UE	CS	C[C@@H](C/C=C/C1=CC(=CN=C1)OC(C)C)NC
DMKY2UE	IK	RPCVIAXDAUMJJP-PZBABLGHSA-N
DMKY2UE	IU	(E,2S)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine
DMKY2UE	CA	CAS 252870-53-4
DMKY2UE	DE	Alzheimer disease; Schizophrenia

DMWN09H	ID	DMWN09H
DMWN09H	DN	Istaroxime
DMWN09H	HS	Discontinued in Phase 2
DMWN09H	SN	Debio-0614; PST-2107; PST-2744; PST-2915; ST-2744; Digitalis-like compounds, Sigma-Tau; Sodium/potassium-ATPase inhibitors (infusion, cardiac failure), Sigma-Tau/Debiopharm; Na(+)-/K(+)-ATPase inhibitors (cardiac failure), Sigma-Tau; Na(+)-/K(+)-ATPase inhibitors (infusion, cardiac failure), Sigma-Tau/ Debiopharm
DMWN09H	CP	Sigma-Tau Pharmaceuticals
DMWN09H	DT	Small molecular drug
DMWN09H	PC	9841834
DMWN09H	MW	360.5
DMWN09H	FM	C21H32N2O3
DMWN09H	IC	InChI=1S/C21H32N2O3/c1-20-7-5-13(23-26-10-9-22)11-17(20)18(24)12-14-15-3-4-19(25)21(15,2)8-6-16(14)20/h14-17H,3-12,22H2,1-2H3/b23-13+/t14-,15-,16-,17+,20+,21-/m0/s1
DMWN09H	CS	C[C@]12CC/C(=N\\OCCN)/C[C@@H]1C(=O)C[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C
DMWN09H	IK	MPYLDWFDPHRTEG-PAAYLBSLSA-N
DMWN09H	IU	(3E,5S,8R,9S,10R,13S,14S)-3-(2-aminoethoxyimino)-10,13-dimethyl-1,2,4,5,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-6,17-dione
DMWN09H	CA	CAS 203737-93-3
DMWN09H	DE	Cardiac disease

DM4TE8R	ID	DM4TE8R
DM4TE8R	DN	IX207-887
DM4TE8R	HS	Discontinued in Phase 2
DM4TE8R	CP	Sandoz AG
DM4TE8R	PC	6509858
DM4TE8R	MW	284.3
DM4TE8R	FM	C16H12O3S
DM4TE8R	IC	InChI=1S/C16H12O3S/c1-19-14-8-10-4-2-3-5-11(10)13(9-15(17)18)12-6-7-20-16(12)14/h2-9H,1H3,(H,17,18)/b13-9-
DM4TE8R	CS	COC1=CC2=CC=CC=C2/C(=C/C(=O)O)/C3=C1SC=C3
DM4TE8R	IK	XIKRQPKFOKKGGW-LCYFTJDESA-N
DM4TE8R	IU	(2Z)-2-(8-methoxy-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,8,10,12-hexaen-2-ylidene)acetic acid
DM4TE8R	DE	Rheumatoid arthritis

DM5E6MK	ID	DM5E6MK
DM5E6MK	DN	J-104132
DM5E6MK	HS	Discontinued in Phase 2
DM5E6MK	SN	L-753037; (5S,6R,7R)-2-Butyl-7-[2-[2(S)-carboxypropyl]-4-methoxyphenyl]-5-(3,4-methylenedioxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid
DM5E6MK	DT	Small molecular drug
DM5E6MK	PC	186002
DM5E6MK	MW	531.6
DM5E6MK	FM	C31H33NO7
DM5E6MK	IC	InChI=1S/C31H33NO7/c1-4-5-6-20-8-10-23-26(18-7-12-24-25(15-18)39-16-38-24)28(31(35)36)27(29(23)32-20)22-11-9-21(37-3)14-19(22)13-17(2)30(33)34/h7-12,14-15,17,26-28H,4-6,13,16H2,1-3H3,(H,33,34)(H,35,36)/t17-,26-,27-,28+/m0/s1
DM5E6MK	CS	CCCCC1=NC2=C(C=C1)[C@@H]([C@H]([C@@H]2C3=C(C=C(C=C3)OC)C[C@H](C)C(=O)O)C(=O)O)C4=CC5=C(C=C4)OCO5
DM5E6MK	IK	IUHMIOAKWHUFKU-YINIXLNUSA-N
DM5E6MK	IU	(5S,6R,7R)-5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2-[(2S)-2-carboxypropyl]-4-methoxyphenyl]-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid
DM5E6MK	CA	CAS 198279-45-7
DM5E6MK	DE	Pulmonary arterial hypertension

DMV3UN4	ID	DMV3UN4
DMV3UN4	DN	JTC-801
DMV3UN4	HS	Discontinued in Phase 2
DMV3UN4	SN	UNII-BXU45ZH6LI; BXU45ZH6LI; 244218-93-7; CHEMBL140979; N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide; N-(4-amino-2-methylquinolin-6-yl)-2-[(4-ethylphenoxy)methyl]benzamide; JTC-801 free base; AC1NSKGH; SCHEMBL4916443; GTPL1692; CHEBI:92314; MolPort-021-804-962; ZINC602902; BCPP000197; BDBM50094634; N-(4-amino-2-methyl-6-quinolinyl)-2-[(4-ethylphenoxy)methyl]Benzamide; Benzamide, N-(4-amino-2-methyl-6-quinolinyl)-2-((4-ethylphenoxy)methyl)-; SB19531; BCP9000806; NCGC00161418-01; NCGC00161418-02
DMV3UN4	TC	Analgesics
DMV3UN4	DT	Small molecular drug
DMV3UN4	PC	5311339
DMV3UN4	MW	448
DMV3UN4	FM	C26H26ClN3O2
DMV3UN4	IC	InChI=1S/C26H25N3O2.ClH/c1-3-18-8-11-21(12-9-18)31-16-19-6-4-5-7-22(19)26(30)29-20-10-13-25-23(15-20)24(27)14-17(2)28-25;/h4-15H,3,16H2,1-2H3,(H2,27,28)(H,29,30);1H
DMV3UN4	CS	CCC1=CC=C(C=C1)OCC2=CC=CC=C2C(=O)NC3=CC4=C(C=C(N=C4C=C3)C)N.Cl
DMV3UN4	IK	NQLIYKXNAXKMBL-UHFFFAOYSA-N
DMV3UN4	IU	N-(4-amino-2-methylquinolin-6-yl)-2-[(4-ethylphenoxy)methyl]benzamide;hydrochloride
DMV3UN4	CA	CAS 244218-51-7
DMV3UN4	DE	Pain

DM1BQFY	ID	DM1BQFY
DM1BQFY	DN	JTE-607
DM1BQFY	HS	Discontinued in Phase 2
DM1BQFY	SN	UNII-2B68H6BWCX; JTE-607; 2B68H6BWCX; 188791-09-5; JTE 607; JTE 607 dihydrochloride; (-)-ethyl N-(3,5-dichloro-2-hydroxy-4-(2-(4-methylpiperazin-1-yl))ethoxybenzoyl)-L-phenylamine dihydrochloride; SCHEMBL5961033; MolPort-039-052-197; AKOS025293489; L-Phenylalanine, N-(3,5-dichloro-2-hydroxy-4-(2-(4-methyl-1-piperazinyl)ethoxy)benzoyl)-, ethyl ester, dihydrochloride; L-Phenylalanine, N-(3,5-dichloro-2-hydroxy-4-(2-(4-methyl-1-piperazinyl)ethoxy)benzoyl)-, ethyl ester, hydrochloride (1:2)
DM1BQFY	CP	Japan Tobacco Inc
DM1BQFY	DT	Small molecular drug
DM1BQFY	PC	9938544
DM1BQFY	MW	597.4
DM1BQFY	FM	C25H33Cl4N3O5
DM1BQFY	IC	InChI=1S/C25H31Cl2N3O5.2ClH/c1-3-34-25(33)20(15-17-7-5-4-6-8-17)28-24(32)18-16-19(26)23(21(27)22(18)31)35-14-13-30-11-9-29(2)10-12-30;;/h4-8,16,20,31H,3,9-15H2,1-2H3,(H,28,32);2*1H/t20-;;/m0../s1
DM1BQFY	CS	CCOC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=CC(=C(C(=C2O)Cl)OCCN3CCN(CC3)C)Cl.Cl.Cl
DM1BQFY	IK	JUJAUEQJEWIWCQ-FJSYBICCSA-N
DM1BQFY	IU	ethyl (2S)-2-[[3,5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl]amino]-3-phenylpropanoate;dihydrochloride
DM1BQFY	CA	CAS 188791-09-5
DM1BQFY	DE	Sepsis

DMQRKH4	ID	DMQRKH4
DMQRKH4	DN	JTH-601
DMQRKH4	HS	Discontinued in Phase 2
DMQRKH4	SN	JTH-601-G-1
DMQRKH4	CP	Japan Tobacco Inc
DMQRKH4	DT	Small molecular drug
DMQRKH4	PC	119026061
DMQRKH4	MW	633.7
DMQRKH4	FM	C32H43NO12
DMQRKH4	IC	InChI=1S/C24H35NO4.2C4H4O4/c1-14(2)19-12-21(26)15(3)11-22(19)29-10-9-25(7)13-20-18(6)23(27)16(4)17(5)24(20)28-8;2*5-3(6)1-2-4(7)8/h11-12,14,26-27H,9-10,13H2,1-8H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1+
DMQRKH4	CS	CC1=CC(=C(C=C1O)C(C)C)OCCN(CC2=C(C(=C(C(=C2C)O)C)C)OC)C.C(=C/C(=O)O)\\C(=O)O.C(=C/C(=O)O)\\C(=O)O
DMQRKH4	IK	SZSMNSNVWDKMMN-LVEZLNDCSA-N
DMQRKH4	IU	(E)-but-2-enedioic acid;3-[[2-(4-hydroxy-5-methyl-2-propan-2-ylphenoxy)ethyl-methylamino]methyl]-4-methoxy-2,5,6-trimethylphenol
DMQRKH4	CA	CAS 171277-07-9
DMQRKH4	DE	Prostate disease

DMB0V5Y	ID	DMB0V5Y
DMB0V5Y	DN	JTK-003
DMB0V5Y	HS	Discontinued in Phase 2
DMB0V5Y	CP	Japan Tobacco Inc
DMB0V5Y	DE	Hepatitis C virus infection

DM29C6S	ID	DM29C6S
DM29C6S	DN	JTP-2942
DM29C6S	HS	Discontinued in Phase 2
DM29C6S	SN	Jtp-2942; Jtp 2942; AC1L2RRV; 148152-77-6; SCHEMBL194880; N(alpha)-(2-Methyl-4-oxocyclopentanecarbonyl)-L-histidyl-L-prolinamide; L-Prolinamide, N-((2-methyl-4-oxocyclopentyl)carbonyl)-L-histidyl-, (1S-cis)-; L-Prolinamide, N-((-methyl-4-oxocyclopentyl)carbonyl)-L-histidyl-, (1S-cis)-
DM29C6S	CP	Japan Tobacco Inc
DM29C6S	DT	Small molecular drug
DM29C6S	PC	127299
DM29C6S	MW	375.4
DM29C6S	FM	C18H25N5O4
DM29C6S	IC	InChI=1S/C18H25N5O4/c1-10-5-12(24)7-13(10)17(26)22-14(6-11-8-20-9-21-11)18(27)23-4-2-3-15(23)16(19)25/h8-10,13-15H,2-7H2,1H3,(H2,19,25)(H,20,21)(H,22,26)/t10-,13+,14+,15+/m1/s1
DM29C6S	CS	C[C@@H]1CC(=O)C[C@@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N
DM29C6S	IK	MVRLGJKFVUDFCR-KJEVXHAQSA-N
DM29C6S	IU	(2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(1S,2R)-2-methyl-4-oxocyclopentanecarbonyl]amino]propanoyl]pyrrolidine-2-carboxamide
DM29C6S	CA	CAS 148152-77-6
DM29C6S	DE	Cognitive impairment

DMI0UJS	ID	DMI0UJS
DMI0UJS	DN	JTP-4819
DMI0UJS	HS	Discontinued in Phase 2
DMI0UJS	SN	JTP-3399
DMI0UJS	CP	Japan Tobacco Inc
DMI0UJS	DT	Small molecular drug
DMI0UJS	PC	178060
DMI0UJS	MW	359.4
DMI0UJS	FM	C19H25N3O4
DMI0UJS	IC	InChI=1S/C19H25N3O4/c23-13-17(24)15-8-4-10-21(15)18(25)16-9-5-11-22(16)19(26)20-12-14-6-2-1-3-7-14/h1-3,6-7,15-16,23H,4-5,8-13H2,(H,20,26)/t15-,16-/m0/s1
DMI0UJS	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)NCC3=CC=CC=C3)C(=O)CO
DMI0UJS	IK	ICULFJDHZQTNRB-HOTGVXAUSA-N
DMI0UJS	IU	(2S)-N-benzyl-2-[(2S)-2-(2-hydroxyacetyl)pyrrolidine-1-carbonyl]pyrrolidine-1-carboxamide
DMI0UJS	CA	CAS 162203-65-8
DMI0UJS	DE	Cognitive impairment

DM35CQ4	ID	DM35CQ4
DM35CQ4	DN	JTS-653
DM35CQ4	HS	Discontinued in Phase 2
DM35CQ4	CP	Japan Tobacco
DM35CQ4	DE	Pain; Overactive bladder

DMJ1ZTB	ID	DMJ1ZTB
DMJ1ZTB	DN	JTT-811
DMJ1ZTB	HS	Discontinued in Phase 2
DMJ1ZTB	CP	Japan Tobacco Inc
DMJ1ZTB	DE	Diabetic complication

DMM8UNL	ID	DMM8UNL
DMM8UNL	DN	JTV-506
DMM8UNL	HS	Discontinued in Phase 2
DMM8UNL	CP	Japan Tobacco Inc
DMM8UNL	DT	Small molecular drug
DMM8UNL	DE	Angina pectoris

DM7IP8U	ID	DM7IP8U
DM7IP8U	DN	KB-5492
DM7IP8U	HS	Discontinued in Phase 2
DM7IP8U	SN	KB 5492; AC1O5RCN; 1-((4-Methoxyphenoxy)carbonylmethyl)-4-(3,4,5-trimethoxybenzyl)piperazine difumarate hydrate; (4-methoxyphenyl) 2-[4-[(3,4,5-trimethoxyphenyl)methyl]piperazin-1-yl]acetate; 1-Piperazineacetic acid, 4-((3,4,5-trimethoxyphenyl)methyl)-, 4-methoxyphenyl ester, (E)-2-butenedioate, hydrate (1:2:1); LS-110141; 1-(3,4,5-Trimethoxybenzyl)-4-((4-methoxyphenyl)oxycarbonylmethyl)piperazine; 4-Methoxyphenyl 4-((3,4,5-trimethoxyphenyl)methyl)-1-piperazineacetate (E)-2-butened
DM7IP8U	CP	Kanebo KK
DM7IP8U	DT	Small molecular drug
DM7IP8U	PC	6439276
DM7IP8U	MW	546.6
DM7IP8U	FM	C27H34N2O10
DM7IP8U	IC	InChI=1S/C23H30N2O6.C4H4O4/c1-27-18-5-7-19(8-6-18)31-22(26)16-25-11-9-24(10-12-25)15-17-13-20(28-2)23(30-4)21(14-17)29-3;5-3(6)1-2-4(7)8/h5-8,13-14H,9-12,15-16H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DM7IP8U	CS	COC1=CC=C(C=C1)OC(=O)CN2CCN(CC2)CC3=CC(=C(C(=C3)OC)OC)OC.C(=C/C(=O)O)\\C(=O)O
DM7IP8U	IK	JUOYRBCKLAPYBI-WLHGVMLRSA-N
DM7IP8U	IU	(E)-but-2-enedioic acid;(4-methoxyphenyl) 2-[4-[(3,4,5-trimethoxyphenyl)methyl]piperazin-1-yl]acetate
DM7IP8U	CA	CAS 129200-10-8
DM7IP8U	DE	Peptic ulcer

DMOITN2	ID	DMOITN2
DMOITN2	DN	KC-11458
DMOITN2	HS	Discontinued in Phase 2
DMOITN2	CP	Solvay SA
DMOITN2	DE	Gastric motility disorder

DMBX6C7	ID	DMBX6C7
DMBX6C7	DN	KC706
DMBX6C7	HS	Discontinued in Phase 2
DMBX6C7	CP	Kemia
DMBX6C7	DE	Psoriasis vulgaris; Cardiovascular disease; Rheumatoid arthritis; Inflammatory bowel disease

DMC30N4	ID	DMC30N4
DMC30N4	DN	KCO-912
DMC30N4	HS	Discontinued in Phase 2
DMC30N4	CP	Novartis AG
DMC30N4	DE	Chronic obstructive pulmonary disease

DMX9M53	ID	DMX9M53
DMX9M53	DN	KDS-2000
DMX9M53	HS	Discontinued in Phase 2
DMX9M53	CP	Kadmus Pharmaceuticals
DMX9M53	DE	Postherpetic neuralgia

DMN4BIA	ID	DMN4BIA
DMN4BIA	DN	KN-38-7271
DMN4BIA	HS	Discontinued in Phase 2
DMN4BIA	SN	Cannabinoid 1/2 receptor agonists (cerebrovascular ischemia/pain), Bayer; Cannabinoid 1/2 receptor agonists (traumatic brain injury/stroke), KeyNeurotek
DMN4BIA	CP	Bayer AG
DMN4BIA	DE	Ischemia

DMM1SLF	ID	DMM1SLF
DMM1SLF	DN	KP-736
DMM1SLF	HS	Discontinued in Phase 2
DMM1SLF	SN	E-2-carboxylic acid disodium salt; [6R-[6alpha,7beta(Z)]-7-[[(2-Amino-4-thiazolyl)[[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]acetyl]amino]-8-oxo-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-en; (6R,7R)-7-[2-(2-Aminothiazol-4-yl)-2(Z)-(1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-ylmethoxyimino)acetamido]-3-(1,2,3-thiadiazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid disodium salt
DMM1SLF	DT	Small molecular drug
DMM1SLF	PC	9690114
DMM1SLF	MW	682.6
DMM1SLF	FM	C21H16N8Na2O8S4
DMM1SLF	IC	InChI=1S/C21H18N8O8S4.2Na/c22-21-24-10(7-40-21)14(26-37-4-9-1-11(30)12(31)3-28(9)36)17(32)25-15-18(33)29-16(20(34)35)8(6-39-19(15)29)5-38-13-2-23-27-41-13;;/h1-3,7,15,19,31,36H,4-6H2,(H2,22,24)(H,25,32)(H,34,35);;/q;2*+1/p-2/b26-14-;;/t15-,19-;;/m1../s1
DMM1SLF	CS	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=N\\OCC3=CC(=O)C(=CN3O)[O-])/C4=CSC(=N4)N)C(=O)[O-])CSC5=CN=NS5.[Na+].[Na+]
DMM1SLF	IK	RNPRGWFDYQHVDK-PUZJMABTSA-L
DMM1SLF	IU	disodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-hydroxy-5-oxido-4-oxopyridin-2-yl)methoxyimino]acetyl]amino]-8-oxo-3-(thiadiazol-5-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMM1SLF	DE	Bacterial infection

DMIJ6FX	ID	DMIJ6FX
DMIJ6FX	DN	KRH-594
DMIJ6FX	HS	Discontinued in Phase 2
DMIJ6FX	SN	KRG-594; WK-1492; WK-1492-2K
DMIJ6FX	CP	Wakunaga Pharmaceutical Co Ltd
DMIJ6FX	DT	Small molecular drug
DMIJ6FX	PC	23703120
DMIJ6FX	MW	539.7
DMIJ6FX	FM	C25H22KN7O3S
DMIJ6FX	IC	InChI=1S/C25H23N7O3S.K/c1-2-21-29-32(25(36-21)26-23(33)19-8-5-9-20(19)24(34)35)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-30-31-28-22;/h3-4,6-7,10-13H,2,5,8-9,14H2,1H3,(H,34,35)(H,27,28,30,31);/q;+1/p-1
DMIJ6FX	CS	CCC1=NN(C(=NC(=O)C2=C(CCC2)C(=O)[O-])S1)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5.[K+]
DMIJ6FX	IK	IYBVDYGNSNOZHQ-UHFFFAOYSA-M
DMIJ6FX	IU	potassium;2-[[5-ethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3,4-thiadiazol-2-ylidene]carbamoyl]cyclopentene-1-carboxylate
DMIJ6FX	DE	Hypertension

DMZ1SEW	ID	DMZ1SEW
DMZ1SEW	DN	KRN-2391
DMZ1SEW	HS	Discontinued in Phase 2
DMZ1SEW	SN	Ki-3315
DMZ1SEW	CP	Kirin Brewery Co Ltd
DMZ1SEW	DT	Small molecular drug
DMZ1SEW	PC	123957
DMZ1SEW	MW	331.31
DMZ1SEW	FM	C10H13N5O6S
DMZ1SEW	IC	InChI=1S/C9H9N5O3.CH4O3S/c10-7-13-9(8-2-1-3-11-6-8)12-4-5-17-14(15)16;1-5(2,3)4/h1-3,6H,4-5H2,(H,12,13);1H3,(H,2,3,4)
DMZ1SEW	CS	CS(=O)(=O)O.C1=CC(=CN=C1)C(=NCCO[N+](=O)[O-])NC#N
DMZ1SEW	IK	BIBJJSCMCXFMML-UHFFFAOYSA-N
DMZ1SEW	IU	2-[[(cyanoamino)-pyridin-3-ylmethylidene]amino]ethyl nitrate;methanesulfonic acid
DMZ1SEW	CA	CAS 134431-49-5
DMZ1SEW	DE	Angina pectoris

DMBU9O4	ID	DMBU9O4
DMBU9O4	DN	KRP-101
DMBU9O4	HS	Discontinued in Phase 2
DMBU9O4	SN	PPAR alpha agonist (hyperlipidemia), Kyorin
DMBU9O4	CP	Kyorin Pharmaceutical Co Ltd
DMBU9O4	PC	9825046
DMBU9O4	MW	451.5
DMBU9O4	FM	C26H26FNO5
DMBU9O4	IC	InChI=1S/C26H26FNO5/c1-3-19(26(30)31)14-18-6-13-24(32-2)23(15-18)25(29)28-16-17-4-9-21(10-5-17)33-22-11-7-20(27)8-12-22/h4-13,15,19H,3,14,16H2,1-2H3,(H,28,29)(H,30,31)/t19-/m0/s1
DMBU9O4	CS	CC[C@@H](CC1=CC(=C(C=C1)OC)C(=O)NCC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)O
DMBU9O4	IK	VRHOBXXCNBZJRX-IBGZPJMESA-N
DMBU9O4	IU	(2S)-2-[[3-[[4-(4-fluorophenoxy)phenyl]methylcarbamoyl]-4-methoxyphenyl]methyl]butanoic acid
DMBU9O4	CA	CAS 311770-26-0
DMBU9O4	DE	Hyperlipidaemia

DM9VHZC	ID	DM9VHZC
DM9VHZC	DN	KRP-297
DM9VHZC	HS	Discontinued in Phase 2
DM9VHZC	SN	KRP-297; MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384
DM9VHZC	CP	Merck
DM9VHZC	DT	Small molecular drug
DM9VHZC	PC	151183
DM9VHZC	MW	438.4
DM9VHZC	FM	C20H17F3N2O4S
DM9VHZC	IC	InChI=1S/C20H17F3N2O4S/c1-29-15-7-4-12(9-16-18(27)25-19(28)30-16)8-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)
DM9VHZC	CS	COC1=C(C=C(C=C1)CC2C(=O)NC(=O)S2)C(=O)NCC3=CC=C(C=C3)C(F)(F)F
DM9VHZC	IK	NFFXEUUOMTXWCX-UHFFFAOYSA-N
DM9VHZC	IU	5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide
DM9VHZC	CA	CAS 213252-19-8
DM9VHZC	DE	Type-2 diabetes; Hyperlipidaemia

DM5YHJ2	ID	DM5YHJ2
DM5YHJ2	DN	KW-2170
DM5YHJ2	HS	Discontinued in Phase 2
DM5YHJ2	CP	Kyowa Hakko Kogyo Co Ltd
DM5YHJ2	DT	Small molecular drug
DM5YHJ2	PC	3075774
DM5YHJ2	MW	470.3
DM5YHJ2	FM	C20H25Cl2N5O4
DM5YHJ2	IC	InChI=1S/C20H23N5O4.2ClH/c21-6-1-7-23-12-3-2-11-13(10-22-8-9-26)24-25-18(11)16(12)20(29)17-14(27)4-5-15(28)19(17)25;;/h2-5,22-23,26,28-29H,1,6-10,21H2;2*1H
DM5YHJ2	CS	C1=CC(=C2C3=C1C(=NN3C4=C(C=CC(=O)C4=C2O)O)CNCCO)NCCCN.Cl.Cl
DM5YHJ2	IK	FSJDQJHSJAGEJV-UHFFFAOYSA-N
DM5YHJ2	IU	10-(3-aminopropylamino)-3,8-dihydroxy-14-[(2-hydroxyethylamino)methyl]-1,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,7,9,11,13(16),14-heptaen-6-one;dihydrochloride
DM5YHJ2	CA	CAS 207862-44-0
DM5YHJ2	DE	Breast cancer

DMSWDKX	ID	DMSWDKX
DMSWDKX	DN	KW-4490
DMSWDKX	HS	Discontinued in Phase 2
DMSWDKX	CP	Kyowa Hakko Kogyo Co Ltd
DMSWDKX	PC	9883436
DMSWDKX	MW	317.34
DMSWDKX	FM	C17H19NO5
DMSWDKX	IC	InChI=1S/C17H19NO5/c1-21-13-3-2-12(14-15(13)23-9-8-22-14)17(10-18)6-4-11(5-7-17)16(19)20/h2-3,11H,4-9H2,1H3,(H,19,20)
DMSWDKX	CS	COC1=C2C(=C(C=C1)C3(CCC(CC3)C(=O)O)C#N)OCCO2
DMSWDKX	IK	SBCKAEJLDHJBNZ-UHFFFAOYSA-N
DMSWDKX	IU	4-cyano-4-(5-methoxy-2,3-dihydro-1,4-benzodioxin-8-yl)cyclohexane-1-carboxylic acid
DMSWDKX	DE	Asthma

DMLOKXI	ID	DMLOKXI
DMLOKXI	DN	KW-5139
DMLOKXI	HS	Discontinued in Phase 2
DMLOKXI	SN	KW-1539; [Leu13]-motilin
DMLOKXI	CP	Kyowa Hakko Kogyo Co Ltd
DMLOKXI	PC	16130985
DMLOKXI	MW	2681
DMLOKXI	FM	C121H190N34O35
DMLOKXI	IC	InChI=1S/C121H190N34O35/c1-10-65(8)98(153-115(185)87-32-23-53-155(87)118(188)97(64(6)7)152-100(170)71(124)56-67-24-13-11-14-25-67)116(186)151-85(57-68-26-15-12-16-27-68)114(184)154-99(66(9)156)117(187)150-84(58-69-33-35-70(157)36-34-69)102(172)136-60-92(162)137-76(40-46-94(164)165)106(176)148-83(55-63(4)5)112(182)145-77(37-43-88(125)158)107(177)141-74(30-21-51-133-120(129)130)104(174)147-82(54-62(2)3)111(181)146-78(38-44-89(126)159)108(178)144-80(42-48-96(168)169)109(179)140-73(29-18-20-50-123)103(173)143-79(41-47-95(166)167)110(180)142-75(31-22-52-134-121(131)132)105(175)149-86(59-91(128)161)113(183)139-72(28-17-19-49-122)101(171)135-61-93(163)138-81(119(189)190)39-45-90(127)160/h11-16,24-27,33-36,62-66,71-87,97-99,156-157H,10,17-23,28-32,37-61,122-124H2,1-9H3,(H2,125,158)(H2,126,159)(H2,127,160)(H2,128,161)(H,135,171)(H,136,172)(H,137,162)(H,138,163)(H,139,183)(H,140,179)(H,141,177)(H,142,180)(H,143,173)(H,144,178)(H,145,182)(H,146,181)(H,147,174)(H,148,176)(H,149,175)(H,150,187)(H,151,186)(H,152,170)(H,153,185)(H,154,184)(H,164,165)(H,166,167)(H,168,169)(H,189,190)(H4,129,130,133)(H4,131,132,134)/t65-,66+,71-,72-,73-,74-,75+,76-,77-,78-,79-,80-,81+,82-,83-,84-,85-,86+,87-,97-,98-,99-/m0/s1
DMLOKXI	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](CCC(=O)N)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N
DMLOKXI	IK	GFOZQXMKARUPQI-DFIBRNPJSA-N
DMLOKXI	IU	(2R)-5-amino-2-[[2-[[(2S)-6-amino-2-[[(2R)-4-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMLOKXI	CA	CAS 59530-69-7
DMLOKXI	DE	Pain

DMJNSML	ID	DMJNSML
DMJNSML	DN	KW-7158
DMJNSML	HS	Discontinued in Phase 2
DMJNSML	SN	Non-cholinergic tricyclic (irritable bowel syndrome), Kyowa Hakko Kirin
DMJNSML	CP	Kyowa Hakko
DMJNSML	DT	Small molecular drug
DMJNSML	PC	9844981
DMJNSML	MW	419.4
DMJNSML	FM	C16H12F3NO5S2
DMJNSML	IC	InChI=1S/C16H12F3NO5S2/c1-15(23,16(17,18)19)14(22)20-9-3-2-4-10-11(9)12(21)13-8(5-6-26-13)7-27(10,24)25/h2-6,23H,7H2,1H3,(H,20,22)/t15-/m0/s1
DMJNSML	CS	C[C@](C(=O)NC1=C2C(=CC=C1)S(=O)(=O)CC3=C(C2=O)SC=C3)(C(F)(F)F)O
DMJNSML	IK	NAFSYPCVPLWHFY-HNNXBMFYSA-N
DMJNSML	IU	(2S)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4H-thieno[3,2-c][1]benzothiepin-9-yl)propanamide
DMJNSML	CA	CAS 214764-26-8
DMJNSML	DE	Urinary incontinence

DMKSEIY	ID	DMKSEIY
DMKSEIY	DN	L-158282
DMKSEIY	HS	Discontinued in Phase 2
DMKSEIY	DT	Small molecular drug
DMKSEIY	PC	133031
DMKSEIY	MW	524.6
DMKSEIY	FM	C30H28N4O3S
DMKSEIY	IC	InChI=1S/C30H28N4O3S/c1-4-27-32-28-20(2)18-21(3)31-29(28)34(27)19-22-14-16-23(17-15-22)25-12-8-9-13-26(25)38(36,37)33-30(35)24-10-6-5-7-11-24/h5-18H,4,19H2,1-3H3,(H,33,35)
DMKSEIY	CS	CCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC(=O)C5=CC=CC=C5)N=C(C=C2C)C
DMKSEIY	IK	LIUNMFCWFYFUGQ-UHFFFAOYSA-N
DMKSEIY	IU	N-[2-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]phenyl]sulfonylbenzamide
DMKSEIY	CA	CAS 157263-00-8

DMT13ZR	ID	DMT13ZR
DMT13ZR	DN	L-365260
DMT13ZR	HS	Discontinued in Phase 2
DMT13ZR	SN	1-(1-Methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea; CHEMBL289498; 1-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea; L 365260; L365260; AC1L2XQK; [3H]L365260; [3H]L-365,260; GTPL879; GTPL3477; SCHEMBL1650330; KDFQABSFVYLGPM-UHFFFAOYSA-N; BDBM50452555; (R)-L 365260; L000333; 1-Methyl-3-[3-(3-methylphenyl)ureido]-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one
DMT13ZR	DT	Small molecular drug
DMT13ZR	PC	5311201
DMT13ZR	MW	398.5
DMT13ZR	FM	C24H22N4O2
DMT13ZR	IC	InChI=1S/C24H22N4O2/c1-16-9-8-12-18(15-16)25-24(30)27-22-23(29)28(2)20-14-7-6-13-19(20)21(26-22)17-10-4-3-5-11-17/h3-15,22H,1-2H3,(H2,25,27,30)/t22-/m0/s1
DMT13ZR	CS	CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)C4=CC=CC=C4)C
DMT13ZR	IK	KDFQABSFVYLGPM-QFIPXVFZSA-N
DMT13ZR	IU	1-[(3R)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DMT13ZR	CA	CAS 118101-09-0
DMT13ZR	CB	CHEBI:79548
DMT13ZR	DE	Anxiety disorder

DM7JZ53	ID	DM7JZ53
DM7JZ53	DN	L-4-OXALYSINE
DM7JZ53	HS	Discontinued in Phase 2
DM7JZ53	SN	I-677; Oxalysine-L; O-(2-Aminoethyl)-L-serine
DM7JZ53	DT	Small molecular drug
DM7JZ53	PC	160555
DM7JZ53	MW	148.16
DM7JZ53	FM	C5H12N2O3
DM7JZ53	IC	InChI=1S/C5H12N2O3/c6-1-2-10-3-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1
DM7JZ53	CS	C(COC[C@@H](C(=O)O)N)N
DM7JZ53	IK	SLTGLTLBIVDQKE-BYPYZUCNSA-N
DM7JZ53	IU	(2S)-2-amino-3-(2-aminoethoxy)propanoic acid
DM7JZ53	CA	CAS 15219-97-3
DM7JZ53	CB	CHEBI:72341
DM7JZ53	DE	Solid tumour/cancer

DMG5VJF	ID	DMG5VJF
DMG5VJF	DN	L-660771
DMG5VJF	HS	Discontinued in Phase 2
DMG5VJF	SN	MK-571
DMG5VJF	DT	Small molecular drug
DMG5VJF	PC	16760063
DMG5VJF	MW	514.1
DMG5VJF	FM	C26H26ClN2O3S2-
DMG5VJF	IC	InChI=1S/C26H27ClN2O3S2/c1-29(2)24(30)12-14-33-26(34-15-13-25(31)32)20-5-3-4-18(16-20)6-10-22-11-8-19-7-9-21(27)17-23(19)28-22/h3-11,16-17,26H,12-15H2,1-2H3,(H,31,32)/p-1/b10-6+
DMG5VJF	CS	CN(C)C(=O)CCSC(C1=CC=CC(=C1)/C=C/C2=NC3=C(C=CC(=C3)Cl)C=C2)SCCC(=O)[O-]
DMG5VJF	IK	AXUZQJFHDNNPFG-UXBLZVDNSA-M
DMG5VJF	IU	3-[[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanylpropanoate

DM54I8A	ID	DM54I8A
DM54I8A	DN	L-696229
DM54I8A	HS	Discontinued in Phase 2
DM54I8A	SN	3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridine-2(1H)-one
DM54I8A	DT	Small molecular drug
DM54I8A	PC	72352
DM54I8A	MW	282.34
DM54I8A	FM	C17H18N2O2
DM54I8A	IC	InChI=1S/C17H18N2O2/c1-3-12-10-13(17(20)18-11(12)2)8-9-16-19-14-6-4-5-7-15(14)21-16/h4-7,10H,3,8-9H2,1-2H3,(H,18,20)
DM54I8A	CS	CCC1=C(NC(=O)C(=C1)CCC2=NC3=CC=CC=C3O2)C
DM54I8A	IK	MHUVLRNBDLFMHQ-UHFFFAOYSA-N
DM54I8A	IU	3-[2-(1,3-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-1H-pyridin-2-one
DM54I8A	CA	CAS 135525-71-2
DM54I8A	DE	Human immunodeficiency virus infection

DMW8NOH	ID	DMW8NOH
DMW8NOH	DN	L-771688
DMW8NOH	HS	Discontinued in Phase 2
DMW8NOH	SN	L-771688; IW9MH6LGKH; UNII-IW9MH6LGKH; CHEMBL182998; SCHEMBL6735535; HY-U00237; BDBM50160148; CS-7401; 200050-59-5; L 771688; Methyl (4S)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-3-(3-(4-(2-pyridyl)-1-piperidyl)propylcarbamoyl)-1,4-dihydropyrimidine-5-carboxylate; 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-1-(((3-(4-(2-pyridinyl)-1-piperidinyl)propyl)amino)carbonyl)-, methyl ester, (6S)-
DMW8NOH	DT	Small molecular drug
DMW8NOH	PC	9874983
DMW8NOH	MW	557.6
DMW8NOH	FM	C28H33F2N5O5
DMW8NOH	IC	InChI=1S/C28H33F2N5O5/c1-39-17-23-24(26(36)40-2)25(19-7-8-20(29)21(30)16-19)35(28(38)33-23)27(37)32-12-5-13-34-14-9-18(10-15-34)22-6-3-4-11-31-22/h3-4,6-8,11,16,18,25H,5,9-10,12-15,17H2,1-2H3,(H,32,37)(H,33,38)/t25-/m0/s1
DMW8NOH	CS	COCC1=C([C@@H](N(C(=O)N1)C(=O)NCCCN2CCC(CC2)C3=CC=CC=N3)C4=CC(=C(C=C4)F)F)C(=O)OC
DMW8NOH	IK	FFXFCSQUTLDLAR-VWLOTQADSA-N
DMW8NOH	IU	methyl (4S)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-3-[3-(4-pyridin-2-ylpiperidin-1-yl)propylcarbamoyl]-1,4-dihydropyrimidine-5-carboxylate
DMW8NOH	CA	CAS 200050-59-5
DMW8NOH	DE	Prostate disease

DMSFL76	ID	DMSFL76
DMSFL76	DN	Labradimil
DMSFL76	HS	Discontinued in Phase 2
DMSFL76	SN	Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide
DMSFL76	CP	Alkermes
DMSFL76	TC	Anticancer Agents
DMSFL76	DT	Small molecular drug
DMSFL76	PC	6918284
DMSFL76	MW	1098.3
DMSFL76	FM	C49H75N15O12S
DMSFL76	IC	InChI=1S/C49H75N15O12S/c1-76-31-14-12-28(13-15-31)21-29(24-57-34(47(74)75)9-3-17-56-49(53)54)59-43(70)37-10-4-18-62(37)45(72)36(27-65)61-41(68)35(23-32-7-6-20-77-32)60-40(67)25-58-42(69)39-22-30(66)26-64(39)46(73)38-11-5-19-63(38)44(71)33(50)8-2-16-55-48(51)52/h6-7,12-15,20,29-30,33-39,57,65-66H,2-5,8-11,16-19,21-27,50H2,1H3,(H,58,69)(H,59,70)(H,60,67)(H,61,68)(H,74,75)(H4,51,52,55)(H4,53,54,56)/t29-,30+,33-,34-,35-,36-,37-,38-,39-/m0/s1
DMSFL76	CS	COC1=CC=C(C=C1)C[C@@H](CN[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCCN=C(N)N)N)O
DMSFL76	IK	IDXCXSCCZNCXCL-XMADEQCMSA-N
DMSFL76	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-methoxyphenyl)propyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMSFL76	CA	CAS 159768-75-9
DMSFL76	DE	Brain cancer

DM3YABD	ID	DM3YABD
DM3YABD	DN	LANIQUIDAR
DM3YABD	HS	Discontinued in Phase 2
DM3YABD	SN	R-101933; Laniquidar; 11-[1-[2-[4-(2-Quinolylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carboxylic acid methyl ester
DM3YABD	DT	Small molecular drug
DM3YABD	PC	6450806
DM3YABD	MW	584.7
DM3YABD	FM	C37H36N4O3
DM3YABD	IC	InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3
DM3YABD	CS	COC(=O)C1=CN=C2N1CCC3=CC=CC=C3C2=C4CCN(CC4)CCC5=CC=C(C=C5)OCC6=NC7=CC=CC=C7C=C6
DM3YABD	IK	TULGGJGJQXESOO-UHFFFAOYSA-N
DM3YABD	IU	methyl 11-[1-[2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carboxylate
DM3YABD	CA	CAS 197509-46-9
DM3YABD	DE	Solid tumour/cancer

DM9J6BX	ID	DM9J6BX
DM9J6BX	DN	LAS-37779
DM9J6BX	HS	Discontinued in Phase 2
DM9J6BX	CP	Almirall Prodesfarma SA
DM9J6BX	DE	Psoriasis vulgaris

DMTY5VE	ID	DMTY5VE
DMTY5VE	DN	Lavoltidine
DMTY5VE	HS	Discontinued in Phase 2
DMTY5VE	SN	Loxtidine; AH-234844; GSK-1023911a; GSK-1040323b; Histamine H2 receptor antagonist (GERD), GlaxoSmithKline; Histamine H2 receptor antagonist (gastroesophageal reflux disorder), GlaxoSmithKline
DMTY5VE	CP	GlaxoSmithKline plc
DMTY5VE	DT	Small molecular drug
DMTY5VE	PC	55473
DMTY5VE	MW	359.5
DMTY5VE	FM	C19H29N5O2
DMTY5VE	IC	InChI=1S/C19H29N5O2/c1-23-19(21-18(15-25)22-23)20-9-6-12-26-17-8-5-7-16(13-17)14-24-10-3-2-4-11-24/h5,7-8,13,25H,2-4,6,9-12,14-15H2,1H3,(H,20,21,22)
DMTY5VE	CS	CN1C(=NC(=N1)CO)NCCCOC2=CC=CC(=C2)CN3CCCCC3
DMTY5VE	IK	VTLNPNNUIJHJQB-UHFFFAOYSA-N
DMTY5VE	IU	[1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
DMTY5VE	CA	CAS 76956-02-0
DMTY5VE	CB	CHEBI:6550
DMTY5VE	DE	Gastroesophageal reflux disease

DMGQJ2U	ID	DMGQJ2U
DMGQJ2U	DN	LESOPITRON DIHYDROCHLORIDE
DMGQJ2U	HS	Discontinued in Phase 2
DMGQJ2U	SN	Lesopitran; Lesopitran); E-4424; Lesopitron dihydrochloride; 2-[4-[4-(4-Chloropyrazol-1-yl)butyl]piperazin-1-yl]pyrimidine dihydrochloride
DMGQJ2U	CP	Esteve Group
DMGQJ2U	DT	Small molecular drug
DMGQJ2U	PC	60812
DMGQJ2U	MW	393.7
DMGQJ2U	FM	C15H23Cl3N6
DMGQJ2U	IC	InChI=1S/C15H21ClN6.2ClH/c16-14-12-19-22(13-14)7-2-1-6-20-8-10-21(11-9-20)15-17-4-3-5-18-15;;/h3-5,12-13H,1-2,6-11H2;2*1H
DMGQJ2U	CS	C1CN(CCN1CCCCN2C=C(C=N2)Cl)C3=NC=CC=N3.Cl.Cl
DMGQJ2U	IK	RGDLQJUAYQRGBC-UHFFFAOYSA-N
DMGQJ2U	IU	2-[4-[4-(4-chloropyrazol-1-yl)butyl]piperazin-1-yl]pyrimidine;dihydrochloride
DMGQJ2U	CA	CAS 132449-89-9
DMGQJ2U	DE	Mood disorder

DMKSY2R	ID	DMKSY2R
DMKSY2R	DN	Levosemotiadil
DMKSY2R	HS	Discontinued in Phase 2
DMKSY2R	SN	DS-4824; SA-3212; SD-3212
DMKSY2R	CP	Santen Pharmaceutical Co Ltd
DMKSY2R	DT	Small molecular drug
DMKSY2R	PC	9852564
DMKSY2R	MW	536.6
DMKSY2R	FM	C29H32N2O6S
DMKSY2R	IC	InChI=1S/C29H32N2O6S/c1-30(14-16-34-21-10-12-25-26(18-21)37-19-36-25)13-6-15-35-24-11-9-20(33-3)17-22(24)28-29(32)31(2)23-7-4-5-8-27(23)38-28/h4-5,7-12,17-18,28H,6,13-16,19H2,1-3H3/t28-/m0/s1
DMKSY2R	CS	CN1C2=CC=CC=C2S[C@H](C1=O)C3=C(C=CC(=C3)OC)OCCCN(C)CCOC4=CC5=C(C=C4)OCO5
DMKSY2R	IK	RKXVEXUAWGRFNP-NDEPHWFRSA-N
DMKSY2R	IU	(2S)-2-[2-[3-[2-(1,3-benzodioxol-5-yloxy)ethyl-methylamino]propoxy]-5-methoxyphenyl]-4-methyl-1,4-benzothiazin-3-one
DMKSY2R	CA	CAS 116476-16-5
DMKSY2R	DE	Cardiac arrhythmias

DMJ3ZT8	ID	DMJ3ZT8
DMJ3ZT8	DN	Lexacalcitol
DMJ3ZT8	HS	Discontinued in Phase 2
DMJ3ZT8	SN	KH-106; KH-1060; MC-1357; Vitamin D3 agonist, Leo
DMJ3ZT8	CP	LEO Pharma A/S
DMJ3ZT8	DT	Small molecular drug
DMJ3ZT8	PC	5288670
DMJ3ZT8	MW	460.7
DMJ3ZT8	FM	C29H48O4
DMJ3ZT8	IC	InChI=1S/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1
DMJ3ZT8	CS	CCC(CC)(CCCO[C@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C)O
DMJ3ZT8	IK	KLZOTDOJMRMLDX-YBBVPDDNSA-N
DMJ3ZT8	IU	(1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMJ3ZT8	CA	CAS 131875-08-6
DMJ3ZT8	DE	Solid tumour/cancer

DM8W31H	ID	DM8W31H
DM8W31H	DN	LG-1550
DM8W31H	HS	Discontinued in Phase 2
DM8W31H	SN	ALRT-1550; ALRT-550; LGD-1550; Pre-Registered; (2E,4E,6E)-7-(3,5-Di-tert-butylphenyl)-3-methylocta-2,4,6-trienoic acid
DM8W31H	CP	Ligand Pharmaceuticals
DM8W31H	DT	Small molecular drug
DM8W31H	PC	5287705
DM8W31H	MW	340.5
DM8W31H	FM	C23H32O2
DM8W31H	IC	InChI=1S/C23H32O2/c1-16(12-21(24)25)10-9-11-17(2)18-13-19(22(3,4)5)15-20(14-18)23(6,7)8/h9-15H,1-8H3,(H,24,25)/b10-9+,16-12+,17-11+
DM8W31H	CS	C/C(=C\\C(=O)O)/C=C/C=C(\\C)/C1=CC(=CC(=C1)C(C)(C)C)C(C)(C)C
DM8W31H	IK	JMPZTWDLOGTBPM-OUQSKUGOSA-N
DM8W31H	IU	(2E,4E,6E)-7-(3,5-ditert-butylphenyl)-3-methylocta-2,4,6-trienoic acid
DM8W31H	CA	CAS 178600-20-9
DM8W31H	DE	Solid tumour/cancer

DM3R8TI	ID	DM3R8TI
DM3R8TI	DN	Lifarizine
DM3R8TI	HS	Discontinued in Phase 2
DM3R8TI	SN	BANM; Lifarizine hydrochloride < Rec INNM; RS-87476; 1-(Diphenylmethyl)-4-[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-ylmethyl]piperazine trihydrochloride
DM3R8TI	DT	Small molecular drug
DM3R8TI	PC	71336
DM3R8TI	MW	436.6
DM3R8TI	FM	C29H32N4
DM3R8TI	IC	InChI=1S/C29H32N4/c1-22-13-15-26(16-14-22)29-30-23(2)27(31-29)21-32-17-19-33(20-18-32)28(24-9-5-3-6-10-24)25-11-7-4-8-12-25/h3-16,28H,17-21H2,1-2H3,(H,30,31)
DM3R8TI	CS	CC1=CC=C(C=C1)C2=NC(=C(N2)C)CN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
DM3R8TI	IK	HTDFEXRUDGWNHA-UHFFFAOYSA-N
DM3R8TI	IU	1-benzhydryl-4-[[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-yl]methyl]piperazine
DM3R8TI	CA	119514-66-8
DM3R8TI	DE	Nerve injury

DMF8B62	ID	DMF8B62
DMF8B62	DN	Linetastine
DMF8B62	HS	Discontinued in Phase 2
DMF8B62	SN	Tmk688; UNII-7U248Z56LA; 110501-66-1; TMK-688; 159776-68-8; 7U248Z56LA; Linetastine [INN]; Tmk 688; Linazolast; CCRIS 6902; Linazolast (JAN); YM-257; AC1O5R98; CHEMBL314338; SCHEMBL1614484; [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; D09850;  Linazolast; Molecule 26
DMF8B62	CP	Sankyo
DMF8B62	DT	Small molecular drug
DMF8B62	PC	6439232
DMF8B62	MW	584.7
DMF8B62	FM	C35H40N2O6
DMF8B62	IC	InChI=1S/C35H40N2O6/c1-3-41-35(39)43-31-19-18-27(26-32(31)40-2)12-10-11-17-33(38)36-22-25-37-23-20-30(21-24-37)42-34(28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-19,26,30,34H,3,20-25H2,1-2H3,(H,36,38)/b12-10+,17-11+
DMF8B62	CS	CCOC(=O)OC1=C(C=C(C=C1)/C=C/C=C/C(=O)NCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4)OC
DMF8B62	IK	LUOUCHOLMUUZBO-SVSXJNCISA-N
DMF8B62	IU	[4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate
DMF8B62	CA	CAS 110501-66-1
DMF8B62	DE	Rhinitis

DM32JL5	ID	DM32JL5
DM32JL5	DN	Linotroban
DM32JL5	HS	Discontinued in Phase 2
DM32JL5	SN	CL-871502; HN-11500
DM32JL5	CP	Nycomed AS
DM32JL5	DT	Small molecular drug
DM32JL5	PC	65940
DM32JL5	MW	341.4
DM32JL5	FM	C14H15NO5S2
DM32JL5	IC	InChI=1S/C14H15NO5S2/c16-13(17)10-20-14-7-6-11(21-14)8-9-15-22(18,19)12-4-2-1-3-5-12/h1-7,15H,8-10H2,(H,16,17)
DM32JL5	CS	C1=CC=C(C=C1)S(=O)(=O)NCCC2=CC=C(S2)OCC(=O)O
DM32JL5	IK	ISSKMEQROMFEHL-UHFFFAOYSA-N
DM32JL5	IU	2-[5-[2-(benzenesulfonamido)ethyl]thiophen-2-yl]oxyacetic acid
DM32JL5	CA	CAS 120824-08-0
DM32JL5	DE	Thrombosis

DMS5X94	ID	DMS5X94
DMS5X94	DN	Lintitript
DMS5X94	HS	Discontinued in Phase 2
DMS5X94	SN	SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid
DMS5X94	CP	Sanofi-aventis
DMS5X94	TC	Anticancer Agents
DMS5X94	DT	Small molecular drug
DMS5X94	PC	122077
DMS5X94	MW	411.9
DMS5X94	FM	C20H14ClN3O3S
DMS5X94	IC	InChI=1S/C20H14ClN3O3S/c21-14-7-3-2-6-13(14)15-11-28-20(22-15)23-19(27)17-9-12-5-1-4-8-16(12)24(17)10-18(25)26/h1-9,11H,10H2,(H,25,26)(H,22,23,27)
DMS5X94	CS	C1=CC=C2C(=C1)C=C(N2CC(=O)O)C(=O)NC3=NC(=CS3)C4=CC=CC=C4Cl
DMS5X94	IK	ILNRQFBVVQUOLP-UHFFFAOYSA-N
DMS5X94	IU	2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid
DMS5X94	CA	CAS 136381-85-6
DMS5X94	CB	CHEBI:92624
DMS5X94	DE	Obesity; Pancreatic cancer

DMD39G4	ID	DMD39G4
DMD39G4	DN	Lintuzumab
DMD39G4	HS	Discontinued in Phase 2
DMD39G4	SN	Zamyl; HuM195; HuM195, PDL; Humanized M195, PDL; KB-195; SGN-33; SMART M195, PDL; M195 (humanized), Protein Design Labs; Anti-CD33 mAb (leukemia), Seattle Genetics
DMD39G4	CP	PDL BioPharma Inc; Seattle Genetics
DMD39G4	DT	Antibody
DMD39G4	DE	leukaemia

DM5ENKG	ID	DM5ENKG
DM5ENKG	DN	Lirequinil
DM5ENKG	HS	Discontinued in Phase 2
DM5ENKG	SN	Ro-41-3696
DM5ENKG	CP	Roche Holding AG
DM5ENKG	DT	Small molecular drug
DM5ENKG	PC	3045375
DM5ENKG	MW	448.9
DM5ENKG	FM	C26H25ClN2O3
DM5ENKG	IC	InChI=1S/C26H25ClN2O3/c1-2-32-20-11-12-28(16-20)25(30)23-15-22(17-6-4-3-5-7-17)26(31)29-13-10-18-8-9-19(27)14-21(18)24(23)29/h3-9,14-15,20H,2,10-13,16H2,1H3/t20-/m0/s1
DM5ENKG	CS	CCO[C@H]1CCN(C1)C(=O)C2=C3C4=C(CCN3C(=O)C(=C2)C5=CC=CC=C5)C=CC(=C4)Cl
DM5ENKG	IK	CBSWRAUYCIIUEI-FQEVSTJZSA-N
DM5ENKG	IU	10-chloro-1-[(3S)-3-ethoxypyrrolidine-1-carbonyl]-3-phenyl-6,7-dihydrobenzo[a]quinolizin-4-one
DM5ENKG	CA	CAS 143943-73-1
DM5ENKG	DE	Anxiety disorder

DMGZ3BF	ID	DMGZ3BF
DMGZ3BF	DN	Lodenosine
DMGZ3BF	HS	Discontinued in Phase 2
DMGZ3BF	SN	FddA; FddI; F-ddN; Fdd analogs, NIH/US Bioscience
DMGZ3BF	CP	National Cancer Institute
DMGZ3BF	DT	Small molecular drug
DMGZ3BF	PC	72180
DMGZ3BF	MW	253.23
DMGZ3BF	FM	C10H12FN5O2
DMGZ3BF	IC	InChI=1S/C10H12FN5O2/c11-6-1-5(2-17)18-10(6)16-4-15-7-8(12)13-3-14-9(7)16/h3-6,10,17H,1-2H2,(H2,12,13,14)/t5-,6-,10+/m0/s1
DMGZ3BF	CS	C1[C@H](O[C@H]([C@H]1F)N2C=NC3=C(N=CN=C32)N)CO
DMGZ3BF	IK	KBEMFSMODRNJHE-JFWOZONXSA-N
DMGZ3BF	IU	[(2S,4S,5R)-5-(6-aminopurin-9-yl)-4-fluorooxolan-2-yl]methanol
DMGZ3BF	CA	CAS 110143-10-7
DMGZ3BF	DE	Human immunodeficiency virus infection

DMW9MOK	ID	DMW9MOK
DMW9MOK	DN	Lomeguatrib
DMW9MOK	HS	Discontinued in Phase 2
DMW9MOK	SN	Patrin; AZD-5896; Patrin-2; O6-(4-bromothenylguanine), Cancer Research UK/KuDOS; 4-BTG (cancer), Paterson/Trinity/CRC/KuDOS/AstraZeneca
DMW9MOK	CP	Cancer Research Campaign
DMW9MOK	DT	Small molecular drug
DMW9MOK	PC	3025944
DMW9MOK	MW	326.17
DMW9MOK	FM	C10H8BrN5OS
DMW9MOK	IC	InChI=1S/C10H8BrN5OS/c11-5-1-6(18-3-5)2-17-9-7-8(14-4-13-7)15-10(12)16-9/h1,3-4H,2H2,(H3,12,13,14,15,16)
DMW9MOK	CS	C1=C(SC=C1Br)COC2=NC(=NC3=C2NC=N3)N
DMW9MOK	IK	JUJPKFNFCWJBCX-UHFFFAOYSA-N
DMW9MOK	IU	6-[(4-bromothiophen-2-yl)methoxy]-7H-purin-2-amine
DMW9MOK	CA	CAS 192441-08-0
DMW9MOK	DE	Solid tumour/cancer

DMCZI62	ID	DMCZI62
DMCZI62	DN	LORECLEZOLE
DMCZI62	HS	Discontinued in Phase 2
DMCZI62	SN	Loreclezole < Rec INN; R-72063; (Z)-1-(alpha,2,4-Trichlorostyryl)-1H-1,2,4-triazole; (Z)-1-[2-Chloro-2-(2,4-dichlorophenyl)vinyl]-1H-1,2,4-triazole
DMCZI62	DT	Small molecular drug
DMCZI62	PC	3034012
DMCZI62	MW	274.5
DMCZI62	FM	C10H6Cl3N3
DMCZI62	IC	InChI=1S/C10H6Cl3N3/c11-7-1-2-8(9(12)3-7)10(13)4-16-6-14-5-15-16/h1-6H/b10-4-
DMCZI62	CS	C1=CC(=C(C=C1Cl)Cl)/C(=C/N2C=NC=N2)/Cl
DMCZI62	IK	XGLHZTBDUXXHOM-WMZJFQQLSA-N
DMCZI62	IU	1-[(Z)-2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole
DMCZI62	CA	CAS 117857-45-1
DMCZI62	CB	CHEBI:92491
DMCZI62	DE	Epileptic seizures

DMM843E	ID	DMM843E
DMM843E	DN	LOSOXANTRONE
DMM843E	HS	Discontinued in Phase 2
DMM843E	SN	Losoxantrone; 88303-60-0; Losoxantrone [INN:BAN]; Bis-alkylamino anthrapyrazole; UNII-47KPH00809; CHEMBL83520; 47KPH00809; CI-941; bianthrazole; C22H27N5O4; DuP-941; DUP 941; Anthra(1,9-cd)pyrazol-6(2H)-one, 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)-; AC1Q6OLU; AC1L2HG1; SCHEMBL61319; DTXSID60236949; ZINC1583637; BDBM50240660; NCI60_003246; LS-178051; 33933-EP2311453A1; 33933-EP2308855A1; 33933-EP2275420A1; 33933-EP2270008A1; 33933-EP2298765A1; 33933-EP2298764A1; 33933-EP2292617A1
DMM843E	DT	Small molecular drug
DMM843E	PC	72116
DMM843E	MW	425.5
DMM843E	FM	C22H27N5O4
DMM843E	IC	InChI=1S/C22H27N5O4/c28-12-9-23-6-7-25-15-4-5-16-20-19(15)22(31)18-14(2-1-3-17(18)30)21(20)26-27(16)11-8-24-10-13-29/h1-5,23-25,28-30H,6-13H2
DMM843E	CS	C1=CC2=C(C(=C1)O)C(=O)C3=C(C=CC4=C3C2=NN4CCNCCO)NCCNCCO
DMM843E	IK	YROQEQPFUCPDCP-UHFFFAOYSA-N
DMM843E	IU	6-hydroxy-14-[2-(2-hydroxyethylamino)ethyl]-10-[2-(2-hydroxyethylamino)ethylamino]-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one
DMM843E	CA	CAS 88303-60-0
DMM843E	DE	Breast cancer

DMD16VS	ID	DMD16VS
DMD16VS	DN	Loviride
DMD16VS	HS	Discontinued in Phase 2
DMD16VS	SN	R-089439; R-89439
DMD16VS	CP	Janssen Pharmaceutica NV
DMD16VS	DT	Small molecular drug
DMD16VS	PC	3963
DMD16VS	MW	351.2
DMD16VS	FM	C17H16Cl2N2O2
DMD16VS	IC	InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23)
DMD16VS	CS	CC1=CC(=C(C=C1)C(=O)C)NC(C2=C(C=CC=C2Cl)Cl)C(=O)N
DMD16VS	IK	CJPLEFFCVDQQFZ-UHFFFAOYSA-N
DMD16VS	IU	2-(2-acetyl-5-methylanilino)-2-(2,6-dichlorophenyl)acetamide
DMD16VS	CA	CAS 147362-57-0
DMD16VS	DE	Human immunodeficiency virus infection

DM6G0PN	ID	DM6G0PN
DM6G0PN	DN	LTB 019
DM6G0PN	HS	Discontinued in Phase 2
DM6G0PN	CP	Novartis
DM6G0PN	DT	Small molecular drug
DM6G0PN	PC	9959759
DM6G0PN	MW	571.7
DM6G0PN	FM	C30H41N3O8
DM6G0PN	IC	InChI=1S/C26H37N3O4.C4H4O4/c1-18(2)29(19(3)4)26(30)21-11-14-23(24(17-21)31-5)33-16-8-6-7-15-32-22-12-9-20(10-13-22)25(27)28;5-3(6)1-2-4(7)8/h9-14,17-19H,6-8,15-16H2,1-5H3,(H3,27,28);1-2H,(H,5,6)(H,7,8)/b;2-1-
DM6G0PN	CS	CC(C)N(C(C)C)C(=O)C1=CC(=C(C=C1)OCCCCCOC2=CC=C(C=C2)C(=N)N)OC.C(=C\\C(=O)O)\\C(=O)O
DM6G0PN	IK	BUMMZWFWCNQFPS-BTJKTKAUSA-N
DM6G0PN	IU	(Z)-but-2-enedioic acid;4-[5-(4-carbamimidoylphenoxy)pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide
DM6G0PN	CA	CAS 147398-01-4
DM6G0PN	DE	Asthma

DMQ7A35	ID	DMQ7A35
DMQ7A35	DN	Lu-35138
DMQ7A35	HS	Discontinued in Phase 2
DMQ7A35	CP	H Lundbeck A/S
DMQ7A35	DE	Psychotic disorder

DMYR2U3	ID	DMYR2U3
DMYR2U3	DN	Lurosetron
DMYR2U3	HS	Discontinued in Phase 2
DMYR2U3	SN	Lurosetron mesylate; GR-87442; GR-87442N
DMYR2U3	CP	Glaxo Wellcome plc
DMYR2U3	DT	Small molecular drug
DMYR2U3	PC	172999
DMYR2U3	MW	312.34
DMYR2U3	FM	C17H17FN4O
DMYR2U3	IC	InChI=1S/C17H17FN4O/c1-10-13(20-9-19-10)8-22-7-6-14-15(17(22)23)11-4-3-5-12(18)16(11)21(14)2/h3-5,9H,6-8H2,1-2H3,(H,19,20)
DMYR2U3	CS	CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=C(N3C)C(=CC=C4)F
DMYR2U3	IK	NUMKWGDDRWJQMY-UHFFFAOYSA-N
DMYR2U3	IU	6-fluoro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one
DMYR2U3	CA	CAS 128486-54-4
DMYR2U3	DE	Vomiting

DMF1RTW	ID	DMF1RTW
DMF1RTW	DN	Lurtotecan
DMF1RTW	HS	Discontinued in Phase 2
DMF1RTW	SN	OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358;  Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan
DMF1RTW	CP	Glaxo Inc
DMF1RTW	DT	Small molecular drug
DMF1RTW	PC	60956
DMF1RTW	MW	518.6
DMF1RTW	FM	C28H30N4O6
DMF1RTW	IC	InChI=1S/C28H30N4O6/c1-3-28(35)20-11-22-25-18(14-32(22)26(33)19(20)15-38-27(28)34)17(13-31-6-4-30(2)5-7-31)16-10-23-24(12-21(16)29-25)37-9-8-36-23/h10-12,35H,3-9,13-15H2,1-2H3/t28-/m0/s1
DMF1RTW	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC6=C(C=C5N=C4C3=C2)OCCO6)CN7CCN(CC7)C)O
DMF1RTW	IK	RVFGKBWWUQOIOU-NDEPHWFRSA-N
DMF1RTW	IU	(18S)-18-ethyl-18-hydroxy-2-[(4-methylpiperazin-1-yl)methyl]-6,9,20-trioxa-13,24-diazahexacyclo[12.11.0.03,12.05,10.015,24.017,22]pentacosa-1,3,5(10),11,13,15,17(22)-heptaene-19,23-dione
DMF1RTW	CA	CAS 149882-10-0
DMF1RTW	DE	Lung cancer; Ovarian cancer

DMWB7DO	ID	DMWB7DO
DMWB7DO	DN	LY-223982
DMWB7DO	HS	Discontinued in Phase 2
DMWB7DO	SN	CGS-23131; LY-223980; LY-255253; SKF-107324
DMWB7DO	CP	Eli Lilly & Co
DMWB7DO	DT	Small molecular drug
DMWB7DO	PC	6444688
DMWB7DO	MW	502.6
DMWB7DO	FM	C30H30O7
DMWB7DO	IC	InChI=1S/C30H30O7/c1-36-26-14-10-21(11-15-26)7-4-2-3-5-18-37-27-16-12-24(19-22(27)13-17-28(31)32)29(33)23-8-6-9-25(20-23)30(34)35/h4,6-12,14-16,19-20H,2-3,5,13,17-18H2,1H3,(H,31,32)(H,34,35)/b7-4+
DMWB7DO	CS	COC1=CC=C(C=C1)/C=C/CCCCOC2=C(C=C(C=C2)C(=O)C3=CC(=CC=C3)C(=O)O)CCC(=O)O
DMWB7DO	IK	SYZSSLLFRVDRHL-QPJJXVBHSA-N
DMWB7DO	IU	3-[3-(2-carboxyethyl)-4-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]benzoyl]benzoic acid
DMWB7DO	CA	CAS 117423-74-2
DMWB7DO	DE	Asthma

DMTS1X5	ID	DMTS1X5
DMTS1X5	DN	LY-2300559
DMTS1X5	HS	Discontinued in Phase 2
DMTS1X5	SN	MGlu2 Pot/Cys (migraine prevention), Eli Lilly; Metabotropic glutamate 2 receptor potentiator/cysteinyl leukotriene receptor 1 antagonist (migraine), Eli Lilly; Mglu2 potentiator/CysLT1 antagonist (migraine prevention), Eli Lilly
DMTS1X5	CP	Eli Lilly & Co
DMTS1X5	PC	11611800
DMTS1X5	MW	434.5
DMTS1X5	FM	C26H26O6
DMTS1X5	IC	InChI=1S/C26H26O6/c1-3-5-22-23(13-12-21(16(2)27)25(22)29)32-15-17-8-10-18(11-9-17)24(28)19-6-4-7-20(14-19)26(30)31/h4,6-14,24,28-29H,3,5,15H2,1-2H3,(H,30,31)/t24-/m0/s1
DMTS1X5	CS	CCCC1=C(C=CC(=C1O)C(=O)C)OCC2=CC=C(C=C2)[C@@H](C3=CC(=CC=C3)C(=O)O)O
DMTS1X5	IK	DWQVYDLTPMGYNE-DEOSSOPVSA-N
DMTS1X5	IU	3-[(S)-[4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]phenyl]-hydroxymethyl]benzoic acid
DMTS1X5	CA	CAS 889116-06-7
DMTS1X5	DE	Migraine

DMGE9OA	ID	DMGE9OA
DMGE9OA	DN	LY-2523199
DMGE9OA	HS	Discontinued in Phase 2
DMGE9OA	SN	11-beta hydroxysteroid dehydrogenase type 1 inhibitor (diabetes), Eli Lilly; 11-beta-HSD-1 inhibitor (type 2 diabetes), Eli Lilly
DMGE9OA	CP	Eli Lilly & Co
DMGE9OA	DE	Type-2 diabetes

DM03FHA	ID	DM03FHA
DM03FHA	DN	LY293111
DM03FHA	HS	Discontinued in Phase 2
DM03FHA	SN	Etalocib; LY293111; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny
DM03FHA	CP	Sawyer & Brooks
DM03FHA	TC	Anticancer Agents
DM03FHA	DT	Small molecular drug
DM03FHA	PC	177941
DM03FHA	MW	544.6
DM03FHA	FM	C33H33FO6
DM03FHA	IC	InChI=1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37)
DM03FHA	CS	CCCC1=C(C=CC=C1OC2=CC=CC=C2C(=O)O)OCCCOC3=CC(=C(C=C3CC)C4=CC=C(C=C4)F)O
DM03FHA	IK	YFIZRWPXUYFCSN-UHFFFAOYSA-N
DM03FHA	IU	2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid
DM03FHA	CA	CAS 161172-51-6
DM03FHA	DE	Pancreatic cancer

DMIS7DW	ID	DMIS7DW
DMIS7DW	DN	LY-307161
DMIS7DW	HS	Discontinued in Phase 2
DMIS7DW	CP	Eli Lilly & Co
DMIS7DW	DE	Type-2 diabetes

DM08BIZ	ID	DM08BIZ
DM08BIZ	DN	LY354740
DM08BIZ	HS	Discontinued in Phase 2
DM08BIZ	SN	Eglumetad; Eglumegad; 176199-48-7; (1S,2S,5R,6S)-2-aminobicyclo[310]hexane-2,6-dicarboxylic acid; Eglumegad [INN]; UNII-ONU5A67T2S; LY-354740; LY 354740; ONU5A67T2S; CHEMBL8759; Eglumegad (INN); (1S,2S,5R,6S)-2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid; (1R,4S,5S,6S)-4-aminobicyclo[310]hexane-4,6-dicarboxylic acid; (1S,2S,5R,6S)-2-Amino-bicyclo[310]hexane-2,6-dicarboxylic acid; [3H]Eglumegad; LY366563; Eglumetad [USAN:INN]; (+)-2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid; 40F; PubChem18158;  Eglumegad; Eglumegad [USAN]; Eglumegad hydrate; Eglumetad hydrate; LY 314582; LY 366563; LY314582; Eglumegad (USAN); LY-314582; LY-354740 monohydrate; LY-366563; Eglumetad (INN/USAN); (1R,4S,5S,6S)-4-aminobicyclo[310]hexane-4,6-dicarboxylic acid hydrate; (1S,2S,5R,6S)-2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid monohydrate; 2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid; 4-aminobicyclo[310]hexane-4,6-dicarboxylic acid; [3H]eglumegad
DM08BIZ	CP	Eli Lilly
DM08BIZ	DT	Small molecular drug
DM08BIZ	PC	213056
DM08BIZ	MW	185.18
DM08BIZ	FM	C8H11NO4
DM08BIZ	IC	InChI=1S/C8H11NO4/c9-8(7(12)13)2-1-3-4(5(3)8)6(10)11/h3-5H,1-2,9H2,(H,10,11)(H,12,13)/t3-,4-,5-,8-/m0/s1
DM08BIZ	CS	C1C[C@]([C@H]2[C@@H]1[C@@H]2C(=O)O)(C(=O)O)N
DM08BIZ	IK	VTAARTQTOOYTES-RGDLXGNYSA-N
DM08BIZ	IU	(1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DM08BIZ	CA	CAS 176199-48-7
DM08BIZ	DE	Anxiety disorder

DMQ1LWU	ID	DMQ1LWU
DMQ1LWU	DN	M-100240
DMQ1LWU	HS	Discontinued in Phase 2
DMQ1LWU	SN	Mdl 100240; M100,240; MDL-100240; Mdl 100,142; Mdl 100,240; (4S,7S,12bR)-7-[[(2S)-2-acetylsulfanyl-3-phenylpropanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid
DMQ1LWU	CP	Aventis Pharma
DMQ1LWU	DT	Small molecular drug
DMQ1LWU	PC	133985
DMQ1LWU	MW	480.6
DMQ1LWU	FM	C26H28N2O5S
DMQ1LWU	IC	InChI=1S/C26H28N2O5S/c1-16(29)34-23(14-17-8-3-2-4-9-17)24(30)27-20-15-18-10-5-6-11-19(18)21-12-7-13-22(26(32)33)28(21)25(20)31/h2-6,8-11,20-23H,7,12-15H2,1H3,(H,27,30)(H,32,33)/t20-,21+,22-,23-/m0/s1
DMQ1LWU	CS	CC(=O)S[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]2CC3=CC=CC=C3[C@H]4CCC[C@H](N4C2=O)C(=O)O
DMQ1LWU	IK	AIEZUMPHACQOGT-BJESRGMDSA-N
DMQ1LWU	IU	(4S,7S,12bR)-7-[[(2S)-2-acetylsulfanyl-3-phenylpropanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid
DMQ1LWU	CA	CAS 142695-08-7
DMQ1LWU	DE	Hypotension

DMRN7GC	ID	DMRN7GC
DMRN7GC	DN	Manifaxine
DMRN7GC	HS	Discontinued in Phase 2
DMRN7GC	SN	BW-1555U88; GW-320659; GW-320659A
DMRN7GC	CP	Glaxo Wellcome plc
DMRN7GC	DT	Small molecular drug
DMRN7GC	PC	60829
DMRN7GC	MW	243.25
DMRN7GC	FM	C12H15F2NO2
DMRN7GC	IC	InChI=1S/C12H15F2NO2/c1-7-6-17-12(16,8(2)15-7)9-3-10(13)5-11(14)4-9/h3-5,7-8,15-16H,6H2,1-2H3/t7-,8+,12-/m1/s1
DMRN7GC	CS	C[C@@H]1CO[C@]([C@@H](N1)C)(C2=CC(=CC(=C2)F)F)O
DMRN7GC	IK	OZGPVYJHWWPEFT-RGNHYFCHSA-N
DMRN7GC	IU	(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol
DMRN7GC	CA	CAS 135306-39-7
DMRN7GC	DE	Major depressive disorder

DM1LM7D	ID	DM1LM7D
DM1LM7D	DN	Mannose phosphate
DM1LM7D	HS	Discontinued in Phase 2
DM1LM7D	SN	MANNOSE PHOSPHATE; SCHEMBL285569; SB17274
DM1LM7D	CP	Santa Cruz Biotechnology
DM1LM7D	DT	Small molecular drug
DM1LM7D	PC	73014169
DM1LM7D	MW	278.15
DM1LM7D	FM	C6H15O10P
DM1LM7D	IC	InChI=1S/C6H12O6.H3O4P/c7-1-3(9)5(11)6(12)4(10)2-8;1-5(2,3)4/h1,3-6,8-12H,2H2;(H3,1,2,3,4)/t3-,4-,5-,6-;/m1./s1
DM1LM7D	CS	C([C@H]([C@H]([C@@H]([C@@H](C=O)O)O)O)O)O.OP(=O)(O)O
DM1LM7D	IK	NDVRKEKNSBMTAX-MVNLRXSJSA-N
DM1LM7D	IU	(2S,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid
DM1LM7D	DE	Lesion

DMRHYAU	ID	DMRHYAU
DMRHYAU	DN	MAZAPERTINE
DMRHYAU	HS	Discontinued in Phase 2
DMRHYAU	SN	Mazapertine; UNII-N0X1XW704P; CHEMBL10085; N0X1XW704P; 134208-17-6; RWJ-377796; Mazapertine [INN]; AC1L1TZN; AC1Q5K4U; SCHEMBL636631; DTXSID40158594; ZKZFPRUSWCYSGT-UHFFFAOYSA-N; BDBM50029257; L001470; Piperidino[3-[[4-(2-isopropoxyphenyl)piperazino]methyl]phenyl] ketone; 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]piperidine; {3-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-phenyl}-piperidin-1-yl-methanone; piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
DMRHYAU	DT	Small molecular drug
DMRHYAU	PC	60820
DMRHYAU	MW	421.6
DMRHYAU	FM	C26H35N3O2
DMRHYAU	IC	InChI=1S/C26H35N3O2/c1-21(2)31-25-12-5-4-11-24(25)28-17-15-27(16-18-28)20-22-9-8-10-23(19-22)26(30)29-13-6-3-7-14-29/h4-5,8-12,19,21H,3,6-7,13-18,20H2,1-2H3
DMRHYAU	CS	CC(C)OC1=CC=CC=C1N2CCN(CC2)CC3=CC(=CC=C3)C(=O)N4CCCCC4
DMRHYAU	IK	ZKZFPRUSWCYSGT-UHFFFAOYSA-N
DMRHYAU	IU	piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
DMRHYAU	CA	CAS 134208-17-6

DMIG5W8	ID	DMIG5W8
DMIG5W8	DN	MCPP
DMIG5W8	HS	Discontinued in Phase 2
DMIG5W8	SN	1-(3-Chlorophenyl)piperazine
DMIG5W8	DT	Small molecular drug
DMIG5W8	PC	7153
DMIG5W8	MW	214.64
DMIG5W8	FM	C10H11ClO3
DMIG5W8	IC	InChI=1S/C10H11ClO3/c1-6-5-8(11)3-4-9(6)14-7(2)10(12)13/h3-5,7H,1-2H3,(H,12,13)
DMIG5W8	CS	CC1=C(C=CC(=C1)Cl)OC(C)C(=O)O
DMIG5W8	IK	WNTGYJSOUMFZEP-UHFFFAOYSA-N
DMIG5W8	IU	2-(4-chloro-2-methylphenoxy)propanoic acid
DMIG5W8	CA	CAS 93-65-2
DMIG5W8	CB	CHEBI:75704
DMIG5W8	DE	Mood disorder

DMKEYSX	ID	DMKEYSX
DMKEYSX	DN	MDL 101,731
DMKEYSX	HS	Discontinued in Phase 2
DMKEYSX	SN	Tezacitabine; Fmdc cpd; 130306-02-4; Mdl 101,731; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331
DMKEYSX	DT	Small molecular drug
DMKEYSX	PC	6435808
DMKEYSX	MW	257.22
DMKEYSX	FM	C10H12FN3O4
DMKEYSX	IC	InChI=1S/C10H12FN3O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-3,6,8-9,15-16H,4H2,(H2,12,13,17)/b5-3+/t6-,8+,9-/m1/s1
DMKEYSX	CS	C1=CN(C(=O)N=C1N)[C@H]2/C(=C/F)/[C@@H]([C@H](O2)CO)O
DMKEYSX	IK	GFFXZLZWLOBBLO-ASKVSEFXSA-N
DMKEYSX	IU	4-amino-1-[(2R,3E,4S,5R)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMKEYSX	CA	CAS 130306-02-4
DMKEYSX	DE	Gastric adenocarcinoma

DM9ZEGT	ID	DM9ZEGT
DM9ZEGT	DN	MDX-070
DM9ZEGT	HS	Discontinued in Phase 2
DM9ZEGT	CP	Medarex
DM9ZEGT	DT	Antibody
DM9ZEGT	DE	Prostate cancer

DM3HIQY	ID	DM3HIQY
DM3HIQY	DN	Melanoma vaccine (ALVAC)
DM3HIQY	HS	Discontinued in Phase 2
DM3HIQY	SN	Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur
DM3HIQY	CP	Sanofi Pasteur
DM3HIQY	DT	Vaccine
DM3HIQY	DE	Melanoma

DM2DK4A	ID	DM2DK4A
DM2DK4A	DN	Mequitamium iodide
DM2DK4A	HS	Discontinued in Phase 2
DM2DK4A	SN	LG-30435
DM2DK4A	CP	Laboratorio Guidotti SpA
DM2DK4A	DT	Small molecular drug
DM2DK4A	PC	72028
DM2DK4A	MW	464.4
DM2DK4A	FM	C21H25IN2S
DM2DK4A	IC	InChI=1S/C21H25N2S.HI/c1-23-12-10-16(11-13-23)17(15-23)14-22-18-6-2-4-8-20(18)24-21-9-5-3-7-19(21)22;/h2-9,16-17H,10-15H2,1H3;1H/q+1;/p-1
DM2DK4A	CS	C[N+]12CCC(CC1)C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53.[I-]
DM2DK4A	IK	SWVANDLDSRKJFI-UHFFFAOYSA-M
DM2DK4A	IU	10-[(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl)methyl]phenothiazine;iodide
DM2DK4A	CA	CAS 101396-42-3
DM2DK4A	DE	Asthma

DMMZ4E9	ID	DMMZ4E9
DMMZ4E9	DN	Merbarone
DMMZ4E9	HS	Discontinued in Phase 2
DMMZ4E9	SN	NSC-336628
DMMZ4E9	CP	Uniroyal Chemical Co Inc
DMMZ4E9	DT	Small molecular drug
DMMZ4E9	PC	4990817
DMMZ4E9	MW	263.27
DMMZ4E9	FM	C11H9N3O3S
DMMZ4E9	IC	InChI=1S/C11H9N3O3S/c15-8(12-6-4-2-1-3-5-6)7-9(16)13-11(18)14-10(7)17/h1-5,7H,(H,12,15)(H2,13,14,16,17,18)
DMMZ4E9	CS	C1=CC=C(C=C1)NC(=O)C2C(=O)NC(=S)NC2=O
DMMZ4E9	IK	JARCFMKMOFFIGZ-UHFFFAOYSA-N
DMMZ4E9	IU	4,6-dioxo-N-phenyl-2-sulfanylidene-1,3-diazinane-5-carboxamide
DMMZ4E9	CA	CAS 97534-21-9
DMMZ4E9	DE	Pancreatic cancer

DM90SHY	ID	DM90SHY
DM90SHY	DN	METIAPRIL
DM90SHY	HS	Discontinued in Phase 2
DM90SHY	SN	Methiopril; Cis-1-[3-(Acetylsulfanyl)propionyl]-6-methylpiperidine-2-carboxylic acid
DM90SHY	PC	788183
DM90SHY	MW	273.35
DM90SHY	FM	C12H19NO4S
DM90SHY	IC	InChI=1S/C12H19NO4S/c1-8-4-3-5-10(12(16)17)13(8)11(15)6-7-18-9(2)14/h8,10H,3-7H2,1-2H3,(H,16,17)/t8-,10-/m0/s1
DM90SHY	CS	C[C@H]1CCC[C@H](N1C(=O)CCSC(=O)C)C(=O)O
DM90SHY	IK	JHFOAISYWJRTIM-WPRPVWTQSA-N
DM90SHY	IU	(2S,6S)-1-(3-acetylsulfanylpropanoyl)-6-methylpiperidine-2-carboxylic acid
DM90SHY	DE	Hypotension

DMJLNUD	ID	DMJLNUD
DMJLNUD	DN	MILACAINIDE TARTRATE
DMJLNUD	HS	Discontinued in Phase 2
DMJLNUD	SN	(R)-RO-22-9194.tartrate; 2(R)-Amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate
DMJLNUD	PC	15298297
DMJLNUD	MW	461.5
DMJLNUD	FM	C23H31N3O7
DMJLNUD	IC	InChI=1S/C19H25N3O.C4H6O6/c1-14-7-4-8-15(2)18(14)22(19(23)16(3)20)12-6-10-17-9-5-11-21-13-17;5-1(3(7)8)2(6)4(9)10/h4-5,7-9,11,13,16H,6,10,12,20H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t16-;1-,2-/m10/s1
DMJLNUD	CS	CC1=C(C(=CC=C1)C)N(CCCC2=CN=CC=C2)C(=O)[C@@H](C)N.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O
DMJLNUD	IK	UKFWRCBTXJZERY-ZKBHHEPKSA-N
DMJLNUD	IU	(2R)-2-amino-N-(2,6-dimethylphenyl)-N-(3-pyridin-3-ylpropyl)propanamide;(2S,3S)-2,3-dihydroxybutanedioic acid
DMJLNUD	CA	CAS 141725-10-2
DMJLNUD	DE	Cardiac arrhythmias

DMTX97J	ID	DMTX97J
DMTX97J	DN	MILFASARTAN
DMTX97J	HS	Discontinued in Phase 2
DMTX97J	SN	Tienartan; Arwin (Knoll); LR-B/081; Milfasartan; 2-[4-Butyl-2-methyl-6-oxo-5-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1,6-dihydropyrimidin-1-ylmethyl]thiophene-3-carboxylic acid methyl ester; 4-Butyl-1-[3-(methoxycarbonyl)thien-2-ylmethyl]-2-methyl-5-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl-1,6-dihydropyrimidin-6-one
DMTX97J	DT	Small molecular drug
DMTX97J	PC	3047757
DMTX97J	MW	554.7
DMTX97J	FM	C30H30N6O3S
DMTX97J	IC	InChI=1S/C30H30N6O3S/c1-4-5-10-26-25(29(37)36(19(2)31-26)18-27-24(15-16-40-27)30(38)39-3)17-20-11-13-21(14-12-20)22-8-6-7-9-23(22)28-32-34-35-33-28/h6-9,11-16H,4-5,10,17-18H2,1-3H3,(H,32,33,34,35)
DMTX97J	CS	CCCCC1=C(C(=O)N(C(=N1)C)CC2=C(C=CS2)C(=O)OC)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMTX97J	IK	QVFVAKQHELFATN-UHFFFAOYSA-N
DMTX97J	IU	methyl 2-[[4-butyl-2-methyl-6-oxo-5-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-1-yl]methyl]thiophene-3-carboxylate
DMTX97J	CA	CAS 148564-47-0
DMTX97J	DE	Hypertension

DMF1IH5	ID	DMF1IH5
DMF1IH5	DN	Milveterol
DMF1IH5	HS	Discontinued in Phase 2
DMF1IH5	SN	UNII-LGY1VQ9622; LGY1VQ9622; 652990-07-3; Milveterol [INN]; SCHEMBL265694; CHEMBL1940832; DTXSID30215640; BMKINZUHKYLSKI-DQEYMECFSA-N; BDBM50419652
DMF1IH5	CP	GSK
DMF1IH5	DT	Small molecular drug
DMF1IH5	PC	9892481
DMF1IH5	MW	435.5
DMF1IH5	FM	C25H29N3O4
DMF1IH5	IC	InChI=1S/C25H29N3O4/c29-17-28-22-14-20(8-11-23(22)30)24(31)15-26-13-12-18-6-9-21(10-7-18)27-16-25(32)19-4-2-1-3-5-19/h1-11,14,17,24-27,30-32H,12-13,15-16H2,(H,28,29)/t24-,25-/m0/s1
DMF1IH5	CS	C1=CC=C(C=C1)[C@H](CNC2=CC=C(C=C2)CCNC[C@@H](C3=CC(=C(C=C3)O)NC=O)O)O
DMF1IH5	IK	BMKINZUHKYLSKI-DQEYMECFSA-N
DMF1IH5	IU	N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[2-[4-[[(2R)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide
DMF1IH5	CA	CAS 652990-07-3
DMF1IH5	DE	Asthma

DMP8CVD	ID	DMP8CVD
DMP8CVD	DN	Milveterol+Fluticasone
DMP8CVD	HS	Discontinued in Phase 2
DMP8CVD	SN	S-(fluoromethyl) (6S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate; 90566-53-3; S-(fluoromethyl) (6a,8x,11b,16a,17a)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate; AC1Q68ZV; AC1L1Y1V; AN-15808; s-(fluoromethyl)(6; A,8; I,11
DMP8CVD	CP	GlaxoSmithKline
DMP8CVD	DT	Small molecular drug
DMP8CVD	PC	62924
DMP8CVD	MW	444.5
DMP8CVD	FM	C22H27F3O4S
DMP8CVD	IC	InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14?,16+,17+,19+,20+,21+,22+/m1/s1
DMP8CVD	CS	C[C@@H]1C[C@H]2C3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)O)C)O)F)C)F
DMP8CVD	IK	MGNNYOODZCAHBA-AZYZPMHWSA-N
DMP8CVD	IU	S-(fluoromethyl) (6S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
DMP8CVD	DE	Chronic obstructive pulmonary disease

DMVF2R1	ID	DMVF2R1
DMVF2R1	DN	Minopafant
DMVF2R1	HS	Discontinued in Phase 2
DMVF2R1	SN	E-5880
DMVF2R1	CP	Eisai Co Ltd
DMVF2R1	DT	Small molecular drug
DMVF2R1	PC	130990
DMVF2R1	MW	861.5
DMVF2R1	FM	C46H73ClN4O9
DMVF2R1	IC	InChI=1S/C46H72N4O9.ClH/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-31-47-44(52)59-39-29-33-49(34-30-39)45(53)57-36-40(55-3)37-58-46(54)50(35-38-26-23-25-32-48(38)6-2)43(51)41-27-21-22-28-42(41)56-4;/h21-23,25-28,32,39-40H,5-20,24,29-31,33-37H2,1-4H3;1H/t40-;/m1./s1
DMVF2R1	CS	CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(CC1)C(=O)OC[C@H](COC(=O)N(CC2=CC=CC=[N+]2CC)C(=O)C3=CC=CC=C3OC)OC.[Cl-]
DMVF2R1	IK	IXRMFSBOHHRXSS-YPMTVOEDSA-N
DMVF2R1	IU	[(2R)-3-[(1-ethylpyridin-1-ium-2-yl)methyl-(2-methoxybenzoyl)carbamoyl]oxy-2-methoxypropyl] 4-(octadecylcarbamoyloxy)piperidine-1-carboxylate;chloride
DMVF2R1	CA	CAS 128420-61-1
DMVF2R1	DE	Sepsis

DMT6IUR	ID	DMT6IUR
DMT6IUR	DN	MIRFENTANIL HYDROCHLORIDE
DMT6IUR	HS	Discontinued in Phase 2
DMT6IUR	SN	A-3508 hydrochloride; ANQ-3508 HCl; Mirfentanil hydrochloride < Rec INNM; OHM-10579 (free base); N-(1-Phenethyl-4-piperidinyl)-N-(2-pyrazinyl)furan-2-carboxamide hydrochloride
DMT6IUR	DT	Small molecular drug
DMT6IUR	PC	60697
DMT6IUR	MW	412.9
DMT6IUR	FM	C22H25ClN4O2
DMT6IUR	IC	InChI=1S/C22H24N4O2.ClH/c27-22(20-7-4-16-28-20)26(21-17-23-11-12-24-21)19-9-14-25(15-10-19)13-8-18-5-2-1-3-6-18;/h1-7,11-12,16-17,19H,8-10,13-15H2;1H
DMT6IUR	CS	C1CN(CCC1N(C2=NC=CN=C2)C(=O)C3=CC=CO3)CCC4=CC=CC=C4.Cl
DMT6IUR	IK	KVCOVXMNIYUKBS-UHFFFAOYSA-N
DMT6IUR	IU	N-[1-(2-phenylethyl)piperidin-4-yl]-N-pyrazin-2-ylfuran-2-carboxamide;hydrochloride
DMT6IUR	CA	CAS 119413-53-5
DMT6IUR	DE	Pain

DMW59FE	ID	DMW59FE
DMW59FE	DN	Mitonafide
DMW59FE	HS	Discontinued in Phase 2
DMW59FE	SN	Mitonafide; N-[2-(Dimethylamino)ethyl]-3-nitronaphthalimide; 2-[2-(Dimethylamino)ethyl]-5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione
DMW59FE	DT	Small molecular drug
DMW59FE	PC	327044
DMW59FE	MW	313.31
DMW59FE	FM	C16H15N3O4
DMW59FE	IC	InChI=1S/C16H15N3O4/c1-17(2)6-7-18-15(20)12-5-3-4-10-8-11(19(22)23)9-13(14(10)12)16(18)21/h3-5,8-9H,6-7H2,1-2H3
DMW59FE	CS	CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)[N+](=O)[O-]
DMW59FE	IK	XXVLKDRPHSFIIB-UHFFFAOYSA-N
DMW59FE	IU	2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione
DMW59FE	CA	CAS 54824-17-8
DMW59FE	DE	Solid tumour/cancer

DMCAKPG	ID	DMCAKPG
DMCAKPG	DN	MK-287
DMCAKPG	HS	Discontinued in Phase 2
DMCAKPG	SN	L-680573; (-)-(S,S)-2-[3-(2-Hydroxyethylsulfonyl)-5-methoxy-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran
DMCAKPG	DT	Small molecular drug
DMCAKPG	PC	131925
DMCAKPG	MW	510.6
DMCAKPG	FM	C25H34O9S
DMCAKPG	IC	InChI=1S/C25H34O9S/c1-6-10-33-25-22(31-4)14-17(15-23(25)35(27,28)11-9-26)19-8-7-18(34-19)16-12-20(29-2)24(32-5)21(13-16)30-3/h12-15,18-19,26H,6-11H2,1-5H3/t18-,19-/m0/s1
DMCAKPG	CS	CCCOC1=C(C=C(C=C1S(=O)(=O)CCO)[C@@H]2CC[C@H](O2)C3=CC(=C(C(=C3)OC)OC)OC)OC
DMCAKPG	IK	WXIDMVGKJBAEFP-OALUTQOASA-N
DMCAKPG	IU	2-[3-methoxy-2-propoxy-5-[(2S,5S)-5-(3,4,5-trimethoxyphenyl)oxolan-2-yl]phenyl]sulfonylethanol
DMCAKPG	CA	CAS 135947-75-0
DMCAKPG	DE	Sepsis

DM48ELZ	ID	DM48ELZ
DM48ELZ	DN	MK-386
DM48ELZ	HS	Discontinued in Phase 2
DM48ELZ	SN	CHEMBL25448; MK-386
DM48ELZ	DT	Small molecular drug
DM48ELZ	PC	9888107
DM48ELZ	MW	415.7
DM48ELZ	FM	C28H49NO
DM48ELZ	IC	InChI=1S/C28H49NO/c1-18(2)9-8-10-19(3)21-11-12-22-26-20(4)17-24-28(6,16-14-25(30)29(24)7)23(26)13-15-27(21,22)5/h18-24,26H,8-17H2,1-7H3/t19-,20+,21-,22+,23+,24-,26+,27-,28-/m1/s1
DM48ELZ	CS	C[C@H]1C[C@@H]2[C@](CCC(=O)N2C)([C@@H]3[C@@H]1[C@@H]4CC[C@@H]([C@]4(CC3)C)[C@H](C)CCCC(C)C)C
DM48ELZ	IK	XUTZDXHKQDPUMA-MVJJLJOTSA-N
DM48ELZ	IU	(1R,3aS,3bS,4S,5aR,9aR,9bS,11aR)-4,6,9a,11a-tetramethyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinolin-7-one
DM48ELZ	CA	CAS 158493-17-5
DM48ELZ	DE	Acne vulgaris

DMVEGW6	ID	DMVEGW6
DMVEGW6	DN	MK-499
DMVEGW6	HS	Discontinued in Phase 2
DMVEGW6	SN	MK-499; MK 499; L-706000; L 706000; L-706,000; SCHEMBL4706649; CHEMBL477015; GTPL2607; BDBM24064; MK499; [35S]-MK499; N-[[3,4-Dihydro-4beta-hydroxy-1'-[[(R)-6-cyano-1,2,3,4-tetrahydronaphthalen]-2-yl]spiro[2H-1-benzopyran-2,4'-piperidin]]-6-yl]methanesulfonamide; N-[(4R)-1''-[(2R)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-3,4-dihydrospiro[1-benzopyran-2,4''-piperidine]-4-ol]methanesulfonamide
DMVEGW6	DT	Small molecular drug
DMVEGW6	PC	9934294
DMVEGW6	MW	467.6
DMVEGW6	FM	C25H29N3O4S
DMVEGW6	IC	InChI=1S/C25H29N3O4S/c1-33(30,31)27-20-5-7-24-22(14-20)23(29)15-25(32-24)8-10-28(11-9-25)21-6-4-18-12-17(16-26)2-3-19(18)13-21/h2-3,5,7,12,14,21,23,27,29H,4,6,8-11,13,15H2,1H3/t21-,23-/m1/s1
DMVEGW6	CS	CS(=O)(=O)NC1=CC2=C(C=C1)OC3(CCN(CC3)[C@@H]4CCC5=C(C4)C=CC(=C5)C#N)C[C@H]2O
DMVEGW6	IK	NIYGLRKUBPNXQS-FYYLOGMGSA-N
DMVEGW6	IU	N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl]methanesulfonamide
DMVEGW6	CA	CAS 150481-98-4
DMVEGW6	DE	Cardiac arrhythmias

DMVXTZG	ID	DMVXTZG
DMVXTZG	DN	MK-591
DMVXTZG	HS	Discontinued in Phase 2
DMVXTZG	SN	Quiflapon; Quiflapon [INN]; L 686708; MK 0591; MK 591; L-686708; MK-0591; L-686,708; 3-(1-(4-chlorobenzyl-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl))-2,2-dimethyl propanoic acid; 3-(tert-Butylthio)-1-(p-chlorobenzyl)-alpha,alpha-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-(tert-butylthio)-1-(p-chlorobenzyl)-a,a-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid
DMVXTZG	CP	Merck
DMVXTZG	DT	Small molecular drug
DMVXTZG	PC	23672584
DMVXTZG	MW	609.2
DMVXTZG	FM	C34H34ClN2NaO3S
DMVXTZG	IC	InChI=1S/C34H35ClN2O3S.Na/c1-33(2,3)41-31-27-18-26(40-21-25-15-12-23-8-6-7-9-28(23)36-25)16-17-29(27)37(20-22-10-13-24(35)14-11-22)30(31)19-34(4,5)32(38)39;/h6-18H,19-21H2,1-5H3,(H,38,39);/q;+1/p-1
DMVXTZG	CS	CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)[O-].[Na+]
DMVXTZG	IK	YPURUCMVRRNPHJ-UHFFFAOYSA-M
DMVXTZG	IU	sodium;3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate
DMVXTZG	CA	CAS 147030-01-1
DMVXTZG	DE	Asthma

DMBJLZG	ID	DMBJLZG
DMBJLZG	DN	MK-852
DMBJLZG	HS	Discontinued in Phase 2
DMBJLZG	SN	MK-852; CHEMBL331559; BDBM50092127; 8-Acetylamino-22-(4-aminomethyl-benzyl)-5-carbamoylmethyl-16-carboxymethyl-1,1-dimethyl-4,7,15,18,21,24-hexaoxo-icosahydro-2,10,11-trithia-3a,6,14,17,20,23-hexaaza-cyclopentacyclotricosene-13-carboxylic acid (MK-0852)
DMBJLZG	DT	Small molecular drug
DMBJLZG	PC	44344173
DMBJLZG	MW	870
DMBJLZG	FM	C34H47N9O12S3
DMBJLZG	IC	InChI=1S/C34H47N9O12S3/c1-16(44)38-22-13-57-58-14-23(33(54)55)42-29(50)20(10-26(47)48)39-25(46)12-37-28(49)19(8-17-4-6-18(11-35)7-5-17)40-31(52)27-34(2,3)56-15-43(27)32(53)21(9-24(36)45)41-30(22)51/h4-7,19-23,27H,8-15,35H2,1-3H3,(H2,36,45)(H,37,49)(H,38,44)(H,39,46)(H,40,52)(H,41,51)(H,42,50)(H,47,48)(H,54,55)/t19?,20-,21-,22+,23+,27-/m0/s1
DMBJLZG	CS	CC(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)C(NC(=O)[C@H]2C(SCN2C(=O)[C@@H](NC1=O)CC(=O)N)(C)C)CC3=CC=C(C=C3)CN)CC(=O)O)C(=O)O
DMBJLZG	IK	IHTQUFFCUYSOIH-JUXWROAHSA-N
DMBJLZG	IU	(3S,6S,11S,14S,23S)-6-acetamido-20-[[4-(aminomethyl)phenyl]methyl]-3-(2-amino-2-oxoethyl)-14-(carboxymethyl)-24,24-dimethyl-2,5,13,16,19,22-hexaoxo-8,9,25-trithia-1,4,12,15,18,21-hexazabicyclo[21.3.0]hexacosane-11-carboxylic acid
DMBJLZG	DE	Thrombosis

DMT0O7H	ID	DMT0O7H
DMT0O7H	DN	MK-886
DMT0O7H	HS	Discontinued in Phase 2
DMT0O7H	SN	MK-886; 118414-82-7; MK 886; MK886; 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid; UNII-080626SQ8C; QAOAOVKBIIKRNL-UHFFFAOYSA-N; L-663,536; CHEMBL29097; CHEBI:75390; L 663536; MK-886 (L-663,536); 080626SQ8C; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid; 1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS]; L-663536; SMR000466278
DMT0O7H	DT	Small molecular drug
DMT0O7H	PC	3651377
DMT0O7H	MW	472.1
DMT0O7H	FM	C27H34ClNO2S
DMT0O7H	IC	InChI=1S/C27H34ClNO2S/c1-17(2)19-10-13-22-21(14-19)24(32-26(3,4)5)23(15-27(6,7)25(30)31)29(22)16-18-8-11-20(28)12-9-18/h8-14,17H,15-16H2,1-7H3,(H,30,31)
DMT0O7H	CS	CC(C)C1=CC2=C(C=C1)N(C(=C2SC(C)(C)C)CC(C)(C)C(=O)O)CC3=CC=C(C=C3)Cl
DMT0O7H	IK	QAOAOVKBIIKRNL-UHFFFAOYSA-N
DMT0O7H	IU	3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid
DMT0O7H	CA	CAS 118414-82-7
DMT0O7H	CB	CHEBI:75390
DMT0O7H	DE	Asthma

DMMNUZC	ID	DMMNUZC
DMMNUZC	DN	MK-912
DMMNUZC	HS	Discontinued in Phase 2
DMMNUZC	SN	MK-912; L 657743; MK 912; L-657,743; L-657,743-002W; L 657,743; 1',3'-Dimethylspiro(1,3,4,5',6,6',7,12b-octahydro-2H-benzo(b)furo(2,3-a)quinolizine)-2,4'-pyrimidin-2'-one; AC1L3X3J; Lopac0_000760; CHEMBL1256985; BDBM81811; Spiro(2H-benzofuro(2,3-a)quinolizine-2,4'(1'H)-pyrimidin)-2'(3'H)-one, 1,3,4,5',6,6',7,12b-octahydro-1',3'-dimethyl-, (2S-trans)-; PDSP2_001636; PDSP1_001652; NSC_123679; CCG-204845; CAS_123679; NCGC00015699-02; NCGC00162243-01; NCGC00015699-03; LS-187521; LS-186865; L023963
DMMNUZC	DT	Small molecular drug
DMMNUZC	PC	189711
DMMNUZC	MW	339.4
DMMNUZC	FM	C20H25N3O2
DMMNUZC	IC	InChI=1S/C20H25N3O2/c1-21-11-8-20(22(2)19(21)24)9-12-23-10-7-15-14-5-3-4-6-17(14)25-18(15)16(23)13-20/h3-6,16H,7-13H2,1-2H3/t16-,20+/m0/s1
DMMNUZC	CS	CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C
DMMNUZC	IK	JRDUBBHIPPPSLP-OXJNMPFZSA-N
DMMNUZC	IU	(2S,12bS)-1',3'-dimethylspiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,4'-1,3-diazinane]-2'-one
DMMNUZC	CA	CAS 111466-41-2

DMOZUPB	ID	DMOZUPB
DMOZUPB	DN	MK-944a
DMOZUPB	HS	Discontinued in Phase 2
DMOZUPB	SN	L-756423
DMOZUPB	CP	Merck & Co Inc
DMOZUPB	DT	Small molecular drug
DMOZUPB	PC	5481481
DMOZUPB	MW	652.8
DMOZUPB	FM	C39H48N4O5
DMOZUPB	IC	InChI=1S/C39H48N4O5/c1-39(2,3)41-38(47)33-25-42(24-31-21-28-14-8-10-16-35(28)48-31)17-18-43(33)23-30(44)20-29(19-26-11-5-4-6-12-26)37(46)40-36-32-15-9-7-13-27(32)22-34(36)45/h4-16,21,29-30,33-34,36,44-45H,17-20,22-25H2,1-3H3,(H,40,46)(H,41,47)/t29-,30+,33+,34-,36+/m1/s1
DMOZUPB	CS	CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CC6=CC=CC=C6O5
DMOZUPB	IK	AOMZDQMIOCTPQP-QHQMVRJISA-N
DMOZUPB	IU	(2S)-4-(1-benzofuran-2-ylmethyl)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butylpiperazine-2-carboxamide
DMOZUPB	CA	CAS 216863-66-0
DMOZUPB	DE	Human immunodeficiency virus infection

DMRA3EZ	ID	DMRA3EZ
DMRA3EZ	DN	MLN3897
DMRA3EZ	HS	Discontinued in Phase 2
DMRA3EZ	CP	Millenium Pharmacenticals; Sanofi Aventis
DMRA3EZ	DE	Rheumatoid arthritis

DMTWLG8	ID	DMTWLG8
DMTWLG8	DN	MLN-977
DMTWLG8	HS	Discontinued in Phase 2
DMTWLG8	SN	CHEMBL73148; CMI977; LDP-977; SCHEMBL16932371; LDP 977; CMI 977; HY-U00260; BDBM50144621; CS-7474; 175212-04-1; UNII-VNR0T3Q498 component YANONWCPCKIWEC-CABCVRRESA-N; N-(4-{(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydrofuran-2-yl}but-3-ynyl)-N-hydroxyurea; Urea, N-(4-((2S,5S)-5-((4-fluorophenoxy)methyl)tetrahydro-2-furanyl)-3-butyn-1-yl)-N-hydroxy-
DMTWLG8	CP	PharmaEngine
DMTWLG8	DT	Small molecular drug
DMTWLG8	PC	9905233
DMTWLG8	MW	322.33
DMTWLG8	FM	C16H19FN2O4
DMTWLG8	IC	InChI=1S/C16H19FN2O4/c17-12-4-6-13(7-5-12)22-11-15-9-8-14(23-15)3-1-2-10-19(21)16(18)20/h4-7,14-15,21H,2,8-11H2,(H2,18,20)/t14-,15+/m1/s1
DMTWLG8	CS	C1C[C@H](O[C@@H]1COC2=CC=C(C=C2)F)C#CCCN(C(=O)N)O
DMTWLG8	IK	YANONWCPCKIWEC-CABCVRRESA-N
DMTWLG8	IU	1-[4-[(2S,5S)-5-[(4-fluorophenoxy)methyl]oxolan-2-yl]but-3-ynyl]-1-hydroxyurea
DMTWLG8	CA	CAS 175212-04-1
DMTWLG8	DE	Chronic obstructive pulmonary disease

DMLG7QB	ID	DMLG7QB
DMLG7QB	DN	Mozenavir
DMLG7QB	HS	Discontinued in Phase 2
DMLG7QB	SN	DMP-450; Mozenavir mesilate; XM-412 (free base); (4R,5S,6S,7R)-1,3-Bis(3-aminobenzyl)-4,7-dibenzyl-5,6-dihydroxyhexahydro-1,3-diazepin-2-one dimethanesulfonate
DMLG7QB	CP	Bristol-Myers Squibb
DMLG7QB	DT	Small molecular drug
DMLG7QB	PC	154044
DMLG7QB	MW	536.7
DMLG7QB	FM	C33H36N4O3
DMLG7QB	IC	InChI=1S/C33H36N4O3/c34-27-15-7-13-25(17-27)21-36-29(19-23-9-3-1-4-10-23)31(38)32(39)30(20-24-11-5-2-6-12-24)37(33(36)40)22-26-14-8-16-28(35)18-26/h1-18,29-32,38-39H,19-22,34-35H2/t29-,30-,31+,32+/m1/s1
DMLG7QB	CS	C1=CC=C(C=C1)C[C@@H]2[C@@H]([C@H]([C@H](N(C(=O)N2CC3=CC(=CC=C3)N)CC4=CC(=CC=C4)N)CC5=CC=CC=C5)O)O
DMLG7QB	IK	KYRSNWPSSXSNEP-ZRTHHSRSSA-N
DMLG7QB	IU	(4R,5S,6S,7R)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one
DMLG7QB	CA	174391-92-5
DMLG7QB	DE	Human immunodeficiency virus infection

DMMKHGN	ID	DMMKHGN
DMMKHGN	DN	MP-435
DMMKHGN	HS	Discontinued in Phase 2
DMMKHGN	SN	C5a antagonist (rheumatoid arthritis), Mitsubishi Tanabe
DMMKHGN	CP	Mitsubishi Tanabe Pharma Corp
DMMKHGN	DE	Rheumatoid arthritis

DMKF3TD	ID	DMKF3TD
DMKF3TD	DN	Nafagrel
DMKF3TD	HS	Discontinued in Phase 2
DMKF3TD	SN	Nafagrel hydrochloride; DP-1904; SR-96325
DMKF3TD	CP	Daiichi Seiyaku Co Ltd
DMKF3TD	DT	Small molecular drug
DMKF3TD	PC	65851
DMKF3TD	MW	256.3
DMKF3TD	FM	C15H16N2O2
DMKF3TD	IC	InChI=1S/C15H16N2O2/c18-15(19)14-4-3-12-7-11(1-2-13(12)8-14)9-17-6-5-16-10-17/h3-6,8,10-11H,1-2,7,9H2,(H,18,19)
DMKF3TD	CS	C1CC2=C(CC1CN3C=CN=C3)C=CC(=C2)C(=O)O
DMKF3TD	IK	VJJHOPPXRPHVCA-UHFFFAOYSA-N
DMKF3TD	IU	6-(imidazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
DMKF3TD	CA	CAS 97901-21-8
DMKF3TD	DE	Asthma

DMF9Y57	ID	DMF9Y57
DMF9Y57	DN	Napitane mesilate
DMF9Y57	HS	Discontinued in Phase 2
DMF9Y57	SN	A-75200; ABT-200; Napitane mesilate < Prop INNM; Rac-1-[5,6-(Methylenedioxy)-1,2,3,4-tetrahydronaphth-1(R*)-ylmethyl]-3(R*)-phenylpyrrolidine methanesulfonate; Rac-3(R*)-Phenyl-1-[6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6(R*)-ylmethyl]pyrrolidine methanesulfonate
DMF9Y57	DT	Small molecular drug
DMF9Y57	PC	60932
DMF9Y57	MW	335.4
DMF9Y57	FM	C22H25NO2
DMF9Y57	IC	InChI=1S/C22H25NO2/c1-2-5-16(6-3-1)17-11-12-23(13-17)14-18-7-4-8-20-19(18)9-10-21-22(20)25-15-24-21/h1-3,5-6,9-10,17-18H,4,7-8,11-15H2
DMF9Y57	CS	C1CC(C2=C(C1)C3=C(C=C2)OCO3)CN4CCC(C4)C5=CC=CC=C5
DMF9Y57	IK	HAEPGZUGYMHCJE-UHFFFAOYSA-N
DMF9Y57	IU	3-phenyl-1-(6,7,8,9-tetrahydrobenzo[g][1,3]benzodioxol-6-ylmethyl)pyrrolidine
DMF9Y57	DE	Major depressive disorder

DM8L4Z0	ID	DM8L4Z0
DM8L4Z0	DN	Napsagatran
DM8L4Z0	HS	Discontinued in Phase 2
DM8L4Z0	SN	Ro-46-6240
DM8L4Z0	CP	Roche Holding AG
DM8L4Z0	DT	Small molecular drug
DM8L4Z0	PC	6918278
DM8L4Z0	MW	558.7
DM8L4Z0	FM	C26H34N6O6S
DM8L4Z0	IC	InChI=1S/C26H34N6O6S/c27-26(28)31-11-3-4-17(15-31)14-29-23(33)13-22(25(36)32(16-24(34)35)20-8-9-20)30-39(37,38)21-10-7-18-5-1-2-6-19(18)12-21/h1-2,5-7,10,12,17,20,22,30H,3-4,8-9,11,13-16H2,(H3,27,28)(H,29,33)(H,34,35)/t17-,22-/m0/s1
DM8L4Z0	CS	C1C[C@H](CN(C1)C(=N)N)CNC(=O)C[C@@H](C(=O)N(CC(=O)O)C2CC2)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3
DM8L4Z0	IK	BYDKEYCXCIVOOV-JTSKRJEESA-N
DM8L4Z0	IU	2-[[(2S)-4-[[(3S)-1-carbamimidoylpiperidin-3-yl]methylamino]-2-(naphthalen-2-ylsulfonylamino)-4-oxobutanoyl]-cyclopropylamino]acetic acid
DM8L4Z0	CA	CAS 154397-77-0
DM8L4Z0	DE	Myocardial infarction

DM8BHL6	ID	DM8BHL6
DM8BHL6	DN	Naronapride
DM8BHL6	HS	Discontinued in Phase 2
DM8BHL6	SN	Naronapride dihydrochloride; ATI-7500; ATI-7505; Cisapride analog, ARYx Therapeutics; ATI-7000 series, ARYx Therapeutics; Cisapride analog, Procter & Gamble; ATI-7000 series, Procter & Gamble; 5-HT 4 receptor agonist (oral, gastroesophageal reflux/irritable bowel syndrome/gastric motilitydisorder/constipation/dyspepsia), ARYx Therapeutics/Procter & Gamble Pharmaceuticals Inc
DM8BHL6	CP	ARYx Therapeutics
DM8BHL6	DT	Small molecular drug
DM8BHL6	PC	11237985
DM8BHL6	MW	537.1
DM8BHL6	FM	C27H41ClN4O5
DM8BHL6	IC	InChI=1S/C27H41ClN4O5/c1-35-23-15-21(29)20(28)14-19(23)27(34)30-22-9-13-31(17-25(22)36-2)10-5-3-4-6-26(33)37-24-16-32-11-7-18(24)8-12-32/h14-15,18,22,24-25H,3-13,16-17,29H2,1-2H3,(H,30,34)/t22-,24+,25+/m1/s1
DM8BHL6	CS	CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCCCC(=O)O[C@H]3CN4CCC3CC4
DM8BHL6	IK	VGDDOIZXGFJDRC-VJTSUQJLSA-N
DM8BHL6	IU	[(3R)-1-azabicyclo[2.2.2]octan-3-yl] 6-[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxypiperidin-1-yl]hexanoate
DM8BHL6	CA	CAS 860174-12-5
DM8BHL6	DE	Gastroesophageal reflux disease

DM9K2IO	ID	DM9K2IO
DM9K2IO	DN	Naxagolide
DM9K2IO	HS	Discontinued in Phase 2
DM9K2IO	SN	Dopazinol; Nazagolide; PHNO; Naxagolide hydrochloride; L-647339; MK-458; (+)-PHNO
DM9K2IO	CP	Merck & Co Inc
DM9K2IO	DT	Small molecular drug
DM9K2IO	PC	57533
DM9K2IO	MW	247.33
DM9K2IO	FM	C15H21NO2
DM9K2IO	IC	InChI=1S/C15H21NO2/c1-2-7-16-8-9-18-15-13-10-12(17)5-3-11(13)4-6-14(15)16/h3,5,10,14-15,17H,2,4,6-9H2,1H3/t14-,15-/m1/s1
DM9K2IO	CS	CCCN1CCO[C@H]2[C@H]1CCC3=C2C=C(C=C3)O
DM9K2IO	IK	JCSREICEMHWFAY-HUUCEWRRSA-N
DM9K2IO	IU	(4aR,10bR)-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazin-9-ol
DM9K2IO	CA	CAS 88058-88-2
DM9K2IO	DE	Parkinson disease

DMGVYXB	ID	DMGVYXB
DMGVYXB	DN	NB-506
DMGVYXB	HS	Discontinued in Phase 2
DMGVYXB	SN	J-107185; L-753000; N-[12-(beta-D-Glucopyranosyl)-1,11-dihydroxy-5,7-dioxo-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl]formamide; 6-(Formamido)-12-(beta-D-glucopyranosyl)-1,11-dihydroxy-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
DMGVYXB	PC	9915861
DMGVYXB	MW	562.5
DMGVYXB	FM	C27H22N4O10
DMGVYXB	IC	InChI=1S/C27H22N4O10/c32-7-13-22(36)23(37)24(38)27(41-13)30-20-10(4-2-6-12(20)35)15-17-16(25(39)31(26(17)40)28-8-33)14-9-3-1-5-11(34)18(9)29-19(14)21(15)30/h1-6,8,13,22-24,27,29,32,34-38H,7H2,(H,28,33)/t13-,22-,23+,24-,27-/m1/s1
DMGVYXB	CS	C1=CC2=C(C(=C1)O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC=O)C6=C(N4[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C(=CC=C6)O
DMGVYXB	IK	WHTCLLAVOBBKHK-ISCYQWKGSA-N
DMGVYXB	IU	N-[5,21-dihydroxy-12,14-dioxo-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]formamide
DMGVYXB	CA	CAS 151069-12-4
DMGVYXB	DE	Solid tumour/cancer

DMTRMBL	ID	DMTRMBL
DMTRMBL	DN	NBI-6024
DMTRMBL	HS	Discontinued in Phase 2
DMTRMBL	SN	Diabetes therapeutics, Neurocrine/Taisho; APL (diabetes), Neurocrine/Taisho; Applied Peptide Ligand(diabetes), Neurocrine/Taisho; Insulin B9-23 peptide analog, Taisho/Neurocrine
DMTRMBL	CP	Neurocrine Biosciences
DMTRMBL	DE	Type-1 diabetes

DMGEBUQ	ID	DMGEBUQ
DMGEBUQ	DN	NC-190
DMGEBUQ	HS	Discontinued in Phase 2
DMGEBUQ	SN	NCU-190Na
DMGEBUQ	CP	Taisho Pharmaceutical Co Ltd
DMGEBUQ	DT	Small molecular drug
DMGEBUQ	PC	135413513
DMGEBUQ	MW	456.4
DMGEBUQ	FM	C23H21N4NaO5
DMGEBUQ	IC	InChI=1S/C23H22N4O5.Na/c1-27(2)9-8-24-22(29)18-20-19(12-6-4-5-7-13(12)21(18)28)25-16-11-17(32-3)14(23(30)31)10-15(16)26-20;/h4-7,10-11,28H,8-9H2,1-3H3,(H,24,29)(H,30,31);/q;+1/p-1
DMGEBUQ	CS	CN(C)CCNC(=O)C1=C(C2=CC=CC=C2C3=NC4=C(C=C(C(=C4)OC)C(=O)[O-])N=C13)O.[Na+]
DMGEBUQ	IK	GHPJVVCCBMRQAR-UHFFFAOYSA-M
DMGEBUQ	IU	sodium;6-[2-(dimethylamino)ethylcarbamoyl]-5-hydroxy-10-methoxybenzo[a]phenazine-9-carboxylate
DMGEBUQ	CA	CAS 120602-99-5
DMGEBUQ	DE	Solid tumour/cancer

DMWROJ5	ID	DMWROJ5
DMWROJ5	DN	NCX-701
DMWROJ5	HS	Discontinued in Phase 2
DMWROJ5	SN	Nitroparacetamol; NO-acetaminophen, NicOx; NO-paracetamol, NicOx
DMWROJ5	CP	NicOx SA
DMWROJ5	DT	Small molecular drug
DMWROJ5	PC	6918532
DMWROJ5	MW	282.25
DMWROJ5	FM	C12H14N2O6
DMWROJ5	IC	InChI=1S/C12H14N2O6/c1-9(15)13-10-4-6-11(7-5-10)20-12(16)3-2-8-19-14(17)18/h4-7H,2-3,8H2,1H3,(H,13,15)
DMWROJ5	CS	CC(=O)NC1=CC=C(C=C1)OC(=O)CCCO[N+](=O)[O-]
DMWROJ5	IK	XTMOQAKCOFLCRZ-UHFFFAOYSA-N
DMWROJ5	IU	(4-acetamidophenyl) 4-nitrooxybutanoate
DMWROJ5	CA	CAS 326850-30-0
DMWROJ5	DE	Pain

DM6VP9U	ID	DM6VP9U
DM6VP9U	DN	Nemifitide
DM6VP9U	HS	Discontinued in Phase 2
DM6VP9U	SN	SCHEMBL678511; AC1L42N3
DM6VP9U	CP	Tetragenex Pharmaceuticals
DM6VP9U	DT	Small molecular drug
DM6VP9U	PC	6918348
DM6VP9U	MW	694.8
DM6VP9U	FM	C33H43FN10O6
DM6VP9U	IC	InChI=1S/C33H43FN10O6/c34-20-9-7-18(8-10-20)12-23(35)32(50)44-17-21(45)14-27(44)31(49)43-25(6-3-11-39-33(37)38)30(48)41-16-28(46)42-26(29(36)47)13-19-15-40-24-5-2-1-4-22(19)24/h1-2,4-5,7-10,15,21,23,25-27,40,45H,3,6,11-14,16-17,35H2,(H2,36,47)(H,41,48)(H,42,46)(H,43,49)(H4,37,38,39)/t21-,23+,25+,26+,27+/m1/s1
DM6VP9U	CS	C1[C@H](CN([C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N)C(=O)[C@H](CC4=CC=C(C=C4)F)N)O
DM6VP9U	IK	SGXPTOACEHQGHL-RCNLLYRESA-N
DM6VP9U	IU	(2S,4R)-1-[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]-N-[(2S)-1-[[2-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide
DM6VP9U	CA	CAS 173240-15-8
DM6VP9U	DE	Major depressive disorder

DMDAUCR	ID	DMDAUCR
DMDAUCR	DN	NGD 91-3
DMDAUCR	HS	Discontinued in Phase 2
DMDAUCR	CP	Neurogen Corporation
DMDAUCR	DE	Anxiety disorder

DMOWLVF	ID	DMOWLVF
DMOWLVF	DN	NGD-8243
DMOWLVF	HS	Discontinued in Phase 2
DMOWLVF	SN	SCHEMBL17320582
DMOWLVF	CP	Neurogen Corp
DMOWLVF	TC	Analgesics
DMOWLVF	DT	Small molecular drug
DMOWLVF	PC	11247522
DMOWLVF	MW	434.3
DMOWLVF	FM	C21H12F6N4
DMOWLVF	IC	InChI=1S/C21H12F6N4/c22-20(23,24)13-4-6-14(7-5-13)31-19-15-8-3-12(10-17(15)29-11-30-19)18-16(21(25,26)27)2-1-9-28-18/h1-11H,(H,29,30,31)
DMOWLVF	CS	C1=CC(=C(N=C1)C2=CC3=C(C=C2)C(=NC=N3)NC4=CC=C(C=C4)C(F)(F)F)C(F)(F)F
DMOWLVF	IK	VTANGSDRFFLTSQ-UHFFFAOYSA-N
DMOWLVF	IU	N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-amine
DMOWLVF	CA	CAS 573678-04-3
DMOWLVF	DE	Acute or chronic pain

DMSJYEX	ID	DMSJYEX
DMSJYEX	DN	Nitecapone
DMSJYEX	HS	Discontinued in Phase 2
DMSJYEX	SN	OR-462
DMSJYEX	CP	Orion Corp
DMSJYEX	DT	Small molecular drug
DMSJYEX	PC	5464105
DMSJYEX	MW	265.22
DMSJYEX	FM	C12H11NO6
DMSJYEX	IC	InChI=1S/C12H11NO6/c1-6(14)9(7(2)15)3-8-4-10(13(18)19)12(17)11(16)5-8/h3-5,16-17H,1-2H3
DMSJYEX	CS	CC(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C(=O)C
DMSJYEX	IK	UPMRZALMHVUCIN-UHFFFAOYSA-N
DMSJYEX	IU	3-[(3,4-dihydroxy-5-nitrophenyl)methylidene]pentane-2,4-dione
DMSJYEX	CA	CAS 116313-94-1
DMSJYEX	CB	CHEBI:166596
DMSJYEX	DE	Pain

DMZMQDN	ID	DMZMQDN
DMZMQDN	DN	NK-1001
DMZMQDN	HS	Discontinued in Phase 2
DMZMQDN	SN	NNYK-1001; NYK-1001
DMZMQDN	CP	Nyken BV
DMZMQDN	DT	Small molecular drug
DMZMQDN	PC	3040841
DMZMQDN	MW	485.5
DMZMQDN	FM	C18H35N3O12
DMZMQDN	IC	InChI=1S/C18H35N3O12/c19-2-6-8(23)10(25)12(27)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)11(26)9(24)7(3-22)31-18/h4-18,22-29H,1-3,19-21H2/t4-,5+,6-,7-,8-,9-,10+,11+,12-,13-,14-,15+,16-,17-,18-/m1/s1
DMZMQDN	CS	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
DMZMQDN	IK	NZCOZAMBHLSNDW-GUKOCFKPSA-N
DMZMQDN	IU	(2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1S,2R,3R,4S,6R)-4,6-diamino-2-hydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexyl]oxyoxane-3,4,5-triol
DMZMQDN	CA	CAS 53025-93-7
DMZMQDN	DE	Atrial fibrillation

DM5OVGH	ID	DM5OVGH
DM5OVGH	DN	NK-611
DM5OVGH	HS	Discontinued in Phase 2
DM5OVGH	SN	2''-Deoxy-2''-(dimethylamino)etoposide
DM5OVGH	DT	Small molecular drug
DM5OVGH	PC	159302
DM5OVGH	MW	652.1
DM5OVGH	FM	C31H38ClNO12
DM5OVGH	IC	InChI=1S/C31H37NO12.ClH/c1-13-38-11-22-29(42-13)27(34)25(32(2)3)31(43-22)44-28-16-9-19-18(40-12-41-19)8-15(16)23(24-17(28)10-39-30(24)35)14-6-20(36-4)26(33)21(7-14)37-5;/h6-9,13,17,22-25,27-29,31,33-34H,10-12H2,1-5H3;1H
DM5OVGH	CS	CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)N(C)C)O.Cl
DM5OVGH	IK	PYLTTZZOZBYUEI-UHFFFAOYSA-N
DM5OVGH	IU	5-[[7-(dimethylamino)-8-hydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;hydrochloride
DM5OVGH	CA	CAS 105760-98-3
DM5OVGH	DE	Solid tumour/cancer

DMV5FN1	ID	DMV5FN1
DMV5FN1	DN	NKS-01
DMV5FN1	HS	Discontinued in Phase 2
DMV5FN1	SN	14alpha-Hydroxy-4-androstene-3,6,17-trione
DMV5FN1	DT	Small molecular drug
DMV5FN1	PC	6918079
DMV5FN1	MW	316.4
DMV5FN1	FM	C19H24O4
DMV5FN1	IC	InChI=1S/C19H24O4/c1-17-6-3-11(20)9-14(17)15(21)10-13-12(17)4-7-18(2)16(22)5-8-19(13,18)23/h9,12-13,23H,3-8,10H2,1-2H3/t12-,13+,17+,18+,19+/m0/s1
DMV5FN1	CS	C[C@]12CCC(=O)C=C1C(=O)C[C@@H]3[C@@H]2CC[C@]4([C@]3(CCC4=O)O)C
DMV5FN1	IK	UKVVNEHFNYKGMX-KIVPVIKRSA-N
DMV5FN1	IU	(8R,9S,10R,13S,14R)-14-hydroxy-10,13-dimethyl-2,7,8,9,11,12,15,16-octahydro-1H-cyclopenta[a]phenanthrene-3,6,17-trione
DMV5FN1	CA	CAS 120051-39-0
DMV5FN1	DE	Bladder cancer

DM6NPUJ	ID	DM6NPUJ
DM6NPUJ	DN	NLX-P101
DM6NPUJ	HS	Discontinued in Phase 2
DM6NPUJ	SN	RAAV-GAD; STN AAV-GAD gene therapy, Neurologix; Subthalamic nucleus AAV-glutamic acid decarboxylase gene therapy, Neurologix; NLX gene therapy (Parkinson's), Neurologix
DM6NPUJ	CP	Neurologix Inc
DM6NPUJ	DE	Parkinson disease

DMVH3I7	ID	DMVH3I7
DMVH3I7	DN	NM-135
DMVH3I7	HS	Discontinued in Phase 2
DMVH3I7	SN	Glucocorticoid, Nissin Food
DMVH3I7	CP	Nissin Foods Holdings Co Ltd
DMVH3I7	PC	9963271
DMVH3I7	MW	1029.099
DMVH3I7	FM	C60H62F2O13
DMVH3I7	IC	InChI=1S/C60H62F2O13/c1-32-8-16-37(17-9-32)53(66)70-31-47-50(73-54(67)38-18-10-33(2)11-19-38)51(74-55(68)39-20-12-34(3)13-21-39)52(75-56(69)40-22-14-35(4)15-23-40)57(72-47)71-30-46(64)49-36(5)26-42-43-28-45(61)44-27-41(63)24-25-59(44,7)60(43,62)48(65)29-58(42,49)6/h8-25,27,36,42-43,45,47-52,57,65H,26,28-31H2,1-7H3/t36-,42+,43+,45+,47-,48+,49-,50-,51+,52-,57-,58+,59+,60+/m1/s1
DMVH3I7	CS	C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)C6=CC=C(C=C6)C)OC(=O)C7=CC=C(C=C7)C)OC(=O)C8=CC=C(C=C8)C)OC(=O)C9=CC=C(C=C9)C)C)O)F)C)F
DMVH3I7	IK	BVEAZFTXNPWHMR-QBKHVOGRSA-N
DMVH3I7	IU	[(2R,3R,4S,5R,6R)-6-[2-[(6S,8S,9R,10S,11S,13S,14S,16R,17S)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-3,4,5-tris[(4-methylbenzoyl)oxy]oxan-2-yl]methyl 4-methylbenzoate
DMVH3I7	DE	Dermatitis

DMU596F	ID	DMU596F
DMU596F	DN	NMI-870
DMU596F	HS	Discontinued in Phase 2
DMU596F	CP	NitroMed
DMU596F	DE	Sexual dysfunction

DM2TDE7	ID	DM2TDE7
DM2TDE7	DN	NN8209
DM2TDE7	HS	Discontinued in Phase 2
DM2TDE7	CP	Novo Nordisk
DM2TDE7	DE	Rheumatoid arthritis

DMK5WLZ	ID	DMK5WLZ
DMK5WLZ	DN	Nolpitantium besilate
DMK5WLZ	HS	Discontinued in Phase 2
DMK5WLZ	SN	SR-140333; SR-140333B
DMK5WLZ	CP	Sanofi-Synthelabo; Sanofi-aventis
DMK5WLZ	DT	Small molecular drug
DMK5WLZ	PC	3047794
DMK5WLZ	MW	777.8
DMK5WLZ	FM	C43H50Cl2N2O5S
DMK5WLZ	IC	InChI=1S/C37H45Cl2N2O2.C6H6O3S/c1-28(2)43-32-11-6-8-29(24-32)25-35(42)40-19-7-14-37(27-40,31-12-13-33(38)34(39)26-31)18-23-41-20-15-36(16-21-41,17-22-41)30-9-4-3-5-10-30;7-10(8,9)6-4-2-1-3-5-6/h3-6,8-13,24,26,28H,7,14-23,25,27H2,1-2H3;1-5H,(H,7,8,9)/q+1;/p-1/t36?,37-,41?;/m1./s1
DMK5WLZ	CS	CC(C)OC1=CC=CC(=C1)CC(=O)N2CCC[C@](C2)(CC[N+]34CCC(CC3)(CC4)C5=CC=CC=C5)C6=CC(=C(C=C6)Cl)Cl.C1=CC=C(C=C1)S(=O)(=O)[O-]
DMK5WLZ	IK	PQRLQZNKDQQMBC-LSYPWIJNSA-M
DMK5WLZ	IU	benzenesulfonate;1-[(3S)-3-(3,4-dichlorophenyl)-3-[2-(4-phenyl-1-azoniabicyclo[2.2.2]octan-1-yl)ethyl]piperidin-1-yl]-2-(3-propan-2-yloxyphenyl)ethanone
DMK5WLZ	CA	CAS 155418-06-7
DMK5WLZ	DE	Asthma

DMJSKUI	ID	DMJSKUI
DMJSKUI	DN	Norcisapride
DMJSKUI	HS	Discontinued in Phase 2
DMJSKUI	SN	Norcisapride; 84946-16-7; CHEMBL1748; 4-Amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidyl)benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)benzamide; (4-Amino-5-chloro-2-methoxy)-N-[3-methoxy(4-piperidyl)]benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide; Benzamide,4-amino-5-chloro-2-methoxy-N-[(3S,4R)-3-methoxy-4-piperidinyl]-, hydrochloride(1:1); EINECS 284-619-3; AC1MI81F; SCHEMBL593405; CTK4E8653; OMLDMGPCWMBPAN-UHFFFAOYSA-N; BDBM50301927; AKOS030254741; API0006151; DB-076176
DMJSKUI	DT	Small molecular drug
DMJSKUI	PC	3019427
DMJSKUI	MW	313.78
DMJSKUI	FM	C14H20ClN3O3
DMJSKUI	IC	InChI=1S/C14H20ClN3O3/c1-20-12-6-10(16)9(15)5-8(12)14(19)18-11-3-4-17-7-13(11)21-2/h5-6,11,13,17H,3-4,7,16H2,1-2H3,(H,18,19)
DMJSKUI	CS	COC1CNCCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl
DMJSKUI	IK	OMLDMGPCWMBPAN-UHFFFAOYSA-N
DMJSKUI	IU	4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide
DMJSKUI	CA	CAS 84946-16-7
DMJSKUI	DE	Gastroesophageal reflux disease

DMYCLZR	ID	DMYCLZR
DMYCLZR	DN	Norelin
DMYCLZR	HS	Discontinued in Phase 2
DMYCLZR	CP	YM Biosciences
DMYCLZR	DE	Prostate cancer

DM8A64W	ID	DM8A64W
DM8A64W	DN	NP-118809
DM8A64W	HS	Discontinued in Phase 2
DM8A64W	SN	41332-24-5; NP118809; Z-160; 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone; UNII-TX3R141LEP; TX3R141LEP; CHEMBL604710; Piperazine, 1-(diphenylmethyl)-4-(1-oxo-3,3-diphenylpropyl)-; 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one; AC1NLRM8; GTPL7765; SCHEMBL4180792; CTK1D3910; DTXSID70407284; VCPMZDWBEWTGNW-UHFFFAOYSA-N; MolPort-001-545-055; EX-A2422; BCP08259; KS-00000T6R; ZINC20509316; 3934AH; STK411255; AKOS003297641; MK-6721; DB12743; MCULE-3294187169; CS-1361; API0014038; ACM41332245
DM8A64W	TC	Analgesics
DM8A64W	DT	Small molecular drug
DM8A64W	PC	4988454
DM8A64W	MW	460.6
DM8A64W	FM	C32H32N2O
DM8A64W	IC	InChI=1S/C32H32N2O/c35-31(25-30(26-13-5-1-6-14-26)27-15-7-2-8-16-27)33-21-23-34(24-22-33)32(28-17-9-3-10-18-28)29-19-11-4-12-20-29/h1-20,30,32H,21-25H2
DM8A64W	CS	C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)CC(C4=CC=CC=C4)C5=CC=CC=C5
DM8A64W	IK	VCPMZDWBEWTGNW-UHFFFAOYSA-N
DM8A64W	IU	1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one
DM8A64W	CA	CAS 41332-24-5
DM8A64W	DE	Pain

DMPMR2I	ID	DMPMR2I
DMPMR2I	DN	NP-50301
DMPMR2I	HS	Discontinued in Phase 2
DMPMR2I	SN	IDESTRIN; Estrogen ester (eyedrop, dry eye syndrome), Nascent
DMPMR2I	CP	Nascent Pharmaceuticals
DMPMR2I	DE	Eye disorder

DM50PZH	ID	DM50PZH
DM50PZH	DN	NP-619
DM50PZH	HS	Discontinued in Phase 2
DM50PZH	CP	Biophysica Inc
DM50PZH	DE	Alopecia

DMAVZ1F	ID	DMAVZ1F
DMAVZ1F	DN	NPC-567
DMAVZ1F	HS	Discontinued in Phase 2
DMAVZ1F	SN	Npc-567; Npc 567; Arg-3-hyp-7-phe-bradykinin; UNII-DV64B0PLEH; 109333-26-8; Bradykinin, arg-hyp(3)-phe(7)-; DV64B0PLEH; Bradykinin, arg(0)-hyp(3)-phe(7)-; CHEMBL446325; CHEBI:73294; arg(0)-hyp(3)-phe(7)-bradykinin; Bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-; [D-Arg(0),Hyp(3),D-Phe(7)]bradykinin; Bradykinin, N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalanine-
DMAVZ1F	DT	Small molecular drug
DMAVZ1F	PC	119343
DMAVZ1F	MW	1282.5
DMAVZ1F	FM	C60H87N19O13
DMAVZ1F	IC	InChI=1S/C60H87N19O13/c61-39(20-10-24-68-58(62)63)49(83)73-40(21-11-25-69-59(64)65)55(89)78-27-13-23-46(78)56(90)79-33-38(81)31-47(79)54(88)71-32-48(82)72-42(28-35-14-4-1-5-15-35)50(84)77-45(34-80)53(87)76-44(30-37-18-8-3-9-19-37)52(86)75-43(29-36-16-6-2-7-17-36)51(85)74-41(57(91)92)22-12-26-70-60(66)67/h1-9,14-19,38-47,80-81H,10-13,20-34,61H2,(H,71,88)(H,72,82)(H,73,83)(H,74,85)(H,75,86)(H,76,87)(H,77,84)(H,91,92)(H4,62,63,68)(H4,64,65,69)(H4,66,67,70)/t38-,39-,40+,41+,42+,43+,44-,45+,46+,47+/m1/s1
DMAVZ1F	CS	C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)N2C[C@@H](C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)O
DMAVZ1F	IK	RBIXVHPHNGXTCI-QJTYZATASA-N
DMAVZ1F	IU	(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMAVZ1F	CA	CAS 109333-26-8
DMAVZ1F	CB	CHEBI:73294
DMAVZ1F	DE	Rhinitis

DM0CF3B	ID	DM0CF3B
DM0CF3B	DN	NPS 1776
DM0CF3B	HS	Discontinued in Phase 2
DM0CF3B	SN	Isovaleramide
DM0CF3B	CP	NPS Pharmaceuticals
DM0CF3B	DT	Small molecular drug
DM0CF3B	PC	10930
DM0CF3B	MW	101.15
DM0CF3B	FM	C5H11NO
DM0CF3B	IC	InChI=1S/C5H11NO/c1-4(2)3-5(6)7/h4H,3H2,1-2H3,(H2,6,7)
DM0CF3B	CS	CC(C)CC(=O)N
DM0CF3B	IK	SANOUVWGPVYVAV-UHFFFAOYSA-N
DM0CF3B	IU	3-methylbutanamide
DM0CF3B	CA	CAS 541-46-8
DM0CF3B	DE	Epilepsy

DMQPXLF	ID	DMQPXLF
DMQPXLF	DN	NPS-2143
DMQPXLF	HS	Discontinued in Phase 2
DMQPXLF	SN	NPS-2143; 284035-33-2; NPS 2143; NPS2143; UNII-Z25PJ77W7V; SB-262470; Z25PJ77W7V; CHEMBL180672; 2-CHLORO-6-[(2R)-3-[[1,1-DIMETHYL-2-(2-NAPHTHALENYL)ETHYL]AMINO]-2-HYDROXYPROPOXY]BENZONITRILE; C24H25ClN2O2; 2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzonitrile; (R)-2-chloro-6-(2-hydroxy-3-((2-methyl-1-(naphthalen-2-yl)propan-2-yl)amino)propoxy)benzonitrile; SB-262470A; (+)-NPS-2143; AC1OCFG2; GTPL716; SCHEMBL13597018; EX-A017; DTXSID10426075; MolPort-021-805-006; BCPP000077; ZINC3975668
DMQPXLF	CP	NPS Pharmaceuticals
DMQPXLF	DT	Small molecular drug
DMQPXLF	PC	6918446
DMQPXLF	MW	408.9
DMQPXLF	FM	C24H25ClN2O2
DMQPXLF	IC	InChI=1S/C24H25ClN2O2/c1-24(2,13-17-10-11-18-6-3-4-7-19(18)12-17)27-15-20(28)16-29-23-9-5-8-22(25)21(23)14-26/h3-12,20,27-28H,13,15-16H2,1-2H3/t20-/m1/s1
DMQPXLF	CS	CC(C)(CC1=CC2=CC=CC=C2C=C1)NC[C@H](COC3=C(C(=CC=C3)Cl)C#N)O
DMQPXLF	IK	PZUJQWHTIRWCID-HXUWFJFHSA-N
DMQPXLF	IU	2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzonitrile
DMQPXLF	CA	CAS 284035-33-2
DMQPXLF	DE	Osteoporosis

DMQ82T5	ID	DMQ82T5
DMQ82T5	DN	NS-220
DMQ82T5	HS	Discontinued in Phase 2
DMQ82T5	SN	R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid
DMQ82T5	DT	Small molecular drug
DMQ82T5	PC	9947731
DMQ82T5	MW	373.4
DMQ82T5	FM	C21H27NO5
DMQ82T5	IC	InChI=1S/C21H27NO5/c1-14-8-10-17(11-9-14)19-22-18(15(2)27-19)7-5-4-6-16-12-25-21(3,20(23)24)26-13-16/h8-11,16H,4-7,12-13H2,1-3H3,(H,23,24)
DMQ82T5	CS	CC1=CC=C(C=C1)C2=NC(=C(O2)C)CCCCC3COC(OC3)(C)C(=O)O
DMQ82T5	IK	IMYPSTHZBIWMNA-UHFFFAOYSA-N
DMQ82T5	IU	2-methyl-5-[4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid
DMQ82T5	DE	Hyperlipidaemia

DMVRJ8D	ID	DMVRJ8D
DMVRJ8D	DN	NS-2389
DMVRJ8D	HS	Discontinued in Phase 2
DMVRJ8D	SN	GW-650250; GW-650250A; NS-2347
DMVRJ8D	CP	NeuroSearch A/S
DMVRJ8D	DE	Major depressive disorder

DMQ8P4U	ID	DMQ8P4U
DMQ8P4U	DN	NS-49
DMQ8P4U	HS	Discontinued in Phase 2
DMQ8P4U	SN	Garomefrine hydrochloride; ABT-232; PNO-49B
DMQ8P4U	CP	Nippon Shinyaku Co Ltd
DMQ8P4U	DT	Small molecular drug
DMQ8P4U	PC	9838763
DMQ8P4U	MW	248.28
DMQ8P4U	FM	C9H13FN2O3S
DMQ8P4U	IC	InChI=1S/C9H13FN2O3S/c1-16(14,15)12-6-2-3-8(10)7(4-6)9(13)5-11/h2-4,9,12-13H,5,11H2,1H3/t9-/m0/s1
DMQ8P4U	CS	CS(=O)(=O)NC1=CC(=C(C=C1)F)[C@H](CN)O
DMQ8P4U	IK	XYLJNMCMDOOJRW-VIFPVBQESA-N
DMQ8P4U	IU	N-[3-[(1R)-2-amino-1-hydroxyethyl]-4-fluorophenyl]methanesulfonamide
DMQ8P4U	CA	CAS 137431-02-8
DMQ8P4U	DE	Urinary incontinence

DMH2QBM	ID	DMH2QBM
DMH2QBM	DN	NSP-805
DMH2QBM	HS	Discontinued in Phase 2
DMH2QBM	SN	TZN-01; 5-Methyl-6-[4-(2-methyl-3-oxo-1-cyclopentenylamino)phenyl]-2,3,4,5-tetrahydropyridazin-3-one
DMH2QBM	DT	Small molecular drug
DMH2QBM	PC	130349
DMH2QBM	MW	297.35
DMH2QBM	FM	C17H19N3O2
DMH2QBM	IC	InChI=1S/C17H19N3O2/c1-10-9-16(22)19-20-17(10)12-3-5-13(6-4-12)18-14-7-8-15(21)11(14)2/h3-6,10,18H,7-9H2,1-2H3,(H,19,22)
DMH2QBM	CS	CC1CC(=O)NN=C1C2=CC=C(C=C2)NC3=C(C(=O)CC3)C
DMH2QBM	IK	DSRIICXPBQXOKK-UHFFFAOYSA-N
DMH2QBM	IU	4-methyl-3-[4-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]-4,5-dihydro-1H-pyridazin-6-one
DMH2QBM	CA	CAS 125068-54-4
DMH2QBM	DE	Heart failure

DMGZ3DR	ID	DMGZ3DR
DMGZ3DR	DN	NT-3
DMGZ3DR	HS	Discontinued in Phase 2
DMGZ3DR	SN	Neurotrophin-3; NT-3, Amgen-Regeneron Partners; NT-3, Amgen/ Regeneron; Neurotrophin-3, Amgen-Regeneron Partners; Neurotrophin-3, Amgen/ Regeneron
DMGZ3DR	CP	Takeda Pharmaceutical Co Ltd
DMGZ3DR	DE	Constipation

DMX9KYW	ID	DMX9KYW
DMX9KYW	DN	NTx-488
DMX9KYW	HS	Discontinued in Phase 2
DMX9KYW	SN	Prolactin-containing multiple sclerosis therapy, Stem Cell Therapeutics
DMX9KYW	CP	Stem Cell Therapeutics Corp
DMX9KYW	DE	Multiple sclerosis

DMPM58S	ID	DMPM58S
DMPM58S	DN	Nuvanil
DMPM58S	HS	Discontinued in Phase 2
DMPM58S	SN	NE-21610
DMPM58S	CP	Procter & Gamble Pharmaceuticals Inc
DMPM58S	DE	Pain

DM9HKOM	ID	DM9HKOM
DM9HKOM	DN	NVP-DPP728
DM9HKOM	HS	Discontinued in Phase 2
DM9HKOM	SN	NVP-DPP728; HCX5M1YIOM; UNII-HCX5M1YIOM; CHEMBL77538; NVP-DPP-728; NVP-728; 247016-69-9; dpp-728; BMCL15687 Compound 2; cyanopyrrolidine derivative 2; SCHEMBL160102; BDBM11113; cyano-(S)-pyrrolidine deriv. 1; ZINC26396245; AKOS030529265; LS-137333; (2S)-1-(2-((2-((5-Cyano-2-pyridyl)amino)ethyl)amino)acetyl)pyrrolidine-2-carbonitrile; 1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(s)-pyrroli-dine; (S)-6-((2-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)amino)ethyl)amino)nicotinonitrile; 3-Pyridinecarbonitrile, 6-((2
DM9HKOM	DT	Small molecular drug
DM9HKOM	PC	9796290
DM9HKOM	MW	298.34
DM9HKOM	FM	C15H18N6O
DM9HKOM	IC	InChI=1S/C15H18N6O/c16-8-12-3-4-14(20-10-12)19-6-5-18-11-15(22)21-7-1-2-13(21)9-17/h3-4,10,13,18H,1-2,5-7,11H2,(H,19,20)/t13-/m0/s1
DM9HKOM	CS	C1C[C@H](N(C1)C(=O)CNCCNC2=NC=C(C=C2)C#N)C#N
DM9HKOM	IK	VFFZWMWTUSXDCB-ZDUSSCGKSA-N
DM9HKOM	IU	6-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile
DM9HKOM	CA	CAS 247016-69-9
DM9HKOM	DE	Type-2 diabetes

DMO8PN9	ID	DMO8PN9
DMO8PN9	DN	OBERADILOL MONOETHYL MALEATE
DMO8PN9	HS	Discontinued in Phase 2
DMO8PN9	SN	TZC-5665; Oberadilol monoethyl maleate; Rac-6-[4-[2-[3-(5-Chloro-2-cyanophenoxy)-2-hydroxypropylamino]-2-methylpropylamino]phenyl]-4,5-dihydro-5-methyl-3(2H)-pyridazinone monoethylmaleate; Rac-6-[4-[2-[3-(5-Chloro-2-cyanophenoxy)-2-hydroxy-propylamino]-2-methylpropylamino]phenyl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one maleic acid monoethyl ester; Rac-4-Chloro-2-[3-[[1,1-dimethyl-2-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]amino]ethyl]amino]-2-hydroxypropoxy]benzonitrile mono[ethyl 2(Z)-butenedioate]
DMO8PN9	DT	Small molecular drug
DMO8PN9	PC	3047798
DMO8PN9	MW	484
DMO8PN9	FM	C25H30ClN5O3
DMO8PN9	IC	InChI=1S/C25H30ClN5O3/c1-16-10-23(33)30-31-24(16)17-5-8-20(9-6-17)28-15-25(2,3)29-13-21(32)14-34-22-11-19(26)7-4-18(22)12-27/h4-9,11,16,21,28-29,32H,10,13-15H2,1-3H3,(H,30,33)
DMO8PN9	CS	CC1CC(=O)NN=C1C2=CC=C(C=C2)NCC(C)(C)NCC(COC3=C(C=CC(=C3)Cl)C#N)O
DMO8PN9	IK	SHAJOALCPZUGLR-UHFFFAOYSA-N
DMO8PN9	IU	4-chloro-2-[2-hydroxy-3-[[2-methyl-1-[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)anilino]propan-2-yl]amino]propoxy]benzonitrile
DMO8PN9	CA	CAS 114856-44-9
DMO8PN9	DE	Hypertension

DMX6GFR	ID	DMX6GFR
DMX6GFR	DN	Omega interferon
DMX6GFR	HS	Discontinued in Phase 2
DMX6GFR	CP	Intarcia Therapeutics
DMX6GFR	DE	Hepatitis C virus infection

DMIZXFJ	ID	DMIZXFJ
DMIZXFJ	DN	ONO-4007
DMIZXFJ	HS	Discontinued in Phase 2
DMIZXFJ	SN	Ono-4007
DMIZXFJ	CP	Ono Pharmaceutical Co Ltd
DMIZXFJ	DT	Small molecular drug
DMIZXFJ	PC	23663416
DMIZXFJ	MW	940.2
DMIZXFJ	FM	C50H78NNaO12S
DMIZXFJ	IC	InChI=1S/C50H79NO12S.Na/c1-2-3-4-5-6-7-8-15-26-35-42(60-45(54)36-27-16-11-9-13-20-29-40-31-22-18-23-32-40)38-44(53)51-47-49(48(63-64(57,58)59)43(39-52)61-50(47)56)62-46(55)37-28-17-12-10-14-21-30-41-33-24-19-25-34-41;/h18-19,22-25,31-34,42-43,47-50,52,56H,2-17,20-21,26-30,35-39H2,1H3,(H,51,53)(H,57,58,59);/q;+1/p-1/t42-,43+,47+,48+,49+,50?;/m0./s1
DMIZXFJ	CS	CCCCCCCCCCC[C@@H](CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)OS(=O)(=O)[O-])OC(=O)CCCCCCCCC2=CC=CC=C2)OC(=O)CCCCCCCCC3=CC=CC=C3.[Na+]
DMIZXFJ	IK	KSLCVWMGAOQHEA-TZBBHZOSSA-M
DMIZXFJ	IU	sodium;[(2R,3S,4R,5R)-6-hydroxy-2-(hydroxymethyl)-4-(9-phenylnonanoyloxy)-5-[[(3S)-3-(9-phenylnonanoyloxy)tetradecanoyl]amino]oxan-3-yl] sulfate
DMIZXFJ	DE	Immune System disease

DMNEA78	ID	DMNEA78
DMNEA78	DN	ONO-4057
DMNEA78	HS	Discontinued in Phase 2
DMNEA78	SN	Ono-LB-457; 5-[2-(2-Carboxyethyl)-3-[6-(4-methoxyphenyl)-5(E)-hexenyloxy]phenoxy]pentanoic acid
DMNEA78	DT	Small molecular drug
DMNEA78	PC	6438358
DMNEA78	MW	470.6
DMNEA78	FM	C27H34O7
DMNEA78	IC	InChI=1S/C27H34O7/c1-32-22-15-13-21(14-16-22)9-4-2-3-6-19-33-24-10-8-11-25(23(24)17-18-27(30)31)34-20-7-5-12-26(28)29/h4,8-11,13-16H,2-3,5-7,12,17-20H2,1H3,(H,28,29)(H,30,31)/b9-4+
DMNEA78	CS	COC1=CC=C(C=C1)/C=C/CCCCOC2=C(C(=CC=C2)OCCCCC(=O)O)CCC(=O)O
DMNEA78	IK	JOPSSWGWLCLPPF-RUDMXATFSA-N
DMNEA78	IU	5-[2-(2-carboxyethyl)-3-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid
DMNEA78	CA	CAS 134578-96-4
DMNEA78	DE	Inflammatory bowel disease

DMSVQK2	ID	DMSVQK2
DMSVQK2	DN	ONO-4819
DMSVQK2	HS	Discontinued in Phase 2
DMSVQK2	SN	Rivenprost; AE1-734; ONO-4819CD; ONO-4819.CD; ONO-AE1-734
DMSVQK2	CP	Novartis
DMSVQK2	DT	Small molecular drug
DMSVQK2	PC	9803828
DMSVQK2	MW	450.6
DMSVQK2	FM	C24H34O6S
DMSVQK2	IC	InChI=1S/C24H34O6S/c1-29-16-18-6-3-5-17(13-18)14-19(25)8-9-20-21(23(27)15-22(20)26)10-12-31-11-4-7-24(28)30-2/h3,5-6,8-9,13,19-22,25-26H,4,7,10-12,14-16H2,1-2H3/b9-8+/t19-,20-,21-,22-/m1/s1
DMSVQK2	CS	COCC1=CC=CC(=C1)C[C@@H](/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCSCCCC(=O)OC)O)O
DMSVQK2	IK	FBQUXLIJKPWCAO-AZIFJQEOSA-N
DMSVQK2	IU	methyl 4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-5-oxocyclopentyl]ethylsulfanyl]butanoate
DMSVQK2	CA	CAS 256382-08-8
DMSVQK2	DE	Fracture

DMWS7C2	ID	DMWS7C2
DMWS7C2	DN	ONO-5334
DMWS7C2	HS	Discontinued in Phase 2
DMWS7C2	SN	Bone resorption inhibitor (tablet/oral, osteoporosis/osteopenia), Ono; Cathepsin K inhibitor (tablet/oral formulation, osteoporosis/osteopenia), Ono
DMWS7C2	CP	Ono Pharmaceutical Co Ltd
DMWS7C2	PC	11582982
DMWS7C2	MW	438.6
DMWS7C2	FM	C21H34N4O4S
DMWS7C2	IC	InChI=1S/C21H34N4O4S/c1-14-13-30-21(25(14)2)24-23-20(28)18(26)17(15-9-11-29-12-10-15)22-19(27)16-7-5-3-4-6-8-16/h14-17H,3-13H2,1-2H3,(H,22,27)(H,23,28)/b24-21-/t14-,17+/m1/s1
DMWS7C2	CS	C[C@@H]1CS/C(=N\\NC(=O)C(=O)[C@H](C2CCOCC2)NC(=O)C3CCCCCC3)/N1C
DMWS7C2	IK	BTZCSXIUAFVRTE-CHGLIHOBSA-N
DMWS7C2	IU	N-[(1S)-3-[(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazinyl]-1-(oxan-4-yl)-2,3-dioxopropyl]cycloheptanecarboxamide
DMWS7C2	CA	CAS 868273-90-9
DMWS7C2	DE	Osteoporosis

DMQM4OV	ID	DMQM4OV
DMQM4OV	DN	OP-2507
DMQM4OV	HS	Discontinued in Phase 2
DMQM4OV	SN	OP-2507; AC1OCEV0; op2507; methyl 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-3-(4-propylcyclohexyl)prop-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]pyrrol-2-yl]pentanoate
DMQM4OV	CP	Ono Pharmaceutical Co Ltd
DMQM4OV	DT	Small molecular drug
DMQM4OV	PC	6917967
DMQM4OV	MW	419.6
DMQM4OV	FM	C25H41NO4
DMQM4OV	IC	InChI=1S/C25H41NO4/c1-3-6-17-9-11-18(12-10-17)23(27)14-13-20-21-15-19(26-22(21)16-24(20)28)7-4-5-8-25(29)30-2/h13-14,17-18,20-24,27-28H,3-12,15-16H2,1-2H3/b14-13+/t17?,18?,20-,21-,22+,23-,24-/m1/s1
DMQM4OV	CS	CCCC1CCC(CC1)[C@@H](/C=C/[C@H]2[C@@H](C[C@H]3[C@@H]2CC(=N3)CCCCC(=O)OC)O)O
DMQM4OV	IK	UQEOPLABKYFAJH-FPNSLHOUSA-N
DMQM4OV	IU	methyl 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-3-(4-propylcyclohexyl)prop-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]pyrrol-2-yl]pentanoate
DMQM4OV	DE	Hypertension

DMP0ARJ	ID	DMP0ARJ
DMP0ARJ	DN	Opaviraline
DMP0ARJ	HS	Discontinued in Phase 2
DMP0ARJ	SN	Opaviraline; GW420867X; UNII-Q3A8EU2NMU; 178040-94-3; Q3A8EU2NMU; GW-420867X; Isopropyl (2s)-2-Ethyl-7-Fluoro-3-Oxo-3,4-Dihydroquinoxaline-1(2h)-Carboxylate; isopropyl (2S)-2-ethyl-7-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxylate; Opaviraline [INN]; HBQ; AC1L4BLF; SCHEMBL464732; Opaviraline (GW 420867); CHEMBL301370; BDBM2955; GW 867X; HBY1293; DTXSID60170415; GW867; HBY1293/GW867; ZINC3916138; HBY-1293; GW-867; AKOS027326866; DB07884; 1(2H)-Quinoxalinecarboxylic acid,2-ethyl-7-fluoro-3,4-dihydro-3-oxo-,1-methylethyl ester,(2S)-
DMP0ARJ	DT	Small molecular drug
DMP0ARJ	PC	154048
DMP0ARJ	MW	280.29
DMP0ARJ	FM	C14H17FN2O3
DMP0ARJ	IC	InChI=1S/C14H17FN2O3/c1-4-11-13(18)16-10-6-5-9(15)7-12(10)17(11)14(19)20-8(2)3/h5-8,11H,4H2,1-3H3,(H,16,18)/t11-/m0/s1
DMP0ARJ	CS	CC[C@H]1C(=O)NC2=C(N1C(=O)OC(C)C)C=C(C=C2)F
DMP0ARJ	IK	KELNNWMENBUHNS-NSHDSACASA-N
DMP0ARJ	IU	propan-2-yl (2S)-2-ethyl-7-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxylate
DMP0ARJ	CA	CAS 178040-94-3
DMP0ARJ	DE	Human immunodeficiency virus infection

DM7OVMH	ID	DM7OVMH
DM7OVMH	DN	OPC-21268
DM7OVMH	HS	Discontinued in Phase 2
DM7OVMH	SN	Acetamide, N-(3-(4-((4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl)carbonyl)phenoxy)propyl)-; Opc 21268; 131631-89-5; Fuscoside; 1-(1-(4-(3-Acetylaminopropoxy)benzoyl)-4-piperidyl)-3,4-dihydro-2(1H)-quinolinone; CHEMBL296908; OPC-1268; N-[3-[4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy]propyl]acetamide; N-(3-(4-(4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidine-1-carbonyl)phenoxy)propyl)acetamide; ACMC-20mu6h; AC1L3G6H; SCHEMBL3504368; GTPL2196; CTK0H6673; EX-A593
DM7OVMH	DT	Small molecular drug
DM7OVMH	PC	114904
DM7OVMH	MW	449.5
DM7OVMH	FM	C26H31N3O4
DM7OVMH	IC	InChI=1S/C26H31N3O4/c1-19(30)27-15-4-18-33-23-10-7-21(8-11-23)26(32)28-16-13-22(14-17-28)29-24-6-3-2-5-20(24)9-12-25(29)31/h2-3,5-8,10-11,22H,4,9,12-18H2,1H3,(H,27,30)
DM7OVMH	CS	CC(=O)NCCCOC1=CC=C(C=C1)C(=O)N2CCC(CC2)N3C(=O)CCC4=CC=CC=C43
DM7OVMH	IK	KSNUCNRMDYJBKT-UHFFFAOYSA-N
DM7OVMH	IU	N-[3-[4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy]propyl]acetamide
DM7OVMH	CA	CAS 131631-89-5
DM7OVMH	DE	Cardiac disease

DMYM8OG	ID	DMYM8OG
DMYM8OG	DN	OPC-28326
DMYM8OG	HS	Discontinued in Phase 2
DMYM8OG	SN	N-[2,6-Dimethyl-4-[4-[N-methyl-N-(2-phenylethyl)amino]piperidin-1-ylcarbonyl]phenyl]propionamide hydrochloride monohydrate
DMYM8OG	CP	Otsuka America Pharmaceutical
DMYM8OG	DT	Small molecular drug
DMYM8OG	PC	219020
DMYM8OG	MW	421.6
DMYM8OG	FM	C26H35N3O2
DMYM8OG	IC	InChI=1S/C26H35N3O2/c1-5-24(30)27-25-19(2)17-22(18-20(25)3)26(31)29-15-12-23(13-16-29)28(4)14-11-21-9-7-6-8-10-21/h6-10,17-18,23H,5,11-16H2,1-4H3,(H,27,30)
DMYM8OG	CS	CCC(=O)NC1=C(C=C(C=C1C)C(=O)N2CCC(CC2)N(C)CCC3=CC=CC=C3)C
DMYM8OG	IK	BESKMDLUOAVUJF-UHFFFAOYSA-N
DMYM8OG	IU	N-[2,6-dimethyl-4-[4-[methyl(2-phenylethyl)amino]piperidine-1-carbonyl]phenyl]propanamide
DMYM8OG	DE	Peripheral vascular disease

DM9ORUL	ID	DM9ORUL
DM9ORUL	DN	OPC-8490
DM9ORUL	HS	Discontinued in Phase 2
DM9ORUL	SN	Opc 8490; Opc-8490; 123941-50-4; 6-[4-(4-oxo-4-phenyl-butyl)piperazine-1-carbonyl]-3,4-dihydro-1H-quinolin-2-one; ACMC-20mqub; AC1MI0AB; SCHEMBL8212456; CTK0I0428; DTXSID40154152; 3,4-Dihydro-6-(4-(4-oxo-4-phenylbutyl)-1-piperazinylcarbonyl)-2(1H)-quinolinone; Piperazine, 1-(4-oxo-4-phenylbutyl)-4-((1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)carbonyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
DM9ORUL	CP	Otsuka Pharmaceutical Co Ltd
DM9ORUL	DT	Small molecular drug
DM9ORUL	PC	3035953
DM9ORUL	MW	597.6
DM9ORUL	FM	C30H35N3O10
DM9ORUL	IC	InChI=1S/C24H27N3O3.C6H8O7/c28-22(18-5-2-1-3-6-18)7-4-12-26-13-15-27(16-14-26)24(30)20-8-10-21-19(17-20)9-11-23(29)25-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h1-3,5-6,8,10,17H,4,7,9,11-16H2,(H,25,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DM9ORUL	CS	C1CC(=O)NC2=C1C=C(C=C2)C(=O)N3CCN(CC3)CCCC(=O)C4=CC=CC=C4.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DM9ORUL	IK	ONELTIQETCJUSG-UHFFFAOYSA-N
DM9ORUL	IU	2-hydroxypropane-1,2,3-tricarboxylic acid;6-[4-(4-oxo-4-phenylbutyl)piperazine-1-carbonyl]-3,4-dihydro-1H-quinolin-2-one
DM9ORUL	CA	CAS 123941-50-4
DM9ORUL	DE	Cardiovascular disease

DMVM4NE	ID	DMVM4NE
DMVM4NE	DN	OPM-3023
DMVM4NE	HS	Discontinued in Phase 2
DMVM4NE	SN	OPM-3023; Bone metabolism modulator (periodontitis), Bionetworks; Bone metabolism modulator (periodontitis), Onepharm; OPM-3023 (local extended release formulation, peridontitis), OnePharm; OPM-3023 (oral, peridontitis), OnePharm
DMVM4NE	CP	Bionetworks GmbH
DMVM4NE	DE	Inflammation

DMWZXF7	ID	DMWZXF7
DMWZXF7	DN	ORG-33628
DMWZXF7	HS	Discontinued in Phase 2
DMWZXF7	SN	11beta-(4-Acetylphenyl)-3'-methylenespiro[estra-4,9-dien-17(R),2'-tetrahydrofuran]-3-one
DMWZXF7	DT	Small molecular drug
DMWZXF7	PC	9846209
DMWZXF7	MW	442.6
DMWZXF7	FM	C30H34O3
DMWZXF7	IC	InChI=1S/C30H34O3/c1-18-13-15-33-30(18)14-12-27-25-10-8-22-16-23(32)9-11-24(22)28(25)26(17-29(27,30)3)21-6-4-20(5-7-21)19(2)31/h4-7,16,25-27H,1,8-15,17H2,2-3H3/t25-,26+,27-,29-,30+/m0/s1
DMWZXF7	CS	CC(=O)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@@]34C(=C)CCO4)[C@H]5C2=C6CCC(=O)C=C6CC5)C
DMWZXF7	IK	YNWTZVKFWBTFFE-ONBAZCQBSA-N
DMWZXF7	IU	(8S,11R,13S,14S,17R)-11-(4-acetylphenyl)-13-methyl-3'-methylidenespiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one
DMWZXF7	CA	CAS 155768-17-5
DMWZXF7	DE	Contraception

DMU5PFD	ID	DMU5PFD
DMU5PFD	DN	Org-7797
DMU5PFD	HS	Discontinued in Phase 2
DMU5PFD	SN	org7797; 80177-51-1; Org 7797; SCHEMBL11227348; EINECS 279-413-5; AKOS030532756; (3,16alpha-Dihydroxyestra-1,3,5(10)-trien-17beta-yl)(methyl)ammonium hydrogen maleate; Estra-1,3,5(10)-triene-3,16-diol, 17-(methylamino)-, (16alpha,17beta)-, (Z)-2-butenedioate (1:1) (salt)
DMU5PFD	CP	Organon BioSciences
DMU5PFD	DT	Small molecular drug
DMU5PFD	PC	9866662
DMU5PFD	MW	417.5
DMU5PFD	FM	C23H31NO6
DMU5PFD	IC	InChI=1S/C19H27NO2.C4H4O4/c1-19-8-7-14-13-6-4-12(21)9-11(13)3-5-15(14)16(19)10-17(22)18(19)20-2;5-3(6)1-2-4(7)8/h4,6,9,14-18,20-22H,3,5,7-8,10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-,16+,17-,18+,19+;/m1./s1
DMU5PFD	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2NC)O)CCC4=C3C=CC(=C4)O.C(=C\\C(=O)O)\\C(=O)O
DMU5PFD	IK	UDCGSEPMGRJOAG-IQQQYFTASA-N
DMU5PFD	IU	(Z)-but-2-enedioic acid;(8R,9S,13S,14S,16R,17R)-13-methyl-17-(methylamino)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol
DMU5PFD	CA	CAS 80177-51-1
DMU5PFD	DE	Cardiac arrhythmias

DMW1FT0	ID	DMW1FT0
DMW1FT0	DN	ORG-9273
DMW1FT0	HS	Discontinued in Phase 2
DMW1FT0	SN	1-[(2beta,3alpha,5alpha,16beta,17beta)-17-Acetoxy-3-hydroxy-2-morpholinoandrostan-16-yl]-1-methylpiperidinium bromide; 17beta-Acetoxy-3alpha-hydroxy-16beta-(1-methylhexahydropyridinio-1-yl)-2beta-morpholino-5alpha-androstane bromide
DMW1FT0	DT	Small molecular drug
DMW1FT0	PC	131901
DMW1FT0	MW	517.799
DMW1FT0	FM	C31H53N2O4+
DMW1FT0	IC	InChI=1S/C31H53N2O4/c1-21(34)37-29-27(33(4)14-6-5-7-15-33)19-25-23-9-8-22-18-28(35)26(32-12-16-36-17-13-32)20-31(22,3)24(23)10-11-30(25,29)2/h22-29,35H,5-20H2,1-4H3/q+1/t22-,23?,24?,25?,26-,27-,28-,29-,30-,31-/m0/s1
DMW1FT0	CS	CC(=O)O[C@H]1[C@H](CC2[C@@]1(CCC3C2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCCC6)C
DMW1FT0	IK	DHYOZTTVCWLBTR-JHKQNVCFSA-N
DMW1FT0	IU	[(2S,3S,5S,10S,13S,16S,17R)-3-hydroxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-morpholin-4-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMW1FT0	CA	CAS 135644-85-8
DMW1FT0	DE	Paralysis

DMZEV63	ID	DMZEV63
DMZEV63	DN	Org-9731
DMZEV63	HS	Discontinued in Phase 2
DMZEV63	SN	IDDB3777
DMZEV63	CP	Organon BioSciences
DMZEV63	DE	Heart failure

DMRXHAC	ID	DMRXHAC
DMRXHAC	DN	Otenzepad
DMRXHAC	HS	Discontinued in Phase 2
DMRXHAC	SN	Otenzepad; AF-DX 116; 102394-31-0; AF-DX-116; 11-(2-(2-((Diethylamino)methyl)piperidin-1-yl)acetyl)-5H-benzo[e]pyrido[3,2-b][1,4]diazepin-6(11H)-one; UNII-WW6A9TFL2C; UNII-SX2WTG9R3Z; WW6A9TFL2C; SX2WTG9R3Z; 11-[[2-[(DIETHYLAMINO)METHYL]-1-PIPERIDINYL]ACETYL]-5,11-DIHYDRO-6H-PYRIDO[2,3-B][1,4]BENZODIAZEPIN-6-ONE; BRN 4212983; CHEMBL17045; NSC664529; 100158-38-1; NCGC00025002-02; DSSTox_RID_81048; DSSTox_CID_25674; DSSTox_GSID_45674; 6H-Pyrido(2,3-b)(1,4)benzodiazepin-6-one, 11-((2-((diethylamino)methyl)-1-piperidinyl)acetyl)
DMRXHAC	DT	Small molecular drug
DMRXHAC	PC	107867
DMRXHAC	MW	421.5
DMRXHAC	FM	C24H31N5O2
DMRXHAC	IC	InChI=1S/C24H31N5O2/c1-3-27(4-2)16-18-10-7-8-15-28(18)17-22(30)29-21-13-6-5-11-19(21)24(31)26-20-12-9-14-25-23(20)29/h5-6,9,11-14,18H,3-4,7-8,10,15-17H2,1-2H3,(H,26,31)
DMRXHAC	CS	CCN(CC)CC1CCCCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMRXHAC	IK	UBRKDAVQCKZSPO-UHFFFAOYSA-N
DMRXHAC	IU	11-[2-[2-(diethylaminomethyl)piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMRXHAC	CA	CAS 102394-31-0
DMRXHAC	CB	CHEBI:111174
DMRXHAC	DE	Heart failure

DMHFOIX	ID	DMHFOIX
DMHFOIX	DN	OxycoDex
DMHFOIX	HS	Discontinued in Phase 2
DMHFOIX	SN	Oxycodone/dextromethorphan
DMHFOIX	CP	Endo Pharmaceuticals
DMHFOIX	DE	Pain

DM02ANM	ID	DM02ANM
DM02ANM	DN	P-1075
DM02ANM	HS	Discontinued in Phase 2
DM02ANM	SN	60559-98-0; P1075; N-Cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridylguanidine; P-1075; BRN 0480738; 2-Cyano-1-tert-pentyl-3-(3-pyridyl)guanidine; CHEMBL11458; Guanidine, N-cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridinyl-; N-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine; P 1075; GUANIDINE, 2-CYANO-1-tert-PENTYL-3-(3-PYRIDYL)-; Guanidine, N-cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridinyl- [CAS]; SMR000466288; Tocris-1355; AC1L29NR; MLS000758317; MLS001424147; SCHEMBL2129487; SCHEMBL8747731; BDBM86250; CTK8J5792; CTK2F3712
DM02ANM	CP	LEO Pharma A/S
DM02ANM	DT	Small molecular drug
DM02ANM	PC	43345
DM02ANM	MW	231.3
DM02ANM	FM	C12H17N5
DM02ANM	IC	InChI=1S/C12H17N5/c1-4-12(2,3)17-11(15-9-13)16-10-6-5-7-14-8-10/h5-8H,4H2,1-3H3,(H2,15,16,17)
DM02ANM	CS	CCC(C)(C)N=C(NC#N)NC1=CN=CC=C1
DM02ANM	IK	HKZNADVVGXKQDL-UHFFFAOYSA-N
DM02ANM	IU	1-cyano-2-(2-methylbutan-2-yl)-3-pyridin-3-ylguanidine
DM02ANM	CA	CAS 60559-98-0
DM02ANM	CB	CHEBI:92004
DM02ANM	DE	Hypertension

DMWCAQD	ID	DMWCAQD
DMWCAQD	DN	P1A
DMWCAQD	HS	Discontinued in Phase 2
DMWCAQD	SN	IPSAT P1A; P1A, Ipsat Therapies
DMWCAQD	CP	Ipsat Therapies Oy
DMWCAQD	DT	Small molecular drug
DMWCAQD	PC	115127
DMWCAQD	MW	464.6
DMWCAQD	FM	C27H44O6
DMWCAQD	IC	InChI=1S/C27H44O6/c1-15(2)6-7-23(31)26(5,32)22-9-11-27(33)17-12-19(28)18-13-20(29)21(30)14-24(18,3)16(17)8-10-25(22,27)4/h12,15-16,18,20-23,29-33H,6-11,13-14H2,1-5H3/t16-,18-,20+,21-,22-,23+,24+,25+,26+,27+/m0/s1
DMWCAQD	CS	CC(C)CC[C@H]([C@@](C)([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O)O)O
DMWCAQD	IK	PJYYBCXMCWDUAZ-JJJZTNILSA-N
DMWCAQD	IU	(2S,3R,5R,9R,10R,13R,14S,17S)-17-[(2R,3R)-2,3-dihydroxy-6-methylheptan-2-yl]-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
DMWCAQD	CA	CAS 13408-56-5
DMWCAQD	CB	CHEBI:28135
DMWCAQD	DE	Toxicity

DM4ZNKX	ID	DM4ZNKX
DM4ZNKX	DN	PA-1806
DM4ZNKX	HS	Discontinued in Phase 2
DM4ZNKX	SN	BMS-180680; SQ-32633; SQ-33110; BMS-180680-01
DM4ZNKX	CP	Bristol-Myers Squibb Co
DM4ZNKX	PC	135462917
DM4ZNKX	MW	567.5
DM4ZNKX	FM	C19H17N7O10S2
DM4ZNKX	IC	InChI=1S/C19H17N7O10S2/c1-6-13(17(30)26(6)38(33,34)35)24-16(29)14(10-5-37-19(20)23-10)25-36-4-9-15(18(31)32)22-8-3-12(28)11(27)2-7(8)21-9/h2-3,5-6,13,27-28H,4H2,1H3,(H2,20,23)(H,24,29)(H,31,32)(H,33,34,35)/b25-14-/t6-,13+/m1/s1
DM4ZNKX	CS	C[C@@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\\OCC2=NC3=CC(=C(C=C3N=C2C(=O)O)O)O)/C4=CSC(=N4)N
DM4ZNKX	IK	FAUHVXXXXAHABE-VHLYPECSSA-N
DM4ZNKX	IU	3-[[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2R,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxymethyl]-6,7-dihydroxyquinoxaline-2-carboxylic acid
DM4ZNKX	DE	Bacterial infection

DMRSMW8	ID	DMRSMW8
DMRSMW8	DN	PAI-2
DMRSMW8	HS	Discontinued in Phase 2
DMRSMW8	SN	N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, &gt
DMRSMW8	DT	Small molecular drug
DMRSMW8	PC	443433
DMRSMW8	MW	171.19
DMRSMW8	FM	C8H13NO3
DMRSMW8	IC	InChI=1S/C8H13NO3/c1-2-3-7(10)9-6-4-5-12-8(6)11/h6H,2-5H2,1H3,(H,9,10)
DMRSMW8	CS	CCCC(=O)NC1CCOC1=O
DMRSMW8	IK	VFFNZZXXTGXBOG-UHFFFAOYSA-N
DMRSMW8	IU	N-(2-oxooxolan-3-yl)butanamide

DMWCLZ6	ID	DMWCLZ6
DMWCLZ6	DN	PALOSURAN
DMWCLZ6	HS	Discontinued in Phase 2
DMWCLZ6	SN	Palosuran; 540769-28-6; ACT-058362; UNII-ULD9ZKE457; 1-(2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea; ULD9ZKE457; ACT 058362; Palosuran; CHEMBL567303; Palosuran [INN]; 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea; ACT 058362; ACT058362 (Palosuran); GTPL3516; SCHEMBL1363480; DTXSID00202406; WYJCYXOCHXWTHG-UHFFFAOYSA-N; BCP15786; BDBM50302272; ZINC34375693; AKOS026750332; 1-(2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl-3-(2-methylquinolin-4-yl)urea; CS-1722; NCGC00408890-01
DMWCLZ6	DT	Small molecular drug
DMWCLZ6	PC	10173280
DMWCLZ6	MW	418.5
DMWCLZ6	FM	C25H30N4O2
DMWCLZ6	IC	InChI=1S/C25H30N4O2/c1-19-17-23(21-9-5-6-10-22(21)27-19)28-24(30)26-13-16-29-14-11-25(31,12-15-29)18-20-7-3-2-4-8-20/h2-10,17,31H,11-16,18H2,1H3,(H2,26,27,28,30)
DMWCLZ6	CS	CC1=NC2=CC=CC=C2C(=C1)NC(=O)NCCN3CCC(CC3)(CC4=CC=CC=C4)O
DMWCLZ6	IK	WYJCYXOCHXWTHG-UHFFFAOYSA-N
DMWCLZ6	IU	1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea
DMWCLZ6	CA	CAS 540769-28-6
DMWCLZ6	DE	Renal failure

DM9SYUT	ID	DM9SYUT
DM9SYUT	DN	PAMAPIMOD
DM9SYUT	HS	Discontinued in Phase 2
DM9SYUT	SN	Pamapimod; 449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
DM9SYUT	DT	Small molecular drug
DM9SYUT	PC	16220188
DM9SYUT	MW	406.4
DM9SYUT	FM	C19H20F2N4O4
DM9SYUT	IC	InChI=1S/C19H20F2N4O4/c1-25-17-11(10-22-19(24-17)23-13(4-6-26)5-7-27)8-16(18(25)28)29-15-3-2-12(20)9-14(15)21/h2-3,8-10,13,26-27H,4-7H2,1H3,(H,22,23,24)
DM9SYUT	CS	CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC(CCO)CCO
DM9SYUT	IK	JYYLVUFNAHSSFE-UHFFFAOYSA-N
DM9SYUT	IU	6-(2,4-difluorophenoxy)-2-(1,5-dihydroxypentan-3-ylamino)-8-methylpyrido[2,3-d]pyrimidin-7-one
DM9SYUT	CA	CAS 449811-01-2
DM9SYUT	CB	CHEBI:90685
DM9SYUT	DE	Rheumatoid arthritis

DM6TPCJ	ID	DM6TPCJ
DM6TPCJ	DN	Panamesine
DM6TPCJ	HS	Discontinued in Phase 2
DM6TPCJ	SN	EMD-57445; EMD-59983
DM6TPCJ	CP	Merck KGaA
DM6TPCJ	DT	Small molecular drug
DM6TPCJ	PC	3047810
DM6TPCJ	MW	426.5
DM6TPCJ	FM	C23H26N2O6
DM6TPCJ	IC	InChI=1S/C23H26N2O6/c1-28-18-5-3-17(4-6-18)25-14-19(31-22(25)26)13-24-10-8-23(27,9-11-24)16-2-7-20-21(12-16)30-15-29-20/h2-7,12,19,27H,8-11,13-15H2,1H3/t19-/m0/s1
DM6TPCJ	CS	COC1=CC=C(C=C1)N2C[C@@H](OC2=O)CN3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O
DM6TPCJ	IK	NINYZUDVKTUKIA-IBGZPJMESA-N
DM6TPCJ	IU	(5S)-5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxypiperidin-1-yl]methyl]-3-(4-methoxyphenyl)-1,3-oxazolidin-2-one
DM6TPCJ	CA	CAS 139225-22-2
DM6TPCJ	DE	Psychotic disorder

DME4RSI	ID	DME4RSI
DME4RSI	DN	Panomifene
DME4RSI	HS	Discontinued in Phase 2
DME4RSI	SN	Panomifine; EGIS-5650
DME4RSI	CP	EGIS Gyogyszergyar RT
DME4RSI	DT	Small molecular drug
DME4RSI	PC	3033654
DME4RSI	MW	427.5
DME4RSI	FM	C25H24F3NO2
DME4RSI	IC	InChI=1S/C25H24F3NO2/c26-25(27,28)24(21-9-5-2-6-10-21)23(19-7-3-1-4-8-19)20-11-13-22(14-12-20)31-18-16-29-15-17-30/h1-14,29-30H,15-18H2/b24-23+
DME4RSI	CS	C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\C(F)(F)F)/C3=CC=C(C=C3)OCCNCCO
DME4RSI	IK	MHXVDXXARZCVRK-WCWDXBQESA-N
DME4RSI	IU	2-[2-[4-[(E)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol
DME4RSI	CA	CAS 77599-17-8
DME4RSI	DE	Solid tumour/cancer

DM80UNM	ID	DM80UNM
DM80UNM	DN	PD-134308
DM80UNM	HS	Discontinued in Phase 2
DM80UNM	SN	CI-988; 130332-27-3; CI 988; PD-134308; UNII-2637PDX9SI; 2637PDX9SI; CHEMBL287735; CHEMBL2062154; PD 134308; 4-(((R)-2-((R)-2-(((Adamantan-2-yloxy)carbonyl)amino)-3-(1H-indol-3-yl)-2-methylpropanamido)-1-phenylethyl)amino)-4-oxobutanoic acid; 4-[[(1R)-2-[[(2R)-3-(1H-Indol-3-yl)-2-methyl-1-oxo-2-[[(tricyclo[3.3.1.13,7]dec-2-yloxy)carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic Acid
DM80UNM	DT	Small molecular drug
DM80UNM	PC	108187
DM80UNM	MW	614.7
DM80UNM	FM	C35H42N4O6
DM80UNM	IC	InChI=1S/C35H42N4O6/c1-35(18-26-19-36-28-10-6-5-9-27(26)28,39-34(44)45-32-24-14-21-13-22(16-24)17-25(32)15-21)33(43)37-20-29(23-7-3-2-4-8-23)38-30(40)11-12-31(41)42/h2-10,19,21-22,24-25,29,32,36H,11-18,20H2,1H3,(H,37,43)(H,38,40)(H,39,44)(H,41,42)/t21?,22?,24?,25?,29-,32?,35+/m0/s1
DM80UNM	CS	C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)NC[C@@H](C3=CC=CC=C3)NC(=O)CCC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DM80UNM	IK	FVQSSYMRZKLFDR-ZABPBAJSSA-N
DM80UNM	IU	4-[[(1R)-2-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid
DM80UNM	CA	CAS 130332-27-3
DM80UNM	DE	Anxiety disorder

DMMYNKH	ID	DMMYNKH
DMMYNKH	DN	PD-348292
DMMYNKH	HS	Discontinued in Phase 2
DMMYNKH	SN	Eribaxaban; PD 0348292; PD 348292; PD0348292; Eribaxaban (USAN); PD-0348292; N-(4-Chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidiine-1,2-dicarboxamide
DMMYNKH	CP	Pfizer
DMMYNKH	DT	Small molecular drug
DMMYNKH	PC	11634458
DMMYNKH	MW	484.9
DMMYNKH	FM	C24H22ClFN4O4
DMMYNKH	IC	InChI=1S/C24H22ClFN4O4/c1-34-18-13-21(30(14-18)24(33)27-16-7-5-15(25)6-8-16)23(32)28-20-10-9-17(12-19(20)26)29-11-3-2-4-22(29)31/h2-12,18,21H,13-14H2,1H3,(H,27,33)(H,28,32)/t18-,21-/m1/s1
DMMYNKH	CS	CO[C@@H]1C[C@@H](N(C1)C(=O)NC2=CC=C(C=C2)Cl)C(=O)NC3=C(C=C(C=C3)N4C=CC=CC4=O)F
DMMYNKH	IK	QQBKAVAGLMGMHI-WIYYLYMNSA-N
DMMYNKH	IU	(2R,4R)-1-N-(4-chlorophenyl)-2-N-[2-fluoro-4-(2-oxopyridin-1-yl)phenyl]-4-methoxypyrrolidine-1,2-dicarboxamide
DMMYNKH	CA	CAS 536748-46-6
DMMYNKH	CB	CHEBI:140420
DMMYNKH	DE	Thrombosis

DMGD20T	ID	DMGD20T
DMGD20T	DN	PEG-Infergen
DMGD20T	HS	Discontinued in Phase 2
DMGD20T	SN	PEG-Alfacon; PEGylated interferon alpha, Intermune; PEG-Infergen, InterMune; PEG-Interferon alfacon-1, InterMune
DMGD20T	CP	InterMune
DMGD20T	DE	Hepatitis virus infection

DMTGBPW	ID	DMTGBPW
DMTGBPW	DN	Pentisomide
DMTGBPW	HS	Discontinued in Phase 2
DMTGBPW	SN	Penticainide; Propisomide; ME 3202; CM-7857
DMTGBPW	CP	Sanofi
DMTGBPW	DT	Small molecular drug
DMTGBPW	PC	65847
DMTGBPW	MW	319.5
DMTGBPW	FM	C19H33N3O
DMTGBPW	IC	InChI=1S/C19H33N3O/c1-14(2)13-19(18(20)23,17-9-7-8-11-21-17)10-12-22(15(3)4)16(5)6/h7-9,11,14-16H,10,12-13H2,1-6H3,(H2,20,23)
DMTGBPW	CS	CC(C)CC(CCN(C(C)C)C(C)C)(C1=CC=CC=N1)C(=O)N
DMTGBPW	IK	ZZOZYGHXNQPIPS-UHFFFAOYSA-N
DMTGBPW	IU	2-[2-[di(propan-2-yl)amino]ethyl]-4-methyl-2-pyridin-2-ylpentanamide
DMTGBPW	CA	CAS 78833-03-1
DMTGBPW	DE	Heart arrhythmia

DMFWC3O	ID	DMFWC3O
DMFWC3O	DN	Perillyl alcohol
DMFWC3O	HS	Discontinued in Phase 2
DMFWC3O	SN	Monoterpenes, University of Wisconsin; Perillyl alcohol, University of Wisconsin; Perillyl alcohol, WARF
DMFWC3O	CP	University of Wisconsin-Madison
DMFWC3O	DT	Small molecular drug
DMFWC3O	PC	10819
DMFWC3O	MW	152.23
DMFWC3O	FM	C10H16O
DMFWC3O	IC	InChI=1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3
DMFWC3O	CS	CC(=C)C1CCC(=CC1)CO
DMFWC3O	IK	NDTYTMIUWGWIMO-UHFFFAOYSA-N
DMFWC3O	IU	(4-prop-1-en-2-ylcyclohexen-1-yl)methanol
DMFWC3O	CA	CAS 536-59-4
DMFWC3O	CB	CHEBI:15420
DMFWC3O	DE	Solid tumour/cancer

DMBDPN2	ID	DMBDPN2
DMBDPN2	DN	PF-217830
DMBDPN2	HS	Discontinued in Phase 2
DMBDPN2	SN	PF-00217830; 7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one
DMBDPN2	CP	Pfizer
DMBDPN2	DT	Small molecular drug
DMBDPN2	PC	11697676
DMBDPN2	MW	430.5
DMBDPN2	FM	C26H30N4O2
DMBDPN2	IC	InChI=1S/C26H30N4O2/c31-24-12-10-21-11-13-25(28-26(21)27-24)32-19-4-3-14-29-15-17-30(18-16-29)23-9-5-7-20-6-1-2-8-22(20)23/h1-2,5-9,11,13H,3-4,10,12,14-19H2,(H,27,28,31)
DMBDPN2	CS	C1CC(=O)NC2=C1C=CC(=N2)OCCCCN3CCN(CC3)C4=CC=CC5=CC=CC=C54
DMBDPN2	IK	QGNOXTFZOLDODX-UHFFFAOYSA-N
DMBDPN2	IU	7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one
DMBDPN2	CA	CAS 846032-02-8
DMBDPN2	DE	Schizophrenia; Bipolar disorder

DMWYJHC	ID	DMWYJHC
DMWYJHC	DN	PF-4480682
DMWYJHC	HS	Discontinued in Phase 2
DMWYJHC	CP	Pfizer Inc
DMWYJHC	DE	Neuropathic pain

DM6XEQA	ID	DM6XEQA
DM6XEQA	DN	PF-610355
DM6XEQA	HS	Discontinued in Phase 2
DM6XEQA	SN	PF-00610355; Beta 2 adrenoceptor agonist (asthma), Pfizer
DM6XEQA	CP	Pfizer Inc
DM6XEQA	PC	11505444
DM6XEQA	MW	617.8
DM6XEQA	FM	C34H39N3O6S
DM6XEQA	IC	InChI=1S/C34H39N3O6S/c1-34(2,36-22-32(40)28-12-15-31(39)30(19-28)37-44(3,42)43)20-24-7-4-6-23(16-24)18-33(41)35-21-25-8-5-9-27(17-25)26-10-13-29(38)14-11-26/h4-17,19,32,36-40H,18,20-22H2,1-3H3,(H,35,41)/t32-/m0/s1
DM6XEQA	CS	CC(C)(CC1=CC=CC(=C1)CC(=O)NCC2=CC(=CC=C2)C3=CC=C(C=C3)O)NC[C@@H](C4=CC(=C(C=C4)O)NS(=O)(=O)C)O
DM6XEQA	IK	YPHDIMUXXABSSO-YTTGMZPUSA-N
DM6XEQA	IU	2-[3-[2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(methanesulfonamido)phenyl]ethyl]amino]-2-methylpropyl]phenyl]-N-[[3-(4-hydroxyphenyl)phenyl]methyl]acetamide
DM6XEQA	CA	CAS 862541-45-5
DM6XEQA	DE	Chronic obstructive pulmonary disease

DMELXBQ	ID	DMELXBQ
DMELXBQ	DN	PG-530742
DMELXBQ	HS	Discontinued in Phase 2
DMELXBQ	SN	PG 116800; PG 530742; PGE 530742; PGE 7113313; PG-116800
DMELXBQ	CP	Pharmagenesis
DMELXBQ	DT	Small molecular drug
DMELXBQ	PC	9848869
DMELXBQ	MW	501.6
DMELXBQ	FM	C24H27N3O7S
DMELXBQ	IC	InChI=1S/C24H27N3O7S/c1-33-20-9-5-18(6-10-20)23(28)25-19-7-11-21(12-8-19)35(31,32)26-22(24(29)30)4-2-3-13-27-14-16-34-17-15-27/h5-12,22,26H,4,13-17H2,1H3,(H,25,28)(H,29,30)
DMELXBQ	CS	COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC(CC#CCN3CCOCC3)C(=O)O
DMELXBQ	IK	JAYVKNDQKXUNOJ-UHFFFAOYSA-N
DMELXBQ	IU	2-[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonylamino]-6-morpholin-4-ylhex-4-ynoic acid
DMELXBQ	CA	CAS 291533-11-4
DMELXBQ	DE	Myocardial infarction; Osteoarthritis

DM2N0TO	ID	DM2N0TO
DM2N0TO	DN	Physostigmine
DM2N0TO	HS	Discontinued in Phase 2
DM2N0TO	SN	Xalieve; Acetylcholinesterase inhibitor (dry mouth), Calabar; Physostigmine (local acting gel, xerostomia); Physostigmine (buccal, xerostomia), Calabar; Physostigmine (local acting gel, xerostomia), Calabar
DM2N0TO	CP	Calabar AB
DM2N0TO	DT	Small molecular drug
DM2N0TO	PC	5983
DM2N0TO	MW	275.35
DM2N0TO	FM	C15H21N3O2
DM2N0TO	IC	InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1
DM2N0TO	CS	C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C
DM2N0TO	IK	PIJVFDBKTWXHHD-HIFRSBDPSA-N
DM2N0TO	IU	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate
DM2N0TO	CA	CAS 57-47-6
DM2N0TO	CB	CHEBI:27953
DM2N0TO	DE	Xerostomia

DMJKN0B	ID	DMJKN0B
DMJKN0B	DN	PIBROZELESIN HYDROCHLORIDE
DMJKN0B	HS	Discontinued in Phase 2
DMJKN0B	SN	KW-2189; Pibrozelesin hydrochloride < Prop INNM; 8(S)-(Bromomethyl)-2-methyl-4-(4-methylpiperazin-1-ylcarbonyloxy)-6-(5,6,7-trimethoxyindol-2-ylcarbonyl)-3,6,7,8-tetrahydrobenzo[1,2-b:4,3-b']dipyrrole-1-carboxylic acid methyl ester hydrochloride
DMJKN0B	DT	Small molecular drug
DMJKN0B	PC	6918188
DMJKN0B	MW	735
DMJKN0B	FM	C32H37BrClN5O8
DMJKN0B	IC	InChI=1S/C32H36BrN5O8.ClH/c1-16-23(31(40)45-6)25-24-18(14-33)15-38(20(24)13-21(27(25)34-16)46-32(41)37-9-7-36(2)8-10-37)30(39)19-11-17-12-22(42-3)28(43-4)29(44-5)26(17)35-19;/h11-13,18,34-35H,7-10,14-15H2,1-6H3;1H/t18-;/m1./s1
DMJKN0B	CS	CC1=C(C2=C3[C@@H](CN(C3=CC(=C2N1)OC(=O)N4CCN(CC4)C)C(=O)C5=CC6=CC(=C(C(=C6N5)OC)OC)OC)CBr)C(=O)OC.Cl
DMJKN0B	IK	LXRTZQKDZOKJRQ-GMUIIQOCSA-N
DMJKN0B	IU	methyl (8S)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-7,8-dihydro-3H-pyrrolo[3,2-e]indole-1-carboxylate;hydrochloride
DMJKN0B	DE	Solid tumour/cancer

DMA13WI	ID	DMA13WI
DMA13WI	DN	Picumeterol
DMA13WI	HS	Discontinued in Phase 2
DMA13WI	SN	Levopicumeterol; Picumeterol fumarate; GX 63411; GR-114297; GR-114297A; GR-114297X; GR-63411
DMA13WI	CP	Glaxo Wellcome plc
DMA13WI	DT	Small molecular drug
DMA13WI	PC	131251
DMA13WI	MW	426.4
DMA13WI	FM	C21H29Cl2N3O2
DMA13WI	IC	InChI=1S/C21H29Cl2N3O2/c22-18-13-16(14-19(23)21(18)24)20(27)15-25-9-4-1-2-6-11-28-12-8-17-7-3-5-10-26-17/h3,5,7,10,13-14,20,25,27H,1-2,4,6,8-9,11-12,15,24H2/t20-/m0/s1
DMA13WI	CS	C1=CC=NC(=C1)CCOCCCCCCNC[C@@H](C2=CC(=C(C(=C2)Cl)N)Cl)O
DMA13WI	IK	NUBLQEKABJXICM-FQEVSTJZSA-N
DMA13WI	IU	(1R)-1-(4-amino-3,5-dichlorophenyl)-2-[6-(2-pyridin-2-ylethoxy)hexylamino]ethanol
DMA13WI	CA	CAS 130641-36-0
DMA13WI	DE	Asthma

DM3ISKB	ID	DM3ISKB
DM3ISKB	DN	PIRODAVIR
DM3ISKB	HS	Discontinued in Phase 2
DM3ISKB	SN	Pirodavir < Rec INN; R-77975; 4-[2-[1-(6-Methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]benzoic acid ethyl ester
DM3ISKB	DT	Small molecular drug
DM3ISKB	PC	71345
DM3ISKB	MW	369.5
DM3ISKB	FM	C21H27N3O3
DM3ISKB	IC	InChI=1S/C21H27N3O3/c1-3-26-21(25)18-5-7-19(8-6-18)27-15-12-17-10-13-24(14-11-17)20-9-4-16(2)22-23-20/h4-9,17H,3,10-15H2,1-2H3
DM3ISKB	CS	CCOC(=O)C1=CC=C(C=C1)OCCC2CCN(CC2)C3=NN=C(C=C3)C
DM3ISKB	IK	KCHIOGFOPPOUJC-UHFFFAOYSA-N
DM3ISKB	IU	ethyl 4-[2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy]benzoate
DM3ISKB	CA	CAS 124436-59-5
DM3ISKB	DE	Virus infection

DMSQ794	ID	DMSQ794
DMSQ794	DN	PKI166
DMSQ794	HS	Discontinued in Phase 2
DMSQ794	SN	PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol
DMSQ794	DT	Small molecular drug
DMSQ794	PC	6918403
DMSQ794	MW	330.4
DMSQ794	FM	C20H18N4O
DMSQ794	IC	InChI=1S/C20H18N4O/c1-13(14-5-3-2-4-6-14)23-19-17-11-18(24-20(17)22-12-21-19)15-7-9-16(25)10-8-15/h2-13,25H,1H3,(H2,21,22,23,24)/t13-/m1/s1
DMSQ794	CS	C[C@H](C1=CC=CC=C1)NC2=NC=NC3=C2C=C(N3)C4=CC=C(C=C4)O
DMSQ794	IK	XRYJULCDUUATMC-CYBMUJFWSA-N
DMSQ794	IU	4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol
DMSQ794	DE	Esophageal cancer

DMLK5IM	ID	DMLK5IM
DMLK5IM	DN	PNU-142633
DMLK5IM	HS	Discontinued in Phase 2
DMLK5IM	SN	PNU 142633; PNU-142633; 187665-65-2; UNII-B54P1BQ73L; B54P1BQ73L; CHEMBL441095; PNU-142633F; SCHEMBL6871704; CTK8E8481; DTXSID00431734; MolPort-023-276-296; ZINC13587959; BDBM50136471; AKOS024456892; NCGC00378553-01; 1H-2-Benzopyran-6-carboxamide, 1-(2-(4-(4-(aminocarbonyl)phenyl)-1-piperazinyl)ethyl)-3,4-dihydro-N-methyl-, (1S)-; (1S)-1-[2-[4-[4-(AMINOCARBONYL)PHENYL]-1-PIPERAZINYL]ETHYL]-3,4-DIHYDRO-N-METHYL-1H-2-BENZOPYRAN-6-CARBOXAMIDE; RT-015081; KB-275102; B6906; J-012076
DMLK5IM	CP	Pharmacia & Upjohn Inc
DMLK5IM	DT	Small molecular drug
DMLK5IM	PC	9845148
DMLK5IM	MW	422.5
DMLK5IM	FM	C24H30N4O3
DMLK5IM	IC	InChI=1S/C24H30N4O3/c1-26-24(30)19-4-7-21-18(16-19)9-15-31-22(21)8-10-27-11-13-28(14-12-27)20-5-2-17(3-6-20)23(25)29/h2-7,16,22H,8-15H2,1H3,(H2,25,29)(H,26,30)/t22-/m0/s1
DMLK5IM	CS	CNC(=O)C1=CC2=C(C=C1)[C@@H](OCC2)CCN3CCN(CC3)C4=CC=C(C=C4)C(=O)N
DMLK5IM	IK	PNTVCCRNJOGKGA-QFIPXVFZSA-N
DMLK5IM	IU	(1S)-1-[2-[4-(4-carbamoylphenyl)piperazin-1-yl]ethyl]-N-methyl-3,4-dihydro-1H-isochromene-6-carboxamide
DMLK5IM	CA	CAS 187665-65-2
DMLK5IM	DE	Migraine

DMP43IR	ID	DMP43IR
DMP43IR	DN	Pranazepide
DMP43IR	HS	Discontinued in Phase 2
DMP43IR	SN	Pranazepide; UNII-10TO0RP68C; FK 480; FK-480; 150408-73-4; FR-120480; FR 120480; CHEMBL300072; 10TO0RP68C; Panazepide; Pranazepide [INN:JAN]; NCGC00183009-01; NCGC00183006-01; Panazepide (JAN); AC1L31TI; DSSTox_RID_82980; DSSTox_CID_28711; DSSTox_GSID_48785; GTPL874; SCHEMBL2110207; DTXSID8048785; CHEBI:32039; ZINC3798924; Tox21_113262; PDSP2_000866; BDBM50290400; PDSP1_000880; N-(1-(2-Fluorophenyl)-3,4,6,7-tetrahydro-4-oxo-pyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-1H-indole-2-carboxamide; CAS-150408-73-4; D01858
DMP43IR	DT	Small molecular drug
DMP43IR	PC	132916
DMP43IR	MW	438.5
DMP43IR	FM	C26H19FN4O2
DMP43IR	IC	InChI=1S/C26H19FN4O2/c27-19-10-3-2-8-17(19)22-18-9-5-7-15-12-13-31(23(15)18)26(33)24(29-22)30-25(32)21-14-16-6-1-4-11-20(16)28-21/h1-11,14,24,28H,12-13H2,(H,30,32)/t24-/m1/s1
DMP43IR	CS	C1CN2C(=O)[C@H](N=C(C3=CC=CC1=C32)C4=CC=CC=C4F)NC(=O)C5=CC6=CC=CC=C6N5
DMP43IR	IK	WKJDXKWFGJWGAS-XMMPIXPASA-N
DMP43IR	IU	N-[(11S)-9-(2-fluorophenyl)-12-oxo-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl]-1H-indole-2-carboxamide
DMP43IR	CA	CAS 150408-73-4
DMP43IR	CB	CHEBI:32039
DMP43IR	DE	Pancreatic malfunction

DM082ZW	ID	DM082ZW
DM082ZW	DN	Prednisolone sodium metazoate
DM082ZW	HS	Discontinued in Phase 2
DM082ZW	SN	Prednisolone metasulfobenzoate; Prednisolone sodium metasulfobenzoate; ATL-2502; ATL-2505; COLAL-PRED; Prednisolone sodium metazoate (COLAL); Program AZM-110; Prednisolone sodium metasulfobenzoate (COLAL), Alizyme; Prednisolone sodium metazoate (COLAL), Alizyme; Prednisolone (colonic delivery, COLAL, ulcerative colitis), Alizyme; Prednisolone (colonic delivery, COLAL, ulcerative colitis), Prometheus/TSD Japan
DM082ZW	CP	Alizyme
DM082ZW	TC	Anticancer Agents
DM082ZW	DT	Small molecular drug
DM082ZW	PC	23675004
DM082ZW	MW	566.6
DM082ZW	FM	C28H31NaO9S
DM082ZW	IC	InChI=1S/C28H32O9S.Na/c1-26-10-8-18(29)13-17(26)6-7-20-21-9-11-28(33,27(21,2)14-22(30)24(20)26)23(31)15-37-25(32)16-4-3-5-19(12-16)38(34,35)36;/h3-5,8,10,12-13,20-22,24,30,33H,6-7,9,11,14-15H2,1-2H3,(H,34,35,36);/q;+1/p-1/t20-,21-,22-,24+,26-,27-,28-;/m0./s1
DM082ZW	CS	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)C4=CC(=CC=C4)S(=O)(=O)[O-])O)CCC5=CC(=O)C=C[C@]35C)O.[Na+]
DM082ZW	IK	RWFZSORKWFPGNE-VDYYWZOJSA-M
DM082ZW	IU	sodium;3-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]carbonylbenzenesulfonate
DM082ZW	CA	CAS 630-67-1
DM082ZW	DE	Inflammatory bowel disease

DMLOGR3	ID	DMLOGR3
DMLOGR3	DN	Pro 542
DMLOGR3	HS	Discontinued in Phase 2
DMLOGR3	CP	Progenics
DMLOGR3	DE	Human immunodeficiency virus infection

DM8U3R6	ID	DM8U3R6
DM8U3R6	DN	PROXODOLOL
DM8U3R6	HS	Discontinued in Phase 2
DM8U3R6	SN	Rac-5-[2-(3-tert-Butylamino-2-hydroxypropoxy)phenoxymethyl]-3-methyl-1,2,4-oxadiazole hydrochloride
DM8U3R6	DT	Small molecular drug
DM8U3R6	PC	133046
DM8U3R6	MW	387.9
DM8U3R6	FM	C17H26ClN3O5
DM8U3R6	IC	InChI=1S/C17H25N3O5.ClH/c1-17(2,3)18-9-12(21)10-23-13-7-5-6-8-14(13)24-11-15-19-16(22-4)20-25-15;/h5-8,12,18,21H,9-11H2,1-4H3;1H
DM8U3R6	CS	CC(C)(C)NCC(COC1=CC=CC=C1OCC2=NC(=NO2)OC)O.Cl
DM8U3R6	IK	IQEOUWNTUSFDSZ-UHFFFAOYSA-N
DM8U3R6	IU	1-(tert-butylamino)-3-[2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy]propan-2-ol;hydrochloride
DM8U3R6	CA	CAS 158446-41-4
DM8U3R6	DE	Glaucoma/ocular hypertension

DMHDP9R	ID	DMHDP9R
DMHDP9R	DN	PRS-211375 iv
DMHDP9R	HS	Discontinued in Phase 2
DMHDP9R	SN	Cannabinor; Bicyclic cannabinoids, Pharmos; HU-308; PRS-211058; PRS-211096; PRS-211335; PRS-211359; PRS-211375; CB2-selective cannabinoid platform, Pharmos; Oral Cannabinor (pain), Pharmos; PRS-211375 (oral, pain), Pharmos; PRS-211375 (iv, inflammation/autoimmune disease), Pharmos
DMHDP9R	CP	Pharmos
DMHDP9R	DT	Small molecular drug
DMHDP9R	PC	9844711
DMHDP9R	MW	414.6
DMHDP9R	FM	C27H42O3
DMHDP9R	IC	InChI=1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1
DMHDP9R	CS	CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)[C@H]2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC
DMHDP9R	IK	CFMRIVODIXTERW-FDFHNCONSA-N
DMHDP9R	IU	[(1R,4S,5R)-4-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-2-bicyclo[3.1.1]hept-2-enyl]methanol
DMHDP9R	DE	Pain

DMN4RV0	ID	DMN4RV0
DMN4RV0	DN	PRX-00023
DMN4RV0	HS	Discontinued in Phase 2
DMN4RV0	SN	Naluzotan; 740873-06-7; PRX-00023; UNII-LQ54E5B4EW; LQ54E5B4EW; CHEMBL209821; Naluzotan [USAN:INN]; PRX 00023; Naluzotan (USAN/INN); SCHEMBL678016; ZINC3963096; BCP20177; BDBM50187377; CS-6740; SB16847; N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide; HY-14848; AN-27536; D09358; L001689; 833C676; Acetamide, N-(3-(4-(4-(((cyclohexylmethyl)sulfonyl)amino)butyl)-1-piperazinyl)phenyl)-; N-(3-[4-(4-Cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl]phenyl)acetamide
DMN4RV0	CP	Epix
DMN4RV0	DT	Small molecular drug
DMN4RV0	PC	11430856
DMN4RV0	MW	450.6
DMN4RV0	FM	C23H38N4O3S
DMN4RV0	IC	InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
DMN4RV0	CS	CC(=O)NC1=CC(=CC=C1)N2CCN(CC2)CCCCNS(=O)(=O)CC3CCCCC3
DMN4RV0	IK	SPWZXWDPAWDKQE-UHFFFAOYSA-N
DMN4RV0	IU	N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide
DMN4RV0	CA	CAS 740873-06-7
DMN4RV0	DE	Mood disorder

DMT0KB1	ID	DMT0KB1
DMT0KB1	DN	PSD-506
DMT0KB1	HS	Discontinued in Phase 2
DMT0KB1	SN	Muscarinic M2 antagonists, Roche; Ro-320-2904; M2/M3 muscarinic antagonists (benign prostate hyperplasia), Roche/Plethora; M2/M3 muscarinic antagonists (overactive bladder), Roche/Plethora; M2/M3 muscarinic antagonists (urge incontinence), Roche/Plethora; M2/M3 muscarinic antagonists (urological disorders), Roche/Plethora
DMT0KB1	CP	Roche Bioscience
DMT0KB1	DE	Overactive bladder

DMR1OJM	ID	DMR1OJM
DMR1OJM	DN	PSD-508
DMR1OJM	HS	Discontinued in Phase 2
DMR1OJM	SN	M-5003; Dysmenorrhea therapy (intravaginal), Metris/Plethora; Intravaginal NSAID (dysmenorrhea), Plethora Solutions/Metris
DMR1OJM	CP	Metris Therapeutics Ltd
DMR1OJM	DE	Dysmenorrhea

DMDOFE7	ID	DMDOFE7
DMDOFE7	DN	PSN357
DMDOFE7	HS	Discontinued in Phase 2
DMDOFE7	SN	SCHEMBL2607197
DMDOFE7	CP	OSI Pharma
DMDOFE7	DT	Small molecular drug
DMDOFE7	PC	56603686
DMDOFE7	MW	501
DMDOFE7	FM	C25H30ClFN6O2
DMDOFE7	IC	InChI=1S/C25H30ClFN6O2/c1-31(2)7-8-32-9-11-33(12-10-32)25(35)21(13-17-3-5-19(27)6-4-17)30-24(34)20-14-18-15-23(26)28-16-22(18)29-20/h3-6,14-16,21,29H,7-13H2,1-2H3,(H,30,34)/t21-/m0/s1
DMDOFE7	CS	CN(C)CCN1CCN(CC1)C(=O)[C@H](CC2=CC=C(C=C2)F)NC(=O)C3=CC4=CC(=NC=C4N3)Cl
DMDOFE7	IK	RDFYSUFNGGYNSK-NRFANRHFSA-N
DMDOFE7	IU	5-chloro-N-[(2S)-1-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-3-(4-fluorophenyl)-1-oxopropan-2-yl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
DMDOFE7	DE	Type-2 diabetes

DMMF9RS	ID	DMMF9RS
DMMF9RS	DN	PSN-9301
DMMF9RS	HS	Discontinued in Phase 2
DMMF9RS	SN	P93/01; DPP-IV inhibitor (type 2 diabetes), Probiodrug; Dipeptidyl peptidase IV inhibitor (type 2 diabetes), (OSI) Prosidion; DPP-IV inhibitor (type 2 diabetes), (OSI) Prosidion
DMMF9RS	CP	OSI Pharmaceuticals
DMMF9RS	DE	Diabetic complication

DMYM9JL	ID	DMYM9JL
DMYM9JL	DN	PT-14
DMYM9JL	HS	Discontinued in Phase 2
DMYM9JL	SN	Erectide; PT-14 (transmucosal); PT-14 (transmucosal), Palatin/TheraTech
DMYM9JL	CP	Competitive Technologies Inc
DMYM9JL	PC	6875
DMYM9JL	MW	248.32
DMYM9JL	FM	C14H20N2O2
DMYM9JL	IC	InChI=1S/C14H20N2O2/c15-13-7-2-1-6-12(13)14(17)18-10-8-11-5-3-4-9-16-11/h1-2,6-7,11,16H,3-5,8-10,15H2
DMYM9JL	CS	C1CCNC(C1)CCOC(=O)C2=CC=CC=C2N
DMYM9JL	IK	BMIJYAZXNZEMLI-UHFFFAOYSA-N
DMYM9JL	IU	2-piperidin-2-ylethyl 2-aminobenzoate
DMYM9JL	CA	CAS 87-21-8
DMYM9JL	CB	CHEBI:135011
DMYM9JL	DE	Erectile dysfunction

DMGO2AV	ID	DMGO2AV
DMGO2AV	DN	PTI-701
DMGO2AV	HS	Discontinued in Phase 2
DMGO2AV	SN	Hydrocodone + acetaminophen + naltrexone
DMGO2AV	CP	Pain Therapeutics
DMGO2AV	DE	Pain

DMI8T41	ID	DMI8T41
DMI8T41	DN	Pumafentrine
DMI8T41	HS	Discontinued in Phase 2
DMI8T41	SN	Pumafentrin; BY-343; BYK-33043
DMI8T41	CP	ALTANA Pharma AG
DMI8T41	DT	Small molecular drug
DMI8T41	PC	3052763
DMI8T41	MW	477.6
DMI8T41	FM	C29H39N3O3
DMI8T41	IC	InChI=1S/C29H39N3O3/c1-8-35-27-15-22-23(16-26(27)34-7)28(30-25-13-14-31(6)17-24(22)25)20-9-11-21(12-10-20)29(33)32(18(2)3)19(4)5/h9-12,15-16,18-19,24-25H,8,13-14,17H2,1-7H3/t24-,25-/m1/s1
DMI8T41	CS	CCOC1=C(C=C2C(=C1)[C@H]3CN(CC[C@H]3N=C2C4=CC=C(C=C4)C(=O)N(C(C)C)C(C)C)C)OC
DMI8T41	IK	CVDXFPBVOIERBH-JWQCQUIFSA-N
DMI8T41	IU	4-[(4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-3,4,4a,10b-tetrahydro-1H-benzo[c][1,6]naphthyridin-6-yl]-N,N-di(propan-2-yl)benzamide
DMI8T41	CA	CAS 207993-12-2
DMI8T41	DE	Asthma

DMWE6V1	ID	DMWE6V1
DMWE6V1	DN	Putrescine
DMWE6V1	HS	Discontinued in Phase 2
DMWE6V1	SN	putrescine; 1,4-diaminobutane; 1,4-butanediamine; butane-1,4-diamine; 110-60-1; tetramethylenediamine; Butylenediamine; Putrescin; 1,4-Butylenediamine; Tetramethyldiamine; 1,4-Tetramethylenediamine; putrescina; Putreszin; Tetramethylendiamin; UNII-V10TVZ52E4; NSC 60545; BRN 0605282; H2N(CH2)4NH2; CCRIS 6751; AI3-25444; 1,4-Diamino-n-butane; EINECS 203-782-3; 1,4-Diaminobutane, 99%; CHEMBL46257; V10TVZ52E4; CHEBI:17148; KIDHWZJUCRJVML-UHFFFAOYSA-N; MFCD00008235; 1,4-butanediammonium; Diaminobutane dihydrochloride; PUT; HSDB 7865
DMWE6V1	DT	Small molecular drug
DMWE6V1	PC	1045
DMWE6V1	MW	88.15
DMWE6V1	FM	C4H12N2
DMWE6V1	IC	InChI=1S/C4H12N2/c5-3-1-2-4-6/h1-6H2
DMWE6V1	CS	C(CCN)CN
DMWE6V1	IK	KIDHWZJUCRJVML-UHFFFAOYSA-N
DMWE6V1	IU	butane-1,4-diamine
DMWE6V1	CA	CAS 110-60-1
DMWE6V1	CB	CHEBI:17148
DMWE6V1	DE	Burn and burn infection

DMRODZS	ID	DMRODZS
DMRODZS	DN	PV-707
DMRODZS	HS	Discontinued in Phase 2
DMRODZS	CP	Novozymes GroPep Limited
DMRODZS	DE	Skin burns

DMD308S	ID	DMD308S
DMD308S	DN	Pyrazinoylguanidine
DMD308S	HS	Discontinued in Phase 2
DMD308S	SN	PZG
DMD308S	CP	Sparta Pharmaceuticals Inc
DMD308S	PC	124704
DMD308S	MW	165.15
DMD308S	FM	C6H7N5O
DMD308S	IC	InChI=1S/C6H7N5O/c7-6(8)11-5(12)4-3-9-1-2-10-4/h1-3H,(H4,7,8,11,12)
DMD308S	CS	C1=CN=C(C=N1)C(=O)N=C(N)N
DMD308S	IK	WNBSDCKJFDZMHT-UHFFFAOYSA-N
DMD308S	IU	N-(diaminomethylidene)pyrazine-2-carboxamide
DMD308S	CA	CAS 60398-24-5
DMD308S	DE	Diabetic complication

DMTGFV6	ID	DMTGFV6
DMTGFV6	DN	PYY3-36
DMTGFV6	HS	Discontinued in Phase 2
DMTGFV6	CP	Nastech; Merck
DMTGFV6	DE	Obesity

DM2Q5IS	ID	DM2Q5IS
DM2Q5IS	DN	R-1438
DM2Q5IS	HS	Discontinued in Phase 2
DM2Q5IS	CP	Roche
DM2Q5IS	DE	Type-2 diabetes

DMAPRGQ	ID	DMAPRGQ
DMAPRGQ	DN	R-1578
DMAPRGQ	HS	Discontinued in Phase 2
DMAPRGQ	SN	MGluR2 antagonist (depression), Roche; MGluR2 antagonist (Alzheimer's disease/depression), Roche
DMAPRGQ	CP	Abiocode; Hoffmann-La Roche AG
DMAPRGQ	DE	Mood disorder

DMGVRQ2	ID	DMGVRQ2
DMGVRQ2	DN	R-18893
DMGVRQ2	HS	Discontinued in Phase 2
DMGVRQ2	CP	Janssen Pharmaceutica NV
DMGVRQ2	PC	486457
DMGVRQ2	MW	340.2
DMGVRQ2	FM	C14H11Cl2N3O3
DMGVRQ2	IC	InChI=1S/C14H11Cl2N3O3/c15-8-4-3-5-9(16)12(8)13(14(17)20)18-10-6-1-2-7-11(10)19(21)22/h1-7,13,18H,(H2,17,20)
DMGVRQ2	CS	C1=CC=C(C(=C1)NC(C2=C(C=CC=C2Cl)Cl)C(=O)N)[N+](=O)[O-]
DMGVRQ2	IK	BSFPWNBIKBSHRL-UHFFFAOYSA-N
DMGVRQ2	IU	2-(2,6-dichlorophenyl)-2-(2-nitroanilino)acetamide
DMGVRQ2	DE	Human immunodeficiency virus infection

DMEJNM1	ID	DMEJNM1
DMEJNM1	DN	R-343
DMEJNM1	HS	Discontinued in Phase 2
DMEJNM1	SN	R-921303; Syk tyrosine kinase inhibitor (allergic asthma), Rigel/Pfizer
DMEJNM1	CP	Rigel Pharmaceuticals Inc
DMEJNM1	DT	Small molecular drug
DMEJNM1	PC	10344820
DMEJNM1	MW	474.4
DMEJNM1	FM	C21H17F3N6O4
DMEJNM1	IC	InChI=1S/C21H17F3N6O4/c1-25-17(31)10-33-13-4-2-3-11(7-13)28-20-26-9-14(22)18(30-20)27-12-5-6-16-15(8-12)29-19(32)21(23,24)34-16/h2-9H,10H2,1H3,(H,25,31)(H,29,32)(H2,26,27,28,30)
DMEJNM1	CS	CNC(=O)COC1=CC=CC(=C1)NC2=NC=C(C(=N2)NC3=CC4=C(C=C3)OC(C(=O)N4)(F)F)F
DMEJNM1	IK	MOXXQFNQDDSJHT-UHFFFAOYSA-N
DMEJNM1	IU	2-[3-[[4-[(2,2-difluoro-3-oxo-4H-1,4-benzoxazin-6-yl)amino]-5-fluoropyrimidin-2-yl]amino]phenoxy]-N-methylacetamide
DMEJNM1	DE	Asthma

DM5NWPD	ID	DM5NWPD
DM5NWPD	DN	R-568
DM5NWPD	HS	Discontinued in Phase 2
DM5NWPD	SN	Tecalcet; Tecalcet [INN]; NPS-R-568; UNII-8I16YLE4US; R 568; NPS R 568; NPS R-568; 148717-54-8; 8I16YLE4US; CHEMBL292376; (R)-2-Chloro-N-(1-(3-methoxyphenyl)ethyl)benzenepropanamine; Benzenepropanamine, 2-chloro-N-(1-(3-methoxyphenyl)ethyl)-, (R)-; 3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]propan-1-amine; AC1L4KMU; GTPL718; SCHEMBL311950; NPS R568; DTXSID90164084; ZVQUCWXZCKWZBP-CQSZACIVSA-N; ZINC1538900; BDBM50432960; BDBM50299670; NCGC00344508-01; LS-31029; KB-80823
DM5NWPD	DT	Small molecular drug
DM5NWPD	PC	158796
DM5NWPD	MW	340.3
DM5NWPD	FM	C18H23Cl2NO
DM5NWPD	IC	InChI=1S/C18H22ClNO.ClH/c1-14(16-8-5-10-17(13-16)21-2)20-12-6-9-15-7-3-4-11-18(15)19;/h3-5,7-8,10-11,13-14,20H,6,9,12H2,1-2H3;1H/t14-;/m1./s1
DM5NWPD	CS	C[C@H](C1=CC(=CC=C1)OC)NCCCC2=CC=CC=C2Cl.Cl
DM5NWPD	IK	YJXUXANREVNZLH-PFEQFJNWSA-N
DM5NWPD	IU	3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]propan-1-amine;hydrochloride
DM5NWPD	CA	CAS 177172-49-5

DMJTOP8	ID	DMJTOP8
DMJTOP8	DN	R-61837
DMJTOP8	HS	Discontinued in Phase 2
DMJTOP8	SN	3-Methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine
DMJTOP8	DT	Small molecular drug
DMJTOP8	PC	127504
DMJTOP8	MW	284.36
DMJTOP8	FM	C16H20N4O
DMJTOP8	IC	InChI=1S/C16H20N4O/c1-13-4-3-5-14(12-13)19-8-10-20(11-9-19)15-6-7-16(21-2)18-17-15/h3-7,12H,8-11H2,1-2H3
DMJTOP8	CS	CC1=CC(=CC=C1)N2CCN(CC2)C3=NN=C(C=C3)OC
DMJTOP8	IK	DDOAUTHWSCUHQA-UHFFFAOYSA-N
DMJTOP8	IU	3-methoxy-6-[4-(3-methylphenyl)piperazin-1-yl]pyridazine
DMJTOP8	CA	CAS 100241-46-1
DMJTOP8	DE	Virus infection

DM2NTJY	ID	DM2NTJY
DM2NTJY	DN	R-68151
DM2NTJY	HS	Discontinued in Phase 2
DM2NTJY	SN	1-Ethyl-3-{4-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-phenyl}-5,5-dimethyl-2-thioxo-imidazolidin-4-one; 5-Lipoxygenase-In-1; R 68151; CHEMBL85599; 138331-04-1; AC1L30HG; SCHEMBL13696698; DTXSID10160583; BDBM50006793; HY-U00308; CS-7300; (1-Ethyl-3(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-5-dimethyl)-2-thioxo-4-imidazolidinone; 1-ethyl-3-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-5,5-dimethyl-2-sulfanylideneimidazolidin-4-one; M55551
DM2NTJY	DT	Small molecular drug
DM2NTJY	PC	132150
DM2NTJY	MW	424.6
DM2NTJY	FM	C23H28N4O2S
DM2NTJY	IC	InChI=1S/C23H28N4O2S/c1-4-26-22(30)27(21(29)23(26,2)3)19-7-5-17(6-8-19)24-13-15-25(16-14-24)18-9-11-20(28)12-10-18/h5-12,28H,4,13-16H2,1-3H3
DM2NTJY	CS	CCN1C(=S)N(C(=O)C1(C)C)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)O
DM2NTJY	IK	AHWDHLCCXRVAIC-UHFFFAOYSA-N
DM2NTJY	IU	1-ethyl-3-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-5,5-dimethyl-2-sulfanylideneimidazolidin-4-one
DM2NTJY	CA	CAS 138331-04-1
DM2NTJY	DE	Psoriasis vulgaris

DM9BI3Y	ID	DM9BI3Y
DM9BI3Y	DN	R7128
DM9BI3Y	HS	Discontinued in Phase 2
DM9BI3Y	SN	R-4048; R-7128; RG-7128; RO-5024048
DM9BI3Y	CP	Roche
DM9BI3Y	DT	Small molecular drug
DM9BI3Y	PC	16122663
DM9BI3Y	MW	399.4
DM9BI3Y	FM	C18H26FN3O6
DM9BI3Y	IC	InChI=1S/C18H26FN3O6/c1-9(2)14(23)26-8-11-13(28-15(24)10(3)4)18(5,19)16(27-11)22-7-6-12(20)21-17(22)25/h6-7,9-11,13,16H,8H2,1-5H3,(H2,20,21,25)/t11-,13-,16-,18-/m1/s1
DM9BI3Y	CS	CC(C)C(=O)OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=NC2=O)N)(C)F)OC(=O)C(C)C
DM9BI3Y	IK	MLESJYFEMSJZLZ-MAAOGQSESA-N
DM9BI3Y	IU	[(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
DM9BI3Y	CA	CAS 940908-79-2
DM9BI3Y	DE	Hepatitis C virus infection

DM4O7KA	ID	DM4O7KA
DM4O7KA	DN	R-84760
DM4O7KA	HS	Discontinued in Phase 2
DM4O7KA	SN	R-84760; R-84761; R-86436; R 86428; R 84761; R-86428; R 86436; R 84760; 3-(1-Pyrrolidinylmethyl)-4-(5,6-dichloro-1-indancarbonyl)-tetrahydro-1,4-thiazine hydrochloride; Thiomorpholine, 4-((5,6-dichloro-2,3-dihydro-1H-inden-1-yl)carbonyl)-3-(1-pyrrolidinylmethyl)-, monohydrochloride, (R-(R*,S*))-; C19H24Cl2N2OS.HCl; 157824-23-2; AC1L3220; LS-173526; [(1S)-5,6-dichloro-2,3-dihydro-1H-inden-1-yl]-[(3R)-3-(pyrrolidin-1-ylmethyl)thiomorpholin-4-yl]methanone hydrochloride
DM4O7KA	CP	Sankyo Co Ltd
DM4O7KA	DT	Small molecular drug
DM4O7KA	PC	133035
DM4O7KA	MW	435.8
DM4O7KA	FM	C19H25Cl3N2OS
DM4O7KA	IC	InChI=1S/C19H24Cl2N2OS.ClH/c20-17-9-13-3-4-15(16(13)10-18(17)21)19(24)23-7-8-25-12-14(23)11-22-5-1-2-6-22;/h9-10,14-15H,1-8,11-12H2;1H/t14-,15+;/m1./s1
DM4O7KA	CS	C1CCN(C1)C[C@@H]2CSCCN2C(=O)[C@H]3CCC4=CC(=C(C=C34)Cl)Cl.Cl
DM4O7KA	IK	KSUNRZWFIKXTKO-LIOBNPLQSA-N
DM4O7KA	IU	[(1S)-5,6-dichloro-2,3-dihydro-1H-inden-1-yl]-[(3R)-3-(pyrrolidin-1-ylmethyl)thiomorpholin-4-yl]methanone;hydrochloride
DM4O7KA	CA	CAS 157824-23-2
DM4O7KA	DE	Pain

DMDOETQ	ID	DMDOETQ
DMDOETQ	DN	R-873
DMDOETQ	HS	Discontinued in Phase 2
DMDOETQ	CP	Roche Holding AG
DMDOETQ	DE	Erectile dysfunction

DMRZI3C	ID	DMRZI3C
DMRZI3C	DN	R-87366
DMRZI3C	HS	Discontinued in Phase 2
DMRZI3C	SN	Quinoxalin-2-ylcarbonyl-L-asparaginyl-[3(S)-amino-2(S)-hydroxy-4-phenylbutyryl]-L-proline tert-butylamide
DMRZI3C	DT	Small molecular drug
DMRZI3C	PC	464206
DMRZI3C	MW	617.7
DMRZI3C	FM	C32H39N7O6
DMRZI3C	IC	InChI=1S/C32H39N7O6/c1-32(2,3)38-30(44)25-14-9-15-39(25)31(45)27(41)22(16-19-10-5-4-6-11-19)36-28(42)23(17-26(33)40)37-29(43)24-18-34-20-12-7-8-13-21(20)35-24/h4-8,10-13,18,22-23,25,27,41H,9,14-17H2,1-3H3,(H2,33,40)(H,36,42)(H,37,43)(H,38,44)/t22-,23-,25-,27-/m0/s1
DMRZI3C	CS	CC(C)(C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)C3=NC4=CC=CC=C4N=C3)O
DMRZI3C	IK	UYZMZENNYRSFDS-QNWDWTFCSA-N
DMRZI3C	IU	(2S)-N-[(2S,3S)-4-[(2S)-2-(tert-butylcarbamoyl)pyrrolidin-1-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-2-(quinoxaline-2-carbonylamino)butanediamide
DMRZI3C	CA	CAS 144779-91-9
DMRZI3C	DE	Human immunodeficiency virus infection

DMARQE0	ID	DMARQE0
DMARQE0	DN	Radafaxine
DMARQE0	HS	Discontinued in Phase 2
DMARQE0	SN	Hydroxybupropion
DMARQE0	CP	GlaxoSmithKline
DMARQE0	DT	Small molecular drug
DMARQE0	PC	9795056
DMARQE0	MW	255.74
DMARQE0	FM	C13H18ClNO2
DMARQE0	IC	InChI=1S/C13H18ClNO2/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3/t9-,13+/m0/s1
DMARQE0	CS	C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O
DMARQE0	IK	RCOBKSKAZMVBHT-TVQRCGJNSA-N
DMARQE0	IU	(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol
DMARQE0	CA	CAS 192374-14-4
DMARQE0	DE	Major depressive disorder

DMI1SXB	ID	DMI1SXB
DMI1SXB	DN	Rafabegron
DMI1SXB	HS	Discontinued in Phase 2
DMI1SXB	SN	AD-9677; AJ-9677; TAK-677
DMI1SXB	CP	Dainippon Pharmaceutical Co Ltd
DMI1SXB	DT	Small molecular drug
DMI1SXB	PC	5493324
DMI1SXB	MW	402.9
DMI1SXB	FM	C21H23ClN2O4
DMI1SXB	IC	InChI=1S/C21H23ClN2O4/c1-13(23-11-18(25)14-4-2-5-16(22)9-14)8-15-10-24-21-17(15)6-3-7-19(21)28-12-20(26)27/h2-7,9-10,13,18,23-25H,8,11-12H2,1H3,(H,26,27)/t13-,18+/m1/s1
DMI1SXB	CS	C[C@H](CC1=CNC2=C1C=CC=C2OCC(=O)O)NC[C@@H](C3=CC(=CC=C3)Cl)O
DMI1SXB	IK	FHEYFIGWYQJVDR-ACJLOTCBSA-N
DMI1SXB	IU	2-[[3-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]acetic acid
DMI1SXB	CA	CAS 244081-42-3
DMI1SXB	DE	Type-2 diabetes

DMYSADI	ID	DMYSADI
DMYSADI	DN	RBx10558
DMYSADI	HS	Discontinued in Phase 2
DMYSADI	CP	PPD Wilmington
DMYSADI	DE	Hyperlipidaemia

DM7OD3J	ID	DM7OD3J
DM7OD3J	DN	RBx-2258
DM7OD3J	HS	Discontinued in Phase 2
DM7OD3J	SN	Pamirosin; Parvosin; SPM-969
DM7OD3J	CP	Ranbaxy Laboratories Ltd
DM7OD3J	DE	Prostate hyperplasia

DMIEFH0	ID	DMIEFH0
DMIEFH0	DN	REC-15/3079
DMIEFH0	HS	Discontinued in Phase 2
DMIEFH0	SN	REC-3079; 5 HT1A antagonist, Recordati
DMIEFH0	CP	Recordati SpA
DMIEFH0	DT	Small molecular drug
DMIEFH0	PC	9847377
DMIEFH0	MW	466.6
DMIEFH0	FM	C26H34N4O4
DMIEFH0	IC	InChI=1S/C26H34N4O4/c1-34-25-14-8-7-13-24(25)28-18-15-27(16-19-28)17-20-29(26(31)21-9-3-2-4-10-21)22-11-5-6-12-23(22)30(32)33/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3
DMIEFH0	CS	COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=C3[N+](=O)[O-])C(=O)C4CCCCC4
DMIEFH0	IK	HVMKWKIPLGPYAR-UHFFFAOYSA-N
DMIEFH0	IU	N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-(2-nitrophenyl)cyclohexanecarboxamide
DMIEFH0	DE	Urinary incontinence

DMX4ZWK	ID	DMX4ZWK
DMX4ZWK	DN	REC-15-2739
DMX4ZWK	HS	Discontinued in Phase 2
DMX4ZWK	SN	Upidosin; UPIDOSIN; Rec-15-2739; 152735-23-4; UNII-TXG28R7G4Y; TXG28R7G4Y; CHEMBL278865; 4H-1-Benzopyran-8-carboxamide,N-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-3-methyl-4-oxo-2-phenyl-; Upidosin [INN]; N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-methyl-4-oxo-2-phenylchromene-8-carboxamide; SB 216469-S; Rec 15-2739; ACMC-20n6iu; AC1L3XX2; GTPL496; SCHEMBL6638869; CTK4C7558; DTXSID70165115; Rec 15/2739; ZINC3796141; BDBM50057465; AKOS030553705; SB 216469; L000508;  SB-216469; REC-15-2869; REC-15-3011; REC-22/009
DMX4ZWK	CP	Recordati SpA
DMX4ZWK	DT	Small molecular drug
DMX4ZWK	PC	148842
DMX4ZWK	MW	511.6
DMX4ZWK	FM	C31H33N3O4
DMX4ZWK	IC	InChI=1S/C31H33N3O4/c1-22-28(35)24-12-8-13-25(30(24)38-29(22)23-10-4-3-5-11-23)31(36)32-16-9-17-33-18-20-34(21-19-33)26-14-6-7-15-27(26)37-2/h3-8,10-15H,9,16-21H2,1-2H3,(H,32,36)
DMX4ZWK	CS	CC1=C(OC2=C(C1=O)C=CC=C2C(=O)NCCCN3CCN(CC3)C4=CC=CC=C4OC)C5=CC=CC=C5
DMX4ZWK	IK	DUCNHKDCVVSJLG-UHFFFAOYSA-N
DMX4ZWK	IU	N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-methyl-4-oxo-2-phenylchromene-8-carboxamide
DMX4ZWK	CA	CAS 152735-23-4
DMX4ZWK	DE	Prostate disease

DMIN73Y	ID	DMIN73Y
DMIN73Y	DN	Reglixane
DMIN73Y	HS	Discontinued in Phase 2
DMIN73Y	CP	Pfizer
DMIN73Y	DE	Diabetic complication

DMLJEFH	ID	DMLJEFH
DMLJEFH	DN	Relacatib
DMLJEFH	HS	Discontinued in Phase 2
DMLJEFH	SN	GSK-462795; SB-462795; Azepan-3-one compound 10; Relacatib (USAN/INN); N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide
DMLJEFH	CP	GlaxoSmithKline
DMLJEFH	DT	Small molecular drug
DMLJEFH	PC	6918602
DMLJEFH	MW	540.6
DMLJEFH	FM	C27H32N4O6S
DMLJEFH	IC	InChI=1S/C27H32N4O6S/c1-17(2)14-21(30-27(34)24-15-19-8-4-5-9-23(19)37-24)26(33)29-20-12-11-18(3)31(16-22(20)32)38(35,36)25-10-6-7-13-28-25/h4-10,13,15,17-18,20-21H,11-12,14,16H2,1-3H3,(H,29,33)(H,30,34)/t18-,20+,21+/m1/s1
DMLJEFH	CS	C[C@@H]1CC[C@@H](C(=O)CN1S(=O)(=O)C2=CC=CC=N2)NC(=O)[C@H](CC(C)C)NC(=O)C3=CC4=CC=CC=C4O3
DMLJEFH	IK	BWYBBMQLUKXECQ-GIVPXCGWSA-N
DMLJEFH	IU	N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide
DMLJEFH	CA	CAS 362505-84-8
DMLJEFH	DE	Osteoporosis; Bone metastases

DMHCBQS	ID	DMHCBQS
DMHCBQS	DN	ReN-1869
DMHCBQS	HS	Discontinued in Phase 2
DMHCBQS	SN	Neurin project, ReNeuron; ReN-0189; NNC-05-1869; NNC-47-0189
DMHCBQS	CP	Novo Nordisk Pharmaceuticals Ltd
DMHCBQS	PC	9799039
DMHCBQS	MW	361.5
DMHCBQS	FM	C24H27NO2
DMHCBQS	IC	InChI=1S/C24H27NO2/c26-24(27)20-9-5-15-25(17-20)16-6-12-23-21-10-3-1-7-18(21)13-14-19-8-2-4-11-22(19)23/h1-4,7-8,10-12,20H,5-6,9,13-17H2,(H,26,27)/t20-/m1/s1
DMHCBQS	CS	C1C[C@H](CN(C1)CCC=C2C3=CC=CC=C3CCC4=CC=CC=C42)C(=O)O
DMHCBQS	IK	RXWDEUWOJGGNHU-HXUWFJFHSA-N
DMHCBQS	IU	(3R)-1-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propyl]piperidine-3-carboxylic acid
DMHCBQS	DE	Pain

DMSOALX	ID	DMSOALX
DMSOALX	DN	Repifermin
DMSOALX	HS	Discontinued in Phase 2
DMSOALX	SN	FGF 10; FGF-10, HGS; Fibroblast growth factor-10, HGS; KGF-2, HGS; KGF-2D33, HGS; Keratinocyte growth factor-2, HGS; S69-S208, HGS
DMSOALX	CP	Human Genome Sciences Inc
DMSOALX	DE	Oral mucositis

DM3EAYN	ID	DM3EAYN
DM3EAYN	DN	RESEQUINIL
DM3EAYN	HS	Discontinued in Phase 2
DM3EAYN	SN	AVE-3933; SX-3933; Resequinil; 5-(3-Methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
DM3EAYN	DT	Small molecular drug
DM3EAYN	PC	135418404
DM3EAYN	MW	334.3
DM3EAYN	FM	C18H14N4O3
DM3EAYN	IC	InChI=1S/C18H14N4O3/c1-10-20-17(22-25-10)14-9-13-15(21-18(14)23)6-7-19-16(13)11-4-3-5-12(8-11)24-2/h3-9H,1-2H3,(H,21,23)
DM3EAYN	CS	CC1=NC(=NO1)C2=CC3=C(C=CN=C3C4=CC(=CC=C4)OC)NC2=O
DM3EAYN	IK	JQOFKKWHXGQABB-UHFFFAOYSA-N
DM3EAYN	IU	5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1H-1,6-naphthyridin-2-one
DM3EAYN	CA	CAS 219846-31-8
DM3EAYN	DE	Epilepsy

DM3TU7D	ID	DM3TU7D
DM3TU7D	DN	RG1578
DM3TU7D	HS	Discontinued in Phase 2
DM3TU7D	CP	Roche
DM3TU7D	DE	Major depressive disorder

DM5KJGB	ID	DM5KJGB
DM5KJGB	DN	RG7160
DM5KJGB	HS	Discontinued in Phase 2
DM5KJGB	CP	Roche
DM5KJGB	DE	Metastatic colorectal cancer

DMCQRS2	ID	DMCQRS2
DMCQRS2	DN	RG7414
DMCQRS2	HS	Discontinued in Phase 2
DMCQRS2	CP	Genentech
DMCQRS2	DE	Non-small-cell lung cancer; Colorectal cancer

DM32IV4	ID	DM32IV4
DM32IV4	DN	RG7593
DM32IV4	HS	Discontinued in Phase 2
DM32IV4	CP	Seattle Genetics; Roche
DM32IV4	DE	Haematological malignancy

DMPQC18	ID	DMPQC18
DMPQC18	DN	RG7685
DMPQC18	HS	Discontinued in Phase 2
DMPQC18	CP	Roche
DMPQC18	DE	Type-2 diabetes

DMI1XQ9	ID	DMI1XQ9
DMI1XQ9	DN	RG7697
DMI1XQ9	HS	Discontinued in Phase 2
DMI1XQ9	CP	Roche
DMI1XQ9	DE	Type-2 diabetes

DMQ4IKZ	ID	DMQ4IKZ
DMQ4IKZ	DN	RHIZOXIN
DMQ4IKZ	HS	Discontinued in Phase 2
DMQ4IKZ	SN	90996-54-6; Rhizoxin from Rhizopus sp.
DMQ4IKZ	DT	Small molecular drug
DMQ4IKZ	PC	6437358
DMQ4IKZ	MW	625.7
DMQ4IKZ	FM	C35H47NO9
DMQ4IKZ	IC	InChI=1S/C35H47NO9/c1-19(13-25-18-41-23(5)36-25)9-8-10-21(3)32(40-7)22(4)27-17-29(37)35(6)30(45-35)12-11-20(2)26-14-24(16-31(38)42-26)15-28-33(43-28)34(39)44-27/h8-13,18,20,22,24,26-30,32-33,37H,14-17H2,1-7H3/b9-8+,12-11+,19-13+,21-10+/t20-,22+,24+,26-,27+,28+,29+,30-,32+,33-,35-/m1/s1
DMQ4IKZ	CS	C[C@@H]1/C=C/[C@@H]2[C@](O2)([C@H](C[C@H](OC(=O)[C@H]3[C@@H](O3)C[C@@H]4C[C@H]1OC(=O)C4)[C@H](C)[C@H](/C(=C/C=C/C(=C/C5=COC(=N5)C)/C)/C)OC)O)C
DMQ4IKZ	IK	OWPCHSCAPHNHAV-QIPOKPRISA-N
DMQ4IKZ	IU	(1S,3S,5R,8S,10S,11R,13R,14E,16R,17R)-10-hydroxy-8-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]henicos-14-ene-6,19-dione
DMQ4IKZ	CA	CAS 90996-54-6
DMQ4IKZ	CB	CHEBI:72590
DMQ4IKZ	DE	Breast cancer

DMD8ZSW	ID	DMD8ZSW
DMD8ZSW	DN	Rilotumumab
DMD8ZSW	HS	Discontinued in Phase 2
DMD8ZSW	CP	Amgen
DMD8ZSW	DT	Antibody
DMD8ZSW	DE	Grade IV malignant glioma

DME5MGP	ID	DME5MGP
DME5MGP	DN	RIPISARTAN
DME5MGP	HS	Discontinued in Phase 2
DME5MGP	SN	Ripisartan; UP-269-6; 5-Methyl-7-propyl-8-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1,2,4-triazolo[1,5-c]pyrimidin-2(3H)-one
DME5MGP	DT	Small molecular drug
DME5MGP	PC	132840
DME5MGP	MW	426.5
DME5MGP	FM	C23H22N8O
DME5MGP	IC	InChI=1S/C23H22N8O/c1-3-6-20-19(22-25-23(32)28-31(22)14(2)24-20)13-15-9-11-16(12-10-15)17-7-4-5-8-18(17)21-26-29-30-27-21/h4-5,7-12H,3,6,13H2,1-2H3,(H,28,32)(H,26,27,29,30)
DME5MGP	CS	CCCC1=C(C2=NC(=O)NN2C(=N1)C)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DME5MGP	IK	OLJAPHMBAMBVKL-UHFFFAOYSA-N
DME5MGP	IU	5-methyl-7-propyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-[1,2,4]triazolo[1,5-c]pyrimidin-2-one
DME5MGP	CA	CAS 148504-51-2
DME5MGP	DE	Hypertension

DMNRGB7	ID	DMNRGB7
DMNRGB7	DN	Risotilide
DMNRGB7	HS	Discontinued in Phase 2
DMNRGB7	SN	Risotilide hydrochloride; WY-48986
DMNRGB7	CP	Wyeth
DMNRGB7	DT	Small molecular drug
DMNRGB7	PC	60667
DMNRGB7	MW	377.5
DMNRGB7	FM	C15H27N3O4S2
DMNRGB7	IC	InChI=1S/C15H27N3O4S2/c1-12(2)16-10-11-18(13(3)4)24(21,22)15-8-6-14(7-9-15)17-23(5,19)20/h6-9,12-13,16-17H,10-11H2,1-5H3
DMNRGB7	CS	CC(C)NCCN(C(C)C)S(=O)(=O)C1=CC=C(C=C1)NS(=O)(=O)C
DMNRGB7	IK	GLIRXHQYWRYQDV-UHFFFAOYSA-N
DMNRGB7	IU	4-(methanesulfonamido)-N-propan-2-yl-N-[2-(propan-2-ylamino)ethyl]benzenesulfonamide
DMNRGB7	CA	CAS 120688-08-6
DMNRGB7	DE	Heart arrhythmia

DMVHT6F	ID	DMVHT6F
DMVHT6F	DN	Rispenzepine
DMVHT6F	HS	Discontinued in Phase 2
DMVHT6F	SN	Nuvenzepine; DF-545
DMVHT6F	CP	Merck & Co Inc
DMVHT6F	DT	Small molecular drug
DMVHT6F	PC	129505
DMVHT6F	MW	336.4
DMVHT6F	FM	C19H20N4O2
DMVHT6F	IC	InChI=1S/C19H20N4O2/c1-22-11-5-6-13(12-22)19(25)23-16-9-3-2-8-15(16)21-18(24)14-7-4-10-20-17(14)23/h2-4,7-10,13H,5-6,11-12H2,1H3,(H,21,24)
DMVHT6F	CS	CN1CCCC(C1)C(=O)N2C3=CC=CC=C3NC(=O)C4=C2N=CC=C4
DMVHT6F	IK	LPLNSPKKMWHFAU-UHFFFAOYSA-N
DMVHT6F	IU	11-(1-methylpiperidine-3-carbonyl)-6H-pyrido[3,2-c][1,5]benzodiazepin-5-one
DMVHT6F	CA	CAS 96449-05-7
DMVHT6F	DE	Chronic obstructive pulmonary disease

DMOZEN6	ID	DMOZEN6
DMOZEN6	DN	RJR-2403
DMOZEN6	HS	Discontinued in Phase 2
DMOZEN6	SN	Metanicotine; Rivanicline; RJR-2403; Trans-metanicotine; 15585-43-0; Rivanicline [INN]; 538-79-4; (E)-Metanicotine; UNII-6H35LF645A; NSC 66331; 3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-; TC-2403; AI3-18211; CHEMBL132966; 6H35LF645A; (3E)-N-Methyl-4-(pyridin-3-yl)but-3-en-1-amine; But-3-en-1-amine, N-methyl-4-(pyridin-3-yl)-, (E)-; Pyridine, 3-(4-(methylamino)-1-butenyl)-; (E)-N-methyl-4-pyridin-3-ylbut-3-en-1-amine; (3E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine
DMOZEN6	DT	Small molecular drug
DMOZEN6	PC	5310967
DMOZEN6	MW	162.23
DMOZEN6	FM	C10H14N2
DMOZEN6	IC	InChI=1S/C10H14N2/c1-11-7-3-2-5-10-6-4-8-12-9-10/h2,4-6,8-9,11H,3,7H2,1H3/b5-2+
DMOZEN6	CS	CNCC/C=C/C1=CN=CC=C1
DMOZEN6	IK	JUOSGGQXEBBCJB-GORDUTHDSA-N
DMOZEN6	IU	(E)-N-methyl-4-pyridin-3-ylbut-3-en-1-amine
DMOZEN6	CA	CAS 15585-43-0
DMOZEN6	DE	Cognitive impairment

DMHSUQ1	ID	DMHSUQ1
DMHSUQ1	DN	R-ketoprofen
DMHSUQ1	HS	Discontinued in Phase 2
DMHSUQ1	SN	(R)-Ketoprofen; 56105-81-8; (R)-Ketoprophen; UNII-S03709D0TH; (R)-(-)-Ketoprofen; (R)-2-(3-benzoylphenyl)propanoic acid; CHEMBL372052; S03709D0TH; (R)-2-(3-Benzoylphenyl)propionic acid; Benzeneacetic acid,3-benzoyl-a-methyl-, (aR)-; Ketoprofen, (R)-; NCGC00016757-01; CAS-22071-15-4; (2R)-2-(3-benzoylphenyl)propanoic acid; Lopac-K-1751; SCHEMBL195303; ZINC2272; AC1L47D6; CTK5A4646; DTXSID50204652; DKYWVDODHFEZIM-LLVKDONJSA-N; BDBM50169048; AKOS022182275
DMHSUQ1	DT	Small molecular drug
DMHSUQ1	PC	180540
DMHSUQ1	MW	254.28
DMHSUQ1	FM	C16H14O3
DMHSUQ1	IC	InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/t11-/m1/s1
DMHSUQ1	CS	C[C@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
DMHSUQ1	IK	DKYWVDODHFEZIM-LLVKDONJSA-N
DMHSUQ1	IU	(2R)-2-(3-benzoylphenyl)propanoic acid
DMHSUQ1	CA	CAS 56105-81-8

DM5P1KQ	ID	DM5P1KQ
DM5P1KQ	DN	RN6G
DM5P1KQ	HS	Discontinued in Phase 2
DM5P1KQ	SN	PF-04382923; PF-4382923
DM5P1KQ	CP	Pfizer
DM5P1KQ	DE	Age-related macular degeneration

DME9V0I	ID	DME9V0I
DME9V0I	DN	RNAPc2
DME9V0I	HS	Discontinued in Phase 2
DME9V0I	SN	RAcAPc2; Recombinant nematode anticoagulant protein, Dendreon; Recombinant nematode anticoagulant protein, Nuvelo
DME9V0I	CP	Dendreon San Diego LLC
DME9V0I	DE	Colorectal cancer

DM4YA63	ID	DM4YA63
DM4YA63	DN	Ro-23-9424
DM4YA63	HS	Discontinued in Phase 2
DM4YA63	SN	Ro-23-9424
DM4YA63	CP	Roche
DM4YA63	DT	Small molecular drug
DM4YA63	PC	6918090
DM4YA63	MW	764.8
DM4YA63	FM	C31H31F3N8O8S2
DM4YA63	IC	InChI=1S/C31H31F3N8O8S2/c1-39-5-7-40(8-6-39)24-17(33)9-15-23(19(24)34)41(4-3-32)10-16(25(15)43)30(48)50-11-14-12-51-28-21(27(45)42(28)22(14)29(46)47)37-26(44)20(38-49-2)18-13-52-31(35)36-18/h9-10,13,21,28H,3-8,11-12H2,1-2H3,(H2,35,36)(H,37,44)(H,46,47)/b38-20+/t21-,28-/m1/s1
DM4YA63	CS	CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)OCC4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N/OC)/C6=CSC(=N6)N)SC4)C(=O)O)CCF)F
DM4YA63	IK	IKYGJSBKPPIKJK-YZURVANNSA-N
DM4YA63	IU	(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carbonyl]oxymethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM4YA63	DE	Bacterial infection

DM01MRZ	ID	DM01MRZ
DM01MRZ	DN	Ro-24-4736
DM01MRZ	HS	Discontinued in Phase 2
DM01MRZ	SN	Ro-24-4736; Ro 24-4736; UNII-I2MJ13SOFO; I2MJ13SOFO; 125030-71-9; CHEMBL277650; 5-(3-(4-(2-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-2-yl)-2-propynyl)phenanthridin-6(5H)-one; AC1L1TWB; AC1Q3P7I; SCHEMBL7528667; DTXSID80154550; ro24-4736; ZINC1550948; BDBM50011638; CS-6683; HY-19097; 5-{3-[4-(2-Chloro-phenyl)-9-methyl-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-prop-2-ynyl}-5H-phenanthridin-6-one; 6(5H)-Phenanthridinone, 5-(3-(4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triaz
DM01MRZ	CP	Roche Holding AG
DM01MRZ	DT	Small molecular drug
DM01MRZ	PC	60775
DM01MRZ	MW	546
DM01MRZ	FM	C31H20ClN5OS
DM01MRZ	IC	InChI=1S/C31H20ClN5OS/c1-19-34-35-28-18-33-29(24-13-4-6-14-26(24)32)25-17-20(39-31(25)37(19)28)9-8-16-36-27-15-7-5-11-22(27)21-10-2-3-12-23(21)30(36)38/h2-7,10-15,17H,16,18H2,1H3
DM01MRZ	CS	CC1=NN=C2N1C3=C(C=C(S3)C#CCN4C5=CC=CC=C5C6=CC=CC=C6C4=O)C(=NC2)C7=CC=CC=C7Cl
DM01MRZ	IK	MPMZSZMDCRPSRF-UHFFFAOYSA-N
DM01MRZ	IU	5-[3-[7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-4-yl]prop-2-ynyl]phenanthridin-6-one
DM01MRZ	CA	CAS 125030-71-9
DM01MRZ	DE	Sepsis

DMPB80O	ID	DMPB80O
DMPB80O	DN	RO-26-9228
DMPB80O	HS	Discontinued in Phase 2
DMPB80O	SN	Elocalcitol; BXL628; BXL-628; (23E)-1alpha-Fluoro-25-hydroxy-16,17,23,24-tetradehydro-26,27-bishomo-20-epicholecalciferol
DMPB80O	CP	BioXell
DMPB80O	DT	Small molecular drug
DMPB80O	PC	11396600
DMPB80O	MW	442.6
DMPB80O	FM	C29H43FO2
DMPB80O	IC	InChI=1S/C29H43FO2/c1-6-29(32,7-2)17-8-10-20(3)25-14-15-26-22(11-9-16-28(25,26)5)12-13-23-18-24(31)19-27(30)21(23)4/h8,12-14,17,20,24,26-27,31-32H,4,6-7,9-11,15-16,18-19H2,1-3,5H3/b17-8+,22-12+,23-13-/t20-,24+,26-,27-,28+/m0/s1
DMPB80O	CS	CCC(CC)(/C=C/C[C@H](C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)F)O)C)O
DMPB80O	IK	LRLWXBHFPGSUOX-GJQYOBCGSA-N
DMPB80O	IU	(1R,3Z,5S)-3-[(2E)-2-[(3aS,7aS)-1-[(E,2S)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol
DMPB80O	CA	CAS 199798-84-0
DMPB80O	DE	Urinary incontinence

DMH912O	ID	DMH912O
DMH912O	DN	RO-48-6791
DMH912O	HS	Discontinued in Phase 2
DMH912O	SN	3-[5-(Dipropylaminomethyl)-1,2,4-oxadiazol-3-yl]-8-fluoro-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMH912O	DT	Small molecular drug
DMH912O	PC	9953485
DMH912O	MW	412.5
DMH912O	FM	C21H25FN6O2
DMH912O	IC	InChI=1S/C21H25FN6O2/c1-4-8-27(9-5-2)12-18-24-20(25-30-18)19-17-11-26(3)21(29)15-10-14(22)6-7-16(15)28(17)13-23-19/h6-7,10,13H,4-5,8-9,11-12H2,1-3H3
DMH912O	CS	CCCN(CCC)CC1=NC(=NO1)C2=C3CN(C(=O)C4=C(N3C=N2)C=CC(=C4)F)C
DMH912O	IK	NOQIYRGMEFBZTI-UHFFFAOYSA-N
DMH912O	IU	3-[5-[(dipropylamino)methyl]-1,2,4-oxadiazol-3-yl]-8-fluoro-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMH912O	CA	CAS 172407-17-9
DMH912O	DE	Anxiety disorder

DMZAISC	ID	DMZAISC
DMZAISC	DN	Robalzotan
DMZAISC	HS	Discontinued in Phase 2
DMZAISC	SN	Robalzotan; 169758-66-1; NAD-299; UNII-I18M56OGME; I18M56OGME; AZD-7371; (R)-3-(Dicyclobutylamino)-8-fluoro-5-chromancarboxamide; (R)-3-(Dicyclobutylamino)-8-fluorochroman-5-carboxamide; Robalzotan [INN]; Robalzotan [INN:BAN]; (3R)-3-[di(cyclobutyl)amino]-8-fluoro-3,4-dihydro-2H-chromene-5-carboxamide; AC1MHOZC; GTPL72; SCHEMBL115079; NAD299; CHEMBL1628569; DTXSID30168743; ZINC3811952; AKOS022180489; VC30713; NCGC00370859-01; AJ-45676; LS-182403; (R)-3-(dicyclobutylamino)-8-fluorochromane-5-carboxamide
DMZAISC	DT	Small molecular drug
DMZAISC	PC	3055171
DMZAISC	MW	318.4
DMZAISC	FM	C18H23FN2O2
DMZAISC	IC	InChI=1S/C18H23FN2O2/c19-16-8-7-14(18(20)22)15-9-13(10-23-17(15)16)21(11-3-1-4-11)12-5-2-6-12/h7-8,11-13H,1-6,9-10H2,(H2,20,22)/t13-/m1/s1
DMZAISC	CS	C1CC(C1)N([C@@H]2CC3=C(C=CC(=C3OC2)F)C(=O)N)C4CCC4
DMZAISC	IK	MQTUXRKNJYPMCG-CYBMUJFWSA-N
DMZAISC	IU	(3R)-3-[di(cyclobutyl)amino]-8-fluoro-3,4-dihydro-2H-chromene-5-carboxamide
DMZAISC	CA	CAS 169758-66-1
DMZAISC	DE	Anxiety disorder

DM6OSPQ	ID	DM6OSPQ
DM6OSPQ	DN	Rofleponide
DM6OSPQ	HS	Discontinued in Phase 2
DM6OSPQ	SN	RPL; RPNS; Rofleponide palmitate; D-5522; Rofleponide 21-palmitate
DM6OSPQ	CP	AstraZeneca plc
DM6OSPQ	DT	Small molecular drug
DM6OSPQ	PC	3055174
DM6OSPQ	MW	468.5
DM6OSPQ	FM	C25H34F2O6
DM6OSPQ	IC	InChI=1S/C25H34F2O6/c1-4-5-21-32-20-10-14-15-9-17(26)16-8-13(29)6-7-22(16,2)24(15,27)18(30)11-23(14,3)25(20,33-21)19(31)12-28/h8,14-15,17-18,20-21,28,30H,4-7,9-12H2,1-3H3/t14-,15-,17-,18-,20+,21+,22-,23-,24-,25+/m0/s1
DM6OSPQ	CS	CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4C[C@@H](C5=CC(=O)CC[C@@]5([C@]4([C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)F)C)F
DM6OSPQ	IK	IXTCZMJQGGONPY-XJAYAHQCSA-N
DM6OSPQ	IU	(1S,2S,4R,6R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DM6OSPQ	CA	CAS 144459-70-1
DM6OSPQ	DE	Allergic rhinitis

DM8Q7XV	ID	DM8Q7XV
DM8Q7XV	DN	Rolafagrel
DM8Q7XV	HS	Discontinued in Phase 2
DM8Q7XV	SN	FCE-22178
DM8Q7XV	CP	Pharmacia & Upjohn AB
DM8Q7XV	DT	Small molecular drug
DM8Q7XV	PC	56009
DM8Q7XV	MW	240.26
DM8Q7XV	FM	C14H12N2O2
DM8Q7XV	IC	InChI=1S/C14H12N2O2/c17-14(18)11-2-1-10-3-4-13(8-12(10)7-11)16-6-5-15-9-16/h1-2,5-9H,3-4H2,(H,17,18)
DM8Q7XV	CS	C1CC(=CC2=C1C=CC(=C2)C(=O)O)N3C=CN=C3
DM8Q7XV	IK	DQEDSIVMYUUZCK-UHFFFAOYSA-N
DM8Q7XV	IU	7-imidazol-1-yl-5,6-dihydronaphthalene-2-carboxylic acid
DM8Q7XV	CA	CAS 89781-55-5
DM8Q7XV	DE	Nephritis

DMYDWHN	ID	DMYDWHN
DMYDWHN	DN	Romergoline
DMYDWHN	HS	Discontinued in Phase 2
DMYDWHN	SN	FCE-23884
DMYDWHN	CP	Pharmacia & Upjohn AB
DMYDWHN	DT	Small molecular drug
DMYDWHN	PC	65898
DMYDWHN	MW	350.4
DMYDWHN	FM	C20H22N4O2
DMYDWHN	IC	InChI=1S/C20H22N4O2/c1-23-8-12(9-24-10-18(25)22-19(26)11-24)5-15-14-3-2-4-16-20(14)13(7-21-16)6-17(15)23/h2-5,7,12,17,21H,6,8-11H2,1H3,(H,22,25,26)/t12-,17-/m1/s1
DMYDWHN	CS	CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)CN5CC(=O)NC(=O)C5
DMYDWHN	IK	RJCXNCSJGRUWRW-SJKOYZFVSA-N
DMYDWHN	IU	4-[[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]methyl]piperazine-2,6-dione
DMYDWHN	CA	CAS 107052-56-2
DMYDWHN	DE	Anxiety disorder

DM10ZJP	ID	DM10ZJP
DM10ZJP	DN	Ronacaleret
DM10ZJP	HS	Discontinued in Phase 2
DM10ZJP	SN	Ronacaleret; UNII-DIH95YP7J3; DIH95YP7J3; CHEMBL1198855; 753449-67-1; SB-751689; Ronacaleret [INN]; SCHEMBL3737849; GTPL9473; BDBM50346036; AKOS030261487; DB05255; SB16763; SB 751689; 3-[3-[(2R)-3-[[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]-4,5-difluorophenyl]propanoic acid; 3-[3-[[(2R)-3-[[2-(2,3-Dihydro-1H-indene-2-yl)-1,1-dimethylethyl]amino]-2-hydroxypropyl]oxy]-4,5-difluorophenyl]propionic acid
DM10ZJP	CP	GSK
DM10ZJP	DT	Small molecular drug
DM10ZJP	PC	10345214
DM10ZJP	MW	447.5
DM10ZJP	FM	C25H31F2NO4
DM10ZJP	IC	InChI=1S/C25H31F2NO4/c1-25(2,13-17-9-18-5-3-4-6-19(18)10-17)28-14-20(29)15-32-22-12-16(7-8-23(30)31)11-21(26)24(22)27/h3-6,11-12,17,20,28-29H,7-10,13-15H2,1-2H3,(H,30,31)/t20-/m1/s1
DM10ZJP	CS	CC(C)(CC1CC2=CC=CC=C2C1)NC[C@H](COC3=C(C(=CC(=C3)CCC(=O)O)F)F)O
DM10ZJP	IK	FQJISUPNMFRIFZ-HXUWFJFHSA-N
DM10ZJP	IU	3-[3-[(2R)-3-[[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]-4,5-difluorophenyl]propanoic acid
DM10ZJP	CA	CAS 753449-67-1
DM10ZJP	DE	Osteoporosis

DMNBUS7	ID	DMNBUS7
DMNBUS7	DN	Rozrolimupab
DMNBUS7	HS	Discontinued in Phase 2
DMNBUS7	SN	SYM-001; Symphoglobulin-D; Recombinant human polyclonal antibodies (rhesus D), Symphogen/Biovitrum; Recombinant polyclonal antibodies (idiopathic thrombocytopenic purpura), Symphogen/Biovitrum; Symphobodies (hemolytic disease of the newborn), Symphogen/Biovitrum; Anti-RhD (trombocytopeni, anti-D-profylax), Symphogen/Biovitrum
DMNBUS7	CP	Symphogen A/S
DMNBUS7	DT	Antibody
DMNBUS7	DE	Anemia

DMTQ3BS	ID	DMTQ3BS
DMTQ3BS	DN	RP-64477
DMTQ3BS	HS	Discontinued in Phase 2
DMTQ3BS	CP	Rhone-Poulenc SA
DMTQ3BS	PC	9870538
DMTQ3BS	MW	498.7
DMTQ3BS	FM	C29H42N2O3S
DMTQ3BS	IC	InChI=1S/C29H42N2O3S/c1-4-6-8-9-10-11-12-13-21-34-25-17-14-23(15-18-25)29(33)31-26-22-24(16-19-27(26)35-3)28(32)30-20-7-5-2/h14-19,22H,4-13,20-21H2,1-3H3,(H,30,32)(H,31,33)
DMTQ3BS	CS	CCCCCCCCCCOC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C(=O)NCCCC)SC
DMTQ3BS	IK	OZMWNRSILHTVFV-UHFFFAOYSA-N
DMTQ3BS	IU	N-butyl-3-[(4-decoxybenzoyl)amino]-4-methylsulfanylbenzamide
DMTQ3BS	CA	CAS 135239-65-5
DMTQ3BS	DE	Hyperlipidaemia

DMRGC5B	ID	DMRGC5B
DMRGC5B	DN	RPR-106541
DMRGC5B	HS	Discontinued in Phase 2
DMRGC5B	CP	Aventis Pharma AG
DMRGC5B	PC	9846880
DMRGC5B	MW	456.6
DMRGC5B	FM	C24H34F2O4S
DMRGC5B	IC	InChI=1S/C24H34F2O4S/c1-5-6-20-29-19-11-14-15-10-17(25)16-9-13(27)7-8-21(16,2)23(15,26)18(28)12-22(14,3)24(19,30-20)31-4/h9,14-15,17-20,28H,5-8,10-12H2,1-4H3/t14-,15-,17-,18-,19+,20+,21-,22-,23-,24-/m0/s1
DMRGC5B	CS	CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4C[C@@H](C5=CC(=O)CC[C@@]5([C@]4([C@H](C[C@@]3([C@@]2(O1)SC)C)O)F)C)F
DMRGC5B	IK	QGBIFMJAQARMNQ-QISPFCDLSA-N
DMRGC5B	IU	(1S,2S,4R,6R,8R,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-8-methylsulfanyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DMRGC5B	CA	CAS 159001-35-1
DMRGC5B	DE	Asthma

DM4GVZ9	ID	DM4GVZ9
DM4GVZ9	DN	RQ-00317076
DM4GVZ9	HS	Discontinued in Phase 2
DM4GVZ9	SN	COX-2 inhibitor (oral, pain), RaQualia
DM4GVZ9	CP	RaQualia Pharma Inc
DM4GVZ9	DE	Pain

DMOTANY	ID	DMOTANY
DMOTANY	DN	RS-130830
DMOTANY	HS	Discontinued in Phase 2
DMOTANY	SN	CTS-1027; 193022-04-7; RS-130830; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690
DMOTANY	DT	Small molecular drug
DMOTANY	PC	3342298
DMOTANY	MW	425.9
DMOTANY	FM	C19H20ClNO6S
DMOTANY	IC	InChI=1S/C19H20ClNO6S/c20-14-1-3-15(4-2-14)27-16-5-7-17(8-6-16)28(24,25)13-19(18(22)21-23)9-11-26-12-10-19/h1-8,23H,9-13H2,(H,21,22)
DMOTANY	CS	C1COCCC1(CS(=O)(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C(=O)NO
DMOTANY	IK	ROSNVSQTEGHUKU-UHFFFAOYSA-N
DMOTANY	IU	4-[[4-(4-chlorophenoxy)phenyl]sulfonylmethyl]-N-hydroxyoxane-4-carboxamide
DMOTANY	CA	CAS 193022-04-7
DMOTANY	DE	Hepatitis C virus infection

DMERM0K	ID	DMERM0K
DMERM0K	DN	RS-8359
DMERM0K	HS	Discontinued in Phase 2
DMERM0K	SN	CS-8359; TUK-9261; TUK-9262; TUK-9508
DMERM0K	CP	Sankyo Co Ltd
DMERM0K	DT	Small molecular drug
DMERM0K	PC	164116
DMERM0K	MW	252.27
DMERM0K	FM	C14H12N4O
DMERM0K	IC	InChI=1S/C14H12N4O/c15-7-9-1-3-10(4-2-9)18-14-11-5-6-12(19)13(11)16-8-17-14/h1-4,8,12,19H,5-6H2,(H,16,17,18)
DMERM0K	CS	C1CC2=C(C1O)N=CN=C2NC3=CC=C(C=C3)C#N
DMERM0K	IK	YKTSVZRWKHWINV-UHFFFAOYSA-N
DMERM0K	IU	4-[(7-hydroxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino]benzonitrile
DMERM0K	CA	CAS 105365-76-2
DMERM0K	DE	Major depressive disorder

DMIKUXN	ID	DMIKUXN
DMIKUXN	DN	RSD-921
DMIKUXN	HS	Discontinued in Phase 2
DMIKUXN	SN	PD 123497
DMIKUXN	CP	University of British Columbia
DMIKUXN	DT	Small molecular drug
DMIKUXN	PC	122115
DMIKUXN	MW	356.5
DMIKUXN	FM	C21H28N2OS
DMIKUXN	IC	InChI=1S/C21H28N2OS/c1-22(18-8-2-3-9-19(18)23-12-4-5-13-23)21(24)15-16-7-6-10-20-17(16)11-14-25-20/h6-7,10-11,14,18-19H,2-5,8-9,12-13,15H2,1H3/t18-,19-/m1/s1
DMIKUXN	CS	CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)CC3=C4C=CSC4=CC=C3
DMIKUXN	IK	SYHJZCCNQDFHJQ-RTBURBONSA-N
DMIKUXN	IU	2-(1-benzothiophen-4-yl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide
DMIKUXN	CA	CAS 111728-01-9
DMIKUXN	DE	Anaesthesia

DMPAH74	ID	DMPAH74
DMPAH74	DN	R-sibutramine metabolite
DMPAH74	HS	Discontinued in Phase 2
DMPAH74	CP	Sepracor
DMPAH74	DE	Attention deficit hyperactivity disorder; Depression

DMR0K85	ID	DMR0K85
DMR0K85	DN	RX-77368
DMR0K85	HS	Discontinued in Phase 2
DMR0K85	SN	TRH analog, Reckitt & Colman
DMR0K85	CP	Reckitt; Colman plc
DMR0K85	DT	Small molecular drug
DMR0K85	PC	107823
DMR0K85	MW	390.4
DMR0K85	FM	C18H26N6O4
DMR0K85	IC	InChI=1S/C18H26N6O4/c1-18(2)5-6-24(14(18)15(19)26)17(28)12(7-10-8-20-9-21-10)23-16(27)11-3-4-13(25)22-11/h8-9,11-12,14H,3-7H2,1-2H3,(H2,19,26)(H,20,21)(H,22,25)(H,23,27)/t11-,12-,14+/m0/s1
DMR0K85	CS	CC1(CCN([C@@H]1C(=O)N)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C
DMR0K85	IK	ZEQAPQNFHVYDEL-SGMGOOAPSA-N
DMR0K85	IU	(2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]-3,3-dimethylpyrrolidine-2-carboxamide
DMR0K85	CA	CAS 76820-40-1
DMR0K85	DE	Dementia

DMS6NAK	ID	DMS6NAK
DMS6NAK	DN	S-12363
DMS6NAK	HS	Discontinued in Phase 2
DMS6NAK	SN	S-12363 (liposomal, cancer); S-12363 (liposomal, cancer), Servier
DMS6NAK	CP	Servier
DMS6NAK	PC	6918169
DMS6NAK	MW	1044.2
DMS6NAK	FM	C51H74N5O14PS
DMS6NAK	IC	InChI=1S/C51H72N5O10P.H2O4S/c1-10-47(60)27-32-28-50(46(59)64-9,40-34(19-23-55(29-32)30-47)33-17-14-15-18-37(33)52-40)36-25-35-38(26-39(36)63-8)54(7)43-49(35)21-24-56-22-16-20-48(11-2,42(49)56)44(57)51(43,61)45(58)53-41(31(5)6)67(62,65-12-3)66-13-4;1-5(2,3)4/h14-18,20,25-26,31-32,41-44,52,57,60-61H,10-13,19,21-24,27-30H2,1-9H3,(H,53,58);(H2,1,2,3,4)/t32-,41+,42+,43-,44-,47+,48-,49-,50+,51+;/m1./s1
DMS6NAK	CS	CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N[C@H](C(C)C)P(=O)(OCC)OCC)O)O)CC)OC)C(=O)OC)O.OS(=O)(=O)O
DMS6NAK	IK	BZUUMJJIORUJAU-XFLWUYJZSA-N
DMS6NAK	IU	methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-[[(1S)-1-diethoxyphosphoryl-2-methylpropyl]carbamoyl]-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate;sulfuric acid
DMS6NAK	DE	Solid tumour/cancer

DMLCYX8	ID	DMLCYX8
DMLCYX8	DN	S-15261
DMLCYX8	HS	Discontinued in Phase 2
DMLCYX8	SN	L-4-[2-[2-(9-Fluorenyl)acetamido]ethyl]benzoic acid 2-[2-methoxy-2-[3-(trifluoromethyl)phenyl]ethylamino]ethyl ester
DMLCYX8	DT	Small molecular drug
DMLCYX8	PC	3074609
DMLCYX8	MW	616.7
DMLCYX8	FM	C36H35F3N2O4
DMLCYX8	IC	InChI=1S/C36H35F3N2O4/c1-44-33(26-7-6-8-27(21-26)36(37,38)39)23-40-19-20-45-35(43)25-15-13-24(14-16-25)17-18-41-34(42)22-32-30-11-4-2-9-28(30)29-10-3-5-12-31(29)32/h2-16,21,32-33,40H,17-20,22-23H2,1H3,(H,41,42)
DMLCYX8	CS	COC(CNCCOC(=O)C1=CC=C(C=C1)CCNC(=O)CC2C3=CC=CC=C3C4=CC=CC=C24)C5=CC(=CC=C5)C(F)(F)F
DMLCYX8	IK	ASWYZRRXMGAWGN-UHFFFAOYSA-N
DMLCYX8	IU	2-[[2-methoxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]ethyl 4-[2-[[2-(9H-fluoren-9-yl)acetyl]amino]ethyl]benzoate
DMLCYX8	CA	CAS 159978-02-6
DMLCYX8	DE	Diabetic complication

DM51WJN	ID	DM51WJN
DM51WJN	DN	S-16020-2
DM51WJN	HS	Discontinued in Phase 2
DM51WJN	SN	N-[2-(Dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide dihydrochloride
DM51WJN	DT	Small molecular drug
DM51WJN	PC	177329
DM51WJN	MW	449.4
DM51WJN	FM	C22H26Cl2N4O2
DM51WJN	IC	InChI=1S/C22H24N4O2.2ClH/c1-13-15-7-8-23-20(22(28)24-9-10-25(2)3)17(15)12-18-16-11-14(27)5-6-19(16)26(4)21(13)18;;/h5-8,11-12,27H,9-10H2,1-4H3,(H,24,28);2*1H
DM51WJN	CS	CC1=C2C=CN=C(C2=CC3=C1N(C4=C3C=C(C=C4)O)C)C(=O)NCCN(C)C.Cl.Cl
DM51WJN	IK	DSJBVXJNKBKZSB-UHFFFAOYSA-N
DM51WJN	IU	N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethylpyrido[4,3-b]carbazole-1-carboxamide;dihydrochloride
DM51WJN	CA	CAS 178169-99-8
DM51WJN	DE	Solid tumour/cancer

DMA01BV	ID	DMA01BV
DMA01BV	DN	S-18986
DMA01BV	HS	Discontinued in Phase 2
DMA01BV	SN	S 18986; S-18986; UNII-IA262432Y9; 175340-20-2; S18986; IA262432Y9; MNTIJYGEITVWHU-SNVBAGLBSA-N; AC1LCV4Z; S18986-1; SCHEMBL6622911; S 18986-1; GTPL4304; CHEMBL320642; EX-A818; MolPort-023-276-986; (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide; ZINC3827020; AKOS024457867; (S)-2,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide; B5493; (3aS)-5,5Dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine
DMA01BV	CP	Shionogi
DMA01BV	TC	Neurodegenerative
DMA01BV	DT	Small molecular drug
DMA01BV	PC	637863
DMA01BV	MW	224.28
DMA01BV	FM	C10H12N2O2S
DMA01BV	IC	InChI=1S/C10H12N2O2S/c13-15(14)9-5-2-1-4-8(9)12-7-3-6-10(12)11-15/h1-2,4-5,10-11H,3,6-7H2/t10-/m1/s1
DMA01BV	CS	C1C[C@@H]2NS(=O)(=O)C3=CC=CC=C3N2C1
DMA01BV	IK	MNTIJYGEITVWHU-SNVBAGLBSA-N
DMA01BV	IU	(3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide
DMA01BV	CA	CAS 175340-20-2
DMA01BV	DE	Alzheimer disease

DMMSZ1A	ID	DMMSZ1A
DMMSZ1A	DN	S-2474
DMMSZ1A	HS	Discontinued in Phase 2
DMMSZ1A	SN	158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-
DMMSZ1A	CP	Shionogi & Co Ltd
DMMSZ1A	DT	Small molecular drug
DMMSZ1A	PC	57370228
DMMSZ1A	MW	365.5
DMMSZ1A	FM	C20H31NO3S
DMMSZ1A	IC	InChI=1S/C20H31NO3S/c1-8-21-10-9-15(25(21,23)24)11-14-12-16(19(2,3)4)18(22)17(13-14)20(5,6)7/h11-13,22H,8-10H2,1-7H3
DMMSZ1A	CS	CCN1CCC(=CC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C)S1(=O)=O
DMMSZ1A	IK	HFWZBWTWCKQUCB-UHFFFAOYSA-N
DMMSZ1A	IU	2,6-ditert-butyl-4-[(2-ethyl-1,1-dioxo-1,2-thiazolidin-5-ylidene)methyl]phenol
DMMSZ1A	CA	CAS 158089-95-3
DMMSZ1A	DE	Rheumatoid arthritis

DMQ2RDZ	ID	DMQ2RDZ
DMQ2RDZ	DN	S-312-d
DMQ2RDZ	HS	Discontinued in Phase 2
DMQ2RDZ	SN	S-312; S-830312
DMQ2RDZ	CP	Shionogi & Co Ltd
DMQ2RDZ	DT	Small molecular drug
DMQ2RDZ	PC	189723
DMQ2RDZ	MW	386.5
DMQ2RDZ	FM	C20H22N2O4S
DMQ2RDZ	IC	InChI=1S/C20H22N2O4S/c1-11(2)8-14-10-27-19-18(14)17(16(12(3)21-19)20(23)26-4)13-6-5-7-15(9-13)22(24)25/h5-7,9-11,17,21H,8H2,1-4H3/t17-/m0/s1
DMQ2RDZ	CS	CC1=C([C@@H](C2=C(N1)SC=C2CC(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMQ2RDZ	IK	UTLPUICHKZBRCI-KRWDZBQOSA-N
DMQ2RDZ	IU	methyl (4S)-6-methyl-3-(2-methylpropyl)-4-(3-nitrophenyl)-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate
DMQ2RDZ	CA	CAS 120056-57-7
DMQ2RDZ	DE	Epilepsy

DM2X6ME	ID	DM2X6ME
DM2X6ME	DN	S-5751
DM2X6ME	HS	Discontinued in Phase 2
DM2X6ME	SN	S-5751; AC1NSK82; GTPL1898; S5751; (Z)-7-[(1R,2R,3R,5S)-2-[(5-hydroxy1-benzothiophene-3-carbonyl)amino]-7,7-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid; (Z)-7-[(1S,3R,4R,5R)-4-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DM2X6ME	DT	Small molecular drug
DM2X6ME	PC	9867949
DM2X6ME	MW	441.6
DM2X6ME	FM	C25H31NO4S
DM2X6ME	IC	InChI=1S/C25H31NO4S/c1-25(2)16-11-15(7-5-3-4-6-8-22(28)29)23(20(25)12-16)26-24(30)19-14-31-21-10-9-17(27)13-18(19)21/h3,5,9-10,13-16,20,23,27H,4,6-8,11-12H2,1-2H3,(H,26,30)(H,28,29)/b5-3-/t15-,16-,20-,23+/m0/s1
DM2X6ME	CS	CC1([C@H]2C[C@@H]([C@H]([C@@H]1C2)NC(=O)C3=CSC4=C3C=C(C=C4)O)C/C=C\\CCCC(=O)O)C
DM2X6ME	IK	ZXBHFWFKSIYJEK-MFJOXFORSA-N
DM2X6ME	IU	(Z)-7-[(1R,2R,3S,5S)-2-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DM2X6ME	CA	CAS 209268-36-0
DM2X6ME	DE	Rhinitis

DM9BEDL	ID	DM9BEDL
DM9BEDL	DN	S-8510
DM9BEDL	HS	Discontinued in Phase 2
DM9BEDL	DT	Small molecular drug
DM9BEDL	PC	135409387
DM9BEDL	MW	242.23
DM9BEDL	FM	C12H10N4O2
DM9BEDL	IC	InChI=1S/C12H10N4O2/c1-3-17-6-7-8(1)13-5-10-11(7)15-12(14-10)9-2-4-18-16-9/h2,4-5H,1,3,6H2,(H,14,15)
DM9BEDL	CS	C1COCC2=C3C(=CN=C21)NC(=N3)C4=NOC=C4
DM9BEDL	IK	ITPFSYAYHHPKRT-UHFFFAOYSA-N
DM9BEDL	IU	4-(1,2-oxazol-3-yl)-12-oxa-3,5,8-triazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraene
DM9BEDL	DE	Cognitive impairment

DMER3I9	ID	DMER3I9
DMER3I9	DN	S-9788
DMER3I9	HS	Discontinued in Phase 2
DMER3I9	SN	S-9788; S9788; S 9788; CHEMBL85156; 140945-01-3; 6-(4-(2,2-di(4-Fluorophenyl)ethylamino)-1-piperidinyl)-N,N'-di-2-propenyl-1,3,5-triazine-2,4-diamine; 1,3,5-Triazine-2,4-diamine, 6-(4-((2,2-bis(4-fluorophenyl)ethyl)amino)-1-piperidinyl)-N,N'-di-2-propenyl-; AC1L32YH; SCHEMBL1527824; DTXSID80161502; GERNFWKTMKWULM-UHFFFAOYSA-N; BDBM50053888; LS-187603; LS-186957; N,N''-Diallyl-6-{4-[2,2-bis-(4-fluoro-phenyl)-ethylamino]-piperidin-1-yl}-[1,3,5]triazine-2,4-diamine; H2O
DMER3I9	CP	Servier
DMER3I9	DT	Small molecular drug
DMER3I9	PC	107903
DMER3I9	MW	505.6
DMER3I9	FM	C28H33F2N7
DMER3I9	IC	InChI=1S/C28H33F2N7/c1-3-15-31-26-34-27(32-16-4-2)36-28(35-26)37-17-13-24(14-18-37)33-19-25(20-5-9-22(29)10-6-20)21-7-11-23(30)12-8-21/h3-12,24-25,33H,1-2,13-19H2,(H2,31,32,34,35,36)
DMER3I9	CS	C=CCNC1=NC(=NC(=N1)N2CCC(CC2)NCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C
DMER3I9	IK	GERNFWKTMKWULM-UHFFFAOYSA-N
DMER3I9	IU	6-[4-[2,2-bis(4-fluorophenyl)ethylamino]piperidin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DMER3I9	CA	CAS 140945-01-3
DMER3I9	DE	Solid tumour/cancer

DMEO6A5	ID	DMEO6A5
DMEO6A5	DN	S-9977
DMEO6A5	HS	Discontinued in Phase 2
DMEO6A5	SN	S-9977-2
DMEO6A5	CP	Servier
DMEO6A5	DT	Small molecular drug
DMEO6A5	PC	132156
DMEO6A5	MW	456
DMEO6A5	FM	C20H34ClN7O3
DMEO6A5	IC	InChI=1S/C20H33N7O3.ClH/c1-6-26(7-2)20(30)27-13-11-25(12-14-27)10-8-9-15-21-17-16(22(15)3)18(28)24(5)19(29)23(17)4;/h6-14H2,1-5H3;1H
DMEO6A5	CS	CCN(CC)C(=O)N1CCN(CC1)CCCC2=NC3=C(N2C)C(=O)N(C(=O)N3C)C.Cl
DMEO6A5	IK	GVHZRDKDUVIRNY-UHFFFAOYSA-N
DMEO6A5	IU	N,N-diethyl-4-[3-(1,3,7-trimethyl-2,6-dioxopurin-8-yl)propyl]piperazine-1-carboxamide;hydrochloride
DMEO6A5	CA	CAS 138472-18-1
DMEO6A5	DE	Cognitive impairment

DMC57JU	ID	DMC57JU
DMC57JU	DN	Saperconazole
DMC57JU	HS	Discontinued in Phase 2
DMC57JU	SN	R-66905
DMC57JU	CP	Janssen Pharmaceutica NV
DMC57JU	DT	Small molecular drug
DMC57JU	PC	9809993
DMC57JU	MW	672.7
DMC57JU	FM	C35H38F2N8O4
DMC57JU	IC	InChI=1S/C35H38F2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3
DMC57JU	CS	CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
DMC57JU	IK	HUADITLKOCMHSB-UHFFFAOYSA-N
DMC57JU	IU	2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
DMC57JU	DE	Fungal infection

DMQMA17	ID	DMQMA17
DMQMA17	DN	SAVOXEPIN MESYLATE
DMQMA17	HS	Discontinued in Phase 2
DMQMA17	SN	CIPA; Cipazoxapine; CGP-19486A; Savoxepin mesylate; 3-(Cyclopentylmethyl)-2,3,4,5-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-d]azepine-7-carbonitrile methanesulfonate
DMQMA17	DT	Small molecular drug
DMQMA17	PC	71587288
DMQMA17	MW	466.6
DMQMA17	FM	C26H30N2O4S
DMQMA17	IC	InChI=1S/C25H26N2O.CH4O3S/c26-16-19-9-10-25-23(15-19)21-12-14-27(17-18-5-1-2-6-18)13-11-20(21)22-7-3-4-8-24(22)28-25;1-5(2,3)4/h3-4,7-10,15,18H,1-2,5-6,11-14,17H2;1H3,(H,2,3,4)
DMQMA17	CS	CS(=O)(=O)O.C1CCC(C1)CN2CCC3=C(CC2)C4=C(C=CC(=C4)C#N)OC5=CC=CC=C35
DMQMA17	IK	PDYLRPIUJQGVNY-UHFFFAOYSA-N
DMQMA17	IU	18-(cyclopentylmethyl)-8-oxa-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2(7),3,5,9,11,13-heptaene-4-carbonitrile;methanesulfonic acid
DMQMA17	CA	CAS 79262-47-8
DMQMA17	DE	Psychotic disorder

DMIF4VJ	ID	DMIF4VJ
DMIF4VJ	DN	SB-201993
DMIF4VJ	HS	Discontinued in Phase 2
DMIF4VJ	SN	SB-201993; UNII-4TWC061LPM; 4TWC061LPM; CHEMBL422598; SB 201993; AC1O5KJ7; SCHEMBL1893839; SCHEMBL1893835; sb201993; BDBM50037385; (E)-3-((((6-(2-Carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid; L009321; 3-[[6-[(E)-3-hydroxy-3-oxoprop-1-enyl]-5-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]methylsulfanylmethyl]benzoic acid; 3-{6-((E)-2-Carboxy-vinyl)-5-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid; Benzoic acid, 3-((((6-(2-carboxyethenyl)-5-((8-(4-m
DMIF4VJ	DT	Small molecular drug
DMIF4VJ	PC	6435820
DMIF4VJ	MW	563.7
DMIF4VJ	FM	C32H37NO6S
DMIF4VJ	IC	InChI=1S/C32H37NO6S/c1-38-28-15-12-24(13-16-28)9-6-4-2-3-5-7-20-39-30-18-14-27(33-29(30)17-19-31(34)35)23-40-22-25-10-8-11-26(21-25)32(36)37/h8,10-19,21H,2-7,9,20,22-23H2,1H3,(H,34,35)(H,36,37)/b19-17+
DMIF4VJ	CS	COC1=CC=C(C=C1)CCCCCCCCOC2=C(N=C(C=C2)CSCC3=CC(=CC=C3)C(=O)O)/C=C/C(=O)O
DMIF4VJ	IK	QQUXZUFSDIOIFJ-HTXNQAPBSA-N
DMIF4VJ	IU	3-[[6-[(E)-2-carboxyethenyl]-5-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]methylsulfanylmethyl]benzoic acid
DMIF4VJ	CA	CAS 150399-22-7
DMIF4VJ	DE	Psoriasis vulgaris

DMJYW80	ID	DMJYW80
DMJYW80	DN	SB-209670
DMJYW80	HS	Discontinued in Phase 2
DMJYW80	SN	SKF-66861; (+/-)-SB 209670
DMJYW80	CP	SmithKline Beecham plc
DMJYW80	DT	Small molecular drug
DMJYW80	PC	108002
DMJYW80	MW	520.5
DMJYW80	FM	C29H28O9
DMJYW80	IC	InChI=1S/C29H28O9/c1-3-10-35-18-6-7-19-21(12-18)27(20-8-5-17(34-2)13-23(20)36-14-25(30)31)28(29(32)33)26(19)16-4-9-22-24(11-16)38-15-37-22/h4-9,11-13,26-28H,3,10,14-15H2,1-2H3,(H,30,31)(H,32,33)/t26-,27+,28+/m0/s1
DMJYW80	CS	CCCOC1=CC2=C(C=C1)[C@@H]([C@H]([C@@H]2C3=C(C=C(C=C3)OC)OCC(=O)O)C(=O)O)C4=CC5=C(C=C4)OCO5
DMJYW80	IK	UUAVCCWBNUITBB-UPRLRBBYSA-N
DMJYW80	IU	(1S,2R,3S)-1-(1,3-benzodioxol-5-yl)-3-[2-(carboxymethoxy)-4-methoxyphenyl]-5-propoxy-2,3-dihydro-1H-indene-2-carboxylic acid
DMJYW80	CA	CAS 157659-79-5
DMJYW80	DE	Arrhythmia

DMXFQS1	ID	DMXFQS1
DMXFQS1	DN	SB-756050
DMXFQS1	HS	Discontinued in Phase 2
DMXFQS1	CP	GlaxoSmithKline
DMXFQS1	PC	1520267
DMXFQS1	MW	500.6
DMXFQS1	FM	C21H28N2O8S2
DMXFQS1	IC	InChI=1S/C21H28N2O8S2/c1-28-18-8-6-16(14-20(18)30-3)32(24,25)22-10-5-11-23(13-12-22)33(26,27)17-7-9-19(29-2)21(15-17)31-4/h6-9,14-15H,5,10-13H2,1-4H3
DMXFQS1	CS	COC1=C(C=C(C=C1)S(=O)(=O)N2CCCN(CC2)S(=O)(=O)C3=CC(=C(C=C3)OC)OC)OC
DMXFQS1	IK	GJUFPAZNBPFNRI-UHFFFAOYSA-N
DMXFQS1	IU	1,4-bis[(3,4-dimethoxyphenyl)sulfonyl]-1,4-diazepane
DMXFQS1	DE	Type-2 diabetes

DMTZ7E4	ID	DMTZ7E4
DMTZ7E4	DN	SC-106
DMTZ7E4	HS	Discontinued in Phase 2
DMTZ7E4	SN	SC-106; AC1LAPZA; SCHEMBL6773940; IABCGGIFHPDBCJ-JTQLQIEISA-N; (3R)-3-[[2-[(3-guanidinobenzoyl)amino]acetyl]amino]pent-4-ynoic acid; (R)-3-(2-{[1-(3-Guanidino-phenyl)-methanoyl]-amino}-ethanoylamino)-pent-4-ynoic acid; (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid
DMTZ7E4	CP	Scotia Holdings plc
DMTZ7E4	DT	Small molecular drug
DMTZ7E4	PC	492984
DMTZ7E4	MW	331.33
DMTZ7E4	FM	C15H17N5O4
DMTZ7E4	IC	InChI=1S/C15H17N5O4/c1-2-10(7-13(22)23)19-12(21)8-18-14(24)9-4-3-5-11(6-9)20-15(16)17/h1,3-6,10H,7-8H2,(H,18,24)(H,19,21)(H,22,23)(H4,16,17,20)/t10-/m0/s1
DMTZ7E4	CS	C#C[C@@H](CC(=O)O)NC(=O)CNC(=O)C1=CC(=CC=C1)N=C(N)N
DMTZ7E4	IK	IABCGGIFHPDBCJ-JTQLQIEISA-N
DMTZ7E4	IU	(3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid
DMTZ7E4	DE	Rheumatoid arthritis

DMQ0T6L	ID	DMQ0T6L
DMQ0T6L	DN	SC-45662
DMQ0T6L	HS	Discontinued in Phase 2
DMQ0T6L	SN	CHEMBL84566; SC-45662; UNII-TPG7IO601I component ADVNUIUADIXWMI-QWHCGFSZSA-N; 2-[[(1S,2R)-2-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylpropyl]oxy]acetic acid
DMQ0T6L	CP	GD Searle & Co
DMQ0T6L	DT	Small molecular drug
DMQ0T6L	PC	5487420
DMQ0T6L	MW	368.5
DMQ0T6L	FM	C20H32O4S
DMQ0T6L	IC	InChI=1S/C20H32O4S/c1-12(24-11-17(21)22)13(2)25-14-9-15(19(3,4)5)18(23)16(10-14)20(6,7)8/h9-10,12-13,23H,11H2,1-8H3,(H,21,22)/t12-,13+/m1/s1
DMQ0T6L	CS	C[C@H]([C@H](C)SC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)OCC(=O)O
DMQ0T6L	IK	ADVNUIUADIXWMI-OLZOCXBDSA-N
DMQ0T6L	IU	2-[(2R,3S)-3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylbutan-2-yl]oxyacetic acid
DMQ0T6L	CA	CAS 135133-84-5
DMQ0T6L	DE	Asthma

DMAGBM2	ID	DMAGBM2
DMAGBM2	DN	SCH-32615
DMAGBM2	HS	Discontinued in Phase 2
DMAGBM2	SN	(S)-N-[N-(1-Carboxy-2-phenylethyl)-L-phenylalanyl]-beta-alanine; 83861-02-3
DMAGBM2	DT	Small molecular drug
DMAGBM2	PC	5486715
DMAGBM2	MW	384.4
DMAGBM2	FM	C21H24N2O5
DMAGBM2	IC	InChI=1S/C21H24N2O5/c24-19(25)11-12-22-20(26)17(13-15-7-3-1-4-8-15)23-18(21(27)28)14-16-9-5-2-6-10-16/h1-10,17-18,23H,11-14H2,(H,22,26)(H,24,25)(H,27,28)/t17-,18-/m0/s1
DMAGBM2	CS	C1=CC=C(C=C1)C[C@@H](C(=O)NCCC(=O)O)N[C@@H](CC2=CC=CC=C2)C(=O)O
DMAGBM2	IK	WOVRTBFSWOVRST-ROUUACIJSA-N
DMAGBM2	IU	(2S)-2-[[(2S)-1-(2-carboxyethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-phenylpropanoic acid
DMAGBM2	CA	CAS 83861-02-3
DMAGBM2	DE	Pain

DMZR6GI	ID	DMZR6GI
DMZR6GI	DN	Sch-34826
DMZR6GI	HS	Discontinued in Phase 2
DMZR6GI	SN	Sch-34826; Sch 34826; 105262-04-2; N-(N-(1-(((2,2-Dimethyl-1,3-dioxolan-4-yl) methoxy)carbonyl)-2-phenylethyl)phenylalanine)alanine; beta-Alanine, N-(N-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-oxo-1-(phenylmethyl)ethyl)-L-phenylalanyl)-; SCHEMBL489561; AC1L3U54; LS-186875; LS-187530; 3-[[(2S)-2-[[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1-oxo-3-phenylpropan-2-yl]amino]-3-phenylpropanoyl]amino]propanoic acid
DMZR6GI	CP	Schering-Plough Corp
DMZR6GI	DT	Small molecular drug
DMZR6GI	PC	122184
DMZR6GI	MW	498.6
DMZR6GI	FM	C27H34N2O7
DMZR6GI	IC	InChI=1S/C27H34N2O7/c1-27(2)35-18-21(36-27)17-34-26(33)23(16-20-11-7-4-8-12-20)29-22(15-19-9-5-3-6-10-19)25(32)28-14-13-24(30)31/h3-12,21-23,29H,13-18H2,1-2H3,(H,28,32)(H,30,31)/t21?,22-,23?/m0/s1
DMZR6GI	CS	CC1(OCC(O1)COC(=O)C(CC2=CC=CC=C2)N[C@@H](CC3=CC=CC=C3)C(=O)NCCC(=O)O)C
DMZR6GI	IK	GWLFRMJMKXSMSR-KOENEWCDSA-N
DMZR6GI	IU	3-[[(2S)-2-[[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1-oxo-3-phenylpropan-2-yl]amino]-3-phenylpropanoyl]amino]propanoic acid
DMZR6GI	CA	CAS 105262-04-2
DMZR6GI	DE	Hypertension

DM2RH51	ID	DM2RH51
DM2RH51	DN	SCH-42495
DM2RH51	HS	Discontinued in Phase 2
DM2RH51	SN	N-[2(S)-(Acetylsulfanylmethyl)-3-(2-methylphenyl)propionyl]-L-methionine ethyl ester
DM2RH51	DT	Small molecular drug
DM2RH51	PC	131965
DM2RH51	MW	411.6
DM2RH51	FM	C20H29NO4S2
DM2RH51	IC	InChI=1S/C20H29NO4S2/c1-5-25-20(24)18(10-11-26-4)21-19(23)17(13-27-15(3)22)12-16-9-7-6-8-14(16)2/h6-9,17-18H,5,10-13H2,1-4H3,(H,21,23)/t17-,18+/m1/s1
DM2RH51	CS	CCOC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=CC=C1C)CSC(=O)C
DM2RH51	IK	ZVQXPUMRSJGLSF-MSOLQXFVSA-N
DM2RH51	IU	ethyl (2S)-2-[[(2S)-2-(acetylsulfanylmethyl)-3-(2-methylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate
DM2RH51	CA	CAS 136511-43-8
DM2RH51	DE	Hypotension

DM28AFU	ID	DM28AFU
DM28AFU	DN	SCH-48461
DM28AFU	HS	Discontinued in Phase 2
DM28AFU	SN	(-)-(3R,4S)-1,4-Bis(4-methoxyphenyl)-3-(3-phenylpropyl)azetidin-2-one; 148260-92-8
DM28AFU	DT	Small molecular drug
DM28AFU	PC	132832
DM28AFU	MW	401.5
DM28AFU	FM	C26H27NO3
DM28AFU	IC	InChI=1S/C26H27NO3/c1-29-22-15-11-20(12-16-22)25-24(10-6-9-19-7-4-3-5-8-19)26(28)27(25)21-13-17-23(30-2)18-14-21/h3-5,7-8,11-18,24-25H,6,9-10H2,1-2H3/t24-,25-/m1/s1
DM28AFU	CS	COC1=CC=C(C=C1)[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)OC)CCCC4=CC=CC=C4
DM28AFU	IK	IMNTVVOUWFPRSB-JWQCQUIFSA-N
DM28AFU	IU	(3R,4S)-1,4-bis(4-methoxyphenyl)-3-(3-phenylpropyl)azetidin-2-one
DM28AFU	CA	CAS 148260-92-8
DM28AFU	DE	Hyperlipidaemia

DMX4938	ID	DMX4938
DMX4938	DN	SDZ-LAP-977
DMX4938	HS	Discontinued in Phase 2
DMX4938	SN	SDZ-281-977
DMX4938	CP	Novartis AG
DMX4938	PC	9818362
DMX4938	MW	316.3
DMX4938	FM	C18H20O5
DMX4938	IC	InChI=1S/C18H20O5/c1-21-14-7-9-17(22-2)13(11-14)6-4-12-5-8-16(19)15(10-12)18(20)23-3/h5,7-11,19H,4,6H2,1-3H3
DMX4938	CS	COC1=CC(=C(C=C1)OC)CCC2=CC(=C(C=C2)O)C(=O)OC
DMX4938	IK	GZOFTOHENYHNMS-UHFFFAOYSA-N
DMX4938	IU	methyl 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoate
DMX4938	CA	CAS 150779-71-8
DMX4938	DE	Psoriasis vulgaris

DMXZVPH	ID	DMXZVPH
DMXZVPH	DN	SEGLITIDE
DMXZVPH	HS	Discontinued in Phase 2
DMXZVPH	SN	L-363586; MK-678; Seglitide; Cyclic (N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe)
DMXZVPH	DT	Small molecular drug
DMXZVPH	PC	5311430
DMXZVPH	MW	809
DMXZVPH	FM	C44H56N8O7
DMXZVPH	IC	InChI=1S/C44H56N8O7/c1-26(2)38-43(58)50-37(23-28-12-6-5-7-13-28)44(59)52(4)27(3)39(54)48-35(22-29-17-19-31(53)20-18-29)41(56)49-36(24-30-25-46-33-15-9-8-14-32(30)33)42(57)47-34(40(55)51-38)16-10-11-21-45/h5-9,12-15,17-20,25-27,34-38,46,53H,10-11,16,21-24,45H2,1-4H3,(H,47,57)(H,48,54)(H,49,56)(H,50,58)(H,51,55)/t27-,34-,35-,36+,37-,38-/m0/s1
DMXZVPH	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1C)CC2=CC=CC=C2)C(C)C)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=C(C=C5)O
DMXZVPH	IK	NPJIOCBFOAHEDO-AVWFULIKSA-N
DMXZVPH	IU	(3S,6S,9S,12R,15S,18S)-9-(4-aminobutyl)-3-benzyl-15-[(4-hydroxyphenyl)methyl]-12-(1H-indol-3-ylmethyl)-1,18-dimethyl-6-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone
DMXZVPH	CA	CAS 81377-02-8
DMXZVPH	DE	Pain

DMLK605	ID	DMLK605
DMLK605	DN	Semparatide
DMLK605	HS	Discontinued in Phase 2
DMLK605	SN	RS-66271
DMLK605	CP	Roche Bioscience
DMLK605	PC	16131055
DMLK605	MW	4005
DMLK605	FM	C175H300N56O51
DMLK605	IC	InChI=1S/C175H300N56O51/c1-24-93(20)138(230-169(279)127(80-233)227-143(253)101(37-26-30-56-177)201-130(237)78-196-142(252)100(36-25-29-55-176)202-165(275)124(73-135(246)247)226-164(274)122(71-98-76-191-82-198-98)223-162(272)120(69-91(16)17)220-160(270)117(66-88(10)11)216-151(261)107(43-49-128(181)235)209-163(273)121(70-97-75-190-81-197-97)222-154(264)112(48-54-134(244)245)212-168(278)126(79-232)228-170(280)137(92(18)19)229-141(251)94(21)180)171(281)213-108(44-50-129(182)236)152(262)225-125(74-136(248)249)166(276)221-113(62-84(2)3)155(265)207-106(42-35-61-195-175(188)189)145(255)205-104(40-33-59-193-173(184)185)144(254)206-105(41-34-60-194-174(186)187)146(256)208-111(47-53-133(242)243)153(263)217-118(67-89(12)13)159(269)219-115(64-86(6)7)157(267)211-109(45-51-131(238)239)149(259)203-102(38-27-31-57-178)147(257)214-116(65-87(8)9)158(268)218-114(63-85(4)5)156(266)210-110(46-52-132(240)241)150(260)204-103(39-28-32-58-179)148(258)215-119(68-90(14)15)161(271)224-123(72-99-77-192-83-199-99)167(277)231-139(96(23)234)172(282)200-95(22)140(183)250/h75-77,81-96,100-127,137-139,232-234H,24-74,78-80,176-180H2,1-23H3,(H2,181,235)(H2,182,236)(H2,183,250)(H,190,197)(H,191,198)(H,192,199)(H,196,252)(H,200,282)(H,201,237)(H,202,275)(H,203,259)(H,204,260)(H,205,255)(H,206,254)(H,207,265)(H,208,256)(H,209,273)(H,210,266)(H,211,267)(H,212,278)(H,213,281)(H,214,257)(H,215,258)(H,216,261)(H,217,263)(H,218,268)(H,219,269)(H,220,270)(H,221,276)(H,222,264)(H,223,272)(H,224,271)(H,225,262)(H,226,274)(H,227,253)(H,228,280)(H,229,251)(H,230,279)(H,231,277)(H,238,239)(H,240,241)(H,242,243)(H,244,245)(H,246,247)(H,248,249)(H4,184,185,193)(H4,186,187,194)(H4,188,189,195)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,137-,138-,139-/m0/s1
DMLK605	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
DMLK605	IK	BLQSIKSVAXFNRH-ZMWZJJJDSA-N
DMLK605	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMLK605	CA	CAS 154906-40-8
DMLK605	DE	Osteoporosis

DM75ZO0	ID	DM75ZO0
DM75ZO0	DN	SERAZAPINE HYDROCHLORIDE
DM75ZO0	HS	Discontinued in Phase 2
DM75ZO0	SN	CGS-15040A; Serazapine hydrochloride < Rec INNM; Rac-2-Methyl-1,3,4,16b-tetrahydro-2H,10H-indolo[2,1-c]pyrazino[1,2-a][1,4]benzodiazepine-16-carboxylic acid methyl ester monohydrochloride
DM75ZO0	DT	Small molecular drug
DM75ZO0	PC	60676
DM75ZO0	MW	397.9
DM75ZO0	FM	C22H24ClN3O2
DM75ZO0	IC	InChI=1S/C22H23N3O2.ClH/c1-23-11-12-24-17-9-5-3-7-15(17)13-25-18-10-6-4-8-16(18)20(22(26)27-2)21(25)19(24)14-23;/h3-10,19H,11-14H2,1-2H3;1H
DM75ZO0	CS	CN1CCN2C(C1)C3=C(C4=CC=CC=C4N3CC5=CC=CC=C52)C(=O)OC.Cl
DM75ZO0	IK	YEITZTKANLXOTH-UHFFFAOYSA-N
DM75ZO0	IU	methyl 4-methyl-4,7,15-triazapentacyclo[13.7.0.02,7.08,13.016,21]docosa-1(22),8,10,12,16,18,20-heptaene-22-carboxylate;hydrochloride
DM75ZO0	CA	CAS 117581-05-2
DM75ZO0	DE	Anxiety disorder

DM9KB8A	ID	DM9KB8A
DM9KB8A	DN	SERGOLEXOLE MALEATE
DM9KB8A	HS	Discontinued in Phase 2
DM9KB8A	SN	LY-281067; Sergolexole maleate < Rec INNM; [trans-(8beta)]-1-Isopropyl-6-methylergoline-8-carboxylic acid 4-methoxycyclohexyl ester maleate; (9S)-4-Isopropyl-7-methyl-4,6,6abeta,7,8,9,10,10aalpha-octahydroindolo[3,4-fg]quinoline-9beta-carboxylic acid trans-4-methoxycyclohexyl ester maleate
DM9KB8A	DT	Small molecular drug
DM9KB8A	PC	6435752
DM9KB8A	MW	540.6
DM9KB8A	FM	C30H40N2O7
DM9KB8A	IC	InChI=1S/C26H36N2O3.C4H4O4/c1-16(2)28-15-17-13-24-22(21-6-5-7-23(28)25(17)21)12-18(14-27(24)3)26(29)31-20-10-8-19(30-4)9-11-20;5-3(6)1-2-4(7)8/h5-7,15-16,18-20,22,24H,8-14H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t18-,19?,20?,22-,24-;/m1./s1
DM9KB8A	CS	CC(C)N1C=C2C[C@@H]3[C@H](C[C@H](CN3C)C(=O)OC4CCC(CC4)OC)C5=C2C1=CC=C5.C(=C\\C(=O)O)\\C(=O)O
DM9KB8A	IK	AWRYUNKJBYLYFR-VRUJKGOYSA-N
DM9KB8A	IU	(Z)-but-2-enedioic acid;(4-methoxycyclohexyl) (6aR,9R,10aR)-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxylate
DM9KB8A	CA	CAS 108674-87-9
DM9KB8A	DE	Migraine

DMSLP2O	ID	DMSLP2O
DMSLP2O	DN	SERM-3339
DMSLP2O	HS	Discontinued in Phase 2
DMSLP2O	SN	HMR-3339; SERM compound, Aventis; 3339
DMSLP2O	CP	Hoechst Marion Roussel Inc
DMSLP2O	DE	Osteoporosis

DMBG6LP	ID	DMBG6LP
DMBG6LP	DN	SGB-1534
DMBG6LP	HS	Discontinued in Phase 2
DMBG6LP	SN	Sgb-1534; 3-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}quinazoline-2,4(1h,3h)-dione hydrochloride(1:1); SGB 1534; AC1Q3ELH; AC1L3TWP; SCHEMBL3624263; CTK8D4853; AKOS030540550; 88068-72-8; 3-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)-(1H,3H)-quinazoline-2,4-dione hcl; 3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-1H-quinazoline-2,4-dione hydrochloride; 2,4(1H,3H)-Quinazolinedione,3-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-, monohydrochloride
DMBG6LP	CP	Chugai Pharmaceutical Co Ltd
DMBG6LP	DT	Small molecular drug
DMBG6LP	PC	122064
DMBG6LP	MW	416.9
DMBG6LP	FM	C21H25ClN4O3
DMBG6LP	IC	InChI=1S/C21H24N4O3.ClH/c1-28-19-9-5-4-8-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-6-2-3-7-17(16)22-21(25)27;/h2-9H,10-15H2,1H3,(H,22,27);1H
DMBG6LP	CS	COC1=CC=CC=C1N2CCN(CC2)CCN3C(=O)C4=CC=CC=C4NC3=O.Cl
DMBG6LP	IK	NPNDIKQZGVCHMQ-UHFFFAOYSA-N
DMBG6LP	IU	3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-1H-quinazoline-2,4-dione;hydrochloride
DMBG6LP	CA	CAS 88068-72-8
DMBG6LP	DE	Hypotension

DM6XJ9D	ID	DM6XJ9D
DM6XJ9D	DN	SGS-111
DM6XJ9D	HS	Discontinued in Phase 2
DM6XJ9D	SN	Noopept; DVD-111; GVS-111
DM6XJ9D	CP	Russian Academy of Sciences
DM6XJ9D	DE	Cognitive impairment

DM7XC0U	ID	DM7XC0U
DM7XC0U	DN	SIB-1553A
DM7XC0U	HS	Discontinued in Phase 2
DM7XC0U	SN	191611-89-9; SIB 1553A hydrochloride; SIB 1553A Hyrdrochloride; SIB 1553A HCl; SCHEMBL6333252; SIB 1553A; MolPort-035-765-827; AKOS024458336; LS-104963; J-012387; (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride; (+-)-4-((2-(1-Methyl-2-pyrrolidinyl)ethyl)thio)phenol hydrochloride; Phenol, 4-((2-(1-methyl-2-pyrrolidinyl)ethyl)thio)-, hydrochloride
DM7XC0U	DT	Small molecular drug
DM7XC0U	PC	5310968
DM7XC0U	MW	237.36
DM7XC0U	FM	C13H19NOS
DM7XC0U	IC	InChI=1S/C13H19NOS/c1-14-9-2-3-11(14)8-10-16-13-6-4-12(15)5-7-13/h4-7,11,15H,2-3,8-10H2,1H3
DM7XC0U	CS	CN1CCCC1CCSC2=CC=C(C=C2)O
DM7XC0U	IK	NVZGJSVPOOILDI-UHFFFAOYSA-N
DM7XC0U	IU	4-[2-(1-methylpyrrolidin-2-yl)ethylsulfanyl]phenol
DM7XC0U	CA	CAS 191611-76-4
DM7XC0U	CB	CHEBI:125446
DM7XC0U	DE	Alzheimer disease

DMY30G2	ID	DMY30G2
DMY30G2	DN	SILPERISONE HYDROCHLORIDE
DMY30G2	HS	Discontinued in Phase 2
DMY30G2	SN	RGH-5002; SILA-336; Silperisone hydrochloride; 1-[(4-Fluorobenzyl)dimethylsilylmethyl]piperidine hydrochloride
DMY30G2	DT	Small molecular drug
DMY30G2	PC	178567
DMY30G2	MW	301.9
DMY30G2	FM	C15H25ClFNSi
DMY30G2	IC	InChI=1S/C15H24FNSi.ClH/c1-18(2,13-17-10-4-3-5-11-17)12-14-6-8-15(16)9-7-14;/h6-9H,3-5,10-13H2,1-2H3;1H
DMY30G2	CS	C[Si](C)(CC1=CC=C(C=C1)F)CN2CCCCC2.Cl
DMY30G2	IK	VGKGHWXDGBFJTP-UHFFFAOYSA-N
DMY30G2	IU	(4-fluorophenyl)methyl-dimethyl-(piperidin-1-ylmethyl)silane;hydrochloride
DMY30G2	CA	CAS 140944-30-5
DMY30G2	DE	Spasm

DMMZ2JT	ID	DMMZ2JT
DMMZ2JT	DN	SINITRODIL
DMMZ2JT	HS	Discontinued in Phase 2
DMMZ2JT	SN	ITF-296; Sinitrodil; 3-[2-(Nitrooxy)ethyl]-2H-1,3-benzoxazin-4(3H)-one
DMMZ2JT	DT	Small molecular drug
DMMZ2JT	PC	121985
DMMZ2JT	MW	238.2
DMMZ2JT	FM	C10H10N2O5
DMMZ2JT	IC	InChI=1S/C10H10N2O5/c13-10-8-3-1-2-4-9(8)16-7-11(10)5-6-17-12(14)15/h1-4H,5-7H2
DMMZ2JT	CS	C1N(C(=O)C2=CC=CC=C2O1)CCO[N+](=O)[O-]
DMMZ2JT	IK	POVFCWQCRHXYAB-UHFFFAOYSA-N
DMMZ2JT	IU	2-(4-oxo-2H-1,3-benzoxazin-3-yl)ethyl nitrate
DMMZ2JT	CA	CAS 143248-63-9
DMMZ2JT	DE	Angina pectoris

DMYP3KI	ID	DMYP3KI
DMYP3KI	DN	SINOMENINE
DMYP3KI	HS	Discontinued in Phase 2
DMYP3KI	SN	Cucoline; Kukoline; (9alpha,13alpha,14alpha)-4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one
DMYP3KI	DT	Small molecular drug
DMYP3KI	PC	5459308
DMYP3KI	MW	329.4
DMYP3KI	FM	C19H23NO4
DMYP3KI	IC	InChI=1S/C19H23NO4/c1-20-7-6-19-10-14(21)16(24-3)9-12(19)13(20)8-11-4-5-15(23-2)18(22)17(11)19/h4-5,9,12-13,22H,6-8,10H2,1-3H3/t12-,13+,19-/m1/s1
DMYP3KI	CS	CN1CC[C@@]23CC(=O)C(=C[C@@H]2[C@@H]1CC4=C3C(=C(C=C4)OC)O)OC
DMYP3KI	IK	INYYVPJSBIVGPH-QHRIQVFBSA-N
DMYP3KI	IU	(1R,9S,10S)-3-hydroxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-one
DMYP3KI	CA	CAS 115-53-7
DMYP3KI	CB	CHEBI:9163
DMYP3KI	DE	Arthritis

DMMQ4GC	ID	DMMQ4GC
DMMQ4GC	DN	Sipatrigine
DMMQ4GC	HS	Discontinued in Phase 2
DMMQ4GC	SN	Sipatrigine; 130800-90-7; Sipatrigine [INN:BAN]; 619C89; 2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine; UNII-OON9AVW1T3; BW619C89; BW-619C89; BW 619C89; OON9AVW1T3; CHEMBL28854; CHEBI:34977; 2-(4-Methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinamine; 4-Amino-2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)pyrimidine; 4-Pyrimidinamine, 2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-; AC1Q3LMC; AC1L1TYB; MLS006010764; SCHEMBL135888; C16H17Cl3N4; DTXSID20156750; MolPort-023-277-047
DMMQ4GC	DT	Small molecular drug
DMMQ4GC	PC	60803
DMMQ4GC	MW	372.7
DMMQ4GC	FM	C15H16Cl3N5
DMMQ4GC	IC	InChI=1S/C15H16Cl3N5/c1-22-2-4-23(5-3-22)15-20-8-11(14(19)21-15)10-6-9(16)7-12(17)13(10)18/h6-8H,2-5H2,1H3,(H2,19,20,21)
DMMQ4GC	CS	CN1CCN(CC1)C2=NC=C(C(=N2)N)C3=C(C(=CC(=C3)Cl)Cl)Cl
DMMQ4GC	IK	PDOCBJADCWMDGL-UHFFFAOYSA-N
DMMQ4GC	IU	2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine
DMMQ4GC	CA	CAS 130800-90-7
DMMQ4GC	CB	CHEBI:34977
DMMQ4GC	DE	Neurological disorder

DM2BDAW	ID	DM2BDAW
DM2BDAW	DN	SK&F-S-106203
DM2BDAW	HS	Discontinued in Phase 2
DM2BDAW	SN	SK&F-106203; (S)-beta-[(2-Carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid; 3(S)-[2-(Carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl]propionic acid
DM2BDAW	PC	3035514
DM2BDAW	MW	442.6
DM2BDAW	FM	C26H34O4S
DM2BDAW	IC	InChI=1S/C26H34O4S/c27-25(28)17-18-31-24(20-26(29)30)23-16-10-15-22(19-23)14-7-4-2-1-3-6-11-21-12-8-5-9-13-21/h5,8-10,12-13,15-16,19,24H,1-4,6-7,11,14,17-18,20H2,(H,27,28)(H,29,30)/t24-/m0/s1
DM2BDAW	CS	C1=CC=C(C=C1)CCCCCCCCC2=CC(=CC=C2)[C@H](CC(=O)O)SCCC(=O)O
DM2BDAW	IK	IEOUXQMKLRALNJ-DEOSSOPVSA-N
DM2BDAW	IU	(3S)-3-(2-carboxyethylsulfanyl)-3-[3-(8-phenyloctyl)phenyl]propanoic acid
DM2BDAW	CA	CAS 129047-98-9
DM2BDAW	DE	Asthma

DM40HTZ	ID	DM40HTZ
DM40HTZ	DN	SKF-97426
DM40HTZ	HS	Discontinued in Phase 2
DM40HTZ	SN	SKF-97426A
DM40HTZ	CP	SmithKline Beecham plc
DM40HTZ	DE	Hyperlipidaemia

DME1JYP	ID	DME1JYP
DME1JYP	DN	SL-25.1039
DME1JYP	HS	Discontinued in Phase 2
DME1JYP	CP	Sanofi-Synthelabo
DME1JYP	DE	Urinary incontinence

DMAM9BD	ID	DMAM9BD
DMAM9BD	DN	SL65.0155
DMAM9BD	HS	Discontinued in Phase 2
DMAM9BD	SN	capeserod; 769901-96-4; 5-(8-Amino-7-chloro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3-(1-phenethylpiperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one; SL65.0155; UNII-8163770L8P; 8163770L8P; 5-(8-AMINO-7-CHLORO-2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-3-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL]-1,3,4-OXADIAZOL-2(3H)-ONE; Capeserod [INN]; GTPL29; SCHEMBL4707724; CHEMBL2027925; BDBM86038; ZINC603773; PDSP2_001247; PDSP1_001263; 2009AC; AKOS016011606; SL650155; AJ-23687; DB-030409; KB-243722; FT-0735661
DMAM9BD	DT	Small molecular drug
DMAM9BD	PC	9805719
DMAM9BD	MW	456.9
DMAM9BD	FM	C23H25ClN4O4
DMAM9BD	IC	InChI=1S/C23H25ClN4O4/c24-18-14-17(20-21(19(18)25)31-13-12-30-20)22-26-28(23(29)32-22)16-7-10-27(11-8-16)9-6-15-4-2-1-3-5-15/h1-5,14,16H,6-13,25H2
DMAM9BD	CS	C1CN(CCC1N2C(=O)OC(=N2)C3=CC(=C(C4=C3OCCO4)N)Cl)CCC5=CC=CC=C5
DMAM9BD	IK	MDBNTXARNGRHEV-UHFFFAOYSA-N
DMAM9BD	IU	5-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-[1-(2-phenylethyl)piperidin-4-yl]-1,3,4-oxadiazol-2-one
DMAM9BD	CA	CAS 769901-96-4
DMAM9BD	DE	Parkinson disease

DMU5RKC	ID	DMU5RKC
DMU5RKC	DN	SL65.0472
DMU5RKC	HS	Discontinued in Phase 2
DMU5RKC	DT	Small molecular drug
DMU5RKC	PC	9869105
DMU5RKC	MW	465.5
DMU5RKC	FM	C24H24FN5O2S
DMU5RKC	IC	InChI=1S/C24H24FN5O2S/c25-17-1-2-18-16(13-23(32)30(15-22(26)31)20(18)14-17)4-7-28-8-10-29(11-9-28)24-19-5-12-33-21(19)3-6-27-24/h1-3,5-6,12-14H,4,7-11,15H2,(H2,26,31)
DMU5RKC	CS	C1CN(CCN1CCC2=CC(=O)N(C3=C2C=CC(=C3)F)CC(=O)N)C4=NC=CC5=C4C=CS5
DMU5RKC	IK	JDLYOFUDIKMYBL-UHFFFAOYSA-N
DMU5RKC	IU	2-[7-fluoro-2-oxo-4-[2-(4-thieno[3,2-c]pyridin-4-ylpiperazin-1-yl)ethyl]quinolin-1-yl]acetamide
DMU5RKC	CA	CAS 189003-92-7
DMU5RKC	DE	Cardiovascular disease

DMS8AHE	ID	DMS8AHE
DMS8AHE	DN	SL-65.1498
DMS8AHE	HS	Discontinued in Phase 2
DMS8AHE	SN	SL-651498; 6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-ylcarbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indole-1-one
DMS8AHE	DE	Anxiety disorder

DMOXUEP	ID	DMOXUEP
DMOXUEP	DN	SL-89.0591
DMOXUEP	HS	Discontinued in Phase 2
DMOXUEP	CP	Synthelabo
DMOXUEP	DE	Prostate disease

DMBZM0D	ID	DMBZM0D
DMBZM0D	DN	SLV-305
DMBZM0D	HS	Discontinued in Phase 2
DMBZM0D	CP	Solvay SA
DMBZM0D	DE	Gastric motility disorder

DM71WGZ	ID	DM71WGZ
DM71WGZ	DN	SLV-310
DM71WGZ	HS	Discontinued in Phase 2
DM71WGZ	SN	L001635; 2-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]isoindole-1,3-dione
DM71WGZ	CP	Solvay Pharma
DM71WGZ	DT	Small molecular drug
DM71WGZ	PC	9888211
DM71WGZ	MW	417.5
DM71WGZ	FM	C25H24FN3O2
DM71WGZ	IC	InChI=1S/C25H24FN3O2/c26-18-7-8-23-21(15-18)22(16-27-23)17-9-13-28(14-10-17)11-3-4-12-29-24(30)19-5-1-2-6-20(19)25(29)31/h1-2,5-9,15-16,27H,3-4,10-14H2
DM71WGZ	CS	C1CN(CC=C1C2=CNC3=C2C=C(C=C3)F)CCCCN4C(=O)C5=CC=CC=C5C4=O
DM71WGZ	IK	NECJNLXOJRDELU-UHFFFAOYSA-N
DM71WGZ	IU	2-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]isoindole-1,3-dione
DM71WGZ	CA	CAS 264869-71-8
DM71WGZ	DE	Schizophrenia

DM0GKHX	ID	DM0GKHX
DM0GKHX	DN	SLV319
DM0GKHX	HS	Discontinued in Phase 2
DM0GKHX	CP	Solvay Pharmaceuticals
DM0GKHX	DT	Small molecular drug
DM0GKHX	PC	11179267
DM0GKHX	MW	487.4
DM0GKHX	FM	C23H20Cl2N4O2S
DM0GKHX	IC	InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28)
DM0GKHX	CS	CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2CC(C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4
DM0GKHX	IK	AXJQVVLKUYCICH-UHFFFAOYSA-N
DM0GKHX	IU	5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-N'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide
DM0GKHX	CA	CAS 362519-49-1
DM0GKHX	DE	Obesity

DM1J0YB	ID	DM1J0YB
DM1J0YB	DN	SLX-2101
DM1J0YB	HS	Discontinued in Phase 2
DM1J0YB	CP	Kadmon Pharmaceuticals; Nano Terra
DM1J0YB	DE	Raynaud disease; Hypertension; Erectile dysfunction

DMZYGW0	ID	DMZYGW0
DMZYGW0	DN	SM-10661
DMZYGW0	HS	Discontinued in Phase 2
DMZYGW0	SN	SM-12502; SM-10661 (racemate); Rac-cis-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride; (+)-cis-(2R,5S)-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride
DMZYGW0	DT	Small molecular drug
DMZYGW0	PC	178014
DMZYGW0	MW	244.74
DMZYGW0	FM	C10H13ClN2OS
DMZYGW0	IC	InChI=1S/C10H12N2OS.ClH/c1-7-9(13)12(2)10(14-7)8-4-3-5-11-6-8;/h3-7,10H,1-2H3;1H/t7-,10+;/m0./s1
DMZYGW0	CS	C[C@H]1C(=O)N([C@H](S1)C2=CN=CC=C2)C.Cl
DMZYGW0	IK	CXHDSLQCNYLQND-XQRIHRDZSA-N
DMZYGW0	IU	(2R,5S)-3,5-dimethyl-2-pyridin-3-yl-1,3-thiazolidin-4-one;hydrochloride
DMZYGW0	CA	CAS 158511-47-8
DMZYGW0	DE	Sepsis

DMBUH7E	ID	DMBUH7E
DMBUH7E	DN	SM-10888
DMBUH7E	HS	Discontinued in Phase 2
DMBUH7E	SN	AC1L52EB; 2,4-Methanoacridin-9-amine, 8-fluoro-1,2,3,4-tetrahydro-, 2-hydroxy-1,2,3-propanetricarboxylate (3:2)
DMBUH7E	CP	Sumitomo Pharmaceuticals Co Ltd
DMBUH7E	PC	6918149
DMBUH7E	MW	420.4
DMBUH7E	FM	C20H21FN2O7
DMBUH7E	IC	InChI=1S/C14H13FN2.C6H8O7/c15-10-2-1-3-11-12(10)13(16)9-6-7-4-8(5-7)14(9)17-11;7-3(8)1-6(13,5(11)12)2-4(9)10/h1-3,7-8H,4-6H2,(H2,16,17);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMBUH7E	CS	C1C2CC1C3=NC4=C(C(=CC=C4)F)C(=C3C2)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMBUH7E	IK	ZCELBELLETVSEJ-UHFFFAOYSA-N
DMBUH7E	IU	8-fluoro-3-azatetracyclo[11.1.1.02,11.04,9]pentadeca-2,4(9),5,7,10-pentaen-10-amine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMBUH7E	DE	Cognitive impairment

DMJ816F	ID	DMJ816F
DMJ816F	DN	Sodelglitazar
DMJ816F	HS	Discontinued in Phase 2
DMJ816F	SN	Sodelglitazar; 447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac
DMJ816F	CP	GlaxoSmithKline
DMJ816F	DT	Small molecular drug
DMJ816F	PC	9805950
DMJ816F	MW	499.5
DMJ816F	FM	C23H21F4NO3S2
DMJ816F	IC	InChI=1S/C23H21F4NO3S2/c1-12-9-15(6-8-18(12)31-22(3,4)21(29)30)32-11-19-13(2)28-20(33-19)16-7-5-14(10-17(16)24)23(25,26)27/h5-10H,11H2,1-4H3,(H,29,30)
DMJ816F	CS	CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=C(C=C(C=C3)C(F)(F)F)F)C)OC(C)(C)C(=O)O
DMJ816F	IK	ZUGQWAYOWCBWGM-UHFFFAOYSA-N
DMJ816F	IU	2-[4-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid
DMJ816F	CA	CAS 447406-78-2
DMJ816F	DE	Hyperlipidaemia

DMHITR4	ID	DMHITR4
DMHITR4	DN	SOLPECAINOL HYDROCHLORIDE
DMHITR4	HS	Discontinued in Phase 2
DMHITR4	SN	EGYT-2936; Solpecainol hydrochloride; Rac-threo-2-(1-Methyl-2-phenoxyethylamino)-1-phenyl-1,3-propanediol hydrochloride; Rac-[1R*,2S*(S*)]-2-[(1-Methyl-2-phenoxyethyl)amino]-1-phenyl-1,3-propanediol hydrochloride
DMHITR4	DT	Small molecular drug
DMHITR4	PC	6918180
DMHITR4	MW	337.8
DMHITR4	FM	C18H24ClNO3
DMHITR4	IC	InChI=1S/C18H23NO3.ClH/c1-14(13-22-16-10-6-3-7-11-16)19-17(12-20)18(21)15-8-4-2-5-9-15;/h2-11,14,17-21H,12-13H2,1H3;1H/t14-,17-,18+;/m0./s1
DMHITR4	CS	C[C@@H](COC1=CC=CC=C1)N[C@@H](CO)[C@@H](C2=CC=CC=C2)O.Cl
DMHITR4	IK	ZERZMJPMHWGYET-QSCFYETBSA-N
DMHITR4	IU	(1R,2S)-2-[[(2S)-1-phenoxypropan-2-yl]amino]-1-phenylpropane-1,3-diol;hydrochloride
DMHITR4	DE	Cardiac arrhythmias

DMCS8FM	ID	DMCS8FM
DMCS8FM	DN	SORAPRAZAN
DMCS8FM	HS	Discontinued in Phase 2
DMCS8FM	SN	BY-359; Soraprazan; 2,3-Dimethyl-7(R)-(2-methoxyethoxy)-9(R)-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8(R)-ol
DMCS8FM	DT	Small molecular drug
DMCS8FM	PC	213054
DMCS8FM	MW	367.4
DMCS8FM	FM	C21H25N3O3
DMCS8FM	IC	InChI=1S/C21H25N3O3/c1-13-14(2)24-10-9-16-18(21(24)22-13)23-17(15-7-5-4-6-8-15)19(25)20(16)27-12-11-26-3/h4-10,17,19-20,23,25H,11-12H2,1-3H3/t17-,19-,20-/m1/s1
DMCS8FM	CS	CC1=C(N2C=CC3=C(C2=N1)N[C@@H]([C@H]([C@@H]3OCCOC)O)C4=CC=CC=C4)C
DMCS8FM	IK	PWILYDZRJORZDR-MISYRCLQSA-N
DMCS8FM	IU	(7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-ol
DMCS8FM	CA	CAS 261944-46-1
DMCS8FM	DE	Peptic ulcer

DMPAEK5	ID	DMPAEK5
DMPAEK5	DN	SOU-001
DMPAEK5	HS	Discontinued in Phase 2
DMPAEK5	SN	AA-10020; DRP-001
DMPAEK5	CP	Arachnova Therapeutics Ltd
DMPAEK5	DE	Urinary incontinence

DMTJNRL	ID	DMTJNRL
DMTJNRL	DN	SPD-473
DMTJNRL	HS	Discontinued in Phase 2
DMTJNRL	SN	BTS-74398
DMTJNRL	CP	Shire Pharmaceuticals; Knoll Pharmaceuticals Co
DMTJNRL	DE	Mood disorder

DMTC4VY	ID	DMTC4VY
DMTC4VY	DN	SQ-30741
DMTC4VY	HS	Discontinued in Phase 2
DMTC4VY	SN	[1S-(1beta,2alpha(5Z),3alpha,4beta)]-7-[3-[[[[(1-Oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid
DMTC4VY	DT	Small molecular drug
DMTC4VY	PC	5311394
DMTC4VY	MW	422.6
DMTC4VY	FM	C23H38N2O5
DMTC4VY	IC	InChI=1S/C23H38N2O5/c1-2-3-4-8-11-21(26)25-16-22(27)24-15-18-17(19-13-14-20(18)30-19)10-7-5-6-9-12-23(28)29/h5,7,17-20H,2-4,6,8-16H2,1H3,(H,24,27)(H,25,26)(H,28,29)/b7-5-/t17-,18+,19+,20-/m1/s1
DMTC4VY	CS	CCCCCCC(=O)NCC(=O)NC[C@@H]1[C@H]2CC[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O2
DMTC4VY	IK	OPZODFCEYJMBAM-OXVBEWKXSA-N
DMTC4VY	IU	(Z)-7-[(1S,2R,3R,4R)-3-[[[2-(heptanoylamino)acetyl]amino]methyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DMTC4VY	CA	CAS 107332-47-8
DMTC4VY	DE	Thrombosis

DMSQRXW	ID	DMSQRXW
DMSQRXW	DN	SQ-32709
DMSQRXW	HS	Discontinued in Phase 2
DMSQRXW	SN	farnesyl diphosphate; farnesyl pyrophosphate; (2E,6E)-Farnesyl diphosphate; trans,trans-Farnesyl diphosphate; all-trans-Farnesyl pyrophosphate; (all-E)-Farnesyl diphosphate; (E,E)-Farnesyl pyrophosphate; (2E,6E)-Farnesyl pyrophosphate; trans-Farnesyl pyrophosphate; 2-trans,6-trans-Farnesyl pyrophosphate; farnesyl-PP; (E,E)-Farnesyl diphosphate; 2-trans,6-trans-farnesyl diphosphate; trans-trans-farnesyl diphosphate; UNII-79W6B01D07; CHEBI:17407; trans,trans-Farnesyl pyrophosphate; Sq 32709; 13058-04-3; CHEMBL69330
DMSQRXW	CP	Bristol-Myers Squibb Co
DMSQRXW	DT	Small molecular drug
DMSQRXW	PC	445713
DMSQRXW	MW	382.33
DMSQRXW	FM	C15H28O7P2
DMSQRXW	IC	InChI=1S/C15H28O7P2/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-21-24(19,20)22-23(16,17)18/h7,9,11H,5-6,8,10,12H2,1-4H3,(H,19,20)(H2,16,17,18)/b14-9+,15-11+
DMSQRXW	CS	CC(=CCC/C(=C/CC/C(=C/COP(=O)(O)OP(=O)(O)O)/C)/C)C
DMSQRXW	IK	VWFJDQUYCIWHTN-YFVJMOTDSA-N
DMSQRXW	IU	phosphono [(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl] hydrogen phosphate
DMSQRXW	CA	CAS 372-97-4
DMSQRXW	CB	CHEBI:17407
DMSQRXW	DE	Arteriosclerosis

DMCEQKG	ID	DMCEQKG
DMCEQKG	DN	SR-121787
DMCEQKG	HS	Discontinued in Phase 2
DMCEQKG	SN	SR-121566; SR-121566a
DMCEQKG	CP	Sanofi-Synthelabo
DMCEQKG	DT	Small molecular drug
DMCEQKG	PC	9833004
DMCEQKG	MW	559.7
DMCEQKG	FM	C27H37N5O6S
DMCEQKG	IC	InChI=1S/C27H37N5O6S/c1-4-36-23(33)13-16-32(21-11-14-31(15-12-21)17-24(34)37-5-2)26-29-22(18-39-26)19-7-9-20(10-8-19)25(28)30-27(35)38-6-3/h7-10,18,21H,4-6,11-17H2,1-3H3,(H2,28,30,35)
DMCEQKG	CS	CCOC(=O)CCN(C1CCN(CC1)CC(=O)OCC)C2=NC(=CS2)C3=CC=C(C=C3)/C(=N/C(=O)OCC)/N
DMCEQKG	IK	WJMRSKGCJGOLKV-UHFFFAOYSA-N
DMCEQKG	IU	ethyl 3-[[4-[4-[(Z)-N'-ethoxycarbonylcarbamimidoyl]phenyl]-1,3-thiazol-2-yl]-[1-(2-ethoxy-2-oxoethyl)piperidin-4-yl]amino]propanoate
DMCEQKG	DE	Thrombosis

DMV4FT2	ID	DMV4FT2
DMV4FT2	DN	SR-57227
DMV4FT2	HS	Discontinued in Phase 2
DMV4FT2	SN	SR-57227A
DMV4FT2	CP	Sanofi
DMV4FT2	DT	Small molecular drug
DMV4FT2	PC	131747
DMV4FT2	MW	211.69
DMV4FT2	FM	C10H14ClN3
DMV4FT2	IC	InChI=1S/C10H14ClN3/c11-9-2-1-3-10(13-9)14-6-4-8(12)5-7-14/h1-3,8H,4-7,12H2
DMV4FT2	CS	C1CN(CCC1N)C2=NC(=CC=C2)Cl
DMV4FT2	IK	WPVVMKYQOMJPIN-UHFFFAOYSA-N
DMV4FT2	IU	1-(6-chloropyridin-2-yl)piperidin-4-amine
DMV4FT2	CA	CAS 77145-51-8
DMV4FT2	CB	CHEBI:92163
DMV4FT2	DE	Major depressive disorder

DMROKDM	ID	DMROKDM
DMROKDM	DN	SR-90067
DMROKDM	HS	Discontinued in Phase 2
DMROKDM	SN	Estradiol spray (menopausis), Sanofi-Synthelabo
DMROKDM	CP	Sanofi-Synthelabo
DMROKDM	DE	Hormone deficiency

DMRKE9G	ID	DMRKE9G
DMRKE9G	DN	SRI-62-834
DMRKE9G	HS	Discontinued in Phase 2
DMRKE9G	SN	CRC-8605; Rac-2-[Hydroxy[2-(octadecyloxymethyl)tetrahydrofuran-2-ylmethoxy]phosphinyloxy]-N,N,N-trimethylethylamminium hydroxyde,inner salt P-oxide
DMRKE9G	DT	Small molecular drug
DMRKE9G	PC	130724
DMRKE9G	MW	549.8
DMRKE9G	FM	C29H60NO6P
DMRKE9G	IC	InChI=1S/C29H60NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-33-27-29(22-21-25-34-29)28-36-37(31,32)35-26-23-30(2,3)4/h5-28H2,1-4H3
DMRKE9G	CS	CCCCCCCCCCCCCCCCCCOCC1(CCCO1)COP(=O)([O-])OCC[N+](C)(C)C
DMRKE9G	IK	OEWZGBLJCYAMEG-UHFFFAOYSA-N
DMRKE9G	IU	[2-(octadecoxymethyl)oxolan-2-yl]methyl 2-(trimethylazaniumyl)ethyl phosphate
DMRKE9G	CA	CAS 113201-37-9
DMRKE9G	DE	Solid tumour/cancer

DMN7BM3	ID	DMN7BM3
DMN7BM3	DN	SSR-182289
DMN7BM3	HS	Discontinued in Phase 2
DMN7BM3	SN	SSR-182289A; N-[3-[N-[4-(5-Aminopyridin-2-yl)-1(S)-[4-(difluoromethylene)piperidin-1-ylcarbonyl]butyl]sulfamoyl]biphenyl-2-yl]acetamide hydrochloride
DMN7BM3	DE	Myocardial infarction

DMNRW68	ID	DMNRW68
DMNRW68	DN	SU-14813
DMNRW68	HS	Discontinued in Phase 2
DMNRW68	SN	SU 14813; SU14813; 5-((5-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
DMNRW68	CP	Pfizer
DMNRW68	TC	Anticancer Agents
DMNRW68	DT	Small molecular drug
DMNRW68	PC	73755145
DMNRW68	MW	442.5
DMNRW68	FM	C23H27FN4O4
DMNRW68	IC	InChI=1S/C23H27FN4O4/c1-13-20(10-18-17-9-15(24)3-4-19(17)27-22(18)30)26-14(2)21(13)23(31)25-11-16(29)12-28-5-7-32-8-6-28/h3-4,9-10,16,21,29H,5-8,11-12H2,1-2H3,(H,25,31)(H,27,30)/b18-10-/t16-,21?/m0/s1
DMNRW68	CS	CC1=C(N=C(C1C(=O)NC[C@@H](CN2CCOCC2)O)C)/C=C\\3/C4=C(C=CC(=C4)F)NC3=O
DMNRW68	IK	XWPFYHDOZULRTD-ROUJOJKSSA-N
DMNRW68	IU	5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-3H-pyrrole-3-carboxamide
DMNRW68	DE	Breast cancer

DMBSLZV	ID	DMBSLZV
DMBSLZV	DN	Sulukast
DMBSLZV	HS	Discontinued in Phase 2
DMBSLZV	SN	LY-170680
DMBSLZV	CP	Eli Lilly & Co
DMBSLZV	DT	Small molecular drug
DMBSLZV	PC	6436123
DMBSLZV	MW	472.6
DMBSLZV	FM	C25H36N4O3S
DMBSLZV	IC	InChI=1S/C25H36N4O3S/c1-2-3-4-5-6-7-8-9-10-11-12-16-22(33-18-17-23(30)31)24(32)20-14-13-15-21(19-20)25-26-28-29-27-25/h10-16,19,22,24,32H,2-9,17-18H2,1H3,(H,30,31)(H,26,27,28,29)/b11-10-,16-12+/t22-,24+/m1/s1
DMBSLZV	CS	CCCCCCCCC/C=C\\C=C\\[C@H]([C@H](C1=CC=CC(=C1)C2=NNN=N2)O)SCCC(=O)O
DMBSLZV	IK	YPHOSUPSOWQQCB-AFOLHBCXSA-N
DMBSLZV	IU	3-[(1S,2R,3E,5Z)-1-hydroxy-1-[3-(2H-tetrazol-5-yl)phenyl]pentadeca-3,5-dien-2-yl]sulfanylpropanoic acid
DMBSLZV	CA	CAS 98116-53-1
DMBSLZV	DE	Asthma

DMWTLQ4	ID	DMWTLQ4
DMWTLQ4	DN	SUN-1334H
DMWTLQ4	HS	Discontinued in Phase 2
DMWTLQ4	SN	Histamine H1 receptor antagonist (oral, allergy) Sun Pharmaceutical
DMWTLQ4	CP	Sun Pharmaceutical Industries Ltd
DMWTLQ4	PC	69509032
DMWTLQ4	MW	489.4
DMWTLQ4	FM	C23H28Cl2F2N2O3
DMWTLQ4	IC	InChI=1S/C23H26F2N2O3.2ClH/c24-20-7-3-18(4-8-20)23(19-5-9-21(25)10-6-19)27-14-12-26(13-15-27)11-1-2-16-30-17-22(28)29;;/h1-10,23H,11-17H2,(H,28,29);2*1H/b2-1+;;
DMWTLQ4	CS	C1CN(CCN1C/C=C/COCC(=O)O)C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F.Cl.Cl
DMWTLQ4	IK	KAQMKGKFTBFMGE-SEPHDYHBSA-N
DMWTLQ4	IU	2-[(E)-4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]but-2-enoxy]acetic acid;dihydrochloride
DMWTLQ4	DE	Allergic rhinitis

DMZ8VI0	ID	DMZ8VI0
DMZ8VI0	DN	SUN-C5174
DMZ8VI0	HS	Discontinued in Phase 2
DMZ8VI0	SN	5-[3-[4-(4-Fluorophenyl)piperazin-1-yl]propyl]-8(S)-hydroxy-1-methyl-1,4,5,6,7,8-hexahydropyrrolo[3,2-c]azepin-4-one
DMZ8VI0	DE	Peripheral vascular disease

DM19Y0T	ID	DM19Y0T
DM19Y0T	DN	SUPER-LEU-DOX
DM19Y0T	HS	Discontinued in Phase 2
DM19Y0T	SN	CPI-0004; CPI-0004Na; CPI-004Na; DTS-201; TAP-doxorubicin; TSP-doxorubicin; Phthacene-5,12-dione sodium salt; N-[N-(3-Carboxypropionyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucyl]daunorubicin sodium salt; (8S,10S)-10-[3-[N-(3-Carboxy-1-oxopropyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucylamido]-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy]-8-(hydroxyacetyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrona
DM19Y0T	CP	Diatos SA
DM19Y0T	DE	Solid tumour/cancer

DMDZ7AY	ID	DMDZ7AY
DMDZ7AY	DN	Suritozole
DMDZ7AY	HS	Discontinued in Phase 2
DMDZ7AY	SN	MDL-26479
DMDZ7AY	CP	Hoechst Marion Roussel Inc
DMDZ7AY	DT	Small molecular drug
DMDZ7AY	PC	25431
DMDZ7AY	MW	223.27
DMDZ7AY	FM	C10H10FN3S
DMDZ7AY	IC	InChI=1S/C10H10FN3S/c1-13-9(12-14(2)10(13)15)7-4-3-5-8(11)6-7/h3-6H,1-2H3
DMDZ7AY	CS	CN1C(=NN(C1=S)C)C2=CC(=CC=C2)F
DMDZ7AY	IK	IWDUZEHNLHFBRZ-UHFFFAOYSA-N
DMDZ7AY	IU	5-(3-fluorophenyl)-2,4-dimethyl-1,2,4-triazole-3-thione
DMDZ7AY	CA	CAS 110623-33-1
DMDZ7AY	DE	Major depressive disorder

DMGFS51	ID	DMGFS51
DMGFS51	DN	T-1095
DMGFS51	HS	Discontinued in Phase 2
DMGFS51	SN	RWJ-394718; T-0687; T-1095A; SGLT-2 inhibitors (diabetes), Tanabe/Johnson & Johnson
DMGFS51	CP	Tanabe Seiyaku Co Ltd
DMGFS51	DT	Small molecular drug
DMGFS51	PC	6918410
DMGFS51	MW	516.5
DMGFS51	FM	C26H28O11
DMGFS51	IC	InChI=1S/C26H28O11/c1-13-9-17(28)21(16(27)5-3-14-4-6-18-15(11-14)7-8-34-18)19(10-13)36-25-24(31)23(30)22(29)20(37-25)12-35-26(32)33-2/h4,6-11,20,22-25,28-31H,3,5,12H2,1-2H3/t20-,22-,23+,24-,25-/m1/s1
DMGFS51	CS	CC1=CC(=C(C(=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)OC)O)O)O)C(=O)CCC3=CC4=C(C=C3)OC=C4)O
DMGFS51	IK	BXNCIERBDJYIQT-PRDVQWLOSA-N
DMGFS51	IU	[(2R,3S,4S,5R,6S)-6-[2-[3-(1-benzofuran-5-yl)propanoyl]-3-hydroxy-5-methylphenoxy]-3,4,5-trihydroxyoxan-2-yl]methyl methyl carbonate
DMGFS51	CA	CAS 209746-59-8
DMGFS51	DE	Diabetic complication

DMZTL7H	ID	DMZTL7H
DMZTL7H	DN	T487
DMZTL7H	HS	Discontinued in Phase 2
DMZTL7H	SN	AC1MVK5U; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methyl-ethanamine; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methylethanamine
DMZTL7H	CP	Amgen
DMZTL7H	DT	Small molecular drug
DMZTL7H	PC	12896
DMZTL7H	MW	242.23
DMZTL7H	FM	C12H10N4O2
DMZTL7H	IC	InChI=1S/C12H10N4O2/c13-9-1-3-10(4-2-9)14-15-11-5-7-12(8-6-11)16(17)18/h1-8H,13H2
DMZTL7H	CS	C1=CC(=CC=C1N)N=NC2=CC=C(C=C2)[N+](=O)[O-]
DMZTL7H	IK	UNBOSJFEZZJZLR-UHFFFAOYSA-N
DMZTL7H	IU	4-[(4-nitrophenyl)diazenyl]aniline
DMZTL7H	CA	CAS 730-40-5
DMZTL7H	CB	CHEBI:75648
DMZTL7H	DE	Inflammation; Psoriatic disorder

DM7XGJY	ID	DM7XGJY
DM7XGJY	DN	T-506
DM7XGJY	HS	Discontinued in Phase 2
DM7XGJY	SN	2'-Deoxy-5-fluoro-3'-oleoyluridine 5'-[2-(trimethylammonio)ethyl]phosphate hydrate
DM7XGJY	DT	Small molecular drug
DM7XGJY	PC	6441168
DM7XGJY	MW	675.8
DM7XGJY	FM	C32H55FN3O9P
DM7XGJY	IC	InChI=1S/C32H55FN3O9P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-30(37)45-27-23-29(35-24-26(33)31(38)34-32(35)39)44-28(27)25-43-46(40,41)42-22-21-36(2,3)4/h12-13,24,27-29H,5-11,14-23,25H2,1-4H3,(H-,34,38,39,40,41)/b13-12+
DM7XGJY	CS	CCCCCCCC/C=C/CCCCCCCC(=O)OC1CC(OC1COP(=O)([O-])OCC[N+](C)(C)C)N2C=C(C(=O)NC2=O)F
DM7XGJY	IK	JLGWAGKPIWGUEH-OUKQBFOZSA-N
DM7XGJY	IU	[5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-[(E)-octadec-9-enoyl]oxyoxolan-2-yl]methyl 2-(trimethylazaniumyl)ethyl phosphate
DM7XGJY	CA	CAS 104884-43-7
DM7XGJY	DE	Solid tumour/cancer

DMD3CUJ	ID	DMD3CUJ
DMD3CUJ	DN	T-5224
DMD3CUJ	HS	Discontinued in Phase 2
DMD3CUJ	SN	AKOS003047196; T5224
DMD3CUJ	CP	Toyama Chemical
DMD3CUJ	DT	Small molecular drug
DMD3CUJ	PC	23626877
DMD3CUJ	MW	517.5
DMD3CUJ	FM	C29H27NO8
DMD3CUJ	IC	InChI=1S/C29H27NO8/c31-24-15-21(37-20-3-1-2-4-20)8-10-22(24)28(34)19-6-11-25(18(14-19)7-12-27(32)33)36-16-17-5-9-23-26(13-17)38-30-29(23)35/h5-6,8-11,13-15,20,31H,1-4,7,12,16H2,(H,30,35)(H,32,33)
DMD3CUJ	CS	C1CCC(C1)OC2=CC(=C(C=C2)C(=O)C3=CC(=C(C=C3)OCC4=CC5=C(C=C4)C(=O)NO5)CCC(=O)O)O
DMD3CUJ	IK	DALCQQSLNPLQFZ-UHFFFAOYSA-N
DMD3CUJ	IU	3-[5-(4-cyclopentyloxy-2-hydroxybenzoyl)-2-[(3-oxo-1,2-benzoxazol-6-yl)methoxy]phenyl]propanoic acid
DMD3CUJ	DE	Rheumatoid arthritis

DM3M5TU	ID	DM3M5TU
DM3M5TU	DN	T-588
DM3M5TU	HS	Discontinued in Phase 2
DM3M5TU	SN	(-)-(R)-1-(Benzothiophen-5-yl)-2-[2-(diethylamino)ethoxy]ethanol hydrochloride; 131965-06-5
DM3M5TU	DT	Small molecular drug
DM3M5TU	PC	132522
DM3M5TU	MW	329.9
DM3M5TU	FM	C16H24ClNO2S
DM3M5TU	IC	InChI=1S/C16H23NO2S.ClH/c1-3-17(4-2)8-9-19-12-15(18)13-5-6-16-14(11-13)7-10-20-16;/h5-7,10-11,15,18H,3-4,8-9,12H2,1-2H3;1H/t15-;/m0./s1
DM3M5TU	CS	CCN(CC)CCOC[C@@H](C1=CC2=C(C=C1)SC=C2)O.Cl
DM3M5TU	IK	BKMCUGFGPQNYHG-RSAXXLAASA-N
DM3M5TU	IU	(1R)-1-(1-benzothiophen-5-yl)-2-[2-(diethylamino)ethoxy]ethanol;hydrochloride
DM3M5TU	CA	CAS 142935-03-3
DM3M5TU	DE	Amyotrophic lateral sclerosis

DMDN3TV	ID	DMDN3TV
DMDN3TV	DN	T611
DMDN3TV	HS	Discontinued in Phase 2
DMDN3TV	SN	T-0902611; T-611; T-902611; T-902611); 4-[4-(1H-Imidazol-1-yl)-6-methyl-5-nitropyrimidin-2-yl]-3(S)-methylmorpholine benzenesulfonate
DMDN3TV	CP	Amgen
DMDN3TV	PC	135465071
DMDN3TV	MW	416.4
DMDN3TV	FM	C20H13N2NaO5S
DMDN3TV	IC	InChI=1S/C20H14N2O5S.Na/c23-17-11-18(28(25,26)27)14-7-3-4-8-15(14)19(17)22-21-16-10-9-12-5-1-2-6-13(12)20(16)24;/h1-11,23-24H,(H,25,26,27);/q;+1/p-1
DMDN3TV	CS	C1=CC=C2C(=C1)C=CC(=C2O)N=NC3=C(C=C(C4=CC=CC=C43)S(=O)(=O)[O-])O.[Na+]
DMDN3TV	IK	HOWITLLZNKSJOJ-UHFFFAOYSA-M
DMDN3TV	IU	sodium;3-hydroxy-4-[(1-hydroxynaphthalen-2-yl)diazenyl]naphthalene-1-sulfonate
DMDN3TV	CA	CAS 3564-14-5
DMDN3TV	DE	Virus infection

DMBZG2Y	ID	DMBZG2Y
DMBZG2Y	DN	TA-5538
DMBZG2Y	HS	Discontinued in Phase 2
DMBZG2Y	SN	IDDBCP232835
DMBZG2Y	CP	Tanabe Seiyaku Co Ltd
DMBZG2Y	DE	Overactive bladder

DMB3W20	ID	DMB3W20
DMB3W20	DN	TA-6666
DMB3W20	HS	Discontinued in Phase 2
DMB3W20	SN	T-6666; 815541
DMB3W20	CP	GlaxoSmithKline plc
DMB3W20	DE	Type-2 diabetes

DM1Z74X	ID	DM1Z74X
DM1Z74X	DN	Tacedinaline
DM1Z74X	HS	Discontinued in Phase 2
DM1Z74X	SN	Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide
DM1Z74X	CP	National Cancer Institute (NCI)
DM1Z74X	DT	Small molecular drug
DM1Z74X	PC	2746
DM1Z74X	MW	269.3
DM1Z74X	FM	C15H15N3O2
DM1Z74X	IC	InChI=1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)
DM1Z74X	CS	CC(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N
DM1Z74X	IK	VAZAPHZUAVEOMC-UHFFFAOYSA-N
DM1Z74X	IU	4-acetamido-N-(2-aminophenyl)benzamide
DM1Z74X	CA	CAS 112522-64-2
DM1Z74X	CB	CHEBI:90195
DM1Z74X	DE	Solid tumour/cancer

DM0TDZI	ID	DM0TDZI
DM0TDZI	DN	TAK-013
DM0TDZI	HS	Discontinued in Phase 2
DM0TDZI	SN	Sufugolix; TAK-013; 308831-61-0; UNII-56S17Z6X9M; CHEMBL22055; 56S17Z6X9M; TAK 013; Sufugolix [INN:BAN]; Sufugolix(TAK-013); SCHEMBL209021; GTPL1185; AC1MI503; DTXSID40184893; UCQSBGOFELXYIN-UHFFFAOYSA-N; MolPort-046-033-569; ZINC3842924; BDBM50122654; AKOS030629545; CS-6434; AS-35342; HY-100209; L001648; N-(4-(5-((benzyl(methyl)amino)methyl)-1-(2,6-difluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea
DM0TDZI	DT	Small molecular drug
DM0TDZI	PC	3038517
DM0TDZI	MW	667.7
DM0TDZI	FM	C36H31F2N5O4S
DM0TDZI	IC	InChI=1S/C36H31F2N5O4S/c1-41(20-23-10-5-3-6-11-23)21-28-31-33(44)43(26-12-7-4-8-13-26)36(46)42(22-27-29(37)14-9-15-30(27)38)34(31)48-32(28)24-16-18-25(19-17-24)39-35(45)40-47-2/h3-19H,20-22H2,1-2H3,(H2,39,40,45)
DM0TDZI	CS	CN(CC1=CC=CC=C1)CC2=C(SC3=C2C(=O)N(C(=O)N3CC4=C(C=CC=C4F)F)C5=CC=CC=C5)C6=CC=C(C=C6)NC(=O)NOC
DM0TDZI	IK	UCQSBGOFELXYIN-UHFFFAOYSA-N
DM0TDZI	IU	1-[4-[5-[[benzyl(methyl)amino]methyl]-1-[(2,6-difluorophenyl)methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
DM0TDZI	CA	CAS 308831-61-0
DM0TDZI	DE	Uterine fibroids

DMBQ87R	ID	DMBQ87R
DMBQ87R	DN	TAK-044
DMBQ87R	HS	Discontinued in Phase 2
DMBQ87R	SN	TAK 044; 2-[(2R,5S,8S,11S,14S,17R)-8-(carboxymethyl)-17-(1H-indol-3-ylmethyl)-14-(2-methylpropyl)-3,6,9,12,15,18-hexaoxo-5-[2-oxo-2-(4-phenylpiperidin-1-yl)ethyl]-11-thiophen-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl]acetic acid; AC1NSKOX; TAK044
DMBQ87R	CP	Takeda Pharmaceutical Co Ltd
DMBQ87R	DT	Small molecular drug
DMBQ87R	PC	123882
DMBQ87R	MW	972
DMBQ87R	FM	C45H51N9Na2O11S
DMBQ87R	IC	InChI=1S/C45H53N9O11S.2Na/c1-25(2)19-30-40(60)47-31(20-26-24-46-29-12-7-6-11-28(26)29)41(61)49-33(22-37(56)57)43(63)48-32(21-36(55)54-16-14-53(15-17-54)27-9-4-3-5-10-27)42(62)50-34(23-38(58)59)44(64)52-39(45(65)51-30)35-13-8-18-66-35;;/h3-13,18,24-25,30-34,39,46H,14-17,19-23H2,1-2H3,(H,47,60)(H,48,63)(H,49,61)(H,50,62)(H,51,65)(H,52,64)(H,56,57)(H,58,59);;/q;2*+1/p-2/t30-,31+,32-,33+,34-,39+;;/m0../s1
DMBQ87R	CS	CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)C2=CC=CS2)CC(=O)[O-])CC(=O)N3CCN(CC3)C4=CC=CC=C4)CC(=O)[O-])CC5=CNC6=CC=CC=C65.[Na+].[Na+]
DMBQ87R	IK	UWHBIISPHYTOGL-PFSAEEMXSA-L
DMBQ87R	IU	disodium;2-[(2R,5S,8S,11S,14S,17R)-8-(carboxylatomethyl)-17-(1H-indol-3-ylmethyl)-14-(2-methylpropyl)-3,6,9,12,15,18-hexaoxo-5-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-11-thiophen-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl]acetate
DMBQ87R	CA	CAS 157380-72-8
DMBQ87R	DE	Renal failure

DM8S173	ID	DM8S173
DM8S173	DN	TAK-201
DM8S173	HS	Discontinued in Phase 2
DM8S173	SN	TAC-201; MT-201, Meiji
DM8S173	CP	Meiji Dairies Corp
DM8S173	DE	Allergy

DM7S69Q	ID	DM7S69Q
DM7S69Q	DN	TAK-218
DM7S69Q	HS	Discontinued in Phase 2
DM7S69Q	CP	TAP Pharmaceuticals Inc
DM7S69Q	DE	Neurological disorder

DMG4RFO	ID	DMG4RFO
DMG4RFO	DN	TAK-442
DMG4RFO	HS	Discontinued in Phase 2
DMG4RFO	SN	Letaxaban; TAK-442; 870262-90-1; UNII-Y3WB03966W; TAK 442; CHEMBL1095032; Y3WB03966W; 1-(1-{(2S)-3-[(6-Chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}piperidin-4-yl)tetrahydropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone,1-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]tetrahydro-; Letaxaban [USAN:INN]; 1-[1-[(2S)-3-[(6-Chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl]piperidin-4-yl]tetrahydropyrimidin-2(1H)-one; 3kl6; Letaxaban (USAN/INN); SCHEMBL766143; GEHAEMCVKDPMKO-HXUWFJFHSA-N
DMG4RFO	CP	Takeda
DMG4RFO	DT	Small molecular drug
DMG4RFO	PC	11641515
DMG4RFO	MW	480
DMG4RFO	FM	C22H26ClN3O5S
DMG4RFO	IC	InChI=1S/C22H26ClN3O5S/c23-17-4-2-16-13-19(5-3-15(16)12-17)32(30,31)14-20(27)21(28)25-10-6-18(7-11-25)26-9-1-8-24-22(26)29/h2-5,12-13,18,20,27H,1,6-11,14H2,(H,24,29)/t20-/m1/s1
DMG4RFO	CS	C1CNC(=O)N(C1)C2CCN(CC2)C(=O)[C@@H](CS(=O)(=O)C3=CC4=C(C=C3)C=C(C=C4)Cl)O
DMG4RFO	IK	GEHAEMCVKDPMKO-HXUWFJFHSA-N
DMG4RFO	IU	1-[1-[(2S)-3-(6-chloronaphthalen-2-yl)sulfonyl-2-hydroxypropanoyl]piperidin-4-yl]-1,3-diazinan-2-one
DMG4RFO	CA	CAS 870262-90-1
DMG4RFO	DE	Thrombosis

DMN1YHP	ID	DMN1YHP
DMN1YHP	DN	TAK-603
DMN1YHP	HS	Discontinued in Phase 2
DMN1YHP	CP	Takeda Pharmaceutical Co Ltd
DMN1YHP	PC	153980
DMN1YHP	MW	478.5
DMN1YHP	FM	C25H26N4O6
DMN1YHP	IC	InChI=1S/C25H26N4O6/c1-6-35-25(30)24-18(12-29-14-26-13-27-29)28-17-11-22(34-5)21(33-4)10-16(17)23(24)15-7-8-19(31-2)20(9-15)32-3/h7-11,13-14H,6,12H2,1-5H3
DMN1YHP	CS	CCOC(=O)C1=C(C2=CC(=C(C=C2N=C1CN3C=NC=N3)OC)OC)C4=CC(=C(C=C4)OC)OC
DMN1YHP	IK	CLQRMSBSMHXMMC-UHFFFAOYSA-N
DMN1YHP	IU	ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate
DMN1YHP	CA	CAS 158146-85-1
DMN1YHP	DE	Inflammatory bowel disease

DMDVJKW	ID	DMDVJKW
DMDVJKW	DN	TAK-637
DMDVJKW	HS	Discontinued in Phase 2
DMDVJKW	SN	TAK-637; UNII-QRT7W0TL6X; QRT7W0TL6X; CHEMBL339486; SCHEMBL122948; TAK637; GTPL9329; TAK 637; BDBM50081420; compound (aR,9R)-8b [PMID: 10508446]; 7H-(1,4)Diazocino(2,1-g)(1,7)naphthyridine-6,13-dione, 7-((3,5-bis(trifluoromethyl)phenyl)methyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9R)-; (Ar,9R)-7-(3,5-bis(trifluoromethyl)benzyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-(1,4)diazocino(2,1-g)(1,7)naphthyridine-6,13-dione
DMDVJKW	CP	Takeda
DMDVJKW	DT	Small molecular drug
DMDVJKW	PC	9894349
DMDVJKW	MW	573.5
DMDVJKW	FM	C30H25F6N3O2
DMDVJKW	IC	InChI=1S/C30H25F6N3O2/c1-17-5-7-20(8-6-17)24-23-4-3-10-37-25(23)27(40)39-11-9-18(2)15-38(28(41)26(24)39)16-19-12-21(29(31,32)33)14-22(13-19)30(34,35)36/h3-8,10,12-14,18H,9,11,15-16H2,1-2H3/t18-/m1/s1
DMDVJKW	CS	C[C@@H]1CCN2C(=C(C3=C(C2=O)N=CC=C3)C4=CC=C(C=C4)C)C(=O)N(C1)CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F
DMDVJKW	IK	LDXQLWNPGRANTO-GOSISDBHSA-N
DMDVJKW	IU	(9R)-7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione
DMDVJKW	CA	CAS 183549-93-1
DMDVJKW	DE	Depression

DMHNZ31	ID	DMHNZ31
DMHNZ31	DN	TAK-802
DMHNZ31	HS	Discontinued in Phase 2
DMHNZ31	CP	Takeda Pharmaceutical Co Ltd
DMHNZ31	PC	9888392
DMHNZ31	MW	420.5
DMHNZ31	FM	C26H29FN2O2
DMHNZ31	IC	InChI=1S/C26H29FN2O2/c27-23-3-1-2-19(14-23)17-28-11-8-18(9-12-28)4-6-24(30)22-15-20-5-7-25(31)29-13-10-21(16-22)26(20)29/h1-3,14-16,18H,4-13,17H2
DMHNZ31	CS	C1CN(CCC1CCC(=O)C2=CC3=C4C(=C2)CCN4C(=O)CC3)CC5=CC(=CC=C5)F
DMHNZ31	IK	RAYMNBAAUXRZHA-UHFFFAOYSA-N
DMHNZ31	IU	6-[3-[1-[(3-fluorophenyl)methyl]piperidin-4-yl]propanoyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-11-one
DMHNZ31	DE	Urinary dysfunction

DMWVPEU	ID	DMWVPEU
DMWVPEU	DN	Tallimustine
DMWVPEU	HS	Discontinued in Phase 2
DMWVPEU	SN	Tallimustine; Tallimustine [INN]; UNII-71193OXG6S; 115308-98-0; 71193OXG6S; N'-(2-Amidinoethyl)-4-(p-(bis(2-chloroethyl)amino)benzamido)-1,1',1'-trimethyl-N,4':N',4'-ter(pyrrole-2-carboxamide); 1H-Pyrrole-2-carboxamide, N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1- methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-; 1H-Pyrrole-2-carboxamide, N-(5-(((3-amino-3-iminopropyl)amino)carbonyl)-1-methyl-1H-pyrrol-3-yl)-4-(((4-((4-(bis(2-chloroethy
DMWVPEU	DT	Small molecular drug
DMWVPEU	PC	65924
DMWVPEU	MW	697.6
DMWVPEU	FM	C32H38Cl2N10O4
DMWVPEU	IC	InChI=1S/C32H38Cl2N10O4/c1-41-18-22(14-25(41)30(46)37-11-8-28(35)36)39-32(48)27-16-23(19-43(27)3)40-31(47)26-15-21(17-42(26)2)38-29(45)20-4-6-24(7-5-20)44(12-9-33)13-10-34/h4-7,14-19H,8-13H2,1-3H3,(H3,35,36)(H,37,46)(H,38,45)(H,39,48)(H,40,47)
DMWVPEU	CS	CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CN(C(=C3)C(=O)NCCC(=N)N)C)C)NC(=O)C4=CC=C(C=C4)N(CCCl)CCCl
DMWVPEU	IK	ARKYUICTMUZVEW-UHFFFAOYSA-N
DMWVPEU	IU	N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide
DMWVPEU	CA	CAS 115308-98-0
DMWVPEU	DE	Solid tumour/cancer

DM2KH9Y	ID	DM2KH9Y
DM2KH9Y	DN	Talsaclidine fumarate
DM2KH9Y	HS	Discontinued in Phase 2
DM2KH9Y	SN	Wal 2014 FU; Talsaclidine fumarate (USAN); 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1); 3-(2-Propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; 3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane
DM2KH9Y	CP	Boehringer
DM2KH9Y	DT	Small molecular drug
DM2KH9Y	PC	6918244
DM2KH9Y	MW	281.3
DM2KH9Y	FM	C14H19NO5
DM2KH9Y	IC	InChI=1S/C10H15NO.C4H4O4/c1-2-7-12-10-8-11-5-3-9(10)4-6-11;5-3(6)1-2-4(7)8/h1,9-10H,3-8H2;1-2H,(H,5,6)(H,7,8)/b;2-1+/t10-;/m0./s1
DM2KH9Y	CS	C#CCO[C@H]1CN2CCC1CC2.C(=C/C(=O)O)\\C(=O)O
DM2KH9Y	IK	SBCXBWBXWKVIFK-PBBCPHEYSA-N
DM2KH9Y	IU	(E)-but-2-enedioic acid;(3R)-3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane
DM2KH9Y	CA	CAS 147025-54-5
DM2KH9Y	DE	Alzheimer disease

DM1L5UX	ID	DM1L5UX
DM1L5UX	DN	TAMOLARIZINE HYDROCHLORIDE
DM1L5UX	HS	Discontinued in Phase 2
DM1L5UX	SN	NC-1100; Tamolarizine hydrochloride; Rac-alpha-(3,4-Dimethoxyphenyl)-4-(diphenylmethyl)-1-piperazineethanol dihydrochloride; Rac-1-(3,4-Dimethoxyphenyl)-2-(4-diphenylmethyl-1-piperazinyl)ethanol dihydrochloride
DM1L5UX	DT	Small molecular drug
DM1L5UX	PC	146395
DM1L5UX	MW	505.5
DM1L5UX	FM	C27H34Cl2N2O3
DM1L5UX	IC	InChI=1S/C27H32N2O3.2ClH/c1-31-25-14-13-23(19-26(25)32-2)24(30)20-28-15-17-29(18-16-28)27(21-9-5-3-6-10-21)22-11-7-4-8-12-22;;/h3-14,19,24,27,30H,15-18,20H2,1-2H3;2*1H
DM1L5UX	CS	COC1=C(C=C(C=C1)C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O)OC.Cl.Cl
DM1L5UX	IK	ZIGNSXDSBVYYFD-UHFFFAOYSA-N
DM1L5UX	IU	2-(4-benzhydrylpiperazin-1-yl)-1-(3,4-dimethoxyphenyl)ethanol;dihydrochloride
DM1L5UX	CA	CAS 93035-33-7
DM1L5UX	DE	Cognitive impairment

DMNU2MH	ID	DMNU2MH
DMNU2MH	DN	Tandutinib
DMNU2MH	HS	Discontinued in Phase 2
DMNU2MH	SN	CT 53518; CT53518; MLN 518; CT-53518; MLN-0518; MLN-518; MLN518, CT53518; Tandutinib (USAN/INN); (4-(6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-N-(4-(methylethoxy)phenyl)carboxamide; 4-(6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide; 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide
DMNU2MH	CP	Millenium; Takeda
DMNU2MH	TC	Anticancer Agents
DMNU2MH	DT	Small molecular drug
DMNU2MH	PC	3038522
DMNU2MH	MW	562.7
DMNU2MH	FM	C31H42N6O4
DMNU2MH	IC	InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)
DMNU2MH	CS	CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCCC5
DMNU2MH	IK	UXXQOJXBIDBUAC-UHFFFAOYSA-N
DMNU2MH	IU	4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide
DMNU2MH	CA	CAS 387867-13-2
DMNU2MH	CB	CHEBI:90237
DMNU2MH	DE	Anaplastic mixed oligoastrocytoma

DMF1VY4	ID	DMF1VY4
DMF1VY4	DN	Taprizosin
DMF1VY4	HS	Discontinued in Phase 2
DMF1VY4	SN	UK-338003
DMF1VY4	CP	Pfizer Inc
DMF1VY4	DT	Small molecular drug
DMF1VY4	PC	6433102
DMF1VY4	MW	506.6
DMF1VY4	FM	C25H26N6O4S
DMF1VY4	IC	InChI=1S/C25H26N6O4S/c1-34-20-13-19-22(21(23(20)35-2)18-8-4-5-11-27-18)24(26)29-25(28-19)31-12-10-16-15(14-31)7-6-9-17(16)30-36(3,32)33/h4-9,11,13,30H,10,12,14H2,1-3H3,(H2,26,28,29)
DMF1VY4	CS	COC1=C(C(=C2C(=C1)N=C(N=C2N)N3CCC4=C(C3)C=CC=C4NS(=O)(=O)C)C5=CC=CC=N5)OC
DMF1VY4	IK	OLYXPBZBZBVRGD-UHFFFAOYSA-N
DMF1VY4	IU	N-[2-(4-amino-6,7-dimethoxy-5-pyridin-2-ylquinazolin-2-yl)-3,4-dihydro-1H-isoquinolin-5-yl]methanesulfonamide
DMF1VY4	CA	CAS 210538-44-6
DMF1VY4	DE	Prostate hyperplasia

DMX6ZYE	ID	DMX6ZYE
DMX6ZYE	DN	Tarazepide
DMX6ZYE	HS	Discontinued in Phase 2
DMX6ZYE	SN	Tarazepide (INN)
DMX6ZYE	CP	Solvay Pharma
DMX6ZYE	DT	Small molecular drug
DMX6ZYE	PC	10343641
DMX6ZYE	MW	448.5
DMX6ZYE	FM	C28H24N4O2
DMX6ZYE	IC	InChI=1S/C28H24N4O2/c1-31-22-15-6-5-14-21(22)24(18-9-3-2-4-10-18)29-26(28(31)34)30-27(33)23-17-20-12-7-11-19-13-8-16-32(23)25(19)20/h2-7,9-12,14-15,17,26H,8,13,16H2,1H3,(H,30,33)/t26-/m1/s1
DMX6ZYE	CS	CN1C2=CC=CC=C2C(=N[C@@H](C1=O)NC(=O)C3=CC4=C5N3CCCC5=CC=C4)C6=CC=CC=C6
DMX6ZYE	IK	CZPILLBHPRAPCB-AREMUKBSSA-N
DMX6ZYE	IU	N-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraene-2-carboxamide
DMX6ZYE	CA	CAS 141374-81-4
DMX6ZYE	DE	Gastrointestinal disease

DMJG7VP	ID	DMJG7VP
DMJG7VP	DN	Tariquidar
DMJG7VP	HS	Discontinued in Phase 2
DMJG7VP	SN	Tariquidarth; XR 9576; XR9576; Tariquidar (USAN/INN); N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide; N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide
DMJG7VP	CP	Xenova Group Ltd.
DMJG7VP	DT	Small molecular drug
DMJG7VP	PC	148201
DMJG7VP	MW	646.7
DMJG7VP	FM	C38H38N4O6
DMJG7VP	IC	InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)
DMJG7VP	CS	COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC
DMJG7VP	IK	LGGHDPFKSSRQNS-UHFFFAOYSA-N
DMJG7VP	IU	N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide
DMJG7VP	CA	CAS 206873-63-4
DMJG7VP	DE	Adrenocortical carcinoma

DMP1A4S	ID	DMP1A4S
DMP1A4S	DN	TC-2696
DMP1A4S	HS	Discontinued in Phase 2
DMP1A4S	SN	Neuronal nicotinic receptor alpha4beta2 agonist (pain), Targacept
DMP1A4S	CP	Targacept
DMP1A4S	DE	Pain

DM3VZ87	ID	DM3VZ87
DM3VZ87	DN	TCV-309
DM3VZ87	HS	Discontinued in Phase 2
DM3VZ87	SN	AC1L3GRQ; LS-184311; 2-[3-(N-(2-bromo-1-propylpyridin-1-ium-4-carbonyl)anilino)propanoylamino]ethyl 3,4-dihydro-1H-isoquinoline-2-carboxylate nitrate
DM3VZ87	DT	Small molecular drug
DM3VZ87	PC	6918166
DM3VZ87	MW	656.5
DM3VZ87	FM	C30H34BrN5O7
DM3VZ87	IC	InChI=1S/C30H33BrN4O4.NO3/c1-2-15-33-20-25(19-26(31)22-33)29(37)35(27-10-4-3-5-11-27)17-13-28(36)32-14-18-39-30(38)34-16-12-23-8-6-7-9-24(23)21-34;2-1(3)4/h3-11,19-20,22H,2,12-18,21H2,1H3;/q;-1/p+1
DM3VZ87	CS	CCC[N+]1=CC(=CC(=C1)Br)C(=O)N(CCC(=O)NCCOC(=O)N2CCC3=CC=CC=C3C2)C4=CC=CC=C4.[N+](=O)([O-])[O-]
DM3VZ87	IK	DVGLBKDNVHDMTD-UHFFFAOYSA-O
DM3VZ87	IU	2-[3-(N-(5-bromo-1-propylpyridin-1-ium-3-carbonyl)anilino)propanoylamino]ethyl 3,4-dihydro-1H-isoquinoline-2-carboxylate;nitrate
DM3VZ87	CA	CAS 131311-25-6
DM3VZ87	DE	Sepsis

DMMUE8P	ID	DMMUE8P
DMMUE8P	DN	TEBUFELONE
DMMUE8P	HS	Discontinued in Phase 2
DMMUE8P	SN	Tebufelone; 112018-00-5; Tebufelone [USAN:INN]; Tebufelonum [INN-Latin]; Tebufelona [INN-Spanish]; UNII-O048K9ZFHO; O048K9ZFHO; NE 11740; CHEMBL13878; 3',5'-Di-tert-butyl-4'-hydroxy-5-hexynophenone; NE-11740; 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one; 1-(3,5-di-tert-butyl-4-hydroxyphenyl)hex-5-yn-1-one; Tebufelonum; Tebufelona; 5-Hexyn-1-one, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-; 5-Hexyn-1-one, 1-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-; Tebufelone (USAN/INN); AC1Q5DB7; AC1L1TG2; SCHEMBL43674
DMMUE8P	DT	Small molecular drug
DMMUE8P	PC	60542
DMMUE8P	MW	300.4
DMMUE8P	FM	C20H28O2
DMMUE8P	IC	InChI=1S/C20H28O2/c1-8-9-10-11-17(21)14-12-15(19(2,3)4)18(22)16(13-14)20(5,6)7/h1,12-13,22H,9-11H2,2-7H3
DMMUE8P	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C(=O)CCCC#C
DMMUE8P	IK	ZHXUEUKVDMWSKV-UHFFFAOYSA-N
DMMUE8P	IU	1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one
DMMUE8P	CA	CAS 112018-00-5
DMMUE8P	DE	Pain

DMPCRUT	ID	DMPCRUT
DMPCRUT	DN	Teglicar
DMPCRUT	HS	Discontinued in Phase 2
DMPCRUT	SN	Reversible palmitoyltransferase inhibitor; ST-1326
DMPCRUT	CP	Sigma-Tau SpA
DMPCRUT	DT	Small molecular drug
DMPCRUT	PC	9843897
DMPCRUT	MW	399.6
DMPCRUT	FM	C22H45N3O3
DMPCRUT	IC	InChI=1S/C22H45N3O3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-23-22(28)24-20(18-21(26)27)19-25(2,3)4/h20H,5-19H2,1-4H3,(H2-,23,24,26,27,28)/t20-/m1/s1
DMPCRUT	CS	CCCCCCCCCCCCCCNC(=O)N[C@H](CC(=O)[O-])C[N+](C)(C)C
DMPCRUT	IK	BMZYTDRMCBZVNH-HXUWFJFHSA-N
DMPCRUT	IU	(3R)-3-(tetradecylcarbamoylamino)-4-(trimethylazaniumyl)butanoate
DMPCRUT	CA	CAS 250694-07-6
DMPCRUT	DE	Diabetic complication

DM3F5E0	ID	DM3F5E0
DM3F5E0	DN	TEI-6122
DM3F5E0	HS	Discontinued in Phase 2
DM3F5E0	SN	TFC-612
DM3F5E0	CP	Teijin Ltd
DM3F5E0	DT	Small molecular drug
DM3F5E0	PC	6439638
DM3F5E0	MW	414.6
DM3F5E0	FM	C22H38O5S
DM3F5E0	IC	InChI=1S/C22H38O5S/c1-4-5-9-16(2)14-17(23)11-12-18-19(24)15-20(25)22(18)28-13-8-6-7-10-21(26)27-3/h11-12,16-19,22-24H,4-10,13-15H2,1-3H3/b12-11+/t16-,17?,18+,19-,22-/m1/s1
DM3F5E0	CS	CCCC[C@@H](C)CC(/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1SCCCCCC(=O)OC)O)O
DM3F5E0	IK	KMYUINCCFSNYPC-VPTZPLTNSA-N
DM3F5E0	IU	methyl 6-[(1R,2S,3R)-3-hydroxy-2-[(E,5R)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]sulfanylhexanoate
DM3F5E0	CA	CAS 83058-69-9
DM3F5E0	DE	Diabetic complication

DMIDGZU	ID	DMIDGZU
DMIDGZU	DN	Telbermin
DMIDGZU	HS	Discontinued in Phase 2
DMIDGZU	SN	Telbermin (USAN/INN)
DMIDGZU	CP	Genentech
DMIDGZU	DE	Diabetic foot ulcer

DM8OWID	ID	DM8OWID
DM8OWID	DN	Telinavir
DM8OWID	HS	Discontinued in Phase 2
DM8OWID	SN	SC-52151
DM8OWID	CP	GD Searle & Co
DM8OWID	DT	Small molecular drug
DM8OWID	PC	382974
DM8OWID	MW	604.7
DM8OWID	FM	C33H44N6O5
DM8OWID	IC	InChI=1S/C33H44N6O5/c1-21(2)19-39(32(44)38-33(3,4)5)20-28(40)26(17-22-11-7-6-8-12-22)36-31(43)27(18-29(34)41)37-30(42)25-16-15-23-13-9-10-14-24(23)35-25/h6-16,21,26-28,40H,17-20H2,1-5H3,(H2,34,41)(H,36,43)(H,37,42)(H,38,44)/t26-,27-,28+/m0/s1
DM8OWID	CS	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)N)NC(=O)C2=NC3=CC=CC=C3C=C2)O)C(=O)NC(C)(C)C
DM8OWID	IK	ZILOOGIOHVCEKS-HZFUHODCSA-N
DM8OWID	IU	(2S)-N-[(2S,3R)-4-[tert-butylcarbamoyl(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
DM8OWID	CA	CAS 143224-34-4
DM8OWID	DE	Human immunodeficiency virus infection

DM4K3P9	ID	DM4K3P9
DM4K3P9	DN	Terflavoxate
DM4K3P9	HS	Discontinued in Phase 2
DM4K3P9	SN	ND-907; Rec-15-2053
DM4K3P9	CP	Recordati SpA
DM4K3P9	DT	Small molecular drug
DM4K3P9	PC	135750
DM4K3P9	MW	419.5
DM4K3P9	FM	C26H29NO4
DM4K3P9	IC	InChI=1S/C26H29NO4/c1-18-22(28)20-13-10-14-21(24(20)30-23(18)19-11-6-4-7-12-19)25(29)31-26(2,3)17-27-15-8-5-9-16-27/h4,6-7,10-14H,5,8-9,15-17H2,1-3H3
DM4K3P9	CS	CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OC(C)(C)CN3CCCCC3)C4=CC=CC=C4
DM4K3P9	IK	VQTYZZPDAFGNCK-UHFFFAOYSA-N
DM4K3P9	IU	(2-methyl-1-piperidin-1-ylpropan-2-yl) 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
DM4K3P9	CA	CAS 86433-40-1
DM4K3P9	DE	Urinary incontinence

DMPB36I	ID	DMPB36I
DMPB36I	DN	Tesmilifene
DMPB36I	HS	Discontinued in Phase 2
DMPB36I	SN	DPPE; DPPE hydrocloride; Tesmilifene hydrochloride; BMS 217380-01; BMS-217380; BMY-33419; DPPE, BMS; YMB-1002; Anticancer, BMS/Manitoba Univ/MTCR
DMPB36I	CP	YM Biosciences
DMPB36I	DT	Small molecular drug
DMPB36I	PC	108092
DMPB36I	MW	283.4
DMPB36I	FM	C19H25NO
DMPB36I	IC	InChI=1S/C19H25NO/c1-3-20(4-2)14-15-21-19-12-10-18(11-13-19)16-17-8-6-5-7-9-17/h5-13H,3-4,14-16H2,1-2H3
DMPB36I	CS	CCN(CC)CCOC1=CC=C(C=C1)CC2=CC=CC=C2
DMPB36I	IK	NFIXBCVWIPOYCD-UHFFFAOYSA-N
DMPB36I	IU	2-(4-benzylphenoxy)-N,N-diethylethanamine
DMPB36I	CA	CAS 98774-23-3
DMPB36I	CB	CHEBI:93414
DMPB36I	DE	Breast cancer

DM5O6HM	ID	DM5O6HM
DM5O6HM	DN	Testosterone glucoside
DM5O6HM	HS	Discontinued in Phase 2
DM5O6HM	SN	S-403-G
DM5O6HM	CP	Strakan Group plc
DM5O6HM	DE	Hypogonadism

DMC0WNB	ID	DMC0WNB
DMC0WNB	DN	Tetramethylpyrazine
DMC0WNB	HS	Discontinued in Phase 2
DMC0WNB	SN	Ligustizine; Ligustrazine; 2,3,5,6-Tetramethylpyrazine
DMC0WNB	DT	Small molecular drug
DMC0WNB	PC	14296
DMC0WNB	MW	136.19
DMC0WNB	FM	C8H12N2
DMC0WNB	IC	InChI=1S/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3
DMC0WNB	CS	CC1=C(N=C(C(=N1)C)C)C
DMC0WNB	IK	FINHMKGKINIASC-UHFFFAOYSA-N
DMC0WNB	IU	2,3,5,6-tetramethylpyrazine
DMC0WNB	CA	CAS 1124-11-4
DMC0WNB	CB	CHEBI:133246
DMC0WNB	DE	Neurological disorder

DMS4BUK	ID	DMS4BUK
DMS4BUK	DN	TG-1042
DMS4BUK	HS	Discontinued in Phase 2
DMS4BUK	SN	TG-1041; Adv-IFN-gamma; Adenovirus-interferon gamma based therapy (basal cell carcinoma), Virax; Adenovirus-interferon gamma based therapy (cancer), Transgene; Ad-IFN-gamma (basal cell carcinoma), Virax; Ad-IFN-gamma (lymphoma), Transgene
DMS4BUK	CP	Transgene SA
DMS4BUK	DE	B-cell lymphoma

DMQSNV8	ID	DMQSNV8
DMQSNV8	DN	TgAAV-CFTR
DMQSNV8	HS	Discontinued in Phase 2
DMQSNV8	SN	TgAAV-CF; Gene therapy (CFTR), Targeted Genetics; Gene therapy (CFTR), Targeted Genetics/Celltech
DMQSNV8	CP	Targeted Genetics Corp
DMQSNV8	DE	Cystic fibrosis

DMYN6G0	ID	DMYN6G0
DMYN6G0	DN	TGP-580
DMYN6G0	HS	Discontinued in Phase 2
DMYN6G0	SN	CS-23; HbFGF, Takeda
DMYN6G0	CP	Takeda Pharmaceutical Co Ltd
DMYN6G0	DE	Neurodegenerative disorder

DMGR7Y3	ID	DMGR7Y3
DMGR7Y3	DN	Theradigm-HBV
DMGR7Y3	HS	Discontinued in Phase 2
DMGR7Y3	SN	CY-1899; Theradigm-hepatitis B virus
DMGR7Y3	CP	Genencor International Inc
DMGR7Y3	DE	Virus infection

DMYH2PU	ID	DMYH2PU
DMYH2PU	DN	TIBENELAST
DMYH2PU	HS	Discontinued in Phase 2
DMYH2PU	SN	LY-186655 (sodium salt); Tibenelast; 5,6-Diethoxybenzothiophene-2-carboxylic acid
DMYH2PU	DT	Small molecular drug
DMYH2PU	PC	59913
DMYH2PU	MW	266.31
DMYH2PU	FM	C13H14O4S
DMYH2PU	IC	InChI=1S/C13H14O4S/c1-3-16-9-5-8-6-12(13(14)15)18-11(8)7-10(9)17-4-2/h5-7H,3-4H2,1-2H3,(H,14,15)
DMYH2PU	CS	CCOC1=C(C=C2C(=C1)C=C(S2)C(=O)O)OCC
DMYH2PU	IK	PDUXMHXBBXXJFQ-UHFFFAOYSA-N
DMYH2PU	IU	5,6-diethoxy-1-benzothiophene-2-carboxylic acid
DMYH2PU	CA	CAS 97852-72-7
DMYH2PU	DE	Asthma

DMLWBYO	ID	DMLWBYO
DMLWBYO	DN	Tienoxolol
DMLWBYO	HS	Discontinued in Phase 2
DMLWBYO	SN	UP-788-42
DMLWBYO	CP	Laboratories UPSA
DMLWBYO	DT	Small molecular drug
DMLWBYO	PC	65678
DMLWBYO	MW	420.5
DMLWBYO	FM	C21H28N2O5S
DMLWBYO	IC	InChI=1S/C21H28N2O5S/c1-5-27-20(26)16-11-14(23-19(25)18-7-6-10-29-18)8-9-17(16)28-13-15(24)12-22-21(2,3)4/h6-11,15,22,24H,5,12-13H2,1-4H3,(H,23,25)
DMLWBYO	CS	CCOC(=O)C1=C(C=CC(=C1)NC(=O)C2=CC=CS2)OCC(CNC(C)(C)C)O
DMLWBYO	IK	PHMRLCQEIQGCHH-UHFFFAOYSA-N
DMLWBYO	IU	ethyl 2-[3-(tert-butylamino)-2-hydroxypropoxy]-5-(thiophene-2-carbonylamino)benzoate
DMLWBYO	CA	CAS 90055-97-3
DMLWBYO	DE	Hypertension

DMPWSRA	ID	DMPWSRA
DMPWSRA	DN	Tilmacoxib
DMPWSRA	HS	Discontinued in Phase 2
DMPWSRA	SN	Tilmacoxib; JTE-522; 180200-68-4; RWJ-57504; JTP-19605; UNII-G6VI5P84SX; 4-(4-Cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro-; G6VI5P84SX; CHEMBL34913; JTE522; 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo(4,5)imidazo(1,2a)pyridine-4-N-(2-fluorophenyl)carboxamide; CHEBI:73041; 4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluorobenzenesulfonamide; 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide
DMPWSRA	DT	Small molecular drug
DMPWSRA	PC	159271
DMPWSRA	MW	338.4
DMPWSRA	FM	C16H19FN2O3S
DMPWSRA	IC	InChI=1S/C16H19FN2O3S/c1-10-19-15(11-5-3-2-4-6-11)16(22-10)12-7-8-14(13(17)9-12)23(18,20)21/h7-9,11H,2-6H2,1H3,(H2,18,20,21)
DMPWSRA	CS	CC1=NC(=C(O1)C2=CC(=C(C=C2)S(=O)(=O)N)F)C3CCCCC3
DMPWSRA	IK	MIMJSJSRRDZIPW-UHFFFAOYSA-N
DMPWSRA	IU	4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluorobenzenesulfonamide
DMPWSRA	CA	CAS 180200-68-4
DMPWSRA	CB	CHEBI:73041
DMPWSRA	DE	Colon polyp

DMUJ2X6	ID	DMUJ2X6
DMUJ2X6	DN	Tiqueside
DMUJ2X6	HS	Discontinued in Phase 2
DMUJ2X6	SN	Tigogenin cellobioside; CP-88818
DMUJ2X6	CP	Pfizer Inc
DMUJ2X6	DT	Small molecular drug
DMUJ2X6	PC	9896801
DMUJ2X6	MW	740.9
DMUJ2X6	FM	C39H64O13
DMUJ2X6	IC	InChI=1S/C39H64O13/c1-18-7-12-39(47-17-18)19(2)28-25(52-39)14-24-22-6-5-20-13-21(8-10-37(20,3)23(22)9-11-38(24,28)4)48-35-33(46)31(44)34(27(16-41)50-35)51-36-32(45)30(43)29(42)26(15-40)49-36/h18-36,40-46H,5-17H2,1-4H3/t18-,19+,20+,21+,22-,23+,24+,25+,26-,27-,28+,29-,30+,31-,32-,33-,34-,35-,36+,37+,38+,39-/m1/s1
DMUJ2X6	CS	C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)C)C)C)OC1
DMUJ2X6	IK	GUSVHVVOABZHAH-OPZWKQDFSA-N
DMUJ2X6	IU	(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1R,2S,4S,5'R,6R,7S,8R,9S,12S,13S,16S,18S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMUJ2X6	CA	CAS 99759-19-0
DMUJ2X6	DE	Hyperlipidaemia

DMGF35T	ID	DMGF35T
DMGF35T	DN	Tisocalcitate
DMGF35T	HS	Discontinued in Phase 2
DMGF35T	SN	SH-597; ZK-156942; Calcitriol analog (topical formulation), Schering AG
DMGF35T	CP	Bayer Schering Pharma AG
DMGF35T	DT	Small molecular drug
DMGF35T	PC	9913924
DMGF35T	MW	500.7
DMGF35T	FM	C31H48O5
DMGF35T	IC	InChI=1S/C31H48O5/c1-19(2)36-29(35)30(5,6)28(34)15-10-20(3)25-13-14-26-22(9-8-16-31(25,26)7)11-12-23-17-24(32)18-27(33)21(23)4/h10-12,15,19-20,24-28,32-34H,4,8-9,13-14,16-18H2,1-3,5-7H3/b15-10+,22-11+,23-12-/t20-,24-,25-,26+,27+,28-,31-/m1/s1
DMGF35T	CS	C[C@H](/C=C/[C@H](C(C)(C)C(=O)OC(C)C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DMGF35T	IK	AUMBXYDXKLLKEK-BGMQPCSBSA-N
DMGF35T	IU	propan-2-yl (E,3R,6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-3-hydroxy-2,2-dimethylhept-4-enoate
DMGF35T	CA	CAS 156965-06-9
DMGF35T	DE	Psoriasis vulgaris

DMXNQLU	ID	DMXNQLU
DMXNQLU	DN	TM30338
DMXNQLU	HS	Discontinued in Phase 2
DMXNQLU	CP	7TMPharma.
DMXNQLU	DE	Obesity

DMW7LQT	ID	DMW7LQT
DMW7LQT	DN	TM30339
DMW7LQT	HS	Discontinued in Phase 2
DMW7LQT	CP	7TMPharma.
DMW7LQT	DT	Small molecular drug
DMW7LQT	PC	56603693
DMW7LQT	MW	4231
DMW7LQT	FM	C185H286N52O58S2
DMW7LQT	IC	InChI=1S/C185H286N52O58S2/c1-20-92(10)144(172(282)222-122(83-136(189)246)161(271)213-115(64-75-297-19)158(268)218-120(78-90(6)7)163(273)229-146(99(17)239)181(292)295-231-117(33-24-68-202-185(197)198)175(285)236-72-27-36-131(236)167(277)214-110(32-23-67-201-184(195)196)154(264)224-126(178(288)289)81-102-43-51-106(242)52-44-102)227-164(274)121(79-100-39-47-104(240)48-40-100)220-153(263)109(31-22-66-200-183(193)194)209-152(262)108(30-21-65-199-182(191)192)210-159(269)118(76-88(2)3)219-162(272)123(85-141(253)254)217-148(258)94(12)204-150(260)97(15)230-293-179(290)127(82-103-45-53-107(243)54-46-103)225-157(267)111(55-59-134(187)244)208-147(257)95(13)205-151(261)114(63-74-296-18)212-155(265)112(56-60-135(188)245)211-156(266)113(57-61-139(249)250)215-168(278)132-37-29-73-237(132)177(287)145(98(16)238)228-149(259)96(14)206-165(275)124(84-137(190)247)232-294-180(291)128(86-142(255)256)207-138(248)87-203-166(276)129-34-25-70-234(129)176(286)125(80-101-41-49-105(241)50-42-101)223-171(281)143(91(8)9)226-170(280)133-38-28-71-235(133)174(284)116(58-62-140(251)252)216-160(270)119(77-89(4)5)221-169(279)130-35-26-69-233(130)173(283)93(11)186/h39-54,88-99,108-133,143-146,230-232,238-243H,20-38,55-87,186H2,1-19H3,(H2,187,244)(H2,188,245)(H2,189,246)(H2,190,247)(H,203,276)(H,204,260)(H,205,261)(H,206,275)(H,207,248)(H,208,257)(H,209,262)(H,210,269)(H,211,266)(H,212,265)(H,213,271)(H,214,277)(H,215,278)(H,216,270)(H,217,258)(H,218,268)(H,219,272)(H,220,263)(H,221,279)(H,222,282)(H,223,281)(H,224,264)(H,225,267)(H,226,280)(H,227,274)(H,228,259)(H,229,273)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,288,289)(H4,191,192,199)(H4,193,194,200)(H4,195,196,201)(H4,197,198,202)
DMW7LQT	CS	CCC(C)C(C(=O)NC(CC(=O)N)C(=O)NC(CCSC)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)ONC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(CCCNC(=N)N)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(C)NOC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C5CCCN5C(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(CC(=O)N)NOC(=O)C(CC(=O)O)NC(=O)CNC(=O)C6CCCN6C(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(C(C)C)NC(=O)C8CCCN8C(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C9CCCN9C(=O)C(C)N
DMW7LQT	IK	ZECLZCGVVAIWHI-UHFFFAOYSA-N
DMW7LQT	IU	5-[[5-amino-1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[4-amino-1-[[1-[[1-[[1-[[5-carbamimidamido-1-[2-[[5-carbamimidamido-1-[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]oxy-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]oxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-[[1-[2-[2-[[4-amino-2-[[2-[[2-[[1-[2-[[2-[[1-[2-[[2-[[1-(2-aminopropanoyl)pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-carboxypropanoyl]oxyamino]-4-oxobutanoyl]amino]propanoylamino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid
DMW7LQT	DE	Schizophrenia

DMW05DS	ID	DMW05DS
DMW05DS	DN	TNP-351
DMW05DS	HS	Discontinued in Phase 2
DMW05DS	SN	N-[4-[3-(2,4-Diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid
DMW05DS	DT	Small molecular drug
DMW05DS	PC	5487322
DMW05DS	MW	440.5
DMW05DS	FM	C21H24N6O5
DMW05DS	IC	InChI=1S/C21H24N6O5/c22-17-16-13(10-24-18(16)27-21(23)26-17)3-1-2-11-4-6-12(7-5-11)19(30)25-14(20(31)32)8-9-15(28)29/h4-7,10,14H,1-3,8-9H2,(H,25,30)(H,28,29)(H,31,32)(H5,22,23,24,26,27)/t14-/m0/s1
DMW05DS	CS	C1=CC(=CC=C1CCCC2=CNC3=NC(=NC(=C23)N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMW05DS	IK	WLGCEMWNUHSIIS-AWEZNQCLSA-N
DMW05DS	IU	(2S)-2-[[4-[3-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]amino]pentanedioic acid
DMW05DS	CA	CAS 125991-51-7
DMW05DS	DE	Solid tumour/cancer

DMT0QK8	ID	DMT0QK8
DMT0QK8	DN	TNP-470
DMT0QK8	HS	Discontinued in Phase 2
DMT0QK8	SN	tnp 470; CCRIS 8049; C19H28ClNO6; O-chloroacetylcarbamoyl fumagillol; MSHZHSPISPJWHW-HUTWWKRSSA-N; Carbamic acid, (chloroacetyl)-, 5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl ester, (3R-(3alpha,4alpha(2R*,3R*),5beta,6beta))-
DMT0QK8	DT	Small molecular drug
DMT0QK8	PC	369976
DMT0QK8	MW	401.9
DMT0QK8	FM	C19H28ClNO6
DMT0QK8	IC	InChI=1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)/t12-,13-,15-,16-,18+,19+/m1/s1
DMT0QK8	CS	CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)NC(=O)CCl)OC)C
DMT0QK8	IK	MSHZHSPISPJWHW-PVDLLORBSA-N
DMT0QK8	IU	[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-(2-chloroacetyl)carbamate
DMT0QK8	CA	CAS 129298-91-5
DMT0QK8	CB	CHEBI:90748
DMT0QK8	DE	Solid tumour/cancer

DMEROU4	ID	DMEROU4
DMEROU4	DN	Tolafentrine
DMEROU4	HS	Discontinued in Phase 2
DMEROU4	SN	BY-4070
DMEROU4	CP	ALTANA Pharma AG
DMEROU4	DT	Small molecular drug
DMEROU4	PC	65990
DMEROU4	MW	505.6
DMEROU4	FM	C28H31N3O4S
DMEROU4	IC	InChI=1S/C28H31N3O4S/c1-18-5-11-21(12-6-18)36(32,33)30-20-9-7-19(8-10-20)28-23-16-27(35-4)26(34-3)15-22(23)24-17-31(2)14-13-25(24)29-28/h5-12,15-16,24-25,30H,13-14,17H2,1-4H3/t24-,25-/m0/s1
DMEROU4	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C3=N[C@H]4CCN(C[C@H]4C5=CC(=C(C=C53)OC)OC)C
DMEROU4	IK	FVZJIAUYFDQQKJ-DQEYMECFSA-N
DMEROU4	IU	N-[4-[(4aS,10bR)-8,9-dimethoxy-2-methyl-3,4,4a,10b-tetrahydro-1H-benzo[c][1,6]naphthyridin-6-yl]phenyl]-4-methylbenzenesulfonamide
DMEROU4	CA	CAS 139308-65-9
DMEROU4	DE	Chronic obstructive pulmonary disease

DMY40KZ	ID	DMY40KZ
DMY40KZ	DN	Tomeglovir
DMY40KZ	HS	Discontinued in Phase 2
DMY40KZ	SN	BAY-38-4766; BAY-40-1007; BAY-43-9695
DMY40KZ	CP	Bayer AG
DMY40KZ	DT	Small molecular drug
DMY40KZ	PC	475330
DMY40KZ	MW	441.5
DMY40KZ	FM	C23H27N3O4S
DMY40KZ	IC	InChI=1S/C23H27N3O4S/c1-23(2,15-27)22(28)24-16-11-13-17(14-12-16)25-31(29,30)21-10-6-7-18-19(21)8-5-9-20(18)26(3)4/h5-14,25,27H,15H2,1-4H3,(H,24,28)
DMY40KZ	CS	CC(C)(CO)C(=O)NC1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC3=C2C=CC=C3N(C)C
DMY40KZ	IK	OSQAKHSYTKBSPB-UHFFFAOYSA-N
DMY40KZ	IU	N-[4-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]phenyl]-3-hydroxy-2,2-dimethylpropanamide
DMY40KZ	CA	CAS 233254-24-5
DMY40KZ	DE	Virus infection

DM1YXPL	ID	DM1YXPL
DM1YXPL	DN	Tomopenem
DM1YXPL	HS	Discontinued in Phase 2
DM1YXPL	SN	R 115685; CS-023; R-1558; RO-4908463
DM1YXPL	CP	Sankyo Co Ltd
DM1YXPL	DT	Small molecular drug
DM1YXPL	PC	9809656
DM1YXPL	MW	537.6
DM1YXPL	FM	C23H35N7O6S
DM1YXPL	IC	InChI=1S/C23H35N7O6S/c1-10-17-16(11(2)31)21(34)30(17)18(22(35)36)19(10)37-13-6-14(28(3)9-13)20(33)29-5-4-12(8-29)27-15(32)7-26-23(24)25/h10-14,16-17,31H,4-9H2,1-3H3,(H,27,32)(H,35,36)(H4,24,25,26)/t10-,11-,12+,13+,14+,16-,17-/m1/s1
DM1YXPL	CS	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](N(C3)C)C(=O)N4CC[C@@H](C4)NC(=O)CN=C(N)N)C(=O)O)[C@@H](C)O
DM1YXPL	IK	KEDAXBWZURNCHS-GPODMPQUSA-N
DM1YXPL	IU	(4R,5S,6S)-3-[(3S,5S)-5-[(3S)-3-[[2-(diaminomethylideneamino)acetyl]amino]pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM1YXPL	CA	CAS 222400-20-6
DM1YXPL	DE	Bacterial infection

DMZA06U	ID	DMZA06U
DMZA06U	DN	TOPIXANTRONE HYDROCHLORIDE
DMZA06U	HS	Discontinued in Phase 2
DMZA06U	SN	Topixantrone hydrochloride; SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride
DMZA06U	DT	Small molecular drug
DMZA06U	PC	6918273
DMZA06U	MW	467.4
DMZA06U	FM	C21H28Cl2N6O2
DMZA06U	IC	InChI=1S/C21H26N6O2.2ClH/c1-26(2)10-8-24-16-3-4-17-19-18(16)21(29)14-5-6-23-13-15(14)20(19)25-27(17)11-7-22-9-12-28;;/h3-6,13,22,24,28H,7-12H2,1-2H3;2*1H
DMZA06U	CS	CN(C)CCNC1=C2C3=C(C=C1)N(N=C3C4=C(C2=O)C=CN=C4)CCNCCO.Cl.Cl
DMZA06U	IK	CQZQVNJGECUKMB-UHFFFAOYSA-N
DMZA06U	IU	10-[2-(dimethylamino)ethylamino]-14-[2-(2-hydroxyethylamino)ethyl]-4,14,15-triazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one;dihydrochloride
DMZA06U	DE	Gastric adenocarcinoma

DMDHYM7	ID	DMDHYM7
DMDHYM7	DN	Torcetrapib
DMDHYM7	HS	Discontinued in Phase 2
DMDHYM7	SN	Torcetrapib [USAN]; CP 529414; CP-529414; CP-529,414; Torcetrapib (USAN/INN); Ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate; Ethyl (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; Ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; (2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
DMDHYM7	CP	Pfizer
DMDHYM7	DT	Small molecular drug
DMDHYM7	PC	159325
DMDHYM7	MW	600.5
DMDHYM7	FM	C26H25F9N2O4
DMDHYM7	IC	InChI=1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3/t18-,21+/m1/s1
DMDHYM7	CS	CC[C@@H]1C[C@@H](C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)OC
DMDHYM7	IK	CMSGWTNRGKRWGS-NQIIRXRSSA-N
DMDHYM7	IU	ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate
DMDHYM7	CA	CAS 262352-17-0
DMDHYM7	CB	CHEBI:49203
DMDHYM7	DE	Hyperlipidaemia; Peripheral vascular disease

DMX32RC	ID	DMX32RC
DMX32RC	DN	Transdur-sufentanil
DMX32RC	HS	Discontinued in Phase 2
DMX32RC	SN	Sufentanil transdermal patch
DMX32RC	CP	Durect
DMX32RC	DT	Small molecular drug
DMX32RC	PC	65494
DMX32RC	MW	578.7
DMX32RC	FM	C28H38N2O9S
DMX32RC	IC	InChI=1S/C22H30N2O2S.C6H8O7/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-10,17H,3,11-16,18H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMX32RC	CS	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMX32RC	IK	OJCZPLDERGDQRJ-UHFFFAOYSA-N
DMX32RC	IU	2-hydroxypropane-1,2,3-tricarboxylic acid;N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
DMX32RC	CA	CAS 60561-17-3
DMX32RC	CB	CHEBI:9317
DMX32RC	DE	Pain

DME85Z9	ID	DME85Z9
DME85Z9	DN	TREFENTANIL HYDROCHLORIDE
DME85Z9	HS	Discontinued in Phase 2
DME85Z9	SN	A-3665; ANQ-3665; Trefentanil hydrochloride < Rec INNM; N-[1-[2-(4-Ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-phenylpiperidin-4-yl]-N-(2-fluorophenyl)propionamide hydrochloride; 1-[2-(4-Ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[N-(2-fluorophenyl)propionamido]-4-phenylpiperidine hydrochloride
DME85Z9	DT	Small molecular drug
DME85Z9	PC	60727
DME85Z9	MW	503
DME85Z9	FM	C25H32ClFN6O2
DME85Z9	IC	InChI=1S/C25H31FN6O2.ClH/c1-3-23(33)32(22-13-9-8-12-21(22)26)25(20-10-6-5-7-11-20)14-16-29(17-15-25)18-19-31-24(34)30(4-2)27-28-31;/h5-13H,3-4,14-19H2,1-2H3;1H
DME85Z9	CS	CCC(=O)N(C1=CC=CC=C1F)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)C4=CC=CC=C4.Cl
DME85Z9	IK	YMRJQYDWCFOMRR-UHFFFAOYSA-N
DME85Z9	IU	N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-phenylpiperidin-4-yl]-N-(2-fluorophenyl)propanamide;hydrochloride
DME85Z9	CA	CAS 120656-93-1
DME85Z9	DE	Pain

DMUZNF0	ID	DMUZNF0
DMUZNF0	DN	Tridolgosir
DMUZNF0	HS	Discontinued in Phase 2
DMUZNF0	SN	Swainsonine; Swainsonine hydrochloride; Tridolgosir hydrochloride; Carbohydrate processing inhibitors, GLYCODesign; GD-0039; Transforming growth factor beta inhibitors, GLYCODesign; GD-0039 analogs, GlycoDESIGN
DMUZNF0	CP	GLYCODesign Inc
DMUZNF0	DT	Small molecular drug
DMUZNF0	PC	51683
DMUZNF0	MW	173.21
DMUZNF0	FM	C8H15NO3
DMUZNF0	IC	InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1
DMUZNF0	CS	C1C[C@H]([C@@H]2[C@@H]([C@@H](CN2C1)O)O)O
DMUZNF0	IK	FXUAIOOAOAVCGD-WCTZXXKLSA-N
DMUZNF0	IU	(1S,2R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,8-triol
DMUZNF0	CA	CAS 72741-87-8
DMUZNF0	CB	CHEBI:9367
DMUZNF0	DE	Solid tumour/cancer

DMZ98Y4	ID	DMZ98Y4
DMZ98Y4	DN	TRO-40303
DMZ98Y4	HS	Discontinued in Phase 2
DMZ98Y4	SN	Ischemia-reperfusion injury agent, Trophos; Neuroprotectant (motor neuron disease), Trophos
DMZ98Y4	CP	Trophos SA
DMZ98Y4	DT	Small molecular drug
DMZ98Y4	PC	16734938
DMZ98Y4	MW	405.7
DMZ98Y4	FM	C26H47NO2
DMZ98Y4	IC	InChI=1S/C26H47NO2/c1-18(2)8-6-9-19(3)21-11-12-22-20-10-13-24(27-29)26(5,15-7-17-28)23(20)14-16-25(21,22)4/h18-23,28-29H,6-17H2,1-5H3/b27-24-/t19-,20+,21-,22+,23+,25-,26-/m1/s1
DMZ98Y4	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC/C(=N/O)/[C@]3(C)CCCO)C
DMZ98Y4	IK	OBKBVSFXEIFOMS-GHCPFUIOSA-N
DMZ98Y4	IU	3-[(3R,3aR,5aS,6R,7Z,9aS,9bS)-7-hydroxyimino-3a,6-dimethyl-3-[(2R)-6-methylheptan-2-yl]-1,2,3,4,5,5a,8,9,9a,9b-decahydrocyclopenta[a]naphthalen-6-yl]propan-1-ol
DMZ98Y4	DE	Lateral sclerosis

DM6032E	ID	DM6032E
DM6032E	DN	Trombodipine
DM6032E	HS	Discontinued in Phase 2
DM6032E	SN	Thrombodipine; PCA-4230
DM6032E	CP	Alter SA
DM6032E	DT	Small molecular drug
DM6032E	PC	124236
DM6032E	MW	448.5
DM6032E	FM	C21H24N2O7S
DM6032E	IC	InChI=1S/C21H24N2O7S/c1-5-29-20(25)17-12(2)18(14(4)22-13(17)3)21(26)30-11-10-23-19(24)15-8-6-7-9-16(15)31(23,27)28/h6-9,12,22H,5,10-11H2,1-4H3
DM6032E	CS	CCOC(=O)C1=C(NC(=C(C1C)C(=O)OCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C)C
DM6032E	IK	MCNAAGLIGWJLQX-UHFFFAOYSA-N
DM6032E	IU	3-O-ethyl 5-O-[2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)ethyl] 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM6032E	CA	CAS 113658-85-8
DM6032E	DE	Platelet aggregation disorder

DMALIFO	ID	DMALIFO
DMALIFO	DN	TS-033
DMALIFO	HS	Discontinued in Phase 2
DMALIFO	SN	SGL-0010; SGLT-2 inhibitor (diabetes), Taisho; Sodium-dependent glucose transporter-2 inhibitor (diabetes), Taisho
DMALIFO	CP	Taisho Pharmaceutical Co Ltd
DMALIFO	DE	Diabetic complication

DMWXOJN	ID	DMWXOJN
DMWXOJN	DN	TT-62
DMWXOJN	HS	Discontinued in Phase 2
DMWXOJN	SN	TEI-6170 (free acid); 2'-Deoxy-5-fluoro-5'-uridylic acid monotetradecyl ester sodium salt; 5-Fluoro-2'-deoxyuridine 5'-myristylphosphate sodium salt; 5-Fluoro-2'-deoxyuridine 5'-tetradecylphosphate sodium salt
DMWXOJN	DT	Small molecular drug
DMWXOJN	PC	23663410
DMWXOJN	MW	544.5
DMWXOJN	FM	C23H39FN2NaO8P
DMWXOJN	IC	InChI=1S/C23H40FN2O8P.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-32-35(30,31)33-17-20-19(27)15-21(34-20)26-16-18(24)22(28)25-23(26)29;/h16,19-21,27H,2-15,17H2,1H3,(H,30,31)(H,25,28,29);/q;+1/p-1/t19-,20+,21+;/m0./s1
DMWXOJN	CS	CCCCCCCCCCCCCCOP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)F)O.[Na+]
DMWXOJN	IK	YUGLAGAQPWTRTP-HWAJWLCKSA-M
DMWXOJN	IU	sodium;[(2R,3S,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl tetradecyl phosphate
DMWXOJN	DE	Virus infection

DMCEGN4	ID	DMCEGN4
DMCEGN4	DN	TTP-355
DMCEGN4	HS	Discontinued in Phase 2
DMCEGN4	SN	Glucokinase activator (type 2 diabetes), TransTech Pharma
DMCEGN4	CP	TransTech Pharma Inc
DMCEGN4	DE	Diabetic complication

DM81XLA	ID	DM81XLA
DM81XLA	DN	TV-4710
DM81XLA	HS	Discontinued in Phase 2
DM81XLA	CP	Teva
DM81XLA	PC	16214485
DM81XLA	MW	2309.5
DM81XLA	FM	C111H149N27O28
DM81XLA	IC	InChI=1S/C111H149N27O28/c1-5-59(3)94(107(163)123-57-93(150)151)135-103(159)82(49-64-53-119-72-22-11-8-19-69(64)72)131-99(155)77(38-41-92(148)149)127-98(154)76(37-40-91(146)147)125-89(144)55-121-96(152)74(24-13-14-42-112)124-90(145)56-122-106(162)85-26-16-44-137(85)110(166)86-27-17-45-138(86)109(165)78(36-39-87(114)142)129-97(153)75(25-15-43-117-111(115)116)128-108(164)95(60(4)6-2)136-104(160)83(50-65-54-120-73-23-12-9-20-70(65)73)133-105(161)84(58-139)134-102(158)81(48-63-52-118-71-21-10-7-18-68(63)71)132-101(157)80(47-62-30-34-67(141)35-31-62)130-100(156)79(126-88(143)51-113)46-61-28-32-66(140)33-29-61/h7-12,18-23,28-35,52-54,59-60,74-86,94-95,118-120,139-141H,5-6,13-17,24-27,36-51,55-58,112-113H2,1-4H3,(H2,114,142)(H,121,152)(H,122,162)(H,123,163)(H,124,145)(H,125,144)(H,126,143)(H,127,154)(H,128,164)(H,129,153)(H,130,156)(H,131,155)(H,132,157)(H,133,161)(H,134,158)(H,135,159)(H,136,160)(H,146,147)(H,148,149)(H,150,151)(H4,115,116,117)/t59-,60-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,94-,95-/m0/s1
DM81XLA	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN
DM81XLA	IK	VXXZQHUWZSRPAM-CDJUQFLLSA-N
DM81XLA	IU	(4S)-4-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]hexanoyl]amino]acetyl]amino]-5-[[(2S)-4-carboxy-1-[[(2S)-1-[[(2S,3S)-1-(carboxymethylamino)-3-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM81XLA	CA	CAS 433922-67-9
DM81XLA	DE	Systemic lupus erythematosus

DMQWA2R	ID	DMQWA2R
DMQWA2R	DN	TY-11345
DMQWA2R	HS	Discontinued in Phase 2
DMQWA2R	SN	TY 11345; (+-)-2-((4-Methoxy-6,7,8,9-tetrahydro-5H-cyclohepta(b)pyridin-9-yl)sulfinyl)-1H-benzimidazole sodium salt; 5H-Cyclohepta(b)pyridine, 9-(1H-benzimidazol-2-ylsulfinyl)-6,7,8,9-tetrahydro-4-methoxy-, sodium salt
DMQWA2R	CP	Toa Eiyo KK
DMQWA2R	DT	Small molecular drug
DMQWA2R	PC	23689269
DMQWA2R	MW	365.4
DMQWA2R	FM	C18H20N3NaO2S
DMQWA2R	IC	InChI=1S/C18H20N3O2S.Na/c1-23-15-10-11-19-17-12(15)6-2-5-9-16(17)24(22)18-20-13-7-3-4-8-14(13)21-18;/h3-4,7-8,10,16H,2,5-6,9,11H2,1H3,(H,20,21);/q-1;+1
DMQWA2R	CS	COC1=CC[N-]C2=C1CCCCC2S(=O)C3=NC4=CC=CC=C4N3.[Na+]
DMQWA2R	IK	IPAJARTUAXFVLF-UHFFFAOYSA-N
DMQWA2R	IU	sodium;9-(1H-benzimidazol-2-ylsulfinyl)-4-methoxy-2,5,6,7,8,9-hexahydrocyclohepta[b]pyridin-1-ide
DMQWA2R	CA	CAS 137927-14-1
DMQWA2R	DE	Peptic ulcer

DM4FZWP	ID	DM4FZWP
DM4FZWP	DN	UK-279,276
DM4FZWP	HS	Discontinued in Phase 2
DM4FZWP	CP	Corvas
DM4FZWP	DE	Stroke

DMAD1S5	ID	DMAD1S5
DMAD1S5	DN	UK-74505
DMAD1S5	HS	Discontinued in Phase 2
DMAD1S5	SN	rac-Modipafant; UK-74505; Modipafant racemate; 122956-68-7; UK 74505; 3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(4-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)phenyl)-5-((2-pyridinylamino)carbonyl)-, ethyl ester; UK 80067; Modipafant (racemate); AC1L2W8B; C34H29ClN6O3; SCHEMBL6995473; AN-3660; LS-172547; KB-276046; FT-0672447; ethyl 4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(2-pyridylcarbamoyl)-1,4-dihydropyridine-3-carboxylate; ethyl 4-(2-chlorophenyl)-6-methyl-2
DMAD1S5	CP	Pfizer Ltd
DMAD1S5	DT	Small molecular drug
DMAD1S5	PC	129796
DMAD1S5	MW	605.1
DMAD1S5	FM	C34H29ClN6O3
DMAD1S5	IC	InChI=1S/C34H29ClN6O3/c1-4-44-34(43)31-30(24-9-5-6-10-25(24)35)29(33(42)40-28-11-7-8-17-37-28)20(2)38-32(31)22-12-14-23(15-13-22)41-21(3)39-26-19-36-18-16-27(26)41/h5-19,30,38H,4H2,1-3H3,(H,37,40,42)
DMAD1S5	CS	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)NC3=CC=CC=N3)C)C4=CC=C(C=C4)N5C(=NC6=C5C=CN=C6)C
DMAD1S5	IK	ODRYSCQFUGFOSU-UHFFFAOYSA-N
DMAD1S5	IU	ethyl 4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(pyridin-2-ylcarbamoyl)-1,4-dihydropyridine-3-carboxylate
DMAD1S5	CA	CAS 122956-68-7
DMAD1S5	DE	Sepsis

DMRDXYV	ID	DMRDXYV
DMRDXYV	DN	Ultramorph
DMRDXYV	HS	Discontinued in Phase 2
DMRDXYV	CP	Innovata plc
DMRDXYV	DE	Pain

DMBJ8KG	ID	DMBJ8KG
DMBJ8KG	DN	Urtoxazumab
DMBJ8KG	HS	Discontinued in Phase 2
DMBJ8KG	SN	TMA-15; Anti shiga-like toxin 2 humanized MAb, Teijin; HuVTm1.1.1; Anti-SLT-2 humanized MAb (E coli infection), Teijin
DMBJ8KG	CP	Teijin Ltd
DMBJ8KG	DT	Antibody
DMBJ8KG	DE	Escherichia coli infection

DMOB2K5	ID	DMOB2K5
DMOB2K5	DN	UTIBAPRIL
DMOB2K5	HS	Discontinued in Phase 2
DMOB2K5	SN	FPL-63547; Utibapril < Rec INN; (S)-2-tert-Butyl-4-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]-DELTA2-1,3,4-thiadiazoline-5-carboxylic acid 4-ethyl ester; 5-tert-Butyl-3-[N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2(S)-carboxylic acid
DMOB2K5	DT	Small molecular drug
DMOB2K5	PC	9803778
DMOB2K5	MW	449.6
DMOB2K5	FM	C22H31N3O5S
DMOB2K5	IC	InChI=1S/C22H31N3O5S/c1-6-30-20(29)16(13-12-15-10-8-7-9-11-15)23-14(2)17(26)25-18(19(27)28)31-21(24-25)22(3,4)5/h7-11,14,16,18,23H,6,12-13H2,1-5H3,(H,27,28)/t14-,16-,18-/m0/s1
DMOB2K5	CS	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](SC(=N2)C(C)(C)C)C(=O)O
DMOB2K5	IK	FTYVYAGWBXTWTN-ZVZYQTTQSA-N
DMOB2K5	IU	(2S)-5-tert-butyl-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2H-1,3,4-thiadiazole-2-carboxylic acid
DMOB2K5	CA	CAS 109683-61-6
DMOB2K5	DE	Hypertension

DMEV1H5	ID	DMEV1H5
DMEV1H5	DN	V-11294A
DMEV1H5	HS	Discontinued in Phase 2
DMEV1H5	SN	Rolipram derivatives, Napp
DMEV1H5	CP	Napp Pharmaceutical Group Ltd
DMEV1H5	PC	135430158
DMEV1H5	MW	409.5
DMEV1H5	FM	C23H31N5O2
DMEV1H5	IC	InChI=1S/C23H31N5O2/c1-5-24-22-20-23(27-21(26-20)15(2)3)28(14-25-22)13-16-10-11-18(29-4)19(12-16)30-17-8-6-7-9-17/h10-12,14-15,17H,5-9,13H2,1-4H3,(H,26,27)
DMEV1H5	CS	CCN=C1C2=C(N=C(N2)C(C)C)N(C=N1)CC3=CC(=C(C=C3)OC)OC4CCCC4
DMEV1H5	IK	KLPQJJKXRIDASJ-UHFFFAOYSA-N
DMEV1H5	IU	3-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-N-ethyl-8-propan-2-yl-7H-purin-6-imine
DMEV1H5	DE	Asthma

DMXQCBU	ID	DMXQCBU
DMXQCBU	DN	Valtorcitabine
DMXQCBU	HS	Discontinued in Phase 2
DMXQCBU	SN	Epcitabine; Torcitabine; LDC-300; NV-02C; L-2-deoxycytidine; Val-L-dC; Beta-L-2`-deoxycytidine; L-dC prodrug, Idenix/Novartis; L-dC, Idenix/Novartis
DMXQCBU	CP	Idenix Pharmaceuticals
DMXQCBU	DT	Small molecular drug
DMXQCBU	PC	9927346
DMXQCBU	MW	326.35
DMXQCBU	FM	C14H22N4O5
DMXQCBU	IC	InChI=1S/C14H22N4O5/c1-7(2)12(16)13(20)23-8-5-11(22-9(8)6-19)18-4-3-10(15)17-14(18)21/h3-4,7-9,11-12,19H,5-6,16H2,1-2H3,(H2,15,17,21)/t8-,9+,11+,12+/m1/s1
DMXQCBU	CS	CC(C)[C@@H](C(=O)O[C@@H]1C[C@H](O[C@H]1CO)N2C=CC(=NC2=O)N)N
DMXQCBU	IK	VFCYZPOEGWLYRM-QCZKYFFMSA-N
DMXQCBU	IU	[(2S,3R,5S)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] (2S)-2-amino-3-methylbutanoate
DMXQCBU	CA	CAS 380886-95-3
DMXQCBU	DE	Hepatitis virus infection

DMHCOFM	ID	DMHCOFM
DMHCOFM	DN	Vasoflux
DMHCOFM	HS	Discontinued in Phase 2
DMHCOFM	CP	Vascular Therapeutics Inc
DMHCOFM	DE	Myocardial infarction

DMROSHN	ID	DMROSHN
DMROSHN	DN	Velneperit
DMROSHN	HS	Discontinued in Phase 2
DMROSHN	SN	Velneperit; 342577-38-2; S-2367; UNII-09BQ2KJ22J; 09BQ2KJ22J; Velneperit [USAN:INN]; Velneperit (USAN/INN); SCHEMBL2806595; SCHEMBL13204979; SCHEMBL10114559; CHEMBL2016681; SCHEMBL10134095; BCP16623; BDBM50380914; AKOS027338754; ZINC257354192; DB12889; CS-5388; KB-81432; HY-14423; BC282913; D08026; 577V382; S-2367;S2367;S 2367; trans-4-(((1,1-Dimethylethyl)sulfonyl)amino)-N-(5-(trifluoromethyl)pyridin-2-yl)cyclohexanecarboxamide; Cyclohexanecarboxamide, 4-(((1,1-dimethylethyl)sulfonyl)amino)-N-(5-(trifluoromethyl)-2-pyridinyl)-, tr
DMROSHN	CP	Shionogi & Co Ltd
DMROSHN	DT	Small molecular drug
DMROSHN	PC	20629114
DMROSHN	MW	407.5
DMROSHN	FM	C17H24F3N3O3S
DMROSHN	IC	InChI=1S/C17H24F3N3O3S/c1-16(2,3)27(25,26)23-13-7-4-11(5-8-13)15(24)22-14-9-6-12(10-21-14)17(18,19)20/h6,9-11,13,23H,4-5,7-8H2,1-3H3,(H,21,22,24)
DMROSHN	CS	CC(C)(C)S(=O)(=O)NC1CCC(CC1)C(=O)NC2=NC=C(C=C2)C(F)(F)F
DMROSHN	IK	WGEWUYACXPEFPO-UHFFFAOYSA-N
DMROSHN	IU	4-(tert-butylsulfonylamino)-N-[5-(trifluoromethyl)pyridin-2-yl]cyclohexane-1-carboxamide
DMROSHN	CA	CAS 342577-38-2
DMROSHN	DE	Obesity

DMHCLVQ	ID	DMHCLVQ
DMHCLVQ	DN	Vitaxin
DMHCLVQ	HS	Discontinued in Phase 2
DMHCLVQ	DE	Solid tumour/cancer

DMOS6CM	ID	DMOS6CM
DMOS6CM	DN	VLTS-587
DMOS6CM	HS	Discontinued in Phase 2
DMOS6CM	SN	Gene therapy (IL-2, cLipid) iv, Valentis; Gene therapy (interleukin-2, cLipid) iv, Valentis
DMOS6CM	CP	Valentis Inc
DMOS6CM	DE	Lung cancer

DM32N5G	ID	DM32N5G
DM32N5G	DN	VOROZOLE
DM32N5G	HS	Discontinued in Phase 2
DM32N5G	SN	Vorozole; Rivizor; 129731-10-8; R-83842; UNII-1E2S9YXV2A; 1E2S9YXV2A; Vorozol [INN-Spanish]; Vorozolum [INN-Latin]; (+)-Vorozole; CCRIS 7482; Vorozolum; Vorozol; Rivizor (TN); 6-[(S)-(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole; Vorozole (USAN/INN); AC1OCF4T; (S)-VOROZOLE; SCHEMBL4554; Vorozole [USAN:INN:BAN]; CHEMBL224060; DTXSID20156230; (+)-(S)-6-(p-Chloro-alpha-1H-1,2,4-triazol-1-ylbenzyl)-1-methyl-1H-benzotriazole; CHEBI:135387; 1H-Benzotriazole, 6-((4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl)-1-methyl
DM32N5G	DT	Small molecular drug
DM32N5G	PC	6918191
DM32N5G	MW	324.77
DM32N5G	FM	C16H13ClN6
DM32N5G	IC	InChI=1S/C16H13ClN6/c1-22-15-8-12(4-7-14(15)20-21-22)16(23-10-18-9-19-23)11-2-5-13(17)6-3-11/h2-10,16H,1H3/t16-/m0/s1
DM32N5G	CS	CN1C2=C(C=CC(=C2)[C@H](C3=CC=C(C=C3)Cl)N4C=NC=N4)N=N1
DM32N5G	IK	XLMPPFTZALNBFS-INIZCTEOSA-N
DM32N5G	IU	6-[(S)-(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole
DM32N5G	CA	CAS 129731-10-8
DM32N5G	CB	CHEBI:135387

DMFYM61	ID	DMFYM61
DMFYM61	DN	VTP-201227
DMFYM61	HS	Discontinued in Phase 2
DMFYM61	CP	Vitae Pharmaceuticals
DMFYM61	DE	Psoriatic disorder

DMLCTBP	ID	DMLCTBP
DMLCTBP	DN	VTX-2337
DMLCTBP	HS	Discontinued in Phase 2
DMLCTBP	SN	Motolimod; 926927-61-9; VTX-2337; Motolimod (VTX-2337); UNII-WP6PY72ZH3; VTX-378; VTX 2337; WP6PY72ZH3; AK171372; Motolimod [USAN:INN]; Motolimod (USAN/INN); SCHEMBL254984; GTPL9026; CHEMBL3301618; KS-00000SZB; DTXSID10239107; MolPort-039-136-930; EX-A1102; BCP16667; ZINC34946588; s7161; AKOS025289797; SB16930; DB12303; HY-13773; KB-146010; J3.657.311B; D10716; 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
DMLCTBP	CP	VentiRx Pharmaceuticals
DMLCTBP	DT	Small molecular drug
DMLCTBP	PC	16049404
DMLCTBP	MW	458.6
DMLCTBP	FM	C28H34N4O2
DMLCTBP	IC	InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30)
DMLCTBP	CS	CCCN(CCC)C(=O)C1=CC2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4)N=C(C1)N
DMLCTBP	IK	QSPOQCXMGPDIHI-UHFFFAOYSA-N
DMLCTBP	IU	2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
DMLCTBP	CA	CAS 926927-61-9
DMLCTBP	DE	Allergy

DMH4U87	ID	DMH4U87
DMH4U87	DN	VX-366
DMH4U87	HS	Discontinued in Phase 2
DMH4U87	SN	Isobutyramide; Isobutyramide, Vertex
DMH4U87	CP	Vertex Pharmaceuticals Inc
DMH4U87	DE	Constitutional neutropenia

DMPE5XM	ID	DMPE5XM
DMPE5XM	DN	WAY-123641
DMPE5XM	HS	Discontinued in Phase 2
DMPE5XM	CP	Wyeth-Ayerst Pharmaceuticals Inc
DMPE5XM	DE	Asthma

DMLA4DU	ID	DMLA4DU
DMLA4DU	DN	WC-3027
DMLA4DU	HS	Discontinued in Phase 2
DMLA4DU	SN	SEGRA, Warner Chilcott; SEGRA, Warner Chilcott/Schering AG; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott/Schering AG
DMLA4DU	CP	AstraZeneca
DMLA4DU	DE	Chronic obstructive pulmonary disease

DM7VCDZ	ID	DM7VCDZ
DM7VCDZ	DN	WY-47766
DM7VCDZ	HS	Discontinued in Phase 2
DM7VCDZ	SN	OST-766
DM7VCDZ	CP	Wyeth-Ayerst Pharmaceuticals Inc
DM7VCDZ	PC	9882376
DM7VCDZ	MW	287.34
DM7VCDZ	FM	C14H13N3O2S
DM7VCDZ	IC	InChI=1S/C14H13N3O2S/c1-19-11-4-2-3-10(7-11)9-20(18)14-16-12-5-6-15-8-13(12)17-14/h2-8H,9H2,1H3,(H,16,17)
DM7VCDZ	CS	COC1=CC=CC(=C1)CS(=O)C2=NC3=C(N2)C=NC=C3
DM7VCDZ	IK	SWPJMIZLPONDGF-UHFFFAOYSA-N
DM7VCDZ	IU	2-[(3-methoxyphenyl)methylsulfinyl]-3H-imidazo[4,5-c]pyridine
DM7VCDZ	CA	CAS 134217-27-9
DM7VCDZ	DE	Osteoporosis

DMICR39	ID	DMICR39
DMICR39	DN	XL784
DMICR39	HS	Discontinued in Phase 2
DMICR39	CP	Exelixis
DMICR39	DE	Diabetic nephropathy

DMO90RN	ID	DMO90RN
DMO90RN	DN	Y-27152
DMO90RN	HS	Discontinued in Phase 2
DMO90RN	SN	Y-27152; 127408-30-4; N-(Benzyloxy)-N-((3S,4R)-6-cyano-3-hydroxy-2,2-dimethylchroman-4-yl)acetamide; N-[(3S,4R)-6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-(phenylmethoxy)acetamide; NCGC00092304-01; AC1OCF4F; SCHEMBL8864736; CHEMBL1476996; CHEBI:92752; CTK4B5603; MolPort-003-983-713; HMS3268J07; ZINC3789145; Acetamide,N-[(3S,4R)-6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-(phenylmethoxy)-; BN0549; AKOS022180527; AJ-45617; CC-31938; B6940; FT-0643069; C-35545; BRD-K42679050-001-01-3
DMO90RN	CP	Mitsubishi Pharma Corp
DMO90RN	DT	Small molecular drug
DMO90RN	PC	6918184
DMO90RN	MW	366.4
DMO90RN	FM	C21H22N2O4
DMO90RN	IC	InChI=1S/C21H22N2O4/c1-14(24)23(26-13-15-7-5-4-6-8-15)19-17-11-16(12-22)9-10-18(17)27-21(2,3)20(19)25/h4-11,19-20,25H,13H2,1-3H3/t19-,20+/m1/s1
DMO90RN	CS	CC(=O)N([C@H]1[C@@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O)OCC3=CC=CC=C3
DMO90RN	IK	RHFUXPCCELGMFC-UXHICEINSA-N
DMO90RN	IU	N-[(3S,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-N-phenylmethoxyacetamide
DMO90RN	CA	CAS 127408-30-4
DMO90RN	CB	CHEBI:92752
DMO90RN	DE	Angina pectoris

DMHFTD0	ID	DMHFTD0
DMHFTD0	DN	Y-700
DMHFTD0	HS	Discontinued in Phase 2
DMHFTD0	SN	niraxostat; Piraxostat; Y-700; UNII-246FR6022S; CHEMBL169526; 206884-98-2; 1-[3-CYANO-4-(NEOPENTYLOXY)PHENYL]-1H-PYRAZOLE-4-CARBOXYLIC ACID; 246FR6022S; YSH; 1-(3-cyano-4-neopentyloxyphenyl) pyrazole-4-carboxylic acid; 1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]-1h-pyrazole-4-carboxylic acid; Niraxostat [INN]; Y 700; AC1L9MN7; MLS006010327; SCHEMBL440021; ZINC7343; DTXSID70174747; AETHRPHBGJAIBT-UHFFFAOYSA-N; MolPort-005-943-250; BDBM50098068; DB03841; NCGC00263135-01; ACM206884982; SMR004701391; FT-0728443
DMHFTD0	DT	Small molecular drug
DMHFTD0	PC	449035
DMHFTD0	MW	299.32
DMHFTD0	FM	C16H17N3O3
DMHFTD0	IC	InChI=1S/C16H17N3O3/c1-16(2,3)10-22-14-5-4-13(6-11(14)7-17)19-9-12(8-18-19)15(20)21/h4-6,8-9H,10H2,1-3H3,(H,20,21)
DMHFTD0	CS	CC(C)(C)COC1=C(C=C(C=C1)N2C=C(C=N2)C(=O)O)C#N
DMHFTD0	IK	AETHRPHBGJAIBT-UHFFFAOYSA-N
DMHFTD0	IU	1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]pyrazole-4-carboxylic acid
DMHFTD0	CA	CAS 206884-98-2
DMHFTD0	DE	Gout

DML2IXO	ID	DML2IXO
DML2IXO	DN	YM-114
DML2IXO	HS	Discontinued in Phase 2
DML2IXO	SN	KAE-393; (R)-5-(2,3-Dihydro-1H-indol-1-ylcarbonyl)-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride
DML2IXO	DT	Small molecular drug
DML2IXO	PC	132963
DML2IXO	MW	303.78
DML2IXO	FM	C16H18ClN3O
DML2IXO	IC	InChI=1S/C16H17N3O.ClH/c20-16(12-5-6-13-14(9-12)18-10-17-13)19-8-7-11-3-1-2-4-15(11)19;/h1-4,10,12H,5-9H2,(H,17,18);1H/t12-;/m1./s1
DML2IXO	CS	C1CC2=C(C[C@@H]1C(=O)N3CCC4=CC=CC=C43)NC=N2.Cl
DML2IXO	IK	GZXONPGTMHLBKQ-UTONKHPSSA-N
DML2IXO	IU	2,3-dihydroindol-1-yl-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone;hydrochloride
DML2IXO	CA	CAS 153608-99-2
DML2IXO	DE	Nausea

DMIRSLV	ID	DMIRSLV
DMIRSLV	DN	YM-17K
DMIRSLV	HS	Discontinued in Phase 2
DMIRSLV	SN	MC-352
DMIRSLV	CP	Yamanouchi Pharmaceutical Co Ltd
DMIRSLV	DE	Bacterial infection

DMCZIGQ	ID	DMCZIGQ
DMCZIGQ	DN	YM-337
DMCZIGQ	HS	Discontinued in Phase 2
DMCZIGQ	SN	SMART anti-platelet; YM-387; Anti-gpIIb/IIIa (platelet) MAb, Yamanouchi
DMCZIGQ	CP	Yamanouchi Pharmaceutical Co Ltd
DMCZIGQ	DE	Angiogenesis disorder

DM7OHR6	ID	DM7OHR6
DM7OHR6	DN	YM-440
DM7OHR6	HS	Discontinued in Phase 2
DM7OHR6	SN	2,2'-[2(Z)-Butene-1,4-diyl]dioxybis(1,4-phenylene)bis(methylene)bis[1,2,4-oxadiazole-3,5(2H,4H)-dione]
DM7OHR6	PC	9890786
DM7OHR6	MW	468.4
DM7OHR6	FM	C22H20N4O8
DM7OHR6	IC	InChI=1S/C22H20N4O8/c27-19-23-21(29)33-25(19)13-15-3-7-17(8-4-15)31-11-1-2-12-32-18-9-5-16(6-10-18)14-26-20(28)24-22(30)34-26/h1-10H,11-14H2,(H,23,27,29)(H,24,28,30)/b2-1-
DM7OHR6	CS	C1=CC(=CC=C1CN2C(=O)NC(=O)O2)OC/C=C\\COC3=CC=C(C=C3)CN4C(=O)NC(=O)O4
DM7OHR6	IK	LUACLLSCZRRTIH-UPHRSURJSA-N
DM7OHR6	IU	2-[[4-[(Z)-4-[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]but-2-enoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione
DM7OHR6	DE	Type-1 diabetes

DM7WDAG	ID	DM7WDAG
DM7WDAG	DN	YM-511
DM7WDAG	HS	Discontinued in Phase 2
DM7WDAG	SN	YM 511; YM511 (pharmaceutical); 148869-05-0; YM-511; Benzonitrile,4-[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]-; 4-[[(4-BROMOPHENYL)METHYL]-4H-1,2,4-TRIAZOL-4-YLAMINO]BENZONITRILE; YM511; ACMC-20n5jr; SCHEMBL544997; CHEMBL108425; AC1L430I; CTK4C5946; BDBM10016; DTXSID50164121; GGPPBTSXFROGAE-UHFFFAOYSA-N; MolPort-023-276-728; ZINC598425; AKOS024457519; B5405; 4-[N-(4-bromobenzyl)-N-(4-cyanophenyl)amino]-4H-1,2,4-triazole; 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile; Benzonitrile, 4-(((4-bromophenyl
DM7WDAG	DT	Small molecular drug
DM7WDAG	PC	177865
DM7WDAG	MW	354.2
DM7WDAG	FM	C16H12BrN5
DM7WDAG	IC	InChI=1S/C16H12BrN5/c17-15-5-1-14(2-6-15)10-22(21-11-19-20-12-21)16-7-3-13(9-18)4-8-16/h1-8,11-12H,10H2
DM7WDAG	CS	C1=CC(=CC=C1CN(C2=CC=C(C=C2)C#N)N3C=NN=C3)Br
DM7WDAG	IK	GGPPBTSXFROGAE-UHFFFAOYSA-N
DM7WDAG	IU	4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile
DM7WDAG	CA	CAS 148869-05-0
DM7WDAG	DE	Breast cancer

DMDXP3C	ID	DMDXP3C
DMDXP3C	DN	YM-796
DMDXP3C	HS	Discontinued in Phase 2
DMDXP3C	SN	(S)-(-)-2,8-Dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane L-tartrate monohydrate; 132041-81-7
DMDXP3C	DT	Small molecular drug
DMDXP3C	PC	10313386
DMDXP3C	MW	181.27
DMDXP3C	FM	C11H19NO
DMDXP3C	IC	InChI=1S/C11H19NO/c1-9-8-11(13-10(9)2)4-6-12(3)7-5-11/h10H,1,4-8H2,2-3H3/t10-/m1/s1
DMDXP3C	CS	C[C@@H]1C(=C)CC2(O1)CCN(CC2)C
DMDXP3C	IK	HDTOQYUZMCNTBZ-SNVBAGLBSA-N
DMDXP3C	IU	(2R)-2,8-dimethyl-3-methylidene-1-oxa-8-azaspiro[4.5]decane
DMDXP3C	DE	Cognitive impairment

DMWRT4L	ID	DMWRT4L
DMWRT4L	DN	YM-90K
DMWRT4L	HS	Discontinued in Phase 2
DMWRT4L	SN	154164-30-4; YM 90K hydrochloride; YM 90K; YM-90K; UAEXCLWI0Q; YM-90K hydrochloride; UNII-UAEXCLWI0Q; 6-(1H-Imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione; 2,3-Quinoxalinedione, 1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-, monohydrochloride; 1,4-Dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride; 6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione hydrochloride; YM-900; YM90K hydrochloride; AC1NUOLT; YM90KHYDROCHLORIDE; YM 90K HCl; YM-90K HCl; CHEMBL3400490; C11H7N5O4; EX-A113; DTXSID00165547
DMWRT4L	DT	Small molecular drug
DMWRT4L	PC	5486547
DMWRT4L	MW	309.66
DMWRT4L	FM	C11H8ClN5O4
DMWRT4L	IC	InChI=1S/C11H7N5O4.ClH/c17-10-11(18)14-7-4-9(16(19)20)8(3-6(7)13-10)15-2-1-12-5-15;/h1-5H,(H,13,17)(H,14,18);1H
DMWRT4L	CS	C1=CN(C=N1)C2=C(C=C3C(=C2)NC(=O)C(=O)N3)[N+](=O)[O-].Cl
DMWRT4L	IK	UMLFDVOHVJPDIZ-UHFFFAOYSA-N
DMWRT4L	IU	6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione;hydrochloride
DMWRT4L	CA	CAS 154164-30-4
DMWRT4L	DE	Convulsion

DM845NM	ID	DM845NM
DM845NM	DN	YM-992
DM845NM	HS	Discontinued in Phase 2
DM845NM	SN	Lubazodone HCl; Lubazodone hydrochloride; Lubazodone hydrochloride [USAN]; YM992; Lubazodone (TN); Lubazodone hydrochloride (USAN); SM-50C; YM-35992; (2S)-2-[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxymethyl]morpholine hydrochloride; (S)-2-(((7-fluoro-4-indanyl)oxy)methyl)morpholine hydrochloride
DM845NM	CP	Yamanouchi
DM845NM	TC	Psychiatric
DM845NM	DT	Small molecular drug
DM845NM	PC	157918
DM845NM	MW	287.76
DM845NM	FM	C14H19ClFNO2
DM845NM	IC	InChI=1S/C14H18FNO2.ClH/c15-13-4-5-14(12-3-1-2-11(12)13)18-9-10-8-16-6-7-17-10;/h4-5,10,16H,1-3,6-9H2;1H/t10-;/m0./s1
DM845NM	CS	C1CC2=C(C=CC(=C2C1)F)OC[C@@H]3CNCCO3.Cl
DM845NM	IK	HWEMEKZYQCJVEZ-PPHPATTJSA-N
DM845NM	IU	(2S)-2-[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxymethyl]morpholine;hydrochloride
DM845NM	CA	CAS 161178-10-5
DM845NM	DE	Depression

DM2438J	ID	DM2438J
DM2438J	DN	Z-335
DM2438J	HS	Discontinued in Phase 2
DM2438J	SN	2-[2-(4-Chlorophenylsulfonamidomethyl)indan-5-yl]acetic acid sodium salt
DM2438J	DT	Small molecular drug
DM2438J	PC	23669776
DM2438J	MW	401.8
DM2438J	FM	C18H17ClNNaO4S
DM2438J	IC	InChI=1S/C18H18ClNO4S.Na/c19-16-3-5-17(6-4-16)25(23,24)20-11-13-8-14-2-1-12(10-18(21)22)7-15(14)9-13;/h1-7,13,20H,8-11H2,(H,21,22);/q;+1/p-1
DM2438J	CS	C1C(CC2=C1C=CC(=C2)CC(=O)[O-])CNS(=O)(=O)C3=CC=C(C=C3)Cl.[Na+]
DM2438J	IK	UEPBEZPJELQKJV-UHFFFAOYSA-M
DM2438J	IU	sodium;2-[2-[[(4-chlorophenyl)sulfonylamino]methyl]-2,3-dihydro-1H-inden-5-yl]acetate
DM2438J	CA	CAS 146731-14-8
DM2438J	DE	Thrombosis

DMBSHJ6	ID	DMBSHJ6
DMBSHJ6	DN	Zabiciprilat
DMBSHJ6	HS	Discontinued in Phase 2
DMBSHJ6	SN	Zabicipril; S-10211; S-9650
DMBSHJ6	CP	Servier
DMBSHJ6	DT	Small molecular drug
DMBSHJ6	PC	65680
DMBSHJ6	MW	388.5
DMBSHJ6	FM	C21H28N2O5
DMBSHJ6	IC	InChI=1S/C21H28N2O5/c1-13(22-17(20(25)26)12-7-14-5-3-2-4-6-14)19(24)23-16-10-8-15(9-11-16)18(23)21(27)28/h2-6,13,15-18,22H,7-12H2,1H3,(H,25,26)(H,27,28)/t13-,15?,16?,17-,18-/m0/s1
DMBSHJ6	CS	C[C@@H](C(=O)N1[C@@H](C2CCC1CC2)C(=O)O)N[C@@H](CCC3=CC=CC=C3)C(=O)O
DMBSHJ6	IK	HBZJVGFXZTUXNI-XMQLQKOFSA-N
DMBSHJ6	IU	(3S)-2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]-2-azabicyclo[2.2.2]octane-3-carboxylic acid
DMBSHJ6	CA	CAS 90103-92-7
DMBSHJ6	DE	Hypertension

DM9F650	ID	DM9F650
DM9F650	DN	ZANKIREN
DM9F650	HS	Discontinued in Phase 2
DM9F650	SN	Zankiren; UNII-I36B16A34Q; CHEMBL113841; I36B16A34Q; A-72517; Zankiren [INN]; 138742-43-5; A 72517; AC1MJ6K5; SCHEMBL180700; ZINC27084753; BDBM50046798; (S)-N-((1S,2R,3S)-1-(Cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-((alphaS)-alpha-(((4-methyl-1-piperazinyl)sulfonyl)methyl)hydrocinnamamido)-4-thiazolepropionamide; (1S-(1R*(R*(R*)),2S*,3R*))-N-(1-(Cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-((2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-4-thiazolepropanamide
DM9F650	DT	Small molecular drug
DM9F650	PC	3086652
DM9F650	MW	706
DM9F650	FM	C35H55N5O6S2
DM9F650	IC	InChI=1S/C35H55N5O6S2/c1-25(2)18-32(41)33(42)30(20-27-12-8-5-9-13-27)37-35(44)31(21-29-22-47-24-36-29)38-34(43)28(19-26-10-6-4-7-11-26)23-48(45,46)40-16-14-39(3)15-17-40/h4,6-7,10-11,22,24-25,27-28,30-33,41-42H,5,8-9,12-21,23H2,1-3H3,(H,37,44)(H,38,43)/t28-,30+,31+,32+,33-/m1/s1
DM9F650	CS	CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC2=CSC=N2)NC(=O)[C@H](CC3=CC=CC=C3)CS(=O)(=O)N4CCN(CC4)C)O)O
DM9F650	IK	YFDSDRDMDDGDFC-HOQQKOLYSA-N
DM9F650	IU	(2S)-2-benzyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]-3-(4-methylpiperazin-1-yl)sulfonylpropanamide
DM9F650	CA	CAS 138742-43-5
DM9F650	DE	Hypertension

DMS95DX	ID	DMS95DX
DMS95DX	DN	ZD-0947
DMS95DX	HS	Discontinued in Phase 2
DMS95DX	SN	AZD-0947
DMS95DX	CP	AstraZeneca plc
DMS95DX	DT	Small molecular drug
DMS95DX	PC	9818432
DMS95DX	MW	318.29
DMS95DX	FM	C17H13F3N2O
DMS95DX	IC	InChI=1S/C17H13F3N2O/c18-17(19,20)15-8-12(11-4-1-3-10(7-11)9-21)16-13(22-15)5-2-6-14(16)23/h1,3-4,7-8,12,22H,2,5-6H2/t12-/m0/s1
DMS95DX	CS	C1CC2=C([C@@H](C=C(N2)C(F)(F)F)C3=CC=CC(=C3)C#N)C(=O)C1
DMS95DX	IK	RUVMMEREJMHLOS-LBPRGKRZSA-N
DMS95DX	IU	3-[(4S)-5-oxo-2-(trifluoromethyl)-4,6,7,8-tetrahydro-1H-quinolin-4-yl]benzonitrile
DMS95DX	CA	CAS 172649-40-0
DMS95DX	DE	Overactive bladder

DMVFCX7	ID	DMVFCX7
DMVFCX7	DN	ZD-2138
DMVFCX7	HS	Discontinued in Phase 2
DMVFCX7	SN	Ici D2138; 140841-32-3; ZD-2138; UNII-B6G6OX1ZH5; B6G6OX1ZH5; CHEMBL20403; 2(1H)-Quinolinone,6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-; Ici-D2138; 6-((3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinolin-2(1H)-one; ZD 2138; ACMC-20mzth; AC1L30RD; zd2138; 6-((3-Fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinol-2-one; SCHEMBL1083603; CTK4C2357; DTXSID90161477; BDBM50000829; AKOS025404954; ACN-048395
DMVFCX7	DT	Small molecular drug
DMVFCX7	PC	132306
DMVFCX7	MW	397.4
DMVFCX7	FM	C23H24FNO4
DMVFCX7	IC	InChI=1S/C23H24FNO4/c1-25-21-5-3-16(11-17(21)4-6-22(25)26)15-29-20-13-18(12-19(24)14-20)23(27-2)7-9-28-10-8-23/h3-6,11-14H,7-10,15H2,1-2H3
DMVFCX7	CS	CN1C2=C(C=CC1=O)C=C(C=C2)COC3=CC(=CC(=C3)C4(CCOCC4)OC)F
DMVFCX7	IK	SLZBEPLWGGRZAY-UHFFFAOYSA-N
DMVFCX7	IU	6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]-1-methylquinolin-2-one
DMVFCX7	CA	CAS 140841-32-3
DMVFCX7	DE	Asthma

DMLFNMB	ID	DMLFNMB
DMLFNMB	DN	ZD-2486
DMLFNMB	HS	Discontinued in Phase 2
DMLFNMB	SN	ZD-2486; CHEMBL118090; SCHEMBL5144316; BDBM50092099; 3-Methyl-4-[4-(4-pyridin-4-yl-piperazin-1-yl)-phenoxy]-butyric acid (ZD 2486)
DMLFNMB	DT	Small molecular drug
DMLFNMB	PC	9906649
DMLFNMB	MW	355.4
DMLFNMB	FM	C20H25N3O3
DMLFNMB	IC	InChI=1S/C20H25N3O3/c1-16(14-20(24)25)15-26-19-4-2-17(3-5-19)22-10-12-23(13-11-22)18-6-8-21-9-7-18/h2-9,16H,10-15H2,1H3,(H,24,25)/t16-/m1/s1
DMLFNMB	CS	C[C@H](CC(=O)O)COC1=CC=C(C=C1)N2CCN(CC2)C3=CC=NC=C3
DMLFNMB	IK	RVVTUJLHUHZYOD-MRXNPFEDSA-N
DMLFNMB	IU	(3R)-3-methyl-4-[4-(4-pyridin-4-ylpiperazin-1-yl)phenoxy]butanoic acid
DMLFNMB	DE	Angina pectoris

DM5UCHW	ID	DM5UCHW
DM5UCHW	DN	ZD-4953
DM5UCHW	HS	Discontinued in Phase 2
DM5UCHW	CP	AstraZeneca plc
DM5UCHW	DE	Pain

DMVBL25	ID	DMVBL25
DMVBL25	DN	ZD-6169
DMVBL25	HS	Discontinued in Phase 2
DMVBL25	SN	ZD-6169; ZD 6169; UNII-H6UIO70F5E; H6UIO70F5E; Zeneca ZD 6169; LVEDGSIMCSQNNX-INIZCTEOSA-N; ZD6169; 147696-46-6; CHEMBL18861; SCHEMBL4261046; BDBM86249; AC1L4306; ZINC1535218; LS-119034; (2S)-N-(4-benzoylphenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide
DMVBL25	CP	AstraZeneca plc
DMVBL25	DT	Small molecular drug
DMVBL25	PC	177852
DMVBL25	MW	337.29
DMVBL25	FM	C17H14F3NO3
DMVBL25	IC	InChI=1S/C17H14F3NO3/c1-16(24,17(18,19)20)15(23)21-13-9-7-12(8-10-13)14(22)11-5-3-2-4-6-11/h2-10,24H,1H3,(H,21,23)/t16-/m0/s1
DMVBL25	CS	C[C@](C(=O)NC1=CC=C(C=C1)C(=O)C2=CC=CC=C2)(C(F)(F)F)O
DMVBL25	IK	LVEDGSIMCSQNNX-INIZCTEOSA-N
DMVBL25	IU	(2S)-N-(4-benzoylphenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide
DMVBL25	CA	CAS 147696-46-6
DMVBL25	DE	Urinary incontinence

DM46JIR	ID	DM46JIR
DM46JIR	DN	ZD6416
DM46JIR	HS	Discontinued in Phase 2
DM46JIR	DE	Pain

DMBSXPJ	ID	DMBSXPJ
DMBSXPJ	DN	ZD-8321
DMBSXPJ	HS	Discontinued in Phase 2
DMBSXPJ	PC	9910174
DMBSXPJ	MW	423.4
DMBSXPJ	FM	C18H28F3N3O5
DMBSXPJ	IC	InChI=1S/C18H28F3N3O5/c1-9(2)12(14(25)18(19,20)21)22-15(26)11-7-6-8-24(11)16(27)13(10(3)4)23-17(28)29-5/h9-13H,6-8H2,1-5H3,(H,22,26)(H,23,28)/t11-,12-,13-/m0/s1
DMBSXPJ	CS	CC(C)[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC
DMBSXPJ	IK	ZYLBZJKJNAYAFU-AVGNSLFASA-N
DMBSXPJ	IU	methyl N-[(2S)-3-methyl-1-oxo-1-[(2S)-2-[[(3S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]carbamoyl]pyrrolidin-1-yl]butan-2-yl]carbamate
DMBSXPJ	CA	CAS 182073-77-4
DMBSXPJ	DE	Acute lung injury

DM1QXPE	ID	DM1QXPE
DM1QXPE	DN	ZELANDOPAM HYDROCHLORIDE
DM1QXPE	HS	Discontinued in Phase 2
DM1QXPE	SN	MYD-37; YM-435; Zelandopam hydrochloride; (-)-(S)-4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol hydrochloride hydrate; (-)-(S)-4-(3,4-Dihydroxyphenyl)-7,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride hydrate
DM1QXPE	DT	Small molecular drug
DM1QXPE	PC	3078104
DM1QXPE	MW	309.74
DM1QXPE	FM	C15H16ClNO4
DM1QXPE	IC	InChI=1S/C15H15NO4.ClH/c17-12-3-1-8(5-14(12)19)10-6-16-7-11-9(10)2-4-13(18)15(11)20;/h1-5,10,16-20H,6-7H2;1H/t10-;/m0./s1
DM1QXPE	CS	C1[C@H](C2=C(CN1)C(=C(C=C2)O)O)C3=CC(=C(C=C3)O)O.Cl
DM1QXPE	IK	NHCWZEQEFHNLBQ-PPHPATTJSA-N
DM1QXPE	IU	(4S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-7,8-diol;hydrochloride
DM1QXPE	CA	CAS 138086-00-7
DM1QXPE	DE	Hypertension

DMC6H4Y	ID	DMC6H4Y
DMC6H4Y	DN	ZIFROSILONE
DMC6H4Y	HS	Discontinued in Phase 2
DMC6H4Y	SN	MDL-73745; Zifrosilone < Rec INN; 2,2,2-Trifluoro-1-[3-(trimethylsilyl)phenyl]ethanone
DMC6H4Y	DT	Small molecular drug
DMC6H4Y	PC	60811
DMC6H4Y	MW	246.3
DMC6H4Y	FM	C11H13F3OSi
DMC6H4Y	IC	InChI=1S/C11H13F3OSi/c1-16(2,3)9-6-4-5-8(7-9)10(15)11(12,13)14/h4-7H,1-3H3
DMC6H4Y	CS	C[Si](C)(C)C1=CC=CC(=C1)C(=O)C(F)(F)F
DMC6H4Y	IK	GAPOASFZXBWUGS-UHFFFAOYSA-N
DMC6H4Y	IU	2,2,2-trifluoro-1-(3-trimethylsilylphenyl)ethanone
DMC6H4Y	CA	CAS 132236-18-1
DMC6H4Y	DE	Cognitive impairment

DM3IRES	ID	DM3IRES
DM3IRES	DN	Zilascorb (2H)
DM3IRES	HS	Discontinued in Phase 2
DM3IRES	SN	Zoxxoz
DM3IRES	CP	Pronova BioPharma ASA
DM3IRES	DT	Small molecular drug
DM3IRES	PC	54679297
DM3IRES	MW	265.24
DM3IRES	FM	C13H12O6
DM3IRES	IC	InChI=1S/C13H12O6/c14-9-10(15)12(16)19-11(9)8-6-17-13(18-8)7-4-2-1-3-5-7/h1-5,8,11,13-15H,6H2/t8-,11+,13?/m0/s1/i13D
DM3IRES	CS	[2H]C1(OC[C@H](O1)[C@@H]2C(=C(C(=O)O2)O)O)C3=CC=CC=C3
DM3IRES	IK	SWTGJCNCBUCXSS-GUFVNPKRSA-N
DM3IRES	IU	(2R)-2-[(4S)-2-deuterio-2-phenyl-1,3-dioxolan-4-yl]-3,4-dihydroxy-2H-furan-5-one
DM3IRES	CA	CAS 122431-96-3
DM3IRES	DE	Solid tumour/cancer

DM9FQI0	ID	DM9FQI0
DM9FQI0	DN	Zolasartan
DM9FQI0	HS	Discontinued in Phase 2
DM9FQI0	SN	GR-117289
DM9FQI0	CP	Glaxo Wellcome plc
DM9FQI0	DT	Small molecular drug
DM9FQI0	PC	72168
DM9FQI0	MW	555.8
DM9FQI0	FM	C24H20BrClN6O3
DM9FQI0	IC	InChI=1S/C24H20BrClN6O3/c1-2-3-8-18-27-22(26)20(24(33)34)32(18)12-13-9-10-17-16(11-13)19(25)21(35-17)14-6-4-5-7-15(14)23-28-30-31-29-23/h4-7,9-11H,2-3,8,12H2,1H3,(H,33,34)(H,28,29,30,31)
DM9FQI0	CS	CCCCC1=NC(=C(N1CC2=CC3=C(C=C2)OC(=C3Br)C4=CC=CC=C4C5=NNN=N5)C(=O)O)Cl
DM9FQI0	IK	FIKYECRHLXONOX-UHFFFAOYSA-N
DM9FQI0	IU	3-[[3-bromo-2-[2-(2H-tetrazol-5-yl)phenyl]-1-benzofuran-5-yl]methyl]-2-butyl-5-chloroimidazole-4-carboxylic acid
DM9FQI0	CA	CAS 145781-32-4
DM9FQI0	CB	CHEBI:149761
DM9FQI0	DE	Hypotension

DMWOT92	ID	DMWOT92
DMWOT92	DN	ZOPOLRESTAT
DMWOT92	HS	Discontinued in Phase 2
DMWOT92	SN	ZOPOLRESTAT; 110703-94-1; Xedia; Alond; CP-73850; Zopolrestatum [INN-Latin]; UNII-1PV3S9WP3D; C19H12F3N3O3S; CP 73850; 1PV3S9WP3D; CHEMBL10372; 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid; 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid; 2-[4-oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]phthalazin-1-yl]acetic acid; 3,4-Dihydro-4-oxo-3-((5-(trifluoromethyl)-2-benzothiazolyl)methyl)-1-phthalazineacetic acid; Zopolrestatum
DMWOT92	DT	Small molecular drug
DMWOT92	PC	1613
DMWOT92	MW	419.4
DMWOT92	FM	C19H12F3N3O3S
DMWOT92	IC	InChI=1S/C19H12F3N3O3S/c20-19(21,22)10-5-6-15-14(7-10)23-16(29-15)9-25-18(28)12-4-2-1-3-11(12)13(24-25)8-17(26)27/h1-7H,8-9H2,(H,26,27)
DMWOT92	CS	C1=CC=C2C(=C1)C(=NN(C2=O)CC3=NC4=C(S3)C=CC(=C4)C(F)(F)F)CC(=O)O
DMWOT92	IK	BCSVCWVQNOXFGL-UHFFFAOYSA-N
DMWOT92	IU	2-[4-oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]phthalazin-1-yl]acetic acid
DMWOT92	CA	CAS 110703-94-1
DMWOT92	DE	Diabetic complication

DMB8XJM	ID	DMB8XJM
DMB8XJM	DN	AD-121
DMB8XJM	HS	Discontinued in Phase 1/2
DMB8XJM	SN	PW-9101; Rheumatoid arthritis therapeutic (oral controlled release, Syncrodose), Arakis/Penwest; Rheumatoid arthritis therapeutic (oral controlled release, TIMERx), Arakis/Penwest
DMB8XJM	CP	Sosei R&D Ltd
DMB8XJM	DE	Rheumatoid arthritis

DMR8XEN	ID	DMR8XEN
DMR8XEN	DN	AME-527
DMR8XEN	HS	Discontinued in Phase 1/2
DMR8XEN	CP	Applied Molecular Evoltion
DMR8XEN	DT	Antibody
DMR8XEN	DE	Rheumatoid arthritis

DM3P84V	ID	DM3P84V
DM3P84V	DN	AVE-5883
DM3P84V	HS	Discontinued in Phase 1/2
DM3P84V	CP	Aventis SA
DM3P84V	DE	Asthma

DMGEDAY	ID	DMGEDAY
DMGEDAY	DN	AVI-4065
DMGEDAY	HS	Discontinued in Phase 1/2
DMGEDAY	CP	AVI BioPharma
DMGEDAY	TC	Antisense
DMGEDAY	DT	Antisense drug
DMGEDAY	DE	Hepatitis virus infection

DM7L8SG	ID	DM7L8SG
DM7L8SG	DN	AZD8055
DM7L8SG	HS	Discontinued in Phase 1/2
DM7L8SG	SN	AZD8055; 1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
DM7L8SG	CP	AstraZeneca
DM7L8SG	DT	Small molecular drug
DM7L8SG	PC	25262965
DM7L8SG	MW	465.5
DM7L8SG	FM	C25H31N5O4
DM7L8SG	IC	InChI=1S/C25H31N5O4/c1-16-14-33-10-8-29(16)24-20-5-6-21(18-4-7-22(32-3)19(12-18)13-31)26-23(20)27-25(28-24)30-9-11-34-15-17(30)2/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3/t16-,17-/m0/s1
DM7L8SG	CS	C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOC[C@@H]5C
DM7L8SG	IK	KVLFRAWTRWDEDF-IRXDYDNUSA-N
DM7L8SG	IU	[5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol
DM7L8SG	CA	CAS 1009298-09-2
DM7L8SG	CB	CHEBI:91329
DM7L8SG	DE	Solid tumour/cancer

DMJTB4E	ID	DMJTB4E
DMJTB4E	DN	CDP-484
DMJTB4E	HS	Discontinued in Phase 1/2
DMJTB4E	SN	Anti-IL-1 beta FAb-PEG, Celltech
DMJTB4E	CP	UCB Celltech
DMJTB4E	DE	Immune System disease

DMMZ79C	ID	DMMZ79C
DMMZ79C	DN	CER-227185
DMMZ79C	HS	Discontinued in Phase 1/2
DMMZ79C	SN	TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis
DMMZ79C	CP	Cerenis
DMMZ79C	DE	Acute myeloid leukaemia

DMH40I3	ID	DMH40I3
DMH40I3	DN	CM-GLP-1
DMH40I3	HS	Discontinued in Phase 1/2
DMH40I3	SN	CellBead Neuro; GLP-1-expressing stem cell therapy (drug eluting bead, neurological trauma/neurodegeneration); CM-1-expressing stem cell therapy (drug eluting bead, neurological trauma/neurodegeneration), CellMed; GLP-1-expressing stem cell therapy (drug eluting bead, neurological trauma/neurodegeneration), CellMed
DMH40I3	CP	CellMed AG
DMH40I3	DE	Brain injury

DMKFIBH	ID	DMKFIBH
DMKFIBH	DN	CYT-007-TNFQb
DMKFIBH	HS	Discontinued in Phase 1/2
DMKFIBH	CP	Cytos Biotechnology
DMKFIBH	DE	Allergic rhinitis

DMCWRYS	ID	DMCWRYS
DMCWRYS	DN	CYT-009-GhrQb
DMCWRYS	HS	Discontinued in Phase 1/2
DMCWRYS	CP	Cytos Biotechnology
DMCWRYS	DT	Small molecular drug
DMCWRYS	PC	9963889
DMCWRYS	MW	1410.9
DMCWRYS	FM	C42H59N14O31P5
DMCWRYS	IC	InChI=1S/C21H30N7O17P3.C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32;22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35);1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t2*10-,11-,13-,14-,15-,16-,20-,21-/m11/s1
DMCWRYS	CS	C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O.C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O
DMCWRYS	IK	HDXXPHUBUBEPGJ-JJVDBIKMSA-N
DMCWRYS	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate;[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMCWRYS	DE	Obesity

DM17GMN	ID	DM17GMN
DM17GMN	DN	EG-011
DM17GMN	HS	Discontinued in Phase 1/2
DM17GMN	SN	Ad-VEGF D; Trinam-variants (refractory angina), Ark Therpeutics Group; Adenoviral short-form VEGF D gene therapy (angina/peripheral vascular disease), Ark Therapeutics; Short form VEGF-D gene therapy (refractory angina/peripheral vascular disease), Ark Therapeutics Group
DM17GMN	CP	Ark Therapeutics Group plc
DM17GMN	DE	Angina pectoris

DM7JMVR	ID	DM7JMVR
DM7JMVR	DN	EG-016
DM7JMVR	HS	Discontinued in Phase 1/2
DM7JMVR	CP	Ark Therapeutics Group plc
DM7JMVR	DE	Peripheral vascular disease

DMB35UN	ID	DMB35UN
DMB35UN	DN	FGF-21
DMB35UN	HS	Discontinued in Phase 1/2
DMB35UN	SN	Fibroblast growth factor 21, Lilly; LP-10152; FGF-21, Lilly
DMB35UN	CP	Eli Lilly & Co
DMB35UN	DE	Type-2 diabetes

DMYR7LO	ID	DMYR7LO
DMYR7LO	DN	GPG
DMYR7LO	HS	Discontinued in Phase 1/2
DMYR7LO	SN	AlfaHGA
DMYR7LO	CP	Tripep
DMYR7LO	DT	Small molecular drug
DMYR7LO	PC	145459100
DMYR7LO	MW	624.5
DMYR7LO	FM	C22H29N10O10P
DMYR7LO	IC	InChI=1S/C22H29N10O10P/c23-21-27-17-11(19(37)29-21)25-5-31(17)9-2-8(13(34)14(9)35)4-41-43(39,40)42-16-7(3-33)1-10(15(16)36)32-6-26-12-18(32)28-22(24)30-20(12)38/h5-10,13-16,33-36H,1-4H2,(H,39,40)(H3,23,27,29,37)(H3,24,28,30,38)/t7-,8-,9-,10-,13-,14+,15+,16-/m1/s1
DMYR7LO	CS	C1[C@@H]([C@H]([C@H]([C@@H]1N2C=NC3=C2N=C(NC3=O)N)O)OP(=O)(O)OC[C@H]4C[C@H]([C@@H]([C@@H]4O)O)N5C=NC6=C5N=C(NC6=O)N)CO
DMYR7LO	IK	WGYAYVXBDYHRBW-QPVXRGBGSA-N
DMYR7LO	IU	[(1R,2R,3S,4R)-4-(2-amino-6-oxo-1H-purin-9-yl)-2,3-dihydroxycyclopentyl]methyl [(1R,2S,3R,5R)-3-(2-amino-6-oxo-1H-purin-9-yl)-2-hydroxy-5-(hydroxymethyl)cyclopentyl] hydrogen phosphate
DMYR7LO	CB	CHEBI:165826
DMYR7LO	DE	Human immunodeficiency virus infection

DM7R126	ID	DM7R126
DM7R126	DN	GS-9005
DM7R126	HS	Discontinued in Phase 1/2
DM7R126	SN	GS-224338; GS-4338
DM7R126	CP	Gilead Sciences Inc
DM7R126	PC	6539952
DM7R126	MW	482.6
DM7R126	FM	C29H34N6O
DM7R126	IC	InChI=1S/C29H34N6O/c1-33-15-17-34(18-16-33)22-9-11-23(12-10-22)35-19-26(27-28(30)31-20-32-29(27)35)21-7-13-25(14-8-21)36-24-5-3-2-4-6-24/h2-8,13-14,19-20,22-23H,9-12,15-18H2,1H3,(H2,30,31,32)
DM7R126	CS	CN1CCN(CC1)C2CCC(CC2)N3C=C(C4=C(N=CN=C43)N)C5=CC=C(C=C5)OC6=CC=CC=C6
DM7R126	IK	FDVSOQRNTAPCHB-UHFFFAOYSA-N
DM7R126	IU	7-[4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine
DM7R126	DE	Human immunodeficiency virus infection

DMXB4T9	ID	DMXB4T9
DMXB4T9	DN	GS-9132
DMXB4T9	HS	Discontinued in Phase 1/2
DMXB4T9	SN	ACH-806; HCV replication inhibitors, Achillion/Gilead Sciences; Hepatitis C virus replication inhibitors, Achillion/Gilead
DMXB4T9	CP	Achillion Pharmaceuticals Inc
DMXB4T9	DT	Small molecular drug
DMXB4T9	PC	11640186
DMXB4T9	MW	411.4
DMXB4T9	FM	C19H20F3N3O2S
DMXB4T9	IC	InChI=1S/C19H20F3N3O2S/c1-2-3-4-10-27-16-8-7-14(11-15(16)19(20,21)22)24-18(28)25-17(26)13-6-5-9-23-12-13/h5-9,11-12H,2-4,10H2,1H3,(H2,24,25,26,28)
DMXB4T9	CS	CCCCCOC1=C(C=C(C=C1)NC(=S)NC(=O)C2=CN=CC=C2)C(F)(F)F
DMXB4T9	IK	WJSGOXONRXFGRY-UHFFFAOYSA-N
DMXB4T9	IU	N-[[4-pentoxy-3-(trifluoromethyl)phenyl]carbamothioyl]pyridine-3-carboxamide
DMXB4T9	CA	CAS 870142-71-5
DMXB4T9	DE	Hepatitis C virus infection

DM9AOJT	ID	DM9AOJT
DM9AOJT	DN	HuM-195-Bi-213
DM9AOJT	HS	Discontinued in Phase 1/2
DM9AOJT	SN	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195
DM9AOJT	CP	PDL BioPharma Inc
DM9AOJT	DE	Acute myeloid leukaemia

DMAYLS3	ID	DMAYLS3
DMAYLS3	DN	IDX-320
DMAYLS3	HS	Discontinued in Phase 1/2
DMAYLS3	SN	Hepatitis C virus NS3/4A protease inhibitor (oral/tablet formulation), Idenix Pharmaceuticals; Hepatitis C virus replication inhibitor (oral/tablet formulation, HCV infection), Idenix Pharmaceuticals
DMAYLS3	CP	Idenix Pharmaceuticals Inc
DMAYLS3	DT	Small molecular drug
DMAYLS3	PC	71768520
DMAYLS3	MW	804.9
DMAYLS3	FM	C37H43F3N6O7S2
DMAYLS3	IC	InChI=1S/C37H43F3N6O7S2/c1-21-27(52-4)11-10-24-28(18-25(41-30(21)24)32-42-29(20-54-32)37(38,39)40)53-23-12-16-46-26(17-23)31(47)43-36(33(48)44-55(50,51)35(2)13-14-35)19-22(36)9-7-5-6-8-15-45(3)34(46)49/h7,9-11,18,20,22-23,26H,5-6,8,12-17,19H2,1-4H3,(H,43,47)(H,44,48)/b9-7+/t22-,23+,26+,36-/m1/s1
DMAYLS3	CS	CC1=C(C=CC2=C1N=C(C=C2O[C@H]3CCN4[C@@H](C3)C(=O)N[C@@]5(C[C@H]5/C=C/CCCCN(C4=O)C)C(=O)NS(=O)(=O)C6(CC6)C)C7=NC(=CS7)C(F)(F)F)OC
DMAYLS3	IK	YEPBUHWNLNKZBW-FDVAVYTKSA-N
DMAYLS3	IU	(1S,4R,6S,7E,18S)-18-[7-methoxy-8-methyl-2-[4-(trifluoromethyl)-1,3-thiazol-2-yl]quinolin-4-yl]oxy-13-methyl-N-(1-methylcyclopropyl)sulfonyl-2,14-dioxo-3,13,15-triazatricyclo[13.4.0.04,6]nonadec-7-ene-4-carboxamide
DMAYLS3	CA	CAS 1251165-81-7
DMAYLS3	DE	Hepatitis C virus infection

DMEF9JW	ID	DMEF9JW
DMEF9JW	DN	IM0-8400
DMEF9JW	HS	Discontinued in Phase 1/2
DMEF9JW	CP	Idera pharmaceuticals
DMEF9JW	DE	Diffuse large B-cell lymphoma

DMMJC4Q	ID	DMMJC4Q
DMMJC4Q	DN	KSB-303
DMMJC4Q	HS	Discontinued in Phase 1/2
DMMJC4Q	SN	YMB-1003 Mab
DMMJC4Q	CP	YM Biosciences
DMMJC4Q	DT	Antibody
DMMJC4Q	DE	Colorectal cancer

DM7QGSX	ID	DM7QGSX
DM7QGSX	DN	KW-2450
DM7QGSX	HS	Discontinued in Phase 1/2
DM7QGSX	CP	Kyowa Hakko Kirin Pharma
DM7QGSX	PC	56847547
DM7QGSX	MW	687.8
DM7QGSX	FM	C35H37N5O6S2
DM7QGSX	IC	InChI=1S/C28H29N5O3S.C7H8O3S/c1-19-10-15-37-27(19)28(36)29-25-16-20(17-32-11-13-33(14-12-32)26(35)18-34)6-7-21(25)8-9-24-22-4-2-3-5-23(22)30-31-24;1-6-2-4-7(5-3-6)11(8,9)10/h2-10,15-16,34H,11-14,17-18H2,1H3,(H,29,36)(H,30,31);2-5H,1H3,(H,8,9,10)/b9-8+;
DM7QGSX	CS	CC1=CC=C(C=C1)S(=O)(=O)O.CC1=C(SC=C1)C(=O)NC2=C(C=CC(=C2)CN3CCN(CC3)C(=O)CO)/C=C/C4=NNC5=CC=CC=C54
DM7QGSX	IK	SIJKXSMUXNJNQM-HRNDJLQDSA-N
DM7QGSX	IU	N-[5-[[4-(2-hydroxyacetyl)piperazin-1-yl]methyl]-2-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-3-methylthiophene-2-carboxamide;4-methylbenzenesulfonic acid
DM7QGSX	CA	CAS 1360433-93-7
DM7QGSX	DE	Breast cancer

DMXB20Y	ID	DMXB20Y
DMXB20Y	DN	MDX-214
DMXB20Y	HS	Discontinued in Phase 1/2
DMXB20Y	SN	CD89 monoclonal antibody (cancer, autoimmune disease), Medarex
DMXB20Y	CP	Medarex Inc
DMXB20Y	DT	Antibody
DMXB20Y	DE	Autoimmune diabetes

DMNXCFZ	ID	DMNXCFZ
DMNXCFZ	DN	NCX 950
DMNXCFZ	HS	Discontinued in Phase 1/2
DMNXCFZ	CP	NicOx SA
DMNXCFZ	DE	Asthma

DMO34NQ	ID	DMO34NQ
DMO34NQ	DN	PD-151832
DMO34NQ	HS	Discontinued in Phase 1/2
DMO34NQ	SN	PD-142505 (racemate); (-)-(R)-(Z)-3-[3-(3-Methoxyphenyl)-2-propynyloxyimino]-1-azabicyclo[2.2.1]heptane
DMO34NQ	DT	Small molecular drug
DMO34NQ	PC	9795428
DMO34NQ	MW	270.33
DMO34NQ	FM	C16H18N2O2
DMO34NQ	IC	InChI=1S/C16H18N2O2/c1-19-15-6-2-4-13(10-15)5-3-9-20-17-16-12-18-8-7-14(16)11-18/h2,4,6,10,14H,7-9,11-12H2,1H3/b17-16+/t14-/m1/s1
DMO34NQ	CS	COC1=CC=CC(=C1)C#CCO/N=C/2\\CN3CC[C@@H]2C3
DMO34NQ	IK	FXBXWJPMXQHOGD-UVTIVQHFSA-N
DMO34NQ	IU	(Z,4R)-N-[3-(3-methoxyphenyl)prop-2-ynoxy]-1-azabicyclo[2.2.1]heptan-3-imine
DMO34NQ	CA	CAS 149929-39-5
DMO34NQ	DE	Parkinson disease

DMRQPOD	ID	DMRQPOD
DMRQPOD	DN	R-803
DMRQPOD	HS	Discontinued in Phase 1/2
DMRQPOD	SN	R-111706; R-940803
DMRQPOD	CP	Rigel Pharmaceuticals Inc
DMRQPOD	DT	Small molecular drug
DMRQPOD	PC	37801
DMRQPOD	MW	266.29
DMRQPOD	FM	C17H14O3
DMRQPOD	IC	InChI=1S/C17H14O3/c1-11(17(18)19)13-8-5-9-14-15(10-20-16(13)14)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
DMRQPOD	CS	CC(C1=CC=CC2=C1OC=C2C3=CC=CC=C3)C(=O)O
DMRQPOD	IK	ODZUWQAFWMLWCF-UHFFFAOYSA-N
DMRQPOD	IU	2-(3-phenyl-1-benzofuran-7-yl)propanoic acid
DMRQPOD	CA	CAS 67700-30-5
DMRQPOD	DE	Hepatitis C virus infection

DMIAZJ9	ID	DMIAZJ9
DMIAZJ9	DN	RhApo2L/TRAIL
DMIAZJ9	HS	Discontinued in Phase 1/2
DMIAZJ9	CP	Amgen
DMIAZJ9	DE	Solid tumour/cancer

DMHXRZF	ID	DMHXRZF
DMHXRZF	DN	UK-369003
DMHXRZF	HS	Discontinued in Phase 1/2
DMHXRZF	CP	Pfizer
DMHXRZF	DT	Small molecular drug
DMHXRZF	PC	135536943
DMHXRZF	MW	519.6
DMHXRZF	FM	C23H33N7O5S
DMHXRZF	IC	InChI=1S/C23H33N7O5S/c1-5-18-19-20(27-30(18)12-13-34-4)22(31)26-21(25-19)17-14-16(15-24-23(17)35-7-3)36(32,33)29-10-8-28(6-2)9-11-29/h14-15H,5-13H2,1-4H3,(H,25,26,31)
DMHXRZF	CS	CCC1=C2C(=NN1CCOC)C(=O)NC(=N2)C3=C(N=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC
DMHXRZF	IK	YPFZMBHKIVDSNR-UHFFFAOYSA-N
DMHXRZF	IU	5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-6H-pyrazolo[4,3-d]pyrimidin-7-one
DMHXRZF	CA	CAS 334826-98-1
DMHXRZF	DE	Erectile dysfunction

DM8Q2ZR	ID	DM8Q2ZR
DM8Q2ZR	DN	WX-UK1
DM8Q2ZR	HS	Discontinued in Phase 1/2
DM8Q2ZR	SN	UKI-1; UNII-00LOF6890B; CHEMBL107955; WX-UK1; 00LOF6890B; 220355-63-5; Wx-uk1 free base; compound 2r-L; GTPL6498; BDBM23891; 3-amidinophenylalanine deriv., 35; ZINC4426028; AKOS030526723; CS-5726; HY-100415; 1-Piperazinecarboxylic acid, 4-((2S)-3-(3-(aminoiminomethyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, ethyl ester; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-{[2,4,6
DM8Q2ZR	CP	Wilex
DM8Q2ZR	DT	Small molecular drug
DM8Q2ZR	PC	9895194
DM8Q2ZR	MW	613.8
DM8Q2ZR	FM	C32H47N5O5S
DM8Q2ZR	IC	InChI=1S/C32H47N5O5S/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34)
DM8Q2ZR	CS	CCOC(=O)N1CCN(CC1)C(=O)C(CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C
DM8Q2ZR	IK	ISJSHQTWOHGCMM-UHFFFAOYSA-N
DM8Q2ZR	IU	ethyl 4-[3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate
DM8Q2ZR	DE	Solid tumour/cancer

DMC7M3K	ID	DMC7M3K
DMC7M3K	DN	447C88
DMC7M3K	HS	Discontinued in Phase 1
DMC7M3K	SN	BW-447C88
DMC7M3K	CP	GlaxoSmithKline Inc
DMC7M3K	PC	9889686
DMC7M3K	MW	444.6
DMC7M3K	FM	C27H38F2N2O
DMC7M3K	IC	InChI=1S/C27H38F2N2O/c1-5-6-7-8-9-16-30-26(32)31-25-22(17-23(28)18-24(25)29)15-14-20-10-12-21(13-11-20)19-27(2,3)4/h10-13,17-18H,5-9,14-16,19H2,1-4H3,(H2,30,31,32)
DMC7M3K	CS	CCCCCCCNC(=O)NC1=C(C=C(C=C1F)F)CCC2=CC=C(C=C2)CC(C)(C)C
DMC7M3K	IK	XWWXRQIQZOTQGF-UHFFFAOYSA-N
DMC7M3K	IU	1-[2-[2-[4-(2,2-dimethylpropyl)phenyl]ethyl]-4,6-difluorophenyl]-3-heptylurea
DMC7M3K	DE	Hyperlipidaemia

DMHT84I	ID	DMHT84I
DMHT84I	DN	A-216546
DMHT84I	HS	Discontinued in Phase 1
DMHT84I	SN	ABT-546; (2S,3R,4S)-1-[2-(Dibutylamino)-2-oxoethyl]-2-(2,2-dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)tetrahydro-1H-pyrrole-3-carboxylic acid
DMHT84I	DT	Small molecular drug
DMHT84I	PC	71587660
DMHT84I	MW	569.2
DMHT84I	FM	C30H49ClN2O6
DMHT84I	IC	InChI=1S/C30H48N2O6.ClH/c1-7-10-13-31(14-11-8-2)26(33)19-32-18-22(21-15-24(36-6)28-25(16-21)37-20-38-28)27(29(34)35)23(32)17-30(4,5)12-9-3;/h15-16,22-23,27H,7-14,17-20H2,1-6H3,(H,34,35);1H/t22-,23+,27-;/m1./s1
DMHT84I	CS	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1CC(C)(C)CCC)C(=O)O)C2=CC3=C(C(=C2)OC)OCO3.Cl
DMHT84I	IK	KMKKFZCVBRAWNX-KQQHTNMISA-N
DMHT84I	IU	(2S,3R,4S)-1-[2-(dibutylamino)-2-oxoethyl]-2-(2,2-dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)pyrrolidine-3-carboxylic acid;hydrochloride
DMHT84I	CA	CAS 223756-43-2
DMHT84I	DE	Solid tumour/cancer

DM0DLC1	ID	DM0DLC1
DM0DLC1	DN	A-75998
DM0DLC1	HS	Discontinued in Phase 1
DM0DLC1	SN	CHEMBL263839
DM0DLC1	CP	Abbott Laboratories
DM0DLC1	PC	44383749
DM0DLC1	MW	1535.2
DM0DLC1	FM	C80H104ClN15O14
DM0DLC1	IC	InChI=1S/C80H104ClN15O14/c1-46(2)38-63(73(103)90-62(20-10-17-59(82)47(3)4)80(110)96-37-13-21-68(96)77(107)87-48(5)71(84)101)91-72(102)61(19-11-18-60(83)70(100)55-32-35-85-36-33-55)89-78(108)69(43-51-25-30-58(99)31-26-51)95(7)79(109)67(45-97)94-76(106)66(42-53-14-12-34-86-44-53)93-75(105)65(40-50-23-28-57(81)29-24-50)92-74(104)64(88-49(6)98)41-52-22-27-54-15-8-9-16-56(54)39-52/h8-9,12,14-16,22-36,39,44,46-48,59-69,97,99H,10-11,13,17-21,37-38,40-43,45,82-83H2,1-7H3,(H2,84,101)(H,87,107)(H,88,98)(H,89,108)(H,90,103)(H,91,102)(H,92,104)(H,93,105)(H,94,106)/t48-,59?,60?,61-,62-,63-,64-,65-,66-,67-,68+,69-/m0/s1
DM0DLC1	CS	C[C@@H](C(=O)N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CCCC(C(C)C)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCC(C(=O)C2=CC=NC=C2)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N(C)C(=O)[C@H](CO)NC(=O)[C@H](CC4=CN=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM0DLC1	IK	WGWPBHBZVYAVTQ-HQDLIPOVSA-N
DM0DLC1	IU	(2R)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-amino-7-oxo-7-pyridin-4-ylheptanoyl]amino]-4-methylpentanoyl]amino]-6-amino-7-methyloctanoyl]-N-[(2S)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM0DLC1	DE	Hormone deficiency

DMGEWQ7	ID	DMGEWQ7
DMGEWQ7	DN	A-80987
DMGEWQ7	HS	Discontinued in Phase 1
DMGEWQ7	SN	ABT-987
DMGEWQ7	CP	Abbott Laboratories
DMGEWQ7	DT	Small molecular drug
DMGEWQ7	PC	461207
DMGEWQ7	MW	653.8
DMGEWQ7	FM	C37H43N5O6
DMGEWQ7	IC	InChI=1S/C37H43N5O6/c1-26(2)34(42-37(46)48-25-30-17-9-10-19-39-30)35(44)41-32(21-28-14-7-4-8-15-28)33(43)22-31(20-27-12-5-3-6-13-27)40-36(45)47-24-29-16-11-18-38-23-29/h3-19,23,26,31-34,43H,20-22,24-25H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)/t31-,32-,33-,34-/m0/s1
DMGEWQ7	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](C[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CC=C3)O)NC(=O)OCC4=CC=CC=N4
DMGEWQ7	IK	SSIBMWPFXYSVEK-CUPIEXAXSA-N
DMGEWQ7	IU	pyridin-2-ylmethyl N-[(2S)-1-[[(2S,3S,5S)-3-hydroxy-1,6-diphenyl-5-(pyridin-3-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
DMGEWQ7	CA	CAS 144141-97-9
DMGEWQ7	CB	CHEBI:80009
DMGEWQ7	DE	Human immunodeficiency virus infection

DMJTIUP	ID	DMJTIUP
DMJTIUP	DN	ABJ-879
DMJTIUP	HS	Discontinued in Phase 1
DMJTIUP	CP	Novartis AG
DMJTIUP	PC	9871979
DMJTIUP	MW	539.8
DMJTIUP	FM	C27H41NO6S2
DMJTIUP	IC	InChI=1S/C27H41NO6S2/c1-15-9-8-10-27(6)21(34-27)12-19(16(2)11-18-14-36-25(28-18)35-7)33-22(30)13-20(29)26(4,5)24(32)17(3)23(15)31/h11,14-15,17,19-21,23,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,19-,20-,21-,23-,27+/m0/s1
DMJTIUP	CS	C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)SC)/C)C
DMJTIUP	IK	FODFUEDBIXOGNY-AKXQMUJXSA-N
DMJTIUP	IU	(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methylsulfanyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMJTIUP	CA	CAS 252981-48-9
DMJTIUP	DE	Solid tumour/cancer

DMADKHB	ID	DMADKHB
DMADKHB	DN	ABN-912
DMADKHB	HS	Discontinued in Phase 1
DMADKHB	SN	Anti-CD46 mAb, Novartis; Anti-MCP1 monoclonal antibody, Novartis
DMADKHB	CP	Novartis AG
DMADKHB	DT	Antibody
DMADKHB	DE	Asthma

DMTYWE9	ID	DMTYWE9
DMTYWE9	DN	ABT-080
DMTYWE9	HS	Discontinued in Phase 1
DMTYWE9	SN	VML-530; 4,4-Bis[4-(quinolin-2-ylmethoxy)phenyl]pentanoic acid sodium salt
DMTYWE9	DE	Asthma

DMPCYV6	ID	DMPCYV6
DMPCYV6	DN	ABT-107
DMPCYV6	HS	Discontinued in Phase 1
DMPCYV6	SN	Alpha 7 NNR (CNS diseases, schizophrenia, ADHD), Abbott; Alpha 7 NNR (CNS diseases, schizophrenia, ADHD), NeuroSearch; Alpha 7 neuronal nicotinic receptors (central nervous system diseases, schizophrenia, ADHD), Abbott; Alpha 7 neuronal nicotinic receptors (central nervous system diseases, schizophrenia, ADHD), NeuroSearch; NAChR alpha 7 (CNS diseases, schizophrenia, ADHD), Abbott; NAChR alpha 7 (CNS diseases, schizophrenia, ADHD), NeuroSearch; Nicotinic acetylcholine receptor alpha 7 (central nervous system diseases, schizophrenia, ADHD), Abbott; Nicotinic acetylcholine receptor alpha 7 (central nervous system diseases, schizophrenia, ADHD), NeuroSearch
DMPCYV6	CP	NeuroSearch A/S
DMPCYV6	DT	Small molecular drug
DMPCYV6	PC	11151363
DMPCYV6	MW	320.4
DMPCYV6	FM	C19H20N4O
DMPCYV6	IC	InChI=1S/C19H20N4O/c1-2-16-15(5-8-20-16)11-14(1)17-3-4-19(22-21-17)24-18-12-23-9-6-13(18)7-10-23/h1-5,8,11,13,18,20H,6-7,9-10,12H2/t18-/m0/s1
DMPCYV6	CS	C1CN2CCC1[C@H](C2)OC3=NN=C(C=C3)C4=CC5=C(C=C4)NC=C5
DMPCYV6	IK	LUKNJAQKVPBDSC-SFHVURJKSA-N
DMPCYV6	IU	5-[6-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1H-indole
DMPCYV6	CA	CAS 855291-54-2
DMPCYV6	DE	Attention deficit hyperactivity disorder

DMG9Y80	ID	DMG9Y80
DMG9Y80	DN	ABT-202
DMG9Y80	HS	Discontinued in Phase 1
DMG9Y80	SN	A-429202
DMG9Y80	CP	NeuroSearch A/S
DMG9Y80	DT	Small molecular drug
DMG9Y80	PC	17928441
DMG9Y80	MW	163.22
DMG9Y80	FM	C9H13N3
DMG9Y80	IC	InChI=1S/C9H13N3/c10-8-3-5-12(7-8)9-2-1-4-11-6-9/h1-2,4,6,8H,3,5,7,10H2
DMG9Y80	CS	C1CN(CC1N)C2=CN=CC=C2
DMG9Y80	IK	LVGMMVAWLISWJD-UHFFFAOYSA-N
DMG9Y80	IU	1-pyridin-3-ylpyrrolidin-3-amine
DMG9Y80	DE	Pain

DMWVFDH	ID	DMWVFDH
DMWVFDH	DN	ABT-279
DMWVFDH	HS	Discontinued in Phase 1
DMWVFDH	SN	LS-193221
DMWVFDH	CP	Abbott Lab
DMWVFDH	DT	Small molecular drug
DMWVFDH	PC	16049769
DMWVFDH	MW	395.5
DMWVFDH	FM	C21H25N5O3
DMWVFDH	IC	InChI=1S/C21H25N5O3/c1-3-16-4-5-17(13-22)26(16)19(27)14-24-21(2)7-10-25(11-8-21)18-12-15(20(28)29)6-9-23-18/h1,6,9,12,16-17,24H,4-5,7-8,10-11,14H2,2H3,(H,28,29)/t16-,17-/m0/s1
DMWVFDH	CS	CC1(CCN(CC1)C2=NC=CC(=C2)C(=O)O)NCC(=O)N3[C@H](CC[C@H]3C#N)C#C
DMWVFDH	IK	FIMRNLAKAARHPD-IRXDYDNUSA-N
DMWVFDH	IU	2-[4-[[2-[(2S,5R)-2-cyano-5-ethynylpyrrolidin-1-yl]-2-oxoethyl]amino]-4-methylpiperidin-1-yl]pyridine-4-carboxylic acid
DMWVFDH	CA	CAS 676559-83-4
DMWVFDH	DE	Type-2 diabetes

DM8GZAS	ID	DM8GZAS
DM8GZAS	DN	ABT-299
DM8GZAS	HS	Discontinued in Phase 1
DM8GZAS	SN	A-85783
DM8GZAS	CP	Abbott Laboratories
DM8GZAS	DT	Small molecular drug
DM8GZAS	PC	9830503
DM8GZAS	MW	619.1
DM8GZAS	FM	C32H28ClFN4O4S
DM8GZAS	IC	InChI=1S/C32H28FN4O4S.ClH/c1-20(38)41-19-35-13-4-5-23(16-35)31-36-14-12-26(29(36)18-42-31)30(39)27-17-37(32(40)34(2)3)28-15-22(8-11-25(27)28)21-6-9-24(33)10-7-21;/h4-17,31H,18-19H2,1-3H3;1H/q+1;/p-1/t31-;/m1./s1
DM8GZAS	CS	CC(=O)OC[N+]1=CC=CC(=C1)[C@@H]2N3C=CC(=C3CS2)C(=O)C4=CN(C5=C4C=CC(=C5)C6=CC=C(C=C6)F)C(=O)N(C)C.[Cl-]
DM8GZAS	IK	NKIONDJYXPXFFL-JSSVAETHSA-M
DM8GZAS	IU	[3-[(3R)-7-[1-(dimethylcarbamoyl)-6-(4-fluorophenyl)indole-3-carbonyl]-1,3-dihydropyrrolo[1,2-c][1,3]thiazol-3-yl]pyridin-1-ium-1-yl]methyl acetate;chloride
DM8GZAS	CA	CAS 161395-35-3
DM8GZAS	DE	Sepsis

DMA2RM3	ID	DMA2RM3
DMA2RM3	DN	ABT-518
DMA2RM3	HS	Discontinued in Phase 1
DMA2RM3	SN	N-[1(S)-[2,2-Dimethyl-1,3-dioxolan-4(S)-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenylsulfonyl]ethyl]-N-hydroxyformamide
DMA2RM3	DT	Small molecular drug
DMA2RM3	PC	9827497
DMA2RM3	MW	505.5
DMA2RM3	FM	C21H22F3NO8S
DMA2RM3	IC	InChI=1S/C21H22F3NO8S/c1-20(2)30-11-19(33-20)18(25(27)13-26)12-34(28,29)17-9-7-15(8-10-17)31-14-3-5-16(6-4-14)32-21(22,23)24/h3-10,13,18-19,27H,11-12H2,1-2H3/t18-,19-/m1/s1
DMA2RM3	CS	CC1(OC[C@@H](O1)[C@@H](CS(=O)(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)OC(F)(F)F)N(C=O)O)C
DMA2RM3	IK	IVPPTWCRAFCOFJ-RTBURBONSA-N
DMA2RM3	IU	N-[(1S)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylethyl]-N-hydroxyformamide
DMA2RM3	CA	CAS 286845-00-9
DMA2RM3	DE	Solid tumour/cancer

DMZYVPB	ID	DMZYVPB
DMZYVPB	DN	ABX-MA1
DMZYVPB	HS	Discontinued in Phase 1
DMZYVPB	SN	Anti-MUC18 MAb, Abgenix
DMZYVPB	CP	Abgenix Inc
DMZYVPB	DT	Antibody
DMZYVPB	DE	Melanoma

DME98LV	ID	DME98LV
DME98LV	DN	AC-162352
DME98LV	HS	Discontinued in Phase 1
DME98LV	CP	Amylin
DME98LV	DE	Obesity

DM704HO	ID	DM704HO
DM704HO	DN	AC-253
DM704HO	HS	Discontinued in Phase 1
DM704HO	SN	Antam; Amylin antagonist, Amylin; Amylin antagonist, Glaxo; GG-747
DM704HO	CP	Amylin Pharmaceuticals Inc
DM704HO	DE	Hypertension

DM54W9A	ID	DM54W9A
DM54W9A	DN	AC3056
DM54W9A	HS	Discontinued in Phase 1
DM54W9A	CP	Amylin Pharmaceuticals
DM54W9A	DE	Arteriosclerosis

DMIJB68	ID	DMIJB68
DMIJB68	DN	AC-625
DMIJB68	HS	Discontinued in Phase 1
DMIJB68	CP	Amylin Pharmaceuticals Inc
DMIJB68	DE	Hypertension

DMSPW3N	ID	DMSPW3N
DMSPW3N	DN	ACH-2928
DMSPW3N	HS	Discontinued in Phase 1
DMSPW3N	CP	Achillion Pharmaceuticals Inc
DMSPW3N	DE	Hepatitis C virus infection

DML1AUZ	ID	DML1AUZ
DML1AUZ	DN	ADL-7445
DML1AUZ	HS	Discontinued in Phase 1
DML1AUZ	SN	Mu-opioid antagonists (opioid-induced bowel disorder), Adolor; 14-beta-aminonaltrexone
DML1AUZ	CP	Adolor Corp
DML1AUZ	DE	Constipation

DMRSEZD	ID	DMRSEZD
DMRSEZD	DN	AE-3763
DMRSEZD	HS	Discontinued in Phase 1
DMRSEZD	DT	Small molecular drug
DMRSEZD	PC	9807572
DMRSEZD	MW	549.5
DMRSEZD	FM	C23H34F3N5O7
DMRSEZD	IC	InChI=1S/C23H34F3N5O7/c1-12(2)17(19(35)23(24,25)26)28-20(36)14-6-5-7-31(14)21(37)18(13(3)4)27-15(32)10-29-8-9-30(22(29)38)11-16(33)34/h12-14,17-18H,5-11H2,1-4H3,(H,27,32)(H,28,36)(H,33,34)/t14-,17-,18-/m0/s1
DMRSEZD	CS	CC(C)[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)CN2CCN(C2=O)CC(=O)O
DMRSEZD	IK	DHQQXRRWRZFGDW-WBAXXEDZSA-N
DMRSEZD	IU	2-[3-[2-[[(2S)-3-methyl-1-oxo-1-[(2S)-2-[[(3S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]carbamoyl]pyrrolidin-1-yl]butan-2-yl]amino]-2-oxoethyl]-2-oxoimidazolidin-1-yl]acetic acid
DMRSEZD	DE	Chronic obstructive pulmonary disease

DM1TYM4	ID	DM1TYM4
DM1TYM4	DN	AG-021541
DM1TYM4	HS	Discontinued in Phase 1
DM1TYM4	SN	SCHEMBL5880778
DM1TYM4	CP	Agouron; Pfizer
DM1TYM4	DT	Small molecular drug
DM1TYM4	PC	54684477
DM1TYM4	MW	559.1
DM1TYM4	FM	C27H31ClN4O5S
DM1TYM4	IC	InChI=1S/C27H31ClN4O5S/c1-15-11-16(2)32-25(29-15)30-26(31-32)38-23-20(33)14-27(37-24(23)34,18-7-5-6-8-18)10-9-17-12-19(28)22(36-4)13-21(17)35-3/h11-13,18,33H,5-10,14H2,1-4H3
DM1TYM4	CS	CC1=CC(=NC2=NC(=NN12)SC3=C(CC(OC3=O)(CCC4=CC(=C(C=C4OC)OC)Cl)C5CCCC5)O)C
DM1TYM4	IK	MKOFABQFNUCNTD-UHFFFAOYSA-N
DM1TYM4	IU	2-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfanyl]-4-hydroxy-3H-pyran-6-one
DM1TYM4	DE	Hepatitis C virus infection

DMCEM0L	ID	DMCEM0L
DMCEM0L	DN	AG-331
DMCEM0L	HS	Discontinued in Phase 1
DMCEM0L	SN	Metesind glucuronate
DMCEM0L	CP	Agouron Pharmaceuticals Inc
DMCEM0L	DT	Small molecular drug
DMCEM0L	PC	3047716
DMCEM0L	MW	436.5
DMCEM0L	FM	C23H24N4O3S
DMCEM0L	IC	InChI=1S/C23H24N4O3S/c1-26(21-10-9-20-22-18(21)3-2-4-19(22)23(24)25-20)15-16-5-7-17(8-6-16)31(28,29)27-11-13-30-14-12-27/h2-10H,11-15H2,1H3,(H2,24,25)
DMCEM0L	CS	CN(CC1=CC=C(C=C1)S(=O)(=O)N2CCOCC2)C3=C4C=CC=C5C4=C(C=C3)N=C5N
DMCEM0L	IK	CVEGTZWWWRJCFK-UHFFFAOYSA-N
DMCEM0L	IU	6-N-methyl-6-N-[(4-morpholin-4-ylsulfonylphenyl)methyl]benzo[cd]indole-2,6-diamine
DMCEM0L	CA	CAS 138384-68-6
DMCEM0L	DE	Solid tumour/cancer

DM8XODL	ID	DM8XODL
DM8XODL	DN	AGN-191743
DM8XODL	HS	Discontinued in Phase 1
DM8XODL	CP	Roche Holding AG
DM8XODL	DE	Allergy

DMGAERX	ID	DMGAERX
DMGAERX	DN	AIR-Epinephrine
DMGAERX	HS	Discontinued in Phase 1
DMGAERX	CP	Alkermes
DMGAERX	DE	Allergy

DMVBKLO	ID	DMVBKLO
DMVBKLO	DN	ALBIFYLLINE
DMVBKLO	HS	Discontinued in Phase 1
DMVBKLO	SN	HWA-138; Albifylline; 1-(5-Hydroxy-5-methylhexyl)-3-methylxanthine
DMVBKLO	DT	Small molecular drug
DMVBKLO	PC	115359
DMVBKLO	MW	280.32
DMVBKLO	FM	C13H20N4O3
DMVBKLO	IC	InChI=1S/C13H20N4O3/c1-13(2,20)6-4-5-7-17-11(18)9-10(15-8-14-9)16(3)12(17)19/h8,20H,4-7H2,1-3H3,(H,14,15)
DMVBKLO	CS	CC(C)(CCCCN1C(=O)C2=C(N=CN2)N(C1=O)C)O
DMVBKLO	IK	NWXULHNEYYFVMF-UHFFFAOYSA-N
DMVBKLO	IU	1-(5-hydroxy-5-methylhexyl)-3-methyl-7H-purine-2,6-dione
DMVBKLO	CA	CAS 107767-55-5
DMVBKLO	DE	Sepsis

DM2QMKJ	ID	DM2QMKJ
DM2QMKJ	DN	ALS-00T2-0501
DM2QMKJ	HS	Discontinued in Phase 1
DM2QMKJ	SN	TNF Blocker (Intradel, psoriasis), Apollo Life Sciences; TNF Blocker (TransD, psoriasis), Apollo Life Sciences; TNF Blocker (transdermal cream, psoriasis), Apollo Life Sciences; TNF receptor antagonist (Intradel, psoriasis), Apollo Life Sciences; TNF receptor antagonist (TransD, psoriasis), Apollo Life Sciences; TNF receptor antagonist (transdermal cream, psoriasis), Apollo Life Sciences
DM2QMKJ	CP	Apollo Life Sciences Pty Ltd
DM2QMKJ	DE	Psoriasis vulgaris

DMS5C06	ID	DMS5C06
DMS5C06	DN	ALTU-237
DMS5C06	HS	Discontinued in Phase 1
DMS5C06	SN	Oxalate oxidase (oral crystalline, kidney stones), Altus
DMS5C06	CP	Altus Pharmaceuticals Inc
DMS5C06	DE	Hyperoxaluria

DMNOZAI	ID	DMNOZAI
DMNOZAI	DN	ALX-0646
DMNOZAI	HS	Discontinued in Phase 1
DMNOZAI	SN	ALC-2527XX; ALC-900XX; ALC-901XX; ALC-902XX; ALC-905XX; ALC-907XX; ALC-913; ALC-918; ALC-918XX; ALC-947XX; ALC-948XX; ALC-962XX; ALC-963XX; ALC-973XX; ALC-974XX; ALX-2324; ALX-2325; ALX-2326; ALX-2354XX; ALX-2355XX; ALX-2356XX; ALX-2357XX; ALX-2436XX; ALX-2437XX; ALX-2458XX; ALX-2459XX; ALX-2476XX; ALX-2477XX; ALX-2503XX; ALX-2504XX; ALX-2581; ALX-2582; ALX-2592; ALX-646CL; ALX-912
DMNOZAI	CP	NPS Allelix Corp
DMNOZAI	DT	Small molecular drug
DMNOZAI	PC	9860595
DMNOZAI	MW	283.4
DMNOZAI	FM	C18H25N3
DMNOZAI	IC	InChI=1S/C18H25N3/c1-20(2)9-6-16-13-19-18-5-4-15(12-17(16)18)14-7-10-21(3)11-8-14/h4-5,7,12-13,19H,6,8-11H2,1-3H3
DMNOZAI	CS	CN1CCC(=CC1)C2=CC3=C(C=C2)NC=C3CCN(C)C
DMNOZAI	IK	RQTZMTMTBWAQAI-UHFFFAOYSA-N
DMNOZAI	IU	N,N-dimethyl-2-[5-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-1H-indol-3-yl]ethanamine
DMNOZAI	CA	CAS 208464-67-9
DMNOZAI	DE	Migraine

DMO7920	ID	DMO7920
DMO7920	DN	AM-831
DMO7920	HS	Discontinued in Phase 1
DMO7920	SN	199330-66-0; METHYL 4-AMINOTETRAHYDRO-2H-PYRAN-4-CARBOXYLATE HYDROCHLORIDE; methyl 4-aminooxane-4-carboxylate hydrochloride; METHYL 4-AMINOTETRAHYDROPYRAN-4-CARBOXYLATE HCL; methyl 4-aminotetrahydropyran-4-carboxylate hydrochloride; 2H-Pyran-4-carboxylic acid, 4-aminotetrahydro-, methyl ester, hydrochloride (1:1); SCHEMBL1818830; MolPort-009-013-807; VNPBPEQYIQVYDP-UHFFFAOYSA-N; AM831; KS-000008CU; SBB091929; AKOS025147281; PB10899; AS-36521; DB-065487; CS-0049053; FT-0768000; Q-1506; methyl 4-aminooxane-4-carboxylate,hydroch
DMO7920	CP	ACADIA Pharmaceuticals
DMO7920	DT	Small molecular drug
DMO7920	PC	43811077
DMO7920	MW	195.64
DMO7920	FM	C7H14ClNO3
DMO7920	IC	InChI=1S/C7H13NO3.ClH/c1-10-6(9)7(8)2-4-11-5-3-7;/h2-5,8H2,1H3;1H
DMO7920	CS	COC(=O)C1(CCOCC1)N.Cl
DMO7920	IK	VNPBPEQYIQVYDP-UHFFFAOYSA-N
DMO7920	IU	methyl 4-aminooxane-4-carboxylate;hydrochloride
DMO7920	DE	Schizophrenia

DMALVX2	ID	DMALVX2
DMALVX2	DN	AMELTOLIDE
DMALVX2	HS	Discontinued in Phase 1
DMALVX2	SN	ADD-75073; Ameltolide < Prop INN; LY-201116; 4-Amino-N-(2,6-dimethylphenyl)benzamide
DMALVX2	DT	Small molecular drug
DMALVX2	PC	13086
DMALVX2	MW	240.3
DMALVX2	FM	C15H16N2O
DMALVX2	IC	InChI=1S/C15H16N2O/c1-10-4-3-5-11(2)14(10)17-15(18)12-6-8-13(16)9-7-12/h3-9H,16H2,1-2H3,(H,17,18)
DMALVX2	CS	CC1=C(C(=CC=C1)C)NC(=O)C2=CC=C(C=C2)N
DMALVX2	IK	HZIWGOAXOBPQGY-UHFFFAOYSA-N
DMALVX2	IU	4-amino-N-(2,6-dimethylphenyl)benzamide
DMALVX2	CA	CAS 787-93-9
DMALVX2	CB	CHEBI:6342
DMALVX2	DE	Epileptic seizures

DMIKQ40	ID	DMIKQ40
DMIKQ40	DN	AMG 076
DMIKQ40	HS	Discontinued in Phase 1
DMIKQ40	SN	AMG-076 free base; UNII-HX4T7JEV3D; HX4T7JEV3D; CHEMBL2032049; 693823-79-9; SCHEMBL2742722; DTXSID70219485; BDBM50383522; Cyclohexanecarboxylic acid, 1-(2-((4aR,11R,11aS)-1,3,4,4a,5,6,11,11a-octahydro-11-methyl-9-(trifluoromethyl)-2H-pyrido(4,3-b)carbazol-2-yl)ethyl)-; (4aR)-2-[2-(1-Carboxycyclohexyl)ethyl]-2,3,4,4abeta,5,6,11,11aalpha-octahydro-9-(trifluoromethyl)-11alpha-methyl-1H-pyrido[4,3-b]carbazole
DMIKQ40	CP	Amgen
DMIKQ40	DT	Small molecular drug
DMIKQ40	PC	23642854
DMIKQ40	MW	620.7
DMIKQ40	FM	C32H39F3N2O5S
DMIKQ40	IC	InChI=1S/C26H33F3N2O2.C6H6O3S/c1-16-20-15-31(12-10-25(24(32)33)8-3-2-4-9-25)11-7-17(20)13-22-23(16)19-14-18(26(27,28)29)5-6-21(19)30-22;7-10(8,9)6-4-2-1-3-5-6/h5-6,14,16-17,20,30H,2-4,7-13,15H2,1H3,(H,32,33);1-5H,(H,7,8,9)/t16-,17-,20-;/m1./s1
DMIKQ40	CS	C[C@@H]1[C@H]2CN(CC[C@@H]2CC3=C1C4=C(N3)C=CC(=C4)C(F)(F)F)CCC5(CCCCC5)C(=O)O.C1=CC=C(C=C1)S(=O)(=O)O
DMIKQ40	IK	IBDOVKSLMMFQPJ-IUPOGUASSA-N
DMIKQ40	IU	1-[2-[(4aR,11R,11aS)-11-methyl-9-(trifluoromethyl)-1,3,4,4a,5,6,11,11a-octahydropyrido[4,3-b]carbazol-2-yl]ethyl]cyclohexane-1-carboxylic acid;benzenesulfonic acid
DMIKQ40	CA	CAS 1001438-96-5
DMIKQ40	DE	Obesity

DMUO3T2	ID	DMUO3T2
DMUO3T2	DN	AMG 317
DMUO3T2	HS	Discontinued in Phase 1
DMUO3T2	CP	Amgen
DMUO3T2	DE	Asthma

DMFCKJ1	ID	DMFCKJ1
DMFCKJ1	DN	AMG-221
DMFCKJ1	HS	Discontinued in Phase 1
DMFCKJ1	DT	Small molecular drug
DMFCKJ1	PC	135565424
DMFCKJ1	MW	266.4
DMFCKJ1	FM	C14H22N2OS
DMFCKJ1	IC	InChI=1S/C14H22N2OS/c1-8(2)14(3)12(17)16-13(18-14)15-11-7-9-4-5-10(11)6-9/h8-11H,4-7H2,1-3H3,(H,15,16,17)/t9-,10+,11+,14+/m1/s1
DMFCKJ1	CS	CC(C)[C@]1(C(=O)NC(=N[C@H]2C[C@@H]3CC[C@H]2C3)S1)C
DMFCKJ1	IK	YCNCXQNUXCHRRX-ZHPDPMBESA-N
DMFCKJ1	IU	(5S)-2-[[(1S,2S,4R)-2-bicyclo[2.2.1]heptanyl]imino]-5-methyl-5-propan-2-yl-1,3-thiazolidin-4-one
DMFCKJ1	CA	CAS 1095565-81-3
DMFCKJ1	DE	Metabolic disorder

DM3HB06	ID	DM3HB06
DM3HB06	DN	AMG-517
DM3HB06	HS	Discontinued in Phase 1
DM3HB06	SN	AMG 517; BD-0082
DM3HB06	CP	Amgen
DM3HB06	TC	Analgesics
DM3HB06	DT	Small molecular drug
DM3HB06	PC	16007367
DM3HB06	MW	430.4
DM3HB06	FM	C20H13F3N4O2S
DM3HB06	IC	InChI=1S/C20H13F3N4O2S/c1-11(28)26-19-27-18-15(3-2-4-16(18)30-19)29-17-9-14(24-10-25-17)12-5-7-13(8-6-12)20(21,22)23/h2-10H,1H3,(H,26,27,28)
DM3HB06	CS	CC(=O)NC1=NC2=C(C=CC=C2S1)OC3=NC=NC(=C3)C4=CC=C(C=C4)C(F)(F)F
DM3HB06	IK	YUTIXVXZQIQWGY-UHFFFAOYSA-N
DM3HB06	IU	N-[4-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide
DM3HB06	CA	CAS 659730-32-2
DM3HB06	DE	Chronic pain

DMFR3PD	ID	DMFR3PD
DMFR3PD	DN	ANA-975
DMFR3PD	HS	Discontinued in Phase 1
DMFR3PD	SN	Isatoribine prodrug, Anadys; ANA-245 prodrug, Anadys; ANA-97X program, Anadys
DMFR3PD	CP	Anadys Pharmaceuticals Inc
DMFR3PD	DE	Immune System disease

DMRQFIE	ID	DMRQFIE
DMRQFIE	DN	ANQ-9040
DMRQFIE	HS	Discontinued in Phase 1
DMRQFIE	SN	3alpha-Acetoxy-3beta-(hexahydroazepinomethyl)-17a,17a-dimethyl-17-homo-17a-azonia-5alpha-androstane benzenesulfonate
DMRQFIE	PC	9939141
DMRQFIE	MW	630.9
DMRQFIE	FM	C36H58N2O5S
DMRQFIE	IC	InChI=1S/C30H53N2O2.C6H6O3S/c1-23(33)34-30(22-31-18-8-6-7-9-19-31)17-16-28(2)24(21-30)12-13-25-26(28)14-15-29(3)27(25)11-10-20-32(29,4)5;7-10(8,9)6-4-2-1-3-5-6/h24-27H,6-22H2,1-5H3;1-5H,(H,7,8,9)/q+1;/p-1/t24-,25+,26-,27-,28-,29-,30+;/m0./s1
DMRQFIE	CS	CC(=O)O[C@@]1(CC[C@]2([C@H](C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC[N+]4(C)C)C)C)CN5CCCCCC5.C1=CC=C(C=C1)S(=O)(=O)[O-]
DMRQFIE	IK	MUVZCNJMKMCHMD-IBSDALFFSA-M
DMRQFIE	IU	[(4aS,4bR,6aS,8R,10aS,10bS,12aS)-8-(azepan-1-ylmethyl)-1,1,10a,12a-tetramethyl-2,3,4,4a,4b,5,6,6a,7,9,10,10b,11,12-tetradecahydronaphtho[2,1-f]quinolin-1-ium-8-yl] acetate;benzenesulfonate
DMRQFIE	CA	CAS 142021-80-5
DMRQFIE	DE	Paralysis

DM9GSWY	ID	DM9GSWY
DM9GSWY	DN	Anthrax vaccine
DM9GSWY	HS	Discontinued in Phase 1
DM9GSWY	SN	Anthrax vaccine, DynPort/AVANT; Injectable anthrax vaccine, DynPort/AVANT; Anthrax vaccine (injectable), DynPort/AVANT
DM9GSWY	CP	Celldex Therapeutics Inc
DM9GSWY	DT	Vaccine
DM9GSWY	DE	Bacillus anthracis infection

DMN8R2U	ID	DMN8R2U
DMN8R2U	DN	APD668
DMN8R2U	HS	Discontinued in Phase 1
DMN8R2U	SN	832714-46-2; APD-668; CHEMBL1775179; Isopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)piperidine-1-carboxylate; isopropyl 4-(1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)piperidine-1-carboxylate; 1-Piperidinecarboxylic acid,4-[[1-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]-, 1-methylethyl ester; SCHEMBL389323; AOB6271; XTRUQJBVQBUKSQ-UHFFFAOYSA-N; MolPort-039-331-631; EX-A1795; BCP10207; BDBM50343442; ZINC68266967
DMN8R2U	CP	Arena Pharma.
DMN8R2U	DT	Small molecular drug
DMN8R2U	PC	11705608
DMN8R2U	MW	477.5
DMN8R2U	FM	C21H24FN5O5S
DMN8R2U	IC	InChI=1S/C21H24FN5O5S/c1-13(2)31-21(28)26-8-6-14(7-9-26)32-20-16-11-25-27(19(16)23-12-24-20)18-5-4-15(10-17(18)22)33(3,29)30/h4-5,10-14H,6-9H2,1-3H3
DMN8R2U	CS	CC(C)OC(=O)N1CCC(CC1)OC2=NC=NC3=C2C=NN3C4=C(C=C(C=C4)S(=O)(=O)C)F
DMN8R2U	IK	XTRUQJBVQBUKSQ-UHFFFAOYSA-N
DMN8R2U	IU	propan-2-yl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate
DMN8R2U	DE	Type-2 diabetes

DM71C6D	ID	DM71C6D
DM71C6D	DN	Aphidicolin
DM71C6D	HS	Discontinued in Phase 1
DM71C6D	SN	bis(hydroxymethyl)-dimethyl-[ ]diol; AC1LA8KN; 8,11a-Methano-11aH-cyclohepta[a]naphthalene-4,9-dimethanol, tetradecahydro-3,9-dihydroxy-4,11b-dimethyl-, (3R,4R,9R,11bS)-
DM71C6D	DT	Small molecular drug
DM71C6D	PC	457964
DM71C6D	MW	338.5
DM71C6D	FM	C20H34O4
DM71C6D	IC	InChI=1S/C20H34O4/c1-17(11-21)15-4-3-13-9-14-10-19(13,7-8-20(14,24)12-22)18(15,2)6-5-16(17)23/h13-16,21-24H,3-12H2,1-2H3/t13-,14+,15-,16+,17-,18-,19-,20-/m0/s1
DM71C6D	CS	C[C@]12CC[C@H]([C@@]([C@@H]1CC[C@@H]3[C@@]24CC[C@@]([C@H](C3)C4)(CO)O)(C)CO)O
DM71C6D	IK	NOFOAYPPHIUXJR-APNQCZIXSA-N
DM71C6D	IU	(1S,2S,5R,6R,7R,10S,12R,13R)-6,13-bis(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.01,10.02,7]hexadecane-5,13-diol
DM71C6D	CA	CAS 38966-21-1
DM71C6D	CB	CHEBI:2766

DM5L9I2	ID	DM5L9I2
DM5L9I2	DN	APP-018
DM5L9I2	HS	Discontinued in Phase 1
DM5L9I2	SN	D-4F; Apolipoprotein A1 mimetic (atherosclerosis), Bruin Pharma; Apolipoprotein A1 mimetic (atherosclerosis),Novartis
DM5L9I2	CP	Bruin Pharma Inc
DM5L9I2	PC	72941823
DM5L9I2	MW	2310.6
DM5L9I2	FM	C114H156N24O28
DM5L9I2	IC	InChI=1S/C114H156N24O28/c1-64(2)96(114(166)123-67(5)98(150)125-83(48-50-93(143)144)105(157)126-80(41-23-27-53-117)104(156)133-86(57-71-33-15-9-16-34-71)107(159)128-79(40-22-26-52-116)103(155)130-82(47-49-92(141)142)102(154)122-65(3)99(151)131-84(97(119)149)55-69-29-11-7-12-30-69)138-106(158)81(42-24-28-54-118)129-113(165)91(62-95(147)148)137-110(162)88(59-73-43-45-75(140)46-44-73)134-109(161)85(56-70-31-13-8-14-32-70)132-100(152)66(4)121-101(153)78(39-21-25-51-115)127-108(160)87(58-72-35-17-10-18-36-72)135-111(163)89(60-74-63-120-77-38-20-19-37-76(74)77)136-112(164)90(61-94(145)146)124-68(6)139/h7-20,29-38,43-46,63-67,78-91,96,120,140H,21-28,39-42,47-62,115-118H2,1-6H3,(H2,119,149)(H,121,153)(H,122,154)(H,123,166)(H,124,139)(H,125,150)(H,126,157)(H,127,160)(H,128,159)(H,129,165)(H,130,155)(H,131,151)(H,132,152)(H,133,156)(H,134,161)(H,135,163)(H,136,164)(H,137,162)(H,138,158)(H,141,142)(H,143,144)(H,145,146)(H,147,148)/t65-,66-,67-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,96-/m1/s1
DM5L9I2	CS	C[C@H](C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@H](CC2=CC=C(C=C2)O)C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)[C@@H](CC6=CNC7=CC=CC=C76)NC(=O)[C@@H](CC(=O)O)NC(=O)C
DM5L9I2	IK	ZKKBZMXTFBAQLP-INNXVHPBSA-N
DM5L9I2	IU	(4R)-4-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-carboxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-6-aminohexanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-[[(2R)-6-amino-1-[[(2R)-1-[[(2R)-6-amino-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DM5L9I2	CA	CAS 452782-06-8
DM5L9I2	DE	Arteriosclerosis

DMRLHNW	ID	DMRLHNW
DMRLHNW	DN	Aprosulate sodium
DMRLHNW	HS	Discontinued in Phase 1
DMRLHNW	SN	Aprosulate; LW-10082; MW-2388
DMRLHNW	CP	Luitpold Pharma GmbH
DMRLHNW	PC	72125
DMRLHNW	MW	2387.4
DMRLHNW	FM	C27H34N2Na16O70S16
DMRLHNW	IC	InChI=1S/C27H50N2O70S16.16Na/c30-24(20(96-112(68,69)70)16(92-108(56,57)58)12(10(88-104(44,45)46)6-82-102(38,39)40)86-26-22(98-114(74,75)76)18(94-110(62,63)64)14(90-106(50,51)52)8(84-26)4-80-100(32,33)34)28-2-1-3-29-25(31)21(97-113(71,72)73)17(93-109(59,60)61)13(11(89-105(47,48)49)7-83-103(41,42)43)87-27-23(99-115(77,78)79)19(95-111(65,66)67)15(91-107(53,54)55)9(85-27)5-81-101(35,36)37;;;;;;;;;;;;;;;;/h8-23,26-27H,1-7H2,(H,28,30)(H,29,31)(H,32,33,34)(H,35,36,37)(H,38,39,40)(H,41,42,43)(H,44,45,46)(H,47,48,49)(H,50,51,52)(H,53,54,55)(H,56,57,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76)(H,77,78,79);;;;;;;;;;;;;;;;/q;16*+1/p-16/t8-,9-,10-,11-,12-,13-,14+,15+,16+,17+,18+,19+,20-,21-,22-,23-,26+,27+;;;;;;;;;;;;;;;;/m1................/s1
DMRLHNW	CS	C(CNC(=O)[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])CNC(=O)[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMRLHNW	IK	CXKOATPJKFZCEL-HPXJARCXSA-A
DMRLHNW	IU	hexadecasodium;[(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R)-6-oxo-1,2,4,5-tetrasulfonatooxy-6-[3-[[(2R,3S,4R,5R)-2,3,5,6-tetrasulfonatooxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxyhexanoyl]amino]propylamino]hexan-3-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate
DMRLHNW	CA	CAS 123072-45-7
DMRLHNW	DE	Coagulation defect

DMKLCRI	ID	DMKLCRI
DMKLCRI	DN	ARC-183
DMKLCRI	HS	Discontinued in Phase 1
DMKLCRI	SN	Anti-thrombin aptamer (CABG surgery), Archemix/Nuvelo
DMKLCRI	CP	Archemix; Archemix Corp
DMKLCRI	DT	Aptamer
DMKLCRI	DE	Blood forming organ disorder

DMHZN42	ID	DMHZN42
DMHZN42	DN	AR-H049020
DMHZN42	HS	Discontinued in Phase 1
DMHZN42	CP	AstraZeneca plc
DMHZN42	DE	Type-1 diabetes

DMXD93K	ID	DMXD93K
DMXD93K	DN	ARRY-614
DMXD93K	HS	Discontinued in Phase 1
DMXD93K	SN	Pexmetinib; 945614-12-0; ARRY-614; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-
DMXD93K	CP	Array BioPharma
DMXD93K	DT	Small molecular drug
DMXD93K	PC	24765037
DMXD93K	MW	556.6
DMXD93K	FM	C31H33FN6O3
DMXD93K	IC	InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,39H,13-14,18H2,1-4H3,(H2,33,35,40)
DMXD93K	CS	CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NCC3=C(C=CC(=C3)F)OC4=CC5=C(C=C4)N(N=C5)CCO
DMXD93K	IK	LNMRSSIMGCDUTP-UHFFFAOYSA-N
DMXD93K	IU	1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea
DMXD93K	CA	CAS 945614-12-0
DMXD93K	DE	Myelodysplastic syndrome; Arthritis

DMJDYBX	ID	DMJDYBX
DMJDYBX	DN	Artilide
DMJDYBX	HS	Discontinued in Phase 1
DMJDYBX	SN	Artilide fumarate; U-88943E
DMJDYBX	CP	Pharmacia & Upjohn Co
DMJDYBX	DT	Small molecular drug
DMJDYBX	PC	131606
DMJDYBX	MW	370.6
DMJDYBX	FM	C19H34N2O3S
DMJDYBX	IC	InChI=1S/C19H34N2O3S/c1-4-6-14-21(15-7-5-2)16-8-9-19(22)17-10-12-18(13-11-17)20-25(3,23)24/h10-13,19-20,22H,4-9,14-16H2,1-3H3/t19-/m1/s1
DMJDYBX	CS	CCCCN(CCCC)CCC[C@H](C1=CC=C(C=C1)NS(=O)(=O)C)O
DMJDYBX	IK	UAARDOOBGJGDJV-LJQANCHMSA-N
DMJDYBX	IU	N-[4-[(1R)-4-(dibutylamino)-1-hydroxybutyl]phenyl]methanesulfonamide
DMJDYBX	CA	CAS 133267-19-3
DMJDYBX	DE	Cardiac arrhythmias

DMINF80	ID	DMINF80
DMINF80	DN	AS-601811
DMINF80	HS	Discontinued in Phase 1
DMINF80	SN	4,8-Dimethyl-2,3,5,6-tetrahydro-1H-benzo[c]quinolizin-3-one
DMINF80	DT	Small molecular drug
DMINF80	PC	10220187
DMINF80	MW	227.3
DMINF80	FM	C15H17NO
DMINF80	IC	InChI=1S/C15H17NO/c1-10-3-5-14-12(9-10)4-6-13-11(2)15(17)7-8-16(13)14/h3,5,9H,4,6-8H2,1-2H3
DMINF80	CS	CC1=CC2=C(C=C1)N3CCC(=O)C(=C3CC2)C
DMINF80	IK	SNEPAAKJPPNOQM-UHFFFAOYSA-N
DMINF80	IU	4,8-dimethyl-1,2,5,6-tetrahydrobenzo[f]quinolizin-3-one
DMINF80	CA	CAS 194979-95-8
DMINF80	DE	Acne vulgaris

DMKXDOI	ID	DMKXDOI
DMKXDOI	DN	AS602868
DMKXDOI	HS	Discontinued in Phase 1
DMKXDOI	SN	Angelicin; ISOPSORALEN; 523-50-2; 2H-Furo[2,3-H]chromen-2-one; Angecin; furo[2,3-h]chromen-2-one; Isopsoralin; Furo(2,3-h)coumarin; Angelecin; Angelicin (coumarin derivative); 2H-Furo[2,3-H]-1-benzopyran-2-one; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; UNII-CZZ080D7BD; Angelicin (coumarin deriv); NSC 404563; Furo(5',4':7,8)coumarin; CCRIS 4276; HSDB 3554; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; BRN 0153970; CZZ080D7BD; 2H-Furo(2,3-H)-1-benzopyran-2-one; CHEMBL53569; Furo[5',4':7,8]coumarin; Isopsoralen
DMKXDOI	CP	Merck
DMKXDOI	DT	Small molecular drug
DMKXDOI	PC	9820526
DMKXDOI	MW	366.4
DMKXDOI	FM	C18H14N4O3S
DMKXDOI	IC	InChI=1S/C18H14N4O3S/c1-10-9-14(23)22(18(10)24)21-17-15-11(5-3-6-12(15)25-2)19-16(20-17)13-7-4-8-26-13/h3-9H,1-2H3,(H,19,20,21)
DMKXDOI	CS	CC1=CC(=O)N(C1=O)NC2=NC(=NC3=C2C(=CC=C3)OC)C4=CC=CS4
DMKXDOI	IK	GZGLPBNOIFLLRE-UHFFFAOYSA-N
DMKXDOI	IU	1-[(5-methoxy-2-thiophen-2-ylquinazolin-4-yl)amino]-3-methylpyrrole-2,5-dione
DMKXDOI	CA	CAS 219773-55-4
DMKXDOI	DE	Multiple myeloma

DMMPBZF	ID	DMMPBZF
DMMPBZF	DN	AVE-3247
DMMPBZF	HS	Discontinued in Phase 1
DMMPBZF	CP	Sanofi-Aventis
DMMPBZF	DE	Thrombosis

DM5FDX2	ID	DM5FDX2
DM5FDX2	DN	AVE-5997EF
DM5FDX2	HS	Discontinued in Phase 1
DM5FDX2	SN	UNII-7E6G867INX; 7E6G867INX; SCHEMBL5667413; L001680; 1-p-Tolyl-3-(4-(4-(6-trifluoromethylbenzo(b)thien-3-yl)piperazin-1-yl)butyl)urea; Urea, N-(4-methylphenyl)-N'-(4-(4-(6-(trifluoromethyl)benzo(b)thien-3-yl)-1-piperazinyl)butyl)-
DM5FDX2	CP	Sanofi-Aventis
DM5FDX2	DT	Small molecular drug
DM5FDX2	PC	9891761
DM5FDX2	MW	490.6
DM5FDX2	FM	C25H29F3N4OS
DM5FDX2	IC	InChI=1S/C25H29F3N4OS/c1-18-4-7-20(8-5-18)30-24(33)29-10-2-3-11-31-12-14-32(15-13-31)22-17-34-23-16-19(25(26,27)28)6-9-21(22)23/h4-9,16-17H,2-3,10-15H2,1H3,(H2,29,30,33)
DM5FDX2	CS	CC1=CC=C(C=C1)NC(=O)NCCCCN2CCN(CC2)C3=CSC4=C3C=CC(=C4)C(F)(F)F
DM5FDX2	IK	XVFIYMFVLGFALY-UHFFFAOYSA-N
DM5FDX2	IU	1-(4-methylphenyl)-3-[4-[4-[6-(trifluoromethyl)-1-benzothiophen-3-yl]piperazin-1-yl]butyl]urea
DM5FDX2	CA	CAS 452917-21-4
DM5FDX2	DE	Psychotic disorder; Schizophrenia

DMIB3AT	ID	DMIB3AT
DMIB3AT	DN	AVE-9940
DMIB3AT	HS	Discontinued in Phase 1
DMIB3AT	CP	Aventis SA
DMIB3AT	DE	Rheumatoid arthritis

DMTG9EZ	ID	DMTG9EZ
DMTG9EZ	DN	AWD-140-190
DMTG9EZ	HS	Discontinued in Phase 1
DMTG9EZ	SN	AWD-12-151
DMTG9EZ	CP	ASTA Medica AG
DMTG9EZ	DE	Epileptic seizures

DM1JN6A	ID	DM1JN6A
DM1JN6A	DN	Axovan-3
DM1JN6A	HS	Discontinued in Phase 1
DM1JN6A	CP	Axovan AG
DM1JN6A	DE	Obesity; Eating disorder

DMIM9N1	ID	DMIM9N1
DMIM9N1	DN	AZD-1080
DMIM9N1	HS	Discontinued in Phase 1
DMIM9N1	CP	AstraZeneca plc
DMIM9N1	DT	Small molecular drug
DMIM9N1	PC	135564570
DMIM9N1	MW	334.4
DMIM9N1	FM	C19H18N4O2
DMIM9N1	IC	InChI=1S/C19H18N4O2/c20-10-13-1-3-16-15(9-13)18(19(24)22-16)17-4-2-14(11-21-17)12-23-5-7-25-8-6-23/h1-4,9,11,22,24H,5-8,12H2
DMIM9N1	CS	C1COCCN1CC2=CN=C(C=C2)C3=C(NC4=C3C=C(C=C4)C#N)O
DMIM9N1	IK	BLTVBQXJFVRPFK-UHFFFAOYSA-N
DMIM9N1	IU	2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile
DMIM9N1	CA	CAS 612487-72-6
DMIM9N1	DE	Alzheimer disease

DM65MUI	ID	DM65MUI
DM65MUI	DN	AZD1175
DM65MUI	HS	Discontinued in Phase 1
DM65MUI	CP	AstraZeneca
DM65MUI	PC	11250433
DM65MUI	MW	605.5
DM65MUI	FM	C25H25Cl2F3N4O4S
DM65MUI	IC	InChI=1S/C25H25Cl2F3N4O4S/c1-16-22(24(35)32-33-12-3-2-4-13-33)31-34(21-10-7-18(26)15-20(21)27)23(16)17-5-8-19(9-6-17)38-39(36,37)14-11-25(28,29)30/h5-10,15H,2-4,11-14H2,1H3,(H,32,35)
DM65MUI	CS	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)OS(=O)(=O)CCC(F)(F)F
DM65MUI	IK	AUAVZPQYSXVTLQ-UHFFFAOYSA-N
DM65MUI	IU	[4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin-1-ylcarbamoyl)pyrazol-3-yl]phenyl] 3,3,3-trifluoropropane-1-sulfonate
DM65MUI	CA	CAS 863639-43-4
DM65MUI	DE	Obesity; Diabetic complication; Hypertension

DMVE4P3	ID	DMVE4P3
DMVE4P3	DN	AZD1704
DMVE4P3	HS	Discontinued in Phase 1
DMVE4P3	CP	AstraZeneca
DMVE4P3	DE	Pain

DMCOMG5	ID	DMCOMG5
DMCOMG5	DN	AZD-1744
DMCOMG5	HS	Discontinued in Phase 1
DMCOMG5	SN	Dual CCR3/H-1 receptor antagonist (chronic obstructive pulmonary disease (COPD)), AstraZeneca
DMCOMG5	CP	AstraZeneca plc
DMCOMG5	DE	Asthma

DMUCQPB	ID	DMUCQPB
DMUCQPB	DN	AZD-3342
DMUCQPB	HS	Discontinued in Phase 1
DMUCQPB	CP	AstraZeneca plc
DMUCQPB	DE	Chronic obstructive pulmonary disease

DM7XQTM	ID	DM7XQTM
DM7XQTM	DN	AZD-4407
DM7XQTM	HS	Discontinued in Phase 1
DM7XQTM	SN	ZD-4407
DM7XQTM	CP	AstraZeneca plc
DM7XQTM	DE	Chronic obstructive pulmonary disease

DMQ2VYT	ID	DMQ2VYT
DMQ2VYT	DN	AZD-4750
DMQ2VYT	HS	Discontinued in Phase 1
DMQ2VYT	CP	AstraZeneca plc
DMQ2VYT	DE	Multiple sclerosis

DMA3OWI	ID	DMA3OWI
DMA3OWI	DN	AZD4769
DMA3OWI	HS	Discontinued in Phase 1
DMA3OWI	SN	Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic
DMA3OWI	CP	AstraZeneca
DMA3OWI	DT	Small molecular drug
DMA3OWI	PC	124437
DMA3OWI	MW	457.6
DMA3OWI	FM	C28H27NO3S
DMA3OWI	IC	InChI=1S/C28H27NO3S/c30-28(31)20-33-27(12-6-9-21-7-2-1-3-8-21)23-14-17-25(18-15-23)32-19-24-16-13-22-10-4-5-11-26(22)29-24/h1-5,7-8,10-11,13-18,27H,6,9,12,19-20H2,(H,30,31)
DMA3OWI	CS	C1=CC=C(C=C1)CCCC(C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)SCC(=O)O
DMA3OWI	IK	JOIXGLLMSDPZDN-UHFFFAOYSA-N
DMA3OWI	IU	2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic acid
DMA3OWI	CA	CAS 127481-29-2
DMA3OWI	DE	Solid tumour/cancer

DMWKYV7	ID	DMWKYV7
DMWKYV7	DN	AZD-5099
DMWKYV7	HS	Discontinued in Phase 1
DMWKYV7	SN	Gyrase B inhibitor (serious infection), AstraZeneca
DMWKYV7	CP	AstraZeneca plc
DMWKYV7	PC	11995990
DMWKYV7	MW	548.4
DMWKYV7	FM	C21H27Cl2N5O6S
DMWKYV7	IC	InChI=1S/C21H27Cl2N5O6S/c1-9(8-33-3)24-19(30)16-17(20(31)32)35-21(27-16)28-6-5-11(12(7-28)34-4)26-18(29)15-14(23)13(22)10(2)25-15/h9,11-12,25H,5-8H2,1-4H3,(H,24,30)(H,26,29)(H,31,32)/t9-,11+,12-/m0/s1
DMWKYV7	CS	CC1=C(C(=C(N1)C(=O)N[C@@H]2CCN(C[C@@H]2OC)C3=NC(=C(S3)C(=O)O)C(=O)N[C@@H](C)COC)Cl)Cl
DMWKYV7	IK	KGZHRAVDXGQUQM-WCQGTBRESA-N
DMWKYV7	IU	2-[(3S,4R)-4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]-3-methoxypiperidin-1-yl]-4-[[(2S)-1-methoxypropan-2-yl]carbamoyl]-1,3-thiazole-5-carboxylic acid
DMWKYV7	CA	CAS 907543-25-3
DMWKYV7	DE	Infectious disease

DM8SCON	ID	DM8SCON
DM8SCON	DN	AZD5904
DM8SCON	HS	Discontinued in Phase 1
DM8SCON	SN	AZD5904; UNII-62A9CG81VN; 62A9CG81VN; AZD-5904; 3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one; 3-(((2R)-Oxolan-2-yl)methyl)-2-sulfanylidene-7H-purin-6-one; 2-Thioxanthine, TX4; SCHEMBL2288062; GTPL7728; TX-4; BDBM92469; AZD 5904; 618913-30-7; HY-111341; CS-0035112; 6H-Purin-6-one, 1,2,3,9-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-; (R)-3-((Tetrahydrofuran-2-yl)methyl)-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one; 6H-Purin-6-one, 1,2,3,7-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-
DM8SCON	CP	AstraZeneca
DM8SCON	DT	Small molecular drug
DM8SCON	PC	10264211
DM8SCON	MW	252.3
DM8SCON	FM	C10H12N4O2S
DM8SCON	IC	InChI=1S/C10H12N4O2S/c15-9-7-8(12-5-11-7)14(10(17)13-9)4-6-2-1-3-16-6/h5-6H,1-4H2,(H,11,12)(H,13,15,17)/t6-/m1/s1
DM8SCON	CS	C1C[C@@H](OC1)CN2C3=C(C(=O)NC2=S)NC=N3
DM8SCON	IK	RSPDBEVKURKEII-ZCFIWIBFSA-N
DM8SCON	IU	3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one
DM8SCON	CA	CAS 618913-30-7
DM8SCON	DE	Multiple sclerosis; Chronic obstructive pulmonary disease

DMCAKMV	ID	DMCAKMV
DMCAKMV	DN	AZD5985
DMCAKMV	HS	Discontinued in Phase 1
DMCAKMV	CP	AstraZeneca
DMCAKMV	DT	Small molecular drug
DMCAKMV	PC	9811072
DMCAKMV	MW	808.8
DMCAKMV	FM	C38H43Cl2N9O5S
DMCAKMV	IC	InChI=1S/C22H28N6O3S.C16H15Cl2N3O2/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20;1-3-9-6-12(16(22)20-8(9)2)19-7-13-21-14-10(17)4-5-11(18)15(14)23-13/h4-8,13-15,24-26H,9-12H2,1-3H3;4-6,19H,3,7H2,1-2H3,(H,20,22)
DMCAKMV	CS	CCC1=C(NC(=O)C(=C1)NCC2=NC3=C(C=CC(=C3O2)Cl)Cl)C.CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C
DMCAKMV	IK	XOJHGEHJHFRZRW-UHFFFAOYSA-N
DMCAKMV	IU	3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one;N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
DMCAKMV	DE	Chronic obstructive pulmonary disease

DMFAZLU	ID	DMFAZLU
DMFAZLU	DN	AZD6280
DMFAZLU	HS	Discontinued in Phase 1
DMFAZLU	CP	AstraZeneca
DMFAZLU	DT	Small molecular drug
DMFAZLU	PC	23630026
DMFAZLU	MW	366.4
DMFAZLU	FM	C20H22N4O3
DMFAZLU	IC	InChI=1S/C20H22N4O3/c1-4-10-22-20(25)19-17(21)14-7-5-6-13(18(14)23-24-19)15-11-12(26-2)8-9-16(15)27-3/h5-9,11H,4,10H2,1-3H3,(H2,21,23)(H,22,25)
DMFAZLU	CS	CCCNC(=O)C1=NN=C2C(=C1N)C=CC=C2C3=C(C=CC(=C3)OC)OC
DMFAZLU	IK	NVWCZRPXYVDQEE-UHFFFAOYSA-N
DMFAZLU	IU	4-amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxamide
DMFAZLU	CA	CAS 942436-93-3
DMFAZLU	DE	Schizophrenia; Anxiety disorder

DMQZCET	ID	DMQZCET
DMQZCET	DN	AZD-6553
DMQZCET	HS	Discontinued in Phase 1
DMQZCET	SN	Neutrophil elastase inhibitor (oral, COPD), AstraZeneca/Quintiles
DMQZCET	CP	AstraZeneca plc
DMQZCET	DE	Chronic obstructive pulmonary disease

DM9KLD3	ID	DM9KLD3
DM9KLD3	DN	AZD-6703
DM9KLD3	HS	Discontinued in Phase 1
DM9KLD3	SN	P38 MAP kinase inhibitors (rheumatoid arthritis), AstraZeneca
DM9KLD3	CP	AstraZeneca plc
DM9KLD3	DT	Small molecular drug
DM9KLD3	PC	11373432
DM9KLD3	MW	417.5
DM9KLD3	FM	C24H27N5O2
DM9KLD3	IC	InChI=1S/C24H27N5O2/c1-16-3-4-17(23(30)26-18-5-6-18)13-22(16)29-15-25-21-8-7-19(14-20(21)24(29)31)28-11-9-27(2)10-12-28/h3-4,7-8,13-15,18H,5-6,9-12H2,1-2H3,(H,26,30)
DM9KLD3	CS	CC1=C(C=C(C=C1)C(=O)NC2CC2)N3C=NC4=C(C3=O)C=C(C=C4)N5CCN(CC5)C
DM9KLD3	IK	ZMAZXHICVRYLQN-UHFFFAOYSA-N
DM9KLD3	IU	N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3-yl]benzamide
DM9KLD3	CA	CAS 851845-37-9
DM9KLD3	DE	Rheumatoid arthritis

DMHV3IW	ID	DMHV3IW
DMHV3IW	DN	AZD-6714
DMHV3IW	HS	Discontinued in Phase 1
DMHV3IW	CP	Astra zeneca
DMHV3IW	DE	Type-2 diabetes

DM2QHVW	ID	DM2QHVW
DM2QHVW	DN	AZD6918
DM2QHVW	HS	Discontinued in Phase 1
DM2QHVW	CP	AstraZeneca
DM2QHVW	DE	Advanced solid tumour

DMX63W1	ID	DMX63W1
DMX63W1	DN	AZD-7140
DMX63W1	HS	Discontinued in Phase 1
DMX63W1	CP	AstraZeneca plc
DMX63W1	DE	Rheumatoid arthritis; Chronic obstructive pulmonary disease

DMKF9U3	ID	DMKF9U3
DMKF9U3	DN	AZD8075
DMKF9U3	HS	Discontinued in Phase 1
DMKF9U3	CP	AstraZeneca
DMKF9U3	DE	Chronic obstructive pulmonary disease

DMW6IUB	ID	DMW6IUB
DMW6IUB	DN	AZD-8309
DMW6IUB	HS	Discontinued in Phase 1
DMW6IUB	CP	AstraZeneca plc
DMW6IUB	DE	Rheumatoid arthritis; Chronic obstructive pulmonary disease

DMUKNQ5	ID	DMUKNQ5
DMUKNQ5	DN	AZD8330
DMUKNQ5	HS	Discontinued in Phase 1
DMUKNQ5	SN	AZD8330; 869357-68-6; AZD-8330; ARRY-424704; ARRY-704; UNII-G4990BOZ66; AZD 8330; 2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; G4990BOZ66; C16H17FIN3O4; 2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide; RWEVIPRMPFNTLO-UHFFFAOYSA-N
DMUKNQ5	CP	AstraZeneca
DMUKNQ5	DT	Small molecular drug
DMUKNQ5	PC	16666708
DMUKNQ5	MW	461.23
DMUKNQ5	FM	C16H17FIN3O4
DMUKNQ5	IC	InChI=1S/C16H17FIN3O4/c1-9-7-11(15(23)20-25-6-5-22)14(21(2)16(9)24)19-13-4-3-10(18)8-12(13)17/h3-4,7-8,19,22H,5-6H2,1-2H3,(H,20,23)
DMUKNQ5	CS	CC1=CC(=C(N(C1=O)C)NC2=C(C=C(C=C2)I)F)C(=O)NOCCO
DMUKNQ5	IK	RWEVIPRMPFNTLO-UHFFFAOYSA-N
DMUKNQ5	IU	2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide
DMUKNQ5	CA	CAS 869357-68-6
DMUKNQ5	CB	CHEBI:91424
DMUKNQ5	DE	Solid tumour/cancer

DMIYEZG	ID	DMIYEZG
DMIYEZG	DN	AZD8566
DMIYEZG	HS	Discontinued in Phase 1
DMIYEZG	CP	AstraZeneca
DMIYEZG	DE	Rheumatoid arthritis; Chronic obstructive pulmonary disease

DMYSBN3	ID	DMYSBN3
DMYSBN3	DN	AZD-9272
DMYSBN3	HS	Discontinued in Phase 1
DMYSBN3	SN	AZD 9272; 327056-26-8; UNII-54SQ9B412I; AZD9272; 54SQ9B412I; 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile; CHEMBL2164550; 3-Fluoro-5-(3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl)benzonitrile; RBSPCALDSNXWEP-UHFFFAOYSA-N; SCHEMBL2027395; GTPL6439; CHEMBL2164551; MolPort-039-338-067; ZINC33980255; BDBM50395923; AKOS027470228; HY-110254; AZD9272, &gt; CS-0033119; J3.560.338G; 3-Fluoro-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]benzonitrile
DMYSBN3	CP	AstraZeneca
DMYSBN3	TC	Analgesics
DMYSBN3	DT	Small molecular drug
DMYSBN3	PC	9838729
DMYSBN3	MW	284.22
DMYSBN3	FM	C14H6F2N4O
DMYSBN3	IC	InChI=1S/C14H6F2N4O/c15-10-1-2-12(18-7-10)13-19-14(21-20-13)9-3-8(6-17)4-11(16)5-9/h1-5,7H
DMYSBN3	CS	C1=CC(=NC=C1F)C2=NOC(=N2)C3=CC(=CC(=C3)C#N)F
DMYSBN3	IK	RBSPCALDSNXWEP-UHFFFAOYSA-N
DMYSBN3	IU	3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile
DMYSBN3	CA	CAS 327056-26-8
DMYSBN3	DE	Neuropathic pain

DM1ZVO3	ID	DM1ZVO3
DM1ZVO3	DN	AZD-9343
DM1ZVO3	HS	Discontinued in Phase 1
DM1ZVO3	CP	AstraZeneca plc
DM1ZVO3	DE	Gastroesophageal reflux disease

DMK5I07	ID	DMK5I07
DMK5I07	DN	Banoxantrone
DMK5I07	HS	Discontinued in Phase 1
DMK5I07	SN	AQ4M; AQ4N; AZD-1689; AQ4N, AstraZeneca/Novacea
DMK5I07	CP	KuDOS Pharmaceuticals; Novacea
DMK5I07	DT	Small molecular drug
DMK5I07	PC	9955116
DMK5I07	MW	444.5
DMK5I07	FM	C22H28N4O6
DMK5I07	IC	InChI=1S/C22H28N4O6/c1-25(2,31)11-9-23-13-5-6-14(24-10-12-26(3,4)32)18-17(13)21(29)19-15(27)7-8-16(28)20(19)22(18)30/h5-8,23-24,27-28H,9-12H2,1-4H3
DMK5I07	CS	C[N+](C)(CCNC1=C2C(=C(C=C1)NCC[N+](C)(C)[O-])C(=O)C3=C(C=CC(=C3C2=O)O)O)[O-]
DMK5I07	IK	YZBAXVICWUUHGG-UHFFFAOYSA-N
DMK5I07	IU	2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-N,N-dimethylethanamine oxide
DMK5I07	CA	CAS 136470-65-0
DMK5I07	DE	Acute lymphoblastic leukaemia

DMGDSCK	ID	DMGDSCK
DMGDSCK	DN	BAY-27-9955
DMGDSCK	HS	Discontinued in Phase 1
DMGDSCK	SN	Glucagon antagonists, Bayer
DMGDSCK	CP	Bayer AG
DMGDSCK	DT	Small molecular drug
DMGDSCK	PC	5311277
DMGDSCK	MW	342.5
DMGDSCK	FM	C23H31FO
DMGDSCK	IC	InChI=1S/C23H31FO/c1-7-8-19-20(14(2)3)13-21(15(4)5)22(16(6)25)23(19)17-9-11-18(24)12-10-17/h9-16,25H,7-8H2,1-6H3
DMGDSCK	CS	CCCC1=C(C(=C(C=C1C(C)C)C(C)C)C(C)O)C2=CC=C(C=C2)F
DMGDSCK	IK	VDTWKXAPIQBOMO-UHFFFAOYSA-N
DMGDSCK	IU	1-[2-(4-fluorophenyl)-4,6-di(propan-2-yl)-3-propylphenyl]ethanol
DMGDSCK	CA	CAS 202855-56-9
DMGDSCK	DE	Type-2 diabetes

DMKJ3IA	ID	DMKJ3IA
DMKJ3IA	DN	BAY-73-7977
DMKJ3IA	HS	Discontinued in Phase 1
DMKJ3IA	SN	Dual-acting GLP modulator/ glucagon antagonist (diabetes), Bayer; Dual-acting glucagon-like peptide modulator/ glucagon antagonist (diabetes), Bayer
DMKJ3IA	CP	Bayer AG
DMKJ3IA	DE	Diabetic complication

DM0UEKF	ID	DM0UEKF
DM0UEKF	DN	BAY-Y-1015
DM0UEKF	HS	Discontinued in Phase 1
DM0UEKF	CP	Bayer AG
DM0UEKF	PC	9825810
DM0UEKF	MW	466.6
DM0UEKF	FM	C26H30N2O4S
DM0UEKF	IC	InChI=1S/C26H30N2O4S/c1-33(30,31)28-26(29)25(20-9-4-2-3-5-10-20)21-13-16-23(17-14-21)32-18-22-15-12-19-8-6-7-11-24(19)27-22/h6-8,11-17,20,25H,2-5,9-10,18H2,1H3,(H,28,29)/t25-/m1/s1
DM0UEKF	CS	CS(=O)(=O)NC(=O)[C@H](C1CCCCCC1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3
DM0UEKF	IK	YAWBFCPZMALJCE-RUZDIDTESA-N
DM0UEKF	IU	(2R)-2-cycloheptyl-N-methylsulfonyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetamide
DM0UEKF	CA	CAS 133012-05-2
DM0UEKF	DE	Inflammation

DMYK8OG	ID	DMYK8OG
DMYK8OG	DN	BB-2983
DMYK8OG	HS	Discontinued in Phase 1
DMYK8OG	SN	GI-245402
DMYK8OG	CP	Vernalis plc
DMYK8OG	DE	Inflammatory bowel disease

DMN2XR7	ID	DMN2XR7
DMN2XR7	DN	BCX-1470
DMN2XR7	HS	Discontinued in Phase 1
DMN2XR7	SN	BCX 1470; 217099-43-9; CHEMBL2220483; 2-(Aminoiminomethyl)benzo[b]thiophen-6-yl ester-2-Thiophenecarboxylic acid; SCHEMBL7614663; DTXSID30431348; ZINC95558579; BDBM50201566; AKOS030526719; 2-(Aminoiminomethyl)benzo[b]thiophen-6-yl ester 2-thiophenecarboxylic acid; CS-0313; RL02657; KB-74872; HY-50874; W-5553; 099A439; J-506195; 2-Thiophenecarboxylic acid 2-(aminoiminomethyl)benzo[b]thiophene-6-yl ester
DMN2XR7	CP	BioCryst Pharmaceuticals Inc
DMN2XR7	DT	Small molecular drug
DMN2XR7	PC	9822205
DMN2XR7	MW	302.4
DMN2XR7	FM	C14H10N2O2S2
DMN2XR7	IC	InChI=1S/C14H10N2O2S2/c15-13(16)12-6-8-3-4-9(7-11(8)20-12)18-14(17)10-2-1-5-19-10/h1-7H,(H3,15,16)
DMN2XR7	CS	C1=CSC(=C1)C(=O)OC2=CC3=C(C=C2)C=C(S3)C(=N)N
DMN2XR7	IK	OTGQTQBPQCRNRG-UHFFFAOYSA-N
DMN2XR7	IU	(2-carbamimidoyl-1-benzothiophen-6-yl) thiophene-2-carboxylate
DMN2XR7	DE	Bleeding disorder

DMCOKFY	ID	DMCOKFY
DMCOKFY	DN	Beloxepin
DMCOKFY	HS	Discontinued in Phase 1
DMCOKFY	SN	ADL-6906; Beloxepin (oral, pain); Beloxepin (oral, depression), Organon; Beloxepin (oral, pain), Adolor
DMCOKFY	CP	Adolor Corp; Organon BioSciences
DMCOKFY	PC	166560
DMCOKFY	MW	295.4
DMCOKFY	FM	C19H21NO2
DMCOKFY	IC	InChI=1S/C19H21NO2/c1-13-6-5-7-14-16-12-20(2)11-10-19(16,21)15-8-3-4-9-17(15)22-18(13)14/h3-9,16,21H,10-12H2,1-2H3/t16-,19-/m0/s1
DMCOKFY	CS	CC1=C2C(=CC=C1)[C@@H]3CN(CC[C@@]3(C4=CC=CC=C4O2)O)C
DMCOKFY	IK	RPMDQAYGQBREBS-LPHOPBHVSA-N
DMCOKFY	IU	(2R,7R)-4,16-dimethyl-14-oxa-4-azatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaen-7-ol
DMCOKFY	CA	CAS 135928-30-2
DMCOKFY	DE	Depression

DMQI2F4	ID	DMQI2F4
DMQI2F4	DN	BEPH
DMQI2F4	HS	Discontinued in Phase 1
DMQI2F4	SN	MDL-28314; N,N'-Bis[3-(ethylamino)propyl]-1,7-heptanediamine
DMQI2F4	DT	Small molecular drug
DMQI2F4	PC	60826
DMQI2F4	MW	300.5
DMQI2F4	FM	C17H40N4
DMQI2F4	IC	InChI=1S/C17H40N4/c1-3-18-14-10-16-20-12-8-6-5-7-9-13-21-17-11-15-19-4-2/h18-21H,3-17H2,1-2H3
DMQI2F4	CS	CCNCCCNCCCCCCCNCCCNCC
DMQI2F4	IK	WIOJAQYPAPCEMC-UHFFFAOYSA-N
DMQI2F4	IU	N,N'-bis[3-(ethylamino)propyl]heptane-1,7-diamine
DMQI2F4	CA	CAS 132004-62-7
DMQI2F4	DE	Solid tumour/cancer

DMU1YON	ID	DMU1YON
DMU1YON	DN	Berupipam
DMU1YON	HS	Discontinued in Phase 1
DMU1YON	SN	NNC-22-0010
DMU1YON	CP	Novo Nordisk A/S
DMU1YON	DT	Small molecular drug
DMU1YON	PC	66002
DMU1YON	MW	408.7
DMU1YON	FM	C19H19BrClNO2
DMU1YON	IC	InChI=1S/C19H19BrClNO2/c1-22-4-2-11-7-17(21)18(23)9-14(11)16(10-22)15-8-13(20)6-12-3-5-24-19(12)15/h6-9,16,23H,2-5,10H2,1H3/t16-/m0/s1
DMU1YON	CS	CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC(=CC4=C3OCC4)Br)O)Cl
DMU1YON	IK	DIKLCFJDIZFAOM-INIZCTEOSA-N
DMU1YON	IU	(5S)-5-(5-bromo-2,3-dihydro-1-benzofuran-7-yl)-8-chloro-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
DMU1YON	CA	CAS 150490-85-0
DMU1YON	DE	Psychotic disorder

DMMAFQP	ID	DMMAFQP
DMMAFQP	DN	Besonprodil
DMMAFQP	HS	Discontinued in Phase 1
DMMAFQP	SN	Co 200461; PD 0196860; PD 196860; PD196860; Besonprodil (USAN); 2(3H)-Benzoxazolone, 6-((2-(4-((4-fluorophenyl)methyl)-1-piperidinyl)ethyl)sulfinyl); 6-(2-(4-(4-Fluorobenzyl)-piperidin-1-yl)-ethanesulfinyl)-3H-benzoxazol-2-one; 6-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethylsulfinyl]-3H-1,3-benzoxazol-2-one
DMMAFQP	TC	Neurodegenerative
DMMAFQP	DT	Small molecular drug
DMMAFQP	PC	156328
DMMAFQP	MW	402.5
DMMAFQP	FM	C21H23FN2O3S
DMMAFQP	IC	InChI=1S/C21H23FN2O3S/c22-17-3-1-15(2-4-17)13-16-7-9-24(10-8-16)11-12-28(26)18-5-6-19-20(14-18)27-21(25)23-19/h1-6,14,16H,7-13H2,(H,23,25)
DMMAFQP	CS	C1CN(CCC1CC2=CC=C(C=C2)F)CCS(=O)C3=CC4=C(C=C3)NC(=O)O4
DMMAFQP	IK	FCBQJNCAKZSIAH-UHFFFAOYSA-N
DMMAFQP	IU	6-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethylsulfinyl]-3H-1,3-benzoxazol-2-one
DMMAFQP	CA	CAS 253450-09-8
DMMAFQP	DE	Parkinson disease

DM9F4LP	ID	DM9F4LP
DM9F4LP	DN	BIM-26226
DM9F4LP	HS	Discontinued in Phase 1
DM9F4LP	SN	D-Pentafluorophenylalanyl-L-glutaminyl-L-tryptophyl-L-alanyl-L-valyl-D-alanyl-L-histidyl-L-leucine methyl ester; (D-Pentafluorophenylalanyl6,D-alanyl11)bombesin (6-13) methyl ester
DM9F4LP	PC	9833285
DM9F4LP	MW	1075.1
DM9F4LP	FM	C49H63F5N12O10
DM9F4LP	IC	InChI=1S/C49H63F5N12O10/c1-21(2)14-34(49(75)76-7)65-47(73)33(16-26-19-57-20-59-26)63-42(68)23(5)61-48(74)41(22(3)4)66-43(69)24(6)60-46(72)32(15-25-18-58-30-11-9-8-10-27(25)30)64-45(71)31(12-13-35(56)67)62-44(70)29(55)17-28-36(50)38(52)40(54)39(53)37(28)51/h8-11,18-24,29,31-34,41,58H,12-17,55H2,1-7H3,(H2,56,67)(H,57,59)(H,60,72)(H,61,74)(H,62,70)(H,63,68)(H,64,71)(H,65,73)(H,66,69)/t23-,24+,29-,31+,32+,33+,34+,41+/m1/s1
DM9F4LP	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)OC)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H](CC4=C(C(=C(C(=C4F)F)F)F)F)N
DM9F4LP	IK	ZCTCXFYZJYFGAQ-ZZXDJSGYSA-N
DM9F4LP	IU	methyl (2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2R)-2-amino-3-(2,3,4,5,6-pentafluorophenyl)propanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoate
DM9F4LP	DE	Solid tumour/cancer

DM3HRQI	ID	DM3HRQI
DM3HRQI	DN	BINOSPIRONE MESYLATE
DM3HRQI	HS	Discontinued in Phase 1
DM3HRQI	SN	Binospirone mesylate < Rec INNM; MDL-73005EF; Rac-N-[2-[(1,4-Benzodioxan-2-ylmethyl)amino]ethyl]-1,1-cyclopentanediazetimide methanesulfonate; Rac-N-[4-(1,4-Benzodioxan-2-ylmethylamino)ethyl]-3,3-tetramethyleneglutarimide methanesulfonate; Rac-8-[2-[(2,3-Dihydro-1,4-benzodioxin-2-yl)methylamino]ethyl]-8-azaspiro[4.5]decane-7,9-dione methanesulfonate
DM3HRQI	DT	Small molecular drug
DM3HRQI	PC	71346
DM3HRQI	MW	454.5
DM3HRQI	FM	C21H30N2O7S
DM3HRQI	IC	InChI=1S/C20H26N2O4.CH4O3S/c23-18-11-20(7-3-4-8-20)12-19(24)22(18)10-9-21-13-15-14-25-16-5-1-2-6-17(16)26-15;1-5(2,3)4/h1-2,5-6,15,21H,3-4,7-14H2;1H3,(H,2,3,4)
DM3HRQI	CS	CS(=O)(=O)O.C1CCC2(C1)CC(=O)N(C(=O)C2)CCNCC3COC4=CC=CC=C4O3
DM3HRQI	IK	JXBLEDCYKVWLJI-UHFFFAOYSA-N
DM3HRQI	IU	8-[2-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)ethyl]-8-azaspiro[4.5]decane-7,9-dione;methanesulfonic acid
DM3HRQI	CA	CAS 124756-23-6
DM3HRQI	DE	Anxiety disorder

DMJWLBU	ID	DMJWLBU
DMJWLBU	DN	BL-1827
DMJWLBU	HS	Discontinued in Phase 1
DMJWLBU	CP	Bioglan Pharmaceuticals Co
DMJWLBU	DE	Cancer related pain

DMR7WYX	ID	DMR7WYX
DMR7WYX	DN	BLX-883
DMR7WYX	HS	Discontinued in Phase 1
DMR7WYX	SN	A Form of Alfa Interferon
DMR7WYX	CP	Biolex
DMR7WYX	DE	Hepatitis C virus infection

DMKFXTD	ID	DMKFXTD
DMKFXTD	DN	BMS-191095
DMKFXTD	HS	Discontinued in Phase 1
DMKFXTD	SN	BMS-199080
DMKFXTD	CP	Bristol-Myers Squibb Co
DMKFXTD	DT	Small molecular drug
DMKFXTD	PC	9822753
DMKFXTD	MW	408.9
DMKFXTD	FM	C22H21ClN4O2
DMKFXTD	IC	InChI=1S/C22H21ClN4O2/c1-22(2)21(28)20(17-11-14(12-24)3-8-18(17)29-22)27(13-19-25-9-10-26-19)16-6-4-15(23)5-7-16/h3-11,20-21,28H,13H2,1-2H3,(H,25,26)/t20-,21+/m0/s1
DMKFXTD	CS	CC1([C@@H]([C@H](C2=C(O1)C=CC(=C2)C#N)N(CC3=NC=CN3)C4=CC=C(C=C4)Cl)O)C
DMKFXTD	IK	SMIKIPXIDLITMP-LEWJYISDSA-N
DMKFXTD	IU	(3R,4S)-4-[4-chloro-N-(1H-imidazol-2-ylmethyl)anilino]-3-hydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile
DMKFXTD	DE	Angina pectoris

DMIX9O0	ID	DMIX9O0
DMIX9O0	DN	BRL-44154
DMIX9O0	HS	Discontinued in Phase 1
DMIX9O0	SN	6beta-[2-(2-Aminothiazol-4-yl)-2(Z)-(cyclopentyloxyimino)acetamido]penicillanic acid sodium salt
DMIX9O0	PC	145705961
DMIX9O0	MW	489.5
DMIX9O0	FM	C19H24N5NaO5S2
DMIX9O0	IC	InChI=1S/C19H25N5O5S2.Na/c1-19(2)14(17(27)28)24-12(25)7-10(16(24)31-19)21-15(26)13(11-8-30-18(20)22-11)23-29-9-5-3-4-6-9;/h8-10,14,16H,3-7H2,1-2H3,(H2,20,22)(H,21,26)(H,27,28);/q;+1/p-1/t10?,14?,16-;/m0./s1
DMIX9O0	CS	CC1(C(N2[C@@H](S1)C(CC2=O)NC(=O)C(=NOC3CCCC3)C4=CSC(=N4)N)C(=O)[O-])C.[Na+]
DMIX9O0	IK	YNLKSESNCYDAMV-UNXXQQGRSA-M
DMIX9O0	IU	sodium;(7aS)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-cyclopentyloxyiminoacetyl]amino]-2,2-dimethyl-5-oxo-3,6,7,7a-tetrahydropyrrolo[2,1-b][1,3]thiazole-3-carboxylate
DMIX9O0	DE	Bacterial infection

DMGVEJ6	ID	DMGVEJ6
DMGVEJ6	DN	BTS-73947
DMGVEJ6	HS	Discontinued in Phase 1
DMGVEJ6	SN	BTS-72428 (HBr salt); (+)-1-[1-(2-Chlorophenyl)cyclopropyl]-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline
DMGVEJ6	DE	Psychotic disorder

DM296HE	ID	DM296HE
DM296HE	DN	BW-1370U87
DM296HE	HS	Discontinued in Phase 1
DM296HE	SN	1-Ethylphenoxathiin-10,10-dioxide
DM296HE	DT	Small molecular drug
DM296HE	PC	126111
DM296HE	MW	260.31
DM296HE	FM	C14H12O3S
DM296HE	IC	InChI=1S/C14H12O3S/c1-2-10-6-5-8-12-14(10)18(15,16)13-9-4-3-7-11(13)17-12/h3-9H,2H2,1H3
DM296HE	CS	CCC1=C2C(=CC=C1)OC3=CC=CC=C3S2(=O)=O
DM296HE	IK	HQSRQKBSOOZLHH-UHFFFAOYSA-N
DM296HE	IU	1-ethylphenoxathiine 10,10-dioxide
DM296HE	CA	CAS 134476-36-1
DM296HE	DE	Major depressive disorder

DMUD6IK	ID	DMUD6IK
DMUD6IK	DN	BXL-746
DMUD6IK	HS	Discontinued in Phase 1
DMUD6IK	SN	VD3 analogs (inflammation), BioXell; VD3 analogs (inflammation), Roche; Vitamin D3 analogs (inflammation), BioXell; Vitamin D3 analogs (inflammation), Roche; Deuterated Gemini, (inflammation), BioXell
DMUD6IK	CP	Roche Holding AG
DMUD6IK	DE	Inflammation

DMSTN6W	ID	DMSTN6W
DMSTN6W	DN	CA9-ADC
DMSTN6W	HS	Discontinued in Phase 1
DMSTN6W	SN	MN-IC; CA IX inhibitor (solid tumor, ADC, HuCAL), MorphoSys/Bayer Schering Pharma; Carbonic anhydrase IX inhibitor (solid tumor, antibody-drug conjugate, HuCAL), MorphoSys/Bayer Schering Pharma
DMSTN6W	CP	MorphoSys AG
DMSTN6W	DT	Antibody
DMSTN6W	DE	Solid tumour/cancer

DMQ4HUA	ID	DMQ4HUA
DMQ4HUA	DN	CAB-2
DMQ4HUA	HS	Discontinued in Phase 1
DMQ4HUA	SN	MLN2222
DMQ4HUA	CP	Millennium Pharmaceuticals
DMQ4HUA	DE	Coronary artery disease

DMQIWZL	ID	DMQIWZL
DMQIWZL	DN	Candoxatrilat
DMQIWZL	HS	Discontinued in Phase 1
DMQIWZL	SN	Candoxatrilat < Rec INN; UK-69578; UK-73967; Cis-4-[[[1-[2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; (+)-cis-4-[1-[(S)-2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentylcarbonylamino]cyclohexanecarboxylic acid; 3-[1-(4-cis-Carboxycyclohexylcarbamoyl)cyclopentyl]-2(R,S)-(2-methoxyethoxymethyl)propanoic acid
DMQIWZL	DT	Small molecular drug
DMQIWZL	PC	443380
DMQIWZL	MW	399.5
DMQIWZL	FM	C20H33NO7
DMQIWZL	IC	InChI=1S/C20H33NO7/c1-27-10-11-28-13-15(18(24)25)12-20(8-2-3-9-20)19(26)21-16-6-4-14(5-7-16)17(22)23/h14-16H,2-13H2,1H3,(H,21,26)(H,22,23)(H,24,25)/t14?,15-,16?/m0/s1
DMQIWZL	CS	COCCOC[C@H](CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)O
DMQIWZL	IK	ACZWIDANLCXHBM-PCKAHOCUSA-N
DMQIWZL	IU	4-[[1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
DMQIWZL	CA	CAS 123122-54-3
DMQIWZL	CB	CHEBI:3354
DMQIWZL	DE	Heart failure

DMYCPF9	ID	DMYCPF9
DMYCPF9	DN	CB-182804
DMYCPF9	HS	Discontinued in Phase 1
DMYCPF9	SN	Polymyxin B analog (iv antibiotic, multidrug-resistant Gram negative bacterial infection), Cubist/BioSource
DMYCPF9	CP	Cubist Pharmaceuticals Inc
DMYCPF9	PC	52918383
DMYCPF9	MW	1216.8
DMYCPF9	FM	C54H86ClN17O13
DMYCPF9	IC	InChI=1S/C54H86ClN17O13/c1-28(2)26-40-50(81)64-34(14-20-56)44(75)63-37(17-23-59)48(79)71-42(29(3)73)52(83)61-25-19-39(47(78)62-35(15-21-57)46(77)68-41(51(82)67-40)27-31-10-6-5-7-11-31)65-45(76)36(16-22-58)66-53(84)43(30(4)74)72-49(80)38(18-24-60)70-54(85)69-33-13-9-8-12-32(33)55/h5-13,28-30,34-43,73-74H,14-27,56-60H2,1-4H3,(H,61,83)(H,62,78)(H,63,75)(H,64,81)(H,65,76)(H,66,84)(H,67,82)(H,68,77)(H,71,79)(H,72,80)(H2,69,70,85)/t29-,30-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+/m1/s1
DMYCPF9	CS	C[C@H]([C@H]1C(=O)NCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCN)CCN)CC(C)C)CC2=CC=CC=C2)CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)NC3=CC=CC=C3Cl)O
DMYCPF9	IK	OINMSSZOBLWDTB-SHGLBBHXSA-N
DMYCPF9	IU	(2S,3R)-2-[[(2S)-4-amino-2-[(2-chlorophenyl)carbamoylamino]butanoyl]amino]-N-[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15S,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]-3-hydroxybutanamide
DMYCPF9	DE	Bacterial infection

DM3G4JD	ID	DM3G4JD
DM3G4JD	DN	CBD cannabis derivative
DM3G4JD	HS	Discontinued in Phase 1
DM3G4JD	SN	AC1L5AAH; (6,6-dimethyl-3-nonan-2-yl-7,8,9,10-tetrahydrobenzo[c]chromen-1-yl) 5-(diethylamino)pentanoate
DM3G4JD	CP	GW Pharmaceuticals
DM3G4JD	DT	Small molecular drug
DM3G4JD	PC	173616
DM3G4JD	MW	511.8
DM3G4JD	FM	C33H53NO3
DM3G4JD	IC	InChI=1S/C33H53NO3/c1-7-10-11-12-13-18-25(4)26-23-29(36-31(35)21-16-17-22-34(8-2)9-3)32-27-19-14-15-20-28(27)33(5,6)37-30(32)24-26/h23-25H,7-22H2,1-6H3
DM3G4JD	CS	CCCCCCCC(C)C1=CC2=C(C3=C(CCCC3)C(O2)(C)C)C(=C1)OC(=O)CCCCN(CC)CC
DM3G4JD	IK	LKZQTNSAWVCNMU-UHFFFAOYSA-N
DM3G4JD	IU	(6,6-dimethyl-3-nonan-2-yl-7,8,9,10-tetrahydrobenzo[c]chromen-1-yl) 5-(diethylamino)pentanoate
DM3G4JD	DE	Schizophrenia

DMMEC1W	ID	DMMEC1W
DMMEC1W	DN	CCD-3693
DMMEC1W	HS	Discontinued in Phase 1
DMMEC1W	SN	CCD 3000 series, CoCensys; CCD-3393; Epalon series member (3693), CoCensys; Insomnia therapy, CoCensys/Searle
DMMEC1W	CP	Purdue Neuroscience Corp
DMMEC1W	DT	Small molecular drug
DMMEC1W	PC	192705
DMMEC1W	MW	386.5
DMMEC1W	FM	C22H33F3O2
DMMEC1W	IC	InChI=1S/C22H33F3O2/c1-13(26)16-6-7-17-15-5-4-14-12-21(27,22(23,24)25)11-10-19(14,2)18(15)8-9-20(16,17)3/h14-18,27H,4-12H2,1-3H3/t14-,15-,16+,17-,18-,19-,20+,21-/m0/s1
DMMEC1W	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@](C4)(C(F)(F)F)O)C)C
DMMEC1W	IK	BLMOPJSSNJGYSZ-PECKBWEZSA-N
DMMEC1W	IU	1-[(3S,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-3-(trifluoromethyl)-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
DMMEC1W	CA	CAS 177080-77-2
DMMEC1W	DE	Anxiety disorder

DMD8QHV	ID	DMD8QHV
DMD8QHV	DN	CCX-832
DMD8QHV	HS	Discontinued in Phase 1
DMD8QHV	SN	ChemR2 receptor antagonist (inflammation), ChemoCentryx/GlaxoSmithKline
DMD8QHV	CP	ChemoCentryx Inc
DMD8QHV	DE	Psoriasis vulgaris

DMHMST3	ID	DMHMST3
DMHMST3	DN	CCX915
DMHMST3	HS	Discontinued in Phase 1
DMHMST3	SN	Meglitinide; 54870-28-9; Meglitinide [INN]; Meglitinidum [INN-Latin]; Meglitinido [INN-Spanish]; HB 699; UNII-8V6OK1I088; BRN 2817215; 8V6OK1I088; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)benzoic acid; 4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)benzoasaeure [German]; p-(2-(5-Chloro-o-anisamido)ethyl)benzoic acid; C17H16ClNO4; 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid; Meglitinido; Meglitinidum; Benzoic acid, 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]-
DMHMST3	CP	ChemoCentryx
DMHMST3	DT	Small molecular drug
DMHMST3	PC	41214
DMHMST3	MW	333.8
DMHMST3	FM	C17H16ClNO4
DMHMST3	IC	InChI=1S/C17H16ClNO4/c1-23-15-7-6-13(18)10-14(15)16(20)19-9-8-11-2-4-12(5-3-11)17(21)22/h2-7,10H,8-9H2,1H3,(H,19,20)(H,21,22)
DMHMST3	CS	COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)C(=O)O
DMHMST3	IK	SWLAMJPTOQZTAE-UHFFFAOYSA-N
DMHMST3	IU	4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid
DMHMST3	CA	CAS 54870-28-9
DMHMST3	DE	Multiple sclerosis

DMOCBQW	ID	DMOCBQW
DMOCBQW	DN	CD-581
DMOCBQW	HS	Discontinued in Phase 1
DMOCBQW	SN	1-(Eicosa-5,8,11-triynoyl)-4-(2-hydroxyethyl)piperazine; 4-(1-Oxo-5,8,11-eicosatriynyl)-1-piprazineethanol
DMOCBQW	DE	Atopic dermatitis

DM5BG4P	ID	DM5BG4P
DM5BG4P	DN	CDP-1050
DM5BG4P	HS	Discontinued in Phase 1
DM5BG4P	SN	Ryanodine receptor modulators (heart failure), Cordex; Ryanodine receptor modulators (heart failure), Duke University; Ryanodine receptor modulators (heart failure), Duska Therapeutics
DM5BG4P	CP	Duke University
DM5BG4P	DE	Heart failure

DMJVZ9O	ID	DMJVZ9O
DMJVZ9O	DN	Cefdaloxime pentexil tosilate
DMJVZ9O	HS	Discontinued in Phase 1
DMJVZ9O	SN	HR-916B; HRT-916K; Cefdaloxime Pentexil Tosilate; HR-916J (1'R,6R, 7R);HR-916K (1'S,6R,7R); (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(pivaloyloxy)ethyl ester 7(2)-(Z)-oxime tosylate; (6R,7R)-7-[2-(2-Aminothiazol-4-yl)-2(Z)-(hydroxyimino)acetamido]-3-(methoxymethyl)-3-cephem-4-carboxylic acid 1-(2,2-dimethylpropanoyloxy)ethyl ester tosylate
DMJVZ9O	DE	Bacterial infection

DMO075K	ID	DMO075K
DMO075K	DN	CEFTRAZONAL BOPENTIL
DMO075K	HS	Discontinued in Phase 1
DMO075K	SN	Ro-41-3399; (6R,7R)-7-[2-(2-Aminothiazol-4-yl)-2(Z)-(methoxyimino)acetamido]-3-(azidomethyl)-3-cephem-4-carboxylic acid 2-(isobutoxycarbonyl)-2(E)-pentenyl ester
DMO075K	DT	Small molecular drug
DMO075K	PC	9577440
DMO075K	MW	606.7
DMO075K	FM	C24H30N8O7S2
DMO075K	IC	InChI=1S/C24H30N8O7S2/c1-5-6-13(22(35)38-8-12(2)3)9-39-23(36)18-14(7-27-31-26)10-40-21-17(20(34)32(18)21)29-19(33)16(30-37-4)15-11-41-24(25)28-15/h6,11-12,17,21H,5,7-10H2,1-4H3,(H2,25,28)(H,29,33)/b13-6-,30-16+/t17-,21-/m1/s1
DMO075K	CS	CC/C=C(/COC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N/OC)/C3=CSC(=N3)N)CN=[N+]=[N-])\\C(=O)OCC(C)C
DMO075K	IK	FHPWLEQQFDSPCU-SVEZEBCVSA-N
DMO075K	IU	[(Z)-2-(2-methylpropoxycarbonyl)pent-2-enyl] (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(azidomethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMO075K	CA	CAS 124084-44-2
DMO075K	DE	Bacterial infection

DMH1PQ0	ID	DMH1PQ0
DMH1PQ0	DN	CEP-2563
DMH1PQ0	HS	Discontinued in Phase 1
DMH1PQ0	SN	KT-8391; L-Lysyl-beta-alanine 9(S),12(R)-Epoxy-10(S)-methoxy-9-methyl-1-oxo-2,3,9,10,11,12-hexahydro-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-ylmethyl ester dihydrochloride
DMH1PQ0	DE	Solid tumour/cancer

DMK93VQ	ID	DMK93VQ
DMK93VQ	DN	CEREBROCRAST
DMK93VQ	HS	Discontinued in Phase 1
DMK93VQ	SN	IOS-1.1212; 4-[2-(Difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid di(2-propoxyethyl) diester
DMK93VQ	DT	Small molecular drug
DMK93VQ	PC	159556
DMK93VQ	MW	511.6
DMK93VQ	FM	C26H35F2NO7
DMK93VQ	IC	InChI=1S/C26H35F2NO7/c1-5-11-32-13-15-34-24(30)21-17(3)29-18(4)22(25(31)35-16-14-33-12-6-2)23(21)19-9-7-8-10-20(19)36-26(27)28/h7-10,23,26,29H,5-6,11-16H2,1-4H3
DMK93VQ	CS	CCCOCCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2OC(F)F)C(=O)OCCOCCC)C)C
DMK93VQ	IK	ASCWBYZMMHUZMQ-UHFFFAOYSA-N
DMK93VQ	IU	bis(2-propoxyethyl) 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMK93VQ	CA	CAS 118790-71-9
DMK93VQ	DE	Nerve injury

DMQKRWO	ID	DMQKRWO
DMQKRWO	DN	CERM-11956
DMQKRWO	HS	Discontinued in Phase 1
DMQKRWO	SN	N-(1,3-Benzodioxolan-5-yl)-N-phenylmethyl-beta-[(2-methylpropoxy)methyl]-1-pyrrolidinylethanamine fumarate; 2-(N-Pyrrolidino)-3-isobutoxy-N-(3,4-methylenedioxyphenyl)-N-benzylpropylamine fumarate
DMQKRWO	DT	Small molecular drug
DMQKRWO	PC	6438764
DMQKRWO	MW	526.6
DMQKRWO	FM	C29H38N2O7
DMQKRWO	IC	InChI=1S/C25H34N2O3.C4H4O4/c1-3-20(2)28-18-23(26-13-7-8-14-26)17-27(16-21-9-5-4-6-10-21)22-11-12-24-25(15-22)30-19-29-24;5-3(6)1-2-4(7)8/h4-6,9-12,15,20,23H,3,7-8,13-14,16-19H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMQKRWO	CS	CCC(C)OCC(CN(CC1=CC=CC=C1)C2=CC3=C(C=C2)OCO3)N4CCCC4.C(=C/C(=O)O)\\C(=O)O
DMQKRWO	IK	RDZJRZMQCVQTSK-WLHGVMLRSA-N
DMQKRWO	IU	N-benzyl-N-(3-butan-2-yloxy-2-pyrrolidin-1-ylpropyl)-1,3-benzodioxol-5-amine;(E)-but-2-enedioic acid
DMQKRWO	CA	CAS 97631-49-7
DMQKRWO	DE	Angina pectoris

DM85SYL	ID	DM85SYL
DM85SYL	DN	Cetefloxacin
DM85SYL	HS	Discontinued in Phase 1
DM85SYL	SN	E-4868
DM85SYL	CP	Esteve
DM85SYL	DT	Small molecular drug
DM85SYL	PC	65995
DM85SYL	MW	403.4
DM85SYL	FM	C20H16F3N3O3
DM85SYL	IC	InChI=1S/C20H16F3N3O3/c1-9-15(24)8-25(9)18-6-17-11(5-14(18)23)19(27)12(20(28)29)7-26(17)16-3-2-10(21)4-13(16)22/h2-7,9,15H,8,24H2,1H3,(H,28,29)/t9-,15+/m0/s1
DM85SYL	CS	C[C@H]1[C@@H](CN1C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F)N
DM85SYL	IK	LTDOHCZUKCZDEQ-BJOHPYRUSA-N
DM85SYL	IU	7-[(2S,3R)-3-amino-2-methylazetidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
DM85SYL	CA	CAS 141725-88-4
DM85SYL	DE	Bacterial infection

DMOULQ4	ID	DMOULQ4
DMOULQ4	DN	CGP-37849
DMOULQ4	HS	Discontinued in Phase 1
DMOULQ4	SN	CGP-39551; CGP-40116; CGP-43487; Ethyl ester of CGP-37849; 4-methyl-APPA
DMOULQ4	CP	Novartis AG
DMOULQ4	DT	Small molecular drug
DMOULQ4	PC	5950212
DMOULQ4	MW	209.14
DMOULQ4	FM	C6H12NO5P
DMOULQ4	IC	InChI=1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+
DMOULQ4	CS	C/C(=C\\C(C(=O)O)N)/CP(=O)(O)O
DMOULQ4	IK	BDYHNCZIGYIOGJ-DUXPYHPUSA-N
DMOULQ4	IU	(E)-2-amino-4-methyl-5-phosphonopent-3-enoic acid
DMOULQ4	CA	CAS 127910-31-0
DMOULQ4	DE	Neurological disorder

DMY8KO4	ID	DMY8KO4
DMY8KO4	DN	CGP-48369
DMY8KO4	HS	Discontinued in Phase 1
DMY8KO4	SN	CGS-48369
DMY8KO4	CP	Novartis AG
DMY8KO4	DT	Small molecular drug
DMY8KO4	PC	135423125
DMY8KO4	MW	442.6
DMY8KO4	FM	C26H30N6O
DMY8KO4	IC	InChI=1S/C26H30N6O/c1-3-5-11-23-22(26(33)28-24(27-23)12-6-4-2)17-18-13-15-19(16-14-18)20-9-7-8-10-21(20)25-29-31-32-30-25/h7-10,13-16H,3-6,11-12,17H2,1-2H3,(H,27,28,33)(H,29,30,31,32)
DMY8KO4	CS	CCCCC1=C(C(=O)NC(=N1)CCCC)CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4
DMY8KO4	IK	UKEZYWUWLICNPR-UHFFFAOYSA-N
DMY8KO4	IU	2,4-dibutyl-5-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1H-pyrimidin-6-one
DMY8KO4	CA	CAS 135689-23-5
DMY8KO4	DE	Hypertension

DMF0O2H	ID	DMF0O2H
DMF0O2H	DN	CGP-53437
DMF0O2H	HS	Discontinued in Phase 1
DMF0O2H	SN	CGP-58707
DMF0O2H	CP	Novartis AG
DMF0O2H	DT	Small molecular drug
DMF0O2H	PC	5480679
DMF0O2H	MW	728.9
DMF0O2H	FM	C42H56N4O7
DMF0O2H	IC	InChI=1S/C42H56N4O7/c1-29(2)37(39(49)43-35(27-32-19-13-8-14-20-32)40(50)46-21-23-52-24-22-46)45-38(48)33(25-30-15-9-6-10-16-30)28-36(47)34(26-31-17-11-7-12-18-31)44-41(51)53-42(3,4)5/h6-20,29,33-37,47H,21-28H2,1-5H3,(H,43,49)(H,44,51)(H,45,48)/t33-,34+,35+,36+,37+/m1/s1
DMF0O2H	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCOCC2)NC(=O)[C@H](CC3=CC=CC=C3)C[C@@H]([C@H](CC4=CC=CC=C4)NC(=O)OC(C)(C)C)O
DMF0O2H	IK	NAJDZKGRZBLNON-RKGCBODKSA-N
DMF0O2H	IU	tert-butyl N-[(2S,3S,5R)-5-benzyl-3-hydroxy-6-[[(2S)-3-methyl-1-[[(2S)-1-morpholin-4-yl-1-oxo-3-phenylpropan-2-yl]amino]-1-oxobutan-2-yl]amino]-6-oxo-1-phenylhexan-2-yl]carbamate
DMF0O2H	DE	Human immunodeficiency virus infection

DMF05DL	ID	DMF05DL
DMF05DL	DN	CGS-22652
DMF05DL	HS	Discontinued in Phase 1
DMF05DL	SN	Cgs 22652; CGS-22652; CHEMBL65414; (+-)-gamma-(4-(((4-Chlorophenyl)sulfonyl)amino)butyl)-3-pyridineheptanoic acid; (R,S)-8-((4-Chlorophenylsulfonyl)amino)-4-(3-(3-pyridinyl)propyl)octanoic acid; 3-Pyridineheptanoic acid, gamma-(4-(((4-chlorophenyl)sulfonyl)amino)butyl)-, (+-)-; C22H29ClN2O4S; AC1L2ZNZ; 8-CSAPOA; SCHEMBL9710116; 8-(4-Chloro-benzenesulfonylamino)-4-(3-pyridin-3-yl-propyl)-octanoic acid; ISMHAZMNDUAHLK-UHFFFAOYSA-N; BDBM50003776; 134235-78-2; LS-131625; L004635
DMF05DL	DT	Small molecular drug
DMF05DL	PC	131717
DMF05DL	MW	453
DMF05DL	FM	C22H29ClN2O4S
DMF05DL	IC	InChI=1S/C22H29ClN2O4S/c23-20-10-12-21(13-11-20)30(28,29)25-16-2-1-5-18(9-14-22(26)27)6-3-7-19-8-4-15-24-17-19/h4,8,10-13,15,17-18,25H,1-3,5-7,9,14,16H2,(H,26,27)
DMF05DL	CS	C1=CC(=CN=C1)CCCC(CCCCNS(=O)(=O)C2=CC=C(C=C2)Cl)CCC(=O)O
DMF05DL	IK	ISMHAZMNDUAHLK-UHFFFAOYSA-N
DMF05DL	IU	8-[(4-chlorophenyl)sulfonylamino]-4-(3-pyridin-3-ylpropyl)octanoic acid
DMF05DL	CA	CAS 134235-78-2
DMF05DL	DE	Angina pectoris

DM0JUAL	ID	DM0JUAL
DM0JUAL	DN	ChelASE
DM0JUAL	HS	Discontinued in Phase 1
DM0JUAL	SN	VitrenASE; VIT-100
DM0JUAL	CP	Immusol
DM0JUAL	DE	Retina disorder

DMJ5UYL	ID	DMJ5UYL
DMJ5UYL	DN	Chpmpc
DMJ5UYL	HS	Discontinued in Phase 1
DMJ5UYL	SN	Cyclic HPMPC; Cyclic cidofovir; Cidofovir prodrug, Gilead; GS-504 analog; GS-930
DMJ5UYL	CP	Gilead Sciences Inc
DMJ5UYL	DT	Small molecular drug
DMJ5UYL	PC	122873
DMJ5UYL	MW	261.17
DMJ5UYL	FM	C8H12N3O5P
DMJ5UYL	IC	InChI=1S/C8H12N3O5P/c9-7-1-2-11(8(12)10-7)3-6-4-16-17(13,14)5-15-6/h1-2,6H,3-5H2,(H,13,14)(H2,9,10,12)/t6-/m0/s1
DMJ5UYL	CS	C1[C@@H](OCP(=O)(O1)O)CN2C=CC(=NC2=O)N
DMJ5UYL	IK	YXQUGSXUDFTPLL-LURJTMIESA-N
DMJ5UYL	IU	4-amino-1-[[(5S)-2-hydroxy-2-oxo-1,4,2lambda5-dioxaphosphinan-5-yl]methyl]pyrimidin-2-one
DMJ5UYL	CA	CAS 127757-45-3
DMJ5UYL	DE	Virus infection

DM9ZBO0	ID	DM9ZBO0
DM9ZBO0	DN	CI-972
DM9ZBO0	HS	Discontinued in Phase 1
DM9ZBO0	DT	Small molecular drug
DM9ZBO0	PC	135418360
DM9ZBO0	MW	297.76
DM9ZBO0	FM	C11H12ClN5OS
DM9ZBO0	IC	InChI=1S/C11H11N5OS.ClH/c12-9-6(3-5-1-2-18-4-5)7-8(14-9)10(17)16-11(13)15-7;/h1-2,4,14H,3,12H2,(H3,13,15,16,17);1H
DM9ZBO0	CS	C1=CSC=C1CC2=C(NC3=C2N=C(NC3=O)N)N.Cl
DM9ZBO0	IK	SLNICZJKQXPOJA-UHFFFAOYSA-N
DM9ZBO0	IU	2,6-diamino-7-(thiophen-3-ylmethyl)-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one;hydrochloride
DM9ZBO0	CA	CAS 115787-68-3
DM9ZBO0	DE	Rheumatoid arthritis

DM3Q8UW	ID	DM3Q8UW
DM3Q8UW	DN	CJC-1004
DM3Q8UW	HS	Discontinued in Phase 1
DM3Q8UW	SN	CCI-1004; DAC-TI; DAC-Thrombin Inhibitor; Thrombin inhibitor, Conjuchem
DM3Q8UW	CP	ConjuChem Biotechnologies Inc
DM3Q8UW	DE	Thrombosis

DMSB7WV	ID	DMSB7WV
DMSB7WV	DN	CL-277082
DMSB7WV	HS	Discontinued in Phase 1
DMSB7WV	SN	CL-277082; UNII-KOF50RA8PQ; KOF50RA8PQ; CHEMBL277986; 3-(2,4-difluorophenyl)-1-[4-(2,2-dimethylpropyl)benzyl]-1-heptylurea; Ddpmhu; AC1Q5MV2; AC1L2PE2; SCHEMBL408973; CTK8D5698; BDBM50022279; ZINC36330844; CL 277082; N'-(2,4-DIFLUOROPHENYL)-N-HEPTYL-N-(4-NEOPENTYLBENZYL)UREA; Urea, N'-(2,4-difluorophenyl)-N-((4-(2,2-dimethylpropyl)phenyl)methyl)-N-heptyl-; 3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea; 3-(2,4-Difluoro-phenyl)-1-[4-(2,2-dimethyl-propyl)-benzyl]-1-heptyl-urea
DMSB7WV	CP	Lederle Laboratories
DMSB7WV	DT	Small molecular drug
DMSB7WV	PC	125893
DMSB7WV	MW	430.6
DMSB7WV	FM	C26H36F2N2O
DMSB7WV	IC	InChI=1S/C26H36F2N2O/c1-5-6-7-8-9-16-30(25(31)29-24-15-14-22(27)17-23(24)28)19-21-12-10-20(11-13-21)18-26(2,3)4/h10-15,17H,5-9,16,18-19H2,1-4H3,(H,29,31)
DMSB7WV	CS	CCCCCCCN(CC1=CC=C(C=C1)CC(C)(C)C)C(=O)NC2=C(C=C(C=C2)F)F
DMSB7WV	IK	QKJLDOBXDUVGEE-UHFFFAOYSA-N
DMSB7WV	IU	3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea
DMSB7WV	CA	CAS 96224-26-9
DMSB7WV	DE	Arteriosclerosis

DMYPFLR	ID	DMYPFLR
DMYPFLR	DN	Clomet
DMYPFLR	HS	Discontinued in Phase 1
DMYPFLR	SN	DMPEN (cancer), Xanthus Pharmaceuticals; Demethylpenclomedine (cancer), Xanthus Pharmaceuticals
DMYPFLR	CP	Xanthus Life Sciences
DMYPFLR	DE	Solid tumour/cancer

DM1C4IN	ID	DM1C4IN
DM1C4IN	DN	CP-105696
DM1C4IN	HS	Discontinued in Phase 1
DM1C4IN	SN	CP-105696; UNII-Z7354TW4BM; CP 105696; CP-105,696; CP105696; CHEMBL51770; Z7354TW4BM; 158081-99-3; Pfizer 105696; 1-(3-(4-phenylbenzyl)-4-hydroxychroman-7-yl)cyclopentane-1-carboxylic acid; DSSTox_RID_82258; DSSTox_CID_27308; DSSTox_GSID_47308; Cyclopentanecarboxylic acid, 1-((3S,4R)-3-((1,1'-biphenyl)-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl)-; SCHEMBL1898224; GTPL3368; DTXSID7047308; Tox21_300468; BDBM50037218; 1-[(3S,4R)-4-hydroxy-3-[(4-phenylphenyl)methyl]chroman-7-yl]cyclopentane-1-carboxylic Acid
DM1C4IN	DT	Small molecular drug
DM1C4IN	PC	9867257
DM1C4IN	MW	428.5
DM1C4IN	FM	C28H28O4
DM1C4IN	IC	InChI=1S/C28H28O4/c29-26-22(16-19-8-10-21(11-9-19)20-6-2-1-3-7-20)18-32-25-17-23(12-13-24(25)26)28(27(30)31)14-4-5-15-28/h1-3,6-13,17,22,26,29H,4-5,14-16,18H2,(H,30,31)/t22-,26+/m0/s1
DM1C4IN	CS	C1CCC(C1)(C2=CC3=C(C=C2)[C@@H]([C@H](CO3)CC4=CC=C(C=C4)C5=CC=CC=C5)O)C(=O)O
DM1C4IN	IK	KMNLXCBYBKHKSK-BKMJKUGQSA-N
DM1C4IN	IU	1-[(3S,4R)-4-hydroxy-3-[(4-phenylphenyl)methyl]-3,4-dihydro-2H-chromen-7-yl]cyclopentane-1-carboxylic acid
DM1C4IN	CA	CAS 158081-99-3
DM1C4IN	DE	Inflammatory bowel disease

DMTM0UI	ID	DMTM0UI
DMTM0UI	DN	CP-66948
DMTM0UI	HS	Discontinued in Phase 1
DMTM0UI	SN	N1-[4-(2-Methyl-1H-imidazol-4-yl)-2-thiazolyl]-N3-pentylguanidine; 4-(2-Methylimidazol-4-yl)-2-(N-pentyldiaminomethyleneamino)thiazole
DMTM0UI	DT	Small molecular drug
DMTM0UI	PC	127772
DMTM0UI	MW	292.41
DMTM0UI	FM	C13H20N6S
DMTM0UI	IC	InChI=1S/C13H20N6S/c1-3-4-5-6-15-12(14)19-13-18-11(8-20-13)10-7-16-9(2)17-10/h7-8H,3-6H2,1-2H3,(H,16,17)(H3,14,15,18,19)
DMTM0UI	CS	CCCCCN=C(N)NC1=NC(=CS1)C2=CN=C(N2)C
DMTM0UI	IK	OZSXWXGDJLBJQO-UHFFFAOYSA-N
DMTM0UI	IU	1-[4-(2-methyl-1H-imidazol-5-yl)-1,3-thiazol-2-yl]-2-pentylguanidine
DMTM0UI	CA	CAS 101189-47-3
DMTM0UI	DE	Gastric ulcer

DMZ0YU7	ID	DMZ0YU7
DMZ0YU7	DN	CP-800569
DMZ0YU7	HS	Discontinued in Phase 1
DMZ0YU7	SN	(2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol
DMZ0YU7	CP	Pfizer
DMZ0YU7	DT	Small molecular drug
DMZ0YU7	PC	6918520
DMZ0YU7	MW	565.9
DMZ0YU7	FM	C26H23ClF7NO3
DMZ0YU7	IC	InChI=1S/C26H23ClF7NO3/c1-2-17-12-20(9-10-22(17)27)37-19-7-4-6-18(13-19)35(15-23(36)25(30,31)32)14-16-5-3-8-21(11-16)38-26(33,34)24(28)29/h3-13,23-24,36H,2,14-15H2,1H3/t23-/m1/s1
DMZ0YU7	CS	CCC1=C(C=CC(=C1)OC2=CC=CC(=C2)N(CC3=CC(=CC=C3)OC(C(F)F)(F)F)C[C@H](C(F)(F)F)O)Cl
DMZ0YU7	IK	VHSPKQAESIGBIC-HSZRJFAPSA-N
DMZ0YU7	IU	(2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol
DMZ0YU7	DE	Arteriosclerosis

DMWVBGD	ID	DMWVBGD
DMWVBGD	DN	CR-2093
DMWVBGD	HS	Discontinued in Phase 1
DMWVBGD	SN	CR-2093; CR 2093; 136374-73-7; AC1L303W; 4-(3-Chlorobenzamido)-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid; (R)-4-(3-Chlorobenzoylamino)-5-oxo-5-(3,3-dimethylbutylamino)valeric acid; (4R)-4-[(3-chlorobenzoyl)amino]-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid; Pentanoic acid, 4-((3-chlorobenzoyl)amino)-5-((3,3-dimethylbutyl)amino)-5-oxo-, (R)-
DMWVBGD	CP	Rotta Research Lab SpA
DMWVBGD	DT	Small molecular drug
DMWVBGD	PC	131954
DMWVBGD	MW	368.9
DMWVBGD	FM	C18H25ClN2O4
DMWVBGD	IC	InChI=1S/C18H25ClN2O4/c1-18(2,3)9-10-20-17(25)14(7-8-15(22)23)21-16(24)12-5-4-6-13(19)11-12/h4-6,11,14H,7-10H2,1-3H3,(H,20,25)(H,21,24)(H,22,23)/t14-/m1/s1
DMWVBGD	CS	CC(C)(C)CCNC(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=CC=C1)Cl
DMWVBGD	IK	VUYSXYHJEIPUTG-CQSZACIVSA-N
DMWVBGD	IU	(4R)-4-[(3-chlorobenzoyl)amino]-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid
DMWVBGD	CA	CAS 136374-73-7
DMWVBGD	DE	Intestine cancer

DMVDLT4	ID	DMVDLT4
DMVDLT4	DN	CS-4771
DMVDLT4	HS	Discontinued in Phase 1
DMVDLT4	CP	Daiichi Sankyo
DMVDLT4	PC	288
DMVDLT4	MW	161.2
DMVDLT4	FM	C7H15NO3
DMVDLT4	IC	InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3
DMVDLT4	CS	C[N+](C)(C)CC(CC(=O)[O-])O
DMVDLT4	IK	PHIQHXFUZVPYII-UHFFFAOYSA-N
DMVDLT4	IU	3-hydroxy-4-(trimethylazaniumyl)butanoate
DMVDLT4	CA	CAS 406-76-8
DMVDLT4	CB	CHEBI:17126
DMVDLT4	DE	Sepsis

DMXKB8V	ID	DMXKB8V
DMXKB8V	DN	CS-526
DMXKB8V	HS	Discontinued in Phase 1
DMXKB8V	SN	AKU-517; R-105266
DMXKB8V	CP	Sankyo Co Ltd
DMXKB8V	PC	9833312
DMXKB8V	MW	339.4
DMXKB8V	FM	C20H22FN3O
DMXKB8V	IC	InChI=1S/C20H22FN3O/c1-12-8-16(12)10-24-14(3)13(2)18-9-22-23-20(19(18)24)25-11-15-4-6-17(21)7-5-15/h4-7,9,12,16H,8,10-11H2,1-3H3/t12-,16+/m0/s1
DMXKB8V	CS	C[C@H]1C[C@@H]1CN2C(=C(C3=CN=NC(=C32)OCC4=CC=C(C=C4)F)C)C
DMXKB8V	IK	NXPLYKRKIFPEOA-BLLLJJGKSA-N
DMXKB8V	IU	7-[(4-fluorophenyl)methoxy]-2,3-dimethyl-1-[[(1S,2S)-2-methylcyclopropyl]methyl]pyrrolo[2,3-d]pyridazine
DMXKB8V	DE	Gastroesophageal reflux disease

DMXY43L	ID	DMXY43L
DMXY43L	DN	CTP-354
DMXY43L	HS	Discontinued in Phase 1
DMXY43L	CP	Concert pharmaceuticals
DMXY43L	PC	46183193
DMXY43L	MW	408.5
DMXY43L	FM	C19H19F2N7O
DMXY43L	IC	InChI=1S/C19H19F2N7O/c1-19(2,3)13-8-15-24-25-17(12-7-11(20)5-6-14(12)21)28(15)26-18(13)29-9-16-22-10-23-27(16)4/h5-8,10H,9H2,1-4H3/i1D3,2D3,3D3
DMXY43L	CS	[2H]C([2H])([2H])C(C1=CC2=NN=C(N2N=C1OCC3=NC=NN3C)C4=C(C=CC(=C4)F)F)(C([2H])([2H])[2H])C([2H])([2H])[2H]
DMXY43L	IK	BQDUNOMMYOKHEP-GQALSZNTSA-N
DMXY43L	IU	3-(2,5-difluorophenyl)-7-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine
DMXY43L	DE	Pain

DMDRFZV	ID	DMDRFZV
DMDRFZV	DN	CVS-1123
DMDRFZV	HS	Discontinued in Phase 1
DMDRFZV	SN	Corthrombin oral
DMDRFZV	CP	Dendreon San Diego LLC
DMDRFZV	PC	9806376
DMDRFZV	MW	510.6
DMDRFZV	FM	C24H42N6O6
DMDRFZV	IC	InChI=1S/C24H42N6O6/c1-4-8-16(9-5-2)21(33)29-18(14-20(32)36-3)23(35)30-13-7-11-19(30)22(34)28-17(15-31)10-6-12-27-24(25)26/h15-19H,4-14H2,1-3H3,(H,28,34)(H,29,33)(H4,25,26,27)/t17-,18-,19-/m0/s1
DMDRFZV	CS	CCCC(CCC)C(=O)N[C@@H](CC(=O)OC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C=O
DMDRFZV	IK	ICMSWQUELAGTTR-FHWLQOOXSA-N
DMDRFZV	IU	methyl (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoate
DMDRFZV	DE	Myocardial infarction

DMWY2NT	ID	DMWY2NT
DMWY2NT	DN	CY-1787
DMWY2NT	HS	Discontinued in Phase 1
DMWY2NT	CP	Epimmune Inc
DMWY2NT	DE	Allergy

DM1I7UO	ID	DM1I7UO
DM1I7UO	DN	Cyclocreatine
DM1I7UO	HS	Discontinued in Phase 1
DM1I7UO	SN	Cyclocreatinine; AM-285
DM1I7UO	CP	Repligen Corp
DM1I7UO	DT	Small molecular drug
DM1I7UO	PC	2896
DM1I7UO	MW	143.14
DM1I7UO	FM	C5H9N3O2
DM1I7UO	IC	InChI=1S/C5H9N3O2/c6-5-7-1-2-8(5)3-4(9)10/h1-3H2,(H2,6,7)(H,9,10)
DM1I7UO	CS	C1CN(C(=N1)N)CC(=O)O
DM1I7UO	IK	AMHZIUVRYRVYBA-UHFFFAOYSA-N
DM1I7UO	IU	2-(2-amino-4,5-dihydroimidazol-1-yl)acetic acid
DM1I7UO	CA	CAS 35404-50-3
DM1I7UO	DE	Virus infection

DMB24V7	ID	DMB24V7
DMB24V7	DN	D-1367
DMB24V7	HS	Discontinued in Phase 1
DMB24V7	SN	167692-94-6; 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; D-1367; SCHEMBL15923700; DTXSID80570615; ZINC196470483; SC-92964; 2-(3,3-dimethylbutyl)-4,4,5,5,-tetramethyl-1,3,2-d; 1,3,2-Dioxaborolane, 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-
DMB24V7	CP	UCB Celltech
DMB24V7	DT	Small molecular drug
DMB24V7	PC	15259989
DMB24V7	MW	212.14
DMB24V7	FM	C12H25BO2
DMB24V7	IC	InChI=1S/C12H25BO2/c1-10(2,3)8-9-13-14-11(4,5)12(6,7)15-13/h8-9H2,1-7H3
DMB24V7	CS	B1(OC(C(O1)(C)C)(C)C)CCC(C)(C)C
DMB24V7	IK	JAHKBUBFJVAEDA-UHFFFAOYSA-N
DMB24V7	IU	2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
DMB24V7	CA	CAS 167692-94-6
DMB24V7	DE	Arthritis

DM5D8JW	ID	DM5D8JW
DM5D8JW	DN	D-1927
DM5D8JW	HS	Discontinued in Phase 1
DM5D8JW	CP	Chiroscience R&D Ltd
DM5D8JW	DE	Solid tumour/cancer

DMUPEJK	ID	DMUPEJK
DMUPEJK	DN	D-4418
DMUPEJK	HS	Discontinued in Phase 1
DMUPEJK	SN	UNII-24A61J8R9E; D-4418; 257892-34-5; 24A61J8R9E; SCHEMBL450642; 5-Quinolinecarboxamide, N-(2,5-dichloro-3-pyridinyl)-8-methoxy-
DMUPEJK	CP	Chiroscience R&D Ltd
DMUPEJK	DT	Small molecular drug
DMUPEJK	PC	9928260
DMUPEJK	MW	348.2
DMUPEJK	FM	C16H11Cl2N3O2
DMUPEJK	IC	InChI=1S/C16H11Cl2N3O2/c1-23-13-5-4-11(10-3-2-6-19-14(10)13)16(22)21-12-7-9(17)8-20-15(12)18/h2-8H,1H3,(H,21,22)
DMUPEJK	CS	COC1=C2C(=C(C=C1)C(=O)NC3=C(N=CC(=C3)Cl)Cl)C=CC=N2
DMUPEJK	IK	FSDOTMQXIKBFKJ-UHFFFAOYSA-N
DMUPEJK	IU	N-(2,5-dichloropyridin-3-yl)-8-methoxyquinoline-5-carboxamide
DMUPEJK	CA	CAS 257892-34-5
DMUPEJK	DE	Cutaneous T-cell lymphoma

DMDUZ5W	ID	DMDUZ5W
DMDUZ5W	DN	DACOPAFANT
DMDUZ5W	HS	Discontinued in Phase 1
DMDUZ5W	SN	RP-55778; Dacopafant; (+)-3(R)-(3-Pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide
DMDUZ5W	DT	Small molecular drug
DMDUZ5W	PC	205955
DMDUZ5W	MW	245.3
DMDUZ5W	FM	C12H11N3OS
DMDUZ5W	IC	InChI=1S/C12H11N3OS/c13-11(16)9-3-5-15-10(9)7-17-12(15)8-2-1-4-14-6-8/h1-6,12H,7H2,(H2,13,16)/t12-/m1/s1
DMDUZ5W	CS	C1C2=C(C=CN2[C@H](S1)C3=CN=CC=C3)C(=O)N
DMDUZ5W	IK	ARFOASMERCHFBY-GFCCVEGCSA-N
DMDUZ5W	IU	(3R)-3-pyridin-3-yl-1,3-dihydropyrrolo[1,2-c][1,3]thiazole-7-carboxamide
DMDUZ5W	CA	CAS 125372-33-0
DMDUZ5W	DE	Sepsis

DMAOZH3	ID	DMAOZH3
DMAOZH3	DN	DE-310
DMAOZH3	HS	Discontinued in Phase 1
DMAOZH3	SN	Exatecan prodrug, Daiichi
DMAOZH3	CP	Daiichi Seiyaku Co Ltd
DMAOZH3	DE	Solid tumour/cancer

DMFUCZQ	ID	DMFUCZQ
DMFUCZQ	DN	Delucemine
DMFUCZQ	HS	Discontinued in Phase 1
DMFUCZQ	SN	Delucemine hydrochloride; NPS-1506
DMFUCZQ	CP	NPS Pharmaceuticals Inc
DMFUCZQ	DT	Small molecular drug
DMFUCZQ	PC	156421
DMFUCZQ	MW	261.31
DMFUCZQ	FM	C16H17F2N
DMFUCZQ	IC	InChI=1S/C16H17F2N/c1-19-9-8-16(12-4-2-6-14(17)10-12)13-5-3-7-15(18)11-13/h2-7,10-11,16,19H,8-9H2,1H3
DMFUCZQ	CS	CNCCC(C1=CC(=CC=C1)F)C2=CC(=CC=C2)F
DMFUCZQ	IK	MUGNLPWYHGOJEG-UHFFFAOYSA-N
DMFUCZQ	IU	3,3-bis(3-fluorophenyl)-N-methylpropan-1-amine
DMFUCZQ	CA	CAS 186495-49-8
DMFUCZQ	DE	Depression

DM5G43H	ID	DM5G43H
DM5G43H	DN	Denibulin
DM5G43H	HS	Discontinued in Phase 1
DM5G43H	SN	Denibulin hydrochloride; ANG-600 series; ANG-615; MN-029; Second generation VTAs, Angiogene Pharmaceuticals; Second generation VTAs, MediciNova; Vascular targeting agents (benzimidazole carbamates), Angiogene Pharmaceuticals; Vascular targeting agents (benzimidazole carbamates), MediciNova
DM5G43H	CP	Angiogene Pharmaceuticals Ltd
DM5G43H	DT	Small molecular drug
DM5G43H	PC	11661758
DM5G43H	MW	385.4
DM5G43H	FM	C18H19N5O3S
DM5G43H	IC	InChI=1S/C18H19N5O3S/c1-10(19)16(24)20-11-3-5-12(6-4-11)27-13-7-8-14-15(9-13)22-17(21-14)23-18(25)26-2/h3-10H,19H2,1-2H3,(H,20,24)(H2,21,22,23,25)/t10-/m0/s1
DM5G43H	CS	C[C@@H](C(=O)NC1=CC=C(C=C1)SC2=CC3=C(C=C2)N=C(N3)NC(=O)OC)N
DM5G43H	IK	GAOHLWCIAJNSEE-JTQLQIEISA-N
DM5G43H	IU	methyl N-[6-[4-[[(2S)-2-aminopropanoyl]amino]phenyl]sulfanyl-1H-benzimidazol-2-yl]carbamate
DM5G43H	CA	CAS 284019-34-7
DM5G43H	DE	Solid tumour/cancer

DMZYVFH	ID	DMZYVFH
DMZYVFH	DN	DF-1111301
DMZYVFH	HS	Discontinued in Phase 1
DMZYVFH	SN	2-[2-(Dimethylamino)ethyl]-1-(2-ethoxyethyl)benzimidazole dihydrochloride
DMZYVFH	DE	Allergy

DMAR068	ID	DMAR068
DMAR068	DN	Discodermolide
DMAR068	HS	Discontinued in Phase 1
DMAR068	SN	Discodermolide, Novartis; XAA-296
DMAR068	CP	Harbor Branch Oceanographic Institute Inc
DMAR068	DT	Small molecular drug
DMAR068	PC	643668
DMAR068	MW	593.8
DMAR068	FM	C33H55NO8
DMAR068	IC	InChI=1S/C33H55NO8/c1-10-11-12-20(4)31(42-33(34)40)24(8)29(37)22(6)16-18(2)15-21(5)28(36)19(3)13-14-26(35)17-27-23(7)30(38)25(9)32(39)41-27/h10-15,19-31,35-38H,1,16-17H2,2-9H3,(H2,34,40)/b12-11-,14-13-,18-15-/t19-,20-,21-,22-,23-,24-,25+,26+,27-,28-,29+,30-,31-/m0/s1
DMAR068	CS	C[C@H]1[C@@H](OC(=O)[C@@H]([C@H]1O)C)C[C@@H](/C=C\\[C@H](C)[C@@H]([C@@H](C)/C=C(/C)\\C[C@H](C)[C@H]([C@H](C)[C@H]([C@@H](C)/C=C\\C=C)OC(=O)N)O)O)O
DMAR068	IK	AADVCYNFEREWOS-OBRABYBLSA-N
DMAR068	IU	[(3Z,5S,6S,7S,8R,9S,11Z,13S,14S,15S,16Z,18S)-8,14,18-trihydroxy-19-[(2S,3R,4S,5R)-4-hydroxy-3,5-dimethyl-6-oxooxan-2-yl]-5,7,9,11,13,15-hexamethylnonadeca-1,3,11,16-tetraen-6-yl] carbamate
DMAR068	CA	CAS 127943-53-7
DMAR068	CB	CHEBI:80700
DMAR068	DE	Immune System disease

DME5PXL	ID	DME5PXL
DME5PXL	DN	DK-507k
DME5PXL	HS	Discontinued in Phase 1
DME5PXL	CP	Daiichi Seiyaku Co Ltd
DME5PXL	DT	Small molecular drug
DME5PXL	PC	5271826
DME5PXL	MW	405.4
DME5PXL	FM	C20H21F2N3O4
DME5PXL	IC	InChI=1S/C20H21F2N3O4/c1-29-18-15-9(17(26)10(19(27)28)6-25(15)13-5-11(13)21)4-12(22)16(18)24-7-14(23)20(8-24)2-3-20/h4,6,11,13-14H,2-3,5,7-8,23H2,1H3,(H,27,28)/t11-,13+,14+/m0/s1
DME5PXL	CS	COC1=C2C(=CC(=C1N3C[C@H](C4(C3)CC4)N)F)C(=O)C(=CN2[C@@H]5C[C@@H]5F)C(=O)O
DME5PXL	IK	JYRHGXXQSIPDDP-IACUBPJLSA-N
DME5PXL	IU	7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid
DME5PXL	CA	CAS 364069-14-7
DME5PXL	DE	Bacterial infection

DMCK7LM	ID	DMCK7LM
DMCK7LM	DN	DMP-728
DMCK7LM	HS	Discontinued in Phase 1
DMCK7LM	SN	CHEMBL114946; BDBM50369582
DMCK7LM	DT	Small molecular drug
DMCK7LM	PC	9831047
DMCK7LM	MW	656.7
DMCK7LM	FM	C26H40N8O10S
DMCK7LM	IC	InChI=1S/C25H36N8O7.CH4O3S/c1-3-16-24(40)33(2)18(8-5-9-28-25(26)27)23(39)30-13-19(34)31-17(11-20(35)36)22(38)29-12-14-6-4-7-15(10-14)21(37)32-16;1-5(2,3)4/h4,6-7,10,16-18H,3,5,8-9,11-13H2,1-2H3,(H,29,38)(H,30,39)(H,31,34)(H,32,37)(H,35,36)(H4,26,27,28);1H3,(H,2,3,4)/t16-,17+,18+;/m1./s1
DMCK7LM	CS	CC[C@@H]1C(=O)N([C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC2=CC(=CC=C2)C(=O)N1)CC(=O)O)CCCN=C(N)N)C.CS(=O)(=O)O
DMCK7LM	IK	CSRWGJAILKTYLJ-PWGAQZMISA-N
DMCK7LM	IU	2-[(5S,11S,14R)-11-[3-(diaminomethylideneamino)propyl]-14-ethyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentazabicyclo[15.3.1]henicosa-1(21),17,19-trien-5-yl]acetic acid;methanesulfonic acid
DMCK7LM	CA	CAS 155158-97-7
DMCK7LM	DE	Thrombosis

DMDK6HP	ID	DMDK6HP
DMDK6HP	DN	DMP-802
DMDK6HP	HS	Discontinued in Phase 1
DMDK6HP	SN	CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid
DMDK6HP	DT	Small molecular drug
DMDK6HP	PC	9812185
DMDK6HP	MW	492.5
DMDK6HP	FM	C20H24N6O7S
DMDK6HP	IC	InChI=1S/C20H24N6O7S/c1-10-18(11(2)32-24-10)34(30,31)26-16(20(28)29)9-23-17(27)8-14-7-15(25-33-14)12-3-5-13(6-4-12)19(21)22/h3-6,14,16,26H,7-9H2,1-2H3,(H3,21,22)(H,23,27)(H,28,29)/t14-,16+/m1/s1
DMDK6HP	CS	CC1=C(C(=NO1)C)S(=O)(=O)N[C@@H](CNC(=O)C[C@H]2CC(=NO2)C3=CC=C(C=C3)C(=N)N)C(=O)O
DMDK6HP	IK	XKFYFSNOQRUIAO-ZBFHGGJFSA-N
DMDK6HP	IU	(2S)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]-2-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfonylamino]propanoic acid

DM412S9	ID	DM412S9
DM412S9	DN	DMP-851
DM412S9	HS	Discontinued in Phase 1
DM412S9	SN	XQ-443; (4R,5S,6S,7R)-1-(3-Amino-1H-indazol-5-ylmethyl)-4,7-dibenzyl-3-butyl-5,6-dihydroxyperhydro-1,3-diazepin-2-one
DM412S9	DT	Small molecular drug
DM412S9	PC	470551
DM412S9	MW	527.7
DM412S9	FM	C31H37N5O3
DM412S9	IC	InChI=1S/C31H37N5O3/c1-2-3-16-35-26(18-21-10-6-4-7-11-21)28(37)29(38)27(19-22-12-8-5-9-13-22)36(31(35)39)20-23-14-15-25-24(17-23)30(32)34-33-25/h4-15,17,26-29,37-38H,2-3,16,18-20H2,1H3,(H3,32,33,34)/t26-,27-,28+,29+/m1/s1
DM412S9	CS	CCCCN1[C@@H]([C@@H]([C@H]([C@H](N(C1=O)CC2=CC3=C(C=C2)NN=C3N)CC4=CC=CC=C4)O)O)CC5=CC=CC=C5
DM412S9	IK	CGEJBZXGNPASAG-GKQHHHCTSA-N
DM412S9	IU	(4R,5S,6S,7R)-1-[(3-amino-1H-indazol-5-yl)methyl]-4,7-dibenzyl-3-butyl-5,6-dihydroxy-1,3-diazepan-2-one
DM412S9	CA	CAS 188978-02-1
DM412S9	DE	Human immunodeficiency virus infection

DMR6INY	ID	DMR6INY
DMR6INY	DN	DPC 423
DMR6INY	HS	Discontinued in Phase 1
DMR6INY	SN	DPC602; 228258-45-5; DPC-423; 209957-47-1; SCHEMBL3052253; CHEMBL176140; BDBM12657; ZINC1490578; 1H-Pyrazole-5-carboxamide,1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-; KB-65316; KB-76718; 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2-(methylsulfonyl)-[1,1-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
DMR6INY	DT	Small molecular drug
DMR6INY	PC	9895762
DMR6INY	MW	532.5
DMR6INY	FM	C25H20F4N4O3S
DMR6INY	IC	InChI=1S/C25H20F4N4O3S/c1-37(35,36)22-8-3-2-7-18(22)16-9-10-20(19(26)12-16)31-24(34)21-13-23(25(27,28)29)32-33(21)17-6-4-5-15(11-17)14-30/h2-13H,14,30H2,1H3,(H,31,34)
DMR6INY	CS	CS(=O)(=O)C1=CC=CC=C1C2=CC(=C(C=C2)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)F
DMR6INY	IK	ZLUOAFAJSUPHOG-UHFFFAOYSA-N
DMR6INY	IU	2-[3-(aminomethyl)phenyl]-N-[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMR6INY	DE	Thrombosis

DMSOHR6	ID	DMSOHR6
DMSOHR6	DN	DPC-082
DMSOHR6	HS	Discontinued in Phase 1
DMSOHR6	SN	(E)-4(S)-(2-Cyclopropylvinyl)-5,6-difluoro-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one; 214287-98-6
DMSOHR6	DT	Small molecular drug
DMSOHR6	PC	6451134
DMSOHR6	MW	318.24
DMSOHR6	FM	C14H11F5N2O
DMSOHR6	IC	InChI=1S/C14H11F5N2O/c15-8-3-4-9-10(11(8)16)13(14(17,18)19,21-12(22)20-9)6-5-7-1-2-7/h3-7H,1-2H2,(H2,20,21,22)/b6-5+/t13-/m0/s1
DMSOHR6	CS	C1CC1/C=C/[C@]2(C3=C(C=CC(=C3F)F)NC(=O)N2)C(F)(F)F
DMSOHR6	IK	JUCDJPCFPITYRP-GFUIURDCSA-N
DMSOHR6	IU	(4S)-4-[(E)-2-cyclopropylethenyl]-5,6-difluoro-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one
DMSOHR6	CA	CAS 214287-98-6
DMSOHR6	DE	Human immunodeficiency virus infection

DMA7DH0	ID	DMA7DH0
DMA7DH0	DN	DPC-168
DMA7DH0	HS	Discontinued in Phase 1
DMA7DH0	CP	Bristol-Myers Squibb Pharma Co
DMA7DH0	PC	129734673
DMA7DH0	MW	465.6
DMA7DH0	FM	C28H36FN3O2
DMA7DH0	IC	InChI=1S/C28H36FN3O2/c1-20(33)23-8-4-9-26(17-23)30-28(34)31-27-10-3-2-7-24(27)19-32-15-5-6-22(18-32)16-21-11-13-25(29)14-12-21/h4,8-9,11-14,17,22,24,27H,2-3,5-7,10,15-16,18-19H2,1H3,(H2,30,31,34)/t22-,24?,27+/m0/s1
DMA7DH0	CS	CC(=O)C1=CC(=CC=C1)NC(=O)N[C@@H]2CCCCC2CN3CCC[C@H](C3)CC4=CC=C(C=C4)F
DMA7DH0	IK	ASRDPULQBHFPGU-RJCBHOSBSA-N
DMA7DH0	IU	1-(3-acetylphenyl)-3-[(1R)-2-[[(3S)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea
DMA7DH0	DE	Allergic rhinitis

DM5HAG0	ID	DM5HAG0
DM5HAG0	DN	DPC-681
DM5HAG0	HS	Discontinued in Phase 1
DM5HAG0	SN	N-(3-Fluorobenzyl)glycyl-N-[3-[N-(3-aminophenylsulfonyl)-N-isobutylamino]-1(S)-benzyl-2(R)-hydroxypropyl]-3-methyl-L-valinamide mesylate
DM5HAG0	DT	Small molecular drug
DM5HAG0	PC	456215
DM5HAG0	MW	669.9
DM5HAG0	FM	C35H48FN5O5S
DM5HAG0	IC	InChI=1S/C35H48FN5O5S/c1-24(2)22-41(47(45,46)29-16-10-15-28(37)19-29)23-31(42)30(18-25-11-7-6-8-12-25)39-34(44)33(35(3,4)5)40-32(43)21-38-20-26-13-9-14-27(36)17-26/h6-17,19,24,30-31,33,38,42H,18,20-23,37H2,1-5H3,(H,39,44)(H,40,43)/t30-,31+,33+/m0/s1
DM5HAG0	CS	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)(C)C)NC(=O)CNCC2=CC(=CC=C2)F)O)S(=O)(=O)C3=CC=CC(=C3)N
DM5HAG0	IK	PNIFFZXGBAYVMQ-RKKDRKJOSA-N
DM5HAG0	IU	(2S)-N-[(2S,3R)-4-[(3-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide
DM5HAG0	CA	CAS 367281-49-0
DM5HAG0	DE	Human immunodeficiency virus infection

DMS19VG	ID	DMS19VG
DMS19VG	DN	DPC-684
DMS19VG	HS	Discontinued in Phase 1
DMS19VG	SN	N-(3-Fluorobenzyl)glycyl-N-[3-[N-(4-aminophenylsulfonyl)-N-isobutylamino]-1(S)-benzyl-2(R)-hydroxypropyl]-3-methyl-L-valinamide
DMS19VG	DT	Small molecular drug
DMS19VG	PC	101143534
DMS19VG	MW	669.9
DMS19VG	FM	C35H48FN5O5S
DMS19VG	IC	InChI=1S/C35H48FN5O5S/c1-24(2)22-41(47(45,46)29-16-14-28(37)15-17-29)23-31(42)30(19-25-10-7-6-8-11-25)39-34(44)33(35(3,4)5)40-32(43)21-38-20-26-12-9-13-27(36)18-26/h6-18,24,30-31,33,38,42H,19-23,37H2,1-5H3,(H,39,44)(H,40,43)/t30-,31-,33+/m0/s1
DMS19VG	CS	CC(C)CN(C[C@@H]([C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)(C)C)NC(=O)CNCC2=CC(=CC=C2)F)O)S(=O)(=O)C3=CC=C(C=C3)N
DMS19VG	IK	IXZYCIFRVZKVRJ-MZSJJGOWSA-N
DMS19VG	IU	(2S)-N-[(2S,3S)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide
DMS19VG	DE	Human immunodeficiency virus infection

DMOPM7L	ID	DMOPM7L
DMOPM7L	DN	DRF 10945
DMOPM7L	HS	Discontinued in Phase 1
DMOPM7L	CP	Dr. Reddy's Laboratories
DMOPM7L	DE	Hyperlipidaemia

DMS4IBW	ID	DMS4IBW
DMS4IBW	DN	DS-1442
DMS4IBW	HS	Discontinued in Phase 1
DMS4IBW	CP	Daiichi Sankyo
DMS4IBW	PC	260936
DMS4IBW	MW	173.17
DMS4IBW	FM	C10H7NO2
DMS4IBW	IC	InChI=1S/C10H7NO2/c12-10(13)9-3-1-2-7-6-11-5-4-8(7)9/h1-6H,(H,12,13)
DMS4IBW	CS	C1=CC2=C(C=CN=C2)C(=C1)C(=O)O
DMS4IBW	IK	ZIPLFLRGHZAXSJ-UHFFFAOYSA-N
DMS4IBW	IU	isoquinoline-5-carboxylic acid
DMS4IBW	CA	CAS 27810-64-6
DMS4IBW	DE	Dyslipidemia

DMDAO8E	ID	DMDAO8E
DMDAO8E	DN	DS-6930
DMDAO8E	HS	Discontinued in Phase 1
DMDAO8E	CP	Daiichi Sankyo
DMDAO8E	DE	Diabetic complication

DMQK53O	ID	DMQK53O
DMQK53O	DN	DS-7250
DMQK53O	HS	Discontinued in Phase 1
DMQK53O	CP	Daiichi Sankyo
DMQK53O	PC	18464794
DMQK53O	MW	225.71
DMQK53O	FM	C12H16ClNO
DMQK53O	IC	InChI=1S/C12H16ClNO/c13-11-3-1-10(2-4-11)12(6-8-15)5-7-14-9-12/h1-4,14-15H,5-9H2
DMQK53O	CS	C1CNCC1(CCO)C2=CC=C(C=C2)Cl
DMQK53O	IK	ILTULPUUFNFODT-UHFFFAOYSA-N
DMQK53O	IU	2-[3-(4-chlorophenyl)pyrrolidin-3-yl]ethanol
DMQK53O	CA	CAS 52423-70-8
DMQK53O	DE	Diabetic complication

DMN9KXU	ID	DMN9KXU
DMN9KXU	DN	DU-29894
DMN9KXU	HS	Discontinued in Phase 1
DMN9KXU	CP	Solvay Pharmaceuticals BV
DMN9KXU	PC	208917
DMN9KXU	MW	375.4
DMN9KXU	FM	C23H22FN3O
DMN9KXU	IC	InChI=1S/C23H22FN3O/c24-19-6-4-17(5-7-19)21-9-8-20(25-21)16-26-11-13-27(14-12-26)22-3-1-2-18-10-15-28-23(18)22/h1-10,15,25H,11-14,16H2
DMN9KXU	CS	C1CN(CCN1CC2=CC=C(N2)C3=CC=C(C=C3)F)C4=CC=CC5=C4OC=C5
DMN9KXU	IK	PGNHBJGIQAEIHD-UHFFFAOYSA-N
DMN9KXU	IU	1-(1-benzofuran-7-yl)-4-[[5-(4-fluorophenyl)-1H-pyrrol-2-yl]methyl]piperazine
DMN9KXU	CA	CAS 115464-77-2
DMN9KXU	DE	Psychotic disorder

DM9S51Q	ID	DM9S51Q
DM9S51Q	DN	DU-6681
DM9S51Q	HS	Discontinued in Phase 1
DM9S51Q	SN	DU-6681a (Na salt); (1R,5S,6S)-2-[6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-6(S)-ylsulfanyl]-6-[1(R)-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid
DM9S51Q	PC	100935628
DM9S51Q	MW	349.4
DM9S51Q	FM	C16H19N3O4S
DM9S51Q	IC	InChI=1S/C16H19N3O4S/c1-7-12-11(8(2)20)15(21)19(12)13(16(22)23)14(7)24-9-5-10-17-3-4-18(10)6-9/h3-4,7-9,11-12,20H,5-6H2,1-2H3,(H,22,23)/t7-,8-,9+,11-,12+/m1/s1
DM9S51Q	CS	C[C@@H]1[C@H]2[C@H](C(=O)N2C(=C1S[C@H]3CC4=NC=CN4C3)C(=O)O)[C@@H](C)O
DM9S51Q	IK	SYFIHQJVKJGGGB-VZSYODPGSA-N
DM9S51Q	IU	(4R,5R,6S)-3-[[(6S)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9S51Q	DE	Bacterial infection

DMUMAHC	ID	DMUMAHC
DMUMAHC	DN	DUP 697
DMUMAHC	HS	Discontinued in Phase 1
DMUMAHC	SN	Dup 697; dup-697; 88149-94-4; MRWLZPOFPA; UNII-MRWLZPOFPA; CHEMBL42485; CHEBI:4720; 5-Bromo-2-(4-fluorophenyl)-3-(4-methysulfonylphenyl)thiophene; 5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)thiophene; CPD000466299; Thiophene, 5-bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-; Thiophene, 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- [CAS]; 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]thiophene; 5-Bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)thiophene; SMR000466299
DMUMAHC	TC	Analgesics
DMUMAHC	DT	Small molecular drug
DMUMAHC	PC	3177
DMUMAHC	MW	411.3
DMUMAHC	FM	C17H12BrFO2S2
DMUMAHC	IC	InChI=1S/C17H12BrFO2S2/c1-23(20,21)14-8-4-11(5-9-14)15-10-16(18)22-17(15)12-2-6-13(19)7-3-12/h2-10H,1H3
DMUMAHC	CS	CS(=O)(=O)C1=CC=C(C=C1)C2=C(SC(=C2)Br)C3=CC=C(C=C3)F
DMUMAHC	IK	AJFTZWGGHJXZOB-UHFFFAOYSA-N
DMUMAHC	IU	5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)thiophene
DMUMAHC	CA	CAS 88149-94-4
DMUMAHC	CB	CHEBI:4720
DMUMAHC	DE	Pain

DM59WQ7	ID	DM59WQ7
DM59WQ7	DN	DuP-532
DM59WQ7	HS	Discontinued in Phase 1
DM59WQ7	SN	Dup-532; Dup 532; 124750-95-4; CHEMBL443269; 1H-Imidazole-5-carboxylicacid,4-(1,1,2,2,2-pentafluoroethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; dup532; ACMC-20mr6i; SCHEMBL62; AC1L1TVZ; AC1Q4ICA; CTK4B4065; BDBM82428; DTXSID00154476; PDSP2_000123; PDSP1_000124; PDSP1_000123; BDBM50230908; 2-Propyl-4-pentafluoroethyl-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxylic acid; CAS_124750-95-4; CB91356279; L002873; 1H-Imidazole-5-carboxylic acid, 4-(pentafluoroethyl)-2-propyl-1-((2'-(1H-te
DM59WQ7	CP	Bristol-Myers Squibb Pharma Co
DM59WQ7	DT	Small molecular drug
DM59WQ7	PC	60770
DM59WQ7	MW	506.4
DM59WQ7	FM	C23H19F5N6O2
DM59WQ7	IC	InChI=1S/C23H19F5N6O2/c1-2-5-17-29-19(22(24,25)23(26,27)28)18(21(35)36)34(17)12-13-8-10-14(11-9-13)15-6-3-4-7-16(15)20-30-32-33-31-20/h3-4,6-11H,2,5,12H2,1H3,(H,35,36)(H,30,31,32,33)
DM59WQ7	CS	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C(F)(F)F)(F)F
DM59WQ7	IK	RQGDXPDTZWGCQI-UHFFFAOYSA-N
DM59WQ7	IU	5-(1,1,2,2,2-pentafluoroethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
DM59WQ7	CA	CAS 124750-95-4
DM59WQ7	DE	Hypertension

DMI5EPB	ID	DMI5EPB
DMI5EPB	DN	DUP-734
DMI5EPB	HS	Discontinued in Phase 1
DMI5EPB	SN	1-(Cyclopropylmethyl)-4-[2-(4-fluorophenyl)-2-oxoethyl]piperidine hydrobromide
DMI5EPB	DT	Small molecular drug
DMI5EPB	PC	121967
DMI5EPB	MW	356.3
DMI5EPB	FM	C17H23BrFNO
DMI5EPB	IC	InChI=1S/C17H22FNO.BrH/c18-16-5-3-15(4-6-16)17(20)11-13-7-9-19(10-8-13)12-14-1-2-14;/h3-6,13-14H,1-2,7-12H2;1H
DMI5EPB	CS	C1CC1CN2CCC(CC2)CC(=O)C3=CC=C(C=C3)F.Br
DMI5EPB	IK	QLZIAKMYJFJBKA-UHFFFAOYSA-N
DMI5EPB	IU	2-[1-(cyclopropylmethyl)piperidin-4-yl]-1-(4-fluorophenyl)ethanone;hydrobromide
DMI5EPB	CA	CAS 135135-87-4
DMI5EPB	DE	Psychotic disorder

DMDC4BA	ID	DMDC4BA
DMDC4BA	DN	DV-7751A
DMDC4BA	HS	Discontinued in Phase 1
DMDC4BA	SN	10-[8(S)-Amino-6-azaspiro[3.4]octan-6-yl]-9-fluoro-3(S)-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid hemihydrate
DMDC4BA	DT	Small molecular drug
DMDC4BA	PC	122823
DMDC4BA	MW	387.4
DMDC4BA	FM	C20H22FN3O4
DMDC4BA	IC	InChI=1S/C20H22FN3O4/c1-10-8-28-18-15-11(17(25)12(19(26)27)6-24(10)15)5-13(21)16(18)23-7-14(22)20(9-23)3-2-4-20/h5-6,10,14H,2-4,7-9,22H2,1H3,(H,26,27)/t10-,14+/m0/s1
DMDC4BA	CS	C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4C[C@H](C5(C4)CCC5)N)F)C(=O)O
DMDC4BA	IK	UGGPRXAHUOKTKV-IINYFYTJSA-N
DMDC4BA	IU	(2S)-6-[(8S)-8-amino-6-azaspiro[3.4]octan-6-yl]-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMDC4BA	CA	CAS 129321-78-4
DMDC4BA	DE	Bacterial infection

DMXJ54Z	ID	DMXJ54Z
DMXJ54Z	DN	DW-908e
DMXJ54Z	HS	Discontinued in Phase 1
DMXJ54Z	SN	Allergy therapeutics, Daiichi; Asthma therapeutics, Daiichi; PS-181895; PS-460644; PS-489655; PS-969819; Asthma/allergy therapeutics, Daiichi
DMXJ54Z	CP	Pharmacopeia Inc
DMXJ54Z	PC	23704320
DMXJ54Z	MW	638.5
DMXJ54Z	FM	C31H34Cl2N3NaO6
DMXJ54Z	IC	InChI=1S/C31H35Cl2N3O6.Na/c1-35-16-24(23-5-3-4-6-28(23)35)30(38)34-27-14-25(32)19(11-26(27)33)12-29(37)36-15-22(41-2)13-20(36)17-42-21-9-7-18(8-10-21)31(39)40;/h3-6,11,14,16,18,20-22H,7-10,12-13,15,17H2,1-2H3,(H,34,38)(H,39,40);/q;+1/p-1/t18?,20-,21?,22-;/m0./s1
DMXJ54Z	CS	CN1C=C(C2=CC=CC=C21)C(=O)NC3=C(C=C(C(=C3)Cl)CC(=O)N4C[C@H](C[C@H]4COC5CCC(CC5)C(=O)[O-])OC)Cl.[Na+]
DMXJ54Z	IK	YWWOTADRIASLGN-VMAKYHEJSA-M
DMXJ54Z	IU	sodium;4-[[(2S,4S)-1-[2-[2,5-dichloro-4-[(1-methylindole-3-carbonyl)amino]phenyl]acetyl]-4-methoxypyrrolidin-2-yl]methoxy]cyclohexane-1-carboxylate
DMXJ54Z	DE	Allergy

DMI9NZ3	ID	DMI9NZ3
DMI9NZ3	DN	E2101
DMI9NZ3	HS	Discontinued in Phase 1
DMI9NZ3	SN	UNII-7X2U66KMP7; 7X2U66KMP7; E2101; SCHEMBL4081913; L001631; 1H-Indole-6-acetamide, 1-(1-(2-(2-fluorophenyl)ethyl)-4-piperidinyl)-N-methyl-; 1-(1-(2-(2-Fluorophenyl)ethyl)-4-piperidinyl)-N-methyl-1H-indole-6-acetamide
DMI9NZ3	CP	Eisai Co. Ltd.
DMI9NZ3	DT	Small molecular drug
DMI9NZ3	PC	9908587
DMI9NZ3	MW	393.5
DMI9NZ3	FM	C24H28FN3O
DMI9NZ3	IC	InChI=1S/C24H28FN3O/c1-26-24(29)17-18-6-7-20-9-15-28(23(20)16-18)21-10-13-27(14-11-21)12-8-19-4-2-3-5-22(19)25/h2-7,9,15-16,21H,8,10-14,17H2,1H3,(H,26,29)
DMI9NZ3	CS	CNC(=O)CC1=CC2=C(C=C1)C=CN2C3CCN(CC3)CCC4=CC=CC=C4F
DMI9NZ3	IK	CQEOXWCXSBFJMB-UHFFFAOYSA-N
DMI9NZ3	IU	2-[1-[1-[2-(2-fluorophenyl)ethyl]piperidin-4-yl]indol-6-yl]-N-methylacetamide
DMI9NZ3	CA	CAS 265667-22-9
DMI9NZ3	DE	Spasm; Cervical dystonia

DMJWR1I	ID	DMJWR1I
DMJWR1I	DN	E-3030
DMJWR1I	HS	Discontinued in Phase 1
DMJWR1I	SN	Dual PPAR alpha/gamma agonists, Eisai
DMJWR1I	CP	Eisai Co Ltd
DMJWR1I	PC	11949481
DMJWR1I	MW	909.8
DMJWR1I	FM	C44H44CaCl2F2N2O10
DMJWR1I	IC	InChI=1S/2C22H23ClFNO5.Ca/c2*1-14(2)30-21(22(26)27)9-15-4-3-5-19(8-15)28-12-18(24)13-29-20-7-6-17(23)10-16(20)11-25;/h2*3-8,10,14,18,21H,9,12-13H2,1-2H3,(H,26,27);/q;;+2/p-2/t2*18-,21-;/m00./s1
DMJWR1I	CS	CC(C)O[C@@H](CC1=CC(=CC=C1)OC[C@@H](COC2=C(C=C(C=C2)Cl)C#N)F)C(=O)[O-].CC(C)O[C@@H](CC1=CC(=CC=C1)OC[C@@H](COC2=C(C=C(C=C2)Cl)C#N)F)C(=O)[O-].[Ca+2]
DMJWR1I	IK	QBPOEQDRFVFZRI-ATAMATRTSA-L
DMJWR1I	IU	calcium;(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-propan-2-yloxypropanoate
DMJWR1I	CA	CAS 913722-93-7
DMJWR1I	DE	Hyperlipidaemia

DM79MI4	ID	DM79MI4
DM79MI4	DN	E-6087
DM79MI4	HS	Discontinued in Phase 1
DM79MI4	SN	E-6231 ((R)-(+)-isomer); E-6232 ((S)-(-)-isomer); Rac-4-[5-(2,4-Difluorophenyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl]benzenesulfonamide
DM79MI4	PC	9953093
DM79MI4	MW	405.3
DM79MI4	FM	C16H12F5N3O2S
DM79MI4	IC	InChI=1S/C16H12F5N3O2S/c17-9-1-6-12(13(18)7-9)14-8-15(16(19,20)21)23-24(14)10-2-4-11(5-3-10)27(22,25)26/h1-7,14H,8H2,(H2,22,25,26)
DM79MI4	CS	C1C(N(N=C1C(F)(F)F)C2=CC=C(C=C2)S(=O)(=O)N)C3=C(C=C(C=C3)F)F
DM79MI4	IK	ZZMJXWXXMAAPLI-UHFFFAOYSA-N
DM79MI4	IU	4-[3-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide
DM79MI4	CA	CAS 251442-94-1
DM79MI4	DE	Pain

DMSOH09	ID	DMSOH09
DMSOH09	DN	Ebalzotan
DMSOH09	HS	Discontinued in Phase 1
DMSOH09	SN	NAE-086
DMSOH09	CP	Astra AB
DMSOH09	DT	Small molecular drug
DMSOH09	PC	9797080
DMSOH09	MW	318.5
DMSOH09	FM	C19H30N2O2
DMSOH09	IC	InChI=1S/C19H30N2O2/c1-6-10-21(14(4)5)15-11-17-16(19(22)20-13(2)3)8-7-9-18(17)23-12-15/h7-9,13-15H,6,10-12H2,1-5H3,(H,20,22)/t15-/m1/s1
DMSOH09	CS	CCCN([C@@H]1CC2=C(C=CC=C2OC1)C(=O)NC(C)C)C(C)C
DMSOH09	IK	UEAKCKJAKUFIQP-OAHLLOKOSA-N
DMSOH09	IU	(3R)-N-propan-2-yl-3-[propan-2-yl(propyl)amino]-3,4-dihydro-2H-chromene-5-carboxamide
DMSOH09	CA	CAS 149494-37-1
DMSOH09	DE	Anxiety disorder

DMURVE8	ID	DMURVE8
DMURVE8	DN	Elacridar
DMURVE8	HS	Discontinued in Phase 1
DMURVE8	SN	Elacridar hydrochloride; 143851-98-3; Elacridar HCl; Elacridar (hydrochloride); gf 120918a; UNII-NX2BHH1A5B; NX2BHH1A5B; Elacridar hydrochloride [USAN]; GF-120918A; Elacridar hydrochloride (USAN); GF 120918; AC1Q3EOG; AC1L55DX; C34H34ClN3O5; SCHEMBL15847793; CHEMBL2074730; AOB5938; MolPort-023-332-877; BCP14056; 7066AA; AKOS016005297; CS-1113; ACN-041487; 4CA-0489; HY-50880; AC-30266; FT-0696337; W-5457; D03968; N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide hydro
DMURVE8	DT	Small molecular drug
DMURVE8	PC	119373
DMURVE8	MW	563.6
DMURVE8	FM	C34H33N3O5
DMURVE8	IC	InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)
DMURVE8	CS	COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC
DMURVE8	IK	OSFCMRGOZNQUSW-UHFFFAOYSA-N
DMURVE8	IU	N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide
DMURVE8	CA	CAS 143664-11-3
DMURVE8	DE	Solid tumour/cancer

DMWRQG7	ID	DMWRQG7
DMWRQG7	DN	Eltenac
DMWRQG7	HS	Discontinued in Phase 1
DMWRQG7	SN	BY-820; B-788-20
DMWRQG7	CP	ALTANA Pharma AG
DMWRQG7	DT	Small molecular drug
DMWRQG7	PC	51717
DMWRQG7	MW	302.2
DMWRQG7	FM	C12H9Cl2NO2S
DMWRQG7	IC	InChI=1S/C12H9Cl2NO2S/c13-8-2-1-3-9(14)12(8)15-10-6-18-5-7(10)4-11(16)17/h1-3,5-6,15H,4H2,(H,16,17)
DMWRQG7	CS	C1=CC(=C(C(=C1)Cl)NC2=CSC=C2CC(=O)O)Cl
DMWRQG7	IK	AELILMBZWCGOSB-UHFFFAOYSA-N
DMWRQG7	IU	2-[4-(2,6-dichloroanilino)thiophen-3-yl]acetic acid
DMWRQG7	CA	CAS 72895-88-6
DMWRQG7	DE	Arthritis

DM2V5XP	ID	DM2V5XP
DM2V5XP	DN	Emakalim
DM2V5XP	HS	Discontinued in Phase 1
DM2V5XP	SN	EMD-56431
DM2V5XP	CP	Merck KGaA
DM2V5XP	DT	Small molecular drug
DM2V5XP	PC	9839143
DM2V5XP	MW	296.32
DM2V5XP	FM	C17H16N2O3
DM2V5XP	IC	InChI=1S/C17H16N2O3/c1-17(2)16(21)15(19-8-4-3-5-14(19)20)12-9-11(10-18)6-7-13(12)22-17/h3-9,15-16,21H,1-2H3/t15-,16+/m1/s1
DM2V5XP	CS	CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N3C=CC=CC3=O)O)C
DM2V5XP	IK	MMSFHQSHXRMPLJ-CVEARBPZSA-N
DM2V5XP	IU	(3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxopyridin-1-yl)-3,4-dihydrochromene-6-carbonitrile
DM2V5XP	CA	CAS 129729-66-4
DM2V5XP	DE	Angina pectoris

DMQH8L2	ID	DMQH8L2
DMQH8L2	DN	EMD-503982
DMQH8L2	HS	Discontinued in Phase 1
DMQH8L2	SN	EMD-495235; Factor Xa inhibitors, Merck KGaA
DMQH8L2	CP	Merck KGaA
DMQH8L2	PC	9912033
DMQH8L2	MW	458.9
DMQH8L2	FM	C22H23ClN4O5
DMQH8L2	IC	InChI=1S/C22H23ClN4O5/c23-14-1-3-16(4-2-14)25-22(31)27-12-18(28)11-19(27)21(30)24-15-5-7-17(8-6-15)26-9-10-32-13-20(26)29/h1-8,18-19,28H,9-13H2,(H,24,30)(H,25,31)/t18-,19-/m1/s1
DMQH8L2	CS	C1COCC(=O)N1C2=CC=C(C=C2)NC(=O)[C@H]3C[C@H](CN3C(=O)NC4=CC=C(C=C4)Cl)O
DMQH8L2	IK	DMYZJLOWGSRVKP-RTBURBONSA-N
DMQH8L2	IU	(2R,4R)-1-N-(4-chlorophenyl)-4-hydroxy-2-N-[4-(3-oxomorpholin-4-yl)phenyl]pyrrolidine-1,2-dicarboxamide
DMQH8L2	DE	Thrombosis

DMVS8IE	ID	DMVS8IE
DMVS8IE	DN	EMD-53998
DMVS8IE	HS	Discontinued in Phase 1
DMVS8IE	SN	5-[1-(3,4-Dimethoxybenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl]-6-methyl-3,6-dihydro-2H-1,3,4-thiadiazin-2-one
DMVS8IE	DT	Small molecular drug
DMVS8IE	PC	187079
DMVS8IE	MW	425.5
DMVS8IE	FM	C22H23N3O4S
DMVS8IE	IC	InChI=1S/C22H23N3O4S/c1-13-20(23-24-22(27)30-13)15-6-8-17-14(11-15)5-4-10-25(17)21(26)16-7-9-18(28-2)19(12-16)29-3/h6-9,11-13H,4-5,10H2,1-3H3,(H,24,27)
DMVS8IE	CS	CC1C(=NNC(=O)S1)C2=CC3=C(C=C2)N(CCC3)C(=O)C4=CC(=C(C=C4)OC)OC
DMVS8IE	IK	IZLRMTJLQCLMKF-UHFFFAOYSA-N
DMVS8IE	IU	5-[1-(3,4-dimethoxybenzoyl)-3,4-dihydro-2H-quinolin-6-yl]-6-methyl-3,6-dihydro-1,3,4-thiadiazin-2-one
DMVS8IE	CA	CAS 120223-04-3
DMVS8IE	DE	Cardiovascular disease

DMFGTMR	ID	DMFGTMR
DMFGTMR	DN	Eptapirone
DMFGTMR	HS	Discontinued in Phase 1
DMFGTMR	SN	F-11440
DMFGTMR	CP	Pierre Fabre SA
DMFGTMR	DT	Small molecular drug
DMFGTMR	PC	208928
DMFGTMR	MW	345.4
DMFGTMR	FM	C16H23N7O2
DMFGTMR	IC	InChI=1S/C16H23N7O2/c1-20-14(24)13-19-23(16(20)25)8-3-2-7-21-9-11-22(12-10-21)15-17-5-4-6-18-15/h4-6,13H,2-3,7-12H2,1H3
DMFGTMR	CS	CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=NC=CC=N3
DMFGTMR	IK	NMYAHEULKSYAPP-UHFFFAOYSA-N
DMFGTMR	IU	4-methyl-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2,4-triazine-3,5-dione
DMFGTMR	CA	CAS 179756-85-5
DMFGTMR	DE	Anxiety disorder

DM3LKAR	ID	DM3LKAR
DM3LKAR	DN	ER-35786
DM3LKAR	HS	Discontinued in Phase 1
DM3LKAR	SN	E-1010; (1R,5S,6S)-6-[1(R)-Hydroxymethyl]-2-[2(S)-[1(R)-hydroxy-1-[pyrrolidin-3(R)-yl]methyl]pyrrolidin-4(S)-ylsulfanyl]-1-methyl-1-carba-2-penem-3-carboxylic acid monohydrochloride
DM3LKAR	DT	Small molecular drug
DM3LKAR	PC	6918311
DM3LKAR	MW	448
DM3LKAR	FM	C19H30ClN3O5S
DM3LKAR	IC	InChI=1S/C19H29N3O5S.ClH/c1-8-14-13(9(2)23)18(25)22(14)15(19(26)27)17(8)28-11-5-12(21-7-11)16(24)10-3-4-20-6-10;/h8-14,16,20-21,23-24H,3-7H2,1-2H3,(H,26,27);1H/t8-,9-,10-,11+,12+,13-,14-,16-;/m1./s1
DM3LKAR	CS	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)[C@@H]([C@@H]4CCNC4)O)C(=O)O)[C@@H](C)O.Cl
DM3LKAR	IK	WRVJTXDJDKITNK-XNGFCKKMSA-N
DM3LKAR	IU	(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(R)-hydroxy-[(3R)-pyrrolidin-3-yl]methyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrochloride
DM3LKAR	CA	CAS 186319-97-1
DM3LKAR	DE	Bacterial infection

DMGX08C	ID	DMGX08C
DMGX08C	DN	ERB-196
DMGX08C	HS	Discontinued in Phase 1
DMGX08C	SN	WAY-196; WAY-202196; Estrogen receptor beta agonist (oral, inflammation/sepsis), Wyeth
DMGX08C	CP	Wyeth
DMGX08C	PC	6102691
DMGX08C	MW	279.26
DMGX08C	FM	C17H10FNO2
DMGX08C	IC	InChI=1S/C17H10FNO2/c18-16-7-10(2-4-17(16)21)12-5-11-1-3-14(20)8-15(11)13(6-12)9-19/h1-8,20-21H
DMGX08C	CS	C1=CC(=CC2=C(C=C(C=C21)C3=CC(=C(C=C3)O)F)C#N)O
DMGX08C	IK	NSSOSHDCWCMNDM-UHFFFAOYSA-N
DMGX08C	IU	3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthalene-1-carbonitrile
DMGX08C	CA	CAS 550997-55-2
DMGX08C	DE	Inflammatory bowel disease

DMW9LHG	ID	DMW9LHG
DMW9LHG	DN	ES-285
DMW9LHG	HS	Discontinued in Phase 1
DMW9LHG	SN	Spisulosine-285
DMW9LHG	CP	PharmaMar SA
DMW9LHG	PC	9925886
DMW9LHG	MW	285.5
DMW9LHG	FM	C18H39NO
DMW9LHG	IC	InChI=1S/C18H39NO/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18(20)17(2)19/h17-18,20H,3-16,19H2,1-2H3/t17-,18+/m0/s1
DMW9LHG	CS	CCCCCCCCCCCCCCC[C@H]([C@H](C)N)O
DMW9LHG	IK	YRYJJIXWWQLGGV-ZWKOTPCHSA-N
DMW9LHG	IU	(2S,3R)-2-aminooctadecan-3-ol
DMW9LHG	CA	CAS 196497-48-0
DMW9LHG	CB	CHEBI:67106
DMW9LHG	DE	Solid tumour/cancer

DM9450Z	ID	DM9450Z
DM9450Z	DN	EVT-103
DM9450Z	HS	Discontinued in Phase 1
DM9450Z	SN	ENS-103
DM9450Z	CP	Roche Holding AG
DM9450Z	DE	Major depressive disorder

DMCZ8SF	ID	DMCZ8SF
DMCZ8SF	DN	EVT-301
DMCZ8SF	HS	Discontinued in Phase 1
DMCZ8SF	SN	MAO B inhibitors (Alzheimer's disease), Evotec/Roche; Monoamineoxidase B inhibitors (Alzheimer's disease),Evotec/Roche
DMCZ8SF	CP	Roche Holding AG
DMCZ8SF	DE	Alzheimer disease

DMLRF7U	ID	DMLRF7U
DMLRF7U	DN	F-11105
DMLRF7U	HS	Discontinued in Phase 1
DMLRF7U	CP	Pierre Fabre SA
DMLRF7U	DE	Asthma

DMPC9K3	ID	DMPC9K3
DMPC9K3	DN	F-1394
DMPC9K3	HS	Discontinued in Phase 1
DMPC9K3	SN	AC1OCF5R; SCHEMBL4296509; [(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate
DMPC9K3	CP	Fujirebio KK
DMPC9K3	DT	Small molecular drug
DMPC9K3	PC	6918210
DMPC9K3	MW	595.9
DMPC9K3	FM	C33H61N3O6
DMPC9K3	IC	InChI=1S/C33H61N3O6/c1-9-10-11-12-13-14-17-22-36(23-31(2,3)4)30(39)35-25-18-15-16-19-26(25)41-27(37)20-21-34-29(38)28-32(5,6)24-40-33(7,8)42-28/h25-26,28H,9-24H2,1-8H3,(H,34,38)(H,35,39)/t25-,26-,28?/m0/s1
DMPC9K3	CS	CCCCCCCCCN(CC(C)(C)C)C(=O)N[C@H]1CCCC[C@@H]1OC(=O)CCNC(=O)C2C(COC(O2)(C)C)(C)C
DMPC9K3	IK	NWLFOBZKYXKBOF-QIELNMHASA-N
DMPC9K3	IU	[(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate
DMPC9K3	DE	Arteriosclerosis

DMMG6W5	ID	DMMG6W5
DMMG6W5	DN	F-50040
DMMG6W5	HS	Discontinued in Phase 1
DMMG6W5	SN	Metastatic melanoma vaccine, Pierre Fabre; P40-ELA; Metastatic melanoma vaccine, BioMerieux-Pierre Fabre; Vaccine (melanoma), Pierre Fabre; Vaccine (melanoma), BioMerieux-Pierre Fabre
DMMG6W5	CP	Pierre Fabre SA
DMMG6W5	DE	Melanoma

DM76GRQ	ID	DM76GRQ
DM76GRQ	DN	Farampator
DM76GRQ	HS	Discontinued in Phase 1
DM76GRQ	SN	CX 691; CX-691; Farampator (USAN/INN); 1-(Benzofurazan-5-ylcarbonyl)piperidine; 2,1,3-benzoxadiazol-5-yl(piperidin-1-yl)methanone
DM76GRQ	CP	Cortex Pharmaceuticals
DM76GRQ	DT	Small molecular drug
DM76GRQ	PC	4118151
DM76GRQ	MW	231.25
DM76GRQ	FM	C12H13N3O2
DM76GRQ	IC	InChI=1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2
DM76GRQ	CS	C1CCN(CC1)C(=O)C2=CC3=NON=C3C=C2
DM76GRQ	IK	XFVRBYKKGGDPAJ-UHFFFAOYSA-N
DM76GRQ	IU	2,1,3-benzoxadiazol-5-yl(piperidin-1-yl)methanone
DM76GRQ	CA	CAS 211735-76-1
DM76GRQ	DE	Schizophrenia; Major depressive disorder

DMEX12T	ID	DMEX12T
DMEX12T	DN	FC EPO
DMEX12T	HS	Discontinued in Phase 1
DMEX12T	SN	Long acting erythropoietin (anemia), Merck Serono
DMEX12T	CP	Merck Serono SA
DMEX12T	DE	Anemia

DMSFA7L	ID	DMSFA7L
DMSFA7L	DN	FCE-28161
DMSFA7L	HS	Discontinued in Phase 1
DMSFA7L	SN	PNU-166945; Lodeca[3,4]benz[1,2-b]oxet-5-one; Copolymer of N-(2-hydroxypropyl)methacrylamide,methacryloylglycine 2-hydroxypropylamide and [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha,12aalpha,12balpha]]-6,12b-diacetoxy-9-[3-benza; Mido-2-(methacryloyl-glycyl-L-phenylalanyl-L-leucyl-glycyloxy)-3-phenylpropionyloxy]-12-benzoyloxy-4,11-dihydroxy-4a,8,13,13-tetramethyl-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyc
DMSFA7L	DE	Solid tumour/cancer

DMC3DVB	ID	DMC3DVB
DMC3DVB	DN	Figitumumab
DMC3DVB	HS	Discontinued in Phase 1
DMC3DVB	SN	AC1OCENC; (2R)-3-[(4S,6R,7R,10S)-4-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(6S,9R,10S)-9-methyl-5,11-dioxaspiro[5.5]undecan-10-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-7-hydroxy-2-methyl-5,11-dioxaspiro[5.5]undec-1-en-10-yl]-2-hydroxy-2-methylpropanoic acid
DMC3DVB	CP	Pfizer
DMC3DVB	DT	Monoclonal antibody
DMC3DVB	DE	Malignant adrenal gland cancer

DMVL5RC	ID	DMVL5RC
DMVL5RC	DN	FK-041
DMVL5RC	HS	Discontinued in Phase 1
DMVL5RC	CP	Fujisawa Pharmaceutical Co Ltd
DMVL5RC	PC	102315666
DMVL5RC	MW	481.5
DMVL5RC	FM	C16H15N7O5S3
DMVL5RC	IC	InChI=1S/C16H15N7O5S3/c17-16-20-7(4-31-16)9(22-28)12(24)21-10-13(25)23-11(15(26)27)8(5-30-14(10)23)29-3-6-1-18-19-2-6/h1-2,4,10,14,28H,3,5H2,(H2,17,20)(H,18,19)(H,21,24)(H,26,27)/b22-9+/t10-,14-/m1/s1
DMVL5RC	CS	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=N/O)/C3=CSC(=N3)N)C(=O)O)SCC4=CNN=C4
DMVL5RC	IK	RNWMKMFWVBYAMX-KXDGEKGBSA-N
DMVL5RC	IU	(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-(1H-pyrazol-4-ylmethylsulfanyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMVL5RC	DE	Bacterial infection

DMB5HMS	ID	DMB5HMS
DMB5HMS	DN	FK-973
DMB5HMS	HS	Discontinued in Phase 1
DMB5HMS	SN	FK-973
DMB5HMS	CP	Fujisawa Pharmaceutical Co Ltd
DMB5HMS	DT	Small molecular drug
DMB5HMS	PC	6917966
DMB5HMS	MW	447.4
DMB5HMS	FM	C20H21N3O9
DMB5HMS	IC	InChI=1S/C20H21N3O9/c1-9(25)23-15-6-22-14-4-12(7-24)5-16(30-10(2)26)17(14)13(8-29-19(21)28)20(32-22,18(15)23)31-11(3)27/h4-5,7,13,15,18H,6,8H2,1-3H3,(H2,21,28)/t13-,15-,18-,20?,23?/m0/s1
DMB5HMS	CS	CC(=O)N1[C@@H]2[C@H]1C3([C@H](C4=C(C=C(C=C4OC(=O)C)C=O)N(C2)O3)COC(=O)N)OC(=O)C
DMB5HMS	IK	FBXPCVIKIBWXAE-GFUNNECNSA-N
DMB5HMS	IU	[(8R,10S,12S)-11-acetyl-9-acetyloxy-8-(carbamoyloxymethyl)-4-formyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-trien-6-yl] acetate
DMB5HMS	DE	Solid tumour/cancer

DMKWTPX	ID	DMKWTPX
DMKWTPX	DN	FLM-5011
DMKWTPX	HS	Discontinued in Phase 1
DMKWTPX	SN	1-(2-Hydroxy-5-methylphenyl)-1-dodecanone oxime; 2-Hydroxy-5-methylaurophenone oxime
DMKWTPX	DT	Small molecular drug
DMKWTPX	PC	136029274
DMKWTPX	MW	305.5
DMKWTPX	FM	C19H31NO2
DMKWTPX	IC	InChI=1S/C19H31NO2/c1-3-4-5-6-7-8-9-10-11-12-18(20-22)17-15-16(2)13-14-19(17)21/h13-15,21-22H,3-12H2,1-2H3/b20-18-
DMKWTPX	CS	CCCCCCCCCCC/C(=N/O)/C1=C(C=CC(=C1)C)O
DMKWTPX	IK	OOXQDZTUGOJLHK-ZZEZOPTASA-N
DMKWTPX	IU	2-[(Z)-N-hydroxy-C-undecylcarbonimidoyl]-4-methylphenol
DMKWTPX	CA	CAS 105634-48-8
DMKWTPX	DE	Inflammation

DM5FW8Y	ID	DM5FW8Y
DM5FW8Y	DN	FR-158999
DM5FW8Y	HS	Discontinued in Phase 1
DM5FW8Y	SN	4-[4-(4-Amidinophenoxy)butyryl-L-aspartyl-L-valyl]thiomorpholine S,S-dioxide
DM5FW8Y	DT	Small molecular drug
DM5FW8Y	PC	178035
DM5FW8Y	MW	553.6
DM5FW8Y	FM	C24H35N5O8S
DM5FW8Y	IC	InChI=1S/C24H35N5O8S/c1-15(2)21(24(34)29-9-12-38(35,36)13-10-29)28-23(33)18(14-20(31)32)27-19(30)4-3-11-37-17-7-5-16(6-8-17)22(25)26/h5-8,15,18,21H,3-4,9-14H2,1-2H3,(H3,25,26)(H,27,30)(H,28,33)(H,31,32)/t18-,21-/m0/s1
DM5FW8Y	CS	CC(C)[C@@H](C(=O)N1CCS(=O)(=O)CC1)NC(=O)[C@H](CC(=O)O)NC(=O)CCCOC2=CC=C(C=C2)C(=N)N
DM5FW8Y	IK	FPOQHPVEVPIFME-RXVVDRJESA-N
DM5FW8Y	IU	(3S)-3-[4-(4-carbamimidoylphenoxy)butanoylamino]-4-[[(2S)-1-(1,1-dioxo-1,4-thiazinan-4-yl)-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM5FW8Y	CA	CAS 160138-41-0
DM5FW8Y	DE	Thrombosis

DM69OR8	ID	DM69OR8
DM69OR8	DN	FR167653
DM69OR8	HS	Discontinued in Phase 1
DM69OR8	SN	HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818
DM69OR8	DT	Small molecular drug
DM69OR8	PC	135484078
DM69OR8	MW	525.5
DM69OR8	FM	C24H20FN5O6S
DM69OR8	IC	InChI=1S/C24H18FN5O2.H2O4S/c25-19-8-6-17(7-9-19)21-20(16-10-12-26-13-11-16)23-28-30(15-14-29(23)27-21)24(32)22(31)18-4-2-1-3-5-18;1-5(2,3)4/h1-13,28H,14-15H2;(H2,1,2,3,4)
DM69OR8	CS	C1CN(NC2=C(C(=NN21)C3=CC=C(C=C3)F)C4=CC=NC=C4)C(=O)C(=O)C5=CC=CC=C5.OS(=O)(=O)O
DM69OR8	IK	KCPHXRBKBLJJJJ-UHFFFAOYSA-N
DM69OR8	IU	1-[7-(4-fluorophenyl)-8-pyridin-4-yl-3,4-dihydro-1H-pyrazolo[5,1-c][1,2,4]triazin-2-yl]-2-phenylethane-1,2-dione;sulfuric acid
DM69OR8	CA	CAS 158876-66-5
DM69OR8	DE	Chronic obstructive pulmonary disease

DMDW64X	ID	DMDW64X
DMDW64X	DN	FT-105
DMDW64X	HS	Discontinued in Phase 1
DMDW64X	SN	FT-105 (long-acting, Medusa), Flamel
DMDW64X	CP	Flamel Technologies SA
DMDW64X	DE	Diabetic complication

DMCZAJW	ID	DMCZAJW
DMCZAJW	DN	Garnocestim
DMCZAJW	HS	Discontinued in Phase 1
DMCZAJW	SN	SB-251353
DMCZAJW	CP	SmithKline Beecham plc
DMCZAJW	DE	Bone marrow transplantation

DM041IZ	ID	DM041IZ
DM041IZ	DN	GED-aPC
DM041IZ	HS	Discontinued in Phase 1
DM041IZ	SN	LY458202; LY-458202
DM041IZ	CP	Eli Lilly
DM041IZ	DE	Cardiovascular disease

DMNFWR1	ID	DMNFWR1
DMNFWR1	DN	Gedocarnil
DMNFWR1	HS	Discontinued in Phase 1
DMNFWR1	SN	SH-530
DMNFWR1	CP	Bayer Schering Pharma AG
DMNFWR1	DT	Small molecular drug
DMNFWR1	PC	219095
DMNFWR1	MW	424.9
DMNFWR1	FM	C23H21ClN2O4
DMNFWR1	IC	InChI=1S/C23H21ClN2O4/c1-13(2)29-23(27)22-16(12-28-3)20-18(11-25-22)26-17-5-4-6-19(21(17)20)30-15-9-7-14(24)8-10-15/h4-11,13,26H,12H2,1-3H3
DMNFWR1	CS	CC(C)OC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC=C3OC4=CC=C(C=C4)Cl
DMNFWR1	IK	SLYDYLLJUXFULK-UHFFFAOYSA-N
DMNFWR1	IU	propan-2-yl 5-(4-chlorophenoxy)-4-(methoxymethyl)-9H-pyrido[3,4-b]indole-3-carboxylate
DMNFWR1	CA	CAS 109623-97-4
DMNFWR1	DE	Anxiety disorder

DM4ZDVY	ID	DM4ZDVY
DM4ZDVY	DN	Gem 92
DM4ZDVY	HS	Discontinued in Phase 1
DM4ZDVY	CP	Idera Pharmaceuticals
DM4ZDVY	TC	Antisense
DM4ZDVY	DT	Antisense drug
DM4ZDVY	DE	Human immunodeficiency virus-1 infection

DM520D8	ID	DM520D8
DM520D8	DN	Gevotroline
DM520D8	HS	Discontinued in Phase 1
DM520D8	SN	Carvotroline; Carvotroline hydrochloride; Gevotroline hydrochloride; WY-47384; WY-47791; Wy-46320
DM520D8	CP	Wyeth; Wyeth-Ayerst Pharmaceuticals Inc
DM520D8	DT	Small molecular drug
DM520D8	PC	60547
DM520D8	MW	309.4
DM520D8	FM	C19H20FN3
DM520D8	IC	InChI=1S/C19H20FN3/c20-15-5-6-18-16(11-15)17-13-23(10-7-19(17)22-18)9-2-4-14-3-1-8-21-12-14/h1,3,5-6,8,11-12,22H,2,4,7,9-10,13H2
DM520D8	CS	C1CN(CC2=C1NC3=C2C=C(C=C3)F)CCCC4=CN=CC=C4
DM520D8	IK	RZXHTPCHKSYGIB-UHFFFAOYSA-N
DM520D8	IU	8-fluoro-2-(3-pyridin-3-ylpropyl)-1,3,4,5-tetrahydropyrido[4,3-b]indole
DM520D8	CA	CAS 107266-06-8
DM520D8	CB	CHEBI:142391
DM520D8	DE	Psychotic disorder

DMSGUY9	ID	DMSGUY9
DMSGUY9	DN	Goxalapladib
DMSGUY9	HS	Discontinued in Phase 1
DMSGUY9	SN	Goxalapladib < USAN; 2-[2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,4-dihydro-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[4'-(trifluoromethyl)biphenyl-4-ylmethyl]acetamide; 677116
DMSGUY9	DT	Small molecular drug
DMSGUY9	PC	11686305
DMSGUY9	MW	718.8
DMSGUY9	FM	C40H39F5N4O3
DMSGUY9	IC	InChI=1S/C40H39F5N4O3/c1-52-23-22-47-20-17-32(18-21-47)48(25-27-7-9-28(10-8-27)29-11-14-31(15-12-29)40(43,44)45)37(51)26-49-33(16-13-30-4-2-6-35(41)38(30)42)24-36(50)34-5-3-19-46-39(34)49/h2-12,14-15,19,24,32H,13,16-18,20-23,25-26H2,1H3
DMSGUY9	CS	COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C(=CC(=O)C5=C4N=CC=C5)CCC6=C(C(=CC=C6)F)F
DMSGUY9	IK	OBJKLVFDRLAGJI-UHFFFAOYSA-N
DMSGUY9	IU	2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
DMSGUY9	CA	CAS 412950-27-7
DMSGUY9	DE	Arteriosclerosis

DMRNI6K	ID	DMRNI6K
DMRNI6K	DN	GR-127607
DMRNI6K	HS	Discontinued in Phase 1
DMRNI6K	CP	Glaxo Group Research Ltd
DMRNI6K	DE	Migraine

DMWY2F6	ID	DMWY2F6
DMWY2F6	DN	GR-253035
DMWY2F6	HS	Discontinued in Phase 1
DMWY2F6	CP	Glaxo Wellcome plc
DMWY2F6	DE	Alzheimer disease

DMUANK9	ID	DMUANK9
DMUANK9	DN	GR-328713
DMUANK9	HS	Discontinued in Phase 1
DMUANK9	SN	GW-320449X; GW-328713X
DMUANK9	CP	Glaxo Wellcome plc
DMUANK9	DE	Arteriosclerosis

DM13GK8	ID	DM13GK8
DM13GK8	DN	GR-63799X
DM13GK8	HS	Discontinued in Phase 1
DM13GK8	SN	(-)-[1(R)-[1alpha(Z),2beta(R*),3alpha]-7-[3-Hydroxy-2-(2-hydroxy-3-phenoxypropoxy)-5-oxocyclopentyl]-4-heptenoic acid 4-(benzoylamino)phenyl ester; (Z)-4,5-Didehydro-13-oxa-16-phenoxy-13,14-dihydro-17,18,19,20-tetranor-PGE1 4-(benzoylamino)phenyl ester; 119906-28-4
DM13GK8	DT	Small molecular drug
DM13GK8	PC	6439068
DM13GK8	MW	587.7
DM13GK8	FM	C34H37NO8
DM13GK8	IC	InChI=1S/C34H37NO8/c36-26(22-41-27-13-7-4-8-14-27)23-42-33-29(30(37)21-31(33)38)15-9-1-2-10-16-32(39)43-28-19-17-25(18-20-28)35-34(40)24-11-5-3-6-12-24/h1-8,11-14,17-20,26,29,31,33,36,38H,9-10,15-16,21-23H2,(H,35,40)/b2-1-/t26?,29-,31+,33+/m0/s1
DM13GK8	CS	C1[C@H]([C@@H]([C@H](C1=O)CC/C=C\\CCC(=O)OC2=CC=C(C=C2)NC(=O)C3=CC=CC=C3)OCC(COC4=CC=CC=C4)O)O
DM13GK8	IK	QQTQLHVRUZWVQZ-WYFSZTNASA-N
DM13GK8	IU	(4-benzamidophenyl) (Z)-7-[(1R,2R,3R)-3-hydroxy-2-(2-hydroxy-3-phenoxypropoxy)-5-oxocyclopentyl]hept-4-enoate
DM13GK8	CA	CAS 106342-69-2
DM13GK8	DE	Asthma

DM9C1LQ	ID	DM9C1LQ
DM9C1LQ	DN	GR-79236
DM9C1LQ	HS	Discontinued in Phase 1
DM9C1LQ	SN	GR79236; 124555-18-6; GR-79236; GR 79236; UNII-Q4H682B2VZ; GR 79236X; N-((1S,trans)-2-Hydroxycyclopentyl)adenosine; Q4H682B2VZ; CHEMBL2163568; N-((1S,2S)-2-Hydroxycyclopentyl)adenosine; N-[(1S, trans)-2-Hydroxycyclopentyl]adenosine; N-[(1S,2S)-2-Hydroxycyclopentyl]adenosine; N-[(1S,trans)-2-hydroxycyclopentyl]adenosine; Adenosine, N-(2-hydroxycyclopentyl)-, (1S-trans)-; gr79236x; SCHEMBL2779184; GTPL3288; CHEBI:92714; DTXSID10154427; MolPort-023-276-288; GYWXTRVEUURNEW-TVDBPQCTSA-N; HMS3268O08; ZINC3794575; MFCD00884605
DM9C1LQ	CP	Glaxo Group Research Ltd
DM9C1LQ	DT	Small molecular drug
DM9C1LQ	PC	9884817
DM9C1LQ	MW	351.36
DM9C1LQ	FM	C15H21N5O5
DM9C1LQ	IC	InChI=1S/C15H21N5O5/c21-4-9-11(23)12(24)15(25-9)20-6-18-10-13(16-5-17-14(10)20)19-7-2-1-3-8(7)22/h5-9,11-12,15,21-24H,1-4H2,(H,16,17,19)/t7-,8-,9+,11+,12+,15+/m0/s1
DM9C1LQ	CS	C1C[C@@H]([C@H](C1)O)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DM9C1LQ	IK	GYWXTRVEUURNEW-TVDBPQCTSA-N
DM9C1LQ	IU	(2R,3R,4S,5R)-2-[6-[[(1S,2S)-2-hydroxycyclopentyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM9C1LQ	CA	CAS 124555-18-6
DM9C1LQ	CB	CHEBI:92714
DM9C1LQ	DE	Diabetic complication

DMEC6RD	ID	DMEC6RD
DMEC6RD	DN	GSK1004723
DMEC6RD	HS	Discontinued in Phase 1
DMEC6RD	SN	CHEMBL1767168; SCHEMBL2819051
DMEC6RD	CP	GSK
DMEC6RD	DT	Small molecular drug
DMEC6RD	PC	17747460
DMEC6RD	MW	641.3
DMEC6RD	FM	C39H49ClN4O2
DMEC6RD	IC	InChI=1S/C39H49ClN4O2/c40-33-19-15-32(16-20-33)29-38-36-13-3-4-14-37(36)39(45)44(41-38)30-34-12-9-27-43(34)26-8-5-11-31-17-21-35(22-18-31)46-28-10-25-42-23-6-1-2-7-24-42/h3-4,13-22,34H,1-2,5-12,23-30H2/t34-/m1/s1
DMEC6RD	CS	C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
DMEC6RD	IK	YANGEESWIGIKOP-UUWRZZSWSA-N
DMEC6RD	IU	2-[[(2R)-1-[4-[4-[3-(azepan-1-yl)propoxy]phenyl]butyl]pyrrolidin-2-yl]methyl]-4-[(4-chlorophenyl)methyl]phthalazin-1-one
DMEC6RD	CA	CAS 955359-72-5
DMEC6RD	DE	Allergic rhinitis

DM7ACJ4	ID	DM7ACJ4
DM7ACJ4	DN	GSK1018921
DM7ACJ4	HS	Discontinued in Phase 1
DM7ACJ4	CP	GSK
DM7ACJ4	DE	Schizophrenia

DMI6KQM	ID	DMI6KQM
DMI6KQM	DN	GSK1059615
DMI6KQM	HS	Discontinued in Phase 1
DMI6KQM	SN	KS-00001CUQ; CTK8F0346; HMS3654N17; BCP02498; AKOS026750445; NCGC00346509-01; FT-0669060
DMI6KQM	CP	GlaxoSmithKline
DMI6KQM	DT	Small molecular drug
DMI6KQM	PC	23582824
DMI6KQM	MW	333.4
DMI6KQM	FM	C18H11N3O2S
DMI6KQM	IC	InChI=1S/C18H11N3O2S/c22-17-16(24-18(23)21-17)10-11-1-2-15-14(9-11)13(5-8-20-15)12-3-6-19-7-4-12/h1-10H,(H,21,22,23)/b16-10-
DMI6KQM	CS	C1=CC2=NC=CC(=C2C=C1/C=C\\3/C(=O)NC(=O)S3)C4=CC=NC=C4
DMI6KQM	IK	QDITZBLZQQZVEE-YBEGLDIGSA-N
DMI6KQM	IU	(5Z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione
DMI6KQM	CA	CAS 958852-01-2
DMI6KQM	CB	CHEBI:71955
DMI6KQM	DE	Lymphoma; Endometrial cancer; Breast cancer

DMBXYKG	ID	DMBXYKG
DMBXYKG	DN	GSK-1362885
DMBXYKG	HS	Discontinued in Phase 1
DMBXYKG	SN	1362885
DMBXYKG	CP	GlaxoSmithKline plc
DMBXYKG	DE	Type-2 diabetes

DMM7Q3L	ID	DMM7Q3L
DMM7Q3L	DN	GSK2849466
DMM7Q3L	HS	Discontinued in Phase 1
DMM7Q3L	CP	Glaxosmithkline
DMM7Q3L	DE	Heart failure

DM6E84O	ID	DM6E84O
DM6E84O	DN	GSK568859
DM6E84O	HS	Discontinued in Phase 1
DM6E84O	CP	GlaxoSmithKline
DM6E84O	DE	Arteriosclerosis

DMRTPY6	ID	DMRTPY6
DMRTPY6	DN	GSK729327
DMRTPY6	HS	Discontinued in Phase 1
DMRTPY6	CP	GSK
DMRTPY6	DE	Schizophrenia

DM2AP64	ID	DM2AP64
DM2AP64	DN	GSK945237
DM2AP64	HS	Discontinued in Phase 1
DM2AP64	CP	GSK
DM2AP64	DE	Bacterial infection

DMWJZAP	ID	DMWJZAP
DMWJZAP	DN	GW-250495
DMWJZAP	HS	Discontinued in Phase 1
DMWJZAP	SN	GR-250495; GR-250495X; GW-250495X
DMWJZAP	CP	Glaxo Wellcome plc
DMWJZAP	DE	Asthma

DM62T1C	ID	DM62T1C
DM62T1C	DN	GW-311616
DM62T1C	HS	Discontinued in Phase 1
DM62T1C	SN	XVDWNSFFSMWXJJ-BDRHRQAXSA-N; UNII-HN0T99OO4V component XVDWNSFFSMWXJJ-BDRHRQAXSA-N; N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl) ethyl]amino]methyl]phenyl]-2E-2-propenamide D-(-)-lactate salt; n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide d-(-)-lactate salt
DM62T1C	DT	Small molecular drug
DM62T1C	PC	9800961
DM62T1C	MW	397.5
DM62T1C	FM	C19H31N3O4S
DM62T1C	IC	InChI=1S/C19H31N3O4S/c1-14(2)17-18-15(22(19(17)24)27(3,25)26)9-13-21(18)16(23)8-7-12-20-10-5-4-6-11-20/h7-8,14-15,17-18H,4-6,9-13H2,1-3H3/b8-7+/t15-,17+,18-/m1/s1
DM62T1C	CS	CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)/C=C/CN3CCCCC3)N(C1=O)S(=O)(=O)C
DM62T1C	IK	NDNKNUMSTIMSHQ-URZKGLGPSA-N
DM62T1C	IU	(3aR,6S,6aS)-4-methylsulfonyl-1-[(E)-4-piperidin-1-ylbut-2-enoyl]-6-propan-2-yl-3,3a,6,6a-tetrahydro-2H-pyrrolo[3,2-b]pyrrol-5-one
DM62T1C	CA	CAS 198062-54-3

DMRQVI9	ID	DMRQVI9
DMRQVI9	DN	GW-473178
DMRQVI9	HS	Discontinued in Phase 1
DMRQVI9	SN	473178
DMRQVI9	CP	Glaxo Wellcome plc
DMRQVI9	DE	Heart arrhythmia

DMQNX02	ID	DMQNX02
DMQNX02	DN	GYKI-12743
DMQNX02	HS	Discontinued in Phase 1
DMQNX02	SN	GYKI-12743; Gyki 12743; GKYI-12743; 110714-10-8; 2-(3-(Benzo(1,4)dioxan-2-ylmethylamino)-1-propyl)-3(2H)-pyridazinone hydrochloride; 2-{3-[(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)amino]propyl}pyridazin-3(2h)-one hydrochloride(1:1); 133983-22-9; 3(2H)-Pyridazinone, 2-[3-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]propyl]-, hydrochloride (1:1); 3(2H)-Pyridazinone, 2-(3-(((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)amino)propyl)-, monohydrochloride; AC1Q3EJF; AC1L4TO4; SCHEMBL7284667; CTK4B8909; LS-129872
DMQNX02	CP	Gedeon Richter Ltd
DMQNX02	DT	Small molecular drug
DMQNX02	PC	163825
DMQNX02	MW	337.8
DMQNX02	FM	C16H20ClN3O3
DMQNX02	IC	InChI=1S/C16H19N3O3.ClH/c20-16-7-3-9-18-19(16)10-4-8-17-11-13-12-21-14-5-1-2-6-15(14)22-13;/h1-3,5-7,9,13,17H,4,8,10-12H2;1H
DMQNX02	CS	C1C(OC2=CC=CC=C2O1)CNCCCN3C(=O)C=CC=N3.Cl
DMQNX02	IK	WJDFSAOMSJHHCG-UHFFFAOYSA-N
DMQNX02	IU	2-[3-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)propyl]pyridazin-3-one;hydrochloride
DMQNX02	CA	CAS 110714-10-8
DMQNX02	DE	Hypertension

DM2RF06	ID	DM2RF06
DM2RF06	DN	HCV-086
DM2RF06	HS	Discontinued in Phase 1
DM2RF06	SN	VP-18344
DM2RF06	CP	ViroPharma; ViroPharma Inc
DM2RF06	DT	Small molecular drug
DM2RF06	PC	10409873
DM2RF06	MW	420.5
DM2RF06	FM	C20H21FN2O5S
DM2RF06	IC	InChI=1S/C20H21FN2O5S/c1-11(2)27-17-9-14-16(10-15(17)23-29(4,25)26)28-19(18(14)20(24)22-3)12-5-7-13(21)8-6-12/h5-11,23H,1-4H3,(H,22,24)
DM2RF06	CS	CC(C)OC1=C(C=C2C(=C1)C(=C(O2)C3=CC=C(C=C3)F)C(=O)NC)NS(=O)(=O)C
DM2RF06	IK	VBRUONUESYTIDA-UHFFFAOYSA-N
DM2RF06	IU	2-(4-fluorophenyl)-6-(methanesulfonamido)-N-methyl-5-propan-2-yloxy-1-benzofuran-3-carboxamide
DM2RF06	DE	Hepatitis virus infection

DMCP2KH	ID	DMCP2KH
DMCP2KH	DN	HE2100
DMCP2KH	HS	Discontinued in Phase 1
DMCP2KH	SN	Androstenediol; Hermaphrodiol; 5-Androstenediol; Androst-5-enediol; 521-17-5; Androst-5-ene-3beta,17beta-diol; Neumune; 3beta,17beta-Dihydroxyandrost-5-ene; delta(sup 5)-Androstenediol; Androstenediol [JAN]; UNII-95PS51EMXY; Androst-5-enediol (VAN); (3beta,17beta)-androst-5-ene-3,17-diol; 5-AED; 3beta,17beta-Dihydroxy-5-androstene; androst-5-en-3beta,17beta-diol; EINECS 208-306-8; NSC 12163; 95PS51EMXY; ANDROST-5-ENE-3-beta,17-beta-DIOL; CHEMBL440283; CHEBI:2710; (3-beta,17-beta)-Androst-5-ene-3,17-diol; delta(sup; ANDROSTENEDIOL
DMCP2KH	CP	Hollis-Eden Pharmaceuticals
DMCP2KH	DT	Small molecular drug
DMCP2KH	PC	10634
DMCP2KH	MW	290.4
DMCP2KH	FM	C19H30O2
DMCP2KH	IC	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1
DMCP2KH	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC=C4[C@@]3(CC[C@@H](C4)O)C
DMCP2KH	IK	QADHLRWLCPCEKT-LOVVWNRFSA-N
DMCP2KH	IU	(3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
DMCP2KH	CA	CAS 521-17-5
DMCP2KH	CB	CHEBI:2710
DMCP2KH	DE	Thrombocytopenia

DM0W2TA	ID	DM0W2TA
DM0W2TA	DN	HGS-TR2J
DM0W2TA	HS	Discontinued in Phase 1
DM0W2TA	SN	KMTR2; Trail-R2 human antibody; TRAIL-R2 mAbs, HGS/Kirin; TRAIL-R2 monoclonal antibody (cancer), Human Genome Sciences/Kirin; TRAIL-R2 monoclonal antibody (cancer), Human Genome Sciences/Kyowa Hakko Kirin
DM0W2TA	CP	Kirin Brewery Co Ltd
DM0W2TA	DT	Antibody
DM0W2TA	DE	Solid tumour/cancer

DMH4ANG	ID	DMH4ANG
DMH4ANG	DN	HMN-214
DMH4ANG	HS	Discontinued in Phase 1
DMH4ANG	SN	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide
DMH4ANG	CP	Nippon Shinyaku
DMH4ANG	TC	Anticancer Agents
DMH4ANG	DT	Small molecular drug
DMH4ANG	PC	9888590
DMH4ANG	MW	424.5
DMH4ANG	FM	C22H20N2O5S
DMH4ANG	IC	InChI=1S/C22H20N2O5S/c1-17(25)24(30(27,28)21-11-9-20(29-2)10-12-21)22-6-4-3-5-19(22)8-7-18-13-15-23(26)16-14-18/h3-16H,1-2H3/b8-7+
DMH4ANG	CS	CC(=O)N(C1=CC=CC=C1/C=C/C2=CC=[N+](C=C2)[O-])S(=O)(=O)C3=CC=C(C=C3)OC
DMH4ANG	IK	OCKHRKSTDPOHEN-BQYQJAHWSA-N
DMH4ANG	IU	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide
DMH4ANG	CA	CAS 173529-46-9
DMH4ANG	CB	CHEBI:91440
DMH4ANG	DE	Prostate cancer; Pancreatic cancer

DMKA612	ID	DMKA612
DMKA612	DN	HMR-3562
DMKA612	HS	Discontinued in Phase 1
DMKA612	SN	11-Deoxy-3-des(hexopyranosyloxy)-2-fluoro-11-[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butylamino]-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate
DMKA612	DT	Small molecular drug
DMKA612	PC	6918484
DMKA612	MW	830
DMKA612	FM	C43H64FN5O10
DMKA612	IC	InChI=1S/C43H64FN5O10/c1-12-32-43(8)35(49(40(54)59-43)19-14-13-18-48-23-30(46-24-48)29-16-15-17-45-22-29)27(4)33(50)25(2)21-41(6,55-11)37(28(5)36(52)42(7,44)39(53)57-32)58-38-34(51)31(47(9)10)20-26(3)56-38/h15-17,22-28,31-32,34-35,37-38,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1
DMKA612	CS	CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@](C(=O)O1)(C)F)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
DMKA612	IK	RSIQCUSPSFSWMQ-XXTFOGKVSA-N
DMKA612	IU	(1S,2R,5S,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-5-fluoro-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMKA612	DE	Bacterial infection

DMQOW8H	ID	DMQOW8H
DMQOW8H	DN	HO-221
DMQOW8H	HS	Discontinued in Phase 1
DMQOW8H	SN	N-(2-Nitrobenzoyl)-N'-[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]urea; N-[4-(5-Bromo-2-pyrimidinyloxy)-3-chlorophenyl]-N'-(2-nitrobenzoyl)urea
DMQOW8H	DT	Small molecular drug
DMQOW8H	PC	128803
DMQOW8H	MW	492.7
DMQOW8H	FM	C18H11BrClN5O5
DMQOW8H	IC	InChI=1S/C18H11BrClN5O5/c19-10-8-21-18(22-9-10)30-15-6-5-11(7-13(15)20)23-17(27)24-16(26)12-3-1-2-4-14(12)25(28)29/h1-9H,(H2,23,24,26,27)
DMQOW8H	CS	C1=CC=C(C(=C1)C(=O)NC(=O)NC2=CC(=C(C=C2)OC3=NC=C(C=N3)Br)Cl)[N+](=O)[O-]
DMQOW8H	IK	WKXWMGOTZJGIIK-UHFFFAOYSA-N
DMQOW8H	IU	N-[[4-(5-bromopyrimidin-2-yl)oxy-3-chlorophenyl]carbamoyl]-2-nitrobenzamide
DMQOW8H	CA	CAS 105128-93-6
DMQOW8H	DE	Virus infection

DMNC1A3	ID	DMNC1A3
DMNC1A3	DN	HOE-065
DMNC1A3	HS	Discontinued in Phase 1
DMNC1A3	SN	2-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid n-octyl ester maleate
DMNC1A3	DT	Small molecular drug
DMNC1A3	PC	6444220
DMNC1A3	MW	644.8
DMNC1A3	FM	C35H52N2O9
DMNC1A3	IC	InChI=1S/C31H48N2O5.C4H4O4/c1-4-6-7-8-9-13-21-38-31(36)28-22-25-17-14-18-27(25)33(28)29(34)23(3)32-26(30(35)37-5-2)20-19-24-15-11-10-12-16-24;5-3(6)1-2-4(7)8/h10-12,15-16,23,25-28,32H,4-9,13-14,17-22H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-,25-,26-,27-,28-;/m0./s1
DMNC1A3	CS	CCCCCCCCOC(=O)[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC.C(=C/C(=O)O)\\C(=O)O
DMNC1A3	IK	RCEDCOCCCMIKCY-ZVCJTHDASA-N
DMNC1A3	IU	(E)-but-2-enedioic acid;octyl (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylate
DMNC1A3	CA	CAS 123060-44-6
DMNC1A3	DE	Cognitive impairment

DMH32LM	ID	DMH32LM
DMH32LM	DN	HRC-302
DMH32LM	HS	Discontinued in Phase 1
DMH32LM	SN	HML-115; XL-2; Cell therapy, X-Cell Biotech; GDT-CML, Hemosol; Stem cells, X-Cell Biotech; Gamma delta T-cells (selectively expanded), Hemosol; GDT-CML (HRC-302-expanded), Hemosol
DMH32LM	CP	Ontario Inc
DMH32LM	DE	Chronic myelogenous leukaemia

DMQYWAH	ID	DMQYWAH
DMQYWAH	DN	HRT
DMQYWAH	HS	Discontinued in Phase 1
DMQYWAH	SN	HRT (oral); IP-1162; IP-1163; IP-1164; HRT (oral), Shire
DMQYWAH	CP	Shire Pharmaceutical Development Ltd
DMQYWAH	DE	Estrogen deficiency

DMCS06R	ID	DMCS06R
DMCS06R	DN	HSR-6071
DMCS06R	HS	Discontinued in Phase 1
DMCS06R	SN	PTPC; 6-(1-Pyrrolidinyl)-N-(1H-tetrazol-5-yl)pyrazine-2-carboxamide
DMCS06R	DT	Small molecular drug
DMCS06R	PC	159466
DMCS06R	MW	260.26
DMCS06R	FM	C10H12N8O
DMCS06R	IC	InChI=1S/C10H12N8O/c19-9(13-10-14-16-17-15-10)7-5-11-6-8(12-7)18-3-1-2-4-18/h5-6H,1-4H2,(H2,13,14,15,16,17,19)
DMCS06R	CS	C1CCN(C1)C2=NC(=CN=C2)C(=O)NC3=NNN=N3
DMCS06R	IK	LUJDHCXCWJFNOJ-UHFFFAOYSA-N
DMCS06R	IU	6-pyrrolidin-1-yl-N-(2H-tetrazol-5-yl)pyrazine-2-carboxamide
DMCS06R	CA	CAS 111374-21-1
DMCS06R	DE	Asthma

DMUPOIG	ID	DMUPOIG
DMUPOIG	DN	HT-1067
DMUPOIG	HS	Discontinued in Phase 1
DMUPOIG	SN	MOA-B inhibitor (memory impairement) Helicon; MOA-B inhibitor (cognitive disorder/Parkinson's Disease) Helicon
DMUPOIG	CP	Dart neuroscience
DMUPOIG	DE	Parkinson disease

DM9LY4Q	ID	DM9LY4Q
DM9LY4Q	DN	HuMV833
DM9LY4Q	HS	Discontinued in Phase 1
DM9LY4Q	SN	Anti-VEGF antibody, Toagosei; MAb (cancer), Toagosei; SMART anti-VEGF MAb, Protein Design Labs; SMART anti-VEGF, Toagosei/PDL
DM9LY4Q	CP	Toagosei Co Ltd
DM9LY4Q	DT	Antibody
DM9LY4Q	DE	Solid tumour/cancer

DMZYA9E	ID	DMZYA9E
DMZYA9E	DN	ICI-D-6888
DMZYA9E	HS	Discontinued in Phase 1
DMZYA9E	SN	ZD-6888
DMZYA9E	CP	Zeneca Group plc
DMZYA9E	PC	19935771
DMZYA9E	MW	448
DMZYA9E	FM	C25H26ClN5O
DMZYA9E	IC	InChI=1S/C25H25N5O.ClH/c1-2-19-15-24(22-9-5-6-10-23(22)26-19)31-16-17-11-13-18(14-12-17)20-7-3-4-8-21(20)25-27-29-30-28-25;/h3-4,7-8,11-15H,2,5-6,9-10,16H2,1H3,(H,27,28,29,30);1H
DMZYA9E	CS	CCC1=CC(=C2CCCCC2=N1)OCC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5.Cl
DMZYA9E	IK	RPRNBLHRKYAXSM-UHFFFAOYSA-N
DMZYA9E	IU	2-ethyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methoxy]-5,6,7,8-tetrahydroquinoline;hydrochloride
DMZYA9E	CA	CAS 138620-17-4
DMZYA9E	DE	Hypertension

DMAU79Q	ID	DMAU79Q
DMAU79Q	DN	IDEC-131
DMAU79Q	HS	Discontinued in Phase 1
DMAU79Q	CP	Biogen Idec
DMAU79Q	DT	Antibody
DMAU79Q	DE	Thrombocytopenia

DMP8MBW	ID	DMP8MBW
DMP8MBW	DN	IGANIDIPINE HYDROCHLORIDE
DMP8MBW	HS	Discontinued in Phase 1
DMP8MBW	SN	NKY-722; Iganidipine hydrochloride; Rac-2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl] 5-methyl diester dihydrochloride
DMP8MBW	DT	Small molecular drug
DMP8MBW	PC	164031
DMP8MBW	MW	599.5
DMP8MBW	FM	C28H40Cl2N4O6
DMP8MBW	IC	InChI=1S/C28H38N4O6.2ClH/c1-7-11-30-12-14-31(15-13-30)17-28(4,5)18-38-27(34)24-20(3)29-19(2)23(26(33)37-6)25(24)21-9-8-10-22(16-21)32(35)36;;/h7-10,16,25,29H,1,11-15,17-18H2,2-6H3;2*1H
DMP8MBW	CS	CC1=C(C(C(=C(N1)C)C(=O)OCC(C)(C)CN2CCN(CC2)CC=C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC.Cl.Cl
DMP8MBW	IK	PJGTYHKZUAHNHC-UHFFFAOYSA-N
DMP8MBW	IU	5-O-[2,2-dimethyl-3-(4-prop-2-enylpiperazin-1-yl)propyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;dihydrochloride
DMP8MBW	CA	CAS 117241-46-0
DMP8MBW	DE	Glaucoma/ocular hypertension

DMRSJ49	ID	DMRSJ49
DMRSJ49	DN	IL-18BP
DMRSJ49	HS	Discontinued in Phase 1
DMRSJ49	CP	Yeda; Merck Serono
DMRSJ49	DE	Rheumatoid arthritis; B-cell non-hodgkin lymphoma

DMQIXD2	ID	DMQIXD2
DMQIXD2	DN	IMC-1C11
DMQIXD2	HS	Discontinued in Phase 1
DMQIXD2	DT	Antibody
DMQIXD2	DE	Solid tumour/cancer

DM8OYZB	ID	DM8OYZB
DM8OYZB	DN	Imepitoin
DM8OYZB	HS	Discontinued in Phase 1
DM8OYZB	SN	ADD-233089; AWD-131-138
DM8OYZB	CP	ASTA Medica AG
DM8OYZB	DT	Small molecular drug
DM8OYZB	PC	3083511
DM8OYZB	MW	279.72
DM8OYZB	FM	C13H14ClN3O2
DM8OYZB	IC	InChI=1S/C13H14ClN3O2/c14-10-1-3-11(4-2-10)17-9-12(15-13(17)18)16-5-7-19-8-6-16/h1-4H,5-9H2
DM8OYZB	CS	C1COCCN1C2=NC(=O)N(C2)C3=CC=C(C=C3)Cl
DM8OYZB	IK	IQHYCZKIFIHTAI-UHFFFAOYSA-N
DM8OYZB	IU	3-(4-chlorophenyl)-5-morpholin-4-yl-4H-imidazol-2-one
DM8OYZB	CA	CAS 188116-07-6
DM8OYZB	DE	Convulsion

DMFACQU	ID	DMFACQU
DMFACQU	DN	IMS
DMFACQU	HS	Discontinued in Phase 1
DMFACQU	SN	INO-2002
DMFACQU	CP	Inotek Pharmaceuticals
DMFACQU	DT	Small molecular drug
DMFACQU	PC	13551
DMFACQU	MW	138.19
DMFACQU	FM	C4H10O3S
DMFACQU	IC	InChI=1S/C4H10O3S/c1-4(2)7-8(3,5)6/h4H,1-3H3
DMFACQU	CS	CC(C)OS(=O)(=O)C
DMFACQU	IK	SWWHCQCMVCPLEQ-UHFFFAOYSA-N
DMFACQU	IU	propan-2-yl methanesulfonate
DMFACQU	CA	CAS 926-06-7
DMFACQU	DE	Inflammatory bowel disease

DM8PTUC	ID	DM8PTUC
DM8PTUC	DN	INCB8696
DM8PTUC	HS	Discontinued in Phase 1
DM8PTUC	CP	Incyte
DM8PTUC	DE	Multiple sclerosis

DMGCUTI	ID	DMGCUTI
DMGCUTI	DN	INOC-002
DMGCUTI	HS	Discontinued in Phase 1
DMGCUTI	SN	Chemotherapy potentiator (colon cancer), Innovate Oncology
DMGCUTI	CP	Targent Inc
DMGCUTI	DE	Solid tumour/cancer

DMCF0XK	ID	DMCF0XK
DMCF0XK	DN	IPI-493
DMCF0XK	HS	Discontinued in Phase 1
DMCF0XK	SN	[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851
DMCF0XK	CP	AstraZeneca
DMCF0XK	DT	Small molecular drug
DMCF0XK	PC	9893658
DMCF0XK	MW	545.6
DMCF0XK	FM	C28H39N3O8
DMCF0XK	IC	InChI=1S/C28H39N3O8/c1-14-10-18-23(29)20(32)13-19(25(18)34)31-27(35)15(2)8-7-9-21(37-5)26(39-28(30)36)17(4)12-16(3)24(33)22(11-14)38-6/h7-9,12-14,16,21-22,24,26,33H,10-11,29H2,1-6H3,(H2,30,36)(H,31,35)/b9-7-,15-8+,17-12+/t14-,16+,21+,22+,24-,26+/m1/s1
DMCF0XK	CS	C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)N)/C)OC)OC(=O)N)\\C)C)O)OC
DMCF0XK	IK	XYFFWTYOFPSZRM-TWNAANEASA-N
DMCF0XK	IU	[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-amino-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DMCF0XK	CA	CAS 64202-81-9
DMCF0XK	DE	Gastric adenocarcinoma

DM8139E	ID	DM8139E
DM8139E	DN	ITAMELINE
DM8139E	HS	Discontinued in Phase 1
DM8139E	SN	RU-47213; Itameline; (E)-3-[(Methoxyimino)methyl]-1,2,5,6-tetrahydropyridine-1-carboxylic acid 4-chlorophenyl ester
DM8139E	DT	Small molecular drug
DM8139E	PC	9571042
DM8139E	MW	294.73
DM8139E	FM	C14H15ClN2O3
DM8139E	IC	InChI=1S/C14H15ClN2O3/c1-19-16-9-11-3-2-8-17(10-11)14(18)20-13-6-4-12(15)5-7-13/h3-7,9H,2,8,10H2,1H3/b16-9+
DM8139E	CS	CO/N=C/C1=CCCN(C1)C(=O)OC2=CC=C(C=C2)Cl
DM8139E	IK	CTVQNEVLCGSTKL-CXUHLZMHSA-N
DM8139E	IU	(4-chlorophenyl) 5-[(E)-methoxyiminomethyl]-3,6-dihydro-2H-pyridine-1-carboxylate
DM8139E	CA	CAS 121750-57-0
DM8139E	DE	Cognitive impairment

DMUNYR7	ID	DMUNYR7
DMUNYR7	DN	JTK-109
DMUNYR7	HS	Discontinued in Phase 1
DMUNYR7	SN	CHEMBL379677; 2-[4-(benzyloxy)phenyl]-1-cyclohexyl-1h-benzimidazole-5-carboxylic acid; AC1LAMB2; SCHEMBL791364; CTK7I8521; GWCTUYUNVJTNJR-UHFFFAOYSA-N; MolPort-039-347-685; BDBM50181950; ZINC28572342; AKOS027470656; 2-(4-benzyloxyphenyl)-1-cyclohexyl-benzimidazole-5-carboxylic acid; 1-cyclohexyl-2-(4-phenylmethoxyphenyl)benzimidazole-5-carboxylic acid; 2-(4-(benzyloxy)phenyl)-1-cyclohexyl-1H-benzo[d]imidazole-5-carboxylic acid; 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-
DMUNYR7	CP	Japan Tobacco Inc
DMUNYR7	DT	Small molecular drug
DMUNYR7	PC	491098
DMUNYR7	MW	426.5
DMUNYR7	FM	C27H26N2O3
DMUNYR7	IC	InChI=1S/C27H26N2O3/c30-27(31)21-13-16-25-24(17-21)28-26(29(25)22-9-5-2-6-10-22)20-11-14-23(15-12-20)32-18-19-7-3-1-4-8-19/h1,3-4,7-8,11-17,22H,2,5-6,9-10,18H2,(H,30,31)
DMUNYR7	CS	C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)O)N=C2C4=CC=C(C=C4)OCC5=CC=CC=C5
DMUNYR7	IK	GWCTUYUNVJTNJR-UHFFFAOYSA-N
DMUNYR7	IU	1-cyclohexyl-2-(4-phenylmethoxyphenyl)benzimidazole-5-carboxylic acid
DMUNYR7	DE	Hepatitis C virus infection

DMZFEY1	ID	DMZFEY1
DMZFEY1	DN	JTK-652
DMZFEY1	HS	Discontinued in Phase 1
DMZFEY1	SN	HCV NS5B polymerase inhibitors (JTK-109 derivatives), Japan Tobacco; JTK-109 derivatives (HCV), Japan Tobacco
DMZFEY1	CP	Japan Tobacco Inc
DMZFEY1	DE	Hepatitis C virus infection

DMEADBG	ID	DMEADBG
DMEADBG	DN	JTK-656
DMEADBG	HS	Discontinued in Phase 1
DMEADBG	CP	Japan Tobacco Inc
DMEADBG	DE	Human immunodeficiency virus infection

DM64FX9	ID	DM64FX9
DM64FX9	DN	JTK-853
DM64FX9	HS	Discontinued in Phase 1
DM64FX9	SN	JTK-853; UNII-WDX8QQD13B; WDX8QQD13B; 954389-09-4; (2r)-4-(5-Cyclopropyl[1,3]thiazolo[4,5-D]pyrimidin-2-Yl)-N-[3-Fluoro-4-(Trifluoromethoxy)benzyl]-1-{[4-(Trifluoromethyl)phenyl]sulfonyl}piperazine-2-Carboxamide; 3vqs; JTK 853; SCHEMBL2440999; DTXSID60241836; JQLOVYLALGSISI-HXUWFJFHSA-N; DB13095; HY-19921; 2-Piperazinecarboxamide, 4-(5-cyclopropylthiazolo(4,5-d)pyrimidin-2-yl)-n-((3-fluoro-4-(trifluoromethoxy)phenyl)methyl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)-, (2R)-; CS-0016935; JT1
DM64FX9	CP	Japan Tobacco Inc
DM64FX9	DT	Small molecular drug
DM64FX9	PC	57519700
DM64FX9	MW	704.6
DM64FX9	FM	C28H23F7N6O4S2
DM64FX9	IC	InChI=1S/C28H23F7N6O4S2/c29-19-11-15(1-8-21(19)45-28(33,34)35)12-37-25(42)20-14-40(26-39-24-22(46-26)13-36-23(38-24)16-2-3-16)9-10-41(20)47(43,44)18-6-4-17(5-7-18)27(30,31)32/h1,4-8,11,13,16,20H,2-3,9-10,12,14H2,(H,37,42)/t20-/m1/s1
DM64FX9	CS	C1CC1C2=NC=C3C(=N2)N=C(S3)N4CCN([C@H](C4)C(=O)NCC5=CC(=C(C=C5)OC(F)(F)F)F)S(=O)(=O)C6=CC=C(C=C6)C(F)(F)F
DM64FX9	IK	JQLOVYLALGSISI-HXUWFJFHSA-N
DM64FX9	IU	(2R)-4-(5-cyclopropyl-[1,3]thiazolo[4,5-d]pyrimidin-2-yl)-N-[[3-fluoro-4-(trifluoromethoxy)phenyl]methyl]-1-[4-(trifluoromethyl)phenyl]sulfonylpiperazine-2-carboxamide
DM64FX9	CA	CAS 954389-09-4
DM64FX9	DE	Hepatitis C virus infection

DMI7Z1Y	ID	DMI7Z1Y
DMI7Z1Y	DN	JTT-553
DMI7Z1Y	HS	Discontinued in Phase 1
DMI7Z1Y	SN	DGAT1 inhibitor (oral, obesity) Japan Tobacco
DMI7Z1Y	CP	Japan Tobacco Inc
DMI7Z1Y	PC	10435589
DMI7Z1Y	MW	488.5
DMI7Z1Y	FM	C25H27F3N4O3
DMI7Z1Y	IC	InChI=1S/C25H27F3N4O3/c1-23(2)19(30-18-20(29)31-22(25(26,27)28)32-21(18)35-23)15-3-4-16-14(12-15)7-10-24(16)8-5-13(6-9-24)11-17(33)34/h3-4,12-13H,5-11H2,1-2H3,(H,33,34)(H2,29,31,32)
DMI7Z1Y	CS	CC1(C(=NC2=C(N=C(N=C2O1)C(F)(F)F)N)C3=CC4=C(C=C3)C5(CCC(CC5)CC(=O)O)CC4)C
DMI7Z1Y	IK	YFJNLPDVCDNOMJ-UHFFFAOYSA-N
DMI7Z1Y	IU	2-[6-[4-amino-7,7-dimethyl-2-(trifluoromethyl)pyrimido[4,5-b][1,4]oxazin-6-yl]spiro[1,2-dihydroindene-3,4'-cyclohexane]-1'-yl]acetic acid
DMI7Z1Y	CA	CAS 701232-94-2
DMI7Z1Y	DE	Obesity

DMGP42Q	ID	DMGP42Q
DMGP42Q	DN	JTT-651
DMGP42Q	HS	Discontinued in Phase 1
DMGP42Q	SN	Glycogen phosphorylase inhibitor (oral, diabetes) Japan Tobacco
DMGP42Q	CP	Japan Tobacco Inc
DMGP42Q	DE	Type-2 diabetes

DMXUH6W	ID	DMXUH6W
DMXUH6W	DN	JTV-803
DMXUH6W	HS	Discontinued in Phase 1
DMXUH6W	SN	UNII-7PT6AGF1ST; JTV 803; 7PT6AGF1ST; 247131-79-9; JTV-803; SCHEMBL6191062; NOBZETMXGVAWIM-UHFFFAOYSA-N; 4-Piperidinecarboxylic acid, 4-(((2-(aminoiminomethyl)-1,2,3,4-tetrahydro-7-isoquinolinyl)oxy)methyl)-1-(4-pyridinyl)-, monomethanesulfonate; 4-Piperidinecarboxylic acid, 4-(((2-(aminoiminomethyl)-1,2,3,4-tetrahydro-7-isoquinolinyl)oxy)methyl)-1-(4-pyridinyl)-, methanesulfonate (1:1); KB-78007; 4-(2-amidino-1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)-1-(pyridin-4-yl)piperidine-4-carboxylic acid methanesulfonate
DMXUH6W	CP	Japan Tobacco Inc
DMXUH6W	DT	Small molecular drug
DMXUH6W	PC	11432124
DMXUH6W	MW	505.6
DMXUH6W	FM	C23H31N5O6S
DMXUH6W	IC	InChI=1S/C22H27N5O3.CH4O3S/c23-21(24)27-10-5-16-1-2-19(13-17(16)14-27)30-15-22(20(28)29)6-11-26(12-7-22)18-3-8-25-9-4-18;1-5(2,3)4/h1-4,8-9,13H,5-7,10-12,14-15H2,(H3,23,24)(H,28,29);1H3,(H,2,3,4)
DMXUH6W	CS	CS(=O)(=O)O.C1CN(CC2=C1C=CC(=C2)OCC3(CCN(CC3)C4=CC=NC=C4)C(=O)O)C(=N)N
DMXUH6W	IK	NOBZETMXGVAWIM-UHFFFAOYSA-N
DMXUH6W	IU	4-[(2-carbamimidoyl-3,4-dihydro-1H-isoquinolin-7-yl)oxymethyl]-1-pyridin-4-ylpiperidine-4-carboxylic acid;methanesulfonic acid
DMXUH6W	CA	CAS 247131-79-9
DMXUH6W	DE	Thrombosis

DM37IH5	ID	DM37IH5
DM37IH5	DN	KN-203
DM37IH5	HS	Discontinued in Phase 1
DM37IH5	SN	Mu-opioid recceptor agonist (urinary incontinence), Grunenthal/KeyNeurotek
DM37IH5	CP	Grunenthal GmbH
DM37IH5	DE	Urinary incontinence

DM6LTRC	ID	DM6LTRC
DM6LTRC	DN	KNI-764
DM6LTRC	HS	Discontinued in Phase 1
DM6LTRC	SN	KNI-764; JE-2147; AG1776; 186538-00-1; AG 1776; JE-2147, AG1776, KNI-764; JE2; (4r)-3-{(2s,3s)-2-Hydroxy-3-[(3-Hydroxy-2-Methylbenzoyl)amino]-4-Phenylbutanoyl}-5,5-Dimethyl-N-(2-Methylbenzyl)-1,3-Thiazolidine-4-Carboxamide; 1msn; 2anl; 1kzk; 1msm; 4-Thiazolidinecarboxamide, 3-((2S,3S)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-1-oxo-4-phenylbutyl)-5,5-dimethyl-N-((2-methylphenyl)methyl)-, (4R)-; 4-Thiazolidinecarboxamide, 3-[(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-1-oxo-4-phenylbutyl]-5,5-dimethyl-N-[
DM6LTRC	DT	Small molecular drug
DM6LTRC	PC	446837
DM6LTRC	MW	575.7
DM6LTRC	FM	C32H37N3O5S
DM6LTRC	IC	InChI=1S/C32H37N3O5S/c1-20-11-8-9-14-23(20)18-33-30(39)28-32(3,4)41-19-35(28)31(40)27(37)25(17-22-12-6-5-7-13-22)34-29(38)24-15-10-16-26(36)21(24)2/h5-16,25,27-28,36-37H,17-19H2,1-4H3,(H,33,39)(H,34,38)/t25-,27-,28+/m0/s1
DM6LTRC	CS	CC1=CC=CC=C1CNC(=O)[C@@H]2C(SCN2C(=O)[C@H]([C@H](CC3=CC=CC=C3)NC(=O)C4=C(C(=CC=C4)O)C)O)(C)C
DM6LTRC	IK	CUFQBQOBLVLKRF-RZDMPUFOSA-N
DM6LTRC	IU	(4R)-3-[(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-N-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide
DM6LTRC	CA	CAS 186538-00-1
DM6LTRC	DE	Human immunodeficiency virus infection

DMICLMR	ID	DMICLMR
DMICLMR	DN	KP106
DMICLMR	HS	Discontinued in Phase 1
DMICLMR	CP	KemPharm
DMICLMR	DE	Attention deficit hyperactivity disorder

DMMD6LR	ID	DMMD6LR
DMMD6LR	DN	KR-30450
DMMD6LR	HS	Discontinued in Phase 1
DMMD6LR	SN	SKP-450; 1-[2(R)-(1,3-Dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]pyrrolidin-2-one
DMMD6LR	PC	9906213
DMMD6LR	MW	346.3
DMMD6LR	FM	C17H18N2O6
DMMD6LR	IC	InChI=1S/C17H18N2O6/c1-17(16-23-7-8-24-16)10-13(18-6-2-3-15(18)20)12-9-11(19(21)22)4-5-14(12)25-17/h4-5,9-10,16H,2-3,6-8H2,1H3/t17-/m1/s1
DMMD6LR	CS	C[C@@]1(C=C(C2=C(O1)C=CC(=C2)[N+](=O)[O-])N3CCCC3=O)C4OCCO4
DMMD6LR	IK	NJJPKIPOZSWUHV-QGZVFWFLSA-N
DMMD6LR	IU	1-[(2R)-2-(1,3-dioxolan-2-yl)-2-methyl-6-nitrochromen-4-yl]pyrrolidin-2-one
DMMD6LR	CA	CAS 172489-10-0
DMMD6LR	DE	Hypertension

DMBH5G3	ID	DMBH5G3
DMBH5G3	DN	KT2-962
DMBH5G3	HS	Discontinued in Phase 1
DMBH5G3	SN	3-[4-(4-Chlorophenylsulfonamido)butyl]-6-isopropylazulene-1-sulfonic acid sodium salt
DMBH5G3	DT	Small molecular drug
DMBH5G3	PC	23661969
DMBH5G3	MW	518
DMBH5G3	FM	C23H25ClNNaO5S2
DMBH5G3	IC	InChI=1S/C23H26ClNO5S2.Na/c1-16(2)17-6-12-21-18(15-23(32(28,29)30)22(21)13-7-17)5-3-4-14-25-31(26,27)20-10-8-19(24)9-11-20;/h6-13,15-16,25H,3-5,14H2,1-2H3,(H,28,29,30);/q;+1/p-1
DMBH5G3	CS	CC(C)C1=CC=C2C(=C(C=C2S(=O)(=O)[O-])CCCCNS(=O)(=O)C3=CC=C(C=C3)Cl)C=C1.[Na+]
DMBH5G3	IK	QIBQVFYOTMPEIP-UHFFFAOYSA-M
DMBH5G3	IU	sodium;3-[4-[(4-chlorophenyl)sulfonylamino]butyl]-6-propan-2-ylazulene-1-sulfonate
DMBH5G3	CA	CAS 129648-96-0
DMBH5G3	DE	Thrombosis

DM74BK8	ID	DM74BK8
DM74BK8	DN	KT-362
DM74BK8	HS	Discontinued in Phase 1
DM74BK8	SN	3-[2-(3,4-dimethoxyphenyl)ethylamino]-1-(2-thia-6-azabicyclo[5.4.0]undeca-7,9,11-trien-6-yl)propan-1-one; ACMC-20m87t
DM74BK8	CP	Kotobuki Pharmaceutical Co Ltd
DM74BK8	DT	Small molecular drug
DM74BK8	PC	6438134
DM74BK8	MW	516.6
DM74BK8	FM	C26H32N2O7S
DM74BK8	IC	InChI=1S/C22H28N2O3S.C4H4O4/c1-26-19-9-8-17(16-20(19)27-2)10-12-23-13-11-22(25)24-14-5-15-28-21-7-4-3-6-18(21)24;5-3(6)1-2-4(7)8/h3-4,6-9,16,23H,5,10-15H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DM74BK8	CS	COC1=C(C=C(C=C1)CCNCCC(=O)N2CCCSC3=CC=CC=C32)OC.C(=C/C(=O)O)\\C(=O)O
DM74BK8	IK	YIVXAQUBENUHJC-WLHGVMLRSA-N
DM74BK8	IU	(E)-but-2-enedioic acid;1-(3,4-dihydro-2H-1,5-benzothiazepin-5-yl)-3-[2-(3,4-dimethoxyphenyl)ethylamino]propan-1-one
DM74BK8	CA	CAS 105394-80-7
DM74BK8	DE	Heart arrhythmia

DMG068H	ID	DMG068H
DMG068H	DN	KW-3635
DMG068H	HS	Discontinued in Phase 1
DMG068H	SN	KW-3635; GTPL1977; KW3635
DMG068H	CP	Kyowa Hakko Kogyo Co Ltd
DMG068H	DT	Small molecular drug
DMG068H	PC	23673318
DMG068H	MW	432.4
DMG068H	FM	C26H21N2NaO3
DMG068H	IC	InChI=1S/C26H22N2O3.Na/c1-16-11-23-24(12-17(16)2)28(15-27-23)10-9-21-20-6-4-3-5-19(20)14-31-25-8-7-18(26(29)30)13-22(21)25;/h3-9,11-13,15H,10,14H2,1-2H3,(H,29,30);/q;+1/p-1/b21-9+;
DMG068H	CS	CC1=CC2=C(C=C1C)N(C=N2)C/C=C/3\\C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)[O-].[Na+]
DMG068H	IK	KWELWDMCBFWKQN-CSFJJMQLSA-M
DMG068H	IU	sodium;(11E)-11-[2-(5,6-dimethylbenzimidazol-1-yl)ethylidene]-6H-benzo[c][1]benzoxepine-2-carboxylate
DMG068H	CA	CAS 127166-41-0
DMG068H	DE	Thrombosis

DM76O23	ID	DM76O23
DM76O23	DN	KW-6055
DM76O23	HS	Discontinued in Phase 1
DM76O23	SN	N-[3-Nitro-4-(2-pyridinylmethyl)phenyl]butanamide; 2-[4-(Butyrylamino)-2-nitrobenzyl]pyridine
DM76O23	DT	Small molecular drug
DM76O23	PC	3047323
DM76O23	MW	299.32
DM76O23	FM	C16H17N3O3
DM76O23	IC	InChI=1S/C16H17N3O3/c1-2-5-16(20)18-14-8-7-12(15(11-14)19(21)22)10-13-6-3-4-9-17-13/h3-4,6-9,11H,2,5,10H2,1H3,(H,18,20)
DM76O23	CS	CCCC(=O)NC1=CC(=C(C=C1)CC2=CC=CC=N2)[N+](=O)[O-]
DM76O23	IK	CZKQVCYQBJJAGG-UHFFFAOYSA-N
DM76O23	IU	N-[3-nitro-4-(pyridin-2-ylmethyl)phenyl]butanamide
DM76O23	CA	CAS 63233-46-5
DM76O23	DE	Inflammation

DM5LRKC	ID	DM5LRKC
DM5LRKC	DN	L-368899
DM5LRKC	HS	Discontinued in Phase 1
DM5LRKC	SN	UNII-ER33G946JT; L-368899; ER33G946JT; CHEMBL1253853; L 368,899; L 368899; 148927-60-0; (S)-2-amino-N-((1S,2S,4R)-7,7-dimethyl-1-((4-o-tolylpiperazin-1-ylsulfonyl)methyl)bicyclo[2.2.1]heptan-2-yl)-4-(methylsulfonyl)butanamide; GTPL2249; SCHEMBL17423276; ZINC3923061; BDBM50326719; NCGC00485193-01; 1-(((7,7-Dimethyl-2-(2-amino-4-(methylsulfonyl)butyramido)bicyclo(2.2.1)heptan-1-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine; Butanamide, 2-amino-N-(7,7-dimethyl-1-(((4-(2-methylphenyl)-1-piperazinyl)sulfonyl)methyl)bicyclo
DM5LRKC	CP	Merck & Co Inc
DM5LRKC	DT	Small molecular drug
DM5LRKC	PC	9872389
DM5LRKC	MW	554.8
DM5LRKC	FM	C26H42N4O5S2
DM5LRKC	IC	InChI=1S/C26H42N4O5S2/c1-19-7-5-6-8-22(19)29-12-14-30(15-13-29)37(34,35)18-26-11-9-20(25(26,2)3)17-23(26)28-24(31)21(27)10-16-36(4,32)33/h5-8,20-21,23H,9-18,27H2,1-4H3,(H,28,31)/t20-,21+,23+,26-/m1/s1
DM5LRKC	CS	CC1=CC=CC=C1N2CCN(CC2)S(=O)(=O)C[C@@]34CC[C@@H](C3(C)C)C[C@@H]4NC(=O)[C@H](CCS(=O)(=O)C)N
DM5LRKC	IK	MWIASLNTAGRGGA-ZJPWWDJASA-N
DM5LRKC	IU	(2S)-2-amino-N-[(1S,2S,4R)-7,7-dimethyl-1-[[4-(2-methylphenyl)piperazin-1-yl]sulfonylmethyl]-2-bicyclo[2.2.1]heptanyl]-4-methylsulfonylbutanamide
DM5LRKC	CA	CAS 148927-60-0
DM5LRKC	DE	Miscarriage

DMLHE5A	ID	DMLHE5A
DMLHE5A	DN	L-692429
DMLHE5A	HS	Discontinued in Phase 1
DMLHE5A	SN	3-Amino-3-methyl-N-[2-oxo-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2,3,4,5-tetrahydro-1H-1-benzazepin-3(R)-yl]butyramide
DMLHE5A	DT	Small molecular drug
DMLHE5A	PC	121879
DMLHE5A	MW	509.6
DMLHE5A	FM	C29H31N7O2
DMLHE5A	IC	InChI=1S/C29H31N7O2/c1-29(2,30)17-26(37)31-24-16-15-21-7-3-6-10-25(21)36(28(24)38)18-19-11-13-20(14-12-19)22-8-4-5-9-23(22)27-32-34-35-33-27/h3-14,24H,15-18,30H2,1-2H3,(H,31,37)(H,32,33,34,35)/t24-/m1/s1
DMLHE5A	CS	CC(C)(CC(=O)N[C@@H]1CCC2=CC=CC=C2N(C1=O)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)N
DMLHE5A	IK	SBJLJOFPWOYATP-XMMPIXPASA-N
DMLHE5A	IU	3-amino-3-methyl-N-[(3R)-2-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4,5-dihydro-3H-1-benzazepin-3-yl]butanamide
DMLHE5A	CA	CAS 145455-23-8
DMLHE5A	DE	Growth hormone deficiency

DMBIR5P	ID	DMBIR5P
DMBIR5P	DN	L-697639
DMBIR5P	HS	Discontinued in Phase 1
DMBIR5P	SN	HND0YP0TJG; 135525-77-8; UNII-HND0YP0TJG; L 697639; L-697,639; L-697639; 3-[(4,7-dimethyl-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one; 2(1H)-Pyridinone,3-[[(4,7-dimethyl-2-benzoxazolyl) methyl]amino]-5-ethyl-6-methyl-; DRG-0101; ACMC-20mvsl; 3benzoxazolMeNH deriv.; AC1L1U0H; CHEMBL37803; SCHEMBL6367001; BDBM1314; AC1Q69B1; CTK4B9862; DTXSID50159456; VDZJXIOFISBBLT-UHFFFAOYSA-N; 3-(((4,7-Dimethyl-1,3-benzoxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one
DMBIR5P	CP	Merck & Co Inc
DMBIR5P	DT	Small molecular drug
DMBIR5P	PC	60832
DMBIR5P	MW	311.4
DMBIR5P	FM	C18H21N3O2
DMBIR5P	IC	InChI=1S/C18H21N3O2/c1-5-13-8-14(18(22)20-12(13)4)19-9-15-21-16-10(2)6-7-11(3)17(16)23-15/h6-8,19H,5,9H2,1-4H3,(H,20,22)
DMBIR5P	CS	CCC1=C(NC(=O)C(=C1)NCC2=NC3=C(C=CC(=C3O2)C)C)C
DMBIR5P	IK	VDZJXIOFISBBLT-UHFFFAOYSA-N
DMBIR5P	IU	3-[(4,7-dimethyl-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one
DMBIR5P	CA	CAS 135525-77-8
DMBIR5P	DE	Human immunodeficiency virus infection

DMSB0J8	ID	DMSB0J8
DMSB0J8	DN	L-734217
DMSB0J8	HS	Discontinued in Phase 1
DMSB0J8	SN	L-734217; UNII-3JRV8H947H; CHEMBL48371; 3JRV8H947H; 146144-48-1; AC1L42ZO; L 734217; SCHEMBL6886518; L-734,217; CTK4C4832; Butanoic acid,3-[[2-[(3R)-2-oxo-3-[2-(4-piperidinyl)ethyl]-1-piperidinyl]acetyl]amino]-,(3R)-; BDBM50033030; AKOS030571127; 3-{2-[2-Oxo-3-(2-piperidin-4-yl-ethyl)-piperidin-1-yl]-acetylamino}-butyric acid (L-734217); (R)-3-{2-[(R)-2-Oxo-3-(2-piperidin-4-yl-ethyl)-piperidin-1-yl]-acetylamino}-butyric acid; (3R)-3-[[2-[(3R)-2-oxo-3-(2-piperidin-4-ylethyl)piperidin-1-yl]acetyl]amino]butanoic acid
DMSB0J8	DT	Small molecular drug
DMSB0J8	PC	177831
DMSB0J8	MW	353.5
DMSB0J8	FM	C18H31N3O4
DMSB0J8	IC	InChI=1S/C18H31N3O4/c1-13(11-17(23)24)20-16(22)12-21-10-2-3-15(18(21)25)5-4-14-6-8-19-9-7-14/h13-15,19H,2-12H2,1H3,(H,20,22)(H,23,24)/t13-,15+/m1/s1
DMSB0J8	CS	C[C@H](CC(=O)O)NC(=O)CN1CCC[C@H](C1=O)CCC2CCNCC2
DMSB0J8	IK	SFFMYDBKYYBJRY-HIFRSBDPSA-N
DMSB0J8	IU	(3R)-3-[[2-[(3R)-2-oxo-3-(2-piperidin-4-ylethyl)piperidin-1-yl]acetyl]amino]butanoic acid
DMSB0J8	CA	CAS 146144-48-1
DMSB0J8	DE	Thrombosis

DMHEKIN	ID	DMHEKIN
DMHEKIN	DN	LASINAVIR
DMHEKIN	HS	Discontinued in Phase 1
DMHEKIN	SN	BMS-234475; CGP-61755; Lasinavir; N-[5(S)-(tert-Butoxycarbonylamino)-4(S)-hydroxy-6-phenyl-2(R)-(2,3,4-trimethoxybenzyl)hexanoyl]-L-valine 2-methoxyethylamide
DMHEKIN	DT	Small molecular drug
DMHEKIN	PC	464372
DMHEKIN	MW	659.8
DMHEKIN	FM	C35H53N3O9
DMHEKIN	IC	InChI=1S/C35H53N3O9/c1-22(2)29(33(41)36-17-18-43-6)38-32(40)25(20-24-15-16-28(44-7)31(46-9)30(24)45-8)21-27(39)26(19-23-13-11-10-12-14-23)37-34(42)47-35(3,4)5/h10-16,22,25-27,29,39H,17-21H2,1-9H3,(H,36,41)(H,37,42)(H,38,40)/t25-,26+,27+,29+/m1/s1
DMHEKIN	CS	CC(C)[C@@H](C(=O)NCCOC)NC(=O)[C@H](CC1=C(C(=C(C=C1)OC)OC)OC)C[C@@H]([C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C)O
DMHEKIN	IK	BEUUJDAEPJZWHM-COROXYKFSA-N
DMHEKIN	IU	tert-butyl N-[(2S,3S,5R)-3-hydroxy-6-[[(2S)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate
DMHEKIN	CA	CAS 175385-62-3
DMHEKIN	DE	Human immunodeficiency virus infection

DMSRD5U	ID	DMSRD5U
DMSRD5U	DN	LBY-135
DMSRD5U	HS	Discontinued in Phase 1
DMSRD5U	SN	LCR-211; Anti-DR5 agonist chimerics mAb (cancer), Novartis; Anti-death receptor5 agonist chimeric monoclonal antibody (cancer), Novartis
DMSRD5U	CP	Novartis AG
DMSRD5U	DT	Antibody
DMSRD5U	DE	Solid tumour/cancer

DM41RK2	ID	DM41RK2
DM41RK2	DN	LG100268
DM41RK2	HS	Discontinued in Phase 1
DM41RK2	SN	AmbkkkkK580; LG 100268; LG2; LG-100268; 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)nicotinic acid; 6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)CYCLOPROPYL]PYRIDINE-3-CARBOXYLIC ACID; 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-nicotinic acid; 6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
DM41RK2	CP	Ligand Pharmaceuticals
DM41RK2	DT	Small molecular drug
DM41RK2	PC	3922
DM41RK2	MW	363.5
DM41RK2	FM	C24H29NO2
DM41RK2	IC	InChI=1S/C24H29NO2/c1-15-12-18-19(23(4,5)9-8-22(18,2)3)13-17(15)24(10-11-24)20-7-6-16(14-25-20)21(26)27/h6-7,12-14H,8-11H2,1-5H3,(H,26,27)
DM41RK2	CS	CC1=CC2=C(C=C1C3(CC3)C4=NC=C(C=C4)C(=O)O)C(CCC2(C)C)(C)C
DM41RK2	IK	SLXTWXQUEZSSTJ-UHFFFAOYSA-N
DM41RK2	IU	6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
DM41RK2	CA	CAS 153559-76-3
DM41RK2	DE	Acquired immune deficiency syndrome

DM0PXGU	ID	DM0PXGU
DM0PXGU	DN	LG-101280
DM0PXGU	HS	Discontinued in Phase 1
DM0PXGU	SN	LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly
DM0PXGU	CP	Ligand Pharmaceuticals Inc
DM0PXGU	DE	Arteriosclerosis

DM9LEGU	ID	DM9LEGU
DM9LEGU	DN	LGD2941
DM9LEGU	HS	Discontinued in Phase 1
DM9LEGU	SN	LGD2941; CHEMBL467888; SCHEMBL3015188; BDBM18522; DB05234; 6-(1-Pyrrolidine)quinolin-2(1H)-one, 6a
DM9LEGU	CP	Ligand Pharmaceuticals
DM9LEGU	DT	Small molecular drug
DM9LEGU	PC	16750192
DM9LEGU	MW	394.31
DM9LEGU	FM	C17H16F6N2O2
DM9LEGU	IC	InChI=1S/C17H16F6N2O2/c1-8-2-5-13(15(27)17(21,22)23)25(8)9-3-4-12-10(6-9)11(16(18,19)20)7-14(26)24-12/h3-4,6-8,13,15,27H,2,5H2,1H3,(H,24,26)/t8-,13-,15-/m1/s1
DM9LEGU	CS	C[C@@H]1CC[C@@H](N1C2=CC3=C(C=C2)NC(=O)C=C3C(F)(F)F)[C@H](C(F)(F)F)O
DM9LEGU	IK	HWLLYFXDDGGHOE-BCSUUIJWSA-N
DM9LEGU	IU	6-[(2R,5R)-2-methyl-5-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-4-(trifluoromethyl)-1H-quinolin-2-one
DM9LEGU	DE	Osteoporosis

DM7HLFD	ID	DM7HLFD
DM7HLFD	DN	Licofelone
DM7HLFD	HS	Discontinued in Phase 1
DM7HLFD	SN	LCF; Licofelone [INN]; ML 3000; ML-3000; [6-(4-CHLOROPHENYL)-2,2-DIMETHYL-7-PHENYL-2,3-DIHYDRO-1H-PYRROLIZIN-5-YL]ACETIC ACID; (2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl)acetic acid; (6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid; 2,2-Dimethyl-6-(4-chlorophenyl-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl)acetic acid; 2,3-Dihydro-6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid; 2-[2-(4-chlorophenyl)-6,6-dimethyl-1-phenyl-5,7-dihydropyrrolizin-3-yl]acetic acid; 6-(4-Chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid
DM7HLFD	CP	Merckle GmbH
DM7HLFD	DT	Small molecular drug
DM7HLFD	PC	133021
DM7HLFD	MW	379.9
DM7HLFD	FM	C23H22ClNO2
DM7HLFD	IC	InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)
DM7HLFD	CS	CC1(CC2=C(C(=C(N2C1)CC(=O)O)C3=CC=C(C=C3)Cl)C4=CC=CC=C4)C
DM7HLFD	IK	UAWXGRJVZSAUSZ-UHFFFAOYSA-N
DM7HLFD	IU	2-[2-(4-chlorophenyl)-6,6-dimethyl-1-phenyl-5,7-dihydropyrrolizin-3-yl]acetic acid
DM7HLFD	CA	CAS 156897-06-2
DM7HLFD	DE	Osteoarthritis

DMMWCU3	ID	DMMWCU3
DMMWCU3	DN	Licostinel
DMMWCU3	HS	Discontinued in Phase 1
DMMWCU3	SN	Licostinel; 153504-81-5; ACEA 1021; ACEA-1021; UNII-3Z3037LJTC; 6,7-Dichloro-5-nitro-2,3-quinoxalinedione; 5-Nitro-6,7-dichloro-2,3-quinoxalinedione; 5-Nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione; 6,7-Dichloro-1,4-dihydro-5-nitro-2,3-quinoxalinedione; CHEMBL289832; 3Z3037LJTC; 6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione; 6,7-DICHLORO-5-NITROQUINOXALINE-2,3(1H,4H)-DIONE; 2,3-Quinoxalinedione, 6,7-dichloro-1,4-dihydro-5-nitro-; Licostinel [USAN]; Licostinel [USAN:INN]; C8H3Cl2N3O4; AC1NUOFE; Licostinel (USAN/
DMMWCU3	DT	Small molecular drug
DMMWCU3	PC	5486198
DMMWCU3	MW	276.03
DMMWCU3	FM	C8H3Cl2N3O4
DMMWCU3	IC	InChI=1S/C8H3Cl2N3O4/c9-2-1-3-5(6(4(2)10)13(16)17)12-8(15)7(14)11-3/h1H,(H,11,14)(H,12,15)
DMMWCU3	CS	C1=C2C(=C(C(=C1Cl)Cl)[N+](=O)[O-])NC(=O)C(=O)N2
DMMWCU3	IK	CHFSOFHQIZKQCR-UHFFFAOYSA-N
DMMWCU3	IU	6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione
DMMWCU3	CA	CAS 153504-81-5
DMMWCU3	DE	Neurological disorder

DM9WEP5	ID	DM9WEP5
DM9WEP5	DN	LJP-1082
DM9WEP5	HS	Discontinued in Phase 1
DM9WEP5	SN	Quinacrine azide; 3-Azido-9-((4-(diethylamino)-1-methylbutyl)amino)-7-methoxyacridine; AC1MI36Z; 73332-88-4; 1,4-Pentanediamine, N4-(6-azido-2-methoxy-9-acridinyl)-N1,N1-diethyl-
DM9WEP5	CP	La Jolla Pharmaceutical
DM9WEP5	DT	Small molecular drug
DM9WEP5	PC	3037609
DM9WEP5	MW	406.5
DM9WEP5	FM	C23H30N6O
DM9WEP5	IC	InChI=1S/C23H30N6O/c1-5-29(6-2)13-7-8-16(3)25-23-19-11-9-17(27-28-24)14-22(19)26-21-12-10-18(30-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)
DM9WEP5	CS	CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)N=[N+]=[N-])OC
DM9WEP5	IK	OJZRYFDOXJOKNZ-UHFFFAOYSA-N
DM9WEP5	IU	4-N-(6-azido-2-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine
DM9WEP5	CA	CAS 73332-88-4
DM9WEP5	DE	Hughes syndrome

DMSL0Y5	ID	DMSL0Y5
DMSL0Y5	DN	LOR-2501
DMSL0Y5	HS	Discontinued in Phase 1
DMSL0Y5	SN	GTI-2501; R1 ribonucleotide reductase mRNA antisense oligo, Lorus; Antisense oligonucleotide (cancer), Lorus; U-sense technology, Lorus
DMSL0Y5	CP	Lorus Therapeutics Inc
DMSL0Y5	DT	Antisense drug
DMSL0Y5	DE	Solid tumour/cancer

DMGUX5Y	ID	DMGUX5Y
DMGUX5Y	DN	Lu-AA38466
DMGUX5Y	HS	Discontinued in Phase 1
DMGUX5Y	SN	Ion channel modulator (neurological disease), H Lundbeck
DMGUX5Y	CP	H Lundbeck A/S
DMGUX5Y	DE	Neurological disorder

DMH0AMG	ID	DMH0AMG
DMH0AMG	DN	Lu-AA44608
DMH0AMG	HS	Discontinued in Phase 1
DMH0AMG	CP	H. Lundbeck A/S
DMH0AMG	DE	Mood disorder

DML86MJ	ID	DML86MJ
DML86MJ	DN	Lu-AA47070
DML86MJ	HS	Discontinued in Phase 1
DML86MJ	SN	Adenosine A2a antagonists (Parkinson's disease), Lundbeck
DML86MJ	CP	H. Lundbeck A/S
DML86MJ	DE	Parkinson disease

DMKMIQ6	ID	DMKMIQ6
DMKMIQ6	DN	LY-315902
DMKMIQ6	HS	Discontinued in Phase 1
DMKMIQ6	CP	Eli Lilly & Co
DMKMIQ6	DE	Type-2 diabetes

DMNPJL3	ID	DMNPJL3
DMNPJL3	DN	LY-444711
DMNPJL3	HS	Discontinued in Phase 1
DMNPJL3	SN	2(R)-(2-Amino-2-methylpropanamido)-N-[1-[1(R)-(4-methoxyphenyl)-1-methyl-2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]-5-phenylpentanamide dihydrochloride
DMNPJL3	PC	9872936
DMNPJL3	MW	574.7
DMNPJL3	FM	C32H42N6O4
DMNPJL3	IC	InChI=1S/C32H42N6O4/c1-31(2,33)29(40)35-26(14-10-13-23-11-6-5-7-12-23)28(39)36-27-21-38(22-34-27)32(3,30(41)37-19-8-9-20-37)24-15-17-25(42-4)18-16-24/h5-7,11-12,15-18,21-22,26H,8-10,13-14,19-20,33H2,1-4H3,(H,35,40)(H,36,39)/t26-,32-/m1/s1
DMNPJL3	CS	C[C@@](C1=CC=C(C=C1)OC)(C(=O)N2CCCC2)N3C=C(N=C3)NC(=O)[C@@H](CCCC4=CC=CC=C4)NC(=O)C(C)(C)N
DMNPJL3	IK	MJUQKUGRKDKGBY-HVIPQOSHSA-N
DMNPJL3	IU	(2R)-2-[(2-amino-2-methylpropanoyl)amino]-N-[1-[(2R)-2-(4-methoxyphenyl)-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]imidazol-4-yl]-5-phenylpentanamide
DMNPJL3	DE	Growth hormone deficiency

DMB1OAR	ID	DMB1OAR
DMB1OAR	DN	LY-73497
DMB1OAR	HS	Discontinued in Phase 1
DMB1OAR	SN	LY73497; Thiourea, N-(2-phenylethyl)-N'-2-thiazolyl-; LY 73497; 149485-30-3; LY-73497; CHEMBL33981; AC1MHDK1; MLS001243522; SCHEMBL1520344; BDBM1894; DTXSID90164286; HMS3338J14; HMS2211G04; 1-Phenethyl-3-thiazol-2-yl-thiourea; AKOS030011215; NCGC00247398-01; SMR000841574; Phenylethylthiazolylthiourea (PETT) Analog; N-(2-phenethyl)-N -(2-thiazolyl)thiourea; 1-phenethyl-3-(1,3-thiazol-2-yl)thiourea
DMB1OAR	DT	Small molecular drug
DMB1OAR	PC	3001082
DMB1OAR	MW	263.4
DMB1OAR	FM	C12H13N3S2
DMB1OAR	IC	InChI=1S/C12H13N3S2/c16-11(15-12-14-8-9-17-12)13-7-6-10-4-2-1-3-5-10/h1-5,8-9H,6-7H2,(H2,13,14,15,16)
DMB1OAR	CS	C1=CC=C(C=C1)CCNC(=S)NC2=NC=CS2
DMB1OAR	IK	ANUSGJXVCFPWMQ-UHFFFAOYSA-N
DMB1OAR	IU	1-(2-phenylethyl)-3-(1,3-thiazol-2-yl)thiourea
DMB1OAR	CA	CAS 149485-30-3

DMVYG5X	ID	DMVYG5X
DMVYG5X	DN	LY-929
DMVYG5X	HS	Discontinued in Phase 1
DMVYG5X	SN	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists
DMVYG5X	CP	Ligand Pharmaceuticals Inc
DMVYG5X	DT	Small molecular drug
DMVYG5X	PC	9890585
DMVYG5X	MW	463.5
DMVYG5X	FM	C26H25NO5S
DMVYG5X	IC	InChI=1S/C26H25NO5S/c1-18-22(27-24(31-18)23-9-6-16-33-23)14-15-30-20-12-10-19(11-13-20)17-26(2,25(28)29)32-21-7-4-3-5-8-21/h3-13,16H,14-15,17H2,1-2H3,(H,28,29)/t26-/m0/s1
DMVYG5X	CS	CC1=C(N=C(O1)C2=CC=CS2)CCOC3=CC=C(C=C3)C[C@@](C)(C(=O)O)OC4=CC=CC=C4
DMVYG5X	IK	KWSPYUOBNIMILB-SANMLTNESA-N
DMVYG5X	IU	(2S)-2-methyl-3-[4-[2-(5-methyl-2-thiophen-2-yl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-phenoxypropanoic acid
DMVYG5X	DE	Lipid metabolism disorder

DMDUM0Z	ID	DMDUM0Z
DMDUM0Z	DN	LymphoRad-131
DMDUM0Z	HS	Discontinued in Phase 1
DMDUM0Z	SN	Ardenermin; LymphoRad; LR-131; Radiolabeled BLyS protein, HGS; Radiolabeled ardenermine, HGS
DMDUM0Z	CP	Human Genome Sciences Inc
DMDUM0Z	DE	Lymphoma

DMP19KT	ID	DMP19KT
DMP19KT	DN	MBI 1121
DMP19KT	HS	Discontinued in Phase 1
DMP19KT	CP	Migenix
DMP19KT	TC	Antisense
DMP19KT	DT	Antisense drug
DMP19KT	DE	Solid tumour/cancer

DMRIK2Y	ID	DMRIK2Y
DMRIK2Y	DN	MC-02,479
DMRIK2Y	HS	Discontinued in Phase 1
DMRIK2Y	SN	RWJ-54428; (6R,7R)-7-[2-(2-Amino-5-chlorothiazol-4-yl)-2(Z)-(hydroxyimino)acetamido]-3-[3-(2-aminoethylsulfanylmethyl)pyridin-4-ylsulfanyl]-3-cephem-4-carboxylic acid methanesulfonate
DMRIK2Y	DE	Bacterial infection

DMUMSFR	ID	DMUMSFR
DMUMSFR	DN	ME-3277
DMUMSFR	HS	Discontinued in Phase 1
DMUMSFR	SN	4-[2-(4,5,6,7-Tetrahydrothieno[3,2-c]pyridin-2-ylcarboxamido)acetyl]phenylene-1,2-dioxybis(acetic acid)
DMUMSFR	PC	9955286
DMUMSFR	MW	448.4
DMUMSFR	FM	C20H20N2O8S
DMUMSFR	IC	InChI=1S/C20H20N2O8S/c23-13(8-22-20(28)17-6-12-7-21-4-3-16(12)31-17)11-1-2-14(29-9-18(24)25)15(5-11)30-10-19(26)27/h1-2,5-6,21H,3-4,7-10H2,(H,22,28)(H,24,25)(H,26,27)
DMUMSFR	CS	C1CNCC2=C1SC(=C2)C(=O)NCC(=O)C3=CC(=C(C=C3)OCC(=O)O)OCC(=O)O
DMUMSFR	IK	NCPUFPHVKAPNOO-UHFFFAOYSA-N
DMUMSFR	IU	2-[2-(carboxymethoxy)-4-[2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carbonylamino)acetyl]phenoxy]acetic acid
DMUMSFR	DE	Thrombosis

DMC2V5J	ID	DMC2V5J
DMC2V5J	DN	Mirisetron maleate
DMC2V5J	HS	Discontinued in Phase 1
DMC2V5J	SN	SEC-579; WAY-100579; WAY-SEC-579
DMC2V5J	CP	Wyeth
DMC2V5J	DT	Small molecular drug
DMC2V5J	PC	6435818
DMC2V5J	MW	509.6
DMC2V5J	FM	C28H35N3O6
DMC2V5J	IC	InChI=1S/C24H31N3O2.C4H4O4/c1-26-18-11-12-19(26)14-16(13-18)25-24(29)21-15-27(17-7-3-2-4-8-17)22-10-6-5-9-20(22)23(21)28;5-3(6)1-2-4(7)8/h5-6,9-10,15-19H,2-4,7-8,11-14H2,1H3,(H,25,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t16?,18-,19+;
DMC2V5J	CS	CN1[C@@H]2CC[C@H]1CC(C2)NC(=O)C3=CN(C4=CC=CC=C4C3=O)C5CCCCC5.C(=C\\C(=O)O)\\C(=O)O
DMC2V5J	IK	OQIHDZMOAKTHKW-WPJOOPQGSA-N
DMC2V5J	IU	(Z)-but-2-enedioic acid;1-cyclohexyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-4-oxoquinoline-3-carboxamide
DMC2V5J	CA	CAS 148611-75-0
DMC2V5J	DE	Anxiety disorder

DM23KBM	ID	DM23KBM
DM23KBM	DN	MIV-701
DM23KBM	HS	Discontinued in Phase 1
DM23KBM	CP	Medivir
DM23KBM	DE	Osteoporosis

DMNAJGK	ID	DMNAJGK
DMNAJGK	DN	MK-0963
DMNAJGK	HS	Discontinued in Phase 1
DMNAJGK	SN	L-654066; MK-963; (5alpha)-23-Methyl-4-aza-21-norchol-1-ene-3,20-dione; 23-Methyl-21-nor-4-aza-5alpha-chol-1-ene-3,20-dione
DMNAJGK	DT	Small molecular drug
DMNAJGK	PC	6918127
DMNAJGK	MW	357.5
DMNAJGK	FM	C23H35NO2
DMNAJGK	IC	InChI=1S/C23H35NO2/c1-14(2)13-19(25)18-7-6-16-15-5-8-20-23(4,12-10-21(26)24-20)17(15)9-11-22(16,18)3/h10,12,14-18,20H,5-9,11,13H2,1-4H3,(H,24,26)/t15-,16-,17-,18+,20+,22-,23+/m0/s1
DMNAJGK	CS	CC(C)CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C=CC(=O)N4)C)C
DMNAJGK	IK	RDPJISLOFXUIDK-RLAPWRJVSA-N
DMNAJGK	IU	(1S,3aS,3bS,5aR,9aR,9bS,11aS)-9a,11a-dimethyl-1-(3-methylbutanoyl)-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinolin-7-one
DMNAJGK	CA	CAS 103497-68-3
DMNAJGK	DE	Prostate disease

DMERKWM	ID	DMERKWM
DMERKWM	DN	MK-434
DMERKWM	HS	Discontinued in Phase 1
DMERKWM	SN	17beta-Benzoyl-4-aza-5alpha-androst-1-en-3-one
DMERKWM	DT	Small molecular drug
DMERKWM	PC	131705
DMERKWM	MW	377.5
DMERKWM	FM	C25H31NO2
DMERKWM	IC	InChI=1S/C25H31NO2/c1-24-14-12-19-17(8-11-21-25(19,2)15-13-22(27)26-21)18(24)9-10-20(24)23(28)16-6-4-3-5-7-16/h3-7,13,15,17-21H,8-12,14H2,1-2H3,(H,26,27)/t17-,18-,19-,20+,21+,24-,25+/m0/s1
DMERKWM	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)C4=CC=CC=C4)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
DMERKWM	IK	ZYTQEOWFSVTRLX-QKONGSNMSA-N
DMERKWM	IU	(1S,3aS,3bS,5aR,9aR,9bS,11aS)-1-benzoyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinolin-7-one
DMERKWM	CA	CAS 134067-56-4
DMERKWM	DE	Prostate disease

DMB5NOI	ID	DMB5NOI
DMB5NOI	DN	MK-6592
DMB5NOI	HS	Discontinued in Phase 1
DMB5NOI	SN	VX-667
DMB5NOI	CP	Vertex Pharmaceuticals Inc
DMB5NOI	PC	16731225
DMB5NOI	MW	530
DMB5NOI	FM	C25H26ClF2N7O2
DMB5NOI	IC	InChI=1S/C25H26ClF2N7O2/c1-14-8-21(33-32-14)29-20-10-22(35-12-25(28,13-35)15-2-3-15)31-24(30-20)37-17-6-7-34(11-17)23(36)18-9-16(26)4-5-19(18)27/h4-5,8-10,15,17H,2-3,6-7,11-13H2,1H3,(H2,29,30,31,32,33)/t17-/m0/s1
DMB5NOI	CS	CC1=CC(=NN1)NC2=CC(=NC(=N2)O[C@H]3CCN(C3)C(=O)C4=C(C=CC(=C4)Cl)F)N5CC(C5)(C6CC6)F
DMB5NOI	IK	SLUHYAXFRJQTGB-KRWDZBQOSA-N
DMB5NOI	IU	(5-chloro-2-fluorophenyl)-[(3S)-3-[4-(3-cyclopropyl-3-fluoroazetidin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]oxypyrrolidin-1-yl]methanone
DMB5NOI	DE	Solid tumour/cancer

DMG72VK	ID	DMG72VK
DMG72VK	DN	MLN0415
DMG72VK	HS	Discontinued in Phase 1
DMG72VK	SN	SCHEMBL3805703
DMG72VK	CP	Takeda
DMG72VK	DT	Small molecular drug
DMG72VK	PC	86630595
DMG72VK	MW	610.1
DMG72VK	FM	C27H36ClN5O7S
DMG72VK	IC	InChI=1S/C26H32ClN5O4.CH4O3S/c1-15-10-31(11-16(2)36-15)23(33)12-32-14-26(3,4)35-13-22(32)25(34)30-20-8-17(27)7-19-18-5-6-28-9-21(18)29-24(19)20;1-5(2,3)4/h5-9,15-16,22,29H,10-14H2,1-4H3,(H,30,34);1H3,(H,2,3,4)/t15-,16+,22-;/m0./s1
DMG72VK	CS	C[C@@H]1CN(C[C@@H](O1)C)C(=O)CN2CC(OC[C@H]2C(=O)NC3=CC(=CC4=C3NC5=C4C=CN=C5)Cl)(C)C.CS(=O)(=O)O
DMG72VK	IK	VCONVNPAMVXEOA-ZOPSOCCDSA-N
DMG72VK	IU	(3S)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-oxoethyl]-6,6-dimethylmorpholine-3-carboxamide;methanesulfonic acid
DMG72VK	DE	Arthritis

DMQA5JW	ID	DMQA5JW
DMQA5JW	DN	MLN-2201
DMQA5JW	HS	Discontinued in Phase 1
DMQA5JW	SN	LDP-01; MLN-01; Anti-beta2-integrin MAb, LeukoSite
DMQA5JW	CP	LeukoSite Inc
DMQA5JW	DT	Antibody
DMQA5JW	DE	Cerebrovascular ischaemia

DM2PUYI	ID	DM2PUYI
DM2PUYI	DN	MN-246
DM2PUYI	HS	Discontinued in Phase 1
DM2PUYI	SN	Incontinence therapy, MediciNova; TT-138; Beta 3 adrenoceptor agonist (incontinence), MediciNova
DM2PUYI	CP	Mitsubishi Pharma Corp
DM2PUYI	DE	Urinary incontinence

DMKHEQL	ID	DMKHEQL
DMKHEQL	DN	Mofarotene
DMKHEQL	HS	Discontinued in Phase 1
DMKHEQL	SN	Ro-40-8757
DMKHEQL	CP	Roche Holding AG
DMKHEQL	DT	Small molecular drug
DMKHEQL	PC	5467732
DMKHEQL	MW	433.6
DMKHEQL	FM	C29H39NO2
DMKHEQL	IC	InChI=1S/C29H39NO2/c1-22(24-8-11-26-27(21-24)29(4,5)13-12-28(26,2)3)20-23-6-9-25(10-7-23)32-19-16-30-14-17-31-18-15-30/h6-11,20-21H,12-19H2,1-5H3/b22-20+
DMKHEQL	CS	C/C(=C\\C1=CC=C(C=C1)OCCN2CCOCC2)/C3=CC4=C(C=C3)C(CCC4(C)C)(C)C
DMKHEQL	IK	OUQPTBCOEKUHBH-LSDHQDQOSA-N
DMKHEQL	IU	4-[2-[4-[(E)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine
DMKHEQL	CA	CAS 125533-88-2
DMKHEQL	DE	Solid tumour/cancer

DMK91WR	ID	DMK91WR
DMK91WR	DN	MP-136
DMK91WR	HS	Discontinued in Phase 1
DMK91WR	CP	Mitsubishi Tanabe Pharma
DMK91WR	DE	Lipid metabolism disorder

DMMVG34	ID	DMMVG34
DMMVG34	DN	MPC-0920
DMMVG34	HS	Discontinued in Phase 1
DMMVG34	CP	Myriad Genetics
DMMVG34	DE	Thrombosis

DMCMNKV	ID	DMCMNKV
DMCMNKV	DN	MPC-9055
DMCMNKV	HS	Discontinued in Phase 1
DMCMNKV	SN	Vivecon
DMCMNKV	CP	Myriad Genetics
DMCMNKV	DE	Human immunodeficiency virus infection

DMCJ1B2	ID	DMCJ1B2
DMCJ1B2	DN	MT-500
DMCJ1B2	HS	Discontinued in Phase 1
DMCJ1B2	SN	199864-87-4; RS-127445; 4-(4-fluoronaphthalen-1-yl)-6-isopropylpyrimidin-2-amine; RS 127445; UNII-0JAU3P8OBM; MT 500; 0JAU3P8OBM; CHEMBL473186; C17H16FN3; RS-127445 HCl; 2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine; RS127445; 2-Pyrimidinamine, 4-(4-fluoro-1-naphthalenyl)-6-(1-methylethyl)-; RS-127,445; 4-(4-fluoronaphthalen-1-yl)-6-propan-2-ylpyrimidin-2-amine; AC1L52MZ; GTPL188; RS 127445 hydrochloride/; SCHEMBL375979; MolPort-021-804-999; ZZZQXCUPAJFVBN-UHFFFAOYSA-N; HMS3651H11; BCPP000085; BCP02714; ZINC3961115
DMCJ1B2	DT	Small molecular drug
DMCJ1B2	PC	196968
DMCJ1B2	MW	281.33
DMCJ1B2	FM	C17H16FN3
DMCJ1B2	IC	InChI=1S/C17H16FN3/c1-10(2)15-9-16(21-17(19)20-15)13-7-8-14(18)12-6-4-3-5-11(12)13/h3-10H,1-2H3,(H2,19,20,21)
DMCJ1B2	CS	CC(C)C1=NC(=NC(=C1)C2=CC=C(C3=CC=CC=C32)F)N
DMCJ1B2	IK	ZZZQXCUPAJFVBN-UHFFFAOYSA-N
DMCJ1B2	IU	4-(4-fluoronaphthalen-1-yl)-6-propan-2-ylpyrimidin-2-amine
DMCJ1B2	CA	CAS 199864-87-4
DMCJ1B2	DE	Migraine

DMC4RK7	ID	DMC4RK7
DMC4RK7	DN	MX-4509
DMC4RK7	HS	Discontinued in Phase 1
DMC4RK7	SN	17alpha-Estradiol; 57-91-0; Alfatradiol; Epiestradiol; 17-alpha-Estradiol; 3,17-Dihydroxyestratriene; 17a-estradiol; Estradiol-17alpha; Epiestrol; 17-Epiestradiol; Estra-1,3,5(10)-triene-3,17alpha-diol; 17alpha estradiol; NSC 20293; UNII-3VQ38D63M7; Alfatradiol [INN]; Oestradiol-17alpha; 17alpha-Oestradiol; Estradiol, 17alpha-; CHEBI:17160; VOXZDWNPVJITMN-SFFUCWETSA-N; 3VQ38D63M7; 17-epi-Estradiol; Alfatradiol (INN); Oestradiol-17-alpha; MITO-4509; Parkinsons therapeutics, MitoKor; Drug screening (Parkinsons), MitoKor; Estrogen analogs (Parkinsons), Mitokor
DMC4RK7	CP	MitoKor; Migenix
DMC4RK7	DT	Small molecular drug
DMC4RK7	PC	68570
DMC4RK7	MW	272.4
DMC4RK7	FM	C18H24O2
DMC4RK7	IC	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17-,18+/m1/s1
DMC4RK7	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@H]2O)CCC4=C3C=CC(=C4)O
DMC4RK7	IK	VOXZDWNPVJITMN-SFFUCWETSA-N
DMC4RK7	IU	(8R,9S,13S,14S,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMC4RK7	CA	CAS 57-91-0
DMC4RK7	CB	CHEBI:17160
DMC4RK7	DE	Neurological disorder

DM4MTPU	ID	DM4MTPU
DM4MTPU	DN	NBI-42902
DM4MTPU	HS	Discontinued in Phase 1
DM4MTPU	SN	352290-60-9; UNII-3FWQ4MD98O; 3FWQ4MD98O; CHEMBL179691; NBI42902; GTPL1187; GTPL1178; SCHEMBL5758034; ZINC6716969; BDBM50162007; NBI 42902; API0005260; 2,4(1H,3H)-Pyrimidinedione, 3-((2R)-2-amino-2-phenylethyl)-1-((2,6-difluorophenyl)methyl)-5-(2-fluoro-3-methoxyphenyl)-6-methyl-; KB-138000; FT-0771447; 3-[(2R)-2-amino-2-phenylethyl]-1-[(2,6-difluorophenyl)methyl]-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidine-2,4-dione
DM4MTPU	DT	Small molecular drug
DM4MTPU	PC	11167850
DM4MTPU	MW	495.5
DM4MTPU	FM	C27H24F3N3O3
DM4MTPU	IC	InChI=1S/C27H24F3N3O3/c1-16-24(18-10-6-13-23(36-2)25(18)30)26(34)33(15-22(31)17-8-4-3-5-9-17)27(35)32(16)14-19-20(28)11-7-12-21(19)29/h3-13,22H,14-15,31H2,1-2H3/t22-/m0/s1
DM4MTPU	CS	CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)F)C[C@@H](C3=CC=CC=C3)N)C4=C(C(=CC=C4)OC)F
DM4MTPU	IK	CJUWBZDJMYYRDG-QFIPXVFZSA-N
DM4MTPU	IU	3-[(2R)-2-amino-2-phenylethyl]-1-[(2,6-difluorophenyl)methyl]-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidine-2,4-dione
DM4MTPU	CA	CAS 352290-60-9
DM4MTPU	DE	Prostate cancer

DMMLESX	ID	DMMLESX
DMMLESX	DN	ND1251
DMMLESX	HS	Discontinued in Phase 1
DMMLESX	SN	JLFMYEAXZNPWBK-REWPJTCUSA-N; Ro64-6198; Ro-64-6198; CHEMBL2088034; Ro-646198; Ro 64-6198; GTPL1684; SCHEMBL2240259; ZINC3963671; BDBM50420802; Ro646198; (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[45]decan-4-one
DMMLESX	CP	Neuro3d
DMMLESX	DT	Small molecular drug
DMMLESX	PC	9844019
DMMLESX	MW	401.5
DMMLESX	FM	C26H31N3O
DMMLESX	IC	InChI=1S/C26H31N3O/c30-25-26(29(18-27-25)21-9-2-1-3-10-21)14-16-28(17-15-26)23-13-12-20-7-4-6-19-8-5-11-22(23)24(19)20/h1-3,5,8-11,20,23H,4,6-7,12-18H2,(H,27,30)/t20-,23-/m0/s1
DMMLESX	CS	C1C[C@H]2CC[C@@H](C3=CC=CC(=C23)C1)N4CCC5(CC4)C(=O)NCN5C6=CC=CC=C6
DMMLESX	IK	JLFMYEAXZNPWBK-REWPJTCUSA-N
DMMLESX	IU	8-[(1S,3aS)-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DMMLESX	CA	CAS 280783-56-4
DMMLESX	DE	Depression

DMK5VB2	ID	DMK5VB2
DMK5VB2	DN	Nerisopam
DMK5VB2	HS	Discontinued in Phase 1
DMK5VB2	SN	EGIS-6775
DMK5VB2	CP	EGIS Gyogyszergyar RT
DMK5VB2	DT	Small molecular drug
DMK5VB2	PC	65875
DMK5VB2	MW	309.4
DMK5VB2	FM	C18H19N3O2
DMK5VB2	IC	InChI=1S/C18H19N3O2/c1-11-8-13-9-16(22-2)17(23-3)10-15(13)18(21-20-11)12-4-6-14(19)7-5-12/h4-7,9-10H,8,19H2,1-3H3
DMK5VB2	CS	CC1=NN=C(C2=CC(=C(C=C2C1)OC)OC)C3=CC=C(C=C3)N
DMK5VB2	IK	WWQDEXGFYVSTCX-UHFFFAOYSA-N
DMK5VB2	IU	4-(7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl)aniline
DMK5VB2	CA	CAS 102771-12-0
DMK5VB2	DE	Anxiety disorder

DMXDLUH	ID	DMXDLUH
DMXDLUH	DN	NGD-4715
DMXDLUH	HS	Discontinued in Phase 1
DMXDLUH	SN	NGD-4715; 476322-70-0; 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine; SCHEMBL4712990; DTXSID10432090; VAKYVNYLCIABRV-UHFFFAOYSA-N; HY-100318
DMXDLUH	CP	Neurogen Corp
DMXDLUH	DT	Small molecular drug
DMXDLUH	PC	9866893
DMXDLUH	MW	422.3
DMXDLUH	FM	C19H24BrN3O3
DMXDLUH	IC	InChI=1S/C19H24BrN3O3/c1-24-16-6-4-14(12-17(16)25-2)13-22-8-10-23(11-9-22)18-7-5-15(20)19(21-18)26-3/h4-7,12H,8-11,13H2,1-3H3
DMXDLUH	CS	COC1=C(C=C(C=C1)CN2CCN(CC2)C3=NC(=C(C=C3)Br)OC)OC
DMXDLUH	IK	VAKYVNYLCIABRV-UHFFFAOYSA-N
DMXDLUH	IU	1-(5-bromo-6-methoxypyridin-2-yl)-4-[(3,4-dimethoxyphenyl)methyl]piperazine
DMXDLUH	CA	CAS 476322-70-0
DMXDLUH	DE	Obesity

DMZ9WLO	ID	DMZ9WLO
DMZ9WLO	DN	NGD-94-4
DMZ9WLO	HS	Discontinued in Phase 1
DMZ9WLO	CP	Neurogen Corp
DMZ9WLO	DE	Schizophrenia

DMMT7BC	ID	DMMT7BC
DMMT7BC	DN	NIP-520
DMMT7BC	HS	Discontinued in Phase 1
DMMT7BC	SN	NIP-502
DMMT7BC	CP	Nissan Chemical Industries Ltd
DMMT7BC	DE	Asthma

DM95NDT	ID	DM95NDT
DM95NDT	DN	NN-2501
DM95NDT	HS	Discontinued in Phase 1
DM95NDT	CP	Novo Nordisk A/S
DM95NDT	DE	Type-2 diabetes

DM8Z5VH	ID	DM8Z5VH
DM8Z5VH	DN	NN8210
DM8Z5VH	HS	Discontinued in Phase 1
DM8Z5VH	CP	Novo Nordisk
DM8Z5VH	DE	Rheumatoid arthritis

DMWDE8K	ID	DMWDE8K
DMWDE8K	DN	NOStentin
DMWDE8K	HS	Discontinued in Phase 1
DMWDE8K	SN	Gene therapy (restenosis); Gene therapy (iNOS), Cardion; Gene therapy (restenosis), Cardion
DMWDE8K	CP	Stanford University
DMWDE8K	DE	Artery stenosis

DMT8IGE	ID	DMT8IGE
DMT8IGE	DN	NP-252
DMT8IGE	HS	Discontinued in Phase 1
DMT8IGE	SN	3-(Cyclopropylcarbonyl)-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-5-carboxylic acid octyl ester
DMT8IGE	DT	Small molecular drug
DMT8IGE	PC	131462
DMT8IGE	MW	469.6
DMT8IGE	FM	C26H35N3O5
DMT8IGE	IC	InChI=1S/C26H35N3O5/c1-4-5-6-7-8-11-16-34-26(31)23-18(3)27-17(2)22(25(30)28-19-14-15-19)24(23)20-12-9-10-13-21(20)29(32)33/h9-10,12-13,19,24,27H,4-8,11,14-16H2,1-3H3,(H,28,30)
DMT8IGE	CS	CCCCCCCCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2[N+](=O)[O-])C(=O)NC3CC3)C)C
DMT8IGE	IK	IAWVGADTHVEXRD-UHFFFAOYSA-N
DMT8IGE	IU	octyl 5-(cyclopropylcarbamoyl)-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
DMT8IGE	CA	CAS 132031-81-3
DMT8IGE	DE	Hypertension

DMXI5YW	ID	DMXI5YW
DMXI5YW	DN	NP-61
DMXI5YW	HS	Discontinued in Phase 1
DMXI5YW	SN	Dual binding site acetylcholinesterase inhibitor, Neuropharma; NP-00361; NP-0361; AChE inhibitor (Alzheimer's) Neuropharma (Zeltia); AChE inhibitor/beta amyloid secretion inhibitor (oral formulation, Alzheimer's disease), Noscira
DMXI5YW	CP	Noscira SA
DMXI5YW	DE	Alzheimer disease

DMOMVW9	ID	DMOMVW9
DMOMVW9	DN	NPC-15669
DMOMVW9	HS	Discontinued in Phase 1
DMOMVW9	SN	Npc-15669; Npc 15669; UNII-K6JBN2T3Z4; K6JBN2T3Z4; N-(9H-(2,7-Dimethylfluoren-9-ylmethoxy)carbonyl)leucine; N-(((2,7-Dimethyl-9H-fluoren-9-yl)methoxy)carbonyl)-L-leucine; L-Leucine, N-(((2,7-dimethyl-9H-fluoren-9-yl)methoxy)carbonyl)-; AC1L3OOH; 132684-62-9; CHEMBL42385; SCHEMBL8066678; LS-187592; LS-186942; (2S)-2-[(2,7-dimethyl-9H-fluoren-9-yl)methoxycarbonylamino]-4-methylpentanoic acid
DMOMVW9	CP	Scios Inc
DMOMVW9	DT	Small molecular drug
DMOMVW9	PC	119365
DMOMVW9	MW	381.5
DMOMVW9	FM	C23H27NO4
DMOMVW9	IC	InChI=1S/C23H27NO4/c1-13(2)9-21(22(25)26)24-23(27)28-12-20-18-10-14(3)5-7-16(18)17-8-6-15(4)11-19(17)20/h5-8,10-11,13,20-21H,9,12H2,1-4H3,(H,24,27)(H,25,26)/t21-/m0/s1
DMOMVW9	CS	CC1=CC2=C(C=C1)C3=C(C2COC(=O)N[C@@H](CC(C)C)C(=O)O)C=C(C=C3)C
DMOMVW9	IK	SEHPSBSPFWAVPK-NRFANRHFSA-N
DMOMVW9	IU	(2S)-2-[(2,7-dimethyl-9H-fluoren-9-yl)methoxycarbonylamino]-4-methylpentanoic acid
DMOMVW9	CA	CAS 132684-62-9
DMOMVW9	DE	Inflammation

DMNL9DS	ID	DMNL9DS
DMNL9DS	DN	NSD-644
DMNL9DS	HS	Discontinued in Phase 1
DMNL9DS	SN	Serotonin/noradrenaline/dopamine activator (pain, depression, CNS disorder), NeuroSearch
DMNL9DS	CP	NeuroSearch A/S
DMNL9DS	DE	Neurological disorder

DM1QZKS	ID	DM1QZKS
DM1QZKS	DN	NTC-801
DM1QZKS	HS	Discontinued in Phase 1
DM1QZKS	CP	Bristol-Myers Squibb; Nissan Chemical; Teijin Pharma
DM1QZKS	DE	Atrial flutter; Atrial fibrillation

DMXJO5F	ID	DMXJO5F
DMXJO5F	DN	NZ-107
DMXJO5F	HS	Discontinued in Phase 1
DMXJO5F	SN	4-Bromo-5-(3-ethoxy-4-methoxybenzylamino)pyridazin-3(2H)-one
DMXJO5F	DT	Small molecular drug
DMXJO5F	PC	129496
DMXJO5F	MW	354.2
DMXJO5F	FM	C14H16BrN3O3
DMXJO5F	IC	InChI=1S/C14H16BrN3O3/c1-3-21-12-6-9(4-5-11(12)20-2)7-16-10-8-17-18-14(19)13(10)15/h4-6,8H,3,7H2,1-2H3,(H2,16,18,19)
DMXJO5F	CS	CCOC1=C(C=CC(=C1)CNC2=C(C(=O)NN=C2)Br)OC
DMXJO5F	IK	KNIKAZNCSPYOED-UHFFFAOYSA-N
DMXJO5F	IU	5-bromo-4-[(3-ethoxy-4-methoxyphenyl)methylamino]-1H-pyridazin-6-one
DMXJO5F	CA	CAS 107186-52-7
DMXJO5F	DE	Asthma

DMZN6F3	ID	DMZN6F3
DMZN6F3	DN	Odapipam
DMZN6F3	HS	Discontinued in Phase 1
DMZN6F3	SN	NNC 0756; NNC-756; NNC-01-0756
DMZN6F3	CP	Novo Nordisk A/S
DMZN6F3	DT	Small molecular drug
DMZN6F3	PC	132421
DMZN6F3	MW	329.8
DMZN6F3	FM	C19H20ClNO2
DMZN6F3	IC	InChI=1S/C19H20ClNO2/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1
DMZN6F3	CS	CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC4=C3OCC4)O)Cl
DMZN6F3	IK	SKMVRXPBCSTNKE-MRXNPFEDSA-N
DMZN6F3	IU	(5S)-8-chloro-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
DMZN6F3	CA	CAS 131796-63-9
DMZN6F3	DE	Psychotic disorder

DM47ELH	ID	DM47ELH
DM47ELH	DN	Oncolysin M
DM47ELH	HS	Discontinued in Phase 1
DM47ELH	SN	Anti-CD33-bR; Anti-My9-bR
DM47ELH	CP	Dana-Farber Cancer Institute Inc
DM47ELH	DE	leukaemia

DML7Q56	ID	DML7Q56
DML7Q56	DN	ONO-1714
DML7Q56	HS	Discontinued in Phase 1
DML7Q56	SN	CHEMBL1800346; CHEMBL105792; SCHEMBL2717045; BDBM50386178
DML7Q56	DT	Small molecular drug
DML7Q56	PC	9815538
DML7Q56	MW	195.09
DML7Q56	FM	C7H12Cl2N2
DML7Q56	IC	InChI=1S/C7H11ClN2.ClH/c1-3-2-4(9)10-7-5(3)6(7)8;/h3,5-7H,2H2,1H3,(H2,9,10);1H/t3-,5-,6+,7-;/m0./s1
DML7Q56	CS	C[C@H]1CC(=N[C@H]2[C@@H]1[C@H]2Cl)N.Cl
DML7Q56	IK	IZIZKGZAEABSET-IEUZAGAGSA-N
DML7Q56	IU	(1S,5S,6R,7R)-7-chloro-5-methyl-2-azabicyclo[4.1.0]hept-2-en-3-amine;hydrochloride
DML7Q56	DE	Sepsis

DM8KN2M	ID	DM8KN2M
DM8KN2M	DN	ONO-2231
DM8KN2M	HS	Discontinued in Phase 1
DM8KN2M	SN	ONO-1924H; PARP inhibitor (intravenous, stroke), ONO; Poly ADP ribose polymerase inhibitors (intravenous formulation, stroke), ONO
DM8KN2M	CP	Ono Pharmaceutical Co Ltd
DM8KN2M	DE	Cerebrovascular ischaemia

DMUSKY0	ID	DMUSKY0
DMUSKY0	DN	ONO-4127
DMUSKY0	HS	Discontinued in Phase 1
DMUSKY0	SN	Allergic rhinitis agent, Ono
DMUSKY0	CP	Ono Pharmaceutical Co Ltd
DMUSKY0	DE	Allergic rhinitis

DMKRVUN	ID	DMKRVUN
DMKRVUN	DN	ONO-4817
DMKRVUN	HS	Discontinued in Phase 1
DMKRVUN	SN	ONO-MI1-335
DMKRVUN	CP	Ono Pharmaceutical Co Ltd
DMKRVUN	DT	Small molecular drug
DMKRVUN	PC	9888141
DMKRVUN	MW	416.5
DMKRVUN	FM	C22H28N2O6
DMKRVUN	IC	InChI=1S/C22H28N2O6/c1-3-28-15-29-14-18(13-16(2)21(25)24-27)23-22(26)17-9-11-20(12-10-17)30-19-7-5-4-6-8-19/h4-12,16,18,27H,3,13-15H2,1-2H3,(H,23,26)(H,24,25)/t16-,18-/m0/s1
DMKRVUN	CS	CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)C1=CC=C(C=C1)OC2=CC=CC=C2
DMKRVUN	IK	HDWWQELUBWGQGA-WMZOPIPTSA-N
DMKRVUN	IU	N-[(2S,4S)-1-(ethoxymethoxy)-5-(hydroxyamino)-4-methyl-5-oxopentan-2-yl]-4-phenoxybenzamide
DMKRVUN	DE	Inflammatory bowel disease

DMB8T5U	ID	DMB8T5U
DMB8T5U	DN	ONT-093
DMB8T5U	HS	Discontinued in Phase 1
DMB8T5U	SN	MDR inhibitors, Ontogen; OC-144-093
DMB8T5U	CP	Ontogen Corp
DMB8T5U	DT	Small molecular drug
DMB8T5U	PC	6450807
DMB8T5U	MW	494.7
DMB8T5U	FM	C32H38N4O
DMB8T5U	IC	InChI=1S/C32H38N4O/c1-6-37-21-7-8-24-9-11-27(12-10-24)32-35-30(25-13-17-28(18-14-25)33-22(2)3)31(36-32)26-15-19-29(20-16-26)34-23(4)5/h7-20,22-23,33-34H,6,21H2,1-5H3,(H,35,36)/b8-7+
DMB8T5U	CS	CCOC/C=C/C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=C(C=C3)NC(C)C)C4=CC=C(C=C4)NC(C)C
DMB8T5U	IK	RSJCLODJSVZNQA-BQYQJAHWSA-N
DMB8T5U	IU	4-[2-[4-[(E)-3-ethoxyprop-1-enyl]phenyl]-4-[4-(propan-2-ylamino)phenyl]-1H-imidazol-5-yl]-N-propan-2-ylaniline
DMB8T5U	CA	CAS 216227-54-2
DMB8T5U	DE	Solid tumour/cancer

DMDCOSP	ID	DMDCOSP
DMDCOSP	DN	OPC-51803
DMDCOSP	HS	Discontinued in Phase 1
DMDCOSP	SN	SOU-003; 2-[1-[2-Chloro-4-(1-pyrrolidinyl)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepin-5(R)-yl]-N-isopropylacetamide
DMDCOSP	CP	Otsuka America Pharmaceutical; Sosei
DMDCOSP	DT	Small molecular drug
DMDCOSP	PC	3038506
DMDCOSP	MW	454
DMDCOSP	FM	C26H32ClN3O2
DMDCOSP	IC	InChI=1S/C26H32ClN3O2/c1-18(2)28-25(31)16-19-8-7-15-30(24-10-4-3-9-21(19)24)26(32)22-12-11-20(17-23(22)27)29-13-5-6-14-29/h3-4,9-12,17-19H,5-8,13-16H2,1-2H3,(H,28,31)/t19-/m1/s1
DMDCOSP	CS	CC(C)NC(=O)C[C@H]1CCCN(C2=CC=CC=C12)C(=O)C3=C(C=C(C=C3)N4CCCC4)Cl
DMDCOSP	IK	INGXCNVWWKKWOO-LJQANCHMSA-N
DMDCOSP	IU	2-[(5R)-1-(2-chloro-4-pyrrolidin-1-ylbenzoyl)-2,3,4,5-tetrahydro-1-benzazepin-5-yl]-N-propan-2-ylacetamide
DMDCOSP	CA	CAS 192514-54-8
DMDCOSP	DE	Urinary incontinence

DMPDJC8	ID	DMPDJC8
DMPDJC8	DN	Opterone
DMPDJC8	HS	Discontinued in Phase 1
DMPDJC8	SN	SEPA testosterone cream
DMPDJC8	CP	MacroChem Corporation
DMPDJC8	DE	Hormone deficiency

DMB5TL9	ID	DMB5TL9
DMB5TL9	DN	Orazipone
DMB5TL9	HS	Discontinued in Phase 1
DMB5TL9	SN	OR-1384
DMB5TL9	CP	Orion Corp
DMB5TL9	DT	Small molecular drug
DMB5TL9	PC	178387
DMB5TL9	MW	266.31
DMB5TL9	FM	C13H14O4S
DMB5TL9	IC	InChI=1S/C13H14O4S/c1-9(14)13(10(2)15)8-11-4-6-12(7-5-11)18(3,16)17/h4-8H,1-3H3
DMB5TL9	CS	CC(=O)C(=CC1=CC=C(C=C1)S(=O)(=O)C)C(=O)C
DMB5TL9	IK	CAWYWWPWSAMGBV-UHFFFAOYSA-N
DMB5TL9	IU	3-[(4-methylsulfonylphenyl)methylidene]pentane-2,4-dione
DMB5TL9	CA	CAS 137109-78-5
DMB5TL9	DE	Inflammatory bowel disease

DMQBURK	ID	DMQBURK
DMQBURK	DN	Ordopidine
DMQBURK	HS	Discontinued in Phase 1
DMQBURK	SN	ACR-321; ACR-325
DMQBURK	CP	A Carlsson Research AB
DMQBURK	DT	Small molecular drug
DMQBURK	PC	11701939
DMQBURK	MW	285.38
DMQBURK	FM	C14H20FNO2S
DMQBURK	IC	InChI=1S/C14H20FNO2S/c1-3-16-9-7-11(8-10-16)12-5-4-6-13(14(12)15)19(2,17)18/h4-6,11H,3,7-10H2,1-2H3
DMQBURK	CS	CCN1CCC(CC1)C2=C(C(=CC=C2)S(=O)(=O)C)F
DMQBURK	IK	UKUPJASJNQDHPH-UHFFFAOYSA-N
DMQBURK	IU	1-ethyl-4-(2-fluoro-3-methylsulfonylphenyl)piperidine
DMQBURK	CA	CAS 871351-60-9
DMQBURK	DE	Psychotic disorder

DMMYI9U	ID	DMMYI9U
DMMYI9U	DN	Org-21465
DMMYI9U	HS	Discontinued in Phase 1
DMMYI9U	SN	SCHEMBL8751071; Org 21465
DMMYI9U	CP	Organon BioSciences
DMMYI9U	DT	Small molecular drug
DMMYI9U	PC	9803583
DMMYI9U	MW	445.6
DMMYI9U	FM	C27H43NO4
DMMYI9U	IC	InChI=1S/C27H43NO4/c1-16(29)19-8-9-20-18-7-6-17-12-22(30)21(28-10-11-32-25(2,3)15-28)13-26(17,4)24(18)23(31)14-27(19,20)5/h17-22,24,30H,6-15H2,1-5H3/t17-,18-,19+,20-,21-,22-,24+,26-,27+/m0/s1
DMMYI9U	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOC(C5)(C)C)C)C
DMMYI9U	IK	HQEJMKVZYCQIIH-JJLPOIBOSA-N
DMMYI9U	IU	(2S,3S,5S,8S,9S,10S,13S,14S,17S)-17-acetyl-2-(2,2-dimethylmorpholin-4-yl)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one
DMMYI9U	CA	CAS 167946-96-5
DMMYI9U	DE	Anaesthesia

DMZKTU5	ID	DMZKTU5
DMZKTU5	DN	Org-31710
DMZKTU5	HS	Discontinued in Phase 1
DMZKTU5	SN	Org-31806
DMZKTU5	CP	Organon BioSciences
DMZKTU5	DT	Small molecular drug
DMZKTU5	PC	164090
DMZKTU5	MW	445.6
DMZKTU5	FM	C30H39NO2
DMZKTU5	IC	InChI=1S/C30H39NO2/c1-19-16-25-27-12-14-30(13-5-15-33-30)29(27,2)18-26(20-6-8-21(9-7-20)31(3)4)28(25)23-11-10-22(32)17-24(19)23/h6-9,17,19,25-27H,5,10-16,18H2,1-4H3/t19-,25+,26-,27+,29+,30+/m1/s1
DMZKTU5	CS	C[C@@H]1C[C@H]2[C@@H]3CC[C@]4([C@]3(C[C@@H](C2=C5C1=CC(=O)CC5)C6=CC=C(C=C6)N(C)C)C)CCCO4
DMZKTU5	IK	HFDGABTZPISMDD-IEVXGSBISA-N
DMZKTU5	IU	(6R,8S,11R,13S,14S,17R)-11-[4-(dimethylamino)phenyl]-6,13-dimethylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one
DMZKTU5	CA	CAS 118968-41-5
DMZKTU5	DE	Contraception

DM5UYI7	ID	DM5UYI7
DM5UYI7	DN	OX 19
DM5UYI7	HS	Discontinued in Phase 1
DM5UYI7	SN	Sublingual desmopressin
DM5UYI7	CP	Orexo
DM5UYI7	DE	Urinary incontinence

DMF4KPM	ID	DMF4KPM
DMF4KPM	DN	PA-1050040
DMF4KPM	HS	Discontinued in Phase 1
DMF4KPM	SN	PA-040
DMF4KPM	CP	Panacos
DMF4KPM	DE	Human immunodeficiency virus infection

DM6LQGO	ID	DM6LQGO
DM6LQGO	DN	Pafenolol
DM6LQGO	HS	Discontinued in Phase 1
DM6LQGO	SN	H-138/03; Pafenolol; Rac-N-[2-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]ethyl]-N'-isopropylurea
DM6LQGO	DT	Small molecular drug
DM6LQGO	PC	71144
DM6LQGO	MW	337.5
DM6LQGO	FM	C18H31N3O3
DM6LQGO	IC	InChI=1S/C18H31N3O3/c1-13(2)20-11-16(22)12-24-17-7-5-15(6-8-17)9-10-19-18(23)21-14(3)4/h5-8,13-14,16,20,22H,9-12H2,1-4H3,(H2,19,21,23)
DM6LQGO	CS	CC(C)NCC(COC1=CC=C(C=C1)CCNC(=O)NC(C)C)O
DM6LQGO	IK	PKWZWSXSCKVUJB-UHFFFAOYSA-N
DM6LQGO	IU	1-[2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]ethyl]-3-propan-2-ylurea
DM6LQGO	CA	CAS 75949-61-0
DM6LQGO	DE	Hypertension

DMVFGWM	ID	DMVFGWM
DMVFGWM	DN	PD-131112
DMVFGWM	HS	Discontinued in Phase 1
DMVFGWM	SN	7-[(3S)-3-Aminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 7-[(3S)-3-amino-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; (S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 127967-03-7; 7-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; ci-990; 1,8-Naphthyridine-3-carboxylic acid, 7-((3S)-3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; CI-990 (Hydrochloride); AC1L2I3J; CHEMBL51678; PD131628;  CI-990; [S-(R*,R*)]-7-[3-(2-Aminopropanamido)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; (S,S)-7-[3-(Alanylamino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 122536-20-3; PD-131628
DMVFGWM	DT	Small molecular drug
DMVFGWM	PC	9953002
DMVFGWM	MW	403.4
DMVFGWM	FM	C19H22FN5O4
DMVFGWM	IC	InChI=1S/C19H22FN5O4/c1-9(21)18(27)22-10-4-5-24(7-10)17-14(20)6-12-15(26)13(19(28)29)8-25(11-2-3-11)16(12)23-17/h6,8-11H,2-5,7,21H2,1H3,(H,22,27)(H,28,29)/t9-,10-/m0/s1
DMVFGWM	CS	C[C@@H](C(=O)N[C@H]1CCN(C1)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F)N
DMVFGWM	IK	ZVZRDFTXNAZBOX-UWVGGRQHSA-N
DMVFGWM	IU	7-[(3S)-3-[[(2S)-2-aminopropanoyl]amino]pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMVFGWM	DE	Bacterial infection

DM7KJTI	ID	DM7KJTI
DM7KJTI	DN	PD-153035
DM7KJTI	HS	Discontinued in Phase 1
DM7KJTI	SN	183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo
DM7KJTI	DT	Small molecular drug
DM7KJTI	PC	4705
DM7KJTI	MW	360.2
DM7KJTI	FM	C16H14BrN3O2
DM7KJTI	IC	InChI=1S/C16H14BrN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)
DM7KJTI	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Br)OC
DM7KJTI	IK	LSPANGZZENHZNJ-UHFFFAOYSA-N
DM7KJTI	IU	N-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine
DM7KJTI	CA	CAS 153436-54-5
DM7KJTI	CB	CHEBI:91076
DM7KJTI	DE	Psoriasis vulgaris

DMO4S6T	ID	DMO4S6T
DMO4S6T	DN	PF-03814735
DMO4S6T	HS	Discontinued in Phase 1
DMO4S6T	SN	PF-03814735; 942490-07-5; PF 03814735; PF-3814735; PF03814735; Kinome_1769; MLS006010949; CHEMBL1983111; SB19308; NCGC00389594-01; KB-74441; SMR004703046; BCP0726000114; J3.628.238J; N-(2-(6-((4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)-2-oxoethyl)acetamide; N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide
DMO4S6T	CP	Pfizer
DMO4S6T	DT	Small molecular drug
DMO4S6T	PC	51346455
DMO4S6T	MW	474.5
DMO4S6T	FM	C23H25F3N6O2
DMO4S6T	IC	InChI=1S/C23H25F3N6O2/c1-12(33)27-11-20(34)32-18-7-8-19(32)16-9-14(5-6-15(16)18)30-22-28-10-17(23(24,25)26)21(31-22)29-13-3-2-4-13/h5-6,9-10,13,18-19H,2-4,7-8,11H2,1H3,(H,27,33)(H2,28,29,30,31)/t18-,19+/m0/s1
DMO4S6T	CS	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C3=C2C=CC(=C3)NC4=NC=C(C(=N4)NC5CCC5)C(F)(F)F
DMO4S6T	IK	RYYNGWLOYLRZLK-RBUKOAKNSA-N
DMO4S6T	IU	N-[2-[(1R,8S)-4-[[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-11-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-11-yl]-2-oxoethyl]acetamide
DMO4S6T	CA	CAS 942487-16-3
DMO4S6T	DE	Advanced solid tumour

DMD83VY	ID	DMD83VY
DMD83VY	DN	PF-05212372
DMD83VY	HS	Discontinued in Phase 1
DMD83VY	SN	PLA-950; Asthma therapy (inhaled, asthma), Pfizer; Asthma therapy (inhaled, asthma), Wyeth
DMD83VY	CP	Wyeth
DMD83VY	DE	Asthma

DM68PYA	ID	DM68PYA
DM68PYA	DN	PF-05236812
DM68PYA	HS	Discontinued in Phase 1
DM68PYA	SN	AAB-003
DM68PYA	CP	Wyeth
DM68PYA	DE	Alzheimer disease

DMSE3WP	ID	DMSE3WP
DMSE3WP	DN	PF-06260414
DMSE3WP	HS	Discontinued in Phase 1
DMSE3WP	SN	PF-14
DMSE3WP	CP	PharmacoFore Inc
DMSE3WP	PC	76071881
DMSE3WP	MW	302.35
DMSE3WP	FM	C14H14N4O2S
DMSE3WP	IC	InChI=1S/C14H14N4O2S/c1-10-8-17-21(19,20)18(9-10)12-2-3-13-11(6-12)4-5-16-14(13)7-15/h2-6,10,17H,8-9H2,1H3/t10-/m1/s1
DMSE3WP	CS	C[C@@H]1CNS(=O)(=O)N(C1)C2=CC3=C(C=C2)C(=NC=C3)C#N
DMSE3WP	IK	ZKAVFOXYJCREBQ-SNVBAGLBSA-N
DMSE3WP	IU	6-[(4R)-4-methyl-1,1-dioxo-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
DMSE3WP	CA	CAS 1612755-71-1
DMSE3WP	DE	Cachexia; Pain

DM5R2MG	ID	DM5R2MG
DM5R2MG	DN	PF-2393296
DM5R2MG	HS	Discontinued in Phase 1
DM5R2MG	SN	IDDBCP185108
DM5R2MG	CP	Pfizer Inc
DM5R2MG	DE	Neuropathic pain

DM2V7WH	ID	DM2V7WH
DM2V7WH	DN	PF-251802
DM2V7WH	HS	Discontinued in Phase 1
DM2V7WH	SN	PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer
DM2V7WH	CP	Pfizer Inc
DM2V7WH	DE	Rheumatoid arthritis

DMOQZIW	ID	DMOQZIW
DMOQZIW	DN	PF-3052334
DMOQZIW	HS	Discontinued in Phase 1
DMOQZIW	SN	PF-3052334; SCHEMBL3959323
DMOQZIW	DT	Small molecular drug
DMOQZIW	PC	24742042
DMOQZIW	MW	533.6
DMOQZIW	FM	C28H33FN3NaO5
DMOQZIW	IC	InChI=1S/C28H34FN3O5.Na/c1-17(2)26-24(13-12-22(33)14-23(34)15-25(35)36)32(21-10-8-20(29)9-11-21)31-27(26)28(37)30-16-19-6-4-18(3)5-7-19;/h4-11,17,22-23,33-34H,12-16H2,1-3H3,(H,30,37)(H,35,36);/q;+1/p-1/t22-,23-;/m1./s1
DMOQZIW	CS	CC1=CC=C(C=C1)CNC(=O)C2=NN(C(=C2C(C)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+]
DMOQZIW	IK	VEGKDAAILHTMLD-OHIDFYLOSA-M
DMOQZIW	IU	sodium;(3R,5R)-7-[2-(4-fluorophenyl)-5-[(4-methylphenyl)methylcarbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate
DMOQZIW	DE	Arteriosclerosis

DMCFYZM	ID	DMCFYZM
DMCFYZM	DN	PF-3185043
DMCFYZM	HS	Discontinued in Phase 1
DMCFYZM	CP	Pfizer
DMCFYZM	DE	Arteriosclerosis

DMD42MN	ID	DMD42MN
DMD42MN	DN	PF-3274167
DMD42MN	HS	Discontinued in Phase 1
DMD42MN	SN	PF-3274167; Cligosiban; 900510-03-4; UNII-D361S17AIF; D361S17AIF; CHEMBL594828; 5-(3-(3-(2-chloro-4-fluorophenoxy)azetidin-1-yl)-5-(methoxymethyl)-4H-1,2,4-triazol-4-yl)-2-methoxypyridine; Cligosiban [INN]; 5-{3-[3-(2-chloro-4-fluorophenoxy)azetidin-1-yl]-5-(methoxymethyl)-4H-1,2,4-triazol-4-yl}-2-methoxypyridine; SCHEMBL4126605; EX-A297; MolPort-044-567-557; BCP08878; ZINC38239529; BDBM50305506; AKOS030526977; CS-5337; HY-15023; PF3274167; B5924; PF 3274167; J-690387; Pyridine, 5-(3-(3-(2-chloro-4-fluorophenoxy)-1-azetidinyl)-5
DMD42MN	DT	Small molecular drug
DMD42MN	PC	11683187
DMD42MN	MW	419.8
DMD42MN	FM	C19H19ClFN5O3
DMD42MN	IC	InChI=1S/C19H19ClFN5O3/c1-27-11-17-23-24-19(26(17)13-4-6-18(28-2)22-8-13)25-9-14(10-25)29-16-5-3-12(21)7-15(16)20/h3-8,14H,9-11H2,1-2H3
DMD42MN	CS	COCC1=NN=C(N1C2=CN=C(C=C2)OC)N3CC(C3)OC4=C(C=C(C=C4)F)Cl
DMD42MN	IK	HNIFCPBQMKPRCX-UHFFFAOYSA-N
DMD42MN	IU	5-[3-[3-(2-chloro-4-fluorophenoxy)azetidin-1-yl]-5-(methoxymethyl)-1,2,4-triazol-4-yl]-2-methoxypyridine
DMD42MN	CA	CAS 900510-03-4
DMD42MN	DE	Female sexual arousal dysfunction

DMMU1W3	ID	DMMU1W3
DMMU1W3	DN	PF-3526299
DMMU1W3	HS	Discontinued in Phase 1
DMMU1W3	CP	Pfizer Inc
DMMU1W3	DE	Asthma

DMITYCN	ID	DMITYCN
DMITYCN	DN	PF-3557156
DMITYCN	HS	Discontinued in Phase 1
DMITYCN	SN	PDE 7 inhibitor (pain), Pfizer; Phosphodiesterase 7 inhibitor (pain), Pfizer
DMITYCN	CP	Pfizer Inc
DMITYCN	DE	Pain

DMNLAU7	ID	DMNLAU7
DMNLAU7	DN	PF-4629991
DMNLAU7	HS	Discontinued in Phase 1
DMNLAU7	SN	PF-991; S1P1 receptor agonist (autoimmune disease), Pfizer
DMNLAU7	CP	Pfizer Inc
DMNLAU7	DE	Rheumatoid arthritis

DMDOTW0	ID	DMDOTW0
DMDOTW0	DN	PF-477736
DMDOTW0	HS	Discontinued in Phase 1
DMDOTW0	CP	Pfizer
DMDOTW0	DT	Small molecular drug
DMDOTW0	PC	135565545
DMDOTW0	MW	419.5
DMDOTW0	FM	C22H25N7O2
DMDOTW0	IC	InChI=1S/C22H25N7O2/c1-29-11-13(9-25-29)20-16-10-24-28-21(30)15-7-14(8-17(27-20)18(15)16)26-22(31)19(23)12-5-3-2-4-6-12/h7-12,19,27H,2-6,23H2,1H3,(H,26,31)(H,28,30)/t19-/m1/s1
DMDOTW0	CS	CN1C=C(C=N1)C2=C3C=NNC(=O)C4=C3C(=CC(=C4)NC(=O)[C@@H](C5CCCCC5)N)N2
DMDOTW0	IK	NDEXUOWTGYUVGA-LJQANCHMSA-N
DMDOTW0	IU	(2R)-2-amino-2-cyclohexyl-N-[2-(1-methylpyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-6-yl]acetamide
DMDOTW0	CA	CAS 952021-60-2
DMDOTW0	CB	CHEBI:91385
DMDOTW0	DE	Advanced solid tumour

DMS7M0U	ID	DMS7M0U
DMS7M0U	DN	PF-514273
DMS7M0U	HS	Discontinued in Phase 1
DMS7M0U	SN	PF 514273; 2-(2-CHLOROPHENYL)-3-(4-CHLOROPHENYL)-7-(2,2-DIFLUOROPROPYL)-6,7-DIHYDRO-2H-PYRAZOLO[3,4-F][1,4]OXAZEPIN-8(5H)-ONE; FJMQJSUOOGOWBD-UHFFFAOYSA-N; SCHEMBL1315434; CHEMBL484929; BDBM29075; DTXSID80462142; MolPort-023-276-895; ZINC40939374; AKOS024457743; API0006251; NCGC00370822-01; PF-0514273; FT-0673651; PF-514273, &gt
DMS7M0U	CP	Pfizer Inc
DMS7M0U	DT	Small molecular drug
DMS7M0U	PC	11316919
DMS7M0U	MW	452.3
DMS7M0U	FM	C21H17Cl2F2N3O2
DMS7M0U	IC	InChI=1S/C21H17Cl2F2N3O2/c1-21(24,25)12-27-10-11-30-19-17(20(27)29)26-28(16-5-3-2-4-15(16)23)18(19)13-6-8-14(22)9-7-13/h2-9H,10-12H2,1H3
DMS7M0U	CS	CC(CN1CCOC2=C(N(N=C2C1=O)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl)(F)F
DMS7M0U	IK	FJMQJSUOOGOWBD-UHFFFAOYSA-N
DMS7M0U	IU	2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one
DMS7M0U	CA	CAS 851728-60-4
DMS7M0U	DE	Obesity

DMB7EIN	ID	DMB7EIN
DMB7EIN	DN	PF-915275
DMB7EIN	HS	Discontinued in Phase 1
DMB7EIN	SN	PF-915275; 857290-04-1; PF 915275; UNII-388927163B; N-(6-aminopyridin-2-yl)-4'-cyanobiphenyl-4-sulfonamide; 388927163B; ZESFDAKNYJQYKO-UHFFFAOYSA-N; SCHEMBL4384483; CHEMBL495841; CTK5F5674; BDBM29864; DTXSID00235037; MolPort-023-276-737; KS-00001D9U; BCP28049; ZINC40955326; AKOS024457530; CS-5559; N-(Pyridin-2-yl) arylsulfonamide, 26; NCGC00370811-01; HY-18056; RT-015014; KB-274983; B7346; N-(6-Aminopyridin-2-yl)4'-cyanobiphenyl-4-sulfonamide; N-(6-Amino-2-pyridinyl)-4'-cyano-[1,1'-biphenyl]-4-sulfonamide
DMB7EIN	DT	Small molecular drug
DMB7EIN	PC	23725123
DMB7EIN	MW	350.4
DMB7EIN	FM	C18H14N4O2S
DMB7EIN	IC	InChI=1S/C18H14N4O2S/c19-12-13-4-6-14(7-5-13)15-8-10-16(11-9-15)25(23,24)22-18-3-1-2-17(20)21-18/h1-11H,(H3,20,21,22)
DMB7EIN	CS	C1=CC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C#N)N
DMB7EIN	IK	ZESFDAKNYJQYKO-UHFFFAOYSA-N
DMB7EIN	IU	N-(6-aminopyridin-2-yl)-4-(4-cyanophenyl)benzenesulfonamide
DMB7EIN	CA	CAS 857290-04-1
DMB7EIN	DE	Non-insulin dependent diabetes

DMAPD6M	ID	DMAPD6M
DMAPD6M	DN	PLD-147
DMAPD6M	HS	Discontinued in Phase 1
DMAPD6M	SN	LA-12; (OC-6-43)Bis(acetato-kappaO)amminedichloro(adamant-1-ylamine)platinum
DMAPD6M	DT	Small molecular drug
DMAPD6M	PC	10007773
DMAPD6M	MW	552.4
DMAPD6M	FM	C14H26Cl2N2O4Pt
DMAPD6M	IC	InChI=1S/C10H17N.2C2H4O2.2ClH.H3N.Pt/c11-10-4-7-1-8(5-10)3-9(2-7)6-10;2*1-2(3)4;;;;/h7-9H,1-6,11H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4
DMAPD6M	CS	CC(=O)[O-].CC(=O)[O-].C1C2CC3CC1CC(C2)(C3)N.N.[Cl-].[Cl-].[Pt+4]
DMAPD6M	IK	RGCIZXNKLJAKIS-UHFFFAOYSA-J
DMAPD6M	IU	adamantan-1-amine;azane;platinum(4+);diacetate;dichloride
DMAPD6M	CA	CAS 250611-20-2
DMAPD6M	DE	Solid tumour/cancer

DMFKC7L	ID	DMFKC7L
DMFKC7L	DN	PN-355
DMFKC7L	HS	Discontinued in Phase 1
DMFKC7L	SN	AndroVir; Tyrosine kinase inhibitors (HIV infection), Paracelsian
DMFKC7L	CP	Paracelsian Inc
DMFKC7L	DE	Human immunodeficiency virus-1 infection

DMPWG2K	ID	DMPWG2K
DMPWG2K	DN	PNU-142721
DMPWG2K	HS	Discontinued in Phase 1
DMPWG2K	SN	PNU-109866; PNU-142721E
DMPWG2K	CP	Pharmacia & Upjohn Inc
DMPWG2K	DT	Small molecular drug
DMPWG2K	PC	446309
DMPWG2K	MW	306.77
DMPWG2K	FM	C13H11ClN4OS
DMPWG2K	IC	InChI=1S/C13H11ClN4OS/c1-7(20-13-17-11(14)5-12(15)18-13)9-4-8-2-3-19-10(8)6-16-9/h2-7H,1H3,(H2,15,17,18)/t7-/m0/s1
DMPWG2K	CS	C[C@@H](C1=NC=C2C(=C1)C=CO2)SC3=NC(=CC(=N3)Cl)N
DMPWG2K	IK	ATCRIOJPQXDFNY-ZETCQYMHSA-N
DMPWG2K	IU	6-chloro-2-[(1S)-1-furo[2,3-c]pyridin-5-ylethyl]sulfanylpyrimidin-4-amine
DMPWG2K	CA	CAS 185220-03-5
DMPWG2K	DE	Human immunodeficiency virus infection

DMG2WAX	ID	DMG2WAX
DMG2WAX	DN	Prostate cancer vaccine
DMG2WAX	HS	Discontinued in Phase 1
DMG2WAX	SN	Prostate cancer vaccine, United Biomedical; SUIS-LHRH; UBITh LHRH peptide, UBI; Peptide (prostate cancer), UBI; UBITh LHRH immunotherapeutics (prostate cancer), United Biomedical
DMG2WAX	CP	United Biomedical Inc
DMG2WAX	DT	Vaccine
DMG2WAX	DE	Prostate cancer

DM4LNBQ	ID	DM4LNBQ
DM4LNBQ	DN	Pyroxamide
DM4LNBQ	HS	Discontinued in Phase 1
DM4LNBQ	SN	POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide
DM4LNBQ	CP	National Cancer Institute (NCI) 
DM4LNBQ	DT	Small molecular drug
DM4LNBQ	PC	4996
DM4LNBQ	MW	265.31
DM4LNBQ	FM	C13H19N3O3
DM4LNBQ	IC	InChI=1S/C13H19N3O3/c17-12(15-11-6-5-9-14-10-11)7-3-1-2-4-8-13(18)16-19/h5-6,9-10,19H,1-4,7-8H2,(H,15,17)(H,16,18)
DM4LNBQ	CS	C1=CC(=CN=C1)NC(=O)CCCCCCC(=O)NO
DM4LNBQ	IK	PTJGLFIIZFVFJV-UHFFFAOYSA-N
DM4LNBQ	IU	N'-hydroxy-N-pyridin-3-yloctanediamide
DM4LNBQ	CA	CAS 382180-17-8
DM4LNBQ	CB	CHEBI:93953
DM4LNBQ	DE	Solid tumour/cancer

DMU93JL	ID	DMU93JL
DMU93JL	DN	R 80122
DMU93JL	HS	Discontinued in Phase 1
DMU93JL	DT	Small molecular drug
DMU93JL	PC	135544124
DMU93JL	MW	459.5
DMU93JL	FM	C26H29N5O3
DMU93JL	IC	InChI=1S/C26H29N5O3/c1-30(21-10-6-3-7-11-21)24(33)17-34-29-25(18-8-4-2-5-9-18)19-12-13-22-20(14-19)15-31-16-23(32)28-26(31)27-22/h2,4-5,8-9,12-14,21H,3,6-7,10-11,15-17H2,1H3,(H,27,28,32)/b29-25+
DMU93JL	CS	CN(C1CCCCC1)C(=O)CO/N=C(\\C2=CC=CC=C2)/C3=CC4=C(C=C3)N=C5NC(=O)CN5C4
DMU93JL	IK	VHDUUXNHZLBGHQ-XLVZBRSZSA-N
DMU93JL	IU	N-cyclohexyl-N-methyl-2-[(E)-[(2-oxo-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-7-yl)-phenylmethylidene]amino]oxyacetamide
DMU93JL	CA	CAS 133718-29-3
DMU93JL	DE	Cardiovascular disease

DMHPV1D	ID	DMHPV1D
DMHPV1D	DN	R-1065
DMHPV1D	HS	Discontinued in Phase 1
DMHPV1D	SN	VR-1065; Ro-60-0332
DMHPV1D	CP	Vernalis Group plc
DMHPV1D	DE	Obesity

DML7M3S	ID	DML7M3S
DML7M3S	DN	R-1068
DML7M3S	HS	Discontinued in Phase 1
DML7M3S	CP	Roche Holding AG
DML7M3S	DE	Vomiting

DMRHF97	ID	DMRHF97
DMRHF97	DN	R1204
DMRHF97	HS	Discontinued in Phase 1
DMRHF97	CP	Roche
DMRHF97	PC	15461
DMRHF97	MW	162.23
DMRHF97	FM	C11H14O
DMRHF97	IC	InChI=1S/C11H14O/c1-7-5-8(2)11(10(4)12)9(3)6-7/h5-6H,1-4H3
DMRHF97	CS	CC1=CC(=C(C(=C1)C)C(=O)C)C
DMRHF97	IK	XWCIICLTKWRWCI-UHFFFAOYSA-N
DMRHF97	IU	1-(2,4,6-trimethylphenyl)ethanone
DMRHF97	CA	CAS 1667-01-2
DMRHF97	DE	Depression

DMT8V9G	ID	DMT8V9G
DMT8V9G	DN	R1295
DMT8V9G	HS	Discontinued in Phase 1
DMT8V9G	SN	CHEMBL2146615
DMT8V9G	CP	Roche
DMT8V9G	DT	Small molecular drug
DMT8V9G	PC	70329
DMT8V9G	MW	166.17
DMT8V9G	FM	C9H10O3
DMT8V9G	IC	InChI=1S/C9H10O3/c1-7-2-4-8(5-3-7)12-6-9(10)11/h2-5H,6H2,1H3,(H,10,11)
DMT8V9G	CS	CC1=CC=C(C=C1)OCC(=O)O
DMT8V9G	IK	SFTDDFBJWUWKMN-UHFFFAOYSA-N
DMT8V9G	IU	2-(4-methylphenoxy)acetic acid
DMT8V9G	CA	CAS 940-64-7
DMT8V9G	DE	Rheumatoid arthritis

DM9C6LN	ID	DM9C6LN
DM9C6LN	DN	R-1479
DM9C6LN	HS	Discontinued in Phase 1
DM9C6LN	SN	4-Azidocytidine
DM9C6LN	CP	Roche Holding AG
DM9C6LN	DT	Small molecular drug
DM9C6LN	PC	457388
DM9C6LN	MW	284.23
DM9C6LN	FM	C9H12N6O5
DM9C6LN	IC	InChI=1S/C9H12N6O5/c10-4-1-2-15(8(19)12-4)7-5(17)6(18)9(3-16,20-7)13-14-11/h1-2,5-7,16-18H,3H2,(H2,10,12,19)/t5-,6+,7-,9-/m1/s1
DM9C6LN	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@](O2)(CO)N=[N+]=[N-])O)O
DM9C6LN	IK	ODLGMSQBFONGNG-JVZYCSMKSA-N
DM9C6LN	IU	4-amino-1-[(2R,3R,4S,5R)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DM9C6LN	CA	CAS 478182-28-4
DM9C6LN	DE	Hepatitis C virus infection

DM7WPI0	ID	DM7WPI0
DM7WPI0	DN	R-1487
DM7WPI0	HS	Discontinued in Phase 1
DM7WPI0	SN	449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; R-1487; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921
DM7WPI0	CP	Roche Holding AG
DM7WPI0	DT	Small molecular drug
DM7WPI0	PC	11406590
DM7WPI0	MW	388.4
DM7WPI0	FM	C19H18F2N4O3
DM7WPI0	IC	InChI=1S/C19H18F2N4O3/c1-25-17-11(10-22-19(24-17)23-13-4-6-27-7-5-13)8-16(18(25)26)28-15-3-2-12(20)9-14(15)21/h2-3,8-10,13H,4-7H2,1H3,(H,22,23,24)
DM7WPI0	CS	CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC4CCOCC4
DM7WPI0	IK	KKKRKRMVJRHDMG-UHFFFAOYSA-N
DM7WPI0	IU	6-(2,4-difluorophenoxy)-8-methyl-2-(oxan-4-ylamino)pyrido[2,3-d]pyrimidin-7-one
DM7WPI0	CA	CAS 449811-92-1
DM7WPI0	DE	Rheumatoid arthritis

DM2J5AO	ID	DM2J5AO
DM2J5AO	DN	R-1518
DM2J5AO	HS	Discontinued in Phase 1
DM2J5AO	SN	Levovirin prodrug, Roche
DM2J5AO	CP	Roche Holding AG
DM2J5AO	PC	10249157
DM2J5AO	MW	379.8
DM2J5AO	FM	C13H22ClN5O6
DM2J5AO	IC	InChI=1S/C13H21N5O6.ClH/c1-5(2)7(14)13(22)23-3-6-8(19)9(20)12(24-6)18-4-16-11(17-18)10(15)21;/h4-9,12,19-20H,3,14H2,1-2H3,(H2,15,21);1H/t6-,7-,8-,9-,12-;/m0./s1
DM2J5AO	CS	CC(C)[C@@H](C(=O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC(=N2)C(=O)N)O)O)N.Cl
DM2J5AO	IK	BZAMJGAXDMZZKX-JSNLFJDGSA-N
DM2J5AO	IU	[(2S,3R,4S,5S)-5-(3-carbamoyl-1,2,4-triazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DM2J5AO	CA	CAS 705930-02-5
DM2J5AO	DE	Hepatitis C virus infection

DMK25FU	ID	DMK25FU
DMK25FU	DN	R547
DMK25FU	HS	Discontinued in Phase 1
DMK25FU	SN	LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone
DMK25FU	CP	Hoffmann CLa Roche
DMK25FU	DT	Small molecular drug
DMK25FU	PC	6918852
DMK25FU	MW	441.5
DMK25FU	FM	C18H21F2N5O4S
DMK25FU	IC	InChI=1S/C18H21F2N5O4S/c1-29-13-4-3-12(19)15(20)14(13)16(26)11-9-22-18(24-17(11)21)23-10-5-7-25(8-6-10)30(2,27)28/h3-4,9-10H,5-8H2,1-2H3,(H3,21,22,23,24)
DMK25FU	CS	COC1=C(C(=C(C=C1)F)F)C(=O)C2=CN=C(N=C2N)NC3CCN(CC3)S(=O)(=O)C
DMK25FU	IK	JRNJNYBQQYBCLE-UHFFFAOYSA-N
DMK25FU	IU	[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone
DMK25FU	CA	CAS 741713-40-6
DMK25FU	DE	Advanced solid tumour

DMF3A6H	ID	DMF3A6H
DMF3A6H	DN	R-701
DMF3A6H	HS	Discontinued in Phase 1
DMF3A6H	CP	Roche Holding AG
DMF3A6H	DE	Overactive bladder

DMETAP8	ID	DMETAP8
DMETAP8	DN	R7232
DMETAP8	HS	Discontinued in Phase 1
DMETAP8	CP	Roche
DMETAP8	PC	13637622
DMETAP8	MW	172.61
DMETAP8	FM	C7H9ClN2O
DMETAP8	IC	InChI=1S/C7H9ClN2O/c1-4-6(7(8)11)5(2)10(3)9-4/h1-3H3
DMETAP8	CS	CC1=C(C(=NN1C)C)C(=O)Cl
DMETAP8	IK	UFNVZQRBSDFSPY-UHFFFAOYSA-N
DMETAP8	IU	1,3,5-trimethylpyrazole-4-carbonyl chloride
DMETAP8	CA	CAS 98298-63-6
DMETAP8	DE	Dyslipidemia

DMTK3DR	ID	DMTK3DR
DMTK3DR	DN	R-82150
DMTK3DR	HS	Discontinued in Phase 1
DMTK3DR	SN	R 82150; R82150; NSC633810; 126320-77-2; CHEMBL46961; methyl(3-methylbut-2-enyl)[ ]thione; NSC-633810; AC1MHD28; SCHEMBL599870; BDBM1433; TIBO R82150; TIBO-R82150; DTXSID60155141; 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione; (5R)-5beta-Methyl-6-(3-methyl-2-butenyl)-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione; (+)-S-4,6,7-Tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione
DMTK3DR	DT	Small molecular drug
DMTK3DR	PC	3000236
DMTK3DR	MW	287.4
DMTK3DR	FM	C16H21N3S
DMTK3DR	IC	InChI=1S/C16H21N3S/c1-11(2)7-8-18-10-13-5-4-6-14-15(13)19(9-12(18)3)16(20)17-14/h4-7,12H,8-10H2,1-3H3,(H,17,20)/t12-/m0/s1
DMTK3DR	CS	C[C@H]1CN2C3=C(CN1CC=C(C)C)C=CC=C3NC2=S
DMTK3DR	IK	WTTIBCHOELPGFK-LBPRGKRZSA-N
DMTK3DR	IU	(11S)-11-methyl-10-(3-methylbut-2-enyl)-1,3,10-triazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-thione
DMTK3DR	CA	CAS 126320-77-2
DMTK3DR	DE	Human immunodeficiency virus infection

DM4WJHY	ID	DM4WJHY
DM4WJHY	DN	R-82913
DM4WJHY	HS	Discontinued in Phase 1
DM4WJHY	SN	9-Cl-Tibo; R-82913; 9-Cmbib; r82913; R 82913; UNII-4FOI87E52P; 4-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE; NSC 637653; CHEMBL293498; 4FOI87E52P; 126347-69-1; 9-Chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo(4,5,1-jk)(1,4)benzodiazepine-2-(1H)-thione; 4,5,6,7-Tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo(4,5,1-jk)(1,4)benzodiazepin-2-(1H)-thione; TB9; Imidazo(4,5,1-jk)(1,4)benzodiazepine-2(1H)-thione, 9-chloro-4,5,6,7-tetrahydro-5-
DM4WJHY	DT	Small molecular drug
DM4WJHY	PC	3000237
DM4WJHY	MW	321.9
DM4WJHY	FM	C16H20ClN3S
DM4WJHY	IC	InChI=1S/C16H20ClN3S/c1-10(2)4-5-19-9-12-6-13(17)7-14-15(12)20(8-11(19)3)16(21)18-14/h4,6-7,11H,5,8-9H2,1-3H3,(H,18,21)/t11-/m0/s1
DM4WJHY	CS	C[C@H]1CN2C3=C(CN1CC=C(C)C)C=C(C=C3NC2=S)Cl
DM4WJHY	IK	RCSLUNOLLUVOOG-NSHDSACASA-N
DM4WJHY	IU	(11S)-6-chloro-11-methyl-10-(3-methylbut-2-enyl)-1,3,10-triazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-thione
DM4WJHY	CA	CAS 126347-69-1
DM4WJHY	DE	Human immunodeficiency virus infection

DMJ2ZVW	ID	DMJ2ZVW
DMJ2ZVW	DN	R-944
DMJ2ZVW	HS	Discontinued in Phase 1
DMJ2ZVW	SN	HIV protease inhibitors, Roche; Ro-332910
DMJ2ZVW	CP	Roche Products Ltd
DMJ2ZVW	DE	Human immunodeficiency virus infection

DMVID8E	ID	DMVID8E
DMVID8E	DN	Ramorelix
DMVID8E	HS	Discontinued in Phase 1
DMVID8E	SN	Hoe-013
DMVID8E	CP	Aventis Pharma AG
DMVID8E	PC	25077455
DMVID8E	MW	1532.1
DMVID8E	FM	C74H95ClN16O18
DMVID8E	IC	InChI=1S/C74H95ClN16O18/c1-38(2)29-52(63(98)82-51(15-9-27-79-73(76)77)71(106)91-28-10-16-59(91)70(105)89-90-74(78)107)83-69(104)58(37-108-72-62(97)61(96)60(95)39(3)109-72)88-66(101)55(32-42-20-25-48(94)26-21-42)85-68(103)57(36-92)87-67(102)56(34-46-35-80-50-14-8-7-13-49(46)50)86-65(100)54(31-41-18-23-47(75)24-19-41)84-64(99)53(81-40(4)93)33-43-17-22-44-11-5-6-12-45(44)30-43/h5-8,11-14,17-26,30,35,38-39,51-62,72,80,92,94-97H,9-10,15-16,27-29,31-34,36-37H2,1-4H3,(H,81,93)(H,82,98)(H,83,104)(H,84,99)(H,85,103)(H,86,100)(H,87,102)(H,88,101)(H,89,105)(H4,76,77,79)(H3,78,90,107)/t39-,51-,52-,53+,54+,55-,56+,57-,58+,59-,60-,61+,62+,72+/m0/s1
DMVID8E	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N2CCC[C@H]2C(=O)NNC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C)O)O)O
DMVID8E	IK	WDYSQADGBBEGRQ-APSDYLPASA-N
DMVID8E	IU	(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]-N-[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-methylpentanamide
DMVID8E	CA	CAS 127932-90-5
DMVID8E	DE	Esophageal cancer

DM3V5O2	ID	DM3V5O2
DM3V5O2	DN	RB-6145
DM3V5O2	HS	Discontinued in Phase 1
DM3V5O2	SN	PD-144872
DM3V5O2	CP	BTG plc
DM3V5O2	DT	Small molecular drug
DM3V5O2	PC	125377
DM3V5O2	MW	374.03
DM3V5O2	FM	C8H14Br2N4O3
DM3V5O2	IC	InChI=1S/C8H13BrN4O3.BrH/c9-1-2-10-5-7(14)6-12-4-3-11-8(12)13(15)16;/h3-4,7,10,14H,1-2,5-6H2;1H
DM3V5O2	CS	C1=CN(C(=N1)[N+](=O)[O-])CC(CNCCBr)O.Br
DM3V5O2	IK	XPBJPGMCFKYBBV-UHFFFAOYSA-N
DM3V5O2	IU	1-(2-bromoethylamino)-3-(2-nitroimidazol-1-yl)propan-2-ol;hydrobromide
DM3V5O2	CA	CAS 129448-97-1
DM3V5O2	DE	Solid tumour/cancer

DMR6QMJ	ID	DMR6QMJ
DMR6QMJ	DN	RC-8800
DMR6QMJ	HS	Discontinued in Phase 1
DMR6QMJ	SN	24-hydroxylase inhibitor (prostate cancer), Rejuvenon; 24-hydroxylase inhibitor (prostate cancer), Sapphire
DMR6QMJ	CP	Novo Nordisk A/S
DMR6QMJ	DE	Solid tumour/cancer

DM0ILRU	ID	DM0ILRU
DM0ILRU	DN	RDEA-436
DM0ILRU	HS	Discontinued in Phase 1
DM0ILRU	SN	MEK inhibitor, Ardea; MEK inhibitor (cancer), Bayer; MEK inhibitor 200 series (cancer), Bayer HealthCare; MEK inhibitor 200 series (inflammation), Ardea; Mitogen-activated ERK kinase inhibitor (inflammation), Ardea; RDEA-436 (cancer), Bayer HealthCare; RDEA-436 (cancer/inflammation), Ardea
DM0ILRU	CP	Ardea Biosciences Inc
DM0ILRU	DE	Solid tumour/cancer

DMW08TD	ID	DMW08TD
DMW08TD	DN	REGN 3048
DMW08TD	HS	Discontinue in Phase 1 Trial
DMW08TD	TC	Antiviral Agents
DMW08TD	DT	Monoclonal antibody
DMW08TD	DE	Middle East Respiratory Syndrome (MERS)

DMLH28J	ID	DMLH28J
DMLH28J	DN	REGN 3051
DMLH28J	HS	Discontinue in Phase 1 Trial
DMLH28J	TC	Antiviral Agents
DMLH28J	DT	Monoclonal antibody
DMLH28J	DE	Middle East Respiratory Syndrome (MERS)

DMT5VXF	ID	DMT5VXF
DMT5VXF	DN	Revatropate
DMT5VXF	HS	Discontinued in Phase 1
DMT5VXF	SN	UK-112166; UK-112,166; UK-112166-04; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2S)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; (3R-(3R*(S*(R*))))-1-Azabicyclo(2.2.2)oct-3-yl alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)benzenacetate
DMT5VXF	CP	Pfizer
DMT5VXF	DT	Small molecular drug
DMT5VXF	PC	9690123
DMT5VXF	MW	365.5
DMT5VXF	FM	C19H27NO4S
DMT5VXF	IC	InChI=1S/C19H27NO4S/c1-25(23)12-9-19(14-21,16-5-3-2-4-6-16)18(22)24-17-13-20-10-7-15(17)8-11-20/h2-6,15,17,21H,7-14H2,1H3/t17-,19-,25-/m0/s1
DMT5VXF	CS	C[S@](=O)CC[C@](CO)(C1=CC=CC=C1)C(=O)O[C@H]2CN3CCC2CC3
DMT5VXF	IK	VGXACJMXDYPFDB-KMEZTADASA-N
DMT5VXF	IU	[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-[(S)-methylsulfinyl]-2-phenylbutanoate
DMT5VXF	DE	Chronic obstructive pulmonary disease

DMW4G68	ID	DMW4G68
DMW4G68	DN	RG-201
DMW4G68	HS	Discontinued in Phase 1
DMW4G68	CP	Questcor Pharmaceuticals Inc
DMW4G68	DE	Acquired immune deficiency syndrome

DMOI037	ID	DMOI037
DMOI037	DN	RG-4934
DMOI037	HS	Discontinued in Phase 1
DMOI037	SN	IL-17 huMAb (psoriatic arthritis), Roche
DMOI037	CP	Roche Holding AG
DMOI037	DT	Antibody
DMOI037	DE	Arthritis

DMG9U8D	ID	DMG9U8D
DMG9U8D	DN	RG-7152
DMG9U8D	HS	Discontinued in Phase 1
DMG9U8D	SN	5-[3-[3-(2-Quinolinylmethoxy)phenoxy]propyl]-1H-tetrazole
DMG9U8D	DT	Small molecular drug
DMG9U8D	PC	129968
DMG9U8D	MW	361.4
DMG9U8D	FM	C20H19N5O2
DMG9U8D	IC	InChI=1S/C20H19N5O2/c1-2-8-19-15(5-1)10-11-16(21-19)14-27-18-7-3-6-17(13-18)26-12-4-9-20-22-24-25-23-20/h1-3,5-8,10-11,13H,4,9,12,14H2,(H,22,23,24,25)
DMG9U8D	CS	C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=CC(=C3)OCCCC4=NNN=N4
DMG9U8D	IK	XDPLTERFGJAMRU-UHFFFAOYSA-N
DMG9U8D	IU	2-[[3-[3-(2H-tetrazol-5-yl)propoxy]phenoxy]methyl]quinoline
DMG9U8D	CA	CAS 107813-63-8
DMG9U8D	DE	Asthma

DMKLPMW	ID	DMKLPMW
DMKLPMW	DN	RG-7166
DMKLPMW	HS	Discontinued in Phase 1
DMKLPMW	SN	Triple reuptake inhibitors (depression), Roche; Serotonin/norephineprine/dopamine reuptake inhibitors (depression), Roche
DMKLPMW	CP	Roche Holding AG
DMKLPMW	DE	Major depressive disorder

DMGLRK0	ID	DMGLRK0
DMGLRK0	DN	RG-7167
DMGLRK0	HS	Discontinued in Phase 1
DMGLRK0	SN	CIF; R-7167; CIF (solid tumors), Chugai/Roche; MEK inhibitor (oral, solid tumors), Roche/Chugai
DMGLRK0	CP	Chugai Pharmaceutical Co Ltd
DMGLRK0	DE	Solid tumour/cancer

DM12VHC	ID	DM12VHC
DM12VHC	DN	RG-7185
DM12VHC	HS	Discontinued in Phase 1
DM12VHC	SN	CRTH2 antagonist (asthma), Roche
DM12VHC	CP	Roche Holding AG
DM12VHC	DE	Asthma

DMDPWCM	ID	DMDPWCM
DMDPWCM	DN	RG-7236
DMDPWCM	HS	Discontinued in Phase 1
DMDPWCM	SN	RG7236
DMDPWCM	CP	Hoffmann-La Roche
DMDPWCM	DE	Cardiovascular disease

DM0LXBW	ID	DM0LXBW
DM0LXBW	DN	RG-7256
DM0LXBW	HS	Discontinued in Phase 1
DM0LXBW	SN	B-raf inhibitor (melanoma), Roche/Plexxikon
DM0LXBW	CP	Roche Holding AG
DM0LXBW	DE	Melanoma

DMXMQAT	ID	DMXMQAT
DMXMQAT	DN	RG-7273
DMXMQAT	HS	Discontinued in Phase 1
DMXMQAT	SN	RG 7273; RG7273
DMXMQAT	CP	Hoffmann-La Roche
DMXMQAT	DE	Lipid metabolism disorder

DMUR6OV	ID	DMUR6OV
DMUR6OV	DN	RG-7356
DMUR6OV	HS	Discontinued in Phase 1
DMUR6OV	SN	RO-5429083; AR-001 series, ARIUS; ARH460-16-2; ChARH460-16-2; H460-16-2; MuARH460-16-2; Anti-CD44 antibody (cancer), ARIUS; Anti-CD44 mAb (cancer), Roche; Chimeric ARH460-16-2-IgG1; Chimeric ARH460-16-2-IgG2; (ch)ARH460-16-2-IgG1; (ch)ARH460-16-2-IgG2
DMUR6OV	CP	ARIUS Research Inc
DMUR6OV	DT	Antibody
DMUR6OV	DE	Haematological malignancy

DMXRHDL	ID	DMXRHDL
DMXRHDL	DN	RG7418
DMXRHDL	HS	Discontinued in Phase 1
DMXRHDL	SN	BI204
DMXRHDL	CP	BioInvent; Genentech
DMXRHDL	DE	Arteriosclerosis

DMSUV3B	ID	DMSUV3B
DMSUV3B	DN	RG-7432
DMSUV3B	HS	Discontinued in Phase 1
DMSUV3B	CP	Roche Holding AG
DMSUV3B	DE	Hepatitis C virus infection

DMW87YE	ID	DMW87YE
DMW87YE	DN	RG7458
DMW87YE	HS	Discontinued in Phase 1
DMW87YE	CP	Genentech
DMW87YE	DT	Antibody
DMW87YE	DE	Ovarian cancer

DMXJAFC	ID	DMXJAFC
DMXJAFC	DN	RG7602
DMXJAFC	HS	Discontinued in Phase 1
DMXJAFC	CP	Array BioPharma; Roche
DMXJAFC	DE	Lymphoma

DMQAK6T	ID	DMQAK6T
DMQAK6T	DN	Rhodamine-123
DMQAK6T	HS	Discontinued in Phase 1
DMQAK6T	SN	RH 123; Rhodamine 123; Rh-123, Huntington; Rhodamine-123 (intravenous infusion); Rhodamine-123 (intravenous infusion), Huntington Medical Research Institutes
DMQAK6T	CP	Huntington Medical Research Institutes
DMQAK6T	DT	Small molecular drug
DMQAK6T	PC	9929799
DMQAK6T	MW	380.8
DMQAK6T	FM	C21H17ClN2O3
DMQAK6T	IC	InChI=1S/C21H16N2O3.ClH/c1-25-21(24)15-5-3-2-4-14(15)20-16-8-6-12(22)10-18(16)26-19-11-13(23)7-9-17(19)20;/h2-11,22H,23H2,1H3;1H
DMQAK6T	CS	COC(=O)C1=CC=CC=C1C2=C3C=CC(=N)C=C3OC4=C2C=CC(=C4)N.Cl
DMQAK6T	IK	MYFATKRONKHHQL-UHFFFAOYSA-N
DMQAK6T	IU	methyl 2-(3-amino-6-iminoxanthen-9-yl)benzoate;hydrochloride
DMQAK6T	CA	CAS 62669-70-9
DMQAK6T	CB	CHEBI:8828
DMQAK6T	DE	Prostate cancer

DMLQD6F	ID	DMLQD6F
DMLQD6F	DN	RIG-200
DMLQD6F	HS	Discontinued in Phase 1
DMLQD6F	SN	1,3,4,6-Tetra-O-acetyl-2-[2(S)-(acetylamino)-3-methyl-3-(nitrososulfanyl)butyramido]-2-deoxy-beta-D-glucopyranose
DMLQD6F	DT	Small molecular drug
DMLQD6F	PC	6918441
DMLQD6F	MW	549.6
DMLQD6F	FM	C21H31N3O12S
DMLQD6F	IC	InChI=1S/C21H31N3O12S/c1-9(25)22-18(21(6,7)37-24-31)19(30)23-15-17(34-12(4)28)16(33-11(3)27)14(8-32-10(2)26)36-20(15)35-13(5)29/h14-18,20H,8H2,1-7H3,(H,22,25)(H,23,30)/t14-,15-,16-,17-,18+,20-/m1/s1
DMLQD6F	CS	CC(=O)N[C@@H](C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC(=O)C)COC(=O)C)OC(=O)C)OC(=O)C)C(C)(C)SN=O
DMLQD6F	IK	VISYVRBZWPNIOD-GFJCLWMYSA-N
DMLQD6F	IU	[(2R,3S,4R,5R,6S)-5-[[(2S)-2-acetamido-3-methyl-3-nitrososulfanylbutanoyl]amino]-3,4,6-triacetyloxyoxan-2-yl]methyl acetate
DMLQD6F	DE	Hypertension

DMBQZTO	ID	DMBQZTO
DMBQZTO	DN	Rilmakalim
DMBQZTO	HS	Discontinued in Phase 1
DMBQZTO	SN	Hoe-234
DMBQZTO	CP	Hoechst AG
DMBQZTO	DT	Small molecular drug
DMBQZTO	PC	65966
DMBQZTO	MW	401.5
DMBQZTO	FM	C21H23NO5S
DMBQZTO	IC	InChI=1S/C21H23NO5S/c1-21(2)20(24)19(22-12-6-9-18(22)23)16-13-15(10-11-17(16)27-21)28(25,26)14-7-4-3-5-8-14/h3-5,7-8,10-11,13,19-20,24H,6,9,12H2,1-2H3/t19-,20+/m1/s1
DMBQZTO	CS	CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)S(=O)(=O)C3=CC=CC=C3)N4CCCC4=O)O)C
DMBQZTO	IK	LKAQWOWWTKFLNX-UXHICEINSA-N
DMBQZTO	IU	1-[(3S,4R)-6-(benzenesulfonyl)-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]pyrrolidin-2-one
DMBQZTO	CA	CAS 132014-21-2
DMBQZTO	DE	Chronic obstructive pulmonary disease

DMOVZDY	ID	DMOVZDY
DMOVZDY	DN	RO-16-8714
DMOVZDY	HS	Discontinued in Phase 1
DMOVZDY	SN	P-[(R)-3-[Bis-[(R)-beta-hydroxyphenethyl]amino]butyl]benzamide
DMOVZDY	DT	Small molecular drug
DMOVZDY	PC	146200
DMOVZDY	MW	432.6
DMOVZDY	FM	C27H32N2O3
DMOVZDY	IC	InChI=1S/C27H32N2O3/c1-20(12-13-21-14-16-24(17-15-21)27(28)32)29(18-25(30)22-8-4-2-5-9-22)19-26(31)23-10-6-3-7-11-23/h2-11,14-17,20,25-26,30-31H,12-13,18-19H2,1H3,(H2,28,32)
DMOVZDY	CS	CC(CCC1=CC=C(C=C1)C(=O)N)N(CC(C2=CC=CC=C2)O)CC(C3=CC=CC=C3)O
DMOVZDY	IK	OPPQEWZOPDBGAS-UHFFFAOYSA-N
DMOVZDY	IU	4-[3-[bis(2-hydroxy-2-phenylethyl)amino]butyl]benzamide
DMOVZDY	CA	CAS 90505-66-1
DMOVZDY	DE	Diabetic complication

DMAJDPN	ID	DMAJDPN
DMAJDPN	DN	Ro-31-6930
DMAJDPN	HS	Discontinued in Phase 1
DMAJDPN	SN	Ro-31-6930; 120280-37-7; 2H-1-Benzopyran-6-carbonitrile,2,2-dimethyl-4-(1-oxido-2-pyridinyl)-; Ro 31-6930; ACMC-20motq; AC1MI1CT; CHEMBL97196; SCHEMBL6369348; CTK4B1782; DTXSID70152787; PQVILGHAVGQHRP-UHFFFAOYSA-N; 2-(6-cyano-2,2-dimethyl-2H1-benzopyran-4-yl)pyridine N-oxide; 2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)chromene-6-carbonitrile; 2-(6-cyano-2,2-dimethyl-2H-1-benzopyran-4-yl)pyridine 1-oxide; 2-(6-cyano-2,2-dimethyl-2H-1-benzopyran-4-yl)pyridine N-oxide
DMAJDPN	CP	Roche Holding AG
DMAJDPN	DT	Small molecular drug
DMAJDPN	PC	3036546
DMAJDPN	MW	278.3
DMAJDPN	FM	C17H14N2O2
DMAJDPN	IC	InChI=1S/C17H14N2O2/c1-17(2)10-14(15-5-3-4-8-19(15)20)13-9-12(11-18)6-7-16(13)21-17/h3-10H,1-2H3
DMAJDPN	CS	CC1(C=C(C2=C(O1)C=CC(=C2)C#N)C3=CC=CC=[N+]3[O-])C
DMAJDPN	IK	PQVILGHAVGQHRP-UHFFFAOYSA-N
DMAJDPN	IU	2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)chromene-6-carbonitrile
DMAJDPN	CA	CAS 120280-37-7
DMAJDPN	DE	Hypertension

DMOX8AD	ID	DMOX8AD
DMOX8AD	DN	RO-48-8684
DMOX8AD	HS	Discontinued in Phase 1
DMOX8AD	SN	3-[5-(Dipropylaminomethyl)oxazol-2-yl]-8-fluoro-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMOX8AD	PC	9866317
DMOX8AD	MW	411.5
DMOX8AD	FM	C22H26FN5O2
DMOX8AD	IC	InChI=1S/C22H26FN5O2/c1-4-8-27(9-5-2)12-16-11-24-21(30-16)20-19-13-26(3)22(29)17-10-15(23)6-7-18(17)28(19)14-25-20/h6-7,10-11,14H,4-5,8-9,12-13H2,1-3H3
DMOX8AD	CS	CCCN(CCC)CC1=CN=C(O1)C2=C3CN(C(=O)C4=C(N3C=N2)C=CC(=C4)F)C
DMOX8AD	IK	YKKLHEHNUYCLQQ-UHFFFAOYSA-N
DMOX8AD	IU	3-[5-[(dipropylamino)methyl]-1,3-oxazol-2-yl]-8-fluoro-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMOX8AD	DE	Anxiety disorder

DMMF0OP	ID	DMMF0OP
DMMF0OP	DN	RO-4987655
DMMF0OP	HS	Discontinued in Phase 1
DMMF0OP	SN	CH-4987655; RO-04927350; MEK inhibitors (solid tumor), Roche
DMMF0OP	CP	F Hoffmann-La Roche Ltd
DMMF0OP	DT	Small molecular drug
DMMF0OP	PC	11548630
DMMF0OP	MW	565.3
DMMF0OP	FM	C20H19F3IN3O5
DMMF0OP	IC	InChI=1S/C20H19F3IN3O5/c21-14-9-12(24)3-4-15(14)25-19-13(20(30)26-31-7-5-28)8-11(17(22)18(19)23)10-27-16(29)2-1-6-32-27/h3-4,8-9,25,28H,1-2,5-7,10H2,(H,26,30)
DMMF0OP	CS	C1CC(=O)N(OC1)CC2=CC(=C(C(=C2F)F)NC3=C(C=C(C=C3)I)F)C(=O)NOCCO
DMMF0OP	IK	FIMYFEGKMOCQKT-UHFFFAOYSA-N
DMMF0OP	IU	3,4-difluoro-2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide
DMMF0OP	CA	CAS 874101-00-5
DMMF0OP	DE	Solid tumour/cancer

DMP0YNU	ID	DMP0YNU
DMP0YNU	DN	RO7040547
DMP0YNU	HS	Discontinued in Phase 1
DMP0YNU	SN	BITS7201A; RG7990
DMP0YNU	CP	Roche
DMP0YNU	DT	Antibody
DMP0YNU	DE	Asthma

DMMK42O	ID	DMMK42O
DMMK42O	DN	Roquinimex
DMMK42O	HS	Discontinued in Phase 1
DMMK42O	SN	Linomide
DMMK42O	CP	Pharmacia & Upjohn AB
DMMK42O	DT	Small molecular drug
DMMK42O	PC	54676478
DMMK42O	MW	308.3
DMMK42O	FM	C18H16N2O3
DMMK42O	IC	InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3
DMMK42O	CS	CN1C2=CC=CC=C2C(=C(C1=O)C(=O)N(C)C3=CC=CC=C3)O
DMMK42O	IK	SGOOQMRIPALTEL-UHFFFAOYSA-N
DMMK42O	IU	4-hydroxy-N,1-dimethyl-2-oxo-N-phenylquinoline-3-carboxamide
DMMK42O	CA	CAS 84088-42-6
DMMK42O	CB	CHEBI:92056
DMMK42O	DE	Rheumatoid arthritis

DM94R8B	ID	DM94R8B
DM94R8B	DN	RS-100975
DM94R8B	HS	Discontinued in Phase 1
DM94R8B	SN	RS-97078; Ro-70-0004
DM94R8B	CP	Roche Bioscience
DM94R8B	DT	Small molecular drug
DM94R8B	PC	9872515
DM94R8B	MW	444.4
DM94R8B	FM	C20H24F4N4O3
DM94R8B	IC	InChI=1S/C20H24F4N4O3/c1-14-12-25-19(30)28(18(14)29)6-2-5-26-7-9-27(10-8-26)16-4-3-15(21)11-17(16)31-13-20(22,23)24/h3-4,11-12H,2,5-10,13H2,1H3,(H,25,30)
DM94R8B	CS	CC1=CNC(=O)N(C1=O)CCCN2CCN(CC2)C3=C(C=C(C=C3)F)OCC(F)(F)F
DM94R8B	IK	WEZFJPKJUIGDPS-UHFFFAOYSA-N
DM94R8B	IU	3-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5-methyl-1H-pyrimidine-2,4-dione
DM94R8B	CA	CAS 186386-21-0
DM94R8B	DE	Prostate disease

DM4P5WO	ID	DM4P5WO
DM4P5WO	DN	RS-8891
DM4P5WO	HS	Discontinued in Phase 1
DM4P5WO	CP	Sankyo Co Ltd
DM4P5WO	DE	Hypertension

DMMEAZ2	ID	DMMEAZ2
DMMEAZ2	DN	RU-58841
DMMEAZ2	HS	Discontinued in Phase 1
DMMEAZ2	SN	154992-24-2; RU 58841; RU58841; 4-(3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile; ARBYGDBJECGMGA-UHFFFAOYSA-N; UNII-0D8FJQ0ADW; 0D8FJQ0ADW; CHEMBL9337; 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; AK-64424; 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile; Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)-
DMMEAZ2	DT	Small molecular drug
DMMEAZ2	PC	132981
DMMEAZ2	MW	369.34
DMMEAZ2	FM	C17H18F3N3O3
DMMEAZ2	IC	InChI=1S/C17H18F3N3O3/c1-16(2)14(25)23(15(26)22(16)7-3-4-8-24)12-6-5-11(10-21)13(9-12)17(18,19)20/h5-6,9,24H,3-4,7-8H2,1-2H3
DMMEAZ2	CS	CC1(C(=O)N(C(=O)N1CCCCO)C2=CC(=C(C=C2)C#N)C(F)(F)F)C
DMMEAZ2	IK	ARBYGDBJECGMGA-UHFFFAOYSA-N
DMMEAZ2	IU	4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
DMMEAZ2	CA	CAS 154992-24-2
DMMEAZ2	DE	Acne vulgaris

DMSHYAP	ID	DMSHYAP
DMSHYAP	DN	RUS 3108
DMSHYAP	HS	Discontinued in Phase 1
DMSHYAP	CP	Dr. Reddy's Laboratories
DMSHYAP	DE	Arteriosclerosis

DM6BIHE	ID	DM6BIHE
DM6BIHE	DN	RWJ-56423
DM6BIHE	HS	Discontinued in Phase 1
DM6BIHE	SN	RWJ-56423; CHEMBL256892; CHEMBL124571; (2S,4R)-1-ACETYL-N-[(1S)-4-[(AMINOIMINOMETHYL)AMINO]-1-(2-BENZOTHIAZOLYLCARBONYL)BUTYL]-4-HYDROXY-2-PYRROLIDINECARBOXAMIDE; (2S,4R)-1-acetyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide; AC1NR9Y0; SCHEMBL4314345; GTPL9333; VXDAVYUFYPFGDX-SNPRPXQTSA-N; BDBM50228764; BDBM50131977; DB02812; (2S)-6; (4R)-1-acetyl-N-[(1S)-1-(1,3-benzothiazol-2-ylcarbonyl)-4-carbamimidamidobutyl]-4-hydroxy-L-prolinamide
DM6BIHE	DT	Small molecular drug
DM6BIHE	PC	5287596
DM6BIHE	MW	446.5
DM6BIHE	FM	C20H26N6O4S
DM6BIHE	IC	InChI=1S/C20H26N6O4S/c1-11(27)26-10-12(28)9-15(26)18(30)24-14(6-4-8-23-20(21)22)17(29)19-25-13-5-2-3-7-16(13)31-19/h2-3,5,7,12,14-15,28H,4,6,8-10H2,1H3,(H,24,30)(H4,21,22,23)/t12-,14+,15+/m1/s1
DM6BIHE	CS	CC(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)C2=NC3=CC=CC=C3S2)O
DM6BIHE	IK	VXDAVYUFYPFGDX-SNPRPXQTSA-N
DM6BIHE	IU	(2S,4R)-1-acetyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide
DM6BIHE	DE	Asthma

DMRXB8F	ID	DMRXB8F
DMRXB8F	DN	S-1746
DMRXB8F	HS	Discontinued in Phase 1
DMRXB8F	CP	Shionogi & Co Ltd
DMRXB8F	DE	Cerebrovascular ischaemia

DMX59E8	ID	DMX59E8
DMX59E8	DN	S-18326
DMX59E8	HS	Discontinued in Phase 1
DMX59E8	SN	Acetyl-D-phenylalanyl-N-(cyclopentyl)-glycyl-L-1-boroarginine
DMX59E8	PC	9891654
DMX59E8	MW	488.4
DMX59E8	FM	C23H37BN6O5
DMX59E8	IC	InChI=1S/C23H37BN6O5/c1-16(31)28-19(14-17-8-3-2-4-9-17)22(33)30(18-10-5-6-11-18)15-21(32)29-20(24(34)35)12-7-13-27-23(25)26/h2-4,8-9,18-20,34-35H,5-7,10-15H2,1H3,(H,28,31)(H,29,32)(H4,25,26,27)/t19-,20+/m1/s1
DMX59E8	CS	B([C@H](CCCN=C(N)N)NC(=O)CN(C1CCCC1)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DMX59E8	IK	XSHCQGJMSFRKKN-UXHICEINSA-N
DMX59E8	IU	[(1R)-1-[[2-[[(2R)-2-acetamido-3-phenylpropanoyl]-cyclopentylamino]acetyl]amino]-4-(diaminomethylideneamino)butyl]boronic acid
DMX59E8	DE	Myocardial infarction

DML6A8X	ID	DML6A8X
DML6A8X	DN	S-18327
DML6A8X	HS	Discontinued in Phase 1
DML6A8X	CP	Servier
DML6A8X	PC	9953269
DML6A8X	MW	408.5
DML6A8X	FM	C23H25FN4O2
DML6A8X	IC	InChI=1S/C23H25FN4O2/c24-18-6-7-20-21(16-18)30-25-22(20)17-8-10-26(11-9-17)12-13-27-14-15-28(23(27)29)19-4-2-1-3-5-19/h1-7,16-17H,8-15H2
DML6A8X	CS	C1CN(CCC1C2=NOC3=C2C=CC(=C3)F)CCN4CCN(C4=O)C5=CC=CC=C5
DML6A8X	IK	ULCAXFRFGIKHRG-UHFFFAOYSA-N
DML6A8X	IU	1-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3-phenylimidazolidin-2-one
DML6A8X	CA	CAS 200398-40-9
DML6A8X	DE	Psychotic disorder

DM80P4U	ID	DM80P4U
DM80P4U	DN	S-234462
DM80P4U	HS	Discontinued in Phase 1
DM80P4U	CP	Shionogi & Co Ltd
DM80P4U	DE	Obesity

DM6SON1	ID	DM6SON1
DM6SON1	DN	S-23906-1
DM6SON1	HS	Discontinued in Phase 1
DM6SON1	SN	S-23906; Rac-cis-1,2-Bis(acetoxy)-6-methoxy-3,3,14-trimethyl-2,3,7,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridin-7-one
DM6SON1	PC	20684516
DM6SON1	MW	489.5
DM6SON1	FM	C28H27NO7
DM6SON1	IC	InChI=1S/C28H27NO7/c1-14(30)34-26-23-21(36-28(3,4)27(26)35-15(2)31)13-20(33-6)22-24(23)29(5)19-12-17-10-8-7-9-16(17)11-18(19)25(22)32/h7-13,26-27H,1-6H3/t26-,27-/m0/s1
DM6SON1	CS	CC(=O)O[C@@H]1[C@@H](C(OC2=CC(=C3C(=C12)N(C4=CC5=CC=CC=C5C=C4C3=O)C)OC)(C)C)OC(=O)C
DM6SON1	IK	OASYWNFOHKQIGI-SVBPBHIXSA-N
DM6SON1	IU	[(5S,6S)-6-acetyloxy-11-methoxy-2,7,7-trimethyl-13-oxo-8-oxa-2-azapentacyclo[12.8.0.03,12.04,9.016,21]docosa-1(22),3,9,11,14,16,18,20-octaen-5-yl] acetate
DM6SON1	DE	Solid tumour/cancer

DM1R8Z7	ID	DM1R8Z7
DM1R8Z7	DN	S-33138
DM1R8Z7	HS	Discontinued in Phase 1
DM1R8Z7	SN	N-[4-[2-[(3aS,9bR)-8-Cyano-1,2,3,3a,4,9b-hexahydro[1]benzopyrano[3,4-c]pyrrol-2-yl]ethyl]phenyl]acetamide
DM1R8Z7	DT	Small molecular drug
DM1R8Z7	PC	9841864
DM1R8Z7	MW	361.4
DM1R8Z7	FM	C22H23N3O2
DM1R8Z7	IC	InChI=1S/C22H23N3O2/c1-15(26)24-19-5-2-16(3-6-19)8-9-25-12-18-14-27-22-7-4-17(11-23)10-20(22)21(18)13-25/h2-7,10,18,21H,8-9,12-14H2,1H3,(H,24,26)/t18-,21+/m0/s1
DM1R8Z7	CS	CC(=O)NC1=CC=C(C=C1)CCN2C[C@H]3COC4=C([C@@H]3C2)C=C(C=C4)C#N
DM1R8Z7	IK	ZDZWIQDJFWTDAM-GHTZIAJQSA-N
DM1R8Z7	IU	N-[4-[2-[(3aS,9bR)-8-cyano-3,3a,4,9b-tetrahydro-1H-chromeno[3,4-c]pyrrol-2-yl]ethyl]phenyl]acetamide
DM1R8Z7	DE	Psychotic disorder

DMZYRI3	ID	DMZYRI3
DMZYRI3	DN	S-3536
DMZYRI3	HS	Discontinued in Phase 1
DMZYRI3	CP	Shionogi & Co Ltd
DMZYRI3	PC	11040978
DMZYRI3	MW	159.18
DMZYRI3	FM	C10H9NO
DMZYRI3	IC	InChI=1S/C10H9NO/c1-12-10-3-2-9-7-11-5-4-8(9)6-10/h2-7H,1H3
DMZYRI3	CS	COC1=CC2=C(C=C1)C=NC=C2
DMZYRI3	IK	XZNUJESLPUNSNO-UHFFFAOYSA-N
DMZYRI3	IU	6-methoxyisoquinoline
DMZYRI3	CA	CAS 52986-70-6
DMZYRI3	DE	Osteoarthritis

DMCEOAJ	ID	DMCEOAJ
DMCEOAJ	DN	Sabcomeline
DMCEOAJ	HS	Discontinued in Phase 1
DMCEOAJ	SN	Sabcomeline; 159912-53-5; UNII-P8P92V596C; SB-202026; CHEMBL134641; P8P92V596C; Sabcomeline [INN:BAN]; SCHEMBL3838658; sb202026; CHEBI:134846; BDBM50061705; AKOS022181195; AKOS006331527; AN-31122; 912S535; (3Z,3R)-N-methoxyquinuclidine-3-carboximidoyl cyanide
DMCEOAJ	DT	Small molecular drug
DMCEOAJ	PC	9577995
DMCEOAJ	MW	193.25
DMCEOAJ	FM	C10H15N3O
DMCEOAJ	IC	InChI=1S/C10H15N3O/c1-14-12-10(6-11)9-7-13-4-2-8(9)3-5-13/h8-9H,2-5,7H2,1H3/b12-10+/t9-/m0/s1
DMCEOAJ	CS	CO/N=C(\\C#N)/[C@H]1CN2CCC1CC2
DMCEOAJ	IK	IQWCBYSUUOFOMF-QTLFRQQHSA-N
DMCEOAJ	IU	(3Z,3R)-N-methoxy-1-azabicyclo[2.2.2]octane-3-carboximidoyl cyanide
DMCEOAJ	CA	CAS 159912-53-5
DMCEOAJ	CB	CHEBI:134846

DMIZ7Q4	ID	DMIZ7Q4
DMIZ7Q4	DN	SAR101099
DMIZ7Q4	HS	Discontinued in Phase 1
DMIZ7Q4	CP	Sanofi
DMIZ7Q4	DE	Diabetic nephropathy

DM7OR48	ID	DM7OR48
DM7OR48	DN	SAR-152954
DM7OR48	HS	Discontinued in Phase 1
DM7OR48	SN	Histamine H3 antagonist (sleep disorder), Sanofi-aventis
DM7OR48	CP	Sanofi
DM7OR48	DE	Sleep-wake disorder

DMNH8XU	ID	DMNH8XU
DMNH8XU	DN	SB 235699
DMNH8XU	HS	Discontinued in Phase 1
DMNH8XU	SN	4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-
DMNH8XU	DT	Small molecular drug
DMNH8XU	PC	9797240
DMNH8XU	MW	322.4
DMNH8XU	FM	C19H19FN4
DMNH8XU	IC	InChI=1S/C19H19FN4/c20-16-3-1-14(2-4-16)18-19(15-5-9-21-10-6-15)24(13-23-18)17-7-11-22-12-8-17/h1-6,9-10,13,17,22H,7-8,11-12H2
DMNH8XU	CS	C1CNCCC1N2C=NC(=C2C3=CC=NC=C3)C4=CC=C(C=C4)F
DMNH8XU	IK	QBACMJFLMUCPNA-UHFFFAOYSA-N
DMNH8XU	IU	4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]pyridine
DMNH8XU	CA	CAS 180869-32-3
DMNH8XU	DE	Psoriasis vulgaris

DM2C0LN	ID	DM2C0LN
DM2C0LN	DN	SB 249417
DM2C0LN	HS	Discontinued in Phase 1
DM2C0LN	CP	GlaxoSmithKline
DM2C0LN	DT	Antibody
DM2C0LN	DE	Sepsis

DMGHDTB	ID	DMGHDTB
DMGHDTB	DN	SB 418790
DMGHDTB	HS	Discontinued in Phase 1
DMGHDTB	CP	Asahi Kasei Pharma
DMGHDTB	DE	Type-2 diabetes

DMX7PNY	ID	DMX7PNY
DMX7PNY	DN	SB-234551
DMX7PNY	HS	Discontinued in Phase 1
DMX7PNY	SN	2-[2-[1-Butyl-4-[2-carboxy-3-(6-methoxy-1,3-benzodioxol-5-yl)-1(E)-propenyl]pyrazol-5-yl]-5-methoxyphenoxymethyl]benzoic acid
DMX7PNY	DT	Small molecular drug
DMX7PNY	PC	5311425
DMX7PNY	MW	614.6
DMX7PNY	FM	C34H34N2O9
DMX7PNY	IC	InChI=1S/C34H34N2O9/c1-4-5-12-36-32(27-11-10-25(41-2)16-29(27)43-19-21-8-6-7-9-26(21)34(39)40)24(18-35-36)14-23(33(37)38)13-22-15-30-31(45-20-44-30)17-28(22)42-3/h6-11,14-18H,4-5,12-13,19-20H2,1-3H3,(H,37,38)(H,39,40)/b23-14+
DMX7PNY	CS	CCCCN1C(=C(C=N1)/C=C(\\CC2=CC3=C(C=C2OC)OCO3)/C(=O)O)C4=C(C=C(C=C4)OC)OCC5=CC=CC=C5C(=O)O
DMX7PNY	IK	MCHCGWZNXSZKJY-OEAKJJBVSA-N
DMX7PNY	IU	2-[[2-[2-butyl-4-[(E)-2-carboxy-3-(6-methoxy-1,3-benzodioxol-5-yl)prop-1-enyl]pyrazol-3-yl]-5-methoxyphenoxy]methyl]benzoic acid
DMX7PNY	DE	Nerve injury

DMKSFL0	ID	DMKSFL0
DMKSFL0	DN	SB-242235
DMKSFL0	HS	Discontinued in Phase 1
DMKSFL0	SN	193746-75-7; SB-242235; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03
DMKSFL0	DT	Small molecular drug
DMKSFL0	PC	9863367
DMKSFL0	MW	353.4
DMKSFL0	FM	C19H20FN5O
DMKSFL0	IC	InChI=1S/C19H20FN5O/c1-26-19-22-11-8-16(24-19)18-17(13-2-4-14(20)5-3-13)23-12-25(18)15-6-9-21-10-7-15/h2-5,8,11-12,15,21H,6-7,9-10H2,1H3
DMKSFL0	CS	COC1=NC=CC(=N1)C2=C(N=CN2C3CCNCC3)C4=CC=C(C=C4)F
DMKSFL0	IK	PDTYLGXVBIWRIM-UHFFFAOYSA-N
DMKSFL0	IU	4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine
DMKSFL0	DE	Arthritis

DMOVLDT	ID	DMOVLDT
DMOVLDT	DN	SB-247853
DMOVLDT	HS	Discontinued in Phase 1
DMOVLDT	SN	5-Methyl-N-[6-(2-pyridylmethoxy)pyridin-3-yl]-6-(trifluoromethyl)indoline-1-carboxamide
DMOVLDT	PC	9888804
DMOVLDT	MW	428.4
DMOVLDT	FM	C22H19F3N4O2
DMOVLDT	IC	InChI=1S/C22H19F3N4O2/c1-14-10-15-7-9-29(19(15)11-18(14)22(23,24)25)21(30)28-16-5-6-20(27-12-16)31-13-17-4-2-3-8-26-17/h2-6,8,10-12H,7,9,13H2,1H3,(H,28,30)
DMOVLDT	CS	CC1=CC2=C(C=C1C(F)(F)F)N(CC2)C(=O)NC3=CN=C(C=C3)OCC4=CC=CC=N4
DMOVLDT	IK	KLAHZRONIHBPPB-UHFFFAOYSA-N
DMOVLDT	IU	5-methyl-N-[6-(pyridin-2-ylmethoxy)pyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide
DMOVLDT	DE	Anxiety disorder

DMIBFAV	ID	DMIBFAV
DMIBFAV	DN	SB-267268
DMIBFAV	HS	Discontinued in Phase 1
DMIBFAV	SN	2-[3-Oxo-8-[3-(2-pyridylamino)propoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4(S)-yl]acetic acid
DMIBFAV	DT	Small molecular drug
DMIBFAV	PC	9955461
DMIBFAV	MW	451.4
DMIBFAV	FM	C22H24F3N3O4
DMIBFAV	IC	InChI=1S/C22H24F3N3O4/c23-22(24,25)14-28-13-17-11-18(32-9-3-8-27-19-4-1-2-7-26-19)6-5-15(17)10-16(21(28)31)12-20(29)30/h1-2,4-7,11,16H,3,8-10,12-14H2,(H,26,27)(H,29,30)/t16-/m0/s1
DMIBFAV	CS	C1[C@H](C(=O)N(CC2=C1C=CC(=C2)OCCCNC3=CC=CC=N3)CC(F)(F)F)CC(=O)O
DMIBFAV	IK	PVDGZHKJXXVONO-INIZCTEOSA-N
DMIBFAV	IU	2-[(4S)-3-oxo-8-[3-(pyridin-2-ylamino)propoxy]-2-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-2-benzazepin-4-yl]acetic acid
DMIBFAV	DE	Osteoporosis

DMV7M1H	ID	DMV7M1H
DMV7M1H	DN	SB-273005
DMV7M1H	HS	Discontinued in Phase 1
DMV7M1H	SN	SB-267597
DMV7M1H	CP	SmithKline Beecham plc
DMV7M1H	PC	9868426
DMV7M1H	MW	451.4
DMV7M1H	FM	C22H24F3N3O4
DMV7M1H	IC	InChI=1S/C22H24F3N3O4/c1-26-19-4-2-3-17(27-19)7-8-32-18-6-5-14-9-15(11-20(29)30)21(31)28(12-16(14)10-18)13-22(23,24)25/h2-6,10,15H,7-9,11-13H2,1H3,(H,26,27)(H,29,30)/t15-/m0/s1
DMV7M1H	CS	CNC1=CC=CC(=N1)CCOC2=CC3=C(C[C@H](C(=O)N(C3)CC(F)(F)F)CC(=O)O)C=C2
DMV7M1H	IK	KSSPHFGIOASRDE-HNNXBMFYSA-N
DMV7M1H	IU	2-[(4S)-8-[2-[6-(methylamino)pyridin-2-yl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-2-benzazepin-4-yl]acetic acid
DMV7M1H	CA	CAS 205678-31-5
DMV7M1H	DE	Osteoporosis

DMYTAJW	ID	DMYTAJW
DMYTAJW	DN	SB-281832
DMYTAJW	HS	Discontinued in Phase 1
DMYTAJW	CP	GlaxoSmithKline plc
DMYTAJW	DE	Asthma

DM57HZW	ID	DM57HZW
DM57HZW	DN	SB-332235
DM57HZW	HS	Discontinued in Phase 1
DM57HZW	SN	1-(4-Chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; 276702-15-9; SB 332235; UNII-5HLP8UVL8M; 5HLP8UVL8M; CHEMBL3819292; WTLRWOHEKQGKDS-UHFFFAOYSA-N; SCHEMBL1535901; sb332235; MolPort-042-624-550; ZINC3990011; BDBM50182254; 1-(4-chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; AKOS027470251; N-(4-Chloro-2hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) urea; n-(4-chloro-2-hydroxy-3-aminosulfonylphenyl)-n'-(2,3-dichlorophenyl)urea; N-(4-Chloro-2-hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) Urea; N-(3-(aminosulfonyl)-4-chloro-2-hydroxyphenyl)-N'-(2,3-dichlorophenyl) urea
DM57HZW	CP	GlaxoSmithKline
DM57HZW	DT	Small molecular drug
DM57HZW	PC	9887803
DM57HZW	MW	410.7
DM57HZW	FM	C13H10Cl3N3O4S
DM57HZW	IC	InChI=1S/C13H10Cl3N3O4S/c14-6-2-1-3-8(10(6)16)18-13(21)19-9-5-4-7(15)12(11(9)20)24(17,22)23/h1-5,20H,(H2,17,22,23)(H2,18,19,21)
DM57HZW	CS	C1=CC(=C(C(=C1)Cl)Cl)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)N)O
DM57HZW	IK	WTLRWOHEKQGKDS-UHFFFAOYSA-N
DM57HZW	IU	1-(4-chloro-2-hydroxy-3-sulfamoylphenyl)-3-(2,3-dichlorophenyl)urea
DM57HZW	CA	CAS 276702-15-9
DM57HZW	DE	Chronic obstructive pulmonary disease

DM92BXN	ID	DM92BXN
DM92BXN	DN	SB-435495
DM92BXN	HS	Discontinued in Phase 1
DM92BXN	CP	GlaxoSmithKline plc
DM92BXN	PC	10417440
DM92BXN	MW	720.8
DM92BXN	FM	C38H40F4N6O2S
DM92BXN	IC	InChI=1S/C38H40F4N6O2S/c1-4-46(5-2)18-19-47(23-27-6-10-30(11-7-27)31-12-14-33(15-13-31)38(40,41)42)35(49)25-48-24-32(20-29-21-43-45(3)22-29)36(50)44-37(48)51-26-28-8-16-34(39)17-9-28/h6-17,21-22,24H,4-5,18-20,23,25-26H2,1-3H3
DM92BXN	CS	CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C
DM92BXN	IK	VGIQUSQBXZXBGW-UHFFFAOYSA-N
DM92BXN	IU	N-[2-(diethylamino)ethyl]-2-[2-[(4-fluorophenyl)methylsulfanyl]-5-[(1-methylpyrazol-4-yl)methyl]-4-oxopyrimidin-1-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
DM92BXN	CA	CAS 304694-39-1
DM92BXN	DE	Arteriosclerosis

DMFC19E	ID	DMFC19E
DMFC19E	DN	SC-52012
DMFC19E	HS	Discontinued in Phase 1
DMFC19E	SN	N-[5-(4-Amidinophenyl)-1-oxopentyl]-L-aspartyl-L-phenylalanine
DMFC19E	DT	Small molecular drug
DMFC19E	PC	9805266
DMFC19E	MW	482.5
DMFC19E	FM	C25H30N4O6
DMFC19E	IC	InChI=1S/C25H30N4O6/c26-23(27)18-12-10-16(11-13-18)6-4-5-9-21(30)28-19(15-22(31)32)24(33)29-20(25(34)35)14-17-7-2-1-3-8-17/h1-3,7-8,10-13,19-20H,4-6,9,14-15H2,(H3,26,27)(H,28,30)(H,29,33)(H,31,32)(H,34,35)/t19-,20-/m0/s1
DMFC19E	CS	C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCC2=CC=C(C=C2)C(=N)N
DMFC19E	IK	VUUBSMRWDWDDPT-PMACEKPBSA-N
DMFC19E	IU	(3S)-3-[5-(4-carbamimidoylphenyl)pentanoylamino]-4-[[(1S)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid
DMFC19E	DE	Thrombosis

DMIVRWS	ID	DMIVRWS
DMIVRWS	DN	SC-57666
DMIVRWS	HS	Discontinued in Phase 1
DMIVRWS	SN	SC-57666; CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene
DMIVRWS	DT	Small molecular drug
DMIVRWS	PC	443373
DMIVRWS	MW	316.4
DMIVRWS	FM	C18H17FO2S
DMIVRWS	IC	InChI=1S/C18H17FO2S/c1-22(20,21)16-11-7-14(8-12-16)18-4-2-3-17(18)13-5-9-15(19)10-6-13/h5-12H,2-4H2,1H3
DMIVRWS	CS	CS(=O)(=O)C1=CC=C(C=C1)C2=C(CCC2)C3=CC=C(C=C3)F
DMIVRWS	IK	GJGZQTGPOKPFES-UHFFFAOYSA-N
DMIVRWS	IU	1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene
DMIVRWS	CB	CHEBI:8982
DMIVRWS	DE	Rheumatoid arthritis

DM92E0W	ID	DM92E0W
DM92E0W	DN	SCH-211803
DM92E0W	HS	Discontinued in Phase 1
DM92E0W	SN	SCH-211803; UNII-61GSP3D46U; CHEMBL12098; 61GSP3D46U; Sch211803; SCHEMBL12124213; ZINC3994912; BDBM50111346; L001654; (2-Amino-3-methylphenyl)(4-((4-((3-chlorophenyl)sulfonyl)phenyl)methyl)(1,4'-bipiperidin)-1'-yl)methanone; Piperidine, 1-(1-(3-methyl-2-aminophenyl)carbonylpiperidin-4-yl)-4-((3-chlorophenypsulphonylphenyl-4)methyl-); (2-Amino-3-methyl-phenyl)-{4-[4-(3-chloro-benzenesulfonyl)-benzyl]-[1,4'']bipiperidinyl-1''-yl}-methanone; Methanone, (2-amino-3-methylphenyl)(4-((4-((3-chlorophenyl)sulfonyl)phenyl)methyl
DM92E0W	DT	Small molecular drug
DM92E0W	PC	9894173
DM92E0W	MW	566.2
DM92E0W	FM	C31H36ClN3O3S
DM92E0W	IC	InChI=1S/C31H36ClN3O3S/c1-22-4-2-7-29(30(22)33)31(36)35-18-14-26(15-19-35)34-16-12-24(13-17-34)20-23-8-10-27(11-9-23)39(37,38)28-6-3-5-25(32)21-28/h2-11,21,24,26H,12-20,33H2,1H3
DM92E0W	CS	CC1=C(C(=CC=C1)C(=O)N2CCC(CC2)N3CCC(CC3)CC4=CC=C(C=C4)S(=O)(=O)C5=CC(=CC=C5)Cl)N
DM92E0W	IK	VMJKUCKTXMESQR-UHFFFAOYSA-N
DM92E0W	IU	(2-amino-3-methylphenyl)-[4-[4-[[4-(3-chlorophenyl)sulfonylphenyl]methyl]piperidin-1-yl]piperidin-1-yl]methanone
DM92E0W	CA	CAS 331765-50-5
DM92E0W	DE	Parkinson disease

DMK40VO	ID	DMK40VO
DMK40VO	DN	SCH-351591
DMK40VO	HS	Discontinued in Phase 1
DMK40VO	SN	SCH-351591; SCH 351591; UNII-G6EF7V146S; CHEMBL250546; G6EF7V146S; CHEBI:77774; N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide; 444659-43-2; N-(3,5-dichloro-1-oxidopyridin-4-yl)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide; SCH351591; SCHEMBL157018; DTXSID8044125; NOCAS_44125; BDBM50219270; D 4396; 8-methoxy-2-trifluoromethyl-quinoline-5-carboxylic acid (3,5-dichloro-1-oxy-pyridin-4-yl)-amide; 5-Quinolinecarboxamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-     (
DMK40VO	DT	Small molecular drug
DMK40VO	PC	9802841
DMK40VO	MW	432.2
DMK40VO	FM	C17H10Cl2F3N3O3
DMK40VO	IC	InChI=1S/C17H10Cl2F3N3O3/c1-28-12-4-2-9(8-3-5-13(17(20,21)22)23-14(8)12)16(26)24-15-10(18)6-25(27)7-11(15)19/h2-7,27H,1H3
DMK40VO	CS	COC1=C2C(=C(C=C1)C(=O)N=C3C(=CN(C=C3Cl)O)Cl)C=CC(=N2)C(F)(F)F
DMK40VO	IK	NPGREARFJMFTDF-UHFFFAOYSA-N
DMK40VO	IU	N-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide
DMK40VO	CA	CAS 444659-43-2
DMK40VO	CB	CHEBI:77774
DMK40VO	DE	Chronic obstructive pulmonary disease

DM8J9SF	ID	DM8J9SF
DM8J9SF	DN	SCH-C
DM8J9SF	HS	Discontinued in Phase 1
DM8J9SF	SN	Ancriviroc; SCH-C &amp; AOP-RANTES; SCH 351125 &amp; SCH 351125 (non-stereospecific); SCH 351125; CHEMBL78535; 305792-46-5; Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide &amp; Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-pipiperidin)-4-yl)-, O-ethyloxime, N1-oxide; 1'-[(2,4-Dimethyl-1-oxidopyridin-3-yl)carbonyl]-4'-methyl-1,4'-bipiperidine; Methanone,;  Ancriviroc; SCH C; SCH351125; SC-351125; SCH 351125 AOP-RANTES; SCH-351125; SCH-C cpd; AK671/SCH-C; SCH 351125 & AOP-RANTES; SCH-C & PA14; SCH-C AOP-RANTES; SCH-C & AOP-RANTES; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide & AOP-RANTES; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide & PRO 140 (Anti-CCR5 monoclonal antibody); Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide AOP-RANTES; Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide & AOP-RANTES; (2,4-Dimethyl-1-oxy-pyridin-3-yl)-(4'-methyl-[1,4']bipiperidinyl-1'-yl)-methanone; 4-((4-bromophenyl)-(ethoxyimino)methyl)-1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl-1,4'-bipiperidine N-oxide; [3H]ancriviroc
DM8J9SF	CP	Schering-Plough
DM8J9SF	DT	Small molecular drug
DM8J9SF	PC	9574343
DM8J9SF	MW	557.5
DM8J9SF	FM	C28H37BrN4O3
DM8J9SF	IC	InChI=1S/C28H37BrN4O3/c1-5-36-30-26(22-6-8-24(29)9-7-22)23-11-15-32(16-12-23)28(4)13-18-31(19-14-28)27(34)25-20(2)10-17-33(35)21(25)3/h6-10,17,23H,5,11-16,18-19H2,1-4H3/b30-26+
DM8J9SF	CS	CCO/N=C(/C1CCN(CC1)C2(CCN(CC2)C(=O)C3=C(C=C[N+](=C3C)[O-])C)C)\\C4=CC=C(C=C4)Br
DM8J9SF	IK	ZGDKVKUWTCGYOA-URGPHPNLSA-N
DM8J9SF	IU	[4-[4-[(Z)-C-(4-bromophenyl)-N-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone
DM8J9SF	CA	CAS 305792-46-5
DM8J9SF	DE	Human immunodeficiency virus infection

DM8BIV4	ID	DM8BIV4
DM8BIV4	DN	SDZ-210-086
DM8BIV4	HS	Discontinued in Phase 1
DM8BIV4	SN	SDZ-BOP-086
DM8BIV4	CP	Novartis AG
DM8BIV4	PC	9860700
DM8BIV4	MW	171.24
DM8BIV4	FM	C9H17NO2
DM8BIV4	IC	InChI=1S/C9H17NO2/c1-8-11-7-9(12-8)3-5-10(2)6-4-9/h8H,3-7H2,1-2H3/t8-/m0/s1
DM8BIV4	CS	C[C@H]1OCC2(O1)CCN(CC2)C
DM8BIV4	IK	VHBBMEXIWWKUNY-QMMMGPOBSA-N
DM8BIV4	IU	(2S)-2,8-dimethyl-1,3-dioxa-8-azaspiro[4.5]decane
DM8BIV4	DE	Cognitive impairment

DMU3TQJ	ID	DMU3TQJ
DMU3TQJ	DN	SDZ-62-434
DMU3TQJ	HS	Discontinued in Phase 1
DMU3TQJ	SN	5-[4-(Piperidinomethyl)phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline dihydrochloride
DMU3TQJ	DT	Small molecular drug
DMU3TQJ	PC	130786
DMU3TQJ	MW	402.4
DMU3TQJ	FM	C22H25Cl2N3
DMU3TQJ	IC	InChI=1S/C22H23N3.2ClH/c1-4-13-24(14-5-1)19-10-8-17(9-11-19)21-16-18-6-2-3-7-20(18)22-23-12-15-25(21)22;;/h2-3,6-11,16H,1,4-5,12-15H2;2*1H
DMU3TQJ	CS	C1CCN(CC1)C2=CC=C(C=C2)C3=CC4=CC=CC=C4C5=NCCN35.Cl.Cl
DMU3TQJ	IK	BKOQATFPPHQOQH-UHFFFAOYSA-N
DMU3TQJ	IU	5-(4-piperidin-1-ylphenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline;dihydrochloride
DMU3TQJ	CA	CAS 115621-95-9
DMU3TQJ	DE	Solid tumour/cancer

DM70MJQ	ID	DM70MJQ
DM70MJQ	DN	SDZ-CPI-975
DM70MJQ	HS	Discontinued in Phase 1
DM70MJQ	SN	CPT inhibitors, Sandoz; Carnitine palmitoyl transferase I inhbitors, Sandoz; SDZ-267-894
DM70MJQ	CP	Sandoz Research Institute
DM70MJQ	DT	Small molecular drug
DM70MJQ	PC	9954767
DM70MJQ	MW	437.6
DM70MJQ	FM	C21H44NO6P
DM70MJQ	IC	InChI=1S/C21H44NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-27-29(25,26)28-20(18-21(23)24)19-22(2,3)4/h20H,5-19H2,1-4H3,(H-,23,24,25,26)/t20-/m1/s1
DM70MJQ	CS	CCCCCCCCCCCCCCOP(=O)([O-])O[C@H](CC(=O)O)C[N+](C)(C)C
DM70MJQ	IK	HSNUXANXVHLGQT-HXUWFJFHSA-N
DM70MJQ	IU	[(2R)-1-carboxy-3-(trimethylazaniumyl)propan-2-yl] tetradecyl phosphate
DM70MJQ	CA	CAS 157244-53-6
DM70MJQ	DE	Diabetic complication

DM1C0K4	ID	DM1C0K4
DM1C0K4	DN	SDZ-GLC-756
DM1C0K4	HS	Discontinued in Phase 1
DM1C0K4	SN	GLC-756; SDZ GLC 756; SCHEMBL14392424; BDBM85047; PDSP1_000850
DM1C0K4	CP	Novartis AG
DM1C0K4	DT	Small molecular drug
DM1C0K4	PC	101061738
DM1C0K4	MW	324.5
DM1C0K4	FM	C20H24N2S
DM1C0K4	IC	InChI=1S/C20H24N2S/c1-22-13-15(14-23-20-8-4-5-9-21-20)10-18-11-16-6-2-3-7-17(16)12-19(18)22/h2-9,15,18-19H,10-14H2,1H3/t15-,18-,19-/m1/s1
DM1C0K4	CS	CN1C[C@@H](C[C@H]2[C@H]1CC3=CC=CC=C3C2)CSC4=CC=CC=N4
DM1C0K4	IK	JVCCQRRESBKGJS-ATZDWAIDSA-N
DM1C0K4	IU	(3R,4aR,10aR)-1-methyl-3-(pyridin-2-ylsulfanylmethyl)-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
DM1C0K4	DE	Glaucoma/ocular hypertension

DM8C3G5	ID	DM8C3G5
DM8C3G5	DN	SDZ-NKT-343
DM8C3G5	HS	Discontinued in Phase 1
DM8C3G5	SN	NKT-343; SDZ-250343
DM8C3G5	CP	Novartis AG
DM8C3G5	DT	Small molecular drug
DM8C3G5	PC	9851211
DM8C3G5	MW	579.6
DM8C3G5	FM	C33H33N5O5
DM8C3G5	IC	InChI=1S/C33H33N5O5/c1-36(22-23-10-3-2-4-11-23)32(40)28(21-24-17-18-25-12-5-6-13-26(25)20-24)34-31(39)30-16-9-19-37(30)33(41)35-27-14-7-8-15-29(27)38(42)43/h2-8,10-15,17-18,20,28,30H,9,16,19,21-22H2,1H3,(H,34,39)(H,35,41)/t28-,30-/m0/s1
DM8C3G5	CS	CN(CC1=CC=CC=C1)C(=O)[C@H](CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@@H]4CCCN4C(=O)NC5=CC=CC=C5[N+](=O)[O-]
DM8C3G5	IK	PCVSIMQAFWRUEC-JDXGNMNLSA-N
DM8C3G5	IU	(2S)-2-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-N-(2-nitrophenyl)pyrrolidine-1,2-dicarboxamide
DM8C3G5	CA	CAS 180046-99-5
DM8C3G5	DE	Pain

DMTOH03	ID	DMTOH03
DMTOH03	DN	SDZ-NVI-085
DMTOH03	HS	Discontinued in Phase 1
DMTOH03	SN	Sdz-nvi-085; Sdz nvi-085; 104195-17-7; Sdz nvi 085; 2H-Naphth[2,3-b]-1,4-oxazine, 3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-, (4aR,10aR)-;2H-Naphth[2,3-b]-1,4-oxazine, 3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-, (4aR,10aR)-; SLMAGYSTRWJTMF-TZMCWYRMSA-N; sdznvi-085; AC1L2TWR; SCHEMBL194836; CHEMBL337879; DTXSID60146337; 3,4,4a,5,10,10a-Hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth(2,3-b)-1,4-oxazine
DMTOH03	CP	Novartis AG
DMTOH03	DT	Small molecular drug
DMTOH03	PC	128503
DMTOH03	MW	279.4
DMTOH03	FM	C15H21NO2S
DMTOH03	IC	InChI=1S/C15H21NO2S/c1-16-6-7-18-14-9-11-10(8-12(14)16)13(17-2)4-5-15(11)19-3/h4-5,12,14H,6-9H2,1-3H3/t12-,14-/m1/s1
DMTOH03	CS	CN1CCO[C@H]2[C@H]1CC3=C(C=CC(=C3C2)SC)OC
DMTOH03	IK	SLMAGYSTRWJTMF-TZMCWYRMSA-N
DMTOH03	IU	(4aR,10aR)-6-methoxy-4-methyl-9-methylsulfanyl-2,3,4a,5,10,10a-hexahydrobenzo[g][1,4]benzoxazine
DMTOH03	CA	CAS 104195-17-7
DMTOH03	DE	Major depressive disorder

DMZHOYM	ID	DMZHOYM
DMZHOYM	DN	SDZ-PCO-400
DMZHOYM	HS	Discontinued in Phase 1
DMZHOYM	SN	PCO-400
DMZHOYM	CP	Novartis AG
DMZHOYM	DT	Small molecular drug
DMZHOYM	PC	129348
DMZHOYM	MW	299.32
DMZHOYM	FM	C17H17NO4
DMZHOYM	IC	InChI=1S/C17H17NO4/c1-17(2)16(20)15(21-12-5-4-11(19)8-12)13-7-10(9-18)3-6-14(13)22-17/h3,6-8,15-16,20H,4-5H2,1-2H3/t15-,16+/m1/s1
DMZHOYM	CS	CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)OC3=CC(=O)CC3)O)C
DMZHOYM	IK	WJBHHTPFTVKZCV-CVEARBPZSA-N
DMZHOYM	IU	(3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopenten-1-yl)oxy-3,4-dihydrochromene-6-carbonitrile
DMZHOYM	CA	CAS 121055-10-5
DMZHOYM	CB	CHEBI:92920
DMZHOYM	DE	Asthma

DMFLOT4	ID	DMFLOT4
DMFLOT4	DN	SDZ-WAG-994
DMFLOT4	HS	Discontinued in Phase 1
DMFLOT4	SN	WAG-994
DMFLOT4	CP	Novartis AG
DMFLOT4	DT	Small molecular drug
DMFLOT4	PC	164305
DMFLOT4	MW	363.4
DMFLOT4	FM	C17H25N5O4
DMFLOT4	IC	InChI=1S/C17H25N5O4/c1-25-14-13(24)11(7-23)26-17(14)22-9-20-12-15(18-8-19-16(12)22)21-10-5-3-2-4-6-10/h8-11,13-14,17,23-24H,2-7H2,1H3,(H,18,19,21)/t11-,13-,14-,17-/m1/s1
DMFLOT4	CS	CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)NC4CCCCC4)CO)O
DMFLOT4	IK	JAKAFSGZUXCHLF-LSCFUAHRSA-N
DMFLOT4	IU	(2R,3R,4R,5R)-5-[6-(cyclohexylamino)purin-9-yl]-2-(hydroxymethyl)-4-methoxyoxolan-3-ol
DMFLOT4	CA	CAS 130714-47-5
DMFLOT4	DE	Hypertension

DMCQI25	ID	DMCQI25
DMCQI25	DN	SEP-226332
DMCQI25	HS	Discontinued in Phase 1
DMCQI25	SN	SEP-0226332; 5-HT3 receptor antagonist (sleep apnea), Sepracor
DMCQI25	CP	Sunovion Pharmaceuticals Inc
DMCQI25	DE	Obstructive sleep apnea

DMTGCSX	ID	DMTGCSX
DMTGCSX	DN	SIM-916
DMTGCSX	HS	Discontinued in Phase 1
DMTGCSX	SN	Womens health therapeutics, ArQule/Wyeth; Rheumatoid arthritis therapeutics (1), ArQule/Wyeth
DMTGCSX	CP	ArQule Inc
DMTGCSX	DE	Gynecological disease

DM1XEUV	ID	DM1XEUV
DM1XEUV	DN	SKF-97574
DM1XEUV	HS	Discontinued in Phase 1
DM1XEUV	SN	3-Butyryl-4-(2-methylphenylamino)-8-(2-hydroxyethoxy)quinoline; SCHEMBL9264291; FOYCAZSJGNVMMS-UHFFFAOYSA-N; SKF 97574; F-97574; 3-butyryl-4-(2-methylphenylamino)-8-(2-hydroxyethoxy)quinoline hydrochloride; 1-(8-(2-Hydroxyethoxy)-4-((2-methylphenyl)amino)-3-quinolinyl)-1-butanone monohydrochloride; 1-Butanone, 1-(8-(2-hydroxyethoxy)-4-((2-methylphenyl)amino)-3-quinolinyl)-, monohydrochloride
DM1XEUV	CP	SmithKline Beecham plc
DM1XEUV	DT	Small molecular drug
DM1XEUV	PC	9887258
DM1XEUV	MW	364.4
DM1XEUV	FM	C22H24N2O3
DM1XEUV	IC	InChI=1S/C22H24N2O3/c1-3-7-19(26)17-14-23-22-16(9-6-11-20(22)27-13-12-25)21(17)24-18-10-5-4-8-15(18)2/h4-6,8-11,14,25H,3,7,12-13H2,1-2H3,(H,23,24)
DM1XEUV	CS	CCCC(=O)C1=CN=C2C(=C1NC3=CC=CC=C3C)C=CC=C2OCCO
DM1XEUV	IK	BMCBJKLELCZGBF-UHFFFAOYSA-N
DM1XEUV	IU	1-[8-(2-hydroxyethoxy)-4-(2-methylanilino)quinolin-3-yl]butan-1-one
DM1XEUV	DE	Peptic ulcer

DMP0DLW	ID	DMP0DLW
DMP0DLW	DN	SL-25.1188
DMP0DLW	HS	Discontinued in Phase 1
DMP0DLW	CP	Sanofi-Synthelabo
DMP0DLW	DE	Alzheimer disease

DMFUTHB	ID	DMFUTHB
DMFUTHB	DN	SL-90.0571
DMFUTHB	HS	Discontinued in Phase 1
DMFUTHB	CP	Synthelabo
DMFUTHB	DE	Epilepsy

DM5TJIY	ID	DM5TJIY
DM5TJIY	DN	SLV-311
DM5TJIY	HS	Discontinued in Phase 1
DM5TJIY	CP	Solvay SA
DM5TJIY	DE	Gastrointestinal disease

DMJFWB7	ID	DMJFWB7
DMJFWB7	DN	SLV-313
DMJFWB7	HS	Discontinued in Phase 1
DMJFWB7	SN	L001624
DMJFWB7	CP	Solvay Pharma
DMJFWB7	DT	Small molecular drug
DMJFWB7	PC	9887537
DMJFWB7	MW	405.5
DMJFWB7	FM	C24H24FN3O2
DMJFWB7	IC	InChI=1S/C24H24FN3O2/c25-21-6-4-19(5-7-21)20-14-18(15-26-16-20)17-27-8-10-28(11-9-27)22-2-1-3-23-24(22)30-13-12-29-23/h1-7,14-16H,8-13,17H2
DMJFWB7	CS	C1CN(CCN1CC2=CC(=CN=C2)C3=CC=C(C=C3)F)C4=C5C(=CC=C4)OCCO5
DMJFWB7	IK	IUVSEUFHPNITEQ-UHFFFAOYSA-N
DMJFWB7	IU	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine
DMJFWB7	CA	CAS 222551-17-9
DMJFWB7	DE	Schizophrenia

DMHRYX6	ID	DMHRYX6
DMHRYX6	DN	SLV-323
DMHRYX6	HS	Discontinued in Phase 1
DMHRYX6	CP	Solvay
DMHRYX6	DE	Gastric motility disorder; Chemotherapy-induced nausea; Irritable bowel syndrome

DM6CLX9	ID	DM6CLX9
DM6CLX9	DN	SM-6586
DM6CLX9	HS	Discontinued in Phase 1
DM6CLX9	CP	Sumitomo Pharmaceuticals Co Ltd
DM6CLX9	DT	Small molecular drug
DM6CLX9	PC	128443
DM6CLX9	MW	489.5
DM6CLX9	FM	C26H27N5O5
DM6CLX9	IC	InChI=1S/C26H27N5O5/c1-16-22(25-28-21(29-36-25)15-30(3)14-18-9-6-5-7-10-18)24(23(17(2)27-16)26(32)35-4)19-11-8-12-20(13-19)31(33)34/h5-13,24,27H,14-15H2,1-4H3
DM6CLX9	CS	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C3=NC(=NO3)CN(C)CC4=CC=CC=C4
DM6CLX9	IK	HHVCXSOKQHQGFB-UHFFFAOYSA-N
DM6CLX9	IU	methyl 5-[3-[[benzyl(methyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
DM6CLX9	CA	CAS 103898-38-0
DM6CLX9	DE	Hypertension

DMC49KO	ID	DMC49KO
DMC49KO	DN	SMART anti-E/P selectin
DMC49KO	HS	Discontinued in Phase 1
DMC49KO	SN	HuEP5C7; Bispecific anti-E/P selectin, PDL; SMART anti-E/P selectin, PDL; SMART anti-E/P selectin, Protein Design Labs; Anti-E/P selectin (humanized), PDL
DMC49KO	CP	PDL BioPharma Inc
DMC49KO	DE	Asthma

DMQSGOD	ID	DMQSGOD
DMQSGOD	DN	SMP-028
DMQSGOD	HS	Discontinued in Phase 1
DMQSGOD	CP	Dainippon Sumitomo Pharma Co Ltd
DMQSGOD	PC	11949660
DMQSGOD	MW	455.6
DMQSGOD	FM	C23H26FN5O2S
DMQSGOD	IC	InChI=1S/C23H26FN5O2S/c1-25-22(30)26-9-10-29-21(16-32-23(29)27-19-4-2-3-18(24)15-19)17-5-7-20(8-6-17)28-11-13-31-14-12-28/h2-8,15-16H,9-14H2,1H3,(H2,25,26,30)
DMQSGOD	CS	CNC(=O)NCCN1C(=CSC1=NC2=CC(=CC=C2)F)C3=CC=C(C=C3)N4CCOCC4
DMQSGOD	IK	NBGPMRBRSOZDOV-UHFFFAOYSA-N
DMQSGOD	IU	1-[2-[2-(3-fluorophenyl)imino-4-(4-morpholin-4-ylphenyl)-1,3-thiazol-3-yl]ethyl]-3-methylurea
DMQSGOD	CA	CAS 914389-14-3
DMQSGOD	DE	Asthma

DMKGL2I	ID	DMKGL2I
DMKGL2I	DN	SPI-256
DMKGL2I	HS	Discontinued in Phase 1
DMKGL2I	SN	HIV protease inhibitors (Resistant-Repellent), Sequoia
DMKGL2I	CP	Sequoia Pharmaceuticals Inc
DMKGL2I	DE	Human immunodeficiency virus infection

DMWQKEN	ID	DMWQKEN
DMWQKEN	DN	SPP-1148
DMWQKEN	HS	Discontinued in Phase 1
DMWQKEN	SN	SPP-1100; SPP-1193; Renin inhibitors (hypertension), Novartis; Renin inhibitors (hypertension), Speedel
DMWQKEN	CP	Speedel Holding AG
DMWQKEN	DE	Hypertension

DMKEHGT	ID	DMKEHGT
DMKEHGT	DN	SPP-676
DMKEHGT	HS	Discontinued in Phase 1
DMKEHGT	CP	Speedel Holding AG
DMKEHGT	DE	Hypertension

DMK4XT8	ID	DMK4XT8
DMK4XT8	DN	SR 144190
DMK4XT8	HS	Discontinued in Phase 1
DMK4XT8	SN	SR-144190; 3-(1-(2-(4-benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl)ethyl)-4-phenylpiperidin-4-yl)-1-dimethylurea
DMK4XT8	CP	Sanofi-aventis
DMK4XT8	TC	Analgesics
DMK4XT8	DT	Small molecular drug
DMK4XT8	PC	9810217
DMK4XT8	MW	576.7
DMK4XT8	FM	C33H38F2N4O3
DMK4XT8	IC	InChI=1S/C33H38F2N4O3/c1-37(2)31(41)36-32(26-11-7-4-8-12-26)15-18-38(19-16-32)20-17-33(27-13-14-28(34)29(35)23-27)24-39(21-22-42-33)30(40)25-9-5-3-6-10-25/h3-14,23H,15-22,24H2,1-2H3,(H,36,41)
DMK4XT8	CS	CN(C)C(=O)NC1(CCN(CC1)CCC2(CN(CCO2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)F)F)C5=CC=CC=C5
DMK4XT8	IK	QNLIUVLFRVYNCV-UHFFFAOYSA-N
DMK4XT8	IU	3-[1-[2-[4-benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl]ethyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea
DMK4XT8	DE	Urinary incontinence; Anxiety disorder; Acute or chronic pain; Depression

DML7KCO	ID	DML7KCO
DML7KCO	DN	SR-146131
DML7KCO	HS	Discontinued in Phase 1
DML7KCO	SN	SR 146131; SR-146131; SR146131; 221671-61-0; NFDFTMICKVDYLQ-UHFFFAOYSA-N; GTPL868; SCHEMBL1008694; DTXSID5047370; CHEMBL3302616; NCGC00247967-01; HY-11077; CS-0003037; L000574; 2-(4- (4-Chloro-2,5-dimethoxyphenyl)-5-cyclohexylethyl-2-thiazolylcarbamoyl)-5,7-dimethyl-1-indoleacetic acid; 2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid
DML7KCO	CP	Sanofi-Synthelabo
DML7KCO	DT	Small molecular drug
DML7KCO	PC	9852833
DML7KCO	MW	610.2
DML7KCO	FM	C32H36ClN3O5S
DML7KCO	IC	InChI=1S/C32H36ClN3O5S/c1-18-12-19(2)30-21(13-18)14-24(36(30)17-28(37)38)31(39)35-32-34-29(22-15-26(41-4)23(33)16-25(22)40-3)27(42-32)11-10-20-8-6-5-7-9-20/h12-16,20H,5-11,17H2,1-4H3,(H,37,38)(H,34,35,39)
DML7KCO	CS	CC1=CC(=C2C(=C1)C=C(N2CC(=O)O)C(=O)NC3=NC(=C(S3)CCC4CCCCC4)C5=CC(=C(C=C5OC)Cl)OC)C
DML7KCO	IK	NFDFTMICKVDYLQ-UHFFFAOYSA-N
DML7KCO	IU	2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid
DML7KCO	CA	CAS 221671-61-0
DML7KCO	DE	Obesity

DM6X9M8	ID	DM6X9M8
DM6X9M8	DN	SR-271425
DM6X9M8	HS	Discontinued in Phase 1
DM6X9M8	SN	BCN-326862; SW-71425; WIN-71425; 1-[2-(Diethylamino)ethylamino]-4-(formamidomethyl)-7-methoxy-9H-thioxanthen-9-one
DM6X9M8	DT	Small molecular drug
DM6X9M8	PC	9909677
DM6X9M8	MW	413.5
DM6X9M8	FM	C22H27N3O3S
DM6X9M8	IC	InChI=1S/C22H27N3O3S/c1-4-25(5-2)11-10-24-18-8-6-15(13-23-14-26)22-20(18)21(27)17-12-16(28-3)7-9-19(17)29-22/h6-9,12,14,24H,4-5,10-11,13H2,1-3H3,(H,23,26)
DM6X9M8	CS	CCN(CC)CCNC1=C2C(=C(C=C1)CNC=O)SC3=C(C2=O)C=C(C=C3)OC
DM6X9M8	IK	GWLFIMOOGVXSMZ-UHFFFAOYSA-N
DM6X9M8	IU	N-[[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]formamide
DM6X9M8	CA	CAS 155990-20-8
DM6X9M8	DE	Solid tumour/cancer

DM471IG	ID	DM471IG
DM471IG	DN	SR-33805
DM471IG	HS	Discontinued in Phase 1
DM471IG	SN	SR 33805; 121345-64-0; AC1L2VL6; SCHEMBL7268066; CHEMBL287679; DTXSID40153241; 3,4-Dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phenoxy)propyl)benzeneethanamine; N-[3-[4-[(1-Methyl-2-isopropyl-1H-indol-3-yl)sulfonyl]phenoxy]propyl]-N-methyl-3,4-dimethoxyphenethylamine; N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-2-propan-2-ylindol-3-yl)sulfonylphenoxy]propan-1-amine; Benzeneethanamine, 3,4-dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phen
DM471IG	CP	Sanofi
DM471IG	DT	Small molecular drug
DM471IG	PC	9850876
DM471IG	MW	564.7
DM471IG	FM	C32H40N2O5S
DM471IG	IC	InChI=1S/C32H40N2O5S/c1-23(2)31-27-10-7-8-11-28(27)34(4)32(31)40(35,36)26-15-13-25(14-16-26)39-21-9-19-33(3)20-18-24-12-17-29(37-5)30(22-24)38-6/h7-8,10-17,22-23H,9,18-21H2,1-6H3
DM471IG	CS	CC(C)C1=C(N(C2=CC=CC=C21)C)S(=O)(=O)C3=CC=C(C=C3)OCCCN(C)CCC4=CC(=C(C=C4)OC)OC
DM471IG	IK	GCVFQRRBTCHIPK-UHFFFAOYSA-N
DM471IG	IU	N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-3-propan-2-ylindol-2-yl)sulfonylphenoxy]propan-1-amine
DM471IG	DE	Angina pectoris

DMAICVN	ID	DMAICVN
DMAICVN	DN	SR-47063
DMAICVN	HS	Discontinued in Phase 1
DMAICVN	SN	SR-47063; SR 47063; 135809-60-8; SCHEMBL3694183; SCHEMBL9205867; sr47063; AC1L3015; 4-(2-Cyanimino-1,2-dihydropyrid-1-yl)-2,2-dimethyl-6-nitrochromene; (1-(2,2-Dimethyl-6-nitro-2H-1-benzopyran-4-yl)-2(1H)-pyridinylidene)cyanamide; [1-(2,2-dimethyl-6-nitrochromen-4-yl)pyridin-2-ylidene]cyanamide; Cyanamide, (1-(2,2-dimethyl-6-nitro-2H-1-benzopyran-4-yl)-2(1H)-pyridinylidene)-
DMAICVN	CP	Sanofi
DMAICVN	DT	Small molecular drug
DMAICVN	PC	131912
DMAICVN	MW	322.32
DMAICVN	FM	C17H14N4O3
DMAICVN	IC	InChI=1S/C17H14N4O3/c1-17(2)10-14(20-8-4-3-5-16(20)19-11-18)13-9-12(21(22)23)6-7-15(13)24-17/h3-10H,1-2H3
DMAICVN	CS	CC1(C=C(C2=C(O1)C=CC(=C2)[N+](=O)[O-])N3C=CC=CC3=NC#N)C
DMAICVN	IK	ZOHLDHMGABPLCB-UHFFFAOYSA-N
DMAICVN	IU	[1-(2,2-dimethyl-6-nitrochromen-4-yl)pyridin-2-ylidene]cyanamide
DMAICVN	CA	CAS 135809-60-8
DMAICVN	DE	Cardiac arrhythmias

DM3O4ST	ID	DM3O4ST
DM3O4ST	DN	SS1(dsFv)-PE38
DM3O4ST	HS	Discontinued in Phase 1
DM3O4ST	SN	CAT-5001; SS (dsFv) PE38 immunotoxin); SS1-PE38; SS (dsFv) PE38 immunotoxin, NCI; SS1P, Enzon/NCI
DM3O4ST	CP	National Cancer Institute
DM3O4ST	DT	Antibody
DM3O4ST	DE	Solid tumour/cancer

DMSOBW2	ID	DMSOBW2
DMSOBW2	DN	SSR-125180
DMSOBW2	HS	Discontinued in Phase 1
DMSOBW2	CP	Sanofi-Synthelabo
DMSOBW2	DE	Obesity

DMR9JA8	ID	DMR9JA8
DMR9JA8	DN	SSR-146977
DMR9JA8	HS	Discontinued in Phase 1
DMR9JA8	SN	N-[1-[3-[1-Benzoyl-3(R)-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N',N'-dimethylurea
DMR9JA8	DT	Small molecular drug
DMR9JA8	PC	9938990
DMR9JA8	MW	621.6
DMR9JA8	FM	C35H42Cl2N4O2
DMR9JA8	IC	InChI=1S/C35H42Cl2N4O2/c1-39(2)33(43)38-35(28-13-7-4-8-14-28)19-23-40(24-20-35)21-9-17-34(29-15-16-30(36)31(37)25-29)18-10-22-41(26-34)32(42)27-11-5-3-6-12-27/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3,(H,38,43)/t34-/m0/s1
DMR9JA8	CS	CN(C)C(=O)NC1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
DMR9JA8	IK	XWPBINGFFFZAOZ-UMSFTDKQSA-N
DMR9JA8	IU	3-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea
DMR9JA8	CA	CAS 264618-44-2
DMR9JA8	DE	Psychotic disorder

DMI3K2D	ID	DMI3K2D
DMI3K2D	DN	SSR-162369
DMI3K2D	HS	Discontinued in Phase 1
DMI3K2D	CP	Sanofi-Aventis
DMI3K2D	DT	Small molecular drug
DMI3K2D	PC	56603733
DMI3K2D	MW	459.6
DMI3K2D	FM	C27H33N5O2
DMI3K2D	IC	InChI=1S/C27H33N5O2/c1-17(2)13-15-31-24-26(29-25(31)21-10-11-22-20(21)12-14-28-22)30(4)18(3)32(27(24)34)16-23(33)19-8-6-5-7-9-19/h5-9,13,20-22,28H,3,10-12,14-16H2,1-2,4H3/t20-,21?,22+/m0/s1
DMI3K2D	CS	CC(=CCN1C(=NC2=C1C(=O)N(C(=C)N2C)CC(=O)C3=CC=CC=C3)C4CC[C@@H]5[C@H]4CCN5)C
DMI3K2D	IK	PBLJWGCWKPKYPH-JAFNVKOHSA-N
DMI3K2D	IU	8-[(3aS,6aR)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-4-yl]-3-methyl-7-(3-methylbut-2-enyl)-2-methylidene-1-phenacylpurin-6-one
DMI3K2D	DE	Type-2 diabetes

DMBCQFH	ID	DMBCQFH
DMBCQFH	DN	SUN-8399
DMBCQFH	HS	Discontinued in Phase 1
DMBCQFH	SN	Sun-8399; Sun 8399; 131112-58-8; SCHEMBL9370364; AC1L2Z10; DTXSID50156900; 4-(4-(4-(2-Pyrimidyl)-1-piperazinyl)butyl)-1,4-benzoxazepine-3,5(2H,4H)-dione; 4-(4-(4-(2-Pyrimidinyl)piperazin-1-yl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione; L004090; 4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,4-benzoxazepine-3,5-dione; 1,4-Benzoxazepine-3,5(2H,4H)-dione, 4-(4-(4-(2-pyrimidyl)-1-piperazinyl)butyl)-
DMBCQFH	CP	Suntory Ltd
DMBCQFH	DT	Small molecular drug
DMBCQFH	PC	131339
DMBCQFH	MW	395.5
DMBCQFH	FM	C21H25N5O3
DMBCQFH	IC	InChI=1S/C21H25N5O3/c27-19-16-29-18-7-2-1-6-17(18)20(28)26(19)11-4-3-10-24-12-14-25(15-13-24)21-22-8-5-9-23-21/h1-2,5-9H,3-4,10-16H2
DMBCQFH	CS	C1CN(CCN1CCCCN2C(=O)COC3=CC=CC=C3C2=O)C4=NC=CC=N4
DMBCQFH	IK	ITTHDTFPCPHJOU-UHFFFAOYSA-N
DMBCQFH	IU	4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,4-benzoxazepine-3,5-dione
DMBCQFH	CA	CAS 131112-58-8
DMBCQFH	DE	Anxiety disorder

DM6BO7R	ID	DM6BO7R
DM6BO7R	DN	SUN-9221
DM6BO7R	HS	Discontinued in Phase 1
DM6BO7R	CP	Suntory Ltd
DM6BO7R	DE	Hypertension

DM1Z42H	ID	DM1Z42H
DM1Z42H	DN	SURADISTA
DM1Z42H	HS	Discontinued in Phase 1
DM1Z42H	SN	PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt
DM1Z42H	DE	Solid tumour/cancer

DMY3FES	ID	DMY3FES
DMY3FES	DN	SW-33377
DMY3FES	HS	Discontinued in Phase 1
DMY3FES	SN	SR-233377; Win-33377; N-[1-[2-(Diethylamino)ethylamino]-9-oxothioxanthen-4-ylmethyl]methanesulfonamide; 1-[2-(Diethylamino)ethylamino]-4-(methanesulfonamidomethyl)thioxanthen-9-one
DMY3FES	DT	Small molecular drug
DMY3FES	PC	3035776
DMY3FES	MW	433.6
DMY3FES	FM	C21H27N3O3S2
DMY3FES	IC	InChI=1S/C21H27N3O3S2/c1-4-24(5-2)13-12-22-17-11-10-15(14-23-29(3,26)27)21-19(17)20(25)16-8-6-7-9-18(16)28-21/h6-11,22-23H,4-5,12-14H2,1-3H3
DMY3FES	CS	CCN(CC)CCNC1=C2C(=C(C=C1)CNS(=O)(=O)C)SC3=CC=CC=C3C2=O
DMY3FES	IK	NAMOLZVVTPNNTE-UHFFFAOYSA-N
DMY3FES	IU	N-[[1-[2-(diethylamino)ethylamino]-9-oxothioxanthen-4-yl]methyl]methanesulfonamide
DMY3FES	CA	CAS 146537-07-7
DMY3FES	DE	Solid tumour/cancer

DMSPBJ9	ID	DMSPBJ9
DMSPBJ9	DN	Symakalim
DMSPBJ9	HS	Discontinued in Phase 1
DMSPBJ9	SN	EMD-57283
DMSPBJ9	CP	Merck KGaA
DMSPBJ9	PC	9840338
DMSPBJ9	MW	327.33
DMSPBJ9	FM	C17H17N3O4
DMSPBJ9	IC	InChI=1S/C17H17N3O4/c1-17(2)16(22)15(23-13-6-7-14(21)20(3)19-13)11-8-10(9-18)4-5-12(11)24-17/h4-8,15-16,22H,1-3H3
DMSPBJ9	CS	CC1(C(C(C2=C(O1)C=CC(=C2)C#N)OC3=NN(C(=O)C=C3)C)O)C
DMSPBJ9	IK	RIBYSHCVSQIIJE-UHFFFAOYSA-N
DMSPBJ9	IU	3-hydroxy-2,2-dimethyl-4-(1-methyl-6-oxopyridazin-3-yl)oxy-3,4-dihydrochromene-6-carbonitrile
DMSPBJ9	DE	Hypertension

DM4JPLM	ID	DM4JPLM
DM4JPLM	DN	SYN-114
DM4JPLM	HS	Discontinued in Phase 1
DM4JPLM	SN	5-HT 6 receptor antagonists (cognitive disorders), Synosia/Roche
DM4JPLM	CP	Roche Holding AG
DM4JPLM	DE	Cognitive impairment

DML4M5K	ID	DML4M5K
DML4M5K	DN	T-0632
DML4M5K	HS	Discontinued in Phase 1
DML4M5K	SN	Z-203; (S)-1-(2-Fluorophenyl)-3-(3-isoquinolinylcarboxamido)-6-methoxy-2-oxo-1H-indole-3-propionic acid sodium salt
DML4M5K	DT	Small molecular drug
DML4M5K	PC	127948
DML4M5K	MW	502.5
DML4M5K	FM	C29H27FN2O5
DML4M5K	IC	InChI=1S/C29H27FN2O5/c1-37-21-12-13-22-25(17-21)32(24-9-5-4-8-23(24)30)28(36)29(22,15-14-26(33)34)31-27(35)20-11-10-18-6-2-3-7-19(18)16-20/h2-9,12-13,17,20H,10-11,14-16H2,1H3,(H,31,35)(H,33,34)/t20?,29-/m0/s1
DML4M5K	CS	COC1=CC2=C(C=C1)[C@](C(=O)N2C3=CC=CC=C3F)(CCC(=O)O)NC(=O)C4CCC5=CC=CC=C5C4
DML4M5K	IK	RORYEMYJJAIHBK-PRTIIRGTSA-N
DML4M5K	IU	3-[(3S)-1-(2-fluorophenyl)-6-methoxy-2-oxo-3-(1,2,3,4-tetrahydronaphthalene-2-carbonylamino)indol-3-yl]propanoic acid
DML4M5K	DE	Pancreatic malfunction

DMQVLZH	ID	DMQVLZH
DMQVLZH	DN	T-62
DMQVLZH	HS	Discontinued in Phase 1
DMQVLZH	SN	40312-34-3; T-62; T62; UNII-9Q765ZIF8L; CHEMBL57997; 9Q765ZIF8L; 3-(4-chlorobenzoyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-amine; (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone; 2-Amino-3-(4-chlorobenzoyl)-5,6,7,8-tetrahydrobenzothiophene; (2-amino-4,5,6,7-tetrahydro-1-benzothien-3-yl)(4-chlorophenyl)methanone; (2-Amino-4,5,6,7-tetrahydro-benzo[b]thiophen-3-yl)-(4-chloro-phenyl)-methanone; BAS 01842965; AC1Q50OD; AC1LH2S9; Oprea1_104969; Oprea1_077736; SCHEMBL135569; CTK6G9061; DTXSID20193322
DMQVLZH	CP	King Pharmaceuticals
DMQVLZH	TC	Analgesics
DMQVLZH	DT	Small molecular drug
DMQVLZH	PC	855908
DMQVLZH	MW	291.8
DMQVLZH	FM	C15H14ClNOS
DMQVLZH	IC	InChI=1S/C15H14ClNOS/c16-10-7-5-9(6-8-10)14(18)13-11-3-1-2-4-12(11)19-15(13)17/h5-8H,1-4,17H2
DMQVLZH	CS	C1CCC2=C(C1)C(=C(S2)N)C(=O)C3=CC=C(C=C3)Cl
DMQVLZH	IK	OTZVBZFYMFTYKH-UHFFFAOYSA-N
DMQVLZH	IU	(2-amino-4,5,6,7-tetrahydro-1-benzothiophen-3-yl)-(4-chlorophenyl)methanone
DMQVLZH	CA	CAS 40312-34-3
DMQVLZH	DE	Neuropathic pain

DMFES2K	ID	DMFES2K
DMFES2K	DN	TA-5493
DMFES2K	HS	Discontinued in Phase 1
DMFES2K	SN	P38 inhibitor (rheumatoid arthritis/ psoriasis), Mitsubishi Tanabe
DMFES2K	CP	Tanabe Seiyaku Co Ltd
DMFES2K	DE	Inflammation

DMI52NT	ID	DMI52NT
DMI52NT	DN	TAFA-93
DMI52NT	HS	Discontinued in Phase 1
DMI52NT	SN	MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika
DMI52NT	CP	Isotechnika Pharma Inc; Isotechnika
DMI52NT	DT	Small molecular drug
DMI52NT	PC	54601137
DMI52NT	MW	1095.4
DMI52NT	FM	C56H90N2O17S
DMI52NT	IC	InChI=1S/C55H86N2O14.CH4O3S/c1-33-18-14-13-15-19-34(2)45(66-10)30-41-23-21-39(7)55(65,71-41)52(62)53(63)57-25-17-16-20-42(57)54(64)69-46(36(4)28-40-22-24-43(58)47(29-40)67-11)31-44(59)35(3)27-38(6)50(70-48(60)32-56(8)9)51(68-12)49(61)37(5)26-33;1-5(2,3)4/h13-15,18-19,27,33,35-37,39-43,45-47,50-51,58,65H,16-17,20-26,28-32H2,1-12H3;1H3,(H,2,3,4)/b15-13+,18-14+,34-19-,38-27?;/t33?,35?,36?,37?,39?,40?,41?,42?,43?,45?,46?,47?,50?,51?,55-;/m0./s1
DMI52NT	CS	CC1CCC2CC(/C(=C\\C=C\\C=C\\C(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)[C@]1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)OC(=O)CN(C)C)OC)C)C)/C)OC.CS(=O)(=O)O
DMI52NT	IK	XVNMRKHCSMPLOF-CPNVPWJOSA-N
DMI52NT	IU	[(1S,24E,26E,28Z)-1-hydroxy-12-[1-(4-hydroxy-3-methoxycyclohexyl)propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-18-yl] 2-(dimethylamino)acetate;methanesulfonic acid
DMI52NT	DE	Transplant rejection

DMN02XD	ID	DMN02XD
DMN02XD	DN	TAK-029
DMN02XD	HS	Discontinued in Phase 1
DMN02XD	CP	Takeda Pharmaceutical Co Ltd
DMN02XD	PC	9824171
DMN02XD	MW	433.4
DMN02XD	FM	C19H23N5O7
DMN02XD	IC	InChI=1S/C19H23N5O7/c1-31-16(28)8-13-19(30)23(10-15(26)27)6-7-24(13)14(25)9-22-18(29)12-4-2-11(3-5-12)17(20)21/h2-5,13H,6-10H2,1H3,(H3,20,21)(H,22,29)(H,26,27)/t13-/m0/s1
DMN02XD	CS	COC(=O)C[C@H]1C(=O)N(CCN1C(=O)CNC(=O)C2=CC=C(C=C2)C(=N)N)CC(=O)O
DMN02XD	IK	CRFQJHNXTNBRQR-ZDUSSCGKSA-N
DMN02XD	IU	2-[(3S)-4-[2-[(4-carbamimidoylbenzoyl)amino]acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazin-1-yl]acetic acid
DMN02XD	CA	CAS 176655-58-6
DMN02XD	DE	Thrombosis

DMH16ND	ID	DMH16ND
DMH16ND	DN	TAK-100
DMH16ND	HS	Discontinued in Phase 1
DMH16ND	SN	CHEMBL1672127
DMH16ND	CP	Takeda
DMH16ND	DT	Small molecular drug
DMH16ND	PC	11996845
DMH16ND	MW	354.5
DMH16ND	FM	C22H30N2O2
DMH16ND	IC	InChI=1S/C22H30N2O2/c1-6-18-16(11-20(25)26)21(15-9-7-14(2)8-10-15)17(13-23)19(24-18)12-22(3,4)5/h7-10H,6,11-13,23H2,1-5H3,(H,25,26)
DMH16ND	CS	CCC1=C(C(=C(C(=N1)CC(C)(C)C)CN)C2=CC=C(C=C2)C)CC(=O)O
DMH16ND	IK	HQVOROHHYWZJLD-UHFFFAOYSA-N
DMH16ND	IU	2-[5-(aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)pyridin-3-yl]acetic acid
DMH16ND	DE	Diabetic complication

DMBE5OF	ID	DMBE5OF
DMBE5OF	DN	TAK165
DMBE5OF	HS	Discontinued in Phase 1
DMBE5OF	SN	Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole
DMBE5OF	CP	Takeda Pharmaceuticals
DMBE5OF	TC	Anticancer Agents
DMBE5OF	DT	Small molecular drug
DMBE5OF	PC	6444692
DMBE5OF	MW	468.5
DMBE5OF	FM	C25H23F3N4O2
DMBE5OF	IC	InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
DMBE5OF	CS	C1=CC(=CC=C1CCCCN2C=CN=N2)OCC3=COC(=N3)/C=C/C4=CC=C(C=C4)C(F)(F)F
DMBE5OF	IK	ZTFBIUXIQYRUNT-MDWZMJQESA-N
DMBE5OF	IU	4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole
DMBE5OF	CA	CAS 366017-09-6
DMBE5OF	DE	Solid tumour/cancer

DM25DB4	ID	DM25DB4
DM25DB4	DN	TAK-591
DM25DB4	HS	Discontinued in Phase 1
DM25DB4	CP	Takeda
DM25DB4	DE	Hypertension

DMRD8HK	ID	DMRD8HK
DMRD8HK	DN	TAK-683
DMRD8HK	HS	Discontinued in Phase 1
DMRD8HK	SN	(5S)-6-[6-[(1E,3R,5Z)-3-Hydroxyundeca-1,5-dienyl]pyridin-2-yl]hexane-1,5-diol; U 75302; U-75302; 119477-85-9; (5S)-6-[6-[(1E,3R,5Z)-3-hydroxyundeca-1,5-dienyl]pyridin-2-yl]hexane-1,5-diol; 6-(6-(3-Hydroxy-1,5-undecadien-1-yl)-2-pyridinyl)-1,5-hexanediol; U75302; AC1O6A9C; SCHEMBL1894359; GTPL3325; ZINC4489632; SR-01000946976; SR-01000946976-1; 1,5-Hexanediol, 6-(6-(3-hydroxy-1,5-undecadienyl)-2-pyridinyl)-,
DMRD8HK	CP	Takeda
DMRD8HK	DT	Small molecular drug
DMRD8HK	PC	49787129
DMRD8HK	MW	1298.4
DMRD8HK	FM	C64H83N17O13
DMRD8HK	IC	InChI=1S/C64H83N17O13/c1-34(2)26-48(57(88)73-46(20-13-25-69-63(67)68-5)56(87)74-47(55(66)86)29-39-32-70-44-18-11-9-16-42(39)44)78-64(94)81-80-61(92)50(27-37-14-7-6-8-15-37)77-62(93)54(35(3)82)79-60(91)52(31-53(65)85)76-59(90)51(30-40-33-71-45-19-12-10-17-43(40)45)75-58(89)49(72-36(4)83)28-38-21-23-41(84)24-22-38/h6-12,14-19,21-24,32-35,46-52,54,70-71,82,84H,13,20,25-31H2,1-5H3,(H2,65,85)(H2,66,86)(H,72,83)(H,73,88)(H,74,87)(H,75,89)(H,76,90)(H,77,93)(H,79,91)(H,80,92)(H3,67,68,69)(H2,78,81,94)/t35-,46+,47+,48+,49-,50+,51-,52+,54+/m1/s1
DMRD8HK	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=NC)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@@H](CC6=CC=C(C=C6)O)NC(=O)C)O
DMRD8HK	IK	BDPDXFSIFWZPCE-PHOVXGMNSA-N
DMRD8HK	IU	(2S)-2-[[(2R)-2-[[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide
DMRD8HK	DE	Allergy; Prostate cancer

DMCFOSG	ID	DMCFOSG
DMCFOSG	DN	TAK-810
DMCFOSG	HS	Discontinued in Phase 1
DMCFOSG	SN	N-[4-[3-(N-Benzyl-N-methylaminomethyl)-7-(2,6-difluorobenzyl)-5-isobutyryl-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-2-yl]phenyl]-1-hydroxycyclopropanecarboxamide
DMCFOSG	PC	9939511
DMCFOSG	MW	655.8
DMCFOSG	FM	C37H35F2N3O4S
DMCFOSG	IC	InChI=1S/C37H35F2N3O4S/c1-22(2)32(43)28-21-42(20-26-29(38)10-7-11-30(26)39)35-31(33(28)44)27(19-41(3)18-23-8-5-4-6-9-23)34(47-35)24-12-14-25(15-13-24)40-36(45)37(46)16-17-37/h4-15,21-22,46H,16-20H2,1-3H3,(H,40,45)
DMCFOSG	CS	CC(C)C(=O)C1=CN(C2=C(C1=O)C(=C(S2)C3=CC=C(C=C3)NC(=O)C4(CC4)O)CN(C)CC5=CC=CC=C5)CC6=C(C=CC=C6F)F
DMCFOSG	IK	NWNSIURBDQNMCZ-UHFFFAOYSA-N
DMCFOSG	IU	N-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-1-hydroxycyclopropane-1-carboxamide
DMCFOSG	DE	Prostate cancer

DM13YN0	ID	DM13YN0
DM13YN0	DN	TAK-937
DM13YN0	HS	Discontinued in Phase 1
DM13YN0	SN	Cerebroprotectant (acute stroke, injection), Takeda; CB1/CB2 receptor agonist (acute stroke, injection), Takeda
DM13YN0	CP	Takeda Pharmaceutical Co Ltd
DM13YN0	DE	Cerebrovascular ischaemia

DM1ZYCA	ID	DM1ZYCA
DM1ZYCA	DN	TALTOBULIN
DM1ZYCA	HS	Discontinued in Phase 1
DM1ZYCA	SN	HTI-286; SPA-110 (trifluoroacetate salt); Taltobulin; N,3,3-Trimethyl-L-phenylalanyl-N1-[3-carboxy-1(S)-isopropyl-2(E)-butenyl]-N1,3-dimethyl-L-valinamide
DM1ZYCA	DT	Small molecular drug
DM1ZYCA	PC	6918637
DM1ZYCA	MW	473.6
DM1ZYCA	FM	C27H43N3O4
DM1ZYCA	IC	InChI=1S/C27H43N3O4/c1-17(2)20(16-18(3)25(33)34)30(10)24(32)22(26(4,5)6)29-23(31)21(28-9)27(7,8)19-14-12-11-13-15-19/h11-17,20-22,28H,1-10H3,(H,29,31)(H,33,34)/b18-16+/t20-,21-,22-/m1/s1
DM1ZYCA	CS	CC(C)[C@@H](/C=C(\\C)/C(=O)O)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C(C)(C)C1=CC=CC=C1)NC
DM1ZYCA	IK	CNTMOLDWXSVYKD-PSRNMDMQSA-N
DM1ZYCA	IU	(E,4S)-4-[[(2S)-3,3-dimethyl-2-[[(2S)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid
DM1ZYCA	CA	CAS 228266-40-8
DM1ZYCA	DE	Solid tumour/cancer

DM5PZ60	ID	DM5PZ60
DM5PZ60	DN	TAZOMELINE
DM5PZ60	HS	Discontinued in Phase 1
DM5PZ60	SN	Hexylthio-TZTP; LY-287041; Tazomeline < Prop INN; NNC-11-0309; 3-[3-(Hexylthio)-1,2,5-thiadiazol-4-yl]-1-methyl-1,2,5,6-tetrahydropyridine
DM5PZ60	DT	Small molecular drug
DM5PZ60	PC	131460
DM5PZ60	MW	297.5
DM5PZ60	FM	C14H23N3S2
DM5PZ60	IC	InChI=1S/C14H23N3S2/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12/h8H,3-7,9-11H2,1-2H3
DM5PZ60	CS	CCCCCCSC1=NSN=C1C2=CCCN(C2)C
DM5PZ60	IK	XUHMGFKQBWZWPO-UHFFFAOYSA-N
DM5PZ60	IU	3-hexylsulfanyl-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DM5PZ60	CA	CAS 131987-54-7
DM5PZ60	DE	Cognitive impairment

DMCA97F	ID	DMCA97F
DMCA97F	DN	TD-2749
DMCA97F	HS	Discontinued in Phase 1
DMCA97F	CP	Theravance
DMCA97F	PC	11225102
DMCA97F	MW	466.6
DMCA97F	FM	C26H38N6O2
DMCA97F	IC	InChI=1S/C26H38N6O2/c1-18(2)32-24-7-5-4-6-23(24)25(28-32)26(34)27-20-16-21-8-9-22(17-20)31(21)15-12-29-10-13-30(14-11-29)19(3)33/h4-7,18,20-22H,8-17H2,1-3H3,(H,27,34)/t20?,21-,22+
DMCA97F	CS	CC(C)N1C2=CC=CC=C2C(=N1)C(=O)NC3C[C@H]4CC[C@@H](C3)N4CCN5CCN(CC5)C(=O)C
DMCA97F	IK	ZQMXTDPQEHZTBG-FRIKZZABSA-N
DMCA97F	IU	N-[(1R,5S)-8-[2-(4-acetylpiperazin-1-yl)ethyl]-8-azabicyclo[3.2.1]octan-3-yl]-1-propan-2-ylindazole-3-carboxamide
DMCA97F	CA	CAS 863248-59-3
DMCA97F	DE	Gastrointestinal disease

DMDT5HZ	ID	DMDT5HZ
DMDT5HZ	DN	Teloxantrone
DMDT5HZ	HS	Discontinued in Phase 1
DMDT5HZ	SN	Moxantrazole; Teloxantrone hydrochloride; Teloxantrone hydrochloride hydrate; DuP-937; PD-113309
DMDT5HZ	CP	Parke-Davis & Co
DMDT5HZ	DT	Small molecular drug
DMDT5HZ	PC	124644
DMDT5HZ	MW	411.5
DMDT5HZ	FM	C21H25N5O4
DMDT5HZ	IC	InChI=1S/C21H25N5O4/c1-22-6-7-24-12-2-3-13-17-16(12)21(30)19-15(29)5-4-14(28)18(19)20(17)25-26(13)10-8-23-9-11-27/h2-5,22-23,25,27,29-30H,6-11H2,1H3
DMDT5HZ	CS	CNCCN=C1C=CC2=C3C1=C(C4=C(C=CC(=O)C4=C3NN2CCNCCO)O)O
DMDT5HZ	IK	WOPAVGQTOMNFGS-UHFFFAOYSA-N
DMDT5HZ	IU	6,8-dihydroxy-14-[2-(2-hydroxyethylamino)ethyl]-10-[2-(methylamino)ethylimino]-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1,4,6,8,11,13(16)-hexaen-3-one
DMDT5HZ	CA	CAS 91441-48-4
DMDT5HZ	DE	Solid tumour/cancer

DM9KYVQ	ID	DM9KYVQ
DM9KYVQ	DN	TG-1024
DM9KYVQ	HS	Discontinued in Phase 1
DM9KYVQ	SN	Ad-IL-2, Transgene; Adenoviral-IL-2, Transgene
DM9KYVQ	CP	Transgene SA; Transgene
DM9KYVQ	DE	Solid tumour/cancer

DMELNA8	ID	DMELNA8
DMELNA8	DN	TGN-1412
DMELNA8	HS	Discontinued in Phase 1
DMELNA8	SN	SuperMAB; CD28-SuperMAB; Superagonistic monoclonal antibodies, TeGenero
DMELNA8	CP	TeGenero ImmunoTherapeutics AG
DMELNA8	DT	Antibody
DMELNA8	DE	Autoimmune diabetes

DMTC4LP	ID	DMTC4LP
DMTC4LP	DN	Tidembersat
DMTC4LP	HS	Discontinued in Phase 1
DMTC4LP	SN	SB-218842
DMTC4LP	CP	SmithKline Beecham plc
DMTC4LP	DT	Small molecular drug
DMTC4LP	PC	170378
DMTC4LP	MW	375.4
DMTC4LP	FM	C20H19F2NO4
DMTC4LP	IC	InChI=1S/C20H19F2NO4/c1-10(24)11-4-5-16-15(8-11)17(18(25)20(2,3)27-16)23-19(26)12-6-13(21)9-14(22)7-12/h4-9,17-18,25H,1-3H3,(H,23,26)/t17-,18+/m0/s1
DMTC4LP	CS	CC(=O)C1=CC2=C(C=C1)OC([C@@H]([C@H]2NC(=O)C3=CC(=CC(=C3)F)F)O)(C)C
DMTC4LP	IK	NWHCDESSIHFNIJ-ZWKOTPCHSA-N
DMTC4LP	IU	N-[(3R,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3,5-difluorobenzamide
DMTC4LP	CA	CAS 175013-73-7
DMTC4LP	DE	Migraine

DMI0Q8Y	ID	DMI0Q8Y
DMI0Q8Y	DN	TOP-53
DMI0Q8Y	HS	Discontinued in Phase 1
DMI0Q8Y	SN	Top 53; (5R,5aR,8aR,9S)-9-[2-[2-dimethylaminoethyl(methyl)amino]ethyl]-5-(4-hydroxy-3,5-dimethoxyphenyl)-5a,8,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-6-one dihydrochloride
DMI0Q8Y	CP	Taiho Pharmaceutical Co Ltd
DMI0Q8Y	DT	Small molecular drug
DMI0Q8Y	PC	177859
DMI0Q8Y	MW	512.6
DMI0Q8Y	FM	C28H36N2O7
DMI0Q8Y	IC	InChI=1S/C28H36N2O7/c1-29(2)8-9-30(3)7-6-17-18-12-21-22(37-15-36-21)13-19(18)25(26-20(17)14-35-28(26)32)16-10-23(33-4)27(31)24(11-16)34-5/h10-13,17,20,25-26,31H,6-9,14-15H2,1-5H3/t17-,20-,25-,26+/m1/s1
DMI0Q8Y	CS	CN(C)CCN(C)CC[C@H]1[C@H]2COC(=O)[C@@H]2[C@@H](C3=CC4=C(C=C13)OCO4)C5=CC(=C(C(=C5)OC)O)OC
DMI0Q8Y	IK	KLCCMMSKRMSMKI-QVNMXXJYSA-N
DMI0Q8Y	IU	(5R,5aR,8aR,9S)-9-[2-[2-(dimethylamino)ethyl-methylamino]ethyl]-5-(4-hydroxy-3,5-dimethoxyphenyl)-5a,8,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-6-one
DMI0Q8Y	CA	CAS 148262-19-5
DMI0Q8Y	CB	CHEBI:134547
DMI0Q8Y	DE	Metastatic lung cancer

DM6SUDC	ID	DM6SUDC
DM6SUDC	DN	Totrombopag
DM6SUDC	HS	Discontinued in Phase 1
DM6SUDC	SN	Totrombopag; SB-559448; 376592-42-6; Totrombopag [INN]; 5-(3'-((2Z)-2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxybiphenyl-3-yl)tetrazol-1-ide; 1H-Pyrazole-4,5-dione,1-(3,4-dimethylphenyl)-3-methyl-,4-((2-hydroxy-3'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-3-yl)hydrazone), ion(1-), (4Z)-
DM6SUDC	CP	GSK
DM6SUDC	DT	Small molecular drug
DM6SUDC	PC	135871124
DM6SUDC	MW	466.5
DM6SUDC	FM	C25H22N8O2
DM6SUDC	IC	InChI=1S/C25H22N8O2/c1-14-10-11-19(12-15(14)2)33-25(35)22(16(3)30-33)27-26-21-9-5-8-20(23(21)34)17-6-4-7-18(13-17)24-28-31-32-29-24/h4-13,22,34H,1-3H3,(H,28,29,31,32)
DM6SUDC	CS	CC1=C(C=C(C=C1)N2C(=O)C(C(=N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C5=NNN=N5)C
DM6SUDC	IK	KWJKFQSAMABKBG-UHFFFAOYSA-N
DM6SUDC	IU	2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3-[3-(2H-tetrazol-5-yl)phenyl]phenyl]diazenyl]-5-methyl-4H-pyrazol-3-one
DM6SUDC	DE	Thrombocytopenia

DMCV2KQ	ID	DMCV2KQ
DMCV2KQ	DN	TP-9201
DMCV2KQ	HS	Discontinued in Phase 1
DMCV2KQ	SN	Acetyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-arginyl-glycyl-L-aspartyl-L-(4-O-methyl)-tyrosyl-L-arginyl-L-cysteinamide cyclic 1-9-disulfide
DMCV2KQ	DT	Small molecular drug
DMCV2KQ	PC	6918252
DMCV2KQ	MW	1136.3
DMCV2KQ	FM	C45H69N17O14S2
DMCV2KQ	IC	InChI=1S/C45H69N17O14S2/c1-22(63)55-31-21-78-77-20-30(36(47)68)61-38(70)26(7-4-14-53-45(50)51)57-39(71)27(16-23-9-11-24(76-2)12-10-23)59-40(72)28(18-35(66)67)56-34(65)19-54-37(69)25(6-3-13-52-44(48)49)58-42(74)32-8-5-15-62(32)43(75)29(17-33(46)64)60-41(31)73/h9-12,25-32H,3-8,13-21H2,1-2H3,(H2,46,64)(H2,47,68)(H,54,69)(H,55,63)(H,56,65)(H,57,71)(H,58,74)(H,59,72)(H,60,73)(H,61,70)(H,66,67)(H4,48,49,52)(H4,50,51,53)/t25-,26-,27-,28-,29-,30-,31-,32-/m0/s1
DMCV2KQ	CS	CC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC1=O)CC(=O)N)CCCN=C(N)N)CC(=O)O)CC3=CC=C(C=C3)OC)CCCN=C(N)N)C(=O)N
DMCV2KQ	IK	RRPUNOOJZOAZNU-ALERXTORSA-N
DMCV2KQ	IU	2-[(3S,6R,11R,14S,17S,20S,26S,29S)-6-acetamido-3-(2-amino-2-oxoethyl)-11-carbamoyl-14,26-bis[3-(diaminomethylideneamino)propyl]-17-[(4-methoxyphenyl)methyl]-2,5,13,16,19,22,25,28-octaoxo-8,9-dithia-1,4,12,15,18,21,24,27-octazabicyclo[27.3.0]dotriacontan-20-yl]acetic acid
DMCV2KQ	CA	CAS 138297-15-1
DMCV2KQ	DE	Thrombosis

DMWD39E	ID	DMWD39E
DMWD39E	DN	Tr-14035
DMWD39E	HS	Discontinued in Phase 1
DMWD39E	SN	232271-19-1; TR-14035; (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid; CHEMBL91485; N-(2,6-DICHLOROBENZOYL)-4-(2,6-DIMETHOXYPHENYL)-L-PHENYLALANINE; C24H21Cl2NO5; DRSJLVGDSNWQBI-SFHVURJKSA-N; TR 14035; SCHEMBL1222491; BDBM16801; CTK8C1530; MolPort-023-334-229; ZINC1490484; ANW-66841; N-Acyl-4-arylphenylalanine analogue.; AKOS016008162; CS-1812; CS-W000631; MP-2027; NCGC00390619-01; SB683698; HY-15770; AK-95353; AJ-26339; KB-210922; TC-155586; AB0077984; AX8237663; ST24020804; Z4458
DMWD39E	DT	Small molecular drug
DMWD39E	PC	9912743
DMWD39E	MW	474.3
DMWD39E	FM	C24H21Cl2NO5
DMWD39E	IC	InChI=1S/C24H21Cl2NO5/c1-31-19-7-4-8-20(32-2)21(19)15-11-9-14(10-12-15)13-18(24(29)30)27-23(28)22-16(25)5-3-6-17(22)26/h3-12,18H,13H2,1-2H3,(H,27,28)(H,29,30)/t18-/m0/s1
DMWD39E	CS	COC1=C(C(=CC=C1)OC)C2=CC=C(C=C2)C[C@@H](C(=O)O)NC(=O)C3=C(C=CC=C3Cl)Cl
DMWD39E	IK	DRSJLVGDSNWQBI-SFHVURJKSA-N
DMWD39E	IU	(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(2,6-dimethoxyphenyl)phenyl]propanoic acid
DMWD39E	CA	CAS 232271-19-1
DMWD39E	DE	Multiple sclerosis

DMH5SA6	ID	DMH5SA6
DMH5SA6	DN	TR-14531
DMH5SA6	HS	Discontinued in Phase 1
DMH5SA6	SN	IDDB25065
DMH5SA6	CP	Tanabe Seiyaku Co Ltd
DMH5SA6	DE	Asthma

DMZ5RA7	ID	DMZ5RA7
DMZ5RA7	DN	TRK-851
DMZ5RA7	HS	Discontinued in Phase 1
DMZ5RA7	SN	(4bS,8R,8aS,16bR)-7-(Cyclopropylmethyl)-11-fluoro-5,6,7,8,9,14,15,16b-octahydro-4,8-methano-8aH,13H-[1]benzofuro[2,3-a]dipyrido[4,3-b:3',2',1'-jk]carbazole-1,8a-diol; 189015-25-6
DMZ5RA7	DE	Cough

DMSFV9T	ID	DMSFV9T
DMSFV9T	DN	TRM-115
DMSFV9T	HS	Discontinued in Phase 1
DMSFV9T	SN	TRM-15
DMSFV9T	CP	Terumo Corp
DMSFV9T	DT	Small molecular drug
DMSFV9T	PC	6918243
DMSFV9T	MW	512.7
DMSFV9T	FM	C27H36N4O4S
DMSFV9T	IC	InChI=1S/C27H36N4O4S/c32-26(9-5-12-29-27(36)30-22-10-11-24-25(18-22)35-20-34-24)28-13-6-16-33-23-8-4-7-21(17-23)19-31-14-2-1-3-15-31/h4,7-8,10-11,17-18H,1-3,5-6,9,12-16,19-20H2,(H,28,32)(H2,29,30,36)
DMSFV9T	CS	C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC(=O)CCCNC(=S)NC3=CC4=C(C=C3)OCO4
DMSFV9T	IK	DZSMTMGGLVZZLW-UHFFFAOYSA-N
DMSFV9T	IU	4-(1,3-benzodioxol-5-ylcarbamothioylamino)-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]butanamide
DMSFV9T	DE	Gastric ulcer

DMOHEYU	ID	DMOHEYU
DMOHEYU	DN	TS-032
DMOHEYU	HS	Discontinued in Phase 1
DMOHEYU	SN	PF-04802540; PF-4802540; MGluR agonists (schizophrenia), Taisho; Metabotropic glutamate receptor agonists (schizophrenia), Taisho; MGluR agonists (schizophrenia), Taisho/Pfizer; Metabotropic glutamate receptor agonists (schizophrenia), Taisho/Pfizer
DMOHEYU	CP	Taisho Pharmaceutical Co Ltd
DMOHEYU	DE	Schizophrenia

DMHJXL6	ID	DMHJXL6
DMHJXL6	DN	TT-235
DMHJXL6	HS	Discontinued in Phase 1
DMHJXL6	SN	[beta,beta-(3-Thiapentamethylene)-beta-sulfanylpropionic acid,D-Trp2,Pen6,Arg8]-oxytocin acetate
DMHJXL6	DE	Miscarriage

DMTVC3W	ID	DMTVC3W
DMTVC3W	DN	U-103017
DMTVC3W	HS	Discontinued in Phase 1
DMTVC3W	SN	Pnu-103017; Pnu 103017; U-103017; 166335-18-8; PNU-103264; AC1Q4RFB; AC1L1KS2; SCHEMBL7352941; CHEMBL2062136; 4-cyano-n-{3-[cyclopropyl(2-hydroxy-4-oxo-5,6,7,8,9,10-hexahydro-4h-cycloocta[b]pyran-3-yl)methyl]phenyl}benzenesulfonamide; HY-19236; 4-Cyano-N-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2H-cycloocta(b)pyran-3-yl)methyl )phenyl)benzenesulfonamide; 4-Cyano-N-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2H-cycloocta(b)pyran-3-yl)methyl)phenyl)benzenesulfonamide; CS-0014977; U103017
DMTVC3W	CP	Upjohn Co Ltd
DMTVC3W	DT	Small molecular drug
DMTVC3W	PC	54692909
DMTVC3W	MW	504.6
DMTVC3W	FM	C28H28N2O5S
DMTVC3W	IC	InChI=1S/C28H28N2O5S/c29-17-18-10-14-22(15-11-18)36(33,34)30-21-7-5-6-20(16-21)25(19-12-13-19)26-27(31)23-8-3-1-2-4-9-24(23)35-28(26)32/h5-7,10-11,14-16,19,25,30-31H,1-4,8-9,12-13H2
DMTVC3W	CS	C1CCCC2=C(CC1)C(=C(C(=O)O2)C(C3CC3)C4=CC(=CC=C4)NS(=O)(=O)C5=CC=C(C=C5)C#N)O
DMTVC3W	IK	VCYQENLVFRTJIC-UHFFFAOYSA-N
DMTVC3W	IU	4-cyano-N-[3-[cyclopropyl-(4-hydroxy-2-oxo-5,6,7,8,9,10-hexahydrocycloocta[b]pyran-3-yl)methyl]phenyl]benzenesulfonamide
DMTVC3W	CA	CAS 166335-18-8
DMTVC3W	DE	Human immunodeficiency virus infection

DMC94D2	ID	DMC94D2
DMC94D2	DN	U-104067F
DMC94D2	HS	Discontinued in Phase 1
DMC94D2	SN	U-104067 (anhydrous free base); 9-[2-(4-Morpholinyl)ethyl]-2,4-bis(pyrrolidin-1-yl]-9H-pyrimido[4,5-b]indole monohydrochloride hemihydrate
DMC94D2	DT	Small molecular drug
DMC94D2	PC	9890309
DMC94D2	MW	457
DMC94D2	FM	C24H33ClN6O
DMC94D2	IC	InChI=1S/C24H32N6O.ClH/c1-2-8-20-19(7-1)21-22(28-9-3-4-10-28)25-24(29-11-5-6-12-29)26-23(21)30(20)14-13-27-15-17-31-18-16-27;/h1-2,7-8H,3-6,9-18H2;1H
DMC94D2	CS	C1CCN(C1)C2=NC(=NC3=C2C4=CC=CC=C4N3CCN5CCOCC5)N6CCCC6.Cl
DMC94D2	IK	OTTSSGXCAVAVKV-UHFFFAOYSA-N
DMC94D2	IU	4-[2-(2,4-dipyrrolidin-1-ylpyrimido[4,5-b]indol-9-yl)ethyl]morpholine;hydrochloride
DMC94D2	CA	CAS 172035-75-5
DMC94D2	DE	Neurological disorder

DM2WOPX	ID	DM2WOPX
DM2WOPX	DN	U-78875
DM2WOPX	HS	Discontinued in Phase 1
DM2WOPX	SN	PANADIPLON; 124423-84-3; U-78875; UNII-V4PW0S7ZP7; V4PW0S7ZP7; FG-10571; CHEMBL279867; Panadiplonum; Panadiplone; AC1MHWDJ; Panadiplon (USAN/INN); Panadiplon (U-78875); SCHEMBL123304; ZINC4220; DTXSID40869698; BDBM50048837; AKOS015904452; RL01109; API0007797; ZB000564; D05346; J-523865; 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-propan-2-ylimidazo[1,5-a]quinoxalin-4-one; 3-(5-Cyclopropyl-[1,2,4]oxadiazol-3-yl)-5-isopropyl-5H-imidazo[1,5-a]quinoxalin-4-one
DM2WOPX	DT	Small molecular drug
DM2WOPX	PC	3033821
DM2WOPX	MW	335.4
DM2WOPX	FM	C18H17N5O2
DM2WOPX	IC	InChI=1S/C18H17N5O2/c1-10(2)23-13-6-4-3-5-12(13)22-9-19-14(15(22)18(23)24)16-20-17(25-21-16)11-7-8-11/h3-6,9-11H,7-8H2,1-2H3
DM2WOPX	CS	CC(C)N1C2=CC=CC=C2N3C=NC(=C3C1=O)C4=NOC(=N4)C5CC5
DM2WOPX	IK	ZGEGOFCLSWVVKG-UHFFFAOYSA-N
DM2WOPX	IU	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-propan-2-ylimidazo[1,5-a]quinoxalin-4-one
DM2WOPX	CA	CAS 124423-84-3
DM2WOPX	DE	Anxiety disorder

DMMSWJ3	ID	DMMSWJ3
DMMSWJ3	DN	U-93385
DMMSWJ3	HS	Discontinued in Phase 1
DMMSWJ3	SN	(-)-cis-3-Propyl-2,3,3a(R),4,5,9b-hexahydro-1H-benz[e]indole-9-carboxamide
DMMSWJ3	DT	Small molecular drug
DMMSWJ3	PC	132792
DMMSWJ3	MW	258.36
DMMSWJ3	FM	C16H22N2O
DMMSWJ3	IC	InChI=1S/C16H22N2O/c1-2-9-18-10-8-12-14(18)7-6-11-4-3-5-13(15(11)12)16(17)19/h3-5,12,14H,2,6-10H2,1H3,(H2,17,19)/t12-,14-/m1/s1
DMMSWJ3	CS	CCCN1CC[C@@H]2[C@H]1CCC3=C2C(=CC=C3)C(=O)N
DMMSWJ3	IK	JSZBRMZCAIJCKB-TZMCWYRMSA-N
DMMSWJ3	IU	(3aR,9bS)-3-propyl-1,2,3a,4,5,9b-hexahydrobenzo[e]indole-9-carboxamide
DMMSWJ3	CA	CAS 147145-16-2
DMMSWJ3	DE	Anxiety disorder

DML73BR	ID	DML73BR
DML73BR	DN	U-96988
DML73BR	HS	Discontinued in Phase 1
DML73BR	SN	U-96988; CHEMBL22164; PNU-96988; AC1LA3LC; BDBM770; SCHEMBL6173602; 149394-65-0; U96988; 6-(1-benzylpropyl)-4-hydroxy-3-(1-phenylpropyl)pyran-2-one; 2-hydroxy-6-(1-phenylbutan-2-yl)-3-(1-phenylpropyl)pyran-4-one
DML73BR	CP	Pharmacia & Upjohn Co
DML73BR	DT	Small molecular drug
DML73BR	PC	54686718
DML73BR	MW	362.5
DML73BR	FM	C24H26O3
DML73BR	IC	InChI=1S/C24H26O3/c1-3-18(15-17-11-7-5-8-12-17)22-16-21(25)23(24(26)27-22)20(4-2)19-13-9-6-10-14-19/h5-14,16,18,20,25H,3-4,15H2,1-2H3
DML73BR	CS	CCC(CC1=CC=CC=C1)C2=CC(=C(C(=O)O2)C(CC)C3=CC=CC=C3)O
DML73BR	IK	HALPINAQGOXQAN-UHFFFAOYSA-N
DML73BR	IU	4-hydroxy-6-(1-phenylbutan-2-yl)-3-(1-phenylpropyl)pyran-2-one
DML73BR	DE	Human immunodeficiency virus infection

DML51D0	ID	DML51D0
DML51D0	DN	UCL-2000; butabindide
DML51D0	HS	Discontinued in Phase 1
DML51D0	CP	University College London
DML51D0	DE	Obesity

DMGFPIY	ID	DMGFPIY
DMGFPIY	DN	UK-156406
DMGFPIY	HS	Discontinued in Phase 1
DMGFPIY	SN	1-[3-(3-Amidinophenyl)-2(S)-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ylsulfonamido)propionyl]-4-methyl-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid; 1-[3-Amidino-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ylsulfonyl)-L-phenylalanyl]-4-methyl-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid
DMGFPIY	DT	Small molecular drug
DMGFPIY	PC	44342278
DMGFPIY	MW	539.6
DMGFPIY	FM	C27H33N5O5S
DMGFPIY	IC	InChI=1S/C27H33N5O5S/c1-17-9-12-32(24(13-17)27(34)35)26(33)23(14-18-3-5-20(6-4-18)25(28)29)30-38(36,37)22-8-7-19-10-11-31(2)16-21(19)15-22/h3-9,15,23-24,30H,10-14,16H2,1-2H3,(H3,28,29)(H,34,35)/t23-,24+/m0/s1
DMGFPIY	CS	CC1=CCN([C@H](C1)C(=O)O)C(=O)[C@H](CC2=CC=C(C=C2)C(=N)N)NS(=O)(=O)C3=CC4=C(CCN(C4)C)C=C3
DMGFPIY	IK	ZDHBBBQAVLNJBL-BJKOFHAPSA-N
DMGFPIY	IU	(2R)-1-[(2S)-3-(4-carbamimidoylphenyl)-2-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)sulfonylamino]propanoyl]-4-methyl-3,6-dihydro-2H-pyridine-2-carboxylic acid
DMGFPIY	DE	Myocardial infarction

DMDTRJB	ID	DMDTRJB
DMDTRJB	DN	UK-224671
DMDTRJB	HS	Discontinued in Phase 1
DMDTRJB	SN	UK-369202; UK-416960
DMDTRJB	CP	Pfizer Inc
DMDTRJB	DT	Small molecular drug
DMDTRJB	PC	9915372
DMDTRJB	MW	544.5
DMDTRJB	FM	C24H35Cl2N5O3S
DMDTRJB	IC	InChI=1S/C24H35Cl2N5O3S/c25-21-4-3-19(13-22(21)26)24(6-5-23(32)30(17-24)14-18-1-2-18)7-8-28-15-20(16-28)29-9-11-31(12-10-29)35(27,33)34/h3-4,13,18,20H,1-2,5-12,14-17H2,(H2,27,33,34)/t24-/m1/s1
DMDTRJB	CS	C1CC1CN2C[C@@](CCC2=O)(CCN3CC(C3)N4CCN(CC4)S(=O)(=O)N)C5=CC(=C(C=C5)Cl)Cl
DMDTRJB	IK	OQXJUJDDCWHRLA-XMMPIXPASA-N
DMDTRJB	IU	4-[1-[2-[(3S)-1-(cyclopropylmethyl)-3-(3,4-dichlorophenyl)-6-oxopiperidin-3-yl]ethyl]azetidin-3-yl]piperazine-1-sulfonamide
DMDTRJB	DE	Urinary incontinence

DMXN9Z5	ID	DMXN9Z5
DMXN9Z5	DN	UR-7198
DMXN9Z5	HS	Discontinued in Phase 1
DMXN9Z5	SN	UR-7247; UR-7280; Angiotensin II AT-1 antagonists, Uriach; UR-7280 analogs, Uriach
DMXN9Z5	CP	Grupo Uriach
DMXN9Z5	DE	Hypertension

DMR2EUV	ID	DMR2EUV
DMR2EUV	DN	V-102862
DMR2EUV	HS	Discontinued in Phase 1
DMR2EUV	SN	CO 102862; UNII-0KN11H90GF; 181144-66-1; V-102862; CHEMBL287833; 0KN11H90GF; 4-(4-fluorophenoxy)benzaldehyde semicarbazone; (E)-2-(4-(4-fluorophenoxy)benz-ylidene)hydrazinecarboxamide; V102862; 2-(4-(4-Fluorophenoxy)benzylidene)hydrazinecarboxamide; 2-((4-(4-Fluorophenoxy)phenyl)methylene)hydrazinecarboxamide; CO-102862; 2-[[4-(4-Fluorophenoxy)phenyl]methylene]hydrazinecarboxamide; Hydrazinecarboxamide, 2-((4-(4-fluorophenoxy)phenyl)methylene)-; CHEBI:92156; MolPort-022-863-701; BDBM50141073; AKOS016004881; NCGC00167807-01
DMR2EUV	DT	Small molecular drug
DMR2EUV	PC	9816959
DMR2EUV	MW	273.26
DMR2EUV	FM	C14H12FN3O2
DMR2EUV	IC	InChI=1S/C14H12FN3O2/c15-11-3-7-13(8-4-11)20-12-5-1-10(2-6-12)9-17-18-14(16)19/h1-9H,(H3,16,18,19)/b17-9+
DMR2EUV	CS	C1=CC(=CC=C1/C=N/NC(=O)N)OC2=CC=C(C=C2)F
DMR2EUV	IK	MHUUDVZSPFRUSK-RQZCQDPDSA-N
DMR2EUV	IU	[(E)-[4-(4-fluorophenoxy)phenyl]methylideneamino]urea
DMR2EUV	CA	CAS 181144-66-1
DMR2EUV	CB	CHEBI:92156

DMLFMSY	ID	DMLFMSY
DMLFMSY	DN	V85546
DMLFMSY	HS	Discontinued in Phase 1
DMLFMSY	CP	Vernalis
DMLFMSY	TC	Antiinflammatory Agents
DMLFMSY	DE	Inflammation

DMBQPA5	ID	DMBQPA5
DMBQPA5	DN	Vanoxerine
DMBQPA5	HS	Discontinued in Phase 1
DMBQPA5	SN	Vanoxerina; Vanoxerinum; Vanoxerine [INN]; D-052; Vanoxerina [INN-Spanish]; Vanoxerinum [INN-Latin]; Piperazine, 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)-, dihydrochloride; 1-(2 (Bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine di-hcl; 1-(2-(Bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine; 1-(2-bis-[4-FLUOROPHENYL]-METHOXYETHYL)-4-(3-PHENYL-2-PROPYL)PIPERAZINE; 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
DMBQPA5	CP	National Institute on Drug Abuse
DMBQPA5	DT	Small molecular drug
DMBQPA5	PC	3455
DMBQPA5	MW	450.6
DMBQPA5	FM	C28H32F2N2O
DMBQPA5	IC	InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2
DMBQPA5	CS	C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMBQPA5	IK	NAUWTFJOPJWYOT-UHFFFAOYSA-N
DMBQPA5	IU	1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
DMBQPA5	CA	CAS 67469-69-6
DMBQPA5	CB	CHEBI:64089
DMBQPA5	DE	Cocaine addiction

DMKRG0I	ID	DMKRG0I
DMKRG0I	DN	VNA-932
DMKRG0I	HS	Discontinued in Phase 1
DMKRG0I	SN	WAY-VNA-932; [2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)phenyl](10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-10-y-)methanone; 10-[2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine
DMKRG0I	DT	Small molecular drug
DMKRG0I	PC	5311500
DMKRG0I	MW	402.9
DMKRG0I	FM	C23H19ClN4O
DMKRG0I	IC	InChI=1S/C23H19ClN4O/c1-16-10-12-28(25-16)18-8-9-20(21(24)13-18)23(29)27-15-19-6-4-11-26(19)14-17-5-2-3-7-22(17)27/h2-13H,14-15H2,1H3
DMKRG0I	CS	CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
DMKRG0I	IK	JXKQHDZUZGKDGO-UHFFFAOYSA-N
DMKRG0I	IU	[2-chloro-4-(3-methylpyrazol-1-yl)phenyl]-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepin-5-yl)methanone
DMKRG0I	CA	CAS 220460-92-4
DMKRG0I	DE	Urinary incontinence

DMATEL0	ID	DMATEL0
DMATEL0	DN	Vorsetuzumab mafodotin
DMATEL0	HS	Discontinued in Phase 1
DMATEL0	CP	Seattle Genetics
DMATEL0	DT	Antibody
DMATEL0	DE	Renal cell carcinoma

DMXK8FQ	ID	DMXK8FQ
DMXK8FQ	DN	VP004
DMXK8FQ	HS	Discontinued in Phase 1
DMXK8FQ	CP	Indevus Pharmaceuticals
DMXK8FQ	DT	Antibody
DMXK8FQ	DE	Substance use disorder

DM0HZBU	ID	DM0HZBU
DM0HZBU	DN	VP-025
DM0HZBU	HS	Discontinued in Phase 1
DM0HZBU	SN	Inflammation therapeutics, Vasogen; VP-015
DM0HZBU	CP	Vasogen
DM0HZBU	DE	Alzheimer disease

DMFQWNI	ID	DMFQWNI
DMFQWNI	DN	VR-776
DMFQWNI	HS	Discontinued in Phase 1
DMFQWNI	SN	Premature ejaculation therapy (inhaled, PowerHale), Vectura
DMFQWNI	CP	Vectura Group plc
DMFQWNI	DT	Small molecular drug
DMFQWNI	PC	68539
DMFQWNI	MW	351.3
DMFQWNI	FM	C19H24Cl2N2
DMFQWNI	IC	InChI=1S/C19H23ClN2.ClH/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22;/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3;1H
DMFQWNI	CS	CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl
DMFQWNI	IK	WIMWMKZEIBHDTH-UHFFFAOYSA-N
DMFQWNI	IU	3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;hydrochloride
DMFQWNI	CA	CAS 17321-77-6
DMFQWNI	CB	CHEBI:3755
DMFQWNI	DE	Premature ejaculation

DM3GD7V	ID	DM3GD7V
DM3GD7V	DN	WAY-100289
DM3GD7V	HS	Discontinued in Phase 1
DM3GD7V	SN	Endo-2-(Cyclopropylmethoxy)-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-ylcarbamoyl)benzamide maleate; Endo-1-[2-(Cyclopropylmethoxy)benzoyl]-3-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)urea maleate
DM3GD7V	DT	Small molecular drug
DM3GD7V	PC	6918186
DM3GD7V	MW	357.4
DM3GD7V	FM	C20H27N3O3
DM3GD7V	IC	InChI=1S/C20H27N3O3/c1-23-15-8-9-16(23)11-14(10-15)21-20(25)22-19(24)17-4-2-3-5-18(17)26-12-13-6-7-13/h2-5,13-16H,6-12H2,1H3,(H2,21,22,24,25)/t14?,15-,16+
DM3GD7V	CS	CN1[C@@H]2CC[C@H]1CC(C2)NC(=O)NC(=O)C3=CC=CC=C3OCC4CC4
DM3GD7V	IK	VFRIHPWRNNTKEX-MQVJKMGUSA-N
DM3GD7V	IU	2-(cyclopropylmethoxy)-N-[[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]carbamoyl]benzamide
DM3GD7V	CA	CAS 136013-69-9
DM3GD7V	DE	Anxiety disorder

DM8SVHI	ID	DM8SVHI
DM8SVHI	DN	WAY-181187
DM8SVHI	HS	Discontinued in Phase 1
DM8SVHI	SN	WAY-181187; 554403-49-5; UNII-WXE3H7W295; WXE3H7W295; WAY-181,187; WAY 181187; SCHEMBL801436; WAY181187 HCl; GTPL3240; CHEMBL392760; BDBM21358; SAX-187; DTXSID50204011; EX-A799; MolPort-005-933-335; ZINC3816551; AKOS028111927; WAY-181187(SAX-187); KB-81479; FT-0700331; WAY181187.HCl pound WAY-181 187 pound(c); J-690323; N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine; 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-1H-indole-3-ethanamine
DM8SVHI	DT	Small molecular drug
DM8SVHI	PC	10150497
DM8SVHI	MW	380.9
DM8SVHI	FM	C15H13ClN4O2S2
DM8SVHI	IC	InChI=1S/C15H13ClN4O2S2/c16-13-14(19-7-8-23-15(19)18-13)24(21,22)20-9-10(5-6-17)11-3-1-2-4-12(11)20/h1-4,7-9H,5-6,17H2
DM8SVHI	CS	C1=CC=C2C(=C1)C(=CN2S(=O)(=O)C3=C(N=C4N3C=CS4)Cl)CCN
DM8SVHI	IK	RYBOXBBYCVOYNO-UHFFFAOYSA-N
DM8SVHI	IU	2-[1-(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonylindol-3-yl]ethanamine
DM8SVHI	CA	CAS 554403-49-5
DM8SVHI	DE	Anxiety disorder

DMSZJ5H	ID	DMSZJ5H
DMSZJ5H	DN	Wetimicin
DMSZJ5H	HS	Discontinued in Phase 1
DMSZJ5H	SN	Aminoglycoside antibiotic (infection), Jiangsu Institute of Microbiology
DMSZJ5H	CP	Jiangsu Institute of Microbiology
DMSZJ5H	DE	Infectious disease

DMHTG38	ID	DMHTG38
DMHTG38	DN	XL844
DMHTG38	HS	Discontinued in Phase 1
DMHTG38	SN	SCHEMBL14517914; XL-844
DMHTG38	CP	Exelixis
DMHTG38	TC	Anticancer Agents
DMHTG38	DT	Small molecular drug
DMHTG38	PC	10016910
DMHTG38	MW	287.32
DMHTG38	FM	C14H17N5O2
DMHTG38	IC	InChI=1S/C14H17N5O2/c15-6-3-9-21-12-5-2-1-4-11(12)18-14(20)19-13-10-16-7-8-17-13/h1-2,4-5,7-8,10H,3,6,9,15H2,(H2,17,18,19,20)
DMHTG38	CS	C1=CC=C(C(=C1)NC(=O)NC2=NC=CN=C2)OCCCN
DMHTG38	IK	UVSSZSQSZGKMAL-UHFFFAOYSA-N
DMHTG38	IU	1-[2-(3-aminopropoxy)phenyl]-3-pyrazin-2-ylurea
DMHTG38	DE	Solid tumour/cancer

DMQKH07	ID	DMQKH07
DMQKH07	DN	XM-323
DMQKH07	HS	Discontinued in Phase 1
DMQKH07	SN	DM-323; DMP-323; JCR-424
DMQKH07	CP	Bristol-Myers Squibb Pharma Co
DMQKH07	DT	Small molecular drug
DMQKH07	PC	72404
DMQKH07	MW	566.7
DMQKH07	FM	C35H38N2O5
DMQKH07	IC	InChI=1S/C35H38N2O5/c38-23-29-15-11-27(12-16-29)21-36-31(19-25-7-3-1-4-8-25)33(40)34(41)32(20-26-9-5-2-6-10-26)37(35(36)42)22-28-13-17-30(24-39)18-14-28/h1-18,31-34,38-41H,19-24H2/t31-,32-,33+,34+/m1/s1
DMQKH07	CS	C1=CC=C(C=C1)C[C@@H]2[C@@H]([C@H]([C@H](N(C(=O)N2CC3=CC=C(C=C3)CO)CC4=CC=C(C=C4)CO)CC5=CC=CC=C5)O)O
DMQKH07	IK	XCVGQMUMMDXKCY-WZJLIZBTSA-N
DMQKH07	IU	(4R,5S,6S,7R)-4,7-dibenzyl-5,6-dihydroxy-1,3-bis[[4-(hydroxymethyl)phenyl]methyl]-1,3-diazepan-2-one
DMQKH07	CA	CAS 151867-81-1
DMQKH07	CB	CHEBI:42082
DMQKH07	DE	Human immunodeficiency virus infection

DMCK210	ID	DMCK210
DMCK210	DN	XR-9051
DMCK210	HS	Discontinued in Phase 1
DMCK210	SN	Multidrug resistance inhibitor, Xenova
DMCK210	CP	Xenova Ltd
DMCK210	DT	Small molecular drug
DMCK210	PC	9917447
DMCK210	MW	642.7
DMCK210	FM	C39H38N4O5
DMCK210	IC	InChI=1S/C39H38N4O5/c1-42-34(22-27-8-5-4-6-9-27)38(45)41-33(39(42)46)21-28-10-7-11-30(20-28)37(44)40-32-14-12-26(13-15-32)16-18-43-19-17-29-23-35(47-2)36(48-3)24-31(29)25-43/h4-15,20-24H,16-19,25H2,1-3H3,(H,40,44)(H,41,45)/b33-21-,34-22-
DMCK210	CS	CN1/C(=C\\C2=CC=CC=C2)/C(=O)N/C(=C\\C3=CC(=CC=C3)C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC)/C1=O
DMCK210	IK	RTIZZWMBGKGLFO-YWQXDYITSA-N
DMCK210	IU	3-[(Z)-[(5Z)-5-benzylidene-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]benzamide
DMCK210	DE	Solid tumour/cancer

DM3Y6M7	ID	DM3Y6M7
DM3Y6M7	DN	XTL-2125
DM3Y6M7	HS	Discontinued in Phase 1
DM3Y6M7	CP	XTL Biopharmaceutical
DM3Y6M7	DE	Hepatitis C virus infection

DM0FSA9	ID	DM0FSA9
DM0FSA9	DN	YM-17E
DM0FSA9	HS	Discontinued in Phase 1
DM0FSA9	SN	YM-17E; YM17E; 124884-99-7; AC1L46WN; SCHEMBL6340546; DTXSID80154515; 1-cycloheptyl-1-[[3-[[cycloheptyl-[(4-dimethylaminophenyl)carbamoyl]amino]methyl]phenyl]methyl]-3-(4-dimethylaminophenyl)urea dihydrochloride
DM0FSA9	CP	Yamanouchi Pharmaceutical Co Ltd
DM0FSA9	DT	Small molecular drug
DM0FSA9	PC	180288
DM0FSA9	MW	725.8
DM0FSA9	FM	C40H58Cl2N6O2
DM0FSA9	IC	InChI=1S/C40H56N6O2.2ClH/c1-43(2)35-24-20-33(21-25-35)41-39(47)45(37-16-9-5-6-10-17-37)29-31-14-13-15-32(28-31)30-46(38-18-11-7-8-12-19-38)40(48)42-34-22-26-36(27-23-34)44(3)4;;/h13-15,20-28,37-38H,5-12,16-19,29-30H2,1-4H3,(H,41,47)(H,42,48);2*1H
DM0FSA9	CS	CN(C)C1=CC=C(C=C1)NC(=O)N(CC2=CC(=CC=C2)CN(C3CCCCCC3)C(=O)NC4=CC=C(C=C4)N(C)C)C5CCCCCC5.Cl.Cl
DM0FSA9	IK	AKJWTZIUYIFCCS-UHFFFAOYSA-N
DM0FSA9	IU	1-cycloheptyl-1-[[3-[[cycloheptyl-[[4-(dimethylamino)phenyl]carbamoyl]amino]methyl]phenyl]methyl]-3-[4-(dimethylamino)phenyl]urea;dihydrochloride
DM0FSA9	CA	CAS 124884-99-7
DM0FSA9	DE	Hyperlipidaemia

DMLD2R0	ID	DMLD2R0
DMLD2R0	DN	YM-750
DMLD2R0	HS	Discontinued in Phase 1
DMLD2R0	SN	ACAT inhibitors, Yamanouchi
DMLD2R0	CP	Yamanouchi Pharmaceutical Co Ltd
DMLD2R0	DT	Small molecular drug
DMLD2R0	PC	9911716
DMLD2R0	MW	452.6
DMLD2R0	FM	C31H36N2O
DMLD2R0	IC	InChI=1S/C31H36N2O/c1-21-16-22(2)30(23(3)17-21)32-31(34)33(27-11-6-4-5-7-12-27)20-24-14-15-29-26(18-24)19-25-10-8-9-13-28(25)29/h8-10,13-18,27H,4-7,11-12,19-20H2,1-3H3,(H,32,34)
DMLD2R0	CS	CC1=CC(=C(C(=C1)C)NC(=O)N(CC2=CC3=C(C=C2)C4=CC=CC=C4C3)C5CCCCCC5)C
DMLD2R0	IK	FMLJREWZCZHGGW-UHFFFAOYSA-N
DMLD2R0	IU	1-cycloheptyl-1-(9H-fluoren-2-ylmethyl)-3-(2,4,6-trimethylphenyl)urea
DMLD2R0	CA	CAS 138046-43-2
DMLD2R0	DE	Hyperlipidaemia

DMDJ2O5	ID	DMDJ2O5
DMDJ2O5	DN	YM-75466
DMDJ2O5	HS	Discontinued in Phase 1
DMDJ2O5	SN	YM-466 (free base); YM-60828 (free base); 2-[N-(7-Amidinonaphthalen-2-ylmethyl)-N-[4-[1-(1-iminoethyl)piperidin-4-yloxy]phenyl]sulfamoyl]acetic acid methanesulfonate
DMDJ2O5	PC	9874074
DMDJ2O5	MW	633.7
DMDJ2O5	FM	C28H35N5O8S2
DMDJ2O5	IC	InChI=1S/C27H31N5O5S.CH4O3S/c1-18(28)31-12-10-25(11-13-31)37-24-8-6-23(7-9-24)32(38(35,36)17-26(33)34)16-19-2-3-20-4-5-21(27(29)30)15-22(20)14-19;1-5(2,3)4/h2-9,14-15,25,28H,10-13,16-17H2,1H3,(H3,29,30)(H,33,34);1H3,(H,2,3,4)
DMDJ2O5	CS	CC(=N)N1CCC(CC1)OC2=CC=C(C=C2)N(CC3=CC4=C(C=C3)C=CC(=C4)C(=N)N)S(=O)(=O)CC(=O)O.CS(=O)(=O)O
DMDJ2O5	IK	YRIFGKTUAWTSFP-UHFFFAOYSA-N
DMDJ2O5	IU	2-[(7-carbamimidoylnaphthalen-2-yl)methyl-[4-(1-ethanimidoylpiperidin-4-yl)oxyphenyl]sulfamoyl]acetic acid;methanesulfonic acid
DMDJ2O5	DE	Thrombosis

DMCDK6S	ID	DMCDK6S
DMCDK6S	DN	YM-976
DMCDK6S	HS	Discontinued in Phase 1
DMCDK6S	SN	4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one
DMCDK6S	DT	Small molecular drug
DMCDK6S	PC	6604918
DMCDK6S	MW	313.8
DMCDK6S	FM	C17H16ClN3O
DMCDK6S	IC	InChI=1S/C17H16ClN3O/c1-3-13-8-9-14-15(11-6-5-7-12(18)10-11)20-17(22)21(4-2)16(14)19-13/h5-10H,3-4H2,1-2H3
DMCDK6S	CS	CCC1=NC2=C(C=C1)C(=NC(=O)N2CC)C3=CC(=CC=C3)Cl
DMCDK6S	IK	MNHXYNNKDDXKNP-UHFFFAOYSA-N
DMCDK6S	IU	4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2-one
DMCDK6S	CA	CAS 191219-80-4
DMCDK6S	CB	CHEBI:92225
DMCDK6S	DE	Asthma

DMA412G	ID	DMA412G
DMA412G	DN	Z-300
DMA412G	HS	Discontinued in Phase 1
DMA412G	SN	2-(2-Hydroxyethylsulfanyl)-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide 2-(4-hydroxybenzoyl)benzoate
DMA412G	DT	Small molecular drug
DMA412G	PC	124488
DMA412G	MW	366.5
DMA412G	FM	C19H30N2O3S
DMA412G	IC	InChI=1S/C19H30N2O3S/c22-11-13-25-16-19(23)20-8-5-12-24-18-7-4-6-17(14-18)15-21-9-2-1-3-10-21/h4,6-7,14,22H,1-3,5,8-13,15-16H2,(H,20,23)
DMA412G	CS	C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC(=O)CSCCO
DMA412G	IK	ZRVDLLKTYZXNAD-UHFFFAOYSA-N
DMA412G	IU	2-(2-hydroxyethylsulfanyl)-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide
DMA412G	CA	CAS 127966-78-3
DMA412G	DE	Gastric ulcer

DMLO2QY	ID	DMLO2QY
DMLO2QY	DN	Z-321
DMLO2QY	HS	Discontinued in Phase 1
DMLO2QY	SN	1-[3-(2-Indanylacetyl)thiazolidin-4(R)-ylcarbonyl]pyrrolidine; 1-[N-(2-Indanylacetyl)-4-thia-L-prolyl]pyrrolidine
DMLO2QY	DT	Small molecular drug
DMLO2QY	PC	9798234
DMLO2QY	MW	344.5
DMLO2QY	FM	C19H24N2O2S
DMLO2QY	IC	InChI=1S/C19H24N2O2S/c22-18(11-14-9-15-5-1-2-6-16(15)10-14)21-13-24-12-17(21)19(23)20-7-3-4-8-20/h1-2,5-6,14,17H,3-4,7-13H2/t17-/m0/s1
DMLO2QY	CS	C1CCN(C1)C(=O)[C@@H]2CSCN2C(=O)CC3CC4=CC=CC=C4C3
DMLO2QY	IK	GDOVFSONSLOIAK-KRWDZBQOSA-N
DMLO2QY	IU	2-(2,3-dihydro-1H-inden-2-yl)-1-[(4R)-4-(pyrrolidine-1-carbonyl)-1,3-thiazolidin-3-yl]ethanone
DMLO2QY	CA	CAS 130849-58-0
DMLO2QY	DE	Parkinson disease

DM82V1D	ID	DM82V1D
DM82V1D	DN	ZD-0892
DM82V1D	HS	Discontinued in Phase 1
DM82V1D	SN	CHEMBL55210; SCHEMBL7363455; CTK4D4091; BDBM50058391; HY-19254; 171964-73-1; CS-0014993; L-Prolinamide,N-(4-methoxybenzoyl)-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-; (S)-1-[(S)-2-(4-Methoxy-benzoylamino)-3-methyl-butyryl]-pyrrolidine-2-carboxylic acid
DM82V1D	DT	Small molecular drug
DM82V1D	PC	9892148
DM82V1D	MW	499.5
DM82V1D	FM	C24H32F3N3O5
DM82V1D	IC	InChI=1S/C24H32F3N3O5/c1-13(2)18(20(31)24(25,26)27)28-22(33)17-7-6-12-30(17)23(34)19(14(3)4)29-21(32)15-8-10-16(35-5)11-9-15/h8-11,13-14,17-19H,6-7,12H2,1-5H3,(H,28,33)(H,29,32)/t17-,18-,19-/m0/s1
DM82V1D	CS	CC(C)[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)C2=CC=C(C=C2)OC
DM82V1D	IK	PNILZVBINXNWHW-FHWLQOOXSA-N
DM82V1D	IU	(2S)-1-[(2S)-2-[(4-methoxybenzoyl)amino]-3-methylbutanoyl]-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]pyrrolidine-2-carboxamide
DM82V1D	DE	Chronic obstructive pulmonary disease

DMUDLFM	ID	DMUDLFM
DMUDLFM	DN	ZD-1611
DMUDLFM	HS	Discontinued in Phase 1
DMUDLFM	SN	Endothelin antagonist, Zeneca
DMUDLFM	CP	AstraZeneca plc
DMUDLFM	PC	9933752
DMUDLFM	MW	456.5
DMUDLFM	FM	C22H24N4O5S
DMUDLFM	IC	InChI=1S/C22H24N4O5S/c1-14-13-24-19(20(25-14)31-4)26-32(29,30)17-6-5-11-23-18(17)16-9-7-15(8-10-16)12-22(2,3)21(27)28/h5-11,13H,12H2,1-4H3,(H,24,26)(H,27,28)
DMUDLFM	CS	CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)CC(C)(C)C(=O)O
DMUDLFM	IK	CDBNTQYPMBJKQZ-UHFFFAOYSA-N
DMUDLFM	IU	3-[4-[3-[(3-methoxy-5-methylpyrazin-2-yl)sulfamoyl]pyridin-2-yl]phenyl]-2,2-dimethylpropanoic acid
DMUDLFM	DE	Hypotension

DM7JUCI	ID	DM7JUCI
DM7JUCI	DN	ZD-2767
DM7JUCI	HS	Discontinued in Phase 1
DM7JUCI	SN	Colorectal cancer therapy (ADEPT), AstraZeneca/CRCT; Colorectal cancer therapy (ADEPT), Zeneca/CRCT
DM7JUCI	CP	AstraZeneca plc
DM7JUCI	DE	Solid tumour/cancer

DMQDNU1	ID	DMQDNU1
DMQDNU1	DN	ZD-4927
DMQDNU1	HS	Discontinued in Phase 1
DMQDNU1	CP	AstraZeneca plc
DMQDNU1	DE	Thrombosis

DM1EB6H	ID	DM1EB6H
DM1EB6H	DN	ZD-7349
DM1EB6H	HS	Discontinued in Phase 1
DM1EB6H	SN	VLA-4 antagonists, Zeneca
DM1EB6H	CP	Zeneca Group plc
DM1EB6H	DE	Multiple sclerosis

DMJ9R4A	ID	DMJ9R4A
DMJ9R4A	DN	ZK 304709
DMJ9R4A	HS	Discontinued in Phase 1
DMJ9R4A	SN	ZK 304709; 1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701
DMJ9R4A	CP	Schering AG
DMJ9R4A	DT	Small molecular drug
DMJ9R4A	PC	59733314
DMJ9R4A	MW	445
DMJ9R4A	FM	C22H29ClN6O2
DMJ9R4A	IC	InChI=1S/C22H29ClN6O2/c1-28-7-9-29(10-8-28)18-12-15(11-16(23)13-18)21(30)26-19-14-24-27-20(19)22(31)25-17-5-3-2-4-6-17/h11-14,17H,2-10H2,1H3,(H,24,27)(H,25,31)(H,26,30)
DMJ9R4A	CS	CN1CCN(CC1)C2=CC(=CC(=C2)C(=O)NC3=C(NN=C3)C(=O)NC4CCCCC4)Cl
DMJ9R4A	IK	OALDDSAHYZPJQM-UHFFFAOYSA-N
DMJ9R4A	IU	4-[[3-chloro-5-(4-methylpiperazin-1-yl)benzoyl]amino]-N-cyclohexyl-1H-pyrazole-5-carboxamide
DMJ9R4A	CA	CAS 1010440-84-2
DMJ9R4A	DE	Advanced solid tumour

DMHXVN1	ID	DMHXVN1
DMHXVN1	DN	DFD-11
DMHXVN1	HS	Application submitted
DMHXVN1	CP	Promius Pharma Princeton, NJ
DMHXVN1	DE	Head and body lice

DMCA7LN	ID	DMCA7LN
DMCA7LN	DN	Oxycodone hydrochloride
DMCA7LN	HS	Application submitted
DMCA7LN	SN	oxycodone ER
DMCA7LN	CP	Intellipharmaceutics International Toronto, Canada
DMCA7LN	PC	5462350
DMCA7LN	MW	351.8
DMCA7LN	FM	C18H22ClNO4
DMCA7LN	IC	InChI=1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1
DMCA7LN	CS	CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O.Cl
DMCA7LN	IK	MUZQPDBAOYKNLO-RKXJKUSZSA-N
DMCA7LN	IU	(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
DMCA7LN	CA	CAS 124-90-3
DMCA7LN	CB	CHEBI:7859
DMCA7LN	DE	Chronic pain

DMC7EQT	ID	DMC7EQT
DMC7EQT	DN	AAB-002
DMC7EQT	HS	Phase 0
DMC7EQT	CP	Janssen Alzheimer Immunotherapy; Pfizer
DMC7EQT	DE	Alzheimer disease

DM3V8JN	ID	DM3V8JN
DM3V8JN	DN	Anti-CD19 CAR T cells
DM3V8JN	HS	Phase 0
DM3V8JN	CP	University of Pennsylvania
DM3V8JN	DT	CAR T Cell Therapy
DM3V8JN	DE	Hodgkin lymphoma

DMYZ3O9	ID	DMYZ3O9
DMYZ3O9	DN	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
DMYZ3O9	HS	Phase 0
DMYZ3O9	CP	University of Pennsylvania
DMYZ3O9	DT	CAR T Cell Therapy
DMYZ3O9	DE	Acute myeloid leukaemia

DMFRA38	ID	DMFRA38
DMFRA38	DN	CART19 cells
DMFRA38	HS	Phase 0
DMFRA38	CP	University of Pennsylvania
DMFRA38	DT	CAR T Cell Therapy
DMFRA38	DE	Hodgkin lymphoma

DMA85ND	ID	DMA85ND
DMA85ND	DN	ET-1
DMA85ND	HS	Phase 0
DMA85ND	SN	Endothelin-1
DMA85ND	PC	16212950
DMA85ND	MW	2491.9
DMA85ND	FM	C109H159N25O32S5
DMA85ND	IC	InChI=1S/C109H159N25O32S5/c1-12-56(9)87(107(163)125-76(109(165)166)39-60-43-113-65-24-18-17-23-63(60)65)134-108(164)88(57(10)13-2)133-99(155)75(42-85(143)144)123-94(150)70(36-54(5)6)118-97(153)73(40-61-44-112-52-114-61)121-103(159)80-49-169-168-48-64(111)89(145)126-77(45-135)102(158)131-81-50-170-171-51-82(105(161)132-86(55(7)8)106(162)124-72(38-59-26-28-62(138)29-27-59)95(151)120-71(96(152)130-80)37-58-21-15-14-16-22-58)129-91(147)67(30-31-83(139)140)116-90(146)66(25-19-20-33-110)115-98(154)74(41-84(141)142)122-92(148)68(32-34-167-11)117-93(149)69(35-53(3)4)119-100(156)78(46-136)127-101(157)79(47-137)128-104(81)160/h14-18,21-24,26-29,43-44,52-57,64,66-82,86-88,113,135-138H,12-13,19-20,25,30-42,45-51,110-111H2,1-11H3,(H,112,114)(H,115,154)(H,116,146)(H,117,149)(H,118,153)(H,119,156)(H,120,151)(H,121,159)(H,122,148)(H,123,150)(H,124,162)(H,125,163)(H,126,145)(H,127,157)(H,128,160)(H,129,147)(H,130,152)(H,131,158)(H,132,161)(H,133,155)(H,134,164)(H,139,140)(H,141,142)(H,143,144)(H,165,166)/t56-,57-,64-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,86-,87-,88-/m0/s1
DMA85ND	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC6=CC=CC=C6)CC7=CC=C(C=C7)O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC5=O)CO)CO)CC(C)C)CCSC)CC(=O)O)CCCCN)CCC(=O)O)CO)N
DMA85ND	IK	ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N
DMA85ND	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(1R,4S,7S,10S,13S,16S,19S,22S,25R,28S,31R,36R,39S,42S,45S)-31-amino-7-(4-aminobutyl)-39-benzyl-4-(2-carboxyethyl)-10-(carboxymethyl)-19,22,28-tris(hydroxymethyl)-42-[(4-hydroxyphenyl)methyl]-16-(2-methylpropyl)-13-(2-methylsulfanylethyl)-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-45-propan-2-yl-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecazabicyclo[23.22.4]henpentacontane-36-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMA85ND	CA	CAS 123626-67-5

DMIUZEX	ID	DMIUZEX
DMIUZEX	DN	(R)-PFI-2
DMIUZEX	HS	Preclinical
DMIUZEX	SN	PFI-2; 1627676-59-8; (R)-PFI-2; CHEMBL3414622; PFI-2 HCl; 8-Fluoro-N-{(2r)-1-Oxo-1-(Pyrrolidin-1-Yl)-3-[3-(Trifluoromethyl)phenyl]propan-2-Yl}-1,2,3,4-Tetrahydroisoquinoline-6-Sulfonamide; 1L8; GTPL8235; C23H25F4N3O3S; MolPort-035-789-712; EX-A1603; s7294; ZINC95920703; BDBM50075073; 2648AH; AKOS030526617; CS-4177; NCGC00351479-01; HY-18627; BC600610; (R)-8-Fluoro-N-(1-oxo-1-(pyrrolidin-1-yl)-3-(3-(trifluoromethyl)phenyl)propan-2-yl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide
DMIUZEX	DT	Small molecular drug
DMIUZEX	PC	71300326
DMIUZEX	MW	499.5
DMIUZEX	FM	C23H25F4N3O3S
DMIUZEX	IC	InChI=1S/C23H25F4N3O3S/c24-20-13-18(12-16-6-7-28-14-19(16)20)34(32,33)29-21(22(31)30-8-1-2-9-30)11-15-4-3-5-17(10-15)23(25,26)27/h3-5,10,12-13,21,28-29H,1-2,6-9,11,14H2/t21-/m1/s1
DMIUZEX	CS	C1CCN(C1)C(=O)[C@@H](CC2=CC(=CC=C2)C(F)(F)F)NS(=O)(=O)C3=CC4=C(CNCC4)C(=C3)F
DMIUZEX	IK	JCKGSPAAPQRPBW-OAQYLSRUSA-N
DMIUZEX	IU	8-fluoro-N-[(2R)-1-oxo-1-pyrrolidin-1-yl-3-[3-(trifluoromethyl)phenyl]propan-2-yl]-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide
DMIUZEX	DE	Breast cancer

DMXWD08	ID	DMXWD08
DMXWD08	DN	(R)-Xamoterol
DMXWD08	HS	Preclinical
DMXWD08	PC	155774
DMXWD08	FM	C16H25N3O5
DMXWD08	IC	InChI=1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)
DMXWD08	CS	C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O
DMXWD08	IK	DXPOSRCHIDYWHW-UHFFFAOYSA-N
DMXWD08	IU	N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide
DMXWD08	CA	CAS 81801-12-9
DMXWD08	CB	CHEBI:10055
DMXWD08	DE	Heart failure

DMEJYV4	ID	DMEJYV4
DMEJYV4	DN	(S)-4-(Ethylsulfonyl)benzoylalanine
DMEJYV4	HS	Preclinical
DMEJYV4	SN	S-ESBA
DMEJYV4	DT	Small molecular drug
DMEJYV4	DE	Cognitive impairment; Schizophrenia

DM1ZQ5G	ID	DM1ZQ5G
DM1ZQ5G	DN	(S)-Xamoterol
DM1ZQ5G	HS	Preclinical
DM1ZQ5G	SN	UNII-ZIB581LRDV; ZIB581LRDV; (S)-Xamoterol; Xamoterol, (S)-; 69630-22-4; SCHEMBL11533496; ZINC1532365; UNII-7HE0JQL703 component DXPOSRCHIDYWHW-AWEZNQCLSA-N; 4-Morpholinecarboxamide, N-(2-(((2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)-
DM1ZQ5G	PC	12681891
DM1ZQ5G	MW	339.39
DM1ZQ5G	FM	C16H25N3O5
DM1ZQ5G	IC	InChI=1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)/t14-/m0/s1
DM1ZQ5G	CS	C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O
DM1ZQ5G	IK	DXPOSRCHIDYWHW-AWEZNQCLSA-N
DM1ZQ5G	IU	N-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide
DM1ZQ5G	CA	CAS 69630-22-4
DM1ZQ5G	DE	Heart failure

DM9TQDE	ID	DM9TQDE
DM9TQDE	DN	111In-hEGF
DM9TQDE	HS	Preclinical
DM9TQDE	SN	Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto
DM9TQDE	CP	University of Toronto
DM9TQDE	DE	Breast cancer

DM5IUN8	ID	DM5IUN8
DM5IUN8	DN	12B9m
DM5IUN8	HS	Preclinical
DM5IUN8	CP	Amgen
DM5IUN8	DT	Antibody
DM5IUN8	DE	Anaemia

DM503DN	ID	DM503DN
DM503DN	DN	1954U89
DM503DN	HS	Preclinical
DM503DN	CP	Glaxo Wellcome plc
DM503DN	PC	177894
DM503DN	MW	283.37
DM503DN	FM	C16H21N5
DM503DN	IC	InChI=1S/C16H21N5/c1-4-10(5-2)21-9(3)8-11-13(21)7-6-12-14(11)15(17)20-16(18)19-12/h6-8,10H,4-5H2,1-3H3,(H4,17,18,19,20)
DM503DN	CS	CCC(CC)N1C(=CC2=C1C=CC3=C2C(=NC(=N3)N)N)C
DM503DN	IK	YBHNZQJIFKDDHM-UHFFFAOYSA-N
DM503DN	IU	8-methyl-7-pentan-3-ylpyrrolo[3,2-f]quinazoline-1,3-diamine
DM503DN	CA	CAS 150057-49-1
DM503DN	DE	Solid tumour/cancer

DMT8SFV	ID	DMT8SFV
DMT8SFV	DN	1-methyl-L-tryptophan
DMT8SFV	HS	Preclinical
DMT8SFV	SN	1-L-MT; 1-LMT
DMT8SFV	DT	Small molecular drug
DMT8SFV	PC	676159
DMT8SFV	MW	218.25
DMT8SFV	FM	C12H14N2O2
DMT8SFV	IC	InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m0/s1
DMT8SFV	CS	CN1C=C(C2=CC=CC=C21)C[C@@H](C(=O)O)N
DMT8SFV	IK	ZADWXFSZEAPBJS-JTQLQIEISA-N
DMT8SFV	IU	(2S)-2-amino-3-(1-methylindol-3-yl)propanoic acid
DMT8SFV	CA	CAS 21339-55-9
DMT8SFV	DE	Solid tumour/cancer

DMIS1G7	ID	DMIS1G7
DMIS1G7	DN	2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester
DMIS1G7	HS	Preclinical
DMIS1G7	DT	Small molecular drug
DMIS1G7	DE	Glioma

DMLVADH	ID	DMLVADH
DMLVADH	DN	212Pb-labelled aCD37
DMLVADH	HS	Preclinical
DMLVADH	SN	212PB-NNV003
DMLVADH	CP	OranoMed/NordicNanovector
DMLVADH	DT	Radiopharmaceutical therapy agent
DMLVADH	DE	leukaemia

DM1O2C3	ID	DM1O2C3
DM1O2C3	DN	227Th-labelled HER2-TTC
DM1O2C3	HS	Preclinical
DM1O2C3	CP	Bayer
DM1O2C3	DT	Radiopharmaceutical therapy agent
DM1O2C3	DE	Solid tumour/cancer

DM1R3VC	ID	DM1R3VC
DM1R3VC	DN	2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid
DM1R3VC	HS	Preclinical
DM1R3VC	DT	Small molecular drug
DM1R3VC	DE	Breast cancer

DMRDQPT	ID	DMRDQPT
DMRDQPT	DN	2-D08
DMRDQPT	HS	Preclinical
DMRDQPT	SN	144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE
DMRDQPT	DT	Small molecular drug
DMRDQPT	PC	22507438
DMRDQPT	MW	270.24
DMRDQPT	FM	C15H10O5
DMRDQPT	IC	InChI=1S/C15H10O5/c16-10-6-5-9(14(18)15(10)19)13-7-11(17)8-3-1-2-4-12(8)20-13/h1-7,16,18-19H
DMRDQPT	CS	C1=CC=C2C(=C1)C(=O)C=C(O2)C3=C(C(=C(C=C3)O)O)O
DMRDQPT	IK	JJAXTFSPCLZPIW-UHFFFAOYSA-N
DMRDQPT	IU	2-(2,3,4-trihydroxyphenyl)chromen-4-one
DMRDQPT	DE	Acute myeloid leukaemia

DM4NURZ	ID	DM4NURZ
DM4NURZ	DN	2E9IgA1
DM4NURZ	HS	Preclinical
DM4NURZ	DT	Antibody
DM4NURZ	DE	Mycobacterium infection

DMAM4FE	ID	DMAM4FE
DMAM4FE	DN	2-Ethoxypropanoic acid
DMAM4FE	HS	Preclinical
DMAM4FE	SN	2-ethoxypropanoic acid; 53103-75-6; 2-ethoxypropionic acid; MFCD09940775; Propanoic acid, 2-ethoxy-; SCHEMBL142064; DTXSID00570733; 2-Ethoxypropanoic acid, AldrichCPR; STL508457; AKOS000184266; AKOS016903919; MCULE-2185795311; SY040144; DB-104575; EN300-39488; Y-6023
DMAM4FE	DT	Small molecular drug
DMAM4FE	PC	15268841
DMAM4FE	MW	118.13
DMAM4FE	FM	C5H10O3
DMAM4FE	IC	InChI=1S/C5H10O3/c1-3-8-4(2)5(6)7/h4H,3H2,1-2H3,(H,6,7)
DMAM4FE	CS	CCOC(C)C(=O)O
DMAM4FE	IK	XBHQOMRKOUANQQ-UHFFFAOYSA-N
DMAM4FE	IU	2-ethoxypropanoic acid
DMAM4FE	CA	CAS 53103-75-6
DMAM4FE	DE	Breast cancer

DM5CVBM	ID	DM5CVBM
DM5CVBM	DN	3-Oxo-C12-(2-amino-cyclohexanone)
DM5CVBM	HS	Preclinical
DM5CVBM	DT	Small molecular drug
DM5CVBM	DE	Pseudomonas infection

DM57GL1	ID	DM57GL1
DM57GL1	DN	4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine
DM57GL1	HS	Preclinical
DM57GL1	SN	CHEMBL4166624; BDBM50321330
DM57GL1	CP	Genentech
DM57GL1	DT	Small molecular drug
DM57GL1	PC	145952699
DM57GL1	MW	168.13
DM57GL1	FM	C6H5FN4O
DM57GL1	IC	InChI=1S/C6H5FN4O/c7-4-1-9-11(3-4)5-2-10-12-6(5)8/h1-3H,8H2
DM57GL1	CS	C1=C(C=NN1C2=C(ON=C2)N)F
DM57GL1	IK	YCBKZPFCIBXKIG-UHFFFAOYSA-N
DM57GL1	IU	4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine
DM57GL1	DE	Solid tumour/cancer

DMXFC3W	ID	DMXFC3W
DMXFC3W	DN	4SC-202
DMXFC3W	HS	Preclinical
DMXFC3W	CP	4SC AG
DMXFC3W	DT	Small molecular drug
DMXFC3W	PC	44217246
DMXFC3W	MW	619.7
DMXFC3W	FM	C30H29N5O6S2
DMXFC3W	IC	InChI=1S/C23H21N5O3S.C7H8O3S/c1-27-16-19(14-25-27)18-7-9-20(10-8-18)32(30,31)28-13-12-17(15-28)6-11-23(29)26-22-5-3-2-4-21(22)24;1-6-2-4-7(5-3-6)11(8,9)10/h2-16H,24H2,1H3,(H,26,29);2-5H,1H3,(H,8,9,10)/b11-6+;
DMXFC3W	CS	CC1=CC=C(C=C1)S(=O)(=O)O.CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N
DMXFC3W	IK	IAVXAZDVNICKFJ-ICSBZGNSSA-N
DMXFC3W	IU	(E)-N-(2-aminophenyl)-3-[1-[4-(1-methylpyrazol-4-yl)phenyl]sulfonylpyrrol-3-yl]prop-2-enamide;4-methylbenzenesulfonic acid
DMXFC3W	CA	CAS 1186222-89-8
DMXFC3W	DE	Solid tumour/cancer

DMAJWLD	ID	DMAJWLD
DMAJWLD	DN	5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one
DMAJWLD	HS	Preclinical
DMAJWLD	DT	Small molecular drug
DMAJWLD	DE	Pompe disease

DMC4IUQ	ID	DMC4IUQ
DMC4IUQ	DN	5-(N,N-hexamethylene)-amiloride
DMC4IUQ	HS	Preclinical
DMC4IUQ	SN	5-(N,N-Hexamethylene)amiloride; Hexamethyleneamiloride; 1428-95-1; Hexamethylene amiloride; HMA-5; HMA; C12H18ClN7O; 3-Amino-6-chloro-5-(1-homopiperidyl)-N-(diaminomethylene)pyrazinecarboxamide; N,N-HEXAMETHYLENEAMILORIDE; CHEBI:76400; 3-amino-5-(azepan-1-yl)-6-chloro-N-(diaminomethylene)pyrazine-2-carboxamide; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-(hexahydro-1H-azepin-1-yl)pyrazinecarboxamide; Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-(hexahydro-1H-azepin-1-yl)-; 5-HMA; Spectrum_001596
DMC4IUQ	DT	Small molecular drug
DMC4IUQ	PC	1794
DMC4IUQ	MW	311.77
DMC4IUQ	FM	C12H18ClN7O
DMC4IUQ	IC	InChI=1S/C12H18ClN7O/c13-8-10(20-5-3-1-2-4-6-20)18-9(14)7(17-8)11(21)19-12(15)16/h1-6H2,(H2,14,18)(H4,15,16,19,21)
DMC4IUQ	CS	C1CCCN(CC1)C2=NC(=C(N=C2Cl)C(=O)N=C(N)N)N
DMC4IUQ	IK	RQQJJXVETXFINY-UHFFFAOYSA-N
DMC4IUQ	IU	3-amino-5-(azepan-1-yl)-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
DMC4IUQ	CA	CAS 1428-95-1
DMC4IUQ	CB	CHEBI:76400
DMC4IUQ	DE	Coronavirus infection

DM7RHOC	ID	DM7RHOC
DM7RHOC	DN	5N,6S-(N'-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin
DM7RHOC	HS	Preclinical
DM7RHOC	DT	Small molecular drug
DM7RHOC	DE	GM1 gangliosidosis

DMCDTIG	ID	DMCDTIG
DMCDTIG	DN	680C91
DMCDTIG	HS	Preclinical
DMCDTIG	SN	163239-22-3; CHEMBL355606; 6-Fluoro-3-((E)-2-pyridin-3-yl-vinyl)-1H-indole; 6-fluoro-3-[(E)-2-pyridin-3-ylethenyl]-1H-indole; SCHEMBL3262721; SCHEMBL3262726; ZINC19965; CHEBI:131851; EX-A4573; BDBM50289137; s8997; AKOS024458137; 680C91, >=98% (HPLC); 680C-91; (e)-6-fluoro-3-[2-(3-pyridyl)vinyl]-1h-indole; (E)-6-Fluoro-3-(2-(pyridin-3-yl)vinyl)-1H-indole; 6-fluoro-3-[(E)-2-(pyridin-3-yl)vinyl]-1H-indole; Q27225279; 6-Fluoro-3-[(1E)-2-(3-pyridinyl)ethenyl]-1H-indole; 1H-Indole, 6-fluoro-3-[(1E)-2-(3-pyridinyl)ethenyl]-
DMCDTIG	CP	Glaxo Wellcome
DMCDTIG	DT	Small molecular drug
DMCDTIG	PC	10014426
DMCDTIG	MW	238.26
DMCDTIG	FM	C15H11FN2
DMCDTIG	IC	InChI=1S/C15H11FN2/c16-13-5-6-14-12(10-18-15(14)8-13)4-3-11-2-1-7-17-9-11/h1-10,18H/b4-3+
DMCDTIG	CS	C1=CC(=CN=C1)/C=C/C2=CNC3=C2C=CC(=C3)F
DMCDTIG	IK	YBSDQTBCNYWBMX-ONEGZZNKSA-N
DMCDTIG	IU	6-fluoro-3-[(E)-2-pyridin-3-ylethenyl]-1H-indole
DMCDTIG	CA	CAS 163239-22-3
DMCDTIG	CB	CHEBI:131851
DMCDTIG	DE	Solid tumour/cancer

DMEKMV0	ID	DMEKMV0
DMEKMV0	DN	9-(Ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile
DMEKMV0	HS	Preclinical
DMEKMV0	SN	HY50737A; 924296-19-5; 9-(ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile; USP8-IN-22e; (9E)-9-ethoxyiminoindeno[1,2-b]pyrazine-2,3-dicarbonitrile; SCHEMBL1512635; 9-ethoxyiminoindeno[1,2-b]pyrazine-2,3-dicarbonitrile; 9-ethyloxyimino-9h-indeno[1,2-b]pyrazine-2,3-dicarbonitrile
DMEKMV0	CP	Hybrigenics
DMEKMV0	DT	Small molecular drug
DMEKMV0	PC	73230796
DMEKMV0	MW	275.26
DMEKMV0	FM	C15H9N5O
DMEKMV0	IC	InChI=1S/C15H9N5O/c1-2-21-20-14-10-6-4-3-5-9(10)13-15(14)19-12(8-17)11(7-16)18-13/h3-6H,2H2,1H3
DMEKMV0	CS	CCON=C1C2=CC=CC=C2C3=NC(=C(N=C31)C#N)C#N
DMEKMV0	IK	VKVAJBRQGBRHIK-UHFFFAOYSA-N
DMEKMV0	IU	9-ethoxyiminoindeno[1,2-b]pyrazine-2,3-dicarbonitrile
DMEKMV0	DE	Solid tumour/cancer

DMFP316	ID	DMFP316
DMFP316	DN	A-196
DMFP316	HS	Preclinical
DMFP316	SN	1982372-88-2; 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine; A 196; SGC A-196; Cyclopentyl-(6,7-dichloro-4-pyridin-4-yl-phthalazin-1-yl)-amine; GTPL8949; CHEMBL4521971; SCHEMBL17968181; BDBM223981; EX-A4473; s7983; AKOS032945052; ZINC521836458; CCG-268144; CS-5613; NCGC00387310-01; AK685671; BS-15880; HY-100201; A-196, >=98% (HPLC); A-196 (3); Q27074057; 6,7-Dichloro-N-cyclopentyl-4-(4-pyridinyl)-1-phthalazinamine; ClC=1C=C2C(=NN=C(C2=CC=1Cl)NC1CCCC1)C1=CC=NC=C1
DMFP316	DT	Small molecular drug
DMFP316	PC	117072548
DMFP316	MW	359.2
DMFP316	FM	C18H16Cl2N4
DMFP316	IC	InChI=1S/C18H16Cl2N4/c19-15-9-13-14(10-16(15)20)18(22-12-3-1-2-4-12)24-23-17(13)11-5-7-21-8-6-11/h5-10,12H,1-4H2,(H,22,24)
DMFP316	CS	C1CCC(C1)NC2=NN=C(C3=CC(=C(C=C32)Cl)Cl)C4=CC=NC=C4
DMFP316	IK	ABGOSOMRWSYAOB-UHFFFAOYSA-N
DMFP316	IU	6,7-dichloro-N-cyclopentyl-4-pyridin-4-ylphthalazin-1-amine
DMFP316	DE	Discovery agent

DM1H45U	ID	DM1H45U
DM1H45U	DN	A-366
DM1H45U	HS	Preclinical
DM1H45U	SN	A 366; A366
DM1H45U	DT	Small molecular drug
DM1H45U	PC	76285486
DM1H45U	MW	329.4
DM1H45U	FM	C19H27N3O2
DM1H45U	IC	InChI=1S/C19H27N3O2/c1-23-16-12-14-15(21-18(20)19(14)6-4-7-19)13-17(16)24-11-5-10-22-8-2-3-9-22/h12-13H,2-11H2,1H3,(H2,20,21)
DM1H45U	CS	COC1=C(C=C2C(=C1)C3(CCC3)C(=N2)N)OCCCN4CCCC4
DM1H45U	IK	BKCDJTRMYWSXMC-UHFFFAOYSA-N
DM1H45U	IU	5'-methoxy-6'-(3-pyrrolidin-1-ylpropoxy)spiro[cyclobutane-1,3'-indole]-2'-amine
DM1H45U	DE	Solid tumour/cancer

DML5SO1	ID	DML5SO1
DML5SO1	DN	A-366833
DML5SO1	HS	Preclinical
DML5SO1	SN	5-[(1R,5S)-3,6-Diazabicyclo[3.2.0]hept-6-yl]pyridine-3-carbonitrile
DML5SO1	DT	Small molecular drug
DML5SO1	PC	9942427
DML5SO1	MW	200.24
DML5SO1	FM	C11H12N4
DML5SO1	IC	InChI=1S/C11H12N4/c12-2-8-1-10(5-13-3-8)15-7-9-4-14-6-11(9)15/h1,3,5,9,11,14H,4,6-7H2/t9-,11-/m1/s1
DML5SO1	CS	C1[C@@H]2CN([C@@H]2CN1)C3=CN=CC(=C3)C#N
DML5SO1	IK	GPXAWLDGWSBLKM-MWLCHTKSSA-N
DML5SO1	IU	5-[(1R,5S)-3,6-diazabicyclo[3.2.0]heptan-6-yl]pyridine-3-carbonitrile
DML5SO1	CA	CAS 370882-41-0
DML5SO1	DE	Pain

DMECV6L	ID	DMECV6L
DMECV6L	DN	A-425619
DMECV6L	HS	Preclinical
DMECV6L	SN	AC1OYT5J; T5512318; LS-192912; 1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea; 1-isoquinolin-5-yl-3-[[4-(trifluoromethyl)phenyl]methyl]urea
DMECV6L	CP	Abbott
DMECV6L	TC	Analgesics
DMECV6L	DT	Small molecular drug
DMECV6L	PC	8068410
DMECV6L	MW	345.3
DMECV6L	FM	C18H14F3N3O
DMECV6L	IC	InChI=1S/C18H14F3N3O/c19-18(20,21)14-6-4-12(5-7-14)10-23-17(25)24-16-3-1-2-13-11-22-9-8-15(13)16/h1-9,11H,10H2,(H2,23,24,25)
DMECV6L	CS	C1=CC2=C(C=CN=C2)C(=C1)NC(=O)NCC3=CC=C(C=C3)C(F)(F)F
DMECV6L	IK	SJGVXVZUSQLLJB-UHFFFAOYSA-N
DMECV6L	IU	1-isoquinolin-5-yl-3-[[4-(trifluoromethyl)phenyl]methyl]urea
DMECV6L	CA	CAS 581809-67-8
DMECV6L	DE	Pain

DMZ4HMP	ID	DMZ4HMP
DMZ4HMP	DN	A-71378
DMZ4HMP	HS	Preclinical
DMZ4HMP	SN	A 71378; Desamino-tyr(SO3H)-nle-gly-trp-nle-(N-methyl)asp-phe-NH2; (3S)-4-[[(2R)-1-[2-[[(2S)-2-[[1H-indol-3-ylmethyl-[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]carbamoyl]amino]hexanoyl]carbamoyl]phenyl]propan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid; (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]-methylamino]-4-oxobutanoic acid
DMZ4HMP	CP	Abbott
DMZ4HMP	DT	Small molecular drug
DMZ4HMP	PC	5489450
DMZ4HMP	MW	991.1
DMZ4HMP	FM	C48H62N8O13S
DMZ4HMP	IC	InChI=1S/C48H62N8O13S/c1-5-7-16-38(53-41(57)24-21-31-19-22-34(23-20-31)69-70(66,67)68)45(62)51-28-42(58)56(29-33-27-50-37-18-12-11-14-35(33)37)48(65)54-39(17-8-6-2)46(63)55-44(61)36-15-10-9-13-32(36)25-30(3)52-47(64)40(49-4)26-43(59)60/h9-15,18-20,22-23,27,30,38-40,49-50H,5-8,16-17,21,24-26,28-29H2,1-4H3,(H,51,62)(H,52,64)(H,53,57)(H,54,65)(H,59,60)(H,55,61,63)(H,66,67,68)/t30-,38+,39+,40+/m1/s1
DMZ4HMP	CS	CCCC[C@@H](C(=O)NCC(=O)N(CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)NC(=O)C3=CC=CC=C3C[C@@H](C)NC(=O)[C@H](CC(=O)O)NC)NC(=O)CCC4=CC=C(C=C4)OS(=O)(=O)O
DMZ4HMP	IK	DLOJBPLQFCFYKX-QQYYTUMTSA-N
DMZ4HMP	IU	(3S)-4-[[(2R)-1-[2-[[(2S)-2-[[1H-indol-3-ylmethyl-[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]carbamoyl]amino]hexanoyl]carbamoyl]phenyl]propan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid
DMZ4HMP	CA	CAS 127902-33-4
DMZ4HMP	DE	Obesity

DMAK6H3	ID	DMAK6H3
DMAK6H3	DN	A-74498
DMAK6H3	HS	Preclinical
DMAK6H3	CP	Abbott
DMAK6H3	PC	9962628
DMAK6H3	MW	841
DMAK6H3	FM	C44H56N8O9
DMAK6H3	IC	InChI=1S/C44H56N8O9/c1-27-15-9-11-19-31(27)50-42(59)46-22-14-13-21-33(41(58)52(5)36(25-37(53)54)40(57)49-34(38(45)55)23-28-16-7-6-8-17-28)48-39(56)35(51-43(60)61-44(2,3)4)24-29-26-47-32-20-12-10-18-30(29)32/h6-12,15-20,26,33-36,47H,13-14,21-25H2,1-5H3,(H2,45,55)(H,48,56)(H,49,57)(H,51,60)(H,53,54)(H2,46,50,59)/t33-,34-,35-,36-/m0/s1
DMAK6H3	CS	CC1=CC=CC=C1NC(=O)NCCCC[C@@H](C(=O)N(C)[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)OC(C)(C)C
DMAK6H3	IK	KONMZUWCOVKBMG-ZYADHFCISA-N
DMAK6H3	IU	(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-6-[(2-methylphenyl)carbamoylamino]hexanoyl]-methylamino]-4-oxobutanoic acid
DMAK6H3	DE	Obesity

DMSO8IE	ID	DMSO8IE
DMSO8IE	DN	A-841720
DMSO8IE	HS	Preclinical
DMSO8IE	SN	869802-58-4; A-841720; A 841720; UNII-U8C5C9D65S; U8C5C9D65S; CHEMBL386565; SCHEMBL8237949; GTPL3953; CTK5F7481; DTXSID10236030; MolPort-023-276-650; ZINC13676140; BDBM50177080; AKOS024457407; 3-(azepan-1-yl)-9-(dimethylamino)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3H)-one; NCGC00371083-02; Pyrido(3',2':4,5)thieno(3,2-d)pyrimidin-4(3H)-one, 9-(dimethylamino)-3-(hexahydro-1H-azepin-1-yl)-; RT-011135; KB-270514; A-440; B7258; 3-(azepan-1-yl)-9-(dimethylamino)pyrido[1,2]thieno[3,4-d]pyrimidin-4-one
DMSO8IE	CP	Abbott Laboratories
DMSO8IE	DT	Small molecular drug
DMSO8IE	PC	11559235
DMSO8IE	MW	343.4
DMSO8IE	FM	C17H21N5OS
DMSO8IE	IC	InChI=1S/C17H21N5OS/c1-20(2)12-7-8-18-16-13(12)14-15(24-16)17(23)22(11-19-14)21-9-5-3-4-6-10-21/h7-8,11H,3-6,9-10H2,1-2H3
DMSO8IE	CS	CN(C)C1=C2C3=C(C(=O)N(C=N3)N4CCCCCC4)SC2=NC=C1
DMSO8IE	IK	GYWGXEGOXODOQU-UHFFFAOYSA-N
DMSO8IE	IU	5-(azepan-1-yl)-13-(dimethylamino)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMSO8IE	CA	CAS 869802-58-4
DMSO8IE	DE	Pain

DM8XHJG	ID	DM8XHJG
DM8XHJG	DN	A-893
DM8XHJG	HS	Preclinical
DM8XHJG	SN	1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide
DM8XHJG	DT	Small molecular drug
DM8XHJG	PC	91757965
DM8XHJG	MW	577.5
DM8XHJG	FM	C29H38Cl2N4O4
DM8XHJG	IC	InChI=1S/C29H38Cl2N4O4/c30-23-10-9-20(17-24(23)31)11-13-32-14-12-28(38)35(21-5-2-1-3-6-21)16-15-33-18-26(36)22-7-4-8-25-29(22)39-19-27(37)34-25/h4,7-10,17,21,26,32-33,36H,1-3,5-6,11-16,18-19H2,(H,34,37)/t26-/m0/s1
DM8XHJG	CS	C1CCC(CC1)N(CCNC[C@@H](C2=C3C(=CC=C2)NC(=O)CO3)O)C(=O)CCNCCC4=CC(=C(C=C4)Cl)Cl
DM8XHJG	IK	WVRBXBROEPXZHF-SANMLTNESA-N
DM8XHJG	IU	N-cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide
DM8XHJG	DE	Lung cancer

DMRSATG	ID	DMRSATG
DMRSATG	DN	Abamectin B1A
DMRSATG	HS	Preclinical
DMRSATG	SN	AVERMECTIN B1A; abamectin component B1a; Avermectin B(1)a; Abamectine [French]; Abamectinum [Latin]; Abamectina [Spanish]; Caswell No. 063AB; Antibiotic C 076B1a; Abamectin komponente B1a; 5-O-Demethylavermectin A1a; UNII-K54ZMM929K; Avermectin; Avermectin A1a, 5-O-demethyl-; EINECS 265-610-3; Antibiotic C 076A1a, 5-O-demethyl-; K54ZMM929K; CHEBI:29534; Avermectin A(sub 1a), 5-O-demethyl-; DSSTox_CID_3892; DSSTox_RID_77221; DSSTox_GSID_23892; Abamectina; Abamectine; C48H72O14; Abamectin B1a
DMRSATG	PC	6434889
DMRSATG	MW	873.1
DMRSATG	FM	C48H72O14
DMRSATG	IC	InChI=1S/C48H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,17-19,25-26,28,30-31,33-45,49-50,52H,11,16,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1
DMRSATG	CS	CCC(C)C1C(C=CC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C
DMRSATG	IK	RRZXIRBKKLTSOM-XPNPUAGNSA-N
DMRSATG	IU	(1'R,2R,3S,4'S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-2-[(2S)-butan-2-yl]-21',24'-dihydroxy-12'-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-3,11',13',22'-tetramethylspiro[2,3-dihydropyran-6,6'-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2'-one
DMRSATG	CA	CAS 65195-55-3
DMRSATG	CB	CHEBI:29534
DMRSATG	DE	Parasitic worm infestations

DMQ0NU1	ID	DMQ0NU1
DMQ0NU1	DN	ABI-013
DMQ0NU1	HS	Preclinical
DMQ0NU1	SN	Nab-CY196; Nab-ABI-139; Nanoparticle albumin-bound ABI-139 (injectable, cancer), Abraxis; Nanoparticle albumin-bound ABI-139 (injectable, cancer), Celgene
DMQ0NU1	CP	Abraxis BioScience Inc
DMQ0NU1	DT	Antibody
DMQ0NU1	DE	Solid tumour/cancer

DMKUPW0	ID	DMKUPW0
DMKUPW0	DN	ABX-0401
DMKUPW0	HS	Preclinical
DMKUPW0	SN	ALX-0071; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Pfizer; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Wyeth
DMKUPW0	CP	Ablynx NV
DMKUPW0	DE	Inflammatory bowel disease

DMBI1H2	ID	DMBI1H2
DMBI1H2	DN	AD-529
DMBI1H2	HS	Preclinical
DMBI1H2	CP	Sosei R&D Ltd
DMBI1H2	DE	Neuropathic pain

DM19R28	ID	DM19R28
DM19R28	DN	ADC-01
DM19R28	HS	Preclinical
DM19R28	CP	Almac Discovery
DM19R28	DT	Small molecular drug
DM19R28	DE	Solid tumour/cancer

DM21I35	ID	DM21I35
DM21I35	DN	ADC-03
DM21I35	HS	Preclinical
DM21I35	CP	Almac Discovery
DM21I35	DT	Small molecular drug
DM21I35	DE	Solid tumour/cancer

DM2WKDN	ID	DM2WKDN
DM2WKDN	DN	ADX-2 series
DM2WKDN	HS	Preclinical
DM2WKDN	CP	Addex
DM2WKDN	DT	Small molecular drug
DM2WKDN	PC	9821813
DM2WKDN	MW	391.3
DM2WKDN	FM	C20H27BrN2O
DM2WKDN	IC	InChI=1S/C20H26N2O.BrH/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19;/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3;1H
DM2WKDN	CS	CCC1CC2CC3C1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC.Br
DM2WKDN	IK	NVBHPBGGYJRLTF-UHFFFAOYSA-N
DM2WKDN	IU	17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene;hydrobromide
DM2WKDN	DE	Schizophrenia

DMEWFOL	ID	DMEWFOL
DMEWFOL	DN	ADX-71943
DMEWFOL	HS	Preclinical
DMEWFOL	CP	Addex Pharmaceuticals SA
DMEWFOL	DE	Gastroesophageal reflux disease

DM13YRT	ID	DM13YRT
DM13YRT	DN	AEOL-10150
DM13YRT	HS	Preclinical
DM13YRT	SN	AEOL-10112; AEOL-10113; AEOL-10113); AEOL-10123
DM13YRT	CP	Aeolus Pharmaceuticals; Aeolus Pharmaceuticals Inc
DM13YRT	PC	42609702
DM13YRT	MW	1033.2
DM13YRT	FM	C48H56Cl5MnN12
DM13YRT	IC	InChI=1S/C48H56N12.5ClH.Mn/c1-9-53-25-26-54(10-2)45(53)41-33-17-19-35(49-33)42(46-55(11-3)27-28-56(46)12-4)37-21-23-39(51-37)44(48-59(15-7)31-32-60(48)16-8)40-24-22-38(52-40)43(36-20-18-34(41)50-36)47-57(13-5)29-30-58(47)14-6;;;;;;/h17-32H,9-16H2,1-8H3;5*1H;/q+2;;;;;;+3/p-5
DM13YRT	CS	CCN1C=C[N+](=C1C2=C3C=CC(=C(C4=NC(=C(C5=CC=C([N-]5)C(=C6C=CC2=N6)C7=[N+](C=CN7CC)CC)C8=[N+](C=CN8CC)CC)C=C4)C9=[N+](C=CN9CC)CC)[N-]3)CC.[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3]
DM13YRT	IK	XMYHQLIAYLLEKT-UHFFFAOYSA-I
DM13YRT	IU	manganese(3+);5,10,15,20-tetrakis(1,3-diethylimidazol-1-ium-2-yl)porphyrin-22,24-diide;pentachloride
DM13YRT	DE	Multiple sclerosis

DMYIK5D	ID	DMYIK5D
DMYIK5D	DN	AEZS-123
DMYIK5D	HS	Preclinical
DMYIK5D	CP	Aeterna Zentaris Inc.
DMYIK5D	DE	Alcohol dependence

DM648KQ	ID	DM648KQ
DM648KQ	DN	ALN-FLU01
DM648KQ	HS	Preclinical
DM648KQ	SN	RNAi therapeutic (influenza), Alnylam/Novartis; NP/NA gene-silencing siRNA (influenza infection), Alnylam/Novartis
DM648KQ	CP	Alnylam Pharmaceuticals Inc
DM648KQ	DT	siRNA drug
DM648KQ	DE	Influenza virus infection

DM8T6H7	ID	DM8T6H7
DM8T6H7	DN	ALN-HTT
DM8T6H7	HS	Preclinical
DM8T6H7	CP	Alnylam Pharmaceuticals
DM8T6H7	DT	RNAi therapeutics
DM8T6H7	DE	Huntington disease

DMCJMOS	ID	DMCJMOS
DMCJMOS	DN	ALN-PCS
DMCJMOS	HS	Preclinical
DMCJMOS	CP	Alnylam Pharmaceuticals
DMCJMOS	DT	RNAi therapeutics
DMCJMOS	DE	Hypercholesterolaemia

DMW7XEU	ID	DMW7XEU
DMW7XEU	DN	ALN-TMP
DMW7XEU	HS	Preclinical
DMW7XEU	CP	Alnylam Pharmaceuticals
DMW7XEU	DT	Small interfering RNA
DMW7XEU	DE	Beta thalassemia

DMATQB7	ID	DMATQB7
DMATQB7	DN	Alpha-Helical lipopeptides FFS
DMATQB7	HS	Preclinical
DMATQB7	SN	FFS
DMATQB7	TC	Antiviral Agents
DMATQB7	DT	Protein/peptide drug
DMATQB7	SQ	FEEFSKKFEEFSKKFEEFSKKFEEFSKKFEEFSKK-A-K(C16)
DMATQB7	DE	Middle East Respiratory Syndrome (MERS)

DMVSKQF	ID	DMVSKQF
DMVSKQF	DN	Alpha-Helical lipopeptides IIK
DMVSKQF	HS	Preclinical
DMVSKQF	SN	IIK
DMVSKQF	TC	Antiviral Agents
DMVSKQF	DT	Protein/peptide drug
DMVSKQF	SQ	IEEIKKKIEEIKKKIEEIKKKIEEIKKKIEEIKKK-A-K(C16)
DMVSKQF	DE	Middle East Respiratory Syndrome (MERS)

DM1MGBX	ID	DM1MGBX
DM1MGBX	DN	Alpha-Helical lipopeptides IIS
DM1MGBX	HS	Preclinical
DM1MGBX	SN	IIS
DM1MGBX	TC	Antiviral Agents
DM1MGBX	DT	Protein/peptide drug
DM1MGBX	SQ	IEEISKKIEEISKKIEEISKKIEEISKKIEEISKK-A-K(C16)
DM1MGBX	DE	Middle East Respiratory Syndrome (MERS)

DM3WVM4	ID	DM3WVM4
DM3WVM4	DN	Alpha-Helical lipopeptides LLS
DM3WVM4	HS	Preclinical
DM3WVM4	SN	LLS
DM3WVM4	TC	Antiviral Agents
DM3WVM4	DT	Protein/peptide drug
DM3WVM4	SQ	LEELSKKLEELSKKLEELSKKLEELSKKLEELSKK-A-K(C16)
DM3WVM4	DE	Middle East Respiratory Syndrome (MERS)

DMQMAWK	ID	DMQMAWK
DMQMAWK	DN	Alpha-Zearalenol
DMQMAWK	HS	Preclinical
DMQMAWK	SN	alpha-Zearalenol; trans-Zearalenol; cis-Zearalenol; alpha zearalenol; UNII-59D4EVJ5KC; Zearalenol; 59D4EVJ5KC; CHEMBL371463; CHEBI:35065; A-ZEARALENOL; (3S,7R,11E)-7,14,16-trihydroxy-3-methyl-3,4,5,6,7,8,9,10-octahydro-1H-2-benzoxacyclotetradecin-1-one; .alpha.-Zearalenol; (-)-; A-Zearalenol; (2E,7R,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,14,16-tetraen-13-one; 36J; AC1NR4TQ; SCHEMBL343610; SCHEMBL109175; BIDD:ER0100; SGCUT00105; DTXSID8022402; FPQFYIAXQDXNOR-QDKLYSGJSA-N
DMQMAWK	PC	5284645
DMQMAWK	MW	320.4
DMQMAWK	FM	C18H24O5
DMQMAWK	IC	InChI=1S/C18H24O5/c1-12-6-5-9-14(19)8-4-2-3-7-13-10-15(20)11-16(21)17(13)18(22)23-12/h3,7,10-12,14,19-21H,2,4-6,8-9H2,1H3/b7-3+/t12-,14+/m0/s1
DMQMAWK	CS	CC1CCCC(CCCC=CC2=C(C(=CC(=C2)O)O)C(=O)O1)O
DMQMAWK	IK	FPQFYIAXQDXNOR-QDKLYSGJSA-N
DMQMAWK	IU	(4S,8R,12E)-8,16,18-trihydroxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),12,15,17-tetraen-2-one
DMQMAWK	CA	CAS 36455-71-7
DMQMAWK	CB	CHEBI:35065
DMQMAWK	DE	Cardiovascular disease

DM2U16Z	ID	DM2U16Z
DM2U16Z	DN	ANAVEX 1007
DM2U16Z	HS	Preclinical
DM2U16Z	CP	Anavex
DM2U16Z	DE	Pancreatic cancer; Prostate cancer; Melanoma

DM1MQON	ID	DM1MQON
DM1MQON	DN	ANAVEX 1-41
DM1MQON	HS	Preclinical
DM1MQON	CP	Anavex
DM1MQON	PC	10446473
DM1MQON	MW	281.4
DM1MQON	FM	C19H23NO
DM1MQON	IC	InChI=1S/C19H23NO/c1-20(2)14-16-13-19(21-15-16,17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,16H,13-15H2,1-2H3
DM1MQON	CS	CN(C)CC1CC(OC1)(C2=CC=CC=C2)C3=CC=CC=C3
DM1MQON	IK	AMVCMSPVJGQNFF-UHFFFAOYSA-N
DM1MQON	IU	1-(5,5-diphenyloxolan-3-yl)-N,N-dimethylmethanamine
DM1MQON	DE	Alzheimer disease

DM61TDB	ID	DM61TDB
DM61TDB	DN	ARI-809
DM61TDB	HS	Preclinical
DM61TDB	SN	Aldose reductase inhibitors (diabetes); CP-744809; Aldose reductase inhibitors (diabetes), Pfizer
DM61TDB	CP	Pfizer Inc
DM61TDB	DT	Small molecular drug
DM61TDB	PC	6420118
DM61TDB	MW	324.74
DM61TDB	FM	C13H9ClN2O4S
DM61TDB	IC	InChI=1S/C13H9ClN2O4S/c1-7-9-6-8(14)2-3-10(9)20-13(7)21(18,19)12-5-4-11(17)15-16-12/h2-6H,1H3,(H,15,17)
DM61TDB	CS	CC1=C(OC2=C1C=C(C=C2)Cl)S(=O)(=O)C3=NNC(=O)C=C3
DM61TDB	IK	FXFPQPNUMWQRAO-UHFFFAOYSA-N
DM61TDB	IU	3-[(5-chloro-3-methyl-1-benzofuran-2-yl)sulfonyl]-1H-pyridazin-6-one
DM61TDB	CA	CAS 463976-07-0
DM61TDB	DE	Diabetic complication

DMMD8VY	ID	DMMD8VY
DMMD8VY	DN	AR-R-1589
DMMD8VY	HS	Preclinical
DMMD8VY	CP	Fisons; AstraZeneca
DMMD8VY	DE	Eating disorder; Obesity

DMRPX4W	ID	DMRPX4W
DMRPX4W	DN	ASP8497
DMRPX4W	HS	Preclinical
DMRPX4W	CP	Astellas Pharma
DMRPX4W	DE	Type-2 diabetes

DM34FEA	ID	DM34FEA
DM34FEA	DN	ATA2431
DM34FEA	HS	Preclinical
DM34FEA	CP	Atara Biotherapeutics
DM34FEA	DT	CAR T Cell Therapy
DM34FEA	DE	B-cell lymphoma

DMJTYH3	ID	DMJTYH3
DMJTYH3	DN	ATA3219
DMJTYH3	HS	Preclinical
DMJTYH3	CP	Atara Biotherapeutics
DMJTYH3	DT	CAR T Cell Therapy
DMJTYH3	DE	B-cell lymphoma

DMXQVBT	ID	DMXQVBT
DMXQVBT	DN	ATA3271
DMXQVBT	HS	Preclinical
DMXQVBT	CP	Atara Biotherapeutics
DMXQVBT	DT	CAR T Cell Therapy
DMXQVBT	DE	Solid tumour/cancer; Mesothelioma

DMZJVR5	ID	DMZJVR5
DMZJVR5	DN	ATI-17000
DMZJVR5	HS	Preclinical
DMZJVR5	SN	CompB; J-113397; UNII-00M5444DIY; CHEMBL357076; 00M5444DIY; J113397; 1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one; 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; AC1NSK6N; J-113,397; 1-(1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; 256640-45-6; SCHEMBL875219; J 113397; GTPL1691; (+)-J-113397; ZINC1483900; BDBM50083230; NCGC00344513-02; 2H-Benzimidazol-2-one,
DMZJVR5	CP	ARY x Therapeutics
DMZJVR5	DT	Small molecular drug
DMZJVR5	PC	5311194
DMZJVR5	MW	399.6
DMZJVR5	FM	C24H37N3O2
DMZJVR5	IC	InChI=1S/C24H37N3O2/c1-2-26-22-12-8-9-13-23(22)27(24(26)29)21-14-15-25(17-20(21)18-28)16-19-10-6-4-3-5-7-11-19/h8-9,12-13,19-21,28H,2-7,10-11,14-18H2,1H3/t20-,21+/m0/s1
DMZJVR5	CS	CCN1C2=CC=CC=C2N(C1=O)[C@@H]3CCN(C[C@H]3CO)CC4CCCCCCC4
DMZJVR5	IK	MBGVUMXBUGIIBQ-LEWJYISDSA-N
DMZJVR5	IU	1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one
DMZJVR5	CA	CAS 256640-45-6
DMZJVR5	DE	Irritable bowel syndrome

DM4XZU2	ID	DM4XZU2
DM4XZU2	DN	ATL-1101
DM4XZU2	HS	Preclinical
DM4XZU2	CP	Antisense Therapeutics
DM4XZU2	DT	Antisense drug
DM4XZU2	DE	Psoriatic disorder

DM0KM6F	ID	DM0KM6F
DM0KM6F	DN	AUNP-12
DM0KM6F	HS	Preclinical
DM0KM6F	SN	Aurigene NP-12; Aurigene-012; Aur-012; GTPL10117; MolPort-044-830-666; s8549; compound #8 [WO2011161699A3]
DM0KM6F	CP	Aurigene/Curis
DM0KM6F	DT	Peptide
DM0KM6F	PC	131709240
DM0KM6F	MW	3261.6
DM0KM6F	FM	C142H226N40O48
DM0KM6F	IC	InChI=1S/C142H226N40O48/c1-12-71(6)110(176-124(213)83(36-22-25-51-143)158-125(214)89(180-152)45-50-108(201)202)137(226)163-85(41-46-102(146)193)118(207)156-73(8)116(205)165-90(38-23-26-52-144)141(230)182-55-29-40-101(182)135(224)155-72(7)114(203)115(204)91(56-69(2)3)166-120(209)86(42-47-103(147)194)164-138(227)113(76(11)192)179-136(225)109(70(4)5)175-123(212)84(39-28-53-153-142(150)151)160-127(216)92(57-77-30-16-13-17-31-77)168-119(208)82(159-128(217)93(58-78-32-18-14-19-33-78)169-133(222)98(66-187)171-121(210)87(43-48-106(197)198)162-132(221)99(67-188)174-140(229)112(75(10)191)177-129(218)95(61-105(149)196)167-117(206)81(145)64-185)37-24-27-54-154-181-96(59-79-34-20-15-21-35-79)130(219)173-97(65-186)131(220)161-88(44-49-107(199)200)122(211)172-100(68-189)134(223)178-111(74(9)190)139(228)170-94(60-104(148)195)126(215)157-80(62-183)63-184/h13-21,30-35,62,69-76,80-101,109-113,154,180-181,184-192H,12,22-29,36-61,63-68,143-145,152H2,1-11H3,(H2,146,193)(H2,147,194)(H2,148,195)(H2,149,196)(H,155,224)(H,156,207)(H,157,215)(H,158,214)(H,159,217)(H,160,216)(H,161,220)(H,162,221)(H,163,226)(H,164,227)(H,165,205)(H,166,209)(H,167,206)(H,168,208)(H,169,222)(H,170,228)(H,171,210)(H,172,211)(H,173,219)(H,174,229)(H,175,212)(H,176,213)(H,177,218)(H,178,223)(H,179,225)(H,197,198)(H,199,200)(H,201,202)(H4,150,151,153)/t71-,72-,73-,74+,75+,76+,80-,81+,82?,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,109+,110+,111+,112+,113+/m1/s1
DM0KM6F	CS	CC[C@@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)C(CCCCNN[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C=O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NN
DM0KM6F	IK	YQYGGOPUTPQHAY-KIQLFZLRSA-N
DM0KM6F	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[2-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(4S,7R)-7-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-carboxy-2-hydrazinylbutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-2-methyl-5,6-dioxooctan-4-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]hydrazinyl]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-hydroxy-3-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

DMKQ20J	ID	DMKQ20J
DMKQ20J	DN	AZ505
DMKQ20J	HS	Preclinical
DMKQ20J	SN	AZ 505; AZ-505
DMKQ20J	DT	Small molecular drug
DMKQ20J	PC	24961094
DMKQ20J	MW	577.5
DMKQ20J	FM	C29H38Cl2N4O4
DMKQ20J	IC	InChI=1S/C29H38Cl2N4O4/c30-23-8-6-20(18-24(23)31)10-13-32-15-12-27(38)35(22-4-2-1-3-5-22)17-16-33-14-11-21-7-9-25(36)28-29(21)39-19-26(37)34-28/h6-9,18,22,32-33,36H,1-5,10-17,19H2,(H,34,37)
DMKQ20J	CS	C1CCC(CC1)N(CCNCCC2=C3C(=C(C=C2)O)NC(=O)CO3)C(=O)CCNCCC4=CC(=C(C=C4)Cl)Cl
DMKQ20J	IK	LIBVHXXKHSODII-UHFFFAOYSA-N
DMKQ20J	IU	N-cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[2-(5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl)ethylamino]ethyl]propanamide
DMKQ20J	DE	Solid tumour/cancer

DMY7R3X	ID	DMY7R3X
DMY7R3X	DN	AZD-1678
DMY7R3X	HS	Preclinical
DMY7R3X	SN	CCR4 antagonist (asthma), AstraZeneca
DMY7R3X	CP	AstraZeneca plc
DMY7R3X	PC	23585443
DMY7R3X	MW	352.2
DMY7R3X	FM	C11H8Cl2FN3O3S
DMY7R3X	IC	InChI=1S/C11H8Cl2FN3O3S/c1-20-11-10(15-5-8(14)16-11)17-21(18,19)7-4-2-3-6(12)9(7)13/h2-5H,1H3,(H,15,17)
DMY7R3X	CS	COC1=NC(=CN=C1NS(=O)(=O)C2=C(C(=CC=C2)Cl)Cl)F
DMY7R3X	IK	NWSUDJQTTGDPIR-UHFFFAOYSA-N
DMY7R3X	IU	2,3-dichloro-N-(5-fluoro-3-methoxypyrazin-2-yl)benzenesulfonamide
DMY7R3X	DE	Asthma

DM3FLMR	ID	DM3FLMR
DM3FLMR	DN	Azidothymidine monophosphate
DM3FLMR	HS	Preclinical
DM3FLMR	SN	azidothymidine monophosphate; SCHEMBL17515060
DM3FLMR	PC	118879755
DM3FLMR	MW	363.223
DM3FLMR	FM	C10H14N5O8P
DM3FLMR	IC	InChI=1S/C10H14N5O8P/c1-5-3-15(9(18)12-8(5)17)10(13-14-11)2-6(16)7(23-10)4-22-24(19,20)21/h3,6-7,16H,2,4H2,1H3,(H,12,17,18)(H2,19,20,21)/t6-,7+,10-/m0/s1
DM3FLMR	CS	CC1=CN(C(=O)NC1=O)C2(CC(C(O2)COP(=O)(O)O)O)N=[N+]=[N-]
DM3FLMR	IK	VUEHGFOETMXHKA-PJKMHFRUSA-N
DM3FLMR	IU	[(2R,3S,5R)-5-azido-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DM3FLMR	DE	Cancer

DMOW07D	ID	DMOW07D
DMOW07D	DN	BAP-15
DMOW07D	HS	Preclinical
DMOW07D	DT	Small molecular drug
DMOW07D	DE	Solid tumour/cancer

DMTJZIL	ID	DMTJZIL
DMTJZIL	DN	Barasertib-hQPA
DMTJZIL	HS	Preclinical
DMTJZIL	SN	AZD1152-HQPA; Barasertib (AZD1152-HQPA); AZD-1152HQPA; barasertib-hQPA; UNII-29P8LWS24N; INH 34; AZD1152 HPQA; 29P8LWS24N; CHEMBL215152; 2-[5-(7-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propoxy}-quinazolin-4-ylamino)-2H-pyrazol-3-yl]-N-(3-fluoro-phenyl)-acetamide; 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide; 5-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-1H-pyrazole-3-acetamide; AZD 1152
DMTJZIL	PC	16007391
DMTJZIL	MW	507.6
DMTJZIL	FM	C26H30FN7O3
DMTJZIL	IC	InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)
DMTJZIL	CS	CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO
DMTJZIL	IK	QYZOGCMHVIGURT-UHFFFAOYSA-N
DMTJZIL	IU	2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide
DMTJZIL	CA	CAS 722544-51-6
DMTJZIL	CB	CHEBI:91367
DMTJZIL	DE	Cancer

DM92VRP	ID	DM92VRP
DM92VRP	DN	Batimastat
DM92VRP	HS	Preclinical
DM92VRP	SN	batimastat; 130370-60-4; BB-94; Batimastat (BB-94); BB 94; UNII-BK349F52C9; BB94; Batimastat(BB-94); C23H31N3O4S2; CHEMBL279786; BK349F52C9; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; 4-(N-HYDROXYAMINO)-2R-ISOBUTYL-2S-(2-THIENYLTHIOMETHYL)SUCCINYL-L-PHENYLALANINE-N-METHYLAMIDE; (2S,3R)-5-Methyl-3-(((alphaS)-alpha-(methylcarbamoyl)phenethyl)carbamoyl)-2-((2-thienylthio)methyl)hexanohydroxamic acid
DM92VRP	CP	Pfizer
DM92VRP	DT	Small molecular drug
DM92VRP	PC	5362422
DM92VRP	MW	477.6
DM92VRP	FM	C23H31N3O4S2
DM92VRP	IC	InChI=1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1
DM92VRP	CS	CC(C)C[C@H]([C@H](CSC1=CC=CS1)C(=O)NO)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NC
DM92VRP	IK	XFILPEOLDIKJHX-QYZOEREBSA-N
DM92VRP	IU	(2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide
DM92VRP	CA	CAS 130370-60-4
DM92VRP	DE	Idiopathic pulmonary fibrosis

DMWH19X	ID	DMWH19X
DMWH19X	DN	BAY 598
DMWH19X	HS	Preclinical
DMWH19X	SN	BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide
DMWH19X	DT	Small molecular drug
DMWH19X	PC	117072551
DMWH19X	MW	525.3
DMWH19X	FM	C22H20Cl2F2N6O3
DMWH19X	IC	InChI=1S/C22H20Cl2F2N6O3/c1-2-31(19(34)11-33)18-10-32(30-20(18)13-6-7-16(23)17(24)8-13)22(28-12-27)29-14-4-3-5-15(9-14)35-21(25)26/h3-9,18,21,33H,2,10-11H2,1H3,(H,28,29)/t18-/m0/s1
DMWH19X	CS	CCN([C@H]1CN(N=C1C2=CC(=C(C=C2)Cl)Cl)C(=NC3=CC(=CC=C3)OC(F)F)NC#N)C(=O)CO
DMWH19X	IK	OTTJIRVZJJGFTK-SFHVURJKSA-N
DMWH19X	IU	N-[(4S)-2-[N-cyano-N'-[3-(difluoromethoxy)phenyl]carbamimidoyl]-5-(3,4-dichlorophenyl)-3,4-dihydropyrazol-4-yl]-N-ethyl-2-hydroxyacetamide
DMWH19X	DE	Discovery agent

DMTEJV1	ID	DMTEJV1
DMTEJV1	DN	BAY 60-6583
DMTEJV1	HS	Preclinical
DMTEJV1	SN	BAY-60-6583; BAY60-6583
DMTEJV1	DT	Small molecular drug
DMTEJV1	PC	11717831
DMTEJV1	MW	379.4
DMTEJV1	FM	C19H17N5O2S
DMTEJV1	IC	InChI=1S/C19H17N5O2S/c20-7-14-17(12-3-5-13(6-4-12)26-9-11-1-2-11)15(8-21)19(24-18(14)23)27-10-16(22)25/h3-6,11H,1-2,9-10H2,(H2,22,25)(H2,23,24)
DMTEJV1	CS	C1CC1COC2=CC=C(C=C2)C3=C(C(=NC(=C3C#N)SCC(=O)N)N)C#N
DMTEJV1	IK	ZTYHZMAZUWOXNC-UHFFFAOYSA-N
DMTEJV1	IU	2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl]sulfanylacetamide
DMTEJV1	CA	CAS 910487-58-0
DMTEJV1	CB	CHEBI:131358
DMTEJV1	DE	Myocardial ischemia

DMVESTF	ID	DMVESTF
DMVESTF	DN	BAY-38-1315
DMVESTF	HS	Preclinical
DMVESTF	SN	BAY-19-4789
DMVESTF	CP	Bayer AG
DMVESTF	DT	Small molecular drug
DMVESTF	PC	46880878
DMVESTF	MW	501.5
DMVESTF	FM	C29H28F5NO
DMVESTF	IC	InChI=1S/C29H28F5NO/c1-16(2)27-25(26(31)18-4-8-19(9-5-18)29(32,33)34)23(17-6-10-20(30)11-7-17)24-21(35-27)14-28(12-3-13-28)15-22(24)36/h4-11,16,22,26,36H,3,12-15H2,1-2H3/t22-,26-/m0/s1
DMVESTF	CS	CC(C)C1=NC2=C([C@H](CC3(C2)CCC3)O)C(=C1[C@H](C4=CC=C(C=C4)C(F)(F)F)F)C5=CC=C(C=C5)F
DMVESTF	IK	HNPNOKPKJPAVPV-NVQXNPDNSA-N
DMVESTF	IU	(5S)-4-(4-fluorophenyl)-3-[(S)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-propan-2-ylspiro[6,8-dihydro-5H-quinoline-7,1'-cyclobutane]-5-ol
DMVESTF	DE	Arteriosclerosis

DM3EUBA	ID	DM3EUBA
DM3EUBA	DN	BC-1215
DM3EUBA	HS	Preclinical
DM3EUBA	SN	1507370-20-8; N1,N2-Bis(4-(pyridin-2-yl)benzyl)ethane-1,2-diamine; C26H26N4; N1,N2-Bis[4-(2-pyridinyl)benzyl]-1,2-ethanediamine; CHEMBL4549895; SCHEMBL16781356; AOB4428; SYN5093; EX-A4964; MFCD28118991; ZINC205895150; AS-16457; HY-117937; CS-0068629; N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine
DM3EUBA	DT	Small molecular drug
DM3EUBA	PC	72201045
DM3EUBA	MW	394.5
DM3EUBA	FM	C26H26N4
DM3EUBA	IC	InChI=1S/C26H26N4/c1-3-15-29-25(5-1)23-11-7-21(8-12-23)19-27-17-18-28-20-22-9-13-24(14-10-22)26-6-2-4-16-30-26/h1-16,27-28H,17-20H2
DM3EUBA	CS	C1=CC=NC(=C1)C2=CC=C(C=C2)CNCCNCC3=CC=C(C=C3)C4=CC=CC=N4
DM3EUBA	IK	IXEPQJQQSLMESJ-UHFFFAOYSA-N
DM3EUBA	IU	N,N'-bis[(4-pyridin-2-ylphenyl)methyl]ethane-1,2-diamine
DM3EUBA	DE	Inflammation

DMSJ2I6	ID	DMSJ2I6
DMSJ2I6	DN	Beta-aminopropionitrile
DMSJ2I6	HS	Preclinical
DMSJ2I6	SN	3-aminopropionitrile; 3-Aminopropanenitrile; 151-18-8; 2-Cyanoethylamine; Aminopropionitrile; BETA-AMINOPROPIONITRILE; Propanenitrile, 3-amino-; BAPN; 3-Aminopropiononitrile; beta-Cyanoethylamine; beta-Alaninenitrile; Propionitrile, 3-amino-; beta-Aminoethyl cyanide; beta-Alaminenitrile; UNII-38D5LJ4KH2; NSC 40641; 3-amino-propionitrile; beta-Alaninenitrile; CHEBI:27413; beta-Cyanoethylamine; beta-Aminopropionitrile; H2NCH2CH2CN; MFCD00014820; 38D5LJ4KH2; CHEMBL1618272; 3-Aminopropionitrile, 98%, stabilized; 3-Aminopropionitrile; Aminopropionitrile; BAPN; N-(2-Cyanoethyl)amine; NSC 40641; HSDB 2897; EINECS 205-786-0; BRN 1698848; cyanoethylamine; aminoethylcyanide; b-Alaminenitrile; b-Alaninenitrile; CCRIS 8134; b-Cyanoethylamine; 3-Aminopropanitrile; EINECS 268-598-8; b-Aminoethyl cyanide; 3-aminopropanonitrile; Propanenitrile, 3-amino-, N-C11-13-isoalkyl derivs.; n-(2-cyanoethyl)amine; PubChem19134; beta-amino propionitrile; beta-amino-propionitrile; (C12-C18)Alkyl alkoxyethyleneaminonitrile; Lopac-A-3134; beta-Aminoethyl cyanide; (C11-C13)Branched alkyl aminoethylenenitrile; WLN: Z2CN; ACMC-1B8B9; Lopac0_000055; 68130-65-4; 68130-66-5; C(#N)CC[N]; DTXSID6048418; AGSPXMVUFBBBMO-UHFFFAOYSA-; 3-amino-propionitrile, AldrichCPR; SODIUMBITARTRATE,MONOHYDRATE; CS-D1507; HY-Y1750; NSC40641; STR02529; ZINC1530259; ANW-43145; BBL101609; BDBM50232678; NSC-40641; Propanenitrile, 3-amino-, N-(3-(C12-18-alkyloxy)propyl) derivs.; STL555405; AKOS000121388; NCGC00015048-01; NCGC00015048-02; NCGC00015048-03; NCGC00015048-05; NCGC00162054-01; 3-Aminopropionitrile stabilized with K2CO3; A0408; FT-0615060; C05670; 97104-EP2298731A1; 97104-EP2305660A1; Q3614347; W-109080
DMSJ2I6	DT	Small molecular drug
DMSJ2I6	PC	1647
DMSJ2I6	MW	70.09
DMSJ2I6	FM	C3H6N2
DMSJ2I6	IC	InChI=1S/C3H6N2/c4-2-1-3-5/h1-2,4H2
DMSJ2I6	CS	C(CN)C#N
DMSJ2I6	IK	AGSPXMVUFBBBMO-UHFFFAOYSA-N
DMSJ2I6	IU	3-aminopropanenitrile
DMSJ2I6	CA	CAS 151-18-8
DMSJ2I6	CB	CHEBI:27413
DMSJ2I6	DE	Cardiac arrest

DM6BGJ9	ID	DM6BGJ9
DM6BGJ9	DN	BFF-122
DM6BGJ9	HS	Preclinical
DM6BGJ9	DT	Small molecular drug
DM6BGJ9	PC	102425126
DM6BGJ9	MW	364.4
DM6BGJ9	FM	C17H21FN4O4
DM6BGJ9	IC	InChI=1S/C17H21FN4O4/c1-9-8-26-16-13-10(15(23)11(17(24)25)7-22(9)13)6-12(18)14(16)20-2-4-21(19)5-3-20/h6,9,11H,2-5,7-8,19H2,1H3,(H,24,25)/t9-,11?/m0/s1
DM6BGJ9	CS	C[C@H]1COC2=C3N1CC(C(=O)C3=CC(=C2N4CCN(CC4)N)F)C(=O)O
DM6BGJ9	IK	SBYIJFJAUBGBOA-FTNKSUMCSA-N
DM6BGJ9	IU	(2S)-6-(4-aminopiperazin-1-yl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8-triene-11-carboxylic acid
DM6BGJ9	DE	Cognitive impairment; Schizophrenia

DMK3SAF	ID	DMK3SAF
DMK3SAF	DN	BI-D1870
DMK3SAF	HS	Preclinical
DMK3SAF	SN	501437-28-1; 2-((3,5-difluoro-4-hydroxyphenyl)amino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one; 2-(3,5-difluoro-4-hydroxyanilino)-5,7-dimethyl-8-(3-methylbutyl)-7H-pteridin-6-one; C19H23F2N5O2; 2-(3,5-difluoro-4-hydroxyphenylamino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one; BI-D 1870; CHEMBL573107; GTPL8038; SCHEMBL13881333; CTK8I8998; BDBM25017; DTXSID40648506; BID1870; MolPort-008-266-821; HMS3244D11; HMS3244C12; HMS3244C11; BCPP000343; HMS3651D17; BCP01977; EX-A2471; NSC747342
DMK3SAF	DT	Small molecular drug
DMK3SAF	PC	25023738
DMK3SAF	MW	391.4
DMK3SAF	FM	C19H23F2N5O2
DMK3SAF	IC	InChI=1S/C19H23F2N5O2/c1-10(2)5-6-26-11(3)18(28)25(4)15-9-22-19(24-17(15)26)23-12-7-13(20)16(27)14(21)8-12/h7-11,27H,5-6H2,1-4H3,(H,22,23,24)
DMK3SAF	CS	CC1C(=O)N(C2=CN=C(N=C2N1CCC(C)C)NC3=CC(=C(C(=C3)F)O)F)C
DMK3SAF	IK	DTEKTGDVSARYDS-UHFFFAOYSA-N
DMK3SAF	IU	2-(3,5-difluoro-4-hydroxyanilino)-5,7-dimethyl-8-(3-methylbutyl)-7H-pteridin-6-one
DMK3SAF	CA	CAS 501437-28-1
DMK3SAF	DE	Chronic lymphocytic leukaemia

DM2JOXF	ID	DM2JOXF
DM2JOXF	DN	BIIR-777
DM2JOXF	HS	Preclinical
DM2JOXF	SN	AMPA receptor modulator (memory/neurological disorders); AMPA receptor modulator (memory/neurological disorders), Boehringer Ingelheim
DM2JOXF	CP	Boehringer Ingelheim Corp
DM2JOXF	DE	Neurological disorder

DMPUBK8	ID	DMPUBK8
DMPUBK8	DN	BIO-306
DMPUBK8	HS	Preclinical
DMPUBK8	SN	AC1L1H3K; CTK6E1327; CCG-204816; NCGC00162232-03; NCGC00162232-02; NCGC00162232-01; AB00513961; AB00513961_07; 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoate
DMPUBK8	CP	Enhance Biotech
DMPUBK8	DT	Small molecular drug
DMPUBK8	PC	3959
DMPUBK8	MW	458.4
DMPUBK8	FM	C22H31Cl2N2O4-
DMPUBK8	IC	InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)/p-1
DMPUBK8	CS	CCCCCN(CCCCC)C(=O)C(CCC(=O)[O-])NC(=O)C1=CC(=C(C=C1)Cl)Cl
DMPUBK8	IK	IEKOTSCYBBDIJC-UHFFFAOYSA-M
DMPUBK8	IU	4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoate
DMPUBK8	DE	Migraine

DM5CBNY	ID	DM5CBNY
DM5CBNY	DN	BIX-01294
DM5CBNY	HS	Preclinical
DM5CBNY	SN	BIX01294; BIX 01294
DM5CBNY	DT	Small molecular drug
DM5CBNY	PC	25150857
DM5CBNY	MW	490.6
DM5CBNY	FM	C28H38N6O2
DM5CBNY	IC	InChI=1S/C28H38N6O2/c1-32-12-7-13-34(17-16-32)28-30-24-19-26(36-3)25(35-2)18-23(24)27(31-28)29-22-10-14-33(15-11-22)20-21-8-5-4-6-9-21/h4-6,8-9,18-19,22H,7,10-17,20H2,1-3H3,(H,29,30,31)
DM5CBNY	CS	CN1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)NC4CCN(CC4)CC5=CC=CC=C5)OC)OC
DM5CBNY	IK	OSXFATOLZGZLSK-UHFFFAOYSA-N
DM5CBNY	IU	N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine
DM5CBNY	CA	CAS 935693-62-2
DM5CBNY	CB	CHEBI:93986
DM5CBNY	DE	Breast cancer

DMDJH2L	ID	DMDJH2L
DMDJH2L	DN	BMS 536924
DMDJH2L	HS	Preclinical
DMDJH2L	SN	BMS-536924; BMS 536924; BMS536924; UNII-40E3AZG1MX; 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone; 40E3AZG1MX; CHEMBL401930; CS-0117; HY-10262; MLS006011171; SCHEMBL4132577; SCHEMBL15974144; BDBM27879; BCP02116; ZINC6718468; 2278AH; s1012; ABP000159; ZINC140935730; AKOS024458339; AKOS025149514; SB19378; RL03740; KIN0000061; NCGC00346460-05; NCGC00346460-02; SMR004702940; BMS-536924/BMS536924; A2238; X5078; SW218124-2; S-7752
DMDJH2L	PC	135440466
DMDJH2L	MW	479.965
DMDJH2L	FM	C25H26ClN5O3
DMDJH2L	IC	InChI=1S/C25H26ClN5O3/c1-15-11-18(31-7-9-34-10-8-31)13-20-23(15)30-24(29-20)22-19(5-6-27-25(22)33)28-14-21(32)16-3-2-4-17(26)12-16/h2-6,11-13,21,32H,7-10,14H2,1H3,(H,29,30)(H2,27,28,33)/t21-/m1/s1
DMDJH2L	CS	CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5
DMDJH2L	IK	ZWVZORIKUNOTCS-OAQYLSRUSA-N
DMDJH2L	IU	4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one
DMDJH2L	CA	CAS 468740-43-4
DMDJH2L	CB	CHEBI:91454
DMDJH2L	DE	Cancer

DMHAWBR	ID	DMHAWBR
DMHAWBR	DN	BMS-192548
DMHAWBR	HS	Preclinical
DMHAWBR	CP	BMS
DMHAWBR	PC	9887988
DMHAWBR	MW	414.4
DMHAWBR	FM	C21H18O9
DMHAWBR	IC	InChI=1S/C21H18O9/c1-8(22)14-13(24)7-20(28)6-10-3-9-4-11(30-2)5-12(23)15(9)17(25)16(10)19(27)21(20,29)18(14)26/h3-5,23,25-26,28-29H,6-7H2,1-2H3
DMHAWBR	CS	CC(=O)C1=C(C2(C(=O)C3=C(C4=C(C=C(C=C4C=C3CC2(CC1=O)O)OC)O)O)O)O
DMHAWBR	IK	GEIAHRUFSQGALU-UHFFFAOYSA-N
DMHAWBR	IU	3-acetyl-4,4a,6,7,12a-pentahydroxy-9-methoxy-1,12-dihydrotetracene-2,5-dione
DMHAWBR	CB	CHEBI:133806
DMHAWBR	DE	Obesity

DMCWIBU	ID	DMCWIBU
DMCWIBU	DN	BMS-3870032
DMCWIBU	HS	Preclinical
DMCWIBU	SN	SNS-032; BMS-387032; SNS 032; BMS 387032; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; SNS-032 (BMS-387032); N-(5-(((5-(tert-Butyl)oxazol-2-yl)methyl)thio)thiazol-2-yl)piperidine-4-carboxamide; N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide; UNII-9979I93686; N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; CHEMBL296468; SNS032; C17H24N4O2S2; BMS387032
DMCWIBU	PC	3025986
DMCWIBU	MW	380.5
DMCWIBU	FM	C17H24N4O2S2
DMCWIBU	IC	InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)
DMCWIBU	CS	CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)C3CCNCC3
DMCWIBU	IK	OUSFTKFNBAZUKL-UHFFFAOYSA-N
DMCWIBU	IU	N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
DMCWIBU	CA	CAS 345627-80-7
DMCWIBU	CB	CHEBI:91399
DMCWIBU	DE	Cancer

DMQG39T	ID	DMQG39T
DMQG39T	DN	BMS-695735
DMQG39T	HS	Preclinical
DMQG39T	DT	Small molecular drug
DMQG39T	PC	135441202
DMQG39T	MW	512
DMQG39T	FM	C26H31ClFN7O
DMQG39T	IC	InChI=1S/C26H31ClFN7O/c1-17-13-19(18-4-10-34(11-5-18)9-2-6-28)14-22-24(17)33-25(32-22)23-21(3-7-30-26(23)36)29-8-12-35-16-20(27)15-31-35/h3,7,13-16,18H,2,4-6,8-12H2,1H3,(H,32,33)(H2,29,30,36)
DMQG39T	CS	CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)CCCF
DMQG39T	IK	VWELCPLMPPEKOL-UHFFFAOYSA-N
DMQG39T	IU	4-[2-(4-chloropyrazol-1-yl)ethylamino]-3-[6-[1-(3-fluoropropyl)piperidin-4-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one
DMQG39T	CA	CAS 1054315-48-8
DMQG39T	DE	Solid tumour/cancer

DM4BZEJ	ID	DM4BZEJ
DM4BZEJ	DN	BMS-986118
DM4BZEJ	HS	Preclinical
DM4BZEJ	SN	CHEMBL4080226; 1610562-74-7; 2-((4S,5S)-1-(4-(((3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl)oxy)phenyl)-4-methyl-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-5-yl)acetic acid; SCHEMBL15710831; BDBM50243975; 2-[(3S,4S)-2-[4-[(3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl]oxyphenyl]-4-methyl-5-(trifluoromethyl)-3,4-dihydropyrazol-3-yl]acetic acid
DM4BZEJ	DT	Small molecular drug
DM4BZEJ	PC	76900387
DM4BZEJ	MW	541
DM4BZEJ	FM	C25H28ClF3N4O4
DM4BZEJ	IC	InChI=1S/C25H28ClF3N4O4/c1-14-13-32(20-10-22(36-3)30-12-18(20)26)9-8-21(14)37-17-6-4-16(5-7-17)33-19(11-23(34)35)15(2)24(31-33)25(27,28)29/h4-7,10,12,14-15,19,21H,8-9,11,13H2,1-3H3,(H,34,35)/t14-,15+,19+,21-/m1/s1
DM4BZEJ	CS	C[C@@H]1CN(CC[C@H]1OC2=CC=C(C=C2)N3[C@H]([C@@H](C(=N3)C(F)(F)F)C)CC(=O)O)C4=CC(=NC=C4Cl)OC
DM4BZEJ	IK	GKIUHMMLGAMMOO-OITFXXTJSA-N
DM4BZEJ	IU	2-[(3S,4S)-2-[4-[(3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl]oxyphenyl]-4-methyl-5-(trifluoromethyl)-3,4-dihydropyrazol-3-yl]acetic acid
DM4BZEJ	DE	Type 2 diabetes

DM8TAI9	ID	DM8TAI9
DM8TAI9	DN	BMS-986202
DM8TAI9	HS	Preclinical
DM8TAI9	SN	AM-095; AM-966; LPA1 antagonists (fibrotic disease), Amira; Lysophosphatidic acid antagonists (fibrotic disease), Amira
DM8TAI9	CP	Bristol-myers squibb; Amira Pharmaceuticals Inc
DM8TAI9	DT	Small molecular drug
DM8TAI9	PC	49838688
DM8TAI9	MW	482.5
DM8TAI9	FM	C29H26N2O5
DM8TAI9	IC	InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m0/s1
DM8TAI9	CS	CC1=NOC(=C1NC(=O)O[C@@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O
DM8TAI9	IK	GQBRZBHEPUQRPL-IBGZPJMESA-N
DM8TAI9	IU	1-[4-[4-[3-methyl-4-[[(1S)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid
DM8TAI9	DE	Idiopathic pulmonary fibrosis

DMRCMEK	ID	DMRCMEK
DMRCMEK	DN	BMS-PCSK9
DMRCMEK	HS	Preclinical
DMRCMEK	CP	ISIS Pharm; Bristol-Myers Squibb
DMRCMEK	DT	Antisense drug
DMRCMEK	DE	Coronary artery disease

DMCPQJ9	ID	DMCPQJ9
DMCPQJ9	DN	BN-AA-003-NY
DMCPQJ9	HS	Preclinical
DMCPQJ9	SN	Selective estrogen receptor modulators (menopause symptoms); Selective estrogen receptor modulators (menopause symptoms), Bionovo
DMCPQJ9	CP	Bionovo Inc
DMCPQJ9	DE	Estrogen deficiency

DMVMY4X	ID	DMVMY4X
DMVMY4X	DN	BN-AO-014
DMVMY4X	HS	Preclinical
DMVMY4X	SN	Selective estrogen receptor modulators (genitourinary atrophy); Selective estrogen receptor modulators (genitourinary atrophy), Bionovo
DMVMY4X	CP	Bionovo Inc
DMVMY4X	DE	Atrophy

DMM1O0P	ID	DMM1O0P
DMM1O0P	DN	BNC-102
DMM1O0P	HS	Preclinical
DMM1O0P	CP	Bionomics
DMM1O0P	DT	Antibody
DMM1O0P	DE	Solid tumour/cancer

DMBPTDC	ID	DMBPTDC
DMBPTDC	DN	BN-CB-045
DMBPTDC	HS	Preclinical
DMBPTDC	SN	Selective estrogen receptor modulators (female sexual dysfunction); BN-ES-022; Selective estrogen receptor modulators (female sexual dysfunction), Bionovo
DMBPTDC	CP	Bionovo Inc
DMBPTDC	DE	Female sexual arousal dysfunction

DMFNLE6	ID	DMFNLE6
DMFNLE6	DN	BN-DF-037
DMFNLE6	HS	Preclinical
DMFNLE6	SN	Selective estrogen receptor modulators (osteoporosis); BN-EU-036; Selective estrogen receptor modulators (osteoporosis), Bionovo; BN-AM-008-XG; BN-PC-049-BK
DMFNLE6	CP	Bionovo Inc
DMFNLE6	DE	Osteoporosis

DM0PJU9	ID	DM0PJU9
DM0PJU9	DN	BN-GU-005-DHP
DM0PJU9	HS	Preclinical
DM0PJU9	SN	Selective estrogen receptor modulators (arthralgia); Selective estrogen receptor modulators (arthralgia), Bionovo
DM0PJU9	CP	Bionovo Inc
DM0PJU9	DE	Arthralgia

DM8WDAL	ID	DM8WDAL
DM8WDAL	DN	BN-OD-026
DM8WDAL	HS	Preclinical
DM8WDAL	SN	Selective estrogen receptor modulators (colon/breast cancer); BN-RP-006-OHA; Selective estrogen receptor modulators (colon/breast cancer), Bionovo
DM8WDAL	CP	Bionovo Inc
DM8WDAL	DE	Solid tumour/cancer

DM5O3HC	ID	DM5O3HC
DM5O3HC	DN	Bouvardin
DM5O3HC	HS	Preclinical
DM5O3HC	SN	Bouvardin; MLS002703036; NSC259968; NSC 259968; NSC-259968; AC1L8NRS; Neuro_000123; SCHEMBL8739404; SMR001566844; From fraction F049 of Bouvardia ternifolia; Cyclic(D-alanyl-L-alanyl-N, cyclic(54.fwdarw.63)-ether, (S)-; 17,24-dihydroxy-10-(4-methoxybenzyl)-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexaazatetracyclo[14.12.2.2~18,21~.1~23,27~]tritriaconta-18,20,23(31),24,26,32-hexaene-2,5,8,11,14,30-hexone
DM5O3HC	PC	429598
DM5O3HC	MW	772.8
DM5O3HC	FM	C40H48N6O10
DM5O3HC	IC	InChI=1S/C40H48N6O10/c1-21-35(49)42-22(2)38(52)44(4)29(18-24-8-13-27(55-7)14-9-24)37(51)43-23(3)39(53)46(6)33-34(48)26-11-15-28(16-12-26)56-32-20-25(10-17-31(32)47)19-30(36(50)41-21)45(5)40(33)54/h8-17,20-23,29-30,33-34,47-48H,18-19H2,1-7H3,(H,41,50)(H,42,49)(H,43,51)
DM5O3HC	CS	CC1C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)N(C2C(C3=CC=C(C=C3)OC4=C(C=CC(=C4)CC(C(=O)N1)N(C2=O)C)O)O)C)C)CC5=CC=C(C=C5)OC)C)C
DM5O3HC	IK	TWOWSRSKGJSZHZ-UHFFFAOYSA-N
DM5O3HC	IU	17,24-dihydroxy-10-[(4-methoxyphenyl)methyl]-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexazatetracyclo[14.12.2.218,21.123,27]tritriaconta-18,20,23,25,27(31),32-hexaene-2,5,8,11,14,30-hexone
DM5O3HC	CA	CAS 64755-14-2
DM5O3HC	DE	Cancer

DMT2C78	ID	DMT2C78
DMT2C78	DN	Brensocatib
DMT2C78	HS	Preclinical
DMT2C78	SN	AZD7986; AZD-7986; UNII-25CG88L0BB; 25CG88L0BB; INS1007; INS-1007; AZD 7986
DMT2C78	TC	Antiviral Agents
DMT2C78	DT	Small molecular drug
DMT2C78	PC	118253852
DMT2C78	MW	420.5
DMT2C78	FM	C23H24N4O4
DMT2C78	IC	InChI=1S/C23H24N4O4/c1-27-19-12-17(7-8-20(19)31-23(27)29)16-5-3-15(4-6-16)11-18(13-24)26-22(28)21-14-25-9-2-10-30-21/h3-8,12,18,21,25H,2,9-11,14H2,1H3,(H,26,28)/t18-,21-/m0/s1
DMT2C78	CS	CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)OC1=O
DMT2C78	IK	AEXFXNFMSAAELR-RXVVDRJESA-N
DMT2C78	IU	(2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
DMT2C78	CA	CAS 1802148-05-5
DMT2C78	DE	Coronavirus Disease 2019 (COVID-19)

DMO15TX	ID	DMO15TX
DMO15TX	DN	BSF-78438
DMO15TX	HS	Preclinical
DMO15TX	CP	Abbott
DMO15TX	DE	Schizophrenia

DM3WHB2	ID	DM3WHB2
DM3WHB2	DN	BST-1005
DM3WHB2	HS	Preclinical
DM3WHB2	SN	BST-1004; Anti-laminin gamma2 mAbs (cancer), BioStratum; Anti-laminin gamma2 monoclonal antibodies (cancer), BioStratum
DM3WHB2	CP	BioStratum Inc
DM3WHB2	DT	Antibody
DM3WHB2	DE	Solid tumour/cancer

DMT4532	ID	DMT4532
DMT4532	DN	Bunitrolol
DMT4532	HS	Preclinical
DMT4532	SN	Bunitrolol; 2-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitrile; Bunitrolol [INN]; Stresson; Bunitrololum [INN-Latin]; KO-1366; Bunitrolol HCl; BRN 2374567; 2-Nitrilo-N-tert-butylphenoxypropanolamine; Koe 1366; o-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitrile; 2-Propanol, 3-(tert-butylamino)-1-(m-cyanophenoxy)-; (RS)-2-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitril; 2-[3-(tert-butylamino)-2-hydroxypropoxy]benzonitrile; Bunitrololum; BENZONITRILE, o-(3-(tert-BUTYLAMINO)-2-HYDROXYPROPOXY)-
DMT4532	PC	2473
DMT4532	MW	248.32
DMT4532	FM	C14H20N2O2
DMT4532	IC	InChI=1S/C14H20N2O2/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15/h4-7,12,16-17H,9-10H2,1-3H3
DMT4532	CS	CC(C)(C)NCC(COC1=CC=CC=C1C#N)O
DMT4532	IK	VCVQSRCYSKKPBA-UHFFFAOYSA-N
DMT4532	IU	2-[3-(tert-butylamino)-2-hydroxypropoxy]benzonitrile
DMT4532	CA	CAS 34915-68-9
DMT4532	CB	CHEBI:135012

DMDSX58	ID	DMDSX58
DMDSX58	DN	BVT-A
DMDSX58	HS	Preclinical
DMDSX58	CP	BioVitrum
DMDSX58	DE	Acromegaly

DMY9F1M	ID	DMY9F1M
DMY9F1M	DN	C30
DMY9F1M	HS	Preclinical
DMY9F1M	DT	Small molecular drug
DMY9F1M	PC	134820957
DMY9F1M	MW	795.9
DMY9F1M	FM	C38H71NO12P2-6
DMY9F1M	IC	InChI=1S/C38H71NO12P2/c1-27(2)14-9-15-28(3)16-10-17-29(4)18-11-19-30(5)20-12-21-31(6)22-13-23-32(7)24-25-48-52(44,45)51-53(46,47)50-38-35(39-33(8)41)37(43)36(42)34(26-40)49-38/h14,16,18,20,22,24,27-32,34-38,40,42-43H,9-13,15,17,19,21,23,25-26H2,1-8H3,(H,39,41)(H,44,45)(H,46,47)/q-6/t28?,29?,30?,31?,32?,34-,35-,36-,37-,38-/m1/s1
DMY9F1M	CS	CC(C)[CH-]CCC(C)[CH-]CCC(C)[CH-]CCC(C)[CH-]CCC(C)[CH-]CCC(C)[CH-]COP(=O)(O)OP(=O)(O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C
DMY9F1M	IK	CREFDRPJYMJUQD-PVHPPTMHSA-N
DMY9F1M	IU	[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [3,7,11,15,19,23-hexamethyltetracosoxy(hydroxy)phosphoryl] hydrogen phosphate
DMY9F1M	DE	Pseudomonas infection

DMVN3FU	ID	DMVN3FU
DMVN3FU	DN	CA-074Me
DMVN3FU	HS	Preclinical
DMVN3FU	SN	147859-80-1; Cathepsin B Inhibitor IV; CA-074 methyl ester; CA-074 Me; Methyl N-({(2s,3s)-3-[(Propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-Isoleucyl-L-Prolinate; CA-074-Me; MFCD03452890; methyl N-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]carbonyl}-L-isoleucyl-L-prolinate; CA 074 methyl ester; CA 074Me; CA074Me; CA inhibitor 6; (S)-methyl 1-((2S,3S)-3-methyl-2-((2S,3S)-3-(propylcarbamoyl)oxirane-2-carboxamido)pentanoyl)pyrrolidine-2-carboxylate; PrNH-tES-Ile-Pro-OMe; epoxysuccinyl derivative 6; KBioGR_000234; KBioSS_000234; CHEMBL262103; SCHEMBL1974424; BDBM16503; KBio2_000234; KBio2_002802; KBio2_005370; KBio3_000467; KBio3_000468; DTXSID50881386; Bio2_000234; Bio2_000714; HMS1361L16; HMS3886D15; EX-A1196; ZINC4899858; s7420; CCG-268623; CS-6086; DB07223; CA-074 methyl ester (CA-074 Me); IDI1_033984; NCGC00163431-01; AC-32670; methyl (2S)-1-[(2S,3S)-3-methyl-2-[[(2S,3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylate; methyl (2S)-1-[(2S,3S)-3-methyl-2-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]formamido}pentanoyl]pyrrolidine-2-carboxylate; QC-10413; HY-100350; 859C801; Q27096448; (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester; CA074ME; N-(L-3-TRANS-PROPYLCARBAMOYLOXIRANE-2-CARBONYL)-L-ISOLEUCYL-L-PROLINE METHYL ESTER
DMVN3FU	DT	Small molecular drug
DMVN3FU	PC	6610318
DMVN3FU	MW	397.5
DMVN3FU	FM	C19H31N3O6
DMVN3FU	IC	InChI=1S/C19H31N3O6/c1-5-9-20-16(23)14-15(28-14)17(24)21-13(11(3)6-2)18(25)22-10-7-8-12(22)19(26)27-4/h11-15H,5-10H2,1-4H3,(H,20,23)(H,21,24)/t11-,12-,13-,14-,15-/m0/s1
DMVN3FU	CS	CCCNC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2CCC[C@H]2C(=O)OC
DMVN3FU	IK	XGWSRLSPWIEMLQ-YTFOTSKYSA-N
DMVN3FU	IU	methyl (2S)-1-[(2S,3S)-3-methyl-2-[[(2S,3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylate
DMVN3FU	CA	CAS 147859-80-1
DMVN3FU	DE	Cardiac arrest; Pulmonary fibrosis; Cystic fibrosis

DM9HG6S	ID	DM9HG6S
DM9HG6S	DN	CAR-T cells targeting CD117
DM9HG6S	HS	Preclinical
DM9HG6S	CP	Zhujiang Hospital
DM9HG6S	DT	CAR T Cell Therapy
DM9HG6S	DE	Acute myeloid leukaemia

DMSZNQE	ID	DMSZNQE
DMSZNQE	DN	CAR-T cells targeting CD123
DMSZNQE	HS	Preclinical
DMSZNQE	CP	Zhujiang Hospital
DMSZNQE	DT	CAR T Cell Therapy
DMSZNQE	DE	Acute myeloid leukaemia

DMYOR5T	ID	DMYOR5T
DMYOR5T	DN	CAR-T cells targeting CD133
DMYOR5T	HS	Preclinical
DMYOR5T	CP	Zhujiang Hospital
DMYOR5T	DT	CAR T Cell Therapy
DMYOR5T	DE	Acute myeloid leukaemia

DMH7BT9	ID	DMH7BT9
DMH7BT9	DN	CAR-T cells targeting CD33
DMH7BT9	HS	Preclinical
DMH7BT9	CP	Zhujiang Hospital
DMH7BT9	DT	CAR T Cell Therapy
DMH7BT9	DE	Acute myeloid leukaemia

DM3G0OP	ID	DM3G0OP
DM3G0OP	DN	CAR-T cells targeting CD34
DM3G0OP	HS	Preclinical
DM3G0OP	CP	Zhujiang Hospital
DM3G0OP	DT	CAR T Cell Therapy
DM3G0OP	DE	Acute myeloid leukaemia

DMA1BLC	ID	DMA1BLC
DMA1BLC	DN	CAR-T cells targeting Mucl
DMA1BLC	HS	Preclinical
DMA1BLC	CP	Zhujiang Hospital
DMA1BLC	DT	CAR T Cell Therapy
DMA1BLC	DE	Acute myeloid leukaemia

DMDUKMR	ID	DMDUKMR
DMDUKMR	DN	CAT4001
DMDUKMR	HS	Preclinical
DMDUKMR	CP	Catabasis
DMDUKMR	DT	Small molecular drug
DMDUKMR	DE	Alpha-1 antitrypsin deficiency; Friedreich's ataxia

DMKFAG3	ID	DMKFAG3
DMKFAG3	DN	CB-01-16
DMKFAG3	HS	Preclinical
DMKFAG3	SN	Opioid antagonist (MMX, opioid-induced constipation), Cosmo
DMKFAG3	CP	Cosmo Pharmaceuticals SpA
DMKFAG3	DE	Constipation

DM53JW0	ID	DM53JW0
DM53JW0	DN	CB1 antagonist, Bayer
DM53JW0	HS	Preclinical
DM53JW0	SN	2-[(2,6-dichloro-3-methylphenyl)amino]benzoate; CHEMBL876; CL-583.NA SALT; meclofenamic acid(1-); UPCMLD-DP012; AC1L1H9Q; UPCMLD-DP012:001; CTK5I4915; CHEBI:76230; BDBM50012896; MCULE-3600081195; CCG-204812; NCGC00023217-05; NCGC00023217-04; NCGC00023217-03; NCGC00023217-06; ZB000384; 2-(2,6-dichloro-3-methylanilino)benzoate; AB00053494; AB00053494_19; 2-(2,6-dichloro-3-methyl-phenylamino)-benzoate; 2-(2,6-dichloro-3-methyl-phenylamino)-benzoate(Fenamate series)
DM53JW0	CP	Bayer
DM53JW0	DT	Small molecular drug
DM53JW0	PC	4036
DM53JW0	MW	295.1
DM53JW0	FM	C14H10Cl2NO2-
DM53JW0	IC	InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)/p-1
DM53JW0	CS	CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl
DM53JW0	IK	SBDNJUWAMKYJOX-UHFFFAOYSA-M
DM53JW0	IU	2-(2,6-dichloro-3-methylanilino)benzoate
DM53JW0	CB	CHEBI:76230
DM53JW0	DE	Obesity

DMJUQ6E	ID	DMJUQ6E
DMJUQ6E	DN	CB7993113
DMJUQ6E	HS	Preclinical
DMJUQ6E	DT	Small molecular drug
DMJUQ6E	DE	Solid tumour/cancer

DMCFEUG	ID	DMCFEUG
DMCFEUG	DN	CCG-208408
DMCFEUG	HS	Preclinical
DMCFEUG	SN	Narirutin; Naringenin 7-rutinoside; Naringenin-7-O-rutinoside; (S)-7-[[6-O-(6-deoxy-a-L-mannopyranosyl)-ss-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; AK554011; CCG-208408; CHEMBL3185240; NCGC00163600-01
DMCFEUG	PC	85704
DMCFEUG	MW	580.5
DMCFEUG	FM	C27H32O14
DMCFEUG	IC	HXTFHSYLYXVTHC-UHFFFAOYSA-N
DMCFEUG	CS	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC=C(C=C5)O)O)O)O)O)O)O)O
DMCFEUG	IK	1S/C27H32O14/c1-10-20(31)22(33)24(35)26(38-10)37-9-18-21(32)23(34)25(36)27(41-18)39-13-6-14(29)19-15(30)8-16(40-17(19)7-13)11-2-4-12(28)5-3-11/h2-7,10,16,18,20-29,31-36H,8-9H2,1H3
DMCFEUG	IU	5-hydroxy-2-(4-hydroxyphenyl)-7-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
DMCFEUG	CA	CAS 14259-46-2
DMCFEUG	DE	Depression

DM065ZH	ID	DM065ZH
DM065ZH	DN	CCT-018159
DM065ZH	HS	Preclinical
DM065ZH	SN	CCT 018159; CCT018159; (6Z)-6-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1,2-dihydropyrazol-3-ylidene]-4-ethyl-3-hydroxycyclohexa-2,4-dien-1-one; 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol
DM065ZH	CP	Vernalis; Novartis
DM065ZH	TC	Anticancer Agents
DM065ZH	DT	Small molecular drug
DM065ZH	PC	984170
DM065ZH	MW	352.4
DM065ZH	FM	C20H20N2O4
DM065ZH	IC	InChI=1S/C20H20N2O4/c1-3-12-8-14(16(24)10-15(12)23)20-19(11(2)21-22-20)13-4-5-17-18(9-13)26-7-6-25-17/h4-5,8-10,23-24H,3,6-7H2,1-2H3,(H,21,22)
DM065ZH	CS	CCC1=CC(=C(C=C1O)O)C2=NNC(=C2C3=CC4=C(C=C3)OCCO4)C
DM065ZH	IK	OWPMENVYXDJDOW-UHFFFAOYSA-N
DM065ZH	IU	4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol
DM065ZH	CA	CAS 171009-07-7
DM065ZH	CB	CHEBI:41656
DM065ZH	DE	Solid tumour/cancer

DMNA9KW	ID	DMNA9KW
DMNA9KW	DN	CCT251545
DMNA9KW	HS	Preclinical
DMNA9KW	SN	1661839-45-7; 8-(3-chloro-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one; CHEMBL3408213; 8-[3-chloro-5-[4-(1-methylpyrazol-4-yl)phenyl]pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one; CCT-251545; 8-{3-Chloro-5-[4-(1-Methyl-1h-Pyrazol-4-Yl)phenyl]pyridin-4-Yl}-2,8-Diazaspiro[4.5]decan-1-One; GTPL8945; SCHEMBL17113515; CHEBI:143114; AMY16654; BCP17378; EX-A2539; BDBM50073190; NSC784591; s7981; ZINC212373586; CCT 251545; CS-5359; NSC-784591; AC-31717; HY-12681; DB-119021; CCT 251545;CCT-251545; CCT-251545;CCT 251545; Q27075796; 2,8-Diazaspiro[4.5]decan-1-one, 8-[3-chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-4-pyridinyl]-; 4TV; 8-[3-Chloro-5-[4-(1-methyl-1H-pyrazole-4-yl)phenyl]-4-pyridyl]-2,8-diazaspiro[4.5]decane-1-one
DMNA9KW	CP	Merck
DMNA9KW	DT	Small molecular drug
DMNA9KW	PC	77050682
DMNA9KW	MW	421.9
DMNA9KW	FM	C23H24ClN5O
DMNA9KW	IC	InChI=1S/C23H24ClN5O/c1-28-15-18(12-27-28)16-2-4-17(5-3-16)19-13-25-14-20(24)21(19)29-10-7-23(8-11-29)6-9-26-22(23)30/h2-5,12-15H,6-11H2,1H3,(H,26,30)
DMNA9KW	CS	CN1C=C(C=N1)C2=CC=C(C=C2)C3=CN=CC(=C3N4CCC5(CCNC5=O)CC4)Cl
DMNA9KW	IK	LBFYQISQYCGDDW-UHFFFAOYSA-N
DMNA9KW	IU	8-[3-chloro-5-[4-(1-methylpyrazol-4-yl)phenyl]pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one
DMNA9KW	CB	CHEBI:143114
DMNA9KW	DE	Colorectal cancer

DMWQIJX	ID	DMWQIJX
DMWQIJX	DN	Celastrol
DMWQIJX	HS	Preclinical
DMWQIJX	SN	Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid
DMWQIJX	CP	Schering-Plough
DMWQIJX	DT	Small molecular drug
DMWQIJX	PC	122724
DMWQIJX	MW	450.6
DMWQIJX	FM	C29H38O4
DMWQIJX	IC	InChI=1S/C29H38O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h7-8,15,22,31H,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26-,27+,28-,29+/m1/s1
DMWQIJX	CS	CC1=C(C(=O)C=C2C1=CC=C3[C@]2(CC[C@@]4([C@@]3(CC[C@@]5([C@H]4C[C@](CC5)(C)C(=O)O)C)C)C)C)O
DMWQIJX	IK	KQJSQWZMSAGSHN-JJWQIEBTSA-N
DMWQIJX	IU	(2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
DMWQIJX	CA	CAS 34157-83-0
DMWQIJX	CB	CHEBI:63959
DMWQIJX	DE	Motor neurone disease

DM1ZFCS	ID	DM1ZFCS
DM1ZFCS	DN	Cephaeline
DM1ZFCS	HS	Preclinical
DM1ZFCS	SN	Cephaeline; Cephaelin; 483-17-0; 7',10,11-Trimethoxyemetan-6'-ol; UNII-QA971541A1; Desmethylemetine; QA971541A1; Dihydropsychotrine; Cepheline; GNF-Pf-307; (1R)-1-[[(2S,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol; NSC32944; Cephaelinel; (-)-Cephaeline; EINECS 207-591-6; Prestwick2_000428; Prestwick3_000428; Prestwick1_000428; Prestwick0_000428; AC1L9CF2; BSPBio_000416; SCHEMBL181711; SPBio_002355; CHEMBL255708
DM1ZFCS	PC	442195
DM1ZFCS	MW	466.6
DM1ZFCS	FM	C28H38N2O4
DM1ZFCS	IC	InChI=1S/C28H38N2O4/c1-5-17-16-30-9-7-19-13-27(33-3)28(34-4)15-22(19)24(30)11-20(17)10-23-21-14-26(32-2)25(31)12-18(21)6-8-29-23/h12-15,17,20,23-24,29,31H,5-11,16H2,1-4H3/t17-,20-,23+,24-/m0/s1
DM1ZFCS	CS	CCC1CN2CCC3=CC(=C(C=C3C2CC1CC4C5=CC(=C(C=C5CCN4)O)OC)OC)OC
DM1ZFCS	IK	DTGZHCFJNDAHEN-OZEXIGSWSA-N
DM1ZFCS	IU	(1R)-1-[[(2S,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol
DM1ZFCS	CA	CAS 483-17-0
DM1ZFCS	CB	CHEBI:3533
DM1ZFCS	DE	Accidental poisoning

DMQSJ20	ID	DMQSJ20
DMQSJ20	DN	CF502
DMQSJ20	HS	Preclinical
DMQSJ20	SN	CHEMBL175543; MRS-3558; CF502; GTPL5601; MRS3558; MRS-5358; MRS 3558; BDBM50163020; (1S,2R,3S,4R,5S)-4-[2-Chloro-6-(3-chloro-benzylamino)-purin-9-yl]-2,3-dihydroxy-bicyclo[3.1.0]hexane-1-carboxylic acid methylamide; (1S,2R,3S,4R,5S)-4-(6-(3-chlorobenzylamino)-2-chloro-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide; 1N-methyl-4-[2-chloro-6-(3-chlorobenzylamino)-9H-9-purinyl]-2,3-dihydroxy-(1S,2R,3S,4R,5S)-bicyclo[3.1.0]hexane-1-carboxamide
DMQSJ20	CP	Can-Fite BioPharm
DMQSJ20	DT	Small molecular drug
DMQSJ20	PC	11248240
DMQSJ20	MW	463.3
DMQSJ20	FM	C20H20Cl2N6O3
DMQSJ20	IC	InChI=1S/C20H20Cl2N6O3/c1-23-18(31)20-6-11(20)13(14(29)15(20)30)28-8-25-12-16(26-19(22)27-17(12)28)24-7-9-3-2-4-10(21)5-9/h2-5,8,11,13-15,29-30H,6-7H2,1H3,(H,23,31)(H,24,26,27)/t11-,13-,14+,15+,20+/m1/s1
DMQSJ20	CS	CNC(=O)[C@@]12C[C@@H]1[C@H]([C@@H]([C@@H]2O)O)N3C=NC4=C(N=C(N=C43)Cl)NCC5=CC(=CC=C5)Cl
DMQSJ20	IK	GAYWHRPOIWFKIF-DDDALXFXSA-N
DMQSJ20	IU	(1S,2R,3S,4R,5S)-4-[2-chloro-6-[(3-chlorophenyl)methylamino]purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide
DMQSJ20	DE	Inflammation

DM0ULO2	ID	DM0ULO2
DM0ULO2	DN	CF602
DM0ULO2	HS	Preclinical
DM0ULO2	SN	UNII-QXA2220N3T; CF-602; 1116652-18-6; QXA2220N3T; SCHEMBL196780; CHEMBL472925; GTPL9447; DTXSID60149702; Cyclohexanecarboxamide, N-(2-((3,4-dichlorophenyl)amino)-4-quinolinyl)-; SB17193
DM0ULO2	CP	Can-Fite BioPharm
DM0ULO2	DT	Small molecular drug
DM0ULO2	PC	25191023
DM0ULO2	MW	414.3
DM0ULO2	FM	C22H21Cl2N3O
DM0ULO2	IC	InChI=1S/C22H21Cl2N3O/c23-17-11-10-15(12-18(17)24)25-21-13-20(16-8-4-5-9-19(16)26-21)27-22(28)14-6-2-1-3-7-14/h4-5,8-14H,1-3,6-7H2,(H2,25,26,27,28)
DM0ULO2	CS	C1CCC(CC1)C(=O)NC2=CC(=NC3=CC=CC=C32)NC4=CC(=C(C=C4)Cl)Cl
DM0ULO2	IK	UWEIQVQNNLVOEI-UHFFFAOYSA-N
DM0ULO2	IU	N-[2-(3,4-dichloroanilino)quinolin-4-yl]cyclohexanecarboxamide
DM0ULO2	CA	CAS 1116652-18-6
DM0ULO2	DE	Inflammation

DMYGITU	ID	DMYGITU
DMYGITU	DN	CHDI-340246
DMYGITU	HS	Preclinical
DMYGITU	DT	Small molecular drug
DMYGITU	DE	Huntington disease

DM89DQP	ID	DM89DQP
DM89DQP	DN	Chlamydocin
DM89DQP	HS	Preclinical
DM89DQP	SN	HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone
DM89DQP	TC	Anticancer Agents
DM89DQP	DT	Small molecular drug
DM89DQP	PC	124134
DM89DQP	MW	526.6
DM89DQP	FM	C28H38N4O6
DM89DQP	IC	InChI=1S/C28H38N4O6/c1-28(2)27(37)30-20(16-18-10-5-3-6-11-18)26(36)32-15-9-13-21(32)25(35)29-19(24(34)31-28)12-7-4-8-14-22(33)23-17-38-23/h3,5-6,10-11,19-21,23H,4,7-9,12-17H2,1-2H3,(H,29,35)(H,30,37)(H,31,34)/t19-,20-,21+,23-/m0/s1
DM89DQP	CS	CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCC(=O)[C@@H]3CO3)CC4=CC=CC=C4)C
DM89DQP	IK	SGYJGGKDGBXCNY-QXUYBEEESA-N
DM89DQP	IU	(3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM89DQP	CA	CAS 53342-16-8
DM89DQP	DE	Solid tumour/cancer

DMAPO0T	ID	DMAPO0T
DMAPO0T	DN	Ciglitazone
DMAPO0T	HS	Preclinical
DMAPO0T	SN	ciglitazone; 74772-77-3; Ciglitizone; ADD-3878; Ciglitazonum; Ciglitazona; Ciglitazonum [Latin]; Ciglitazona [Spanish]; Ciglitazone [USAN:INN]; ADD 3878; CHEBI:64227; U-63287; (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione; C18H23NO3S; 5-(4-((1-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione; YZFWTZACSRHJQD-UHFFFAOYSA-N; (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione; U 63287; 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione; NCGC00164446-01
DMAPO0T	DT	Small molecular drug
DMAPO0T	PC	2750
DMAPO0T	MW	333.4
DMAPO0T	FM	C18H23NO3S
DMAPO0T	IC	InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21)
DMAPO0T	CS	CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMAPO0T	IK	YZFWTZACSRHJQD-UHFFFAOYSA-N
DMAPO0T	IU	5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMAPO0T	CA	CAS 74772-77-3
DMAPO0T	CB	CHEBI:64227
DMAPO0T	DE	Pulmonary fibrosis

DM37NYK	ID	DM37NYK
DM37NYK	DN	Citrate
DM37NYK	HS	Preclinical
DM37NYK	PC	311
DM37NYK	MW	192.123
DM37NYK	FM	C6H8O7
DM37NYK	IC	InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DM37NYK	CS	C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DM37NYK	IK	KRKNYBCHXYNGOX-UHFFFAOYSA-N
DM37NYK	IU	2-hydroxypropane-1,2,3-tricarboxylic acid
DM37NYK	CA	CAS 77-92-9
DM37NYK	CB	CHEBI:30769
DM37NYK	DE	Acute kidney injury

DMV0RFU	ID	DMV0RFU
DMV0RFU	DN	CKI-7
DMV0RFU	HS	Preclinical
DMV0RFU	SN	120615-25-0; N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide; CKI 7; N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulphonamide; CKI-7 (free base); UNII-3IE84W82O5; CHEBI:47322; 3IE84W82O5; 8-Isoquinolinesulfonamide,N-(2-aminoethyl)-5-chloro-; 8-Isoquinolinesulfonamide, N-(2-aminoethyl)-5-chloro-; 2csn; CKI; ACMC-20efrf; CHEMBL489157; Isoquinolinesulfonamide, CKI-7; SCHEMBL3491587; BDBM92674; DTXSID20152934; ZINC6415144; MFCD00269886; AKOS027446743; DB03693; NCGC00165762-01; DB-082055; HY-133028; B4936; CS-0109499; FT-0661792; Y7241; W-205095; N-(2-aminoethyl)-5-chloro-isoquinoline-8-sulfonamide; Q27094604; 5-Chloro-isoquinoline-8-sulfonic acid, (2-amino-ethyl)-amide
DMV0RFU	DT	Small molecular drug
DMV0RFU	PC	129236
DMV0RFU	MW	285.75
DMV0RFU	FM	C11H12ClN3O2S
DMV0RFU	IC	InChI=1S/C11H12ClN3O2S/c12-10-1-2-11(18(16,17)15-6-4-13)9-7-14-5-3-8(9)10/h1-3,5,7,15H,4,6,13H2
DMV0RFU	CS	C1=CC(=C2C=CN=CC2=C1S(=O)(=O)NCCN)Cl
DMV0RFU	IK	OGKYMFFYOWUTKV-UHFFFAOYSA-N
DMV0RFU	IU	N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide
DMV0RFU	CA	CAS 120615-25-0
DMV0RFU	CB	CHEBI:47322
DMV0RFU	DE	Mood disorder

DM6HADZ	ID	DM6HADZ
DM6HADZ	DN	CL-314698
DM6HADZ	HS	Preclinical
DM6HADZ	CP	Cyanamid
DM6HADZ	DE	Type-2 diabetes; Obesity

DM0BHL8	ID	DM0BHL8
DM0BHL8	DN	CLIK-148
DM0BHL8	HS	Preclinical
DM0BHL8	SN	SCHEMBL7207304
DM0BHL8	DT	Small molecular drug
DM0BHL8	PC	9801663
DM0BHL8	MW	410.5
DM0BHL8	FM	C22H26N4O4
DM0BHL8	IC	InChI=1S/C22H26N4O4/c1-26(2)22(29)17(14-15-8-4-3-5-9-15)25-21(28)19-18(30-19)20(27)24-13-11-16-10-6-7-12-23-16/h3-10,12,17-19H,11,13-14H2,1-2H3,(H,24,27)(H,25,28)/t17-,18-,19-/m0/s1
DM0BHL8	CS	CN(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2[C@H](O2)C(=O)NCCC3=CC=CC=N3
DM0BHL8	IK	SXMRSAGDCJGMTG-FHWLQOOXSA-N
DM0BHL8	IU	(2S,3S)-2-N-[(2S)-1-(dimethylamino)-1-oxo-3-phenylpropan-2-yl]-3-N-(2-pyridin-2-ylethyl)oxirane-2,3-dicarboxamide
DM0BHL8	DE	Rheumatoid arthritis

DMXKN6R	ID	DMXKN6R
DMXKN6R	DN	CLIK-181
DMXKN6R	HS	Preclinical
DMXKN6R	SN	J3.633.044I
DMXKN6R	DT	Small molecular drug
DMXKN6R	PC	132504749
DMXKN6R	MW	466.5
DMXKN6R	FM	C25H30N4O5
DMXKN6R	IC	InChI=1S/C25H30N4O5/c1-16(30)27-19-11-9-17(10-12-19)13-14-26-23(31)21-22(34-21)24(32)28-20(25(33)29(2)3)15-18-7-5-4-6-8-18/h4-12,20-22H,13-15H2,1-3H3,(H,26,31)(H,27,30)(H,28,32)/t20-,21-,22+/m0/s1
DMXKN6R	CS	CC(=O)NC1=CC=C(C=C1)CCNC(=O)[C@@H]2[C@@H](O2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N(C)C
DMXKN6R	IK	BULLLJQHDGSHOZ-FDFHNCONSA-N
DMXKN6R	IU	(2R,3S)-3-N-[2-(4-acetamidophenyl)ethyl]-2-N-[(2S)-1-(dimethylamino)-1-oxo-3-phenylpropan-2-yl]oxirane-2,3-dicarboxamide
DMXKN6R	DE	Rheumatoid arthritis

DMP9EJ7	ID	DMP9EJ7
DMP9EJ7	DN	CM-2236
DMP9EJ7	HS	Preclinical
DMP9EJ7	SN	Psychomodulator (post-traumatic stress disorder), Cenomed BioSciences
DMP9EJ7	CP	Cenomed BioSciences LLC
DMP9EJ7	DE	Post-traumatic stress disorder

DMHAI0M	ID	DMHAI0M
DMHAI0M	DN	CNSB-004
DMHAI0M	HS	Preclinical
DMHAI0M	SN	Drug combination (intractable severe pain), CNSbio
DMHAI0M	CP	Relevare Pharmaceuticals Ltd
DMHAI0M	DE	Pain

DM1H8D6	ID	DM1H8D6
DM1H8D6	DN	CNX-011-67
DM1H8D6	HS	Preclinical
DM1H8D6	DT	Small molecular drug
DM1H8D6	DE	Type 2 diabetes

DMG3BE1	ID	DMG3BE1
DMG3BE1	DN	Coelenterazine
DMG3BE1	HS	Preclinical
DMG3BE1	SN	coelenterazine; Coelenteramine; Oplophorus luciferin; UNII-3O1CB88RRD; CLZN; 8-benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one; coelenterate luciferin; Coelenterazine, native; 3O1CB88RRD; MFCD00467176; C-7001; C-7002; 8-benzyl-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]-7H-imidazo[1,2-a]pyrazin-3-one; 8-Benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo-[1,2a]pyrazin-3(7H)-one; 2-(p-Hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazin-3-(7H)-one
DMG3BE1	PC	135445694
DMG3BE1	MW	423.472
DMG3BE1	FM	C26H21N3O3
DMG3BE1	IC	InChI=1S/C26H21N3O3/c30-20-10-6-18(7-11-20)15-23-26(32)29-16-24(19-8-12-21(31)13-9-19)27-22(25(29)28-23)14-17-4-2-1-3-5-17/h1-13,16,30-32H,14-15H2
DMG3BE1	CS	C1=CC=C(C=C1)CC2=NC(=CN3C2=NC(=C3O)CC4=CC=C(C=C4)O)C5=CC=C(C=C5)O
DMG3BE1	IK	LNCOEGVEEQDKGX-UHFFFAOYSA-N
DMG3BE1	IU	8-benzyl-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]imidazo[1,2-a]pyrazin-3-ol
DMG3BE1	CA	CAS 55779-48-1
DMG3BE1	CB	CHEBI:2311
DMG3BE1	DE	Inflammatory bowel disease

DMN0GTR	ID	DMN0GTR
DMN0GTR	DN	COR100140
DMN0GTR	HS	Preclinical
DMN0GTR	CP	Cortical
DMN0GTR	DT	Small molecular drug
DMN0GTR	PC	9853902
DMN0GTR	DE	Inflammation

DMLXMCB	ID	DMLXMCB
DMLXMCB	DN	COR-D
DMLXMCB	HS	Preclinical
DMLXMCB	DT	Small molecular drug
DMLXMCB	DE	T-cell leukaemia

DMATUKO	ID	DMATUKO
DMATUKO	DN	CP-114271
DMATUKO	HS	Preclinical
DMATUKO	CP	Pfizer
DMATUKO	PC	9953045
DMATUKO	MW	404.4
DMATUKO	FM	C17H19F3N2O4S
DMATUKO	IC	InChI=1S/C17H19F3N2O4S/c1-10(6-11-2-4-12(5-3-11)26-8-15(24)25)21-7-14(23)13-9-27-16(22-13)17(18,19)20/h2-5,9-10,14,21,23H,6-8H2,1H3,(H,24,25)/t10-,14+/m1/s1
DMATUKO	CS	C[C@H](CC1=CC=C(C=C1)OCC(=O)O)NC[C@@H](C2=CSC(=N2)C(F)(F)F)O
DMATUKO	IK	YVIXXPCJZAUQHJ-YGRLFVJLSA-N
DMATUKO	IU	2-[4-[(2R)-2-[[(2S)-2-hydroxy-2-[2-(trifluoromethyl)-1,3-thiazol-4-yl]ethyl]amino]propyl]phenoxy]acetic acid
DMATUKO	CA	CAS 162326-86-5
DMATUKO	DE	Obesity

DMQGRC8	ID	DMQGRC8
DMQGRC8	DN	CPH-102
DMQGRC8	HS	Preclinical
DMQGRC8	SN	IABP; INH2BP, Crimson Pharmaceutical; INH2BP, Octamer; PARP inhibitors, Crimson Pharmaceutical; PARP inhibitors, Octamer; CPH-101, Crimson Pharma
DMQGRC8	CP	Octamer Inc
DMQGRC8	DE	Solid tumour/cancer

DMWMBIV	ID	DMWMBIV
DMWMBIV	DN	CRA1000
DMWMBIV	HS	Preclinical
DMWMBIV	SN	CRA-1000; CRA1000; UNII-3899V9A17F; 3899V9A17F; CRA 1000; 226948-11-4; 2-Pyrimidinamine, N-ethyl-4-(4-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-6-methyl-N-(4-(1-methylethyl)-2-(methylthio)phenyl)-; 2-(N-(2-methylthio-4-isopropylphenyl)-N-ethylamino)-4-(4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridin-1-yl)-6-methylpyrimidine; CHEMBL297986; SCHEMBL6171730; GTPL3498; PDSP2_001710; PDSP1_001727
DMWMBIV	DT	Small molecular drug
DMWMBIV	PC	9849313
DMWMBIV	MW	476.7
DMWMBIV	FM	C28H33FN4S
DMWMBIV	IC	InChI=1S/C28H33FN4S/c1-6-33(25-11-10-22(19(2)3)18-26(25)34-5)28-30-20(4)16-27(31-28)32-14-12-21(13-15-32)23-8-7-9-24(29)17-23/h7-12,16-19H,6,13-15H2,1-5H3
DMWMBIV	CS	CCN(C1=C(C=C(C=C1)C(C)C)SC)C2=NC(=CC(=N2)N3CCC(=CC3)C4=CC(=CC=C4)F)C
DMWMBIV	IK	DDSMCPASYQDKFS-UHFFFAOYSA-N
DMWMBIV	IU	N-ethyl-4-[4-(3-fluorophenyl)-3,6-dihydro-2H-pyridin-1-yl]-6-methyl-N-(2-methylsulfanyl-4-propan-2-ylphenyl)pyrimidin-2-amine
DMWMBIV	CA	CAS 226948-11-4
DMWMBIV	DE	Anxiety disorder

DM8AR0E	ID	DM8AR0E
DM8AR0E	DN	Cruentaren
DM8AR0E	HS	Preclinical
DM8AR0E	TC	Antifungal Agents
DM8AR0E	DE	Fungal infection

DMB4FWX	ID	DMB4FWX
DMB4FWX	DN	CS-00028
DMB4FWX	HS	Preclinical
DMB4FWX	SN	CS-028; HDAC antagonist (cancer), Shenzhen Chipscreen Biosciences
DMB4FWX	CP	Shenzhen Chipscreen Biosciences Ltd
DMB4FWX	DE	Solid tumour/cancer

DMK230A	ID	DMK230A
DMK230A	DN	CS-3030
DMK230A	HS	Preclinical
DMK230A	SN	R-142086; Factor Xa inhibitor (DVT/ pulmonary embolism), Daiichi Sankyo; Factor Xa inhibitor (DVT/ pulmonary embolism), Sankyo; Factor Xa inhibitor (deep vein thrombosis/ pulmonary embolism), Daiichi Sankyo; Factor Xa inhibitor (deep vein thrombosis/ pulmonary embolism), Sankyo
DMK230A	CP	Daiichi-Sankyo
DMK230A	DE	Thrombosis

DMKVW25	ID	DMKVW25
DMKVW25	DN	Cu-anti-hAXL
DMKVW25	HS	Preclinical
DMKVW25	DT	Antibody
DMKVW25	DE	Breast cancer

DMB1ET0	ID	DMB1ET0
DMB1ET0	DN	Cutamesine
DMB1ET0	HS	Preclinical
DMB1ET0	SN	AGY-94806; Msc-1; SA-4502; SA-4503; Sigma opioid receptor agonist, Santen
DMB1ET0	CP	Santen Pharmaceutical Co Ltd
DMB1ET0	DT	Small molecular drug
DMB1ET0	PC	9907323
DMB1ET0	MW	368.5
DMB1ET0	FM	C23H32N2O2
DMB1ET0	IC	InChI=1S/C23H32N2O2/c1-26-22-11-10-21(19-23(22)27-2)12-14-25-17-15-24(16-18-25)13-6-9-20-7-4-3-5-8-20/h3-5,7-8,10-11,19H,6,9,12-18H2,1-2H3
DMB1ET0	CS	COC1=C(C=C(C=C1)CCN2CCN(CC2)CCCC3=CC=CC=C3)OC
DMB1ET0	IK	UVSWWUWQVAQPJR-UHFFFAOYSA-N
DMB1ET0	IU	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine
DMB1ET0	CA	CAS 165377-43-5
DMB1ET0	DE	Major depressive disorder

DM8YUJT	ID	DM8YUJT
DM8YUJT	DN	CWHM-12
DM8YUJT	HS	Preclinical
DM8YUJT	SN	cwhm-12; CWHM12; 1564286-55-0; (3S)-3-(3-bromo-5-(tert-butyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid; CHEMBL3319237; CWHM 12; SCHEMBL15475283; GTPL10495; AOB2397; EX-A850; (3S)-3-(3-bromo-5-tert-butylphenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid; BDBM50497716; MFCD28385850; AKOS027423695; CS-3537; NCGC00390566-03; AS-16717; HY-18644; J-690209; (3S)-3-(3-bromo-5-tert-butylphenyl)-3-(2-(3-hydroxy-5-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-ylamino)benzamido)acetamido)propanoic acid
DM8YUJT	DT	Small molecular drug
DM8YUJT	PC	72949858
DM8YUJT	MW	590.5
DM8YUJT	FM	C26H32BrN5O6
DM8YUJT	IC	InChI=1S/C26H32BrN5O6/c1-26(2,3)16-4-14(5-17(27)8-16)21(10-23(36)37)32-22(35)13-28-24(38)15-6-18(9-19(33)7-15)31-25-29-11-20(34)12-30-25/h4-9,20-21,33-34H,10-13H2,1-3H3,(H,28,38)(H,32,35)(H,36,37)(H2,29,30,31)/t21-/m0/s1
DM8YUJT	CS	CC(C)(C)C1=CC(=CC(=C1)[C@H](CC(=O)O)NC(=O)CNC(=O)C2=CC(=CC(=C2)O)NC3=NCC(CN3)O)Br
DM8YUJT	IK	YDHAGPCZRFQPOI-NRFANRHFSA-N
DM8YUJT	IU	(3S)-3-(3-bromo-5-tert-butylphenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid
DM8YUJT	DE	Hepatic fibrosis; Pulmonary fibrosis

DMKZCBE	ID	DMKZCBE
DMKZCBE	DN	CX-1501
DMKZCBE	HS	Preclinical
DMKZCBE	SN	AMPA receptor modulators (ADHD, AD, sleep disorders), Cortex Pharmaceuticals
DMKZCBE	CP	Cortex Pharmaceuticals Inc
DMKZCBE	DE	Alzheimer disease

DMA1MK5	ID	DMA1MK5
DMA1MK5	DN	CYC-800
DMA1MK5	HS	Preclinical
DMA1MK5	CP	Cyclacel
DMA1MK5	TC	Anticancer Agents
DMA1MK5	DT	Small molecular drug
DMA1MK5	PC	24759764
DMA1MK5	MW	424.4
DMA1MK5	FM	C21H25FO8
DMA1MK5	IC	InChI=1S/C15H13FO2.C6H12O6/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11;7-1-2(8)4(10)6(12)5(11)3(1)9/h2-10H,1H3,(H,17,18);1-12H/t10-;/m1./s1
DMA1MK5	CS	C[C@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O.C1(C(C(C(C(C1O)O)O)O)O)O
DMA1MK5	IK	XXWQLQXGYRVJNJ-HNCPQSOCSA-N
DMA1MK5	IU	cyclohexane-1,2,3,4,5,6-hexol;(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
DMA1MK5	DE	Solid tumour/cancer

DMV8APG	ID	DMV8APG
DMV8APG	DN	Cytolin
DMV8APG	HS	Preclinical
DMV8APG	CP	CytoDyn
DMV8APG	DT	Antibody
DMV8APG	DE	Human immunodeficiency virus infection

DMHD3R8	ID	DMHD3R8
DMHD3R8	DN	D-4476
DMHD3R8	HS	Preclinical
DMHD3R8	SN	CK1 inhibitor; D 4476
DMHD3R8	DT	Small molecular drug
DMHD3R8	PC	6419753
DMHD3R8	MW	398.4
DMHD3R8	FM	C23H18N4O3
DMHD3R8	IC	InChI=1S/C23H18N4O3/c24-22(28)14-4-6-15(7-5-14)23-26-20(21(27-23)17-3-1-2-10-25-17)16-8-9-18-19(13-16)30-12-11-29-18/h1-10,13H,11-12H2,(H2,24,28)(H,26,27)
DMHD3R8	CS	C1COC2=C(O1)C=CC(=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5
DMHD3R8	IK	DPDZHVCKYBCJHW-UHFFFAOYSA-N
DMHD3R8	IU	4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide
DMHD3R8	CA	CAS 301836-43-1
DMHD3R8	CB	CHEBI:91448
DMHD3R8	DE	Chronic lymphocytic leukaemia

DMUWRIF	ID	DMUWRIF
DMUWRIF	DN	DAP-81
DMUWRIF	HS	Preclinical
DMUWRIF	CP	RottaPharma
DMUWRIF	TC	Anticancer Agents
DMUWRIF	PC	9548005
DMUWRIF	MW	468.5
DMUWRIF	FM	C25H20N6O4
DMUWRIF	IC	InChI=1S/C25H20N6O4/c1-16(32)27-18-11-13-19(14-12-18)28-25-26-15-22(31(34)35)24(30-25)29-21-10-6-5-9-20(21)23(33)17-7-3-2-4-8-17/h2-15H,1H3,(H,27,32)(H2,26,28,29,30)
DMUWRIF	CS	CC(=O)NC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC=CC=C3C(=O)C4=CC=CC=C4)[N+](=O)[O-]
DMUWRIF	IK	LOMJSEHTDFISSP-UHFFFAOYSA-N
DMUWRIF	IU	N-[4-[[4-(2-benzoylanilino)-5-nitropyrimidin-2-yl]amino]phenyl]acetamide
DMUWRIF	DE	Solid tumour/cancer

DM8WTAZ	ID	DM8WTAZ
DM8WTAZ	DN	Debio1453
DM8WTAZ	HS	Preclinical
DM8WTAZ	CP	Debiopharm
DM8WTAZ	DT	Small molecular drug
DM8WTAZ	DE	Neisseria gonorrhoeae infection

DMAUILH	ID	DMAUILH
DMAUILH	DN	DecRVKRCMK
DMAUILH	HS	Preclinical
DMAUILH	DT	Small molecular drug
DMAUILH	DE	Coronavirus infection

DMJKQFT	ID	DMJKQFT
DMJKQFT	DN	Dec-RVKR-CMK
DMJKQFT	HS	Preclinical
DMJKQFT	SN	AKOS024457645; DECANOYL-ARG-VAL-LYS-ARG-CHLOROMETHYLKETONE; Decanoyl-Arg-Val-Lys-Arg-chloromethylketone trifluoroacetate salt; ZINC98052548; decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone
DMJKQFT	TC	Antiviral Agents
DMJKQFT	DT	Protein/peptide drug
DMJKQFT	PC	9962075
DMJKQFT	MW	744.4
DMJKQFT	FM	C34H66ClN11O5
DMJKQFT	IC	InChI=1S/C34H66ClN11O5/c1-4-5-6-7-8-9-10-18-28(48)43-25(17-14-21-42-34(39)40)31(50)46-29(23(2)3)32(51)45-26(15-11-12-19-36)30(49)44-24(27(47)22-35)16-13-20-41-33(37)38/h23-26,29H,4-22,36H2,1-3H3,(H,43,48)(H,44,49)(H,45,51)(H,46,50)(H4,37,38,41)(H4,39,40,42)/t24-,25-,26-,29-/m0/s1
DMJKQFT	CS	CCCCCCCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl
DMJKQFT	IK	NHBJTTGFHCHQHS-VZTVMPNDSA-N
DMJKQFT	IU	N-[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(3S)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]decanamide
DMJKQFT	DE	Middle East Respiratory Syndrome (MERS)

DMD0T1U	ID	DMD0T1U
DMD0T1U	DN	Depudecin
DMD0T1U	HS	Preclinical
DMD0T1U	SN	(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9
DMD0T1U	DT	Small molecular drug
DMD0T1U	PC	16219259
DMD0T1U	MW	212.24
DMD0T1U	FM	C11H16O4
DMD0T1U	IC	InChI=1S/C11H16O4/c1-3-7(13)11-9(15-11)5-4-8-10(14-8)6(2)12/h3-13H,1H2,2H3/b5-4+/t6-,7-,8+,9+,10+,11+/m1/s1
DMD0T1U	CS	C[C@H]([C@H]1[C@@H](O1)/C=C/[C@H]2[C@@H](O2)[C@@H](C=C)O)O
DMD0T1U	IK	DLVJMFOLJOOWFS-INMLLLKOSA-N
DMD0T1U	IU	(1R)-1-[(2S,3S)-3-[(E)-2-[(2S,3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol
DMD0T1U	CA	CAS 139508-73-9
DMD0T1U	CB	CHEBI:64143
DMD0T1U	DE	Solid tumour/cancer

DM2I76R	ID	DM2I76R
DM2I76R	DN	Desmethylsertraline
DM2I76R	HS	Preclinical
DM2I76R	SN	Desmethylsertraline; Norsertraline; (1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine; UNII-CJJ71O9BE8; CJJ71O9BE8; CHEMBL40733; (1S,4S)-4-(3,4-Dichloro-phenyl)-1,2,3,4-tetrahydronaphthalen-1-amine; CHEMBL1743864; N-Demethylsertraline; N-Desmethylsertraline; Demethylsertraline; CP 62508; CP-53261; AC1L3FVW; AC1Q3O5M; SCHEMBL145234; NAP005; CTK8E0157; DTXSID60236666; SRPXSILJHWNFMK-ZBEGNZNMSA-N; ZINC6117444; PDSP2_001789; BDBM50367182; MFCD00871799; BDBM50028066; AKOS027382323
DM2I76R	PC	114743
DM2I76R	MW	292.2
DM2I76R	FM	C16H15Cl2N
DM2I76R	IC	InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16-/m0/s1
DM2I76R	CS	C1CC(C2=CC=CC=C2C1C3=CC(=C(C=C3)Cl)Cl)N
DM2I76R	IK	SRPXSILJHWNFMK-ZBEGNZNMSA-N
DM2I76R	IU	(1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
DM2I76R	CA	CAS 87857-41-8
DM2I76R	DE	Major depressive disorder

DM5H2W9	ID	DM5H2W9
DM5H2W9	DN	Dioscin
DM5H2W9	HS	Preclinical
DM5H2W9	SN	Dioscin; 19057-60-4; Collettiside III; Dioscine; CHEBI:74023; CCRIS 4123; UNII-3B95U4OLWV; 3-O-(Rhaalpha1-4(Rhaalpha1-2)Glcbeta)-(25R)-spirost-5-en-3beta-ol; 3-O-[alpha-L-Rha-(1-&gt;4)-[alpha-L-Rha-(1-&gt;2)]-beta-D-Glc]-diosgenin; 3-O-[alpha-L-Rhap-(1-&gt;4)-[alpha-L-Rhap-(1-&gt;2)]-beta-D-Glcp]-diosgenin; (25R)-spirost-5-en-3beta-yl alpha-L-rhamnopyranosyl-(1-&gt;2)-[alpha-L-mannopyranosyl-(1-&gt;4)]-beta-D-glucopyranoside; 3B95U4OLWV; AC1L3OGN; Dioscin(Collettiside III); Dioscin (Collettiside III); GTPL840
DM5H2W9	DT	Small molecular drug
DM5H2W9	PC	119245
DM5H2W9	MW	869
DM5H2W9	FM	C45H72O16
DM5H2W9	IC	InChI=1S/C45H72O16/c1-19-9-14-45(54-18-19)20(2)30-28(61-45)16-27-25-8-7-23-15-24(10-12-43(23,5)26(25)11-13-44(27,30)6)57-42-39(60-41-36(52)34(50)32(48)22(4)56-41)37(53)38(29(17-46)58-42)59-40-35(51)33(49)31(47)21(3)55-40/h7,19-22,24-42,46-53H,8-18H2,1-6H3/t19-,20+,21+,22+,24+,25-,26+,27+,28+,29-,30+,31+,32+,33-,34-,35-,36-,37+,38-,39-,40+,41+,42-,43+,44+,45-/m1/s1
DM5H2W9	CS	C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)OC1
DM5H2W9	IK	VNONINPVFQTJOC-ZGXDEBHDSA-N
DM5H2W9	IU	(2S,3R,4R,5R,6S)-2-[(2R,3S,4S,5R,6R)-4-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
DM5H2W9	CA	CAS 19057-60-4
DM5H2W9	CB	CHEBI:74023
DM5H2W9	DE	Hepatic fibrosis

DMA2K7C	ID	DMA2K7C
DMA2K7C	DN	Donitriptan
DMA2K7C	HS	Preclinical
DMA2K7C	SN	Donitriptan mesylate; F-11356; F-12640; Migraine therapy, Pierre Fabre; 5-HT1D agonist, Pierre Fabre
DMA2K7C	CP	Pierre Fabre SA
DMA2K7C	DT	Small molecular drug
DMA2K7C	PC	197706
DMA2K7C	MW	403.5
DMA2K7C	FM	C23H25N5O2
DMA2K7C	IC	InChI=1S/C23H25N5O2/c24-8-7-18-15-26-22-6-5-20(13-21(18)22)30-16-23(29)28-11-9-27(10-12-28)19-3-1-17(14-25)2-4-19/h1-6,13,15,26H,7-12,16,24H2
DMA2K7C	CS	C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN
DMA2K7C	IK	SOHCKWZVTCTQBG-UHFFFAOYSA-N
DMA2K7C	IU	4-[4-[2-[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]piperazin-1-yl]benzonitrile
DMA2K7C	CA	CAS 170912-52-4
DMA2K7C	DE	Migraine

DMYH3VR	ID	DMYH3VR
DMYH3VR	DN	DP-3975
DMYH3VR	HS	Preclinical
DMYH3VR	CP	Deciphera Pharmaceuticals
DMYH3VR	DT	Small molecular drug
DMYH3VR	DE	Mesothelioma

DMMI2EY	ID	DMMI2EY
DMMI2EY	DN	DS-1558
DMMI2EY	HS	Preclinical
DMMI2EY	SN	1202575-67-4; CHEMBL3427712; (S)-3-ethoxy-3-(4-(((R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)propanoic acid; SCHEMBL1508316; BDBM50085568; SB18922; (3S)-3-ethoxy-3-[4-[[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy]phenyl]propanoic acid; (3S)-3-Ethoxy-3-[4-[[(R)-4-(trifluoromethyl)-2,3-dihydro-1H-indene-1alpha-yl]oxy]phenyl]propanoic acid
DMMI2EY	DT	Small molecular drug
DMMI2EY	PC	45107312
DMMI2EY	MW	394.4
DMMI2EY	FM	C21H21F3O4
DMMI2EY	IC	InChI=1S/C21H21F3O4/c1-2-27-19(12-20(25)26)13-6-8-14(9-7-13)28-18-11-10-15-16(18)4-3-5-17(15)21(22,23)24/h3-9,18-19H,2,10-12H2,1H3,(H,25,26)/t18-,19+/m1/s1
DMMI2EY	CS	CCO[C@@H](CC(=O)O)C1=CC=C(C=C1)O[C@@H]2CCC3=C2C=CC=C3C(F)(F)F
DMMI2EY	IK	YHLQVQKZDZYMIP-MOPGFXCFSA-N
DMMI2EY	IU	(3S)-3-ethoxy-3-[4-[[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy]phenyl]propanoic acid
DMMI2EY	DE	Type 2 diabetes

DM8YSW7	ID	DM8YSW7
DM8YSW7	DN	DX-2802
DM8YSW7	HS	Preclinical
DM8YSW7	CP	Dyax Corp
DM8YSW7	DT	Antibody
DM8YSW7	DE	Solid tumour/cancer

DMCVXBE	ID	DMCVXBE
DMCVXBE	DN	E-64D
DMCVXBE	HS	Preclinical
DMCVXBE	SN	E64D; E64d; Aloxistatin; Aloxistatin [INN]; Aloxistatina; Aloxistatina [Spanish]; Aloxistatine; Aloxistatine [French]; Aloxistatinum; Aloxistatinum [Latin]; BRN 5354546; C17H30N2O5; CCRIS 1934; CHEMBL63440; E 64c ethyl ester; E 64d; EP 453; EST; EST (pharmaceutical); L5W337AOUR; Loxistatin; MLS000028372; NSC 694281; SMR000058552; UNII-L5W337AOUR
DMCVXBE	TC	Antiviral Agents
DMCVXBE	DT	Small molecular drug
DMCVXBE	PC	65663
DMCVXBE	MW	342.4
DMCVXBE	FM	C17H30N2O5
DMCVXBE	IC	InChI=1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)/t12-,13-,14-/m0/s1
DMCVXBE	CS	CCOC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C
DMCVXBE	IK	SRVFFFJZQVENJC-IHRRRGAJSA-N
DMCVXBE	IU	ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
DMCVXBE	CA	CAS 88321-09-9
DMCVXBE	CB	CHEBI:101381
DMCVXBE	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMG4DHX	ID	DMG4DHX
DMG4DHX	DN	ED-1812
DMG4DHX	HS	Preclinical
DMG4DHX	CP	Sosei R&D Ltd
DMG4DHX	DE	Pain

DMELPJM	ID	DMELPJM
DMELPJM	DN	EDD7H9
DMELPJM	HS	Preclinical
DMELPJM	SN	Anti S1P3 antibody (breast cancer), Expression Drug Designs; Anti-GPCR Abs (cancer), Expression Drug Designs; G-protein-coupled receptor inhibitor antibodies (breast cancer), Expression Drug Designs
DMELPJM	CP	Expression Drug Designs
DMELPJM	DT	Antibody
DMELPJM	DE	Breast cancer

DMZ3YP6	ID	DMZ3YP6
DMZ3YP6	DN	EGFR/IGFR tandem adnectin
DMZ3YP6	HS	Preclinical
DMZ3YP6	SN	BMS-964210
DMZ3YP6	CP	Bristol-Myers Squibb
DMZ3YP6	DE	Solid tumour/cancer

DMK6WIO	ID	DMK6WIO
DMK6WIO	DN	Enrofloxacin
DMK6WIO	HS	Preclinical
DMK6WIO	SN	Enrofloxacin; 93106-60-6; Baytril; Enrofloxacine; CFPQ; Enrofloxacinum; Enrofloxacino; endrofloxicin; BAY VP 2674; Bay-Vp-2674; Enrofloxacine [French]; Enrofloxacinum [Latin]; Enrofloxacino [Spanish]; UNII-3DX3XEK1BN; N-Ethylciprofloxacin; Baytril (TN); ERFX; Enrofloxacin [USAN:BAN:INN]; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; HSDB 6952; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 3DX3XEK1BN; Enrofloxacin (USAN/INN)
DMK6WIO	PC	71188
DMK6WIO	MW	359.4
DMK6WIO	FM	C19H22FN3O3
DMK6WIO	IC	InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
DMK6WIO	CS	CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F
DMK6WIO	IK	SPFYMRJSYKOXGV-UHFFFAOYSA-N
DMK6WIO	IU	1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMK6WIO	CA	CAS 93106-60-6
DMK6WIO	CB	CHEBI:35720
DMK6WIO	DE	Bacterial infections

DM2K51E	ID	DM2K51E
DM2K51E	DN	EP-01492
DM2K51E	HS	Preclinical
DM2K51E	CP	Ardana
DM2K51E	DT	Small molecular drug
DM2K51E	PC	56603735
DM2K51E	MW	514.7
DM2K51E	FM	C31H38N4O3
DM2K51E	IC	InChI=1S/C31H38N4O3/c1-31(2,32)19-11-16-27(36)34(4)26(21-22-17-18-23-12-9-10-15-25(23)20-22)30(38)35(5)28(29(37)33-3)24-13-7-6-8-14-24/h6-18,20,26,28H,19,21,32H2,1-5H3,(H,33,37)/b16-11+/t26-,28-/m1/s1
DM2K51E	CS	CC(C)(C/C=C/C(=O)N(C)[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N(C)[C@H](C3=CC=CC=C3)C(=O)NC)N
DM2K51E	IK	DPTDDSCCZNKDBZ-JABCAPRSSA-N
DM2K51E	IU	(E)-5-amino-N,5-dimethyl-N-[(2R)-1-[methyl-[(1R)-2-(methylamino)-2-oxo-1-phenylethyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide
DM2K51E	DE	Obesity

DMJEKQM	ID	DMJEKQM
DMJEKQM	DN	EP-128504
DMJEKQM	HS	Preclinical
DMJEKQM	SN	MX-116839; MX-126374; MX-126911; MX-128504; MX-74420; MX-77356; IGF modulator (cancer), Maxim; IGF-2 receptor modulators (cancer); IGF-2 receptor modulators (cancer), EpiCept; IGF-2 receptor modulators (cancer), Maxim; Insulin-like growth factor modulator (cancer), Maxim
DMJEKQM	CP	Maxim Pharmaceuticals Inc
DMJEKQM	DE	Solid tumour/cancer

DMERKYO	ID	DMERKYO
DMERKYO	DN	EP-2167
DMERKYO	HS	Preclinical
DMERKYO	SN	MX-2167; Transferrin modulating apoptosis inducers (cancer); Transferrin modulating apoptosis inducers (cancer), EpiCept;Transferrin modulating apoptosis inducers (cancer), Maxim
DMERKYO	CP	Maxim Pharmaceuticals Inc
DMERKYO	DE	Solid tumour/cancer

DMVNR20	ID	DMVNR20
DMVNR20	DN	Epipodophyllotoxins
DMVNR20	HS	Preclinical
DMVNR20	SN	(-)-epipodophyllotoxin; 137513-EP2272827A1; 137513-EP2292088A1; AC1L2Y2E; AJ-42064; BRN 0099162; C22H22O8; CHEMBL282256; Epipodophyllotoxin; Etopside; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R,5aR,8aR,9S)-; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R-(5-alpha,5a-beta,8a-alpha,9-beta))-; LS-70861; SCHEMBL5792464; VP16; ZINC2572657
DMVNR20	TC	Anticancer Agents
DMVNR20	DT	Small molecular drug
DMVNR20	PC	105111
DMVNR20	MW	414.41
DMVNR20	FM	C22H22O8
DMVNR20	IC	InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20+/m0/s1
DMVNR20	CS	COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O
DMVNR20	IK	YJGVMLPVUAXIQN-LGWHJFRWSA-N
DMVNR20	IU	(5S,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMVNR20	CA	CAS 4375-07-9
DMVNR20	DE	External genital and perianal warts; Molluscum contagiosum infection

DM5K17C	ID	DM5K17C
DM5K17C	DN	EPL-1410
DM5K17C	HS	Preclinical
DM5K17C	CP	Emcure Pharmaceuticals
DM5K17C	DT	Small molecular drug
DM5K17C	DE	Solid tumour/cancer

DMX2FZS	ID	DMX2FZS
DMX2FZS	DN	Epothilone A
DMX2FZS	HS	Preclinical
DMX2FZS	SN	Epothilone A; (-)-Epothilone A; Epo A; epothile; Epothilone-A; UNII-51E07YBX96; Epoa; 51E07YBX96; EP; Epothilones; Epothilon A; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione; 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-,(1S,3S,7S,10R,11S,12S,16R)-
DMX2FZS	PC	448799
DMX2FZS	MW	493.7
DMX2FZS	FM	C26H39NO6S
DMX2FZS	IC	InChI=1S/C26H39NO6S/c1-14-8-7-9-19-21(32-19)11-20(15(2)10-18-13-34-17(4)27-18)33-23(29)12-22(28)26(5,6)25(31)16(3)24(14)30/h10,13-14,16,19-22,24,28,30H,7-9,11-12H2,1-6H3/b15-10+/t14-,16+,19+,20-,21-,22-,24-/m0/s1
DMX2FZS	CS	CC1CCCC2C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C
DMX2FZS	IK	HESCAJZNRMSMJG-KKQRBIROSA-N
DMX2FZS	IU	(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMX2FZS	CA	CAS 152044-53-6
DMX2FZS	CB	CHEBI:31549
DMX2FZS	DE	Cancer

DM2TESM	ID	DM2TESM
DM2TESM	DN	EPZ028862
DM2TESM	HS	Preclinical
DM2TESM	DT	Small molecular drug
DM2TESM	DE	Solid tumour/cancer

DM8UKL0	ID	DM8UKL0
DM8UKL0	DN	EPZ031686
DM8UKL0	HS	Preclinical
DM8UKL0	SN	1808011-22-4; 6-chloro-2-oxo-N-((1R,3r,5S)-8-(((1-(4,4,4-trifluorobutyl)piperidin-4-yl)methyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)indoline-5-carboxamide; EPZ-031686; CHEMBL3798741; SCHEMBL17591794; SCHEMBL17591795; SCHEMBL21490167; BDBM378462; EX-A1613; NSC804862; US10266526, Compound 595; ZINC521836533; CS-5775; NSC-804862; HY-19324; A16375
DM8UKL0	DT	Small molecular drug
DM8UKL0	PC	118946372
DM8UKL0	MW	591.1
DM8UKL0	FM	C26H34ClF3N4O4S
DM8UKL0	IC	InChI=1S/C26H34ClF3N4O4S/c27-22-14-23-17(11-24(35)32-23)10-21(22)25(36)31-18-12-19-2-3-20(13-18)34(19)39(37,38)15-16-4-8-33(9-5-16)7-1-6-26(28,29)30/h10,14,16,18-20H,1-9,11-13,15H2,(H,31,36)(H,32,35)/t18?,19-,20+
DM8UKL0	CS	C1C[C@H]2CC(C[C@@H]1N2S(=O)(=O)CC3CCN(CC3)CCCC(F)(F)F)NC(=O)C4=C(C=C5C(=C4)CC(=O)N5)Cl
DM8UKL0	IK	OTEIUEJPHNOGBG-IHWFROFDSA-N
DM8UKL0	IU	6-chloro-2-oxo-N-[(1S,5R)-8-[[1-(4,4,4-trifluorobutyl)piperidin-4-yl]methylsulfonyl]-8-azabicyclo[3.2.1]octan-3-yl]-1,3-dihydroindole-5-carboxamide
DM8UKL0	DE	Solid tumour/cancer

DMHU742	ID	DMHU742
DMHU742	DN	EPZ032597
DMHU742	HS	Preclinical
DMHU742	DT	Small molecular drug
DMHU742	DE	Solid tumour/cancer

DMUKVYL	ID	DMUKVYL
DMUKVYL	DN	EPZ0330456
DMUKVYL	HS	Preclinical
DMUKVYL	DT	Small molecular drug
DMUKVYL	DE	Colon cancer

DMDO6NZ	ID	DMDO6NZ
DMDO6NZ	DN	EPZ033294
DMDO6NZ	HS	Preclinical
DMDO6NZ	DT	Small molecular drug
DMDO6NZ	DE	Solid tumour/cancer

DMBINP0	ID	DMBINP0
DMBINP0	DN	ER-319711-15
DMBINP0	HS	Preclinical
DMBINP0	CP	Eisai Co Ltd
DMBINP0	DE	Type-2 diabetes

DMUFP05	ID	DMUFP05
DMUFP05	DN	F-15063
DMUFP05	HS	Preclinical
DMUFP05	SN	D2/D3 antagonists (psychosis/schizophrenia), Pierre Fabre
DMUFP05	CP	Centre de Recherche Pierre Fabre
DMUFP05	DT	Small molecular drug
DMUFP05	PC	10248159
DMUFP05	MW	363.5
DMUFP05	FM	C24H29NO2
DMUFP05	IC	InChI=1S/C24H29NO2/c1-24(2)16-21-11-6-12-22(23(21)27-24)26-14-13-25-17-18-7-5-10-20(15-18)19-8-3-4-9-19/h5-8,10-12,15,25H,3-4,9,13-14,16-17H2,1-2H3
DMUFP05	CS	CC1(CC2=C(O1)C(=CC=C2)OCCNCC3=CC(=CC=C3)C4=CCCC4)C
DMUFP05	IK	RAIDOKRWKAIHOH-UHFFFAOYSA-N
DMUFP05	IU	N-[[3-(cyclopenten-1-yl)phenyl]methyl]-2-[(2,2-dimethyl-3H-1-benzofuran-7-yl)oxy]ethanamine
DMUFP05	CA	CAS 680203-70-7
DMUFP05	DE	Schizophrenia

DM29M4R	ID	DM29M4R
DM29M4R	DN	F24F2
DM29M4R	HS	Preclinical
DM29M4R	DT	Antibody
DM29M4R	DE	Anthrax

DM2GEHA	ID	DM2GEHA
DM2GEHA	DN	F26G3
DM2GEHA	HS	Preclinical
DM2GEHA	DT	Antibody
DM2GEHA	DE	Anthrax

DMAVQ2X	ID	DMAVQ2X
DMAVQ2X	DN	F26G4
DMAVQ2X	HS	Preclinical
DMAVQ2X	DT	Antibody
DMAVQ2X	DE	Anthrax

DMTHLB8	ID	DMTHLB8
DMTHLB8	DN	FA-613
DMTHLB8	HS	Preclinical
DMTHLB8	SN	6-bromo-2-(4-ethoxyphenyl)-4-quinolinecarboxylic acid
DMTHLB8	TC	Antiviral Agents
DMTHLB8	DT	Small molecular drug
DMTHLB8	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMYFVZ3	ID	DMYFVZ3
DMYFVZ3	DN	FAP5-DM1
DMYFVZ3	HS	Preclinical
DMYFVZ3	DT	Antibody
DMYFVZ3	DE	Solid tumour/cancer

DMAX2EW	ID	DMAX2EW
DMAX2EW	DN	FAS1
DMAX2EW	HS	Preclinical
DMAX2EW	TC	Antifungal Agents
DMAX2EW	DE	Fungal infection

DMBZVYG	ID	DMBZVYG
DMBZVYG	DN	FOXO4-DRI
DMBZVYG	HS	Preclinical
DMBZVYG	DT	Peptide
DMBZVYG	DE	Hypogonadism

DMUHVEA	ID	DMUHVEA
DMUHVEA	DN	FPL-14294
DMUHVEA	HS	Preclinical
DMUHVEA	SN	Fpl 14294; Hpa(SO3H)-met-gly-trp-met-asp-mephe-NH2NH3; (3S)-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-4-methylsulfanyl-2-[[2-(4-sulfooxyphenyl)acetyl]amino]butanoyl]amino]acetyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2S)-2-(methylamino)-3-phenylpropanoyl]amino]-4-oxobutanoic acid; 4-(Sulfoxy)-phenylacetyl(mephe6)cck-6; 4-(Sulfoxy)phenylacetyl-methionyl-glycyl-trptophyl-methionyl-aspartyl-methylphenylalaninehydrazide
DMUHVEA	CP	Fisons
DMUHVEA	DT	Small molecular drug
DMUHVEA	PC	132969
DMUHVEA	MW	1013.2
DMUHVEA	FM	C45H56N8O13S3
DMUHVEA	IC	InChI=1S/C45H56N8O13S3/c1-46-35(21-27-9-5-4-6-10-27)43(60)53-45(62)37(24-40(56)57)52-42(59)34(18-20-68-3)51-44(61)36(23-29-25-47-32-12-8-7-11-31(29)32)50-39(55)26-48-41(58)33(17-19-67-2)49-38(54)22-28-13-15-30(16-14-28)66-69(63,64)65/h4-16,25,33-37,46-47H,17-24,26H2,1-3H3,(H,48,58)(H,49,54)(H,50,55)(H,51,61)(H,52,59)(H,56,57)(H,53,60,62)(H,63,64,65)/t33-,34-,35-,36-,37-/m0/s1
DMUHVEA	CS	CN[C@@H](CC1=CC=CC=C1)C(=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)CC4=CC=C(C=C4)OS(=O)(=O)O
DMUHVEA	IK	PKMRCHBERGHHNY-LTLCPEALSA-N
DMUHVEA	IU	(3S)-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-4-methylsulfanyl-2-[[2-(4-sulfooxyphenyl)acetyl]amino]butanoyl]amino]acetyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2S)-2-(methylamino)-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMUHVEA	CA	CAS 154132-95-3
DMUHVEA	DE	Obesity

DMF53Z7	ID	DMF53Z7
DMF53Z7	DN	FR167356
DMF53Z7	HS	Preclinical
DMF53Z7	PC	10068207
DMF53Z7	MW	378.2
DMF53Z7	FM	C19H17Cl2NO3
DMF53Z7	IC	InChI=1S/C19H17Cl2NO3/c1-10-16(19(2,3)24)11-6-4-9-14(17(11)25-10)22-18(23)15-12(20)7-5-8-13(15)21/h4-9,24H,1-3H3,(H,22,23)
DMF53Z7	CS	CC1=C(C2=C(O1)C(=CC=C2)NC(=O)C3=C(C=CC=C3Cl)Cl)C(C)(C)O
DMF53Z7	IK	GCAOVMKRBUCSET-UHFFFAOYSA-N
DMF53Z7	IU	2,6-dichloro-N-[3-(2-hydroxypropan-2-yl)-2-methyl-1-benzofuran-7-yl]benzamide
DMF53Z7	CA	CAS 174185-16-1
DMF53Z7	DE	Osteoporosis

DMXR287	ID	DMXR287
DMXR287	DN	FR-79620
DMXR287	HS	Preclinical
DMXR287	SN	3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine
DMXR287	CP	Fujisawa
DMXR287	DT	Small molecular drug
DMXR287	PC	10421577
DMXR287	MW	235.28
DMXR287	FM	C15H13N3
DMXR287	IC	InChI=1S/C15H13N3/c1-11-14(13-8-5-9-16-10-13)18-15(17-11)12-6-3-2-4-7-12/h2-10H,1H3,(H,17,18)
DMXR287	CS	CC1=C(N=C(N1)C2=CC=CC=C2)C3=CN=CC=C3
DMXR287	IK	CAQAIFUDUGDPFB-UHFFFAOYSA-N
DMXR287	IU	3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine
DMXR287	DE	Diabetic complication; Obesity; Eating disorder

DMLNRCI	ID	DMLNRCI
DMLNRCI	DN	FSA2
DMLNRCI	HS	Preclinical
DMLNRCI	TC	Antifungal Agents
DMLNRCI	DE	Fungal infection

DMXE6ML	ID	DMXE6ML
DMXE6ML	DN	FX-007
DMXE6ML	HS	Preclinical
DMXE6ML	CP	Flexion Therapeutics
DMXE6ML	DE	Pain

DM7UJ1I	ID	DM7UJ1I
DM7UJ1I	DN	FX-107
DM7UJ1I	HS	Preclinical
DM7UJ1I	SN	FX-06; FX-06); FX-06HS; FX-06MRI; FX-108; FX-201; IK-600X program; Bbeta(15-42); FX-06 analogs (transplantation), Fibrex Medical; FX-06 analogs (transplantation), Ikaria; Peptide leukocyte migration inhibitor (reperfusion injury/hemorrhagic shock), Ikaria; Peptide leukocyte migration inhibitor (reperfusion injury/hemorrhagic shock), FIBREX Medical R&D; FX-06 analogs (sepsis, septic shock, Dengue), Fibrex Medical
DM7UJ1I	CP	Fibrex Medical R&D GmbH
DM7UJ1I	DE	Dengue fever

DMR1CLY	ID	DMR1CLY
DMR1CLY	DN	GC376
DMR1CLY	HS	Preclinical
DMR1CLY	SN	CS-6923; HY-100721; CHEMBL2315036
DMR1CLY	TC	Antiviral Agents
DMR1CLY	DT	Small molecular drug
DMR1CLY	PC	71481119
DMR1CLY	MW	507.5
DMR1CLY	FM	C21H30N3NaO8S
DMR1CLY	IC	InChI=1S/C21H31N3O8S.Na/c1-13(2)10-16(24-21(28)32-12-14-6-4-3-5-7-14)19(26)23-17(20(27)33(29,30)31)11-15-8-9-22-18(15)25;/h3-7,13,15-17,20,27H,8-12H2,1-2H3,(H,22,25)(H,23,26)(H,24,28)(H,29,30,31);/q;+1/p-1/t15?,16-,17-,20?;/m0./s1
DMR1CLY	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2=CC=CC=C2.[Na+]
DMR1CLY	IK	BSPJDKCMFIPBAW-JPBGFCRCSA-M
DMR1CLY	IU	sodium;(2S)-1-hydroxy-2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate
DMR1CLY	CA	CAS 1416992-39-6
DMR1CLY	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM7PBJC	ID	DM7PBJC
DM7PBJC	DN	GC813
DM7PBJC	HS	Preclinical
DM7PBJC	SN	GC813 compound
DM7PBJC	TC	Antiviral Agents
DM7PBJC	DT	Small molecular drug
DM7PBJC	DE	Middle East Respiratory Syndrome (MERS)

DMFW0H9	ID	DMFW0H9
DMFW0H9	DN	GCR-1087
DMFW0H9	HS	Preclinical
DMFW0H9	CP	Glenmark
DMFW0H9	DE	Type-2 diabetes; Obesity

DMFQI38	ID	DMFQI38
DMFQI38	DN	GG-8573
DMFQI38	HS	Preclinical
DMFQI38	CP	GSK
DMFQI38	DE	Obesity

DM25N8B	ID	DM25N8B
DM25N8B	DN	GI-264879A
DM25N8B	HS	Preclinical
DM25N8B	SN	gi264879a
DM25N8B	CP	GSK
DM25N8B	DT	Small molecular drug
DM25N8B	PC	9875299
DM25N8B	MW	743.8
DM25N8B	FM	C41H44F3N5O5
DM25N8B	IC	InChI=1S/C39H43N5O3.C2HF3O2/c1-47-26-30(24-27-12-3-2-4-13-27)43-38(46)36(22-11-23-42-39(40)41)44-37(45)25-35(33-20-9-16-28-14-5-7-18-31(28)33)34-21-10-17-29-15-6-8-19-32(29)34;3-2(4,5)1(6)7/h2-10,12-21,30,35-36H,11,22-26H2,1H3,(H,43,46)(H,44,45)(H4,40,41,42);(H,6,7)/t30-,36+;/m0./s1
DM25N8B	CS	COC[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)CC(C2=CC=CC3=CC=CC=C32)C4=CC=CC5=CC=CC=C54.C(=O)(C(F)(F)F)O
DM25N8B	IK	NZGALICACGXBQM-HOBHVFGFSA-N
DM25N8B	IU	(2R)-5-(diaminomethylideneamino)-2-(3,3-dinaphthalen-1-ylpropanoylamino)-N-[(2S)-1-methoxy-3-phenylpropan-2-yl]pentanamide;2,2,2-trifluoroacetic acid
DM25N8B	DE	Obesity

DMZC91G	ID	DMZC91G
DMZC91G	DN	GL21.T
DMZC91G	HS	Preclinical
DMZC91G	DT	Oligonucleotide
DMZC91G	DE	Non-small-cell lung cancer

DMSW07R	ID	DMSW07R
DMSW07R	DN	GLPG-0492
DMSW07R	HS	Preclinical
DMSW07R	SN	G-100192; Selective androgen receptor modulators, Galapagos; Selective androgen receptor modulators, ProSkelia; Selective androgen receptor modulators, ProStrakan; SARMs (osteoporosis), ProSkelia; SARMs (osteoporosis), ProStraken; SARMs (osteoporosis/cachexia), Galapagos
DMSW07R	CP	ProSkelia Pharmaceuticals SAS
DMSW07R	PC	59317190
DMSW07R	MW	389.3
DMSW07R	FM	C19H14F3N3O3
DMSW07R	IC	InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3/t18-/m1/s1
DMSW07R	CS	CN1C(=O)N(C(=O)[C@@]1(CO)C2=CC=CC=C2)C3=CC(=C(C=C3)C#N)C(F)(F)F
DMSW07R	IK	VAJGULUVTFDTAS-GOSISDBHSA-N
DMSW07R	IU	4-[(4S)-4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
DMSW07R	CA	CAS 1215085-92-9
DMSW07R	DE	Cachexia

DMXVHOQ	ID	DMXVHOQ
DMXVHOQ	DN	GNE684
DMXVHOQ	HS	Preclinical
DMXVHOQ	SN	(5S)-N-[(3S)-7-methoxy-1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[3,4-b]azepin-3-yl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide; HY-128585; CS-0095948; (s)-N-((s)-7-methoxy-1-methyl-2-oxo-2,3,4,5-tetrahydro-1h-pyrido[3,4-b]azepin-3-yl)-5-phenyl-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide; 2438637-64-8; L8D; rel-(S)-N-((S)-7-Methoxy-1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[3,4-b]azepin-3-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide
DMXVHOQ	CP	Genentech
DMXVHOQ	DT	Small molecular drug
DMXVHOQ	PC	138377384
DMXVHOQ	MW	432.5
DMXVHOQ	FM	C23H24N6O3
DMXVHOQ	IC	InChI=1S/C23H24N6O3/c1-28-18-13-24-20(32-2)12-15(18)8-9-16(23(28)31)25-22(30)21-26-19-11-10-17(29(19)27-21)14-6-4-3-5-7-14/h3-7,12-13,16-17H,8-11H2,1-2H3,(H,25,30)/t16-,17-/m0/s1
DMXVHOQ	CS	CN1C2=CN=C(C=C2CC[C@@H](C1=O)NC(=O)C3=NN4[C@@H](CCC4=N3)C5=CC=CC=C5)OC
DMXVHOQ	IK	JXFYROJRZJPKTQ-IRXDYDNUSA-N
DMXVHOQ	IU	(5S)-N-[(3S)-7-methoxy-1-methyl-2-oxo-4,5-dihydro-3H-pyrido[3,4-b]azepin-3-yl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide
DMXVHOQ	DE	Inflammation

DMTJRLU	ID	DMTJRLU
DMTJRLU	DN	GNTI
DMTJRLU	HS	Preclinical
DMTJRLU	SN	G 3416; GNTI di-trifluoroacetate; Guanidinyl-naltrindole di-trifluoroacetate; 5'-Guanidinonaltrindole di(trifluoroacetate) salt hydrate; 5'-Guanidinylnaltrindole dihydrochloride
DMTJRLU	CP	University of Minneapolis
DMTJRLU	DT	Small molecular drug
DMTJRLU	PC	9826034
DMTJRLU	MW	471.5
DMTJRLU	FM	C27H29N5O3
DMTJRLU	IC	InChI=1S/C27H29N5O3/c28-25(29)30-15-4-5-18-16(10-15)17-11-27(34)20-9-14-3-6-19(33)23-21(14)26(27,24(35-23)22(17)31-18)7-8-32(20)12-13-1-2-13/h3-6,10,13,20,24,31,33-34H,1-2,7-9,11-12H2,(H4,28,29,30)/t20-,24+,26+,27-/m1/s1
DMTJRLU	CS	C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)C=CC(=C8)N=C(N)N
DMTJRLU	IK	VLNHDKDBGWXJEE-GYHUNEDQSA-N
DMTJRLU	IU	2-[(1S,2S,13R,21R)-22-(cyclopropylmethyl)-2,16-dihydroxy-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5(10),6,8,15,17,19(25)-heptaen-7-yl]guanidine
DMTJRLU	DE	Obesity

DMNZA4L	ID	DMNZA4L
DMNZA4L	DN	Griffithsin
DMNZA4L	HS	Preclinical
DMNZA4L	SN	GRFT
DMNZA4L	TC	Antiviral Agents
DMNZA4L	DT	Protein/peptide drug
DMNZA4L	SQ	SLTHRKFGGSGGSPFSGLSSIAVRSGSYLDAIIIDGVHHGGSGGNLSPTFTFGSGEYISNMTIRSGDYINISFETNMGRRFGPTYGGSGGSANTLSNVKVIQINGSAGDYLDSLDIYYEQY
DMNZA4L	DE	Severe acute respiratory syndrome (SARS)

DM19T2V	ID	DM19T2V
DM19T2V	DN	GRL001
DM19T2V	HS	Preclinical
DM19T2V	DT	Small molecular drug
DM19T2V	DE	Coronavirus infection

DMVB1PD	ID	DMVB1PD
DMVB1PD	DN	GRL-001
DMVB1PD	HS	Preclinical
DMVB1PD	SN	CE-5
DMVB1PD	TC	Antiviral Agents
DMVB1PD	DT	Small molecular drug
DMVB1PD	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMX9AGF	ID	DMX9AGF
DMX9AGF	DN	GRL0617
DMX9AGF	HS	Preclinical
DMX9AGF	SN	5-Amino-2-Methyl-N-[(1r)-1-Naphthalen-1-Ylethyl]benzamide; GRL-0617; 5-Amino-2-methyl-N-[(1R)-1-(1-naphthalenyl)ethyl]benzamide; 5-Amino-2-methyl-N-[(R)-1-(1-naphthyl)ethyl]benzamide; 5-Amino-2-methyl-N-(1R-naphthalen-1-yl-ethyl)-benzamide; CHEMBL549695; SCHEMBL1319181; BDBM31524; GTPL11078; CHEBI:167176; 5-amino-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide; EX-A4032; GRL 0617; s6845; ZINC43012570; AKOS015840255; AKOS015924263; DB08656; compound 25 [PMID: 19645480]; NCGC00188640-01; Naphthalene and Benzamide Derivative, 25; HY-117043; CS-0063568; Q27097846
DMX9AGF	DT	Small molecular drug
DMX9AGF	PC	24941262
DMX9AGF	MW	304.4
DMX9AGF	FM	C20H20N2O
DMX9AGF	IC	InChI=1S/C20H20N2O/c1-13-10-11-16(21)12-19(13)20(23)22-14(2)17-9-5-7-15-6-3-4-8-18(15)17/h3-12,14H,21H2,1-2H3,(H,22,23)/t14-/m1/s1
DMX9AGF	CS	CC1=C(C=C(C=C1)N)C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C32
DMX9AGF	IK	UVERBUNNCOKGNZ-CQSZACIVSA-N
DMX9AGF	IU	5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
DMX9AGF	CB	CHEBI:167176
DMX9AGF	DE	Coronavirus infection

DMNU3SI	ID	DMNU3SI
DMNU3SI	DN	GSK180
DMNU3SI	HS	Preclinical
DMNU3SI	SN	1799725-26-0; CHEMBL4092205; 3-(5,6-dichloro-2-oxo-1,3-benzoxazol-3-yl)propanoic acid; 3-(5,6-Dichloro-2-Oxobenzo[d]oxazol-3(2h)-Yl)propanoic Acid; JHY; GTPL9007; SCHEMBL16836556; GSK-180; BCP33987; EX-A4035; GSK 180; GSK-180; BDBM50266036; SB19707; inhibitor A1 [PMID: 28604669]; HY-112179; CS-0043620; ClC=1C(=CC2=C(N(C(O2)=O)CCC(=O)O)C1)Cl; Q27077878
DMNU3SI	CP	GlaxoSmithKline
DMNU3SI	DT	Small molecular drug
DMNU3SI	PC	105539874
DMNU3SI	MW	276.07
DMNU3SI	FM	C10H7Cl2NO4
DMNU3SI	IC	InChI=1S/C10H7Cl2NO4/c11-5-3-7-8(4-6(5)12)17-10(16)13(7)2-1-9(14)15/h3-4H,1-2H2,(H,14,15)
DMNU3SI	CS	C1=C2C(=CC(=C1Cl)Cl)OC(=O)N2CCC(=O)O
DMNU3SI	IK	MIGAKMWKMLYGJX-UHFFFAOYSA-N
DMNU3SI	IU	3-(5,6-dichloro-2-oxo-1,3-benzoxazol-3-yl)propanoic acid
DMNU3SI	DE	Neurodegenerative disorder; Pancreatitis

DM5AOI3	ID	DM5AOI3
DM5AOI3	DN	GSK2643943A
DM5AOI3	HS	Preclinical
DM5AOI3	SN	2449301-27-1; EX-A4538; s6878; HY-111458; CS-0041056
DM5AOI3	CP	GlaxoSmithKline
DM5AOI3	DT	Small molecular drug
DM5AOI3	PC	137319705
DM5AOI3	MW	277.29
DM5AOI3	FM	C17H12FN3
DM5AOI3	IC	InChI=1S/C17H12FN3/c18-13-3-1-2-11(8-13)4-5-12-6-7-14-15(10-19)17(20)21-16(14)9-12/h1-9,21H,20H2/b5-4+
DM5AOI3	CS	C1=CC(=CC(=C1)F)/C=C/C2=CC3=C(C=C2)C(=C(N3)N)C#N
DM5AOI3	IK	CGXBPMZRTMXEIA-SNAWJCMRSA-N
DM5AOI3	IU	2-amino-6-[(E)-2-(3-fluorophenyl)ethenyl]-1H-indole-3-carbonitrile
DM5AOI3	DE	Solid tumour/cancer

DMAZROV	ID	DMAZROV
DMAZROV	DN	GSK2807
DMAZROV	HS	Preclinical
DMAZROV	SN	GSK-2807 free base; 5'-{[(3s)-3-Amino-3-Carboxypropyl][3-(Dimethylamino)propyl]amino}-5'-Deoxyadenosine; 2245255-65-4 (free base); (S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(3-(dimethylamino)propyl)amino)butanoic acid; 2245255-65-4; SCHEMBL19586501; EX-A2734; GSK-2807; Q27456186; 62X
DMAZROV	DT	Small molecular drug
DMAZROV	PC	118797898
DMAZROV	MW	452.5
DMAZROV	FM	C19H32N8O5
DMAZROV	IC	InChI=1S/C19H32N8O5/c1-25(2)5-3-6-26(7-4-11(20)19(30)31)8-12-14(28)15(29)18(32-12)27-10-24-13-16(21)22-9-23-17(13)27/h9-12,14-15,18,28-29H,3-8,20H2,1-2H3,(H,30,31)(H2,21,22,23)/t11-,12+,14+,15+,18+/m0/s1
DMAZROV	CS	CN(C)CCCN(CC[C@@H](C(=O)O)N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMAZROV	IK	FYXRZDCUJHGULY-URQYDQELSA-N
DMAZROV	IU	(2S)-2-amino-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-[3-(dimethylamino)propyl]amino]butanoic acid
DMAZROV	DE	Solid tumour/cancer

DMFJ0ZA	ID	DMFJ0ZA
DMFJ0ZA	DN	GSK-326416
DMFJ0ZA	HS	Preclinical
DMFJ0ZA	CP	GlaxoSmithKline
DMFJ0ZA	DE	Gastroparesis

DM04UGQ	ID	DM04UGQ
DM04UGQ	DN	GSK366
DM04UGQ	HS	Preclinical
DM04UGQ	SN	CHEMBL4081917; GSK 366; 1953157-39-5; (R)-3-(5-Chloro-6-(1-(6-methylpyridazin-3-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid; 3-[5-Chloranyl-6-[(1~{r})-1-(6-Methylpyridazin-3-Yl)ethoxy]-1,2-Benzoxazol-3-Yl]propanoic Acid; SCHEMBL17844503; EX-A4734; BDBM50266002; HY-119171; CS-0069358; ClC=1C(=CC2=C(C(=NO2)CCC(=O)O)C=1)O[C@H](C)C=1N=NC(=CC=1)C; 8RB
DM04UGQ	CP	GlaxoSmithKline
DM04UGQ	DT	Small molecular drug
DM04UGQ	PC	121415048
DM04UGQ	MW	361.8
DM04UGQ	FM	C17H16ClN3O4
DM04UGQ	IC	InChI=1S/C17H16ClN3O4/c1-9-3-4-13(20-19-9)10(2)24-16-8-15-11(7-12(16)18)14(21-25-15)5-6-17(22)23/h3-4,7-8,10H,5-6H2,1-2H3,(H,22,23)/t10-/m1/s1
DM04UGQ	CS	CC1=NN=C(C=C1)[C@@H](C)OC2=C(C=C3C(=C2)ON=C3CCC(=O)O)Cl
DM04UGQ	IK	YWASLAPMFGBZQP-SNVBAGLBSA-N
DM04UGQ	IU	3-[5-chloro-6-[(1R)-1-(6-methylpyridazin-3-yl)ethoxy]-1,2-benzoxazol-3-yl]propanoic acid
DM04UGQ	DE	Pancreatitis

DM1S5UO	ID	DM1S5UO
DM1S5UO	DN	GSK4112
DM1S5UO	HS	Preclinical
DM1S5UO	SN	SR6452; GSK-4112
DM1S5UO	DT	Small molecular drug
DM1S5UO	PC	50905018
DM1S5UO	MW	396.9
DM1S5UO	FM	C18H21ClN2O4S
DM1S5UO	IC	InChI=1S/C18H21ClN2O4S/c1-18(2,3)25-17(22)12-20(10-13-4-6-14(19)7-5-13)11-15-8-9-16(26-15)21(23)24/h4-9H,10-12H2,1-3H3
DM1S5UO	CS	CC(C)(C)OC(=O)CN(CC1=CC=C(C=C1)Cl)CC2=CC=C(S2)[N+](=O)[O-]
DM1S5UO	IK	WYSLOKHVFKLWOU-UHFFFAOYSA-N
DM1S5UO	IU	tert-butyl 2-[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]acetate
DM1S5UO	DE	Inflammation

DMNAT5V	ID	DMNAT5V
DMNAT5V	DN	GW-2592X
DMNAT5V	HS	Preclinical
DMNAT5V	SN	Azepanone inhibitors, GlaxoSmithKline; Cathepsin K inhibitors (bone disorder); Cathepsin K inhibitors, SmithKline Beecham; GW-2637X; GW-2934X; GW-9696X; SB-237632; SB-244875; SB-267320; SB-271194; SB-327537; SB-331750; SB-357114; SB-432238; SB-553484; Cathepsin K inhibitors (bone disorder), GlaxoSmithKline
DMNAT5V	CP	SmithKline Beecham Pharmaceuticals
DMNAT5V	DE	Bone disease; Osteoporosis

DM3PMAZ	ID	DM3PMAZ
DM3PMAZ	DN	GW-3333
DM3PMAZ	HS	Preclinical
DM3PMAZ	SN	SMZPWUUYPYYHIV-HNJRGHQBSA-N; GW3333; CHEMBL514958; UNII-54J77T5T74; 54J77T5T74; 212609-68-2; AC1Q5NWC; AC1L50QR; BIDD:PXR0031; n2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; SCHEMBL2875070; BDBM50247805; (2R,3S)-3-[formyl(hydroxy)amino]-4-methyl-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylamino)pentan-2-yl]-2-(2-methylpropyl)pentanamide; (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid, ((1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl)amide;  GW3333; Gw 3333; N2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; 5-carboxymethylthio-3-(3'-chlorophenyl)-1,2,4-oxadiazol
DM3PMAZ	CP	GlaxoSmithKline
DM3PMAZ	DT	Small molecular drug
DM3PMAZ	PC	216470
DM3PMAZ	MW	420.5
DM3PMAZ	FM	C22H36N4O4
DM3PMAZ	IC	InChI=1S/C22H36N4O4/c1-7-16(6)19(22(29)24-18-10-8-9-11-23-18)25-21(28)17(12-14(2)3)20(15(4)5)26(30)13-27/h8-11,13-17,19-20,30H,7,12H2,1-6H3,(H,25,28)(H,23,24,29)/t16-,17+,19-,20-/m0/s1
DM3PMAZ	CS	CC[C@H](C)[C@@H](C(=O)NC1=CC=CC=N1)NC(=O)[C@H](CC(C)C)[C@H](C(C)C)N(C=O)O
DM3PMAZ	IK	SMZPWUUYPYYHIV-HNJRGHQBSA-N
DM3PMAZ	IU	(2R,3S)-3-[formyl(hydroxy)amino]-4-methyl-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylamino)pentan-2-yl]-2-(2-methylpropyl)pentanamide
DM3PMAZ	CA	CAS 212609-68-2
DM3PMAZ	DE	Chronic obstructive pulmonary disease

DMHUD27	ID	DMHUD27
DMHUD27	DN	GW-594884A
DMHUD27	HS	Preclinical
DMHUD27	CP	GSK
DMHUD27	DE	Obesity

DM97RV4	ID	DM97RV4
DM97RV4	DN	GYKI-47261
DM97RV4	HS	Preclinical
DM97RV4	SN	GYKI 47261
DM97RV4	DT	Small molecular drug
DM97RV4	PC	9927197
DM97RV4	MW	322.8
DM97RV4	FM	C18H15ClN4
DM97RV4	IC	InChI=1S/C18H15ClN4/c1-11-10-23-17(21-11)8-13-2-5-14(19)9-16(13)18(22-23)12-3-6-15(20)7-4-12/h2-7,9-10H,8,20H2,1H3
DM97RV4	CS	CC1=CN2C(=N1)CC3=C(C=C(C=C3)Cl)C(=N2)C4=CC=C(C=C4)N
DM97RV4	IK	FPXVCCSOTAQPIV-UHFFFAOYSA-N
DM97RV4	IU	4-(8-chloro-2-methyl-11H-imidazo[1,2-c][2,3]benzodiazepin-6-yl)aniline
DM97RV4	CA	CAS 220445-20-5
DM97RV4	DE	Parkinson disease

DM6GSI1	ID	DM6GSI1
DM6GSI1	DN	HBX19818
DM6GSI1	HS	Preclinical
DM6GSI1	SN	HBX 19818; 1426944-49-1; CHEMBL2398213; 9-Chloro-5,6,7,8-tetrahydro-N-[3-[methyl(phenylmethyl)amino]propyl]-2-acridinecarboxamide; N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; SCHEMBL20007093; BDBM50436150; HBX-19818; NCGC00378705-01; HY-17540; J3.502.626F
DM6GSI1	CP	Hybrigenics
DM6GSI1	DT	Small molecular drug
DM6GSI1	PC	73349008
DM6GSI1	MW	422
DM6GSI1	FM	C25H28ClN3O
DM6GSI1	IC	InChI=1S/C25H28ClN3O/c1-29(17-18-8-3-2-4-9-18)15-7-14-27-25(30)19-12-13-23-21(16-19)24(26)20-10-5-6-11-22(20)28-23/h2-4,8-9,12-13,16H,5-7,10-11,14-15,17H2,1H3,(H,27,30)
DM6GSI1	CS	CN(CCCNC(=O)C1=CC2=C(C=C1)N=C3CCCCC3=C2Cl)CC4=CC=CC=C4
DM6GSI1	IK	ZCALMLVWZSQGGR-UHFFFAOYSA-N
DM6GSI1	IU	N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide
DM6GSI1	DE	Solid tumour/cancer

DMPLZ7E	ID	DMPLZ7E
DMPLZ7E	DN	HC-Toxin
DMPLZ7E	HS	Preclinical
DMPLZ7E	SN	HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMPLZ7E	TC	Anticancer Agents
DMPLZ7E	DT	Small molecular drug
DMPLZ7E	PC	107864
DMPLZ7E	MW	436.5
DMPLZ7E	FM	C21H32N4O6
DMPLZ7E	IC	InChI=1S/C21H32N4O6/c1-12-18(27)22-13(2)19(28)24-14(7-4-3-5-9-16(26)17-11-31-17)21(30)25-10-6-8-15(25)20(29)23-12/h12-15,17H,3-11H2,1-2H3,(H,22,27)(H,23,29)(H,24,28)/t12-,13+,14-,15+,17?/m0/s1
DMPLZ7E	CS	C[C@@H]1C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)C)CCCCCC(=O)C3CO3
DMPLZ7E	IK	GNYCTMYOHGBSBI-KVUCBBCISA-N
DMPLZ7E	IU	(3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMPLZ7E	CB	CHEBI:48028
DMPLZ7E	DE	Solid tumour/cancer

DMLZ5TQ	ID	DMLZ5TQ
DMLZ5TQ	DN	Hexamethylene amiloride
DMLZ5TQ	HS	Preclinical
DMLZ5TQ	SN	5-(N,N-Hexamethylene)amiloride; 5-HMA; BIDD; BSPBio_003443; C12H18ClN7O; DivK1c_006875; HMA; HMA-5; Hexamethyleneamiloride; KBioGR_001206; KBioSS_002076; Lopac-A-9561; Lopac0_000104; MLS002153208; N,N-HEXAMETHYLENEAMILORIDE; SPECTRUM1504215; SpecPlus_000779; Spectrum2_001669; Spectrum3_001662; Spectrum4_000623; Spectrum5_001388; Spectrum_001596
DMLZ5TQ	TC	Antiviral Agents
DMLZ5TQ	DT	Small molecular drug
DMLZ5TQ	PC	1794
DMLZ5TQ	MW	311.77
DMLZ5TQ	FM	C12H18ClN7O
DMLZ5TQ	IC	InChI=1S/C12H18ClN7O/c13-8-10(20-5-3-1-2-4-6-20)18-9(14)7(17-8)11(21)19-12(15)16/h1-6H2,(H2,14,18)(H4,15,16,19,21)
DMLZ5TQ	CS	C1CCCN(CC1)C2=NC(=C(N=C2Cl)C(=O)N=C(N)N)N
DMLZ5TQ	IK	RQQJJXVETXFINY-UHFFFAOYSA-N
DMLZ5TQ	IU	3-amino-5-(azepan-1-yl)-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
DMLZ5TQ	CA	CAS 1428-95-1
DMLZ5TQ	CB	CHEBI:76400
DMLZ5TQ	DE	Severe acute respiratory syndrome (SARS)

DMRE52S	ID	DMRE52S
DMRE52S	DN	HL-004
DMRE52S	HS	Preclinical
DMRE52S	SN	TS-962
DMRE52S	CP	Taisho Pharmaceutical Co Ltd
DMRE52S	PC	6426883
DMRE52S	MW	447.8
DMRE52S	FM	C28H49NOS
DMRE52S	IC	InChI=1S/C28H49NOS/c1-6-7-8-9-10-11-12-13-14-15-16-17-21-31-22-27(30)29-28-25(23(2)3)19-18-20-26(28)24(4)5/h18-20,23-24H,6-17,21-22H2,1-5H3,(H,29,30)
DMRE52S	CS	CCCCCCCCCCCCCCSCC(=O)NC1=C(C=CC=C1C(C)C)C(C)C
DMRE52S	IK	KRMKZDOWCOBWNU-UHFFFAOYSA-N
DMRE52S	IU	N-[2,6-di(propan-2-yl)phenyl]-2-tetradecylsulfanylacetamide
DMRE52S	DE	Arteriosclerosis

DMBQDA3	ID	DMBQDA3
DMBQDA3	DN	Homocamptothecin
DMBQDA3	HS	Preclinical
DMBQDA3	SN	homocamptothecin; UNII-5B3LFU8GLM; 5B3LFU8GLM; E-Homocamptothecin; E-Homocamptothecine; (20R)-Homocamptothecin; E-Homocamptothecin, (R)-; CHEMBL74190; SCHEMBL5860320; PAEZRCINULFAGO-OAQYLSRUSA-N; ZINC840834; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (5R)-; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (R)-
DMBQDA3	PC	10666346
DMBQDA3	MW	362.4
DMBQDA3	FM	C21H18N2O4
DMBQDA3	IC	InChI=1S/C21H18N2O4/c1-2-21(26)9-18(24)27-11-14-15(21)8-17-19-13(10-23(17)20(14)25)7-12-5-3-4-6-16(12)22-19/h3-8,26H,2,9-11H2,1H3/t21-/m1/s1
DMBQDA3	CS	CCC1(CC(=O)OCC2=C1C=C3C4=NC5=CC=CC=C5C=C4CN3C2=O)O
DMBQDA3	IK	PAEZRCINULFAGO-OAQYLSRUSA-N
DMBQDA3	IU	(20R)-20-ethyl-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4,6,8,10,15(21)-heptaene-14,18-dione
DMBQDA3	CA	CAS 186669-19-2
DMBQDA3	DE	Cancer

DM69UZG	ID	DM69UZG
DM69UZG	DN	HPP-851
DM69UZG	HS	Preclinical
DM69UZG	SN	11-beta HSD-1 (metabolic disorders), High Point; 11-beta HSD-1 (metabolic disorders), TransTech Pharma; 11-beta hydroxysteroid dehydrogenase-1 inhibitors (metabolic disorders), Novo Nordisk; 11-beta hydroxysteroid dehydrogenase-1 inhibitors (metabolic disorders), TransTech Pharma
DM69UZG	CP	Novo Nordisk A/S
DM69UZG	DE	Metabolic disorder

DMNF9P5	ID	DMNF9P5
DMNF9P5	DN	HR1P peptide
DMNF9P5	HS	Preclinical
DMNF9P5	SN	HR1P
DMNF9P5	TC	Antiviral Agents
DMNF9P5	DT	Protein/peptide drug
DMNF9P5	SQ	ANKFNQALGAMQTGFTTTNEAFQKVQDAVNNNAQALSKLASE
DMNF9P5	DE	Middle East Respiratory Syndrome (MERS)

DM6WC1Q	ID	DM6WC1Q
DM6WC1Q	DN	HR2P peptide
DM6WC1Q	HS	Preclinical
DM6WC1Q	SN	HR2P
DM6WC1Q	TC	Antiviral Agents
DM6WC1Q	DT	Protein/peptide drug
DM6WC1Q	SQ	SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL
DM6WC1Q	DE	Middle East Respiratory Syndrome (MERS)

DMSR96X	ID	DMSR96X
DMSR96X	DN	HR2P-M1 peptide
DMSR96X	HS	Preclinical
DMSR96X	SN	HR2P-M1
DMSR96X	TC	Antiviral Agents
DMSR96X	DT	Protein/peptide drug
DMSR96X	SQ	SLTQINTTLLDLEYEMRSLQQVVKALNESYIDLKEL
DMSR96X	DE	Middle East Respiratory Syndrome (MERS)

DM7X4SV	ID	DM7X4SV
DM7X4SV	DN	HR2P-M2 peptide
DM7X4SV	HS	Preclinical
DM7X4SV	SN	HR2P-M2
DM7X4SV	TC	Antiviral Agents
DM7X4SV	DT	Protein/peptide drug
DM7X4SV	SQ	SLTQINTTLLDLEYEMKKLEEVVKKLEESYIDLKEL
DM7X4SV	DE	Middle East Respiratory Syndrome (MERS)

DMR8VJA	ID	DMR8VJA
DMR8VJA	DN	HSDB-41
DMR8VJA	HS	Preclinical
DMR8VJA	SN	Aceton; Aceton [German, Dutch, Polish]; Acetone (natural); Acetone; Acetone [NF]; Chevron acetone; Dimethyl formaldehyde; Dimethyl ketone; Dimethylformaldehyde; Dimethylketal; Ketone propane; Ketone, dimethyl; Ketone, dimethyl-; Methyl ketone; Pyroacetic acid; Pyroacetic ether; RCRA waste number U002; UN1090; acetone; beta-Ketopropane; dimethylketone; propan-2-one; propanone; .beta.-Ketopropane; 2-propanone; 67-64-1; CCRIS 5953; Caswell No. 004; EINECS 200-662-2; FEMA No. 3326; HSDB 41; MFCD00008765; NSC 135802; UNII-1364PS73AF
DMR8VJA	PC	180
DMR8VJA	MW	58.08
DMR8VJA	FM	C3H6O
DMR8VJA	IC	CSCPPACGZOOCGX-UHFFFAOYSA-N
DMR8VJA	CS	CC(=O)C
DMR8VJA	IK	1S/C3H6O/c1-3(2)4/h1-2H3
DMR8VJA	IU	propan-2-one
DMR8VJA	CA	CAS 67-64-1
DMR8VJA	CB	CHEBI:15347
DMR8VJA	DE	Epilepsy

DMUAPNF	ID	DMUAPNF
DMUAPNF	DN	humanin
DMUAPNF	HS	Preclinical
DMUAPNF	SN	formyl humanin
DMUAPNF	DT	Small molecular drug
DMUAPNF	PC	16131438
DMUAPNF	MW	2687.2
DMUAPNF	FM	C119H204N34O32S2
DMUAPNF	IC	InChI=1S/C119H204N34O32S2/c1-19-65(14)92(112(180)144-81(54-90(160)161)104(172)145-82(52-63(10)11)115(183)153-46-29-37-87(153)110(178)149-91(64(12)13)111(179)139-72(32-23-24-41-120)97(165)136-74(35-27-44-130-119(126)127)98(166)135-73(34-26-43-129-118(124)125)96(164)133-67(16)116(184)185)150-99(167)75(38-39-89(158)159)137-106(174)84(57-155)147-113(181)93(68(17)156)151-105(173)79(51-62(8)9)142-101(169)77(49-60(4)5)140-100(168)76(48-59(2)3)141-102(170)78(50-61(6)7)143-108(176)85(58-186)148-107(175)83(56-154)146-103(171)80(53-69-30-21-20-22-31-69)134-88(157)55-131-95(163)71(33-25-42-128-117(122)123)138-109(177)86-36-28-45-152(86)114(182)66(15)132-94(162)70(121)40-47-187-18/h20-22,30-31,59-68,70-87,91-93,154-156,186H,19,23-29,32-58,120-121H2,1-18H3,(H,131,163)(H,132,162)(H,133,164)(H,134,157)(H,135,166)(H,136,165)(H,137,174)(H,138,177)(H,139,179)(H,140,168)(H,141,170)(H,142,169)(H,143,176)(H,144,180)(H,145,172)(H,146,171)(H,147,181)(H,148,175)(H,149,178)(H,150,167)(H,151,173)(H,158,159)(H,160,161)(H,184,185)(H4,122,123,128)(H4,124,125,129)(H4,126,127,130)/t65-,66-,67-,68+,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,91-,92-,93-/m0/s1
DMUAPNF	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H](CCSC)N
DMUAPNF	IK	DPEUWKZJZIPZKE-OFANTOPUSA-N
DMUAPNF	IU	(4S)-5-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-1-carboxyethyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DMUAPNF	CA	CAS 330936-69-1
DMUAPNF	DE	Alzheimer disease

DM3NP4I	ID	DM3NP4I
DM3NP4I	DN	Huntingtin gene antisense
DM3NP4I	HS	Preclinical
DM3NP4I	CP	Alnylam Pharmaceuticals & Medtronic, Inc.
DM3NP4I	TC	Antisense
DM3NP4I	DT	Antisense drug
DM3NP4I	DE	Huntington disease

DM349AM	ID	DM349AM
DM349AM	DN	HY-N0040
DM349AM	HS	Preclinical
DM349AM	SN	Ginsenoside C; Ginsenoside Rb2; Ginsenoside-Rb2; (20S)-ginsenoside Rb2; 11021-13-9; 20-[(6-O-a-L-arabinopyranosyl-ss-D-glucopyranosyl)oxy]-12ss-hydroxydammar-24-en-3ss-yl 2-O-ss-D-glucopyranosyl-ss-D-glucopyranoside; CHEBI:77152; CHEMBL449303; EINECS 234-251-4; HY-N0040; N219O0L31C; NSC 308878; UNII-N219O0L31C; beta-D-Glucopyranoside, (3-beta,12-beta)-20-((6-O-alpha-L-arabinopyranosyl-beta-D-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-
DM349AM	PC	6917976
DM349AM	MW	1079.3
DM349AM	FM	C53H90O22
DM349AM	IC	NODILNFGTFIURN-GZPRDHCNSA-N
DM349AM	CS	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(CO8)O)O)O)O)O)O)C
DM349AM	IK	1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-69-45-41(65)34(58)26(57)21-68-45)24-11-16-52(7)33(24)25(56)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)36(60)28(20-55)71-48)74-46-42(66)38(62)35(59)27(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26-,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39-,40-,41+,42+,43+,44+,45-,46-,47-,48-,50-,51+,52+,53-/m0/s1
DM349AM	IU	(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM349AM	CA	CAS 11021-13-9
DM349AM	CB	CHEBI:77152
DM349AM	DE	Rotavirus gastroenteritis

DML4IAX	ID	DML4IAX
DML4IAX	DN	HY-N2258
DML4IAX	HS	Preclinical
DML4IAX	SN	Citrifolioside; Poncirin; Poncirin, analytical standard; SCHEMBL123069; SureCN123069; ZINC8234320; (2S)-poncirin; 14941-08-3; 8MUY4P95B4; AKOS037514792; CHEBI:66773; CHEMBL451050; CP0093; DTXSID00933642; EINECS 239-020-1; HY-N2258; Isosakuranetin 7-O-neohesperidoside; NLAWPKPYBMEWIR-SKYQDXIQSA-N; Isosakuranetin-7-O-beta-D-neohesperidoside; Isosakuranetin-7-O-neohesperidoside; NCGC00163611-01; UNII-8MUY4P95B4; s9165
DML4IAX	PC	442456
DML4IAX	MW	594.6
DML4IAX	FM	C28H34O14
DML4IAX	IC	NLAWPKPYBMEWIR-SKYQDXIQSA-N
DML4IAX	CS	CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC=C(C=C5)OC)O)CO)O)O)O)O)O
DML4IAX	IK	1S/C28H34O14/c1-11-21(32)23(34)25(36)27(38-11)42-26-24(35)22(33)19(10-29)41-28(26)39-14-7-15(30)20-16(31)9-17(40-18(20)8-14)12-3-5-13(37-2)6-4-12/h3-8,11,17,19,21-30,32-36H,9-10H2,1-2H3/t11-,17-,19+,21-,22+,23+,24-,25+,26+,27-,28+/m0/s1
DML4IAX	IU	(2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
DML4IAX	CA	CAS 14941-08-3
DML4IAX	CB	CHEBI:66773
DML4IAX	DE	Anaesthesia

DMXB95R	ID	DMXB95R
DMXB95R	DN	IC261
DMXB95R	HS	Preclinical
DMXB95R	SN	IC-261; IC 261
DMXB95R	DT	Small molecular drug
DMXB95R	PC	5288600
DMXB95R	MW	311.3
DMXB95R	FM	C18H17NO4
DMXB95R	IC	InChI=1S/C18H17NO4/c1-21-11-8-16(22-2)14(17(9-11)23-3)10-13-12-6-4-5-7-15(12)19-18(13)20/h4-10H,1-3H3,(H,19,20)/b13-10+
DMXB95R	CS	COC1=CC(=C(C(=C1)OC)/C=C/2\\C3=CC=CC=C3NC2=O)OC
DMXB95R	IK	JBJYTZXCZDNOJW-JLHYYAGUSA-N
DMXB95R	IU	(3E)-3-[(2,4,6-trimethoxyphenyl)methylidene]-1H-indol-2-one
DMXB95R	DE	Pancreatic cancer

DM1RZVI	ID	DM1RZVI
DM1RZVI	DN	ICA-69673
DM1RZVI	HS	Preclinical
DM1RZVI	SN	ICA-069673; Ion channel modulators (epilepsy), ICAgen; Ion channel modulators, ICAgen/ArQule
DM1RZVI	CP	Icagen Inc
DM1RZVI	PC	10149311
DM1RZVI	MW	269.63
DM1RZVI	FM	C11H6ClF2N3O
DM1RZVI	IC	InChI=1S/C11H6ClF2N3O/c12-11-15-4-7(5-16-11)17-10(18)6-1-2-8(13)9(14)3-6/h1-5H,(H,17,18)
DM1RZVI	CS	C1=CC(=C(C=C1C(=O)NC2=CN=C(N=C2)Cl)F)F
DM1RZVI	IK	IIBSHMFXVWTQSJ-UHFFFAOYSA-N
DM1RZVI	IU	N-(2-chloropyrimidin-5-yl)-3,4-difluorobenzamide
DM1RZVI	CA	CAS 582323-16-8
DM1RZVI	DE	Pain

DMIYSD4	ID	DMIYSD4
DMIYSD4	DN	IDDB-41331
DMIYSD4	HS	Preclinical
DMIYSD4	CP	Amgen
DMIYSD4	DE	Obesity

DMQ3BXV	ID	DMQ3BXV
DMQ3BXV	DN	IDDBCP-150101
DMQ3BXV	HS	Preclinical
DMQ3BXV	CP	Amgen
DMQ3BXV	DE	Sexual dysfunction; Obesity

DMRIMZL	ID	DMRIMZL
DMRIMZL	DN	IDX136
DMRIMZL	HS	Preclinical
DMRIMZL	CP	Idenix
DMRIMZL	DE	Hepatitis C virus infection

DMXN2ZQ	ID	DMXN2ZQ
DMXN2ZQ	DN	IMO-2134
DMXN2ZQ	HS	Preclinical
DMXN2ZQ	CP	Idera Pharmaceuticals
DMXN2ZQ	DE	Allergy; Asthma

DMV5KSA	ID	DMV5KSA
DMV5KSA	DN	IMX-942
DMV5KSA	HS	Preclinical
DMV5KSA	SN	IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex
DMV5KSA	CP	Inimex Pharmaceuticals Inc
DMV5KSA	DE	Mucositis

DMXJO20	ID	DMXJO20
DMXJO20	DN	Indol-3-carbinol
DMXJO20	HS	Preclinical
DMXJO20	SN	Pinusolide; 31685-80-0; CHEBI:69237; 1-Naphthalenecarboxylicacid,5-[2-(2,5-dihydro-2-oxo-3-furanyl)ethyl]decahydro-1,4a-dimethyl-6-methylene-,methyl ester, (1S,4aR,5S,8aR)-; AC1L4PYK; CHEMBL425068; CTK4G7584; MolPort-039-052-550; ZINC6067611; AKOS032948704; methyl (1S,4aR,5S,8aR)-1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylate; 1-Naphthalenecarboxylic acid, 5-(2-(2,5-dihydro-2-oxo-3-furanyl)ethyl)decahydro-1,4a-dimethyl-6-methylene-, methyl ester,
DMXJO20	TC	Antifungal Agents
DMXJO20	DT	Small molecular drug
DMXJO20	PC	161721
DMXJO20	MW	346.5
DMXJO20	FM	C21H30O4
DMXJO20	IC	InChI=1S/C21H30O4/c1-14-6-9-17-20(2,11-5-12-21(17,3)19(23)24-4)16(14)8-7-15-10-13-25-18(15)22/h10,16-17H,1,5-9,11-13H2,2-4H3/t16-,17+,20+,21-/m0/s1
DMXJO20	CS	C[C@]12CCC[C@]([C@@H]1CCC(=C)[C@@H]2CCC3=CCOC3=O)(C)C(=O)OC
DMXJO20	IK	WTKBZJAWPZXKJU-NLEAXPPASA-N
DMXJO20	IU	methyl (1S,4aR,5S,8aR)-1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylate
DMXJO20	CA	CAS 31685-80-0
DMXJO20	CB	CHEBI:69237
DMXJO20	DE	Fungal infection

DMBQGZ9	ID	DMBQGZ9
DMBQGZ9	DN	INOC-005
DMBQGZ9	HS	Preclinical
DMBQGZ9	SN	Capridine beta (prostate cancer), Prostagenics
DMBQGZ9	CP	Prostagenics LLC
DMBQGZ9	DE	Solid tumour/cancer

DMRJ9P4	ID	DMRJ9P4
DMRJ9P4	DN	INT-767
DMRJ9P4	HS	Preclinical
DMRJ9P4	SN	INT-767 sodium; 1000403-03-1 (sodium); 1000403-03-1; sodium (R)-3-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)butyl sulfate; CS-5007; HY-12434; Sulfuric acid sodium 3alpha,7alpha-dihydroxy-6alpha-ethyl-24-nor-5beta-cholane-23-yl ester salt
DMRJ9P4	CP	Intercept
DMRJ9P4	DT	Small molecular drug
DMRJ9P4	PC	23712772
DMRJ9P4	MW	494.7
DMRJ9P4	FM	C25H43NaO6S
DMRJ9P4	IC	InChI=1S/C25H44O6S.Na/c1-5-17-21-14-16(26)8-11-25(21,4)20-9-12-24(3)18(6-7-19(24)22(20)23(17)27)15(2)10-13-31-32(28,29)30;/h15-23,26-27H,5-14H2,1-4H3,(H,28,29,30);/q;+1/p-1/t15-,16-,17-,18-,19+,20+,21+,22+,23-,24-,25-;/m1./s1
DMRJ9P4	CS	CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCOS(=O)(=O)[O-])C)C)O.[Na+]
DMRJ9P4	IK	TXIWHUPIUUZFFK-PMWRKVJASA-M
DMRJ9P4	IU	sodium;[(3R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl] sulfate
DMRJ9P4	DE	Hepatic fibrosis

DMMUVAF	ID	DMMUVAF
DMMUVAF	DN	IRX-4
DMMUVAF	HS	Preclinical
DMMUVAF	SN	IRX-2 + tumor-specific antigen (cancer), IRx Therapeutics
DMMUVAF	CP	IRX Therapeutics Inc
DMMUVAF	DE	Prostate cancer

DMJ0A2R	ID	DMJ0A2R
DMJ0A2R	DN	IU1
DMJ0A2R	HS	Preclinical
DMJ0A2R	SN	314245-33-5; 1-[1-(4-Fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(1-pyrrolidinyl)ethanone; 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one; IU-1; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethanone; CHEMBL1410015; MFCD01917473; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethan-1-one; 1-[1-(4-Fluoro-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone; Usp14 inhibitor; MLS001032847; GTPL8880; SCHEMBL6923146; ZINC38235; DTXSID80350196; HMS1726C11; HMS2742M13; HMS3653I09; HMS3743A07; AMY24153; BCP12722; EX-A2079; 2486AH; BDBM50437694; s7134; AKOS000811299; IU1, >=98% (HPLC); CCG-190730; CS-7546; MCULE-9620933012; NE48827; QC-8208; SB19054; NCGC00249377-01; NCGC00249377-04; NCGC00249377-08; AC-32694; DA-33458; HY-13817; SMR000363441; ST054127; AB0097167; FT-0716455; MLS001032847-02; SW219677-1; EN300-72884; SR-01000010584; J-018415; SR-01000010584-1; Z55133506; F1142-1244; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidinylethan-1-one; 1-[1-(4-FLUOROPHENYL)-2,5-DIMETHYLPYRROL-3-YL]-2-(PYRROLIDIN-1-YL)ETHANONE
DMJ0A2R	CP	Proteostasis Therapeutics
DMJ0A2R	DT	Small molecular drug
DMJ0A2R	PC	675434
DMJ0A2R	MW	300.4
DMJ0A2R	FM	C18H21FN2O
DMJ0A2R	IC	InChI=1S/C18H21FN2O/c1-13-11-17(18(22)12-20-9-3-4-10-20)14(2)21(13)16-7-5-15(19)6-8-16/h5-8,11H,3-4,9-10,12H2,1-2H3
DMJ0A2R	CS	CC1=CC(=C(N1C2=CC=C(C=C2)F)C)C(=O)CN3CCCC3
DMJ0A2R	IK	JUWDSDKJBMFLHE-UHFFFAOYSA-N
DMJ0A2R	IU	1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone
DMJ0A2R	CA	CAS 314245-33-5
DMJ0A2R	DE	Neurodegenerative disorder

DMTGI64	ID	DMTGI64
DMTGI64	DN	JD-5037
DMTGI64	HS	Preclinical
DMTGI64	CP	Jenrin Discovery Inc.
DMTGI64	PC	66553204
DMTGI64	MW	572.5
DMTGI64	FM	C27H27Cl2N5O3S
DMTGI64	IC	InChI=1S/C27H27Cl2N5O3S/c1-17(2)24(26(30)35)31-27(33-38(36,37)22-14-12-21(29)13-15-22)34-16-23(18-6-4-3-5-7-18)25(32-34)19-8-10-20(28)11-9-19/h3-15,17,23-24H,16H2,1-2H3,(H2,30,35)(H,31,33)/t23-,24+/m1/s1
DMTGI64	CS	CC(C)[C@@H](C(=O)N)N=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4
DMTGI64	IK	GTCSIQFTNPTSLO-RPWUZVMVSA-N
DMTGI64	IU	(2S)-2-[[[(4S)-5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-[(4-chlorophenyl)sulfonylamino]methylidene]amino]-3-methylbutanamide
DMTGI64	CA	CAS 1392116-14-1
DMTGI64	DE	Diabetic complication; Obesity

DMSXOPE	ID	DMSXOPE
DMSXOPE	DN	JNJ-26070109
DMSXOPE	HS	Preclinical
DMSXOPE	SN	CCK2 receptor antagonists, (oral, cancer); CCK2 receptor antagonists, (oral, cancer),Johnson & Johnson Pharmaceutical Research & Development
DMSXOPE	CP	Johnson & Johnson Pharmaceutical Research & Development LLC
DMSXOPE	DT	Small molecular drug
DMSXOPE	PC	11307323
DMSXOPE	MW	547.4
DMSXOPE	FM	C23H17BrF2N4O3S
DMSXOPE	IC	InChI=1S/C23H17BrF2N4O3S/c1-13(16-8-6-15(25)12-18(16)26)29-23(31)17-7-5-14(24)11-20(17)30-34(32,33)21-4-2-3-19-22(21)28-10-9-27-19/h2-13,30H,1H3,(H,29,31)/t13-/m1/s1
DMSXOPE	CS	C[C@H](C1=C(C=C(C=C1)F)F)NC(=O)C2=C(C=C(C=C2)Br)NS(=O)(=O)C3=CC=CC4=NC=CN=C43
DMSXOPE	IK	TZKCPFFVWLRNRZ-CYBMUJFWSA-N
DMSXOPE	IU	4-bromo-N-[(1R)-1-(2,4-difluorophenyl)ethyl]-2-(quinoxalin-5-ylsulfonylamino)benzamide
DMSXOPE	DE	Gastroesophageal reflux disease

DMCNBHY	ID	DMCNBHY
DMCNBHY	DN	JNJ-42905343
DMCNBHY	HS	Preclinical
DMCNBHY	CP	Janssen
DMCNBHY	DT	Small molecular drug
DMCNBHY	DE	Anaemia; Iron deficiency

DMHBWOP	ID	DMHBWOP
DMHBWOP	DN	JT07
DMHBWOP	HS	Preclinical
DMHBWOP	CP	Jyant Technologies
DMHBWOP	DT	Antibody
DMHBWOP	DE	Solid tumour/cancer

DM8OAZ6	ID	DM8OAZ6
DM8OAZ6	DN	JT08
DM8OAZ6	HS	Preclinical
DM8OAZ6	CP	Jyant Technologies
DM8OAZ6	DT	Antibody
DM8OAZ6	DE	Solid tumour/cancer

DM86YBK	ID	DM86YBK
DM86YBK	DN	K11777
DM86YBK	HS	Preclinical
DM86YBK	SN	N-methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl
DM86YBK	TC	Antiviral Agents
DM86YBK	DT	Small molecular drug
DM86YBK	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMIQXEP	ID	DMIQXEP
DMIQXEP	DN	KD-3020
DMIQXEP	HS	Preclinical
DMIQXEP	CP	Kalypsys
DMIQXEP	DE	Non-alcoholic fatty liver disease

DML93TN	ID	DML93TN
DML93TN	DN	Kestose
DML93TN	HS	Preclinical
DML93TN	SN	Kestose; Kestose, 6-; Q27133478; (Fruf)2 (Glc)1; 562-68-5; 6-Kestose; 6-kestotriose; AAE9A8CC-2223-4E2E-84C7-100A261F8834; Beta-D-Fructofuranosyl-(2-&gt;6)-Beta-D-Fructofuranosyl Alpha-D-Glucopyranoside; CHEBI:64833; EINECS 209-232-9; G7AZF7CGY8; O-beta-D-Fructofuranosyl-(2.6)-beta-D-fructofuranosyl-alpha-D-glucopyranoside; UNII-19B0LEI158 component ODEHMIGXGLNAKK-OESPXIITSA-N; UNII-G7AZF7CGY8; UNII-YUH1C99228 component ODEHMIGXGLNAKK-OESPXIITSA-N
DML93TN	PC	9914062
DML93TN	MW	504.4
DML93TN	FM	C18H32O16
DML93TN	IC	ODEHMIGXGLNAKK-OESPXIITSA-N
DML93TN	CS	C(C1C(C(C(C(O1)OC2(C(C(C(O2)COC3(C(C(C(O3)CO)O)O)CO)O)O)CO)O)O)O)O
DML93TN	IK	1S/C18H32O16/c19-1-6-9(23)12(26)13(27)16(31-6)34-18(5-22)15(29)11(25)8(33-18)3-30-17(4-21)14(28)10(24)7(2-20)32-17/h6-16,19-29H,1-5H2/t6-,7-,8-,9-,10-,11-,12+,13-,14+,15+,16-,17-,18+/m1/s1
DML93TN	IU	(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-5-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DML93TN	CA	CAS 562-68-5
DML93TN	CB	CHEBI:64833
DML93TN	DE	Atopic dermatitis

DMHX1LA	ID	DMHX1LA
DMHX1LA	DN	KL001
DMHX1LA	HS	Preclinical
DMHX1LA	SN	309928-48-1; N-(3-(9H-carbazol-9-yl)-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; SMR000106264; MLS000110334; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; KL-001; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-[(furan-2-yl)methyl]methanesulfonamide; N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-(furan-2-ylmethyl)methanesulfonamide; CBMicro_005790; ChemDiv2_003790; Oprea1_152161; Oprea1_419357; MLS002540427; MLS006011739; CHEMBL1498001; SCHEMBL15380452; BDBM56256; cid_2888648; HMS1379M06; HMS2371E17; SMSF0015860; STK839587; AKOS000581142; AKOS016386481; CB08282; MCULE-8116422943; IDI1_002505; NCGC00079434-02; NCGC00079434-03; NCGC00079434-06; BIM-0006034.P001; KL001(KL-001;KL 001); EU-0005302; ST50257205; 10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; doi:10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; SR-01000436091; SR-01000436091-1; BRD-A94580299-001-08-8; F1345-0456; (3-carbazol-9-yl-2-hydroxypropyl)(2-furylmethyl)(methylsulfonyl)amine; N-(3-carbazol-9-yl-2-hydroxy-propyl)-N-(2-furfuryl)methanesulfonamide; N-[3-(9-carbazolyl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-oxidanyl-propyl)-N-(furan-2-ylmethyl)methanesulfonamide
DMHX1LA	DT	Small molecular drug
DMHX1LA	PC	2888648
DMHX1LA	MW	398.5
DMHX1LA	FM	C21H22N2O4S
DMHX1LA	IC	InChI=1S/C21H22N2O4S/c1-28(25,26)22(15-17-7-6-12-27-17)13-16(24)14-23-20-10-4-2-8-18(20)19-9-3-5-11-21(19)23/h2-12,16,24H,13-15H2,1H3
DMHX1LA	CS	CS(=O)(=O)N(CC1=CC=CO1)CC(CN2C3=CC=CC=C3C4=CC=CC=C42)O
DMHX1LA	IK	OQAFDLPAPSSOHY-UHFFFAOYSA-N
DMHX1LA	IU	N-(3-carbazol-9-yl-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide
DMHX1LA	DE	Glioblastoma of brain

DMFLIC0	ID	DMFLIC0
DMFLIC0	DN	KOS-1803
DMFLIC0	HS	Preclinical
DMFLIC0	SN	Isoxazole-fludelone; SK-10105; Third generation epothilone (cancer), Bristol-Myers Squibb; Third generation epothilone (cancer),Kosan/Roche; 9,10-didehydro-26-trifluoro-isoazole-epothilone D
DMFLIC0	CP	Memorial Sloan-Kettering Cancer Center
DMFLIC0	PC	10436928
DMFLIC0	MW	527.6
DMFLIC0	FM	C27H36F3NO6
DMFLIC0	IC	InChI=1S/C27H36F3NO6/c1-15-8-7-9-19(27(28,29)30)10-11-21(16(2)12-20-13-17(3)37-31-20)36-23(33)14-22(32)26(5,6)25(35)18(4)24(15)34/h7-8,10,12-13,15,18,21-22,24,32,34H,9,11,14H2,1-6H3/b8-7+,16-12+,19-10+/t15-,18+,21-,22-,24-/m0/s1
DMFLIC0	CS	C[C@H]1/C=C/C/C(=C\\C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C2=NOC(=C2)C)/C)/C(F)(F)F
DMFLIC0	IK	DNCHSYUWCVTLJJ-PHNYORQKSA-N
DMFLIC0	IU	(4S,7R,8S,9S,10E,13E,16S)-4,8-dihydroxy-5,5,7,9-tetramethyl-16-[(E)-1-(5-methyl-1,2-oxazol-3-yl)prop-1-en-2-yl]-13-(trifluoromethyl)-1-oxacyclohexadeca-10,13-diene-2,6-dione
DMFLIC0	DE	Solid tumour/cancer

DMCGFY6	ID	DMCGFY6
DMCGFY6	DN	KOS-1815
DMCGFY6	HS	Preclinical
DMCGFY6	SN	CRM1 and nuclear export inhibitors (cancer); KOS-2385; KOS-2464; CRM1 and nuclear export inhibitors (cancer), Kosan
DMCGFY6	CP	Kosan Biosciences Inc
DMCGFY6	DE	Solid tumour/cancer

DMXY81K	ID	DMXY81K
DMXY81K	DN	KOS-2484
DMXY81K	HS	Preclinical
DMXY81K	SN	KOS-2539; KOS-2540; HSP90 inhibitors (cancer), Kosan
DMXY81K	CP	Kosan Biosciences Inc
DMXY81K	DE	Solid tumour/cancer

DMZCW3J	ID	DMZCW3J
DMZCW3J	DN	KP3
DMZCW3J	HS	Preclinical
DMZCW3J	DT	Antibody
DMZCW3J	DE	Pneumonia due to Klebsiella pneumoniae

DMMEH12	ID	DMMEH12
DMMEH12	DN	L-006235-1
DMMEH12	HS	Preclinical
DMMEH12	SN	294623-49-7; L 006235; CHEMBL426819; N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)benzamide; L006235; N-[1-[[(Cyanomethyl)amino]carbonyl]cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzamide; L-006235-1; SCHEMBL6183485; CTK8E9371; BDBM19854; DTXSID90432735; MolPort-023-276-653; BCP28510; ZINC3993799; AKOS024457410; basic piperazine-containing compound, 1; NCGC00371088-01; RT-013466; CRA-013783/L-006235; J-017526; L-006235; L-006,235
DMMEH12	DT	Small molecular drug
DMMEH12	PC	9912381
DMMEH12	MW	466.6
DMMEH12	FM	C24H30N6O2S
DMMEH12	IC	InChI=1S/C24H30N6O2S/c1-29-13-15-30(16-14-29)23-27-20(17-33-23)18-5-7-19(8-6-18)21(31)28-24(9-3-2-4-10-24)22(32)26-12-11-25/h5-8,17H,2-4,9-10,12-16H2,1H3,(H,26,32)(H,28,31)
DMMEH12	CS	CN1CCN(CC1)C2=NC(=CS2)C3=CC=C(C=C3)C(=O)NC4(CCCCC4)C(=O)NCC#N
DMMEH12	IK	FIVYCSWOCXEWSE-UHFFFAOYSA-N
DMMEH12	IU	N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzamide
DMMEH12	CA	CAS 294623-49-7
DMMEH12	DE	Osteoarthritis

DMK3TXY	ID	DMK3TXY
DMK3TXY	DN	L-742791
DMK3TXY	HS	Preclinical
DMK3TXY	SN	CHEMBL276257; SCHEMBL289708; L-742791; GTPL3467; compound 3 [PMID:9873496]; BDBM50070152; L742791; L 742791; L-742,791; N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-iodobenzenesulfonamide
DMK3TXY	CP	Merck
DMK3TXY	DT	Small molecular drug
DMK3TXY	PC	16118894
DMK3TXY	MW	568.4
DMK3TXY	FM	C23H25IN2O5S
DMK3TXY	IC	InChI=1S/C23H25IN2O5S/c24-18-3-11-23(12-4-18)32(29,30)26-19-5-1-17(2-6-19)13-14-25-15-21(28)16-31-22-9-7-20(27)8-10-22/h1-12,21,25-28H,13-16H2/t21-/m0/s1
DMK3TXY	CS	C1=CC(=CC=C1CCNC[C@@H](COC2=CC=C(C=C2)O)O)NS(=O)(=O)C3=CC=C(C=C3)I
DMK3TXY	IK	ZNTDIRUBXSTBGJ-NRFANRHFSA-N
DMK3TXY	IU	N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-iodobenzenesulfonamide
DMK3TXY	DE	Obesity

DMOERXK	ID	DMOERXK
DMOERXK	DN	L-751250
DMOERXK	HS	Preclinical
DMOERXK	SN	Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB
DMOERXK	CP	Merck
DMOERXK	DT	Small molecular drug
DMOERXK	PC	448991
DMOERXK	MW	432.9
DMOERXK	FM	C20H25ClN6O3
DMOERXK	IC	InChI=1S/C20H25ClN6O3/c1-10(2)15(8-28)24-20-25-17(16-18(26-20)27(9-22-16)11(3)4)23-12-5-6-13(19(29)30)14(21)7-12/h5-7,9-11,15,28H,8H2,1-4H3,(H,29,30)(H2,23,24,25,26)/t15-/m0/s1
DMOERXK	CS	CC(C)[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=C(C=C3)C(=O)O)Cl
DMOERXK	IK	ZKDXRFMOHZVXSG-HNNXBMFYSA-N
DMOERXK	IU	2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid
DMOERXK	CA	CAS 212844-54-7
DMOERXK	CB	CHEBI:49840
DMOERXK	DE	Obesity

DMFBMXD	ID	DMFBMXD
DMFBMXD	DN	LAS-101057
DMFBMXD	HS	Preclinical
DMFBMXD	SN	LAS-38096; Adenosine A2b receptor antagonists (inflammation), Almirall
DMFBMXD	CP	Almirall Prodesfarma SA
DMFBMXD	DT	Small molecular drug
DMFBMXD	PC	11716665
DMFBMXD	MW	316.32
DMFBMXD	FM	C17H12N6O
DMFBMXD	IC	InChI=1S/C17H12N6O/c1-3-12(9-18-6-1)22-17-20-10-13(14-5-7-19-11-21-14)16(23-17)15-4-2-8-24-15/h1-11H,(H,20,22,23)
DMFBMXD	CS	C1=CC(=CN=C1)NC2=NC=C(C(=N2)C3=CC=CO3)C4=NC=NC=C4
DMFBMXD	IK	YRPIMMMBNUUYLG-UHFFFAOYSA-N
DMFBMXD	IU	4-(furan-2-yl)-N-pyridin-3-yl-5-pyrimidin-4-ylpyrimidin-2-amine
DMFBMXD	CA	CAS 851371-22-7
DMFBMXD	DE	Asthma

DM1982I	ID	DM1982I
DM1982I	DN	LDN-57444
DM1982I	HS	Preclinical
DM1982I	SN	668467-91-2; CHEMBL3407553; LDN 57444; (Z)-3-(acetoxyimino)-5-chloro-1-(2,5-dichlorobenzyl)indolin-2-one; C17H11Cl3N2O3; LDN57444; Ubiquitin Thiolesterase L1 Inhibitor; Ubiquitin C-Terminal Esterase L1 Inhibitor; Ubiquitin C-Terminal Hydrolase L1 Inhibitor; SCHEMBL16249746; BDBM65518; AOB1095; EX-A700; 5-Chloro-1-[(2,5-dichlorophenyl)methyl]-1H-indole-2,3-dione 3-(O-acetyloxime); 2511AH; BDBM50514120; MFCD09037562; ZINC83434034; AKOS025295611; CS-3923; 3-(O-acetyloxime), 5-chloro-1-[(2,5-dichlorophenyl)methyl]-1H-Indole-2,3-dione; NCGC00247668-01; AC-32696; AS-56100; HY-18637; SW219408-1; LDN-57444, >=98% (HPLC); [(E)-[5-Chloro-1-[(2,5-dichlorophenyl)methyl]-2-oxoindol-3-ylidene]amino] acetate
DM1982I	CP	Brigham and Women's Hospital
DM1982I	DT	Small molecular drug
DM1982I	PC	16760696
DM1982I	MW	397.6
DM1982I	FM	C17H11Cl3N2O3
DM1982I	IC	InChI=1S/C17H11Cl3N2O3/c1-9(23)25-21-16-13-7-12(19)3-5-15(13)22(17(16)24)8-10-6-11(18)2-4-14(10)20/h2-7H,8H2,1H3/b21-16-
DM1982I	CS	CC(=O)O/N=C\\1/C2=C(C=CC(=C2)Cl)N(C1=O)CC3=C(C=CC(=C3)Cl)Cl
DM1982I	IK	OPQRFPHLZZPCCH-PGMHBOJBSA-N
DM1982I	IU	[(Z)-[5-chloro-1-[(2,5-dichlorophenyl)methyl]-2-oxoindol-3-ylidene]amino] acetate
DM1982I	DE	Solid tumour/cancer

DMGJL16	ID	DMGJL16
DMGJL16	DN	LE-300
DMGJL16	HS	Preclinical
DMGJL16	SN	L 8401; LE 300; 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine
DMGJL16	CP	Sanofi-Aventis
DMGJL16	DT	Small molecular drug
DMGJL16	PC	4350931
DMGJL16	MW	290.4
DMGJL16	FM	C20H22N2
DMGJL16	IC	InChI=1S/C20H22N2/c1-22-12-10-15-6-2-3-7-16(15)14-20-18(11-13-22)17-8-4-5-9-19(17)21-20/h2-9,21H,10-14H2,1H3
DMGJL16	CS	CN1CCC2=CC=CC=C2CC3=C(CC1)C4=CC=CC=C4N3
DMGJL16	IK	YEWGIGCYIAMFMA-UHFFFAOYSA-N
DMGJL16	IU	11-methyl-11,21-diazatetracyclo[12.7.0.03,8.015,20]henicosa-1(14),3,5,7,15,17,19-heptaene
DMGJL16	CA	CAS 274694-98-3
DMGJL16	CB	CHEBI:92030
DMGJL16	DE	Schizophrenia

DMJXZIS	ID	DMJXZIS
DMJXZIS	DN	LH846
DMJXZIS	HS	Preclinical
DMJXZIS	SN	639052-78-1; LH-846; LH 846; N-(5-chloro-6-methyl-1,3-benzothiazol-2-yl)-2-phenylacetamide; N-(5-Chloro-6-methyl-2-benzothiazolyl)benzeneacetamide; Benzeneacetamide, N-(5-chloro-6-methyl-2-benzothiazolyl)-; N-(5-chloro-6-methylbenzo[d]thiazol-2-yl)-2-phenylacetamide; N-(5-Chloro-6-methyl-benzothiazol-2-yl)-2-phenyl-acetamide; Oprea1_693221; CHEMBL4303305; SCHEMBL18921565; AOB3510; ZINC386312; BCP09669; EX-A2092; 3782AH; MFCD03786038; STK241276; AKOS000461714; CCG-357108; CS-1810; MCULE-4592612500; NCGC00371143-05; AK205552; AS-55880; DA-33437; HY-15704; FT-0768032; ST51028673; AP-970/41681903; N-(5-chloro-6-methylbenzothiazol-2-yl)-2-phenylacetamide
DMJXZIS	DT	Small molecular drug
DMJXZIS	PC	851474
DMJXZIS	MW	316.8
DMJXZIS	FM	C16H13ClN2OS
DMJXZIS	IC	InChI=1S/C16H13ClN2OS/c1-10-7-14-13(9-12(10)17)18-16(21-14)19-15(20)8-11-5-3-2-4-6-11/h2-7,9H,8H2,1H3,(H,18,19,20)
DMJXZIS	CS	CC1=CC2=C(C=C1Cl)N=C(S2)NC(=O)CC3=CC=CC=C3
DMJXZIS	IK	DYHAMRNAHTWYKY-UHFFFAOYSA-N
DMJXZIS	IU	N-(5-chloro-6-methyl-1,3-benzothiazol-2-yl)-2-phenylacetamide
DMJXZIS	DE	Mood disorder

DMNOE1M	ID	DMNOE1M
DMNOE1M	DN	LLY-507
DMNOE1M	HS	Preclinical
DMNOE1M	SN	LLY-507; 1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126
DMNOE1M	DT	Small molecular drug
DMNOE1M	PC	91623361
DMNOE1M	MW	574.8
DMNOE1M	FM	C36H42N6O
DMNOE1M	IC	InChI=1S/C36H42N6O/c1-28-27-42(34-11-4-2-9-32(28)34)22-19-40-17-20-41(21-18-40)35-12-5-3-10-33(35)30-23-29(26-37)24-31(25-30)36(43)38-13-8-16-39-14-6-7-15-39/h2-5,9-12,23-25,27H,6-8,13-22H2,1H3,(H,38,43)
DMNOE1M	CS	CC1=CN(C2=CC=CC=C12)CCN3CCN(CC3)C4=CC=CC=C4C5=CC(=CC(=C5)C#N)C(=O)NCCCN6CCCC6
DMNOE1M	IK	PNYRDVBFYVDJJI-UHFFFAOYSA-N
DMNOE1M	IU	3-cyano-5-[2-[4-[2-(3-methylindol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-(3-pyrrolidin-1-ylpropyl)benzamide
DMNOE1M	DE	Solid tumour/cancer

DMXYDMP	ID	DMXYDMP
DMXYDMP	DN	LM10
DMXYDMP	HS	Preclinical
DMXYDMP	SN	1316695-35-8; (E)-3-(2-(1H-TETRAZOL-5-YL)VINYL)-6-FLUORO-1H-INDOLE; CHEMBL1812545; LM-10; 6-fluoro-3-[(E)-2-(1H-1,2,3,4-tetrazol-5-yl)ethenyl]-1H-indole; 6-Fluoro-3-[(1E)-2-(2H-tetrazol-5-yl)ethenyl]-1H-indole; 1H-Indole, 6-fluoro-3-[(1E)-2-(2H-tetrazol-5-yl)ethenyl]-; LM 10; GTPL9016; SCHEMBL16820602; SCHEMBL16820603; BDBM311862; CS-D0342; BDBM50350248; MFCD26097257; s8368; US10155972, Compound LM10; ZINC72108665; AKOS024464444; CCG-266788; AS-30527; Q27081058
DMXYDMP	DT	Small molecular drug
DMXYDMP	PC	135743630
DMXYDMP	MW	229.21
DMXYDMP	FM	C11H8FN5
DMXYDMP	IC	InChI=1S/C11H8FN5/c12-8-2-3-9-7(6-13-10(9)5-8)1-4-11-14-16-17-15-11/h1-6,13H,(H,14,15,16,17)/b4-1+
DMXYDMP	CS	C1=CC2=C(C=C1F)NC=C2/C=C/C3=NNN=N3
DMXYDMP	IK	JDBSZVDIUIRSDG-DAFODLJHSA-N
DMXYDMP	IU	6-fluoro-3-[(E)-2-(2H-tetrazol-5-yl)ethenyl]-1H-indole
DMXYDMP	DE	Solid tumour/cancer

DMNIWF5	ID	DMNIWF5
DMNIWF5	DN	Lopinavir
DMNIWF5	HS	Preclinical
DMNIWF5	SN	AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346; A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378
DMNIWF5	CP	Abbott Laboratories
DMNIWF5	TC	Antiviral Agents
DMNIWF5	DT	Small molecular drug
DMNIWF5	PC	92727
DMNIWF5	MW	628.8
DMNIWF5	FM	C37H48N4O5
DMNIWF5	IC	InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
DMNIWF5	CS	CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
DMNIWF5	IK	KJHKTHWMRKYKJE-SUGCFTRWSA-N
DMNIWF5	IU	(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
DMNIWF5	CA	CAS 192725-17-0
DMNIWF5	CB	CHEBI:31781
DMNIWF5	DE	Human immunodeficiency virus infection; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM0URLP	ID	DM0URLP
DM0URLP	DN	Lopinavir + ritonavir + interferon alpha
DM0URLP	HS	Preclinical
DM0URLP	SN	Aluviran + norvir + interferon apha
DM0URLP	TC	Antiviral Agents
DM0URLP	DT	Combination drug
DM0URLP	DE	Coronavirus Disease 2019 (COVID-19)

DMV1A25	ID	DMV1A25
DMV1A25	DN	LpxC-1
DMV1A25	HS	Preclinical
DMV1A25	DT	Small molecular drug
DMV1A25	DE	Acinetobacter baumannii infection

DM7XPDB	ID	DM7XPDB
DM7XPDB	DN	LY-2463665
DM7XPDB	HS	Preclinical
DM7XPDB	CP	Eli Lilly
DM7XPDB	DE	Type-2 diabetes

DM2N637	ID	DM2N637
DM2N637	DN	LY-25582
DM2N637	HS	Preclinical
DM2N637	SN	3-[1-(3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; LY-255582; LY255582; CHEMBL300662; 119193-09-8; LY 255582; SCHEMBL2740453; AOB5354; (3R,4R)3-[1-(3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; ZINC3783617; BDBM50045775; NCGC00408804-01; AS-16869; LY255582, &gt; 3-[(3R,4R)-1-((S)-3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; 3-((3R,4R)-1-((S)-3-cyclohexyl-3-hydroxypropyl)-3,4-dimethylpiperidin-4-yl)phenol; 1-Piperidinepropanol,
DM2N637	CP	Eli Lilly
DM2N637	DT	Small molecular drug
DM2N637	PC	9906198
DM2N637	MW	345.5
DM2N637	FM	C22H35NO2
DM2N637	IC	InChI=1S/C22H35NO2/c1-17-16-23(13-11-21(25)18-7-4-3-5-8-18)14-12-22(17,2)19-9-6-10-20(24)15-19/h6,9-10,15,17-18,21,24-25H,3-5,7-8,11-14,16H2,1-2H3/t17-,21-,22+/m0/s1
DM2N637	CS	C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)CC[C@@H](C3CCCCC3)O
DM2N637	IK	LVVHEFJXPXAUDD-BULFRSBZSA-N
DM2N637	IU	3-[(3R,4R)-1-[(3S)-3-cyclohexyl-3-hydroxypropyl]-3,4-dimethylpiperidin-4-yl]phenol
DM2N637	CA	CAS 119193-09-8
DM2N637	DE	Obesity

DMUFIO9	ID	DMUFIO9
DMUFIO9	DN	M102
DMUFIO9	HS	Preclinical
DMUFIO9	CP	Aclipse Therapeutics
DMUFIO9	DE	Amyotrophic lateral sclerosis

DM7HUVB	ID	DM7HUVB
DM7HUVB	DN	m337
DM7HUVB	HS	Preclinical
DM7HUVB	DT	Antibody
DM7HUVB	DE	Coronavirus infection

DM32XJS	ID	DM32XJS
DM32XJS	DN	M64
DM32XJS	HS	Preclinical
DM32XJS	DT	Small molecular drug
DM32XJS	DE	Pseudomonas infection

DM5IMAU	ID	DM5IMAU
DM5IMAU	DN	MAb173
DM5IMAU	HS	Preclinical
DM5IMAU	DT	Antibody
DM5IMAU	DE	Kaposi sarcoma

DMNO20J	ID	DMNO20J
DMNO20J	DN	mAb926
DMNO20J	HS	Preclinical
DMNO20J	DT	Antibody
DMNO20J	DE	Urinary tract infection

DMZHT39	ID	DMZHT39
DMZHT39	DN	Macrolactin A
DMZHT39	HS	Preclinical
DMZHT39	SN	7-O-succinyl macrolactin A; 7-O-Succinyl Macrolactin F; CHEMBL528105; CHEMBL485779
DMZHT39	PC	10601542
DMZHT39	MW	502.6
DMZHT39	FM	C28H38O8
DMZHT39	IC	QPJULYYJHQTWML-GIDLKBJSSA-N
DMZHT39	CS	CC1CCCC=CC=CC(CC(CC=CC=CC(CC=CC=CC(=O)O1)OC(=O)CCC(=O)O)O)O
DMZHT39	IK	1S/C28H38O8/c1-22-13-7-3-2-4-8-14-23(29)21-24(30)15-9-5-10-16-25(36-28(34)20-19-26(31)32)17-11-6-12-18-27(33)35-22/h2,4-6,8-12,14,16,18,22-25,29-30H,3,7,13,15,17,19-21H2,1H3,(H,31,32)/b4-2+,9-5-,11-6+,14-8+,16-10+,18-12-/t22-,23+,24+,25-/m1/s1
DMZHT39	IU	4-[[(3Z,5E,8S,9E,11Z,14S,16R,17E,19E,24R)-14,16-dihydroxy-24-methyl-2-oxo-1-oxacyclotetracosa-3,5,9,11,17,19-hexaen-8-yl]oxy]-4-oxobutanoic acid
DMZHT39	DE	Colon cancer

DM1XYGF	ID	DM1XYGF
DM1XYGF	DN	MAX-10129
DM1XYGF	HS	Preclinical
DM1XYGF	CP	Guangzhou Maxinovel Pharmaceuticals
DM1XYGF	DT	Small molecule immunotherapy 

DMBT2RJ	ID	DMBT2RJ
DMBT2RJ	DN	MC-2001
DMBT2RJ	HS	Preclinical
DMBT2RJ	SN	MC-2002; MC-2006; Multiple selective kinase inhibitors (leukemia); Dual Flt3/ABL inhibitors, MaxoCore; Multiple selective kinase inhibitors (leukemia), Maxocore
DMBT2RJ	CP	MaxoCore Pharmaceuticals Inc
DMBT2RJ	DE	leukaemia

DMLK2D0	ID	DMLK2D0
DMLK2D0	DN	MC-3001
DMLK2D0	HS	Preclinical
DMLK2D0	SN	MC-3004; PPAR-alpha agonists, MaxoCore
DMLK2D0	CP	MaxoCore Pharmaceuticals Inc
DMLK2D0	DE	Lipid metabolism disorder

DM7UGY9	ID	DM7UGY9
DM7UGY9	DN	MC-3002
DM7UGY9	HS	Preclinical
DM7UGY9	SN	PPAR dual agonists, MaxoCore
DM7UGY9	CP	MaxoCore Pharmaceuticals Inc
DM7UGY9	DE	Metabolic disorder

DMHJLPS	ID	DMHJLPS
DMHJLPS	DN	M-carboxycinnamic acid bishydroxamide
DMHJLPS	HS	Preclinical
DMHJLPS	SN	Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide
DMHJLPS	DT	Small molecular drug
DMHJLPS	PC	5353484
DMHJLPS	MW	222.2
DMHJLPS	FM	C10H10N2O4
DMHJLPS	IC	InChI=1S/C10H10N2O4/c13-9(11-15)5-4-7-2-1-3-8(6-7)10(14)12-16/h1-6,15-16H,(H,11,13)(H,12,14)/b5-4+
DMHJLPS	CS	C1=CC(=CC(=C1)C(=O)NO)/C=C/C(=O)NO
DMHJLPS	IK	OYKBQNOPCSXWBL-SNAWJCMRSA-N
DMHJLPS	IU	N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide
DMHJLPS	CA	CAS 174664-65-4
DMHJLPS	DE	Solid tumour/cancer

DMYEFKH	ID	DMYEFKH
DMYEFKH	DN	MCP-1
DMYEFKH	HS	Preclinical
DMYEFKH	CP	Pfizer
DMYEFKH	DE	Rheumatoid arthritis

DM7Q1PF	ID	DM7Q1PF
DM7Q1PF	DN	MEDI-543
DM7Q1PF	HS	Preclinical
DM7Q1PF	SN	MEDI-EphA2; L/A Lm-MCMV vaccine, Cerus/MedImmune; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus/MedImmune; Live-attenuated Listeria monocytogenes (Lm)-based vaccine (CMV), Cerus/MedImmune
DM7Q1PF	CP	Cerus Corp
DM7Q1PF	DT	Vaccine
DM7Q1PF	DE	Solid tumour/cancer

DMYK8MV	ID	DMYK8MV
DMYK8MV	DN	Melanotetan II
DMYK8MV	HS	Preclinical
DMYK8MV	SN	Monorden; UNII-I60EH8GECX; I60EH8GECX; CHEMBL414883; CHEBI:556075; (1aR,2Z,4E,14R,15aR)-8-chloro-9,11-dihydroxy-14-methyl-1a,14,15,15a-tetrahydro-6H-oxireno[e][2]benzoxacyclotetradecine-6,12(7H)-dione; Monorderne; RDC; C18H17ClO6; Radisicol; Radicolol; Monorden A; RHI-12648; Microlactone, 1; 3cgy; NSC-294404; 4egk; 2wer; NSC 294404; 2zbk; 1bgq; (+)-Monorden A; Radicicol R 2146; 2q8i; SCHEMBL868832; BDBM15361; MolPort-003-959-447; HMS3648C16; BDBM227589; 6H-Oxireno(e)(2)benzoxacyclotetradecin-6,12(7H)-dione, 8-chlor
DMYK8MV	CP	Clinuvel Pharmaceuticals
DMYK8MV	DT	Small molecular drug
DMYK8MV	DE	Type-2 diabetes; Obesity; Sexual dysfunction

DMX4IS3	ID	DMX4IS3
DMX4IS3	DN	Mephenoxalone
DMX4IS3	HS	Preclinical
DMX4IS3	SN	5-((2-Methoxyphenoxy)methyl)oxazolidin-2-one; 5-(o-Methoxyphenoxymethyl)-2-oxazolidinone; 5-(o-Methoxyphenoxymethyl)-2-oxazolidone; AHR 233; Alkapol peg-400; CL 27,319; Control-OM; Dorsiflex; Dorsilon; EINECS 200-723-3; Ekilan; Lenetran; Lenetran TAB; Lenetranat; MEPHENOXALONE; Mefenoxalona; Mefenoxalona [INN-Spanish]; Mefenoxalone; Mephenoxalone [INN:DCF]; Mephenoxalonum [INN-Latin]; Methoxadone; Methoxydon; Methoxydon(E); Methoxydone; Metoxadone; Moderamin; Placidex; Riself; Transpoise; Trepidone; Valanas; Xerene
DMX4IS3	TC	Anxiolytic Agents
DMX4IS3	DT	Small molecular drug
DMX4IS3	PC	6257
DMX4IS3	MW	223.228
DMX4IS3	FM	C11H13NO4
DMX4IS3	IC	InChI=1S/C11H13NO4/c1-14-9-4-2-3-5-10(9)15-7-8-6-12-11(13)16-8/h2-5,8H,6-7H2,1H3,(H,12,13)
DMX4IS3	CS	COC1=CC=CC=C1OCC2CNC(=O)O2
DMX4IS3	IK	ZMNSRFNUONFLSP-UHFFFAOYSA-N
DMX4IS3	IU	5-[(2-methoxyphenoxy)methyl]-1,3-oxazolidin-2-one
DMX4IS3	CA	CAS 70-07-5
DMX4IS3	CB	CHEBI:134916
DMX4IS3	DE	Anxiety

DMTQXS7	ID	DMTQXS7
DMTQXS7	DN	Mercaptopurine
DMTQXS7	HS	Preclinical
DMTQXS7	SN	6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog)
DMTQXS7	CP	Novopharm
DMTQXS7	TC	Antiviral Agents
DMTQXS7	DT	Small molecular drug
DMTQXS7	PC	667490
DMTQXS7	MW	152.18
DMTQXS7	FM	C5H4N4S
DMTQXS7	IC	InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
DMTQXS7	CS	C1=NC2=C(N1)C(=S)N=CN2
DMTQXS7	IK	GLVAUDGFNGKCSF-UHFFFAOYSA-N
DMTQXS7	IU	3,7-dihydropurine-6-thione
DMTQXS7	CA	CAS 50-44-2
DMTQXS7	CB	CHEBI:2208
DMTQXS7	DE	Acute lymphoblastic leukaemia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMVGIB4	ID	DMVGIB4
DMVGIB4	DN	MERS-27
DMVGIB4	HS	Preclinical
DMVGIB4	DT	Antibody
DMVGIB4	DE	Coronavirus infection

DMS6KT8	ID	DMS6KT8
DMS6KT8	DN	MERS-4
DMS6KT8	HS	Preclinical
DMS6KT8	DT	Antibody
DMS6KT8	DE	Coronavirus infection

DMG5YRP	ID	DMG5YRP
DMG5YRP	DN	MERS-five-helix bundle
DMG5YRP	HS	Preclinical
DMG5YRP	SN	MERS-5HB
DMG5YRP	TC	Antiviral Agents
DMG5YRP	DT	Protein/peptide drug
DMG5YRP	SQ	GITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFQKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRLDVLESGGRGGSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGNYGGSGGSGGGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFQKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRLDVLESGGRGGSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGNYGGSGGSGGGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFQKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRLDVLE
DMG5YRP	DE	Middle East Respiratory Syndrome (MERS)

DMQW5MH	ID	DMQW5MH
DMQW5MH	DN	Metampicillin
DMQW5MH	HS	Preclinical
DMQW5MH	SN	(2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-(methylideneamino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-[(2R)-2-(methylideneamino)-2-phenylacetamido]penicillanic acid; Blomopen; Bonopen; CHEBI:52060; Celinmicina; Elatocilline; G0H6U7VSTK; METHAMPICILLIN; Magnipen; Metampicilina; Metampicillina; Metampicilline; Metampicillinum; Micinovo; Pangocilin; Probiotic; Relyothenate; Ruticina; Rutizina; Sedomycin; Suvipen; UNII-G0H6U7VSTK; Viderpen; Viderpin; Vioplex; metampicillin; metampilene
DMQW5MH	TC	Anti-Bacterial Agents
DMQW5MH	DT	Small molecular drug
DMQW5MH	PC	6713928
DMQW5MH	MW	361.416
DMQW5MH	FM	C17H19N3O4S
DMQW5MH	IC	InChI=1S/C17H19N3O4S/c1-17(2)12(16(23)24)20-14(22)11(15(20)25-17)19-13(21)10(18-3)9-7-5-4-6-8-9/h4-8,10-12,15H,3H2,1-2H3,(H,19,21)(H,23,24)/t10-,11-,12+,15-/m1/s1
DMQW5MH	CS	CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N=C)C(=O)O)C
DMQW5MH	IK	FZECHKJQHUVANE-MCYUEQNJSA-N
DMQW5MH	IU	(2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-(methylideneamino)-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMQW5MH	CA	CAS 6489-97-0
DMQW5MH	CB	CHEBI:52060
DMQW5MH	DE	Bacterial infections

DMDPV82	ID	DMDPV82
DMDPV82	DN	Metildigoxin
DMDPV82	HS	Preclinical
DMDPV82	SN	4'''-Methyldigoxin; 4'''-O-Methyldigoxin; Betamethyl digoxin; Digoxin, 4'''-O-methyl-; Lanirapid; Lanitop; MEDIGOXIN; Medigossina; Medigossina [DCIT]; Medigoxina; Medigoxina [Spanish]; Methyldigoxin; Metildigoxin; Metildigoxin [INN:BAN:JAN]; Metildigoxina; Metildigoxina [INN-Spanish]; Metildigoxine; Metildigoxine [INN-French]; Metildigoxinum; Metildigoxinum [INN-Latin]; beta-Methyl Digoxin; beta-Methyldigoxin; beta-Metildigoxina; beta-Metildigoxina [Spanish]
DMDPV82	DT	Small molecular drug
DMDPV82	PC	443946
DMDPV82	MW	794.976
DMDPV82	FM	C42H66O14
DMDPV82	IC	InChI=1S/C42H66O14/c1-20-37(49-6)29(43)16-35(51-20)55-39-22(3)53-36(18-31(39)45)56-38-21(2)52-34(17-30(38)44)54-25-9-11-40(4)24(14-25)7-8-27-28(40)15-32(46)41(5)26(10-12-42(27,41)48)23-13-33(47)50-19-23/h13,20-22,24-32,34-39,43-46,48H,7-12,14-19H2,1-6H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,34+,35+,36+,37-,38-,39-,40+,41+,42+/m1/s1
DMDPV82	CS	CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)OC
DMDPV82	IK	IYJMSDVSVHDVGT-PEQKVOOWSA-N
DMDPV82	IU	3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMDPV82	CA	CAS 30685-43-9
DMDPV82	CB	ChEBI:135885
DMDPV82	DE	Cardiac arrhythmias; Congestive heart failure

DMDU8KC	ID	DMDU8KC
DMDU8KC	DN	Metkephamid
DMDU8KC	HS	Preclinical
DMDU8KC	SN	METKEFAMIDE; UNII-MNL20FXH9Y; MNL20FXH9Y; Metkephamid; Metkephamide; Metkefamida; Metkefamidum; L-Methioninamide, L-tyrosyl-D-alanylglycyl-L-phenylalanyl-N2-methyl-; Metkefamidum [INN-Latin]; Metkefamida [INN-Spanish]; L-Tyrosyl-D-alanylglycyl-L-phenylalanyl-N2-methyl-L-methioninamide; Metkefamide [INN]; AC1NUZ1B; SCHEMBL329997; CHEMBL2220405; CTK2F4766
DMDU8KC	PC	5464184
DMDU8KC	MW	600.7
DMDU8KC	FM	C29H40N6O6S
DMDU8KC	IC	InChI=1S/C29H40N6O6S/c1-18(33-28(40)22(30)15-20-9-11-21(36)12-10-20)27(39)32-17-25(37)34-23(16-19-7-5-4-6-8-19)29(41)35(2)24(26(31)38)13-14-42-3/h4-12,18,22-24,36H,13-17,30H2,1-3H3,(H2,31,38)(H,32,39)(H,33,40)(H,34,37)/t18-,22+,23+,24+/m1/s1
DMDU8KC	CS	CC(C(=O)NCC(=O)NC(CC1=CC=CC=C1)C(=O)N(C)C(CCSC)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)N
DMDU8KC	IK	FWDIKROEWJOQIQ-JMBSJVKXSA-N
DMDU8KC	IU	(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-methylamino]-4-methylsulfanylbutanamide
DMDU8KC	CA	CAS 66960-34-7
DMDU8KC	DE	Pain

DMKA2YS	ID	DMKA2YS
DMKA2YS	DN	MG-132
DMKA2YS	HS	Preclinical
DMKA2YS	SN	MG-132; Z-Leu-leu-leu-al; MG132; Zlllal; MG 132; Z-LLL-CHO; Zlll-cho; Z-Leu-leu-leucinal; Z-Leu-Leu-Leu-H; Z-Leu-Leu-Leu-CHO; Carbobenzoxy-leucyl-leucyl-leucinal; UNII-RF1P63GW3K; Benzyloxycarbonyl-leu-leu-leu-aldehyde; Benzyloxycarbonyl-leucyl-leucyl-leucinal; Lll cpd; Carbobenzoxyl-leucinyl-leucinyl-leucinal-H; Cbz-Leu-Leu-Leu-H; Benzyloxycarbonylleucyl-leucyl-leucine aldehyde; benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate; RF1P63GW3K
DMKA2YS	PC	462382
DMKA2YS	MW	475.6
DMKA2YS	FM	C26H41N3O5
DMKA2YS	IC	InChI=1S/C26H41N3O5/c1-17(2)12-21(15-30)27-24(31)22(13-18(3)4)28-25(32)23(14-19(5)6)29-26(33)34-16-20-10-8-7-9-11-20/h7-11,15,17-19,21-23H,12-14,16H2,1-6H3,(H,27,31)(H,28,32)(H,29,33)/t21-,22-,23-/m0/s1
DMKA2YS	CS	CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1
DMKA2YS	IK	TZYWCYJVHRLUCT-VABKMULXSA-N
DMKA2YS	IU	benzyl N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DMKA2YS	CA	CAS 133407-82-6
DMKA2YS	CB	CHEBI:75142
DMKA2YS	DE	Cancer

DMI3E0Y	ID	DMI3E0Y
DMI3E0Y	DN	MK6-83
DMI3E0Y	HS	Preclinical
DMI3E0Y	SN	1062271-24-2; UNII-RE9JUR6NT4; RE9JUR6NT4; 5-Methyl-N-[2-(1-piperidinyl)phenyl]-2-thiophenesulfonamide; C16H20N2O2S2; 5-methyl-N-(2-(piperidin-1-yl)phenyl)thiophene-2-sulfonamide; 5-methyl-N-(2-piperidin-1-ylphenyl)thiophene-2-sulfonamide; 5-Methyl-N-(2-(1-piperidinyl)phenyl)-2-thiophenesulfonamide; GTPL9783; AOB6422; SYN5108; ZINC69572886; AKOS025147398; NCGC00402264-02; NCGC00402264-04; AS-16472; CID 18191179; HY-110238; CS-0033102; 2-Thiophenesulfonamide, 5-methyl-N-(2-(1-piperidinyl)phenyl)-
DMI3E0Y	DT	Small molecular drug
DMI3E0Y	PC	18191179
DMI3E0Y	MW	336.5
DMI3E0Y	FM	C16H20N2O2S2
DMI3E0Y	IC	InChI=1S/C16H20N2O2S2/c1-13-9-10-16(21-13)22(19,20)17-14-7-3-4-8-15(14)18-11-5-2-6-12-18/h3-4,7-10,17H,2,5-6,11-12H2,1H3
DMI3E0Y	CS	CC1=CC=C(S1)S(=O)(=O)NC2=CC=CC=C2N3CCCCC3
DMI3E0Y	IK	IRGYSXZCDAWOOC-UHFFFAOYSA-N
DMI3E0Y	IU	5-methyl-N-(2-piperidin-1-ylphenyl)thiophene-2-sulfonamide
DMI3E0Y	CA	CAS 1062271-24-2
DMI3E0Y	DE	Discovery agent

DMV2F84	ID	DMV2F84
DMV2F84	DN	ML209
DMV2F84	HS	Preclinical
DMV2F84	SN	CHEMBL2326408; 3-(1,3-Benzodioxol-5-yl)-1-(cis-3,5-dimethyl-1-piperidinyl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-1-propanone; NCGC00238427-01; SCHEMBL14826293; BDBM50426366; AKOS032947172; NCGC00238427-02; 1-[(3S)-3beta,5beta-Dimethylpiperidino]-3-(1,3-benzodioxole-5-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-1-propanone
DMV2F84	DT	Small molecular drug
DMV2F84	PC	53385590
DMV2F84	MW	441.5
DMV2F84	FM	C25H31NO6
DMV2F84	IC	InChI=1S/C25H31NO6/c1-15-7-16(2)13-26(12-15)24(28)11-19(17-5-6-21-22(8-17)32-14-31-21)25-20(27)9-18(29-3)10-23(25)30-4/h5-6,8-10,15-16,19,27H,7,11-14H2,1-4H3/t15-,16+,19?
DMV2F84	CS	C[C@@H]1C[C@@H](CN(C1)C(=O)CC(C2=CC3=C(C=C2)OCO3)C4=C(C=C(C=C4OC)OC)O)C
DMV2F84	IK	YEKVAIMYYCZDLI-MCPYQZEQSA-N
DMV2F84	IU	3-(1,3-benzodioxol-5-yl)-1-[(3S,5R)-3,5-dimethylpiperidin-1-yl]-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one
DMV2F84	DE	Autoimmune disease

DMY91A3	ID	DMY91A3
DMY91A3	DN	ML323
DMY91A3	HS	Preclinical
DMY91A3	SN	ML 323; ML-323
DMY91A3	DT	Small molecular drug
DMY91A3	PC	60167849
DMY91A3	MW	384.5
DMY91A3	FM	C23H24N6
DMY91A3	IC	InChI=1S/C23H24N6/c1-16(2)20-6-4-5-7-21(20)23-24-14-17(3)22(27-23)25-15-18-8-10-19(11-9-18)29-13-12-26-28-29/h4-14,16H,15H2,1-3H3,(H,24,25,27)
DMY91A3	CS	CC1=CN=C(N=C1NCC2=CC=C(C=C2)N3C=CN=N3)C4=CC=CC=C4C(C)C
DMY91A3	IK	VUIRVWPJNKZOSS-UHFFFAOYSA-N
DMY91A3	IU	5-methyl-2-(2-propan-2-ylphenyl)-N-[[4-(triazol-1-yl)phenyl]methyl]pyrimidin-4-amine
DMY91A3	DE	Solid tumour/cancer

DM6RFLE	ID	DM6RFLE
DM6RFLE	DN	ML364
DM6RFLE	HS	Preclinical
DM6RFLE	SN	1991986-30-1; 2-[(4-methylphenyl)sulfonylamino]-n-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide; NCGC00262995-02; CHEMBL3392741; SCHEMBL20782884; BCP20769; EX-A4472; ML-364; s6748; AKOS032944928; ZINC169341604; CS-6197; NCGC00262995-01; AS-55828; HY-100900; 2-((4-methylphenyl)sulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide; 2-(4-Methylphenylsulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide
DM6RFLE	CP	National Institutes of Health
DM6RFLE	DT	Small molecular drug
DM6RFLE	PC	70789348
DM6RFLE	MW	517.5
DM6RFLE	FM	C24H18F3N3O3S2
DM6RFLE	IC	InChI=1S/C24H18F3N3O3S2/c1-15-7-10-18(11-8-15)35(32,33)30-20-13-17(24(25,26)27)9-12-19(20)22(31)29-23-28-21(14-34-23)16-5-3-2-4-6-16/h2-14,30H,1H3,(H,28,29,31)
DM6RFLE	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC(=C2)C(F)(F)F)C(=O)NC3=NC(=CS3)C4=CC=CC=C4
DM6RFLE	IK	QZUGMNXETPARLI-UHFFFAOYSA-N
DM6RFLE	IU	2-[(4-methylphenyl)sulfonylamino]-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide
DM6RFLE	DE	Inflammation

DMEK78T	ID	DMEK78T
DMEK78T	DN	MNLP-18
DMEK78T	HS	Preclinical
DMEK78T	SN	MNLP-41; Glycosidase inhibitors (HCV Infection/Influenza); Imino sugar (antiviral), MNLpharma; Glycosidase inhibitors (HCV Infection/Influenza), MNLPharma
DMEK78T	CP	MNLpharma Ltd
DMEK78T	DE	Virus infection

DMG2UJS	ID	DMG2UJS
DMG2UJS	DN	Monomethyl-auristatin-E
DMG2UJS	HS	Preclinical
DMG2UJS	SN	Monomethyl auristatin E; UNII-V7I58RC5EJ; MMAE; V7I58RC5EJ; N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide; Monomethyl auristatin E (MMAE); Monomethylauristatin E; 4Q5; monomethyl-auristatin-e-mmae; MMAE, monomethyl auristatin E; SCHEMBL5402144; CHEMBL2103835; AOB5196; DASWEROEPLKSEI-UIJRFTGLSA-N; C39H67N5O7; MFCD22124498; ZINC85537145; s7721; CS-0837
DMG2UJS	PC	11542188
DMG2UJS	MW	718
DMG2UJS	FM	C39H67N5O7
DMG2UJS	IC	InChI=1S/C39H67N5O7/c1-13-25(6)34(43(10)39(49)33(24(4)5)42-38(48)32(40-9)23(2)3)30(50-11)22-31(45)44-21-17-20-29(44)36(51-12)26(7)37(47)41-27(8)35(46)28-18-15-14-16-19-28/h14-16,18-19,23-27,29-30,32-36,40,46H,13,17,20-22H2,1-12H3,(H,41,47)(H,42,48)/t25-,26+,27+,29-,30+,32-,33-,34-,35+,36+/m0/s1
DMG2UJS	CS	CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)NC
DMG2UJS	IK	DASWEROEPLKSEI-UIJRFTGLSA-N
DMG2UJS	IU	(2S)-N-[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide
DMG2UJS	CA	CAS 474645-27-7
DMG2UJS	DE	Cancer

DM5AMFV	ID	DM5AMFV
DM5AMFV	DN	MS012
DM5AMFV	HS	Preclinical
DM5AMFV	SN	CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine
DM5AMFV	DT	Small molecular drug
DM5AMFV	PC	137348638
DM5AMFV	MW	401.5
DM5AMFV	FM	C22H35N5O2
DM5AMFV	IC	InChI=1S/C22H35N5O2/c1-5-6-7-8-11-23-22-25-18-15-20(29-4)19(28-3)14-17(18)21(26-22)24-16-9-12-27(2)13-10-16/h14-16H,5-13H2,1-4H3,(H2,23,24,25,26)
DM5AMFV	CS	CCCCCCNC1=NC2=CC(=C(C=C2C(=N1)NC3CCN(CC3)C)OC)OC
DM5AMFV	IK	ZYNUWSFRZCRKSN-UHFFFAOYSA-N
DM5AMFV	IU	2-N-hexyl-6,7-dimethoxy-4-N-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine
DM5AMFV	DE	Inflammation

DMDEJBQ	ID	DMDEJBQ
DMDEJBQ	DN	MS2177
DMDEJBQ	HS	Preclinical
DMDEJBQ	DT	Small molecular drug
DMDEJBQ	DE	Solid tumour/cancer

DMCZW4Q	ID	DMCZW4Q
DMCZW4Q	DN	Mteron-F1
DMCZW4Q	HS	Preclinical
DMCZW4Q	CP	Dompe
DMCZW4Q	DE	Mucositis

DMC3NSK	ID	DMC3NSK
DMC3NSK	DN	MUT-056399
DMC3NSK	HS	Preclinical
DMC3NSK	SN	Fab-001; MUT-1; MUT-2; MUT-3; MUT-37307; MUT-4; FabI inhibitors (antibacterial), Mutabilis; FabI inhibitors (bacterial infection), FAB Pharma
DMC3NSK	CP	Mutabilis SA
DMC3NSK	PC	44208849
DMC3NSK	MW	293.26
DMC3NSK	FM	C15H13F2NO3
DMC3NSK	IC	InChI=1S/C15H13F2NO3/c1-2-8-6-12(19)14(7-10(8)16)21-13-4-3-9(15(18)20)5-11(13)17/h3-7,19H,2H2,1H3,(H2,18,20)
DMC3NSK	CS	CCC1=CC(=C(C=C1F)OC2=C(C=C(C=C2)C(=O)N)F)O
DMC3NSK	IK	QUHARGDBJJUOEB-UHFFFAOYSA-N
DMC3NSK	IU	4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide
DMC3NSK	CA	CAS 1269055-85-7
DMC3NSK	DE	Methicillin-resistant staphylococci infection

DMDE7OR	ID	DMDE7OR
DMDE7OR	DN	NA-808
DMDE7OR	HS	Preclinical
DMDE7OR	SN	HCV replication inhibitors, Chugai; Hepatitis C virus replication inhibitors, Chugai; NA-255; SPT inhibitor (injection, HCV infection), Roche/Chugai; SPT inhibitor (injection, hepatitis C virus infection), Roche/Chugai; Serine palmitoyltransferase inhibitor (injection, HCV infection), Roche/Chugai; Serine palmitoyltransferase inhibitor (injection, hepatitis C virus infection), Roche/Chugai
DMDE7OR	CP	Chugai Pharmaceutical Co Ltd
DMDE7OR	PC	101837495
DMDE7OR	MW	600.7
DMDE7OR	FM	C34H48O9
DMDE7OR	IC	InChI=1S/C34H48O9/c1-3-5-7-10-13-16-27(35)17-14-11-8-9-12-15-18-30(34(42,33(40)41)25-31(36)37)29(32(38)39)24-26-19-21-28(22-20-26)43-23-6-4-2/h15,18-22,29-30,42H,3,5,7-14,16-17,23-25H2,1-2H3,(H,36,37)(H,38,39)(H,40,41)/b18-15+/t29-,30-,34-/m0/s1
DMDE7OR	CS	CCCCCCCC(=O)CCCCCC/C=C/[C@@H]([C@H](CC1=CC=C(C=C1)OCC#CC)C(=O)O)[C@@](CC(=O)O)(C(=O)O)O
DMDE7OR	IK	XQPJMZTYCIBZTB-UIWDEBCHSA-N
DMDE7OR	IU	(2S,3S,4S)-5-(4-but-2-ynoxyphenyl)-2-hydroxy-3-[(E)-9-oxohexadec-1-enyl]pentane-1,2,4-tricarboxylic acid
DMDE7OR	DE	Hepatitis C virus infection

DMEHO9G	ID	DMEHO9G
DMEHO9G	DN	NC043
DMEHO9G	HS	Preclinical
DMEHO9G	SN	15-oxospiramilactone; 1053172-87-4; Q35479640
DMEHO9G	CP	Chinese Academy of Sciences
DMEHO9G	DT	Small molecular drug
DMEHO9G	PC	139033589
DMEHO9G	MW	358.5
DMEHO9G	FM	C22H30O4
DMEHO9G	IC	InChI=1S/C22H30O4/c1-13-14-4-7-22(19(13)25)16(10-14)21-6-3-5-20(2,15(21)11-17(22)23)8-9-26-12-18(21)24/h14-17,23H,1,3-12H2,2H3/t14-,15+,16-,17+,20-,21-,22+/m0/s1
DMEHO9G	CS	C[C@@]12CCC[C@@]3([C@@H]1C[C@H]([C@]45[C@H]3C[C@H](CC4)C(=C)C5=O)O)C(=O)COCC2
DMEHO9G	IK	RCPPZYXWUAJXMA-KGYWYPJXSA-N
DMEHO9G	IU	(1S,2S,4S,7R,8R,10R,11S)-8-hydroxy-11-methyl-5-methylidene-14-oxapentacyclo[9.5.3.24,7.01,10.02,7]henicosane-6,16-dione
DMEHO9G	DE	Neurodegenerative disorder

DMXG0O1	ID	DMXG0O1
DMXG0O1	DN	NCGC607
DMXG0O1	HS	Preclinical
DMXG0O1	SN	1462267-07-7; MLS003874050; KUC107647N; KUC107647N-02; SMR002530685; 2-[2-(4-iodoanilino)-2-oxoethoxy]-N-[2-(N-methylanilino)-2-oxoethyl]benzamide; 2-(2-((4-iodophenyl)amino)-2-oxoethoxy)-N-(2-(methyl(phenyl)amino)-2-oxoethyl)benzamide; ksc-22-92-D69; SCHEMBL16534468; GTPL10697; EX-A4846; NCGC00241607; NCGC00241607-01; KSC-242-13-2; 2-[2-[(4-Iodophenyl)amino]-2-oxoethoxy]-N-[2-(methylphenylamino)-2-oxoethyl]-benzamide
DMXG0O1	DT	Small molecular drug
DMXG0O1	PC	46943210
DMXG0O1	MW	543.4
DMXG0O1	FM	C24H22IN3O4
DMXG0O1	IC	InChI=1S/C24H22IN3O4/c1-28(19-7-3-2-4-8-19)23(30)15-26-24(31)20-9-5-6-10-21(20)32-16-22(29)27-18-13-11-17(25)12-14-18/h2-14H,15-16H2,1H3,(H,26,31)(H,27,29)
DMXG0O1	CS	CN(C1=CC=CC=C1)C(=O)CNC(=O)C2=CC=CC=C2OCC(=O)NC3=CC=C(C=C3)I
DMXG0O1	IK	HFVDMJQQAKLUSN-UHFFFAOYSA-N
DMXG0O1	IU	2-[2-(4-iodoanilino)-2-oxoethoxy]-N-[2-(N-methylanilino)-2-oxoethyl]benzamide
DMXG0O1	DE	Gaucher disease

DM5ATJ0	ID	DM5ATJ0
DM5ATJ0	DN	N-desethyl sunitinib
DM5ATJ0	HS	Preclinical
DM5ATJ0	SN	N-Desethyl Sunitinib; N-DesethylSunitinib; UNII-42LJ35612R; 42LJ35612R; C20H23FN4O2; N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; SCHEMBL2115189; CHEMBL3542344; DTXSID10437828
DM5ATJ0	PC	10292573
DM5ATJ0	MW	370.4
DM5ATJ0	FM	C20H23FN4O2
DM5ATJ0	IC	InChI=1S/C20H23FN4O2/c1-4-22-7-8-23-20(27)18-11(2)17(24-12(18)3)10-15-14-9-13(21)5-6-16(14)25-19(15)26/h5-6,9-10,22,24H,4,7-8H2,1-3H3,(H,23,27)(H,25,26)/b15-10-
DM5ATJ0	CS	CCNCCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
DM5ATJ0	IK	LIZNIAKSBJKPQC-GDNBJRDFSA-N
DM5ATJ0	IU	N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DM5ATJ0	CA	CAS 356068-97-8
DM5ATJ0	DE	Cancer

DMX7Q3H	ID	DMX7Q3H
DMX7Q3H	DN	Nemorubicin
DMX7Q3H	HS	Preclinical
DMX7Q3H	SN	Nemorubicinol; FCE-23762; PNU-152243; PNU-156685; PNU-156686; PNU-159682
DMX7Q3H	CP	Pharmacia & Upjohn AB
DMX7Q3H	DT	Small molecular drug
DMX7Q3H	PC	65907
DMX7Q3H	MW	643.6
DMX7Q3H	FM	C32H37NO13
DMX7Q3H	IC	InChI=1S/C32H37NO13/c1-14-27(36)17(33-7-8-44-22(12-33)43-3)9-21(45-14)46-19-11-32(41,20(35)13-34)10-16-24(19)31(40)26-25(29(16)38)28(37)15-5-4-6-18(42-2)23(15)30(26)39/h4-6,14,17,19,21-22,27,34,36,38,40-41H,7-13H2,1-3H3/t14-,17-,19-,21-,22-,27+,32-/m0/s1
DMX7Q3H	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N6CCO[C@@H](C6)OC)O
DMX7Q3H	IK	CTMCWCONSULRHO-UHQPFXKFSA-N
DMX7Q3H	IU	(7S,9S)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2R,4S,5S,6S)-5-hydroxy-4-[(2S)-2-methoxymorpholin-4-yl]-6-methyloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMX7Q3H	CA	CAS 108852-90-0
DMX7Q3H	CB	CHEBI:42053
DMX7Q3H	DE	Solid tumour/cancer

DMW1LKP	ID	DMW1LKP
DMW1LKP	DN	Nicotinamide mononucleotide
DMW1LKP	HS	Preclinical
DMW1LKP	SN	Beta-NMN; Beta-Nicotinamide mononucleotide; Beta-Nicotinamide ribonucleotide; Nicotinamide D-ribonucleotide; Nicotinamide mononucleotide; Nicotinamide nucleotide; Nicotinamide ribonucleotide; Nicotinamide ribotide
DMW1LKP	TC	Bone Density Conservation Agents
DMW1LKP	DT	Small molecular drug
DMW1LKP	PC	14180
DMW1LKP	MW	334.221
DMW1LKP	FM	C11H15N2O8P
DMW1LKP	IC	InChI=1S/C11H15N2O8P/c12-10(16)6-2-1-3-13(4-6)11-9(15)8(14)7(21-11)5-20-22(17,18)19/h1-4,7-9,11,14-15H,5H2,(H3-,12,16,17,18,19)/t7-,8-,9-,11-/m1/s1
DMW1LKP	CS	C1=CC(=C[N+](=C1)C2C(C(C(O2)COP(=O)(O)[O-])O)O)C(=O)N
DMW1LKP	IK	DAYLJWODMCOQEW-TURQNECASA-N
DMW1LKP	IU	[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMW1LKP	CA	CAS 1094-61-7
DMW1LKP	CB	CHEBI:16171
DMW1LKP	DE	Dietary shortage

DMK8UD0	ID	DMK8UD0
DMK8UD0	DN	NKP-46
DMK8UD0	HS	Preclinical
DMK8UD0	SN	FFC-11; KP-46
DMK8UD0	CP	University of Vienna
DMK8UD0	DT	Antibody
DMK8UD0	DE	Solid tumour/cancer

DMVUKEW	ID	DMVUKEW
DMVUKEW	DN	N-methylpyridinium
DMVUKEW	HS	Preclinical
DMVUKEW	SN	1-Methyl-Pyridinium; 1-Methylpyridin-1-ium; 1-Methylpyridinium; N-Methylpyridinium; Pyridinium, 1-methyl-
DMVUKEW	TC	Anticancer Agents
DMVUKEW	DT	Small molecular drug
DMVUKEW	PC	13597
DMVUKEW	MW	94.137
DMVUKEW	FM	C6H8N+
DMVUKEW	IC	InChI=1S/C6H8N/c1-7-5-3-2-4-6-7/h2-6H,1H3/q+1
DMVUKEW	CS	C[N+]1=CC=CC=C1
DMVUKEW	IK	PQBAWAQIRZIWIV-UHFFFAOYSA-N
DMVUKEW	IU	1-methylpyridin-1-ium
DMVUKEW	CB	ChEBI:15761
DMVUKEW	DE	Colon cancer

DMLNYGX	ID	DMLNYGX
DMLNYGX	DN	NN-818
DMLNYGX	HS	Preclinical
DMLNYGX	SN	Beta-amyloid precursor protein modulator (CNS disorders), NewNeural
DMLNYGX	CP	University of Illinois
DMLNYGX	DE	Brain injury

DM7R3B6	ID	DM7R3B6
DM7R3B6	DN	Nobiletin
DM7R3B6	HS	Preclinical
DM7R3B6	SN	478-01-3; Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; UNII-D65ILJ7WLY; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; NSC-76751; D65ILJ7WLY; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one; CHEMBL76447; Nobiletin (Hexamethoxyflavone); CHEBI:7602; NSC76751; MFCD03273560; Flavone, 5,6,7,8,3',4'-hexamethoxy; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; SMR000156231; CCRIS 9012; NSC 76751; CPD000156231; Nobiletin, >=97%; Spectrum2_001697; Spectrum3_000921; Spectrum4_001020; KBioGR_001519; MLS000574877; MLS000759462; MLS000877030; MLS001424129; Nobiletin, analytical standard; SCHEMBL244029; SPECTRUM1505268; SPBio_001654; MEGxp0_000930; ACon1_000921; KBio3_001922; DTXSID30197275; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one; HMS2051D09; HMS2234A09; HMS3373C14; HMS3393D09; HMS3651G20; HY-N0155; ZINC1531669; 3'4'5,6,7,8-Hexamethoxyflavone; 3,4,5,6,7,8-Hexamethoxyflavone; ANW-42631; BDBM50338976; CCG-38781; CN0043; LMPK12111468; NSC618903; STL565829; AKOS015965334; NOBILETIN, 20% (Technical Grade); AC-1023; CS-5518; MCULE-1015144950; NC00186; NSC-618903; SDCCGMLS-0066776.P001; NCGC00095703-01; NCGC00095703-02; NCGC00169228-01; 5,6,7,8,3'',4''-hexamethoxyflavone; AK168175; AS-17452; NCI60_041691; DB-050181; FT-0686667; N0871; N1311; S2333; SW197566-2; V0181; C10112; SR-01000712262; Q-100511; Q2402963; SR-01000712262-5; BRD-K06753942-001-02-0; 2-(3,4-Dimethoxy-phenyl)-5,6,7,8-tetramethoxy-chromen-4-one; 4H-1-Benzopyran-4-one,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 9CI; 3 inverted exclamation mark ,4 inverted exclamation mark ,5,6,7,8-HEXAMETHOXYFLAVONE; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (9CI)
DM7R3B6	DT	Small molecular drug
DM7R3B6	PC	72344
DM7R3B6	MW	402.4
DM7R3B6	FM	C21H22O8
DM7R3B6	IC	InChI=1S/C21H22O8/c1-23-13-8-7-11(9-15(13)24-2)14-10-12(22)16-17(25-3)19(26-4)21(28-6)20(27-5)18(16)29-14/h7-10H,1-6H3
DM7R3B6	CS	COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC
DM7R3B6	IK	MRIAQLRQZPPODS-UHFFFAOYSA-N
DM7R3B6	IU	2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one
DM7R3B6	CA	CAS 478-01-3
DM7R3B6	CB	CHEBI:7602
DM7R3B6	DE	Atherosclerosis

DMTQ2UD	ID	DMTQ2UD
DMTQ2UD	DN	N-Octyl-4-epi-beta-valienamine
DMTQ2UD	HS	Preclinical
DMTQ2UD	SN	CHEMBL1922581; (1s,2s,3s,6r)-4-(Hydroxymethyl)-6-(Octylamino)cyclohex-4-Ene-1,2,3-Triol; CHEMBL1922579; N-Octyl-4-epi-beta-Valienamine; BDBM50358321; Q27463709
DMTQ2UD	DT	Small molecular drug
DMTQ2UD	PC	10039700
DMTQ2UD	MW	287.39
DMTQ2UD	FM	C15H29NO4
DMTQ2UD	IC	InChI=1S/C15H29NO4/c1-2-3-4-5-6-7-8-16-12-9-11(10-17)13(18)15(20)14(12)19/h9,12-20H,2-8,10H2,1H3/t12-,13+,14+,15+/m1/s1
DMTQ2UD	CS	CCCCCCCCN[C@@H]1C=C([C@@H]([C@@H]([C@H]1O)O)O)CO
DMTQ2UD	IK	UPZUHYMBTUUPML-QPSCCSFWSA-N
DMTQ2UD	IU	(1S,2S,3S,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol
DMTQ2UD	DE	GM1 gangliosidosis

DM39C47	ID	DM39C47
DM39C47	DN	N-Octyl-beta-valienamine
DM39C47	HS	Preclinical
DM39C47	SN	(1s,2s,3r,6r)-4-(Hydroxymethyl)-6-(Octylamino)cyclohex-4-Ene-1,2,3-Triol; CHEMBL1922580; N-Octylvalienamine; CHEMBL1234952; SCHEMBL21067585; BDBM50358322; DB08321; Q27097540; OEV
DM39C47	DT	Small molecular drug
DM39C47	PC	9817381
DM39C47	MW	287.39
DM39C47	FM	C15H29NO4
DM39C47	IC	InChI=1S/C15H29NO4/c1-2-3-4-5-6-7-8-16-12-9-11(10-17)13(18)15(20)14(12)19/h9,12-20H,2-8,10H2,1H3/t12-,13-,14+,15+/m1/s1
DM39C47	CS	CCCCCCCCN[C@@H]1C=C([C@H]([C@@H]([C@H]1O)O)O)CO
DM39C47	IK	UPZUHYMBTUUPML-KBXIAJHMSA-N
DM39C47	IU	(1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol
DM39C47	DE	Gaucher disease

DMKF2H0	ID	DMKF2H0
DMKF2H0	DN	Nonactin
DMKF2H0	HS	Preclinical
DMKF2H0	SN	nonactin; Werramycin-A; Antibiotic from Actinomycete; Upjohn 170t (high melting); UPJOHN 170T, high melting; UNII-TTP24WX8P7; 5342 PFW 19; TA-25-M-I; EINECS 229-911-3; A 4426; NSC 56409; E-79-C; NSC 52141; N-329-A; BRN 0076434; TTP24WX8P7; CHEBI:7614; GNF-PF-1094; 3584-A; NSC52141; 4,13,22,31,37,38,39,40-Octaoxapentacyclo(32.2.1.1(sup 7,10).1(sup 16,19).1(sup 25,28))tetracontane-3,12,21,30-tetrone, 2,5,11,14,20,23,29,32-octamethyl-, (1R-(1R*,2R*,5R*,7R*,10S*,11S*,14S*,16S*,19R*,20R*,23R*,25R*,28S*,29S*,32S*,34S*))-
DMKF2H0	PC	72519
DMKF2H0	MW	736.9
DMKF2H0	FM	C40H64O12
DMKF2H0	IC	InChI=1S/C40H64O12/c1-21-17-29-9-13-34(49-29)26(6)38(42)46-23(3)19-31-11-15-36(51-31)28(8)40(44)48-24(4)20-32-12-16-35(52-32)27(7)39(43)47-22(2)18-30-10-14-33(50-30)25(5)37(41)45-21/h21-36H,9-20H2,1-8H3/t21-,22+,23+,24-,25-,26+,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-
DMKF2H0	CS	CC1CC2CCC(O2)C(C(=O)OC(CC3CCC(O3)C(C(=O)OC(CC4CCC(O4)C(C(=O)OC(CC5CCC(O5)C(C(=O)O1)C)C)C)C)C)C)C
DMKF2H0	IK	RMIXHJPMNBXMBU-QIIXEHPYSA-N
DMKF2H0	IU	(1R,2R,5R,7R,10S,11S,14S,16S,19R,20R,23R,25R,28S,29S,32S,34S)-2,5,11,14,20,23,29,32-octamethyl-4,13,22,31,37,38,39,40-octaoxapentacyclo[32.2.1.17,10.116,19.125,28]tetracontane-3,12,21,30-tetrone
DMKF2H0	CA	CAS 6833-84-7
DMKF2H0	CB	CHEBI:7614
DMKF2H0	DE	Cancer

DM83DSA	ID	DM83DSA
DM83DSA	DN	NOX-F37
DM83DSA	HS	Preclinical
DM83DSA	DE	Acute and chronic heart failure

DMOGRWB	ID	DMOGRWB
DMOGRWB	DN	NPS-1034
DMOGRWB	HS	Preclinical
DMOGRWB	SN	1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K
DMOGRWB	CP	NeoPharm
DMOGRWB	DT	Small molecular drug
DMOGRWB	PC	46194178
DMOGRWB	MW	551.5
DMOGRWB	FM	C31H23F2N5O3
DMOGRWB	IC	InChI=1S/C31H23F2N5O3/c1-18-27(31(40)38(37(18)2)22-11-8-20(32)9-12-22)30(39)36-21-10-13-25(24(33)16-21)41-26-14-15-34-29-28(26)23(17-35-29)19-6-4-3-5-7-19/h3-17H,1-2H3,(H,34,35)(H,36,39)
DMOGRWB	CS	CC1=C(C(=O)N(N1C)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C5C(=CNC5=NC=C4)C6=CC=CC=C6)F
DMOGRWB	IK	RGAZVGZUBCFHRJ-UHFFFAOYSA-N
DMOGRWB	IU	1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide
DMOGRWB	DE	Solid tumour/cancer

DMMRY0Z	ID	DMMRY0Z
DMMRY0Z	DN	NPS-2390
DMMRY0Z	HS	Preclinical
DMMRY0Z	SN	N-(Adamantan-1-yl)quinoxaline-2-carboxamide; NPS 2390; 226878-01-9; NPS2390; N-(1-adamantyl)quinoxaline-2-carboxamide; CHEMBL399160; N-(adamantan-1-yl)quinoxaline-2-carboxamide; quinoxaline-2-carboxylic acid adamantan-1-ylamide; N-tricyclo[33113,7]dec-1-yl-2-quinoxalinecarboxamide; AC1OF2ZL; SCHEMBL659603; GTPL1384; NPS-239; DTXSID10427729; MolPort-003-351-281; ZKFVOZCCAXQXBU-UHFFFAOYSA-N; ZINC3966256; PDSP2_001301; BDBM50231744; PDSP1_001317; AKOS001304198; NPS-2390 solution, 30 mM in DMSO; N-(1-Adamantyl)-2-quinoxalinecarboxamide; Quinoxaline-2-carboxylic acid adamantan-1-ylamide
DMMRY0Z	CP	NPS Pharmaceuticals Inc
DMMRY0Z	DT	Small molecular drug
DMMRY0Z	PC	7067728
DMMRY0Z	MW	307.4
DMMRY0Z	FM	C19H21N3O
DMMRY0Z	IC	InChI=1S/C19H21N3O/c23-18(17-11-20-15-3-1-2-4-16(15)21-17)22-19-8-12-5-13(9-19)7-14(6-12)10-19/h1-4,11-14H,5-10H2,(H,22,23)
DMMRY0Z	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)C4=NC5=CC=CC=C5N=C4
DMMRY0Z	IK	ZKFVOZCCAXQXBU-UHFFFAOYSA-N
DMMRY0Z	IU	N-(1-adamantyl)quinoxaline-2-carboxamide
DMMRY0Z	CA	CAS 226878-01-9
DMMRY0Z	DE	Cerebrovascular ischaemia

DMXUCSN	ID	DMXUCSN
DMXUCSN	DN	NPY5RA-972
DMXUCSN	HS	Preclinical
DMXUCSN	SN	NPY 5RA972; 439861-56-0; CHEMBL325226; N-[4-METHYL-9-(1-METHYLETHYL)-9H-CARBAZOL-3-YL]-4-MORPHOLINECARBOXAMIDE; SCHEMBL6826732; CTK8F0016; DTXSID30432395; MolPort-023-276-896; ZINC27101553; BDBM50116592; AKOS024457744; NCGC00370914-01; RT-014756; B7466; N-(4-Methyl-9-isopropyl-9H-carbazole-3-yl)morpholine-4-carboxamide; Morpholine-4-carboxylic acid (9-isopropyl-4-methyl-9H-carbazol-3-yl)-amide
DMXUCSN	CP	AstraZeneca
DMXUCSN	DT	Small molecular drug
DMXUCSN	PC	9884833
DMXUCSN	MW	351.4
DMXUCSN	FM	C21H25N3O2
DMXUCSN	IC	InChI=1S/C21H25N3O2/c1-14(2)24-18-7-5-4-6-16(18)20-15(3)17(8-9-19(20)24)22-21(25)23-10-12-26-13-11-23/h4-9,14H,10-13H2,1-3H3,(H,22,25)
DMXUCSN	CS	CC1=C(C=CC2=C1C3=CC=CC=C3N2C(C)C)NC(=O)N4CCOCC4
DMXUCSN	IK	ZNFMHLDBJPAFEQ-UHFFFAOYSA-N
DMXUCSN	IU	N-(4-methyl-9-propan-2-ylcarbazol-3-yl)morpholine-4-carboxamide
DMXUCSN	CA	CAS 439861-56-0
DMXUCSN	DE	Obesity

DMO5MUY	ID	DMO5MUY
DMO5MUY	DN	NSC-207895
DMO5MUY	HS	Preclinical
DMO5MUY	SN	58131-57-0; NSC 207895; NSC207895; NSC 179940; MLS000756495; Benzofurazan, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide; 4-(4-Methyl-1-piperazinyl)-7-nitro-benzofurazan 3-oxide; BENZOFURAZAN, 7-(4-METHYL-1-PIPERAZINYL)-4-NITRO-, 1-OXIDE; 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium; SMR000528763; NSC 207895 (XI-006); NSC-207895 (XI-006); 4-(4-methyl-1-piperazinyl)-7-nitro-2,1,3-benzoxadiazole, 3-oxide; XI-006; WLN: T56 BNONJ BO FNW I- AT6N DNTJ D1; 7-(4-Methyl-1-piperazinyl)-4-nitrobenzofurazan 1-oxide; B2368; NCIStruc1_000831; NCIStruc2_001869; cc-262; cid_42640; MLS006011023; SCHEMBL8738959; CHEMBL1608727; BDBM51256; DTXSID50206858; HMS2861M23; XI006; ZINC5180959; NSC179940; s2678; BCP9000997; NCGC00246958-01; NCGC00246958-02; NCGC00246958-03; HY-14714; NCI60_001741; BCP0726000315; NSC-207895?XI-006?; A4209; CS-0003525; NSC-207895 - XI-006; NSC?207895?(XI-006); X7598; Z-3234; 7-(4-methylpiperazino)-4-nitro-1-oxido-benzofurazan-1-ium; 2,1,3-Benzoxadiazole, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide; 2,1,3-benzoxadiazole, 7-(4-methyl-1-piperazinyl)-4-nitro-, 1-oxide; 4-(4-methyl-1-piperazinyl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium; 7-(4-methylpiperazin-1-yl)-4-nitrobenzo[c][1,2,5]oxadiazole 1-oxide; 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxidanidyl-2,1,3-benzoxadiazol-3-ium; 4-(hydroxy(oxido)amino)-7-(4-methyl-1-piperazinyl)-2,15,3-benzoxadiazol-1-ol
DMO5MUY	DT	Small molecular drug
DMO5MUY	PC	42640
DMO5MUY	MW	279.25
DMO5MUY	FM	C11H13N5O4
DMO5MUY	IC	InChI=1S/C11H13N5O4/c1-13-4-6-14(7-5-13)9-3-2-8(15(17)18)10-11(9)16(19)20-12-10/h2-3H,4-7H2,1H3
DMO5MUY	CS	CN1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-]
DMO5MUY	IK	MWFZDJLPWDCQIL-UHFFFAOYSA-N
DMO5MUY	IU	4-(4-methylpiperazin-1-yl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium
DMO5MUY	CA	CAS 58131-57-0
DMO5MUY	DE	Solid tumour/cancer

DMQRZ4T	ID	DMQRZ4T
DMQRZ4T	DN	NSC632839
DMQRZ4T	HS	Preclinical
DMQRZ4T	SN	157654-67-6; NSC 632839 hydrochloride; NSC-632839; Nsc 632839; NSC-632839 hydrochloride; 3,5-BIS[(4-METHYLPHENYL)METHYLENE]-4-PIPERIDONE HYDROCHLORIDE; 157654-67-6 (HCl); MLS002701647; C21H21NO.ClH; (3E,5E)-3,5-bis[(4-methylphenyl)methylidene]piperidin-4-one;hydrochloride; CHEMBL1990474; DTXSID10417701; AMY19345; BCP28077; EX-A4187; 2599AH; s4922; AKOS024457219; CS-6014; BS-15510; HY-100708; NSC 632839, >=98% (HPLC); J-009433; 3,5-bis((E)-4-methylbenzylidene)piperidin-4-one hydrochloride; 4-Piperidione,3,5-bis[(4-methylphenyl)methylene] hydrochloride; 4-Piperidinone,5-bis[(4-methylphenyl)methylene]-, hydrochloride; 4-Piperidinone, 3,5-bis[(4-methylphenyl)methylene]-, hydrochloride (1:1)
DMQRZ4T	DT	Small molecular drug
DMQRZ4T	PC	5351362
DMQRZ4T	MW	339.9
DMQRZ4T	FM	C21H22ClNO
DMQRZ4T	IC	InChI=1S/C21H21NO.ClH/c1-15-3-7-17(8-4-15)11-19-13-22-14-20(21(19)23)12-18-9-5-16(2)6-10-18;/h3-12,22H,13-14H2,1-2H3;1H/b19-11+,20-12+;
DMQRZ4T	CS	CC1=CC=C(C=C1)/C=C\\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl
DMQRZ4T	IK	ZOKZLTXPTLIWOJ-BYCVLTJGSA-N
DMQRZ4T	IU	(3E,5E)-3,5-bis[(4-methylphenyl)methylidene]piperidin-4-one;hydrochloride
DMQRZ4T	CA	CAS 157654-67-6
DMQRZ4T	DE	Solid tumour/cancer

DM65UZ2	ID	DM65UZ2
DM65UZ2	DN	NTU281
DM65UZ2	HS	Preclinical
DM65UZ2	DT	Small molecular drug
DM65UZ2	DE	Renal fibrosis

DMO5EXL	ID	DMO5EXL
DMO5EXL	DN	NVP-2
DMO5EXL	HS	Preclinical
DMO5EXL	SN	NVP-2; SCHEMBL1192176; SCHEMBL1192177; GTPL8053; SCHEMBL12850532; CHEMBL3656841; BDBM126500; BDBM126547; Example 93 [US8778951]; HY-12214A; Compound 310 [US8778951]; CS-0015386; US8778951, 310; US8778951, 358; 4-({[6-(5-chloro-2-{[(1r,4r)-4-{[(2R)-1-methoxypropan-2-yl]amino}cyclohexyl]amino}pyridin-4-yl)pyridin-2-yl]amino}methyl)oxane-4-carbonitrile
DMO5EXL	DT	Small molecular drug
DMO5EXL	PC	66937006
DMO5EXL	MW	513.1
DMO5EXL	FM	C27H37ClN6O2
DMO5EXL	IC	InChI=1S/C27H37ClN6O2/c1-19(16-35-2)32-20-6-8-21(9-7-20)33-26-14-22(23(28)15-30-26)24-4-3-5-25(34-24)31-18-27(17-29)10-12-36-13-11-27/h3-5,14-15,19-21,32H,6-13,16,18H2,1-2H3,(H,30,33)(H,31,34)/t19-,20?,21?/m1/s1
DMO5EXL	CS	C[C@H](COC)NC1CCC(CC1)NC2=NC=C(C(=C2)C3=NC(=CC=C3)NCC4(CCOCC4)C#N)Cl
DMO5EXL	IK	XWQVQSXLXAXOPJ-QNGMFEMESA-N
DMO5EXL	IU	4-[[[6-[5-chloro-2-[[4-[[(2R)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile
DMO5EXL	DE	Solid tumour/cancer

DMEXLU5	ID	DMEXLU5
DMEXLU5	DN	ON-01135
DMEXLU5	HS	Preclinical
DMEXLU5	SN	Amerliorex; CDK1 inhibitors, Onconova; Novonex analogs, Onconova; ON-01060; ON-01130; ON-01220; ON-01250; ON-01300; ON-01330; ON-01370; ON-01500; ON-01560; ON-01590; ON-01620; Cell cycle checkpoint activators (cytoprotection), Onconova; ON-01060 derivatives, Onconova; ON-01500 series, Onconova; ON-01910 analogs, Onconova; Styryl benzyl sulfones (cell cycle checkpoint activators), Onconova
DMEXLU5	CP	Onconova Therapeutics Inc
DMEXLU5	DE	Solid tumour/cancer

DMMBIHO	ID	DMMBIHO
DMMBIHO	DN	ONO-1301
DMMBIHO	HS	Preclinical
DMMBIHO	SN	Ono-1301; 176391-41-6; AC1O6W2S; SCHEMBL3771841; CHEMBL188539; MFCD00936504; AKOS032954172; NCGC00165852-01; ONO-1301, &gt; J-011185; 7,8-Dihydro-5-[(E)-[[alpha-(3-pyridyl)benzylidene]aminooxy]ethyl]-1-naphthyloxy]acetic acid; 2-[[5-[2-[(E)-[phenyl(pyridin-3-yl)methylidene]amino]oxyethyl]-7,8-dihydronaphthalen-1-yl]oxy]acetic acid; [[7,8-Dihydro-5-[2-[[[phenyl(3-pyridinyl)methylene]amino]oxy]ethyl]naphthalene-1-yl]oxy]acetic acid
DMMBIHO	CP	Ono Pharmaceutical Co Ltd
DMMBIHO	DT	Small molecular drug
DMMBIHO	PC	6536812
DMMBIHO	MW	428.5
DMMBIHO	FM	C26H24N2O4
DMMBIHO	IC	InChI=1S/C26H24N2O4/c29-25(30)18-31-24-13-5-11-22-19(9-4-12-23(22)24)14-16-32-28-26(20-7-2-1-3-8-20)21-10-6-15-27-17-21/h1-3,5-11,13,15,17H,4,12,14,16,18H2,(H,29,30)/b28-26+
DMMBIHO	CS	C1CC2=C(C=CC=C2OCC(=O)O)C(=C1)CCO/N=C(\\C3=CC=CC=C3)/C4=CN=CC=C4
DMMBIHO	IK	WBBLIRPKRKYMTD-BYCLXTJYSA-N
DMMBIHO	IU	2-[[5-[2-[(E)-[phenyl(pyridin-3-yl)methylidene]amino]oxyethyl]-7,8-dihydronaphthalen-1-yl]oxy]acetic acid
DMMBIHO	DE	Angina pectoris

DMHQUM2	ID	DMHQUM2
DMHQUM2	DN	Org-23366
DMHQUM2	HS	Preclinical
DMHQUM2	SN	SCHEMBL7887966; CHEMBL2078915
DMHQUM2	CP	Akzo Nobel
DMHQUM2	DT	Small molecular drug
DMHQUM2	PC	9804326
DMHQUM2	MW	424.5
DMHQUM2	FM	C26H30F2N2O
DMHQUM2	IC	InChI=1S/C26H30F2N2O/c27-23-9-5-20(6-10-23)26(21-7-11-24(28)12-8-21)22-13-18-29(19-14-22)15-3-4-25(31)30-16-1-2-17-30/h5-12H,1-4,13-19H2
DMHQUM2	CS	C1CCN(C1)C(=O)CCCN2CCC(=C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CC2
DMHQUM2	IK	FZWURHPZIJCZOY-UHFFFAOYSA-N
DMHQUM2	IU	4-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]-1-pyrrolidin-1-ylbutan-1-one
DMHQUM2	DE	Schizophrenia

DMCMS7V	ID	DMCMS7V
DMCMS7V	DN	Org-24461
DMCMS7V	HS	Preclinical
DMCMS7V	SN	ORG-24461
DMCMS7V	CP	Servier
DMCMS7V	DT	Small molecular drug
DMCMS7V	PC	23670635
DMCMS7V	MW	373.3
DMCMS7V	FM	C19H19F3LiNO3
DMCMS7V	IC	InChI=1S/C19H20F3NO3.Li/c1-23(13-18(24)25)12-11-17(14-5-3-2-4-6-14)26-16-9-7-15(8-10-16)19(20,21)22;/h2-10,17H,11-13H2,1H3,(H,24,25);/q;+1/p-1
DMCMS7V	CS	[Li+].CN(CCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F)CC(=O)[O-]
DMCMS7V	IK	VMQXVSNARQMSDL-UHFFFAOYSA-M
DMCMS7V	IU	lithium;2-[methyl-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetate
DMCMS7V	CA	CAS 722456-08-8
DMCMS7V	DE	Schizophrenia

DMERWUC	ID	DMERWUC
DMERWUC	DN	Organon
DMERWUC	HS	Preclinical
DMERWUC	SN	Allylestrenol; Allyloestrenol; Allyloestrenolum; Gestanin; Gestanol; Gestanon; Gestanyn; Orageston; Perselin; Turinal; Allilestrenolo [DCIT]; Alilestrenol [INN-Spanish]; Allylestrenol [INN:JAN]; Allylestrenol(jan); Allylestrenolum [INN-Latin]; Gestanon-r; Perselin (TN); Allylestrenol (JAN/INN); (17beta)-17-prop-2-en-1-ylestr-4-en-17-ol; (8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol; 17-(2-Propenyl)estr-4-en-17-ol; 17-Hydroxy-17-alpha-allyl-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-delta(sup 4)-estren; 17-alpha-Allyl-3-deoxy-19-nortestosterone; 17-alpha-Allyl-4-oestrene-17-beta-ol; 17-alpha-Allylestr-4-en-17-beta-ol; 17-alpha-Allylhydroxy-19-nor-4-androstene; 17.alpha.-Allyl-17-.beta.-hydroxy-.delta.(sup 4)-estren; 17.alpha.-Allyl-17.beta.-hydroxy-4-estrene; 17.alpha.-Allyl-3-deoxy-19-nortestosterone; 17.alpha.-Allyl-4-destrene-17.beta.-ol; 17.alpha.-Allyl-4-estren-17.beta.-ol; 17.alpha.-Allyl-4-oestrene-17.beta.-ol; 17.alpha.-Allylestr-4-en-17.beta.-ol; 17.alpha.-Allylestrenol; 17alpha-Allyl-17beta-hydroxy-4-estrene; 17alpha-Allyl-19-nor-delta-4-androstene-17beta-ol; 17alpha-Allyl-3-deoxy-19-nortestosterone; 17alpha-Allyl-4-destrene-17beta-ol; 17alpha-Allyl-4-estren-17beta-ol; 17alpha-Allyl-4-oestrene-17beta-ol; 17alpha-Allylestr-4-en-17beta-ol; 17alpha-Allylestrenol; 21-Methylene-19-nor-17-alpha-preg-4-en-17-ol; 3-Deoxy-17-alpha-allyl-19-nortestosterone
DMERWUC	CP	Akzo Nobel
DMERWUC	DT	Small molecular drug
DMERWUC	PC	235905
DMERWUC	MW	300.5
DMERWUC	FM	C21H32O
DMERWUC	IC	InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1
DMERWUC	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(CC=C)O)CCC4=CCCC[C@H]34
DMERWUC	IK	ATXHVCQZZJYMCF-XUDSTZEESA-N
DMERWUC	IU	(8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
DMERWUC	CA	CAS 432-60-0
DMERWUC	CB	CHEBI:31189
DMERWUC	DE	Schizophrenia

DM46QXZ	ID	DM46QXZ
DM46QXZ	DN	Organon-2
DM46QXZ	HS	Preclinical
DM46QXZ	CP	Akzo Nobel
DM46QXZ	DE	Schizophrenia

DM07EU4	ID	DM07EU4
DM07EU4	DN	Organon-3
DM07EU4	HS	Preclinical
DM07EU4	CP	Akzo Nobel
DM07EU4	DE	Schizophrenia

DMPUSM5	ID	DMPUSM5
DMPUSM5	DN	Otamixaban
DMPUSM5	HS	Preclinical
DMPUSM5	SN	XRP0673; FXV-673; XRP-0673; FXV673; UNII-S173RED00L
DMPUSM5	TC	Antiviral Agents
DMPUSM5	DT	Small molecular drug
DMPUSM5	PC	5496659
DMPUSM5	MW	446.5
DMPUSM5	FM	C25H26N4O4
DMPUSM5	IC	InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1
DMPUSM5	CS	C[C@H]([C@@H](CC1=CC(=CC=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-]
DMPUSM5	IK	PFGVNLZDWRZPJW-OPAMFIHVSA-N
DMPUSM5	IU	methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate
DMPUSM5	CA	CAS 193153-04-7
DMPUSM5	DE	Coronavirus Disease 2019 (COVID-19)

DMYKG8R	ID	DMYKG8R
DMYKG8R	DN	Oxypertine
DMYKG8R	HS	Preclinical
DMYKG8R	SN	1H-Indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-; 5,6-Dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)indole; 5,6-Dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]-1H-indole; 5JGL4G25R7; BRN 0899339; DO 180; EINECS 205-818-3; Equipertine; Forit; Opertil; Oxipertina [INN-Spanish]; Oxipertine; Oxipertinum; Oxypertine [USAN:INN:BAN:JAN]; Oxypertinum [INN-Latin]; UNII-5JGL4G25R7; WIN 18501-2; XCWPUUGSGHNIDZ-UHFFFAOYSA-N; oxypertine
DMYKG8R	DT	Small molecular drug
DMYKG8R	PC	4640
DMYKG8R	MW	379.504
DMYKG8R	FM	C23H29N3O2
DMYKG8R	IC	InChI=1S/C23H29N3O2/c1-17-19(20-15-22(27-2)23(28-3)16-21(20)24-17)9-10-25-11-13-26(14-12-25)18-7-5-4-6-8-18/h4-8,15-16,24H,9-14H2,1-3H3
DMYKG8R	CS	CC1=C(C2=CC(=C(C=C2N1)OC)OC)CCN3CCN(CC3)C4=CC=CC=C4
DMYKG8R	IK	XCWPUUGSGHNIDZ-UHFFFAOYSA-N
DMYKG8R	IU	5,6-dimethoxy-2-methyl-3-[2-(4-phenylpiperazin-1-yl)ethyl]-1H-indole
DMYKG8R	CA	CAS 153-87-7
DMYKG8R	CB	CHEBI:31952
DMYKG8R	DE	Schizophrenia

DMD8JIC	ID	DMD8JIC
DMD8JIC	DN	P22077
DMD8JIC	HS	Preclinical
DMD8JIC	SN	1247819-59-5; P 22077; 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159498; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone; 1-(5-(2,4-difluorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-22077; 1-(5-((2,4-Difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; 1-{5-[(2,4-Difluorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one; C12H7F2NO3S2; SCHEMBL2680945; DTXSID40677376; HMS3653G09; BCP07858; EX-A1445; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 2624AH; BDBM50393440; MFCD22580421; s7133; ZINC91696068; AKOS024458186; CCG-267643; CS-1860; QC-8199; AC-32695; AK313221; AS-55923; DA-46729; HY-13865; AB0003913; FT-0707469; SW219709-1; EC-000.2542; J3.502.624J; Z1646327284; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]ethanon; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl) ethanone
DMD8JIC	CP	Progenra
DMD8JIC	DT	Small molecular drug
DMD8JIC	PC	46931953
DMD8JIC	MW	315.3
DMD8JIC	FM	C12H7F2NO3S2
DMD8JIC	IC	InChI=1S/C12H7F2NO3S2/c1-6(16)11-5-9(15(17)18)12(20-11)19-10-3-2-7(13)4-8(10)14/h2-5H,1H3
DMD8JIC	CS	CC(=O)C1=CC(=C(S1)SC2=C(C=C(C=C2)F)F)[N+](=O)[O-]
DMD8JIC	IK	RMAMGGNACJHXHO-UHFFFAOYSA-N
DMD8JIC	IU	1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone
DMD8JIC	CA	CAS 1247819-59-5
DMD8JIC	DE	Inflammation

DMGIR3F	ID	DMGIR3F
DMGIR3F	DN	P5091
DMGIR3F	HS	Preclinical
DMGIR3F	SN	882257-11-6; P005091; 1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-5091; 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159495; P5091 (P005091); 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; Cyto5D7; C12H7Cl2NO3S2; SCHEMBL2681288; DTXSID90384841; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; HMS3653E09; HMS3743M19; ZINC125366; BCP07750; EX-A2120; BDBM50393437; MFCD00123202; s7132; AKOS024458314; CCG-240421; CS-1445; MCULE-6661883192; QC-8200; SB19505; AC-32692; AK270202; BS-17872; DA-40897; HY-15667; FT-0714931; SW219710-1; Y1893; J3.502.625H; P 5091; P-05091; P005091(P5091); P 005091; P-005091; 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone; 1-[5-[(2,3-Dichlorophenyl)thio]-4-n?itro-2-thienyl]ethanone; 1-{5-[(2,3-Dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one
DMGIR3F	CP	Progenra
DMGIR3F	DT	Small molecular drug
DMGIR3F	PC	2819993
DMGIR3F	MW	348.2
DMGIR3F	FM	C12H7Cl2NO3S2
DMGIR3F	IC	InChI=1S/C12H7Cl2NO3S2/c1-6(16)10-5-8(15(17)18)12(20-10)19-9-4-2-3-7(13)11(9)14/h2-5H,1H3
DMGIR3F	CS	CC(=O)C1=CC(=C(S1)SC2=C(C(=CC=C2)Cl)Cl)[N+](=O)[O-]
DMGIR3F	IK	LKZLGMAAKNEGCH-UHFFFAOYSA-N
DMGIR3F	IU	1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone
DMGIR3F	CA	CAS 882257-11-6
DMGIR3F	DE	Solid tumour/cancer

DM3YUGA	ID	DM3YUGA
DM3YUGA	DN	Pancratistatin
DM3YUGA	HS	Preclinical
DM3YUGA	SN	Pancratistatin; (+)-Pancratistatin; NSC349156; MLS002701837; AC1L9BE4; SCHEMBL93612; CHEMBL419335; VREZDOWOLGNDPW-ALTGWBOUSA-N; ZINC4097654; (1R,2S,3S,4S,4aR,11bR)-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-[1,3]dioxolo[4,5-j]phenanthridin-6-one; NSC-349156; SMP1_000217; NCI60_003105; B844009K070; C08535
DM3YUGA	PC	441597
DM3YUGA	MW	325.27
DM3YUGA	FM	C14H15NO8
DM3YUGA	IC	InChI=1S/C14H15NO8/c16-8-5-3-1-4-13(23-2-22-4)9(17)6(3)14(21)15-7(5)10(18)12(20)11(8)19/h1,5,7-8,10-12,16-20H,2H2,(H,15,21)/t5-,7-,8-,10+,11+,12+/m1/s1
DM3YUGA	CS	C1OC2=C(O1)C(=C3C(=C2)C4C(C(C(C(C4O)O)O)O)NC3=O)O
DM3YUGA	IK	VREZDOWOLGNDPW-ALTGWBOUSA-N
DM3YUGA	IU	(1R,2S,3S,4S,4aR,11bR)-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-[1,3]dioxolo[4,5-j]phenanthridin-6-one
DM3YUGA	CA	CAS 96203-70-2
DM3YUGA	CB	CHEBI:7906
DM3YUGA	DE	Cancer

DMNIM96	ID	DMNIM96
DMNIM96	DN	P-BCMA-ALL01
DMNIM96	HS	Preclinical
DMNIM96	CP	Poseida Therapeutics
DMNIM96	DT	CAR T Cell Therapy
DMNIM96	DE	Multiple myeloma

DMW3TGI	ID	DMW3TGI
DMW3TGI	DN	PCI-45292
DMW3TGI	HS	Preclinical
DMW3TGI	SN	Btk inhibitors (autoimmune disease); Btk inhibitors (autoimmune disease), Pharmacyclics; Bruton's tyrosine kinase inhibitors (autoimmune disease), Pharmacyclics
DMW3TGI	CP	Pharmacyclics Inc
DMW3TGI	DE	Autoimmune diabetes

DMTG730	ID	DMTG730
DMTG730	DN	PD-157533
DMTG730	HS	Preclinical
DMTG730	CP	Pfizer
DMTG730	DE	Schizophrenia

DMDSR1X	ID	DMDSR1X
DMDSR1X	DN	PD-157695
DMDSR1X	HS	Preclinical
DMDSR1X	CP	Pfizer
DMDSR1X	DT	Small molecular drug
DMDSR1X	PC	3854666
DMDSR1X	MW	352.14
DMDSR1X	FM	C13H10BrN3O4
DMDSR1X	IC	InChI=1S/C13H10BrN3O4/c14-9-3-1-2-4-10(9)15-13(19)16-11-6-5-8(17(20)21)7-12(11)18/h1-7,18H,(H2,15,16,19)
DMDSR1X	CS	C1=CC=C(C(=C1)NC(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])O)Br
DMDSR1X	IK	MQBZVUNNWUIPMK-UHFFFAOYSA-N
DMDSR1X	IU	1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea
DMDSR1X	CA	CAS 182498-32-4
DMDSR1X	CB	CHEBI:93074
DMDSR1X	DE	Schizophrenia

DM682UV	ID	DM682UV
DM682UV	DN	PD-158771
DM682UV	HS	Preclinical
DM682UV	SN	PD 158771; N-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]pyrimidin-2-amine; Trans-N-(4-(2-(4-Phenyl-1-piperazinyl)ethyl)cyclohexyl)-2-pyrimidinamine
DM682UV	CP	Pfizer
DM682UV	DT	Small molecular drug
DM682UV	PC	3075615
DM682UV	MW	365.5
DM682UV	FM	C22H31N5
DM682UV	IC	InChI=1S/C22H31N5/c1-2-5-21(6-3-1)27-17-15-26(16-18-27)14-11-19-7-9-20(10-8-19)25-22-23-12-4-13-24-22/h1-6,12-13,19-20H,7-11,14-18H2,(H,23,24,25)
DM682UV	CS	C1CC(CCC1CCN2CCN(CC2)C3=CC=CC=C3)NC4=NC=CC=N4
DM682UV	IK	OUUMPVSFLSOGJZ-UHFFFAOYSA-N
DM682UV	IU	N-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]pyrimidin-2-amine
DM682UV	CA	CAS 189152-50-9
DM682UV	DE	Schizophrenia

DMB9Z4C	ID	DMB9Z4C
DMB9Z4C	DN	PD-160170
DMB9Z4C	HS	Preclinical
DMB9Z4C	SN	NCGC00092332-01; BRD-K12079898-001-01-8; 5-nitro-6-(2-propan-2-ylphenyl)sulfonyl-quinolin-8-amine
DMB9Z4C	CP	Parke CDavis
DMB9Z4C	DT	Small molecular drug
DMB9Z4C	PC	9820766
DMB9Z4C	MW	371.4
DMB9Z4C	FM	C18H17N3O4S
DMB9Z4C	IC	InChI=1S/C18H17N3O4S/c1-11(2)12-6-3-4-8-15(12)26(24,25)16-10-14(19)17-13(7-5-9-20-17)18(16)21(22)23/h3-11H,19H2,1-2H3
DMB9Z4C	CS	CC(C)C1=CC=CC=C1S(=O)(=O)C2=C(C3=C(C(=C2)N)N=CC=C3)[N+](=O)[O-]
DMB9Z4C	IK	YUVNGBZROXQYQH-UHFFFAOYSA-N
DMB9Z4C	IU	5-nitro-6-(2-propan-2-ylphenyl)sulfonylquinolin-8-amine
DMB9Z4C	CA	CAS 181468-88-2
DMB9Z4C	CB	CHEBI:92206
DMB9Z4C	DE	Heart disease; Obesity; Hypertension

DMD0GB4	ID	DMD0GB4
DMD0GB4	DN	PD-165167
DMD0GB4	HS	Preclinical
DMD0GB4	SN	CHEMBL332154; SCHEMBL8169927; BDBM50080797; 7-[[(2-Anilinoethyl)amino]methyl]coumarin; L017812
DMD0GB4	CP	Pfizer
DMD0GB4	DT	Small molecular drug
DMD0GB4	PC	9926143
DMD0GB4	MW	294.3
DMD0GB4	FM	C18H18N2O2
DMD0GB4	IC	InChI=1S/C18H18N2O2/c21-18-9-8-15-7-6-14(12-17(15)22-18)13-19-10-11-20-16-4-2-1-3-5-16/h1-9,12,19-20H,10-11,13H2
DMD0GB4	CS	C1=CC=C(C=C1)NCCNCC2=CC3=C(C=C2)C=CC(=O)O3
DMD0GB4	IK	RNNKCHJUBXFBQB-UHFFFAOYSA-N
DMD0GB4	IU	7-[(2-anilinoethylamino)methyl]chromen-2-one
DMD0GB4	DE	Schizophrenia

DMEOVDQ	ID	DMEOVDQ
DMEOVDQ	DN	PD-170292
DMEOVDQ	HS	Preclinical
DMEOVDQ	SN	PD-170292; CHEMBL14153
DMEOVDQ	CP	Pfizer
DMEOVDQ	DT	Small molecular drug
DMEOVDQ	PC	44269000
DMEOVDQ	MW	671.8
DMEOVDQ	FM	C38H49N5O6
DMEOVDQ	IC	InChI=1S/C38H49N5O6/c1-23-9-3-5-12-31(23)42-36(47)39-14-8-7-10-29(20-33(44)45)41-35(46)38(2,21-28-22-40-32-13-6-4-11-30(28)32)43-37(48)49-34-26-16-24-15-25(18-26)19-27(34)17-24/h3-6,9,11-13,22,24-27,29,34,40H,7-8,10,14-21H2,1-2H3,(H,41,46)(H,43,48)(H,44,45)(H2,39,42,47)/t24?,25?,26?,27?,29-,34?,38+/m0/s1
DMEOVDQ	CS	CC1=CC=CC=C1NC(=O)NCCCC[C@@H](CC(=O)O)NC(=O)[C@@](C)(CC2=CNC3=CC=CC=C32)NC(=O)OC4C5CC6CC(C5)CC4C6
DMEOVDQ	IK	LMIPXHAXVWAMTP-VUFPLIBQSA-N
DMEOVDQ	IU	(3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-7-[(2-methylphenyl)carbamoylamino]heptanoic acid
DMEOVDQ	DE	Obesity

DMA5T3J	ID	DMA5T3J
DMA5T3J	DN	Pepticlere
DMA5T3J	HS	Preclinical
DMA5T3J	SN	DP-68; DP-74; Small peptide beta amyloid protein fibril formation inhibitors, Proteotech; Alzheimers disease therapy (nasal spray), ProteTech; Small peptide A-beta protein fibril formation inhibitors, Proteotech; Laminin alpha chain derivatives (Alzheimer's disease), Proteotech; 6-9 mer peptide analogs (Alzheimer's disease), Proteotech
DMA5T3J	CP	Proteotech
DMA5T3J	DE	Alzheimer disease

DMMWQTI	ID	DMMWQTI
DMMWQTI	DN	Peptide P21S10
DMMWQTI	HS	Preclinical
DMMWQTI	SN	P21S10
DMMWQTI	TC	Antiviral Agents
DMMWQTI	DT	Protein/peptide drug
DMMWQTI	SQ	LDLTYEM LSLQQVV K*LNE*Y
DMMWQTI	DE	Middle East Respiratory Syndrome (MERS)

DM3U2S5	ID	DM3U2S5
DM3U2S5	DN	PF-04859989
DM3U2S5	HS	Preclinical
DM3U2S5	SN	(3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one; (S)-3-Amino-1-hydroxy-3,4-dihydroquinolin-2(1H)-one; CHEMBL2047851; 34783-48-7 (free base); 34783-48-7; (3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-2-one; GTPL9038; SCHEMBL2132616; ZINC6117343; BDBM50386292; AKOS006281463; compound 1 [PMID: 23466229]; NCGC00485082-01; Q27088318; (3s)-3-amino-1-hydroxy-3,4-dihydroquinolin-2(1h)-one; Z1601186413
DM3U2S5	CP	Pfizer
DM3U2S5	DT	Small molecular drug
DM3U2S5	PC	22868923
DM3U2S5	MW	178.19
DM3U2S5	FM	C9H10N2O2
DM3U2S5	IC	InChI=1S/C9H10N2O2/c10-7-5-6-3-1-2-4-8(6)11(13)9(7)12/h1-4,7,13H,5,10H2/t7-/m0/s1
DM3U2S5	CS	C1[C@@H](C(=O)N(C2=CC=CC=C21)O)N
DM3U2S5	IK	HYTRYTZFJVVZAF-ZETCQYMHSA-N
DM3U2S5	IU	(3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-2-one
DM3U2S5	DE	Cognitive impairment; Schizophrenia

DM8P9ST	ID	DM8P9ST
DM8P9ST	DN	PF-4800567
DM8P9ST	HS	Preclinical
DM8P9ST	SN	PF4800567; PF 4800567
DM8P9ST	DT	Small molecular drug
DM8P9ST	PC	53472153
DM8P9ST	MW	359.8
DM8P9ST	FM	C17H18ClN5O2
DM8P9ST	IC	InChI=1S/C17H18ClN5O2/c18-11-2-1-3-13(8-11)25-9-14-15-16(19)20-10-21-17(15)23(22-14)12-4-6-24-7-5-12/h1-3,8,10,12H,4-7,9H2,(H2,19,20,21)
DM8P9ST	CS	C1COCCC1N2C3=NC=NC(=C3C(=N2)COC4=CC(=CC=C4)Cl)N
DM8P9ST	IK	AUMDBEHGJRZSOO-UHFFFAOYSA-N
DM8P9ST	IU	3-[(3-chlorophenoxy)methyl]-1-(oxan-4-yl)pyrazolo[3,4-d]pyrimidin-4-amine
DM8P9ST	CA	CAS 1188296-52-7
DM8P9ST	CB	CHEBI:87237
DM8P9ST	DE	Chronic lymphocytic leukaemia

DMTJBP9	ID	DMTJBP9
DMTJBP9	DN	PF-670462
DMTJBP9	HS	Preclinical
DMTJBP9	SN	950912-80-8; PF 670462; PF670462; UNII-D68ANS5I8B; D68ANS5I8B; 4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidinamine Dihydrochloride; PF-670462 HCl; 950912-80-8 (HCl); 4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidinaminedihydrochloride; 4-[1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyrimidin-2-amine dihydrochloride; 4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine;dihydrochloride; 4-[3-Cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine dihydrochloride; 4-(1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyrimidin-2-amine dihydrochloride; PF670462 dihydrochloride; cc-367; C19H20FN5.2ClH; C19H20FN5.2HCl; SCHEMBL18921552; CHEBI:87236; AOB3526; DTXSID50679609; BCP04305; EX-A2193; 3966AH; MFCD12828759; AKOS024457546; BCP9000015; CS-1015; QC-8952; 2-Pyrimidinamine, 4-(1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-, hydrochloride (1:2); AC-32583; AK232229; AS-73728; HY-15490; BCP0726000078; FT-0673653; S6734; A11781; S-7816; PF670462/ PF-670462; J-514222; Q27159459; 4-[1-Cyclohexyl-4-(4-fluorophenyl)- 1H-imidazol-5-yl]-2-pyrimidinamine dihydrochloride; 4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-aminedihydrochloride; 4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyrimidin-2-amine--hydrogen chloride (1/2)
DMTJBP9	DT	Small molecular drug
DMTJBP9	PC	51049607
DMTJBP9	MW	410.3
DMTJBP9	FM	C19H22Cl2FN5
DMTJBP9	IC	InChI=1S/C19H20FN5.2ClH/c20-14-8-6-13(7-9-14)17-18(16-10-11-22-19(21)24-16)25(12-23-17)15-4-2-1-3-5-15;;/h6-12,15H,1-5H2,(H2,21,22,24);2*1H
DMTJBP9	CS	C1CCC(CC1)N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F.Cl.Cl
DMTJBP9	IK	PSNKGVAXBSAHCH-UHFFFAOYSA-N
DMTJBP9	IU	4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine;dihydrochloride
DMTJBP9	CA	CAS 950912-80-8
DMTJBP9	CB	CHEBI:87236
DMTJBP9	DE	Chronic lymphocytic leukaemia

DMNZG8T	ID	DMNZG8T
DMNZG8T	DN	PF-821385
DMNZG8T	HS	Preclinical
DMNZG8T	SN	PF-348089; Gp120 inhibitor (HIV), Pfizer
DMNZG8T	CP	Pfizer Inc
DMNZG8T	DE	Human immunodeficiency virus infection

DM1A2UI	ID	DM1A2UI
DM1A2UI	DN	PGX-200097
DM1A2UI	HS	Preclinical
DM1A2UI	SN	COMT/dopamine D2 receptor inhibitors (schizophrenia), Psychiatric Genomics; Catechol-O-methyltransferase/dopamine D2 receptor inhibitors (schizophrenia), Psychiatric Genomics
DM1A2UI	CP	Psychiatric Genomics Inc
DM1A2UI	DE	Schizophrenia

DMM149N	ID	DMM149N
DMM149N	DN	PHA-568487
DMM149N	HS	Preclinical
DMM149N	CP	Pfizer Inc
DMM149N	PC	9932000
DMM149N	MW	288.34
DMM149N	FM	C16H20N2O3
DMM149N	IC	InChI=1S/C16H20N2O3/c19-16(17-13-10-18-5-3-11(13)4-6-18)12-1-2-14-15(9-12)21-8-7-20-14/h1-2,9,11,13H,3-8,10H2,(H,17,19)/t13-/m0/s1
DMM149N	CS	C1CN2CCC1[C@H](C2)NC(=O)C3=CC4=C(C=C3)OCCO4
DMM149N	IK	LUVXHMJTVXZFPD-ZDUSSCGKSA-N
DMM149N	IU	N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide
DMM149N	CA	CAS 527680-56-4
DMM149N	DE	Cognitive impairment

DMIGH6W	ID	DMIGH6W
DMIGH6W	DN	PHENSERINE TARTRATE
DMIGH6W	HS	Preclinical
DMIGH6W	SN	N-Phenylcarbamic acid (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl ester L-tartrate; (-)-5-O-(N-Phenylcarbamoyl)eseroline L-tartrate
DMIGH6W	DT	Small molecular drug
DMIGH6W	PC	6918263
DMIGH6W	MW	487.5
DMIGH6W	FM	C24H29N3O8
DMIGH6W	IC	InChI=1S/C20H23N3O2.C4H6O6/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14;5-1(3(7)8)2(6)4(9)10/h4-10,13,18H,11-12H2,1-3H3,(H,21,24);1-2,5-6H,(H,7,8)(H,9,10)/t18-,20+;1-,2-/m11/s1
DMIGH6W	CS	C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMIGH6W	IK	XKKPTCVQEJZDGT-PWUAAHBCSA-N
DMIGH6W	IU	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate;(2R,3R)-2,3-dihydroxybutanedioic acid
DMIGH6W	CA	CAS 156910-61-1
DMIGH6W	DE	Parkinson disease

DM16W8F	ID	DM16W8F
DM16W8F	DN	Phenylisoserine derivatives SK80
DM16W8F	HS	Preclinical
DM16W8F	SN	SK80
DM16W8F	TC	Antiviral Agents
DM16W8F	DT	Small molecular drug
DM16W8F	DE	Severe acute respiratory syndrome (SARS)

DMIZCOE	ID	DMIZCOE
DMIZCOE	DN	Piperlongumine
DMIZCOE	HS	Preclinical
DMIZCOE	SN	Piplartine; 20069-09-4; Piperlongumin; UNII-SGD66V4SVJ; (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one; CHEBI:8241; SGD66V4SVJ; MFCD00075706; ST079382; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-1,2,5,6-tetrahydropyridin-2-one; 2(1H)-Pyridinone, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-; 5,6-Dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-2(1H)-pyridinone; BRD2293; Piplartin; BRD-2293; PPLGM; (E)-1-[3-(3,4,5-Trimethoxyphenyl)acryloyl]-5,6-dihydropyridin-2(1H)-one; 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one; 5,6-Dihydro-1-(1-oxo-3-[3,4,5-trimethoxyphenyl]-trans-2-propenyl)-2[1H]-pyridinone; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-trans-2-propenyl]-2(1H)-pyridinone; Piplartine;PPLGM; Prestwick_399; FERROUSFLUOBORATE; Prestwick2_000604; Prestwick3_000604; Piperlongumine; Piplartine; BSPBio_000508; MLS002153903; SCHEMBL173092; SPECTRUM1505135; BPBio1_000560; CHEMBL465843; SCHEMBL2465593; 1-[3-(3,4,5-Trimethoxy-phenyl)-acryloyl]-5,6-dihydro-1H-pyridin-2-one; ACon1_001541; CHEBI:92424; HMS1569J10; HMS2096J10; HMS2234K24; Piperlongumine, >=97% (HPLC); ZINC899053; BCP13030; EX-A2925; HY-N2329; 2659AH; BDBM50462013; NSC794671; s7551; AKOS024284776; CCG-214375; NSC-794671; 2(1H)-Pyridinone, 5,6-dihydro-1-(1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-, (E)-; NCGC00096028-01; NCGC00096028-02; NCGC00096028-03; NCGC00096028-04; NCGC00096028-14; AC-32683; AS-74140; BP-25401; LS-14579; SMR001233252; CS-0021113; P2361; A14124; C10166; SR-01000841248; A1-00162; J-012992; N-(3,4,5-Trimethoxycinnamoyl)-D3-piperidin-2-one; Q7197361; SR-01000841248-2; BRD-K24132293-001-05-3; BRD-K24132293-001-09-5; BRD-K24132293-001-16-0; 5,6-Dihydro-1-(3,4,5-trimethoxycinnamoyl)-2(1H)-pyridinone; 1-[(2E)-3-(3,4,5-Trimethoxyphenyl)-2-propenoyl]-5,6-dihydro-2(1H)-pyridinone #; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-1,5,6-trihydropyridin-2-one; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone, 9CI; Prop-2-en-1-one, 3-(3,4,5-trimethoxyphenyl)-1-(2,3-dihydropyridin-6(1H)-one-1-yl)-; (2E)-1-(1,2,5,6-Tetrahydro-2-oxopyridine-1-yl)-3-(3,4,5-trimethoxyphenyl)-2-propene-1-one
DMIZCOE	DT	Small molecular drug
DMIZCOE	PC	637858
DMIZCOE	MW	317.34
DMIZCOE	FM	C17H19NO5
DMIZCOE	IC	InChI=1S/C17H19NO5/c1-21-13-10-12(11-14(22-2)17(13)23-3)7-8-16(20)18-9-5-4-6-15(18)19/h4,6-8,10-11H,5,9H2,1-3H3/b8-7+
DMIZCOE	CS	COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)N2CCC=CC2=O
DMIZCOE	IK	VABYUUZNAVQNPG-BQYQJAHWSA-N
DMIZCOE	IU	1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one
DMIZCOE	CA	CAS 20069-09-4
DMIZCOE	CB	CHEBI:8241
DMIZCOE	DE	Solid tumour/cancer

DM82Y75	ID	DM82Y75
DM82Y75	DN	PIRINIXIC ACID
DM82Y75	HS	Preclinical
DM82Y75	SN	Pirinixic acid; 50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-(
DM82Y75	DT	Small molecular drug
DM82Y75	PC	5694
DM82Y75	MW	323.8
DM82Y75	FM	C14H14ClN3O2S
DM82Y75	IC	InChI=1S/C14H14ClN3O2S/c1-8-4-3-5-10(9(8)2)16-12-6-11(15)17-14(18-12)21-7-13(19)20/h3-6H,7H2,1-2H3,(H,19,20)(H,16,17,18)
DM82Y75	CS	CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C
DM82Y75	IK	SZRPDCCEHVWOJX-UHFFFAOYSA-N
DM82Y75	IU	2-[4-chloro-6-(2,3-dimethylanilino)pyrimidin-2-yl]sulfanylacetic acid
DM82Y75	CA	CAS 50892-23-4
DM82Y75	CB	CHEBI:32509
DM82Y75	DE	Pulmonary fibrosis

DMXO6YH	ID	DMXO6YH
DMXO6YH	DN	PJ34
DMXO6YH	HS	Preclinical
DMXO6YH	SN	PJ34; 344458-19-1; pj-34; N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE; CHEMBL372303; P34; 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide; Acetamide, N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)-; UYJZZVDLGDDTCL-UHFFFAOYSA-N; PJ34(free base); 1xk9; SCHEMBL422317; ZINC8960; AC1L1J45; BDBM27497; CTK1B7701; MolPort-035-395-737; Ibrutinib (PCI32765 pound(c); HMS3651B06; BCP07990; HY-13688A; 2662AH; AKOS030229047; SB19292; DB08348; CS-1463; NCGC00370866-10; DA-42692; BC600341
DMXO6YH	DT	Small molecular drug
DMXO6YH	PC	4858
DMXO6YH	MW	295.34
DMXO6YH	FM	C17H17N3O2
DMXO6YH	IC	InChI=1S/C17H17N3O2/c1-20(2)10-16(21)18-11-7-8-15-14(9-11)12-5-3-4-6-13(12)17(22)19-15/h3-9H,10H2,1-2H3,(H,18,21)(H,19,22)
DMXO6YH	CS	CN(C)CC(=O)NC1=CC2=C(C=C1)NC(=O)C3=CC=CC=C32
DMXO6YH	IK	UYJZZVDLGDDTCL-UHFFFAOYSA-N
DMXO6YH	IU	2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide
DMXO6YH	DE	Coronavirus infection

DM94ZOI	ID	DM94ZOI
DM94ZOI	DN	PMID21925774-compound-5e
DM94ZOI	HS	Preclinical
DM94ZOI	SN	PMID21925774-C-5e
DM94ZOI	TC	Antiviral Agents
DM94ZOI	DT	Small molecular drug
DM94ZOI	DE	Severe acute respiratory syndrome (SARS)

DMOHPX4	ID	DMOHPX4
DMOHPX4	DN	PMID25197057-Compound6e
DMOHPX4	HS	Preclinical
DMOHPX4	DT	Small molecular drug
DMOHPX4	DE	Staphylococcus infection

DMFNS7U	ID	DMFNS7U
DMFNS7U	DN	PMID26048809-compound2
DMFNS7U	HS	Preclinical
DMFNS7U	SN	PMID26048809-C2
DMFNS7U	TC	Antiviral Agents
DMFNS7U	DT	Small molecular drug
DMFNS7U	DE	Middle East Respiratory Syndrome (MERS)

DMZMYU5	ID	DMZMYU5
DMZMYU5	DN	PMID26868298-compound-5705213
DMZMYU5	HS	Preclinical
DMZMYU5	SN	PMID26868298-C-5705213
DMZMYU5	TC	Antiviral Agents
DMZMYU5	DT	Small molecular drug
DMZMYU5	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMQFUCD	ID	DMQFUCD
DMQFUCD	DN	PMID26868298-compound-N3
DMQFUCD	HS	Preclinical
DMQFUCD	SN	PMID26868298-C-N3
DMQFUCD	TC	Antiviral Agents
DMQFUCD	DT	Small molecular drug
DMQFUCD	DE	Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMUH012	ID	DMUH012
DMUH012	DN	PMID26911565-peptide-P9
DMUH012	HS	Preclinical
DMUH012	SN	PMID26911565-P9
DMUH012	TC	Antiviral Agents
DMUH012	DT	Protein/peptide drug
DMUH012	SQ	NGAICWGPCPTAFRQIGNCGHFKVRCCKIR
DMUH012	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMPC29W	ID	DMPC29W
DMPC29W	DN	PMID27240464-compound-3f
DMPC29W	HS	Preclinical
DMPC29W	SN	PMID27240464-C-3f
DMPC29W	TC	Antiviral Agents
DMPC29W	DT	Small molecular drug
DMPC29W	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMPWUFT	ID	DMPWUFT
DMPWUFT	DN	PMID28216367-compound-6d
DMPWUFT	HS	Preclinical
DMPWUFT	SN	PMID28216367-C-6d
DMPWUFT	TC	Antiviral Agents
DMPWUFT	DT	Small molecular drug
DMPWUFT	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMYNCWK	ID	DMYNCWK
DMYNCWK	DN	PMID28624700-compound-3-31
DMYNCWK	HS	Preclinical
DMYNCWK	SN	Unsymmetrical aromatic disulfides 3-31
DMYNCWK	TC	Antiviral Agents
DMYNCWK	DT	Small molecular drug
DMYNCWK	DE	Severe acute respiratory syndrome (SARS)

DMVB0P3	ID	DMVB0P3
DMVB0P3	DN	PMID30784880-compound-6-5
DMVB0P3	HS	Preclinical
DMVB0P3	SN	PMID30784880-C-6-5
DMVB0P3	TC	Antiviral Agents
DMVB0P3	DT	Small molecular drug
DMVB0P3	DE	Severe acute respiratory syndrome (SARS)

DMXCKL9	ID	DMXCKL9
DMXCKL9	DN	PMID30940566-compound-6
DMXCKL9	HS	Preclinical
DMXCKL9	SN	PMID30940566-C-6
DMXCKL9	TC	Antiviral Agents
DMXCKL9	DT	Small molecular drug
DMXCKL9	DE	Middle East Respiratory Syndrome (MERS)

DMZJWON	ID	DMZJWON
DMZJWON	DN	PMID31244113-compound-2c
DMZJWON	HS	Preclinical
DMZJWON	SN	PMID31244113-C-2c
DMZJWON	TC	Antiviral Agents
DMZJWON	DT	Small molecular drug
DMZJWON	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM9LS0R	ID	DM9LS0R
DM9LS0R	DN	PMID31955138-compound-16
DM9LS0R	HS	Preclinical
DM9LS0R	SN	PMID31955138-C-16
DM9LS0R	TC	Antiviral Agents
DM9LS0R	DT	Small molecular drug
DM9LS0R	DE	Middle East Respiratory Syndrome (MERS)

DMMXR3L	ID	DMMXR3L
DMMXR3L	DN	PMX205
DMMXR3L	HS	Preclinical
DMMXR3L	SN	PMX 205; 514814-49-4; PMX-205; UNII-DC25O3L7KZ; Hydrocinnamate-(orn-Pro-dcha-Trp-Arg); DC25O3L7KZ; Cyclic hexapeptide complement C5a antagonist; N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide; HC-[OP(D-Cha)WR]; SCHEMBL12971708; CHEBI:144869; LP-16; ZINC95627847; HY-110136; CS-0032991; A16946; hydrocinnamate-cyclo(ornithyl-prolyl-D-cyclohexylalanyl-tryptophyl-arginyl); (5->1)-lactam-N(2)-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginine; N-[(3R,6S,9S,15S,20aS)-9-(3-carbamimidamidopropyl)-3-(cyclohexylmethyl)-6-(1H-indol-3-ylmethyl)-1,4,7,10,16-pentaoxoicosahydropyrrolo[1,2-a][1,4,7,10,13]pentaazacyclooctadecin-15-yl]-3-phenylpropanamide
DMMXR3L	DT	Small molecular drug
DMMXR3L	PC	6918845
DMMXR3L	MW	839
DMMXR3L	FM	C45H62N10O6
DMMXR3L	IC	InChI=1S/C45H62N10O6/c46-45(47)49-24-9-18-34-40(57)48-23-10-19-35(51-39(56)22-21-29-12-3-1-4-13-29)44(61)55-25-11-20-38(55)43(60)54-36(26-30-14-5-2-6-15-30)41(58)53-37(42(59)52-34)27-31-28-50-33-17-8-7-16-32(31)33/h1,3-4,7-8,12-13,16-17,28,30,34-38,50H,2,5-6,9-11,14-15,18-27H2,(H,48,57)(H,51,56)(H,52,59)(H,53,58)(H,54,60)(H4,46,47,49)/t34-,35-,36+,37-,38-/m0/s1
DMMXR3L	CS	C1CCC(CC1)C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)NCCC[C@@H](C(=O)N3CCC[C@H]3C(=O)N2)NC(=O)CCC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65
DMMXR3L	IK	VATFHFJULBPYLM-ILOBPARPSA-N
DMMXR3L	IU	N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide
DMMXR3L	CA	CAS 514814-49-4
DMMXR3L	CB	CHEBI:144869
DMMXR3L	DE	Central nervous system disease

DM9SY8E	ID	DM9SY8E
DM9SY8E	DN	PT630
DM9SY8E	HS	Preclinical
DM9SY8E	DT	Peptide
DM9SY8E	DE	Lung cancer; Colon cancer

DMDKLB5	ID	DMDKLB5
DMDKLB5	DN	Puromycin
DMDKLB5	HS	Preclinical
DMDKLB5	SN	puromycin; Stylomycin; Puromycinum; Puromycine; Puromicina; UNII-4A6ZS6Q2CL; P-638; Stillomycin; CL 13900; 3123L; 4A6ZS6Q2CL; 3'-(L-alpha-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine; (S)-3'-((2-Amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyladenosine; GNF-PF-2016; Puromycinum [INN-Latin]; Puromycine [INN-French]; Puromicina [INN-Spanish]; 9-{3-deoxy-3-[(O-methyl-L-tyrosyl)amino]-beta-D-xylofuranosyl}-N,N-dimethyl-9H-purin-6-amine; Bacterenomycin
DMDKLB5	PC	439530
DMDKLB5	MW	471.5
DMDKLB5	FM	C22H29N7O5
DMDKLB5	IC	InChI=1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1
DMDKLB5	CS	CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O
DMDKLB5	IK	RXWNCPJZOCPEPQ-NVWDDTSBSA-N
DMDKLB5	IU	(2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide
DMDKLB5	CA	CAS 53-79-2
DMDKLB5	CB	CHEBI:17939
DMDKLB5	DE	Bacterial infections

DMLBFC0	ID	DMLBFC0
DMLBFC0	DN	Q-44287045
DMLBFC0	HS	Preclinical
DMLBFC0	SN	Macrolactin A; Macrolactin-A; (-)-Macrolactin A; (3Z,5E,8R,9E,11Z,14S,16S,17E,19E,24R)-8,14,16-trihydroxy-24-methyl-1-oxacyclotetracosa-3,5,9,11,17,19-hexaen-2-one; 122540-27-6; Oxacyclotetracosa-3,5,9,11,17,19-hexaen-2-one, 8,14,16-trihydroxy-24-methyl-, (3Z,5E,8S,9E,11Z,14S,16R,17E,19E,24R)-
DMLBFC0	PC	6451096
DMLBFC0	MW	402.5
DMLBFC0	FM	C24H34O5
DMLBFC0	IC	XXDIJWSZFWZBRM-QCEWEWFLSA-N
DMLBFC0	CS	CC1CCCC=CC=CC(CC(CC=CC=CC(CC=CC=CC(=O)O1)O)O)O
DMLBFC0	IK	1S/C24H34O5/c1-20-13-7-3-2-4-8-16-22(26)19-23(27)17-11-5-9-14-21(25)15-10-6-12-18-24(28)29-20/h2,4-6,8-12,14,16,18,20-23,25-27H,3,7,13,15,17,19H2,1H3/b4-2+,10-6+,11-5-,14-9+,16-8+,18-12-/t20-,21+,22-,23+/m1/s1
DMLBFC0	IU	(3Z,5E,8R,9E,11Z,14S,16S,17E,19E,24R)-8,14,16-trihydroxy-24-methyl-1-oxacyclotetracosa-3,5,9,11,17,19-hexaen-2-one
DMLBFC0	CA	CAS 122540-27-6
DMLBFC0	DE	Colon cancer

DMASVOD	ID	DMASVOD
DMASVOD	DN	QSP
DMASVOD	HS	Preclinical
DMASVOD	DE	Acetabular fracture

DMRZBM7	ID	DMRZBM7
DMRZBM7	DN	RANBEZOLID HYDROCHLORIDE
DMRZBM7	HS	Preclinical
DMRZBM7	SN	RBx-7644; N-[3-[3-Fluoro-4-[4-(5-nitrofuran-2-ylmethyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5(S)-ylmethyl]acetamide monohydrochloride
DMRZBM7	DT	Small molecular drug
DMRZBM7	PC	6918631
DMRZBM7	MW	497.9
DMRZBM7	FM	C21H25ClFN5O6
DMRZBM7	IC	InChI=1S/C21H24FN5O6.ClH/c1-14(28)23-11-17-13-26(21(29)33-17)15-2-4-19(18(22)10-15)25-8-6-24(7-9-25)12-16-3-5-20(32-16)27(30)31;/h2-5,10,17H,6-9,11-13H2,1H3,(H,23,28);1H/t17-;/m0./s1
DMRZBM7	CS	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCN(CC3)CC4=CC=C(O4)[N+](=O)[O-])F.Cl
DMRZBM7	IK	XYGNKPXLGBABKJ-LMOVPXPDSA-N
DMRZBM7	IU	N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitrofuran-2-yl)methyl]piperazin-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide;hydrochloride
DMRZBM7	DE	Bacterial infection

DM7JH0K	ID	DM7JH0K
DM7JH0K	DN	RG70099
DM7JH0K	HS	Preclinical
DM7JH0K	CP	Roche
DM7JH0K	DT	Small molecular drug
DM7JH0K	DE	Solid tumour/cancer

DMJGQD2	ID	DMJGQD2
DMJGQD2	DN	RMG-40083
DMJGQD2	HS	Preclinical
DMJGQD2	CP	Remergent
DMJGQD2	DE	Schizophrenia

DMWAR1T	ID	DMWAR1T
DMWAR1T	DN	Ro 61-8048
DMWAR1T	HS	Preclinical
DMWAR1T	SN	199666-03-0; Ro61-8048; 3,4-dimethoxy-N-(4-(3-nitrophenyl)thiazol-2-yl)benzenesulfonamide; Ro-61-8048; 3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide; CHEMBL134915; 3,4-Dimethoxy-N-[4-(3-nitro-phenyl)-thiazol-2-yl]-benzenesulfonamide; CHEBI:34953; C14126; MFCD11040807; 3,4-Dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide; C17H15N3O6S2; Benzenesulfonamide, 3,4-dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]-; AC1NQZWG; 7ZR; SCHEMBL424256; AOB1234; DTXSID20415218; EX-A805; SYN5225; HMS3886F06; BCP07470; ZINC1546077; 4013AH; BDBM50061916; s8172; AKOS024457509; CCG-222062; CS-3332; NE62855; SB19626; NCGC00370730-07; NCGC00370730-09; NCGC00370730-13; AC-32906; AK312615; AS-16581; DA-43342; HY-12347; B7334; FT-0700256; EC-000.2437; Ro 61-8048, >=98% (HPLC); J-012900; Q27116332; 3,4-Dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]-benzenesulfonamide; 3,4-Dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]benzenesulfonamide; 3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzene-1-sulfonamide
DMWAR1T	CP	Roche
DMWAR1T	DT	Small molecular drug
DMWAR1T	PC	5282337
DMWAR1T	MW	421.5
DMWAR1T	FM	C17H15N3O6S2
DMWAR1T	IC	InChI=1S/C17H15N3O6S2/c1-25-15-7-6-13(9-16(15)26-2)28(23,24)19-17-18-14(10-27-17)11-4-3-5-12(8-11)20(21)22/h3-10H,1-2H3,(H,18,19)
DMWAR1T	CS	COC1=C(C=C(C=C1)S(=O)(=O)NC2=NC(=CS2)C3=CC(=CC=C3)[N+](=O)[O-])OC
DMWAR1T	IK	NDPBMCKQJOZAQX-UHFFFAOYSA-N
DMWAR1T	IU	3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide
DMWAR1T	CA	CAS 199666-03-0
DMWAR1T	CB	CHEBI:34953
DMWAR1T	DE	Neurodegenerative disorder

DM3ZE5A	ID	DM3ZE5A
DM3ZE5A	DN	RO-26-2853
DM3ZE5A	HS	Preclinical
DM3ZE5A	CP	Roche
DM3ZE5A	DE	Solid tumour/cancer

DMF3YQZ	ID	DMF3YQZ
DMF3YQZ	DN	Ro-27-3225
DMF3YQZ	HS	Preclinical
DMF3YQZ	CP	Roche; Millenium
DMF3YQZ	DT	Small molecular drug
DMF3YQZ	PC	56603736
DMF3YQZ	MW	782.9
DMF3YQZ	FM	C41H54N10O6
DMF3YQZ	IC	InChI=1S/C41H54N10O6/c1-3-12-36(53)47-32(21-27-15-7-8-16-27)38(55)49-33(22-26-13-5-4-6-14-26)39(56)48-31(19-11-20-45-41(43)44)37(54)50-34(40(57)51(2)25-35(42)52)23-28-24-46-30-18-10-9-17-29(28)30/h4-10,13-15,17-18,31-34H,3,11-12,16,19-25H2,1-2H3,(H2,42,52)(H,47,53)(H,48,56)(H,49,55)(H,50,54)(H4,43,44,45)/t31-,32-,33?,34?/m0/s1
DMF3YQZ	CS	CCCC(=O)N[C@@H](CC1=CC=CC1)C(=O)NC(CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC(CC3=C4C=CC=CC4=NC3)C(=O)N(C)CC(=O)N
DMF3YQZ	IK	IRCWGIYPMAYZQR-URRMOVRVSA-N
DMF3YQZ	IU	(2S)-N-[1-[(2-amino-2-oxoethyl)-methylamino]-3-(2H-indol-3-yl)-1-oxopropan-2-yl]-2-[[2-[[(2S)-2-(butanoylamino)-3-cyclopenta-1,3-dien-1-ylpropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DMF3YQZ	DE	Obesity

DMRT3FK	ID	DMRT3FK
DMRT3FK	DN	RO5461111
DMRT3FK	HS	Preclinical
DMRT3FK	CP	Roche
DMRT3FK	DE	Systemic lupus erythematosus

DMZOUX4	ID	DMZOUX4
DMZOUX4	DN	Romazarit
DMZOUX4	HS	Preclinical
DMZOUX4	SN	ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals
DMZOUX4	CP	Roche Holding AG
DMZOUX4	DT	Small molecular drug
DMZOUX4	PC	71321
DMZOUX4	MW	309.74
DMZOUX4	FM	C15H16ClNO4
DMZOUX4	IC	InChI=1S/C15H16ClNO4/c1-9-12(8-20-15(2,3)14(18)19)21-13(17-9)10-4-6-11(16)7-5-10/h4-7H,8H2,1-3H3,(H,18,19)
DMZOUX4	CS	CC1=C(OC(=N1)C2=CC=C(C=C2)Cl)COC(C)(C)C(=O)O
DMZOUX4	IK	LNXXSBRGLBOASF-UHFFFAOYSA-N
DMZOUX4	IU	2-[[2-(4-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methoxy]-2-methylpropanoic acid
DMZOUX4	CA	CAS 109543-76-2
DMZOUX4	DE	Rheumatoid arthritis

DMOQ63E	ID	DMOQ63E
DMOQ63E	DN	Rottlerin
DMOQ63E	HS	Preclinical
DMOQ63E	SN	Kamalin; Mallotoxin; R 5648; BMK1-F10; (E)-1-(6-((3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl)-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl)-3-phenyl-2-propen-1-one; (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one; 1-[6-(3-Acetyl-2,4,6-trihydroxy-5-methyl-benzyl)-5,7-dihydroxy-2,2-dimethyl-2H-chromen-8-yl]-3-phenyl-propenone; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one
DMOQ63E	DT	Small molecular drug
DMOQ63E	PC	5281847
DMOQ63E	MW	516.5
DMOQ63E	FM	C30H28O8
DMOQ63E	IC	InChI=1S/C30H28O8/c1-15-24(33)19(27(36)22(16(2)31)25(15)34)14-20-26(35)18-12-13-30(3,4)38-29(18)23(28(20)37)21(32)11-10-17-8-6-5-7-9-17/h5-13,33-37H,14H2,1-4H3/b11-10+
DMOQ63E	CS	CC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C(=C3C(=C2O)C=CC(O3)(C)C)C(=O)/C=C/C4=CC=CC=C4)O)O
DMOQ63E	IK	DEZFNHCVIZBHBI-ZHACJKMWSA-N
DMOQ63E	IU	(E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one
DMOQ63E	CA	CAS 82-08-6
DMOQ63E	CB	CHEBI:8899
DMOQ63E	DE	Parkinson disease

DM89VIO	ID	DM89VIO
DM89VIO	DN	RS2-1G9
DM89VIO	HS	Preclinical
DM89VIO	DT	Antibody
DM89VIO	DE	Pseudomonas infection

DMB9IPR	ID	DMB9IPR
DMB9IPR	DN	RS-504393
DMB9IPR	HS	Preclinical
DMB9IPR	SN	300816-15-3; RS 504393; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; RS-504393; RS504393; CHEMBL134074; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; 6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one; ACMC-20a25e; GTPL781; SCHEMBL9972645; CTK4G4374; CHEBI:93525; DTXSID20433290; MolPort-021-804-998; BCPP000086; HMS3269M19; BCP02713; ZINC13527116; ABP000463
DMB9IPR	CP	Roche
DMB9IPR	DT	Small molecular drug
DMB9IPR	PC	9953769
DMB9IPR	MW	417.5
DMB9IPR	FM	C25H27N3O3
DMB9IPR	IC	InChI=1S/C25H27N3O3/c1-17-8-9-22-20(16-17)25(31-24(29)27-22)11-14-28(15-12-25)13-10-21-18(2)30-23(26-21)19-6-4-3-5-7-19/h3-9,16H,10-15H2,1-2H3,(H,27,29)
DMB9IPR	CS	CC1=CC2=C(C=C1)NC(=O)OC23CCN(CC3)CCC4=C(OC(=N4)C5=CC=CC=C5)C
DMB9IPR	IK	ODNICNWASXKNNQ-UHFFFAOYSA-N
DMB9IPR	IU	6-methyl-1'-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]spiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one
DMB9IPR	CA	CAS 300816-15-3
DMB9IPR	CB	CHEBI:93525
DMB9IPR	DE	Chronic obstructive pulmonary disease

DMH1FRY	ID	DMH1FRY
DMH1FRY	DN	RWJ-416457
DMH1FRY	HS	Preclinical
DMH1FRY	SN	JNJ-10283104; JNJ-10391849; Oxazolidinones, RW Johnson; RJW-334181; RWJ-302377; RWJ-306490; RWJ-334181; RWJ-337813; RWJ-400294; RWJ-417174; RWJ-445158
DMH1FRY	CP	RW Johnson Pharmaceutical Research Institute
DMH1FRY	DT	Small molecular drug
DMH1FRY	PC	15984076
DMH1FRY	MW	373.4
DMH1FRY	FM	C18H20FN5O3
DMH1FRY	IC	InChI=1S/C18H20FN5O3/c1-11(25)20-6-14-9-24(18(26)27-14)13-3-4-17(15(19)5-13)23-8-12-7-22(2)21-16(12)10-23/h3-5,7,14H,6,8-10H2,1-2H3,(H,20,25)/t14-/m0/s1
DMH1FRY	CS	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CC4=CN(N=C4C3)C)F
DMH1FRY	IK	UCBHICFFJKDMMR-AWEZNQCLSA-N
DMH1FRY	IU	N-[[(5S)-3-[3-fluoro-4-(2-methyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
DMH1FRY	CA	CAS 474016-05-2
DMH1FRY	DE	Bacterial infection

DMMVS07	ID	DMMVS07
DMMVS07	DN	RWJ-51204
DMMVS07	HS	Preclinical
DMMVS07	SN	5-(Ethoxymethyl)-7-fluoro-N-(2-fluorophenyl)-3-oxo-1,2,3,5-tetrahydropyrido[1,2-a]benzimidazole-4-carboxamide
DMMVS07	DT	Small molecular drug
DMMVS07	PC	9822240
DMMVS07	MW	399.4
DMMVS07	FM	C21H19F2N3O3
DMMVS07	IC	InChI=1S/C21H19F2N3O3/c1-2-29-12-26-17-11-13(22)7-8-16(17)25-10-9-18(27)19(21(25)26)20(28)24-15-6-4-3-5-14(15)23/h3-8,11H,2,9-10,12H2,1H3,(H,24,28)
DMMVS07	CS	CCOCN1C2=C(C=CC(=C2)F)N3C1=C(C(=O)CC3)C(=O)NC4=CC=CC=C4F
DMMVS07	IK	VQOQDABVGWLROX-UHFFFAOYSA-N
DMMVS07	IU	5-(ethoxymethyl)-7-fluoro-N-(2-fluorophenyl)-3-oxo-1,2-dihydropyrido[1,2-a]benzimidazole-4-carboxamide
DMMVS07	CA	CAS 205701-85-5
DMMVS07	DE	Anxiety disorder

DM3AIQO	ID	DM3AIQO
DM3AIQO	DN	RX-01-423
DM3AIQO	HS	Preclinical
DM3AIQO	SN	RX-01 series; RX-01-413; RX-01-445; Non-macrolide antibiotics, Rib-X; Translation inhibitor (50s ribosome subunit), Rib-X
DM3AIQO	CP	Rib-X Pharmaceuticals Inc
DM3AIQO	DE	Bacterial infection

DMXM2BZ	ID	DMXM2BZ
DMXM2BZ	DN	Rycals
DMXM2BZ	HS	Preclinical
DMXM2BZ	SN	Rycals (cardiac disease/muscle disorders); Calcium release channel stabilizers (cardiac disease/muscle disorders), Armgo; Rycals (cardiac disease/muscle disorders), Armgo
DMXM2BZ	CP	Columbia University
DMXM2BZ	DE	Heart failure

DM9Y05C	ID	DM9Y05C
DM9Y05C	DN	S-(2-Aminophenyl)-L-cysteine S,S-dioxide
DM9Y05C	HS	Preclinical
DM9Y05C	SN	SCHEMBL9065263
DM9Y05C	DT	Small molecular drug
DM9Y05C	PC	10263849
DM9Y05C	MW	244.27
DM9Y05C	FM	C9H12N2O4S
DM9Y05C	IC	InChI=1S/C9H12N2O4S/c10-6-3-1-2-4-8(6)16(14,15)5-7(11)9(12)13/h1-4,7H,5,10-11H2,(H,12,13)/t7-/m0/s1
DM9Y05C	CS	C1=CC=C(C(=C1)N)S(=O)(=O)C[C@@H](C(=O)O)N
DM9Y05C	IK	JJUXYMMPJKOKBD-ZETCQYMHSA-N
DM9Y05C	IU	(2R)-2-amino-3-(2-aminophenyl)sulfonylpropanoic acid
DM9Y05C	DE	Bacterial infection

DM4V8ZD	ID	DM4V8ZD
DM4V8ZD	DN	S32504
DM4V8ZD	HS	Preclinical
DM4V8ZD	SN	CHEMBL484599; SCHEMBL3831115; BDBM86473; LS-192133; S32504 (+); (+/-)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4-propyl-2h-naphth[1,2-b]-1,4-oxazine
DM4V8ZD	CP	Shionogi
DM4V8ZD	DT	Small molecular drug
DM4V8ZD	PC	15389743
DM4V8ZD	MW	274.36
DM4V8ZD	FM	C16H22N2O2
DM4V8ZD	IC	InChI=1S/C16H22N2O2/c1-2-7-18-8-9-20-15-13-10-12(16(17)19)4-3-11(13)5-6-14(15)18/h3-4,10,14-15H,2,5-9H2,1H3,(H2,17,19)/t14-,15-/m1/s1
DM4V8ZD	CS	CCCN1CCO[C@H]2[C@H]1CCC3=C2C=C(C=C3)C(=O)N
DM4V8ZD	IK	XKTRZPQOQOCNJU-HUUCEWRRSA-N
DM4V8ZD	IU	(4aR,10bR)-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazine-9-carboxamide
DM4V8ZD	DE	Parkinson disease; Major depressive disorder

DMWQ3TH	ID	DMWQ3TH
DMWQ3TH	DN	S-33084
DMWQ3TH	HS	Preclinical
DMWQ3TH	SN	Benzopyrano[3,4-c]pyrrole derivs, Servier
DMWQ3TH	CP	Servier
DMWQ3TH	DT	Small molecular drug
DMWQ3TH	PC	9868452
DMWQ3TH	MW	451.6
DMWQ3TH	FM	C29H29N3O2
DMWQ3TH	IC	InChI=1S/C29H29N3O2/c30-17-21-8-13-28-26(16-21)27-19-32(18-25(27)20-34-28)15-5-4-14-31-29(33)24-11-9-23(10-12-24)22-6-2-1-3-7-22/h1-3,6-13,16,25,27H,4-5,14-15,18-20H2,(H,31,33)/t25-,27+/m1/s1
DMWQ3TH	CS	C1[C@@H]2COC3=C([C@H]2CN1CCCCNC(=O)C4=CC=C(C=C4)C5=CC=CC=C5)C=C(C=C3)C#N
DMWQ3TH	IK	QQJHRQZZCNYDMX-VPUSJEBWSA-N
DMWQ3TH	IU	N-[4-[(3aR,9bS)-8-cyano-3,3a,4,9b-tetrahydro-1H-chromeno[3,4-c]pyrrol-2-yl]butyl]-4-phenylbenzamide
DMWQ3TH	CA	CAS 273203-30-8
DMWQ3TH	DE	Psychotic disorder

DMGXVRZ	ID	DMGXVRZ
DMGXVRZ	DN	Salicylihalamide A
DMGXVRZ	HS	Preclinical
DMGXVRZ	SN	SCHEMBL2401788
DMGXVRZ	DT	Small molecular drug
DMGXVRZ	PC	643725
DMGXVRZ	MW	439.5
DMGXVRZ	FM	C26H33NO5
DMGXVRZ	IC	InChI=1S/C26H33NO5/c1-3-4-5-6-16-24(30)27-17-10-14-21-18-23(29)19(2)11-7-8-12-20-13-9-15-22(28)25(20)26(31)32-21/h4-10,13,15-17,19,21,23,28-29H,3,11-12,14,18H2,1-2H3,(H,27,30)/b5-4-,8-7+,16-6-,17-10+/t19-,21-,23+/m0/s1
DMGXVRZ	CS	CC/C=C\\C=C/C(=O)N/C=C/C[C@H]1C[C@H]([C@H](C/C=C/CC2=C(C(=CC=C2)O)C(=O)O1)C)O
DMGXVRZ	IK	VFCUJHFLFHQCRD-PFIOQAQVSA-N
DMGXVRZ	IU	(2Z,4Z)-N-[(E)-3-[(4S,6R,7S,9E)-6,16-dihydroxy-7-methyl-2-oxo-3-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraen-4-yl]prop-1-enyl]hepta-2,4-dienamide
DMGXVRZ	CA	CAS 198481-99-1
DMGXVRZ	DE	Solid tumour/cancer

DMLMRGH	ID	DMLMRGH
DMLMRGH	DN	Saliphenylhalamide
DMLMRGH	HS	Preclinical
DMLMRGH	SN	RTA-203; Saliphenylhalamide (cancer); Saliphenylhalamide (cancer), Reata; V-ATPase inhibitor (cancer), Reata; Vacuolar H+-ATPase inhibitors (anticancer), Reata
DMLMRGH	CP	Reata Pharmaceuticals Inc
DMLMRGH	DT	Small molecular drug
DMLMRGH	PC	11271117
DMLMRGH	MW	459.5
DMLMRGH	FM	C28H29NO5
DMLMRGH	IC	InChI=1S/C28H29NO5/c1-20-9-5-6-12-22-13-7-15-24(30)27(22)28(33)34-23(19-25(20)31)14-8-18-29-26(32)17-16-21-10-3-2-4-11-21/h2-8,10-11,13,15,18,20,23,25,30-31H,9,12,14,19H2,1H3,(H,29,32)/b6-5+,18-8+/t20-,23-,25+/m0/s1
DMLMRGH	CS	C[C@H]1C/C=C/CC2=C(C(=CC=C2)O)C(=O)O[C@H](C[C@H]1O)C/C=C/NC(=O)C#CC3=CC=CC=C3
DMLMRGH	IK	FTBLSENPBXIDKK-ZZHCZQHNSA-N
DMLMRGH	IU	N-[(E)-3-[(4S,6R,7S,9E)-6,16-dihydroxy-7-methyl-2-oxo-3-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraen-4-yl]prop-1-enyl]-3-phenylprop-2-ynamide
DMLMRGH	DE	Solid tumour/cancer

DM7E324	ID	DM7E324
DM7E324	DN	SAND-5
DM7E324	HS	Preclinical
DM7E324	SN	Mubodina; Complement C5 minibody (hemolytic uremic syndrome/hemolytic uremic syndrome), ADIENNE
DM7E324	CP	ADIENNE Pharma & Biotech
DM7E324	DE	Glomerulonephritis

DM7NS1L	ID	DM7NS1L
DM7NS1L	DN	Savirin
DM7NS1L	HS	Preclinical
DM7NS1L	SN	3-(4-propan-2-ylphenyl)sulfonyl-1H-triazolo[1,5-a]quinazolin-5-one; 866350-26-7; 3-[(4-isopropylphenyl)sulfonyl][1,2,3]triazolo[1,5-a]quinazolin-5(4H)-one; 3-[4-(propan-2-yl)benzenesulfonyl]-4H,5H-[1,2,3]triazolo[1,5-a]quinazolin-5-one; SMR000016143; MLS000103489; MLS000044860; CHEMBL1494499; CHEBI:107601; HMS2494G18; ZINC8762827; CCG-27345; HTS003632; MFCD05899664; STL094729; AKOS005723252; BS-6686; MCULE-8359721687; UNM000011043901; SR-01000104752; SR-01000104752-1; Q27185926; 3-{[4-(propan-2-yl)phenyl]sulfonyl}[1,2,3]triazolo[1,5-a]quinazolin-5(4H)-one
DM7NS1L	DT	Small molecular drug
DM7NS1L	PC	3243271
DM7NS1L	MW	368.4
DM7NS1L	FM	C18H16N4O3S
DM7NS1L	IC	InChI=1S/C18H16N4O3S/c1-11(2)12-7-9-13(10-8-12)26(24,25)18-16-19-17(23)14-5-3-4-6-15(14)22(16)21-20-18/h3-11,21H,1-2H3
DM7NS1L	CS	CC(C)C1=CC=C(C=C1)S(=O)(=O)C2=NNN3C2=NC(=O)C4=CC=CC=C43
DM7NS1L	IK	GIFXGSITUBUVGH-UHFFFAOYSA-N
DM7NS1L	IU	3-(4-propan-2-ylphenyl)sulfonyl-1H-triazolo[1,5-a]quinazolin-5-one
DM7NS1L	CB	CHEBI:107601
DM7NS1L	DE	Staphylococcus infection

DMFXJDL	ID	DMFXJDL
DMFXJDL	DN	SB 242784
DMFXJDL	HS	Preclinical
DMFXJDL	CP	SmithKline Beecham Biologicals
DMFXJDL	DT	Small molecular drug
DMFXJDL	DE	Arterial calcification

DM6X0PZ	ID	DM6X0PZ
DM6X0PZ	DN	SB222200
DM6X0PZ	HS	Preclinical
DM6X0PZ	SN	S 5192; SB 222200; SB-222200; N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide; (S)-3-Methyl-2-phenyl-N-(1-phenylpropyl)-4-quinolinecarboxamide; 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DM6X0PZ	CP	GlaxoSmithKline
DM6X0PZ	DT	Small molecular drug
DM6X0PZ	PC	6604009
DM6X0PZ	MW	380.5
DM6X0PZ	FM	C26H24N2O
DM6X0PZ	IC	InChI=1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1
DM6X0PZ	CS	CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)C
DM6X0PZ	IK	MQNYRKWJSMQECI-QFIPXVFZSA-N
DM6X0PZ	IU	3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DM6X0PZ	CA	CAS 174635-69-9
DM6X0PZ	CB	CHEBI:92079
DM6X0PZ	DE	Schizoaffective disorder; Schizophrenia

DM0YOXQ	ID	DM0YOXQ
DM0YOXQ	DN	SB-431542
DM0YOXQ	HS	Preclinical
DM0YOXQ	SN	301836-41-9; SB-431542; SB 431542; 4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide; SB431542; UNII-E1557V1V0N; CHEMBL440084; E1557V1V0N; 4-[4-(1,3-BENZODIOXOL-5-YL)-5-(2-PYRIDINYL)-1H-IMIDAZOL-2-YL]BENZAMIDE; 4-(4-(1,3-Benzodioxole-5-yl)-5-(2-pyridyl)-1H-imidazole-2-yl)benzamide; SB 431542 hydrate; C22H16N4O3; 4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide; 4-(4-Benzo[1,3]dioxol-5-yl-5-pyridin-2-yl-1H-imidazol-2-yl)-benzamide
DM0YOXQ	DT	Small molecular drug
DM0YOXQ	PC	4521392
DM0YOXQ	MW	384.4
DM0YOXQ	FM	C22H16N4O3
DM0YOXQ	IC	InChI=1S/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)
DM0YOXQ	CS	C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5
DM0YOXQ	IK	FHYUGAJXYORMHI-UHFFFAOYSA-N
DM0YOXQ	IU	4-[4-(1,3-benzodioxol-5-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide
DM0YOXQ	CA	CAS 301836-41-9
DM0YOXQ	CB	CHEBI:91108
DM0YOXQ	DE	Pulmonary fibrosis

DMXN4UC	ID	DMXN4UC
DMXN4UC	DN	SBX-101
DMXN4UC	HS	Preclinical
DMXN4UC	CP	Symberix
DMXN4UC	DE	Intestinal toxicities from therapy

DMLG682	ID	DMLG682
DMLG682	DN	SCH-1359113
DMLG682	HS	Preclinical
DMLG682	SN	SCH-1341030; SCH-1682496; SCH-745966; SCH-747123; SCH-785532; BACE-1 inhibitors (Alzheimer's disease); BACE-1 inhibitors (Alzheimer's disease), Merck & Co; BACE-1 inhibitors (Alzheimer's disease), Schering-Plough; Beta-secretase inhibitors (Alzheimer's disease), Schering-Plough
DMLG682	CP	Schering-Plough Corp
DMLG682	DT	Small molecular drug
DMLG682	PC	23627211
DMLG682	MW	338.4
DMLG682	FM	C18H18N4OS
DMLG682	IC	InChI=1S/C18H18N4OS/c1-4-5-12-6-13(10-20-9-12)14-7-15(24-11-14)18(2)8-16(23)22(3)17(19)21-18/h6-7,9-11H,8H2,1-3H3,(H2,19,21)/t18-/m0/s1
DMLG682	CS	CC#CC1=CC(=CN=C1)C2=CSC(=C2)[C@@]3(CC(=O)N(C(=N3)N)C)C
DMLG682	IK	IKFZEHQGULJMKI-SFHVURJKSA-N
DMLG682	IU	(6S)-2-amino-3,6-dimethyl-6-[4-(5-prop-1-ynylpyridin-3-yl)thiophen-2-yl]-5H-pyrimidin-4-one
DMLG682	CA	CAS 1613380-81-6
DMLG682	DE	Alzheimer disease

DM9JZ21	ID	DM9JZ21
DM9JZ21	DN	Scriptaid
DM9JZ21	HS	Preclinical
DM9JZ21	SN	CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide
DM9JZ21	CP	Alexis Biochemicals
DM9JZ21	DT	Small molecular drug
DM9JZ21	PC	5186
DM9JZ21	MW	326.3
DM9JZ21	FM	C18H18N2O4
DM9JZ21	IC	InChI=1S/C18H18N2O4/c21-15(19-24)10-2-1-3-11-20-17(22)13-8-4-6-12-7-5-9-14(16(12)13)18(20)23/h4-9,24H,1-3,10-11H2,(H,19,21)
DM9JZ21	CS	C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO
DM9JZ21	IK	JTDYUFSDZATMKU-UHFFFAOYSA-N
DM9JZ21	IU	6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide
DM9JZ21	CA	CAS 287383-59-9
DM9JZ21	CB	CHEBI:92401
DM9JZ21	DE	Solid tumour/cancer

DMJT1E5	ID	DMJT1E5
DMJT1E5	DN	Scutellarin
DMJT1E5	HS	Preclinical
DMJT1E5	SN	Scutellarin; Breviscapin; Scutellarein-7-glucuronide; Scutellarin B; Breviscapine; Scutellarein-7beta-D-glucuronide; Scutellarein 7-beta-D-glucuronide; Scutellarein-7beta-D-glucuronoside; Scutellarein-7-O-beta-D-glucuronide; UNII-16IGP0ML9A; Scutellarein 7-b-D-glucuronide; Scutellarein 7-O-beta-D-glucuronide; 16IGP0ML9A; SCUTELLAREIN 7-O-GLUCURONIDE; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl
DMJT1E5	PC	185617
DMJT1E5	MW	462.4
DMJT1E5	FM	C21H18O12
DMJT1E5	IC	InChI=1S/C21H18O12/c22-8-3-1-7(2-4-8)10-5-9(23)13-11(31-10)6-12(14(24)15(13)25)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-22,24-28H,(H,29,30)/t16-,17-,18+,19-,21+/m0/s1
DMJT1E5	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O
DMJT1E5	IK	DJSISFGPUUYILV-ZFORQUDYSA-N
DMJT1E5	IU	(2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMJT1E5	CA	CAS 27740-01-8
DMJT1E5	CB	CHEBI:61278
DMJT1E5	DE	Cerebrovascular ischaemia

DMELFBU	ID	DMELFBU
DMELFBU	DN	SCY-641
DMELFBU	HS	Preclinical
DMELFBU	CP	SCYNEXIS
DMELFBU	DE	Ocular inflammation

DMLAF6C	ID	DMLAF6C
DMLAF6C	DN	SD1002
DMLAF6C	HS	Preclinical
DMLAF6C	DT	Small molecular drug
DMLAF6C	DE	Alzheimer disease

DM29BW1	ID	DM29BW1
DM29BW1	DN	SD1003
DM29BW1	HS	Preclinical
DM29BW1	DT	Small molecular drug
DM29BW1	DE	Alzheimer disease

DM5LU3N	ID	DM5LU3N
DM5LU3N	DN	Selamectin
DM5LU3N	HS	Preclinical
DM5LU3N	SN	selamectin; UNII-A2669OWX9N; A2669OWX9N; UK-124,114; 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin B1 monosaccharide; Stronghold; Revolution; 220119-17-5; 25-Cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-avermectin A1a
DM5LU3N	PC	9578507
DM5LU3N	MW	770
DM5LU3N	FM	C43H63NO11
DM5LU3N	IC	InChI=1S/C43H63NO11/c1-24-11-10-14-30-23-50-40-36(44-48)27(4)19-33(43(30,40)47)41(46)52-32-20-31(16-15-25(2)38(24)53-35-21-34(49-6)37(45)28(5)51-35)54-42(22-32)18-17-26(3)39(55-42)29-12-8-7-9-13-29/h10-11,14-15,19,24,26,28-29,31-35,37-40,45,47-48H,7-9,12-13,16-18,20-23H2,1-6H3/b11-10+,25-15+,30-14+,44-36-/t24-,26-,28-,31+,32-,33-,34-,35-,37-,38-,39-,40+,42+,43+/m0/s1
DM5LU3N	CS	CC1CCC2(CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5=NO)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)O)OC)C)OC1C7CCCCC7
DM5LU3N	IK	AFJYYKSVHJGXSN-XHKIUTQPSA-N
DM5LU3N	IU	(1R,4S,5'S,6R,6'S,8R,10E,12S,13S,14E,16E,20R,21Z,24S)-6'-cyclohexyl-24-hydroxy-21-hydroxyimino-12-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
DM5LU3N	CA	CAS 165108-07-6
DM5LU3N	DE	Infections disease

DMH1WNI	ID	DMH1WNI
DMH1WNI	DN	SGN-19A
DMH1WNI	HS	Preclinical
DMH1WNI	CP	Seattle Genetics
DMH1WNI	DT	Antibody
DMH1WNI	DE	Haematological malignancy

DMHAONP	ID	DMHAONP
DMHAONP	DN	SHP-627
DMHAONP	HS	Preclinical
DMHAONP	SN	FT011; 1001288-58-9; FT-011; UNII-C6V7ZU2NPR; C6V7ZU2NPR; 2-(3-Methoxy-4-propargyloxycinnamoyl)aminobenzoic acid; 2-[[(E)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoyl]amino]benzoic acid; Benzoic acid, 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)-; Benzoic acid, 2-[[(2E)-3-[3-methoxy-4-(2-propyn-1-yloxy)phenyl]-1-oxo-2-propen-1-yl]amino]-; SCHEMBL1590608; SCHEMBL1590611; CHEMBL1075834; FT 011; ZINC49050436; CS-5842; SB16798; HY-100495; (E)-2-[[3-(3-methoxy-4-(prop-2-ynyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid; (E)-2-[[3-(3-methoxy-4-propargyloxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid; 2-(((2E)-3-(3-Methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid
DMHAONP	DT	Small molecular drug
DMHAONP	PC	23648966
DMHAONP	MW	351.4
DMHAONP	FM	C20H17NO5
DMHAONP	IC	InChI=1S/C20H17NO5/c1-3-12-26-17-10-8-14(13-18(17)25-2)9-11-19(22)21-16-7-5-4-6-15(16)20(23)24/h1,4-11,13H,12H2,2H3,(H,21,22)(H,23,24)/b11-9+
DMHAONP	CS	COC1=C(C=CC(=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OCC#C
DMHAONP	IK	UIWZIDIJCUEOMT-PKNBQFBNSA-N
DMHAONP	IU	2-[[(E)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoyl]amino]benzoic acid
DMHAONP	CA	CAS 1001288-58-9
DMHAONP	DE	Cardiac arrest

DM8DYJQ	ID	DM8DYJQ
DM8DYJQ	DN	SHP656
DM8DYJQ	HS	Preclinical
DM8DYJQ	DT	Small molecular drug
DM8DYJQ	DE	Glioblastoma of brain

DMWBCTA	ID	DMWBCTA
DMWBCTA	DN	SIS-3
DMWBCTA	HS	Preclinical
DMWBCTA	SN	SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-
DMWBCTA	DT	Small molecular drug
DMWBCTA	PC	10138988
DMWBCTA	MW	453.5
DMWBCTA	FM	C28H27N3O3
DMWBCTA	IC	InChI=1S/C28H27N3O3/c1-30-27(19-8-5-4-6-9-19)22(23-10-7-14-29-28(23)30)11-12-26(32)31-15-13-20-16-24(33-2)25(34-3)17-21(20)18-31/h4-12,14,16-17H,13,15,18H2,1-3H3/b12-11+
DMWBCTA	CS	CN1C(=C(C2=C1N=CC=C2)/C=C/C(=O)N3CCC4=CC(=C(C=C4C3)OC)OC)C5=CC=CC=C5
DMWBCTA	IK	IJYPHMXWKKKHGT-VAWYXSNFSA-N
DMWBCTA	IU	(E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one
DMWBCTA	CA	CAS 1009104-85-1
DMWBCTA	CB	CHEBI:87589
DMWBCTA	DE	Renal fibrosis

DM7DNOG	ID	DM7DNOG
DM7DNOG	DN	SK-7041
DM7DNOG	HS	Preclinical
DM7DNOG	SN	IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide
DM7DNOG	DT	Small molecular drug
DM7DNOG	PC	6918714
DM7DNOG	MW	339.4
DM7DNOG	FM	C19H21N3O3
DM7DNOG	IC	InChI=1S/C19H21N3O3/c1-22(2)17-10-8-16(9-11-17)19(24)20-13-15-5-3-14(4-6-15)7-12-18(23)21-25/h3-12,25H,13H2,1-2H3,(H,20,24)(H,21,23)/b12-7+
DM7DNOG	CS	CN(C)C1=CC=C(C=C1)C(=O)NCC2=CC=C(C=C2)/C=C/C(=O)NO
DM7DNOG	IK	WWMASNYTEATYTC-KPKJPENVSA-N
DM7DNOG	IU	4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide
DM7DNOG	DE	Solid tumour/cancer

DMCI371	ID	DMCI371
DMCI371	DN	SK-7068
DMCI371	HS	Preclinical
DMCI371	SN	N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide
DMCI371	DT	Small molecular drug
DMCI371	PC	9799221
DMCI371	MW	365.4
DMCI371	FM	C21H23N3O3
DMCI371	IC	InChI=1S/C21H23N3O3/c25-20(23-27)12-7-16-3-5-17(6-4-16)15-22-21(26)18-8-10-19(11-9-18)24-13-1-2-14-24/h3-12,27H,1-2,13-15H2,(H,22,26)(H,23,25)/b12-7+
DMCI371	CS	C1CCN(C1)C2=CC=C(C=C2)C(=O)NCC3=CC=C(C=C3)/C=C/C(=O)NO
DMCI371	IK	JKVNVKOVLBVYHQ-KPKJPENVSA-N
DMCI371	IU	N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]-4-pyrrolidin-1-ylbenzamide
DMCI371	DE	Solid tumour/cancer

DMY9DA3	ID	DMY9DA3
DMY9DA3	DN	SLV-332
DMY9DA3	HS	Preclinical
DMY9DA3	SN	AC1MHEA6; Isoxyl &amp
DMY9DA3	CP	Solvay
DMY9DA3	DT	Small molecular drug
DMY9DA3	PC	3002337
DMY9DA3	MW	553.7
DMY9DA3	FM	C30H39N3O5S
DMY9DA3	IC	InChI=1S/C23H32N2O2S.C7H7NO3/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4;8-4-1-2-5(7(10)11)6(9)3-4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28);1-3,9H,8H2,(H,10,11)
DMY9DA3	CS	CC(C)CCOC1=CC=C(C=C1)NC(=S)NC2=CC=C(C=C2)OCCC(C)C.C1=CC(=C(C=C1N)O)C(=O)O
DMY9DA3	IK	HHBOLVQEBVCBNA-UHFFFAOYSA-N
DMY9DA3	IU	4-amino-2-hydroxybenzoic acid;1,3-bis[4-(3-methylbutoxy)phenyl]thiourea
DMY9DA3	DE	Irritable bowel syndrome

DM3X4JL	ID	DM3X4JL
DM3X4JL	DN	SMITB14
DM3X4JL	HS	Preclinical
DM3X4JL	DT	Antibody
DM3X4JL	DE	Mycobacterium infection

DM5KE4R	ID	DM5KE4R
DM5KE4R	DN	SNAP-7941
DM5KE4R	HS	Preclinical
DM5KE4R	SN	Snap7941
DM5KE4R	CP	Synaptic
DM5KE4R	DT	Small molecular drug
DM5KE4R	PC	11520239
DM5KE4R	MW	613.7
DM5KE4R	FM	C31H37F2N5O6
DM5KE4R	IC	InChI=1S/C31H37F2N5O6/c1-19(39)35-23-7-4-6-21(16-23)20-10-14-37(15-11-20)13-5-12-34-30(41)38-28(22-8-9-24(32)25(33)17-22)27(29(40)44-3)26(18-43-2)36-31(38)42/h4,6-9,16-17,20,28H,5,10-15,18H2,1-3H3,(H,34,41)(H,35,39)(H,36,42)/t28-/m0/s1
DM5KE4R	CS	CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCNC(=O)N3[C@H](C(=C(NC3=O)COC)C(=O)OC)C4=CC(=C(C=C4)F)F
DM5KE4R	IK	FWMHZWMPUWAUPL-NDEPHWFRSA-N
DM5KE4R	IU	methyl (4S)-3-[3-[4-(3-acetamidophenyl)piperidin-1-yl]propylcarbamoyl]-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,4-dihydropyrimidine-5-carboxylate
DM5KE4R	DE	Depression; Anxiety disorder; Obesity

DMSNX4O	ID	DMSNX4O
DMSNX4O	DN	SoRI-9409
DMSNX4O	HS	Preclinical
DMSNX4O	SN	SoRI-9409; CHEMBL610261
DMSNX4O	CP	Southern Research Institute
DMSNX4O	DT	Small molecular drug
DMSNX4O	PC	9805452
DMSNX4O	MW	487
DMSNX4O	FM	C29H27ClN2O3
DMSNX4O	IC	InChI=1S/C29H27ClN2O3/c30-21-6-3-17(4-7-21)20-11-19-13-29(34)23-12-18-5-8-22(33)26-24(18)28(29,27(35-26)25(19)31-14-20)9-10-32(23)15-16-1-2-16/h3-8,11,14,16,23,27,33-34H,1-2,9-10,12-13,15H2/t23-,27+,28+,29-/m1/s1
DMSNX4O	CS	C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C=C(C=N6)C8=CC=C(C=C8)Cl
DMSNX4O	IK	WRVDUHKCIPYGNZ-FQYQUSJJSA-N
DMSNX4O	IU	(1S,2S,10R,18R)-6-(4-chlorophenyl)-19-(cyclopropylmethyl)-11-oxa-8,19-diazahexacyclo[10.9.1.01,10.02,18.04,9.016,22]docosa-4(9),5,7,12,14,16(22)-hexaene-2,13-diol
DMSNX4O	DE	Alcohol dependence

DMJHWYP	ID	DMJHWYP
DMJHWYP	DN	Spautin 1
DMJHWYP	HS	Preclinical
DMJHWYP	SN	Spautin-1; 1262888-28-7; 6-Fluoro-N-(4-fluorobenzyl)quinazolin-4-amine; 6-fluoro-N-[(4-fluorophenyl)methyl]quinazolin-4-amine; CHEMBL2391504; 6-Fluoro-N-[(4-Fluorophenyl)methyl]-4-quinazolinamine; 4-Quinazolinamine, 6-fluoro-N-[(4-fluorophenyl)methyl]-; Spautin-1 analogue; MBCQ derivative C43; MLS006010730; SCHEMBL1068401; AOB5088; EX-A668; HMS3750O05; HMS3871D13; Spautin-1, >=98% (HPLC); BCP15695; BCP16463; BDBM50069761; MFCD16962292; s7888; ZINC41470892; AKOS016367939; CCG-267171; CS-4616; MCULE-4088585655; SB19056; NCGC00263555-02; NCGC00263555-05; NCGC00263555-07; AK161228; AS-69827; HY-12990; SMR004701692; DS-017062; B5873; FT-0700152; J-690113; Spautin 1 analogue;Spautin1 analogue;N-(4-chlorobenzyl)-6-fluoroquinazoline-4-amine; C43
DMJHWYP	CP	Shanghai Institute of Organic Chemistry; Harvard Medical School
DMJHWYP	DT	Small molecular drug
DMJHWYP	PC	51037431
DMJHWYP	MW	271.26
DMJHWYP	FM	C15H11F2N3
DMJHWYP	IC	InChI=1S/C15H11F2N3/c16-11-3-1-10(2-4-11)8-18-15-13-7-12(17)5-6-14(13)19-9-20-15/h1-7,9H,8H2,(H,18,19,20)
DMJHWYP	CS	C1=CC(=CC=C1CNC2=NC=NC3=C2C=C(C=C3)F)F
DMJHWYP	IK	AWIVHRPYFSSVOG-UHFFFAOYSA-N
DMJHWYP	IU	6-fluoro-N-[(4-fluorophenyl)methyl]quinazolin-4-amine
DMJHWYP	CA	CAS 1262888-28-7
DMJHWYP	DE	Inflammation

DMMA2ZW	ID	DMMA2ZW
DMMA2ZW	DN	SPH-1285
DMMA2ZW	HS	Preclinical
DMMA2ZW	SN	Galantamine derivatives, Sanochemia; SPH-1286; SPH-1359
DMMA2ZW	CP	Sanochemia Pharmazeutika AG
DMMA2ZW	DE	Alzheimer disease

DM32NMB	ID	DM32NMB
DM32NMB	DN	S-Phenyl-L-cysteine sulfoxide
DM32NMB	HS	Preclinical
DM32NMB	SN	S-phenyl-l-cysteine sulfoxide; 3-(Phenylsulfinyl)-L-alanine; SCHEMBL17894423; (2R)-2-Amino-3-(phenylsulfinyl)propanoic acid; 103000-63-1
DM32NMB	DT	Small molecular drug
DM32NMB	PC	101712556
DM32NMB	MW	213.26
DM32NMB	FM	C9H11NO3S
DM32NMB	IC	InChI=1S/C9H11NO3S/c10-8(9(11)12)6-14(13)7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-,14?/m0/s1
DM32NMB	CS	C1=CC=C(C=C1)S(=O)C[C@@H](C(=O)O)N
DM32NMB	IK	YIYUCMJLQCHZLS-BVVIDWAXSA-N
DM32NMB	IU	(2R)-2-amino-3-(benzenesulfinyl)propanoic acid
DM32NMB	DE	Bacterial infection

DMYZQKC	ID	DMYZQKC
DMYZQKC	DN	SPHINX31
DMYZQKC	HS	Preclinical
DMYZQKC	SN	1818389-84-2; N-(2-(4-(pyridin-2-ylmethyl)piperazin-1-yl)-5-(trifluoromethyl)phenyl)-5-(pyridin-4-yl)furan-2-carboxamide; 5-(4-pyridinyl)-N-[2-[4-(2-pyridinylmethyl)-1-piperazinyl]-5-(trifluoromethyl)phenyl]-2-furancarboxamide; SPHINX 31;SPHINX-31; SCHEMBL17196904; BDBM221074; AMY11306; BCP30381; EX-A2804; s8810; BS-16147; HY-117661; CS-0066777; US9695160, 12; RXZ
DMYZQKC	CP	Exonate
DMYZQKC	DT	Small molecular drug
DMYZQKC	PC	91972002
DMYZQKC	MW	507.5
DMYZQKC	FM	C27H24F3N5O2
DMYZQKC	IC	InChI=1S/C27H24F3N5O2/c28-27(29,30)20-4-5-23(35-15-13-34(14-16-35)18-21-3-1-2-10-32-21)22(17-20)33-26(36)25-7-6-24(37-25)19-8-11-31-12-9-19/h1-12,17H,13-16,18H2,(H,33,36)
DMYZQKC	CS	C1CN(CCN1CC2=CC=CC=N2)C3=C(C=C(C=C3)C(F)(F)F)NC(=O)C4=CC=C(O4)C5=CC=NC=C5
DMYZQKC	IK	VURLRACCOCGFDB-UHFFFAOYSA-N
DMYZQKC	IU	5-pyridin-4-yl-N-[2-[4-(pyridin-2-ylmethyl)piperazin-1-yl]-5-(trifluoromethyl)phenyl]furan-2-carboxamide
DMYZQKC	DE	Wet age-related macular degeneration

DMC1WAJ	ID	DMC1WAJ
DMC1WAJ	DN	SPI-376
DMC1WAJ	HS	Preclinical
DMC1WAJ	SN	NEO 376; SCHEMBL1253420; CQSQHUPRBBCQRE-UHFFFAOYSA-N; CS-6790; HY-101583; L001673; 1-{2-[4-(3-Chlorophenyl)piperazin-1-yl]ethyl}-1,5,6,7-tetrahydroindol 4-one; 1-{2-[4-(3-Chlorophenyl)piperazin-1-yl]ethyl}-1,5,6,7-tetrahydroindol-4-one; 1-{2-[4-(3-Chloro-phenyl)-piperazin-1-yl]-ethyl}-1,5,6,7-tetrahydro-indol 4-one
DMC1WAJ	CP	Spectrum Pharmaceuticals
DMC1WAJ	DT	Small molecular drug
DMC1WAJ	PC	9906770
DMC1WAJ	MW	357.9
DMC1WAJ	FM	C20H24ClN3O
DMC1WAJ	IC	InChI=1S/C20H24ClN3O/c21-16-3-1-4-17(15-16)23-12-9-22(10-13-23)11-14-24-8-7-18-19(24)5-2-6-20(18)25/h1,3-4,7-8,15H,2,5-6,9-14H2
DMC1WAJ	CS	C1CC2=C(C=CN2CCN3CCN(CC3)C4=CC(=CC=C4)Cl)C(=O)C1
DMC1WAJ	IK	CQSQHUPRBBCQRE-UHFFFAOYSA-N
DMC1WAJ	IU	1-[2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl]-6,7-dihydro-5H-indol-4-one
DMC1WAJ	DE	Schizophrenia

DMO2UKI	ID	DMO2UKI
DMO2UKI	DN	SP-MET-1
DMO2UKI	HS	Preclinical
DMO2UKI	SN	S1004A receptor antagonist (cancer), Supratek; SP-MET-X1; Antimetastatic agent (oral, cancer), Supratek; S1004A receptor antagonist (oral, melanoma/breast/colorectal cancer), Supratek
DMO2UKI	CP	Supratek Pharma Inc
DMO2UKI	DE	Breast cancer

DM7MDZE	ID	DM7MDZE
DM7MDZE	DN	SR1078
DM7MDZE	HS	Preclinical
DM7MDZE	SN	1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2
DM7MDZE	DT	Small molecular drug
DM7MDZE	PC	17980288
DM7MDZE	MW	431.25
DM7MDZE	FM	C17H10F9NO2
DM7MDZE	IC	InChI=1S/C17H10F9NO2/c18-15(19,20)11-3-1-9(2-4-11)13(28)27-12-7-5-10(6-8-12)14(29,16(21,22)23)17(24,25)26/h1-8,29H,(H,27,28)
DM7MDZE	CS	C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O)C(F)(F)F
DM7MDZE	IK	DUXWIYXHHGNUJU-UHFFFAOYSA-N
DM7MDZE	IU	N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide
DM7MDZE	CA	CAS 1246525-60-9
DM7MDZE	DE	Liver cancer

DMZV9JX	ID	DMZV9JX
DMZV9JX	DN	SR1555
DMZV9JX	HS	Preclinical
DMZV9JX	SN	CHEMBL3218917; SR-1555; 1386439-51-5; 1-(4-((4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)ethan-1-one; 1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone; SCHEMBL13974905; GTPL10145; BDBM50044227; ZINC95537675
DMZV9JX	DT	Small molecular drug
DMZV9JX	PC	71470549
DMZV9JX	MW	460.4
DMZV9JX	FM	C22H22F6N2O2
DMZV9JX	IC	InChI=1S/C22H22F6N2O2/c1-15(31)30-12-10-29(11-13-30)14-16-2-4-17(5-3-16)18-6-8-19(9-7-18)20(32,21(23,24)25)22(26,27)28/h2-9,32H,10-14H2,1H3
DMZV9JX	CS	CC(=O)N1CCN(CC1)CC2=CC=C(C=C2)C3=CC=C(C=C3)C(C(F)(F)F)(C(F)(F)F)O
DMZV9JX	IK	LTFVNEZXOPUABB-UHFFFAOYSA-N
DMZV9JX	IU	1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone
DMZV9JX	DE	Rheumatoid arthritis

DMWCBG8	ID	DMWCBG8
DMWCBG8	DN	SR2211
DMWCBG8	HS	Preclinical
DMWCBG8	SN	1359164-11-6; sr-2211; SR 2211; CHEMBL2137199; 1,1,1,3,3,3-hexafluoro-2-[3-fluoro-4-[4-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]phenyl]propan-2-ol; 1,1,1,3,3,3-hexafluoro-2-[2-fluoro-4'-({4-[(pyridin-4-yl)methyl]piperazin-1-yl}methyl)[1,1'-biphenyl]-4-yl]propan-2-ol; 2-Fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-; A,; A-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol; 2-fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-aa-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol; MLS004256334; SCHEMBL13974431; C26H24F7N3O; GTPL10144; AOB1053; SYN5040; ML310; BDBM50005410; ZINC95571083; AKOS024458387; NCGC00379220-06; AS-16406; HY-16998; SMR003081219; B5743; CS-0013508; J3.525.407B; SR-03000002211; SR-03000002211-1; 1,1,1,3,3,3-hexafluoro-2-(2-fluoro-4'-((4-(pyridin-4-ylmethyl)piperazin-1-yl)methyl)-[1,1'-biphenyl]-4-yl)propan-2-ol; 2-Fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-?,?-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol; 2-Fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-a,a-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol; 2-Fluoro-4'-[[4-(4-pyridinylMethyl)-1-piperazinyl]Methyl]-alpha,alpha-bis(trifluoroMethyl)-[1,1'-biphenyl]-4-Methanol; L7P
DMWCBG8	DT	Small molecular drug
DMWCBG8	PC	51035449
DMWCBG8	MW	527.5
DMWCBG8	FM	C26H24F7N3O
DMWCBG8	IC	InChI=1S/C26H24F7N3O/c27-23-15-21(24(37,25(28,29)30)26(31,32)33)5-6-22(23)20-3-1-18(2-4-20)16-35-11-13-36(14-12-35)17-19-7-9-34-10-8-19/h1-10,15,37H,11-14,16-17H2
DMWCBG8	CS	C1CN(CCN1CC2=CC=C(C=C2)C3=C(C=C(C=C3)C(C(F)(F)F)(C(F)(F)F)O)F)CC4=CC=NC=C4
DMWCBG8	IK	KVHKWAZUPPBMLL-UHFFFAOYSA-N
DMWCBG8	IU	1,1,1,3,3,3-hexafluoro-2-[3-fluoro-4-[4-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]phenyl]propan-2-ol
DMWCBG8	DE	Autoimmune disease

DM96IUW	ID	DM96IUW
DM96IUW	DN	SR3335
DM96IUW	HS	Preclinical
DM96IUW	SN	293753-05-6; SR-3335; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]thiophene-2-sulfonamide; 2-Thiophenesulfonamide, N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-thiophenesulfonamide; N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-2-thiophenesulfonamide; N-(4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl)thiophene-2-sulfonamide; MLS003126319; C13H9F6NO3S2; CHEMBL3218916; SCHEMBL12334063; CHEBI:92371; DTXSID70368245; HMS3740K07; ML176; BCP13177; ZINC3243391; 4064AH; CS-1044; NCGC00378899-02; NCGC00378899-03; AC-32811; AK547718; AS-74314; HY-14413; SMR001835204; W-5295; SR-06000113335-2; Q27164113; ML-176;SR 3335;SR-3335;ML176;ML 176; SR-3335;SR 3335; ML 176; ML-176; ML176; N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}thiophene-2-sulfonamide
DM96IUW	DT	Small molecular drug
DM96IUW	PC	2360837
DM96IUW	MW	405.3
DM96IUW	FM	C13H9F6NO3S2
DM96IUW	IC	InChI=1S/C13H9F6NO3S2/c14-12(15,16)11(21,13(17,18)19)8-3-5-9(6-4-8)20-25(22,23)10-2-1-7-24-10/h1-7,20-21H
DM96IUW	CS	C1=CSC(=C1)S(=O)(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O
DM96IUW	IK	LZWUNZRMANFRAO-UHFFFAOYSA-N
DM96IUW	IU	N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]thiophene-2-sulfonamide
DM96IUW	CA	CAS 293753-05-6
DM96IUW	CB	CHEBI:92371
DM96IUW	DE	Type-2 diabetes

DMSK5N3	ID	DMSK5N3
DMSK5N3	DN	SR8278
DMSK5N3	HS	Preclinical
DMSK5N3	SN	SR 8278; SR-8278
DMSK5N3	DT	Small molecular drug
DMSK5N3	PC	53393127
DMSK5N3	MW	361.5
DMSK5N3	FM	C18H19NO3S2
DMSK5N3	IC	InChI=1S/C18H19NO3S2/c1-3-22-18(21)14-10-12-6-4-5-7-13(12)11-19(14)17(20)15-8-9-16(23-2)24-15/h4-9,14H,3,10-11H2,1-2H3
DMSK5N3	CS	CCOC(=O)C1CC2=CC=CC=C2CN1C(=O)C3=CC=C(S3)SC
DMSK5N3	IK	UIEBLUZPSFAFOC-UHFFFAOYSA-N
DMSK5N3	IU	ethyl 2-(5-methylsulfanylthiophene-2-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylate
DMSK5N3	CA	CAS 1254944-66-5
DMSK5N3	DE	Myocardial disease

DM8SKU1	ID	DM8SKU1
DM8SKU1	DN	SR9009
DM8SKU1	HS	Preclinical
DM8SKU1	SN	1379686-30-2; SR-9009; Stenabolic (SR9009); SR 9009; ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate; CHEMBL1961796; 1-Pyrrolidinecarboxylic acid, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-, ethyl ester; 1-pyrrolidinecarboxylic acid, 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-, ethyl ester; GTPL8901; EX-A726; BCP16215; BDBM50366238; MFCD29472236; s8692; AKOS027470307; CCG-269102; CS-4669; DB14013; SB19006; NCGC00384202-01; AC-30219; AK547297; AS-55859; HY-16989; J-690150; Q15410184; N'-[(1E)-1-(5-Chloro-2-hydroxyphenyl)ethylidene]-3-(4-morpholinylsulfonyl)benzohydrazide; ethyl 3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate; ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitro-2-thienyl)methyl]amino]methyl]pyrrolidine-1-carboxylate; Ethyl 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-1-pyrrolidinecarboxylate
DM8SKU1	DT	Small molecular drug
DM8SKU1	PC	57394020
DM8SKU1	MW	437.9
DM8SKU1	FM	C20H24ClN3O4S
DM8SKU1	IC	InChI=1S/C20H24ClN3O4S/c1-2-28-20(25)23-10-9-16(13-23)12-22(11-15-3-5-17(21)6-4-15)14-18-7-8-19(29-18)24(26)27/h3-8,16H,2,9-14H2,1H3
DM8SKU1	CS	CCOC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]
DM8SKU1	IK	MMJJNHOIVCGAAP-UHFFFAOYSA-N
DM8SKU1	IU	ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate
DM8SKU1	CA	CAS 1379686-30-2
DM8SKU1	DE	Solid tumour/cancer

DMZ9BO8	ID	DMZ9BO8
DMZ9BO8	DN	SR9011
DMZ9BO8	HS	Preclinical
DMZ9BO8	SN	SR-9011; 1379686-29-9; CHEMBL1961797; 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide; 1-Pyrrolidinecarboxamide, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-n-pentyl-; GTPL8900; BDBM50366239; CS-4668; DB14014; SB19005; SR 9011; NCGC00347956-01; AK547296; AS-55867; HY-16988; Q15410183
DMZ9BO8	DT	Small molecular drug
DMZ9BO8	PC	57394021
DMZ9BO8	MW	479
DMZ9BO8	FM	C23H31ClN4O3S
DMZ9BO8	IC	InChI=1S/C23H31ClN4O3S/c1-2-3-4-12-25-23(29)27-13-11-19(16-27)15-26(14-18-5-7-20(24)8-6-18)17-21-9-10-22(32-21)28(30)31/h5-10,19H,2-4,11-17H2,1H3,(H,25,29)
DMZ9BO8	CS	CCCCCNC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]
DMZ9BO8	IK	PPUYOYQTTWJTIU-UHFFFAOYSA-N
DMZ9BO8	IU	3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide
DMZ9BO8	CA	CAS 1379686-29-9
DMZ9BO8	DE	Solid tumour/cancer

DM84EOW	ID	DM84EOW
DM84EOW	DN	SSR-103800
DM84EOW	HS	Preclinical
DM84EOW	CP	Sanofi-Aventis
DM84EOW	DE	Schizophrenia

DMQTR4I	ID	DMQTR4I
DMQTR4I	DN	SSR-504734
DMQTR4I	HS	Preclinical
DMQTR4I	SN	2-chloro-N-[(R)-phenyl-(2-piperidyl)methyl]-3-(trifluoromethyl)benzamide Hydrochloride
DMQTR4I	CP	Sanofi-Aventis
DMQTR4I	DT	Small molecular drug
DMQTR4I	PC	9954540
DMQTR4I	MW	396.8
DMQTR4I	FM	C20H20ClF3N2O
DMQTR4I	IC	InChI=1S/C20H20ClF3N2O/c21-17-14(9-6-10-15(17)20(22,23)24)19(27)26-18(13-7-2-1-3-8-13)16-11-4-5-12-25-16/h1-3,6-10,16,18,25H,4-5,11-12H2,(H,26,27)/t16-,18-/m0/s1
DMQTR4I	CS	C1CCN[C@@H](C1)[C@H](C2=CC=CC=C2)NC(=O)C3=C(C(=CC=C3)C(F)(F)F)Cl
DMQTR4I	IK	MEZRZVWPLXVLSO-WMZOPIPTSA-N
DMQTR4I	IU	2-chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide
DMQTR4I	CA	CAS 742693-38-5
DMQTR4I	DE	Schizophrenia

DM0NPIO	ID	DM0NPIO
DM0NPIO	DN	SSYA10-001
DM0NPIO	HS	Preclinical
DM0NPIO	SN	3-[(2-Nitrophenyl)sulfanylmethyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
DM0NPIO	TC	Antiviral Agents
DM0NPIO	DT	Small molecular drug
DM0NPIO	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMXZ08K	ID	DMXZ08K
DMXZ08K	DN	SSYA10-001
DMXZ08K	HS	Preclinical
DMXZ08K	SN	3-[(2-nitrophenyl)sulfanylmethyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione; MLS001181552; DSHS00884; SMR000567368; 675104-49-1; CHEMBL1595621; SCHEMBL15398584; BDBM61876; cid_2807230; HMS2884A17; CCG-45281; ZINC15923400; MCULE-1412768678; HY-113794; CS-0065749; SR-01000635060-1; 4-allyl-3-[[(2-nitrophenyl)thio]methyl]-1H-1,2,4-triazole-5-thione; 3-[(2-nitrophenyl)sulphanylmethyl]-4prop-2-enyl-1h-1,2,4-triazole-5-thione; 3-[[(2-nitrophenyl)thio]methyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
DMXZ08K	DT	Small molecular drug
DMXZ08K	PC	2807230
DMXZ08K	MW	308.4
DMXZ08K	FM	C12H12N4O2S2
DMXZ08K	IC	InChI=1S/C12H12N4O2S2/c1-2-7-15-11(13-14-12(15)19)8-20-10-6-4-3-5-9(10)16(17)18/h2-6H,1,7-8H2,(H,14,19)
DMXZ08K	CS	C=CCN1C(=NNC1=S)CSC2=CC=CC=C2[N+](=O)[O-]
DMXZ08K	IK	VWFIHGWHMXSTAO-UHFFFAOYSA-N
DMXZ08K	IU	3-[(2-nitrophenyl)sulfanylmethyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
DMXZ08K	DE	Coronavirus infection

DM7Y4GT	ID	DM7Y4GT
DM7Y4GT	DN	T-226293
DM7Y4GT	HS	Preclinical
DM7Y4GT	SN	Triparanol; TRIPARANOL; Metasqualene; MER 29; 78-41-1; triparanolum; valip; Metasclene; Clotrox; Triparanolo [DCIT]; Hipocolestina; Acosterina; Drenaren; Diticyl; Triparanol [INN:BAN]; Triparanolum [INN-Latin]; EINECS 201-115-0; NSC 65345; BRN 2064866; 1-(4-(2-Diethylaminoethoxy)phenyl)-1-p-tolyl-2-(4-chlorophenyl)ethanol; CHEMBL187709; 2-p-Chlorophenyl-1-(p-(2-diethylaminoethoxy)phenyl)-1-p-tolylethanol; 1-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(p-tolyl)-2-(p-chlorophenyl)ethanol; NCGC00165907-02
DM7Y4GT	CP	Schering Plough
DM7Y4GT	DT	Small molecular drug
DM7Y4GT	PC	6536
DM7Y4GT	MW	438
DM7Y4GT	FM	C27H32ClNO2
DM7Y4GT	IC	InChI=1S/C27H32ClNO2/c1-4-29(5-2)18-19-31-26-16-12-24(13-17-26)27(30,23-10-6-21(3)7-11-23)20-22-8-14-25(28)15-9-22/h6-17,30H,4-5,18-20H2,1-3H3
DM7Y4GT	CS	CCN(CC)CCOC1=CC=C(C=C1)C(CC2=CC=C(C=C2)Cl)(C3=CC=C(C=C3)C)O
DM7Y4GT	IK	SYHDSBBKRLVLFF-UHFFFAOYSA-N
DM7Y4GT	IU	2-(4-chlorophenyl)-1-[4-[2-(diethylamino)ethoxy]phenyl]-1-(4-methylphenyl)ethanol
DM7Y4GT	CA	CAS 78-41-1
DM7Y4GT	CB	CHEBI:135714
DM7Y4GT	DE	Obesity

DMJ6P9U	ID	DMJ6P9U
DMJ6P9U	DN	T-226296
DMJ6P9U	HS	Preclinical
DMJ6P9U	SN	N-[6-(Dimethylaminomethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]-4-(4-fluorophenyl)benzamide; T 226296; CHEMBL178707; 331758-35-1; 4'-Fluoro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide; 4'-Fluoro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl)[1,1'-biphenyl]-4-carboxamide; PDSP1_000981; LS-44229; LS-193063; SCHEMBL5582818; GTPL1314; GXAQELJVODWLDD-UHFFFAOYSA-N; BDBM50150715; PDSP2_000965; KB-80782; T226296; 102690-EP2272841A1; 102690-EP2301936A1; N-[6-(dimethylaminomethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]-4-(4-fluorophenyl)benzamide;  LS-193063; S-20951
DMJ6P9U	CP	Takeda
DMJ6P9U	DT	Small molecular drug
DMJ6P9U	PC	9865843
DMJ6P9U	MW	402.5
DMJ6P9U	FM	C26H27FN2O
DMJ6P9U	IC	InChI=1S/C26H27FN2O/c1-29(2)17-18-3-4-23-16-25(14-11-22(23)15-18)28-26(30)21-7-5-19(6-8-21)20-9-12-24(27)13-10-20/h5-14,16,18H,3-4,15,17H2,1-2H3,(H,28,30)
DMJ6P9U	CS	CN(C)CC1CCC2=C(C1)C=CC(=C2)NC(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)F
DMJ6P9U	IK	GXAQELJVODWLDD-UHFFFAOYSA-N
DMJ6P9U	IU	N-[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydronaphthalen-2-yl]-4-(4-fluorophenyl)benzamide
DMJ6P9U	DE	Atrial fibrillation; Obesity

DMQJSF9	ID	DMQJSF9
DMQJSF9	DN	Taxifolin
DMQJSF9	HS	Preclinical
DMQJSF9	SN	TAXIFOLIN; (+)-Taxifolin; dihydroquercetin; Distylin; Taxifoliol; (2R,3R)-Dihydroquercetin; (+)-Dihydroquercetin; TAXIFOLIN-(+); Lavitol; Lariksin; taxifolin (dihydroquercetin); 3,5,7,3',4'-Pentahydroxyflavanone; UNII-9SOB9E3987; trans-Dihydroquercetin; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)-; (+)-trans-Taxifolin; (2R,3R)-2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-2,3-DIHYDRO-4H-CHROMEN-4-ONE; (2R,3R)-3,3',4',5,7-Pentahydroxyflavanone
DMQJSF9	PC	439533
DMQJSF9	MW	304.25
DMQJSF9	FM	C15H12O7
DMQJSF9	IC	InChI=1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H/t14-,15+/m0/s1
DMQJSF9	CS	C1=CC(=C(C=C1C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
DMQJSF9	IK	CXQWRCVTCMQVQX-LSDHHAIUSA-N
DMQJSF9	IU	(2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one
DMQJSF9	CA	CAS 480-18-2
DMQJSF9	CB	CHEBI:17948
DMQJSF9	DE	Ovarian cancer

DMY8QP5	ID	DMY8QP5
DMY8QP5	DN	TFM735
DMY8QP5	HS	Preclinical
DMY8QP5	CP	Mochida
DMY8QP5	DT	Small molecular drug
DMY8QP5	DE	Multiple sclerosis

DM1KTOC	ID	DM1KTOC
DM1KTOC	DN	TGX-6B4
DM1KTOC	HS	Preclinical
DM1KTOC	SN	Antiglycoprotein 1b monoclonal antibodies, CuraGen; GPIb-blocking MAb, Thromb-X; GPIb-blocking Fab fragment (thrombosis), Thromb-X
DM1KTOC	CP	ThromboGenics NV
DM1KTOC	DT	Antibody
DM1KTOC	DE	Thrombosis

DM4BDGW	ID	DM4BDGW
DM4BDGW	DN	TH301
DM4BDGW	HS	Preclinical
DM4BDGW	DT	Small molecular drug
DM4BDGW	DE	Glioblastoma of brain

DMDMQIE	ID	DMDMQIE
DMDMQIE	DN	THAPSIGARGIN
DMDMQIE	HS	Preclinical
DMDMQIE	SN	thapsigargin; 67526-95-8; UNII-Z96BQ26RZD; Z96BQ26RZD; CHEMBL96926; CHEBI:9516; OCTANOIC ACID [3S-[3ALPHA, 3ABETA, 4ALPHA, 6BETA, 6ABETA, 7BETA, 8ALPHA(Z), 9BALPHA]]-6-(ACETYLOXY)-2,3,-3A,4,5,6,6A,7,8,9B-DECAHYDRO-3,3A-DIHYDROXY-3,6,9-TRIMETHYL-8-[(2-METHYL-1-OXO-2-BUTENYL)OXY]-2-OXO-4-(1-OXOBUTOXY)-AZULENO[4,5-B]FURAN-7-YL ESTER
DMDMQIE	DT	Small molecular drug
DMDMQIE	PC	446378
DMDMQIE	MW	650.8
DMDMQIE	FM	C34H50O12
DMDMQIE	IC	InChI=1S/C34H50O12/c1-9-12-13-14-15-17-24(37)43-28-26-25(20(5)27(28)44-30(38)19(4)11-3)29-34(41,33(8,40)31(39)45-29)22(42-23(36)16-10-2)18-32(26,7)46-21(6)35/h11,22,26-29,40-41H,9-10,12-18H2,1-8H3/b19-11-/t22-,26+,27-,28-,29-,32-,33+,34+/m0/s1
DMDMQIE	CS	CCCCCCCC(=O)O[C@H]1[C@H]2C(=C([C@@H]1OC(=O)/C(=C\\C)/C)C)[C@H]3[C@]([C@H](C[C@]2(C)OC(=O)C)OC(=O)CCC)([C@](C(=O)O3)(C)O)O
DMDMQIE	IK	IXFPJGBNCFXKPI-FSIHEZPISA-N
DMDMQIE	IU	[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-acetyloxy-4-butanoyloxy-3,3a-dihydroxy-3,6,9-trimethyl-8-[(Z)-2-methylbut-2-enoyl]oxy-2-oxo-4,5,6a,7,8,9b-hexahydroazuleno[4,5-b]furan-7-yl] octanoate
DMDMQIE	CA	CAS 67526-95-8
DMDMQIE	CB	CHEBI:9516

DM7RMG9	ID	DM7RMG9
DM7RMG9	DN	Thioguanine
DM7RMG9	HS	Preclinical
DM7RMG9	SN	6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)
DM7RMG9	CP	Glaxo Smith Kline Pharmaceuticals
DM7RMG9	TC	Antiviral Agents
DM7RMG9	DT	Small molecular drug
DM7RMG9	PC	2723601
DM7RMG9	MW	167.19
DM7RMG9	FM	C5H5N5S
DM7RMG9	IC	InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
DM7RMG9	CS	C1=NC2=C(N1)C(=S)N=C(N2)N
DM7RMG9	IK	WYWHKKSPHMUBEB-UHFFFAOYSA-N
DM7RMG9	IU	2-amino-3,7-dihydropurine-6-thione
DM7RMG9	CA	CAS 154-42-7
DM7RMG9	CB	CHEBI:9555
DM7RMG9	DE	Acute myeloid leukaemia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMDSJO8	ID	DMDSJO8
DMDSJO8	DN	TMC-353121
DMDSJO8	HS	Preclinical
DMDSJO8	SN	JNJ-2408068; R-170591; Viral fusion inhibitor (RSV infection), J&J; Viral fusion inhibitor (respiratory syncytial virus infection), J&J
DMDSJO8	CP	Johnson & Johnson
DMDSJO8	DT	Small molecular drug
DMDSJO8	PC	11249932
DMDSJO8	MW	558.7
DMDSJO8	FM	C32H42N6O3
DMDSJO8	IC	InChI=1S/C32H42N6O3/c1-23-6-9-26(5-3-16-39)28(19-23)34-21-25-8-10-27-30(20-25)38(22-29-31(40)11-7-24(2)35-29)32(36-27)33-12-4-13-37-14-17-41-18-15-37/h6-11,19-20,34,39-40H,3-5,12-18,21-22H2,1-2H3,(H,33,36)
DMDSJO8	CS	CC1=CC(=C(C=C1)CCCO)NCC2=CC3=C(C=C2)N=C(N3CC4=C(C=CC(=N4)C)O)NCCCN5CCOCC5
DMDSJO8	IK	DKORMNNYNRPTBJ-UHFFFAOYSA-N
DMDSJO8	IU	2-[[6-[[2-(3-hydroxypropyl)-5-methylanilino]methyl]-2-(3-morpholin-4-ylpropylamino)benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
DMDSJO8	CA	CAS 857066-90-1
DMDSJO8	DE	Respiratory syncytial virus infection

DMONGIR	ID	DMONGIR
DMONGIR	DN	Tosyl-l-arginine methyl ester
DMONGIR	HS	Preclinical
DMONGIR	SN	Tame; 901-47-3; Methyl P-toluenesulfonyl-L-argininate; Ts-Arg-OMe; tosyl-arginine methyl ester; UNII-1H7BKF44U1; p-toluenesulfonyl-L-arginine methyl ester; tosyl-L-arginine methyl ester; CHEMBL44752; methyl (2S)-5-(diaminomethylideneamino)-2-[(4-methylphenyl)sulfonylamino]pentanoate; 1H7BKF44U1; CHEBI:62167; methyl N(2)-(p-tosyl)-L-argininate; p-toluensulfonyl-L-arginine methyl ester; N(alpha)-p-tosyl-L-arginine methyl ester; (S)-methyl 5-guanidino-2-(4-methylphenylsulfonamido)pentanoate; methyl N(2)-(p-toluenenesulfonyl)-L-argininate; methyl N(2)-[(p-tolyl)sulphonyl]-L-argininate; N(2)-(p-tolylsulfonyl)-L-arginine methyl ester; methyl N(2)-[(4-methylphenyl)sulfonyl]-L-argininate; L-Arginine, N2-((4-methylphenyl)sulfonyl)-, methyl ester; TOSYLARGININE METHYL ESTER; TAME/; SCHEMBL324561; p-tosyl-l-arginine methyl ester; Nalpha-tosylarginine methyl ester; BCPP000052; ZINC1639578; ABP000326; BDBM50070707; s2225; AKOS030214485; CCG-264948; CS-0466; alpha-N-p-Tosyl-L-arginine methyl ester; NCGC00346615-01; HY-13255; SW219688-1; X7573; N-alpha-Toluenesulfonyl-L-arginine methyl ester; W-5260; AB01566842_01; p-TOLUENESULFONYL-L-ARGININE METHYL ESTER HCl; Q27131658; (S)-5-Guanidino-2-(toluene-4-sulfonylamino)-pentanoic acid methyl ester
DMONGIR	DT	Small molecular drug
DMONGIR	PC	1550286
DMONGIR	MW	342.42
DMONGIR	FM	C14H22N4O4S
DMONGIR	IC	InChI=1S/C14H22N4O4S/c1-10-5-7-11(8-6-10)23(20,21)18-12(13(19)22-2)4-3-9-17-14(15)16/h5-8,12,18H,3-4,9H2,1-2H3,(H4,15,16,17)/t12-/m0/s1
DMONGIR	CS	CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCCN=C(N)N)C(=O)OC
DMONGIR	IK	FKMJXALNHKIDOD-LBPRGKRZSA-N
DMONGIR	IU	methyl (2S)-5-(diaminomethylideneamino)-2-[(4-methylphenyl)sulfonylamino]pentanoate
DMONGIR	CA	CAS 901-47-3
DMONGIR	CB	CHEBI:62167
DMONGIR	DE	Solid tumour/cancer

DM6W9YM	ID	DM6W9YM
DM6W9YM	DN	TP-023
DM6W9YM	HS	Preclinical
DM6W9YM	TC	Psychiatric
DM6W9YM	DE	Anxiety disorder

DM06BUL	ID	DM06BUL
DM06BUL	DN	TPT-43
DM06BUL	HS	Preclinical
DM06BUL	TC	Neurodegenerative
DM06BUL	DE	Alzheimer disease

DMY8GDA	ID	DMY8GDA
DMY8GDA	DN	Trimidox
DMY8GDA	HS	Preclinical
DMY8GDA	SN	3,4,5-Trihydroxybenzamidoxime; CCRIS 7910; Benzenecarboximidamide, N,3,4,5-tetrahydroxy-; 95933-74-7; AC1NUZ8S; SCHEMBL4168968; CHEMBL1214553; CHEBI:94508; N,3,4,5-tetrahydroxybenzamidine; MolPort-044-561-997; N',3,4,5-Tetrahydroxybenzimidamide; 3,4,5-Trihydroxybenzamidoxamic acid; LS-29453; BRD-K11801786-003-01-7; T01312
DMY8GDA	DT	Small molecular drug
DMY8GDA	PC	135409350
DMY8GDA	MW	184.15
DMY8GDA	FM	C7H8N2O4
DMY8GDA	IC	InChI=1S/C7H8N2O4/c8-7(9-13)3-1-4(10)6(12)5(11)2-3/h1-2,10-13H,(H2,8,9)
DMY8GDA	CS	C1=C(C=C(C(=C1O)O)O)/C(=N/O)/N
DMY8GDA	IK	MSLJYSGFUMYUDX-UHFFFAOYSA-N
DMY8GDA	IU	N',3,4,5-tetrahydroxybenzenecarboximidamide
DMY8GDA	CA	CAS 95933-74-7
DMY8GDA	CB	CHEBI:94508
DMY8GDA	DE	Solid tumour/cancer

DMWZCIF	ID	DMWZCIF
DMWZCIF	DN	TTA-A8
DMWZCIF	HS	Preclinical
DMWZCIF	SN	TTA-A2; TTA-P2; T-type calcium channel antagonists, Merck & Co
DMWZCIF	CP	Merck & Co Inc
DMWZCIF	DT	Small molecular drug
DMWZCIF	PC	42609962
DMWZCIF	MW	430.4
DMWZCIF	FM	C22H21F3N4O2
DMWZCIF	IC	InChI=1S/C22H21F3N4O2/c1-14(19-8-7-18(12-28-19)31-13-22(23,24)25)29-20(30)11-16-3-5-17(6-4-16)21-15(2)26-9-10-27-21/h3-10,12,14H,11,13H2,1-2H3,(H,29,30)/t14-/m1/s1
DMWZCIF	CS	CC1=NC=CN=C1C2=CC=C(C=C2)CC(=O)N[C@H](C)C3=NC=C(C=C3)OCC(F)(F)F
DMWZCIF	IK	OURCOVUGQRXRTE-CQSZACIVSA-N
DMWZCIF	IU	2-[4-(3-methylpyrazin-2-yl)phenyl]-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl]acetamide
DMWZCIF	DE	Insomnia

DMB7WEY	ID	DMB7WEY
DMB7WEY	DN	TV-1390
DMB7WEY	HS	Preclinical
DMB7WEY	SN	Multiple sclerosis therapy, Teva Pharmaceuticals
DMB7WEY	CP	Aventis Behring LLC
DMB7WEY	DE	Multiple sclerosis

DMRGZQA	ID	DMRGZQA
DMRGZQA	DN	TZP-202
DMRGZQA	HS	Preclinical
DMRGZQA	CP	Tranzyme Pharma Inc
DMRGZQA	DE	Dyspepsia

DME8AL0	ID	DME8AL0
DME8AL0	DN	TZP-301
DME8AL0	HS	Preclinical
DME8AL0	CP	Tranzyme Pharma Inc
DME8AL0	DE	Metabolic disorder

DMW87JR	ID	DMW87JR
DMW87JR	DN	U-99194A
DMW87JR	HS	Preclinical
DMW87JR	SN	U 99194A; (5,6-dimethoxyindan-2-yl)dipropylamine; 1H-Indan-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-, hydrochloride; 1H-Inden-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-, hydrochloride; 5,6-Dimethoxy-2-(dipropylamino)indan hydrochloride; 5,6-Dimethoxy-N,N-dipropyl-2,3-dihydro-1H-indan-2-amine; 5,6-Dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine hydrochloride; 5,6-dimethoxy-2-(di-n-propylamino)indan; 5,6-dimethoxy-n,n-dipropyl-2,3-dihydro-1h-inden-2-amine hydrochloride(1:1)
DMW87JR	CP	Pfizer
DMW87JR	DT	Small molecular drug
DMW87JR	PC	119195
DMW87JR	MW	313.9
DMW87JR	FM	C17H28ClNO2
DMW87JR	IC	InChI=1S/C17H27NO2.ClH/c1-5-7-18(8-6-2)15-9-13-11-16(19-3)17(20-4)12-14(13)10-15;/h11-12,15H,5-10H2,1-4H3;1H
DMW87JR	CS	CCCN(CCC)C1CC2=CC(=C(C=C2C1)OC)OC.Cl
DMW87JR	IK	NMBUOXDBNWBGIM-UHFFFAOYSA-N
DMW87JR	IU	5,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine;hydrochloride
DMW87JR	CA	CAS 83598-46-3
DMW87JR	DE	Schizophrenia

DMOIWVC	ID	DMOIWVC
DMOIWVC	DN	U-99363E
DMOIWVC	HS	Preclinical
DMOIWVC	SN	U 99363; U 99363E; U-99363; N-(1-benzylpiperidin-4-yl)-3-ethoxy-N-methylpyridin-2-amine; 3-Ethoxy-N-methyl-N-(1-(phenylmethyl)-4-piperidinyl)-2-pyridinylamine
DMOIWVC	CP	Pfizer
DMOIWVC	DT	Small molecular drug
DMOIWVC	PC	133107
DMOIWVC	MW	325.4
DMOIWVC	FM	C20H27N3O
DMOIWVC	IC	InChI=1S/C20H27N3O/c1-3-24-19-10-7-13-21-20(19)22(2)18-11-14-23(15-12-18)16-17-8-5-4-6-9-17/h4-10,13,18H,3,11-12,14-16H2,1-2H3
DMOIWVC	CS	CCOC1=C(N=CC=C1)N(C)C2CCN(CC2)CC3=CC=CC=C3
DMOIWVC	IK	VNSBZWKWQFCKGO-UHFFFAOYSA-N
DMOIWVC	IU	N-(1-benzylpiperidin-4-yl)-3-ethoxy-N-methylpyridin-2-amine
DMOIWVC	CA	CAS 170856-57-2
DMOIWVC	DE	Schizophrenia

DMT06MI	ID	DMT06MI
DMT06MI	DN	UCART-CLL1
DMT06MI	HS	Preclinical
DMT06MI	CP	Cellectis
DMT06MI	DT	CAR T Cell Therapy
DMT06MI	DE	Multiple myeloma

DMD1E4J	ID	DMD1E4J
DMD1E4J	DN	UNC0379
DMD1E4J	HS	Preclinical
DMD1E4J	SN	1620401-82-2; 6,7-Dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine; UNC-0379; CHEMBL3318285; UNC 0379; 6,7-Dimethoxy-2-pyrrolidin-1-yl-N-(5-pyrrolidin-1-ylpentyl)quinazolin-4-amine; C23H35N5O2; 4-Quinazolinamine, 6,7-dimethoxy-2-(1-pyrrolidinyl)-N-[5-(1-pyrrolidinyl)pentyl]-; CS-3345; HY-12335; SCHEMBL22568439; AOB6365; EX-A461; SYN5081; BCP10429; 3362AH; BDBM50051117; MFCD28167817; s7570; ZINC98214604; AKOS025404942; UNC 0379;UNC-0379; CCG-268809; SB19349; NCGC00384189-06; NCGC00384189-10; AK174945; AS-16447; DA-43617; B8009; FT-0699830; A14320; UNC0379 trifluoroacetate salt, >=98% (HPLC)
DMD1E4J	DT	Small molecular drug
DMD1E4J	PC	78357767
DMD1E4J	MW	413.6
DMD1E4J	FM	C23H35N5O2
DMD1E4J	IC	InChI=1S/C23H35N5O2/c1-29-20-16-18-19(17-21(20)30-2)25-23(28-14-8-9-15-28)26-22(18)24-10-4-3-5-11-27-12-6-7-13-27/h16-17H,3-15H2,1-2H3,(H,24,25,26)
DMD1E4J	CS	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCCC3)NCCCCCN4CCCC4)OC
DMD1E4J	IK	WEXCGGWTIDNVNT-UHFFFAOYSA-N
DMD1E4J	IU	6,7-dimethoxy-2-pyrrolidin-1-yl-N-(5-pyrrolidin-1-ylpentyl)quinazolin-4-amine
DMD1E4J	DE	Hepatocellular carcinoma

DMDVZQ8	ID	DMDVZQ8
DMDVZQ8	DN	UPF-648
DMDVZQ8	HS	Preclinical
DMDVZQ8	SN	213400-34-1; (1s,2s)-2-(3,4-Dichlorobenzoyl)cyclopropanecarboxylic Acid; UPF 648; CHEMBL3407929; (1S,2S)-2-(3,4-DICHLOROBENZOYL)CYCLOPROPANE-1-CARBOXYLIC ACID; DBCC; SCHEMBL5310798; BDBM50072083; ZINC33994919; AKOS027470152; CS-3567; HY-15600; Q27452085; (1s,2s)-2-(3,4-dichlorobenzoyl)-cyclopropane-1-carboxylic acid; (1S,2S)-2-[(3,4-dichlorophenyl)carbonyl]cyclopropane-1-carboxylic acid; 1HR
DMDVZQ8	DT	Small molecular drug
DMDVZQ8	PC	9859947
DMDVZQ8	MW	259.079
DMDVZQ8	FM	C11H8Cl2O3
DMDVZQ8	IC	InChI=1S/C11H8Cl2O3/c12-8-2-1-5(3-9(8)13)10(14)6-4-7(6)11(15)16/h1-3,6-7H,4H2,(H,15,16)/t6-,7-/m0/s1
DMDVZQ8	CS	C1[C@@H]([C@H]1C(=O)O)C(=O)C2=CC(=C(C=C2)Cl)Cl
DMDVZQ8	IK	ZBRKMOHDGFGXLN-BQBZGAKWSA-N
DMDVZQ8	IU	(1S,2S)-2-(3,4-dichlorobenzoyl)cyclopropane-1-carboxylic acid
DMDVZQ8	DE	Neurodegenerative disorder

DMUO6XC	ID	DMUO6XC
DMUO6XC	DN	VCB101
DMUO6XC	HS	Preclinical
DMUO6XC	CP	V ClinBio
DMUO6XC	DT	Small molecular drug
DMUO6XC	DE	Multiple sclerosis

DMR3XDH	ID	DMR3XDH
DMR3XDH	DN	VCB102
DMR3XDH	HS	Preclinical
DMR3XDH	CP	V ClinBio
DMR3XDH	DT	Small molecular drug
DMR3XDH	DE	Psoriasis vulgaris

DM95VQ6	ID	DM95VQ6
DM95VQ6	DN	vialinin A
DM95VQ6	HS	Preclinical
DM95VQ6	SN	ganbajunin C
DM95VQ6	DT	Small molecular drug
DM95VQ6	PC	11563133
DM95VQ6	MW	562.6
DM95VQ6	FM	C34H26O8
DM95VQ6	IC	InChI=1S/C34H26O8/c35-25-15-11-23(12-16-25)29-31(39)32(40)30(24-13-17-26(36)18-14-24)34(42-28(38)20-22-9-5-2-6-10-22)33(29)41-27(37)19-21-7-3-1-4-8-21/h1-18,35-36,39-40H,19-20H2
DM95VQ6	CS	C1=CC=C(C=C1)CC(=O)OC2=C(C(=C(C(=C2C3=CC=C(C=C3)O)O)O)C4=CC=C(C=C4)O)OC(=O)CC5=CC=CC=C5
DM95VQ6	IK	NOJUKCRPSUMHQQ-UHFFFAOYSA-N
DM95VQ6	IU	[3,4-dihydroxy-2,5-bis(4-hydroxyphenyl)-6-(2-phenylacetyl)oxyphenyl] 2-phenylacetate
DM95VQ6	CA	CAS 858134-23-3
DM95VQ6	DE	Inflammation

DMS5LPF	ID	DMS5LPF
DMS5LPF	DN	Viquidacin
DMS5LPF	HS	Preclinical
DMS5LPF	SN	AVE-4221; AVE-6971; NXL-101; Topoisomerase IV inhibitor antibacterials, Novexel
DMS5LPF	CP	Aventis Pharma AG
DMS5LPF	DT	Small molecular drug
DMS5LPF	PC	11591505
DMS5LPF	MW	504.6
DMS5LPF	FM	C25H29FN2O4S2
DMS5LPF	IC	InChI=1S/C25H29FN2O4S2/c1-32-17-5-6-21-18(13-17)24(20(26)14-27-21)22(29)7-4-16-8-9-28(15-19(16)25(30)31)10-12-34-23-3-2-11-33-23/h2-3,5-6,11,13-14,16,19,22,29H,4,7-10,12,15H2,1H3,(H,30,31)/t16-,19+,22+/m1/s1
DMS5LPF	CS	COC1=CC2=C(C(=CN=C2C=C1)F)[C@H](CC[C@@H]3CCN(C[C@@H]3C(=O)O)CCSC4=CC=CS4)O
DMS5LPF	IK	USGHRRVFKSLEJT-WVBUVRCRSA-N
DMS5LPF	IU	(3R,4R)-4-[(3S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl]-1-(2-thiophen-2-ylsulfanylethyl)piperidine-3-carboxylic acid
DMS5LPF	CA	CAS 904302-98-3
DMS5LPF	DE	Bacterial infection

DMQG2EY	ID	DMQG2EY
DMQG2EY	DN	Virstatin
DMQG2EY	HS	Preclinical
DMQG2EY	SN	88909-96-0; Isodibut; 4-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-butyric acid; 4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butanoic acid; 4-NAPHTHALIMIDOBUTYRIC ACID; 4-(N-(1,8-naphthalimide))-n-butyric acid; 4-(1,3-dioxobenzo[de]isoquinolin-2-yl)butanoic acid; UNII-24SR2Q1Y6M; 24SR2Q1Y6M; MFCD00181400; 1,3-Dioxo-1H-benz(de)isoquinoline-2(3H)-butanoic acid; 1,3-dioxo-1H-Benz[de]isoquinoline-2(3H)-butanoic acid; 4-{2,4-dioxo-3-azatricyclo[7.3.1.0^{5,13}]trideca-1(13),5,7,9,11-pentaen-3-yl}butanoic acid; Izodibut; 1,3-Dioxo-1H-benz(de)isoquinoline-2(3H)-butyric acid; ACMC-209qxu; SpecPlus_000928; Spectrum2_000449; Spectrum3_001240; CBMicro_014897; CBKinase1_000229; CBKinase1_012629; BSPBio_002720; CBDivE_001858; CBDivE_003272; MLS001207259; DivK1c_007024; SPBio_000498; CHEMBL403272; SCHEMBL3134908; SCHEMBL3852274; KBio1_001968; KBio3_002220; 1H-Benz(de)isoquinoline-2(3H)-butanoic acid, 1,3-dioxo-; DTXSID10237406; ZINC3884670; ANW-39184; CCG-39963; KM2782; SBB043186; STK395003; AKOS000114634; DG-0077; MCULE-6695567974; NCGC00178507-01; SMR000504925; FT-0734904; ST50049126; X6840; EN300-00247; AB00053241-05; BRD-K60241851-001-02-8; BRD-K60241851-001-06-9; Z56891243; 1h,3H-benzo(de)isoquinoline-2-butyric acid-1,3-dione; F0303-0081; 4-{2,4-Dioxo-3-azatricyclo[7.3.1.0 {5,13}]trideca- 1(13),5,7,9,11-pentaen-3-yl}butanoic acid
DMQG2EY	DT	Small molecular drug
DMQG2EY	PC	145949
DMQG2EY	MW	283.28
DMQG2EY	FM	C16H13NO4
DMQG2EY	IC	InChI=1S/C16H13NO4/c18-13(19)8-3-9-17-15(20)11-6-1-4-10-5-2-7-12(14(10)11)16(17)21/h1-2,4-7H,3,8-9H2,(H,18,19)
DMQG2EY	CS	C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCC(=O)O
DMQG2EY	IK	ZHXRDXTYPCPBTI-UHFFFAOYSA-N
DMQG2EY	IU	4-(1,3-dioxobenzo[de]isoquinolin-2-yl)butanoic acid
DMQG2EY	CA	CAS 88909-96-0
DMQG2EY	DE	Acinetobacter baumannii infection

DMJDT5O	ID	DMJDT5O
DMJDT5O	DN	VIS513
DMJDT5O	HS	Preclinical
DMJDT5O	CP	Visterra
DMJDT5O	DT	Antibody
DMJDT5O	DE	Dengue

DMZHAVG	ID	DMZHAVG
DMZHAVG	DN	VPM-4-001
DMZHAVG	HS	Preclinical
DMZHAVG	SN	Allogenic LNCaP cell vaccine (prostate tumor), Vakzine Projekt Management; Cell vaccine (prostate cancer), Vakzine Projekt Management; Allogenic LNCaP cells (IL-2, IFN-gamma), Vakzine Projekt Management
DMZHAVG	CP	Memorial Sloan-Kettering Cancer Center
DMZHAVG	DT	Vaccine
DMZHAVG	DE	Prostate cancer

DMOY15R	ID	DMOY15R
DMOY15R	DN	VT-111
DMOY15R	HS	Preclinical
DMOY15R	CP	Viron Therapeutics
DMOY15R	DE	Graft rejection in heart transplantation

DM7WFR0	ID	DM7WFR0
DM7WFR0	DN	VUFB-11502
DM7WFR0	HS	Preclinical
DM7WFR0	SN	Ciadox; Ciadox [INN]; Cyadox; Ciadoxum [INN-Latin]; SCHEMBL1817373; VUFB 11502; 2-formylquinoxaline-1,4-dioxide cyanoacetylhydrazone; 65884-46-0; ACETIC ACID, CYANO-, (2-QUINOXALINYLMETHYLENE)HYDRAZIDE, N,N-DIOXIDE; BRN 0826894; C12H8N5O3; Cyanoacetic acid (2-quinoxalinylmethylene)hydrazide, N(sup 1),N(sup 4)-dioxide; Cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide; EINECS 265-963-3; N'-(2-Chinoxalinylmethylen)cyanacetohydrazid 1,4-dioxid; SCHEMBL10793569
DM7WFR0	PC	135412736
DM7WFR0	MW	271.23
DM7WFR0	FM	C12H9N5O3
DM7WFR0	IC	MBCZYLSVSCJJJQ-VGOFMYFVSA-N
DM7WFR0	CS	C1=CC=C2C(=C1)[N+](=CC(=[N+]2[O-])C=NNC(=O)CC#N)[O-]
DM7WFR0	IK	1S/C12H9N5O3/c13-6-5-12(18)15-14-7-9-8-16(19)10-3-1-2-4-11(10)17(9)20/h1-4,7-8H,5H2,(H,15,18)/b14-7+
DM7WFR0	IU	2-cyano-N-[(E)-(1,4-dioxidoquinoxaline-1,4-diium-2-yl)methylideneamino]acetamide
DM7WFR0	CA	CAS 65884-46-0
DM7WFR0	DE	Amebiasis

DMZKY56	ID	DMZKY56
DMZKY56	DN	VX-166
DMZKY56	HS	Preclinical
DMZKY56	SN	800408-39-3; (S)-3-((S)-2-(3-((methoxycarbonyl)amino)-2-oxopyridin-1(2H)-yl)butanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid; SCHEMBL473147; CHEMBL1935078; ZINC82158134; (3S)-3-[[(2S)-2-[3-(methoxycarbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
DMZKY56	DT	Small molecular drug
DMZKY56	PC	42602413
DMZKY56	MW	531.4
DMZKY56	FM	C22H21F4N3O8
DMZKY56	IC	InChI=1S/C22H21F4N3O8/c1-3-14(29-6-4-5-12(21(29)34)28-22(35)36-2)20(33)27-13(8-16(31)32)15(30)9-37-19-17(25)10(23)7-11(24)18(19)26/h4-7,13-14H,3,8-9H2,1-2H3,(H,27,33)(H,28,35)(H,31,32)/t13-,14-/m0/s1
DMZKY56	CS	CC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=CC=C(C2=O)NC(=O)OC
DMZKY56	IK	WQNDPVUOABHOHK-KBPBESRZSA-N
DMZKY56	IU	(3S)-3-[[(2S)-2-[3-(methoxycarbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
DMZKY56	DE	Hepatic fibrosis

DM68HNR	ID	DM68HNR
DM68HNR	DN	W-201259
DM68HNR	HS	Preclinical
DM68HNR	SN	A-D-Mannopyranosyl-D-mannose; Mannobiose; BDH pure salt; GUBGYTABKSRVRQ-KWCWEWCRSA-N; SCHEMBL162205; beta-1,4-Mannobiose; 14417-51-7; 15548-43-3; 4-O-; 4-O-(b-D-Mannopyranosyl)-D-mannose; 4-O-(beta-D-Mannopyranosyl)-D-mannose; 4-O-beta-D-Mannopyranosyl-D-mannopyranose; C20861; CHEBI:25164; D-Mannopyranose, 4-O-beta-D-mannopyranosyl-; Mannopyranose, 4-O-beta-D-mannopyranosyl-; Mannopyranose, 4-O-beta-D-mannopyranosyl-, D-; O-MBI; beta-D-mannopyranosyl-(1-&gt;4)-D-mannopyranose; beta-D-mannopyranosyl-(1-&gt;4)-D-mannose
DM68HNR	PC	152109
DM68HNR	MW	342.3
DM68HNR	FM	C12H22O11
DM68HNR	IC	GUBGYTABKSRVRQ-KWCWEWCRSA-N
DM68HNR	CS	C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)O)CO)O)O)O)O
DM68HNR	IK	1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7-,8+,9+,10-,11?,12+/m1/s1
DM68HNR	IU	(2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DM68HNR	CA	CAS 15548-43-3
DM68HNR	CB	CHEBI:25164
DM68HNR	DE	Salmonella infection

DMKE5QH	ID	DMKE5QH
DMKE5QH	DN	WZB-117
DMKE5QH	HS	Preclinical
DMKE5QH	SN	WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester
DMKE5QH	DT	Small molecular drug
DMKE5QH	PC	46830365
DMKE5QH	MW	368.3
DMKE5QH	FM	C20H13FO6
DMKE5QH	IC	InChI=1S/C20H13FO6/c21-16-8-3-9-17(26-19(24)12-4-1-6-14(22)10-12)18(16)27-20(25)13-5-2-7-15(23)11-13/h1-11,22-23H
DMKE5QH	CS	C1=CC(=CC(=C1)O)C(=O)OC2=C(C(=CC=C2)F)OC(=O)C3=CC(=CC=C3)O
DMKE5QH	IK	FRSWCCBXIHFKKY-UHFFFAOYSA-N
DMKE5QH	IU	[3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate
DMKE5QH	DE	Skin fibrosis

DMD8TNK	ID	DMD8TNK
DMD8TNK	DN	XL475
DMD8TNK	HS	Preclinical
DMD8TNK	CP	Exelixis
DMD8TNK	DE	Type-2 diabetes

DMINSA5	ID	DMINSA5
DMINSA5	DN	XL-499
DMINSA5	HS	Preclinical
DMINSA5	SN	PI3K delta inhibitor (cancer/inflammatory disease), Exelixis
DMINSA5	CP	Exelixis Inc
DMINSA5	DE	Solid tumour/cancer

DMU86XT	ID	DMU86XT
DMU86XT	DN	YM-201636
DMU86XT	HS	Preclinical
DMU86XT	SN	371942-69-7; YM201636; YM 201636; 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide; 3-pyridinecarboxamide, 6-amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-; 6-amino-n-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide; 6-amino-N-[3-[4-(4-morpholinyl)-2-pyrido[2,3]furo[2,4-b]pyrimidinyl]phenyl]-3-pyridinecarboxamide; PubChem22459; cc-386; MLS006010997; SCHEMBL258416; CHEMBL2178735; CHEBI:91382; AOB1919; DTXSID90433303; EX-A037; QCR-257; BCPP000006; HMS3229J15; HMS3295C07; HMS3654F03; AMY23718; BCP01972; ABP000099; MFCD16038303; s1219; ZINC34048998; AKOS027250783; CCG-264866; CS-0592; NCGC00346683-01; NCGC00346683-09; 6-amino-N-[3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenyl]pyridine-3-carboxamide; AK175782; AS-16693; HY-13228; SMR004702795; AB0035851; FT-0756177; SW218129-2; Y0272; A19418; W-5608; 942Y697; J-518249; BRD-K48488978-001-01-2; Q27163245; YM-201636,CAS:371942-69-7; 6-Amino-N-[3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenyl]pyridine-3-carboxamide; 6-Amino-N-{3-[4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl}pyridine-3-carboxamide
DMU86XT	DT	Small molecular drug
DMU86XT	PC	9956222
DMU86XT	MW	467.5
DMU86XT	FM	C25H21N7O3
DMU86XT	IC	InChI=1S/C25H21N7O3/c26-19-7-6-16(14-28-19)24(33)29-17-4-1-3-15(13-17)22-30-20-18-5-2-8-27-25(18)35-21(20)23(31-22)32-9-11-34-12-10-32/h1-8,13-14H,9-12H2,(H2,26,28)(H,29,33)
DMU86XT	CS	C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N
DMU86XT	IK	YBPIBGNBHHGLEB-UHFFFAOYSA-N
DMU86XT	IU	6-amino-N-[3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenyl]pyridine-3-carboxamide
DMU86XT	CA	CAS 371942-69-7
DMU86XT	CB	CHEBI:91382
DMU86XT	DE	Discovery agent

DMMUYC2	ID	DMMUYC2
DMMUYC2	DN	YM-344031
DMMUYC2	HS	Preclinical
DMMUYC2	CP	Astellas
DMMUYC2	DT	Small molecular drug
DMMUYC2	PC	56603737
DMMUYC2	MW	502.6
DMMUYC2	FM	C29H31FN4O3
DMMUYC2	IC	InChI=1S/C29H31FN4O3/c1-20-3-2-11-34(37)28(20)29(36)33-13-8-21(9-14-33)16-27(35)31-26-10-12-32(19-26)18-22-4-5-24-17-25(30)7-6-23(24)15-22/h2-7,11,15-17,26H,8-10,12-14,18-19H2,1H3,(H,31,35)
DMMUYC2	CS	CC1=C([N+](=CC=C1)[O-])C(=O)N2CCC(=CC(=O)NC3CCN(C3)CC4=CC5=C(C=C4)C=C(C=C5)F)CC2
DMMUYC2	IK	AINQBHMFEKHERT-UHFFFAOYSA-N
DMMUYC2	IU	N-[1-[(6-fluoronaphthalen-2-yl)methyl]pyrrolidin-3-yl]-2-[1-(3-methyl-1-oxidopyridin-1-ium-2-carbonyl)piperidin-4-ylidene]acetamide
DMMUYC2	DE	Asthma

DMTM1LK	ID	DMTM1LK
DMTM1LK	DN	YM-355179
DMTM1LK	HS	Preclinical
DMTM1LK	SN	YM-355179; GTPL793; SCHEMBL3808393
DMTM1LK	CP	Astellas
DMTM1LK	DT	Small molecular drug
DMTM1LK	PC	11556309
DMTM1LK	MW	502.6
DMTM1LK	FM	C29H31FN4O3
DMTM1LK	IC	InChI=1S/C29H31FN4O3/c1-19-12-26(35)28(31-16-19)29(37)34-10-6-20(7-11-34)14-27(36)32-25-8-9-33(18-25)17-21-2-3-23-15-24(30)5-4-22(23)13-21/h2-5,12-16,25,35H,6-11,17-18H2,1H3,(H,32,36)/t25-/m1/s1
DMTM1LK	CS	CC1=CC(=C(N=C1)C(=O)N2CCC(=CC(=O)N[C@@H]3CCN(C3)CC4=CC5=C(C=C4)C=C(C=C5)F)CC2)O
DMTM1LK	IK	LHTPHICFHRATTG-RUZDIDTESA-N
DMTM1LK	IU	N-[(3R)-1-[(6-fluoronaphthalen-2-yl)methyl]pyrrolidin-3-yl]-2-[1-(3-hydroxy-5-methylpyridine-2-carbonyl)piperidin-4-ylidene]acetamide
DMTM1LK	DE	Asthma

DMH0I9N	ID	DMH0I9N
DMH0I9N	DN	YW327.6S2
DMH0I9N	HS	Preclinical
DMH0I9N	DT	Antibody
DMH0I9N	DE	Non-small-cell lung cancer; Breast cancer

DMDRQIA	ID	DMDRQIA
DMDRQIA	DN	ZBzl-YAA5911
DMDRQIA	HS	Preclinical
DMDRQIA	DT	Peptide
DMDRQIA	DE	Enterococcus faecium infection

DMNG84V	ID	DMNG84V
DMNG84V	DN	ZK-thiazolidinone
DMNG84V	HS	Preclinical
DMNG84V	SN	Zoledronate trisodium; Zoledronate trisodium hydrate; UNII-ARL915IH66; Zoledronate trisodium [USAN]; ARL915IH66; 165800-08-8; Zoledronate trisodium (USAN); CGP-42446B; CGP 42446B; CHEMBL3989655; D06379; Trisodium hydrogen (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonate, hydrate (5:2); Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-, trisodium salt hydrate (5:2)
DMNG84V	CP	Bayer Schering Pharma.
DMNG84V	TC	Anticancer Agents
DMNG84V	DT	Small molecular drug
DMNG84V	PC	73442801
DMNG84V	MW	497.6
DMNG84V	FM	C23H30F3N5O2S
DMNG84V	IC	InChI=1S/C23H30F3N5O2S/c1-2-31-21(33)19(34-22(31)18(13-27)20(32)29-15-23(24,25)26)14-28-17-7-5-6-16(12-17)8-11-30-9-3-4-10-30/h5-7,12,18-19,22,28H,2-4,8-11,14-15H2,1H3,(H,29,32)
DMNG84V	CS	CCN1C(SC(C1=O)CNC2=CC=CC(=C2)CCN3CCCC3)C(C#N)C(=O)NCC(F)(F)F
DMNG84V	IK	WFZRONKPJVZNAO-UHFFFAOYSA-N
DMNG84V	IU	2-cyano-2-[3-ethyl-4-oxo-5-[[3-(2-pyrrolidin-1-ylethyl)anilino]methyl]-1,3-thiazolidin-2-yl]-N-(2,2,2-trifluoroethyl)acetamide
DMNG84V	DE	Solid tumour/cancer

DMX23CZ	ID	DMX23CZ
DMX23CZ	DN	Z-Phe-Ala-diazomethylketone
DMX23CZ	HS	Preclinical
DMX23CZ	SN	Z-Phe-Ala-Diazomethylketone; 71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate
DMX23CZ	DT	Small molecular drug
DMX23CZ	PC	155664
DMX23CZ	MW	394.4
DMX23CZ	FM	C21H22N4O4
DMX23CZ	IC	InChI=1S/C21H22N4O4/c1-15(19(26)13-23-22)24-20(27)18(12-16-8-4-2-5-9-16)25-21(28)29-14-17-10-6-3-7-11-17/h2-11,13,15,18H,12,14H2,1H3,(H,24,27)(H,25,28)/t15-,18-/m0/s1
DMX23CZ	CS	C[C@@H](C(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2
DMX23CZ	IK	QMPATRQNERZOMF-YJBOKZPZSA-N
DMX23CZ	IU	benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate
DMX23CZ	DE	Alzheimer disease

DMTDG7L	ID	DMTDG7L
DMTDG7L	DN	Z-VAD-fmk
DMTDG7L	HS	Preclinical
DMTDG7L	SN	187389-52-2; Z-VAD(OMe)-FMK; z-vad-FMK; Z-VAD (OMe)-FMK; Z-Val-Ala-Asp(OMe)-FMK; ZVAD-FMK; 5-Bromo-2 -deoxyuridine; Z-Val-Ala-Asp(OMe)-fluoromethyl ketone; Z-Val-Ala-Asp(OMe)-CH2F; C22H30FN3O7; Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone; Caspase-1 Inhibitor Z-Val-Ala-DL-Asp-fluoromethylketone; z-Val-Ala-Asp(OMe)-fluoromethylketone; Z-Val-Ala-Asp(OCH3)-fluoromethylketone; L-alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-; methyl 5-fluoro-3-[2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoylamino]-4-oxopentanoate; benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone; N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone; MFCD02684037; Bio2_000471; zVAD; pan-caspase inhibitor; Z-VAD-(OMe)-FMK; Probes1_000501; CBiol_001923; BSPBio_001262; KBioGR_000602; KBioSS_000602; CHEMBL1213366; SCHEMBL15012737; Z-Val-Ala-Asp(OCH3)-CH2F; KBio2_000602; KBio2_003170; KBio2_005738; KBio3_001063; KBio3_001064; AOB5976; DTXSID40420586; CHEBI:137045; Bio1_000209; Bio1_000698; Bio1_001187; Bio2_000951; HMS1362P03; HMS1792P03; HMS1990P03; HMS3403P03; EX-A2192; ZINC3875327; 2822AH; Z-L-Val-L-Ala-L-Asp(OMe)-CH2F; AKOS024456966; z-Val-Ala-Asp(OMe) fluoromethylketone; CCG-207882; CS-3153; IDI1_002226; z-Val-Ala-Asp(OMe)-fluoromethyl-ketone; Cbz-Val-Ala-Asp(OMe)-fluoromethylketone; NCGC00163487-01; NCGC00163487-02; AS-74918; Cbz-Val-Ala-Asp(OMe)-fluoromethyl ketone; HY-16658; Z-Val-Ala-Asp(OCH3)-fluoromethyl ketone; z-Val-Ala-Asp(O-methyl)-fluoromethylketone; S7023; SW219162-1; Caspase Inhibitor I - CAS 187389-52-2; A12373; Z-VAD(OMe)-FMK;  Z-Val-Ala-Asp(OMe)-FMK; J-012061; benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethyl ketone; benzyloxycarbonyl-Val-Ala-Asp(OMe)fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe)fluoromethylketone; benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethylketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe)fluoromethyl ketone; benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethylketone; N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl) fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethylketone; L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]- (9CI); METHYL (3S)-3-[(2S)-2-[(2S)-2-{[(BENZYLOXY)CARBONYL]AMINO}-3-METHYLBUTANAMIDO]PROPANAMIDO]-5-FLUORO-4-OXOPENTANOATE; N-[(benzyloxy)carbonyl]-L-valyl-N-[(3S)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]-L-alaninamide; Methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate
DMTDG7L	CP	InvivoGen
DMTDG7L	DT	Small molecular drug
DMTDG7L	PC	5497174
DMTDG7L	MW	467.5
DMTDG7L	FM	C22H30FN3O7
DMTDG7L	IC	InChI=1S/C22H30FN3O7/c1-13(2)19(26-22(31)33-12-15-8-6-5-7-9-15)21(30)24-14(3)20(29)25-16(17(27)11-23)10-18(28)32-4/h5-9,13-14,16,19H,10-12H2,1-4H3,(H,24,30)(H,25,29)(H,26,31)/t14-,16-,19-/m0/s1
DMTDG7L	CS	C[C@@H](C(=O)N[C@@H](CC(=O)OC)C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1
DMTDG7L	IK	MIFGOLAMNLSLGH-QOKNQOGYSA-N
DMTDG7L	IU	methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate
DMTDG7L	CA	CAS 187389-52-2
DMTDG7L	CB	CHEBI:137045
DMTDG7L	DE	Pulmonary fibrosis

DMVO0LU	ID	DMVO0LU
DMVO0LU	DN	131I-81C6
DMVO0LU	HS	Terminated
DMVO0LU	SN	Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6
DMVO0LU	CP	Duke University
DMVO0LU	DT	Antibody
DMVO0LU	DE	Brain cancer

DMTH52F	ID	DMTH52F
DMTH52F	DN	21-AMINOEPOTHILONE B
DMTH52F	HS	Terminated
DMTH52F	SN	BMS-310705; (4S,7R,8S,9S,13R,14S,16S)-13,14-Epoxy-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[1-methyl-2(E)-[2-(aminomethyl)thiazol-4-yl]vinyl]-1-oxacyclohexadecane-2,6-dione
DMTH52F	DT	Small molecular drug
DMTH52F	PC	9828138
DMTH52F	MW	522.7
DMTH52F	FM	C27H42N2O6S
DMTH52F	IC	InChI=1S/C27H42N2O6S/c1-15-8-7-9-27(6)21(35-27)11-19(16(2)10-18-14-36-22(13-28)29-18)34-23(31)12-20(30)26(4,5)25(33)17(3)24(15)32/h10,14-15,17,19-21,24,30,32H,7-9,11-13,28H2,1-6H3/b16-10+/t15-,17+,19-,20-,21-,24-,27+/m0/s1
DMTH52F	CS	C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)CN)/C)C
DMTH52F	IK	PFJFPBDHCFMQPN-RGJAOAFDSA-N
DMTH52F	IU	(1S,3S,7S,10R,11S,12S,16R)-3-[(E)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMTH52F	CA	CAS 280578-49-6
DMTH52F	DE	Solid tumour/cancer

DMO6BA0	ID	DMO6BA0
DMO6BA0	DN	3-DEAZAADENOSINE
DMO6BA0	HS	Terminated
DMO6BA0	SN	Cc3Ado; BW-91Y78; 3DZA; 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine
DMO6BA0	DT	Small molecular drug
DMO6BA0	PC	23190
DMO6BA0	MW	266.25
DMO6BA0	FM	C11H14N4O4
DMO6BA0	IC	InChI=1S/C11H14N4O4/c12-10-7-5(1-2-13-10)15(4-14-7)11-9(18)8(17)6(3-16)19-11/h1-2,4,6,8-9,11,16-18H,3H2,(H2,12,13)/t6-,8-,9-,11-/m1/s1
DMO6BA0	CS	C1=CN=C(C2=C1N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DMO6BA0	IK	DBZQFUNLCALWDY-PNHWDRBUSA-N
DMO6BA0	IU	(2R,3R,4S,5R)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMO6BA0	CA	CAS 6736-58-9
DMO6BA0	DE	Arthritis

DMQ4X7Y	ID	DMQ4X7Y
DMQ4X7Y	DN	443C81
DMQ4X7Y	HS	Terminated
DMQ4X7Y	SN	BW 443C; BW-443C81
DMQ4X7Y	CP	Burroughs Wellcome Inc
DMQ4X7Y	PC	101630908
DMQ4X7Y	MW	682.7
DMQ4X7Y	FM	C31H42N10O8
DMQ4X7Y	IC	InChI=1S/C31H42N10O8/c32-22(15-18-7-11-21(42)12-8-18)28(45)39-23(3-1-13-36-31(34)35)29(46)37-17-26(43)38-24(16-19-5-9-20(10-6-19)41(48)49)30(47)40-14-2-4-25(40)27(33)44/h5-12,22-25H,1-4,13-17,32H2,(H10,33,34,35,36,37,38,39,42,43,44,45,46)/t22-,23+,24+,25+/m1/s1
DMQ4X7Y	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)CNC(=O)[C@H](CCCN=C(N)[NH-])NC(=O)[C@@H](CC3=CC=C(C=C3)O)[NH3+])C(=O)N
DMQ4X7Y	IK	CQEKFKUITZRTPQ-ROHNOIKCSA-N
DMQ4X7Y	IU	[N'-[(4S)-4-[[(2R)-2-azaniumyl-3-(4-hydroxyphenyl)propanoyl]amino]-5-[[2-[[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(4-nitrophenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentyl]carbamimidoyl]azanide
DMQ4X7Y	DE	Asthma

DMM3UK5	ID	DMM3UK5
DMM3UK5	DN	50-235
DMM3UK5	HS	Terminated
DMM3UK5	SN	Myriceric acid A
DMM3UK5	CP	Shionogi & Co Ltd
DMM3UK5	DE	Hypertension

DM5MVF9	ID	DM5MVF9
DM5MVF9	DN	6-nitroquipazine
DM5MVF9	HS	Terminated
DM5MVF9	SN	6-nitroquipazine; 77372-73-7; 6-nitro-2-(piperazin-1-yl)quinoline; 6-Nitro-2-piperazin-1-yl-quinoline; 6-Nitro,2-(1-piperazinyl)quinoline; DU-24565; DU 24565; UNII-28M0X094BH; Quinoline,6-nitro-2-(1-piperazinyl)-; Quinoline, 6-nitro-2-(1-piperazinyl)-; CHEMBL41140; 28M0X094BH; 6-nitro-2-piperazin-1-ylquinoline; 6-Nitro-2-(1-piperazinyl)quinoline maleate salt; Lopac-Q-109; Biomol-NT_000101; AC1L1JF0; AC1Q1XW4; Lopac0_001010; SCHEMBL401156; AC1Q21C2; BPBio1_001389; DTXSID7044001; CTK5E4324; GGDBEAVVGFNWIA-UHFFFAOYSA-N; CHEBI:104164
DM5MVF9	DT	Small molecular drug
DM5MVF9	PC	5012
DM5MVF9	MW	258.279
DM5MVF9	FM	C13H14N4O2
DM5MVF9	IC	InChI=1S/C13H14N4O2/c18-17(19)11-2-3-12-10(9-11)1-4-13(15-12)16-7-5-14-6-8-16/h1-4,9,14H,5-8H2
DM5MVF9	CS	C1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)[N+](=O)[O-]
DM5MVF9	IK	GGDBEAVVGFNWIA-UHFFFAOYSA-N
DM5MVF9	IU	6-nitro-2-piperazin-1-ylquinoline
DM5MVF9	CA	CAS 77372-73-7
DM5MVF9	CB	CHEBI:104164

DMX5K4C	ID	DMX5K4C
DMX5K4C	DN	7-methoxytacrine
DMX5K4C	HS	Terminated
DMX5K4C	SN	7-Methoxytacrine; 7-Meota; 7-methoxy-1,2,3,4-tetrahydroacridin-9-amine; TA-03; 5778-80-3; BRN 0477401; CHEMBL1256415; 1,2,3,4-Tetrahydro-7-methoxy-9-acridinamine; 9-Amino-7-methoxy-1,2,3,4-tetrahydroacridine; 9-Amino-7-methoxy-1,2,3,4-tetrahydroakridin [Czech]; Acridine, 1,2,3,4-tetrahydro-9-amino-7-methoxy-; 9-Amino-7-methoxy-1,2,3,4-tetrahydroakridin; AC1L3O4H; 9-Acridinamine, 1,2,3,4-tetrahydro-7-methoxy-; 5-22-12-00199 (Beilstein Handbook Reference); SCHEMBL195752; AC1Q582Q; CTK8D9577; MolPort-013-241-798; ZINC6018808
DMX5K4C	DT	Small molecular drug
DMX5K4C	PC	119053
DMX5K4C	MW	228.29
DMX5K4C	FM	C14H16N2O
DMX5K4C	IC	InChI=1S/C14H16N2O/c1-17-9-6-7-13-11(8-9)14(15)10-4-2-3-5-12(10)16-13/h6-8H,2-5H2,1H3,(H2,15,16)
DMX5K4C	CS	COC1=CC2=C(C=C1)N=C3CCCCC3=C2N
DMX5K4C	IK	APQPVVOYBLOJDY-UHFFFAOYSA-N
DMX5K4C	IU	7-methoxy-1,2,3,4-tetrahydroacridin-9-amine
DMX5K4C	CA	CAS 5778-80-3

DM0NY6K	ID	DM0NY6K
DM0NY6K	DN	A 77636
DM0NY6K	HS	Terminated
DM0NY6K	SN	A77636; 1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-tricyclo(3.3.1.1(3,7))dec-1-yl-, hydrochloride, (1R-cis)-; UNII-WA6RGP1J4W; WA6RGP1J4W; 3-(1'-Adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride; C20H27NO3.HCl; 145307-34-2; AC1Q3F7L; AC1L21MK; LS-173243; (1R)-3-(1-adamantyl)-1-(aminomethyl)-3,4-dihydro-1H-isochromene-5,6-diol hydrochloride; (1r)-1-(aminomethyl)-3-(tricyclo[3.3.1.13,7]dec-1-yl)-3,4-dihydro-1h-isochromene-5,6-diol hydrochloride(1:1)
DM0NY6K	DT	Small molecular drug
DM0NY6K	PC	6603703
DM0NY6K	MW	329.4
DM0NY6K	FM	C20H27NO3
DM0NY6K	IC	InChI=1S/C20H27NO3/c21-10-17-14-1-2-16(22)19(23)15(14)6-18(24-17)20-7-11-3-12(8-20)5-13(4-11)9-20/h1-2,11-13,17-18,22-23H,3-10,21H2/t11?,12?,13?,17-,18-,20?/m0/s1
DM0NY6K	CS	C1[C@H](O[C@H](C2=C1C(=C(C=C2)O)O)CN)C34CC5CC(C3)CC(C5)C4
DM0NY6K	IK	QLJOSZATCBCBDR-DFKUFRTHSA-N
DM0NY6K	IU	(1R,3S)-3-(1-adamantyl)-1-(aminomethyl)-3,4-dihydro-1H-isochromene-5,6-diol
DM0NY6K	CA	CAS 778546-51-3
DM0NY6K	CB	CHEBI:64080
DM0NY6K	DE	Parkinson disease

DMZ5NQP	ID	DMZ5NQP
DMZ5NQP	DN	A-11259
DMZ5NQP	HS	Terminated
DMZ5NQP	SN	A-00000762; A-00000764; A-00026158; A-00026161; A-764; Shikimate kinase inhibitors (antibacterial); Shikimate kinase inhibitors (antibacterial), Arrow
DMZ5NQP	CP	Arrow Therapeutics Ltd
DMZ5NQP	DE	Bacterial infection

DM6CSRU	ID	DM6CSRU
DM6CSRU	DN	A-131701
DM6CSRU	HS	Terminated
DM6CSRU	SN	A-131701; CHEMBL40650; SCHEMBL7637490; BDBM50060965; 2-[2-(6-Methoxy-1,3,3a,4,5,9b-hexahydro-benzo[e]isoindol-2-yl)-ethyl]-4H-9-thia-2,4,5-triaza-fluorene-1,3-dione; 2-[2-((3aR,9bR)-6-Methoxy-1,3,3a,4,5,9b-hexahydro-benzo[e]isoindol-2-yl)-ethyl]-4H-9-thia-2,4,5-triaza-fluorene-1,3-dione
DM6CSRU	DT	Small molecular drug
DM6CSRU	PC	10527469
DM6CSRU	MW	448.5
DM6CSRU	FM	C24H24N4O3S
DM6CSRU	IC	InChI=1S/C24H24N4O3S/c1-31-18-5-2-4-15-16(18)8-7-14-12-27(13-17(14)15)10-11-28-23(29)22-21(26-24(28)30)20-19(32-22)6-3-9-25-20/h2-6,9,14,17H,7-8,10-13H2,1H3,(H,26,30)/t14-,17+/m0/s1
DM6CSRU	CS	COC1=CC=CC2=C1CC[C@@H]3[C@H]2CN(C3)CCN4C(=O)C5=C(C6=C(S5)C=CC=N6)NC4=O
DM6CSRU	IK	OLPQNRLJYOGSGV-WMLDXEAASA-N
DM6CSRU	IU	5-[2-[(3aR,9bR)-6-methoxy-1,3,3a,4,5,9b-hexahydrobenzo[e]isoindol-2-yl]ethyl]-8-thia-3,5,13-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraene-4,6-dione

DMRWDX5	ID	DMRWDX5
DMRWDX5	DN	A-134974
DMRWDX5	HS	Terminated
DMRWDX5	SN	a-134974; GTPL5130; CHEMBL1591918; ZINC3827162; SMP2_000021; NCGC00186045-01; A134974; A 134974
DMRWDX5	CP	Abbott Laboratories
DMRWDX5	DT	Small molecular drug
DMRWDX5	PC	9885936
DMRWDX5	MW	375.17
DMRWDX5	FM	C11H14IN5O2
DMRWDX5	IC	InChI=1S/C11H14IN5O2/c12-4-2-17(6-1-5(13)8(18)9(6)19)11-7(4)10(14)15-3-16-11/h2-3,5-6,8-9,18-19H,1,13H2,(H2,14,15,16)/t5-,6+,8+,9-/m0/s1
DMRWDX5	CS	C1[C@@H]([C@H]([C@H]([C@@H]1N2C=C(C3=C(N=CN=C32)N)I)O)O)N
DMRWDX5	IK	NSXJHIFQIZKLGF-LWIVVEGESA-N
DMRWDX5	IU	(1S,2R,3S,5R)-3-amino-5-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
DMRWDX5	DE	Epilepsy

DMPEJ4O	ID	DMPEJ4O
DMPEJ4O	DN	A-204176
DMPEJ4O	HS	Terminated
DMPEJ4O	CP	Abbott Laboratories
DMPEJ4O	PC	9904117
DMPEJ4O	MW	291.37
DMPEJ4O	FM	C14H17N3O2S
DMPEJ4O	IC	InChI=1S/C14H17N3O2S/c1-20(18,19)17-13-7-3-4-10-11(13)5-2-6-12(10)14-8-15-9-16-14/h3-4,7-9,12,17H,2,5-6H2,1H3,(H,15,16)
DMPEJ4O	CS	CS(=O)(=O)NC1=CC=CC2=C1CCCC2C3=CN=CN3
DMPEJ4O	IK	FTWWLMPVXHMPNP-UHFFFAOYSA-N
DMPEJ4O	IU	N-[5-(1H-imidazol-5-yl)-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide
DMPEJ4O	DE	Stress urinary incontinence

DMDTA36	ID	DMDTA36
DMDTA36	DN	A-252444.0
DMDTA36	HS	Terminated
DMDTA36	SN	A-155918; A-205804; A-241548
DMDTA36	CP	Abbott Laboratories
DMDTA36	DE	Inflammation

DMKL482	ID	DMKL482
DMKL482	DN	A-364
DMKL482	HS	Terminated
DMKL482	SN	A-358; Dehydroquinate synthase inhibitors (antibacterial); Dehydroquinate synthase inhibitors (antibacterial), Arrow
DMKL482	CP	Arrow Therapeutics Ltd
DMKL482	DE	Bacterial infection

DM4WT7Z	ID	DM4WT7Z
DM4WT7Z	DN	A-62176
DM4WT7Z	HS	Terminated
DM4WT7Z	SN	A-62176
DM4WT7Z	DT	Small molecular drug
DM4WT7Z	PC	10474948
DM4WT7Z	MW	381.4
DM4WT7Z	FM	C20H16FN3O4
DM4WT7Z	IC	InChI=1S/C20H16FN3O4/c21-13-7-11-16-19(17(13)23-6-5-10(22)8-23)28-15-4-2-1-3-14(15)24(16)9-12(18(11)25)20(26)27/h1-4,7,9-10H,5-6,8,22H2,(H,26,27)/t10-/m0/s1
DM4WT7Z	CS	C1CN(C[C@H]1N)C2=C(C=C3C4=C2OC5=CC=CC=C5N4C=C(C3=O)C(=O)O)F
DM4WT7Z	IK	OLNJLTFSGFZCKE-JTQLQIEISA-N
DM4WT7Z	IU	10-[(3S)-3-aminopyrrolidin-1-yl]-11-fluoro-14-oxo-8-oxa-1-azatetracyclo[7.7.1.02,7.013,17]heptadeca-2,4,6,9(17),10,12,15-heptaene-15-carboxylic acid

DM1BDHY	ID	DM1BDHY
DM1BDHY	DN	A-68552
DM1BDHY	HS	Terminated
DM1BDHY	SN	IDDB2379
DM1BDHY	CP	Abbott Laboratories
DM1BDHY	DT	Small molecular drug
DM1BDHY	PC	194986
DM1BDHY	MW	991.1
DM1BDHY	FM	C48H62N8O13S
DM1BDHY	IC	InChI=1S/C48H62N8O13S/c1-4-6-16-36(52-41(57)24-21-30-19-22-33(23-20-30)69-70(66,67)68)44(61)51-29-42(58)53-39(26-32-28-50-35-18-12-11-15-34(32)35)47(64)54-37(17-7-5-2)45(62)55-40(27-43(59)60)48(65)56-46(63)38(49-3)25-31-13-9-8-10-14-31/h8-15,18-20,22-23,28,36-40,49-50H,4-7,16-17,21,24-27,29H2,1-3H3,(H,51,61)(H,52,57)(H,53,58)(H,54,64)(H,55,62)(H,59,60)(H,56,63,65)(H,66,67,68)/t36-,37-,38-,39-,40-/m0/s1
DM1BDHY	CS	CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)NC(=O)[C@H](CC3=CC=CC=C3)NC)NC(=O)CCC4=CC=C(C=C4)OS(=O)(=O)O
DM1BDHY	IK	HTISDDBHNNOAGK-HECCNADXSA-N
DM1BDHY	IU	(3S)-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-4-[[(2S)-2-(methylamino)-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DM1BDHY	CA	CAS 112882-74-3
DM1BDHY	DE	Obesity

DMUJ94B	ID	DMUJ94B
DMUJ94B	DN	A-68930
DMUJ94B	HS	Terminated
DMUJ94B	SN	5,6-Dihydroxy-3-phenyl-1-aminomethylisochroman; A-70108; A 68930; A70360; A70108; A68930; A 70360; A-70360; A 70108; UNII-B4NI77O5D4; CHEMBL86931; B4NI77O5D4; 1-(Aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran; 130465-45-1; 1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-phenyl-, (1R-cis)-; Tocris-1534; AC1L3UDV; GTPL6077; SCHEMBL10380334; CHEBI:103966; ZINC3787668; BDBM50007129; NCGC00025206-01; NCGC00025206-02; LS-172768; BRD-K33400588-003-01-2
DMUJ94B	CP	Abbott Laboratories
DMUJ94B	DT	Small molecular drug
DMUJ94B	PC	122324
DMUJ94B	MW	271.31
DMUJ94B	FM	C16H17NO3
DMUJ94B	IC	InChI=1S/C16H17NO3/c17-9-15-11-6-7-13(18)16(19)12(11)8-14(20-15)10-4-2-1-3-5-10/h1-7,14-15,18-19H,8-9,17H2/t14-,15-/m0/s1
DMUJ94B	CS	C1[C@H](O[C@H](C2=C1C(=C(C=C2)O)O)CN)C3=CC=CC=C3
DMUJ94B	IK	SUHGRZPINGKYNV-GJZGRUSLSA-N
DMUJ94B	IU	(1R,3S)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1H-isochromene-5,6-diol
DMUJ94B	CA	CAS 130465-45-1
DMUJ94B	CB	CHEBI:103966
DMUJ94B	DE	Hypertension

DMPL1OV	ID	DMPL1OV
DMPL1OV	DN	A-69024
DMPL1OV	HS	Terminated
DMPL1OV	SN	A-69024; 58939-37-0; 7-Isoquinolinol, 1-((2-bromo-4,5-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6-methoxy-2-methyl-; A 69024; A-66359; A 66359; 1-[(2-bromo-4,5-dimethoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; AC1L5ACF; 1-(2-Bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline; Oprea1_293762; SCHEMBL462517; CTK1H3031
DMPL1OV	CP	Abbott Laboratories
DMPL1OV	DT	Small molecular drug
DMPL1OV	PC	173657
DMPL1OV	MW	422.3
DMPL1OV	FM	C20H24BrNO4
DMPL1OV	IC	InChI=1S/C20H24BrNO4/c1-22-6-5-12-8-18(24-2)17(23)10-14(12)16(22)7-13-9-19(25-3)20(26-4)11-15(13)21/h8-11,16,23H,5-7H2,1-4H3
DMPL1OV	CS	CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3Br)OC)OC)O)OC
DMPL1OV	IK	YVBUTIYRCMQJHW-UHFFFAOYSA-N
DMPL1OV	IU	1-[(2-bromo-4,5-dimethoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol
DMPL1OV	CA	CAS 58939-37-0
DMPL1OV	DE	Psychotic disorder

DM9KNFZ	ID	DM9KNFZ
DM9KNFZ	DN	A-70276
DM9KNFZ	HS	Terminated
DM9KNFZ	SN	A-71134
DM9KNFZ	CP	Abbott Laboratories
DM9KNFZ	DE	Gastrointestinal disease

DM9X24J	ID	DM9X24J
DM9X24J	DN	A-70826
DM9X24J	HS	Terminated
DM9X24J	SN	A-70826; AC1OCF5L; 7-[3-[[(2S)-2-[[(2S)-2-aminopentanoyl]amino]pentanoyl]amino]pyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride
DM9X24J	CP	Abbott Laboratories
DM9X24J	DT	Small molecular drug
DM9X24J	PC	6918207
DM9X24J	MW	639.1
DM9X24J	FM	C29H34ClF3N6O5
DM9X24J	IC	InChI=1S/C29H33F3N6O5.ClH/c1-3-5-21(33)27(40)35-22(6-4-2)28(41)34-16-9-10-37(13-16)26-20(32)12-17-24(39)18(29(42)43)14-38(25(17)36-26)23-8-7-15(30)11-19(23)31;/h7-8,11-12,14,16,21-22H,3-6,9-10,13,33H2,1-2H3,(H,34,41)(H,35,40)(H,42,43);1H/t16?,21-,22-;/m0./s1
DM9X24J	CS	CCC[C@@H](C(=O)N[C@@H](CCC)C(=O)NC1CCN(C1)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F)N.Cl
DM9X24J	IK	FTKPWZYQYLDWSN-KSNQKOBFSA-N
DM9X24J	IU	7-[3-[[(2S)-2-[[(2S)-2-aminopentanoyl]amino]pentanoyl]amino]pyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;hydrochloride
DM9X24J	DE	Bacterial infection

DMKZNTY	ID	DMKZNTY
DMKZNTY	DN	A-71623
DMKZNTY	HS	Terminated
DMKZNTY	SN	A-71623; 130408-77-4; CHEMBL323521; A 71623; A71623; (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-6-[(2-methylphenyl)carbamoylamino]hexanoyl]amino]-4-oxobutanoic acid; PDSP1_000879; AC1L3TQM; GTPL858; CHEMBL337366; ZINC95610808; PDSP2_000865; BDBM50003666; Boc-trp-lys(epsilon-N-2-methylphenylaminocarbonyl)-asp-(N-methyl)-phe-NH2; AKOS024457082; KB-270509; B7046; J-005804
DMKZNTY	CP	Abbott Laboratories
DMKZNTY	DT	Small molecular drug
DMKZNTY	PC	121964
DMKZNTY	MW	841
DMKZNTY	FM	C44H56N8O9
DMKZNTY	IC	InChI=1S/C44H56N8O9/c1-27-15-9-11-19-31(27)50-42(59)46-22-14-13-21-33(39(56)49-35(25-37(53)54)41(58)52(5)36(38(45)55)23-28-16-7-6-8-17-28)48-40(57)34(51-43(60)61-44(2,3)4)24-29-26-47-32-20-12-10-18-30(29)32/h6-12,15-20,26,33-36,47H,13-14,21-25H2,1-5H3,(H2,45,55)(H,48,57)(H,49,56)(H,51,60)(H,53,54)(H2,46,50,59)/t33-,34-,35-,36-/m0/s1
DMKZNTY	CS	CC1=CC=CC=C1NC(=O)NCCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N(C)[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)OC(C)(C)C
DMKZNTY	IK	KNHCBYMGWWTGSO-ZYADHFCISA-N
DMKZNTY	IU	(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-6-[(2-methylphenyl)carbamoylamino]hexanoyl]amino]-4-oxobutanoic acid
DMKZNTY	CA	CAS 130408-77-4
DMKZNTY	DE	Obesity

DM7FI3S	ID	DM7FI3S
DM7FI3S	DN	A-72055
DM7FI3S	HS	Terminated
DM7FI3S	CP	Abbott Laboratories
DM7FI3S	DE	Alzheimer disease

DMBEIFL	ID	DMBEIFL
DMBEIFL	DN	A-74273
DMBEIFL	HS	Terminated
DMBEIFL	SN	A-74723
DMBEIFL	CP	Abbott Laboratories
DMBEIFL	DT	Small molecular drug
DMBEIFL	PC	5483842
DMBEIFL	MW	787.1
DMBEIFL	FM	C44H74N4O8
DMBEIFL	IC	InChI=1S/C44H74N4O8/c1-5-6-18-40(56-41(30-35-16-11-8-12-17-35)44(52)48-23-19-36(20-24-48)55-32-53-4)43(51)46-38(29-34-14-9-7-10-15-34)39(49)31-37(33(2)3)42(50)45-21-13-22-47-25-27-54-28-26-47/h8,11-12,16-17,33-34,36-41,49H,5-7,9-10,13-15,18-32H2,1-4H3,(H,45,50)(H,46,51)/t37?,38?,39?,40-,41-/m0/s1
DMBEIFL	CS	CCCC[C@@H](C(=O)NC(CC1CCCCC1)C(CC(C(C)C)C(=O)NCCCN2CCOCC2)O)O[C@@H](CC3=CC=CC=C3)C(=O)N4CCC(CC4)OCOC
DMBEIFL	IK	NVMVSIUABPBQIL-UOKFUGOKSA-N
DMBEIFL	IU	6-cyclohexyl-4-hydroxy-5-[[(2S)-2-[(2S)-1-[4-(methoxymethoxy)piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]oxyhexanoyl]amino]-N-(3-morpholin-4-ylpropyl)-2-propan-2-ylhexanamide
DMBEIFL	CA	CAS 130316-95-9
DMBEIFL	DE	Hypertension

DMS3R15	ID	DMS3R15
DMS3R15	DN	A-74283
DMS3R15	HS	Terminated
DMS3R15	CP	Abbott Laboratories
DMS3R15	PC	9935515
DMS3R15	MW	458.6
DMS3R15	FM	C29H34N2O3
DMS3R15	IC	InChI=1S/C29H34N2O3/c1-34-24-6-4-5-17-7-8-18-15-30(16-23(18)25(17)24)13-2-3-14-31-28(32)26-21-11-12-22(27(26)29(31)33)20-10-9-19(20)21/h4-6,9-12,18-23,26-27H,2-3,7-8,13-16H2,1H3/t18-,19?,20?,21-,22+,23-,26?,27?/m1/s1
DMS3R15	CS	COC1=CC=CC2=C1[C@@H]3CN(C[C@H]3CC2)CCCCN4C(=O)C5[C@@H]6C=C[C@H](C5C4=O)C7C6C=C7
DMS3R15	IK	FIVMUTRIOVYDHZ-TZNWWNPGSA-N
DMS3R15	IU	(1S,7R)-4-[4-[(3aS,9bR)-9-methoxy-1,3,3a,4,5,9b-hexahydrobenzo[e]isoindol-2-yl]butyl]-4-azatetracyclo[5.4.2.02,6.08,11]trideca-9,12-diene-3,5-dione
DMS3R15	DE	Hypertension

DMNCGOP	ID	DMNCGOP
DMNCGOP	DN	A-74932
DMNCGOP	HS	Terminated
DMNCGOP	SN	A-74932; A 74932; 3H-Pyrido(3,2,1-kl)phenoxazine-2-carboxylic acid, 6-(2-((2-amino-1-oxopentyl)amino)-1-pyrrolidinyl)-5-fluoro-3-oxo-, monohydrochloride; 3H-Pyrido(3,2,1-k1)phenoxazine-2-carboxylic acid, 6-(2-((2-amino-1-oxopentyl)amino)-1-pyrrolidinyl)-5-fluoro-3-oxo-, monohydrochloride; AC1L31MU; 148201-60-9
DMNCGOP	CP	Abbott Laboratories
DMNCGOP	DT	Small molecular drug
DMNCGOP	PC	132825
DMNCGOP	MW	516.9
DMNCGOP	FM	C25H26ClFN4O5
DMNCGOP	IC	InChI=1S/C25H25FN4O5.ClH/c1-2-6-16(27)24(32)28-19-9-5-10-29(19)21-15(26)11-13-20-23(21)35-18-8-4-3-7-17(18)30(20)12-14(22(13)31)25(33)34;/h3-4,7-8,11-12,16,19H,2,5-6,9-10,27H2,1H3,(H,28,32)(H,33,34);1H
DMNCGOP	CS	CCCC(C(=O)NC1CCCN1C2=C(C=C3C4=C2OC5=CC=CC=C5N4C=C(C3=O)C(=O)O)F)N.Cl
DMNCGOP	IK	UFBYBJURMXBKFU-UHFFFAOYSA-N
DMNCGOP	IU	10-[2-(2-aminopentanoylamino)pyrrolidin-1-yl]-11-fluoro-14-oxo-8-oxa-1-azatetracyclo[7.7.1.02,7.013,17]heptadeca-2,4,6,9(17),10,12,15-heptaene-15-carboxylic acid;hydrochloride
DMNCGOP	CA	CAS 148201-60-9
DMNCGOP	DE	Lung cancer

DMPX37E	ID	DMPX37E
DMPX37E	DN	A-75169
DMPX37E	HS	Terminated
DMPX37E	SN	A-74324; A-74325
DMPX37E	CP	Abbott Laboratories
DMPX37E	PC	70208442
DMPX37E	MW	331.9
DMPX37E	FM	C20H26ClNO
DMPX37E	IC	InChI=1S/C20H25NO.ClH/c1-21(13-12-16-6-3-2-4-7-16)15-18-9-5-8-17-14-19(22)10-11-20(17)18;/h2-4,6-7,10-11,14,18,22H,5,8-9,12-13,15H2,1H3;1H
DMPX37E	CS	CN(CCC1=CC=CC=C1)CC2CCCC3=C2C=CC(=C3)O.Cl
DMPX37E	IK	APKIWAWHUXJRIV-UHFFFAOYSA-N
DMPX37E	IU	5-[[methyl(2-phenylethyl)amino]methyl]-5,6,7,8-tetrahydronaphthalen-2-ol;hydrochloride
DMPX37E	DE	Glaucoma/ocular hypertension

DMC3MH5	ID	DMC3MH5
DMC3MH5	DN	A-75729
DMC3MH5	HS	Terminated
DMC3MH5	SN	A-75290; A-75619
DMC3MH5	CP	Abbott Laboratories
DMC3MH5	DE	Bacterial infection

DMRHEWX	ID	DMRHEWX
DMRHEWX	DN	A-76202M
DMRHEWX	HS	Terminated
DMRHEWX	SN	A 76202
DMRHEWX	CP	Sankyo Co Ltd
DMRHEWX	DE	Acquired immune deficiency syndrome

DMTF6D9	ID	DMTF6D9
DMTF6D9	DN	A-76895
DMTF6D9	HS	Terminated
DMTF6D9	SN	IDDB2395
DMTF6D9	CP	Abbott Laboratories
DMTF6D9	DE	Epilepsy

DM4HRXI	ID	DM4HRXI
DM4HRXI	DN	A-78773
DM4HRXI	HS	Terminated
DM4HRXI	SN	141579-67-1; A 78773; CHEMBL59598; N-Hydroxy-N-(4-(5-(4-fluorophenoxy)-2-furyl)-3-butyn-2-yl)urea; N-(3-(5-(4-Fluorophenoxy)-2-furanyl)-1-methyl-2-propynyl)-N-hydroxyurea; 1-{4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl}-1-hydroxyurea; 1-[4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea; Urea,N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propyn-1-yl]-N-hydroxy-; CCRIS 8531
DM4HRXI	DT	Small molecular drug
DM4HRXI	PC	71460
DM4HRXI	MW	304.27
DM4HRXI	FM	C15H13FN2O4
DM4HRXI	IC	InChI=1S/C15H13FN2O4/c1-10(18(20)15(17)19)2-5-12-8-9-14(21-12)22-13-6-3-11(16)4-7-13/h3-4,6-10,20H,1H3,(H2,17,19)
DM4HRXI	CS	CC(C#CC1=CC=C(O1)OC2=CC=C(C=C2)F)N(C(=O)N)O
DM4HRXI	IK	OLZHFFKRBCZHHT-UHFFFAOYSA-N
DM4HRXI	IU	1-[4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DM4HRXI	CA	CAS 141579-67-1
DM4HRXI	DE	Asthma

DMT5ZFG	ID	DMT5ZFG
DMT5ZFG	DN	A-79175
DMT5ZFG	HS	Terminated
DMT5ZFG	SN	CHEMBL90552; UNII-25B75ID70W; 25B75ID70W; AC1L43J2; ZINC5333; SCHEMBL6438420; BDBM50369068; 141579-87-5; 1-[(2R)-4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DMT5ZFG	DT	Small molecular drug
DMT5ZFG	PC	178577
DMT5ZFG	MW	304.27
DMT5ZFG	FM	C15H13FN2O4
DMT5ZFG	IC	InChI=1S/C15H13FN2O4/c1-10(18(20)15(17)19)2-5-12-8-9-14(21-12)22-13-6-3-11(16)4-7-13/h3-4,6-10,20H,1H3,(H2,17,19)/t10-/m1/s1
DMT5ZFG	CS	C[C@H](C#CC1=CC=C(O1)OC2=CC=C(C=C2)F)N(C(=O)N)O
DMT5ZFG	IK	OLZHFFKRBCZHHT-SNVBAGLBSA-N
DMT5ZFG	IU	1-[(2R)-4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DMT5ZFG	CA	CAS 141579-87-5
DMT5ZFG	DE	Asthma

DM3IYMF	ID	DM3IYMF
DM3IYMF	DN	A-79296
DM3IYMF	HS	Terminated
DM3IYMF	CP	Abbott Laboratories
DM3IYMF	DE	Herpes simplex virus infection

DMXWG6Z	ID	DMXWG6Z
DMXWG6Z	DN	A-798
DMXWG6Z	HS	Terminated
DMXWG6Z	SN	A-429; A-655; A-665798; A-748; A-761; A-780748; MCHR-1 antagonists (obesity); Melanin concentrating hormone-1 receptor antagonists, Abbott; MCH-1 antagonists (obesity), Abbott; MCHR-1 antagonists (obesity), Abbott
DMXWG6Z	CP	Abbott Laboratories
DMXWG6Z	DE	Obesity

DM89BGE	ID	DM89BGE
DM89BGE	DN	A-80263
DM89BGE	HS	Terminated
DM89BGE	CP	Abbott Laboratories
DM89BGE	DE	Inflammation

DMBC3DG	ID	DMBC3DG
DMBC3DG	DN	A-80426
DMBC3DG	HS	Terminated
DMBC3DG	SN	A-80426; CHEMBL268258; SCHEMBL647243; ZINC3810797; BDBM50057128; AKOS030558130; NCGC00378605-01
DMBC3DG	DT	Small molecular drug
DMBC3DG	PC	9928332
DMBC3DG	MW	349.5
DMBC3DG	FM	C23H27NO2
DMBC3DG	IC	InChI=1S/C23H27NO2/c1-24(13-11-17-9-10-18-12-14-26-23(18)15-17)16-19-5-3-7-21-20(19)6-4-8-22(21)25-2/h4,6,8-10,12,14-15,19H,3,5,7,11,13,16H2,1-2H3/t19-/m0/s1
DMBC3DG	CS	CN(CCC1=CC2=C(C=C1)C=CO2)C[C@@H]3CCCC4=C3C=CC=C4OC
DMBC3DG	IK	MHPMXTGKTXJIDI-IBGZPJMESA-N
DMBC3DG	IU	2-(1-benzofuran-6-yl)-N-[[(1R)-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]-N-methylethanamine

DMH6LCD	ID	DMH6LCD
DMH6LCD	DN	A-81282
DMH6LCD	HS	Terminated
DMH6LCD	SN	141872-46-0; Abbott 81282; A-81282; CHEMBL333534; 4-[butyl([2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl)amino]-5-pyrimidinecarboxylic acid; 5-Pyrimidinecarboxylicacid, 4-[butyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-; Abbott-81282; ACMC-20cd64; AC1Q5UC5; AC1L4U4U; A 81282; Oprea1_016094; SCHEMBL7939345; CTK8G9360; CTK0I0417; DTXSID70161839; MolPort-039-032-861; ZINC1533713; BDBM50003155; AKOS027380884; 4-(butyl{[2'-(2h-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)pyrimidine-5-carboxylic acid; CC-17571
DMH6LCD	CP	Abbott Laboratories
DMH6LCD	DT	Small molecular drug
DMH6LCD	PC	192314
DMH6LCD	MW	429.5
DMH6LCD	FM	C23H23N7O2
DMH6LCD	IC	InChI=1S/C23H23N7O2/c1-2-3-12-30(22-20(23(31)32)13-24-15-25-22)14-16-8-10-17(11-9-16)18-6-4-5-7-19(18)21-26-28-29-27-21/h4-11,13,15H,2-3,12,14H2,1H3,(H,31,32)(H,26,27,28,29)
DMH6LCD	CS	CCCCN(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C4=NC=NC=C4C(=O)O
DMH6LCD	IK	AHZXSVWCNDLJER-UHFFFAOYSA-N
DMH6LCD	IU	4-[butyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyrimidine-5-carboxylic acid
DMH6LCD	CA	CAS 141872-46-0
DMH6LCD	DE	Hypertension

DM1GLIN	ID	DM1GLIN
DM1GLIN	DN	A-81988
DM1GLIN	HS	Terminated
DM1GLIN	SN	2-[Propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid; 141887-34-5; A81988; A 81988; CHEMBL416477; Abbott-81988; 2-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid; 3-Pyridinecarboxylicacid, 2-[propyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-; ACMC-20n0yv; [3H]A81988; [3H]-A81988; AC1L30WD; 2-(N-Propyl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)amino)pyridine-3-carboxylic acid; Oprea1_714523; SCHEMBL7048946; GTPL3938; CTK0H8555; DTXSID40161846; BDBM50003154; HY-U00188; CS-7281; L007227;  Abbott-81988
DM1GLIN	CP	Abbott Laboratories
DM1GLIN	DT	Small molecular drug
DM1GLIN	PC	132387
DM1GLIN	MW	414.5
DM1GLIN	FM	C23H22N6O2
DM1GLIN	IC	InChI=1S/C23H22N6O2/c1-2-14-29(22-20(23(30)31)8-5-13-24-22)15-16-9-11-17(12-10-16)18-6-3-4-7-19(18)21-25-27-28-26-21/h3-13H,2,14-15H2,1H3,(H,30,31)(H,25,26,27,28)
DM1GLIN	CS	CCCN(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C4=C(C=CC=N4)C(=O)O
DM1GLIN	IK	DLMNZGAILMQDHA-UHFFFAOYSA-N
DM1GLIN	IU	2-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid
DM1GLIN	CA	CAS 141887-34-5
DM1GLIN	DE	Hypertension

DMUID46	ID	DMUID46
DMUID46	DN	A-87049
DMUID46	HS	Terminated
DMUID46	SN	A-87049; CHEMBL445618; BDBM50058945; (1S,2S,3S,4S)-3,4-Bis-[(4-phenoxy-benzyl)-propyl-carbamoyl]-cyclobutane-1,2-dicarboxylic acid
DMUID46	DT	Small molecular drug
DMUID46	PC	9810076
DMUID46	MW	678.8
DMUID46	FM	C40H42N2O8
DMUID46	IC	InChI=1S/C40H42N2O8/c1-3-23-41(25-27-15-19-31(20-16-27)49-29-11-7-5-8-12-29)37(43)33-34(36(40(47)48)35(33)39(45)46)38(44)42(24-4-2)26-28-17-21-32(22-18-28)50-30-13-9-6-10-14-30/h5-22,33-36H,3-4,23-26H2,1-2H3,(H,45,46)(H,47,48)/t33-,34-,35-,36-/m0/s1
DMUID46	CS	CCCN(CC1=CC=C(C=C1)OC2=CC=CC=C2)C(=O)[C@H]3[C@@H]([C@@H]([C@H]3C(=O)O)C(=O)O)C(=O)N(CCC)CC4=CC=C(C=C4)OC5=CC=CC=C5
DMUID46	IK	PNOGMVDDWILAMR-ZYADHFCISA-N
DMUID46	IU	(1S,2S,3S,4S)-3,4-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclobutane-1,2-dicarboxylic acid

DM1KBAY	ID	DM1KBAY
DM1KBAY	DN	A-93178
DM1KBAY	HS	Terminated
DM1KBAY	SN	A-93178.5
DM1KBAY	CP	Abbott Laboratories
DM1KBAY	PC	101018054
DM1KBAY	MW	432.5
DM1KBAY	FM	C26H28N2O4
DM1KBAY	IC	InChI=1S/C26H28N2O4/c1-18(26(29)30)28-32-25(20-8-3-2-4-9-20)21-12-15-23(16-13-21)31-17-22-14-11-19-7-5-6-10-24(19)27-22/h5-7,10-16,20,25H,2-4,8-9,17H2,1H3,(H,29,30)/b28-18-
DM1KBAY	CS	C/C(=N/OC(C1CCCCC1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)/C(=O)O
DM1KBAY	IK	USBHSZPRMPADOE-VEILYXNESA-N
DM1KBAY	IU	(2Z)-2-[cyclohexyl-[4-(quinolin-2-ylmethoxy)phenyl]methoxy]iminopropanoic acid
DM1KBAY	DE	Allergy

DMPEB0Z	ID	DMPEB0Z
DMPEB0Z	DN	AA-861
DMPEB0Z	HS	Terminated
DMPEB0Z	SN	aa-861; DOCEBENONE; 80809-81-0; Docebenonum; Docebenona; AA861; Docebenone [USAN:INN]; Docebenonum [INN-Latin]; Docebenona [INN-Spanish]; UNII-2XRX3BD53M; 2-(12-hydroxydodeca-5,10-diyn-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione; CHEBI:2340; A-61589; 2-(12-Hydroxy-5,10-dodecadiynyl)-3,5,6-trimethyl-p-benzoquinone; 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone; 2XRX3BD53M; MLS000028467; A 61589; NCGC00015053-05; SMR000058412; 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone
DMPEB0Z	DT	Small molecular drug
DMPEB0Z	PC	1967
DMPEB0Z	MW	326.4
DMPEB0Z	FM	C21H26O3
DMPEB0Z	IC	InChI=1S/C21H26O3/c1-16-17(2)21(24)19(18(3)20(16)23)14-12-10-8-6-4-5-7-9-11-13-15-22/h22H,5,7-10,12,14-15H2,1-3H3
DMPEB0Z	CS	CC1=C(C(=O)C(=C(C1=O)C)CCCCC#CCCCC#CCO)C
DMPEB0Z	IK	WDEABJKSGGRCQA-UHFFFAOYSA-N
DMPEB0Z	IU	2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione
DMPEB0Z	CA	CAS 80809-81-0
DMPEB0Z	CB	CHEBI:2340
DMPEB0Z	DE	Allergy

DMDOQCV	ID	DMDOQCV
DMDOQCV	DN	ABANOQUIL
DMDOQCV	HS	Terminated
DMDOQCV	SN	TCMDC-131968; UNII-MAX6HQS78D; MAX6HQS78D; UK 52046; UK 52046 mesylate; UK-52,046; UK 52046-27; Abanoquil mesilate; 118931-00-3; AC1Q6WCW; 4-Amino-6,7-dimethoxy-2-(1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl)quinoline methanesulfonate; CHEMBL527515; AC1L4U62; SCHEMBL3672975; UK-52046-27; A807482; 4-Quinolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monomethanesulfonate; 2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-quinolin-4-amine
DMDOQCV	DT	Small molecular drug
DMDOQCV	PC	164089
DMDOQCV	MW	395.5
DMDOQCV	FM	C22H25N3O4
DMDOQCV	IC	InChI=1S/C22H25N3O4/c1-26-18-7-13-5-6-25(12-14(13)8-19(18)27-2)22-10-16(23)15-9-20(28-3)21(29-4)11-17(15)24-22/h7-11H,5-6,12H2,1-4H3,(H2,23,24)
DMDOQCV	CS	COC1=C(C=C2CN(CCC2=C1)C3=NC4=CC(=C(C=C4C(=C3)N)OC)OC)OC
DMDOQCV	IK	ANZIISNSHPKVRV-UHFFFAOYSA-N
DMDOQCV	IU	2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxyquinolin-4-amine
DMDOQCV	CA	CAS 90402-40-7

DMALPDW	ID	DMALPDW
DMALPDW	DN	ABS-205
DMALPDW	HS	Terminated
DMALPDW	SN	ABS-205R; ABS-205S
DMALPDW	CP	American Biogenetic Sciences Inc
DMALPDW	DE	Neurodegenerative disorder

DMZ52P6	ID	DMZ52P6
DMZ52P6	DN	ABS-212
DMZ52P6	HS	Terminated
DMZ52P6	SN	Neurotensin derivative (pain), Argolyn
DMZ52P6	CP	Argolyn Bioscience Inc
DMZ52P6	DE	Pain

DMCW5DJ	ID	DMCW5DJ
DMCW5DJ	DN	ABS-301
DMCW5DJ	HS	Terminated
DMCW5DJ	SN	ABS-302; ABS-303; ABS-304; Tacrine analogs, ABS
DMCW5DJ	CP	American Biogenetic Sciences Inc
DMCW5DJ	DE	Alzheimer disease

DMPFLS5	ID	DMPFLS5
DMPFLS5	DN	ABT-100
DMPFLS5	HS	Terminated
DMPFLS5	SN	A-367074; A-409100; A-367074.1
DMPFLS5	CP	Abbott Laboratories
DMPFLS5	DT	Small molecular drug
DMPFLS5	PC	6451154
DMPFLS5	MW	504.5
DMPFLS5	FM	C27H19F3N4O3
DMPFLS5	IC	InChI=1S/C27H19F3N4O3/c1-34-17-33-15-25(34)26(35,21-7-2-18(13-31)3-8-21)16-36-24-11-4-19(14-32)12-23(24)20-5-9-22(10-6-20)37-27(28,29)30/h2-12,15,17,35H,16H2,1H3/t26-/m0/s1
DMPFLS5	CS	CN1C=NC=C1[C@](COC2=C(C=C(C=C2)C#N)C3=CC=C(C=C3)OC(F)(F)F)(C4=CC=C(C=C4)C#N)O
DMPFLS5	IK	HEUVRFNVTLGKMZ-SANMLTNESA-N
DMPFLS5	IU	4-[(2S)-2-(4-cyanophenyl)-2-hydroxy-2-(3-methylimidazol-4-yl)ethoxy]-3-[4-(trifluoromethoxy)phenyl]benzonitrile
DMPFLS5	CA	CAS 450839-40-4
DMPFLS5	DE	Solid tumour/cancer

DMYJMV9	ID	DMYJMV9
DMYJMV9	DN	ABT-702
DMYJMV9	HS	Terminated
DMYJMV9	SN	abt-702; Abt 702; ABT702; CHEMBL66089; UNII-2P206WS5B3; 2P206WS5B3; 5-(3-bromophenyl)-7-[6-(morpholin-4-yl)pyridin-3-yl]pyrido[2,3-d]pyrimidin-4-amine; 5-(3-Bromo-phenyl)-7-(6-morpholin-4-yl-pyridin-3-yl)-pyrido[2,3-d]pyrimidin-4-ylamine; AC1L1CN5; SCHEMBL1914142; GTPL5131; CTK5I8409; MolPort-035-936-400; CHEBI:104129; ZINC21288919; BDBM50094703; AKOS030589605; SMP2_000264; NCGC00092381-03; NCGC00092381-02; LS-134028; BRD-K36021395-300-01-6; 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine
DMYJMV9	CP	Abbott Laboratories
DMYJMV9	DT	Small molecular drug
DMYJMV9	PC	1973
DMYJMV9	MW	463.3
DMYJMV9	FM	C22H19BrN6O
DMYJMV9	IC	InChI=1S/C22H19BrN6O/c23-16-3-1-2-14(10-16)17-11-18(28-22-20(17)21(24)26-13-27-22)15-4-5-19(25-12-15)29-6-8-30-9-7-29/h1-5,10-13H,6-9H2,(H2,24,26,27,28)
DMYJMV9	CS	C1COCCN1C2=NC=C(C=C2)C3=NC4=NC=NC(=C4C(=C3)C5=CC(=CC=C5)Br)N
DMYJMV9	IK	RQCXKDWOCUJWQZ-UHFFFAOYSA-N
DMYJMV9	IU	5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine
DMYJMV9	CA	CAS 214697-26-4
DMYJMV9	CB	CHEBI:104129
DMYJMV9	DE	Pain

DML0DBV	ID	DML0DBV
DML0DBV	DN	ABT-737
DML0DBV	HS	Terminated
DML0DBV	SN	ABT-737; 852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide
DML0DBV	DT	Small molecular drug
DML0DBV	PC	11228183
DML0DBV	MW	813.4
DML0DBV	FM	C42H45ClN6O5S2
DML0DBV	IC	InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1
DML0DBV	CS	CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]
DML0DBV	IK	HPLNQCPCUACXLM-PGUFJCEWSA-N
DML0DBV	IU	4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide
DML0DBV	CA	CAS 852808-04-9

DM4UN9A	ID	DM4UN9A
DM4UN9A	DN	ABT-839
DM4UN9A	HS	Terminated
DM4UN9A	SN	ABT-839; CHEMBL29982; 216234-25-2; 2-{(5-{[BUTYL-(2-CYCLOHEXYL-ETHYL)-AMINO]-METHYL}-2'-METHYL-BIPHENYL-2-CARBONYL)-AMINO]-4-METHYLSULFANYL-BUTYRIC ACID; A 228839; AC1L9KPG; SCHEMBL629301; BDBM17325; 1n94; ZINC3973581; KB-74366; (2S)-2-[(4-{[butyl(2-cyclohexylethyl)amino]methyl}-2-(2-methylphenyl)phenyl)formamido]-4-(methylsulfanyl)butanoic acid; N-[(5-{[butyl(2-cyclohexylethyl)amino]methyl}-2'-methylbiphenyl-2-yl)carbonyl]-L-methionine
DM4UN9A	DT	Small molecular drug
DM4UN9A	PC	447312
DM4UN9A	MW	538.8
DM4UN9A	FM	C32H46N2O3S
DM4UN9A	IC	InChI=1S/C32H46N2O3S/c1-4-5-19-34(20-17-25-12-7-6-8-13-25)23-26-15-16-28(29(22-26)27-14-10-9-11-24(27)2)31(35)33-30(32(36)37)18-21-38-3/h9-11,14-16,22,25,30H,4-8,12-13,17-21,23H2,1-3H3,(H,33,35)(H,36,37)/t30-/m0/s1
DM4UN9A	CS	CCCCN(CCC1CCCCC1)CC2=CC(=C(C=C2)C(=O)N[C@@H](CCSC)C(=O)O)C3=CC=CC=C3C
DM4UN9A	IK	GAQHYZNOMLXSEA-PMERELPUSA-N
DM4UN9A	IU	(2S)-2-[[4-[[butyl(2-cyclohexylethyl)amino]methyl]-2-(2-methylphenyl)benzoyl]amino]-4-methylsulfanylbutanoic acid
DM4UN9A	DE	Non-small-cell lung cancer

DMDPUK6	ID	DMDPUK6
DMDPUK6	DN	ABX-PTH
DMDPUK6	HS	Terminated
DMDPUK6	CP	Amgen
DMDPUK6	DT	Antibody
DMDPUK6	DE	Parathyroid disease

DM5IDAQ	ID	DM5IDAQ
DM5IDAQ	DN	AC-187
DM5IDAQ	HS	Terminated
DM5IDAQ	SN	AC 187; 151804-77-2; AC187; salmon calcitonin (8-32) reduced; GTPL689; AKOS024457619
DM5IDAQ	CP	Amylin Pharmaceuticals Inc
DM5IDAQ	DT	Small molecular drug
DM5IDAQ	PC	16133792
DM5IDAQ	MW	2890.2
DM5IDAQ	FM	C127H205N37O40
DM5IDAQ	IC	InChI=1S/C127H205N37O40/c1-59(2)44-81(156-122(200)99(63(9)10)142-68(15)171)105(183)139-54-96(178)143-74(22-16-18-40-128)106(184)151-84(47-62(7)8)114(192)159-90(57-166)119(197)148-77(34-37-92(130)174)108(186)146-79(36-39-98(180)181)109(187)153-83(46-61(5)6)113(191)154-85(50-71-53-137-58-141-71)115(193)145-75(23-17-19-41-129)107(185)152-82(45-60(3)4)112(190)147-78(35-38-93(131)175)111(189)162-103(67(14)170)125(203)158-88(49-70-28-32-73(173)33-29-70)126(204)164-43-21-25-91(164)120(198)149-76(24-20-42-138-127(135)136)110(188)161-102(66(13)169)124(202)157-87(52-95(133)177)117(195)160-100(64(11)167)121(199)140-55-97(179)144-89(56-165)118(196)155-86(51-94(132)176)116(194)163-101(65(12)168)123(201)150-80(104(134)182)48-69-26-30-72(172)31-27-69/h26-33,53,58-67,74-91,99-103,165-170,172-173H,16-25,34-52,54-57,128-129H2,1-15H3,(H2,130,174)(H2,131,175)(H2,132,176)(H2,133,177)(H2,134,182)(H,137,141)(H,139,183)(H,140,199)(H,142,171)(H,143,178)(H,144,179)(H,145,193)(H,146,186)(H,147,190)(H,148,197)(H,149,198)(H,150,201)(H,151,184)(H,152,185)(H,153,187)(H,154,191)(H,155,196)(H,156,200)(H,157,202)(H,158,203)(H,159,192)(H,160,195)(H,161,188)(H,162,189)(H,163,194)(H,180,181)(H4,135,136,138)/t64-,65-,66-,67-,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,99+,100+,101+,102+,103+/m1/s1
DM5IDAQ	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)C)O
DM5IDAQ	IK	ZLFXHYNEZYAYPG-AABHONRUSA-N
DM5IDAQ	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-6-aminohexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM5IDAQ	DE	Type-2 diabetes

DMA93D8	ID	DMA93D8
DMA93D8	DN	AC-260584
DMA93D8	HS	Terminated
DMA93D8	SN	UNII-M4PN46N313; AC260584; AC-260584; CHEMBL2022960; M4PN46N313; 560083-42-3; 4-(3-(4-Butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one; BWAKMLKESHKOHK-UHFFFAOYSA-N; GTPL334; SCHEMBL4069821; BDBM50382122; ZINC34033125; CS-6425; 2H-1,4-Benzoxazin-3(4H)-one, 4-(3-(4-butyl-1-piperidinyl)propyl)-7-fluoro-; AC 260584; HY-100336; 4-[3-(4-butylpiperidin-1-yl)propyl]-7-fluoro-1,4-benzoxazin-3-one
DMA93D8	DT	Small molecular drug
DMA93D8	PC	9928284
DMA93D8	MW	348.5
DMA93D8	FM	C20H29FN2O2
DMA93D8	IC	InChI=1S/C20H29FN2O2/c1-2-3-5-16-8-12-22(13-9-16)10-4-11-23-18-7-6-17(21)14-19(18)25-15-20(23)24/h6-7,14,16H,2-5,8-13,15H2,1H3
DMA93D8	CS	CCCCC1CCN(CC1)CCCN2C(=O)COC3=C2C=CC(=C3)F
DMA93D8	IK	BWAKMLKESHKOHK-UHFFFAOYSA-N
DMA93D8	IU	4-[3-(4-butylpiperidin-1-yl)propyl]-7-fluoro-1,4-benzoxazin-3-one
DMA93D8	CA	CAS 560083-42-3
DMA93D8	DE	Schizophrenia

DMBY7AZ	ID	DMBY7AZ
DMBY7AZ	DN	ACEA-1011
DMBY7AZ	HS	Terminated
DMBY7AZ	SN	Glystatin series member (1011), CoCensys
DMBY7AZ	CP	Acea Pharmaceuticals Inc
DMBY7AZ	DT	Small molecular drug
DMBY7AZ	PC	127872
DMBY7AZ	MW	264.59
DMBY7AZ	FM	C9H4ClF3N2O2
DMBY7AZ	IC	InChI=1S/C9H4ClF3N2O2/c10-4-1-3(9(11,12)13)2-5-6(4)15-8(17)7(16)14-5/h1-2H,(H,14,16)(H,15,17)
DMBY7AZ	CS	C1=C(C=C(C2=C1NC(=O)C(=O)N2)Cl)C(F)(F)F
DMBY7AZ	IK	JDCKMCIQUXTYQI-UHFFFAOYSA-N
DMBY7AZ	IU	5-chloro-7-(trifluoromethyl)-1,4-dihydroquinoxaline-2,3-dione
DMBY7AZ	CA	CAS 153504-72-4
DMBY7AZ	DE	Cerebral infarction

DMCWNVB	ID	DMCWNVB
DMCWNVB	DN	ACEA-1031
DMCWNVB	HS	Terminated
DMCWNVB	SN	Glystatin 1000 series member (1031), ACEA; Glystatin 1000 series member (1031), CoCensys
DMCWNVB	CP	Acea Pharmaceuticals Inc
DMCWNVB	PC	9799201
DMCWNVB	MW	364.93
DMCWNVB	FM	C8H3Br2N3O4
DMCWNVB	IC	InChI=1S/C8H3Br2N3O4/c9-2-1-3-5(6(4(2)10)13(16)17)12-8(15)7(14)11-3/h1H,(H,11,14)(H,12,15)
DMCWNVB	CS	C1=C2C(=C(C(=C1Br)Br)[N+](=O)[O-])NC(=O)C(=O)N2
DMCWNVB	IK	HPDZNXVZXICVSF-UHFFFAOYSA-N
DMCWNVB	IU	6,7-dibromo-5-nitro-1,4-dihydroquinoxaline-2,3-dione
DMCWNVB	DE	Cerebrovascular ischaemia

DMEH9OY	ID	DMEH9OY
DMEH9OY	DN	ACEA-1328
DMEH9OY	HS	Terminated
DMEH9OY	TC	Analgesics
DMEH9OY	PC	9816093
DMEH9OY	MW	235.2
DMEH9OY	FM	C10H9N3O4
DMEH9OY	IC	InChI=1S/C10H9N3O4/c1-4-3-6-7(8(5(4)2)13(16)17)12-10(15)9(14)11-6/h3H,1-2H3,(H,11,14)(H,12,15)
DMEH9OY	CS	CC1=CC2=C(C(=C1C)[N+](=O)[O-])NC(=O)C(=O)N2
DMEH9OY	IK	CYJRVSOLVYLORV-UHFFFAOYSA-N
DMEH9OY	IU	6,7-dimethyl-5-nitro-1,4-dihydroquinoxaline-2,3-dione
DMEH9OY	DE	Cancer related pain

DMRHSG4	ID	DMRHSG4
DMRHSG4	DN	ACEA-1416
DMRHSG4	HS	Terminated
DMRHSG4	SN	Glystatin series member (1416), CoCensys
DMRHSG4	CP	Purdue Neuroscience Corp
DMRHSG4	PC	9816526
DMRHSG4	MW	255.61
DMRHSG4	FM	C9H6ClN3O4
DMRHSG4	IC	InChI=1S/C9H6ClN3O4/c1-3-4(10)2-5-6(7(3)13(16)17)12-9(15)8(14)11-5/h2H,1H3,(H,11,14)(H,12,15)
DMRHSG4	CS	CC1=C(C=C2C(=C1[N+](=O)[O-])NC(=O)C(=O)N2)Cl
DMRHSG4	IK	CODLITRXBIRDTG-UHFFFAOYSA-N
DMRHSG4	IU	7-chloro-6-methyl-5-nitro-1,4-dihydroquinoxaline-2,3-dione
DMRHSG4	DE	Cerebrovascular ischaemia

DMXLB02	ID	DMXLB02
DMXLB02	DN	ACEA-2085
DMXLB02	HS	Terminated
DMXLB02	SN	AMPA/glycine antagonist, CoCensys
DMXLB02	CP	Purdue Neuroscience Corp
DMXLB02	DE	Pain

DM0YHKB	ID	DM0YHKB
DM0YHKB	DN	Acteoside
DM0YHKB	HS	Terminated
DM0YHKB	SN	TJC-160
DM0YHKB	CP	Tsumura & Co
DM0YHKB	DT	Small molecular drug
DM0YHKB	PC	5281800
DM0YHKB	MW	624.6
DM0YHKB	FM	C29H36O15
DM0YHKB	IC	InChI=1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29-/m0/s1
DM0YHKB	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O
DM0YHKB	IK	FBSKJMQYURKNSU-ZLSOWSIRSA-N
DM0YHKB	IU	[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DM0YHKB	CA	CAS 61276-17-3
DM0YHKB	CB	CHEBI:9953
DM0YHKB	DE	Nephritis

DMT4P89	ID	DMT4P89
DMT4P89	DN	Actinonin
DMT4P89	HS	Terminated
DMT4P89	SN	actinonin; Actinonine; UNII-P18SPA8N0K; P18SPA8N0K; 13434-13-4; CHEMBL308333; Octanohydroxamic acid, 3-((1-((2-(hydroxymethyl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamoyl)-; 2-[(FORMYL-HYDROXY-AMINO)-METHYL]-HEPTANOIC ACID [1-(2-HYDROXYMETHYL-PYRROLIDINE-1-CARBONYL)-2-METHYL-PROPYL]-AMIDE; BB2; Butanediamide, N4-hydroxy-N1-(1-((2-(hydroxymethyl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)-2-pentyl-, stereoisomer; SR-01000075681; ( )-Actinonin; 4je7; 3pn4; 3m6p; 4dr9; 3m6q; 3m6r; 3g5k; Spectrum2_000628; Spectrum5_000728
DMT4P89	DT	Small molecular drug
DMT4P89	PC	443600
DMT4P89	MW	385.5
DMT4P89	FM	C19H35N3O5
DMT4P89	IC	InChI=1S/C19H35N3O5/c1-4-5-6-8-14(11-16(24)21-27)18(25)20-17(13(2)3)19(26)22-10-7-9-15(22)12-23/h13-15,17,23,27H,4-12H2,1-3H3,(H,20,25)(H,21,24)/t14-,15+,17+/m1/s1
DMT4P89	CS	CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO
DMT4P89	IK	XJLATMLVMSFZBN-VYDXJSESSA-N
DMT4P89	IU	(2R)-N'-hydroxy-N-[(2S)-1-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-pentylbutanediamide
DMT4P89	CA	CAS 13434-13-4

DMJFY2I	ID	DMJFY2I
DMJFY2I	DN	AD 198
DMJFY2I	HS	Terminated
DMJFY2I	SN	N-Benzyladriamycin-14-valerate; AD 198; 98983-21-2; Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((phenylmethyl)amino)-alpha-L-lyxo-hexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester, (2S-cis)-; AC1L2RLY; AC1Q62MI; CTK8F7586; DTXSID40243893; 2-[(2s,4s)-4-{[3-(benzylamino)-2,3,6-trideoxy-; A-l-lyxo-hexopyranosyl]oxy}-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl]-2-oxoethyl pentanoate; LS-101847
DMJFY2I	DT	Small molecular drug
DMJFY2I	PC	117072592
DMJFY2I	MW	717.8
DMJFY2I	FM	C39H43NO12
DMJFY2I	IC	InChI=1S/C39H43NO12/c1-4-5-14-28(41)49-19-29(42)51-22-15-24-32(39(47)34-33(37(24)45)36(44)23-12-9-13-26(48-3)31(23)38(34)46)27(16-22)52-30-17-25(35(43)20(2)50-30)40-18-21-10-7-6-8-11-21/h6-13,20,22,25,27,30,35,40,43,45,47H,4-5,14-19H2,1-3H3/t20-,22-,25-,27-,30-,35-/m0/s1
DMJFY2I	CS	CCCCC(=O)OCC(=O)O[C@@H]1C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O)NCC6=CC=CC=C6
DMJFY2I	IK	DFEZNIBKLJWMIQ-VEUGUUDJSA-N
DMJFY2I	IU	[2-[[(2S,4S)-4-[(2R,4S,5R,6S)-4-(benzylamino)-5-hydroxy-6-methyloxan-2-yl]oxy-5,12-dihydroxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen-2-yl]oxy]-2-oxoethyl] pentanoate

DM1SLJ9	ID	DM1SLJ9
DM1SLJ9	DN	AD-5075
DM1SLJ9	HS	Terminated
DM1SLJ9	SN	2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075
DM1SLJ9	CP	Dainippon Pharmaceutical Co Ltd
DM1SLJ9	DT	Small molecular drug
DM1SLJ9	PC	128440
DM1SLJ9	MW	424.5
DM1SLJ9	FM	C22H20N2O5S
DM1SLJ9	IC	InChI=1S/C22H20N2O5S/c1-13-19(23-21(29-13)15-5-3-2-4-6-15)17(25)12-28-16-9-7-14(8-10-16)11-18-20(26)24-22(27)30-18/h2-10,17-18,25H,11-12H2,1H3,(H,24,26,27)
DM1SLJ9	CS	CC1=C(N=C(O1)C2=CC=CC=C2)C(COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)O
DM1SLJ9	IK	YVQKIDLSVHRBGZ-UHFFFAOYSA-N
DM1SLJ9	IU	5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM1SLJ9	CA	CAS 103788-05-2
DM1SLJ9	DE	Type-2 diabetes

DMQNFZE	ID	DMQNFZE
DMQNFZE	DN	Ad5-AC6
DMQNFZE	HS	Terminated
DMQNFZE	SN	Corgenic; AC6 gene therapy, Collateral/UCSD; Adenylyl cyclase gene therapy, Collateral/UCSD; CHF gene therapy, Collateral/UCSD; Gene therapy (CHF), Collateral/USCD; Gene therapy (adenylate cyclase), Collateral/USCD
DMQNFZE	CP	University of California San Diego
DMQNFZE	DE	Cardiac failure

DM61AV4	ID	DM61AV4
DM61AV4	DN	ADX415
DM61AV4	HS	Terminated
DM61AV4	CP	Shionogi
DM61AV4	DE	Hypertension

DM625LN	ID	DM625LN
DM625LN	DN	AG-041R
DM625LN	HS	Terminated
DM625LN	SN	AG-041R; LS-83786; 199800-49-2; GTPL901; MLS006010838; AG041R; CTK8E8139; DTXSID40430968; AG 041R; MolPort-009-019-290; ZINC3930890; NCGC00263225-01; SMR004701765; RT-011212; FT-0773348; J-012912
DM625LN	CP	Chugai Pharmaceutical Co Ltd
DM625LN	DT	Small molecular drug
DM625LN	PC	9807431
DM625LN	MW	544.6
DM625LN	FM	C31H36N4O5
DM625LN	IC	InChI=1S/C31H36N4O5/c1-5-39-28(40-6-2)20-35-26-10-8-7-9-25(26)31(29(35)37,19-27(36)32-23-15-11-21(3)12-16-23)34-30(38)33-24-17-13-22(4)14-18-24/h7-18,28H,5-6,19-20H2,1-4H3,(H,32,36)(H2,33,34,38)/t31-/m1/s1
DM625LN	CS	CCOC(CN1C2=CC=CC=C2[C@@](C1=O)(CC(=O)NC3=CC=C(C=C3)C)NC(=O)NC4=CC=C(C=C4)C)OCC
DM625LN	IK	KOLPMNSDISYEBU-WJOKGBTCSA-N
DM625LN	IU	2-[(3R)-1-(2,2-diethoxyethyl)-3-[(4-methylphenyl)carbamoylamino]-2-oxoindol-3-yl]-N-(4-methylphenyl)acetamide
DM625LN	CA	CAS 159883-95-1
DM625LN	DE	Ulcerative colitis

DMRI7YB	ID	DMRI7YB
DMRI7YB	DN	AG-1284
DMRI7YB	HS	Terminated
DMRI7YB	SN	Enantiomer of AG1284; 2-[4-[2-[(1-ethylcyclopentyl)-(2-hydroxyethyl)carbamoyl]phenyl]-2-hydroxy-butyl]-N-(2-hydroxyethyl)-5-methyl-N-(1-methyl-1-phenyl-ethyl)benzamide; N-(1-Ethylcyclopentyl)-N-(2-hydroxyethyl)-2-[3(R or S)-hydroxy-4-[2-[(2-hydroxyethyl)(1-methyl-1-phenylethyl)carbamoyl]-4-methylphenyl]butyl]benzamide; AG-1284; AC1LA3JC; Tertiary Amide deriv. 42cb; CHEMBL328435; BDBM9664; ag12-84; AG1284
DMRI7YB	CP	Agouron Pharmaceuticals Inc
DMRI7YB	DT	Small molecular drug
DMRI7YB	PC	461066
DMRI7YB	MW	628.8
DMRI7YB	FM	C39H52N2O5
DMRI7YB	IC	InChI=1S/C39H52N2O5/c1-5-39(21-11-12-22-39)41(24-26-43)36(45)34-16-10-9-13-30(34)19-20-33(44)28-31-18-17-29(2)27-35(31)37(46)40(23-25-42)38(3,4)32-14-7-6-8-15-32/h6-10,13-18,27,33,42-44H,5,11-12,19-26,28H2,1-4H3
DMRI7YB	CS	CCC1(CCCC1)N(CCO)C(=O)C2=CC=CC=C2CCC(CC3=C(C=C(C=C3)C)C(=O)N(CCO)C(C)(C)C4=CC=CC=C4)O
DMRI7YB	IK	MBNPLZRTGOAFGX-UHFFFAOYSA-N
DMRI7YB	IU	2-[4-[2-[(1-ethylcyclopentyl)-(2-hydroxyethyl)carbamoyl]phenyl]-2-hydroxybutyl]-N-(2-hydroxyethyl)-5-methyl-N-(2-phenylpropan-2-yl)benzamide
DMRI7YB	DE	Human immunodeficiency virus infection

DMT10C2	ID	DMT10C2
DMT10C2	DN	AG1295
DMT10C2	HS	Terminated
DMT10C2	SN	6,7-Dimethyl-2-phenylquinoxaline; 71897-07-9; ag1295; AG-1295; AG 1295; CHEMBL7724; TYRPHOSTIN AG 1295; BiomolKI_000019; Tyrphostin AG-1295; AC1Q4WCY; AC1L1CSX; ChemDiv2_000256; BiomolKI2_000029; AC1Q2O4Y; cid_2048; BMK1-C7; MLS001194710; SCHEMBL925674; IFLab1_005463; GTPL5914; AC1Q2E07; CHEBI:94668; BDBM33408; CTK2H8610; DTXSID10274351; MolPort-000-182-258; FQNCLVJEQCJWSU-UHFFFAOYSA-N; 2-Phenyl-6,7-dimethylquinoxaline; HMS1427I07; HMS3229M19; HMS2879L07; HMS1369L14; ZINC257983; HMS3428I13; API01003; 6,7-Dimethyl-2-phenyl-quinoxaline
DMT10C2	DT	Small molecular drug
DMT10C2	PC	2048
DMT10C2	MW	234.29
DMT10C2	FM	C16H14N2
DMT10C2	IC	InChI=1S/C16H14N2/c1-11-8-14-15(9-12(11)2)18-16(10-17-14)13-6-4-3-5-7-13/h3-10H,1-2H3
DMT10C2	CS	CC1=CC2=NC=C(N=C2C=C1C)C3=CC=CC=C3
DMT10C2	IK	FQNCLVJEQCJWSU-UHFFFAOYSA-N
DMT10C2	IU	6,7-dimethyl-2-phenylquinoxaline
DMT10C2	CA	CAS 71897-07-9
DMT10C2	CB	CHEBI:94668

DMALV1W	ID	DMALV1W
DMALV1W	DN	AG-1350
DMALV1W	HS	Terminated
DMALV1W	SN	LY-316957; LY-316340 (free base); N-[3-[(3aR,6S,7aS)-6-(N-tert-Butylcarbamoyl)octahydrothieno[3,2-c]pyridin-5-yl)-2(R)-hydroxy-1(R)-(phenylsulfanylmethyl)propyl]-3-hydroxy-2-methylbenzamide methanesulfonate
DMALV1W	DT	Small molecular drug
DMALV1W	PC	461244
DMALV1W	MW	667.9
DMALV1W	FM	C31H45N3O7S3
DMALV1W	IC	InChI=1S/C30H41N3O4S2.CH4O3S/c1-19-22(11-8-12-25(19)34)28(36)31-23(18-39-21-9-6-5-7-10-21)26(35)17-33-16-20-13-14-38-27(20)15-24(33)29(37)32-30(2,3)4;1-5(2,3)4/h5-12,20,23-24,26-27,34-35H,13-18H2,1-4H3,(H,31,36)(H,32,37);1H3,(H,2,3,4)/t20-,23+,24+,26-,27+;/m1./s1
DMALV1W	CS	CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCS[C@H]4C[C@H]3C(=O)NC(C)(C)C)O.CS(=O)(=O)O
DMALV1W	IK	WYCLUAUPFCMDTI-KZMNDDLNSA-N
DMALV1W	IU	(3aR,6S,7aS)-N-tert-butyl-5-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,3a,4,6,7,7a-hexahydro-2H-thieno[3,2-c]pyridine-6-carboxamide;methanesulfonic acid
DMALV1W	DE	Human immunodeficiency virus infection

DMS7UPZ	ID	DMS7UPZ
DMS7UPZ	DN	AG-2024
DMS7UPZ	HS	Terminated
DMS7UPZ	CP	Agouron Pharmaceuticals Inc
DMS7UPZ	DE	Arthritis

DMF2ME4	ID	DMF2ME4
DMF2ME4	DN	AG-3296
DMF2ME4	HS	Terminated
DMF2ME4	CP	Agouron Pharmaceuticals Inc
DMF2ME4	DE	Solid tumour/cancer

DM3WKO5	ID	DM3WKO5
DM3WKO5	DN	AG490
DM3WKO5	HS	Terminated
DM3WKO5	SN	(E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665
DM3WKO5	DT	Small molecular drug
DM3WKO5	PC	5328779
DM3WKO5	MW	294.3
DM3WKO5	FM	C17H14N2O3
DM3WKO5	IC	InChI=1S/C17H14N2O3/c18-10-14(8-13-6-7-15(20)16(21)9-13)17(22)19-11-12-4-2-1-3-5-12/h1-9,20-21H,11H2,(H,19,22)/b14-8+
DM3WKO5	CS	C1=CC=C(C=C1)CNC(=O)/C(=C/C2=CC(=C(C=C2)O)O)/C#N
DM3WKO5	IK	TUCIOBMMDDOEMM-RIYZIHGNSA-N
DM3WKO5	IU	(E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
DM3WKO5	CA	CAS 133550-30-8
DM3WKO5	CB	CHEBI:131968
DM3WKO5	DE	Multiple myeloma; Renal transplantation

DMVS6BN	ID	DMVS6BN
DMVS6BN	DN	AGN-193080
DMVS6BN	HS	Terminated
DMVS6BN	SN	AGN-193080; CHEMBL298936; SCHEMBL8348700; BDBM50052882; L012655
DMVS6BN	DT	Small molecular drug
DMVS6BN	PC	9837551
DMVS6BN	MW	232.28
DMVS6BN	FM	C12H16N4O
DMVS6BN	IC	InChI=1S/C12H16N4O/c1-8-9(16-12-14-4-5-15-12)2-3-10-11(8)13-6-7-17-10/h2-3,13H,4-7H2,1H3,(H2,14,15,16)
DMVS6BN	CS	CC1=C(C=CC2=C1NCCO2)NC3=NCCN3
DMVS6BN	IK	OSJZLDGTMVBIRV-UHFFFAOYSA-N
DMVS6BN	IU	N-(4,5-dihydro-1H-imidazol-2-yl)-5-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-amine

DMXY5AV	ID	DMXY5AV
DMXY5AV	DN	AH-9700
DMXY5AV	HS	Terminated
DMXY5AV	SN	UNII-2NG1J5TE78; 2NG1J5TE78; AH-9700; 337359-08-7; Pyrrolidine, 1-(2-(3,4-dihydro-6,7-dimethyl-2-naphthalenyl)ethyl)-, (2E)-2-butenedioate (1:1)
DMXY5AV	CP	Dainippon Pharmaceutical Co Ltd
DMXY5AV	DT	Small molecular drug
DMXY5AV	PC	9842381
DMXY5AV	MW	371.5
DMXY5AV	FM	C22H29NO4
DMXY5AV	IC	InChI=1S/C18H25N.C4H4O4/c1-14-11-17-6-5-16(13-18(17)12-15(14)2)7-10-19-8-3-4-9-19;5-3(6)1-2-4(7)8/h11-13H,3-10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMXY5AV	CS	CC1=CC2=C(C=C1C)C=C(CC2)CCN3CCCC3.C(=C/C(=O)O)\\C(=O)O
DMXY5AV	IK	AYOYFVLAAQPHJT-WLHGVMLRSA-N
DMXY5AV	IU	(E)-but-2-enedioic acid;1-[2-(6,7-dimethyl-3,4-dihydronaphthalen-2-yl)ethyl]pyrrolidine
DMXY5AV	CA	CAS 337359-08-7
DMXY5AV	DE	Pollakiuria

DMJZ48W	ID	DMJZ48W
DMJZ48W	DN	AHR-16303B
DMJZ48W	HS	Terminated
DMJZ48W	SN	Ahr-16303B; Ahr 16303B; 117023-62-8; 1-(4-(3-(4-(Bis-(4-fluorophenyl)hydroxymethyl)-1-piperidinyl)propoxy)phenyl)-2-methyl-1-propanone ethanedioate; ACMC-20mmz9; AC1L4DL2; CTK0H5536; DTXSID80151685; 1-[4-[3-[4-[bis(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]propoxy]phenyl]-2-methylpropan-1-one; 1-Propanone, 1-(4-(3-(4-(bis(4-fluorophenyl)hydroxymethyl)-1-piperidinyl)propoxy)phenyl)-2-methyl-, ethanedioate (1:1) (salt)
DMJZ48W	CP	A H Robins Co Inc
DMJZ48W	DT	Small molecular drug
DMJZ48W	PC	183770
DMJZ48W	MW	597.6
DMJZ48W	FM	C33H37F2NO7
DMJZ48W	IC	InChI=1S/C31H35F2NO3.C2H2O4/c1-22(2)30(35)23-4-14-29(15-5-23)37-21-3-18-34-19-16-26(17-20-34)31(36,24-6-10-27(32)11-7-24)25-8-12-28(33)13-9-25;3-1(4)2(5)6/h4-15,22,26,36H,3,16-21H2,1-2H3;(H,3,4)(H,5,6)
DMJZ48W	CS	CC(C)C(=O)C1=CC=C(C=C1)OCCCN2CCC(CC2)C(C3=CC=C(C=C3)F)(C4=CC=C(C=C4)F)O.C(=O)(C(=O)O)O
DMJZ48W	IK	IJLRCTPQUZWJSL-UHFFFAOYSA-N
DMJZ48W	IU	1-[4-[3-[4-[bis(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]propoxy]phenyl]-2-methylpropan-1-one;oxalic acid
DMJZ48W	CA	CAS 117023-62-8
DMJZ48W	DE	Hypertension

DMJ6BEO	ID	DMJ6BEO
DMJ6BEO	DN	AHR-16462B
DMJ6BEO	HS	Terminated
DMJ6BEO	CP	A H Robins Co Inc
DMJ6BEO	DE	Hypertension

DMOJTZV	ID	DMOJTZV
DMOJTZV	DN	AJ-3941
DMOJTZV	HS	Terminated
DMOJTZV	SN	AJ 3941; AC1O5RPK; Piperazine, 1-(3-fluoro-6,11-dihydrodibenz(b,e)oxepin-11-yl)-4-(3-phenyl-2-propenyl)-, (E)-(+-)-, (Z)-2-butenedioate (1:2); 1-(3-Fluoro-6,11-dihydrodibenz(b,e)oxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine dimaleate; (+-)-(E)-1-(3-Fluoro-6,11-dihydrodibenz(b,e)oxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine dimaleate
DMOJTZV	CP	Dainippon Pharmaceutical Co Ltd
DMOJTZV	DT	Small molecular drug
DMOJTZV	PC	154701484
DMOJTZV	DE	Cerebrovascular ischaemia

DM51NI0	ID	DM51NI0
DM51NI0	DN	AK-295
DM51NI0	HS	Terminated
DM51NI0	SN	Vasolex; AK-265; AK-275; CX-295; Calpain inhibitors (neuropathy); Calpain inhibitors (neuropathy), AxoTect; Calpain inhibitors, Cortex/Alkermes
DM51NI0	CP	Alkermes Inc
DM51NI0	DT	Small molecular drug
DM51NI0	PC	183798
DM51NI0	MW	504.6
DM51NI0	FM	C26H40N4O6
DM51NI0	IC	InChI=1S/C26H40N4O6/c1-4-21(23(31)25(33)27-11-8-12-30-13-15-35-16-14-30)28-24(32)22(17-19(2)3)29-26(34)36-18-20-9-6-5-7-10-20/h5-7,9-10,19,21-22H,4,8,11-18H2,1-3H3,(H,27,33)(H,28,32)(H,29,34)/t21?,22-/m0/s1
DM51NI0	CS	CCC(C(=O)C(=O)NCCCN1CCOCC1)NC(=O)[C@H](CC(C)C)NC(=O)OCC2=CC=CC=C2
DM51NI0	IK	TZVQRMYLYQNBOA-KEKNWZKVSA-N
DM51NI0	IU	benzyl N-[(2S)-4-methyl-1-[[1-(3-morpholin-4-ylpropylamino)-1,2-dioxopentan-3-yl]amino]-1-oxopentan-2-yl]carbamate
DM51NI0	CA	CAS 160399-35-9
DM51NI0	DE	Cerebral infarction

DMMTZXV	ID	DMMTZXV
DMMTZXV	DN	AKP-320
DMMTZXV	HS	Terminated
DMMTZXV	SN	Bis(ethylmaltolato)oxovanadium (IV) + rosiglitazone (type 2 diabetes), Akesis
DMMTZXV	CP	Akesis Pharmaceuticals Inc
DMMTZXV	DE	Type-2 diabetes

DMRYJ40	ID	DMRYJ40
DMRYJ40	DN	AL-0671
DMRYJ40	HS	Terminated
DMRYJ40	SN	AL-0670
DMRYJ40	CP	The Green Cross Corp
DMRYJ40	PC	57415651
DMRYJ40	MW	306.79
DMRYJ40	FM	C14H19ClN6
DMRYJ40	IC	InChI=1S/C14H18N6.ClH/c15-8-18-14(19-11-3-4-13(16)17-7-11)20-12-6-9-1-2-10(12)5-9;/h3-4,7,9-10,12H,1-2,5-6H2,(H2,16,17)(H2,18,19,20);1H/t9-,10+,12-;/m1./s1
DMRYJ40	CS	C1C[C@H]2C[C@@H]1C[C@H]2N=C(NC#N)NC3=CN=C(C=C3)N.Cl
DMRYJ40	IK	ZIVGNHQBUJFAOF-QQQUOLKDSA-N
DMRYJ40	IU	1-(6-aminopyridin-3-yl)-2-[(1S,2R,4R)-2-bicyclo[2.2.1]heptanyl]-3-cyanoguanidine;hydrochloride
DMRYJ40	DE	Arteriosclerosis

DMWNMYS	ID	DMWNMYS
DMWNMYS	DN	ALB-127158(a)
DMWNMYS	HS	Terminated
DMWNMYS	CP	Albany Molecular Research Inc.
DMWNMYS	PC	44193892
DMWNMYS	MW	404.4
DMWNMYS	FM	C23H21FN4O2
DMWNMYS	IC	InChI=1S/C23H21FN4O2/c1-27-21-6-8-25-13-20(21)19-5-4-17(10-22(19)27)28-9-7-18(11-23(28)29)30-14-16-3-2-15(24)12-26-16/h2-5,7,9-12,25H,6,8,13-14H2,1H3
DMWNMYS	CS	CN1C2=C(CNCC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)OCC5=NC=C(C=C5)F
DMWNMYS	IK	VUUUHLIHQHVLLE-UHFFFAOYSA-N
DMWNMYS	IU	4-[(5-fluoropyridin-2-yl)methoxy]-1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)pyridin-2-one
DMWNMYS	DE	Obesity

DMXK4CI	ID	DMXK4CI
DMXK4CI	DN	Albupoietin
DMXK4CI	HS	Terminated
DMXK4CI	SN	Long-acting erythropoietin, HGS; Long-acting erythropoietin, Human Genome Sciences; Long-acting erythropoietin, Teva Pharmaceutical
DMXK4CI	CP	Aventis Behring LLC
DMXK4CI	DE	Anemia

DMQALR5	ID	DMQALR5
DMQALR5	DN	Almorexant
DMQALR5	HS	Terminated
DMQALR5	SN	Almorexant [INN]; ACT-078573; (2R)-2-((1S)-6,7-dimethoxy-1-{2-(4-(trifluoromethyl)phenyl)ethyl}-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide
DMQALR5	CP	Actelion Pharma.
DMQALR5	DT	Small molecular drug
DMQALR5	PC	23727689
DMQALR5	MW	512.6
DMQALR5	FM	C29H31F3N2O3
DMQALR5	IC	InChI=1S/C29H31F3N2O3/c1-33-28(35)27(20-7-5-4-6-8-20)34-16-15-21-17-25(36-2)26(37-3)18-23(21)24(34)14-11-19-9-12-22(13-10-19)29(30,31)32/h4-10,12-13,17-18,24,27H,11,14-16H2,1-3H3,(H,33,35)/t24-,27+/m0/s1
DMQALR5	CS	CNC(=O)[C@@H](C1=CC=CC=C1)N2CCC3=CC(=C(C=C3[C@@H]2CCC4=CC=C(C=C4)C(F)(F)F)OC)OC
DMQALR5	IK	DKMACHNQISHMDN-RPLLCQBOSA-N
DMQALR5	IU	(2R)-2-[(1S)-6,7-dimethoxy-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydro-1H-isoquinolin-2-yl]-N-methyl-2-phenylacetamide
DMQALR5	CA	CAS 871224-64-5
DMQALR5	DE	Insomnia; Sleep-wake disorder

DMT584A	ID	DMT584A
DMT584A	DN	ALN-VEG01
DMT584A	HS	Terminated
DMT584A	SN	RNAi therapeutics (ocular disease), Alnylam; VEGF-silencing siRNAs, Alnylam; Vascular endothelial growth factor gene-silencing siRNAs, Alnylam; RNAi therapeutics (ocular disease), Alnylam/Merck; VEGF-silencing siRNAs, Alnylam/Merck; Vascular endothelial growth factor-silencing siRNAs, Alnylam/Merck
DMT584A	CP	Alnylam Pharmaceuticals Inc
DMT584A	DT	siRNA drug
DMT584A	DE	Macular degeneration

DM592WE	ID	DM592WE
DM592WE	DN	ALP-242
DM592WE	HS	Terminated
DM592WE	SN	Antileukoproteinases, Grunenthal
DM592WE	CP	Grunenthal GmbH
DM592WE	DE	Cystic fibrosis

DMGBT9Z	ID	DMGBT9Z
DMGBT9Z	DN	ALS-769
DMGBT9Z	HS	Terminated
DMGBT9Z	SN	ALS-1026; ALS-851; Betulinic acid derivative caspase inducers (cancer); Betulinic acid derivative caspase inducers (cancer), Advanced Life Sciences; Lupane triterpenoids (cancer), Advanced Life Sciences
DMGBT9Z	CP	Advanced Life Sciences Holdings Inc
DMGBT9Z	DE	Solid tumour/cancer

DMLN0Y5	ID	DMLN0Y5
DMLN0Y5	DN	Alvameline
DMLN0Y5	HS	Terminated
DMLN0Y5	SN	Alvameline maleate; LU-25077; LU-25109; LU-31126; LU-32181; Lu-25109M
DMLN0Y5	CP	H Lundbeck A/S
DMLN0Y5	DT	Small molecular drug
DMLN0Y5	PC	178030
DMLN0Y5	MW	193.25
DMLN0Y5	FM	C9H15N5
DMLN0Y5	IC	InChI=1S/C9H15N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5H,3-4,6-7H2,1-2H3
DMLN0Y5	CS	CCN1N=C(N=N1)C2=CCCN(C2)C
DMLN0Y5	IK	RNMOMKCRCIRYCZ-UHFFFAOYSA-N
DMLN0Y5	IU	5-(2-ethyltetrazol-5-yl)-1-methyl-3,6-dihydro-2H-pyridine
DMLN0Y5	CA	CAS 120241-31-8
DMLN0Y5	DE	Alzheimer disease

DMOIWFM	ID	DMOIWFM
DMOIWFM	DN	AM-577
DMOIWFM	HS	Terminated
DMOIWFM	SN	Pain therapeutic (cannabinoid), AMRAD
DMOIWFM	CP	Zenyth Therapeutics Ltd
DMOIWFM	DE	Pain

DMGBT63	ID	DMGBT63
DMGBT63	DN	AM-66
DMGBT63	HS	Terminated
DMGBT63	SN	Pain therapeutic (sodium channel blocker), AMRAD
DMGBT63	CP	Zenyth Therapeutics Ltd
DMGBT63	DE	Pain

DMMZNSC	ID	DMMZNSC
DMMZNSC	DN	AM-92016
DMMZNSC	HS	Terminated
DMMZNSC	SN	COMPOUND II; N-(4-(3-((2-(3,4-Dichlorophenyl)ethyl)methylamino)-2-hydroxypropoxy)phenyl)methanesulfonamide; AM-92016; Bio2_000288; AC1L1CZF; Msaph-2ClPhEA-2-propanol; CBiol_001738; KBioGR_000288; BSPBio_001568; KBioSS_000288; CHEMBL43527; AC1Q3O93; SCHEMBL9655059; KBio3_000575; CHEBI:91532; KBio3_000576; KBio2_002856; KBio2_005424; KBio2_000288; Bio1_000513; HMS1791O10; Bio1_001002; Bio1_000024; HMS1989O10; Bio2_000768; AC-115; IDI1_034038; NCGC00024837-04; NCGC00024837-03; NCGC00024837-02; BRD-A11813248-003-01-6; BRD-A11813248-001-02-8
DMMZNSC	DT	Small molecular drug
DMMZNSC	PC	133104
DMMZNSC	MW	569.5
DMMZNSC	FM	C26H30Cl2N2O6S
DMMZNSC	IC	InChI=1S/C19H24Cl2N2O4S.C7H6O2/c1-23(10-9-14-3-8-18(20)19(21)11-14)12-16(24)13-27-17-6-4-15(5-7-17)22-28(2,25)26;8-7(9)6-4-2-1-3-5-6/h3-8,11,16,22,24H,9-10,12-13H2,1-2H3;1-5H,(H,8,9)
DMMZNSC	CS	CN(CCC1=CC(=C(C=C1)Cl)Cl)CC(COC2=CC=C(C=C2)NS(=O)(=O)C)O.C1=CC=C(C=C1)C(=O)O
DMMZNSC	IK	KLXOTINBPRNEFS-UHFFFAOYSA-N
DMMZNSC	IU	benzoic acid;N-[4-[3-[2-(3,4-dichlorophenyl)ethyl-methylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide
DMMZNSC	CA	CAS 178894-81-0

DMYIPLH	ID	DMYIPLH
DMYIPLH	DN	AMG-548
DMYIPLH	HS	Terminated
DMYIPLH	SN	P38 MAP kinase inhibitor, Amgen
DMYIPLH	CP	Amgen Inc
DMYIPLH	DT	Small molecular drug
DMYIPLH	PC	11167112
DMYIPLH	MW	461.6
DMYIPLH	FM	C29H27N5O
DMYIPLH	IC	InChI=1S/C29H27N5O/c1-34-28(35)26(24-12-11-21-9-5-6-10-23(21)18-24)27(22-13-15-31-16-14-22)33-29(34)32-19-25(30)17-20-7-3-2-4-8-20/h2-16,18,25H,17,19,30H2,1H3,(H,32,33)/t25-/m0/s1
DMYIPLH	CS	CN1C(=O)C(=C(N=C1NC[C@H](CC2=CC=CC=C2)N)C3=CC=NC=C3)C4=CC5=CC=CC=C5C=C4
DMYIPLH	IK	RQVKVJIRFKVPBF-VWLOTQADSA-N
DMYIPLH	IU	2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-naphthalen-2-yl-6-pyridin-4-ylpyrimidin-4-one
DMYIPLH	CA	CAS 864249-60-5
DMYIPLH	DE	Inflammation

DMXRQS6	ID	DMXRQS6
DMXRQS6	DN	AMG-8562
DMXRQS6	HS	Terminated
DMXRQS6	SN	UNII-X2S52Z1DY9; X2S52Z1DY9; AMG-8562; AMG 8562; 1041478-78-7; SCHEMBL14993014; SCHEMBL14993018; 2-Propenamide, N-((2R)-2,3-dihydro-2-hydroxy-1H-inden-4-yl)-3-(2-(1-piperidinyl)-4-(trifluoromethyl)phenyl)-, (2E)-; (r,e)-n-(2-hydroxy-2,3-dihydro-1h-inden-4-yl)-3-(2-(piperidin-1-yl)-4 (trifluoromethyl)phenyl)acrylamide
DMXRQS6	CP	Amgen
DMXRQS6	TC	Analgesics
DMXRQS6	DT	Small molecular drug
DMXRQS6	PC	56603667
DMXRQS6	MW	430.5
DMXRQS6	FM	C24H25F3N2O2
DMXRQS6	IC	InChI=1S/C24H25F3N2O2/c25-24(26,27)18-9-7-16(22(14-18)29-11-2-1-3-12-29)8-10-23(31)28-21-6-4-5-17-13-19(30)15-20(17)21/h4-10,14,19,30H,1-3,11-13,15H2,(H,28,31)/b10-8+/t19-/m1/s1
DMXRQS6	CS	C1CCN(CC1)C2=C(C=CC(=C2)C(F)(F)F)/C=C/C(=O)NC3=CC=CC4=C3C[C@@H](C4)O
DMXRQS6	IK	HAZYXDWNLMGLIS-LHUXKHBRSA-N
DMXRQS6	IU	(E)-N-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]-3-[2-piperidin-1-yl-4-(trifluoromethyl)phenyl]prop-2-enamide
DMXRQS6	CA	CAS 1041478-78-7
DMXRQS6	DE	Pain

DM3D0WA	ID	DM3D0WA
DM3D0WA	DN	Amidox
DM3D0WA	HS	Terminated
DM3D0WA	DT	Small molecular drug
DM3D0WA	PC	135413522
DM3D0WA	MW	168.15
DM3D0WA	FM	C7H8N2O3
DM3D0WA	IC	InChI=1S/C7H8N2O3/c8-7(9-12)4-1-2-5(10)6(11)3-4/h1-3,10-12H,(H2,8,9)
DM3D0WA	CS	C1=CC(=C(C=C1/C(=N/O)/N)O)O
DM3D0WA	IK	JOAASNKBYBFGDN-UHFFFAOYSA-N
DM3D0WA	IU	N',3,4-trihydroxybenzenecarboximidamide
DM3D0WA	CA	CAS 95933-72-5

DM64YJW	ID	DM64YJW
DM64YJW	DN	Amitivir
DM64YJW	HS	Terminated
DM64YJW	SN	LY-217896
DM64YJW	CP	Eli Lilly & Co
DM64YJW	DT	Small molecular drug
DM64YJW	PC	65912
DM64YJW	MW	126.14
DM64YJW	FM	C3H2N4S
DM64YJW	IC	InChI=1S/C3H2N4S/c4-1-5-3-7-6-2-8-3/h2H,(H,5,7)
DM64YJW	CS	C1=NN=C(S1)NC#N
DM64YJW	IK	YUCHAYRHHXJNQK-UHFFFAOYSA-N
DM64YJW	IU	1,3,4-thiadiazol-2-ylcyanamide
DM64YJW	CA	CAS 111393-84-1
DM64YJW	DE	Virus infection

DMDAMBW	ID	DMDAMBW
DMDAMBW	DN	AMPEROZIDE
DMDAMBW	HS	Terminated
DMDAMBW	SN	Amperozide; 75558-90-6; Amperozidum [INN-Latin]; Amperozida [INN-Spanish]; UNII-0M2W3TAG39; FG 5606; 0M2W3TAG39; CHEMBL1079935; 4-(4,4-Bis(p-fluorophenyl)butyl)-N-ethyl-1-piperazinecarboxamide; 4-(4,4-Bis(4-fluorphenyl)butyl)-N-ethyl-1-piperazinecarboxamid; Amperozidum; Amperozida; 4-[4,4-bis(4-fluorophenyl)butyl]-n-ethylpiperazine-1-carboxamide; 1-Piperazinecarboxamide, 4-(4,4-bis(p-fluorophenyl)butyl)-N-ethyl-; Amperozide [INN:BAN]; Amperozide [BAN:INN]; 4-(4,4-Bis(4-fluorophenyl)butyl)-N-ethylpiperazine-1-carboxamide
DMDAMBW	DT	Small molecular drug
DMDAMBW	PC	73333
DMDAMBW	MW	401.5
DMDAMBW	FM	C23H29F2N3O
DMDAMBW	IC	InChI=1S/C23H29F2N3O/c1-2-26-23(29)28-16-14-27(15-17-28)13-3-4-22(18-5-9-20(24)10-6-18)19-7-11-21(25)12-8-19/h5-12,22H,2-4,13-17H2,1H3,(H,26,29)
DMDAMBW	CS	CCNC(=O)N1CCN(CC1)CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F
DMDAMBW	IK	NNAIYOXJNVGUOM-UHFFFAOYSA-N
DMDAMBW	IU	4-[4,4-bis(4-fluorophenyl)butyl]-N-ethylpiperazine-1-carboxamide
DMDAMBW	CA	CAS 75558-90-6
DMDAMBW	CB	CHEBI:92913
DMDAMBW	DE	Alcohol dependence

DMW5RNZ	ID	DMW5RNZ
DMW5RNZ	DN	AMR-103
DMW5RNZ	HS	Terminated
DMW5RNZ	CP	Amarin Corp plc
DMW5RNZ	DE	Parkinson disease

DMD82LM	ID	DMD82LM
DMD82LM	DN	AMT-030
DMD82LM	HS	Terminated
DMD82LM	SN	AAV gene therapy (AGT, hyperoxaluria), AMT; Adeno-associated virus gene therapy (alanine:glyoxylate aminotransferase, hyperoxaluria), Amsterdam Molecular Therapeutics
DMD82LM	CP	Amsterdam Molecular Therapeutics BV
DMD82LM	DE	Hyperoxaluria

DMMKOCL	ID	DMMKOCL
DMMKOCL	DN	AMT-050
DMMKOCL	HS	Terminated
DMMKOCL	SN	ApoA1 deficiency gene therapy, Amsterdam Molecular Therapeutics
DMMKOCL	CP	Amsterdam Molecular Therapeutics BV
DMMKOCL	DE	Cholesterol metabolism disorder

DM50HB8	ID	DM50HB8
DM50HB8	DN	AN-10
DM50HB8	HS	Terminated
DM50HB8	SN	Novaheme
DM50HB8	CP	Discovery Laboratories Inc
DM50HB8	DT	Small molecular drug
DM50HB8	PC	55763
DM50HB8	MW	234.29
DM50HB8	FM	C13H18N2O2
DM50HB8	IC	InChI=1S/C13H18N2O2/c1-3-17-13(16)12-8-9(2)14-10-6-4-5-7-11(10)15-12/h4-7,9,12,14-15H,3,8H2,1-2H3
DM50HB8	CS	CCOC(=O)C1CC(NC2=CC=CC=C2N1)C
DM50HB8	IK	MGQPKIPVCPMXQF-UHFFFAOYSA-N
DM50HB8	IU	ethyl 2-methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-4-carboxylate
DM50HB8	CA	CAS 87896-36-4
DM50HB8	DE	Alopecia

DMMLDG8	ID	DMMLDG8
DMMLDG8	DN	Anatumomab mafenatox
DMMLDG8	HS	Terminated
DMMLDG8	SN	ABR-214936; Fab5T4V13-SEAm9; PNU-214936; TTS-CD2; CD-2, Active Biotech
DMMLDG8	CP	Pharmacia & Upjohn Inc
DMMLDG8	DT	Antibody
DMMLDG8	DE	Breast cancer

DM35LJC	ID	DM35LJC
DM35LJC	DN	Anpirtoline
DM35LJC	HS	Terminated
DM35LJC	SN	D-16949
DM35LJC	CP	ASTA Medica AG
DM35LJC	DT	Small molecular drug
DM35LJC	PC	65854
DM35LJC	MW	228.74
DM35LJC	FM	C10H13ClN2S
DM35LJC	IC	InChI=1S/C10H13ClN2S/c11-9-2-1-3-10(13-9)14-8-4-6-12-7-5-8/h1-3,8,12H,4-7H2
DM35LJC	CS	C1CNCCC1SC2=NC(=CC=C2)Cl
DM35LJC	IK	GGALEXMXDMUMDM-UHFFFAOYSA-N
DM35LJC	IU	2-chloro-6-piperidin-4-ylsulfanylpyridine
DM35LJC	CA	CAS 98330-05-3
DM35LJC	CB	CHEBI:92968
DM35LJC	DE	Pain

DM2EKX5	ID	DM2EKX5
DM2EKX5	DN	Antalarmin
DM2EKX5	HS	Terminated
DM2EKX5	SN	Antalarmin; 157284-96-3; CHEMBL296641; 7H-Pyrrolo(2,3-d)pyrimidin-4-amine, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-; SCHEMBL466243; GTPL3489; AC1L433C; DTXSID50166241; CHEBI:139557; ZINC1539136; NSC715590; BDBM50074501; AKOS030559812; NSC-715590; NCGC00165732-01; NCI60_039940; LS-139513; N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[3,2-e]pyrimidin-4-amine; N-butyl-N-ethyl-7-mesityl-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
DM2EKX5	DT	Small molecular drug
DM2EKX5	PC	177990
DM2EKX5	MW	378.6
DM2EKX5	FM	C24H34N4
DM2EKX5	IC	InChI=1S/C24H34N4/c1-9-11-12-27(10-2)23-21-18(6)19(7)28(24(21)26-20(8)25-23)22-16(4)13-15(3)14-17(22)5/h13-14H,9-12H2,1-8H3
DM2EKX5	CS	CCCCN(CC)C1=NC(=NC2=C1C(=C(N2C3=C(C=C(C=C3C)C)C)C)C)C
DM2EKX5	IK	IXPROWGEHNVJOY-UHFFFAOYSA-N
DM2EKX5	IU	N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine
DM2EKX5	CA	CAS 157284-96-3
DM2EKX5	CB	CHEBI:139557
DM2EKX5	DE	Depression

DMXI185	ID	DMXI185
DMXI185	DN	Anti-IFN gamma
DMXI185	HS	Terminated
DMXI185	SN	AGT-1; Anti-IFN gamma (autoimmune diseases); Anti-cytokine antibodies, Advanced Biotherapy; Anti-cytokine therapy, Advanced Biotherapy; Anti-IFN gamma (autoimmune diseases), Advanced Biotherapy
DMXI185	CP	Advanced Biotherapy Inc
DMXI185	DT	Antibody
DMXI185	DE	Alopecia

DMXKZDU	ID	DMXKZDU
DMXKZDU	DN	Antova
DMXKZDU	HS	Terminated
DMXKZDU	SN	Ruplizumab
DMXKZDU	CP	Biogen Idec
DMXKZDU	DE	Thrombocytopenia

DMOJP9E	ID	DMOJP9E
DMOJP9E	DN	ANX-201
DMOJP9E	HS	Terminated
DMOJP9E	SN	Thiophosphonoformic acid; TPFA; dihydroxyphosphinothioylformic acid; 99107-93-4; Thiofoscarnet; ANX-201; Thiovir (TM); AC1L9PNZ; SCHEMBL6244658; CTK5I0229
DMOJP9E	DT	Small molecular drug
DMOJP9E	PC	451471
DMOJP9E	MW	142.07
DMOJP9E	FM	CH3O4PS
DMOJP9E	IC	InChI=1S/CH3O4PS/c2-1(3)6(4,5)7/h(H,2,3)(H2,4,5,7)
DMOJP9E	CS	C(=O)(O)P(=S)(O)O
DMOJP9E	IK	OSIAURSWRZARKZ-UHFFFAOYSA-N
DMOJP9E	IU	dihydroxyphosphinothioylformic acid
DMOJP9E	CA	CAS 99107-93-4
DMOJP9E	DE	Cytomegalovirus infection

DM5B72D	ID	DM5B72D
DM5B72D	DN	AP22408
DM5B72D	HS	Terminated
DM5B72D	SN	UNII-3U3L5QR4KV; 3U3L5QR4KV; AP-22408; {4-[2-ACETYLAMINO-2-(3-CARBAMOYL-2-CYCLOHEXYLMETHOXY-6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTEN-5YLCARBAMOYL)-ETHYL]-2-PHOSPHONO-PHENYL}-PHOSPHONIC ACID; CC1; 268741-43-1; AP22408; AC1L9I7C; SCHEMBL7245569; DB01830; Phosphonic acid, (4-((2S)-2-(acetylamino)-3-(((5S)-3-(aminocarbonyl)-2-(cyclohexylmethoxy)-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)amino)-3-oxopropyl)-1,2-phenylene)bis-; Phosphonic acid, P,P'-(4-((2S)-2-(acetylamino)-3-(((5S)-3-(aminocarbonyl)-2-(cyclohexylmethoxy)-6
DM5B72D	DT	Small molecular drug
DM5B72D	PC	445561
DM5B72D	MW	665.6
DM5B72D	FM	C30H41N3O10P2
DM5B72D	IC	InChI=1S/C30H41N3O10P2/c1-18(34)32-25(13-20-11-12-27(44(37,38)39)28(14-20)45(40,41)42)30(36)33-24-10-6-5-9-21-15-26(23(29(31)35)16-22(21)24)43-17-19-7-3-2-4-8-19/h11-12,14-16,19,24-25H,2-10,13,17H2,1H3,(H2,31,35)(H,32,34)(H,33,36)(H2,37,38,39)(H2,40,41,42)/t24-,25-/m0/s1
DM5B72D	CS	CC(=O)N[C@@H](CC1=CC(=C(C=C1)P(=O)(O)O)P(=O)(O)O)C(=O)N[C@H]2CCCCC3=CC(=C(C=C23)C(=O)N)OCC4CCCCC4
DM5B72D	IK	SPSGYTWOIGAABK-DQEYMECFSA-N
DM5B72D	IU	[4-[(2S)-2-acetamido-3-[[(5S)-3-carbamoyl-2-(cyclohexylmethoxy)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl]amino]-3-oxopropyl]-2-phosphonophenyl]phosphonic acid
DM5B72D	CA	CAS 268741-43-1
DM5B72D	DE	Osteoporosis

DM7LAXF	ID	DM7LAXF
DM7LAXF	DN	AP-227
DM7LAXF	HS	Terminated
DM7LAXF	SN	CHEMBL268477; AP227; AP-227; BDBM50095205; [6-(2-Benzhydryloxyimino-pentyl)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; (6-{2-[(E)-Benzhydryloxyimino]-pentyl}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid
DM7LAXF	DT	Small molecular drug
DM7LAXF	PC	9847589
DM7LAXF	MW	471.6
DM7LAXF	FM	C30H33NO4
DM7LAXF	IC	InChI=1S/C30H33NO4/c1-2-10-26(31-35-30(23-11-5-3-6-12-23)24-13-7-4-8-14-24)20-22-17-18-27-25(19-22)15-9-16-28(27)34-21-29(32)33/h3-9,11-16,22,30H,2,10,17-21H2,1H3,(H,32,33)/b31-26+
DM7LAXF	CS	CCC/C(=N\\OC(C1=CC=CC=C1)C2=CC=CC=C2)/CC3CCC4=C(C3)C=CC=C4OCC(=O)O
DM7LAXF	IK	XNRBBSJYERPMMB-GKPLWNPISA-N
DM7LAXF	IU	2-[[6-[(2E)-2-benzhydryloxyiminopentyl]-5,6,7,8-tetrahydronaphthalen-1-yl]oxy]acetic acid

DMXLJBA	ID	DMXLJBA
DMXLJBA	DN	AP-23588
DMXLJBA	HS	Terminated
DMXLJBA	SN	AP-23485; AP-23485 analogs, ARIAD
DMXLJBA	CP	ARIAD Pharmaceuticals Inc
DMXLJBA	DE	Osteoporosis

DMBA4DK	ID	DMBA4DK
DMBA4DK	DN	APC-6336
DMBA4DK	HS	Terminated
DMBA4DK	SN	CRA-6336; HCV therapy, BMS/Arris; HCV therapy, BMS/Axys; Hepatitis C therapy, Axys/BMS; Protease inhibitors, BMS/Arris; Protease inhibitors, BMS/Axys
DMBA4DK	CP	Bristol-Myers Squibb Co
DMBA4DK	DT	Small molecular drug
DMBA4DK	PC	72941786
DMBA4DK	MW	500.4
DMBA4DK	FM	C21H21N6O7P
DMBA4DK	IC	InChI=1S/C21H21N6O7P/c1-27-16-7-11(20(29)26-15(21(30)31)9-35(32,33)34)3-5-13(16)25-18(27)8-17-23-12-4-2-10(19(22)28)6-14(12)24-17/h2-7,15H,8-9H2,1H3,(H2,22,28)(H,23,24)(H,26,29)(H,30,31)(H2,32,33,34)/t15-/m0/s1
DMBA4DK	CS	CN1C2=C(C=CC(=C2)C(=O)N[C@@H](CP(=O)(O)O)C(=O)O)N=C1CC3=NC4=C(N3)C=C(C=C4)C(=O)N
DMBA4DK	IK	PEXFKSJDXSBOLP-HNNXBMFYSA-N
DMBA4DK	IU	(2R)-2-[[2-[(6-carbamoyl-1H-benzimidazol-2-yl)methyl]-3-methylbenzimidazole-5-carbonyl]amino]-3-phosphonopropanoic acid
DMBA4DK	CA	CAS 263870-19-5
DMBA4DK	DE	Hepatitis C virus infection

DMYD04O	ID	DMYD04O
DMYD04O	DN	APF-580
DMYD04O	HS	Terminated
DMYD04O	SN	Opiate (controlled-release (Biochronomer), pain), AP Pharma
DMYD04O	CP	A P Pharma Inc
DMYD04O	DE	Pain

DMIYTPE	ID	DMIYTPE
DMIYTPE	DN	Apolipoprotein E
DMIYTPE	HS	Terminated
DMIYTPE	SN	Apolipoprotein E, Bio-Technology General; Apo-A4, Bio-Technology General; Apo-E, Bio-Technology General; Apolipoprotein-A4, Bio-Technology General
DMIYTPE	CP	Savient Pharmaceuticals Inc
DMIYTPE	DE	Glaucoma/ocular hypertension

DMPMW03	ID	DMPMW03
DMPMW03	DN	AQ-RA-741
DMPMW03	HS	Terminated
DMPMW03	SN	AQ-RA 741; 123548-16-3; AQ-RA-741; 11-[[4-[4-(DIETHYLAMINO)BUTYL]-1-PIPERIDINYL]ACETYL]-5,11-DIHYDRO-6H-PYRIDO[2,3-B][1,4]BENZODIAZEPIN-6-ONE; 6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one,11-[2-[4-[4-(diethylamino)butyl]-1-piperidinyl]acetyl]-5,11-dihydro-; 11-(2-(4-(4-(Diethylamino)butyl)piperidin-1-yl)acetyl)-5H-benzo[e]pyrido[3,2-b][1,4]diazepin-6(11H)-one; 11-((4-(4-(Diethylamino)butyl)-1-piperidinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; BCUGCHZRMKTPMU-UHFFFAOYSA-N; AC1L2WKT; ACMC-20ej93
DMPMW03	CP	Dr Karl Thomae GmbH
DMPMW03	DT	Small molecular drug
DMPMW03	PC	129989
DMPMW03	MW	463.6
DMPMW03	FM	C27H37N5O2
DMPMW03	IC	InChI=1S/C27H37N5O2/c1-3-30(4-2)17-8-7-10-21-14-18-31(19-15-21)20-25(33)32-24-13-6-5-11-22(24)27(34)29-23-12-9-16-28-26(23)32/h5-6,9,11-13,16,21H,3-4,7-8,10,14-15,17-20H2,1-2H3,(H,29,34)
DMPMW03	CS	CCN(CC)CCCCC1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMPMW03	IK	BCUGCHZRMKTPMU-UHFFFAOYSA-N
DMPMW03	IU	11-[2-[4-[4-(diethylamino)butyl]piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMPMW03	CA	CAS 123548-16-3
DMPMW03	CB	CHEBI:93432
DMPMW03	DE	Cardiovascular disease

DMHU1E8	ID	DMHU1E8
DMHU1E8	DN	AR177
DMHU1E8	HS	Terminated
DMHU1E8	SN	Zintevir; AR177; T 30177; 171345-51-0; DNA, d(G-sp-T-G-G-T-G-G-G-T-G-G-G-T-G-G-G-sp-T); UNII-RR07N525H5; AR-177 free acid; GsGGTGGGTGGGTGGGsT; 163703-74-0; 5'-GsGGTGGGTGGGTGGGsT-3'; RR07N525H5; DNA, d(P-thio)(G-T-G-G-T-G-G-G-T-G-G-G-T-G-G-G-T); DBM-2245; Deoxyribonucleic acid, d(P-thio)(G-T-G-G-T-G-G-G-T-G-G-G-T-G-G-G-T)
DMHU1E8	DT	Small molecular drug
DMHU1E8	PC	16130283
DMHU1E8	MW	5442
DMHU1E8	FM	C170H210N70O103P16S2
DMHU1E8	IC	InChI=1S/C170H210N70O103P16S2/c1-57-23-224(166(260)219-137(57)243)96-6-62(242)80(312-96)29-309-358(293,360)343-78-22-112(240-56-194-124-136(240)206-165(182)218-153(124)259)327-94(78)43-308-357(291,292)341-77-21-111(239-55-193-123-135(239)205-164(181)217-152(123)258)326-93(77)42-307-356(289,290)337-73-17-107(235-51-189-119-131(235)201-160(177)213-148(119)254)319-86(73)35-300-346(269,270)330-66-10-99(227-26-60(4)140(246)222-169(227)263)315-83(66)32-297-350(277,278)334-70-14-104(232-48-186-116-128(232)198-157(174)210-145(116)251)323-90(70)39-304-355(287,288)340-76-20-110(238-54-192-122-134(238)204-163(180)216-151(122)257)325-92(76)41-306-352(281,282)336-72-16-106(234-50-188-118-130(234)200-159(176)212-147(118)253)318-85(72)34-299-345(267,268)329-65-9-98(226-25-59(3)139(245)221-168(226)262)314-82(65)31-296-349(275,276)333-69-13-103(231-47-185-115-127(231)197-156(173)209-144(115)250)322-89(69)38-303-354(285,286)339-75-19-109(237-53-191-121-133(237)203-162(179)215-150(121)256)324-91(75)40-305-351(279,280)335-71-15-105(233-49-187-117-129(233)199-158(175)211-146(117)252)317-84(71)33-298-344(265,266)328-64-8-97(225-24-58(2)138(244)220-167(225)261)313-81(64)30-295-348(273,274)332-68-12-102(230-46-184-114-126(230)196-155(172)208-143(114)249)321-88(68)37-302-353(283,284)338-74-18-108(236-52-190-120-132(236)202-161(178)214-149(120)255)320-87(74)36-301-347(271,272)331-67-11-100(228-27-61(5)141(247)223-170(228)264)316-95(67)44-310-359(294,361)342-63-7-101(311-79(63)28-241)229-45-183-113-125(229)195-154(171)207-142(113)248/h23-27,45-56,62-112,241-242H,6-22,28-44H2,1-5H3,(H,265,266)(H,267,268)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,360)(H,294,361)(H,219,243,260)(H,220,244,261)(H,221,245,262)(H,222,246,263)(H,223,247,264)(H3,171,195,207,248)(H3,172,196,208,249)(H3,173,197,209,250)(H3,174,198,210,251)(H3,175,199,211,252)(H3,176,200,212,253)(H3,177,201,213,254)(H3,178,202,214,255)(H3,179,203,215,256)(H3,180,204,216,257)(H3,181,205,217,258)(H3,182,206,218,259)
DMHU1E8	CS	CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=O)(O)OC4CC(OC4COP(=O)(O)OC5CC(OC5COP(=O)(O)OC6CC(OC6COP(=O)(O)OC7CC(OC7COP(=O)(O)OC8CC(OC8COP(=O)(O)OC9CC(OC9COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(OC1CC(OC1CO)N1C=NC2=C1N=C(NC2=O)N)S)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)O
DMHU1E8	IK	FTRWNHBXCNPGCA-UHFFFAOYSA-N
DMHU1E8	IU	[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methyl [2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl] hydrogen phosphate
DMHU1E8	DE	Human immunodeficiency virus infection

DMUI81C	ID	DMUI81C
DMUI81C	DN	AR-709
DMUI81C	HS	Terminated
DMUI81C	SN	AR-103; AR-103 program, Arpida
DMUI81C	CP	Evolva Holding SA
DMUI81C	DT	Small molecular drug
DMUI81C	PC	11226413
DMUI81C	MW	535
DMUI81C	FM	C27H27ClN6O4
DMUI81C	IC	InChI=1S/C27H27ClN6O4/c1-34(2)26(35)22-19(18-9-15(28)5-6-20(18)32-22)11-16-10-17-13(7-14-12-31-27(30)33-25(14)29)8-21(36-3)24(37-4)23(17)38-16/h5-6,8-10,12,32H,7,11H2,1-4H3,(H4,29,30,31,33)
DMUI81C	CS	CN(C)C(=O)C1=C(C2=C(N1)C=CC(=C2)Cl)CC3=CC4=C(O3)C(=C(C=C4CC5=CN=C(N=C5N)N)OC)OC
DMUI81C	IK	ASSNCSVJAZEMQG-UHFFFAOYSA-N
DMUI81C	IU	5-chloro-3-[[4-[(2,4-diaminopyrimidin-5-yl)methyl]-6,7-dimethoxy-1-benzofuran-2-yl]methyl]-N,N-dimethyl-1H-indole-2-carboxamide
DMUI81C	CA	CAS 663214-64-0
DMUI81C	DE	Bacterial infection

DMQ52JR	ID	DMQ52JR
DMQ52JR	DN	ARC239
DMQ52JR	HS	Terminated
DMQ52JR	SN	GTPL524; BDBM81772; NSC_122211; CAS_122211
DMQ52JR	DT	Small molecular drug
DMQ52JR	PC	609483
DMQ52JR	MW	407.5
DMQ52JR	FM	C24H29N3O3
DMQ52JR	IC	InChI=1S/C24H29N3O3/c1-24(2)19-9-5-4-8-18(19)22(28)27(23(24)29)17-14-25-12-15-26(16-13-25)20-10-6-7-11-21(20)30-3/h4-11H,12-17H2,1-3H3
DMQ52JR	CS	CC1(C2=CC=CC=C2C(=O)N(C1=O)CCN3CCN(CC3)C4=CC=CC=C4OC)C
DMQ52JR	IK	JFNKXGOEOQCXDM-UHFFFAOYSA-N
DMQ52JR	IU	2-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethylisoquinoline-1,3-dione
DMQ52JR	CA	CAS 67339-62-2
DMQ52JR	CB	CHEBI:93630

DM9HZ8D	ID	DM9HZ8D
DM9HZ8D	DN	AR-C-89855
DM9HZ8D	HS	Terminated
DM9HZ8D	SN	AR-C68164AA; AR-C68475AA; AR-C69457AA; AR-C89855AA
DM9HZ8D	CP	AstraZeneca plc
DM9HZ8D	PC	10206844
DM9HZ8D	MW	493.6
DM9HZ8D	FM	C23H31N3O5S2
DM9HZ8D	IC	InChI=1S/C23H31N3O5S2/c1-17-3-5-18(6-4-17)10-14-31-15-13-25-33(29,30)16-2-11-24-12-9-19-7-8-20(27)21-22(19)32-23(28)26-21/h3-8,24-25,27H,2,9-16H2,1H3,(H,26,28)
DM9HZ8D	CS	CC1=CC=C(C=C1)CCOCCNS(=O)(=O)CCCNCCC2=C3C(=C(C=C2)O)NC(=O)S3
DM9HZ8D	IK	FIDWUJWRKJJJLL-UHFFFAOYSA-N
DM9HZ8D	IU	3-[2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethylamino]-N-[2-[2-(4-methylphenyl)ethoxy]ethyl]propane-1-sulfonamide
DM9HZ8D	CA	CAS 189012-09-7
DM9HZ8D	DE	Chronic obstructive pulmonary disease

DMRXB74	ID	DMRXB74
DMRXB74	DN	ARISTEROMYCIN
DMRXB74	HS	Terminated
DMRXB74	SN	19186-33-5; 3-(6-aminopurin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol; NSC613806; NSC615828; NSC613807; NSC103526; Carbocyclic Lyxo-A; Carbocyclic Xylo-A; AC1Q4VH0; Cyclaradine Carbocyclic Ara A; SCHEMBL9820408; AC1L1D83; CTK4E0829; 3-(6-amino-9h-purin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol; NSC-613807; NSC-613806; NSC-615828; NSC-103526; J-012404; 1,2-Cyclopentanediol,5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)-, (1S,2R,3R,5R)-
DMRXB74	DT	Small molecular drug
DMRXB74	PC	65269
DMRXB74	MW	265.27
DMRXB74	FM	C11H15N5O3
DMRXB74	IC	InChI=1S/C11H15N5O3/c12-10-7-11(14-3-13-10)16(4-15-7)6-1-5(2-17)8(18)9(6)19/h3-6,8-9,17-19H,1-2H2,(H2,12,13,14)/t5-,6-,8-,9+/m1/s1
DMRXB74	CS	C1[C@@H]([C@H]([C@H]([C@@H]1N2C=NC3=C(N=CN=C32)N)O)O)CO
DMRXB74	IK	UGRNVLGKAGREKS-GCXDCGAKSA-N
DMRXB74	IU	(1R,2S,3R,5R)-3-(6-aminopurin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol
DMRXB74	CA	CAS 19186-33-5

DMRYQBE	ID	DMRYQBE
DMRYQBE	DN	AS-1406
DMRYQBE	HS	Terminated
DMRYQBE	SN	Theranase; HuHMFG1-huRNase; Targeted apoptosis (RNase), Antisoma
DMRYQBE	CP	Antisoma plc
DMRYQBE	DE	Solid tumour/cancer

DMH78J6	ID	DMH78J6
DMH78J6	DN	AS-602305
DMH78J6	HS	Terminated
DMH78J6	SN	AS-603831; Oxytocin receptor antagonists (premature labor); Oxytocin receptor antagonists (premature labor), Merck Serono; Oxytocin receptor antagonists (premature labor), Serono
DMH78J6	CP	Merck Serono SA
DMH78J6	DE	Androgen deficiency

DMIFDPL	ID	DMIFDPL
DMIFDPL	DN	AS-8112
DMIFDPL	HS	Terminated
DMIFDPL	CP	Dainippon
DMIFDPL	DE	Vomiting

DMS2FB3	ID	DMS2FB3
DMS2FB3	DN	ATLIPROFEN METHYL ESTER
DMS2FB3	HS	Terminated
DMS2FB3	SN	IDPH-8261; Atliprofen methyl ester; 2-[4-(3-Thienyl)phenyl]propionic acid methyl ester
DMS2FB3	DT	Small molecular drug
DMS2FB3	PC	130978
DMS2FB3	MW	246.33
DMS2FB3	FM	C14H14O2S
DMS2FB3	IC	InChI=1S/C14H14O2S/c1-10(14(15)16-2)11-3-5-12(6-4-11)13-7-8-17-9-13/h3-10H,1-2H3
DMS2FB3	CS	CC(C1=CC=C(C=C1)C2=CSC=C2)C(=O)OC
DMS2FB3	IK	WINXAKJYORVNHU-UHFFFAOYSA-N
DMS2FB3	IU	methyl 2-(4-thiophen-3-ylphenyl)propanoate
DMS2FB3	CA	CAS 108912-17-0
DMS2FB3	DE	Inflammation

DM4UTXV	ID	DM4UTXV
DM4UTXV	DN	AVE0675
DM4UTXV	HS	Terminated
DM4UTXV	CP	Sanofi-Aventis
DM4UTXV	DE	Asthma

DMD8ZM1	ID	DMD8ZM1
DMD8ZM1	DN	AWD-23-111
DMD8ZM1	HS	Terminated
DMD8ZM1	CP	Elbion AG
DMD8ZM1	DE	Heart arrhythmia

DMJH7IX	ID	DMJH7IX
DMJH7IX	DN	AZD-0275
DMJH7IX	HS	Terminated
DMJH7IX	CP	AstraZeneca plc
DMJH7IX	DE	Rheumatoid arthritis; Chronic obstructive pulmonary disease

DMS7INR	ID	DMS7INR
DMS7INR	DN	AZD-0902
DMS7INR	HS	Terminated
DMS7INR	CP	AstraZeneca plc
DMS7INR	DE	Rheumatoid arthritis; Chronic obstructive pulmonary disease

DMPCFRN	ID	DMPCFRN
DMPCFRN	DN	AZD-1134
DMPCFRN	HS	Terminated
DMPCFRN	SN	AZD-1134; CHEMBL602674; SCHEMBL4251105; CKBARMWSFIJZTL-UHFFFAOYSA-N; BDBM50306588; 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-propionyl-piperazin-1-yl)-phenyl]-amide
DMPCFRN	CP	AstraZeneca plc
DMPCFRN	DT	Small molecular drug
DMPCFRN	PC	9830790
DMPCFRN	MW	521.6
DMPCFRN	FM	C28H32FN5O4
DMPCFRN	IC	InChI=1S/C28H32FN5O4/c1-3-26(36)34-14-12-32(13-15-34)21-6-4-20(5-7-21)30-28(37)25-18-24(35)22-16-19(29)17-23(27(22)38-25)33-10-8-31(2)9-11-33/h4-7,16-18H,3,8-15H2,1-2H3,(H,30,37)
DMPCFRN	CS	CCC(=O)N1CCN(CC1)C2=CC=C(C=C2)NC(=O)C3=CC(=O)C4=C(O3)C(=CC(=C4)F)N5CCN(CC5)C
DMPCFRN	IK	CKBARMWSFIJZTL-UHFFFAOYSA-N
DMPCFRN	IU	6-fluoro-8-(4-methylpiperazin-1-yl)-4-oxo-N-[4-(4-propanoylpiperazin-1-yl)phenyl]chromene-2-carboxamide
DMPCFRN	DE	Anxiety disorder

DM3WFB5	ID	DM3WFB5
DM3WFB5	DN	AZD3409
DM3WFB5	HS	Terminated
DM3WFB5	SN	GTPL8027; AZD 3409; propan-2-yl (2S)-2-[1-[2-(2-fluoroethyl)-5-[[(2S,5S)-5-(pyridine-3-carbonylsulfanyl)pyrrolidin-2-yl]methylamino]phenyl]ethenylamino]-4-methylsulfanylbutanoate
DM3WFB5	CP	AstraZeneca
DM3WFB5	TC	Anticancer Agents
DM3WFB5	DT	Small molecular drug
DM3WFB5	PC	56603668
DM3WFB5	MW	574.8
DM3WFB5	FM	C29H39FN4O3S2
DM3WFB5	IC	InChI=1S/C29H39FN4O3S2/c1-19(2)37-28(35)26(12-15-38-4)33-20(3)25-16-23(8-7-21(25)11-13-30)32-18-24-9-10-27(34-24)39-29(36)22-6-5-14-31-17-22/h5-8,14,16-17,19,24,26-27,32-34H,3,9-13,15,18H2,1-2,4H3/t24-,26-,27-/m0/s1
DM3WFB5	CS	CC(C)OC(=O)[C@H](CCSC)NC(=C)C1=C(C=CC(=C1)NC[C@@H]2CC[C@@H](N2)SC(=O)C3=CN=CC=C3)CCF
DM3WFB5	IK	GIJNHMGFNKZBIR-URORMMCBSA-N
DM3WFB5	IU	propan-2-yl (2S)-2-[1-[2-(2-fluoroethyl)-5-[[(2S,5S)-5-(pyridine-3-carbonylsulfanyl)pyrrolidin-2-yl]methylamino]phenyl]ethenylamino]-4-methylsulfanylbutanoate
DM3WFB5	DE	Solid tumour/cancer

DMABY43	ID	DMABY43
DMABY43	DN	AZD-5106
DMABY43	HS	Terminated
DMABY43	CP	AstraZeneca plc
DMABY43	DE	Urinary incontinence

DMQUX28	ID	DMQUX28
DMQUX28	DN	AZD5672
DMQUX28	HS	Terminated
DMQUX28	SN	CHEMBL1951914; SCHEMBL2767780; GTPL7686; QOSMEMHKXNNIGG-SSEXGKCCSA-N; AZD 5672; BDBM50364743; N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide
DMQUX28	CP	AstraZeneca
DMQUX28	DT	Small molecular drug
DMQUX28	PC	11614352
DMQUX28	MW	639.8
DMQUX28	FM	C31H43F2N3O5S2
DMQUX28	IC	InChI=1S/C31H43F2N3O5S2/c1-4-36(31(37)19-23-5-7-29(8-6-23)42(2,38)39)28-11-14-34(15-12-28)16-13-30(25-20-26(32)22-27(33)21-25)24-9-17-35(18-10-24)43(3,40)41/h5-8,20-22,24,28,30H,4,9-19H2,1-3H3/t30-/m1/s1
DMQUX28	CS	CCN(C1CCN(CC1)CC[C@H](C2CCN(CC2)S(=O)(=O)C)C3=CC(=CC(=C3)F)F)C(=O)CC4=CC=C(C=C4)S(=O)(=O)C
DMQUX28	IK	QOSMEMHKXNNIGG-SSEXGKCCSA-N
DMQUX28	IU	N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide
DMQUX28	DE	Rheumatoid arthritis

DMVP4E5	ID	DMVP4E5
DMVP4E5	DN	AZD6482
DMVP4E5	HS	Terminated
DMVP4E5	SN	AZD6482; 1173900-33-8; AZD 6482; (R)-2-(1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino)benzoic acid; 2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid; AZD-6482; CHEMBL2165191; UNII-78G6MP5PZ5; 78G6MP5PZ5; 2-({(1R)-1-[7-Methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl}amino)benzoic acid; 2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxopyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid
DMVP4E5	CP	AstraZeneca
DMVP4E5	DT	Small molecular drug
DMVP4E5	PC	44137675
DMVP4E5	MW	408.4
DMVP4E5	FM	C22H24N4O4
DMVP4E5	IC	InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1
DMVP4E5	CS	CC1=CN2C(=O)C=C(N=C2C(=C1)[C@@H](C)NC3=CC=CC=C3C(=O)O)N4CCOCC4
DMVP4E5	IK	IRTDIKMSKMREGO-OAHLLOKOSA-N
DMVP4E5	IU	2-[[(1R)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoic acid
DMVP4E5	CA	CAS 1173900-33-8
DMVP4E5	CB	CHEBI:91359
DMVP4E5	DE	Thrombosis

DMZ90OV	ID	DMZ90OV
DMZ90OV	DN	AZD-6942
DMZ90OV	HS	Terminated
DMZ90OV	SN	CCR2b antagonists, AstraZeneca; CCR2b, AstraZeneca
DMZ90OV	CP	AstraZeneca plc
DMZ90OV	DE	Rheumatoid arthritis

DMU6L4I	ID	DMU6L4I
DMU6L4I	DN	AZD-7545
DMU6L4I	HS	Terminated
DMU6L4I	SN	AZD7545; 252017-04-2; 4-[(3-Chloro-4-{[(2r)-3,3,3-Trifluoro-2-Hydroxy-2-Methylpropanoyl]amino}phenyl)sulfonyl]-N,N-Dimethylbenzamide; 4-{3-chloro-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamido]benzenesulfonyl}-N,N-dimethylbenzamide; DTDZLJHKVNTQGZ-GOSISDBHSA-N; AZD-7545; AZD 7545; 2q8g; C19H18ClF3N2O5S; GTPL9362; SCHEMBL6350247; AOB6866; MolPort-035-395-876; ZINC1547088; EX-A1208; AZD-7547; BCP07524; KS-00000RM2; s7517; 2244AH; AZD 7545;AZD-7545; AKOS027326647; DB07403; CS-1740; NCGC00250391-07; NCGC00250391-01; HY-16082
DMU6L4I	CP	AstraZeneca plc
DMU6L4I	DT	Small molecular drug
DMU6L4I	PC	16741245
DMU6L4I	MW	478.9
DMU6L4I	FM	C19H18ClF3N2O5S
DMU6L4I	IC	InChI=1S/C19H18ClF3N2O5S/c1-18(28,19(21,22)23)17(27)24-15-9-8-13(10-14(15)20)31(29,30)12-6-4-11(5-7-12)16(26)25(2)3/h4-10,28H,1-3H3,(H,24,27)/t18-/m1/s1
DMU6L4I	CS	C[C@@](C(=O)NC1=C(C=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)C(=O)N(C)C)Cl)(C(F)(F)F)O
DMU6L4I	IK	DTDZLJHKVNTQGZ-GOSISDBHSA-N
DMU6L4I	IU	4-[3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]phenyl]sulfonyl-N,N-dimethylbenzamide
DMU6L4I	DE	Diabetic complication

DMFE3CD	ID	DMFE3CD
DMFE3CD	DN	AZD-9935
DMFE3CD	HS	Terminated
DMFE3CD	CP	AstraZeneca plc
DMFE3CD	DE	Solid tumour/cancer

DMLCSRF	ID	DMLCSRF
DMLCSRF	DN	AZM-131
DMLCSRF	HS	Terminated
DMLCSRF	CP	Alizyme plc
DMLCSRF	DE	Obesity

DMIWC64	ID	DMIWC64
DMIWC64	DN	AZM-134
DMIWC64	HS	Terminated
DMIWC64	SN	AZM-133; GLP-1 mimetics, Alizyme; Glucagon-like peptide-1 mimetics, Alizyme
DMIWC64	CP	Alizyme plc
DMIWC64	DE	Type-2 diabetes

DME6OFU	ID	DME6OFU
DME6OFU	DN	B-428
DME6OFU	HS	Terminated
DME6OFU	CP	Eisai Co Ltd
DME6OFU	PC	1747
DME6OFU	MW	302.14
DME6OFU	FM	C9H7IN2S
DME6OFU	IC	InChI=1S/C9H7IN2S/c10-6-2-1-3-7-5(6)4-8(13-7)9(11)12/h1-4H,(H3,11,12)
DME6OFU	CS	C1=CC2=C(C=C(S2)C(=N)N)C(=C1)I
DME6OFU	IK	YERQOXAYAFWFEJ-UHFFFAOYSA-N
DME6OFU	IU	4-iodo-1-benzothiophene-2-carboximidamide
DME6OFU	CA	CAS 154628-42-9
DME6OFU	DE	Solid tumour/cancer

DM8I5UF	ID	DM8I5UF
DM8I5UF	DN	B-5354a
DM8I5UF	HS	Terminated
DM8I5UF	SN	B-5354b; B-5354c; Sphingosine kinase inhibitors, Sankyo
DM8I5UF	CP	Sankyo Co Ltd
DM8I5UF	DE	Arteriosclerosis

DM5EKPM	ID	DM5EKPM
DM5EKPM	DN	B-581
DM5EKPM	HS	Terminated
DM5EKPM	SN	149759-96-6; B581; FTase Inhibitor I; B 581; B-581; CHEMBL91722; CHEBI:83620; N-[2(S)-(2(R)-2-Amino-3-mercaptopropylamino)-3-methylbutyl]-L-phenylalanyl-L-methionine trifluoroacetate salt; (S)-2-((S)-2-((S)-2-((R)-2-amino-3-mercaptopropylamino)-3-methylbutylamino)-3-phenylpropanamido)-4-(methylthio)butanoic acid; CBiol_001875; H-Cys-psi(CH2NH)Val-psi(CH2NH)Phe-Met-OH; AC1L31RF; BSPBio_001466; KBioSS_000186; KBioGR_000186; SCHEMBL2723960; KBio3_000372; KBio2_005322; KBio2_000186; KBio3_000371; KBio2_002754; CTK8E9094
DM5EKPM	CP	Eisai Co Ltd
DM5EKPM	DT	Small molecular drug
DM5EKPM	PC	132887
DM5EKPM	MW	470.7
DM5EKPM	FM	C22H38N4O3S2
DM5EKPM	IC	InChI=1S/C22H38N4O3S2/c1-15(2)20(24-12-17(23)14-30)13-25-19(11-16-7-5-4-6-8-16)21(27)26-18(22(28)29)9-10-31-3/h4-8,15,17-20,24-25,30H,9-14,23H2,1-3H3,(H,26,27)(H,28,29)/t17-,18+,19+,20-/m1/s1
DM5EKPM	CS	CC(C)[C@@H](CN[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)NC[C@H](CS)N
DM5EKPM	IK	QISLMXIYRQCLIR-FUMNGEBKSA-N
DM5EKPM	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylbutyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DM5EKPM	CA	CAS 149759-96-6
DM5EKPM	CB	CHEBI:83620
DM5EKPM	DE	Solid tumour/cancer

DM1IO9X	ID	DM1IO9X
DM1IO9X	DN	B-956
DM1IO9X	HS	Terminated
DM1IO9X	SN	B-1086; B-957
DM1IO9X	CP	Eisai Co Ltd
DM1IO9X	PC	15379028
DM1IO9X	MW	464.7
DM1IO9X	FM	C24H36N2O3S2
DM1IO9X	IC	InChI=1S/C24H36N2O3S2/c1-17(2)19(11-12-21(25)16-30)9-10-20(15-18-7-5-4-6-8-18)23(27)26-22(24(28)29)13-14-31-3/h4-12,17,19-22,30H,13-16,25H2,1-3H3,(H,26,27)(H,28,29)/b10-9+,12-11+/t19-,20+,21+,22-/m0/s1
DM1IO9X	CS	CC(C)[C@@H](/C=C/[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)/C=C/[C@H](CS)N
DM1IO9X	IK	IPRQDTJTDYDPBX-KPVQYLNHSA-N
DM1IO9X	IU	(2S)-2-[[(2S,3E,5S,6E,8R)-8-amino-2-benzyl-5-propan-2-yl-9-sulfanylnona-3,6-dienoyl]amino]-4-methylsulfanylbutanoic acid
DM1IO9X	DE	Solid tumour/cancer

DM8AGOE	ID	DM8AGOE
DM8AGOE	DN	BABIM
DM8AGOE	HS	Terminated
DM8AGOE	SN	BABIM; Bis(5-amidino-2-benzimidazolyl)methane; 74733-75-8; CHEMBL99951; 1H-Benzimidazole-5-carboximidamide, 2,2'-methylenebis-; 1xug; 1c1v; AC1L1DKB; SCHEMBL65730; AC1Q1U90; CTK5E0415; BDBM16127; DTXSID60225717; AIDS007118; ZINC3871731; AKOS028112598; Bis(5-amidino-1H-benzimidazole-2-yl)methane; 1H-Benzimidazole-6-carboximidamide,2,2'-methylenebis-; 2,2 -methanediylbis(1H-benzimidazole-6-carboximidamide); 2-[(5-carbamimidoyl-1H-benzimidazol-2-yl)methyl]-1H-benzimidazole-5-carboxamidine
DM8AGOE	DT	Small molecular drug
DM8AGOE	PC	2387
DM8AGOE	MW	332.4
DM8AGOE	FM	C17H16N8
DM8AGOE	IC	InChI=1S/C17H16N8/c18-16(19)8-1-3-10-12(5-8)24-14(22-10)7-15-23-11-4-2-9(17(20)21)6-13(11)25-15/h1-6H,7H2,(H3,18,19)(H3,20,21)(H,22,24)(H,23,25)
DM8AGOE	CS	C1=CC2=C(C=C1C(=N)N)NC(=N2)CC3=NC4=C(N3)C=C(C=C4)C(=N)N
DM8AGOE	IK	QZKOOEFIMWKZPK-UHFFFAOYSA-N
DM8AGOE	IU	2-[(6-carbamimidoyl-1H-benzimidazol-2-yl)methyl]-3H-benzimidazole-5-carboximidamide
DM8AGOE	CA	CAS 74733-75-8
DM8AGOE	DE	Asthma

DMY1TLZ	ID	DMY1TLZ
DMY1TLZ	DN	Baicalin
DMY1TLZ	HS	Terminated
DMY1TLZ	SN	Baicalin; 21967-41-9; Baicalein 7-O-glucuronide; 7-D-Glucuronic acid-5,6-dihydroxyflavone; CHEBI:2981; CHEMBL485818; UNII-347Q89U4M5; 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronic acid; Baicalin hydrate; 347Q89U4M5; (2S,3S,4S,5R,6S)-6-((5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; 5,6,7-trihydroxyflavone 7-O-beta-D-glucuronide; BAICAILIN; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl; 31564-28-0
DMY1TLZ	DT	Small molecular drug
DMY1TLZ	PC	64982
DMY1TLZ	MW	446.4
DMY1TLZ	FM	C21H18O11
DMY1TLZ	IC	InChI=1S/C21H18O11/c22-9-6-10(8-4-2-1-3-5-8)30-11-7-12(14(23)15(24)13(9)11)31-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21,23-27H,(H,28,29)/t16-,17-,18+,19-,21+/m0/s1
DMY1TLZ	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O
DMY1TLZ	IK	IKIIZLYTISPENI-ZFORQUDYSA-N
DMY1TLZ	IU	(2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMY1TLZ	CA	CAS 21967-41-9
DMY1TLZ	CB	CHEBI:2981
DMY1TLZ	DE	Human immunodeficiency virus infection

DMDLN9E	ID	DMDLN9E
DMDLN9E	DN	BALANOL
DMDLN9E	HS	Terminated
DMDLN9E	SN	balanol; 63590-19-2; Azepinostatin; CHEMBL60254; Balanol, 1; 2-[2,6-dihydroxy-4-[(3R,4R)-3-[(4-hydroxybenzoyl)amino]azepan-4-yl]oxycarbonylbenzoyl]-3-hydroxybenzoic acid; BA1; (-)-Balanol; (3R-trans)-Balanol; AC1NRA6W; SCHEMBL62128; MEGxm0_000504; GTPL8142; BDBM3149; Acyclic Balanol Analog (-)-1; BDBM36607; ACon0_001438; ZINC3871640; MCULE-9310625171; 167937-47-5; FT-0662471; 33879-EP2275420A1; 33879-EP2295416A2; 33879-EP2295055A2; 33879-EP2311453A1; 33879-EP2305642A2; 33879-EP2298764A1; 33879-EP2298765A1; 33879-EP2298748A2
DMDLN9E	DT	Small molecular drug
DMDLN9E	PC	5287736
DMDLN9E	MW	550.5
DMDLN9E	FM	C28H26N2O10
DMDLN9E	IC	InChI=1S/C28H26N2O10/c31-16-8-6-14(7-9-16)26(36)30-18-13-29-10-2-5-22(18)40-28(39)15-11-20(33)24(21(34)12-15)25(35)23-17(27(37)38)3-1-4-19(23)32/h1,3-4,6-9,11-12,18,22,29,31-34H,2,5,10,13H2,(H,30,36)(H,37,38)/t18-,22-/m1/s1
DMDLN9E	CS	C1C[C@H]([C@@H](CNC1)NC(=O)C2=CC=C(C=C2)O)OC(=O)C3=CC(=C(C(=C3)O)C(=O)C4=C(C=CC=C4O)C(=O)O)O
DMDLN9E	IK	XYUFCXJZFZPEJD-XMSQKQJNSA-N
DMDLN9E	IU	2-[2,6-dihydroxy-4-[(3R,4R)-3-[(4-hydroxybenzoyl)amino]azepan-4-yl]oxycarbonylbenzoyl]-3-hydroxybenzoic acid
DMDLN9E	CA	CAS 63590-19-2

DMTMS3L	ID	DMTMS3L
DMTMS3L	DN	Barucainide
DMTMS3L	HS	Terminated
DMTMS3L	SN	Barucainide; UNII-14NFL30YOH; 79784-22-8; 14NFL30YOH; Barucainidum; Barucainide [INN]; Barucainid; AC1Q1QCZ; AC1L3TX5; SCHEMBL2110723; CHEMBL2105905; DTXSID60229912; ZINC3643459; 4-Benzyl-1,3-dihydro-7-(4-(isopropylamino)butoxy)-6-methylfuro(3,4-c)pyridine; 4-[(4-benzyl-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl)oxy]-N-propan-2-ylbutan-1-amine
DMTMS3L	CP	BASF AG
DMTMS3L	DT	Small molecular drug
DMTMS3L	PC	146795
DMTMS3L	MW	354.5
DMTMS3L	FM	C22H30N2O2
DMTMS3L	IC	InChI=1S/C22H30N2O2/c1-16(2)23-11-7-8-12-26-22-17(3)24-21(19-14-25-15-20(19)22)13-18-9-5-4-6-10-18/h4-6,9-10,16,23H,7-8,11-15H2,1-3H3
DMTMS3L	CS	CC1=C(C2=C(COC2)C(=N1)CC3=CC=CC=C3)OCCCCNC(C)C
DMTMS3L	IK	KXSKBNFNSAMNEZ-UHFFFAOYSA-N
DMTMS3L	IU	4-[(4-benzyl-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl)oxy]-N-propan-2-ylbutan-1-amine
DMTMS3L	CA	CAS 79784-22-8
DMTMS3L	DE	Heart arrhythmia

DM7LZFQ	ID	DM7LZFQ
DM7LZFQ	DN	BAY-17-1998
DM7LZFQ	HS	Terminated
DM7LZFQ	SN	BAY-35-8535
DM7LZFQ	CP	Arris Pharmaceutical Corp
DM7LZFQ	DE	Asthma

DMPUG18	ID	DMPUG18
DMPUG18	DN	BAY-39-9624
DMPUG18	HS	Terminated
DMPUG18	CP	Bayer AG
DMPUG18	DE	Osteoporosis

DM40ORU	ID	DM40ORU
DM40ORU	DN	BAY-44-3428
DM40ORU	HS	Terminated
DM40ORU	SN	APC-1167
DM40ORU	CP	Celera South San Francisco
DM40ORU	DE	Asthma

DMAKXN3	ID	DMAKXN3
DMAKXN3	DN	BAY-50-9062
DMAKXN3	HS	Terminated
DMAKXN3	SN	Osteoporosis therapeutic (2), Bayer; 17beta-hydroxysteroid dehydrogenase inhibitor, Bayer
DMAKXN3	CP	Bayer AG
DMAKXN3	DE	Osteoporosis

DM69EHF	ID	DM69EHF
DM69EHF	DN	BAY-793
DM69EHF	HS	Terminated
DM69EHF	SN	Hoe-793
DM69EHF	CP	Bayer AG
DM69EHF	DE	Human immunodeficiency virus infection

DMZGFM6	ID	DMZGFM6
DMZGFM6	DN	BAY-Z-4305
DMZGFM6	HS	Terminated
DMZGFM6	CP	Bayer AG
DMZGFM6	DE	Human immunodeficiency virus-1 infection

DM7GH5Z	ID	DM7GH5Z
DM7GH5Z	DN	BB-1101
DM7GH5Z	HS	Terminated
DM7GH5Z	SN	BB-1101; CHEMBL432079; SCHEMBL1844243; BDBM50070453
DM7GH5Z	DT	Small molecular drug
DM7GH5Z	PC	9908389
DM7GH5Z	MW	389.5
DM7GH5Z	FM	C21H31N3O4
DM7GH5Z	IC	InChI=1S/C21H31N3O4/c1-5-9-16(20(26)24-28)17(12-14(2)3)19(25)23-18(21(27)22-4)13-15-10-7-6-8-11-15/h5-8,10-11,14,16-18,28H,1,9,12-13H2,2-4H3,(H,22,27)(H,23,25)(H,24,26)/t16-,17+,18-/m0/s1
DM7GH5Z	CS	CC(C)C[C@H]([C@H](CC=C)C(=O)NO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC
DM7GH5Z	IK	GKHRDWHFKKUYAX-KSZLIROESA-N
DM7GH5Z	IU	(2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-prop-2-enylbutanediamide
DM7GH5Z	DE	Multiple sclerosis

DMWAKC8	ID	DMWAKC8
DMWAKC8	DN	BB-1433
DMWAKC8	HS	Terminated
DMWAKC8	SN	BB-2014; BB-2116; BB-2284; BB-2633; BB-3029; BB-3050; BB-3103; BB-3241
DMWAKC8	CP	Vernalis plc
DMWAKC8	PC	101708593
DMWAKC8	MW	357.4
DMWAKC8	FM	C17H31N3O5
DMWAKC8	IC	InChI=1S/C17H31N3O5/c1-10(2)13(14(21)17(24)20-25)16(23)19-12(15(22)18-3)9-11-7-5-4-6-8-11/h10-14,21,25H,4-9H2,1-3H3,(H,18,22)(H,19,23)(H,20,24)/t12-,13+,14-/m0/s1
DMWAKC8	CS	CC(C)[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC
DMWAKC8	IK	OOYLWSYMDSXZMO-MJBXVCDLSA-N
DMWAKC8	IU	(2R,3S)-N-[(2S)-3-cyclohexyl-1-(methylamino)-1-oxopropan-2-yl]-N',3-dihydroxy-2-propan-2-ylbutanediamide
DMWAKC8	DE	Arthritis

DM6ETM8	ID	DM6ETM8
DM6ETM8	DN	BB-2275
DM6ETM8	HS	Terminated
DM6ETM8	CP	Vernalis plc
DM6ETM8	DE	Human immunodeficiency virus infection

DM7YRFE	ID	DM7YRFE
DM7YRFE	DN	BB-3644
DM7YRFE	HS	Terminated
DM7YRFE	SN	SCHEMBL609641
DM7YRFE	CP	Vernalis
DM7YRFE	TC	Anticancer Agents
DM7YRFE	DT	Small molecular drug
DM7YRFE	PC	9822724
DM7YRFE	MW	408.5
DM7YRFE	FM	C20H32N4O5
DM7YRFE	IC	InChI=1S/C20H32N4O5/c1-12(2)11-13(15(29-6)18(26)24-28)17(25)23-16(20(3,4)5)19(27)22-14-9-7-8-10-21-14/h7-10,12-13,15-16,28H,11H2,1-6H3,(H,23,25)(H,24,26)(H,21,22,27)/t13-,15+,16-/m1/s1
DM7YRFE	CS	CC(C)C[C@H]([C@@H](C(=O)NO)OC)C(=O)N[C@H](C(=O)NC1=CC=CC=N1)C(C)(C)C
DM7YRFE	IK	WORSVFBVUCBRIP-VNQPRFMTSA-N
DM7YRFE	IU	(2R,3S)-N-[(2S)-3,3-dimethyl-1-oxo-1-(pyridin-2-ylamino)butan-2-yl]-N'-hydroxy-3-methoxy-2-(2-methylpropyl)butanediamide
DM7YRFE	CA	CAS 226072-63-5
DM7YRFE	DE	Solid tumour/cancer

DMITV4F	ID	DMITV4F
DMITV4F	DN	BBB-022
DMITV4F	HS	Terminated
DMITV4F	CP	Eisai Co Ltd
DMITV4F	DE	Cerebrovascular ischaemia

DMNH9A6	ID	DMNH9A6
DMNH9A6	DN	BCH-150
DMNH9A6	HS	Terminated
DMNH9A6	CP	Shire BioChem Inc
DMNH9A6	DE	Gastrointestinal disease

DM3TP8X	ID	DM3TP8X
DM3TP8X	DN	BCH-2763
DM3TP8X	HS	Terminated
DM3TP8X	SN	UNII-2Y77S7IT1P; 2Y77S7IT1P; BCH 2763; 204641-27-0
DM3TP8X	DT	Small molecular drug
DM3TP8X	PC	72941757
DM3TP8X	MW	1272.5
DM3TP8X	FM	C64H93N11O16
DM3TP8X	IC	InChI=1S/C64H93N11O16/c1-5-40(4)55(71-59(85)48-24-17-33-73(48)61(87)44(28-29-53(78)79)69-56(82)45(37-42-21-10-7-11-22-42)70-57(83)46(38-54(80)81)68-51(76)26-12-14-30-65)63(89)74-34-18-25-49(74)62(88)75(50(64(90)91)35-39(2)3)52(77)27-13-15-31-67-58(84)47-23-16-32-72(47)60(86)43(66)36-41-19-8-6-9-20-41/h6-11,19-22,39-40,43-50,55H,5,12-18,23-38,65-66H2,1-4H3,(H,67,84)(H,68,76)(H,69,82)(H,70,83)(H,71,85)(H,78,79)(H,80,81)(H,90,91)/t40-,43+,44-,45-,46-,47-,48-,49-,50-,55-/m0/s1
DM3TP8X	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N([C@@H](CC(C)C)C(=O)O)C(=O)CCCCNC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC3=CC=CC=C3)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCN
DM3TP8X	IK	VKIPOMGKUAJAEY-GEPLSBMPSA-N
DM3TP8X	IU	(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(5-aminopentanoylamino)-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]-[5-[[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-methylpentanoic acid
DM3TP8X	CA	CAS 204641-27-0
DM3TP8X	DE	Thrombosis

DMBJERO	ID	DMBJERO
DMBJERO	DN	BCX-140
DMBJERO	HS	Terminated
DMBJERO	SN	4-(Acetylamino)-3-guanidinobenzoic acid; BANA-113; UNII-V02KF5948M; BANA 113; CHEMBL55440; 170447-93-5; V02KF5948M; Benzoic acid, 4-(acetylamino)-3-((aminoiminomethyl)amino)-; 4-acetamido-3-guanidino-benzoic acid; Benzoic acid, 4-(acetylamino)-3-[(aminoiminomethyl)amino]-; 1inf; AC1L9JI9; 4-acetamido-3-(diaminomethylideneamino)benzoic acid; SCHEMBL141675; BDBM4707; UDQJOWCVSMIZJP-UHFFFAOYSA-N; 4-Acetylamino-3-guanidino-benzoic acid; 3-carbamimidamido-4-acetamidobenzoic acid; 3-(2,2-diaminoimino)-4-methylcarboxamidobenzoate;  BANA-113; BANA-153; BANA-205; BANA-206; Neuraminidase inhibitors, BioCryst; 4-(Acetylamino)-3-Guanidinobenzoic Acid
DMBJERO	CP	BioCryst Pharmaceuticals Inc
DMBJERO	DT	Small molecular drug
DMBJERO	PC	446323
DMBJERO	MW	236.23
DMBJERO	FM	C10H12N4O3
DMBJERO	IC	InChI=1S/C10H12N4O3/c1-5(15)13-7-3-2-6(9(16)17)4-8(7)14-10(11)12/h2-4H,1H3,(H,13,15)(H,16,17)(H4,11,12,14)
DMBJERO	CS	CC(=O)NC1=C(C=C(C=C1)C(=O)O)N=C(N)N
DMBJERO	IK	UDQJOWCVSMIZJP-UHFFFAOYSA-N
DMBJERO	IU	4-acetamido-3-(diaminomethylideneamino)benzoic acid
DMBJERO	CA	CAS 170447-93-5
DMBJERO	DE	Influenza virus infection

DM4GEUF	ID	DM4GEUF
DM4GEUF	DN	BCX-25
DM4GEUF	HS	Terminated
DM4GEUF	SN	BCX-14
DM4GEUF	CP	BioCryst Pharmaceuticals Inc
DM4GEUF	DE	Arthritis

DMV5K0I	ID	DMV5K0I
DMV5K0I	DN	BDF-9148
DMV5K0I	HS	Terminated
DMV5K0I	SN	BDF-9167; BDF-9196
DMV5K0I	CP	Beiersdorf AG
DMV5K0I	DT	Small molecular drug
DMV5K0I	PC	123765
DMV5K0I	MW	453.5
DMV5K0I	FM	C28H27N3O3
DMV5K0I	IC	InChI=1S/C28H27N3O3/c29-15-22-14-25-26(30-22)12-7-13-27(25)34-19-23(32)18-33-24-16-31(17-24)28(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-14,23-24,28,30,32H,16-19H2
DMV5K0I	CS	C1C(CN1C(C2=CC=CC=C2)C3=CC=CC=C3)OCC(COC4=CC=CC5=C4C=C(N5)C#N)O
DMV5K0I	IK	KQQFGABYYXEKDM-UHFFFAOYSA-N
DMV5K0I	IU	4-[3-(1-benzhydrylazetidin-3-yl)oxy-2-hydroxypropoxy]-1H-indole-2-carbonitrile
DMV5K0I	CA	CAS 120838-62-2
DMV5K0I	DE	Cardiac failure

DM6WQ8F	ID	DM6WQ8F
DM6WQ8F	DN	BE-13793C
DM6WQ8F	HS	Terminated
DM6WQ8F	CP	MSD Japan
DM6WQ8F	DT	Small molecular drug
DM6WQ8F	PC	9928668
DM6WQ8F	MW	357.3
DM6WQ8F	FM	C20H11N3O4
DM6WQ8F	IC	InChI=1S/C20H11N3O4/c24-9-5-1-3-7-11-13-14(20(27)23-19(13)26)12-8-4-2-6-10(25)16(8)22-18(12)17(11)21-15(7)9/h1-6,21-22,24-25H,(H,23,26,27)
DM6WQ8F	CS	C1=CC2=C(C(=C1)O)NC3=C4C(=C5C(=C23)C(=O)NC5=O)C6=C(N4)C(=CC=C6)O
DM6WQ8F	IK	FETFZHLVPOJEBR-UHFFFAOYSA-N
DM6WQ8F	IU	5,21-dihydroxy-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
DM6WQ8F	CA	CAS 133805-03-5
DM6WQ8F	DE	Solid tumour/cancer

DM1SVQX	ID	DM1SVQX
DM1SVQX	DN	BE-16627B
DM1SVQX	HS	Terminated
DM1SVQX	SN	BE-16627B; 137530-61-1; be16627b; AC1L30CH; L-N-(N-Hydroxy-2-isobutylsuccinamoyl)seryl-L-valine; L-Valine, N-(N-(2-(2-(hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-seryl)-; (2S)-2-[[(2S)-3-hydroxy-2-[[2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]propanoyl]amino]-3-methylbutanoic acid
DM1SVQX	CP	MSD Japan
DM1SVQX	DT	Small molecular drug
DM1SVQX	PC	132070
DM1SVQX	MW	375.42
DM1SVQX	FM	C16H29N3O7
DM1SVQX	IC	InChI=1S/C16H29N3O7/c1-8(2)5-10(6-12(21)19-26)14(22)17-11(7-20)15(23)18-13(9(3)4)16(24)25/h8-11,13,20,26H,5-7H2,1-4H3,(H,17,22)(H,18,23)(H,19,21)(H,24,25)/t10?,11-,13-/m0/s1
DM1SVQX	CS	CC(C)CC(CC(=O)NO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O
DM1SVQX	IK	ZTDAMCPLHAKWAY-KUNJKIHDSA-N
DM1SVQX	IU	(2S)-2-[[(2S)-3-hydroxy-2-[[2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]propanoyl]amino]-3-methylbutanoic acid
DM1SVQX	CA	CAS 137530-61-1
DM1SVQX	DE	Inflammation

DM39SEK	ID	DM39SEK
DM39SEK	DN	BE-22179
DM39SEK	HS	Terminated
DM39SEK	SN	BE 22179; AC1L4UUG; AC1Q6NP2; SCHEMBL14221468; FD-179; n,n'-[(1r,7s,14r,20s)-2,12,15,25-tetramethyl-11,24-dimethylidene-3,6,10,13,16,19,23,26-octaoxo-9,22,28,29-tetrathia-2,5,12,15,18,25-hexaazabicyclo[12.12.4]triacontane-7,20-diyl]bis(3-hydroxyquinoline-2-carboxamide); 3-hydroxy-N-[(1R,7S,14R,20S)-7-[(3-hydroxyquinoline-2-carbonyl)amino]-2,12,15,25-tetramethyl-11,24-dimethylidene-3,6,10,13,16,19,23,26-octaoxo-9,22,28,29-tetrathia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-20-yl]quinoline-2-carboxamide
DM39SEK	CP	MSD Japan
DM39SEK	PC	9941484
DM39SEK	MW	1061.2
DM39SEK	FM	C46H48N10O12S4
DM39SEK	IC	InChI=1S/C46H48N10O12S4/c1-23-45(67)69-19-29(51-41(63)37-33(57)15-25-11-7-9-13-27(25)49-37)39(61)47-18-36(60)56(6)32-22-72-71-21-31(43(65)53(23)3)55(5)35(59)17-48-40(62)30(20-70-46(68)24(2)54(4)44(32)66)52-42(64)38-34(58)16-26-12-8-10-14-28(26)50-38/h7-16,29-32,57-58H,1-2,17-22H2,3-6H3,(H,47,61)(H,48,62)(H,51,63)(H,52,64)
DM39SEK	CS	CN1C2CSSCC(C(=O)N(C(=C)C(=O)SCC(C(=O)NCC1=O)NC(=O)C3=NC4=CC=CC=C4C=C3O)C)N(C(=O)CNC(=O)C(CSC(=O)C(=C)N(C2=O)C)NC(=O)C5=NC6=CC=CC=C6C=C5O)C
DM39SEK	IK	QLOZXPNJEDVFIH-UHFFFAOYSA-N
DM39SEK	IU	3-hydroxy-N-[20-[(3-hydroxyquinoline-2-carbonyl)amino]-2,12,15,25-tetramethyl-11,24-dimethylidene-3,6,10,13,16,19,23,26-octaoxo-9,22,28,29-tetrathia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-7-yl]quinoline-2-carboxamide
DM39SEK	DE	leukaemia

DM6KRJW	ID	DM6KRJW
DM6KRJW	DN	BEA-005
DM6KRJW	HS	Terminated
DM6KRJW	SN	HMddC; BEA-005; 3'-Hydroxymethyl-ddC; UNII-C7BPP68MLT; C7BPP68MLT; 2',3'-Dideoxy-3'-hydroxymethyl cytidine; 132235-73-5; AC1L9PVF; SCHEMBL598443; DTXSID60157443; 1-(2',3'-Dideoxy-3'-C-(hydroxymethyl)-beta-D-erythro-pentofuranosyl)cytosine; 2',3'-dideoxy-3'-c-(hydroxymethyl)cytidine; 4-amino-1-[(2R,4R,5S)-4,5-bis(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)-.beta.-D-erythro-pentofuranosyl]cytosine
DM6KRJW	CP	Medivir AB
DM6KRJW	DT	Small molecular drug
DM6KRJW	PC	451819
DM6KRJW	MW	241.24
DM6KRJW	FM	C10H15N3O4
DM6KRJW	IC	InChI=1S/C10H15N3O4/c11-8-1-2-13(10(16)12-8)9-3-6(4-14)7(5-15)17-9/h1-2,6-7,9,14-15H,3-5H2,(H2,11,12,16)/t6-,7-,9-/m1/s1
DM6KRJW	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)CO
DM6KRJW	IK	WZGBNAXNHRMYLG-ZXFLCMHBSA-N
DM6KRJW	IU	4-amino-1-[(2R,4R,5S)-4,5-bis(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DM6KRJW	CA	CAS 132235-73-5
DM6KRJW	DE	Cytomegalovirus infection

DMGAPH1	ID	DMGAPH1
DMGAPH1	DN	Befiperide
DMGAPH1	HS	Terminated
DMGAPH1	CP	Solvay Pharmaceuticals BV
DMGAPH1	PC	182859
DMGAPH1	MW	405.5
DMGAPH1	FM	C25H31N3O2
DMGAPH1	IC	InChI=1S/C25H31N3O2/c1-19(2)20-7-9-22(10-8-20)25(29)26(3)12-13-27-14-16-28(17-15-27)23-6-4-5-21-11-18-30-24(21)23/h4-11,18-19H,12-17H2,1-3H3
DMGAPH1	CS	CC(C)C1=CC=C(C=C1)C(=O)N(C)CCN2CCN(CC2)C3=CC=CC4=C3OC=C4
DMGAPH1	IK	XZHMFCUWVDUYBV-UHFFFAOYSA-N
DMGAPH1	IU	N-[2-[4-(1-benzofuran-7-yl)piperazin-1-yl]ethyl]-N-methyl-4-propan-2-ylbenzamide
DMGAPH1	CA	CAS 100927-14-8
DMGAPH1	DE	Anxiety disorder

DMM0ZIJ	ID	DMM0ZIJ
DMM0ZIJ	DN	Belaperidone
DMM0ZIJ	HS	Terminated
DMM0ZIJ	SN	Balaperidone; Belaperidone [INN]; LU 111995; LU-111995; 3-[2-[(1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]heptan-3-yl]ethyl]-1H-quinazoline-2,4-dione; 3-{2-[(1s,5r,6s)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl}quinazoline-2,4(1h,3h)-dione
DMM0ZIJ	CP	Abbott
DMM0ZIJ	DT	Small molecular drug
DMM0ZIJ	PC	184841
DMM0ZIJ	MW	379.4
DMM0ZIJ	FM	C22H22FN3O2
DMM0ZIJ	IC	InChI=1S/C22H22FN3O2/c23-16-7-5-14(6-8-16)18-11-15-12-25(13-19(15)18)9-10-26-21(27)17-3-1-2-4-20(17)24-22(26)28/h1-8,15,18-19H,9-13H2,(H,24,28)/t15-,18-,19+/m1/s1
DMM0ZIJ	CS	C1[C@@H]2CN(C[C@@H]2[C@H]1C3=CC=C(C=C3)F)CCN4C(=O)C5=CC=CC=C5NC4=O
DMM0ZIJ	IK	XLJWJFKYRFPJSD-LZQZEXGQSA-N
DMM0ZIJ	IU	3-[2-[(1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]heptan-3-yl]ethyl]-1H-quinazoline-2,4-dione
DMM0ZIJ	CA	CAS 208661-17-0
DMM0ZIJ	DE	Schizophrenia

DMXH3A2	ID	DMXH3A2
DMXH3A2	DN	Benafentrine dimaleate
DMXH3A2	HS	Terminated
DMXH3A2	SN	AH-21-132; Benafentrine dimaleate; Cis-6-(4-Acetamidophenyl)-8,9-dimethoxy-2-methyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridine bis(hydrogenmaleate); Cis-4'-(1,2,3,4,4a,10b-Hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl)acetanilide bis(hydrogenmaleate); Cis-N-[4-(1,2,3,4,4a,10b-Hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl)phenyl]acetamide (Z)-2-butenedioate (1:2)
DMXH3A2	DT	Small molecular drug
DMXH3A2	PC	6438805
DMXH3A2	MW	625.6
DMXH3A2	FM	C31H35N3O11
DMXH3A2	IC	InChI=1S/C23H27N3O3.2C4H4O4/c1-14(27)24-16-7-5-15(6-8-16)23-18-12-22(29-4)21(28-3)11-17(18)19-13-26(2)10-9-20(19)25-23;2*5-3(6)1-2-4(7)8/h5-8,11-12,19-20H,9-10,13H2,1-4H3,(H,24,27);2*1-2H,(H,5,6)(H,7,8)/b;2*2-1+/t19-,20-;;/m1../s1
DMXH3A2	CS	CC(=O)NC1=CC=C(C=C1)C2=N[C@H]3[C@@H](C4=CC(=C(C=C24)OC)OC)CN(CC3)C.C(=C/C(=O)O)\\C(=O)O.C(=C/C(=O)O)\\C(=O)O
DMXH3A2	IK	BWJFLHODOYZAML-GODXOYSCSA-N
DMXH3A2	IU	N-[4-[(4aR,10bS)-8,9-dimethoxy-2-methyl-3,4,4a,10b-tetrahydro-1H-benzo[c][1,6]naphthyridin-6-yl]phenyl]acetamide;(E)-but-2-enedioic acid
DMXH3A2	CA	CAS 76166-55-7
DMXH3A2	DE	Sepsis

DMVK78Q	ID	DMVK78Q
DMVK78Q	DN	Bepafant
DMVK78Q	HS	Terminated
DMVK78Q	SN	STY-2108; WEB-2170
DMVK78Q	CP	Boehringer Ingelheim Corp
DMVK78Q	DT	Small molecular drug
DMVK78Q	PC	65923
DMVK78Q	MW	468
DMVK78Q	FM	C23H22ClN5O2S
DMVK78Q	IC	InChI=1S/C23H22ClN5O2S/c1-13-26-27-19-12-25-21(15-4-2-3-5-17(15)24)20-16-10-14(11-18(16)32-23(20)29(13)19)22(30)28-6-8-31-9-7-28/h2-5,14H,6-12H2,1H3
DMVK78Q	CS	CC1=NN=C2N1C3=C(C4=C(S3)CC(C4)C(=O)N5CCOCC5)C(=NC2)C6=CC=CC=C6Cl
DMVK78Q	IK	FWYVRZOREBYLCY-UHFFFAOYSA-N
DMVK78Q	IU	[9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetrazatetracyclo[8.6.0.02,6.011,15]hexadeca-1(10),3,5,8,11(15)-pentaen-13-yl]-morpholin-4-ylmethanone
DMVK78Q	CA	CAS 114776-28-2
DMVK78Q	DE	Sepsis

DMXRTFM	ID	DMXRTFM
DMXRTFM	DN	Ber-H2/saporin
DMXRTFM	HS	Terminated
DMXRTFM	DT	Antibody

DMQA4JU	ID	DMQA4JU
DMQA4JU	DN	Berlafenone
DMQA4JU	HS	Terminated
DMQA4JU	SN	Bipranol; GK-23G
DMQA4JU	CP	Helopharm
DMQA4JU	DT	Small molecular drug
DMQA4JU	PC	65691
DMQA4JU	MW	299.4
DMQA4JU	FM	C19H25NO2
DMQA4JU	IC	InChI=1S/C19H25NO2/c1-19(2,3)20-13-16(21)14-22-18-12-8-7-11-17(18)15-9-5-4-6-10-15/h4-12,16,20-21H,13-14H2,1-3H3
DMQA4JU	CS	CC(C)(C)NCC(COC1=CC=CC=C1C2=CC=CC=C2)O
DMQA4JU	IK	DBHPVKNFKBKJCE-UHFFFAOYSA-N
DMQA4JU	IU	1-(tert-butylamino)-3-(2-phenylphenoxy)propan-2-ol
DMQA4JU	CA	CAS 18965-97-4
DMQA4JU	DE	Heart arrhythmia

DM56WD3	ID	DM56WD3
DM56WD3	DN	Bertosamil
DM56WD3	HS	Terminated
DM56WD3	SN	Bertosamil; 126825-36-3; SCHEMBL379798; CHEMBL2104579; AOIVZQPSIHOHMP-HDICACEKSA-N
DM56WD3	CP	Solvay Pharmaceuticals GmbH
DM56WD3	DT	Small molecular drug
DM56WD3	PC	16092093
DM56WD3	MW	292.5
DM56WD3	FM	C19H36N2
DM56WD3	IC	InChI=1S/C19H36N2/c1-15(2)10-20-11-17-13-21(16(3)4)14-18(12-20)19(17)8-6-5-7-9-19/h15-18H,5-14H2,1-4H3/t17-,18-/m0/s1
DM56WD3	CS	CC(C)CN1C[C@H]2CN(C[C@H](C1)C23CCCCC3)C(C)C
DM56WD3	IK	AOIVZQPSIHOHMP-ROUUACIJSA-N
DM56WD3	IU	(1S,5S)-3-(2-methylpropyl)-7-propan-2-ylspiro[3,7-diazabicyclo[3.3.1]nonane-9,1'-cyclohexane]
DM56WD3	CA	CAS 126825-36-3
DM56WD3	DE	Angina pectoris

DMH7YD4	ID	DMH7YD4
DMH7YD4	DN	Bexlosteride
DMH7YD4	HS	Terminated
DMH7YD4	SN	LY-191704
DMH7YD4	DT	Small molecular drug
DMH7YD4	PC	166562
DMH7YD4	MW	249.73
DMH7YD4	FM	C14H16ClNO
DMH7YD4	IC	InChI=1S/C14H16ClNO/c1-16-13-6-2-9-8-10(15)3-4-11(9)12(13)5-7-14(16)17/h3-4,8,12-13H,2,5-7H2,1H3/t12-,13-/m1/s1
DMH7YD4	CS	CN1[C@@H]2CCC3=C([C@H]2CCC1=O)C=CC(=C3)Cl
DMH7YD4	IK	WQBIOEFDDDEARX-CHWSQXEVSA-N
DMH7YD4	IU	(4aR,10bR)-8-chloro-4-methyl-1,2,4a,5,6,10b-hexahydrobenzo[f]quinolin-3-one
DMH7YD4	CA	CAS 148905-78-6

DM6QT9P	ID	DM6QT9P
DM6QT9P	DN	BIBB-515
DM6QT9P	HS	Terminated
DM6QT9P	SN	BIBB 515; BIBB-515; 156635-05-1; UNII-CG2Q6688S4; CHEMBL417571; CG2Q6688S4; (4-Chloro-phenyl)-{4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-methanone; (4-chloro-phenyl)-(4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl)-methanone; AC1L9UY8; SCHEMBL3676833; CTK8E8258; DTXSID00333401; MolPort-009-019-333; ZINC598970; BDBM50128071; RT-011501; J-009325; 1-(4-Chlorobenzoyl)-4-((4-(2-oxazolin-2-yl) benzylidene))piperidine; Piperidine, 1-(4-chlorobenzoyl)-4-((4-(4,5-dihydro-2-oxazolyl)phenyl)methylene)-
DM6QT9P	CP	Dr Karl Thomae GmbH
DM6QT9P	DT	Small molecular drug
DM6QT9P	PC	501398
DM6QT9P	MW	380.9
DM6QT9P	FM	C22H21ClN2O2
DM6QT9P	IC	InChI=1S/C22H21ClN2O2/c23-20-7-5-19(6-8-20)22(26)25-12-9-17(10-13-25)15-16-1-3-18(4-2-16)21-24-11-14-27-21/h1-8,15H,9-14H2
DM6QT9P	CS	C1CN(CCC1=CC2=CC=C(C=C2)C3=NCCO3)C(=O)C4=CC=C(C=C4)Cl
DM6QT9P	IK	JQNWPWUJMRAASQ-UHFFFAOYSA-N
DM6QT9P	IU	(4-chlorophenyl)-[4-[[4-(4,5-dihydro-1,3-oxazol-2-yl)phenyl]methylidene]piperidin-1-yl]methanone
DM6QT9P	CA	CAS 156635-05-1
DM6QT9P	DE	Arteriosclerosis

DM019Y7	ID	DM019Y7
DM019Y7	DN	BIBN-140
DM019Y7	HS	Terminated
DM019Y7	SN	Bibn 140; 145301-79-7; SCHEMBL8879830; Pentanamide, N-(3-(1-(2-(10,11-dihydro-11-oxo-5H-dibenzo(b,e)(1,4)diazepin-5-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-
DM019Y7	CP	Boehringer Ingelheim Corp
DM019Y7	DT	Small molecular drug
DM019Y7	PC	10030021
DM019Y7	MW	532.7
DM019Y7	FM	C32H44N4O3
DM019Y7	IC	InChI=1S/C32H44N4O3/c1-5-19-32(3,4)31(39)35(6-2)20-11-12-24-17-21-34(22-18-24)23-29(37)36-27-15-9-7-13-25(27)30(38)33-26-14-8-10-16-28(26)36/h7-10,13-16,24H,5-6,11-12,17-23H2,1-4H3,(H,33,38)
DM019Y7	CS	CCCC(C)(C)C(=O)N(CC)CCCC1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=CC=CC=C42
DM019Y7	IK	LOAZWNRCWBWKAC-UHFFFAOYSA-N
DM019Y7	IU	N-ethyl-2,2-dimethyl-N-[3-[1-[2-oxo-2-(6-oxo-5H-benzo[b][1,4]benzodiazepin-11-yl)ethyl]piperidin-4-yl]propyl]pentanamide
DM019Y7	CA	CAS 145301-79-7
DM019Y7	DE	Alzheimer disease

DMZTPCX	ID	DMZTPCX
DMZTPCX	DN	BIBN-99
DMZTPCX	HS	Terminated
DMZTPCX	SN	Bibn-99; Bibn 99; 145301-48-0; AC1L31GK; SCHEMBL194898; DTXSID00162975; N-(3-(1-(2-(8-Chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethylpentanamide; L008252; N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide; Pentanamide, N-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-
DMZTPCX	CP	Boehringer Ingelheim Corp
DMZTPCX	DT	Small molecular drug
DMZTPCX	PC	132712
DMZTPCX	MW	568.1
DMZTPCX	FM	C31H42ClN5O3
DMZTPCX	IC	InChI=1S/C31H42ClN5O3/c1-5-15-31(3,4)30(40)36(6-2)17-8-9-22-13-18-35(19-14-22)21-27(38)37-26-12-11-23(32)20-24(26)29(39)34-25-10-7-16-33-28(25)37/h7,10-12,16,20,22H,5-6,8-9,13-15,17-19,21H2,1-4H3,(H,34,39)
DMZTPCX	CS	CCCC(C)(C)C(=O)N(CC)CCCC1CCN(CC1)CC(=O)N2C3=C(C=C(C=C3)Cl)C(=O)NC4=C2N=CC=C4
DMZTPCX	IK	LUPAFPUKESJDMZ-UHFFFAOYSA-N
DMZTPCX	IU	N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide
DMZTPCX	CA	CAS 145301-48-0
DMZTPCX	DE	Alzheimer disease

DMYBR9D	ID	DMYBR9D
DMYBR9D	DN	BIBP 3226
DMYBR9D	HS	Terminated
DMYBR9D	SN	KUWBXRGRMQZCSS-HSZRJFAPSA-N; BIBP3226; 159013-54-4; BIBP-3226; CHEMBL332347; N2-(Diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D-arginine amide; BIBP 3226 TRIFLUOROACETATE; [3H]BIBP3226; [3H]-BIBP3226; (2R)-5-(diaminomethylideneamino)-2-[[2,2-di(phenyl)acetyl]amino]-N-[(4-hydroxyphenyl)methyl]pentanamide; AC1NSJUK; SCHEMBL650331; GTPL3474; GTPL1485; DTXSID30415502; ZINC3811314; MFCD00938562; BDBM50060728; AKOS034831590; 102691-EP2301936A1; 102691-EP2272841A1; (R)-2-Diphenylacetylamino-5-guanidino-pentanoic acid 4-hydroxy-benzylamide
DMYBR9D	DT	Small molecular drug
DMYBR9D	PC	5311023
DMYBR9D	MW	473.6
DMYBR9D	FM	C27H31N5O3
DMYBR9D	IC	InChI=1S/C27H31N5O3/c28-27(29)30-17-7-12-23(25(34)31-18-19-13-15-22(33)16-14-19)32-26(35)24(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-6,8-11,13-16,23-24,33H,7,12,17-18H2,(H,31,34)(H,32,35)(H4,28,29,30)/t23-/m1/s1
DMYBR9D	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)O
DMYBR9D	IK	KUWBXRGRMQZCSS-HSZRJFAPSA-N
DMYBR9D	IU	(2R)-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]-N-[(4-hydroxyphenyl)methyl]pentanamide
DMYBR9D	CA	CAS 159013-54-4
DMYBR9D	DE	Hypertension

DM5107E	ID	DM5107E
DM5107E	DN	BIBS-222
DM5107E	HS	Terminated
DM5107E	SN	Benzoic acid,2-[[[4-[[2-butyl-6-[[(methylamino)carbonyl]pentylamino]-1H-benzimidazol-1-yl]methyl]phenyl]amino]carbonyl]-3,6-dichloro-; ACMC-20n14b
DM5107E	CP	Boehringer Ingelheim Corp
DM5107E	DT	Small molecular drug
DM5107E	PC	132404
DM5107E	MW	638.6
DM5107E	FM	C33H37Cl2N5O4
DM5107E	IC	InChI=1S/C33H37Cl2N5O4/c1-4-6-8-18-39(33(44)36-3)23-14-17-26-27(19-23)40(28(38-26)9-7-5-2)20-21-10-12-22(13-11-21)37-31(41)29-24(34)15-16-25(35)30(29)32(42)43/h10-17,19H,4-9,18,20H2,1-3H3,(H,36,44)(H,37,41)(H,42,43)
DM5107E	CS	CCCCCN(C1=CC2=C(C=C1)N=C(N2CC3=CC=C(C=C3)NC(=O)C4=C(C=CC(=C4C(=O)O)Cl)Cl)CCCC)C(=O)NC
DM5107E	IK	ZHWGRXBJGUEATA-UHFFFAOYSA-N
DM5107E	IU	2-[[4-[[2-butyl-6-[methylcarbamoyl(pentyl)amino]benzimidazol-1-yl]methyl]phenyl]carbamoyl]-3,6-dichlorobenzoic acid
DM5107E	CA	CAS 142023-57-2
DM5107E	DE	Hypertension

DM098BL	ID	DM098BL
DM098BL	DN	BIBS-39
DM098BL	HS	Terminated
DM098BL	SN	Bibs 39; 133085-33-3; BIBS39; CHEMBL130896; 2-[4-[[2-butyl-6-(cyclohexylcarbamoylamino)benzimidazol-1-yl]methyl]phenyl]benzoic acid; AC1L2ZGG; SCHEMBL6567316; DTXSID60157943; BCP17735; BDBM50035429; ZINC11687040; AKOS030526411; CS-5552; HY-19732; 4'-((2-n-Butyl-6-cyclohexylaminocarbonylaminobenzimidazole-1-yl)methyl)biphenyl-2-carboxylic acid; KB-227067; FT-0700165; 4''-[2-Butyl-6-(3-cyclohexyl-ureido)-benzoimidazol-1-ylmethyl]-biphenyl-2-carboxylic acid; (1,1'-Biphenyl)-2-carboxylic acid, 4'-((2-butyl-6-(((cyclohexylamino)c
DM098BL	CP	Boehringer Ingelheim Corp
DM098BL	DT	Small molecular drug
DM098BL	PC	131590
DM098BL	MW	524.7
DM098BL	FM	C32H36N4O3
DM098BL	IC	InChI=1S/C32H36N4O3/c1-2-3-13-30-35-28-19-18-25(34-32(39)33-24-9-5-4-6-10-24)20-29(28)36(30)21-22-14-16-23(17-15-22)26-11-7-8-12-27(26)31(37)38/h7-8,11-12,14-20,24H,2-6,9-10,13,21H2,1H3,(H,37,38)(H2,33,34,39)
DM098BL	CS	CCCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2)NC(=O)NC5CCCCC5
DM098BL	IK	OLQFKFSAJNUOPT-UHFFFAOYSA-N
DM098BL	IU	2-[4-[[2-butyl-6-(cyclohexylcarbamoylamino)benzimidazol-1-yl]methyl]phenyl]benzoic acid
DM098BL	CA	CAS 133085-33-3
DM098BL	DE	Hypertension

DMMNI5K	ID	DMMNI5K
DMMNI5K	DN	BIBU-251
DMMNI5K	HS	Terminated
DMMNI5K	CP	Boehringer Ingelheim Corp
DMMNI5K	DE	Thrombosis

DMXIH3Q	ID	DMXIH3Q
DMXIH3Q	DN	BIBW-22
DMXIH3Q	HS	Terminated
DMXIH3Q	SN	RMKP-22; BIBW-22-BS
DMXIH3Q	CP	Boehringer Ingelheim Corp
DMXIH3Q	DT	Small molecular drug
DMXIH3Q	PC	132088
DMXIH3Q	MW	565.7
DMXIH3Q	FM	C30H43N7O4
DMXIH3Q	IC	InChI=1S/C30H43N7O4/c1-19-14-36(15-20(2)40-19)27-24(23-10-8-7-9-11-23)31-25-26(32-27)33-29(37-16-21(3)41-22(4)17-37)34-28(25)35(12-13-38)18-30(5,6)39/h7-11,19-22,38-39H,12-18H2,1-6H3/t19-,20+,21-,22+
DMXIH3Q	CS	C[C@@H]1CN(C[C@@H](O1)C)C2=NC3=C(C(=NC(=N3)N4C[C@H](O[C@H](C4)C)C)N(CCO)CC(C)(C)O)N=C2C5=CC=CC=C5
DMXIH3Q	IK	JNHIGDFEPXMPAO-COPRSSIGSA-N
DMXIH3Q	IU	1-[[2,7-bis[(2R,6S)-2,6-dimethylmorpholin-4-yl]-6-phenylpteridin-4-yl]-(2-hydroxyethyl)amino]-2-methylpropan-2-ol
DMXIH3Q	CA	CAS 137694-16-7
DMXIH3Q	DE	Solid tumour/cancer

DMRXWCO	ID	DMRXWCO
DMRXWCO	DN	BIBX-79
DMRXWCO	HS	Terminated
DMRXWCO	SN	175033-26-8; BIBX-79; AC1L9UY2; BIBX 79; SCHEMBL8046646; SCHEMBL3363189; CHEMBL2377448; CHEMBL3765649; MolPort-028-951-512; ZINC59696570; ZINC238856506; ZINC100502012; AKOS034800865; MCULE-9414485243; EN300-155171; Z1768160684; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methyl-benzamide; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methylbenzamide; 4-Chloro-N-[4-(4-dimethylaminomethyl-phenyl)-cyclohexyl]-N-methyl-benzamide
DMRXWCO	CP	Boehringer Ingelheim Corp
DMRXWCO	DT	Small molecular drug
DMRXWCO	PC	501396
DMRXWCO	MW	384.9
DMRXWCO	FM	C23H29ClN2O
DMRXWCO	IC	InChI=1S/C23H29ClN2O/c1-25(2)16-17-4-6-18(7-5-17)19-10-14-22(15-11-19)26(3)23(27)20-8-12-21(24)13-9-20/h4-9,12-13,19,22H,10-11,14-16H2,1-3H3
DMRXWCO	CS	CN(C)CC1=CC=C(C=C1)C2CCC(CC2)N(C)C(=O)C3=CC=C(C=C3)Cl
DMRXWCO	IK	WBNUHWUTAHSPER-UHFFFAOYSA-N
DMRXWCO	IU	4-chloro-N-[4-[4-[(dimethylamino)methyl]phenyl]cyclohexyl]-N-methylbenzamide
DMRXWCO	DE	Arteriosclerosis

DMU73F0	ID	DMU73F0
DMU73F0	DN	Bifemelane
DMU73F0	HS	Terminated
DMU73F0	SN	Alnert; Celeport; E-0687; MCI-2016; SON-216
DMU73F0	CP	Mitsubishi-Tokyo Pharmaceuticals Inc
DMU73F0	DT	Small molecular drug
DMU73F0	PC	2377
DMU73F0	MW	269.4
DMU73F0	FM	C18H23NO
DMU73F0	IC	InChI=1S/C18H23NO/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16/h2-6,9-12,19H,7-8,13-15H2,1H3
DMU73F0	CS	CNCCCCOC1=CC=CC=C1CC2=CC=CC=C2
DMU73F0	IK	QSQQPMHPCBLLGX-UHFFFAOYSA-N
DMU73F0	IU	4-(2-benzylphenoxy)-N-methylbutan-1-amine
DMU73F0	CA	CAS 90293-01-9
DMU73F0	CB	CHEBI:92338
DMU73F0	DE	Alzheimer disease

DMBR48G	ID	DMBR48G
DMBR48G	DN	BI-L-357
DMBR48G	HS	Terminated
DMBR48G	SN	BI-L-226
DMBR48G	CP	Boehringer Ingelheim Corp
DMBR48G	DT	Small molecular drug
DMBR48G	PC	6440014
DMBR48G	MW	330.4
DMBR48G	FM	C18H18O4S
DMBR48G	IC	InChI=1S/C18H18O4S/c1-12-10-14(5-6-15-4-3-9-23-15)11-13(2)18(12)22-17(21)8-7-16(19)20/h3-6,9-11H,7-8H2,1-2H3,(H,19,20)/b6-5+
DMBR48G	CS	CC1=CC(=CC(=C1OC(=O)CCC(=O)O)C)/C=C/C2=CC=CS2
DMBR48G	IK	OIDYLVFJAIPWBI-AATRIKPKSA-N
DMBR48G	IU	4-[2,6-dimethyl-4-[(E)-2-thiophen-2-ylethenyl]phenoxy]-4-oxobutanoic acid
DMBR48G	CA	CAS 125722-33-0
DMBR48G	DE	Asthma

DMRV4UL	ID	DMRV4UL
DMRV4UL	DN	BILA-2157BS
DMRV4UL	HS	Terminated
DMRV4UL	CP	Boehringer Ingelheim Corp
DMRV4UL	PC	10509124
DMRV4UL	MW	727
DMRV4UL	FM	C39H62N6O5S
DMRV4UL	IC	InChI=1S/C39H62N6O5S/c1-27(2)20-34(46)37(49)33(21-28-12-6-4-7-13-28)43-38(50)30(22-32-26-51-39(40)42-32)23-35(47)45(24-29-14-8-5-9-15-29)25-36(48)44(3)19-17-31-16-10-11-18-41-31/h10-11,16,18,26-30,33-34,37,46,49H,4-9,12-15,17,19-25H2,1-3H3,(H2,40,42)(H,43,50)/t30-,33-,34-,37+/m0/s1
DMRV4UL	CS	CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@@H](CC2=CSC(=N2)N)CC(=O)N(CC3CCCCC3)CC(=O)N(C)CCC4=CC=CC=N4)O)O
DMRV4UL	IK	RTFZIRGGIOYLOO-KGVCAXOZSA-N
DMRV4UL	IU	(2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N-[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]-N'-(cyclohexylmethyl)-N'-[2-[methyl(2-pyridin-2-ylethyl)amino]-2-oxoethyl]butanediamide
DMRV4UL	DE	Hypertension

DMUOPBF	ID	DMUOPBF
DMUOPBF	DN	BILD-1263
DMUOPBF	HS	Terminated
DMUOPBF	CP	Bio-Mega Research Division
DMUOPBF	DT	Small molecular drug
DMUOPBF	PC	513004
DMUOPBF	MW	917.2
DMUOPBF	FM	C51H76N6O9
DMUOPBF	IC	InChI=1S/C51H76N6O9/c1-33(2)40(56(9)47(64)36(28-34-20-12-10-13-21-34)29-35-22-14-11-15-23-35)44(61)54-41(50(6,7)8)45(62)53-38(30-39(59)57-26-18-19-27-57)43(60)55-42(51(48(65)66)24-16-17-25-51)46(63)52-37(32-58)31-49(3,4)5/h10-15,20-23,33,36-38,40-42,58H,16-19,24-32H2,1-9H3,(H,52,63)(H,53,62)(H,54,61)(H,55,60)(H,65,66)/t37-,38-,40-,41+,42+/m0/s1
DMUOPBF	CS	CC(C)[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)N1CCCC1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)(C)C)CO)C2(CCCC2)C(=O)O)C(C)(C)C)N(C)C(=O)C(CC3=CC=CC=C3)CC4=CC=CC=C4
DMUOPBF	IK	ZEZGINAYPYMJJU-HOMVEOSBSA-N
DMUOPBF	IU	1-[(1S)-1-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzyl-3-phenylpropanoyl)-methylamino]-3-methylbutanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-oxo-4-pyrrolidin-1-ylbutanoyl]amino]-2-[[(2S)-1-hydroxy-4,4-dimethylpentan-2-yl]amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMUOPBF	DE	Herpes simplex virus infection

DMR01WE	ID	DMR01WE
DMR01WE	DN	BILD-1351
DMR01WE	HS	Terminated
DMR01WE	SN	BILD-1351-SE
DMR01WE	CP	Bio-Mega Research Division
DMR01WE	DT	Small molecular drug
DMR01WE	PC	5478827
DMR01WE	MW	705
DMR01WE	FM	C39H68N4O7
DMR01WE	IC	InChI=1S/C39H68N4O7/c1-13-27(36(4,5)6)40-33(47)31(39(34(48)49)19-14-15-20-39)42-32(46)25(22-28(45)37(7,8)9)21-26(44)30(38(10,11)12)43-35(50)41-29-23(2)17-16-18-24(29)3/h23-25,27,29-31H,13-22H2,1-12H3,(H,40,47)(H,42,46)(H,48,49)(H2,41,43,50)/t23-,24+,25-,27+,29?,30+,31+/m0/s1
DMR01WE	CS	CC[C@H](C(C)(C)C)NC(=O)[C@H](C1(CCCC1)C(=O)O)NC(=O)[C@@H](CC(=O)[C@H](C(C)(C)C)NC(=O)NC2[C@@H](CCC[C@@H]2C)C)CC(=O)C(C)(C)C
DMR01WE	IK	BICMJCLCIQRONK-CVXWQFLKSA-N
DMR01WE	IU	1-[(1S)-1-[[(2R,5S)-5-[[(2S,6R)-2,6-dimethylcyclohexyl]carbamoylamino]-2-(3,3-dimethyl-2-oxobutyl)-6,6-dimethyl-4-oxoheptanoyl]amino]-2-[[(3R)-2,2-dimethylpentan-3-yl]amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMR01WE	DE	Herpes simplex virus infection

DMZMUG2	ID	DMZMUG2
DMZMUG2	DN	BILD-1357
DMZMUG2	HS	Terminated
DMZMUG2	SN	BILD 1357; AC1LAKBO; 1-[[2-(2-{2-[(2-Benzyl-4-phenyl-butyryl)-methyl-amino]-3-methyl-butyrylamino}-3,3-dimethyl-butyrylamino)-4-oxo-4-pyrrolidin-1-yl-butyrylamino]-(1-ethyl-2,2-dimethyl-propylcarbamoyl)-methyl]-cyclopentanecarboxylic acid; 1-[(1S)-1-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzyl-4-phenylbutanoyl)-methylamino]-3-methylbutanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-oxo-4-pyrrolidin-1-ylbutanoyl]amino]-2-[[(3R)-2,2-dimethylpentan-3-yl]amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMZMUG2	CP	Bio-Mega Research Division
DMZMUG2	DT	Small molecular drug
DMZMUG2	PC	9832760
DMZMUG2	MW	901.2
DMZMUG2	FM	C51H76N6O8
DMZMUG2	IC	InChI=1S/C51H76N6O8/c1-11-38(49(4,5)6)53-46(62)42(51(48(64)65)26-18-19-27-51)55-43(59)37(32-39(58)57-28-20-21-29-57)52-45(61)41(50(7,8)9)54-44(60)40(33(2)3)56(10)47(63)36(30-34-22-14-12-15-23-34)31-35-24-16-13-17-25-35/h12-17,22-25,33,36-38,40-42H,11,18-21,26-32H2,1-10H3,(H,52,61)(H,53,62)(H,54,60)(H,55,59)(H,64,65)/t37-,38+,40-,41+,42+/m0/s1
DMZMUG2	CS	CC[C@H](C(C)(C)C)NC(=O)[C@H](C1(CCCC1)C(=O)O)NC(=O)[C@H](CC(=O)N2CCCC2)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)C(CC3=CC=CC=C3)CC4=CC=CC=C4
DMZMUG2	IK	QRACUPFHILQVKO-ZEIRWQBWSA-N
DMZMUG2	IU	1-[(1S)-1-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzyl-3-phenylpropanoyl)-methylamino]-3-methylbutanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-oxo-4-pyrrolidin-1-ylbutanoyl]amino]-2-[[(3R)-2,2-dimethylpentan-3-yl]amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMZMUG2	DE	Herpes simplex virus infection

DMAU5WL	ID	DMAU5WL
DMAU5WL	DN	BILD-733
DMAU5WL	HS	Terminated
DMAU5WL	CP	Boehringer Ingelheim Corp
DMAU5WL	DT	Small molecular drug
DMAU5WL	PC	101684726
DMAU5WL	MW	827.1
DMAU5WL	FM	C44H70N6O9
DMAU5WL	IC	InChI=1S/C44H70N6O9/c1-28(2)34(49(9)32(52)20-19-29-17-11-10-12-18-29)38(55)47-35(43(6,7)8)39(56)46-31(25-33(53)50-23-15-16-24-50)37(54)48-36(44(41(58)59)21-13-14-22-44)40(57)45-30(27-51)26-42(3,4)5/h10-12,17-18,28,30-31,34-36,51H,13-16,19-27H2,1-9H3,(H,45,57)(H,46,56)(H,47,55)(H,48,54)(H,58,59)/t30?,31-,34-,35+,36+/m0/s1
DMAU5WL	CS	CC(C)[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)N1CCCC1)C(=O)N[C@H](C(=O)NC(CC(C)(C)C)CO)C2(CCCC2)C(=O)O)C(C)(C)C)N(C)C(=O)CCC3=CC=CC=C3
DMAU5WL	IK	KEQHTXSUCBEFIM-GSKLOGINSA-N
DMAU5WL	IU	1-[(1S)-1-[[(2S)-2-[[(2S)-3,3-dimethyl-2-[[(2S)-3-methyl-2-[methyl(3-phenylpropanoyl)amino]butanoyl]amino]butanoyl]amino]-4-oxo-4-pyrrolidin-1-ylbutanoyl]amino]-2-[(1-hydroxy-4,4-dimethylpentan-2-yl)amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMAU5WL	DE	Herpes simplex virus infection

DM9X1DZ	ID	DM9X1DZ
DM9X1DZ	DN	BIMG80
DM9X1DZ	HS	Terminated
DM9X1DZ	CP	Boehringer Ingelheim Corp
DM9X1DZ	PC	9866050
DM9X1DZ	MW	406.5
DM9X1DZ	FM	C25H27FN2O2
DM9X1DZ	IC	InChI=1S/C25H27FN2O2/c1-30-22-10-11-24-23(15-22)20(16-27-24)14-18-4-2-12-28(17-18)13-3-5-25(29)19-6-8-21(26)9-7-19/h4,6-11,15-16,27H,2-3,5,12-14,17H2,1H3
DM9X1DZ	CS	COC1=CC2=C(C=C1)NC=C2CC3=CCCN(C3)CCCC(=O)C4=CC=C(C=C4)F
DM9X1DZ	IK	CIPFPNCFILKTBF-UHFFFAOYSA-N
DM9X1DZ	IU	1-(4-fluorophenyl)-4-[5-[(5-methoxy-1H-indol-3-yl)methyl]-3,6-dihydro-2H-pyridin-1-yl]butan-1-one
DM9X1DZ	DE	Psychotic disorder

DMKNS10	ID	DMKNS10
DMKNS10	DN	BIPHALIN
DMKNS10	HS	Terminated
DMKNS10	SN	Biphalin; (Tyr-ala-gly-phe-NH2)2; D-Enk-O; Dala(2); D-ENK; Bis(tyr-ala-gly-phenh2)hydrazide; CHEMBL200199; 83916-01-2; (Tyrosyl-alanyl-glycyl-phenylalaninamide)dimer; Bis(tyrosyl-alanyl-glycyl-phenylalaninamide)hydrazide; L-Phenylalanine, N-(N-(N-L-tyrosyl-D-alanyl)glycyl)-, 2-(N-(N-(N-L-tyrosyl-D-alanyl)glycyl)-L-phenylalanyl)hydrazide; enkephalin dimer; AC1NUPQ3; BDBM21014; DTXSID80232802; ZINC150345473; LS-187519; LS-186863
DMKNS10	DT	Small molecular drug
DMKNS10	PC	5487663
DMKNS10	MW	909
DMKNS10	FM	C46H56N10O10
DMKNS10	IC	InChI=1S/C46H56N10O10/c1-27(51-43(63)35(47)21-31-13-17-33(57)18-14-31)41(61)49-25-39(59)53-37(23-29-9-5-3-6-10-29)45(65)55-56-46(66)38(24-30-11-7-4-8-12-30)54-40(60)26-50-42(62)28(2)52-44(64)36(48)22-32-15-19-34(58)20-16-32/h3-20,27-28,35-38,57-58H,21-26,47-48H2,1-2H3,(H,49,61)(H,50,62)(H,51,63)(H,52,64)(H,53,59)(H,54,60)(H,55,65)(H,56,66)/t27-,28-,35+,36+,37+,38+/m1/s1
DMKNS10	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMKNS10	IK	DESSEGDLRYOPTJ-VRANXALZSA-N
DMKNS10	IU	(2S)-2-amino-N-[(2R)-1-[[2-[[(2S)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
DMKNS10	CA	CAS 83916-01-2

DMKRBL2	ID	DMKRBL2
DMKRBL2	DN	Bisbenzimide
DMKRBL2	HS	Terminated
DMKRBL2	SN	Hoechst 33342; 23491-52-3; Bisbenzimide; hoechst33342; UNII-99KZS6CNZX; Ho 342; 2'-(4-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-1H,1'H-2,5'-bibenzo[d]imidazole; EINECS 245-691-1; 99KZS6CNZX; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-benzimidazole; CHEMBL343002; CHEBI:51232; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazole; 2'-(4'-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bis-1H-benzimidazole trihydrochloride trihydrate
DMKRBL2	DT	Small molecular drug
DMKRBL2	PC	1464
DMKRBL2	MW	452.6
DMKRBL2	FM	C27H28N6O
DMKRBL2	IC	InChI=1S/C27H28N6O/c1-3-34-21-8-4-18(5-9-21)26-28-22-10-6-19(16-24(22)30-26)27-29-23-11-7-20(17-25(23)31-27)33-14-12-32(2)13-15-33/h4-11,16-17H,3,12-15H2,1-2H3,(H,28,30)(H,29,31)
DMKRBL2	CS	CCOC1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)C4=NC5=C(N4)C=C(C=C5)N6CCN(CC6)C
DMKRBL2	IK	PRDFBSVERLRRMY-UHFFFAOYSA-N
DMKRBL2	IU	2-(4-ethoxyphenyl)-6-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazole
DMKRBL2	CA	CAS 23491-52-3
DMKRBL2	CB	CHEBI:51232
DMKRBL2	DE	Solid tumour/cancer

DM0DO4S	ID	DM0DO4S
DM0DO4S	DN	Bivatuzumab mertansine
DM0DO4S	HS	Terminated
DM0DO4S	SN	BIWI-1; Bivatuzumab-DM1
DM0DO4S	CP	Boehringer Ingelheim International GmbH
DM0DO4S	DT	Antibody
DM0DO4S	DE	Solid tumour/cancer

DM9IQR6	ID	DM9IQR6
DM9IQR6	DN	BK-218
DM9IQR6	HS	Terminated
DM9IQR6	SN	7-[(3-Chloroisoxazol-5-yl)acetamido]-3-[[(1-methyl-1H-tetrazol-5-yl)thiomethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid sodium salt dihydrate; 7-[2-(3-Chloroisoxazol-5-yl)acetamido]-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid sodium salt dihydrate
DM9IQR6	DT	Small molecular drug
DM9IQR6	PC	23666181
DM9IQR6	MW	493.9
DM9IQR6	FM	C15H13ClN7NaO5S2
DM9IQR6	IC	InChI=1S/C15H14ClN7O5S2.Na/c1-22-15(18-20-21-22)30-5-6-4-29-13-10(12(25)23(13)11(6)14(26)27)17-9(24)3-7-2-8(16)19-28-7;/h2,10,13H,3-5H2,1H3,(H,17,24)(H,26,27);/q;+1/p-1/t10-,13-;/m1./s1
DM9IQR6	CS	CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CC(=NO4)Cl)SC2)C(=O)[O-].[Na+]
DM9IQR6	IK	XQPMNRFOIDADDS-HTMVYDOJSA-M
DM9IQR6	IU	sodium;(6R,7R)-7-[[2-(3-chloro-1,2-oxazol-5-yl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM9IQR6	CA	CAS 110008-56-5
DM9IQR6	DE	Bacterial infection

DMGDTLX	ID	DMGDTLX
DMGDTLX	DN	BL-1872
DMGDTLX	HS	Terminated
DMGDTLX	CP	Bioglan Pharmaceuticals Co
DMGDTLX	DE	Pain

DMKITQN	ID	DMKITQN
DMKITQN	DN	BM-13677
DMKITQN	HS	Terminated
DMKITQN	SN	BM-13677; BM 13677; 129393-59-5; BM 13,677; 2-((3-Phenylpropoxy)imino)butanoic acid; Butanoic acid, 2-((3-phenylpropoxy)imino)-
DMKITQN	CP	Boehringer Mannheim GmbH
DMKITQN	DT	Small molecular drug
DMKITQN	PC	5486935
DMKITQN	MW	235.28
DMKITQN	FM	C13H17NO3
DMKITQN	IC	InChI=1S/C13H17NO3/c1-2-12(13(15)16)14-17-10-6-9-11-7-4-3-5-8-11/h3-5,7-8H,2,6,9-10H2,1H3,(H,15,16)/b14-12-
DMKITQN	CS	CC/C(=N/OCCCC1=CC=CC=C1)/C(=O)O
DMKITQN	IK	TVHDNHNLJMQXMI-OWBHPGMISA-N
DMKITQN	IU	(2Z)-2-(3-phenylpropoxyimino)butanoic acid
DMKITQN	DE	Diabetic complication

DMWDRI0	ID	DMWDRI0
DMWDRI0	DN	BMS-180560
DMWDRI0	HS	Terminated
DMWDRI0	SN	CHEMBL2021417
DMWDRI0	CP	Bristol-Myers Squibb Co
DMWDRI0	DT	Small molecular drug
DMWDRI0	PC	9891811
DMWDRI0	MW	475.9
DMWDRI0	FM	C24H22ClN7O2
DMWDRI0	IC	InChI=1S/C24H22ClN7O2/c1-2-3-11-20-26-22(25)21(24(33)34)32(20)14-15-7-6-10-18-16(15)12-13-31(18)19-9-5-4-8-17(19)23-27-29-30-28-23/h4-10,12-13H,2-3,11,14H2,1H3,(H,33,34)(H,27,28,29,30)
DMWDRI0	CS	CCCCC1=NC(=C(N1CC2=C3C=CN(C3=CC=C2)C4=CC=CC=C4C5=NNN=N5)C(=O)O)Cl
DMWDRI0	IK	AIGVXGCHRIOQNR-UHFFFAOYSA-N
DMWDRI0	IU	2-butyl-5-chloro-3-[[1-[2-(2H-tetrazol-5-yl)phenyl]indol-4-yl]methyl]imidazole-4-carboxylic acid
DMWDRI0	DE	Hypertension

DM1Y75C	ID	DM1Y75C
DM1Y75C	DN	BMS-181184
DM1Y75C	HS	Terminated
DM1Y75C	SN	Pradimicin derivative; BMY 181184; BMY-28864
DM1Y75C	CP	Bristol-Myers Squibb Co
DM1Y75C	DT	Small molecular drug
DM1Y75C	PC	122695
DM1Y75C	MW	843.7
DM1Y75C	FM	C39H41NO20
DM1Y75C	IC	InChI=1S/C39H41NO20/c1-10-4-16-23(30(49)20(10)36(53)40-17(8-41)37(54)55)22-14(7-15-24(31(22)50)27(46)13-5-12(56-3)6-18(42)21(13)26(15)45)28(47)34(16)59-39-33(52)35(25(44)11(2)58-39)60-38-32(51)29(48)19(43)9-57-38/h4-7,11,17,19,25,28-29,32-35,38-39,41-44,47-52H,8-9H2,1-3H3,(H,40,53)(H,54,55)/t11?,17?,19?,25?,28?,29?,32?,33?,34-,35?,38?,39?/m0/s1
DM1Y75C	CS	CC1C(C(C(C(O1)O[C@@H]2C(C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(CO)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)OC7C(C(C(CO7)O)O)O)O
DM1Y75C	IK	AXPBRQZJFXIYTD-PWEAUJHISA-N
DM1Y75C	IU	2-[[(5S)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxypropanoic acid
DM1Y75C	DE	Fungal infection

DMYWI04	ID	DMYWI04
DMYWI04	DN	BMS-181885
DMYWI04	HS	Terminated
DMYWI04	SN	3-[3-[3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-ylamino]-4-methyl-3-cyclobutene-1,2-dione
DMYWI04	PC	153988
DMYWI04	MW	460.5
DMYWI04	FM	C25H28N6O3
DMYWI04	IC	InChI=1S/C25H28N6O3/c1-16-22(24(33)23(16)32)29-18-5-6-20-19(12-18)17(13-27-20)4-3-7-30-8-10-31(11-9-30)25-21(34-2)14-26-15-28-25/h5-6,12-15,27,29H,3-4,7-11H2,1-2H3
DMYWI04	CS	CC1=C(C(=O)C1=O)NC2=CC3=C(C=C2)NC=C3CCCN4CCN(CC4)C5=NC=NC=C5OC
DMYWI04	IK	HCXROGVQIBVJTA-UHFFFAOYSA-N
DMYWI04	IU	3-[[3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-yl]amino]-4-methylcyclobut-3-ene-1,2-dione
DMYWI04	CA	CAS 165250-47-5
DMYWI04	DE	Migraine

DMEDLHG	ID	DMEDLHG
DMEDLHG	DN	BMS-182193
DMEDLHG	HS	Terminated
DMEDLHG	CP	Bristol-Myers Squibb Co
DMEDLHG	PC	447617
DMEDLHG	MW	543.7
DMEDLHG	FM	C30H45N3O6
DMEDLHG	IC	InChI=1S/C30H45N3O6/c1-29(2,3)38-27(36)32-23(17-21-13-9-7-10-14-21)25(34)19-31-20-26(35)24(18-22-15-11-8-12-16-22)33-28(37)39-30(4,5)6/h7-16,23-26,31,34-35H,17-20H2,1-6H3,(H,32,36)(H,33,37)/t23-,24-,25+,26+/m0/s1
DMEDLHG	CS	CC(C)(C)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](CNC[C@H]([C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C)O)O
DMEDLHG	IK	KKRYDPVDJYCEER-QEGGNFSNSA-N
DMEDLHG	IU	tert-butyl N-[(2S,3R)-3-hydroxy-4-[[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutyl]amino]-1-phenylbutan-2-yl]carbamate
DMEDLHG	CA	CAS 161302-38-1
DMEDLHG	DE	Human immunodeficiency virus infection

DMO7C09	ID	DMO7C09
DMO7C09	DN	BMS-182566
DMO7C09	HS	Terminated
DMO7C09	CP	Bristol-Myers Squibb AG
DMO7C09	DE	Solid tumour/cancer

DM0K4DZ	ID	DM0K4DZ
DM0K4DZ	DN	BMS-182657
DM0K4DZ	HS	Terminated
DM0K4DZ	CP	Bristol-Myers Squibb Co
DM0K4DZ	PC	9801007
DM0K4DZ	MW	398.5
DM0K4DZ	FM	C21H22N2O4S
DM0K4DZ	IC	InChI=1S/C21H22N2O4S/c24-19(25)13-23-17-9-5-4-8-15(17)10-11-16(21(23)27)22-20(26)18(28)12-14-6-2-1-3-7-14/h1-9,16,18,28H,10-13H2,(H,22,26)(H,24,25)/t16-,18-/m0/s1
DM0K4DZ	CS	C1CC2=CC=CC=C2N(C(=O)[C@H]1NC(=O)[C@H](CC3=CC=CC=C3)S)CC(=O)O
DM0K4DZ	IK	TYXFDFMUHPWCDX-WMZOPIPTSA-N
DM0K4DZ	IU	2-[(3S)-2-oxo-3-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DM0K4DZ	DE	Cardiovascular disease

DM5PG6C	ID	DM5PG6C
DM5PG6C	DN	BMS-182874
DM5PG6C	HS	Terminated
DM5PG6C	SN	BMS-182874; Bms 182874; 5-Ddins; 153042-42-3; CHEMBL267458; 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide; 1-Naphthalenesulfonamide, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-; Tocris-1441; AC1L3UAG; SCHEMBL802730; ZINC5803; CHEBI:92993; DTXSID60165205; BDBM50034435; NCGC00025164-01; LS-173440; L009159; BRD-K56509348-003-01-3; 5-Dimethylamino-naphthalene-1-sulfonic acid (3,4-dimethyl-isoxazol-5-yl)-amide; 5-Dimethylamino-naphthalene-1-sulfonic acid (3,4-dimethyl-2,3-dihydro-oxazol-5-yl)-amide
DM5PG6C	DT	Small molecular drug
DM5PG6C	PC	122272
DM5PG6C	MW	345.4
DM5PG6C	FM	C17H19N3O3S
DM5PG6C	IC	InChI=1S/C17H19N3O3S/c1-11-12(2)18-23-17(11)19-24(21,22)16-10-6-7-13-14(16)8-5-9-15(13)20(3)4/h5-10,19H,1-4H3
DM5PG6C	CS	CC1=C(ON=C1C)NS(=O)(=O)C2=CC=CC3=C2C=CC=C3N(C)C
DM5PG6C	IK	MJRGSRRZKSJHOE-UHFFFAOYSA-N
DM5PG6C	IU	5-(dimethylamino)-N-(3,4-dimethyl-1,2-oxazol-5-yl)naphthalene-1-sulfonamide
DM5PG6C	CA	CAS 153042-42-3
DM5PG6C	CB	CHEBI:92993
DM5PG6C	DE	Hypertension

DMTA7O8	ID	DMTA7O8
DMTA7O8	DN	BMS-185857
DMTA7O8	HS	Terminated
DMTA7O8	CP	Bristol-Myers Squibb AG
DMTA7O8	DE	Solid tumour/cancer

DMKZ3PW	ID	DMKZ3PW
DMKZ3PW	DN	BMS-186318
DMKZ3PW	HS	Terminated
DMKZ3PW	SN	BMS-186318; BMS 186318; 161302-40-5; 12-Oxa-2,6,10-triazatetradecanoic acid, 4,8-dihydroxy-13,13-dimethyl-3-((4-(2-(4-morpholinyl)-2-oxoethoxy)phenyl)methyl)-11-oxo-9-(phenylmethyl)-, 1,1-dimethylethyl ester, (3S,4R,8R,9S)-; BMS-186318 analog 19; 12-Oxa-2,6,10-triazatetradecanoic acid, 4,8-dihydroxy-13,13-dimethyl-3-[[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-11-oxo-9-(phenylmethyl)-, 1,1-dimethylethyl ester, (3S,4R,8R,9S)-; tert-butyl N-[(1S,2R)-1-benzyl-3-[[(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-4
DMKZ3PW	CP	Bristol-Myers Squibb Co
DMKZ3PW	DT	Small molecular drug
DMKZ3PW	PC	65024
DMKZ3PW	MW	686.8
DMKZ3PW	FM	C36H54N4O9
DMKZ3PW	IC	InChI=1S/C36H54N4O9/c1-35(2,3)48-33(44)38-28(20-25-10-8-7-9-11-25)30(41)22-37-23-31(42)29(39-34(45)49-36(4,5)6)21-26-12-14-27(15-13-26)47-24-32(43)40-16-18-46-19-17-40/h7-15,28-31,37,41-42H,16-24H2,1-6H3,(H,38,44)(H,39,45)/t28-,29-,30+,31+/m0/s1
DMKZ3PW	CS	CC(C)(C)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](CNC[C@H]([C@H](CC2=CC=C(C=C2)OCC(=O)N3CCOCC3)NC(=O)OC(C)(C)C)O)O
DMKZ3PW	IK	OQHZMGOXOOOFEE-SYQUUIDJSA-N
DMKZ3PW	IU	tert-butyl N-[(2S,3R)-3-hydroxy-4-[[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[4-(2-morpholin-4-yl-2-oxoethoxy)phenyl]butyl]amino]-1-phenylbutan-2-yl]carbamate
DMKZ3PW	CA	CAS 161302-40-5
DMKZ3PW	DE	Human immunodeficiency virus-1 infection

DMV3B5Y	ID	DMV3B5Y
DMV3B5Y	DN	BMS-189664
DMV3B5Y	HS	Terminated
DMV3B5Y	SN	N-(1-Amidinopiperidin-4-ylmethyl)-1-[N-(methylsulfonyl)-D-phenylalanyl]-L-prolinamide
DMV3B5Y	DT	Small molecular drug
DMV3B5Y	PC	9869699
DMV3B5Y	MW	478.6
DMV3B5Y	FM	C22H34N6O4S
DMV3B5Y	IC	InChI=1S/C22H34N6O4S/c1-33(31,32)26-18(14-16-6-3-2-4-7-16)21(30)28-11-5-8-19(28)20(29)25-15-17-9-12-27(13-10-17)22(23)24/h2-4,6-7,17-19,26H,5,8-15H2,1H3,(H3,23,24)(H,25,29)/t18-,19+/m1/s1
DMV3B5Y	CS	CS(=O)(=O)N[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)NCC3CCN(CC3)C(=N)N
DMV3B5Y	IK	UCVAQBJLJIKTFJ-MOPGFXCFSA-N
DMV3B5Y	IU	(2S)-N-[(1-carbamimidoylpiperidin-4-yl)methyl]-1-[(2R)-2-(methanesulfonamido)-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMV3B5Y	CA	CAS 162166-80-5
DMV3B5Y	DE	Myocardial infarction

DMMBTU6	ID	DMMBTU6
DMMBTU6	DN	BMS-210285
DMMBTU6	HS	Terminated
DMMBTU6	SN	UNII-WS7S13Q9RH; WS7S13Q9RH; CHEMBL60116; BMS-210285; 344607-69-8; SCHEMBL13550990; BDBM50073046; Methanesulfonamide, N-(5-((1R)-2-(((1R)-2-(3-chlorophenyl)-1-(4-(difluoromethoxy)phenyl)ethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)-; N-(5-{(R)-2-[(R)-2-(3-Chloro-phenyl)-1-(4-difluoromethoxy-phenyl)-ethylamino]-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide
DMMBTU6	CP	Bristol-Myers Squibb Co
DMMBTU6	DT	Small molecular drug
DMMBTU6	PC	9828292
DMMBTU6	MW	527
DMMBTU6	FM	C24H25ClF2N2O5S
DMMBTU6	IC	InChI=1S/C24H25ClF2N2O5S/c1-35(32,33)29-21-13-17(7-10-22(21)30)23(31)14-28-20(12-15-3-2-4-18(25)11-15)16-5-8-19(9-6-16)34-24(26)27/h2-11,13,20,23-24,28-31H,12,14H2,1H3/t20-,23+/m1/s1
DMMBTU6	CS	CS(=O)(=O)NC1=C(C=CC(=C1)[C@H](CN[C@H](CC2=CC(=CC=C2)Cl)C3=CC=C(C=C3)OC(F)F)O)O
DMMBTU6	IK	DSEGFUSAJVUFLK-OFNKIYASSA-N
DMMBTU6	IU	N-[5-[(1R)-2-[[(1R)-2-(3-chlorophenyl)-1-[4-(difluoromethoxy)phenyl]ethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide
DMMBTU6	CA	CAS 344607-69-8
DMMBTU6	DE	Type-2 diabetes

DME20VP	ID	DME20VP
DME20VP	DN	BMS-433771
DME20VP	HS	Terminated
DME20VP	SN	AIDS161903; Bms 433771; 1-cyclopropyl-3-[[1-(3-hydroxypropyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one; 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one
DME20VP	CP	Bristol-Myers Squibb
DME20VP	DT	Small molecular drug
DME20VP	PC	6478034
DME20VP	MW	377.4
DME20VP	FM	C21H23N5O2
DME20VP	IC	InChI=1S/C21H23N5O2/c27-12-4-3-11-24-17-6-2-1-5-16(17)23-20(24)14-25-19-13-22-10-9-18(19)26(21(25)28)15-7-8-15/h1-2,5-6,9-10,13,15,27H,3-4,7-8,11-12,14H2
DME20VP	CS	C1CC1N2C3=C(C=NC=C3)N(C2=O)CC4=NC5=CC=CC=C5N4CCCCO
DME20VP	IK	KSHJXDWYTZJUEI-UHFFFAOYSA-N
DME20VP	IU	1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one
DME20VP	CA	CAS 543700-68-1
DME20VP	DE	Respiratory syncytial virus infection

DMY7ZRA	ID	DMY7ZRA
DMY7ZRA	DN	BMS-605339
DMY7ZRA	HS	Terminated
DMY7ZRA	SN	NS3 protease inhibitor (hepatitis C virus infection), BMS
DMY7ZRA	CP	Bristol-Myers Squibb Co
DMY7ZRA	PC	46862685
DMY7ZRA	MW	713.8
DMY7ZRA	FM	C35H47N5O9S
DMY7ZRA	IC	InChI=1S/C35H47N5O9S/c1-9-21-18-35(21,31(43)39-50(45,46)24-11-12-24)38-28(41)26-17-23(48-29-25-13-10-22(47-8)16-20(25)14-15-36-29)19-40(26)30(42)27(33(2,3)4)37-32(44)49-34(5,6)7/h9-10,13-16,21,23-24,26-27H,1,11-12,17-19H2,2-8H3,(H,37,44)(H,38,41)(H,39,43)/t21-,23-,26+,27-,35-/m1/s1
DMY7ZRA	CS	CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=CC5=C4C=CC(=C5)OC)NC(=O)OC(C)(C)C
DMY7ZRA	IK	IYWRCNFZPNEADN-CXODAYGWSA-N
DMY7ZRA	IU	tert-butyl N-[(2S)-1-[(2S,4R)-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]-4-(6-methoxyisoquinolin-1-yl)oxypyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
DMY7ZRA	CA	CAS 630417-82-2
DMY7ZRA	DE	Hepatitis C virus infection

DMDPJ8M	ID	DMDPJ8M
DMDPJ8M	DN	BMY-20844
DMDPJ8M	HS	Terminated
DMDPJ8M	SN	Bmy-20844; 124886-01-7; UNII-ALR3F45M10; CHEMBL88583; ALR3F45M10; 1,3-Dihydro-7,8-dimethyl-2H-imidazo(4,5-b)quinolin-2-one; 1,3-dihydro-7,8-dimethyl-2H-imidazo[4,5-b]quinolin-2-one; 2H-Imidazo[4,5-b]quinolin-2-one,1,3-dihydro-7,8-dimethyl-; 2H-Imidazo[4,5-b]quinolin-2-one, 1,3-dihydro-7,8-dimethyl-; 2H-Imidazo(4,5-b)quinolin-2-one, 1,3-dihydro-7,8-dimethyl-; AC1NUPC3; ACMC-1C2JD; SCHEMBL2457579; 7,8-dimethyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one; CTK4B4100; DTXSID40154516; ODCKPUDNMNCWMR-UHFFFAOYSA-N; BDBM50000925
DMDPJ8M	DT	Small molecular drug
DMDPJ8M	PC	5487281
DMDPJ8M	MW	213.23
DMDPJ8M	FM	C12H11N3O
DMDPJ8M	IC	InChI=1S/C12H11N3O/c1-6-3-4-9-8(7(6)2)5-10-11(13-9)15-12(16)14-10/h3-5H,1-2H3,(H2,13,14,15,16)
DMDPJ8M	CS	CC1=C(C2=CC3=C(NC(=O)N3)N=C2C=C1)C
DMDPJ8M	IK	ODCKPUDNMNCWMR-UHFFFAOYSA-N
DMDPJ8M	IU	7,8-dimethyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMDPJ8M	CA	CAS 124886-01-7

DMZFTLK	ID	DMZFTLK
DMZFTLK	DN	BMY-22089
DMZFTLK	HS	Terminated
DMZFTLK	SN	(4R,6S)-6-[4,4-Bis(4-fluorophenyl)-3-(1-methyl-1H-tetrazol-5-yl)-1(E),3-butadienyl]-4-hydroxytetrahydropyran-2-one
DMZFTLK	DT	Small molecular drug
DMZFTLK	PC	9932838
DMZFTLK	MW	438.4
DMZFTLK	FM	C23H20F2N4O3
DMZFTLK	IC	InChI=1S/C23H20F2N4O3/c1-29-23(26-27-28-29)20(11-10-19-12-18(30)13-21(31)32-19)22(14-2-6-16(24)7-3-14)15-4-8-17(25)9-5-15/h2-11,18-19,30H,12-13H2,1H3/b11-10+/t18-,19-/m1/s1
DMZFTLK	CS	CN1C(=NN=N1)C(=C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)/C=C/[C@@H]4C[C@H](CC(=O)O4)O
DMZFTLK	IK	VIMMECPCYZXUCI-MMKWGKFASA-N
DMZFTLK	IU	(4R,6S)-6-[(1E)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one
DMZFTLK	CA	CAS 118845-59-3
DMZFTLK	DE	Hyperlipidaemia

DM2TF9P	ID	DM2TF9P
DM2TF9P	DN	BMY-40062
DM2TF9P	HS	Terminated
DM2TF9P	SN	1-(tert-Butyl)-7-(1R,4R-2,5-diazabicyclo[2.2.1]hept-2-yl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
DM2TF9P	DT	Small molecular drug
DM2TF9P	PC	163995
DM2TF9P	MW	360.4
DM2TF9P	FM	C18H21FN4O3
DM2TF9P	IC	InChI=1S/C18H21FN4O3/c1-18(2,3)23-8-12(17(25)26)14(24)11-5-13(19)16(21-15(11)23)22-7-9-4-10(22)6-20-9/h5,8-10,20H,4,6-7H2,1-3H3,(H,25,26)/t9-,10-/m1/s1
DM2TF9P	CS	CC(C)(C)N1C=C(C(=O)C2=CC(=C(N=C21)N3C[C@H]4C[C@@H]3CN4)F)C(=O)O
DM2TF9P	IK	KNHLHFDFFDCJJR-NXEZZACHSA-N
DM2TF9P	IU	1-tert-butyl-7-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DM2TF9P	CA	CAS 116143-32-9
DM2TF9P	DE	Bacterial infection

DM8R3N0	ID	DM8R3N0
DM8R3N0	DN	BMY-44621
DM8R3N0	HS	Terminated
DM8R3N0	SN	CHEMBL304794; BDBM50290020; (S)-5-Guanidino-2-[[1-(phenylacetyl)-L-prolyl]amino]pentanal; (S)-1-Phenylacetyl-pyrrolidine-2-carboxylic acid ((S)-1-formyl-4-guanidino-butyl)-amide
DM8R3N0	DT	Small molecular drug
DM8R3N0	PC	11740077
DM8R3N0	MW	373.4
DM8R3N0	FM	C19H27N5O3
DM8R3N0	IC	InChI=1S/C19H27N5O3/c20-19(21)22-10-4-8-15(13-25)23-18(27)16-9-5-11-24(16)17(26)12-14-6-2-1-3-7-14/h1-3,6-7,13,15-16H,4-5,8-12H2,(H,23,27)(H4,20,21,22)/t15-,16-/m0/s1
DM8R3N0	CS	C1C[C@H](N(C1)C(=O)CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C=O
DM8R3N0	IK	FWMLVCYBCSOEBZ-HOTGVXAUSA-N
DM8R3N0	IU	(2S)-N-[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-(2-phenylacetyl)pyrrolidine-2-carboxamide

DMRHCEG	ID	DMRHCEG
DMRHCEG	DN	BMY-7378
DMRHCEG	HS	Terminated
DMRHCEG	SN	Bmy-7378; UNII-08EI0K81OL; CHEMBL13647; 08EI0K81OL; 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione; BMY7378; 8-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)-8-azaspiro(4.5)decane-7,9-dione; 21102-94-3; 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione; 8-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-8-azaspiro[4.5]decane-7,9-dione; 8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione; 8-Azaspiro(4.5)decane-7,9-dione, 8-(2-(4-(2-methox
DMRHCEG	DT	Small molecular drug
DMRHCEG	PC	2419
DMRHCEG	MW	385.5
DMRHCEG	FM	C22H31N3O3
DMRHCEG	IC	InChI=1S/C22H31N3O3/c1-28-19-7-3-2-6-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-22(17-21(25)27)8-4-5-9-22/h2-3,6-7H,4-5,8-17H2,1H3
DMRHCEG	CS	COC1=CC=CC=C1N2CCN(CC2)CCN3C(=O)CC4(CCCC4)CC3=O
DMRHCEG	IK	AYYCFGDXLUPJAQ-UHFFFAOYSA-N
DMRHCEG	IU	8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione
DMRHCEG	CA	CAS 21102-94-3
DMRHCEG	CB	CHEBI:92539

DMTKJDS	ID	DMTKJDS
DMTKJDS	DN	BN-50726
DMTKJDS	HS	Terminated
DMTKJDS	SN	BN-50726; BN 50726; 127279-06-5; 4H-Pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine,6-(2-chlorophenyl)-9-(hexadecylsulfonyl)-7,8,9,10-tetrahydro-1-methyl-; ACMC-20c9sz; AC1L4UGJ; AC1Q6VN1; bn50726; CTK4B5547; DTXSID80155486; AKOS030566818
DMTKJDS	CP	Ipsen
DMTKJDS	DT	Small molecular drug
DMTKJDS	PC	164238
DMTKJDS	MW	658.4
DMTKJDS	FM	C34H48ClN5O2S2
DMTKJDS	IC	InChI=1S/C34H48ClN5O2S2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-18-23-44(41,42)39-22-21-28-30(25-39)43-34-32(28)33(27-19-16-17-20-29(27)35)36-24-31-38-37-26(2)40(31)34/h16-17,19-20H,3-15,18,21-25H2,1-2H3
DMTKJDS	CS	CCCCCCCCCCCCCCCCS(=O)(=O)N1CCC2=C(C1)SC3=C2C(=NCC4=NN=C(N43)C)C5=CC=CC=C5Cl
DMTKJDS	IK	XYNVFDKKFDLTPP-UHFFFAOYSA-N
DMTKJDS	IU	9-(2-chlorophenyl)-14-hexadecylsulfonyl-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaene
DMTKJDS	CA	CAS 127279-06-5
DMTKJDS	DE	Nerve injury

DMU1TRQ	ID	DMU1TRQ
DMU1TRQ	DN	BN50739
DMU1TRQ	HS	Terminated
DMU1TRQ	SN	BN 50739; BN-50739; 128672-07-1; BN50739; Tetrahydro-4,7,8,10 methyl-(chloro-2-phenyl)-6-((3,4-dimethoxyphenyl)thio)methylthiocarbonyl-9-pyrido(4',3'-4,5)thieno(3,2-f)triazolo-1,2,4(4,3-a)diazepine-1,4; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(2-((3,4-dimethoxyphenyl)thio)-1-thioxoethyl)-7,8,9,10-tetrahydro-1-methyl-; AC1L3GCW; GTPL1851; DTXSID60155969; LS-187569; LS-186919; L000670
DMU1TRQ	DT	Small molecular drug
DMU1TRQ	PC	115002
DMU1TRQ	MW	596.2
DMU1TRQ	FM	C28H26ClN5O2S3
DMU1TRQ	IC	InChI=1S/C28H26ClN5O2S3/c1-16-31-32-24-13-30-27(18-6-4-5-7-20(18)29)26-19-10-11-33(14-23(19)39-28(26)34(16)24)25(37)15-38-17-8-9-21(35-2)22(12-17)36-3/h4-9,12H,10-11,13-15H2,1-3H3
DMU1TRQ	CS	CC1=NN=C2N1C3=C(C4=C(S3)CN(CC4)C(=S)CSC5=CC(=C(C=C5)OC)OC)C(=NC2)C6=CC=CC=C6Cl
DMU1TRQ	IK	MRVWRDZEYURFSW-UHFFFAOYSA-N
DMU1TRQ	IU	1-[9-(2-chlorophenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaen-14-yl]-2-(3,4-dimethoxyphenyl)sulfanylethanethione
DMU1TRQ	CA	CAS 128672-07-1
DMU1TRQ	DE	Cerebral infarction

DMMZ9DY	ID	DMMZ9DY
DMMZ9DY	DN	BN-80245
DMMZ9DY	HS	Terminated
DMMZ9DY	SN	DU-1441; DU-1442
DMMZ9DY	CP	Institut Henri Beaufour
DMMZ9DY	DT	Small molecular drug
DMMZ9DY	PC	9863779
DMMZ9DY	MW	362.4
DMMZ9DY	FM	C21H18N2O4
DMMZ9DY	IC	InChI=1S/C21H18N2O4/c1-2-21(26)9-18(24)27-11-14-15(21)8-17-19-13(10-23(17)20(14)25)7-12-5-3-4-6-16(12)22-19/h3-8,26H,2,9-11H2,1H3
DMMZ9DY	CS	CCC1(CC(=O)OCC2=C1C=C3C4=NC5=CC=CC=C5C=C4CN3C2=O)O
DMMZ9DY	IK	PAEZRCINULFAGO-UHFFFAOYSA-N
DMMZ9DY	IU	20-ethyl-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4,6,8,10,15(21)-heptaene-14,18-dione
DMMZ9DY	CA	CAS 186668-40-6
DMMZ9DY	DE	Solid tumour/cancer

DMN8FAG	ID	DMN8FAG
DMN8FAG	DN	BP4.879a
DMN8FAG	HS	Terminated
DMN8FAG	CP	Bioprojet
DMN8FAG	DT	Small molecular drug
DMN8FAG	PC	5311254
DMN8FAG	MW	298.4
DMN8FAG	FM	C17H22N4O
DMN8FAG	IC	InChI=1S/C17H22N4O/c1-20-12-7-8-13(20)10-11(9-12)18-17(22)16-14-5-3-4-6-15(14)21(2)19-16/h3-6,11-13H,7-10H2,1-2H3,(H,18,22)/t11?,12-,13+
DMN8FAG	CS	CN1[C@@H]2CC[C@H]1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
DMN8FAG	IK	DDHAJFBBJWHSBR-YHWZYXNKSA-N
DMN8FAG	IU	1-methyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]indazole-3-carboxamide
DMN8FAG	DE	Schizophrenia

DM3O4BG	ID	DM3O4BG
DM3O4BG	DN	BQ-518
DM3O4BG	HS	Terminated
DM3O4BG	SN	BQ 518; CHEBI:2967; CHEMBL2074702; BQ-518; AC1L9EDN; BQ518; BDBM50390984; 136554-29-5; C11589; 2-[(3R,6R,9S,12S,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-thiophen-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid
DM3O4BG	CP	MSD Japan
DM3O4BG	DT	Small molecular drug
DM3O4BG	PC	443291
DM3O4BG	MW	650.7
DM3O4BG	FM	C32H38N6O7S
DM3O4BG	IC	InChI=1S/C32H38N6O7S/c1-17(2)13-21-28(41)34-22(14-18-16-33-20-8-4-3-7-19(18)20)29(42)36-23(15-26(39)40)32(45)38-11-5-9-24(38)30(43)37-27(31(44)35-21)25-10-6-12-46-25/h3-4,6-8,10,12,16-17,21-24,27,33H,5,9,11,13-15H2,1-2H3,(H,34,41)(H,35,44)(H,36,42)(H,37,43)(H,39,40)/t21-,22+,23+,24-,27+/m0/s1
DM3O4BG	CS	CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N1)C3=CC=CS3)CC(=O)O)CC4=CNC5=CC=CC=C54
DM3O4BG	IK	KXUDUVUGZWJNHV-QEXRHJMMSA-N
DM3O4BG	IU	2-[(3R,6R,9S,12S,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-thiophen-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid
DM3O4BG	CB	CHEBI:2967
DM3O4BG	DE	Hypertension

DMPRNQL	ID	DMPRNQL
DMPRNQL	DN	BQ610
DMPRNQL	HS	Terminated
DMPRNQL	SN	BQ-610; 141595-53-1; BQ 610; AZEPANE-1-CARBONYL-LEU-D-TRP(FOR)-D-TRP-OH; BQ610; Hexahydroazepinocarbonyl-leu-D-trp(cho)-D-trp; Hexahydroazepinocarbonyl-leucyl-tryptophyl(cho)-tryptophan; AC1L3XIP; SCHEMBL2678706; CTK8F0466; DTXSID20161768; ZINC72190207; D-Tryptophan, N-(1-formyl-N-(N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-D-tryptophyl)-; RT-011809; J-007520; (R)-2-((R)-2-((S)-2-(azepane-1-carboxamido)-4-methylpentanamido)-3-(1-formyl-1H-indol-3-yl)propanamido)-3-(1H-indol-3-yl)propanoic acid
DMPRNQL	DT	Small molecular drug
DMPRNQL	PC	123905
DMPRNQL	MW	656.8
DMPRNQL	FM	C36H44N6O6
DMPRNQL	IC	InChI=1S/C36H44N6O6/c1-23(2)17-29(40-36(48)41-15-9-3-4-10-16-41)33(44)38-30(19-25-21-42(22-43)32-14-8-6-12-27(25)32)34(45)39-31(35(46)47)18-24-20-37-28-13-7-5-11-26(24)28/h5-8,11-14,20-23,29-31,37H,3-4,9-10,15-19H2,1-2H3,(H,38,44)(H,39,45)(H,40,48)(H,46,47)/t29-,30+,31+/m0/s1
DMPRNQL	CS	CC(C)C[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C=O)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)O)NC(=O)N5CCCCCC5
DMPRNQL	IK	QHSRPPJQBFQWSC-OJDZSJEKSA-N
DMPRNQL	IU	(2R)-2-[[(2R)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-formylindol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMPRNQL	CA	CAS 141595-53-1

DMGX0E1	ID	DMGX0E1
DMGX0E1	DN	BRL 26830A
DMGX0E1	HS	Terminated
DMGX0E1	SN	Brl 26830; BRL 26830A; Methyl 4-(2-((2-hydroxy-2-phenethyl)amino)propyl)benzoate-2-butanedioate; Brl-26830A; Benzoic acid, 4-(2-((2-hydroxy-2-phenylethyl)amino)propyl)-, methyl ester, (R*,R*)-(+-)-, (E)-2-butenedioate (2:1) (salt); 87857-42-9; AC1O5PHH; LS-186797; methyl 4-[(2S)-2-[[(2S)-2-hydroxy-2-phenylethyl]amino]propyl]benzoate; (E)-4-oxopent-2-enoic acid
DMGX0E1	DT	Small molecular drug
DMGX0E1	PC	6438331
DMGX0E1	MW	427.5
DMGX0E1	FM	C24H29NO6
DMGX0E1	IC	InChI=1S/C19H23NO3.C5H6O3/c1-14(20-13-18(21)16-6-4-3-5-7-16)12-15-8-10-17(11-9-15)19(22)23-2;1-4(6)2-3-5(7)8/h3-11,14,18,20-21H,12-13H2,1-2H3;2-3H,1H3,(H,7,8)/b;3-2+/t14-,18+;/m0./s1
DMGX0E1	CS	C[C@@H](CC1=CC=C(C=C1)C(=O)OC)NC[C@H](C2=CC=CC=C2)O.CC(=O)/C=C/C(=O)O
DMGX0E1	IK	OIZISCUUSLPUEN-LMORPYAASA-N
DMGX0E1	IU	methyl 4-[(2S)-2-[[(2S)-2-hydroxy-2-phenylethyl]amino]propyl]benzoate;(E)-4-oxopent-2-enoic acid
DMGX0E1	CA	CAS 87857-42-9
DMGX0E1	DE	Obesity

DMS4320	ID	DMS4320
DMS4320	DN	BRL 37344
DMS4320	HS	Terminated
DMS4320	SN	UNII-42FZ27IZLV; Brl-37344; 42FZ27IZLV; CHEMBL284782; BRL 37344; 2-(4-((2R)-2-(((2R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)acetic acid; SB-206606; BRL37344; SB 206606; 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid; BRL-44092; GTPL567; 116049-78-6; SCHEMBL304308; CHEBI:131180; Acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-; ZINC3871771; BDBM50002133; Acetic acid, 2-(4-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-
DMS4320	DT	Small molecular drug
DMS4320	PC	9841972
DMS4320	MW	363.8
DMS4320	FM	C19H22ClNO4
DMS4320	IC	InChI=1S/C19H22ClNO4/c1-13(21-11-18(22)15-3-2-4-16(20)10-15)9-14-5-7-17(8-6-14)25-12-19(23)24/h2-8,10,13,18,21-22H,9,11-12H2,1H3,(H,23,24)/t13-,18+/m1/s1
DMS4320	CS	C[C@H](CC1=CC=C(C=C1)OCC(=O)O)NC[C@@H](C2=CC(=CC=C2)Cl)O
DMS4320	IK	ZGGNJJJYUVRADP-ACJLOTCBSA-N
DMS4320	IU	2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid
DMS4320	CA	CAS 116049-78-6
DMS4320	CB	CHEBI:131180

DMBC12X	ID	DMBC12X
DMBC12X	DN	BRL-42715
DMBC12X	HS	Terminated
DMBC12X	SN	Brl 42715; Brl-42715; C6-(N1-Methyl-1,2,3-trazolylmethylene)penem; 4-Thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1-methyl-1H-1,2,3-triazol-4-yl)methylene)-7-oxo-, sodium salt, (R-(Z))-; 102209-75-6
DMBC12X	CP	SmithKline Beecham plc
DMBC12X	DT	Small molecular drug
DMBC12X	PC	23705463
DMBC12X	MW	286.24
DMBC12X	FM	C10H7N4NaO3S
DMBC12X	IC	InChI=1S/C10H8N4O3S.Na/c1-13-3-5(11-12-13)2-6-8(15)14-7(10(16)17)4-18-9(6)14;/h2-4,9H,1H3,(H,16,17);/q;+1/p-1/b6-2-;/t9-;/m1./s1
DMBC12X	CS	CN1C=C(N=N1)/C=C/2\\[C@@H]3N(C2=O)C(=CS3)C(=O)[O-].[Na+]
DMBC12X	IK	OMJBLZMKGVWHQP-VKVLVNHFSA-M
DMBC12X	IU	sodium;(5R,6Z)-6-[(1-methyltriazol-4-yl)methylidene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMBC12X	DE	Bacterial infection

DMAH3Z9	ID	DMAH3Z9
DMAH3Z9	DN	BTS-79018
DMAH3Z9	HS	Terminated
DMAH3Z9	SN	CHEMBL418854; SCHEMBL6767394; BDBM50079939; L018296
DMAH3Z9	CP	Abbott
DMAH3Z9	DT	Small molecular drug
DMAH3Z9	PC	9909113
DMAH3Z9	MW	402.9
DMAH3Z9	FM	C22H27ClN2O3
DMAH3Z9	IC	InChI=1S/C22H27ClN2O3/c1-26-20-5-3-2-4-19(20)25-10-8-16(9-11-25)13-24-14-18-15-27-21-7-6-17(23)12-22(21)28-18/h2-7,12,16,18,24H,8-11,13-15H2,1H3/t18-/m0/s1
DMAH3Z9	CS	COC1=CC=CC=C1N2CCC(CC2)CNC[C@H]3COC4=C(O3)C=C(C=C4)Cl
DMAH3Z9	IK	QHLRKDSRGUZHSH-SFHVURJKSA-N
DMAH3Z9	IU	N-[[(3S)-6-chloro-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine
DMAH3Z9	CA	CAS 246517-66-8
DMAH3Z9	DE	Schizophrenia

DMJDMTK	ID	DMJDMTK
DMJDMTK	DN	BU-4514N
DMJDMTK	HS	Terminated
DMJDMTK	SN	BU-4514N; BU 4514N; AC1Q6BPU; AC1L4UFU; SCHEMBL194669; 4-[(2-{2-[(5-amino-6-methyltetrahydro-2h-pyran-2-yl)oxy]propyl}-1,3,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)carbonyl]-5-hydroxy-1,2-dihydro-3h-pyrrol-3-one
DMJDMTK	CP	Bristol-Myers Squibb Co
DMJDMTK	DT	Small molecular drug
DMJDMTK	PC	54704416
DMJDMTK	MW	474.6
DMJDMTK	FM	C27H42N2O5
DMJDMTK	IC	InChI=1S/C27H42N2O5/c1-14-6-7-19-18(10-14)11-15(2)20(12-16(3)33-23-9-8-21(28)17(4)34-23)27(19,5)25(31)24-22(30)13-29-26(24)32/h11,14,16-21,23,31H,6-10,12-13,28H2,1-5H3,(H,29,32)/b25-24-
DMJDMTK	CS	CC1CCC2C(C1)C=C(C(C2(C)/C(=C/3\\C(=O)CNC3=O)/O)CC(C)OC4CCC(C(O4)C)N)C
DMJDMTK	IK	NKWRHFUPAYVQCE-IZHYLOQSSA-N
DMJDMTK	IU	(3Z)-3-[[2-[2-(5-amino-6-methyloxan-2-yl)oxypropyl]-1,3,6-trimethyl-4a,5,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]-hydroxymethylidene]pyrrolidine-2,4-dione
DMJDMTK	CA	CAS 151013-39-7
DMJDMTK	DE	Alzheimer disease

DM4OT0S	ID	DM4OT0S
DM4OT0S	DN	BU-4601A
DM4OT0S	HS	Terminated
DM4OT0S	SN	BU-4601B; BU-4601C
DM4OT0S	CP	Bristol-Myers Squibb Co
DM4OT0S	DT	Small molecular drug
DM4OT0S	PC	192421
DM4OT0S	MW	293.4
DM4OT0S	FM	C17H27NO3
DM4OT0S	IC	InChI=1S/C17H27NO3/c1-13(2)8-6-4-3-5-7-11-21-17(20)15-12-14(19)9-10-16(15)18/h9-10,12-13,19H,3-8,11,18H2,1-2H3
DM4OT0S	CS	CC(C)CCCCCCCOC(=O)C1=C(C=CC(=C1)O)N
DM4OT0S	IK	WQDDSULPVSBTBO-UHFFFAOYSA-N
DM4OT0S	IU	8-methylnonyl 2-amino-5-hydroxybenzoate
DM4OT0S	CA	CAS 148915-76-8
DM4OT0S	DE	Asthma

DMIYPLU	ID	DMIYPLU
DMIYPLU	DN	BVT-142
DMIYPLU	HS	Terminated
DMIYPLU	SN	BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum
DMIYPLU	CP	Swedish Orphan Biovitrum AB
DMIYPLU	DE	Type-2 diabetes

DMHLUFN	ID	DMHLUFN
DMHLUFN	DN	BVT-24834
DMHLUFN	HS	Terminated
DMHLUFN	SN	BVT-1960; Fatty acid-binding protein 4 inhibitors, Biovitrum; FABP-4 inhibitors (obesity), Biovitrum
DMHLUFN	CP	Swedish Orphan Biovitrum AB
DMHLUFN	DE	Obesity

DMOZQHX	ID	DMOZQHX
DMOZQHX	DN	BVT-3498
DMOZQHX	HS	Terminated
DMOZQHX	SN	AMG-311
DMOZQHX	CP	Swedish Orphan Biovitrum AB
DMOZQHX	PC	76849181
DMOZQHX	MW	415.9
DMOZQHX	FM	C16H18ClN3O4S2
DMOZQHX	IC	InChI=1S/C16H18ClN3O4S2/c1-11-13(17)3-2-4-14(11)26(22,23)19-16-18-12(10-25-16)5-6-20-7-8-24-9-15(20)21/h2-4,10H,5-9H2,1H3,(H,18,19)
DMOZQHX	CS	CC1=C(C=CC=C1Cl)S(=O)(=O)NC2=NC(=CS2)CCN3CCOCC3=O
DMOZQHX	IK	WZFZJEPHYDDFCT-UHFFFAOYSA-N
DMOZQHX	IU	3-chloro-2-methyl-N-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide
DMOZQHX	CA	CAS 376641-49-5
DMOZQHX	DE	Metabolic disorder

DMXFZWJ	ID	DMXFZWJ
DMXFZWJ	DN	BW 373U86
DMXFZWJ	HS	Terminated
DMXFZWJ	SN	BW 373U86; BW-373U86; SNC-86; CHEMBL25230; 155836-50-3; BW373U86; 4-((R)-((2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl)(3-hydroxyphenyl)methyl)-N,N-diethylbenzamide; 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide; LBLDMHBSVIVJPM-YZIHRLCOSA-N; 150428-54-9; Tocris-1663; AC1L3O2K; (+-)-4-((alpha-R*)-alpha-((2S*,5R*)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide; SCHEMBL232127; GTPL9002; CHEBI:114187; MolPort-023-276-182
DMXFZWJ	DT	Small molecular drug
DMXFZWJ	PC	119029
DMXFZWJ	MW	435.6
DMXFZWJ	FM	C27H37N3O2
DMXFZWJ	IC	InChI=1S/C27H37N3O2/c1-6-16-29-18-21(5)30(19-20(29)4)26(24-10-9-11-25(31)17-24)22-12-14-23(15-13-22)27(32)28(7-2)8-3/h6,9-15,17,20-21,26,31H,1,7-8,16,18-19H2,2-5H3/t20-,21+,26-/m1/s1
DMXFZWJ	CS	CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)O)N3C[C@H](N(C[C@@H]3C)CC=C)C
DMXFZWJ	IK	LBLDMHBSVIVJPM-YZIHRLCOSA-N
DMXFZWJ	IU	4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide
DMXFZWJ	CA	CAS 150428-54-9
DMXFZWJ	CB	CHEBI:114187

DMNUMDG	ID	DMNUMDG
DMNUMDG	DN	BW A4C
DMNUMDG	HS	Terminated
DMNUMDG	SN	BW4C; Bwa-4C; Bwa 4C; 106328-57-8; BW-A4C; BWA4C; CHEMBL314360; C17H17NO3; N-(E)-3-(3-Phenoxyphenyl)prop-2-enylacetohydroxamine acid; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-; N-[(E)-3-(3-Phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; Acetohydroxamine acid, N-(E)-3-(3-phenoxyphenyl)prop-2-enyl-; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-, (E)-; BW-4AC; AC1O5PJ5; BW-A-4C; BW-A 4C; JMC515449 Compound 7; BDBM22334; ZINC5138195; MFCD00869694; N-(3-phenoxycinnamyl)-N-hydroxyacetamide
DMNUMDG	DT	Small molecular drug
DMNUMDG	PC	6438354
DMNUMDG	MW	283.32
DMNUMDG	FM	C17H17NO3
DMNUMDG	IC	InChI=1S/C17H17NO3/c1-14(19)18(20)12-6-8-15-7-5-11-17(13-15)21-16-9-3-2-4-10-16/h2-11,13,20H,12H2,1H3/b8-6+
DMNUMDG	CS	CC(=O)N(C/C=C/C1=CC(=CC=C1)OC2=CC=CC=C2)O
DMNUMDG	IK	CEUDWZXMLMKPNN-SOFGYWHQSA-N
DMNUMDG	IU	N-hydroxy-N-[(E)-3-(3-phenoxyphenyl)prop-2-enyl]acetamide
DMNUMDG	CA	CAS 106328-57-8
DMNUMDG	DE	Arthritis

DMTYCJ6	ID	DMTYCJ6
DMTYCJ6	DN	BW B70C
DMTYCJ6	HS	Terminated
DMTYCJ6	SN	BW B70C; BWB70C; BW-B 70C; 134470-38-5; BW-B70C; CHEMBL86676; CHEBI:75307; (E)-N-(3-(3-(4-Fluorophenoxy)phenyl)-1-(R,S)-methylprop-2-enyl)-N-hydroxyurea; 70C; N-[3-[3-4(-Fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea; N-(3-(3-(4-Fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxyurea; Urea, N-(3-(3-(4-fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxy-; C17H17FN2O3; SR-01000075717; (e)-N-{3-[3-(4-fluorophenoxy)phenyl]-1-(r,s)-methylprop-2-enyl}-N-hydroxyurea; Lopac0_000202; BSPBio_001512; SCHEMBL2681955
DMTYCJ6	DT	Small molecular drug
DMTYCJ6	PC	5353454
DMTYCJ6	MW	316.33
DMTYCJ6	FM	C17H17FN2O3
DMTYCJ6	IC	InChI=1S/C17H17FN2O3/c1-12(20(22)17(19)21)5-6-13-3-2-4-16(11-13)23-15-9-7-14(18)8-10-15/h2-12,22H,1H3,(H2,19,21)/b6-5+
DMTYCJ6	CS	CC(/C=C/C1=CC(=CC=C1)OC2=CC=C(C=C2)F)N(C(=O)N)O
DMTYCJ6	IK	UAIYNMRLUHHRMF-AATRIKPKSA-N
DMTYCJ6	IU	1-[(E)-4-[3-(4-fluorophenoxy)phenyl]but-3-en-2-yl]-1-hydroxyurea
DMTYCJ6	CA	CAS 134470-38-5
DMTYCJ6	CB	CHEBI:75307
DMTYCJ6	DE	Asthma

DMEP9B6	ID	DMEP9B6
DMEP9B6	DN	BW-1003C87
DMEP9B6	HS	Terminated
DMEP9B6	SN	144425-86-5; BW-1003C87; 5-(2,3,5-Trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate; Ethanesulfonic acid, compd. with 5-(2,3,5-trichlorophenyl)-2,4-pyrimidinediamine (1:1); BW 1003C87; ACMC-20n3z2; AC1L31BW; SCHEMBL15914195; CTK0H6679; DTXSID70162705; AKOS030595718; ethanesulfonic acid
DMEP9B6	CP	Burroughs Wellcome Inc
DMEP9B6	DT	Small molecular drug
DMEP9B6	PC	132630
DMEP9B6	MW	399.7
DMEP9B6	FM	C12H13Cl3N4O3S
DMEP9B6	IC	InChI=1S/C10H7Cl3N4.C2H6O3S/c11-4-1-5(8(13)7(12)2-4)6-3-16-10(15)17-9(6)14;1-2-6(3,4)5/h1-3H,(H4,14,15,16,17);2H2,1H3,(H,3,4,5)
DMEP9B6	CS	CCS(=O)(=O)O.C1=C(C=C(C(=C1C2=CN=C(N=C2N)N)Cl)Cl)Cl
DMEP9B6	IK	NVKJAOGJEDODFZ-UHFFFAOYSA-N
DMEP9B6	IU	ethanesulfonic acid;5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine
DMEP9B6	CA	CAS 144425-86-5
DMEP9B6	DE	Cerebrovascular ischaemia

DMQM3P4	ID	DMQM3P4
DMQM3P4	DN	BW755C
DMQM3P4	HS	Terminated
DMQM3P4	SN	BW755C; 66000-40-6; BW-755C; UNII-6V6JF56BXO; 6V6JF56BXO; CHEMBL274642; 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; 1-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1H-pyrazol-3-amine; 1-(3-trifluoromethylphenyl)-4,5-dihydro-1H-pyrazol-3-amine; 1-(3-Trifluoromethyl-phenyl)-4,5-dihydro-1H-pyrazol-3-ylamine; 4,5-DIHYDRO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H-PYRAZOL-3-AMINE; 1-(3-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-3-amine; BW 755C; EINECS 266-051-8; AC1L2IRR; SCHEMBL2573191; CTK5C3353; DTXSID30216213
DMQM3P4	DT	Small molecular drug
DMQM3P4	PC	47795
DMQM3P4	MW	229.2
DMQM3P4	FM	C10H10F3N3
DMQM3P4	IC	InChI=1S/C10H10F3N3/c11-10(12,13)7-2-1-3-8(6-7)16-5-4-9(14)15-16/h1-3,6H,4-5H2,(H2,14,15)
DMQM3P4	CS	C1CN(N=C1N)C2=CC=CC(=C2)C(F)(F)F
DMQM3P4	IK	CPXGGWXJNQSFEP-UHFFFAOYSA-N
DMQM3P4	IU	2-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-5-amine
DMQM3P4	CA	CAS 66000-40-6
DMQM3P4	DE	Inflammation

DMF6OY8	ID	DMF6OY8
DMF6OY8	DN	BW-A502U
DMF6OY8	HS	Terminated
DMF6OY8	SN	BW-502U83; 2-[10-(2-Hydroxyethoxy)-9-anthracenylmethylamino]-2-methyl-1,3-propanediol
DMF6OY8	DT	Small molecular drug
DMF6OY8	PC	125301
DMF6OY8	MW	355.4
DMF6OY8	FM	C21H25NO4
DMF6OY8	IC	InChI=1S/C21H25NO4/c1-21(13-24,14-25)22-12-19-15-6-2-4-8-17(15)20(26-11-10-23)18-9-5-3-7-16(18)19/h2-9,22-25H,10-14H2,1H3
DMF6OY8	CS	CC(CO)(CO)NCC1=C2C=CC=CC2=C(C3=CC=CC=C31)OCCO
DMF6OY8	IK	JPCHHZXQVHSGGC-UHFFFAOYSA-N
DMF6OY8	IU	2-[[10-(2-hydroxyethoxy)anthracen-9-yl]methylamino]-2-methylpropane-1,3-diol
DMF6OY8	CA	CAS 129026-48-8
DMF6OY8	DE	Solid tumour/cancer

DM0P8CE	ID	DM0P8CE
DM0P8CE	DN	BX-044
DM0P8CE	HS	Terminated
DM0P8CE	SN	Plasminogen activator inhibitor inhibitors, Berlex; ZK-4044; PAI-1 inhibitors, Berlex
DM0P8CE	CP	Berlex Biosciences
DM0P8CE	DE	Thrombosis

DMPL0C9	ID	DMPL0C9
DMPL0C9	DN	C-202
DMPL0C9	HS	Terminated
DMPL0C9	SN	C-301
DMPL0C9	CP	CepTor Corp
DMPL0C9	DE	Epilepsy

DMJQ3WR	ID	DMJQ3WR
DMJQ3WR	DN	C-AFG
DMJQ3WR	HS	Terminated
DMJQ3WR	SN	GR-85478
DMJQ3WR	CP	Glaxo Wellcome plc
DMJQ3WR	DE	Virus infection

DM9X2D0	ID	DM9X2D0
DM9X2D0	DN	Calphostin C
DM9X2D0	HS	Terminated
DM9X2D0	SN	calphostin C; CHEMBL460433; UNII-I271P23G24; I271P23G24; CHEMBL1256495; Ucn 1028 C; UCN 1028C; BSPBio_001520; GTPL5156; SCHEMBL15185703; HSDB 7592; SRJYZPCBWDVSGO-NHCUHLMSSA-N; HMS1989L22; HMS3402L22; HMS1791L22; BDBM213748; Carbonic acid, 2-(12-(2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxyphenyl ester; Carbonic acid, (1R)-2-(12-((2R)-2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxy
DM9X2D0	DT	Small molecular drug
DM9X2D0	PC	2533
DM9X2D0	MW	790.8
DM9X2D0	FM	C44H38O14
DM9X2D0	IC	InChI=1S/C44H38O14/c1-20(56-43(50)22-10-8-7-9-11-22)16-25-31-32-26(17-21(2)57-44(51)58-24-14-12-23(45)13-15-24)42(55-6)40(49)34-28(47)19-30(53-4)36(38(32)34)35-29(52-3)18-27(46)33(37(31)35)39(48)41(25)54-5/h7-15,18-21,45,48-49H,16-17H2,1-6H3
DM9X2D0	CS	CC(CC1=C2C3=C(C(=C(C4=C3C(=C5C2=C(C(=O)C=C5OC)C(=C1OC)O)C(=CC4=O)OC)O)OC)CC(C)OC(=O)OC6=CC=C(C=C6)O)OC(=O)C7=CC=CC=C7
DM9X2D0	IK	LSUTUUOITDQYNO-UHFFFAOYSA-N
DM9X2D0	IU	1-[3,10-dihydroxy-12-[2-(4-hydroxyphenoxy)carbonyloxypropyl]-2,6,7,11-tetramethoxy-4,9-dioxoperylen-1-yl]propan-2-yl benzoate
DM9X2D0	CA	CAS 121263-19-2

DMZ3QHF	ID	DMZ3QHF
DMZ3QHF	DN	CB-102930
DMZ3QHF	HS	Terminated
DMZ3QHF	SN	Antimicrobials, Cubist; CB-193; CB-286; CB-432; CB-447; CB-454; CB-484; CB-545; CB-628; CB-629; TRNA synthetase inhibitors (antimicrobial); TRNA synthetase inhibitors (antimicrobial), Cubist
DMZ3QHF	CP	Cubist Pharmaceuticals Inc
DMZ3QHF	DE	Bacterial infection

DM75KBM	ID	DM75KBM
DM75KBM	DN	CB-1267
DM75KBM	HS	Terminated
DM75KBM	CP	LEO Pharma A/S
DM75KBM	PC	7021558
DM75KBM	MW	293.36
DM75KBM	FM	C16H23NO4
DM75KBM	IC	InChI=1S/C16H23NO4/c1-16(2,3)21-15(20)17-13(11-14(18)19)10-9-12-7-5-4-6-8-12/h4-8,13H,9-11H2,1-3H3,(H,17,20)(H,18,19)/t13-/m1/s1
DM75KBM	CS	CC(C)(C)OC(=O)N[C@H](CCC1=CC=CC=C1)CC(=O)O
DM75KBM	IK	MYWZFJXOLAXENE-CYBMUJFWSA-N
DM75KBM	IU	(3R)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpentanoic acid
DM75KBM	CA	CAS 218608-83-4
DM75KBM	DE	Prostate cancer

DMJAGKY	ID	DMJAGKY
DMJAGKY	DN	CBR-2092
DMJAGKY	HS	Terminated
DMJAGKY	CP	Cumbre
DMJAGKY	DT	Small molecular drug
DMJAGKY	PC	137253362
DMJAGKY	MW	1205.4
DMJAGKY	FM	C65H81FN6O15
DMJAGKY	IC	InChI=1S/C65H81FN6O15/c1-31-13-12-14-32(2)61(80)68-50-44(56(77)47-48(57(50)78)55(76)37(7)59-49(47)60(79)64(9,87-59)85-26-20-46(84-11)33(3)58(86-38(8)73)36(6)54(75)35(5)53(31)74)28-67-71-24-18-41(19-25-71)69(10)65(21-22-65)40-17-23-70(29-40)52-34(4)51-42(39-15-16-39)27-43(63(82)83)62(81)72(51)30-45(52)66/h12-14,20,26-28,30-31,33,35-36,39-41,46,53-54,58,74-78H,15-19,21-25,29H2,1-11H3,(H,68,80)(H,82,83)/b13-12+,26-20+,32-14-,67-28-/t31-,33+,35+,36+,40+,46-,53-,54+,58+,64-/m0/s1
DMJAGKY	CS	C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N\\N5CCC(CC5)N(C)C6(CC6)[C@@H]7CCN(C7)C8=C(C9=C(C=C(C(=O)N9C=C8F)C(=O)O)C1CC1)C)/C
DMJAGKY	IK	OPZFMLLAJBIKAN-OSKJXBEZSA-N
DMJAGKY	IU	8-[(3R)-3-[1-[[1-[(Z)-[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-13-acetyloxy-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-26-yl]methylideneamino]piperidin-4-yl]-methylamino]cyclopropyl]pyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid
DMJAGKY	DE	Bacterial infection

DMAZB1R	ID	DMAZB1R
DMAZB1R	DN	CCR5Qb
DMAZB1R	HS	Terminated
DMAZB1R	SN	HIV vaccine, Cytos Biotechnology; AlphaVaccine (HIV), Cytos; CCR5-targeting HIV vaccine, Cytos; Immunodrug vaccines (CCR5) (HIV infection), Cytos
DMAZB1R	CP	Cytos Biotechnology AG
DMAZB1R	DT	Vaccine
DMAZB1R	DE	Human immunodeficiency virus infection

DM5FEBQ	ID	DM5FEBQ
DM5FEBQ	DN	CD-832
DM5FEBQ	HS	Terminated
DM5FEBQ	CP	Taisho Pharmaceutical Co Ltd
DM5FEBQ	DE	Angina pectoris

DMGQ9WP	ID	DMGQ9WP
DMGQ9WP	DN	CDE-5110
DMGQ9WP	HS	Terminated
DMGQ9WP	SN	CDE-6963; ROCK I/II inhibitors (inflammation); ROCK I/II inhibitors (inflammation), Devgen
DMGQ9WP	CP	Devgen NV
DMGQ9WP	DE	Inflammation

DMVHTQI	ID	DMVHTQI
DMVHTQI	DN	CDE-5498
DMVHTQI	HS	Terminated
DMVHTQI	SN	Dev-0304; Dev-0305; Kv4.3 voltage-dependent potassium channel antagonists (arrhythmia); Kv4.3 voltage-dependent potassium channel antagonists (arrhythmia), Devgen
DMVHTQI	CP	Devgen NV
DMVHTQI	DE	Heart arrhythmia

DMA0DKI	ID	DMA0DKI
DMA0DKI	DN	CDE-6960
DMA0DKI	HS	Terminated
DMA0DKI	SN	Protein kinase C epsilon/theta inhibitors (inflammation); PKC epsilon/theta inhibitors (inflammation), Devgen; Protein kinase C epsilon/theta inhibitors (inflammation), Devgen
DMA0DKI	CP	Devgen NV
DMA0DKI	DE	Inflammation

DMGMS2D	ID	DMGMS2D
DMGMS2D	DN	CDP-845
DMGMS2D	HS	Terminated
DMGMS2D	CP	UCB Celltech
DMGMS2D	DE	Solid tumour/cancer

DMNJXRG	ID	DMNJXRG
DMNJXRG	DN	CEB-925
DMNJXRG	HS	Terminated
DMNJXRG	SN	ACAT inhibitor, AHP
DMNJXRG	CP	Wyeth
DMNJXRG	DE	Hypercholesterolaemia

DMGEFX7	ID	DMGEFX7
DMGEFX7	DN	CEE-03-320
DMGEFX7	HS	Terminated
DMGEFX7	SN	CEE-320; NNC-220215
DMGEFX7	CP	Novo Nordisk A/S
DMGEFX7	DE	Substance use disorder

DMZE0SJ	ID	DMZE0SJ
DMZE0SJ	DN	CEP-4186
DMZE0SJ	HS	Terminated
DMZE0SJ	SN	CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma
DMZE0SJ	CP	LEO Pharma A/S
DMZE0SJ	DE	Acute myeloid leukaemia

DMTI10C	ID	DMTI10C
DMTI10C	DN	CEP-427
DMTI10C	HS	Terminated
DMTI10C	CP	Cephalon Inc
DMTI10C	DE	Alzheimer disease

DMDH0AM	ID	DMDH0AM
DMDH0AM	DN	CEP-431
DMDH0AM	HS	Terminated
DMDH0AM	SN	Clipsin inhibitor, Cephalon
DMDH0AM	CP	Cephalon Inc
DMDH0AM	DE	Alzheimer disease

DMFRW0G	ID	DMFRW0G
DMFRW0G	DN	CEP-5214
DMFRW0G	HS	Terminated
DMFRW0G	SN	12-(3-Hydroxypropyl)-9-(isopropoxymethyl)-6,7,12,13-tetrahydro-5H-indeno[2,1-a]pyrrolo[3,4-c]carbazol-5-one
DMFRW0G	DT	Small molecular drug
DMFRW0G	PC	10275001
DMFRW0G	MW	440.5
DMFRW0G	FM	C28H28N2O3
DMFRW0G	IC	InChI=1S/C28H28N2O3/c1-16(2)33-15-17-8-9-23-20(12-17)25-22-14-29-28(32)26(22)24-19-7-4-3-6-18(19)13-21(24)27(25)30(23)10-5-11-31/h3-4,6-9,12,16,31H,5,10-11,13-15H2,1-2H3,(H,29,32)
DMFRW0G	CS	CC(C)OCC1=CC2=C(C=C1)N(C3=C2C4=C(C5=C3CC6=CC=CC=C65)C(=O)NC4)CCCO
DMFRW0G	IK	MLIFNJABMANKEU-UHFFFAOYSA-N
DMFRW0G	IU	3-(3-hydroxypropyl)-7-(propan-2-yloxymethyl)-3,13-diazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1(16),2(10),4(9),5,7,11(15),17,19,21-nonaen-14-one
DMFRW0G	DE	Solid tumour/cancer

DM956N7	ID	DM956N7
DM956N7	DN	CEP-751
DM956N7	HS	Terminated
DM956N7	DT	Small molecular drug
DM956N7	PC	9868524
DM956N7	MW	453.5
DM956N7	FM	C27H23N3O4
DM956N7	IC	InChI=1S/C27H23N3O4/c1-26-27(13-31,33-2)11-19(34-26)29-17-9-5-3-7-14(17)21-22-16(12-28-25(22)32)20-15-8-4-6-10-18(15)30(26)24(20)23(21)29/h3-10,19,31H,11-13H2,1-2H3,(H,28,32)/t19?,26-,27-/m0/s1
DM956N7	CS	C[C@@]12[C@](CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)OC
DM956N7	IK	NMMGUHANGUWNBN-OGLOGDKOSA-N
DM956N7	IU	(15S,16S)-16-(hydroxymethyl)-16-methoxy-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one
DM956N7	DE	Neurodegenerative disorder

DMIDFLV	ID	DMIDFLV
DMIDFLV	DN	Cetamolol
DMIDFLV	HS	Terminated
DMIDFLV	SN	Betacor; Cetamolol hydrochloride; AI-27303; AY-27303
DMIDFLV	CP	Zeneca Group plc
DMIDFLV	DT	Small molecular drug
DMIDFLV	PC	53698
DMIDFLV	MW	310.39
DMIDFLV	FM	C16H26N2O4
DMIDFLV	IC	InChI=1S/C16H26N2O4/c1-16(2,3)18-9-12(19)10-21-13-7-5-6-8-14(13)22-11-15(20)17-4/h5-8,12,18-19H,9-11H2,1-4H3,(H,17,20)
DMIDFLV	CS	CC(C)(C)NCC(COC1=CC=CC=C1OCC(=O)NC)O
DMIDFLV	IK	UWCBNAVPISMFJZ-UHFFFAOYSA-N
DMIDFLV	IU	2-[2-[3-(tert-butylamino)-2-hydroxypropoxy]phenoxy]-N-methylacetamide
DMIDFLV	CA	CAS 34919-98-7
DMIDFLV	CB	CHEBI:135322
DMIDFLV	DE	Angina pectoris

DM5ESZU	ID	DM5ESZU
DM5ESZU	DN	CGP-25454A
DM5ESZU	HS	Terminated
DM5ESZU	CP	Novartis AG
DM5ESZU	PC	9819590
DM5ESZU	MW	346.2
DM5ESZU	FM	C15H21Cl2N3O2
DM5ESZU	IC	InChI=1S/C15H20ClN3O2.ClH/c1-4-19(5-2)7-6-18-15(20)12-8-11(10-17)13(16)9-14(12)21-3;/h8-9H,4-7H2,1-3H3,(H,18,20);1H
DM5ESZU	CS	CCN(CC)CCNC(=O)C1=C(C=C(C(=C1)C#N)Cl)OC.Cl
DM5ESZU	IK	ZETCQNUMZFZSLJ-UHFFFAOYSA-N
DM5ESZU	IU	4-chloro-5-cyano-N-[2-(diethylamino)ethyl]-2-methoxybenzamide;hydrochloride
DM5ESZU	DE	Major depressive disorder

DMZM70X	ID	DMZM70X
DMZM70X	DN	CGP-35348
DMZM70X	HS	Terminated
DMZM70X	SN	Cgp 35348; Cgp-35348; 123690-79-9; UNII-87TI61875H; P-(3-Aminopropyl)-P-diethoxymethylphosphinic acid; CHEMBL40157; 3-aminopropyl(diethoxymethyl)phosphinic acid; Phosphinic acid, (3-aminopropyl)(diethoxymethyl)-; CGP35348; 87TI61875H; (S)-(3-Aminopropyl)(Diethoxymethyl)phosphinic Acid; CGP 35348 hydrate; (3-Aminopropyl)(diethoxymethyl)phosphinic acid hydrate; Tocris-1245; Biomol-NT_000237; AC1L32KY; C8H20NO4P; SCHEMBL195698; GTPL1069; BPBio1_000508; DTXSID70154064; QIIVUOWTHWIXFO-UHFFFAOYSA-N; MolPort-003-983-819; PDSP2_000408
DMZM70X	DT	Small molecular drug
DMZM70X	PC	107699
DMZM70X	MW	225.22
DMZM70X	FM	C8H20NO4P
DMZM70X	IC	InChI=1S/C8H20NO4P/c1-3-12-8(13-4-2)14(10,11)7-5-6-9/h8H,3-7,9H2,1-2H3,(H,10,11)
DMZM70X	CS	CCOC(OCC)P(=O)(CCCN)O
DMZM70X	IK	QIIVUOWTHWIXFO-UHFFFAOYSA-N
DMZM70X	IU	3-aminopropyl(diethoxymethyl)phosphinic acid
DMZM70X	CA	CAS 123690-79-9
DMZM70X	DE	Epilepsy

DM69YWS	ID	DM69YWS
DM69YWS	DN	CGP-40215A
DM69YWS	HS	Terminated
DM69YWS	SN	Cgp-40215A; Cgp 40215A; Bis((3-(aminoiminomethyl)phenyl)methylene)carbonimidic dihydrazide trihydrochloride; Carbonimidic dihydrazide, bis((3-(aminoiminomethyl)phenyl)methylene)-, trihydrochloride
DM69YWS	CP	Novartis AG
DM69YWS	DT	Small molecular drug
DM69YWS	PC	9576797
DM69YWS	MW	458.8
DM69YWS	FM	C17H22Cl3N9
DM69YWS	IC	InChI=1S/C17H19N9.3ClH/c18-15(19)13-5-1-3-11(7-13)9-23-25-17(22)26-24-10-12-4-2-6-14(8-12)16(20)21;;;/h1-10H,(H3,18,19)(H3,20,21)(H3,22,25,26);3*1H/b23-9+,24-10+;;;
DM69YWS	CS	C1=CC(=CC(=C1)C(=N)N)/C=N/N/C(=N/N=C/C2=CC(=CC=C2)C(=N)N)/N.Cl.Cl.Cl
DM69YWS	IK	OTMBXWAKBWGKPN-VOTJPXFPSA-N
DM69YWS	IU	3-[(E)-[[(E)-N'-[(E)-(3-carbamimidoylphenyl)methylideneamino]carbamimidoyl]hydrazinylidene]methyl]benzenecarboximidamide;trihydrochloride
DM69YWS	CA	CAS 126534-93-8
DM69YWS	DE	Pneumocystis pneumonia

DMIWUFC	ID	DMIWUFC
DMIWUFC	DN	CGP-52411
DMIWUFC	HS	Terminated
DMIWUFC	SN	DAPH
DMIWUFC	CP	Novartis AG
DMIWUFC	DT	Small molecular drug
DMIWUFC	PC	1697
DMIWUFC	MW	329.4
DMIWUFC	FM	C20H15N3O2
DMIWUFC	IC	InChI=1S/C20H15N3O2/c24-19-15-11-17(21-13-7-3-1-4-8-13)18(12-16(15)20(25)23-19)22-14-9-5-2-6-10-14/h1-12,21-22H,(H,23,24,25)
DMIWUFC	CS	C1=CC=C(C=C1)NC2=C(C=C3C(=C2)C(=O)NC3=O)NC4=CC=CC=C4
DMIWUFC	IK	AAALVYBICLMAMA-UHFFFAOYSA-N
DMIWUFC	IU	5,6-dianilinoisoindole-1,3-dione
DMIWUFC	CA	CAS 145915-58-8
DMIWUFC	CB	CHEBI:53110
DMIWUFC	DE	Solid tumour/cancer

DM9VDZP	ID	DM9VDZP
DM9VDZP	DN	CGP-53353
DM9VDZP	HS	Terminated
DM9VDZP	SN	145915-60-2; CGP 53353; CGP-53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492
DM9VDZP	DT	Small molecular drug
DM9VDZP	PC	6711154
DM9VDZP	MW	365.3
DM9VDZP	FM	C20H13F2N3O2
DM9VDZP	IC	InChI=1S/C20H13F2N3O2/c21-11-1-5-13(6-2-11)23-17-9-15-16(20(27)25-19(15)26)10-18(17)24-14-7-3-12(22)4-8-14/h1-10,23-24H,(H,25,26,27)
DM9VDZP	CS	C1=CC(=CC=C1NC2=C(C=C3C(=C2)C(=O)NC3=O)NC4=CC=C(C=C4)F)F
DM9VDZP	IK	RONQPWQYDRPRGG-UHFFFAOYSA-N
DM9VDZP	IU	5,6-bis(4-fluoroanilino)isoindole-1,3-dione
DM9VDZP	CA	CAS 145915-60-2
DM9VDZP	CB	CHEBI:92560

DMJ325M	ID	DMJ325M
DMJ325M	DN	CGP-53716
DMJ325M	HS	Terminated
DMJ325M	SN	CGS-53716
DMJ325M	CP	Novartis AG
DMJ325M	PC	9864718
DMJ325M	MW	381.4
DMJ325M	FM	C23H19N5O
DMJ325M	IC	InChI=1S/C23H19N5O/c1-16-9-10-19(26-22(29)17-6-3-2-4-7-17)14-21(16)28-23-25-13-11-20(27-23)18-8-5-12-24-15-18/h2-15H,1H3,(H,26,29)(H,25,27,28)
DMJ325M	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)NC3=NC=CC(=N3)C4=CN=CC=C4
DMJ325M	IK	UOEJSOXEHKCNAE-UHFFFAOYSA-N
DMJ325M	IU	N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMJ325M	DE	Solid tumour/cancer

DM4TGY0	ID	DM4TGY0
DM4TGY0	DN	CGP-60474
DM4TGY0	HS	Terminated
DM4TGY0	SN	CGP60474; 164658-13-3; CGP-60474; UNII-16IP6G5MLC; CGP 60474; GNF-Pf-88; 16IP6G5MLC; 3-[[4-[2-[(3-Chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-1-propanol; MLS000911536; SMR000463552; 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]-2-pyridyl]amino]propan-1-ol; 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propan-1-ol; 1-Propanol, 3-((4-(2-((3-chlorophenyl)amino)-4-pyrimidinyl)-2-pyridinyl)amino)-; 1-propanol, 3-[[4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-; AC1LD8S6; MLS003105942
DM4TGY0	DT	Small molecular drug
DM4TGY0	PC	644215
DM4TGY0	MW	355.8
DM4TGY0	FM	C18H18ClN5O
DM4TGY0	IC	InChI=1S/C18H18ClN5O/c19-14-3-1-4-15(12-14)23-18-22-9-6-16(24-18)13-5-8-21-17(11-13)20-7-2-10-25/h1,3-6,8-9,11-12,25H,2,7,10H2,(H,20,21)(H,22,23,24)
DM4TGY0	CS	C1=CC(=CC(=C1)Cl)NC2=NC=CC(=N2)C3=CC(=NC=C3)NCCCO
DM4TGY0	IK	IYNDTACKOAXKBJ-UHFFFAOYSA-N
DM4TGY0	IU	3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propan-1-ol
DM4TGY0	CA	CAS 164658-13-3
DM4TGY0	CB	CHEBI:91339
DM4TGY0	DE	Solid tumour/cancer

DMRLXC3	ID	DMRLXC3
DMRLXC3	DN	CGP-70726
DMRLXC3	HS	Terminated
DMRLXC3	CP	Novartis AG
DMRLXC3	PC	469663
DMRLXC3	MW	689.8
DMRLXC3	FM	C38H51N5O7
DMRLXC3	IC	InChI=1S/C38H51N5O7/c1-25(2)32(40-36(47)49-6)34(45)39-30(22-26-14-10-8-11-15-26)31(44)24-43(42-35(46)33(38(3,4)5)41-37(48)50-7)23-27-18-20-29(21-19-27)28-16-12-9-13-17-28/h8-21,25,30-33,44H,22-24H2,1-7H3,(H,39,45)(H,40,47)(H,41,48)(H,42,46)/t30-,31-,32-,33+/m0/s1
DMRLXC3	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=C3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC
DMRLXC3	IK	BYEWWQZDUPJZHX-ZWDYZTTJSA-N
DMRLXC3	IU	methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-phenylphenyl)methyl]amino]-1-phenylbutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
DMRLXC3	CA	CAS 215312-87-1
DMRLXC3	DE	Human immunodeficiency virus-1 infection

DMKUETX	ID	DMKUETX
DMKUETX	DN	CGS 8515
DMKUETX	HS	Terminated
DMKUETX	SN	114832-13-2; CGS-8515; Methyl 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)benzoate; Benzoic acid,2-[(3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino]-, methyl ester; methyl 2-[(3,4-dioxonaphthalen-1-yl)amino]benzoate; AC1L4TWI; AC1Q5ZBK; cgs8515; ACMC-1C4N1; SCHEMBL3273068; CTK4A8934; DTXSID80150875; methyl 2-[(3,4-dioxo-3,4-dihydronaphthalen-1-yl)amino]benzoate; Benzoic acid, 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)-, methyl ester
DMKUETX	DT	Small molecular drug
DMKUETX	PC	163944
DMKUETX	MW	307.3
DMKUETX	FM	C18H13NO4
DMKUETX	IC	InChI=1S/C18H13NO4/c1-23-18(22)13-8-4-5-9-14(13)19-15-10-16(20)17(21)12-7-3-2-6-11(12)15/h2-10,19H,1H3
DMKUETX	CS	COC(=O)C1=CC=CC=C1NC2=CC(=O)C(=O)C3=CC=CC=C32
DMKUETX	IK	PEJZAKFAABRDEN-UHFFFAOYSA-N
DMKUETX	IU	methyl 2-[(3,4-dioxonaphthalen-1-yl)amino]benzoate
DMKUETX	CA	CAS 114832-13-2

DM6MEX4	ID	DM6MEX4
DM6MEX4	DN	CGS-12066B
DM6MEX4	HS	Terminated
DM6MEX4	SN	CGS 12066B; UNII-5TB4SXQ7HG; CGS 12066B-parent; Cgs 12066; CGS12066; 5TB4SXQ7HG; 109028-09-3; 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline; CHEMBL27403; CGS-12066B; CHEBI:64055; CGS-12066A; CGS-12066; CGS-12066A maleate salt; Pyrrolo[1,2-a]quinoxaline, 4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)-; Pyrrolo(1,2-a)quinoxaline, 4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)-; NCGC00024701-01; Tocris-0638; 7-Trifluoromethyl-4-(4-methyl-1-piperazinyl)pyrrolo-[1,2-a]quinoxaline maleate salt
DM6MEX4	DT	Small molecular drug
DM6MEX4	PC	9915956
DM6MEX4	MW	566.5
DM6MEX4	FM	C25H25F3N4O8
DM6MEX4	IC	InChI=1S/C17H17F3N4.2C4H4O4/c1-22-7-9-23(10-8-22)16-15-3-2-6-24(15)14-5-4-12(17(18,19)20)11-13(14)21-16;2*5-3(6)1-2-4(7)8/h2-6,11H,7-10H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
DM6MEX4	CS	CN1CCN(CC1)C2=NC3=C(N4C2=CC=C4)C=CC(=C3)C(F)(F)F.C(=C\\C(=O)O)\\C(=O)O.C(=C\\C(=O)O)\\C(=O)O
DM6MEX4	IK	HTEVMLYDEWVIQE-SPIKMXEPSA-N
DM6MEX4	IU	(Z)-but-2-enedioic acid;4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline
DM6MEX4	CA	CAS 109028-10-6
DM6MEX4	DE	Anxiety disorder

DMUPKYO	ID	DMUPKYO
DMUPKYO	DN	CGS-13080
DMUPKYO	HS	Terminated
DMUPKYO	SN	PIRMAGREL; CGS-13080; Pirmagrelum [Latin]; Pirmgrel; Pirmagrel [USAN:INN]; UNII-9J5H2VA91V; CGS 13080; 85691-74-3; CHEMBL48092; 9J5H2VA91V; Imidazo(1,5-a)pyridine-5-hexanoic acid; Pirmagrelum; Imidazo[1,5-a]pyridine-5-hexanoic acid; Pirmagrel (USAN/INN); AC1L1IZ7; SCHEMBL636018; DTXSID80234982; LIFOFTJHFFTNRV-UHFFFAOYSA-N; ZINC2021333; BDBM50025953; imidazol(1,5-a)pyridine-5-hexanoic acid; LS-177888; 6-imidazo[1,5-a]pyridin-5-ylhexanoic acid; 5-(5-carboxypentyl)imidazo[1,5-a]pyridine; 5-(5-carboxypentyl)-imidazo[1,5-a]pyridine
DMUPKYO	DT	Small molecular drug
DMUPKYO	PC	55390
DMUPKYO	MW	232.28
DMUPKYO	FM	C13H16N2O2
DMUPKYO	IC	InChI=1S/C13H16N2O2/c16-13(17)8-3-1-2-5-11-6-4-7-12-9-14-10-15(11)12/h4,6-7,9-10H,1-3,5,8H2,(H,16,17)
DMUPKYO	CS	C1=CC2=CN=CN2C(=C1)CCCCCC(=O)O
DMUPKYO	IK	LIFOFTJHFFTNRV-UHFFFAOYSA-N
DMUPKYO	IU	6-imidazo[1,5-a]pyridin-5-ylhexanoic acid
DMUPKYO	CA	CAS 85691-74-3
DMUPKYO	DE	Asthma

DMMZJY3	ID	DMMZJY3
DMMZJY3	DN	CGS-17867A
DMMZJY3	HS	Terminated
DMMZJY3	SN	Cgs-17867A; CHEMBL116842; 2-(4-Chloro-phenyl)-2,5,6,7,8,9-hexahydro-pyrazolo[4,3-c]quinolin-3-one; AC1L2T4E; SCHEMBL2287621; OJVURBSORBSWLX-UHFFFAOYSA-N; CGS-17867; BDBM50148320; 2-p-Tolyl-2,5,6,7,8,9-hexahydro-pyrazolo[4,3-c]quinolin-3-one; 2-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrazolo[4,3-c]quinolin-3-one
DMMZJY3	DT	Small molecular drug
DMMZJY3	PC	128064
DMMZJY3	MW	299.75
DMMZJY3	FM	C16H14ClN3O
DMMZJY3	IC	InChI=1S/C16H14ClN3O/c17-10-5-7-11(8-6-10)20-16(21)13-9-18-14-4-2-1-3-12(14)15(13)19-20/h5-9,19H,1-4H2
DMMZJY3	CS	C1CCC2=NC=C3C(=C2C1)NN(C3=O)C4=CC=C(C=C4)Cl
DMMZJY3	IK	NZEIZTTWQRQFFV-UHFFFAOYSA-N
DMMZJY3	IU	2-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrazolo[4,3-c]quinolin-3-one
DMMZJY3	DE	Alcohol dependence

DM4W3MU	ID	DM4W3MU
DM4W3MU	DN	CGS-18102A
DM4W3MU	HS	Terminated
DM4W3MU	SN	CGP-50281; CGS-18102
DM4W3MU	CP	Novartis AG
DM4W3MU	DT	Small molecular drug
DM4W3MU	PC	146963
DM4W3MU	MW	297.82
DM4W3MU	FM	C16H24ClNO2
DM4W3MU	IC	InChI=1S/C16H23NO2.ClH/c1-3-9-17-10-5-6-12-13(17)11-19-15-8-4-7-14(18-2)16(12)15;/h4,7-8,12-13H,3,5-6,9-11H2,1-2H3;1H/t12-,13+;/m1./s1
DM4W3MU	CS	CCCN1CCC[C@@H]2[C@@H]1COC3=C2C(=CC=C3)OC.Cl
DM4W3MU	IK	IIARBXRSECAIPI-KZCZEQIWSA-N
DM4W3MU	IU	(4aR,10bS)-10-methoxy-4-propyl-1,2,3,4a,5,10b-hexahydrochromeno[3,4-b]pyridine;hydrochloride
DM4W3MU	CA	CAS 100746-36-9
DM4W3MU	DE	Anxiety disorder

DMFZM09	ID	DMFZM09
DMFZM09	DN	CGS-26303
DMFZM09	HS	Terminated
DMFZM09	SN	Cgs-26303; Cgs 26303; 154116-31-1; CHEMBL290698; (S)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminomethyl phosphonic acid; cgs26303; SCHEMBL653011; AC1L31X6; CTK4C8115; DTXSID40165541; BDBM50064106; Phosphonic acid, (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)-, (S)-; {[(S)-2-Biphenyl-4-yl-1-(2H-tetrazol-5-yl)-ethylamino]-methyl}-phosphonic acid; {[(S)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)-ethylamino]-methyl}-phosphonic acid; {[(R)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)-ethylamino]-methyl}-phosphonic ac
DMFZM09	DT	Small molecular drug
DMFZM09	PC	132968
DMFZM09	MW	359.32
DMFZM09	FM	C16H18N5O3P
DMFZM09	IC	InChI=1S/C16H18N5O3P/c22-25(23,24)11-17-15(16-18-20-21-19-16)10-12-6-8-14(9-7-12)13-4-2-1-3-5-13/h1-9,15,17H,10-11H2,(H2,22,23,24)(H,18,19,20,21)/t15-/m0/s1
DMFZM09	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C[C@@H](C3=NNN=N3)NCP(=O)(O)O
DMFZM09	IK	UUMKQZVEZSXWBY-HNNXBMFYSA-N
DMFZM09	IU	[[(1S)-2-(4-phenylphenyl)-1-(2H-tetrazol-5-yl)ethyl]amino]methylphosphonic acid
DMFZM09	CA	CAS 154116-31-1

DM4U72A	ID	DM4U72A
DM4U72A	DN	CGS-26393
DM4U72A	HS	Terminated
DM4U72A	SN	Cgs 26393; Cgs-26393; 154116-34-4; AC1L2SSW; cgs26393; CHEMBL36795; SCHEMBL8921559; CTK4C8116; DTXSID00165542; 2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminoethyl phosphonic acid; (S)-Diphenyl (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)phosphonate; (1S)-N-(diphenoxyphosphorylmethyl)-2-(4-phenylphenyl)-1-(2H-tetrazol-5-yl)ethanamine; Phosphonic acid, (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)-, diphenyl ester, (S)-; Phosphonic acid,P-[[[(1S)-2-[1,1'-biphenyl]-4-yl-1-(2H-tetraz
DM4U72A	CP	Novartis AG
DM4U72A	DT	Small molecular drug
DM4U72A	PC	127883
DM4U72A	MW	511.5
DM4U72A	FM	C28H26N5O3P
DM4U72A	IC	InChI=1S/C28H26N5O3P/c34-37(35-25-12-6-2-7-13-25,36-26-14-8-3-9-15-26)21-29-27(28-30-32-33-31-28)20-22-16-18-24(19-17-22)23-10-4-1-5-11-23/h1-19,27,29H,20-21H2,(H,30,31,32,33)/t27-/m0/s1
DM4U72A	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C[C@@H](C3=NNN=N3)NCP(=O)(OC4=CC=CC=C4)OC5=CC=CC=C5
DM4U72A	IK	AHIFMZUYRNPRJK-MHZLTWQESA-N
DM4U72A	IU	(1S)-N-(diphenoxyphosphorylmethyl)-2-(4-phenylphenyl)-1-(2H-tetrazol-5-yl)ethanamine
DM4U72A	CA	CAS 154116-34-4
DM4U72A	DE	Heart disease

DMJ4FGZ	ID	DMJ4FGZ
DMJ4FGZ	DN	CGS-26529
DMJ4FGZ	HS	Terminated
DMJ4FGZ	SN	CGS-265529
DMJ4FGZ	CP	Novartis AG
DMJ4FGZ	PC	9803758
DMJ4FGZ	MW	449.5
DMJ4FGZ	FM	C25H24FN3O4
DMJ4FGZ	IC	InChI=1S/C25H24FN3O4/c26-21-7-5-19(6-8-21)18-3-1-17(2-4-18)16-28-12-11-20-15-22(9-10-23(20)24(28)30)33-14-13-29(32)25(27)31/h1-10,15,32H,11-14,16H2,(H2,27,31)
DMJ4FGZ	CS	C1CN(C(=O)C2=C1C=C(C=C2)OCCN(C(=O)N)O)CC3=CC=C(C=C3)C4=CC=C(C=C4)F
DMJ4FGZ	IK	QFDRKYCYRMSXMS-UHFFFAOYSA-N
DMJ4FGZ	IU	1-[2-[[2-[[4-(4-fluorophenyl)phenyl]methyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]oxy]ethyl]-1-hydroxyurea
DMJ4FGZ	DE	Inflammation

DM8TLY3	ID	DM8TLY3
DM8TLY3	DN	CGS-27830
DM8TLY3	HS	Terminated
DM8TLY3	SN	Cgs-27830; Cgs 27830; AC1L4RBN; AC1Q5XDJ; cgs27830; (4r)-5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic(4s)-5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic anhydride; SCHEMBL9089580; 155485-56-6; meso-1,4-Dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridine carboxylic acid anhydride; 5-O-[(4S)-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carbonyl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydr
DM8TLY3	DT	Small molecular drug
DM8TLY3	PC	190809
DM8TLY3	MW	646.6
DM8TLY3	FM	C32H30N4O11
DM8TLY3	IC	InChI=1S/C32H30N4O11/c1-15-23(29(37)45-5)27(19-9-7-11-21(13-19)35(41)42)25(17(3)33-15)31(39)47-32(40)26-18(4)34-16(2)24(30(38)46-6)28(26)20-10-8-12-22(14-20)36(43)44/h7-14,27-28,33-34H,1-6H3/t27-,28+
DM8TLY3	CS	CC1=C([C@H](C(=C(N1)C)C(=O)OC(=O)C2=C(NC(=C([C@@H]2C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC)C)C)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DM8TLY3	IK	PZNZOWSLQRURNA-HNRBIFIRSA-N
DM8TLY3	IU	5-O-[(4R)-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carbonyl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM8TLY3	CA	CAS 155485-56-6

DM94WIO	ID	DM94WIO
DM94WIO	DN	CGS-30440
DM94WIO	HS	Terminated
DM94WIO	CP	Ciba-Geigy Corp
DM94WIO	PC	87992715
DM94WIO	MW	464.6
DM94WIO	FM	C23H32N2O6S
DM94WIO	IC	InChI=1S/C23H32N2O6S/c1-14(2)19(32-15(3)26)20(27)25-23(11-5-6-12-23)22(30)24-18(21(28)29)13-16-7-9-17(31-4)10-8-16/h7-10,14,18-19H,5-6,11-13H2,1-4H3,(H,24,30)(H,25,27)(H,28,29)/t18-,19-/m0/s1
DM94WIO	CS	CC(C)[C@@H](C(=O)NC1(CCCC1)C(=O)N[C@@H](CC2=CC=C(C=C2)OC)C(=O)O)SC(=O)C
DM94WIO	IK	POVJRTWSWOOUQR-OALUTQOASA-N
DM94WIO	IU	(2S)-2-[[1-[[(2S)-2-acetylsulfanyl-3-methylbutanoyl]amino]cyclopentanecarbonyl]amino]-3-(4-methoxyphenyl)propanoic acid
DM94WIO	DE	Hypertension

DM1VZ2I	ID	DM1VZ2I
DM1VZ2I	DN	CGS-32359
DM1VZ2I	HS	Terminated
DM1VZ2I	SN	C5aRAD
DM1VZ2I	CP	Novartis AG
DM1VZ2I	DE	Inflammation

DM39PQI	ID	DM39PQI
DM39PQI	DN	CGS-9896
DM39PQI	HS	Terminated
DM39PQI	SN	Cgs-9896; Cgs 9896; 77779-36-3; UNII-86PWQ4PVN0; 86PWQ4PVN0; AC1Q3J9C; AC1L337H; SCHEMBL7308514; AC1Q3T13; 2-(4-chlorophenyl)-1H-pyrazolo[4,3-c]quinolin-3-one; SCHEMBL17236324; CTK5E4889; BDBM84957; AOB4759; MolPort-009-714-150; CQINXWYVIOMBEI-UHFFFAOYSA-N; PDSP2_001748; 2-(4-chlorophenyl)-1,2-dihydro-3h-pyrazolo[4,3-c]quinolin-3-one; PDSP1_001765; ZINC100367629; AKOS021973584; MCULE-9708849911; A10022; 2-(p-chlorophenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one; F3406-4901; 2-(4-chlorophenyl)-1H-pyrazolo[4,5-c]quinolin-3-one
DM39PQI	DT	Small molecular drug
DM39PQI	PC	108030
DM39PQI	MW	295.72
DM39PQI	FM	C16H10ClN3O
DM39PQI	IC	InChI=1S/C16H10ClN3O/c17-10-5-7-11(8-6-10)20-16(21)13-9-18-14-4-2-1-3-12(14)15(13)19-20/h1-9,19H
DM39PQI	CS	C1=CC=C2C(=C1)C3=C(C=N2)C(=O)N(N3)C4=CC=C(C=C4)Cl
DM39PQI	IK	QCBUAKLOWCOUCR-UHFFFAOYSA-N
DM39PQI	IU	2-(4-chlorophenyl)-1H-pyrazolo[4,3-c]quinolin-3-one
DM39PQI	CA	CAS 77779-36-3

DMADYF7	ID	DMADYF7
DMADYF7	DN	CGX-1160
DMADYF7	HS	Terminated
DMADYF7	CP	Cognetix
DMADYF7	TC	Analgesics
DMADYF7	DT	Small molecular drug
DMADYF7	PC	56603671
DMADYF7	MW	2038.2
DMADYF7	FM	C89H144N20O34
DMADYF7	IC	InChI=1S/C89H144N20O34/c1-41(2)29-57(89(140)141)106-86(137)69(42(3)4)94-34-49(30-46-16-18-50(115)19-17-46)98-85(136)60-15-12-28-109(60)88(139)55(14-9-11-27-91)104-79(130)51(13-8-10-26-90)103-87(138)70(44(6)142-61-31-48(38-111)73(125)76(71(61)97-45(7)114)143-62-32-47(37-110)72(124)75(127)74(62)126)108-77(128)43(5)96-82(133)56(33-63(92)116)105-83(134)58(39-112)100-66(119)36-93-65(118)35-95-78(129)52(21-24-67(120)121)101-81(132)54(22-25-68(122)123)102-84(135)59(40-113)107-80(131)53-20-23-64(117)99-53/h16-19,41-44,47-49,51-62,69-76,94,110-113,115,124-127H,8-15,20-40,90-91H2,1-7H3,(H2,92,116)(H,93,118)(H,95,129)(H,96,133)(H,97,114)(H,98,136)(H,99,117)(H,100,119)(H,101,132)(H,102,135)(H,103,138)(H,104,130)(H,105,134)(H,106,137)(H,107,131)(H,108,128)(H,120,121)(H,122,123)(H,140,141)/t43-,44-,47-,48?,49-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61?,62+,69-,70+,71?,72+,73?,74+,75+,76?/m0/s1
DMADYF7	CS	C[C@@H]([C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=C(C=C2)O)CN[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H]3CCC(=O)N3)OC4CC(C(C(C4NC(=O)C)O[C@@H]5C[C@H]([C@H]([C@H]([C@@H]5O)O)O)CO)O)CO
DMADYF7	IK	BDYYRSHYAJPHLA-CDMGOGEFSA-N
DMADYF7	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2R,3S)-3-[2-acetamido-4-hydroxy-5-(hydroxymethyl)-3-[(1R,2S,3R,4R,5S)-2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexyl]oxycyclohexyl]oxy-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[2-[[2-[[(2S)-4-carboxy-2-[[(2S)-4-carboxy-2-[[(2S)-3-hydroxy-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]butanoyl]amino]butanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoic acid
DMADYF7	DE	Acute or chronic pain

DMJ2P1Q	ID	DMJ2P1Q
DMJ2P1Q	DN	CI-1002
DMJ2P1Q	HS	Terminated
DMJ2P1Q	SN	PD-142676
DMJ2P1Q	CP	Parke-Davis & Co
DMJ2P1Q	PC	9838284
DMJ2P1Q	MW	269.17
DMJ2P1Q	FM	C13H14Cl2N2
DMJ2P1Q	IC	InChI=1S/C13H14Cl2N2/c14-9-6-11(15)10-8-17-5-3-1-2-4-13(17)16-12(10)7-9/h6-7H,1-5,8H2
DMJ2P1Q	CS	C1CCC2=NC3=C(CN2CC1)C(=CC(=C3)Cl)Cl
DMJ2P1Q	IK	WTPSHLVHJOJDIF-UHFFFAOYSA-N
DMJ2P1Q	IU	1,3-dichloro-6,7,8,9,10,12-hexahydroazepino[2,1-b]quinazoline
DMJ2P1Q	CA	CAS 149028-28-4
DMJ2P1Q	DE	Alzheimer disease

DMUK9L4	ID	DMUK9L4
DMUK9L4	DN	CI-1021
DMUK9L4	HS	Terminated
DMUK9L4	SN	Methyl-GAG pamoate; NSC96016; 18186-55-5; NSC 96016; NSC-96016; 2-Naphthalencarboxylic acid, 4,4'-methylenebis(3-hydroxy-, compd. with 2,2'-(1-methyl-1, 2-ethanediylidene)bis(hydrazinecarboximideamide) (1:1); 2-Naphthoic acid, 4,4'methylenebis[3-hydroxy-, compd with 1, 1'-[(methylethanediyldene)dinitrilo]diguanidine (1:1); 1-[(E)-[(2E)-2-(carbamimidoylhydrazono)-1-methyl-ethylidene]amino]guanidine; 4-[(3-carboxy-2-hydroxy-1-naphthyl)methyl]-3-hydroxy-naphthalene-2-carboxylic acid; 2-Naphthalencarboxylic acid,4'-met
DMUK9L4	DT	Small molecular drug
DMUK9L4	PC	9805809
DMUK9L4	MW	495.6
DMUK9L4	FM	C30H29N3O4
DMUK9L4	IC	InChI=1S/C30H29N3O4/c1-20(21-10-4-3-5-11-21)32-28(34)30(2,17-23-18-31-26-14-8-7-13-25(23)26)33-29(35)36-19-24-16-22-12-6-9-15-27(22)37-24/h3-16,18,20,31H,17,19H2,1-2H3,(H,32,34)(H,33,35)/t20-,30+/m0/s1
DMUK9L4	CS	C[C@@H](C1=CC=CC=C1)NC(=O)[C@@](C)(CC2=CNC3=CC=CC=C32)NC(=O)OCC4=CC5=CC=CC=C5O4
DMUK9L4	IK	IVIQHHCTWSXXCT-WENCNXQZSA-N
DMUK9L4	IU	1-benzofuran-2-ylmethyl N-[(2R)-3-(1H-indol-3-yl)-2-methyl-1-oxo-1-[[(1S)-1-phenylethyl]amino]propan-2-yl]carbamate
DMUK9L4	CA	CAS 158991-23-2

DMI0TD8	ID	DMI0TD8
DMI0TD8	DN	CI-986
DMI0TD8	HS	Terminated
DMI0TD8	SN	CI-986; CI 986; 5-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione; 5-(3,5-Bis(1,1-dimethylethyl)-4-(hydroxyphenyl))-1,3,4-thiadiazole-2(3H)-thione choline salt; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 5-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione (1:1); 130116-16-4; AC1MI25H; C16H22N2OS2.C5H14NO; LS-172752; 2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate
DMI0TD8	CP	Parke-Davis & Co
DMI0TD8	DT	Small molecular drug
DMI0TD8	PC	3037017
DMI0TD8	MW	425.7
DMI0TD8	FM	C21H35N3O2S2
DMI0TD8	IC	InChI=1S/C16H22N2OS2.C5H14NO/c1-15(2,3)10-7-9(13-17-18-14(20)21-13)8-11(12(10)19)16(4,5)6;1-6(2,3)4-5-7/h7-8,19H,1-6H3,(H,18,20);7H,4-5H2,1-3H3/q;+1/p-1
DMI0TD8	CS	CC(C)(C)C1=CC(=CC(=C1[O-])C(C)(C)C)C2=NNC(=S)S2.C[N+](C)(C)CCO
DMI0TD8	IK	BIZSVVIRPJXFOI-UHFFFAOYSA-M
DMI0TD8	IU	2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate;2-hydroxyethyl(trimethyl)azanium
DMI0TD8	CA	CAS 130116-16-4
DMI0TD8	DE	Rheumatoid arthritis

DMBHYIJ	ID	DMBHYIJ
DMBHYIJ	DN	CI-992
DMBHYIJ	HS	Terminated
DMBHYIJ	SN	CI-992; CHEMBL34894; 135704-06-2; CTK4B9950; N-[2-(2-Amino-thiazol-4-yl)-1-(1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-ethyl]-2-(morpholine-4-sulfonylamino)-3-phenyl-propionamide; L-Alaninamide,N-(4-morpholinylsulfonyl)-L-phenylalanyl-3-(2-amino-4-thiazolyl)-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-(9CI); BDBM50006844
DMBHYIJ	DT	Small molecular drug
DMBHYIJ	PC	9875002
DMBHYIJ	MW	708.9
DMBHYIJ	FM	C33H52N6O7S2
DMBHYIJ	IC	InChI=1S/C33H52N6O7S2/c1-22(2)17-29(40)30(41)26(18-23-9-5-3-6-10-23)36-31(42)27(20-25-21-47-33(34)35-25)37-32(43)28(19-24-11-7-4-8-12-24)38-48(44,45)39-13-15-46-16-14-39/h4,7-8,11-12,21-23,26-30,38,40-41H,3,5-6,9-10,13-20H2,1-2H3,(H2,34,35)(H,36,42)(H,37,43)/t26-,27-,28-,29-,30+/m0/s1
DMBHYIJ	CS	CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC2=CSC(=N2)N)NC(=O)[C@H](CC3=CC=CC=C3)NS(=O)(=O)N4CCOCC4)O)O
DMBHYIJ	IK	QGJKHQRFJGLJLV-VFFRCKCKSA-N
DMBHYIJ	IU	(2S)-N-[(2S)-3-(2-amino-1,3-thiazol-4-yl)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-1-oxopropan-2-yl]-2-(morpholin-4-ylsulfonylamino)-3-phenylpropanamide
DMBHYIJ	DE	Hypertension

DMCJ7N1	ID	DMCJ7N1
DMCJ7N1	DN	CI-996
DMCJ7N1	HS	Terminated
DMCJ7N1	CP	Parke-Davis & Co
DMCJ7N1	PC	9828975
DMCJ7N1	MW	549.5
DMCJ7N1	FM	C27H22F3N7O3
DMCJ7N1	IC	InChI=1S/C27H22F3N7O3/c1-2-6-21-31-25(36-14-5-9-20(36)23(38)27(28,29)30)22(26(39)40)37(21)15-16-10-12-17(13-11-16)18-7-3-4-8-19(18)24-32-34-35-33-24/h3-5,7-14H,2,6,15H2,1H3,(H,39,40)(H,32,33,34,35)
DMCJ7N1	CS	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)N5C=CC=C5C(=O)C(F)(F)F
DMCJ7N1	IK	MGSBGAVGFLLRDU-UHFFFAOYSA-N
DMCJ7N1	IU	2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5-[2-(2,2,2-trifluoroacetyl)pyrrol-1-yl]imidazole-4-carboxylic acid
DMCJ7N1	DE	Hypertension

DMV1J0P	ID	DMV1J0P
DMV1J0P	DN	CI-999
DMV1J0P	HS	Terminated
DMV1J0P	SN	PD-138142-15
DMV1J0P	CP	Warner-Lambert Co
DMV1J0P	PC	74083365
DMV1J0P	MW	483.6
DMV1J0P	FM	C25H34NNaO5S
DMV1J0P	IC	InChI=1S/C25H35NO5S.Na/c1-15(2)19-11-9-12-20(16(3)4)23(19)30-25(27)26-32(28,29)31-24-21(17(5)6)13-10-14-22(24)18(7)8;/h9-18H,1-8H3,(H,26,27);/q;+1/p-1
DMV1J0P	CS	CC(C)C1=C(C(=CC=C1)C(C)C)OC(=NS(=O)(=O)OC2=C(C=CC=C2C(C)C)C(C)C)[O-].[Na+]
DMV1J0P	IK	XVUJDEGOJDKQDX-UHFFFAOYSA-M
DMV1J0P	IU	sodium;1-[2,6-di(propan-2-yl)phenoxy]-N-[2,6-di(propan-2-yl)phenoxy]sulfonylmethanimidate
DMV1J0P	DE	Arteriosclerosis

DMBNWM1	ID	DMBNWM1
DMBNWM1	DN	Cilofungin
DMBNWM1	HS	Terminated
DMBNWM1	SN	Cilofungina; Cilofunginum; L-646991; LY-121019; Cilofungin (USAN/INN); L-649,991; 1-[(4R,5R)-4,5-Dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]echinocandin B; 5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-[4-(octyloxy)benzoyl]-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-L-threonyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}
DMBNWM1	CP	Eli Lilly
DMBNWM1	DT	Small molecular drug
DMBNWM1	PC	6918120
DMBNWM1	MW	1030.099
DMBNWM1	FM	C49H71N7O17
DMBNWM1	IC	InChI=1S/C49H71N7O17/c1-5-6-7-8-9-10-19-73-31-17-13-28(14-18-31)42(65)50-32-21-34(61)45(68)54-47(70)38-39(62)24(2)22-56(38)49(72)36(26(4)58)52-46(69)37(41(64)40(63)27-11-15-29(59)16-12-27)53-44(67)33-20-30(60)23-55(33)48(71)35(25(3)57)51-43(32)66/h11-18,24-26,30,32-41,45,57-64,68H,5-10,19-23H2,1-4H3,(H,50,65)(H,51,66)(H,52,69)(H,53,67)(H,54,70)/t24-,25+,26+,30+,32-,33-,34+,35-,36-,37-,38-,39-,40-,41-,45+/m0/s1
DMBNWM1	CS	CCCCCCCCOC1=CC=C(C=C1)C(=O)N[C@H]2C[C@H]([C@H](NC(=O)[C@@H]3[C@H]([C@H](CN3C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H](NC2=O)[C@@H](C)O)O)[C@@H]([C@H](C5=CC=C(C=C5)O)O)O)[C@@H](C)O)C)O)O)O
DMBNWM1	IK	ZKZKCEAHVFVZDJ-MTUMARHDSA-N
DMBNWM1	IU	N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-octoxybenzamide
DMBNWM1	CA	CAS 79404-91-4
DMBNWM1	CB	CHEBI:315019
DMBNWM1	DE	Candidiasis

DM0NJMG	ID	DM0NJMG
DM0NJMG	DN	Ciprokiren
DM0NJMG	HS	Terminated
DM0NJMG	SN	Ro-44-9375
DM0NJMG	CP	F Hoffmann-La Roche Ltd
DM0NJMG	DT	Small molecular drug
DM0NJMG	PC	5312136
DM0NJMG	MW	729.9
DM0NJMG	FM	C37H55N5O8S
DM0NJMG	IC	InChI=1S/C37H55N5O8S/c1-37(2,36(47)42-15-17-50-18-16-42)51(48,49)23-28(19-25-9-5-3-6-10-25)34(45)41-31(21-29-22-38-24-39-29)35(46)40-30(20-26-11-7-4-8-12-26)33(44)32(43)27-13-14-27/h3,5-6,9-10,22,24,26-28,30-33,43-44H,4,7-8,11-21,23H2,1-2H3,(H,38,39)(H,40,46)(H,41,45)/t28-,30+,31+,32+,33-/m1/s1
DM0NJMG	CS	CC(C)(C(=O)N1CCOCC1)S(=O)(=O)C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CC4CCCCC4)[C@H]([C@H](C5CC5)O)O
DM0NJMG	IK	PODHJNNUGIBMOP-HOQQKOLYSA-N
DM0NJMG	IU	(2S)-2-benzyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-3-(2-methyl-1-morpholin-4-yl-1-oxopropan-2-yl)sulfonylpropanamide
DM0NJMG	CA	CAS 143631-62-3
DM0NJMG	DE	Hypertension

DMJBGI1	ID	DMJBGI1
DMJBGI1	DN	CL-184005
DMJBGI1	HS	Terminated
DMJBGI1	SN	GF2IPH21J7; CL 184005; UNII-GF2IPH21J7; CL-184005; CHEMBL296973; 140466-18-8; CL-184,005; AC1L30Q7; DTXSID40161407; BDBM50001754; (2-methoxycarbonyl-3-tetradecoxyphenyl) [3-[(5-methyl-1,3-thiazol-3-ium-3-yl)methyl]phenyl] phosphate; ((CL 184005))3-{3-[Hydroxy-(2-methoxycarbonyl-3-tetradecyloxy-phenoxy)-phosphoryloxy]-benzyl}-5-methyl-thiazol-3-ium; 2-{Hydroxy-[3-(5-methyl-thiazol-3-ylmethyl)-phenoxy]-dihydrogen phosphate}-6-tetradecyloxy-benzoic acid methyl ester(CL 184005); Thiazolium, 3-((3-((hydroxy(2-(methoxycarbony
DMJBGI1	DT	Small molecular drug
DMJBGI1	PC	132290
DMJBGI1	MW	631.8
DMJBGI1	FM	C33H46NO7PS
DMJBGI1	IC	InChI=1S/C33H46NO7PS/c1-4-5-6-7-8-9-10-11-12-13-14-15-22-39-30-20-17-21-31(32(30)33(35)38-3)41-42(36,37)40-29-19-16-18-28(23-29)25-34-24-27(2)43-26-34/h16-21,23-24,26H,4-15,22,25H2,1-3H3
DMJBGI1	CS	CCCCCCCCCCCCCCOC1=C(C(=CC=C1)OP(=O)([O-])OC2=CC=CC(=C2)C[N+]3=CSC(=C3)C)C(=O)OC
DMJBGI1	IK	VGVUQNMRGKNUJA-UHFFFAOYSA-N
DMJBGI1	IU	(2-methoxycarbonyl-3-tetradecoxyphenyl) [3-[(5-methyl-1,3-thiazol-3-ium-3-yl)methyl]phenyl] phosphate
DMJBGI1	CA	CAS 140466-18-8
DMJBGI1	DE	Sepsis

DMYML2N	ID	DMYML2N
DMYML2N	DN	CL-186659
DMYML2N	HS	Terminated
DMYML2N	SN	IDDB8406
DMYML2N	CP	Lederle Laboratories
DMYML2N	DE	Bacterial infection

DMA4DNX	ID	DMA4DNX
DMA4DNX	DN	CL-387626
DMA4DNX	HS	Terminated
DMA4DNX	SN	RFI-641 (free acid); 4,4'-Bis[4,6-bis[3-[bis(3-amino-3-oxopropyl)aminosulfonyl]phenylamino]-1,3,5-triazin-2-ylamino][1,1'-biphenyl]-2,2'-disulfonic acid disodium salt
DMA4DNX	PC	16134411
DMA4DNX	MW	1795.8
DMA4DNX	FM	C66H76N24Na2O22S6
DMA4DNX	IC	InChI=1S/C66H78N24O22S6.2Na/c67-53(91)17-25-87(26-18-54(68)92)113(99,100)45-9-1-5-39(33-45)75-61-81-62(76-40-6-2-10-46(34-40)114(101,102)88(27-19-55(69)93)28-20-56(70)94)84-65(83-61)79-43-13-15-49(51(37-43)117(107,108)109)50-16-14-44(38-52(50)118(110,111)112)80-66-85-63(77-41-7-3-11-47(35-41)115(103,104)89(29-21-57(71)95)30-22-58(72)96)82-64(86-66)78-42-8-4-12-48(36-42)116(105,106)90(31-23-59(73)97)32-24-60(74)98;;/h1-16,33-38H,17-32H2,(H2,67,91)(H2,68,92)(H2,69,93)(H2,70,94)(H2,71,95)(H2,72,96)(H2,73,97)(H2,74,98)(H,107,108,109)(H,110,111,112)(H3,75,76,79,81,83,84)(H3,77,78,80,82,85,86);;/q;2*+1/p-2
DMA4DNX	CS	C1=CC(=CC(=C1)S(=O)(=O)N(CCC(=O)N)CCC(=O)N)NC2=NC(=NC(=N2)NC3=CC(=C(C=C3)C4=C(C=C(C=C4)NC5=NC(=NC(=N5)NC6=CC(=CC=C6)S(=O)(=O)N(CCC(=O)N)CCC(=O)N)NC7=CC(=CC=C7)S(=O)(=O)N(CCC(=O)N)CCC(=O)N)S(=O)(=O)[O-])S(=O)(=O)[O-])NC8=CC(=CC=C8)S(=O)(=O)N(CCC(=O)N)CCC(=O)N.[Na+].[Na+]
DMA4DNX	IK	RHYDQBKNSGARFE-UHFFFAOYSA-L
DMA4DNX	IU	disodium;5-[[4,6-bis[3-[bis(3-amino-3-oxopropyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-[4-[[4,6-bis[3-[bis(3-amino-3-oxopropyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]benzenesulfonate
DMA4DNX	DE	Virus infection

DM8TQC9	ID	DM8TQC9
DM8TQC9	DN	Clentiazem
DM8TQC9	HS	Terminated
DM8TQC9	SN	CLENTIAZEM; Clentiazem [INN]; Clentiazemum [INN-Latin]; UNII-40DK034DRC; 40DK034DRC; 96125-53-0; C22H25ClN2O4S; (+)-cis-2-(4-Methoxyphenyl)-3-acetoxy-5-(2-(N,N-dimethylamino)ethyl)-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; Clentiazemum; 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-8-chloro-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (25-cis)-; 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-8-chloro-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2S,3S)-; AC1L1M5S; SCHEMBL33909
DM8TQC9	DT	Small molecular drug
DM8TQC9	PC	57026
DM8TQC9	MW	449
DM8TQC9	FM	C22H25ClN2O4S
DM8TQC9	IC	InChI=1S/C22H25ClN2O4S/c1-14(26)29-20-21(15-5-8-17(28-4)9-6-15)30-19-13-16(23)7-10-18(19)25(22(20)27)12-11-24(2)3/h5-10,13,20-21H,11-12H2,1-4H3/t20-,21+/m1/s1
DM8TQC9	CS	CC(=O)O[C@@H]1[C@@H](SC2=C(C=CC(=C2)Cl)N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DM8TQC9	IK	GYKFWCDBQAFCLJ-RTWAWAEBSA-N
DM8TQC9	IU	[(2S,3S)-8-chloro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DM8TQC9	CA	CAS 96125-53-0
DM8TQC9	DE	Angina pectoris

DM6F8L5	ID	DM6F8L5
DM6F8L5	DN	Clinafloxacin
DM6F8L5	HS	Terminated
DM6F8L5	SN	Clinafloxacin hydrochloride; AM-1091; PD-127391
DM6F8L5	CP	Parke-Davis & Co
DM6F8L5	DT	Small molecular drug
DM6F8L5	PC	60063
DM6F8L5	MW	365.8
DM6F8L5	FM	C17H17ClFN3O3
DM6F8L5	IC	InChI=1S/C17H17ClFN3O3/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9/h5,7-9H,1-4,6,20H2,(H,24,25)
DM6F8L5	CS	C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)Cl)N4CCC(C4)N)F)C(=O)O
DM6F8L5	IK	QGPKADBNRMWEQR-UHFFFAOYSA-N
DM6F8L5	IU	7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DM6F8L5	CA	CAS 105956-97-6
DM6F8L5	CB	CHEBI:94459
DM6F8L5	DE	Pneumonia

DMVUL4P	ID	DMVUL4P
DMVUL4P	DN	CLX-0301
DMVUL4P	HS	Terminated
DMVUL4P	CP	Calyx Therapeutics Inc
DMVUL4P	DE	Diabetic complication

DMYPRS9	ID	DMYPRS9
DMYPRS9	DN	CLX-0900
DMYPRS9	HS	Terminated
DMYPRS9	SN	CLX-0900E
DMYPRS9	CP	Calyx Therapeutics Inc
DMYPRS9	DE	Hyperlipidaemia

DMEIW7K	ID	DMEIW7K
DMEIW7K	DN	CMI-206
DMEIW7K	HS	Terminated
DMEIW7K	SN	IDDB8444
DMEIW7K	CP	CytoMed Inc
DMEIW7K	DE	Inflammation

DMP3QAZ	ID	DMP3QAZ
DMP3QAZ	DN	CNS-1237
DMP3QAZ	HS	Terminated
DMP3QAZ	CP	CeNeS Pharmaceuticals Inc
DMP3QAZ	PC	9907241
DMP3QAZ	MW	367.4
DMP3QAZ	FM	C24H21N3O
DMP3QAZ	IC	InChI=1S/C24H21N3O/c1-28-22-14-13-20(17-6-2-3-7-18(17)22)26-24(25)27-21-12-11-16-10-9-15-5-4-8-19(21)23(15)16/h2-8,11-14H,9-10H2,1H3,(H3,25,26,27)
DMP3QAZ	CS	COC1=CC=C(C2=CC=CC=C21)NC(=NC3=CC=C4CCC5=C4C3=CC=C5)N
DMP3QAZ	IK	AZZRFSWIWLKNLQ-UHFFFAOYSA-N
DMP3QAZ	IU	2-(1,2-dihydroacenaphthylen-5-yl)-1-(4-methoxynaphthalen-1-yl)guanidine
DMP3QAZ	DE	Cerebrovascular ischaemia

DM03LZB	ID	DM03LZB
DM03LZB	DN	CNS-1307
DM03LZB	HS	Terminated
DM03LZB	CP	CeNeS Pharmaceuticals Inc
DM03LZB	DE	Schizophrenia

DMZ5N2I	ID	DMZ5N2I
DMZ5N2I	DN	CNS-1531
DMZ5N2I	HS	Terminated
DMZ5N2I	CP	CeNeS Pharmaceuticals Inc
DMZ5N2I	DE	Nervous system disease

DMZY0SF	ID	DMZY0SF
DMZY0SF	DN	CNS-5788
DMZY0SF	HS	Terminated
DMZY0SF	SN	UNII-67M8W71RHJ; 67M8W71RHJ
DMZY0SF	CP	CeNeS Pharmaceuticals Inc
DMZY0SF	DT	Small molecular drug
DMZY0SF	PC	9842186
DMZY0SF	MW	367.9
DMZY0SF	FM	C16H18ClN3OS2
DMZY0SF	IC	InChI=1S/C16H18ClN3OS2/c1-20(11-5-4-6-13(9-11)23(3)21)16(18)19-15-10-12(22-2)7-8-14(15)17/h4-10H,1-3H3,(H2,18,19)
DMZY0SF	CS	CN(C1=CC(=CC=C1)S(=O)C)C(=NC2=C(C=CC(=C2)SC)Cl)N
DMZY0SF	IK	RODJWDCTFWIGQR-UHFFFAOYSA-N
DMZY0SF	IU	2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfinylphenyl)guanidine
DMZY0SF	CA	CAS 342047-49-8
DMZY0SF	DE	Cerebrovascular ischaemia

DMU5TZD	ID	DMU5TZD
DMU5TZD	DN	Co-152791
DMU5TZD	HS	Terminated
DMU5TZD	CP	Purdue Neuroscience Corp
DMU5TZD	PC	9825518
DMU5TZD	MW	460.6
DMU5TZD	FM	C31H40O3
DMU5TZD	IC	InChI=1S/C31H40O3/c1-20(32)23-7-5-22(6-8-23)13-16-31(34)18-17-29(3)24(19-31)9-10-25-27-12-11-26(21(2)33)30(27,4)15-14-28(25)29/h5-8,24-28,34H,9-12,14-15,17-19H2,1-4H3/t24-,25-,26+,27-,28-,29-,30+,31+/m0/s1
DMU5TZD	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C#CC5=CC=C(C=C5)C(=O)C)O)C)C
DMU5TZD	IK	ZPPSBQVNGSDAFI-KWJNIICQSA-N
DMU5TZD	IU	1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-[2-(4-acetylphenyl)ethynyl]-3-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
DMU5TZD	DE	Epilepsy

DMGIZHX	ID	DMGIZHX
DMGIZHX	DN	Co-60549
DMGIZHX	HS	Terminated
DMGIZHX	SN	Epalon series member (60549), CoCensys
DMGIZHX	CP	Purdue Neuroscience Corp
DMGIZHX	DE	Anxiety disorder

DMQESM7	ID	DMQESM7
DMQESM7	DN	Cordil
DMQESM7	HS	Terminated
DMQESM7	SN	LND-796; LNF-209
DMQESM7	CP	The Procter & Gamble Co
DMQESM7	PC	3081161
DMQESM7	MW	495.6
DMQESM7	FM	C27H45NO7
DMQESM7	IC	InChI=1S/C27H45NO7/c1-14-20(29)21(30)22(31)24(34-14)35-16-7-10-25(2)15(13-16)5-6-18-17(25)8-11-26(3)19(23(32)33-4)9-12-27(18,26)28/h14-22,24,29-31H,5-13,28H2,1-4H3/t14-,15+,16-,17-,18+,19+,20-,21+,22+,24-,25-,26+,27-/m0/s1
DMQESM7	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(CC[C@@H]5C(=O)OC)N)C)C)O)O)O
DMQESM7	IK	HKWLCBGLVAWZRK-CBYCSKBWSA-N
DMQESM7	IU	methyl (3S,5R,8R,9S,10S,13R,14S,17S)-14-amino-10,13-dimethyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-17-carboxylate
DMQESM7	CA	CAS 118549-42-1
DMQESM7	DE	Heart arrhythmia

DMO3486	ID	DMO3486
DMO3486	DN	COSALANE
DMO3486	HS	Terminated
DMO3486	SN	Cosalane; AC1L2I0J; CHEMBL300101; CTK6A7531; BDBM50036146; LS-187298; 5-[1-(3-carboxy-5-chloro-4-hydroxyphenyl)-4-[(3S,10S,13R,17R)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]but-1-enyl]-3-chloro-2-hydroxybenzoic acid; 5-{1-(3-carboxy-5-chloro-4-hydroxyphenyl-4-[1-(1,5-dimethylhexyl)-9a,11a-dimethylperhydrocyclopenta[a]phenanthren-7-yl]-1-butenyl}-3-chloro-2-hydroxy acetic acid (Cosalane)
DMO3486	DT	Small molecular drug
DMO3486	PC	455040
DMO3486	MW	767.9
DMO3486	FM	C45H60Cl2O6
DMO3486	IC	InChI=1S/C45H60Cl2O6/c1-25(2)8-6-9-26(3)35-14-15-36-32-13-12-30-20-27(16-18-44(30,4)37(32)17-19-45(35,36)5)10-7-11-31(28-21-33(42(50)51)40(48)38(46)23-28)29-22-34(43(52)53)41(49)39(47)24-29/h11,21-27,30,32,35-37,48-49H,6-10,12-20H2,1-5H3,(H,50,51)(H,52,53)/t26-,27+,30+,32+,35-,36+,37+,44+,45-/m1/s1
DMO3486	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@H](C4)CCC=C(C5=CC(=C(C(=C5)Cl)O)C(=O)O)C6=CC(=C(C(=C6)Cl)O)C(=O)O)C)C
DMO3486	IK	VOJOOGPALCATLT-ZFQBPCNVSA-N
DMO3486	IU	5-[1-(3-carboxy-5-chloro-4-hydroxyphenyl)-4-[(3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]but-1-enyl]-3-chloro-2-hydroxybenzoic acid
DMO3486	CA	CAS 154212-56-3

DMS23JX	ID	DMS23JX
DMS23JX	DN	CP-0597
DMS23JX	HS	Terminated
DMS23JX	CP	Cortech Inc
DMS23JX	PC	9833644
DMS23JX	MW	1292.5
DMS23JX	FM	C58H89N19O13S
DMS23JX	IC	InChI=1S/C58H89N19O13S/c59-38(16-6-20-66-56(60)61)48(82)72-39(17-7-21-67-57(62)63)51(85)74-23-9-19-43(74)53(87)77-30-36(79)26-44(77)50(84)69-28-46(80)71-41(27-37-15-10-24-91-37)49(83)73-42(32-78)52(86)76-29-34-12-5-4-11-33(34)25-45(76)54(88)75(35-13-2-1-3-14-35)31-47(81)70-40(55(89)90)18-8-22-68-58(64)65/h4-5,10-12,15,24,35-36,38-45,78-79H,1-3,6-9,13-14,16-23,25-32,59H2,(H,69,84)(H,70,81)(H,71,80)(H,72,82)(H,73,83)(H,89,90)(H4,60,61,66)(H4,62,63,67)(H4,64,65,68)/t36-,38-,39+,40+,41+,42+,43+,44+,45-/m1/s1
DMS23JX	CS	C1CCC(CC1)N(CC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)C(=O)[C@H]2CC3=CC=CC=C3CN2C(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CS4)NC(=O)CNC(=O)[C@@H]5C[C@H](CN5C(=O)[C@@H]6CCCN6C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O
DMS23JX	IK	UZTHIUKOCVEJNZ-GWJNKJQQSA-N
DMS23JX	IU	(2S)-2-[[2-[[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-cyclohexylamino]acetyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMS23JX	DE	Asthma

DMDQBAL	ID	DMDQBAL
DMDQBAL	DN	CP-293019
DMDQBAL	HS	Terminated
DMDQBAL	SN	CP-293019; CHEMBL66227; GTPL977; SCHEMBL6844226; BDBM50069041; CP293019; CP 293019; 7-(4-Fluoro-phenoxymethyl)-2-(5-fluoro-pyrimidin-2-yl)-octahydro-pyrido[1,2-a]pyrazine (CP-293019); (7R,9aalpha)-2-(5-Fluoro-2-pyrimidinyl)-7alpha-(4-fluorophenoxymethyl)octahydro-6H-pyrido[1,2-a]pyrazine; (7R,9aS)-7-[(4-fluorophenoxy)methyl]-2-(5-fluoropyrimidin-2-yl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine
DMDQBAL	DT	Small molecular drug
DMDQBAL	PC	9820261
DMDQBAL	MW	360.4
DMDQBAL	FM	C19H22F2N4O
DMDQBAL	IC	InChI=1S/C19H22F2N4O/c20-15-2-5-18(6-3-15)26-13-14-1-4-17-12-25(8-7-24(17)11-14)19-22-9-16(21)10-23-19/h2-3,5-6,9-10,14,17H,1,4,7-8,11-13H2/t14-,17+/m1/s1
DMDQBAL	CS	C1C[C@H]2CN(CCN2C[C@@H]1COC3=CC=C(C=C3)F)C4=NC=C(C=N4)F
DMDQBAL	IK	QXWNESOGWFJDFR-PBHICJAKSA-N
DMDQBAL	IU	(7R,9aS)-7-[(4-fluorophenoxy)methyl]-2-(5-fluoropyrimidin-2-yl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine

DMCIXYR	ID	DMCIXYR
DMCIXYR	DN	CP-331
DMCIXYR	HS	Terminated
DMCIXYR	CP	Zeria Pharmaceutical Co Ltd
DMCIXYR	DT	Small molecular drug
DMCIXYR	PC	130967
DMCIXYR	MW	706.3
DMCIXYR	FM	C38H44ClN3O6S
DMCIXYR	IC	InChI=1S/C38H44ClN3O6S/c1-27-33(34-23-31(46-2)14-15-35(34)42(27)38(45)29-10-12-30(39)13-11-29)24-37(44)48-20-21-49-26-36(43)40-16-7-19-47-32-9-6-8-28(22-32)25-41-17-4-3-5-18-41/h6,8-15,22-23H,3-5,7,16-21,24-26H2,1-2H3,(H,40,43)
DMCIXYR	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCCSCC(=O)NCCCOC4=CC=CC(=C4)CN5CCCCC5
DMCIXYR	IK	SWFXMFDHMPMWMA-UHFFFAOYSA-N
DMCIXYR	IU	2-[2-oxo-2-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]ethyl]sulfanylethyl 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate
DMCIXYR	CA	CAS 127966-70-5
DMCIXYR	DE	Pain

DMDEPKM	ID	DMDEPKM
DMDEPKM	DN	CP-471358
DMDEPKM	HS	Terminated
DMDEPKM	CP	Pfizer Inc
DMDEPKM	PC	9869142
DMDEPKM	MW	466.5
DMDEPKM	FM	C21H23FN2O7S
DMDEPKM	IC	InChI=1S/C21H23FN2O7S/c22-15-3-5-16(6-4-15)31-17-7-9-18(10-8-17)32(29,30)24(14-11-19(25)26)21(20(27)23-28)12-1-2-13-21/h3-10,28H,1-2,11-14H2,(H,23,27)(H,25,26)
DMDEPKM	CS	C1CCC(C1)(C(=O)NO)N(CCC(=O)O)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)F
DMDEPKM	IK	VHHGUBHZBLPTKL-UHFFFAOYSA-N
DMDEPKM	IU	3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxycarbamoyl)cyclopentyl]amino]propanoic acid
DMDEPKM	DE	Solid tumour/cancer

DMIZMJD	ID	DMIZMJD
DMIZMJD	DN	CP-663427
DMIZMJD	HS	Terminated
DMIZMJD	SN	LNK-427; OSI-427
DMIZMJD	CP	Pfizer Inc
DMIZMJD	DE	Solid tumour/cancer

DMWFI4A	ID	DMWFI4A
DMWFI4A	DN	CP-67015
DMWFI4A	HS	Terminated
DMWFI4A	SN	100325-51-7; CCRIS 2955; CP-67015; CP 67015; CP-67,015; 3-Quinolinecarboxylic acid, 1,4-dihydro-6,8-difluoro-1-ethyl-4-oxo-7-(4-pyridinyl)-; 3-Quinolinecarboxylicacid, 1-ethyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(4-pyridinyl)-; ACMC-20m3dd; AC1L2S7K; SCHEMBL9304919; CTK0H9319; DTXSID00143163; AKOS030543955; LS-141575; 1-ethyl-6,8-difluoro-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(4-pyridinyl)-; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dih
DMWFI4A	CP	Pfizer Inc
DMWFI4A	DT	Small molecular drug
DMWFI4A	PC	127557
DMWFI4A	MW	330.28
DMWFI4A	FM	C17H12F2N2O3
DMWFI4A	IC	InChI=1S/C17H12F2N2O3/c1-2-21-8-11(17(23)24)16(22)10-7-12(18)13(14(19)15(10)21)9-3-5-20-6-4-9/h3-8H,2H2,1H3,(H,23,24)
DMWFI4A	CS	CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)C3=CC=NC=C3)F)C(=O)O
DMWFI4A	IK	AVTJRMCCKOBMQP-UHFFFAOYSA-N
DMWFI4A	IU	1-ethyl-6,8-difluoro-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
DMWFI4A	CA	CAS 100325-51-7
DMWFI4A	DE	Bacterial infection

DMSOT07	ID	DMSOT07
DMSOT07	DN	CP-83101
DMSOT07	HS	Terminated
DMSOT07	SN	AC1O5PZP; SCHEMBL1660808; SCHEMBL1660809; CP-83101; 3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate; methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate; 6,8-Nonadienoic acid, 3,5-dihydroxy-9,9-diphenyl-, methyl ester, (R*,S*-(E))-(+-)-
DMSOT07	CP	Pfizer Inc
DMSOT07	DT	Small molecular drug
DMSOT07	PC	6438614
DMSOT07	MW	352.4
DMSOT07	FM	C22H24O4
DMSOT07	IC	InChI=1S/C22H24O4/c1-26-22(25)16-20(24)15-19(23)13-8-14-21(17-9-4-2-5-10-17)18-11-6-3-7-12-18/h2-14,19-20,23-24H,15-16H2,1H3/b13-8+/t19-,20-/m1/s1
DMSOT07	CS	COC(=O)C[C@@H](C[C@@H](/C=C/C=C(C1=CC=CC=C1)C2=CC=CC=C2)O)O
DMSOT07	IK	NSZBOSJMBQKKKB-ZCBOBATRSA-N
DMSOT07	IU	methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate
DMSOT07	CA	CAS 130746-82-6
DMSOT07	DE	Arteriosclerosis

DMEJBQY	ID	DMEJBQY
DMEJBQY	DN	CP-903397
DMEJBQY	HS	Terminated
DMEJBQY	CP	Pfizer Inc
DMEJBQY	DE	Schizophrenia

DM4HYWR	ID	DM4HYWR
DM4HYWR	DN	CP-96345
DM4HYWR	HS	Terminated
DM4HYWR	SN	CP 96345; CP-96345; 132746-60-2; UNII-W22ILA2I52; CP 96344; CP 96,345; CHEMBL16192; W22ILA2I52; 2-(Diphenylmethyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo(2.2.2)octan-3-amine; CP-96,345; (2S,3S)-cis-2-(Diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine; (2S,3S)-2-benzhydryl-N-[(2-methoxyphenyl)methyl]quinuclidin-3-amine; (2S,3S)-N-(2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine; 1-Azabicyclo(2.2.2)octan-3-amine, 2-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-, (2S-cis
DM4HYWR	DT	Small molecular drug
DM4HYWR	PC	104943
DM4HYWR	MW	412.6
DM4HYWR	FM	C28H32N2O
DM4HYWR	IC	InChI=1S/C28H32N2O/c1-31-25-15-9-8-14-24(25)20-29-27-23-16-18-30(19-17-23)28(27)26(21-10-4-2-5-11-21)22-12-6-3-7-13-22/h2-15,23,26-29H,16-20H2,1H3/t27-,28-/m0/s1
DM4HYWR	CS	COC1=CC=CC=C1CN[C@@H]2[C@@H](N3CCC2CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
DM4HYWR	IK	FLNYLINBEZROPL-NSOVKSMOSA-N
DM4HYWR	IU	(2S,3S)-2-benzhydryl-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
DM4HYWR	CA	CAS 132746-60-2

DM8NVZQ	ID	DM8NVZQ
DM8NVZQ	DN	CR-1795
DM8NVZQ	HS	Terminated
DM8NVZQ	SN	CHEMBL169466; BDBM50281699; 5-Dipentylcarbamoyl-5-[((R)-naphthalene-2-carbonyl)-amino]-pentanoic acid
DM8NVZQ	DT	Small molecular drug
DM8NVZQ	PC	44381915
DM8NVZQ	MW	454.6
DM8NVZQ	FM	C27H38N2O4
DM8NVZQ	IC	InChI=1S/C27H38N2O4/c1-3-5-9-18-29(19-10-6-4-2)27(33)24(14-11-15-25(30)31)28-26(32)23-17-16-21-12-7-8-13-22(21)20-23/h7-8,12-13,16-17,20,24H,3-6,9-11,14-15,18-19H2,1-2H3,(H,28,32)(H,30,31)/t24-/m1/s1
DM8NVZQ	CS	CCCCCN(CCCCC)C(=O)[C@@H](CCCC(=O)O)NC(=O)C1=CC2=CC=CC=C2C=C1
DM8NVZQ	IK	VHCOMPFCZPOZFX-XMMPIXPASA-N
DM8NVZQ	IU	(5R)-6-(dipentylamino)-5-(naphthalene-2-carbonylamino)-6-oxohexanoic acid

DM51XDU	ID	DM51XDU
DM51XDU	DN	CR-2991
DM51XDU	HS	Terminated
DM51XDU	SN	Quinazoline alpha1 adrenoceptor antagonist (hypertension, prostatic hyperplasia), Rottapharm
DM51XDU	CP	Rottapharm Madaus
DM51XDU	DE	Hypertension

DM1MBG9	ID	DM1MBG9
DM1MBG9	DN	CR-3124
DM1MBG9	HS	Terminated
DM1MBG9	CP	RottaPharma
DM1MBG9	DT	Small molecular drug
DM1MBG9	PC	11738327
DM1MBG9	MW	306.4
DM1MBG9	FM	C20H22N2O
DM1MBG9	IC	InChI=1S/C20H22N2O/c1-21-15-8-9-16(21)11-17(10-15)22-12-14-7-6-13-4-2-3-5-18(13)19(14)20(22)23/h2-7,15-17H,8-12H2,1H3/t15-,16+,17?
DM1MBG9	CS	CN1[C@@H]2CC[C@H]1CC(C2)N3CC4=C(C3=O)C5=CC=CC=C5C=C4
DM1MBG9	IK	RCJGTDKFZCRBAH-SJPCQFCGSA-N
DM1MBG9	IU	2-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-3H-benzo[g]isoindol-1-one
DM1MBG9	CA	CAS 263896-41-9
DM1MBG9	DE	Substance use disorder

DMTPDX7	ID	DMTPDX7
DMTPDX7	DN	CR-3834
DMTPDX7	HS	Terminated
DMTPDX7	SN	Angiotensin II antagonist (hypertension), Rottapharm
DMTPDX7	CP	Rottapharm Madaus
DMTPDX7	DE	Hypertension

DMRNB7V	ID	DMRNB7V
DMRNB7V	DN	CRA-028129
DMRNB7V	HS	Terminated
DMRNB7V	CP	Celera Genomics
DMRNB7V	DE	Psoriatic disorder

DM1E7H3	ID	DM1E7H3
DM1E7H3	DN	CS-204
DM1E7H3	HS	Terminated
DM1E7H3	SN	CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience
DM1E7H3	CP	Shenzhen Chipscreen Biosciences Ltd
DM1E7H3	DE	Metabolic disorder

DMFJ4VT	ID	DMFJ4VT
DMFJ4VT	DN	CS-207
DMFJ4VT	HS	Terminated
DMFJ4VT	SN	CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences
DMFJ4VT	CP	Shenzhen Chipscreen Biosciences Ltd
DMFJ4VT	DE	Cardiovascular disease

DM84KOY	ID	DM84KOY
DM84KOY	DN	CT-1746
DM84KOY	HS	Terminated
DM84KOY	CP	Celltech Therapeutics Ltd
DM84KOY	PC	9930721
DM84KOY	MW	397.9
DM84KOY	FM	C19H28ClN3O4
DM84KOY	IC	InChI=1S/C19H28ClN3O4/c1-19(2,3)16(17(21)25)22-18(26)13(11-15(24)23-27)6-4-5-12-7-9-14(20)10-8-12/h7-10,13,16,27H,4-6,11H2,1-3H3,(H2,21,25)(H,22,26)(H,23,24)/t13-,16-/m1/s1
DM84KOY	CS	CC(C)(C)[C@@H](C(=O)N)NC(=O)[C@H](CCCC1=CC=C(C=C1)Cl)CC(=O)NO
DM84KOY	IK	CZCIELLKWLGEFJ-CZUORRHYSA-N
DM84KOY	IU	(2R)-N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-2-[3-(4-chlorophenyl)propyl]-N'-hydroxybutanediamide
DM84KOY	DE	Colorectal cancer

DMQBULC	ID	DMQBULC
DMQBULC	DN	CV 6209
DMQBULC	HS	Terminated
DMQBULC	SN	CHEMBL274420; CV6209; GTPL1852; AC1L32P4; SCHEMBL8538219; CHEMBL1180101; PDSP1_000728; PDSP1_000727; PDSP2_000718; PDSP2_000717; BDBM50005232; 2-(2-Acetyl-6-methoxy-3,9-dioxo-4,8-dioxa-2,10-diazaoctacosan-1-yl)-1-ethylpyridinium; 2-{[Acetyl-(2-methoxy-3-octadecylcarbamoyloxy-propoxycarbonyl)-amino]-methyl}-1-ethyl-pyridinium; [2-methoxy-3-(octadecylcarbamoyloxy)propyl] N-acetyl-N-[(1-ethylpyridin-1-ium-2-yl)methyl]carbamate
DMQBULC	DT	Small molecular drug
DMQBULC	PC	107756
DMQBULC	MW	642.3
DMQBULC	FM	C34H60ClN3O6
DMQBULC	IC	InChI=1S/C34H59N3O6.ClH/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-25-35-33(39)42-28-32(41-4)29-43-34(40)37(30(3)38)27-31-24-21-23-26-36(31)6-2;/h21,23-24,26,32H,5-20,22,25,27-29H2,1-4H3;1H
DMQBULC	CS	CCCCCCCCCCCCCCCCCCNC(=O)OCC(COC(=O)N(CC1=CC=CC=[N+]1CC)C(=O)C)OC.[Cl-]
DMQBULC	IK	APUCCVGQZPNXIO-UHFFFAOYSA-N
DMQBULC	IU	[2-methoxy-3-(octadecylcarbamoyloxy)propyl] N-acetyl-N-[(1-ethylpyridin-1-ium-2-yl)methyl]carbamate;chloride
DMQBULC	CA	CAS 100488-87-7
DMQBULC	DE	Asthma

DMMDO3X	ID	DMMDO3X
DMMDO3X	DN	CVS-995
DMMDO3X	HS	Terminated
DMMDO3X	SN	Corthrombin injectable
DMMDO3X	CP	Dendreon San Diego LLC
DMMDO3X	DE	Myocardial infarction

DMPWZCI	ID	DMPWZCI
DMPWZCI	DN	CVT-1
DMPWZCI	HS	Terminated
DMPWZCI	CP	Gilead Palo Alto Inc
DMPWZCI	DE	Hypercholesterolaemia

DM0X147	ID	DM0X147
DM0X147	DN	CY-1748
DM0X147	HS	Terminated
DM0X147	CP	Epimmune Inc
DM0X147	DE	Deep vein thrombosis

DMPBCLA	ID	DMPBCLA
DMPBCLA	DN	CY-9652
DMPBCLA	HS	Terminated
DMPBCLA	SN	Integrin antagonists, Cytel
DMPBCLA	CP	Epimmune Inc
DMPBCLA	DE	Inflammation

DM17NYA	ID	DM17NYA
DM17NYA	DN	CYC-103
DM17NYA	HS	Terminated
DM17NYA	SN	Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel
DM17NYA	CP	Cyclacel Pharmaceuticals Inc
DM17NYA	DE	Solid tumour/cancer

DMF8TCI	ID	DMF8TCI
DMF8TCI	DN	CZ-112
DMF8TCI	HS	Terminated
DMF8TCI	CP	Stehlin Foundation For Cancer Research
DMF8TCI	DE	Solid tumour/cancer

DME07ML	ID	DME07ML
DME07ML	DN	D-21775
DME07ML	HS	Terminated
DME07ML	CP	ASTA Medica AG
DME07ML	DE	Solid tumour/cancer

DM7FTCV	ID	DM7FTCV
DM7FTCV	DN	D-22888
DM7FTCV	HS	Terminated
DM7FTCV	SN	AWD-12-232
DM7FTCV	CP	ASTA Medica AG
DM7FTCV	DT	Small molecular drug
DM7FTCV	PC	197714
DM7FTCV	MW	300.36
DM7FTCV	FM	C16H20N4O2
DM7FTCV	IC	InChI=1S/C16H20N4O2/c1-5-9-19-11-7-8-13(22-4)18-15(11)20-12(6-2)17-10(3)14(20)16(19)21/h7-8H,5-6,9H2,1-4H3
DM7FTCV	CS	CCCN1C2=C(N=C(C=C2)OC)N3C(=NC(=C3C1=O)C)CC
DM7FTCV	IK	PJRYVTGCPZXGEY-UHFFFAOYSA-N
DM7FTCV	IU	3-ethyl-12-methoxy-5-methyl-8-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,10,12-pentaen-7-one
DM7FTCV	CA	CAS 182282-60-6
DM7FTCV	DE	Allergy

DMBJAUC	ID	DMBJAUC
DMBJAUC	DN	D-26344
DMBJAUC	HS	Terminated
DMBJAUC	CP	ASTA Medica AG
DMBJAUC	DE	Solid tumour/cancer

DM0YFZ6	ID	DM0YFZ6
DM0YFZ6	DN	D-43787
DM0YFZ6	HS	Terminated
DM0YFZ6	SN	D-43787; UNII-18SFZ71BQO; 198016-44-3; 18SFZ71BQO; CTK8E8581; DTXSID30173514; ZINC3960990; d43787; 1H-Indole-1-carboxylic acid, 2-(((2S)-2,3-dihydro-2-((((1S)-1-(methoxycarbonyl)-5-(((phenylmethoxy)carbonyl)amino)pentyl)amino)carbonyl)-1H-indol-1-yl)carbonyl)-2,3-dihydro-, 1,1-dimethylethyl ester, (2S)-; RT-012166; FT-0665439; J-012788; (2S)-2-[[(2S)-2,3-Dihydro-2-[[[(1S)-1-(methoxycarbonyl)-5-[[(phenylmethoxy)carbonyl]amino]pentyl]amino]carbonyl]-1H-indol-1-yl]carbonyl]-2,3-dihydro-1H-Indole-1-carboxylic Acid 1,1-Dime
DM0YFZ6	DT	Small molecular drug
DM0YFZ6	PC	9961556
DM0YFZ6	MW	684.8
DM0YFZ6	FM	C38H44N4O8
DM0YFZ6	IC	InChI=1S/C38H44N4O8/c1-38(2,3)50-37(47)42-30-20-11-9-17-27(30)23-32(42)34(44)41-29-19-10-8-16-26(29)22-31(41)33(43)40-28(35(45)48-4)18-12-13-21-39-36(46)49-24-25-14-6-5-7-15-25/h5-11,14-17,19-20,28,31-32H,12-13,18,21-24H2,1-4H3,(H,39,46)(H,40,43)/t28-,31-,32-/m0/s1
DM0YFZ6	CS	CC(C)(C)OC(=O)N1[C@@H](CC2=CC=CC=C21)C(=O)N3[C@@H](CC4=CC=CC=C43)C(=O)N[C@@H](CCCCNC(=O)OCC5=CC=CC=C5)C(=O)OC
DM0YFZ6	IK	GKYGBJABPHBINI-MHDHXZMLSA-N
DM0YFZ6	IU	tert-butyl (2S)-2-[(2S)-2-[[(2S)-1-methoxy-1-oxo-6-(phenylmethoxycarbonylamino)hexan-2-yl]carbamoyl]-2,3-dihydroindole-1-carbonyl]-2,3-dihydroindole-1-carboxylate
DM0YFZ6	CA	CAS 198016-44-3
DM0YFZ6	DE	Allergy

DMXHN6U	ID	DMXHN6U
DMXHN6U	DN	D-5410
DMXHN6U	HS	Terminated
DMXHN6U	SN	CH-138; CH-263
DMXHN6U	CP	UCB Celltech
DMXHN6U	DE	Rheumatoid arthritis

DMHNZ1P	ID	DMHNZ1P
DMHNZ1P	DN	D-9120
DMHNZ1P	HS	Terminated
DMHNZ1P	CP	UCB Celltech
DMHNZ1P	DE	Inflammatory bowel disease

DM3LJK5	ID	DM3LJK5
DM3LJK5	DN	DAA-1097
DM3LJK5	HS	Terminated
DM3LJK5	SN	DAA-1106
DM3LJK5	CP	Taisho Pharmaceutical Co Ltd
DM3LJK5	DT	Small molecular drug
DM3LJK5	PC	9844410
DM3LJK5	MW	409.9
DM3LJK5	FM	C24H24ClNO3
DM3LJK5	IC	InChI=1S/C24H24ClNO3/c1-17(2)28-23-12-8-7-9-19(23)16-26(18(3)27)22-14-13-20(25)15-24(22)29-21-10-5-4-6-11-21/h4-15,17H,16H2,1-3H3
DM3LJK5	CS	CC(C)OC1=CC=CC=C1CN(C2=C(C=C(C=C2)Cl)OC3=CC=CC=C3)C(=O)C
DM3LJK5	IK	CGUBOFYHGYNUDL-UHFFFAOYSA-N
DM3LJK5	IU	N-(4-chloro-2-phenoxyphenyl)-N-[(2-propan-2-yloxyphenyl)methyl]acetamide
DM3LJK5	CA	CAS 220551-79-1
DM3LJK5	DE	Anxiety disorder

DMP3X6Q	ID	DMP3X6Q
DMP3X6Q	DN	Dacetuzumab
DMP3X6Q	HS	Terminated
DMP3X6Q	SN	SMR000449312; MLS000758226; MLS001424020; CHEMBL1408911; CCG-100789
DMP3X6Q	CP	Roche; Genentech
DMP3X6Q	DT	Monoclonal antibody
DMP3X6Q	DE	Non-hodgkin lymphoma; Diffuse large B-cell lymphoma

DMZ8OMT	ID	DMZ8OMT
DMZ8OMT	DN	DACTIMICIN
DMZ8OMT	HS	Terminated
DMZ8OMT	SN	SF-2052; 4-Amino-1,4-dideoxy-3-O-(2,6-diamino-2,3,4,6,7-pentadeoxy-beta-L-lyxo-heptopyranosyl)-1-[(N-formimidoylglycyl)methylamino]-6-O-methyl-L-chiro-inositol; 4-Amino-1,4-dideoxy-3-O-(2,6-diamino-2,3,4,6,7-pentadeoxy-beta-L-lyxo-heptopyranosyl)-1-[[[(iminomethyl)amino]acetyl]methylamino]-6-O-methyl-L-chiro-inositol
DMZ8OMT	DT	Small molecular drug
DMZ8OMT	PC	107800
DMZ8OMT	MW	432.5
DMZ8OMT	FM	C18H36N6O6
DMZ8OMT	IC	InChI=1S/C18H36N6O6/c1-8(20)10-5-4-9(21)18(29-10)30-16-12(22)14(26)17(28-3)13(15(16)27)24(2)11(25)6-23-7-19/h7-10,12-18,26-27H,4-6,20-22H2,1-3H3,(H2,19,23)
DMZ8OMT	CS	CC(C1CCC(C(O1)OC2C(C(C(C(C2O)N(C)C(=O)CN=CN)OC)O)N)N)N
DMZ8OMT	IK	VFBPKQSATYZKRX-UHFFFAOYSA-N
DMZ8OMT	IU	N-[4-amino-3-[3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2,5-dihydroxy-6-methoxycyclohexyl]-2-(aminomethylideneamino)-N-methylacetamide
DMZ8OMT	CA	CAS 73196-97-1
DMZ8OMT	DE	Bacterial infection

DMFCMPS	ID	DMFCMPS
DMFCMPS	DN	Daidzin
DMFCMPS	HS	Terminated
DMFCMPS	SN	AC1N4RYA; MLS000563445; SCHEMBL3423674; CHEMBL115316; KYQZWONCHDNPDP-UHFFFAOYSA-N; HMS3604G15; HMS3348J07; HMS2194K16; AKOS024284500; AC-6036; MCULE-3802707688; SMR000232339; ST077114; SR-01000721602; SR-01000721602-3; I06-0227; 3-(4-hydroxyphenyl)-7-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; 4H-1-Benzopyran-4-one, 7-(.beta.-D-glucopyranosyloxy)-3-(4-hydroxyphenyl)-; 3-(4-hydroxyphenyl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-one
DMFCMPS	DT	Small molecular drug
DMFCMPS	PC	107971
DMFCMPS	MW	416.4
DMFCMPS	FM	C21H20O9
DMFCMPS	IC	InChI=1S/C21H20O9/c22-8-16-18(25)19(26)20(27)21(30-16)29-12-5-6-13-15(7-12)28-9-14(17(13)24)10-1-3-11(23)4-2-10/h1-7,9,16,18-23,25-27H,8H2/t16-,18-,19+,20-,21-/m1/s1
DMFCMPS	CS	C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
DMFCMPS	IK	KYQZWONCHDNPDP-QNDFHXLGSA-N
DMFCMPS	IU	3-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMFCMPS	CA	CAS 552-66-9
DMFCMPS	CB	CHEBI:42202

DMHJAD4	ID	DMHJAD4
DMHJAD4	DN	Daniplestim
DMHJAD4	HS	Terminated
DMHJAD4	DE	Osteoporosis

DM6IGRL	ID	DM6IGRL
DM6IGRL	DN	DARGLITAZONE
DM6IGRL	HS	Terminated
DM6IGRL	SN	CP-86325; Darglitazone < Rec INN; Rac-5-[4-[3-(5-Methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione
DM6IGRL	DT	Small molecular drug
DM6IGRL	PC	60870
DM6IGRL	MW	420.5
DM6IGRL	FM	C23H20N2O4S
DM6IGRL	IC	InChI=1S/C23H20N2O4S/c1-14-18(24-22(29-14)17-5-3-2-4-6-17)11-12-19(26)16-9-7-15(8-10-16)13-20-21(27)25-23(28)30-20/h2-10,20H,11-13H2,1H3,(H,25,27,28)
DM6IGRL	CS	CC1=C(N=C(O1)C2=CC=CC=C2)CCC(=O)C3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DM6IGRL	IK	QQKNSPHAFATFNQ-UHFFFAOYSA-N
DM6IGRL	IU	5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM6IGRL	CA	CAS 141200-24-0
DM6IGRL	DE	Diabetic complication

DM160FM	ID	DM160FM
DM160FM	DN	Darodipine
DM160FM	HS	Terminated
DM160FM	SN	Dazodipine; Plimo; PY-108-068
DM160FM	CP	Novartis AG
DM160FM	DT	Small molecular drug
DM160FM	PC	51701
DM160FM	MW	371.4
DM160FM	FM	C19H21N3O5
DM160FM	IC	InChI=1S/C19H21N3O5/c1-5-25-18(23)14-10(3)20-11(4)15(19(24)26-6-2)16(14)12-8-7-9-13-17(12)22-27-21-13/h7-9,16,20H,5-6H2,1-4H3
DM160FM	CS	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC3=NON=C32)C(=O)OCC)C)C
DM160FM	IK	QERUYFVNIOLCHV-UHFFFAOYSA-N
DM160FM	IU	diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM160FM	CA	CAS 72803-02-2
DM160FM	DE	Cerebrovascular ischaemia

DMR80AL	ID	DMR80AL
DMR80AL	DN	Datelliptium chloride
DMR80AL	HS	Terminated
DMR80AL	SN	Datelliptinium; Detalliptinium; SR-95156B
DMR80AL	CP	Sanofi
DMR80AL	DT	Small molecular drug
DMR80AL	PC	72034
DMR80AL	MW	397.9
DMR80AL	FM	C23H28ClN3O
DMR80AL	IC	InChI=1S/C23H27N3O.ClH/c1-5-25(6-2)11-12-26-10-9-18-16(4)23-22(15(3)20(18)14-26)19-13-17(27)7-8-21(19)24-23;/h7-10,13-14,27H,5-6,11-12H2,1-4H3;1H
DMR80AL	CS	CCN(CC)CC[N+]1=CC2=C(C3=C(C(=C2C=C1)C)NC4=C3C=C(C=C4)O)C.[Cl-]
DMR80AL	IK	UCICRVXYPSKKJK-UHFFFAOYSA-N
DMR80AL	IU	2-[2-(diethylamino)ethyl]-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;chloride
DMR80AL	CA	CAS 105118-14-7
DMR80AL	DE	Breast cancer

DMP9GFZ	ID	DMP9GFZ
DMP9GFZ	DN	DAU-6285
DMP9GFZ	HS	Terminated
DMP9GFZ	SN	Dau 6285; CHEMBL552854; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 6-methoxy-2-oxo-3H-benzimidazole-1-carboxylate; AC1L2WHB; GTPL246; SCHEMBL2945410; CHEMBL1194556; PDSP1_000035; BDBM50007863; PDSP2_000035; PDSP1_001680; PDSP2_001663; L000897; 6-Methoxy-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester
DMP9GFZ	CP	Boehringer Ingelheim Corp
DMP9GFZ	DT	Small molecular drug
DMP9GFZ	PC	129927
DMP9GFZ	MW	367.8
DMP9GFZ	FM	C17H22ClN3O4
DMP9GFZ	IC	InChI=1S/C17H21N3O4.ClH/c1-19-10-3-4-11(19)8-13(7-10)24-17(22)20-15-9-12(23-2)5-6-14(15)18-16(20)21;/h5-6,9-11,13H,3-4,7-8H2,1-2H3,(H,18,21);1H
DMP9GFZ	CS	CN1C2CCC1CC(C2)OC(=O)N3C4=C(C=CC(=C4)OC)NC3=O.Cl
DMP9GFZ	IK	MXZAMPPIKDHMOJ-UHFFFAOYSA-N
DMP9GFZ	IU	(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 6-methoxy-2-oxo-3H-benzimidazole-1-carboxylate;hydrochloride
DMP9GFZ	CA	CAS 123258-98-0
DMP9GFZ	DE	Vomiting

DMJUW8H	ID	DMJUW8H
DMJUW8H	DN	Dazoxiben
DMJUW8H	HS	Terminated
DMJUW8H	SN	DAZOXIBEN; 78218-09-4; Dazoxibene; Dazoxiben [INN-Spanish]; Dazoxibenum; Dazoxibenum [INN-Latin]; Dazoxibene [INN-French]; Dazoxiben [INN:BAN]; 4-(2-(1H-Imidazol-1-yl)ethoxy)benzoic acid; UNII-09ZFC7974Q; 4-(2-imidazol-1-ylethoxy)benzoic acid; UK 37248; Benzoic acid, 4-(2-(1H-imidazol-1-yl)ethoxy)-; p-(2-Imidazol-1-ylethoxy)benzoic acid; 4-(2-(1-Imidazolyl)ethoxy)benzoesaeure; UK-37248; CHEMBL267473; 103735-00-8; 4-[2-(1H-imidazol-1-yl)ethoxy]benzoic acid; 09ZFC7974Q; AH-P 719 (9CI); NCGC00018938-03
DMJUW8H	DT	Small molecular drug
DMJUW8H	PC	53001
DMJUW8H	MW	232.23
DMJUW8H	FM	C12H12N2O3
DMJUW8H	IC	InChI=1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)
DMJUW8H	CS	C1=CC(=CC=C1C(=O)O)OCCN2C=CN=C2
DMJUW8H	IK	XQGZSYKGWHUSDH-UHFFFAOYSA-N
DMJUW8H	IU	4-(2-imidazol-1-ylethoxy)benzoic acid
DMJUW8H	CA	CAS 78218-09-4

DMTXPSB	ID	DMTXPSB
DMTXPSB	DN	DB-200
DMTXPSB	HS	Terminated
DMTXPSB	SN	DB-200 series (topical, psoriasis); CPT-1 inhibitor (topical, psoriasis), DARA; DB-200 series (topical, psoriasis), DARA BioSciences
DMTXPSB	CP	DARA BioSciences
DMTXPSB	DE	Psoriasis vulgaris

DM8GHT2	ID	DM8GHT2
DM8GHT2	DN	DBO-11
DM8GHT2	HS	Terminated
DM8GHT2	SN	166374-49-8; Naxifylline (USAN/INN)
DM8GHT2	TC	Analgesics
DM8GHT2	DT	Small molecular drug
DM8GHT2	PC	23724971
DM8GHT2	MW	344.4
DM8GHT2	FM	C18H24N4O3
DM8GHT2	IC	InChI=1S/C18H24N4O3/c1-3-5-21-16-12(17(23)22(6-4-2)18(21)24)19-15(20-16)11-8-9-7-10(11)14-13(9)25-14/h9-11,13-14H,3-8H2,1-2H3,(H,19,20)/t9-,10-,11-,13+,14-/m0/s1
DM8GHT2	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)[C@H]3C[C@@H]4C[C@@H]3[C@H]5[C@@H]4O5
DM8GHT2	IK	OQCJPFYWFGUHIN-JZKMBYMZSA-N
DM8GHT2	IU	8-[(1R,2R,4S,5S,6S)-3-oxatricyclo[3.2.1.02,4]octan-6-yl]-1,3-dipropyl-7H-purine-2,6-dione
DM8GHT2	DE	Cancer related pain

DMFJ3UW	ID	DMFJ3UW
DMFJ3UW	DN	DBO-17
DMFJ3UW	HS	Terminated
DMFJ3UW	TC	Analgesics
DMFJ3UW	PC	10042211
DMFJ3UW	MW	329.4
DMFJ3UW	FM	C18H23N3O3
DMFJ3UW	IC	InChI=1S/C18H23N3O3/c1-2-18(22)19-12-16-9-10-17(13-19)20(16)11-3-4-14-5-7-15(8-6-14)21(23)24/h3-8,16-17H,2,9-13H2,1H3/b4-3+
DMFJ3UW	CS	CCC(=O)N1CC2CCC(C1)N2C/C=C/C3=CC=C(C=C3)[N+](=O)[O-]
DMFJ3UW	IK	VWJDGZDXFSHUPA-ONEGZZNKSA-N
DMFJ3UW	IU	1-[8-[(E)-3-(4-nitrophenyl)prop-2-enyl]-3,8-diazabicyclo[3.2.1]octan-3-yl]propan-1-one
DMFJ3UW	DE	Cancer related pain

DM0JDCS	ID	DM0JDCS
DM0JDCS	DN	DBO-83
DM0JDCS	HS	Terminated
DM0JDCS	SN	DBO-83; EU-0100452; CHEMBL1527419; Tox21_500452; LP00452; CCG-221756; NCGC00261137-01; NCGC00093868-01; D 7938; SR-01000075832
DM0JDCS	DT	Small molecular drug
DM0JDCS	PC	9926237
DM0JDCS	MW	297.6
DM0JDCS	FM	C10H15Cl3N4
DM0JDCS	IC	InChI=1S/C10H13ClN4.2ClH/c11-9-3-4-10(14-13-9)15-5-7-1-2-8(6-15)12-7;;/h3-4,7-8,12H,1-2,5-6H2;2*1H
DM0JDCS	CS	C1CC2CN(CC1N2)C3=NN=C(C=C3)Cl.Cl.Cl
DM0JDCS	IK	FMBGHZXNKMHVDT-UHFFFAOYSA-N
DM0JDCS	IU	3-(6-chloropyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane;dihydrochloride
DM0JDCS	CA	CAS 195211-53-1

DMCDMWJ	ID	DMCDMWJ
DMCDMWJ	DN	DC-015
DMCDMWJ	HS	Terminated
DMCDMWJ	DT	Small molecular drug
DMCDMWJ	PC	132891
DMCDMWJ	MW	391.5
DMCDMWJ	FM	C22H25N5O2
DMCDMWJ	IC	InChI=1S/C22H25N5O2/c1-29-20-9-5-4-8-19(20)26-12-10-25(11-13-26)15-16-14-23-21-17-6-2-3-7-18(17)24-22(28)27(16)21/h2-9,16,23H,10-15H2,1H3
DMCDMWJ	CS	COC1=CC=CC=C1N2CCN(CC2)CC3CNC4=C5C=CC=CC5=NC(=O)N34
DMCDMWJ	IK	COCJIISORPXDPN-UHFFFAOYSA-N
DMCDMWJ	IU	3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-one
DMCDMWJ	CA	CAS 149847-87-0

DM5VFR0	ID	DM5VFR0
DM5VFR0	DN	DHP-218
DM5VFR0	HS	Terminated
DM5VFR0	SN	Dhp-218; 102097-78-9; Dhp 218; 3-Pyridinecarboxylicacid,1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxido-1,3,2-dioxaphosphorinan-2-yl)-,methyl ester; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxido-1,3,2-dioxaphosphorinan-2-yl)-, methyl ester;3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxido-1,3,2-dioxaphosphorinan-2-yl)-, methyl ester; AC1O3SAA; ACMC-20m53m; SCHEMBL1356340; CTK4A0679; AKOS030566270; Methyl 2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxo-1,
DM5VFR0	CP	Nippon Shinyaku Co Ltd
DM5VFR0	DT	Small molecular drug
DM5VFR0	PC	6336069
DM5VFR0	MW	408.3
DM5VFR0	FM	C18H21N2O7P
DM5VFR0	IC	InChI=1S/C18H21N2O7P/c1-11-15(18(21)25-3)16(13-7-4-5-8-14(13)20(22)23)17(12(2)19-11)28(24)26-9-6-10-27-28/h4-5,7-8,16,19H,6,9-10H2,1-3H3
DM5VFR0	CS	CC1=C(C(C(=C(N1)C)P2(=O)OCCCO2)C3=CC=CC=C3[N+](=O)[O-])C(=O)OC
DM5VFR0	IK	GSWINTXYUFHJGW-UHFFFAOYSA-N
DM5VFR0	IU	methyl 2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl)-1,4-dihydropyridine-3-carboxylate
DM5VFR0	CA	CAS 102097-78-9
DM5VFR0	DE	Hypertension

DM6LP0R	ID	DM6LP0R
DM6LP0R	DN	Dianicline+rimonabant
DM6LP0R	HS	Terminated
DM6LP0R	SN	[3H]nemonapride; (2R,3R)-nemonapride; 75272-39-8; CHEBI:64219; C21H26ClN3O2; 93664-94-9
DM6LP0R	CP	Sanofi-Aventis
DM6LP0R	DT	Combination drug (Antibody)
DM6LP0R	DE	Tobacco dependence

DM61BWZ	ID	DM61BWZ
DM61BWZ	DN	Diaspirin crosslinked hemoglobin
DM61BWZ	HS	Terminated
DM61BWZ	SN	DCLHb; HemAssist; DCLHb, Baxter; Diaspirin crosslinked hemoglobin, Baxter
DM61BWZ	CP	Baxter Healthcare Ltd
DM61BWZ	DE	Cerebrovascular ischaemia

DMB74CM	ID	DMB74CM
DMB74CM	DN	DIAVERIDINE
DMB74CM	HS	Terminated
DMB74CM	SN	Diaveridine < Rec INN; EGIS-5645; 2,4-Diamino-5-(3',4'-dimethoxybenzyl)pyrimidine; 5-[(3,4-Dimethoxyphenyl)methyl]-2,4-pyrimidinediamine
DMB74CM	DT	Small molecular drug
DMB74CM	PC	21453
DMB74CM	MW	260.29
DMB74CM	FM	C13H16N4O2
DMB74CM	IC	InChI=1S/C13H16N4O2/c1-18-10-4-3-8(6-11(10)19-2)5-9-7-16-13(15)17-12(9)14/h3-4,6-7H,5H2,1-2H3,(H4,14,15,16,17)
DMB74CM	CS	COC1=C(C=C(C=C1)CC2=CN=C(N=C2N)N)OC
DMB74CM	IK	LDBTVAXGKYIFHO-UHFFFAOYSA-N
DMB74CM	IU	5-[(3,4-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine
DMB74CM	CA	CAS 5355-16-8
DMB74CM	CB	CHEBI:123115
DMB74CM	DE	Bacterial infection

DMAK3V7	ID	DMAK3V7
DMAK3V7	DN	DIO-901
DMAK3V7	HS	Terminated
DMAK3V7	SN	CAM-4044; VLD glucagon (diabetes), DiObex; Very low dose glucagon (diabetes), DiObex; VLD glucagon (FluidCrystal, diabetes), DiObex; VLD glucagon (extended-release, diabetes) DiObex
DMAK3V7	CP	DiObex
DMAK3V7	DE	Type-1 diabetes

DMO3XBP	ID	DMO3XBP
DMO3XBP	DN	Divaplon
DMO3XBP	HS	Terminated
DMO3XBP	SN	Divaplon; 90808-12-1; UNII-4AOV43246G; 4AOV43246G; Divaplonum; Divaplone; methanone,(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)phenyl-; Divaplon [INN]; Divaplonum [INN-Latin]; Divaplone [INN-French]; SCHEMBL678101; CHEMBL281164; ZINC1325; DTXSID40238269; AC1L2418; RU-32698; KB-274411; 6-Ethyl-7-methoxy-5-methylimidazo(1,2-a)pyrimidin-2-yl phenyl ketone; (6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-phenylmethanone; Methanone, (6-ethyl-7-methoxy-5-methylimidazo(1,2-a)pyrimidin-2-yl)phenyl-
DMO3XBP	DT	Small molecular drug
DMO3XBP	PC	65822
DMO3XBP	MW	295.34
DMO3XBP	FM	C17H17N3O2
DMO3XBP	IC	InChI=1S/C17H17N3O2/c1-4-13-11(2)20-10-14(18-17(20)19-16(13)22-3)15(21)12-8-6-5-7-9-12/h5-10H,4H2,1-3H3
DMO3XBP	CS	CCC1=C(N2C=C(N=C2N=C1OC)C(=O)C3=CC=CC=C3)C
DMO3XBP	IK	NRJVHCSYLGLURI-UHFFFAOYSA-N
DMO3XBP	IU	(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-phenylmethanone
DMO3XBP	CA	CAS 90808-12-1

DMMGYXR	ID	DMMGYXR
DMMGYXR	DN	Dizocilpine
DMMGYXR	HS	Terminated
DMMGYXR	SN	DIZOCILPINE; 77086-21-6; MK-801 (Dizocilpine); UNII-7PY8KH681I; MK-801; Lopac-M-108; Lopac-M-107; MK 801; Prestwick0_000109; (5S,10R)-5-methyl-10,11-dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene; 7PY8KH681I; CHEMBL284237; CHEBI:34725; Dizocilpine [INN]; Dizocilpinum [INN-Latin]; Dizocilpina [INN-Spanish]; Dizocilpinum; Dizocilpina; MK801; MK-801(Dizocilpine); HSDB 7641; (+)MK-801; (+)-MK-801; (+/-)-MK801; Prestwick2_000109; Prestwick3_000109; Prestwick1_000109; Biomol-NT_000210; SCHEMBL34528; Lopac0_000872; BSPBio_000098; SPBio_002037
DMMGYXR	DT	Small molecular drug
DMMGYXR	PC	180081
DMMGYXR	MW	221.3
DMMGYXR	FM	C16H15N
DMMGYXR	IC	InChI=1S/C16H15N/c1-16-13-8-4-2-6-11(13)10-15(17-16)12-7-3-5-9-14(12)16/h2-9,15,17H,10H2,1H3/t15-,16+/m1/s1
DMMGYXR	CS	C[C@@]12C3=CC=CC=C3C[C@@H](N1)C4=CC=CC=C24
DMMGYXR	IK	LBOJYSIDWZQNJS-CVEARBPZSA-N
DMMGYXR	IU	(1S,9R)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene
DMMGYXR	CA	CAS 77086-21-6
DMMGYXR	CB	CHEBI:34725
DMMGYXR	DE	Cerebrovascular ischaemia

DMNSDM1	ID	DMNSDM1
DMNSDM1	DN	DMP-696
DMNSDM1	HS	Terminated
DMNSDM1	SN	DMP 696; DMP-696; DMP696; CHEMBL44698; SCHEMBL2931046; GTPL3499; ZINC1489783; PDSP1_001296; PDSP2_001280; BDBM50084875; CS-6810; HY-12131; 8-(2,4-dichlorophenyl)-N-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine; [8-(2,4-Dichloro-phenyl)-2,7-dimethyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-(2-methoxy-1-methoxymethyl-ethyl)-amine; N-[1-(Methoxymethyl)-2-methoxyethyl]-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine-4-amine
DMNSDM1	DT	Small molecular drug
DMNSDM1	PC	9909468
DMNSDM1	MW	410.3
DMNSDM1	FM	C18H21Cl2N5O2
DMNSDM1	IC	InChI=1S/C18H21Cl2N5O2/c1-10-16(14-6-5-12(19)7-15(14)20)17-21-11(2)22-18(25(17)24-10)23-13(8-26-3)9-27-4/h5-7,13H,8-9H2,1-4H3,(H,21,22,23)
DMNSDM1	CS	CC1=NN2C(=C1C3=C(C=C(C=C3)Cl)Cl)N=C(N=C2NC(COC)COC)C
DMNSDM1	IK	MDWRPTOUDPFXKK-UHFFFAOYSA-N
DMNSDM1	IU	8-(2,4-dichlorophenyl)-N-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DMNSDM1	CA	CAS 202578-52-7
DMNSDM1	DE	Anxiety disorder

DMGNUXC	ID	DMGNUXC
DMGNUXC	DN	DMP-757
DMGNUXC	HS	Terminated
DMGNUXC	SN	CHEMBL65617; DMP-757; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid
DMGNUXC	DT	Small molecular drug
DMGNUXC	PC	10031011
DMGNUXC	MW	574.6
DMGNUXC	FM	C26H38N8O7
DMGNUXC	IC	InChI=1S/C26H38N8O7/c1-14(2)21-25(41)34(3)18(8-5-9-29-26(27)28)24(40)31-13-19(35)32-17(11-20(36)37)23(39)30-12-15-6-4-7-16(10-15)22(38)33-21/h4,6-7,10,14,17-18,21H,5,8-9,11-13H2,1-3H3,(H,30,39)(H,31,40)(H,32,35)(H,33,38)(H,36,37)(H4,27,28,29)/t17-,18-,21-/m0/s1
DMGNUXC	CS	CC(C)[C@H]1C(=O)N([C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC2=CC(=CC=C2)C(=O)N1)CC(=O)O)CCCN=C(N)N)C
DMGNUXC	IK	TZZMWRLTTWMKCL-WFXMLNOXSA-N
DMGNUXC	IU	2-[(5S,11S,14S)-11-[3-(diaminomethylideneamino)propyl]-12-methyl-4,7,10,13,16-pentaoxo-14-propan-2-yl-3,6,9,12,15-pentazabicyclo[15.3.1]henicosa-1(21),17,19-trien-5-yl]acetic acid

DMO26E7	ID	DMO26E7
DMO26E7	DN	DMP-811
DMO26E7	HS	Terminated
DMO26E7	SN	L-708404
DMO26E7	CP	Bristol-Myers Squibb Pharma Co
DMO26E7	DT	Small molecular drug
DMO26E7	PC	3081289
DMO26E7	MW	416.5
DMO26E7	FM	C23H24N6O2
DMO26E7	IC	InChI=1S/C23H24N6O2/c1-3-7-20-24-19(4-2)21(23(30)31)29(20)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-25-27-28-26-22/h5-6,8-13H,3-4,7,14H2,1-2H3,(H,30,31)(H,25,26,27,28)
DMO26E7	CS	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)CC
DMO26E7	IK	OFYWYKMCRWMPPQ-UHFFFAOYSA-N
DMO26E7	IU	5-ethyl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
DMO26E7	CA	CAS 139964-19-5
DMO26E7	DE	Hypertension

DMKU469	ID	DMKU469
DMKU469	DN	DMP-963
DMKU469	HS	Terminated
DMKU469	SN	DPC-963; 4(S)-(2-Cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one
DMKU469	DT	Small molecular drug
DMKU469	PC	474121
DMKU469	MW	316.23
DMKU469	FM	C14H9F5N2O
DMKU469	IC	InChI=1S/C14H9F5N2O/c15-8-3-4-9-10(11(8)16)13(14(17,18)19,21-12(22)20-9)6-5-7-1-2-7/h3-4,7H,1-2H2,(H2,20,21,22)/t13-/m0/s1
DMKU469	CS	C1CC1C#C[C@]2(C3=C(C=CC(=C3F)F)NC(=O)N2)C(F)(F)F
DMKU469	IK	QCNJQJJFXFJVCX-ZDUSSCGKSA-N
DMKU469	IU	(4S)-4-(2-cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one
DMKU469	CA	CAS 214287-90-8
DMKU469	DE	Human immunodeficiency virus infection

DMLBS83	ID	DMLBS83
DMLBS83	DN	DMPDDF
DMLBS83	HS	Terminated
DMLBS83	SN	IDDB5773
DMLBS83	CP	Glaxo Wellcome plc
DMLBS83	DE	Solid tumour/cancer

DMXR3V1	ID	DMXR3V1
DMXR3V1	DN	DNP-004089
DMXR3V1	HS	Terminated
DMXR3V1	SN	BACE inhibitors, De Novo; Beta-amyloid converting enzyme inhibitors,De Novo; Beta-secretase inhibitors, De Novo
DMXR3V1	CP	De Novo Pharmaceuticals Ltd
DMXR3V1	DE	Alzheimer disease

DM6Q05K	ID	DM6Q05K
DM6Q05K	DN	Dotarizine
DM6Q05K	HS	Terminated
DM6Q05K	SN	Dotarazine; FI-6020; FI-6026
DM6Q05K	CP	Ferrer Internacional SA
DM6Q05K	DT	Small molecular drug
DM6Q05K	PC	55285
DM6Q05K	MW	442.6
DM6Q05K	FM	C29H34N2O2
DM6Q05K	IC	InChI=1S/C29H34N2O2/c1-4-11-25(12-5-1)28(26-13-6-2-7-14-26)31-21-19-30(20-22-31)18-10-17-29(32-23-24-33-29)27-15-8-3-9-16-27/h1-9,11-16,28H,10,17-24H2
DM6Q05K	CS	C1CN(CCN1CCCC2(OCCO2)C3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5
DM6Q05K	IK	LRMJAFKKJLRDLE-UHFFFAOYSA-N
DM6Q05K	IU	1-benzhydryl-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine
DM6Q05K	CA	CAS 84625-59-2
DM6Q05K	CB	CHEBI:138033
DM6Q05K	DE	Migraine

DM4BPFV	ID	DM4BPFV
DM4BPFV	DN	Doxorubicin-CEA conjugate
DM4BPFV	HS	Terminated
DM4BPFV	SN	DOX-CEA; Doxorubicin-CEA conjugate, Immunomedics
DM4BPFV	CP	Immunomedics Inc
DM4BPFV	DE	Breast cancer

DM4JBQD	ID	DM4JBQD
DM4JBQD	DN	DPC-333
DM4JBQD	HS	Terminated
DM4JBQD	SN	BMS-561392; UNII-2X066A8676; BMS 561392; CHEMBL489100; DPC-333; BMS561392; 2X066A8676; DPC 333; 611227-74-8; SCHEMBL6350418; GTPL6509; BDBM50247606; C476910000; (2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide
DM4JBQD	CP	Bristol-Myers Squibb Pharma
DM4JBQD	DT	Small molecular drug
DM4JBQD	PC	9847838
DM4JBQD	MW	476.6
DM4JBQD	FM	C27H32N4O4
DM4JBQD	IC	InChI=1S/C27H32N4O4/c1-17(2)14-24(25(32)30-34)31-13-12-27(28,26(31)33)20-8-10-21(11-9-20)35-16-19-15-18(3)29-23-7-5-4-6-22(19)23/h4-11,15,17,24,34H,12-14,16,28H2,1-3H3,(H,30,32)/t24-,27-/m1/s1
DM4JBQD	CS	CC1=NC2=CC=CC=C2C(=C1)COC3=CC=C(C=C3)[C@@]4(CCN(C4=O)[C@H](CC(C)C)C(=O)NO)N
DM4JBQD	IK	QVNZBDLTUKCPGJ-SHQCIBLASA-N
DM4JBQD	IU	(2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide
DM4JBQD	CA	CAS 611227-74-8
DM4JBQD	DE	Rheumatoid arthritis; Inflammatory bowel disease

DM67VDK	ID	DM67VDK
DM67VDK	DN	DPC-A78277
DM67VDK	HS	Terminated
DM67VDK	CP	Bristol-Myers Squibb Pharma Co
DM67VDK	DE	Human immunodeficiency virus infection

DM1AQVE	ID	DM1AQVE
DM1AQVE	DN	DPI-201-106
DM1AQVE	HS	Terminated
DM1AQVE	SN	4-{3-[4-(Diphenylmethyl)piperazin-1-yl]-2-hydroxypropoxy}-1h-indole-2-carbonitrile; Dpi 201-106; 97730-95-5; SDZ-201106; CHEMBL314639; SDZ-201 106 (+/-); 4-{3-[4-(diphenylmethyl)piperazin-1-yl]-2-hydroxypropoxy}-1h-indole-2-carbonitrile; (+-)-4-(3-(4-(Diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy)-1H-indole-2-carbonitrile; 1H-Indole-2-carbonitrile, 4-(3-(4-(diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy-, (+-)-; 4(3-(4-Diphenylmethylpiperazine-1-yl)-2-hydroxypropoxy)-1H-indol-2-carbonitrile; CBiol_001886; DPI-201106; 4-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy)-1H-indole-2-carbonitrile
DM1AQVE	CP	Novartis AG
DM1AQVE	DT	Small molecular drug
DM1AQVE	PC	5190
DM1AQVE	MW	466.6
DM1AQVE	FM	C29H30N4O2
DM1AQVE	IC	InChI=1S/C29H30N4O2/c30-19-24-18-26-27(31-24)12-7-13-28(26)35-21-25(34)20-32-14-16-33(17-15-32)29(22-8-3-1-4-9-22)23-10-5-2-6-11-23/h1-13,18,25,29,31,34H,14-17,20-21H2
DM1AQVE	CS	C1CN(CCN1CC(COC2=CC=CC3=C2C=C(N3)C#N)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM1AQVE	IK	BYBYHCOEAFHGJL-UHFFFAOYSA-N
DM1AQVE	IU	4-[3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy]-1H-indole-2-carbonitrile
DM1AQVE	CA	CAS 97730-95-5
DM1AQVE	CB	CHEBI:110175
DM1AQVE	DE	Cardiovascular disease

DMX4KIT	ID	DMX4KIT
DMX4KIT	DN	Draculin
DMX4KIT	HS	Terminated
DMX4KIT	CP	Instituto Venezolano de Investigaciones Cientificas
DMX4KIT	DE	Thrombosis

DM6EJVF	ID	DM6EJVF
DM6EJVF	DN	Droxinavir hydrochloride
DM6EJVF	HS	Terminated
DM6EJVF	SN	SC-55389; SC-55389A
DM6EJVF	CP	GD Searle & Co
DM6EJVF	PC	9937952
DM6EJVF	MW	570.2
DM6EJVF	FM	C29H52ClN5O4
DM6EJVF	IC	InChI=1S/C29H51N5O4.ClH/c1-20(2)15-16-34(27(38)33-29(6,7)8)19-23(35)22(17-21-13-11-10-12-14-21)31-26(37)25(28(3,4)5)32-24(36)18-30-9;/h10-14,20,22-23,25,30,35H,15-19H2,1-9H3,(H,31,37)(H,32,36)(H,33,38);1H/t22-,23+,25+;/m0./s1
DM6EJVF	CS	CC(C)CCN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)(C)C)NC(=O)CNC)O)C(=O)NC(C)(C)C.Cl
DM6EJVF	IK	IYKXRORSPVZSHP-ZELIPEIJSA-N
DM6EJVF	IU	(2S)-N-[(2S,3R)-4-[tert-butylcarbamoyl(3-methylbutyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-3,3-dimethyl-2-[[2-(methylamino)acetyl]amino]butanamide;hydrochloride
DM6EJVF	CA	CAS 155662-50-3
DM6EJVF	DE	Human immunodeficiency virus infection

DMAE43P	ID	DMAE43P
DMAE43P	DN	DSP-7238
DMAE43P	HS	Terminated
DMAE43P	CP	Dianippen
DMAE43P	DE	Diabetic complication

DMX5SN8	ID	DMX5SN8
DMX5SN8	DN	Du-123015
DMX5SN8	HS	Terminated
DMX5SN8	SN	Benzopyran piperazine derivative (5HT modulator, neurological disorders), Solvay
DMX5SN8	CP	Solvay SA
DMX5SN8	DE	Anxiety disorder

DM87ZWP	ID	DM87ZWP
DM87ZWP	DN	DU-1777
DM87ZWP	HS	Terminated
DM87ZWP	SN	DU 1777; AC1MIWBL; du1777; 1-(N2-Nicotinoyl-L-lysyl-gamma-D-glutamyl)octahydro-1H-indole-2-carboxylic acid; 5-(2-Carboxyoctahydro-1H-indol-1-yl)-5-oxo-N-(N2-(3-pyridinylcarbonyl)-L-lysyl)-D-norvaline (2S-(2alpha,3abeta,7abeta))-; (2S,3aS,7aS)-1-[(2R)-2-[[(2S)-6-amino-2-(pyridine-3-carbonylamino)hexanoyl]amino]-5-hydroxy-5-oxopentanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; D-Norvaline, 5-(2-carboxyoctahydro-1H-indol-1-yl)-5-oxo-N-(N2-(3-pyridinylcarbonyl)-L-lysyl)-, (2S-(2alpha,3abeta,7abeta))-
DM87ZWP	CP	Dainippon Pharmaceutical Co Ltd
DM87ZWP	DT	Small molecular drug
DM87ZWP	PC	3081108
DM87ZWP	MW	531.6
DM87ZWP	FM	C26H37N5O7
DM87ZWP	IC	InChI=1S/C26H37N5O7/c27-12-4-3-8-18(29-23(34)17-7-5-13-28-15-17)24(35)30-19(10-11-22(32)33)25(36)31-20-9-2-1-6-16(20)14-21(31)26(37)38/h5,7,13,15-16,18-21H,1-4,6,8-12,14,27H2,(H,29,34)(H,30,35)(H,32,33)(H,37,38)/t16-,18-,19+,20-,21-/m0/s1
DM87ZWP	CS	C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)C3=CN=CC=C3)C(=O)O
DM87ZWP	IK	NDXIQTFRXMWLEQ-RQUKQETFSA-N
DM87ZWP	IU	(2S,3aS,7aS)-1-[(2R)-2-[[(2S)-6-amino-2-(pyridine-3-carbonylamino)hexanoyl]amino]-4-carboxybutanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
DM87ZWP	CA	CAS 116662-73-8
DM87ZWP	DE	Hypertension

DMZOCHT	ID	DMZOCHT
DMZOCHT	DN	DuP 714
DMZOCHT	HS	Terminated
DMZOCHT	SN	acetylphenylalanyl-prolyl-boroarginine; Dup-714; Dup 714; Ac-Phe-pro-boroarg-OH; AC-(D)PHE-PRO-BOROARG-OH; CHEMBL290376; 130982-43-3; L-Prolinamide, N-acetyl-D-phenylalanyl-N-(4-((aminoiminomethyl)amino)-1-boronobutyl)-, (S)-; [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-(diaminomethylideneamino)butyl]boronic acid; dup714; AC1L3UBV; SCHEMBL4454615; GTPL8760; CHEBI:42142; DTXSID70156826; BDBM50288406; BDBM50451005; LS-186929; LS-187579
DMZOCHT	DT	Small molecular drug
DMZOCHT	PC	122296
DMZOCHT	MW	460.3
DMZOCHT	FM	C21H33BN6O5
DMZOCHT	IC	InChI=1S/C21H33BN6O5/c1-14(29)26-16(13-15-7-3-2-4-8-15)20(31)28-12-6-9-17(28)19(30)27-18(22(32)33)10-5-11-25-21(23)24/h2-4,7-8,16-18,32-33H,5-6,9-13H2,1H3,(H,26,29)(H,27,30)(H4,23,24,25)/t16-,17+,18+/m1/s1
DMZOCHT	CS	B([C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DMZOCHT	IK	FXFYPTZERULUBS-SQNIBIBYSA-N
DMZOCHT	IU	[(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-(diaminomethylideneamino)butyl]boronic acid
DMZOCHT	CA	CAS 130982-43-3
DMZOCHT	CB	CHEBI:42142
DMZOCHT	DE	Thrombosis

DMJGCYO	ID	DMJGCYO
DMJGCYO	DN	DuP-129
DMJGCYO	HS	Terminated
DMJGCYO	SN	ACAT inhibitors, Du Pont
DMJGCYO	CP	Bristol-Myers Squibb Pharma Co
DMJGCYO	DE	Hypercholesterolaemia

DM7YORJ	ID	DM7YORJ
DM7YORJ	DN	DuP-630
DM7YORJ	HS	Terminated
DM7YORJ	CP	Bristol-Myers Squibb Pharma Co
DM7YORJ	DE	Dermatitis

DM872CU	ID	DM872CU
DM872CU	DN	DuP-983
DM872CU	HS	Terminated
DM872CU	CP	Bristol-Myers Squibb Pharma Co
DM872CU	DE	Pruritus

DMKNJM7	ID	DMKNJM7
DMKNJM7	DN	DV-7028
DMKNJM7	HS	Terminated
DMKNJM7	SN	133364-63-3; DV 7028; AC1O5RHW; SCHEMBL9378376; 3-(2-(4-(4-Fluorobenzoyl)piperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-2H-pyrido(1,2-a)-1,3,5-triazine-2,4(3H)dione maleate; 2H-Pyrido(1,2-a)-1,3,5-triazine-2,4(3H)-dione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-,(Z)-2-butenedioate (1:1)
DMKNJM7	DT	Small molecular drug
DMKNJM7	PC	6439352
DMKNJM7	MW	516.5
DMKNJM7	FM	C25H29FN4O7
DMKNJM7	IC	InChI=1S/C21H25FN4O3.C4H4O4/c22-17-6-4-15(5-7-17)19(27)16-8-11-24(12-9-16)13-14-26-20(28)23-18-3-1-2-10-25(18)21(26)29;5-3(6)1-2-4(7)8/h4-7,16H,1-3,8-14H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMKNJM7	CS	C1CCN2C(=NC(=O)N(C2=O)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F)C1.C(=C\\C(=O)O)\\C(=O)O
DMKNJM7	IK	GVSYIVYQDRVBAL-BTJKTKAUSA-N
DMKNJM7	IU	(Z)-but-2-enedioic acid;3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-6,7,8,9-tetrahydropyrido[1,2-a][1,3,5]triazine-2,4-dione
DMKNJM7	CA	CAS 133364-63-3
DMKNJM7	DE	Cardiovascular disease

DM3L0T1	ID	DM3L0T1
DM3L0T1	DN	DW-1350
DM3L0T1	HS	Terminated
DM3L0T1	SN	DW-1352; Osteoblast modulator (oral, osteoporosis), Dong Wha/ Teijin/ Procter & Gamble
DM3L0T1	CP	Dong Wha Pharmaceutical Co Ltd
DM3L0T1	DT	Small molecular drug
DM3L0T1	PC	10139005
DM3L0T1	MW	453.6
DM3L0T1	FM	C25H31N3O3S
DM3L0T1	IC	InChI=1S/C25H31N3O3S/c1-17(2)24-23(27-18(3)32-24)19-7-11-21(12-8-19)30-15-5-4-6-16-31-22-13-9-20(10-14-22)25(26)28-29/h7-14,17,29H,4-6,15-16H2,1-3H3,(H2,26,28)
DM3L0T1	CS	CC1=NC(=C(S1)C(C)C)C2=CC=C(C=C2)OCCCCCOC3=CC=C(C=C3)/C(=N/O)/N
DM3L0T1	IK	JDXVNCOKDAGOAM-UHFFFAOYSA-N
DM3L0T1	IU	N'-hydroxy-4-[5-[4-(2-methyl-5-propan-2-yl-1,3-thiazol-4-yl)phenoxy]pentoxy]benzenecarboximidamide
DM3L0T1	CA	CAS 491577-61-8
DM3L0T1	DE	Osteoporosis

DM2PVMZ	ID	DM2PVMZ
DM2PVMZ	DN	E-0722
DM2PVMZ	HS	Terminated
DM2PVMZ	SN	Methosorbinil; E-79175; M-79175
DM2PVMZ	CP	Eisai Co Ltd
DM2PVMZ	DT	Small molecular drug
DM2PVMZ	PC	175915
DM2PVMZ	MW	250.23
DM2PVMZ	FM	C12H11FN2O3
DM2PVMZ	IC	InChI=1S/C12H11FN2O3/c1-6-5-12(10(16)14-11(17)15-12)8-4-7(13)2-3-9(8)18-6/h2-4,6H,5H2,1H3,(H2,14,15,16,17)/t6-,12+/m1/s1
DM2PVMZ	CS	C[C@@H]1C[C@]2(C3=C(O1)C=CC(=C3)F)C(=O)NC(=O)N2
DM2PVMZ	IK	SEAQTHCVAGBRFY-INWYIAFRSA-N
DM2PVMZ	IU	(2R,4S)-6-fluoro-2-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione
DM2PVMZ	CA	CAS 102916-95-0
DM2PVMZ	DE	Diabetic cataract

DMD4GQ8	ID	DMD4GQ8
DMD4GQ8	DN	E-2011
DMD4GQ8	HS	Terminated
DMD4GQ8	CP	Eisai Co Ltd
DMD4GQ8	DE	Anxiety disorder

DMZWU8V	ID	DMZWU8V
DMZWU8V	DN	E-2040
DMZWU8V	HS	Terminated
DMZWU8V	CP	Eisai Co Ltd
DMZWU8V	PC	74889592
DMZWU8V	MW	290.17
DMZWU8V	FM	C15H23BN2O3
DMZWU8V	IC	InChI=1S/C15H23BN2O3/c1-6-19-12-9-13(17)18-10-11(12)7-8-16-20-14(2,3)15(4,5)21-16/h7-10H,6H2,1-5H3,(H2,17,18)/b8-7+
DMZWU8V	CS	B1(OC(C(O1)(C)C)(C)C)/C=C/C2=CN=C(C=C2OCC)N
DMZWU8V	IK	LHNZICNYYCFWCS-BQYQJAHWSA-N
DMZWU8V	IU	4-ethoxy-5-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridin-2-amine
DMZWU8V	DE	Schizophrenia

DMQKEHA	ID	DMQKEHA
DMQKEHA	DN	E-2050
DMQKEHA	HS	Terminated
DMQKEHA	CP	Eisai
DMQKEHA	TC	Analgesics
DMQKEHA	DE	Cerebrovascular ischaemia

DMAU0FP	ID	DMAU0FP
DMAU0FP	DN	E-2070
DMAU0FP	HS	Terminated
DMAU0FP	SN	Bayer E-2070; 64050-66-4; ENT 22,742; Phosphoric acid, 2-chloroethyl 2,2-dichlorovinyl propyl ester; AC1Q3VAX; AC1L3IYS; 2-chloroethyl 2,2-dichlorovinyl propyl phosphate; 2-chloroethyl 2,2-dichloroethenyl propyl phosphate; CTK5C0574; ENT-22742; LS-107547; Phosphoric acid,2-chloroethyl 2,2-dichloroethenyl propyl ester
DMAU0FP	CP	Eisai Inc.
DMAU0FP	TC	Analgesics
DMAU0FP	DT	Small molecular drug
DMAU0FP	PC	74788985
DMAU0FP	MW	291.11
DMAU0FP	FM	C14H18BNO5
DMAU0FP	IC	InChI=1S/C14H18BNO5/c1-13(2)14(3,4)21-15(20-13)8-7-9-11(17)6-5-10(16-9)12(18)19/h5-8,17H,1-4H3,(H,18,19)/b8-7+
DMAU0FP	CS	B1(OC(C(O1)(C)C)(C)C)/C=C/C2=C(C=CC(=N2)C(=O)O)O
DMAU0FP	IK	WTOZVQHWGKJNCT-BQYQJAHWSA-N
DMAU0FP	IU	5-hydroxy-6-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridine-2-carboxylic acid
DMAU0FP	DE	Neuropathic pain

DMZ1JKX	ID	DMZ1JKX
DMZ1JKX	DN	E-4080
DMZ1JKX	HS	Terminated
DMZ1JKX	SN	E 4080; AC1O5RBK; E4080; 127404-34-6; E-N-(3-((N'-(2-(3,5-Dimethoxyphenyl)ethyl)-N'-methyl)amino)propyl)-4-(4-(1H-imidazol-1-yl)phenyl)-3-butenamide dihydrochloride dihydrate; e-40-80; 3-Butenamide, N-(3-((2-(3,5-dimethoxyphenyl)ethyl)methylamino)propyl)-4-(4-(1H-imidazol-1-yl)phenyl)-, dihydrochloride, (E)-; (E)-N-[3-[2-(3,5-dimethoxyphenyl)ethyl-methylamino]propyl]-4-(4-imidazol-1-ylphenyl)but-3-enamide dihydrochloride
DMZ1JKX	CP	Eisai Co Ltd
DMZ1JKX	DT	Small molecular drug
DMZ1JKX	PC	6439262
DMZ1JKX	MW	535.5
DMZ1JKX	FM	C27H36Cl2N4O3
DMZ1JKX	IC	InChI=1S/C27H34N4O3.2ClH/c1-30(16-12-23-18-25(33-2)20-26(19-23)34-3)15-5-13-29-27(32)7-4-6-22-8-10-24(11-9-22)31-17-14-28-21-31;;/h4,6,8-11,14,17-21H,5,7,12-13,15-16H2,1-3H3,(H,29,32);2*1H/b6-4+;;
DMZ1JKX	CS	CN(CCCNC(=O)C/C=C/C1=CC=C(C=C1)N2C=CN=C2)CCC3=CC(=CC(=C3)OC)OC.Cl.Cl
DMZ1JKX	IK	KKUNFGOKUGASRQ-SLNOCBGISA-N
DMZ1JKX	IU	(E)-N-[3-[2-(3,5-dimethoxyphenyl)ethyl-methylamino]propyl]-4-(4-imidazol-1-ylphenyl)but-3-enamide;dihydrochloride
DMZ1JKX	CA	CAS 127404-34-6
DMZ1JKX	DE	Angina pectoris

DMR861Q	ID	DMR861Q
DMR861Q	DN	E-5110
DMR861Q	HS	Terminated
DMR861Q	SN	CHEMBL12594; E 5110; E-5110; N-Methoxy-3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-pyrrolidone; 3-((3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-1-methoxy-2-pyrrolidinone; 2-Pyrrolidinone, 3-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-1-methoxy-; 107746-52-1; AC1O5P5J; SCHEMBL5323330; BDBM50008954; LS-138638; 3-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-1-methoxy-pyrrolidin-2-one; N-methoxy-3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-one
DMR861Q	CP	Eisai Co Ltd
DMR861Q	DT	Small molecular drug
DMR861Q	PC	6438164
DMR861Q	MW	331.4
DMR861Q	FM	C20H29NO3
DMR861Q	IC	InChI=1S/C20H29NO3/c1-19(2,3)15-11-13(12-16(17(15)22)20(4,5)6)10-14-8-9-21(24-7)18(14)23/h10-12,22H,8-9H2,1-7H3/b14-10+
DMR861Q	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C/2\\CCN(C2=O)OC
DMR861Q	IK	NJTQENWDJVHUOX-GXDHUFHOSA-N
DMR861Q	IU	(3E)-3-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1-methoxypyrrolidin-2-one
DMR861Q	CA	CAS 107746-52-1
DMR861Q	DE	Inflammation

DMV0QI1	ID	DMV0QI1
DMV0QI1	DN	E-5842
DMV0QI1	HS	Terminated
DMV0QI1	SN	E 5842; E5842; 4-(4-fluorophenil)-1,2,3,4-tetrahydro-1-(4-(1,2,4-triazol-1-il)butyl)pyridine citrate; 4-(4-fluorophenyl)-1-[4-(1,2,4-triazol-1-yl)butyl]-3,6-dihydro-2H-pyridine
DMV0QI1	CP	Esteve
DMV0QI1	DT	Small molecular drug
DMV0QI1	PC	6918385
DMV0QI1	MW	492.5
DMV0QI1	FM	C23H29FN4O7
DMV0QI1	IC	InChI=1S/C17H21FN4.C6H8O7/c18-17-5-3-15(4-6-17)16-7-11-21(12-8-16)9-1-2-10-22-14-19-13-20-22;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-7,13-14H,1-2,8-12H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMV0QI1	CS	C1CN(CC=C1C2=CC=C(C=C2)F)CCCCN3C=NC=N3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMV0QI1	IK	LTBKOSQVBVYJKW-UHFFFAOYSA-N
DMV0QI1	IU	4-(4-fluorophenyl)-1-[4-(1,2,4-triazol-1-yl)butyl]-3,6-dihydro-2H-pyridine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMV0QI1	CA	CAS 220120-14-9
DMV0QI1	DE	Schizophrenia

DMTEY8W	ID	DMTEY8W
DMTEY8W	DN	E-6276
DMTEY8W	HS	Terminated
DMTEY8W	SN	1-(2-Benzhydrylideneaminooxy-ethyl)-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid; UNII-BGU9MZ2G30; BGU9MZ2G30; CHEMBL473104; 159094-94-7; Tocris-1779; Lopac-N-142; Biomol-NT_000271; AC1L1IC7; Lopac0_000880; SCHEMBL5969062; GTPL4669; BPBio1_000948; CTK0H8642; CHEBI:92744; DTXSID30166582; ZINC1534967; BDBM50426075; BDBM50080344; AKOS030543350; CCG-204962; 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-; NCGC00015712-05; NCGC00015712-02; NCGC00025293-03; NCGC00025293-02; NCGC00015712-04; NCGC00025293-01; NCGC00015712-03; NCGC00015712-01; LS-187291
DMTEY8W	CP	Esteve
DMTEY8W	DT	Small molecular drug
DMTEY8W	PC	4515
DMTEY8W	MW	350.4
DMTEY8W	FM	C21H22N2O3
DMTEY8W	IC	InChI=1S/C21H22N2O3/c24-21(25)19-12-7-13-23(16-19)14-15-26-22-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-6,8-12H,7,13-16H2,(H,24,25)
DMTEY8W	CS	C1CN(CC(=C1)C(=O)O)CCON=C(C2=CC=CC=C2)C3=CC=CC=C3
DMTEY8W	IK	NGNALWDRPKNJGR-UHFFFAOYSA-N
DMTEY8W	IU	1-[2-(benzhydrylideneamino)oxyethyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid
DMTEY8W	CA	CAS 159094-94-7
DMTEY8W	CB	CHEBI:92744
DMTEY8W	DE	Schizophrenia

DM5ITJF	ID	DM5ITJF
DM5ITJF	DN	EC-154
DM5ITJF	HS	Terminated
DM5ITJF	SN	Heat shock protein 90 inhibitors (cancer), Biogen Idec; Hsp 90inhibitors (cancer), Biogen Idec
DM5ITJF	CP	Biogen Idec Inc
DM5ITJF	DE	Solid tumour/cancer

DMUR1FK	ID	DMUR1FK
DMUR1FK	DN	Ecalcidene
DMUR1FK	HS	Terminated
DMUR1FK	SN	Vitamin D3 derivative, Barrier
DMUR1FK	CP	Research Institute for Medicine & Chemistry Inc
DMUR1FK	DT	Small molecular drug
DMUR1FK	PC	9955662
DMUR1FK	MW	455.7
DMUR1FK	FM	C29H45NO3
DMUR1FK	IC	InChI=1S/C29H45NO3/c1-20(9-14-28(33)30-16-5-4-6-17-30)25-12-13-26-22(8-7-15-29(25,26)3)10-11-23-18-24(31)19-27(32)21(23)2/h10-11,20,24-27,31-32H,2,4-9,12-19H2,1,3H3/b22-10+,23-11-/t20-,24+,25+,26-,27-,29+/m0/s1
DMUR1FK	CS	C[C@@H](CCC(=O)N1CCCCC1)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DMUR1FK	IK	DXWZPQRKPXFQGC-QCUPEZPBSA-N
DMUR1FK	IU	(4S)-4-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-1-piperidin-1-ylpentan-1-one
DMUR1FK	CA	CAS 150337-94-3
DMUR1FK	CB	CHEBI:137136
DMUR1FK	DE	Acne vulgaris

DMJN7MY	ID	DMJN7MY
DMJN7MY	DN	ED-110
DMJN7MY	HS	Terminated
DMJN7MY	CP	MSD Japan
DMJN7MY	DT	Small molecular drug
DMJN7MY	PC	135705573
DMJN7MY	MW	519.5
DMJN7MY	FM	C26H21N3O9
DMJN7MY	IC	InChI=1S/C26H21N3O9/c30-6-15-22(34)23(35)24(36)25(38-15)9-3-8-12(4-13(9)32)28-21-17(8)18-11(5-27-26(18)37)16-10-1-7(31)2-14(33)19(10)29-20(16)21/h1,4-5,9,15,22-25,30-32,34-36H,2-3,6H2/t9?,15-,22-,23+,24-,25+/m1/s1
DMJN7MY	CS	C1C(C(=CC2=C1C3=C4C(=C5C6=C(C(=O)CC(=C6)O)N=C5C3=N2)C=NC4=O)O)[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O
DMJN7MY	IK	GEFUXTHVYBRRRD-FKKAOLSPSA-N
DMJN7MY	IU	7,20-dihydroxy-19-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1(23),2,4(9),7,10,12,15,17(22),20-nonaene-5,14-dione
DMJN7MY	CA	CAS 139112-73-5
DMJN7MY	DE	Solid tumour/cancer

DMIC460	ID	DMIC460
DMIC460	DN	Edaglitazone
DMIC460	HS	Terminated
DMIC460	SN	Edaglitazone sodium; BM-131258; BM-152054; R-483; Ro-205; BM-13.258; BM-15.2054; Ro-205-2349; Ro-2052349-602
DMIC460	CP	Roche Holding AG
DMIC460	PC	9825701
DMIC460	MW	464.6
DMIC460	FM	C24H20N2O4S2
DMIC460	IC	InChI=1S/C24H20N2O4S2/c1-14-18(25-23(30-14)15-5-3-2-4-6-15)9-11-29-19-8-7-16(21-17(19)10-12-31-21)13-20-22(27)26-24(28)32-20/h2-8,10,12,20H,9,11,13H2,1H3,(H,26,27,28)
DMIC460	CS	CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC5C(=O)NC(=O)S5
DMIC460	IK	HAAXAFNSRADSMK-UHFFFAOYSA-N
DMIC460	IU	5-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]methyl]-1,3-thiazolidine-2,4-dione
DMIC460	CA	CAS 213411-83-7
DMIC460	DE	Type-2 diabetes

DM7ROS1	ID	DM7ROS1
DM7ROS1	DN	Efegatran
DM7ROS1	HS	Terminated
DM7ROS1	SN	efegatran; Efegatran [INN]; UNII-VT0VK2474K; CHEMBL273196; VT0VK2474K; 105806-65-3; L-Prolinamide, N-methyl-D-phenylalanyl-N-(4-((aminoiminomethyl)amino)-1-formylbutyl)-, (S)-; Me-Phe-Pro-Arg-H; AC1L3UA7; Me-(D-Phe)-Pro-Arg-CHO; SCHEMBL635674; SCHEMBL635675; 126721-07-1 (sulfate); (S)-1-((R)-2-Methylamino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid ((S)-1-formyl-4-guanidino-butyl)-amide; D-methyl-phenylalanyl-prolyl-arginal; BDBM50228863; LS-171983
DM7ROS1	DT	Small molecular drug
DM7ROS1	PC	122267
DM7ROS1	MW	416.5
DM7ROS1	FM	C21H32N6O3
DM7ROS1	IC	InChI=1S/C21H32N6O3/c1-24-17(13-15-7-3-2-4-8-15)20(30)27-12-6-10-18(27)19(29)26-16(14-28)9-5-11-25-21(22)23/h2-4,7-8,14,16-18,24H,5-6,9-13H2,1H3,(H,26,29)(H4,22,23,25)/t16-,17+,18-/m0/s1
DM7ROS1	CS	CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O
DM7ROS1	IK	KAGLWQUWUNBAOO-KSZLIROESA-N
DM7ROS1	IU	(2S)-N-[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DM7ROS1	CA	CAS 105806-65-3

DMJ0A5U	ID	DMJ0A5U
DMJ0A5U	DN	EFIPLADIB
DMJ0A5U	HS	Terminated
DMJ0A5U	SN	Efipladib; 381683-94-9; UNII-S97YUG2A91; S97YUG2A91; CHEMBL272342; PLA-902; Efipladib [USAN:INN]; Efipladib (USAN); 4-(3-(1-benzhydryl-5-chloro-2-(2-((3,4-dichlorophenyl)methylsulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic acid; SCHEMBL1500831; HIZOPJQOPKRKFM-UHFFFAOYSA-N; ZINC85536943; BDBM50226792; D06674; 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid
DMJ0A5U	DT	Small molecular drug
DMJ0A5U	PC	9853499
DMJ0A5U	MW	746.1
DMJ0A5U	FM	C40H35Cl3N2O4S
DMJ0A5U	IC	InChI=1S/C40H35Cl3N2O4S/c41-32-19-21-37-34(25-32)33(13-7-8-27-14-17-31(18-15-27)40(46)47)38(22-23-44-50(48,49)26-28-16-20-35(42)36(43)24-28)45(37)39(29-9-3-1-4-10-29)30-11-5-2-6-12-30/h1-6,9-12,14-21,24-25,39,44H,7-8,13,22-23,26H2,(H,46,47)
DMJ0A5U	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)N3C4=C(C=C(C=C4)Cl)C(=C3CCNS(=O)(=O)CC5=CC(=C(C=C5)Cl)Cl)CCCC6=CC=C(C=C6)C(=O)O
DMJ0A5U	IK	HIZOPJQOPKRKFM-UHFFFAOYSA-N
DMJ0A5U	IU	4-[3-[1-benzhydryl-5-chloro-2-[2-[(3,4-dichlorophenyl)methylsulfonylamino]ethyl]indol-3-yl]propyl]benzoic acid
DMJ0A5U	CA	CAS 381683-94-9
DMJ0A5U	DE	Asthma

DMYAMP5	ID	DMYAMP5
DMYAMP5	DN	EHT-1864
DMYAMP5	HS	Terminated
DMYAMP5	SN	EHT-0101; EHT-0206; EHT-101; EHT-206; Rac1 inhibitor (Alzheimer's disease/cancer),Exonhit
DMYAMP5	CP	Exonhit
DMYAMP5	DT	Small molecular drug
DMYAMP5	PC	9938202
DMYAMP5	MW	581.5
DMYAMP5	FM	C25H29Cl2F3N2O4S
DMYAMP5	IC	InChI=1S/C25H27F3N2O4S.2ClH/c26-25(27,28)18-4-5-20-21(14-18)29-7-6-24(20)35-13-3-1-2-10-33-23-17-34-19(15-22(23)31)16-30-8-11-32-12-9-30;;/h4-7,14-15,17H,1-3,8-13,16H2;2*1H
DMYAMP5	CS	C1COCCN1CC2=CC(=O)C(=CO2)OCCCCCSC3=C4C=CC(=CC4=NC=C3)C(F)(F)F.Cl.Cl
DMYAMP5	IK	LSECOAJFCKFQJG-UHFFFAOYSA-N
DMYAMP5	IU	2-(morpholin-4-ylmethyl)-5-[5-[7-(trifluoromethyl)quinolin-4-yl]sulfanylpentoxy]pyran-4-one;dihydrochloride
DMYAMP5	CA	CAS 754240-09-0
DMYAMP5	DE	Alzheimer disease

DMIP8NB	ID	DMIP8NB
DMIP8NB	DN	EK-399
DMIP8NB	HS	Terminated
DMIP8NB	SN	ek-399; AC1L2RJX; AC1Q5SZK; Ekk-399; (2r)-n-(2-{[(2s)-1-(2-acetylhydrazinyl)-1-oxo-3-phenylpropan-2-yl](ethyl)amino}-2-oxoethyl)-2-{[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino}-4-(methylsulfinyl)butanamide acetate(1:1)(non-preferred name); Tyr-met(O)-gly-etphe-nhnhcoch3; 98849-86-6; Tyrosyl-methionyl(O)-glycyl-ethylphenylalanine-2-acetylhydrazide; L-Phenylalanine, L-tyrosyl-4-(methylsulfinyl)-D-2-aminobutanoylglycyl-N-ethyl-, 2-acetylhydrazide, monoacetate (salt)
DMIP8NB	CP	Takeda Pharmaceutical Co Ltd
DMIP8NB	DT	Small molecular drug
DMIP8NB	PC	127164
DMIP8NB	MW	676.8
DMIP8NB	FM	C31H44N6O9S
DMIP8NB	IC	InChI=1S/C29H40N6O7S.C2H4O2/c1-4-35(25(29(41)34-33-19(2)36)17-20-8-6-5-7-9-20)26(38)18-31-28(40)24(14-15-43(3)42)32-27(39)23(30)16-21-10-12-22(37)13-11-21;1-2(3)4/h5-13,23-25,37H,4,14-18,30H2,1-3H3,(H,31,40)(H,32,39)(H,33,36)(H,34,41);1H3,(H,3,4)/t23-,24+,25-,43?;/m0./s1
DMIP8NB	CS	CCN([C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)C)C(=O)CNC(=O)[C@@H](CCS(=O)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N.CC(=O)O
DMIP8NB	IK	NOOIAQHTLKMMAW-VQCKKKRLSA-N
DMIP8NB	IU	acetic acid;(2R)-N-[2-[[(2S)-1-(2-acetylhydrazinyl)-1-oxo-3-phenylpropan-2-yl]-ethylamino]-2-oxoethyl]-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfinylbutanamide
DMIP8NB	CA	CAS 98849-86-6
DMIP8NB	DE	Inflammation

DMG9R8E	ID	DMG9R8E
DMG9R8E	DN	EM-2487
DMG9R8E	HS	Terminated
DMG9R8E	SN	EM2487; AC1L9SS4; N-(2-amino-2-oxoethyl)-[2-[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]oxy-N-[hydroxy-[methyl(12-methyltridecyl)amino]oxyphosphoryl]phosphonamidic acid; N-(2-amino-2-oxo-ethyl)-[2-[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy]-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]oxy-N-[hydroxy-[methyl(12-methyltridecyl)amino]oxy-phosphoryl]phosphonamidic acid
DMG9R8E	CP	Eisai Co Ltd
DMG9R8E	DT	Small molecular drug
DMG9R8E	PC	10440507
DMG9R8E	MW	829.8
DMG9R8E	FM	C32H57N5O16P2
DMG9R8E	IC	InChI=1S/C32H57N5O16P2/c1-20(2)13-11-9-7-5-4-6-8-10-12-15-35(3)53-55(48,49)37(17-23(33)39)54(46,47)52-30-27(43)25(41)21(18-38)29(30)50-19-22-26(42)28(44)31(51-22)36-16-14-24(40)34-32(36)45/h14,16,20,22,25-28,30-31,38,41-44H,4-13,15,17-19H2,1-3H3,(H2,33,39)(H,46,47)(H,48,49)(H,34,40,45)
DMG9R8E	CS	CC(C)CCCCCCCCCCCN(C)OP(=O)(N(CC(=O)N)P(=O)(O)OC1C(C(C(=C1OCC2C(C(C(O2)N3C=CC(=O)NC3=O)O)O)CO)O)O)O
DMG9R8E	IK	MTKDUTOCKQTOED-UHFFFAOYSA-N
DMG9R8E	IU	N-(2-amino-2-oxoethyl)-[2-[[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]oxy-N-[hydroxy-[methyl(12-methyltridecyl)amino]oxyphosphoryl]phosphonamidic acid
DMG9R8E	DE	Human immunodeficiency virus infection

DMFZO4Y	ID	DMFZO4Y
DMFZO4Y	DN	EMBELIN
DMFZO4Y	HS	Terminated
DMFZO4Y	SN	EMBELIN; 550-24-3; Embelic acid; Emberine; 2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione; 2,5-Dihydroxy-3-undecyl-1,4-benzoquinone; 2,5-Dihydroxy-3-undecyl-p-benzoquinone; 2,5-Dihydroxy-3-undecyl-2,5-cyclohexadiene-1,4-dione; UNII-SHC6U8F5ER; CHEBI:4778; Embelin, Embelia ribes; C17H26O4; NSC91874; XIAP inhibitor, Embelin; EINECS 208-979-8; NSC 91874; SHC6U8F5ER; BRN 1885786; Apoptosis Activator III, Embelin; AK115155; p-Benzoquinone, 2,5-dihydroxy-3-undecyl-; SR-01000597536; Spectrum_001513; Tocris-2156; SpecPlus_000501
DMFZO4Y	DT	Small molecular drug
DMFZO4Y	PC	3218
DMFZO4Y	MW	294.4
DMFZO4Y	FM	C17H26O4
DMFZO4Y	IC	InChI=1S/C17H26O4/c1-2-3-4-5-6-7-8-9-10-11-13-16(20)14(18)12-15(19)17(13)21/h12,18,21H,2-11H2,1H3
DMFZO4Y	CS	CCCCCCCCCCCC1=C(C(=O)C=C(C1=O)O)O
DMFZO4Y	IK	IRSFLDGTOHBADP-UHFFFAOYSA-N
DMFZO4Y	IU	2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione
DMFZO4Y	CA	CAS 550-24-3
DMFZO4Y	CB	CHEBI:4778

DMAEDQG	ID	DMAEDQG
DMAEDQG	DN	EMODIN
DMAEDQG	HS	Terminated
DMAEDQG	SN	emodin; 518-82-1; Emodol; Schuttgelb; Frangula emodin; Rheum emodin; Frangulic acid; 3-Methyl-1,6,8-trihydroxyanthraquinone; Archin; 1,3,8-trihydroxy-6-methylanthracene-9,10-dione; Persian Berry Lake; 1,3,8-Trihydroxy-6-methyl-9,10-anthraquinone; 6-Methyl-1,3,8-trihydroxyanthraquinone; C.I. Natural Yellow 14; 9,10-Anthracenedione, 1,3,8-trihydroxy-6-methyl-; 1,3,8-Trihydroxy-6-methylanthraquinone; 1,3,8-Trihydroxy-6-methyl-9,10-anthracenedione; 4,5,7-Trihydroxy-2-methylanthraquinone; UNII-KA46RNI6HN; C.I. 75440; NSC 622947
DMAEDQG	DT	Small molecular drug
DMAEDQG	PC	3220
DMAEDQG	MW	270.24
DMAEDQG	FM	C15H10O5
DMAEDQG	IC	InChI=1S/C15H10O5/c1-6-2-8-12(10(17)3-6)15(20)13-9(14(8)19)4-7(16)5-11(13)18/h2-5,16-18H,1H3
DMAEDQG	CS	CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O
DMAEDQG	IK	RHMXXJGYXNZAPX-UHFFFAOYSA-N
DMAEDQG	IU	1,3,8-trihydroxy-6-methylanthracene-9,10-dione
DMAEDQG	CA	CAS 518-82-1
DMAEDQG	CB	CHEBI:42223

DMW210B	ID	DMW210B
DMW210B	DN	Emopamil
DMW210B	HS	Terminated
DMW210B	SN	Levemopamil
DMW210B	CP	Knoll GmbH
DMW210B	DT	Small molecular drug
DMW210B	PC	71225
DMW210B	MW	334.5
DMW210B	FM	C23H30N2
DMW210B	IC	InChI=1S/C23H30N2/c1-20(2)23(19-24,22-13-8-5-9-14-22)16-10-17-25(3)18-15-21-11-6-4-7-12-21/h4-9,11-14,20H,10,15-18H2,1-3H3
DMW210B	CS	CC(C)C(CCCN(C)CCC1=CC=CC=C1)(C#N)C2=CC=CC=C2
DMW210B	IK	DWAWDSVKAUWFHC-UHFFFAOYSA-N
DMW210B	IU	5-[methyl(2-phenylethyl)amino]-2-phenyl-2-propan-2-ylpentanenitrile
DMW210B	CA	CAS 78370-13-5
DMW210B	CB	CHEBI:34736
DMW210B	DE	Cerebrovascular ischaemia

DMJU39N	ID	DMJU39N
DMJU39N	DN	Endovion
DMJU39N	HS	Terminated
DMJU39N	SN	Angiogenesis inhibitor, NeuroSearch; Chloride channel antagonist, NeuroSearch; NS-1652; NS-3728
DMJU39N	CP	NeuroSearch A/S
DMJU39N	DT	Small molecular drug
DMJU39N	PC	10005966
DMJU39N	MW	495.18
DMJU39N	FM	C16H9BrF6N6O
DMJU39N	IC	InChI=1S/C16H9BrF6N6O/c17-9-1-2-12(11(6-9)13-26-28-29-27-13)25-14(30)24-10-4-7(15(18,19)20)3-8(5-10)16(21,22)23/h1-6H,(H2,24,25,30)(H,26,27,28,29)
DMJU39N	CS	C1=CC(=C(C=C1Br)C2=NNN=N2)NC(=O)NC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMJU39N	IK	AEFYFGMSRKDXHZ-UHFFFAOYSA-N
DMJU39N	IU	1-[3,5-bis(trifluoromethyl)phenyl]-3-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]urea
DMJU39N	CA	CAS 265646-85-3
DMJU39N	DE	Solid tumour/cancer

DMZA5Q4	ID	DMZA5Q4
DMZA5Q4	DN	EP-2060
DMZA5Q4	HS	Terminated
DMZA5Q4	SN	Apoptosis inducers, EpiCept; MX-11697; Anticancer agents, Celera/EpiCept; Apoptosis inducers, Celera/EpiCept; Apoptosis inducers, Celera/Maxim; Anti-cancer agents, Celera/Maxim
DMZA5Q4	CP	Celera South San Francisco
DMZA5Q4	DE	Solid tumour/cancer

DM149HL	ID	DM149HL
DM149HL	DN	EPD-clofarabine
DM149HL	HS	Terminated
DM149HL	SN	Clofarabine (Enhanced Prodrug), Heidelberg Pharma; HDP-15-0001; HDP-15-0022
DM149HL	CP	Heidelberg Pharma Holding GmbH
DM149HL	DE	Solid tumour/cancer

DM6IY4M	ID	DM6IY4M
DM6IY4M	DN	Epiroprim
DM6IY4M	HS	Terminated
DM6IY4M	SN	Epiroprim; Epiroprim [INN]; TCMDC-137295; 73090-70-7; Epiroprimum [INN-Latin]; Epiroprime [INN-French]; Epiroprima [INN-Spanish]; Ro 11-8958; UNII-9G69D95443; BRN 4273487; CHEMBL280378; C19H23N5O2; Ro-11-8958; 9G69D95443; 5-((3,5-Diethoxy-4-(1H-pyrrol-1-yl)phenyl)methyl)-2,4-pyrimidinediamine; Epiroprime; Epiroprimum; Epiroprima; 2,4-Diamino-5-(3,5-diethoxy-4-pyrrol-1-ylbenzyl)pyrimidine; 2,4-Pyrimidinediamine, 5-((3,5-diethoxy-4-(1H-pyrrol-1-yl)phenyl)methyl)-; Epir; AC1L2APS; SCHEMBL75698; AC1Q563X; DTXSID20223355; ZINC598590
DM6IY4M	DT	Small molecular drug
DM6IY4M	PC	68916
DM6IY4M	MW	353.4
DM6IY4M	FM	C19H23N5O2
DM6IY4M	IC	InChI=1S/C19H23N5O2/c1-3-25-15-10-13(9-14-12-22-19(21)23-18(14)20)11-16(26-4-2)17(15)24-7-5-6-8-24/h5-8,10-12H,3-4,9H2,1-2H3,(H4,20,21,22,23)
DM6IY4M	CS	CCOC1=CC(=CC(=C1N2C=CC=C2)OCC)CC3=CN=C(N=C3N)N
DM6IY4M	IK	NMARPFMJVCXSAV-UHFFFAOYSA-N
DM6IY4M	IU	5-[(3,5-diethoxy-4-pyrrol-1-ylphenyl)methyl]pyrimidine-2,4-diamine
DM6IY4M	CA	CAS 73090-70-7
DM6IY4M	DE	Bacterial infection

DMWRSXK	ID	DMWRSXK
DMWRSXK	DN	Epocarbazolin-A
DMWRSXK	HS	Terminated
DMWRSXK	SN	Epocarbazolin-B
DMWRSXK	CP	Bristol-Myers Squibb Co
DMWRSXK	DT	Small molecular drug
DMWRSXK	PC	192365
DMWRSXK	MW	369.5
DMWRSXK	FM	C22H27NO4
DMWRSXK	IC	InChI=1S/C22H27NO4/c1-11(2)7-8-22(4)21(27-22)17-12(3)16(26)9-14-18-13(10-24)5-6-15(25)20(18)23-19(14)17/h5-6,9,11,21,23-26H,7-8,10H2,1-4H3
DMWRSXK	CS	CC1=C(C=C2C3=C(C=CC(=C3NC2=C1C4C(O4)(C)CCC(C)C)O)CO)O
DMWRSXK	IK	JFHJFCCMTNIENN-UHFFFAOYSA-N
DMWRSXK	IU	4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylbutyl)oxiran-2-yl]-9H-carbazole-1,6-diol
DMWRSXK	CA	CAS 146935-39-9
DMWRSXK	DE	Asthma

DM2NHLW	ID	DM2NHLW
DM2NHLW	DN	EPTALOPROST
DM2NHLW	HS	Terminated
DM2NHLW	SN	Eptaprost; ZK-97959; Eptaloprost; (5E)-16(S)-13,14-Didehydro-1a,1b-dihomo-16,20-dimethyl-3-oxa-18,18,19,19-tetrahydro-6a-carbaprostaglandin-I2; 4-[2-[(2E,3aS,4S,5R,6aS)-5-Hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiynyl]hexahydro-2(1H)-pentalenylidene]ethoxy]butyric acid
DM2NHLW	DT	Small molecular drug
DM2NHLW	PC	6436047
DM2NHLW	MW	402.5
DM2NHLW	FM	C24H34O5
DM2NHLW	IC	InChI=1S/C24H34O5/c1-3-4-5-7-17(2)22(25)10-9-20-21-15-18(14-19(21)16-23(20)26)11-13-29-12-6-8-24(27)28/h11,17,19-23,25-26H,3,6-8,12-16H2,1-2H3,(H,27,28)/b18-11+/t17-,19-,20+,21-,22+,23+/m0/s1
DM2NHLW	CS	CCC#CC[C@H](C)[C@@H](C#C[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/COCCCC(=O)O)/C2)O)O
DM2NHLW	IK	MAUUNYHAXGTMMQ-AMXXQSRZSA-N
DM2NHLW	IU	4-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]butanoic acid
DM2NHLW	CA	CAS 90693-76-8
DM2NHLW	DE	Solid tumour/cancer

DMAZVUB	ID	DMAZVUB
DMAZVUB	DN	ER-34122
DMAZVUB	HS	Terminated
DMAZVUB	SN	ER-34122; UNII-72Y1B3J8FS; 72Y1B3J8FS; ER 34122; 179325-62-3; SCHEMBL8854202; 5-((1,5-bis(4-methoxyphenyl)pyrazol-3-yl)dimethoxymethyl)-2-chlorobenzamide; Benzamide, 5-((1,5-bis(4-methoxyphenyl)-1H-pyrazol-3-yl)dimethoxymethyl)-2-chloro-
DMAZVUB	CP	Eisai Co Ltd
DMAZVUB	DT	Small molecular drug
DMAZVUB	PC	9892473
DMAZVUB	MW	508
DMAZVUB	FM	C27H26ClN3O5
DMAZVUB	IC	InChI=1S/C27H26ClN3O5/c1-33-20-10-5-17(6-11-20)24-16-25(30-31(24)19-8-12-21(34-2)13-9-19)27(35-3,36-4)18-7-14-23(28)22(15-18)26(29)32/h5-16H,1-4H3,(H2,29,32)
DMAZVUB	CS	COC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)OC)C(C4=CC(=C(C=C4)Cl)C(=O)N)(OC)OC
DMAZVUB	IK	USJVSASRKOHVHQ-UHFFFAOYSA-N
DMAZVUB	IU	5-[[1,5-bis(4-methoxyphenyl)pyrazol-3-yl]-dimethoxymethyl]-2-chlorobenzamide
DMAZVUB	CA	CAS 179325-62-3
DMAZVUB	DE	Inflammation

DMYSTAD	ID	DMYSTAD
DMYSTAD	DN	ER-37328
DMYSTAD	HS	Terminated
DMYSTAD	SN	ER-37328; SCHEMBL6623792; CHEMBL604052
DMYSTAD	DT	Small molecular drug
DMYSTAD	PC	21849939
DMYSTAD	MW	411.9
DMYSTAD	FM	C22H22ClN3O3
DMYSTAD	IC	InChI=1S/C22H21N3O3.ClH/c1-24(2)9-8-14-21(27)15-10-23-11-25-16-7-6-12-13(4-3-5-17(12)26)18(16)19(20(15)25)22(14)28;/h3,5,10-11,14H,4,6-9H2,1-2H3;1H
DMYSTAD	CS	CN(C)CCC1C(=O)C2=CN=CN3C2=C(C1=O)C4=C3CCC5=C4CC=CC5=O.Cl
DMYSTAD	IK	WTKWSQVGFMBOGJ-UHFFFAOYSA-N
DMYSTAD	IU	18-[2-(dimethylamino)ethyl]-12,14-diazapentacyclo[10.7.1.02,11.03,8.016,20]icosa-1(20),2(11),3(8),5,13,15-hexaene-7,17,19-trione;hydrochloride

DM08XS2	ID	DM08XS2
DM08XS2	DN	ERIC-1
DM08XS2	HS	Terminated
DM08XS2	SN	UJ13A; NCAM antagonist, Imperial Cancer Research Technology; ERIC-1, ICRT; ERIC-1, Imperial CancerResearch Technology
DM08XS2	CP	Imperial Cancer Research Technology Ltd
DM08XS2	DE	Solid tumour/cancer

DMJXEV7	ID	DMJXEV7
DMJXEV7	DN	ERTIPROTAFIB
DMJXEV7	HS	Terminated
DMJXEV7	SN	Ertiprotafib; UNII-5TPM2EB426; PTP-112; CHEMBL184041; 5TPM2EB426; 251303-04-5; Ertiprotafib [USAN:INN]; ptp112; AC1L4HAB; Ertiprotafib (USAN/INN); SCHEMBL6703442; DTXSID30179814; FONCZICQWCUXEB-RUZDIDTESA-N; BDBM50209683; HY-19383; CS-0015482; D04050; (2R)-2-[4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid; (2R)-2-(4-(9-bromo-2,3-dimethylnaphtho(2,3-b)thiophen-4-yl)-2,6-dimethylphenoxy)-3-phenylpropionic  acid; Benzenepropanoic acid, alpha-(4-(9-bromo-2,3-dimethylnaphtho(2,3-
DMJXEV7	DT	Small molecular drug
DMJXEV7	PC	157049
DMJXEV7	MW	559.5
DMJXEV7	FM	C31H27BrO3S
DMJXEV7	IC	InChI=1S/C31H27BrO3S/c1-17-14-22(15-18(2)29(17)35-25(31(33)34)16-21-10-6-5-7-11-21)27-23-12-8-9-13-24(23)28(32)30-26(27)19(3)20(4)36-30/h5-15,25H,16H2,1-4H3,(H,33,34)/t25-/m1/s1
DMJXEV7	CS	CC1=CC(=CC(=C1O[C@H](CC2=CC=CC=C2)C(=O)O)C)C3=C4C(=C(SC4=C(C5=CC=CC=C53)Br)C)C
DMJXEV7	IK	FONCZICQWCUXEB-RUZDIDTESA-N
DMJXEV7	IU	(2R)-2-[4-(9-bromo-2,3-dimethylbenzo[f][1]benzothiol-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid
DMJXEV7	CA	CAS 251303-04-5
DMJXEV7	DE	Type-2 diabetes

DMRP7BX	ID	DMRP7BX
DMRP7BX	DN	ES-1005
DMRP7BX	HS	Terminated
DMRP7BX	SN	ES 1005; ES-1005; AC1MIZDF; Bis((1-naphthyl)methyl)acetyl-histidyl-statyl-leucyl-episilon-lysinol; 115404-79-0; 1H-Imidazole-4-propanamide, N-(4-((1-(((5-amino-6-hydroxyhexyl)amino)carbonyl)-3-methylbutyl)amino)-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl)-alpha-((3-(1-naphthalenyl)-2-(1-naphthalenylmethyl)-1-oxopropyl)amino)-, dihydrochloride, (1S-(1R*(R*),2R*,4(R*(R*))))-
DMRP7BX	CP	Sankyo Co Ltd
DMRP7BX	DT	Small molecular drug
DMRP7BX	PC	3082723
DMRP7BX	MW	935
DMRP7BX	FM	C50H69Cl2N7O6
DMRP7BX	IC	InChI=1S/C50H67N7O6.2ClH/c1-32(2)23-43(46(59)28-47(60)55-44(24-33(3)4)49(62)53-22-10-9-19-39(51)30-58)56-50(63)45(27-40-29-52-31-54-40)57-48(61)38(25-36-17-11-15-34-13-5-7-20-41(34)36)26-37-18-12-16-35-14-6-8-21-42(35)37;;/h5-8,11-18,20-21,29,31-33,38-39,43-46,58-59H,9-10,19,22-28,30,51H2,1-4H3,(H,52,54)(H,53,62)(H,55,60)(H,56,63)(H,57,61);2*1H/t39-,43?,44-,45?,46-;;/m0../s1
DMRP7BX	CS	CC(C)C[C@@H](C(=O)NCCCC[C@@H](CO)N)NC(=O)C[C@@H](C(CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)C(CC2=CC=CC3=CC=CC=C32)CC4=CC=CC5=CC=CC=C54)O.Cl.Cl
DMRP7BX	IK	IYZRFOAPEUBNQP-JPZLKUPGSA-N
DMRP7BX	IU	(3S)-N-[(2S)-1-[[(5S)-5-amino-6-hydroxyhexyl]amino]-4-methyl-1-oxopentan-2-yl]-3-hydroxy-4-[[3-(1H-imidazol-5-yl)-2-[[3-naphthalen-1-yl-2-(naphthalen-1-ylmethyl)propanoyl]amino]propanoyl]amino]-6-methylheptanamide;dihydrochloride
DMRP7BX	CA	CAS 115404-79-0
DMRP7BX	DE	Hypertension

DM3BHN1	ID	DM3BHN1
DM3BHN1	DN	Etomoxir
DM3BHN1	HS	Terminated
DM3BHN1	SN	ETOMOXIR; 82258-36-4; rac- Etomoxir; Etomoxirum [Latin]; Ethyl 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate; BRN 4496620; Oxiranecarboxylic acid, 2-(6-(4-chlorophenoxy)hexyl)-, ethyl ester; B 807-54; Ethyl 2-(6-(4-chlorophenoxy)hexyl)oxiranecarboxylate; Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester- [CAS]; Etomoxirum; etomoxir[inn]; SMR000449321; Rac-Etomoxir Ethyl Ester; C17H23ClO4; ethyl 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate; etoxomir; AC1L3XCY; MLS001424024; MLS000758228; SCHEMBL681359
DM3BHN1	DT	Small molecular drug
DM3BHN1	PC	9840324
DM3BHN1	MW	326.8
DM3BHN1	FM	C17H23ClO4
DM3BHN1	IC	InChI=1S/C17H23ClO4/c1-2-20-16(19)17(13-22-17)11-5-3-4-6-12-21-15-9-7-14(18)8-10-15/h7-10H,2-6,11-13H2,1H3/t17-/m1/s1
DM3BHN1	CS	CCOC(=O)[C@]1(CO1)CCCCCCOC2=CC=C(C=C2)Cl
DM3BHN1	IK	DZLOHEOHWICNIL-QGZVFWFLSA-N
DM3BHN1	IU	ethyl (2R)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate
DM3BHN1	CA	CAS 124083-20-1
DM3BHN1	CB	CHEBI:95011
DM3BHN1	DE	Heart failure

DMRQOXG	ID	DMRQOXG
DMRQOXG	DN	Etrabamine
DMRQOXG	HS	Terminated
DMRQOXG	SN	14839-JL
DMRQOXG	CP	Chiesi SA
DMRQOXG	DT	Small molecular drug
DMRQOXG	PC	68895
DMRQOXG	MW	168.26
DMRQOXG	FM	C8H12N2S
DMRQOXG	IC	InChI=1S/C8H12N2S/c1-9-6-2-3-7-8(4-6)11-5-10-7/h5-6,9H,2-4H2,1H3
DMRQOXG	CS	CNC1CCC2=C(C1)SC=N2
DMRQOXG	IK	YDSVAKPJAOSZJA-UHFFFAOYSA-N
DMRQOXG	IU	N-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-6-amine
DMRQOXG	CA	CAS 70590-58-8
DMRQOXG	DE	Parkinson disease

DMLA3P1	ID	DMLA3P1
DMLA3P1	DN	EUK-207
DMLA3P1	HS	Terminated
DMLA3P1	CP	Eukarion Inc
DMLA3P1	DT	Small molecular drug
DMLA3P1	PC	135469150
DMLA3P1	MW	414.5
DMLA3P1	FM	C22H26N2O6
DMLA3P1	IC	InChI=1S/C22H26N2O6/c25-21-17-3-1-5-19(21)29-13-11-27-9-10-28-12-14-30-20-6-2-4-18(22(20)26)16-24-8-7-23-15-17/h1-6,15-16,25-26H,7-14H2
DMLA3P1	CS	C1CN=CC2=C(C(=CC=C2)OCCOCCOCCOC3=CC=CC(=C3O)C=N1)O
DMLA3P1	IK	IJRRNMCPHVFFMW-UHFFFAOYSA-N
DMLA3P1	IU	13,16,19,22-tetraoxa-3,6-diazatricyclo[21.3.1.18,12]octacosa-1(27),2,6,8(28),9,11,23,25-octaene-27,28-diol
DMLA3P1	DE	Neurodegenerative disorder

DM9P4ZN	ID	DM9P4ZN
DM9P4ZN	DN	EXP-6803
DM9P4ZN	HS	Terminated
DM9P4ZN	SN	114773-44-3; 1H-Imidazole-5-aceticacid, 2-butyl-1-[[4-[(2-carboxybenzoyl)amino]phenyl]methyl]-4-chloro-, 5-methylester, sodium salt (1:1); Exp 6803; AC1Q1VXO; ACMC-20d225; CTK4A8893; sodium 2-(2-butyl-1-{4-[(2-carboxybenzoyl)amino]benzyl}-4-chloro-1h-imidazol-5-yl)propanoate; Methyl 2-n-butyl-1-(4-(2-carboxybenzamido)benzyl)-4-chloroimidazole-5-acetate; 1H-Imidazole-5-acetic acid, 2-butyl-1-((4-((2-carboxybenzoyl)amino)phenyl)methyl)-4-chloro-, alpha-methyl ester, monosodium salt
DM9P4ZN	CP	Bristol-Myers Squibb Pharma Co
DM9P4ZN	DT	Small molecular drug
DM9P4ZN	PC	23695961
DM9P4ZN	MW	505.9
DM9P4ZN	FM	C25H25ClN3NaO5
DM9P4ZN	IC	InChI=1S/C25H26ClN3O5.Na/c1-3-4-9-20-28-22(26)21(15(2)24(31)32)29(20)14-16-10-12-17(13-11-16)27-23(30)18-7-5-6-8-19(18)25(33)34;/h5-8,10-13,15H,3-4,9,14H2,1-2H3,(H,27,30)(H,31,32)(H,33,34);/q;+1/p-1
DM9P4ZN	CS	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)NC(=O)C3=CC=CC=C3C(=O)O)C(C)C(=O)[O-])Cl.[Na+]
DM9P4ZN	IK	OSDQJFVHDVAJSD-UHFFFAOYSA-M
DM9P4ZN	IU	sodium;2-[2-butyl-3-[[4-[(2-carboxybenzoyl)amino]phenyl]methyl]-5-chloroimidazol-4-yl]propanoate
DM9P4ZN	CA	CAS 114773-44-3
DM9P4ZN	DE	Hypertension

DMR1X2U	ID	DMR1X2U
DMR1X2U	DN	F-0401
DMR1X2U	HS	Terminated
DMR1X2U	SN	F 0401; AC1O5R3Q; SCHEMBL7291536; SCHEMBL7291521; f04-01; ((+-)-(E)-3-(4-(1-Imidazolyl)methylphenyl)-2-propen-1-yl)methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; (E)-3-(4-(1H-Imidazol-1-ylmethyl)phenyl)-2-propenyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; 5-O-[(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-ni
DMR1X2U	DT	Small molecular drug
DMR1X2U	PC	6439160
DMR1X2U	MW	528.6
DMR1X2U	FM	C29H28N4O6
DMR1X2U	IC	InChI=1S/C29H28N4O6/c1-19-25(28(34)38-3)27(23-7-4-8-24(16-23)33(36)37)26(20(2)31-19)29(35)39-15-5-6-21-9-11-22(12-10-21)17-32-14-13-30-18-32/h4-14,16,18,27,31H,15,17H2,1-3H3/b6-5+
DMR1X2U	CS	CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=C(C=C2)CN3C=CN=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMR1X2U	IK	CSBQPRGTYHAYKS-AATRIKPKSA-N
DMR1X2U	IU	5-O-[(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMR1X2U	CA	CAS 123852-99-3

DM3786U	ID	DM3786U
DM3786U	DN	F-12509A
DM3786U	HS	Terminated
DM3786U	CP	Sankyo Co Ltd
DM3786U	PC	9862964
DM3786U	MW	344.4
DM3786U	FM	C21H28O4
DM3786U	IC	InChI=1S/C21H28O4/c1-12-6-7-17-20(2,3)8-5-9-21(17,4)14(12)10-13-18(24)15(22)11-16(23)19(13)25/h11,14,17,22,25H,1,5-10H2,2-4H3/t14-,17-,21+/m0/s1
DM3786U	CS	C[C@]12CCCC([C@@H]1CCC(=C)[C@@H]2CC3=C(C(=O)C=C(C3=O)O)O)(C)C
DM3786U	IK	KFAYECQGXSDHKU-XXHMAFKTSA-N
DM3786U	IU	3-[[(1S,4aS,8aS)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]methyl]-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
DM3786U	DE	Arteriosclerosis

DM23OHW	ID	DM23OHW
DM23OHW	DN	F-12682
DM23OHW	HS	Terminated
DM23OHW	SN	Antidepressant, Pierre Fabre; F-12318; 5-HT1B antagonists, Pierre Fabre
DM23OHW	CP	Pierre Fabre SA
DM23OHW	DE	Major depressive disorder

DMGH3QD	ID	DMGH3QD
DMGH3QD	DN	F-14413
DMGH3QD	HS	Terminated
DMGH3QD	SN	Alpha-2 adrenoceptor antagonist (Alzheimer's disease), Pierre Fabre
DMGH3QD	CP	Pierre Fabre SA
DMGH3QD	DE	Alzheimer disease

DMVWZN1	ID	DMVWZN1
DMVWZN1	DN	F-200
DMVWZN1	HS	Terminated
DMVWZN1	SN	Eos-200-F; Anti-alpha-5/beta-1 integrin Ab Fragment, PDL; Anti-alpha-5/beta-1 integrin Fab, PDL; Anti-alpha-5/beta-1 integrin Fab, Protein Design Labs
DMVWZN1	CP	Eos Biotechnology Inc
DMVWZN1	DT	Small molecular drug
DMVWZN1	PC	16660135
DMVWZN1	MW	371.4
DMVWZN1	FM	C18H18FN5OS
DMVWZN1	IC	InChI=1S/C18H18FN5OS/c1-11(2)22-16-8-14(20-10-21-16)15-9-26-18(23-15)24(3)17(25)12-4-6-13(19)7-5-12/h4-11H,1-3H3,(H,20,21,22)
DMVWZN1	CS	CC(C)NC1=NC=NC(=C1)C2=CSC(=N2)N(C)C(=O)C3=CC=C(C=C3)F
DMVWZN1	IK	WIVGIKIKQHUFOD-UHFFFAOYSA-N
DMVWZN1	IU	4-fluoro-N-methyl-N-[4-[6-(propan-2-ylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]benzamide
DMVWZN1	DE	Ocular disease

DMXB8SE	ID	DMXB8SE
DMXB8SE	DN	F-3796
DMXB8SE	HS	Terminated
DMXB8SE	CP	Pierre Fabre SA
DMXB8SE	DE	Alzheimer disease

DMJ3MAZ	ID	DMJ3MAZ
DMJ3MAZ	DN	F-992
DMJ3MAZ	HS	Terminated
DMJ3MAZ	SN	Pulmonary emphysema therapeutic, Fornix; F-992, Fornix
DMJ3MAZ	CP	Fornix BioSciences NV
DMJ3MAZ	DE	Urinary incontinence

DME694O	ID	DME694O
DME694O	DN	Fananserin
DME694O	HS	Terminated
DME694O	SN	127625-29-0; RP 62203; Fananserin [USAN:INN]; RP-62203; UNII-38QJ762ET6; CHEMBL83894; C23H24FN3O2S; VGIGHGMPMUCLIQ-UHFFFAOYSA-N; 38QJ762ET6; NCGC00167808-01; DSSTox_RID_81871; DSSTox_CID_26743; 2-(3-(4-(p-Fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide; 2H-Naphth(1,8-cd)isothiazole, 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-, 1,1-dioxide; DSSTox_GSID_46743; [3H]fananserin; CAS-127625-29-0; Fananserin (USAN/INN); [3H]RP62203; [3H]RP-62203; AC1L1TX5;  RP 62203; 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide
DME694O	CP	Sanofi-Aventis
DME694O	DT	Small molecular drug
DME694O	PC	60785
DME694O	MW	425.5
DME694O	FM	C23H24FN3O2S
DME694O	IC	InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2
DME694O	CS	C1CN(CCN1CCCN2C3=CC=CC4=C3C(=CC=C4)S2(=O)=O)C5=CC=C(C=C5)F
DME694O	IK	VGIGHGMPMUCLIQ-UHFFFAOYSA-N
DME694O	IU	3-[3-[4-(4-fluorophenyl)piperazin-1-yl]propyl]-2lambda6-thia-3-azatricyclo[6.3.1.04,12]dodeca-1(11),4,6,8(12),9-pentaene 2,2-dioxide
DME694O	CA	CAS 127625-29-0
DME694O	CB	CHEBI:92159
DME694O	DE	Schizophrenia

DMR3ZWA	ID	DMR3ZWA
DMR3ZWA	DN	FCE-25876
DMR3ZWA	HS	Terminated
DMR3ZWA	CP	Pharmacia & Upjohn SpA
DMR3ZWA	DE	Major depressive disorder

DMJX1IB	ID	DMJX1IB
DMJX1IB	DN	Fedotozine
DMJX1IB	HS	Terminated
DMJX1IB	SN	AC1L1TVH; SCHEMBL1649900; AC1Q56G3; (2s)-n,n-dimethyl-2-phenyl-1-[(3,4,5-trimethoxybenzyl)oxy]butan-2-amine
DMJX1IB	DT	Small molecular drug
DMJX1IB	PC	6918160
DMJX1IB	MW	373.5
DMJX1IB	FM	C22H31NO4
DMJX1IB	IC	InChI=1S/C22H31NO4/c1-7-22(23(2)3,18-11-9-8-10-12-18)16-27-15-17-13-19(24-4)21(26-6)20(14-17)25-5/h8-14H,7,15-16H2,1-6H3/t22-/m0/s1
DMJX1IB	CS	CC[C@](COCC1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C
DMJX1IB	IK	MVKIWCDXKCUDEH-QFIPXVFZSA-N
DMJX1IB	IU	(2R)-N,N-dimethyl-2-phenyl-1-[(3,4,5-trimethoxyphenyl)methoxy]butan-2-amine
DMJX1IB	CA	CAS 123618-00-8

DMJ35RC	ID	DMJ35RC
DMJ35RC	DN	FH-510
DMJ35RC	HS	Terminated
DMJ35RC	SN	Fh-510; CCRIS 6870; UNII-J02GJE6S84; FH 510; 139304-28-2; J02GJE6S84; 9H-Carbazole-4-ethanamine, 5,8-dimethyl-N,N-dipropyl-, monohydrochloride; AC1L36MK; SCHEMBL467264; DTXSID00161004; LS-189199; N-[2-(5,8-dimethyl-9H-carbazol-4-yl)ethyl]-N-propylpropan-1-amine hydrochloride
DMJ35RC	CP	Taisho Pharmaceutical Co Ltd
DMJ35RC	DT	Small molecular drug
DMJ35RC	PC	135554
DMJ35RC	MW	358.9
DMJ35RC	FM	C22H31ClN2
DMJ35RC	IC	InChI=1S/C22H30N2.ClH/c1-5-13-24(14-6-2)15-12-18-8-7-9-19-21(18)20-16(3)10-11-17(4)22(20)23-19;/h7-11,23H,5-6,12-15H2,1-4H3;1H
DMJ35RC	CS	CCCN(CCC)CCC1=C2C(=CC=C1)NC3=C(C=CC(=C23)C)C.Cl
DMJ35RC	IK	NSLYKDHGJLVNIJ-UHFFFAOYSA-N
DMJ35RC	IU	N-[2-(5,8-dimethyl-9H-carbazol-4-yl)ethyl]-N-propylpropan-1-amine;hydrochloride
DMJ35RC	CA	CAS 139304-28-2
DMJ35RC	DE	Psychotic disorder

DMIGXQF	ID	DMIGXQF
DMIGXQF	DN	FK-355
DMIGXQF	HS	Terminated
DMIGXQF	SN	NK1 antagonists, Fujisawa
DMIGXQF	CP	Fujisawa Pharmaceutical Co Ltd
DMIGXQF	DE	Asthma

DMDVAI5	ID	DMDVAI5
DMDVAI5	DN	Florifenine
DMDVAI5	HS	Terminated
DMDVAI5	SN	Florifenine; 83863-79-0; UNII-S7UT8VQG94; S7UT8VQG94; C23H22F3N3O2; Florifenine [INN]; SCHEMBL379372; AC1L50B0; CHEMBL2104893; ZINC537734; API0011459; FI-2522; M454; FT-0668560; 2-pyrrolidin-1-ylethyl 2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate; 2-(1-Pyrrolidinyl)ethyl N-(7-(trifluoromethyl)-4-quinolyl)anthranilate.; 2-(1-Pyrrolidinyl)ethyl N-(7-(trifluoromethyl)-4-quinolyl)anthranilate; 2-[[7-(Trifluoromethyl)-4-quinolinyl]amino]benzoic Acid 2-(1-Pyrrolidinyl)ethyl Ester
DMDVAI5	CP	Ferrer Internacional SA
DMDVAI5	DT	Small molecular drug
DMDVAI5	PC	216222
DMDVAI5	MW	429.4
DMDVAI5	FM	C23H22F3N3O2
DMDVAI5	IC	InChI=1S/C23H22F3N3O2/c24-23(25,26)16-7-8-17-20(9-10-27-21(17)15-16)28-19-6-2-1-5-18(19)22(30)31-14-13-29-11-3-4-12-29/h1-2,5-10,15H,3-4,11-14H2,(H,27,28)
DMDVAI5	CS	C1CCN(C1)CCOC(=O)C2=CC=CC=C2NC3=C4C=CC(=CC4=NC=C3)C(F)(F)F
DMDVAI5	IK	DQOYUDHAZMAVLD-UHFFFAOYSA-N
DMDVAI5	IU	2-pyrrolidin-1-ylethyl 2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate
DMDVAI5	CA	CAS 83863-79-0
DMDVAI5	DE	Inflammation

DMY89KQ	ID	DMY89KQ
DMY89KQ	DN	Flosequinan
DMY89KQ	HS	Terminated
DMY89KQ	SN	Manoplax; BTS-49465; BTS-53554
DMY89KQ	CP	Knoll Pharmaceuticals Co
DMY89KQ	DT	Small molecular drug
DMY89KQ	PC	4474062
DMY89KQ	MW	239.27
DMY89KQ	FM	C11H10FNO2S
DMY89KQ	IC	InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3
DMY89KQ	CS	CN1C=C(C(=O)C2=C1C=C(C=C2)F)S(=O)C
DMY89KQ	IK	UYGONJYYUKVHDD-UHFFFAOYSA-N
DMY89KQ	IU	7-fluoro-1-methyl-3-methylsulfinylquinolin-4-one
DMY89KQ	CA	CAS 76568-02-0
DMY89KQ	CB	CHEBI:134972
DMY89KQ	DE	Cardiovascular disease

DM6OIJ1	ID	DM6OIJ1
DM6OIJ1	DN	Flosulide
DM6OIJ1	HS	Terminated
DM6OIJ1	SN	CGP-28238; CGP-28328; CGS-28238; SH-459; ZK-38997
DM6OIJ1	CP	Novartis AG
DM6OIJ1	DT	Small molecular drug
DM6OIJ1	PC	71246
DM6OIJ1	MW	353.3
DM6OIJ1	FM	C16H13F2NO4S
DM6OIJ1	IC	InChI=1S/C16H13F2NO4S/c1-24(21,22)19-13-6-9-2-4-14(20)11(9)8-16(13)23-15-5-3-10(17)7-12(15)18/h3,5-8,19H,2,4H2,1H3
DM6OIJ1	CS	CS(=O)(=O)NC1=C(C=C2C(=C1)CCC2=O)OC3=C(C=C(C=C3)F)F
DM6OIJ1	IK	CXJONBHNIJFARE-UHFFFAOYSA-N
DM6OIJ1	IU	N-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide
DM6OIJ1	CA	CAS 80937-31-1
DM6OIJ1	DE	Pain

DM7JT3D	ID	DM7JT3D
DM7JT3D	DN	Fluoratec
DM7JT3D	HS	Terminated
DM7JT3D	SN	Technepine; DAT imaging agent, Alseres; DAT imaging agent, Boston life Sciences; DAT imaging agent, Harvard University; Dopamine transporter imaging agent, Alseres; Dopamine transporter imaging agent, Boston life Sciences; O-1505; O-1505T; O-1506; O-1730; O-1783; O-1794; O-861T; Dopamine transporter imaging agent, Harvard/MIT/Organix; 99mTc-O-1505; 99mTc-O-1505T
DM7JT3D	CP	Harvard University
DM7JT3D	DE	Attention deficit hyperactivity disorder

DMSYLIF	ID	DMSYLIF
DMSYLIF	DN	Fosfluridine tidoxil
DMSYLIF	HS	Terminated
DMSYLIF	SN	Fosfluridine; HDP-99-0006; 5-fluorouridine prodrug, Heidelberg Pharma
DMSYLIF	CP	Heidelberg Pharma Holding GmbH
DMSYLIF	DT	Small molecular drug
DMSYLIF	PC	9875280
DMSYLIF	MW	740.9
DMSYLIF	FM	C34H62FN2O10PS
DMSYLIF	IC	InChI=1S/C34H62FN2O10PS/c1-3-5-7-9-11-13-14-16-18-20-22-49-26-27(44-21-19-17-15-12-10-8-6-4-2)24-45-48(42,43)46-25-29-30(38)31(39)33(47-29)37-23-28(35)32(40)36-34(37)41/h23,27,29-31,33,38-39H,3-22,24-26H2,1-2H3,(H,42,43)(H,36,40,41)/t27?,29-,30-,31-,33-/m1/s1
DMSYLIF	CS	CCCCCCCCCCCCSCC(COP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O)OCCCCCCCCCC
DMSYLIF	IK	LBBDGLOPGRGFDO-FKJRLRTPSA-N
DMSYLIF	IU	(2-decoxy-3-dodecylsulfanylpropyl) [(2R,3S,4R,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMSYLIF	CA	CAS 174638-15-4
DMSYLIF	DE	Keratosis

DMF1CDK	ID	DMF1CDK
DMF1CDK	DN	FPL-55712
DMF1CDK	HS	Terminated
DMF1CDK	SN	Fpl-55712; 40786-08-1; 7-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxyl))-4-oxo-8-propyl-4H-chromene-2-carboxy late, sodium salt; CHEMBL267976; 7-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]- 4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid sodium salt; 4H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy)-4-oxo-8-propyl-, monosodium salt; fpl55712; SCHEMBL1890293; AOB5208; ZDEVPOBNLIVGFA-UHFFFAOYSA-M; MFCD00068619; LS-186693; FT-0639668; FPL-55712, &gt
DMF1CDK	CP	Fisons plc
DMF1CDK	DT	Small molecular drug
DMF1CDK	PC	23662025
DMF1CDK	MW	520.5
DMF1CDK	FM	C27H29NaO9
DMF1CDK	IC	InChI=1S/C27H30O9.Na/c1-4-6-19-22(10-8-17(15(3)28)25(19)31)34-13-16(29)14-35-23-11-9-18-21(30)12-24(27(32)33)36-26(18)20(23)7-5-2;/h8-12,16,29,31H,4-7,13-14H2,1-3H3,(H,32,33);/q;+1/p-1
DMF1CDK	CS	CCCC1=C(C=CC(=C1O)C(=O)C)OCC(COC2=C(C3=C(C=C2)C(=O)C=C(O3)C(=O)[O-])CCC)O.[Na+]
DMF1CDK	IK	ZDEVPOBNLIVGFA-UHFFFAOYSA-M
DMF1CDK	IU	sodium;7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propylchromene-2-carboxylate
DMF1CDK	CA	CAS 40786-08-1
DMF1CDK	DE	Asthma

DMCAZPR	ID	DMCAZPR
DMCAZPR	DN	FR-113680
DMCAZPR	HS	Terminated
DMCAZPR	SN	FR 113680; 126088-92-4; Ac-Thr-trp(cho)-phe-N-mebzl; AC1L2Y4S; DTXSID70155076; fr113680; N(alpha)-(N(alpha)-(N(alpha)-Acetylthreonyl)-N(1)-formyltryptophyl)-N-methyl-N-(phenylmethyl)phenylalaninamide; L-Phenylalaninamide, N-acetyl-L-threonyl-1-formyl-D-tryptophyl-N-methyl-N-(phenylmethyl)-
DMCAZPR	CP	Fujisawa Pharmaceutical Co Ltd
DMCAZPR	DT	Small molecular drug
DMCAZPR	PC	130848
DMCAZPR	MW	625.7
DMCAZPR	FM	C35H39N5O6
DMCAZPR	IC	InChI=1S/C35H39N5O6/c1-23(42)32(37-24(2)43)35(46)40(33(44)29(36)19-27-21-39(22-41)30-17-11-10-16-28(27)30)34(45)31(18-25-12-6-4-7-13-25)38(3)20-26-14-8-5-9-15-26/h4-17,21-23,29,31-32,42H,18-20,36H2,1-3H3,(H,37,43)/t23-,29-,31+,32+/m1/s1
DMCAZPR	CS	C[C@H]([C@@H](C(=O)N(C(=O)[C@@H](CC1=CN(C2=CC=CC=C21)C=O)N)C(=O)[C@H](CC3=CC=CC=C3)N(C)CC4=CC=CC=C4)NC(=O)C)O
DMCAZPR	IK	GUMFSDXELXANKA-KGLGFYCJSA-N
DMCAZPR	IU	(2S,3R)-2-acetamido-N-[(2R)-2-amino-3-(1-formylindol-3-yl)propanoyl]-N-[(2S)-2-[benzyl(methyl)amino]-3-phenylpropanoyl]-3-hydroxybutanamide
DMCAZPR	CA	CAS 126088-92-4
DMCAZPR	DE	Asthma

DMY2IB8	ID	DMY2IB8
DMY2IB8	DN	FR-115427
DMY2IB8	HS	Terminated
DMY2IB8	SN	FR-115427; 1-Methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline; (+)-1,2,3,4-Tetrahydro-1-methyl-1-phenylisoquinoline hydrochloride; Isoquinoline, 1,2,3,4-tetrahydro-1-methyl-1-phenyl-, hydrochloride, (+)-; FR115427; 126114-66-7; SCHEMBL6021932; AC1L2Y54; LS-172648; FR 115427; 1-methyl-1-phenyl-3,4-dihydro-2H-isoquinoline hydrochloride; (+)-1-methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride
DMY2IB8	CP	Fujisawa Pharmaceutical Co Ltd
DMY2IB8	DT	Small molecular drug
DMY2IB8	PC	130852
DMY2IB8	MW	259.769
DMY2IB8	FM	C16H18ClN
DMY2IB8	IC	InChI=1S/C16H17N.ClH/c1-16(14-8-3-2-4-9-14)15-10-6-5-7-13(15)11-12-17-16;/h2-10,17H,11-12H2,1H3;1H
DMY2IB8	CS	CC1(C2=CC=CC=C2CCN1)C3=CC=CC=C3.Cl
DMY2IB8	IK	LUSUZDOXGNAITA-UHFFFAOYSA-N
DMY2IB8	IU	1-methyl-1-phenyl-3,4-dihydro-2H-isoquinoline;hydrochloride
DMY2IB8	CA	CAS 126114-66-7
DMY2IB8	DE	Cerebrovascular ischaemia

DMNRUGA	ID	DMNRUGA
DMNRUGA	DN	FR-121196
DMNRUGA	HS	Terminated
DMNRUGA	SN	FR-121196; FR 121196; 133920-65-7; N-(4-Acetyl-1-piperazinyl)-4-fluorobenzenesulfonamide; PZQKOVUNWPDCCQ-UHFFFAOYSA-N; FR121196; ACMC-20mv5f; AC1L2ZLZ; SCHEMBL195526; CTK4B8875; DTXSID90158423; Piperazine, 1-acetyl-4-(((4-fluorophenyl)sulfonyl)amino)-
DMNRUGA	CP	Fujisawa Pharmaceutical Co Ltd
DMNRUGA	DT	Small molecular drug
DMNRUGA	PC	131688
DMNRUGA	MW	301.34
DMNRUGA	FM	C12H16FN3O3S
DMNRUGA	IC	InChI=1S/C12H16FN3O3S/c1-10(17)15-6-8-16(9-7-15)14-20(18,19)12-4-2-11(13)3-5-12/h2-5,14H,6-9H2,1H3
DMNRUGA	CS	CC(=O)N1CCN(CC1)NS(=O)(=O)C2=CC=C(C=C2)F
DMNRUGA	IK	PZQKOVUNWPDCCQ-UHFFFAOYSA-N
DMNRUGA	IU	N-(4-acetylpiperazin-1-yl)-4-fluorobenzenesulfonamide
DMNRUGA	CA	CAS 133920-65-7
DMNRUGA	DE	Alzheimer disease

DM0582D	ID	DM0582D
DM0582D	DN	FR-123826
DM0582D	HS	Terminated
DM0582D	SN	COX-2 inhibitor, Fujisawa
DM0582D	CP	Fujisawa Pharmaceutical Co Ltd
DM0582D	PC	10042938
DM0582D	MW	341.4
DM0582D	FM	C17H12FN3O2S
DM0582D	IC	InChI=1S/C17H12FN3O2S/c1-24(22,23)16-8-2-12(3-9-16)17-10-14(11-19)20-21(17)15-6-4-13(18)5-7-15/h2-10H,1H3
DM0582D	CS	CS(=O)(=O)C1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)F)C#N
DM0582D	IK	NKBRWXWNSUIHNI-UHFFFAOYSA-N
DM0582D	IU	1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile
DM0582D	DE	Rheumatoid arthritis

DMMOBHW	ID	DMMOBHW
DMMOBHW	DN	FR-128998
DMMOBHW	HS	Terminated
DMMOBHW	CP	Fujisawa Pharmaceutical Co Ltd
DMMOBHW	DE	Thrombocytopenia

DM9V6AU	ID	DM9V6AU
DM9V6AU	DN	FR-129169
DM9V6AU	HS	Terminated
DM9V6AU	CP	Fujisawa Pharmaceutical Co Ltd
DM9V6AU	PC	9803486
DM9V6AU	MW	443.6
DM9V6AU	FM	C30H37NO2
DM9V6AU	IC	InChI=1S/C30H37NO2/c1-2-3-4-5-6-15-22-33-29-21-14-13-20-27(29)24-30(32)31-28(26-18-11-8-12-19-26)23-25-16-9-7-10-17-25/h7-14,16-21,28H,2-6,15,22-24H2,1H3,(H,31,32)
DM9V6AU	CS	CCCCCCCCOC1=CC=CC=C1CC(=O)NC(CC2=CC=CC=C2)C3=CC=CC=C3
DM9V6AU	IK	XUCJTVYTRXSOJC-UHFFFAOYSA-N
DM9V6AU	IU	N-(1,2-diphenylethyl)-2-(2-octoxyphenyl)acetamide
DM9V6AU	CA	CAS 143895-84-5
DM9V6AU	DE	Arteriosclerosis

DMXWL0N	ID	DMXWL0N
DMXWL0N	DN	FR-133605
DMXWL0N	HS	Terminated
DMXWL0N	CP	Fujisawa Pharmaceutical Co Ltd
DMXWL0N	DE	Arthritis

DMHV43M	ID	DMHV43M
DMHV43M	DN	FR-145237
DMHV43M	HS	Terminated
DMHV43M	CP	Fujisawa Pharmaceutical Co Ltd
DMHV43M	PC	9850056
DMHV43M	MW	535
DMHV43M	FM	C30H22ClF3N2O2
DMHV43M	IC	InChI=1S/C30H22ClF3N2O2/c1-18-7-12-26-23(13-18)28(20-8-10-21(31)11-9-20)27(38-26)17-36(16-19-5-3-2-4-6-19)30(37)35-29-24(33)14-22(32)15-25(29)34/h2-15H,16-17H2,1H3,(H,35,37)
DMHV43M	CS	CC1=CC2=C(C=C1)OC(=C2C3=CC=C(C=C3)Cl)CN(CC4=CC=CC=C4)C(=O)NC5=C(C=C(C=C5F)F)F
DMHV43M	IK	GJRPAGNTTAPJCC-UHFFFAOYSA-N
DMHV43M	IU	1-benzyl-1-[[3-(4-chlorophenyl)-5-methyl-1-benzofuran-2-yl]methyl]-3-(2,4,6-trifluorophenyl)urea
DMHV43M	CA	CAS 146011-65-6
DMHV43M	DE	Arteriosclerosis

DMBOFSQ	ID	DMBOFSQ
DMBOFSQ	DN	FR-149581
DMBOFSQ	HS	Terminated
DMBOFSQ	SN	Angiotensin II antagonist, Fujisawa
DMBOFSQ	CP	Fujisawa Pharmaceutical Co Ltd
DMBOFSQ	DE	Hypertension

DMOEYX2	ID	DMOEYX2
DMOEYX2	DN	FR-152558
DMOEYX2	HS	Terminated
DMOEYX2	CP	Fujisawa Pharmaceutical Co Ltd
DMOEYX2	DE	Alzheimer disease

DMIQB9E	ID	DMIQB9E
DMIQB9E	DN	FR-171113
DMIQB9E	HS	Terminated
DMIQB9E	SN	CTK8E8568
DMIQB9E	CP	Fujisawa Pharmaceutical Corp
DMIQB9E	DT	Small molecular drug
DMIQB9E	PC	25015749
DMIQB9E	MW	469.7
DMIQB9E	FM	C19H11Cl3N2O4S
DMIQB9E	IC	InChI=1S/C19H11Cl3N2O4S/c1-28-16(25)9-15-18(27)24(12-5-2-10(20)3-6-12)19(29-15)23-17(26)13-7-4-11(21)8-14(13)22/h2-9H,1H3/b15-9+,23-19?
DMIQB9E	CS	COC(=O)/C=C/1\\C(=O)N(C(=NC(=O)C2=C(C=C(C=C2)Cl)Cl)S1)C3=CC=C(C=C3)Cl
DMIQB9E	IK	SDGLYCKTPKZBGI-DALCUZTNSA-N
DMIQB9E	IU	methyl (2E)-2-[3-(4-chlorophenyl)-2-(2,4-dichlorobenzoyl)imino-4-oxo-1,3-thiazolidin-5-ylidene]acetate
DMIQB9E	DE	Thrombosis

DMY1LRI	ID	DMY1LRI
DMY1LRI	DN	FR-172357
DMY1LRI	HS	Terminated
DMY1LRI	CP	Fujisawa Pharmaceutical Co Ltd
DMY1LRI	DE	Inflammation

DM37OS4	ID	DM37OS4
DM37OS4	DN	FR-173657
DM37OS4	HS	Terminated
DM37OS4	SN	FK-3657; FR-173657; FR173657; FR 173657; CHEMBL130517; XCKWRUGRUFVXGC-NTEUORMPSA-N; AC1NSK08; GTPL674; 167838-64-4; SCHEMBL1559539; SCHEMBL3718364; BDBM50067301; FK 3657; L015626; 3-(6-acetamidopyridin-3-yl)-N-(2-((2,4-dichloro-3-((2-methylquinolin-8-yloxy)methyl)phenyl)(methyl)amino)-2-oxoethyl)acrylamide; (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide
DM37OS4	DT	Small molecular drug
DM37OS4	PC	5311108
DM37OS4	MW	592.5
DM37OS4	FM	C30H27Cl2N5O4
DM37OS4	IC	InChI=1S/C30H27Cl2N5O4/c1-18-7-10-21-5-4-6-25(30(21)35-18)41-17-22-23(31)11-12-24(29(22)32)37(3)28(40)16-34-27(39)14-9-20-8-13-26(33-15-20)36-19(2)38/h4-15H,16-17H2,1-3H3,(H,34,39)(H,33,36,38)/b14-9+
DM37OS4	CS	CC1=NC2=C(C=CC=C2OCC3=C(C=CC(=C3Cl)N(C)C(=O)CNC(=O)/C=C/C4=CN=C(C=C4)NC(=O)C)Cl)C=C1
DM37OS4	IK	XCKWRUGRUFVXGC-NTEUORMPSA-N
DM37OS4	IU	(E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide
DM37OS4	CA	CAS 167838-64-4

DMCQHG4	ID	DMCQHG4
DMCQHG4	DN	FR-183998
DMCQHG4	HS	Terminated
DMCQHG4	SN	FR-183998; AC1OCFC6; SCHEMBL6134503; 3-N-(diaminomethylidene)-5-(2,5-dichlorothiophen-3-yl)-1-N-(2-dimethylaminoethyl)benzene-1,3-dicarboxamide dihydrochloride; 3-(2,5-dichlorothiophen-3-yl)-N-[2-(dimethylamino)ethyl]-5-guanidinocarbonylbenzamide dihydrochloride
DMCQHG4	CP	Fujisawa Pharmaceutical Co Ltd
DMCQHG4	DT	Small molecular drug
DMCQHG4	PC	6918360
DMCQHG4	MW	501.3
DMCQHG4	FM	C17H21Cl4N5O2S
DMCQHG4	IC	InChI=1S/C17H19Cl2N5O2S.2ClH/c1-24(2)4-3-22-15(25)10-5-9(12-8-13(18)27-14(12)19)6-11(7-10)16(26)23-17(20)21;;/h5-8H,3-4H2,1-2H3,(H,22,25)(H4,20,21,23,26);2*1H
DMCQHG4	CS	CN(C)CCNC(=O)C1=CC(=CC(=C1)C2=C(SC(=C2)Cl)Cl)C(=O)N=C(N)N.Cl.Cl
DMCQHG4	IK	NPUVTFLPUFCAOB-UHFFFAOYSA-N
DMCQHG4	IU	3-N-(diaminomethylidene)-5-(2,5-dichlorothiophen-3-yl)-1-N-[2-(dimethylamino)ethyl]benzene-1,3-dicarboxamide;dihydrochloride
DMCQHG4	DE	Hypertension

DMNACIV	ID	DMNACIV
DMNACIV	DN	FR-194738
DMNACIV	HS	Terminated
DMNACIV	SN	FR194738; FR-194738; CHEMBL537176; HY-100303A; CS-0006187; (e)-N-ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-[2-methyl-2-(3-thienyl-methoxy)propyloxy]benzylamine hydrochloride
DMNACIV	CP	Fujisawa Pharmaceutical Co Ltd
DMNACIV	DT	Small molecular drug
DMNACIV	PC	9869566
DMNACIV	MW	476.1
DMNACIV	FM	C27H38ClNO2S
DMNACIV	IC	InChI=1S/C27H37NO2S.ClH/c1-7-28(16-10-8-9-15-26(2,3)4)19-23-12-11-13-25(18-23)29-22-27(5,6)30-20-24-14-17-31-21-24;/h8,10-14,17-18,21H,7,16,19-20,22H2,1-6H3;1H/b10-8+;
DMNACIV	CS	CCN(C/C=C/C#CC(C)(C)C)CC1=CC(=CC=C1)OCC(C)(C)OCC2=CSC=C2.Cl
DMNACIV	IK	XZCWZZDUAVANHV-VRTOBVRTSA-N
DMNACIV	IU	(E)-N-ethyl-6,6-dimethyl-N-[[3-[2-methyl-2-(thiophen-3-ylmethoxy)propoxy]phenyl]methyl]hept-2-en-4-yn-1-amine;hydrochloride
DMNACIV	DE	Hypercholesterolaemia

DMLG426	ID	DMLG426
DMLG426	DN	FR-208419
DMLG426	HS	Terminated
DMLG426	SN	IDDB16886
DMLG426	CP	Fujisawa Pharmaceutical Co Ltd
DMLG426	DT	Small molecular drug
DMLG426	PC	6918392
DMLG426	MW	474.6
DMLG426	FM	C28H34N4O3
DMLG426	IC	InChI=1S/C28H34N4O3/c1-4-23-22-15-9-11-19(3)25(22)32(17-24(33)20-12-6-5-7-13-20)27(34)26(30-23)31-28(35)29-21-14-8-10-18(2)16-21/h8-11,14-16,20,26H,4-7,12-13,17H2,1-3H3,(H2,29,31,35)/t26-/m0/s1
DMLG426	CS	CCC1=N[C@H](C(=O)N(C2=C(C=CC=C12)C)CC(=O)C3CCCCC3)NC(=O)NC4=CC=CC(=C4)C
DMLG426	IK	HEJSSPHGFQDYCH-SANMLTNESA-N
DMLG426	IU	1-[(3R)-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-9-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DMLG426	DE	Dyspepsia

DMT6R8I	ID	DMT6R8I
DMT6R8I	DN	FR-229934
DMT6R8I	HS	Terminated
DMT6R8I	SN	FR-2299340
DMT6R8I	CP	Fujisawa Pharmaceutical Co Ltd
DMT6R8I	DT	Small molecular drug
DMT6R8I	PC	11259905
DMT6R8I	MW	468.4
DMT6R8I	FM	C21H23Cl2N3O3S
DMT6R8I	IC	InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)16-7-9-19-20(12-16)26(14(2)24-19)13-15-6-8-17(22)18(23)11-15/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27)
DMT6R8I	CS	CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(N2CC3=CC(=C(C=C3)Cl)Cl)C
DMT6R8I	IK	QLXVZAXTUBLQJW-UHFFFAOYSA-N
DMT6R8I	IU	3-[(3,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide
DMT6R8I	CA	CAS 799841-02-4
DMT6R8I	DE	Erectile dysfunction

DMJS9YB	ID	DMJS9YB
DMJS9YB	DN	FR-62765
DMJS9YB	HS	Terminated
DMJS9YB	SN	FR-62765; 105346-34-7; FR 62765; ODHJHYPKZNTPCS-UHFFFAOYSA-N; AC1L2TN6; SCHEMBL5953715; Ethyl 2,5-dihydro-4-methoxy-5-oxo-3-phenyl-2-furanpropanoate; ethyl 3-(4-methoxy-5-oxo-3-phenyl-2H-furan-2-yl)propanoate; ethyl 3-(4-methoxy-5-oxo-3-phenyl-2,5-dihydro-2-furyl)propionate; 2-Furanpropanoic acid, 2,5-dihydro-4-methoxy-5-oxo-3-phenyl-, ethyl ester
DMJS9YB	CP	Fujisawa Pharmaceutical Co Ltd
DMJS9YB	DT	Small molecular drug
DMJS9YB	PC	128354
DMJS9YB	MW	290.31
DMJS9YB	FM	C16H18O5
DMJS9YB	IC	InChI=1S/C16H18O5/c1-3-20-13(17)10-9-12-14(11-7-5-4-6-8-11)15(19-2)16(18)21-12/h4-8,12H,3,9-10H2,1-2H3
DMJS9YB	CS	CCOC(=O)CCC1C(=C(C(=O)O1)OC)C2=CC=CC=C2
DMJS9YB	IK	ODHJHYPKZNTPCS-UHFFFAOYSA-N
DMJS9YB	IU	ethyl 3-(4-methoxy-5-oxo-3-phenyl-2H-furan-2-yl)propanoate
DMJS9YB	CA	CAS 105346-34-7
DMJS9YB	DE	Diabetic complication

DM7WGXS	ID	DM7WGXS
DM7WGXS	DN	FR-76830
DM7WGXS	HS	Terminated
DM7WGXS	SN	113243-75-7; FR 76830; 3-Pyridinecarboxamide,2-methyl-N-[2-(4-morpholinyl)ethyl]-4-(3-nitrophenyl)-6-phenyl-; FR-76830; HNBRMVZTOLAZRW-UHFFFAOYSA-N; ACMC-20mhoq; AC1MIZ8R; SCHEMBL9601411; fr76830; CTK4A8167; DTXSID70150329; 2-Methyl-N-(2-(4-morpholinyl)ethyl)-4-(3-nitrophenyl)-6-phenylnicotinamide; AKOS030543198; 2-Methyl-N-(4-morpholinylethyl)-4-(3-nitrophenyl)-6-phenyl-3-pyridinecarboxamide; 3-(2-morpholinoethylcarbamoyl)-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine
DM7WGXS	CP	Fujisawa Pharmaceutical Co Ltd
DM7WGXS	DT	Small molecular drug
DM7WGXS	PC	3082657
DM7WGXS	MW	446.5
DM7WGXS	FM	C25H26N4O4
DM7WGXS	IC	InChI=1S/C25H26N4O4/c1-18-24(25(30)26-10-11-28-12-14-33-15-13-28)22(20-8-5-9-21(16-20)29(31)32)17-23(27-18)19-6-3-2-4-7-19/h2-9,16-17H,10-15H2,1H3,(H,26,30)
DM7WGXS	CS	CC1=C(C(=CC(=N1)C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)NCCN4CCOCC4
DM7WGXS	IK	HNBRMVZTOLAZRW-UHFFFAOYSA-N
DM7WGXS	IU	2-methyl-N-(2-morpholin-4-ylethyl)-4-(3-nitrophenyl)-6-phenylpyridine-3-carboxamide
DM7WGXS	CA	CAS 113243-75-7
DM7WGXS	DE	Angina pectoris

DM6PFVD	ID	DM6PFVD
DM6PFVD	DN	FR-901277
DM6PFVD	HS	Terminated
DM6PFVD	SN	CHEMBL437538; FR-901277; BDBM50080264
DM6PFVD	DT	Small molecular drug
DM6PFVD	PC	44316902
DM6PFVD	MW	962.1
DM6PFVD	FM	C47H63N9O13
DM6PFVD	IC	InChI=1S/C47H63N9O13/c1-8-28-40(61)51-30-16-17-36(59)56(44(30)65)33(19-26-13-10-9-11-14-26)45(66)55(7)32-20-27-21-34(57)35(58)22-31(27)52-47(68)48-18-12-15-29(50-39(60)24(4)5)41(62)54-38(43(64)49-28)25(6)69-46(67)37(23(2)3)53-42(32)63/h8-11,13-14,21-25,29-30,32-33,36-38,57-59H,12,15-20H2,1-7H3,(H,49,64)(H,50,60)(H,51,61)(H,53,63)(H,54,62)(H2,48,52,68)/b28-8-/t25-,29-,30-,32-,33-,36+,37-,38-/m0/s1
DM6PFVD	CS	C/C=C\\1/C(=O)N[C@H]2CC[C@H](N(C2=O)[C@H](C(=O)N([C@H]3CC4=CC(=C(C=C4NC(=O)NCCC[C@@H](C(=O)N[C@@H]([C@@H](OC(=O)[C@@H](NC3=O)C(C)C)C)C(=O)N1)NC(=O)C(C)C)O)O)C)CC5=CC=CC=C5)O
DM6PFVD	IK	MHMMGTGXNPFNAJ-MVPXUFHVSA-N
DM6PFVD	IU	N-[(1S,15S,18S,21Z,24S,27R,29S,34S,37S)-29-benzyl-21-ethylidene-5,6,27-trihydroxy-31,37-dimethyl-10,16,19,22,30,32,35,38-octaoxo-34-propan-2-yl-36-oxa-9,11,17,20,23,28,31,33-octazatetracyclo[16.13.6.124,28.03,8]octatriaconta-3,5,7-trien-15-yl]-2-methylpropanamide

DM2FNPO	ID	DM2FNPO
DM2FNPO	DN	FR-901451
DM2FNPO	HS	Terminated
DM2FNPO	SN	FR-901451; CHEMBL403896; fr901451
DM2FNPO	PC	44445940
DM2FNPO	MW	1284.4
DM2FNPO	FM	C61H81N13O18
DM2FNPO	IC	InChI=1S/C61H81N13O18/c1-30(2)23-39-53(81)65-37-17-10-11-21-63-46(76)27-43(61(89)90)71-55(83)41-28-48(78)91-29-44(72-57(85)45-18-12-22-74(45)60(88)42(70-51(37)79)24-33-13-6-5-7-14-33)56(84)66-38(19-20-47(77)92-32(4)50(59(87)69-39)73-58(86)49(62)31(3)75)52(80)67-40(54(82)68-41)26-35-25-34-15-8-9-16-36(34)64-35/h5-9,13-16,25,30-32,37-45,49-50,64,75H,10-12,17-24,26-29,62H2,1-4H3,(H,63,76)(H,65,81)(H,66,84)(H,67,80)(H,68,82)(H,69,87)(H,70,79)(H,71,83)(H,72,85)(H,73,86)(H,89,90)/t31-,32+,37+,38+,39+,40+,41+,42+,43+,44+,45+,49+,50+/m1/s1
DM2FNPO	CS	C[C@H]1[C@@H](C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)C[C@H](NC(=O)[C@@H]3CC(=O)OC[C@@H](C(=O)N[C@@H](CCC(=O)O1)C(=O)N[C@H](C(=O)N3)CC4=CC5=CC=CC=C5N4)NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC2=O)CC7=CC=CC=C7)C(=O)O)CC(C)C)NC(=O)[C@H]([C@@H](C)O)N
DM2FNPO	IK	OBJRDBYSSAEARM-WSFPPIIISA-N
DM2FNPO	IU	(1S,4S,7S,12S,13S,16S,19S,22S,28S,31S,38S)-13-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-22-benzyl-4-(1H-indol-2-ylmethyl)-12-methyl-16-(2-methylpropyl)-3,6,10,14,17,20,23,29,34,36,40,46-dodecaoxo-11,33-dioxa-2,5,15,18,21,24,30,37,41,47-decazatetracyclo[17.16.10.27,31.024,28]heptatetracontane-38-carboxylic acid

DMN4E5H	ID	DMN4E5H
DMN4E5H	DN	Fradafiban
DMN4E5H	HS	Terminated
DMN4E5H	SN	BIBL-12; BIBU-52; BIBV-52; BIBW-103; BIBW-98
DMN4E5H	CP	Boehringer Ingelheim Corp
DMN4E5H	DT	Small molecular drug
DMN4E5H	PC	66000
DMN4E5H	MW	367.4
DMN4E5H	FM	C20H21N3O4
DMN4E5H	IC	InChI=1S/C20H21N3O4/c21-19(22)14-3-1-12(2-4-14)13-5-7-17(8-6-13)27-11-16-9-15(10-18(24)25)20(26)23-16/h1-8,15-16H,9-11H2,(H3,21,22)(H,23,26)(H,24,25)/t15-,16-/m0/s1
DMN4E5H	CS	C1[C@H](C(=O)N[C@@H]1COC2=CC=C(C=C2)C3=CC=C(C=C3)C(=N)N)CC(=O)O
DMN4E5H	IK	IKZACQMAVUIGPY-HOTGVXAUSA-N
DMN4E5H	IU	2-[(3S,5S)-5-[[4-(4-carbamimidoylphenyl)phenoxy]methyl]-2-oxopyrrolidin-3-yl]acetic acid
DMN4E5H	CA	CAS 148396-36-5
DMN4E5H	CB	CHEBI:73266
DMN4E5H	DE	Thrombosis

DMC5O3X	ID	DMC5O3X
DMC5O3X	DN	FRG-8701
DMC5O3X	HS	Terminated
DMC5O3X	SN	FRG8701; 108498-50-6; Acetamide,2-[(2-furanylmethyl)sulfinyl]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-; Frg 8701; Frg-8701; ACMC-20mbjv; AC1L2WUW; SCHEMBL5083014; CTK4A6065; IWLUMUDDKHJJPB-UHFFFAOYSA-N; HY-U00238; AKOS030565773; N-(3-(3-(Piperidinylmethyl)phenoxy)propyl)-2-(furfurylsulfinyl)acetamide; CS-7405; L002080; N-{3-[3-(piperidinomethyl)phenoxy] propyl]-2-(furfurylsulfinyl) acetamide; Acetamide, 2-((2-furanylmethyl)sulfinyl)-N-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-
DMC5O3X	CP	Fujirebio KK
DMC5O3X	DT	Small molecular drug
DMC5O3X	PC	130145
DMC5O3X	MW	418.6
DMC5O3X	FM	C22H30N2O4S
DMC5O3X	IC	InChI=1S/C22H30N2O4S/c25-22(18-29(26)17-21-9-5-13-28-21)23-10-6-14-27-20-8-4-7-19(15-20)16-24-11-2-1-3-12-24/h4-5,7-9,13,15H,1-3,6,10-12,14,16-18H2,(H,23,25)
DMC5O3X	CS	C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC(=O)CS(=O)CC3=CC=CO3
DMC5O3X	IK	IWLUMUDDKHJJPB-UHFFFAOYSA-N
DMC5O3X	IU	2-(furan-2-ylmethylsulfinyl)-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide
DMC5O3X	CA	CAS 108498-50-6
DMC5O3X	DE	Stomach ulcer

DMI1Y92	ID	DMI1Y92
DMI1Y92	DN	FUSIDIENOL
DMI1Y92	HS	Terminated
DMI1Y92	SN	Fusidienol; CHEMBL35732; 157173-61-0; AC1NUTDT; SCHEMBL9139208; DTXSID10166222; BDBM50059880; methyl 7-hydroxy-3-(hydroxymethyl)-6-oxooxepino[2,3-b]chromene-5-carboxylate; 1-Hydroxy-8-hydroxymethyl-11-oxo-11H-5,6-dioxa-cyclohepta[b]naphthalene-10-carboxylic acid methyl ester; 1-Hydroxy-8-hydroxymethyl-11-oxo-11H-5,6-dioxa-cyclohepta[b]naphthalene-10-carboxylic acid methyl ester(fusidienol)
DMI1Y92	DT	Small molecular drug
DMI1Y92	PC	5492684
DMI1Y92	MW	316.26
DMI1Y92	FM	C16H12O7
DMI1Y92	IC	InChI=1S/C16H12O7/c1-21-15(20)9-5-8(6-17)7-22-16-12(9)14(19)13-10(18)3-2-4-11(13)23-16/h2-5,7,17-18H,6H2,1H3
DMI1Y92	CS	COC(=O)C1=CC(=COC2=C1C(=O)C3=C(C=CC=C3O2)O)CO
DMI1Y92	IK	LJNGMSGIOXTZLN-UHFFFAOYSA-N
DMI1Y92	IU	methyl 7-hydroxy-3-(hydroxymethyl)-6-oxooxepino[2,3-b]chromene-5-carboxylate
DMI1Y92	CA	CAS 157173-61-0

DMZXA0W	ID	DMZXA0W
DMZXA0W	DN	Garenoxacin
DMZXA0W	HS	Terminated
DMZXA0W	SN	T 3811; T-3811; T-3811MEa; BMS 284756 (*Mesylate salt*); BMS-284756 (*Mesylate salt*);1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-(1-methyl-2,3-dihydro-1H-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid
DMZXA0W	CP	Toyama Chemical
DMZXA0W	DT	Small molecular drug
DMZXA0W	PC	124093
DMZXA0W	MW	426.4
DMZXA0W	FM	C23H20F2N2O4
DMZXA0W	IC	InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1
DMZXA0W	CS	C[C@@H]1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F
DMZXA0W	IK	NJDRXTDGYFKORP-LLVKDONJSA-N
DMZXA0W	IU	1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid
DMZXA0W	CA	CAS 194804-75-6
DMZXA0W	CB	CHEBI:131716
DMZXA0W	DE	Endocarditis

DMOAURL	ID	DMOAURL
DMOAURL	DN	GDC-0834
DMOAURL	HS	Terminated
DMOAURL	SN	GDC-0834; 1133432-49-1; UNII-FM7JG3L4SR; FM7JG3L4SR; CHEMBL2057915; N-{3-[6-({4-[(2r)-1,4-Dimethyl-3-Oxopiperazin-2-Yl]phenyl}amino)-4-Methyl-5-Oxo-4,5-Dihydropyrazin-2-Yl]-2-Methylphenyl}-4,5,6,7-Tetrahydro-1-Benzothiophene-2-Carboxamide; GDC0834; CDOOFZZILLRUQH-GDLZYMKVSA-N; 2VL; GTPL9263; SCHEMBL1205333; GDC 0834; GDC 0834;GDC0834; ZINC59185874; BDBM50388183; AKOS030526267; SB18925; CS-3123; Benzo(b)thiophene-2-carboxamide, N-(3-(6-((4-((2R)-1,4-dimethyl-3-oxo-2-piperazinyl)phenyl)amino)-4,5-dihydro-4-methyl-5-oxo-2-pyraz
DMOAURL	CP	CGI Pharmaceuticals Inc
DMOAURL	DT	Small molecular drug
DMOAURL	PC	25234918
DMOAURL	MW	596.7
DMOAURL	FM	C33H36N6O3S
DMOAURL	IC	InChI=1S/C33H36N6O3S/c1-20-24(9-7-10-25(20)36-31(40)28-18-22-8-5-6-11-27(22)43-28)26-19-39(4)33(42)30(35-26)34-23-14-12-21(13-15-23)29-32(41)38(3)17-16-37(29)2/h7,9-10,12-15,18-19,29H,5-6,8,11,16-17H2,1-4H3,(H,34,35)(H,36,40)/t29-/m1/s1
DMOAURL	CS	CC1=C(C=CC=C1NC(=O)C2=CC3=C(S2)CCCC3)C4=CN(C(=O)C(=N4)NC5=CC=C(C=C5)[C@@H]6C(=O)N(CCN6C)C)C
DMOAURL	IK	CDOOFZZILLRUQH-GDLZYMKVSA-N
DMOAURL	IU	N-[3-[6-[4-[(2R)-1,4-dimethyl-3-oxopiperazin-2-yl]anilino]-4-methyl-5-oxopyrazin-2-yl]-2-methylphenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide
DMOAURL	CA	CAS 1133432-49-1
DMOAURL	DE	Rheumatoid arthritis

DMGM3VP	ID	DMGM3VP
DMGM3VP	DN	GE-20372A
DMGM3VP	HS	Terminated
DMGM3VP	SN	GE-20372B; HIV protease inhibitors (II), HMR
DMGM3VP	CP	Biosearch Italia SpA
DMGM3VP	PC	124019
DMGM3VP	MW	611.7
DMGM3VP	FM	C30H41N7O7
DMGM3VP	IC	InChI=1S/C30H41N7O7/c1-18(2)25(27(41)34-21(17-38)15-19-7-4-3-5-8-19)37-26(40)23(9-6-14-33-29(31)32)35-30(44)36-24(28(42)43)16-20-10-12-22(39)13-11-20/h3-5,7-8,10-13,17-18,21,23-25,39H,6,9,14-16H2,1-2H3,(H,34,41)(H,37,40)(H,42,43)(H4,31,32,33)(H2,35,36,44)/t21-,23-,24-,25-/m0/s1
DMGM3VP	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O
DMGM3VP	IK	DYNPEHYVIZVLIF-LFBFJMOVSA-N
DMGM3VP	IU	(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-3-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]amino]-1-oxopentan-2-yl]carbamoylamino]-3-(4-hydroxyphenyl)propanoic acid
DMGM3VP	CA	CAS 163565-75-1
DMGM3VP	DE	Human immunodeficiency virus infection

DMZF9CY	ID	DMZF9CY
DMZF9CY	DN	GE-68
DMZF9CY	HS	Terminated
DMZF9CY	SN	GE-68; GE 68; 158358-22-6; CHEMBL93812; AC1L322R; SCHEMBL9738669; (+-)-3-(2-Phenylethyl)-alpha-((propylamino)methyl)-2-benzofuranmethanol; 1-(3-phenethyl-1-benzofuran-2-yl)-2-(propylamino)ethanol; 2-(Propylamino)-1-[3-(2-phenylethyl)benzofuran-2-yl]ethanol; 2-Benzofuranmethanol, 3-(2-phenylethyl)-alpha-((propylamino)methyl)-, (+-)-
DMZF9CY	CP	University of Vienna
DMZF9CY	DT	Small molecular drug
DMZF9CY	PC	133044
DMZF9CY	MW	323.4
DMZF9CY	FM	C21H25NO2
DMZF9CY	IC	InChI=1S/C21H25NO2/c1-2-14-22-15-19(23)21-18(13-12-16-8-4-3-5-9-16)17-10-6-7-11-20(17)24-21/h3-11,19,22-23H,2,12-15H2,1H3
DMZF9CY	CS	CCCNCC(C1=C(C2=CC=CC=C2O1)CCC3=CC=CC=C3)O
DMZF9CY	IK	XPEXCFSBFPOSQR-UHFFFAOYSA-N
DMZF9CY	IU	1-[3-(2-phenylethyl)-1-benzofuran-2-yl]-2-(propylamino)ethanol
DMZF9CY	CA	CAS 158358-22-6
DMZF9CY	DE	Heart arrhythmia

DMVAM18	ID	DMVAM18
DMVAM18	DN	Gene therapy, IFN-alpha
DMVAM18	HS	Terminated
DMVAM18	SN	Gene therapy (IFN-alpha, PINC); Gene therapy (interferon alpha, PINC), Valentis/ Roche; Gene therapy (IFN-alpha, PINC), Valentis/ Roche
DMVAM18	CP	Valentis Inc
DMVAM18	DE	Head and neck cancer

DM6JNV3	ID	DM6JNV3
DM6JNV3	DN	Genevx
DM6JNV3	HS	Terminated
DM6JNV3	SN	Ad5-VEGF145; Restenosis therapy, Collateral; VEGF gene therapy, Collateral
DM6JNV3	CP	Collateral Therapeutics Inc
DM6JNV3	DE	Angina pectoris

DMGX5Q0	ID	DMGX5Q0
DMGX5Q0	DN	Gepirone
DMGX5Q0	HS	Terminated
DMGX5Q0	SN	83928-76-1; 4,4-Dimethyl-1-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)piperidine-2,6-dione; Gepironum [Latin]; Gepirone [INN]; Gepirona [Spanish]; UNII-JW5Y7B8Z18; BMY-13805; JW5Y7B8Z18; CHEMBL284092; Gepironum; AK115965; Gepirona; Travivo; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; BMY 13805; gepiron ER; MJ 13805-1; ORG-13011(Gepirone); AC1L1IK6; AC1Q6F8Q; 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-2,6-piperidinedione; 3,3-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]glutarimide; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
DMGX5Q0	CP	Fabre-Kramer; GSK
DMGX5Q0	DT	Small molecular drug
DMGX5Q0	PC	55191
DMGX5Q0	MW	359.5
DMGX5Q0	FM	C19H29N5O2
DMGX5Q0	IC	InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3
DMGX5Q0	CS	CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C
DMGX5Q0	IK	QOIGKGMMAGJZNZ-UHFFFAOYSA-N
DMGX5Q0	IU	4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
DMGX5Q0	CA	CAS 83928-76-1
DMGX5Q0	CB	CHEBI:135990
DMGX5Q0	DE	Depression

DM1CG0J	ID	DM1CG0J
DM1CG0J	DN	GGTI-298
DM1CG0J	HS	Terminated
DM1CG0J	SN	GGTI298; GGTI-298; Ggti 298; 180977-44-0; CHEMBL282748; N-4-[2(R)-Amino-3-mercaptopropyl]amino-2-naphthylbenzoyl-(L)-Leucine methyl ester, TFA; (S)-methyl 2-(4-((R)-2-amino-3-mercaptopropylamino)-2-(naphthalen-1-yl)benzamido)-4-methylpentanoate; SCHEMBL4283635; CHEBI:124997; EX-A2390; ZINC1488051; BCP24854; BDBM50076138; AKOS032945065; CS-6098; NCGC00165800-01; HY-100876; BRD-K19669037-019-01-3; 2-[4-((R)-2-Amino-3-mercapto-propylamino)-2-naphthalen-1-yl-benzoylamino]-4-methyl-pentanoic acid (S)-methyl ester
DM1CG0J	DT	Small molecular drug
DM1CG0J	PC	9811606
DM1CG0J	MW	479.6
DM1CG0J	FM	C27H33N3O3S
DM1CG0J	IC	InChI=1S/C27H33N3O3S/c1-17(2)13-25(27(32)33-3)30-26(31)23-12-11-20(29-15-19(28)16-34)14-24(23)22-10-6-8-18-7-4-5-9-21(18)22/h4-12,14,17,19,25,29,34H,13,15-16,28H2,1-3H3,(H,30,31)/t19-,25+/m1/s1
DM1CG0J	CS	CC(C)C[C@@H](C(=O)OC)NC(=O)C1=C(C=C(C=C1)NC[C@H](CS)N)C2=CC=CC3=CC=CC=C32
DM1CG0J	IK	XVWPFYDMUFBHBF-CLOONOSVSA-N
DM1CG0J	IU	methyl (2S)-2-[[4-[[(2R)-2-amino-3-sulfanylpropyl]amino]-2-naphthalen-1-ylbenzoyl]amino]-4-methylpentanoate
DM1CG0J	CA	CAS 180977-44-0
DM1CG0J	CB	CHEBI:124997

DMXVP13	ID	DMXVP13
DMXVP13	DN	GI-129471
DMXVP13	HS	Terminated
DMXVP13	SN	GI-129471; GI 129471; CHEMBL114427; 130370-59-1; AC1NX8L8; SCHEMBL6838720; DTXSID60156496; gi129471; BDBM50069608; GW9471; GW-9471; (2R-(1(S*),2R*,3S*))-N4-Hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((phenylthio)methyl)butanediamide; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((phenylthio)methyl)-, (2R-(1(S*),2R*,3S*))-
DMXVP13	CP	Glaxo Inc
DMXVP13	DT	Small molecular drug
DMXVP13	PC	5748217
DMXVP13	MW	471.6
DMXVP13	FM	C25H33N3O4S
DMXVP13	IC	InChI=1S/C25H33N3O4S/c1-17(2)14-20(21(24(30)28-32)16-33-19-12-8-5-9-13-19)23(29)27-22(25(31)26-3)15-18-10-6-4-7-11-18/h4-13,17,20-22,32H,14-16H2,1-3H3,(H,26,31)(H,27,29)(H,28,30)/t20-,21+,22+/m1/s1
DMXVP13	CS	CC(C)C[C@H]([C@H](CSC1=CC=CC=C1)C(=O)NO)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NC
DMXVP13	IK	UBFGIEDUTRCMEQ-FSSWDIPSSA-N
DMXVP13	IU	(2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(phenylsulfanylmethyl)butanediamide
DMXVP13	CA	CAS 130370-59-1
DMXVP13	DE	Inflammation

DM6HZU1	ID	DM6HZU1
DM6HZU1	DN	GI-197111
DM6HZU1	HS	Terminated
DM6HZU1	CP	Glaxo Wellcome plc
DM6HZU1	DE	Alopecia

DMT6J1E	ID	DMT6J1E
DMT6J1E	DN	GI-248573
DMT6J1E	HS	Terminated
DMT6J1E	CP	Glaxo Wellcome plc
DMT6J1E	DE	Bladder disease

DM3KN2Q	ID	DM3KN2Q
DM3KN2Q	DN	GI-270384X
DM3KN2Q	HS	Terminated
DM3KN2Q	SN	270384
DM3KN2Q	CP	GlaxoSmithKline Inc
DM3KN2Q	DE	Inflammatory bowel disease

DMX0N9P	ID	DMX0N9P
DMX0N9P	DN	Ginkgolide B (GKB)
DMX0N9P	HS	Terminated
DMX0N9P	SN	SCHEMBL464783; MolPort-003-983-580; s1343; BN0224; NCGC00386140-01; BN 52021, 15291-77-7
DMX0N9P	DT	Small molecular drug
DMX0N9P	PC	17751009
DMX0N9P	MW	424.4
DMX0N9P	FM	C20H24O10
DMX0N9P	IC	InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9-,10+,11+,15+,17?,18?,19-,20-/m1/s1
DMX0N9P	CS	C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3([C@@H]2O)C6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O
DMX0N9P	IK	SQOJOAFXDQDRGF-RLAVLKHASA-N
DMX0N9P	IU	(1R,3R,6R,8S,10R,12S,13S,16S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMX0N9P	CA	CAS 15291-77-7

DMLIM7B	ID	DMLIM7B
DMLIM7B	DN	GINKOLIDE B
DMLIM7B	HS	Terminated
DMLIM7B	SN	Ginkolide B; Gingko lactone; C20H24O10; Ginkgolide B from Ginkgo biloba leaves; AK160212; Ginkgolide A, 1-hydroxy-, (1beta)-; BN 52051; SR-01000597598; lide B; 99796-69-7; AC1Q6PCU; CHEMBL266625; AC1L22W1; SCHEMBL14279903; KS-00000IWU; CTK8F0398; 1-Hydroxy-(1beta)-Ginkgolide A; MolPort-003-847-584; 9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta(c)furo(2,3-b)furo(3',2':3,4)cyclopenta(1,2-d)furan-5,9,12(4H)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b,11
DMLIM7B	DT	Small molecular drug
DMLIM7B	PC	65243
DMLIM7B	MW	424.4
DMLIM7B	FM	C20H24O10
DMLIM7B	IC	InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3
DMLIM7B	CS	CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O
DMLIM7B	IK	SQOJOAFXDQDRGF-UHFFFAOYSA-N
DMLIM7B	IU	8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMLIM7B	CA	CAS 15291-77-7
DMLIM7B	DE	Sepsis

DMSVMF2	ID	DMSVMF2
DMSVMF2	DN	Girisopam
DMSVMF2	HS	Terminated
DMSVMF2	SN	EGIS-5810; GYKI-51189
DMSVMF2	CP	EGIS Gyogyszergyar RT
DMSVMF2	DT	Small molecular drug
DMSVMF2	PC	71257
DMSVMF2	MW	328.8
DMSVMF2	FM	C18H17ClN2O2
DMSVMF2	IC	InChI=1S/C18H17ClN2O2/c1-11-7-13-9-16(22-2)17(23-3)10-15(13)18(21-20-11)12-5-4-6-14(19)8-12/h4-6,8-10H,7H2,1-3H3
DMSVMF2	CS	CC1=NN=C(C2=CC(=C(C=C2C1)OC)OC)C3=CC(=CC=C3)Cl
DMSVMF2	IK	VQYLGVVODFDFNK-UHFFFAOYSA-N
DMSVMF2	IU	1-(3-chlorophenyl)-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DMSVMF2	CA	CAS 82230-53-3
DMSVMF2	DE	Anxiety disorder

DM4RKDU	ID	DM4RKDU
DM4RKDU	DN	GK-128
DM4RKDU	HS	Terminated
DM4RKDU	CP	Taisho Pharmaceutical Co Ltd
DM4RKDU	PC	178063
DM4RKDU	MW	342.8
DM4RKDU	FM	C18H15ClN2OS
DM4RKDU	IC	InChI=1S/C18H14N2OS.ClH/c1-12-19-8-9-20(12)10-14-11-22-16-7-6-13-4-2-3-5-15(13)17(16)18(14)21;/h2-9,11H,10H2,1H3;1H
DM4RKDU	CS	CC1=NC=CN1CC2=CSC3=C(C2=O)C4=CC=CC=C4C=C3.Cl
DM4RKDU	IK	DBXKJORICFHAQA-UHFFFAOYSA-N
DM4RKDU	IU	2-[(2-methylimidazol-1-yl)methyl]benzo[f]thiochromen-1-one;hydrochloride
DM4RKDU	CA	CAS 162413-52-7
DM4RKDU	DE	Vomiting

DMONQYZ	ID	DMONQYZ
DMONQYZ	DN	Gliotoxin
DMONQYZ	HS	Terminated
DMONQYZ	SN	gliotoxin; 67-99-2; Aspergillin; UNII-5L648PH06K; CCRIS 4025; Gliotoxin from Gliocladium fimbriatum; NSC 102866; BRN 0050675; AI3-62383; CHEBI:5385; CHEMBL331627; S.N. 12870; Gliotoxin, Gladiocladium fimbriatum; 5L648PH06K; 10H-3,10a-Epidithiopyrazino(1,2-a)indole-1,4-dione, 2,3,5a,6-tetrahydro-6-hydroxy-3-(hydroxymethyl)-2-methyl-; Gliotoxins; 10H-3,10a-Epidithiopyrazino(1,2-a)indole-1,4-dione, 2,3,5a,6-hydroxy-3- (hydroxymethyl)-2-methyl-, (3R-(3-alpha,5a-beta,6-beta,10a-alpha))-
DMONQYZ	DT	Small molecular drug
DMONQYZ	PC	6223
DMONQYZ	MW	326.4
DMONQYZ	FM	C13H14N2O4S2
DMONQYZ	IC	InChI=1S/C13H14N2O4S2/c1-14-10(18)12-5-7-3-2-4-8(17)9(7)15(12)11(19)13(14,6-16)21-20-12/h2-4,8-9,16-17H,5-6H2,1H3/t8-,9-,12+,13+/m0/s1
DMONQYZ	CS	CN1C(=O)[C@]23CC4=CC=C[C@@H]([C@H]4N2C(=O)[C@]1(SS3)CO)O
DMONQYZ	IK	FIVPIPIDMRVLAY-RBJBARPLSA-N
DMONQYZ	IU	(1R,7S,8S,11R)-7-hydroxy-11-(hydroxymethyl)-15-methyl-12,13-dithia-9,15-diazatetracyclo[9.2.2.01,9.03,8]pentadeca-3,5-diene-10,14-dione
DMONQYZ	CA	CAS 67-99-2
DMONQYZ	CB	CHEBI:5385

DM0IKB4	ID	DM0IKB4
DM0IKB4	DN	GLY-515n
DM0IKB4	HS	Terminated
DM0IKB4	CP	GlycoForm Ltd
DM0IKB4	DE	Cerebrovascular ischaemia

DMEVIP9	ID	DMEVIP9
DMEVIP9	DN	GM-7050
DMEVIP9	HS	Terminated
DMEVIP9	CP	Glycomed Inc
DMEVIP9	DE	Inflammation

DMT1RH6	ID	DMT1RH6
DMT1RH6	DN	GMC-283
DMT1RH6	HS	Terminated
DMT1RH6	SN	CHEMBL430798; MolPort-042-665-651; GMC-2-83; ZINC14299682; BDBM50078062; Trifluoro-methanesulfonic acid 11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]oxazepin-2-yl ester
DMT1RH6	CP	Merck KGaA
DMT1RH6	DT	Small molecular drug
DMT1RH6	PC	10026300
DMT1RH6	MW	441.4
DMT1RH6	FM	C19H18F3N3O4S
DMT1RH6	IC	InChI=1S/C19H18F3N3O4S/c1-24-8-10-25(11-9-24)18-14-12-13(29-30(26,27)19(20,21)22)6-7-16(14)28-17-5-3-2-4-15(17)23-18/h2-7,12H,8-11H2,1H3
DMT1RH6	CS	CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)OS(=O)(=O)C(F)(F)F
DMT1RH6	IK	DQNCRNVCBHYBQP-UHFFFAOYSA-N
DMT1RH6	IU	[6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepin-8-yl] trifluoromethanesulfonate
DMT1RH6	DE	Schizophrenia

DMHXRN8	ID	DMHXRN8
DMHXRN8	DN	GNI-104
DMHXRN8	HS	Terminated
DMHXRN8	SN	Ed-004; Neutralizing monoclonal antibodies (HCV), Innogenetics
DMHXRN8	CP	GENimmune NV
DMHXRN8	DT	Antibody
DMHXRN8	DE	Hepatitis C virus infection

DMPODL9	ID	DMPODL9
DMPODL9	DN	GP-683
DMPODL9	HS	Terminated
DMPODL9	SN	Analgesic-sparing agent, Univ Texas
DMPODL9	CP	Metabasis Therapeutics Inc
DMPODL9	DT	Small molecular drug
DMPODL9	PC	5311109
DMPODL9	MW	402.4
DMPODL9	FM	C23H22N4O3
DMPODL9	IC	InChI=1S/C23H22N4O3/c1-14-19(28)20(29)23(30-14)27-12-17(15-8-4-2-5-9-15)18-21(24-13-25-22(18)27)26-16-10-6-3-7-11-16/h2-14,19-20,23,28-29H,1H3,(H,24,25,26)/t14-,19-,20-,23-/m1/s1
DMPODL9	CS	C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C3=C(N=CN=C32)NC4=CC=CC=C4)C5=CC=CC=C5)O)O
DMPODL9	IK	YPWISWJHVQIXIL-DVHMWJAFSA-N
DMPODL9	IU	(2R,3R,4S,5R)-2-(4-anilino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)-5-methyloxolane-3,4-diol
DMPODL9	DE	Pain

DMD5WK4	ID	DMD5WK4
DMD5WK4	DN	Gpi-1046
DMD5WK4	HS	Terminated
DMD5WK4	SN	186452-09-5; gpi-1046; (S)-3-(Pyridin-3-yl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylate; CHEMBL6367; L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester; (2S)-[3-PYRIDYL-1-PROPYL]-1-[3,3-DIMETHYL-1,2-DIOXOPENTYL]-2-PYRROLIDINECARBOXYLATE; 3-pyridin-3-ylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylate; 3-(pyridin-3-yl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylate; GPI; AC1L9I3R; SCHEMBL4766380; BDBM23334; CTK0I3903; DTXSID00332191
DMD5WK4	DT	Small molecular drug
DMD5WK4	PC	445501
DMD5WK4	MW	360.4
DMD5WK4	FM	C20H28N2O4
DMD5WK4	IC	InChI=1S/C20H28N2O4/c1-4-20(2,3)17(23)18(24)22-12-6-10-16(22)19(25)26-13-7-9-15-8-5-11-21-14-15/h5,8,11,14,16H,4,6-7,9-10,12-13H2,1-3H3/t16-/m0/s1
DMD5WK4	CS	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCC2=CN=CC=C2
DMD5WK4	IK	OQAHHWOPVDDWHD-INIZCTEOSA-N
DMD5WK4	IU	3-pyridin-3-ylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylate
DMD5WK4	CA	CAS 186452-09-5
DMD5WK4	DE	Parkinson disease

DMBMAPH	ID	DMBMAPH
DMBMAPH	DN	GPI-3000
DMBMAPH	HS	Terminated
DMBMAPH	SN	NPC-17742
DMBMAPH	CP	Scios Inc
DMBMAPH	DT	Small molecular drug
DMBMAPH	PC	108099
DMBMAPH	MW	279.27
DMBMAPH	FM	C11H22NO5P
DMBMAPH	IC	InChI=1S/C11H22NO5P/c12-10(11(13)14)7-9-4-2-1-3-8(9)5-6-18(15,16)17/h8-10H,1-7,12H2,(H,13,14)(H2,15,16,17)
DMBMAPH	CS	C1CCC(C(C1)CCP(=O)(O)O)CC(C(=O)O)N
DMBMAPH	IK	DHJQWBSZKBDBFP-UHFFFAOYSA-N
DMBMAPH	IU	2-amino-3-[2-(2-phosphonoethyl)cyclohexyl]propanoic acid
DMBMAPH	CA	CAS 117571-54-7
DMBMAPH	DE	Cerebrovascular ischaemia

DM01HLX	ID	DM01HLX
DM01HLX	DN	GR-127935
DM01HLX	HS	Terminated
DM01HLX	SN	148672-13-3; GR 127935; GR-127935; N-(4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-carboxamide; GR127935; UNII-2LLH6CEB40; 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide; 2LLH6CEB40; CHEMBL15928; GR 127935 hydrochloride hydrate; N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE; CHEBI:64114; GR 127935 HCl; C29H31N5O3
DM01HLX	DT	Small molecular drug
DM01HLX	PC	107780
DM01HLX	MW	497.6
DM01HLX	FM	C29H31N5O3
DM01HLX	IC	InChI=1S/C29H31N5O3/c1-19-17-23(28-30-20(2)37-32-28)9-11-25(19)21-5-7-22(8-6-21)29(35)31-24-10-12-27(36-4)26(18-24)34-15-13-33(3)14-16-34/h5-12,17-18H,13-16H2,1-4H3,(H,31,35)
DM01HLX	CS	CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)N5CCN(CC5)C
DM01HLX	IK	YDBCEBYHYKAFRX-UHFFFAOYSA-N
DM01HLX	IU	N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]benzamide
DM01HLX	CA	CAS 148672-13-3
DM01HLX	CB	CHEBI:64114
DM01HLX	DE	Major depressive disorder

DMKAGLV	ID	DMKAGLV
DMKAGLV	DN	GR-131663
DMKAGLV	HS	Terminated
DMKAGLV	SN	AH-002; AH-017; GR-131665
DMKAGLV	CP	Glaxo Group Research Ltd
DMKAGLV	DE	Anxiety disorder

DMNRJA0	ID	DMNRJA0
DMNRJA0	DN	GR-133347
DMNRJA0	HS	Terminated
DMNRJA0	SN	AH-023
DMNRJA0	CP	Glaxo Group Research Ltd
DMNRJA0	DE	Anxiety disorder

DMN8TH1	ID	DMN8TH1
DMN8TH1	DN	GR-144053
DMN8TH1	HS	Terminated
DMN8TH1	SN	GR-144053; CHEMBL36326; GR-144053F; GR144053; 2-[4-[4-(4-carbamimidoylphenyl)piperazin-1-yl]piperidin-1-yl]acetic acid; {4-[4-(4-Carbamimidoyl-phenyl)-piperazin-1-yl]-piperidin-1-yl}-acetic acid; GR 144053; AC1L5AAD; GTPL6587; ZINC5719; SCHEMBL6839445; CHEBI:92207; BDBM50037970; BRD-K12120659-305-01-4; {4-[4-(4-Carbamimidoyl-phenyl)-piperazin-1-yl]-piperidin-1-yl}-acetic acid (GR 144053)
DMN8TH1	CP	Glaxo Wellcome plc
DMN8TH1	DT	Small molecular drug
DMN8TH1	PC	173614
DMN8TH1	MW	345.4
DMN8TH1	FM	C18H27N5O2
DMN8TH1	IC	InChI=1S/C18H27N5O2/c19-18(20)14-1-3-15(4-2-14)22-9-11-23(12-10-22)16-5-7-21(8-6-16)13-17(24)25/h1-4,16H,5-13H2,(H3,19,20)(H,24,25)
DMN8TH1	CS	C1CN(CCC1N2CCN(CC2)C3=CC=C(C=C3)C(=N)N)CC(=O)O
DMN8TH1	IK	QGEGSJUSWLLZLH-UHFFFAOYSA-N
DMN8TH1	IU	2-[4-[4-(4-carbamimidoylphenyl)piperazin-1-yl]piperidin-1-yl]acetic acid
DMN8TH1	CB	CHEBI:92207
DMN8TH1	DE	Thrombosis

DMLQ71Y	ID	DMLQ71Y
DMLQ71Y	DN	GR-159897
DMLQ71Y	HS	Terminated
DMLQ71Y	SN	CHEMBL2110370; GR 159897; 158848-32-9; 5-FLUORO-3-[2-[4-METHOXY-4-[[(R)-PHENYLSULPHINYL]METHYL]-1-PIPERIDINYL]ETHYL]-1H-INDOLE; GR-159897; GR-159,897; GTPL2115; CHEBI:92912; MolPort-023-276-059; ZINC7999073; BDBM50212987; AKOS025147300; AKOS024456505; NCGC00381706-02; KB-309739; SR-01000597395; SR-01000597395-1; 5-fluoro-3-[2-[4-methoxy-4-[[(R)-phenylsulfinyl]methyl]piperidin-1-yl]ethyl]-1H-indole; 5-Fluoro-3-[2-[4-methoxy-4-[[ -phenylsulphinyl]methyl]-1-piperidinyl]ethyl]-1H-indole
DMLQ71Y	CP	Glaxo Group Research Ltd
DMLQ71Y	DT	Small molecular drug
DMLQ71Y	PC	9953599
DMLQ71Y	MW	414.5
DMLQ71Y	FM	C23H27FN2O2S
DMLQ71Y	IC	InChI=1S/C23H27FN2O2S/c1-28-23(17-29(27)20-5-3-2-4-6-20)10-13-26(14-11-23)12-9-18-16-25-22-8-7-19(24)15-21(18)22/h2-8,15-16,25H,9-14,17H2,1H3/t29-/m1/s1
DMLQ71Y	CS	COC1(CCN(CC1)CCC2=CNC3=C2C=C(C=C3)F)C[S@@](=O)C4=CC=CC=C4
DMLQ71Y	IK	BANYJBHWTOJQDU-GDLZYMKVSA-N
DMLQ71Y	IU	5-fluoro-3-[2-[4-methoxy-4-[[(R)-phenylsulfinyl]methyl]piperidin-1-yl]ethyl]-1H-indole
DMLQ71Y	CA	CAS 158848-32-9
DMLQ71Y	CB	CHEBI:92912
DMLQ71Y	DE	Anxiety disorder

DMOY8UA	ID	DMOY8UA
DMOY8UA	DN	GR-175737
DMOY8UA	HS	Terminated
DMOY8UA	SN	GR-175737; CHEMBL276798; GR 175737; SCHEMBL195040; GTPL1243; BDBM50070213; 3-[(4-chlorophenyl)methyl]-5-[2-(3H-imidazol-4-yl)ethyl]-1,2,4-oxadiazole; GR175737; L015003; 3-(4-Chloro-benzyl)-5-[2-(1H-imidazol-4-yl)-ethyl]-[1,2,4]oxadiazole; 1,2,4-Oxadiazole, 3-((4-chlorophenyl)methyl)-5-(2-(1H-imidazol-4-yl)ethyl)-; 203874-78-6
DMOY8UA	DT	Small molecular drug
DMOY8UA	PC	9838905
DMOY8UA	MW	288.73
DMOY8UA	FM	C14H13ClN4O
DMOY8UA	IC	InChI=1S/C14H13ClN4O/c15-11-3-1-10(2-4-11)7-13-18-14(20-19-13)6-5-12-8-16-9-17-12/h1-4,8-9H,5-7H2,(H,16,17)
DMOY8UA	CS	C1=CC(=CC=C1CC2=NOC(=N2)CCC3=CN=CN3)Cl
DMOY8UA	IK	CPOUJACQGWJJQB-UHFFFAOYSA-N
DMOY8UA	IU	3-[(4-chlorophenyl)methyl]-5-[2-(1H-imidazol-5-yl)ethyl]-1,2,4-oxadiazole
DMOY8UA	CA	CAS 176860-26-7

DMA7FX1	ID	DMA7FX1
DMA7FX1	DN	GR-199114X
DMA7FX1	HS	Terminated
DMA7FX1	SN	GR-199114X; CHEMBL320141; SCHEMBL14520869
DMA7FX1	CP	Glaxo Wellcome plc
DMA7FX1	DT	Small molecular drug
DMA7FX1	PC	9914672
DMA7FX1	MW	521.6
DMA7FX1	FM	C28H32FN5O4
DMA7FX1	IC	InChI=1S/C28H32FN5O4/c29-19-12-14-20(15-13-19)30-28(38)31-25-26(36)33(18-24(35)32-16-6-7-17-32)22-10-4-5-11-23(22)34(27(25)37)21-8-2-1-3-9-21/h4-5,10-15,21,25H,1-3,6-9,16-18H2,(H2,30,31,38)/t25-/m0/s1
DMA7FX1	CS	C1CCC(CC1)N2C3=CC=CC=C3N(C(=O)[C@@H](C2=O)NC(=O)NC4=CC=C(C=C4)F)CC(=O)N5CCCC5
DMA7FX1	IK	URMOKEJAUAGZGV-VWLOTQADSA-N
DMA7FX1	IU	1-[(3S)-5-cyclohexyl-2,4-dioxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)-1,5-benzodiazepin-3-yl]-3-(4-fluorophenyl)urea
DMA7FX1	DE	Stomach ulcer

DMIJCH1	ID	DMIJCH1
DMIJCH1	DN	GR-218231
DMIJCH1	HS	Terminated
DMIJCH1	SN	GR 218231; GR218231; CHEMBL131556; 175442-95-2; (+)-(2R)-1,2,3,4-Tetrahydro-6-[[(4-methoxyphenyl)sulfonyl]methyl]-N,N-dipropyl-2-naphthalenamine; (2R)-6-[(4-methoxyphenyl)sulfonylmethyl]-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine; AC1NSM1X; GR 218,231; GTPL70; SCHEMBL626977; DTXSID70415546; ZINC3824084; PDSP2_001398; PDSP1_001414; BDBM50214486; (3R)-N,N-Dipropyl-7-(4-methoxyphenylsulfonylmethyl)tetralin-3beta-amine
DMIJCH1	DT	Small molecular drug
DMIJCH1	PC	24840389
DMIJCH1	MW	415.6
DMIJCH1	FM	C24H33NO3S
DMIJCH1	IC	InChI=1S/C24H33NO3S/c1-4-14-25(15-5-2)22-9-8-20-16-19(6-7-21(20)17-22)18-29(26,27)24-12-10-23(28-3)11-13-24/h6-7,10-13,16,22H,4-5,8-9,14-15,17-18H2,1-3H3
DMIJCH1	CS	CCCN(CCC)C1CCC2=C(C1)C=CC(=C2)CS(=O)(=O)C3=CC=C(C=C3)OC
DMIJCH1	IK	HUXFXXWYIRBVJR-UHFFFAOYSA-N
DMIJCH1	IU	6-[(4-methoxyphenyl)sulfonylmethyl]-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine

DMHM0EU	ID	DMHM0EU
DMHM0EU	DN	GR-233548
DMHM0EU	HS	Terminated
DMHM0EU	SN	Fibrinogen antagonist, Glaxo Wellcome
DMHM0EU	CP	Glaxo Wellcome plc
DMHM0EU	DE	Thrombosis

DMRPE3D	ID	DMRPE3D
DMRPE3D	DN	GR-65630
DMRPE3D	HS	Terminated
DMRPE3D	SN	GR-65630A
DMRPE3D	CP	Glaxo Group Research Ltd
DMRPE3D	DT	Small molecular drug
DMRPE3D	PC	124006
DMRPE3D	MW	267.33
DMRPE3D	FM	C16H17N3O
DMRPE3D	IC	InChI=1S/C16H17N3O/c1-11-13(18-10-17-11)7-8-16(20)15-9-12-5-3-4-6-14(12)19(15)2/h3-6,9-10H,7-8H2,1-2H3,(H,17,18)
DMRPE3D	CS	CC1=C(N=CN1)CCC(=O)C2=CC3=CC=CC=C3N2C
DMRPE3D	IK	AQCBJPZFJDPIGL-UHFFFAOYSA-N
DMRPE3D	IU	3-(5-methyl-1H-imidazol-4-yl)-1-(1-methylindol-2-yl)propan-1-one
DMRPE3D	CA	CAS 117186-80-8
DMRPE3D	DE	Vomiting

DMR2TZK	ID	DMR2TZK
DMR2TZK	DN	GR-82334
DMR2TZK	HS	Terminated
DMR2TZK	SN	GR 82334; 129623-01-4; Physalaemin(1-11), D-pro(9)(spiro-gamma-lactam)leu(10)-trp(11)-; Physalemin, 9-deglycine-10-((5S)-6-oxo-L-alpha-(2-methylpropyl)-1,7-diazaspiro(4.4)nonane-7-acetic acid)-11-L-tryptophanamide-; SCHEMBL7945525; gr82334; DTXSID10156209; MFCD00214619; AKOS024456738; LS-184749; B5161; GR 82334, &gt; pGlu-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Pro(spiro-; A-lactam-Leu-Trp-NH2
DMR2TZK	CP	Glaxo Group Research Ltd
DMR2TZK	PC	16130972
DMR2TZK	MW	1386.6
DMR2TZK	FM	C69H91N15O16
DMR2TZK	IC	InChI=1S/C69H91N15O16/c1-38(2)31-54(65(97)77-48(58(72)90)34-42-37-73-45-16-8-7-15-44(42)45)83-30-26-69(68(83)100)25-12-29-84(69)67(99)51(33-41-19-21-43(85)22-20-41)81-62(94)49(32-40-13-5-4-6-14-40)78-61(93)46(17-9-10-27-70)76-63(95)50(35-55(71)86)79-64(96)53-18-11-28-82(53)66(98)52(36-57(88)89)80-59(91)39(3)74-60(92)47-23-24-56(87)75-47/h4-8,13-16,19-22,37-39,46-54,73,85H,9-12,17-18,23-36,70H2,1-3H3,(H2,71,86)(H2,72,90)(H,74,92)(H,75,87)(H,76,95)(H,77,97)(H,78,93)(H,79,96)(H,80,91)(H,81,94)(H,88,89)/t39-,46-,47-,48-,49-,50-,51-,52-,53-,54-,69-/m0/s1
DMR2TZK	CS	C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N4CCC[C@@]45CCN(C5=O)[C@@H](CC(C)C)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N)NC(=O)[C@@H]8CCC(=O)N8
DMR2TZK	IK	KWECNVXXONDEKG-JTCMYMKESA-N
DMR2TZK	IU	(3S)-4-[(2S)-2-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[(5S)-7-[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-6-oxo-1,7-diazaspiro[4.4]nonan-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-[[(2S)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]butanoic acid
DMR2TZK	CA	CAS 129623-01-4
DMR2TZK	DE	Vomiting

DMTGH8N	ID	DMTGH8N
DMTGH8N	DN	GR-89696
DMTGH8N	HS	Terminated
DMTGH8N	SN	GR-103545; 1-Piperazinecarboxylic acid, 4-[(3,4-dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-, methyl ester
DMTGH8N	CP	Glaxo Group Research Ltd
DMTGH8N	DT	Small molecular drug
DMTGH8N	PC	3505
DMTGH8N	MW	414.3
DMTGH8N	FM	C19H25Cl2N3O3
DMTGH8N	IC	InChI=1S/C19H25Cl2N3O3/c1-27-19(26)23-8-9-24(15(13-23)12-22-6-2-3-7-22)18(25)11-14-4-5-16(20)17(21)10-14/h4-5,10,15H,2-3,6-9,11-13H2,1H3
DMTGH8N	CS	COC(=O)N1CCN(C(C1)CN2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl
DMTGH8N	IK	HJUAKZYKCANOOZ-UHFFFAOYSA-N
DMTGH8N	IU	methyl 4-[2-(3,4-dichlorophenyl)acetyl]-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate
DMTGH8N	CB	CHEBI:91965
DMTGH8N	DE	Neurodegenerative disorder

DM96KF7	ID	DM96KF7
DM96KF7	DN	GR-94839
DM96KF7	HS	Terminated
DM96KF7	SN	GR-94839; 133407-20-2; 1-[4-acetyl-2-[(3-hydroxypyrrolidin-1-yl)methyl]piperazin-1-yl]-2-(3,4-dichlorophenyl)ethanone; GR 94839; ACMC-20muxb; AC1L2ZIM; SCHEMBL9650718; gr94839; CTK0I2209; 4-Acetyl-1-((3,4-dichlorophenyl)acetyl)-2-((3-hydroxy-1-pyrrolidinyl)methyl)piperazine; L004338; Piperazine, 4-acetyl-1-((3,4-dichlorophenyl)acetyl)-2-((3-hydroxy-1-pyrrolidinyl)methyl)-
DM96KF7	CP	Glaxo Group Research Ltd
DM96KF7	DT	Small molecular drug
DM96KF7	PC	131626
DM96KF7	MW	414.3
DM96KF7	FM	C19H25Cl2N3O3
DM96KF7	IC	InChI=1S/C19H25Cl2N3O3/c1-13(25)23-6-7-24(15(11-23)10-22-5-4-16(26)12-22)19(27)9-14-2-3-17(20)18(21)8-14/h2-3,8,15-16,26H,4-7,9-12H2,1H3
DM96KF7	CS	CC(=O)N1CCN(C(C1)CN2CCC(C2)O)C(=O)CC3=CC(=C(C=C3)Cl)Cl
DM96KF7	IK	ZFWNCCCNZIYJAQ-UHFFFAOYSA-N
DM96KF7	IU	1-[4-acetyl-2-[(3-hydroxypyrrolidin-1-yl)methyl]piperazin-1-yl]-2-(3,4-dichlorophenyl)ethanone
DM96KF7	CA	CAS 133407-20-2
DM96KF7	DE	Pain

DMAHNF6	ID	DMAHNF6
DMAHNF6	DN	GR-95168
DMAHNF6	HS	Terminated
DMAHNF6	SN	GR-91568
DMAHNF6	CP	Glaxo Group Research Ltd
DMAHNF6	DE	Virus infection

DMPSZR0	ID	DMPSZR0
DMPSZR0	DN	GS-2992
DMPSZR0	HS	Terminated
DMPSZR0	CP	Gilead Sciences Inc
DMPSZR0	DE	Human immunodeficiency virus infection

DMV7JC6	ID	DMV7JC6
DMV7JC6	DN	GS-3435
DMV7JC6	HS	Terminated
DMV7JC6	CP	Gilead Sciences Inc
DMV7JC6	PC	11150691
DMV7JC6	MW	298.77
DMV7JC6	FM	C13H19ClN4O2
DMV7JC6	IC	InChI=1S/C13H19ClN4O2/c1-13(2,3)20-12(19)18-8-6-17(7-9-18)11-10(14)15-4-5-16-11/h4-5H,6-9H2,1-3H3
DMV7JC6	CS	CC(C)(C)OC(=O)N1CCN(CC1)C2=NC=CN=C2Cl
DMV7JC6	IK	IJINSJSWDSHUBL-UHFFFAOYSA-N
DMV7JC6	IU	tert-butyl 4-(3-chloropyrazin-2-yl)piperazine-1-carboxylate
DMV7JC6	CA	CAS 313654-83-0
DMV7JC6	DE	Influenza virus infection

DMT6S9B	ID	DMT6S9B
DMT6S9B	DN	GS-522
DMT6S9B	HS	Terminated
DMT6S9B	CP	Gilead Sciences Inc
DMT6S9B	PC	9898337
DMT6S9B	MW	1138.1
DMT6S9B	FM	C42H71N15O22
DMT6S9B	IC	InChI=1S/C42H71N15O22/c1-16(58)31(37(74)48-8-23(65)46-13-28(70)55-36(21(6)63)42(79)57-34(19(4)61)40(77)50-10-25(67)47-15-30(72)73)53-29(71)14-51-38(75)32(17(2)59)52-27(69)12-45-24(66)9-49-39(76)33(18(3)60)56-41(78)35(20(5)62)54-26(68)11-44-22(64)7-43/h16-21,31-36,58-63H,7-15,43H2,1-6H3,(H,44,64)(H,45,66)(H,46,65)(H,47,67)(H,48,74)(H,49,76)(H,50,77)(H,51,75)(H,52,69)(H,53,71)(H,54,68)(H,55,70)(H,56,78)(H,57,79)(H,72,73)/t16-,17-,18-,19-,20-,21-,31+,32+,33+,34+,35+,36+/m1/s1
DMT6S9B	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)NCC(=O)O)NC(=O)CNC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)CN)O
DMT6S9B	IK	QHRKUKVLFJBEQL-CPVSMZBNSA-N
DMT6S9B	IU	2-[[2-[[(2S,3R)-2-[[(2S,3R)-2-[[2-[[2-[[(2S,3R)-2-[[2-[[(2S,3R)-2-[[2-[[2-[[(2S,3R)-2-[[(2S,3R)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetic acid
DMT6S9B	DE	Thrombosis

DMCYZL3	ID	DMCYZL3
DMCYZL3	DN	GS-9148
DMCYZL3	HS	Terminated
DMCYZL3	SN	GS-9131; Nucleoside reverse transcriptase inhibitor (HIV infection), Gilead Sciences; Mono-amidate prodrug of GS-9148 (HIV infection), Gilead
DMCYZL3	CP	Gilead Sciences Inc
DMCYZL3	DT	Small molecular drug
DMCYZL3	PC	15958718
DMCYZL3	MW	331.2
DMCYZL3	FM	C10H11FN5O5P
DMCYZL3	IC	InChI=1S/C10H11FN5O5P/c11-5-1-6(20-4-22(17,18)19)21-10(5)16-3-15-7-8(12)13-2-14-9(7)16/h1-3,6,10H,4H2,(H2,12,13,14)(H2,17,18,19)/t6-,10+/m0/s1
DMCYZL3	CS	C1=C([C@@H](O[C@@H]1OCP(=O)(O)O)N2C=NC3=C(N=CN=C32)N)F
DMCYZL3	IK	MPSGQQOHTJUJKB-QUBYGPBYSA-N
DMCYZL3	IU	[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethylphosphonic acid
DMCYZL3	CA	CAS 875608-25-6
DMCYZL3	DE	Human immunodeficiency virus infection

DMQSMB1	ID	DMQSMB1
DMQSMB1	DN	GS-9160
DMQSMB1	HS	Terminated
DMQSMB1	SN	GS-9160; GS9160; N-[7-(4-Fluorobenzyl)-9-Hydroxy-8-Oxo-7,8-Dihydro-6h-Pyrrolo[3,4-G]quinolin-5-Yl]-N-Methylmethanesulfonamide; N-(7-(4-fluorobenzyl)-9-hydroxy-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-5-yl)-N-methylmethanesulfonamide; SCHEMBL4652222; CHEMBL513189; RJWBOLLTMJMYNV-UHFFFAOYSA-N; ZINC35078403; GS 9160; 915407-80-6; ZZV; N-[7-[(4-fluorophenyl)methyl]-9-hydroxy-8-oxo-6H-pyrrolo[3,4-g]quinolin-5-yl]-N-methyl-methanesulfonamide; Methanesulfonamide, N-(7-((4-fluorophenyl)methyl)-7,8-dihydro-9-hydroxy-8-oxo-6H
DMQSMB1	CP	Gilead Sciences Inc
DMQSMB1	DT	Small molecular drug
DMQSMB1	PC	16097721
DMQSMB1	MW	415.4
DMQSMB1	FM	C20H18FN3O4S
DMQSMB1	IC	InChI=1S/C20H18FN3O4S/c1-23(29(2,27)28)18-14-4-3-9-22-17(14)19(25)16-15(18)11-24(20(16)26)10-12-5-7-13(21)8-6-12/h3-9,25H,10-11H2,1-2H3
DMQSMB1	CS	CN(C1=C2CN(C(=O)C2=C(C3=C1C=CC=N3)O)CC4=CC=C(C=C4)F)S(=O)(=O)C
DMQSMB1	IK	RJWBOLLTMJMYNV-UHFFFAOYSA-N
DMQSMB1	IU	N-[7-[(4-fluorophenyl)methyl]-9-hydroxy-8-oxo-6H-pyrrolo[3,4-g]quinolin-5-yl]-N-methylmethanesulfonamide
DMQSMB1	CA	CAS 915407-80-6
DMQSMB1	DE	Human immunodeficiency virus infection

DMOALVR	ID	DMOALVR
DMOALVR	DN	GSK-2485852
DMOALVR	HS	Terminated
DMOALVR	SN	GL-60667; GSK-2485852A; NVP-LDI133; HCV RNA polymerase inhibitors, Genelabs/Novartis; NS5b non-nucleoside inhibitors (HCV infection), GSK/Novartis; NS5b non-nucleoside inhibitors (HCV), Genelabs/Novartis
DMOALVR	CP	Genelabs Technologies Inc
DMOALVR	PC	53354790
DMOALVR	MW	554.4
DMOALVR	FM	C27H25BF2N2O6S
DMOALVR	IC	InChI=1S/C27H25BF2N2O6S/c1-31-27(33)25-20-12-19(16-4-5-16)23(13-24(20)38-26(25)17-6-8-18(29)9-7-17)32(39(2,36)37)14-15-3-10-21(28(34)35)22(30)11-15/h3,6-13,16,34-35H,4-5,14H2,1-2H3,(H,31,33)
DMOALVR	CS	B(C1=C(C=C(C=C1)CN(C2=C(C=C3C(=C2)OC(=C3C(=O)NC)C4=CC=C(C=C4)F)C5CC5)S(=O)(=O)C)F)(O)O
DMOALVR	IK	GDSKPIAEYNJODX-UHFFFAOYSA-N
DMOALVR	IU	[4-[[[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl]-methylsulfonylamino]methyl]-2-fluorophenyl]boronic acid
DMOALVR	CA	CAS 1331942-30-3
DMOALVR	DE	Hepatitis C virus infection

DMMYUWT	ID	DMMYUWT
DMMYUWT	DN	GSK-923295
DMMYUWT	HS	Terminated
DMMYUWT	SN	1088965-37-0; GSK-923295; GSK923295; 3-Chloro-N-((S)-1-(2-(dimethylamino)acetamido)-3-(4-(8-((S)-1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl)phenyl)propan-2-yl)-4-isopropoxybenzamide; 3-Chloro-N-((S)-1-(2-(dimethylamino)acetamido)-3-(4-(8-((S)-1-hydroxyethyl)-imidazo[1,2-a]pyridin-2-yl)phenyl)propan-2-yl)-4-isopropoxybenzamide; GSK 923295; MLS006011170; SCHEMBL1492164; UNII-072702W9QD; CTK8C0600; DTXSID50677145; GSK-295; AOB5937; EX-A633; MolPort-023-332-816; GSK-923295A; BCP09858; ANW-64945; s7090; ZINC68151184; AKOS016005270
DMMYUWT	CP	GlaxoSmithKline
DMMYUWT	TC	Anticancer Agents
DMMYUWT	DT	Small molecular drug
DMMYUWT	PC	46898058
DMMYUWT	MW	592.1
DMMYUWT	FM	C32H38ClN5O4
DMMYUWT	IC	InChI=1S/C32H38ClN5O4/c1-20(2)42-29-13-12-24(16-27(29)33)32(41)35-25(17-34-30(40)19-37(4)5)15-22-8-10-23(11-9-22)28-18-38-14-6-7-26(21(3)39)31(38)36-28/h6-14,16,18,20-21,25,39H,15,17,19H2,1-5H3,(H,34,40)(H,35,41)/t21-,25-/m0/s1
DMMYUWT	CS	C[C@@H](C1=CC=CN2C1=NC(=C2)C3=CC=C(C=C3)C[C@@H](CNC(=O)CN(C)C)NC(=O)C4=CC(=C(C=C4)OC(C)C)Cl)O
DMMYUWT	IK	WHMXDBPHBVLYRC-OFVILXPXSA-N
DMMYUWT	IU	3-chloro-N-[(2S)-1-[[2-(dimethylamino)acetyl]amino]-3-[4-[8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl]phenyl]propan-2-yl]-4-propan-2-yloxybenzamide
DMMYUWT	CA	CAS 1088965-37-0
DMMYUWT	DE	Solid tumour/cancer

DMA6RL2	ID	DMA6RL2
DMA6RL2	DN	GT-16-239
DMA6RL2	HS	Terminated
DMA6RL2	CP	GelTex Pharmaceuticals Inc
DMA6RL2	DE	Arteriosclerosis

DM42XHS	ID	DM42XHS
DM42XHS	DN	GT-2016
DM42XHS	HS	Terminated
DM42XHS	SN	GT 2016; GT-2016; CHEMBL14812; 152241-24-2; SCHEMBL3395544; BDBM86490; MolPort-023-276-421; ZINC1537834; PDSP2_001477; PDSP1_001493; AKOS024457088; API0010299; NCGC00371075-01; LS-193753; L009653
DM42XHS	DT	Small molecular drug
DM42XHS	PC	9839975
DM42XHS	MW	317.5
DM42XHS	FM	C19H31N3O
DM42XHS	IC	InChI=1S/C19H31N3O/c23-19(9-5-4-8-16-6-2-1-3-7-16)22-12-10-17(11-13-22)18-14-20-15-21-18/h14-17H,1-13H2,(H,20,21)
DM42XHS	CS	C1CCC(CC1)CCCCC(=O)N2CCC(CC2)C3=CN=CN3
DM42XHS	IK	YTCGNPGLMAECND-UHFFFAOYSA-N
DM42XHS	IU	5-cyclohexyl-1-[4-(1H-imidazol-5-yl)piperidin-1-yl]pentan-1-one
DM42XHS	DE	Alzheimer disease

DMJ4PNR	ID	DMJ4PNR
DMJ4PNR	DN	GT-2203
DMJ4PNR	HS	Terminated
DMJ4PNR	SN	GT-2144; GT-2204; GT-2223; GT-2328; GT-2396; GT-2397; GT-2431; H3 agonists, Gliatech
DMJ4PNR	CP	Gliatech Inc
DMJ4PNR	PC	10103168
DMJ4PNR	MW	123.16
DMJ4PNR	FM	C6H9N3
DMJ4PNR	IC	InChI=1S/C6H9N3/c7-5-1-4(5)6-2-8-3-9-6/h2-5H,1,7H2,(H,8,9)/t4-,5-/m1/s1
DMJ4PNR	CS	C1[C@H]([C@@H]1N)C2=CN=CN2
DMJ4PNR	IK	OWWNABDDYQLERE-RFZPGFLSSA-N
DMJ4PNR	IU	(1R,2R)-2-(1H-imidazol-5-yl)cyclopropan-1-amine
DMJ4PNR	DE	Anxiety disorder

DMGSN1V	ID	DMGSN1V
DMGSN1V	DN	GW-275175
DMGSN1V	HS	Terminated
DMGSN1V	SN	CMV therapy, Glaxo Wellcome; GW-275175X
DMGSN1V	CP	Glaxo Wellcome plc
DMGSN1V	DE	Virus infection

DMUG82P	ID	DMUG82P
DMUG82P	DN	GW-278884
DMUG82P	HS	Terminated
DMUG82P	SN	BW-668W95; 668W95
DMUG82P	CP	Glaxo Wellcome plc
DMUG82P	DE	Colorectal cancer

DMSZH0I	ID	DMSZH0I
DMSZH0I	DN	GW-3600
DMSZH0I	HS	Terminated
DMSZH0I	SN	Phosphodiesterase 4 inhibitor, Glaxo
DMSZH0I	CP	GlaxoSmithKline Inc
DMSZH0I	PC	9842576
DMSZH0I	MW	375.5
DMSZH0I	FM	C21H29NO5
DMSZH0I	IC	InChI=1S/C21H29NO5/c1-14(23)21(2)13-22(20(24)26-4)12-17(21)15-9-10-18(25-3)19(11-15)27-16-7-5-6-8-16/h9-11,16-17H,5-8,12-13H2,1-4H3/t17-,21-/m0/s1
DMSZH0I	CS	CC(=O)[C@@]1(CN(C[C@H]1C2=CC(=C(C=C2)OC)OC3CCCC3)C(=O)OC)C
DMSZH0I	IK	YTFBNFMILWHYAP-UWJYYQICSA-N
DMSZH0I	IU	methyl (3S,4S)-3-acetyl-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methylpyrrolidine-1-carboxylate
DMSZH0I	DE	Asthma

DMG5A1Z	ID	DMG5A1Z
DMG5A1Z	DN	GW-660511
DMG5A1Z	HS	Terminated
DMG5A1Z	SN	GW-660511X; Z-13752A
DMG5A1Z	CP	Zambon Co SpA
DMG5A1Z	DE	Hypertension

DMPLYHU	ID	DMPLYHU
DMPLYHU	DN	GW-974
DMPLYHU	HS	Terminated
DMPLYHU	SN	GW-282974; GW-2974; GW-449; GW-734; GW-9263; Erb B-2 inhibitor, Glaxo Wellcome
DMPLYHU	CP	Glaxo Wellcome plc
DMPLYHU	PC	6603857
DMPLYHU	MW	395.5
DMPLYHU	FM	C23H21N7
DMPLYHU	IC	InChI=1S/C23H21N7/c1-29(2)22-11-19-20(13-24-22)25-15-26-23(19)28-18-8-9-21-17(10-18)12-27-30(21)14-16-6-4-3-5-7-16/h3-13,15H,14H2,1-2H3,(H,25,26,28)
DMPLYHU	CS	CN(C)C1=NC=C2C(=C1)C(=NC=N2)NC3=CC4=C(C=C3)N(N=C4)CC5=CC=CC=C5
DMPLYHU	IK	DYYZXRCFCVDSKD-UHFFFAOYSA-N
DMPLYHU	IU	4-N-(1-benzylindazol-5-yl)-6-N,6-N-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine
DMPLYHU	CA	CAS 202272-68-2
DMPLYHU	CB	CHEBI:95273
DMPLYHU	DE	Breast cancer

DM3YG5P	ID	DM3YG5P
DM3YG5P	DN	GYKI-52466
DM3YG5P	HS	Terminated
DM3YG5P	SN	Gyki-52466; 102771-26-6; GYKI 52466; UNII-471V8NZ5X3; GYKI 52466 HCl; CHEMBL275006; CHEBI:79560; 471V8NZ5X3; 1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline; 4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine; Benzenamine,4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-; Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-; C17H15N3O2
DM3YG5P	DT	Small molecular drug
DM3YG5P	PC	3538
DM3YG5P	MW	293.32
DM3YG5P	FM	C17H15N3O2
DM3YG5P	IC	InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3
DM3YG5P	CS	CC1=NN=C(C2=CC3=C(C=C2C1)OCO3)C4=CC=C(C=C4)N
DM3YG5P	IK	LFBZZHVSGAHQPP-UHFFFAOYSA-N
DM3YG5P	IU	4-(8-methyl-9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline
DM3YG5P	CA	CAS 102771-26-6
DM3YG5P	CB	CHEBI:79560
DM3YG5P	DE	Alzheimer disease

DMC0JN8	ID	DMC0JN8
DMC0JN8	DN	GYKI-53655
DMC0JN8	HS	Terminated
DMC0JN8	SN	GYKI-53655; Gyki 53655; GYKI53655; 1-(4-AMINOPHENYL)-3-METHYLCARBAMOYL-4-METHYL-7,8-METHYLENEDIOXY-3,4-DIHYDRO-5H-2,3-BENZODIAZEPINE; 143692-18-6; CHEMBL267450; LY 300168; SMGACXZFVXKEAX-UHFFFAOYSA-N; AC1L2QV0; GYKI-53655 free base; MLS006010331; SCHEMBL351325; GTPL4209; DTXSID30276296; MolPort-006-418-196; BCP27661; BDBM50048386; ABP000447; NCGC00263113-03; NCGC00263113-01; SMR004701394; LY300168; LY-300168; FT-0765288; LY 300168(GYKI 53655); LY-300168, (+/-)-; 7H-1,3-Dioxolo(4,5-H)(2,3)benzodiazepine-7-carboxamide, 5-(4-aminopheny
DMC0JN8	DT	Small molecular drug
DMC0JN8	PC	126758
DMC0JN8	MW	352.4
DMC0JN8	FM	C19H20N4O3
DMC0JN8	IC	InChI=1S/C19H20N4O3/c1-11-7-13-8-16-17(26-10-25-16)9-15(13)18(22-23(11)19(24)21-2)12-3-5-14(20)6-4-12/h3-6,8-9,11H,7,10,20H2,1-2H3,(H,21,24)
DMC0JN8	CS	CC1CC2=CC3=C(C=C2C(=NN1C(=O)NC)C4=CC=C(C=C4)N)OCO3
DMC0JN8	IK	SMGACXZFVXKEAX-UHFFFAOYSA-N
DMC0JN8	IU	5-(4-aminophenyl)-N,8-dimethyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide
DMC0JN8	CA	CAS 143692-18-6

DM904UQ	ID	DM904UQ
DM904UQ	DN	H-216/44
DM904UQ	HS	Terminated
DM904UQ	SN	108495-27-8; 1-Piperidinecarboxamide,N-[2-[[3-[4-[2-[2-(cyclopropylmethoxy)ethoxy]ethyl]phenoxy]-2-hydroxypropyl]amino]ethyl]-4-hydroxy-; H 21644; ACMC-20mbju; AC1L2WUQ; H 216-44; H-216-44; H-216/44; CHEMBL151651; CTK4A6062; L002328; N-[2-[[3-[4-[2-[2-(cyclopropylmethoxy)ethoxy]ethyl]phenoxy]-2-hydroxypropyl]amino]ethyl]-4-hydroxypiperidine-1-carboxamide; 1-Piperidinecarboxamide, N-(2-((3-(4-(2-(2-(cyclopropylmethoxy)ethoxy)ethyl)phenoxy)-2-hydroxypropyl)amino)ethyl)-4-hydroxy-
DM904UQ	CP	Astra AB
DM904UQ	DT	Small molecular drug
DM904UQ	PC	130141
DM904UQ	MW	479.6
DM904UQ	FM	C25H41N3O6
DM904UQ	IC	InChI=1S/C25H41N3O6/c29-22-7-12-28(13-8-22)25(31)27-11-10-26-17-23(30)19-34-24-5-3-20(4-6-24)9-14-32-15-16-33-18-21-1-2-21/h3-6,21-23,26,29-30H,1-2,7-19H2,(H,27,31)
DM904UQ	CS	C1CC1COCCOCCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCC(CC3)O)O
DM904UQ	IK	IWACLEHDBMHXHC-UHFFFAOYSA-N
DM904UQ	IU	N-[2-[[3-[4-[2-[2-(cyclopropylmethoxy)ethoxy]ethyl]phenoxy]-2-hydroxypropyl]amino]ethyl]-4-hydroxypiperidine-1-carboxamide
DM904UQ	CA	CAS 108495-27-8
DM904UQ	DE	Glaucoma/ocular hypertension

DMMCI4H	ID	DMMCI4H
DMMCI4H	DN	HELENALIN
DMMCI4H	HS	Terminated
DMMCI4H	SN	HELENALIN; 6754-13-8; PF 56; Helenalin A; HSDB 3490; NSC85236; UNII-4GUY9L896T; NSC 85236; BRN 0028081; MLS000728512; CHEBI:5635; 4GUY9L896T; 6alpha,8beta-Dihydroxy-4-oxoambrosa-2,11(13)-dien-12-oic acid 12,8-lactone; SMR000445626; Ambrosa-2,11(13)-dien-12-oic acid, 6alpha,8beta-dihydroxy-4-oxo-, 12,8-lactone; (3aR,5R,5aR,8aR,9S,9aS)-9-hydroxy-5,8a-dimethyl-1-methylene-3a,4,5,5a,9,9a-hexahydroazuleno[6,7-b]furan-2,8-dione; Azuleno(6,5-b)furan-2,5-dione, 3,3a,4,4a,7a,8,9,9a-octahydro-4-hydroxy-4a,8-dimethyl-3-methylene-, (3
DMMCI4H	DT	Small molecular drug
DMMCI4H	PC	23205
DMMCI4H	MW	262.3
DMMCI4H	FM	C15H18O4
DMMCI4H	IC	InChI=1S/C15H18O4/c1-7-6-10-12(8(2)14(18)19-10)13(17)15(3)9(7)4-5-11(15)16/h4-5,7,9-10,12-13,17H,2,6H2,1,3H3/t7-,9+,10-,12-,13+,15+/m1/s1
DMMCI4H	CS	C[C@@H]1C[C@@H]2[C@H]([C@@H]([C@]3([C@H]1C=CC3=O)C)O)C(=C)C(=O)O2
DMMCI4H	IK	ZVLOPMNVFLSSAA-XEPQRQSNSA-N
DMMCI4H	IU	(3aR,5R,5aR,8aR,9S,9aS)-9-hydroxy-5,8a-dimethyl-1-methylidene-3a,4,5,5a,9,9a-hexahydroazuleno[6,7-b]furan-2,8-dione
DMMCI4H	CA	CAS 6754-13-8
DMMCI4H	CB	CHEBI:5635

DM5HMZW	ID	DM5HMZW
DM5HMZW	DN	Hementin
DM5HMZW	HS	Terminated
DM5HMZW	SN	EMD-66777; Hementin, Biopharm
DM5HMZW	CP	Biopharm (UK) Ltd
DM5HMZW	DE	Thrombosis

DMMXG2I	ID	DMMXG2I
DMMXG2I	DN	Heparin-EGF-like factor
DMMXG2I	HS	Terminated
DMMXG2I	SN	HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova
DMMXG2I	CP	Scios Inc
DMMXG2I	DE	Gastrointestinal disease

DMGAKD8	ID	DMGAKD8
DMGAKD8	DN	HIMBACINE
DMGAKD8	HS	Terminated
DMGAKD8	SN	Himbacine; UNII-M17C7V122D; NSC 23969; HIMBAFCINE; CHEMBL277642; CHEBI:5720; (+)-himbacine; M17C7V122D; 6879-74-9; Naphtho(2,3-c)furan-1(3H)-one, decahydro-4-(2-(1,6-dimethyl-2-piperidinyl)ethenyl)-3-methyl-,(3S-(3-alpha,3a-alpha,4-beta(1E,2(2R*,6S*)),4a-beta,8a-alpha,9a-alpha))-; AC1O5LBZ; GTPL324; SCHEMBL194692; BDBM50076089; CCG-208219; NCGC00163249-01; LS-95329; SR-05000002338; SR-05000002338-2; 4-[2-(1,6-Dimethyl-piperidin-2-yl)-vinyl]-3-methyl-decahydro-naphtho[2,3-c]furan-1-one
DMGAKD8	DT	Small molecular drug
DMGAKD8	PC	6436265
DMGAKD8	MW	345.5
DMGAKD8	FM	C22H35NO2
DMGAKD8	IC	InChI=1S/C22H35NO2/c1-14-7-6-9-17(23(14)3)11-12-19-18-10-5-4-8-16(18)13-20-21(19)15(2)25-22(20)24/h11-12,14-21H,4-10,13H2,1-3H3/b12-11+/t14-,15-,16+,17+,18-,19+,20-,21+/m0/s1
DMGAKD8	CS	C[C@H]1CCC[C@@H](N1C)/C=C/[C@@H]2[C@H]3CCCC[C@@H]3C[C@H]4[C@@H]2[C@@H](OC4=O)C
DMGAKD8	IK	FMPNFDSPHNUFOS-LPJDIUFZSA-N
DMGAKD8	IU	(3S,3aR,4R,4aS,8aR,9aS)-4-[(E)-2-[(2R,6S)-1,6-dimethylpiperidin-2-yl]ethenyl]-3-methyl-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f][2]benzofuran-1-one
DMGAKD8	CA	CAS 6879-74-9
DMGAKD8	CB	CHEBI:5720

DM784QJ	ID	DM784QJ
DM784QJ	DN	Hirufaxin
DM784QJ	HS	Terminated
DM784QJ	CP	Savient Pharmaceuticals Inc
DM784QJ	DE	Thrombosis

DMCHFIT	ID	DMCHFIT
DMCHFIT	DN	HMR-3787
DMCHFIT	HS	Terminated
DMCHFIT	SN	11-Deoxy-3-des(hexopyranosyloxy)-2-fluoro-11-[4-(3H-imidazo[4,5-b]pyridin-3-yl)butylamino]-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate
DMCHFIT	DT	Small molecular drug
DMCHFIT	PC	6918384
DMCHFIT	MW	804
DMCHFIT	FM	C41H62FN5O10
DMCHFIT	IC	InChI=1S/C41H62FN5O10/c1-12-29-41(8)32(47(38(52)57-41)19-14-13-18-46-22-44-27-16-15-17-43-35(27)46)25(4)30(48)23(2)21-39(6,53-11)34(26(5)33(50)40(7,42)37(51)55-29)56-36-31(49)28(45(9)10)20-24(3)54-36/h15-17,22-26,28-29,31-32,34,36,49H,12-14,18-21H2,1-11H3/t23-,24-,25+,26+,28+,29-,31-,32-,34-,36+,39-,40+,41-/m1/s1
DMCHFIT	CS	CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@](C(=O)O1)(C)F)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=NC5=C4N=CC=C5)C
DMCHFIT	IK	NRYQCCZBHGMXIN-SAWHFZNOSA-N
DMCHFIT	IU	(1S,2R,5S,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-5-fluoro-15-(4-imidazo[4,5-b]pyridin-3-ylbutyl)-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMCHFIT	DE	Bacterial infection

DML0B97	ID	DML0B97
DML0B97	DN	HOE-694
DML0B97	HS	Terminated
DML0B97	SN	141923-47-9; 3-METHYLSULFONYL-4-PIPERIDIN-1-YLBENZOYL GUANIDINE; HOE694; AC1L3XEA; CHEMBL62231; SCHEMBL3906516; CTK4C2847; ZINC3915646; AKOS030541973; KB-236684; TX-016775; 3-methylsulphonyl-4-piperidinobenzoyl-guanidine
DML0B97	DT	Small molecular drug
DML0B97	PC	123841
DML0B97	MW	324.4
DML0B97	FM	C14H20N4O3S
DML0B97	IC	InChI=1S/C14H20N4O3S/c1-22(20,21)12-9-10(13(19)17-14(15)16)5-6-11(12)18-7-3-2-4-8-18/h5-6,9H,2-4,7-8H2,1H3,(H4,15,16,17,19)
DML0B97	CS	CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)N2CCCCC2
DML0B97	IK	WITSYJHGEIZBQU-UHFFFAOYSA-N
DML0B97	IU	N-(diaminomethylidene)-3-methylsulfonyl-4-piperidin-1-ylbenzamide
DML0B97	DE	Heart arrhythmia

DMHP9WV	ID	DMHP9WV
DMHP9WV	DN	HOMOEPIBATIDINE
DMHP9WV	HS	Terminated
DMHP9WV	SN	homoepibatidine; CHEMBL94427; CHEMBL535389; BDBM50194073; BDBM50194070
DMHP9WV	DT	Small molecular drug
DMHP9WV	PC	44327552
DMHP9WV	MW	222.71
DMHP9WV	FM	C12H15ClN2
DMHP9WV	IC	InChI=1S/C12H15ClN2/c13-12-5-4-8(7-14-12)10-6-9-2-1-3-11(10)15-9/h4-5,7,9-11,15H,1-3,6H2
DMHP9WV	CS	C1CC2CC(C(C1)N2)C3=CN=C(C=C3)Cl
DMHP9WV	IK	GDSORCYTZJIZHU-UHFFFAOYSA-N
DMHP9WV	IU	6-(6-chloropyridin-3-yl)-8-azabicyclo[3.2.1]octane

DMEZ5P2	ID	DMEZ5P2
DMEZ5P2	DN	HRC-101
DMEZ5P2	HS	Terminated
DMEZ5P2	SN	Oxygain; HML-109
DMEZ5P2	CP	Ontario Inc
DMEZ5P2	DE	Blood transfusion

DMJACXN	ID	DMJACXN
DMJACXN	DN	HRC-102
DMJACXN	HS	Terminated
DMJACXN	SN	Hemolox T; HML-110
DMJACXN	CP	Ontario Inc
DMJACXN	DE	Reperfusion injury

DM5A3GX	ID	DM5A3GX
DM5A3GX	DN	HRC-201
DM5A3GX	HS	Terminated
DM5A3GX	SN	Hemoglobin-imaging conjugate (HepSelect), Hemosol
DM5A3GX	CP	Ontario Inc
DM5A3GX	DE	Liver cancer

DMQINWF	ID	DMQINWF
DMQINWF	DN	HT-90B
DMQINWF	HS	Terminated
DMQINWF	CP	Chugai Pharmaceutical Co Ltd
DMQINWF	PC	9886379
DMQINWF	MW	384.5
DMQINWF	FM	C23H32N2O3
DMQINWF	IC	InChI=1S/C23H32N2O3/c1-15-3-2-4-20-21(15)28-19(14-27-20)13-24-5-6-25-22(26)23-10-16-7-17(11-23)9-18(8-16)12-23/h2-4,16-19,24H,5-14H2,1H3,(H,25,26)
DMQINWF	CS	CC1=C2C(=CC=C1)OCC(O2)CNCCNC(=O)C34CC5CC(C3)CC(C5)C4
DMQINWF	IK	QKQSDPQVNKEJPX-UHFFFAOYSA-N
DMQINWF	IU	N-[2-[(5-methyl-2,3-dihydro-1,4-benzodioxin-3-yl)methylamino]ethyl]adamantane-1-carboxamide
DMQINWF	DE	Anxiety disorder

DMK1VHF	ID	DMK1VHF
DMK1VHF	DN	Hu Dreg 55
DMK1VHF	HS	Terminated
DMK1VHF	SN	SMART Anti-L-Selectin
DMK1VHF	CP	PDL BioPharma
DMK1VHF	DT	Antibody
DMK1VHF	DE	Psoriasis vulgaris

DMTGCA6	ID	DMTGCA6
DMTGCA6	DN	HuCD40L
DMTGCA6	HS	Terminated
DMTGCA6	SN	Avrend; CD40 ligand, Celldex; CD40 ligand, Immunex; HuCD40L, Immunex
DMTGCA6	CP	Amgen
DMTGCA6	DE	Solid tumour/cancer

DMA7EFM	ID	DMA7EFM
DMA7EFM	DN	Human chorionic gonadotropin
DMA7EFM	HS	Terminated
DMA7EFM	SN	Human chorionic gonadotropin (heart disease); HCG (heart disease), Stem Cell Therapeutics; Human chorionic gonadotropin (heart disease), Stem Cell Therapeutics
DMA7EFM	CP	Stem Cell Therapeutics Corp
DMA7EFM	SQ	Alpha Chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>    <sequence format="FASTA">&gt;Beta ChainSKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ
DMA7EFM	DE	Heart disease

DMFVB7Z	ID	DMFVB7Z
DMFVB7Z	DN	HuMax-HepC
DMFVB7Z	HS	Terminated
DMFVB7Z	SN	E2-hmAb; HCV-specific antibody, Genmab; Hepatitis C virus-specific antibody, Connex/INSERM
DMFVB7Z	CP	Genmab A/S
DMFVB7Z	DT	Antibody
DMFVB7Z	DE	Hepatitis C virus infection

DM8BSF3	ID	DM8BSF3
DM8BSF3	DN	HuMax-TAC
DM8BSF3	HS	Terminated
DM8BSF3	SN	Anti-IL-2R antibody, Genmab/Merck Serono
DM8BSF3	CP	Genmab A/S
DM8BSF3	DT	Antibody
DM8BSF3	DE	Autoimmune diabetes

DM37KVY	ID	DM37KVY
DM37KVY	DN	HY-12638
DM37KVY	HS	Discontinued
DM37KVY	SN	Anthiphen; Dichlorophen; Antifen; Antiphen; Cordocel; Dicestal; Dichloorfeen; Dichlorofen; Dichlorophen B; Dichlorophene 10; Dichlorphen; Didroxan; Didroxane; Difentan; Diphenthane 70; Embephen; Fungicide GM; Fungicide M; Gingivit; Halenol; Hyosan; Korium; Palacel; Panacide; Parabis; Plath-Lyse; Prevental; Preventol GD; Preventol GDC; Sandocide; Super mosstox; Taeniatol; Teniathane; Teniatol; Teniotol; Trivex; Vermithana; Wespuril; dichlorophene; 2,2'-Methylenebis(4-chlorophenol); 97-23-4; Bis(5-chloro-2-hydroxyphenyl)methane; DDDM; Gefir
DM37KVY	PC	3037
DM37KVY	MW	269.12
DM37KVY	FM	C13H10Cl2O2
DM37KVY	IC	MDNWOSOZYLHTCG-UHFFFAOYSA-N
DM37KVY	CS	C1=CC(=C(C=C1Cl)CC2=C(C=CC(=C2)Cl)O)O
DM37KVY	IK	1S/C13H10Cl2O2/c14-10-1-3-12(16)8(6-10)5-9-7-11(15)2-4-13(9)17/h1-4,6-7,16-17H,5H2
DM37KVY	IU	4-chloro-2-[(5-chloro-2-hydroxyphenyl)methyl]phenol
DM37KVY	CA	CAS 97-23-4
DM37KVY	CB	CHEBI:34689
DM37KVY	DE	Tapeworm infestation

DM4HA9C	ID	DM4HA9C
DM4HA9C	DN	HydrocoDex
DM4HA9C	HS	Terminated
DM4HA9C	SN	Acetaminophen/dextromethorphan
DM4HA9C	CP	Endo Pharmaceuticals
DM4HA9C	DE	Pain

DM1C4IG	ID	DM1C4IG
DM1C4IG	DN	ICA-1
DM1C4IG	HS	Terminated
DM1C4IG	SN	PKC-iota inhibitor (cancer), Inhibition therapeutics
DM1C4IG	CP	AlumiFuel Power Corp
DM1C4IG	PC	71510744
DM1C4IG	MW	336.24
DM1C4IG	FM	C10H17N4O7P
DM1C4IG	IC	InChI=1S/C10H17N4O7P/c11-9-6(10(12)17)13-3-14(9)5-1-4(7(15)8(5)16)2-21-22(18,19)20/h3-5,7-8,15-16H,1-2,11H2,(H2,12,17)(H2,18,19,20)/t4-,5-,7-,8+/m0/s1
DM1C4IG	CS	C1[C@H]([C@@H]([C@@H]([C@H]1N2C=NC(=C2N)C(=O)N)O)O)COP(=O)(O)O
DM1C4IG	IK	VFGPDCAAUMRRSL-BKMCOVHNSA-N
DM1C4IG	IU	[(1S,2S,3R,4S)-4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl]methyl dihydrogen phosphate
DM1C4IG	DE	Solid tumour/cancer

DMYN3WG	ID	DMYN3WG
DMYN3WG	DN	ICI-164384
DMYN3WG	HS	Terminated
DMYN3WG	SN	Ici 164384; ICI-164384; 98007-99-9; UNII-84LT43726C; ICI M164384; ICI 164,384; CHEMBL1222035; N-n-Butyl-N-methyl-11-(3,17beta-dihydroxyestra-1,3,5(10)-trien-7alpha-yl)undecanamide; 84LT43726C; N-BUTYL-11-[(7R,8R,9S,13S,14S,17S)-3,17-DIHYDROXY-13-METHYL-7,8,9,11,12,13,14,15,16,17-DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-7-YL]-N-METHYLUNDECANAMIDE; Estra-1,3,5(10)-triene-7-undecanamide, N-butyl-3,17-dihydroxy-N-methyl-, (7alpha,17beta)-; AOE
DMYN3WG	DT	Small molecular drug
DMYN3WG	PC	104772
DMYN3WG	MW	525.8
DMYN3WG	FM	C34H55NO3
DMYN3WG	IC	InChI=1S/C34H55NO3/c1-4-5-22-35(3)32(38)15-13-11-9-7-6-8-10-12-14-25-23-26-24-27(36)16-17-28(26)29-20-21-34(2)30(33(25)29)18-19-31(34)37/h16-17,24-25,29-31,33,36-37H,4-15,18-23H2,1-3H3/t25-,29-,30+,31+,33-,34+/m1/s1
DMYN3WG	CS	CCCCN(C)C(=O)CCCCCCCCCC[C@@H]1CC2=C(C=CC(=C2)O)[C@@H]3[C@@H]1[C@@H]4CC[C@@H]([C@]4(CC3)C)O
DMYN3WG	IK	BVVFOLSZMQVDKV-KXQIQQEYSA-N
DMYN3WG	IU	N-butyl-11-[(7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-yl]-N-methylundecanamide
DMYN3WG	CA	CAS 98007-99-9
DMYN3WG	DE	Breast cancer

DMQ0IOF	ID	DMQ0IOF
DMQ0IOF	DN	ICI-169369
DMQ0IOF	HS	Terminated
DMQ0IOF	SN	2-Detpq; Ici 169369; 2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline; 85273-95-6; Ici-169,369; UNII-4CT4CS5BA7; ICI-169369; 4CT4CS5BA7; N,N-dimethyl-2-(3-phenylquinolin-2-yl)sulfanylethanamine; Ethanamine, N,N-dimethyl-2-((3-phenyl-2-quinolinyl)thio)-; Ethanamine, N,N-dimethyl-2-[(3-phenyl-2-quinolinyl)thio]-; AC1L3UA4; GTPL273; AC1Q7E25; SCHEMBL2640021; CHEMBL1191534; CTK2I4265; BDBM84945; DTXSID40234468; 85273-96-7 (hydrochloride); n,n-dimethyl-2-[(3-phenylquinolin-2-yl)sulfanyl]ethanamine; ZINC5140456; PDSP2_001405
DMQ0IOF	CP	Zeneca Group plc
DMQ0IOF	DT	Small molecular drug
DMQ0IOF	PC	122265
DMQ0IOF	MW	308.4
DMQ0IOF	FM	C19H20N2S
DMQ0IOF	IC	InChI=1S/C19H20N2S/c1-21(2)12-13-22-19-17(15-8-4-3-5-9-15)14-16-10-6-7-11-18(16)20-19/h3-11,14H,12-13H2,1-2H3
DMQ0IOF	CS	CN(C)CCSC1=NC2=CC=CC=C2C=C1C3=CC=CC=C3
DMQ0IOF	IK	HYOLQGVNMQNERE-UHFFFAOYSA-N
DMQ0IOF	IU	N,N-dimethyl-2-(3-phenylquinolin-2-yl)sulfanylethanamine
DMQ0IOF	CA	CAS 85273-95-6
DMQ0IOF	DE	Anxiety disorder

DM0XU4P	ID	DM0XU4P
DM0XU4P	DN	ICI-181037
DM0XU4P	HS	Terminated
DM0XU4P	SN	ZM-181037
DM0XU4P	CP	Zeneca Group plc
DM0XU4P	DT	Small molecular drug
DM0XU4P	PC	5487455
DM0XU4P	MW	414.5
DM0XU4P	FM	C24H34N2O4
DM0XU4P	IC	InChI=1S/C24H34N2O4/c1-16(26(5)6)24(28,18-10-8-9-11-21(18)30-15-22(25)27)19-14-17(23(2,3)4)12-13-20(19)29-7/h8-14,16,28H,15H2,1-7H3,(H2,25,27)/t16-,24-/m1/s1
DM0XU4P	CS	C[C@H]([C@@](C1=CC=CC=C1OCC(=O)N)(C2=C(C=CC(=C2)C(C)(C)C)OC)O)N(C)C
DM0XU4P	IK	DLGGQRFVOGBFAX-VOIUYBSRSA-N
DM0XU4P	IU	2-[2-[(1R,2R)-1-(5-tert-butyl-2-methoxyphenyl)-2-(dimethylamino)-1-hydroxypropyl]phenoxy]acetamide
DM0XU4P	CA	CAS 138779-29-0
DM0XU4P	DE	Heart arrhythmia

DM0195G	ID	DM0195G
DM0195G	DN	ICI-198615
DM0195G	HS	Terminated
DM0195G	SN	Cyclopentyl N-[1-[[4-(benzenesulfonylcarbamoyl)-2-methoxyphenyl]methyl]indazol-6-yl]carbamate; Ici 198615; 104448-53-5; CHEMBL22033; Ici-198,615; ZM 198615; ZM-198,615; cyclopentyl N-[1-({4-[(benzenesulfonyl)carbamoyl]-2-methoxyphenyl}methyl)-1H-indazol-6-yl]carbamate; [3H]ICI198615; [3H]-ICI198615; [3H]ICI-198615; [3H]ICI-198,615; AC1L3GQZ; (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester; GTPL3414; GTPL3358; SCHEMBL9806720; DTXSID80146490; BDBM50009075; PDSP1_000520; PDSP2_000518; ICI198615
DM0195G	CP	Zeneca Group plc
DM0195G	DT	Small molecular drug
DM0195G	PC	115219
DM0195G	MW	548.6
DM0195G	FM	C28H28N4O6S
DM0195G	IC	InChI=1S/C28H28N4O6S/c1-37-26-15-19(27(33)31-39(35,36)24-9-3-2-4-10-24)11-12-21(26)18-32-25-16-22(14-13-20(25)17-29-32)30-28(34)38-23-7-5-6-8-23/h2-4,9-17,23H,5-8,18H2,1H3,(H,30,34)(H,31,33)
DM0195G	CS	COC1=C(C=CC(=C1)C(=O)NS(=O)(=O)C2=CC=CC=C2)CN3C4=C(C=CC(=C4)NC(=O)OC5CCCC5)C=N3
DM0195G	IK	YRCPIXCRSAKRGM-UHFFFAOYSA-N
DM0195G	IU	cyclopentyl N-[1-[[4-(benzenesulfonylcarbamoyl)-2-methoxyphenyl]methyl]indazol-6-yl]carbamate
DM0195G	CA	CAS 104448-53-5
DM0195G	DE	Asthma

DMDBICR	ID	DMDBICR
DMDBICR	DN	ICM-3
DMDBICR	HS	Terminated
DMDBICR	SN	ICAM-3 antibodies, ICOS; ICAM-R antibodies, ICOS
DMDBICR	CP	ICOS Corp
DMDBICR	DT	Antibody
DMDBICR	DE	Graft-versus-host disease

DMG1FQW	ID	DMG1FQW
DMG1FQW	DN	IDRA-21
DMG1FQW	HS	Terminated
DMG1FQW	SN	IDRA-21 analogs; IDRA-5
DMG1FQW	CP	Fidia-Georgetown Institute for the Neurosciences
DMG1FQW	DT	Small molecular drug
DMG1FQW	PC	3688
DMG1FQW	MW	232.69
DMG1FQW	FM	C8H9ClN2O2S
DMG1FQW	IC	InChI=1S/C8H9ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-5,10-11H,1H3
DMG1FQW	CS	CC1NC2=C(C=C(C=C2)Cl)S(=O)(=O)N1
DMG1FQW	IK	VZRNTCHTJRLTMU-UHFFFAOYSA-N
DMG1FQW	IU	7-chloro-3-methyl-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine 1,1-dioxide
DMG1FQW	CA	CAS 22503-72-6
DMG1FQW	CB	CHEBI:111162
DMG1FQW	DE	Alzheimer disease

DM16S98	ID	DM16S98
DM16S98	DN	IGE-026
DM16S98	HS	Terminated
DM16S98	SN	IgE inhibitors, Novartis; NVP-VAB-053; NVP-VAD-463
DM16S98	CP	Novartis AG
DM16S98	DE	Allergic rhinitis

DMBKZ4R	ID	DMBKZ4R
DMBKZ4R	DN	IGN-311
DMBKZ4R	HS	Terminated
DMBKZ4R	SN	HuABL-364; IGN-314; Anti-Lewis Y mAb (cancer), Igeneon
DMBKZ4R	CP	PDL BioPharma Inc
DMBKZ4R	DT	Antibody
DMBKZ4R	DE	Solid tumour/cancer

DMKS4Z9	ID	DMKS4Z9
DMKS4Z9	DN	IL1aQb
DMKS4Z9	HS	Terminated
DMKS4Z9	SN	IL1aQb therapeutic vaccines (atherosclerosis); CYT-018-IL1aQb; IL1aQb therapeuticvaccines (atherosclerosis), Cytos; Immunodrug vaccines (atherosclerosis), Cytos
DMKS4Z9	CP	Cytos Biotechnology AG
DMKS4Z9	DT	Vaccine
DMKS4Z9	DE	Arteriosclerosis

DMWTFO3	ID	DMWTFO3
DMWTFO3	DN	IMAZODAN
DMWTFO3	HS	Terminated
DMWTFO3	SN	IMAZODAN HYDROCHLORIDE; Imazodan HCl; CI-914; UNII-5EP74J9Q34; Imazodan hydrochloride [USAN]; 89198-09-4; 4,5-Dihydro-6-(p-imidazol-1-ylphenyl)-3(2H)-pyridazinone monohydrochloride; 5EP74J9Q34; 4,5-Dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-3(2H)-pyridazinone hydrochloride; Imazodan hydrochloride (USAN); 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-, monohydrochloride; 3(2H)-Pyridazinone, 4,5-dihydro-6-(p-(1-imidazolyl)phenyl)-, monohydrochloride; ACMC-20livl; AC1Q3ES0; C13H12N4O.HCl; SCHEMBL124243; AC1L1K29
DMWTFO3	DT	Small molecular drug
DMWTFO3	PC	55918
DMWTFO3	MW	240.26
DMWTFO3	FM	C13H12N4O
DMWTFO3	IC	InChI=1S/C13H12N4O/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17/h1-4,7-9H,5-6H2,(H,16,18)
DMWTFO3	CS	C1CC(=O)NN=C1C2=CC=C(C=C2)N3C=CN=C3
DMWTFO3	IK	VXMYWVMXSWJFCV-UHFFFAOYSA-N
DMWTFO3	IU	3-(4-imidazol-1-ylphenyl)-4,5-dihydro-1H-pyridazin-6-one
DMWTFO3	CA	CAS 84243-58-3

DMW39DV	ID	DMW39DV
DMW39DV	DN	INCB3344
DMW39DV	HS	Terminated
DMW39DV	SN	INCB-3268; INCB-3344; PF-4254196; CCR2 antagonists, Incyte/Pfizer
DMW39DV	CP	Incyte Corp
DMW39DV	DT	Small molecular drug
DMW39DV	PC	10008367
DMW39DV	MW	577.6
DMW39DV	FM	C29H34F3N3O6
DMW39DV	IC	InChI=1S/C29H34F3N3O6/c1-2-39-25-16-35(21-8-10-28(38,11-9-21)19-6-7-23-24(13-19)41-17-40-23)15-22(25)34-26(36)14-33-27(37)18-4-3-5-20(12-18)29(30,31)32/h3-7,12-13,21-22,25,38H,2,8-11,14-17H2,1H3,(H,33,37)(H,34,36)/t21?,22-,25-,28?/m0/s1
DMW39DV	CS	CCO[C@H]1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)C3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O
DMW39DV	IK	MZEOSVPWMSEFPW-XYCDVDSTSA-N
DMW39DV	IU	N-[2-[[(3S,4S)-1-[4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide
DMW39DV	DE	Arteriosclerosis

DMODQW0	ID	DMODQW0
DMODQW0	DN	INXC-ICAM1
DMODQW0	HS	Terminated
DMODQW0	SN	Antisense ICAM-1-TCS, Inex; ICAM-1 antisense (inflammation), INEX; Transmembrane carrier system (antisense ICAM-1), Inex; Antisense (ICAM-1, inflammation), INEX
DMODQW0	CP	Inex Pharmaceuticals Corp
DMODQW0	DT	Antisense drug
DMODQW0	DE	Transplant rejection

DMY3BMC	ID	DMY3BMC
DMY3BMC	DN	IPH-3102
DMY3BMC	HS	Terminated
DMY3BMC	SN	IPH-31XX; TLR-3 receptor agonist (cancer), Innate Pharma; Toll-like receptor 3 agonist (cancer),Innate Pharma
DMY3BMC	CP	Innate Pharma SA
DMY3BMC	DE	Solid tumour/cancer

DM7J8IO	ID	DM7J8IO
DM7J8IO	DN	IPH-3201
DM7J8IO	HS	Terminated
DM7J8IO	SN	IPH-32XX; TLR-7 modulators (cancer), Cancer Research Technology; TLR-7 modulators (cancer), Innate; Toll-like receptor 7 modulators (cancer), Innate
DM7J8IO	CP	Cancer Research Technology Ltd
DM7J8IO	DE	Solid tumour/cancer

DMRVZMX	ID	DMRVZMX
DMRVZMX	DN	IPH-4201
DMRVZMX	HS	Terminated
DMRVZMX	SN	MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM
DMRVZMX	CP	Universite de la Mediterranee
DMRVZMX	DT	Antibody
DMRVZMX	DE	Pancreatic cancer

DMEJU1L	ID	DMEJU1L
DMEJU1L	DN	Ipsapirone
DMEJU1L	HS	Terminated
DMEJU1L	SN	IPSAPIRONE; 95847-70-4; Ipsapironum [Latin]; Ipsapirona [Spanish]; Ipsapirone [INN:BAN]; UNII-6J9B11MN0K; C19H23N5O3S; 2-[4-[4-(2-PYRIMIDINYL)-1-PIPERAZINYL]BUTYL]-1,2-BENZISOTHIAZOL-3(2H)-ONE-1,1-DIOXIDE; BRN 5486134; CHEMBL8412; 6J9B11MN0K; NCGC00025315-01; DSSTox_CID_25688; 2-(4-(4-(2-Pyrimidinyl)-1-piperazinyl)butyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxide; DSSTox_RID_81060; DSSTox_GSID_45688; Ipsapironum; Ipsapirona; 1,1-dioxo-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2-benzothiazol-3-one
DMEJU1L	DT	Small molecular drug
DMEJU1L	PC	56971
DMEJU1L	MW	401.5
DMEJU1L	FM	C19H23N5O3S
DMEJU1L	IC	InChI=1S/C19H23N5O3S/c25-18-16-6-1-2-7-17(16)28(26,27)24(18)11-4-3-10-22-12-14-23(15-13-22)19-20-8-5-9-21-19/h1-2,5-9H,3-4,10-15H2
DMEJU1L	CS	C1CN(CCN1CCCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C4=NC=CC=N4
DMEJU1L	IK	TZJUVVIWVWFLCD-UHFFFAOYSA-N
DMEJU1L	IU	1,1-dioxo-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2-benzothiazol-3-one
DMEJU1L	CA	CAS 95847-70-4
DMEJU1L	CB	CHEBI:93578
DMEJU1L	DE	Anxiety disorder

DMYCPFU	ID	DMYCPFU
DMYCPFU	DN	IQM-95333
DMYCPFU	HS	Terminated
DMYCPFU	SN	IQM-95333; CHEMBL113718; IQM95333; AC1NSK6B; BDBM50060319; tert-butyl N-[(2S)-1-[[(4aS,5R)-2-benzyl-1,3-dioxo-4,4a,5,6,7,8-hexahydropyrido[1,2-c]pyrimidin-5-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamate; [(S)-1-((4aS,5R)-2-Benzyl-1,3-dioxo-octahydro-pyrido[1,2-c]pyrimidin-5-ylcarbamoyl)-2-(1H-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester
DMYCPFU	DT	Small molecular drug
DMYCPFU	PC	5311188
DMYCPFU	MW	559.7
DMYCPFU	FM	C31H37N5O5
DMYCPFU	IC	InChI=1S/C31H37N5O5/c1-31(2,3)41-29(39)34-25(16-21-18-32-23-13-8-7-12-22(21)23)28(38)33-24-14-9-15-35-26(24)17-27(37)36(30(35)40)19-20-10-5-4-6-11-20/h4-8,10-13,18,24-26,32H,9,14-17,19H2,1-3H3,(H,33,38)(H,34,39)/t24-,25+,26+/m1/s1
DMYCPFU	CS	CC(C)(C)OC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H]3CCCN4[C@H]3CC(=O)N(C4=O)CC5=CC=CC=C5
DMYCPFU	IK	JRSRZYFBWXHHNX-ZNZIZOMTSA-N
DMYCPFU	IU	tert-butyl N-[(2S)-1-[[(4aS,5R)-2-benzyl-1,3-dioxo-4,4a,5,6,7,8-hexahydropyrido[1,2-c]pyrimidin-5-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamate

DMJ3ZUN	ID	DMJ3ZUN
DMJ3ZUN	DN	Irindalone
DMJ3ZUN	HS	Terminated
DMJ3ZUN	SN	Irindalone; 96478-43-2; UNII-4F39T8N10K; CHEMBL73461; 4F39T8N10K; Irindalonum; Irindalona; Irindalone [INN]; 1-[2-[4-[(1R,3S)-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazin-1-yl]ethyl]imidazolidin-2-one; Irindalonum [Latin]; Irindalona [Spanish]; SCHEMBL247221; DTXSID30242274; 1-(2-{4-[3-(4-Fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-ethyl)-imidazolidin-2-one; AC1L2435; ZINC22463226; BDBM50020232; CS-6668; HY-101632; (+)-(1R,3S)-1-(2-(4-(3-(p-Fluorophenyl)-1-indanyl)-1-piperazinyl)ethyl)-2-imidazolidinone
DMJ3ZUN	DT	Small molecular drug
DMJ3ZUN	PC	65845
DMJ3ZUN	MW	408.5
DMJ3ZUN	FM	C24H29FN4O
DMJ3ZUN	IC	InChI=1S/C24H29FN4O/c25-19-7-5-18(6-8-19)22-17-23(21-4-2-1-3-20(21)22)28-14-11-27(12-15-28)13-16-29-10-9-26-24(29)30/h1-8,22-23H,9-17H2,(H,26,30)/t22-,23+/m0/s1
DMJ3ZUN	CS	C1CN(C(=O)N1)CCN2CCN(CC2)[C@@H]3C[C@H](C4=CC=CC=C34)C5=CC=C(C=C5)F
DMJ3ZUN	IK	GHAMYXPEZSUOCU-XZOQPEGZSA-N
DMJ3ZUN	IU	1-[2-[4-[(1R,3S)-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazin-1-yl]ethyl]imidazolidin-2-one
DMJ3ZUN	CA	CAS 96478-43-2
DMJ3ZUN	DE	Inflammation

DMH6K7N	ID	DMH6K7N
DMH6K7N	DN	IRL-2500
DMH6K7N	HS	Terminated
DMH6K7N	SN	IRL-2500; 169545-27-1; IRL2500; CHEMBL72410; (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-(4-phenylphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid; Tocris-1838; AC1NSK6K; SCHEMBL7444422; GTPL3887; CTK8E7373; DTXSID20415511; MolPort-003-983-837; IRL 2500; ZINC1891205; BDBM50071433; AKOS024456806; NCGC00025309-02; NCGC00025309-01; RT-013358; B6872; A-360; I-190; SR-01000597543; J-010557; SR-01000597543-1; N-3-[1,1'-Biphenyl]-4-yl-N-(3,5-dimethylbenzoyl)-N-methyl-D-alanyl-L-tryptophan
DMH6K7N	DT	Small molecular drug
DMH6K7N	PC	5311192
DMH6K7N	MW	573.7
DMH6K7N	FM	C36H35N3O4
DMH6K7N	IC	InChI=1S/C36H35N3O4/c1-23-17-24(2)19-28(18-23)35(41)39(3)33(20-25-13-15-27(16-14-25)26-9-5-4-6-10-26)34(40)38-32(36(42)43)21-29-22-37-31-12-8-7-11-30(29)31/h4-19,22,32-33,37H,20-21H2,1-3H3,(H,38,40)(H,42,43)/t32-,33+/m0/s1
DMH6K7N	CS	CC1=CC(=CC(=C1)C(=O)N(C)[C@H](CC2=CC=C(C=C2)C3=CC=CC=C3)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)O)C
DMH6K7N	IK	UZDORQWMYRRLQV-JHOUSYSJSA-N
DMH6K7N	IU	(2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-(4-phenylphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMH6K7N	CA	CAS 169545-27-1

DMD6SXO	ID	DMD6SXO
DMD6SXO	DN	ISIS-1082
DMD6SXO	HS	Terminated
DMD6SXO	SN	IP-1082
DMD6SXO	CP	Isis Pharmaceuticals Inc
DMD6SXO	DE	Virus infection

DM4YJ2W	ID	DM4YJ2W
DM4YJ2W	DN	Isomazole
DM4YJ2W	HS	Terminated
DM4YJ2W	SN	Isosulmazole; Isomazole fumarate; Isomazole hydrochloride; EMD-41064; EMD-47200; EMD-50250; EMD-52750; LY-175326
DM4YJ2W	CP	Merck KGaA
DM4YJ2W	DT	Small molecular drug
DM4YJ2W	PC	55690
DM4YJ2W	MW	287.34
DM4YJ2W	FM	C14H13N3O2S
DM4YJ2W	IC	InChI=1S/C14H13N3O2S/c1-19-13-7-9(20(2)18)3-4-10(13)14-16-11-5-6-15-8-12(11)17-14/h3-8H,1-2H3,(H,16,17)
DM4YJ2W	CS	COC1=C(C=CC(=C1)S(=O)C)C2=NC3=C(N2)C=NC=C3
DM4YJ2W	IK	JQUKCPUPFALELS-UHFFFAOYSA-N
DM4YJ2W	IU	2-(2-methoxy-4-methylsulfinylphenyl)-3H-imidazo[4,5-c]pyridine
DM4YJ2W	CA	CAS 86315-52-8
DM4YJ2W	CB	CHEBI:91691
DM4YJ2W	DE	Asthma

DMU5TGC	ID	DMU5TGC
DMU5TGC	DN	JSM-10292
DMU5TGC	HS	Terminated
DMU5TGC	SN	Bradykinin B2 receptor antagonist (pain/inflammation), Jerini
DMU5TGC	CP	Jerini AG
DMU5TGC	DT	Small molecular drug
DMU5TGC	PC	25019714
DMU5TGC	MW	519.5
DMU5TGC	FM	C28H24F3N5O2
DMU5TGC	IC	InChI=1S/C28H24F3N5O2/c1-16-9-10-32-23(14-36-11-5-7-22(27(36)37)28(29,30)31)21(16)15-38-24-8-4-6-19-20(12-18(3)34-26(19)24)25-17(2)13-33-35-25/h4-13H,14-15H2,1-3H3,(H,33,35)
DMU5TGC	CS	CC1=C(C(=NC=C1)CN2C=CC=C(C2=O)C(F)(F)F)COC3=CC=CC4=C(C=C(N=C43)C)C5=C(C=NN5)C
DMU5TGC	IK	KFVOKCIYVVCZGF-UHFFFAOYSA-N
DMU5TGC	IU	1-[[4-methyl-3-[[2-methyl-4-(4-methyl-1H-pyrazol-5-yl)quinolin-8-yl]oxymethyl]pyridin-2-yl]methyl]-3-(trifluoromethyl)pyridin-2-one
DMU5TGC	CA	CAS 1064674-16-3
DMU5TGC	DE	Pain

DMG7B61	ID	DMG7B61
DMG7B61	DN	JTP-2724
DMG7B61	HS	Terminated
DMG7B61	SN	JTP-3072; JTP-4129
DMG7B61	CP	Japan Tobacco Inc
DMG7B61	DE	Hypertension

DM6TXKR	ID	DM6TXKR
DM6TXKR	DN	JTP-4761
DM6TXKR	HS	Terminated
DM6TXKR	SN	JTV-505
DM6TXKR	CP	Japan Tobacco Inc
DM6TXKR	DE	Hypertension

DM48HVI	ID	DM48HVI
DM48HVI	DN	JTT-551
DM48HVI	HS	Terminated
DM48HVI	CP	Japan Tobacco Inc
DM48HVI	PC	23080446
DM48HVI	MW	605.9
DM48HVI	FM	C34H43N3O3S2
DM48HVI	IC	InChI=1S/C34H43N3O3S2/c1-6-8-25(9-7-2)26-14-16-28(17-15-26)40-22-24-10-12-27(13-11-24)29-23-41-32(36-29)20-37(21-33(38)39)19-31-35-18-30(42-31)34(3,4)5/h10-18,23,25H,6-9,19-22H2,1-5H3,(H,38,39)
DM48HVI	CS	CCCC(CCC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)C3=CSC(=N3)CN(CC4=NC=C(S4)C(C)(C)C)CC(=O)O
DM48HVI	IK	FKGBFRNVTCFMGU-UHFFFAOYSA-N
DM48HVI	IU	2-[(5-tert-butyl-1,3-thiazol-2-yl)methyl-[[4-[4-[(4-heptan-4-ylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]methyl]amino]acetic acid
DM48HVI	DE	Type-2 diabetes

DMZBNHC	ID	DMZBNHC
DMZBNHC	DN	JTT-608
DMZBNHC	HS	Terminated
DMZBNHC	SN	Trans-4-(4-Methylcyclohexyl)-4-oxobutanoic acid
DMZBNHC	DT	Small molecular drug
DMZBNHC	PC	6919096
DMZBNHC	MW	198.26
DMZBNHC	FM	C11H18O3
DMZBNHC	IC	InChI=1S/C11H18O3/c1-8-2-4-9(5-3-8)10(12)6-7-11(13)14/h8-9H,2-7H2,1H3,(H,13,14)
DMZBNHC	CS	CC1CCC(CC1)C(=O)CCC(=O)O
DMZBNHC	IK	JOWMTYWOBJALGB-UHFFFAOYSA-N
DMZBNHC	IU	4-(4-methylcyclohexyl)-4-oxobutanoic acid
DMZBNHC	CA	CAS 195137-72-5
DMZBNHC	DE	Diabetic complication

DM89TXB	ID	DM89TXB
DM89TXB	DN	JTV-605
DM89TXB	HS	Terminated
DM89TXB	SN	CHEMBL430083; BDBM50137940; L001683; Biphenyl-2-carboxylic acid [2-[4-(4-dimethylamino-piperidin-1-yl)-4-oxo-butoxy]-4-(5,6,7,8-tetrahydro-thieno[3,2-b]azepine-4-carbonyl)-phenyl]-amide
DM89TXB	DT	Small molecular drug
DM89TXB	PC	9939929
DM89TXB	MW	664.9
DM89TXB	FM	C39H44N4O4S
DM89TXB	IC	InChI=1S/C39H44N4O4S/c1-41(2)30-19-23-42(24-20-30)37(44)16-10-25-47-35-27-29(39(46)43-22-9-8-15-36-34(43)21-26-48-36)17-18-33(35)40-38(45)32-14-7-6-13-31(32)28-11-4-3-5-12-28/h3-7,11-14,17-18,21,26-27,30H,8-10,15-16,19-20,22-25H2,1-2H3,(H,40,45)
DM89TXB	CS	CN(C)C1CCN(CC1)C(=O)CCCOC2=C(C=CC(=C2)C(=O)N3CCCCC4=C3C=CS4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
DM89TXB	IK	LKUCMBNAHQWPJK-UHFFFAOYSA-N
DM89TXB	IU	N-[2-[4-[4-(dimethylamino)piperidin-1-yl]-4-oxobutoxy]-4-(5,6,7,8-tetrahydrothieno[3,2-b]azepine-4-carbonyl)phenyl]-2-phenylbenzamide
DM89TXB	DE	Dysmenorrhea

DM0MXWC	ID	DM0MXWC
DM0MXWC	DN	KA-398
DM0MXWC	HS	Terminated
DM0MXWC	SN	Scopinast; Scopinast, Wilmar Schwabe
DM0MXWC	CP	Dr Willmar Schwabe GmbH & Co
DM0MXWC	DE	Asthma

DM2LFYD	ID	DM2LFYD
DM2LFYD	DN	KB-5246
DM2LFYD	HS	Terminated
DM2LFYD	SN	9,1-Epoxymethano-7-fluoro-8-(4-methyl-1-piperazinyl)-5-oxo-5H-thiazolo[3,2-a]quinoline-4-carboxylic acid hydrochloride
DM2LFYD	DT	Small molecular drug
DM2LFYD	PC	6918093
DM2LFYD	MW	425.9
DM2LFYD	FM	C18H17ClFN3O4S
DM2LFYD	IC	InChI=1S/C18H16FN3O4S.ClH/c1-20-2-4-21(5-3-20)14-11(19)6-10-13-16(14)26-7-9-8-27-17(22(9)13)12(15(10)23)18(24)25;/h6,8H,2-5,7H2,1H3,(H,24,25);1H
DM2LFYD	CS	CN1CCN(CC1)C2=C(C=C3C4=C2OCC5=CSC(=C(C3=O)C(=O)O)N54)F.Cl
DM2LFYD	IK	YNPLQSCXSPGFPU-UHFFFAOYSA-N
DM2LFYD	IU	6-fluoro-5-(4-methylpiperazin-1-yl)-9-oxo-3-oxa-12-thia-14-azatetracyclo[6.5.2.04,15.011,14]pentadeca-1(13),4(15),5,7,10-pentaene-10-carboxylic acid;hydrochloride
DM2LFYD	DE	Bacterial infection

DMM7S3V	ID	DMM7S3V
DMM7S3V	DN	KB-5359
DMM7S3V	HS	Terminated
DMM7S3V	SN	KB-3495; Selective thyroid hormone agonists (TR STAD, dyslipidemia), Karo Bio
DMM7S3V	CP	Karo Bio AB
DMM7S3V	DE	Lipid metabolism disorder

DM3H90W	ID	DM3H90W
DM3H90W	DN	KC-11404
DM3H90W	HS	Terminated
DM3H90W	CP	Solvay Deutschland GmbH
DM3H90W	DE	Asthma

DMC295V	ID	DMC295V
DMC295V	DN	KC-11425
DMC295V	HS	Terminated
DMC295V	CP	Solvay Pharmaceuticals Inc
DMC295V	DE	Asthma

DMD0FNH	ID	DMD0FNH
DMD0FNH	DN	KC-399
DMD0FNH	HS	Terminated
DMD0FNH	SN	KC-399; 152661-13-7; 2H-1-Benzopyran-4-carbothioamide,N-(2-cyanoethyl)-2,2-bis(fluoromethyl)-6-nitro-; LKUDLWNQCZSCQW-UHFFFAOYSA-N; ACMC-20n6i6; SCHEMBL8314846; CHEMBL291410; CTK4C7529
DMD0FNH	CP	Chugai Pharmaceutical Co Ltd
DMD0FNH	DT	Small molecular drug
DMD0FNH	PC	9863361
DMD0FNH	MW	353.3
DMD0FNH	FM	C15H13F2N3O3S
DMD0FNH	IC	InChI=1S/C15H13F2N3O3S/c16-8-15(9-17)7-12(14(24)19-5-1-4-18)11-6-10(20(21)22)2-3-13(11)23-15/h2-3,6-7H,1,5,8-9H2,(H,19,24)
DMD0FNH	CS	C1=CC2=C(C=C1[N+](=O)[O-])C(=CC(O2)(CF)CF)C(=S)NCCC#N
DMD0FNH	IK	LKUDLWNQCZSCQW-UHFFFAOYSA-N
DMD0FNH	IU	N-(2-cyanoethyl)-2,2-bis(fluoromethyl)-6-nitrochromene-4-carbothioamide
DMD0FNH	DE	Alopecia

DMNZ1LR	ID	DMNZ1LR
DMNZ1LR	DN	KF-15766
DMNZ1LR	HS	Terminated
DMNZ1LR	CP	Kyowa Hakko Kogyo Co Ltd
DMNZ1LR	DE	Allergy

DMQXPJB	ID	DMQXPJB
DMQXPJB	DN	Ki-1769
DMQXPJB	HS	Terminated
DMQXPJB	SN	Ki-1769; Ki 1769; AC1L2ZHG; ki1769; SCHEMBL9214494; SCHEMBL6377119; CHEMBL310746; SUPZSNPDPSPMTK-UHFFFAOYSA-N; N-CYANO-N'-(2-PHENYLETHYL)-3-PYRIDINECARBOXIMIDAMIDE; N-cyano-N'-phenethylpyridine-3-carboximidamide; 3-Pyridinecarboximidamide, N-cyano-N'-(2-phenylethyl)-
DMQXPJB	CP	Kirin Brewery Co Ltd
DMQXPJB	DT	Small molecular drug
DMQXPJB	PC	131608
DMQXPJB	MW	250.3
DMQXPJB	FM	C15H14N4
DMQXPJB	IC	InChI=1S/C15H14N4/c16-12-19-15(14-7-4-9-17-11-14)18-10-8-13-5-2-1-3-6-13/h1-7,9,11H,8,10H2,(H,18,19)
DMQXPJB	CS	C1=CC=C(C=C1)CCN=C(C2=CN=CC=C2)NC#N
DMQXPJB	IK	SUPZSNPDPSPMTK-UHFFFAOYSA-N
DMQXPJB	IU	N-cyano-N'-(2-phenylethyl)pyridine-3-carboximidamide
DMQXPJB	CA	CAS 133300-00-2
DMQXPJB	DE	Hypertension

DMXZNB2	ID	DMXZNB2
DMXZNB2	DN	KNI-102
DMXZNB2	HS	Terminated
DMXZNB2	SN	Kni-102; Kni 102; 139694-65-8; Rpi 312; CHEBI:80005; AHPBA 1a; Z-Asn-apns-pro-NH-t-but; RPI-312; Cbz-Asn-Apns-Pro-NH-tBu; AC1Q5L2D; BDBM4215; AC1L22E8; SCHEMBL2771668; Z-Asparaginyl-allophenylnorstatinyl-t-butylproline amide; CHEMBL3349847; DTXSID70161152; 1-(3-(N-alpha-Benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutyryl)-N-tert-butyl-L-prolinamide; C15654; benzyl N-[(2S)-4-amino-1-[[(2S,3S)-4-[(2S)-2-(tert-butylcarbamoyl)pyrrolidin-1-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamate
DMXZNB2	CP	Japan Energy Corp
DMXZNB2	DT	Small molecular drug
DMXZNB2	PC	65004
DMXZNB2	MW	595.7
DMXZNB2	FM	C31H41N5O7
DMXZNB2	IC	InChI=1S/C31H41N5O7/c1-31(2,3)35-28(40)24-15-10-16-36(24)29(41)26(38)22(17-20-11-6-4-7-12-20)33-27(39)23(18-25(32)37)34-30(42)43-19-21-13-8-5-9-14-21/h4-9,11-14,22-24,26,38H,10,15-19H2,1-3H3,(H2,32,37)(H,33,39)(H,34,42)(H,35,40)/t22-,23-,24-,26-/m0/s1
DMXZNB2	CS	CC(C)(C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)OCC3=CC=CC=C3)O
DMXZNB2	IK	XCVUOCMQYKSJJR-IGRGDXOOSA-N
DMXZNB2	IU	benzyl N-[(2S)-4-amino-1-[[(2S,3S)-4-[(2S)-2-(tert-butylcarbamoyl)pyrrolidin-1-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamate
DMXZNB2	CA	CAS 139694-65-8
DMXZNB2	CB	CHEBI:80005
DMXZNB2	DE	Human immunodeficiency virus infection

DMXT2SL	ID	DMXT2SL
DMXT2SL	DN	KRG-3332
DMXT2SL	HS	Terminated
DMXT2SL	SN	Pivalic acid 3-[7-carbamoyl-5-[2(R)-[2-(2-ethoxyphenoxy)ethylamino]propyl]-1H-indol-1-yl]propyl ester hydrochloride
DMXT2SL	DE	Glaucoma/ocular hypertension

DM2L0VF	ID	DM2L0VF
DM2L0VF	DN	KRH-2731
DM2L0VF	HS	Terminated
DM2L0VF	CP	Kureha
DM2L0VF	DE	Human immunodeficiency virus infection

DM4QHNG	ID	DM4QHNG
DM4QHNG	DN	KRI-1314
DM4QHNG	HS	Terminated
DM4QHNG	SN	CHEMBL3350322; Kri-1314; CHEMBL91826; 4-Cyclohexyl-2-hydroxy-3-[3-(1H-imidazol-4-yl)-2-(4-morpholin-4-yl-2-naphthalen-1-ylmethyl-4-oxo-butyrylamino)-propionylamino]-butyric acid isopropyl ester; BDBM50012951; (2R,3S)-3-[N-[(2R)-3-(Morpholinocarbonyl)-2-[(naphthalen-1-yl)methyl]propionyl]-L-histidyl]amino-4-cyclohexyl-2-hydroxybutanoic acid isopropyl ester
DM4QHNG	CP	Kissei Pharmaceutical Co Ltd
DM4QHNG	DT	Small molecular drug
DM4QHNG	PC	5492607
DM4QHNG	MW	689.8
DM4QHNG	FM	C38H51N5O7
DM4QHNG	IC	InChI=1S/C38H51N5O7/c1-25(2)50-38(48)35(45)32(19-26-9-4-3-5-10-26)41-37(47)33(22-30-23-39-24-40-30)42-36(46)29(21-34(44)43-15-17-49-18-16-43)20-28-13-8-12-27-11-6-7-14-31(27)28/h6-8,11-14,23-26,29,32-33,35,45H,3-5,9-10,15-22H2,1-2H3,(H,39,40)(H,41,47)(H,42,46)/t29-,32?,33+,35?/m1/s1
DM4QHNG	CS	CC(C)OC(=O)C(C(CC1CCCCC1)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CC=CC4=CC=CC=C43)CC(=O)N5CCOCC5)O
DM4QHNG	IK	NQXSBCTYTMQGGJ-GBDGZKRDSA-N
DM4QHNG	IU	propan-2-yl 4-cyclohexyl-2-hydroxy-3-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2R)-4-morpholin-4-yl-2-(naphthalen-1-ylmethyl)-4-oxobutanoyl]amino]propanoyl]amino]butanoate
DM4QHNG	CA	CAS 128053-53-2
DM4QHNG	DE	Hypertension

DMVZSAM	ID	DMVZSAM
DMVZSAM	DN	KRP-105
DMVZSAM	HS	Terminated
DMVZSAM	CP	Kyorin Pharmaceutical Co Ltd
DMVZSAM	DE	Lipid metabolism disorder

DM8VMJ3	ID	DM8VMJ3
DM8VMJ3	DN	KT-95
DM8VMJ3	HS	Terminated
DM8VMJ3	SN	KT-90
DM8VMJ3	CP	Toho Chemical Industry Co
DM8VMJ3	PC	102002354
DM8VMJ3	MW	439.5
DM8VMJ3	FM	C24H25NO5S
DM8VMJ3	IC	InChI=1S/C24H25NO5S/c1-12(26)29-17-7-5-15-19-22(17)30-23-18(31-13(2)27)8-6-16-20(21(15)28)25(11-14-3-4-14)10-9-24(16,19)23/h5-8,14,16,18,20,23H,3-4,9-11H2,1-2H3/t16-,18+,20-,23-,24-/m0/s1
DM8VMJ3	CS	CC(=O)OC1=C2C3=C(C=C1)C(=O)[C@@H]4[C@H]5[C@]3(CCN4CC6CC6)[C@@H](O2)[C@@H](C=C5)SC(=O)C
DM8VMJ3	IK	JALSXEHOWOEHCB-SDAQKBEVSA-N
DM8VMJ3	IU	[(4S,4aR,7R,7aR,12bS)-7-acetylsulfanyl-3-(cyclopropylmethyl)-13-oxo-1,2,4,4a,7,7a-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl] acetate
DM8VMJ3	DE	Inflammatory bowel disease

DMS2KEG	ID	DMS2KEG
DMS2KEG	DN	KW-3433
DMS2KEG	HS	Terminated
DMS2KEG	SN	CHEMBL433895; BDBM50049200
DMS2KEG	CP	Kyowa Hakko Kogyo Co Ltd
DMS2KEG	DT	Small molecular drug
DMS2KEG	PC	44373246
DMS2KEG	MW	435.5
DMS2KEG	FM	C26H25N7
DMS2KEG	IC	InChI=1S/C26H25N7/c1-4-24-28-25-15(2)11-16(3)27-26(25)33(24)14-17-9-10-20-18-7-5-6-8-19(18)22(21(20)12-17)13-23-29-31-32-30-23/h5-12,22H,4,13-14H2,1-3H3,(H,29,30,31,32)
DMS2KEG	CS	CCC1=NC2=C(N1CC3=CC4=C(C=C3)C5=CC=CC=C5C4CC6=NNN=N6)N=C(C=C2C)C
DMS2KEG	IK	DYYWUYUUDYPWON-UHFFFAOYSA-N
DMS2KEG	IU	2-ethyl-5,7-dimethyl-3-[[9-(2H-tetrazol-5-ylmethyl)-9H-fluoren-2-yl]methyl]imidazo[4,5-b]pyridine
DMS2KEG	DE	Hypertension

DMQ4LDB	ID	DMQ4LDB
DMQ4LDB	DN	L-158809
DMQ4LDB	HS	Terminated
DMQ4LDB	SN	2-Ethyl-5,7-dimethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine; CHEMBL7550; 133240-46-7; 2-Ethyl-5,7-dimethyl-3-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)imidazo(4,5-b)pyridine; YFWXFHNZGKNDBC-UHFFFAOYSA-N; 2-ethyl-5,7-dimethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine; [3H]L158809; [3H]-L158809; AC1L4CB2; [3H]L-158,809; SCHEMBL683357; GTPL3939; BDBM50009718; 3H-Imidazo(4,5-b)pyridine, 2-ethyl-5,7-dimethyl-3-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; LS-193980; L004397
DMQ4LDB	DT	Small molecular drug
DMQ4LDB	PC	183134
DMQ4LDB	MW	409.5
DMQ4LDB	FM	C24H23N7
DMQ4LDB	IC	InChI=1S/C24H23N7/c1-4-21-26-22-15(2)13-16(3)25-24(22)31(21)14-17-9-11-18(12-10-17)19-7-5-6-8-20(19)23-27-29-30-28-23/h5-13H,4,14H2,1-3H3,(H,27,28,29,30)
DMQ4LDB	CS	CCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)N=C(C=C2C)C
DMQ4LDB	IK	YFWXFHNZGKNDBC-UHFFFAOYSA-N
DMQ4LDB	IU	2-ethyl-5,7-dimethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine
DMQ4LDB	CA	CAS 133240-46-7
DMQ4LDB	DE	Hypertension

DM9JE7Y	ID	DM9JE7Y
DM9JE7Y	DN	L-159689
DM9JE7Y	HS	Terminated
DM9JE7Y	SN	L-159689; CHEMBL302102; SCHEMBL8852212; BDBM82433; L-159,689
DM9JE7Y	DT	Small molecular drug
DM9JE7Y	PC	9851889
DM9JE7Y	MW	611.7
DM9JE7Y	FM	C37H37N7O2
DM9JE7Y	IC	InChI=1S/C37H37N7O2/c1-3-5-11-23-43(36(45)28-13-7-6-8-14-28)29-21-22-33-32(24-29)37(46)44(34(38-33)12-4-2)25-26-17-19-27(20-18-26)30-15-9-10-16-31(30)35-39-41-42-40-35/h6-10,13-22,24H,3-5,11-12,23,25H2,1-2H3,(H,39,40,41,42)
DM9JE7Y	CS	CCCCCN(C1=CC2=C(C=C1)N=C(N(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)CCC)C(=O)C6=CC=CC=C6
DM9JE7Y	IK	JQXJNTQZCWEHKS-UHFFFAOYSA-N
DM9JE7Y	IU	N-[4-oxo-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-6-yl]-N-pentylbenzamide
DM9JE7Y	DE	Hypertension

DMYSEBK	ID	DMYSEBK
DMYSEBK	DN	L-162234
DMYSEBK	HS	Terminated
DMYSEBK	SN	CHEMBL292150; L-162234; SCHEMBL9377635; IVFMKMCSJZZCKV-UHFFFAOYSA-N; BDBM50035451; L008869; 5-n-Butyl-4-[[2''-[N-(tert-butoxycarbonyl)sulfamoyl]biphenyl-4yl]methyl]-2-[2-trifluoromethyl-phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one; 4''-[3-Butyl-5-oxo-1-(2-trifluoromethyl-phenyl)-1,5-dihydro-[1,2,4]triazol-4-ylmethyl]-biphenyl-2-sulfonic acid amide-N-carbonyoxylterbutyl; 4''-[3-Butyl-5-oxo-1-(2-trifluoromethyl-phenyl)-1,5-dihydro-[1,2,4]triazol-4-ylmethyl]-biphenyl-2-sulfonic acid (2-tert-butoxycarbonyl)amide
DMYSEBK	DT	Small molecular drug
DMYSEBK	PC	9830680
DMYSEBK	MW	630.7
DMYSEBK	FM	C31H33F3N4O5S
DMYSEBK	IC	InChI=1S/C31H33F3N4O5S/c1-5-6-15-27-35-38(25-13-9-8-12-24(25)31(32,33)34)29(40)37(27)20-21-16-18-22(19-17-21)23-11-7-10-14-26(23)44(41,42)36-28(39)43-30(2,3)4/h7-14,16-19H,5-6,15,20H2,1-4H3,(H,36,39)
DMYSEBK	CS	CCCCC1=NN(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3S(=O)(=O)NC(=O)OC(C)(C)C)C4=CC=CC=C4C(F)(F)F
DMYSEBK	IK	IVFMKMCSJZZCKV-UHFFFAOYSA-N
DMYSEBK	IU	tert-butyl N-[2-[4-[[3-butyl-5-oxo-1-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-4-yl]methyl]phenyl]phenyl]sulfonylcarbamate

DMYB5RV	ID	DMYB5RV
DMYB5RV	DN	L-163017
DMYB5RV	HS	Terminated
DMYB5RV	SN	L-163017; CHEMBL160494; SCHEMBL6556686; BDBM50049203; L000330
DMYB5RV	CP	Merck & Co Inc
DMYB5RV	DT	Small molecular drug
DMYB5RV	PC	9895877
DMYB5RV	MW	653.8
DMYB5RV	FM	C36H39N5O5S
DMYB5RV	IC	InChI=1S/C36H39N5O5S/c1-5-11-32-39-33-25(4)30(38-35(42)28-12-7-6-8-13-28)22-37-34(33)41(32)23-26-16-18-27(19-17-26)29-14-9-10-15-31(29)47(44,45)40-36(43)46-21-20-24(2)3/h6-10,12-19,22,24H,5,11,20-21,23H2,1-4H3,(H,38,42)(H,40,43)
DMYB5RV	CS	CCCC1=NC2=C(C(=CN=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC(=O)OCCC(C)C)NC(=O)C5=CC=CC=C5)C
DMYB5RV	IK	WGFOETKPMPCUOG-UHFFFAOYSA-N
DMYB5RV	IU	3-methylbutyl N-[2-[4-[(6-benzamido-7-methyl-2-propylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]phenyl]sulfonylcarbamate
DMYB5RV	DE	Hypertension

DMCRQTH	ID	DMCRQTH
DMCRQTH	DN	L-371257
DMCRQTH	HS	Terminated
DMCRQTH	SN	162042-44-6; L-371257; L-371,257; CHEMBL24781; L 371257; 1-[1-[4-(1-acetylpiperidin-4-yl)oxy-2-methoxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one; AC1OCFAC; NCGC00159562-01; SCHEMBL4954712; GTPL2252; CTK8E8747; DTXSID30426072; MolPort-023-276-417; ZINC3824080; BDBM50029649; ABP001011; AKOS024457081; API0009977; KB-78045; 1-[4-[(1-ACETYL-4-PIPERIDINYL)OXY]-2-METHOXYBENZOYL]-4-(2-OXO-2H-3,1-BENZOXAZIN-1(4H)-YL)PIPERIDINE; RT-013479; B7045; L014161; L371,257
DMCRQTH	DT	Small molecular drug
DMCRQTH	PC	6918320
DMCRQTH	MW	507.6
DMCRQTH	FM	C28H33N3O6
DMCRQTH	IC	InChI=1S/C28H33N3O6/c1-19(32)29-15-11-22(12-16-29)37-23-7-8-24(26(17-23)35-2)27(33)30-13-9-21(10-14-30)31-25-6-4-3-5-20(25)18-36-28(31)34/h3-8,17,21-22H,9-16,18H2,1-2H3
DMCRQTH	CS	CC(=O)N1CCC(CC1)OC2=CC(=C(C=C2)C(=O)N3CCC(CC3)N4C5=CC=CC=C5COC4=O)OC
DMCRQTH	IK	WDERJSQJYIJOPD-UHFFFAOYSA-N
DMCRQTH	IU	1-[1-[4-(1-acetylpiperidin-4-yl)oxy-2-methoxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one
DMCRQTH	CA	CAS 162042-44-6

DMOKZ2V	ID	DMOKZ2V
DMOKZ2V	DN	L-373890
DMOKZ2V	HS	Terminated
DMOKZ2V	CP	Merck & Co Inc
DMOKZ2V	DE	Thrombosis

DMK2QW0	ID	DMK2QW0
DMK2QW0	DN	L-374,087
DMK2QW0	HS	Terminated
DMK2QW0	DE	Thrombosis

DMTKCNJ	ID	DMTKCNJ
DMTKCNJ	DN	L-648051
DMTKCNJ	HS	Terminated
DMTKCNJ	SN	4-Apsob; L-648051; L 648051; UNII-0LGZ40MB45; 0LGZ40MB45; 91541-18-3; 4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid; 4-(4-{[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfonyl}phenyl)-4-oxobutanoic acid; Benzenebutanoic acid, 4-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxo-; AC1Q5VP2; AC1L3TT7; SCHEMBL157166; CHEMBL282253; CTK8D5118; DTXSID50238619; ZAKKEARLDPTRLX-UHFFFAOYSA-N; AKOS030530731; LS-186850; LS-187510
DMTKCNJ	CP	Merck & Co Inc
DMTKCNJ	DT	Small molecular drug
DMTKCNJ	PC	122010
DMTKCNJ	MW	476.5
DMTKCNJ	FM	C24H28O8S
DMTKCNJ	IC	InChI=1S/C24H28O8S/c1-3-5-20-22(12-10-19(16(2)25)24(20)29)32-14-4-15-33(30,31)18-8-6-17(7-9-18)21(26)11-13-23(27)28/h6-10,12,29H,3-5,11,13-15H2,1-2H3,(H,27,28)
DMTKCNJ	CS	CCCC1=C(C=CC(=C1O)C(=O)C)OCCCS(=O)(=O)C2=CC=C(C=C2)C(=O)CCC(=O)O
DMTKCNJ	IK	ZAKKEARLDPTRLX-UHFFFAOYSA-N
DMTKCNJ	IU	4-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl]phenyl]-4-oxobutanoic acid
DMTKCNJ	CA	CAS 91541-18-3
DMTKCNJ	DE	Asthma

DMGX3MK	ID	DMGX3MK
DMGX3MK	DN	L-655240
DMGX3MK	HS	Terminated
DMGX3MK	SN	L-655,240; 103253-15-2; L-655240; L 655240; CHEMBL362223; 3-[1-(4-Chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]-2,2-dimethyl propanoic acid; 1-((4-chlorophenyl)methyl)-5-fluoro-a,a-3-trimethyl-(1h)-indole-2-propanoic acid; SR-01000075967; JLPYLHLUHJOPNL-UHFFFAOYSA-N; Tocris-1698; Lopac-L-9539; AC1L3TX4; Lopac0_000670; SCHEMBL3252820; CHEBI:93563; CTK8E8278; MolPort-003-958-591; HMS3268O17; ZINC2526554; BDBM50168772; AKOS024456751; CCG-204756; 3-(1-(4-Chlorobenzyl)-5-fluoro-3-methylindol-2-yl)-2,2-dimethylpropanoic acid
DMGX3MK	DT	Small molecular drug
DMGX3MK	PC	122070
DMGX3MK	MW	373.8
DMGX3MK	FM	C21H21ClFNO2
DMGX3MK	IC	InChI=1S/C21H21ClFNO2/c1-13-17-10-16(23)8-9-18(17)24(12-14-4-6-15(22)7-5-14)19(13)11-21(2,3)20(25)26/h4-10H,11-12H2,1-3H3,(H,25,26)
DMGX3MK	CS	CC1=C(N(C2=C1C=C(C=C2)F)CC3=CC=C(C=C3)Cl)CC(C)(C)C(=O)O
DMGX3MK	IK	JLPYLHLUHJOPNL-UHFFFAOYSA-N
DMGX3MK	IU	3-[1-[(4-chlorophenyl)methyl]-5-fluoro-3-methylindol-2-yl]-2,2-dimethylpropanoic acid
DMGX3MK	CA	CAS 103253-15-2
DMGX3MK	CB	CHEBI:93563

DMOTY3G	ID	DMOTY3G
DMOTY3G	DN	L-657925
DMOTY3G	HS	Terminated
DMOTY3G	SN	L-657926
DMOTY3G	DT	Small molecular drug
DMOTY3G	PC	129772
DMOTY3G	MW	373.8
DMOTY3G	FM	C21H21ClFNO2
DMOTY3G	IC	InChI=1S/C21H21ClFNO2/c22-15-6-4-13(5-7-15)12-24-19-9-8-16(23)11-18(19)17-3-1-2-14(21(17)24)10-20(25)26/h4-9,11,14,17,21H,1-3,10,12H2,(H,25,26)
DMOTY3G	CS	C1CC(C2C(C1)C3=C(N2CC4=CC=C(C=C4)Cl)C=CC(=C3)F)CC(=O)O
DMOTY3G	IK	USFMJLOJQLMDAA-UHFFFAOYSA-N
DMOTY3G	IU	2-[9-[(4-chlorophenyl)methyl]-6-fluoro-1,2,3,4,4a,9a-hexahydrocarbazol-1-yl]acetic acid
DMOTY3G	CA	CAS 122757-59-9

DMLENQ7	ID	DMLENQ7
DMLENQ7	DN	L-659989
DMLENQ7	HS	Terminated
DMLENQ7	SN	L-659989; 113787-28-3; L-659,989; L659989; L 659989; CHEMBL37781; SCHEMBL6154076; GTPL3426; DTXSID70433028; BDBM50002829; ZINC13650944; FT-0670693; L-662,418; L-659,989, (+); (2S,5S)-2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)oxolane; (2R,5R)-rel-Tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan; trans-( inverted exclamation markA)-Tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan
DMLENQ7	DT	Small molecular drug
DMLENQ7	PC	9934870
DMLENQ7	MW	480.6
DMLENQ7	FM	C24H32O8S
DMLENQ7	IC	InChI=1S/C24H32O8S/c1-7-10-31-24-21(29-4)13-16(14-22(24)33(6,25)26)18-9-8-17(32-18)15-11-19(27-2)23(30-5)20(12-15)28-3/h11-14,17-18H,7-10H2,1-6H3/t17-,18-/m0/s1
DMLENQ7	CS	CCCOC1=C(C=C(C=C1S(=O)(=O)C)[C@@H]2CC[C@H](O2)C3=CC(=C(C(=C3)OC)OC)OC)OC
DMLENQ7	IK	NZWPFJNQOZFEDT-ROUUACIJSA-N
DMLENQ7	IU	(2S,5S)-2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)oxolane
DMLENQ7	CA	CAS 113787-28-3

DM56VPY	ID	DM56VPY
DM56VPY	DN	L-687414
DM56VPY	HS	Terminated
DM56VPY	SN	(3R,4R)-3-Amino-1-hydroxy-4-methylpyrrolidin-2-one; 130931-65-6; L-687414; CHEMBL283819; 132619-43-3; cis-3-amino-1-hydroxy-4-methylpyrrolidin-2-one; SCHEMBL561932; DTXSID00437953; SKYSFPFYQBZGDC-QWWZWVQMSA-N; ZINC3805040; BDBM50038169; AKOS006239328; KB-78073; AJ-45657; 3-Amino-1-hydroxy-4-methyl-pyrrolidin-2-one; r(+)-cis-beta-methyl-3-amino-1-hydroxypyrrolid-2-one
DM56VPY	DT	Small molecular drug
DM56VPY	PC	10313147
DM56VPY	MW	130.15
DM56VPY	FM	C5H10N2O2
DM56VPY	IC	InChI=1S/C5H10N2O2/c1-3-2-7(9)5(8)4(3)6/h3-4,9H,2,6H2,1H3/t3-,4-/m1/s1
DM56VPY	CS	C[C@@H]1CN(C(=O)[C@@H]1N)O
DM56VPY	IK	SKYSFPFYQBZGDC-QWWZWVQMSA-N
DM56VPY	IU	(3R,4R)-3-amino-1-hydroxy-4-methylpyrrolidin-2-one
DM56VPY	CA	CAS 130931-65-6

DMCVY4U	ID	DMCVY4U
DMCVY4U	DN	L-689560
DMCVY4U	HS	Terminated
DMCVY4U	SN	trans-2-Carboxy-5,7-dichloro-4-(((phenylamino)carbonyl)amino)-1,2,3,4-tetrahydroquinoline; C17H15Cl2N3O3; L 689560; L-689,560; 4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline; 139051-78-8; (2S,4R)-5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; 2-Quinolinecarboxylic acid, 5,7-dichloro-1,2,3,4-tetrahydro-4-(((phenylamino)carbonyl)amino)-, trans-(+-)-; [3H]L689560; AC1L3TN7; SCHEMBL193615; GTPL4239; GTPL4086; ZINC2567729; compound 35
DMCVY4U	CP	Merck & Co Inc
DMCVY4U	DT	Small molecular drug
DMCVY4U	PC	121918
DMCVY4U	MW	380.2
DMCVY4U	FM	C17H15Cl2N3O3
DMCVY4U	IC	InChI=1S/C17H15Cl2N3O3/c18-9-6-11(19)15-12(7-9)21-14(16(23)24)8-13(15)22-17(25)20-10-4-2-1-3-5-10/h1-7,13-14,21H,8H2,(H,23,24)(H2,20,22,25)/t13-,14+/m1/s1
DMCVY4U	CS	C1[C@H](C2=C(C=C(C=C2Cl)Cl)N[C@@H]1C(=O)O)NC(=O)NC3=CC=CC=C3
DMCVY4U	IK	UCKHICKHGAOGAP-KGLIPLIRSA-N
DMCVY4U	IU	(2S,4R)-5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid
DMCVY4U	CA	CAS 139051-78-8
DMCVY4U	DE	Neurodegenerative disorder

DM2F4GT	ID	DM2F4GT
DM2F4GT	DN	L-694247
DM2F4GT	HS	Terminated
DM2F4GT	SN	137403-12-4; L-694,247; N-(4-((5-(3-(2-Aminoethyl)-1H-indol-5-yl)-1,2,4-oxadiazol-3-yl)methyl)phenyl)methanesulfonamide; L-694247; L 694247; 2-[5-[3-(4-Methylsulfonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine; N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide; Methanesulfonamide,N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]-; Tocris-0781; Biomol-NT_000112; GTPL15; AC1L30BK
DM2F4GT	CP	Merck & Co Inc
DM2F4GT	DT	Small molecular drug
DM2F4GT	PC	132059
DM2F4GT	MW	411.5
DM2F4GT	FM	C20H21N5O3S
DM2F4GT	IC	InChI=1S/C20H21N5O3S/c1-29(26,27)25-16-5-2-13(3-6-16)10-19-23-20(28-24-19)14-4-7-18-17(11-14)15(8-9-21)12-22-18/h2-7,11-12,22,25H,8-10,21H2,1H3
DM2F4GT	CS	CS(=O)(=O)NC1=CC=C(C=C1)CC2=NOC(=N2)C3=CC4=C(C=C3)NC=C4CCN
DM2F4GT	IK	HKXMQLISPYELRD-UHFFFAOYSA-N
DM2F4GT	IU	N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide
DM2F4GT	CA	CAS 137403-12-4
DM2F4GT	CB	CHEBI:92341
DM2F4GT	DE	Migraine

DMT1DNS	ID	DMT1DNS
DMT1DNS	DN	L-695902
DMT1DNS	HS	Terminated
DMT1DNS	SN	L-695902; CHEMBL104297; SCHEMBL8018550; AKOS022507211; methyl 7-chloro-2,4-dihydroxy-3-quinolinecarboxylate; methyl 7-chloro-2,4-dihydroxyquinoline-3-carboxylate
DMT1DNS	DT	Small molecular drug
DMT1DNS	PC	54695867
DMT1DNS	MW	253.64
DMT1DNS	FM	C11H8ClNO4
DMT1DNS	IC	InChI=1S/C11H8ClNO4/c1-17-11(16)8-9(14)6-3-2-5(12)4-7(6)13-10(8)15/h2-4H,1H3,(H2,13,14,15)
DMT1DNS	CS	COC(=O)C1=C(C2=C(C=C(C=C2)Cl)NC1=O)O
DMT1DNS	IK	GEUWRNTWGHPTPU-UHFFFAOYSA-N
DMT1DNS	IU	methyl 7-chloro-4-hydroxy-2-oxo-1H-quinoline-3-carboxylate

DMV785R	ID	DMV785R
DMV785R	DN	L-696418
DMV785R	HS	Terminated
DMV785R	SN	CHEMBL8494; L-696418; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid
DMV785R	DT	Small molecular drug
DMV785R	PC	10478364
DMV785R	MW	439.5
DMV785R	FM	C25H33N3O4
DMV785R	IC	InChI=1S/C25H33N3O4/c1-17(2)16-22(24(30)27-20-12-8-5-9-13-20)28-23(29)21(26-18(3)25(31)32)15-14-19-10-6-4-7-11-19/h4-13,17-18,21-22,26H,14-16H2,1-3H3,(H,27,30)(H,28,29)(H,31,32)/t18-,21+,22+/m1/s1
DMV785R	CS	C[C@H](C(=O)O)N[C@@H](CCC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)NC2=CC=CC=C2
DMV785R	IK	DLCYKLDSIUJNLE-COPCDDAFSA-N
DMV785R	IU	(2R)-2-[[(2S)-1-[[(2S)-1-anilino-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid

DMO9HM7	ID	DMO9HM7
DMO9HM7	DN	L-698532
DMO9HM7	HS	Terminated
DMO9HM7	SN	28563-19-1; 3-Phenyl-4-hydroxy-7-chloroquinolin-2(1H)-one; L-698532; CHEMBL31661; 7-Chloro-4-hydroxy-3-phenyl-2(1H)-quinolone; 7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolinone; 7-Chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one; Mdl 104,653; ZINC5910; AC1MD767; SCHEMBL1612505; CTK4G1708; DTXSID80182777; RDXQSWLUXKUQSI-UHFFFAOYSA-N; BCP18252; BDBM50041467; AKOS032961557; 7-chloro-4-hydroxy-3-phenylquinolin-2(1H)-one; 7-chloro-2-hydroxy-3-phenyl-1H-quinolin-4-one; 3-phenyl-4-hydroxy-7-chloro-quinolin-2(1h)-one
DMO9HM7	DT	Small molecular drug
DMO9HM7	PC	54697468
DMO9HM7	MW	271.7
DMO9HM7	FM	C15H10ClNO2
DMO9HM7	IC	InChI=1S/C15H10ClNO2/c16-10-6-7-11-12(8-10)17-15(19)13(14(11)18)9-4-2-1-3-5-9/h1-8H,(H2,17,18,19)
DMO9HM7	CS	C1=CC=C(C=C1)C2=C(C3=C(C=C(C=C3)Cl)NC2=O)O
DMO9HM7	IK	RDXQSWLUXKUQSI-UHFFFAOYSA-N
DMO9HM7	IU	7-chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one
DMO9HM7	CA	CAS 28563-19-1
DMO9HM7	DE	Neurological disorder

DMLRBN1	ID	DMLRBN1
DMLRBN1	DN	L-698544
DMLRBN1	HS	Terminated
DMLRBN1	SN	7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; 7-CHLORO-3-NITRO-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553;  CNDQ; 7-Chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one
DMLRBN1	CP	Merck & Co Inc
DMLRBN1	DT	Small molecular drug
DMLRBN1	PC	10220180
DMLRBN1	MW	226.61
DMLRBN1	FM	C9H7ClN2O3
DMLRBN1	IC	InChI=1S/C9H7ClN2O3/c10-6-2-1-5-3-8(12(14)15)9(13)11-7(5)4-6/h1-2,4,8H,3H2,(H,11,13)
DMLRBN1	CS	C1C(C(=O)NC2=C1C=CC(=C2)Cl)[N+](=O)[O-]
DMLRBN1	IK	JXGOSNKBNBJAGV-UHFFFAOYSA-N
DMLRBN1	IU	7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one
DMLRBN1	CA	CAS 147778-05-0
DMLRBN1	DE	Alzheimer disease

DMAIJSX	ID	DMAIJSX
DMAIJSX	DN	L-701324
DMAIJSX	HS	Terminated
DMAIJSX	SN	L-701324; 142326-59-8; L-701,324; L 701324; UNII-I9WY146163; C21H14ClNO3; L 701,324; CHEMBL31741; 7-Chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolone; I9WY146163; 7-Chloro-4-hydroxy-3-(3-pheoxyphenyl)-2(1H)-quinolinone; 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-(3-pheoxyphenyl)-; SMR000326934; compund 13 [PMID: 8182696]; Tocris-0907; AC1L3GJN; Biomol-NT_000206; MLS002153302; MLS000860076; GTPL4240; SCHEMBL1998890; BPBio1_001264; CHEBI:92140; DTXSID00162016; EX-A587; MolPort-003-941-887; 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-(3-ph
DMAIJSX	DT	Small molecular drug
DMAIJSX	PC	54682505
DMAIJSX	MW	363.8
DMAIJSX	FM	C21H14ClNO3
DMAIJSX	IC	InChI=1S/C21H14ClNO3/c22-14-9-10-17-18(12-14)23-21(25)19(20(17)24)13-5-4-8-16(11-13)26-15-6-2-1-3-7-15/h1-12H,(H2,23,24,25)
DMAIJSX	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)C3=C(C4=C(C=C(C=C4)Cl)NC3=O)O
DMAIJSX	IK	FLVRDMUHUXVRET-UHFFFAOYSA-N
DMAIJSX	IU	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-1H-quinolin-2-one
DMAIJSX	CA	CAS 142326-59-8
DMAIJSX	CB	CHEBI:92140
DMAIJSX	DE	Cerebrovascular ischaemia

DMO7GWC	ID	DMO7GWC
DMO7GWC	DN	L-702958
DMO7GWC	HS	Terminated
DMO7GWC	SN	L 702958; 136078-58-5; L-702958; 150576-09-3; AC1L50NP; AC1Q3EU4; SCHEMBL9227313; L-702,958; DTXSID60159644; n-{1'-[(2r)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-oxo-3,4-dihydrospiro[chromene-2,4'-piperidin]-6-yl}methanesulfonamide hydrochloride(1:1); N-[1'-[(2R)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-oxospiro[3H-chromene-2,4'-piperidine]-6-yl]methanesulfonamide hydrochloride; Methanesulfonamide, N-(1'-(6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl)-3,4-dihydro-4-oxospiro(2H-1-benzopyran-2,4'-piperidin)-6-yl)-, 
DMO7GWC	CP	Merck & Co Inc
DMO7GWC	DT	Small molecular drug
DMO7GWC	PC	195821
DMO7GWC	MW	502
DMO7GWC	FM	C25H28ClN3O4S
DMO7GWC	IC	InChI=1S/C25H27N3O4S.ClH/c1-33(30,31)27-20-5-7-24-22(14-20)23(29)15-25(32-24)8-10-28(11-9-25)21-6-4-18-12-17(16-26)2-3-19(18)13-21;/h2-3,5,7,12,14,21,27H,4,6,8-11,13,15H2,1H3;1H/t21-;/m1./s1
DMO7GWC	CS	CS(=O)(=O)NC1=CC2=C(C=C1)OC3(CCN(CC3)[C@@H]4CCC5=C(C4)C=CC(=C5)C#N)CC2=O.Cl
DMO7GWC	IK	BASAUWFNEPUJDQ-ZMBIFBSDSA-N
DMO7GWC	IU	N-[1'-[(2R)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-oxospiro[3H-chromene-2,4'-piperidine]-6-yl]methanesulfonamide;hydrochloride
DMO7GWC	CA	CAS 136078-58-5
DMO7GWC	DE	Cardiac arrhythmias

DM47MKE	ID	DM47MKE
DM47MKE	DN	L-703014
DM47MKE	HS	Terminated
DM47MKE	SN	CHEMBL325687; BDBM50092114; 4-(1H-Indol-3-yl)-2-[2-(4-piperidin-4-yl-butyrylamino)-acetylamino]-butyric acid (L-703014)
DM47MKE	DT	Small molecular drug
DM47MKE	PC	44343739
DM47MKE	MW	428.5
DM47MKE	FM	C23H32N4O4
DM47MKE	IC	InChI=1S/C23H32N4O4/c28-21(7-3-4-16-10-12-24-13-11-16)26-15-22(29)27-20(23(30)31)9-8-17-14-25-19-6-2-1-5-18(17)19/h1-2,5-6,14,16,20,24-25H,3-4,7-13,15H2,(H,26,28)(H,27,29)(H,30,31)/t20-/m1/s1
DM47MKE	CS	C1CNCCC1CCCC(=O)NCC(=O)N[C@H](CCC2=CNC3=CC=CC=C32)C(=O)O
DM47MKE	IK	WDRKDCBKBCRZSK-HXUWFJFHSA-N
DM47MKE	IU	(2R)-4-(1H-indol-3-yl)-2-[[2-(4-piperidin-4-ylbutanoylamino)acetyl]amino]butanoic acid
DM47MKE	DE	Thrombosis

DMQZW6D	ID	DMQZW6D
DMQZW6D	DN	L-709049
DMQZW6D	HS	Terminated
DMQZW6D	SN	Ac-Yvad-cho; L-709049; 143313-51-3; Acetyl-tyrosyl-valyl-alanyl-aspartal; Caspase-1 Inhibitor I; CHEMBL37630; Ac-Tyr-Val-Ala-Asp-H; IL-1beta Converting Enzyme (ICE) Inhibitor I; acetyl-Tyr-Val-Ala-Asp-aldehyde; N-acetyl-Tyr-Val-Ala-Asp-aldehyde; (3S)-3-[(2S)-2-[(2S)-2-[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]-4-oxobutanoic acid; Ac-Tyr-Val-Ala-Asp-Aldehyde; AC1NSK2K; SCHEMBL4349143; BDBM10355; MolPort-016-580-695; N-acetyl-Tyr-Val-Ala-Asp aldehyde; ZINC3915255; 1600AH; NCGC00167338-01
DMQZW6D	DT	Small molecular drug
DMQZW6D	PC	5311139
DMQZW6D	MW	492.5
DMQZW6D	FM	C23H32N4O8
DMQZW6D	IC	InChI=1S/C23H32N4O8/c1-12(2)20(23(35)24-13(3)21(33)26-16(11-28)10-19(31)32)27-22(34)18(25-14(4)29)9-15-5-7-17(30)8-6-15/h5-8,11-13,16,18,20,30H,9-10H2,1-4H3,(H,24,35)(H,25,29)(H,26,33)(H,27,34)(H,31,32)/t13-,16-,18-,20-/m0/s1
DMQZW6D	CS	C[C@@H](C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)C
DMQZW6D	IK	LPIARALSGDVZEP-SJVNDZIOSA-N
DMQZW6D	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid

DMB3ZTI	ID	DMB3ZTI
DMB3ZTI	DN	L-709780
DMB3ZTI	HS	Terminated
DMB3ZTI	SN	CHEMBL32960; L-709780; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid
DMB3ZTI	DT	Small molecular drug
DMB3ZTI	PC	9885190
DMB3ZTI	MW	359.4
DMB3ZTI	FM	C19H25N3O4
DMB3ZTI	IC	InChI=1S/C19H25N3O4/c23-17(24)5-9-21-18(25)14-1-2-15-12-22(19(26)16(15)11-14)10-6-13-3-7-20-8-4-13/h1-2,11,13,20H,3-10,12H2,(H,21,25)(H,23,24)
DMB3ZTI	CS	C1CNCCC1CCN2CC3=C(C2=O)C=C(C=C3)C(=O)NCCC(=O)O
DMB3ZTI	IK	YAAYYZAARZCUQN-UHFFFAOYSA-N
DMB3ZTI	IU	3-[[3-oxo-2-(2-piperidin-4-ylethyl)-1H-isoindole-5-carbonyl]amino]propanoic acid

DM1XBKC	ID	DM1XBKC
DM1XBKC	DN	L-731735
DM1XBKC	HS	Terminated
DM1XBKC	SN	CHEMBL2052018; L-731735; SCHEMBL2723563
DM1XBKC	DT	Small molecular drug
DM1XBKC	PC	54041632
DM1XBKC	MW	420.6
DM1XBKC	FM	C19H40N4O4S
DM1XBKC	IC	InChI=1S/C19H40N4O4S/c1-5-12(3)16(21-9-14(20)11-28)10-22-17(13(4)6-2)18(25)23-15(7-8-24)19(26)27/h12-17,21-22,24,28H,5-11,20H2,1-4H3,(H,23,25)(H,26,27)/t12-,13-,14+,15-,16+,17-/m0/s1
DM1XBKC	CS	CC[C@H](C)[C@@H](CN[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCO)C(=O)O)NC[C@H](CS)N
DM1XBKC	IK	LMTIEVNRUFAFPM-NYXISSTPSA-N
DM1XBKC	IU	(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentyl]amino]-3-methylpentanoyl]amino]-4-hydroxybutanoic acid
DM1XBKC	DE	Solid tumour/cancer

DMVXKMF	ID	DMVXKMF
DMVXKMF	DN	L-732138
DMVXKMF	HS	Terminated
DMVXKMF	SN	L-732,138; 148451-96-1; 3,5-Bis(tfm)Bz nactrp; L-732138; 3,5-Bis(trifluoromethyl)benzyl N-acetyltryptophan; N-Acetyltryptophan 3,5-bis(trifluoromethyl)benzyl ester; L 732138; CHEMBL22870; N-Acetyl-L-trp-3,5-bistrifluoromethylbenzyl ester; L732138; N-Acetyl-L-tryptophan-3,5-bistrifluoromethylbenzyl ester; N-Acetyl-L-tryptophan 3,5-bis(trifluoromethyl)benzyl ester; [3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-acetamido-3-(1H-indol-3-yl)propanoate; AC-TRP-3,5-BIS(TRIFLUOROMETHYL)BENZYL ESTER; L-Tryptophan, N-acetyl-, (3,5-
DMVXKMF	DT	Small molecular drug
DMVXKMF	PC	132837
DMVXKMF	MW	472.4
DMVXKMF	FM	C22H18F6N2O3
DMVXKMF	IC	InChI=1S/C22H18F6N2O3/c1-12(31)30-19(8-14-10-29-18-5-3-2-4-17(14)18)20(32)33-11-13-6-15(21(23,24)25)9-16(7-13)22(26,27)28/h2-7,9-10,19,29H,8,11H2,1H3,(H,30,31)/t19-/m0/s1
DMVXKMF	CS	CC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMVXKMF	IK	BYYQYXVAWXAYQC-IBGZPJMESA-N
DMVXKMF	IU	[3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-acetamido-3-(1H-indol-3-yl)propanoate
DMVXKMF	CA	CAS 148451-96-1

DMA1NJW	ID	DMA1NJW
DMA1NJW	DN	L-733060
DMA1NJW	HS	Terminated
DMA1NJW	SN	L-733060; L 733060; 148700-85-0; L-733,060 hydrochloride; L-733061; L 733061; L 733,061; L 733,060; L-733,061; CHEMBL27006; 3-((3,5-Bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine; L-733,060; (2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine; Tocris-1145; AC1L31OI; Lopac0_000752; SCHEMBL1282817; CHEBI:92286; FCDRFVCGMLUYPG-ROUUACIJSA-N; ZINC3809445; BDBM50049468; AKOS030230939; CCG-204837; API0013970; NCGC00025030-02; NCGC00025030-01; KB-78050; l733060; LS-114326; BRD-K15791587-003-01-7
DMA1NJW	DT	Small molecular drug
DMA1NJW	PC	132846
DMA1NJW	MW	403.4
DMA1NJW	FM	C20H19F6NO
DMA1NJW	IC	InChI=1S/C20H19F6NO/c21-19(22,23)15-9-13(10-16(11-15)20(24,25)26)12-28-17-7-4-8-27-18(17)14-5-2-1-3-6-14/h1-3,5-6,9-11,17-18,27H,4,7-8,12H2/t17-,18-/m0/s1
DMA1NJW	CS	C1C[C@@H]([C@@H](NC1)C2=CC=CC=C2)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMA1NJW	IK	FCDRFVCGMLUYPG-ROUUACIJSA-N
DMA1NJW	IU	(2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine
DMA1NJW	CA	CAS 148700-85-0
DMA1NJW	CB	CHEBI:92286

DMYZPJU	ID	DMYZPJU
DMYZPJU	DN	L-733560
DMYZPJU	HS	Terminated
DMYZPJU	SN	AC1L4318; L 733560; Pneumocandin B0, 1-((4R,5R)-5-(2-aminoethoxy)-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-((3R)-3-hydroxy-L-ornithine)
DMYZPJU	CP	Merck & Co Inc
DMYZPJU	PC	177900
DMYZPJU	MW	1092.3
DMYZPJU	FM	C52H85N9O16
DMYZPJU	IC	InChI=1S/C52H85N9O16/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(68)55-34-26-38(67)50(77-23-21-54)59-49(74)43-37(66)19-22-60(43)52(76)41(36(65)18-20-53)57-48(73)42(45(70)44(69)31-14-16-32(63)17-15-31)58-47(72)35-25-33(64)27-61(35)51(75)40(30(4)62)56-46(34)71/h14-17,28-30,33-38,40-43,45,50,62-67,70H,5-13,18-27,53-54H2,1-4H3,(H,55,68)(H,56,71)(H,57,73)(H,58,72)(H,59,74)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40?,41+,42?,43+,45+,50+/m1/s1
DMYZPJU	CS	CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]3C[C@H](CN3C(=O)C(NC1=O)[C@@H](C)O)O)[C@@H](C(=O)C4=CC=C(C=C4)O)O)[C@@H](CCN)O)O)OCCN)O
DMYZPJU	IK	UWUVRFXWJQIKTQ-NQPUGUJXSA-N
DMYZPJU	IU	N-[(3S,9S,11R,18S,20R,21S,24S,25S)-21-(2-aminoethoxy)-3-[(1R)-3-amino-1-hydroxypropyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-6-[(1S)-1-hydroxy-2-(4-hydroxyphenyl)-2-oxoethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
DMYZPJU	CA	CAS 150283-06-0
DMYZPJU	DE	Aspergillosis

DMO69X8	ID	DMO69X8
DMO69X8	DN	L-738167
DMO69X8	HS	Terminated
DMO69X8	SN	L-738167; CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)
DMO69X8	DT	Small molecular drug
DMO69X8	PC	153986
DMO69X8	MW	546.6
DMO69X8	FM	C25H34N6O6S
DMO69X8	IC	InChI=1S/C25H34N6O6S/c1-17-3-5-19(6-4-17)38(36,37)29-21(25(34)35)16-27-23(32)20-15-22-24(33)30(12-2-13-31(22)28-20)14-9-18-7-10-26-11-8-18/h3-6,15,18,21,26,29H,2,7-14,16H2,1H3,(H,27,32)(H,34,35)/t21-/m0/s1
DMO69X8	CS	CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CNC(=O)C2=NN3CCCN(C(=O)C3=C2)CCC4CCNCC4)C(=O)O
DMO69X8	IK	YLFFZEQHDMFOEC-NRFANRHFSA-N
DMO69X8	IU	(2S)-2-[(4-methylphenyl)sulfonylamino]-3-[[4-oxo-5-(2-piperidin-4-ylethyl)-7,8-dihydro-6H-pyrazolo[1,5-a][1,4]diazepine-2-carbonyl]amino]propanoic acid
DMO69X8	CA	CAS 163212-43-9

DMAUG0L	ID	DMAUG0L
DMAUG0L	DN	L-739749
DMAUG0L	HS	Terminated
DMAUG0L	SN	CHEMBL99645; BDBM50059867; (S)-2-{(S)-2-[(S)-2-((R)-2-Amino-3-mercapto-propylamino)-3-methyl-pentyloxy]-3-phenyl-propionylamino}-4-methanesulfonyl-butyric acid methyl ester; (S)-methyl 2-((S)-2-((2S,3R)-2-((R)-2-amino-3-mercaptopropylamino)-3-methylpentyloxy)-3-phenylpropanamido)-4-(methylsulfonyl)butanoate
DMAUG0L	DT	Small molecular drug
DMAUG0L	PC	158357
DMAUG0L	MW	531.7
DMAUG0L	FM	C24H41N3O6S2
DMAUG0L	IC	InChI=1S/C24H41N3O6S2/c1-5-17(2)21(26-14-19(25)16-34)15-33-22(13-18-9-7-6-8-10-18)23(28)27-20(24(29)32-3)11-12-35(4,30)31/h6-10,17,19-22,26,34H,5,11-16,25H2,1-4H3,(H,27,28)/t17-,19+,20-,21+,22-/m0/s1
DMAUG0L	CS	CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC)NC[C@H](CS)N
DMAUG0L	IK	XDPAYLCHZOZGMW-NDYOWHOSSA-N
DMAUG0L	IU	methyl (2S)-2-[[(2S)-2-[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoate
DMAUG0L	CA	CAS 156511-34-1
DMAUG0L	DE	Solid tumour/cancer

DMNSH0V	ID	DMNSH0V
DMNSH0V	DN	L-741604
DMNSH0V	HS	Terminated
DMNSH0V	SN	L-741604; CHEMBL296161; SCHEMBL6943364; IGNXHSPBUUSUHB-UHFFFAOYSA-N; BDBM50060426; L010084; N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethylamine; Dimethyl-[2-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-ethyl]-amine
DMNSH0V	DT	Small molecular drug
DMNSH0V	PC	9881526
DMNSH0V	MW	255.32
DMNSH0V	FM	C14H17N5
DMNSH0V	IC	InChI=1S/C14H17N5/c1-18(2)6-5-11-8-15-14-4-3-12(7-13(11)14)19-9-16-17-10-19/h3-4,7-10,15H,5-6H2,1-2H3
DMNSH0V	CS	CN(C)CCC1=CNC2=C1C=C(C=C2)N3C=NN=C3
DMNSH0V	IK	IGNXHSPBUUSUHB-UHFFFAOYSA-N
DMNSH0V	IU	N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethanamine

DMRVXEQ	ID	DMRVXEQ
DMRVXEQ	DN	L-741671
DMRVXEQ	HS	Terminated
DMRVXEQ	DT	Small molecular drug
DMRVXEQ	PC	135539114
DMRVXEQ	MW	500.4
DMRVXEQ	FM	C23H22F6N4O2
DMRVXEQ	IC	InChI=1S/C23H22F6N4O2/c24-22(25,26)16-9-14(10-17(11-16)23(27,28)29)13-35-18-7-4-8-33(12-19-30-21(34)32-31-19)20(18)15-5-2-1-3-6-15/h1-3,5-6,9-11,18,20H,4,7-8,12-13H2,(H2,30,31,32,34)/t18-,20-/m0/s1
DMRVXEQ	CS	C1C[C@@H]([C@@H](N(C1)CC2=NNC(=O)N2)C3=CC=CC=C3)OCC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMRVXEQ	IK	ZUWHBRRBKKTMQO-ICSRJNTNSA-N
DMRVXEQ	IU	3-[[(2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidin-1-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one
DMRVXEQ	CA	CAS 187724-85-2
DMRVXEQ	DE	Vomiting

DMOQIWH	ID	DMOQIWH
DMOQIWH	DN	L-745337
DMOQIWH	HS	Terminated
DMOQIWH	SN	Thioflosulide; L-745337; CHEMBL287919; 158205-05-1; L 745337; L 745,337; L-745,337; SCHEMBL2464202; ZINC1887701; BDBM50029603; CS-6783; N-(6-((2,4-Difluorophenyl)thio)-2,3-dihydro-1-oxo-1H-inden-5-yl)methanesulfonamide; HY-19217; L745,337
DMOQIWH	DT	Small molecular drug
DMOQIWH	PC	9799453
DMOQIWH	MW	369.4
DMOQIWH	FM	C16H13F2NO3S2
DMOQIWH	IC	InChI=1S/C16H13F2NO3S2/c1-24(21,22)19-13-6-9-2-4-14(20)11(9)8-16(13)23-15-5-3-10(17)7-12(15)18/h3,5-8,19H,2,4H2,1H3
DMOQIWH	CS	CS(=O)(=O)NC1=C(C=C2C(=C1)CCC2=O)SC3=C(C=C(C=C3)F)F
DMOQIWH	IK	HDUWKQUHMUSICC-UHFFFAOYSA-N
DMOQIWH	IU	N-[6-(2,4-difluorophenyl)sulfanyl-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide
DMOQIWH	CA	CAS 158205-05-1
DMOQIWH	DE	Asthma

DM4UP7R	ID	DM4UP7R
DM4UP7R	DN	L-745631
DM4UP7R	HS	Terminated
DM4UP7R	SN	CHEMBL103575; L-745631; SCHEMBL16111943; BDBM50059846
DM4UP7R	DT	Small molecular drug
DM4UP7R	PC	44332320
DM4UP7R	MW	387.5
DM4UP7R	FM	C21H29N3O2S
DM4UP7R	IC	InChI=1S/C21H29N3O2S/c1-26-12-9-18-14-24(11-10-23(18)13-17(22)15-27)21(25)20-8-4-6-16-5-2-3-7-19(16)20/h2-8,17-18,27H,9-15,22H2,1H3/t17-,18+/m0/s1
DM4UP7R	CS	COCC[C@@H]1CN(CCN1C[C@@H](CS)N)C(=O)C2=CC=CC3=CC=CC=C32
DM4UP7R	IK	GKTZPBPAMFCBNI-ZWKOTPCHSA-N
DM4UP7R	IU	[(3R)-4-[(2S)-2-amino-3-sulfanylpropyl]-3-(2-methoxyethyl)piperazin-1-yl]-naphthalen-1-ylmethanone
DM4UP7R	DE	Solid tumour/cancer

DMPWBNU	ID	DMPWBNU
DMPWBNU	DN	L-755507
DMPWBNU	HS	Terminated
DMPWBNU	SN	159182-43-1; L755507; L-755,507; CHEMBL12998; 4-[[(HEXYLAMINO)CARBONYL]AMINO]-N-[4-[2-[[(2S)-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYL]AMINO]ETHYL]PHENYL]-BENZENESULFONAMIDE; L 755507; SCHEMBL5165122; GTPL3931; MolPort-003-983-607; ZINC3939153; EX-A2397; s7974; BDBM50070156; AKOS024456983; CP-0074; CS-7782; NCGC00092331-01; HY-19334; F10055; L755507, &gt; J-009574; L-755 507; (S)-4-(3-hexylureido)-N-(4-(2-(1-hydroxy-2-(4-hydroxyphenoxy)ethylamino)ethyl)phenyl)benzenesulfonamide
DMPWBNU	DT	Small molecular drug
DMPWBNU	PC	9829836
DMPWBNU	MW	584.7
DMPWBNU	FM	C30H40N4O6S
DMPWBNU	IC	InChI=1S/C30H40N4O6S/c1-2-3-4-5-19-32-30(37)33-24-10-16-29(17-11-24)41(38,39)34-25-8-6-23(7-9-25)18-20-31-21-27(36)22-40-28-14-12-26(35)13-15-28/h6-17,27,31,34-36H,2-5,18-22H2,1H3,(H2,32,33,37)/t27-/m0/s1
DMPWBNU	CS	CCCCCCNC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CCNC[C@@H](COC3=CC=C(C=C3)O)O
DMPWBNU	IK	NYYJKMXNVNFOFQ-MHZLTWQESA-N
DMPWBNU	IU	1-hexyl-3-[4-[[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]sulfamoyl]phenyl]urea
DMPWBNU	CA	CAS 159182-43-1

DM17S85	ID	DM17S85
DM17S85	DN	L-757464
DM17S85	HS	Terminated
DM17S85	SN	5-Chloro-2-[4-[4-(2-oxo-2,3-dihydrobenzoxazol-3-yl)piperidin-1-yl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide
DM17S85	CP	Merck & Co Inc
DM17S85	DE	Prostate hyperplasia

DM7J6QH	ID	DM7J6QH
DM7J6QH	DN	L-768277
DM7J6QH	HS	Terminated
DM7J6QH	SN	L-766112
DM7J6QH	CP	Merck Sharp & Dohme Research Laboratories
DM7J6QH	DE	Hyperthermia

DMZ402C	ID	DMZ402C
DMZ402C	DN	L-768673
DMZ402C	HS	Terminated
DMZ402C	SN	L-768673; CHEMBL16900; SCHEMBL7207125; BDBM50061209; LS-28521; l-768,673
DMZ402C	DT	Small molecular drug
DMZ402C	PC	9851380
DMZ402C	MW	587.4
DMZ402C	FM	C27H18F9N3O2
DMZ402C	IC	InChI=1S/C27H18F9N3O2/c28-25(29,30)14-39-20-9-5-4-8-18(20)22(15-6-2-1-3-7-15)38-23(24(39)41)37-21(40)12-16-10-11-17(26(31,32)33)13-19(16)27(34,35)36/h1-11,13,23H,12,14H2,(H,37,40)/t23-/m1/s1
DMZ402C	CS	C1=CC=C(C=C1)C2=N[C@H](C(=O)N(C3=CC=CC=C32)CC(F)(F)F)NC(=O)CC4=C(C=C(C=C4)C(F)(F)F)C(F)(F)F
DMZ402C	IK	VVCYJFVTVHMTBV-HSZRJFAPSA-N
DMZ402C	IU	2-[2,4-bis(trifluoromethyl)phenyl]-N-[(3R)-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-3-yl]acetamide
DMZ402C	CA	CAS 177954-68-6

DMJ37IX	ID	DMJ37IX
DMJ37IX	DN	L-775606
DMJ37IX	HS	Terminated
DMJ37IX	SN	L-775606; L-775,606; CHEMBL292779; 188400-51-3; 1-(3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl)-4-(2-(3-fluorophenyl)ethyl)piperazine; 3-[3-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]propyl]-5-(1,2,4-triazol-4-yl)-1H-indole; ZUTQCPBDRJBADG-UHFFFAOYSA-N; 1-[3-(5-(1,2,4-Triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(3-fluorophenyl)ethyl]piperazine; 1-(3-[5-{1,2,4-triazol-4-yl}-1h-indol-3-yl]propyl)-4-(2-{3-fluorophenyl}ethyl)piperazine; AC1O52LD; GTPL114; L 775606; SCHEMBL7477108; BDBM50060437; L016148; 1H-Indole, 3-(3-(4-(2-
DMJ37IX	DT	Small molecular drug
DMJ37IX	PC	6426760
DMJ37IX	MW	432.5
DMJ37IX	FM	C25H29FN6
DMJ37IX	IC	InChI=1S/C25H29FN6/c26-22-5-1-3-20(15-22)8-10-31-13-11-30(12-14-31)9-2-4-21-17-27-25-7-6-23(16-24(21)25)32-18-28-29-19-32/h1,3,5-7,15-19,27H,2,4,8-14H2
DMJ37IX	CS	C1CN(CCN1CCCC2=CNC3=C2C=C(C=C3)N4C=NN=C4)CCC5=CC(=CC=C5)F
DMJ37IX	IK	ZUTQCPBDRJBADG-UHFFFAOYSA-N
DMJ37IX	IU	3-[3-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]propyl]-5-(1,2,4-triazol-4-yl)-1H-indole
DMJ37IX	CA	CAS 188400-51-3

DM07S4N	ID	DM07S4N
DM07S4N	DN	LAS-30538
DM07S4N	HS	Terminated
DM07S4N	SN	Las 30538; Las-30538; 145067-04-5; AC1L31FQ; DTXSID60162875; 1-(2-(2,6-Dimethylphenoxy)ethyl)-alpha,alpha-bis-(p-fluorophenyl)-4-piperidine methanol; 4-Piperidinemethanol, 1-(2-(2,6-dimethylphenoxy)ethyl)-alpha,alpha-bis(4-fluorophenyl)-
DM07S4N	CP	Almirall Prodesfarma SA
DM07S4N	DT	Small molecular drug
DM07S4N	PC	132693
DM07S4N	MW	451.5
DM07S4N	FM	C28H31F2NO2
DM07S4N	IC	InChI=1S/C28H31F2NO2/c1-20-4-3-5-21(2)27(20)33-19-18-31-16-14-24(15-17-31)28(32,22-6-10-25(29)11-7-22)23-8-12-26(30)13-9-23/h3-13,24,32H,14-19H2,1-2H3
DM07S4N	CS	CC1=C(C(=CC=C1)C)OCCN2CCC(CC2)C(C3=CC=C(C=C3)F)(C4=CC=C(C=C4)F)O
DM07S4N	IK	BIZCZAJFIUSFDU-UHFFFAOYSA-N
DM07S4N	IU	[1-[2-(2,6-dimethylphenoxy)ethyl]piperidin-4-yl]-bis(4-fluorophenyl)methanol
DM07S4N	CA	CAS 145067-04-5
DM07S4N	DE	Hyperinsulinemia

DMW2K1L	ID	DMW2K1L
DMW2K1L	DN	LAS-31180
DMW2K1L	HS	Terminated
DMW2K1L	SN	LAS-31180; LAS 31180; 137338-43-3; AC1Q6VQ1; AC1L50OY; ZINC8845; SCHEMBL7287896; DTXSID70160140; n-(1-methyl-4-oxo-1,4-dihydroquinolin-3-yl)methanesulfonamide; CS-6714; HY-101811
DMW2K1L	CP	Almirall Prodesfarma SA
DMW2K1L	DT	Small molecular drug
DMW2K1L	PC	195841
DMW2K1L	MW	252.29
DMW2K1L	FM	C11H12N2O3S
DMW2K1L	IC	InChI=1S/C11H12N2O3S/c1-13-7-9(12-17(2,15)16)11(14)8-5-3-4-6-10(8)13/h3-7,12H,1-2H3
DMW2K1L	CS	CN1C=C(C(=O)C2=CC=CC=C21)NS(=O)(=O)C
DMW2K1L	IK	LSIYNVMXGMDGMG-UHFFFAOYSA-N
DMW2K1L	IU	N-(1-methyl-4-oxoquinolin-3-yl)methanesulfonamide
DMW2K1L	CA	CAS 137338-43-3
DMW2K1L	DE	Heart failure

DMYGJCL	ID	DMYGJCL
DMYGJCL	DN	LB30057
DMYGJCL	HS	Terminated
DMYGJCL	DT	Small molecular drug
DMYGJCL	PC	9913629
DMYGJCL	MW	493.6
DMYGJCL	FM	C26H31N5O3S
DMYGJCL	IC	InChI=1S/C26H31N5O3S/c1-31(22-8-4-5-9-22)26(32)24(16-18-10-12-20(13-11-18)25(27)29-28)30-35(33,34)23-15-14-19-6-2-3-7-21(19)17-23/h2-3,6-7,10-15,17,22,24,30H,4-5,8-9,16,28H2,1H3,(H2,27,29)/t24-/m0/s1
DMYGJCL	CS	CN(C1CCCC1)C(=O)[C@H](CC2=CC=C(C=C2)/C(=N/N)/N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3
DMYGJCL	IK	ZPDICRPCOSQEDS-DEOSSOPVSA-N
DMYGJCL	IU	(2S)-3-[4-[(Z)-C-aminocarbonohydrazonoyl]phenyl]-N-cyclopentyl-N-methyl-2-(naphthalen-2-ylsulfonylamino)propanamide
DMYGJCL	CA	CAS 184770-78-3

DMFEMTG	ID	DMFEMTG
DMFEMTG	DN	Lecimibide
DMFEMTG	HS	Terminated
DMFEMTG	SN	DuP-128
DMFEMTG	CP	Bristol-Myers Squibb Pharma Co
DMFEMTG	DT	Small molecular drug
DMFEMTG	PC	71355
DMFEMTG	MW	590.8
DMFEMTG	FM	C34H40F2N4OS
DMFEMTG	IC	InChI=1S/C34H40F2N4OS/c1-2-3-4-5-13-22-40(34(41)37-30-21-20-28(35)25-29(30)36)23-14-8-15-24-42-33-38-31(26-16-9-6-10-17-26)32(39-33)27-18-11-7-12-19-27/h6-7,9-12,16-21,25H,2-5,8,13-15,22-24H2,1H3,(H,37,41)(H,38,39)
DMFEMTG	CS	CCCCCCCN(CCCCCSC1=NC(=C(N1)C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NC4=C(C=C(C=C4)F)F
DMFEMTG	IK	TVXOXGBTADZYCZ-UHFFFAOYSA-N
DMFEMTG	IU	3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfanyl]pentyl]-1-heptylurea
DMFEMTG	CA	CAS 130804-35-2
DMFEMTG	DE	Hyperlipidaemia

DMIYMS2	ID	DMIYMS2
DMIYMS2	DN	LF-984
DMIYMS2	HS	Terminated
DMIYMS2	CP	Fournier Pharma
DMIYMS2	DE	Fibrosis

DMNXKR2	ID	DMNXKR2
DMNXKR2	DN	LG-2293
DMNXKR2	HS	Terminated
DMNXKR2	SN	LG-121100
DMNXKR2	CP	Ligand Pharmaceuticals Inc
DMNXKR2	DE	Prostate cancer

DMF9XU4	ID	DMF9XU4
DMF9XU4	DN	LM-1376
DMF9XU4	HS	Terminated
DMF9XU4	CP	Laboratorios Menarini SA
DMF9XU4	PC	9891157
DMF9XU4	MW	476.5
DMF9XU4	FM	C30H24N2O4
DMF9XU4	IC	InChI=1S/C30H24N2O4/c33-29(31-16-15-20-5-7-23(8-6-20)30(34)35)24-10-9-21-12-14-27(18-25(21)17-24)36-19-26-13-11-22-3-1-2-4-28(22)32-26/h1-14,17-18H,15-16,19H2,(H,31,33)(H,34,35)
DMF9XU4	CS	C1=CC=C2C(=C1)C=CC(=N2)COC3=CC4=C(C=CC(=C4)C(=O)NCCC5=CC=C(C=C5)C(=O)O)C=C3
DMF9XU4	IK	IXSRNSVQRMOPTQ-UHFFFAOYSA-N
DMF9XU4	IU	4-[2-[[7-(quinolin-2-ylmethoxy)naphthalene-2-carbonyl]amino]ethyl]benzoic acid
DMF9XU4	DE	Asthma

DM6Y49D	ID	DM6Y49D
DM6Y49D	DN	L-NIL
DM6Y49D	HS	Terminated
DM6Y49D	SN	L-NIL; N(6)-acetimidoyllysine; H-Lys(acetimidoyl)-OH; N~6~-[(1z)-Ethanimidoyl]-L-Lysine; N(6)-acetimidoyl-L-lysine; N(6)-ethanimidoyl-L-lysine; CHEMBL7889; L-N(6)-(1-iminoethyl)lysine; CHEBI:63971; L-N(omega)-(1-iminoethyl)lysine; 53774-63-3; N-(iminoethyl)-L-lysine; L-NIL;H-Lys(1-iminoethyl)-OH;N-(5-Amino-5-carboxypentyl)-acetamidine; L-N6-(1-Iminoethyl)lysine; Tocris-1139; NCGC00015566-01; N6-ethanimidoyl-L-lysine; Lopac-I-8021; AC1MBZ26; (L-N6-1-iminoethyl)lysine; SCHEMBL322091; L-Lysine,n6-(1-iminoethyl)-; DTXSID9041071
DM6Y49D	DT	Small molecular drug
DM6Y49D	PC	2733506
DM6Y49D	MW	187.24
DM6Y49D	FM	C8H17N3O2
DM6Y49D	IC	InChI=1S/C8H17N3O2/c1-6(9)11-5-3-2-4-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1
DM6Y49D	CS	CC(=NCCCC[C@@H](C(=O)O)N)N
DM6Y49D	IK	ONYFNWIHJBLQKE-ZETCQYMHSA-N
DM6Y49D	IU	(2S)-2-amino-6-(1-aminoethylideneamino)hexanoic acid
DM6Y49D	CB	CHEBI:63971

DM904B6	ID	DM904B6
DM904B6	DN	Lorglumide
DM904B6	HS	Terminated
DM904B6	SN	Lorglumide; 97964-56-2; Lorglumide [INN]; Lorglumidum [Latin]; Lorglumida [Spanish]; CR-1409; CCRIS 6857; CHEMBL24938; CHEBI:88307; CR 1409; D,L-4-(3,4-Dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pentanoic acid; Lorglumida; Lorglumidum; (+-)-4-(3,4-Dichlorobenzamido)-N,N-dipentylglutaramic acid; 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid; Pentanoic acid, 4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxo-, (+-)-; C22H32Cl2N2O4; 4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxopentanoic a
DM904B6	DT	Small molecular drug
DM904B6	PC	3960
DM904B6	MW	459.4
DM904B6	FM	C22H32Cl2N2O4
DM904B6	IC	InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)
DM904B6	CS	CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
DM904B6	IK	IEKOTSCYBBDIJC-UHFFFAOYSA-N
DM904B6	IU	4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
DM904B6	CA	CAS 97964-56-2
DM904B6	CB	CHEBI:88307
DM904B6	DE	Pancreatic malfunction

DMFJPYV	ID	DMFJPYV
DMFJPYV	DN	LSI-518P
DMFJPYV	HS	Terminated
DMFJPYV	SN	HDL mimetics (atherosclerosis), Lipid Sciences
DMFJPYV	CP	Lipid Sciences Inc
DMFJPYV	DE	Cardiovascular disease

DMDHLUC	ID	DMDHLUC
DMDHLUC	DN	LU-29252
DMDHLUC	HS	Terminated
DMDHLUC	CP	H Lundbeck A/S
DMDHLUC	DE	Anxiety disorder

DMXRJQV	ID	DMXRJQV
DMXRJQV	DN	Luzindole
DMXRJQV	HS	Terminated
DMXRJQV	SN	Luzindole, Interneuron
DMXRJQV	CP	Endo Pharmaceuticals Solutions Inc
DMXRJQV	DT	Small molecular drug
DMXRJQV	PC	122162
DMXRJQV	MW	292.4
DMXRJQV	FM	C19H20N2O
DMXRJQV	IC	InChI=1S/C19H20N2O/c1-14(22)20-12-11-17-16-9-5-6-10-18(16)21-19(17)13-15-7-3-2-4-8-15/h2-10,21H,11-13H2,1H3,(H,20,22)
DMXRJQV	CS	CC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3
DMXRJQV	IK	WVVXBPKOIZGVNS-UHFFFAOYSA-N
DMXRJQV	IU	N-[2-(2-benzyl-1H-indol-3-yl)ethyl]acetamide
DMXRJQV	CA	CAS 117946-91-5
DMXRJQV	CB	CHEBI:93173
DMXRJQV	DE	Sleep-wake disorder

DMMRLPF	ID	DMMRLPF
DMMRLPF	DN	LX-2932
DMMRLPF	HS	Terminated
DMMRLPF	SN	S1P lyase inhibitor (autoimmune diseases), Lexicon; Sphingosine-1-phosphate lyase inhibitor (autoimmune diseases), Lexicon
DMMRLPF	CP	Lexicon Pharmaceuticals Inc
DMMRLPF	DT	Small molecular drug
DMMRLPF	PC	135912123
DMMRLPF	MW	255.23
DMMRLPF	FM	C10H13N3O5
DMMRLPF	IC	InChI=1S/C10H13N3O5/c14-4-7(15)9(17)8(16)6-3-11-10(12-6)5-1-2-18-13-5/h1-3,7-9,14-17H,4H2,(H,11,12)/t7-,8-,9-/m1/s1
DMMRLPF	CS	C1=CON=C1C2=NC=C(N2)[C@H]([C@@H]([C@@H](CO)O)O)O
DMMRLPF	IK	WGDPRIZUIYIENM-IWSPIJDZSA-N
DMMRLPF	IU	(1R,2S,3R)-1-[2-(1,2-oxazol-3-yl)-1H-imidazol-5-yl]butane-1,2,3,4-tetrol
DMMRLPF	CA	CAS 1055027-48-9
DMMRLPF	DE	Autoimmune diabetes

DMXYDJR	ID	DMXYDJR
DMXYDJR	DN	LXR-015-2
DMXYDJR	HS	Terminated
DMXYDJR	SN	Elirex; LXR-1035
DMXYDJR	CP	LXR Biotechnology Inc
DMXYDJR	DE	Ischemia

DMUHG0F	ID	DMUHG0F
DMUHG0F	DN	LY-117018
DMUHG0F	HS	Terminated
DMUHG0F	SN	LY-117018; Lilly 117018; LY 117018; 63676-25-5; CHEBI:90187; LY 139478; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}methanone; 6-Hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl 4-(2-(1-pyrrolidinyl)ethoxy) phenyl ketone; Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-; PHENETHIPYLONE; 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-pyrrolidinyl)ethoxy] phenyl ketone; LY117018; AC1L2XRN; AC1Q5D9H; CHEMBL10030
DMUHG0F	DT	Small molecular drug
DMUHG0F	PC	104946
DMUHG0F	MW	459.6
DMUHG0F	FM	C27H25NO4S
DMUHG0F	IC	InChI=1S/C27H25NO4S/c29-20-7-3-19(4-8-20)27-25(23-12-9-21(30)17-24(23)33-27)26(31)18-5-10-22(11-6-18)32-16-15-28-13-1-2-14-28/h3-12,17,29-30H,1-2,13-16H2
DMUHG0F	CS	C1CCN(C1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
DMUHG0F	IK	JLERVPBPJHKRBJ-UHFFFAOYSA-N
DMUHG0F	IU	[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone
DMUHG0F	CA	CAS 63676-25-5
DMUHG0F	CB	CHEBI:90187

DMUEB4P	ID	DMUEB4P
DMUEB4P	DN	LY-210073
DMUEB4P	HS	Terminated
DMUEB4P	SN	LY210073; LY-210073; 148291-65-0; CHEMBL49210; LY 210073; SCHEMBL9148299; AC1O515S; BDBM50045092; HY-U00263; AKOS030562935; CS-7479; L005236; 5-(2-carboxyethyl)-6-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]-9-oxoxanthene-2-carboxylic acid; 7-Carboxy-3-[[(E)-6-(4-methoxyphenyl)-5-hexenyl]oxy]-9-oxo-9H-xanthene-4-propanoic acid; (E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid; 7-Carboxy-3-((6-(methoxyphenyl)-5(E)-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid
DMUEB4P	CP	Eli Lilly & Co
DMUEB4P	DT	Small molecular drug
DMUEB4P	PC	6450158
DMUEB4P	MW	516.5
DMUEB4P	FM	C30H28O8
DMUEB4P	IC	InChI=1S/C30H28O8/c1-36-21-10-7-19(8-11-21)6-4-2-3-5-17-37-25-15-12-23-28(33)24-18-20(30(34)35)9-14-26(24)38-29(23)22(25)13-16-27(31)32/h4,6-12,14-15,18H,2-3,5,13,16-17H2,1H3,(H,31,32)(H,34,35)/b6-4+
DMUEB4P	CS	COC1=CC=C(C=C1)/C=C/CCCCOC2=C(C3=C(C=C2)C(=O)C4=C(O3)C=CC(=C4)C(=O)O)CCC(=O)O
DMUEB4P	IK	MTTBGOLFCYOWSV-GQCTYLIASA-N
DMUEB4P	IU	5-(2-carboxyethyl)-6-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]-9-oxoxanthene-2-carboxylic acid
DMUEB4P	CA	CAS 148291-65-0
DMUEB4P	DE	Asthma

DMJ54E9	ID	DMJ54E9
DMJ54E9	DN	LY-221068
DMJ54E9	HS	Terminated
DMJ54E9	SN	LY 221068; LY-221068; 132392-39-3; AC1O5RGH; SCHEMBL2746042; ly221068; 5-((3,5-Bis(1,1,-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-
DMJ54E9	CP	Eli Lilly & Co
DMJ54E9	DT	Small molecular drug
DMJ54E9	PC	6439333
DMJ54E9	MW	362.5
DMJ54E9	FM	C20H30N2O2S
DMJ54E9	IC	InChI=1S/C20H30N2O2S/c1-19(2,3)14-9-13(10-15(17(14)23)20(4,5)6)11-16-18(24)22(12-25-16)21(7)8/h9-11,23H,12H2,1-8H3/b16-11-
DMJ54E9	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)N(CS2)N(C)C
DMJ54E9	IK	DNXBQWAKVPAADQ-WJDWOHSUSA-N
DMJ54E9	IU	(5Z)-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-3-(dimethylamino)-1,3-thiazolidin-4-one
DMJ54E9	CA	CAS 132392-39-3
DMJ54E9	DE	Arthritis

DMIDK36	ID	DMIDK36
DMIDK36	DN	LY-243062
DMIDK36	HS	Terminated
DMIDK36	CP	Eli Lilly & Co
DMIDK36	DE	Inflammation

DMFIR0S	ID	DMFIR0S
DMFIR0S	DN	LY-255283
DMFIR0S	HS	Terminated
DMFIR0S	SN	GTPL3351; MolPort-009-018-745; HMS3649C08; ZINC27644044; SR-01000946596; SR-01000946596-1
DMFIR0S	DT	Small molecular drug
DMFIR0S	PC	122023
DMFIR0S	MW	360.5
DMFIR0S	FM	C19H28N4O3
DMFIR0S	IC	InChI=1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)
DMFIR0S	CS	CCC1=CC(=C(C=C1OCCCCCC(C)(C)C2=NNN=N2)O)C(=O)C
DMFIR0S	IK	WCGXJPFHTHQNJL-UHFFFAOYSA-N
DMFIR0S	IU	1-[5-ethyl-2-hydroxy-4-[6-methyl-6-(2H-tetrazol-5-yl)heptoxy]phenyl]ethanone
DMFIR0S	CA	CAS 117690-79-6
DMFIR0S	CB	CHEBI:93616
DMFIR0S	DE	Asthma

DMG79NT	ID	DMG79NT
DMG79NT	DN	LY-274614
DMG79NT	HS	Terminated
DMG79NT	SN	LY 235959; 137433-06-8; UNII-AR2BHC0C6P; LY-235959; AR2BHC0C6P; Decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid; 3-Isoquinolinecarboxylic acid, decahydro-6-(phosphonomethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-; LY-274614; C11H20NO5P; LY 274614; 136109-04-1; Tocris-1019; LY274614; LY235959; Biomol-NT_000192; SCHEMBL195083; BPBio1_001216; AC1L302W; CHEMBL1448057; CTK0H8339; MolPort-023-275-977; 3-Isoquinolinecarboxylicacid, decahydro-6-(phosphonomethyl)-, (3S,4aR,6S,8aR)-; ZINC31424744; AKOS024456335; NCGC00024942-02
DMG79NT	CP	Eli Lilly & Co
DMG79NT	DT	Small molecular drug
DMG79NT	PC	131938
DMG79NT	MW	277.25
DMG79NT	FM	C11H20NO5P
DMG79NT	IC	InChI=1S/C11H20NO5P/c13-11(14)10-4-9-3-7(6-18(15,16)17)1-2-8(9)5-12-10/h7-10,12H,1-6H2,(H,13,14)(H2,15,16,17)/t7-,8-,9+,10-/m0/s1
DMG79NT	CS	C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CP(=O)(O)O)C(=O)O
DMG79NT	IK	STIRHCNEGQQBOY-QEYWKRMJSA-N
DMG79NT	IU	(3S,4aR,6S,8aR)-6-(phosphonomethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
DMG79NT	CA	CAS 137433-06-8
DMG79NT	DE	Dementia

DMG8YE9	ID	DMG8YE9
DMG8YE9	DN	LY288513
DMG8YE9	HS	Terminated
DMG8YE9	SN	LY-288512; CHEMBL117281; (4R,5S)-N-(4-bromophenyl)-3-oxo-4,5-diphenylpyrazolidine-1-carboxamide; LY-262691; GTPL902; SCHEMBL8846984; ZINC538559; BDBM50092157; 3-Oxo-4,5-diphenyl-pyrazolidine-1-carboxylic acid (4-bromo-phenyl)-amide(LY288512); (4R,5S)-3-Oxo-4,5-diphenyl-pyrazolidine-1-carboxylic acid (4-bromo-phenyl)-amide
DMG8YE9	DT	Small molecular drug
DMG8YE9	PC	132190
DMG8YE9	MW	436.3
DMG8YE9	FM	C22H18BrN3O2
DMG8YE9	IC	InChI=1S/C22H18BrN3O2/c23-17-11-13-18(14-12-17)24-22(28)26-20(16-9-5-2-6-10-16)19(21(27)25-26)15-7-3-1-4-8-15/h1-14,19-20H,(H,24,28)(H,25,27)
DMG8YE9	CS	C1=CC=C(C=C1)C2C(N(NC2=O)C(=O)NC3=CC=C(C=C3)Br)C4=CC=CC=C4
DMG8YE9	IK	LMUQHXHWJWQXSD-UHFFFAOYSA-N
DMG8YE9	IU	N-(4-bromophenyl)-3-oxo-4,5-diphenylpyrazolidine-1-carboxamide
DMG8YE9	CA	CAS 138932-35-1
DMG8YE9	DE	Anxiety disorder

DMPZ7AO	ID	DMPZ7AO
DMPZ7AO	DN	LY-290154
DMPZ7AO	HS	Terminated
DMPZ7AO	CP	Eli Lilly & Co
DMPZ7AO	DE	Asthma

DMU24HR	ID	DMU24HR
DMU24HR	DN	LY-292728
DMU24HR	HS	Terminated
DMU24HR	SN	LY-292728; LY 292728; 153034-77-6; CHEMBL292782; 9H-Xanthene-4-propanoicacid,7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-; ACMC-20ddq7; AC1Q4NQC; AC1L4UN3; SCHEMBL13696764; CTK4C7669; DTXSID00165204; BDBM50029464; 9h-xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-; L011726; 5-(2-carboxyethyl)-6-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-9-oxoxanthene-2-carboxylic acid
DMU24HR	DT	Small molecular drug
DMU24HR	PC	192617
DMU24HR	MW	600.6
DMU24HR	FM	C34H29FO9
DMU24HR	IC	InChI=1S/C34H29FO9/c1-2-19-16-25(20-4-7-22(35)8-5-20)27(36)18-30(19)43-15-3-14-42-28-12-9-24-32(39)26-17-21(34(40)41)6-11-29(26)44-33(24)23(28)10-13-31(37)38/h4-9,11-12,16-18,36H,2-3,10,13-15H2,1H3,(H,37,38)(H,40,41)
DMU24HR	CS	CCC1=CC(=C(C=C1OCCCOC2=C(C3=C(C=C2)C(=O)C4=C(O3)C=CC(=C4)C(=O)O)CCC(=O)O)O)C5=CC=C(C=C5)F
DMU24HR	IK	DCTKEJXAVFAMFK-UHFFFAOYSA-N
DMU24HR	IU	5-(2-carboxyethyl)-6-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-9-oxoxanthene-2-carboxylic acid
DMU24HR	CA	CAS 153034-77-6

DMH21JG	ID	DMH21JG
DMH21JG	DN	LY-293284
DMH21JG	HS	Terminated
DMH21JG	SN	LY-293284; LY 293284; 141318-62-9; LY293284; 6-Acetyl-4-(di-n-propylamino)-1,3,4,5-tetrahydrobenz(c,d)indole; LY-293,284; 1-(4-Dipropylamino-1,3,4,5-tetrahydro-benzo[cd]indol-6-yl)-ethanone; Ethanone, 1-(4-(dipropylamino)-1,3,4,5-tetrahydrobenz(cd)indol-6-yl)-, (R)-; GTPL19; AC1L30TM; SCHEMBL6902000; DTXSID70161692; LS-173111
DMH21JG	CP	Eli Lilly & Co
DMH21JG	DT	Small molecular drug
DMH21JG	PC	132345
DMH21JG	MW	298.4
DMH21JG	FM	C19H26N2O
DMH21JG	IC	InChI=1S/C19H26N2O/c1-4-8-21(9-5-2)15-10-14-12-20-18-7-6-16(13(3)22)17(11-15)19(14)18/h6-7,12,15,20H,4-5,8-11H2,1-3H3/t15-/m0/s1
DMH21JG	CS	CCCN(CCC)[C@H]1CC2=CNC3=C2C(=C(C=C3)C(=O)C)C1
DMH21JG	IK	CKYZLYQSDNLGPT-HNNXBMFYSA-N
DMH21JG	IU	1-[(4R)-4-(dipropylamino)-1,3,4,5-tetrahydrobenzo[cd]indol-6-yl]ethanone
DMH21JG	CA	CAS 141318-62-9
DMH21JG	DE	Anxiety disorder

DMM20PI	ID	DMM20PI
DMM20PI	DN	LY-317644
DMM20PI	HS	Terminated
DMM20PI	SN	LY-317644; CHEMBL294120; BDBM50285193
DMM20PI	DT	Small molecular drug
DMM20PI	PC	15391529
DMM20PI	MW	455.5
DMM20PI	FM	C27H25N3O4
DMM20PI	IC	InChI=1S/C27H25N3O4/c31-16-17-10-12-30-15-21(19-7-2-4-9-23(19)30)25-24(26(32)28-27(25)33)20-14-29(11-5-13-34-17)22-8-3-1-6-18(20)22/h1-4,6-9,14-15,17,31H,5,10-13,16H2,(H,28,32,33)
DMM20PI	CS	C1CN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCC(OC1)CO)C6=CC=CC=C65)C(=O)NC4=O
DMM20PI	IK	XIFXMAQLEGCDQV-UHFFFAOYSA-N
DMM20PI	IU	17-(hydroxymethyl)-18-oxa-4,14,22-triazahexacyclo[20.6.1.17,14.02,6.08,13.023,28]triaconta-1(29),2(6),7(30),8,10,12,23,25,27-nonaene-3,5-dione

DMFVYID	ID	DMFVYID
DMFVYID	DN	LY-353433
DMFVYID	HS	Terminated
DMFVYID	SN	LY-343031; LY-343032; LY-314580 (oxalate); LY-350355 (maleate)
DMFVYID	CP	Eli Lilly & Co Ltd
DMFVYID	PC	9826941
DMFVYID	MW	491.7
DMFVYID	FM	C29H41N5O2
DMFVYID	IC	InChI=1S/C29H41N5O2/c1-19(2)34-25-6-4-3-5-24(25)26(32-34)27(35)30-9-12-33-10-7-23(8-11-33)31-28(36)29-16-20-13-21(17-29)15-22(14-20)18-29/h3-6,19-23H,7-18H2,1-2H3,(H,30,35)(H,31,36)
DMFVYID	CS	CC(C)N1C2=CC=CC=C2C(=N1)C(=O)NCCN3CCC(CC3)NC(=O)C45CC6CC(C4)CC(C6)C5
DMFVYID	IK	QEZYDSSGVBTNBH-UHFFFAOYSA-N
DMFVYID	IU	N-[2-[4-(adamantane-1-carbonylamino)piperidin-1-yl]ethyl]-1-propan-2-ylindazole-3-carboxamide
DMFVYID	CA	CAS 176390-32-2
DMFVYID	DE	Inflammatory bowel disease

DM98POQ	ID	DM98POQ
DM98POQ	DN	LY-367385
DM98POQ	HS	Terminated
DM98POQ	SN	Metabotropic mGluR1 agonists, Lilly; L-367385 analogs, Lilly
DM98POQ	CP	Lilly Research Centre Ltd
DM98POQ	DT	Small molecular drug
DM98POQ	PC	5311261
DM98POQ	MW	209.2
DM98POQ	FM	C10H11NO4
DM98POQ	IC	InChI=1S/C10H11NO4/c1-5-4-6(9(12)13)2-3-7(5)8(11)10(14)15/h2-4,8H,11H2,1H3,(H,12,13)(H,14,15)/t8-/m0/s1
DM98POQ	CS	CC1=C(C=CC(=C1)C(=O)O)[C@@H](C(=O)O)N
DM98POQ	IK	SGIKDIUCJAUSRD-QMMMGPOBSA-N
DM98POQ	IU	4-[(S)-amino(carboxy)methyl]-3-methylbenzoic acid
DM98POQ	CA	CAS 198419-91-9
DM98POQ	DE	Neurological disorder

DM0TV9L	ID	DM0TV9L
DM0TV9L	DN	LY467711
DM0TV9L	HS	Terminated
DM0TV9L	SN	BDBM86756; LY 467711
DM0TV9L	CP	Eli Lilly
DM0TV9L	TC	Analgesics
DM0TV9L	DT	Small molecular drug
DM0TV9L	PC	129715717
DM0TV9L	MW	435.9
DM0TV9L	FM	C21H30ClN5O3
DM0TV9L	IC	InChI=1S/C21H29N5O3.ClH/c1-13(2)12-28-21(27)18-10-15-9-16(8-7-14(15)11-22-18)29-19-6-4-3-5-17(19)20-23-25-26-24-20;/h3-6,13-16,18,22H,7-12H2,1-2H3,(H,23,24,25,26);1H/t14-,15+,16+,18+;/m0./s1
DM0TV9L	CS	CC(C)COC(=O)[C@H]1C[C@H]2C[C@@H](CC[C@H]2CN1)OC3=CC=CC=C3C4=NNN=N4.Cl
DM0TV9L	IK	STJGUHHJXMUHAN-DYZVKEBGSA-N
DM0TV9L	IU	2-methylpropyl (3R,4aS,6R,8aR)-6-[2-(2H-tetrazol-5-yl)phenoxy]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate;hydrochloride
DM0TV9L	DE	Migraine; Neuropathic pain

DMPNMAR	ID	DMPNMAR
DMPNMAR	DN	LY525327
DMPNMAR	HS	Terminated
DMPNMAR	SN	CHEMBL187941; BDBM86753; BDBM50168966; LY-525327; LY 525327; LS-193664; (3S,4aR,6S,8aR)-6-[2-(1H-Tetrazol-5-yl)-phenylamino]-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester
DMPNMAR	CP	Eli Lilly
DMPNMAR	TC	Analgesics
DMPNMAR	DT	Small molecular drug
DMPNMAR	PC	11249042
DMPNMAR	MW	426.6
DMPNMAR	FM	C23H34N6O2
DMPNMAR	IC	InChI=1S/C23H34N6O2/c1-3-15(4-2)14-31-23(30)21-12-17-11-18(10-9-16(17)13-24-21)25-20-8-6-5-7-19(20)22-26-28-29-27-22/h5-8,15-18,21,24-25H,3-4,9-14H2,1-2H3,(H,26,27,28,29)/t16-,17+,18-,21-/m0/s1
DMPNMAR	CS	CCC(CC)COC(=O)[C@@H]1C[C@H]2C[C@H](CC[C@H]2CN1)NC3=CC=CC=C3C4=NNN=N4
DMPNMAR	IK	KQDBQKHPLFHNIW-NYUBLWNDSA-N
DMPNMAR	IU	2-ethylbutyl (3S,4aR,6S,8aR)-6-[2-(2H-tetrazol-5-yl)anilino]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate
DMPNMAR	DE	Migraine; Neuropathic pain

DMY71LJ	ID	DMY71LJ
DMY71LJ	DN	LY53857
DMY71LJ	HS	Terminated
DMY71LJ	SN	UNII-OK43YC00I7; OK43YC00I7; LY53857; LY 53857; LY-53857 free base; Biomol-NT_000165; AC1MHY97; Lopac0_000721; GTPL183; BPBio1_000595; CHEMBL1356280; CCG-204806; NCGC00163176-01; LY-53,857; LS-187317; Ergoline-8beta-carboxylic acid, 1-isopropyl-6-methyl-, 2-hydroxy-1-methylpropyl ester; 6-Methyl-1-isopropylergoline-8beta-carboxylic acid 2-hydroxy-1-methylpropyl ester; 6-methyl-1-(1-methylethyl)ergoline-8beta-carboxylic acid 2-hydroxy-1-methylpropyl ester; Ergoline-8-carboxylic acid, 6-methyl-1-(1-methylethyl)-, 2-hydroxy-1-m
DMY71LJ	DT	Small molecular drug
DMY71LJ	PC	3034814
DMY71LJ	MW	384.5
DMY71LJ	FM	C23H32N2O3
DMY71LJ	IC	InChI=1S/C23H32N2O3/c1-13(2)25-12-16-10-21-19(18-7-6-8-20(25)22(16)18)9-17(11-24(21)5)23(27)28-15(4)14(3)26/h6-8,12-15,17,19,21,26H,9-11H2,1-5H3/t14?,15?,17-,19-,21-/m1/s1
DMY71LJ	CS	CC(C)N1C=C2C[C@@H]3[C@H](C[C@H](CN3C)C(=O)OC(C)C(C)O)C4=C2C1=CC=C4
DMY71LJ	IK	JQYLIGHHVGCTPR-LYRPIDSHSA-N
DMY71LJ	IU	3-hydroxybutan-2-yl (6aR,9R,10aR)-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxylate
DMY71LJ	CA	CAS 32896-53-0

DM679IY	ID	DM679IY
DM679IY	DN	LZ-8
DM679IY	HS	Terminated
DM679IY	SN	Lzip; FIP-gts; Ling Zhi-8; Protein adjuvant, Yeastern
DM679IY	CP	Meiji Institute of Health Science
DM679IY	DE	Autoimmune diabetes

DMUIGM3	ID	DMUIGM3
DMUIGM3	DN	M-216765
DMUIGM3	HS	Terminated
DMUIGM3	SN	IDDB3562
DMUIGM3	CP	Zeneca Group plc
DMUIGM3	DE	Hypertension

DMIY51U	ID	DMIY51U
DMIY51U	DN	M-241247
DMIY51U	HS	Terminated
DMIY51U	SN	M-244249; NMDA/glycine antagonists, Zeneca
DMIY51U	CP	Zeneca Group plc
DMIY51U	DE	Cerebrovascular ischaemia

DMBFCHW	ID	DMBFCHW
DMBFCHW	DN	M-40401
DMBFCHW	HS	Terminated
DMBFCHW	CP	Metaphore Pharmaceuticals Inc
DMBFCHW	DE	Cerebrovascular ischaemia

DM1SWOY	ID	DM1SWOY
DM1SWOY	DN	MANUMYCIN A
DM1SWOY	HS	Terminated
DM1SWOY	SN	manumycin; Manumycin A; Ucfi-C; UNII-OIQ298X4XD; AC1O5PHE; OIQ298X4XD; CHEBI:29623; C31H38N2O7; 52665-74-4; 2,4-Decadienamide, N-(5-hydroxy-5-(7-((2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino)-7-oxo-1,3,5-heptatrienyl)-2-oxo-7-oxabicyclo(4.1.0)hept-3-en-3-yl)-2,4,6-trimethyl-; (2E,4E,6R)-N-[(1S,5S,6R)-5-hydroxy-5-[(1E,3E,5E)-7-[(2-hydroxy-5-oxo-cyclopenten-1-yl)amino]-7-oxo-hepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyl-deca-2,4-dienamide; ( )-Manumycin A; BSPBio_001231; SCHEMBL12519093
DM1SWOY	DT	Small molecular drug
DM1SWOY	PC	6438330
DM1SWOY	MW	550.6
DM1SWOY	FM	C31H38N2O7
DM1SWOY	IC	InChI=1S/C31H38N2O7/c1-5-6-11-19(2)16-20(3)17-21(4)30(38)32-22-18-31(39,29-28(40-29)27(22)37)15-10-8-7-9-12-25(36)33-26-23(34)13-14-24(26)35/h7-10,12,15-19,28-29,34,39H,5-6,11,13-14H2,1-4H3,(H,32,38)(H,33,36)/b8-7+,12-9+,15-10+,20-16+,21-17+/t19-,28-,29-,31+/m1/s1
DM1SWOY	CS	CCCC[C@@H](C)/C=C(\\C)/C=C(\\C)/C(=O)NC1=C[C@]([C@H]2[C@@H](C1=O)O2)(/C=C/C=C/C=C/C(=O)NC3=C(CCC3=O)O)O
DM1SWOY	IK	TWWQHCKLTXDWBD-MVTGTTCWSA-N
DM1SWOY	IU	(2E,4E,6R)-N-[(1S,5S,6R)-5-hydroxy-5-[(1E,3E,5E)-7-[(2-hydroxy-5-oxocyclopenten-1-yl)amino]-7-oxohepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide
DM1SWOY	CA	CAS 52665-74-4
DM1SWOY	CB	CHEBI:29623

DM31WQC	ID	DM31WQC
DM31WQC	DN	Maxy-10
DM31WQC	HS	Terminated
DM31WQC	SN	Optimized interferon beta, Maxygen; Beta-interferon (optimized), Maxygen
DM31WQC	CP	Maxygen Inc
DM31WQC	DE	Autoimmune diabetes

DMXLCB6	ID	DMXLCB6
DMXLCB6	DN	MCI-826
DMXLCB6	HS	Terminated
DMXLCB6	SN	(E)-2,2-Diethyl-3'-[2-[2-(4-isopropyl)thiazolyl]ethenyl]succinanilic acid; (E)-2,2-Diethyl-N-[3-[2-(4-isopropylthiazol-2-yl)vinyl]phenyl]succinamic acid
DMXLCB6	DT	Small molecular drug
DMXLCB6	PC	6439428
DMXLCB6	MW	400.5
DMXLCB6	FM	C22H28N2O3S
DMXLCB6	IC	InChI=1S/C22H28N2O3S/c1-5-22(6-2,21(26)27)13-19(25)23-17-9-7-8-16(12-17)10-11-20-24-18(14-28-20)15(3)4/h7-12,14-15H,5-6,13H2,1-4H3,(H,23,25)(H,26,27)/b11-10+
DMXLCB6	CS	CCC(CC)(CC(=O)NC1=CC=CC(=C1)/C=C/C2=NC(=CS2)C(C)C)C(=O)O
DMXLCB6	IK	PGLNVMJTDKEOBE-ZHACJKMWSA-N
DMXLCB6	IU	2,2-diethyl-4-oxo-4-[3-[(E)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]anilino]butanoic acid
DMXLCB6	CA	CAS 140646-80-6
DMXLCB6	DE	Asthma

DMRSOBG	ID	DMRSOBG
DMRSOBG	DN	Mdl 101,146
DMRSOBG	HS	Terminated
DMRSOBG	SN	UNII-2D08A509S3; CHEBI:45517; CHEMBL56852; 1-{3-METHYL-2-[4-(MORPHOLINE-4-CARBONYL)-BENZOYLAMINO]-BUTYRYL}-PYRROLIDINE-2-CARBOXYLIC ACID (3,3,4,4,4-PENTAFLUORO-1-ISOPROPYL-2-OXO-BUTYL)-AMIDE; 2D08A509S3; Mdl 101,146; N-[4-(morpholin-4-ylcarbonyl)benzoyl]-L-valyl-N-[(3S)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]-L-prolinamide; N-{[4-(morpholin-4-ylcarbonyl)phenyl]carbonyl}-L-valyl-N-[(1S)-3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-L-prolinamide; MDL-101146, (S)-; AC1NRD4J; BDBM50058341; 163660-59-1
DMRSOBG	DT	Small molecular drug
DMRSOBG	PC	46936357
DMRSOBG	MW	632.6
DMRSOBG	FM	C29H37F5N4O6
DMRSOBG	IC	InChI=1S/C29H37F5N4O6/c1-16(2)21(23(39)28(30,31)29(32,33)34)35-25(41)20-6-5-11-38(20)27(43)22(17(3)4)36-24(40)18-7-9-19(10-8-18)26(42)37-12-14-44-15-13-37/h7-10,16-17,20-22H,5-6,11-15H2,1-4H3,(H,35,41)(H,36,40)/t20-,21-,22-/m1/s1
DMRSOBG	CS	CC(C)[C@H](C(=O)C(C(F)(F)F)(F)F)NC(=O)[C@H]1CCCN1C(=O)[C@@H](C(C)C)NC(=O)C2=CC=C(C=C2)C(=O)N3CCOCC3
DMRSOBG	IK	XQAMVCHQGHAELT-YPAWHYETSA-N
DMRSOBG	IU	(2R)-1-[(2R)-3-methyl-2-[[4-(morpholine-4-carbonyl)benzoyl]amino]butanoyl]-N-[(3R)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]pyrrolidine-2-carboxamide
DMRSOBG	CA	CAS 149859-17-6
DMRSOBG	DE	Inflammation

DMHUJCI	ID	DMHUJCI
DMHUJCI	DN	MDL-105519
DMHUJCI	HS	Terminated
DMHUJCI	SN	Mdl 105519; MDL 105,519; 161230-88-2; Lopac-M-216; AC1O7G4O; Lopac0_000805; C18H11Cl2NO4; SCHEMBL499902; CHEMBL180427; AOB5684; HMS3262B11; ZINC1540415; Tox21_500805; AKOS027324667; LP00805; CCG-204889; CS-3882; NCGC00015639-04; NCGC00015639-01; NCGC00094138-02; NCGC00015639-03; NCGC00261490-01; NCGC00015639-02; HY-15085; X6860; M-216; EU-0100805; SR-01000075460; SR-01000075460-1
DMHUJCI	DT	Small molecular drug
DMHUJCI	PC	6603913
DMHUJCI	MW	376.2
DMHUJCI	FM	C18H11Cl2NO4
DMHUJCI	IC	InChI=1S/C18H11Cl2NO4/c19-10-6-13(20)15-12(16(18(24)25)21-14(15)7-10)8-11(17(22)23)9-4-2-1-3-5-9/h1-8,21H,(H,22,23)(H,24,25)/b11-8+
DMHUJCI	CS	C1=CC=C(C=C1)/C(=C\\C2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O)/C(=O)O
DMHUJCI	IK	LPWVUDLZUVBQGP-DHZHZOJOSA-N
DMHUJCI	IU	3-[(E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-1H-indole-2-carboxylic acid

DMMG1K3	ID	DMMG1K3
DMMG1K3	DN	MDL-201112
DMMG1K3	HS	Terminated
DMMG1K3	SN	Carbocyclic nucleoside, Hoechst; MDL-201449; MDL-201449A
DMMG1K3	CP	Hoechst Marion Roussel Inc
DMMG1K3	DT	Small molecular drug
DMMG1K3	PC	132408
DMMG1K3	MW	219.24
DMMG1K3	FM	C10H13N5O
DMMG1K3	IC	InChI=1S/C10H13N5O/c11-9-8-10(13-4-12-9)15(5-14-8)6-1-2-7(16)3-6/h4-7,16H,1-3H2,(H2,11,12,13)/t6-,7+/m0/s1
DMMG1K3	CS	C1C[C@H](C[C@H]1N2C=NC3=C(N=CN=C32)N)O
DMMG1K3	IK	UZNXSBPBWFLVDK-NKWVEPMBSA-N
DMMG1K3	IU	(1R,3S)-3-(6-aminopurin-9-yl)cyclopentan-1-ol
DMMG1K3	CA	CAS 142130-73-2
DMMG1K3	DE	Colitis

DM6X4IT	ID	DM6X4IT
DM6X4IT	DN	MDL-28133A
DM6X4IT	HS	Terminated
DM6X4IT	SN	Mdl 28133A; 136861-96-6; N-[4-[1-[2-(4-fluorophenyl)-2-oxo-ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide hydrochloride; Mdl-28,133A; ACMC-20mwcf; AC1L307E; CTK0H5594; DTXSID60159987; 1-(4-Fluorophenyl)-2-(4-((4-methanosulfonamidophenyl)carbonyl)-1-piperidinyl)ethanone hydrochloride; N-[4-[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide hydrochloride; Methanesulfonamide, N-(4-((1-(2-(4-fluorophenyl)-2-oxoethyl)-4-piperidinyl)carbonyl)phenyl)-, monohydrochloride
DM6X4IT	CP	Hoechst Marion Roussel Inc
DM6X4IT	DT	Small molecular drug
DM6X4IT	PC	132001
DM6X4IT	MW	454.9
DM6X4IT	FM	C21H24ClFN2O4S
DM6X4IT	IC	InChI=1S/C21H23FN2O4S.ClH/c1-29(27,28)23-19-8-4-16(5-9-19)21(26)17-10-12-24(13-11-17)14-20(25)15-2-6-18(22)7-3-15;/h2-9,17,23H,10-14H2,1H3;1H
DM6X4IT	CS	CS(=O)(=O)NC1=CC=C(C=C1)C(=O)C2CCN(CC2)CC(=O)C3=CC=C(C=C3)F.Cl
DM6X4IT	IK	YVIOSUWCZDHHEI-UHFFFAOYSA-N
DM6X4IT	IU	N-[4-[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide;hydrochloride
DM6X4IT	CA	CAS 136861-96-6
DM6X4IT	DE	Thrombosis

DM8ZDU2	ID	DM8ZDU2
DM8ZDU2	DN	MDL-28161
DM8ZDU2	HS	Terminated
DM8ZDU2	SN	MDL-28161; CHEMBL344273; SCHEMBL9328582
DM8ZDU2	DT	Small molecular drug
DM8ZDU2	PC	44363475
DM8ZDU2	MW	313.4
DM8ZDU2	FM	C20H24FNO
DM8ZDU2	IC	InChI=1S/C20H24FNO/c21-19-8-6-16(7-9-19)10-13-22-14-11-18(12-15-22)20(23)17-4-2-1-3-5-17/h1-9,18,20,23H,10-15H2
DM8ZDU2	CS	C1CN(CCC1C(C2=CC=CC=C2)O)CCC3=CC=C(C=C3)F
DM8ZDU2	IK	HRSUYEGDQAVTRC-UHFFFAOYSA-N
DM8ZDU2	IU	[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]-phenylmethanol

DMYK31O	ID	DMYK31O
DMYK31O	DN	MDL-28170
DMYK31O	HS	Terminated
DMYK31O	SN	MDL-2170
DMYK31O	DT	Small molecular drug
DMYK31O	PC	72430
DMYK31O	MW	382.5
DMYK31O	FM	C22H26N2O4
DMYK31O	IC	InChI=1S/C22H26N2O4/c1-16(2)20(24-22(27)28-15-18-11-7-4-8-12-18)21(26)23-19(14-25)13-17-9-5-3-6-10-17/h3-12,14,16,19-20H,13,15H2,1-2H3,(H,23,26)(H,24,27)/t19-,20-/m0/s1
DMYK31O	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)OCC2=CC=CC=C2
DMYK31O	IK	NGBKFLTYGSREKK-PMACEKPBSA-N
DMYK31O	IU	benzyl N-[(2S)-3-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]carbamate
DMYK31O	CA	CAS 88191-84-8
DMYK31O	CB	CHEBI:82818
DMYK31O	DE	Alzheimer disease

DMBIDQX	ID	DMBIDQX
DMBIDQX	DN	MDL-43291
DMBIDQX	HS	Terminated
DMBIDQX	SN	Mdl 43291; Mdl 43,291; AC1MI0EN; ((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; (4aalpha,7Z,8beta,8abeta)-((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; Acetic acid, ((octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)-, (4aalpha,7Z,8beta,8abeta)-; 2-[[(2Z,4aS,8S,8aS)-2-(2-oxotetradecan-7-ylidene)-3,4,4a,5,6,7,8,8a-octahydrochromen-8-yl]sulfanyl]acetic acid
DMBIDQX	CP	Hoechst Marion Roussel Inc
DMBIDQX	DT	Small molecular drug
DMBIDQX	PC	14430182
DMBIDQX	MW	438.7
DMBIDQX	FM	C25H42O4S
DMBIDQX	IC	InChI=1S/C25H42O4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-21-16-15-20-17-18-23(28)29-24(20)25(21)30-19-22(26)27/h14,20,24-25H,2-13,15-19H2,1H3,(H,26,27)/b21-14+/t20-,24-,25-/m1/s1
DMBIDQX	CS	CCCCCCCCCCCCC/C=C/1\\CC[C@@H]2CCC(=O)O[C@H]2[C@@H]1SCC(=O)O
DMBIDQX	IK	GKTHCWOVKAXGOW-HTJMSZESSA-N
DMBIDQX	IU	2-[[(4aR,7E,8R,8aR)-2-oxo-7-tetradecylidene-4,4a,5,6,8,8a-hexahydro-3H-chromen-8-yl]sulfanyl]acetic acid
DMBIDQX	DE	Asthma

DMHX6IC	ID	DMHX6IC
DMHX6IC	DN	ME-3221
DMHX6IC	HS	Terminated
DMHX6IC	SN	EF-2831
DMHX6IC	CP	Meiji Seika Kaisha Ltd
DMHX6IC	DT	Small molecular drug
DMHX6IC	PC	178553
DMHX6IC	MW	387.4
DMHX6IC	FM	C22H21N5O2
DMHX6IC	IC	InChI=1S/C22H21N5O2/c1-14-12-20(21(28-3)15(2)23-14)29-13-16-8-10-17(11-9-16)18-6-4-5-7-19(18)22-24-26-27-25-22/h4-12H,13H2,1-3H3,(H,24,25,26,27)
DMHX6IC	CS	CC1=CC(=C(C(=N1)C)OC)OCC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4
DMHX6IC	IK	FTDRSCZZEUAAIP-UHFFFAOYSA-N
DMHX6IC	IU	3-methoxy-2,6-dimethyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methoxy]pyridine
DMHX6IC	CA	CAS 139958-16-0
DMHX6IC	DE	Hypertension

DMT3B4G	ID	DMT3B4G
DMT3B4G	DN	MEDI-500
DMT3B4G	HS	Terminated
DMT3B4G	SN	T10B9; T10B9.1A31
DMT3B4G	CP	University of Kentucky
DMT3B4G	DE	Bone marrow transplantation

DM4G0D5	ID	DM4G0D5
DM4G0D5	DN	MEDI-542
DM4G0D5	HS	Terminated
DM4G0D5	SN	Ephrin a4-targeting monoclonal antibody (cancer), MedImmune
DM4G0D5	CP	Medlmmune LLC
DM4G0D5	DT	Antibody
DM4G0D5	DE	Solid tumour/cancer

DM185DR	ID	DM185DR
DM185DR	DN	MEN-10207
DM185DR	HS	Terminated
DM185DR	SN	Men 10207; MEN-10207; 126050-12-2; 5-Tyr-6,8,9-trp-10-arg-nka (4-10); 5-Tyr-6,8,9-trp-10-arg-neurokinin A (4-10); DTXSID50155059; Neurokinin A (4-10), tyrosyl(5)-tryptophyl(6,8,9)-arginine(10)-; Neurokinin A (4-10), tyr(5)-trp(6,8,9)-arg(10)-; L-Argininamide, L-alpha-aspartyl-L-tyrosyl-D-tryptophyl-L-valyl-D-tryptophyl-D-tryptophyl-
DM185DR	CP	The Menarini Group
DM185DR	PC	25079030
DM185DR	MW	1109.2
DM185DR	FM	C57H68N14O10
DM185DR	IC	InChI=1S/C57H68N14O10/c1-30(2)49(71-55(80)47(25-34-29-65-42-15-8-5-12-38(34)42)69-52(77)44(22-31-17-19-35(72)20-18-31)67-51(76)39(58)26-48(73)74)56(81)70-46(24-33-28-64-41-14-7-4-11-37(33)41)54(79)68-45(23-32-27-63-40-13-6-3-10-36(32)40)53(78)66-43(50(59)75)16-9-21-62-57(60)61/h3-8,10-15,17-20,27-30,39,43-47,49,63-65,72H,9,16,21-26,58H2,1-2H3,(H2,59,75)(H,66,78)(H,67,76)(H,68,79)(H,69,77)(H,70,81)(H,71,80)(H,73,74)(H4,60,61,62)/t39-,43-,44-,45+,46+,47+,49-/m0/s1
DM185DR	CS	CC(C)[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CC(=O)O)N
DM185DR	IK	RLHLZLAKTUPWES-PEURKWGASA-N
DM185DR	IU	(3S)-3-amino-4-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DM185DR	CA	CAS 126050-12-2
DM185DR	DE	Pain

DM35ABD	ID	DM35ABD
DM35ABD	DN	MEN-10627
DM35ABD	HS	Terminated
DM35ABD	SN	MEN10627; 157351-81-0; AC1NSKCE; GTPL3901; cyc(2beta-5beta)(Met-Asp-Trp-Phe-Dap-Leu); (1R,4S,7S,10R,13R,16S)-13-(1H-indol-3-ylmethyl)-4-(2-methylpropyl)-7-(2-methylsulfanylethyl)-16-(phenylmethyl)-3,6,9,12,15,18,20-heptazabicyclo[8.8.4]docosane-2,5,8,11,14,17,21-heptone
DM35ABD	CP	The Menarini Group
DM35ABD	DT	Small molecular drug
DM35ABD	PC	10327792
DM35ABD	MW	760.9
DM35ABD	FM	C38H48N8O7S
DM35ABD	IC	InChI=1S/C38H48N8O7S/c1-21(2)15-27-34(49)41-26(13-14-54-3)33(48)45-30-18-32(47)40-20-31(38(53)42-27)46-35(50)28(16-22-9-5-4-6-10-22)43-36(51)29(44-37(30)52)17-23-19-39-25-12-8-7-11-24(23)25/h4-12,19,21,26-31,39H,13-18,20H2,1-3H3,(H,40,47)(H,41,49)(H,42,53)(H,43,51)(H,44,52)(H,45,48)(H,46,50)/t26-,27-,28-,29-,30-,31-/m0/s1
DM35ABD	CS	CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CC(=O)NC[C@@H](C(=O)N1)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CCSC
DM35ABD	IK	CFDNUNSOUUFTQO-HPMAGDRPSA-N
DM35ABD	IU	(1S,4S,7S,10S,13S,16S)-4-benzyl-7-(1H-indol-3-ylmethyl)-16-(2-methylpropyl)-13-(2-methylsulfanylethyl)-2,5,8,11,14,17,20-heptazabicyclo[8.8.4]docosane-3,6,9,12,15,18,21-heptone
DM35ABD	DE	Asthma

DM57S3D	ID	DM57S3D
DM57S3D	DN	MEN-10690
DM57S3D	HS	Terminated
DM57S3D	SN	MEN 10690; AC1LA5QI; CHEMBL36080; 11-ethyl-6,8,9-trimethylpyrido[3,2-c][2,1,5]benzothiadiazepine 5,5-dioxide; 11-ethyl-6,8,9-trimethyl-pyrido[3,2-c][2,1,5]benzothiadiazepine 5,5-dioxide; 5-Ethyl-7,8,10-trimethyl-5,10-dihydro-11-thia-4,5,10-triaza-11H-dibenzo[a,d]cycloheptene 11,11-dioxide
DM57S3D	CP	The Menarini Group
DM57S3D	DT	Small molecular drug
DM57S3D	PC	462253
DM57S3D	MW	317.4
DM57S3D	FM	C16H19N3O2S
DM57S3D	IC	InChI=1S/C16H19N3O2S/c1-5-19-14-10-12(3)11(2)9-13(14)18(4)22(20,21)15-7-6-8-17-16(15)19/h6-10H,5H2,1-4H3
DM57S3D	CS	CCN1C2=C(C=C(C(=C2)C)C)N(S(=O)(=O)C3=C1N=CC=C3)C
DM57S3D	IK	WLQKTBMFEMJDPC-UHFFFAOYSA-N
DM57S3D	IU	11-ethyl-6,8,9-trimethylpyrido[3,2-c][2,1,5]benzothiadiazepine 5,5-dioxide
DM57S3D	DE	Human immunodeficiency virus-1 infection

DMKS1W0	ID	DMKS1W0
DMKS1W0	DN	MEN-10880
DMKS1W0	HS	Terminated
DMKS1W0	SN	MEN 10880; AC1LA5Q9
DMKS1W0	CP	The Menarini Group
DMKS1W0	DT	Small molecular drug
DMKS1W0	PC	462250
DMKS1W0	MW	310.4
DMKS1W0	FM	C16H14N4OS
DMKS1W0	IC	InChI=1S/C16H14N4OS/c1-3-20-13-12-11(7-5-8-17-12)21-14(13)16(22)19(2)10-6-4-9-18-15(10)20/h4-9H,3H2,1-2H3
DMKS1W0	CS	CCN1C2=C(C(=S)N(C3=C1N=CC=C3)C)OC4=C2N=CC=C4
DMKS1W0	IK	SSUWZXRTDXAIQO-UHFFFAOYSA-N
DMKS1W0	IU	2-ethyl-9-methyl-12-oxa-2,4,9,17-tetrazatetracyclo[9.7.0.03,8.013,18]octadeca-1(11),3(8),4,6,13(18),14,16-heptaene-10-thione
DMKS1W0	DE	Human immunodeficiency virus-1 infection

DM6UYN1	ID	DM6UYN1
DM6UYN1	DN	MEN-10979
DM6UYN1	HS	Terminated
DM6UYN1	SN	MEN 10979; AC1LA5PO
DM6UYN1	CP	The Menarini Group
DM6UYN1	DT	Small molecular drug
DM6UYN1	PC	462243
DM6UYN1	MW	326.4
DM6UYN1	FM	C16H14N4S2
DM6UYN1	IC	InChI=1S/C16H14N4S2/c1-3-20-13-12-11(7-5-8-17-12)22-14(13)16(21)19(2)10-6-4-9-18-15(10)20/h4-9H,3H2,1-2H3
DM6UYN1	CS	CCN1C2=C(C(=S)N(C3=C1N=CC=C3)C)SC4=C2N=CC=C4
DM6UYN1	IK	YRSMQXBXGMENSN-UHFFFAOYSA-N
DM6UYN1	IU	2-ethyl-9-methyl-12-thia-2,4,9,17-tetrazatetracyclo[9.7.0.03,8.013,18]octadeca-1(11),3(8),4,6,13(18),14,16-heptaene-10-thione
DM6UYN1	DE	Human immunodeficiency virus-1 infection

DMEYNB0	ID	DMEYNB0
DMEYNB0	DN	MEN-11149
DMEYNB0	HS	Terminated
DMEYNB0	CP	The Menarini Group
DMEYNB0	PC	101940285
DMEYNB0	MW	600.7
DMEYNB0	FM	C38H40N4O3
DMEYNB0	IC	InChI=1S/C38H40N4O3/c1-25-15-17-26(18-16-25)23-36(43)42(2)35(22-27-19-20-28-9-3-4-10-29(28)21-27)41-37(44)31-12-6-8-14-34(31)40-38(45)32-24-39-33-13-7-5-11-30(32)33/h3-5,7,9-11,13,15-21,24,31,34-35,39H,6,8,12,14,22-23H2,1-2H3,(H,40,45)(H,41,44)/t31-,34+,35?/m1/s1
DMEYNB0	CS	CC1=CC=C(C=C1)CC(=O)N(C)C(CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@@H]4CCCC[C@@H]4NC(=O)C5=CNC6=CC=CC=C65
DMEYNB0	IK	DTPDRMYRFVVGJZ-SKZJHLMYSA-N
DMEYNB0	IU	N-[(1S,2R)-2-[[1-[methyl-[2-(4-methylphenyl)acetyl]amino]-2-naphthalen-2-ylethyl]carbamoyl]cyclohexyl]-1H-indole-3-carboxamide
DMEYNB0	DE	Asthma

DMNTIWC	ID	DMNTIWC
DMNTIWC	DN	MEN-11467
DMNTIWC	HS	Terminated
DMNTIWC	CP	The Menarini Group
DMNTIWC	PC	9960352
DMNTIWC	MW	600.7
DMNTIWC	FM	C38H40N4O3
DMNTIWC	IC	InChI=1S/C38H40N4O3/c1-25-15-17-26(18-16-25)23-36(43)42(2)35(22-27-19-20-28-9-3-4-10-29(28)21-27)38(45)41-34-14-8-7-13-33(34)40-37(44)31-24-39-32-12-6-5-11-30(31)32/h3-6,9-12,15-21,24,33-35,39H,7-8,13-14,22-23H2,1-2H3,(H,40,44)(H,41,45)/t33-,34+,35+/m0/s1
DMNTIWC	CS	CC1=CC=C(C=C1)CC(=O)N(C)[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H]4CCCC[C@@H]4NC(=O)C5=CNC6=CC=CC=C65
DMNTIWC	IK	JXDKAWGCUBTYFX-BMPTZRATSA-N
DMNTIWC	IU	N-[(1S,2R)-2-[[(2R)-2-[methyl-[2-(4-methylphenyl)acetyl]amino]-3-naphthalen-2-ylpropanoyl]amino]cyclohexyl]-1H-indole-3-carboxamide
DMNTIWC	DE	Respiratory tract inflammation

DMC8J6F	ID	DMC8J6F
DMC8J6F	DN	Methylthioadenosine
DMC8J6F	HS	Terminated
DMC8J6F	SN	5'-Deoxy-5'-methylthioadenosine; 2457-80-9; Methylthioadenosine; 5'-S-methyl-5'-thioadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-DEOXY-5'-METHYLTHIOADENOSINE; (2R,3R,4S,5S)-2-(6-Amino-9H-purin-9-yl)-5-((methylthio)methyl)tetrahydrofuran-3,4-diol; Thiomethyladenosine; Vitamin L2; ADENOSINE, 5'-S-METHYL-5'-THIO-; 5'-S-Methylthioadenosine; MTA; S-methyl-5'-thioadenosine; Vitamin L(sub 2); UNII-634Z2VK3UQ; 5'-Deoxy(methylthio)adenosine; 5'-Deoxy-5'-Methylthioadenosine
DMC8J6F	DT	Small molecular drug
DMC8J6F	PC	439176
DMC8J6F	MW	297.34
DMC8J6F	FM	C11H15N5O3S
DMC8J6F	IC	InChI=1S/C11H15N5O3S/c1-20-2-5-7(17)8(18)11(19-5)16-4-15-6-9(12)13-3-14-10(6)16/h3-5,7-8,11,17-18H,2H2,1H3,(H2,12,13,14)/t5-,7-,8-,11-/m1/s1
DMC8J6F	CS	CSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMC8J6F	IK	WUUGFSXJNOTRMR-IOSLPCCCSA-N
DMC8J6F	IU	(2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-(methylsulfanylmethyl)oxolane-3,4-diol
DMC8J6F	CA	CAS 2457-80-9
DMC8J6F	CB	CHEBI:17509
DMC8J6F	DE	Multiple sclerosis

DMS5CZ4	ID	DMS5CZ4
DMS5CZ4	DN	METRIFUDIL
DMS5CZ4	HS	Terminated
DMS5CZ4	SN	Metrifudil; UNII-7K4GKQ4XSE; 7K4GKQ4XSE; 23707-33-7; CHEMBL331382; Y-341; N-[(2-Methylphenyl)methyl]adenosine; TH-322; Metrifudilum; Metrifudil [INN]; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[(2-methylphenyl)methylamino]purin-9-yl]oxolane-3,4-diol; Metrifudilum [INN-Latin]; Th 322; NCGC00015640-02; Adenosine analog, 16; Y 341; AC1L23SZ; DSSTox_RID_80718; DSSTox_CID_25168; DSSTox_GSID_45168; GTPL426; SCHEMBL472516; n6 -(2-methylbenzyl)adenosine; DTXSID1045168; OOEMZCZWZXHBKW-SCFUHWHPSA-N; ZINC4216929; Tox21_110187; BDBM50080390
DMS5CZ4	DT	Small molecular drug
DMS5CZ4	PC	65710
DMS5CZ4	MW	371.4
DMS5CZ4	FM	C18H21N5O4
DMS5CZ4	IC	InChI=1S/C18H21N5O4/c1-10-4-2-3-5-11(10)6-19-16-13-17(21-8-20-16)23(9-22-13)18-15(26)14(25)12(7-24)27-18/h2-5,8-9,12,14-15,18,24-26H,6-7H2,1H3,(H,19,20,21)/t12-,14-,15-,18-/m1/s1
DMS5CZ4	CS	CC1=CC=CC=C1CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMS5CZ4	IK	OOEMZCZWZXHBKW-SCFUHWHPSA-N
DMS5CZ4	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[(2-methylphenyl)methylamino]purin-9-yl]oxolane-3,4-diol
DMS5CZ4	CA	CAS 23707-33-7

DM1LGKP	ID	DM1LGKP
DM1LGKP	DN	Mevastatin
DM1LGKP	HS	Terminated
DM1LGKP	SN	Mevastatin; compactin; 73573-88-3; ML-236B; Mevastatinum; Mevastatine; Mevastatina; Mevastatinum [INN-Latin]; Antibiotic ML 236B; Mevastatin [INN]; CS 500; Compactin (penicillium); Mevastatine [INN-French]; UNII-1UQM1K0W9X; ML 236 B; Mevastatina [INN-Spanish]; CCRIS 4505; 1UQM1K0W9X; CHEMBL54440; CHEBI:34848; [(1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; Mevastatin (Compactin); ML236B
DM1LGKP	DT	Small molecular drug
DM1LGKP	PC	64715
DM1LGKP	MW	390.5
DM1LGKP	FM	C23H34O5
DM1LGKP	IC	InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
DM1LGKP	CS	CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O
DM1LGKP	IK	AJLFOPYRIVGYMJ-INTXDZFKSA-N
DM1LGKP	IU	[(1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
DM1LGKP	CA	CAS 73573-88-3
DM1LGKP	CB	CHEBI:34848

DMHV5OD	ID	DMHV5OD
DMHV5OD	DN	MF268
DMHV5OD	HS	Terminated
DMHV5OD	SN	MF 268; 154619-51-9; 5-O-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl {8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octyl}carbamate; Carbamic acid, (8-(2,6-dimethyl-4-morpholinyl)octyl)-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-(3a-alpha,5(2R*,6S*),8a-alpha))-; AC1MINCK; SCHEMBL2405111; CHEBI:43927; LS-49610; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-[8-[(2S,6R)-2,6-dimet
DMHV5OD	DT	Small molecular drug
DMHV5OD	PC	5288799
DMHV5OD	MW	270.41
DMHV5OD	FM	C15H30N2O2
DMHV5OD	IC	InChI=1S/C15H30N2O2/c1-14-11-17(12-15(2)19-14)10-8-6-4-3-5-7-9-16-13-18/h13-15H,3-12H2,1-2H3,(H,16,18)/t14-,15+
DMHV5OD	CS	C[C@@H]1CN(C[C@@H](O1)C)CCCCCCCCNC=O
DMHV5OD	IK	UXVBAZRPAJEAHR-GASCZTMLSA-N
DMHV5OD	IU	N-[8-[(2S,6R)-2,6-dimethylmorpholin-4-yl]octyl]formamide
DMHV5OD	DE	Alzheimer disease

DM72MQP	ID	DM72MQP
DM72MQP	DN	MF-5137
DM72MQP	HS	Terminated
DM72MQP	CP	Mediolanum Farmaceutici SpA
DM72MQP	PC	460150
DM72MQP	MW	389.4
DM72MQP	FM	C23H23N3O3
DM72MQP	IC	InChI=1S/C23H23N3O3/c1-13-20-17(22(27)18(23(28)29)12-26(20)16-6-7-16)10-19(24)21(13)25-9-8-14-4-2-3-5-15(14)11-25/h2-5,10,12,16H,6-9,11,24H2,1H3,(H,28,29)
DM72MQP	CS	CC1=C2C(=CC(=C1N3CCC4=CC=CC=C4C3)N)C(=O)C(=CN2C5CC5)C(=O)O
DM72MQP	IK	LLVLMYRWABCVEU-UHFFFAOYSA-N
DM72MQP	IU	6-amino-1-cyclopropyl-7-(3,4-dihydro-1H-isoquinolin-2-yl)-8-methyl-4-oxoquinoline-3-carboxylic acid
DM72MQP	DE	Staphylococcus infection

DM47WS2	ID	DM47WS2
DM47WS2	DN	MF-8615
DM47WS2	HS	Terminated
DM47WS2	CP	Mediolanum Farmaceutici SpA
DM47WS2	DE	Alzheimer disease

DM9GOT6	ID	DM9GOT6
DM9GOT6	DN	MGBG
DM9GOT6	HS	Terminated
DM9GOT6	SN	MITOGUAZONE; Methyl-Gag; 459-86-9; Methylglyoxal bis(guanylhydrazone); Me-GAG; Methylglyoxal bis(amidinohydrazone); Methyl-G; C5H12N8; Pyruvaldehyde bis(amidinohydrazone); Mitoguazonum; Mitoguazona; CHEMBL216913; CHEBI:43996; Methyl GAG; Mitoguazone [INN:DCF]; Mitoguazonum [INN-Latin]; MGGH; Mitoguazona [INN-Spanish]; (2E,2'E)-2,2'-(1E,2E)-propane-1,2-diylidenedihydrazinecarboximidamide; BRN 1912590; 2-[(E)-[(1E)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine
DM9GOT6	DT	Small molecular drug
DM9GOT6	PC	5351154
DM9GOT6	MW	184.2
DM9GOT6	FM	C5H12N8
DM9GOT6	IC	InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+
DM9GOT6	CS	C/C(=N\\N=C(N)N)/C=N/N=C(N)N
DM9GOT6	IK	MXWHMTNPTTVWDM-NXOFHUPFSA-N
DM9GOT6	IU	2-[(E)-[(1E)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine
DM9GOT6	CA	CAS 459-86-9
DM9GOT6	CB	CHEBI:43996
DM9GOT6	DE	Head and neck cancer

DM96WKA	ID	DM96WKA
DM96WKA	DN	Midaglizole
DM96WKA	HS	Terminated
DM96WKA	SN	Midaglizole hydrochloride; DG 5218; DG-5128; Pyridine, 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]-, monohydrochloride
DM96WKA	CP	Daiichi Seiyaku Co Ltd
DM96WKA	DT	Small molecular drug
DM96WKA	PC	68864
DM96WKA	MW	251.33
DM96WKA	FM	C16H17N3
DM96WKA	IC	InChI=1S/C16H17N3/c1-2-6-13(7-3-1)14(12-16-18-10-11-19-16)15-8-4-5-9-17-15/h1-9,14H,10-12H2,(H,18,19)
DM96WKA	CS	C1CN=C(N1)CC(C2=CC=CC=C2)C3=CC=CC=N3
DM96WKA	IK	TYZQFNOLWJGHRZ-UHFFFAOYSA-N
DM96WKA	IU	2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine
DM96WKA	CA	CAS 66529-17-7
DM96WKA	DE	Asthma

DMJTR0U	ID	DMJTR0U
DMJTR0U	DN	Milacemide
DMJTR0U	HS	Terminated
DMJTR0U	SN	Glyzac; Glyzan; Milacemide hydrochloride; CP-1552S
DMJTR0U	CP	GD Searle & Co
DMJTR0U	DT	Small molecular drug
DMJTR0U	PC	53569
DMJTR0U	MW	144.21
DMJTR0U	FM	C7H16N2O
DMJTR0U	IC	InChI=1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10)
DMJTR0U	CS	CCCCCNCC(=O)N
DMJTR0U	IK	GJNNXIYZWIZFRH-UHFFFAOYSA-N
DMJTR0U	IU	2-(pentylamino)acetamide
DMJTR0U	CA	CAS 76990-56-2
DMJTR0U	DE	Alzheimer disease

DMZNWAV	ID	DMZNWAV
DMZNWAV	DN	Miltirone
DMZNWAV	HS	Terminated
DMZNWAV	SN	Miltiron; Rosmariquinone
DMZNWAV	CP	Abbott Laboratories
DMZNWAV	DT	Small molecular drug
DMZNWAV	PC	160142
DMZNWAV	MW	282.4
DMZNWAV	FM	C19H22O2
DMZNWAV	IC	InChI=1S/C19H22O2/c1-11(2)14-10-12-7-8-15-13(6-5-9-19(15,3)4)16(12)18(21)17(14)20/h7-8,10-11H,5-6,9H2,1-4H3
DMZNWAV	CS	CC(C)C1=CC2=C(C3=C(C=C2)C(CCC3)(C)C)C(=O)C1=O
DMZNWAV	IK	FEFAIBOZOKSLJR-UHFFFAOYSA-N
DMZNWAV	IU	8,8-dimethyl-2-propan-2-yl-6,7-dihydro-5H-phenanthrene-3,4-dione
DMZNWAV	CA	CAS 27210-57-7
DMZNWAV	CB	CHEBI:34851
DMZNWAV	DE	Anxiety disorder

DMQB8TW	ID	DMQB8TW
DMQB8TW	DN	Mimosine
DMQB8TW	HS	Terminated
DMQB8TW	SN	Mimosine; Leucenol; 10182-82-8; WZNJWVWKTVETCG-UHFFFAOYSA-N; NSC69188; NSC159548; 1(4H)-Pyridinealanine, 3-hydroxy-4-oxo-; beta-[N-(3-Hydroxy-4-pyridone)]-alpha-aminopropionic Acid; 1(4H)-Pyridinepropanoic acid, .alpha.-amino-3-hydroxy-4-oxo-, (.alpha.S)-; beta-(N-(3-Hydroxy-4-pyridone))-alpha-aminopropionic acid; Prestwick_830; Spectrum_000287; AC1L1GVQ; Spectrum4_000110; Prestwick0_000379; Mimosine, (+/-)-; Spectrum2_000656; Spectrum3_000722; Prestwick2_000379; Spectrum5_001484; Prestwick1_000379
DMQB8TW	DT	Small molecular drug
DMQB8TW	PC	3862
DMQB8TW	MW	198.18
DMQB8TW	FM	C8H10N2O4
DMQB8TW	IC	InChI=1S/C8H10N2O4/c9-5(8(13)14)3-10-2-1-6(11)7(12)4-10/h1-2,4-5,12H,3,9H2,(H,13,14)
DMQB8TW	CS	C1=CN(C=C(C1=O)O)CC(C(=O)O)N
DMQB8TW	IK	WZNJWVWKTVETCG-UHFFFAOYSA-N
DMQB8TW	IU	2-amino-3-(3-hydroxy-4-oxopyridin-1-yl)propanoic acid
DMQB8TW	CA	CAS 2116-55-4
DMQB8TW	CB	CHEBI:95190

DM7IXH3	ID	DM7IXH3
DM7IXH3	DN	MINAMESTANE
DM7IXH3	HS	Terminated
DM7IXH3	SN	FCE-24928; Minamestane; 4-Aminoandrosta-1,4,6-triene-3,17-dione
DM7IXH3	DT	Small molecular drug
DM7IXH3	PC	65886
DM7IXH3	MW	297.4
DM7IXH3	FM	C19H23NO2
DM7IXH3	IC	InChI=1S/C19H23NO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h3-4,8,10-13H,5-7,9,20H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
DM7IXH3	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)C=CC4=C(C(=O)C=C[C@]34C)N
DM7IXH3	IK	DAKHYLIFCYPHQW-KZQROQTASA-N
DM7IXH3	IU	(8R,9S,10R,13S,14S)-4-amino-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthrene-3,17-dione
DM7IXH3	CA	CAS 105051-87-4
DM7IXH3	DE	Bladder cancer

DMO06JV	ID	DMO06JV
DMO06JV	DN	Mitoflaxone
DMO06JV	HS	Terminated
DMO06JV	SN	Flavone acetic acid; flavone-8-acetic acid; 87626-55-9; LM-975; NSC-347512; Mitoflaxone [INN]; NSC 347512; Mitoflaxonum [INN-Latin]; Mitoflaxona [INN-Spanish]; 4H-1-BENZOPYRAN-8-ACETIC ACID, 4-OXO-2-PHENYL-; UNII-X230G6E63B; 2-Phenyl-8-(carboxymethyl)-benzopyran-4-one; NSC347512; 4-Oxo-2-phenyl-4H-1-benzopyran-8-acetic acid; BRN 4260339; MLS003171055; TZZNWMJZDWYJAZ-UHFFFAOYSA-N; X230G6E63B; Mitoflaxonum; Mitoflaxona; C17H12O4; Flavoneacetic acid; LM 975; Flavone-8- acetic acid; AC1L1JPE; NCIStruc2_000951;  Flavone acetic acid; FAA, Merck; Flavone acetic acid, Merck; Flavone-8-acetic acid
DMO06JV	CP	Merck KGaA
DMO06JV	DT	Small molecular drug
DMO06JV	PC	55748
DMO06JV	MW	280.27
DMO06JV	FM	C17H12O4
DMO06JV	IC	InChI=1S/C17H12O4/c18-14-10-15(11-5-2-1-3-6-11)21-17-12(9-16(19)20)7-4-8-13(14)17/h1-8,10H,9H2,(H,19,20)
DMO06JV	CS	C1=CC=C(C=C1)C2=CC(=O)C3=CC=CC(=C3O2)CC(=O)O
DMO06JV	IK	TZZNWMJZDWYJAZ-UHFFFAOYSA-N
DMO06JV	IU	2-(4-oxo-2-phenylchromen-8-yl)acetic acid
DMO06JV	CA	CAS 87626-55-9
DMO06JV	DE	Solid tumour/cancer

DMT9QB5	ID	DMT9QB5
DMT9QB5	DN	MIV-170
DMT9QB5	HS	Terminated
DMT9QB5	SN	MIV-140; MSK-076; Non-nucleoside reverse transcriptase inhibitors, Medivir; HIV polymerase inhibitors, Medivir/Bristol-Myers Squibb; NNRTIs (HIV infection), Medivir/Bristol-Myers Squibb
DMT9QB5	CP	Medivir AB
DMT9QB5	DT	Small molecular drug
DMT9QB5	PC	71589251
DMT9QB5	MW	485.5
DMT9QB5	FM	C24H21F2N3O4S
DMT9QB5	IC	InChI=1S/C24H21F2N3O4S/c25-19-11-12-20(26)21-17(19)9-10-18-22(21)23(18)29-24(30)28-13-1-3-14(4-2-13)33-15-5-7-16(8-6-15)34(27,31)32/h1-8,11-12,18,22-23H,9-10H2,(H2,27,31,32)(H2,28,29,30)/t18-,22-,23-/m1/s1
DMT9QB5	CS	C1CC2=C(C=CC(=C2[C@H]3[C@@H]1[C@H]3NC(=O)NC4=CC=C(C=C4)OC5=CC=C(C=C5)S(=O)(=O)N)F)F
DMT9QB5	IK	FRIDRXJGZVLPIQ-SXSPYAJSSA-N
DMT9QB5	IU	1-[(1R,1aR,7bR)-4,7-difluoro-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalen-1-yl]-3-[4-(4-sulfamoylphenoxy)phenyl]urea
DMT9QB5	DE	Human immunodeficiency virus infection

DMAITRL	ID	DMAITRL
DMAITRL	DN	MKC-1313
DMAITRL	HS	Terminated
DMAITRL	SN	HDAC inhibitors, EntreMed; HDAC inhibitors, Miikana; Histone deacetylase inhibitors (cancer); MKC-1192; MKC-1704; HDAC inhibitor (cancer), EntreMed; Histone deacetylase inhibitors (cancer), EntreMed; Histone deacetylase inhibitors (cancer), Miikana
DMAITRL	CP	Miikana Therapeutics Inc
DMAITRL	DE	Solid tumour/cancer

DMF27BS	ID	DMF27BS
DMF27BS	DN	MMV00/0053
DMF27BS	HS	Terminated
DMF27BS	SN	PfENR inhibitors, Jacobus; Plasmodium falciparum enoyl acyl carrier protein reductase inhibitors, Jacobus; FAS II inhibitors, Jacobus/MMV; Fatty acid biosynthesis II inhibitors, Jacobus/MMV
DMF27BS	CP	Jacobus Pharmaceutical Co Inc
DMF27BS	DE	Malaria

DM543VY	ID	DM543VY
DM543VY	DN	MOL-218
DM543VY	HS	Terminated
DM543VY	SN	MOL-254; MOL-268; MOL-294; NFkB inhibitors, Molecumetics
DM543VY	CP	Molecumetics Ltd
DM543VY	DE	Asthma

DMRCH1M	ID	DMRCH1M
DMRCH1M	DN	MOR-102
DMRCH1M	HS	Terminated
DMRCH1M	SN	MOR-101; MOR-101); ICAM-1 antibody (inflammation), MorphoSys
DMRCH1M	CP	MorphoSys AG
DMRCH1M	DT	Antibody
DMRCH1M	DE	Psoriasis vulgaris

DMO2S6T	ID	DMO2S6T
DMO2S6T	DN	MOXIFETIN HYDROGEN MALEATE
DMO2S6T	HS	Terminated
DMO2S6T	SN	VUFB-15468; 2-(3-Hydroxyphenylsulfanyl)-N,N-dimethylbenzylamine hydrogen maleate; 3-[2-(Dimethylaminomethyl)phenylsulfanyl]phenol hydrogen maleate
DMO2S6T	DT	Small molecular drug
DMO2S6T	PC	6918142
DMO2S6T	MW	375.4
DMO2S6T	FM	C19H21NO5S
DMO2S6T	IC	InChI=1S/C15H17NOS.C4H4O4/c1-16(2)11-12-6-3-4-9-15(12)18-14-8-5-7-13(17)10-14;5-3(6)1-2-4(7)8/h3-10,17H,11H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMO2S6T	CS	C[NH+](C)CC1=CC=CC=C1SC2=CC=CC(=C2)O.C(=C\\C(=O)[O-])\\C(=O)O
DMO2S6T	IK	YLZUWDVZEDYTBB-BTJKTKAUSA-N
DMO2S6T	IU	(Z)-4-hydroxy-4-oxobut-2-enoate;[2-(3-hydroxyphenyl)sulfanylphenyl]methyl-dimethylazanium
DMO2S6T	DE	Mood disorder

DMAVD4Q	ID	DMAVD4Q
DMAVD4Q	DN	MPI-461359
DMAVD4Q	HS	Terminated
DMAVD4Q	SN	MPI-0461359; Antiviral (HIV infection), Myrexis; Antiviral (HIV infection), Myriad
DMAVD4Q	CP	Myriad Genetics Inc
DMAVD4Q	DE	Human immunodeficiency virus infection

DM4A92X	ID	DM4A92X
DM4A92X	DN	MRL-953
DM4A92X	HS	Terminated
DM4A92X	SN	SDZ-MRL-953
DM4A92X	CP	Novartis AG
DM4A92X	DE	Immune System disease

DMXERCA	ID	DMXERCA
DMXERCA	DN	MS-377
DMXERCA	HS	Terminated
DMXERCA	SN	MS-377; SCHEMBL466934; DKVVPXLIRYCKCS-OAHLLOKOSA-N; AKOS003589066; (R)-1-(4-chlorophenyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)methyl-2-pyrrolidinone; (r)-(+)-1-(4-chlorophenyl)-3-[4-(2-methoxyethyl)piperazin-1-yl]methyl-2-pyrrolidinone
DMXERCA	CP	Schering AG
DMXERCA	DT	Small molecular drug
DMXERCA	PC	9892249
DMXERCA	MW	351.9
DMXERCA	FM	C18H26ClN3O2
DMXERCA	IC	InChI=1S/C18H26ClN3O2/c1-24-13-12-20-8-10-21(11-9-20)14-15-6-7-22(18(15)23)17-4-2-16(19)3-5-17/h2-5,15H,6-14H2,1H3/t15-/m1/s1
DMXERCA	CS	COCCN1CCN(CC1)C[C@H]2CCN(C2=O)C3=CC=C(C=C3)Cl
DMXERCA	IK	DKVVPXLIRYCKCS-OAHLLOKOSA-N
DMXERCA	IU	(3R)-1-(4-chlorophenyl)-3-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]pyrrolidin-2-one
DMXERCA	DE	Schizophrenia

DMNYLEU	ID	DMNYLEU
DMNYLEU	DN	MSC-204
DMNYLEU	HS	Terminated
DMNYLEU	SN	MSC-206; PETT-2; PETT-4
DMNYLEU	CP	Medivir AB
DMNYLEU	DT	Small molecular drug
DMNYLEU	PC	468178
DMNYLEU	MW	422.2
DMNYLEU	FM	C18H17BrFN3O3
DMNYLEU	IC	InChI=1S/C18H17BrFN3O3/c1-2-14(24)10-4-5-12(20)16(17(10)25)11-7-13(11)22-18(26)23-15-6-3-9(19)8-21-15/h3-6,8,11,13,25H,2,7H2,1H3,(H2,21,22,23,26)/t11-,13+/m0/s1
DMNYLEU	CS	CCC(=O)C1=C(C(=C(C=C1)F)[C@H]2C[C@H]2NC(=O)NC3=NC=C(C=C3)Br)O
DMNYLEU	IK	VRAJWAGCJIXJHQ-WCQYABFASA-N
DMNYLEU	IU	1-(5-bromopyridin-2-yl)-3-[(1R,2R)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea
DMNYLEU	DE	Human immunodeficiency virus infection

DMXW67H	ID	DMXW67H
DMXW67H	DN	MX-6120
DMXW67H	HS	Terminated
DMXW67H	SN	Endothelin-1 antagonists (heart disease); ET-1 antagonists (heart disease), Maxia; Endothelin-1 antagonists (heart disease), Maxia
DMXW67H	CP	Maxia Pharmaceuticals Inc
DMXW67H	DE	Heart disease

DMP26BW	ID	DMP26BW
DMP26BW	DN	MX-7065
DMP26BW	HS	Terminated
DMP26BW	SN	Cdc25 phosphatase inhibitors, Maxia Pharmaceuticals; MX-7102; MX-7174; MX-7214; MX-7306
DMP26BW	CP	Maxia Pharmaceuticals Inc
DMP26BW	DE	Solid tumour/cancer

DMNZ356	ID	DMNZ356
DMNZ356	DN	MX-781
DMNZ356	HS	Terminated
DMNZ356	CP	Maxia Pharmaceuticals Inc
DMNZ356	DE	Breast cancer

DM31CV2	ID	DM31CV2
DM31CV2	DN	NAFAZATROM
DM31CV2	HS	Terminated
DM31CV2	SN	NAFAZATROM; Bay-g-6575; Bay-g 6575; Nafazatromum [INN-Latin]; BAY g 6575; 59040-30-1; UNII-K94216221B; EINECS 261-571-1; BRN 0665222; K94216221B; 2,4-Dihydro-5-methyl-2-(2-(2-naphthalenyloxy)ethyl)-3H-pyrazol-3-one; 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-(2-(2-naphthalenyloxy)ethyl)-; 3-Methyl-1-(2-(2-naphthyloxy)ethyl)-2-pyrazolin-5-one; Nafazatromum; Nafazatrom [INN:BAN]; Nafazatrom [BAN:INN]; SCHEMBL93681; Oprea1_097893; AC1L28U1; ZINC1764; 5-methyl-2-(2-naphthalen-2-yloxyethyl)-4H-pyrazol-3-one; DTXSID00207794
DM31CV2	DT	Small molecular drug
DM31CV2	PC	42923
DM31CV2	MW	268.31
DM31CV2	FM	C16H16N2O2
DM31CV2	IC	InChI=1S/C16H16N2O2/c1-12-10-16(19)18(17-12)8-9-20-15-7-6-13-4-2-3-5-14(13)11-15/h2-7,11H,8-10H2,1H3
DM31CV2	CS	CC1=NN(C(=O)C1)CCOC2=CC3=CC=CC=C3C=C2
DM31CV2	IK	ISBUYSPRIJRBKX-UHFFFAOYSA-N
DM31CV2	IU	5-methyl-2-(2-naphthalen-2-yloxyethyl)-4H-pyrazol-3-one
DM31CV2	CA	CAS 59040-30-1

DM7T2FO	ID	DM7T2FO
DM7T2FO	DN	Naltiazem hydrochloride
DM7T2FO	HS	Terminated
DM7T2FO	SN	Ro-23-6152; Ro-23-6152/001; (+)-cis-3-Acetoxy-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-2,3,4,5-tetrahydronaphtho[1,2-b][1,4]thiazepin-4-one hydrochloride
DM7T2FO	DT	Small molecular drug
DM7T2FO	PC	130121
DM7T2FO	MW	501
DM7T2FO	FM	C26H29ClN2O4S
DM7T2FO	IC	InChI=1S/C26H28N2O4S.ClH/c1-17(29)32-23-24(19-9-12-20(31-4)13-10-19)33-25-21-8-6-5-7-18(21)11-14-22(25)28(26(23)30)16-15-27(2)3;/h5-14,23-24H,15-16H2,1-4H3;1H/t23-,24+;/m1./s1
DM7T2FO	CS	CC(=O)O[C@@H]1[C@@H](SC2=C(C=CC3=CC=CC=C32)N(C1=O)CCN(C)C)C4=CC=C(C=C4)OC.Cl
DM7T2FO	IK	SFTBZKFGODNAKF-ITNPDYSASA-N
DM7T2FO	IU	[(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydrobenzo[i][1,5]benzothiazepin-3-yl] acetate;hydrochloride
DM7T2FO	CA	CAS 108383-96-6
DM7T2FO	DE	Angina pectoris

DMML3J4	ID	DMML3J4
DMML3J4	DN	NAN-190
DMML3J4	HS	Terminated
DMML3J4	SN	NAN-190; Nan 190; NAN190; SJDOMIRMMUGQQK-UHFFFAOYSA-N; CHEMBL8618; CHEBI:64131; 2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione; 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine; 2-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1H-isoindole-1,3(2H)-dione; 2-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]isoindole-1,3-dione; 2-{4-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-butyl}-isoindole-1,3-dione; 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine
DMML3J4	DT	Small molecular drug
DMML3J4	PC	4431
DMML3J4	MW	393.5
DMML3J4	FM	C23H27N3O3
DMML3J4	IC	InChI=1S/C23H27N3O3/c1-29-21-11-5-4-10-20(21)25-16-14-24(15-17-25)12-6-7-13-26-22(27)18-8-2-3-9-19(18)23(26)28/h2-5,8-11H,6-7,12-17H2,1H3
DMML3J4	CS	COC1=CC=CC=C1N2CCN(CC2)CCCCN3C(=O)C4=CC=CC=C4C3=O
DMML3J4	IK	SJDOMIRMMUGQQK-UHFFFAOYSA-N
DMML3J4	IU	2-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]isoindole-1,3-dione
DMML3J4	CA	CAS 102392-05-2
DMML3J4	CB	CHEBI:64131

DM8FB6E	ID	DM8FB6E
DM8FB6E	DN	Navuridine
DM8FB6E	HS	Terminated
DM8FB6E	SN	AZDU; Azidouridine; AVS-2353; CS-87
DM8FB6E	CP	Bayer Schering Pharma AG
DM8FB6E	DT	Small molecular drug
DM8FB6E	PC	55262
DM8FB6E	MW	253.22
DM8FB6E	FM	C9H11N5O4
DM8FB6E	IC	InChI=1S/C9H11N5O4/c10-13-12-5-3-8(18-6(5)4-15)14-2-1-7(16)11-9(14)17/h1-2,5-6,8,15H,3-4H2,(H,11,16,17)/t5-,6+,8+/m0/s1
DM8FB6E	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)N=[N+]=[N-]
DM8FB6E	IK	ZSNNBSPEFVIUDS-SHYZEUOFSA-N
DM8FB6E	IU	1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DM8FB6E	CA	CAS 84472-85-5
DM8FB6E	DE	Human immunodeficiency virus infection

DMJVTQN	ID	DMJVTQN
DMJVTQN	DN	NB-598
DMJVTQN	HS	Terminated
DMJVTQN	SN	KIRGLCXNEVICOG-SOFGYWHQSA-N; 131060-14-5; NB 598; CHEMBL27885; (E)-3-[(3,3'-Bithiophen)-5-ylmethoxy]-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-ethylbenzylamine; (2E)-N-({3-[([3,3'-bithiophen]-5-yl)methoxy]phenyl}methyl)-N-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine; AC1O5YMV; SCHEMBL9454494; C27H31NOS2; GTPL3103; SCHEMBL9454490; (E)-N-ethyl-6,6-dimethyl-N-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine; ZINC2003883; BCP28146; EX-A1748; BDBM50032850; 3914AH; AKOS030526399; CS-1274; NCGC00165845-01
DMJVTQN	DT	Small molecular drug
DMJVTQN	PC	6443223
DMJVTQN	MW	449.7
DMJVTQN	FM	C27H31NOS2
DMJVTQN	IC	InChI=1S/C27H31NOS2/c1-5-28(14-8-6-7-13-27(2,3)4)18-22-10-9-11-25(16-22)29-19-26-17-24(21-31-26)23-12-15-30-20-23/h6,8-12,15-17,20-21H,5,14,18-19H2,1-4H3/b8-6+
DMJVTQN	CS	CCN(C/C=C/C#CC(C)(C)C)CC1=CC(=CC=C1)OCC2=CC(=CS2)C3=CSC=C3
DMJVTQN	IK	KIRGLCXNEVICOG-SOFGYWHQSA-N
DMJVTQN	IU	(E)-N-ethyl-6,6-dimethyl-N-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine
DMJVTQN	CA	CAS 131060-14-5

DM3JY2N	ID	DM3JY2N
DM3JY2N	DN	NBI-37582
DM3JY2N	HS	Terminated
DM3JY2N	SN	UNII-PL877312XZ; PL877312XZ; RO-23-9424 dihydrochloride; SCHEMBL9844164
DM3JY2N	CP	Neurocrine Biosci
DM3JY2N	DT	Small molecular drug
DM3JY2N	PC	9690113
DM3JY2N	MW	837.7
DM3JY2N	FM	C31H33Cl2F3N8O8S2
DM3JY2N	IC	InChI=1S/C31H31F3N8O8S2.2ClH/c1-39-5-7-40(8-6-39)24-17(33)9-15-23(19(24)34)41(4-3-32)10-16(25(15)43)30(48)50-11-14-12-51-28-21(27(45)42(28)22(14)29(46)47)37-26(44)20(38-49-2)18-13-52-31(35)36-18;;/h9-10,13,21,28H,3-8,11-12H2,1-2H3,(H2,35,36)(H,37,44)(H,46,47);2*1H/b38-20-;;/t21-,28-;;/m1../s1
DM3JY2N	CS	CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)OCC4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\\OC)/C6=CSC(=N6)N)SC4)C(=O)O)CCF)F.Cl.Cl
DM3JY2N	IK	DSGXXSRGPIYUHF-ZVOUVGCISA-N
DM3JY2N	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carbonyl]oxymethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;dihydrochloride
DM3JY2N	CA	CAS 139263-69-7
DM3JY2N	DE	Depression; Anxiety disorder

DMEH50J	ID	DMEH50J
DMEH50J	DN	NE-033
DMEH50J	HS	Terminated
DMEH50J	SN	IDDB7806
DMEH50J	CP	Taisho Pharmaceutical Co Ltd
DMEH50J	DE	Psychotic disorder

DMP4J7T	ID	DMP4J7T
DMP4J7T	DN	NE-100
DMP4J7T	HS	Terminated
DMP4J7T	SN	NE 100; N,N-diethyl-2-(4-methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride; N,N-Dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride; Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride
DMP4J7T	CP	Taisho
DMP4J7T	DT	Small molecular drug
DMP4J7T	PC	9952420
DMP4J7T	MW	392
DMP4J7T	FM	C23H34ClNO2
DMP4J7T	IC	InChI=1S/C23H33NO2.ClH/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20;/h6-12,19H,4-5,13-18H2,1-3H3;1H
DMP4J7T	CS	CCCN(CCC)CCC1=CC(=C(C=C1)OC)OCCC2=CC=CC=C2.Cl
DMP4J7T	IK	ZHGMDXSHODHWHV-UHFFFAOYSA-N
DMP4J7T	IU	N-[2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethyl]-N-propylpropan-1-amine;hydrochloride
DMP4J7T	CA	CAS 149409-57-4
DMP4J7T	DE	Schizophrenia

DMHYQ8K	ID	DMHYQ8K
DMHYQ8K	DN	Nerve growth factor
DMHYQ8K	HS	Terminated
DMHYQ8K	SN	Neuleze; Nerve growth factor (recombinant); RhNGF, Genentech; NGF-beta, Genentech; Nerve growth factor (recombinant), Genentech; Nerve growth factor, Mitsubishi/Dompe/Fidia
DMHYQ8K	CP	Genentech Inc
DMHYQ8K	DE	Alzheimer disease

DMFA26E	ID	DMFA26E
DMFA26E	DN	NGD-93-1
DMFA26E	HS	Terminated
DMFA26E	CP	Neurogen Corp
DMFA26E	DE	Psychotic disorder

DMSPWMF	ID	DMSPWMF
DMSPWMF	DN	Niguldipine
DMSPWMF	HS	Terminated
DMSPWMF	SN	NIGULDIPINE; S(+)-niguldipine; UNII-Z81N45O25Z; S(+)-Niguldipine hydrochloride; 113165-32-5; Z81N45O25Z; (+)-NIGULDIPINE; Niguldipine [INN]; niguldipine[inn]; (S)-Niguldipine; Tocris-1123; Tocris-1124; AC1Q1ZUF; AC1L1TKT; S(+)-1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(4,4-diphenyl-1-piperidinyl)-propyl methyl ester hydrochloride; GTPL487; SCHEMBL245992; CHEMBL41929; CHEMBL405355; DTXSID60274008; CHEBI:103931; MFCD00873564; BDBM50034683; BDBM50453799; ZINC100001967; DB09239; NCGC00025015-01
DMSPWMF	DT	Small molecular drug
DMSPWMF	PC	1236
DMSPWMF	MW	609.7
DMSPWMF	FM	C36H39N3O6
DMSPWMF	IC	InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3
DMSPWMF	CS	CC1=C(C(C(=C(N1)C)C(=O)OCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC
DMSPWMF	IK	SVJMLYUFVDMUHP-UHFFFAOYSA-N
DMSPWMF	IU	5-O-[3-(4,4-diphenylpiperidin-1-yl)propyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMSPWMF	CA	CAS 102993-22-6
DMSPWMF	CB	CHEBI:7572

DM4U7XB	ID	DM4U7XB
DM4U7XB	DN	NIK-616
DM4U7XB	HS	Terminated
DM4U7XB	CP	Kowa Pharmaceutical Co Ltd
DM4U7XB	DE	Chronic obstructive pulmonary disease

DMR1NMD	ID	DMR1NMD
DMR1NMD	DN	Nimesulide
DMR1NMD	HS	Terminated
DMR1NMD	SN	nimesulide; 51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
DMR1NMD	DT	Small molecular drug
DMR1NMD	PC	4495
DMR1NMD	MW	308.31
DMR1NMD	FM	C13H12N2O5S
DMR1NMD	IC	InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3
DMR1NMD	CS	CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2
DMR1NMD	IK	HYWYRSMBCFDLJT-UHFFFAOYSA-N
DMR1NMD	IU	N-(4-nitro-2-phenoxyphenyl)methanesulfonamide
DMR1NMD	CA	CAS 51803-78-2
DMR1NMD	CB	CHEBI:44445
DMR1NMD	DE	Metastatic colorectal cancer; Non-small-cell lung cancer; Non-hodgkin lymphoma

DM5IFU9	ID	DM5IFU9
DM5IFU9	DN	NMI-1182
DM5IFU9	HS	Terminated
DM5IFU9	SN	Naproxen-related CINOD, NitroMed
DM5IFU9	CP	NitroMed Inc
DM5IFU9	DT	Small molecular drug
DM5IFU9	PC	10250021
DM5IFU9	MW	394.3
DM5IFU9	FM	C17H18N2O9
DM5IFU9	IC	InChI=1S/C17H18N2O9/c1-11(12-3-4-14-8-15(25-2)6-5-13(14)7-12)17(20)26-9-16(28-19(23)24)10-27-18(21)22/h3-8,11,16H,9-10H2,1-2H3/t11-,16+/m0/s1
DM5IFU9	CS	C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OC[C@H](CO[N+](=O)[O-])O[N+](=O)[O-]
DM5IFU9	IK	DHMLCNFGWGUOSW-MEDUHNTESA-N
DM5IFU9	IU	[(2R)-2,3-dinitrooxypropyl] (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DM5IFU9	DE	Inflammation

DMX6DNZ	ID	DMX6DNZ
DMX6DNZ	DN	NMI-150
DMX6DNZ	HS	Terminated
DMX6DNZ	SN	NO-COX-2 inhibitor, NitroMed/Merck & Co; Nitric oxide-enhancing COX-2 inhibitor, NitroMed/Merck & Co
DMX6DNZ	CP	NitroMed Inc
DMX6DNZ	DE	Pain

DMPZ1EC	ID	DMPZ1EC
DMPZ1EC	DN	NNC 05-2045
DMPZ1EC	HS	Terminated

DMGEHZ9	ID	DMGEHZ9
DMGEHZ9	DN	NNC-09-0026
DMGEHZ9	HS	Terminated
DMGEHZ9	SN	Nnc 09-0026; Nnc-09-0026; 141360-03-4; AC1L30TY; 1-Butyl-4-(4-dimethylaminophenyl)-3-(4-trifluoromethylphenoxymethyl)piperidine dihydrochloride; SCHEMBL7413433; DTXSID90161699; 4-(1-Butyl-3-((4-(trifluoromethyl)phenoxy)methyl)-4-piperidinyl)-N,N-dimethylbenzenamine dihydrochloride, trans-(-)-; Benzenamine, 4-(1-butyl-3-((4-(trifluoromethyl)phenoxy)methyl)-4-piperidinyl)-N,N-dimethyl-, dihydrochloride, trans-(-)-; 4-[(3R,4S)-1-butyl-3-[[4-(trifluoromethyl)phenoxy]methyl]piperidin-4-yl]-N,N-dimethylaniline dihydrochlo
DMGEHZ9	CP	Novo Nordisk A/S
DMGEHZ9	DT	Small molecular drug
DMGEHZ9	PC	132350
DMGEHZ9	MW	507.5
DMGEHZ9	FM	C25H35Cl2F3N2O
DMGEHZ9	IC	InChI=1S/C25H33F3N2O.2ClH/c1-4-5-15-30-16-14-24(19-6-10-22(11-7-19)29(2)3)20(17-30)18-31-23-12-8-21(9-13-23)25(26,27)28;;/h6-13,20,24H,4-5,14-18H2,1-3H3;2*1H/t20-,24-;;/m1../s1
DMGEHZ9	CS	CCCCN1CC[C@@H]([C@H](C1)COC2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)N(C)C.Cl.Cl
DMGEHZ9	IK	VAJHWBBBDAHYRE-OYNPXDHBSA-N
DMGEHZ9	IU	4-[(3R,4S)-1-butyl-3-[[4-(trifluoromethyl)phenoxy]methyl]piperidin-4-yl]-N,N-dimethylaniline;dihydrochloride
DMGEHZ9	CA	CAS 141360-03-4
DMGEHZ9	DE	Cerebrovascular ischaemia

DMMOAN0	ID	DMMOAN0
DMMOAN0	DN	NNC-13-8119
DMMOAN0	HS	Terminated
DMMOAN0	SN	FG-8119
DMMOAN0	CP	Novo Nordisk A/S
DMMOAN0	DE	Anxiety disorder

DMK7BV9	ID	DMK7BV9
DMK7BV9	DN	NNC-22-0031
DMK7BV9	HS	Terminated
DMK7BV9	SN	Nnc 220031; 160436-12-4; Nnc 22-0031; AC1MIXSG; 4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-(3-(3,4-methylenedioxyphenylcarbamoyloxy)propyl)piperidine; DTXSID50166882; 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl N-(1,3-benzodioxol-5-yl)carbamate hydrochloride; Carbamic acid, 1,3-benzodioxol-5-yl-, 3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propyl ester, monohydrochloride
DMK7BV9	CP	Novo Nordisk A/S
DMK7BV9	DT	Small molecular drug
DMK7BV9	PC	3081915
DMK7BV9	MW	441.5
DMK7BV9	FM	C23H24FN3O5
DMK7BV9	IC	InChI=1S/C23H24FN3O5/c24-16-2-4-18-20(12-16)32-26-22(18)15-6-9-27(10-7-15)8-1-11-29-23(28)25-17-3-5-19-21(13-17)31-14-30-19/h2-5,12-13,15H,1,6-11,14H2,(H,25,28)
DMK7BV9	CS	C1CN(CCC1C2=NOC3=C2C=CC(=C3)F)CCCOC(=O)NC4=CC5=C(C=C4)OCO5
DMK7BV9	IK	ZEMJDGPKDOUEEZ-UHFFFAOYSA-N
DMK7BV9	IU	3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl N-(1,3-benzodioxol-5-yl)carbamate
DMK7BV9	DE	Psychotic disorder

DM0BYU2	ID	DM0BYU2
DM0BYU2	DN	NNC-252504
DM0BYU2	HS	Terminated
DM0BYU2	SN	Glucagon antagonists, Agouron/Novo Nordisk; NNC-25-0926; NNC-25-2504; NNC-25-2648
DM0BYU2	CP	Agouron Pharmaceuticals Inc
DM0BYU2	DE	Type-2 diabetes

DMLTYFI	ID	DMLTYFI
DMLTYFI	DN	NNC-26-0762
DMLTYFI	HS	Terminated
DMLTYFI	SN	Growth hormone secretagogues, Novo Nordisk; NNC-26-0722
DMLTYFI	CP	Novo Nordisk A/S
DMLTYFI	DE	Growth hormone deficiency

DM1SXG9	ID	DM1SXG9
DM1SXG9	DN	NNC-90-0270
DM1SXG9	HS	Terminated
DM1SXG9	SN	Nicotinic ACh agonists, Novo Nordisk
DM1SXG9	CP	Novo Nordisk A/S
DM1SXG9	DE	Alzheimer disease

DMX24FM	ID	DMX24FM
DMX24FM	DN	Nomifensine
DMX24FM	HS	Discontinued
DMX24FM	SN	Alival; D,L-nomifensine; Linamiphen; Nomifensina; Nomifensina [INN-Spanish]; Nomifensine; Nomifensine [INN:BAN]; Nomifensinum; Nomifensinum [INN-Latin]; nomifensin; (+)-Nomifensine; (+)-Nomiphensine; (+-)-Nomifensin; (+-)-Nomifensine; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine; 2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine; 24526-64-5; 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-; BRN 6064059; CCRIS 9179
DMX24FM	PC	4528
DMX24FM	MW	238.33
DMX24FM	FM	C16H18N2
DMX24FM	IC	XXPANQJNYNUNES-UHFFFAOYSA-N
DMX24FM	CS	CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3
DMX24FM	IK	1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3
DMX24FM	IU	2-methyl-4-phenyl-3,4-dihydro-1H-isoquinolin-8-amine
DMX24FM	CA	CAS 24526-64-5
DMX24FM	CB	CHEBI:116225
DMX24FM	DE	Depression

DM78P4X	ID	DM78P4X
DM78P4X	DN	NOX-200
DM78P4X	HS	Terminated
DM78P4X	SN	2-Amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; alpha-Methyl-DL-tryptophan; 153-91-3; 2-amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; NSC9948; 13510-08-2; alpha-Methyl-L-tryptophan; M-5098; Tryptophan, alpha-methyl-; 16709-25-4; DL-alpha-Methyltryptophan; alpha-methyl-D,L-tryptophan; NSC-9948; NSC 9948; Tryptophan,a-methyl-; ACMC-1BNRO; alpha-Methyltryptophan; AC1L3UBI; AC1Q5S1L; (S)-alpha-Methyl pryptophan; SCHEMBL343309; CHEMBL559578; GTPL4693; CTK4C8033; ZTTWHZHBPDYSQB-UHFFFAOYSA-N; MolPort-003-958-850; KS-000001AA; ANW-21478
DM78P4X	CP	Medinox Inc
DM78P4X	DT	Small molecular drug
DM78P4X	PC	95438
DM78P4X	MW	218.25
DM78P4X	FM	C12H14N2O2
DM78P4X	IC	InChI=1S/C12H14N2O2/c1-12(13,11(15)16)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,14H,6,13H2,1H3,(H,15,16)
DM78P4X	CS	CC(CC1=CNC2=CC=CC=C21)(C(=O)O)N
DM78P4X	IK	ZTTWHZHBPDYSQB-UHFFFAOYSA-N
DM78P4X	IU	2-amino-3-(1H-indol-3-yl)-2-methylpropanoic acid
DM78P4X	CA	CAS 153-91-3
DM78P4X	DE	Rheumatoid arthritis

DM4B1VF	ID	DM4B1VF
DM4B1VF	DN	NP-7557
DM4B1VF	HS	Terminated
DM4B1VF	SN	Alzheimers disease therapy, Nastech; AChEI therapy (intranasal), Nastech
DM4B1VF	CP	Marina Biotech Inc
DM4B1VF	DE	Alzheimer disease

DM35RTJ	ID	DM35RTJ
DM35RTJ	DN	NPC-16377
DM35RTJ	HS	Terminated
DM35RTJ	SN	Npc-16377; 139652-86-1; 6-(6-(4-hydroxypiperidinyl)hexyloxy)-3-methylflavone hydrochloride; Npc 16377; npc16377; SCHEMBL8787810; DTXSID40161144; 6-(6-(4-Hydroxypiperidinyl)hexyloxy)-3-methylflavone HCl; 4H-1-Benzopyran-4-one, 6-((6-(4-hydroxy-1-piperidinyl)hexyl)oxy)-3-methyl-2-phenyl-, hydrochloride
DM35RTJ	CP	Scios Inc
DM35RTJ	DT	Small molecular drug
DM35RTJ	PC	9890958
DM35RTJ	MW	472
DM35RTJ	FM	C27H34ClNO4
DM35RTJ	IC	InChI=1S/C27H33NO4.ClH/c1-20-26(30)24-19-23(11-12-25(24)32-27(20)21-9-5-4-6-10-21)31-18-8-3-2-7-15-28-16-13-22(29)14-17-28;/h4-6,9-12,19,22,29H,2-3,7-8,13-18H2,1H3;1H
DM35RTJ	CS	CC1=C(OC2=C(C1=O)C=C(C=C2)OCCCCCCN3CCC(CC3)O)C4=CC=CC=C4.Cl
DM35RTJ	IK	GWSBQIZSTCDSLE-UHFFFAOYSA-N
DM35RTJ	IU	6-[6-(4-hydroxypiperidin-1-yl)hexoxy]-3-methyl-2-phenylchromen-4-one;hydrochloride
DM35RTJ	CA	CAS 139652-86-1
DM35RTJ	DE	Psychotic disorder

DMGVIZY	ID	DMGVIZY
DMGVIZY	DN	NPC-17731
DMGVIZY	HS	Terminated
DMGVIZY	SN	Bradykinin antagonists, Scios; NPC-16731; NPC-17761; NPC-18521; NPC-18688; NPC-18884
DMGVIZY	CP	Scios Inc
DMGVIZY	DT	Small molecular drug
DMGVIZY	PC	3081308
DMGVIZY	MW	1294.5
DMGVIZY	FM	C59H95N19O14
DMGVIZY	IC	InChI=1S/C59H95N19O14/c1-2-23-92-35-27-42(71-29-35)53(88)78(54(89)43-25-33-13-6-7-15-38(33)73-43)59(55(90)91,48(83)44(31-79)76-51(86)41(24-32-11-4-3-5-12-32)74-46(81)30-72-50(85)40-26-34(80)28-70-40)36(18-21-69-58(65)66)47(82)45-17-10-22-77(45)52(87)39(16-9-20-68-57(63)64)75-49(84)37(60)14-8-19-67-56(61)62/h3-5,11-12,33-45,70-71,73,79-80H,2,6-10,13-31,60H2,1H3,(H,72,85)(H,74,81)(H,75,84)(H,76,86)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,34?,35-,36?,37+,38-,39-,40-,41-,42+,43?,44-,45-,59-/m0/s1
DMGVIZY	CS	CCCO[C@H]1C[C@@H](NC1)C(=O)N(C(=O)C2C[C@@H]3CCCC[C@@H]3N2)[C@@](C(CCN=C(N)N)C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)(C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)CNC(=O)[C@@H]6CC(CN6)O)C(=O)O
DMGVIZY	IK	WYWZCALINPVKJW-KOCZGPIPSA-N
DMGVIZY	IU	(2S,4S)-2-[[(3aS,7aS)-2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carbonyl]-[(2R,4S)-4-propoxypyrrolidine-2-carbonyl]amino]-2-[1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidin-2-yl]-4-(diaminomethylideneamino)-1-oxobutan-2-yl]-5-hydroxy-4-[[(2S)-2-[[2-[[(2S)-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-oxopentanoic acid
DMGVIZY	CA	CAS 147267-10-5
DMGVIZY	DE	Asthma

DMD01GK	ID	DMD01GK
DMD01GK	DN	NPC-17923
DMD01GK	HS	Terminated
DMD01GK	SN	147960-65-4; N-(9H-(2,7-Dichlorofluorenyl)-9-ethoxycarbonyl)-4-aminobenzoic acid; Benzoic acid, 4-((3-((2,7-dichloro-9H-fluoren-9-yl)oxy)-1-oxopropyl)amino)-
DMD01GK	CP	Scios Inc
DMD01GK	DT	Small molecular drug
DMD01GK	PC	9824607
DMD01GK	MW	442.3
DMD01GK	FM	C23H17Cl2NO4
DMD01GK	IC	InChI=1S/C23H17Cl2NO4/c24-14-3-7-17-18-8-4-15(25)12-20(18)22(19(17)11-14)30-10-9-21(27)26-16-5-1-13(2-6-16)23(28)29/h1-8,11-12,22H,9-10H2,(H,26,27)(H,28,29)
DMD01GK	CS	C1=CC(=CC=C1C(=O)O)NC(=O)CCOC2C3=C(C=CC(=C3)Cl)C4=C2C=C(C=C4)Cl
DMD01GK	IK	JTYWUQLFBWFIEV-UHFFFAOYSA-N
DMD01GK	IU	4-[3-[(2,7-dichloro-9H-fluoren-9-yl)oxy]propanoylamino]benzoic acid
DMD01GK	CA	CAS 147960-65-4
DMD01GK	DE	Rheumatoid arthritis

DMAIH90	ID	DMAIH90
DMAIH90	DN	NPC-18166
DMAIH90	HS	Terminated
DMAIH90	SN	IDDB8389
DMAIH90	CP	Scios Inc
DMAIH90	DE	Psychotic disorder

DMH1YL8	ID	DMH1YL8
DMH1YL8	DN	NPI-1999
DMH1YL8	HS	Terminated
DMH1YL8	SN	Serine protease inhibitors, NovoScience
DMH1YL8	CP	NovoScience Pharma Inc
DMH1YL8	DE	Thrombosis

DMTWXE3	ID	DMTWXE3
DMTWXE3	DN	NPS-1392
DMTWXE3	HS	Terminated
DMTWXE3	CP	NPS Pharmaceuticals Inc
DMTWXE3	PC	9860006
DMTWXE3	MW	261.31
DMTWXE3	FM	C16H17F2N
DMTWXE3	IC	InChI=1S/C16H17F2N/c1-11(10-19)16(12-4-2-6-14(17)8-12)13-5-3-7-15(18)9-13/h2-9,11,16H,10,19H2,1H3/t11-/m0/s1
DMTWXE3	CS	C[C@@H](CN)C(C1=CC(=CC=C1)F)C2=CC(=CC=C2)F
DMTWXE3	IK	WEEQOTXCUZRCLD-NSHDSACASA-N
DMTWXE3	IU	(2R)-3,3-bis(3-fluorophenyl)-2-methylpropan-1-amine
DMTWXE3	DE	Cerebrovascular ischaemia

DMNL1VM	ID	DMNL1VM
DMNL1VM	DN	NPS-846
DMNL1VM	HS	Terminated
DMNL1VM	SN	NPS 846.HCl
DMNL1VM	CP	NPS Pharmaceuticals Inc
DMNL1VM	DE	Cerebrovascular ischaemia

DMCHLJ4	ID	DMCHLJ4
DMCHLJ4	DN	NS-004
DMCHLJ4	HS	Terminated
DMCHLJ4	SN	NS004; NS-004; NS-O04; 1-(5-Chloro-2-hydroxyphenyl)-5-trifluoromethyl-1,3-dihydrobenzoimidazol-2-one; WYLYBVMNGZOYOH-UHFFFAOYSA-N; AC1NSKFZ; ZINC5663; SCHEMBL8911620; GTPL4271; CHEMBL375448; SCHEMBL3102522; KB-09311; 1-[2-hydroxy-5-chlorophenyl]-5-trifluoromethyl-2-benzimidazolone; 3-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl)-1H-benzimidazol-2-one; 2H-benzimidazol-2-one, 1-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-5-(trifluoromethyl)-; 1,3-dihydro-1-(5-chloro-2-hydroxyphenyl)-5-trifluoromethyl-2H-benzimidazol-2-one
DMCHLJ4	CP	NeuroSearch A/S
DMCHLJ4	DT	Small molecular drug
DMCHLJ4	PC	5311330
DMCHLJ4	MW	328.67
DMCHLJ4	FM	C14H8ClF3N2O2
DMCHLJ4	IC	InChI=1S/C14H8ClF3N2O2/c15-8-2-4-12(21)11(6-8)20-10-3-1-7(14(16,17)18)5-9(10)19-13(20)22/h1-6,21H,(H,19,22)
DMCHLJ4	CS	C1=CC2=C(C=C1C(F)(F)F)NC(=O)N2C3=C(C=CC(=C3)Cl)O
DMCHLJ4	IK	WYLYBVMNGZOYOH-UHFFFAOYSA-N
DMCHLJ4	IU	3-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl)-1H-benzimidazol-2-one
DMCHLJ4	DE	Hypertension

DM75DZ1	ID	DM75DZ1
DM75DZ1	DN	NS-1546
DM75DZ1	HS	Terminated
DM75DZ1	CP	NeuroSearch A/S
DM75DZ1	DE	Major depressive disorder

DMYV9M1	ID	DMYV9M1
DMYV9M1	DN	NS-1608
DMYV9M1	HS	Terminated
DMYV9M1	SN	NS 1608; CHEMBL33891; NS-1608; Kinome_784; 160383-80-2; AC1L323R; CHEBI:34878; SureCN1463468; ns1608; SCHEMBL1463468; DTXSID80166870; N-(3-(Trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorophenyl)urea; BDBM50158564; AKOS029964740; C13835; 1-(5-chloro-2-hydroxyphenyl)-3-(3-trifluoromethylphenyl)urea; 1-(5-chloro-2-hydroxy-phenyl)-3-[3-(trifluoromethyl)phenyl]urea; 1-(5-Chloro-2-hydroxy-phenyl)-3-(3-trifluoromethyl-phenyl)-urea
DMYV9M1	CP	NeuroSearch A/S
DMYV9M1	DT	Small molecular drug
DMYV9M1	PC	133058
DMYV9M1	MW	330.69
DMYV9M1	FM	C14H10ClF3N2O2
DMYV9M1	IC	InChI=1S/C14H10ClF3N2O2/c15-9-4-5-12(21)11(7-9)20-13(22)19-10-3-1-2-8(6-10)14(16,17)18/h1-7,21H,(H2,19,20,22)
DMYV9M1	CS	C1=CC(=CC(=C1)NC(=O)NC2=C(C=CC(=C2)Cl)O)C(F)(F)F
DMYV9M1	IK	KRHJDJMOIKRPNN-UHFFFAOYSA-N
DMYV9M1	IU	1-(5-chloro-2-hydroxyphenyl)-3-[3-(trifluoromethyl)phenyl]urea
DMYV9M1	CA	CAS 160383-80-2
DMYV9M1	CB	CHEBI:34878
DMYV9M1	DE	Cerebrovascular ischaemia

DMES0OT	ID	DMES0OT
DMES0OT	DN	NS-1619
DMES0OT	HS	Terminated
DMES0OT	SN	NS-1619; 153587-01-0; NS 1619; 1-(2-hydroxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one; NS1619; CHEMBL384903; 1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one; CHEBI:34879; 1-(2'-Hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)-benzimidazolone; 1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-1,3-dihydro-2h-benzimidazol-2-one; 3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one
DMES0OT	CP	NeuroSearch A/S
DMES0OT	DT	Small molecular drug
DMES0OT	PC	4552
DMES0OT	MW	362.23
DMES0OT	FM	C15H8F6N2O2
DMES0OT	IC	InChI=1S/C15H8F6N2O2/c16-14(17,18)7-1-3-10-9(5-7)22-13(25)23(10)11-6-8(15(19,20)21)2-4-12(11)24/h1-6,24H,(H,22,25)
DMES0OT	CS	C1=CC2=C(C=C1C(F)(F)F)NC(=O)N2C3=C(C=CC(=C3)C(F)(F)F)O
DMES0OT	IK	YLFMCMWKHSDUCT-UHFFFAOYSA-N
DMES0OT	IU	3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one
DMES0OT	CA	CAS 153587-01-0
DMES0OT	CB	CHEBI:34879
DMES0OT	DE	Asthma

DM9F81Z	ID	DM9F81Z
DM9F81Z	DN	NS-257
DM9F81Z	HS	Terminated
DM9F81Z	SN	PD-144216
DM9F81Z	CP	NeuroSearch A/S
DM9F81Z	PC	135484540
DM9F81Z	MW	324.36
DM9F81Z	FM	C13H16N4O4S
DM9F81Z	IC	InChI=1S/C13H16N4O4S/c1-16(2)22(20,21)10-4-7-11(14-13(18)12(7)15-19)9-6-17(3)5-8(9)10/h4,14,18H,5-6H2,1-3H3
DM9F81Z	CS	CN1CC2=C(C=C3C(=C2C1)NC(=C3N=O)O)S(=O)(=O)N(C)C
DM9F81Z	IK	ZPJJGAUEQIVPRW-UHFFFAOYSA-N
DM9F81Z	IU	2-hydroxy-N,N,7-trimethyl-3-nitroso-6,8-dihydro-1H-pyrrolo[3,4-g]indole-5-sulfonamide
DM9F81Z	DE	Cerebrovascular ischaemia

DM19OGY	ID	DM19OGY
DM19OGY	DN	NS-2979
DM19OGY	HS	Terminated
DM19OGY	SN	Short-acting anesthetics, NeuroSearch
DM19OGY	CP	NeuroSearch A/S
DM19OGY	DE	Pain

DM2MU98	ID	DM2MU98
DM2MU98	DN	NS-377
DM2MU98	HS	Terminated
DM2MU98	CP	NeuroSearch A/S
DM2MU98	PC	9860852
DM2MU98	MW	292.3
DM2MU98	FM	C18H16N2O2
DM2MU98	IC	InChI=1S/C18H16N2O2/c1-2-20-9-14-12(11-6-4-3-5-7-11)8-13-16(15(14)10-20)19-18(22)17(13)21/h3-8H,2,9-10H2,1H3,(H,19,21,22)
DM2MU98	CS	CCN1CC2=C(C1)C3=C(C=C2C4=CC=CC=C4)C(=O)C(=O)N3
DM2MU98	IK	IWRZGAAKMZJBHL-UHFFFAOYSA-N
DM2MU98	IU	7-ethyl-5-phenyl-6,8-dihydro-1H-pyrrolo[3,4-g]indole-2,3-dione
DM2MU98	DE	Alzheimer disease

DMINUWH	ID	DMINUWH
DMINUWH	DN	NS398
DMINUWH	HS	Terminated
DMINUWH	SN	ns-398; 123653-11-2; NS398; NS 398; N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide; N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; CHEMBL7162; CHEBI:73458; Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-; n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide; N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide; Taisho NS 398; SR-01000597479; N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide; N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide; CCRIS 8523; KTDZCOWXCWUPEO-UHFFFAOYSA-N; Tocris-0942
DMINUWH	TC	Analgesics
DMINUWH	DT	Small molecular drug
DMINUWH	PC	4553
DMINUWH	MW	314.36
DMINUWH	FM	C13H18N2O5S
DMINUWH	IC	InChI=1S/C13H18N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h7-9,11,14H,2-6H2,1H3
DMINUWH	CS	CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2CCCCC2
DMINUWH	IK	KTDZCOWXCWUPEO-UHFFFAOYSA-N
DMINUWH	IU	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
DMINUWH	CA	CAS 123653-11-2
DMINUWH	CB	CHEBI:73458
DMINUWH	DE	Endometriosis

DMPT74G	ID	DMPT74G
DMPT74G	DN	NS-638
DMPT74G	HS	Terminated
DMPT74G	SN	150493-34-8; NS-638; NS638; 2-Amino-1-(4-chlorobenzyl)-5-trifluoromethylbenzimidazole; 1-[(4-chlorophenyl)methyl]-5-(trifluoromethyl)benzimidazol-2-amine; 1H-Benzimidazol-2-amine,1-[(4-chlorophenyl)methyl]-5-(trifluoromethyl)-; NS 638; GXQCVUZORDAARJ-UHFFFAOYSA-N; ACMC-20n5zm; AC1L2SIQ; SCHEMBL3083259; ZINC5752; CTK4C6667; DTXSID10164561; MolPort-046-033-572; BCP20747; AKOS032947353; 1-((4-Chlorophenyl)methyl)-5-(trifluoromethyl)-1H-benzimidazol-2-amine; CS-6337; KB-227320; HY-101428
DMPT74G	CP	NeuroSearch A/S
DMPT74G	DT	Small molecular drug
DMPT74G	PC	127722
DMPT74G	MW	325.71
DMPT74G	FM	C15H11ClF3N3
DMPT74G	IC	InChI=1S/C15H11ClF3N3/c16-11-4-1-9(2-5-11)8-22-13-6-3-10(15(17,18)19)7-12(13)21-14(22)20/h1-7H,8H2,(H2,20,21)
DMPT74G	CS	C1=CC(=CC=C1CN2C3=C(C=C(C=C3)C(F)(F)F)N=C2N)Cl
DMPT74G	IK	GXQCVUZORDAARJ-UHFFFAOYSA-N
DMPT74G	IU	1-[(4-chlorophenyl)methyl]-5-(trifluoromethyl)benzimidazol-2-amine
DMPT74G	CA	CAS 150493-34-8
DMPT74G	DE	Cerebrovascular ischaemia

DMXKMRV	ID	DMXKMRV
DMXKMRV	DN	NS-649
DMXKMRV	HS	Terminated
DMXKMRV	CP	NeuroSearch A/S
DMXKMRV	PC	9905818
DMXKMRV	MW	337.3
DMXKMRV	FM	C16H14F3N3O2
DMXKMRV	IC	InChI=1S/C16H14F3N3O2/c1-23-10-4-6-14(24-2)13(8-10)22-12-5-3-9(16(17,18)19)7-11(12)21-15(22)20/h3-8H,1-2H3,(H2,20,21)
DMXKMRV	CS	COC1=CC(=C(C=C1)OC)N2C3=C(C=C(C=C3)C(F)(F)F)N=C2N
DMXKMRV	IK	RUTNWAGOFFGBCZ-UHFFFAOYSA-N
DMXKMRV	IU	1-(2,5-dimethoxyphenyl)-5-(trifluoromethyl)benzimidazol-2-amine
DMXKMRV	DE	Alzheimer disease

DMI46T3	ID	DMI46T3
DMI46T3	DN	NS-696
DMI46T3	HS	Terminated
DMI46T3	CP	NeuroSearch A/S
DMI46T3	DE	Epilepsy

DMEYMHB	ID	DMEYMHB
DMEYMHB	DN	NSC-303812
DMEYMHB	HS	Discontinued
DMEYMHB	SN	Aphidicolin; (+)-Aphidicolin; (3R,4R,4aR,6aS,8R,9R,11aS,11bS)-4,9-bis(hydroxymethyl)-4,11b-dimethyltetradecahydro-8,11a-methanocyclohepta[a]naphthalene-3,9-diol; 192TJ6PP19; 38966-21-1; 9,15-Cyclo-C,18-dinor-14,15-secoandrostane-4,17-dimethanol, 3,17-dihydroxy-4-methyl-, (3alpha,4alpha,5alpha,17alpha)-; BRN 4689958; CCRIS 1783; CHEBI:2766; CHEMBL29711; ICI 69653; MLS000069677; NSC 234714; NSC-234714; NSC-351140; NSC234714; SMR000058538; UNII-192TJ6PP19
DMEYMHB	PC	457964
DMEYMHB	MW	338.5
DMEYMHB	FM	C20H34O4
DMEYMHB	IC	NOFOAYPPHIUXJR-APNQCZIXSA-N
DMEYMHB	CS	CC12CCC(C(C1CCC3C24CCC(C(C3)C4)(CO)O)(C)CO)O
DMEYMHB	IK	1S/C20H34O4/c1-17(11-21)15-4-3-13-9-14-10-19(13,7-8-20(14,24)12-22)18(15,2)6-5-16(17)23/h13-16,21-24H,3-12H2,1-2H3/t13-,14+,15-,16+,17-,18-,19-,20-/m0/s1
DMEYMHB	IU	(1S,2S,5R,6R,7R,10S,12R,13R)-6,13-bis(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.01,10.02,7]hexadecane-5,13-diol
DMEYMHB	CA	CAS 38966-21-1
DMEYMHB	CB	CHEBI:2766
DMEYMHB	DE	Hyperphosphatemia

DMDJT7U	ID	DMDJT7U
DMDJT7U	DN	NSC-661755
DMDJT7U	HS	Terminated
DMDJT7U	DT	Small molecular drug
DMDJT7U	PC	3246731
DMDJT7U	MW	816.9
DMDJT7U	FM	C48H52N2O10
DMDJT7U	IC	InChI=1S/C46H48N2O8.C2H4O2/c1-19-9-25-27(41-31-13-21(3)47-23(5)39(31)33(49)17-35(41)51)15-29(45(53)43(25)37(11-19)55-7)30-16-28(26-10-20(2)12-38(56-8)44(26)46(30)54)42-32-14-22(4)48-24(6)40(32)34(50)18-36(42)52;1-2(3)4/h9-12,15-18,21-24,47-54H,13-14H2,1-8H3;1H3,(H,3,4)/t21-,22-,23+,24+;/m0./s1
DMDJT7U	CS	C[C@H]1CC2=C(C(=CC(=C2[C@H](N1)C)O)O)C3=CC(=C(C4=C3C=C(C=C4OC)C)O)C5=C(C6=C(C=C(C=C6OC)C)C(=C5)C7=C8C[C@@H](N[C@@H](C8=C(C=C7O)O)C)C)O.CC(=O)O
DMDJT7U	IK	IHCBLDDSPLYUGN-ZODOTUICSA-N
DMDJT7U	IU	acetic acid;(1R,3S)-5-[3-[4-[(1R,3S)-6,8-dihydroxy-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-5-yl]-1-hydroxy-8-methoxy-6-methylnaphthalen-2-yl]-4-hydroxy-5-methoxy-7-methylnaphthalen-1-yl]-1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline-6,8-diol

DMF2XMA	ID	DMF2XMA
DMF2XMA	DN	NSD-721
DMF2XMA	HS	Terminated
DMF2XMA	SN	NS-11394; NS-2552; NS-2664; GABA-A receptor modulators, NeuroSearch; GABA-A receptor modulators, NeuroSearch/Meiji Seika
DMF2XMA	CP	NeuroSearch A/S
DMF2XMA	DE	Anxiety disorder

DMPG703	ID	DMPG703
DMPG703	DN	NSL-036
DMPG703	HS	Terminated
DMPG703	SN	Non-specific tachykinin antagonist (iv, pain), Sosei/NeuroSolutions
DMPG703	CP	Sosei Group Corp
DMPG703	DE	Neuropathic pain

DMU3D1K	ID	DMU3D1K
DMU3D1K	DN	NTE-122
DMU3D1K	HS	Terminated
DMU3D1K	SN	ACAT inhibitor, Nissin Food
DMU3D1K	CP	Nissin Foods Holdings Co Ltd
DMU3D1K	PC	9830692
DMU3D1K	MW	630.9
DMU3D1K	FM	C38H58N6O2
DMU3D1K	IC	InChI=1S/C38H58N6O2/c1-41(2)33-23-19-31(20-24-33)39-37(45)43(35-11-7-5-8-12-35)27-29-15-17-30(18-16-29)28-44(36-13-9-6-10-14-36)38(46)40-32-21-25-34(26-22-32)42(3)4/h19-26,29-30,35-36H,5-18,27-28H2,1-4H3,(H,39,45)(H,40,46)
DMU3D1K	CS	CN(C)C1=CC=C(C=C1)NC(=O)N(CC2CCC(CC2)CN(C3CCCCC3)C(=O)NC4=CC=C(C=C4)N(C)C)C5CCCCC5
DMU3D1K	IK	SIHFCVXQGXGQQO-UHFFFAOYSA-N
DMU3D1K	IU	1-cyclohexyl-1-[[4-[[cyclohexyl-[[4-(dimethylamino)phenyl]carbamoyl]amino]methyl]cyclohexyl]methyl]-3-[4-(dimethylamino)phenyl]urea
DMU3D1K	DE	Arteriosclerosis

DMPA8WO	ID	DMPA8WO
DMPA8WO	DN	NU1025
DMPA8WO	HS	Terminated
DMPA8WO	DT	Small molecular drug
DMPA8WO	PC	135398517
DMPA8WO	MW	176.17
DMPA8WO	FM	C9H8N2O2
DMPA8WO	IC	InChI=1S/C9H8N2O2/c1-5-10-8-6(9(13)11-5)3-2-4-7(8)12/h2-4,12H,1H3,(H,10,11,13)
DMPA8WO	CS	CC1=NC2=C(C=CC=C2O)C(=O)N1
DMPA8WO	IK	YJDAOHJWLUNFLX-UHFFFAOYSA-N
DMPA8WO	IU	8-hydroxy-2-methyl-3H-quinazolin-4-one
DMPA8WO	CA	CAS 90417-38-2
DMPA8WO	CB	CHEBI:75399

DMINSRW	ID	DMINSRW
DMINSRW	DN	NZ-1002
DMINSRW	HS	Terminated
DMINSRW	SN	Mucopolysaccharidosis I (MPS I) therapy, Novazyme; Phosphorylated alpha-L-iduronidase, Novazyme
DMINSRW	CP	Novazyme Pharmaceuticals Inc
DMINSRW	DE	Lysosomal storage disease

DMNAFG1	ID	DMNAFG1
DMNAFG1	DN	Olomoucine
DMNAFG1	HS	Terminated
DMNAFG1	SN	olomoucine; 101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine
DMNAFG1	DT	Small molecular drug
DMNAFG1	PC	4592
DMNAFG1	MW	298.34
DMNAFG1	FM	C15H18N6O
DMNAFG1	IC	InChI=1S/C15H18N6O/c1-21-10-18-12-13(17-9-11-5-3-2-4-6-11)19-15(16-7-8-22)20-14(12)21/h2-6,10,22H,7-9H2,1H3,(H2,16,17,19,20)
DMNAFG1	CS	CN1C=NC2=C(N=C(N=C21)NCCO)NCC3=CC=CC=C3
DMNAFG1	IK	GTVPOLSIJWJJNY-UHFFFAOYSA-N
DMNAFG1	IU	2-[[6-(benzylamino)-9-methylpurin-2-yl]amino]ethanol
DMNAFG1	CA	CAS 101622-51-9
DMNAFG1	CB	CHEBI:44661

DMAGUY0	ID	DMAGUY0
DMAGUY0	DN	Omapatrilat
DMAGUY0	HS	Terminated
DMAGUY0	SN	BMS-186716; Omapatrilat (JAN/USAN/INN); (4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
DMAGUY0	CP	Bristol-Myers Squibb
DMAGUY0	DT	Small molecular drug
DMAGUY0	PC	656629
DMAGUY0	MW	408.5
DMAGUY0	FM	C19H24N2O4S2
DMAGUY0	IC	InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1
DMAGUY0	CS	C1C[C@H](N2[C@H](C1)SCC[C@@H](C2=O)NC(=O)[C@H](CC3=CC=CC=C3)S)C(=O)O
DMAGUY0	IK	LVRLSYPNFFBYCZ-VGWMRTNUSA-N
DMAGUY0	IU	(4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
DMAGUY0	CA	CAS 167305-00-2
DMAGUY0	CB	CHEBI:135660
DMAGUY0	DE	Hypertension

DMSKAGP	ID	DMSKAGP
DMSKAGP	DN	Omniferon
DMSKAGP	HS	Terminated
DMSKAGP	SN	Alpha Leukoferon; Human alpha interferon, Viragen; Leukocyte-derived interferon; Alpha-IFN, Viragen; Topically enhanced Onmiferon (genital herpes), Viragen/Zonagen; BST-GEL (Omniferon), Viragen/Biosyntech
DMSKAGP	CP	Viragen Inc
DMSKAGP	DE	Solid tumour/cancer

DMMLXRG	ID	DMMLXRG
DMMLXRG	DN	ON-09300
DMMLXRG	HS	Terminated
DMMLXRG	SN	Oncoxib; ON-09310; COX2/lipoxygenase inhibitors (cancer), Onconova; ON-09 pyrazoline series (dual COX2/lipoxygenase inhibitors), Onconova
DMMLXRG	CP	Onconova Therapeutics Inc
DMMLXRG	DE	Solid tumour/cancer

DMTS6HB	ID	DMTS6HB
DMTS6HB	DN	ON-579
DMTS6HB	HS	Terminated
DMTS6HB	SN	141286-14-8; ON-579; ON 579; 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethylsulfanyl]-2,6-difluorophenoxy]acetic acid; Acetic acid,2-[4-[[2-[[(4-chlorophenyl)sulfonyl]amino]ethyl]thio]-2,6-difluorophenoxy]-; ACMC-20cvej; AC1Q6UCK; AC1L4U4O; {4-[(2-{[(4-chlorophenyl)sulfonyl]amino}ethyl)sulfanyl]-2,6-difluorophenoxy}acetic acid; CHEMBL312763; SCHEMBL2925987; CTK4C2555; DTXSID70161657; AKOS030574939; 4-(2-(4-Chlorophenylsulfonylamino)-ethylthio)-2,6-difluorophenoxyacetic acid; KB-227077
DMTS6HB	CP	Taisho Pharmaceutical Co Ltd
DMTS6HB	DT	Small molecular drug
DMTS6HB	PC	192308
DMTS6HB	MW	437.9
DMTS6HB	FM	C16H14ClF2NO5S2
DMTS6HB	IC	InChI=1S/C16H14ClF2NO5S2/c17-10-1-3-12(4-2-10)27(23,24)20-5-6-26-11-7-13(18)16(14(19)8-11)25-9-15(21)22/h1-4,7-8,20H,5-6,9H2,(H,21,22)
DMTS6HB	CS	C1=CC(=CC=C1S(=O)(=O)NCCSC2=CC(=C(C(=C2)F)OCC(=O)O)F)Cl
DMTS6HB	IK	FEYKNJZBWNIWJD-UHFFFAOYSA-N
DMTS6HB	IU	2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethylsulfanyl]-2,6-difluorophenoxy]acetic acid
DMTS6HB	CA	CAS 141286-14-8
DMTS6HB	DE	Asthma

DMBDCL4	ID	DMBDCL4
DMBDCL4	DN	ONO-8130
DMBDCL4	HS	Terminated
DMBDCL4	SN	Pollakiuria agent, Ono
DMBDCL4	CP	Ono Pharmaceutical Co Ltd
DMBDCL4	PC	9827317
DMBDCL4	MW	500.6
DMBDCL4	FM	C25H28N2O5S2
DMBDCL4	IC	InChI=1S/C25H28N2O5S2/c1-16(2)13-27(34(30,31)25-26-17(3)15-33-25)22-11-20-5-4-6-21(20)12-23(22)32-14-18-7-9-19(10-8-18)24(28)29/h7-12,15-16H,4-6,13-14H2,1-3H3,(H,28,29)
DMBDCL4	CS	CC1=CSC(=N1)S(=O)(=O)N(CC(C)C)C2=C(C=C3CCCC3=C2)OCC4=CC=C(C=C4)C(=O)O
DMBDCL4	IK	IOXMDBQCUCDLAF-UHFFFAOYSA-N
DMBDCL4	IU	4-[[6-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1H-inden-5-yl]oxymethyl]benzoic acid
DMBDCL4	CA	CAS 459841-96-4
DMBDCL4	DE	Pollakiuria

DM2VRK7	ID	DM2VRK7
DM2VRK7	DN	ONO-8711
DM2VRK7	HS	Terminated
DM2VRK7	SN	6-[(2R,3S)-3-(4-Chloro-2-methylphenylsulfonamidomethyl)bicyclo[2.2.2]oct-2-yl]-5(Z)-hexenoic acid
DM2VRK7	DT	Small molecular drug
DM2VRK7	PC	9824507
DM2VRK7	MW	440
DM2VRK7	FM	C22H30ClNO4S
DM2VRK7	IC	InChI=1S/C22H30ClNO4S/c1-15-13-18(23)11-12-21(15)29(27,28)24-14-20-17-9-7-16(8-10-17)19(20)5-3-2-4-6-22(25)26/h3,5,11-13,16-17,19-20,24H,2,4,6-10,14H2,1H3,(H,25,26)/b5-3-/t16?,17?,19-,20-/m0/s1
DM2VRK7	CS	CC1=C(C=CC(=C1)Cl)S(=O)(=O)NC[C@@H]2[C@H](C3CCC2CC3)/C=C\\CCCC(=O)O
DM2VRK7	IK	VVEXPDRCGCQELD-CFDZEDGGSA-N
DM2VRK7	IU	(Z)-6-[(2R,3S)-3-[[(4-chloro-2-methylphenyl)sulfonylamino]methyl]-2-bicyclo[2.2.2]octanyl]hex-5-enoic acid
DM2VRK7	CA	CAS 216158-34-8
DM2VRK7	DE	Pain

DM4CVEG	ID	DM4CVEG
DM4CVEG	DN	ONO-8815Ly
DM4CVEG	HS	Terminated
DM4CVEG	SN	ONO-8815Lyn; ONO-AE-1259
DM4CVEG	CP	Ono Pharmaceutical Co Ltd
DM4CVEG	DT	Small molecular drug
DM4CVEG	PC	9807448
DM4CVEG	MW	399
DM4CVEG	FM	C22H35ClO4
DM4CVEG	IC	InChI=1S/C22H35ClO4/c1-2-22(13-8-14-22)20(25)11-7-10-17-16(18(23)15-19(17)24)9-5-3-4-6-12-21(26)27/h3,5,7,10,16-20,24-25H,2,4,6,8-9,11-15H2,1H3,(H,26,27)/b5-3-,10-7+/t16-,17-,18-,19-,20+/m1/s1
DM4CVEG	CS	CCC1(CCC1)[C@H](C/C=C/[C@H]2[C@@H](C[C@H]([C@@H]2C/C=C\\CCCC(=O)O)Cl)O)O
DM4CVEG	IK	LBIPUBVVGYRBNA-VGUVCEGPSA-N
DM4CVEG	IU	(Z)-7-[(1R,2R,3R,5R)-5-chloro-2-[(E,4S)-4-(1-ethylcyclobutyl)-4-hydroxybut-1-enyl]-3-hydroxycyclopentyl]hept-5-enoic acid
DM4CVEG	DE	Miscarriage

DMW68CE	ID	DMW68CE
DMW68CE	DN	Oral insulin
DMW68CE	HS	Terminated
DMW68CE	SN	Oral insulin (type I diabetes)
DMW68CE	CP	Oshadi Drug Administration Ltd
DMW68CE	DE	Type-1 diabetes

DMUGC2X	ID	DMUGC2X
DMUGC2X	DN	Org-10490
DMUGC2X	HS	Terminated
DMUGC2X	CP	Organon BioSciences
DMUGC2X	PC	3086163
DMUGC2X	MW	253.34
DMUGC2X	FM	C17H19NO
DMUGC2X	IC	InChI=1S/C17H19NO/c1-18-12-10-14-6-2-4-8-16(14)19-17-9-5-3-7-15(17)11-13-18/h2-9H,10-13H2,1H3
DMUGC2X	CS	CN1CCC2=CC=CC=C2OC3=CC=CC=C3CC1
DMUGC2X	IK	NREYMNFZCFNECP-UHFFFAOYSA-N
DMUGC2X	IU	11-methyl-2-oxa-11-azatricyclo[12.4.0.03,8]octadeca-1(18),3,5,7,14,16-hexaene
DMUGC2X	CA	CAS 83507-02-2
DMUGC2X	DE	Psychotic disorder

DMQU8AR	ID	DMQU8AR
DMQU8AR	DN	Org-20599
DMQU8AR	HS	Terminated
DMQU8AR	SN	Org-20549
DMQU8AR	CP	Organon BioSciences
DMQU8AR	DT	Small molecular drug
DMQU8AR	PC	9850026
DMQU8AR	MW	438
DMQU8AR	FM	C25H40ClNO3
DMQU8AR	IC	InChI=1S/C25H40ClNO3/c1-24-8-7-19-17(18(24)5-6-20(24)23(29)15-26)4-3-16-13-22(28)21(14-25(16,19)2)27-9-11-30-12-10-27/h16-22,28H,3-15H2,1-2H3/t16-,17-,18-,19-,20+,21-,22-,24-,25-/m0/s1
DMQU8AR	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)CCl)CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C
DMQU8AR	IK	NZFNABGZEQPYBX-PMBZPZLSSA-N
DMQU8AR	IU	2-chloro-1-[(2S,3S,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DMQU8AR	CA	CAS 156685-94-8
DMQU8AR	DE	Anaesthesia

DM95QG2	ID	DM95QG2
DM95QG2	DN	Org-20781
DM95QG2	HS	Terminated
DM95QG2	CP	Organon BioSciences
DM95QG2	PC	9861772
DM95QG2	MW	317.4
DM95QG2	FM	C19H27NO3
DM95QG2	IC	InChI=1S/C19H27NO3/c1-19-6-5-11-12(14(19)9-17(23)18(19)20-2)4-3-10-7-15(21)16(22)8-13(10)11/h7-8,11-12,14,17-18,20-23H,3-6,9H2,1-2H3/t11-,12+,14-,17+,18-,19-/m0/s1
DM95QG2	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2NC)O)CCC4=CC(=C(C=C34)O)O
DM95QG2	IK	YVBSZXJRJYYVQR-AFKMTKAPSA-N
DM95QG2	IU	(8R,9S,13S,14S,16R,17R)-13-methyl-17-(methylamino)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,16-triol
DM95QG2	DE	Heart arrhythmia

DMMA92L	ID	DMMA92L
DMMA92L	DN	Org-30035
DMMA92L	HS	Terminated
DMMA92L	CP	Organon BioSciences
DMMA92L	DE	Psychotic disorder

DM3VWZF	ID	DM3VWZF
DM3VWZF	DN	Org-34092
DM3VWZF	HS	Terminated
DM3VWZF	SN	IDDB19835
DM3VWZF	CP	Organon BioSciences
DM3VWZF	DE	Thrombosis

DMB0IQT	ID	DMB0IQT
DMB0IQT	DN	Org-34116
DMB0IQT	HS	Terminated
DMB0IQT	CP	Organon BioSciences
DMB0IQT	DE	Anxiety disorder

DMY3LXH	ID	DMY3LXH
DMY3LXH	DN	Org-37684
DMY3LXH	HS	Terminated
DMY3LXH	SN	Org-36262
DMY3LXH	CP	Organon BioSciences
DMY3LXH	DT	Small molecular drug
DMY3LXH	PC	9794656
DMY3LXH	MW	233.31
DMY3LXH	FM	C14H19NO2
DMY3LXH	IC	InChI=1S/C14H19NO2/c1-16-13-6-5-10-3-2-4-12(10)14(13)17-11-7-8-15-9-11/h5-6,11,15H,2-4,7-9H2,1H3/t11-/m0/s1
DMY3LXH	CS	COC1=C(C2=C(CCC2)C=C1)O[C@H]3CCNC3
DMY3LXH	IK	QDJAYXYEXHVXJV-NSHDSACASA-N
DMY3LXH	IU	(3S)-3-[(5-methoxy-2,3-dihydro-1H-inden-4-yl)oxy]pyrrolidine
DMY3LXH	DE	Anxiety disorder

DMRZCH4	ID	DMRZCH4
DMRZCH4	DN	Org-9935
DMRZCH4	HS	Terminated
DMRZCH4	SN	Org-935
DMRZCH4	CP	Organon BioSciences
DMRZCH4	DT	Small molecular drug
DMRZCH4	PC	131100
DMRZCH4	MW	304.4
DMRZCH4	FM	C15H16N2O3S
DMRZCH4	IC	InChI=1S/C15H16N2O3S/c1-8-4-14(18)16-17-15(8)13-6-9-5-10(19-2)11(20-3)7-12(9)21-13/h5-8H,4H2,1-3H3,(H,16,18)
DMRZCH4	CS	CC1CC(=O)NN=C1C2=CC3=CC(=C(C=C3S2)OC)OC
DMRZCH4	IK	KIYDKXDCNSPKQQ-UHFFFAOYSA-N
DMRZCH4	IU	3-(5,6-dimethoxy-1-benzothiophen-2-yl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one
DMRZCH4	CA	CAS 129425-83-8
DMRZCH4	DE	Asthma

DM9YOMX	ID	DM9YOMX
DM9YOMX	DN	OT-4003
DM9YOMX	HS	Terminated
DM9YOMX	SN	IDDB10966
DM9YOMX	CP	LEO Pharma A/S
DM9YOMX	DE	Asthma

DMESWV1	ID	DMESWV1
DMESWV1	DN	OX-23
DMESWV1	HS	Terminated
DMESWV1	SN	Analgesic (sublingual tablet), Orexo
DMESWV1	CP	Orexo AB
DMESWV1	DT	Antibody
DMESWV1	DE	Pain

DMVPG1N	ID	DMVPG1N
DMVPG1N	DN	OX-30
DMVPG1N	HS	Terminated
DMVPG1N	SN	Opioid (oral controlled-release, pain), Orexo
DMVPG1N	CP	Orexo AB
DMVPG1N	DT	Antibody
DMVPG1N	DE	Pain

DM1TG3C	ID	DM1TG3C
DM1TG3C	DN	Oxamflatin
DM1TG3C	HS	Terminated
DM1TG3C	SN	NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3
DM1TG3C	TC	Anticancer Agents
DM1TG3C	DT	Small molecular drug
DM1TG3C	PC	5353852
DM1TG3C	MW	342.4
DM1TG3C	FM	C17H14N2O4S
DM1TG3C	IC	InChI=1S/C17H14N2O4S/c20-17(18-21)12-5-4-7-14-8-6-9-15(13-14)19-24(22,23)16-10-2-1-3-11-16/h1-3,5-6,8-13,19,21H,(H,18,20)/b12-5+
DM1TG3C	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)C#C/C=C/C(=O)NO
DM1TG3C	IK	QRPSQQUYPMFERG-LFYBBSHMSA-N
DM1TG3C	IU	(E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide
DM1TG3C	CA	CAS 151720-43-3
DM1TG3C	CB	CHEBI:93779
DM1TG3C	DE	Solid tumour/cancer

DMLKQUR	ID	DMLKQUR
DMLKQUR	DN	Palinavir
DMLKQUR	HS	Terminated
DMLKQUR	SN	BILA-2011; BILA-2011 BS
DMLKQUR	CP	Bio-Mega Research Division
DMLKQUR	DT	Small molecular drug
DMLKQUR	PC	72981
DMLKQUR	MW	708.9
DMLKQUR	FM	C41H52N6O5
DMLKQUR	IC	InChI=1S/C41H52N6O5/c1-27(2)37(45-38(49)33-16-15-30-13-9-10-14-32(30)43-33)40(51)44-34(23-28-11-7-6-8-12-28)36(48)25-47-22-19-31(52-26-29-17-20-42-21-18-29)24-35(47)39(50)46-41(3,4)5/h6-18,20-21,27,31,34-37,48H,19,22-26H2,1-5H3,(H,44,51)(H,45,49)(H,46,50)/t31-,34+,35+,36-,37+/m1/s1
DMLKQUR	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](CN2CC[C@H](C[C@H]2C(=O)NC(C)(C)C)OCC3=CC=NC=C3)O)NC(=O)C4=NC5=CC=CC=C5C=C4
DMLKQUR	IK	RXBWRFDZXRAEJT-SZNOJMITSA-N
DMLKQUR	IU	N-[(2S)-1-[[(2S,3R)-4-[(2S,4R)-2-(tert-butylcarbamoyl)-4-(pyridin-4-ylmethoxy)piperidin-1-yl]-3-hydroxy-1-phenylbutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]quinoline-2-carboxamide
DMLKQUR	CA	CAS 154612-39-2
DMLKQUR	DE	Human immunodeficiency virus infection

DM6HBQJ	ID	DM6HBQJ
DM6HBQJ	DN	Patamostat
DM6HBQJ	HS	Terminated
DM6HBQJ	SN	E-3123
DM6HBQJ	CP	Eisai Co Ltd
DM6HBQJ	DT	Small molecular drug
DM6HBQJ	PC	65921
DM6HBQJ	MW	412.5
DM6HBQJ	FM	C20H20N4O4S
DM6HBQJ	IC	InChI=1S/C20H20N4O4S/c21-20(22)23-14-3-1-13(2-4-14)19(27)28-15-5-7-16(8-6-15)29-12-11-24-17(25)9-10-18(24)26/h1-8H,9-12H2,(H4,21,22,23)
DM6HBQJ	CS	C1CC(=O)N(C1=O)CCSC2=CC=C(C=C2)OC(=O)C3=CC=C(C=C3)N=C(N)N
DM6HBQJ	IK	ILRQPCQIFIURTG-UHFFFAOYSA-N
DM6HBQJ	IU	[4-[2-(2,5-dioxopyrrolidin-1-yl)ethylsulfanyl]phenyl] 4-(diaminomethylideneamino)benzoate
DM6HBQJ	CA	CAS 114568-26-2
DM6HBQJ	DE	Hypotension

DMWD1RC	ID	DMWD1RC
DMWD1RC	DN	PBI-1101
DMWD1RC	HS	Terminated
DMWD1RC	CP	ProMetic Life Sciences Inc
DMWD1RC	DE	Inflammation

DMWYP86	ID	DMWYP86
DMWYP86	DN	PD-0183812
DMWYP86	HS	Terminated
DMWYP86	SN	PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813
DMWYP86	DT	Small molecular drug
DMWYP86	PC	5330258
DMWYP86	MW	473.6
DMWYP86	FM	C28H35N5O2
DMWYP86	IC	InChI=1S/C28H35N5O2/c34-15-1-2-19-11-13-32(14-12-19)24-8-6-23(7-9-24)30-28-29-18-22-5-10-26(35)33(27(22)31-28)25-17-20-3-4-21(25)16-20/h5-10,18-21,25,34H,1-4,11-17H2,(H,29,30,31)
DMWYP86	CS	C1CC2CC1CC2N3C(=O)C=CC4=CN=C(N=C43)NC5=CC=C(C=C5)N6CCC(CC6)CCCO
DMWYP86	IK	PETCVZZPKYJZAU-UHFFFAOYSA-N
DMWYP86	IU	8-(2-bicyclo[2.2.1]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one
DMWYP86	DE	Retinoblastoma

DMGKVPH	ID	DMGKVPH
DMGKVPH	DN	PD-0204318
DMGKVPH	HS	Terminated
DMGKVPH	SN	PD-0183764
DMGKVPH	CP	Parke-Davis & Co
DMGKVPH	DE	Pain

DMN1A70	ID	DMN1A70
DMN1A70	DN	PD-117596
DMN1A70	HS	Terminated
DMN1A70	SN	PD-117596-2
DMN1A70	CP	Parke-Davis & Co
DMN1A70	DT	Small molecular drug
DMN1A70	PC	122796
DMN1A70	MW	349.33
DMN1A70	FM	C17H17F2N3O3
DMN1A70	IC	InChI=1S/C17H17F2N3O3/c18-12-5-10-14(13(19)15(12)21-4-3-8(20)6-21)22(9-1-2-9)7-11(16(10)23)17(24)25/h5,7-9H,1-4,6,20H2,(H,24,25)
DMN1A70	CS	C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)F)N4CCC(C4)N)F)C(=O)O
DMN1A70	IK	UHBXZNXCIZHGFF-UHFFFAOYSA-N
DMN1A70	IU	7-(3-aminopyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
DMN1A70	CA	CAS 99734-98-2
DMN1A70	DE	Bacterial infection

DM92VUF	ID	DM92VUF
DM92VUF	DN	PD-123319
DM92VUF	HS	Terminated
DM92VUF	SN	PD123319; PD 123319; 130663-39-7; PD-123319; CHEBI:61014; C31H32N4O3; CHEMBL157946; (S)-1-(4-(dimethylamino)-3-methylbenzyl)-5-(2,2-diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid; (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid; AC1NSKGQ; Epitope ID:140138; GTPL597; SCHEMBL668525; CHEMBL321820; PD-123319 ditrifluoroacetate; MolPort-005-942-100; EX-A2290; BCP08027; s7098; 2633AH; ZINC22015557; BDBM50282396; AKOS030526087
DM92VUF	DT	Small molecular drug
DM92VUF	PC	5311345
DM92VUF	MW	508.6
DM92VUF	FM	C31H32N4O3
DM92VUF	IC	InChI=1S/C31H32N4O3/c1-21-16-22(14-15-26(21)33(2)3)18-34-20-32-25-19-35(28(31(37)38)17-27(25)34)30(36)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-16,20,28-29H,17-19H2,1-3H3,(H,37,38)/t28-/m0/s1
DM92VUF	CS	CC1=C(C=CC(=C1)CN2C=NC3=C2C[C@H](N(C3)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)O)N(C)C
DM92VUF	IK	YSTVFDAKLDMYCR-NDEPHWFRSA-N
DM92VUF	IU	(6S)-1-[[4-(dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
DM92VUF	CA	CAS 130663-39-7
DM92VUF	CB	CHEBI:61014

DM0YXRQ	ID	DM0YXRQ
DM0YXRQ	DN	PD-128483
DM0YXRQ	HS	Terminated
DM0YXRQ	SN	CCRIS 4394; PD-128483; PD 128483; 153260-23-2; 115688-97-6; C11H15N3S; 6-Methyl-4,5,5a,6,7,8-hexahydrothiazolo(4,5-f)quinolin-2-amine; 4,5,5a,6,7,8-Hexahydro-6-methylthiazolo(4,5-f)quinoline-2-amine; Thiazolo(4,5-f)quinolin-2-amine, 4,5,5a,6,7,8-hexahydro-6-methyl-, (+-)-; CCRIS 6698; 6-METHYL-4,5,5A,6,7,8-HEXAHYDROTHIAZOLO[4,5-F]QUINOLIN-2-AMINE; 4,5,5A,6,7,8-HEXAHYDRO-6-METHYLTHIAZOLO[4,5-F]QUINOLINE-2-AMINE; XFJSSDHKIXXJLM-UHFFFAOYSA-N; AC1L2Y0S; CHEMBL350920; SCHEMBL10665477; AKOS022654211; LS-172297; LS-190761
DM0YXRQ	DT	Small molecular drug
DM0YXRQ	PC	130792
DM0YXRQ	MW	221.32
DM0YXRQ	FM	C11H15N3S
DM0YXRQ	IC	InChI=1S/C11H15N3S/c1-14-6-2-3-7-8(14)4-5-9-10(7)13-11(12)15-9/h3,8H,2,4-6H2,1H3,(H2,12,13)
DM0YXRQ	CS	CN1CCC=C2C1CCC3=C2N=C(S3)N
DM0YXRQ	IK	XFJSSDHKIXXJLM-UHFFFAOYSA-N
DM0YXRQ	IU	6-methyl-5,5a,7,8-tetrahydro-4H-[1,3]thiazolo[4,5-f]quinolin-2-amine
DM0YXRQ	CA	CAS 115688-97-6

DMLEVNC	ID	DMLEVNC
DMLEVNC	DN	PD-135666
DMLEVNC	HS	Terminated
DMLEVNC	SN	PD-135666; CHEMBL138534; GTPL903; SCHEMBL6895794; CHEMBL2111312; PDSP2_000908; PDSP1_000922; BDBM50062005; PD135666; 134557-41-8; PD 135666; (S)-3-[(R)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-4-phenyl-butyric acid; 3-[2-(2-Adamantan-2-yl-acetylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-4-phenyl-butyric acid(PD 135666); (3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-phenylbutanoic acid
DMLEVNC	DT	Small molecular drug
DMLEVNC	PC	9850711
DMLEVNC	MW	557.7
DMLEVNC	FM	C33H39N3O5
DMLEVNC	IC	InChI=1S/C33H39N3O5/c1-33(18-25-19-34-28-10-6-5-9-27(25)28,31(39)35-26(17-29(37)38)16-20-7-3-2-4-8-20)36-32(40)41-30-23-12-21-11-22(14-23)15-24(30)13-21/h2-10,19,21-24,26,30,34H,11-18H2,1H3,(H,35,39)(H,36,40)(H,37,38)/t21?,22?,23?,24?,26-,30?,33+/m0/s1
DMLEVNC	CS	C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@@H](CC3=CC=CC=C3)CC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMLEVNC	IK	PGOLWKTUHWHYJS-SFMDGOMNSA-N
DMLEVNC	IU	(3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-phenylbutanoic acid

DMD6L82	ID	DMD6L82
DMD6L82	DN	PD136450
DMD6L82	HS	Terminated
DMD6L82	SN	PD-136450; Cam 1189; PD 136450; CHEMBL341460; CHEMBL3351022; (E)-4-[[(1R)-2-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobut-2-enoic acid; PD136450; CAM-1189; AC1O5RMN; GTPL867; SCHEMBL6895211; BDBM50230677; BDBM50007439; PD-136,450; 2-Butenoic acid, 4-((2-((3-(1H-indol-3-yl)-2-methyl-1-oxo-2-(((tricyclo(3.3.1.1(3,7))dec-2-yloxy)carbonyl)amino)propyl)amino)-1-phenylethyl)amino)-4-oxo-, (R-(R*,R*))-
DMD6L82	DT	Small molecular drug
DMD6L82	PC	6439414
DMD6L82	MW	612.7
DMD6L82	FM	C35H40N4O6
DMD6L82	IC	InChI=1S/C35H40N4O6/c1-35(18-26-19-36-28-10-6-5-9-27(26)28,39-34(44)45-32-24-14-21-13-22(16-24)17-25(32)15-21)33(43)37-20-29(23-7-3-2-4-8-23)38-30(40)11-12-31(41)42/h2-12,19,21-22,24-25,29,32,36H,13-18,20H2,1H3,(H,37,43)(H,38,40)(H,39,44)(H,41,42)/b12-11+/t21?,22?,24?,25?,29-,32?,35+/m0/s1
DMD6L82	CS	C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)NC[C@@H](C3=CC=CC=C3)NC(=O)/C=C/C(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMD6L82	IK	REMAMJQTIPBFTH-MYJPUEAFSA-N
DMD6L82	IU	(E)-4-[[(1R)-2-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobut-2-enoic acid
DMD6L82	CA	CAS 139067-52-0

DMFA27N	ID	DMFA27N
DMFA27N	DN	PD142893
DMFA27N	HS	Terminated
DMFA27N	SN	PD 142893; PD-142893; CHEMBL438194; 143037-36-9; Ac-Dip-leu-asp-ile-ile-trp; Acetyldiphenylalanyl-leucyl-aspartyl-isoleucyl-isoleucyl-tryptophan; AC1L3U2Y; DTXSID40162297; IFDNLSRYZKUGIR-KXXXQFFTSA-N; BDBM50001218; N-(N-(N-(N-(N-(N-Acetyl-3-(1,1'-biphenyl)-4-yl-D-alanyl)-L-leucyl)-L-alpha-aspartyl)-L-isoleucyl)-L-isoleucyl)-L-tryptophan; Ac-3-(1,1'-Biphenyl-4-yl)-D-Ala-L-Leu-L-Asp-L-Ile-L-Ile-L-Trp-OH; L-Tryptophan, N-(N-(N-(N-(N-(N-acetyl-3-(1,1'-biphenyl)-4-yl-D-alanyl)-L-leucyl)-L-alpha-aspartyl)-L-isoleucyl)-L-isol
DMFA27N	DT	Small molecular drug
DMFA27N	PC	122149
DMFA27N	MW	924.1
DMFA27N	FM	C50H65N7O10
DMFA27N	IC	InChI=1S/C50H65N7O10/c1-8-29(5)43(48(64)55-41(50(66)67)25-35-27-51-37-18-14-13-17-36(35)37)57-49(65)44(30(6)9-2)56-47(63)40(26-42(59)60)54-45(61)38(23-28(3)4)53-46(62)39(52-31(7)58)24-32-19-21-34(22-20-32)33-15-11-10-12-16-33/h10-22,27-30,38-41,43-44,51H,8-9,23-26H2,1-7H3,(H,52,58)(H,53,62)(H,54,61)(H,55,64)(H,56,63)(H,57,65)(H,59,60)(H,66,67)/t29-,30-,38-,39+,40-,41-,43-,44-/m0/s1
DMFA27N	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC3=CC=C(C=C3)C4=CC=CC=C4)NC(=O)C
DMFA27N	IK	IFDNLSRYZKUGIR-KXXXQFFTSA-N
DMFA27N	IU	(3S)-3-[[(2S)-2-[[(2R)-2-acetamido-3-(4-phenylphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMFA27N	CA	CAS 143037-36-9

DMHQSF8	ID	DMHQSF8
DMHQSF8	DN	PD-146176
DMHQSF8	HS	Terminated
DMHQSF8	SN	PD 146176; 4079-26-9; 6,11-dihydrothiochromeno[4,3-b]indole; 6,11-Dihydro[1]benzothiopyrano[4,3-b]indole; CHEMBL180917; pd146176; NSC168807; 6,3-b]indole; NSC 168807; AC1L6RUM; 6,11-Dihydro-5-thia-11-aza-benzo(a)fluorene; SCHEMBL1986281; ZINC6892; CTK4I3773; AOB5548; MolPort-003-959-269; BCP24885; BS0260; BDBM50208823; MFCD05664738; AKOS024457313; NSC-168807; [1]Benzothiopyrano[4, 6,11-dihydro-; NCGC00165868-01; B7208; PD 146176, &gt; (1)Benzothiopyrano(4,3-b)indole, 6,11-dihydro-
DMHQSF8	DT	Small molecular drug
DMHQSF8	PC	297589
DMHQSF8	MW	237.32
DMHQSF8	FM	C15H11NS
DMHQSF8	IC	InChI=1S/C15H11NS/c1-3-7-13-10(5-1)12-9-17-14-8-4-2-6-11(14)15(12)16-13/h1-8,16H,9H2
DMHQSF8	CS	C1C2=C(C3=CC=CC=C3S1)NC4=CC=CC=C24
DMHQSF8	IK	ZGOOPZVQMLHPFM-UHFFFAOYSA-N
DMHQSF8	IU	6,11-dihydrothiochromeno[4,3-b]indole
DMHQSF8	CA	CAS 4079-26-9
DMHQSF8	DE	Arteriosclerosis

DMVEXID	ID	DMVEXID
DMVEXID	DN	PD-153103
DMVEXID	HS	Terminated
DMVEXID	CP	Parke-Davis & Co
DMVEXID	DE	Human immunodeficiency virus-1 infection

DMQCNWD	ID	DMQCNWD
DMQCNWD	DN	PD-155080
DMQCNWD	HS	Terminated
DMQCNWD	SN	CHEMBL274383; SCHEMBL8187314; BDBM50034256
DMQCNWD	DT	Small molecular drug
DMQCNWD	PC	11742628
DMQCNWD	MW	416.4
DMQCNWD	FM	C25H20O6
DMQCNWD	IC	InChI=1S/C25H20O6/c1-28-19-10-8-18(9-11-19)25(27)20(13-16-5-3-2-4-6-16)23(24(26)31-25)17-7-12-21-22(14-17)30-15-29-21/h2-12,14,27H,13,15H2,1H3
DMQCNWD	CS	COC1=CC=C(C=C1)C2(C(=C(C(=O)O2)C3=CC4=C(C=C3)OCO4)CC5=CC=CC=C5)O
DMQCNWD	IK	JZHLIUOZBXWYGJ-UHFFFAOYSA-N
DMQCNWD	IU	3-(1,3-benzodioxol-5-yl)-4-benzyl-5-hydroxy-5-(4-methoxyphenyl)furan-2-one
DMQCNWD	DE	Hypertension

DMAVZEJ	ID	DMAVZEJ
DMAVZEJ	DN	PD156707
DMAVZEJ	HS	Terminated
DMAVZEJ	SN	PD-156707; 162412-70-6; CHEMBL25438; GTPL999; DTXSID80635455; HMS3263B04; Tox21_501201; CCG-222505; NCGC00261886-01; LS-34623; P-305; PD-156707, &gt; Sodium (Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate.; Sodium (2Z)-2-(2H-1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate; sodium (Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate
DMAVZEJ	DT	Small molecular drug
DMAVZEJ	PC	23670447
DMAVZEJ	MW	528.5
DMAVZEJ	FM	C28H25NaO9
DMAVZEJ	IC	InChI=1S/C28H26O9.Na/c1-32-19-8-5-17(6-9-19)26(29)20(11-16-12-23(33-2)27(35-4)24(13-16)34-3)25(28(30)31)18-7-10-21-22(14-18)37-15-36-21;/h5-10,12-14H,11,15H2,1-4H3,(H,30,31);/q;+1/p-1/b25-20-;
DMAVZEJ	CS	COC1=CC=C(C=C1)C(=O)/C(=C(/C2=CC3=C(C=C2)OCO3)\\C(=O)[O-])/CC4=CC(=C(C(=C4)OC)OC)OC.[Na+]
DMAVZEJ	IK	ZLHQEGFYBMZQGM-RKVLWQGQSA-M
DMAVZEJ	IU	sodium;(Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate
DMAVZEJ	CA	CAS 162412-70-6

DM61NFD	ID	DM61NFD
DM61NFD	DN	PD-157667
DM61NFD	HS	Terminated
DM61NFD	SN	CHEMBL78017; PD-157667; SCHEMBL7307021; pd157667; BDBM50071611
DM61NFD	DT	Small molecular drug
DM61NFD	PC	9956291
DM61NFD	MW	468.7
DM61NFD	FM	C32H40N2O
DM61NFD	IC	InChI=1S/C32H40N2O/c35-32-29(25-33-20-9-1-2-10-21-33)18-17-28-24-34(23-19-31(28)32)22-11-16-30(26-12-5-3-6-13-26)27-14-7-4-8-15-27/h3-8,12-15,17-18,30,35H,1-2,9-11,16,19-25H2
DM61NFD	CS	C1CCCN(CC1)CC2=C(C3=C(CN(CC3)CCCC(C4=CC=CC=C4)C5=CC=CC=C5)C=C2)O
DM61NFD	IK	SBYWDPHGZJEZBN-UHFFFAOYSA-N
DM61NFD	IU	6-(azepan-1-ylmethyl)-2-(4,4-diphenylbutyl)-3,4-dihydro-1H-isoquinolin-5-ol

DMS1XK5	ID	DMS1XK5
DMS1XK5	DN	PD-158473
DMS1XK5	HS	Terminated
DMS1XK5	SN	SCHEMBL838874; CHEMBL62030; ZINC1542005
DMS1XK5	CP	Pfizer Inc
DMS1XK5	DT	Small molecular drug
DMS1XK5	PC	9821483
DMS1XK5	MW	385.3
DMS1XK5	FM	C20H20NO5P
DMS1XK5	IC	InChI=1S/C20H20NO5P/c21-19(20(22)23)11-13-8-14(12-27(24,25)26)10-16(9-13)18-7-3-5-15-4-1-2-6-17(15)18/h1-10,19H,11-12,21H2,(H,22,23)(H2,24,25,26)/t19-/m0/s1
DMS1XK5	CS	C1=CC=C2C(=C1)C=CC=C2C3=CC(=CC(=C3)CP(=O)(O)O)C[C@@H](C(=O)O)N
DMS1XK5	IK	YFASPHLUVUCGGI-IBGZPJMESA-N
DMS1XK5	IU	(2S)-2-amino-3-[3-naphthalen-1-yl-5-(phosphonomethyl)phenyl]propanoic acid
DMS1XK5	DE	Cerebrovascular ischaemia

DMJ5STO	ID	DMJ5STO
DMJ5STO	DN	PD-159913
DMJ5STO	HS	Terminated
DMJ5STO	SN	PD-159913; CHEMBL60181; SCHEMBL8923309
DMJ5STO	CP	Pfizer Inc
DMJ5STO	DT	Small molecular drug
DMJ5STO	PC	10430161
DMJ5STO	MW	385.3
DMJ5STO	FM	C20H20NO5P
DMJ5STO	IC	InChI=1S/C20H20NO5P/c21-19(20(22)23)10-13-7-14(12-27(24,25)26)9-18(8-13)17-6-5-15-3-1-2-4-16(15)11-17/h1-9,11,19H,10,12,21H2,(H,22,23)(H2,24,25,26)/t19-/m0/s1
DMJ5STO	CS	C1=CC=C2C=C(C=CC2=C1)C3=CC(=CC(=C3)CP(=O)(O)O)C[C@@H](C(=O)O)N
DMJ5STO	IK	GOPXMKDIVJBBQF-IBGZPJMESA-N
DMJ5STO	IU	(2S)-2-amino-3-[3-naphthalen-2-yl-5-(phosphonomethyl)phenyl]propanoic acid
DMJ5STO	DE	Cerebrovascular ischaemia

DMAOHXY	ID	DMAOHXY
DMAOHXY	DN	PD166285
DMAOHXY	HS	Terminated
DMAOHXY	SN	PD0166285; 185039-89-8; TCMDC-140940; CHEMBL49120; PD-0166285; 6-(2,6-dichlorophenyl)-2-({4-[2-(diethylamino)ethoxy]phenyl}amino)-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-2-({4-[2-(Diethylamino)ethoxy]phenyl}amino)-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; IFPPYSWJNWHOLQ-UHFFFAOYSA-N; AC1NSKIX; Kinome_3263; SCHEMBL133914; BDBM3096; GTPL8183; MolPort-044-560-325; ZINC1486219; BCP20228; s8148; AKOS032945173; NCGC00242490-02; NCGC00242490-01; HY-13925; CS-0008610
DMAOHXY	DT	Small molecular drug
DMAOHXY	PC	5311382
DMAOHXY	MW	512.4
DMAOHXY	FM	C26H27Cl2N5O2
DMAOHXY	IC	InChI=1S/C26H27Cl2N5O2/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31)
DMAOHXY	CS	CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl
DMAOHXY	IK	IFPPYSWJNWHOLQ-UHFFFAOYSA-N
DMAOHXY	IU	6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one

DMQRHMT	ID	DMQRHMT
DMQRHMT	DN	PD-29361
DMQRHMT	HS	Terminated
DMQRHMT	DT	Small molecular drug
DMQRHMT	PC	136180343
DMQRHMT	MW	496.6
DMQRHMT	FM	C31H36N4O2
DMQRHMT	IC	InChI=1S/C31H36N4O2/c36-30-24(20-34-12-3-1-4-13-34)17-22(26-9-11-32-19-28(26)30)16-23-18-25(21-35-14-5-2-6-15-35)31(37)29-27(23)8-7-10-33-29/h7-11,17-19,36-37H,1-6,12-16,20-21H2
DMQRHMT	CS	C1CCN(CC1)CC2=C(C3=C(C=CC=N3)C(=C2)CC4=CC(=C(C5=C4C=CN=C5)O)CN6CCCCC6)O
DMQRHMT	IK	WJEZXIYONPULSN-UHFFFAOYSA-N
DMQRHMT	IU	5-[[8-hydroxy-7-(piperidin-1-ylmethyl)isoquinolin-5-yl]methyl]-7-(piperidin-1-ylmethyl)quinolin-8-ol

DMNUKB4	ID	DMNUKB4
DMNUKB4	DN	PD-85639
DMNUKB4	HS	Terminated
DMNUKB4	SN	PD-85639; CHEMBL282833; 150034-24-5; CTK8E7452; BDBM50043993; RT-014971; J-008654; N-[3-(2,6-Dimethyl-piperidin-1-yl)-propyl]-2,2-diphenyl-acetamide
DMNUKB4	DT	Small molecular drug
DMNUKB4	PC	9950970
DMNUKB4	MW	364.5
DMNUKB4	FM	C24H32N2O
DMNUKB4	IC	InChI=1S/C24H32N2O/c1-19-11-9-12-20(2)26(19)18-10-17-25-24(27)23(21-13-5-3-6-14-21)22-15-7-4-8-16-22/h3-8,13-16,19-20,23H,9-12,17-18H2,1-2H3,(H,25,27)
DMNUKB4	CS	CC1CCCC(N1CCCNC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C
DMNUKB4	IK	BPZBEIHSHWNWTE-UHFFFAOYSA-N
DMNUKB4	IU	N-[3-(2,6-dimethylpiperidin-1-yl)propyl]-2,2-diphenylacetamide

DMT819N	ID	DMT819N
DMT819N	DN	Pegorgotein
DMT819N	HS	Terminated
DMT819N	SN	Dismutec; Conjugated bSOD, Oxis; SOD, Sanofi; Superoxide dismutase, Sanofi; PEG-SOD, Oxis; PEG-SOD, Sanofi; PEG-bSOD, Oxis; PEG-bSOD, Sanofi; PEG-superoxide dismutase, Enzon Inc
DMT819N	CP	OXIS International Inc
DMT819N	DT	Small molecular drug
DMT819N	PC	3086673
DMT819N	MW	175.18
DMT819N	FM	C7H13NO4
DMT819N	IC	InChI=1S/C7H13NO4/c1-11-4-5-12-7(10)3-2-6(8)9/h2-5H2,1H3,(H2,8,9)
DMT819N	CS	COCCOC(=O)CCC(=O)N
DMT819N	IK	VJDVWBDSMDTODO-UHFFFAOYSA-N
DMT819N	IU	2-methoxyethyl 4-amino-4-oxobutanoate
DMT819N	CA	CAS 155773-57-2
DMT819N	DE	Head injury

DM9S1EA	ID	DM9S1EA
DM9S1EA	DN	Pepstatin
DM9S1EA	HS	Terminated
DM9S1EA	SN	AC1NUZ3J; L-Valinamide, N-(3-methyl-1-oxobutyl)-L-valyl-N-(4-((2-((1-(2-carboxy-1-hydroxyethyl)-3-methylbutyl)amino)-1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl)-, (1S-(1R*,2R*,4(R*(R*(R*)))))-; N-Isovaleryl-L-valyl-L-valyl-3-hydroxy-6-methyl-gamma-aminoheptanoyl-L-alanyl-3-hydroxy-6-methyl-gamma-aminoheptanoic acid
DM9S1EA	DT	Small molecular drug
DM9S1EA	PC	5478883
DM9S1EA	MW	685.9
DM9S1EA	FM	C34H63N5O9
DM9S1EA	IC	InChI=1S/C34H63N5O9/c1-17(2)12-23(37-33(47)31(21(9)10)39-34(48)30(20(7)8)38-27(42)14-19(5)6)25(40)15-28(43)35-22(11)32(46)36-24(13-18(3)4)26(41)16-29(44)45/h17-26,30-31,40-41H,12-16H2,1-11H3,(H,35,43)(H,36,46)(H,37,47)(H,38,42)(H,39,48)(H,44,45)/t22-,23-,24-,25-,26-,30-,31-/m0/s1
DM9S1EA	CS	C[C@@H](C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)O)O)NC(=O)C[C@@H]([C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C)O
DM9S1EA	IK	FAXGPCHRFPCXOO-LXTPJMTPSA-N
DM9S1EA	IU	(3S,4S)-3-hydroxy-4-[[(2S)-2-[[(3S,4S)-3-hydroxy-6-methyl-4-[[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]heptanoyl]amino]propanoyl]amino]-6-methylheptanoic acid
DM9S1EA	CA	CAS 26305-03-3
DM9S1EA	CB	CHEBI:7989
DM9S1EA	DE	Malaria

DMOS9NZ	ID	DMOS9NZ
DMOS9NZ	DN	PF-03882845
DMOS9NZ	HS	Terminated
DMOS9NZ	SN	UNII-34ZKU73FU3; 34ZKU73FU3; CHEMBL1215331; 1023650-66-9; PF-3882845; (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid; compound 2 [PMID: 24738581]; SCHEMBL552307; GTPL9061; DTXSID70144940; XNULRSOGWPFPBL-REWPJTCUSA-N; (+/-)-(3SR,3aRS)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid; BDBM50324210; ZINC58583489; DB11814; NCGC00485023-01; PF-03882845, &gt
DMOS9NZ	CP	Pfizer
DMOS9NZ	DT	Small molecular drug
DMOS9NZ	PC	46871935
DMOS9NZ	MW	419.9
DMOS9NZ	FM	C24H22ClN3O2
DMOS9NZ	IC	InChI=1S/C24H22ClN3O2/c25-21-12-18(8-5-17(21)13-26)28-23(14-3-1-2-4-14)20-10-6-15-11-16(24(29)30)7-9-19(15)22(20)27-28/h5,7-9,11-12,14,20,23H,1-4,6,10H2,(H,29,30)/t20-,23-/m0/s1
DMOS9NZ	CS	C1CCC(C1)[C@H]2[C@H]3CCC4=C(C3=NN2C5=CC(=C(C=C5)C#N)Cl)C=CC(=C4)C(=O)O
DMOS9NZ	IK	XNULRSOGWPFPBL-REWPJTCUSA-N
DMOS9NZ	IU	(3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydrobenzo[g]indazole-7-carboxylic acid
DMOS9NZ	CA	CAS 1023650-66-9
DMOS9NZ	DE	Diabetic nephropathy

DMSNOH3	ID	DMSNOH3
DMSNOH3	DN	PF-04620110
DMSNOH3	HS	Terminated
DMSNOH3	SN	PF-04620110; 1109276-89-2; CHEMBL1835919; 2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid; PF-4620110; trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexaneacetic acid; 2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f]-[1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid; UNII-CQ4M18RLJW; CQ4M18RLJW; SCHEMBL1424362; SCHEMBL1425038; GTPL7829; SCHEMBL1424359; SCHEMBL13954265; DTXSID90677361; GEVVQZHMFVFGLN-HDJSIYSDSA-N
DMSNOH3	CP	Pfizer
DMSNOH3	DT	Small molecular drug
DMSNOH3	PC	46926360
DMSNOH3	MW	396.4
DMSNOH3	FM	C21H24N4O4
DMSNOH3	IC	InChI=1S/C21H24N4O4/c22-19-18-20(24-12-23-19)29-10-9-25(21(18)28)16-7-5-15(6-8-16)14-3-1-13(2-4-14)11-17(26)27/h5-8,12-14H,1-4,9-11H2,(H,26,27)(H2,22,23,24)
DMSNOH3	CS	C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)N3CCOC4=NC=NC(=C4C3=O)N
DMSNOH3	IK	GEVVQZHMFVFGLN-UHFFFAOYSA-N
DMSNOH3	IU	2-[4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid
DMSNOH3	CA	CAS 1109276-89-2
DMSNOH3	DE	Type-2 diabetes

DMZ8HW7	ID	DMZ8HW7
DMZ8HW7	DN	PF-572778
DMZ8HW7	HS	Terminated
DMZ8HW7	SN	PF-00572778
DMZ8HW7	CP	Pfizer Inc
DMZ8HW7	DE	Generalized anxiety disorder

DMAJ9ZD	ID	DMAJ9ZD
DMAJ9ZD	DN	Phosphonate
DMAJ9ZD	HS	Terminated
DMAJ9ZD	SN	Fitofosine; Antitumor, InflaZyme
DMAJ9ZD	CP	Inflazyme Pharmaceuticals
DMAJ9ZD	DT	Small molecular drug
DMAJ9ZD	PC	6326969
DMAJ9ZD	MW	78.972
DMAJ9ZD	FM	O3P-
DMAJ9ZD	IC	InChI=1S/HO3P/c1-4(2)3/h(H,1,2,3)/p-1
DMAJ9ZD	CS	[O-]P(=O)=O
DMAJ9ZD	IK	UEZVMMHDMIWARA-UHFFFAOYSA-M
DMAJ9ZD	CA	CAS 60118-28-7
DMAJ9ZD	CB	CHEBI:8154
DMAJ9ZD	DE	leukaemia

DM63OD7	ID	DM63OD7
DM63OD7	DN	Pifithrin-alpha
DM63OD7	HS	Terminated
DM63OD7	SN	P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta
DM63OD7	CP	University of Illinois
DM63OD7	DT	Small molecular drug
DM63OD7	PC	9929138
DM63OD7	MW	367.3
DM63OD7	FM	C16H19BrN2OS
DM63OD7	IC	InChI=1S/C16H18N2OS.BrH/c1-11-6-8-12(9-7-11)14(19)10-18-13-4-2-3-5-15(13)20-16(18)17;/h6-9,17H,2-5,10H2,1H3;1H
DM63OD7	CS	CC1=CC=C(C=C1)C(=O)CN2C3=C(CCCC3)SC2=N.Br
DM63OD7	IK	HAGVCKULCLQGRF-UHFFFAOYSA-N
DM63OD7	IU	2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone;hydrobromide
DM63OD7	CA	CAS 63208-82-2
DM63OD7	DE	Toxicity

DMR87MO	ID	DMR87MO
DMR87MO	DN	PIROXANTRONE
DMR87MO	HS	Terminated
DMR87MO	DT	Small molecular drug
DMR87MO	PC	59916
DMR87MO	MW	411.5
DMR87MO	FM	C21H25N5O4
DMR87MO	IC	InChI=1S/C21H25N5O4/c22-6-1-7-24-12-2-3-13-17-16(12)21(30)19-15(29)5-4-14(28)18(19)20(17)25-26(13)10-8-23-9-11-27/h2-5,23,25,27,29-30H,1,6-11,22H2
DMR87MO	CS	C1=CC(=NCCCN)C2=C(C3=C(C=CC(=O)C3=C4C2=C1N(N4)CCNCCO)O)O
DMR87MO	IK	UKNVCOILWOLTLJ-UHFFFAOYSA-N
DMR87MO	IU	10-(3-aminopropylimino)-6,8-dihydroxy-14-[2-(2-hydroxyethylamino)ethyl]-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1,4,6,8,11,13(16)-hexaen-3-one
DMR87MO	CA	CAS 91441-23-5
DMR87MO	DE	Solid tumour/cancer

DMPHUBO	ID	DMPHUBO
DMPHUBO	DN	PLD-177
DMPHUBO	HS	Terminated
DMPHUBO	SN	PLR-13; PLR-2146; Inhaled steroids (asthma), PLIVA; PLD-177 (inhaled, Clickhaler), PLIVA/Innovata Biomed
DMPHUBO	CP	PLIVA dd
DMPHUBO	DE	Allergic rhinitis

DMT83V6	ID	DMT83V6
DMT83V6	DN	PNQX
DMT83V6	HS	Terminated
DMT83V6	SN	NS-409; PD-152247; PD-160359; PD-160725; PD-161384; PD-161989; PD-166732
DMT83V6	CP	NeuroSearch A/S
DMT83V6	PC	9903685
DMT83V6	MW	276.25
DMT83V6	FM	C12H12N4O4
DMT83V6	IC	InChI=1S/C12H12N4O4/c1-15-3-2-6-7(5-15)10-8(4-9(6)16(19)20)13-11(17)12(18)14-10/h4H,2-3,5H2,1H3,(H,13,17)(H,14,18)
DMT83V6	CS	CN1CCC2=C(C=C3C(=C2C1)NC(=O)C(=O)N3)[N+](=O)[O-]
DMT83V6	IK	GDSGJOIKTYTOQG-UHFFFAOYSA-N
DMT83V6	IU	9-methyl-6-nitro-4,7,8,10-tetrahydro-1H-pyrido[3,4-f]quinoxaline-2,3-dione
DMT83V6	DE	Cerebrovascular ischaemia

DMZNM2K	ID	DMZNM2K
DMZNM2K	DN	PNU-109291
DMZNM2K	HS	Terminated
DMZNM2K	SN	U-109291
DMZNM2K	CP	Pharmacia & Upjohn Inc
DMZNM2K	DT	Small molecular drug
DMZNM2K	PC	9909448
DMZNM2K	MW	409.5
DMZNM2K	FM	C24H31N3O3
DMZNM2K	IC	InChI=1S/C24H31N3O3/c1-25-24(28)19-3-8-22-18(17-19)10-16-30-23(22)9-11-26-12-14-27(15-13-26)20-4-6-21(29-2)7-5-20/h3-8,17,23H,9-16H2,1-2H3,(H,25,28)/t23-/m0/s1
DMZNM2K	CS	CNC(=O)C1=CC2=C(C=C1)[C@@H](OCC2)CCN3CCN(CC3)C4=CC=C(C=C4)OC
DMZNM2K	IK	UDLSEQDYARNKTL-QHCPKHFHSA-N
DMZNM2K	IU	(1S)-1-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]-N-methyl-3,4-dihydro-1H-isochromene-6-carboxamide
DMZNM2K	CA	CAS 187665-60-7
DMZNM2K	DE	Migraine

DM23ZHN	ID	DM23ZHN
DM23ZHN	DN	PNU156804
DM23ZHN	HS	Terminated
DM23ZHN	SN	Hexylglutathione; 24425-56-7; UNII-M73SNN908F; S-Hexyl-L-glutathione; L-gamma-glutamyl-S-hexyl-L-cysteinylglycine; NSC 131114; CHEMBL345292; M73SNN908F; CHEBI:27704; Glycine, N-(N-L-gamma-glutamyl-S-hexyl-L-cysteinyl)-; C16H29N3O6S; 1ydk; AC1L3YPR; GTX; S-Hexyl-L-glutathione reduced; SCHEMBL1158164; CTK4F3647; HXJDWCWJDCOHDG-RYUDHWBXSA-N; 2c80; ZINC3874923; BDBM50095998; AKOS015893910; DB04132; LS-174055; Glycine, L-g-glutamyl-S-hexyl-L-cysteinyl-; FT-0770776; C02886; Glycine, L-.gamma.-glutamyl
DM23ZHN	DT	Small molecular drug
DM23ZHN	PC	135484060
DM23ZHN	MW	506.1
DM23ZHN	FM	C31H40ClN3O
DM23ZHN	IC	InChI=1S/C31H39N3O.ClH/c1-2-3-4-5-6-7-8-9-13-17-26-19-20-27(33-26)22-30-31(35-24-25-15-11-10-12-16-25)23-29(34-30)28-18-14-21-32-28;/h10-12,14-16,18-23,32-33H,2-9,13,17,24H2,1H3;1H/b30-22-;
DM23ZHN	CS	CCCCCCCCCCCC1=CC=C(N1)/C=C\\2/C(=CC(=N2)C3=CC=CN3)OCC4=CC=CC=C4.Cl
DM23ZHN	IK	ODJQLZRYBXCIPR-VDFJEELKSA-N
DM23ZHN	IU	(2Z)-3-phenylmethoxy-5-(1H-pyrrol-2-yl)-2-[(5-undecyl-1H-pyrrol-2-yl)methylidene]pyrrole;hydrochloride
DM23ZHN	DE	Renal transplantation

DMRT69H	ID	DMRT69H
DMRT69H	DN	PNU-177864
DMRT69H	HS	Terminated
DMRT69H	CP	Pfizer
DMRT69H	PC	56972219
DMRT69H	MW	438.9
DMRT69H	FM	C18H22ClF3N2O3S
DMRT69H	IC	InChI=1S/C18H21F3N2O3S.ClH/c1-2-12-22-13-11-14-3-5-15(6-4-14)23-27(24,25)17-9-7-16(8-10-17)26-18(19,20)21;/h3-10,22-23H,2,11-13H2,1H3;1H
DMRT69H	CS	CCCNCCC1=CC=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)OC(F)(F)F.Cl
DMRT69H	IK	UOMDLHQTLPWCCE-UHFFFAOYSA-N
DMRT69H	IU	N-[4-[2-(propylamino)ethyl]phenyl]-4-(trifluoromethoxy)benzenesulfonamide;hydrochloride
DMRT69H	DE	Schizophrenia

DMGDC36	ID	DMGDC36
DMGDC36	DN	PNU-282987
DMGDC36	HS	Terminated
DMGDC36	SN	Benzamide, N-(3R)-1-azabicyclo[222]oct-3-yl-4-chloro-; PNU282987; 123464-89-1; 711085-63-1; PNU 282987; UNII-27M563MU5U; N-(3R)-1-Azabicyclo[222]oct-3-yl-4-chlorobenzamide; CHEMBL177611; 27M563MU5U; Benzamide, N-(3R)-1-azabicyclo(222)oct-3-yl-4-chloro-; CHEMBL554984; PNU-282,987; PNU-282987 free base; SCHEMBL677422; PNU282987HCl; GTPL3988; CHEBI:92508; CTK2H4027; MolPort-023-219-197; MolPort-003-983-664; HMS3268J18; ZINC3990028; BDBM50161764; BDBM50161753; ABP000998; AKOS016339643; AKOS024457037; KS-1399; API0008100;  N-((3R)-1-Azabicyclo(222)oct-3-yl)-4-chlorobenzamide hydrochloride; ISIS 25302
DMGDC36	CP	Pfizer
DMGDC36	DT	Small molecular drug
DMGDC36	PC	11243536
DMGDC36	MW	301.2
DMGDC36	FM	C14H18Cl2N2O
DMGDC36	IC	InChI=1S/C14H17ClN2O.ClH/c15-12-3-1-11(2-4-12)14(18)16-13-9-17-7-5-10(13)6-8-17;/h1-4,10,13H,5-9H2,(H,16,18);1H/t13-;/m0./s1
DMGDC36	CS	C1CN2CCC1[C@H](C2)NC(=O)C3=CC=C(C=C3)Cl.Cl
DMGDC36	IK	HSEQUIRZHDYOIX-ZOWNYOTGSA-N
DMGDC36	IU	N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide;hydrochloride
DMGDC36	CA	CAS 123464-89-1
DMGDC36	DE	Schizophrenia

DMLMISK	ID	DMLMISK
DMLMISK	DN	PNU-96391A
DMLMISK	HS	Terminated
DMLMISK	SN	(-)-OSU-6162
DMLMISK	CP	University of Gothenburg
DMLMISK	DT	Small molecular drug
DMLMISK	PC	9836644
DMLMISK	MW	317.9
DMLMISK	FM	C15H24ClNO2S
DMLMISK	IC	InChI=1S/C15H23NO2S.ClH/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18;/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3;1H/t14-;/m1./s1
DMLMISK	CS	CCCN1CCC[C@H](C1)C2=CC(=CC=C2)S(=O)(=O)C.Cl
DMLMISK	IK	LEMGVHZVBREXAD-PFEQFJNWSA-N
DMLMISK	IU	(3S)-3-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride
DMLMISK	CA	CAS 156907-84-5
DMLMISK	DE	Substance use disorder

DMLY2TN	ID	DMLY2TN
DMLY2TN	DN	PPACK
DMLY2TN	HS	Terminated
DMLY2TN	SN	AC1MI1QZ; SCHEMBL871144; LS-186049
DMLY2TN	DT	Small molecular drug
DMLY2TN	PC	5311176
DMLY2TN	MW	451
DMLY2TN	FM	C21H31ClN6O3
DMLY2TN	IC	InChI=1S/C21H31ClN6O3/c22-13-18(29)16(8-4-10-26-21(24)25)27-19(30)17-9-5-11-28(17)20(31)15(23)12-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13,23H2,(H,27,30)(H4,24,25,26)/t15-,16+,17+/m1/s1
DMLY2TN	CS	C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl
DMLY2TN	IK	KWPACVJPAFGBEQ-IKGGRYGDSA-N
DMLY2TN	IU	(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3S)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide
DMLY2TN	CA	CAS 71142-71-7

DMI2N9H	ID	DMI2N9H
DMI2N9H	DN	Pranidipine
DMI2N9H	HS	Terminated
DMI2N9H	SN	Acalas; OPC-13340; OPC-13463
DMI2N9H	CP	Otsuka Pharmaceutical Co Ltd
DMI2N9H	DT	Small molecular drug
DMI2N9H	PC	6436048
DMI2N9H	MW	448.5
DMI2N9H	FM	C25H24N2O6
DMI2N9H	IC	InChI=1S/C25H24N2O6/c1-16-21(24(28)32-3)23(19-12-7-13-20(15-19)27(30)31)22(17(2)26-16)25(29)33-14-8-11-18-9-5-4-6-10-18/h4-13,15,23,26H,14H2,1-3H3/b11-8+
DMI2N9H	CS	CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMI2N9H	IK	XTFPDGZNWTZCMF-DHZHZOJOSA-N
DMI2N9H	IU	3-O-methyl 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMI2N9H	CA	CAS 99522-79-9
DMI2N9H	DE	Angina pectoris

DMDIYFH	ID	DMDIYFH
DMDIYFH	DN	PRE-084
DMDIYFH	HS	Terminated
DMDIYFH	SN	Pre-084; 138847-85-5; 2-Morpholinoethyl 1-Phenylcyclohexanecarboxylate; 2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate; CHEMBL305881; 2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate; Cyclohexanecarboxylic acid, 1-phenyl-, 2-(4-morpholinyl)ethyl ester; Tocris-0589; Lopac-P-2607; AC1L2Q9Z; Lopac0_000927; PRE084; GTPL6678; SCHEMBL5564153; CHEBI:93007; DTXSID40160819; EX-A911; BCP25418; BDBM50039197; ZINC25756875; AKOS027439951; CCG-205008; NCGC00024669-03; NCGC00024669-02; NCGC00024669-01; NCGC00015808-04
DMDIYFH	CP	INSERM
DMDIYFH	DT	Small molecular drug
DMDIYFH	PC	126402
DMDIYFH	MW	317.4
DMDIYFH	FM	C19H27NO3
DMDIYFH	IC	InChI=1S/C19H27NO3/c21-18(23-16-13-20-11-14-22-15-12-20)19(9-5-2-6-10-19)17-7-3-1-4-8-17/h1,3-4,7-8H,2,5-6,9-16H2
DMDIYFH	CS	C1CCC(CC1)(C2=CC=CC=C2)C(=O)OCCN3CCOCC3
DMDIYFH	IK	RQHKZUBCUZVZEF-UHFFFAOYSA-N
DMDIYFH	IU	2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate
DMDIYFH	CA	CAS 138847-85-5
DMDIYFH	CB	CHEBI:93007
DMDIYFH	DE	Aging skin

DMS4FG0	ID	DMS4FG0
DMS4FG0	DN	Promegapoietin
DMS4FG0	HS	Terminated
DMS4FG0	SN	IL-3/TPO agonist, Searle; IL-3/TPO agonist, University of Maryland
DMS4FG0	CP	GD Searle & Co
DMS4FG0	DE	Bone marrow transplantation

DM57YO8	ID	DM57YO8
DM57YO8	DN	Protosufloxacin
DM57YO8	HS	Terminated
DM57YO8	SN	A-71497
DM57YO8	CP	Abbott Laboratories
DM57YO8	DE	Bacterial infection

DMNK2I0	ID	DMNK2I0
DMNK2I0	DN	PRS-639058
DMNK2I0	HS	Terminated
DMNK2I0	CP	Pharmos Corp
DMNK2I0	DE	Neuropathic pain

DM8P05S	ID	DM8P05S
DM8P05S	DN	PS-388023
DM8P05S	HS	Terminated
DM8P05S	SN	PS-680648; PS-780035; Angiogenesis inhibitors (ocular indications), Pharmacopeia/Allergan; Angiogenesis inhibitors (inflammatory/ocular/oncological indications), Pharmacopeia; Dual integrin avb3/avb5 inhibitors (inflammatory/ocular/oncological indications), Pharmacopeia; Dual integrin alpha-5/beta-3 + alpha-5/beta-5 inhibitors (inflammatory/ocular/oncological indications), Pharmacopeia
DM8P05S	CP	Pharmacopeia Inc
DM8P05S	DE	Ocular disease

DMI0WHC	ID	DMI0WHC
DMI0WHC	DN	PS-519
DMI0WHC	HS	Terminated
DMI0WHC	PC	9877196
DMI0WHC	MW	241.28
DMI0WHC	FM	C12H19NO4
DMI0WHC	IC	InChI=1S/C12H19NO4/c1-4-5-7-9-12(11(16)17-9,13-10(7)15)8(14)6(2)3/h6-9,14H,4-5H2,1-3H3,(H,13,15)/t7-,8+,9+,12-/m1/s1
DMI0WHC	CS	CCC[C@@H]1[C@H]2[C@](C(=O)O2)(NC1=O)[C@H](C(C)C)O
DMI0WHC	IK	KMXHEXRPYSXLRN-JDVQERKKSA-N
DMI0WHC	IU	(1R,4R,5S)-1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
DMI0WHC	CB	CHEBI:52724
DMI0WHC	DE	Ischemia-reperfusion injury

DMWUOA8	ID	DMWUOA8
DMWUOA8	DN	PSI-6130
DMWUOA8	HS	Terminated
DMWUOA8	SN	R-1656; RO-4995855; Hepatitis C virus therapy, Pharmasset/Roche; PSI-6130-DP; PSI-6130-MP; PSI-6130-TP
DMWUOA8	CP	Pharmasset Inc
DMWUOA8	DT	Small molecular drug
DMWUOA8	PC	6481236
DMWUOA8	MW	259.23
DMWUOA8	FM	C10H14FN3O4
DMWUOA8	IC	InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1
DMWUOA8	CS	C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O)F
DMWUOA8	IK	NYPIRLYMDJMKGW-VPCXQMTMSA-N
DMWUOA8	IU	4-amino-1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one
DMWUOA8	CA	CAS 817204-33-4
DMWUOA8	DE	Hepatitis C virus infection

DM579WS	ID	DM579WS
DM579WS	DN	PSI-661
DM579WS	HS	Terminated
DM579WS	SN	PSI-353661
DM579WS	CP	Pharmasset Inc
DM579WS	DE	Hepatitis C virus infection

DMGEWUS	ID	DMGEWUS
DMGEWUS	DN	PSN821
DMGEWUS	HS	Terminated
DMGEWUS	CP	Astellas Pharma Inc
DMGEWUS	DE	Type-2 diabetes

DMH3RPO	ID	DMH3RPO
DMH3RPO	DN	PT-630
DMH3RPO	HS	Terminated
DMH3RPO	SN	Non insulin dependent diabetes therapy, DARA BioSciences; Non insulin dependent diabetes therapy, Point Therapeutics
DMH3RPO	CP	DARA BioSciences Inc
DMH3RPO	PC	11673176
DMH3RPO	MW	244.06
DMH3RPO	FM	C9H17BN2O5
DMH3RPO	IC	InChI=1S/C9H17BN2O5/c11-6(3-4-8(13)14)9(15)12-5-1-2-7(12)10(16)17/h6-7,16-17H,1-5,11H2,(H,13,14)/t6-,7-/m0/s1
DMH3RPO	CS	B([C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)N)(O)O
DMH3RPO	IK	DMTPQYQQHYOTQM-BQBZGAKWSA-N
DMH3RPO	IU	(4S)-4-amino-5-[(2R)-2-boronopyrrolidin-1-yl]-5-oxopentanoic acid
DMH3RPO	DE	Type-2 diabetes

DM89RT7	ID	DM89RT7
DM89RT7	DN	PTX-007011
DM89RT7	HS	Terminated
DM89RT7	SN	PTX-040334; PTX-042695; Phosphopantethiene adenyltransferase inhibitors (antibacterial); Phosphopantethiene adenyltransferase inhibitors (antibacterial), PanTherix
DM89RT7	CP	PanTherix Ltd
DM89RT7	DE	Bacterial infection

DM84RHP	ID	DM84RHP
DM84RHP	DN	PTX-008313
DM84RHP	HS	Terminated
DM84RHP	SN	Chorismate synthase inhibitors (antibacterial); PTX-110130; Chorismate synthase inhibitors (antibacterial), PanTherix
DM84RHP	CP	PanTherix Ltd
DM84RHP	DE	Bacterial infection

DM63O4F	ID	DM63O4F
DM63O4F	DN	PURPUROGALLIN
DM63O4F	HS	Terminated
DM63O4F	SN	3tiy; AC1NQYND; BIDD:ER0545
DM63O4F	DT	Small molecular drug
DM63O4F	PC	135403797
DM63O4F	MW	220.18
DM63O4F	FM	C11H8O5
DM63O4F	IC	InChI=1S/C11H8O5/c12-6-3-1-2-5-4-7(13)10(15)11(16)8(5)9(6)14/h1-4,13,15-16H,(H,12,14)
DM63O4F	CS	C1=CC2=CC(=C(C(=C2C(=O)C(=C1)O)O)O)O
DM63O4F	IK	WDGFFVCWBZVLCE-UHFFFAOYSA-N
DM63O4F	IU	2,3,4,6-tetrahydroxybenzo[7]annulen-5-one
DM63O4F	CA	CAS 569-77-7
DM63O4F	CB	CHEBI:8647

DMCNE2G	ID	DMCNE2G
DMCNE2G	DN	PX-867
DMCNE2G	HS	Terminated
DMCNE2G	SN	PI-3-K inhibitor (cardiovascular disease), Oncothyreon; Phosphatidylinositol-3-kinase inhibitor (cardiovascular disease), Oncothyreon
DMCNE2G	CP	Oncothyreon Inc
DMCNE2G	DT	Small molecular drug
DMCNE2G	PC	11191229
DMCNE2G	MW	499.6
DMCNE2G	FM	C27H33NO8
DMCNE2G	IC	InChI=1S/C27H33NO8/c1-14(29)35-17-11-26(2)16(7-8-18(26)30)20-22(17)27(3)19(13-34-4)36-25(33)15(12-28-9-5-6-10-28)21(27)24(32)23(20)31/h12,16-17,19,32H,5-11,13H2,1-4H3/b15-12-/t16-,17+,19+,26-,27-/m0/s1
DMCNE2G	CS	CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C\\N5CCCC5)/C4=C(C3=O)O)COC)C)C
DMCNE2G	IK	JUSZLIOETSSZJM-WQVKNQJISA-N
DMCNE2G	IU	[(3aR,6Z,9S,9aR,10R,11aS)-5-hydroxy-9-(methoxymethyl)-9a,11a-dimethyl-1,4,7-trioxo-6-(pyrrolidin-1-ylmethylidene)-2,3,3a,9,10,11-hexahydroindeno[4,5-h]isochromen-10-yl] acetate
DMCNE2G	DE	Cardiovascular disease

DM1AXZ6	ID	DM1AXZ6
DM1AXZ6	DN	PXS-2076
DM1AXZ6	HS	Terminated
DM1AXZ6	SN	PXS-2000; PXS-2030; Cannabinoid CB2 agonist (rheumatoid arthritis), Pharmaxis; TNFrelease inhibitor (rheumatoid arthritis), Pharmaxis
DM1AXZ6	CP	Pharmaxis Ltd
DM1AXZ6	DE	Rheumatoid arthritis

DM8RHST	ID	DM8RHST
DM8RHST	DN	QAP-642
DM8RHST	HS	Terminated
DM8RHST	SN	CCR3 antagonist (allergic rhinitis), Novartis
DM8RHST	CP	Novartis AG
DM8RHST	DE	Allergic rhinitis

DMAV2FM	ID	DMAV2FM
DMAV2FM	DN	QX-314
DMAV2FM	HS	Terminated
DMAV2FM	SN	QX 314; CHEBI:46937; 2-[(2,6-dimethylphenyl)amino]-N,N,N-triethyl-2-oxoethanaminium; 2-((2,6-Dimethylphenyl)amino)-N,N,N-triethyl-2-oxoethanaminium; Ethanaminium, 2-((2,6-dimethylphenyl)amino)-N,N,N-triethyl-2-oxo-; Tocris-1014; AC1Q5LWR; Lopac-L-5783; UPCMLD-DP014; AC1L1H0Q; SCHEMBL93854; Lopac0_000679; KBioGR_000191; BSPBio_001471; KBioSS_000191; GTPL2405; UPCMLD-DP014:001; CHEMBL1180496; C16H27N2O; KBio3_000382; KBio2_005327; KBio2_002759; KBio2_000191; KBio3_000381; QX314; Bio2_000671; Bio2_000191; ZINC2037285; CCG-204765
DMAV2FM	TC	Analgesics
DMAV2FM	DT	Small molecular drug
DMAV2FM	PC	9884487
DMAV2FM	MW	343.3
DMAV2FM	FM	C16H27BrN2O
DMAV2FM	IC	InChI=1S/C16H26N2O.BrH/c1-6-18(7-2,8-3)12-15(19)17-16-13(4)10-9-11-14(16)5;/h9-11H,6-8,12H2,1-5H3;1H
DMAV2FM	CS	CC[N+](CC)(CC)CC(=O)NC1=C(C=CC=C1C)C.[Br-]
DMAV2FM	IK	DLHMKHREUTXMCH-UHFFFAOYSA-N
DMAV2FM	IU	[2-(2,6-dimethylanilino)-2-oxoethyl]-triethylazanium;bromide
DMAV2FM	CA	CAS 24003-58-5
DMAV2FM	DE	Pain

DMA187T	ID	DMA187T
DMA187T	DN	R zileuton
DMA187T	HS	Terminated
DMA187T	CP	Cornerstone Therapeutics
DMA187T	DE	Asthma

DM46YHG	ID	DM46YHG
DM46YHG	DN	R-102444
DM46YHG	HS	Terminated
DM46YHG	SN	Dopamine D2 antagonists, Sankyo; 5-HT2 antagonists, Sankyo
DM46YHG	CP	Sankyo Co Ltd
DM46YHG	PC	10256696
DM46YHG	MW	537.8
DM46YHG	FM	C34H51NO4
DM46YHG	IC	InChI=1S/C34H51NO4/c1-4-5-6-7-8-9-10-11-12-20-34(36)39-32-26-30(35(2)27-32)23-24-38-33-19-14-13-17-29(33)22-21-28-16-15-18-31(25-28)37-3/h13-19,25,30,32H,4-12,20-24,26-27H2,1-3H3/t30-,32-/m1/s1
DM46YHG	CS	CCCCCCCCCCCC(=O)O[C@@H]1C[C@H](N(C1)C)CCOC2=CC=CC=C2CCC3=CC(=CC=C3)OC
DM46YHG	IK	ZVCROHONSVCKKH-XLJNKUFUSA-N
DM46YHG	IU	[(3R,5R)-5-[2-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]ethyl]-1-methylpyrrolidin-3-yl] dodecanoate
DM46YHG	DE	Pancreatitis

DMIBCZ5	ID	DMIBCZ5
DMIBCZ5	DN	R-1315
DMIBCZ5	HS	Terminated
DMIBCZ5	CP	Roche Holding AG
DMIBCZ5	DE	Alzheimer disease

DMBU24I	ID	DMBU24I
DMBU24I	DN	R-1437
DMBU24I	HS	Terminated
DMBU24I	CP	Roche Holding AG
DMBU24I	DE	Prostate hyperplasia

DM8XBKG	ID	DM8XBKG
DM8XBKG	DN	R-1554
DM8XBKG	HS	Terminated
DM8XBKG	CP	Roche Holding AG
DM8XBKG	DE	Overactive bladder

DM12EYR	ID	DM12EYR
DM12EYR	DN	R348
DM12EYR	HS	Terminated
DM12EYR	CP	Rigel Pharmaceuticals
DM12EYR	PC	68254
DM12EYR	MW	121.18
DM12EYR	FM	C8H11N
DM12EYR	IC	InChI=1S/C8H11N/c1-3-8-6-9-5-4-7(8)2/h4-6H,3H2,1-2H3
DM12EYR	CS	CCC1=C(C=CN=C1)C
DM12EYR	IK	JDQNYWYMNFRKNQ-UHFFFAOYSA-N
DM12EYR	IU	3-ethyl-4-methylpyridine
DM12EYR	CA	CAS 529-21-5
DM12EYR	DE	Psoriasis vulgaris

DMYTI3J	ID	DMYTI3J
DMYTI3J	DN	R-56865
DMYTI3J	HS	Terminated
DMYTI3J	SN	R-56865; UNII-8MUQ2U7UV6; 104606-13-5; R 56865; BRN 6616961; 8MUQ2U7UV6; CHEMBL137009; R56865; N-(1-(4-(4-Fluorophenoxy)butyl)-4-piperidinyl)-N-methyl-2-benzothiazolamine; 2-Benzothiazolamine, N-(1-(4-(4-fluorophenoxy)butyl)-4-piperidinyl)-N-methyl-; 2-Benzothiazolamine,N-[1-[4-(4-fluorophenoxy)butyl]-4-piperidinyl]-N-methyl-; ACMC-20m7dr; SCHEMBL933977; CTK4A3161; DTXSID40146613; AC1L3388; BDBM50067625; LS-40628; Benzothiazol-2-yl-{1-[4-(4-fluoro-phenoxy)-butyl]-piperidin-4-yl}-methyl-amine
DMYTI3J	DT	Small molecular drug
DMYTI3J	PC	108043
DMYTI3J	MW	413.6
DMYTI3J	FM	C23H28FN3OS
DMYTI3J	IC	InChI=1S/C23H28FN3OS/c1-26(23-25-21-6-2-3-7-22(21)29-23)19-12-15-27(16-13-19)14-4-5-17-28-20-10-8-18(24)9-11-20/h2-3,6-11,19H,4-5,12-17H2,1H3
DMYTI3J	CS	CN(C1CCN(CC1)CCCCOC2=CC=C(C=C2)F)C3=NC4=CC=CC=C4S3
DMYTI3J	IK	PZPXREFPAFDHNG-UHFFFAOYSA-N
DMYTI3J	IU	N-[1-[4-(4-fluorophenoxy)butyl]piperidin-4-yl]-N-methyl-1,3-benzothiazol-2-amine
DMYTI3J	CA	CAS 104606-13-5
DMYTI3J	DE	Angina pectoris

DM36JFP	ID	DM36JFP
DM36JFP	DN	R-59494
DM36JFP	HS	Terminated
DM36JFP	SN	R 59494; 136917-41-4; AC1L307W; DTXSID50160007; N-Methyl-N-(1-(4-phenoxybutyl)-3-pyrrolidinyl)-2-benzothiazolamine; N-methyl-N-[1-(4-phenoxybutyl)pyrrol-3-yl]-1,3-benzothiazol-2-amine; 2-Benzothiazolamine, N-methyl-N-(1-(4-phenoxybutyl)-1H-pyrrol-3-yl)-
DM36JFP	CP	Janssen Pharmaceutica NV
DM36JFP	DT	Small molecular drug
DM36JFP	PC	132007
DM36JFP	MW	377.5
DM36JFP	FM	C22H23N3OS
DM36JFP	IC	InChI=1S/C22H23N3OS/c1-24(22-23-20-11-5-6-12-21(20)27-22)18-13-15-25(17-18)14-7-8-16-26-19-9-3-2-4-10-19/h2-6,9-13,15,17H,7-8,14,16H2,1H3
DM36JFP	CS	CN(C1=CN(C=C1)CCCCOC2=CC=CC=C2)C3=NC4=CC=CC=C4S3
DM36JFP	IK	PFBZXLGUUGDBNI-UHFFFAOYSA-N
DM36JFP	IU	N-methyl-N-[1-(4-phenoxybutyl)pyrrol-3-yl]-1,3-benzothiazol-2-amine
DM36JFP	CA	CAS 136917-41-4
DM36JFP	DE	Ischemia

DMLAIZG	ID	DMLAIZG
DMLAIZG	DN	R-7025
DMLAIZG	HS	Terminated
DMLAIZG	SN	Maxy-24; Maxy-alpha; PEGylated IFN alpha, Maxygen/Roche; PEGylated interferonalpha, Maxygen/Roche
DMLAIZG	CP	Maxygen Inc
DMLAIZG	DE	Hepatitis B virus infection

DMZQJVN	ID	DMZQJVN
DMZQJVN	DN	R-85355
DMZQJVN	HS	Terminated
DMZQJVN	SN	SCHEMBL10277001
DMZQJVN	DT	Small molecular drug
DMZQJVN	PC	56603786
DMZQJVN	MW	427.9
DMZQJVN	FM	C21H22ClN5O3
DMZQJVN	IC	InChI=1S/C21H22ClN5O3/c1-15-23-26(14-20(29)16-2-4-17(22)5-3-16)21(30)27(15)25-12-10-24(11-13-25)18-6-8-19(28)9-7-18/h2-9,28H,10-14H2,1H3
DMZQJVN	CS	CC1=NN(C(=O)N1N2CCN(CC2)C3=CC=C(C=C3)O)CC(=O)C4=CC=C(C=C4)Cl
DMZQJVN	IK	VZSLWTZQSOCFIA-UHFFFAOYSA-N
DMZQJVN	IU	2-[2-(4-chlorophenyl)-2-oxoethyl]-4-[4-(4-hydroxyphenyl)piperazin-1-yl]-5-methyl-1,2,4-triazol-3-one

DM7HAE9	ID	DM7HAE9
DM7HAE9	DN	Ralitoline
DM7HAE9	HS	Terminated
DM7HAE9	SN	GO-4942; Goe-4942; PD-117818
DM7HAE9	CP	Parke-Davis & Co
DM7HAE9	DT	Small molecular drug
DM7HAE9	PC	6436118
DM7HAE9	MW	296.77
DM7HAE9	FM	C13H13ClN2O2S
DM7HAE9	IC	InChI=1S/C13H13ClN2O2S/c1-8-4-3-5-9(14)13(8)15-10(17)6-12-16(2)11(18)7-19-12/h3-6H,7H2,1-2H3,(H,15,17)/b12-6-
DM7HAE9	CS	CC1=C(C(=CC=C1)Cl)NC(=O)/C=C\\2/N(C(=O)CS2)C
DM7HAE9	IK	YJXQTIXFPYPQFT-SDQBBNPISA-N
DM7HAE9	IU	(2Z)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-4-oxo-1,3-thiazolidin-2-ylidene)acetamide
DM7HAE9	CA	CAS 93738-40-0
DM7HAE9	DE	Epilepsy

DM4FNWO	ID	DM4FNWO
DM4FNWO	DN	RC-01
DM4FNWO	HS	Terminated
DM4FNWO	CP	Recida Therapeutics
DM4FNWO	DE	Gram-negative bacterial infection

DM08BUV	ID	DM08BUV
DM08BUV	DN	RDEA-427
DM08BUV	HS	Terminated
DM08BUV	SN	Non-nucleoside reverse transcriptase inhibitors (HIV infection), Ardea Bioscience
DM08BUV	CP	Ardea Biosciences Inc
DM08BUV	DE	Human immunodeficiency virus infection

DM61RGQ	ID	DM61RGQ
DM61RGQ	DN	RDEA-640
DM61RGQ	HS	Terminated
DM61RGQ	SN	RDEA-800; RDEA-900; VRX-480773; VRX-840773; NNRTIs (HIV infection), Ardea; NNRTIs (HIV infection), Valeant; Non-nucleoside reverse transcriptase inhibitor 800 series (HIV infection), Ardea; Non-nucleoside reverse transcriptase inhibitor 900 series (HIV infection), Ardea; Non-nucleoside reverse transcriptase inhibitors (HIV infection), Ardea; Non-nucleoside reverse transcriptase inhibitors (HIV infection), Valeant
DM61RGQ	CP	Valeant Pharmaceuticals International Inc
DM61RGQ	DE	Human immunodeficiency virus infection

DMDC2E8	ID	DMDC2E8
DMDC2E8	DN	Recainam
DMDC2E8	HS	Terminated
DMDC2E8	SN	Vanorm; Recainam hydrochloride; Win-42362; Wy-42362
DMDC2E8	CP	Wyeth
DMDC2E8	DT	Small molecular drug
DMDC2E8	PC	53084
DMDC2E8	MW	263.38
DMDC2E8	FM	C15H25N3O
DMDC2E8	IC	InChI=1S/C15H25N3O/c1-11(2)16-9-6-10-17-15(19)18-14-12(3)7-5-8-13(14)4/h5,7-8,11,16H,6,9-10H2,1-4H3,(H2,17,18,19)
DMDC2E8	CS	CC1=C(C(=CC=C1)C)NC(=O)NCCCNC(C)C
DMDC2E8	IK	WHJSFPCTWYLZRC-UHFFFAOYSA-N
DMDC2E8	IU	1-(2,6-dimethylphenyl)-3-[3-(propan-2-ylamino)propyl]urea
DMDC2E8	CA	CAS 74738-24-2
DMDC2E8	DE	Heart arrhythmia

DMWIAUK	ID	DMWIAUK
DMWIAUK	DN	ReN-1820
DMWIAUK	HS	Terminated
DMWIAUK	SN	TrkAd5; HNGF, ReNeuron; Human nerve growth factor, ReNeuron; HNGF, Enact/University of Bristol; Human nerve growth factor, Enact/University of Bristol
DMWIAUK	CP	University of Bristol
DMWIAUK	DE	Cystitis

DMGY51F	ID	DMGY51F
DMGY51F	DN	ReN-1826
DMGY51F	HS	Terminated
DMGY51F	SN	Neurotrophin receptor program, Enact; Neurotrophin receptor program, ReNeuron
DMGY51F	CP	University of Bristol
DMGY51F	DE	Central nervous system disease

DM1XYJU	ID	DM1XYJU
DM1XYJU	DN	RES-701-1
DM1XYJU	HS	Terminated
DM1XYJU	SN	L-Tryptophan, glycyl-L-asparaginyl-L-tryptophyl-L-histidylglycyl-L-threonyl-L-alanyl-L-prolyl-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl-L-phenylalanyl-L-asparaginyl-L-tyrosyl-L-tyrosyl-, cyclic (9-1)-peptide
DM1XYJU	PC	16131113
DM1XYJU	MW	2043.2
DM1XYJU	FM	C103H115N23O23
DM1XYJU	IC	InChI=1S/C103H115N23O23/c1-54-102(147)126-35-15-26-83(126)100(145)123-81(46-85(131)110-51-87(133)114-72(90(105)135)45-86(132)115-77(40-60-47-107-69-23-12-9-20-66(60)69)96(141)121-79(43-63-50-106-53-112-63)91(136)111-52-88(134)125-89(55(2)127)101(146)113-54)99(144)120-78(41-61-48-108-70-24-13-10-21-67(61)70)97(142)118-73(36-56-16-5-3-6-17-56)92(137)116-74(37-57-18-7-4-8-19-57)94(139)122-80(44-84(104)130)98(143)119-75(38-58-27-31-64(128)32-28-58)93(138)117-76(39-59-29-33-65(129)34-30-59)95(140)124-82(103(148)149)42-62-49-109-71-25-14-11-22-68(62)71/h3-14,16-25,27-34,47-50,53-55,72-83,89,107-109,127-129H,15,26,35-46,51-52H2,1-2H3,(H2,104,130)(H2,105,135)(H,106,112)(H,110,131)(H,111,136)(H,113,146)(H,114,133)(H,115,132)(H,116,137)(H,117,138)(H,118,142)(H,119,143)(H,120,144)(H,121,141)(H,122,139)(H,123,145)(H,124,140)(H,125,134)(H,148,149)/t54-,55+,72?,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-/m0/s1
DM1XYJU	CS	C[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(=O)NCC(=O)NC(CC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N1)[C@@H](C)O)CC3=CN=CN3)CC4=CNC5=CC=CC=C54)C(=O)N)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CC9=CC=CC=C9)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O
DM1XYJU	IK	GKJHBAGJUMHZCI-WOMVBXCFSA-N
DM1XYJU	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(3S,6S,12S,15S,26S,29S)-19-carbamoyl-6-[(1R)-1-hydroxyethyl]-12-(1H-imidazol-5-ylmethyl)-15-(1H-indol-3-ylmethyl)-3-methyl-2,5,8,11,14,17,21,24,28-nonaoxo-1,4,7,10,13,16,20,23,27-nonazabicyclo[27.3.0]dotriacontane-26-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DM1XYJU	CA	CAS 151308-34-8

DMI94L1	ID	DMI94L1
DMI94L1	DN	REV-5901
DMI94L1	HS	Terminated
DMI94L1	SN	Rev 5901; REV-5901; 101910-24-1; RG 5901; PF 5901; alpha-Pentyl-3-(2-quinolinylmethoxy)benzenemethanol; 1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-ol; CHEMBL8747; MLS000069771; REV-901; PF-5901; SMR000058509; alpha-Pentyl-3-[2-quinolinylmethoxy]benzyl alcohol; Benzenemethanol, alpha-pentyl-3-(2-quinolinylmethoxy)-; 1-(3-(quinolin-2-ylmethoxy)phenyl)hexan-1-ol; SR-01000076105; ACMC-20d0wb; Opera_ID_512; WNW5RYD8MG; UNII-WNW5RYD8MG; AC1L1JIU; Lopac0_001042; CBiol_001910; KBioGR_000242; BSPBio_001522; KBioSS_000242; MLS001076522
DMI94L1	DT	Small molecular drug
DMI94L1	PC	5059
DMI94L1	MW	335.4
DMI94L1	FM	C22H25NO2
DMI94L1	IC	InChI=1S/C22H25NO2/c1-2-3-4-12-22(24)18-9-7-10-20(15-18)25-16-19-14-13-17-8-5-6-11-21(17)23-19/h5-11,13-15,22,24H,2-4,12,16H2,1H3
DMI94L1	CS	CCCCCC(C1=CC(=CC=C1)OCC2=NC3=CC=CC=C3C=C2)O
DMI94L1	IK	JRLOEMCOOZSCQP-UHFFFAOYSA-N
DMI94L1	IU	1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-ol
DMI94L1	CA	CAS 101910-24-1
DMI94L1	CB	CHEBI:91821

DM314CZ	ID	DM314CZ
DM314CZ	DN	REV-598
DM314CZ	HS	Terminated
DM314CZ	SN	EV-598
DM314CZ	CP	Evolutec Group plc
DM314CZ	DE	Carcinoid syndrome

DMA971L	ID	DMA971L
DMA971L	DN	Reveromycin A
DMA971L	HS	Terminated
DMA971L	DT	Small molecular drug
DMA971L	PC	9939559
DMA971L	MW	660.8
DMA971L	FM	C36H52O11
DMA971L	IC	InChI=1S/C36H52O11/c1-6-7-19-35(47-34(44)17-16-32(40)41)21-22-36(46-30(35)14-10-25(3)23-33(42)43)20-18-27(5)29(45-36)13-9-24(2)8-12-28(37)26(4)11-15-31(38)39/h8-12,14-15,23,26-30,37H,6-7,13,16-22H2,1-5H3,(H,38,39)(H,40,41)(H,42,43)/b12-8+,14-10+,15-11+,24-9+,25-23+/t26-,27-,28-,29+,30-,35+,36-/m0/s1
DMA971L	CS	CCCC[C@]1(CC[C@]2(CC[C@@H]([C@H](O2)C/C=C(\\C)/C=C/[C@@H]([C@@H](C)/C=C/C(=O)O)O)C)O[C@H]1/C=C/C(=C/C(=O)O)/C)OC(=O)CCC(=O)O
DMA971L	IK	ZESGNAJSBDILTB-OXVOKJAASA-N
DMA971L	IU	(2E,4S,5S,6E,8E)-10-[(2S,3R,6S,8R,9S)-3-butyl-2-[(1E,3E)-4-carboxy-3-methylbuta-1,3-dienyl]-3-(3-carboxypropanoyloxy)-9-methyl-1,7-dioxaspiro[5.5]undecan-8-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

DMRFYOS	ID	DMRFYOS
DMRFYOS	DN	RG-13022
DMRFYOS	HS	Terminated
DMRFYOS	SN	RG-13022; RG 13022; CHEMBL67027; NSC666257; (Z)-3-(3,4-Dimethoxy-phenyl)-2-pyridin-3-yl-acrylonitrile; 136831-48-6; DBGZNJVTHYFQJI-RIYZIHGNSA-N; 149286-90-8; Tyrphostin RG13022; AC1NV4OE; SCHEMBL241869; SCHEMBL1959494; CHEBI:93448; MolPort-009-019-306; BDBM50039091; ZINC37858694; HSCI1_000158; AKOS032947325; NSC-666257; NCGC00018297-02; NCGC00018297-01; J-006919; BRD-K82688027-001-01-5; 3-(3,4-Dimethoxyphenyl)-2-(3-pyridinyl)acrylonitrile; (Z)-3-(3,4-dimethoxyphenyl)-2-pyridin-3-ylprop-2-enenitrile
DMRFYOS	DT	Small molecular drug
DMRFYOS	PC	5468216
DMRFYOS	MW	266.29
DMRFYOS	FM	C16H14N2O2
DMRFYOS	IC	InChI=1S/C16H14N2O2/c1-19-15-6-5-12(9-16(15)20-2)8-14(10-17)13-4-3-7-18-11-13/h3-9,11H,1-2H3/b14-8+
DMRFYOS	CS	COC1=C(C=C(C=C1)/C=C(\\C#N)/C2=CN=CC=C2)OC
DMRFYOS	IK	DBGZNJVTHYFQJI-RIYZIHGNSA-N
DMRFYOS	IU	(Z)-3-(3,4-dimethoxyphenyl)-2-pyridin-3-ylprop-2-enenitrile
DMRFYOS	CA	CAS 136831-48-6
DMRFYOS	CB	CHEBI:93448

DMKFQC7	ID	DMKFQC7
DMKFQC7	DN	RG-14893
DMKFQC7	HS	Terminated
DMKFQC7	SN	RG-14893; RG 14893; 141835-49-6; CHEMBL328712; 2-Naphthalenecarboxylicacid, 4-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-8-(phenylmethoxy)-; ACMC-20n0x5; AC1L30VP; SCHEMBL1894401; rg14893; CTK0H7370; DTXSID30161835; BDBM50001609; 4-(2-(Methyl(2-phenylethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; 4-(2-(Methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; L006851; 8-Benzyloxy-4-[(methyl-phenethyl-carbamoyl)-methyl]-naphthalene-2-carboxylic acid
DMKFQC7	CP	Rhone-Poulenc SA
DMKFQC7	DT	Small molecular drug
DMKFQC7	PC	132379
DMKFQC7	MW	453.5
DMKFQC7	FM	C29H27NO4
DMKFQC7	IC	InChI=1S/C29H27NO4/c1-30(16-15-21-9-4-2-5-10-21)28(31)19-23-17-24(29(32)33)18-26-25(23)13-8-14-27(26)34-20-22-11-6-3-7-12-22/h2-14,17-18H,15-16,19-20H2,1H3,(H,32,33)
DMKFQC7	CS	CN(CCC1=CC=CC=C1)C(=O)CC2=C3C=CC=C(C3=CC(=C2)C(=O)O)OCC4=CC=CC=C4
DMKFQC7	IK	VPJQGXIZXVPFOC-UHFFFAOYSA-N
DMKFQC7	IU	4-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-8-phenylmethoxynaphthalene-2-carboxylic acid
DMKFQC7	CA	CAS 141835-49-6
DMKFQC7	DE	Asthma

DMI0CYV	ID	DMI0CYV
DMI0CYV	DN	RG-8803
DMI0CYV	HS	Terminated
DMI0CYV	SN	Angiogenesis inhibitors, Repligen; BFGF inhibitors, Repligen; RG-8803B11; RGEN-1009; VEGF inhibitors, Repligen; 8803B11
DMI0CYV	CP	Repligen Corp
DMI0CYV	DE	Diabetic retinopathy

DM8RIA6	ID	DM8RIA6
DM8RIA6	DN	RGH-1756
DM8RIA6	HS	Terminated
DM8RIA6	SN	NCGC00015909-01; Lopac-S-106; AC1L1JZN; Prestwick3_000443; Lopac0_001152; BSPBio_000486; BPBio1_000536; CHEBI:93632; CTK7A2978; BDBM50000687; ZINC100071375; CCG-205226; NCGC00015909-03; NCGC00162355-01; NCGC00016970-01; NCGC00015909-02; NCGC00015909-04; AB00513839; CAS-105538-73-6; BRD-K93280214-004-02-3; 6-amino-1-(3-carboxypropyl)-3-(4-methoxyphenyl)pyridazin-1-ium; 4-[6-amino-3-(4-methoxyphenyl)pyridazin-1-ium-1-yl]butanoic acid; 6-Amino-1-(3-carboxy-propyl)-3-(4-methoxy-phenyl)-pyridazin-1-ium
DM8RIA6	CP	Gedeon Richter
DM8RIA6	DT	Small molecular drug
DM8RIA6	PC	9868983
DM8RIA6	MW	462.6
DM8RIA6	FM	C26H30N4O2S
DM8RIA6	IC	InChI=1S/C26H30N4O2S/c1-31-25-7-3-2-6-24(25)29-15-13-28(14-16-29)12-4-5-18-32-22-10-8-21(9-11-22)23-20-30-17-19-33-26(30)27-23/h2-3,6-11,17,19-20H,4-5,12-16,18H2,1H3
DM8RIA6	CS	COC1=CC=CC=C1N2CCN(CC2)CCCCOC3=CC=C(C=C3)C4=CN5C=CSC5=N4
DM8RIA6	IK	XFCPMLXQURUUPM-UHFFFAOYSA-N
DM8RIA6	IU	6-[4-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]phenyl]imidazo[2,1-b][1,3]thiazole
DM8RIA6	CA	CAS 207277-37-0
DM8RIA6	DE	Schizophrenia

DMBCIPO	ID	DMBCIPO
DMBCIPO	DN	RGH-2721
DMBCIPO	HS	Terminated
DMBCIPO	SN	IDDB9322
DMBCIPO	CP	Gedeon Richter Ltd
DMBCIPO	DE	Psychotic disorder

DM7CY0T	ID	DM7CY0T
DM7CY0T	DN	RHb1.1
DM7CY0T	HS	Terminated
DM7CY0T	SN	Optro; Hemoglobin, Somatogen
DM7CY0T	CP	Somatogen Inc
DM7CY0T	DE	Anemia

DMW4UTB	ID	DMW4UTB
DMW4UTB	DN	RhuCD40L
DMW4UTB	HS	Terminated

DMKDS1C	ID	DMKDS1C
DMKDS1C	DN	Rimcazole
DMKDS1C	HS	Terminated
DMKDS1C	SN	Rimcazol; Rimcazolum; Rimcazole [INN]; BW 234U; BW-234U; Rimcazol [INN-Spanish]; Rimcazolum [INN-Latin]; Cis-9-(3-(3,5-dimethyl-1-piperazinyl)propyl)carbazole; 9-[3-(Cis-3,5-Dimethyl-1-Piperazinyl)Propyl]Carbazole Hydrochloride; 9-[3-(cis-3,5-Dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride monohydrate; 9-[3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]propyl]carbazole; 9-[3-[(3S,5R)-3,5-dimethylpiperazin-1-yl]propyl]carbazole
DMKDS1C	CP	GlaxoSmithKline
DMKDS1C	DT	Small molecular drug
DMKDS1C	PC	53389
DMKDS1C	MW	321.5
DMKDS1C	FM	C21H27N3
DMKDS1C	IC	InChI=1S/C21H27N3/c1-16-14-23(15-17(2)22-16)12-7-13-24-20-10-5-3-8-18(20)19-9-4-6-11-21(19)24/h3-6,8-11,16-17,22H,7,12-15H2,1-2H3/t16-,17+
DMKDS1C	CS	C[C@@H]1CN(C[C@@H](N1)C)CCCN2C3=CC=CC=C3C4=CC=CC=C42
DMKDS1C	IK	GUDVQJXODNJRIJ-CALCHBBNSA-N
DMKDS1C	IU	9-[3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]propyl]carbazole
DMKDS1C	CA	CAS 75859-04-0
DMKDS1C	CB	CHEBI:94713
DMKDS1C	DE	Schizophrenia

DMHQ5ZE	ID	DMHQ5ZE
DMHQ5ZE	DN	RN-1005
DMHQ5ZE	HS	Terminated
DMHQ5ZE	CP	Renovo Group plc
DMHQ5ZE	DE	Sarcoidosis

DM0PSCF	ID	DM0PSCF
DM0PSCF	DN	Ro 20-1724
DM0PSCF	HS	Terminated
DM0PSCF	SN	4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; RO 20-1724; 29925-17-5; 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one; ro-20-1724; Ro 201724; CHEMBL18701; 4-[(3-butoxy-4-methoxyphenyl)methyl]imidazolidin-2-one; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-; RO-201724; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-, (+-)-; 4-(3-butoxy-4-methoxy-benzyl)imidazolidin-2-one; 34185-37-0; 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone; SR-01000075647; keratan sulfate I; Keratan sulphate I; Naphthoquinone analogs
DM0PSCF	DT	Small molecular drug
DM0PSCF	PC	5087
DM0PSCF	MW	278.35
DM0PSCF	FM	C15H22N2O3
DM0PSCF	IC	InChI=1S/C15H22N2O3/c1-3-4-7-20-14-9-11(5-6-13(14)19-2)8-12-10-16-15(18)17-12/h5-6,9,12H,3-4,7-8,10H2,1-2H3,(H2,16,17,18)
DM0PSCF	CS	CCCCOC1=C(C=CC(=C1)CC2CNC(=O)N2)OC
DM0PSCF	IK	PDMUULPVBYQBBK-UHFFFAOYSA-N
DM0PSCF	IU	4-[(3-butoxy-4-methoxyphenyl)methyl]imidazolidin-2-one
DM0PSCF	CA	CAS 29925-17-5
DM0PSCF	CB	CHEBI:111173
DM0PSCF	DE	Asthma

DMFRCM2	ID	DMFRCM2
DMFRCM2	DN	Ro-19-8022
DMFRCM2	HS	Terminated
DMFRCM2	SN	Ro 19-8022; 104604-66-2; 1-((10-Chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-2-pyrrolidine methanol; (R)-1-((10-Chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-2-pyrrolidinemethanol; 2-Pyrrolidinemethanol, 1-((10-chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-, (R)-; Ro-19-8022; (R)-1-[(10-chloro-4-oxo-3-phenyl-4H-benzo[a]quinolizin-1-yl)carbonyl]-2-pyrrolidinemethanol; AC1MHYOM; SCHEMBL9334361; CTK4A3158; DTXSID20146611; MAHSERINKSLHDX-LJQANCHMSA-N; ro19-8022
DMFRCM2	CP	Roche Holding AG
DMFRCM2	DT	Small molecular drug
DMFRCM2	PC	3035058
DMFRCM2	MW	432.9
DMFRCM2	FM	C25H21ClN2O3
DMFRCM2	IC	InChI=1S/C25H21ClN2O3/c26-18-9-8-17-10-12-28-23(20(17)13-18)22(25(31)27-11-4-7-19(27)15-29)14-21(24(28)30)16-5-2-1-3-6-16/h1-3,5-6,8-10,12-14,19,29H,4,7,11,15H2/t19-/m1/s1
DMFRCM2	CS	C1C[C@@H](N(C1)C(=O)C2=C3C4=C(C=CC(=C4)Cl)C=CN3C(=O)C(=C2)C5=CC=CC=C5)CO
DMFRCM2	IK	MAHSERINKSLHDX-LJQANCHMSA-N
DMFRCM2	IU	10-chloro-1-[(2R)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-3-phenylbenzo[a]quinolizin-4-one
DMFRCM2	CA	CAS 104604-66-2
DMFRCM2	DE	Anxiety disorder

DM7B2WH	ID	DM7B2WH
DM7B2WH	DN	Ro-23-7777
DM7B2WH	HS	Terminated
DM7B2WH	SN	IDDB4246
DM7B2WH	CP	Roche Holding AG
DM7B2WH	DE	Fungal infection

DMJQA0D	ID	DMJQA0D
DMJQA0D	DN	Ro-24-0238
DMJQA0D	HS	Terminated
DMJQA0D	SN	Ro-24-0238; UNII-7G3UI0W9Y5; CHEMBL277245; 7G3UI0W9Y5; 120555-31-9; Ro 24-0238; AC1O5QW5; SCHEMBL9120960; SCHEMBL9120974; 5-(4-Methoxy-phenyl)-deca-2,4-dienoic acid (1-methyl-4-pyridin-3-yl-butyl)-amide; BDBM50011671; 5-(4-Methoxyphenyl)-N-(1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide; CS-6684; (R-(E,E))-5-(4-Methoxyphenyl)-N-(1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide; HY-19084; 2,4-Decadienamide, 5-(4-methoxyphenyl)-N-(1-methyl-4-(3-pyridinyl)butyl)-, (R-(E,E))-
DMJQA0D	DT	Small molecular drug
DMJQA0D	PC	6439060
DMJQA0D	MW	420.6
DMJQA0D	FM	C27H36N2O2
DMJQA0D	IC	InChI=1S/C27H36N2O2/c1-4-5-6-13-24(25-16-18-26(31-3)19-17-25)14-8-15-27(30)29-22(2)10-7-11-23-12-9-20-28-21-23/h8-9,12,14-22H,4-7,10-11,13H2,1-3H3,(H,29,30)/b15-8+,24-14+/t22-/m1/s1
DMJQA0D	CS	CCCCC/C(=C\\C=C\\C(=O)N[C@H](C)CCCC1=CN=CC=C1)/C2=CC=C(C=C2)OC
DMJQA0D	IK	HLCHRSFXEXAMLU-YDQNRGGDSA-N
DMJQA0D	IU	(2E,4E)-5-(4-methoxyphenyl)-N-[(2R)-5-pyridin-3-ylpentan-2-yl]deca-2,4-dienamide
DMJQA0D	CA	CAS 120555-31-9
DMJQA0D	DE	Sepsis

DMVB0C3	ID	DMVB0C3
DMVB0C3	DN	Ro-25-4094
DMVB0C3	HS	Terminated
DMVB0C3	SN	Ro-25-4094; CHEMBL86900; 2-[(5-Carboxypentyl)oxy]-6-[6-[(3,4-dihydro-4-oxo-8-propyl-2H-1-benzopyran-7-yl)oxy]hexyl]benzenepropanoic Acid; 2-[(5-Carboxypentyl)oxy]-6-[6-[[3,4-dihydro-4-oxo-8-propyl-2H-1-benzopyran-7-yl)oxy]hexyl]benzenepropanoic Acid; SCHEMBL9121929; KLENIMLYAFNVOB-UHFFFAOYSA-N; BDBM50052025; Ro-0254094; L011960; 6-{2-(2-Carboxy-ethyl)-3-[6-(4-oxo-8-propyl-chroman-7-yloxy)-hexyl]-phenoxy}-hexanoic acid
DMVB0C3	CP	Roche Holding AG
DMVB0C3	DT	Small molecular drug
DMVB0C3	PC	9850974
DMVB0C3	MW	568.7
DMVB0C3	FM	C33H44O8
DMVB0C3	IC	InChI=1S/C33H44O8/c1-2-11-27-30(18-16-26-28(34)20-23-41-33(26)27)40-21-8-4-3-6-12-24-13-10-14-29(25(24)17-19-32(37)38)39-22-9-5-7-15-31(35)36/h10,13-14,16,18H,2-9,11-12,15,17,19-23H2,1H3,(H,35,36)(H,37,38)
DMVB0C3	CS	CCCC1=C(C=CC2=C1OCCC2=O)OCCCCCCC3=C(C(=CC=C3)OCCCCCC(=O)O)CCC(=O)O
DMVB0C3	IK	KLENIMLYAFNVOB-UHFFFAOYSA-N
DMVB0C3	IU	6-[2-(2-carboxyethyl)-3-[6-[(4-oxo-8-propyl-2,3-dihydrochromen-7-yl)oxy]hexyl]phenoxy]hexanoic acid
DMVB0C3	DE	Inflammation

DM07ZSC	ID	DM07ZSC
DM07ZSC	DN	Ro-25-6833
DM07ZSC	HS	Terminated
DM07ZSC	SN	Ro-25-6833; 161672-76-0; Ro25-6833; RO 25-6833; CHEMBL53624; SCHEMBL7614481; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(hydroxyimino)acetyl)amino)-8-oxo-((2-oxo-1-(2,2,2-trifluoroethyl)-3-pyrrolidinylidene)methyl)-, (6R-(3(E),6a,7b(Z)))-; 3-[[(3E)-1-(2,2,2-Trifluoroethyl)-2-oxopyrrolidin-3-ylidene]methyl]-7beta-[[[(Z)-hydroxyimino](2-aminothiazol-4-yl)acetyl]amino]cepham-3-ene-4-carboxylic acid
DM07ZSC	CP	F Hoffmann-La Roche Ltd
DM07ZSC	DT	Small molecular drug
DM07ZSC	PC	9578062
DM07ZSC	MW	546.5
DM07ZSC	FM	C19H17F3N6O6S2
DM07ZSC	IC	InChI=1S/C19H17F3N6O6S2/c20-19(21,22)6-27-2-1-7(14(27)30)3-8-4-35-16-11(15(31)28(16)12(8)17(32)33)25-13(29)10(26-34)9-5-36-18(23)24-9/h3,5,11,16,34H,1-2,4,6H2,(H2,23,24)(H,25,29)(H,32,33)/b7-3+,26-10-/t11-,16-/m1/s1
DM07ZSC	CS	C\\1CN(C(=O)/C1=C/C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\O)/C4=CSC(=N4)N)SC2)C(=O)O)CC(F)(F)F
DM07ZSC	IK	NOAJGZYUGGBORE-SUVYSZLLSA-N
DM07ZSC	IU	(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-(2,2,2-trifluoroethyl)pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM07ZSC	CA	CAS 161672-76-0
DM07ZSC	DE	Bacterial infection

DM3H921	ID	DM3H921
DM3H921	DN	RO-25-6981
DM3H921	HS	Terminated
DM3H921	SN	Ro 25-6981; Ro-25-6981; CHEMBL305195; ro25-6981; 169274-78-6; 4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol; 4-((1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl)phenol; QEM; Tocris-1594; AC1O7H0A; Lopac0_001082; ZINC7042; SCHEMBL6159263; CHEBI:92897; HMS3268G13; EX-A1825; PDSP2_000361; BDBM50080029; CS-2011; CCG-205159; NCGC00025226-01; NCGC00025226-03; NCGC00025226-02; HY-13993; (AR,BS)-ALPHA-(4-HYDROXYPHENYL)-BETA-METHYL-4-(PHENYLMETHYL)-1-PIPERIDINEPROPANOL MALEATE; BRD-K51541829-001-01-3
DM3H921	TC	Analgesics
DM3H921	DT	Small molecular drug
DM3H921	PC	6604887
DM3H921	MW	339.5
DM3H921	FM	C22H29NO2
DM3H921	IC	InChI=1S/C22H29NO2/c1-17(22(25)20-7-9-21(24)10-8-20)16-23-13-11-19(12-14-23)15-18-5-3-2-4-6-18/h2-10,17,19,22,24-25H,11-16H2,1H3/t17-,22+/m0/s1
DM3H921	CS	C[C@@H](CN1CCC(CC1)CC2=CC=CC=C2)[C@H](C3=CC=C(C=C3)O)O
DM3H921	IK	WVZSEUPGUDIELE-HTAPYJJXSA-N
DM3H921	IU	4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol
DM3H921	CA	CAS 169274-78-6
DM3H921	CB	CHEBI:92897
DM3H921	DE	Cancer related pain

DM8B9YT	ID	DM8B9YT
DM8B9YT	DN	Ro-31-4724
DM8B9YT	HS	Terminated
DM8B9YT	SN	Ro-31-4724; CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate
DM8B9YT	DT	Small molecular drug
DM8B9YT	PC	5487313
DM8B9YT	MW	401.5
DM8B9YT	FM	C19H35N3O6
DM8B9YT	IC	InChI=1S/C19H35N3O6/c1-7-28-19(26)13(6)20-18(25)15(9-12(4)5)21-17(24)14(8-11(2)3)10-16(23)22-27/h11-15,27H,7-10H2,1-6H3,(H,20,25)(H,21,24)(H,22,23)/t13-,14+,15-/m0/s1
DM8B9YT	CS	CCOC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)CC(=O)NO
DM8B9YT	IK	XKRONJXEXGFBRZ-ZNMIVQPWSA-N
DM8B9YT	IU	ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate
DM8B9YT	CA	CAS 112105-54-1
DM8B9YT	DE	Arthritis

DMTIW6K	ID	DMTIW6K
DMTIW6K	DN	Ro-31-8830
DMTIW6K	HS	Terminated
DMTIW6K	SN	Ro-31-8830; 131848-98-1; 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-{8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl}-4-(1-methyl-1h-indol-3-yl)-1h-pyrrole-2,5-dione; Bisindolylmaleimide deriv. 18b; ACMC-20caiw; Ro 31-8830; AC1L1JKR; AC1Q6PDZ; CHEMBL95925; SCHEMBL5036866; BDBM2705; CTK0H9238; HMS3401J16; HMS3401G14; HSCI1_000347; BIM 11; Bisindolylmaleimide XI, HCl; NCGC00163696-04; NCGC00163696-01; K00206
DMTIW6K	CP	Roche Holding AG
DMTIW6K	DT	Small molecular drug
DMTIW6K	PC	5084
DMTIW6K	MW	452.5
DMTIW6K	FM	C28H28N4O2
DMTIW6K	IC	InChI=1S/C28H28N4O2/c1-30(2)15-17-12-13-32-22-11-7-5-9-19(22)24(23(32)14-17)26-25(27(33)29-28(26)34)20-16-31(3)21-10-6-4-8-18(20)21/h4-11,16-17H,12-15H2,1-3H3,(H,29,33,34)
DMTIW6K	CS	CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C5CC(CCN5C6=CC=CC=C64)CN(C)C
DMTIW6K	IK	FXGHOAZJQNLNFD-UHFFFAOYSA-N
DMTIW6K	IU	3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione
DMTIW6K	CA	CAS 131848-98-1
DMTIW6K	DE	Inflammation

DML3NEU	ID	DML3NEU
DML3NEU	DN	RO-319790
DML3NEU	HS	Terminated
DML3NEU	SN	Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703
DML3NEU	DT	Small molecular drug
DML3NEU	PC	9904965
DML3NEU	MW	315.41
DML3NEU	FM	C15H29N3O4
DML3NEU	IC	InChI=1S/C15H29N3O4/c1-9(2)7-10(8-11(19)18-22)13(20)17-12(14(21)16-6)15(3,4)5/h9-10,12,22H,7-8H2,1-6H3,(H,16,21)(H,17,20)(H,18,19)/t10-,12-/m1/s1
DML3NEU	CS	CC(C)C[C@H](CC(=O)NO)C(=O)N[C@H](C(=O)NC)C(C)(C)C
DML3NEU	IK	QRXOZHSEEGNRFC-ZYHUDNBSSA-N
DML3NEU	IU	(2R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N'-hydroxy-2-(2-methylpropyl)butanediamide
DML3NEU	DE	Rheumatoid arthritis

DMFZ1YW	ID	DMFZ1YW
DMFZ1YW	DN	RO-320432
DMFZ1YW	HS	Terminated
DMFZ1YW	SN	ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in
DMFZ1YW	DT	Small molecular drug
DMFZ1YW	PC	127757
DMFZ1YW	MW	452.5
DMFZ1YW	FM	C28H28N4O2
DMFZ1YW	IC	InChI=1S/C28H28N4O2/c1-30(2)15-17-12-13-32-22-11-7-5-9-19(22)24(23(32)14-17)26-25(27(33)29-28(26)34)20-16-31(3)21-10-6-4-8-18(20)21/h4-11,16-17H,12-15H2,1-3H3,(H,29,33,34)/t17-/m0/s1
DMFZ1YW	CS	CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C5C[C@H](CCN5C6=CC=CC=C64)CN(C)C
DMFZ1YW	IK	FXGHOAZJQNLNFD-KRWDZBQOSA-N
DMFZ1YW	IU	3-[(8S)-8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione
DMFZ1YW	CA	CAS 151342-35-7

DMPNHF0	ID	DMPNHF0
DMPNHF0	DN	Ro-43-5054
DMPNHF0	HS	Terminated
DMPNHF0	SN	Ro-43-5054; CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)
DMPNHF0	DT	Small molecular drug
DMPNHF0	PC	44343754
DMPNHF0	MW	449.5
DMPNHF0	FM	C20H27N5O7
DMPNHF0	IC	InChI=1S/C20H27N5O7/c1-10(2)16(20(31)32)25-19(30)13(9-15(27)28)24-14(26)7-8-23-18(29)12-5-3-11(4-6-12)17(21)22/h3-6,10,13,16H,7-9H2,1-2H3,(H3,21,22)(H,23,29)(H,24,26)(H,25,30)(H,27,28)(H,31,32)/t13-,16-/m0/s1
DMPNHF0	CS	CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCNC(=O)C1=CC=C(C=C1)C(=N)N
DMPNHF0	IK	RRUJJOMANFUDEN-BBRMVZONSA-N
DMPNHF0	IU	(2S)-2-[[(2S)-2-[3-[(4-carbamimidoylbenzoyl)amino]propanoylamino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid

DM4VY8S	ID	DM4VY8S
DM4VY8S	DN	Ro-43-8857
DM4VY8S	HS	Terminated
DM4VY8S	SN	Ro-43-8857; CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid
DM4VY8S	DT	Small molecular drug
DM4VY8S	PC	9933077
DM4VY8S	MW	443.4
DM4VY8S	FM	C21H21N3O8
DM4VY8S	IC	InChI=1S/C21H21N3O8/c1-24(21(30)13-4-2-12(3-5-13)20(22)23)9-15(25)14-6-7-16(31-10-18(26)27)17(8-14)32-11-19(28)29/h2-8H,9-11H2,1H3,(H3,22,23)(H,26,27)(H,28,29)
DM4VY8S	CS	CN(CC(=O)C1=CC(=C(C=C1)OCC(=O)O)OCC(=O)O)C(=O)C2=CC=C(C=C2)C(=N)N
DM4VY8S	IK	ZCCMELPMDDSRHL-UHFFFAOYSA-N
DM4VY8S	IU	2-[4-[2-[(4-carbamimidoylbenzoyl)-methylamino]acetyl]-2-(carboxymethoxy)phenoxy]acetic acid

DMRT6FV	ID	DMRT6FV
DMRT6FV	DN	Ro-46-2005
DMRT6FV	HS	Terminated
DMRT6FV	SN	150725-87-4; Ro 46-2005; Ro-46-2005; RO462005; CHEMBL115951; ro46-2005; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)pyrimidin-4-yl]benzenesulfonamide; Benzenesulfonamide,4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]-; 4-tert-butyl-N-{6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)pyrimidin-4-yl}benzenesulfonamide; ZNXOKLWCOWOECF-UHFFFAOYSA-N; AC1L3TVG; ACMC-20n61p; SCHEMBL2678965; KS-00001DFD; CTK4C6747; DTXSID80164598; ZINC1535471; BCP17756; BDBM50105015; AKOS030526571; Ro 462005
DMRT6FV	CP	Roche Holding AG
DMRT6FV	DT	Small molecular drug
DMRT6FV	PC	122044
DMRT6FV	MW	473.5
DMRT6FV	FM	C23H27N3O6S
DMRT6FV	IC	InChI=1S/C23H27N3O6S/c1-23(2,3)16-8-10-19(11-9-16)33(28,29)26-21-20(22(25-15-24-21)31-13-12-27)32-18-7-5-6-17(14-18)30-4/h5-11,14-15,27H,12-13H2,1-4H3,(H,24,25,26)
DMRT6FV	CS	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC=N2)OCCO)OC3=CC=CC(=C3)OC
DMRT6FV	IK	ZNXOKLWCOWOECF-UHFFFAOYSA-N
DMRT6FV	IU	4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)pyrimidin-4-yl]benzenesulfonamide
DMRT6FV	CA	CAS 150725-87-4
DMRT6FV	DE	Hypertension

DMU9JAH	ID	DMU9JAH
DMU9JAH	DN	Ro-46-5934
DMU9JAH	HS	Terminated
DMU9JAH	CP	F Hoffmann-La Roche Ltd
DMU9JAH	DE	Alzheimer disease

DMXMP3D	ID	DMXMP3D
DMXMP3D	DN	Ro-48-1220
DMXMP3D	HS	Terminated
DMXMP3D	CP	Roche Holding AG
DMXMP3D	DT	Small molecular drug
DMXMP3D	PC	10612083
DMXMP3D	MW	270.26
DMXMP3D	FM	C10H10N2O5S
DMXMP3D	IC	InChI=1S/C10H10N2O5S/c1-10(3-2-4-11)8(9(14)15)12-6(13)5-7(12)18(10,16)17/h2-3,7-8H,5H2,1H3,(H,14,15)/b3-2+/t7-,8+,10+/m1/s1
DMXMP3D	CS	C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)/C=C/C#N
DMXMP3D	IK	JYGFUXUBGZBBAC-RCRIAUEHSA-N
DMXMP3D	IU	(2S,3S,5R)-3-[(E)-2-cyanoethenyl]-3-methyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMXMP3D	CA	CAS 768335-49-5
DMXMP3D	DE	Bacterial infection

DM7AUF2	ID	DM7AUF2
DM7AUF2	DN	Ro-48-5545
DM7AUF2	HS	Terminated
DM7AUF2	SN	Bridged beta lactamase inhibitors, Roche; Ro-47-5325; Ro-48-1256; Ro-48-7953
DM7AUF2	CP	F Hoffmann-La Roche Ltd
DM7AUF2	DE	Bacterial infection

DM0RZEO	ID	DM0RZEO
DM0RZEO	DN	Ro-48-8724
DM0RZEO	HS	Terminated
DM0RZEO	CP	F Hoffmann-La Roche Ltd
DM0RZEO	DE	Multidrug resistant infection

DMZSQU8	ID	DMZSQU8
DMZSQU8	DN	Ro-60-0175
DMZSQU8	HS	Terminated
DMZSQU8	SN	Ro-600175
DMZSQU8	DT	Small molecular drug
DMZSQU8	PC	3045227
DMZSQU8	MW	226.68
DMZSQU8	FM	C11H12ClFN2
DMZSQU8	IC	InChI=1S/C11H12ClFN2/c1-7(14)6-15-3-2-8-4-10(13)9(12)5-11(8)15/h2-5,7H,6,14H2,1H3/t7-/m0/s1
DMZSQU8	CS	C[C@@H](CN1C=CC2=CC(=C(C=C21)Cl)F)N
DMZSQU8	IK	XJJZQXUGLLXTHO-ZETCQYMHSA-N
DMZSQU8	IU	(2S)-1-(6-chloro-5-fluoroindol-1-yl)propan-2-amine
DMZSQU8	CB	CHEBI:142183

DM6JO30	ID	DM6JO30
DM6JO30	DN	Rogletimide
DM6JO30	HS	Terminated
DM6JO30	SN	ROGLETIMIDE; Pyridoglutethimide; 92788-10-8; 3-PYG; (+-)-Pyridoglutethimide; Racemic-pyridoglutethimide; 2-Ethyl-2-(4-pyridyl)glutarimide; 121840-95-7; 3-Ethyl-3-(4-pyridyl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-ethyl-3-(4-pyridinyl)-; CHEMBL289116; 3-ethyl-3-pyridin-4-ylpiperidine-2,6-dione; 3-ethyl-3-(pyridin-4-yl)piperidine-2,6-dione; (+/-) 3-Ethyl-3-(4-pyridinyl)-2,6-piperidinedione; 3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione; Rogletimida; Rogletimidum; Rogletimidum [INN-Latin]; Rogletimida [INN-Spanish]
DM6JO30	DT	Small molecular drug
DM6JO30	PC	56487
DM6JO30	MW	218.25
DM6JO30	FM	C12H14N2O2
DM6JO30	IC	InChI=1S/C12H14N2O2/c1-2-12(9-4-7-13-8-5-9)6-3-10(15)14-11(12)16/h4-5,7-8H,2-3,6H2,1H3,(H,14,15,16)
DM6JO30	CS	CCC1(CCC(=O)NC1=O)C2=CC=NC=C2
DM6JO30	IK	QXKJWHWUDVQATH-UHFFFAOYSA-N
DM6JO30	IU	3-ethyl-3-pyridin-4-ylpiperidine-2,6-dione
DM6JO30	CA	CAS 92788-10-8
DM6JO30	DE	Breast cancer

DM4VCJI	ID	DM4VCJI
DM4VCJI	DN	Rovelizumab
DM4VCJI	HS	Terminated
DM4VCJI	SN	LeukArrest; Hu23F2G; Monoclonal antibody (MS), ICOS; 23F2G, ICOS
DM4VCJI	CP	ICOS Corp
DM4VCJI	DT	Antibody
DM4VCJI	DE	Cerebrovascular disease

DMQZ2JA	ID	DMQZ2JA
DMQZ2JA	DN	RP-58802B
DMQZ2JA	HS	Terminated
DMQZ2JA	SN	Imoxiterol; 88578-07-8; Imoxiterolum; Imoxiterol [INN]; Imoxiterolum [Latin]; AC1L23PZ; SCHEMBL249468; CHEMBL2104918; RP 58802B; CS-6651; 2-(3-(1-Benzimidazolyl)-1-methylpropylamino)-1-(4-hydroxy-3-methoxyphenyl)ethanol; RP-58802; HY-101585; L007875; alpha-(((3-(1-Benzimidazolyl)-1-methylpropyl)amino)methyl)vanillyl alcohol
DMQZ2JA	CP	Rhone-Poulenc SA
DMQZ2JA	DT	Small molecular drug
DMQZ2JA	PC	65665
DMQZ2JA	MW	355.4
DMQZ2JA	FM	C20H25N3O3
DMQZ2JA	IC	InChI=1S/C20H25N3O3/c1-14(9-10-23-13-22-16-5-3-4-6-17(16)23)21-12-19(25)15-7-8-18(24)20(11-15)26-2/h3-8,11,13-14,19,21,24-25H,9-10,12H2,1-2H3
DMQZ2JA	CS	CC(CCN1C=NC2=CC=CC=C21)NCC(C3=CC(=C(C=C3)O)OC)O
DMQZ2JA	IK	NKKPVWPMPWLEMY-UHFFFAOYSA-N
DMQZ2JA	IU	4-[2-[4-(benzimidazol-1-yl)butan-2-ylamino]-1-hydroxyethyl]-2-methoxyphenol
DMQZ2JA	CA	CAS 88578-07-8
DMQZ2JA	DE	Asthma

DM09QLY	ID	DM09QLY
DM09QLY	DN	RP-66055
DM09QLY	HS	Terminated
DM09QLY	SN	CHEMBL405225
DM09QLY	CP	Rhone-Poulenc SA
DM09QLY	DT	Small molecular drug
DM09QLY	PC	44277787
DM09QLY	MW	355.5
DM09QLY	FM	C20H22FN3S
DM09QLY	IC	InChI=1S/C20H22FN3S/c21-17-7-5-15(6-8-17)16-9-11-23(12-10-16)13-14-24-18-3-1-2-4-19(18)25-20(24)22/h1-8,16,22H,9-14H2
DM09QLY	CS	C1CN(CCC1C2=CC=C(C=C2)F)CCN3C4=CC=CC=C4SC3=N
DM09QLY	IK	YIJMYOZUUPAERG-UHFFFAOYSA-N
DM09QLY	IU	3-[2-[4-(4-fluorophenyl)piperidin-1-yl]ethyl]-1,3-benzothiazol-2-imine
DM09QLY	DE	Cerebral infarction

DMX4E75	ID	DMX4E75
DMX4E75	DN	RP-66153
DMX4E75	HS	Terminated
DMX4E75	SN	RP-66153; RP 66153; CHEMBL108415; 142422-79-5; AC1L30YM; SCHEMBL4355829; DTXSID80162034; 2,2-Dimethyl-7-(3-(3-phenylpropyl)-2-thienyl)heptanoic acid; BDBM50001162; 2-Thiopheneheptanoic acid, alpha,alpha-dimethyl-3-(3-phenylpropyl); 2,2-dimethyl-7-[3-(3-phenylpropyl)thiophen-2-yl]heptanoic acid; 2,2-Dimethyl-7-[3-(3-phenyl-propyl)-thiophen-2-yl]-heptanoic acid
DMX4E75	CP	Rhone-Poulenc SA
DMX4E75	DT	Small molecular drug
DMX4E75	PC	132425
DMX4E75	MW	358.5
DMX4E75	FM	C22H30O2S
DMX4E75	IC	InChI=1S/C22H30O2S/c1-22(2,21(23)24)16-8-4-7-14-20-19(15-17-25-20)13-9-12-18-10-5-3-6-11-18/h3,5-6,10-11,15,17H,4,7-9,12-14,16H2,1-2H3,(H,23,24)
DMX4E75	CS	CC(C)(CCCCCC1=C(C=CS1)CCCC2=CC=CC=C2)C(=O)O
DMX4E75	IK	QMXLXSYXJOJQSN-UHFFFAOYSA-N
DMX4E75	IU	2,2-dimethyl-7-[3-(3-phenylpropyl)thiophen-2-yl]heptanoic acid
DMX4E75	CA	CAS 142422-79-5
DMX4E75	DE	Asthma

DM6HJX7	ID	DM6HJX7
DM6HJX7	DN	RP-66364
DM6HJX7	HS	Terminated
DM6HJX7	SN	RP-60532; RP-69929
DM6HJX7	CP	Rhone-Poulenc SA
DM6HJX7	DE	Inflammation

DM2GV78	ID	DM2GV78
DM2GV78	DN	RP-66784
DM2GV78	HS	Terminated
DM2GV78	SN	IDDB5413
DM2GV78	CP	Rhone-Poulenc SA
DM2GV78	DT	Small molecular drug
DM2GV78	PC	9823280
DM2GV78	MW	417.6
DM2GV78	FM	C21H27N3O2S2
DM2GV78	IC	InChI=1S/C21H27N3O2S2/c1-22-20(27)21(18-9-7-14-23-16-18)13-6-5-8-17(21)12-15-24-28(25,26)19-10-3-2-4-11-19/h2-4,7,9-11,14,16-17,24H,5-6,8,12-13,15H2,1H3,(H,22,27)/t17-,21+/m1/s1
DM2GV78	CS	CNC(=S)[C@]1(CCCC[C@@H]1CCNS(=O)(=O)C2=CC=CC=C2)C3=CN=CC=C3
DM2GV78	IK	GLFXCUUHWBFHSB-UTKZUKDTSA-N
DM2GV78	IU	(1S,2R)-2-[2-(benzenesulfonamido)ethyl]-N-methyl-1-pyridin-3-ylcyclohexane-1-carbothioamide
DM2GV78	DE	Angina pectoris

DMDLW64	ID	DMDLW64
DMDLW64	DN	RP-67580
DMDLW64	HS	Terminated
DMDLW64	SN	RP-68651
DMDLW64	CP	Rhone-Poulenc SA
DMDLW64	DT	Small molecular drug
DMDLW64	PC	107686
DMDLW64	MW	438.6
DMDLW64	FM	C29H30N2O2
DMDLW64	IC	InChI=1S/C29H30N2O2/c1-33-27-15-9-8-10-21(27)18-28(30)31-19-24-25(20-31)29(17-16-26(24)32,22-11-4-2-5-12-22)23-13-6-3-7-14-23/h2-15,24-25,30H,16-20H2,1H3/t24-,25+/m0/s1
DMDLW64	CS	COC1=CC=CC=C1CC(=N)N2C[C@H]3[C@@H](C2)C(CCC3=O)(C4=CC=CC=C4)C5=CC=CC=C5
DMDLW64	IK	VWBOQFANCXZMAU-LOSJGSFVSA-N
DMDLW64	IU	(3aR,7aR)-2-[2-(2-methoxyphenyl)ethanimidoyl]-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-4-one
DMDLW64	CA	CAS 135911-02-3
DMDLW64	DE	Pain

DM0BEM3	ID	DM0BEM3
DM0BEM3	DN	RP-68303
DM0BEM3	HS	Terminated
DM0BEM3	SN	136701-68-3; RP-68303; CHEMBL274728; 1-(2-(4-((5-Fluoro-1H-indol-3-yl)methyl)-1-piperidinyl)ethyl)-5,6-dihydro-1H,4H-1,2,5-thiadiazolo(4,3,2-ij)quinoline 2,2-dioxide; 1-(Fim-PE)-dtqd; 1H,4H-[1,2,5]Thiadiazolo[4,3,2-ij]quinoline,1-[2-[4-[(5-fluoro-1H-indol-3-yl)methyl]-1-piperidinyl]ethyl]-5,6-dihydro-,2,2-dioxide; ACMC-20mw9l; AC1L4DLH; SCHEMBL9635292; CTK4C0419; DTXSID70159892; BDBM50047098; 1-{2-[4-(5-Fluoro-1H-indol-3-ylmethyl)-piperidin-1-yl]-ethyl}-4,5-dihydro-1H,3H-2-thia-1,2a-diaza-acenaphthylene 2,2-dioxide
DM0BEM3	DT	Small molecular drug
DM0BEM3	PC	183775
DM0BEM3	MW	468.6
DM0BEM3	FM	C25H29FN4O2S
DM0BEM3	IC	InChI=1S/C25H29FN4O2S/c26-21-6-7-23-22(16-21)20(17-27-23)15-18-8-11-28(12-9-18)13-14-29-24-5-1-3-19-4-2-10-30(25(19)24)33(29,31)32/h1,3,5-7,16-18,27H,2,4,8-15H2
DM0BEM3	CS	C1CC2=C3C(=CC=C2)N(S(=O)(=O)N3C1)CCN4CCC(CC4)CC5=CNC6=C5C=C(C=C6)F
DM0BEM3	IK	NZUSTSFFNOEAHE-UHFFFAOYSA-N
DM0BEM3	IU	3-[2-[4-[(5-fluoro-1H-indol-3-yl)methyl]piperidin-1-yl]ethyl]-2lambda6-thia-1,3-diazatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-triene 2,2-dioxide
DM0BEM3	CA	CAS 136701-68-3

DMUY4FD	ID	DMUY4FD
DMUY4FD	DN	RP-69698
DMUY4FD	HS	Terminated
DMUY4FD	SN	CHEMBL95799; SCHEMBL8987246
DMUY4FD	CP	Rhone-Poulenc SA
DMUY4FD	DT	Small molecular drug
DMUY4FD	PC	10452674
DMUY4FD	MW	385.5
DMUY4FD	FM	C23H23N5O
DMUY4FD	IC	InChI=1S/C23H23N5O/c1-4-10-18(11-5-1)20-16-21(19-12-6-2-7-13-19)24-23(17-20)29-15-9-3-8-14-22-25-27-28-26-22/h1-2,4-7,10-13,16-17H,3,8-9,14-15H2,(H,25,26,27,28)
DMUY4FD	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2)OCCCCCC3=NNN=N3)C4=CC=CC=C4
DMUY4FD	IK	MIZPMMYJEGMAHP-UHFFFAOYSA-N
DMUY4FD	IU	2,4-diphenyl-6-[5-(2H-tetrazol-5-yl)pentoxy]pyridine
DMUY4FD	DE	Inflammation

DMHO5AG	ID	DMHO5AG
DMHO5AG	DN	RP-70676
DMHO5AG	HS	Terminated
DMHO5AG	CP	Rhone-Poulenc SA
DMHO5AG	DE	Hyperlipidaemia

DMO3FYI	ID	DMO3FYI
DMO3FYI	DN	RP-73163
DMO3FYI	HS	Terminated
DMO3FYI	SN	CHEMBL434418; BDBM50106700
DMO3FYI	CP	Rhone-Poulenc SA
DMO3FYI	DT	Small molecular drug
DMO3FYI	PC	44356696
DMO3FYI	MW	446.6
DMO3FYI	FM	C26H30N4OS
DMO3FYI	IC	InChI=1S/C26H30N4OS/c1-20-19-21(2)30(29-20)17-11-3-4-12-18-32(31)26-27-24(22-13-7-5-8-14-22)25(28-26)23-15-9-6-10-16-23/h5-10,13-16,19H,3-4,11-12,17-18H2,1-2H3,(H,27,28)
DMO3FYI	CS	CC1=CC(=NN1CCCCCCS(=O)C2=NC(=C(N2)C3=CC=CC=C3)C4=CC=CC=C4)C
DMO3FYI	IK	TVSPJKIQOPZAPE-UHFFFAOYSA-N
DMO3FYI	IU	1-[6-[(4,5-diphenyl-1H-imidazol-2-yl)sulfinyl]hexyl]-3,5-dimethylpyrazole
DMO3FYI	DE	Arteriosclerosis

DMUCP8K	ID	DMUCP8K
DMUCP8K	DN	RPK-739
DMUCP8K	HS	Terminated
DMUCP8K	SN	KUN-CSF; KUN-GMCSF; Cancer vaccine (KUNrep), Replikun
DMUCP8K	CP	Replikun Biotech Pty Ltd
DMUCP8K	DE	Solid tumour/cancer

DM1U0TB	ID	DM1U0TB
DM1U0TB	DN	RPR 200765A
DM1U0TB	HS	Terminated
DM1U0TB	SN	CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648
DM1U0TB	CP	Aventis
DM1U0TB	DT	Small molecular drug
DM1U0TB	PC	9828952
DM1U0TB	MW	452.5
DM1U0TB	FM	C24H25FN4O4
DM1U0TB	IC	InChI=1S/C24H25FN4O4/c1-24(23(30)29-10-12-31-13-11-29)14-32-22(33-15-24)21-27-19(16-2-4-18(25)5-3-16)20(28-21)17-6-8-26-9-7-17/h2-9,22H,10-15H2,1H3,(H,27,28)
DM1U0TB	CS	CC1(COC(OC1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)C(=O)N5CCOCC5
DM1U0TB	IK	YEQUJOKCSZTBFS-UHFFFAOYSA-N
DM1U0TB	IU	[2-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-1,3-dioxan-5-yl]-morpholin-4-ylmethanone
DM1U0TB	DE	Rheumatoid arthritis

DM21Y75	ID	DM21Y75
DM21Y75	DN	RPR-101821
DM21Y75	HS	Terminated
DM21Y75	CP	Rhone-Poulenc Rorer Inc
DM21Y75	DE	Arteriosclerosis

DM9L50N	ID	DM9L50N
DM9L50N	DN	RPR-104632
DM9L50N	HS	Terminated
DM9L50N	SN	RPR-104632; RPR104632; 154106-92-0; Rpr 104632; Rpr 104,632; AC1L53RY; CHEMBL80741; SCHEMBL9280756; 2H-1,2,4-Benzothiadiazine-1-dioxide-3-carboxylate acid; CTK0H7515; BCP08875; CS-6717; RPR-110750; RPR-110754; HY-101600; 2-[(3-bromophenyl)methyl]-6,8-dichloro-1,1-dioxo-3,4-dihydro-1; 2H-1,2,4-Benzothiadiazine-3-carboxylicacid, 2-[(3-bromophenyl)methyl]-6,8-dichloro-3,4-dihydro-, 1,1-dioxide
DM9L50N	DT	Small molecular drug
DM9L50N	PC	197644
DM9L50N	MW	466.1
DM9L50N	FM	C15H11BrCl2N2O4S
DM9L50N	IC	InChI=1S/C15H11BrCl2N2O4S/c16-9-3-1-2-8(4-9)7-20-14(15(21)22)19-12-6-10(17)5-11(18)13(12)25(20,23)24/h1-6,14,19H,7H2,(H,21,22)
DM9L50N	CS	C1=CC(=CC(=C1)Br)CN2C(NC3=C(S2(=O)=O)C(=CC(=C3)Cl)Cl)C(=O)O
DM9L50N	IK	HNXXFIJGNAGRFN-UHFFFAOYSA-N
DM9L50N	IU	2-[(3-bromophenyl)methyl]-6,8-dichloro-1,1-dioxo-3,4-dihydro-1lambda6,2,4-benzothiadiazine-3-carboxylic acid
DM9L50N	CA	CAS 154106-92-0

DMJ63GW	ID	DMJ63GW
DMJ63GW	DN	RPR-113829
DMJ63GW	HS	Terminated
DMJ63GW	SN	RPR-113829; CHEMBL48866; SCHEMBL8750304; BDBM50058204; (S)-2-{[6-((R)-2-Amino-3-mercapto-propylamino)-naphthalene-1-carbonyl]-amino}-4-methylsulfanyl-butyric acid
DMJ63GW	DT	Small molecular drug
DMJ63GW	PC	9953221
DMJ63GW	MW	407.6
DMJ63GW	FM	C19H25N3O3S2
DMJ63GW	IC	InChI=1S/C19H25N3O3S2/c1-27-8-7-17(19(24)25)22-18(23)16-4-2-3-12-9-14(5-6-15(12)16)21-10-13(20)11-26/h2-6,9,13,17,21,26H,7-8,10-11,20H2,1H3,(H,22,23)(H,24,25)/t13-,17+/m1/s1
DMJ63GW	CS	CSCC[C@@H](C(=O)O)NC(=O)C1=CC=CC2=C1C=CC(=C2)NC[C@H](CS)N
DMJ63GW	IK	YUXOGMIOPNYIQR-DYVFJYSZSA-N
DMJ63GW	IU	(2S)-2-[[6-[[(2R)-2-amino-3-sulfanylpropyl]amino]naphthalene-1-carbonyl]amino]-4-methylsulfanylbutanoic acid

DMAIJT6	ID	DMAIJT6
DMAIJT6	DN	RPR-114334
DMAIJT6	HS	Terminated
DMAIJT6	SN	RPR-114334; CHEMBL297520; BDBM50058193; (S)-2-{[6-((R)-2-Amino-3-mercapto-propylamino)-naphthalene-1-carbonyl]-amino}-4-methylsulfanyl-butyric acid methyl ester
DMAIJT6	DT	Small molecular drug
DMAIJT6	PC	10432334
DMAIJT6	MW	421.6
DMAIJT6	FM	C20H27N3O3S2
DMAIJT6	IC	InChI=1S/C20H27N3O3S2/c1-26-20(25)18(8-9-28-2)23-19(24)17-5-3-4-13-10-15(6-7-16(13)17)22-11-14(21)12-27/h3-7,10,14,18,22,27H,8-9,11-12,21H2,1-2H3,(H,23,24)/t14-,18+/m1/s1
DMAIJT6	CS	COC(=O)[C@H](CCSC)NC(=O)C1=CC=CC2=C1C=CC(=C2)NC[C@H](CS)N
DMAIJT6	IK	PXCDDWIKPOASGU-KDOFPFPSSA-N
DMAIJT6	IU	methyl (2S)-2-[[6-[[(2R)-2-amino-3-sulfanylpropyl]amino]naphthalene-1-carbonyl]amino]-4-methylsulfanylbutanoate

DMKQV9A	ID	DMKQV9A
DMKQV9A	DN	RS 86
DMKQV9A	HS	Terminated
DMKQV9A	SN	RS-86; UNII-5ASV6M91QU; 5ASV6M91QU; RS 86; 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione hydrobromide; 2,8-Diazaspiro(4,5)decane-1,3-dione, 2-ethyl-8-methyl-, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione hydrobromide(1:1); CHEMBL542883; RS-86 hydrobromide; RS 86, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione hydrobromide; AC1L3EP8; 7524-74-5; C11H18N2O2.HBr; AC1Q23N4; CTK8D5439; 2-Nitrophenyl  -D-galactopyranoside; 2-Nitrophenyl ; A-D-galactopyranoside
DMKQV9A	DT	Small molecular drug
DMKQV9A	PC	87934
DMKQV9A	MW	210.27
DMKQV9A	FM	C11H18N2O2
DMKQV9A	IC	InChI=1S/C11H18N2O2/c1-3-13-9(14)8-11(10(13)15)4-6-12(2)7-5-11/h3-8H2,1-2H3
DMKQV9A	CS	CCN1C(=O)CC2(C1=O)CCN(CC2)C
DMKQV9A	IK	UIHKDOBBVHGTAQ-UHFFFAOYSA-N
DMKQV9A	IU	2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione
DMKQV9A	CA	CAS 3576-73-6
DMKQV9A	DE	Alzheimer disease

DMFJ0KC	ID	DMFJ0KC
DMFJ0KC	DN	RS-2135
DMFJ0KC	HS	Terminated
DMFJ0KC	SN	(+)-RS-2135; 133775-36-7
DMFJ0KC	CP	Sankyo Co Ltd
DMFJ0KC	DT	Small molecular drug
DMFJ0KC	PC	159591
DMFJ0KC	MW	332.8
DMFJ0KC	FM	C18H21ClN2O2
DMFJ0KC	IC	InChI=1S/C18H20N2O2.ClH/c19-12-8-11-17-13(5-2-6-14(17)21)20-15(22)7-9-3-1-4-10(12)16(9)18(11)20;/h2,5-6,9-10,12,16,21H,1,3-4,7-8,19H2;1H/t9-,10+,12-,16+;/m1./s1
DMFJ0KC	CS	C1C[C@@H]2CC(=O)N3C4=C(C5=C3[C@@H]2[C@@H](C1)[C@@H](C5)N)C(=CC=C4)O.Cl
DMFJ0KC	IK	MTSROZWZVOQAQW-PECACPRSSA-N
DMFJ0KC	IU	(10R,11R,15R,19S)-10-amino-6-hydroxy-1-azapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2(7),3,5,8(18)-tetraen-17-one;hydrochloride
DMFJ0KC	CA	CAS 133775-36-7
DMFJ0KC	DE	Heart arrhythmia

DMT5DH0	ID	DMT5DH0
DMT5DH0	DN	RS-66252
DMT5DH0	HS	Terminated
DMT5DH0	CP	Roche Bioscience
DMT5DH0	PC	9803861
DMT5DH0	MW	451.5
DMT5DH0	FM	C27H25N5O2
DMT5DH0	IC	InChI=1S/C27H25N5O2/c1-2-3-16-32-23-11-7-6-10-22(23)25(27(33)34)24(32)17-18-12-14-19(15-13-18)20-8-4-5-9-21(20)26-28-30-31-29-26/h4-15H,2-3,16-17H2,1H3,(H,33,34)(H,28,29,30,31)
DMT5DH0	CS	CCCCN1C2=CC=CC=C2C(=C1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
DMT5DH0	IK	LGRDYINVULLPLL-UHFFFAOYSA-N
DMT5DH0	IU	1-butyl-2-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]indole-3-carboxylic acid
DMT5DH0	DE	Alzheimer disease

DMZHS9U	ID	DMZHS9U
DMZHS9U	DN	RS-93522
DMZHS9U	HS	Terminated
DMZHS9U	SN	2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid methyl 2-[4-(2,3-dihydroxypropoxy)phenyl]ethyl diester; 2-[4-(2,3-Dihydroxypropoxy)phenyl]ethyl 2,6-dimethyl-3-(methoxycarbonyl)-4-(3-nitrophenyl)-1,4-dihydropyridine-5-carboxylate
DMZHS9U	DT	Small molecular drug
DMZHS9U	PC	128487
DMZHS9U	MW	526.5
DMZHS9U	FM	C27H30N2O9
DMZHS9U	IC	InChI=1S/C27H30N2O9/c1-16-23(26(32)36-3)25(19-5-4-6-20(13-19)29(34)35)24(17(2)28-16)27(33)37-12-11-18-7-9-22(10-8-18)38-15-21(31)14-30/h4-10,13,21,25,28,30-31H,11-12,14-15H2,1-3H3
DMZHS9U	CS	CC1=C(C(C(=C(N1)C)C(=O)OCCC2=CC=C(C=C2)OCC(CO)O)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMZHS9U	IK	QLNAYPDWIWUVHP-UHFFFAOYSA-N
DMZHS9U	IU	5-O-[2-[4-(2,3-dihydroxypropoxy)phenyl]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMZHS9U	CA	CAS 104060-12-0
DMZHS9U	DE	Hypertension

DMVW3I9	ID	DMVW3I9
DMVW3I9	DN	RU 24969
DMVW3I9	HS	Terminated
DMVW3I9	SN	RU 24969; 66611-26-5; RU-24969; 5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole; UNII-2ISE72RACC; 2ISE72RACC; CHEMBL18785; 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole; RU-24,969; KRVMLPUDAOWOGN-UHFFFAOYSA-N; NCGC00024867-01; Tocris-0912; GTPL23; Biomol-NT_000116; AC1Q4F1Q; SCHEMBL2359264; AC1L337E; BPBio1_000177; CHEBI:92005; BDBM81498; CTK1J4546; DTXSID40276045; MolPort-003-983-322; ZINC2568243; PDSP1_001623; PDSP2_001607; PDSP2_001601; PDSP1_001617; AKOS005135871; MCULE-3532976182; CS-3218; CAS_108028; API0006969
DMVW3I9	DT	Small molecular drug
DMVW3I9	PC	108029
DMVW3I9	MW	228.29
DMVW3I9	FM	C14H16N2O
DMVW3I9	IC	InChI=1S/C14H16N2O/c1-17-11-2-3-14-12(8-11)13(9-16-14)10-4-6-15-7-5-10/h2-4,8-9,15-16H,5-7H2,1H3
DMVW3I9	CS	COC1=CC2=C(C=C1)NC=C2C3=CCNCC3
DMVW3I9	IK	KRVMLPUDAOWOGN-UHFFFAOYSA-N
DMVW3I9	IU	5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
DMVW3I9	CA	CAS 66611-26-5
DMVW3I9	CB	CHEBI:92005

DMSWFMQ	ID	DMSWFMQ
DMSWFMQ	DN	RU-33965
DMSWFMQ	HS	Terminated
DMSWFMQ	SN	RU-33965; RU 33965; 122321-05-5; AC1L2W1Z; SCHEMBL195494; DTXSID50153570; 6H-Imidazo(1,5-a)(1,4)benzodiazepin-6-one, 3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-
DMSWFMQ	CP	Aventis Pharma AG
DMSWFMQ	DT	Small molecular drug
DMSWFMQ	PC	129696
DMSWFMQ	MW	281.31
DMSWFMQ	FM	C16H15N3O2
DMSWFMQ	IC	InChI=1S/C16H15N3O2/c1-18-8-13-14(15(20)10-6-7-10)17-9-19(13)12-5-3-2-4-11(12)16(18)21/h2-5,9-10H,6-8H2,1H3
DMSWFMQ	CS	CN1CC2=C(N=CN2C3=CC=CC=C3C1=O)C(=O)C4CC4
DMSWFMQ	IK	KNOYNQIVNYWKJR-UHFFFAOYSA-N
DMSWFMQ	IU	3-(cyclopropanecarbonyl)-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMSWFMQ	CA	CAS 122321-05-5
DMSWFMQ	DE	Alzheimer disease

DM8B1DH	ID	DM8B1DH
DM8B1DH	DN	RU-46556
DM8B1DH	HS	Terminated
DM8B1DH	CP	Aventis Pharma AG
DM8B1DH	DE	Endometrial cancer

DMBXDQG	ID	DMBXDQG
DMBXDQG	DN	RWJ-22108
DMBXDQG	HS	Terminated
DMBXDQG	SN	Rwj-22108; 112769-37-6; 2-(Methyl(phenylmethyl)amino)ethyl 4-(2-chloro-6-fluorophenyl)-1,4,6,7,8,9-hexahydro-2-methylthiepino(3,2-b)pyridine-3-carboxylate 5,5-dioxide; Thiepino[3,2-b]pyridine-3-carboxylicacid, 4-(2-chloro-6-fluorophenyl)-1,4,6,7,8,9-hexahydro-2-methyl-,2-[methyl(phenylmethyl)amino]ethyl ester, 5,5-dioxide; Rwj 22108; ACMC-20cv3e; AC1L4TSX; AC1Q4O13; CTK4A7965
DMBXDQG	CP	RW Johnson Pharmaceutical Research Institute
DMBXDQG	DT	Small molecular drug
DMBXDQG	PC	163892
DMBXDQG	MW	533.1
DMBXDQG	FM	C27H30ClFN2O4S
DMBXDQG	IC	InChI=1S/C27H30ClFN2O4S/c1-18-23(27(32)35-15-14-31(2)17-19-9-4-3-5-10-19)25(24-20(28)11-8-12-21(24)29)26-22(30-18)13-6-7-16-36(26,33)34/h3-5,8-12,25,30H,6-7,13-17H2,1-2H3
DMBXDQG	CS	CC1=C(C(C2=C(N1)CCCCS2(=O)=O)C3=C(C=CC=C3Cl)F)C(=O)OCCN(C)CC4=CC=CC=C4
DMBXDQG	IK	AHYGPFWAZFOLSI-UHFFFAOYSA-N
DMBXDQG	IU	2-[benzyl(methyl)amino]ethyl 4-(2-chloro-6-fluorophenyl)-2-methyl-5,5-dioxo-1,4,6,7,8,9-hexahydrothiepino[3,2-b]pyridine-3-carboxylate
DMBXDQG	CA	CAS 112769-37-6
DMBXDQG	DE	Allergy

DMRQZWN	ID	DMRQZWN
DMRQZWN	DN	RWJ-25730
DMRQZWN	HS	Terminated
DMRQZWN	SN	RWJ-25730; CHEMBL428175; SCHEMBL9751073; BLFPEKXTSDYQOQ-UHFFFAOYSA-N; BDBM50001869; 1-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-piperidin-2-one; 1-[[5-[[4-[2-Isopropyloxyphenyl]-1-piperazinyl]methyl]-1-methyl-1H-pyrrol-2-yl]methyl]piperidin-2-one; 1-[[1-methyl-5-[[4-[2-(1-methylethoxy)phenyl]-1 -piperazinyl]methyl]-lH-pyrrol-2-yl]methyl]-2- piperidinone
DMRQZWN	DT	Small molecular drug
DMRQZWN	PC	9910257
DMRQZWN	MW	424.6
DMRQZWN	FM	C25H36N4O2
DMRQZWN	IC	InChI=1S/C25H36N4O2/c1-20(2)31-24-9-5-4-8-23(24)28-16-14-27(15-17-28)18-21-11-12-22(26(21)3)19-29-13-7-6-10-25(29)30/h4-5,8-9,11-12,20H,6-7,10,13-19H2,1-3H3
DMRQZWN	CS	CC(C)OC1=CC=CC=C1N2CCN(CC2)CC3=CC=C(N3C)CN4CCCCC4=O
DMRQZWN	IK	BLFPEKXTSDYQOQ-UHFFFAOYSA-N
DMRQZWN	IU	1-[[1-methyl-5-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]pyrrol-2-yl]methyl]piperidin-2-one
DMRQZWN	DE	Psychotic disorder

DM17WNG	ID	DM17WNG
DM17WNG	DN	RWJ-37868
DM17WNG	HS	Terminated
DM17WNG	SN	RWJ-37868; CHEMBL43404
DM17WNG	CP	RW Johnson Pharmaceutical Research Institute
DM17WNG	DT	Small molecular drug
DM17WNG	PC	9799646
DM17WNG	MW	372.9
DM17WNG	FM	C21H25ClN2O2
DM17WNG	IC	InChI=1S/C21H25ClN2O2/c1-14-19(18(25)13-24-11-5-4-6-12-24)15(2)23(3)20(14)21(26)16-7-9-17(22)10-8-16/h7-10H,4-6,11-13H2,1-3H3
DM17WNG	CS	CC1=C(N(C(=C1C(=O)CN2CCCCC2)C)C)C(=O)C3=CC=C(C=C3)Cl
DM17WNG	IK	BCRATZJXVPSAOZ-UHFFFAOYSA-N
DM17WNG	IU	1-[5-(4-chlorobenzoyl)-1,2,4-trimethylpyrrol-3-yl]-2-piperidin-1-ylethanone
DM17WNG	DE	Epilepsy

DMEO7YD	ID	DMEO7YD
DMEO7YD	DN	RWJ-46458
DMEO7YD	HS	Terminated
DMEO7YD	SN	RWJ-46458; CHEMBL48602; BDBM50049205; L008047; [4-Ethyl-4-methyl-6-oxo-1-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-piperidin-(2E)-ylidene]-acetic acid ethyl ester
DMEO7YD	CP	RW Johnson Pharmaceutical Research Institute
DMEO7YD	DT	Small molecular drug
DMEO7YD	PC	9912059
DMEO7YD	MW	459.5
DMEO7YD	FM	C26H29N5O3
DMEO7YD	IC	InChI=1S/C26H29N5O3/c1-4-26(3)15-20(14-24(33)34-5-2)31(23(32)16-26)17-18-10-12-19(13-11-18)21-8-6-7-9-22(21)25-27-29-30-28-25/h6-14H,4-5,15-17H2,1-3H3,(H,27,28,29,30)/b20-14+
DMEO7YD	CS	CCC1(C/C(=C\\C(=O)OCC)/N(C(=O)C1)CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C
DMEO7YD	IK	JBEUFWOCGLXNCS-XSFVSMFZSA-N
DMEO7YD	IU	ethyl (2E)-2-[4-ethyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]piperidin-2-ylidene]acetate
DMEO7YD	DE	Hypertension

DMUGZMO	ID	DMUGZMO
DMUGZMO	DN	RWJ-49815
DMUGZMO	HS	Terminated
DMUGZMO	SN	2-[2-[4-(3,3,3-Triphenylpropoxy)phenyl]ethyl]guanidine; AC1LAN8D; SCHEMBL13339359; AJKCPFPHDCULCG-UHFFFAOYSA-N; 2-(4-(3,3,3-triphenylpropoxy)phenyl)ethylguanidine; 1-[2-[4-(3,3,3-triphenylpropoxy)phenyl]ethyl]guanidine; 2-[2-[4-(3,3,3-triphenylpropoxy)phenyl]ethyl]guanidine; RJW-57926
DMUGZMO	TC	Antifungal Agents
DMUGZMO	DT	Small molecular drug
DMUGZMO	PC	516731
DMUGZMO	MW	449.6
DMUGZMO	FM	C30H31N3O
DMUGZMO	IC	InChI=1S/C30H31N3O/c31-29(32)33-22-20-24-16-18-28(19-17-24)34-23-21-30(25-10-4-1-5-11-25,26-12-6-2-7-13-26)27-14-8-3-9-15-27/h1-19H,20-23H2,(H4,31,32,33)
DMUGZMO	CS	C1=CC=C(C=C1)C(CCOC2=CC=C(C=C2)CCN=C(N)N)(C3=CC=CC=C3)C4=CC=CC=C4
DMUGZMO	IK	AJKCPFPHDCULCG-UHFFFAOYSA-N
DMUGZMO	IU	2-[2-[4-(3,3,3-triphenylpropoxy)phenyl]ethyl]guanidine
DMUGZMO	DE	Obesity; Eating disorder; Fungal infection

DMYXD6A	ID	DMYXD6A
DMYXD6A	DN	RWJ-58259
DMYXD6A	HS	Terminated
DMYXD6A	SN	RWJ-58259; CHEMBL7642; SCHEMBL14090275; BDBM50098215; LS-30985
DMYXD6A	CP	RW Johnson Pharmaceutical Research Institute
DMYXD6A	DT	Small molecular drug
DMYXD6A	PC	9832212
DMYXD6A	MW	791.7
DMYXD6A	FM	C40H42Cl2F2N8O3
DMYXD6A	IC	InChI=1S/C40H42Cl2F2N8O3/c41-30-9-6-10-31(42)29(30)23-52-37-21-27(12-13-28(37)36(50-52)24-51-17-4-5-18-51)47-40(55)49-35(20-26-11-14-32(43)33(44)19-26)39(54)48-34(15-16-45)38(53)46-22-25-7-2-1-3-8-25/h1-3,6-14,19,21,34-35H,4-5,15-18,20,22-24,45H2,(H,46,53)(H,48,54)(H2,47,49,55)/t34-,35-/m0/s1
DMYXD6A	CS	C1CCN(C1)CC2=NN(C3=C2C=CC(=C3)NC(=O)N[C@@H](CC4=CC(=C(C=C4)F)F)C(=O)N[C@@H](CCN)C(=O)NCC5=CC=CC=C5)CC6=C(C=CC=C6Cl)Cl
DMYXD6A	IK	KEDDGIDZMJSBEW-PXLJZGITSA-N
DMYXD6A	IU	(2S)-4-amino-N-benzyl-2-[[(2S)-2-[[1-[(2,6-dichlorophenyl)methyl]-3-(pyrrolidin-1-ylmethyl)indazol-6-yl]carbamoylamino]-3-(3,4-difluorophenyl)propanoyl]amino]butanamide
DMYXD6A	DE	Artery stenosis

DMUDE1T	ID	DMUDE1T
DMUDE1T	DN	RWJ-63556
DMUDE1T	HS	Terminated
DMUDE1T	CP	RW Johnson Pharmaceutical Research Institute
DMUDE1T	PC	9882374
DMUDE1T	MW	287.3
DMUDE1T	FM	C11H10FNO3S2
DMUDE1T	IC	InChI=1S/C11H10FNO3S2/c1-18(14,15)13-10-6-7-11(17-10)16-9-4-2-8(12)3-5-9/h2-7,13H,1H3
DMUDE1T	CS	CS(=O)(=O)NC1=CC=C(S1)OC2=CC=C(C=C2)F
DMUDE1T	IK	BEIZIEZPGSIQGR-UHFFFAOYSA-N
DMUDE1T	IU	N-[5-(4-fluorophenoxy)thiophen-2-yl]methanesulfonamide
DMUDE1T	DE	Arthritis

DMDQGFR	ID	DMDQGFR
DMDQGFR	DN	S-1389
DMDQGFR	HS	Terminated
DMDQGFR	SN	711389-S
DMDQGFR	CP	Shionogi & Co Ltd
DMDQGFR	DT	Small molecular drug
DMDQGFR	PC	146863
DMDQGFR	MW	406.7
DMDQGFR	FM	C17H22Cl3N3O2
DMDQGFR	IC	InChI=1S/C17H21Cl2N3O2.ClH/c1-11(2)21-8-13(23)9-24-17-15(19)5-4-14(18)16(17)12(3)22-7-6-20-10-22;/h4-7,10-11,13,21,23H,3,8-9H2,1-2H3;1H
DMDQGFR	CS	CC(C)NCC(COC1=C(C=CC(=C1C(=C)N2C=CN=C2)Cl)Cl)O.Cl
DMDQGFR	IK	DGLQZJPSOFSWLE-UHFFFAOYSA-N
DMDQGFR	IU	1-[3,6-dichloro-2-(1-imidazol-1-ylethenyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride
DMDQGFR	CA	CAS 90742-91-9
DMDQGFR	DE	Heart arrhythmia

DM759KX	ID	DM759KX
DM759KX	DN	S-14080
DM759KX	HS	Terminated
DM759KX	CP	Servier
DM759KX	PC	9794783
DM759KX	MW	241.31
DM759KX	FM	C14H11NOS
DM759KX	IC	InChI=1S/C14H11NOS/c16-14(10-4-2-1-3-5-10)11-6-7-12-13(8-11)17-9-15-12/h1-8,15H,9H2
DM759KX	CS	C1NC2=C(S1)C=C(C=C2)C(=O)C3=CC=CC=C3
DM759KX	IK	BSJCMEIUFYPGNL-UHFFFAOYSA-N
DM759KX	IU	2,3-dihydro-1,3-benzothiazol-6-yl(phenyl)methanone
DM759KX	DE	Inflammation

DM05IQU	ID	DM05IQU
DM05IQU	DN	S-14506
DM05IQU	HS	Terminated
DM05IQU	SN	UNII-YVO8LE53MI; S-14506; YVO8LE53MI; 135722-25-7; CHEBI:64101; S14506; 4-fluoro-N-[2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl]benzamide; 4-fluoro-N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide; NCGC00025289-01; Tocris-1771; J485.975H; GTPL24; AC1L300Q; SCHEMBL6364443; DTXSID9043986; CHEMBL1590266; CTK8G8605; MolPort-042-665-626; ZINC64725931; N-(2-(4-(7-Methoxy-1-naphthyl)piperazino)ethyl)-4-fluorobenzamide; 4-Fluoro-N-(2-(4-(7-methoxy-1-naphthyl)piperazine-1-yl)ethyl)benzamide; Benzamide, 4-fluoro-N
DM05IQU	CP	Servier
DM05IQU	DT	Small molecular drug
DM05IQU	PC	131906
DM05IQU	MW	407.5
DM05IQU	FM	C24H26FN3O2
DM05IQU	IC	InChI=1S/C24H26FN3O2/c1-30-21-10-7-18-3-2-4-23(22(18)17-21)28-15-13-27(14-16-28)12-11-26-24(29)19-5-8-20(25)9-6-19/h2-10,17H,11-16H2,1H3,(H,26,29)
DM05IQU	CS	COC1=CC2=C(C=CC=C2N3CCN(CC3)CCNC(=O)C4=CC=C(C=C4)F)C=C1
DM05IQU	IK	IFMQODYDAUKKEN-UHFFFAOYSA-N
DM05IQU	IU	4-fluoro-N-[2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl]benzamide
DM05IQU	CA	CAS 135722-25-7
DM05IQU	CB	CHEBI:64101
DM05IQU	DE	Anxiety disorder

DMQ8S4L	ID	DMQ8S4L
DMQ8S4L	DN	S-18616
DMQ8S4L	HS	Terminated
DMQ8S4L	CP	Servier
DMQ8S4L	PC	10468498
DMQ8S4L	MW	236.7
DMQ8S4L	FM	C12H13ClN2O
DMQ8S4L	IC	InChI=1S/C12H13ClN2O/c13-10-3-1-2-8-4-5-12(6-9(8)10)7-16-11(14)15-12/h1-3H,4-7H2,(H2,14,15)/t12-/m0/s1
DMQ8S4L	CS	C1C[C@]2(CC3=C1C=CC=C3Cl)COC(=N2)N
DMQ8S4L	IK	OAXNLMLMEYQSSS-LBPRGKRZSA-N
DMQ8S4L	IU	(3S)-5-chlorospiro[2,4-dihydro-1H-naphthalene-3,4'-5H-1,3-oxazole]-2'-amine
DMQ8S4L	DE	Pain

DMQDWMJ	ID	DMQDWMJ
DMQDWMJ	DN	S-20928
DMQDWMJ	HS	Terminated
DMQDWMJ	SN	152302-33-5; S-20928; N-(2-naphthalen-1-ylethyl)cyclobutanecarboxamide; N-(2-(1-Naphthalenyl)ethyl)cyclobutanecarboxamide; Cyclobutanecarboxamide,N-[2-(1-naphthalenyl)ethyl]-; ACMC-20n6et; AC1L2SR8; S 20928; CHEMBL12296; ZINC5833; GTPL1360; SCHEMBL6254856; CTK4C7390; DTXSID00164994; MolPort-009-303-106; GLXSBZGTGMPDKH-UHFFFAOYSA-N; AKOS030612657; MCULE-2771118083; N-[2-(1-naphthyl)ethyl]cyclobutanecarboxamide; S20928; n-[2-naphth-1-yl-ethyl]-cyclobutyl carboxamide; L000529; N-[2-(naphthalen-1-yl)ethyl]cyclobutanecarboxamide
DMQDWMJ	CP	Servier
DMQDWMJ	DT	Small molecular drug
DMQDWMJ	PC	127856
DMQDWMJ	MW	253.34
DMQDWMJ	FM	C17H19NO
DMQDWMJ	IC	InChI=1S/C17H19NO/c19-17(15-8-4-9-15)18-12-11-14-7-3-6-13-5-1-2-10-16(13)14/h1-3,5-7,10,15H,4,8-9,11-12H2,(H,18,19)
DMQDWMJ	CS	C1CC(C1)C(=O)NCCC2=CC=CC3=CC=CC=C32
DMQDWMJ	IK	GLXSBZGTGMPDKH-UHFFFAOYSA-N
DMQDWMJ	IU	N-(2-naphthalen-1-ylethyl)cyclobutanecarboxamide
DMQDWMJ	CA	CAS 152302-33-5
DMQDWMJ	DE	Sleep-wake disorder

DMF710M	ID	DMF710M
DMF710M	DN	S-33516
DMF710M	HS	Terminated
DMF710M	CP	Servier
DMF710M	DE	Arthritis

DMPQIUH	ID	DMPQIUH
DMPQIUH	DN	S-34109
DMPQIUH	HS	Terminated
DMPQIUH	SN	S-32730
DMPQIUH	CP	Kaken Pharmaceutical Co Ltd
DMPQIUH	DE	Staphylococcus infection

DMEN6YO	ID	DMEN6YO
DMEN6YO	DN	Sameridine
DMEN6YO	HS	Terminated
DMEN6YO	SN	Sameridine; 143257-97-0; UNII-NQP2Y50Y6B; NQP2Y50Y6B; Sameridine [INN]; sameridine[inn]; AC1Q5ICP; SCHEMBL419071; AC1L24E2; CHEMBL2104504; DTXSID30162367; 4-Piperidinecarboxamide,N-ethyl-1-hexyl-N-methyl-4-phenyl-; ZINC3797855; AKOS015909863; N-Ethyl-1-hexyl-N-methyl-4-phenylisonipecotamide; I14-31849
DMEN6YO	CP	Astra AB
DMEN6YO	DT	Small molecular drug
DMEN6YO	PC	65996
DMEN6YO	MW	330.5
DMEN6YO	FM	C21H34N2O
DMEN6YO	IC	InChI=1S/C21H34N2O/c1-4-6-7-11-16-23-17-14-21(15-18-23,20(24)22(3)5-2)19-12-9-8-10-13-19/h8-10,12-13H,4-7,11,14-18H2,1-3H3
DMEN6YO	CS	CCCCCCN1CCC(CC1)(C2=CC=CC=C2)C(=O)N(C)CC
DMEN6YO	IK	TYWUGCGYWNSRPS-UHFFFAOYSA-N
DMEN6YO	IU	N-ethyl-1-hexyl-N-methyl-4-phenylpiperidine-4-carboxamide
DMEN6YO	CA	CAS 143257-97-0
DMEN6YO	DE	Pain

DMGUA9Y	ID	DMGUA9Y
DMGUA9Y	DN	SAN-61
DMGUA9Y	HS	Terminated
DMGUA9Y	SN	SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune
DMGUA9Y	CP	Sanomune Inc
DMGUA9Y	DE	Alzheimer disease

DM79E6W	ID	DM79E6W
DM79E6W	DN	Saviprazole
DM79E6W	HS	Terminated
DM79E6W	SN	Hoe-731
DM79E6W	CP	Hoechst AG
DM79E6W	DT	Small molecular drug
DM79E6W	PC	65942
DM79E6W	MW	461.4
DM79E6W	FM	C15H10F7N3O2S2
DM79E6W	IC	InChI=1S/C15H10F7N3O2S2/c16-13(17,14(18,19)15(20,21)22)7-27-9-1-2-23-8(3-9)6-29(26)12-24-10-4-28-5-11(10)25-12/h1-5H,6-7H2,(H,24,25)
DM79E6W	CS	C1=CN=C(C=C1OCC(C(C(F)(F)F)(F)F)(F)F)CS(=O)C2=NC3=CSC=C3N2
DM79E6W	IK	ARFGGIRJBPTBPP-UHFFFAOYSA-N
DM79E6W	IU	2-[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)pyridin-2-yl]methylsulfinyl]-1H-thieno[3,4-d]imidazole
DM79E6W	CA	CAS 121617-11-6
DM79E6W	DE	Peptic ulcer

DMNJ7LY	ID	DMNJ7LY
DMNJ7LY	DN	SB 203186
DMNJ7LY	HS	Terminated
DMNJ7LY	SN	SB 203186; SB-203186; 2-piperidin-1-ylethyl 1H-indole-3-carboxylate; Tocris-0785; NCGC00015921-01; Lopac-S-0443; Biomol-NT_000150; AC1MN68M; Lopac0_000347; GTPL255; BPBio1_000617; SCHEMBL1041116; CHEMBL1255781; ZINC14457; CHEBI:92477; BDBM85778; YGKPIROTKVQCCU-UHFFFAOYSA-N; CCG-204442; NCGC00024790-03; NCGC00015921-02; NCGC00024790-01; NCGC00024790-02; NCGC00015921-04; NCGC00015921-03; CAS_135938-17-9; (1-piperidinyl)ethyl 1h-indole 3-carboxylate; 2-(1-piperidyl)ethyl 1H-indole-3-carboxylate; 2-(1-Piperidyl)ethyl 1 H-indole-3-carboxy
DMNJ7LY	DT	Small molecular drug
DMNJ7LY	PC	3272300
DMNJ7LY	MW	272.34
DMNJ7LY	FM	C16H20N2O2
DMNJ7LY	IC	InChI=1S/C16H20N2O2/c19-16(20-11-10-18-8-4-1-5-9-18)14-12-17-15-7-3-2-6-13(14)15/h2-3,6-7,12,17H,1,4-5,8-11H2
DMNJ7LY	CS	C1CCN(CC1)CCOC(=O)C2=CNC3=CC=CC=C32
DMNJ7LY	IK	YGKPIROTKVQCCU-UHFFFAOYSA-N
DMNJ7LY	IU	2-piperidin-1-ylethyl 1H-indole-3-carboxylate
DMNJ7LY	CB	CHEBI:92477

DMAET6F	ID	DMAET6F
DMAET6F	DN	SB 203580
DMAET6F	HS	Terminated
DMAET6F	SN	152121-47-6; SB-203580; SB203580; 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine; 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole; CHEBI:90705; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; CHEMBL10; RWJ 64809; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; PB 203580; UNII-WS78QR6DSV
DMAET6F	DT	Small molecular drug
DMAET6F	PC	176155
DMAET6F	MW	377.4
DMAET6F	FM	C21H16FN3OS
DMAET6F	IC	InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)
DMAET6F	CS	CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
DMAET6F	IK	CDMGBJANTYXAIV-UHFFFAOYSA-N
DMAET6F	IU	4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine
DMAET6F	CA	CAS 152121-47-6
DMAET6F	CB	CHEBI:90705

DMS0QEP	ID	DMS0QEP
DMS0QEP	DN	SB 206553
DMS0QEP	HS	Terminated
DMS0QEP	SN	SB 206553; 158942-04-2; SB-206553; Tocris-1661; CHEMBL297784; CHEBI:8977; UNII-AL4387525T; AL4387525T; SB-206,553; 1-methyl-N-pyridin-3-yl-6,7-dihydropyrrolo[2,3-f]indole-5-carboxamide; SB-206553 hydrochloride hydrate; SB206553; Lopac-S-180; AC1L1JQU; AC1Q5NRE; Lopac0_001163; GTPL189; SCHEMBL1459242; ZINC5994; DTXSID9043984; CTK8H1211; BDBM50060417; pyrrolo[2,3-f]indole-1(2h)-carboxamide, 3,5-dihydro-5-methyl-n-3-pyridinyl-; AKOS027381420; 5-Methyl-N-(3-pyridinyl)-3,5-dihydropyrrolo[2,3-f]indole-1(2H)-carboxamide; CCG-205237
DMS0QEP	DT	Small molecular drug
DMS0QEP	PC	5163
DMS0QEP	MW	292.33
DMS0QEP	FM	C17H16N4O
DMS0QEP	IC	InChI=1S/C17H16N4O/c1-20-7-4-12-10-16-13(9-15(12)20)5-8-21(16)17(22)19-14-3-2-6-18-11-14/h2-4,6-7,9-11H,5,8H2,1H3,(H,19,22)
DMS0QEP	CS	CN1C=CC2=CC3=C(CCN3C(=O)NC4=CN=CC=C4)C=C21
DMS0QEP	IK	QJQORSLQNXDVGE-UHFFFAOYSA-N
DMS0QEP	IU	1-methyl-N-pyridin-3-yl-6,7-dihydropyrrolo[2,3-f]indole-5-carboxamide
DMS0QEP	CA	CAS 158942-04-2
DMS0QEP	CB	CHEBI:8977

DMGNZUX	ID	DMGNZUX
DMGNZUX	DN	SB-201146
DMGNZUX	HS	Terminated
DMGNZUX	SN	CHEMBL112338; SB-201146; AC1O5RO8; SCHEMBL13696780; BDBM50042182; L009515; (E)-3-{6-(3-Amino-benzenesulfinylmethyl)-3-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-yl}-acrylic acid; 3-{6-(3-Amino-benzenesulfinylmethyl)-3-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-yl}-acrylic acid; (E)-3-[6-[(3-aminophenyl)sulfinylmethyl]-3-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]prop-2-enoic acid; (E)-3-[[8-(4-Methoxyphenyl)octyl]oxy]-6-[[(3-aminophenyl)sulfinyl]methyl]pyridine-2-propenoic acid
DMGNZUX	DT	Small molecular drug
DMGNZUX	PC	23675456
DMGNZUX	MW	542.6
DMGNZUX	FM	C30H35LiN2O5S
DMGNZUX	IC	InChI=1S/C30H36N2O5S.Li/c1-36-26-15-12-23(13-16-26)9-6-4-2-3-5-7-20-37-29-18-14-25(32-28(29)17-19-30(33)34)22-38(35)27-11-8-10-24(31)21-27;/h8,10-19,21H,2-7,9,20,22,31H2,1H3,(H,33,34);/q;+1/p-1/b19-17+;
DMGNZUX	CS	[Li+].COC1=CC=C(C=C1)CCCCCCCCOC2=C(N=C(C=C2)CS(=O)C3=CC=CC(=C3)N)/C=C/C(=O)[O-]
DMGNZUX	IK	RVRATNAADXHAQO-ZJSKVYKZSA-M
DMGNZUX	IU	lithium;(E)-3-[6-[(3-aminophenyl)sulfinylmethyl]-3-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]prop-2-enoate
DMGNZUX	CA	CAS 141311-11-7

DM5ZPQJ	ID	DM5ZPQJ
DM5ZPQJ	DN	SB-206284A
DM5ZPQJ	HS	Terminated
DM5ZPQJ	CP	SmithKline Beecham plc
DM5ZPQJ	DE	Cerebrovascular ischaemia

DMYFE23	ID	DMYFE23
DMYFE23	DN	SB-206343
DMYFE23	HS	Terminated
DMYFE23	SN	SB206343; CHEMBL326473; 2-[(1R,3S,4S)-1-BENZYL-4-[N-(BENZYLOXYCARBONYL)-L-VALYL]AMINO-3-PHENYLPENTYL]-4(5)-(2-METHYLPROPIONYL)IMIDAZOLE; RUN; SB-206343; 1hps; SB 206343; AC1L9J53; SCHEMBL13987202; BDBM50037121; N-{(1S,2S,4R)-1-benzyl-2-hydroxy-4-[5-(2-methylpropanoyl)-1H-imidazol-2-yl]-5-phenylpentyl}-N~2~-[(benzyloxy)carbonyl]-L-valinamide; {(S)-1-[(1S,2S,4R)-1-Benzyl-2-hydroxy-4-(5-isobutyryl-1H-imidazol-2-yl)-5-phenyl-pentylcarbamoyl]-2-methyl-propyl}-carbamic acid benzyl ester; benzyl N-[(2S)-1-[[(2S,3S,5R)-3-hydro
DMYFE23	CP	SmithKline Beecham plc
DMYFE23	DT	Small molecular drug
DMYFE23	PC	446120
DMYFE23	MW	638.8
DMYFE23	FM	C38H46N4O5
DMYFE23	IC	InChI=1S/C38H46N4O5/c1-25(2)34(42-38(46)47-24-29-18-12-7-13-19-29)37(45)41-31(21-28-16-10-6-11-17-28)33(43)22-30(20-27-14-8-5-9-15-27)36-39-23-32(40-36)35(44)26(3)4/h5-19,23,25-26,30-31,33-34,43H,20-22,24H2,1-4H3,(H,39,40)(H,41,45)(H,42,46)/t30-,31+,33+,34+/m1/s1
DMYFE23	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](C[C@@H](CC2=CC=CC=C2)C3=NC=C(N3)C(=O)C(C)C)O)NC(=O)OCC4=CC=CC=C4
DMYFE23	IK	RQAVEWKEUKIFLD-LVPKLHHISA-N
DMYFE23	IU	benzyl N-[(2S)-1-[[(2S,3S,5R)-3-hydroxy-5-[5-(2-methylpropanoyl)-1H-imidazol-2-yl]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
DMYFE23	DE	Human immunodeficiency virus-1 infection

DMJD15H	ID	DMJD15H
DMJD15H	DN	SB-208651
DMJD15H	HS	Terminated
DMJD15H	SN	SB-208651; CHEMBL85094; BDBM50054827; {8-[(4-Carbamimidoyl-phenyl)-methyl-carbamoyl]-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {8-[(4-Carbamimidoyl-phenyl)-methyl-carbamoyl]-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid(SB-208651)
DMJD15H	DT	Small molecular drug
DMJD15H	PC	9827266
DMJD15H	MW	499.6
DMJD15H	FM	C28H29N5O4
DMJD15H	IC	InChI=1S/C28H29N5O4/c1-32(22-11-9-19(10-12-22)26(29)30)27(36)20-7-8-21-17-33(14-13-18-5-3-2-4-6-18)28(37)24(16-25(34)35)31-23(21)15-20/h2-12,15,24,31H,13-14,16-17H2,1H3,(H3,29,30)(H,34,35)
DMJD15H	CS	CN(C1=CC=C(C=C1)C(=N)N)C(=O)C2=CC3=C(CN(C(=O)C(N3)CC(=O)O)CCC4=CC=CC=C4)C=C2
DMJD15H	IK	WCZAIWWFRSMLCO-UHFFFAOYSA-N
DMJD15H	IU	2-[8-[(4-carbamimidoylphenyl)-methylcarbamoyl]-3-oxo-4-(2-phenylethyl)-2,5-dihydro-1H-1,4-benzodiazepin-2-yl]acetic acid
DMJD15H	DE	Thrombosis

DMVBNTP	ID	DMVBNTP
DMVBNTP	DN	SB-209247
DMVBNTP	HS	Terminated
DMVBNTP	SN	Ticolubant; LTB4 antagonist, SB
DMVBNTP	CP	SmithKline Beecham plc
DMVBNTP	DT	Small molecular drug
DMVBNTP	PC	6441619
DMVBNTP	MW	460.4
DMVBNTP	FM	C23H19Cl2NO3S
DMVBNTP	IC	InChI=1S/C23H19Cl2NO3S/c24-18-7-4-8-19(25)23(18)30-15-17-9-11-21(20(26-17)10-12-22(27)28)29-14-13-16-5-2-1-3-6-16/h1-12H,13-15H2,(H,27,28)/b12-10+
DMVBNTP	CS	C1=CC=C(C=C1)CCOC2=C(N=C(C=C2)CSC3=C(C=CC=C3Cl)Cl)/C=C/C(=O)O
DMVBNTP	IK	ZJLFOOWTDISDIO-ZRDIBKRKSA-N
DMVBNTP	IU	(E)-3-[6-[(2,6-dichlorophenyl)sulfanylmethyl]-3-(2-phenylethoxy)pyridin-2-yl]prop-2-enoic acid
DMVBNTP	CA	CAS 154413-61-3
DMVBNTP	DE	Psoriasis vulgaris

DM58PKG	ID	DM58PKG
DM58PKG	DN	SB-213698
DM58PKG	HS	Terminated
DM58PKG	SN	TAN-67
DM58PKG	PC	9950038
DM58PKG	MW	344.4
DM58PKG	FM	C23H24N2O
DM58PKG	IC	InChI=1S/C23H24N2O/c1-25-10-9-23(18-6-4-7-20(26)13-18)14-22-17(12-19(23)15-25)11-16-5-2-3-8-21(16)24-22/h2-8,11,13,19,26H,9-10,12,14-15H2,1H3/t19-,23+/m0/s1
DM58PKG	CS	CN1CC[C@@]2(CC3=NC4=CC=CC=C4C=C3C[C@H]2C1)C5=CC(=CC=C5)O
DM58PKG	IK	LEPBHAAYNPPRRA-WMZHIEFXSA-N
DM58PKG	IU	3-[(4aS,12aR)-2-methyl-1,3,4,5,12,12a-hexahydropyrido[3,4-b]acridin-4a-yl]phenol
DM58PKG	CA	CAS 148545-09-9
DM58PKG	CB	CHEBI:124990

DMQW6B0	ID	DMQW6B0
DMQW6B0	DN	SB-219825
DMQW6B0	HS	Terminated
DMQW6B0	CP	SmithKline Beecham Corp
DMQW6B0	PC	101105102
DMQW6B0	MW	409.6
DMQW6B0	FM	C25H35N3O2
DMQW6B0	IC	InChI=1S/C25H35N3O2/c1-5-27-12-11-25(18-9-8-10-20(29)13-18)15-22-21(14-19(25)16-27)17(4)23(26-22)24(30)28(6-2)7-3/h8-10,13,19,26,29H,5-7,11-12,14-16H2,1-4H3/t19-,25-/m1/s1
DMQW6B0	CS	CCN1CC[C@@]2(CC3=C(C[C@@H]2C1)C(=C(N3)C(=O)N(CC)CC)C)C4=CC(=CC=C4)O
DMQW6B0	IK	LCXJNOQXEGZLDX-KBMIEXCESA-N
DMQW6B0	IU	(4aS,8aS)-N,N,6-triethyl-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,7,8,9-hexahydro-1H-pyrrolo[2,3-g]isoquinoline-2-carboxamide
DMQW6B0	DE	Pain

DMCZDE9	ID	DMCZDE9
DMCZDE9	DN	SB-219994
DMCZDE9	HS	Terminated
DMCZDE9	SN	SB-219993
DMCZDE9	CP	SmithKline Beecham plc
DMCZDE9	DT	Small molecular drug
DMCZDE9	PC	9845965
DMCZDE9	MW	438.4
DMCZDE9	FM	C21H21F3N2O5
DMCZDE9	IC	InChI=1S/C21H21F3N2O5/c1-26(20-25-16-4-2-3-5-17(16)31-20)10-11-29-15-8-6-14(7-9-15)12-18(19(27)28)30-13-21(22,23)24/h2-9,18H,10-13H2,1H3,(H,27,28)/t18-/m0/s1
DMCZDE9	CS	CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)OCC(F)(F)F)C2=NC3=CC=CC=C3O2
DMCZDE9	IK	IRAAJHYKQDFNFO-SFHVURJKSA-N
DMCZDE9	IU	(2S)-3-[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoic acid
DMCZDE9	DE	Diabetic complication

DMSBUET	ID	DMSBUET
DMSBUET	DN	SB220025
DMSBUET	HS	Terminated
DMSBUET	SN	SB220025; 3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole
DMSBUET	DT	Small molecular drug
DMSBUET	PC	5164
DMSBUET	MW	338.4
DMSBUET	FM	C18H19FN6
DMSBUET	IC	InChI=1S/C18H19FN6/c19-13-3-1-12(2-4-13)16-17(15-7-10-22-18(20)24-15)25(11-23-16)14-5-8-21-9-6-14/h1-4,7,10-11,14,21H,5-6,8-9H2,(H2,20,22,24)
DMSBUET	CS	C1CNCCC1N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F
DMSBUET	IK	VSPFURGQAYMVAN-UHFFFAOYSA-N
DMSBUET	IU	4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]pyrimidin-2-amine
DMSBUET	CA	CAS 165806-53-1
DMSBUET	CB	CHEBI:82713
DMSBUET	DE	Arthritis

DM3JQCF	ID	DM3JQCF
DM3JQCF	DN	SB-223245
DM3JQCF	HS	Terminated
DM3JQCF	SN	SB-223245; CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid
DM3JQCF	DT	Small molecular drug
DM3JQCF	PC	9823503
DM3JQCF	MW	421.4
DM3JQCF	FM	C22H23N5O4
DM3JQCF	IC	InChI=1S/C22H23N5O4/c1-26-11-14-9-13(7-8-15(14)23-18(22(26)31)10-20(28)29)21(30)27(2)12-19-24-16-5-3-4-6-17(16)25-19/h3-9,18,23H,10-12H2,1-2H3,(H,24,25)(H,28,29)/t18-/m0/s1
DM3JQCF	CS	CN1CC2=C(C=CC(=C2)C(=O)N(C)CC3=NC4=CC=CC=C4N3)N[C@H](C1=O)CC(=O)O
DM3JQCF	IK	PVNQAXDNDZYXIW-SFHVURJKSA-N
DM3JQCF	IU	2-[(2S)-7-[1H-benzimidazol-2-ylmethyl(methyl)carbamoyl]-4-methyl-3-oxo-2,5-dihydro-1H-1,4-benzodiazepin-2-yl]acetic acid

DM5JDH1	ID	DM5JDH1
DM5JDH1	DN	SB-236049
DM5JDH1	HS	Terminated
DM5JDH1	SN	SB-236080; SB-238569; Tricyclic broad-spectrum metallo-beta-lactamase inhibitors, SmithKline Beecham
DM5JDH1	CP	SmithKline Beecham Pharmaceuticals
DM5JDH1	DT	Small molecular drug
DM5JDH1	PC	9860695
DM5JDH1	MW	287.22
DM5JDH1	FM	C14H9NO6
DM5JDH1	IC	InChI=1S/C14H9NO6/c1-5-2-8-6(4-15-5)12(17)10-9(21-8)3-7(16)13(18)11(10)14(19)20/h2-4,16,18H,1H3,(H,19,20)
DM5JDH1	CS	CC1=CC2=C(C=N1)C(=O)C3=C(O2)C=C(C(=C3C(=O)O)O)O
DM5JDH1	IK	JQSDDXAUCUZICT-UHFFFAOYSA-N
DM5JDH1	IU	7,8-dihydroxy-3-methyl-10-oxochromeno[3,2-c]pyridine-9-carboxylic acid
DM5JDH1	CB	CHEBI:68708
DM5JDH1	DE	Bacterial infection

DMBCANZ	ID	DMBCANZ
DMBCANZ	DN	SB-237376
DMBCANZ	HS	Terminated
DMBCANZ	SN	SB-237376; UNII-JED8M29NSU; JED8M29NSU; CHEMBL184461; SB-237376 free base; SCHEMBL6737235; XEAKAKKNLOUHDV-UHFFFAOYSA-N; BDBM50151854; n-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide; N-{3-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-propyl}-4-nitro-benzamide; Benzamide, N-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-4-nitro-
DMBCANZ	CP	SmithKline Beecham plc
DMBCANZ	DT	Small molecular drug
DMBCANZ	PC	9845214
DMBCANZ	MW	387.4
DMBCANZ	FM	C20H25N3O5
DMBCANZ	IC	InChI=1S/C20H25N3O5/c1-27-18-9-4-15(14-19(18)28-2)10-13-21-11-3-12-22-20(24)16-5-7-17(8-6-16)23(25)26/h4-9,14,21H,3,10-13H2,1-2H3,(H,22,24)
DMBCANZ	CS	COC1=C(C=C(C=C1)CCNCCCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-])OC
DMBCANZ	IK	XEAKAKKNLOUHDV-UHFFFAOYSA-N
DMBCANZ	IU	N-[3-[2-(3,4-dimethoxyphenyl)ethylamino]propyl]-4-nitrobenzamide
DMBCANZ	CA	CAS 179258-59-4
DMBCANZ	DE	Arrhythmia

DM8WTGA	ID	DM8WTGA
DM8WTGA	DN	SB-269970
DM8WTGA	HS	Terminated
DM8WTGA	SN	Pyrrolidine, 1-((3-hydroxyphenyl)sulfonyl)-2-(2-(4-methyl-1-piperidinyl)ethyl)-, (R)-; 201038-74-6; SB 269970; (R)-3-((2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)phenol; CHEMBL282199; SB269970; 3-[(2R)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol; SB-269,970; NCGC00025229-01; Tocris-1612; [3H]SB269970; AC1O7H0E; Lopac0_001059; SCHEMBL375474; GTPL3247; GTPL3233; CHEBI:92426; BCPP000080; ZINC3982174; BDBM50098551; 2921AH; AKOS024465019; CS-1645; CCG-205136; SB19510
DM8WTGA	DT	Small molecular drug
DM8WTGA	PC	6604889
DM8WTGA	MW	352.5
DM8WTGA	FM	C18H28N2O3S
DM8WTGA	IC	InChI=1S/C18H28N2O3S/c1-15-7-11-19(12-8-15)13-9-16-4-3-10-20(16)24(22,23)18-6-2-5-17(21)14-18/h2,5-6,14-16,21H,3-4,7-13H2,1H3/t16-/m1/s1
DM8WTGA	CS	CC1CCN(CC1)CC[C@H]2CCCN2S(=O)(=O)C3=CC=CC(=C3)O
DM8WTGA	IK	HWKROQUZSKPIKQ-MRXNPFEDSA-N
DM8WTGA	IU	3-[(2R)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol
DM8WTGA	CA	CAS 201038-74-6
DM8WTGA	CB	CHEBI:92426
DM8WTGA	DE	Sleep-wake disorder

DM3M16Q	ID	DM3M16Q
DM3M16Q	DN	SB-277011
DM3M16Q	HS	Terminated
DM3M16Q	SN	SB 277011; SB 277011A; SB 277011-A; N-[4-[2-(6-cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]cyclohexyl]quinoline-4-carboxamide
DM3M16Q	CP	GlaxoSmithKline
DM3M16Q	DT	Small molecular drug
DM3M16Q	PC	5311096
DM3M16Q	MW	438.6
DM3M16Q	FM	C28H30N4O
DM3M16Q	IC	InChI=1S/C28H30N4O/c29-18-21-5-8-23-19-32(16-13-22(23)17-21)15-12-20-6-9-24(10-7-20)31-28(33)26-11-14-30-27-4-2-1-3-25(26)27/h1-5,8,11,14,17,20,24H,6-7,9-10,12-13,15-16,19H2,(H,31,33)
DM3M16Q	CS	C1CC(CCC1CCN2CCC3=C(C2)C=CC(=C3)C#N)NC(=O)C4=CC=NC5=CC=CC=C45
DM3M16Q	IK	OLWRVVHPJFLNPW-UHFFFAOYSA-N
DM3M16Q	IU	N-[4-[2-(6-cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]cyclohexyl]quinoline-4-carboxamide
DM3M16Q	CA	CAS 215803-78-4
DM3M16Q	DE	Schizophrenia

DMZLKCF	ID	DMZLKCF
DMZLKCF	DN	SB-282241
DMZLKCF	HS	Terminated
DMZLKCF	SN	CCR2B antagonists, GlaxoSmithKline; SB-380732; MCP-1 antagonists, GlaxoSmithKline
DMZLKCF	CP	SmithKline Beecham Pharmaceuticals
DMZLKCF	DT	Small molecular drug
DMZLKCF	PC	10436045
DMZLKCF	MW	500.5
DMZLKCF	FM	C27H31Cl2N3O2
DMZLKCF	IC	InChI=1S/C27H31Cl2N3O2/c28-24-7-4-19(16-25(24)29)5-9-27(34)30-12-2-1-3-13-32-14-10-20(11-15-32)23-18-31-26-8-6-21(33)17-22(23)26/h4-9,16-18,20,31,33H,1-3,10-15H2,(H,30,34)/b9-5+
DMZLKCF	CS	C1CN(CCC1C2=CNC3=C2C=C(C=C3)O)CCCCCNC(=O)/C=C/C4=CC(=C(C=C4)Cl)Cl
DMZLKCF	IK	QBRLVMQBZIFWTB-WEVVVXLNSA-N
DMZLKCF	IU	(E)-3-(3,4-dichlorophenyl)-N-[5-[4-(5-hydroxy-1H-indol-3-yl)piperidin-1-yl]pentyl]prop-2-enamide
DMZLKCF	DE	Inflammation

DM9F7R0	ID	DM9F7R0
DM9F7R0	DN	SBP-002
DM9F7R0	HS	Terminated
DM9F7R0	SN	Coramsine; Solasonine + solamargine; Solasodine glycosides (cancer, injectable formulation), Solbec; Solasodine glycosides (psoriasis, cream formulation), Solbec; Solasonine + solamargine (cancer), Solbec; Solasonine + solamargine (psoriasis), Solbec; SBP-002 (intravenous, cancer), Solbec; SBP-002 (psoriasis, cream formulation), Solbec
DM9F7R0	CP	Curacel International Pty Ltd; Freedom Eye Ltd
DM9F7R0	DE	Melanoma

DM1MQ6Z	ID	DM1MQ6Z
DM1MQ6Z	DN	SC-102
DM1MQ6Z	HS	Terminated
DM1MQ6Z	SN	4-[3-(4-Fluorophenyl)-1h-Pyrazol-4-Yl]pyridine; 3hvc; GG5; SCHEMBL1554633; CHEMBL1233024; BDBM19429; BILJSHVAAVZERY-UHFFFAOYSA-N; ZINC16052350; DB07829; 5-(4-Fluorophenyl)-4-(pyridin-4-yl)pyrazole; 4-[3-(4-Fluorophenyl)-1H-pyrazole-4-yl]pyridine; 4-(3-(4-fluorophenyl)-1h-pyrazol-4-yl);  SC-102; SPC-0038B; SPC-0172; Temoporfin derivatives (cancer); Temoporfin derivatives (cancer), Scotia Holdings; 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
DM1MQ6Z	CP	Scotia Holdings plc
DM1MQ6Z	DT	Small molecular drug
DM1MQ6Z	PC	12106168
DM1MQ6Z	MW	239.25
DM1MQ6Z	FM	C14H10FN3
DM1MQ6Z	IC	InChI=1S/C14H10FN3/c15-12-3-1-11(2-4-12)14-13(9-17-18-14)10-5-7-16-8-6-10/h1-9H,(H,17,18)
DM1MQ6Z	CS	C1=CC(=CC=C1C2=C(C=NN2)C3=CC=NC=C3)F
DM1MQ6Z	IK	BILJSHVAAVZERY-UHFFFAOYSA-N
DM1MQ6Z	IU	4-[5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine
DM1MQ6Z	DE	Solid tumour/cancer

DMO1URE	ID	DMO1URE
DMO1URE	DN	SC-236
DMO1URE	HS	Terminated
DMO1URE	SN	SC-791; SC-872; COX-2 inhibitors (anticancer), Pfizer; COX-2 inhibitors (anticancer), Pharmacia
DMO1URE	CP	GD Searle & Co
DMO1URE	DT	Small molecular drug
DMO1URE	PC	9865808
DMO1URE	MW	401.8
DMO1URE	FM	C16H11ClF3N3O2S
DMO1URE	IC	InChI=1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)
DMO1URE	CS	C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)Cl
DMO1URE	IK	NSQNZEUFHPTJME-UHFFFAOYSA-N
DMO1URE	IU	4-[5-(4-chlorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DMO1URE	CA	CAS 170569-86-5
DMO1URE	DE	Solid tumour/cancer

DM7I6VO	ID	DM7I6VO
DM7I6VO	DN	SC-241
DM7I6VO	HS	Terminated
DM7I6VO	CP	Bristol-Myers Squibb Pharma Co
DM7I6VO	PC	9934089
DM7I6VO	MW	463.4
DM7I6VO	FM	C20H27BrN6O2
DM7I6VO	IC	InChI=1S/C20H27BrN6O2/c1-13(2)15-6-7-17(16(21)12-15)27-20-18(24-25-27)19(22-14(3)23-20)26(8-10-28-4)9-11-29-5/h6-7,12-13H,8-11H2,1-5H3
DM7I6VO	CS	CC1=NC2=C(C(=N1)N(CCOC)CCOC)N=NN2C3=C(C=C(C=C3)C(C)C)Br
DM7I6VO	IK	DMJNPPHUVMMIEQ-UHFFFAOYSA-N
DM7I6VO	IU	3-(2-bromo-4-propan-2-ylphenyl)-N,N-bis(2-methoxyethyl)-5-methyltriazolo[4,5-d]pyrimidin-7-amine
DM7I6VO	DE	Anxiety disorder

DMBPNKT	ID	DMBPNKT
DMBPNKT	DN	SC-44463
DMBPNKT	HS	Terminated
DMBPNKT	SN	SC-44463; CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth
DMBPNKT	DT	Small molecular drug
DMBPNKT	PC	128564
DMBPNKT	MW	379.5
DMBPNKT	FM	C19H29N3O5
DMBPNKT	IC	InChI=1S/C19H29N3O5/c1-12(2)9-14(11-17(23)22-26)18(24)21-16(19(25)20-3)10-13-5-7-15(27-4)8-6-13/h5-8,12,14,16,26H,9-11H2,1-4H3,(H,20,25)(H,21,24)(H,22,23)/t14-,16+/m1/s1
DMBPNKT	CS	CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC1=CC=C(C=C1)OC)C(=O)NC
DMBPNKT	IK	QYZPDCGWIJYZMN-ZBFHGGJFSA-N
DMBPNKT	IU	(2R)-N'-hydroxy-N-[(2S)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide
DMBPNKT	CA	CAS 104408-38-0

DMIE039	ID	DMIE039
DMIE039	DN	SC-47643
DMIE039	HS	Terminated
DMIE039	SN	CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid
DMIE039	DT	Small molecular drug
DMIE039	PC	124392
DMIE039	MW	449.5
DMIE039	FM	C22H35N5O5
DMIE039	IC	InChI=1S/C22H35N5O5/c1-32-17-10-8-16(9-11-17)12-14-25-21(31)18(15-20(29)30)27-19(28)7-5-3-2-4-6-13-26-22(23)24/h8-11,18H,2-7,12-15H2,1H3,(H,25,31)(H,27,28)(H,29,30)(H4,23,24,26)/t18-/m0/s1
DMIE039	CS	COC1=CC=C(C=C1)CCNC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCN=C(N)N
DMIE039	IK	LVVRYABDHQGPGK-SFHVURJKSA-N
DMIE039	IU	(3S)-3-[8-(diaminomethylideneamino)octanoylamino]-4-[2-(4-methoxyphenyl)ethylamino]-4-oxobutanoic acid
DMIE039	CA	CAS 126631-86-5

DMY7KHW	ID	DMY7KHW
DMY7KHW	DN	SC-49992
DMY7KHW	HS	Terminated
DMY7KHW	SN	(8-Guanidinooctanoyl)-L-aspartyl-L-phenylalanine
DMY7KHW	PC	9804438
DMY7KHW	MW	463.5
DMY7KHW	FM	C22H33N5O6
DMY7KHW	IC	InChI=1S/C22H33N5O6/c23-22(24)25-12-8-3-1-2-7-11-18(28)26-16(14-19(29)30)20(31)27-17(21(32)33)13-15-9-5-4-6-10-15/h4-6,9-10,16-17H,1-3,7-8,11-14H2,(H,26,28)(H,27,31)(H,29,30)(H,32,33)(H4,23,24,25)/t16-,17-/m0/s1
DMY7KHW	CS	C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCN=C(N)N
DMY7KHW	IK	PLSJXKVBQIPFJY-IRXDYDNUSA-N
DMY7KHW	IU	(3S)-4-[[(1S)-1-carboxy-2-phenylethyl]amino]-3-[8-(diaminomethylideneamino)octanoylamino]-4-oxobutanoic acid
DMY7KHW	DE	Arterial thrombosis

DM8UDSF	ID	DM8UDSF
DM8UDSF	DN	SC-50560
DM8UDSF	HS	Terminated
DM8UDSF	SN	SC-50560; CHEMBL85595; SCHEMBL8294789; SCHEMBL6444071; BDBM50046078; L006223; 5-[4''-(3,5-Dibutyl-[1,2,4]triazol-1-ylmethyl)-biphenyl-2-yl]-2H-tetrazole
DM8UDSF	DT	Small molecular drug
DM8UDSF	PC	9931685
DM8UDSF	MW	415.5
DM8UDSF	FM	C24H29N7
DM8UDSF	IC	InChI=1S/C24H29N7/c1-3-5-11-22-25-23(12-6-4-2)31(28-22)17-18-13-15-19(16-14-18)20-9-7-8-10-21(20)24-26-29-30-27-24/h7-10,13-16H,3-6,11-12,17H2,1-2H3,(H,26,27,29,30)
DM8UDSF	CS	CCCCC1=NN(C(=N1)CCCC)CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4
DM8UDSF	IK	LRZYXWIVLLNUPK-UHFFFAOYSA-N
DM8UDSF	IU	5-[2-[4-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]phenyl]phenyl]-2H-tetrazole

DMI0QZ3	ID	DMI0QZ3
DMI0QZ3	DN	SC-51146
DMI0QZ3	HS	Terminated
DMI0QZ3	SN	141059-52-1; CHEMBL328492; 2H-1-Benzopyran-2-propanoicacid,7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-; ACMC-1C1U2; 7-(3-(2-(Cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid; AC1L52J5; SCHEMBL1890696; CTK4C2448; BDBM50052017; 2H-1-Benzopyran-2-propanoic acid, 7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-p
DMI0QZ3	DT	Small molecular drug
DMI0QZ3	PC	196905
DMI0QZ3	MW	539.7
DMI0QZ3	FM	C31H41NO7
DMI0QZ3	IC	InChI=1S/C31H41NO7/c1-4-6-23-26(14-10-21-9-11-22(39-29(21)23)12-16-28(33)34)37-17-5-18-38-27-15-13-24(31(35)32-2)30(36-3)25(27)19-20-7-8-20/h10,13-15,20,22H,4-9,11-12,16-19H2,1-3H3,(H,32,35)(H,33,34)
DMI0QZ3	CS	CCCC1=C(C=CC2=C1OC(CC2)CCC(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)NC)OC)CC4CC4
DMI0QZ3	IK	YWYUQSGYKDEAMJ-UHFFFAOYSA-N
DMI0QZ3	IU	3-[7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid
DMI0QZ3	CA	CAS 141059-52-1

DMB26LO	ID	DMB26LO
DMB26LO	DN	SC-51316
DMB26LO	HS	Terminated
DMB26LO	SN	SC-51316; SC 51316; 133690-62-7; CHEMBL87778; 2,5-Dibutyl-2,4-dihydro-4-((2-(1H-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)-3H-1,2,4-triazol-3-one; ACMC-20mv1m; AC1L2ZJY; SCHEMBL7398914; CTK4B8747; DTXSID30158321; BDBM50044355; 2,5-Dibutyl-2,4-dihydro-4-((2-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4'-yl)methyl)-3H-1,2,4-triazol-3-one; L008865; 2,5-Dibutyl-4-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-[1,2,4]triazolidin-3-one; 2,5-dibutyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,2,4-triazol-3-one
DMB26LO	CP	GD Searle & Co
DMB26LO	DT	Small molecular drug
DMB26LO	PC	131654
DMB26LO	MW	431.5
DMB26LO	FM	C24H29N7O
DMB26LO	IC	InChI=1S/C24H29N7O/c1-3-5-11-22-27-31(16-6-4-2)24(32)30(22)17-18-12-14-19(15-13-18)20-9-7-8-10-21(20)23-25-28-29-26-23/h7-10,12-15H,3-6,11,16-17H2,1-2H3,(H,25,26,28,29)
DMB26LO	CS	CCCCC1=NN(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CCCC
DMB26LO	IK	STODEQQYGGTXOS-UHFFFAOYSA-N
DMB26LO	IU	2,5-dibutyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,2,4-triazol-3-one
DMB26LO	CA	CAS 133690-62-7
DMB26LO	DE	Hypertension

DMWO107	ID	DMWO107
DMWO107	DN	SC-51895
DMWO107	HS	Terminated
DMWO107	SN	SC-51895; CHEMBL9714; SCHEMBL6568041; BDBM50281822; L006787
DMWO107	DT	Small molecular drug
DMWO107	PC	9954408
DMWO107	MW	430.5
DMWO107	FM	C25H30N6O
DMWO107	IC	InChI=1S/C25H30N6O/c1-3-5-9-21-18-30(16-6-4-2)25(32)31(21)17-19-12-14-20(15-13-19)22-10-7-8-11-23(22)24-26-28-29-27-24/h7-8,10-15,18H,3-6,9,16-17H2,1-2H3,(H,26,27,28,29)
DMWO107	CS	CCCCC1=CN(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CCCC
DMWO107	IK	JYOGXGMOSXSRMV-UHFFFAOYSA-N
DMWO107	IU	1,4-dibutyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-2-one

DMKWJ59	ID	DMKWJ59
DMKWJ59	DN	SC-52150
DMKWJ59	HS	Terminated
DMKWJ59	SN	IDDB4363
DMKWJ59	CP	GD Searle & Co
DMKWJ59	PC	2734614
DMKWJ59	MW	173.41
DMKWJ59	FM	C6H9BClNO2
DMKWJ59	IC	InChI=1S/C6H8BNO2.ClH/c8-6-3-1-5(2-4-6)7(9)10;/h1-4,9-10H,8H2;1H
DMKWJ59	CS	B(C1=CC=C(C=C1)N)(O)O.Cl
DMKWJ59	IK	QBYGJJSFMOVYOA-UHFFFAOYSA-N
DMKWJ59	IU	(4-aminophenyl)boronic acid;hydrochloride
DMKWJ59	CA	CAS 80460-73-7
DMKWJ59	DE	Vomiting

DM2O8SF	ID	DM2O8SF
DM2O8SF	DN	SC-53116
DM2O8SF	HS	Terminated
DM2O8SF	SN	SC-53116; SC 53116; CHEMBL34291; SC53116; 4-amino-5-chloro-N-[[(1S,8S)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl]-2-methoxybenzamide; 141196-99-8; PDSP2_001604; AC1L30TD; GTPL238; SCHEMBL678624; ZINC3790774; BDBM50005833; SC49518; 4-Amino-5-chloro-N-((hexahydro-1H-pyrrolizin-1-yl)methyl)-2-methoxybenzamide hydrochloride; 4-Amino-5-chloro-N-((hexahydro-1H-pyrrolizin-1-yl)methyl)-2-methoxybenzamide (1S-cis)-; (1S-cis)-4-Amino-5-chloro-N-((hexahydro-1H-pyrrolizin-1-yl)methyl)-2-methoxybenzamide; NCGC00408826-01
DM2O8SF	DT	Small molecular drug
DM2O8SF	PC	132337
DM2O8SF	MW	323.82
DM2O8SF	FM	C16H22ClN3O2
DM2O8SF	IC	InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-9-10-4-6-20-5-2-3-14(10)20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14-/m0/s1
DM2O8SF	CS	COC1=CC(=C(C=C1C(=O)NC[C@@H]2CCN3[C@H]2CCC3)Cl)N
DM2O8SF	IK	GAYSOZKZPOVDSB-HZMBPMFUSA-N
DM2O8SF	IU	4-amino-5-chloro-N-[[(1S,8S)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl]-2-methoxybenzamide
DM2O8SF	CA	CAS 141196-99-8
DM2O8SF	DE	Gastric motility disorder

DMSKHGQ	ID	DMSKHGQ
DMSKHGQ	DN	SC-53228
DMSKHGQ	HS	Terminated
DMSKHGQ	SN	SC 53228; CHEMBL419948; 153633-01-3; AC1L4BTY; SCHEMBL1447495; DTXSID40165384; BDBM50037390; 3-[(2S)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid; 3-{(S)-7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoyl-phenoxy)-propoxy]-8-propyl-chroman-2-yl}-propionic acid; 2H-1-Benzopyran-2-propanoic acid, 7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-, (S)-
DMSKHGQ	DT	Small molecular drug
DMSKHGQ	PC	204058
DMSKHGQ	MW	539.7
DMSKHGQ	FM	C31H41NO7
DMSKHGQ	IC	InChI=1S/C31H41NO7/c1-4-6-23-26(14-10-21-9-11-22(39-29(21)23)12-16-28(33)34)37-17-5-18-38-27-15-13-24(31(35)32-2)30(36-3)25(27)19-20-7-8-20/h10,13-15,20,22H,4-9,11-12,16-19H2,1-3H3,(H,32,35)(H,33,34)/t22-/m0/s1
DMSKHGQ	CS	CCCC1=C(C=CC2=C1O[C@@H](CC2)CCC(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)NC)OC)CC4CC4
DMSKHGQ	IK	YWYUQSGYKDEAMJ-QFIPXVFZSA-N
DMSKHGQ	IU	3-[(2S)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid
DMSKHGQ	CA	CAS 153633-01-3
DMSKHGQ	DE	Asthma

DM25MUA	ID	DM25MUA
DM25MUA	DN	SC-56525
DM25MUA	HS	Terminated
DM25MUA	CP	GD Searle & Co
DM25MUA	PC	53416685
DM25MUA	MW	356.24
DM25MUA	FM	C14H14BrNO3S
DM25MUA	IC	InChI=1S/C14H14BrNO3S/c1-10-6-5-8-12(19-2)14(10)16-20(17,18)13-9-4-3-7-11(13)15/h3-9,16H,1-2H3
DM25MUA	CS	CC1=C(C(=CC=C1)OC)NS(=O)(=O)C2=CC=CC=C2Br
DM25MUA	IK	ZENBMAKLSOHDBZ-UHFFFAOYSA-N
DM25MUA	IU	2-bromo-N-(2-methoxy-6-methylphenyl)benzenesulfonamide
DM25MUA	DE	Hypertension

DM874YU	ID	DM874YU
DM874YU	DN	SC-58125
DM874YU	HS	Terminated
DM874YU	SN	SC-58125; 162054-19-5; SC 58125; C17H12F4N2O2S; 1-((4-Methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole; CHEBI:8983; CHEMBL274990; 5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazole; 1-[(4-METHYLSULFONYL)PHENYL]-3-TRIFLUOROMETHYL-5-(4-FLUOROPHENYL)PYRAZOLE; 5-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole; 5-(4-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole; 1H-Pyrazole, 5-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-3-(tr
DM874YU	DT	Small molecular drug
DM874YU	PC	115239
DM874YU	MW	384.3
DM874YU	FM	C17H12F4N2O2S
DM874YU	IC	InChI=1S/C17H12F4N2O2S/c1-26(24,25)14-8-6-13(7-9-14)23-15(10-16(22-23)17(19,20)21)11-2-4-12(18)5-3-11/h2-10H,1H3
DM874YU	CS	CS(=O)(=O)C1=CC=C(C=C1)N2C(=CC(=N2)C(F)(F)F)C3=CC=C(C=C3)F
DM874YU	IK	JHBIMJKLBUMNAU-UHFFFAOYSA-N
DM874YU	IU	5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazole
DM874YU	CA	CAS 162054-19-5
DM874YU	CB	CHEBI:8983

DMVGK24	ID	DMVGK24
DMVGK24	DN	SC-58451
DMVGK24	HS	Terminated
DMVGK24	SN	SC-58451; SC58451; CHEMBL92154; SCHEMBL215231; ZINC6366; VZCIAZMKVAJRCL-UHFFFAOYSA-N; HY-U00239; BDBM50049041; CS-7410; 168433-84-9; 5-(4-Fluoro-phenyl)-6-(4-methanesulfonyl-phenyl)-spiro[2.4]hept-5-ene
DMVGK24	DT	Small molecular drug
DMVGK24	PC	9851770
DMVGK24	MW	342.4
DMVGK24	FM	C20H19FO2S
DMVGK24	IC	InChI=1S/C20H19FO2S/c1-24(22,23)17-8-4-15(5-9-17)19-13-20(10-11-20)12-18(19)14-2-6-16(21)7-3-14/h2-9H,10-13H2,1H3
DMVGK24	CS	CS(=O)(=O)C1=CC=C(C=C1)C2=C(CC3(C2)CC3)C4=CC=C(C=C4)F
DMVGK24	IK	VZCIAZMKVAJRCL-UHFFFAOYSA-N
DMVGK24	IU	5-(4-fluorophenyl)-6-(4-methylsulfonylphenyl)spiro[2.4]hept-5-ene

DMW9H4A	ID	DMW9H4A
DMW9H4A	DN	SCH 50911
DMW9H4A	HS	Terminated
DMW9H4A	SN	SCH 50911; 160415-07-6; UNII-13OB0KEU61; 733717-87-8; 13OB0KEU61; SCH50911; (2S)-(+)-5,5-Dimethyl-2-morpholineacetic acid; SCH-50911; NCGC00024915-02; [(2s)-5,5-Dimethylmorpholin-2-Yl]acetic Acid; DSSTox_RID_81045; DSSTox_CID_25670; DSSTox_GSID_45670; 2-[(2S)-5,5-dimethylmorpholin-2-yl]acetic acid; SCH-50911 free base; CAS-160415-07-6; Spectrum_001764; SCH 50911 free base; AC1NSKM9; Biomol-NT_000243; 2-Morpholineacetic acid, 5,5-dimethyl-, (2S)-; KBioSS_002245; SCHEMBL340881; BPBio1_000749; GTPL1075; ZINC6164; CHEMBL1895916
DMW9H4A	DT	Small molecular drug
DMW9H4A	PC	5311429
DMW9H4A	MW	173.21
DMW9H4A	FM	C8H15NO3
DMW9H4A	IC	InChI=1S/C8H15NO3/c1-8(2)5-12-6(4-9-8)3-7(10)11/h6,9H,3-5H2,1-2H3,(H,10,11)/t6-/m0/s1
DMW9H4A	CS	CC1(CO[C@H](CN1)CC(=O)O)C
DMW9H4A	IK	SEYCKMQSPUVYEF-LURJTMIESA-N
DMW9H4A	IU	2-[(2S)-5,5-dimethylmorpholin-2-yl]acetic acid
DMW9H4A	CA	CAS 733717-87-8
DMW9H4A	DE	Absence seizure

DM037SB	ID	DM037SB
DM037SB	DN	Sch-207758
DM037SB	HS	Terminated
DM037SB	CP	Schering-Plough Corp
DM037SB	DE	Solid tumour/cancer

DMXBJCY	ID	DMXBJCY
DMXBJCY	DN	Sch-40120
DMXBJCY	HS	Terminated
DMXBJCY	SN	AC1MIW6C; SCHEMBL9535601; 10-(3-Chlorophenyl)-6,8,9,10-tetrahydrobenzo(b)(1,8)-naphthyridine-5(7H)-one; 113077-44-4; 5-(3-chlorophenyl)-7,8,9,10-tetrahydrobenzo[c][1,8]naphthyridin-6-one; Benzo(c)(1,8)naphthyridin-6(5H)-one, 5-(3-chlorophenyl)-7,8,9,10-tetrahydro-
DMXBJCY	CP	Schering-Plough Corp
DMXBJCY	DT	Small molecular drug
DMXBJCY	PC	184227
DMXBJCY	MW	310.8
DMXBJCY	FM	C18H15ClN2O
DMXBJCY	IC	InChI=1S/C18H15ClN2O/c19-12-5-3-6-13(11-12)21-16-9-2-1-7-14(16)17(22)15-8-4-10-20-18(15)21/h3-6,8,10-11H,1-2,7,9H2
DMXBJCY	CS	C1CCC2=C(C1)C(=O)C3=C(N2C4=CC(=CC=C4)Cl)N=CC=C3
DMXBJCY	IK	SLPWZBSWUHLVRY-UHFFFAOYSA-N
DMXBJCY	IU	10-(3-chlorophenyl)-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridin-5-one
DMXBJCY	CA	CAS 110545-79-4
DMXBJCY	DE	Pruritus

DM3G5IB	ID	DM3G5IB
DM3G5IB	DN	Sch-40338
DM3G5IB	HS	Terminated
DM3G5IB	SN	CHEMBL326821; AIESXMXVDNOKQF-UHFFFAOYSA-N; GTPL1854; SCHEMBL8877591; BDBM50073173; SCH 40338; 1-[4-(8-Chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-piperazin-1-yl]-ethanone; 8-CHLORO-11-(1-ACETYL-4-PIPERAZINYL)-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE
DM3G5IB	CP	Schering-Plough Corp
DM3G5IB	DT	Small molecular drug
DM3G5IB	PC	9950564
DM3G5IB	MW	355.9
DM3G5IB	FM	C20H22ClN3O
DM3G5IB	IC	InChI=1S/C20H22ClN3O/c1-14(25)23-9-11-24(12-10-23)20-18-7-6-17(21)13-16(18)5-4-15-3-2-8-22-19(15)20/h2-3,6-8,13,20H,4-5,9-12H2,1H3
DM3G5IB	CS	CC(=O)N1CCN(CC1)C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl
DM3G5IB	IK	AIESXMXVDNOKQF-UHFFFAOYSA-N
DM3G5IB	IU	1-[4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)piperazin-1-yl]ethanone
DM3G5IB	DE	Allergy

DMUL4VX	ID	DMUL4VX
DMUL4VX	DN	SCH-44342
DMUL4VX	HS	Terminated
DMUL4VX	SN	SCH-44342; CHEMBL289404; SCH 44342; sch44342; SCHEMBL2732013; BDBM14454; 1-(4-pyridylacetyl)-4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine
DMUL4VX	DT	Small molecular drug
DMUL4VX	PC	9845545
DMUL4VX	MW	429.9
DMUL4VX	FM	C26H24ClN3O
DMUL4VX	IC	InChI=1S/C26H24ClN3O/c27-22-5-6-23-21(17-22)4-3-20-2-1-11-29-26(20)25(23)19-9-14-30(15-10-19)24(31)16-18-7-12-28-13-8-18/h1-2,5-8,11-13,17H,3-4,9-10,14-16H2
DMUL4VX	CS	C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)C(=O)CC4=CC=NC=C4)C5=C1C=CC=N5
DMUL4VX	IK	KIFXOXSGYMUANJ-UHFFFAOYSA-N
DMUL4VX	IU	1-[4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidin-1-yl]-2-pyridin-4-ylethanone

DME9Q3V	ID	DME9Q3V
DME9Q3V	DN	Sch-45752
DME9Q3V	HS	Terminated
DME9Q3V	SN	Cephalochromin; MLS000876993; CHEMBL463175; NSC627953; NSC201419; 25908-26-3; SMR000440611; cefalochromin; 5,6,8-trihydroxy-2-methyl-9-(5,6,8-trihydroxy-2-methyl-4-oxo-2,3-dihydrobenzo[g]chromen-9-yl)-2,3-dihydrobenzo[g]chromen-4-one; Sch 45752; AC1Q6DTF; AC1L4N2K; SCHEMBL1111561; MEGxm0_000312; cid_160115; ACon0_000585; ACon1_000126; MolPort-001-739-590; HMS2270H11; BDBM50269745; NSC-201419; NSC-627953; MCULE-6609850631; NCGC00180856-01; SR-01000758207; SR-01000758207-2; CEPHALOCHROMIN
DME9Q3V	CP	Schering-Plough Corp
DME9Q3V	DT	Small molecular drug
DME9Q3V	PC	160115
DME9Q3V	MW	518.5
DME9Q3V	FM	C28H22O10
DME9Q3V	IC	InChI=1S/C28H22O10/c1-9-3-13(29)25-19(37-9)5-11-21(15(31)7-17(33)23(11)27(25)35)22-12-6-20-26(14(30)4-10(2)38-20)28(36)24(12)18(34)8-16(22)32/h5-10,31-36H,3-4H2,1-2H3
DME9Q3V	CS	CC1CC(=O)C2=C(O1)C=C3C(=C2O)C(=CC(=C3C4=C(C=C(C5=C(C6=C(C=C54)OC(CC6=O)C)O)O)O)O)O
DME9Q3V	IK	JGQBYBXYRUCBQY-UHFFFAOYSA-N
DME9Q3V	IU	5,6,8-trihydroxy-2-methyl-9-(5,6,8-trihydroxy-2-methyl-4-oxo-2,3-dihydrobenzo[g]chromen-9-yl)-2,3-dihydrobenzo[g]chromen-4-one
DME9Q3V	CA	CAS 25908-26-3
DME9Q3V	DE	Asthma

DMEWLZ7	ID	DMEWLZ7
DMEWLZ7	DN	SCH-54470
DMEWLZ7	HS	Terminated
DMEWLZ7	SN	CHEMBL43370; SCH-54470; BDBM50287430; (S)-2-[(1-{[(R)-1-((S)-6-Amino-2-methanesulfonylamino-hexanoylamino)-2-phenyl-ethyl]-hydroxy-phosphinoylmethyl}-cyclopentanecarbonyl)-amino]-3-(1H-indol-3-yl)-propionic acid
DMEWLZ7	DT	Small molecular drug
DMEWLZ7	PC	9810328
DMEWLZ7	MW	703.8
DMEWLZ7	FM	C33H46N5O8PS
DMEWLZ7	IC	InChI=1S/C33H46N5O8PS/c1-48(45,46)38-27(15-7-10-18-34)30(39)37-29(19-23-11-3-2-4-12-23)47(43,44)22-33(16-8-9-17-33)32(42)36-28(31(40)41)20-24-21-35-26-14-6-5-13-25(24)26/h2-6,11-14,21,27-29,35,38H,7-10,15-20,22,34H2,1H3,(H,36,42)(H,37,39)(H,40,41)(H,43,44)/t27-,28-,29+/m0/s1
DMEWLZ7	CS	CS(=O)(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)P(=O)(CC2(CCCC2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)O
DMEWLZ7	IK	UBQFBYMIHFXWBF-YTCPBCGMSA-N
DMEWLZ7	IU	(2S)-2-[[1-[[[(1R)-1-[[(2S)-6-amino-2-(methanesulfonamido)hexanoyl]amino]-2-phenylethyl]-hydroxyphosphoryl]methyl]cyclopentanecarbonyl]amino]-3-(1H-indol-3-yl)propanoic acid

DMGCYPE	ID	DMGCYPE
DMGCYPE	DN	Sch-57790
DMGCYPE	HS	Terminated
DMGCYPE	SN	SCH-57790; CHEMBL73341; SCH57790; GTPL350; SCHEMBL194921; SCH 57790; BDBM50092317; 2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile; L018294
DMGCYPE	CP	Schering-Plough Corp
DMGCYPE	DT	Small molecular drug
DMGCYPE	PC	9867750
DMGCYPE	MW	437.6
DMGCYPE	FM	C25H31N3O2S
DMGCYPE	IC	InChI=1S/C25H31N3O2S/c1-30-22-9-13-24(14-10-22)31(29)23-11-7-20(8-12-23)25(19-26)28-17-15-27(16-18-28)21-5-3-2-4-6-21/h7-14,21,25H,2-6,15-18H2,1H3
DMGCYPE	CS	COC1=CC=C(C=C1)S(=O)C2=CC=C(C=C2)C(C#N)N3CCN(CC3)C4CCCCC4
DMGCYPE	IK	BFELQLHLUNQIHL-UHFFFAOYSA-N
DMGCYPE	IU	2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile
DMGCYPE	DE	Alzheimer disease

DMFZNUA	ID	DMFZNUA
DMFZNUA	DN	SCR-44001
DMFZNUA	HS	Terminated
DMFZNUA	SN	MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget
DMFZNUA	CP	BioImage A/S
DMFZNUA	DE	Solid tumour/cancer

DMPUVFH	ID	DMPUVFH
DMPUVFH	DN	SDZ 216-525
DMPUVFH	HS	Terminated
DMPUVFH	SN	Sdz 216-525; Sdz-216-525; 141533-35-9; methyl 4-[4-[4-(1,1,3-trioxo-1,2-benzothiazol-2-yl)butyl]piperazin-1-yl]-1H-indole-2-carboxylate; SDZ216-525; AC1MI2WY; GTPL78; SCHEMBL1041165; BDBM82367; DTXSID10161757; PDSP2_000563; PDSP1_000565; SDZ-216525; SDZ 216,525; Methyl 4-(4-(4-(1,1,3-trioxo-2H-1,2-benzoisothiazol-2-yl)butyl)-1-piperazinyl)-1H-indole-2-carboxylate; CAS_141533-35-9; L006004; 1H-Indole-2-carboxylic acid, 4-(4-(4-(3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl)-1-piperazinyl)-, methyl ester, S,S-dioxide
DMPUVFH	DT	Small molecular drug
DMPUVFH	PC	3037456
DMPUVFH	MW	496.6
DMPUVFH	FM	C25H28N4O5S
DMPUVFH	IC	InChI=1S/C25H28N4O5S/c1-34-25(31)21-17-19-20(26-21)8-6-9-22(19)28-15-13-27(14-16-28)11-4-5-12-29-24(30)18-7-2-3-10-23(18)35(29,32)33/h2-3,6-10,17,26H,4-5,11-16H2,1H3
DMPUVFH	CS	COC(=O)C1=CC2=C(N1)C=CC=C2N3CCN(CC3)CCCCN4C(=O)C5=CC=CC=C5S4(=O)=O
DMPUVFH	IK	LPPRLWFUMJHAKF-UHFFFAOYSA-N
DMPUVFH	IU	methyl 4-[4-[4-(1,1,3-trioxo-1,2-benzothiazol-2-yl)butyl]piperazin-1-yl]-1H-indole-2-carboxylate
DMPUVFH	CA	CAS 141533-35-9

DMY1KE8	ID	DMY1KE8
DMY1KE8	DN	SDZ-224-015
DMY1KE8	HS	Terminated
DMY1KE8	SN	VE-13045
DMY1KE8	CP	Sandoz Research Institute
DMY1KE8	PC	101925102
DMY1KE8	MW	624.5
DMY1KE8	FM	C28H31Cl2N3O9
DMY1KE8	IC	InChI=1S/C28H31Cl2N3O9/c1-16(2)23(32-28(39)42-14-18-8-5-4-6-9-18)25(37)31-17(3)24(36)33-26(40-13-12-34)21(35)15-41-27(38)22-19(29)10-7-11-20(22)30/h4-12,16-17,23,26H,13-15H2,1-3H3,(H,31,37)(H,32,39)(H,33,36)/t17-,23-,26-/m0/s1
DMY1KE8	CS	C[C@@H](C(=O)N[C@H](C(=O)COC(=O)C1=C(C=CC=C1Cl)Cl)OCC=O)NC(=O)[C@H](C(C)C)NC(=O)OCC2=CC=CC=C2
DMY1KE8	IK	ABGURXXQCVTOBD-RUJAXMSRSA-N
DMY1KE8	IU	[(3S)-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-2-oxo-3-(2-oxoethoxy)propyl] 2,6-dichlorobenzoate
DMY1KE8	DE	Rheumatoid arthritis

DMPZLKC	ID	DMPZLKC
DMPZLKC	DN	SDZ-249482
DMPZLKC	HS	Terminated
DMPZLKC	SN	IDDB15566
DMPZLKC	CP	Novartis AG
DMPZLKC	DE	Pain

DMAT657	ID	DMAT657
DMAT657	DN	SDZ-62-826
DMAT657	HS	Terminated
DMAT657	CP	Novartis AG
DMAT657	PC	1393
DMAT657	MW	524.7
DMAT657	FM	C27H59NO6P+
DMAT657	IC	InChI=1S/C27H58NO6P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-23-32-25-27(31-5)26-34-35(29,30)33-24-22-28(2,3)4/h27H,6-26H2,1-5H3/p+1
DMAT657	CS	CCCCCCCCCCCCCCCCCCOCC(COP(=O)(O)OCC[N+](C)(C)C)OC
DMAT657	IK	MHFRGQHAERHWKZ-UHFFFAOYSA-O
DMAT657	IU	2-[hydroxy-(2-methoxy-3-octadecoxypropoxy)phosphoryl]oxyethyl-trimethylazanium
DMAT657	DE	Solid tumour/cancer

DM2CBTU	ID	DM2CBTU
DM2CBTU	DN	SDZ-64-412
DM2CBTU	HS	Terminated
DM2CBTU	SN	SDZ-64-412; PAF-AN-1; CHEMBL449395; 5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline; SDZ-64412; 115622-31-6; 5-{4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl}-2,3-dihydroimidazo[2,1-a]isoquinoline; AC1L4M0I; SCHEMBL9118339; GTPL1855; CTK6J7710; BDBM50041921; HY-U00040; CS-7323; L024111
DM2CBTU	DT	Small molecular drug
DM2CBTU	PC	159547
DM2CBTU	MW	440.5
DM2CBTU	FM	C28H28N2O3
DM2CBTU	IC	InChI=1S/C28H28N2O3/c1-31-25-16-20(17-26(32-2)27(25)33-3)9-8-19-10-12-21(13-11-19)24-18-22-6-4-5-7-23(22)28-29-14-15-30(24)28/h4-7,10-13,16-18H,8-9,14-15H2,1-3H3
DM2CBTU	CS	COC1=CC(=CC(=C1OC)OC)CCC2=CC=C(C=C2)C3=CC4=CC=CC=C4C5=NCCN35
DM2CBTU	IK	FKRBSORUVOGNEK-UHFFFAOYSA-N
DM2CBTU	IU	5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline

DMBY6CQ	ID	DMBY6CQ
DMBY6CQ	DN	SDZ-87-469
DMBY6CQ	HS	Terminated
DMBY6CQ	SN	SDZ-87-469; AC1OCEZP; CHEMBL328466; SCHEMBL10689408; SDZ-87469
DMBY6CQ	CP	Novartis AG
DMBY6CQ	DT	Small molecular drug
DMBY6CQ	PC	6918069
DMBY6CQ	MW	368.4
DMBY6CQ	FM	C19H23Cl2NS
DMBY6CQ	IC	InChI=1S/C19H22ClNS.ClH/c1-19(2,3)11-6-5-7-12-21(4)13-15-9-8-10-16-17(20)14-22-18(15)16;/h5,7-10,14H,12-13H2,1-4H3;1H/b7-5+;
DMBY6CQ	CS	CC(C)(C)C#C/C=C/CN(C)CC1=C2C(=CC=C1)C(=CS2)Cl.Cl
DMBY6CQ	IK	INNKFGGCJAUIMK-GZOLSCHFSA-N
DMBY6CQ	IU	(E)-N-[(3-chloro-1-benzothiophen-7-yl)methyl]-N,6,6-trimethylhept-2-en-4-yn-1-amine;hydrochloride
DMBY6CQ	DE	Coronary artery disease

DMN5IY7	ID	DMN5IY7
DMN5IY7	DN	SDZ-ICM-567
DMN5IY7	HS	Terminated
DMN5IY7	SN	5-HT3 antagonist, Novartis
DMN5IY7	CP	Novartis AG
DMN5IY7	DT	Small molecular drug
DMN5IY7	PC	9972931
DMN5IY7	MW	314.4
DMN5IY7	FM	C18H22N2O3
DMN5IY7	IC	InChI=1S/C18H22N2O3/c1-20-11-6-7-12(20)9-13(8-11)23-18(21)15-10-19-17-14(15)4-3-5-16(17)22-2/h3-5,10-13,19H,6-9H2,1-2H3/t11-,12+,13?
DMN5IY7	CS	CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=C3C=CC=C4OC
DMN5IY7	IK	GMKZFWHCKJSRHX-FUNVUKJBSA-N
DMN5IY7	IU	[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 7-methoxy-1H-indole-3-carboxylate
DMN5IY7	CA	CAS 143207-25-4
DMN5IY7	DE	Anxiety disorder

DMSZJUM	ID	DMSZJUM
DMSZJUM	DN	SDZ-ISQ-844
DMSZJUM	HS	Terminated
DMSZJUM	SN	143526-87-8; Sdz isq 844; Sdz-isq-844; SDZ ISQ-844; SCHEMBL7298437; AC1L317P; CTK4C3695; 3-Isoquinolinemethanol,1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (3S)-; AKOS030566039; 6,7-Dimethoxy-1-(3,4-dimethoxyphenyl)-3-hydroxymethyl-3,4-dihydroisoquinoline; (S)-1-(3,5-Dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-3-isoquinolinemethanol; 3-Isoquinolinemethanol, 1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (S)-
DMSZJUM	CP	Novartis AG
DMSZJUM	DT	Small molecular drug
DMSZJUM	PC	132565
DMSZJUM	MW	357.4
DMSZJUM	FM	C20H23NO5
DMSZJUM	IC	InChI=1S/C20H23NO5/c1-23-15-6-13(7-16(9-15)24-2)20-17-10-19(26-4)18(25-3)8-12(17)5-14(11-22)21-20/h6-10,14,22H,5,11H2,1-4H3/t14-/m0/s1
DMSZJUM	CS	COC1=CC(=CC(=C1)C2=N[C@@H](CC3=CC(=C(C=C32)OC)OC)CO)OC
DMSZJUM	IK	GHBUMWHHZFGRDI-AWEZNQCLSA-N
DMSZJUM	IU	[(3S)-1-(3,5-dimethoxyphenyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-3-yl]methanol
DMSZJUM	CA	CAS 143526-87-8
DMSZJUM	DE	Asthma

DMKCXBJ	ID	DMKCXBJ
DMKCXBJ	DN	SDZ-MTH-958
DMKCXBJ	HS	Terminated
DMKCXBJ	SN	IDDB8852
DMKCXBJ	CP	Novartis AG
DMKCXBJ	DE	Artery stenosis

DM48MCL	ID	DM48MCL
DM48MCL	DN	SDZ-PSD-958
DM48MCL	HS	Terminated
DM48MCL	CP	Sandoz Pharma Ltd
DM48MCL	PC	9906075
DM48MCL	MW	342.9
DM48MCL	FM	C20H23ClN2O
DM48MCL	IC	InChI=1S/C20H23ClN2O/c1-13-10-15(21)6-7-17(13)23-9-8-22(2)18-11-14-4-3-5-20(24)16(14)12-19(18)23/h3-7,10,18-19,24H,8-9,11-12H2,1-2H3/t18-,19-/m1/s1
DM48MCL	CS	CC1=C(C=CC(=C1)Cl)N2CCN([C@H]3[C@H]2CC4=C(C3)C=CC=C4O)C
DM48MCL	IK	VCFAZLUWIBQVRD-RTBURBONSA-N
DM48MCL	IU	(4aR,10aR)-4-(4-chloro-2-methylphenyl)-1-methyl-2,3,4a,5,10,10a-hexahydrobenzo[g]quinoxalin-6-ol
DM48MCL	DE	Psychiatric disorder

DMXHW91	ID	DMXHW91
DMXHW91	DN	SDZ-SER-082
DMXHW91	HS	Terminated
DMXHW91	SN	SDZ SER-082; Biomol-NT_000136; GTPL195; CHEMBL316069; BPBio1_000024; SCHEMBL13073064; BDBM85099; ZINC16077; SER-082; CAS_141474-54-6; BRD-K31339597-051-01-2
DMXHW91	CP	Novartis AG
DMXHW91	DT	Small molecular drug
DMXHW91	PC	9859407
DMXHW91	MW	228.33
DMXHW91	FM	C15H20N2
DMXHW91	IC	InChI=1S/C15H20N2/c1-16-7-5-12-9-17-8-6-11-3-2-4-13(15(11)17)14(12)10-16/h2-4,12,14H,5-10H2,1H3/t12-,14-/m1/s1
DMXHW91	CS	CN1CC[C@@H]2CN3CCC4=C3C(=CC=C4)[C@@H]2C1
DMXHW91	IK	YASBOGFWAMXINH-TZMCWYRMSA-N
DMXHW91	IU	(2R,7S)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene
DMXHW91	CA	CAS 141474-54-6
DMXHW91	DE	Neurological disorder

DM4ESAP	ID	DM4ESAP
DM4ESAP	DN	Selenotifen
DM4ESAP	HS	Terminated
DM4ESAP	SN	BN-52256
DM4ESAP	CP	Ipsen
DM4ESAP	DE	Asthma

DMXRU72	ID	DMXRU72
DMXRU72	DN	SEP-227900
DMXRU72	HS	Terminated
DMXRU72	CP	Sunovion Pharmaceuticals Inc
DMXRU72	DE	Cognitive impairment

DMTBWU1	ID	DMTBWU1
DMTBWU1	DN	Seridopidine
DMTBWU1	HS	Terminated
DMTBWU1	SN	ACR-343
DMTBWU1	CP	A Carlsson Research AB
DMTBWU1	DT	Small molecular drug
DMTBWU1	PC	11572784
DMTBWU1	MW	285.38
DMTBWU1	FM	C14H20FNO2S
DMTBWU1	IC	InChI=1S/C14H20FNO2S/c1-3-16-6-4-11(5-7-16)12-8-13(15)10-14(9-12)19(2,17)18/h8-11H,3-7H2,1-2H3
DMTBWU1	CS	CCN1CCC(CC1)C2=CC(=CC(=C2)S(=O)(=O)C)F
DMTBWU1	IK	PHRDGRSMZPOCAB-UHFFFAOYSA-N
DMTBWU1	IU	1-ethyl-4-(3-fluoro-5-methylsulfonylphenyl)piperidine
DMTBWU1	CA	CAS 883631-51-4
DMTBWU1	DE	Neurological disorder

DMT43AI	ID	DMT43AI
DMT43AI	DN	SIB-1508Y
DMT43AI	HS	Terminated
DMT43AI	SN	CHEMBL111580; 3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine; 179120-51-5; 5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine; 5-Ethynyl Nicotine; 179120-92-4; 3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine; AC1L326X; SCHEMBL1155706; BDBM86544; NUPUDYKEEJNZRG-UHFFFAOYSA-N; CHEBI:125396; NSC_6442277; CAS_192231-16-6; 3-ethynyl-5-(1-methylpyrrolidin-2-yl)-pyridine; 3-(1-Methylpyrrolidine-2-yl)-5-ethynylpyridine; A812432
DMT43AI	DT	Small molecular drug
DMT43AI	PC	3036156
DMT43AI	MW	186.25
DMT43AI	FM	C12H14N2
DMT43AI	IC	InChI=1S/C12H14N2/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2/h1,7-9,12H,4-6H2,2H3/t12-/m0/s1
DMT43AI	CS	CN1CCC[C@H]1C2=CN=CC(=C2)C#C
DMT43AI	IK	NUPUDYKEEJNZRG-LBPRGKRZSA-N
DMT43AI	IU	3-ethynyl-5-[(2S)-1-methylpyrrolidin-2-yl]pyridine
DMT43AI	CA	CAS 179120-92-4
DMT43AI	DE	Parkinson disease

DMO4WB8	ID	DMO4WB8
DMO4WB8	DN	SIB-1663
DMO4WB8	HS	Terminated
DMO4WB8	DT	Small molecular drug
DMO4WB8	PC	10198317
DMO4WB8	MW	218.29
DMO4WB8	FM	C13H18N2O
DMO4WB8	IC	InChI=1S/C13H18N2O/c1-15-6-5-9-3-4-10-7-12(16-2)14-8-11(10)13(9)15/h7-9,13H,3-6H2,1-2H3
DMO4WB8	CS	CN1CCC2C1C3=CN=C(C=C3CC2)OC
DMO4WB8	IK	MMHQNOZJLLYHKX-UHFFFAOYSA-N
DMO4WB8	IU	7-methoxy-1-methyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-h]isoquinoline

DM6MSKT	ID	DM6MSKT
DM6MSKT	DN	SIB-1765F
DM6MSKT	HS	Terminated
DM6MSKT	SN	SIB 1765F; Pyridine, 3-ethynyl-5-(1-methyl-2-pyrrolidinyl)-, (E)-2-butenedioate (1:1); Pyridine, 3-ethynyl-5-(1-methyl-2-pyrrolidinyl)-, (2E)-2-butenedioate (1:1); C12H14N2.C4H4O4; AC1O5WWQ; SCHEMBL194945; SCHEMBL3099334; SIB 1508Y, fumarate, E-isomer; 179120-52-6; LS-173698
DM6MSKT	DT	Small molecular drug
DM6MSKT	PC	6442277
DM6MSKT	MW	302.32
DM6MSKT	FM	C16H18N2O4
DM6MSKT	IC	InChI=1S/C12H14N2.C4H4O4/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2;5-3(6)1-2-4(7)8/h1,7-9,12H,4-6H2,2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DM6MSKT	CS	CN1CCCC1C2=CN=CC(=C2)C#C.C(=C/C(=O)O)\\C(=O)O
DM6MSKT	IK	BCPPKHPWLRPWBJ-WLHGVMLRSA-N
DM6MSKT	IU	(E)-but-2-enedioic acid;3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine
DM6MSKT	CA	CAS 179120-52-6

DM98K76	ID	DM98K76
DM98K76	DN	Siguazodan
DM98K76	HS	Terminated
DM98K76	SN	SKF-94836
DM98K76	CP	SmithKline Beecham plc
DM98K76	DT	Small molecular drug
DM98K76	PC	72124
DM98K76	MW	284.32
DM98K76	FM	C14H16N6O
DM98K76	IC	InChI=1S/C14H16N6O/c1-9-7-12(21)19-20-13(9)10-3-5-11(6-4-10)18-14(16-2)17-8-15/h3-6,9H,7H2,1-2H3,(H,19,21)(H2,16,17,18)
DM98K76	CS	CC1CC(=O)NN=C1C2=CC=C(C=C2)NC(=NC)NC#N
DM98K76	IK	NUHPODZZKHQQET-UHFFFAOYSA-N
DM98K76	IU	1-cyano-2-methyl-3-[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]guanidine
DM98K76	CA	CAS 115344-47-3
DM98K76	CB	CHEBI:91791
DM98K76	DE	Allergy

DMBZ7SF	ID	DMBZ7SF
DMBZ7SF	DN	SIM-6080
DMBZ7SF	HS	Terminated
DMBZ7SF	SN	N1,N2-Dimethyl-N1-[3,3-di(4-fluorophenyl)propyl]-N2-(3,4,5-trimethoxybenzyl)ethylenediamine
DMBZ7SF	DT	Small molecular drug
DMBZ7SF	PC	602534
DMBZ7SF	MW	498.6
DMBZ7SF	FM	C29H36F2N2O3
DMBZ7SF	IC	InChI=1S/C29H36F2N2O3/c1-32(16-17-33(2)20-21-18-27(34-3)29(36-5)28(19-21)35-4)15-14-26(22-6-10-24(30)11-7-22)23-8-12-25(31)13-9-23/h6-13,18-19,26H,14-17,20H2,1-5H3
DMBZ7SF	CS	CN(CCC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)F)CCN(C)CC3=CC(=C(C(=C3)OC)OC)OC
DMBZ7SF	IK	NOMSFNRBXCWAIE-UHFFFAOYSA-N
DMBZ7SF	IU	N-[3,3-bis(4-fluorophenyl)propyl]-N,N'-dimethyl-N'-[(3,4,5-trimethoxyphenyl)methyl]ethane-1,2-diamine
DMBZ7SF	CA	CAS 118790-68-4
DMBZ7SF	DE	Angina pectoris

DM5SBUJ	ID	DM5SBUJ
DM5SBUJ	DN	Sipoglitazar
DM5SBUJ	HS	Terminated
DM5SBUJ	SN	TAK-654
DM5SBUJ	CP	Takeda Pharmaceutical Co Ltd
DM5SBUJ	PC	9825652
DM5SBUJ	MW	463.6
DM5SBUJ	FM	C25H25N3O4S
DM5SBUJ	IC	InChI=1S/C25H25N3O4S/c1-2-31-24-20(10-13-23(29)30)15-28(27-24)14-18-8-11-22(12-9-18)32-16-21-17-33-25(26-21)19-6-4-3-5-7-19/h3-9,11-12,15,17H,2,10,13-14,16H2,1H3,(H,29,30)
DM5SBUJ	CS	CCOC1=NN(C=C1CCC(=O)O)CC2=CC=C(C=C2)OCC3=CSC(=N3)C4=CC=CC=C4
DM5SBUJ	IK	SRFCAWATPLCLMG-UHFFFAOYSA-N
DM5SBUJ	IU	3-[3-ethoxy-1-[[4-[(2-phenyl-1,3-thiazol-4-yl)methoxy]phenyl]methyl]pyrazol-4-yl]propanoic acid
DM5SBUJ	CA	CAS 342026-92-0
DM5SBUJ	DE	Diabetic complication

DMB6T7K	ID	DMB6T7K
DMB6T7K	DN	Siramesine
DMB6T7K	HS	Terminated
DMB6T7K	SN	Siramesine; 147817-50-3; Lu-28-179; UNII-3IX8CWR24V; Lu 28-179; Siramesine(Lu 28-179); 3IX8CWR24V; CHEMBL61479; 1'-(4-(1-(4-fluorophenyl)-1H-indol-3-yl)butyl)-3H-spiro[isobenzofuran-1,4'-piperidine]; Siramesine [INN]; SCHEMBL2090079; QCR-66; C30H31FN2O; EX-A355; DTXSID90163810; XWAONOGAGZNUSF-UHFFFAOYSA-N; ZINC1533883; BCP08745; 4042AH; BDBM50035105; AKOS027251054; CS-1920; API0014138; NCGC00370727-06; HY-14221; 163630-80-6; 1'-(4-(1-(p-Fluorophenyl)indol-3-yl)butyl)spiro(phthalan-1,4'-piperidine)
DMB6T7K	DT	Small molecular drug
DMB6T7K	PC	9829526
DMB6T7K	MW	454.6
DMB6T7K	FM	C30H31FN2O
DMB6T7K	IC	InChI=1S/C30H31FN2O/c31-25-12-14-26(15-13-25)33-21-23(27-9-2-4-11-29(27)33)7-5-6-18-32-19-16-30(17-20-32)28-10-3-1-8-24(28)22-34-30/h1-4,8-15,21H,5-7,16-20,22H2
DMB6T7K	CS	C1CN(CCC12C3=CC=CC=C3CO2)CCCCC4=CN(C5=CC=CC=C54)C6=CC=C(C=C6)F
DMB6T7K	IK	XWAONOGAGZNUSF-UHFFFAOYSA-N
DMB6T7K	IU	1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[1H-2-benzofuran-3,4'-piperidine]
DMB6T7K	CA	CAS 147817-50-3

DMG90YW	ID	DMG90YW
DMG90YW	DN	Siratiazem
DMG90YW	HS	Terminated
DMG90YW	SN	LR-A-113
DMG90YW	CP	Istituto Lusofarmaco D`Italia SpA
DMG90YW	DT	Small molecular drug
DMG90YW	PC	65989
DMG90YW	MW	442.6
DMG90YW	FM	C24H30N2O4S
DMG90YW	IC	InChI=1S/C24H30N2O4S/c1-16(2)25(4)14-15-26-20-8-6-7-9-21(20)31-23(22(24(26)28)30-17(3)27)18-10-12-19(29-5)13-11-18/h6-13,16,22-23H,14-15H2,1-5H3/t22-,23+/m1/s1
DMG90YW	CS	CC(C)N(C)CCN1C2=CC=CC=C2S[C@H]([C@H](C1=O)OC(=O)C)C3=CC=C(C=C3)OC
DMG90YW	IK	VVZILLNNYUUOIY-PKTZIBPZSA-N
DMG90YW	IU	[(2S,3S)-2-(4-methoxyphenyl)-5-[2-[methyl(propan-2-yl)amino]ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMG90YW	CA	CAS 138778-28-6
DMG90YW	DE	Angina pectoris

DM6X430	ID	DM6X430
DM6X430	DN	SJA-6017
DM6X430	HS	Terminated
DM6X430	SN	Calpain Inhibitor VI; SJA-6017; SJA6017; N-(4-Fluorophenylsulfonyl)-L-Valyl-L-Leucinal; CHEMBL288365; SCHEMBL1907361; ZINC1544687; BDBM50114340; J-012283; (S)-2-(4-fluorophenylsulfonamido)-3-methyl-N-((S)-4-methyl-1-oxopentan-2-yl)butanamide; (S)-2-(4-Fluoro-benzenesulfonylamino)-N-((S)-1-formyl-3-methyl-butyl)-3-methyl-butyramide
DM6X430	DT	Small molecular drug
DM6X430	PC	9885817
DM6X430	MW	372.5
DM6X430	FM	C17H25FN2O4S
DM6X430	IC	InChI=1S/C17H25FN2O4S/c1-11(2)9-14(10-21)19-17(22)16(12(3)4)20-25(23,24)15-7-5-13(18)6-8-15/h5-8,10-12,14,16,20H,9H2,1-4H3,(H,19,22)/t14-,16-/m0/s1
DM6X430	CS	CC(C)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NS(=O)(=O)C1=CC=C(C=C1)F
DM6X430	IK	WSJWUIDLGZAXID-HOCLYGCPSA-N
DM6X430	IU	(2S)-2-[(4-fluorophenyl)sulfonylamino]-3-methyl-N-[(2S)-4-methyl-1-oxopentan-2-yl]butanamide
DM6X430	CA	CAS 190274-53-4

DMRADBU	ID	DMRADBU
DMRADBU	DN	SK&F-104078
DMRADBU	HS	Terminated
DMRADBU	SN	SK-104078
DMRADBU	DT	Small molecular drug
DMRADBU	PC	122295
DMRADBU	MW	279.8
DMRADBU	FM	C16H22ClNO
DMRADBU	IC	InChI=1S/C16H22ClNO/c1-12(2)8-11-19-16-5-4-15(17)13-6-9-18(3)10-7-14(13)16/h4-5,8H,6-7,9-11H2,1-3H3
DMRADBU	CS	CC(=CCOC1=C2CCN(CCC2=C(C=C1)Cl)C)C
DMRADBU	IK	MBYSTKNEMJZSIK-UHFFFAOYSA-N
DMRADBU	IU	6-chloro-3-methyl-9-(3-methylbut-2-enoxy)-1,2,4,5-tetrahydro-3-benzazepine
DMRADBU	CA	CAS 110857-22-2
DMRADBU	CB	CHEBI:125603

DMN91EK	ID	DMN91EK
DMN91EK	DN	SK&F-104856
DMN91EK	HS	Terminated
DMN91EK	SN	SK-104856
DMN91EK	DT	Small molecular drug
DMN91EK	PC	126225
DMN91EK	MW	263.8
DMN91EK	FM	C14H14ClNS
DMN91EK	IC	InChI=1S/C14H14ClNS/c1-3-12-10-8-16(2)7-6-9-11(15)4-5-13(17-12)14(9)10/h3-5H,1,6-8H2,2H3
DMN91EK	CS	CN1CCC2=C(C=CC3=C2C(=C(S3)C=C)C1)Cl
DMN91EK	IK	WKXSXFYQPCWZOS-UHFFFAOYSA-N
DMN91EK	IU	7-chloro-2-ethenyl-11-methyl-3-thia-11-azatricyclo[6.4.1.04,13]trideca-1,4(13),5,7-tetraene
DMN91EK	CA	CAS 136427-58-2

DMRM7H0	ID	DMRM7H0
DMRM7H0	DN	SK&F-95601
DMRM7H0	HS	Terminated
DMRM7H0	SN	2-[3-Chloro-4-(4-morpholinyl)pyridin-2-ylmethylsulfinyl]-5-methoxybenzimidazole
DMRM7H0	PC	128449
DMRM7H0	MW	406.9
DMRM7H0	FM	C18H19ClN4O3S
DMRM7H0	IC	InChI=1S/C18H19ClN4O3S/c1-25-12-2-3-13-14(10-12)22-18(21-13)27(24)11-15-17(19)16(4-5-20-15)23-6-8-26-9-7-23/h2-5,10H,6-9,11H2,1H3,(H,21,22)
DMRM7H0	CS	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC3=NC=CC(=C3Cl)N4CCOCC4
DMRM7H0	IK	OGHHMBMLUJWHGH-UHFFFAOYSA-N
DMRM7H0	IU	4-[3-chloro-2-[(6-methoxy-1H-benzimidazol-2-yl)sulfinylmethyl]pyridin-4-yl]morpholine
DMRM7H0	CA	CAS 103949-62-8
DMRM7H0	DE	Peptic ulcer

DM6RVXU	ID	DM6RVXU
DM6RVXU	DN	SK-951
DM6RVXU	HS	Terminated
DM6RVXU	CP	Sanwa Kagaku Kenkyusho Co Ltd
DM6RVXU	DT	Small molecular drug
DM6RVXU	PC	9847989
DM6RVXU	MW	480
DM6RVXU	FM	C23H30ClN3O6
DM6RVXU	IC	InChI=1S/C19H26ClN3O2.C4H4O4/c1-12-10-13-16(21)15(20)11-14(17(13)25-12)18(24)22-7-6-19-4-2-8-23(19)9-3-5-19;5-3(6)1-2-4(7)8/h11-12H,2-10,21H2,1H3,(H,22,24);1-2H,(H,5,6)(H,7,8)/b;2-1+/t12-;/m0./s1
DM6RVXU	CS	C[C@H]1CC2=C(O1)C(=CC(=C2N)Cl)C(=O)NCCC34CCCN3CCC4.C(=C/C(=O)O)\\C(=O)O
DM6RVXU	IK	ILIMVHLSANAUTN-GYDOPSIJSA-N
DM6RVXU	IU	(2S)-4-amino-5-chloro-N-[2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)ethyl]-2-methyl-2,3-dihydro-1-benzofuran-7-carboxamide;(E)-but-2-enedioic acid
DM6RVXU	DE	Gastrointestinal disease

DMIMJ8Z	ID	DMIMJ8Z
DMIMJ8Z	DN	SKF 38393
DMIMJ8Z	HS	Terminated
DMIMJ8Z	SN	SKF-38393; F-38393; 67287-49-4; F 38393; SKF38393; BRN 1543419; CHEMBL286080; 1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol; 2,3,4,5-Tetrahydro-1-phenyl-1H-3-benzazepine-7,8-diol; 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; SKF-38,393; SK-38393; C16H17NO2; 5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 1-Phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol
DMIMJ8Z	DT	Small molecular drug
DMIMJ8Z	PC	1242
DMIMJ8Z	MW	255.31
DMIMJ8Z	FM	C16H17NO2
DMIMJ8Z	IC	InChI=1S/C16H17NO2/c18-15-8-12-6-7-17-10-14(13(12)9-16(15)19)11-4-2-1-3-5-11/h1-5,8-9,14,17-19H,6-7,10H2
DMIMJ8Z	CS	C1CNCC(C2=CC(=C(C=C21)O)O)C3=CC=CC=C3
DMIMJ8Z	IK	JUDKOGFHZYMDMF-UHFFFAOYSA-N
DMIMJ8Z	IU	5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DMIMJ8Z	CA	CAS 67287-49-4
DMIMJ8Z	CB	CHEBI:110200
DMIMJ8Z	DE	Type-2 diabetes

DM8MWFZ	ID	DM8MWFZ
DM8MWFZ	DN	SKF-104351
DM8MWFZ	HS	Terminated
DM8MWFZ	SN	111908-94-2; Skf 104351; F 104351; 5H-Pyrrolo[1,2-a]imidazole,2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; 2-(4-fluorophenyl)-3-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole; F-104351; AC1L3V0R; SCHEMBL7378515; DTXSID90149775; GJFVAEMLAFFGDZ-UHFFFAOYSA-N; ZINC3815711; 5H-Pyrrolo(1,2-a)imidazole, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; KB-292516; 2-p-Fluorophenyl-3-(4-pyridyl)-6,7-dihydro[5H]-pyrrolo[1,2-a]imidazole
DM8MWFZ	CP	SmithKline Beecham plc
DM8MWFZ	DT	Small molecular drug
DM8MWFZ	PC	122656
DM8MWFZ	MW	279.31
DM8MWFZ	FM	C17H14FN3
DM8MWFZ	IC	InChI=1S/C17H14FN3/c18-14-5-3-12(4-6-14)16-17(13-7-9-19-10-8-13)21-11-1-2-15(21)20-16/h3-10H,1-2,11H2
DM8MWFZ	CS	C1CC2=NC(=C(N2C1)C3=CC=NC=C3)C4=CC=C(C=C4)F
DM8MWFZ	IK	GJFVAEMLAFFGDZ-UHFFFAOYSA-N
DM8MWFZ	IU	2-(4-fluorophenyl)-3-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
DM8MWFZ	CA	CAS 111908-94-2
DM8MWFZ	DE	Rheumatoid arthritis

DM7QPYK	ID	DM7QPYK
DM7QPYK	DN	SKF-106760
DM7QPYK	HS	Terminated
DM7QPYK	SN	126053-71-2; F 106760; Skf 106760; F-106760; Ac-Cyclo-S,S-(cys-(N(alpha)-Me)arg-gly-asp-pen)-NH2; AC1Q5IR2; AC1L4UF1; [(4r,7s,13s,16r)-16-(acetylamino)-4-carbamoyl-13-{3-[(diaminomethylidene)amino]propyl}-3,3,14-trimethyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecan-7-yl]acetic acid; CTK4B4925; L-Valinamide,N-acetyl-L-cysteinyl-N2-methyl-L-arginylglycyl-L-a-aspartyl-3-mercapto-, cyclic (1&amp; 5)-disulfide (9CI)
DM7QPYK	DT	Small molecular drug
DM7QPYK	PC	44343680
DM7QPYK	MW	605.7
DM7QPYK	FM	C21H35N9O8S2
DM7QPYK	IC	InChI=1S/C21H35N9O8S2/c1-10(31)27-13-9-40-39-8-12(17(22)35)29-18(36)11(6-16(33)34)28-15(32)7-26-19(37)14(30(2)20(13)38)4-3-5-25-21(23)24/h11-14H,3-9H2,1-2H3,(H2,22,35)(H,26,37)(H,27,31)(H,28,32)(H,29,36)(H,33,34)(H4,23,24,25)/t11-,12-,13-,14-/m0/s1
DM7QPYK	CS	CC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N(C1=O)C)CCCN=C(N)N)CC(=O)O)C(=O)N
DM7QPYK	IK	WZFJXIKSGKCGRW-XUXIUFHCSA-N
DM7QPYK	IU	2-[(4R,7S,13S,16R)-16-acetamido-4-carbamoyl-13-[3-(diaminomethylideneamino)propyl]-14-methyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadec-7-yl]acetic acid
DM7QPYK	DE	Thrombosis

DMM8F0V	ID	DMM8F0V
DMM8F0V	DN	SKF-107260
DMM8F0V	HS	Terminated
DMM8F0V	SN	F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)
DMM8F0V	DT	Small molecular drug
DMM8F0V	PC	164393
DMM8F0V	MW	601.7
DMM8F0V	FM	C26H31N7O6S2
DMM8F0V	IC	InChI=1S/C26H31N7O6S2/c1-33-18(9-6-12-29-26(27)28)24(38)30-14-21(34)31-17(13-22(35)36)23(37)32-16-8-3-5-11-20(16)41-40-19-10-4-2-7-15(19)25(33)39/h2-5,7-8,10-11,17-18H,6,9,12-14H2,1H3,(H,30,38)(H,31,34)(H,32,37)(H,35,36)(H4,27,28,29)/t17-,18-/m0/s1
DMM8F0V	CS	CN1[C@H](C(=O)NCC(=O)N[C@H](C(=O)NC2=CC=CC=C2SSC3=CC=CC=C3C1=O)CC(=O)O)CCCN=C(N)N
DMM8F0V	IK	YITSCMGHJOGUNC-ROUUACIJSA-N
DMM8F0V	IU	2-[(12S,18S)-18-[3-(diaminomethylideneamino)propyl]-19-methyl-11,14,17,20-tetraoxo-2,3-dithia-10,13,16,19-tetrazatricyclo[19.4.0.04,9]pentacosa-1(25),4,6,8,21,23-hexaen-12-yl]acetic acid
DMM8F0V	CA	CAS 136620-00-3

DM4LGPT	ID	DM4LGPT
DM4LGPT	DN	SKF-81297
DM4LGPT	HS	Terminated
DM4LGPT	SN	SKF 81297 hydrochloride
DM4LGPT	CP	SmithKline Beecham Pharmaceuticals
DM4LGPT	DT	Small molecular drug
DM4LGPT	PC	1218
DM4LGPT	MW	289.75
DM4LGPT	FM	C16H16ClNO2
DM4LGPT	IC	InChI=1S/C16H16ClNO2/c17-15-11-6-7-18-9-13(10-4-2-1-3-5-10)12(11)8-14(19)16(15)20/h1-5,8,13,18-20H,6-7,9H2
DM4LGPT	CS	C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=CC=C3
DM4LGPT	IK	GHWJEDJMOVUXEC-UHFFFAOYSA-N
DM4LGPT	IU	9-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DM4LGPT	CA	CAS 71636-61-8
DM4LGPT	CB	CHEBI:91517
DM4LGPT	DE	Parkinson disease

DMS2M58	ID	DMS2M58
DMS2M58	DN	SKF-96231
DMS2M58	HS	Terminated
DMS2M58	CP	SmithKline Beecham plc
DMS2M58	DT	Small molecular drug
DMS2M58	PC	135529458
DMS2M58	MW	270.29
DMS2M58	FM	C14H14N4O2
DMS2M58	IC	InChI=1S/C14H14N4O2/c1-2-7-20-10-6-4-3-5-9(10)12-17-13-11(14(19)18-12)15-8-16-13/h3-6,8H,2,7H2,1H3,(H2,15,16,17,18,19)
DMS2M58	CS	CCCOC1=CC=CC=C1C2=NC3=C(C(=O)N2)NC=N3
DMS2M58	IK	PQTJTRTXCNZDFT-UHFFFAOYSA-N
DMS2M58	IU	2-(2-propoxyphenyl)-1,7-dihydropurin-6-one
DMS2M58	CA	CAS 119409-07-3
DMS2M58	DE	Asthma

DMI79JN	ID	DMI79JN
DMI79JN	DN	SKF-96365
DMI79JN	HS	Terminated
DMI79JN	SN	SK-96365; 1-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]-1H-imidazole; 1-[2-(4-Methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]imidazole; 1-[beta-[3-(4-Methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole; 1-(2-(3-(4-Methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole; AC1L2XSB; SKF-96365 free base; Imidazole-based ligand, 15; KBioSS_000197; KBioGR_000197; BSPBio_001477; SCHEMBL722014; GTPL2441; CHEMBL258502; KBio3_000394; KBio2_000197; KBio3_000393; KBio2_005333; KBio2_002765; CHEBI:91847; BDBM21164
DMI79JN	CP	SmithKline Beecham plc
DMI79JN	DT	Small molecular drug
DMI79JN	PC	104955
DMI79JN	MW	402.9
DMI79JN	FM	C22H27ClN2O3
DMI79JN	IC	InChI=1S/C22H26N2O3.ClH/c1-25-20-9-5-18(6-10-20)4-3-15-27-22(16-24-14-13-23-17-24)19-7-11-21(26-2)12-8-19;/h5-14,17,22H,3-4,15-16H2,1-2H3;1H
DMI79JN	CS	COC1=CC=C(C=C1)CCCOC(CN2C=CN=C2)C3=CC=C(C=C3)OC.Cl
DMI79JN	IK	FWLPKVQUECFKSW-UHFFFAOYSA-N
DMI79JN	IU	1-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]imidazole;hydrochloride
DMI79JN	CA	CAS 130495-35-1
DMI79JN	CB	CHEBI:145121
DMI79JN	DE	Angina pectoris

DMI1WNF	ID	DMI1WNF
DMI1WNF	DN	SL-18.1616
DMI1WNF	HS	Terminated
DMI1WNF	CP	Sanofi-Synthelabo
DMI1WNF	DE	Insomnia

DMJ9RLX	ID	DMJ9RLX
DMJ9RLX	DN	SL-91.0893
DMJ9RLX	HS	Terminated
DMJ9RLX	CP	Synthelabo
DMJ9RLX	DE	Prostate hyperplasia

DMNTGXQ	ID	DMNTGXQ
DMNTGXQ	DN	SL-910102
DMNTGXQ	HS	Terminated
DMNTGXQ	CP	Synthelabo
DMNTGXQ	DE	Hypertension

DMCPDBS	ID	DMCPDBS
DMCPDBS	DN	SLV-307
DMCPDBS	HS	Terminated
DMCPDBS	CP	Solvay SA
DMCPDBS	DE	Parkinson disease

DMF0QMD	ID	DMF0QMD
DMF0QMD	DN	SM 11044
DMF0QMD	HS	Terminated
DMF0QMD	SN	SM 11044; 142784-65-4; SM-11044; DTXSID90162181; AC1L3144; 3-(3,4-Dihydroxyphenyl)-N-(3-(4-fluorophenyl)propyl)serine pyrrolidine amide hydrobromide; Pyrrolidine, 1-(3-(3,4-dihydroxyphenyl)-2-((3-(4-fluorophenyl)propyl)amino)-3-hydroxy-1-oxopropyl)-, monohydrobromide, (R-(R*,S*))-; (2S,3R)-3-(3,4-dihydroxyphenyl)-2-[3-(4-fluorophenyl)propylamino]-3-hydroxy-1-pyrrolidin-1-ylpropan-1-one hydrobromide
DMF0QMD	DT	Small molecular drug
DMF0QMD	PC	132507
DMF0QMD	MW	483.4
DMF0QMD	FM	C22H28BrFN2O4
DMF0QMD	IC	InChI=1S/C22H27FN2O4.BrH/c23-17-8-5-15(6-9-17)4-3-11-24-20(22(29)25-12-1-2-13-25)21(28)16-7-10-18(26)19(27)14-16;/h5-10,14,20-21,24,26-28H,1-4,11-13H2;1H/t20-,21+;/m0./s1
DMF0QMD	CS	C1CCN(C1)C(=O)[C@H]([C@@H](C2=CC(=C(C=C2)O)O)O)NCCCC3=CC=C(C=C3)F.Br
DMF0QMD	IK	VGHBGPUSJITFJL-JUDYQFGCSA-N
DMF0QMD	IU	(2S,3R)-3-(3,4-dihydroxyphenyl)-2-[3-(4-fluorophenyl)propylamino]-3-hydroxy-1-pyrrolidin-1-ylpropan-1-one;hydrobromide
DMF0QMD	CA	CAS 142784-65-4
DMF0QMD	DE	Asthma

DMHXJV2	ID	DMHXJV2
DMHXJV2	DN	SM-16
DMHXJV2	HS	Terminated
DMHXJV2	SN	TGF-beta receptor inhibitors, Biogen; TGF-beta receptor inhibitors, Biogen Idec
DMHXJV2	CP	Biogen Inc
DMHXJV2	DE	Fibrosis

DMNX93E	ID	DMNX93E
DMNX93E	DN	SM-19712
DMNX93E	HS	Terminated
DMNX93E	SN	GTPL5272; sodium 1-[(4-chlorobenzene)sulfonyl]-3-(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)urea
DMNX93E	CP	Sumitomo Pharmaceuticals Co Ltd
DMNX93E	DT	Small molecular drug
DMNX93E	PC	17757228
DMNX93E	MW	437.8
DMNX93E	FM	C18H13ClN5NaO3S
DMNX93E	IC	InChI=1S/C18H14ClN5O3S.Na/c1-12-16(11-20)17(24(22-12)14-5-3-2-4-6-14)21-18(25)23-28(26,27)15-9-7-13(19)8-10-15;/h2-10H,1H3,(H2,21,22,23,25);/q;+1/p-1
DMNX93E	CS	CC1=NN(C(=C1C#N)NC(=O)[N-]S(=O)(=O)C2=CC=C(C=C2)Cl)C3=CC=CC=C3.[Na+]
DMNX93E	IK	FBSZSOXTWRKLKD-UHFFFAOYSA-M
DMNX93E	IU	sodium;(4-chlorophenyl)sulfonyl-[(4-cyano-5-methyl-2-phenylpyrazol-3-yl)carbamoyl]azanide
DMNX93E	DE	Hypertension

DMROJEN	ID	DMROJEN
DMROJEN	DN	SNAP-5089
DMROJEN	HS	Terminated
DMROJEN	SN	SNAP5089; (-)-SNAP-5089; AC1NSKMU; GTPL498; SCHEMBL5165068; ZINC100002054; 2,6-Dimethyl-4alpha-(4-nitrophenyl)-5-[[3-(4,4-diphenylpiperidino)propyl]carbamoyl]-1,4-dihydro-3-pyridinecarboxylic acid methyl ester; methyl (4R)-5-[3-[4,4-di(phenyl)piperidin-1-yl]propylcarbamoyl]-2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; methyl (4R)-5-[3-(4,4-diphenylpiperidin-1-yl)propylcarbamoyl]-2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
DMROJEN	DT	Small molecular drug
DMROJEN	PC	56972175
DMROJEN	MW	645.2
DMROJEN	FM	C36H41ClN4O5
DMROJEN	IC	InChI=1S/C36H40N4O5.ClH/c1-25-31(33(32(26(2)38-25)35(42)45-3)27-15-17-30(18-16-27)40(43)44)34(41)37-21-10-22-39-23-19-36(20-24-39,28-11-6-4-7-12-28)29-13-8-5-9-14-29;/h4-9,11-18,33,38H,10,19-24H2,1-3H3,(H,37,41);1H
DMROJEN	CS	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](=O)[O-])C(=O)NCCCN3CCC(CC3)(C4=CC=CC=C4)C5=CC=CC=C5.Cl
DMROJEN	IK	MXELDPKESKXREN-UHFFFAOYSA-N
DMROJEN	IU	methyl 5-[3-(4,4-diphenylpiperidin-1-yl)propylcarbamoyl]-2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3-carboxylate;hydrochloride
DMROJEN	DE	Heart arrhythmia

DMNE4TS	ID	DMNE4TS
DMNE4TS	DN	SNAP-6201
DMNE4TS	HS	Terminated
DMNE4TS	SN	SNAP-6201; CHEMBL356584; BDBM50082784; L014930; 1-(3-{[5-Carbamoyl-6-(3,4-difluoro-phenyl)-4-ethyl-2-oxo-3,6-dihydro-2H-pyrimidine-1-carbonyl]-amino}-propyl)-4-phenyl-piperidine-4-carboxylic acid methyl ester
DMNE4TS	DT	Small molecular drug
DMNE4TS	PC	10099811
DMNE4TS	MW	583.6
DMNE4TS	FM	C30H35F2N5O5
DMNE4TS	IC	InChI=1S/C30H35F2N5O5/c1-3-23-24(26(33)38)25(19-10-11-21(31)22(32)18-19)37(29(41)35-23)28(40)34-14-7-15-36-16-12-30(13-17-36,27(39)42-2)20-8-5-4-6-9-20/h4-6,8-11,18,25H,3,7,12-17H2,1-2H3,(H2,33,38)(H,34,40)(H,35,41)
DMNE4TS	CS	CCC1=C(C(N(C(=O)N1)C(=O)NCCCN2CCC(CC2)(C3=CC=CC=C3)C(=O)OC)C4=CC(=C(C=C4)F)F)C(=O)N
DMNE4TS	IK	YCUQRVLXIFFFNB-UHFFFAOYSA-N
DMNE4TS	IU	methyl 1-[3-[[5-carbamoyl-4-(3,4-difluorophenyl)-6-ethyl-2-oxo-1,4-dihydropyrimidine-3-carbonyl]amino]propyl]-4-phenylpiperidine-4-carboxylate

DM4CNM9	ID	DM4CNM9
DM4CNM9	DN	SNF-9007
DM4CNM9	HS	Terminated
DM4CNM9	SN	Snf-9007; CHEMBL407057; BDBM21146; Asp-Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-[(3S)-3-amino-3-formamidopropanoic acid]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DM4CNM9	PC	9898185
DM4CNM9	MW	1075.2
DM4CNM9	FM	C55H66N10O13
DM4CNM9	IC	InChI=1S/C55H66N10O13/c1-3-4-19-45(54(77)64-43(29-48(70)71)53(76)61-40(49(57)72)24-32-13-7-5-8-14-32)65(2)55(78)44(27-35-30-58-39-18-12-11-17-37(35)39)60-46(67)31-59-51(74)41(25-33-15-9-6-10-16-33)63-52(75)42(26-34-20-22-36(66)23-21-34)62-50(73)38(56)28-47(68)69/h5-18,20-23,30,38,40-45,58,66H,3-4,19,24-29,31,56H2,1-2H3,(H2,57,72)(H,59,74)(H,60,67)(H,61,76)(H,62,73)(H,63,75)(H,64,77)(H,68,69)(H,70,71)/t38-,40-,41+,42-,43-,44-,45-/m0/s1
DM4CNM9	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)N
DM4CNM9	IK	IJHCWGDIGBABKC-GDHOWUIUSA-N
DM4CNM9	IU	(3S)-3-amino-4-[[(2S)-1-[[(2R)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]-methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid

DMFI0GW	ID	DMFI0GW
DMFI0GW	DN	Sonepiprazole
DMFI0GW	HS	Terminated
DMFI0GW	SN	U 101387; U-101387; Isochr-etpip-phso2NH2; 4-(4-(2-(Isochroman-1-yl)ethyl)piperazin-1-yl)benzenesulfonamide; 4-[4-[2-(3,4-dihydro-1H-isochromen-1-yl)ethyl]piperazin-1-yl]benzenesulfonamide; 4-[4-[2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]ethyl]piperazin-1-yl]benzenesulfonamide
DMFI0GW	CP	Pfizer
DMFI0GW	DT	Small molecular drug
DMFI0GW	PC	133079
DMFI0GW	MW	401.5
DMFI0GW	FM	C21H27N3O3S
DMFI0GW	IC	InChI=1S/C21H27N3O3S/c22-28(25,26)19-7-5-18(6-8-19)24-14-12-23(13-15-24)11-9-21-20-4-2-1-3-17(20)10-16-27-21/h1-8,21H,9-16H2,(H2,22,25,26)/t21-/m0/s1
DMFI0GW	CS	C1CO[C@H](C2=CC=CC=C21)CCN3CCN(CC3)C4=CC=C(C=C4)S(=O)(=O)N
DMFI0GW	IK	WNUQCGWXPNGORO-NRFANRHFSA-N
DMFI0GW	IU	4-[4-[2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]ethyl]piperazin-1-yl]benzenesulfonamide
DMFI0GW	CA	CAS 170858-33-0
DMFI0GW	DE	Schizophrenia

DM31VE4	ID	DM31VE4
DM31VE4	DN	Sorbinil
DM31VE4	HS	Terminated
DM31VE4	SN	SBI; Sorbinilo; Sorbinilum; Sorbinilo [Spanish]; Sorbinilum [Latin]; CP 45634; CP-45634; Sorbinil (USAN/INN); D-6-fluoro-spiro(chroman-4,4'-imidazolidine)-2',5'-dione; (4S)-6-fluoro-2,3-dihydro-2'H,5'H-spiro[chromene-4,4'-imidazolidine]-2',5'-dione; (4S)-6-fluorospiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione
DM31VE4	CP	Pfizer
DM31VE4	DT	Small molecular drug
DM31VE4	PC	337359
DM31VE4	MW	236.2
DM31VE4	FM	C11H9FN2O3
DM31VE4	IC	InChI=1S/C11H9FN2O3/c12-6-1-2-8-7(5-6)11(3-4-17-8)9(15)13-10(16)14-11/h1-2,5H,3-4H2,(H2,13,14,15,16)/t11-/m0/s1
DM31VE4	CS	C1COC2=C([C@]13C(=O)NC(=O)N3)C=C(C=C2)F
DM31VE4	IK	LXANPKRCLVQAOG-NSHDSACASA-N
DM31VE4	IU	(4S)-6-fluorospiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione
DM31VE4	CA	CAS 68367-52-2
DM31VE4	CB	CHEBI:102029
DM31VE4	DE	Diabetic cataract

DMTDLHG	ID	DMTDLHG
DMTDLHG	DN	SORETOLIDE
DMTDLHG	HS	Terminated
DMTDLHG	SN	D-2916; Soretolide; 2,6-Dimethyl-N-(5-methylisozaxol-3-yl)benzamide
DMTDLHG	DT	Small molecular drug
DMTDLHG	PC	198730
DMTDLHG	MW	230.26
DMTDLHG	FM	C13H14N2O2
DMTDLHG	IC	InChI=1S/C13H14N2O2/c1-8-5-4-6-9(2)12(8)13(16)14-11-7-10(3)17-15-11/h4-7H,1-3H3,(H,14,15,16)
DMTDLHG	CS	CC1=C(C(=CC=C1)C)C(=O)NC2=NOC(=C2)C
DMTDLHG	IK	GBTKANSDFYFQBK-UHFFFAOYSA-N
DMTDLHG	IU	2,6-dimethyl-N-(5-methyl-1,2-oxazol-3-yl)benzamide
DMTDLHG	CA	CAS 130403-08-6
DMTDLHG	DE	Convulsion

DM9HFV7	ID	DM9HFV7
DM9HFV7	DN	SPD-756
DM9HFV7	HS	Terminated
DM9HFV7	SN	BCH-13520
DM9HFV7	CP	Shire plc
DM9HFV7	DT	Small molecular drug
DM9HFV7	PC	485995
DM9HFV7	MW	292.29
DM9HFV7	FM	C12H16N6O3
DM9HFV7	IC	InChI=1S/C12H16N6O3/c13-12-16-10(15-6-1-2-6)9-11(17-12)18(5-14-9)7-4-20-8(3-19)21-7/h5-8,19H,1-4H2,(H3,13,15,16,17)/t7-,8-/m1/s1
DM9HFV7	CS	C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@H]4CO[C@H](O4)CO
DM9HFV7	IK	ATSMZGDYBPOXMZ-HTQZYQBOSA-N
DM9HFV7	IU	[(2R,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-1,3-dioxolan-2-yl]methanol
DM9HFV7	CA	CAS 280138-71-8
DM9HFV7	DE	Human immunodeficiency virus infection

DMD4BFY	ID	DMD4BFY
DMD4BFY	DN	Spermine
DMD4BFY	HS	Terminated
DMD4BFY	SN	spermine; 71-44-3; neuridine; musculamine; gerontine; Spermin; 4,9-Diaza-1,12-dodecanediamine; Diaminopropyltetramethylenediamine; N,N'-Bis(3-aminopropyl)-1,4-butanediamine; Spermine, puriss; N,N'-Bis(3-aminopropyl)butane-1,4-diamine; 1,4-Butanediamine, N,N'-bis(3-aminopropyl)-; 1,4-Bis(aminopropyl)butanediamine; 4,9-Diazadodecamethylenediamine; 4,9-Diazadodecane-1,12-diamine; N1,N1'-(Butane-1,4-diyl)bis(propane-1,3-diamine); UNII-2FZ7Y3VOQX; 1,4-Bis(aminopropyl) butanediamine; Spermine Derivative; 1,4-Diaminobutane, N,N'-bis
DMD4BFY	DT	Small molecular drug
DMD4BFY	PC	1103
DMD4BFY	MW	202.34
DMD4BFY	FM	C10H26N4
DMD4BFY	IC	InChI=1S/C10H26N4/c11-5-3-9-13-7-1-2-8-14-10-4-6-12/h13-14H,1-12H2
DMD4BFY	CS	C(CCNCCCN)CNCCCN
DMD4BFY	IK	PFNFFQXMRSDOHW-UHFFFAOYSA-N
DMD4BFY	IU	N,N'-bis(3-aminopropyl)butane-1,4-diamine
DMD4BFY	CA	CAS 71-44-3
DMD4BFY	CB	CHEBI:15746

DMTGIUV	ID	DMTGIUV
DMTGIUV	DN	SPR-210
DMTGIUV	HS	Terminated
DMTGIUV	SN	Spr 210; Spr-210; SCHEMBL1650593; AC1L3164; 2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-((4,5,7-trifuruoro-2-benzothiazolyl)methyl)-; 3,4-Dihydro-3-oxo-4-((4,5,7-trifuruoro-2-benzothiazolyl)methyl)-2H-1,4-benzothiazine-2-acetic acid; 3,4-Dihydro-3-oxo-4-((4,5,7-trifluoro-2-benzothiazolyl)methyl)-2H-1,4-benzothiazine-2-acetic acid; 2-[5-methyl-3-oxo-4-(4,5,7-trifluoro-1,3-benzothiazol-2-yl)-1,4-benzothiazin-2-yl]acetic acid
DMTGIUV	DT	Small molecular drug
DMTGIUV	PC	132542
DMTGIUV	MW	424.4
DMTGIUV	FM	C18H11F3N2O3S2
DMTGIUV	IC	InChI=1S/C18H11F3N2O3S2/c1-7-3-2-4-10-15(7)23(17(26)11(27-10)6-12(24)25)18-22-14-13(21)8(19)5-9(20)16(14)28-18/h2-5,11H,6H2,1H3,(H,24,25)
DMTGIUV	CS	CC1=C2C(=CC=C1)SC(C(=O)N2C3=NC4=C(C(=CC(=C4S3)F)F)F)CC(=O)O
DMTGIUV	IK	ZVSDXQXCVBUOHA-UHFFFAOYSA-N
DMTGIUV	IU	2-[5-methyl-3-oxo-4-(4,5,7-trifluoro-1,3-benzothiazol-2-yl)-1,4-benzothiazin-2-yl]acetic acid
DMTGIUV	DE	Diabetic complication

DM6SW2R	ID	DM6SW2R
DM6SW2R	DN	SQ-26332
DM6SW2R	HS	Terminated
DM6SW2R	DT	Small molecular drug
DM6SW2R	PC	9998020
DM6SW2R	MW	350.4
DM6SW2R	FM	C17H22N2O4S
DM6SW2R	IC	InChI=1S/C17H22N2O4S/c1-11(16(21)19-9-5-8-13(19)17(22)23)18-15(20)14(24)10-12-6-3-2-4-7-12/h2-4,6-7,11,13-14,24H,5,8-10H2,1H3,(H,18,20)(H,22,23)/t11-,13-,14-/m0/s1
DM6SW2R	CS	C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)S
DM6SW2R	IK	YSFYVNRABGRTNY-UBHSHLNASA-N
DM6SW2R	IU	(2S)-1-[(2S)-2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid

DM9DJFS	ID	DM9DJFS
DM9DJFS	DN	SQ-28603
DM9DJFS	HS	Terminated
DM9DJFS	SN	CHEMBL196902; beta-Alanine, N-(2-(mercaptomethyl)-1-oxo-3-phenylpropyl)-; 100845-83-8; AC1L3X7M; SCHEMBL389731; 3-[(2-benzyl-3-sulfanylpropanoyl)amino]propanoic acid; ZCTDTVUDURCGFX-UHFFFAOYSA-N; HY-U00171; BDBM50175499; CS-7234; LS-186925; LS-187575; 3-(2-Benzyl-3-mercapto-propionylamino)-propionic acid; (+/-)-3-[[2-(Mercaptomethyl)-1-oxo-3-phenylpropyl]amino]propanoic acid
DM9DJFS	CP	Squibb Corp
DM9DJFS	DT	Small molecular drug
DM9DJFS	PC	123742
DM9DJFS	MW	267.35
DM9DJFS	FM	C13H17NO3S
DM9DJFS	IC	InChI=1S/C13H17NO3S/c15-12(16)6-7-14-13(17)11(9-18)8-10-4-2-1-3-5-10/h1-5,11,18H,6-9H2,(H,14,17)(H,15,16)
DM9DJFS	CS	C1=CC=C(C=C1)CC(CS)C(=O)NCCC(=O)O
DM9DJFS	IK	ZCTDTVUDURCGFX-UHFFFAOYSA-N
DM9DJFS	IU	3-[(2-benzyl-3-sulfanylpropanoyl)amino]propanoic acid
DM9DJFS	CA	CAS 100845-83-8
DM9DJFS	DE	Hypertension

DM083JB	ID	DM083JB
DM083JB	DN	SQ-33351
DM083JB	HS	Terminated
DM083JB	CP	Squibb Corp
DM083JB	DE	Hypertension

DMT5LX0	ID	DMT5LX0
DMT5LX0	DN	SQ-33600
DMT5LX0	HS	Terminated
DMT5LX0	SN	UNII-3KF8M81W01; 3KF8M81W01; SQ-33600; SQ 33600; SQ 33,600; AC1L2ZMH; SCHEMBL5597751; 133983-25-2; Butanoic acid, 4-(((1-(4-fluorophenyl)-3-(1-methylethyl)-1H-indol-2-yl)ethynyl)hydroxyphosphinyl)-3-hydroxy-, disodium salt, (S)-; disodium (3S)-4-[2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethynyl-oxidophosphoryl]-3-hydroxybutanoate
DMT5LX0	CP	Bristol-Myers Squibb Co
DMT5LX0	DT	Small molecular drug
DMT5LX0	PC	131696
DMT5LX0	MW	487.4
DMT5LX0	FM	C23H21FNNa2O5P
DMT5LX0	IC	InChI=1S/C23H23FNO5P.2Na/c1-15(2)23-19-5-3-4-6-20(19)25(17-9-7-16(24)8-10-17)21(23)11-12-31(29,30)14-18(26)13-22(27)28;;/h3-10,15,18,26H,13-14H2,1-2H3,(H,27,28)(H,29,30);;/q;2*+1/p-2/t18-;;/m0../s1
DMT5LX0	CS	CC(C)C1=C(N(C2=CC=CC=C21)C3=CC=C(C=C3)F)C#CP(=O)(C[C@H](CC(=O)[O-])O)[O-].[Na+].[Na+]
DMT5LX0	IK	FXHKSTYWSZZOBF-NTEVMMBTSA-L
DMT5LX0	IU	disodium;(3S)-4-[2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethynyl-oxidophosphoryl]-3-hydroxybutanoate
DMT5LX0	CA	CAS 133983-25-2
DMT5LX0	DE	Hyperlipidaemia

DMMRWKP	ID	DMMRWKP
DMMRWKP	DN	SQ-33800
DMMRWKP	HS	Terminated
DMMRWKP	CP	Bristol-Myers Squibb Co
DMMRWKP	DE	Hypertension

DMZBQ4I	ID	DMZBQ4I
DMZBQ4I	DN	SQ-33961
DMZBQ4I	HS	Terminated
DMZBQ4I	CP	Squibb Corp
DMZBQ4I	DT	Small molecular drug
DMZBQ4I	PC	9849156
DMZBQ4I	MW	508.6
DMZBQ4I	FM	C30H40N2O5
DMZBQ4I	IC	InChI=1S/C30H40N2O5/c33-27(34)16-13-21-11-4-5-12-22(21)18-23-25-14-15-26(37-25)28(23)30-32-24(19-36-30)29(35)31-17-7-6-10-20-8-2-1-3-9-20/h4-5,11-12,19-20,23,25-26,28H,1-3,6-10,13-18H2,(H,31,35)(H,33,34)/t23-,25-,26+,28-/m0/s1
DMZBQ4I	CS	C1CCC(CC1)CCCCNC(=O)C2=COC(=N2)[C@@H]3[C@H]4CC[C@@H]([C@@H]3CC5=CC=CC=C5CCC(=O)O)O4
DMZBQ4I	IK	MWTFNTGEEFCRGV-ZEIIVYBKSA-N
DMZBQ4I	IU	3-[2-[[(1S,2R,3S,4R)-3-[4-(4-cyclohexylbutylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic acid
DMZBQ4I	DE	Thrombosis

DMT7O9V	ID	DMT7O9V
DMT7O9V	DN	SQ-34919
DMT7O9V	HS	Terminated
DMT7O9V	SN	SQ-34919; CHEMBL286760; SCHEMBL9632769; SCHEMBL9632781; GTPL3101; BDBM50031839; (6,10-Dimethyl-5,9-undecadienylidene)bisphosphonic acid; ((E)-6,10-Dimethyl-1-phosphono-undeca-5,9-dienyl)-phosphonic acid; [(5E)-6,10-dimethyl-1-phosphonoundeca-5,9-dien-1-yl]phosphonic acid
DMT7O9V	DT	Small molecular drug
DMT7O9V	PC	10382597
DMT7O9V	MW	340.29
DMT7O9V	FM	C13H26O6P2
DMT7O9V	IC	InChI=1S/C13H26O6P2/c1-11(2)7-6-9-12(3)8-4-5-10-13(20(14,15)16)21(17,18)19/h7-8,13H,4-6,9-10H2,1-3H3,(H2,14,15,16)(H2,17,18,19)/b12-8+
DMT7O9V	CS	CC(=CCC/C(=C/CCCC(P(=O)(O)O)P(=O)(O)O)/C)C
DMT7O9V	IK	ISMDHWZGHKZNRH-XYOKQWHBSA-N
DMT7O9V	IU	[(5E)-6,10-dimethyl-1-phosphonoundeca-5,9-dienyl]phosphonic acid

DM4JZPT	ID	DM4JZPT
DM4JZPT	DN	Squalestatin 1
DM4JZPT	HS	Terminated
DM4JZPT	SN	Zaragozic acid A; squalestatin 1; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo
DM4JZPT	CP	Glaxo Wellcome plc
DM4JZPT	DT	Small molecular drug
DM4JZPT	PC	6438355
DM4JZPT	MW	690.7
DM4JZPT	FM	C35H46O14
DM4JZPT	IC	InChI=1S/C35H46O14/c1-7-19(2)17-20(3)13-14-25(37)47-28-27(38)33(48-29(30(39)40)34(45,31(41)42)35(28,49-33)32(43)44)16-15-21(4)26(46-23(6)36)22(5)18-24-11-9-8-10-12-24/h8-14,19-20,22,26-29,38,45H,4,7,15-18H2,1-3,5-6H3,(H,39,40)(H,41,42)(H,43,44)/b14-13+/t19-,20+,22+,26+,27+,28+,29+,33-,34+,35-/m0/s1
DM4JZPT	CS	CC[C@H](C)C[C@H](C)/C=C/C(=O)O[C@@H]1[C@H]([C@]2(O[C@@H]([C@]([C@@]1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCC(=C)[C@H]([C@H](C)CC3=CC=CC=C3)OC(=O)C)O
DM4JZPT	IK	DFKDOZMCHOGOBR-NCSQYGPNSA-N
DM4JZPT	IU	(1S,3S,4S,5R,6R,7R)-1-[(4S,5R)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-[(E,4S,6S)-4,6-dimethyloct-2-enoyl]oxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DM4JZPT	CA	CAS 142561-96-4
DM4JZPT	CB	CHEBI:75170
DM4JZPT	DE	Arteriosclerosis

DMETDFM	ID	DMETDFM
DMETDFM	DN	SR 120819A
DMETDFM	HS	Terminated
DMETDFM	SN	SR 120819A; SR120819A; SR-120819A; SR 120107A; AC1NSM40; GTPL1530
DMETDFM	DT	Small molecular drug
DMETDFM	PC	5312150
DMETDFM	MW	751
DMETDFM	FM	C43H54N6O4S
DMETDFM	IC	InChI=1S/C43H54N6O4S/c1-48(2)30-34-16-14-33(15-17-34)29-45-41(44)36-20-18-32(19-21-36)27-40(43(51)49-24-8-9-25-49)46-42(50)39(26-31-10-4-3-5-11-31)47-54(52,53)38-23-22-35-12-6-7-13-37(35)28-38/h3-7,10-13,18-23,28,33-34,39-40,47H,8-9,14-17,24-27,29-30H2,1-2H3,(H2,44,45)(H,46,50)/t33?,34?,39-,40-/m1/s1
DMETDFM	CS	CN(C)CC1CCC(CC1)CN=C(C2=CC=C(C=C2)C[C@H](C(=O)N3CCCC3)NC(=O)[C@@H](CC4=CC=CC=C4)NS(=O)(=O)C5=CC6=CC=CC=C6C=C5)N
DMETDFM	IK	GKKPXBHNFVDHAQ-USNYZCROSA-N
DMETDFM	IU	(2R)-N-[(2R)-3-[4-[N'-[[4-[(dimethylamino)methyl]cyclohexyl]methyl]carbamimidoyl]phenyl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]-2-(naphthalen-2-ylsulfonylamino)-3-phenylpropanamide
DMETDFM	DE	Eating disorder

DMQG3CK	ID	DMQG3CK
DMQG3CK	DN	SR-11237
DMQG3CK	HS	Terminated
DMQG3CK	SN	SR 11237; 146670-40-8; SR-11237; SR11237; BMS 649; BMS 188649; CHEMBL112715; 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid; 4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl]-benzoic acid; UVI 2108; AC1L2RBO; 4-[2-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-[1,3]DIOXOLAN-2-YL]-BENZOIC ACID; 4-(2-(5,6,7,8-Tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl)benzoic acid; SCHEMBL2807932; GTPL2809; CTK8F0685; DTXSID10163433
DMQG3CK	CP	Sanofi
DMQG3CK	DT	Small molecular drug
DMQG3CK	PC	127019
DMQG3CK	MW	380.5
DMQG3CK	FM	C24H28O4
DMQG3CK	IC	InChI=1S/C24H28O4/c1-22(2)11-12-23(3,4)20-15-18(9-10-19(20)22)24(27-13-14-28-24)17-7-5-16(6-8-17)21(25)26/h5-10,15H,11-14H2,1-4H3,(H,25,26)
DMQG3CK	CS	CC1(CCC(C2=C1C=CC(=C2)C3(OCCO3)C4=CC=C(C=C4)C(=O)O)(C)C)C
DMQG3CK	IK	ZZUKALQMHNSWTK-UHFFFAOYSA-N
DMQG3CK	IU	4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid
DMQG3CK	CA	CAS 146670-40-8
DMQG3CK	DE	Solid tumour/cancer

DMU2ZVY	ID	DMU2ZVY
DMU2ZVY	DN	SR12813
DMU2ZVY	HS	Terminated
DMU2ZVY	SN	SR 12813; 126411-39-0; SR-12813; SR12813; CHEBI:77317; GW 485801; CHEMBL458767; [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol; Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate); [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; SRL; 1ilh; AC1L9JHO
DMU2ZVY	DT	Small molecular drug
DMU2ZVY	PC	446313
DMU2ZVY	MW	504.5
DMU2ZVY	FM	C24H42O7P2
DMU2ZVY	IC	InChI=1S/C24H42O7P2/c1-11-28-32(26,29-12-2)21(33(27,30-13-3)31-14-4)17-18-15-19(23(5,6)7)22(25)20(16-18)24(8,9)10/h15-17,25H,11-14H2,1-10H3
DMU2ZVY	CS	CCOP(=O)(C(=CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OCC)OCC)OCC
DMU2ZVY	IK	YQLJDECYQDRSBI-UHFFFAOYSA-N
DMU2ZVY	IU	4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol
DMU2ZVY	CA	CAS 126411-39-0
DMU2ZVY	CB	CHEBI:77317
DMU2ZVY	DE	Arteriosclerosis

DM1GKTS	ID	DM1GKTS
DM1GKTS	DN	SR-26831
DM1GKTS	HS	Terminated
DM1GKTS	SN	SR 26831; AC1L30OS; ((5-(2-Chlorobenzyl-2-tert-butyloxycarbonyl))-4,5,6,7-tetrahydrothieno(3,2-c)pyridine)-N-oxide; Thieno(3,2-c)pyridinium, 5-((2-chlorophenyl)methyl)-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxy-; [5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate
DM1GKTS	CP	Sanofi
DM1GKTS	DT	Small molecular drug
DM1GKTS	PC	132270
DM1GKTS	MW	380.9
DM1GKTS	FM	C19H23ClNO3S+
DM1GKTS	IC	InChI=1S/C19H23ClNO3S/c1-19(2,3)18(22)24-17-10-14-12-21(23,9-8-16(14)25-17)11-13-6-4-5-7-15(13)20/h4-7,10,23H,8-9,11-12H2,1-3H3/q+1
DM1GKTS	CS	CC(C)(C)C(=O)OC1=CC2=C(S1)CC[N+](C2)(CC3=CC=CC=C3Cl)O
DM1GKTS	IK	AZEZNHVYMHQRRH-UHFFFAOYSA-N
DM1GKTS	IU	[5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate
DM1GKTS	CA	CAS 139995-67-8
DM1GKTS	DE	Rheumatoid arthritis

DMZ8SXP	ID	DMZ8SXP
DMZ8SXP	DN	SR-27950
DMZ8SXP	HS	Terminated
DMZ8SXP	SN	SR-27899
DMZ8SXP	CP	Sanofi
DMZ8SXP	DE	Eating disorder

DM7ZOLE	ID	DM7ZOLE
DM7ZOLE	DN	SR-31742A
DM7ZOLE	HS	Terminated
DM7ZOLE	SN	SR 31742A; [(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]cycloheptane hydrochloride; (Z)-1-(3-(3-Chloro-4-cyclohexylphenyl)-2-propenyl)hexahydro-1H-azepine hydrochloride; 3-(Hexahydroazepin-1-yl)-1-(3-chloro-4-cyclohexylphenyl)-1-propene hydrochloride
DM7ZOLE	CP	Sanofi-Aventis
DM7ZOLE	DT	Small molecular drug
DM7ZOLE	PC	6438730
DM7ZOLE	MW	367.4
DM7ZOLE	FM	C22H32Cl2
DM7ZOLE	IC	InChI=1S/C22H31Cl.ClH/c23-22-17-19(12-8-11-18-9-4-1-2-5-10-18)15-16-21(22)20-13-6-3-7-14-20;/h8,12,15-18,20H,1-7,9-11,13-14H2;1H/b12-8-;
DM7ZOLE	CS	C1CCCC(CC1)C/C=C\\C2=CC(=C(C=C2)C3CCCCC3)Cl.Cl
DM7ZOLE	IK	YAPBCZRQTMBLEF-JCTPKUEWSA-N
DM7ZOLE	IU	[(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]cycloheptane;hydrochloride
DM7ZOLE	CA	CAS 139592-99-7
DM7ZOLE	DE	Schizophrenia

DMS9EJ5	ID	DMS9EJ5
DMS9EJ5	DN	SR-58878
DMS9EJ5	HS	Terminated
DMS9EJ5	CP	Sanofi-Synthelabo
DMS9EJ5	PC	68822080
DMS9EJ5	MW	375.8
DMS9EJ5	FM	C20H22ClNO4
DMS9EJ5	IC	InChI=1S/C20H22ClNO4/c21-16-3-1-2-14(8-16)19(23)11-22-17-6-4-13-5-7-18(10-15(13)9-17)26-12-20(24)25/h1-3,5,7-8,10,17,19,22-23H,4,6,9,11-12H2,(H,24,25)/t17-,19?/m0/s1
DMS9EJ5	CS	C1CC2=C(C[C@H]1NCC(C3=CC(=CC=C3)Cl)O)C=C(C=C2)OCC(=O)O
DMS9EJ5	IK	PLYWAKPAFSZPAL-KKFHFHRHSA-N
DMS9EJ5	IU	2-[[(7S)-7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetic acid
DMS9EJ5	DE	Irritable bowel syndrome

DMQUF9I	ID	DMQUF9I
DMQUF9I	DN	SR-58894A
DMQUF9I	HS	Terminated
DMQUF9I	CP	Sanofi-Synthelabo
DMQUF9I	DE	Gastrointestinal disease

DM6ASLF	ID	DM6ASLF
DM6ASLF	DN	SR-80027A
DM6ASLF	HS	Terminated
DM6ASLF	SN	Org-31550
DM6ASLF	CP	Sanofi
DM6ASLF	DE	Thrombosis

DMMPSY2	ID	DMMPSY2
DMMPSY2	DN	SRI 63-441
DMMPSY2	HS	Terminated
DMMPSY2	SN	Sri 63-441; 104786-62-1; Sandoz 63-441; Sdz 63-441; AC1L338B; SCHEMBL8702414; DTXSID60146736; 1-(2-(Hydroxy((tetrahydro-5-((octadecylaminocarbonyl)oxy)methyl)furan-2-yl)methoxyphosphinyloxy)ethyl)quinolinium; erythro-Hexitol, 2,5-anhydro-3,4-dideoxy-, octadecylcarbamate 2-quinolinioethyl hydrogen phosphate, hydroxide, inner salt; [(2R,5S)-5-(octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl 2-quinolin-1-ium-1-ylethyl phosphate; DL-erythro-Hexitol, 2,5-anhydro-3,4-dideoxy-, octadecylcarbamate 2-quinolinioethyl hydrogen p
DMMPSY2	DT	Small molecular drug
DMMPSY2	PC	108044
DMMPSY2	MW	662.8
DMMPSY2	FM	C36H59N2O7P
DMMPSY2	IC	InChI=1S/C36H59N2O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-26-37-36(39)42-30-33-24-25-34(45-33)31-44-46(40,41)43-29-28-38-27-20-22-32-21-17-18-23-35(32)38/h17-18,20-23,27,33-34H,2-16,19,24-26,28-31H2,1H3,(H-,37,39,40,41)/t33-,34+/m0/s1
DMMPSY2	CS	CCCCCCCCCCCCCCCCCCNC(=O)OC[C@@H]1CC[C@@H](O1)COP(=O)([O-])OCC[N+]2=CC=CC3=CC=CC=C32
DMMPSY2	IK	OLDMQSKCCHULOB-SZAHLOSFSA-N
DMMPSY2	IU	[(2R,5S)-5-(octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl 2-quinolin-1-ium-1-ylethyl phosphate
DMMPSY2	CA	CAS 104786-62-1

DMBEUN6	ID	DMBEUN6
DMBEUN6	DN	SRI-3072
DMBEUN6	HS	Terminated
DMBEUN6	SN	Mycobacterium tuberculosis FtsZ polymerization inhibitors, Southern Research Institute; SRI-7614; Antimycobacterials (alkoxycarbonylaminopyridines), Southern Research Institute
DMBEUN6	CP	Southern Research Institute
DMBEUN6	DT	Small molecular drug
DMBEUN6	PC	493469
DMBEUN6	MW	540.7
DMBEUN6	FM	C32H40N6O2
DMBEUN6	IC	InChI=1S/C32H40N6O2/c1-6-38(7-2)21-22(4)19-23(5)33-26-20-27(35-32(39)40-8-3)34-31-30(26)36-28(24-15-11-9-12-16-24)29(37-31)25-17-13-10-14-18-25/h9-18,20,22-23H,6-8,19,21H2,1-5H3,(H2,33,34,35,37,39)
DMBEUN6	CS	CCN(CC)CC(C)CC(C)NC1=CC(=NC2=C1N=C(C(=N2)C3=CC=CC=C3)C4=CC=CC=C4)NC(=O)OCC
DMBEUN6	IK	MKJUVACMILVNTO-UHFFFAOYSA-N
DMBEUN6	IU	ethyl N-[8-[[5-(diethylamino)-4-methylpentan-2-yl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]carbamate
DMBEUN6	DE	Mycobacterium infection

DMFLPU5	ID	DMFLPU5
DMFLPU5	DN	SRSC-355
DMFLPU5	HS	Terminated
DMFLPU5	SN	SGX-211; SGX-355; Neuropathic pain therapeutic (systemic depot, CK polymer), Sirus
DMFLPU5	CP	Sirus Pharmaceuticals Ltd
DMFLPU5	DE	Neuropathic pain

DM8MZWR	ID	DM8MZWR
DM8MZWR	DN	SRSS-021
DM8MZWR	HS	Terminated
DM8MZWR	SN	Anti-emetic, Sirus
DM8MZWR	CP	Sirus Pharmaceuticals Ltd
DM8MZWR	DE	Vomiting

DMUGPDB	ID	DMUGPDB
DMUGPDB	DN	SRSS-023
DMUGPDB	HS	Terminated
DMUGPDB	SN	Triptan (migraine, sublingual), Sirus; 5HT1 agonist (migraine, sublingual), Sirus
DMUGPDB	CP	Sirus Pharmaceuticals Ltd
DMUGPDB	DE	Migraine

DMWL4MI	ID	DMWL4MI
DMWL4MI	DN	SSR-69071
DMWL4MI	HS	Terminated
DMWL4MI	SN	SSR 69071; 344930-95-6; SSR69071; DSSTox_RID_82301; DSSTox_CID_27368; DSSTox_GSID_47368; MLS006010264; SCHEMBL4295477; CHEMBL1354892; DTXSID1047368; CTK8E8740; CHEBI:93283; MolPort-023-276-460; HMS3269M07; ZINC1490807; Tox21_300247; AKOS024457139; NCGC00254231-01; NCGC00167751-02; NCGC00167751-01; NCGC00167751-03; SMR001822512; RT-015782; LS-191133; FT-0724044; CAS-344930-95-6; J-019626; BRD-K72895815-001-01-4
DMWL4MI	CP	Sanofi-Synthelabo
DMWL4MI	DT	Small molecular drug
DMWL4MI	PC	9872438
DMWL4MI	MW	556.6
DMWL4MI	FM	C27H32N4O7S
DMWL4MI	IC	InChI=1S/C27H32N4O7S/c1-18(2)20-14-19(36-3)15-22-25(20)27(33)31(39(22,34)35)17-38-23-16-24(32)30-11-7-8-21(26(30)28-23)37-13-12-29-9-5-4-6-10-29/h7-8,11,14-16,18H,4-6,9-10,12-13,17H2,1-3H3
DMWL4MI	CS	CC(C)C1=C2C(=CC(=C1)OC)S(=O)(=O)N(C2=O)COC3=CC(=O)N4C=CC=C(C4=N3)OCCN5CCCCC5
DMWL4MI	IK	DRZXDZYWZSKFDL-UHFFFAOYSA-N
DMWL4MI	IU	6-methoxy-1,1-dioxo-2-[[4-oxo-9-(2-piperidin-1-ylethoxy)pyrido[1,2-a]pyrimidin-2-yl]oxymethyl]-4-propan-2-yl-1,2-benzothiazol-3-one
DMWL4MI	CA	CAS 344930-95-6
DMWL4MI	CB	CHEBI:93283
DMWL4MI	DE	Chronic obstructive pulmonary disease

DMOJM08	ID	DMOJM08
DMOJM08	DN	Steroid hormone conjugates
DMOJM08	HS	Terminated
DMOJM08	SN	AM-454; Steroid hormone conjugates (diabetes); DHEA-PC, AMUR; DHEA-PC, SuperGen; DHEA-phosphocoline, SuperGen; Steroid hormone conjugates (diabetes), SuperGen
DMOJM08	CP	AMUR Pharmaceuticals Inc
DMOJM08	DE	Cachexia

DMO9UCK	ID	DMO9UCK
DMO9UCK	DN	SU5614
DMO9UCK	HS	Terminated
DMO9UCK	SN	SU 5614; SU-5614; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone
DMO9UCK	CP	Sugen Pharmaceuticals
DMO9UCK	DT	Small molecular drug
DMO9UCK	PC	6536806
DMO9UCK	MW	272.73
DMO9UCK	FM	C15H13ClN2O
DMO9UCK	IC	InChI=1S/C15H13ClN2O/c1-8-5-9(2)17-14(8)7-12-11-6-10(16)3-4-13(11)18-15(12)19/h3-7,17H,1-2H3,(H,18,19)/b12-7-
DMO9UCK	CS	CC1=CC(=C(N1)/C=C\\2/C3=C(C=CC(=C3)Cl)NC2=O)C
DMO9UCK	IK	XLBQNZICMYZIQT-GHXNOFRVSA-N
DMO9UCK	IU	(3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
DMO9UCK	CB	CHEBI:87159
DMO9UCK	DE	Airway inflammation

DMWCR1Z	ID	DMWCR1Z
DMWCR1Z	DN	SU-740
DMWCR1Z	HS	Terminated
DMWCR1Z	SN	SU-840
DMWCR1Z	CP	Taisho Pharmaceutical Co Ltd
DMWCR1Z	PC	6442365
DMWCR1Z	MW	422.5
DMWCR1Z	FM	C26H30O5
DMWCR1Z	IC	InChI=1S/C26H30O5/c1-18(2)14-15-30-21-11-12-22(24(16-21)31-17-25(28)29)23(27)13-8-19-6-9-20(10-7-19)26(3,4)5/h6-14,16H,15,17H2,1-5H3,(H,28,29)/b13-8+
DMWCR1Z	CS	CC(=CCOC1=CC(=C(C=C1)C(=O)/C=C/C2=CC=C(C=C2)C(C)(C)C)OCC(=O)O)C
DMWCR1Z	IK	ANQKJBMYDIXLBL-MDWZMJQESA-N
DMWCR1Z	IU	2-[2-[(E)-3-(4-tert-butylphenyl)prop-2-enoyl]-5-(3-methylbut-2-enoxy)phenoxy]acetic acid
DMWCR1Z	CA	CAS 134336-72-4
DMWCR1Z	DE	Stomach ulcer

DM4SVIR	ID	DM4SVIR
DM4SVIR	DN	Sulotroban
DM4SVIR	HS	Terminated
DM4SVIR	SN	BM-13177; SKF-95587
DM4SVIR	CP	Boehringer Mannheim GmbH
DM4SVIR	DT	Small molecular drug
DM4SVIR	PC	51550
DM4SVIR	MW	335.4
DM4SVIR	FM	C16H17NO5S
DM4SVIR	IC	InChI=1S/C16H17NO5S/c18-16(19)12-22-14-8-6-13(7-9-14)10-11-17-23(20,21)15-4-2-1-3-5-15/h1-9,17H,10-12H2,(H,18,19)
DM4SVIR	CS	C1=CC=C(C=C1)S(=O)(=O)NCCC2=CC=C(C=C2)OCC(=O)O
DM4SVIR	IK	XTNWJMVJVSGKLR-UHFFFAOYSA-N
DM4SVIR	IU	2-[4-[2-(benzenesulfonamido)ethyl]phenoxy]acetic acid
DM4SVIR	CA	CAS 72131-33-0
DM4SVIR	DE	Asthma

DMC1A42	ID	DMC1A42
DMC1A42	DN	SUN-11031
DMC1A42	HS	Terminated
DMC1A42	SN	6,6,6-trifluoromethionine; AC1L5KZ2; SCHEMBL245985; CTK1D7491; NSC73030; NSC-73030; 2-Amino-4-(trifluoromethylthio)butyric acid; 2-amino-4-(trifluoromethylsulfanyl)butanoic acid
DMC1A42	CP	Daiichi Suntory Pharma
DMC1A42	DT	Small molecular drug
DMC1A42	PC	251951
DMC1A42	MW	203.19
DMC1A42	FM	C5H8F3NO2S
DMC1A42	IC	InChI=1S/C5H8F3NO2S/c6-5(7,8)12-2-1-3(9)4(10)11/h3H,1-2,9H2,(H,10,11)
DMC1A42	CS	C(CSC(F)(F)F)C(C(=O)O)N
DMC1A42	IK	YLJLTSVBCXYTQK-UHFFFAOYSA-N
DMC1A42	IU	2-amino-4-(trifluoromethylsulfanyl)butanoic acid
DMC1A42	DE	Anorexia nervosa cachexia

DMAM3OH	ID	DMAM3OH
DMAM3OH	DN	SUN-E3001
DMAM3OH	HS	Terminated
DMAM3OH	SN	CHS-13340; PTH[1,34], Suntory; RhPTH(1-34); RhPTH[1,34], Daiichi Asubio Pharma; Recombinant human parathyroid hormone[residues 1-34] (osteoporosis), Asubio Pharma; RhPTH[1,34] (osteporosis), Asubio Pharma
DMAM3OH	CP	Suntory Ltd
DMAM3OH	DE	Osteoporosis

DMG2SQM	ID	DMG2SQM
DMG2SQM	DN	SYN-1134
DMG2SQM	HS	Terminated
DMG2SQM	SN	Elastase inhibitors, NAEJA; SYN-1360; SYN-1386; SYN-1389; SYN-1390; SYN-1396
DMG2SQM	CP	NAEJA Pharmaceuticals Inc
DMG2SQM	DE	Cystic fibrosis

DMOGQ2L	ID	DMOGQ2L
DMOGQ2L	DN	T-686
DMOGQ2L	HS	Terminated
DMOGQ2L	SN	PAI-1 inhibitor, Tanabe
DMOGQ2L	CP	Tanabe Seiyaku Co Ltd
DMOGQ2L	DT	Small molecular drug
DMOGQ2L	PC	6438903
DMOGQ2L	MW	365.4
DMOGQ2L	FM	C21H19NO5
DMOGQ2L	IC	InChI=1S/C21H19NO5/c1-25-17-11-14(12-18(26-2)19(17)27-3)10-16-15(20(23)22-21(16)24)9-13-7-5-4-6-8-13/h4-12H,1-3H3,(H,22,23,24)/b15-9+,16-10+
DMOGQ2L	CS	COC1=CC(=CC(=C1OC)OC)/C=C/2\\C(=C/C3=CC=CC=C3)\\C(=O)NC2=O
DMOGQ2L	IK	YQALUFAJAWGTQV-KAVGSWPWSA-N
DMOGQ2L	IU	(3E,4E)-3-benzylidene-4-[(3,4,5-trimethoxyphenyl)methylidene]pyrrolidine-2,5-dione
DMOGQ2L	CA	CAS 152815-51-5
DMOGQ2L	DE	Arteriosclerosis

DM0TELR	ID	DM0TELR
DM0TELR	DN	TAK-779
DM0TELR	HS	Terminated
DM0TELR	SN	TAK 779; TAK 799; TAK779; TAK799; E-921; TAK 779 (Chloride); TAK779 & CD4 mAb; E921/TAK-779; TAK-279 & PRO 140; TAK-779 & PA14; TAK-779 (Chloride); TAK 779 (*Chloride*); TAK-779 (*Chloride*); Dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7H-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium; Dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7H-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium chloride; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium & Monoclonal antibody directed against CD4 receptor; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium PRO 140 (Anti-CCR5 monoclonal antibody); N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium & PRO 140 (Anti-CCR5 monoclonal antibody); N,N-Dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium chloride; N,N-Dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium; 2H-Pyran-4-aminium, N,N-dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-, chloride
DM0TELR	CP	Takeda
DM0TELR	DT	Small molecular drug
DM0TELR	PC	183789
DM0TELR	MW	531.1
DM0TELR	FM	C33H39ClN2O2
DM0TELR	IC	InChI=1S/C33H38N2O2.ClH/c1-24-7-11-27(12-8-24)28-14-13-26-5-4-6-29(22-30(26)21-28)33(36)34-31-15-9-25(10-16-31)23-35(2,3)32-17-19-37-20-18-32;/h7-16,21-22,32H,4-6,17-20,23H2,1-3H3;1H
DM0TELR	CS	CC1=CC=C(C=C1)C2=CC3=C(CCCC(=C3)C(=O)NC4=CC=C(C=C4)C[N+](C)(C)C5CCOCC5)C=C2.[Cl-]
DM0TELR	IK	VDALIBWXVQVFGZ-UHFFFAOYSA-N
DM0TELR	IU	dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7H-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;chloride
DM0TELR	CA	CAS 229005-80-5
DM0TELR	DE	Transplant rejection

DM2OFBT	ID	DM2OFBT
DM2OFBT	DN	Talisomycin
DM2OFBT	HS	Terminated
DM2OFBT	SN	Talisomycin; Tallysomycin A; Antibiotic BU 2231A; Talisomycin [USAN:INN]; Talisomycinum [INN-Latin]; Talisomycine [INN-French]; Talisomycina [INN-Spanish]; BU 2231A; AC1Q5FXD; AC1L2HKD; N(sup 1)-(4-Amino-5-((3-((4-aminobutyl)amino)propyl)carbamoyl)pentyl)-13-((4-amino-4,6-dideoxy-alpha-L-talopyranosyl)oxy)-19-demethyl-12-hydroxybleomycinamide; Bleomycinamide, N(sup 1)-(4-amino-6-((3-((4-aminobutyl)amino)propyl)amino)-6-oxohexyl)-13-((4-amino-4,6-dideoxy-alpha-L-talopyranosyl)oxy)-19-demethyl-12-hydroxy-
DM2OFBT	DT	Small molecular drug
DM2OFBT	PC	72173
DM2OFBT	MW	1731.9
DM2OFBT	FM	C68H110N22O27S2
DM2OFBT	IC	InChI=1S/C68H110N22O27S2/c1-25-42(87-57(89-55(25)74)31(16-38(72)95)81-18-30(71)56(75)105)59(107)88-44(52(32-19-78-24-82-32)114-67-54(48(101)45(98)36(20-91)113-67)115-66-50(103)53(116-68(76)110)46(99)37(21-92)112-66)61(109)83-26(2)35(94)17-40(97)86-43(27(3)93)60(108)90-62(117-65-49(102)47(100)41(73)28(4)111-65)51(104)64-85-34(23-119-64)63-84-33(22-118-63)58(106)80-13-7-9-29(70)15-39(96)79-14-8-12-77-11-6-5-10-69/h19,22-24,26-31,35-37,41,43-54,62,65-67,77,81,91-94,98-104H,5-18,20-21,69-71,73H2,1-4H3,(H2,72,95)(H2,75,105)(H2,76,110)(H,78,82)(H,79,96)(H,80,106)(H,83,109)(H,86,97)(H,88,107)(H,90,108)(H2,74,87,89)/t26?,27?,28-,29?,30?,31?,35?,36-,37+,41+,43?,44?,45+,46+,47+,48-,49+,50-,51?,52?,53-,54-,62?,65-,66+,67+/m0/s1
DM2OFBT	CS	C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)OC(C(C2=NC(=CS2)C3=NC(=CS3)C(=O)NCCCC(CC(=O)NCCCNCCCCN)N)O)NC(=O)C(C(C)O)NC(=O)CC(C(C)NC(=O)C(C(C4=CN=CN4)O[C@@H]5[C@H]([C@H]([C@@H]([C@@H](O5)CO)O)O)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)OC(=O)N)O)NC(=O)C7=C(C(=NC(=N7)C(CC(=O)N)NCC(C(=O)N)N)N)C)O)O)O)N
DM2OFBT	IK	VUPBDWQPEOWRQP-SDSCCWNESA-N
DM2OFBT	IU	[(2R,3S,4S,5R,6R)-2-[(2S,3S,4S,5S,6S)-2-[3-[[5-[[1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate

DM54V0X	ID	DM54V0X
DM54V0X	DN	Tamoxifen methyl iodide
DM54V0X	HS	Terminated
DM54V0X	SN	Tamoxifen methiodide; Tamoxifen methyl iodide; CHEMBL1213783; MLS002701640; AC1MHWIV; N-Methyltamoxifen iodide; 107256-99-5; PXJJOGITBQXZEQ-JTHROIFXSA-M; NSC630510; NSC-630510; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N,N-trimethylethanaminium iodide; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium iodide; Ethanaminium, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N,N-trimethyl-, iodide, (Z)-
DM54V0X	DT	Small molecular drug
DM54V0X	PC	3033898
DM54V0X	MW	513.5
DM54V0X	FM	C27H32INO
DM54V0X	IC	InChI=1S/C27H32NO.HI/c1-5-26(22-12-8-6-9-13-22)27(23-14-10-7-11-15-23)24-16-18-25(19-17-24)29-21-20-28(2,3)4;/h6-19H,5,20-21H2,1-4H3;1H/q+1;/p-1/b27-26-;
DM54V0X	CS	CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCC[N+](C)(C)C)/C3=CC=CC=C3.[I-]
DM54V0X	IK	PXJJOGITBQXZEQ-JTHROIFXSA-M
DM54V0X	IU	2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide
DM54V0X	CA	CAS 107256-99-5

DMU3BDY	ID	DMU3BDY
DMU3BDY	DN	TAN-1496
DMU3BDY	HS	Terminated
DMU3BDY	SN	TAN-1496A; TAN-1496B; TAN-1496C; TAN-1496D; TAN-1496E
DMU3BDY	CP	Takeda Pharmaceutical Co Ltd
DMU3BDY	DE	Solid tumour/cancer

DM197D0	ID	DM197D0
DM197D0	DN	TAR-1
DM197D0	HS	Terminated
DM197D0	SN	P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions
DM197D0	CP	Ramot at Tel Aviv University Ltd
DM197D0	DT	Antibody
DM197D0	DE	Solid tumour/cancer

DMCFGS6	ID	DMCFGS6
DMCFGS6	DN	TCV-295
DMCFGS6	HS	Terminated
DMCFGS6	SN	2-(6-Bromo-7-chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine N-oxide
DMCFGS6	PC	9999062
DMCFGS6	MW	367.62
DMCFGS6	FM	C15H12BrClN2O2
DMCFGS6	IC	InChI=1S/C15H12BrClN2O2/c1-15(2)18-14(12-5-3-4-6-19(12)20)9-7-10(16)11(17)8-13(9)21-15/h3-8H,1-2H3
DMCFGS6	CS	CC1(N=C(C2=CC(=C(C=C2O1)Cl)Br)C3=CC=CC=[N+]3[O-])C
DMCFGS6	IK	YUEQBWZPZJXBHY-UHFFFAOYSA-N
DMCFGS6	IU	6-bromo-7-chloro-2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)-1,3-benzoxazine
DMCFGS6	DE	Hypertension

DMHS5DX	ID	DMHS5DX
DMHS5DX	DN	TEI-6522
DMHS5DX	HS	Terminated
DMHS5DX	CP	Teijin Ltd
DMHS5DX	PC	9953017
DMHS5DX	MW	403.6
DMHS5DX	FM	C24H37NO4
DMHS5DX	IC	InChI=1S/C24H37NO4/c1-5-6-7-8-9-10-11-12-16-24(2,3)23(27)25-21-20(28-4)14-13-18-19(26)15-17-29-22(18)21/h13-14H,5-12,15-17H2,1-4H3,(H,25,27)
DMHS5DX	CS	CCCCCCCCCCC(C)(C)C(=O)NC1=C(C=CC2=C1OCCC2=O)OC
DMHS5DX	IK	DJBINNZKEHJIFK-UHFFFAOYSA-N
DMHS5DX	IU	N-(7-methoxy-4-oxo-2,3-dihydrochromen-8-yl)-2,2-dimethyldodecanamide
DMHS5DX	DE	Arteriosclerosis

DMXM3B4	ID	DMXM3B4
DMXM3B4	DN	TEI-9874
DMXM3B4	HS	Terminated
DMXM3B4	CP	Teijin Institute for Biomedical Research
DMXM3B4	PC	9935533
DMXM3B4	MW	495.6
DMXM3B4	FM	C31H29NO5
DMXM3B4	IC	InChI=1S/C31H29NO5/c33-30(32-29-9-5-4-8-28(29)31(34)35)18-21-10-14-25(15-11-21)37-27-17-13-22-19-26(16-12-23(22)20-27)36-24-6-2-1-3-7-24/h4-5,8-17,19-20,24H,1-3,6-7,18H2,(H,32,33)(H,34,35)
DMXM3B4	CS	C1CCC(CC1)OC2=CC3=C(C=C2)C=C(C=C3)OC4=CC=C(C=C4)CC(=O)NC5=CC=CC=C5C(=O)O
DMXM3B4	IK	XNTHZBOCPVDIQB-UHFFFAOYSA-N
DMXM3B4	IU	2-[[2-[4-(6-cyclohexyloxynaphthalen-2-yl)oxyphenyl]acetyl]amino]benzoic acid
DMXM3B4	DE	Allergy

DMQIYZR	ID	DMQIYZR
DMQIYZR	DN	TER-16998
DMQIYZR	HS	Terminated
DMQIYZR	SN	TER-17411; TER-17529; TLK-16998; TLK-17411; TLK-19780; TLK-19781; Insulin receptor activators (oral, diabetes mellitus); Insulin receptor activators (oral, diabetes mellitus), ReceptorBio; Insulin receptor activators (oral, diabetes), Telik/Sanwa
DMQIYZR	CP	Telik Inc
DMQIYZR	DE	Diabetic complication

DM2X5R6	ID	DM2X5R6
DM2X5R6	DN	TERIKALANT
DM2X5R6	HS	Terminated
DM2X5R6	SN	Terikalant; Terikalant [INN]; UNII-G8ZMP77RGJ; Terikalantum [INN-Latin]; G8ZMP77RGJ; RP-58866; CHEMBL96153; Terikalant (INN); RP62719; 121277-96-1; C24H31NO3; Terikalantum; (-)-(S)-1-(2-(4-Chromanyl)ethyl)-4-(3,4-dimethoxyphenyl)piperidine; RP-62719; (-)-(s)-1-[2-(4-chromanyl)ethyl]-4-(3,4-dimethoxyphenyl)piperidine; AC1L24AK; SCHEMBL1815992; AC1Q5768; BDBM50131442; RP 62719; 132338-79-5; RP 58866; LS-172487; D09757; (S)-1-(2-(chroman-4-yl)ethyl)-4-(3,4-dimethoxyphenyl)piperidine
DM2X5R6	DT	Small molecular drug
DM2X5R6	PC	65941
DM2X5R6	MW	381.5
DM2X5R6	FM	C24H31NO3
DM2X5R6	IC	InChI=1S/C24H31NO3/c1-26-23-8-7-20(17-24(23)27-2)18-9-13-25(14-10-18)15-11-19-12-16-28-22-6-4-3-5-21(19)22/h3-8,17-19H,9-16H2,1-2H3/t19-/m0/s1
DM2X5R6	CS	COC1=C(C=C(C=C1)C2CCN(CC2)CC[C@H]3CCOC4=CC=CC=C34)OC
DM2X5R6	IK	UIZPEXQHMIZQPQ-IBGZPJMESA-N
DM2X5R6	IU	1-[2-[(4S)-3,4-dihydro-2H-chromen-4-yl]ethyl]-4-(3,4-dimethoxyphenyl)piperidine
DM2X5R6	CA	CAS 121277-96-1
DM2X5R6	DE	Cardiac arrhythmias

DMSRDGE	ID	DMSRDGE
DMSRDGE	DN	TH-0318
DMSRDGE	HS	Terminated
DMSRDGE	SN	ThGLP-1, Theratechnologies; LAP-stabilized GLP-1 analogs (diabetes), Theratechnologies/OctoPlus
DMSRDGE	CP	Theratechnologies
DMSRDGE	DE	Diabetic complication

DMG1MPD	ID	DMG1MPD
DMG1MPD	DN	TH-9229
DMG1MPD	HS	Terminated
DMG1MPD	SN	Protectazem
DMG1MPD	CP	Theratechnologies Inc
DMG1MPD	DE	Reperfusion injury

DM8S593	ID	DM8S593
DM8S593	DN	Thioperamide
DM8S593	HS	Terminated
DM8S593	SN	Thioperamide; 106243-16-7; Thioperamide maleate; MR 12842; UNII-II4319BWUI; 1-Piperidinecarbothioamide, N-cyclohexyl-4-(1H-imidazol-4-yl)-; II4319BWUI; N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide; CHEMBL260374; N-cyclohexyl-4-(1H-imidazol-5-yl)piperidine-1-carbothioamide; CHEBI:81391; N-Cyclohexyl-4-(1H-imidazol-5-yl)-1-piperidinecarbothioamide; Tocris-0644; Lopac-T-123; Lopac0_001214; SCHEMBL2235762; GTPL1267; AC1MI071; BDBM22914; DTXSID50147555; MolPort-023-275-907; MolPort-015-163-994
DM8S593	DT	Small molecular drug
DM8S593	PC	3035905
DM8S593	MW	292.4
DM8S593	FM	C15H24N4S
DM8S593	IC	InChI=1S/C15H24N4S/c20-15(18-13-4-2-1-3-5-13)19-8-6-12(7-9-19)14-10-16-11-17-14/h10-13H,1-9H2,(H,16,17)(H,18,20)
DM8S593	CS	C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3
DM8S593	IK	QKDDJDBFONZGBW-UHFFFAOYSA-N
DM8S593	IU	N-cyclohexyl-4-(1H-imidazol-5-yl)piperidine-1-carbothioamide
DM8S593	CA	CAS 106243-16-7
DM8S593	CB	CHEBI:81391
DM8S593	DE	Cognitive impairment

DM0SCDB	ID	DM0SCDB
DM0SCDB	DN	TIAPAFANT
DM0SCDB	HS	Terminated
DM0SCDB	SN	PCA-4248; 2,4,6-Trimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid 3-methyl 5-(2-phenylthio)ethyl diester
DM0SCDB	DT	Small molecular drug
DM0SCDB	PC	4698
DM0SCDB	MW	361.5
DM0SCDB	FM	C19H23NO4S
DM0SCDB	IC	InChI=1S/C19H23NO4S/c1-12-16(18(21)23-4)13(2)20-14(3)17(12)19(22)24-10-11-25-15-8-6-5-7-9-15/h5-9,12,20H,10-11H2,1-4H3
DM0SCDB	CS	CC1C(=C(NC(=C1C(=O)OCCSC2=CC=CC=C2)C)C)C(=O)OC
DM0SCDB	IK	DHCNAWNKZMNTIS-UHFFFAOYSA-N
DM0SCDB	IU	3-O-methyl 5-O-(2-phenylsulfanylethyl) 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM0SCDB	CA	CAS 123875-01-4
DM0SCDB	CB	CHEBI:91615
DM0SCDB	DE	Sepsis

DMGCI6E	ID	DMGCI6E
DMGCI6E	DN	Tipredane
DMGCI6E	HS	Terminated
DMGCI6E	SN	Uoderm; Acti-Derm I; SQ-27239
DMGCI6E	CP	Bristol-Myers Squibb Co
DMGCI6E	DT	Small molecular drug
DMGCI6E	PC	6917939
DMGCI6E	MW	410.6
DMGCI6E	FM	C22H31FO2S2
DMGCI6E	IC	InChI=1S/C22H31FO2S2/c1-5-27-21(26-4)11-9-16-17-7-6-14-12-15(24)8-10-19(14,2)22(17,23)18(25)13-20(16,21)3/h8,10,12,16-18,25H,5-7,9,11,13H2,1-4H3/t16-,17-,18-,19-,20-,21+,22-/m0/s1
DMGCI6E	CS	CCS[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)SC
DMGCI6E	IK	DXEXNWDGDYUITL-FXSSSKFRSA-N
DMGCI6E	IU	(8S,9R,10S,11S,13S,14S,17R)-17-ethylsulfanyl-9-fluoro-11-hydroxy-10,13-dimethyl-17-methylsulfanyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMGCI6E	CA	CAS 85197-77-9
DMGCI6E	DE	Allergy

DM4YQDX	ID	DM4YQDX
DM4YQDX	DN	TJN-220
DM4YQDX	HS	Terminated
DM4YQDX	SN	O-Ethylfangchinoline; O-ethylfangchinoline, Tsumura; 7-O-ethylfangchinoline, Tsumura
DM4YQDX	CP	Tsumura & Co
DM4YQDX	DT	Small molecular drug
DM4YQDX	PC	3081672
DM4YQDX	MW	636.8
DM4YQDX	FM	C39H44N2O6
DM4YQDX	IC	InChI=1S/C39H44N2O6/c1-7-45-38-36(44-6)22-27-15-17-41(3)31-19-25-10-13-32(42-4)34(20-25)46-28-11-8-24(9-12-28)18-30-29-23-35(47-39(38)37(27)31)33(43-5)21-26(29)14-16-40(30)2/h8-13,20-23,30-31H,7,14-19H2,1-6H3/t30-,31-/m0/s1
DM4YQDX	CS	CCOC1=C(C=C2CCN([C@@H]3C2=C1OC4=C(C=C5CCN([C@H](C5=C4)CC6=CC=C(C=C6)OC7=C(C=CC(=C7)C3)OC)C)OC)C)OC
DM4YQDX	IK	VNBSKOLSTYLJBG-CONSDPRKSA-N
DM4YQDX	IU	(1S,14S)-21-ethoxy-9,20,25-trimethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene
DM4YQDX	CA	CAS 118160-59-1
DM4YQDX	DE	Hypertension

DMKSPYI	ID	DMKSPYI
DMKSPYI	DN	TJN-598
DMKSPYI	HS	Terminated
DMKSPYI	SN	Glomerulonephritis therapy, Tsumura
DMKSPYI	CP	Tsumura & Co
DMKSPYI	DE	Glomerulonephritis

DMTNB6G	ID	DMTNB6G
DMTNB6G	DN	TNFQb therapeutic vaccines
DMTNB6G	HS	Terminated
DMTNB6G	SN	TNFQb; CYT-020-TNFQb; TNF-targeted vaccine (inflammation, Immunodrug), Cytos Biotechnology; TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease); TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos; Immunodrug vaccines (TNF) (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos
DMTNB6G	CP	Cytos Biotechnology AG
DMTNB6G	DT	Vaccine
DMTNB6G	DE	Crohn disease

DMZKIE0	ID	DMZKIE0
DMZKIE0	DN	Tolerimab
DMZKIE0	HS	Terminated
DMZKIE0	SN	Transplant rejection therapy, Innogenetics; MAbs (organ transplant), Innogenetics; Monoclonal antibodies (organ transplant), Innogenetics; ToleriMab (anti-B7.1/B7.2)
DMZKIE0	CP	Innogenetics NV
DMZKIE0	DT	Antibody
DMZKIE0	DE	Transplant rejection

DM385D9	ID	DM385D9
DM385D9	DN	Tomelukast
DM385D9	HS	Terminated
DM385D9	SN	LY-171883
DM385D9	CP	Eli Lilly & Co
DM385D9	DT	Small molecular drug
DM385D9	PC	3969
DM385D9	MW	318.37
DM385D9	FM	C16H22N4O3
DM385D9	IC	InChI=1S/C16H22N4O3/c1-3-6-13-14(9-8-12(11(2)21)16(13)22)23-10-5-4-7-15-17-19-20-18-15/h8-9,22H,3-7,10H2,1-2H3,(H,17,18,19,20)
DM385D9	CS	CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCC2=NNN=N2
DM385D9	IK	MWYHLEQJTQJHSS-UHFFFAOYSA-N
DM385D9	IU	1-[2-hydroxy-3-propyl-4-[4-(2H-tetrazol-5-yl)butoxy]phenyl]ethanone
DM385D9	CA	CAS 88107-10-2
DM385D9	CB	CHEBI:75310
DM385D9	DE	Asthma

DMRBGI6	ID	DMRBGI6
DMRBGI6	DN	Torbafylline
DMRBGI6	HS	Terminated
DMRBGI6	SN	Torbaphylline; HWA-448
DMRBGI6	CP	Hoechst Marion Roussel Inc
DMRBGI6	DT	Small molecular drug
DMRBGI6	PC	65888
DMRBGI6	MW	338.4
DMRBGI6	FM	C16H26N4O4
DMRBGI6	IC	InChI=1S/C16H26N4O4/c1-5-24-11-19-10-17-13-12(19)14(21)20(15(22)18(13)4)9-7-6-8-16(2,3)23/h10,23H,5-9,11H2,1-4H3
DMRBGI6	CS	CCOCN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(C)(C)O
DMRBGI6	IK	QSXXLDDWVCEBFP-UHFFFAOYSA-N
DMRBGI6	IU	7-(ethoxymethyl)-1-(5-hydroxy-5-methylhexyl)-3-methylpurine-2,6-dione
DMRBGI6	CA	CAS 105102-21-4
DMRBGI6	DE	Peripheral vascular disease

DM5ZNSQ	ID	DM5ZNSQ
DM5ZNSQ	DN	TP-20
DM5ZNSQ	HS	Terminated
DM5ZNSQ	SN	SCR1sLex; SLex/sCR1
DM5ZNSQ	CP	Celldex Therapeutics Inc
DM5ZNSQ	DE	Cerebrovascular ischaemia

DMQRSMD	ID	DMQRSMD
DMQRSMD	DN	Trequinsin
DMQRSMD	HS	Terminated
DMQRSMD	SN	trequinsin; Trequinsin [INN]; Trequinsinum [INN-Latin]; Trequinsine [INN-French]; 79855-88-2; UNII-739I2958C1; CHEMBL285913; (2e)-2-(mesitylimino)-9,10-dimethoxy-3-methyl-2,3,6,7-tetrahydro-4h-pyrimido[6,1-a]isoquinolin-4-one; 739I2958C1; Trequinsinum; Trequinsine; C24H27N3O3; 2,3,6,7-Tetrahydro-2-(mesitylimino)-9,10-dimethoxy-3-methyl-4H-pyrimido(6,1-a)isoquinolin-4-one; AC1L1KKE; AC1Q6LSV; Lopac-T-2057; Lopac0_001165; KBioGR_000072; KBioSS_000072; BSPBio_001352; SCHEMBL2777196; SCHEMBL2396911; CHEMBL588593; CHEMBL1411581
DMQRSMD	DT	Small molecular drug
DMQRSMD	PC	5537
DMQRSMD	MW	405.5
DMQRSMD	FM	C24H27N3O3
DMQRSMD	IC	InChI=1S/C24H27N3O3/c1-14-9-15(2)23(16(3)10-14)25-22-13-19-18-12-21(30-6)20(29-5)11-17(18)7-8-27(19)24(28)26(22)4/h9-13H,7-8H2,1-6H3
DMQRSMD	CS	CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2C)OC)OC)C
DMQRSMD	IK	MCMSJVMUSBZUCN-UHFFFAOYSA-N
DMQRSMD	IU	9,10-dimethoxy-3-methyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one
DMQRSMD	CA	CAS 79855-88-2
DMQRSMD	CB	CHEBI:93477

DMUHBSI	ID	DMUHBSI
DMUHBSI	DN	Tridegin
DMUHBSI	HS	Terminated
DMUHBSI	CP	Biopharm
DMUHBSI	DE	Thrombosis

DMASENP	ID	DMASENP
DMASENP	DN	TULOPAFANT
DMASENP	HS	Terminated
DMASENP	SN	RP-59227; Tulopafant; (R)-(+)-3'-Benzoyl-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxanilide; (R)-(+)-N-(3-Benzoylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide; 59227-RP
DMASENP	DT	Small molecular drug
DMASENP	PC	65927
DMASENP	MW	425.5
DMASENP	FM	C25H19N3O2S
DMASENP	IC	InChI=1S/C25H19N3O2S/c29-23(17-6-2-1-3-7-17)18-8-4-10-20(14-18)27-24(30)21-11-13-28-22(21)16-31-25(28)19-9-5-12-26-15-19/h1-15,25H,16H2,(H,27,30)
DMASENP	CS	C1C2=C(C=CN2C(S1)C3=CN=CC=C3)C(=O)NC4=CC=CC(=C4)C(=O)C5=CC=CC=C5
DMASENP	IK	PQQFNXGONTVQLM-UHFFFAOYSA-N
DMASENP	IU	N-(3-benzoylphenyl)-3-pyridin-3-yl-1,3-dihydropyrrolo[1,2-c][1,3]thiazole-7-carboxamide
DMASENP	DE	Cardiac arrhythmias

DMR3S9B	ID	DMR3S9B
DMR3S9B	DN	Tyloxapol
DMR3S9B	HS	Terminated
DMR3S9B	SN	Alevaire; Enuclene; Macrocyclon; Oxirane; Superinone; Superiuone; Tiloxapol; Tyloxapolum; Tyloxypal; Component of Alevaire; Superiuone [French]; Triton WR 1339; P-Isooctylpolyoxyethylenephenol formaldehyde polymer; Tiloxapol [INN-Spanish]; Triton A-20; Triton WR-1339; Tyloxapolum [INN-Latin]; Oxyethylated tertiary octyl-phenol-formaldehyde polymer; Triton W.R.1339; Tyloxapol [USAN:BAN:INN]; Ethylene oxide-formaldehyde-p-octylphenol copolymer; P-(1,1,3,3-Tetramethylbutyl)phenol polymer with ethylene oxide and formaldehyde; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetra methylbutyl)phenol; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol; Phenol, 4-(1,1,3,3-tetramethylbutyl)-, polymer with formaldehyde and oxirane; Phenol, p-(1,1,3,3-tetramethylbutyl)-, polymer with ethylene oxide and formaldehyde; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde & oxirane; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde oxirane; 4-(1,1,3,3-tetramethylbutyl)phenol; 4-(2,4,4-trimethylpentan-2-yl)phenol
DMR3S9B	CP	Discovery Laboratories
DMR3S9B	DT	Small molecular drug
DMR3S9B	PC	71388
DMR3S9B	MW	280.4
DMR3S9B	FM	C17H28O3
DMR3S9B	IC	InChI=1S/C14H22O.C2H4O.CH2O/c1-13(2,3)10-14(4,5)11-6-8-12(15)9-7-11;1-2-3-1;1-2/h6-9,15H,10H2,1-5H3;1-2H2;1H2
DMR3S9B	CS	CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1
DMR3S9B	IK	MDYZKJNTKZIUSK-UHFFFAOYSA-N
DMR3S9B	IU	formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol
DMR3S9B	CA	CAS 25301-02-4
DMR3S9B	CB	CHEBI:141517
DMR3S9B	DE	Cystic fibrosis

DM4WUEP	ID	DM4WUEP
DM4WUEP	DN	U-54494A
DM4WUEP	HS	Terminated
DM4WUEP	SN	C18H24Cl2N2O; U 54494A; U 54494; U-54494; U-54494A; cis-3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzamide; Benzamide, 3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-, trans-; AC1L3TTM; 92953-41-8; AC1Q3O5Y; SCHEMBL11610023; 3,4-dichloro-n-methyl-n-[(1r,2r)-2-(pyrrolidin-1-yl)cyclohexyl]benzamide; LS-178194; A845921; UNII-I3NE36R0XJ component JUBNVWGVNWIXMB-IAGOWNOFSA-N; trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzamide
DM4WUEP	CP	Pharmacia & Upjohn Co
DM4WUEP	DT	Small molecular drug
DM4WUEP	PC	122015
DM4WUEP	MW	355.3
DM4WUEP	FM	C18H24Cl2N2O
DM4WUEP	IC	InChI=1S/C18H24Cl2N2O/c1-21(18(23)13-8-9-14(19)15(20)12-13)16-6-2-3-7-17(16)22-10-4-5-11-22/h8-9,12,16-17H,2-7,10-11H2,1H3/t16-,17-/m1/s1
DM4WUEP	CS	CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)C3=CC(=C(C=C3)Cl)Cl
DM4WUEP	IK	JUBNVWGVNWIXMB-IAGOWNOFSA-N
DM4WUEP	IU	3,4-dichloro-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]benzamide
DM4WUEP	CA	CAS 92953-41-8
DM4WUEP	DE	Epilepsy

DMRBXEA	ID	DMRBXEA
DMRBXEA	DN	U-75875
DMRBXEA	HS	Terminated
DMRBXEA	SN	U-75875; U 75875; 112190-24-6; CHEMBL3350189; U75875; Pnu-75875; 1hiv; AC1NUHX2; Noa-his-cha-psi(CH(OH)CH(OH))-val-ile-amp; NOA-HIS-CAV-ILE-APY; SCHEMBL15532017; DTXSID20149940; BDBM50212827; 1-Naphthoxyacetyl-histidyl-5-amino-6-cyclohexyl-3,4-dihydroxy-2-isopropylhexanoyl-isoleucyl-2-aminopyridine; Noa-His-Cha.psi.[CHOHCHOH]Val-Ile-Amp; L-Idonamide, 6-cyclohexyl-2,5,6-trideoxy-5-[[(2S)-3-(1H-imidazol-4-yl)-2-[[(1-naphthalenyloxy)acetyl]amino]-1-oxopropyl]amino]-2-(1-methylethyl)-N-[(1S,2S)-2-methyl-1-[[(2-pyridinylmethyl
DMRBXEA	CP	Pharmacia & Upjohn Co
DMRBXEA	DT	Small molecular drug
DMRBXEA	PC	5479205
DMRBXEA	MW	812
DMRBXEA	FM	C45H61N7O7
DMRBXEA	IC	InChI=1S/C45H61N7O7/c1-5-29(4)40(45(58)48-25-32-18-11-12-21-47-32)52-44(57)39(28(2)3)42(55)41(54)35(22-30-14-7-6-8-15-30)51-43(56)36(23-33-24-46-27-49-33)50-38(53)26-59-37-20-13-17-31-16-9-10-19-34(31)37/h9-13,16-21,24,27-30,35-36,39-42,54-55H,5-8,14-15,22-23,25-26H2,1-4H3,(H,46,49)(H,48,58)(H,50,53)(H,51,56)(H,52,57)/t29-,35-,36-,39+,40-,41+,42+/m0/s1
DMRBXEA	CS	CC[C@H](C)[C@@H](C(=O)NCC1=CC=CC=N1)NC(=O)[C@@H]([C@H]([C@@H]([C@H](CC2CCCCC2)NC(=O)[C@H](CC3=CN=CN3)NC(=O)COC4=CC=CC5=CC=CC=C54)O)O)C(C)C
DMRBXEA	IK	ZTKCGLWIXHAITR-JIFWBGJESA-N
DMRBXEA	IU	(2R,3R,4R,5S)-6-cyclohexyl-3,4-dihydroxy-5-[[(2S)-3-(1H-imidazol-5-yl)-2-[(2-naphthalen-1-yloxyacetyl)amino]propanoyl]amino]-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]-2-propan-2-ylhexanamide
DMRBXEA	CA	CAS 112190-24-6
DMRBXEA	DE	Human immunodeficiency virus infection

DMGUMWP	ID	DMGUMWP
DMGUMWP	DN	U-80816
DMGUMWP	HS	Terminated
DMGUMWP	CP	Pharmacia & Upjohn Co
DMGUMWP	PC	10176765
DMGUMWP	MW	216.28
DMGUMWP	FM	C13H16N2O
DMGUMWP	IC	InChI=1S/C13H16N2O/c1-12-6-4-10-14(12)8-2-3-9-15-11-5-7-13(15)16/h4,6,10H,5,7-9,11H2,1H3
DMGUMWP	CS	CC1=CC=CN1CC#CCN2CCCC2=O
DMGUMWP	IK	RBCXUJODVKKGBN-UHFFFAOYSA-N
DMGUMWP	IU	1-[4-(2-methylpyrrol-1-yl)but-2-ynyl]pyrrolidin-2-one
DMGUMWP	DE	Amnesia

DMTMZJ4	ID	DMTMZJ4
DMTMZJ4	DN	U-90042
DMTMZJ4	HS	Terminated
DMTMZJ4	SN	U 90042; 134516-99-7; U90042; Diimidazo[1,5-a:1',2'-c]quinazoline,11-chloro-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-; ACMC-20ejs3; SCHEMBL7326473; CTK4B9224; DTXSID40158771; MolPort-023-276-561; ZINC34033310; AKOS024457266; NCGC00378706-01; B7164; J-006546; 11-Chloro-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydrodiimidazo[1,5-a:1',2'-c]quinazoline
DMTMZJ4	CP	Pharmacia & Upjohn Co
DMTMZJ4	DT	Small molecular drug
DMTMZJ4	PC	9928470
DMTMZJ4	MW	352.8
DMTMZJ4	FM	C17H13ClN6O
DMTMZJ4	IC	InChI=1S/C17H13ClN6O/c18-10-3-4-12-11(7-10)15-19-5-6-23(15)17-13(20-8-24(12)17)14-21-16(25-22-14)9-1-2-9/h3-4,7-9H,1-2,5-6H2
DMTMZJ4	CS	C1CC1C2=NC(=NO2)C3=C4N5CCN=C5C6=C(N4C=N3)C=CC(=C6)Cl
DMTMZJ4	IK	CLPSAAPUJUVQPP-UHFFFAOYSA-N
DMTMZJ4	IU	3-(14-chloro-2,4,7,10-tetrazatetracyclo[10.4.0.02,6.07,11]hexadeca-1(12),3,5,10,13,15-hexaen-5-yl)-5-cyclopropyl-1,2,4-oxadiazole
DMTMZJ4	CA	CAS 134516-99-7
DMTMZJ4	DE	Anxiety disorder

DMTYO3P	ID	DMTYO3P
DMTYO3P	DN	U-92032
DMTYO3P	HS	Terminated
DMTYO3P	SN	U-92032; U 92032; CHEMBL327057; 142223-92-5; AC1L30XY; SCHEMBL195024; DTXSID70161975; BDBM50091592; u92032; 7-((4-(Bis(4-fluorophenyl)methyl)-1-piperazinyl)methyl)-2-((2-hydroxyethyl)amino)-4-(1-methylethylethyl)-2,4,6-cycloheptatrien-1-one; 7-{4-[Bis-(4-fluoro-phenyl)-methyl]-piperazin-1-ylmethyl}-2-(2-hydroxy-ethylamino)-4-isopropyl-cyclohepta-2,4,6-trienone(U-92032); 2,4,6-Cycloheptatrien-1-one, 7-((4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)methyl)-2-((2-hydroxyethyl)amino)-4-(1-methylethyl)-
DMTYO3P	DT	Small molecular drug
DMTYO3P	PC	132417
DMTYO3P	MW	507.6
DMTYO3P	FM	C30H35F2N3O2
DMTYO3P	IC	InChI=1S/C30H35F2N3O2/c1-21(2)24-3-4-25(30(37)28(19-24)33-13-18-36)20-34-14-16-35(17-15-34)29(22-5-9-26(31)10-6-22)23-7-11-27(32)12-8-23/h3-12,19,21,29,36H,13-18,20H2,1-2H3,(H,33,37)
DMTYO3P	CS	CC(C)C1=CC=C(C(=O)C(=C1)NCCO)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMTYO3P	IK	UVPCKMJVJLKETQ-UHFFFAOYSA-N
DMTYO3P	IU	7-[[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]methyl]-2-(2-hydroxyethylamino)-4-propan-2-ylcyclohepta-2,4,6-trien-1-one
DMTYO3P	CA	CAS 142223-92-5

DM0Z7PK	ID	DM0Z7PK
DM0Z7PK	DN	UC-38
DM0Z7PK	HS	Terminated
DM0Z7PK	SN	NSC-629243; NSC-D-629243
DM0Z7PK	CP	Uniroyal Chemical Co Inc
DM0Z7PK	DT	Small molecular drug
DM0Z7PK	PC	3000477
DM0Z7PK	MW	315.8
DM0Z7PK	FM	C14H18ClNO3S
DM0Z7PK	IC	InChI=1S/C14H18ClNO3S/c1-8(2)18-13(17)11-7-10(5-6-12(11)15)16-14(20)19-9(3)4/h5-9H,1-4H3,(H,16,20)
DM0Z7PK	CS	CC(C)OC(=O)C1=C(C=CC(=C1)NC(=S)OC(C)C)Cl
DM0Z7PK	IK	AXTNFJKQZPETJA-UHFFFAOYSA-N
DM0Z7PK	IU	propan-2-yl 2-chloro-5-(propan-2-yloxycarbothioylamino)benzoate
DM0Z7PK	CA	CAS 135812-34-9
DM0Z7PK	DE	Human immunodeficiency virus infection

DMY9UEZ	ID	DMY9UEZ
DMY9UEZ	DN	UC-84
DMY9UEZ	HS	Terminated
DMY9UEZ	SN	NSC-615985; NSC-D-615985
DMY9UEZ	CP	Uniroyal Chemical Co Inc
DMY9UEZ	DT	Small molecular drug
DMY9UEZ	PC	1385
DMY9UEZ	MW	355.8
DMY9UEZ	FM	C16H18ClNO4S
DMY9UEZ	IC	InChI=1S/C16H18ClNO4S/c1-9(2)22-16(20)12-8-11(4-5-13(12)17)18-15(19)14-10(3)21-6-7-23-14/h4-5,8-9H,6-7H2,1-3H3,(H,18,19)
DMY9UEZ	CS	CC1=C(SCCO1)C(=O)NC2=CC(=C(C=C2)Cl)C(=O)OC(C)C
DMY9UEZ	IK	FMQGUMRNTBJHEA-UHFFFAOYSA-N
DMY9UEZ	IU	propan-2-yl 2-chloro-5-[(6-methyl-2,3-dihydro-1,4-oxathiine-5-carbonyl)amino]benzoate
DMY9UEZ	CA	CAS 135812-04-3
DMY9UEZ	DE	Human immunodeficiency virus infection

DMD3CA5	ID	DMD3CA5
DMD3CA5	DN	UCL-1390
DMD3CA5	HS	Terminated
DMD3CA5	SN	UCL-1390; CHEMBL113030; AC1O4XEX; 4-[3-(1H-Imidazol-4-yl)propoxy]benzonitrile; SCHEMBL650642; XQNBJFUWFIHAMW-UHFFFAOYSA-N; ZINC1536439; BDBM50053278; 4-[3-(1H-imidazol-5-yl)propoxy]benzonitrile; 4-[3-(1H-Imidazol-4-yl)-propoxy]-benzonitrile; L009128; 4-[3-(1H-Imidazol-4-yl)-propoxy]-benzonitrile (UCL 1390)
DMD3CA5	CP	University College London
DMD3CA5	TC	Analgesics
DMD3CA5	DT	Small molecular drug
DMD3CA5	PC	6421295
DMD3CA5	MW	227.26
DMD3CA5	FM	C13H13N3O
DMD3CA5	IC	InChI=1S/C13H13N3O/c14-8-11-3-5-13(6-4-11)17-7-1-2-12-9-15-10-16-12/h3-6,9-10H,1-2,7H2,(H,15,16)
DMD3CA5	CS	C1=CC(=CC=C1C#N)OCCCC2=CN=CN2
DMD3CA5	IK	XQNBJFUWFIHAMW-UHFFFAOYSA-N
DMD3CA5	IU	4-[3-(1H-imidazol-5-yl)propoxy]benzonitrile
DMD3CA5	DE	Pain; Epilepsy; Eating disorder

DM9FT5E	ID	DM9FT5E
DM9FT5E	DN	UD-CG-212
DM9FT5E	HS	Terminated
DM9FT5E	SN	UD-CG-212BS; UD-CG-212Cl
DM9FT5E	CP	Boehringer Ingelheim Corp
DM9FT5E	PC	122345
DM9FT5E	MW	320.3
DM9FT5E	FM	C18H16N4O2
DM9FT5E	IC	InChI=1S/C18H16N4O2/c1-10-8-16(24)21-22-17(10)12-4-7-14-15(9-12)20-18(19-14)11-2-5-13(23)6-3-11/h2-7,9-10,23H,8H2,1H3,(H,19,20)(H,21,24)
DM9FT5E	CS	CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)O
DM9FT5E	IK	QOAXSEARPHDXFC-UHFFFAOYSA-N
DM9FT5E	IU	3-[2-(4-hydroxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one
DM9FT5E	CA	CAS 108381-22-2
DM9FT5E	DE	Heart failure

DMQFSAB	ID	DMQFSAB
DMQFSAB	DN	UK-290795
DMQFSAB	HS	Terminated
DMQFSAB	CP	Pfizer Inc
DMQFSAB	DE	Urinary incontinence

DM23YPS	ID	DM23YPS
DM23YPS	DN	UK-51656
DM23YPS	HS	Terminated
DM23YPS	CP	Pfizer Ltd
DM23YPS	PC	9912345
DM23YPS	MW	465.9
DM23YPS	FM	C22H28ClN3O6
DM23YPS	IC	InChI=1S/C22H28ClN3O6/c1-4-32-22(29)20-16(12-31-10-9-25-11-17(24)27)26-13(2)18(21(28)30-3)19(20)14-7-5-6-8-15(14)23/h5-8,19,25-26H,4,9-12H2,1-3H3,(H2,24,27)
DM23YPS	CS	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCNCC(=O)N
DM23YPS	IK	FAKQIHAUXYAVJI-UHFFFAOYSA-N
DM23YPS	IU	3-O-ethyl 5-O-methyl 2-[2-[(2-amino-2-oxoethyl)amino]ethoxymethyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DM23YPS	DE	Cardiovascular disease

DMKBILF	ID	DMKBILF
DMKBILF	DN	UK-78282
DMKBILF	HS	Terminated
DMKBILF	SN	UK-78282; CHEMBL9653; AC1LCVJE; UK 78282; UK-78282 monohydrochloride; CHEBI:35042; C13848; 4-(benzhydryloxymethyl)-1-[3-(4-methoxyphenyl)propyl]piperidine; ZINC3798289; DNC004154; BDBM50098785; NCGC00370962-01; AJ-45641; RT-016190; J-006878
DMKBILF	DT	Small molecular drug
DMKBILF	PC	656768
DMKBILF	MW	429.6
DMKBILF	FM	C29H35NO2
DMKBILF	IC	InChI=1S/C29H35NO2/c1-31-28-16-14-24(15-17-28)9-8-20-30-21-18-25(19-22-30)23-32-29(26-10-4-2-5-11-26)27-12-6-3-7-13-27/h2-7,10-17,25,29H,8-9,18-23H2,1H3
DMKBILF	CS	COC1=CC=C(C=C1)CCCN2CCC(CC2)COC(C3=CC=CC=C3)C4=CC=CC=C4
DMKBILF	IK	WRTXEGOLODUQIE-UHFFFAOYSA-N
DMKBILF	IU	4-(benzhydryloxymethyl)-1-[3-(4-methoxyphenyl)propyl]piperidine
DMKBILF	CB	CHEBI:35042
DMKBILF	DE	Inflammation

DMEIR7F	ID	DMEIR7F
DMEIR7F	DN	UP-116-77
DMEIR7F	HS	Terminated
DMEIR7F	SN	Mipitroban
DMEIR7F	CP	Laboratories UPSA
DMEIR7F	DT	Small molecular drug
DMEIR7F	PC	3086644
DMEIR7F	MW	392.3
DMEIR7F	FM	C19H19Cl2N3O2
DMEIR7F	IC	InChI=1S/C19H19Cl2N3O2/c1-19(2,9-17(25)26)8-16-23-15-7-14(21)10-22-18(15)24(16)11-12-3-5-13(20)6-4-12/h3-7,10H,8-9,11H2,1-2H3,(H,25,26)
DMEIR7F	CS	CC(C)(CC1=NC2=C(N1CC3=CC=C(C=C3)Cl)N=CC(=C2)Cl)CC(=O)O
DMEIR7F	IK	NJDYXRUUHUXUDU-UHFFFAOYSA-N
DMEIR7F	IU	4-[6-chloro-3-[(4-chlorophenyl)methyl]imidazo[4,5-b]pyridin-2-yl]-3,3-dimethylbutanoic acid
DMEIR7F	CA	CAS 136122-46-8
DMEIR7F	DE	Thrombosis

DM37DOC	ID	DM37DOC
DM37DOC	DN	UP-275-22
DM37DOC	HS	Terminated
DM37DOC	CP	Laboratories UPSA
DM37DOC	DE	Hypertension

DMV8GUE	ID	DMV8GUE
DMV8GUE	DN	UR-12460
DMV8GUE	HS	Terminated
DMV8GUE	CP	Grupo Uriach
DMV8GUE	PC	9889404
DMV8GUE	MW	439.6
DMV8GUE	FM	C27H29N5O
DMV8GUE	IC	InChI=1S/C27H29N5O/c1-21-24(13-8-14-29-21)25(19-28)31-15-17-32(18-16-31)26(33)20-30-27(22-9-4-2-5-10-22)23-11-6-3-7-12-23/h2-14,25,27,30H,15-18,20H2,1H3
DMV8GUE	CS	CC1=C(C=CC=N1)C(C#N)N2CCN(CC2)C(=O)CNC(C3=CC=CC=C3)C4=CC=CC=C4
DMV8GUE	IK	RJKFZZBPTCGMAY-UHFFFAOYSA-N
DMV8GUE	IU	2-[4-[2-(benzhydrylamino)acetyl]piperazin-1-yl]-2-(2-methylpyridin-3-yl)acetonitrile
DMV8GUE	DE	Thrombosis

DM7F94W	ID	DM7F94W
DM7F94W	DN	UR-12670
DM7F94W	HS	Terminated
DM7F94W	SN	UR-12670; SCHEMBL8120303
DM7F94W	DT	Small molecular drug
DM7F94W	PC	9867789
DM7F94W	MW	438.6
DM7F94W	FM	C28H30N4O
DM7F94W	IC	InChI=1S/C28H30N4O/c1-21-30-26-19-29-15-12-27(26)32(21)20-22-13-16-31(17-14-22)28(33)18-25(23-8-4-2-5-9-23)24-10-6-3-7-11-24/h2-12,15,19,22,25H,13-14,16-18,20H2,1H3
DM7F94W	CS	CC1=NC2=C(N1CC3CCN(CC3)C(=O)CC(C4=CC=CC=C4)C5=CC=CC=C5)C=CN=C2
DM7F94W	IK	HXCOKIFMWJDWPX-UHFFFAOYSA-N
DM7F94W	IU	1-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]-3,3-diphenylpropan-1-one

DMJC82N	ID	DMJC82N
DMJC82N	DN	UR-8225
DMJC82N	HS	Terminated
DMJC82N	SN	UR 8225; 149455-36-7; UR-8225; 5,6-Dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-2-naphthalenecarbonitrile; 1,2-Dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile; 2-Naphthalenecarbonitrile, 5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; 2-Naphthalenecarbonitrile,5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; ACMC-20n5pl; AC1L560X; SCHEMBL6369766; CHEMBL303682; CTK4C6217; DTXSID60164273; LS-94452
DMJC82N	CP	Grupo Uriach
DMJC82N	DT	Small molecular drug
DMJC82N	PC	198778
DMJC82N	MW	290.3
DMJC82N	FM	C18H14N2O2
DMJC82N	IC	InChI=1S/C18H14N2O2/c1-18(2)10-15(20-8-4-3-5-16(20)21)14-9-12(11-19)6-7-13(14)17(18)22/h3-10H,1-2H3
DMJC82N	CS	CC1(C=C(C2=C(C1=O)C=CC(=C2)C#N)N3C=CC=CC3=O)C
DMJC82N	IK	PJCGOKFHROWGBX-UHFFFAOYSA-N
DMJC82N	IU	6,6-dimethyl-5-oxo-8-(2-oxopyridin-1-yl)naphthalene-2-carbonitrile
DMJC82N	CA	CAS 149455-36-7
DMJC82N	DE	Asthma

DM6C7WJ	ID	DM6C7WJ
DM6C7WJ	DN	UR-8308
DM6C7WJ	HS	Terminated
DM6C7WJ	CP	Grupo Uriach
DM6C7WJ	DE	Asthma

DM4KOTA	ID	DM4KOTA
DM4KOTA	DN	UR-8328
DM4KOTA	HS	Terminated
DM4KOTA	CP	Grupo Uriach
DM4KOTA	DE	Asthma

DM73EPK	ID	DM73EPK
DM73EPK	DN	Vapaliximab
DM73EPK	HS	Terminated
DM73EPK	SN	Huvap; HuvapR; BTT-1002; Chimeric VAP-1 monoclonal antibody (inflammation), BioTie; Chimeric VAP-1 mAb (inflammation), BioTie/Seikagaku
DM73EPK	CP	BioTie Therapies Corp
DM73EPK	DT	Antibody
DM73EPK	DE	Inflammation

DMJLV03	ID	DMJLV03
DMJLV03	DN	Vapiprost
DMJLV03	HS	Terminated
DMJLV03	SN	Vapiprost hydrochloride; GR-32191; GR-32191B; SN-309
DMJLV03	CP	GlaxoSmithKline KK
DMJLV03	DT	Small molecular drug
DMJLV03	PC	6918030
DMJLV03	MW	477.6
DMJLV03	FM	C30H39NO4
DMJLV03	IC	InChI=1S/C30H39NO4/c32-27-21-28(35-22-23-15-17-25(18-16-23)24-11-5-3-6-12-24)26(13-7-1-2-8-14-29(33)34)30(27)31-19-9-4-10-20-31/h1-3,5-6,11-12,15-18,26-28,30,32H,4,7-10,13-14,19-22H2,(H,33,34)/b2-1-/t26-,27-,28-,30+/m0/s1
DMJLV03	CS	C1CCN(CC1)[C@H]2[C@H](C[C@@H]([C@@H]2CC/C=C\\CCC(=O)O)OCC3=CC=C(C=C3)C4=CC=CC=C4)O
DMJLV03	IK	GQGRDYWMOPRROR-XUSMOFMBSA-N
DMJLV03	IU	(Z)-7-[(1R,2R,3S,5S)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid
DMJLV03	CA	CAS 85505-64-2
DMJLV03	DE	Cardiovascular disease

DMHG70W	ID	DMHG70W
DMHG70W	DN	VE-16084
DMHG70W	HS	Terminated
DMHG70W	SN	ICE inhibitors, Sanofi Winthrop; WIN-67694
DMHG70W	CP	Sterling Winthrop Products Inc
DMHG70W	PC	10009105
DMHG70W	MW	624.5
DMHG70W	FM	C28H31Cl2N3O9
DMHG70W	IC	InChI=1S/C28H31Cl2N3O9/c1-15(2)24(33-28(40)42-13-17-8-5-4-6-9-17)26(38)31-16(3)25(37)32-20(12-22(35)36)21(34)14-41-27(39)23-18(29)10-7-11-19(23)30/h4-11,15-16,20,24H,12-14H2,1-3H3,(H,31,38)(H,32,37)(H,33,40)(H,35,36)/t16-,20+,24-/m0/s1
DMHG70W	CS	C[C@@H](C(=O)N[C@H](CC(=O)O)C(=O)COC(=O)C1=C(C=CC=C1Cl)Cl)NC(=O)[C@H](C(C)C)NC(=O)OCC2=CC=CC=C2
DMHG70W	IK	DFQKZFFVISYVDA-GANZUKCXSA-N
DMHG70W	IU	(3R)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid
DMHG70W	DE	Rheumatoid arthritis

DMY0V6J	ID	DMY0V6J
DMY0V6J	DN	VG-106
DMY0V6J	HS	Terminated
DMY0V6J	SN	Anticancer cytokine, Viragen
DMY0V6J	CP	Viragen Inc
DMY0V6J	DE	Solid tumour/cancer

DMLWQOP	ID	DMLWQOP
DMLWQOP	DN	VR-147
DMLWQOP	HS	Terminated
DMLWQOP	SN	Migraine therapeutic, Vectura; Migraine therapy, Vectura; Triptan (inhaled, migraine), Vectura
DMLWQOP	CP	Vectura Group plc
DMLWQOP	DE	Migraine

DM0CWJZ	ID	DM0CWJZ
DM0CWJZ	DN	VUF-8929
DM0CWJZ	HS	Terminated
DM0CWJZ	SN	140890-71-7; Vuf 8929; AC1O5RNQ; N-(2-Bis(4-fluorophenyl)methoxy)ethyl-(2-phenyl)ethylamine maleate; Benzeneethanamine, N-(2-(bis(4-fluorophenyl)methoxy)ethyl)-, (2Z)-2-butenedioate (1:1)
DM0CWJZ	CP	Organon BioSciences
DM0CWJZ	DT	Small molecular drug
DM0CWJZ	PC	6439429
DM0CWJZ	MW	483.5
DM0CWJZ	FM	C27H27F2NO5
DM0CWJZ	IC	InChI=1S/C23H23F2NO.C4H4O4/c1-2-26(15-14-18-6-4-3-5-7-18)27-17-20-10-13-22(25)16-23(20)19-8-11-21(24)12-9-19;5-3(6)1-2-4(7)8/h3-13,16H,2,14-15,17H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DM0CWJZ	CS	CCN(CCC1=CC=CC=C1)OCC2=C(C=C(C=C2)F)C3=CC=C(C=C3)F.C(=C\\C(=O)O)\\C(=O)O
DM0CWJZ	IK	GMPALWBPFJCWPO-BTJKTKAUSA-N
DM0CWJZ	IU	(Z)-but-2-enedioic acid;N-ethyl-N-[[4-fluoro-2-(4-fluorophenyl)phenyl]methoxy]-2-phenylethanamine
DM0CWJZ	CA	CAS 140890-71-7
DM0CWJZ	DE	Heart failure

DMG58FX	ID	DMG58FX
DMG58FX	DN	WAY-100635
DMG58FX	HS	Terminated
DMG58FX	SN	N-[2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide; 162760-96-5; Way 100635; UNII-71IH826FEG; CHEMBL31354; 71IH826FEG; N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide; WAY100635; Rec 0/0277; [3H]WAY100635; WAY 100,635; WAY-100,635; Lopac-W-108; AC1L1KWK; GTPL80; AC1Q5IB0; SCHEMBL84178; Lopac0_001229; WAY-100635 maleate salt/; GTPL3251; BDBM86708; DTXSID20167467; CHEBI:125619; EX-A1053; ZINC52541473; 2799AH; PDSP2_001699; PDSP1_001716; ABP000343; AKOS027313833; SB19513; NSC_104911; CS-0418; CCG-205303
DMG58FX	DT	Small molecular drug
DMG58FX	PC	5684
DMG58FX	MW	422.6
DMG58FX	FM	C25H34N4O2
DMG58FX	IC	InChI=1S/C25H34N4O2/c1-31-23-12-6-5-11-22(23)28-18-15-27(16-19-28)17-20-29(24-13-7-8-14-26-24)25(30)21-9-3-2-4-10-21/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3
DMG58FX	CS	COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4
DMG58FX	IK	SBPRIAGPYFYCRT-UHFFFAOYSA-N
DMG58FX	IU	N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide
DMG58FX	CA	CAS 162760-96-5
DMG58FX	CB	CHEBI:125619
DMG58FX	DE	Eating disorder

DMMOS8G	ID	DMMOS8G
DMMOS8G	DN	WAY-123223
DMMOS8G	HS	Terminated
DMMOS8G	SN	Way 123223; Way-123,223; 137941-92-5; AC1L30E8; N-(4-(Phenyloxy-3-(methyl-(2-quinolinylmethyl)amino)propoxy)phenyl)methanesulfonamide
DMMOS8G	CP	Wyeth-Ayerst Pharmaceuticals Inc
DMMOS8G	DT	Small molecular drug
DMMOS8G	PC	9931676
DMMOS8G	MW	415.5
DMMOS8G	FM	C21H25N3O4S
DMMOS8G	IC	InChI=1S/C21H25N3O4S/c1-24(13-18-8-7-16-5-3-4-6-21(16)22-18)14-19(25)15-28-20-11-9-17(10-12-20)23-29(2,26)27/h3-12,19,23,25H,13-15H2,1-2H3
DMMOS8G	CS	CN(CC1=NC2=CC=CC=C2C=C1)CC(COC3=CC=C(C=C3)NS(=O)(=O)C)O
DMMOS8G	IK	DOUINBOCIFSYBA-UHFFFAOYSA-N
DMMOS8G	IU	N-[4-[2-hydroxy-3-[methyl(quinolin-2-ylmethyl)amino]propoxy]phenyl]methanesulfonamide
DMMOS8G	DE	Heart arrhythmia

DMTY7PE	ID	DMTY7PE
DMTY7PE	DN	WAY-126227
DMTY7PE	HS	Terminated
DMTY7PE	CP	Wyeth-Ayerst Pharmaceuticals Inc
DMTY7PE	DE	Hypertension

DM2XTB9	ID	DM2XTB9
DM2XTB9	DN	WAY-132983
DM2XTB9	HS	Terminated
DM2XTB9	SN	WAY-132983
DM2XTB9	DT	Small molecular drug
DM2XTB9	PC	45260374
DM2XTB9	MW	343.9
DM2XTB9	FM	C16H26ClN3OS
DM2XTB9	IC	InChI=1S/C16H25N3OS.ClH/c1-2-3-4-5-10-21-16-15(17-7-8-18-16)20-14-12-19-9-6-13(14)11-19;/h7-8,13-14H,2-6,9-12H2,1H3;1H/t13?,14-;/m0./s1
DM2XTB9	CS	CCCCCCSC1=NC=CN=C1O[C@H]2CN3CCC2C3.Cl
DM2XTB9	IK	QAXRREHLPKHWBI-IJDFPQMLSA-N
DM2XTB9	IU	(3R)-3-(3-hexylsulfanylpyrazin-2-yl)oxy-1-azabicyclo[2.2.1]heptane;hydrochloride

DMQU8B1	ID	DMQU8B1
DMQU8B1	DN	WB-4101
DMQU8B1	HS	Terminated
DMQU8B1	SN	WB-4101; WB4101; WB 4101; (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane; (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzodioxan; 613-67-2; CHEMBL25554; CHEBI:64098; N-(2-(2,6-Dimethoxyphenoxy)ethyl)-2,3-dihydro-1,4-benzodioxin-2-methanamine; 1,4-Benzodioxin-2-methanamine, N-(2-(2,6-dimethoxyphenoxy)ethyl)-2,3-dihydro-; N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine; 1,4-benzodioxin-2-methanamine, n-[2-(2,6-dimethoxyphenoxy)ethyl]-2,3-dihydro-; MLS000859914
DMQU8B1	DT	Small molecular drug
DMQU8B1	PC	5685
DMQU8B1	MW	345.4
DMQU8B1	FM	C19H23NO5
DMQU8B1	IC	InChI=1S/C19H23NO5/c1-21-17-8-5-9-18(22-2)19(17)23-11-10-20-12-14-13-24-15-6-3-4-7-16(15)25-14/h3-9,14,20H,10-13H2,1-2H3
DMQU8B1	CS	COC1=C(C(=CC=C1)OC)OCCNCC2COC3=CC=CC=C3O2
DMQU8B1	IK	GYSZUJHYXCZAKI-UHFFFAOYSA-N
DMQU8B1	IU	N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine
DMQU8B1	CA	CAS 613-67-2
DMQU8B1	CB	CHEBI:64098

DMY9NG1	ID	DMY9NG1
DMY9NG1	DN	WEB-2347
DMY9NG1	HS	Terminated
DMY9NG1	SN	Web-2347; Web 2347; AC1MIW90; SCHEMBL8440056; 6-(2-Chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-4H,7H-cyclopenta(4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-8-carboxamide; 4H,7H-Cyclopenta(4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-8-carboxamide, 6-(2-chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-
DMY9NG1	CP	Boehringer Ingelheim Corp
DMY9NG1	DT	Small molecular drug
DMY9NG1	PC	3081067
DMY9NG1	MW	482
DMY9NG1	FM	C25H28ClN5OS
DMY9NG1	IC	InChI=1S/C25H28ClN5OS/c1-4-10-30(11-5-2)24(32)16-12-18-20(13-16)33-25-22(18)23(17-8-6-7-9-19(17)26)27-14-21-29-28-15(3)31(21)25/h6-9,16H,4-5,10-14H2,1-3H3
DMY9NG1	CS	CCCN(CCC)C(=O)C1CC2=C(C1)SC3=C2C(=NCC4=NN=C(N43)C)C5=CC=CC=C5Cl
DMY9NG1	IK	SCSIRWUYQVAIRL-UHFFFAOYSA-N
DMY9NG1	IU	9-(2-chlorophenyl)-3-methyl-N,N-dipropyl-16-thia-2,4,5,8-tetrazatetracyclo[8.6.0.02,6.011,15]hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxamide
DMY9NG1	CA	CAS 114800-19-0
DMY9NG1	DE	Allergy

DMBMOI6	ID	DMBMOI6
DMBMOI6	DN	WF-2421
DMBMOI6	HS	Terminated
DMBMOI6	SN	FR-900280
DMBMOI6	CP	Fujisawa Pharmaceutical Co Ltd
DMBMOI6	DT	Small molecular drug
DMBMOI6	PC	195567
DMBMOI6	MW	404.4
DMBMOI6	FM	C19H20N2O8
DMBMOI6	IC	InChI=1S/C19H20N2O8/c22-8-20-7-16(26)10-1-3-14(24)12(5-10)13-6-11(2-4-15(13)25)18(27)17(19(28)29)21-9-23/h1-6,8-9,16-18,24-27H,7H2,(H,20,22)(H,21,23)(H,28,29)
DMBMOI6	CS	C1=CC(=C(C=C1C(CNC=O)O)C2=C(C=CC(=C2)C(C(C(=O)O)NC=O)O)O)O
DMBMOI6	IK	WQVWUCSBLUJLNT-UHFFFAOYSA-N
DMBMOI6	IU	2-formamido-3-[3-[5-(2-formamido-1-hydroxyethyl)-2-hydroxyphenyl]-4-hydroxyphenyl]-3-hydroxypropanoic acid
DMBMOI6	CA	CAS 128429-19-6
DMBMOI6	DE	Diabetic complication

DMACBIW	ID	DMACBIW
DMACBIW	DN	WIN-55212-2
DMACBIW	HS	Terminated
DMACBIW	SN	Win-55212-2; WIN 55212-2; UNII-5H31GI9502; 131543-22-1; CHEMBL188; WIN55212-2; WIN 55,212-2; CHEBI:73295; 5H31GI9502; (2,3-Dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate; [(3R)-5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](1-naphthyl)methanone; (r)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone
DMACBIW	DT	Small molecular drug
DMACBIW	PC	5311501
DMACBIW	MW	426.5
DMACBIW	FM	C27H26N2O3
DMACBIW	IC	InChI=1S/C27H26N2O3/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28/h2-11,20H,12-17H2,1H3/t20-/m1/s1
DMACBIW	CS	CC1=C(C2=C3N1[C@@H](COC3=CC=C2)CN4CCOCC4)C(=O)C5=CC=CC6=CC=CC=C65
DMACBIW	IK	HQVHOQAKMCMIIM-HXUWFJFHSA-N
DMACBIW	IU	[(11R)-2-methyl-11-(morpholin-4-ylmethyl)-9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraen-3-yl]-naphthalen-1-ylmethanone
DMACBIW	CA	CAS 131543-22-1
DMACBIW	CB	CHEBI:73295

DMRV48P	ID	DMRV48P
DMRV48P	DN	WIN-63759
DMRV48P	HS	Terminated
DMRV48P	SN	WIN-63759; CHEMBL114992; SCHEMBL7305284; BDBM50036477; 2,6-Dichloro-3-(2-morpholin-4-yl-ethoxy)-benzoic acid 4-isopropyl-6-methoxy-1,1,3-trioxo-1,3-dihydro-1lambda*6*-benzo[d]isothiazol-2-ylmethyl ester(WIN63759); 2,6-Dichloro-3-(2-morpholin-4-yl-ethoxy)-benzoic acid 4-isopropyl-6-methoxy-1,1,3-trioxo-1,3-dihydro-1lambda*6*-benzo[d]isothiazol-2-ylmethyl ester
DMRV48P	CP	Sterling Winthrop Group Ltd
DMRV48P	DT	Small molecular drug
DMRV48P	PC	9938355
DMRV48P	MW	587.5
DMRV48P	FM	C25H28Cl2N2O8S
DMRV48P	IC	InChI=1S/C25H28Cl2N2O8S/c1-15(2)17-12-16(34-3)13-20-21(17)24(30)29(38(20,32)33)14-37-25(31)22-18(26)4-5-19(23(22)27)36-11-8-28-6-9-35-10-7-28/h4-5,12-13,15H,6-11,14H2,1-3H3
DMRV48P	CS	CC(C)C1=C2C(=CC(=C1)OC)S(=O)(=O)N(C2=O)COC(=O)C3=C(C=CC(=C3Cl)OCCN4CCOCC4)Cl
DMRV48P	IK	AGROLWZEYXFDEB-UHFFFAOYSA-N
DMRV48P	IU	(6-methoxy-1,1,3-trioxo-4-propan-2-yl-1,2-benzothiazol-2-yl)methyl 2,6-dichloro-3-(2-morpholin-4-ylethoxy)benzoate
DMRV48P	DE	Emphysema

DM960I8	ID	DM960I8
DM960I8	DN	WIN-64821
DM960I8	HS	Terminated
DM960I8	SN	Q-20547A
DM960I8	CP	Sterling Winthrop Products Inc
DM960I8	DT	Small molecular drug
DM960I8	PC	158365
DM960I8	MW	664.7
DM960I8	FM	C40H36N6O4
DM960I8	IC	InChI=1S/C40H36N6O4/c47-33-31-21-39(25-15-7-9-17-27(25)43-37(39)45(31)35(49)29(41-33)19-23-11-3-1-4-12-23)40-22-32-34(48)42-30(20-24-13-5-2-6-14-24)36(50)46(32)38(40)44-28-18-10-8-16-26(28)40/h1-18,29-32,37-38,43-44H,19-22H2,(H,41,47)(H,42,48)/t29-,30-,31-,32-,37+,38+,39-,40-/m0/s1
DM960I8	CS	C1[C@H]2C(=O)N[C@H](C(=O)N2[C@@H]3[C@]1(C4=CC=CC=C4N3)[C@]56C[C@H]7C(=O)N[C@H](C(=O)N7[C@H]5NC8=CC=CC=C68)CC9=CC=CC=C9)CC1=CC=CC=C1
DM960I8	IK	ZEANERNKMXBETI-BJHDJDSNSA-N
DM960I8	IU	(1R,4S,7S,9R)-4-benzyl-9-[(1R,4S,7S,9R)-4-benzyl-3,6-dioxo-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-trien-9-yl]-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-triene-3,6-dione
DM960I8	CA	CAS 150881-27-9
DM960I8	DE	Asthma

DM8EVK5	ID	DM8EVK5
DM8EVK5	DN	Wortmannin
DM8EVK5	HS	Terminated
DM8EVK5	SN	wortmannin; 19545-26-7; Wartmannin; KY 12420; Antibiotic SL-2052; SL-2052; UNII-XVA4O219QW; NSC221019; XVA4O219QW; MLS002703028; CHEMBL428496; CHEBI:52289; Wortmannin, 98%; Pi 3-Kinase Inhibitor; NSC 627609; BRN 0067676; (1S,6bR,9aS,11R,11bR)-9a,11b-dimethyl-1-[(methyloxy)methyl]-3,6,9-trioxo-1,6,6b,7,8,9,9a,10,11,11b-decahydro-3H-furo[4,3,2-de]indeno[4,5-h]isochromen-11-yl acetate
DM8EVK5	DT	Small molecular drug
DM8EVK5	PC	312145
DM8EVK5	MW	428.4
DM8EVK5	FM	C23H24O8
DM8EVK5	IC	InChI=1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3/t12-,13+,15+,22-,23-/m0/s1
DM8EVK5	CS	CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C
DM8EVK5	IK	QDLHCMPXEPAAMD-QAIWCSMKSA-N
DM8EVK5	IU	[(1R,3R,5S,9R,18S)-18-(methoxymethyl)-1,5-dimethyl-6,11,16-trioxo-13,17-dioxapentacyclo[10.6.1.02,10.05,9.015,19]nonadeca-2(10),12(19),14-trien-3-yl] acetate
DM8EVK5	CA	CAS 19545-26-7
DM8EVK5	CB	CHEBI:52289
DM8EVK5	DE	Haematological malignancy

DM89BA1	ID	DM89BA1
DM89BA1	DN	WS-75624B
DM89BA1	HS	Terminated
DM89BA1	CP	Fujisawa Pharmaceutical Co Ltd
DM89BA1	DT	Small molecular drug
DM89BA1	PC	9951814
DM89BA1	MW	380.5
DM89BA1	FM	C18H24N2O5S
DM89BA1	IC	InChI=1S/C18H24N2O5S/c1-11(21)7-5-4-6-8-15-19-13(10-26-15)16-17(25-3)14(24-2)9-12(20-16)18(22)23/h9-11,21H,4-8H2,1-3H3,(H,22,23)
DM89BA1	CS	CC(CCCCCC1=NC(=CS1)C2=C(C(=CC(=N2)C(=O)O)OC)OC)O
DM89BA1	IK	RGHLFUKUTGFTCO-UHFFFAOYSA-N
DM89BA1	IU	6-[2-(6-hydroxyheptyl)-1,3-thiazol-4-yl]-4,5-dimethoxypyridine-2-carboxylic acid
DM89BA1	DE	Cardiovascular disease

DMAG86C	ID	DMAG86C
DMAG86C	DN	WY-28342
DMAG86C	HS	Terminated
DMAG86C	CP	Wyeth-Ayerst International Inc
DMAG86C	PC	9882188
DMAG86C	MW	281.4
DMAG86C	FM	C19H23NO
DMAG86C	IC	InChI=1S/C19H23NO/c1-13-8-10-15(11-9-13)19(21)18-14(2)12-16-6-4-3-5-7-17(16)20-18/h8-12,19,21H,3-7H2,1-2H3
DMAG86C	CS	CC1=CC=C(C=C1)C(C2=NC3=C(CCCCC3)C=C2C)O
DMAG86C	IK	KLGYQZZTJRHYIN-UHFFFAOYSA-N
DMAG86C	IU	(4-methylphenyl)-(3-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-yl)methanol
DMAG86C	DE	Rheumatoid arthritis

DMGJNQW	ID	DMGJNQW
DMGJNQW	DN	WY-48989
DMGJNQW	HS	Terminated
DMGJNQW	SN	WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; Wy-48989; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile
DMGJNQW	CP	Wyeth-Ayerst Pharmaceuticals Inc
DMGJNQW	DT	Small molecular drug
DMGJNQW	PC	132006
DMGJNQW	MW	423.9
DMGJNQW	FM	C25H18ClN5
DMGJNQW	IC	InChI=1S/C25H18ClN5/c26-18-8-11-21-24(14-18)29-23(12-13-28-19-9-6-17(15-27)7-10-19)22-16-31(30-25(21)22)20-4-2-1-3-5-20/h1-11,14,16,28H,12-13H2
DMGJNQW	CS	C1=CC=C(C=C1)N2C=C3C(=NC4=C(C3=N2)C=CC(=C4)Cl)CCNC5=CC=C(C=C5)C#N
DMGJNQW	IK	GYVYUQVVKBZPRY-UHFFFAOYSA-N
DMGJNQW	IU	4-[2-(7-chloro-2-phenylpyrazolo[4,3-c]quinolin-4-yl)ethylamino]benzonitrile
DMGJNQW	CA	CAS 136917-40-3
DMGJNQW	DE	Rheumatoid arthritis

DM965P4	ID	DM965P4
DM965P4	DN	XL-541
DM965P4	HS	Terminated
DM965P4	SN	S1P1R antagonists (oral, cancer), Exelixis
DM965P4	CP	Exelixis Inc
DM965P4	DE	Solid tumour/cancer

DMFHR2O	ID	DMFHR2O
DMFHR2O	DN	XR-1853
DMFHR2O	HS	Terminated
DMFHR2O	SN	XR 1853; XR-1853; AC1O5RT5; 3-((4-(2-(Dimethylamino)ethoxy)phenyl)methylene)-6-(phenylmethylene)-2,5-piperazinedione; 158944-02-6
DMFHR2O	CP	Xenova Ltd
DMFHR2O	DT	Small molecular drug
DMFHR2O	PC	6439506
DMFHR2O	MW	377.4
DMFHR2O	FM	C22H23N3O3
DMFHR2O	IC	InChI=1S/C22H23N3O3/c1-25(2)12-13-28-18-10-8-17(9-11-18)15-20-22(27)23-19(21(26)24-20)14-16-6-4-3-5-7-16/h3-11,14-15H,12-13H2,1-2H3,(H,23,27)(H,24,26)/b19-14+,20-15-
DMFHR2O	CS	CN(C)CCOC1=CC=C(C=C1)/C=C\\2/C(=O)N/C(=C/C3=CC=CC=C3)/C(=O)N2
DMFHR2O	IK	SKAOOZAHHYQXKN-WOBBTWAASA-N
DMFHR2O	IU	(3E,6Z)-3-benzylidene-6-[[4-[2-(dimethylamino)ethoxy]phenyl]methylidene]piperazine-2,5-dione
DMFHR2O	CA	CAS 158944-02-6
DMFHR2O	DE	Thrombosis

DMJLRC7	ID	DMJLRC7
DMJLRC7	DN	XR-3005
DMJLRC7	HS	Terminated
DMJLRC7	CP	Xenova Group plc
DMJLRC7	DE	Colorectal cancer

DMXI39O	ID	DMXI39O
DMXI39O	DN	XR-3054
DMXI39O	HS	Terminated
DMXI39O	CP	Xenova Group plc
DMXI39O	DE	Solid tumour/cancer

DMX0PTO	ID	DMX0PTO
DMX0PTO	DN	XR-368
DMX0PTO	HS	Terminated
DMX0PTO	SN	Xenovulene; XR-7009
DMX0PTO	CP	Xenova Ltd
DMX0PTO	PC	9863607
DMX0PTO	MW	358.5
DMX0PTO	FM	C22H30O4
DMX0PTO	IC	InChI=1S/C22H30O4/c1-13-6-7-15-19-16-14(12-25-19)17(23)18(24)20(16)26-22(15,4)10-5-9-21(2,3)11-8-13/h5,8-9,14-16,19,24H,6-7,10-12H2,1-4H3/b9-5+,13-8+/t14-,15-,16-,19-,22+/m0/s1
DMX0PTO	CS	C/C/1=C\\CC(/C=C/C[C@@]2([C@@H](CC1)[C@H]3[C@@H]4[C@H](CO3)C(=O)C(=C4O2)O)C)(C)C
DMX0PTO	IK	WDFUVZRTUNQXHC-KVPIFFDFSA-N
DMX0PTO	IU	(1S,2S,5E,9E,12R,17R,20S)-15-hydroxy-5,8,8,12-tetramethyl-13,19-dioxatetracyclo[12.5.1.02,12.017,20]icosa-5,9,14-trien-16-one
DMX0PTO	CB	CHEBI:66336
DMX0PTO	DE	Anxiety disorder

DMEVSZO	ID	DMEVSZO
DMEVSZO	DN	XR-5082
DMEVSZO	HS	Terminated
DMEVSZO	SN	Plasminogen activator inhibitor inhibitor, Xenova
DMEVSZO	CP	Xenova Ltd
DMEVSZO	DT	Small molecular drug
DMEVSZO	PC	6439510
DMEVSZO	MW	393.5
DMEVSZO	FM	C22H23N3O2S
DMEVSZO	IC	InChI=1S/C22H23N3O2S/c1-25(2)12-13-28-18-10-8-17(9-11-18)15-20-22(27)23-19(21(26)24-20)14-16-6-4-3-5-7-16/h3-11,14-15H,12-13H2,1-2H3,(H,23,27)(H,24,26)/b19-14+,20-15-
DMEVSZO	CS	CN(C)CCSC1=CC=C(C=C1)/C=C\\2/C(=O)N/C(=C/C3=CC=CC=C3)/C(=O)N2
DMEVSZO	IK	RYRKPESQGOEIQY-WOBBTWAASA-N
DMEVSZO	IU	(3E,6Z)-3-benzylidene-6-[[4-[2-(dimethylamino)ethylsulfanyl]phenyl]methylidene]piperazine-2,5-dione
DMEVSZO	CA	CAS 174849-68-4
DMEVSZO	DE	Thrombosis

DMA13OD	ID	DMA13OD
DMA13OD	DN	XR-510
DMA13OD	HS	Terminated
DMA13OD	SN	CHEMBL100119; XR-510; SCHEMBL243027; BDBM50032353; N-{3-[5-Ethyl-3-(3-fluoro-2''-isopentyloxycarbonylsulfamoyl-biphenyl-4-ylmethyl)-2-propyl-3H-imidazol-4-yl]-3-oxo-propyl}-N-pyridin-3-yl-butyramide(XR510); isopentyloxy 2-[2-(4-{4-ethyl-5-[3-[3-pyridyl(propyl)carboxamidopropanoyl]-2-propyl-1H-1-imidazolylmethyl}-3-fluorophenyl)phenylsulfonyl]caboxamido
DMA13OD	CP	Xenova Ltd
DMA13OD	DT	Small molecular drug
DMA13OD	PC	9896750
DMA13OD	MW	733.9
DMA13OD	FM	C39H48FN5O6S
DMA13OD	IC	InChI=1S/C39H48FN5O6S/c1-6-12-36-42-33(8-3)38(34(46)19-22-44(37(47)13-7-2)30-14-11-21-41-25-30)45(36)26-29-18-17-28(24-32(29)40)31-15-9-10-16-35(31)52(49,50)43-39(48)51-23-20-27(4)5/h9-11,14-18,21,24-25,27H,6-8,12-13,19-20,22-23,26H2,1-5H3,(H,43,48)
DMA13OD	CS	CCCC1=NC(=C(N1CC2=C(C=C(C=C2)C3=CC=CC=C3S(=O)(=O)NC(=O)OCCC(C)C)F)C(=O)CCN(C4=CN=CC=C4)C(=O)CCC)CC
DMA13OD	IK	QBFKQSDMKSSMRE-UHFFFAOYSA-N
DMA13OD	IU	3-methylbutyl N-[2-[4-[[5-[3-[butanoyl(pyridin-3-yl)amino]propanoyl]-4-ethyl-2-propylimidazol-1-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate
DMA13OD	DE	Hypertension

DMIK72F	ID	DMIK72F
DMIK72F	DN	XR-5118
DMIK72F	HS	Terminated
DMIK72F	SN	XR-5118; CHEMBL40180; CHEMBL544314; xr5118; SCHEMBL7359291; BDBM50104518; 3-[1-[5-(2-Dimethylamino-ethylsulfanyl)-thiophen-2-yl]-meth-(Z)-ylidene]-6-[1-phenyl-meth-(Z)-ylidene]-piperazine-2,5-dione
DMIK72F	DT	Small molecular drug
DMIK72F	PC	9932718
DMIK72F	MW	399.5
DMIK72F	FM	C20H21N3O2S2
DMIK72F	IC	InChI=1S/C20H21N3O2S2/c1-23(2)10-11-26-18-9-8-15(27-18)13-17-20(25)21-16(19(24)22-17)12-14-6-4-3-5-7-14/h3-9,12-13H,10-11H2,1-2H3,(H,21,25)(H,22,24)/b16-12-,17-13-
DMIK72F	CS	CN(C)CCSC1=CC=C(S1)/C=C\\2/C(=O)N/C(=C\\C3=CC=CC=C3)/C(=O)N2
DMIK72F	IK	ODQGWMYUSNRXFW-MCOFMCJXSA-N
DMIK72F	IU	(3Z,6Z)-3-benzylidene-6-[[5-[2-(dimethylamino)ethylsulfanyl]thiophen-2-yl]methylidene]piperazine-2,5-dione
DMIK72F	DE	Solid tumour/cancer

DM7TQYF	ID	DM7TQYF
DM7TQYF	DN	Y-20024
DM7TQYF	HS	Terminated
DM7TQYF	SN	N-(1-Butyl-2-pyrrolidinylmethyl)-2-methyl-5-sulfamoyl-2,3-dihydrobenzofuran-7-carboxamide hydrochloride; 5-(Aminosulfonyl)-N-[(1-butyl-2-pyrrolidinyl)methyl]-2-methyl-2,3-dihydro-7-benzofurancarboxamide hydrochloride
DM7TQYF	DT	Small molecular drug
DM7TQYF	PC	130281
DM7TQYF	MW	432
DM7TQYF	FM	C19H30ClN3O4S
DM7TQYF	IC	InChI=1S/C19H29N3O4S.ClH/c1-3-4-7-22-8-5-6-15(22)12-21-19(23)17-11-16(27(20,24)25)10-14-9-13(2)26-18(14)17;/h10-11,13,15H,3-9,12H2,1-2H3,(H,21,23)(H2,20,24,25);1H
DM7TQYF	CS	CCCCN1CCCC1CNC(=O)C2=CC(=CC3=C2OC(C3)C)S(=O)(=O)N.Cl
DM7TQYF	IK	GZXVXVNELOPJSZ-UHFFFAOYSA-N
DM7TQYF	IU	N-[(1-butylpyrrolidin-2-yl)methyl]-2-methyl-5-sulfamoyl-2,3-dihydro-1-benzofuran-7-carboxamide;hydrochloride
DM7TQYF	CA	CAS 124842-93-9
DM7TQYF	DE	Psychotic disorder

DMLAVES	ID	DMLAVES
DMLAVES	DN	Y-29794
DMLAVES	HS	Terminated
DMLAVES	SN	Y-29794; Y 29794; 129184-48-1; CHEMBL294803; Y29794; AC1L50AM; AC1Q5D6Y; SCHEMBL195545; ZINC3803304; BDBM50038881; 2-(8-Dimethylaminooctylthio)-6-isopropyl-3-pyridyl-2-thienyl ketone citrate; methanone,(2-((8-(dimethylamino)octyl)thio)-6-(1-methylethyl)-3-pyridinyl)-2-thienyl-; KB-81512; BRD-K48449073-034-01-9; [2-[8-(dimethylamino)octylsulfanyl]-6-propan-2-ylpyridin-3-yl]-thiophen-2-ylmethanone; Methanone, (2-((8-(dimethylamino)octyl)thio)-6-(1-methylethyl)-3-pyridinyl)-2-thienyl-
DMLAVES	DT	Small molecular drug
DMLAVES	PC	195609
DMLAVES	MW	418.7
DMLAVES	FM	C23H34N2OS2
DMLAVES	IC	InChI=1S/C23H34N2OS2/c1-18(2)20-14-13-19(22(26)21-12-11-17-27-21)23(24-20)28-16-10-8-6-5-7-9-15-25(3)4/h11-14,17-18H,5-10,15-16H2,1-4H3
DMLAVES	CS	CC(C)C1=NC(=C(C=C1)C(=O)C2=CC=CS2)SCCCCCCCCN(C)C
DMLAVES	IK	HAGHKJDWBDSFKC-UHFFFAOYSA-N
DMLAVES	IU	[2-[8-(dimethylamino)octylsulfanyl]-6-propan-2-ylpyridin-3-yl]-thiophen-2-ylmethanone
DMLAVES	CA	CAS 129184-48-1

DMG024B	ID	DMG024B
DMG024B	DN	Y-931
DMG024B	HS	Terminated
DMG024B	CP	Mitsubishi Pharma
DMG024B	DT	Small molecular drug
DMG024B	PC	9913124
DMG024B	MW	366.5
DMG024B	FM	C20H19FN4S
DMG024B	IC	InChI=1S/C20H19FN4S/c1-24-8-10-25(11-9-24)19-18-14-4-2-3-5-17(14)26-20(18)23-16-12-13(21)6-7-15(16)22-19/h2-7,12,23H,8-11H2,1H3
DMG024B	CS	CN1CCN(CC1)C2=NC3=C(C=C(C=C3)F)NC4=C2C5=CC=CC=C5S4
DMG024B	IK	ILMHNKKMKWQVCE-UHFFFAOYSA-N
DMG024B	IU	8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothiolo[2,3-b][1,5]benzodiazepine
DMG024B	DE	Schizophrenia

DM97ULM	ID	DM97ULM
DM97ULM	DN	YM-022
DM97ULM	HS	Terminated
DM97ULM	SN	145084-28-2; YM022; YM-022; YM 022; UNII-772CP7W12N; CHEMBL115121; C32H28N4O3; 772CP7W12N; 1-(2,3-Dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea; (R)-N-[2,3-DIHYDRO-1-[2-(2-METHYLPHENYL)-2-OXOETHYL]-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-N'-(3-METHYLPHENYL)-UREA; Urea,N-[(3R)-2,3-dihydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)-; Urea, N-(2,3-dihydro-1-(2-(2-methylphenyl)-2-oxoethyl)-2-oxo-5-phenyl-1H-1,4-benzodia
DM97ULM	CP	Yamanouchi Pharmaceutical Co Ltd
DM97ULM	DT	Small molecular drug
DM97ULM	PC	122130
DM97ULM	MW	516.6
DM97ULM	FM	C32H28N4O3
DM97ULM	IC	InChI=1S/C32H28N4O3/c1-21-11-10-15-24(19-21)33-32(39)35-30-31(38)36(20-28(37)25-16-7-6-12-22(25)2)27-18-9-8-17-26(27)29(34-30)23-13-4-3-5-14-23/h3-19,30H,20H2,1-2H3,(H2,33,35,39)/t30-/m0/s1
DM97ULM	CS	CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)C4=CC=CC=C4)CC(=O)C5=CC=CC=C5C
DM97ULM	IK	YCXFHPUBGMMWJQ-PMERELPUSA-N
DM97ULM	IU	1-(3-methylphenyl)-3-[(3R)-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea
DM97ULM	CA	CAS 145084-28-2
DM97ULM	DE	Gastrointestinal disease

DMDXLG2	ID	DMDXLG2
DMDXLG2	DN	YM-099
DMDXLG2	HS	Terminated
DMDXLG2	CP	Yamanouchi Pharmaceutical Co Ltd
DMDXLG2	DE	Hypertension

DMEHAI2	ID	DMEHAI2
DMEHAI2	DN	YM-26734
DMEHAI2	HS	Terminated
DMEHAI2	SN	YM 26734; 144337-18-8; CHEMBL444450; 1-Dodecanone,1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-; 1,1'-[5-[3,4-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-1-dodecanone; ACMC-20n3vr; CTK4C4039; AOB2291; SYN5086; MolPort-023-276-467; BDBM50274336; AKOS024457146; 4-(3,5-Didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman; KB-276131; YM-26734, &gt; J-007943; 1-Dodecanone, 1
DMEHAI2	DT	Small molecular drug
DMEHAI2	PC	9853400
DMEHAI2	MW	731
DMEHAI2	FM	C45H62O8
DMEHAI2	IC	InChI=1S/C45H62O8/c1-3-5-7-9-11-13-15-17-19-21-36(48)41-43(50)40(44(51)42(45(41)52)37(49)22-20-18-16-14-12-10-8-6-4-2)35-30-38(31-23-25-32(46)26-24-31)53-39-29-33(47)27-28-34(35)39/h23-29,35,38,46-47,50-52H,3-22,30H2,1-2H3
DMEHAI2	CS	CCCCCCCCCCCC(=O)C1=C(C(=C(C(=C1O)C2CC(OC3=C2C=CC(=C3)O)C4=CC=C(C=C4)O)O)C(=O)CCCCCCCCCCC)O
DMEHAI2	IK	CEJAYJCUSZHYDS-UHFFFAOYSA-N
DMEHAI2	IU	1-[3-dodecanoyl-2,4,6-trihydroxy-5-[7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]dodecan-1-one
DMEHAI2	CA	CAS 144337-18-8
DMEHAI2	DE	Rheumatoid arthritis

DMWI094	ID	DMWI094
DMWI094	DN	YM-43611
DMWI094	HS	Terminated
DMWI094	CP	Yamanouchi Pharmaceutical Co Ltd
DMWI094	PC	9802631
DMWI094	MW	427.9
DMWI094	FM	C23H26ClN3O3
DMWI094	IC	InChI=1S/C23H26ClN3O3/c1-30-21-12-20(26-22(28)16-7-8-16)19(24)11-18(21)23(29)25-17-9-10-27(14-17)13-15-5-3-2-4-6-15/h2-6,11-12,16-17H,7-10,13-14H2,1H3,(H,25,29)(H,26,28)/t17-/m0/s1
DMWI094	CS	COC1=CC(=C(C=C1C(=O)N[C@H]2CCN(C2)CC3=CC=CC=C3)Cl)NC(=O)C4CC4
DMWI094	IK	CPVZPPFHQBIJNB-KRWDZBQOSA-N
DMWI094	IU	N-[(3S)-1-benzylpyrrolidin-3-yl]-5-chloro-4-(cyclopropanecarbonylamino)-2-methoxybenzamide
DMWI094	DE	Psychotic disorder

DM7VGOC	ID	DM7VGOC
DM7VGOC	DN	Ym60828
DM7VGOC	HS	Terminated
DM7VGOC	SN	YM-60828; YM 60828; 201933-41-7; CHEMBL20240; 179755-65-8; {[(7-Carbamimidoylnaphthalen-2-Yl)methyl][4-({1-[(1e)-Ethanimidoyl]piperidin-4-Yl}oxy)phenyl]sulfamoyl}acetic Acid; SCHEMBL676753; DTXSID80430967; ZINC3952416; BDBM50084617; ACM179755658; KB-81529; FT-0675886; 2-[[[[7-(Aminoiminomethyl)-2-naphthalenyl]methyl][4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]amino]sulfonyl]acetic Acid Dihydrochloride; [[4-[(1-Acetimidoylpiperidin-4-yl)oxy]phenyl][(7-amidino-2-naphthyl)methyl]sulfamoyl]acetic acid; 0CB
DM7VGOC	DT	Small molecular drug
DM7VGOC	PC	9807238
DM7VGOC	MW	537.6
DM7VGOC	FM	C27H31N5O5S
DM7VGOC	IC	InChI=1S/C27H31N5O5S/c1-18(28)31-12-10-25(11-13-31)37-24-8-6-23(7-9-24)32(38(35,36)17-26(33)34)16-19-2-3-20-4-5-21(27(29)30)15-22(20)14-19/h2-9,14-15,25,28H,10-13,16-17H2,1H3,(H3,29,30)(H,33,34)
DM7VGOC	CS	CC(=N)N1CCC(CC1)OC2=CC=C(C=C2)N(CC3=CC4=C(C=C3)C=CC(=C4)C(=N)N)S(=O)(=O)CC(=O)O
DM7VGOC	IK	NPBKHEMDWREFJJ-UHFFFAOYSA-N
DM7VGOC	IU	2-[(7-carbamimidoylnaphthalen-2-yl)methyl-[4-(1-ethanimidoylpiperidin-4-yl)oxyphenyl]sulfamoyl]acetic acid
DM7VGOC	CA	CAS 179755-65-8

DMK1UJM	ID	DMK1UJM
DMK1UJM	DN	YP-004
DMK1UJM	HS	Terminated
DMK1UJM	SN	MP-004
DMK1UJM	CP	Molecular SkinCare Ltd
DMK1UJM	DE	Solid tumour/cancer

DM2N76V	ID	DM2N76V
DM2N76V	DN	YP-008
DM2N76V	HS	Terminated
DM2N76V	SN	RPL-228; Cyclopentenone prostaglandin mimetic (PGM) (topical, psoriasis), York Pharma; Natural-defence-prostanoid mimetic (topical, psoriasis), York Pharma
DM2N76V	CP	Rosanto Pharmaceuticals Ltd
DM2N76V	DE	Psoriasis vulgaris

DMPXLG2	ID	DMPXLG2
DMPXLG2	DN	YP-009
DMPXLG2	HS	Terminated
DMPXLG2	SN	RPL-208; Cyclopentenone prostaglandin mimetic (PGM) (cancer), Rosanto; Cyclopentenone prostaglandin mimetic (PGM) (cancer), York Pharma
DMPXLG2	CP	Rosanto Pharmaceuticals Ltd
DMPXLG2	DE	Solid tumour/cancer

DMQ6K8J	ID	DMQ6K8J
DMQ6K8J	DN	Z-6568
DMQ6K8J	HS	Terminated
DMQ6K8J	CP	Zambon Co SpA
DMQ6K8J	PC	53408000
DMQ6K8J	MW	281.26
DMQ6K8J	FM	C13H15NO6
DMQ6K8J	IC	InChI=1S/C13H15NO6/c1-3-19-12(15)8-9-5-6-10(13(16)20-4-2)7-11(9)14(17)18/h5-7H,3-4,8H2,1-2H3
DMQ6K8J	CS	CCOC(=O)CC1=C(C=C(C=C1)C(=O)OCC)[N+](=O)[O-]
DMQ6K8J	IK	SKZKACZIGOSXQL-UHFFFAOYSA-N
DMQ6K8J	IU	ethyl 4-(2-ethoxy-2-oxoethyl)-3-nitrobenzoate
DMQ6K8J	CA	CAS 891782-57-3
DMQ6K8J	DE	Hypertension

DMGH3T5	ID	DMGH3T5
DMGH3T5	DN	Zaprinast
DMGH3T5	HS	Terminated
DMGH3T5	DT	Small molecular drug
DMGH3T5	PC	135399235
DMGH3T5	MW	271.27
DMGH3T5	FM	C13H13N5O2
DMGH3T5	IC	InChI=1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19)
DMGH3T5	CS	CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2
DMGH3T5	IK	REZGGXNDEMKIQB-UHFFFAOYSA-N
DMGH3T5	IU	5-(2-propoxyphenyl)-2,6-dihydrotriazolo[4,5-d]pyrimidin-7-one
DMGH3T5	CA	CAS 37762-06-4
DMGH3T5	CB	CHEBI:92215

DMC38FO	ID	DMC38FO
DMC38FO	DN	ZARDAVERINE
DMC38FO	HS	Terminated
DMC38FO	SN	zardaverine; 101975-10-4; Zardaverina; Zardaverinum; Zardaverine [INN]; Zardaverinum [INN-Latin]; UNII-TQ358GWH6Y; Zardaverina [INN-Spanish]; 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE; C12H10F2N2O3; 6-(4-(Difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone; TQ358GWH6Y; CHEMBL313842; CHEBI:46548; 6-[4-(difluoromethoxy)-3-methoxyphenyl]pyridazin-3(2H)-one; HJMQDJPMQIHLPB-UHFFFAOYSA-N; 6-(4-Difluoromethoxy-3-methoxyphenyl)-3(2H)-pyridazinone; NCGC00016106-04
DMC38FO	DT	Small molecular drug
DMC38FO	PC	5723
DMC38FO	MW	268.22
DMC38FO	FM	C12H10F2N2O3
DMC38FO	IC	InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17)
DMC38FO	CS	COC1=C(C=CC(=C1)C2=NNC(=O)C=C2)OC(F)F
DMC38FO	IK	HJMQDJPMQIHLPB-UHFFFAOYSA-N
DMC38FO	IU	3-[4-(difluoromethoxy)-3-methoxyphenyl]-1H-pyridazin-6-one
DMC38FO	CA	CAS 101975-10-4
DMC38FO	CB	CHEBI:46548
DMC38FO	DE	Chronic obstructive pulmonary disease

DMNYKOT	ID	DMNYKOT
DMNYKOT	DN	Zatebradine
DMNYKOT	HS	Terminated
DMNYKOT	SN	UL-FS-49; UL-FS-49CL
DMNYKOT	CP	Boehringer Ingelheim Corp
DMNYKOT	DT	Small molecular drug
DMNYKOT	PC	65637
DMNYKOT	MW	456.6
DMNYKOT	FM	C26H36N2O5
DMNYKOT	IC	InChI=1S/C26H36N2O5/c1-27(13-9-19-7-8-22(30-2)23(15-19)31-3)11-6-12-28-14-10-20-16-24(32-4)25(33-5)17-21(20)18-26(28)29/h7-8,15-17H,6,9-14,18H2,1-5H3
DMNYKOT	CS	CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CCC3=CC(=C(C=C3)OC)OC
DMNYKOT	IK	KEDQCFRVSHYKLR-UHFFFAOYSA-N
DMNYKOT	IU	3-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
DMNYKOT	CA	CAS 85175-67-3
DMNYKOT	CB	CHEBI:93613
DMNYKOT	DE	Angina pectoris

DM6M9GC	ID	DM6M9GC
DM6M9GC	DN	ZD-3638
DM6M9GC	HS	Terminated
DM6M9GC	SN	ZD-3638; SCHEMBL1152094; CHEMBL264026
DM6M9GC	CP	AstraZeneca
DM6M9GC	DT	Small molecular drug
DM6M9GC	PC	9955820
DM6M9GC	MW	458.6
DM6M9GC	FM	C28H30N2O2S
DM6M9GC	IC	InChI=1S/C28H30N2O2S/c1-2-33(32)26-25(12-7-15-29-26)28(31)13-16-30(17-14-28)19-27-18-22(20-8-3-5-10-23(20)27)21-9-4-6-11-24(21)27/h3-12,15,22,31H,2,13-14,16-19H2,1H3
DM6M9GC	CS	CCS(=O)C1=C(C=CC=N1)C2(CCN(CC2)CC34CC(C5=CC=CC=C53)C6=CC=CC=C46)O
DM6M9GC	IK	LVMVFEHQMHETDS-UHFFFAOYSA-N
DM6M9GC	IU	4-(2-ethylsulfinylpyridin-3-yl)-1-(1-tetracyclo[6.6.1.02,7.09,14]pentadeca-2,4,6,9,11,13-hexaenylmethyl)piperidin-4-ol
DM6M9GC	DE	Schizophrenia

DM91IPH	ID	DM91IPH
DM91IPH	DN	ZD-3980
DM91IPH	HS	Terminated
DM91IPH	CP	AstraZeneca plc
DM91IPH	DE	Prostate hyperplasia

DMVWRU9	ID	DMVWRU9
DMVWRU9	DN	ZD-4190
DMVWRU9	HS	Terminated
DMVWRU9	SN	AC1OCFDK; CHEMBL3544937; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(triazol-1-yl)ethoxy]quinazolin-4-amine hydrochloride
DMVWRU9	CP	AstraZeneca plc
DMVWRU9	DT	Small molecular drug
DMVWRU9	PC	5329032
DMVWRU9	MW	459.3
DMVWRU9	FM	C19H16BrFN6O2
DMVWRU9	IC	InChI=1S/C19H16BrFN6O2/c1-28-17-9-13-16(10-18(17)29-7-6-27-5-4-24-26-27)22-11-23-19(13)25-15-3-2-12(20)8-14(15)21/h2-5,8-11H,6-7H2,1H3,(H,22,23,25)
DMVWRU9	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=C(C=C(C=C3)Br)F)OCCN4C=CN=N4
DMVWRU9	IK	YBTGTVGEKMZEQX-UHFFFAOYSA-N
DMVWRU9	IU	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(triazol-1-yl)ethoxy]quinazolin-4-amine
DMVWRU9	DE	Solid tumour/cancer

DMU2F6Q	ID	DMU2F6Q
DMU2F6Q	DN	ZD-6003
DMU2F6Q	HS	Terminated
DMU2F6Q	CP	Zeneca Group plc
DMU2F6Q	DE	Solid tumour/cancer

DM5KSCI	ID	DM5KSCI
DM5KSCI	DN	ZD-7155
DM5KSCI	HS	Terminated
DM5KSCI	SN	ZD-7155; CHEMBL159096; 5,7-diethyl-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3,4-dihydro-1,6-naphthyridin-2-one; 5,7-Diethyl-1-{[2'-(1h-Tetrazol-5-Yl)biphenyl-4-Yl]methyl}-3,4-Dihydro-1,6-Naphthyridin-2(1h)-One; ZD 7155; Tocris-1211; NCGC00025043-01; AC1NGE69; SCHEMBL7286312; GTPL8324; CHEBI:92194; ZINC3784334; BDBM50049187; L007754; BRD-K11373525-003-01-3; ZD7; 5,7-diethyl-1-[2'-(1h-1,2,3,4-tetrazol-5-yl)-bi-phenyl-4-ylmethyl]-1,2,3,4-tetrahydro-1,6-naphthyridin-2-one
DM5KSCI	CP	Zeneca Group plc
DM5KSCI	DT	Small molecular drug
DM5KSCI	PC	4673492
DM5KSCI	MW	438.5
DM5KSCI	FM	C26H26N6O
DM5KSCI	IC	InChI=1S/C26H26N6O/c1-3-19-15-24-22(23(4-2)27-19)13-14-25(33)32(24)16-17-9-11-18(12-10-17)20-7-5-6-8-21(20)26-28-30-31-29-26/h5-12,15H,3-4,13-14,16H2,1-2H3,(H,28,29,30,31)
DM5KSCI	CS	CCC1=CC2=C(CCC(=O)N2CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=N1)CC
DM5KSCI	IK	BFVNEYDCFJNLGN-UHFFFAOYSA-N
DM5KSCI	IU	5,7-diethyl-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3,4-dihydro-1,6-naphthyridin-2-one
DM5KSCI	CB	CHEBI:92194
DM5KSCI	DE	Hypertension

DMJEZOP	ID	DMJEZOP
DMJEZOP	DN	ZD-7717
DMJEZOP	HS	Terminated
DMJEZOP	SN	ICI D7717
DMJEZOP	CP	Zeneca Group plc
DMJEZOP	DE	Asthma

DMCT1IX	ID	DMCT1IX
DMCT1IX	DN	ZD-7944
DMCT1IX	HS	Terminated
DMCT1IX	SN	CHEMBL339767; ZD-7944; ZD7944; SCHEMBL7501969; BDBM50409575; (R)-3-((S)-1-(3,4-dichlorophenyl)-3-(4-(2-((S)-methylsulfinyl)phenyl)piperidin-1-yl)propyl)-2-ethylisoindolin-1-one
DMCT1IX	CP	Zeneca Group plc
DMCT1IX	DT	Small molecular drug
DMCT1IX	PC	44351946
DMCT1IX	MW	569.6
DMCT1IX	FM	C31H34Cl2N2O2S
DMCT1IX	IC	InChI=1S/C31H34Cl2N2O2S/c1-3-35-30(25-9-4-5-10-26(25)31(35)36)24(22-12-13-27(32)28(33)20-22)16-19-34-17-14-21(15-18-34)23-8-6-7-11-29(23)38(2)37/h4-13,20-21,24,30H,3,14-19H2,1-2H3/t24-,30+,38-/m0/s1
DMCT1IX	CS	CCN1[C@@H](C2=CC=CC=C2C1=O)[C@@H](CCN3CCC(CC3)C4=CC=CC=C4[S@@](=O)C)C5=CC(=C(C=C5)Cl)Cl
DMCT1IX	IK	JYCLPXSCZKCIMO-YEFUCVGBSA-N
DMCT1IX	IU	(3R)-3-[(1S)-1-(3,4-dichlorophenyl)-3-[4-[2-[(S)-methylsulfinyl]phenyl]piperidin-1-yl]propyl]-2-ethyl-3H-isoindol-1-one
DMCT1IX	DE	Asthma

DMFV47R	ID	DMFV47R
DMFV47R	DN	ZD-9720
DMFV47R	HS	Terminated
DMFV47R	SN	ZD-7851
DMFV47R	CP	AstraZeneca plc
DMFV47R	DE	Arteriosclerosis

DMQUSG9	ID	DMQUSG9
DMQUSG9	DN	Zenarestat
DMQUSG9	HS	Terminated
DMQUSG9	SN	112733-06-9; FR-74366; FK-366; Zenarestat [USAN:INN]; Zenarestatum [INN-Latin]; FR 74366; UNII-180C9PJ8JT; FK 366; [3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-3,4-dihydroquinazolin-1(2h)-yl]acetic acid; CI-1014; CI 1014; CHEMBL10413; 180C9PJ8JT; 2-(7-Chloro-3-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxoquinazolin)-1-acetic acid; Zenarestatum; DSSTox_RID_82249; 3-(4-Bromo-2-fluorobenzyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid; DSSTox_CID_27296;  ZES; FR74366; Fk366; Zenarestat (USAN/INN); [3-(4-BROMO-2-FLUORO-BENZYL)-7-CHLORO-2,4-DIOXO-3,4-DIHYDRO-2H-QUINAZOLIN-1-YL]-ACETIC ACID; (3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)acetic acid; 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid; 3-((4-Bromo-2-fluorophenyl)methyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineaceticacid
DMQUSG9	CP	Ono Pharmaceutical; Fujisawa Pharmaceutical
DMQUSG9	DT	Small molecular drug
DMQUSG9	PC	5724
DMQUSG9	MW	441.6
DMQUSG9	FM	C17H11BrClFN2O4
DMQUSG9	IC	InChI=1S/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24)
DMQUSG9	CS	C1=CC2=C(C=C1Cl)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
DMQUSG9	IK	SXONDGSPUVNZLO-UHFFFAOYSA-N
DMQUSG9	IU	2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid
DMQUSG9	CA	CAS 112733-06-9
DMQUSG9	DE	Diabetic neuropathy

DM81DJV	ID	DM81DJV
DM81DJV	DN	Zindoxifene
DM81DJV	HS	Terminated
DM81DJV	SN	D-16726
DM81DJV	CP	Evonik Degussa GmbH
DM81DJV	DT	Small molecular drug
DM81DJV	PC	65645
DM81DJV	MW	351.4
DM81DJV	FM	C21H21NO4
DM81DJV	IC	InChI=1S/C21H21NO4/c1-5-22-20-11-10-18(26-15(4)24)12-19(20)13(2)21(22)16-6-8-17(9-7-16)25-14(3)23/h6-12H,5H2,1-4H3
DM81DJV	CS	CCN1C2=C(C=C(C=C2)OC(=O)C)C(=C1C3=CC=C(C=C3)OC(=O)C)C
DM81DJV	IK	KSZGVNZSUJHOJA-UHFFFAOYSA-N
DM81DJV	IU	[4-(5-acetyloxy-1-ethyl-3-methylindol-2-yl)phenyl] acetate
DM81DJV	CA	CAS 86111-26-4
DM81DJV	CB	CHEBI:35052
DM81DJV	DE	Breast cancer

DMJZH7N	ID	DMJZH7N
DMJZH7N	DN	ZK-118182
DMJZH7N	HS	Terminated
DMJZH7N	SN	ZK118182; 2-[(Z)-4-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E,3R)-3-hydroxy-3-(2-methylcyclohexyl)prop-1-enyl]cyclopentyl]but-2-enoxy]acetic acid; AC1NSK7N
DMJZH7N	CP	Bayer Schering Pharma AG
DMJZH7N	DT	Small molecular drug
DMJZH7N	PC	5311208
DMJZH7N	MW	400.9
DMJZH7N	FM	C21H33ClO5
DMJZH7N	IC	InChI=1S/C21H33ClO5/c1-14-6-2-3-7-15(14)19(23)10-9-17-16(18(22)12-20(17)24)8-4-5-11-27-13-21(25)26/h4-5,9-10,14-20,23-24H,2-3,6-8,11-13H2,1H3,(H,25,26)/b5-4-,10-9+/t14?,15?,16-,17-,18-,19-,20-/m1/s1
DMJZH7N	CS	CC1CCCCC1[C@@H](/C=C/[C@H]2[C@@H](C[C@H]([C@@H]2C/C=C\\COCC(=O)O)Cl)O)O
DMJZH7N	IK	JPMWVHYATGJOOX-OSIODEBVSA-N
DMJZH7N	IU	2-[(Z)-4-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E,3R)-3-hydroxy-3-(2-methylcyclohexyl)prop-1-enyl]cyclopentyl]but-2-enoxy]acetic acid
DMJZH7N	DE	Thrombosis

DMKFYDE	ID	DMKFYDE
DMKFYDE	DN	ZK-119010
DMKFYDE	HS	Terminated
DMKFYDE	SN	ZK-119010; ZK 119010; UNII-80Z22M837F; CHEMBL46903; 80Z22M837F; 127451-69-8; AC1L2YAG; 2-(4-Hydroxyphenyl)-3-methyl-1-(6-(1-pyrrolidinyl)hexyl)indol-5-ol; SCHEMBL9028173; DTXSID50155574; zk119010; BDBM50099586; 1H-Indol-5-ol, 2-(4-hydroxyphenyl)-3-methyl-1-(6-(1-pyrrolidinyl)hexyl)-; LS-191850; 2-(4-hydroxyphenyl)-3-methyl-1-(6-pyrrolidin-1-ylhexyl)indol-5-ol
DMKFYDE	DT	Small molecular drug
DMKFYDE	PC	130936
DMKFYDE	MW	392.5
DMKFYDE	FM	C25H32N2O2
DMKFYDE	IC	InChI=1S/C25H32N2O2/c1-19-23-18-22(29)12-13-24(23)27(25(19)20-8-10-21(28)11-9-20)17-5-3-2-4-14-26-15-6-7-16-26/h8-13,18,28-29H,2-7,14-17H2,1H3
DMKFYDE	CS	CC1=C(N(C2=C1C=C(C=C2)O)CCCCCCN3CCCC3)C4=CC=C(C=C4)O
DMKFYDE	IK	SACIXOLGIWUXTG-UHFFFAOYSA-N
DMKFYDE	IU	2-(4-hydroxyphenyl)-3-methyl-1-(6-pyrrolidin-1-ylhexyl)indol-5-ol
DMKFYDE	CA	CAS 127451-69-8
DMKFYDE	DE	Carcinoma

DMJYIVA	ID	DMJYIVA
DMJYIVA	DN	ZK-91296
DMJYIVA	HS	Terminated
DMJYIVA	SN	ZK 91296; 83910-34-3; Ethyl 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-5-(phenylmethoxy)-, ethyl ester; WFPXOWCKXUEKCA-UHFFFAOYSA-N; AC1Q64YJ; SCHEMBL8845201; AC1L3X51; zk91296; BDBM85040; PDSP2_001753; ethyl 5-(benzyloxy)-4-(methoxymethyl)-9h-; PDSP1_001770; CAS_123700; NSC_123700; LS-187464; LS-186794; 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid-ethyl ester
DMJYIVA	CP	Bayer Schering Pharma AG
DMJYIVA	DT	Small molecular drug
DMJYIVA	PC	123700
DMJYIVA	MW	390.4
DMJYIVA	FM	C23H22N2O4
DMJYIVA	IC	InChI=1S/C23H22N2O4/c1-3-28-23(26)22-16(14-27-2)20-18(12-24-22)25-17-10-7-11-19(21(17)20)29-13-15-8-5-4-6-9-15/h4-12,25H,3,13-14H2,1-2H3
DMJYIVA	CS	CCOC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC=C3OCC4=CC=CC=C4
DMJYIVA	IK	WFPXOWCKXUEKCA-UHFFFAOYSA-N
DMJYIVA	IU	ethyl 4-(methoxymethyl)-5-phenylmethoxy-9H-pyrido[3,4-b]indole-3-carboxylate
DMJYIVA	CA	CAS 83910-34-3
DMJYIVA	DE	Alzheimer disease

DMMDQ5T	ID	DMMDQ5T
DMMDQ5T	DN	ZK-93426
DMMDQ5T	HS	Terminated
DMMDQ5T	SN	ZK-93426; ZK 93426; ZK93426; ZK 93 426; CHEMBL1271047; 89592-45-0; 5-Isopropoxy-4-methyl-beta-carboline-3-carboxylic acid ethyl ester; Ethyl 4-methyl-5-(1-methylethoxy)-9H-pyrido(3,4-b)indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-methyl-5-(1-methylethoxy)-, ethyl ester; AC1L3GQB; SCHEMBL195334; GTPL4347; CHEBI:93201; ZINC5857864; BDBM50329658; NCGC00161396-01; LS-178094; BRD-K68392338-003-01-2; ethyl 5-isopropoxy-4-methyl-9H-pyrido[3,4-b]indole-3-carboxylate; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-
DMMDQ5T	CP	Bayer Schering Pharma AG
DMMDQ5T	DT	Small molecular drug
DMMDQ5T	PC	115210
DMMDQ5T	MW	312.4
DMMDQ5T	FM	C18H20N2O3
DMMDQ5T	IC	InChI=1S/C18H20N2O3/c1-5-22-18(21)17-11(4)15-13(9-19-17)20-12-7-6-8-14(16(12)15)23-10(2)3/h6-10,20H,5H2,1-4H3
DMMDQ5T	CS	CCOC(=O)C1=NC=C2C(=C1C)C3=C(N2)C=CC=C3OC(C)C
DMMDQ5T	IK	VMDUABMKBUKKPG-UHFFFAOYSA-N
DMMDQ5T	IU	ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[3,4-b]indole-3-carboxylate
DMMDQ5T	CA	CAS 89592-45-0
DMMDQ5T	CB	CHEBI:93201
DMMDQ5T	DE	Alzheimer disease

DM8V0YA	ID	DM8V0YA
DM8V0YA	DN	ZM-224832
DM8V0YA	HS	Terminated
DM8V0YA	CP	Zeneca Group plc
DM8V0YA	DE	Hypertension

DM0TBQK	ID	DM0TBQK
DM0TBQK	DN	ZM-230487
DM0TBQK	HS	Terminated
DM0TBQK	SN	ZM-230487; ZM 230487; 155944-23-3; CHEMBL459236; Ici 230487; ICI-230487; AC1L31ZC; 1-Ethyl-6-((3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-2-quinolone; SCHEMBL6008852; CTK4C8893; DTXSID70165998; zm230487; ZINC1484223; BDBM50250926; 1-Ethyl-6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-2(1H)-quinolinone; KB-276139; 1-ethyl-6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]quinolin-2-one
DM0TBQK	DT	Small molecular drug
DM0TBQK	PC	132998
DM0TBQK	MW	411.5
DM0TBQK	FM	C24H26FNO4
DM0TBQK	IC	InChI=1S/C24H26FNO4/c1-3-26-22-6-4-17(12-18(22)5-7-23(26)27)16-30-21-14-19(13-20(25)15-21)24(28-2)8-10-29-11-9-24/h4-7,12-15H,3,8-11,16H2,1-2H3
DM0TBQK	CS	CCN1C2=C(C=CC1=O)C=C(C=C2)COC3=CC(=CC(=C3)C4(CCOCC4)OC)F
DM0TBQK	IK	ZROVOGSXAWNIQB-UHFFFAOYSA-N
DM0TBQK	IU	1-ethyl-6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]quinolin-2-one
DM0TBQK	CA	CAS 155944-23-3
DM0TBQK	DE	Asthma

DMWQ38G	ID	DMWQ38G
DMWQ38G	DN	ZM-241385
DMWQ38G	HS	Terminated
DMWQ38G	SN	ZM241385; 139180-30-6; ZM 241385; ZM-241385; CHEMBL113142; 4-(2-(7-Amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5)triazin-5-ylamino)ethyl)phenol; 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol; 4-(2-(7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol; 4-{2-[(7-Amino-2-Furan-2-Yl[1,2,4]triazolo[1,5-A][1,3,5]triazin-5-Yl)amino]ethyl}phenol; 4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol
DMWQ38G	DT	Small molecular drug
DMWQ38G	PC	176407
DMWQ38G	MW	337.34
DMWQ38G	FM	C16H15N7O2
DMWQ38G	IC	InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22)
DMWQ38G	CS	C1=COC(=C1)C2=NN3C(=NC(=NC3=N2)NCCC4=CC=C(C=C4)O)N
DMWQ38G	IK	PWTBZOIUWZOPFT-UHFFFAOYSA-N
DMWQ38G	IU	4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol
DMWQ38G	CA	CAS 139180-30-6
DMWQ38G	CB	CHEBI:92361

DM70HZD	ID	DM70HZD
DM70HZD	DN	Zonampanel
DM70HZD	HS	Terminated
DM70HZD	SN	Zonampanel; Ym 872; 210245-80-0; YM-872; UNII-9X33544ILS; CHEMBL119625; 9X33544ILS; Zonampanel [USAN:INN]; YM872 anhydrous; Zonampanel anhydrous; YM 872 anhydrous; Zonampanel (INN/USAN); AC1L3WN2; SCHEMBL678832; DTXSID50175232; ZINC1891930; BDBM50133599; AKOS030257633; CS-6830; KB-81523; HY-15072; QC-11463; D09035; 2-(7-imidazol-1-yl-6-nitro-2,3-dioxo-4H-quinoxalin-1-yl)acetic acid; 7-(1H-Imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl)acetic acid
DM70HZD	DT	Small molecular drug
DM70HZD	PC	148200
DM70HZD	MW	331.24
DM70HZD	FM	C13H9N5O6
DM70HZD	IC	InChI=1S/C13H9N5O6/c19-11(20)5-17-8-4-9(16-2-1-14-6-16)10(18(23)24)3-7(8)15-12(21)13(17)22/h1-4,6H,5H2,(H,15,21)(H,19,20)
DM70HZD	CS	C1=CN(C=N1)C2=C(C=C3C(=C2)N(C(=O)C(=O)N3)CC(=O)O)[N+](=O)[O-]
DM70HZD	IK	SPXYHZRWPRQLNS-UHFFFAOYSA-N
DM70HZD	IU	2-(7-imidazol-1-yl-6-nitro-2,3-dioxo-4H-quinoxalin-1-yl)acetic acid
DM70HZD	CA	CAS 210245-80-0

DM70TKB	ID	DM70TKB
DM70TKB	DN	zoxazolamine
DM70TKB	HS	Terminated
DM70TKB	SN	Zoxazolamine; 61-80-3; 2-Amino-5-chlorobenzoxazole; 5-chlorobenzo[d]oxazol-2-amine; 5-Chloro-1,3-benzoxazol-2-amine; Flexin; 2-Benzoxazolamine, 5-chloro-; Contrazole; Deflexol; Flexilon; Zoxamin; Zoxine; USAF MA-12; McN-485; 5-Chloro-2-benzoxazolamine; Zossazolamina [DCIT]; C7H5ClN2O; Zoxazolaminum [INN-Latin]; Zoxazolamina [INN-Spanish]; NSC 24995; UNII-9DOW362Q29; BENZOXAZOLE, 2-AMINO-5-CHLORO-; CHEBI:35053; EINECS 200-519-4; MLS002639033; AI3-63120; YGCODSQDUUUKIV-UHFFFAOYSA-N; 9DOW362Q29; 2-Amino-5-chlorobenzoxazole, 97%
DM70TKB	DT	Small molecular drug
DM70TKB	PC	6103
DM70TKB	MW	168.58
DM70TKB	FM	C7H5ClN2O
DM70TKB	IC	InChI=1S/C7H5ClN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)
DM70TKB	CS	C1=CC2=C(C=C1Cl)N=C(O2)N
DM70TKB	IK	YGCODSQDUUUKIV-UHFFFAOYSA-N
DM70TKB	IU	5-chloro-1,3-benzoxazol-2-amine
DM70TKB	CA	CAS 61-80-3
DM70TKB	CB	CHEBI:35053
DM70TKB	DE	Multiple myeloma

DM193WR	ID	DM193WR
DM193WR	DN	ZT-386
DM193WR	HS	Terminated
DM193WR	CP	Taisho Pharmaceutical Co Ltd
DM193WR	DE	Asthma

DM2TIU3	ID	DM2TIU3
DM2TIU3	DN	((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine
DM2TIU3	HS	Investigative
DM2TIU3	SN	CHEMBL498509; ((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine; SCHEMBL5808356; BDBM50272715
DM2TIU3	DT	Small molecular drug
DM2TIU3	PC	44593693
DM2TIU3	MW	269.34
DM2TIU3	FM	C17H19NO2
DM2TIU3	IC	InChI=1S/C17H19NO2/c1-12-6-2-4-8-15(12)20-17-13(10-18)11-19-16-9-5-3-7-14(16)17/h2-9,13,17H,10-11,18H2,1H3/t13-,17-/m1/s1
DM2TIU3	CS	CC1=CC=CC=C1O[C@@H]2[C@@H](COC3=CC=CC=C23)CN
DM2TIU3	IK	RQRGTZIPGLRQOJ-CXAGYDPISA-N
DM2TIU3	IU	[(3R,4R)-4-(2-methylphenoxy)-3,4-dihydro-2H-chromen-3-yl]methanamine
DM2TIU3	DE	Discovery agent

DMEJRVW	ID	DMEJRVW
DMEJRVW	DN	((E)-3-Amino-propenyl)-methyl-phosphinic acid
DMEJRVW	HS	Investigative
DMEJRVW	SN	3-aminoprop-1-enyl(methyl)phosphinic acid
DMEJRVW	DE	Discovery agent

DMCW65Q	ID	DMCW65Q
DMCW65Q	DN	((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine
DMCW65Q	HS	Investigative
DMCW65Q	SN	CHEMBL89459; ((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine; BDBM50104655
DMCW65Q	DT	Small molecular drug
DMCW65Q	PC	10012278
DMCW65Q	MW	166.26
DMCW65Q	FM	C10H18N2
DMCW65Q	IC	InChI=1S/C10H18N2/c1-2-3-6-9-7-4-5-8-10(11)12-9/h2-3,9H,4-8H2,1H3,(H2,11,12)/b3-2+
DMCW65Q	CS	C/C=C/CC1CCCCC(=N1)N
DMCW65Q	IK	JYALIDLLQJSBKD-NSCUHMNNSA-N
DMCW65Q	IU	2-[(E)-but-2-enyl]-3,4,5,6-tetrahydro-2H-azepin-7-amine
DMCW65Q	DE	Discovery agent

DM6H0FW	ID	DM6H0FW
DM6H0FW	DN	((Z)-3-Amino-propenyl)-methyl-phosphinic acid
DM6H0FW	HS	Investigative
DM6H0FW	SN	CGP-70523; SCHEMBL6679937; PDSP2_001466; PDSP1_001482
DM6H0FW	DT	Small molecular drug
DM6H0FW	PC	91929120
DM6H0FW	MW	135.1
DM6H0FW	FM	C4H10NO2P
DM6H0FW	IC	InChI=1S/C4H10NO2P/c1-8(6,7)4-2-3-5/h3,5H,2,4H2,1H3,(H,6,7)
DM6H0FW	CS	CP(=O)(CCC=N)O
DM6H0FW	IK	CLJLMKDNJNIXPO-UHFFFAOYSA-N
DM6H0FW	IU	3-iminopropyl(methyl)phosphinic acid
DM6H0FW	DE	Discovery agent

DM974LP	ID	DM974LP
DM974LP	DN	(-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride
DM974LP	HS	Investigative
DM974LP	SN	CHEMBL507970
DM974LP	DT	Small molecular drug
DM974LP	PC	44584678
DM974LP	MW	675.2
DM974LP	FM	C39H47ClN2O6
DM974LP	IC	InChI=1S/C39H46N2O6.ClH/c1-40-16-14-27-21-35(43-4)37(45-6)23-30(27)32(40)18-25-8-11-29(12-9-25)47-39-20-26(10-13-34(39)42-3)19-33-31-24-38(46-7)36(44-5)22-28(31)15-17-41(33)2;/h8-13,20-24,32-33H,14-19H2,1-7H3;1H/t32-,33+;/m1./s1
DM974LP	CS	CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@H]5C6=CC(=C(C=C6CCN5C)OC)OC)OC)OC)OC.Cl
DM974LP	IK	OEBMBMKSAQUFSL-VMXYRSAXSA-N
DM974LP	IU	(1R)-1-[[4-[5-[[(1S)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]phenyl]methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline;hydrochloride
DM974LP	DE	Discovery agent

DMV6EMN	ID	DMV6EMN
DMV6EMN	DN	(-)-(R)-efonidipine
DMV6EMN	HS	Investigative
DMV6EMN	SN	UNII-BF2E1WS195; BF2E1WS195; ()-2-[benzyl (phenyl) amino] ethyl 1,4-dihydro-2,6- dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethano; Efonidipine, (-)-; (-)-(R)-efonidipine; (R)-(-)-Efonidipine; 128194-13-8; Efonidipine (R)-form [MI]; GTPL2519; ZINC38139973; 3-Pyridinecarboxylic acid, 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(phenyl(phenylmethyl)amino)ethyl ester, (4R)-
DMV6EMN	DT	Small molecular drug
DMV6EMN	PC	9830707
DMV6EMN	MW	631.7
DMV6EMN	FM	C34H38N3O7P
DMV6EMN	IC	InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3/t31-/m1/s1
DMV6EMN	CS	CC1=C([C@H](C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5
DMV6EMN	IK	NSVFSAJIGAJDMR-WJOKGBTCSA-N
DMV6EMN	IU	2-(N-benzylanilino)ethyl (4R)-5-(5,5-dimethyl-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
DMV6EMN	CA	CAS 128194-13-8
DMV6EMN	CB	CHEBI:146219
DMV6EMN	DE	Discovery agent

DMEA9KH	ID	DMEA9KH
DMEA9KH	DN	(-)-(S)-BayK8644
DMEA9KH	HS	Investigative
DMEA9KH	SN	98625-26-4; (S)-(-)-BAY K 8644; Bay-K-8644 ((S)-(-)-); Bay-K-8644 (S)-(-)-; (S)-(-)-Bay K8644; methyl (4S)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate; S-(-)-1,4-Dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid methyl ester; CHEMBL283013; Tocris-1544; Lopac-B-112; (S)-BayK8644; GTPL4065; AC1O7G05; SCHEMBL2845539; (S)-Bay K8644; CHEBI:93962; (S)-Bay-K-8644; DTXSID50424954; MolPort-003-940-398; CHEBI:131347
DMEA9KH	DT	Small molecular drug
DMEA9KH	PC	6603728
DMEA9KH	MW	356.3
DMEA9KH	FM	C16H15F3N2O4
DMEA9KH	IC	InChI=1S/C16H15F3N2O4/c1-8-12(15(22)25-3)13(14(21(23)24)9(2)20-8)10-6-4-5-7-11(10)16(17,18)19/h4-7,13,20H,1-3H3/t13-/m0/s1
DMEA9KH	CS	CC1=C([C@@H](C(=C(N1)C)[N+](=O)[O-])C2=CC=CC=C2C(F)(F)F)C(=O)OC
DMEA9KH	IK	ZFLWDHHVRRZMEI-ZDUSSCGKSA-N
DMEA9KH	IU	methyl (4S)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate
DMEA9KH	CA	CAS 98625-26-4
DMEA9KH	CB	CHEBI:93962
DMEA9KH	DE	Discovery agent

DME5TIR	ID	DME5TIR
DME5TIR	DN	(-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile
DME5TIR	HS	Investigative
DME5TIR	SN	3-(1-Propyl-3-piperidinyl)benzonitrile; 150336-90-6; 3-(1-propylpiperidin-3-yl)benzonitrile; CHEMBL107492; Benzonitrile,3-(1-propyl-3-piperidinyl)-; DS121 Cpd; 3-(3-Cyanophenyl)-N-n-propylpiperidine; AC1L1JNG; AC1Q4RGX; ACMC-1C3WE; SCHEMBL872942; CTK4C6605; BDBM50041960; 3-(1-Propylpiperidine-3-yl)benzonitrile; 3-(1-Propyl-piperidin-3-yl)-benzonitrile; (+)-3-(1-Propyl-piperidin-3-yl)-benzonitrile; L007862; Benzonitrile, 3-(1-propyl-3-piperidinyl)-, (+-)-
DME5TIR	DT	Small molecular drug
DME5TIR	PC	5119
DME5TIR	MW	228.33
DME5TIR	FM	C15H20N2
DME5TIR	IC	InChI=1S/C15H20N2/c1-2-8-17-9-4-7-15(12-17)14-6-3-5-13(10-14)11-16/h3,5-6,10,15H,2,4,7-9,12H2,1H3
DME5TIR	CS	CCCN1CCCC(C1)C2=CC=CC(=C2)C#N
DME5TIR	IK	GQRIAOUUYRIMLH-UHFFFAOYSA-N
DME5TIR	IU	3-(1-propylpiperidin-3-yl)benzonitrile
DME5TIR	CA	CAS 150336-90-6
DME5TIR	DE	Discovery agent

DMGC7F5	ID	DMGC7F5
DMGC7F5	DN	(-)-3,3'-bisdemethylpinoresinol
DMGC7F5	HS	Investigative
DMGC7F5	SN	CHEMBL227187; BDBM50208822; J3.605.566I
DMGC7F5	DT	Small molecular drug
DMGC7F5	PC	24992964
DMGC7F5	MW	330.3
DMGC7F5	FM	C18H18O6
DMGC7F5	IC	InChI=1S/C18H18O6/c19-13-3-1-9(5-15(13)21)17-11-7-24-18(12(11)8-23-17)10-2-4-14(20)16(22)6-10/h1-6,11-12,17-22H,7-8H2/t11-,12-,17+,18+/m1/s1
DMGC7F5	CS	C1[C@@H]2[C@@H](CO[C@H]2C3=CC(=C(C=C3)O)O)[C@@H](O1)C4=CC(=C(C=C4)O)O
DMGC7F5	IK	OQSOTSIYXPYTRE-VVDPLQPHSA-N
DMGC7F5	IU	4-[(3R,3aS,6R,6aS)-3-(3,4-dihydroxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]benzene-1,2-diol
DMGC7F5	DE	Discovery agent

DMKRTBM	ID	DMKRTBM
DMKRTBM	DN	(-)-3-O-acetylspectaline
DMKRTBM	HS	Investigative
DMKRTBM	SN	(-)-3-O-Acetylspectaline
DMKRTBM	DT	Small molecular drug
DMKRTBM	PC	10474155
DMKRTBM	MW	367.6
DMKRTBM	FM	C22H41NO3
DMKRTBM	IC	InChI=1S/C22H41NO3/c1-18(24)14-12-10-8-6-4-5-7-9-11-13-15-21-16-17-22(19(2)23-21)26-20(3)25/h19,21-23H,4-17H2,1-3H3/t19-,21+,22-/m1/s1
DMKRTBM	CS	C[C@@H]1[C@@H](CC[C@@H](N1)CCCCCCCCCCCCC(=O)C)OC(=O)C
DMKRTBM	IK	LRKWDKCSHJWJST-BAGYTPMASA-N
DMKRTBM	IU	[(2R,3R,6S)-2-methyl-6-(13-oxotetradecyl)piperidin-3-yl] acetate
DMKRTBM	DE	Discovery agent

DM396OK	ID	DM396OK
DM396OK	DN	(-)-7-N-methyldibromophakellin
DM396OK	HS	Investigative
DM396OK	SN	CHEMBL505073; (-)-7-N-methyldibromophakellin
DM396OK	DT	Small molecular drug
DM396OK	PC	11211821
DM396OK	MW	403.07
DM396OK	FM	C12H13Br2N5O
DM396OK	IC	InChI=1S/C12H13Br2N5O/c1-17-10-12(16-11(17)15)3-2-4-18(12)9(20)7-5-6(13)8(14)19(7)10/h5,10H,2-4H2,1H3,(H2,15,16)/t10-,12+/m0/s1
DM396OK	CS	CN1[C@@H]2[C@]3(CCCN3C(=O)C4=CC(=C(N24)Br)Br)N=C1N
DM396OK	IK	YPAFHZXYEACLQB-CMPLNLGQSA-N
DM396OK	IU	(1R,5S)-3-amino-7,8-dibromo-4-methyl-2,4,6,12-tetrazatetracyclo[10.3.0.01,5.06,10]pentadeca-2,7,9-trien-11-one
DM396OK	DE	Discovery agent

DMZOGSK	ID	DMZOGSK
DMZOGSK	DN	(-)-CATECHINGALLATE
DMZOGSK	HS	Investigative
DMZOGSK	SN	(-)-Catechin gallate; 130405-40-2; (2S,3R)-2-(3,4-Dihydroxyphenyl)-5,7-dihydroxychroman-3-yl 3,4,5-trihydroxybenzoate; catechin gallate; UNII-0KT1FO6VO6; ent-Catechin 3-O-gallate; 0KT1FO6VO6; CHEMBL129451; CHEBI:76131; (2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; (2S,3R)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); (-)-CATECHINGALLATE; Catechin gallate, (-)-; CCRIS 9303; Catechin gallateCG; (-)-Catechin gallate
DMZOGSK	DT	Small molecular drug
DMZOGSK	PC	6419835
DMZOGSK	MW	442.4
DMZOGSK	FM	C22H18O10
DMZOGSK	IC	InChI=1S/C22H18O10/c23-11-6-14(25)12-8-19(32-22(30)10-4-16(27)20(29)17(28)5-10)21(31-18(12)7-11)9-1-2-13(24)15(26)3-9/h1-7,19,21,23-29H,8H2/t19-,21+/m1/s1
DMZOGSK	CS	C1[C@H]([C@@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMZOGSK	IK	LSHVYAFMTMFKBA-CTNGQTDRSA-N
DMZOGSK	IU	[(2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMZOGSK	CA	CAS 130405-40-2
DMZOGSK	CB	CHEBI:76131
DMZOGSK	DE	Discovery agent

DMJ249P	ID	DMJ249P
DMJ249P	DN	(-)-Cercosporamide
DMJ249P	HS	Investigative
DMJ249P	SN	Cercosporamide; 131436-22-1; CHEBI:78696; ( )-Cercosporamide; AC1L2Z33; SCHEMBL12658718; CTK8E7014; MolPort-006-822-609; GEWLYFZWVLXQME-MRXNPFEDSA-N; ZINC5114136; ZINC100098020; AKOS024458192; CS-4664; HY-16982; RT-011975; J-006002; (9aS)-8-acetyl-1,3,7-trihydroxy-9a-methyl-9-oxodibenzofuran-4-carboxamide; 4-Dibenzofurancarboxamide, 8-acetyl-9,9a-dihydro-1,3,7-trihydroxy-9a-methyl-9-oxo-, (S)-; (9aS)-8-Acetyl-9,9a-dihydro-1,3,7-trihydroxy-9a-methyl-9-oxo-4-dibenzofurancaboxamide
DMJ249P	DT	Small molecular drug
DMJ249P	PC	131379
DMJ249P	MW	331.28
DMJ249P	FM	C16H13NO7
DMJ249P	IC	InChI=1S/C16H13NO7/c1-5(18)10-7(20)4-9-16(2,14(10)22)12-8(21)3-6(19)11(15(17)23)13(12)24-9/h3-4,19-21H,1-2H3,(H2,17,23)/t16-/m1/s1
DMJ249P	CS	CC(=O)C1=C(C=C2[C@@](C1=O)(C3=C(C=C(C(=C3O2)C(=O)N)O)O)C)O
DMJ249P	IK	GEWLYFZWVLXQME-MRXNPFEDSA-N
DMJ249P	IU	(9aS)-8-acetyl-1,3,7-trihydroxy-9a-methyl-9-oxodibenzofuran-4-carboxamide
DMJ249P	CA	CAS 131436-22-1
DMJ249P	CB	CHEBI:78696
DMJ249P	DE	Discovery agent

DMPGJE6	ID	DMPGJE6
DMPGJE6	DN	(-)-clusin
DMPGJE6	HS	Investigative
DMPGJE6	SN	(-)-clusin; CHEMBL479701; BDBM50259867
DMPGJE6	DT	Small molecular drug
DMPGJE6	PC	44575398
DMPGJE6	MW	402.4
DMPGJE6	FM	C22H26O7
DMPGJE6	IC	InChI=1S/C22H26O7/c1-24-19-9-14(10-20(25-2)21(19)26-3)7-16-15(11-27-22(16)23)6-13-4-5-17-18(8-13)29-12-28-17/h4-5,8-10,15-16,22-23H,6-7,11-12H2,1-3H3/t15-,16+,22?/m0/s1
DMPGJE6	CS	COC1=CC(=CC(=C1OC)OC)C[C@@H]2[C@H](COC2O)CC3=CC4=C(C=C3)OCO4
DMPGJE6	IK	SOCNBZCAGNYAED-OKFXBHNASA-N
DMPGJE6	IU	(3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-ol
DMPGJE6	DE	Discovery agent

DM57LVW	ID	DM57LVW
DM57LVW	DN	(-)-cubebin
DM57LVW	HS	Investigative
DM57LVW	SN	Cubebin; (-)-Cubebin; 18423-69-3; beta-cubebin; UNII-J237078S8A; (2s,3r,4r)-3,4-bis(1,3-benzodioxol-5-ylmethyl)tetrahydrofuran-2-ol; EINECS 242-300-6; Tetrahydro-3,4-dipiperonylfuran-2-ol; (8R,8'R,9S)-cubebin; AI3-62265; CHEMBL399831; CHEBI:65684; J237078S8A; 2-Furanol, 3,4-bis(1,3-benzodioxol-5-ylmethyl)tetrahydro-; Cubebine; 9-Hydroxy-3,4:3',4'-bis(methylenedioxy)-9,9'-epoxylignan; 3,4-bis(2H-1,3-benzodioxol-5-ylmethyl)oxolan-2-ol; .beta.-Cubebin; 2-Furanol, tetrahydro-3,4-dipiperonyl-; AC1Q59VI; AC1L3KW2; SCHEMBL4884683
DM57LVW	DT	Small molecular drug
DM57LVW	PC	117443
DM57LVW	MW	356.4
DM57LVW	FM	C20H20O6
DM57LVW	IC	InChI=1S/C20H20O6/c21-20-15(6-13-2-4-17-19(8-13)26-11-24-17)14(9-22-20)5-12-1-3-16-18(7-12)25-10-23-16/h1-4,7-8,14-15,20-21H,5-6,9-11H2/t14-,15+,20-/m0/s1
DM57LVW	CS	C1[C@@H]([C@H]([C@H](O1)O)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5
DM57LVW	IK	DIYWRNLYKJKHAM-MDOVXXIYSA-N
DM57LVW	IU	(2S,3R,4R)-3,4-bis(1,3-benzodioxol-5-ylmethyl)oxolan-2-ol
DM57LVW	CA	CAS 18423-69-3
DM57LVW	CB	CHEBI:65684
DM57LVW	DE	Discovery agent

DMSTZF9	ID	DMSTZF9
DMSTZF9	DN	(-)-cubebinin
DMSTZF9	HS	Investigative
DMSTZF9	SN	(-)-cubebinin; CHEMBL480296; (-)-Cubebinin; BDBM50259873
DMSTZF9	DT	Small molecular drug
DMSTZF9	PC	44575401
DMSTZF9	MW	448.5
DMSTZF9	FM	C24H32O8
DMSTZF9	IC	InChI=1S/C24H32O8/c1-26-18-9-14(10-19(27-2)22(18)30-5)7-16-13-32-24(25)17(16)8-15-11-20(28-3)23(31-6)21(12-15)29-4/h9-12,16-17,24-25H,7-8,13H2,1-6H3/t16-,17+,24?/m0/s1
DMSTZF9	CS	COC1=CC(=CC(=C1OC)OC)C[C@H]2COC([C@@H]2CC3=CC(=C(C(=C3)OC)OC)OC)O
DMSTZF9	IK	PIYHDSUVUSVLGU-HSQXHLSASA-N
DMSTZF9	IU	(3R,4R)-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-ol
DMSTZF9	DE	Discovery agent

DM8Q6I0	ID	DM8Q6I0
DM8Q6I0	DN	(-)-cubebininolide
DM8Q6I0	HS	Investigative
DM8Q6I0	SN	(-)-cubebininolide; CHEMBL479314; Cordigerin; (-)-Cordigerine; (-)-Cubebininolide; VUNCHONBJWJYID-DLBZAZTESA-N; BDBM50259868; (3R,4R)-3,4-bis(3,4,5-Trimethoxybenzyl)dihydrofuran-2(3H)-one; 2(3H)-Furanone, dihydro-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]-, (3R-trans)-; 2(3H)-Furanone, dihydro-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]-, (3R,4R)-
DM8Q6I0	DT	Small molecular drug
DM8Q6I0	PC	13916150
DM8Q6I0	MW	446.5
DM8Q6I0	FM	C24H30O8
DM8Q6I0	IC	InChI=1S/C24H30O8/c1-26-18-9-14(10-19(27-2)22(18)30-5)7-16-13-32-24(25)17(16)8-15-11-20(28-3)23(31-6)21(12-15)29-4/h9-12,16-17H,7-8,13H2,1-6H3/t16-,17+/m0/s1
DM8Q6I0	CS	COC1=CC(=CC(=C1OC)OC)C[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C(=C3)OC)OC)OC
DM8Q6I0	IK	VUNCHONBJWJYID-DLBZAZTESA-N
DM8Q6I0	IU	(3R,4R)-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one
DM8Q6I0	CA	CAS 93395-16-5
DM8Q6I0	DE	Discovery agent

DMC8WS4	ID	DMC8WS4
DMC8WS4	DN	(-)-cyclorphan
DMC8WS4	HS	Investigative
DMC8WS4	SN	CHEMBL291468; BDBM50105483; 17-cyclopropylmethyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-4-ol; 17-cyclopropylmethyl-(1R,9R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMC8WS4	DT	Small molecular drug
DMC8WS4	PC	44299063
DMC8WS4	MW	297.4
DMC8WS4	FM	C20H27NO
DMC8WS4	IC	InChI=1S/C20H27NO/c22-16-7-6-15-11-19-17-3-1-2-8-20(17,18(15)12-16)9-10-21(19)13-14-4-5-14/h6-7,12,14,17,19,22H,1-5,8-11,13H2/t17?,19-,20-/m1/s1
DMC8WS4	CS	C1CC[C@@]23CCN([C@@H](C2C1)CC4=C3C=C(C=C4)O)CC5CC5
DMC8WS4	IK	NLBUEDSBXVNAPB-IPNZSQQUSA-N
DMC8WS4	IU	(1R,9R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMC8WS4	DE	Discovery agent

DM6LGHU	ID	DM6LGHU
DM6LGHU	DN	(-)-DEBROMOFLUSTRAMINE B
DM6LGHU	HS	Investigative
DM6LGHU	SN	CHEMBL383307; (-)-DEBROMOFLUSTRAMINE B; (-)-DebromoflustramineB; BDBM50241051
DM6LGHU	DT	Small molecular drug
DM6LGHU	PC	10403152
DM6LGHU	MW	310.5
DM6LGHU	FM	C21H30N2
DM6LGHU	IC	InChI=1S/C21H30N2/c1-16(2)10-12-21-13-15-22(5)20(21)23(14-11-17(3)4)19-9-7-6-8-18(19)21/h6-11,20H,12-15H2,1-5H3/t20-,21+/m1/s1
DM6LGHU	CS	CC(=CC[C@@]12CCN([C@@H]1N(C3=CC=CC=C23)CC=C(C)C)C)C
DM6LGHU	IK	NUWYFFDZPIGJJO-RTWAWAEBSA-N
DM6LGHU	IU	(3aR,8bS)-3-methyl-4,8b-bis(3-methylbut-2-enyl)-2,3a-dihydro-1H-pyrrolo[2,3-b]indole
DM6LGHU	DE	Discovery agent

DMNYH3X	ID	DMNYH3X
DMNYH3X	DN	(-)-dihydroclusin
DMNYH3X	HS	Investigative
DMNYH3X	SN	(-)-dihydroclusin; CHEMBL469916; 73149-51-6; (-)-Dihydroclusin; AC1L7BWU; DTXSID10318502; BDBM50259874; NSC332042; NSC-332042
DMNYH3X	DT	Small molecular drug
DMNYH3X	PC	332806
DMNYH3X	MW	404.5
DMNYH3X	FM	C22H28O7
DMNYH3X	IC	InChI=1S/C22H28O7/c1-25-20-9-15(10-21(26-2)22(20)27-3)7-17(12-24)16(11-23)6-14-4-5-18-19(8-14)29-13-28-18/h4-5,8-10,16-17,23-24H,6-7,11-13H2,1-3H3/t16-,17-/m0/s1
DMNYH3X	CS	COC1=CC(=CC(=C1OC)OC)C[C@@H](CO)[C@@H](CC2=CC3=C(C=C2)OCO3)CO
DMNYH3X	IK	FDHFWHRGVDRJIK-IRXDYDNUSA-N
DMNYH3X	IU	(2R,3R)-2-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]butane-1,4-diol
DMNYH3X	CA	CAS 73149-51-6
DMNYH3X	DE	Discovery agent

DMPQBWY	ID	DMPQBWY
DMPQBWY	DN	(-)-englerin A
DMPQBWY	HS	Investigative
DMPQBWY	SN	Englerin A; (-)-englerin A; CHEBI:72441; (1R,3aR,4S,5R,7R,8S,8aR)-5-(glycoloyloxy)-7-isopropyl-1,4-dimethyldecahydro-4,7-epoxyazulen-8-yl (2E)-3-phenylacrylate; GTPL8372; SCHEMBL12280306
DMPQBWY	DT	Small molecular drug
DMPQBWY	PC	46242512
DMPQBWY	MW	442.5
DMPQBWY	FM	C26H34O6
DMPQBWY	IC	InChI=1S/C26H34O6/c1-16(2)26-14-20(30-22(29)15-27)25(4,32-26)19-12-10-17(3)23(19)24(26)31-21(28)13-11-18-8-6-5-7-9-18/h5-9,11,13,16-17,19-20,23-24,27H,10,12,14-15H2,1-4H3/b13-11+/t17-,19-,20-,23-,24+,25+,26-/m1/s1
DMPQBWY	CS	C[C@@H]1CC[C@@H]2[C@@H]1[C@@H]([C@@]3(C[C@H]([C@]2(O3)C)OC(=O)CO)C(C)C)OC(=O)/C=C/C4=CC=CC=C4
DMPQBWY	IK	GACOFEKSDCOVMV-RRYXBOBMSA-N
DMPQBWY	IU	[(1S,2R,5R,6R,7S,8R,10R)-10-(2-hydroxyacetyl)oxy-1,5-dimethyl-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-7-yl] (E)-3-phenylprop-2-enoate
DMPQBWY	CB	CHEBI:72441
DMPQBWY	DE	Discovery agent

DMJD34Q	ID	DMJD34Q
DMJD34Q	DN	(-)-eseroline
DMJD34Q	HS	Investigative
DMJD34Q	SN	Eseroline; (-)-Eseroline; UNII-Q22H41O18D; CHEMBL310934; CHEBI:48845; C13H18N2O; HKGWQUVGHPDEBZ-OLZOCXBDSA-N; Q22H41O18D; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-ol; 469-22-7; (3as-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aS,8aR)-; (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol; Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aS,8aR)-
DMJD34Q	DT	Small molecular drug
DMJD34Q	PC	119198
DMJD34Q	MW	218.29
DMJD34Q	FM	C13H18N2O
DMJD34Q	IC	InChI=1S/C13H18N2O/c1-13-6-7-14(2)12(13)15(3)11-5-4-9(16)8-10(11)13/h4-5,8,12,16H,6-7H2,1-3H3/t12-,13+/m1/s1
DMJD34Q	CS	C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)O)C)C
DMJD34Q	IK	HKGWQUVGHPDEBZ-OLZOCXBDSA-N
DMJD34Q	IU	(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-ol
DMJD34Q	CA	CAS 469-22-7
DMJD34Q	CB	CHEBI:48845
DMJD34Q	DE	Discovery agent

DMBO9J3	ID	DMBO9J3
DMBO9J3	DN	(-)-huperzine B
DMBO9J3	HS	Investigative
DMBO9J3	SN	(-)-Huperzine B; SCHEMBL2759896; BDBM10632
DMBO9J3	DT	Small molecular drug
DMBO9J3	PC	23645296
DMBO9J3	MW	256.339
DMBO9J3	FM	C16H20N2O
DMBO9J3	IC	InChI=1S/C16H20N2O/c1-10-7-11-8-14-13(4-5-15(19)18-14)16(9-10)12(11)3-2-6-17-16/h4-5,7,11-12,17H,2-3,6,8-9H2,1H3,(H,18,19)/t11?,12-,16-/m1/s1
DMBO9J3	CS	CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4
DMBO9J3	IK	YYWGABLTRMRUIT-ZLXOECBPSA-N
DMBO9J3	IU	(1R,10R)-16-methyl-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMBO9J3	DE	Discovery agent

DMJVNQB	ID	DMJVNQB
DMJVNQB	DN	(-)-hydroxycitrate
DMJVNQB	HS	Investigative
DMJVNQB	SN	Garcinia acid; 3-c-carboxy-2-deoxy-d-erythro-pentaric acid; CHEMBL118715; UNII-8W94T9026R; (1S,2S)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid; 8W94T9026R; Super CitriMax HCA 600SXS; 4373-35-7; (-)-Hydroxycitrate; 27750-10-3; 7A3; Citric acid, 2-hydroxy-, (-)-; AC1Q5QYE; AC1L4H7S; (2S,3S)-3-Carboxy-2,3-dihydroxy-pentanedioic acid; SCHEMBL6773065; DTXSID20276669; ZINC1656422; BDBM50036210; LMFA01050511; AJ-28889; D-erythro-Pentaric acid,
DMJVNQB	DT	Small molecular drug
DMJVNQB	PC	185620
DMJVNQB	MW	208.12
DMJVNQB	FM	C6H8O8
DMJVNQB	IC	InChI=1S/C6H8O8/c7-2(8)1-6(14,5(12)13)3(9)4(10)11/h3,9,14H,1H2,(H,7,8)(H,10,11)(H,12,13)/t3-,6+/m1/s1
DMJVNQB	CS	C(C(=O)O)[C@]([C@@H](C(=O)O)O)(C(=O)O)O
DMJVNQB	IK	ZMJBYMUCKBYSCP-CVYQJGLWSA-N
DMJVNQB	IU	(1S,2S)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid
DMJVNQB	CA	CAS 27750-10-3
DMJVNQB	CB	CHEBI:165420
DMJVNQB	DE	Discovery agent

DMJS6IZ	ID	DMJS6IZ
DMJS6IZ	DN	(-)-isoelaeocarpiline
DMJS6IZ	HS	Investigative
DMJS6IZ	SN	(-)-isoelaeocarpiline; CHEMBL521711; (-)-Isoelaeocarpiline
DMJS6IZ	DT	Small molecular drug
DMJS6IZ	PC	44583898
DMJS6IZ	MW	259.339
DMJS6IZ	FM	C16H21NO2
DMJS6IZ	IC	InChI=1S/C16H21NO2/c1-10-4-2-6-12-14(10)16(18)15-11-5-3-8-17(11)9-7-13(15)19-12/h2,6,10-11,13,15H,3-5,7-9H2,1H3/t10-,11-,13+,15-/m0/s1
DMJS6IZ	CS	C[C@H]1CC=CC2=C1C(=O)[C@H]3[C@@H]4CCCN4CC[C@H]3O2
DMJS6IZ	IK	RETGXUCYBMOWOH-MEDZGJRSSA-N
DMJS6IZ	IU	(6aR,11S,12aS,12bS)-11-methyl-1,2,3,5,6,6a,10,11,12a,12b-decahydrochromeno[2,3-g]indolizin-12-one
DMJS6IZ	DE	Discovery agent

DMOY9J8	ID	DMOY9J8
DMOY9J8	DN	(-)-norfenfluramine
DMOY9J8	HS	Investigative
DMOY9J8	SN	l-norfenfluramine; 37577-22-3; (R)-1-(3-TRIFLUOROMETHYLPHENYL)-2-AMINOPROPANE; UNII-ODG984O60W; ODG984O60W; (2R)-1-[3-(trifluoromethyl)phenyl]propan-2-amine; Benzeneethanamine, a-methyl-3-(trifluoromethyl)-, (; (R)-Norfenfluramin; (R)-Norfenfluramine; Norfenfluramine, (R)-; GTPL217; (R)-1-(3-(trifluoromethyl)phenyl)propan-2-amine; SCHEMBL895637; CHEMBL250881; BDBM85598; CTK4H8426; MLBHFBKZUPLWBD-SSDOTTSWSA-N; CHEBI:125653; ZINC2039145; PDSP1_000697; PDSP2_000687; PDSP1_001422; AKOS030231006
DMOY9J8	DT	Small molecular drug
DMOY9J8	PC	12895728
DMOY9J8	MW	203.2
DMOY9J8	FM	C10H12F3N
DMOY9J8	IC	InChI=1S/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3/t7-/m1/s1
DMOY9J8	CS	C[C@H](CC1=CC(=CC=C1)C(F)(F)F)N
DMOY9J8	IK	MLBHFBKZUPLWBD-SSDOTTSWSA-N
DMOY9J8	IU	(2R)-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DMOY9J8	CA	CAS 37577-22-3
DMOY9J8	CB	CHEBI:125653
DMOY9J8	DE	Discovery agent

DMVUEW5	ID	DMVUEW5
DMVUEW5	DN	(-)-Phenethylcymserine
DMVUEW5	HS	Investigative
DMVUEW5	SN	(-)-Phenethylcymserine; CHEMBL54577; BDBM50077263; (4-Isopropyl-phenyl)-carbamic acid (S)-3a,8-dimethyl-1-phenethyl-1,2,3,3a,8,8a-hexahydro-pyrrolo[2,3-b]indol-5-yl ester
DMVUEW5	DT	Small molecular drug
DMVUEW5	PC	11385845
DMVUEW5	MW	469.6
DMVUEW5	FM	C30H35N3O2
DMVUEW5	IC	InChI=1S/C30H35N3O2/c1-21(2)23-10-12-24(13-11-23)31-29(34)35-25-14-15-27-26(20-25)30(3)17-19-33(28(30)32(27)4)18-16-22-8-6-5-7-9-22/h5-15,20-21,28H,16-19H2,1-4H3,(H,31,34)/t28?,30-/m0/s1
DMVUEW5	CS	CC(C)C1=CC=C(C=C1)NC(=O)OC2=CC3=C(C=C2)N(C4[C@]3(CCN4CCC5=CC=CC=C5)C)C
DMVUEW5	IK	WKDFOVDLOVYRAJ-TXDWVUBVSA-N
DMVUEW5	IU	[(8bS)-4,8b-dimethyl-3-(2-phenylethyl)-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(4-propan-2-ylphenyl)carbamate
DMVUEW5	DE	Discovery agent

DM4INSG	ID	DM4INSG
DM4INSG	DN	(-)-pinoresinol
DM4INSG	HS	Investigative
DM4INSG	SN	Pinoresinol; NSC35444; NSC-35444; bmse010297; AC1Q70QC; (+/-)-PINORESINOL; SCHEMBL122106; AC1L5T18; CHEMBL2252392; CTK2H0032; 4,4'-[(1S,3aR,4S,6aR)-Tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl]bis(2-methoxyphenol); HMS3347E17; AKOS025404740; 4,4'-tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diylbis(2-methoxyphenol); phenol, 4,4'-(tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl)bis[2-methoxy-; Phenol,4'-(tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl)bis[2-methoxy-, [1S-(1.alpha.,3a.alpha.,4.alpha.,6a.alpha.)]-
DM4INSG	DT	Small molecular drug
DM4INSG	PC	12309636
DM4INSG	MW	358.4
DM4INSG	FM	C20H22O6
DM4INSG	IC	InChI=1S/C20H22O6/c1-23-17-7-11(3-5-15(17)21)19-13-9-26-20(14(13)10-25-19)12-4-6-16(22)18(8-12)24-2/h3-8,13-14,19-22H,9-10H2,1-2H3/t13-,14-,19+,20+/m1/s1
DM4INSG	CS	COC1=C(C=CC(=C1)[C@H]2[C@@H]3CO[C@H]([C@@H]3CO2)C4=CC(=C(C=C4)O)OC)O
DM4INSG	IK	HGXBRUKMWQGOIE-NSMLZSOPSA-N
DM4INSG	IU	4-[(3R,3aS,6R,6aS)-6-(4-hydroxy-3-methoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenol
DM4INSG	CB	CHEBI:67245
DM4INSG	DE	Discovery agent

DMH6EVM	ID	DMH6EVM
DMH6EVM	DN	(-)-Ro 363
DMH6EVM	HS	Investigative
DMH6EVM	SN	RO 363
DMH6EVM	DT	Small molecular drug
DMH6EVM	PC	156297
DMH6EVM	MW	363.4
DMH6EVM	FM	C19H25NO6
DMH6EVM	IC	InChI=1S/C19H25NO6/c1-24-18-6-3-13(9-19(18)25-2)7-8-20-11-14(21)12-26-15-4-5-16(22)17(23)10-15/h3-6,9-10,14,20-23H,7-8,11-12H2,1-2H3
DMH6EVM	CS	COC1=C(C=C(C=C1)CCNCC(COC2=CC(=C(C=C2)O)O)O)OC
DMH6EVM	IK	RFNBEBPVKCJZPV-UHFFFAOYSA-N
DMH6EVM	IU	4-[3-[2-(3,4-dimethoxyphenyl)ethylamino]-2-hydroxypropoxy]benzene-1,2-diol
DMH6EVM	CA	CAS 74513-77-2
DMH6EVM	DE	Discovery agent

DMFE3YK	ID	DMFE3YK
DMFE3YK	DN	(-)-SNAP-5399
DMFE3YK	HS	Investigative
DMFE3YK	SN	SNAP-5399
DMFE3YK	DT	Small molecular drug
DMFE3YK	PC	44390708
DMFE3YK	MW	666.8
DMFE3YK	FM	C38H46N6O5
DMFE3YK	IC	InChI=1S/C38H46N6O5/c1-2-31-34(36(40)45)33(27-14-16-30(17-15-27)44(47)48)35(32(42-31)26-49-25-20-39)37(46)41-21-9-22-43-23-18-38(19-24-43,28-10-5-3-6-11-28)29-12-7-4-8-13-29/h3-8,10-17,33,42H,2,9,18-26,39H2,1H3,(H2,40,45)(H,41,46)/t33-/m0/s1
DMFE3YK	CS	CCC1=C([C@@H](C(=C(N1)COCCN)C(=O)NCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC=C(C=C5)[N+](=O)[O-])C(=O)N
DMFE3YK	IK	FLMJQBHJNDEDJH-XIFFEERXSA-N
DMFE3YK	IU	(4S)-2-(2-aminoethoxymethyl)-3-N-[3-(4,4-diphenylpiperidin-1-yl)propyl]-6-ethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxamide
DMFE3YK	DE	Discovery agent

DMKWIYP	ID	DMKWIYP
DMKWIYP	DN	(-)-thujaplicatintrimethyl ether
DMKWIYP	HS	Investigative
DMKWIYP	SN	Thujaplicatin methyl ether; (-)-thujaplicatintrimethyl ether; UNII-2VJD5SJF7V; 2VJD5SJF7V; CHEMBL469917; 6512-67-0; 2(3H)-Furanone, dihydro-3-((4-hydroxy-3,5-dimethoxyphenyl)methyl)-4-((4-hydroxy-3-methoxyphenyl)methyl)-, (3S-trans)-; 3-O-Methylthujaplicatin; AC1Q6MJF; AC1L4V25; CTK2F4686; DTXSID40215434; BDBM50259876; 2(3h)-furanone, dihydro-3-((4-hydroxy-3,5-dimethoxyphenyl)methyl)-4-((4-hydroxy-3-methoxyphenyl)methyl)-,(3s-trans)-
DMKWIYP	DT	Small molecular drug
DMKWIYP	PC	192827
DMKWIYP	MW	388.4
DMKWIYP	FM	C21H24O7
DMKWIYP	IC	InChI=1S/C21H24O7/c1-25-17-8-12(4-5-16(17)22)6-14-11-28-21(24)15(14)7-13-9-18(26-2)20(23)19(10-13)27-3/h4-5,8-10,14-15,22-23H,6-7,11H2,1-3H3/t14-,15+/m1/s1
DMKWIYP	CS	COC1=CC(=CC(=C1O)OC)C[C@H]2[C@@H](COC2=O)CC3=CC(=C(C=C3)O)OC
DMKWIYP	IK	XMLWGUKRPGLJGA-CABCVRRESA-N
DMKWIYP	IU	(3S,4S)-3-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]-4-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
DMKWIYP	CA	CAS 6512-67-0
DMKWIYP	DE	Discovery agent

DMAT58Z	ID	DMAT58Z
DMAT58Z	DN	(-)-Tolserine
DMAT58Z	HS	Investigative
DMAT58Z	SN	CHEMBL300143; Physostigmine Carbamate 17a; SCHEMBL14242946; BDBM10611; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-(2-methylphenyl)carbamate
DMAT58Z	DT	Small molecular drug
DMAT58Z	PC	9906452
DMAT58Z	MW	351.4
DMAT58Z	FM	C21H25N3O2
DMAT58Z	IC	InChI=1S/C21H25N3O2/c1-14-7-5-6-8-17(14)22-20(25)26-15-9-10-18-16(13-15)21(2)11-12-23(3)19(21)24(18)4/h5-10,13,19H,11-12H2,1-4H3,(H,22,25)/t19?,21-/m0/s1
DMAT58Z	CS	CC1=CC=CC=C1NC(=O)OC2=CC3=C(C=C2)N(C4[C@]3(CCN4C)C)C
DMAT58Z	IK	JGAGHIIOCADQOV-QWAKEFERSA-N
DMAT58Z	IU	[(8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(2-methylphenyl)carbamate
DMAT58Z	DE	Discovery agent

DMITWZ7	ID	DMITWZ7
DMITWZ7	DN	(-)-trans-H2-PAT
DMITWZ7	HS	Investigative
DMITWZ7	SN	H2-Pat
DMITWZ7	DT	Small molecular drug
DMITWZ7	PC	10015055
DMITWZ7	MW	251.4
DMITWZ7	FM	C18H21N
DMITWZ7	IC	InChI=1S/C18H21N/c1-19(2)16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,12-13H2,1-2H3/t16-,18-/m0/s1
DMITWZ7	CS	CN(C)[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3
DMITWZ7	IK	DXJUCAUQIHNOAF-WMZOPIPTSA-N
DMITWZ7	IU	(2R,4S)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMITWZ7	CA	CAS 152786-06-6
DMITWZ7	DE	Discovery agent

DMRGVNJ	ID	DMRGVNJ
DMRGVNJ	DN	(-)-uniflorine A
DMRGVNJ	HS	Investigative
DMRGVNJ	SN	(-)-uniflorine A; CHEMBL1076191; Uniflorine A
DMRGVNJ	DT	Small molecular drug
DMRGVNJ	PC	9794258
DMRGVNJ	MW	205.21
DMRGVNJ	FM	C8H15NO5
DMRGVNJ	IC	InChI=1S/C8H15NO5/c10-3-1-9-2-4(11)7(13)8(14)5(9)6(3)12/h3-8,10-14H,1-2H2/t3-,4+,5-,6-,7-,8-/m1/s1
DMRGVNJ	CS	C1[C@H]([C@H]([C@H]2N1C[C@@H]([C@H]([C@@H]2O)O)O)O)O
DMRGVNJ	IK	KSWHMQGAWBUNLD-XAZAIFFQSA-N
DMRGVNJ	IU	(1S,2R,6S,7R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,6,7,8-pentol
DMRGVNJ	DE	Discovery agent

DMDHGIR	ID	DMDHGIR
DMDHGIR	DN	(-)-yatein
DMDHGIR	HS	Investigative
DMDHGIR	SN	Yatein; (-)-yatein; Dihydroanhydropodorhizol; 40456-50-6; (-)-deoxypodorhizone; Deoxypodorhizone; AC1L9DHE; CHEBI:4553; CHEMBL471067; C22H24O7; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]tetrahydrofuran-2-one; 2(3H)-Furanone, 4-(1,3-benzodioxol-5-ylmethyl)dihydro-3-[(3,4,5-trimethoxyphenyl)methyl]-, (3R,4R)-; Deoxypodorhizon; SCHEMBL1037807; DTXSID50193471; MolPort-035-706-087; GMLDZDDTZKXJLU-JKSUJKDBSA-N
DMDHGIR	DT	Small molecular drug
DMDHGIR	PC	442835
DMDHGIR	MW	400.4
DMDHGIR	FM	C22H24O7
DMDHGIR	IC	InChI=1S/C22H24O7/c1-24-19-9-14(10-20(25-2)21(19)26-3)7-16-15(11-27-22(16)23)6-13-4-5-17-18(8-13)29-12-28-17/h4-5,8-10,15-16H,6-7,11-12H2,1-3H3/t15-,16+/m0/s1
DMDHGIR	CS	COC1=CC(=CC(=C1OC)OC)C[C@@H]2[C@H](COC2=O)CC3=CC4=C(C=C3)OCO4
DMDHGIR	IK	GMLDZDDTZKXJLU-JKSUJKDBSA-N
DMDHGIR	IU	(3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one
DMDHGIR	CA	CAS 40456-50-6
DMDHGIR	CB	CHEBI:4553
DMDHGIR	DE	Discovery agent

DMF62GN	ID	DMF62GN
DMF62GN	DN	(+)-(1R,1'S)-berbamunine hydrochloride
DMF62GN	HS	Investigative
DMF62GN	SN	CHEMBL503882; (+)-(1R,1'S)-Berbamunine HCl
DMF62GN	DT	Small molecular drug
DMF62GN	PC	44584679
DMF62GN	MW	633.2
DMF62GN	FM	C36H41ClN2O6
DMF62GN	IC	InChI=1S/C36H40N2O6.ClH/c1-37-13-11-24-18-34(42-3)32(40)20-27(24)29(37)15-22-5-8-26(9-6-22)44-36-17-23(7-10-31(36)39)16-30-28-21-33(41)35(43-4)19-25(28)12-14-38(30)2;/h5-10,17-21,29-30,39-41H,11-16H2,1-4H3;1H/t29-,30+;/m0./s1
DMF62GN	CS	CN1CCC2=CC(=C(C=C2[C@@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)O)O)O)OC.Cl
DMF62GN	IK	JOARPLDATXXJHM-XCCPJCIBSA-N
DMF62GN	IU	(1S)-1-[[4-[2-hydroxy-5-[[(1R)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]phenoxy]phenyl]methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol;hydrochloride
DMF62GN	DE	Discovery agent

DM521S4	ID	DM521S4
DM521S4	DN	(+)-(1R,1'S)-thaligrisine hydrochloride
DM521S4	HS	Investigative
DM521S4	SN	CHEMBL451734; (+)-(1R,1'S)-Thaligrisine HCl
DM521S4	DT	Small molecular drug
DM521S4	PC	44584680
DM521S4	MW	647.2
DM521S4	FM	C37H43ClN2O6
DM521S4	IC	InChI=1S/C37H42N2O6.ClH/c1-38-14-12-25-19-35(43-4)32(40)21-28(25)30(38)16-23-6-9-27(10-7-23)45-37-18-24(8-11-34(37)42-3)17-31-29-22-33(41)36(44-5)20-26(29)13-15-39(31)2;/h6-11,18-22,30-31,40-41H,12-17H2,1-5H3;1H/t30-,31+;/m0./s1
DM521S4	CS	CN1CCC2=CC(=C(C=C2[C@@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)O)OC)O)OC.Cl
DM521S4	IK	NSNGMSCZFBHCEX-LBYXUWKHSA-N
DM521S4	IU	(1S)-1-[[4-[5-[[(1R)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]phenyl]methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol;hydrochloride
DM521S4	DE	Discovery agent

DMLDQWT	ID	DMLDQWT
DMLDQWT	DN	(+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol
DMLDQWT	HS	Investigative
DMLDQWT	SN	CHEMBL456949; (+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol
DMLDQWT	DT	Small molecular drug
DMLDQWT	PC	44584373
DMLDQWT	MW	328.4
DMLDQWT	FM	C21H28O3
DMLDQWT	IC	InChI=1S/C21H28O3/c1-20(2)8-5-9-21(3)14-10-13-11-18(23-4)15(22)12-17(13)24-16(14)6-7-19(20)21/h10-12,16,19,22H,5-9H2,1-4H3/t16-,19-,21+/m0/s1
DMLDQWT	CS	C[C@]12CCCC([C@@H]1CC[C@H]3C2=CC4=CC(=C(C=C4O3)O)OC)(C)C
DMLDQWT	IK	VKVKDSPLZVAEMG-NBHGPNQESA-N
DMLDQWT	IU	(4aS,6aS,12bS)-10-methoxy-4,4,12b-trimethyl-2,3,4a,5,6,6a-hexahydro-1H-benzo[a]xanthen-9-ol
DMLDQWT	DE	Discovery agent

DMU7BJA	ID	DMU7BJA
DMU7BJA	DN	(+)-(5S,8S,10S)-20-methoxypuupehenol
DMU7BJA	HS	Investigative
DMU7BJA	SN	CHEMBL459185; (+)-(5S,8S,10S)-20-methoxypuupehenol; BDBM50242017; (+)-(5S,8S,9R,10S)-15,20-Dimethoxypuupehenol
DMU7BJA	DT	Small molecular drug
DMU7BJA	PC	11740143
DMU7BJA	MW	374.5
DMU7BJA	FM	C23H34O4
DMU7BJA	IC	InChI=1S/C23H34O4/c1-21(2)9-7-10-22(3)18(21)8-11-23(4)20(22)19(26-6)14-12-17(25-5)15(24)13-16(14)27-23/h12-13,18-20,24H,7-11H2,1-6H3/t18-,19+,20+,22-,23-/m0/s1
DMU7BJA	CS	C[C@]12CCCC([C@@H]1CC[C@]3([C@@H]2[C@@H](C4=CC(=C(C=C4O3)O)OC)OC)C)(C)C
DMU7BJA	IK	JAGJWSBNJZPDNL-FCSJJDFTSA-N
DMU7BJA	IU	(4aS,6aS,12S,12aS,12bS)-10,12-dimethoxy-4,4,6a,12b-tetramethyl-1,2,3,4a,5,6,12,12a-octahydrobenzo[a]xanthen-9-ol
DMU7BJA	DE	Discovery agent

DMD4YPO	ID	DMD4YPO
DMD4YPO	DN	(+)-(5S,8S,9R,10S)-20-methoxypuupehenone
DMD4YPO	HS	Investigative
DMD4YPO	SN	(+)-(5S,8S,9R,10S)-20-Methoxypuupehenone; CHEMBL463805; Methoxypuupehenone; AC1LCV1Q; BDBM50242010; (4aS,6aS,12aR,12bS)-10-methoxy-4,4,6a,12b-tetramethyl-2,3,4a,5,6,12a-hexahydro-1H-benzo[a]xanthen-9-one; 9H-benzo[a]xanthen-9-one, 1,2,3,4,4a,5,6,6a,12a,12b-decahydro-10-methoxy-4,4,6a,12b-tetramethyl-, (4aS,6aS,12aR,12bS)-; InChI=1/C22H30O3/c1-20(2)8-6-9-21(3)18(20)7-10-22(4)19(21)12-14-11-17(24-5)15(23)13-16(14)25-22/h11-13,18-19H,6-10H2,1-5H3/t18-,19+,21-,22-/m0/s
DMD4YPO	DT	Small molecular drug
DMD4YPO	PC	637821
DMD4YPO	MW	342.5
DMD4YPO	FM	C22H30O3
DMD4YPO	IC	InChI=1S/C22H30O3/c1-20(2)8-6-9-21(3)18(20)7-10-22(4)19(21)12-14-11-17(24-5)15(23)13-16(14)25-22/h11-13,18-19H,6-10H2,1-5H3/t18-,19+,21-,22-/m0/s1
DMD4YPO	CS	C[C@]12CCCC([C@@H]1CC[C@]3([C@@H]2C=C4C=C(C(=O)C=C4O3)OC)C)(C)C
DMD4YPO	IK	ZBJMJNFORKVCHU-MXNKGDRCSA-N
DMD4YPO	IU	(4aS,6aS,12aR,12bS)-10-methoxy-4,4,6a,12b-tetramethyl-2,3,4a,5,6,12a-hexahydro-1H-benzo[a]xanthen-9-one
DMD4YPO	DE	Discovery agent

DMNUWVB	ID	DMNUWVB
DMNUWVB	DN	(+)-3,3'-bisdemethyltanegool
DMNUWVB	HS	Investigative
DMNUWVB	SN	CHEMBL436990; (+)-3,3'-bisdemethyltanegool; (+)-3,3''-bisdemethyltanegool
DMNUWVB	DT	Small molecular drug
DMNUWVB	PC	44423052
DMNUWVB	MW	348.3
DMNUWVB	FM	C18H20O7
DMNUWVB	IC	InChI=1S/C18H20O7/c19-7-11-12(17(24)9-1-3-13(20)15(22)5-9)8-25-18(11)10-2-4-14(21)16(23)6-10/h1-6,11-12,17-24H,7-8H2/t11-,12+,17-,18-/m1/s1
DMNUWVB	CS	C1[C@@H]([C@H]([C@H](O1)C2=CC(=C(C=C2)O)O)CO)[C@@H](C3=CC(=C(C=C3)O)O)O
DMNUWVB	IK	XRDXBFUYROIFCX-FVEFGIFQSA-N
DMNUWVB	IU	4-[(2S,3S,4R)-4-[(S)-(3,4-dihydroxyphenyl)-hydroxymethyl]-3-(hydroxymethyl)oxolan-2-yl]benzene-1,2-diol
DMNUWVB	DE	Discovery agent

DM2CHX8	ID	DM2CHX8
DM2CHX8	DN	(+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid
DM2CHX8	HS	Investigative
DM2CHX8	SN	CHEMBL375493; GTPL1589; SCHEMBL3111157; BDBM50208137; (+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid; 5-(5-bromothiophen-3-yl)-5-methyl-4-oxofuran-2-carboxylic acid; 5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydrofuran-2-carboxylic acid; (+)-5-(5-bromo-thiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid; 5-(5-bromo-thiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid
DM2CHX8	DT	Small molecular drug
DM2CHX8	PC	11483496
DM2CHX8	MW	303.13
DM2CHX8	FM	C10H7BrO4S
DM2CHX8	IC	InChI=1S/C10H7BrO4S/c1-10(5-2-8(11)16-4-5)7(12)3-6(15-10)9(13)14/h2-4H,1H3,(H,13,14)
DM2CHX8	CS	CC1(C(=O)C=C(O1)C(=O)O)C2=CSC(=C2)Br
DM2CHX8	IK	WJDLYZAOTHNUJX-UHFFFAOYSA-N
DM2CHX8	IU	5-(5-bromothiophen-3-yl)-5-methyl-4-oxofuran-2-carboxylic acid
DM2CHX8	DE	Discovery agent

DMF8C50	ID	DMF8C50
DMF8C50	DN	(+)-5-deoxyadeenophorine
DMF8C50	HS	Investigative
DMF8C50	SN	(+)-5-deoxyadeenophorine; CHEMBL380089; 262615-98-5; 5-Deoxyadenophorine; SCHEMBL17249944; CTK0I6251; DTXSID00441676; BDBM50185228; AKOS030538296; 3,4-Piperidinediol, 6-ethyl-2-(hydroxymethyl)-, (2R,3S,4S,6R)-
DMF8C50	DT	Small molecular drug
DMF8C50	PC	10559165
DMF8C50	MW	175.23
DMF8C50	FM	C8H17NO3
DMF8C50	IC	InChI=1S/C8H17NO3/c1-2-5-3-7(11)8(12)6(4-10)9-5/h5-12H,2-4H2,1H3/t5-,6-,7+,8+/m1/s1
DMF8C50	CS	CC[C@@H]1C[C@@H]([C@H]([C@H](N1)CO)O)O
DMF8C50	IK	QWEWPBRDYZVGBR-NGJRWZKOSA-N
DMF8C50	IU	(2R,3S,4S,6R)-6-ethyl-2-(hydroxymethyl)piperidine-3,4-diol
DMF8C50	CA	CAS 262615-98-5
DMF8C50	DE	Discovery agent

DMXWCVY	ID	DMXWCVY
DMXWCVY	DN	(+)-ADTN
DMXWCVY	HS	Investigative
DMXWCVY	SN	(+)-ADTN (aminotetralin-6,7-diol)
DMXWCVY	DT	Small molecular drug
DMXWCVY	PC	3153
DMXWCVY	MW	179.22
DMXWCVY	FM	C10H13NO2
DMXWCVY	IC	InChI=1S/C10H13NO2/c11-8-2-1-6-4-9(12)10(13)5-7(6)3-8/h4-5,8,12-13H,1-3,11H2
DMXWCVY	CS	C1CC2=CC(=C(C=C2CC1N)O)O
DMXWCVY	IK	ASXGAOFCKGHGMF-UHFFFAOYSA-N
DMXWCVY	IU	6-amino-5,6,7,8-tetrahydronaphthalene-2,3-diol
DMXWCVY	CA	CAS 53463-78-8
DMXWCVY	DE	Discovery agent

DMEDMC0	ID	DMEDMC0
DMEDMC0	DN	(+)-AJ76
DMEDMC0	HS	Investigative
DMEDMC0	SN	AJ 76; AJ-76; 5-methoxy-1-methyl-2-(n-propylamino)tetralin; 85379-09-5; CHEMBL27441; (+)-AJ 76; CHEBI:64117; (1S,2R)-5-methoxy-1-methyl-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine; cis-(+)-5-methoxy-1-methyl-2-(propylamino)tetralin; (1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin; 2-Naphthalenamine, 1,2,3,4-tetrahydro-5-methoxy-1-methyl-N-propyl-, (1S-cis)-; Tocris-0678; (+)-AJ76; AC1L3UEJ; a j76; Biomol-NT_000004; GTPL970; SCHEMBL276252; AJ76; BPBio1_001129; DTXSID1043889; BDBM81797; ZINC3995669; PDSP2_000777; BDBM50041959
DMEDMC0	DT	Small molecular drug
DMEDMC0	PC	122334
DMEDMC0	MW	233.35
DMEDMC0	FM	C15H23NO
DMEDMC0	IC	InChI=1S/C15H23NO/c1-4-10-16-14-9-8-13-12(11(14)2)6-5-7-15(13)17-3/h5-7,11,14,16H,4,8-10H2,1-3H3/t11-,14+/m0/s1
DMEDMC0	CS	CCCN[C@@H]1CCC2=C([C@@H]1C)C=CC=C2OC
DMEDMC0	IK	YGHLYBIUVOLKCV-SMDDNHRTSA-N
DMEDMC0	IU	(1S,2R)-5-methoxy-1-methyl-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMEDMC0	CA	CAS 85379-09-5
DMEDMC0	CB	CHEBI:64117
DMEDMC0	DE	Discovery agent

DMX6UYN	ID	DMX6UYN
DMX6UYN	DN	(+)-BUTACLAMOL
DMX6UYN	HS	Investigative
DMX6UYN	SN	d-Butaclamol; (+)-Butaclamol; BUTACLAMOL; CHEMBL8514; 56245-67-1; 1H-Benzo(6,7)cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 2,3,4,4a,8,9,13b,14-octahydro-3-(1,1-dimethylethyl)-, (3S-(3-alpha,4a-alpha,13b-beta))-; (+/-)-Butaclamol hydrochloride; BUTACLAMOL,d-; AC1L1XRQ; BUTACLAMOL,(+); GTPL62; BUTACLAMOL, (-); Biomol-NT_000018; Lopac0_000475; Lopac0_000187; SCHEMBL122821; BPBio1_001177; ZZJYIKPMDIWRSN-HWBMXIPRSA-N; CHEBI:109533; HMS2089C08; ZINC2008410; PDSP2_000547; PDSP2_001512; BDBM50008735; CCG-204282; NCGC00162085-04
DMX6UYN	DT	Small molecular drug
DMX6UYN	PC	37459
DMX6UYN	MW	361.5
DMX6UYN	FM	C25H31NO
DMX6UYN	IC	InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3/t21-,22-,25-/m0/s1
DMX6UYN	CS	CC(C)(C)[C@@]1(CCN2C[C@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@@H]2C1)O
DMX6UYN	IK	ZZJYIKPMDIWRSN-HWBMXIPRSA-N
DMX6UYN	IU	(1S,6S,8S)-6-tert-butyl-3-azapentacyclo[11.8.1.03,8.09,22.016,21]docosa-9,11,13(22),16,18,20-hexaen-6-ol
DMX6UYN	CA	CAS 56245-67-1
DMX6UYN	CB	CHEBI:109533
DMX6UYN	DE	Discovery agent

DMDFR59	ID	DMDFR59
DMDFR59	DN	(+)-cis-H2-PAT
DMDFR59	HS	Investigative
DMDFR59	SN	N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine; GTPL1208; BDBM86031; ZINC5965220
DMDFR59	DT	Small molecular drug
DMDFR59	PC	15657195
DMDFR59	MW	251.4
DMDFR59	FM	C18H21N
DMDFR59	IC	InChI=1S/C18H21N/c1-19(2)16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,12-13H2,1-2H3/t16-,18+/m0/s1
DMDFR59	CS	CN(C)[C@@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC=CC=C3
DMDFR59	IK	DXJUCAUQIHNOAF-FUHWJXTLSA-N
DMDFR59	IU	(2R,4R)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMDFR59	DE	Discovery agent

DMKWEAJ	ID	DMKWEAJ
DMKWEAJ	DN	(+)-HA966
DMKWEAJ	HS	Investigative
DMKWEAJ	SN	(R)-(+)-HA-966
DMKWEAJ	DT	Small molecular drug
DMKWEAJ	PC	6603720
DMKWEAJ	MW	116.12
DMKWEAJ	FM	C4H8N2O2
DMKWEAJ	IC	InChI=1S/C4H8N2O2/c5-3-1-2-6(8)4(3)7/h3,8H,1-2,5H2/t3-/m1/s1
DMKWEAJ	CS	C1CN(C(=O)[C@@H]1N)O
DMKWEAJ	IK	HCKUBNLZMKAEIN-GSVOUGTGSA-N
DMKWEAJ	IU	(3R)-3-amino-1-hydroxypyrrolidin-2-one
DMKWEAJ	CA	CAS 123931-04-4
DMKWEAJ	DE	Discovery agent

DMG5QJB	ID	DMG5QJB
DMG5QJB	DN	(+)-MCPG
DMG5QJB	HS	Investigative
DMG5QJB	SN	(S)-Mcpg; (S)-MCPG; (+)-alpha-Methyl-4-carboxyphenylglycine; (S)-(ALPHA)-METHYL-4-CARBOXYPHENYLGLYCINE; 4-[(1S)-1-amino-1-carboxyethyl]benzoic acid; 4-(1-AMINO-1-CARBOXY-ETHYL)-BENZOIC ACID; UNII-61F6J48NHR; alpha-Mcpg; 61F6J48NHR; CHEMBL257626; CHEBI:43876; alpha-Methyl-cpgly; (S)-a-methyl-4-carboxyphenylglycine; (S)- -Methyl-4-carboxyphenylglycine; (S)-4-(1-amino-1-carboxyethyl)benzoic acid; (S)-(+)-alpha-methyl-4-carboxyphenylglycine; MCG; (S)-(+)-alpha-amino-4-carboxy-2-methylbenzeneacetic;  alpha-Mcpg; alpha-methyl-4-carboxyphenylglycine; alpha-methyl-cpgly; 4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid
DMG5QJB	DT	Small molecular drug
DMG5QJB	PC	446355
DMG5QJB	MW	209.2
DMG5QJB	FM	C10H11NO4
DMG5QJB	IC	InChI=1S/C10H11NO4/c1-10(11,9(14)15)7-4-2-6(3-5-7)8(12)13/h2-5H,11H2,1H3,(H,12,13)(H,14,15)/t10-/m0/s1
DMG5QJB	CS	C[C@](C1=CC=C(C=C1)C(=O)O)(C(=O)O)N
DMG5QJB	IK	DNCAZYRLRMTVSF-JTQLQIEISA-N
DMG5QJB	IU	4-[(1S)-1-amino-1-carboxyethyl]benzoic acid
DMG5QJB	CA	CAS 150145-89-4
DMG5QJB	CB	CHEBI:43876
DMG5QJB	DE	Discovery agent

DM7FZHI	ID	DM7FZHI
DM7FZHI	DN	(+)-Myristinin A
DM7FZHI	HS	Investigative
DM7FZHI	SN	(+)-Myristinin A; Myristinin A; CHEMBL465365; 1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]dodecan-1-one; 1-(2,4,6-TRIHYDROXY-3-((2S,4R)-7-HYDROXY-2-(4-HYDROXYPHENYL)-3,4-DIHYDRO-2H-CHROMEN-4-YL)PHENYL)DODECAN-1-ONE; AC1LAXHL; SCHEMBL3486855; LMPK12020229; BDBM50250426; 1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-yl]phenyl]dodecan-1-one; 1-Dodecanone, 1-[3-[(2S,4R)-3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydr
DM7FZHI	DT	Small molecular drug
DM7FZHI	PC	497359
DM7FZHI	MW	548.7
DM7FZHI	FM	C33H40O7
DM7FZHI	IC	InChI=1S/C33H40O7/c1-2-3-4-5-6-7-8-9-10-11-26(36)32-28(38)20-27(37)31(33(32)39)25-19-29(21-12-14-22(34)15-13-21)40-30-18-23(35)16-17-24(25)30/h12-18,20,25,29,34-35,37-39H,2-11,19H2,1H3/t25-,29+/m1/s1
DM7FZHI	CS	CCCCCCCCCCCC(=O)C1=C(C=C(C(=C1O)[C@@H]2C[C@H](OC3=C2C=CC(=C3)O)C4=CC=C(C=C4)O)O)O
DM7FZHI	IK	JGXZVDAPLSTBGZ-IRPSRAIASA-N
DM7FZHI	IU	1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]dodecan-1-one
DM7FZHI	DE	Discovery agent

DMEK07T	ID	DMEK07T
DMEK07T	DN	(+)-Myristinin D
DMEK07T	HS	Investigative
DMEK07T	SN	(+)-Myristinin D; CHEMBL448072; Myristinis D; Myristinin D; AC1LAXHR; BDBM50250427; 9-phenyl-1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-yl]phenyl]nonan-1-one; 9-phenyl-1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]nonan-1-one; 1-Nonanone, 1-[3-[(2S,4R)-3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxyphenyl]-9-phenyl-
DMEK07T	DT	Small molecular drug
DMEK07T	PC	497362
DMEK07T	MW	582.7
DMEK07T	FM	C36H38O7
DMEK07T	IC	InChI=1S/C36H38O7/c37-25-16-14-24(15-17-25)32-21-28(27-19-18-26(38)20-33(27)43-32)34-30(40)22-31(41)35(36(34)42)29(39)13-9-4-2-1-3-6-10-23-11-7-5-8-12-23/h5,7-8,11-12,14-20,22,28,32,37-38,40-42H,1-4,6,9-10,13,21H2/t28-,32+/m1/s1
DMEK07T	CS	C1[C@H](C2=C(C=C(C=C2)O)O[C@@H]1C3=CC=C(C=C3)O)C4=C(C(=C(C=C4O)O)C(=O)CCCCCCCCC5=CC=CC=C5)O
DMEK07T	IK	NWJOIWGNEIDTTG-NSJVFKKDSA-N
DMEK07T	IU	9-phenyl-1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]nonan-1-one
DMEK07T	DE	Discovery agent

DMOZJA5	ID	DMOZJA5
DMOZJA5	DN	(+)-norfenfluramine
DMOZJA5	HS	Investigative
DMOZJA5	SN	(S)-norfenfluramine
DMOZJA5	DT	Small molecular drug
DMOZJA5	PC	9815618
DMOZJA5	MW	203.2
DMOZJA5	FM	C10H12F3N
DMOZJA5	IC	InChI=1S/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3/t7-/m0/s1
DMOZJA5	CS	C[C@@H](CC1=CC(=CC=C1)C(F)(F)F)N
DMOZJA5	IK	MLBHFBKZUPLWBD-ZETCQYMHSA-N
DMOZJA5	IU	(2S)-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DMOZJA5	CA	CAS 19036-73-8
DMOZJA5	CB	CHEBI:125533
DMOZJA5	DE	Discovery agent

DMX7ECD	ID	DMX7ECD
DMX7ECD	DN	(+)-S-14297
DMX7ECD	HS	Investigative
DMX7ECD	SN	(+)S14297
DMX7ECD	DT	Small molecular drug
DMX7ECD	PC	115007
DMX7ECD	MW	273.4
DMX7ECD	FM	C18H27NO
DMX7ECD	IC	InChI=1S/C18H27NO/c1-3-8-19(9-4-2)17-6-5-14-11-15-7-10-20-18(15)13-16(14)12-17/h11,13,17H,3-10,12H2,1-2H3
DMX7ECD	CS	CCCN(CCC)C1CCC2=CC3=C(C=C2C1)OCC3
DMX7ECD	IK	IJICKINLCUKIHY-UHFFFAOYSA-N
DMX7ECD	IU	N,N-dipropyl-2,3,5,6,7,8-hexahydrobenzo[f][1]benzofuran-7-amine
DMX7ECD	CA	CAS 121454-18-0
DMX7ECD	DE	Discovery agent

DM1QPA4	ID	DM1QPA4
DM1QPA4	DN	(+)-SK&F10047
DM1QPA4	HS	Investigative
DM1QPA4	SN	(+)-SKF 10.047
DM1QPA4	DT	Small molecular drug
DM1QPA4	PC	3036222
DM1QPA4	MW	257.37
DM1QPA4	FM	C17H23NO
DM1QPA4	IC	InChI=1S/C17H23NO/c1-4-8-18-9-7-17(3)12(2)16(18)10-13-5-6-14(19)11-15(13)17/h4-6,11-12,16,19H,1,7-10H2,2-3H3/t12-,16+,17+/m1/s1
DM1QPA4	CS	C[C@@H]1[C@@H]2CC3=C([C@]1(CCN2CC=C)C)C=C(C=C3)O
DM1QPA4	IK	LGQCVMYAEFTEFN-DQYPLSBCSA-N
DM1QPA4	IU	(1S,9S,13S)-1,13-dimethyl-10-prop-2-enyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DM1QPA4	CA	CAS 58640-82-7
DM1QPA4	DE	Discovery agent

DMAN63P	ID	DMAN63P
DMAN63P	DN	(+)-trans-H2-PAT
DMAN63P	HS	Investigative
DMAN63P	SN	(2S,4R)-N,N-Dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine; trans-PAT; (2S,4R)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine; (plusmn)-trans-H2-PAT; SCHEMBL3755418; CHEMBL127307; GTPL1209; GTPL1207; BDBM86032; ZINC5965166; PDSP2_000942; PDSP1_000957
DMAN63P	DT	Small molecular drug
DMAN63P	PC	10106214
DMAN63P	MW	251.4
DMAN63P	FM	C18H21N
DMAN63P	IC	InChI=1S/C18H21N/c1-19(2)16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,12-13H2,1-2H3/t16-,18-/m1/s1
DMAN63P	CS	CN(C)[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC=CC=C3
DMAN63P	IK	DXJUCAUQIHNOAF-SJLPKXTDSA-N
DMAN63P	IU	(2S,4R)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMAN63P	DE	Discovery agent

DMDXKQ6	ID	DMDXKQ6
DMDXKQ6	DN	(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholin-5-one
DMDXKQ6	HS	Investigative
DMDXKQ6	SN	CHEMBL598394; BDBM50307363
DMDXKQ6	DT	Small molecular drug
DMDXKQ6	PC	46233265
DMDXKQ6	MW	299.4
DMDXKQ6	FM	C17H17NO2S
DMDXKQ6	IC	InChI=1S/C17H17NO2S/c19-17-12-21-16(10-18-17)14-6-8-15(9-7-14)20-11-13-4-2-1-3-5-13/h1-9,16H,10-12H2,(H,18,19)
DMDXKQ6	CS	C1C(SCC(=O)N1)C2=CC=C(C=C2)OCC3=CC=CC=C3
DMDXKQ6	IK	WREDZZPMENXHRK-UHFFFAOYSA-N
DMDXKQ6	IU	6-(4-phenylmethoxyphenyl)thiomorpholin-3-one
DMDXKQ6	DE	Discovery agent

DMCB74T	ID	DMCB74T
DMCB74T	DN	(+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine
DMCB74T	HS	Investigative
DMCB74T	SN	CHEMBL597373; BDBM50307362
DMCB74T	DT	Small molecular drug
DMCB74T	PC	46233269
DMCB74T	MW	285.4
DMCB74T	FM	C17H19NOS
DMCB74T	IC	InChI=1S/C17H19NOS/c1-2-4-14(5-3-1)13-19-16-8-6-15(7-9-16)17-12-18-10-11-20-17/h1-9,17-18H,10-13H2
DMCB74T	CS	C1CSC(CN1)C2=CC=C(C=C2)OCC3=CC=CC=C3
DMCB74T	IK	JTMKALFHDSWYGH-UHFFFAOYSA-N
DMCB74T	IU	2-(4-phenylmethoxyphenyl)thiomorpholine
DMCB74T	DE	Discovery agent

DM1WCJV	ID	DM1WCJV
DM1WCJV	DN	(+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one
DM1WCJV	HS	Investigative
DM1WCJV	SN	CHEMBL598393; BDBM50307364
DM1WCJV	DT	Small molecular drug
DM1WCJV	PC	46233264
DM1WCJV	MW	265.37
DM1WCJV	FM	C14H19NO2S
DM1WCJV	IC	InChI=1S/C14H19NO2S/c1-2-3-8-17-12-6-4-11(5-7-12)13-9-15-14(16)10-18-13/h4-7,13H,2-3,8-10H2,1H3,(H,15,16)
DM1WCJV	CS	CCCCOC1=CC=C(C=C1)C2CNC(=O)CS2
DM1WCJV	IK	ATDGSQDDAVNPIE-UHFFFAOYSA-N
DM1WCJV	IU	6-(4-butoxyphenyl)thiomorpholin-3-one
DM1WCJV	DE	Discovery agent

DMG3MF2	ID	DMG3MF2
DMG3MF2	DN	(+/-)-2-(4'-Butoxyphenyl)thiomorpholine
DMG3MF2	HS	Investigative
DMG3MF2	SN	CHEMBL597372; BDBM50307367
DMG3MF2	DT	Small molecular drug
DMG3MF2	PC	46233268
DMG3MF2	MW	251.39
DMG3MF2	FM	C14H21NOS
DMG3MF2	IC	InChI=1S/C14H21NOS/c1-2-3-9-16-13-6-4-12(5-7-13)14-11-15-8-10-17-14/h4-7,14-15H,2-3,8-11H2,1H3
DMG3MF2	CS	CCCCOC1=CC=C(C=C1)C2CNCCS2
DMG3MF2	IK	SHHIIRIFRIVAFS-UHFFFAOYSA-N
DMG3MF2	IU	2-(4-butoxyphenyl)thiomorpholine
DMG3MF2	DE	Discovery agent

DM1YBJ2	ID	DM1YBJ2
DM1YBJ2	DN	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one
DM1YBJ2	HS	Investigative
DM1YBJ2	SN	CHEMBL597769; 2-(4'-ethoxyphenyl)thiomorpholin-5-one; BDBM50307371; 1218947-79-5
DM1YBJ2	DT	Small molecular drug
DM1YBJ2	PC	46233198
DM1YBJ2	MW	237.32
DM1YBJ2	FM	C12H15NO2S
DM1YBJ2	IC	InChI=1S/C12H15NO2S/c1-2-15-10-5-3-9(4-6-10)11-7-13-12(14)8-16-11/h3-6,11H,2,7-8H2,1H3,(H,13,14)
DM1YBJ2	CS	CCOC1=CC=C(C=C1)C2CNC(=O)CS2
DM1YBJ2	IK	CBRYZPDPVZGCMA-UHFFFAOYSA-N
DM1YBJ2	IU	6-(4-ethoxyphenyl)thiomorpholin-3-one
DM1YBJ2	DE	Discovery agent

DMKPX7W	ID	DMKPX7W
DMKPX7W	DN	(+/-)-2-(4'-Ethoxyphenyl)thiomorpholine
DMKPX7W	HS	Investigative
DMKPX7W	SN	CHEMBL597371; 2-(4'-ethoxyphenyl)thiomorpholine; BDBM50307370; AKOS022307820; 1218947-83-1
DMKPX7W	DT	Small molecular drug
DMKPX7W	PC	46233266
DMKPX7W	MW	223.34
DMKPX7W	FM	C12H17NOS
DMKPX7W	IC	InChI=1S/C12H17NOS/c1-2-14-11-5-3-10(4-6-11)12-9-13-7-8-15-12/h3-6,12-13H,2,7-9H2,1H3
DMKPX7W	CS	CCOC1=CC=C(C=C1)C2CNCCS2
DMKPX7W	IK	GGYNYZIHJHLRIZ-UHFFFAOYSA-N
DMKPX7W	IU	2-(4-ethoxyphenyl)thiomorpholine
DMKPX7W	DE	Discovery agent

DMGY5WB	ID	DMGY5WB
DMGY5WB	DN	(+/-)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DMGY5WB	HS	Investigative
DMGY5WB	SN	CHEMBL598746
DMGY5WB	DT	Small molecular drug
DMGY5WB	PC	15731432
DMGY5WB	MW	272.27
DMGY5WB	FM	C16H13FO3
DMGY5WB	IC	InChI=1S/C16H13FO3/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-8,15H,9H2,1H3
DMGY5WB	CS	COC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=C(C=C3)F
DMGY5WB	IK	LIINIWOYEGBFDA-UHFFFAOYSA-N
DMGY5WB	IU	2-(4-fluorophenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMGY5WB	DE	Discovery agent

DMHL7BC	ID	DMHL7BC
DMHL7BC	DN	(+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one
DMHL7BC	HS	Investigative
DMHL7BC	SN	CHEMBL600596; (+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one
DMHL7BC	DT	Small molecular drug
DMHL7BC	PC	46231665
DMHL7BC	MW	256.269
DMHL7BC	FM	C16H13FO2
DMHL7BC	IC	InChI=1S/C16H13FO2/c1-10-2-7-13-14(18)9-15(19-16(13)8-10)11-3-5-12(17)6-4-11/h2-8,15H,9H2,1H3
DMHL7BC	CS	CC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=C(C=C3)F
DMHL7BC	IK	ZWJDAELXCJQOJQ-UHFFFAOYSA-N
DMHL7BC	IU	2-(4-fluorophenyl)-7-methyl-2,3-dihydrochromen-4-one
DMHL7BC	DE	Discovery agent

DMXK4HR	ID	DMXK4HR
DMXK4HR	DN	(+/-)-2-(4-fluorophenyl)chroman-4-one
DMXK4HR	HS	Investigative
DMXK4HR	SN	4'-(Fluoro)flavanone; CHEMBL60720; 1840-02-4; 4h-1-benzopyran-4-one,2-(4-fluorophenyl)-2,3-dihydro-; 4'-Fluoroflavanone; (+/-)-2-(4-fluorophenyl)chroman-4-one; SCHEMBL2474548; CTK0E2543; DTXSID90452670; RFDPVHCUOLBALB-UHFFFAOYSA-N; BDBM50310197; AKOS030552931; KB-290728; 4H-1-Benzopyran-4-one, 2-(4-fluorophenyl)-2,3-dihydro-
DMXK4HR	DT	Small molecular drug
DMXK4HR	PC	11032058
DMXK4HR	MW	242.24
DMXK4HR	FM	C15H11FO2
DMXK4HR	IC	InChI=1S/C15H11FO2/c16-11-7-5-10(6-8-11)15-9-13(17)12-3-1-2-4-14(12)18-15/h1-8,15H,9H2
DMXK4HR	CS	C1C(OC2=CC=CC=C2C1=O)C3=CC=C(C=C3)F
DMXK4HR	IK	RFDPVHCUOLBALB-UHFFFAOYSA-N
DMXK4HR	IU	2-(4-fluorophenyl)-2,3-dihydrochromen-4-one
DMXK4HR	CA	CAS 1840-02-4
DMXK4HR	DE	Discovery agent

DMTUFOE	ID	DMTUFOE
DMTUFOE	DN	(+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one
DMTUFOE	HS	Investigative
DMTUFOE	SN	CHEMBL598913; 7-Methyl-4'-methoxyflavanone; (+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one
DMTUFOE	DT	Small molecular drug
DMTUFOE	PC	15462540
DMTUFOE	MW	268.31
DMTUFOE	FM	C17H16O3
DMTUFOE	IC	InChI=1S/C17H16O3/c1-11-3-8-14-15(18)10-16(20-17(14)9-11)12-4-6-13(19-2)7-5-12/h3-9,16H,10H2,1-2H3
DMTUFOE	CS	CC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=C(C=C3)OC
DMTUFOE	IK	OVTRXNFXZXVKKU-UHFFFAOYSA-N
DMTUFOE	IU	2-(4-methoxyphenyl)-7-methyl-2,3-dihydrochromen-4-one
DMTUFOE	DE	Discovery agent

DM7BY4T	ID	DM7BY4T
DM7BY4T	DN	(+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one
DM7BY4T	HS	Investigative
DM7BY4T	SN	CHEMBL597768; 2-(4'-methoxyphenyl)thiomorpholin-5-one; BDBM50307373; 42109-48-8
DM7BY4T	DT	Small molecular drug
DM7BY4T	PC	46233197
DM7BY4T	MW	223.29
DM7BY4T	FM	C11H13NO2S
DM7BY4T	IC	InChI=1S/C11H13NO2S/c1-14-9-4-2-8(3-5-9)10-6-12-11(13)7-15-10/h2-5,10H,6-7H2,1H3,(H,12,13)
DM7BY4T	CS	COC1=CC=C(C=C1)C2CNC(=O)CS2
DM7BY4T	IK	KTKPTOSTWLGTNI-UHFFFAOYSA-N
DM7BY4T	IU	6-(4-methoxyphenyl)thiomorpholin-3-one
DM7BY4T	DE	Discovery agent

DMKFSQ8	ID	DMKFSQ8
DMKFSQ8	DN	(+/-)-2-(4'-Methoxyphenyl)thiomorpholine
DMKFSQ8	HS	Investigative
DMKFSQ8	SN	2-(4-methoxyphenyl)thiomorpholine; CHEMBL598395; AC1Q4AWZ; 2-(4-Methoxyphenyl) Thiomorpholine Hydrochloride; SCHEMBL1636984; AC1NM467; YAPWTYUHWOWUHY-UHFFFAOYSA-N; 2-(4-methoxyphenyl)-thiomorpholine; 2-(4'-methoxyphenyl)thiomorpholine; BDBM50307365; AKOS022304555; MCULE-4309621221; 1001940-39-1
DMKFSQ8	DT	Small molecular drug
DMKFSQ8	PC	4996817
DMKFSQ8	MW	209.31
DMKFSQ8	FM	C11H15NOS
DMKFSQ8	IC	InChI=1S/C11H15NOS/c1-13-10-4-2-9(3-5-10)11-8-12-6-7-14-11/h2-5,11-12H,6-8H2,1H3
DMKFSQ8	CS	COC1=CC=C(C=C1)C2CNCCS2
DMKFSQ8	IK	YAPWTYUHWOWUHY-UHFFFAOYSA-N
DMKFSQ8	IU	2-(4-methoxyphenyl)thiomorpholine
DMKFSQ8	CA	CAS 1001940-39-1
DMKFSQ8	DE	Discovery agent

DMY1W20	ID	DMY1W20
DMY1W20	DN	(+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one
DMY1W20	HS	Investigative
DMY1W20	SN	CHEMBL596955; BDBM50307368
DMY1W20	DT	Small molecular drug
DMY1W20	PC	46233199
DMY1W20	MW	251.35
DMY1W20	FM	C13H17NO2S
DMY1W20	IC	InChI=1S/C13H17NO2S/c1-2-7-16-11-5-3-10(4-6-11)12-8-14-13(15)9-17-12/h3-6,12H,2,7-9H2,1H3,(H,14,15)
DMY1W20	CS	CCCOC1=CC=C(C=C1)C2CNC(=O)CS2
DMY1W20	IK	WOEGUBDEEHNIKD-UHFFFAOYSA-N
DMY1W20	IU	6-(4-propoxyphenyl)thiomorpholin-3-one
DMY1W20	DE	Discovery agent

DMUPYN1	ID	DMUPYN1
DMUPYN1	DN	(+/-)-2-(4'-Propoxyphenyl)thiomorpholine
DMUPYN1	HS	Investigative
DMUPYN1	SN	CHEMBL608141; BDBM50307366; AKOS022549334
DMUPYN1	DT	Small molecular drug
DMUPYN1	PC	46233267
DMUPYN1	MW	237.36
DMUPYN1	FM	C13H19NOS
DMUPYN1	IC	InChI=1S/C13H19NOS/c1-2-8-15-12-5-3-11(4-6-12)13-10-14-7-9-16-13/h3-6,13-14H,2,7-10H2,1H3
DMUPYN1	CS	CCCOC1=CC=C(C=C1)C2CNCCS2
DMUPYN1	IK	MHUSNQPPWZGBBB-UHFFFAOYSA-N
DMUPYN1	IU	2-(4-propoxyphenyl)thiomorpholine
DMUPYN1	DE	Discovery agent

DMX768L	ID	DMX768L
DMX768L	DN	(+/-)-2-Amino-1,2,3,4-tetrahydro-2-naphthoic acid
DMX768L	HS	Investigative
DMX768L	SN	2-Aminotetralin-2-carboxylic acid; 74444-77-2; D,L-2-Aminotetralin-2-carboxylic acid; 2-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid; 6331-63-1; CHEMBL8708; 2-amino-3,4-dihydro-1H-naphthalene-2-carboxylic acid; 2-Amino-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid; 2-AMINO-1,2,3,4-TETRAHYDRO-2-NAPHTHALENECARBOXYLIC ACID; 2-Naphthalenecarboxylic acid, 2-amino-1,2,3,4-tetrahydro-; ACMC-20apiw; ACMC-20apfh; CB 1647; AC1L5ULH; SCHEMBL268919; (+/-)-2-Amino-1,2,3,4-tetrahydro-2-naphthoic acid; NIOSH/QL2303010
DMX768L	DT	Small molecular drug
DMX768L	PC	235533
DMX768L	MW	191.23
DMX768L	FM	C11H13NO2
DMX768L	IC	InChI=1S/C11H13NO2/c12-11(10(13)14)6-5-8-3-1-2-4-9(8)7-11/h1-4H,5-7,12H2,(H,13,14)
DMX768L	CS	C1CC(CC2=CC=CC=C21)(C(=O)O)N
DMX768L	IK	CDULPPOISZOUTK-UHFFFAOYSA-N
DMX768L	IU	2-amino-3,4-dihydro-1H-naphthalene-2-carboxylic acid
DMX768L	CA	CAS 74444-77-2
DMX768L	DE	Discovery agent

DML5URN	ID	DML5URN
DML5URN	DN	(+/-)-2-Aminoindane-2-carboxylic acid
DML5URN	HS	Investigative
DML5URN	SN	27473-62-7; 2-Amino-2-indancarboxylic acid; 2-amino-2,3-dihydro-1H-indene-2-carboxylic acid; 2-Aminoindane-2-carboxylic acid; 2-AMINOINDAN-2-CARBOXYLIC ACID; 2-Aminoindan-2-carboxylicacid; 2-Amino-indan-2-carboxylic acid; 2-amino-1,3-dihydroindene-2-carboxylic acid; CHEMBL1082953; 2-azanyl-1,3-dihydroindene-2-carboxylic acid; 1H-Indene-2-carboxylicacid, 2-amino-2,3-dihydro-; 2-amino-2-indancarboxylicacid; NSC70943; (+/-)-2-Aminoindane-2-carboxylic acid; AC1L5IQE; AC1Q50FV; AC1Q5UK7; SCHEMBL122942; 1H-Indene-2-carboxylic acid
DML5URN	DT	Small molecular drug
DML5URN	PC	250936
DML5URN	MW	177.2
DML5URN	FM	C10H11NO2
DML5URN	IC	InChI=1S/C10H11NO2/c11-10(9(12)13)5-7-3-1-2-4-8(7)6-10/h1-4H,5-6,11H2,(H,12,13)
DML5URN	CS	C1C2=CC=CC=C2CC1(C(=O)O)N
DML5URN	IK	UHQFXIWMAQOCAN-UHFFFAOYSA-N
DML5URN	IU	2-amino-1,3-dihydroindene-2-carboxylic acid
DML5URN	CA	CAS 27473-62-7
DML5URN	DE	Discovery agent

DMJ6MPO	ID	DMJ6MPO
DMJ6MPO	DN	(+/-)-2-Methyl-1-(1-phenylethyl)-1H-imidazole
DMJ6MPO	HS	Investigative
DMJ6MPO	SN	Efetozole; CHEMBL1269155; Efetozole [INN]; 2-methyl-1-(1-phenylethyl)-1H-imidazole; AC1L4LLD; (+/-)-2-Methyl-1-(1-phenylethyl)-1H-imidazole; SCHEMBL2109012; MolPort-020-890-666; CGP-22364A; BDBM50330055; 2-methyl-1-(1-phenylethyl)imidazole; AKOS013440375; 90408-21-2; (+-)-2-Methyl-1-(alpha-methylbenzyl)imidazole; (- )-2-Methyl-1-(alpha-methylbenzyl)imidazole.
DMJ6MPO	DT	Small molecular drug
DMJ6MPO	PC	208911
DMJ6MPO	MW	186.25
DMJ6MPO	FM	C12H14N2
DMJ6MPO	IC	InChI=1S/C12H14N2/c1-10(12-6-4-3-5-7-12)14-9-8-13-11(14)2/h3-10H,1-2H3
DMJ6MPO	CS	CC1=NC=CN1C(C)C2=CC=CC=C2
DMJ6MPO	IK	CILDGVODBJAMGO-UHFFFAOYSA-N
DMJ6MPO	IU	2-methyl-1-(1-phenylethyl)imidazole
DMJ6MPO	CA	CAS 99500-54-6
DMJ6MPO	DE	Discovery agent

DMSHDNO	ID	DMSHDNO
DMSHDNO	DN	(+/-)-2-Phenylthiomorpholin-5-one
DMSHDNO	HS	Investigative
DMSHDNO	SN	2-phenylthiomorpholin-5-one; CHEMBL592160; 42109-49-9; (+/-)-2-Phenylthiomorpholin-5-one; 6-phenylthiomorpholin-3-one; SCHEMBL10833495; MolPort-039-240-430; BDBM50307372; AKOS027196661
DMSHDNO	DT	Small molecular drug
DMSHDNO	PC	20242416
DMSHDNO	MW	193.27
DMSHDNO	FM	C10H11NOS
DMSHDNO	IC	InChI=1S/C10H11NOS/c12-10-7-13-9(6-11-10)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,11,12)
DMSHDNO	CS	C1C(SCC(=O)N1)C2=CC=CC=C2
DMSHDNO	IK	RTCSYBNOEYGSSX-UHFFFAOYSA-N
DMSHDNO	IU	6-phenylthiomorpholin-3-one
DMSHDNO	DE	Discovery agent

DMNR3YL	ID	DMNR3YL
DMNR3YL	DN	(+/-)-2-Phenylthiomorpholine
DMNR3YL	HS	Investigative
DMNR3YL	SN	2-phenylthiomorpholine; 77082-31-6; 2-PHENYL-THIOMORPHOLINE; CHEMBL608438; Thiomorpholine,2-phenyl-; (+/-)-2-Phenylthiomorpholine; AC1NMBWZ; AC1Q1ICC; Thiomorpholine, 2-phenyl-; SCHEMBL1636929; CTK5E3816; DTXSID20407436; MolPort-001-791-006; SRYHBJDVLOEJNP-UHFFFAOYSA-N; 2-Phenyl-thiomorpholine, AldrichCPR; BDBM50307369; AKOS006230101; MCULE-8074427790; QC-5067; NE56940; KB-69531; EN300-80273
DMNR3YL	DT	Small molecular drug
DMNR3YL	PC	5004199
DMNR3YL	MW	179.28
DMNR3YL	FM	C10H13NS
DMNR3YL	IC	InChI=1S/C10H13NS/c1-2-4-9(5-3-1)10-8-11-6-7-12-10/h1-5,10-11H,6-8H2
DMNR3YL	CS	C1CSC(CN1)C2=CC=CC=C2
DMNR3YL	IK	SRYHBJDVLOEJNP-UHFFFAOYSA-N
DMNR3YL	IU	2-phenylthiomorpholine
DMNR3YL	CA	CAS 77082-31-6
DMNR3YL	DE	Discovery agent

DMYJGZ4	ID	DMYJGZ4
DMYJGZ4	DN	(+/-)-2-p-tolylchroman-4-one
DMYJGZ4	HS	Investigative
DMYJGZ4	SN	4'-methylflavanone; CHEMBL596690; (+/-)-2-p-tolylchroman-4-one; AC1MCXMJ; Oprea1_810740; Oprea1_128105; SCHEMBL1890733; MolPort-003-699-848; HITISLKGAFZTFZ-UHFFFAOYSA-N; 2-(4-methylphenyl)chroman-4-one; BDBM50310196; AKOS003614932
DMYJGZ4	DT	Small molecular drug
DMYJGZ4	PC	2802466
DMYJGZ4	MW	238.28
DMYJGZ4	FM	C16H14O2
DMYJGZ4	IC	InChI=1S/C16H14O2/c1-11-6-8-12(9-7-11)16-10-14(17)13-4-2-3-5-15(13)18-16/h2-9,16H,10H2,1H3
DMYJGZ4	CS	CC1=CC=C(C=C1)C2CC(=O)C3=CC=CC=C3O2
DMYJGZ4	IK	HITISLKGAFZTFZ-UHFFFAOYSA-N
DMYJGZ4	IU	2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMYJGZ4	DE	Discovery agent

DML68KX	ID	DML68KX
DML68KX	DN	(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine
DML68KX	HS	Investigative
DML68KX	SN	CHEMBL451460; (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine; SCHEMBL2227832; BDBM50278523
DML68KX	DT	Small molecular drug
DML68KX	PC	44592197
DML68KX	MW	227.3
DML68KX	FM	C15H17NO
DML68KX	IC	InChI=1S/C15H17NO/c1-2-4-14-9-15(6-5-13(14)3-1)17-11-12-7-8-16-10-12/h1-6,9,12,16H,7-8,10-11H2
DML68KX	CS	C1CNCC1COC2=CC3=CC=CC=C3C=C2
DML68KX	IK	FXQBHPKGRGPIKE-UHFFFAOYSA-N
DML68KX	IU	3-(naphthalen-2-yloxymethyl)pyrrolidine
DML68KX	CA	CAS 946682-24-2
DML68KX	DE	Discovery agent

DM9AJSU	ID	DM9AJSU
DM9AJSU	DN	(+/-)-3-(but-3-enyl)-1-pent-4-enoylazetidin-2-one
DM9AJSU	HS	Investigative
DM9AJSU	SN	CHEMBL454297; (+/-)-3-(but-3-enyl)-1-pent-4-enoylazetidin-2-one
DM9AJSU	DT	Small molecular drug
DM9AJSU	PC	44560666
DM9AJSU	MW	207.27
DM9AJSU	FM	C12H17NO2
DM9AJSU	IC	InChI=1S/C12H17NO2/c1-3-5-7-10-9-13(12(10)15)11(14)8-6-4-2/h3-4,10H,1-2,5-9H2
DM9AJSU	CS	C=CCCC1CN(C1=O)C(=O)CCC=C
DM9AJSU	IK	GINOGVHXZZDXCD-UHFFFAOYSA-N
DM9AJSU	IU	3-but-3-enyl-1-pent-4-enoylazetidin-2-one
DM9AJSU	DE	Discovery agent

DMWIABE	ID	DMWIABE
DMWIABE	DN	(+/-)-3-(pent-4-enyl)azetidin-2-one
DMWIABE	HS	Investigative
DMWIABE	SN	CHEMBL505129
DMWIABE	DT	Small molecular drug
DMWIABE	PC	44560663
DMWIABE	MW	139.19
DMWIABE	FM	C8H13NO
DMWIABE	IC	InChI=1S/C8H13NO/c1-2-3-4-5-7-6-9-8(7)10/h2,7H,1,3-6H2,(H,9,10)
DMWIABE	CS	C=CCCCC1CNC1=O
DMWIABE	IK	ABPZGIHKPZCCMN-UHFFFAOYSA-N
DMWIABE	IU	3-pent-4-enylazetidin-2-one
DMWIABE	DE	Discovery agent

DMS5AWP	ID	DMS5AWP
DMS5AWP	DN	(+/-)-3-allyl-1-pent-4-enoylazetidin-2-one
DMS5AWP	HS	Investigative
DMS5AWP	SN	CHEMBL487448; (+/-)-3-allyl-1-pent-4-enoylazetidin-2-one; 1-(4'-pentenoyl)-3-(2'-propenyl)-2-azetidinone; BDBM50243198
DMS5AWP	DT	Small molecular drug
DMS5AWP	PC	44560665
DMS5AWP	MW	193.24
DMS5AWP	FM	C11H15NO2
DMS5AWP	IC	InChI=1S/C11H15NO2/c1-3-5-7-10(13)12-8-9(6-4-2)11(12)14/h3-4,9H,1-2,5-8H2
DMS5AWP	CS	C=CCCC(=O)N1CC(C1=O)CC=C
DMS5AWP	IK	QVTWEMBUZOBMIJ-UHFFFAOYSA-N
DMS5AWP	IU	1-pent-4-enoyl-3-prop-2-enylazetidin-2-one
DMS5AWP	DE	Discovery agent

DMK42RU	ID	DMK42RU
DMK42RU	DN	(+/-)-3-allylazetidin-2-one
DMK42RU	HS	Investigative
DMK42RU	SN	3-(2'-propenyl)-2-azetidinone; 1058693-04-1; allyl-beta-lactam; CHEMBL447982
DMK42RU	DT	Small molecular drug
DMK42RU	PC	20449950
DMK42RU	MW	111.14
DMK42RU	FM	C6H9NO
DMK42RU	IC	InChI=1S/C6H9NO/c1-2-3-5-4-7-6(5)8/h2,5H,1,3-4H2,(H,7,8)
DMK42RU	CS	C=CCC1CNC1=O
DMK42RU	IK	XWLCLNCCEDQVSS-UHFFFAOYSA-N
DMK42RU	IU	3-prop-2-enylazetidin-2-one
DMK42RU	DE	Discovery agent

DMSN7GJ	ID	DMSN7GJ
DMSN7GJ	DN	(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid
DMSN7GJ	HS	Investigative
DMSN7GJ	SN	CHEMBL572982; (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid
DMSN7GJ	DT	Small molecular drug
DMSN7GJ	PC	11391583
DMSN7GJ	MW	270.32
DMSN7GJ	FM	C17H18O3
DMSN7GJ	IC	InChI=1S/C17H18O3/c18-16(12-17(19)20)11-8-13-6-9-15(10-7-13)14-4-2-1-3-5-14/h1-7,9-10,16,18H,8,11-12H2,(H,19,20)
DMSN7GJ	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCC(CC(=O)O)O
DMSN7GJ	IK	ILGSIIFHQGOKKV-UHFFFAOYSA-N
DMSN7GJ	IU	3-hydroxy-5-(4-phenylphenyl)pentanoic acid
DMSN7GJ	DE	Discovery agent

DMSNWA6	ID	DMSNWA6
DMSNWA6	DN	(+/-)-5-amino-2-(mercaptomethyl)pentanoic acid
DMSNWA6	HS	Investigative
DMSNWA6	SN	CHEMBL237008; (+/-)-5-amino-2-(mercaptomethyl)pentanoic acid; SCHEMBL11507369; IKYCTNVIQZAWIB-UHFFFAOYSA-N; BDBM50226603; 5-Amino-2-mercaptomethylpentanoic acid
DMSNWA6	DT	Small molecular drug
DMSNWA6	PC	20384315
DMSNWA6	MW	163.24
DMSNWA6	FM	C6H13NO2S
DMSNWA6	IC	InChI=1S/C6H13NO2S/c7-3-1-2-5(4-10)6(8)9/h5,10H,1-4,7H2,(H,8,9)
DMSNWA6	CS	C(CC(CS)C(=O)O)CN
DMSNWA6	IK	IKYCTNVIQZAWIB-UHFFFAOYSA-N
DMSNWA6	IU	5-amino-2-(sulfanylmethyl)pentanoic acid
DMSNWA6	DE	Discovery agent

DMQP5U9	ID	DMQP5U9
DMQP5U9	DN	(+/-)-5'-deoxy-4'-fluoro-5'-methylthio-DADMe-ImmH
DMQP5U9	HS	Investigative
DMQP5U9	DT	Small molecular drug
DMQP5U9	PC	44563309
DMQP5U9	DE	Discovery agent

DM23W58	ID	DM23W58
DM23W58	DN	(+/-)-6-(2-chlorophenyl)cyclohex-3-enamine
DM23W58	HS	Investigative
DM23W58	SN	cyclohexene analog 6; SCHEMBL3750136; CHEMBL216578; BDBM12649
DM23W58	DT	Small molecular drug
DM23W58	PC	16049437
DM23W58	MW	207.7
DM23W58	FM	C12H14ClN
DM23W58	IC	InChI=1S/C12H14ClN/c13-11-7-3-1-5-9(11)10-6-2-4-8-12(10)14/h1-5,7,10,12H,6,8,14H2/t10-,12+/m1/s1
DM23W58	CS	C1C=CC[C@@H]([C@H]1C2=CC=CC=C2Cl)N
DM23W58	IK	UAUINBMLUPAKPF-PWSUYJOCSA-N
DM23W58	IU	(1S,6R)-6-(2-chlorophenyl)cyclohex-3-en-1-amine
DM23W58	DE	Discovery agent

DMKWBY8	ID	DMKWBY8
DMKWBY8	DN	(+/-)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DMKWBY8	HS	Investigative
DMKWBY8	SN	CHEMBL600390
DMKWBY8	DT	Small molecular drug
DMKWBY8	PC	46231663
DMKWBY8	MW	260.23
DMKWBY8	FM	C15H10F2O2
DMKWBY8	IC	InChI=1S/C15H10F2O2/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14H,8H2
DMKWBY8	CS	C1C(OC2=C(C1=O)C=CC(=C2)F)C3=CC=C(C=C3)F
DMKWBY8	IK	YKJLGNVYFBPKJK-UHFFFAOYSA-N
DMKWBY8	IU	7-fluoro-2-(4-fluorophenyl)-2,3-dihydrochromen-4-one
DMKWBY8	DE	Discovery agent

DMYHV9P	ID	DMYHV9P
DMYHV9P	DN	(+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one
DMYHV9P	HS	Investigative
DMYHV9P	SN	CHEMBL598720; 844-66-6; 4h-1-benzopyran-4-one,7-fluoro-2,3-dihydro-2-(4-methoxyphenyl)-; 4H-1-Benzopyran-4-one, 7-fluoro-2,3-dihydro-2-(4-methoxyphenyl)-; AC1NRRFL; (+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one; CTK3D0370; DTXSID70414918; BDBM50310194; AKOS030553462; KB-306159; 7-fluoro-2-(4-methoxyphenyl)chroman-4-one
DMYHV9P	DT	Small molecular drug
DMYHV9P	PC	5271543
DMYHV9P	MW	272.27
DMYHV9P	FM	C16H13FO3
DMYHV9P	IC	InChI=1S/C16H13FO3/c1-19-12-5-2-10(3-6-12)15-9-14(18)13-7-4-11(17)8-16(13)20-15/h2-8,15H,9H2,1H3
DMYHV9P	CS	COC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)F
DMYHV9P	IK	MQUZZZVJAVDIPR-UHFFFAOYSA-N
DMYHV9P	IU	7-fluoro-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMYHV9P	CA	CAS 844-66-6
DMYHV9P	DE	Discovery agent

DMJEBXA	ID	DMJEBXA
DMJEBXA	DN	(+/-)-7-fluoro-2-phenylchroman-4-one
DMJEBXA	HS	Investigative
DMJEBXA	SN	7-Fluoroflavanone; 4H-1-Benzopyran-4-one, 7-fluoro-2,3-dihydro-2-phenyl-; 98769-92-7; 7-fluoro-flavanone; AC1NRPFB; ACMC-20m2iw; CHEMBL596693; SCHEMBL10360962; CTK3G7728; DTXSID20414862; SZNYRENOXQIQMR-UHFFFAOYSA-N; 7-fluoro-2-phenyl-chroman-4-one; AKOS030553463
DMJEBXA	DT	Small molecular drug
DMJEBXA	PC	5270543
DMJEBXA	MW	242.24
DMJEBXA	FM	C15H11FO2
DMJEBXA	IC	InChI=1S/C15H11FO2/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14H,9H2
DMJEBXA	CS	C1C(OC2=C(C1=O)C=CC(=C2)F)C3=CC=CC=C3
DMJEBXA	IK	SZNYRENOXQIQMR-UHFFFAOYSA-N
DMJEBXA	IU	7-fluoro-2-phenyl-2,3-dihydrochromen-4-one
DMJEBXA	CA	CAS 98769-92-7
DMJEBXA	DE	Discovery agent

DM4H1JO	ID	DM4H1JO
DM4H1JO	DN	(+/-)-7-fluoro-2-p-tolylchroman-4-one
DM4H1JO	HS	Investigative
DM4H1JO	SN	CHEMBL600391
DM4H1JO	DT	Small molecular drug
DM4H1JO	PC	46231664
DM4H1JO	MW	256.269
DM4H1JO	FM	C16H13FO2
DM4H1JO	IC	InChI=1S/C16H13FO2/c1-10-2-4-11(5-3-10)15-9-14(18)13-7-6-12(17)8-16(13)19-15/h2-8,15H,9H2,1H3
DM4H1JO	CS	CC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)F
DM4H1JO	IK	QNQXLNDULBVXEX-UHFFFAOYSA-N
DM4H1JO	IU	7-fluoro-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DM4H1JO	DE	Discovery agent

DMYJGDK	ID	DMYJGDK
DMYJGDK	DN	(+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one
DMYJGDK	HS	Investigative
DMYJGDK	SN	7-methoxy-2-(4-methoxyphenyl)chroman-4-one
DMYJGDK	PC	5271544
DMYJGDK	MW	284.31
DMYJGDK	FM	C17H16O4
DMYJGDK	IC	InChI=1S/C17H16O4/c1-19-12-5-3-11(4-6-12)16-10-15(18)14-8-7-13(20-2)9-17(14)21-16/h3-9,16H,10H2,1-2H3
DMYJGDK	CS	COC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)OC
DMYJGDK	IK	YAEYGSBLDUIDTP-UHFFFAOYSA-N
DMYJGDK	IU	7-methoxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMYJGDK	CA	CAS 25826-69-1
DMYJGDK	CB	CHEBI:91819
DMYJGDK	DE	Discovery agent

DMC0OKA	ID	DMC0OKA
DMC0OKA	DN	(+/-)-7-methoxy-2-phenylchroman-4-one
DMC0OKA	HS	Investigative
DMC0OKA	SN	7-methoxy-2-phenylchroman-4-one
DMC0OKA	PC	2825024
DMC0OKA	MW	254.28
DMC0OKA	FM	C16H14O3
DMC0OKA	IC	InChI=1S/C16H14O3/c1-18-12-7-8-13-14(17)10-15(19-16(13)9-12)11-5-3-2-4-6-11/h2-9,15H,10H2,1H3
DMC0OKA	CS	COC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=CC=C3
DMC0OKA	IK	VYESEQLQFXUROZ-UHFFFAOYSA-N
DMC0OKA	IU	7-methoxy-2-phenyl-2,3-dihydrochromen-4-one
DMC0OKA	DE	Discovery agent

DMJMTVQ	ID	DMJMTVQ
DMJMTVQ	DN	(+/-)-7-methoxy-2-p-tolylchroman-4-one
DMJMTVQ	HS	Investigative
DMJMTVQ	SN	CHEMBL602141; (+/-)-7-methoxy-2-p-tolylchroman-4-one; SCHEMBL13394439
DMJMTVQ	DT	Small molecular drug
DMJMTVQ	PC	15098246
DMJMTVQ	MW	268.31
DMJMTVQ	FM	C17H16O3
DMJMTVQ	IC	InChI=1S/C17H16O3/c1-11-3-5-12(6-4-11)16-10-15(18)14-8-7-13(19-2)9-17(14)20-16/h3-9,16H,10H2,1-2H3
DMJMTVQ	CS	CC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)OC
DMJMTVQ	IK	JVZDRFASOQJJTF-UHFFFAOYSA-N
DMJMTVQ	IU	7-methoxy-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMJMTVQ	DE	Discovery agent

DMI3URD	ID	DMI3URD
DMI3URD	DN	(+/-)-7-methyl-2-phenylchroman-4-one
DMI3URD	HS	Investigative
DMI3URD	SN	64919-60-4; 7-Methylflavanone; SCHEMBL1895393; CHEMBL600392; CTK1I3915; DTXSID70502203; AKOS030552841; 7-Methyl-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-methyl-2-phenyl-
DMI3URD	DT	Small molecular drug
DMI3URD	PC	12549536
DMI3URD	MW	238.28
DMI3URD	FM	C16H14O2
DMI3URD	IC	InChI=1S/C16H14O2/c1-11-7-8-13-14(17)10-15(18-16(13)9-11)12-5-3-2-4-6-12/h2-9,15H,10H2,1H3
DMI3URD	CS	CC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=CC=C3
DMI3URD	IK	FNOKOVWLKVWYRY-UHFFFAOYSA-N
DMI3URD	IU	7-methyl-2-phenyl-2,3-dihydrochromen-4-one
DMI3URD	CA	CAS 64919-60-4
DMI3URD	DE	Discovery agent

DMBN3WE	ID	DMBN3WE
DMBN3WE	DN	(+/-)-7-methyl-2-p-tolylchroman-4-one
DMBN3WE	HS	Investigative
DMBN3WE	SN	CHEMBL600597
DMBN3WE	DT	Small molecular drug
DMBN3WE	PC	46231666
DMBN3WE	MW	252.31
DMBN3WE	FM	C17H16O2
DMBN3WE	IC	InChI=1S/C17H16O2/c1-11-3-6-13(7-4-11)16-10-15(18)14-8-5-12(2)9-17(14)19-16/h3-9,16H,10H2,1-2H3
DMBN3WE	CS	CC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)C
DMBN3WE	IK	MIEPNGHJBCGJAW-UHFFFAOYSA-N
DMBN3WE	IU	7-methyl-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMBN3WE	DE	Discovery agent

DMY3J0B	ID	DMY3J0B
DMY3J0B	DN	(+/-)-cis-2-CAMP
DMY3J0B	HS	Investigative
DMY3J0B	SN	215597-45-8; 2-(Aminomethyl)cyclopropanecarboxylic acid; 2-(aminomethyl)cyclopropane-1-carboxylic acid; Cyclopropanecarboxylicacid, 2-(aminomethyl)-; (plusmn)-cis-2-CAMP; AC1N3MNT; SCHEMBL3943045; GTPL4067; CHEMBL284310; CTK1A0098; BDBM50087269; AKOS006277884; KB-163238; (cis)-2-Aminomethyl-cyclopropanecarboxylic acid; A29700; (trans)-2-Aminomethyl-cyclopropanecarboxylic acid; (+)-2-(aminomethyl)-cyclopropane-1-carboxylic acid
DMY3J0B	DT	Small molecular drug
DMY3J0B	PC	4067175
DMY3J0B	MW	115.13
DMY3J0B	FM	C5H9NO2
DMY3J0B	IC	InChI=1S/C5H9NO2/c6-2-3-1-4(3)5(7)8/h3-4H,1-2,6H2,(H,7,8)
DMY3J0B	CS	C1C(C1C(=O)O)CN
DMY3J0B	IK	QUFMERRXRMSAPZ-UHFFFAOYSA-N
DMY3J0B	IU	2-(aminomethyl)cyclopropane-1-carboxylic acid
DMY3J0B	DE	Discovery agent

DMAHO9M	ID	DMAHO9M
DMAHO9M	DN	(+/-)-cis-H2-PAT
DMAHO9M	HS	Investigative
DMAHO9M	SN	(plusmn)-cis-H2-PAT; GTPL1206; CHEMBL340199; SCHEMBL12998410; BDBM86030; ZINC5965164; N,N-Dimethyl-4beta-phenyltetralin-2beta-amine
DMAHO9M	DT	Small molecular drug
DMAHO9M	PC	10037815
DMAHO9M	MW	251.4
DMAHO9M	FM	C18H21N
DMAHO9M	IC	InChI=1S/C18H21N/c1-19(2)16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,12-13H2,1-2H3/t16-,18+/m1/s1
DMAHO9M	CS	CN(C)[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3
DMAHO9M	IK	DXJUCAUQIHNOAF-AEFFLSMTSA-N
DMAHO9M	IU	(2S,4S)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMAHO9M	DE	Discovery agent

DMBSH5L	ID	DMBSH5L
DMBSH5L	DN	(+/-)-Daedalin A
DMBSH5L	HS	Investigative
DMBSH5L	SN	CHEMBL590726
DMBSH5L	DT	Small molecular drug
DMBSH5L	PC	46230831
DMBSH5L	MW	192.21
DMBSH5L	FM	C11H12O3
DMBSH5L	IC	InChI=1S/C11H12O3/c1-11(13-2)6-5-8-7-9(12)3-4-10(8)14-11/h3-7,12H,1-2H3
DMBSH5L	CS	CC1(C=CC2=C(O1)C=CC(=C2)O)OC
DMBSH5L	IK	DLZKKUHAZDHCSL-UHFFFAOYSA-N
DMBSH5L	IU	2-methoxy-2-methylchromen-6-ol
DMBSH5L	DE	Discovery agent

DM0L3GE	ID	DM0L3GE
DM0L3GE	DN	(+/-)-nantenine
DM0L3GE	HS	Investigative
DM0L3GE	PC	181743
DM0L3GE	MW	339.4
DM0L3GE	FM	C20H21NO4
DM0L3GE	IC	InChI=1S/C20H21NO4/c1-21-5-4-11-7-17(22-2)20(23-3)19-13-9-16-15(24-10-25-16)8-12(13)6-14(21)18(11)19/h7-9,14H,4-6,10H2,1-3H3
DM0L3GE	CS	CN1CCC2=CC(=C(C3=C2C1CC4=CC5=C(C=C43)OCO5)OC)OC
DM0L3GE	IK	WSVWKHTVFGTTKJ-UHFFFAOYSA-N
DM0L3GE	IU	18,19-dimethoxy-13-methyl-5,7-dioxa-13-azapentacyclo[10.7.1.02,10.04,8.016,20]icosa-1(20),2,4(8),9,16,18-hexaene
DM0L3GE	CA	CAS 42971-15-3
DM0L3GE	DE	Discovery agent

DM8023E	ID	DM8023E
DM8023E	DN	(+/-)-oxiran-2-ylmethyl (9Z)-hexadec-9-enoate
DM8023E	HS	Investigative
DM8023E	SN	CHEMBL230968; 213738-77-3; SCHEMBL4979121; BDBM50220357; UCM710, &gt; oxiran-2-ylmethyl (9z)-hexadec-9-enoate
DM8023E	DT	Small molecular drug
DM8023E	PC	23624909
DM8023E	MW	310.5
DM8023E	FM	C19H34O3
DM8023E	IC	InChI=1S/C19H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(20)22-17-18-16-21-18/h7-8,18H,2-6,9-17H2,1H3/b8-7-
DM8023E	CS	CCCCCC/C=C\\CCCCCCCC(=O)OCC1CO1
DM8023E	IK	FWEHVPCBXKCYHE-FPLPWBNLSA-N
DM8023E	IU	oxiran-2-ylmethyl (Z)-hexadec-9-enoate
DM8023E	DE	Discovery agent

DMI5R3E	ID	DMI5R3E
DMI5R3E	DN	(+/-)-oxiran-2-ylmethyl (9Z)-octadec-9-enoate
DMI5R3E	HS	Investigative
DMI5R3E	SN	Glycidyl oleate; Glycidol oleate; Oleic acid glycidyl ester; 2,3-Epoxypropyl oleate; Glycidyl octadecenoate; 5431-33-4; 2,3-Epoxy-1-propanol oleate; NSC 13542; 2,3-Epoxypropyl ester of oleic acid; Oxiranylmethyl ester of 9-octadecenoic acid; Oleic acid, 2,3-epoxypropyl ester; EINECS 226-588-0; Glycidylester kyseliny olejove [Czech]; AI3-03518; CHEMBL230967; CHEBI:82469; VWYIWOYBERNXLX-KTKRTIGZSA-N; 9-OCTADECENOIC ACID (Z)-, OXIRANYLMETHYL ESTER; Oxiranyl methyl ester 9-octadecenoic acid; 9-Octadecenoic acid (9Z)-, oxiranylmet
DMI5R3E	DT	Small molecular drug
DMI5R3E	PC	5354568
DMI5R3E	MW	338.5
DMI5R3E	FM	C21H38O3
DMI5R3E	IC	InChI=1S/C21H38O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(22)24-19-20-18-23-20/h9-10,20H,2-8,11-19H2,1H3/b10-9-
DMI5R3E	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OCC1CO1
DMI5R3E	IK	VWYIWOYBERNXLX-KTKRTIGZSA-N
DMI5R3E	IU	oxiran-2-ylmethyl (Z)-octadec-9-enoate
DMI5R3E	CA	CAS 5431-33-4
DMI5R3E	CB	CHEBI:82469
DMI5R3E	DE	Discovery agent

DMFSZ8H	ID	DMFSZ8H
DMFSZ8H	DN	(+/-)-threo-3',4'-Dichloromethylphenidate amide
DMFSZ8H	HS	Investigative
DMFSZ8H	SN	CHEMBL1253379; BDBM50327177; (+/-)-threo-3'',4''-Dichloromethylphenidate amide
DMFSZ8H	DT	Small molecular drug
DMFSZ8H	PC	52941144
DMFSZ8H	MW	287.18
DMFSZ8H	FM	C13H16Cl2N2O
DMFSZ8H	IC	InChI=1S/C13H16Cl2N2O/c14-9-5-4-8(7-10(9)15)12(13(16)18)11-3-1-2-6-17-11/h4-5,7,11-12,17H,1-3,6H2,(H2,16,18)/t11-,12-/m1/s1
DMFSZ8H	CS	C1CCN[C@H](C1)[C@@H](C2=CC(=C(C=C2)Cl)Cl)C(=O)N
DMFSZ8H	IK	OUZYXOJONCTZTI-VXGBXAGGSA-N
DMFSZ8H	IU	(2R)-2-(3,4-dichlorophenyl)-2-[(2R)-piperidin-2-yl]acetamide
DMFSZ8H	DE	Discovery agent

DM5MLZ0	ID	DM5MLZ0
DM5MLZ0	DN	(+/-)-threo-3',4'-Dichlororitalinol methyl ether
DM5MLZ0	HS	Investigative
DM5MLZ0	SN	CHEMBL1253378; BDBM50327167; (+/-)-threo-3'',4''-Dichlororitalinol methyl ether
DM5MLZ0	DT	Small molecular drug
DM5MLZ0	PC	52942344
DM5MLZ0	MW	288.2
DM5MLZ0	FM	C14H19Cl2NO
DM5MLZ0	IC	InChI=1S/C14H19Cl2NO/c1-18-9-11(14-4-2-3-7-17-14)10-5-6-12(15)13(16)8-10/h5-6,8,11,14,17H,2-4,7,9H2,1H3/t11-,14-/m1/s1
DM5MLZ0	CS	COC[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)Cl)Cl
DM5MLZ0	IK	JJZIIHYRMWUFJU-BXUZGUMPSA-N
DM5MLZ0	IU	(2R)-2-[(1R)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine
DM5MLZ0	DE	Discovery agent

DM4UQBI	ID	DM4UQBI
DM4UQBI	DN	(+/-)-threo-3',5'-Dichloromethylphenidate
DM4UQBI	HS	Investigative
DM4UQBI	SN	CHEMBL1253691; BDBM50327135
DM4UQBI	DT	Small molecular drug
DM4UQBI	PC	52942419
DM4UQBI	MW	302.2
DM4UQBI	FM	C14H17Cl2NO2
DM4UQBI	IC	InChI=1S/C14H17Cl2NO2/c1-19-14(18)13(12-4-2-3-5-17-12)9-6-10(15)8-11(16)7-9/h6-8,12-13,17H,2-5H2,1H3/t12-,13-/m1/s1
DM4UQBI	CS	COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=CC(=C2)Cl)Cl
DM4UQBI	IK	DRFWSKBVUOJFQQ-CHWSQXEVSA-N
DM4UQBI	IU	methyl (2R)-2-(3,5-dichlorophenyl)-2-[(2R)-piperidin-2-yl]acetate
DM4UQBI	DE	Discovery agent

DMUWKNX	ID	DMUWKNX
DMUWKNX	DN	(+/-)-threo-3',5'-Dimethylmethylphenidate
DMUWKNX	HS	Investigative
DMUWKNX	SN	CHEMBL1253692; BDBM50327134
DMUWKNX	DT	Small molecular drug
DMUWKNX	PC	52946039
DMUWKNX	MW	261.36
DMUWKNX	FM	C16H23NO2
DMUWKNX	IC	InChI=1S/C16H23NO2/c1-11-8-12(2)10-13(9-11)15(16(18)19-3)14-6-4-5-7-17-14/h8-10,14-15,17H,4-7H2,1-3H3/t14-,15-/m1/s1
DMUWKNX	CS	CC1=CC(=CC(=C1)[C@H]([C@H]2CCCCN2)C(=O)OC)C
DMUWKNX	IK	OQNVWHLLYQJVEV-HUUCEWRRSA-N
DMUWKNX	IU	methyl (2R)-2-(3,5-dimethylphenyl)-2-[(2R)-piperidin-2-yl]acetate
DMUWKNX	DE	Discovery agent

DM3O4FI	ID	DM3O4FI
DM3O4FI	DN	(+/-)-threo-3-Fluororitalinol
DM3O4FI	HS	Investigative
DM3O4FI	SN	CHEMBL1253340; (+/-)-threo-3-Fluororitalinol
DM3O4FI	DT	Small molecular drug
DM3O4FI	PC	52947218
DM3O4FI	MW	223.29
DM3O4FI	FM	C13H18FNO
DM3O4FI	IC	InChI=1S/C13H18FNO/c14-11-5-3-4-10(8-11)12(9-16)13-6-1-2-7-15-13/h3-5,8,12-13,15-16H,1-2,6-7,9H2/t12-,13-/m1/s1
DM3O4FI	CS	C1CCN[C@H](C1)[C@H](CO)C2=CC(=CC=C2)F
DM3O4FI	IK	AXNMDZNGNYLXHQ-CHWSQXEVSA-N
DM3O4FI	IU	(2R)-2-(3-fluorophenyl)-2-[(2R)-piperidin-2-yl]ethanol
DM3O4FI	DE	Discovery agent

DMU5T28	ID	DMU5T28
DMU5T28	DN	(+/-)-threo-4'-Ethylmethylphenidate
DMU5T28	HS	Investigative
DMU5T28	SN	CHEMBL1253519; BDBM50327106
DMU5T28	DT	Small molecular drug
DMU5T28	PC	52947243
DMU5T28	MW	261.36
DMU5T28	FM	C16H23NO2
DMU5T28	IC	InChI=1S/C16H23NO2/c1-3-12-7-9-13(10-8-12)15(16(18)19-2)14-6-4-5-11-17-14/h7-10,14-15,17H,3-6,11H2,1-2H3/t14-,15-/m1/s1
DMU5T28	CS	CCC1=CC=C(C=C1)[C@H]([C@H]2CCCCN2)C(=O)OC
DMU5T28	IK	WNIYTNIFAQJHLP-HUUCEWRRSA-N
DMU5T28	IU	methyl (2R)-2-(4-ethylphenyl)-2-[(2R)-piperidin-2-yl]acetate
DMU5T28	DE	Discovery agent

DM9TSW0	ID	DM9TSW0
DM9TSW0	DN	(+/-)-threo-Benzylphenidate
DM9TSW0	HS	Investigative
DM9TSW0	SN	CHEMBL1254759; (+/-)-threo-Benzylphenidate
DM9TSW0	DT	Small molecular drug
DM9TSW0	PC	52948225
DM9TSW0	MW	309.4
DM9TSW0	FM	C20H23NO2
DM9TSW0	IC	InChI=1S/C20H23NO2/c22-20(23-15-16-9-3-1-4-10-16)19(17-11-5-2-6-12-17)18-13-7-8-14-21-18/h1-6,9-12,18-19,21H,7-8,13-15H2/t18-,19-/m1/s1
DM9TSW0	CS	C1CCN[C@H](C1)[C@@H](C2=CC=CC=C2)C(=O)OCC3=CC=CC=C3
DM9TSW0	IK	MNFUKEWWCUWTRK-RTBURBONSA-N
DM9TSW0	IU	benzyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate
DM9TSW0	DE	Discovery agent

DMRZOVP	ID	DMRZOVP
DMRZOVP	DN	(+/-)-threo-Methylphenidate amide
DMRZOVP	HS	Investigative
DMRZOVP	SN	UNII-HS1P4T2LCV; HS1P4T2LCV; CHEMBL1253490; 160707-37-9; 50288-62-5; SCHEMBL14453323; ZINC5934431; BDBM50327105; D-threo-; A-Phenyl-2-piperidineacetamide; AJ-55250; AR,2R)-; FT-0673813; FT-0673810; (D,L)-threo-; (alphaR,2R)-alpha-Phenyl-2-piperidineacetamide; AR,2R)-rel-; (D,L)-threo-alpha-Phenyl-2-piperidineacetamide; alpha-Phenyl-2-piperidineacetamide, threo-(+)-
DMRZOVP	DT	Small molecular drug
DMRZOVP	PC	11085277
DMRZOVP	MW	218.29
DMRZOVP	FM	C13H18N2O
DMRZOVP	IC	InChI=1S/C13H18N2O/c14-13(16)12(10-6-2-1-3-7-10)11-8-4-5-9-15-11/h1-3,6-7,11-12,15H,4-5,8-9H2,(H2,14,16)/t11-,12-/m1/s1
DMRZOVP	CS	C1CCN[C@H](C1)[C@@H](C2=CC=CC=C2)C(=O)N
DMRZOVP	IK	LJLMNWPXAYKPGV-VXGBXAGGSA-N
DMRZOVP	IU	(2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetamide
DMRZOVP	CA	CAS 160707-37-9
DMRZOVP	DE	Discovery agent

DM80JOH	ID	DM80JOH
DM80JOH	DN	(+/-)-threo-N-(2-Chlorobenzyl)methylphenidate
DM80JOH	HS	Investigative
DM80JOH	SN	CHEMBL1253919; (+/-)-threo-N-(2-Chlorobenzyl)methylphenidate
DM80JOH	DT	Small molecular drug
DM80JOH	PC	52945289
DM80JOH	MW	357.9
DM80JOH	FM	C21H24ClNO2
DM80JOH	IC	InChI=1S/C21H24ClNO2/c1-25-21(24)20(16-9-3-2-4-10-16)19-13-7-8-14-23(19)15-17-11-5-6-12-18(17)22/h2-6,9-12,19-20H,7-8,13-15H2,1H3/t19-,20-/m1/s1
DM80JOH	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2Cl)C3=CC=CC=C3
DM80JOH	IK	AQQXLSKTANRVGK-WOJBJXKFSA-N
DM80JOH	IU	methyl (2R)-2-[(2R)-1-[(2-chlorophenyl)methyl]piperidin-2-yl]-2-phenylacetate
DM80JOH	DE	Discovery agent

DM6CWBO	ID	DM6CWBO
DM6CWBO	DN	(+/-)-threo-N-(2-Methylfuran)methylphenidate
DM6CWBO	HS	Investigative
DM6CWBO	SN	CHEMBL1254929; (+/-)-threo-N-(2-Methylfuran)methylphenidate; BDBM50327129; (alphaR)-alpha-[(2R)-1-(2-Furanylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DM6CWBO	DT	Small molecular drug
DM6CWBO	PC	52947085
DM6CWBO	MW	313.4
DM6CWBO	FM	C19H23NO3
DM6CWBO	IC	InChI=1S/C19H23NO3/c1-22-19(21)18(15-8-3-2-4-9-15)17-11-5-6-12-20(17)14-16-10-7-13-23-16/h2-4,7-10,13,17-18H,5-6,11-12,14H2,1H3/t17-,18-/m1/s1
DM6CWBO	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CO2)C3=CC=CC=C3
DM6CWBO	IK	PKLJJOYWJBBUAO-QZTJIDSGSA-N
DM6CWBO	IU	methyl (2R)-2-[(2R)-1-(furan-2-ylmethyl)piperidin-2-yl]-2-phenylacetate
DM6CWBO	DE	Discovery agent

DMN6ZX9	ID	DMN6ZX9
DMN6ZX9	DN	(+/-)-threo-N-(2-Methylpyridine)methylphenidate
DMN6ZX9	HS	Investigative
DMN6ZX9	SN	CHEMBL1255015; (+/-)-threo-N-(2-Methylpyridine)methylphenidate; BDBM50327126; (alphaR)-alpha-[(2R)-1-(2-Pyridinylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMN6ZX9	DT	Small molecular drug
DMN6ZX9	PC	52943483
DMN6ZX9	MW	324.4
DMN6ZX9	FM	C20H24N2O2
DMN6ZX9	IC	InChI=1S/C20H24N2O2/c1-24-20(23)19(16-9-3-2-4-10-16)18-12-6-8-14-22(18)15-17-11-5-7-13-21-17/h2-5,7,9-11,13,18-19H,6,8,12,14-15H2,1H3/t18-,19-/m1/s1
DMN6ZX9	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=N2)C3=CC=CC=C3
DMN6ZX9	IK	AZQUBJDTVAIXBC-RTBURBONSA-N
DMN6ZX9	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(pyridin-2-ylmethyl)piperidin-2-yl]acetate
DMN6ZX9	DE	Discovery agent

DMWUGSV	ID	DMWUGSV
DMWUGSV	DN	(+/-)-threo-N-(2-Methylthiopene)methylphenidate
DMWUGSV	HS	Investigative
DMWUGSV	SN	CHEMBL1254843; (+/-)-threo-N-(2-Methylthiopene)methylphenidate; BDBM50327131; (alphaR)-alpha-[(2R)-1-(2-Thienylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMWUGSV	DT	Small molecular drug
DMWUGSV	PC	52945836
DMWUGSV	MW	329.5
DMWUGSV	FM	C19H23NO2S
DMWUGSV	IC	InChI=1S/C19H23NO2S/c1-22-19(21)18(15-8-3-2-4-9-15)17-11-5-6-12-20(17)14-16-10-7-13-23-16/h2-4,7-10,13,17-18H,5-6,11-12,14H2,1H3/t17-,18-/m1/s1
DMWUGSV	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CS2)C3=CC=CC=C3
DMWUGSV	IK	XGTZBGNNSZZVLK-QZTJIDSGSA-N
DMWUGSV	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(thiophen-2-ylmethyl)piperidin-2-yl]acetate
DMWUGSV	DE	Discovery agent

DM2WRED	ID	DM2WRED
DM2WRED	DN	(+/-)-threo-N-(2-Phenylethyl)methylphenidate
DM2WRED	HS	Investigative
DM2WRED	SN	CHEMBL1254101; (+/-)-threo-N-(2-Phenylethyl)methylphenidate; BDBM50327116; (alphaR,2R)-alpha-Phenyl-1-phenethylpiperidine-2beta-acetic acid methyl ester
DM2WRED	DT	Small molecular drug
DM2WRED	PC	52943716
DM2WRED	MW	337.5
DM2WRED	FM	C22H27NO2
DM2WRED	IC	InChI=1S/C22H27NO2/c1-25-22(24)21(19-12-6-3-7-13-19)20-14-8-9-16-23(20)17-15-18-10-4-2-5-11-18/h2-7,10-13,20-21H,8-9,14-17H2,1H3/t20-,21-/m1/s1
DM2WRED	CS	COC(=O)[C@@H]([C@H]1CCCCN1CCC2=CC=CC=C2)C3=CC=CC=C3
DM2WRED	IK	XALKSMFHDRJAKZ-NHCUHLMSSA-N
DM2WRED	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(2-phenylethyl)piperidin-2-yl]acetate
DM2WRED	DE	Discovery agent

DM9Y3MT	ID	DM9Y3MT
DM9Y3MT	DN	(+/-)-threo-N-(2-Phenylethyl)ritalinol
DM9Y3MT	HS	Investigative
DM9Y3MT	SN	CHEMBL1254280; (+/-)-threo-N-(2-Phenylethyl)ritalinol; BDBM50327113; (betaR)-beta-[(2R)-1-Phenethylpiperidine-2beta-yl]phenethyl alcohol
DM9Y3MT	DT	Small molecular drug
DM9Y3MT	PC	52944989
DM9Y3MT	MW	309.4
DM9Y3MT	FM	C21H27NO
DM9Y3MT	IC	InChI=1S/C21H27NO/c23-17-20(19-11-5-2-6-12-19)21-13-7-8-15-22(21)16-14-18-9-3-1-4-10-18/h1-6,9-12,20-21,23H,7-8,13-17H2/t20-,21-/m1/s1
DM9Y3MT	CS	C1CCN([C@H](C1)[C@H](CO)C2=CC=CC=C2)CCC3=CC=CC=C3
DM9Y3MT	IK	BWPOQJVXDJYEQS-NHCUHLMSSA-N
DM9Y3MT	IU	(2R)-2-phenyl-2-[(2R)-1-(2-phenylethyl)piperidin-2-yl]ethanol
DM9Y3MT	DE	Discovery agent

DMU08WO	ID	DMU08WO
DMU08WO	DN	(+/-)-threo-N-(3-Chlorobenzyl)methylphenidate
DMU08WO	HS	Investigative
DMU08WO	SN	CHEMBL1254195; (+/-)-threo-N-(3-Chlorobenzyl)methylphenidate
DMU08WO	DT	Small molecular drug
DMU08WO	PC	52943751
DMU08WO	MW	357.9
DMU08WO	FM	C21H24ClNO2
DMU08WO	IC	InChI=1S/C21H24ClNO2/c1-25-21(24)20(17-9-3-2-4-10-17)19-12-5-6-13-23(19)15-16-8-7-11-18(22)14-16/h2-4,7-11,14,19-20H,5-6,12-13,15H2,1H3/t19-,20-/m1/s1
DMU08WO	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC(=CC=C2)Cl)C3=CC=CC=C3
DMU08WO	IK	MOEMZDNFRMSDIA-WOJBJXKFSA-N
DMU08WO	IU	methyl (2R)-2-[(2R)-1-[(3-chlorophenyl)methyl]piperidin-2-yl]-2-phenylacetate
DMU08WO	DE	Discovery agent

DMHPE4L	ID	DMHPE4L
DMHPE4L	DN	(+/-)-threo-N-(3-Methylfuran)methylphenidate
DMHPE4L	HS	Investigative
DMHPE4L	SN	CHEMBL1254842; (+/-)-threo-N-(3-Methylfuran)methylphenidate; BDBM50327132; (alphaR)-alpha-[(2R)-1-(3-Furanylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMHPE4L	DT	Small molecular drug
DMHPE4L	PC	52942853
DMHPE4L	MW	313.4
DMHPE4L	FM	C19H23NO3
DMHPE4L	IC	InChI=1S/C19H23NO3/c1-22-19(21)18(16-7-3-2-4-8-16)17-9-5-6-11-20(17)13-15-10-12-23-14-15/h2-4,7-8,10,12,14,17-18H,5-6,9,11,13H2,1H3/t17-,18-/m1/s1
DMHPE4L	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=COC=C2)C3=CC=CC=C3
DMHPE4L	IK	GUHBNEJVQSVUMF-QZTJIDSGSA-N
DMHPE4L	IU	methyl (2R)-2-[(2R)-1-(furan-3-ylmethyl)piperidin-2-yl]-2-phenylacetate
DMHPE4L	DE	Discovery agent

DMDMTZK	ID	DMDMTZK
DMDMTZK	DN	(+/-)-threo-N-(3-Methylpyridine)methylphenidate
DMDMTZK	HS	Investigative
DMDMTZK	SN	CHEMBL1255014; (+/-)-threo-N-(3-Methylpyridine)methylphenidate; BDBM50327127; (alphaR)-alpha-[(2R)-1-(3-Pyridinylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMDMTZK	DT	Small molecular drug
DMDMTZK	PC	52943482
DMDMTZK	MW	324.4
DMDMTZK	FM	C20H24N2O2
DMDMTZK	IC	InChI=1S/C20H24N2O2/c1-24-20(23)19(17-9-3-2-4-10-17)18-11-5-6-13-22(18)15-16-8-7-12-21-14-16/h2-4,7-10,12,14,18-19H,5-6,11,13,15H2,1H3/t18-,19-/m1/s1
DMDMTZK	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CN=CC=C2)C3=CC=CC=C3
DMDMTZK	IK	NCMGDVQEMNIZAB-RTBURBONSA-N
DMDMTZK	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(pyridin-3-ylmethyl)piperidin-2-yl]acetate
DMDMTZK	DE	Discovery agent

DMIJ7PC	ID	DMIJ7PC
DMIJ7PC	DN	(+/-)-threo-N-(3-Methylthiopene)methylphenidate
DMIJ7PC	HS	Investigative
DMIJ7PC	SN	CHEMBL1254928; (+/-)-threo-N-(3-Methylthiopene)methylphenidate; BDBM50327130; (alphaR)-alpha-[(2R)-1-(3-Thienylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMIJ7PC	DT	Small molecular drug
DMIJ7PC	PC	52947084
DMIJ7PC	MW	329.5
DMIJ7PC	FM	C19H23NO2S
DMIJ7PC	IC	InChI=1S/C19H23NO2S/c1-22-19(21)18(16-7-3-2-4-8-16)17-9-5-6-11-20(17)13-15-10-12-23-14-15/h2-4,7-8,10,12,14,17-18H,5-6,9,11,13H2,1H3/t17-,18-/m1/s1
DMIJ7PC	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CSC=C2)C3=CC=CC=C3
DMIJ7PC	IK	LNROKOGUORZBBV-QZTJIDSGSA-N
DMIJ7PC	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(thiophen-3-ylmethyl)piperidin-2-yl]acetate
DMIJ7PC	DE	Discovery agent

DMD926H	ID	DMD926H
DMD926H	DN	(+/-)-threo-N-(3-Phenylpropyl)methylphenidate
DMD926H	HS	Investigative
DMD926H	SN	CHEMBL1254196; (+/-)-threo-N-(3-Phenylpropyl)methylphenidate
DMD926H	DT	Small molecular drug
DMD926H	PC	52948633
DMD926H	MW	351.5
DMD926H	FM	C23H29NO2
DMD926H	IC	InChI=1S/C23H29NO2/c1-26-23(25)22(20-14-6-3-7-15-20)21-16-8-9-17-24(21)18-10-13-19-11-4-2-5-12-19/h2-7,11-12,14-15,21-22H,8-10,13,16-18H2,1H3/t21-,22-/m1/s1
DMD926H	CS	COC(=O)[C@@H]([C@H]1CCCCN1CCCC2=CC=CC=C2)C3=CC=CC=C3
DMD926H	IK	ALPWYQATULXWEM-FGZHOGPDSA-N
DMD926H	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(3-phenylpropyl)piperidin-2-yl]acetate
DMD926H	DE	Discovery agent

DMVP183	ID	DMVP183
DMVP183	DN	(+/-)-threo-N-(3-Phenylpropyl)ritalinol
DMVP183	HS	Investigative
DMVP183	SN	CHEMBL1254359; (+/-)-threo-N-(3-Phenylpropyl)ritalinol
DMVP183	DT	Small molecular drug
DMVP183	PC	52945256
DMVP183	MW	323.5
DMVP183	FM	C22H29NO
DMVP183	IC	InChI=1S/C22H29NO/c24-18-21(20-13-5-2-6-14-20)22-15-7-8-16-23(22)17-9-12-19-10-3-1-4-11-19/h1-6,10-11,13-14,21-22,24H,7-9,12,15-18H2/t21-,22-/m1/s1
DMVP183	CS	C1CCN([C@H](C1)[C@H](CO)C2=CC=CC=C2)CCCC3=CC=CC=C3
DMVP183	IK	QQICWLNJJOCDRX-FGZHOGPDSA-N
DMVP183	IU	(2R)-2-phenyl-2-[(2R)-1-(3-phenylpropyl)piperidin-2-yl]ethanol
DMVP183	DE	Discovery agent

DM3HWQY	ID	DM3HWQY
DM3HWQY	DN	(+/-)-threo-N-(4-Chlorobenzyl)methylphenidate
DM3HWQY	HS	Investigative
DM3HWQY	SN	CHEMBL1253840; (+/-)-threo-N-(4-Chlorobenzyl)methylphenidate
DM3HWQY	DT	Small molecular drug
DM3HWQY	PC	52949753
DM3HWQY	MW	357.9
DM3HWQY	FM	C21H24ClNO2
DM3HWQY	IC	InChI=1S/C21H24ClNO2/c1-25-21(24)20(17-7-3-2-4-8-17)19-9-5-6-14-23(19)15-16-10-12-18(22)13-11-16/h2-4,7-8,10-13,19-20H,5-6,9,14-15H2,1H3/t19-,20-/m1/s1
DM3HWQY	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=C(C=C2)Cl)C3=CC=CC=C3
DM3HWQY	IK	SUYRDAUAEDYGHW-WOJBJXKFSA-N
DM3HWQY	IU	methyl (2R)-2-[(2R)-1-[(4-chlorophenyl)methyl]piperidin-2-yl]-2-phenylacetate
DM3HWQY	DE	Discovery agent

DMHIKD2	ID	DMHIKD2
DMHIKD2	DN	(+/-)-threo-N-(4-Methoxybenzyl)methylphenidate
DMHIKD2	HS	Investigative
DMHIKD2	SN	CHEMBL1255100; (+/-)-threo-N-(4-Methoxybenzyl)methylphenidate
DMHIKD2	DT	Small molecular drug
DMHIKD2	PC	52942312
DMHIKD2	MW	353.5
DMHIKD2	FM	C22H27NO3
DMHIKD2	IC	InChI=1S/C22H27NO3/c1-25-19-13-11-17(12-14-19)16-23-15-7-6-10-20(23)21(22(24)26-2)18-8-4-3-5-9-18/h3-5,8-9,11-14,20-21H,6-7,10,15-16H2,1-2H3/t20-,21-/m1/s1
DMHIKD2	CS	COC1=CC=C(C=C1)CN2CCCC[C@@H]2[C@@H](C3=CC=CC=C3)C(=O)OC
DMHIKD2	IK	PMKFGPNZRGUOSJ-NHCUHLMSSA-N
DMHIKD2	IU	methyl (2R)-2-[(2R)-1-[(4-methoxyphenyl)methyl]piperidin-2-yl]-2-phenylacetate
DMHIKD2	DE	Discovery agent

DM9QIAL	ID	DM9QIAL
DM9QIAL	DN	(+/-)-threo-N-(4-Methylpyridine)methylphenidate
DM9QIAL	HS	Investigative
DM9QIAL	SN	CHEMBL1254930; (+/-)-threo-N-(4-Methylpyridine)methylphenidate; BDBM50327128; (alphaR)-alpha-[(2R)-1-(4-Pyridinylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DM9QIAL	DT	Small molecular drug
DM9QIAL	PC	52950138
DM9QIAL	MW	324.4
DM9QIAL	FM	C20H24N2O2
DM9QIAL	IC	InChI=1S/C20H24N2O2/c1-24-20(23)19(17-7-3-2-4-8-17)18-9-5-6-14-22(18)15-16-10-12-21-13-11-16/h2-4,7-8,10-13,18-19H,5-6,9,14-15H2,1H3/t18-,19-/m1/s1
DM9QIAL	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=NC=C2)C3=CC=CC=C3
DM9QIAL	IK	RLLOCIZJNXWKIC-RTBURBONSA-N
DM9QIAL	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(pyridin-4-ylmethyl)piperidin-2-yl]acetate
DM9QIAL	DE	Discovery agent

DMB3JY8	ID	DMB3JY8
DMB3JY8	DN	(+/-)-threo-N-(4-Nitrobenzyl)methylphenidate
DMB3JY8	HS	Investigative
DMB3JY8	SN	CHEMBL1253839; (+/-)-threo-N-(4-Nitrobenzyl)methylphenidate
DMB3JY8	DT	Small molecular drug
DMB3JY8	PC	52943636
DMB3JY8	MW	368.4
DMB3JY8	FM	C21H24N2O4
DMB3JY8	IC	InChI=1S/C21H24N2O4/c1-27-21(24)20(17-7-3-2-4-8-17)19-9-5-6-14-22(19)15-16-10-12-18(13-11-16)23(25)26/h2-4,7-8,10-13,19-20H,5-6,9,14-15H2,1H3/t19-,20-/m1/s1
DMB3JY8	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=C(C=C2)[N+](=O)[O-])C3=CC=CC=C3
DMB3JY8	IK	WXZFAWFIMBPTEP-WOJBJXKFSA-N
DMB3JY8	IU	methyl (2R)-2-[(2R)-1-[(4-nitrophenyl)methyl]piperidin-2-yl]-2-phenylacetate
DMB3JY8	DE	Discovery agent

DMK6IJW	ID	DMK6IJW
DMK6IJW	DN	(+/-)-threo-N-(4-Phenylbutyl)methylphenidate
DMK6IJW	HS	Investigative
DMK6IJW	SN	CHEMBL1254100; (+/-)-threo-N-(4-Phenylbutyl)methylphenidate; BDBM50327117; (alphaR)-alpha-[(2R)-1-(4-Phenylbutyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMK6IJW	DT	Small molecular drug
DMK6IJW	PC	52946144
DMK6IJW	MW	365.5
DMK6IJW	FM	C24H31NO2
DMK6IJW	IC	InChI=1S/C24H31NO2/c1-27-24(26)23(21-15-6-3-7-16-21)22-17-9-11-19-25(22)18-10-8-14-20-12-4-2-5-13-20/h2-7,12-13,15-16,22-23H,8-11,14,17-19H2,1H3/t22-,23-/m1/s1
DMK6IJW	CS	COC(=O)[C@@H]([C@H]1CCCCN1CCCCC2=CC=CC=C2)C3=CC=CC=C3
DMK6IJW	IK	TYKSHJPRQWJNHO-DHIUTWEWSA-N
DMK6IJW	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(4-phenylbutyl)piperidin-2-yl]acetate
DMK6IJW	DE	Discovery agent

DMG3FA1	ID	DMG3FA1
DMG3FA1	DN	(+/-)-threo-N-(4-Phenylbutyl)ritalinol
DMG3FA1	HS	Investigative
DMG3FA1	SN	CHEMBL1254281; (+/-)-threo-N-(4-Phenylbutyl)ritalinol
DMG3FA1	DT	Small molecular drug
DMG3FA1	PC	52941366
DMG3FA1	MW	337.5
DMG3FA1	FM	C23H31NO
DMG3FA1	IC	InChI=1S/C23H31NO/c25-19-22(21-14-5-2-6-15-21)23-16-8-10-18-24(23)17-9-7-13-20-11-3-1-4-12-20/h1-6,11-12,14-15,22-23,25H,7-10,13,16-19H2/t22-,23-/m1/s1
DMG3FA1	CS	C1CCN([C@H](C1)[C@H](CO)C2=CC=CC=C2)CCCCC3=CC=CC=C3
DMG3FA1	IK	MGISPZACVQKKJZ-DHIUTWEWSA-N
DMG3FA1	IU	(2R)-2-phenyl-2-[(2R)-1-(4-phenylbutyl)piperidin-2-yl]ethanol
DMG3FA1	DE	Discovery agent

DMHNQO9	ID	DMHNQO9
DMHNQO9	DN	(+/-)-threo-N-(5-Phenylpentyl)methylphenidate
DMHNQO9	HS	Investigative
DMHNQO9	SN	CHEMBL1254009; (+/-)-threo-N-(5-Phenylpentyl)methylphenidate; BDBM50327118; (alphaR)-alpha-[(2R)-1-(5-Phenylpentyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMHNQO9	DT	Small molecular drug
DMHNQO9	PC	52943691
DMHNQO9	MW	379.5
DMHNQO9	FM	C25H33NO2
DMHNQO9	IC	InChI=1S/C25H33NO2/c1-28-25(27)24(22-16-8-3-9-17-22)23-18-10-12-20-26(23)19-11-4-7-15-21-13-5-2-6-14-21/h2-3,5-6,8-9,13-14,16-17,23-24H,4,7,10-12,15,18-20H2,1H3/t23-,24-/m1/s1
DMHNQO9	CS	COC(=O)[C@@H]([C@H]1CCCCN1CCCCCC2=CC=CC=C2)C3=CC=CC=C3
DMHNQO9	IK	CYCPZJLWKPRDTM-DNQXCXABSA-N
DMHNQO9	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(5-phenylpentyl)piperidin-2-yl]acetate
DMHNQO9	DE	Discovery agent

DMG1K5H	ID	DMG1K5H
DMG1K5H	DN	(+/-)-threo-N-(6-Phenylhexyl)methylphenidate
DMG1K5H	HS	Investigative
DMG1K5H	SN	CHEMBL1254008; (+/-)-threo-N-(6-Phenylhexyl)methylphenidate; BDBM50327119; (alphaR)-alpha-[(2R)-1-(6-Phenylhexyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMG1K5H	DT	Small molecular drug
DMG1K5H	PC	52945263
DMG1K5H	MW	393.6
DMG1K5H	FM	C26H35NO2
DMG1K5H	IC	InChI=1S/C26H35NO2/c1-29-26(28)25(23-17-9-5-10-18-23)24-19-11-13-21-27(24)20-12-3-2-6-14-22-15-7-4-8-16-22/h4-5,7-10,15-18,24-25H,2-3,6,11-14,19-21H2,1H3/t24-,25-/m1/s1
DMG1K5H	CS	COC(=O)[C@@H]([C@H]1CCCCN1CCCCCCC2=CC=CC=C2)C3=CC=CC=C3
DMG1K5H	IK	JMGUVGDMBREFCW-JWQCQUIFSA-N
DMG1K5H	IU	methyl (2R)-2-phenyl-2-[(2R)-1-(6-phenylhexyl)piperidin-2-yl]acetate
DMG1K5H	DE	Discovery agent

DMYNO71	ID	DMYNO71
DMYNO71	DN	(+/-)-threo-N-Allylmethylphenidate
DMYNO71	HS	Investigative
DMYNO71	SN	CHEMBL1253918; (+/-)-threo-N-Allylmethylphenidate
DMYNO71	DT	Small molecular drug
DMYNO71	PC	52947332
DMYNO71	MW	273.37
DMYNO71	FM	C17H23NO2
DMYNO71	IC	InChI=1S/C17H23NO2/c1-3-12-18-13-8-7-11-15(18)16(17(19)20-2)14-9-5-4-6-10-14/h3-6,9-10,15-16H,1,7-8,11-13H2,2H3/t15-,16-/m1/s1
DMYNO71	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC=C)C2=CC=CC=C2
DMYNO71	IK	WMEIWLRYZFKRDU-HZPDHXFCSA-N
DMYNO71	IU	methyl (2R)-2-phenyl-2-[(2R)-1-prop-2-enylpiperidin-2-yl]acetate
DMYNO71	DE	Discovery agent

DMOJXCK	ID	DMOJXCK
DMOJXCK	DN	(+/-)-threo-N-Benzyl-3',4'-dichlororitalinol
DMOJXCK	HS	Investigative
DMOJXCK	SN	CHEMBL1254675; BDBM50327175
DMOJXCK	DT	Small molecular drug
DMOJXCK	PC	52945159
DMOJXCK	MW	364.3
DMOJXCK	FM	C20H23Cl2NO
DMOJXCK	IC	InChI=1S/C20H23Cl2NO/c21-18-10-9-16(12-19(18)22)17(14-24)20-8-4-5-11-23(20)13-15-6-2-1-3-7-15/h1-3,6-7,9-10,12,17,20,24H,4-5,8,11,13-14H2/t17-,20-/m1/s1
DMOJXCK	CS	C1CCN([C@H](C1)[C@H](CO)C2=CC(=C(C=C2)Cl)Cl)CC3=CC=CC=C3
DMOJXCK	IK	NRJOAYKSGZHTCR-YLJYHZDGSA-N
DMOJXCK	IU	(2R)-2-[(2R)-1-benzylpiperidin-2-yl]-2-(3,4-dichlorophenyl)ethanol
DMOJXCK	DE	Discovery agent

DM15LE0	ID	DM15LE0
DM15LE0	DN	(+/-)-threo-N-Benzyl-3'-chloromethylphenidate
DM15LE0	HS	Investigative
DM15LE0	SN	CHEMBL1254517; BDBM50327168
DM15LE0	DT	Small molecular drug
DM15LE0	PC	52945094
DM15LE0	MW	357.9
DM15LE0	FM	C21H24ClNO2
DM15LE0	IC	InChI=1S/C21H24ClNO2/c1-25-21(24)20(17-10-7-11-18(22)14-17)19-12-5-6-13-23(19)15-16-8-3-2-4-9-16/h2-4,7-11,14,19-20H,5-6,12-13,15H2,1H3/t19-,20-/m1/s1
DM15LE0	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2)C3=CC(=CC=C3)Cl
DM15LE0	IK	QUIVXFJDADACBW-WOJBJXKFSA-N
DM15LE0	IU	methyl (2R)-2-[(2R)-1-benzylpiperidin-2-yl]-2-(3-chlorophenyl)acetate
DM15LE0	DE	Discovery agent

DMUACDH	ID	DMUACDH
DMUACDH	DN	(+/-)-threo-N-Benzylmethylphenidate amide
DMUACDH	HS	Investigative
DMUACDH	SN	CHEMBL1254596; (+/-)-threo-N-Benzylmethylphenidate amide
DMUACDH	DT	Small molecular drug
DMUACDH	PC	52946374
DMUACDH	MW	308.4
DMUACDH	FM	C20H24N2O
DMUACDH	IC	InChI=1S/C20H24N2O/c21-20(23)19(17-11-5-2-6-12-17)18-13-7-8-14-22(18)15-16-9-3-1-4-10-16/h1-6,9-12,18-19H,7-8,13-15H2,(H2,21,23)/t18-,19-/m1/s1
DMUACDH	CS	C1CCN([C@H](C1)[C@@H](C2=CC=CC=C2)C(=O)N)CC3=CC=CC=C3
DMUACDH	IK	UMTRWYIEQNNYPX-RTBURBONSA-N
DMUACDH	IU	(2R)-2-[(2R)-1-benzylpiperidin-2-yl]-2-phenylacetamide
DMUACDH	DE	Discovery agent

DM6D18M	ID	DM6D18M
DM6D18M	DN	(+/-)-threo-N-Methyl-30-methylmethylphenidate
DM6D18M	HS	Investigative
DM6D18M	SN	CHEMBL19686; BDBM50291690; (R)-((R)-1-Methyl-piperidin-2-yl)-m-tolyl-acetic acid methyl ester
DM6D18M	DT	Small molecular drug
DM6D18M	PC	44273085
DM6D18M	MW	261.36
DM6D18M	FM	C16H23NO2
DM6D18M	IC	InChI=1S/C16H23NO2/c1-12-7-6-8-13(11-12)15(16(18)19-3)14-9-4-5-10-17(14)2/h6-8,11,14-15H,4-5,9-10H2,1-3H3/t14-,15-/m1/s1
DM6D18M	CS	CC1=CC(=CC=C1)[C@H]([C@H]2CCCCN2C)C(=O)OC
DM6D18M	IK	NEQATLAJGKQCLO-HUUCEWRRSA-N
DM6D18M	IU	methyl (2R)-2-(3-methylphenyl)-2-[(2R)-1-methylpiperidin-2-yl]acetate
DM6D18M	DE	Discovery agent

DMYE0MZ	ID	DMYE0MZ
DMYE0MZ	DN	(+/-)-threo-N-Propargylmethylphenidate
DMYE0MZ	HS	Investigative
DMYE0MZ	SN	CHEMBL1254282; (+/-)-threo-N-Propargylmethylphenidate
DMYE0MZ	DT	Small molecular drug
DMYE0MZ	PC	52948667
DMYE0MZ	MW	271.35
DMYE0MZ	FM	C17H21NO2
DMYE0MZ	IC	InChI=1S/C17H21NO2/c1-3-12-18-13-8-7-11-15(18)16(17(19)20-2)14-9-5-4-6-10-14/h1,4-6,9-10,15-16H,7-8,11-13H2,2H3/t15-,16-/m1/s1
DMYE0MZ	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC#C)C2=CC=CC=C2
DMYE0MZ	IK	JZWSHRDYZHBSBM-HZPDHXFCSA-N
DMYE0MZ	IU	methyl (2R)-2-phenyl-2-[(2R)-1-prop-2-ynylpiperidin-2-yl]acetate
DMYE0MZ	DE	Discovery agent

DMM2QOX	ID	DMM2QOX
DMM2QOX	DN	(+/-)-TRANS-U-50488 METHANESULFONATE
DMM2QOX	HS	Investigative
DMM2QOX	SN	NCG-C00093883-01
DMM2QOX	DT	Small molecular drug
DMM2QOX	PC	9912313
DMM2QOX	MW	465.4
DMM2QOX	FM	C20H30Cl2N2O4S
DMM2QOX	IC	InChI=1S/C19H26Cl2N2O.CH4O3S/c1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23;1-5(2,3)4/h8-9,12,17-18H,2-7,10-11,13H2,1H3;1H3,(H,2,3,4)/t17-,18-;/m0./s1
DMM2QOX	CS	CN([C@H]1CCCC[C@@H]1N2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl.CS(=O)(=O)O
DMM2QOX	IK	OJPHNZCUXUUVKU-APTPAJQOSA-N
DMM2QOX	IU	2-(3,4-dichlorophenyl)-N-methyl-N-[(1S,2S)-2-pyrrolidin-1-ylcyclohexyl]acetamide;methanesulfonic acid
DMM2QOX	DE	Discovery agent

DMDK59X	ID	DMDK59X
DMDK59X	DN	(1,1-Difluoro-pentadecyl)-phosphonic acid
DMDK59X	HS	Investigative
DMDK59X	SN	CHEMBL188859; (1,1-Difluoro-pentadecyl)-phosphonic acid; SCHEMBL193245; YGXPAGSHLFJKFV-UHFFFAOYSA-N; BDBM50170861; ZINC36178965; (1,1-Difluoro-pentadecyl)Phosphonic Acid; (1,1-Difluoro-pentadecyl) Phosphonic Acid
DMDK59X	DT	Small molecular drug
DMDK59X	PC	11393306
DMDK59X	MW	328.37
DMDK59X	FM	C15H31F2O3P
DMDK59X	IC	InChI=1S/C15H31F2O3P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(16,17)21(18,19)20/h2-14H2,1H3,(H2,18,19,20)
DMDK59X	CS	CCCCCCCCCCCCCCC(F)(F)P(=O)(O)O
DMDK59X	IK	YGXPAGSHLFJKFV-UHFFFAOYSA-N
DMDK59X	IU	1,1-difluoropentadecylphosphonic acid
DMDK59X	DE	Discovery agent

DMF6WHC	ID	DMF6WHC
DMF6WHC	DN	(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol
DMF6WHC	HS	Investigative
DMF6WHC	SN	63006-93-9; (1,2,3,4-Tetrahydroisoquinolin-3-yl)methanol; 1,2,3,4-Tetrahydroisoquinoline-3-methanol; (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol; 1,2,3,4-tetrahydroisoquinolin-3-ylmethanol; (S)-(-)-1,2,3,4-Tetrahydro-3-isoquinolinemethanol; 62928-94-3; CHEMBL60068; 1,2,3,4-tetrahydro-3-isoquinolinemethanol; 3-Isoquinolinemethanol, 1,2,3,4-tetrahydro-; 3-Hydroxymethyl-1,2,3,4-tetrahydroisoquinoline; F2147-1627; PubChem5794; AC1MWNWL; (S)-1,2,3,4-Tetrahydroisoquinolylmethan-3-ol; ACMC-209err; ChemDiv2_003241
DMF6WHC	DT	Small molecular drug
DMF6WHC	PC	3752277
DMF6WHC	MW	163.22
DMF6WHC	FM	C10H13NO
DMF6WHC	IC	InChI=1S/C10H13NO/c12-7-10-5-8-3-1-2-4-9(8)6-11-10/h1-4,10-12H,5-7H2
DMF6WHC	CS	C1C(NCC2=CC=CC=C21)CO
DMF6WHC	IK	ZSKDXMLMMQFHGW-UHFFFAOYSA-N
DMF6WHC	IU	1,2,3,4-tetrahydroisoquinolin-3-ylmethanol
DMF6WHC	DE	Discovery agent

DM2J9RI	ID	DM2J9RI
DM2J9RI	DN	(10H-phenothiazin-10-yl)(m-tolyl)methanone
DM2J9RI	HS	Investigative
DM2J9RI	SN	CHEMBL239401; AC1MRTR9; (10H-phenothiazin-10-yl)(m-tolyl)methanone; Oprea1_358386; BDBM50219209; AKOS005197735; AKOS002684869
DM2J9RI	DT	Small molecular drug
DM2J9RI	PC	3473842
DM2J9RI	MW	317.4
DM2J9RI	FM	C20H15NOS
DM2J9RI	IC	InChI=1S/C20H15NOS/c1-14-7-6-8-15(13-14)20(22)21-16-9-2-4-11-18(16)23-19-12-5-3-10-17(19)21/h2-13H,1H3
DM2J9RI	CS	CC1=CC(=CC=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM2J9RI	IK	JSMJNESPMFVMAA-UHFFFAOYSA-N
DM2J9RI	IU	(3-methylphenyl)-phenothiazin-10-ylmethanone
DM2J9RI	DE	Discovery agent

DM8BKTV	ID	DM8BKTV
DM8BKTV	DN	(10H-phenothiazin-10-yl)(o-tolyl)methanone
DM8BKTV	HS	Investigative
DM8BKTV	SN	CHEMBL397099; AC1MRTR1; (10H-phenothiazin-10-yl)(o-tolyl)methanone; Oprea1_791821; BDBM50219215
DM8BKTV	DT	Small molecular drug
DM8BKTV	PC	3473839
DM8BKTV	MW	317.4
DM8BKTV	FM	C20H15NOS
DM8BKTV	IC	InChI=1S/C20H15NOS/c1-14-8-2-3-9-15(14)20(22)21-16-10-4-6-12-18(16)23-19-13-7-5-11-17(19)21/h2-13H,1H3
DM8BKTV	CS	CC1=CC=CC=C1C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM8BKTV	IK	PYIIIOAOKBCILO-UHFFFAOYSA-N
DM8BKTV	IU	(2-methylphenyl)-phenothiazin-10-ylmethanone
DM8BKTV	DE	Discovery agent

DMT3GAD	ID	DMT3GAD
DMT3GAD	DN	(10H-phenothiazin-10-yl)(phenyl)methanone
DMT3GAD	HS	Investigative
DMT3GAD	SN	10h-phenothiazin-10-yl(phenyl)methanone; CHEMBL239400; phenothiazin-10-yl(phenyl)methanone; 10-BENZOYL-10H-PHENOTHIAZINE; 38076-73-2; NSC95774; 10-benzoylphenothiazine; (10H-phenothiazin-10-yl)(phenyl)methanone; AC1Q5K0F; Oprea1_507390; Oprea1_637573; SCHEMBL343497; AC1L678I; CTK4H9286; phenyl phenothiazin-10-yl ketone; DTXSID00294306; MolPort-000-182-685; ZINC402121; NSC-95774; BDBM50219217; STL371969; AKOS000279791; MCULE-2324671928
DMT3GAD	DT	Small molecular drug
DMT3GAD	PC	262319
DMT3GAD	MW	303.4
DMT3GAD	FM	C19H13NOS
DMT3GAD	IC	InChI=1S/C19H13NOS/c21-19(14-8-2-1-3-9-14)20-15-10-4-6-12-17(15)22-18-13-7-5-11-16(18)20/h1-13H
DMT3GAD	CS	C1=CC=C(C=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMT3GAD	IK	RVBAUHGQSLEOSR-UHFFFAOYSA-N
DMT3GAD	IU	phenothiazin-10-yl(phenyl)methanone
DMT3GAD	CA	CAS 38076-73-2
DMT3GAD	DE	Discovery agent

DMRQ0ZF	ID	DMRQ0ZF
DMRQ0ZF	DN	(10H-phenothiazin-10-yl)(p-tolyl)methanone
DMRQ0ZF	HS	Investigative
DMRQ0ZF	SN	CHEMBL397100; AC1MRSS1; (10H-phenothiazin-10-yl)(p-tolyl)methanone; Oprea1_194230; MLS002608923; cid_3473393; CHEBI:93656; BDBM50219212; SMR001537727; (4-methylphenyl)-phenothiazin-10-ylmethanone
DMRQ0ZF	DT	Small molecular drug
DMRQ0ZF	PC	3473393
DMRQ0ZF	MW	317.4
DMRQ0ZF	FM	C20H15NOS
DMRQ0ZF	IC	InChI=1S/C20H15NOS/c1-14-10-12-15(13-11-14)20(22)21-16-6-2-4-8-18(16)23-19-9-5-3-7-17(19)21/h2-13H,1H3
DMRQ0ZF	CS	CC1=CC=C(C=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMRQ0ZF	IK	BXCIQPXSBSOIQX-UHFFFAOYSA-N
DMRQ0ZF	IU	(4-methylphenyl)-phenothiazin-10-ylmethanone
DMRQ0ZF	CB	CHEBI:93656
DMRQ0ZF	DE	Discovery agent

DMVTLF9	ID	DMVTLF9
DMVTLF9	DN	(10r)-10-Formyl-5,8,10-Trideazafolic Acid
DMVTLF9	HS	Investigative
DMVTLF9	SN	(10R)-10-FORMYL-5,8,10-TRIDEAZAFOLIC ACID; NHR; 2-{4-[2-(2-AMINO-4-HYDROXY-QUINAZOLIN-6-YL)-1-CARBOXY-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; 1c3e; AC1L9GSR; DB04264; 8937-EP2308866A1; 8937-EP2308846A2; 8937-EP2305697A2; 8937-EP2298780A1; 8937-EP2277872A1; 8937-EP2316829A1; 8937-EP2308872A1; 8937-EP2308845A2; 8937-EP2305698A2; 8937-EP2305695A2; 8937-EP2301932A1; 8937-EP2287167A1; 8937-EP2283898A1; 8937-EP2281563A1; 8937-EP2316459A1; 8937-EP2308844A2; 8937-EP2277869A1; 8937-EP2270018A1; 8937-EP2308812A2; 8937-EP2305696A2
DMVTLF9	DT	Small molecular drug
DMVTLF9	PC	135460968
DMVTLF9	MW	482.4
DMVTLF9	FM	C23H22N4O8
DMVTLF9	IC	InChI=1S/C23H22N4O8/c24-23-26-16-6-1-11(10-15(16)20(31)27-23)9-14(21(32)33)12-2-4-13(5-3-12)19(30)25-17(22(34)35)7-8-18(28)29/h1-6,10,14,17H,7-9H2,(H,25,30)(H,28,29)(H,32,33)(H,34,35)(H3,24,26,27,31)/t14-,17+/m1/s1
DMVTLF9	CS	C1=CC(=CC=C1[C@@H](CC2=CC3=C(C=C2)N=C(NC3=O)N)C(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMVTLF9	IK	DAOQLLQRJAXMGY-PBHICJAKSA-N
DMVTLF9	IU	(2S)-2-[[4-[(1R)-2-(2-amino-4-oxo-3H-quinazolin-6-yl)-1-carboxyethyl]benzoyl]amino]pentanedioic acid
DMVTLF9	DE	Discovery agent

DMTPQ84	ID	DMTPQ84
DMTPQ84	DN	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE
DMTPQ84	HS	Investigative
DMTPQ84	SN	Corticosterone; CORTICOSTERONE; 50-22-6; 17-Deoxycortisol; Reichstein's substance H; Kendall's compound B; Corticosteron; 11beta,21-Dihydroxyprogesterone; Compound B; Reichstein's B; 11-Hydroxycorticoaldosterone; (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione; 11beta,21-Dihydroxy-4-pregnene-3,20-dione; 4-Pregnene-11beta,21-diol-3,20-dione; 11,21-Dihydroxyprogesterone; 11Beta,21-dihydroxypregn-4-ene-3,20-dione; 11,12-Dihydroxyprogesterone; UNII-W980KJ009P; CCRIS 6753; 11-beta,21-Dihydroxypregn-3,20-dione; CHEBI:16827; NSC9705; corticosterone
DMTPQ84	DT	Small molecular drug
DMTPQ84	PC	5753
DMTPQ84	MW	346.5
DMTPQ84	FM	C21H30O4
DMTPQ84	IC	InChI=1S/C21H30O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-17,19,22,24H,3-8,10-11H2,1-2H3/t14-,15-,16+,17-,19+,20-,21-/m0/s1
DMTPQ84	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C)O
DMTPQ84	IK	OMFXVFTZEKFJBZ-HJTSIMOOSA-N
DMTPQ84	IU	(8S,9S,10R,11S,13S,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMTPQ84	CA	CAS 50-22-6
DMTPQ84	CB	CHEBI:16827
DMTPQ84	DE	Discovery agent

DMZ5YMH	ID	DMZ5YMH
DMZ5YMH	DN	(11E)-OCTADEC-11-ENOIC ACID
DMZ5YMH	HS	Investigative
DMZ5YMH	SN	cis-vaccenic acid; (Z)-octadec-11-enoic acid; cis-11-Octadecenoic acid; 506-17-2; 11Z-Octadecenoic acid; (11E)-octadec-11-enoic acid; Asclepic acid; (Z)-11-Octadecenoic acid; 11-Octadecenoic acid, (Z)-; UNII-400K7322UW; CHEBI:50464; 400K7322UW; cis-octadec-11-enoic acid; VCA; trans-11-Octadecensaeure; 11-cis-Octadecenoic acid; C18:1n-7; cis-11-Vaccenic acid; AC1NR0QT; 11(Z)-Octadecenoic acid; cis-D11-Octadecenoic acid; SCHEMBL97463; (11Z)octadec-11-enoic acid; (11Z)-octadec-11-enoic acid; CHEMBL1236642; UWHZIFQPPBDJPM-FPLPWBNLSA-N
DMZ5YMH	DT	Small molecular drug
DMZ5YMH	PC	5282761
DMZ5YMH	MW	282.5
DMZ5YMH	FM	C18H34O2
DMZ5YMH	IC	InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h7-8H,2-6,9-17H2,1H3,(H,19,20)/b8-7-
DMZ5YMH	CS	CCCCCC/C=C\\CCCCCCCCCC(=O)O
DMZ5YMH	IK	UWHZIFQPPBDJPM-FPLPWBNLSA-N
DMZ5YMH	IU	(Z)-octadec-11-enoic acid
DMZ5YMH	CA	CAS 506-17-2
DMZ5YMH	CB	CHEBI:50464
DMZ5YMH	DE	Discovery agent

DMSUPVE	ID	DMSUPVE
DMSUPVE	DN	(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid
DMSUPVE	HS	Investigative
DMSUPVE	SN	CHEMBL33378; ZINC29221898
DMSUPVE	DT	Small molecular drug
DMSUPVE	PC	13640140
DMSUPVE	MW	256.25
DMSUPVE	FM	C15H12O4
DMSUPVE	IC	InChI=1S/C15H12O4/c16-15(17)8-10-5-6-12-11(7-10)9-18-13-3-1-2-4-14(13)19-12/h1-7H,8-9H2,(H,16,17)
DMSUPVE	CS	C1C2=C(C=CC(=C2)CC(=O)O)OC3=CC=CC=C3O1
DMSUPVE	IK	UCLQILVHNXYKJH-UHFFFAOYSA-N
DMSUPVE	IU	2-(6H-benzo[b][1,4]benzodioxepin-8-yl)acetic acid
DMSUPVE	DE	Discovery agent

DM5ZTXL	ID	DM5ZTXL
DM5ZTXL	DN	(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid
DM5ZTXL	HS	Investigative
DM5ZTXL	SN	CHEMBL32961; ZINC29223888
DM5ZTXL	DT	Small molecular drug
DM5ZTXL	PC	13640143
DM5ZTXL	MW	256.25
DM5ZTXL	FM	C15H12O4
DM5ZTXL	IC	InChI=1S/C15H12O4/c16-15(17)8-10-5-6-13-14(7-10)19-12-4-2-1-3-11(12)9-18-13/h1-7H,8-9H2,(H,16,17)
DM5ZTXL	CS	C1C2=CC=CC=C2OC3=C(O1)C=CC(=C3)CC(=O)O
DM5ZTXL	IK	MREFHNNUMIAIHP-UHFFFAOYSA-N
DM5ZTXL	IU	2-(6H-benzo[b][1,4]benzodioxepin-2-yl)acetic acid
DM5ZTXL	DE	Discovery agent

DMBY623	ID	DMBY623
DMBY623	DN	(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid
DMBY623	HS	Investigative
DMBY623	SN	CHEMBL33814; ZINC29223313
DMBY623	DT	Small molecular drug
DMBY623	PC	13640144
DMBY623	MW	256.25
DMBY623	FM	C15H12O4
DMBY623	IC	InChI=1S/C15H12O4/c16-15(17)8-10-5-6-13-14(7-10)18-9-11-3-1-2-4-12(11)19-13/h1-7H,8-9H2,(H,16,17)
DMBY623	CS	C1C2=CC=CC=C2OC3=C(O1)C=C(C=C3)CC(=O)O
DMBY623	IK	QTBPZEAQRRAFFF-UHFFFAOYSA-N
DMBY623	IU	2-(6H-benzo[b][1,4]benzodioxepin-3-yl)acetic acid
DMBY623	DE	Discovery agent

DMJNLQ5	ID	DMJNLQ5
DMJNLQ5	DN	(12E,20Z,18S)-8-hydroxyvariabilin
DMJNLQ5	HS	Investigative
DMJNLQ5	SN	(12E,20Z,18S)-8-hydroxyvariabilin; GTPL4072
DMJNLQ5	DT	Small molecular drug
DMJNLQ5	PC	54726845
DMJNLQ5	MW	416.5
DMJNLQ5	FM	C25H36O5
DMJNLQ5	IC	InChI=1S/C25H36O5/c1-18(8-5-9-19(2)16-22-23(26)20(3)24(27)30-22)10-6-13-25(4,28)14-7-11-21-12-15-29-17-21/h10,12,15-17,19,26,28H,5-9,11,13-14H2,1-4H3/b18-10+,22-16-/t19-,25?/m0/s1
DMJNLQ5	CS	CC1=C(/C(=C/[C@@H](C)CCC/C(=C/CCC(C)(CCCC2=COC=C2)O)/C)/OC1=O)O
DMJNLQ5	IK	QFBUNOKEKXMSCV-UYYPKTQPSA-N
DMJNLQ5	IU	(5Z)-5-[(E,2S)-13-(furan-3-yl)-10-hydroxy-2,6,10-trimethyltridec-6-enylidene]-4-hydroxy-3-methylfuran-2-one
DMJNLQ5	DE	Discovery agent

DMXD8H1	ID	DMXD8H1
DMXD8H1	DN	(1-Amino-2-phenyl-ethyl)-phosphinic acid
DMXD8H1	HS	Investigative
DMXD8H1	SN	CHEMBL37846; 80744-66-7; (1-AMINO-2-PHENYLETHYL)PHOSPHINIC ACID; Phosphinic acid, (1-amino-2-phenylethyl)-; AC1O49RT; MLS004256549; SCHEMBL3862224; CTK5E8078; DTXSID90422994; APQRSTHZZSRXIS-UHFFFAOYSA-N; AKOS006273173; SMR003081569; (1-amino-2-phenylethyl)-hydroxy-oxophosphanium; Phosphinic acid,(1-amino-2-phenylethyl)- (9CI)
DMXD8H1	DT	Small molecular drug
DMXD8H1	PC	54297424
DMXD8H1	MW	183.14
DMXD8H1	FM	C8H10NO2P
DMXD8H1	IC	InChI=1S/C8H10NO2P/c9-8(12(10)11)6-7-4-2-1-3-5-7/h1-5,9-11H,6H2
DMXD8H1	CS	C1=CC=C(C=C1)CC(=N)P(O)O
DMXD8H1	IK	SBTPFRFIHZOOQM-UHFFFAOYSA-N
DMXD8H1	IU	(2-phenylethanimidoyl)phosphonous acid
DMXD8H1	DE	Discovery agent

DMNUO79	ID	DMNUO79
DMNUO79	DN	(1-Amino-3-methyl-butyl)-phosphinic acid
DMNUO79	HS	Investigative
DMNUO79	SN	AC1O4HVH; Phosphinic acid, P-(1-amino-3-methylbutyl)-; SCHEMBL5037193; 80744-65-6
DMNUO79	DT	Small molecular drug
DMNUO79	PC	54361028
DMNUO79	MW	149.13
DMNUO79	FM	C5H12NO2P
DMNUO79	IC	InChI=1S/C5H12NO2P/c1-4(2)3-5(6)9(7)8/h4,6-8H,3H2,1-2H3
DMNUO79	CS	CC(C)CC(=N)P(O)O
DMNUO79	IK	UMMREILHNONHFP-UHFFFAOYSA-N
DMNUO79	IU	3-methylbutanimidoylphosphonous acid
DMNUO79	DE	Discovery agent

DMJL8QZ	ID	DMJL8QZ
DMJL8QZ	DN	(1-Amino-3-methylsulfanyl-propyl)-phosphinic acid
DMJL8QZ	HS	Investigative
DMJL8QZ	SN	METHIONINE PHOSPHINATE; (1-AMINO-3-METHYLSULFANYL-PROPYL)-PHOSPHINIC ACID; MPJ; AC1O4QJ4; SCHEMBL4316253; ZINC29326788; DB04015; [(1R)-1-amino-3-methylsulfanylpropyl]-hydroxy-oxophosphanium; (R)-[(1R)-1-amino-3-(methylsulfanyl)propyl]phosphinic acid
DMJL8QZ	DT	Small molecular drug
DMJL8QZ	PC	6398483
DMJL8QZ	MW	168.18
DMJL8QZ	FM	C4H11NO2PS+
DMJL8QZ	IC	InChI=1S/C4H10NO2PS/c1-9-3-2-4(5)8(6)7/h4H,2-3,5H2,1H3/p+1/t4-/m1/s1
DMJL8QZ	CS	CSCC[C@H](N)[P+](=O)O
DMJL8QZ	IK	BSTOZABDPPHMGK-SCSAIBSYSA-O
DMJL8QZ	IU	[(1R)-1-amino-3-methylsulfanylpropyl]-hydroxy-oxophosphanium
DMJL8QZ	DE	Discovery agent

DMXD697	ID	DMXD697
DMXD697	DN	(1-Amino-3-phenyl-propyl)-phosphinic acid
DMXD697	HS	Investigative
DMXD697	SN	SCHEMBL11199485
DMXD697	DT	Small molecular drug
DMXD697	PC	91931115
DMXD697	MW	197.17
DMXD697	FM	C9H12NO2P
DMXD697	IC	InChI=1S/C9H12NO2P/c10-9(13(11)12)7-6-8-4-2-1-3-5-8/h1-5,10-12H,6-7H2
DMXD697	CS	C1=CC=C(C=C1)CCC(=N)P(O)O
DMXD697	IK	YDYGVRIQAWAHCJ-UHFFFAOYSA-N
DMXD697	IU	3-phenylpropanimidoylphosphonous acid
DMXD697	DE	Discovery agent

DMUACZF	ID	DMUACZF
DMUACZF	DN	(1-Amino-ethyl)-phosphinic acid
DMUACZF	HS	Investigative
DMUACZF	SN	1-Aminoethylphosphinic acid; AMINOETHYLPHOSPHINIC ACID; 74333-44-1; 71937-28-5; 1-Aminoethylphosphinate; (1-Aminoethyl)phosphonous acid; Aminoethylphosphinic acid [INCI]; Phosphinic acid, (1-aminoethyl)-; Phosphinic acid, P-(1-aminoethyl)-; AC1O4DZP; Phosphinic acid, (1-aminoethyl)-, (+/-)-; 1-aminoethyl phosphinic acid; SCHEMBL579981; (1-aminoethyl)phosphinic acid; (1-Aminoethyl)-phosphinic acid; CTK5D5277; TVKUNRSARHGLNB-UHFFFAOYSA-N; 1-aminoethyl-hydroxy-oxophosphanium; AKOS006273172; Phosphinic acid, (1-aminoethyl)-, (-)-
DMUACZF	DT	Small molecular drug
DMUACZF	PC	53957231
DMUACZF	MW	107.05
DMUACZF	FM	C2H6NO2P
DMUACZF	IC	InChI=1S/C2H6NO2P/c1-2(3)6(4)5/h3-5H,1H3
DMUACZF	CS	CC(=N)P(O)O
DMUACZF	IK	JIMKERQURQBVPW-UHFFFAOYSA-N
DMUACZF	IU	ethanimidoylphosphonous acid
DMUACZF	DE	Discovery agent

DMNIP7J	ID	DMNIP7J
DMNIP7J	DN	(1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine
DMNIP7J	HS	Investigative
DMNIP7J	SN	CHEMBL284485; (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine; SCHEMBL8561085; BDBM50099965
DMNIP7J	DT	Small molecular drug
DMNIP7J	PC	44279444
DMNIP7J	MW	351.4
DMNIP7J	FM	C22H17N5
DMNIP7J	IC	InChI=1S/C22H17N5/c1-2-6-16(7-3-1)14-27-21-11-10-18(12-17(21)13-25-27)26-22-19-8-4-5-9-20(19)23-15-24-22/h1-13,15H,14H2,(H,23,24,26)
DMNIP7J	CS	C1=CC=C(C=C1)CN2C3=C(C=C(C=C3)NC4=NC=NC5=CC=CC=C54)C=N2
DMNIP7J	IK	FIBNGENIDQNCFP-UHFFFAOYSA-N
DMNIP7J	IU	N-(1-benzylindazol-5-yl)quinazolin-4-amine
DMNIP7J	DE	Discovery agent

DM0SCW9	ID	DM0SCW9
DM0SCW9	DN	(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine
DM0SCW9	HS	Investigative
DM0SCW9	SN	CHEMBL287591; (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine; SCHEMBL8554934; BDBM50099967
DM0SCW9	DT	Small molecular drug
DM0SCW9	PC	44279279
DM0SCW9	MW	350.4
DM0SCW9	FM	C23H18N4
DM0SCW9	IC	InChI=1S/C23H18N4/c1-2-6-17(7-3-1)15-27-13-12-18-14-19(10-11-22(18)27)26-23-20-8-4-5-9-21(20)24-16-25-23/h1-14,16H,15H2,(H,24,25,26)
DM0SCW9	CS	C1=CC=C(C=C1)CN2C=CC3=C2C=CC(=C3)NC4=NC=NC5=CC=CC=C54
DM0SCW9	IK	HSEFNFDMTWKPLM-UHFFFAOYSA-N
DM0SCW9	IU	N-(1-benzylindol-5-yl)quinazolin-4-amine
DM0SCW9	CA	CAS 187667-74-9
DM0SCW9	DE	Discovery agent

DMWK3RO	ID	DMWK3RO
DMWK3RO	DN	(1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester
DMWK3RO	HS	Investigative
DMWK3RO	SN	Cbz-L-Phenylalaninal; 59830-60-3; (S)-Benzyl (1-oxo-3-phenylpropan-2-yl)carbamate; CHEMBL412423; AK-43912; N-Cbz-phenylalaninal; PubChem16008; N-Cbz-L-Phenylalaninal; AC1ODUQ7; (1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester; SCHEMBL630290; KS-00000FVM; DTXSID40427338; ZX-AFC000446; MolPort-009-682-951; HZDPJHOWPIVWMR-INIZCTEOSA-N; n-benzyloxycarbonyl-l-phenylalaninal; ZINC2569810; BDBM50014568; 8910AB; ANW-72305; AKOS005146049; CC-1855; KB-75975; N-((Benzyloxy)carbonyl)-L-phenylalaninal; AC-23793; DS-14328; AJ-41774; AX8120205
DMWK3RO	DT	Small molecular drug
DMWK3RO	PC	7021150
DMWK3RO	MW	283.32
DMWK3RO	FM	C17H17NO3
DMWK3RO	IC	InChI=1S/C17H17NO3/c19-12-16(11-14-7-3-1-4-8-14)18-17(20)21-13-15-9-5-2-6-10-15/h1-10,12,16H,11,13H2,(H,18,20)/t16-/m0/s1
DMWK3RO	CS	C1=CC=C(C=C1)C[C@@H](C=O)NC(=O)OCC2=CC=CC=C2
DMWK3RO	IK	HZDPJHOWPIVWMR-INIZCTEOSA-N
DMWK3RO	IU	benzyl N-[(2S)-1-oxo-3-phenylpropan-2-yl]carbamate
DMWK3RO	CA	CAS 59830-60-3
DMWK3RO	DE	Discovery agent

DMPKM9B	ID	DMPKM9B
DMPKM9B	DN	(1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine
DMPKM9B	HS	Investigative
DMPKM9B	SN	CHEMBL74544; 1H-Benzimidazol-6-amine, N-1H-imidazol-2-yl-; 185312-13-4; (1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine; BDBM50055831; AKOS027401219
DMPKM9B	DT	Small molecular drug
DMPKM9B	PC	10655607
DMPKM9B	MW	199.21
DMPKM9B	FM	C10H9N5
DMPKM9B	IC	InChI=1S/C10H9N5/c1-2-8-9(14-6-13-8)5-7(1)15-10-11-3-4-12-10/h1-6H,(H,13,14)(H2,11,12,15)
DMPKM9B	CS	C1=CC2=C(C=C1NC3=NC=CN3)NC=N2
DMPKM9B	IK	NFSIDEIKDWWMOX-UHFFFAOYSA-N
DMPKM9B	IU	N-(1H-imidazol-2-yl)-3H-benzimidazol-5-amine
DMPKM9B	DE	Discovery agent

DM4FSTL	ID	DM4FSTL
DM4FSTL	DN	(1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl
DM4FSTL	HS	Investigative
DM4FSTL	SN	CHEMBL19533; BDBM50011598; ZINC13821052; 4-Phenylamino-1H-imidazo[4,5-c]quinoline
DM4FSTL	DT	Small molecular drug
DM4FSTL	PC	14896611
DM4FSTL	MW	260.29
DM4FSTL	FM	C16H12N4
DM4FSTL	IC	InChI=1S/C16H12N4/c1-2-6-11(7-3-1)19-16-15-14(17-10-18-15)12-8-4-5-9-13(12)20-16/h1-10H,(H,17,18)(H,19,20)
DM4FSTL	CS	C1=CC=C(C=C1)NC2=NC3=CC=CC=C3C4=C2NC=N4
DM4FSTL	IK	BWQWMNKFCIJEBY-UHFFFAOYSA-N
DM4FSTL	IU	N-phenyl-3H-imidazo[4,5-c]quinolin-4-amine
DM4FSTL	DE	Discovery agent

DMRDHL2	ID	DMRDHL2
DMRDHL2	DN	(1H-Imidazol-2-yl)-quinoxalin-6-yl-amine
DMRDHL2	HS	Investigative
DMRDHL2	SN	CHEMBL74449; 6-Quinoxalinamine, N-1H-imidazol-2-yl-; (1H-Imidazol-2-yl)-quinoxalin-6-yl-amine; BDBM50055838
DMRDHL2	DT	Small molecular drug
DMRDHL2	PC	10632290
DMRDHL2	MW	211.22
DMRDHL2	FM	C11H9N5
DMRDHL2	IC	InChI=1S/C11H9N5/c1-2-9-10(13-4-3-12-9)7-8(1)16-11-14-5-6-15-11/h1-7H,(H2,14,15,16)
DMRDHL2	CS	C1=CC2=NC=CN=C2C=C1NC3=NC=CN3
DMRDHL2	IK	CDFWKVORAWOKDO-UHFFFAOYSA-N
DMRDHL2	IU	N-(1H-imidazol-2-yl)quinoxalin-6-amine
DMRDHL2	DE	Discovery agent

DM21CXZ	ID	DM21CXZ
DM21CXZ	DN	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone
DM21CXZ	HS	Investigative
DM21CXZ	SN	CHEMBL7296; Bis(1H-2-indolyl)methanone 11; AC1NS9BZ; BDBM6573; ZINC8571; SCHEMBL6865103; 5-Methoxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-5-methoxy-1H-indole; 1H-indol-2-yl-(5-methoxy-1H-indol-2-yl)methanone
DM21CXZ	DT	Small molecular drug
DM21CXZ	PC	5330527
DM21CXZ	MW	290.3
DM21CXZ	FM	C18H14N2O2
DM21CXZ	IC	InChI=1S/C18H14N2O2/c1-22-13-6-7-15-12(8-13)10-17(20-15)18(21)16-9-11-4-2-3-5-14(11)19-16/h2-10,19-20H,1H3
DM21CXZ	CS	COC1=CC2=C(C=C1)NC(=C2)C(=O)C3=CC4=CC=CC=C4N3
DM21CXZ	IK	QTIQVLAVCXXZPS-UHFFFAOYSA-N
DM21CXZ	IU	1H-indol-2-yl-(5-methoxy-1H-indol-2-yl)methanone
DM21CXZ	DE	Discovery agent

DM94XJ2	ID	DM94XJ2
DM94XJ2	DN	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone
DM94XJ2	HS	Investigative
DM94XJ2	SN	CHEMBL210425; (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone
DM94XJ2	DT	Small molecular drug
DM94XJ2	PC	44411967
DM94XJ2	MW	352.4
DM94XJ2	FM	C23H16N2O2
DM94XJ2	IC	InChI=1S/C23H16N2O2/c26-23(21-13-15-6-4-5-9-19(15)24-21)22-14-16-12-18(10-11-20(16)25-22)27-17-7-2-1-3-8-17/h1-14,24-25H
DM94XJ2	CS	C1=CC=C(C=C1)OC2=CC3=C(C=C2)NC(=C3)C(=O)C4=CC5=CC=CC=C5N4
DM94XJ2	IK	XSKBJPGCRXDUEV-UHFFFAOYSA-N
DM94XJ2	IU	1H-indol-2-yl-(5-phenoxy-1H-indol-2-yl)methanone
DM94XJ2	DE	Discovery agent

DM7KDNM	ID	DM7KDNM
DM7KDNM	DN	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone
DM7KDNM	HS	Investigative
DM7KDNM	SN	CHEMBL7602; Bis(1H-2-indolyl)methanone 12; AC1NS9C2; SCHEMBL6864570; BDBM6574; ZINC13472534; 6-Methoxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-6-methoxy-1H-indole; 1H-indol-2-yl-(6-methoxy-1H-indol-2-yl)methanone
DM7KDNM	DT	Small molecular drug
DM7KDNM	PC	5330528
DM7KDNM	MW	290.3
DM7KDNM	FM	C18H14N2O2
DM7KDNM	IC	InChI=1S/C18H14N2O2/c1-22-13-7-6-12-9-17(20-15(12)10-13)18(21)16-8-11-4-2-3-5-14(11)19-16/h2-10,19-20H,1H3
DM7KDNM	CS	COC1=CC2=C(C=C1)C=C(N2)C(=O)C3=CC4=CC=CC=C4N3
DM7KDNM	IK	RSMLCEQJLGXMPQ-UHFFFAOYSA-N
DM7KDNM	IU	1H-indol-2-yl-(6-methoxy-1H-indol-2-yl)methanone
DM7KDNM	DE	Discovery agent

DMW15DS	ID	DMW15DS
DMW15DS	DN	(1H-indol-2-yl)(piperazin-1-yl)methanone
DMW15DS	HS	Investigative
DMW15DS	SN	2-(piperazin-1-ylcarbonyl)-1H-indole; 136818-95-6; CHEMBL129660; 1H-indol-2-yl-1-piperazinyl-Methanone; 1H-indol-2-yl(piperazin-1-yl)methanone; 2-(piperazine-1-carbonyl)-1H-indole; (1H-Indol-2-yl)-piperazin-1-yl-methanone; piperazoylindole; AC1LJDZ7; (1H-indol-2-yl)(piperazin-1-yl)methanone; Oprea1_711133; SCHEMBL2679610; DTXSID30358889; MolPort-002-566-226; FIVCRRVYLAXYFC-UHFFFAOYSA-N; ZINC509902; ALBB-016237; STL484224; BDBM50133002; 4012AD; AKOS000210389; MCULE-2536499366; NS-02944; Piperazine, 1-(1H-indol-2-ylcarbonyl)-
DMW15DS	DT	Small molecular drug
DMW15DS	PC	921599
DMW15DS	MW	229.28
DMW15DS	FM	C13H15N3O
DMW15DS	IC	InChI=1S/C13H15N3O/c17-13(16-7-5-14-6-8-16)12-9-10-3-1-2-4-11(10)15-12/h1-4,9,14-15H,5-8H2
DMW15DS	CS	C1CN(CCN1)C(=O)C2=CC3=CC=CC=C3N2
DMW15DS	IK	FIVCRRVYLAXYFC-UHFFFAOYSA-N
DMW15DS	IU	1H-indol-2-yl(piperazin-1-yl)methanone
DMW15DS	CA	CAS 136818-95-6
DMW15DS	DE	Discovery agent

DMHEYOK	ID	DMHEYOK
DMHEYOK	DN	(1'H-Phenothiazin-1'-yl)(piperidin-1-yl)methanone
DMHEYOK	HS	Investigative
DMHEYOK	SN	CHEMBL589252; Phenothiazin-10-yl-piperidin-1-yl-methanone; AC1LE3IL; ChemDiv3_004237; Oprea1_668518; ZINC91249; MolPort-001-995-166; HMS1485A13; STK004206; BDBM50308415; AKOS000643159; CCG-113845; MCULE-9139922844; IDI1_022147; BAS 04087808; phenothiazin-10-yl(piperidin-1-yl)methanone; SR-01000506180; 10H-phenothiazin-10-yl(piperidin-1-yl)methanone; SR-01000506180-1
DMHEYOK	DT	Small molecular drug
DMHEYOK	PC	705775
DMHEYOK	MW	310.4
DMHEYOK	FM	C18H18N2OS
DMHEYOK	IC	InChI=1S/C18H18N2OS/c21-18(19-12-6-1-7-13-19)20-14-8-2-4-10-16(14)22-17-11-5-3-9-15(17)20/h2-5,8-11H,1,6-7,12-13H2
DMHEYOK	CS	C1CCN(CC1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMHEYOK	IK	ZYAXTAFPNAMCKA-UHFFFAOYSA-N
DMHEYOK	IU	phenothiazin-10-yl(piperidin-1-yl)methanone
DMHEYOK	DE	Discovery agent

DMACN68	ID	DMACN68
DMACN68	DN	(1H-pyrazol-1-yl)(o-tolyl)methanone
DMACN68	HS	Investigative
DMACN68	SN	AC1LEF7F; Methanone, (2-methylphenyl)-1H-pyrazol-1-yl-; N-Benzoylpyrazole deriv., 26; SCHEMBL5091107; CHEMBL243419; 2-methylphenyl pyrazolyl ketone; ZINC52093; BDBM23718; MolPort-001-495-866; STK458861; AKOS003267448; MCULE-5548346973; (2-methylphenyl)-pyrazol-1-ylmethanone; ST073761; 312317-26-3; 1-[(2-methylphenyl)carbonyl]-1H-pyrazole; (2-methylphenyl)(1H-pyrazol-1-yl)methanone; SR-01000520970; SR-01000520970-1
DMACN68	DT	Small molecular drug
DMACN68	PC	685230
DMACN68	MW	186.21
DMACN68	FM	C11H10N2O
DMACN68	IC	InChI=1S/C11H10N2O/c1-9-5-2-3-6-10(9)11(14)13-8-4-7-12-13/h2-8H,1H3
DMACN68	CS	CC1=CC=CC=C1C(=O)N2C=CC=N2
DMACN68	IK	RYSRFZOAAPABLM-UHFFFAOYSA-N
DMACN68	IU	(2-methylphenyl)-pyrazol-1-ylmethanone
DMACN68	DE	Discovery agent

DM5L8WX	ID	DM5L8WX
DM5L8WX	DN	(1-hydroxy-1-phosphono-heptyl)-phosphonic acid
DM5L8WX	HS	Investigative
DM5L8WX	SN	(1-Hydroxyheptane-1,1-Diyl)bis(Phosphonic Acid); CHEMBL55264; Phosphonic acid, (1-hydroxyheptylidene)bis-; (1-hydroxy-1-phosphonoheptyl)phosphonic acid; bisphosphonate, 10; AC1NQOTY; SCHEMBL10686529; BDBM25298; 1-Hydroxyheptylidenebisphosphonic acid; AKOS028110532; DB06830; 56375-74-7; 1-hydroxy-1-phosphonoheptylphosphonic acid; (1-hydroxy-1-phosphono-heptyl)phosphonic acid
DM5L8WX	DT	Small molecular drug
DM5L8WX	PC	5276520
DM5L8WX	MW	276.16
DM5L8WX	FM	C7H18O7P2
DM5L8WX	IC	InChI=1S/C7H18O7P2/c1-2-3-4-5-6-7(8,15(9,10)11)16(12,13)14/h8H,2-6H2,1H3,(H2,9,10,11)(H2,12,13,14)
DM5L8WX	CS	CCCCCCC(O)(P(=O)(O)O)P(=O)(O)O
DM5L8WX	IK	IJEGNOYPWRBKAE-UHFFFAOYSA-N
DM5L8WX	IU	(1-hydroxy-1-phosphonoheptyl)phosphonic acid
DM5L8WX	DE	Discovery agent

DMXY9R5	ID	DMXY9R5
DMXY9R5	DN	(1-Phenethyl-piperidin-4-yl)-phenyl-methanone
DMXY9R5	HS	Investigative
DMXY9R5	SN	CHEMBL19589; (1-Phenethyl-piperidin-4-yl)-phenyl-methanone; SCHEMBL7839803; GEFOLRNTTIQKBZ-UHFFFAOYSA-N; ZINC13740924; BDBM50034203; Phenyl(1-phenethyl-4-piperidinyl) ketone; phenyl-[1-(2-phenylethyl)-4-piperidyl]-ketone
DMXY9R5	DT	Small molecular drug
DMXY9R5	PC	10379653
DMXY9R5	MW	293.4
DMXY9R5	FM	C20H23NO
DMXY9R5	IC	InChI=1S/C20H23NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19H,11-16H2
DMXY9R5	CS	C1CN(CCC1C(=O)C2=CC=CC=C2)CCC3=CC=CC=C3
DMXY9R5	IK	GEFOLRNTTIQKBZ-UHFFFAOYSA-N
DMXY9R5	IU	phenyl-[1-(2-phenylethyl)piperidin-4-yl]methanone
DMXY9R5	DE	Discovery agent

DM0TUKZ	ID	DM0TUKZ
DM0TUKZ	DN	(1-phenylcyclopentyl)methanamine
DM0TUKZ	HS	Investigative
DM0TUKZ	SN	(1-Phenylcyclopentyl)methanamine; 17511-89-6; 1-Phenylcyclopentanemethylamine; 1-(1-PHENYLCYCLOPENTYL)METHANAMINE; (1-phenylcyclopentyl)methylamine; 1-(1-phenylcyclopentyl)methylamine; 1-METHYLAMINE-1-BENZYL-CYCLOPENTANE; 1-Phenylcyclopentanemethanamine; C-(1-Phenyl-cyclopentyl)-methylamine; Cyclopentanemethylamine, 1-phenyl-; BRN 2936636; Cyclopentanemethanamine,1-phenyl-; CHEMBL382127; CHEBI:39505; Cyclopentanemethanamine, 1-phenyl-; (phenylcyclopentyl)methylamine; (1-Phenylcyclopentyl)methylamine hydrochloride; 2bua
DM0TUKZ	DT	Small molecular drug
DM0TUKZ	PC	205131
DM0TUKZ	MW	175.27
DM0TUKZ	FM	C12H17N
DM0TUKZ	IC	InChI=1S/C12H17N/c13-10-12(8-4-5-9-12)11-6-2-1-3-7-11/h1-3,6-7H,4-5,8-10,13H2
DM0TUKZ	CS	C1CCC(C1)(CN)C2=CC=CC=C2
DM0TUKZ	IK	SJWOFBVBNFLWLP-UHFFFAOYSA-N
DM0TUKZ	IU	(1-phenylcyclopentyl)methanamine
DM0TUKZ	CA	CAS 17511-89-6
DM0TUKZ	CB	CHEBI:39505
DM0TUKZ	DE	Discovery agent

DMECH9W	ID	DMECH9W
DMECH9W	DN	(1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine
DMECH9W	HS	Investigative
DMECH9W	SN	CHEMBL72703; AC1LTN5B; (1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine; cid_5051334; ZINC1773076; BDBM50116318; 2-phenyl-N-[(1S)-1-phenylethyl]quinazolin-4-amine
DMECH9W	DT	Small molecular drug
DMECH9W	PC	1564646
DMECH9W	MW	325.4
DMECH9W	FM	C22H19N3
DMECH9W	IC	InChI=1S/C22H19N3/c1-16(17-10-4-2-5-11-17)23-22-19-14-8-9-15-20(19)24-21(25-22)18-12-6-3-7-13-18/h2-16H,1H3,(H,23,24,25)/t16-/m1/s1
DMECH9W	CS	C[C@H](C1=CC=CC=C1)NC2=NC(=NC3=CC=CC=C32)C4=CC=CC=C4
DMECH9W	IK	AEXWSMVZORVWML-MRXNPFEDSA-N
DMECH9W	IU	2-phenyl-N-[(1R)-1-phenylethyl]quinazolin-4-amine
DMECH9W	DE	Discovery agent

DMZU2VG	ID	DMZU2VG
DMZU2VG	DN	(1-Phenyl-propyl)-(9-phenyl-9H-purin-6-yl)-amine
DMZU2VG	HS	Investigative
DMZU2VG	SN	CHEMBL96014; (1-Phenyl-propyl)-(9-phenyl-9H-purin-6-yl)-amine
DMZU2VG	DT	Small molecular drug
DMZU2VG	PC	44329715
DMZU2VG	MW	329.4
DMZU2VG	FM	C20H19N5
DMZU2VG	IC	InChI=1S/C20H19N5/c1-2-17(15-9-5-3-6-10-15)24-19-18-20(22-13-21-19)25(14-23-18)16-11-7-4-8-12-16/h3-14,17H,2H2,1H3,(H,21,22,24)/t17-/m1/s1
DMZU2VG	CS	CC[C@H](C1=CC=CC=C1)NC2=C3C(=NC=N2)N(C=N3)C4=CC=CC=C4
DMZU2VG	IK	KOEVJHYBDHDPOK-QGZVFWFLSA-N
DMZU2VG	IU	9-phenyl-N-[(1R)-1-phenylpropyl]purin-6-amine
DMZU2VG	DE	Discovery agent

DMVE34H	ID	DMVE34H
DMVE34H	DN	(1r)-1,2,2-trimethylpropyl (r)-methylphosphinate
DMVE34H	HS	Investigative
DMVE34H	SN	GD7
DMVE34H	DT	Small molecular drug
DMVE34H	PC	52947808
DMVE34H	MW	163.17
DMVE34H	FM	C7H16O2P+
DMVE34H	IC	InChI=1S/C7H16O2P/c1-6(7(2,3)4)9-10(5)8/h6H,1-5H3/q+1/t6-/m1/s1
DMVE34H	CS	C[C@H](C(C)(C)C)O[P+](=O)C
DMVE34H	IK	AYQIEWWYFGQKPK-ZCFIWIBFSA-N
DMVE34H	IU	[(2R)-3,3-dimethylbutan-2-yl]oxy-methyl-oxophosphanium
DMVE34H	DE	Discovery agent

DMCVKTB	ID	DMCVKTB
DMCVKTB	DN	(1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE
DMCVKTB	HS	Investigative
DMCVKTB	SN	GD8
DMCVKTB	DT	Small molecular drug
DMCVKTB	PC	16058619
DMCVKTB	MW	180.18
DMCVKTB	FM	C7H17O3P
DMCVKTB	IC	InChI=1S/C7H17O3P/c1-6(7(2,3)4)10-11(5,8)9/h6H,1-5H3,(H,8,9)/t6-/m1/s1
DMCVKTB	CS	C[C@H](C(C)(C)C)OP(=O)(C)O
DMCVKTB	IK	BLALDUPQYCGKAG-ZCFIWIBFSA-N
DMCVKTB	IU	[(2R)-3,3-dimethylbutan-2-yl]oxy-methylphosphinic acid
DMCVKTB	DE	Discovery agent

DMGAJYW	ID	DMGAJYW
DMGAJYW	DN	(1R)-MENTHYL HEXYL PHOSPHONATE GROUP
DMGAJYW	HS	Investigative
DMGAJYW	SN	(1R)-MENTHYL HEXYL PHOSPHONATE GROUP; AC1L9KBM; DB08200; hexyl[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]oxyphosphinic acid; hexyl-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxyphosphinic acid; (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl hydrogen (S)-hexylphosphonate
DMGAJYW	DT	Small molecular drug
DMGAJYW	PC	446980
DMGAJYW	MW	304.4
DMGAJYW	FM	C16H33O3P
DMGAJYW	IC	InChI=1S/C16H33O3P/c1-5-6-7-8-11-20(17,18)19-16-12-14(4)9-10-15(16)13(2)3/h13-16H,5-12H2,1-4H3,(H,17,18)/t14-,15+,16-/m1/s1
DMGAJYW	CS	CCCCCCP(=O)(O)O[C@@H]1C[C@@H](CC[C@H]1C(C)C)C
DMGAJYW	IK	WAVIZOVSJOXCKT-OWCLPIDISA-N
DMGAJYW	IU	hexyl-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxyphosphinic acid
DMGAJYW	DE	Discovery agent

DM18E9D	ID	DM18E9D
DM18E9D	DN	(1R,2R)-1,2-diphenylethane-1,2-diamine
DM18E9D	HS	Investigative
DM18E9D	SN	35132-20-8; (1R,2R)-(+)-1,2-Diphenylethylenediamine; (1R,2R)-rel-1,2-Diphenylethane-1,2-diamine; (1R,2R)-1,2-Diphenylethylenediamine; 16635-95-3; (+)-1,2-diphenylethylenediamine; MFCD00082769; (+)-STILBENEDIAMINE; (R,R)-DPEN; (r,r)-(+)-1,2-diphenylethylenediamine; CHEMBL381340; (1r,2r)-1,2-diphenyl-ethane-1,2-diamine; 1,2-Ethanediamine, 1,2-diphenyl-, (1R,2R)-; (1R,2R)-(+)-1,2-Diphenyl-1,2-ethane diam
DM18E9D	DT	Small molecular drug
DM18E9D	PC	2724998
DM18E9D	MW	212.29
DM18E9D	FM	C14H16N2
DM18E9D	IC	InChI=1S/C14H16N2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13-14H,15-16H2/t13-,14-/m1/s1
DM18E9D	CS	C1=CC=C(C=C1)[C@H]([C@@H](C2=CC=CC=C2)N)N
DM18E9D	IK	PONXTPCRRASWKW-ZIAGYGMSSA-N
DM18E9D	IU	(1R,2R)-1,2-diphenylethane-1,2-diamine
DM18E9D	CA	CAS 35132-20-8
DM18E9D	DE	Discovery agent

DM5ROS1	ID	DM5ROS1
DM5ROS1	DN	(1R,2R)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine
DM5ROS1	HS	Investigative
DM5ROS1	SN	CHEMBL40378; (1R,2R)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine; BDBM50034706; AKOS006360607
DM5ROS1	DT	Small molecular drug
DM5ROS1	PC	10374533
DM5ROS1	MW	139.2
DM5ROS1	FM	C7H13N3
DM5ROS1	IC	InChI=1S/C7H13N3/c1-5(6(2)8)7-3-9-4-10-7/h3-6H,8H2,1-2H3,(H,9,10)/t5-,6-/m1/s1
DM5ROS1	CS	C[C@@H](C1=CN=CN1)[C@@H](C)N
DM5ROS1	IK	QQTWSOMOTYJIQP-PHDIDXHHSA-N
DM5ROS1	IU	(2R,3R)-3-(1H-imidazol-5-yl)butan-2-amine
DM5ROS1	DE	Discovery agent

DMYLPV1	ID	DMYLPV1
DMYLPV1	DN	(1R,2R)-N-Arachidonoylcyclopropanolamide
DMYLPV1	HS	Investigative
DMYLPV1	SN	Rac-trans N-arachidonoylcyclopropanolamide
DMYLPV1	DT	Small molecular drug
DMYLPV1	PC	42617984
DMYLPV1	MW	359.5
DMYLPV1	FM	C23H37NO2
DMYLPV1	IC	InChI=1S/C23H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)24-21-20-22(21)25/h6-7,9-10,12-13,15-16,21-22,25H,2-5,8,11,14,17-20H2,1H3,(H,24,26)/b7-6-,10-9-,13-12-,16-15-/t21-,22-/m1/s1
DMYLPV1	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N[C@@H]1C[C@H]1O
DMYLPV1	IK	LZHCSJBKBARIFQ-OXAAUTCPSA-N
DMYLPV1	IU	(5Z,8Z,11Z,14Z)-N-[(1R,2R)-2-hydroxycyclopropyl]icosa-5,8,11,14-tetraenamide
DMYLPV1	DE	Discovery agent

DM28D9E	ID	DM28D9E
DM28D9E	DN	(1R,2S)-1,2-diphenylethane-1,2-diamine
DM28D9E	HS	Investigative
DM28D9E	SN	meso-1,2-Diphenylethylenediamine; 951-87-1; CHEMBL206743; (1S,2R)-1,2-diphenylethane-1,2-diamine; Racemic stilbenediamine; AC1OC2I9; SCHEMBL2067094; MolPort-002-746-466; ZINC6581845; STK689613; BDBM50178427; BBL104274; AKOS005602166; MCULE-2915779897; meso-1,2-Diphenylethylenediamine, 98%; SC-21360; ST084935; AJ-94609; AS-11936; AB1010174; Z3396
DM28D9E	DT	Small molecular drug
DM28D9E	PC	6931234
DM28D9E	MW	212.29
DM28D9E	FM	C14H16N2
DM28D9E	IC	InChI=1S/C14H16N2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13-14H,15-16H2/t13-,14+
DM28D9E	CS	C1=CC=C(C=C1)[C@H]([C@H](C2=CC=CC=C2)N)N
DM28D9E	IK	PONXTPCRRASWKW-OKILXGFUSA-N
DM28D9E	IU	(1R,2S)-1,2-diphenylethane-1,2-diamine
DM28D9E	DE	Discovery agent

DMZ3DMX	ID	DMZ3DMX
DMZ3DMX	DN	(1R,2S)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine
DMZ3DMX	HS	Investigative
DMZ3DMX	SN	CHEMBL277341; (1R,2S)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine; BDBM50034711
DMZ3DMX	DT	Small molecular drug
DMZ3DMX	PC	9972056
DMZ3DMX	MW	139.2
DMZ3DMX	FM	C7H13N3
DMZ3DMX	IC	InChI=1S/C7H13N3/c1-5(6(2)8)7-3-9-4-10-7/h3-6H,8H2,1-2H3,(H,9,10)/t5-,6+/m0/s1
DMZ3DMX	CS	C[C@H](C1=CN=CN1)[C@@H](C)N
DMZ3DMX	IK	QQTWSOMOTYJIQP-NTSWFWBYSA-N
DMZ3DMX	IU	(2R,3S)-3-(1H-imidazol-5-yl)butan-2-amine
DMZ3DMX	DE	Discovery agent

DM39AFU	ID	DM39AFU
DM39AFU	DN	(1R,2S)-N-Arachidonoylcyclopropanolamide
DM39AFU	HS	Investigative
DM39AFU	SN	(1R,2S)-N-Arachidonoylcyclopropanolamide; cyclopropanolamide, 14a; CHEMBL485368
DM39AFU	DT	Small molecular drug
DM39AFU	PC	42617989
DM39AFU	MW	359.5
DM39AFU	FM	C23H37NO2
DM39AFU	IC	InChI=1S/C23H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)24-21-20-22(21)25/h6-7,9-10,12-13,15-16,21-22,25H,2-5,8,11,14,17-20H2,1H3,(H,24,26)/b7-6-,10-9-,13-12-,16-15-/t21-,22+/m0/s1
DM39AFU	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N[C@H]1C[C@H]1O
DM39AFU	IK	LZHCSJBKBARIFQ-MTVZMXCXSA-N
DM39AFU	IU	(5Z,8Z,11Z,14Z)-N-[(1S,2R)-2-hydroxycyclopropyl]icosa-5,8,11,14-tetraenamide
DM39AFU	DE	Discovery agent

DMITW5P	ID	DMITW5P
DMITW5P	DN	(1R,2S)-N-Oleoylcyclopropanolamide
DMITW5P	HS	Investigative
DMITW5P	SN	(1R,2S)-N-Oleoylcyclopropanolamide
DMITW5P	DT	Small molecular drug
DMITW5P	PC	44591632
DMITW5P	MW	311.5
DMITW5P	FM	C19H37NO2
DMITW5P	IC	InChI=1S/C19H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(22)20-17-16-18(17)21/h17-18,21H,2-16H2,1H3,(H,20,22)/t17-,18+/m0/s1
DMITW5P	CS	CCCCCCCCCCCCCCCC(=O)N[C@H]1C[C@H]1O
DMITW5P	IK	LIBNBUULGCFJNR-ZWKOTPCHSA-N
DMITW5P	IU	N-[(1S,2R)-2-hydroxycyclopropyl]hexadecanamide
DMITW5P	DE	Discovery agent

DMUJ7ZE	ID	DMUJ7ZE
DMUJ7ZE	DN	(1R,5R)-30-OXO-19-OXA-2,6,10,12-TETRAAZAHEXACYCLO[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]TRIACONTA-8,10,14(29),15,17,20(28),21,23(27)-OCTAENE-17-CARBONITRILE (STRUCTURAL MIX)
DMUJ7ZE	HS	Investigative
DMUJ7ZE	SN	CHEMBL525369; BDBM14023; (1R,5R)-30-OXO-19-OXA-2,6,10,12-TETRAAZAHEXACYCLO[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]TRIACONTA-8,10,14(29),15,17,20(28),21,23(27)-OCTAENE-17-CARBONITRILE (STRUCTURAL MIX); Macrocyclic 3-Aminopyrrolidinone analog 83
DMUJ7ZE	DT	Small molecular drug
DMUJ7ZE	PC	11761968
DMUJ7ZE	MW	439.5
DMUJ7ZE	FM	C26H25N5O2
DMUJ7ZE	IC	InChI=1S/C26H25N5O2/c27-12-19-5-4-17-10-25(19)33-21-7-6-18-2-1-3-24(22(18)11-21)31-9-8-23(26(31)32)29-14-20-13-28-16-30(20)15-17/h4-7,10-11,13,16,23-24,29H,1-3,8-9,14-15H2/t23-,24-/m1/s1
DMUJ7ZE	CS	C1C[C@@H]2C3=C(C1)C=CC(=C3)OC4=C(C=CC(=C4)CN5C=NC=C5CN[C@@H]6CCN2C6=O)C#N
DMUJ7ZE	IK	VWNBOOIWICWEPL-DNQXCXABSA-N
DMUJ7ZE	IU	(1R,5R)-30-oxo-19-oxa-2,6,10,12-tetrazahexacyclo[18.6.2.12,5.114,18.08,12.023,27]triaconta-8,10,14(29),15,17,20(28),21,23(27)-octaene-17-carbonitrile
DMUJ7ZE	DE	Discovery agent

DMJ2WD5	ID	DMJ2WD5
DMJ2WD5	DN	(1S)-MENTHYL HEXYL PHOSPHONATE GROUP
DMJ2WD5	HS	Investigative
DMJ2WD5	SN	(1S)-MENTHYL HEXYL PHOSPHONATE GROUP; AC1L9KBO; DB08201; hexyl[(1S,2R,5S)-2-isopropyl-5-methylcyclohexyl]oxyphosphinic acid; hexyl-[(1S,2R,5S)-5-methyl-2-propan-2-ylcyclohexyl]oxyphosphinic acid; (1S,2R,5S)-5-methyl-2-(1-methylethyl)cyclohexyl hydrogen (S)-hexylphosphonate
DMJ2WD5	DT	Small molecular drug
DMJ2WD5	PC	446981
DMJ2WD5	MW	304.4
DMJ2WD5	FM	C16H33O3P
DMJ2WD5	IC	InChI=1S/C16H33O3P/c1-5-6-7-8-11-20(17,18)19-16-12-14(4)9-10-15(16)13(2)3/h13-16H,5-12H2,1-4H3,(H,17,18)/t14-,15+,16-/m0/s1
DMJ2WD5	CS	CCCCCCP(=O)(O)O[C@H]1C[C@H](CC[C@@H]1C(C)C)C
DMJ2WD5	IK	WAVIZOVSJOXCKT-XHSDSOJGSA-N
DMJ2WD5	IU	hexyl-[(1S,2R,5S)-5-methyl-2-propan-2-ylcyclohexyl]oxyphosphinic acid
DMJ2WD5	DE	Discovery agent

DMZCS2K	ID	DMZCS2K
DMZCS2K	DN	(1S,2S)-2-(1H-Imidazol-4-yl)-cyclopentylamine
DMZCS2K	HS	Investigative
DMZCS2K	SN	CHEMBL289383; (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopentylamine
DMZCS2K	DT	Small molecular drug
DMZCS2K	PC	10240978
DMZCS2K	MW	151.21
DMZCS2K	FM	C8H13N3
DMZCS2K	IC	InChI=1S/C8H13N3/c9-7-3-1-2-6(7)8-4-10-5-11-8/h4-7H,1-3,9H2,(H,10,11)/t6-,7-/m0/s1
DMZCS2K	CS	C1C[C@@H]([C@H](C1)N)C2=CN=CN2
DMZCS2K	IK	MUHUWRJWVGDFJX-BQBZGAKWSA-N
DMZCS2K	IU	(1S,2S)-2-(1H-imidazol-5-yl)cyclopentan-1-amine
DMZCS2K	DE	Discovery agent

DMKA0ON	ID	DMKA0ON
DMKA0ON	DN	(1S,2S)-N-Arachidonoylcyclopropanolamide
DMKA0ON	HS	Investigative
DMKA0ON	SN	(1S,2S)-N-Arachidonoylcyclopropanolamide; cyclopropanolamide, 11a; CHEMBL485369
DMKA0ON	DT	Small molecular drug
DMKA0ON	PC	42617990
DMKA0ON	MW	359.5
DMKA0ON	FM	C23H37NO2
DMKA0ON	IC	InChI=1S/C23H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)24-21-20-22(21)25/h6-7,9-10,12-13,15-16,21-22,25H,2-5,8,11,14,17-20H2,1H3,(H,24,26)/b7-6-,10-9-,13-12-,16-15-/t21-,22-/m0/s1
DMKA0ON	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N[C@H]1C[C@@H]1O
DMKA0ON	IK	LZHCSJBKBARIFQ-NILUWUTCSA-N
DMKA0ON	IU	(5Z,8Z,11Z,14Z)-N-[(1S,2S)-2-hydroxycyclopropyl]icosa-5,8,11,14-tetraenamide
DMKA0ON	DE	Discovery agent

DMIV2OY	ID	DMIV2OY
DMIV2OY	DN	(1S,2S)-N-Oleoylcyclopropanolamide
DMIV2OY	HS	Investigative
DMIV2OY	SN	(1S,2S)-N-Oleoylcyclopropanolamide
DMIV2OY	DT	Small molecular drug
DMIV2OY	PC	44591633
DMIV2OY	MW	311.5
DMIV2OY	FM	C19H37NO2
DMIV2OY	IC	InChI=1S/C19H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(22)20-17-16-18(17)21/h17-18,21H,2-16H2,1H3,(H,20,22)/t17-,18-/m0/s1
DMIV2OY	CS	CCCCCCCCCCCCCCCC(=O)N[C@H]1C[C@@H]1O
DMIV2OY	IK	LIBNBUULGCFJNR-ROUUACIJSA-N
DMIV2OY	IU	N-[(1S,2S)-2-hydroxycyclopropyl]hexadecanamide
DMIV2OY	DE	Discovery agent

DM5DOAF	ID	DM5DOAF
DM5DOAF	DN	(1S,3R)-ACPD
DM5DOAF	HS	Investigative
DM5DOAF	SN	(1S,3R)-1-ACPD; trans-ACPD; (1S,3S)-ACPD; 1S,3R-ACPD
DM5DOAF	DT	Small molecular drug
DM5DOAF	PC	104766
DM5DOAF	MW	173.17
DM5DOAF	FM	C7H11NO4
DM5DOAF	IC	InChI=1S/C7H11NO4/c8-7(6(11)12)2-1-4(3-7)5(9)10/h4H,1-3,8H2,(H,9,10)(H,11,12)/t4-,7+/m1/s1
DM5DOAF	CS	C1C[C@](C[C@@H]1C(=O)O)(C(=O)O)N
DM5DOAF	IK	YFYNOWXBIBKGHB-FBCQKBJTSA-N
DM5DOAF	IU	(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid
DM5DOAF	CA	CAS 111900-32-4
DM5DOAF	DE	Discovery agent

DMYOTMP	ID	DMYOTMP
DMYOTMP	DN	(2-(2-chlorophenyl)pyridin-3-yl)methanamine
DMYOTMP	HS	Investigative
DMYOTMP	SN	CHEMBL378152; (2-(2-chlorophenyl)pyridin-3-yl)methanamine
DMYOTMP	DT	Small molecular drug
DMYOTMP	PC	44408767
DMYOTMP	MW	218.68
DMYOTMP	FM	C12H11ClN2
DMYOTMP	IC	InChI=1S/C12H11ClN2/c13-11-6-2-1-5-10(11)12-9(8-14)4-3-7-15-12/h1-7H,8,14H2
DMYOTMP	CS	C1=CC=C(C(=C1)C2=C(C=CC=N2)CN)Cl
DMYOTMP	IK	FTTHUIFIPJIQEI-UHFFFAOYSA-N
DMYOTMP	IU	[2-(2-chlorophenyl)pyridin-3-yl]methanamine
DMYOTMP	CA	CAS 876170-47-7
DMYOTMP	DE	Discovery agent

DMA15WU	ID	DMA15WU
DMA15WU	DN	(2-(4-chlorobenzyloxy)-5-bromophenyl)methanamine
DMA15WU	HS	Investigative
DMA15WU	SN	CHEMBL233845; (2-(4-chlorobenzyloxy)-5-bromophenyl)methanamine; SCHEMBL5699914; [5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methanamine; BDBM50205765; AKOS010099713; Benzenemethanamine, 5-bromo-2-[(4-chlorophenyl)methoxy]-
DMA15WU	DT	Small molecular drug
DMA15WU	PC	11267381
DMA15WU	MW	326.61
DMA15WU	FM	C14H13BrClNO
DMA15WU	IC	InChI=1S/C14H13BrClNO/c15-12-3-6-14(11(7-12)8-17)18-9-10-1-4-13(16)5-2-10/h1-7H,8-9,17H2
DMA15WU	CS	C1=CC(=CC=C1COC2=C(C=C(C=C2)Br)CN)Cl
DMA15WU	IK	YKPADUDRSOXMQB-UHFFFAOYSA-N
DMA15WU	IU	[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methanamine
DMA15WU	DE	Discovery agent

DM2ATRC	ID	DM2ATRC
DM2ATRC	DN	(2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate
DM2ATRC	HS	Investigative
DM2ATRC	SN	CHEMBL172215; (2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate; 103596-21-0; Sulfamic acid, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester; ACMC-20m6fs; SCHEMBL18063439; CTK0G6911; DTXSID50545931; BDBM50188393; Sulfamic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester
DM2ATRC	DT	Small molecular drug
DM2ATRC	PC	13654029
DM2ATRC	MW	211.24
DM2ATRC	FM	C6H13NO5S
DM2ATRC	IC	InChI=1S/C6H13NO5S/c1-6(2)10-3-5(12-6)4-11-13(7,8)9/h5H,3-4H2,1-2H3,(H2,7,8,9)
DM2ATRC	CS	CC1(OCC(O1)COS(=O)(=O)N)C
DM2ATRC	IK	QFFBTRPNKKXQCZ-UHFFFAOYSA-N
DM2ATRC	IU	(2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate
DM2ATRC	CA	CAS 103596-21-0
DM2ATRC	DE	Discovery agent

DMNGEFS	ID	DMNGEFS
DMNGEFS	DN	(2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine
DMNGEFS	HS	Investigative
DMNGEFS	SN	CHEMBL175596; 872872-12-3; (2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; SCHEMBL4045943; CTK3C4931; DTXSID20468426; BDBM50179205; AKOS030605024; Indeno[1,2-c]pyrazol-3-amine, 1,4-dihydro-N-phenyl-
DMNGEFS	DT	Small molecular drug
DMNGEFS	PC	11550535
DMNGEFS	MW	247.29
DMNGEFS	FM	C16H13N3
DMNGEFS	IC	InChI=1S/C16H13N3/c1-2-7-12(8-3-1)17-16-14-10-11-6-4-5-9-13(11)15(14)18-19-16/h1-9H,10H2,(H2,17,18,19)
DMNGEFS	CS	C1C2=CC=CC=C2C3=C1C(=NN3)NC4=CC=CC=C4
DMNGEFS	IK	HXUODZKNCJWKGP-UHFFFAOYSA-N
DMNGEFS	IU	N-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-3-amine
DMNGEFS	CA	CAS 872872-12-3
DMNGEFS	DE	Discovery agent

DM97GFB	ID	DM97GFB
DM97GFB	DN	(2,5-Diphenyl-furan-3-yl)-phenyl-methanone
DM97GFB	HS	Investigative
DM97GFB	SN	2,5-Diphenyl-3-benzoylfuran; CHEMBL109280; (2,5-Diphenyl-furan-3-yl)-phenyl-methanone
DM97GFB	DT	Small molecular drug
DM97GFB	PC	44339577
DM97GFB	MW	324.4
DM97GFB	FM	C23H16O2
DM97GFB	IC	InChI=1S/C23H16O2/c24-22(18-12-6-2-7-13-18)20-16-21(17-10-4-1-5-11-17)25-23(20)19-14-8-3-9-15-19/h1-16H
DM97GFB	CS	C1=CC=C(C=C1)C2=CC(=C(O2)C3=CC=CC=C3)C(=O)C4=CC=CC=C4
DM97GFB	IK	QGPDONYUANCEMJ-UHFFFAOYSA-N
DM97GFB	IU	(2,5-diphenylfuran-3-yl)-phenylmethanone
DM97GFB	DE	Discovery agent

DMWRCM1	ID	DMWRCM1
DMWRCM1	DN	(2,6-Diamino-pyridin-3-yl)-phenyl-methanone
DMWRCM1	HS	Investigative
DMWRCM1	SN	(2,6-Diaminopyridin-3-yl)(phenyl)methanone; 157924-28-2; 3-Acyl-2,6-diaminopyridine deriv. 3c; (2,6-diamino-3-pyridinyl)phenylmethanone; AC1NS9QT; SCHEMBL4419093; BDBM6908; CHEMBL193590; 3-benzoylpyridine-2,6-diamine; 852997-66-1
DMWRCM1	DT	Small molecular drug
DMWRCM1	PC	5330842
DMWRCM1	MW	213.23
DMWRCM1	FM	C12H11N3O
DMWRCM1	IC	InChI=1S/C12H11N3O/c13-10-7-6-9(12(14)15-10)11(16)8-4-2-1-3-5-8/h1-7H,(H4,13,14,15)
DMWRCM1	CS	C1=CC=C(C=C1)C(=O)C2=C(N=C(C=C2)N)N
DMWRCM1	IK	CUQWNLDNYKQYLY-UHFFFAOYSA-N
DMWRCM1	IU	(2,6-diaminopyridin-3-yl)-phenylmethanone
DMWRCM1	DE	Discovery agent

DM27TH9	ID	DM27TH9
DM27TH9	DN	(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine
DM27TH9	HS	Investigative
DM27TH9	SN	CHEMBL1022; (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine; SCHEMBL13767327
DM27TH9	DT	Small molecular drug
DM27TH9	PC	10489502
DM27TH9	MW	228.07
DM27TH9	FM	C9H7Cl2N3
DM27TH9	IC	InChI=1S/C9H7Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-5H,(H2,12,13,14)
DM27TH9	CS	C1=CC(=C(C(=C1)Cl)NC2=NC=CN2)Cl
DM27TH9	IK	JMIQFISPBOHMQG-UHFFFAOYSA-N
DM27TH9	IU	N-(2,6-dichlorophenyl)-1H-imidazol-2-amine
DM27TH9	DE	Discovery agent

DM1RYH9	ID	DM1RYH9
DM1RYH9	DN	(24E)-3beta-hydroxy-7,24-euphadien-26-oic acid
DM1RYH9	HS	Investigative
DM1RYH9	SN	CHEMBL519411; (24E)-3beta-hydroxy-7,24-euphadien-26-oic acid
DM1RYH9	DT	Small molecular drug
DM1RYH9	PC	44558952
DM1RYH9	MW	470.7
DM1RYH9	FM	C31H50O3
DM1RYH9	IC	InChI=1S/C31H50O3/c1-20(26(33)34)10-9-11-21(2)29(6)18-19-30(7)23-12-13-24-27(3,4)25(32)15-16-28(24,5)22(23)14-17-31(29,30)8/h10,12,21-22,24-25,32H,9,11,13-19H2,1-8H3,(H,33,34)/b20-10+/t21-,22-,24-,25-,28+,29-,30+,31-/m0/s1
DM1RYH9	CS	C[C@@H](CC/C=C(\\C)/C(=O)O)[C@@]1(CC[C@]2([C@]1(CC[C@H]3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C)C
DM1RYH9	IK	PSSOTMPEBLYOAS-MGULVPRESA-N
DM1RYH9	IU	(E,6S)-6-[(3S,5R,9R,10R,13S,14R,17S)-3-hydroxy-4,4,10,13,14,17-hexamethyl-1,2,3,5,6,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid
DM1RYH9	DE	Discovery agent

DMPL80G	ID	DMPL80G
DMPL80G	DN	(24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol
DMPL80G	HS	Investigative
DMPL80G	SN	CHEMBL202119; (24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol
DMPL80G	DT	Small molecular drug
DMPL80G	PC	44407193
DMPL80G	MW	410.7
DMPL80G	FM	C29H46O
DMPL80G	IC	InChI=1S/C29H46O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h8-11,15,19-26,30H,7,12-14,16-18H2,1-6H3/b9-8+/t20-,21-,22?,23+,24+,25-,26+,28+,29-/m1/s1
DMPL80G	CS	CC[C@H](/C=C/[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC=C3[C@H]2C=CC4[C@@]3(CC[C@@H](C4)O)C)C)C(C)C
DMPL80G	IK	ZFRLPKWDPDXIMP-BLDYNFBXSA-N
DMPL80G	IU	(3S,8S,10S,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,5,8,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DMPL80G	DE	Discovery agent

DMLEZKJ	ID	DMLEZKJ
DMLEZKJ	DN	(2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid
DMLEZKJ	HS	Investigative
DMLEZKJ	SN	CHEMBL79325; 2-(2-Amino-2-thiazolin-4-yl)acetic acid; AC1NQ6SQ; SCHEMBL2711624; 2-(2-amino-4,5-dihydro-1,3-thiazol-4-yl)acetic Acid; ANCWBXJZUCHVHL-UHFFFAOYSA-N
DMLEZKJ	DT	Small molecular drug
DMLEZKJ	PC	5216267
DMLEZKJ	MW	160.2
DMLEZKJ	FM	C5H8N2O2S
DMLEZKJ	IC	InChI=1S/C5H8N2O2S/c6-5-7-3(2-10-5)1-4(8)9/h3H,1-2H2,(H2,6,7)(H,8,9)
DMLEZKJ	CS	C1C(N=C(S1)N)CC(=O)O
DMLEZKJ	IK	ANCWBXJZUCHVHL-UHFFFAOYSA-N
DMLEZKJ	IU	2-(2-amino-4,5-dihydro-1,3-thiazol-4-yl)acetic acid
DMLEZKJ	DE	Discovery agent

DMFRPGX	ID	DMFRPGX
DMFRPGX	DN	(2-Benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine
DMFRPGX	HS	Investigative
DMFRPGX	SN	CHEMBL187420; (2-Benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine; BDBM50151051
DMFRPGX	DT	Small molecular drug
DMFRPGX	PC	11437461
DMFRPGX	MW	280.4
DMFRPGX	FM	C19H24N2
DMFRPGX	IC	InChI=1S/C19H24N2/c1-2-8-17(9-3-1)16-18-10-4-5-11-19(18)20-12-15-21-13-6-7-14-21/h1-5,8-11,20H,6-7,12-16H2
DMFRPGX	CS	C1CCN(C1)CCNC2=CC=CC=C2CC3=CC=CC=C3
DMFRPGX	IK	KMSBBZPJDRRRGH-UHFFFAOYSA-N
DMFRPGX	IU	2-benzyl-N-(2-pyrrolidin-1-ylethyl)aniline
DMFRPGX	DE	Discovery agent

DMTW0GD	ID	DMTW0GD
DMTW0GD	DN	(2-biphenyl-3-yl-ethyl)-dimethyl-amine
DMTW0GD	HS	Investigative
DMTW0GD	SN	CHEMBL234882
DMTW0GD	DT	Small molecular drug
DMTW0GD	PC	44431718
DMTW0GD	MW	225.33
DMTW0GD	FM	C16H19N
DMTW0GD	IC	InChI=1S/C16H19N/c1-17(2)12-11-14-7-6-10-16(13-14)15-8-4-3-5-9-15/h3-10,13H,11-12H2,1-2H3
DMTW0GD	CS	CN(C)CCC1=CC(=CC=C1)C2=CC=CC=C2
DMTW0GD	IK	ZMTHYJFLTGNPHJ-UHFFFAOYSA-N
DMTW0GD	IU	N,N-dimethyl-2-(3-phenylphenyl)ethanamine
DMTW0GD	DE	Discovery agent

DMZSP7F	ID	DMZSP7F
DMZSP7F	DN	(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE
DMZSP7F	HS	Investigative
DMZSP7F	SN	(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE; 2-bromoethyl 2-(4-amino-2-formylphenyl)acetate; AC1NE0SL; DB07955; 2-bromoethyl (4-amino-2-formylphenyl)acetate
DMZSP7F	DT	Small molecular drug
DMZSP7F	PC	4634717
DMZSP7F	MW	286.12
DMZSP7F	FM	C11H12BrNO3
DMZSP7F	IC	InChI=1S/C11H12BrNO3/c12-3-4-16-11(15)6-8-1-2-10(13)5-9(8)7-14/h1-2,5,7H,3-4,6,13H2
DMZSP7F	CS	C1=CC(=C(C=C1N)C=O)CC(=O)OCCBr
DMZSP7F	IK	SMKXVWWBCFWRMP-UHFFFAOYSA-N
DMZSP7F	IU	2-bromoethyl 2-(4-amino-2-formylphenyl)acetate
DMZSP7F	DE	Discovery agent

DM8N79M	ID	DM8N79M
DM8N79M	DN	(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine
DM8N79M	HS	Investigative
DM8N79M	SN	CHEMBL76457; (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine; 2-(2-Bromoanilino)-1H-imidazole; BDBM50055833
DM8N79M	DT	Small molecular drug
DM8N79M	PC	10490084
DM8N79M	MW	238.08
DM8N79M	FM	C9H8BrN3
DM8N79M	IC	InChI=1S/C9H8BrN3/c10-7-3-1-2-4-8(7)13-9-11-5-6-12-9/h1-6H,(H2,11,12,13)
DM8N79M	CS	C1=CC=C(C(=C1)NC2=NC=CN2)Br
DM8N79M	IK	KHNAVCNEASQADL-UHFFFAOYSA-N
DM8N79M	IU	N-(2-bromophenyl)-1H-imidazol-2-amine
DM8N79M	DE	Discovery agent

DMFX9H8	ID	DMFX9H8
DMFX9H8	DN	(2-bromophenyl)difluoromethanesulfonamide
DMFX9H8	HS	Investigative
DMFX9H8	SN	CHEMBL199493; (2-bromophenyl)difluoromethanesulfonamide
DMFX9H8	DT	Small molecular drug
DMFX9H8	PC	44405179
DMFX9H8	MW	286.1
DMFX9H8	FM	C7H6BrF2NO2S
DMFX9H8	IC	InChI=1S/C7H6BrF2NO2S/c8-6-4-2-1-3-5(6)7(9,10)14(11,12)13/h1-4H,(H2,11,12,13)
DMFX9H8	CS	C1=CC=C(C(=C1)C(F)(F)S(=O)(=O)N)Br
DMFX9H8	IK	QUUHLCHEVDHKEL-UHFFFAOYSA-N
DMFX9H8	IU	(2-bromophenyl)-difluoromethanesulfonamide
DMFX9H8	DE	Discovery agent

DMLTMPC	ID	DMLTMPC
DMLTMPC	DN	(2-Butyryloxy-ethyl)-trimethyl-ammonium iodide
DMLTMPC	HS	Investigative
DMLTMPC	DE	Discovery agent

DMOS864	ID	DMOS864
DMOS864	DN	(2-chloro-6-phenoxyphenyl)methanamine
DMOS864	HS	Investigative
DMOS864	SN	2-Chloro-6-phenoxybenzylamine; 175136-89-7; (2-chloro-6-phenoxyphenyl)methanamine; CHEMBL203105; AC1MCRJE; rarechem al bw 1398; SCHEMBL112755; AC1Q53T0; 2-chloro-6-phenoxy-benzylamine; CTK4D5311; DTXSID20380412; SNTOZVXKDWQFEW-UHFFFAOYSA-N; MolPort-000-144-285; ZINC159665; ZX-AT024720; 2-aminomethyl-3-chlorodiphenylether; SBB098143; BDBM50178429; (6-chloro-2-phenoxyphenyl)methylamine; 2-chloro-6-phenoxybenzylamine, 95+%; AKOS009159323; Benzenemethanamine,2-chloro-6-phenoxy-; KB-68526; SC-40136; AJ-15516; ACM175136897; DB-030613
DMOS864	DT	Small molecular drug
DMOS864	PC	2777206
DMOS864	MW	233.69
DMOS864	FM	C13H12ClNO
DMOS864	IC	InChI=1S/C13H12ClNO/c14-12-7-4-8-13(11(12)9-15)16-10-5-2-1-3-6-10/h1-8H,9,15H2
DMOS864	CS	C1=CC=C(C=C1)OC2=C(C(=CC=C2)Cl)CN
DMOS864	IK	SNTOZVXKDWQFEW-UHFFFAOYSA-N
DMOS864	IU	(2-chloro-6-phenoxyphenyl)methanamine
DMOS864	CA	CAS 175136-89-7
DMOS864	DE	Discovery agent

DMCE1SU	ID	DMCE1SU
DMCE1SU	DN	(2-Chloro-9-methyl-9H-purin-6-yl)-phenyl-amine
DMCE1SU	HS	Investigative
DMCE1SU	SN	CHEMBL98779; (2-Chloro-9-methyl-9H-purin-6-yl)-phenyl-amine; 2-chloro-9-methyl-N6-phenyladenine; 135394-17-1; SCHEMBL183230; DBTWDYPKBBODMU-UHFFFAOYSA-N; BDBM50009679; 2-Chloro-9-methyl-N-phenyl-9H-purin-6-amine
DMCE1SU	DT	Small molecular drug
DMCE1SU	PC	15693956
DMCE1SU	MW	259.69
DMCE1SU	FM	C12H10ClN5
DMCE1SU	IC	InChI=1S/C12H10ClN5/c1-18-7-14-9-10(16-12(13)17-11(9)18)15-8-5-3-2-4-6-8/h2-7H,1H3,(H,15,16,17)
DMCE1SU	CS	CN1C=NC2=C(N=C(N=C21)Cl)NC3=CC=CC=C3
DMCE1SU	IK	DBTWDYPKBBODMU-UHFFFAOYSA-N
DMCE1SU	IU	2-chloro-9-methyl-N-phenylpurin-6-amine
DMCE1SU	CA	CAS 135394-17-1
DMCE1SU	DE	Discovery agent

DM6DH15	ID	DM6DH15
DM6DH15	DN	(2-Chloro-ethyl)-trimethyl-ammonium chloride
DM6DH15	HS	Investigative
DM6DH15	DE	Discovery agent

DMKWRFA	ID	DMKWRFA
DMKWRFA	DN	(2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID
DMKWRFA	HS	Investigative
DMKWRFA	SN	(2e)-3-(2-Oct-1-Yn-1-Ylphenyl)acrylic Acid; 1lox; SCHEMBL4947304; SCHEMBL4947296; DB08492; (2E)-3-(2-oct-1-yn-1-ylphenyl)prop-2-enoic acid; (2E)-3-[2-(oct-1-yn-1-yl)phenyl]prop-2-enoic acid
DMKWRFA	DT	Small molecular drug
DMKWRFA	PC	10308106
DMKWRFA	MW	256.339
DMKWRFA	FM	C17H20O2
DMKWRFA	IC	InChI=1S/C17H20O2/c1-2-3-4-5-6-7-10-15-11-8-9-12-16(15)13-14-17(18)19/h8-9,11-14H,2-6H2,1H3,(H,18,19)/b14-13+
DMKWRFA	CS	CCCCCCC#CC1=CC=CC=C1/C=C/C(=O)O
DMKWRFA	IK	KRDSGPLHVQJFLM-BUHFOSPRSA-N
DMKWRFA	IU	(E)-3-(2-oct-1-ynylphenyl)prop-2-enoic acid
DMKWRFA	DE	Discovery agent

DM3ST2Y	ID	DM3ST2Y
DM3ST2Y	DN	(2E, 6E)-farnesylbisphosphonate
DM3ST2Y	HS	Investigative
DM3ST2Y	SN	(2E, 6E)-farnesylbisphosphonate; GTPL3200; SCHEMBL8916061; SCHEMBL2875241; (e,e)-(4,8,12-trimethyl-3,7,11-tridecatrienylidene)bisphosphonic acid; [(3E,7E)-4,8,12-trimethyl-1-phosphonotrideca-3,7,11-trien-1-yl]phosphonic acid
DM3ST2Y	DT	Small molecular drug
DM3ST2Y	PC	9871730
DM3ST2Y	MW	380.35
DM3ST2Y	FM	C16H30O6P2
DM3ST2Y	IC	InChI=1S/C16H30O6P2/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16(23(17,18)19)24(20,21)22/h7,9,11,16H,5-6,8,10,12H2,1-4H3,(H2,17,18,19)(H2,20,21,22)/b14-9+,15-11+
DM3ST2Y	CS	CC(=CCC/C(=C/CC/C(=C/CC(P(=O)(O)O)P(=O)(O)O)/C)/C)C
DM3ST2Y	IK	QBAOBDKNTDWTHR-YFVJMOTDSA-N
DM3ST2Y	IU	[(3E,7E)-4,8,12-trimethyl-1-phosphonotrideca-3,7,11-trienyl]phosphonic acid
DM3ST2Y	DE	Discovery agent

DMA9RIS	ID	DMA9RIS
DMA9RIS	DN	(2E,4S)-4-ammoniopent-2-enoate
DMA9RIS	HS	Investigative
DMA9RIS	SN	CHEMBL31541; SCHEMBL3063088; (4S)-4-Amino-2-pentenoic acid; [S,E,( )]-4-Amino-2-pentenoic acid
DMA9RIS	DT	Small molecular drug
DMA9RIS	PC	14074394
DMA9RIS	MW	115.13
DMA9RIS	FM	C5H9NO2
DMA9RIS	IC	InChI=1S/C5H9NO2/c1-4(6)2-3-5(7)8/h2-4H,6H2,1H3,(H,7,8)/b3-2+/t4-/m0/s1
DMA9RIS	CS	C[C@@H](/C=C/C(=O)O)N
DMA9RIS	IK	SCUXCFWYAJSHJI-ZPYNKGFJSA-N
DMA9RIS	IU	(E,4S)-4-aminopent-2-enoic acid
DMA9RIS	DE	Discovery agent

DMN7XT9	ID	DMN7XT9
DMN7XT9	DN	(2-Ethoxy-ethyl)-trimethyl-ammonium iodide
DMN7XT9	HS	Investigative
DMN7XT9	DE	Discovery agent

DMFV76H	ID	DMFV76H
DMFV76H	DN	(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide
DMFV76H	HS	Investigative
DMFV76H	SN	CHEMBL42205; (2-fluorophenyl)-(4-fluorophenyl)phenylacetamide; SCHEMBL1443821; UFALWTGZIJAUPP-UHFFFAOYSA-N; BDBM50099566; ICA-15451; (2-fluorophenyl)-(4 fluorophenyl)phenylacetamide
DMFV76H	DT	Small molecular drug
DMFV76H	PC	9966986
DMFV76H	MW	323.3
DMFV76H	FM	C20H15F2NO
DMFV76H	IC	InChI=1S/C20H15F2NO/c21-16-12-10-15(11-13-16)20(19(23)24,14-6-2-1-3-7-14)17-8-4-5-9-18(17)22/h1-13H,(H2,23,24)
DMFV76H	CS	C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=CC=C3F)C(=O)N
DMFV76H	IK	UFALWTGZIJAUPP-UHFFFAOYSA-N
DMFV76H	IU	2-(2-fluorophenyl)-2-(4-fluorophenyl)-2-phenylacetamide
DMFV76H	DE	Discovery agent

DMCHJL1	ID	DMCHJL1
DMCHJL1	DN	(2-hydroxy-3-phenoxypropyl)(propan-2-yl)amine
DMCHJL1	HS	Investigative
DMCHJL1	SN	1-(Isopropylamino)-3-phenoxypropan-2-ol; 7695-63-8; 1-phenoxy-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-phenoxy-propan-2-ol; 1-(isopropylamino)-3-phenoxy-2-propanol; Metoprolol IMpurity 06; CHEMBL7154; H-9/64; 2-PROPANOL, 1-[(1-METHYLETHYL)AMINO]-3-PHENOXY-; 1-[(1-methylethyl)amino]-3-phenoxy-2-Propanol; 2-Propanol, 1-((1-methylethyl)amino)-3-phenoxy-; (2RS)-1-((1-Methylethyl)amino)-3-phenoxypropan-2-ol; Desmethoxyethyl metoprolol; NIP
DMCHJL1	DT	Small molecular drug
DMCHJL1	PC	3123920
DMCHJL1	MW	209.28
DMCHJL1	FM	C12H19NO2
DMCHJL1	IC	InChI=1S/C12H19NO2/c1-10(2)13-8-11(14)9-15-12-6-4-3-5-7-12/h3-7,10-11,13-14H,8-9H2,1-2H3
DMCHJL1	CS	CC(C)NCC(COC1=CC=CC=C1)O
DMCHJL1	IK	ONXLHKFGTDDVLQ-UHFFFAOYSA-N
DMCHJL1	IU	1-phenoxy-3-(propan-2-ylamino)propan-2-ol
DMCHJL1	CA	CAS 7695-63-8
DMCHJL1	DE	Discovery agent

DMEZNXS	ID	DMEZNXS
DMEZNXS	DN	(2-hydroxyphenyl)(4-hydroxyphenyl)methanone
DMEZNXS	HS	Investigative
DMEZNXS	SN	2,4'-Dihydroxybenzophenone; 606-12-2; (2-Hydroxyphenyl)(4-hydroxyphenyl)methanone; Benzophenone, 2,4'-dihydroxy-; Methanone, (2-hydroxyphenyl)(4-hydroxyphenyl)-; CHEMBL510074; HUYKZYIAFUBPAQ-UHFFFAOYSA-N; (2-hydroxyphenyl)-(4-hydroxyphenyl)methanone; Methanone,(2-hydroxyphenyl)(4-hydroxyphenyl)-; NSC2832; ACMC-209mky; AC1Q5FLY; AC1L58KX; Benzophenone,4'-dihydroxy-; Oprea1_236403; 4,2'-dihydroxy-benzophenone; SCHEMBL1568564; CTK5B1906; DTXSID80277556; MolPort-003-809-367; ZINC340411; KS-000014KT; NSC-2832; BDBM50262042; ANW-33536
DMEZNXS	DT	Small molecular drug
DMEZNXS	PC	220295
DMEZNXS	MW	214.22
DMEZNXS	FM	C13H10O3
DMEZNXS	IC	InChI=1S/C13H10O3/c14-10-7-5-9(6-8-10)13(16)11-3-1-2-4-12(11)15/h1-8,14-15H
DMEZNXS	CS	C1=CC=C(C(=C1)C(=O)C2=CC=C(C=C2)O)O
DMEZNXS	IK	HUYKZYIAFUBPAQ-UHFFFAOYSA-N
DMEZNXS	IU	(2-hydroxyphenyl)-(4-hydroxyphenyl)methanone
DMEZNXS	CA	CAS 606-12-2
DMEZNXS	DE	Discovery agent

DM24E08	ID	DM24E08
DM24E08	DN	(2-Indol-1-yl-ethyl)-dimethyl-amine
DM24E08	HS	Investigative
DM24E08	SN	1H-Indole-1-ethanamine, N,N-dimethyl-; CHEMBL38633; 87482-09-5; (2-Indol-1-yl-ethyl)-dimethyl-amine; SCHEMBL4060777; CTK3C3615; DTXSID80579188; PSHKCPACSIZILK-UHFFFAOYSA-N; (2-Indol-1-ylethyl)dimethylamine; BDBM50108308; N,N-Dimethyl-1H-indole-1-ethanamine; AKOS013123773; [2-(1H-indol-1-yl)ethyl]dimethylamine; 2-(1H-Indol-1-yl)-N,N-dimethylethan-1-amine
DM24E08	DT	Small molecular drug
DM24E08	PC	15893127
DM24E08	MW	188.27
DM24E08	FM	C12H16N2
DM24E08	IC	InChI=1S/C12H16N2/c1-13(2)9-10-14-8-7-11-5-3-4-6-12(11)14/h3-8H,9-10H2,1-2H3
DM24E08	CS	CN(C)CCN1C=CC2=CC=CC=C21
DM24E08	IK	PSHKCPACSIZILK-UHFFFAOYSA-N
DM24E08	IU	2-indol-1-yl-N,N-dimethylethanamine
DM24E08	CA	CAS 87482-09-5
DM24E08	DE	Discovery agent

DMCJKOQ	ID	DMCJKOQ
DMCJKOQ	DN	(2-Mercapto-ethyl)-trimethyl-ammonium iodide
DMCJKOQ	HS	Investigative
DMCJKOQ	DE	Discovery agent

DMQWD75	ID	DMQWD75
DMQWD75	DN	(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
DMQWD75	HS	Investigative
DMQWD75	SN	N-(2-methoxyphenyl)-5-phenyl-1,3-oxazol-2-amine; GW577921A; 2-Anilino-5-aryloxazole 9; AC1NS7R2; SCHEMBL5232183; CHEMBL194027; BDBM5848; NCGC00242189-01; AB01092075-01; N-(2-methoxyphenyl)-5-phenyl-1,3-oxazol-2-amine Hydrochloride
DMQWD75	DT	Small molecular drug
DMQWD75	PC	5329844
DMQWD75	MW	266.29
DMQWD75	FM	C16H14N2O2
DMQWD75	IC	InChI=1S/C16H14N2O2/c1-19-14-10-6-5-9-13(14)18-16-17-11-15(20-16)12-7-3-2-4-8-12/h2-11H,1H3,(H,17,18)
DMQWD75	CS	COC1=CC=CC=C1NC2=NC=C(O2)C3=CC=CC=C3
DMQWD75	IK	DLHCYJIQXKETIN-UHFFFAOYSA-N
DMQWD75	IU	N-(2-methoxyphenyl)-5-phenyl-1,3-oxazol-2-amine
DMQWD75	DE	Discovery agent

DME6MYZ	ID	DME6MYZ
DME6MYZ	DN	(2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DME6MYZ	HS	Investigative
DME6MYZ	SN	CHEMBL154945; (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine; SCHEMBL7608050; BDBM50048573
DME6MYZ	DT	Small molecular drug
DME6MYZ	PC	10515839
DME6MYZ	MW	265.35
DME6MYZ	FM	C17H19N3
DME6MYZ	IC	InChI=1S/C17H19N3/c1-3-12-19(16-8-10-18-11-9-16)20-14(2)13-15-6-4-5-7-17(15)20/h4-11,13H,3,12H2,1-2H3
DME6MYZ	CS	CCCN(C1=CC=NC=C1)N2C(=CC3=CC=CC=C32)C
DME6MYZ	IK	JCEBKNUYKMFQGZ-UHFFFAOYSA-N
DME6MYZ	IU	2-methyl-N-propyl-N-pyridin-4-ylindol-1-amine
DME6MYZ	DE	Discovery agent

DMQ2XUE	ID	DMQ2XUE
DMQ2XUE	DN	(2R)-1-(2,6-dimethylphenoxy)propan-2-amine
DMQ2XUE	HS	Investigative
DMQ2XUE	SN	94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; (2R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N
DMQ2XUE	DT	Small molecular drug
DMQ2XUE	PC	180621
DMQ2XUE	MW	179.26
DMQ2XUE	FM	C11H17NO
DMQ2XUE	IC	InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m1/s1
DMQ2XUE	CS	CC1=C(C(=CC=C1)C)OC[C@@H](C)N
DMQ2XUE	IK	VLPIATFUUWWMKC-SNVBAGLBSA-N
DMQ2XUE	IU	(2R)-1-(2,6-dimethylphenoxy)propan-2-amine
DMQ2XUE	CA	CAS 94991-73-8
DMQ2XUE	DE	Discovery agent

DM3K2TI	ID	DM3K2TI
DM3K2TI	DN	(2R)-2-Methyl-4,5-dideoxy
DM3K2TI	HS	Investigative
DM3K2TI	DT	Small molecular drug
DM3K2TI	PC	11064567
DM3K2TI	MW	242.16
DM3K2TI	FM	C7H15O7P
DM3K2TI	IC	InChI=1S/C7H15O7P/c1-5(7(9)10)6(8)3-2-4-14-15(11,12)13/h5-6,8H,2-4H2,1H3,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1
DM3K2TI	CS	C[C@H]([C@H](CCCOP(=O)(O)O)O)C(=O)O
DM3K2TI	IK	MQRCYOMQUQMVCH-RITPCOANSA-N
DM3K2TI	IU	(2R,3S)-3-hydroxy-2-methyl-6-phosphonooxyhexanoic acid
DM3K2TI	DE	Discovery agent

DMXPQU6	ID	DMXPQU6
DMXPQU6	DN	(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMXPQU6	HS	Investigative
DMXPQU6	SN	CHEMBL1083646; (2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX); SCHEMBL1404538; BDBM50320177
DMXPQU6	DT	Small molecular drug
DMXPQU6	PC	25059294
DMXPQU6	MW	505.8
DMXPQU6	FM	C25H23Cl3N2O3
DMXPQU6	IC	InChI=1S/C25H23Cl3N2O3/c1-13(31)23(32)29-21-12-25(2,3)33-24-19(21)11-18(14-4-6-15(26)7-5-14)22(30-24)17-9-8-16(27)10-20(17)28/h4-11,13,21,31H,12H2,1-3H3,(H,29,32)/t13-,21?/m1/s1
DMXPQU6	CS	C[C@H](C(=O)NC1CC(OC2=C1C=C(C(=N2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl)(C)C)O
DMXPQU6	IK	XCFWDLWOCXSJOK-ILRUXTBWSA-N
DMXPQU6	IU	(2R)-N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide
DMXPQU6	DE	Discovery agent

DMX0YIV	ID	DMX0YIV
DMX0YIV	DN	(2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMX0YIV	HS	Investigative
DMX0YIV	SN	CHEMBL1083619; SCHEMBL1404711; BDBM50320187; (2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX); (2R)-N-(7''-(2-CHLOROPHENYL)-6''-(4-CHLOROPHENYL)-3'',4''-DIHYDROSPIRO[CYCLOHEXANE-1,2''-PYRANO[2,3-B]PYRIDINE]-4''-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMX0YIV	DT	Small molecular drug
DMX0YIV	PC	24995603
DMX0YIV	MW	511.4
DMX0YIV	FM	C28H28Cl2N2O3
DMX0YIV	IC	InChI=1S/C28H28Cl2N2O3/c1-17(33)26(34)31-24-16-28(13-5-2-6-14-28)35-27-22(24)15-21(18-9-11-19(29)12-10-18)25(32-27)20-7-3-4-8-23(20)30/h3-4,7-12,15,17,24,33H,2,5-6,13-14,16H2,1H3,(H,31,34)/t17-,24?/m1/s1
DMX0YIV	CS	C[C@H](C(=O)NC1CC2(CCCCC2)OC3=C1C=C(C(=N3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl)O
DMX0YIV	IK	CBNQOXMUNJAOJO-BPNWFJGMSA-N
DMX0YIV	IU	(2R)-N-[7-(2-chlorophenyl)-6-(4-chlorophenyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclohexane]-4-yl]-2-hydroxypropanamide
DMX0YIV	DE	Discovery agent

DMYRHFI	ID	DMYRHFI
DMYRHFI	DN	(2R,3R)-iodoreboxetine
DMYRHFI	HS	Investigative
DMYRHFI	SN	(2R,3R)-iodoreboxetine; CHEMBL477406
DMYRHFI	DT	Small molecular drug
DMYRHFI	PC	44578857
DMYRHFI	MW	439.3
DMYRHFI	FM	C19H22INO3
DMYRHFI	IC	InChI=1S/C19H22INO3/c1-2-22-16-5-3-4-6-17(16)24-19(18-13-21-11-12-23-18)14-7-9-15(20)10-8-14/h3-10,18-19,21H,2,11-13H2,1H3/t18-,19-/m1/s1
DMYRHFI	CS	CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=C(C=C3)I
DMYRHFI	IK	RVASAZVCHKJYMY-RTBURBONSA-N
DMYRHFI	IU	(2R)-2-[(R)-(2-ethoxyphenoxy)-(4-iodophenyl)methyl]morpholine
DMYRHFI	DE	Discovery agent

DMY2FX8	ID	DMY2FX8
DMY2FX8	DN	(2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine
DMY2FX8	HS	Investigative
DMY2FX8	SN	CHEMBL568336; (2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine
DMY2FX8	DT	Small molecular drug
DMY2FX8	PC	45487451
DMY2FX8	MW	395.23
DMY2FX8	FM	C17H18INO2
DMY2FX8	IC	InChI=1S/C17H18INO2/c18-14-8-4-5-9-15(14)21-17(13-6-2-1-3-7-13)16-12-19-10-11-20-16/h1-9,16-17,19H,10-12H2/t16-,17+/m1/s1
DMY2FX8	CS	C1CO[C@H](CN1)[C@H](C2=CC=CC=C2)OC3=CC=CC=C3I
DMY2FX8	IK	BHMLFPOTZYRDKA-SJORKVTESA-N
DMY2FX8	IU	(2R)-2-[(S)-(2-iodophenoxy)-phenylmethyl]morpholine
DMY2FX8	DE	Discovery agent

DM260TI	ID	DM260TI
DM260TI	DN	(2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine
DM260TI	HS	Investigative
DM260TI	SN	CHEMBL569927; (2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine
DM260TI	DT	Small molecular drug
DM260TI	PC	45487450
DM260TI	MW	395.23
DM260TI	FM	C17H18INO2
DM260TI	IC	InChI=1S/C17H18INO2/c18-14-7-4-8-15(11-14)21-17(13-5-2-1-3-6-13)16-12-19-9-10-20-16/h1-8,11,16-17,19H,9-10,12H2/t16-,17+/m1/s1
DM260TI	CS	C1CO[C@H](CN1)[C@H](C2=CC=CC=C2)OC3=CC(=CC=C3)I
DM260TI	IK	DUYCYXZOEGDUNB-SJORKVTESA-N
DM260TI	IU	(2R)-2-[(S)-(3-iodophenoxy)-phenylmethyl]morpholine
DM260TI	DE	Discovery agent

DMKM8E2	ID	DMKM8E2
DMKM8E2	DN	(2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine
DMKM8E2	HS	Investigative
DMKM8E2	SN	CHEMBL579221; (2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine
DMKM8E2	DT	Small molecular drug
DMKM8E2	PC	45487461
DMKM8E2	MW	395.23
DMKM8E2	FM	C17H18INO2
DMKM8E2	IC	InChI=1S/C17H18INO2/c18-14-6-8-15(9-7-14)21-17(13-4-2-1-3-5-13)16-12-19-10-11-20-16/h1-9,16-17,19H,10-12H2/t16-,17+/m1/s1
DMKM8E2	CS	C1CO[C@H](CN1)[C@H](C2=CC=CC=C2)OC3=CC=C(C=C3)I
DMKM8E2	IK	SFIZDMBLVRMOCD-SJORKVTESA-N
DMKM8E2	IU	(2R)-2-[(S)-(4-iodophenoxy)-phenylmethyl]morpholine
DMKM8E2	DE	Discovery agent

DM852Z6	ID	DM852Z6
DM852Z6	DN	(2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol
DM852Z6	HS	Investigative
DM852Z6	SN	3-(6-Amino-purin-9-yl)-nonan-2-ol
DM852Z6	PC	149784
DM852Z6	MW	277.37
DM852Z6	FM	C14H23N5O
DM852Z6	IC	InChI=1S/C14H23N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-7H2,1-2H3,(H2,15,16,17)/t10-,11+/m1/s1
DM852Z6	CS	CCCCCC[C@@H]([C@@H](C)O)N1C=NC2=C(N=CN=C21)N
DM852Z6	IK	IOSAAWHGJUZBOG-MNOVXSKESA-N
DM852Z6	IU	(2R,3S)-3-(6-aminopurin-9-yl)nonan-2-ol
DM852Z6	CA	CAS 79813-68-6
DM852Z6	CB	CHEBI:63058
DM852Z6	DE	Discovery agent

DMDS8AN	ID	DMDS8AN
DMDS8AN	DN	(2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol
DMDS8AN	HS	Investigative
DMDS8AN	SN	CHEMBL1090540; (2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol; SCHEMBL19829307; BDBM50315255
DMDS8AN	DT	Small molecular drug
DMDS8AN	PC	46866608
DMDS8AN	MW	217.31
DMDS8AN	FM	C11H23NO3
DMDS8AN	IC	InChI=1S/C11H23NO3/c1-2-3-4-5-6-8-10(14)11(15)9(13)7-12-8/h8-15H,2-7H2,1H3/t8-,9-,10+,11+/m1/s1
DMDS8AN	CS	CCCCCC[C@@H]1[C@@H]([C@H]([C@@H](CN1)O)O)O
DMDS8AN	IK	JVCIUBNETYXXOR-ZNSHCXBVSA-N
DMDS8AN	IU	(2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol
DMDS8AN	DE	Discovery agent

DMIQNX9	ID	DMIQNX9
DMIQNX9	DN	(2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol
DMIQNX9	HS	Investigative
DMIQNX9	SN	CHEMBL1091214; (2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol; SCHEMBL19831655; BDBM50315250
DMIQNX9	DT	Small molecular drug
DMIQNX9	PC	11988371
DMIQNX9	MW	259.38
DMIQNX9	FM	C14H29NO3
DMIQNX9	IC	InChI=1S/C14H29NO3/c1-2-3-4-5-6-7-8-9-11-13(17)14(18)12(16)10-15-11/h11-18H,2-10H2,1H3/t11-,12-,13+,14+/m1/s1
DMIQNX9	CS	CCCCCCCCC[C@@H]1[C@@H]([C@H]([C@@H](CN1)O)O)O
DMIQNX9	IK	WVYPOMDXOXCTJU-MQYQWHSLSA-N
DMIQNX9	IU	(2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol
DMIQNX9	DE	Discovery agent

DM7GI94	ID	DM7GI94
DM7GI94	DN	(2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol
DM7GI94	HS	Investigative
DM7GI94	SN	CHEMBL1089185; (2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol
DM7GI94	DT	Small molecular drug
DM7GI94	PC	46884602
DM7GI94	MW	175.23
DM7GI94	FM	C8H17NO3
DM7GI94	IC	InChI=1S/C8H17NO3/c1-2-3-5-7(11)8(12)6(10)4-9-5/h5-12H,2-4H2,1H3/t5-,6-,7+,8+/m1/s1
DM7GI94	CS	CCC[C@@H]1[C@@H]([C@H]([C@@H](CN1)O)O)O
DM7GI94	IK	JFOGNLDWQBZRQJ-NGJRWZKOSA-N
DM7GI94	IU	(2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol
DM7GI94	DE	Discovery agent

DMYW40T	ID	DMYW40T
DMYW40T	DN	(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate
DMYW40T	HS	Investigative
DMYW40T	SN	(2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylic acid; (2R,4R)-APDC; (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid; 169209-63-6; 2R,4R-APDC; CHEMBL40086; CHEBI:40139; EN300-88063; 2R, 4R-APDC monohydrate; 52A; 4-amino-2,4-pyrrolidinedicarboxylic acid; AC1NSJRT; AC1Q4UAD; SCHEMBL158843; 2R, 4R-APDC; (2R,3R)-APDC; GTPL1392; CTK0E5090; DTXSID10415500; MolPort-003-982-102; BDBM50052398; ZINC32628523; SBB067830; MFCD16875409; AKOS015916056; AKOS015854214; RTC-065564; FCH3884669; NCGC00025040-02; LY314593; AJ-85443; SC-48823; TC-065564; B6634
DMYW40T	DT	Small molecular drug
DMYW40T	PC	5310984
DMYW40T	MW	174.15
DMYW40T	FM	C6H10N2O4
DMYW40T	IC	InChI=1S/C6H10N2O4/c7-6(5(11)12)1-3(4(9)10)8-2-6/h3,8H,1-2,7H2,(H,9,10)(H,11,12)/t3-,6-/m1/s1
DMYW40T	CS	C1[C@@H](NC[C@]1(C(=O)O)N)C(=O)O
DMYW40T	IK	XZFMJVJDSYRWDQ-AWFVSMACSA-N
DMYW40T	IU	(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid
DMYW40T	CA	CAS 169209-63-6
DMYW40T	CB	CHEBI:40139
DMYW40T	DE	Discovery agent

DMSFXEO	ID	DMSFXEO
DMSFXEO	DN	(2R,5R)-delta-methyl-alpha-acetylenic putrescine
DMSFXEO	HS	Investigative
DMSFXEO	SN	6-Heptyne-2,5-diamine; Methylacetylenic putrescine; Methyl-acetylenicputrescine; Mdl 72175; 8-Methyl-8-acetylenic putrescine; delta-Methyl-alpha acetylene putrescine; Hept-6-yne-2,5-diamine; MDL-72175; AC1L3U4J; 81645-70-7; SCHEMBL4808395; CTK5F9486; AC1Q2832; AKOS006338563; 1-Ethynyl-4-methyl-1,4-butanediamine
DMSFXEO	DT	Small molecular drug
DMSFXEO	PC	122175
DMSFXEO	MW	126.2
DMSFXEO	FM	C7H14N2
DMSFXEO	IC	InChI=1S/C7H14N2/c1-3-7(9)5-4-6(2)8/h1,6-7H,4-5,8-9H2,2H3
DMSFXEO	CS	CC(CCC(C#C)N)N
DMSFXEO	IK	QIADQCOYEFCREQ-UHFFFAOYSA-N
DMSFXEO	IU	hept-6-yne-2,5-diamine
DMSFXEO	CA	CAS 81645-70-7
DMSFXEO	DE	Discovery agent

DMIS39C	ID	DMIS39C
DMIS39C	DN	(2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine
DMIS39C	HS	Investigative
DMIS39C	SN	CHEMBL261476; SCHEMBL905958
DMIS39C	DT	Small molecular drug
DMIS39C	PC	44452811
DMIS39C	MW	215.25
DMIS39C	FM	C12H13N3O
DMIS39C	IC	InChI=1S/C12H13N3O/c1-8(13)7-15-12-9(6-14-15)2-3-11-10(12)4-5-16-11/h2-6,8H,7,13H2,1H3/t8-/m0/s1
DMIS39C	CS	C[C@@H](CN1C2=C(C=CC3=C2C=CO3)C=N1)N
DMIS39C	IK	XAEAYQWCVVRSFL-QMMMGPOBSA-N
DMIS39C	IU	(2S)-1-furo[2,3-g]indazol-1-ylpropan-2-amine
DMIS39C	DE	Discovery agent

DMW4ARM	ID	DMW4ARM
DMW4ARM	DN	(2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine
DMW4ARM	HS	Investigative
DMW4ARM	SN	CHEMBL257503; (S)-1-(5-Fluoro-1H-indazol-1-yl)propan-2-amine; 210580-57-7; BDBM50375463; AKOS024258782
DMW4ARM	DT	Small molecular drug
DMW4ARM	PC	44452853
DMW4ARM	MW	193.22
DMW4ARM	FM	C10H12FN3
DMW4ARM	IC	InChI=1S/C10H12FN3/c1-7(12)6-14-10-3-2-9(11)4-8(10)5-13-14/h2-5,7H,6,12H2,1H3/t7-/m0/s1
DMW4ARM	CS	C[C@@H](CN1C2=C(C=C(C=C2)F)C=N1)N
DMW4ARM	IK	ILPBKZWYZJHZAZ-ZETCQYMHSA-N
DMW4ARM	IU	(2S)-1-(5-fluoroindazol-1-yl)propan-2-amine
DMW4ARM	DE	Discovery agent

DM31SNW	ID	DM31SNW
DM31SNW	DN	(2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine
DM31SNW	HS	Investigative
DM31SNW	SN	CHEMBL256623
DM31SNW	DT	Small molecular drug
DM31SNW	PC	9859429
DM31SNW	MW	193.22
DM31SNW	FM	C10H12FN3
DM31SNW	IC	InChI=1S/C10H12FN3/c1-7(12)6-14-10-4-9(11)3-2-8(10)5-13-14/h2-5,7H,6,12H2,1H3/t7-/m0/s1
DM31SNW	CS	C[C@@H](CN1C2=C(C=CC(=C2)F)C=N1)N
DM31SNW	IK	OARAVURQNSHWSP-ZETCQYMHSA-N
DM31SNW	IU	(2S)-1-(6-fluoroindazol-1-yl)propan-2-amine
DM31SNW	DE	Discovery agent

DMYALON	ID	DMYALON
DMYALON	DN	(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine
DMYALON	HS	Investigative
DMYALON	SN	(S)-2-(6-methoxyindazol-1-yl)-1-methylethylamine
DMYALON	PC	11708275
DMYALON	MW	205.26
DMYALON	FM	C11H15N3O
DMYALON	IC	InChI=1S/C11H15N3O/c1-8(12)7-14-11-5-10(15-2)4-3-9(11)6-13-14/h3-6,8H,7,12H2,1-2H3/t8-/m0/s1
DMYALON	CS	C[C@@H](CN1C2=C(C=CC(=C2)OC)C=N1)N
DMYALON	IK	WSEWULCWBQDNEH-QMMMGPOBSA-N
DMYALON	IU	(2S)-1-(6-methoxyindazol-1-yl)propan-2-amine
DMYALON	DE	Discovery agent

DMNKEUG	ID	DMNKEUG
DMNKEUG	DN	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
DMNKEUG	HS	Investigative
DMNKEUG	SN	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; CHEMBL364748; SCHEMBL20553473; ZINC13671687; BDBM50171897; DB08760; (S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; (S)-2-(4-Chloro-phenoxy)-3-phenyl-propionic acid
DMNKEUG	DT	Small molecular drug
DMNKEUG	PC	11460087
DMNKEUG	MW	276.71
DMNKEUG	FM	C15H13ClO3
DMNKEUG	IC	InChI=1S/C15H13ClO3/c16-12-6-8-13(9-7-12)19-14(15(17)18)10-11-4-2-1-3-5-11/h1-9,14H,10H2,(H,17,18)/t14-/m0/s1
DMNKEUG	CS	C1=CC=C(C=C1)C[C@@H](C(=O)O)OC2=CC=C(C=C2)Cl
DMNKEUG	IK	CPBLTMSKPQDJPW-AWEZNQCLSA-N
DMNKEUG	IU	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
DMNKEUG	DE	Discovery agent

DMYBXHF	ID	DMYBXHF
DMYBXHF	DN	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
DMYBXHF	HS	Investigative
DMYBXHF	SN	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid; CHEMBL191060; ZINC13671697; BDBM50171895; DB07842; (S)-2-(4-Ethyl-phenoxy)-3-phenyl-propionic acid
DMYBXHF	DT	Small molecular drug
DMYBXHF	PC	11149906
DMYBXHF	MW	270.32
DMYBXHF	FM	C17H18O3
DMYBXHF	IC	InChI=1S/C17H18O3/c1-2-13-8-10-15(11-9-13)20-16(17(18)19)12-14-6-4-3-5-7-14/h3-11,16H,2,12H2,1H3,(H,18,19)/t16-/m0/s1
DMYBXHF	CS	CCC1=CC=C(C=C1)O[C@@H](CC2=CC=CC=C2)C(=O)O
DMYBXHF	IK	CJMVTSLLWMPEKQ-INIZCTEOSA-N
DMYBXHF	IU	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
DMYBXHF	DE	Discovery agent

DM73TPQ	ID	DM73TPQ
DM73TPQ	DN	(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
DM73TPQ	HS	Investigative
DM73TPQ	SN	LT175; (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid; 862901-87-9; CHEMBL191275; LRG; (2S)-3-phenyl-2-(4-phenylphenoxy)propanoic Acid; SCHEMBL20553479; BDBM28759; SYN5198; AOB2972; MolPort-039-138-772; ZINC13671695; LT 175; DB08121; LT175 (S-1); NCGC00402292-03
DM73TPQ	DT	Small molecular drug
DM73TPQ	PC	11483970
DM73TPQ	MW	318.4
DM73TPQ	FM	C21H18O3
DM73TPQ	IC	InChI=1S/C21H18O3/c22-21(23)20(15-16-7-3-1-4-8-16)24-19-13-11-18(12-14-19)17-9-5-2-6-10-17/h1-14,20H,15H2,(H,22,23)/t20-/m0/s1
DM73TPQ	CS	C1=CC=C(C=C1)C[C@@H](C(=O)O)OC2=CC=C(C=C2)C3=CC=CC=C3
DM73TPQ	IK	TZTPJJNNACUQQR-FQEVSTJZSA-N
DM73TPQ	IU	(2S)-3-phenyl-2-(4-phenylphenoxy)propanoic acid
DM73TPQ	DE	Discovery agent

DMMP8TR	ID	DMMP8TR
DMMP8TR	DN	(2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE
DMMP8TR	HS	Investigative
DMMP8TR	SN	(2s)-2-(Butyryloxy)-3-Hydroxypropyl Nonanoate; (2S)-2-(butanoyloxy)-3-hydroxypropyl nonanoate; B3H; AC1L9LSC; DB07416; [(2S)-2-butanoyloxy-3-hydroxypropyl] nonanoate
DMMP8TR	DT	Small molecular drug
DMMP8TR	PC	448271
DMMP8TR	MW	302.41
DMMP8TR	FM	C16H30O5
DMMP8TR	IC	InChI=1S/C16H30O5/c1-3-5-6-7-8-9-11-15(18)20-13-14(12-17)21-16(19)10-4-2/h14,17H,3-13H2,1-2H3/t14-/m0/s1
DMMP8TR	CS	CCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCC
DMMP8TR	IK	JCEXPOMAGTUEEX-AWEZNQCLSA-N
DMMP8TR	IU	[(2S)-2-butanoyloxy-3-hydroxypropyl] nonanoate
DMMP8TR	DE	Discovery agent

DMZOX43	ID	DMZOX43
DMZOX43	DN	(2S)-2'-methoxy kurarinone
DMZOX43	HS	Investigative
DMZOX43	SN	2'-Methoxykurarinone; (2S)-2'-methoxykurarinone; 270249-38-2; CHEMBL496451; CHEBI:66151; (2S)-2'-methoxy kurarinone; (2S)-7,4'-Dihydroxy-8-lavandulyl-5,2'-dimethoxyflavanone; MolPort-039-337-150; ZINC14711635; LMPK12140500; BDBM50377944; AKOS032962578; 7,4'-dihydroxy-5,2'-dimethoxy-8-lavandulylflavanone; 4H-1-Benzopyran-4-one,2,3-dihydro-7-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-5-methoxy-8-[(2R)-5-methyl-2-(1-methylethenyl)-4-hexenyl]-, (2S)-
DMZOX43	DT	Small molecular drug
DMZOX43	PC	11982641
DMZOX43	MW	452.5
DMZOX43	FM	C27H32O6
DMZOX43	IC	InChI=1S/C27H32O6/c1-15(2)7-8-17(16(3)4)11-20-21(29)13-25(32-6)26-22(30)14-24(33-27(20)26)19-10-9-18(28)12-23(19)31-5/h7,9-10,12-13,17,24,28-29H,3,8,11,14H2,1-2,4-6H3/t17-,24+/m1/s1
DMZOX43	CS	CC(=CC[C@H](CC1=C2C(=C(C=C1O)OC)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)OC)C(=C)C)C
DMZOX43	IK	KTAQQSUPNZAWEY-OSPHWJPCSA-N
DMZOX43	IU	(2S)-7-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-5-methoxy-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
DMZOX43	CB	CHEBI:66151
DMZOX43	DE	Discovery agent

DMYVBHT	ID	DMYVBHT
DMYVBHT	DN	(2S)-5,7,2',4'-tetrahydroxyflavanone
DMYVBHT	HS	Investigative
DMYVBHT	SN	steppogenin; 56486-94-3; (2S)-5,7,2',4'-tetrahydroxyflavanone; CHEMBL458395; (+)-Norartocarpanone; SCHEMBL6822729; QBLQLKNOKUHRCH-ZDUSSCGKSA-N; MolPort-035-705-966; ZINC14728050; BDBM50251005; AKOS032962442; (2S)-5,7,2'',4''-tetrahydroxyflavanone; W1600; (S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; (2s)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydro-4h-chromen -4-one
DMYVBHT	DT	Small molecular drug
DMYVBHT	PC	10356745
DMYVBHT	MW	288.25
DMYVBHT	FM	C15H12O6
DMYVBHT	IC	InChI=1S/C15H12O6/c16-7-1-2-9(10(18)3-7)13-6-12(20)15-11(19)4-8(17)5-14(15)21-13/h1-5,13,16-19H,6H2/t13-/m0/s1
DMYVBHT	CS	C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=C(C=C(C=C3)O)O
DMYVBHT	IK	QBLQLKNOKUHRCH-ZDUSSCGKSA-N
DMYVBHT	IU	(2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one
DMYVBHT	CA	CAS 56486-94-3
DMYVBHT	DE	Discovery agent

DM5V3M1	ID	DM5V3M1
DM5V3M1	DN	(2S)-abyssinone II
DM5V3M1	HS	Investigative
DM5V3M1	SN	Licoflavanone; (2S)-abyssinone II; CHEMBL457680; SCHEMBL3364539; MolPort-006-668-332; BDBM50251004; LMPK12140288; AKOS027393733; MCULE-9485581712; 4',5,7-trihydroxy-3'-prenylflavanone; (S)-4',5,7-Trihydroxy-3'-prenylflavanone
DM5V3M1	DT	Small molecular drug
DM5V3M1	PC	14218027
DM5V3M1	MW	340.4
DM5V3M1	FM	C20H20O5
DM5V3M1	IC	InChI=1S/C20H20O5/c1-11(2)3-4-12-7-13(5-6-15(12)22)18-10-17(24)20-16(23)8-14(21)9-19(20)25-18/h3,5-9,18,21-23H,4,10H2,1-2H3
DM5V3M1	CS	CC(=CCC1=C(C=CC(=C1)C2CC(=O)C3=C(C=C(C=C3O2)O)O)O)C
DM5V3M1	IK	CGKWSLSAYABZTL-UHFFFAOYSA-N
DM5V3M1	IU	5,7-dihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DM5V3M1	CA	CAS 119240-82-3
DM5V3M1	DE	Discovery agent

DMWQK86	ID	DMWQK86
DMWQK86	DN	(2S)-aminobutyryl-(R)-pipecolinic acid amide
DMWQK86	HS	Investigative
DMWQK86	SN	CHEMBL225617; (2S)-aminobutyryl-(R)-pipecolinic acid amide
DMWQK86	DT	Small molecular drug
DMWQK86	PC	11672950
DMWQK86	MW	213.28
DMWQK86	FM	C10H19N3O2
DMWQK86	IC	InChI=1S/C10H19N3O2/c1-2-7(11)10(15)13-6-4-3-5-8(13)9(12)14/h7-8H,2-6,11H2,1H3,(H2,12,14)/t7-,8+/m0/s1
DMWQK86	CS	CC[C@@H](C(=O)N1CCCC[C@@H]1C(=O)N)N
DMWQK86	IK	CRFULCBPWYMTAL-JGVFFNPUSA-N
DMWQK86	IU	(2R)-1-[(2S)-2-aminobutanoyl]piperidine-2-carboxamide
DMWQK86	DE	Discovery agent

DMG0QKL	ID	DMG0QKL
DMG0QKL	DN	(2S)-aminobutyryl-L-prolinamide
DMG0QKL	HS	Investigative
DMG0QKL	SN	CHEMBL224063; (2S)-aminobutyryl-L-prolinamide
DMG0QKL	DT	Small molecular drug
DMG0QKL	PC	11579307
DMG0QKL	MW	199.25
DMG0QKL	FM	C9H17N3O2
DMG0QKL	IC	InChI=1S/C9H17N3O2/c1-2-6(10)9(14)12-5-3-4-7(12)8(11)13/h6-7H,2-5,10H2,1H3,(H2,11,13)/t6-,7-/m0/s1
DMG0QKL	CS	CC[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DMG0QKL	IK	JNTYXKIFNYMZLM-BQBZGAKWSA-N
DMG0QKL	IU	(2S)-1-[(2S)-2-aminobutanoyl]pyrrolidine-2-carboxamide
DMG0QKL	DE	Discovery agent

DMTFP0Z	ID	DMTFP0Z
DMTFP0Z	DN	(2S)-aminobutyryl-L-proline (R)-sec-butylamide
DMTFP0Z	HS	Investigative
DMTFP0Z	SN	CHEMBL376183; (2S)-aminobutyryl-L-proline (R)-sec-butylamide
DMTFP0Z	DT	Small molecular drug
DMTFP0Z	PC	11579736
DMTFP0Z	MW	255.36
DMTFP0Z	FM	C13H25N3O2
DMTFP0Z	IC	InChI=1S/C13H25N3O2/c1-4-9(3)15-12(17)11-7-6-8-16(11)13(18)10(14)5-2/h9-11H,4-8,14H2,1-3H3,(H,15,17)/t9-,10+,11+/m1/s1
DMTFP0Z	CS	CC[C@@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DMTFP0Z	IK	VEBCSYAWQCGSMV-VWYCJHECSA-N
DMTFP0Z	IU	(2S)-1-[(2S)-2-aminobutanoyl]-N-[(2R)-butan-2-yl]pyrrolidine-2-carboxamide
DMTFP0Z	CA	CAS 885007-99-8
DMTFP0Z	DE	Discovery agent

DMO5ZEK	ID	DMO5ZEK
DMO5ZEK	DN	(2S)-aminobutyryl-L-proline isobutylamide
DMO5ZEK	HS	Investigative
DMO5ZEK	SN	CHEMBL223556; (2S)-aminobutyryl-L-proline isobutylamide; SCHEMBL6241779
DMO5ZEK	DT	Small molecular drug
DMO5ZEK	PC	11499834
DMO5ZEK	MW	255.36
DMO5ZEK	FM	C13H25N3O2
DMO5ZEK	IC	InChI=1S/C13H25N3O2/c1-4-10(14)13(18)16-7-5-6-11(16)12(17)15-8-9(2)3/h9-11H,4-8,14H2,1-3H3,(H,15,17)/t10-,11-/m0/s1
DMO5ZEK	CS	CC[C@@H](C(=O)N1CCC[C@H]1C(=O)NCC(C)C)N
DMO5ZEK	IK	IJQXRRHHARNIBV-QWRGUYRKSA-N
DMO5ZEK	IU	(2S)-1-[(2S)-2-aminobutanoyl]-N-(2-methylpropyl)pyrrolidine-2-carboxamide
DMO5ZEK	DE	Discovery agent

DM12Q9O	ID	DM12Q9O
DM12Q9O	DN	(2S)-aminobutyryl-L-proline n-butylamide
DM12Q9O	HS	Investigative
DM12Q9O	SN	CHEMBL225540; (2S)-aminobutyryl-L-proline n-butylamide; SCHEMBL6242775
DM12Q9O	DT	Small molecular drug
DM12Q9O	PC	11514390
DM12Q9O	MW	255.36
DM12Q9O	FM	C13H25N3O2
DM12Q9O	IC	InChI=1S/C13H25N3O2/c1-3-5-8-15-12(17)11-7-6-9-16(11)13(18)10(14)4-2/h10-11H,3-9,14H2,1-2H3,(H,15,17)/t10-,11-/m0/s1
DM12Q9O	CS	CCCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DM12Q9O	IK	ZUFOHXXZTMOECH-QWRGUYRKSA-N
DM12Q9O	IU	(2S)-1-[(2S)-2-aminobutanoyl]-N-butylpyrrolidine-2-carboxamide
DM12Q9O	DE	Discovery agent

DM1DJX2	ID	DM1DJX2
DM1DJX2	DN	(2S)-aminobutyryl-L-proline n-pentylamide
DM1DJX2	HS	Investigative
DM1DJX2	SN	CHEMBL376374; (2S)-aminobutyryl-L-proline n-pentylamide; SCHEMBL6242559
DM1DJX2	DT	Small molecular drug
DM1DJX2	PC	11615987
DM1DJX2	MW	269.38
DM1DJX2	FM	C14H27N3O2
DM1DJX2	IC	InChI=1S/C14H27N3O2/c1-3-5-6-9-16-13(18)12-8-7-10-17(12)14(19)11(15)4-2/h11-12H,3-10,15H2,1-2H3,(H,16,18)/t11-,12-/m0/s1
DM1DJX2	CS	CCCCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DM1DJX2	IK	DFWCJPNYAWVSTR-RYUDHWBXSA-N
DM1DJX2	IU	(2S)-1-[(2S)-2-aminobutanoyl]-N-pentylpyrrolidine-2-carboxamide
DM1DJX2	DE	Discovery agent

DM6WXJO	ID	DM6WXJO
DM6WXJO	DN	(2S)-aminobutyryl-L-proline n-propylamide
DM6WXJO	HS	Investigative
DM6WXJO	SN	CHEMBL225539; (2S)-aminobutyryl-L-proline n-propylamide; SCHEMBL6243789
DM6WXJO	DT	Small molecular drug
DM6WXJO	PC	11637307
DM6WXJO	MW	241.33
DM6WXJO	FM	C12H23N3O2
DM6WXJO	IC	InChI=1S/C12H23N3O2/c1-3-7-14-11(16)10-6-5-8-15(10)12(17)9(13)4-2/h9-10H,3-8,13H2,1-2H3,(H,14,16)/t9-,10-/m0/s1
DM6WXJO	CS	CCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DM6WXJO	IK	PGTCIDPUBJUXTD-UWVGGRQHSA-N
DM6WXJO	IU	(2S)-1-[(2S)-2-aminobutanoyl]-N-propylpyrrolidine-2-carboxamide
DM6WXJO	DE	Discovery agent

DMEWU6Z	ID	DMEWU6Z
DMEWU6Z	DN	(2S)-aminobutyryl-L-proline-(2S)-methylbutylamide
DMEWU6Z	HS	Investigative
DMEWU6Z	SN	CHEMBL223719; (2S)-aminobutyryl-L-proline-(2S)-methylbutylamide
DMEWU6Z	DT	Small molecular drug
DMEWU6Z	PC	11623159
DMEWU6Z	MW	269.38
DMEWU6Z	FM	C14H27N3O2
DMEWU6Z	IC	InChI=1S/C14H27N3O2/c1-4-10(3)9-16-13(18)12-7-6-8-17(12)14(19)11(15)5-2/h10-12H,4-9,15H2,1-3H3,(H,16,18)/t10-,11-,12-/m0/s1
DMEWU6Z	CS	CC[C@H](C)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DMEWU6Z	IK	KKFKEHDSJNUMHG-SRVKXCTJSA-N
DMEWU6Z	IU	(2S)-1-[(2S)-2-aminobutanoyl]-N-[(2S)-2-methylbutyl]pyrrolidine-2-carboxamide
DMEWU6Z	DE	Discovery agent

DM6L0KZ	ID	DM6L0KZ
DM6L0KZ	DN	(2S)-euchrenone a7
DM6L0KZ	HS	Investigative
DM6L0KZ	SN	(2S)-euchrenone a7; CHEMBL457686; JJOUBYOHNYJCOU-IBGZPJMESA-N
DM6L0KZ	DT	Small molecular drug
DM6L0KZ	PC	44593508
DM6L0KZ	MW	340.4
DM6L0KZ	FM	C20H20O5
DM6L0KZ	IC	InChI=1S/C20H20O5/c1-11(2)3-5-14-16(22)8-7-15-18(24)10-19(25-20(14)15)13-6-4-12(21)9-17(13)23/h3-4,6-9,19,21-23H,5,10H2,1-2H3/t19-/m0/s1
DM6L0KZ	CS	CC(=CCC1=C(C=CC2=C1O[C@@H](CC2=O)C3=C(C=C(C=C3)O)O)O)C
DM6L0KZ	IK	JJOUBYOHNYJCOU-IBGZPJMESA-N
DM6L0KZ	IU	(2S)-2-(2,4-dihydroxyphenyl)-7-hydroxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
DM6L0KZ	DE	Discovery agent

DMRCMIT	ID	DMRCMIT
DMRCMIT	DN	(2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMRCMIT	HS	Investigative
DMRCMIT	SN	CHEMBL1084820; SCHEMBL1404587; BDBM50320186; (2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX); (2S)-N-(7''-(2-CHLOROPHENYL)-6''-(4-CHLOROPHENYL)-3'',4''-DIHYDROSPIRO[CYCLOHEXANE-1,2''-PYRANO[2,3-B]PYRIDINE]-4''-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMRCMIT	DT	Small molecular drug
DMRCMIT	PC	24995604
DMRCMIT	MW	511.4
DMRCMIT	FM	C28H28Cl2N2O3
DMRCMIT	IC	InChI=1S/C28H28Cl2N2O3/c1-17(33)26(34)31-24-16-28(13-5-2-6-14-28)35-27-22(24)15-21(18-9-11-19(29)12-10-18)25(32-27)20-7-3-4-8-23(20)30/h3-4,7-12,15,17,24,33H,2,5-6,13-14,16H2,1H3,(H,31,34)/t17-,24?/m0/s1
DMRCMIT	CS	C[C@@H](C(=O)NC1CC2(CCCCC2)OC3=C1C=C(C(=N3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl)O
DMRCMIT	IK	CBNQOXMUNJAOJO-KEJDIYNNSA-N
DMRCMIT	IU	(2S)-N-[7-(2-chlorophenyl)-6-(4-chlorophenyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclohexane]-4-yl]-2-hydroxypropanamide
DMRCMIT	DE	Discovery agent

DMZON3T	ID	DMZON3T
DMZON3T	DN	(2s)-Pyrrolidin-2-Ylmethylamine
DMZON3T	HS	Investigative
DMZON3T	SN	(S)-pyrrolidin-2-ylmethanamine; 69500-64-7; (S)-(+)-2-(Aminomethyl)pyrrolidine; (2S)-PYRROLIDIN-2-YLMETHYLAMINE; (S)-2-(Aminomethyl)pyrrolidine; (S)-2-aminomethylpyrrolidine; (S)-pyrrolidin-2-ylmethylamine; [(2S)-pyrrolidin-2-yl]methanamine; 1-[(2S)-pyrrolidin-2-yl]methanamine; 2-Pyrrolidinemethanamine, (2S)-; (S)-(+)-2-(Aminomethyl)pyrrolidine, 98%; AC1MC09B; SCHEMBL83314; CHEBI:44632; CTK5D0186; (2S)-pyrrolidin-2-ylmethanamine; MolPort-003-932-494; AUKXFNABVHIUAC-YFKPBYRVSA-N; (2S)-Pyrrolidin-2-yl-methylamine; ZINC39357503
DMZON3T	DT	Small molecular drug
DMZON3T	PC	2734054
DMZON3T	MW	100.16
DMZON3T	FM	C5H12N2
DMZON3T	IC	InChI=1S/C5H12N2/c6-4-5-2-1-3-7-5/h5,7H,1-4,6H2/t5-/m0/s1
DMZON3T	CS	C1C[C@H](NC1)CN
DMZON3T	IK	AUKXFNABVHIUAC-YFKPBYRVSA-N
DMZON3T	IU	[(2S)-pyrrolidin-2-yl]methanamine
DMZON3T	CB	CHEBI:44632
DMZON3T	DE	Discovery agent

DMLS29E	ID	DMLS29E
DMLS29E	DN	(2S,1'R,2'S)-2-(2'-phosphonocyclopropyl)glycine
DMLS29E	HS	Investigative
DMLS29E	SN	CHEMBL442076; BDBM50207814
DMLS29E	DT	Small molecular drug
DMLS29E	PC	11708219
DMLS29E	MW	195.11
DMLS29E	FM	C5H10NO5P
DMLS29E	IC	InChI=1S/C5H10NO5P/c6-4(5(7)8)2-1-3(2)12(9,10)11/h2-4H,1,6H2,(H,7,8)(H2,9,10,11)/t2-,3-,4?/m0/s1
DMLS29E	CS	C1[C@@H]([C@H]1P(=O)(O)O)C(C(=O)O)N
DMLS29E	IK	KZOMBNQLBSHMFV-LPGMDIISSA-N
DMLS29E	IU	2-amino-2-[(1R,2S)-2-phosphonocyclopropyl]acetic acid
DMLS29E	DE	Discovery agent

DMJE83O	ID	DMJE83O
DMJE83O	DN	(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone
DMJE83O	HS	Investigative
DMJE83O	SN	CHEMBL212678; (2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone; BDBM50186510
DMJE83O	DT	Small molecular drug
DMJE83O	PC	44413811
DMJE83O	MW	234.29
DMJE83O	FM	C14H18O3
DMJE83O	IC	InChI=1S/C14H18O3/c1-16-13-9-5-8-12(15)14(13)17-10-11-6-3-2-4-7-11/h2-4,6-7,13-14H,5,8-10H2,1H3/t13-,14-/m1/s1
DMJE83O	CS	CO[C@@H]1CCCC(=O)[C@H]1OCC2=CC=CC=C2
DMJE83O	IK	KUAHCCGAHBFAKU-ZIAGYGMSSA-N
DMJE83O	IU	(2S,3R)-3-methoxy-2-phenylmethoxycyclohexan-1-one
DMJE83O	DE	Discovery agent

DM4JQCR	ID	DM4JQCR
DM4JQCR	DN	(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol
DM4JQCR	HS	Investigative
DM4JQCR	SN	CHEMBL296435; (2S,3R)-EHNA; CHEBI:63059; (2S,3R)-3-(6-aminopurin-9-yl)nonan-2-ol; 79813-69-7; (S,R)-6-amino-beta-hexyl-alpha-methyl-9H-purine-9-ethanol; HWC 46; 2z7g; AC1L3ZQL; (+)-erythro-9-(2-Hydroxy-3-nonyl)adenine; SCHEMBL1742728; CTK2H9986; BDBM28393; IOSAAWHGJUZBOG-WDEREUQCSA-N; ZINC1558334; EH9; (S-(R*,S*))-6-Amino-beta-hexyl-alpha-methyl-9H-purine-9-ethanol; AKOS030531307; 9H-Purine-9-ethanol, 6-amino-beta-hexyl-alpha-methyl-, (S-(R*,S*))-; DB07711
DM4JQCR	DT	Small molecular drug
DM4JQCR	PC	149790
DM4JQCR	MW	277.37
DM4JQCR	FM	C14H23N5O
DM4JQCR	IC	InChI=1S/C14H23N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-7H2,1-2H3,(H2,15,16,17)/t10-,11+/m0/s1
DM4JQCR	CS	CCCCCC[C@H]([C@H](C)O)N1C=NC2=C(N=CN=C21)N
DM4JQCR	IK	IOSAAWHGJUZBOG-WDEREUQCSA-N
DM4JQCR	IU	(2S,3R)-3-(6-aminopurin-9-yl)nonan-2-ol
DM4JQCR	CA	CAS 79813-69-7
DM4JQCR	CB	CHEBI:63059
DM4JQCR	DE	Discovery agent

DMDUI8R	ID	DMDUI8R
DMDUI8R	DN	(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol
DMDUI8R	HS	Investigative
DMDUI8R	SN	CHEMBL1173277; (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol; SCHEMBL15007654; RLZACOPBIXSOEX-SMDDNHRTSA-N
DMDUI8R	DT	Small molecular drug
DMDUI8R	PC	46837650
DMDUI8R	MW	235.32
DMDUI8R	FM	C14H21NO2
DMDUI8R	IC	InChI=1S/C14H21NO2/c1-10-6-5-7-12(8-10)14(16)11(2)15-13(3,4)9-17-14/h5-8,11,15-16H,9H2,1-4H3/t11-,14+/m0/s1
DMDUI8R	CS	C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=CC(=C2)C)O
DMDUI8R	IK	RLZACOPBIXSOEX-SMDDNHRTSA-N
DMDUI8R	IU	(2S,3S)-3,5,5-trimethyl-2-(3-methylphenyl)morpholin-2-ol
DMDUI8R	DE	Discovery agent

DMDUGZS	ID	DMDUGZS
DMDUGZS	DN	(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol
DMDUGZS	HS	Investigative
DMDUGZS	SN	CHEMBL1173274; (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol; SCHEMBL15007461; NGHJSSNVKXEBAB-GXFFZTMASA-N
DMDUGZS	DT	Small molecular drug
DMDUGZS	PC	46837647
DMDUGZS	MW	221.29
DMDUGZS	FM	C13H19NO2
DMDUGZS	IC	InChI=1S/C13H19NO2/c1-10-13(15,11-7-5-4-6-8-11)16-9-12(2,3)14-10/h4-8,10,14-15H,9H2,1-3H3/t10-,13+/m0/s1
DMDUGZS	CS	C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=CC=C2)O
DMDUGZS	IK	NGHJSSNVKXEBAB-GXFFZTMASA-N
DMDUGZS	IU	(2S,3S)-3,5,5-trimethyl-2-phenylmorpholin-2-ol
DMDUGZS	DE	Discovery agent

DMBEOIQ	ID	DMBEOIQ
DMBEOIQ	DN	(2S,3S)-iodoreboxetine
DMBEOIQ	HS	Investigative
DMBEOIQ	SN	(2S,3S)-iodoreboxetine; CHEMBL490996; BDBM50264064
DMBEOIQ	DT	Small molecular drug
DMBEOIQ	PC	44579601
DMBEOIQ	MW	439.3
DMBEOIQ	FM	C19H22INO3
DMBEOIQ	IC	InChI=1S/C19H22INO3/c1-2-22-16-5-3-4-6-17(16)24-19(18-13-21-11-12-23-18)14-7-9-15(20)10-8-14/h3-10,18-19,21H,2,11-13H2,1H3/t18-,19-/m0/s1
DMBEOIQ	CS	CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=C(C=C3)I
DMBEOIQ	IK	RVASAZVCHKJYMY-OALUTQOASA-N
DMBEOIQ	IU	(2S)-2-[(S)-(2-ethoxyphenoxy)-(4-iodophenyl)methyl]morpholine
DMBEOIQ	DE	Discovery agent

DMTQF2G	ID	DMTQF2G
DMTQF2G	DN	(2S,4R)-4-(3-Methoxy-3-oxopropyl)glutamic Acid
DMTQF2G	HS	Investigative
DMTQF2G	SN	CHEMBL482080; (2s,4r)-4-(3-Methoxy-3-Oxopropyl) Glutamic Acid; (2S,4R)-4-(3-Methoxy-3-oxopropyl)glutamic Acid; ZINC40934342; BDBM50252048; (4R)-4-(3-methoxy-3-oxopropyl)-L-glutamic acid; (2S,4R)-2-amino-4-(3-methoxy-3-oxopropyl)pentanedioic acid
DMTQF2G	DT	Small molecular drug
DMTQF2G	PC	24905704
DMTQF2G	MW	233.22
DMTQF2G	FM	C9H15NO6
DMTQF2G	IC	InChI=1S/C9H15NO6/c1-16-7(11)3-2-5(8(12)13)4-6(10)9(14)15/h5-6H,2-4,10H2,1H3,(H,12,13)(H,14,15)/t5-,6+/m1/s1
DMTQF2G	CS	COC(=O)CC[C@H](C[C@@H](C(=O)O)N)C(=O)O
DMTQF2G	IK	IPTIKQIFOOZKAT-RITPCOANSA-N
DMTQF2G	IU	(2S,4R)-2-amino-4-(3-methoxy-3-oxopropyl)pentanedioic acid
DMTQF2G	DE	Discovery agent

DMGXRSZ	ID	DMGXRSZ
DMGXRSZ	DN	(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime
DMGXRSZ	HS	Investigative
DMGXRSZ	DT	Small molecular drug
DMGXRSZ	PC	46222473
DMGXRSZ	DE	Discovery agent

DM6AUHR	ID	DM6AUHR
DM6AUHR	DN	(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime
DM6AUHR	HS	Investigative
DM6AUHR	DT	Small molecular drug
DM6AUHR	PC	46222693
DM6AUHR	DE	Discovery agent

DMD7WGM	ID	DMD7WGM
DMD7WGM	DN	(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime
DMD7WGM	HS	Investigative
DMD7WGM	DT	Small molecular drug
DMD7WGM	PC	46222245
DMD7WGM	DE	Discovery agent

DMZ0V6G	ID	DMZ0V6G
DMZ0V6G	DN	(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime
DMZ0V6G	HS	Investigative
DMZ0V6G	DT	Small molecular drug
DMZ0V6G	PC	46222697
DMZ0V6G	DE	Discovery agent

DMO7RFL	ID	DMO7RFL
DMO7RFL	DN	(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime
DMO7RFL	HS	Investigative
DMO7RFL	DT	Small molecular drug
DMO7RFL	PC	46222474
DMO7RFL	DE	Discovery agent

DMJ4ABD	ID	DMJ4ABD
DMJ4ABD	DN	(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime
DMJ4ABD	HS	Investigative
DMJ4ABD	DT	Small molecular drug
DMJ4ABD	PC	46222694
DMJ4ABD	DE	Discovery agent

DM9LQH1	ID	DM9LQH1
DM9LQH1	DN	(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime
DM9LQH1	HS	Investigative
DM9LQH1	DT	Small molecular drug
DM9LQH1	PC	46222470
DM9LQH1	DE	Discovery agent

DMQDH3N	ID	DMQDH3N
DMQDH3N	DN	(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime
DMQDH3N	HS	Investigative
DMQDH3N	DT	Small molecular drug
DMQDH3N	PC	46223585
DMQDH3N	DE	Discovery agent

DMAS3JC	ID	DMAS3JC
DMAS3JC	DN	(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime
DMAS3JC	HS	Investigative
DMAS3JC	DT	Small molecular drug
DMAS3JC	PC	46222698
DMAS3JC	DE	Discovery agent

DMYLX0U	ID	DMYLX0U
DMYLX0U	DN	(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime
DMYLX0U	HS	Investigative
DMYLX0U	DT	Small molecular drug
DMYLX0U	PC	46222472
DMYLX0U	DE	Discovery agent

DMXZ2UC	ID	DMXZ2UC
DMXZ2UC	DN	(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime
DMXZ2UC	HS	Investigative
DMXZ2UC	DT	Small molecular drug
DMXZ2UC	PC	46222476
DMXZ2UC	DE	Discovery agent

DM0S82C	ID	DM0S82C
DM0S82C	DN	(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime
DM0S82C	HS	Investigative
DM0S82C	DT	Small molecular drug
DM0S82C	PC	46222244
DM0S82C	DE	Discovery agent

DMLOIUK	ID	DMLOIUK
DMLOIUK	DN	(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime
DMLOIUK	HS	Investigative
DMLOIUK	DT	Small molecular drug
DMLOIUK	PC	46223584
DMLOIUK	DE	Discovery agent

DM6BA5L	ID	DM6BA5L
DM6BA5L	DN	(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime
DM6BA5L	HS	Investigative
DM6BA5L	DT	Small molecular drug
DM6BA5L	PC	46222696
DM6BA5L	DE	Discovery agent

DMUIOAP	ID	DMUIOAP
DMUIOAP	DN	(2'Z,3'E)-7-Azaindirubin-3'-oxime
DMUIOAP	HS	Investigative
DMUIOAP	DT	Small molecular drug
DMUIOAP	PC	44614397
DMUIOAP	DE	Discovery agent

DMBZJT5	ID	DMBZJT5
DMBZJT5	DN	(3-((1H-imidazol-1-yl)methyl)phenyl)methanol
DMBZJT5	HS	Investigative
DMBZJT5	SN	[3-(1H-Imidazol-1-ylmethyl)phenyl]methanol; 151055-79-7; CHEMBL597368; W-205714; [3-(imidazol-1-ylmethyl)phenyl]methanol; Benzenemethanol, 3-(1H-imidazol-1-ylmethyl)-; (3-((1H-imidazol-1-yl)methyl)phenyl)methanol; SCHEMBL3092795; DTXSID60439216; MolPort-000-143-255; ZX-AT016572; BDBM50307217; ZINC12370274; SBB090815; FCH921386; AKOS006343964; RP03595; [3-(imidazolylmethyl)phenyl]methan-1-ol; DB-063877; FT-0703495; Y7599; Benzenemethanol,3-(1H-imidazol-1-ylmethyl)-
DMBZJT5	DT	Small molecular drug
DMBZJT5	PC	10397593
DMBZJT5	MW	188.23
DMBZJT5	FM	C11H12N2O
DMBZJT5	IC	InChI=1S/C11H12N2O/c14-8-11-3-1-2-10(6-11)7-13-5-4-12-9-13/h1-6,9,14H,7-8H2
DMBZJT5	CS	C1=CC(=CC(=C1)CO)CN2C=CN=C2
DMBZJT5	IK	TXQZIKDWFOLTSC-UHFFFAOYSA-N
DMBZJT5	IU	[3-(imidazol-1-ylmethyl)phenyl]methanol
DMBZJT5	CA	CAS 151055-79-7
DMBZJT5	DE	Discovery agent

DMR6JTQ	ID	DMR6JTQ
DMR6JTQ	DN	(3-(2-methylquinolin-7-yl)phenyl)methanol
DMR6JTQ	HS	Investigative
DMR6JTQ	SN	CHEMBL231986; (3-(2-methylquinolin-7-yl)phenyl)methanol
DMR6JTQ	DT	Small molecular drug
DMR6JTQ	PC	44432665
DMR6JTQ	MW	249.31
DMR6JTQ	FM	C17H15NO
DMR6JTQ	IC	InChI=1S/C17H15NO/c1-12-5-6-14-7-8-16(10-17(14)18-12)15-4-2-3-13(9-15)11-19/h2-10,19H,11H2,1H3
DMR6JTQ	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC(=C3)CO
DMR6JTQ	IK	IPRCARTWCVTTOP-UHFFFAOYSA-N
DMR6JTQ	IU	[3-(2-methylquinolin-7-yl)phenyl]methanol
DMR6JTQ	DE	Discovery agent

DMNVDLI	ID	DMNVDLI
DMNVDLI	DN	(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone
DMNVDLI	HS	Investigative
DMNVDLI	SN	AC1LDSBN; BAS 02052919; (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone; N-Benzoylpyrazole deriv., 8; CHEMBL244917; ZINC37156; BDBM23706; MolPort-001-906-669; 3,4-dichlorophenyl pyrazolyl ketone; STK044137; AKOS000577014; MCULE-6190861509; ST033189; (3,4-dichlorophenyl)-pyrazol-1-ylmethanone; (3,4-Dichloro-phenyl)-pyrazol-1-yl-methanone; 1-[(3,4-dichlorophenyl)carbonyl]-1H-pyrazole; SR-01000521426; SR-01000521426-1
DMNVDLI	DT	Small molecular drug
DMNVDLI	PC	674628
DMNVDLI	MW	241.07
DMNVDLI	FM	C10H6Cl2N2O
DMNVDLI	IC	InChI=1S/C10H6Cl2N2O/c11-8-3-2-7(6-9(8)12)10(15)14-5-1-4-13-14/h1-6H
DMNVDLI	CS	C1=CN(N=C1)C(=O)C2=CC(=C(C=C2)Cl)Cl
DMNVDLI	IK	PPOZMMBGUFTQOQ-UHFFFAOYSA-N
DMNVDLI	IU	(3,4-dichlorophenyl)-pyrazol-1-ylmethanone
DMNVDLI	DE	Discovery agent

DMTB41W	ID	DMTB41W
DMTB41W	DN	(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE
DMTB41W	HS	Investigative
DMTB41W	SN	(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE; BIE; AC1OCAA0; SCHEMBL5898857; ICLKAUQIPVFHOI-UHFFFAOYSA-N; 3,4-dihydroxy-2-nitrobenzophenone; 4-benzoyl-3-nitrobenzene-1,2-diol; BIA-8-176; ZINC13677656; DB07462; (3,4-dihydroxy-2-nitrophenyl)phenylmethanone
DMTB41W	DT	Small molecular drug
DMTB41W	PC	6914595
DMTB41W	MW	259.209
DMTB41W	FM	C13H9NO5
DMTB41W	IC	InChI=1S/C13H9NO5/c15-10-7-6-9(11(13(10)17)14(18)19)12(16)8-4-2-1-3-5-8/h1-7,15,17H
DMTB41W	CS	C1=CC=C(C=C1)C(=O)C2=C(C(=C(C=C2)O)O)[N+](=O)[O-]
DMTB41W	IK	ICLKAUQIPVFHOI-UHFFFAOYSA-N
DMTB41W	IU	(3,4-dihydroxy-2-nitrophenyl)-phenylmethanone
DMTB41W	DE	Discovery agent

DMAF43E	ID	DMAF43E
DMAF43E	DN	(3,4-dimethylphenyl)(4-phenoxyphenyl)methanone
DMAF43E	HS	Investigative
DMAF43E	SN	(3,4-dimethylphenyl)(4-phenoxyphenyl)methanone; CHEMBL557722; CBDivE_001397; AC1MOFBF; AC1Q2DSA; Oprea1_371703; Oprea1_274103; MolPort-001-813-132; (3,4-DIMETHYL-PHENYL)-(4-PHENOXY-PHENYL)-METHANONE; ZINC2496519; STK333119; BDBM50296685; AKOS024330770; MCULE-5159255282
DMAF43E	DT	Small molecular drug
DMAF43E	PC	3342765
DMAF43E	MW	302.4
DMAF43E	FM	C21H18O2
DMAF43E	IC	InChI=1S/C21H18O2/c1-15-8-9-18(14-16(15)2)21(22)17-10-12-20(13-11-17)23-19-6-4-3-5-7-19/h3-14H,1-2H3
DMAF43E	CS	CC1=C(C=C(C=C1)C(=O)C2=CC=C(C=C2)OC3=CC=CC=C3)C
DMAF43E	IK	WAJARHMGAQFYHB-UHFFFAOYSA-N
DMAF43E	IU	(3,4-dimethylphenyl)-(4-phenoxyphenyl)methanone
DMAF43E	DE	Discovery agent

DM9PDCA	ID	DM9PDCA
DM9PDCA	DN	(3,5-Dibromo-4-butoxy-phenyl)-acetic acid
DM9PDCA	HS	Investigative
DM9PDCA	SN	Benzeneacetic acid, 3,5-dibromo-4-butoxy-; SCHEMBL4890007; CHEMBL192490; BDBM18899; 340697-16-7; 2-(3,5-dibromo-4-butoxyphenyl)acetic acid; 3,5-Dibromo-4-alkoxyphenylalkanoic Acid, 9b
DM9PDCA	DT	Small molecular drug
DM9PDCA	PC	9925361
DM9PDCA	MW	366.05
DM9PDCA	FM	C12H14Br2O3
DM9PDCA	IC	InChI=1S/C12H14Br2O3/c1-2-3-4-17-12-9(13)5-8(6-10(12)14)7-11(15)16/h5-6H,2-4,7H2,1H3,(H,15,16)
DM9PDCA	CS	CCCCOC1=C(C=C(C=C1Br)CC(=O)O)Br
DM9PDCA	IK	PDWWLSBHJFKDFA-UHFFFAOYSA-N
DM9PDCA	IU	2-(3,5-dibromo-4-butoxyphenyl)acetic acid
DM9PDCA	DE	Discovery agent

DM5GN46	ID	DM5GN46
DM5GN46	DN	(3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid
DM5GN46	HS	Investigative
DM5GN46	SN	CHEMBL192639; SCHEMBL4900725; BDBM18902; ZINC13643202; 3,5-Dibromo-4-alkoxyphenylalkanoic Acid, 9e; 2-[3,5-dibromo-4-(hexyloxy)phenyl]acetic acid
DM5GN46	DT	Small molecular drug
DM5GN46	PC	11153607
DM5GN46	MW	394.1
DM5GN46	FM	C14H18Br2O3
DM5GN46	IC	InChI=1S/C14H18Br2O3/c1-2-3-4-5-6-19-14-11(15)7-10(8-12(14)16)9-13(17)18/h7-8H,2-6,9H2,1H3,(H,17,18)
DM5GN46	CS	CCCCCCOC1=C(C=C(C=C1Br)CC(=O)O)Br
DM5GN46	IK	VJKVJESSSPWLJY-UHFFFAOYSA-N
DM5GN46	IU	2-(3,5-dibromo-4-hexoxyphenyl)acetic acid
DM5GN46	DE	Discovery agent

DMB5KVZ	ID	DMB5KVZ
DMB5KVZ	DN	(3,5-Dibromo-4-pentyloxy-phenyl)-acetic acid
DMB5KVZ	HS	Investigative
DMB5KVZ	SN	SCHEMBL4899221; CHEMBL193152; BDBM18900; ZINC13643198; 3,5-Dibromo-4-alkoxyphenylalkanoic Acid, 9c; 2-[3,5-dibromo-4-(pentyloxy)phenyl]acetic acid
DMB5KVZ	DT	Small molecular drug
DMB5KVZ	PC	11291923
DMB5KVZ	MW	380.07
DMB5KVZ	FM	C13H16Br2O3
DMB5KVZ	IC	InChI=1S/C13H16Br2O3/c1-2-3-4-5-18-13-10(14)6-9(7-11(13)15)8-12(16)17/h6-7H,2-5,8H2,1H3,(H,16,17)
DMB5KVZ	CS	CCCCCOC1=C(C=C(C=C1Br)CC(=O)O)Br
DMB5KVZ	IK	DMILDBSUKKQQDG-UHFFFAOYSA-N
DMB5KVZ	IU	2-(3,5-dibromo-4-pentoxyphenyl)acetic acid
DMB5KVZ	DE	Discovery agent

DM3OPNE	ID	DM3OPNE
DM3OPNE	DN	(35)S-labeled oligonucleotide
DM3OPNE	HS	Investigative
DM3OPNE	TC	Antisense
DM3OPNE	DT	Antisense drug
DM3OPNE	DE	Discovery agent

DMPHCX7	ID	DMPHCX7
DMPHCX7	DN	(3-Amino-1-ethyl-propyl)-methyl-phosphinic acid
DMPHCX7	HS	Investigative
DMPHCX7	SN	CHEMBL113092; 133345-70-7; Phosphinic acid, (3-amino-1-ethylpropyl)methyl-; ACMC-20muwd; (3-Amino-1-ethyl-propyl)-methyl-phosphinic acid; SCHEMBL341182; CTK0C0402; DTXSID30435583; CCGFQGUALPHBIC-UHFFFAOYSA-N; BDBM50032974; P-(5-aminopent-3-yl)-P-methylphosphinic acid; P-(5-aminopent-3-yl)-P-methyl-phosphinic acid; Phosphinic acid, P-(3-amino-1-ethylpropyl)-P-methyl-
DMPHCX7	DT	Small molecular drug
DMPHCX7	PC	10103488
DMPHCX7	MW	165.17
DMPHCX7	FM	C6H16NO2P
DMPHCX7	IC	InChI=1S/C6H16NO2P/c1-3-6(4-5-7)10(2,8)9/h6H,3-5,7H2,1-2H3,(H,8,9)
DMPHCX7	CS	CCC(CCN)P(=O)(C)O
DMPHCX7	IK	CCGFQGUALPHBIC-UHFFFAOYSA-N
DMPHCX7	IU	1-aminopentan-3-yl(methyl)phosphinic acid
DMPHCX7	CA	CAS 133345-70-7
DMPHCX7	DE	Discovery agent

DM7HF4I	ID	DM7HF4I
DM7HF4I	DN	(3-Amino-1-hydroxy-propyl)-methyl-phosphinic acid
DM7HF4I	HS	Investigative
DM7HF4I	SN	SCHEMBL341289
DM7HF4I	DT	Small molecular drug
DM7HF4I	PC	53719915
DM7HF4I	MW	152.11
DM7HF4I	FM	C4H11NO3P+
DM7HF4I	IC	InChI=1S/C4H11NO3P/c1-9(7,8)4(6)2-3-5/h7-8H,2-3,5H2,1H3/q+1
DM7HF4I	CS	C[P+](C(=O)CCN)(O)O
DM7HF4I	IK	XRHWOLGPXAOKPF-UHFFFAOYSA-N
DM7HF4I	IU	3-aminopropanoyl-dihydroxy-methylphosphanium
DM7HF4I	DE	Discovery agent

DMP2G5W	ID	DMP2G5W
DMP2G5W	DN	(3-amino-5-bromobenzofuran-2-yl)(phenyl)methanone
DMP2G5W	HS	Investigative
DMP2G5W	SN	CHEMBL591458; (3-Amino-5-bromo-benzofuran-2-yl)-phenyl-methanone; (3-amino-5-bromo-1-benzofuran-2-yl)(phenyl)methanone; SMR000010549; MLS000031617; AC1LCKCT; regid849115; Oprea1_732422; Oprea1_454471; MLS002534670; (3-amino-5-bromobenzofuran-2-yl)(phenyl)methanone; SCHEMBL13102601; ZINC97827; CTK5I8073; MolPort-000-164-762; HMS2395L21; STK078344; BDBM50306745; AKOS000510990; MCULE-9438936220; ST037109; BAS 01507283; EU-0018517; 3-amino-5-bromobenzo[d]furan-2-yl phenyl ketone; SR-01000523207; SR-01000523207-1
DMP2G5W	DT	Small molecular drug
DMP2G5W	PC	651586
DMP2G5W	MW	316.15
DMP2G5W	FM	C15H10BrNO2
DMP2G5W	IC	InChI=1S/C15H10BrNO2/c16-10-6-7-12-11(8-10)13(17)15(19-12)14(18)9-4-2-1-3-5-9/h1-8H,17H2
DMP2G5W	CS	C1=CC=C(C=C1)C(=O)C2=C(C3=C(O2)C=CC(=C3)Br)N
DMP2G5W	IK	SBFAYONAJFSEPC-UHFFFAOYSA-N
DMP2G5W	IU	(3-amino-5-bromo-1-benzofuran-2-yl)-phenylmethanone
DMP2G5W	DE	Discovery agent

DMDGFS0	ID	DMDGFS0
DMDGFS0	DN	(3-Amino-phenyl)-phosphonic acid diphenyl ester
DMDGFS0	HS	Investigative
DMDGFS0	SN	CHEMBL158955
DMDGFS0	DT	Small molecular drug
DMDGFS0	PC	44373237
DMDGFS0	MW	325.3
DMDGFS0	FM	C18H16NO3P
DMDGFS0	IC	InChI=1S/C18H16NO3P/c19-15-8-7-13-18(14-15)23(20,21-16-9-3-1-4-10-16)22-17-11-5-2-6-12-17/h1-14H,19H2
DMDGFS0	CS	C1=CC=C(C=C1)OP(=O)(C2=CC=CC(=C2)N)OC3=CC=CC=C3
DMDGFS0	IK	CJCPJYQCUVSSBA-UHFFFAOYSA-N
DMDGFS0	IU	3-diphenoxyphosphorylaniline
DMDGFS0	DE	Discovery agent

DMBJYTD	ID	DMBJYTD
DMBJYTD	DN	(3-Amino-propyl)-hexyl-phosphinic acid
DMBJYTD	HS	Investigative
DMBJYTD	SN	3-Aminopropyl(hexyl)phosphinic acid; 3-Aphpa; 123691-31-6; 3-Aminopropyl(n-hexyl)phosphinic acid; CHEMBL113571; Phosphinic acid,(3-aminopropyl)hexyl- (9CI); ACMC-20mqpl; (3-Amino-propyl)-hexyl-phosphinic acid; AC1L2WN2; SCHEMBL6354602; CTK4B3595; DTXSID90154066
DMBJYTD	DT	Small molecular drug
DMBJYTD	PC	130023
DMBJYTD	MW	207.25
DMBJYTD	FM	C9H22NO2P
DMBJYTD	IC	InChI=1S/C9H22NO2P/c1-2-3-4-5-8-13(11,12)9-6-7-10/h2-10H2,1H3,(H,11,12)
DMBJYTD	CS	CCCCCCP(=O)(CCCN)O
DMBJYTD	IK	QVUUPQCCYOPHFY-UHFFFAOYSA-N
DMBJYTD	IU	3-aminopropyl(hexyl)phosphinic acid
DMBJYTD	CA	CAS 123691-31-6
DMBJYTD	DE	Discovery agent

DMGFIJV	ID	DMGFIJV
DMGFIJV	DN	(3-Amino-propyl)-hydroxymethyl-phosphinic acid
DMGFIJV	HS	Investigative
DMGFIJV	SN	AC1MTETN; SCHEMBL341290; MolPort-002-514-611; STL513587; ZINC20112625; AKOS030493595; MCULE-2944312169; 3-aminopropyl(hydroxymethyl)phosphinic acid; (Hydroxymethyl)(3-aminopropyl)phosphinic acid; (3-aminopropyl)(hydroxymethyl)phosphinic acid
DMGFIJV	DT	Small molecular drug
DMGFIJV	PC	91929121
DMGFIJV	MW	152.11
DMGFIJV	FM	C4H11NO3P+
DMGFIJV	IC	InChI=1S/C4H11NO3P/c5-2-1-3-9(7,8)4-6/h4,7-8H,1-3,5H2/q+1
DMGFIJV	CS	C(CN)C[P+](C=O)(O)O
DMGFIJV	IK	WKJVZSFFUHQPOM-UHFFFAOYSA-N
DMGFIJV	IU	3-aminopropyl-formyl-dihydroxyphosphanium
DMGFIJV	DE	Discovery agent

DMK3JZS	ID	DMK3JZS
DMK3JZS	DN	(3-Amino-propyl)-phosphonic acid
DMK3JZS	HS	Investigative
DMK3JZS	SN	3-Aminopropylphosphonic acid; 13138-33-5; (3-aminopropyl)phosphonic acid; Aminopropylphosphonate; 3-Aminopropylphosphonicacid; UNII-VM92T06VPB; (3-Amino-propyl)-phosphonic acid; Phosphonic acid, (3-aminopropyl)-; VM92T06VPB; CHEMBL286077; GSZQTIFGANBTNF-UHFFFAOYSA-N; GEO-00218; NSC-133832; 3-phosphonopropylamine; AK-33107; 3-Appn; (3-Aminopropyl)phosphonic acid, 97%; NSC 133832; Phosphate analogue, 8; PubChem10325; ACMC-1BXXY; AC1L3YTO; 3-aminopropyl-phosphonate; timtec-bb sbb004184; Lopac-A-7162; AC1Q6RQ7; SCHEMBL35883
DMK3JZS	DT	Small molecular drug
DMK3JZS	PC	97587
DMK3JZS	MW	139.09
DMK3JZS	FM	C3H10NO3P
DMK3JZS	IC	InChI=1S/C3H10NO3P/c4-2-1-3-8(5,6)7/h1-4H2,(H2,5,6,7)
DMK3JZS	CS	C(CN)CP(=O)(O)O
DMK3JZS	IK	GSZQTIFGANBTNF-UHFFFAOYSA-N
DMK3JZS	IU	3-aminopropylphosphonic acid
DMK3JZS	CA	CAS 13138-33-5
DMK3JZS	CB	CHEBI:142993
DMK3JZS	DE	Discovery agent

DMHF01G	ID	DMHF01G
DMHF01G	DN	(3-Bromobenzoylpyridine)thiosemicarbazone
DMHF01G	HS	Investigative
DMHF01G	SN	(3-Bromobenzoylpyridine)thiosemicarbazone; CHEMBL1269715
DMHF01G	DT	Small molecular drug
DMHF01G	PC	52940642
DMHF01G	MW	335.22
DMHF01G	FM	C13H11BrN4S
DMHF01G	IC	InChI=1S/C13H11BrN4S/c14-11-5-1-3-9(7-11)12(17-18-13(15)19)10-4-2-6-16-8-10/h1-8H,(H3,15,18,19)/b17-12-
DMHF01G	CS	C1=CC(=CC(=C1)Br)/C(=N/NC(=S)N)/C2=CN=CC=C2
DMHF01G	IK	DPTPEKAUCAAQNG-ATVHPVEESA-N
DMHF01G	IU	[(Z)-[(3-bromophenyl)-pyridin-3-ylmethylidene]amino]thiourea
DMHF01G	DE	Discovery agent

DMIJH7W	ID	DMIJH7W
DMIJH7W	DN	(3-bromophenyl)(10H-phenothiazin-10-yl)methanone
DMIJH7W	HS	Investigative
DMIJH7W	SN	CHEMBL239616; (3-bromophenyl)(10H-phenothiazin-10-yl)methanone; (3-Bromo-phenyl)-phenothiazin-10-yl-methanone; AC1LCW7V; ChemDiv1_023786; C19H12BrNOS; HMS654J04; XWGLMCFWNRNHDU-UHFFFAOYSA-N; MolPort-002-545-921; 10-(3-Bromobenzoyl)phenothiazine; ZINC4785817; STL361327; BDBM50219221; AKOS001639315; MCULE-3829813488; BAS 00721881; 10-(3-Bromobenzoyl)-10H-phenothiazine #; (3-bromophenyl)-phenothiazin-10-ylmethanone; EU-0008504; SR-01000465493; SR-01000465493-1
DMIJH7W	DT	Small molecular drug
DMIJH7W	PC	607810
DMIJH7W	MW	382.3
DMIJH7W	FM	C19H12BrNOS
DMIJH7W	IC	InChI=1S/C19H12BrNOS/c20-14-7-5-6-13(12-14)19(22)21-15-8-1-3-10-17(15)23-18-11-4-2-9-16(18)21/h1-12H
DMIJH7W	CS	C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)C4=CC(=CC=C4)Br
DMIJH7W	IK	XWGLMCFWNRNHDU-UHFFFAOYSA-N
DMIJH7W	IU	(3-bromophenyl)-phenothiazin-10-ylmethanone
DMIJH7W	DE	Discovery agent

DMHLF2S	ID	DMHLF2S
DMHLF2S	DN	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine
DMHLF2S	HS	Investigative
DMHLF2S	SN	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41
DMHLF2S	DT	Small molecular drug
DMHLF2S	PC	5328038
DMHLF2S	MW	345.15
DMHLF2S	FM	C14H9BrN4O2
DMHLF2S	IC	InChI=1S/C14H9BrN4O2/c15-9-3-1-4-10(7-9)18-14-13-11(16-8-17-14)5-2-6-12(13)19(20)21/h1-8H,(H,16,17,18)
DMHLF2S	CS	C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C(=CC=C3)[N+](=O)[O-]
DMHLF2S	IK	CFLDNHCFXUEPKN-UHFFFAOYSA-N
DMHLF2S	IU	N-(3-bromophenyl)-5-nitroquinazolin-4-amine
DMHLF2S	DE	Discovery agent

DMMIPZ8	ID	DMMIPZ8
DMMIPZ8	DN	(3-Bromo-phenyl)-quinazolin-4-yl-amine
DMMIPZ8	HS	Investigative
DMMIPZ8	SN	N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-
DMMIPZ8	DT	Small molecular drug
DMMIPZ8	PC	735125
DMMIPZ8	MW	300.15
DMMIPZ8	FM	C14H10BrN3
DMMIPZ8	IC	InChI=1S/C14H10BrN3/c15-10-4-3-5-11(8-10)18-14-12-6-1-2-7-13(12)16-9-17-14/h1-9H,(H,16,17,18)
DMMIPZ8	CS	C1=CC=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Br
DMMIPZ8	IK	SUTRLYZWRGPLSJ-UHFFFAOYSA-N
DMMIPZ8	IU	N-(3-bromophenyl)quinazolin-4-amine
DMMIPZ8	DE	Discovery agent

DMUJ18K	ID	DMUJ18K
DMUJ18K	DN	(3-Bromo-propyl)-trimethyl-ammonium
DMUJ18K	HS	Investigative
DMUJ18K	DT	Small molecular drug
DMUJ18K	PC	151145
DMUJ18K	MW	261
DMUJ18K	FM	C6H15Br2N
DMUJ18K	IC	InChI=1S/C6H15BrN.BrH/c1-8(2,3)6-4-5-7;/h4-6H2,1-3H3;1H/q+1;/p-1
DMUJ18K	CS	C[N+](C)(C)CCCBr.[Br-]
DMUJ18K	IK	NNZGNZHUGJAKKT-UHFFFAOYSA-M
DMUJ18K	IU	3-bromopropyl(trimethyl)azanium;bromide
DMUJ18K	CA	CAS 3779-42-8
DMUJ18K	DE	Discovery agent

DMHODXG	ID	DMHODXG
DMHODXG	DN	(3-Chloro-4-Propoxy-Phenyl)-Acetic Acid
DMHODXG	HS	Investigative
DMHODXG	SN	(3-chloro-4-propoxyphenyl)acetic acid; (3-CHLORO-4-PROPOXY-PHENYL)-ACETIC ACID; 2-(3-chloro-4-propoxyphenyl)acetic acid; AC1L1CVR; SCHEMBL4321455; CTK6E6068; MolPort-005-983-242; HMS3604N10; ZINC3871464; STL386671; AKOS000296250; MCULE-5882985924
DMHODXG	DT	Small molecular drug
DMHODXG	PC	2084
DMHODXG	MW	228.67
DMHODXG	FM	C11H13ClO3
DMHODXG	IC	InChI=1S/C11H13ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h3-4,6H,2,5,7H2,1H3,(H,13,14)
DMHODXG	CS	CCCOC1=C(C=C(C=C1)CC(=O)O)Cl
DMHODXG	IK	QEJHPAGTOOIBFT-UHFFFAOYSA-N
DMHODXG	IU	2-(3-chloro-4-propoxyphenyl)acetic acid
DMHODXG	CA	CAS 23914-91-2
DMHODXG	DE	Discovery agent

DM7U02R	ID	DM7U02R
DM7U02R	DN	(3-Chloro-phenyl)-piperazin-1-yl-methanone
DM7U02R	HS	Investigative
DM7U02R	SN	100939-90-0; 1-(3-chlorobenzoyl)piperazine; (3-chlorophenyl)(piperazin-1-yl)methanone; (3-Chloro-phenyl)-piperazin-1-yl-methanone; BAS 04443403; (3-Chlorophenyl)(1-piperazinyl)methanone; CHEMBL160911; Methanone, (3-chlorophenyl)-1-piperazinyl-; 1-[(3-chlorophenyl)carbonyl]piperazine; 3-chlorophenyl piperazinyl ketone; AC1LLWSU; AC1Q3I0G; TimTec1_008470; 4-(3-chlorobenzoyl)piperazine; SCHEMBL2733887; 1-(3-Chlorobenzoyl)-piperazine; CTK6H2326; DTXSID70360082; MolPort-000-163-293; FBTDRVSCKFZIQH-UHFFFAOYSA-N; ZINC782987
DM7U02R	DT	Small molecular drug
DM7U02R	PC	1074765
DM7U02R	MW	224.68
DM7U02R	FM	C11H13ClN2O
DM7U02R	IC	InChI=1S/C11H13ClN2O/c12-10-3-1-2-9(8-10)11(15)14-6-4-13-5-7-14/h1-3,8,13H,4-7H2
DM7U02R	CS	C1CN(CCN1)C(=O)C2=CC(=CC=C2)Cl
DM7U02R	IK	FBTDRVSCKFZIQH-UHFFFAOYSA-N
DM7U02R	IU	(3-chlorophenyl)-piperazin-1-ylmethanone
DM7U02R	CA	CAS 100939-90-0
DM7U02R	DE	Discovery agent

DMG1KIJ	ID	DMG1KIJ
DMG1KIJ	DN	(3-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amine
DMG1KIJ	HS	Investigative
DMG1KIJ	SN	CHEMBL194743; (3-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amine; SCHEMBL5582608
DMG1KIJ	DT	Small molecular drug
DMG1KIJ	PC	11321863
DMG1KIJ	MW	215.25
DMG1KIJ	FM	C12H13N3O
DMG1KIJ	IC	InChI=1S/C12H13N3O/c1-2-16-10-6-5-9-14-12(10)15-11-7-3-4-8-13-11/h3-9H,2H2,1H3,(H,13,14,15)
DMG1KIJ	CS	CCOC1=C(N=CC=C1)NC2=CC=CC=N2
DMG1KIJ	IK	QXDACVHUAQTTKS-UHFFFAOYSA-N
DMG1KIJ	IU	3-ethoxy-N-pyridin-2-ylpyridin-2-amine
DMG1KIJ	DE	Discovery agent

DM5WJBH	ID	DM5WJBH
DM5WJBH	DN	(3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DM5WJBH	HS	Investigative
DM5WJBH	SN	CHEMBL154228; (3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine; SCHEMBL7616000; BDBM50048611
DM5WJBH	DT	Small molecular drug
DM5WJBH	PC	10850308
DM5WJBH	MW	279.4
DM5WJBH	FM	C18H21N3
DM5WJBH	IC	InChI=1S/C18H21N3/c1-3-13-20(16-9-11-19-12-10-16)21-14-15(4-2)17-7-5-6-8-18(17)21/h5-12,14H,3-4,13H2,1-2H3
DM5WJBH	CS	CCCN(C1=CC=NC=C1)N2C=C(C3=CC=CC=C32)CC
DM5WJBH	IK	KHGNFQVPPCBUSI-UHFFFAOYSA-N
DM5WJBH	IU	3-ethyl-N-propyl-N-pyridin-4-ylindol-1-amine
DM5WJBH	DE	Discovery agent

DMPHM23	ID	DMPHM23
DMPHM23	DN	(3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMPHM23	HS	Investigative
DMPHM23	SN	CHEMBL382214; (3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMPHM23	DT	Small molecular drug
DMPHM23	PC	11530398
DMPHM23	MW	350.3
DMPHM23	FM	C21H15FO4
DMPHM23	IC	InChI=1S/C21H15FO4/c22-19-12-14(13-20(23)24)6-11-18(19)21(25)15-7-9-17(10-8-15)26-16-4-2-1-3-5-16/h1-12H,13H2,(H,23,24)
DMPHM23	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=C(C=C(C=C3)CC(=O)O)F
DMPHM23	IK	DXGWDHUXZJQMIN-UHFFFAOYSA-N
DMPHM23	IU	2-[3-fluoro-4-(4-phenoxybenzoyl)phenyl]acetic acid
DMPHM23	DE	Discovery agent

DM08UQF	ID	DM08UQF
DM08UQF	DN	(3-Hydroxy-2-methyl-phenyl)-trimethyl-ammonium
DM08UQF	HS	Investigative
DM08UQF	DT	Small molecular drug
DM08UQF	PC	46905907
DM08UQF	MW	313.05
DM08UQF	FM	C9H17Br2N2+
DM08UQF	IC	InChI=1S/C9H15N2.2BrH/c1-11(2,3)9-6-4-5-8(10)7-9;;/h4-7H,10H2,1-3H3;2*1H/q+1;;
DM08UQF	CS	C[N+](C)(C)C1=CC=CC(=C1)N.Br.Br
DM08UQF	IK	XSYKHNGMJVWEPB-UHFFFAOYSA-N
DM08UQF	IU	(3-aminophenyl)-trimethylazanium;dihydrobromide
DM08UQF	DE	Discovery agent

DMX5CY3	ID	DMX5CY3
DMX5CY3	DN	(3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMX5CY3	HS	Investigative
DMX5CY3	SN	CHEMBL201762; (3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMX5CY3	DT	Small molecular drug
DMX5CY3	PC	11717189
DMX5CY3	MW	346.4
DMX5CY3	FM	C22H18O4
DMX5CY3	IC	InChI=1S/C22H18O4/c1-15-13-16(14-21(23)24)7-12-20(15)22(25)17-8-10-19(11-9-17)26-18-5-3-2-4-6-18/h2-13H,14H2,1H3,(H,23,24)
DMX5CY3	CS	CC1=C(C=CC(=C1)CC(=O)O)C(=O)C2=CC=C(C=C2)OC3=CC=CC=C3
DMX5CY3	IK	XPAYPQXQKZWIEL-UHFFFAOYSA-N
DMX5CY3	IU	2-[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
DMX5CY3	DE	Discovery agent

DMHED9G	ID	DMHED9G
DMHED9G	DN	(3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DMHED9G	HS	Investigative
DMHED9G	SN	CHEMBL350692; (3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine; SCHEMBL7612026; BDBM50048587
DMHED9G	DT	Small molecular drug
DMHED9G	PC	10635415
DMHED9G	MW	265.35
DMHED9G	FM	C17H19N3
DMHED9G	IC	InChI=1S/C17H19N3/c1-3-12-19(15-8-10-18-11-9-15)20-13-14(2)16-6-4-5-7-17(16)20/h4-11,13H,3,12H2,1-2H3
DMHED9G	CS	CCCN(C1=CC=NC=C1)N2C=C(C3=CC=CC=C32)C
DMHED9G	IK	JFXXREWKFGYUCE-UHFFFAOYSA-N
DMHED9G	IU	3-methyl-N-propyl-N-pyridin-4-ylindol-1-amine
DMHED9G	DE	Discovery agent

DMD4Z6H	ID	DMD4Z6H
DMD4Z6H	DN	(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMD4Z6H	HS	Investigative
DMD4Z6H	SN	(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone; AC1LDSPA; 3-nitropyrazolyl phenyl ketone; N-Benzoylpyrazole deriv., 19; CHEMBL244940; 1-benzoyl-3-nitro-1H-pyrazole; BDBM23711; ZINC79624; MolPort-002-705-611; STK760577; AKOS001756309; (3-nitropyrazol-1-yl)-phenylmethanone; MCULE-2233615430; ST073764; SR-01000524822; SR-01000524822-1
DMD4Z6H	DT	Small molecular drug
DMD4Z6H	PC	700133
DMD4Z6H	MW	217.18
DMD4Z6H	FM	C10H7N3O3
DMD4Z6H	IC	InChI=1S/C10H7N3O3/c14-10(8-4-2-1-3-5-8)12-7-6-9(11-12)13(15)16/h1-7H
DMD4Z6H	CS	C1=CC=C(C=C1)C(=O)N2C=CC(=N2)[N+](=O)[O-]
DMD4Z6H	IK	MIWUBRDWBKJULS-UHFFFAOYSA-N
DMD4Z6H	IU	(3-nitropyrazol-1-yl)-phenylmethanone
DMD4Z6H	DE	Discovery agent

DMT9FZD	ID	DMT9FZD
DMT9FZD	DN	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone
DMT9FZD	HS	Investigative
DMT9FZD	SN	(4-methylphenyl)(3-nitro-1H-pyrazol-1-yl)methanone; AC1LF99H; N-Benzoylpyrazole deriv., 18; CHEMBL244939; ZINC78678; BDBM23710; A2012/0084499; MolPort-002-705-255; STK760276; AKOS001746005; 4-methylphenyl 3-nitropyrazolyl ketone; MCULE-9242110239; ST073763; (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone; SR-01000524341; 1-[(4-methylphenyl)carbonyl]-3-nitro-1H-pyrazole
DMT9FZD	DT	Small molecular drug
DMT9FZD	PC	699665
DMT9FZD	MW	231.21
DMT9FZD	FM	C11H9N3O3
DMT9FZD	IC	InChI=1S/C11H9N3O3/c1-8-2-4-9(5-3-8)11(15)13-7-6-10(12-13)14(16)17/h2-7H,1H3
DMT9FZD	CS	CC1=CC=C(C=C1)C(=O)N2C=CC(=N2)[N+](=O)[O-]
DMT9FZD	IK	PQRIEIACDJITID-UHFFFAOYSA-N
DMT9FZD	IU	(4-methylphenyl)-(3-nitropyrazol-1-yl)methanone
DMT9FZD	DE	Discovery agent

DMGYAP7	ID	DMGYAP7
DMGYAP7	DN	(3-Phenoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
DMGYAP7	HS	Investigative
DMGYAP7	SN	N-(3-phenoxyphenyl)-5-phenyl-1,3-oxazol-2-amine; 2-Anilino-5-aryloxazole 11; AC1NS7R8; CHEMBL191626
DMGYAP7	DT	Small molecular drug
DMGYAP7	PC	5329846
DMGYAP7	MW	328.4
DMGYAP7	FM	C21H16N2O2
DMGYAP7	IC	InChI=1S/C21H16N2O2/c1-3-8-16(9-4-1)20-15-22-21(25-20)23-17-10-7-13-19(14-17)24-18-11-5-2-6-12-18/h1-15H,(H,22,23)
DMGYAP7	CS	C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC(=CC=C3)OC4=CC=CC=C4
DMGYAP7	IK	JTIZQZSOCSALNJ-UHFFFAOYSA-N
DMGYAP7	IU	N-(3-phenoxyphenyl)-5-phenyl-1,3-oxazol-2-amine
DMGYAP7	DE	Discovery agent

DM1C90Y	ID	DM1C90Y
DM1C90Y	DN	(3-Phenyl-propyl)-quinazolin-4-yl-amine
DM1C90Y	HS	Investigative
DM1C90Y	SN	CHEMBL42565; N-(3-phenylpropyl)quinazolin-4-amine; (3-Phenyl-propyl)-quinazolin-4-yl-amine; MolPort-011-928-362; BDBM50282106; ZINC13476428; AKOS009045718; MCULE-1024483265; Z127145812
DM1C90Y	DT	Small molecular drug
DM1C90Y	PC	44288306
DM1C90Y	MW	263.34
DM1C90Y	FM	C17H17N3
DM1C90Y	IC	InChI=1S/C17H17N3/c1-2-7-14(8-3-1)9-6-12-18-17-15-10-4-5-11-16(15)19-13-20-17/h1-5,7-8,10-11,13H,6,9,12H2,(H,18,19,20)
DM1C90Y	CS	C1=CC=C(C=C1)CCCNC2=NC=NC3=CC=CC=C32
DM1C90Y	IK	OAPMCZLOWYUSSD-UHFFFAOYSA-N
DM1C90Y	IU	N-(3-phenylpropyl)quinazolin-4-amine
DM1C90Y	DE	Discovery agent

DM49YTN	ID	DM49YTN
DM49YTN	DN	(3r)-1-Acetyl-3-Methylpiperidine
DM49YTN	HS	Investigative
DM49YTN	SN	(3R)-1-ACETYL-3-METHYLPIPERIDINE; 1-[(3R)-3-methylpiperidin-1-yl]ethanone; 1P3; 1w8l; AC1L9MR1; SCHEMBL4309663; ZINC389643; DB01742
DM49YTN	DT	Small molecular drug
DM49YTN	PC	449120
DM49YTN	MW	141.21
DM49YTN	FM	C8H15NO
DM49YTN	IC	InChI=1S/C8H15NO/c1-7-4-3-5-9(6-7)8(2)10/h7H,3-6H2,1-2H3/t7-/m1/s1
DM49YTN	CS	C[C@@H]1CCCN(C1)C(=O)C
DM49YTN	IK	XKFPNHDGLSYZRC-SSDOTTSWSA-N
DM49YTN	IU	1-[(3R)-3-methylpiperidin-1-yl]ethanone
DM49YTN	DE	Discovery agent

DMEUBGY	ID	DMEUBGY
DMEUBGY	DN	(3R)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine
DMEUBGY	HS	Investigative
DMEUBGY	SN	CHEMBL566788; (3R)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine
DMEUBGY	DT	Small molecular drug
DMEUBGY	PC	11275885
DMEUBGY	MW	212.29
DMEUBGY	FM	C14H16N2
DMEUBGY	IC	InChI=1S/C14H16N2/c1-9-6-7-11-13(8-9)16-12-5-3-2-4-10(12)14(11)15/h2-5,9H,6-8H2,1H3,(H2,15,16)/t9-/m1/s1
DMEUBGY	CS	C[C@@H]1CCC2=C(C3=CC=CC=C3N=C2C1)N
DMEUBGY	IK	WVQOYPIATZDPLZ-SECBINFHSA-N
DMEUBGY	IU	(3R)-3-methyl-1,2,3,4-tetrahydroacridin-9-amine
DMEUBGY	DE	Discovery agent

DM47BEG	ID	DM47BEG
DM47BEG	DN	(3R,4S)-293B
DM47BEG	HS	Investigative
DM47BEG	SN	LS-185874
DM47BEG	DT	Small molecular drug
DM47BEG	PC	121846
DM47BEG	MW	324.4
DM47BEG	FM	C15H20N2O4S
DM47BEG	IC	InChI=1S/C15H20N2O4S/c1-5-22(19,20)17(4)13-11-8-10(9-16)6-7-12(11)21-15(2,3)14(13)18/h6-8,13-14,18H,5H2,1-4H3/t13-,14+/m0/s1
DM47BEG	CS	CCS(=O)(=O)N(C)[C@@H]1[C@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O
DM47BEG	IK	HVSJHHXUORMCGK-UONOGXRCSA-N
DM47BEG	IU	N-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-N-methylethanesulfonamide
DM47BEG	CA	CAS 163163-23-3
DM47BEG	CB	CHEBI:34637
DM47BEG	DE	Discovery agent

DMET6IS	ID	DMET6IS
DMET6IS	DN	(3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol
DMET6IS	HS	Investigative
DMET6IS	SN	CHEMBL311850
DMET6IS	DT	Small molecular drug
DMET6IS	PC	44314178
DMET6IS	MW	282.4
DMET6IS	FM	C19H22O2
DMET6IS	IC	InChI=1S/C19H22O2/c1-13(2)15-8-9-17-18(11-15)21-12-16(19(17)20)10-14-6-4-3-5-7-14/h3-9,11,13,16,19-20H,10,12H2,1-2H3/t16-,19+/m0/s1
DMET6IS	CS	CC(C)C1=CC2=C(C=C1)[C@@H]([C@H](CO2)CC3=CC=CC=C3)O
DMET6IS	IK	OJNGOFXPXHHONH-QFBILLFUSA-N
DMET6IS	IU	(3S,4R)-3-benzyl-7-propan-2-yl-3,4-dihydro-2H-chromen-4-ol
DMET6IS	DE	Discovery agent

DMAEXO3	ID	DMAEXO3
DMAEXO3	DN	(3S,4R)-3-butyl-1-phenylpiperidin-4-amine
DMAEXO3	HS	Investigative
DMAEXO3	SN	CHEMBL394662; (3S,4R)-3-butyl-1-phenylpiperidin-4-amine
DMAEXO3	DT	Small molecular drug
DMAEXO3	PC	44431745
DMAEXO3	MW	232.36
DMAEXO3	FM	C15H24N2
DMAEXO3	IC	InChI=1S/C15H24N2/c1-2-3-7-13-12-17(11-10-15(13)16)14-8-5-4-6-9-14/h4-6,8-9,13,15H,2-3,7,10-12,16H2,1H3/t13-,15+/m0/s1
DMAEXO3	CS	CCCC[C@H]1CN(CC[C@H]1N)C2=CC=CC=C2
DMAEXO3	IK	YRWPYATYRUCVQO-DZGCQCFKSA-N
DMAEXO3	IU	(3S,4R)-3-butyl-1-phenylpiperidin-4-amine
DMAEXO3	DE	Discovery agent

DM6P35D	ID	DM6P35D
DM6P35D	DN	(3-Tetradecylamino-cyclohexyl)-phosphonic acid
DM6P35D	HS	Investigative
DM6P35D	SN	CHEMBL186921; (3-Tetradecylamino-cyclohexyl)-phosphonic acid
DM6P35D	DT	Small molecular drug
DM6P35D	PC	44394220
DM6P35D	MW	375.5
DM6P35D	FM	C20H42NO3P
DM6P35D	IC	InChI=1S/C20H42NO3P/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-21-19-15-14-16-20(18-19)25(22,23)24/h19-21H,2-18H2,1H3,(H2,22,23,24)
DM6P35D	CS	CCCCCCCCCCCCCCNC1CCCC(C1)P(=O)(O)O
DM6P35D	IK	GFAWKWDBAGVYFO-UHFFFAOYSA-N
DM6P35D	IU	[3-(tetradecylamino)cyclohexyl]phosphonic acid
DM6P35D	DE	Discovery agent

DMFMBPT	ID	DMFMBPT
DMFMBPT	DN	(3-Tetradecylamino-cyclopentyl)-phosphonic acid
DMFMBPT	HS	Investigative
DMFMBPT	SN	CHEMBL184591; (3-Tetradecylamino-cyclopentyl)-phosphonic acid
DMFMBPT	DT	Small molecular drug
DMFMBPT	PC	44394248
DMFMBPT	MW	361.5
DMFMBPT	FM	C19H40NO3P
DMFMBPT	IC	InChI=1S/C19H40NO3P/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-20-18-14-15-19(17-18)24(21,22)23/h18-20H,2-17H2,1H3,(H2,21,22,23)
DMFMBPT	CS	CCCCCCCCCCCCCCNC1CCC(C1)P(=O)(O)O
DMFMBPT	IK	MVIUMKOQNNKAJB-UHFFFAOYSA-N
DMFMBPT	IU	[3-(tetradecylamino)cyclopentyl]phosphonic acid
DMFMBPT	DE	Discovery agent

DMI9N8G	ID	DMI9N8G
DMI9N8G	DN	(3Z)-1H-indole-2,3-dione 3-thiosemicarbazone
DMI9N8G	HS	Investigative
DMI9N8G	DT	Small molecular drug
DMI9N8G	PC	690109
DMI9N8G	MW	220.25
DMI9N8G	FM	C9H8N4OS
DMI9N8G	IC	InChI=1S/C9H8N4OS/c10-9(15)13-12-7-5-3-1-2-4-6(5)11-8(7)14/h1-4,11,14H,(H2,10,15)
DMI9N8G	CS	C1=CC=C2C(=C1)C(=C(N2)O)N=NC(=S)N
DMI9N8G	IK	PEYNLAQGUNUQLY-UHFFFAOYSA-N
DMI9N8G	IU	(2-hydroxy-1H-indol-3-yl)iminothiourea
DMI9N8G	CA	CAS 487-16-1
DMI9N8G	DE	Discovery agent

DMWS35F	ID	DMWS35F
DMWS35F	DN	(4-((1H-imidazol-1-yl)methyl)phenyl)methanol
DMWS35F	HS	Investigative
DMWS35F	SN	[4-(1H-Imidazol-1-ylmethyl)phenyl]methanol; 103573-92-8; CHEMBL590987; (4-((1H-imidazol-1-yl)methyl)phenyl)methanol; {4-[(1H-Imidazol-1-yl)methyl]phenyl}methanol; [4-(imidazol-1-ylmethyl)phenyl]methanol; SCHEMBL10661787; CTK8G4735; DTXSID80575387; FSLVBXCLXDGFRE-UHFFFAOYSA-N; MolPort-000-143-260; SBB090788; ZINC12370277; BDBM50307211; AKOS006344218; RP03593; [4-(imidazolylmethyl)phenyl]methan-1-ol; KB-63739; DB-059022; 4-(1H-Imidazole-1-ylmethyl)benzenemethanol; Y6875; FT-0708208; 4-((1H-imidazol-1-yl)methyl)phenylmethanol
DMWS35F	DT	Small molecular drug
DMWS35F	PC	15594569
DMWS35F	MW	188.23
DMWS35F	FM	C11H12N2O
DMWS35F	IC	InChI=1S/C11H12N2O/c14-8-11-3-1-10(2-4-11)7-13-6-5-12-9-13/h1-6,9,14H,7-8H2
DMWS35F	CS	C1=CC(=CC=C1CN2C=CN=C2)CO
DMWS35F	IK	FSLVBXCLXDGFRE-UHFFFAOYSA-N
DMWS35F	IU	[4-(imidazol-1-ylmethyl)phenyl]methanol
DMWS35F	CA	CAS 103573-92-8
DMWS35F	DE	Discovery agent

DMUOFW8	ID	DMUOFW8
DMUOFW8	DN	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol
DMUOFW8	HS	Investigative
DMUOFW8	SN	CHEMBL594669; (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol; SCHEMBL4442909
DMUOFW8	DT	Small molecular drug
DMUOFW8	PC	25069592
DMUOFW8	MW	311.34
DMUOFW8	FM	C16H17N5O2
DMUOFW8	IC	InChI=1S/C16H17N5O2/c22-9-11-1-3-12(4-2-11)14-19-15-13(17-10-18-15)16(20-14)21-5-7-23-8-6-21/h1-4,10,22H,5-9H2,(H,17,18,19,20)
DMUOFW8	CS	C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC=C(C=C4)CO
DMUOFW8	IK	GSYUMLARWMDMOF-UHFFFAOYSA-N
DMUOFW8	IU	[4-(6-morpholin-4-yl-7H-purin-2-yl)phenyl]methanol
DMUOFW8	DE	Discovery agent

DMV2CKN	ID	DMV2CKN
DMV2CKN	DN	(4-(thiophen-2-yl)phenyl)methanamine
DMV2CKN	HS	Investigative
DMV2CKN	SN	4-(2-Thienyl)benzylamine; 4-(2-THIENYL)BENZYLAMINE; 203436-48-0; 1-(4-thiophen-2-ylphenyl)methanamine; [4-(Thiophen-2-Yl)Phenyl]Methanamine; CHEMBL539640; Benzenemethanamine,4-(2-thienyl)-; Benzenemethanamine, 4-(2-thienyl)-; SDCCGMLS-0065961P001; AC1MCQW2; AC1Q53XJ; 4-(2-thienyl) benzylamine; 4-(Thien-2-yl)benzylamine; SCHEMBL112455; CTK4E3973; DTXSID90379994; YKNLMMDEWQZCLJ-UHFFFAOYSA-N; MolPort-000-142-431; HMS3604G04; ZINC158702; (4-(2-thienyl)phenyl)methylamine; (4-thiophen-2-ylphenyl)methanamine; SBB091000
DMV2CKN	DT	Small molecular drug
DMV2CKN	PC	2776332
DMV2CKN	MW	189.28
DMV2CKN	FM	C11H11NS
DMV2CKN	IC	InChI=1S/C11H11NS/c12-8-9-3-5-10(6-4-9)11-2-1-7-13-11/h1-7H,8,12H2
DMV2CKN	CS	C1=CSC(=C1)C2=CC=C(C=C2)CN
DMV2CKN	IK	YKNLMMDEWQZCLJ-UHFFFAOYSA-N
DMV2CKN	IU	(4-thiophen-2-ylphenyl)methanamine
DMV2CKN	CA	CAS 203436-48-0
DMV2CKN	DE	Discovery agent

DM1XY7C	ID	DM1XY7C
DM1XY7C	DN	(4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone
DM1XY7C	HS	Investigative
DM1XY7C	SN	CHEMBL1088730; AC1LKN75; (4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone; Oprea1_813517; Oprea1_627428; AC1Q5F91; MolPort-001-543-551; STK413456; BDBM50312578; ZINC19834645; AKOS003287837; MCULE-5141193554; ST50927985; 4-(diphenylmethyl)piperazinyl cyclohexyl ketone; (4-benzhydrylpiperazin-1-yl)-cyclohexylmethanone; 1-cyclohexanecarbonyl-4-(diphenylmethyl)piperazine
DM1XY7C	DT	Small molecular drug
DM1XY7C	PC	994313
DM1XY7C	MW	362.5
DM1XY7C	FM	C24H30N2O
DM1XY7C	IC	InChI=1S/C24H30N2O/c27-24(22-14-8-3-9-15-22)26-18-16-25(17-19-26)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-2,4-7,10-13,22-23H,3,8-9,14-19H2
DM1XY7C	CS	C1CCC(CC1)C(=O)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4
DM1XY7C	IK	OZIJATBNGVKZLU-UHFFFAOYSA-N
DM1XY7C	IU	(4-benzhydrylpiperazin-1-yl)-cyclohexylmethanone
DM1XY7C	DE	Discovery agent

DMGVDEL	ID	DMGVDEL
DMGVDEL	DN	(4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone
DMGVDEL	HS	Investigative
DMGVDEL	SN	piperidine, b2; AC1LDIRK; BAS 00406731; TimTec1_006842; Oprea1_680829; Oprea1_417039; (4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone; CHEMBL437002; BDBM25791; ZINC27165; MolPort-001-494-392; HMS1553G22; STK183068; AKOS000612363; MCULE-2005927034; 2-fluorophenyl 4-benzylpiperidyl ketone; ST50002204; (4-benzylpiperidino)(2-fluorophenyl)methanone; 4-benzyl-1-[(2-fluorophenyl)carbonyl]piperidine; (4-benzylpiperidin-1-yl)-(2-fluorophenyl)methanone
DMGVDEL	DT	Small molecular drug
DMGVDEL	PC	667749
DMGVDEL	MW	297.4
DMGVDEL	FM	C19H20FNO
DMGVDEL	IC	InChI=1S/C19H20FNO/c20-18-9-5-4-8-17(18)19(22)21-12-10-16(11-13-21)14-15-6-2-1-3-7-15/h1-9,16H,10-14H2
DMGVDEL	CS	C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3F
DMGVDEL	IK	LEVTWCPGXIVKEH-UHFFFAOYSA-N
DMGVDEL	IU	(4-benzylpiperidin-1-yl)-(2-fluorophenyl)methanone
DMGVDEL	DE	Discovery agent

DMEQZ5M	ID	DMEQZ5M
DMEQZ5M	DN	(4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone
DMEQZ5M	HS	Investigative
DMEQZ5M	SN	(4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone; (4-Benzyl-piperidin-1-yl)-(3-chloro-phenyl)-methanone; piperidine, b1; Oprea1_631709; Oprea1_092044; AC1LG526; CHEMBL240318; SCHEMBL17730065; BDBM25790; MolPort-001-632-510; GHPWLZRRFXHNMA-UHFFFAOYSA-N; ZINC327248; STK093701; AKOS000612405; MCULE-5547370853; 3-chlorophenyl 4-benzylpiperidyl ketone; BAS 00406738; ST50299727; 4-benzyl-1-[(3-chlorophenyl)carbonyl]piperidine; AB00087773-01; SR-01000478204; SR-01000478204-1
DMEQZ5M	DT	Small molecular drug
DMEQZ5M	PC	814705
DMEQZ5M	MW	313.8
DMEQZ5M	FM	C19H20ClNO
DMEQZ5M	IC	InChI=1S/C19H20ClNO/c20-18-8-4-7-17(14-18)19(22)21-11-9-16(10-12-21)13-15-5-2-1-3-6-15/h1-8,14,16H,9-13H2
DMEQZ5M	CS	C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC(=CC=C3)Cl
DMEQZ5M	IK	GHPWLZRRFXHNMA-UHFFFAOYSA-N
DMEQZ5M	IU	(4-benzylpiperidin-1-yl)-(3-chlorophenyl)methanone
DMEQZ5M	DE	Discovery agent

DMS16CO	ID	DMS16CO
DMS16CO	DN	(4-benzylpiperidin-1-yl)(m-tolyl)methanone
DMS16CO	HS	Investigative
DMS16CO	SN	piperidine, b4; BAS 00542495; AC1LQMX7; Cambridge id 5343426; Oprea1_494969; Oprea1_767846; SCHEMBL8299183; CHEMBL240531; BDBM25793; MolPort-000-214-462; ZINC1230195; STK396149; AKOS002707217; MCULE-3325448237; 3-methylphenyl 4-benzylpiperidyl ketone; ST50683773; (4-Benzyl-piperidin-1-yl)-m-tolyl-methanone; AB00081546-01; 4-benzyl-1-[(3-methylphenyl)carbonyl]piperidine; (4-benzylpiperidin-1-yl)(3-methylphenyl)methanone
DMS16CO	DT	Small molecular drug
DMS16CO	PC	1378917
DMS16CO	MW	293.4
DMS16CO	FM	C20H23NO
DMS16CO	IC	InChI=1S/C20H23NO/c1-16-6-5-9-19(14-16)20(22)21-12-10-18(11-13-21)15-17-7-3-2-4-8-17/h2-9,14,18H,10-13,15H2,1H3
DMS16CO	CS	CC1=CC(=CC=C1)C(=O)N2CCC(CC2)CC3=CC=CC=C3
DMS16CO	IK	POFAJEKTXKRKHK-UHFFFAOYSA-N
DMS16CO	IU	(4-benzylpiperidin-1-yl)-(3-methylphenyl)methanone
DMS16CO	DE	Discovery agent

DMJ81M3	ID	DMJ81M3
DMJ81M3	DN	(4-benzylpiperidin-1-yl)(p-tolyl)methanone
DMJ81M3	HS	Investigative
DMJ81M3	SN	N-(4-Methylbenzoyl)-4-Benzylpiperidine; 4-benzyl-1-[(4-methylphenyl)carbonyl]piperidine; piperidine, b3; BAS 00804661; AC1LR0DT; Oprea1_533510; Oprea1_593272; CHEMBL240530; BDBM25792; MolPort-000-214-461; HMS3604C03; ZINC1295794; STK003473; AKOS000595364; MCULE-3623165331; DB07123; 4-methylphenyl 4-benzylpiperidyl ketone; 4-benzyl-1-(4-methylbenzoyl)piperidine; ST50324491; (4-benzylpiperidino)(4-methylphenyl)methanone; (4-Benzyl-piperidin-1-yl)-p-tolyl-methanone; AB00081647-01; N-(4-METHYLBENZOYL)-4-BENZYLPIPERIDINE
DMJ81M3	DT	Small molecular drug
DMJ81M3	PC	1415427
DMJ81M3	MW	293.4
DMJ81M3	FM	C20H23NO
DMJ81M3	IC	InChI=1S/C20H23NO/c1-16-7-9-19(10-8-16)20(22)21-13-11-18(12-14-21)15-17-5-3-2-4-6-17/h2-10,18H,11-15H2,1H3
DMJ81M3	CS	CC1=CC=C(C=C1)C(=O)N2CCC(CC2)CC3=CC=CC=C3
DMJ81M3	IK	DVOLWKZEIDCCES-UHFFFAOYSA-N
DMJ81M3	IU	(4-benzylpiperidin-1-yl)-(4-methylphenyl)methanone
DMJ81M3	DE	Discovery agent

DMS9125	ID	DMS9125
DMS9125	DN	(4-bromo-1H-pyrazol-1-yl)(m-tolyl)methanone
DMS9125	HS	Investigative
DMS9125	SN	(4-bromo-1H-pyrazol-1-yl)(3-methylphenyl)methanone; AC1LDSCC; N-Benzoylpyrazole deriv., 22; CHEMBL397270; BDBM23714; ZINC37185; MolPort-002-705-233; STK662514; 4-bromopyrazolyl 3-methylphenyl ketone; AKOS005526022; MCULE-2046425213; ST033221; (4-bromopyrazol-1-yl)-(3-methylphenyl)methanone; SR-01000524314; 4-bromo-1-[(3-methylphenyl)carbonyl]-1H-pyrazole; SR-01000524314-1
DMS9125	DT	Small molecular drug
DMS9125	PC	674653
DMS9125	MW	265.11
DMS9125	FM	C11H9BrN2O
DMS9125	IC	InChI=1S/C11H9BrN2O/c1-8-3-2-4-9(5-8)11(15)14-7-10(12)6-13-14/h2-7H,1H3
DMS9125	CS	CC1=CC(=CC=C1)C(=O)N2C=C(C=N2)Br
DMS9125	IK	WACJMZOPBBWBAJ-UHFFFAOYSA-N
DMS9125	IU	(4-bromopyrazol-1-yl)-(3-methylphenyl)methanone
DMS9125	DE	Discovery agent

DM5QDK9	ID	DM5QDK9
DM5QDK9	DN	(4-bromo-1H-pyrazol-1-yl)(o-tolyl)methanone
DM5QDK9	HS	Investigative
DM5QDK9	SN	(4-bromo-1H-pyrazol-1-yl)(2-methylphenyl)methanone; AC1LDSC9; N-Benzoylpyrazole deriv., 23; CHEMBL245163; ZINC37182; BDBM23715; MolPort-002-118-506; STK059624; AKOS001747311; 4-bromopyrazolyl 2-methylphenyl ketone; MCULE-5811997287; ST033218; (4-bromopyrazol-1-yl)-(2-methylphenyl)methanone; SR-01000524307; SR-01000524307-1; 4-bromo-1-[(2-methylphenyl)carbonyl]-1H-pyrazole
DM5QDK9	DT	Small molecular drug
DM5QDK9	PC	674650
DM5QDK9	MW	265.11
DM5QDK9	FM	C11H9BrN2O
DM5QDK9	IC	InChI=1S/C11H9BrN2O/c1-8-4-2-3-5-10(8)11(15)14-7-9(12)6-13-14/h2-7H,1H3
DM5QDK9	CS	CC1=CC=CC=C1C(=O)N2C=C(C=N2)Br
DM5QDK9	IK	PNYXHXJNRYYIKD-UHFFFAOYSA-N
DM5QDK9	IU	(4-bromopyrazol-1-yl)-(2-methylphenyl)methanone
DM5QDK9	DE	Discovery agent

DM31OSD	ID	DM31OSD
DM31OSD	DN	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone
DM31OSD	HS	Investigative
DM31OSD	SN	AC1LDSCF; N-Benzoylpyrazole deriv., 7; CHEMBL244909; ZINC37188; BDBM23705; MolPort-002-174-815; AKOS000576906; 4-bromopyrazolyl 4-methylphenyl ketone; MCULE-8194486011; ST033225; AB00100488-01; (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone; SR-01000521427; SR-01000521427-1
DM31OSD	DT	Small molecular drug
DM31OSD	PC	674656
DM31OSD	MW	265.11
DM31OSD	FM	C11H9BrN2O
DM31OSD	IC	InChI=1S/C11H9BrN2O/c1-8-2-4-9(5-3-8)11(15)14-7-10(12)6-13-14/h2-7H,1H3
DM31OSD	CS	CC1=CC=C(C=C1)C(=O)N2C=C(C=N2)Br
DM31OSD	IK	ZIILQHVFVJLRAB-UHFFFAOYSA-N
DM31OSD	IU	(4-bromopyrazol-1-yl)-(4-methylphenyl)methanone
DM31OSD	DE	Discovery agent

DMU1HFM	ID	DMU1HFM
DMU1HFM	DN	(4-Bromo-butyl)-trimethyl-ammonium
DMU1HFM	HS	Investigative
DMU1HFM	DT	Small molecular drug
DMU1HFM	PC	15209645
DMU1HFM	MW	275.02
DMU1HFM	FM	C7H17Br2N
DMU1HFM	IC	InChI=1S/C7H17BrN.BrH/c1-9(2,3)7-5-4-6-8;/h4-7H2,1-3H3;1H/q+1;/p-1
DMU1HFM	CS	C[N+](C)(C)CCCCBr.[Br-]
DMU1HFM	IK	ZQKJDSWJSPZYNR-UHFFFAOYSA-M
DMU1HFM	IU	4-bromobutyl(trimethyl)azanium;bromide
DMU1HFM	CA	CAS 6875-49-6
DMU1HFM	DE	Discovery agent

DMLAEPF	ID	DMLAEPF
DMLAEPF	DN	(4-bromophenyl)(10H-phenothiazin-10-yl)methanone
DMLAEPF	HS	Investigative
DMLAEPF	SN	CHEMBL239617; AC1MRSRY; Oprea1_099691; (4-bromophenyl)(10H-phenothiazin-10-yl)methanone; BDBM50219219; AKOS002684887
DMLAEPF	DT	Small molecular drug
DMLAEPF	PC	3473392
DMLAEPF	MW	382.3
DMLAEPF	FM	C19H12BrNOS
DMLAEPF	IC	InChI=1S/C19H12BrNOS/c20-14-11-9-13(10-12-14)19(22)21-15-5-1-3-7-17(15)23-18-8-4-2-6-16(18)21/h1-12H
DMLAEPF	CS	C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)C4=CC=C(C=C4)Br
DMLAEPF	IK	HIHPKBOMPNDAIA-UHFFFAOYSA-N
DMLAEPF	IU	(4-bromophenyl)-phenothiazin-10-ylmethanone
DMLAEPF	DE	Discovery agent

DMOCYZJ	ID	DMOCYZJ
DMOCYZJ	DN	(4-bromophenyl)difluoromethanesulfonamide
DMOCYZJ	HS	Investigative
DMOCYZJ	SN	CHEMBL370854; (4-bromophenyl)difluoromethanesulfonamide; BDBM50175009
DMOCYZJ	DT	Small molecular drug
DMOCYZJ	PC	44405186
DMOCYZJ	MW	286.1
DMOCYZJ	FM	C7H6BrF2NO2S
DMOCYZJ	IC	InChI=1S/C7H6BrF2NO2S/c8-6-3-1-5(2-4-6)7(9,10)14(11,12)13/h1-4H,(H2,11,12,13)
DMOCYZJ	CS	C1=CC(=CC=C1C(F)(F)S(=O)(=O)N)Br
DMOCYZJ	IK	LKSACQKQUJUBBP-UHFFFAOYSA-N
DMOCYZJ	IU	(4-bromophenyl)-difluoromethanesulfonamide
DMOCYZJ	DE	Discovery agent

DM4MAZ1	ID	DM4MAZ1
DM4MAZ1	DN	(4-chloro-1H-pyrazol-1-yl)(o-tolyl)methanone
DM4MAZ1	HS	Investigative
DM4MAZ1	SN	Pyrazole, 4-chloro-1-(2-methylbenzoyl)-; Cambridge id 5909430; TimTec1_002284; N-Benzoylpyrazole deriv., 21; AC1LB684; CHEMBL396796; ZINC37175; BDBM23713; CTK6H3704; LBFRMVGIANQWAQ-UHFFFAOYSA-N; MolPort-002-174-898; HMS1540H18; STK023958; AKOS000576907; MCULE-4587218544; 4-chloropyrazolyl 2-methylphenyl ketone; ST033210; 4-Chloro-1-(2-methylbenzoyl)-1H-pyrazole; 4-Chloro-1-(2-methylbenzoyl)-1H-pyrazole #; SR-01000524613; (4-chloropyrazol-1-yl)-(2-methylphenyl)methanone; SR-01000524613-1
DM4MAZ1	DT	Small molecular drug
DM4MAZ1	PC	577102
DM4MAZ1	MW	220.65
DM4MAZ1	FM	C11H9ClN2O
DM4MAZ1	IC	InChI=1S/C11H9ClN2O/c1-8-4-2-3-5-10(8)11(15)14-7-9(12)6-13-14/h2-7H,1H3
DM4MAZ1	CS	CC1=CC=CC=C1C(=O)N2C=C(C=N2)Cl
DM4MAZ1	IK	LBFRMVGIANQWAQ-UHFFFAOYSA-N
DM4MAZ1	IU	(4-chloropyrazol-1-yl)-(2-methylphenyl)methanone
DM4MAZ1	DE	Discovery agent

DMRIWH2	ID	DMRIWH2
DMRIWH2	DN	(4-Dipropylamino-cyclohexylidene)-acetonitrile
DMRIWH2	HS	Investigative
DMRIWH2	SN	CHEMBL350161
DMRIWH2	DT	Small molecular drug
DMRIWH2	PC	10775317
DMRIWH2	MW	220.35
DMRIWH2	FM	C14H24N2
DMRIWH2	IC	InChI=1S/C14H24N2/c1-3-11-16(12-4-2)14-7-5-13(6-8-14)9-10-15/h9,14H,3-8,11-12H2,1-2H3
DMRIWH2	CS	CCCN(CCC)C1CCC(=CC#N)CC1
DMRIWH2	IK	FMKZTRTUGPXJFV-UHFFFAOYSA-N
DMRIWH2	IU	2-[4-(dipropylamino)cyclohexylidene]acetonitrile
DMRIWH2	DE	Discovery agent

DMG27K1	ID	DMG27K1
DMG27K1	DN	(4e)-4-Aminohex-4-Enoic Acid
DMG27K1	HS	Investigative
DMG27K1	SN	(4E)-4-AMINOHEX-4-ENOIC ACID; AC1NRBEN; SCHEMBL4320657; (E)-4-aminohex-4-enoic acid
DMG27K1	DT	Small molecular drug
DMG27K1	PC	5288385
DMG27K1	MW	129.16
DMG27K1	FM	C6H11NO2
DMG27K1	IC	InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2H,3-4,7H2,1H3,(H,8,9)/b5-2+
DMG27K1	CS	C/C=C(\\CCC(=O)O)/N
DMG27K1	IK	KQFBUAIXCIGKAP-GORDUTHDSA-N
DMG27K1	IU	(E)-4-aminohex-4-enoic acid
DMG27K1	DE	Discovery agent

DMHQCRU	ID	DMHQCRU
DMHQCRU	DN	(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine
DMHQCRU	HS	Investigative
DMHQCRU	SN	4-ethynyl-N,N-dipropylcyclohex-3-enamine
DMHQCRU	PC	4420454
DMHQCRU	MW	205.34
DMHQCRU	FM	C14H23N
DMHQCRU	IC	InChI=1S/C14H23N/c1-4-11-15(12-5-2)14-9-7-13(6-3)8-10-14/h3,7,14H,4-5,8-12H2,1-2H3
DMHQCRU	CS	CCCN(CCC)C1CCC(=CC1)C#C
DMHQCRU	IK	IOUKEEFTYOZOKJ-UHFFFAOYSA-N
DMHQCRU	IU	4-ethynyl-N,N-dipropylcyclohex-3-en-1-amine
DMHQCRU	DE	Discovery agent

DM75EAT	ID	DM75EAT
DM75EAT	DN	(4-Fluoro-phenyl)-(9H-purin-6-yl)-amine
DM75EAT	HS	Investigative
DM75EAT	SN	73663-95-3; N-(p-Fluorophenyl)adenine; (4-Fluorophenyl)(9H-purin-6-yl)amine; NSC 21554; N-(4-fluorophenyl)-9H-purin-6-amine; 7H-ADENINE, N-(p-FLUOROPHENYL)-; N-(4-fluorophenyl)-7H-purin-6-amine; 1H-Purin-6-amine, N-(4-fluorophenyl)-; CHEMBL361227; N-(4-Fluorophenyl)-1H-purin-6-amine; W-203680; (4-Fluoro-phenyl)-(9H-purin-6-yl)-amine; AC1L1C3G; 6-(4-Fluoroanilino)purine; Oprea1_396984; SCHEMBL4922514; N-(p-Fluorophenyl)-1H-adenine; CTK5D8432; (4-fluorophenyl)purin-6-ylamine; DTXSID30223881; MolPort-000-384-310; NSC21554
DM75EAT	DT	Small molecular drug
DM75EAT	PC	51998
DM75EAT	MW	229.21
DM75EAT	FM	C11H8FN5
DM75EAT	IC	InChI=1S/C11H8FN5/c12-7-1-3-8(4-2-7)17-11-9-10(14-5-13-9)15-6-16-11/h1-6H,(H2,13,14,15,16,17)
DM75EAT	CS	C1=CC(=CC=C1NC2=NC=NC3=C2NC=N3)F
DM75EAT	IK	SCRHVVOELSYCSO-UHFFFAOYSA-N
DM75EAT	IU	N-(4-fluorophenyl)-7H-purin-6-amine
DM75EAT	CA	CAS 73663-95-3
DM75EAT	DE	Discovery agent

DMYAJQU	ID	DMYAJQU
DMYAJQU	DN	(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine
DMYAJQU	HS	Investigative
DMYAJQU	SN	SCHEMBL6659391
DMYAJQU	DT	Small molecular drug
DMYAJQU	PC	11195892
DMYAJQU	MW	243.24
DMYAJQU	FM	C12H10FN5
DMYAJQU	IC	InChI=1S/C12H10FN5/c1-18-7-16-10-11(14-6-15-12(10)18)17-9-4-2-8(13)3-5-9/h2-7H,1H3,(H,14,15,17)
DMYAJQU	CS	CN1C=NC2=C(N=CN=C21)NC3=CC=C(C=C3)F
DMYAJQU	IK	JDDWQQHPEXJAKO-UHFFFAOYSA-N
DMYAJQU	IU	N-(4-fluorophenyl)-9-methylpurin-6-amine
DMYAJQU	DE	Discovery agent

DMOS68D	ID	DMOS68D
DMOS68D	DN	(4-fluorophenyl)(pyridin-4-yl)methanone
DMOS68D	HS	Investigative
DMOS68D	SN	4-(4-Fluorobenzoyl)pyridine; 41538-36-7; (4-fluorophenyl)(pyridin-4-yl)methanone; Methanone, (4-fluorophenyl)-4-pyridinyl-; CHEMBL563196; 4-fluorophenyl 4-pyridyl ketone; (4-fluorophenyl)-pyridin-4-ylmethanone; AC1ODYVS; 3fu0; ACMC-20amw5; AC1Q4LVT; SCHEMBL4618020; CTK1D3778; DTXSID60427471; MolPort-001-628-204; WTRWBYGUMQEFFI-UHFFFAOYSA-N; ZINC2583439; (4-Pyridyl)(p-fluorophenyl) ketone; BDBM50294173; MFCD02683088; SBB092751; 4-[(4-fluorophenyl)carbonyl]pyridine; AKOS003603273; MCULE-1391167832; DB06917; NE40002
DMOS68D	DT	Small molecular drug
DMOS68D	PC	7023019
DMOS68D	MW	201.2
DMOS68D	FM	C12H8FNO
DMOS68D	IC	InChI=1S/C12H8FNO/c13-11-3-1-9(2-4-11)12(15)10-5-7-14-8-6-10/h1-8H
DMOS68D	CS	C1=CC(=CC=C1C(=O)C2=CC=NC=C2)F
DMOS68D	IK	WTRWBYGUMQEFFI-UHFFFAOYSA-N
DMOS68D	IU	(4-fluorophenyl)-pyridin-4-ylmethanone
DMOS68D	CA	CAS 41538-36-7
DMOS68D	DE	Discovery agent

DM0KXP1	ID	DM0KXP1
DM0KXP1	DN	(4-guanidino-benzyl)-carbamic acid benzyl ester
DM0KXP1	HS	Investigative
DM0KXP1	SN	CHEMBL391969; (4-guanidino-benzyl)-carbamic acid benzyl ester
DM0KXP1	DT	Small molecular drug
DM0KXP1	PC	44436702
DM0KXP1	MW	298.34
DM0KXP1	FM	C16H18N4O2
DM0KXP1	IC	InChI=1S/C16H18N4O2/c17-15(18)20-14-8-6-12(7-9-14)10-19-16(21)22-11-13-4-2-1-3-5-13/h1-9H,10-11H2,(H,19,21)(H4,17,18,20)
DM0KXP1	CS	C1=CC=C(C=C1)COC(=O)NCC2=CC=C(C=C2)N=C(N)N
DM0KXP1	IK	NXBMHZOVQPKBKA-UHFFFAOYSA-N
DM0KXP1	IU	benzyl N-[[4-(diaminomethylideneamino)phenyl]methyl]carbamate
DM0KXP1	DE	Discovery agent

DM1WZXL	ID	DM1WZXL
DM1WZXL	DN	(4-hexylphenyl)(oxiran-2-yl)methanone
DM1WZXL	HS	Investigative
DM1WZXL	SN	epoxy-ketone, 8g; CHEMBL236543; BDBM18859
DM1WZXL	DT	Small molecular drug
DM1WZXL	PC	23635860
DM1WZXL	MW	232.32
DM1WZXL	FM	C15H20O2
DM1WZXL	IC	InChI=1S/C15H20O2/c1-2-3-4-5-6-12-7-9-13(10-8-12)15(16)14-11-17-14/h7-10,14H,2-6,11H2,1H3
DM1WZXL	CS	CCCCCCC1=CC=C(C=C1)C(=O)C2CO2
DM1WZXL	IK	MHFYINHLDHITER-UHFFFAOYSA-N
DM1WZXL	IU	(4-hexylphenyl)-(oxiran-2-yl)methanone
DM1WZXL	DE	Discovery agent

DMRCM5O	ID	DMRCM5O
DMRCM5O	DN	(4-Hydroxy-phenoxy)-acetic acid
DMRCM5O	HS	Investigative
DMRCM5O	SN	1878-84-8; 4-Hydroxyphenoxyacetic acid; (4-Hydroxyphenoxy)acetic acid; 2-(4-Hydroxyphenoxy)acetic acid; 4-Hydroxypheoxyacetate; Acetic acid, (4-hydroxyphenoxy)-; (4-Hydroxy-phenoxy)-acetic acid; Acetic acid, 2-(4-hydroxyphenoxy)-; CHEBI:1881; CHEMBL297343; P-HYDROXYPHENOXYACETIC ACID; PKGWLCZTTHWKIZ-UHFFFAOYSA-N; MFCD00014362; (4-Hydroxyphenoxy)acetic acid, 98%; Acetic acid, (p-hydroxyphenoxy)-; EINECS 217-525-8; 4-(Carboxymethoxy)phenol; AC1L26TI; ACMC-1CC13; (4-Hydroxyphenoxy)aceticAcid; SCHEMBL274850; AC1Q766A
DMRCM5O	DT	Small molecular drug
DMRCM5O	PC	15881
DMRCM5O	MW	168.15
DMRCM5O	FM	C8H8O4
DMRCM5O	IC	InChI=1S/C8H8O4/c9-6-1-3-7(4-2-6)12-5-8(10)11/h1-4,9H,5H2,(H,10,11)
DMRCM5O	CS	C1=CC(=CC=C1O)OCC(=O)O
DMRCM5O	IK	PKGWLCZTTHWKIZ-UHFFFAOYSA-N
DMRCM5O	IU	2-(4-hydroxyphenoxy)acetic acid
DMRCM5O	CA	CAS 1878-84-8
DMRCM5O	CB	CHEBI:1881
DMRCM5O	DE	Discovery agent

DMOWFE5	ID	DMOWFE5
DMOWFE5	DN	(4-Iodo-butyl)-trimethyl-ammonium iodide
DMOWFE5	HS	Investigative
DMOWFE5	DE	Discovery agent

DMZD0KG	ID	DMZD0KG
DMZD0KG	DN	(4-methoxyphenyl)(4-phenylazepan-1-yl)methanone
DMZD0KG	HS	Investigative
DMZD0KG	SN	CHEMBL562195; (4-methoxyphenyl)(4-phenylazepan-1-yl)methanone; SCHEMBL19248204
DMZD0KG	DT	Small molecular drug
DMZD0KG	PC	45269321
DMZD0KG	MW	309.4
DMZD0KG	FM	C20H23NO2
DMZD0KG	IC	InChI=1S/C20H23NO2/c1-23-19-11-9-18(10-12-19)20(22)21-14-5-8-17(13-15-21)16-6-3-2-4-7-16/h2-4,6-7,9-12,17H,5,8,13-15H2,1H3
DMZD0KG	CS	COC1=CC=C(C=C1)C(=O)N2CCCC(CC2)C3=CC=CC=C3
DMZD0KG	IK	SLZXHOMMTNEABC-UHFFFAOYSA-N
DMZD0KG	IU	(4-methoxyphenyl)-(4-phenylazepan-1-yl)methanone
DMZD0KG	DE	Discovery agent

DMPU7KE	ID	DMPU7KE
DMPU7KE	DN	(4-Methyl-2-oxo-2H-quinolin-1-yl)-acetic acid
DMPU7KE	HS	Investigative
DMPU7KE	SN	103368-21-4; (4-Methyl-2-oxo-2H-quinolin-1-yl)-acetic acid; 1(2h)-quinolineacetic acid, 4-methyl-2-oxo-; NSC108456; (4-methyl-2-oxoquinolin-1(2H)-yl)acetic acid; CHEMBL64455; 2-(4-methyl-2-oxoquinolin-1(2H)-yl)acetic acid; BAS 02839786; (4-Methyl-2-oxo-1(2H)-quinolinyl)acetic acid; 2-(4-methyl-2-oxohydroquinolyl)acetic acid; AC1L6JZ1; AC1Q6I1O; MLS000714792; SCHEMBL15709048; CTK4A2028; DTXSID20296246; MolPort-001-984-878; ZINC380285; HMS2670L06; HMS1681E20; HMS3482A22; ZX-AN005388; ALBB-005471; BB_SC-06267; ZX-CM004260; BBL010328
DMPU7KE	DT	Small molecular drug
DMPU7KE	PC	268297
DMPU7KE	MW	217.22
DMPU7KE	FM	C12H11NO3
DMPU7KE	IC	InChI=1S/C12H11NO3/c1-8-6-11(14)13(7-12(15)16)10-5-3-2-4-9(8)10/h2-6H,7H2,1H3,(H,15,16)
DMPU7KE	CS	CC1=CC(=O)N(C2=CC=CC=C12)CC(=O)O
DMPU7KE	IK	VKKWCKNFSMMXJZ-UHFFFAOYSA-N
DMPU7KE	IU	2-(4-methyl-2-oxoquinolin-1-yl)acetic acid
DMPU7KE	CA	CAS 103368-21-4
DMPU7KE	DE	Discovery agent

DMBPL3J	ID	DMBPL3J
DMBPL3J	DN	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone
DMBPL3J	HS	Investigative
DMBPL3J	SN	BAS 02052986; AC1LDSC0; N-Benzoylpyrazole deriv., 20; CHEMBL244072; ZINC37170; BDBM23712; MolPort-001-971-782; AKOS000577347; 2-methylphenyl 4-nitropyrazolyl ketone; MCULE-4726161589; ST033205; (4-Nitro-pyrazol-1-yl)-o-tolyl-methanone; (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone
DMBPL3J	DT	Small molecular drug
DMBPL3J	PC	674641
DMBPL3J	MW	231.21
DMBPL3J	FM	C11H9N3O3
DMBPL3J	IC	InChI=1S/C11H9N3O3/c1-8-4-2-3-5-10(8)11(15)13-7-9(6-12-13)14(16)17/h2-7H,1H3
DMBPL3J	CS	CC1=CC=CC=C1C(=O)N2C=C(C=N2)[N+](=O)[O-]
DMBPL3J	IK	ORXYMBYYSLQOLK-UHFFFAOYSA-N
DMBPL3J	IU	(2-methylphenyl)-(4-nitropyrazol-1-yl)methanone
DMBPL3J	DE	Discovery agent

DMIDUO9	ID	DMIDUO9
DMIDUO9	DN	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMIDUO9	HS	Investigative
DMIDUO9	SN	BAS 02052938; AC1LDSCA; N-Benzoylpyrazole deriv., 5; 4-nitropyrazolyl phenyl ketone; CHEMBL244908; 1-benzoyl-4-nitro-1H-pyrazole; ZINC37183; BDBM23703; AKOS000577075; (4-nitropyrazol-1-yl)-phenylmethanone; MCULE-3158742884; ST033219; (4-Nitro-pyrazol-1-yl)-phenyl-methanone; SR-01000312627
DMIDUO9	DT	Small molecular drug
DMIDUO9	PC	674651
DMIDUO9	MW	217.18
DMIDUO9	FM	C10H7N3O3
DMIDUO9	IC	InChI=1S/C10H7N3O3/c14-10(8-4-2-1-3-5-8)12-7-9(6-11-12)13(15)16/h1-7H
DMIDUO9	CS	C1=CC=C(C=C1)C(=O)N2C=C(C=N2)[N+](=O)[O-]
DMIDUO9	IK	DLDKTRBBAKTGJH-UHFFFAOYSA-N
DMIDUO9	IU	(4-nitropyrazol-1-yl)-phenylmethanone
DMIDUO9	DE	Discovery agent

DM1YC0B	ID	DM1YC0B
DM1YC0B	DN	(4-nitrophenyl)(10H-phenothiazin-10-yl)methanone
DM1YC0B	HS	Investigative
DM1YC0B	SN	CHEMBL239834; AC1MJHMR; Oprea1_338082; Oprea1_035764; (4-nitrophenyl)(10H-phenothiazin-10-yl)methanone; SCHEMBL10490281; ZINC4725769; BDBM50219213; AKOS000731103; BAS 00604089; (4-nitrophenyl)-phenothiazin-10-ylmethanone
DM1YC0B	DT	Small molecular drug
DM1YC0B	PC	3112604
DM1YC0B	MW	348.4
DM1YC0B	FM	C19H12N2O3S
DM1YC0B	IC	InChI=1S/C19H12N2O3S/c22-19(13-9-11-14(12-10-13)21(23)24)20-15-5-1-3-7-17(15)25-18-8-4-2-6-16(18)20/h1-12H
DM1YC0B	CS	C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)C4=CC=C(C=C4)[N+](=O)[O-]
DM1YC0B	IK	TUBVLHCMQWIBNP-UHFFFAOYSA-N
DM1YC0B	IU	(4-nitrophenyl)-phenothiazin-10-ylmethanone
DM1YC0B	DE	Discovery agent

DMFO8DR	ID	DMFO8DR
DMFO8DR	DN	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine
DMFO8DR	HS	Investigative
DMFO8DR	SN	CHEMBL304760; N-(4-phenoxyphenyl)quinazolin-4-amine; (4-Phenoxy-phenyl)-quinazolin-4-yl-amine; AC1LEH7Z; Neuro1_000298; Oprea1_168469; SCHEMBL5568872; MolPort-000-668-533; ZINC104659; BDBM50092231; STK918072; (4-phenoxyphenyl)quinazolin-4-ylamine; AKOS002241807; N-(4-Phenoxyphenyl)-4-quinazolinamine; MCULE-2087445269; ST50197248; EU-0074581; SR-01000459365
DMFO8DR	DT	Small molecular drug
DMFO8DR	PC	712152
DMFO8DR	MW	313.4
DMFO8DR	FM	C20H15N3O
DMFO8DR	IC	InChI=1S/C20H15N3O/c1-2-6-16(7-3-1)24-17-12-10-15(11-13-17)23-20-18-8-4-5-9-19(18)21-14-22-20/h1-14H,(H,21,22,23)
DMFO8DR	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)NC3=NC=NC4=CC=CC=C43
DMFO8DR	IK	RJOICMFRJBMONF-UHFFFAOYSA-N
DMFO8DR	IU	N-(4-phenoxyphenyl)quinazolin-4-amine
DMFO8DR	DE	Discovery agent

DMQM8O5	ID	DMQM8O5
DMQM8O5	DN	(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine
DMQM8O5	HS	Investigative
DMQM8O5	SN	CHEMBL166325; (4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine
DMQM8O5	DT	Small molecular drug
DMQM8O5	PC	10564794
DMQM8O5	MW	281.4
DMQM8O5	FM	C20H27N
DMQM8O5	IC	InChI=1S/C20H27N/c1-3-16-21(17-4-2)20-14-12-19(13-15-20)11-10-18-8-6-5-7-9-18/h5-9,12,20H,3-4,13-17H2,1-2H3
DMQM8O5	CS	CCCN(CCC)C1CCC(=CC1)C#CC2=CC=CC=C2
DMQM8O5	IK	QQFDMLZEFWKHHH-UHFFFAOYSA-N
DMQM8O5	IU	4-(2-phenylethynyl)-N,N-dipropylcyclohex-3-en-1-amine
DMQM8O5	DE	Discovery agent

DM0NTA3	ID	DM0NTA3
DM0NTA3	DN	(4-phenylpiperazin-1-yl)(p-tolyl)methanone
DM0NTA3	HS	Investigative
DM0NTA3	SN	(4-Phenyl-piperazin-1-yl)-p-tolyl-methanone; piperazine, a2; Cambridge id 5345452; AC1LF9G0; Oprea1_767331; Oprea1_285639; CHEMBL239457; SCHEMBL10721885; BDBM25773; MolPort-001-016-695; ZINC196133; HMS1676A12; STK020131; AKOS000671240; MCULE-2746904510; BAS 00500757; 4-methylphenyl 4-phenylpiperazinyl ketone; ST50682677; AB00081719-01; 1-[(4-methylphenyl)carbonyl]-4-phenylpiperazine; SR-01000406866; (4-methylphenyl)(4-phenylpiperazin-1-yl)methanone; (4-methylphenyl)-(4-phenylpiperazin-1-yl)methanone
DM0NTA3	DT	Small molecular drug
DM0NTA3	PC	749125
DM0NTA3	MW	280.4
DM0NTA3	FM	C18H20N2O
DM0NTA3	IC	InChI=1S/C18H20N2O/c1-15-7-9-16(10-8-15)18(21)20-13-11-19(12-14-20)17-5-3-2-4-6-17/h2-10H,11-14H2,1H3
DM0NTA3	CS	CC1=CC=C(C=C1)C(=O)N2CCN(CC2)C3=CC=CC=C3
DM0NTA3	IK	MPTWQLUMMRYFPO-UHFFFAOYSA-N
DM0NTA3	IU	(4-methylphenyl)-(4-phenylpiperazin-1-yl)methanone
DM0NTA3	CA	CAS 219989-26-1
DM0NTA3	DE	Discovery agent

DMKF3U6	ID	DMKF3U6
DMKF3U6	DN	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid
DMKF3U6	HS	Investigative
DMKF3U6	SN	CHEMBL468498; AC1LEONH; (4-Quinolin-2-ylpiperazin-1-yl)acetic Acid; SCHEMBL13780710; A3329/0141355; BDBM50258497; AKOS009544966; 2-(4-quinolin-2-ylpiperazin-1-yl)acetic acid
DMKF3U6	DT	Small molecular drug
DMKF3U6	PC	715494
DMKF3U6	MW	271.31
DMKF3U6	FM	C15H17N3O2
DMKF3U6	IC	InChI=1S/C15H17N3O2/c19-15(20)11-17-7-9-18(10-8-17)14-6-5-12-3-1-2-4-13(12)16-14/h1-6H,7-11H2,(H,19,20)
DMKF3U6	CS	C1CN(CCN1CC(=O)O)C2=NC3=CC=CC=C3C=C2
DMKF3U6	IK	HCRXUFYSLPXCDW-UHFFFAOYSA-N
DMKF3U6	IU	2-(4-quinolin-2-ylpiperazin-1-yl)acetic acid
DMKF3U6	DE	Discovery agent

DMZFTI4	ID	DMZFTI4
DMZFTI4	DN	(4R)-4-ammoniopentanoate
DMZFTI4	HS	Investigative
DMZFTI4	SN	(R)-4-Aminopentanoic acid; 4R-aminopentanoic acid; 5937-83-7; UNII-UPX83HFN1B; UPX83HFN1B; (4R)-4-aminopentanoic acid; (R)-(+)-4-Aminovaleric acid; (4R)-4-ammoniopentanoate; AC1L9GD1; 4-Aminovaleric acid, (R)-; CHEMBL281098; SCHEMBL15177649; Pentanoic acid, 4-amino-, (R)-; ZINC1706201; Pentanoic acid, 4-amino-, (4R)-; LMFA01100021; AKOS006337463; Valeric acid, 4-amino-, (R)-(+)-; UNII-CDM626IVRT component ABSTXSZPGHDTAF-SCSAIBSYSA-N
DMZFTI4	DT	Small molecular drug
DMZFTI4	PC	444458
DMZFTI4	MW	117.15
DMZFTI4	FM	C5H11NO2
DMZFTI4	IC	InChI=1S/C5H11NO2/c1-4(6)2-3-5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1
DMZFTI4	CS	C[C@H](CCC(=O)O)N
DMZFTI4	IK	ABSTXSZPGHDTAF-SCSAIBSYSA-N
DMZFTI4	IU	(4R)-4-aminopentanoic acid
DMZFTI4	CA	CAS 5937-83-7
DMZFTI4	DE	Discovery agent

DMBLAY1	ID	DMBLAY1
DMBLAY1	DN	(4S)-4-ammoniopentanoate
DMBLAY1	HS	Investigative
DMBLAY1	SN	(S)-4-Aminovaleric acid; (S)-4-Aminopentanoic acid; (4S)-4-aminopentanoic acid; 4S-aminopentanoic acid; UNII-G98ZJ0KD1D; G98ZJ0KD1D; 1558-59-4; Pentanoic acid, 4-amino-, (S)-; (4S)-4-ammoniopentanoate; 4-Aminovaleric acid, (S)-; AC1NSNZ5; SCHEMBL288484; CHEMBL284327; ZINC3581353; LMFA01100022; Pentanoic acid, 4-amino-, (4S)-; (2E,4S)-4-aminopent-2-enoic acid; AKOS027321168; UNII-CDM626IVRT component ABSTXSZPGHDTAF-BYPYZUCNSA-N
DMBLAY1	DT	Small molecular drug
DMBLAY1	PC	5312968
DMBLAY1	MW	117.15
DMBLAY1	FM	C5H11NO2
DMBLAY1	IC	InChI=1S/C5H11NO2/c1-4(6)2-3-5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1
DMBLAY1	CS	C[C@@H](CCC(=O)O)N
DMBLAY1	IK	ABSTXSZPGHDTAF-BYPYZUCNSA-N
DMBLAY1	IU	(4S)-4-aminopentanoic acid
DMBLAY1	CA	CAS 1558-59-4
DMBLAY1	DE	Discovery agent

DMM6QV5	ID	DMM6QV5
DMM6QV5	DN	(4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine
DMM6QV5	HS	Investigative
DMM6QV5	SN	CHEMBL108319; (4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine; BDBM50138198
DMM6QV5	DT	Small molecular drug
DMM6QV5	PC	44337349
DMM6QV5	MW	142.2
DMM6QV5	FM	C7H14N2O
DMM6QV5	IC	InChI=1S/C7H14N2O/c1-3-5-6(4-2)10-7(8)9-5/h5-6H,3-4H2,1-2H3,(H2,8,9)/t5-,6+/m0/s1
DMM6QV5	CS	CC[C@H]1[C@H](OC(=N1)N)CC
DMM6QV5	IK	KYKDCIRQVPPSOP-NTSWFWBYSA-N
DMM6QV5	IU	(4S,5R)-4,5-diethyl-4,5-dihydro-1,3-oxazol-2-amine
DMM6QV5	DE	Discovery agent

DM0V9HB	ID	DM0V9HB
DM0V9HB	DN	(4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine
DM0V9HB	HS	Investigative
DM0V9HB	SN	CHEMBL110789; (4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine; BDBM50138184
DM0V9HB	DT	Small molecular drug
DM0V9HB	PC	44337382
DM0V9HB	MW	114.15
DM0V9HB	FM	C5H10N2O
DM0V9HB	IC	InChI=1S/C5H10N2O/c1-3-4(2)8-5(6)7-3/h3-4H,1-2H3,(H2,6,7)/t3-,4+/m0/s1
DM0V9HB	CS	C[C@H]1[C@H](OC(=N1)N)C
DM0V9HB	IK	CBBZZWUQMBKNEY-IUYQGCFVSA-N
DM0V9HB	IU	(4S,5R)-4,5-dimethyl-4,5-dihydro-1,3-oxazol-2-amine
DM0V9HB	DE	Discovery agent

DMDC84U	ID	DMDC84U
DMDC84U	DN	(4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine
DMDC84U	HS	Investigative
DMDC84U	SN	CHEMBL322085; (4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine; BDBM50138197
DMDC84U	DT	Small molecular drug
DMDC84U	PC	44337347
DMDC84U	MW	170.25
DMDC84U	FM	C9H18N2O
DMDC84U	IC	InChI=1S/C9H18N2O/c1-3-5-7-8(6-4-2)12-9(10)11-7/h7-8H,3-6H2,1-2H3,(H2,10,11)/t7-,8+/m0/s1
DMDC84U	CS	CCC[C@H]1[C@H](OC(=N1)N)CCC
DMDC84U	IK	LRHNWJTUXJXJRP-JGVFFNPUSA-N
DMDC84U	IU	(4S,5R)-4,5-dipropyl-4,5-dihydro-1,3-oxazol-2-amine
DMDC84U	DE	Discovery agent

DM1VJUZ	ID	DM1VJUZ
DM1VJUZ	DN	(4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine
DM1VJUZ	HS	Investigative
DM1VJUZ	SN	CHEMBL105820; (4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine; BDBM50138195; AKOS006377258
DM1VJUZ	DT	Small molecular drug
DM1VJUZ	PC	44337366
DM1VJUZ	MW	142.2
DM1VJUZ	FM	C7H14N2O
DM1VJUZ	IC	InChI=1S/C7H14N2O/c1-3-5-6(4-2)10-7(8)9-5/h5-6H,3-4H2,1-2H3,(H2,8,9)/t5-,6-/m0/s1
DM1VJUZ	CS	CC[C@H]1[C@@H](OC(=N1)N)CC
DM1VJUZ	IK	KYKDCIRQVPPSOP-WDSKDSINSA-N
DM1VJUZ	IU	(4S,5S)-4,5-diethyl-4,5-dihydro-1,3-oxazol-2-amine
DM1VJUZ	DE	Discovery agent

DM5EKF4	ID	DM5EKF4
DM5EKF4	DN	(4S,5S)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine
DM5EKF4	HS	Investigative
DM5EKF4	SN	CHEMBL110498; (4S,5S)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine; BDBM50138199
DM5EKF4	DT	Small molecular drug
DM5EKF4	PC	10678756
DM5EKF4	MW	170.25
DM5EKF4	FM	C9H18N2O
DM5EKF4	IC	InChI=1S/C9H18N2O/c1-3-5-7-8(6-4-2)12-9(10)11-7/h7-8H,3-6H2,1-2H3,(H2,10,11)/t7-,8-/m0/s1
DM5EKF4	CS	CCC[C@H]1[C@@H](OC(=N1)N)CCC
DM5EKF4	IK	LRHNWJTUXJXJRP-YUMQZZPRSA-N
DM5EKF4	IU	(4S,5S)-4,5-dipropyl-4,5-dihydro-1,3-oxazol-2-amine
DM5EKF4	DE	Discovery agent

DMGCZOI	ID	DMGCZOI
DMGCZOI	DN	(4-sulfamoylphenylethylthioureido)fluorescein
DMGCZOI	HS	Investigative
DMGCZOI	SN	CHEMBL501130; SCHEMBL13263774
DMGCZOI	DT	Small molecular drug
DMGCZOI	PC	44577440
DMGCZOI	MW	573.6
DMGCZOI	FM	C29H23N3O8S
DMGCZOI	IC	InChI=1S/C29H23N3O8S/c30-41(38,39)20-6-1-16(2-7-20)11-12-31-29(37)32-17-3-8-21(24(13-17)28(35)36)27-22-9-4-18(33)14-25(22)40-26-15-19(34)5-10-23(26)27/h1-10,13-15,33H,11-12H2,(H,35,36)(H2,30,38,39)(H2,31,32,37)
DMGCZOI	CS	C1=CC(=CC=C1CCNC(=O)NC2=CC(=C(C=C2)C3=C4C=CC(=O)C=C4OC5=C3C=CC(=C5)O)C(=O)O)S(=O)(=O)N
DMGCZOI	IK	IYBVEUKFGRJHGL-UHFFFAOYSA-N
DMGCZOI	IU	2-(3-hydroxy-6-oxoxanthen-9-yl)-5-[2-(4-sulfamoylphenyl)ethylcarbamoylamino]benzoic acid
DMGCZOI	DE	Discovery agent

DM15P2G	ID	DM15P2G
DM15P2G	DN	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol
DM15P2G	HS	Investigative
DM15P2G	SN	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol; YC-1
DM15P2G	DT	Small molecular drug
DM15P2G	PC	5712
DM15P2G	MW	304.3
DM15P2G	FM	C19H16N2O2
DM15P2G	IC	InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2
DM15P2G	CS	C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)C4=CC=C(O4)CO
DM15P2G	IK	OQQVFCKUDYMWGV-UHFFFAOYSA-N
DM15P2G	IU	[5-(1-benzylindazol-3-yl)furan-2-yl]methanol
DM15P2G	CA	CAS 170632-47-0
DM15P2G	CB	CHEBI:93060
DM15P2G	DE	Discovery agent

DMTC5VF	ID	DMTC5VF
DMTC5VF	DN	(5-(pyridin-3-yl)furan-2-yl)methanamine
DMTC5VF	HS	Investigative
DMTC5VF	SN	(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE; [5-(pyridin-3-yl)furan-2-yl]methanamine; (5-pyridin-3-ylfuran-2-yl)methanamine; 1-(5-pyridin-3-ylfuran-2-yl)methanamine; CHEMBL178090; CHEBI:41804; (5-Pyridin-3-yl-2-furyl)methylamine; 837376-48-4; 2-Furanmethanamine, 5-(3-pyridinyl)-; SCHEMBL1791769; GTPL8754; BDBM12345; MolPort-022-593-431; ZINC13607134; nicotine 3-heteroaromatic analogue 2a; AKOS022808436; DB07621; compound 39a [PMID: 15634016]; D3G; US8609708, 2; US8609708, 47; F2167-0893
DMTC5VF	DT	Small molecular drug
DMTC5VF	PC	11332763
DMTC5VF	MW	174.2
DMTC5VF	FM	C10H10N2O
DMTC5VF	IC	InChI=1S/C10H10N2O/c11-6-9-3-4-10(13-9)8-2-1-5-12-7-8/h1-5,7H,6,11H2
DMTC5VF	CS	C1=CC(=CN=C1)C2=CC=C(O2)CN
DMTC5VF	IK	LENAVORGWBTPJR-UHFFFAOYSA-N
DMTC5VF	IU	(5-pyridin-3-ylfuran-2-yl)methanamine
DMTC5VF	CA	CAS 837376-48-4
DMTC5VF	CB	CHEBI:41804
DMTC5VF	DE	Discovery agent

DMF0YJ3	ID	DMF0YJ3
DMF0YJ3	DN	(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone
DMF0YJ3	HS	Investigative
DMF0YJ3	SN	54606-37-0; (5-Amino-1-phenyl-1H-pyrazol-4-yl)phenyl methanone; (5-AMINO-1-PHENYL-1H-PYRAZOL-4-YL)(PHENYL)METHANONE; 4-benzoyl-5-aminopyrazole 1; CHEMBL203333; (5-amino-1-phenyl-1H-pyrazol-4-yl)-phenyl-methanone; SCHEMBL13662120; BDBM15714; 5-amino-4-benzoyl-1-phenylpyrazole; ZINC12365464; 1-Phenyl-4-benzoyl-1H-pyrazol-5-amine; 4-benzoyl-1-phenyl-1H-pyrazol-5-amine; KB-208557; FT-0728731; (5-Amino-1-phenyl-1H-pyrazol-4-yl)(phenyl)methanone, AldrichCPR
DMF0YJ3	DT	Small molecular drug
DMF0YJ3	PC	15311937
DMF0YJ3	MW	263.29
DMF0YJ3	FM	C16H13N3O
DMF0YJ3	IC	InChI=1S/C16H13N3O/c17-16-14(15(20)12-7-3-1-4-8-12)11-18-19(16)13-9-5-2-6-10-13/h1-11H,17H2
DMF0YJ3	CS	C1=CC=C(C=C1)C(=O)C2=C(N(N=C2)C3=CC=CC=C3)N
DMF0YJ3	IK	YMGWYPXWGVJIAJ-UHFFFAOYSA-N
DMF0YJ3	IU	(5-amino-1-phenylpyrazol-4-yl)-phenylmethanone
DMF0YJ3	DE	Discovery agent

DMVQ6RN	ID	DMVQ6RN
DMVQ6RN	DN	(5BETA)-PREGNANE-3,20-DIONE
DMVQ6RN	HS	Investigative
DMVQ6RN	SN	5beta-Pregnane-3,20-dione; 3,20-Pregnanedione; 5beta-Pregnan-3,20-dione; 128-23-4; 5beta-Dihydroprogesterone; (5BETA)-PREGNANE-3,20-DIONE; NSC 82868; UNII-105J2Q45A0; 5beta-Dihydro Progesterone; 5.beta.-Dihydroprogesterone; 5.beta.-Pregnan-3,20-dione; CHEBI:30154; Pregnane-3,20-dione, (5b)-; XMRPGKVKISIQBV-XWOJZHJZSA-N; 105J2Q45A0; 5b-pregnane-3,20-dione; CI2; (5R,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; 5.beta.-Pregnane-3,20-dione
DMVQ6RN	DT	Small molecular drug
DMVQ6RN	PC	92745
DMVQ6RN	MW	316.5
DMVQ6RN	FM	C21H32O2
DMVQ6RN	IC	InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14,16-19H,4-12H2,1-3H3/t14-,16+,17-,18+,19+,20+,21-/m1/s1
DMVQ6RN	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CCC(=O)C4)C)C
DMVQ6RN	IK	XMRPGKVKISIQBV-XWOJZHJZSA-N
DMVQ6RN	IU	(5R,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
DMVQ6RN	CA	CAS 128-23-4
DMVQ6RN	CB	CHEBI:30154
DMVQ6RN	DE	Discovery agent

DM4EH2J	ID	DM4EH2J
DM4EH2J	DN	(5-Bromo-pentyl)-trimethyl-ammonium
DM4EH2J	HS	Investigative
DM4EH2J	DT	Small molecular drug
DM4EH2J	PC	11098210
DM4EH2J	MW	289.05
DM4EH2J	FM	C8H19Br2N
DM4EH2J	IC	InChI=1S/C8H19BrN.BrH/c1-10(2,3)8-6-4-5-7-9;/h4-8H2,1-3H3;1H/q+1;/p-1
DM4EH2J	CS	C[N+](C)(C)CCCCCBr.[Br-]
DM4EH2J	IK	GEIHNRASRNQTDE-UHFFFAOYSA-M
DM4EH2J	IU	5-bromopentyl(trimethyl)azanium;bromide
DM4EH2J	CA	CAS 15008-33-0
DM4EH2J	DE	Discovery agent

DM8JHWS	ID	DM8JHWS
DM8JHWS	DN	(5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenal
DM8JHWS	HS	Investigative
DM8JHWS	SN	CHEMBL373333; (5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenal; SCHEMBL1800772
DM8JHWS	DT	Small molecular drug
DM8JHWS	PC	22020504
DM8JHWS	MW	288.5
DM8JHWS	FM	C20H32O
DM8JHWS	IC	InChI=1S/C20H32O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21/h6-7,9-10,12-13,15-16,20H,2-5,8,11,14,17-19H2,1H3/b7-6+,10-9+,13-12+,16-15+
DM8JHWS	CS	CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCC=O
DM8JHWS	IK	XTZSIVLWZNRBAB-CGRWFSSPSA-N
DM8JHWS	IU	(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenal
DM8JHWS	DE	Discovery agent

DMIV4BU	ID	DMIV4BU
DMIV4BU	DN	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMIV4BU	HS	Investigative
DMIV4BU	SN	CHEMBL209042; (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMIV4BU	DT	Small molecular drug
DMIV4BU	PC	11500099
DMIV4BU	MW	278.28
DMIV4BU	FM	C17H11FN2O
DMIV4BU	IC	InChI=1S/C17H11FN2O/c18-12-5-6-14-11(7-12)9-16(20-14)17(21)15-8-10-3-1-2-4-13(10)19-15/h1-9,19-20H
DMIV4BU	CS	C1=CC=C2C(=C1)C=C(N2)C(=O)C3=CC4=C(N3)C=CC(=C4)F
DMIV4BU	IK	HXWDONFZGUZRTN-UHFFFAOYSA-N
DMIV4BU	IU	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMIV4BU	DE	Discovery agent

DMPBNYM	ID	DMPBNYM
DMPBNYM	DN	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone
DMPBNYM	HS	Investigative
DMPBNYM	SN	CHEMBL7735; PDGF Receptor Tyrosine Kinase Inhibitor I; D-64406; (5-Hydroxy-1H-2-indolyl)(1H-2-indolyl)-methanone; 249762-62-7; AC1NS9CN; BDBM6581; SCHEMBL4456469; CHEBI:92486; ZINC24261; CTK0J4476; DTXSID20416205; Bis(1H-2-indolyl)methanone 39; IN1158; HSCI1_000198; NCGC00185731-01; 5-Hydroxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-1H-indol-5-ol; BRD-K27665173-001-01-3; (5-hydroxy-1H-indol-2-yl)-(1H-indol-2-yl)methanone; Methanone, (5-hydroxy-1H-indol-2-yl)-1H-indol-2-yl-
DMPBNYM	DT	Small molecular drug
DMPBNYM	PC	5330535
DMPBNYM	MW	276.29
DMPBNYM	FM	C17H12N2O2
DMPBNYM	IC	InChI=1S/C17H12N2O2/c20-12-5-6-14-11(7-12)9-16(19-14)17(21)15-8-10-3-1-2-4-13(10)18-15/h1-9,18-20H
DMPBNYM	CS	C1=CC=C2C(=C1)C=C(N2)C(=O)C3=CC4=C(N3)C=CC(=C4)O
DMPBNYM	IK	AALNCHNFTKRFEL-UHFFFAOYSA-N
DMPBNYM	IU	(5-hydroxy-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMPBNYM	CA	CAS 249762-62-7
DMPBNYM	CB	CHEBI:92486
DMPBNYM	DE	Discovery agent

DMBKZDJ	ID	DMBKZDJ
DMBKZDJ	DN	(5-Imino-[1,4]thiazepan-3-yl)-methanol
DMBKZDJ	HS	Investigative
DMBKZDJ	SN	CHEMBL361722; (5-Imino-[1,4]thiazepan-3-yl)-methanol
DMBKZDJ	DT	Small molecular drug
DMBKZDJ	PC	44396191
DMBKZDJ	MW	160.24
DMBKZDJ	FM	C6H12N2OS
DMBKZDJ	IC	InChI=1S/C6H12N2OS/c7-6-1-2-10-4-5(3-9)8-6/h5,9H,1-4H2,(H2,7,8)
DMBKZDJ	CS	C1CSCC(N=C1N)CO
DMBKZDJ	IK	LARUWSZSMYBJIP-UHFFFAOYSA-N
DMBKZDJ	IU	(5-amino-2,3,6,7-tetrahydro-1,4-thiazepin-3-yl)methanol
DMBKZDJ	DE	Discovery agent

DMOPMNC	ID	DMOPMNC
DMOPMNC	DN	(5-methoxy-1H-indol-3-yl)methanamine
DMOPMNC	HS	Investigative
DMOPMNC	SN	(5-methoxy-1H-indol-3-yl)methanamine; 60523-82-2; 5-Methoxy-1h-indol-3-methylamine; 3-(AMINOMETHYL)-5-METHOXYINDOLE; CHEMBL1276050; 5-METHOXYINDOLE-3-METHYLAMINE; SCHEMBL3976318; CTK5B1636; DTXSID20563182; MolPort-006-831-850; ZX-AN081076; ALBB-030269; FCH853008; BDBM50330861; 9026AB; ZINC20269183; AKOS005214650; MB03907; CM-1862; SC-45599; KB-43524; AJ-76727; AK112525; ST2402466; DB-012273; AX8104451; FT-0691098; 4CH-017193; 1-(5-METHOXY-1H-INDOL-3-YL)METHANAMINE
DMOPMNC	DT	Small molecular drug
DMOPMNC	PC	14702424
DMOPMNC	MW	176.21
DMOPMNC	FM	C10H12N2O
DMOPMNC	IC	InChI=1S/C10H12N2O/c1-13-8-2-3-10-9(4-8)7(5-11)6-12-10/h2-4,6,12H,5,11H2,1H3
DMOPMNC	CS	COC1=CC2=C(C=C1)NC=C2CN
DMOPMNC	IK	CAHOMULUOHSWPI-UHFFFAOYSA-N
DMOPMNC	IU	(5-methoxy-1H-indol-3-yl)methanamine
DMOPMNC	CA	CAS 60523-82-2
DMOPMNC	DE	Discovery agent

DM4FJHO	ID	DM4FJHO
DM4FJHO	DN	(5-Methoxy-chroman-3-yl)-dipropyl-amine
DM4FJHO	HS	Investigative
DM4FJHO	SN	5-Meo-dpac; 5-Methoxy-3-(di-n-propylamino)chroman; CHEMBL283606; 3-Dipropylamino-5-methyloxychroman; 5-Methoxy-3-(dipropylamino)chroman; (5-Methoxy-chroman-3-yl)-dipropyl-amine; AC1MIZ4R; 110927-00-9; SCHEMBL2217080; CTK8G5655; GOWYIQOIWRLZLO-UHFFFAOYSA-N; BDBM50036862; 3-(Di-n-propylamino)-5-methoxychroman; L023817; 5-methoxy-N,N-dipropyl-3,4-dihydro-2H-chromen-3-amine; 5-methoxy-3,4-dihydro-N,N-dipropyl-2H-[1]-benzopyran-3-amine; 2H-1-Benzopyran-3-amine, 3,4-dihydro-5-methoxy-N,N-dipropyl-
DM4FJHO	DT	Small molecular drug
DM4FJHO	PC	3082597
DM4FJHO	MW	263.37
DM4FJHO	FM	C16H25NO2
DM4FJHO	IC	InChI=1S/C16H25NO2/c1-4-9-17(10-5-2)13-11-14-15(18-3)7-6-8-16(14)19-12-13/h6-8,13H,4-5,9-12H2,1-3H3
DM4FJHO	CS	CCCN(CCC)C1CC2=C(C=CC=C2OC)OC1
DM4FJHO	IK	GOWYIQOIWRLZLO-UHFFFAOYSA-N
DM4FJHO	IU	5-methoxy-N,N-dipropyl-3,4-dihydro-2H-chromen-3-amine
DM4FJHO	CA	CAS 110927-00-9
DM4FJHO	DE	Discovery agent

DM2HCUK	ID	DM2HCUK
DM2HCUK	DN	(5-phenyl-3H-benzo[d]imidazol-4-yl)methanamine
DM2HCUK	HS	Investigative
DM2HCUK	SN	CHEMBL255554; SCHEMBL3149686; ZINC11687646
DM2HCUK	DT	Small molecular drug
DM2HCUK	PC	11615508
DM2HCUK	MW	223.27
DM2HCUK	FM	C14H13N3
DM2HCUK	IC	InChI=1S/C14H13N3/c15-8-12-11(10-4-2-1-3-5-10)6-7-13-14(12)17-9-16-13/h1-7,9H,8,15H2,(H,16,17)
DM2HCUK	CS	C1=CC=C(C=C1)C2=C(C3=C(C=C2)NC=N3)CN
DM2HCUK	IK	IYXQHXUCPDCZDQ-UHFFFAOYSA-N
DM2HCUK	IU	(5-phenyl-1H-benzimidazol-4-yl)methanamine
DM2HCUK	DE	Discovery agent

DMORD8S	ID	DMORD8S
DMORD8S	DN	(5-phenylfuran-2-yl)methanamine
DMORD8S	HS	Investigative
DMORD8S	SN	(5-phenylfuran-2-yl)methanamine; 39170-18-8; 2-Furanmethanamine, 5-phenyl-; 5-phenylfurfurylamine; AC1Q53ZI; SCHEMBL720013; (5-phenyl-2-furyl)methylamine; CHEMBL214859; CTK7E5186; BDBM12363; MolPort-004-306-048; 1-(5-phenyl-2-furyl)methanamine; ZINC14949858; nicotine 3-heteroaromatic analogue 22; AKOS000143046; MCULE-3484411839; AJ-65506; EN300-49879
DMORD8S	DT	Small molecular drug
DMORD8S	PC	11993871
DMORD8S	MW	173.21
DMORD8S	FM	C11H11NO
DMORD8S	IC	InChI=1S/C11H11NO/c12-8-10-6-7-11(13-10)9-4-2-1-3-5-9/h1-7H,8,12H2
DMORD8S	CS	C1=CC=C(C=C1)C2=CC=C(O2)CN
DMORD8S	IK	HQHHWOJYOUTZHZ-UHFFFAOYSA-N
DMORD8S	IU	(5-phenylfuran-2-yl)methanamine
DMORD8S	CA	CAS 39170-18-8
DMORD8S	DE	Discovery agent

DM1R5SF	ID	DM1R5SF
DM1R5SF	DN	(5-Phenyl-oxazol-2-yl)-m-tolyl-amine
DM1R5SF	HS	Investigative
DM1R5SF	SN	GW632046X; N-(3-methylphenyl)-5-phenyl-1,3-oxazol-2-amine; 2-Anilino-5-aryloxazole 14; AC1NS7RH; SCHEMBL5475472; CHEMBL192417; BDBM5853; HMS3305J21; HMS3303N24; NCGC00242232-01
DM1R5SF	DT	Small molecular drug
DM1R5SF	PC	5329849
DM1R5SF	MW	250.29
DM1R5SF	FM	C16H14N2O
DM1R5SF	IC	InChI=1S/C16H14N2O/c1-12-6-5-9-14(10-12)18-16-17-11-15(19-16)13-7-3-2-4-8-13/h2-11H,1H3,(H,17,18)
DM1R5SF	CS	CC1=CC(=CC=C1)NC2=NC=C(O2)C3=CC=CC=C3
DM1R5SF	IK	XLGKHWGSIZWZNN-UHFFFAOYSA-N
DM1R5SF	IU	N-(3-methylphenyl)-5-phenyl-1,3-oxazol-2-amine
DM1R5SF	DE	Discovery agent

DMKC2BE	ID	DMKC2BE
DMKC2BE	DN	(5-pyridin-3-yl-furan-2-yl)methanethiol
DMKC2BE	HS	Investigative
DMKC2BE	SN	2-Furanmethanethiol, 5-(3-pyridinyl)-; 859239-19-3; (5-pyridin-3-yl-furan-2-yl)methanethiol; CHEMBL214784; SCHEMBL3611340; CTK2I3858; BDBM12360; DTXSID30475409; GLMNDKCXHHOKIQ-UHFFFAOYSA-N; nicotine 3-heteroaromatic analogue 14; [5-(pyridin-3-yl)furan-2-yl]methanethiol
DMKC2BE	DT	Small molecular drug
DMKC2BE	PC	11993866
DMKC2BE	MW	191.25
DMKC2BE	FM	C10H9NOS
DMKC2BE	IC	InChI=1S/C10H9NOS/c13-7-9-3-4-10(12-9)8-2-1-5-11-6-8/h1-6,13H,7H2
DMKC2BE	CS	C1=CC(=CN=C1)C2=CC=C(O2)CS
DMKC2BE	IK	GLMNDKCXHHOKIQ-UHFFFAOYSA-N
DMKC2BE	IU	(5-pyridin-3-ylfuran-2-yl)methanethiol
DMKC2BE	CA	CAS 859239-19-3
DMKC2BE	DE	Discovery agent

DMREVX9	ID	DMREVX9
DMREVX9	DN	(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone
DMREVX9	HS	Investigative
DMREVX9	SN	CHEMBL378672; (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone; GS416
DMREVX9	DT	Small molecular drug
DMREVX9	PC	11809004
DMREVX9	MW	308.4
DMREVX9	FM	C20H20O3
DMREVX9	IC	InChI=1S/C20H20O3/c21-18-12-7-13-19(22-14-16-8-3-1-4-9-16)20(18)23-15-17-10-5-2-6-11-17/h1-12,19-20H,13-15H2/t19-,20-/m1/s1
DMREVX9	CS	C1C=CC(=O)[C@H]([C@@H]1OCC2=CC=CC=C2)OCC3=CC=CC=C3
DMREVX9	IK	PHZAKVRYDXRMRQ-WOJBJXKFSA-N
DMREVX9	IU	(5R,6S)-5,6-bis(phenylmethoxy)cyclohex-2-en-1-one
DMREVX9	DE	Discovery agent

DMHG7MU	ID	DMHG7MU
DMHG7MU	DN	(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone
DMHG7MU	HS	Investigative
DMHG7MU	SN	CHEMBL212055; (5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone; BDBM50186506
DMHG7MU	DT	Small molecular drug
DMHG7MU	PC	15071517
DMHG7MU	MW	232.27
DMHG7MU	FM	C14H16O3
DMHG7MU	IC	InChI=1S/C14H16O3/c1-16-13-9-5-8-12(15)14(13)17-10-11-6-3-2-4-7-11/h2-8,13-14H,9-10H2,1H3/t13-,14-/m1/s1
DMHG7MU	CS	CO[C@@H]1CC=CC(=O)[C@H]1OCC2=CC=CC=C2
DMHG7MU	IK	KGCDPLUOCMBBAM-ZIAGYGMSSA-N
DMHG7MU	IU	(5R,6S)-5-methoxy-6-phenylmethoxycyclohex-2-en-1-one
DMHG7MU	DE	Discovery agent

DMA5DO2	ID	DMA5DO2
DMA5DO2	DN	(5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione
DMA5DO2	HS	Investigative
DMA5DO2	SN	(5s)-5-iododihydro-2,4(1h,3h)-pyrimidinedione; IDH; AC1NRBRW; SCHEMBL4316335; DB02303; (5S)-5-iodo-1,3-diazinane-2,4-dione
DMA5DO2	DT	Small molecular drug
DMA5DO2	PC	5288605
DMA5DO2	MW	240
DMA5DO2	FM	C4H5IN2O2
DMA5DO2	IC	InChI=1S/C4H5IN2O2/c5-2-1-6-4(9)7-3(2)8/h2H,1H2,(H2,6,7,8,9)/t2-/m0/s1
DMA5DO2	CS	C1[C@@H](C(=O)NC(=O)N1)I
DMA5DO2	IK	YGKCTZPSAOUUMT-REOHCLBHSA-N
DMA5DO2	IU	(5S)-5-iodo-1,3-diazinane-2,4-dione
DMA5DO2	DE	Discovery agent

DMT9CXD	ID	DMT9CXD
DMT9CXD	DN	(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine
DMT9CXD	HS	Investigative
DMT9CXD	SN	CHEMBL193007; (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine
DMT9CXD	DT	Small molecular drug
DMT9CXD	PC	44399940
DMT9CXD	MW	152.24
DMT9CXD	FM	C9H16N2
DMT9CXD	IC	InChI=1S/C9H16N2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h7-8H,1-6H2,(H2,10,11)/t7-,8+/m1/s1
DMT9CXD	CS	C1CC[C@H]2[C@H](C1)CCC(=N2)N
DMT9CXD	IK	AEIXJVBMYJIICX-SFYZADRCSA-N
DMT9CXD	IU	(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydroquinolin-2-amine
DMT9CXD	DE	Discovery agent

DMP4UC1	ID	DMP4UC1
DMP4UC1	DN	(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine
DMP4UC1	HS	Investigative
DMP4UC1	SN	CHEMBL364230; (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine
DMP4UC1	DT	Small molecular drug
DMP4UC1	PC	44399941
DMP4UC1	MW	152.24
DMP4UC1	FM	C9H16N2
DMP4UC1	IC	InChI=1S/C9H16N2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h7-8H,1-6H2,(H2,10,11)/t7-,8-/m0/s1
DMP4UC1	CS	C1CC[C@H]2[C@@H](C1)CCC(=N2)N
DMP4UC1	IK	AEIXJVBMYJIICX-YUMQZZPRSA-N
DMP4UC1	IU	(4aS,8aS)-3,4,4a,5,6,7,8,8a-octahydroquinolin-2-amine
DMP4UC1	DE	Discovery agent

DMA97CS	ID	DMA97CS
DMA97CS	DN	(5Z,9Z)-5,9-heptacosadienoic acid
DMA97CS	HS	Investigative
DMA97CS	SN	(5Z,9Z)-5,9-heptacosadienoic acid; 5Z,9Z-heptacosadienoic acid; CHEMBL463437; 27:2(5Z,9Z); LMFA01020363
DMA97CS	DT	Small molecular drug
DMA97CS	PC	44567153
DMA97CS	MW	406.7
DMA97CS	FM	C27H50O2
DMA97CS	IC	InChI=1S/C27H50O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27(28)29/h18-19,22-23H,2-17,20-21,24-26H2,1H3,(H,28,29)/b19-18-,23-22-
DMA97CS	CS	CCCCCCCCCCCCCCCCC/C=C\\CC/C=C\\CCCC(=O)O
DMA97CS	IK	QHCUSXRHMXVISV-ZCIBKELESA-N
DMA97CS	IU	(5Z,9Z)-heptacosa-5,9-dienoic acid
DMA97CS	DE	Discovery agent

DMAXS9H	ID	DMAXS9H
DMAXS9H	DN	(6-Benzylamino-9H-beta-carbolin-3-yl)-methanol
DMAXS9H	HS	Investigative
DMAXS9H	SN	[6-(benzylamino)-9H-pyrido[3,4-b]indol-3-yl]methanol; NSC629814; AC1NTT2B; CHEMBL166270; CHEMBL2008860; NCI60_009695; (6-(Benzylamino)-9H-beta-carbolin-3-yl)methanol hydrochloride
DMAXS9H	DT	Small molecular drug
DMAXS9H	PC	5387929
DMAXS9H	MW	303.4
DMAXS9H	FM	C19H17N3O
DMAXS9H	IC	InChI=1S/C19H17N3O/c23-12-15-9-17-16-8-14(20-10-13-4-2-1-3-5-13)6-7-18(16)22-19(17)11-21-15/h1-9,11,20,22-23H,10,12H2
DMAXS9H	CS	C1=CC=C(C=C1)CNC2=CC3=C(C=C2)NC4=C3C=C(N=C4)CO
DMAXS9H	IK	PCESGKMKSBKSOT-UHFFFAOYSA-N
DMAXS9H	IU	[6-(benzylamino)-9H-pyrido[3,4-b]indol-3-yl]methanol
DMAXS9H	DE	Discovery agent

DMF7LST	ID	DMF7LST
DMF7LST	DN	(6-Benzyloxy-2-naphthyl)-2-aminopropane
DMF7LST	HS	Investigative
DMF7LST	SN	CHEMBL456006; (6-Benzyloxy-2-naphthyl)-2-aminopropane
DMF7LST	DT	Small molecular drug
DMF7LST	PC	44590780
DMF7LST	MW	291.4
DMF7LST	FM	C20H21NO
DMF7LST	IC	InChI=1S/C20H21NO/c1-15(21)11-17-7-8-19-13-20(10-9-18(19)12-17)22-14-16-5-3-2-4-6-16/h2-10,12-13,15H,11,14,21H2,1H3
DMF7LST	CS	CC(CC1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=CC=C3)N
DMF7LST	IK	KDDLNYYBHKHYRE-UHFFFAOYSA-N
DMF7LST	IU	1-(6-phenylmethoxynaphthalen-2-yl)propan-2-amine
DMF7LST	DE	Discovery agent

DM7BK9A	ID	DM7BK9A
DM7BK9A	DN	(6-Butoxy-2-naphthyl)-2-aminopropane
DM7BK9A	HS	Investigative
DM7BK9A	SN	CHEMBL447882; (6-Butoxy-2-naphthyl)-2-aminopropane
DM7BK9A	DT	Small molecular drug
DM7BK9A	PC	44590779
DM7BK9A	MW	257.37
DM7BK9A	FM	C17H23NO
DM7BK9A	IC	InChI=1S/C17H23NO/c1-3-4-9-19-17-8-7-15-11-14(10-13(2)18)5-6-16(15)12-17/h5-8,11-13H,3-4,9-10,18H2,1-2H3
DM7BK9A	CS	CCCCOC1=CC2=C(C=C1)C=C(C=C2)CC(C)N
DM7BK9A	IK	HQJXBGMWVQCDJS-UHFFFAOYSA-N
DM7BK9A	IU	1-(6-butoxynaphthalen-2-yl)propan-2-amine
DM7BK9A	DE	Discovery agent

DMM2EX6	ID	DMM2EX6
DMM2EX6	DN	(6-Ethoxy-2-naphthyl)-2-aminopropane
DMM2EX6	HS	Investigative
DMM2EX6	SN	CHEMBL450964; (6-Ethoxy-2-naphthyl)-2-aminopropane
DMM2EX6	DT	Small molecular drug
DMM2EX6	PC	44590294
DMM2EX6	MW	229.32
DMM2EX6	FM	C15H19NO
DMM2EX6	IC	InChI=1S/C15H19NO/c1-3-17-15-7-6-13-9-12(8-11(2)16)4-5-14(13)10-15/h4-7,9-11H,3,8,16H2,1-2H3
DMM2EX6	CS	CCOC1=CC2=C(C=C1)C=C(C=C2)CC(C)N
DMM2EX6	IK	RIBPBDJODPIITD-UHFFFAOYSA-N
DMM2EX6	IU	1-(6-ethoxynaphthalen-2-yl)propan-2-amine
DMM2EX6	DE	Discovery agent

DMQJ5RU	ID	DMQJ5RU
DMQJ5RU	DN	(6-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid
DMQJ5RU	HS	Investigative
DMQJ5RU	SN	CHEMBL291659; (6-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid; BDBM50022252
DMQJ5RU	DT	Small molecular drug
DMQJ5RU	PC	13683080
DMQJ5RU	MW	219.19
DMQJ5RU	FM	C11H9NO4
DMQJ5RU	IC	InChI=1S/C11H9NO4/c13-8-2-3-9-7(5-8)1-4-10(14)12(9)6-11(15)16/h1-5,13H,6H2,(H,15,16)
DMQJ5RU	CS	C1=CC2=C(C=CC(=O)N2CC(=O)O)C=C1O
DMQJ5RU	IK	VDYFIKQEBBKQES-UHFFFAOYSA-N
DMQJ5RU	IU	2-(6-hydroxy-2-oxoquinolin-1-yl)acetic acid
DMQJ5RU	DE	Discovery agent

DM6YGQ3	ID	DM6YGQ3
DM6YGQ3	DN	(6-Methoxy-2-naphthyl)-2-aminopropane
DM6YGQ3	HS	Investigative
DM6YGQ3	SN	CHEMBL443427; (6-Methoxy-2-naphthyl)-2-aminopropane; SCHEMBL13484409; CTK7A8193; BDBM50276190; AKOS000161922; AKOS022489543
DM6YGQ3	DT	Small molecular drug
DM6YGQ3	PC	18070083
DM6YGQ3	MW	215.29
DM6YGQ3	FM	C14H17NO
DM6YGQ3	IC	InChI=1S/C14H17NO/c1-10(15)7-11-3-4-13-9-14(16-2)6-5-12(13)8-11/h3-6,8-10H,7,15H2,1-2H3
DM6YGQ3	CS	CC(CC1=CC2=C(C=C1)C=C(C=C2)OC)N
DM6YGQ3	IK	YYZOZFYDYBTLPQ-UHFFFAOYSA-N
DM6YGQ3	IU	1-(6-methoxynaphthalen-2-yl)propan-2-amine
DM6YGQ3	DE	Discovery agent

DMTYXFU	ID	DMTYXFU
DMTYXFU	DN	(6-Methoxy-2-oxo-2H-quinolin-1-yl)-acetic acid
DMTYXFU	HS	Investigative
DMTYXFU	SN	CHEMBL305164; 6-methoxy-2-oxo-1,2-dihydro-1-quinolineacetic acid; 103368-22-5; (6-Methoxy-2-oxo-2H-quinolin-1-yl)-acetic acid; SCHEMBL8368861; BDBM50022249
DMTYXFU	DT	Small molecular drug
DMTYXFU	PC	13683078
DMTYXFU	MW	233.22
DMTYXFU	FM	C12H11NO4
DMTYXFU	IC	InChI=1S/C12H11NO4/c1-17-9-3-4-10-8(6-9)2-5-11(14)13(10)7-12(15)16/h2-6H,7H2,1H3,(H,15,16)
DMTYXFU	CS	COC1=CC2=C(C=C1)N(C(=O)C=C2)CC(=O)O
DMTYXFU	IK	CHNXZDVEGNIZLG-UHFFFAOYSA-N
DMTYXFU	IU	2-(6-methoxy-2-oxoquinolin-1-yl)acetic acid
DMTYXFU	CA	CAS 103368-22-5
DMTYXFU	DE	Discovery agent

DM39W5K	ID	DM39W5K
DM39W5K	DN	(6-methylthio-2-naphthyl)isopropylamine
DM39W5K	HS	Investigative
DM39W5K	SN	CHEMBL455558; (6-methylthio-2-naphthyl)isopropylamine
DM39W5K	DT	Small molecular drug
DM39W5K	PC	44590781
DM39W5K	MW	231.36
DM39W5K	FM	C14H17NS
DM39W5K	IC	InChI=1S/C14H17NS/c1-10(15)7-11-3-4-13-9-14(16-2)6-5-12(13)8-11/h3-6,8-10H,7,15H2,1-2H3
DM39W5K	CS	CC(CC1=CC2=C(C=C1)C=C(C=C2)SC)N
DM39W5K	IK	YTLQCSVRMANEOQ-UHFFFAOYSA-N
DM39W5K	IU	1-(6-methylsulfanylnaphthalen-2-yl)propan-2-amine
DM39W5K	DE	Discovery agent

DMIFL3V	ID	DMIFL3V
DMIFL3V	DN	(6-Propoxy-2-naphthyl)-2-aminopropane
DMIFL3V	HS	Investigative
DMIFL3V	SN	CHEMBL471840; (6-Propoxy-2-naphthyl)-2-aminopropane
DMIFL3V	DT	Small molecular drug
DMIFL3V	PC	44590295
DMIFL3V	MW	243.34
DMIFL3V	FM	C16H21NO
DMIFL3V	IC	InChI=1S/C16H21NO/c1-3-8-18-16-7-6-14-10-13(9-12(2)17)4-5-15(14)11-16/h4-7,10-12H,3,8-9,17H2,1-2H3
DMIFL3V	CS	CCCOC1=CC2=C(C=C1)C=C(C=C2)CC(C)N
DMIFL3V	IK	CRXAYNAYXGFRGO-UHFFFAOYSA-N
DMIFL3V	IU	1-(6-propoxynaphthalen-2-yl)propan-2-amine
DMIFL3V	DE	Discovery agent

DMOD9R7	ID	DMOD9R7
DMOD9R7	DN	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin
DMOD9R7	HS	Investigative
DMOD9R7	DT	Small molecular drug
DMOD9R7	PC	135905887
DMOD9R7	MW	241.25
DMOD9R7	FM	C9H15N5O3
DMOD9R7	IC	InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4-,6+/m1/s1
DMOD9R7	CS	C[C@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DMOD9R7	IK	FNKQXYHWGSIFBK-KODRXGBYSA-N
DMOD9R7	IU	(6R)-2-amino-6-[(1R,2R)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one
DMOD9R7	DE	Discovery agent

DMRAC6T	ID	DMRAC6T
DMRAC6T	DN	(6s)-5,6,7,8-Tetrahydrofolate
DMRAC6T	HS	Investigative
DMRAC6T	DT	Small molecular drug
DMRAC6T	PC	135398650
DMRAC6T	MW	445.4
DMRAC6T	FM	C19H23N7O6
DMRAC6T	IC	InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11-,12-/m0/s1
DMRAC6T	CS	C1[C@@H](NC2=C(N1)N=C(NC2=O)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMRAC6T	IK	MSTNYGQPCMXVAQ-RYUDHWBXSA-N
DMRAC6T	IU	(2S)-2-[[4-[[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
DMRAC6T	CA	CAS 135-16-0
DMRAC6T	CB	CHEBI:15635
DMRAC6T	DE	Discovery agent

DMB9YAO	ID	DMB9YAO
DMB9YAO	DN	(7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
DMB9YAO	HS	Investigative
DMB9YAO	SN	CHEMBL572768; (7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
DMB9YAO	DT	Small molecular drug
DMB9YAO	PC	44541754
DMB9YAO	MW	291.3
DMB9YAO	FM	C18H13NO3
DMB9YAO	IC	InChI=1S/C18H13NO3/c19-9-8-14-10-18(20)22-17-11-15(6-7-16(14)17)21-12-13-4-2-1-3-5-13/h1-7,10-11H,8,12H2
DMB9YAO	CS	C1=CC=C(C=C1)COC2=CC3=C(C=C2)C(=CC(=O)O3)CC#N
DMB9YAO	IK	QXYWJHCXXQZBTQ-UHFFFAOYSA-N
DMB9YAO	IU	2-(2-oxo-7-phenylmethoxychromen-4-yl)acetonitrile
DMB9YAO	DE	Discovery agent

DMRU0IB	ID	DMRU0IB
DMRU0IB	DN	(8-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid
DMRU0IB	HS	Investigative
DMRU0IB	SN	CHEMBL64312; (8-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid; BDBM50022245
DMRU0IB	DT	Small molecular drug
DMRU0IB	PC	13683079
DMRU0IB	MW	219.19
DMRU0IB	FM	C11H9NO4
DMRU0IB	IC	InChI=1S/C11H9NO4/c13-8-3-1-2-7-4-5-9(14)12(11(7)8)6-10(15)16/h1-5,13H,6H2,(H,15,16)
DMRU0IB	CS	C1=CC2=C(C(=C1)O)N(C(=O)C=C2)CC(=O)O
DMRU0IB	IK	YRQSYBRKGTYSAL-UHFFFAOYSA-N
DMRU0IB	IU	2-(8-hydroxy-2-oxoquinolin-1-yl)acetic acid
DMRU0IB	DE	Discovery agent

DM1UGQN	ID	DM1UGQN
DM1UGQN	DN	(8R,8'R)-4-hydroxycubebinone
DM1UGQN	HS	Investigative
DM1UGQN	SN	(8R,8'R)-4-hydroxycubebinone; CHEMBL482034; AC1MHYPL; (8R,8''R)-4-hydroxycubebinone; BDBM50259848; 2(3H)-furanone, dihydro-4-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]-3-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]-, (3R,4R)-
DM1UGQN	DT	Small molecular drug
DM1UGQN	PC	3013841
DM1UGQN	MW	416.4
DM1UGQN	FM	C22H24O8
DM1UGQN	IC	InChI=1S/C22H24O8/c1-25-16-6-12(7-17(26-2)20(16)23)4-14-10-28-22(24)15(14)5-13-8-18(27-3)21-19(9-13)29-11-30-21/h6-9,14-15,23H,4-5,10-11H2,1-3H3/t14-,15+/m0/s1
DM1UGQN	CS	COC1=CC(=CC(=C1O)OC)C[C@H]2COC(=O)[C@@H]2CC3=CC4=C(C(=C3)OC)OCO4
DM1UGQN	IK	LSSNBHGWOAHIQS-LSDHHAIUSA-N
DM1UGQN	IU	(3R,4R)-4-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]-3-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]oxolan-2-one
DM1UGQN	DE	Discovery agent

DMVIHTF	ID	DMVIHTF
DMVIHTF	DN	(8R,8'R,9'S)-5-methoxyclusin
DMVIHTF	HS	Investigative
DMVIHTF	SN	(8R,8'R,9'S)-5-methoxyclusin; CHEMBL482233; BDBM50259849
DMVIHTF	DT	Small molecular drug
DMVIHTF	PC	11259008
DMVIHTF	MW	432.5
DMVIHTF	FM	C23H28O8
DMVIHTF	IC	InChI=1S/C23H28O8/c1-25-17-8-14(9-18(26-2)21(17)28-4)6-16-15(11-29-23(16)24)5-13-7-19(27-3)22-20(10-13)30-12-31-22/h7-10,15-16,23-24H,5-6,11-12H2,1-4H3/t15-,16+,23-/m0/s1
DMVIHTF	CS	COC1=CC(=CC2=C1OCO2)C[C@H]3CO[C@@H]([C@@H]3CC4=CC(=C(C(=C4)OC)OC)OC)O
DMVIHTF	IK	ADGULOHTKSMBCP-PXAQALGRSA-N
DMVIHTF	IU	(2S,3R,4R)-4-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-ol
DMVIHTF	DE	Discovery agent

DMHJG5N	ID	DMHJG5N
DMHJG5N	DN	(9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine
DMHJG5N	HS	Investigative
DMHJG5N	SN	CHEMBL7583
DMHJG5N	DT	Small molecular drug
DMHJG5N	PC	14022446
DMHJG5N	MW	265.31
DMHJG5N	FM	C15H15N5
DMHJG5N	IC	InChI=1S/C15H15N5/c1-2-4-11(5-3-1)8-20-10-18-13-14(19-12-6-7-12)16-9-17-15(13)20/h1-5,9-10,12H,6-8H2,(H,16,17,19)
DMHJG5N	CS	C1CC1NC2=C3C(=NC=N2)N(C=N3)CC4=CC=CC=C4
DMHJG5N	IK	AVSPKBDDPGPKRA-UHFFFAOYSA-N
DMHJG5N	IU	9-benzyl-N-cyclopropylpurin-6-amine
DMHJG5N	DE	Discovery agent

DMKI2Y9	ID	DMKI2Y9
DMKI2Y9	DN	(9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester
DMKI2Y9	HS	Investigative
DMKI2Y9	SN	NSC608075; AC1Q65MC; AC1L75O0; SCHEMBL2215023; CHEMBL353674; ZINC1610755; ethyl 9H-; A-carbolin-3-ylcarbamate; NSC-608075; ethyl N-(9H-pyrido[3,4-b]indol-3-yl)carbamate
DMKI2Y9	DT	Small molecular drug
DMKI2Y9	PC	355090
DMKI2Y9	MW	255.27
DMKI2Y9	FM	C14H13N3O2
DMKI2Y9	IC	InChI=1S/C14H13N3O2/c1-2-19-14(18)17-13-7-10-9-5-3-4-6-11(9)16-12(10)8-15-13/h3-8,16H,2H2,1H3,(H,15,17,18)
DMKI2Y9	CS	CCOC(=O)NC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMKI2Y9	IK	ABHBEIYQTPYXQQ-UHFFFAOYSA-N
DMKI2Y9	IU	ethyl N-(9H-pyrido[3,4-b]indol-3-yl)carbamate
DMKI2Y9	DE	Discovery agent

DMVHMPC	ID	DMVHMPC
DMVHMPC	DN	(9H-beta-Carbolin-3-yl)-ethyl-amine
DMVHMPC	HS	Investigative
DMVHMPC	SN	9H-Pyrido[3,4-b]indol-3-amine, N-ethyl-; 95935-52-7; ACMC-20m0fc; CHEMBL353967; N-Ethyl-beta-carboline-3-amine; CTK3F3147; DTXSID30541219; N-Ethyl-9H-beta-carbolin-3-amine
DMVHMPC	DT	Small molecular drug
DMVHMPC	PC	13450926
DMVHMPC	MW	211.26
DMVHMPC	FM	C13H13N3
DMVHMPC	IC	InChI=1S/C13H13N3/c1-2-14-13-7-10-9-5-3-4-6-11(9)16-12(10)8-15-13/h3-8,16H,2H2,1H3,(H,14,15)
DMVHMPC	CS	CCNC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMVHMPC	IK	AANHPEPPBKKLLX-UHFFFAOYSA-N
DMVHMPC	IU	N-ethyl-9H-pyrido[3,4-b]indol-3-amine
DMVHMPC	CA	CAS 95935-52-7
DMVHMPC	DE	Discovery agent

DMUF16A	ID	DMUF16A
DMUF16A	DN	(9H-beta-Carbolin-3-yl)-methanol
DMUF16A	HS	Investigative
DMUF16A	SN	3-hydroxymethyl-beta-carboline; 65474-79-5; UNII-00QJ5EQT3E; 9H-pyrido[3,4-b]indol-3-ylmethanol; 00QJ5EQT3E; 3-HMC; 3-(hydroxymethyl)-beta-carboline; 3-HYDROXYMETHYL-b-CARBOLINE; 9H-Pyrido[3,4-b]indole-3-methanol; 9H-pyrido(3,4-b)indole-3-methanol; Prestwick_970; Biomol-NT_000286; AC1NS42Q; DivK1c_000628; 9H-beta-carboline-3-methanol; CHEMBL417982; SCHEMBL2216848; BPBio1_001234; KBio1_000628; CTK2F5969; HMS501P10; DTXSID20215795; MolPort-005-942-230; CPBYHTDUBNSBQM-UHFFFAOYSA-N; CHEBI:114188; NINDS_000628; ZINC11535632
DMUF16A	DT	Small molecular drug
DMUF16A	PC	5353338
DMUF16A	MW	198.22
DMUF16A	FM	C12H10N2O
DMUF16A	IC	InChI=1S/C12H10N2O/c15-7-8-5-10-9-3-1-2-4-11(9)14-12(10)6-13-8/h1-6,14-15H,7H2
DMUF16A	CS	C1=CC=C2C(=C1)C3=C(N2)C=NC(=C3)CO
DMUF16A	IK	CPBYHTDUBNSBQM-UHFFFAOYSA-N
DMUF16A	IU	9H-pyrido[3,4-b]indol-3-ylmethanol
DMUF16A	CA	CAS 65474-79-5
DMUF16A	CB	CHEBI:114188
DMUF16A	DE	Discovery agent

DMWJNFC	ID	DMWJNFC
DMWJNFC	DN	(9-Methyl-9H-purin-6-yl)-phenyl-amine
DMWJNFC	HS	Investigative
DMWJNFC	SN	CHEMBL321749; 9H-Purin-6-amine, 9-methyl-N-phenyl-; (9-Methyl-9H-purin-6-yl)-phenyl-amine; SCHEMBL6660171; ZINC4055; 6-Phenylamino-9-methyl-9H-purine; BDBM50009703; 84602-82-4
DMWJNFC	DT	Small molecular drug
DMWJNFC	PC	13439250
DMWJNFC	MW	225.25
DMWJNFC	FM	C12H11N5
DMWJNFC	IC	InChI=1S/C12H11N5/c1-17-8-15-10-11(13-7-14-12(10)17)16-9-5-3-2-4-6-9/h2-8H,1H3,(H,13,14,16)
DMWJNFC	CS	CN1C=NC2=C(N=CN=C21)NC3=CC=CC=C3
DMWJNFC	IK	STTSYIXNIOADQX-UHFFFAOYSA-N
DMWJNFC	IU	9-methyl-N-phenylpurin-6-amine
DMWJNFC	DE	Discovery agent

DM12GHQ	ID	DM12GHQ
DM12GHQ	DN	(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
DM12GHQ	HS	Investigative
DM12GHQ	SN	13(S)-Hydroxyoctadeca-9Z,11E-dienoic acid; 29623-28-7; 13(S)-HODE; (13S)-Hydroxyoctadecadienoic acid; 13S-HODE; 13-Hydroxyoctadecadienoic acid; CHEMBL451721; CHEBI:34154; 13S-Hydroxy-9Z,11E-octadecadienoic acid; 13(S)-Hydroxy-9(Z),11(E)-octadecadienoic acid; (9Z, 11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; (9Z,11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; 9,11-Octadecadienoic acid, 13-hydroxy-, (R-(E,Z))-; 5204-88-6; 10219-69-9; (S)-Coriolic acid; AC1O5YAH
DM12GHQ	DT	Small molecular drug
DM12GHQ	PC	6443013
DM12GHQ	MW	296.4
DM12GHQ	FM	C18H32O3
DM12GHQ	IC	InChI=1S/C18H32O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h7,9,12,15,17,19H,2-6,8,10-11,13-14,16H2,1H3,(H,20,21)/b9-7-,15-12+/t17-/m0/s1
DM12GHQ	CS	CCCCC[C@@H](/C=C/C=C\\CCCCCCCC(=O)O)O
DM12GHQ	IK	HNICUWMFWZBIFP-IRQZEAMPSA-N
DM12GHQ	IU	(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
DM12GHQ	CA	CAS 29623-28-7
DM12GHQ	CB	CHEBI:34154
DM12GHQ	DE	Discovery agent

DM2REIN	ID	DM2REIN
DM2REIN	DN	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid
DM2REIN	HS	Investigative
DM2REIN	SN	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid; 12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid
DM2REIN	DT	Small molecular drug
DM2REIN	PC	5282316
DM2REIN	MW	325.4
DM2REIN	FM	C18H31NO4
DM2REIN	IC	InChI=1S/C18H31NO4/c1-2-3-4-11-14-17(19(22)23)15-12-9-7-5-6-8-10-13-16-18(20)21/h9,12,14H,2-8,10-11,13,15-16H2,1H3,(H,20,21)/b12-9-,17-14+
DM2REIN	CS	CCCCC/C=C(\\C/C=C\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DM2REIN	IK	ZYFTUIURWQWFKQ-QIAGQCQHSA-N
DM2REIN	IU	(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid
DM2REIN	CB	CHEBI:34150
DM2REIN	DE	Discovery agent

DMS4ZVK	ID	DMS4ZVK
DMS4ZVK	DN	(Amino-phenyl-methyl)-phosphinic acid
DMS4ZVK	HS	Investigative
DMS4ZVK	SN	Phosphinic acid, (aminophenylmethyl)-; 126529-62-2; 1-amino-1-phenylmethylphosphinic acid; ACMC-20ms0y; AC1O46MZ; SCHEMBL1764684; CTK0F6605; (aminophenylmethyl)phosphinic acid; DTXSID00422960; JLTNHFQJNQZJTC-UHFFFAOYSA-N
DMS4ZVK	DT	Small molecular drug
DMS4ZVK	PC	57013015
DMS4ZVK	MW	169.12
DMS4ZVK	FM	C7H8NO2P
DMS4ZVK	IC	InChI=1S/C7H8NO2P/c8-7(11(9)10)6-4-2-1-3-5-6/h1-5,8-10H
DMS4ZVK	CS	C1=CC=C(C=C1)C(=N)P(O)O
DMS4ZVK	IK	HYRMSZQUBBPTOQ-UHFFFAOYSA-N
DMS4ZVK	IU	benzenecarboximidoylphosphonous acid
DMS4ZVK	DE	Discovery agent

DME80RK	ID	DME80RK
DME80RK	DN	(benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone
DME80RK	HS	Investigative
DME80RK	SN	CHEMBL226183; (benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone; BDBM50202215; (Benzofuran-2-yl)(1H-indole-2-yl) ketone
DME80RK	DT	Small molecular drug
DME80RK	PC	44423635
DME80RK	MW	261.269
DME80RK	FM	C17H11NO2
DME80RK	IC	InChI=1S/C17H11NO2/c19-17(14-9-11-5-1-3-7-13(11)18-14)16-10-12-6-2-4-8-15(12)20-16/h1-10,18H
DME80RK	CS	C1=CC=C2C(=C1)C=C(N2)C(=O)C3=CC4=CC=CC=C4O3
DME80RK	IK	NWBGABGOSKEFQJ-UHFFFAOYSA-N
DME80RK	IU	1-benzofuran-2-yl(1H-indol-2-yl)methanone
DME80RK	DE	Discovery agent

DMVWQ26	ID	DMVWQ26
DMVWQ26	DN	(beta-CCE)9H-beta-Carboline-3-carboxylic acid
DMVWQ26	HS	Investigative
DMVWQ26	SN	Carboline-3-carboxylic acid; 9H-pyrido[3,4-b]indole-3-carboxylic acid; 74214-63-4; 9H-beta-carboline-3-carboxylic acid; beta-carboline-3-carboxylic acid; NSC623957; 9H-Pyrido(3,4-b)indole-3-carboxylic acid; beta-Carboline carboxylic acid; 3-carboxy-beta-carboline; AC1L59WQ; MLS001198085; CHEMBL11908; b-carboline-3-carboxylic acid; SCHEMBL1180278; beta-carbolin-3-carboxylic acid; DTXSID30225209; MolPort-000-872-217; ARLVFKCLBYUINL-UHFFFAOYSA-N; HMS3433I21; HMS1620B11; ZINC20104435; AKOS021730281; CCG-125106; NSC-623957
DMVWQ26	DT	Small molecular drug
DMVWQ26	PC	173262
DMVWQ26	MW	212.2
DMVWQ26	FM	C12H8N2O2
DMVWQ26	IC	InChI=1S/C12H8N2O2/c15-12(16)10-5-8-7-3-1-2-4-9(7)14-11(8)6-13-10/h1-6,14H,(H,15,16)
DMVWQ26	CS	C1=CC=C2C(=C1)C3=CC(=NC=C3N2)C(=O)O
DMVWQ26	IK	ARLVFKCLBYUINL-UHFFFAOYSA-N
DMVWQ26	IU	9H-pyrido[3,4-b]indole-3-carboxylic acid
DMVWQ26	CA	CAS 74214-63-4
DMVWQ26	DE	Discovery agent

DMGB97I	ID	DMGB97I
DMGB97I	DN	(biphenyl-3-ylamino)methylenediphosphonic acid
DMGB97I	HS	Investigative
DMGB97I	SN	CHEMBL55371; AC1NQQUY; (biphenyl-3-ylamino)methylenediphosphonic acid; BPH-218; NSC725581; BDBM50138040; ZINC13532369; NSC-725581; [(3-phenylanilino)-phosphonomethyl]phosphonic acid; [(3-phenylanilino)-phosphono-methyl]phosphonic acid; [(Biphenyl-3-ylamino)-phosphono-methyl]-phosphonic acid; (Biphenyl-3-yl)- aminomethylene-1,1-bisphosphonate (dihydrate); Phosphonic acid, [([1,1'-biphenyl]-3-ylamino)methylene]bis-
DMGB97I	DT	Small molecular drug
DMGB97I	PC	5277466
DMGB97I	MW	343.21
DMGB97I	FM	C13H15NO6P2
DMGB97I	IC	InChI=1S/C13H15NO6P2/c15-21(16,17)13(22(18,19)20)14-12-8-4-7-11(9-12)10-5-2-1-3-6-10/h1-9,13-14H,(H2,15,16,17)(H2,18,19,20)
DMGB97I	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)NC(P(=O)(O)O)P(=O)(O)O
DMGB97I	IK	IXFMBXNLOHKCPT-UHFFFAOYSA-N
DMGB97I	IU	[(3-phenylanilino)-phosphonomethyl]phosphonic acid
DMGB97I	DE	Discovery agent

DM5WH6R	ID	DM5WH6R
DM5WH6R	DN	(C8-R)-Hydantocidin 5'-Phosphate
DM5WH6R	HS	Investigative
DM5WH6R	SN	(C8-R)-HYDANTOCIDIN 5'-PHOSPHATE; 1qf4; AC1L9LL4; DB02666; 5-{(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-7-[(phosphonooxy)methyl]-6-oxa-1,3-diazaspiro[4.4]non-3-yl}-N-hydroxy-N-(hydroxymethyl)-D-norvaline; (2R)-5-[(1R,2S,3R,5S)-1,2-dihydroxy-6,8-dioxo-3-(phosphonooxymethyl)-4-oxa-7,9-diazaspiro[4.4]nonan-7-yl]-2-[hydroxy(hydroxymethyl)amino]pentanoic acid
DM5WH6R	DT	Small molecular drug
DM5WH6R	PC	448088
DM5WH6R	MW	459.3
DM5WH6R	FM	C13H22N3O13P
DM5WH6R	IC	InChI=1S/C13H22N3O13P/c17-5-16(24)6(10(20)21)2-1-3-15-11(22)13(14-12(15)23)9(19)8(18)7(29-13)4-28-30(25,26)27/h6-9,17-19,24H,1-5H2,(H,14,23)(H,20,21)(H2,25,26,27)/t6-,7-,8-,9-,13+/m1/s1
DM5WH6R	CS	C(C[C@H](C(=O)O)N(CO)O)CN1C(=O)[C@@]2([C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)NC1=O
DM5WH6R	IK	MAXSFYCTFIBEAR-OJMIUMIFSA-N
DM5WH6R	IU	(2R)-5-[(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-7-(phosphonooxymethyl)-6-oxa-1,3-diazaspiro[4.4]nonan-3-yl]-2-[hydroxy(hydroxymethyl)amino]pentanoic acid
DM5WH6R	DE	Discovery agent

DMMH179	ID	DMMH179
DMMH179	DN	(C8-S)-Hydantocidin 5'-Phosphate
DMMH179	HS	Investigative
DMMH179	SN	(C8-S)-HYDANTOCIDIN 5'-PHOSPHATE; 1qf5; AC1NRD1T; DB04460; 5-{(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-7-[(phosphonooxy)methyl]-6-oxa-1,3-diazaspiro[4.4]non-3-yl}-N-hydroxy-N-(hydroxymethyl)-L-norvaline; (2S)-5-[(1R,2S,3R,5S)-1,2-dihydroxy-6,8-dioxo-3-(phosphonooxymethyl)-4-oxa-7,9-diazaspiro[4.4]nonan-7-yl]-2-[hydroxy(hydroxymethyl)amino]pentanoic acid
DMMH179	DT	Small molecular drug
DMMH179	PC	5289306
DMMH179	MW	459.3
DMMH179	FM	C13H22N3O13P
DMMH179	IC	InChI=1S/C13H22N3O13P/c17-5-16(24)6(10(20)21)2-1-3-15-11(22)13(14-12(15)23)9(19)8(18)7(29-13)4-28-30(25,26)27/h6-9,17-19,24H,1-5H2,(H,14,23)(H,20,21)(H2,25,26,27)/t6-,7+,8+,9+,13-/m0/s1
DMMH179	CS	C(C[C@@H](C(=O)O)N(CO)O)CN1C(=O)[C@@]2([C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)NC1=O
DMMH179	IK	MAXSFYCTFIBEAR-FUIMDIGMSA-N
DMMH179	IU	(2S)-5-[(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-7-(phosphonooxymethyl)-6-oxa-1,3-diazaspiro[4.4]nonan-3-yl]-2-[hydroxy(hydroxymethyl)amino]pentanoic acid
DMMH179	DE	Discovery agent

DMZB0C3	ID	DMZB0C3
DMZB0C3	DN	(Carboxyhydroxyamino)Ethanoic Acid
DMZB0C3	HS	Investigative
DMZB0C3	SN	AC1NRBMN; N-(carboxymethyl)-N-hydroxycarbamate
DMZB0C3	DT	Small molecular drug
DMZB0C3	PC	4633094
DMZB0C3	MW	135.08
DMZB0C3	FM	C3H5NO5
DMZB0C3	IC	InChI=1S/C3H5NO5/c5-2(6)1-4(9)3(7)8/h9H,1H2,(H,5,6)(H,7,8)
DMZB0C3	CS	C(C(=O)O)N(C(=O)O)O
DMZB0C3	IK	LJSQPIOQKDFEKE-UHFFFAOYSA-N
DMZB0C3	IU	2-[carboxy(hydroxy)amino]acetic acid
DMZB0C3	DE	Discovery agent

DMD0P4G	ID	DMD0P4G
DMD0P4G	DN	(CH3)CCO-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
DMD0P4G	HS	Investigative
DMD0P4G	SN	CHEMBL440986; (CH3)CCO-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
DMD0P4G	PC	44306414
DMD0P4G	MW	1033.3
DMD0P4G	FM	C49H72N14O9S
DMD0P4G	IC	InChI=1S/C49H72N14O9S/c1-26(2)16-35(44(68)59-34(41(50)65)14-15-73-9)60-45(69)37(18-30-21-51-24-55-30)58-39(64)23-54-47(71)40(27(3)4)63-42(66)28(5)57-43(67)36(17-29-20-53-33-13-11-10-12-32(29)33)61-46(70)38(19-31-22-52-25-56-31)62-48(72)49(6,7)8/h10-13,20-22,24-28,34-38,40,53H,14-19,23H2,1-9H3,(H2,50,65)(H,51,55)(H,52,56)(H,54,71)(H,57,67)(H,58,64)(H,59,68)(H,60,69)(H,61,70)(H,62,72)(H,63,66)/t28-,34-,35-,36-,37-,38-,40-/m0/s1
DMD0P4G	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C(C)(C)C
DMD0P4G	IK	PKBMJVZFJGPSPI-MEIFHOCSSA-N
DMD0P4G	IU	(2S)-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(2,2-dimethylpropanoylamino)-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanamide
DMD0P4G	DE	Discovery agent

DMMC139	ID	DMMC139
DMMC139	DN	(cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane
DMMC139	HS	Investigative
DMMC139	SN	CHEMBL488473; (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane
DMMC139	DT	Small molecular drug
DMMC139	PC	44561135
DMMC139	MW	235.32
DMMC139	FM	C17H17N
DMMC139	IC	InChI=1S/C17H17N/c1-3-7-13(8-4-1)16-15-11-18-12-17(15,16)14-9-5-2-6-10-14/h1-10,15-16,18H,11-12H2/t15-,16-,17+/m1/s1
DMMC139	CS	C1[C@@H]2[C@H]([C@@]2(CN1)C3=CC=CC=C3)C4=CC=CC=C4
DMMC139	IK	MVCAANSQOXMPQN-ZACQAIPSSA-N
DMMC139	IU	(1S,5R,6S)-1,6-diphenyl-3-azabicyclo[3.1.0]hexane
DMMC139	DE	Discovery agent

DMGXTSB	ID	DMGXTSB
DMGXTSB	DN	(D)-Ala-Pro-Glu
DMGXTSB	HS	Investigative
DMGXTSB	SN	CHEMBL205662
DMGXTSB	DT	Small molecular drug
DMGXTSB	PC	11370470
DMGXTSB	MW	315.32
DMGXTSB	FM	C13H21N3O6
DMGXTSB	IC	InChI=1S/C13H21N3O6/c1-7(14)12(20)16-6-2-3-9(16)11(19)15-8(13(21)22)4-5-10(17)18/h7-9H,2-6,14H2,1H3,(H,15,19)(H,17,18)(H,21,22)/t7-,8+,9+/m1/s1
DMGXTSB	CS	C[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N
DMGXTSB	IK	IORKCNUBHNIMKY-VGMNWLOBSA-N
DMGXTSB	IU	(2S)-2-[[(2S)-1-[(2R)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid
DMGXTSB	DE	Discovery agent

DMWE42T	ID	DMWE42T
DMWE42T	DN	(D)Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(d)Phe-Phe-Arg
DMWE42T	HS	Investigative
DMWE42T	PC	44273865
DMWE42T	MW	1282.5
DMWE42T	FM	C60H87N19O13
DMWE42T	IC	InChI=1S/C60H87N19O13/c61-39(20-10-24-68-58(62)63)49(83)73-40(21-11-25-69-59(64)65)55(89)78-27-13-23-46(78)56(90)79-33-38(81)31-47(79)54(88)71-32-48(82)72-42(28-35-14-4-1-5-15-35)50(84)77-45(34-80)53(87)76-44(30-37-18-8-3-9-19-37)52(86)75-43(29-36-16-6-2-7-17-36)51(85)74-41(57(91)92)22-12-26-70-60(66)67/h1-9,14-19,38-47,80-81H,10-13,20-34,61H2,(H,71,88)(H,72,82)(H,73,83)(H,74,85)(H,75,86)(H,76,87)(H,77,84)(H,91,92)(H4,62,63,68)(H4,64,65,69)(H4,66,67,70)/t38?,39-,40-,41?,42+,43?,44?,45?,46-,47-/m0/s1
DMWE42T	CS	C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)N[C@H](CC3=CC=CC=C3)C(=O)NC(CO)C(=O)NC(CC4=CC=CC=C4)C(=O)NC(CC5=CC=CC=C5)C(=O)NC(CCCN=C(N)N)C(=O)O)O
DMWE42T	IK	RBIXVHPHNGXTCI-QWTWDILDSA-N
DMWE42T	IU	2-[[2-[[2-[[2-[[(2R)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMWE42T	DE	Discovery agent

DMYSE3O	ID	DMYSE3O
DMYSE3O	DN	(D)Arg-Arg-Pro-Hyp-Gly-Thi-Cys-(D)Phe-Phe-Cys-Arg
DMYSE3O	HS	Investigative
DMYSE3O	PC	44274056
DMYSE3O	MW	1405.7
DMYSE3O	FM	C61H88N20O13S3
DMYSE3O	IC	InChI=1S/C61H88N20O13S3/c62-38(17-7-21-69-59(63)64)49(84)74-39(18-8-22-70-60(65)66)56(91)80-24-10-20-46(80)57(92)81-31-36(82)28-47(81)55(90)72-30-48(83)73-43(29-37-16-11-25-95-37)52(87)79-45-33-97-96-32-44(53(88)75-40(58(93)94)19-9-23-71-61(67)68)78-51(86)42(27-35-14-5-2-6-15-35)76-50(85)41(77-54(45)89)26-34-12-3-1-4-13-34/h1-6,11-16,25,36,38-47,82H,7-10,17-24,26-33,62H2,(H,72,90)(H,73,83)(H,74,84)(H,75,88)(H,76,85)(H,77,89)(H,78,86)(H,79,87)(H,93,94)(H4,63,64,69)(H4,65,66,70)(H4,67,68,71)/t36?,38-,39-,40?,41-,42?,43?,44?,45-,46-,47-/m1/s1
DMYSE3O	CS	C1C[C@@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)N2CC(C[C@@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@@H]4CSSCC(NC(=O)C(NC(=O)[C@H](NC4=O)CC5=CC=CC=C5)CC6=CC=CC=C6)C(=O)NC(CCCN=C(N)N)C(=O)O)O
DMYSE3O	IK	QRPRDXXCSGEGJN-AAAINLOGSA-N
DMYSE3O	IU	2-[[(10R,13S)-13-[[2-[[2-[[(2R)-1-[(2R)-1-[(2R)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-7,10-dibenzyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMYSE3O	DE	Discovery agent

DMLSJKM	ID	DMLSJKM
DMLSJKM	DN	(D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Aoc-Arg
DMLSJKM	HS	Investigative
DMLSJKM	PC	44273898
DMLSJKM	MW	1290.5
DMLSJKM	FM	C58H87N19O13S
DMLSJKM	IC	InChI=1S/C58H87N19O13S/c59-36(13-4-18-66-56(60)61)47(81)71-37(14-5-19-67-57(62)63)51(85)74-21-7-17-42(74)53(87)76-29-34(79)25-43(76)49(83)69-27-46(80)70-39(26-35-12-8-22-91-35)48(82)73-40(30-78)52(86)75-28-33-10-2-1-9-31(33)23-45(75)54(88)77-41-16-3-11-32(41)24-44(77)50(84)72-38(55(89)90)15-6-20-68-58(64)65/h1-2,8-10,12,22,32,34,36-45,78-79H,3-7,11,13-21,23-30,59H2,(H,69,83)(H,70,80)(H,71,81)(H,72,84)(H,73,82)(H,89,90)(H4,60,61,66)(H4,62,63,67)(H4,64,65,68)/t32?,34?,36-,37-,38?,39?,40-,41?,42-,43-,44?,45?/m1/s1
DMLSJKM	CS	C1C[C@@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)N2CC(C[C@@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@H](CO)C(=O)N4CC5=CC=CC=C5CC4C(=O)N6C7CCCC7CC6C(=O)NC(CCCN=C(N)N)C(=O)O)O
DMLSJKM	IK	TZXGWOFUQYJXKR-OSXXQWSASA-N
DMLSJKM	IU	2-[[1-[2-[(2R)-2-[[2-[[2-[[(2R)-1-[(2R)-1-[(2R)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMLSJKM	DE	Discovery agent

DMP0627	ID	DMP0627
DMP0627	DN	(D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Tic-Arg
DMP0627	HS	Investigative
DMP0627	PC	44274015
DMP0627	MW	1312.5
DMP0627	FM	C60H85N19O13S
DMP0627	IC	InChI=1S/C60H85N19O13S/c61-39(15-5-19-68-58(62)63)49(83)73-40(16-6-20-69-59(64)65)53(87)76-22-8-18-44(76)55(89)79-31-37(81)26-46(79)51(85)71-28-48(82)72-42(27-38-14-9-23-93-38)50(84)75-43(32-80)54(88)78-30-36-13-4-2-11-34(36)25-47(78)56(90)77-29-35-12-3-1-10-33(35)24-45(77)52(86)74-41(57(91)92)17-7-21-70-60(66)67/h1-4,9-14,23,37,39-47,80-81H,5-8,15-22,24-32,61H2,(H,71,85)(H,72,82)(H,73,83)(H,74,86)(H,75,84)(H,91,92)(H4,62,63,68)(H4,64,65,69)(H4,66,67,70)/t37?,39-,40-,41?,42?,43-,44-,45?,46-,47?/m1/s1
DMP0627	CS	C1C[C@@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)N2CC(C[C@@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@H](CO)C(=O)N4CC5=CC=CC=C5CC4C(=O)N6CC7=CC=CC=C7CC6C(=O)NC(CCCN=C(N)N)C(=O)O)O
DMP0627	IK	GFWURPIOGZMEAS-RFHUBXOQSA-N
DMP0627	IU	2-[[2-[2-[(2R)-2-[[2-[[2-[[(2R)-1-[(2R)-1-[(2R)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMP0627	DE	Discovery agent

DM5ZIUW	ID	DM5ZIUW
DM5ZIUW	DN	(D)-Phe-(D)-Phe-NH2
DM5ZIUW	HS	Investigative
DM5ZIUW	SN	CHEMBL590276; (D)-Phe-(D)-Phe-NH2; AC1OEQ8I; BDBM50308389
DM5ZIUW	DT	Small molecular drug
DM5ZIUW	PC	7037588
DM5ZIUW	MW	311.4
DM5ZIUW	FM	C18H21N3O2
DM5ZIUW	IC	InChI=1S/C18H21N3O2/c19-15(11-13-7-3-1-4-8-13)18(23)21-16(17(20)22)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12,19H2,(H2,20,22)(H,21,23)/t15-,16-/m1/s1
DM5ZIUW	CS	C1=CC=C(C=C1)C[C@H](C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N)N
DM5ZIUW	IK	XXPXQEQOAZMUDD-HZPDHXFCSA-N
DM5ZIUW	IU	(2R)-2-amino-N-[(2R)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
DM5ZIUW	DE	Discovery agent

DMS32YA	ID	DMS32YA
DMS32YA	DN	(D)-Phe-(L)-Phe-NH2
DMS32YA	HS	Investigative
DMS32YA	SN	CHEMBL592133; (D)-Phe-(L)-Phe-NH2; AC1OEWDU; BDBM50308390
DMS32YA	DT	Small molecular drug
DMS32YA	PC	7088456
DMS32YA	MW	311.4
DMS32YA	FM	C18H21N3O2
DMS32YA	IC	InChI=1S/C18H21N3O2/c19-15(11-13-7-3-1-4-8-13)18(23)21-16(17(20)22)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12,19H2,(H2,20,22)(H,21,23)/t15-,16+/m1/s1
DMS32YA	CS	C1=CC=C(C=C1)C[C@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)N
DMS32YA	IK	XXPXQEQOAZMUDD-CVEARBPZSA-N
DMS32YA	IU	(2R)-2-amino-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
DMS32YA	DE	Discovery agent

DMQN14X	ID	DMQN14X
DMQN14X	DN	(D)Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2
DMQN14X	HS	Investigative
DMQN14X	SN	CHEMBL269024; (D)Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2
DMQN14X	PC	44315629
DMQN14X	MW	1069.3
DMQN14X	FM	C53H76N14O10
DMQN14X	IC	InChI=1S/C53H76N14O10/c1-28(2)19-39(46(56)70)64-51(75)40(20-29(3)4)65-52(76)42(23-34-25-57-27-60-34)62-44(69)26-59-53(77)45(30(5)6)67-47(71)31(7)61-50(74)41(22-33-24-58-37-16-12-11-15-35(33)37)66-49(73)38(17-18-43(55)68)63-48(72)36(54)21-32-13-9-8-10-14-32/h8-16,24-25,27-31,36,38-42,45,58H,17-23,26,54H2,1-7H3,(H2,55,68)(H2,56,70)(H,57,60)(H,59,77)(H,61,74)(H,62,69)(H,63,72)(H,64,75)(H,65,76)(H,66,73)(H,67,71)/t31-,36-,38-,39-,40-,41-,42-,45-/m0/s1
DMQN14X	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC4=CC=CC=C4)N
DMQN14X	IK	HLAREJIMNCKKSS-CENAJWRVSA-N
DMQN14X	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]pentanediamide
DMQN14X	DE	Discovery agent

DMI39LV	ID	DMI39LV
DMI39LV	DN	(D-Arg)(9)-p19(ARF) 26-44 peptide
DMI39LV	HS	Investigative
DMI39LV	DE	Discovery agent

DMHSJAT	ID	DMHSJAT
DMHSJAT	DN	(E)-(thiophen-2-ylmethylidene)amino benzoate
DMHSJAT	HS	Investigative
DMHSJAT	SN	CHEMBL362066; (E)-(thiophen-2-ylmethylidene)amino benzoate; SCHEMBL13431312
DMHSJAT	DT	Small molecular drug
DMHSJAT	PC	11701397
DMHSJAT	MW	231.27
DMHSJAT	FM	C12H9NO2S
DMHSJAT	IC	InChI=1S/C12H9NO2S/c14-12(10-5-2-1-3-6-10)15-13-9-11-7-4-8-16-11/h1-9H/b13-9+
DMHSJAT	CS	C1=CC=C(C=C1)C(=O)O/N=C/C2=CC=CS2
DMHSJAT	IK	VRGHYBJYCUKCSY-UKTHLTGXSA-N
DMHSJAT	IU	[(E)-thiophen-2-ylmethylideneamino] benzoate
DMHSJAT	DE	Discovery agent

DMBXK5L	ID	DMBXK5L
DMBXK5L	DN	(E)-1-(4-heptylphenyl)but-2-en-1-one
DMBXK5L	HS	Investigative
DMBXK5L	SN	Enone, 4b; CHEMBL396089; BDBM18827; ZINC14968962
DMBXK5L	DT	Small molecular drug
DMBXK5L	PC	23635476
DMBXK5L	MW	244.37
DMBXK5L	FM	C17H24O
DMBXK5L	IC	InChI=1S/C17H24O/c1-3-5-6-7-8-10-15-11-13-16(14-12-15)17(18)9-4-2/h4,9,11-14H,3,5-8,10H2,1-2H3/b9-4+
DMBXK5L	CS	CCCCCCCC1=CC=C(C=C1)C(=O)/C=C/C
DMBXK5L	IK	LCSOCUYXJADQCV-RUDMXATFSA-N
DMBXK5L	IU	(E)-1-(4-heptylphenyl)but-2-en-1-one
DMBXK5L	DE	Discovery agent

DMEP903	ID	DMEP903
DMEP903	DN	(E)-1-(4-Nitro-phenyl)-3-pyridin-2-yl-propenone
DMEP903	HS	Investigative
DMEP903	SN	CHEMBL187434; (E)-1-(4-Nitro-phenyl)-3-pyridin-2-yl-propenone; SCHEMBL4298443; ZINC13584328
DMEP903	DT	Small molecular drug
DMEP903	PC	44396914
DMEP903	MW	254.24
DMEP903	FM	C14H10N2O3
DMEP903	IC	InChI=1S/C14H10N2O3/c17-14(9-6-12-3-1-2-10-15-12)11-4-7-13(8-5-11)16(18)19/h1-10H/b9-6+
DMEP903	CS	C1=CC=NC(=C1)/C=C/C(=O)C2=CC=C(C=C2)[N+](=O)[O-]
DMEP903	IK	DYGZKSFWHRDUCX-RMKNXTFCSA-N
DMEP903	IU	(E)-1-(4-nitrophenyl)-3-pyridin-2-ylprop-2-en-1-one
DMEP903	DE	Discovery agent

DMO38CP	ID	DMO38CP
DMO38CP	DN	(E)-10-Nitrohexadec-9-enoic Acid
DMO38CP	HS	Investigative
DMO38CP	SN	CHEMBL564368; (E)-10-Nitrohexadec-9-enoic Acid; 10-nitropalmitoleic acid; E-10-nitropalmitoleic acid; SCHEMBL15633718; WZWPBDQYCAJWSX-FYWRMAATSA-N
DMO38CP	DT	Small molecular drug
DMO38CP	PC	44220887
DMO38CP	MW	299.41
DMO38CP	FM	C16H29NO4
DMO38CP	IC	InChI=1S/C16H29NO4/c1-2-3-4-9-12-15(17(20)21)13-10-7-5-6-8-11-14-16(18)19/h13H,2-12,14H2,1H3,(H,18,19)/b15-13+
DMO38CP	CS	CCCCCC/C(=C\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DMO38CP	IK	WZWPBDQYCAJWSX-FYWRMAATSA-N
DMO38CP	IU	(E)-10-nitrohexadec-9-enoic acid
DMO38CP	DE	Discovery agent

DMTF7JA	ID	DMTF7JA
DMTF7JA	DN	(E)-10-nitrooctadec-9-enoic acid
DMTF7JA	HS	Investigative
DMTF7JA	SN	10-nitrooleic acid; 10-nitro-9E-octadecenoic acid; 10-Nitro Oleic Acid; (E)-10-nitrooctadec-9-enoic acid; 10-nitroelaidic acid; 875685-46-4; UNII-1N19AGY57Y; CHEMBL561371; 1N19AGY57Y; CHEBI:86285; (9E)-10-nitrooctadecenoic acid; 10-Nitrooleate; 10-nitro-oleic acid; 10-Nitroelaidate; 88127-53-1; 9-Octadecenoic acid, 10-nitro-, (9E)-; E-10-nitrooleic acid; Oa-NO2; 10-nitro-9E-Octadecenoate; (9E)-10-Nitrooctadecenoate; 10-Nitro-9-octadecenoic acid; SCHEMBL1018141; CXA-10; (e)-10-Nitrooctadec-9-enoate; WRADPCFZZWXOTI-BMRADRMJSA-N
DMTF7JA	DT	Small molecular drug
DMTF7JA	PC	24836820
DMTF7JA	MW	327.5
DMTF7JA	FM	C18H33NO4
DMTF7JA	IC	InChI=1S/C18H33NO4/c1-2-3-4-5-8-11-14-17(19(22)23)15-12-9-6-7-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
DMTF7JA	CS	CCCCCCCC/C(=C\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DMTF7JA	IK	WRADPCFZZWXOTI-BMRADRMJSA-N
DMTF7JA	IU	(E)-10-nitrooctadec-9-enoic acid
DMTF7JA	CB	CHEBI:86285
DMTF7JA	DE	Discovery agent

DMBQTZL	ID	DMBQTZL
DMBQTZL	DN	(E)-12-Nitrooctadec-12-enoic Acid
DMBQTZL	HS	Investigative
DMBQTZL	SN	CHEMBL549351; (E)-12-Nitrooctadec-12-enoic Acid; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid
DMBQTZL	DT	Small molecular drug
DMBQTZL	PC	44221100
DMBQTZL	MW	327.5
DMBQTZL	FM	C18H33NO4
DMBQTZL	IC	InChI=1S/C18H33NO4/c1-2-3-4-11-14-17(19(22)23)15-12-9-7-5-6-8-10-13-16-18(20)21/h14H,2-13,15-16H2,1H3,(H,20,21)/b17-14+
DMBQTZL	CS	CCCCC/C=C(\\CCCCCCCCCCC(=O)O)/[N+](=O)[O-]
DMBQTZL	IK	LCOAELZDXRYQHF-SAPNQHFASA-N
DMBQTZL	IU	(E)-12-nitrooctadec-12-enoic acid
DMBQTZL	DE	Discovery agent

DMF74GJ	ID	DMF74GJ
DMF74GJ	DN	(E)-13-Nitrooctadec-12-enoic Acid
DMF74GJ	HS	Investigative
DMF74GJ	SN	CHEMBL540732; (E)-13-Nitrooctadec-12-enoic Acid
DMF74GJ	DT	Small molecular drug
DMF74GJ	PC	44221101
DMF74GJ	MW	327.5
DMF74GJ	FM	C18H33NO4
DMF74GJ	IC	InChI=1S/C18H33NO4/c1-2-3-11-14-17(19(22)23)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
DMF74GJ	CS	CCCCC/C(=C\\CCCCCCCCCCC(=O)O)/[N+](=O)[O-]
DMF74GJ	IK	PQAOIUQONUIELV-BMRADRMJSA-N
DMF74GJ	IU	(E)-13-nitrooctadec-12-enoic acid
DMF74GJ	DE	Discovery agent

DMQ9TWD	ID	DMQ9TWD
DMQ9TWD	DN	(E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone
DMQ9TWD	HS	Investigative
DMQ9TWD	SN	CHEMBL554700; (E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone; SCHEMBL5511163
DMQ9TWD	DT	Small molecular drug
DMQ9TWD	PC	44517772
DMQ9TWD	MW	317.4
DMQ9TWD	FM	C22H23NO
DMQ9TWD	IC	InChI=1S/C22H23NO/c24-21(22-11-16-7-17(12-22)9-18(8-16)13-22)6-5-15-10-19-3-1-2-4-20(19)23-14-15/h1-6,10,14,16-18H,7-9,11-13H2/b6-5+
DMQ9TWD	CS	C1C2CC3CC1CC(C2)(C3)C(=O)/C=C/C4=CC5=CC=CC=C5N=C4
DMQ9TWD	IK	IHMKNCCPYWKVEH-AATRIKPKSA-N
DMQ9TWD	IU	(E)-1-(1-adamantyl)-3-quinolin-3-ylprop-2-en-1-one
DMQ9TWD	DE	Discovery agent

DMI146O	ID	DMI146O
DMI146O	DN	(E)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMI146O	HS	Investigative
DMI146O	SN	CHEMBL496308; (E)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMI146O	DT	Small molecular drug
DMI146O	PC	44576946
DMI146O	MW	329.4
DMI146O	FM	C20H27NO3
DMI146O	IC	InChI=1S/C20H27NO3/c1-2-3-4-5-6-7-8-11-14-21-18-13-10-9-12-16(18)17(20(21)24)15-19(22)23/h9-10,12-13,15H,2-8,11,14H2,1H3,(H,22,23)/b17-15+
DMI146O	CS	CCCCCCCCCCN1C2=CC=CC=C2/C(=C\\C(=O)O)/C1=O
DMI146O	IK	LIUQXAWYSKFADK-BMRADRMJSA-N
DMI146O	IU	(2E)-2-(1-decyl-2-oxoindol-3-ylidene)acetic acid
DMI146O	DE	Discovery agent

DMH2U4Z	ID	DMH2U4Z
DMH2U4Z	DN	(E)-2-(4-(methylsulfonyl)styryl)furan
DMH2U4Z	HS	Investigative
DMH2U4Z	SN	CHEMBL1288742; (E)-2-(4-(methylsulfonyl)styryl)furan
DMH2U4Z	DT	Small molecular drug
DMH2U4Z	PC	52946891
DMH2U4Z	MW	248.3
DMH2U4Z	FM	C13H12O3S
DMH2U4Z	IC	InChI=1S/C13H12O3S/c1-17(14,15)13-8-5-11(6-9-13)4-7-12-3-2-10-16-12/h2-10H,1H3/b7-4+
DMH2U4Z	CS	CS(=O)(=O)C1=CC=C(C=C1)/C=C/C2=CC=CO2
DMH2U4Z	IK	WFCBWFJZEUDGIS-QPJJXVBHSA-N
DMH2U4Z	IU	2-[(E)-2-(4-methylsulfonylphenyl)ethenyl]furan
DMH2U4Z	DE	Discovery agent

DMDFE1R	ID	DMDFE1R
DMDFE1R	DN	(E)-2-(4-(methylsulfonyl)styryl)thiophene
DMDFE1R	HS	Investigative
DMDFE1R	SN	CHEMBL1288781; (E)-2-(4-(methylsulfonyl)styryl)thiophene
DMDFE1R	DT	Small molecular drug
DMDFE1R	PC	50908698
DMDFE1R	MW	264.4
DMDFE1R	FM	C13H12O2S2
DMDFE1R	IC	InChI=1S/C13H12O2S2/c1-17(14,15)13-8-5-11(6-9-13)4-7-12-3-2-10-16-12/h2-10H,1H3/b7-4+
DMDFE1R	CS	CS(=O)(=O)C1=CC=C(C=C1)/C=C/C2=CC=CS2
DMDFE1R	IK	JTGRXCMSCWBAQN-QPJJXVBHSA-N
DMDFE1R	IU	2-[(E)-2-(4-methylsulfonylphenyl)ethenyl]thiophene
DMDFE1R	DE	Discovery agent

DMTJI4F	ID	DMTJI4F
DMTJI4F	DN	(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine
DMTJI4F	HS	Investigative
DMTJI4F	SN	CHEMBL240886; (E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine
DMTJI4F	DT	Small molecular drug
DMTJI4F	PC	44439386
DMTJI4F	MW	323.4
DMTJI4F	FM	C19H14FNOS
DMTJI4F	IC	InChI=1S/C19H14FNOS/c20-16-9-6-15(7-10-16)8-11-17-12-13-19(14-21-17)23(22)18-4-2-1-3-5-18/h1-14H/b11-8+
DMTJI4F	CS	C1=CC=C(C=C1)S(=O)C2=CN=C(C=C2)/C=C/C3=CC=C(C=C3)F
DMTJI4F	IK	YFWOOEBYKGJCJO-DHZHZOJOSA-N
DMTJI4F	IU	5-(benzenesulfinyl)-2-[(E)-2-(4-fluorophenyl)ethenyl]pyridine
DMTJI4F	DE	Discovery agent

DM7P5VM	ID	DM7P5VM
DM7P5VM	DN	(E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine
DM7P5VM	HS	Investigative
DM7P5VM	SN	CHEMBL394729; (E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine
DM7P5VM	DT	Small molecular drug
DM7P5VM	PC	44439376
DM7P5VM	MW	339.4
DM7P5VM	FM	C19H14FNO2S
DM7P5VM	IC	InChI=1S/C19H14FNO2S/c20-16-9-6-15(7-10-16)8-11-17-12-13-19(14-21-17)24(22,23)18-4-2-1-3-5-18/h1-14H/b11-8+
DM7P5VM	CS	C1=CC=C(C=C1)S(=O)(=O)C2=CN=C(C=C2)/C=C/C3=CC=C(C=C3)F
DM7P5VM	IK	ANNXZFGXMGNRDN-DHZHZOJOSA-N
DM7P5VM	IU	5-(benzenesulfonyl)-2-[(E)-2-(4-fluorophenyl)ethenyl]pyridine
DM7P5VM	DE	Discovery agent

DM1LG27	ID	DM1LG27
DM1LG27	DN	(E)-3-(2,3-dichlorophenylimino)indolin-2-one
DM1LG27	HS	Investigative
DM1LG27	DT	Small molecular drug
DM1LG27	PC	135559217
DM1LG27	MW	291.1
DM1LG27	FM	C14H8Cl2N2O
DM1LG27	IC	InChI=1S/C14H8Cl2N2O/c15-9-5-3-7-11(12(9)16)17-13-8-4-1-2-6-10(8)18-14(13)19/h1-7H,(H,17,18,19)
DM1LG27	CS	C1=CC=C2C(=C1)C(=NC3=C(C(=CC=C3)Cl)Cl)C(=O)N2
DM1LG27	IK	AUBZCTXOLGPERG-UHFFFAOYSA-N
DM1LG27	IU	3-(2,3-dichlorophenyl)imino-1H-indol-2-one
DM1LG27	DE	Discovery agent

DMOWGT3	ID	DMOWGT3
DMOWGT3	DN	(E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid
DMOWGT3	HS	Investigative
DMOWGT3	SN	CHEMBL201736; (E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid
DMOWGT3	DT	Small molecular drug
DMOWGT3	PC	11501077
DMOWGT3	MW	344.4
DMOWGT3	FM	C22H16O4
DMOWGT3	IC	InChI=1S/C22H16O4/c23-21(24)15-8-16-6-9-17(10-7-16)22(25)18-11-13-20(14-12-18)26-19-4-2-1-3-5-19/h1-15H,(H,23,24)/b15-8+
DMOWGT3	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)/C=C/C(=O)O
DMOWGT3	IK	UXUCKEBTHPCTFJ-OVCLIPMQSA-N
DMOWGT3	IU	(E)-3-[4-(4-phenoxybenzoyl)phenyl]prop-2-enoic acid
DMOWGT3	DE	Discovery agent

DMUS0D8	ID	DMUS0D8
DMUS0D8	DN	(E)-3-(4-(methylsulfonyl)styryl)thiophene
DMUS0D8	HS	Investigative
DMUS0D8	SN	CHEMBL1288782; (E)-3-(4-(methylsulfonyl)styryl)thiophene
DMUS0D8	DT	Small molecular drug
DMUS0D8	PC	52949357
DMUS0D8	MW	264.4
DMUS0D8	FM	C13H12O2S2
DMUS0D8	IC	InChI=1S/C13H12O2S2/c1-17(14,15)13-6-4-11(5-7-13)2-3-12-8-9-16-10-12/h2-10H,1H3/b3-2+
DMUS0D8	CS	CS(=O)(=O)C1=CC=C(C=C1)/C=C/C2=CSC=C2
DMUS0D8	IK	HPDGNEAMPZEKTB-NSCUHMNNSA-N
DMUS0D8	IU	3-[(E)-2-(4-methylsulfonylphenyl)ethenyl]thiophene
DMUS0D8	DE	Discovery agent

DMPOYK2	ID	DMPOYK2
DMPOYK2	DN	(E)-3-(4-chlorophenylimino)indolin-2-one
DMPOYK2	HS	Investigative
DMPOYK2	DT	Small molecular drug
DMPOYK2	PC	135411931
DMPOYK2	MW	256.68
DMPOYK2	FM	C14H9ClN2O
DMPOYK2	IC	InChI=1S/C14H9ClN2O/c15-9-5-7-10(8-6-9)16-13-11-3-1-2-4-12(11)17-14(13)18/h1-8H,(H,16,17,18)
DMPOYK2	CS	C1=CC=C2C(=C1)C(=NC3=CC=C(C=C3)Cl)C(=O)N2
DMPOYK2	IK	CPOOLXVTWFEFNO-UHFFFAOYSA-N
DMPOYK2	IU	3-(4-chlorophenyl)imino-1H-indol-2-one
DMPOYK2	CA	CAS 57644-24-3
DMPOYK2	DE	Discovery agent

DMX4U9L	ID	DMX4U9L
DMX4U9L	DN	(E)-3-(4-hydroxybenzylidene)indolin-2-one
DMX4U9L	HS	Investigative
DMX4U9L	SN	CHEMBL103307; (E)-3-(4-hydroxybenzylidene)indolin-2-one; 3-(4-Hydroxybenzylidenyl)indolin-2-one; SCHEMBL16442341; BDBM50131995; ZINC12568108; AKOS001309473; 3-(4-hydroxybenzylidene)indolin-2-one; NCGC00343741-01; ACM293302144; AB00756566-01
DMX4U9L	DT	Small molecular drug
DMX4U9L	PC	10561847
DMX4U9L	MW	237.25
DMX4U9L	FM	C15H11NO2
DMX4U9L	IC	InChI=1S/C15H11NO2/c17-11-7-5-10(6-8-11)9-13-12-3-1-2-4-14(12)16-15(13)18/h1-9,17H,(H,16,18)/b13-9+
DMX4U9L	CS	C1=CC=C2C(=C1)/C(=C\\C3=CC=C(C=C3)O)/C(=O)N2
DMX4U9L	IK	PLAOAGFXNCEZMZ-UKTHLTGXSA-N
DMX4U9L	IU	(3E)-3-[(4-hydroxyphenyl)methylidene]-1H-indol-2-one
DMX4U9L	DE	Discovery agent

DMTKCAL	ID	DMTKCAL
DMTKCAL	DN	(E)-3-(4-tert-Butyl-phenyl)-N-phenyl-acrylamide
DMTKCAL	HS	Investigative
DMTKCAL	SN	CHEMBL426634; (2E)-3-[4-(tert-butyl)phenyl]-N-phenylprop-2-enamide; AC1NYN2M; (E)-3-(4-tert-Butyl-phenyl)-N-phenyl-acrylamide; SCHEMBL4006434; SCHEMBL4006429; MolPort-006-388-008; AVMIAJAOFXDOSN-SDNWHVSQSA-N; ZINC5903656; STK411584; BDBM50158648; AKOS003298323; 3-(4-tert-butylphenyl)-N-phenylacrylamide; ST50943451; (E)-3-(4-tert-butylphenyl)-N-phenylprop-2-enamide
DMTKCAL	DT	Small molecular drug
DMTKCAL	PC	5885566
DMTKCAL	MW	279.4
DMTKCAL	FM	C19H21NO
DMTKCAL	IC	InChI=1S/C19H21NO/c1-19(2,3)16-12-9-15(10-13-16)11-14-18(21)20-17-7-5-4-6-8-17/h4-14H,1-3H3,(H,20,21)/b14-11+
DMTKCAL	CS	CC(C)(C)C1=CC=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2
DMTKCAL	IK	AVMIAJAOFXDOSN-SDNWHVSQSA-N
DMTKCAL	IU	(E)-3-(4-tert-butylphenyl)-N-phenylprop-2-enamide
DMTKCAL	DE	Discovery agent

DMITXKJ	ID	DMITXKJ
DMITXKJ	DN	(E)-3-[2-(2-methyl-4-thiazolyl)vinyl]pyridine
DMITXKJ	HS	Investigative
DMITXKJ	SN	CHEMBL382527; (E)-3-[2-(2-methyl-4-thiazolyl)vinyl]pyridine; SCHEMBL4148449; SCHEMBL4148438
DMITXKJ	DT	Small molecular drug
DMITXKJ	PC	11715388
DMITXKJ	MW	202.28
DMITXKJ	FM	C11H10N2S
DMITXKJ	IC	InChI=1S/C11H10N2S/c1-9-13-11(8-14-9)5-4-10-3-2-6-12-7-10/h2-8H,1H3/b5-4+
DMITXKJ	CS	CC1=NC(=CS1)/C=C/C2=CN=CC=C2
DMITXKJ	IK	HHLKCNHXNVMBFW-SNAWJCMRSA-N
DMITXKJ	IU	2-methyl-4-[(E)-2-pyridin-3-ylethenyl]-1,3-thiazole
DMITXKJ	DE	Discovery agent

DMDF7M4	ID	DMDF7M4
DMDF7M4	DN	(E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide
DMDF7M4	HS	Investigative
DMDF7M4	SN	CHEMBL1288783; (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide
DMDF7M4	DT	Small molecular drug
DMDF7M4	PC	52946892
DMDF7M4	MW	249.29
DMDF7M4	FM	C12H11NO3S
DMDF7M4	IC	InChI=1S/C12H11NO3S/c13-17(14,15)12-7-4-10(5-8-12)3-6-11-2-1-9-16-11/h1-9H,(H2,13,14,15)/b6-3+
DMDF7M4	CS	C1=COC(=C1)/C=C/C2=CC=C(C=C2)S(=O)(=O)N
DMDF7M4	IK	LUXIPMZZPXZHSJ-ZZXKWVIFSA-N
DMDF7M4	IU	4-[(E)-2-(furan-2-yl)ethenyl]benzenesulfonamide
DMDF7M4	DE	Discovery agent

DM7204O	ID	DM7204O
DM7204O	DN	(E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide
DM7204O	HS	Investigative
DM7204O	SN	CHEMBL1288801; (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide
DM7204O	DT	Small molecular drug
DM7204O	PC	50908697
DM7204O	MW	265.4
DM7204O	FM	C12H11NO2S2
DM7204O	IC	InChI=1S/C12H11NO2S2/c13-17(14,15)12-7-4-10(5-8-12)3-6-11-2-1-9-16-11/h1-9H,(H2,13,14,15)/b6-3+
DM7204O	CS	C1=CSC(=C1)/C=C/C2=CC=C(C=C2)S(=O)(=O)N
DM7204O	IK	OZEBJQJPQRQDDH-ZZXKWVIFSA-N
DM7204O	IU	4-[(E)-2-thiophen-2-ylethenyl]benzenesulfonamide
DM7204O	DE	Discovery agent

DMTAB8W	ID	DMTAB8W
DMTAB8W	DN	(E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide
DMTAB8W	HS	Investigative
DMTAB8W	SN	CHEMBL1288802; (E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide
DMTAB8W	DT	Small molecular drug
DMTAB8W	PC	50908699
DMTAB8W	MW	265.4
DMTAB8W	FM	C12H11NO2S2
DMTAB8W	IC	InChI=1S/C12H11NO2S2/c13-17(14,15)12-5-3-10(4-6-12)1-2-11-7-8-16-9-11/h1-9H,(H2,13,14,15)/b2-1+
DMTAB8W	CS	C1=CC(=CC=C1/C=C/C2=CSC=C2)S(=O)(=O)N
DMTAB8W	IK	JQHQATMSMAURMY-OWOJBTEDSA-N
DMTAB8W	IU	4-[(E)-2-thiophen-3-ylethenyl]benzenesulfonamide
DMTAB8W	DE	Discovery agent

DMYXI2V	ID	DMYXI2V
DMYXI2V	DN	(E)-4-(3,5-dimethoxystyryl)phenol
DMYXI2V	HS	Investigative
DMYXI2V	SN	Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus; pterostilbene
DMYXI2V	DT	Small molecular drug
DMYXI2V	PC	5281727
DMYXI2V	MW	256.3
DMYXI2V	FM	C16H16O3
DMYXI2V	IC	InChI=1S/C16H16O3/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11,17H,1-2H3/b4-3+
DMYXI2V	CS	COC1=CC(=CC(=C1)/C=C/C2=CC=C(C=C2)O)OC
DMYXI2V	IK	VLEUZFDZJKSGMX-ONEGZZNKSA-N
DMYXI2V	IU	4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol
DMYXI2V	CA	CAS 537-42-8
DMYXI2V	CB	CHEBI:8630
DMYXI2V	DE	Discovery agent

DMJGAFV	ID	DMJGAFV
DMJGAFV	DN	(E)-4,4-Dimethyl-1-quinolin-3-yl-pent-1-en-3-one
DMJGAFV	HS	Investigative
DMJGAFV	SN	CHEMBL572128; (E)-4,4-dimethyl-1-quinolin-3-yl-pent-1-en-3-one; SCHEMBL5503755
DMJGAFV	DT	Small molecular drug
DMJGAFV	PC	11644388
DMJGAFV	MW	239.31
DMJGAFV	FM	C16H17NO
DMJGAFV	IC	InChI=1S/C16H17NO/c1-16(2,3)15(18)9-8-12-10-13-6-4-5-7-14(13)17-11-12/h4-11H,1-3H3/b9-8+
DMJGAFV	CS	CC(C)(C)C(=O)/C=C/C1=CC2=CC=CC=C2N=C1
DMJGAFV	IK	XROFVTPRFZVYMN-CMDGGOBGSA-N
DMJGAFV	IU	(E)-4,4-dimethyl-1-quinolin-3-ylpent-1-en-3-one
DMJGAFV	DE	Discovery agent

DM75OHG	ID	DM75OHG
DM75OHG	DN	(E)-4-Methyl-6-(prop-1-enyl)pyridin-2-amine
DM75OHG	HS	Investigative
DM75OHG	SN	CHEMBL501620; (E)-4-Methyl-6-(prop-1-enyl)pyridin-2-amine; SCHEMBL15091007; SCHEMBL15091006; QHUQCHMVBGZYHI-ONEGZZNKSA-N; ZINC40424901; BDBM50267274
DM75OHG	DT	Small molecular drug
DM75OHG	PC	42625452
DM75OHG	MW	148.2
DM75OHG	FM	C9H12N2
DM75OHG	IC	InChI=1S/C9H12N2/c1-3-4-8-5-7(2)6-9(10)11-8/h3-6H,1-2H3,(H2,10,11)/b4-3+
DM75OHG	CS	C/C=C/C1=NC(=CC(=C1)C)N
DM75OHG	IK	QHUQCHMVBGZYHI-ONEGZZNKSA-N
DM75OHG	IU	4-methyl-6-[(E)-prop-1-enyl]pyridin-2-amine
DM75OHG	DE	Discovery agent

DMLIQUA	ID	DMLIQUA
DMLIQUA	DN	(E)-5-(3-Chlorostyryl)isatin
DMLIQUA	HS	Investigative
DMLIQUA	SN	CHEMBL447307; (E)-5-(3-Chlorostyryl)isatin
DMLIQUA	DT	Small molecular drug
DMLIQUA	PC	44575103
DMLIQUA	MW	283.71
DMLIQUA	FM	C16H10ClNO2
DMLIQUA	IC	InChI=1S/C16H10ClNO2/c17-12-3-1-2-10(8-12)4-5-11-6-7-14-13(9-11)15(19)16(20)18-14/h1-9H,(H,18,19,20)/b5-4+
DMLIQUA	CS	C1=CC(=CC(=C1)Cl)/C=C/C2=CC3=C(C=C2)NC(=O)C3=O
DMLIQUA	IK	ZKYUNESJTCRBIF-SNAWJCMRSA-N
DMLIQUA	IU	5-[(E)-2-(3-chlorophenyl)ethenyl]-1H-indole-2,3-dione
DMLIQUA	DE	Discovery agent

DMP4T9Z	ID	DMP4T9Z
DMP4T9Z	DN	(E)-5-(3-Fluorostyryl)isatin
DMP4T9Z	HS	Investigative
DMP4T9Z	SN	CHEMBL506301; (E)-5-(3-Fluorostyryl)isatin
DMP4T9Z	DT	Small molecular drug
DMP4T9Z	PC	44575104
DMP4T9Z	MW	267.25
DMP4T9Z	FM	C16H10FNO2
DMP4T9Z	IC	InChI=1S/C16H10FNO2/c17-12-3-1-2-10(8-12)4-5-11-6-7-14-13(9-11)15(19)16(20)18-14/h1-9H,(H,18,19,20)/b5-4+
DMP4T9Z	CS	C1=CC(=CC(=C1)F)/C=C/C2=CC3=C(C=C2)NC(=O)C3=O
DMP4T9Z	IK	UQOGXLMBLXKBJJ-SNAWJCMRSA-N
DMP4T9Z	IU	5-[(E)-2-(3-fluorophenyl)ethenyl]-1H-indole-2,3-dione
DMP4T9Z	DE	Discovery agent

DM81JRF	ID	DM81JRF
DM81JRF	DN	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin
DM81JRF	HS	Investigative
DM81JRF	SN	CHEMBL213560; (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin; SCHEMBL16693054; BDBM50187134
DM81JRF	DT	Small molecular drug
DM81JRF	PC	15984068
DM81JRF	MW	308.3
DM81JRF	FM	C18H16N2O3
DM81JRF	IC	InChI=1S/C18H16N2O3/c21-15-8-6-14(7-9-15)12-16-17(22)19-18(23)20(16)11-10-13-4-2-1-3-5-13/h1-9,12,21H,10-11H2,(H,19,22,23)/b16-12+
DM81JRF	CS	C1=CC=C(C=C1)CCN2/C(=C/C3=CC=C(C=C3)O)/C(=O)NC2=O
DM81JRF	IK	SXBULDIKCMKRBS-FOWTUZBSSA-N
DM81JRF	IU	(5E)-5-[(4-hydroxyphenyl)methylidene]-1-(2-phenylethyl)imidazolidine-2,4-dione
DM81JRF	DE	Discovery agent

DMJKOFW	ID	DMJKOFW
DMJKOFW	DN	(E)-5-Nitrooctadec-5-enoic Acid
DMJKOFW	HS	Investigative
DMJKOFW	SN	CHEMBL561776; (E)-5-Nitrooctadec-5-enoic Acid; (E)-5-Nitro-5-octadecenoic acid; BDBM50295050
DMJKOFW	DT	Small molecular drug
DMJKOFW	PC	44220888
DMJKOFW	MW	327.5
DMJKOFW	FM	C18H33NO4
DMJKOFW	IC	InChI=1S/C18H33NO4/c1-2-3-4-5-6-7-8-9-10-11-12-14-17(19(22)23)15-13-16-18(20)21/h14H,2-13,15-16H2,1H3,(H,20,21)/b17-14+
DMJKOFW	CS	CCCCCCCCCCCC/C=C(\\CCCC(=O)O)/[N+](=O)[O-]
DMJKOFW	IK	UWYMGOJUTJPTOD-SAPNQHFASA-N
DMJKOFW	IU	(E)-5-nitrooctadec-5-enoic acid
DMJKOFW	DE	Discovery agent

DMIPY3W	ID	DMIPY3W
DMIPY3W	DN	(E)-5-octadecen-7,9-diynoic acid
DMIPY3W	HS	Investigative
DMIPY3W	SN	5E-Octadecene-7,9-diynoic acid; CHEMBL489540; LMFA01030737; GTPL2963; ACon1_001719; BDBM50292398; compound 6a [Patil et al, 1989]; (5E)-octadec-5-en-7,9-diynoic acid; NCGC00180210-01; compound 6a (Patil et al., 1989)
DMIPY3W	DT	Small molecular drug
DMIPY3W	PC	9543636
DMIPY3W	MW	274.4
DMIPY3W	FM	C18H26O2
DMIPY3W	IC	InChI=1S/C18H26O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h13-14H,2-8,15-17H2,1H3,(H,19,20)/b14-13+
DMIPY3W	CS	CCCCCCCCC#CC#C/C=C/CCCC(=O)O
DMIPY3W	IK	IGVKWAAPMVVTFX-BUHFOSPRSA-N
DMIPY3W	IU	(E)-octadec-5-en-7,9-diynoic acid
DMIPY3W	DE	Discovery agent

DM1PCIX	ID	DM1PCIX
DM1PCIX	DN	(E)-5-Styrylisatin
DM1PCIX	HS	Investigative
DM1PCIX	SN	(E)-5-Styrylisatin; CHEMBL466872
DM1PCIX	DT	Small molecular drug
DM1PCIX	PC	42628986
DM1PCIX	MW	249.26
DM1PCIX	FM	C16H11NO2
DM1PCIX	IC	InChI=1S/C16H11NO2/c18-15-13-10-12(8-9-14(13)17-16(15)19)7-6-11-4-2-1-3-5-11/h1-10H,(H,17,18,19)/b7-6+
DM1PCIX	CS	C1=CC=C(C=C1)/C=C/C2=CC3=C(C=C2)NC(=O)C3=O
DM1PCIX	IK	KJZBRZRRHIURGP-VOTSOKGWSA-N
DM1PCIX	IU	5-[(E)-2-phenylethenyl]-1H-indole-2,3-dione
DM1PCIX	DE	Discovery agent

DMACVNM	ID	DMACVNM
DMACVNM	DN	(E)-6-Nitrooctadec-5-enoic Acid
DMACVNM	HS	Investigative
DMACVNM	SN	CHEMBL569372; (E)-6-Nitrooctadec-5-enoic Acid
DMACVNM	DT	Small molecular drug
DMACVNM	PC	44220889
DMACVNM	MW	327.5
DMACVNM	FM	C18H33NO4
DMACVNM	IC	InChI=1S/C18H33NO4/c1-2-3-4-5-6-7-8-9-10-11-14-17(19(22)23)15-12-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
DMACVNM	CS	CCCCCCCCCCCC/C(=C\\CCCC(=O)O)/[N+](=O)[O-]
DMACVNM	IK	ZNCCLONFJQTFGL-BMRADRMJSA-N
DMACVNM	IU	(E)-6-nitrooctadec-5-enoic acid
DMACVNM	DE	Discovery agent

DMG47QU	ID	DMG47QU
DMG47QU	DN	(E)-6-Styrylisatin
DMG47QU	HS	Investigative
DMG47QU	SN	(E)-6-Styrylisatin; CHEMBL450239
DMG47QU	DT	Small molecular drug
DMG47QU	PC	42629116
DMG47QU	MW	249.26
DMG47QU	FM	C16H11NO2
DMG47QU	IC	InChI=1S/C16H11NO2/c18-15-13-9-8-12(10-14(13)17-16(15)19)7-6-11-4-2-1-3-5-11/h1-10H,(H,17,18,19)/b7-6+
DMG47QU	CS	C1=CC=C(C=C1)/C=C/C2=CC3=C(C=C2)C(=O)C(=O)N3
DMG47QU	IK	ZQOJVXBKHOCLGH-VOTSOKGWSA-N
DMG47QU	IU	6-[(E)-2-phenylethenyl]-1H-indole-2,3-dione
DMG47QU	DE	Discovery agent

DMQT15Z	ID	DMQT15Z
DMQT15Z	DN	(E)-8-(3-chlorostyryl)-caffeine
DMQT15Z	HS	Investigative
DMQT15Z	SN	8-[(E)-2-(3-Chlorophenyl)ethenyl]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-(3-Chlorostyryl)caffeine; Csc cpd; 8-CSC; CSC; 148589-13-3; CHEMBL26138; CHEBI:53115; 8-(2-(3-Chlorophenyl)methyl)-3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 8-(2-(3-chlorophenyl)methyl)-3,7-dihydro-1,3,7-trimethyl-; Lopac0_000393; 8-(3-chlorostyryl) caffine; MLS000860039; SCHEMBL537055; 8-[2-(3-chlorophenyl)ethenyl]-1,3,7-trimethylpurine-2,6-dione; AC1NS448; GTPL5609; cid_5353365; AOB5970; DTXSID60872447
DMQT15Z	DT	Small molecular drug
DMQT15Z	PC	5353365
DMQT15Z	MW	330.77
DMQT15Z	FM	C16H15ClN4O2
DMQT15Z	IC	InChI=1S/C16H15ClN4O2/c1-19-12(8-7-10-5-4-6-11(17)9-10)18-14-13(19)15(22)21(3)16(23)20(14)2/h4-9H,1-3H3/b8-7+
DMQT15Z	CS	CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C3=CC(=CC=C3)Cl
DMQT15Z	IK	WBWFIUAVMCNYPG-BQYQJAHWSA-N
DMQT15Z	IU	8-[(E)-2-(3-chlorophenyl)ethenyl]-1,3,7-trimethylpurine-2,6-dione
DMQT15Z	CA	CAS 147700-11-6
DMQT15Z	CB	CHEBI:53115
DMQT15Z	DE	Discovery agent

DM5LSY9	ID	DM5LSY9
DM5LSY9	DN	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one
DM5LSY9	HS	Investigative
DM5LSY9	SN	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201
DM5LSY9	DT	Small molecular drug
DM5LSY9	PC	44350655
DM5LSY9	MW	345.4
DM5LSY9	FM	C23H23NO2
DM5LSY9	IC	InChI=1S/C23H23NO2/c25-22(23-24-17-18-26-23)12-8-3-1-2-5-9-19-13-15-21(16-14-19)20-10-6-4-7-11-20/h4-7,9-11,13-18H,1-3,8,12H2/b9-5+
DM5LSY9	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)/C=C/CCCCCC(=O)C3=NC=CO3
DM5LSY9	IK	AHIZRRNUFLYTPT-WEVVVXLNSA-N
DM5LSY9	IU	(E)-1-(1,3-oxazol-2-yl)-8-(4-phenylphenyl)oct-7-en-1-one
DM5LSY9	DE	Discovery agent

DMULW35	ID	DMULW35
DMULW35	DN	(E)-9-Nitrohexadec-9-enoicAcid
DMULW35	HS	Investigative
DMULW35	SN	CHEMBL560513; (E)-9-Nitrohexadec-9-enoicAcid; 9-nitropalmitoleic acid; E-9-nitropalmitoleic acid; SCHEMBL15633556; YZNSJIAWRWPQGX-NTCAYCPXSA-N; (E)-9-Nitro-9-hexadecenoic acid; BDBM50295047
DMULW35	DT	Small molecular drug
DMULW35	PC	44220886
DMULW35	MW	299.41
DMULW35	FM	C16H29NO4
DMULW35	IC	InChI=1S/C16H29NO4/c1-2-3-4-6-9-12-15(17(20)21)13-10-7-5-8-11-14-16(18)19/h12H,2-11,13-14H2,1H3,(H,18,19)/b15-12+
DMULW35	CS	CCCCCC/C=C(\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DMULW35	IK	YZNSJIAWRWPQGX-NTCAYCPXSA-N
DMULW35	IU	(E)-9-nitrohexadec-9-enoic acid
DMULW35	DE	Discovery agent

DMWC2F9	ID	DMWC2F9
DMWC2F9	DN	(E)-9-nitrooctadec-9-enoic acid
DMWC2F9	HS	Investigative
DMWC2F9	SN	(E)-9-Nitrooctadec-9-enoic Acid; 9-nitro-9E-octadecenoic acid; 9-Nitro Oleic Acid; (E)-9-nitrooctadec-9-enoic Acid; 9-Nitrooleic acid; Nitroleic Acid; 875685-44-2; 9-Nitrooleate; CHEMBL550762; (9E)-9-nitrooctadecenoic acid; CHEBI:86329; 9-nitro-9E-Octadecenoate; (9E)-9-Nitrooctadecenoate; 9-Nitro-9-octadecenoic acid; (e)-9-Nitrooctadec-9-enoate; GTPL6296; SCHEMBL1015108; MolPort-027-641-228; CQOAKBVRRVHWKV-SAPNQHFASA-N; (e)-9-nitro-octadec-9-enoic acid; (9E)-9-nitrooctadec-9-enoic acid; (9E)-9-Nitro-9-octadecenoic Acid; BDBM50295048; 1573AH; LMFA01120004; nitrooleic acid
DMWC2F9	DT	Small molecular drug
DMWC2F9	PC	11645581
DMWC2F9	MW	327.5
DMWC2F9	FM	C18H33NO4
DMWC2F9	IC	InChI=1S/C18H33NO4/c1-2-3-4-5-6-8-11-14-17(19(22)23)15-12-9-7-10-13-16-18(20)21/h14H,2-13,15-16H2,1H3,(H,20,21)/b17-14+
DMWC2F9	CS	CCCCCCCC/C=C(\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DMWC2F9	IK	CQOAKBVRRVHWKV-SAPNQHFASA-N
DMWC2F9	IU	(E)-9-nitrooctadec-9-enoic acid
DMWC2F9	CA	CAS 875685-44-2
DMWC2F9	CB	CHEBI:86329
DMWC2F9	DE	Discovery agent

DM9WHD2	ID	DM9WHD2
DM9WHD2	DN	(E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide
DM9WHD2	HS	Investigative
DM9WHD2	SN	CHEMBL373056; (E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide
DM9WHD2	DT	Small molecular drug
DM9WHD2	PC	44406064
DM9WHD2	MW	347.5
DM9WHD2	FM	C21H33NO3
DM9WHD2	IC	InChI=1S/C21H33NO3/c1-4-5-6-7-8-9-10-11-12-21(23)22-14-13-18-15-19(24-2)17-20(16-18)25-3/h11-12,15-17H,4-10,13-14H2,1-3H3,(H,22,23)/b12-11+
DM9WHD2	CS	CCCCCCCC/C=C/C(=O)NCCC1=CC(=CC(=C1)OC)OC
DM9WHD2	IK	RWXZZBVYJHEKRB-VAWYXSNFSA-N
DM9WHD2	IU	(E)-N-[2-(3,5-dimethoxyphenyl)ethyl]undec-2-enamide
DM9WHD2	DE	Discovery agent

DMW3RJL	ID	DMW3RJL
DMW3RJL	DN	(E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n
DMW3RJL	HS	Investigative
DMW3RJL	DE	Discovery agent

DML6PJD	ID	DML6PJD
DML6PJD	DN	(E)-N-(4-methoxyphenethyl)undec-2-enamide
DML6PJD	HS	Investigative
DML6PJD	SN	CHEMBL198182; (E)-N-(4-methoxyphenethyl)undec-2-enamide
DML6PJD	DT	Small molecular drug
DML6PJD	PC	44406097
DML6PJD	MW	317.5
DML6PJD	FM	C20H31NO2
DML6PJD	IC	InChI=1S/C20H31NO2/c1-3-4-5-6-7-8-9-10-11-20(22)21-17-16-18-12-14-19(23-2)15-13-18/h10-15H,3-9,16-17H2,1-2H3,(H,21,22)/b11-10+
DML6PJD	CS	CCCCCCCC/C=C/C(=O)NCCC1=CC=C(C=C1)OC
DML6PJD	IK	WHWQEVQBWRYYLL-ZHACJKMWSA-N
DML6PJD	IU	(E)-N-[2-(4-methoxyphenyl)ethyl]undec-2-enamide
DML6PJD	DE	Discovery agent

DM1PCEM	ID	DM1PCEM
DM1PCEM	DN	(E)-N-(4-methoxyphenyl)undec-2-enamide
DM1PCEM	HS	Investigative
DM1PCEM	SN	CHEMBL198132; (E)-N-(4-methoxyphenyl)undec-2-enamide
DM1PCEM	DT	Small molecular drug
DM1PCEM	PC	44406107
DM1PCEM	MW	289.4
DM1PCEM	FM	C18H27NO2
DM1PCEM	IC	InChI=1S/C18H27NO2/c1-3-4-5-6-7-8-9-10-11-18(20)19-16-12-14-17(21-2)15-13-16/h10-15H,3-9H2,1-2H3,(H,19,20)/b11-10+
DM1PCEM	CS	CCCCCCCC/C=C/C(=O)NC1=CC=C(C=C1)OC
DM1PCEM	IK	ZYKABORTQCIYBC-ZHACJKMWSA-N
DM1PCEM	IU	(E)-N-(4-methoxyphenyl)undec-2-enamide
DM1PCEM	DE	Discovery agent

DM7XIH3	ID	DM7XIH3
DM7XIH3	DN	(E)-N-(4-Phenylthiazol-2-yl) cinnamamide
DM7XIH3	HS	Investigative
DM7XIH3	SN	CHEMBL452100; 2-Cinnamamido-4-phenylthiazole; (2E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide; 1107621-03-3; AC1LEPJR; (E)-N-(4-Phenylthiazol-2-yl) cinnamamide; ZINC60264; WOJRHCOBUKJCAJ-VAWYXSNFSA-N; MolPort-019-760-060; MolPort-001-931-977; HMS1397P15; STK173781; BDBM50255301; N-(4-phenylthiazol-2-yl)cinnamamide; AKOS000523355; MCULE-8934603681; BAS 00417267; ST4016450; 3-Phenyl-N-(4-phenyl-thiazol-2-yl)-acrylamide; AG-690/11629440; 3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)acrylamide; F0298-0058; A0793/0037152
DM7XIH3	DT	Small molecular drug
DM7XIH3	PC	690181
DM7XIH3	MW	306.4
DM7XIH3	FM	C18H14N2OS
DM7XIH3	IC	InChI=1S/C18H14N2OS/c21-17(12-11-14-7-3-1-4-8-14)20-18-19-16(13-22-18)15-9-5-2-6-10-15/h1-13H,(H,19,20,21)/b12-11+
DM7XIH3	CS	C1=CC=C(C=C1)/C=C/C(=O)NC2=NC(=CS2)C3=CC=CC=C3
DM7XIH3	IK	WOJRHCOBUKJCAJ-VAWYXSNFSA-N
DM7XIH3	IU	(E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide
DM7XIH3	DE	Discovery agent

DMHKXPM	ID	DMHKXPM
DMHKXPM	DN	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide
DMHKXPM	HS	Investigative
DMHKXPM	SN	CHEMBL1086176; (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide
DMHKXPM	DT	Small molecular drug
DMHKXPM	PC	22319483
DMHKXPM	MW	243.3
DMHKXPM	FM	C14H17N3O
DMHKXPM	IC	InChI=1S/C14H17N3O/c1-3-5-10-7-8-11-12(9-10)16-17-14(11)15-13(18)6-4-2/h3,5,7-9H,4,6H2,1-2H3,(H2,15,16,17,18)/b5-3+
DMHKXPM	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)/C=C/C
DMHKXPM	IK	KPYYGELCJSEEPK-HWKANZROSA-N
DMHKXPM	IU	N-[6-[(E)-prop-1-enyl]-1H-indazol-3-yl]butanamide
DMHKXPM	DE	Discovery agent

DMXYAIQ	ID	DMXYAIQ
DMXYAIQ	DN	(E)-Octadec-9-enal
DMXYAIQ	HS	Investigative
DMXYAIQ	SN	9-OCTADECENAL; Octadecenyl aldehyde; (E)-Octadec-9-enal; UNII-979G27P46D; CHEMBL190707; 979G27P46D; 9-Octadecenal, (9E)-; 5090-41-5; E-9-Octadecenal; 9-Octadecenal, (E)-; FEMA No. 4059, E-; 10009-79-7; (9E)-9-Octadecenal; (9E)-9-Octadecenal #; AC1NR25P; SCHEMBL260834; DTXSID9074305; ZENZJGDPWWLORF-MDZDMXLPSA-N; MolPort-044-723-520; LMFA06000099; BDBM50170061; UNII-971UC454BB component ZENZJGDPWWLORF-MDZDMXLPSA-N
DMXYAIQ	DT	Small molecular drug
DMXYAIQ	PC	5283381
DMXYAIQ	MW	266.5
DMXYAIQ	FM	C18H34O
DMXYAIQ	IC	InChI=1S/C18H34O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h9-10,18H,2-8,11-17H2,1H3/b10-9+
DMXYAIQ	CS	CCCCCCCC/C=C/CCCCCCCC=O
DMXYAIQ	IK	ZENZJGDPWWLORF-MDZDMXLPSA-N
DMXYAIQ	IU	(E)-octadec-9-enal
DMXYAIQ	CA	CAS 5090-41-5
DMXYAIQ	DE	Discovery agent

DMP7TK0	ID	DMP7TK0
DMP7TK0	DN	(E)-Octadec-9-enoic acid phenylamide
DMP7TK0	HS	Investigative
DMP7TK0	SN	n-phenyloctadec-9-enamide; AC1O0YDP; AC1Q5NBV; SCHEMBL4143904; (E)-N-phenyloctadec-9-enamide; (9E)-N-phenyl-9-octadecenamide
DMP7TK0	DT	Small molecular drug
DMP7TK0	PC	6105762
DMP7TK0	MW	357.6
DMP7TK0	FM	C24H39NO
DMP7TK0	IC	InChI=1S/C24H39NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-24(26)25-23-20-17-16-18-21-23/h9-10,16-18,20-21H,2-8,11-15,19,22H2,1H3,(H,25,26)/b10-9+
DMP7TK0	CS	CCCCCCCC/C=C/CCCCCCCC(=O)NC1=CC=CC=C1
DMP7TK0	IK	YPUOCYKJOLQYQS-MDZDMXLPSA-N
DMP7TK0	IU	(E)-N-phenyloctadec-9-enamide
DMP7TK0	DE	Discovery agent

DMBLGF6	ID	DMBLGF6
DMBLGF6	DN	(E)-octadecan-9-ynoic acid
DMBLGF6	HS	Investigative
DMBLGF6	SN	CHEMBL482803; (E)-octadecan-9-ynoic acid; 7E-Octadecen-9-ynoic acid; LMFA01031047
DMBLGF6	DT	Small molecular drug
DMBLGF6	PC	14309404
DMBLGF6	MW	278.4
DMBLGF6	FM	C18H30O2
DMBLGF6	IC	InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h11-12H,2-8,13-17H2,1H3,(H,19,20)/b12-11+
DMBLGF6	CS	CCCCCCCCC#C/C=C/CCCCCC(=O)O
DMBLGF6	IK	BWSIKEZDJMZITO-VAWYXSNFSA-N
DMBLGF6	IU	(E)-octadec-7-en-9-ynoic acid
DMBLGF6	DE	Discovery agent

DMWU17O	ID	DMWU17O
DMWU17O	DN	(E,E)-1,7-Diphenyl-4,6-heptadien-3-one
DMWU17O	HS	Investigative
DMWU17O	SN	Alnustone; 33457-62-4; Alnusone; CHEMBL461082; 1,7-diphenylhepta-4,6-dien-3-one; 1,7-Diphenyl-4,6-heptadien-3-one; HEP-DIENE-ONE DER FR ALPINA KATSUMANDAI; AC1NSVUW; 4,6-Heptadien-3-one, 1,7-diphenyl-; (E,E)-1,7-Diphenyl-4,6-heptadien-3-one; DAH-3-keto-4,6-dien; (4E,6E)-1,7-diphenylhepta-4,6-dien-3-one; DTXSID30415724; OWMJDOUOHDOUFG-FNCQTZNRSA-N; MolPort-028-600-133; ZINC1538308; NSC378841; BDBM50300191; AKOS030524791; NSC-378841; AK544086; Y0026; trans,trans-1,7-diphenyl-1,3-heptadien-5-one
DMWU17O	DT	Small molecular drug
DMWU17O	PC	5317598
DMWU17O	MW	262.3
DMWU17O	FM	C19H18O
DMWU17O	IC	InChI=1S/C19H18O/c20-19(16-15-18-11-5-2-6-12-18)14-8-7-13-17-9-3-1-4-10-17/h1-14H,15-16H2/b13-7+,14-8+
DMWU17O	CS	C1=CC=C(C=C1)CCC(=O)/C=C/C=C/C2=CC=CC=C2
DMWU17O	IK	OWMJDOUOHDOUFG-FNCQTZNRSA-N
DMWU17O	IU	(4E,6E)-1,7-diphenylhepta-4,6-dien-3-one
DMWU17O	CA	CAS 33457-62-4
DMWU17O	DE	Discovery agent

DMBIV6M	ID	DMBIV6M
DMBIV6M	DN	(E,E)-5-Hydroxy-1,7-diphenyl-4,6-heptadien-3-one
DMBIV6M	HS	Investigative
DMBIV6M	DT	Small molecular drug
DMBIV6M	PC	13347323
DMBIV6M	MW	278.3
DMBIV6M	FM	C19H18O2
DMBIV6M	IC	InChI=1S/C19H18O2/c20-18(13-11-16-7-3-1-4-8-16)15-19(21)14-12-17-9-5-2-6-10-17/h1-11,13H,12,14-15H2/b13-11+
DMBIV6M	CS	C1=CC=C(C=C1)CCC(=O)CC(=O)/C=C/C2=CC=CC=C2
DMBIV6M	IK	WKUKRFYTEUQNEF-ACCUITESSA-N
DMBIV6M	IU	(E)-1,7-diphenylhept-1-ene-3,5-dione
DMBIV6M	DE	Discovery agent

DMPIUKZ	ID	DMPIUKZ
DMPIUKZ	DN	(E,E)-8-(4-Phenylbutadien-1-yl)caffeine
DMPIUKZ	HS	Investigative
DMPIUKZ	SN	CHEMBL483663; (E,E)-8-(4-Phenylbutadien-1-yl)caffeine; SCHEMBL15647106; BDBM50264585; (e,e)-8-(4-phenylbutadien-1-yl) caffeine
DMPIUKZ	DT	Small molecular drug
DMPIUKZ	PC	44579939
DMPIUKZ	MW	322.4
DMPIUKZ	FM	C18H18N4O2
DMPIUKZ	IC	InChI=1S/C18H18N4O2/c1-20-14(12-8-7-11-13-9-5-4-6-10-13)19-16-15(20)17(23)22(3)18(24)21(16)2/h4-12H,1-3H3/b11-7+,12-8+
DMPIUKZ	CS	CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C=C/C3=CC=CC=C3
DMPIUKZ	IK	NDTZOLIJIQKCRC-MKICQXMISA-N
DMPIUKZ	IU	1,3,7-trimethyl-8-[(1E,3E)-4-phenylbuta-1,3-dienyl]purine-2,6-dione
DMPIUKZ	DE	Discovery agent

DMPEV7S	ID	DMPEV7S
DMPEV7S	DN	(E,E)-8-[4-(3-Bromophenyl)butadien-1-yl]caffeine
DMPEV7S	HS	Investigative
DMPEV7S	SN	CHEMBL522256; (E,E)-8-[4-(3-Bromophenyl)butadien-1-yl]caffeine
DMPEV7S	DT	Small molecular drug
DMPEV7S	PC	44579962
DMPEV7S	MW	401.3
DMPEV7S	FM	C18H17BrN4O2
DMPEV7S	IC	InChI=1S/C18H17BrN4O2/c1-21-14(10-5-4-7-12-8-6-9-13(19)11-12)20-16-15(21)17(24)23(3)18(25)22(16)2/h4-11H,1-3H3/b7-4+,10-5+
DMPEV7S	CS	CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C=C/C3=CC(=CC=C3)Br
DMPEV7S	IK	YJBUYKLAHVOOFW-HOZCHFDZSA-N
DMPEV7S	IU	8-[(1E,3E)-4-(3-bromophenyl)buta-1,3-dienyl]-1,3,7-trimethylpurine-2,6-dione
DMPEV7S	DE	Discovery agent

DMY4W25	ID	DMY4W25
DMY4W25	DN	(E,E)-8-[4-(3-Chlorophenyl)butadien-1-yl]caffeine
DMY4W25	HS	Investigative
DMY4W25	SN	CHEMBL489390; (E,E)-8-[4-(3-Chlorophenyl)butadien-1-yl]caffeine
DMY4W25	DT	Small molecular drug
DMY4W25	PC	44579960
DMY4W25	MW	356.8
DMY4W25	FM	C18H17ClN4O2
DMY4W25	IC	InChI=1S/C18H17ClN4O2/c1-21-14(10-5-4-7-12-8-6-9-13(19)11-12)20-16-15(21)17(24)23(3)18(25)22(16)2/h4-11H,1-3H3/b7-4+,10-5+
DMY4W25	CS	CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C=C/C3=CC(=CC=C3)Cl
DMY4W25	IK	MINUIDFUFCXYDK-HOZCHFDZSA-N
DMY4W25	IU	8-[(1E,3E)-4-(3-chlorophenyl)buta-1,3-dienyl]-1,3,7-trimethylpurine-2,6-dione
DMY4W25	DE	Discovery agent

DMPHJO2	ID	DMPHJO2
DMPHJO2	DN	(E,E)-8-[4-(3-Fluorophenyl)butadien-1-yl]caffeine
DMPHJO2	HS	Investigative
DMPHJO2	SN	CHEMBL489391; (E,E)-8-[4-(3-Fluorophenyl)butadien-1-yl]caffeine
DMPHJO2	DT	Small molecular drug
DMPHJO2	PC	44579961
DMPHJO2	MW	340.4
DMPHJO2	FM	C18H17FN4O2
DMPHJO2	IC	InChI=1S/C18H17FN4O2/c1-21-14(10-5-4-7-12-8-6-9-13(19)11-12)20-16-15(21)17(24)23(3)18(25)22(16)2/h4-11H,1-3H3/b7-4+,10-5+
DMPHJO2	CS	CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C=C/C3=CC(=CC=C3)F
DMPHJO2	IK	PAJAMQUTBUEFEH-HOZCHFDZSA-N
DMPHJO2	IU	8-[(1E,3E)-4-(3-fluorophenyl)buta-1,3-dienyl]-1,3,7-trimethylpurine-2,6-dione
DMPHJO2	DE	Discovery agent

DMVKJ0H	ID	DMVKJ0H
DMVKJ0H	DN	(H-261)Boc-His-Pro-Phe-His-Leu(OH)-Val-Ile-His-OH
DMVKJ0H	HS	Investigative
DMVKJ0H	PC	44293339
DMVKJ0H	MW	1101.3
DMVKJ0H	FM	C54H80N14O11
DMVKJ0H	IC	InChI=1S/C54H80N14O11/c1-10-32(6)44(50(74)64-41(52(76)77)23-36-26-57-29-60-36)67-49(73)43(31(4)5)66-47(71)37(19-30(2)3)61-46(70)39(21-34-24-55-27-58-34)62-45(69)38(20-33-15-12-11-13-16-33)63-48(72)42-17-14-18-68(42)51(75)40(22-35-25-56-28-59-35)65-53(78)79-54(7,8)9/h11-13,15-16,24-32,37-44,47,66,71H,10,14,17-23H2,1-9H3,(H,55,58)(H,56,59)(H,57,60)(H,61,70)(H,62,69)(H,63,72)(H,64,74)(H,65,78)(H,67,73)(H,76,77)
DMVKJ0H	CS	CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)O)NC(=O)C(C(C)C)NC(C(CC(C)C)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC3=CC=CC=C3)NC(=O)C4CCCN4C(=O)C(CC5=CN=CN5)NC(=O)OC(C)(C)C)O
DMVKJ0H	IK	UIOXZRLXAROYRL-UHFFFAOYSA-N
DMVKJ0H	IU	2-[[2-[[2-[[1-hydroxy-2-[[3-(1H-imidazol-5-yl)-2-[[2-[[1-[3-(1H-imidazol-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid
DMVKJ0H	DE	Discovery agent

DMSCQ64	ID	DMSCQ64
DMSCQ64	DN	(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)
DMSCQ64	HS	Investigative
DMSCQ64	SN	CHEMBL426320; (H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)
DMSCQ64	DT	Small molecular drug
DMSCQ64	PC	44412158
DMSCQ64	MW	919
DMSCQ64	FM	C49H58N8O10
DMSCQ64	IC	InChI=1S/C49H58N8O10/c1-27-18-34(58)19-28(2)35(27)24-38(50)49(67)56-25-31-11-8-7-10-29(31)23-41(56)46(64)54-39(15-16-43(60)61)45(63)52-17-9-5-6-12-42(59)53-40(44(51)62)26-57-47(65)36-21-30-13-14-33(55(3)4)20-32(30)22-37(36)48(57)66/h7-8,10-11,13-14,18-22,38-41,58H,5-6,9,12,15-17,23-26,50H2,1-4H3,(H2,51,62)(H,52,63)(H,53,59)(H,54,64)(H,60,61)/t38-,39-,40?,41?/m0/s1
DMSCQ64	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H](CCC(=O)O)C(=O)NCCCCCC(=O)NC(CN4C(=O)C5=C(C4=O)C=C6C=C(C=CC6=C5)N(C)C)C(=O)N)N)C)O
DMSCQ64	IK	DURKEIXAKJIEGD-JHIBKCPMSA-N
DMSCQ64	IU	(4S)-5-[[6-[[1-amino-3-[6-(dimethylamino)-1,3-dioxobenzo[f]isoindol-2-yl]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-4-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-oxopentanoic acid
DMSCQ64	DE	Discovery agent

DMY6FUD	ID	DMY6FUD
DMY6FUD	DN	(Hydroxyethyloxy)Tri(Ethyloxy)Octane
DMY6FUD	HS	Investigative
DMY6FUD	SN	19327-39-0; 3,6,9,12-tetraoxaicosan-1-ol; 3,6,9,12-Tetraoxaeicosan-1-ol; TETRAETHYLENE GLYCOL MONOOCTYL ETHER; (Hydroxyethyloxy)tri(Ethyloxy)octane; Tetraethylene glycol monoctyl ether; C8E4; FEOZZFHAVXYAMB-UHFFFAOYSA-N; C8E; Octyltetraglycol; Octyltetraethyleneoxide; AC1L1KAZ; AC1Q58VY; SCHEMBL185557; Octyl tetraethylene glycol ether; DTXSID3066479; CHEBI:41323; CTK0H5811; Tetraethylene glycol, octyl ether; tetraethyleneglycol monooctyl ether; MolPort-003-939-472; MFCD00043033; ZINC14881140; AKOS027320403; DB04233; KS-00000Y06
DMY6FUD	DT	Small molecular drug
DMY6FUD	PC	5414
DMY6FUD	MW	306.44
DMY6FUD	FM	C16H34O5
DMY6FUD	IC	InChI=1S/C16H34O5/c1-2-3-4-5-6-7-9-18-11-13-20-15-16-21-14-12-19-10-8-17/h17H,2-16H2,1H3
DMY6FUD	CS	CCCCCCCCOCCOCCOCCOCCO
DMY6FUD	IK	FEOZZFHAVXYAMB-UHFFFAOYSA-N
DMY6FUD	IU	2-[2-[2-(2-octoxyethoxy)ethoxy]ethoxy]ethanol
DMY6FUD	CA	CAS 19327-39-0
DMY6FUD	CB	CHEBI:41323
DMY6FUD	DE	Discovery agent

DMOJUEC	ID	DMOJUEC
DMOJUEC	DN	(hydroxymethylphenyl)agomelatine
DMOJUEC	HS	Investigative
DMOJUEC	SN	compound 21 [PMID: 18778943]
DMOJUEC	DT	Small molecular drug
DMOJUEC	PC	9798456
DMOJUEC	MW	349.4
DMOJUEC	FM	C22H23NO3
DMOJUEC	IC	InChI=1S/C22H23NO3/c1-15(25)23-9-8-19-12-20(17-5-3-4-16(10-17)14-24)11-18-6-7-21(26-2)13-22(18)19/h3-7,10-13,24H,8-9,14H2,1-2H3,(H,23,25)
DMOJUEC	CS	CC(=O)NCCC1=C2C=C(C=CC2=CC(=C1)C3=CC=CC(=C3)CO)OC
DMOJUEC	IK	BHDVJMSEODZSTD-UHFFFAOYSA-N
DMOJUEC	IU	N-[2-[3-[3-(hydroxymethyl)phenyl]-7-methoxynaphthalen-1-yl]ethyl]acetamide
DMOJUEC	DE	Discovery agent

DMP9ZVQ	ID	DMP9ZVQ
DMP9ZVQ	DN	(L)-Phe-(D)-Phe-NH2
DMP9ZVQ	HS	Investigative
DMP9ZVQ	SN	CHEMBL590275; (L)-Phe-(D)-Phe-NH2; AC1OEWE6; BDBM50308388
DMP9ZVQ	DT	Small molecular drug
DMP9ZVQ	PC	7088460
DMP9ZVQ	MW	311.4
DMP9ZVQ	FM	C18H21N3O2
DMP9ZVQ	IC	InChI=1S/C18H21N3O2/c19-15(11-13-7-3-1-4-8-13)18(23)21-16(17(20)22)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12,19H2,(H2,20,22)(H,21,23)/t15-,16+/m0/s1
DMP9ZVQ	CS	C1=CC=C(C=C1)C[C@@H](C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N)N
DMP9ZVQ	IK	XXPXQEQOAZMUDD-JKSUJKDBSA-N
DMP9ZVQ	IU	(2S)-2-amino-N-[(2R)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
DMP9ZVQ	DE	Discovery agent

DMDUN83	ID	DMDUN83
DMDUN83	DN	(L-)-S-adenosyl-L-homocysteine
DMDUN83	HS	Investigative
DMDUN83	SN	S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; S-adenosyl-L-homocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH; S-Adenosylhomocysteine; S-Adenosyl-L-Homocysteine
DMDUN83	DT	Small molecular drug
DMDUN83	PC	439155
DMDUN83	MW	384.41
DMDUN83	FM	C14H20N6O5S
DMDUN83	IC	InChI=1S/C14H20N6O5S/c15-6(14(23)24)1-2-26-3-7-9(21)10(22)13(25-7)20-5-19-8-11(16)17-4-18-12(8)20/h4-7,9-10,13,21-22H,1-3,15H2,(H,23,24)(H2,16,17,18)/t6-,7+,9+,10+,13+/m0/s1
DMDUN83	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CSCC[C@@H](C(=O)O)N)O)O)N
DMDUN83	IK	ZJUKTBDSGOFHSH-WFMPWKQPSA-N
DMDUN83	IU	(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid
DMDUN83	CA	CAS 979-92-0
DMDUN83	CB	CHEBI:16680
DMDUN83	DE	Discovery agent

DMRGIF3	ID	DMRGIF3
DMRGIF3	DN	(LTB4-(Csa)4)2-Glu-H Conjugate
DMRGIF3	HS	Investigative
DMRGIF3	SN	CHEMBL412510; (LTB4-(Csa)4)2-Glu-H Conjugate; SCHEMBL5052860
DMRGIF3	PC	44403368
DMRGIF3	MW	2752.1
DMRGIF3	FM	C109H159N23O44S8
DMRGIF3	IC	InChI=1S/C109H159N23O44S8/c1-108(2,41-19-23-53-175-95-65-79(75-29-9-5-10-30-75)63-82(116-95)77-33-13-7-14-34-77)106-125-127-129-131(106)47-21-17-37-92(133)111-43-25-49-169-55-59-173-61-57-171-51-27-45-113-98(137)84(67-177(145,146)147)119-102(141)88(71-181(157,158)159)123-104(143)90(73-183(163,164)165)121-100(139)86(69-179(151,152)153)115-94(135)40-39-81(110)97(136)118-87(70-180(154,155)156)101(140)122-91(74-184(166,167)168)105(144)124-89(72-182(160,161)162)103(142)120-85(68-178(148,149)150)99(138)114-46-28-52-172-58-62-174-60-56-170-50-26-44-112-93(134)38-18-22-48-132-107(126-128-130-132)109(3,4)42-20-24-54-176-96-66-80(76-31-11-6-12-32-76)64-83(117-96)78-35-15-8-16-36-78/h5-16,29-36,63-66,81,84-91H,17-28,37-62,67-74,110H2,1-4H3,(H,111,133)(H,112,134)(H,113,137)(H,114,138)(H,115,135)(H,118,136)(H,119,141)(H,120,142)(H,121,139)(H,122,140)(H,123,143)(H,124,144)(H,145,146,147)(H,148,149,150)(H,151,152,153)(H,154,155,156)(H,157,158,159)(H,160,161,162)(H,163,164,165)(H,166,167,168)/t81-,84-,85-,86-,87-,88-,89-,90-,91-/m0/s1
DMRGIF3	CS	CC(C)(CCCCOC1=CC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)C4=NN=NN4CCCCC(=O)NCCCOCCOCCOCCCNC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CC[C@@H](C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCCCOCCOCCOCCCNC(=O)CCCCN5C(=NN=N5)C(C)(C)CCCCOC6=CC(=CC(=N6)C7=CC=CC=C7)C8=CC=CC=C8)N
DMRGIF3	IK	LBTVXEXIIAMTIW-WSJKXOGOSA-N
DMRGIF3	IU	(2R)-2-[[(4S)-4-amino-5-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[3-[2-[2-[3-[5-[5-[6-(4,6-diphenylpyridin-2-yl)oxy-2-methylhexan-2-yl]tetrazol-1-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propylamino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-5-oxopentanoyl]amino]-3-[[(2R)-1-[[(2R)-1-[[(2R)-1-[3-[2-[2-[3-[5-[5-[6-(4,6-diphenylpyridin-2-yl)oxy-2-methylhexan-2-yl]tetrazol-1-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propylamino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-3-oxopropane-1-sulfonic acid
DMRGIF3	DE	Discovery agent

DM9ATZ8	ID	DM9ATZ8
DM9ATZ8	DN	(N-(3-phenoxycinnamyl)-acetohydroxamic acid
DM9ATZ8	HS	Investigative
DM9ATZ8	SN	CHEMBL529218
DM9ATZ8	DT	Small molecular drug
DM9ATZ8	PC	44583183
DM9ATZ8	MW	297.3
DM9ATZ8	FM	C17H15NO4
DM9ATZ8	IC	InChI=1S/C17H15NO4/c1-13(19)18(21)17(20)11-10-14-6-5-9-16(12-14)22-15-7-3-2-4-8-15/h2-12,21H,1H3/b11-10+
DM9ATZ8	CS	CC(=O)N(C(=O)/C=C/C1=CC(=CC=C1)OC2=CC=CC=C2)O
DM9ATZ8	IK	REDOCAPSVCSQLX-ZHACJKMWSA-N
DM9ATZ8	IU	(E)-N-acetyl-N-hydroxy-3-(3-phenoxyphenyl)prop-2-enamide
DM9ATZ8	DE	Discovery agent

DM6SV7I	ID	DM6SV7I
DM6SV7I	DN	(N)methanocarba-UTP
DM6SV7I	HS	Investigative
DM6SV7I	SN	(N)methanocarba-UTP; GTPL1740; ({[({[4-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2,3-dihydroxybicyclo[3.1.0]hexan-1-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid
DM6SV7I	DT	Small molecular drug
DM6SV7I	PC	44309485
DM6SV7I	MW	494.18
DM6SV7I	FM	C11H17N2O14P3
DM6SV7I	IC	InChI=1S/C11H17N2O14P3/c14-6-1-2-13(10(17)12-6)7-5-3-11(5,9(16)8(7)15)4-25-29(21,22)27-30(23,24)26-28(18,19)20/h1-2,5,7-9,15-16H,3-4H2,(H,21,22)(H,23,24)(H,12,14,17)(H2,18,19,20)
DM6SV7I	CS	C1C2C1(C(C(C2N3C=CC(=O)NC3=O)O)O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
DM6SV7I	IK	XWFVJTIKQWQNID-UHFFFAOYSA-N
DM6SV7I	IU	[[4-(2,4-dioxopyrimidin-1-yl)-2,3-dihydroxy-1-bicyclo[3.1.0]hexanyl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM6SV7I	DE	Discovery agent

DMPYK1T	ID	DMPYK1T
DMPYK1T	DN	(O10eq)-Benzyloxycarbonyl-beta-alanylryanodine
DMPYK1T	HS	Investigative
DMPYK1T	SN	CHEMBL435162; (O10eq)-Benzyloxycarbonyl-beta-alanylryanodine
DMPYK1T	DT	Small molecular drug
DMPYK1T	PC	44275861
DMPYK1T	MW	698.8
DMPYK1T	FM	C36H46N2O12
DMPYK1T	IC	InChI=1S/C36H46N2O12/c1-20(2)33(44)27(49-26(40)23-12-9-16-37-23)34(45)29(4)19-32(43)30(33,5)36(34,46)35(50-32)25(21(3)13-15-31(29,35)42)48-24(39)14-17-38-28(41)47-18-22-10-7-6-8-11-22/h6-12,16,20-21,25,27,37,42-46H,13-15,17-19H2,1-5H3,(H,38,41)/t21?,25-,27-,29+,30?,31?,32?,33?,34?,35?,36?/m1/s1
DMPYK1T	CS	CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CCNC(=O)OCC6=CC=CC=C6)O4)O)O)OC(=O)C7=CC=CN7)(C(C)C)O)C)O)C)O
DMPYK1T	IK	YNAMTGCWRIKJBG-IQCGZQJLSA-N
DMPYK1T	IU	[(2R,7S,12R)-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-2-[3-(phenylmethoxycarbonylamino)propanoyloxy]-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMPYK1T	DE	Discovery agent

DMRSZGB	ID	DMRSZGB
DMRSZGB	DN	(O10eq)-beta-alanyl-anhydro-ryanodine
DMRSZGB	HS	Investigative
DMRSZGB	SN	CHEMBL28261; (O10eq)-beta-alanyl-anhydro-ryanodine
DMRSZGB	DT	Small molecular drug
DMRSZGB	PC	44275928
DMRSZGB	MW	546.6
DMRSZGB	FM	C28H38N2O9
DMRSZGB	IC	InChI=1S/C28H38N2O9/c1-14(2)20-16(4)26(35)27(36,22(20)38-23(33)17-7-6-12-30-17)24(5)13-19(32)39-28(26)21(37-18(31)9-11-29)15(3)8-10-25(24,28)34/h6-7,12,14-15,21-22,30,34-36H,8-11,13,29H2,1-5H3/t15?,21-,22-,24+,25?,26?,27?,28?/m1/s1
DMRSZGB	CS	CC1CCC2([C@@]3(CC(=O)OC2([C@@H]1OC(=O)CCN)C4(C3([C@@H](C(=C4C)C(C)C)OC(=O)C5=CC=CN5)O)O)C)O
DMRSZGB	IK	NJCSEUYLWFFKSS-FCKNYIKNSA-N
DMRSZGB	IU	[(5R,7S,12R)-12-(3-aminopropanoyloxy)-2,6,8-trihydroxy-3,7,11-trimethyl-14-oxo-4-propan-2-yl-13-oxatetracyclo[5.5.3.01,8.02,6]pentadec-3-en-5-yl] 1H-pyrrole-2-carboxylate
DMRSZGB	DE	Discovery agent

DMVGARN	ID	DMVGARN
DMVGARN	DN	(O10eq)-beta-alanylryanodine
DMVGARN	HS	Investigative
DMVGARN	SN	CHEMBL282089; (O10eq)-beta-alanylryanodine
DMVGARN	DT	Small molecular drug
DMVGARN	PC	44275867
DMVGARN	MW	564.6
DMVGARN	FM	C28H40N2O10
DMVGARN	IC	InChI=1S/C28H40N2O10/c1-14(2)25(35)20(39-19(32)16-7-6-12-30-16)26(36)21(4)13-24(34)22(25,5)28(26,37)27(40-24)18(38-17(31)9-11-29)15(3)8-10-23(21,27)33/h6-7,12,14-15,18,20,30,33-37H,8-11,13,29H2,1-5H3/t15?,18-,20-,21+,22?,23?,24?,25?,26?,27?,28?/m1/s1
DMVGARN	CS	CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CCN)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DMVGARN	IK	RNYNXNCQNFQWFI-UHHIQCFMSA-N
DMVGARN	IU	[(2R,7S,12R)-2-(3-aminopropanoyloxy)-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMVGARN	DE	Discovery agent

DMSV8XM	ID	DMSV8XM
DMSV8XM	DN	(O10eq)-beta-guanidinopropionylryanodine
DMSV8XM	HS	Investigative
DMSV8XM	SN	CHEMBL27669; (O10eq)-beta-guanidinopropionylryanodine
DMSV8XM	DT	Small molecular drug
DMSV8XM	PC	44275926
DMSV8XM	MW	606.7
DMSV8XM	FM	C29H42N4O10
DMSV8XM	IC	InChI=1S/C29H42N4O10/c1-14(2)26(38)20(42-19(35)16-7-6-11-32-16)27(39)22(4)13-25(37)23(26,5)29(27,40)28(43-25)18(15(3)8-10-24(22,28)36)41-17(34)9-12-33-21(30)31/h6-7,11,14-15,18,20,32,36-40H,8-10,12-13H2,1-5H3,(H4,30,31,33)/t15?,18-,20-,22+,23?,24?,25?,26?,27?,28?,29?/m1/s1
DMSV8XM	CS	CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CCN=C(N)N)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DMSV8XM	IK	ZCZPMYVYWWNDNA-IYRTUPHRSA-N
DMSV8XM	IU	[(2R,7S,12R)-2-[3-(diaminomethylideneamino)propanoyloxy]-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMSV8XM	DE	Discovery agent

DM97W5T	ID	DM97W5T
DM97W5T	DN	(O10eq)-guanidino acetylryanodine
DM97W5T	HS	Investigative
DM97W5T	SN	CHEMBL435362; (O10eq)-guanidino acetylryanodine
DM97W5T	DT	Small molecular drug
DM97W5T	PC	44275894
DM97W5T	MW	592.6
DM97W5T	FM	C28H40N4O10
DM97W5T	IC	InChI=1S/C28H40N4O10/c1-13(2)25(37)19(41-18(34)15-7-6-10-31-15)26(38)21(4)12-24(36)22(25,5)28(26,39)27(42-24)17(14(3)8-9-23(21,27)35)40-16(33)11-32-20(29)30/h6-7,10,13-14,17,19,31,35-39H,8-9,11-12H2,1-5H3,(H4,29,30,32)/t14?,17-,19-,21+,22?,23?,24?,25?,26?,27?,28?/m1/s1
DM97W5T	CS	CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CN=C(N)N)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DM97W5T	IK	JJIABRHLFSNGBC-BTZWEUFCSA-N
DM97W5T	IU	[(2R,7S,12R)-2-[2-(diaminomethylideneamino)acetyl]oxy-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DM97W5T	DE	Discovery agent

DMB8NWI	ID	DMB8NWI
DMB8NWI	DN	(P-Iodophenylacetylamino)Methylphosphinic Acid
DMB8NWI	HS	Investigative
DMB8NWI	SN	(p-iodophenylacetylamino)methylphosphinic acid; AC1O3GBT; AC1L1B5E; C9H11INO3P; SCHEMBL4311614; [[2-(4-iodophenyl)acetyl]amino]methylphosphinic acid; (R)-({[(4-iodophenyl)acetyl]amino}methyl)phosphinic acid
DMB8NWI	DT	Small molecular drug
DMB8NWI	PC	6327749
DMB8NWI	MW	338.06
DMB8NWI	FM	C9H10INO3P+
DMB8NWI	IC	InChI=1S/C9H9INO3P/c10-8-3-1-7(2-4-8)5-9(12)11-6-15(13)14/h1-4H,5-6H2,(H-,11,12,13,14)/p+1
DMB8NWI	CS	C1=CC(=CC=C1CC(=O)NC[P+](=O)O)I
DMB8NWI	IK	HVYODBROOQYJGM-UHFFFAOYSA-O
DMB8NWI	IU	hydroxy-[[[2-(4-iodophenyl)acetyl]amino]methyl]-oxophosphanium
DMB8NWI	DE	Discovery agent

DMYJAM5	ID	DMYJAM5
DMYJAM5	DN	(R)-(-)-10-methyl-11-hydroxyaporphine
DMYJAM5	HS	Investigative
DMYJAM5	SN	PM 1000; PM-1000; CHEMBL53510; (R)-(-)-10-methyl-11-hydroxyaporphine; 111635-19-9; 10-Methyl-11-hydroxyaporphine; 11-Hmapp; 11-Hydroxy-10-methylaporphine; AC1MIZ6C; ZINC6368; SCHEMBL1349467; DTXSID90149699; BDBM50036286; (R)-6,10-Dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol; 4H-Dibenzo(de,g)quinolin-11-ol, 5,6,6a,7-tetrahydro-6,10-dimethyl-, (R)-
DMYJAM5	DT	Small molecular drug
DMYJAM5	PC	3082625
DMYJAM5	MW	265.3
DMYJAM5	FM	C18H19NO
DMYJAM5	IC	InChI=1S/C18H19NO/c1-11-6-7-13-10-15-16-12(8-9-19(15)2)4-3-5-14(16)17(13)18(11)20/h3-7,15,20H,8-10H2,1-2H3/t15-/m1/s1
DMYJAM5	CS	CC1=C(C2=C(C[C@@H]3C4=C(CCN3C)C=CC=C42)C=C1)O
DMYJAM5	IK	YGOZTDLAUVOPMF-OAHLLOKOSA-N
DMYJAM5	IU	(6aR)-6,10-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol
DMYJAM5	CA	CAS 111635-19-9
DMYJAM5	DE	Discovery agent

DMKB621	ID	DMKB621
DMKB621	DN	(R)-(-)-11-hydroxy-N-n-propylnoraporphine
DMKB621	HS	Investigative
DMKB621	SN	11-Hydroxy-N-propylnoraporphine
DMKB621	DE	Discovery agent

DMQ2INJ	ID	DMQ2INJ
DMQ2INJ	DN	(R)-(-)-2-methoxy-11-hydroxyaporphine
DMQ2INJ	HS	Investigative
DMQ2INJ	SN	CHEMBL270426; 2-Methoxy-11-hydroxyaporphine; (R)-(-)-2-methoxy-11-hydroxyaporphine; SCHEMBL1204517; BDBM50234265
DMQ2INJ	DT	Small molecular drug
DMQ2INJ	PC	24766199
DMQ2INJ	MW	281.3
DMQ2INJ	FM	C18H19NO2
DMQ2INJ	IC	InChI=1S/C18H19NO2/c1-19-7-6-12-8-13(21-2)10-14-17(12)15(19)9-11-4-3-5-16(20)18(11)14/h3-5,8,10,15,20H,6-7,9H2,1-2H3/t15-/m1/s1
DMQ2INJ	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=CC=C4)O
DMQ2INJ	IK	UGNGRDRWDHJJJI-OAHLLOKOSA-N
DMQ2INJ	IU	(6aR)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol
DMQ2INJ	DE	Discovery agent

DMLXB62	ID	DMLXB62
DMLXB62	DN	(R)-(-)-2-methoxy-N-npropylnorapomorphine
DMLXB62	HS	Investigative
DMLXB62	SN	2-Methoxy-N-n-propylnorapomorphine; CHEMBL53294; 126874-82-6; 2-Mnpna; (R)-(-)-2-methoxy-N-npropylnorapomorphine; AC1L2Y8J; SCHEMBL12284193; DTXSID70155319; 2-Methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; BDBM50010692; (R)-2-methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; 4H-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-2-methoxy-6-propyl-, (R)-
DMLXB62	DT	Small molecular drug
DMLXB62	PC	130907
DMLXB62	MW	325.4
DMLXB62	FM	C20H23NO3
DMLXB62	IC	InChI=1S/C20H23NO3/c1-3-7-21-8-6-13-9-14(24-2)11-15-18(13)16(21)10-12-4-5-17(22)20(23)19(12)15/h4-5,9,11,16,22-23H,3,6-8,10H2,1-2H3/t16-/m1/s1
DMLXB62	CS	CCCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=C(C=C4)O)O
DMLXB62	IK	WNNMRMNAGNMVEW-MRXNPFEDSA-N
DMLXB62	IU	(6aR)-2-methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMLXB62	CA	CAS 126874-82-6
DMLXB62	DE	Discovery agent

DMAYEJL	ID	DMAYEJL
DMAYEJL	DN	(R)-(-)-2-Methyl-apomorphine hydrochloride
DMAYEJL	HS	Investigative
DMAYEJL	SN	CHEMBL507567
DMAYEJL	DT	Small molecular drug
DMAYEJL	PC	44567292
DMAYEJL	MW	281.3
DMAYEJL	FM	C18H19NO2
DMAYEJL	IC	InChI=1S/C18H19NO2/c1-10-7-12-5-6-19(2)14-9-11-3-4-15(20)18(21)17(11)13(8-10)16(12)14/h3-4,7-8,14,20-21H,5-6,9H2,1-2H3/t14-/m1/s1
DMAYEJL	CS	CC1=CC2=C3[C@@H](CC4=C(C3=C1)C(=C(C=C4)O)O)N(CC2)C
DMAYEJL	IK	QRJZCXSRTBCYIW-CQSZACIVSA-N
DMAYEJL	IU	(6aR)-2,6-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMAYEJL	DE	Discovery agent

DME62U0	ID	DME62U0
DME62U0	DN	(R)-(-)-2-Phenyl-apomorphine hydrochloride
DME62U0	HS	Investigative
DME62U0	SN	CHEMBL458397
DME62U0	DT	Small molecular drug
DME62U0	PC	11515697
DME62U0	MW	343.4
DME62U0	FM	C23H21NO2
DME62U0	IC	InChI=1S/C23H21NO2/c1-24-10-9-16-11-17(14-5-3-2-4-6-14)12-18-21(16)19(24)13-15-7-8-20(25)23(26)22(15)18/h2-8,11-12,19,25-26H,9-10,13H2,1H3/t19-/m1/s1
DME62U0	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)C5=CC=CC=C5)C(=C(C=C4)O)O
DME62U0	IK	NJWHLJABYCIZPL-LJQANCHMSA-N
DME62U0	IU	(6aR)-6-methyl-2-phenyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DME62U0	DE	Discovery agent

DMPSEZV	ID	DMPSEZV
DMPSEZV	DN	(R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine
DMPSEZV	HS	Investigative
DMPSEZV	SN	SCHEMBL1204538
DMPSEZV	DT	Small molecular drug
DMPSEZV	PC	57340748
DMPSEZV	MW	295.4
DMPSEZV	FM	C19H21NO2
DMPSEZV	IC	InChI=1S/C19H21NO2/c1-3-20-8-7-13-9-14(22-2)11-15-18(13)16(20)10-12-5-4-6-17(21)19(12)15/h4-6,9,11,16,21H,3,7-8,10H2,1-2H3
DMPSEZV	CS	CCN1CCC2=C3C1CC4=C(C3=CC(=C2)OC)C(=CC=C4)O
DMPSEZV	IK	OQCBYARNXRSEMX-UHFFFAOYSA-N
DMPSEZV	IU	6-ethyl-2-methoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol
DMPSEZV	DE	Discovery agent

DM48SML	ID	DM48SML
DM48SML	DN	(R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine
DM48SML	HS	Investigative
DM48SML	SN	CHEMBL405345; 2-methoxy-11-hydroxy-N-propylnoraporphine; (R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine; SCHEMBL1204062; BDBM50336856
DM48SML	DT	Small molecular drug
DM48SML	PC	24800688
DM48SML	MW	309.4
DM48SML	FM	C20H23NO2
DM48SML	IC	InChI=1S/C20H23NO2/c1-3-8-21-9-7-14-10-15(23-2)12-16-19(14)17(21)11-13-5-4-6-18(22)20(13)16/h4-6,10,12,17,22H,3,7-9,11H2,1-2H3/t17-/m1/s1
DM48SML	CS	CCCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=CC=C4)O
DM48SML	IK	PGKMOUOGPCFQTK-QGZVFWFLSA-N
DM48SML	IU	(6aR)-2-methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol
DM48SML	DE	Discovery agent

DM9DBHU	ID	DM9DBHU
DM9DBHU	DN	(R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine
DM9DBHU	HS	Investigative
DM9DBHU	SN	CHEMBL379780; 890309-57-6; Jimscaline; (R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine; CTK2I1398; DTXSID30470414; ZINC35569551; BDBM50190615; 1H-Indene-1-methanamine, 2,3-dihydro-4,5,6-trimethoxy-, (1R)-
DM9DBHU	DT	Small molecular drug
DM9DBHU	PC	11673493
DM9DBHU	MW	237.29
DM9DBHU	FM	C13H19NO3
DM9DBHU	IC	InChI=1S/C13H19NO3/c1-15-11-6-10-8(7-14)4-5-9(10)12(16-2)13(11)17-3/h6,8H,4-5,7,14H2,1-3H3/t8-/m0/s1
DM9DBHU	CS	COC1=C(C(=C2CC[C@H](C2=C1)CN)OC)OC
DM9DBHU	IK	AFTIZGHFDCOQFS-QMMMGPOBSA-N
DM9DBHU	IU	[(1R)-4,5,6-trimethoxy-2,3-dihydro-1H-inden-1-yl]methanamine
DM9DBHU	CA	CAS 890309-57-6
DM9DBHU	DE	Discovery agent

DM5UOFY	ID	DM5UOFY
DM5UOFY	DN	(R)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DM5UOFY	HS	Investigative
DM5UOFY	SN	CHEMBL600385; (R)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DM5UOFY	DT	Small molecular drug
DM5UOFY	PC	46232144
DM5UOFY	MW	272.27
DM5UOFY	FM	C16H13FO3
DM5UOFY	IC	InChI=1S/C16H13FO3/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-8,15H,9H2,1H3/t15-/m1/s1
DM5UOFY	CS	COC1=CC2=C(C=C1)C(=O)C[C@@H](O2)C3=CC=C(C=C3)F
DM5UOFY	IK	LIINIWOYEGBFDA-OAHLLOKOSA-N
DM5UOFY	IU	(2R)-2-(4-fluorophenyl)-7-methoxy-2,3-dihydrochromen-4-one
DM5UOFY	DE	Discovery agent

DM6WTLZ	ID	DM6WTLZ
DM6WTLZ	DN	(R)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DM6WTLZ	HS	Investigative
DM6WTLZ	SN	CHEMBL599762; (R)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DM6WTLZ	DT	Small molecular drug
DM6WTLZ	PC	46232077
DM6WTLZ	MW	260.23
DM6WTLZ	FM	C15H10F2O2
DM6WTLZ	IC	InChI=1S/C15H10F2O2/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14H,8H2/t14-/m1/s1
DM6WTLZ	CS	C1[C@@H](OC2=C(C1=O)C=CC(=C2)F)C3=CC=C(C=C3)F
DM6WTLZ	IK	YKJLGNVYFBPKJK-CQSZACIVSA-N
DM6WTLZ	IU	(2R)-7-fluoro-2-(4-fluorophenyl)-2,3-dihydrochromen-4-one
DM6WTLZ	DE	Discovery agent

DMJCN0Y	ID	DMJCN0Y
DMJCN0Y	DN	(R)(+)-7-fluoro-2-phenylchroman-4-one
DMJCN0Y	HS	Investigative
DMJCN0Y	SN	CHEMBL599761; (R)(+)-7-fluoro-2-phenylchroman-4-one; SCHEMBL10360819
DMJCN0Y	DT	Small molecular drug
DMJCN0Y	PC	46232075
DMJCN0Y	MW	242.24
DMJCN0Y	FM	C15H11FO2
DMJCN0Y	IC	InChI=1S/C15H11FO2/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14H,9H2/t14-/m1/s1
DMJCN0Y	CS	C1[C@@H](OC2=C(C1=O)C=CC(=C2)F)C3=CC=CC=C3
DMJCN0Y	IK	SZNYRENOXQIQMR-CQSZACIVSA-N
DMJCN0Y	IU	(2R)-7-fluoro-2-phenyl-2,3-dihydrochromen-4-one
DMJCN0Y	DE	Discovery agent

DMHNKWR	ID	DMHNKWR
DMHNKWR	DN	(R)(+)-7-fluoro-2-p-tolylchroman-4-one
DMHNKWR	HS	Investigative
DMHNKWR	SN	CHEMBL598151; (R)(+)-7-fluoro-2-p-tolylchroman-4-one
DMHNKWR	DT	Small molecular drug
DMHNKWR	PC	46232079
DMHNKWR	MW	256.269
DMHNKWR	FM	C16H13FO2
DMHNKWR	IC	InChI=1S/C16H13FO2/c1-10-2-4-11(5-3-10)15-9-14(18)13-7-6-12(17)8-16(13)19-15/h2-8,15H,9H2,1H3/t15-/m1/s1
DMHNKWR	CS	CC1=CC=C(C=C1)[C@H]2CC(=O)C3=C(O2)C=C(C=C3)F
DMHNKWR	IK	QNQXLNDULBVXEX-OAHLLOKOSA-N
DMHNKWR	IU	(2R)-7-fluoro-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMHNKWR	DE	Discovery agent

DM8ZHYR	ID	DM8ZHYR
DM8ZHYR	DN	(R)(+)-7-methyl-2-phenylchroman-4-one
DM8ZHYR	HS	Investigative
DM8ZHYR	SN	CHEMBL601844; (R)(+)-7-methyl-2-phenylchroman-4-one; SCHEMBL1895390; FNOKOVWLKVWYRY-OAHLLOKOSA-N; BDBM50310170; (R)-7-methyl-2-phenylchroman-4-one
DM8ZHYR	DT	Small molecular drug
DM8ZHYR	PC	46232081
DM8ZHYR	MW	238.28
DM8ZHYR	FM	C16H14O2
DM8ZHYR	IC	InChI=1S/C16H14O2/c1-11-7-8-13-14(17)10-15(18-16(13)9-11)12-5-3-2-4-6-12/h2-9,15H,10H2,1H3/t15-/m1/s1
DM8ZHYR	CS	CC1=CC2=C(C=C1)C(=O)C[C@@H](O2)C3=CC=CC=C3
DM8ZHYR	IK	FNOKOVWLKVWYRY-OAHLLOKOSA-N
DM8ZHYR	IU	(2R)-7-methyl-2-phenyl-2,3-dihydrochromen-4-one
DM8ZHYR	DE	Discovery agent

DMVN50D	ID	DMVN50D
DMVN50D	DN	(R)(+)-7-methyl-2-p-tolylchroman-4-one
DMVN50D	HS	Investigative
DMVN50D	SN	CHEMBL598321; (R)(+)-7-methyl-2-p-tolylchroman-4-one
DMVN50D	DT	Small molecular drug
DMVN50D	PC	46232142
DMVN50D	MW	252.31
DMVN50D	FM	C17H16O2
DMVN50D	IC	InChI=1S/C17H16O2/c1-11-3-6-13(7-4-11)16-10-15(18)14-8-5-12(2)9-17(14)19-16/h3-9,16H,10H2,1-2H3/t16-/m1/s1
DMVN50D	CS	CC1=CC=C(C=C1)[C@H]2CC(=O)C3=C(O2)C=C(C=C3)C
DMVN50D	IK	MIEPNGHJBCGJAW-MRXNPFEDSA-N
DMVN50D	IU	(2R)-7-methyl-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMVN50D	DE	Discovery agent

DM7C148	ID	DM7C148
DM7C148	DN	(R)-(+)-coclaurine
DM7C148	HS	Investigative
DM7C148	SN	(R)-Coclaurine; d-Coclaurine; 2196-60-3; Sanjoinine K; CHEMBL256448; CHEBI:27482; (1R)-1-(4-hydroxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol; 6-Methoxy-7-hydroxy-(1R)-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline; (1R)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-((4-hydroxyphenyl)methyl)-6-methoxy-, (R)-; (R)-1,2,3,4-Tetrahydro-1-[(4-hydroxyphenyl)methyl]-6-methoxy-7-isoquinolinol; (R)-d-Coclaurine
DM7C148	DT	Small molecular drug
DM7C148	PC	440989
DM7C148	MW	285.34
DM7C148	FM	C17H19NO3
DM7C148	IC	InChI=1S/C17H19NO3/c1-21-17-9-12-6-7-18-15(14(12)10-16(17)20)8-11-2-4-13(19)5-3-11/h2-5,9-10,15,18-20H,6-8H2,1H3/t15-/m1/s1
DM7C148	CS	COC1=C(C=C2[C@H](NCCC2=C1)CC3=CC=C(C=C3)O)O
DM7C148	IK	LVVKXRQZSRUVPY-OAHLLOKOSA-N
DM7C148	IU	(1R)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol
DM7C148	CA	CAS 2196-60-3
DM7C148	CB	CHEBI:27482
DM7C148	DE	Discovery agent

DMBXRKS	ID	DMBXRKS
DMBXRKS	DN	(R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol
DMBXRKS	HS	Investigative
DMBXRKS	SN	CHEMBL207712; (R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol; SCHEMBL14202964
DMBXRKS	DT	Small molecular drug
DMBXRKS	PC	44410091
DMBXRKS	MW	283.4
DMBXRKS	FM	C18H21NO2
DMBXRKS	IC	InChI=1S/C18H21NO2/c20-18(16-9-5-2-6-10-16,17-14-19-11-12-21-17)13-15-7-3-1-4-8-15/h1-10,17,19-20H,11-14H2/t17-,18+/m0/s1
DMBXRKS	CS	C1CO[C@@H](CN1)[C@@](CC2=CC=CC=C2)(C3=CC=CC=C3)O
DMBXRKS	IK	VGJFVJKZCAUGKE-ZWKOTPCHSA-N
DMBXRKS	IU	(1R)-1-[(2S)-morpholin-2-yl]-1,2-diphenylethanol
DMBXRKS	DE	Discovery agent

DMYBC24	ID	DMYBC24
DMYBC24	DN	(R)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea
DMYBC24	HS	Investigative
DMYBC24	SN	CHEMBL397459; indazole antagonist, (R)-16b; BDBM20407
DMYBC24	DT	Small molecular drug
DMYBC24	PC	24768211
DMYBC24	MW	294.35
DMYBC24	FM	C17H18N4O
DMYBC24	IC	InChI=1S/C17H18N4O/c1-11-6-8-13(9-7-11)12(2)19-17(22)20-15-4-3-5-16-14(15)10-18-21-16/h3-10,12H,1-2H3,(H,18,21)(H2,19,20,22)/t12-/m1/s1
DMYBC24	CS	CC1=CC=C(C=C1)[C@@H](C)NC(=O)NC2=CC=CC3=C2C=NN3
DMYBC24	IK	SHOUDGQMQHLAFL-GFCCVEGCSA-N
DMYBC24	IU	1-(1H-indazol-4-yl)-3-[(1R)-1-(4-methylphenyl)ethyl]urea
DMYBC24	DE	Discovery agent

DMGD026	ID	DMGD026
DMGD026	DN	(R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid
DMGD026	HS	Investigative
DMGD026	SN	Gly-boroPro; CHEMBL67089; Glycinyl-(R)-Boroproline; (R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid; SCHEMBL10022738
DMGD026	DT	Small molecular drug
DMGD026	PC	10607286
DMGD026	MW	171.99
DMGD026	FM	C6H13BN2O3
DMGD026	IC	InChI=1S/C6H13BN2O3/c8-4-6(10)9-3-1-2-5(9)7(11)12/h5,11-12H,1-4,8H2/t5-/m0/s1
DMGD026	CS	B([C@@H]1CCCN1C(=O)CN)(O)O
DMGD026	IK	BZTBBVKEKPNNBE-YFKPBYRVSA-N
DMGD026	IU	[(2R)-1-(2-aminoacetyl)pyrrolidin-2-yl]boronic acid
DMGD026	DE	Discovery agent

DMMY0NF	ID	DMMY0NF
DMMY0NF	DN	(R)-1-(2-methoxyphenethyl)-2-methylpyrrolidine
DMMY0NF	HS	Investigative
DMMY0NF	SN	CHEMBL404375
DMMY0NF	DT	Small molecular drug
DMMY0NF	PC	44456095
DMMY0NF	MW	219.32
DMMY0NF	FM	C14H21NO
DMMY0NF	IC	InChI=1S/C14H21NO/c1-12-6-5-10-15(12)11-9-13-7-3-4-8-14(13)16-2/h3-4,7-8,12H,5-6,9-11H2,1-2H3/t12-/m1/s1
DMMY0NF	CS	C[C@@H]1CCCN1CCC2=CC=CC=C2OC
DMMY0NF	IK	KDVUGYDZNTZESD-GFCCVEGCSA-N
DMMY0NF	IU	(2R)-1-[2-(2-methoxyphenyl)ethyl]-2-methylpyrrolidine
DMMY0NF	DE	Discovery agent

DM76SZK	ID	DM76SZK
DM76SZK	DN	(R)-1-(3-methoxyphenethyl)-2-methylpyrrolidine
DM76SZK	HS	Investigative
DM76SZK	SN	CHEMBL439429
DM76SZK	DT	Small molecular drug
DM76SZK	PC	44456091
DM76SZK	MW	219.32
DM76SZK	FM	C14H21NO
DM76SZK	IC	InChI=1S/C14H21NO/c1-12-5-4-9-15(12)10-8-13-6-3-7-14(11-13)16-2/h3,6-7,11-12H,4-5,8-10H2,1-2H3/t12-/m1/s1
DM76SZK	CS	C[C@@H]1CCCN1CCC2=CC(=CC=C2)OC
DM76SZK	IK	INKHQVYBVMGBHD-GFCCVEGCSA-N
DM76SZK	IU	(2R)-1-[2-(3-methoxyphenyl)ethyl]-2-methylpyrrolidine
DM76SZK	DE	Discovery agent

DMDC297	ID	DMDC297
DMDC297	DN	(R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine
DMDC297	HS	Investigative
DMDC297	SN	(R)-1-(4-Iodo-2,5-dimethoxyphenyl)propan-2-amine; CHEMBL134519; R-DOI; Lopac0_000478; GTPL157; (R)-DOI; SCHEMBL713061; ZINC2516053; PDSP2_001372; Benzeneethanamine, 4-iodo-2,5-dimethoxy-alpha-methyl-, (alphaR)-; BDBM50133231; PDSP1_001388; CCG-204569; NCGC00162167-01; AJ-36945; 82864-06-0; (2R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine; (r)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane; (R)-2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine; (R)-2-(4-Iodo-2,5-dimethoxy-phenyl)-1-methyl-ethylamine; UNII-OOM10GW9UE
DMDC297	DT	Small molecular drug
DMDC297	PC	9840090
DMDC297	MW	321.15
DMDC297	FM	C11H16INO2
DMDC297	IC	InChI=1S/C11H16INO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3/t7-/m1/s1
DMDC297	CS	C[C@H](CC1=CC(=C(C=C1OC)I)OC)N
DMDC297	IK	BGMZUEKZENQUJY-SSDOTTSWSA-N
DMDC297	IU	(2R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine
DMDC297	DE	Discovery agent

DMR3DSG	ID	DMR3DSG
DMR3DSG	DN	(R)-1-(4-methoxyphenethyl)-2-methylpyrrolidine
DMR3DSG	HS	Investigative
DMR3DSG	SN	CHEMBL271898
DMR3DSG	DT	Small molecular drug
DMR3DSG	PC	44456056
DMR3DSG	MW	219.32
DMR3DSG	FM	C14H21NO
DMR3DSG	IC	InChI=1S/C14H21NO/c1-12-4-3-10-15(12)11-9-13-5-7-14(16-2)8-6-13/h5-8,12H,3-4,9-11H2,1-2H3/t12-/m1/s1
DMR3DSG	CS	C[C@@H]1CCCN1CCC2=CC=C(C=C2)OC
DMR3DSG	IK	NPUSLESRSBDEHN-GFCCVEGCSA-N
DMR3DSG	IU	(2R)-1-[2-(4-methoxyphenyl)ethyl]-2-methylpyrrolidine
DMR3DSG	DE	Discovery agent

DMNROUV	ID	DMNROUV
DMNROUV	DN	(R)-1-(4-nitrophenethyl)-2-methylpyrrolidine
DMNROUV	HS	Investigative
DMNROUV	SN	CHEMBL440996; SCHEMBL1574678; PFZYNGPCNCRLFU-LLVKDONJSA-N; BDBM50372333; ZINC29131354
DMNROUV	DT	Small molecular drug
DMNROUV	PC	23635021
DMNROUV	MW	234.29
DMNROUV	FM	C13H18N2O2
DMNROUV	IC	InChI=1S/C13H18N2O2/c1-11-3-2-9-14(11)10-8-12-4-6-13(7-5-12)15(16)17/h4-7,11H,2-3,8-10H2,1H3/t11-/m1/s1
DMNROUV	CS	C[C@@H]1CCCN1CCC2=CC=C(C=C2)[N+](=O)[O-]
DMNROUV	IK	PFZYNGPCNCRLFU-LLVKDONJSA-N
DMNROUV	IU	(2R)-2-methyl-1-[2-(4-nitrophenyl)ethyl]pyrrolidine
DMNROUV	DE	Discovery agent

DMKJWMC	ID	DMKJWMC
DMKJWMC	DN	(R)-11-Amino-2-methoxyaporphine
DMKJWMC	HS	Investigative
DMKJWMC	SN	CHEMBL506721; (R)-11-Amino-2-methoxyaporphine
DMKJWMC	DT	Small molecular drug
DMKJWMC	PC	44568533
DMKJWMC	MW	280.4
DMKJWMC	FM	C18H20N2O
DMKJWMC	IC	InChI=1S/C18H20N2O/c1-20-7-6-12-8-13(21-2)10-14-17-11(4-3-5-15(17)19)9-16(20)18(12)14/h3-5,8,10,16H,6-7,9,19H2,1-2H3/t16-/m1/s1
DMKJWMC	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=CC=C4)N
DMKJWMC	IK	RHZAGARGKYFZJB-MRXNPFEDSA-N
DMKJWMC	IU	(6aR)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-amine
DMKJWMC	DE	Discovery agent

DMXUHV3	ID	DMXUHV3
DMXUHV3	DN	(R)-2-((4-benzylphenoxy)methyl)piperidine
DMXUHV3	HS	Investigative
DMXUHV3	SN	CHEMBL1099180; (R)-2-((4-benzylphenoxy)methyl)piperidine; SCHEMBL13809077
DMXUHV3	DT	Small molecular drug
DMXUHV3	PC	46888101
DMXUHV3	MW	281.4
DMXUHV3	FM	C19H23NO
DMXUHV3	IC	InChI=1S/C19H23NO/c1-2-6-16(7-3-1)14-17-9-11-19(12-10-17)21-15-18-8-4-5-13-20-18/h1-3,6-7,9-12,18,20H,4-5,8,13-15H2/t18-/m1/s1
DMXUHV3	CS	C1CCN[C@H](C1)COC2=CC=C(C=C2)CC3=CC=CC=C3
DMXUHV3	IK	YZRAMLLKPOGYCE-GOSISDBHSA-N
DMXUHV3	IU	(2R)-2-[(4-benzylphenoxy)methyl]piperidine
DMXUHV3	DE	Discovery agent

DM6KJ3D	ID	DM6KJ3D
DM6KJ3D	DN	(R)-2-((4-phenoxyphenoxy)methyl)piperidine
DM6KJ3D	HS	Investigative
DM6KJ3D	SN	CHEMBL1099181; (R)-2-((4-phenoxyphenoxy)methyl)piperidine; SCHEMBL13809073
DM6KJ3D	DT	Small molecular drug
DM6KJ3D	PC	29293603
DM6KJ3D	MW	283.4
DM6KJ3D	FM	C18H21NO2
DM6KJ3D	IC	InChI=1S/C18H21NO2/c1-2-7-17(8-3-1)21-18-11-9-16(10-12-18)20-14-15-6-4-5-13-19-15/h1-3,7-12,15,19H,4-6,13-14H2/t15-/m1/s1
DM6KJ3D	CS	C1CCN[C@H](C1)COC2=CC=C(C=C2)OC3=CC=CC=C3
DM6KJ3D	IK	CSJNBXMUZIPBKQ-OAHLLOKOSA-N
DM6KJ3D	IU	(2R)-2-[(4-phenoxyphenoxy)methyl]piperidine
DM6KJ3D	DE	Discovery agent

DMFDW4C	ID	DMFDW4C
DMFDW4C	DN	(R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol
DMFDW4C	HS	Investigative
DMFDW4C	SN	CHEMBL404834
DMFDW4C	DT	Small molecular drug
DMFDW4C	PC	44456330
DMFDW4C	MW	205.3
DMFDW4C	FM	C13H19NO
DMFDW4C	IC	InChI=1S/C13H19NO/c1-11-5-4-9-14(11)10-8-12-6-2-3-7-13(12)15/h2-3,6-7,11,15H,4-5,8-10H2,1H3/t11-/m1/s1
DMFDW4C	CS	C[C@@H]1CCCN1CCC2=CC=CC=C2O
DMFDW4C	IK	XLLMSPMZEFQVLD-LLVKDONJSA-N
DMFDW4C	IU	2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]phenol
DMFDW4C	DE	Discovery agent

DM0L6ES	ID	DM0L6ES
DM0L6ES	DN	(R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DM0L6ES	HS	Investigative
DM0L6ES	SN	CHEMBL270807
DM0L6ES	DT	Small molecular drug
DM0L6ES	PC	44455953
DM0L6ES	MW	190.28
DM0L6ES	FM	C12H18N2
DM0L6ES	IC	InChI=1S/C12H18N2/c1-11-5-4-9-14(11)10-7-12-6-2-3-8-13-12/h2-3,6,8,11H,4-5,7,9-10H2,1H3/t11-/m1/s1
DM0L6ES	CS	C[C@@H]1CCCN1CCC2=CC=CC=N2
DM0L6ES	IK	ICWSPDRNRGQWAB-LLVKDONJSA-N
DM0L6ES	IU	2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DM0L6ES	DE	Discovery agent

DMVEMNA	ID	DMVEMNA
DMVEMNA	DN	(R)-2-(2-naphthamido)-3-m-tolylpropanoic acid
DMVEMNA	HS	Investigative
DMVEMNA	SN	CHEMBL1091064; (R)-2-(2-naphthamido)-3-m-tolylpropanoic acid
DMVEMNA	DT	Small molecular drug
DMVEMNA	PC	46884012
DMVEMNA	MW	333.4
DMVEMNA	FM	C21H19NO3
DMVEMNA	IC	InChI=1S/C21H19NO3/c1-14-5-4-6-15(11-14)12-19(21(24)25)22-20(23)18-10-9-16-7-2-3-8-17(16)13-18/h2-11,13,19H,12H2,1H3,(H,22,23)(H,24,25)/t19-/m1/s1
DMVEMNA	CS	CC1=CC(=CC=C1)C[C@H](C(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DMVEMNA	IK	ZDRUGIXKFVQOIJ-LJQANCHMSA-N
DMVEMNA	IU	(2R)-3-(3-methylphenyl)-2-(naphthalene-2-carbonylamino)propanoic acid
DMVEMNA	DE	Discovery agent

DMXGCYZ	ID	DMXGCYZ
DMXGCYZ	DN	(R)-2-(2-naphthamido)-3-p-tolylpropanoic acid
DMXGCYZ	HS	Investigative
DMXGCYZ	SN	CHEMBL1093715; (R)-2-(2-naphthamido)-3-p-tolylpropanoic acid
DMXGCYZ	DT	Small molecular drug
DMXGCYZ	PC	46884149
DMXGCYZ	MW	333.4
DMXGCYZ	FM	C21H19NO3
DMXGCYZ	IC	InChI=1S/C21H19NO3/c1-14-6-8-15(9-7-14)12-19(21(24)25)22-20(23)18-11-10-16-4-2-3-5-17(16)13-18/h2-11,13,19H,12H2,1H3,(H,22,23)(H,24,25)/t19-/m1/s1
DMXGCYZ	CS	CC1=CC=C(C=C1)C[C@H](C(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DMXGCYZ	IK	AYMZFPGSRYDLJL-LJQANCHMSA-N
DMXGCYZ	IU	(2R)-3-(4-methylphenyl)-2-(naphthalene-2-carbonylamino)propanoic acid
DMXGCYZ	DE	Discovery agent

DM9WL6O	ID	DM9WL6O
DM9WL6O	DN	(R)-2-(2-naphthamido)-5-phenylpent-4-ynoic acid
DM9WL6O	HS	Investigative
DM9WL6O	SN	CHEMBL1090378; (R)-2-(2-naphthamido)-5-phenylpent-4-ynoic acid; SCHEMBL16550496
DM9WL6O	DT	Small molecular drug
DM9WL6O	PC	46884229
DM9WL6O	MW	343.4
DM9WL6O	FM	C22H17NO3
DM9WL6O	IC	InChI=1S/C22H17NO3/c24-21(19-14-13-17-10-4-5-11-18(17)15-19)23-20(22(25)26)12-6-9-16-7-2-1-3-8-16/h1-5,7-8,10-11,13-15,20H,12H2,(H,23,24)(H,25,26)/t20-/m1/s1
DM9WL6O	CS	C1=CC=C(C=C1)C#CC[C@H](C(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DM9WL6O	IK	IIZVJSCXCNYCFJ-HXUWFJFHSA-N
DM9WL6O	IU	(2R)-2-(naphthalene-2-carbonylamino)-5-phenylpent-4-ynoic acid
DM9WL6O	DE	Discovery agent

DM74IWX	ID	DM74IWX
DM74IWX	DN	(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM74IWX	HS	Investigative
DM74IWX	SN	CHEMBL1084971; (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM74IWX	DT	Small molecular drug
DM74IWX	PC	46890321
DM74IWX	MW	282.4
DM74IWX	FM	C18H22N2O
DM74IWX	IC	InChI=1S/C18H22N2O/c21-18-9-5-4-8-16(18)14-17(15-6-2-1-3-7-15)20-12-10-19-11-13-20/h1-9,17,19,21H,10-14H2/t17-/m1/s1
DM74IWX	CS	C1CN(CCN1)[C@H](CC2=CC=CC=C2O)C3=CC=CC=C3
DM74IWX	IK	SBKGLFTUHHUCII-QGZVFWFLSA-N
DM74IWX	IU	2-[(2R)-2-phenyl-2-piperazin-1-ylethyl]phenol
DM74IWX	CA	CAS 1238669-95-8
DM74IWX	DE	Discovery agent

DM1GCV3	ID	DM1GCV3
DM1GCV3	DN	(R)-2-(4-Benzylphenoxymethyl)pyrrolidine
DM1GCV3	HS	Investigative
DM1GCV3	SN	(R)-2-(4-Benzylphenoxymethyl)pyrrolidine; CHEMBL571091; (2r)-2-[(4-Benzylphenoxy)methyl]pyrrolidine; SCHEMBL4319733; NXNMORHGFGYRDN-QGZVFWFLSA-N; BDBM50303648
DM1GCV3	DT	Small molecular drug
DM1GCV3	PC	16222640
DM1GCV3	MW	267.4
DM1GCV3	FM	C18H21NO
DM1GCV3	IC	InChI=1S/C18H21NO/c1-2-5-15(6-3-1)13-16-8-10-18(11-9-16)20-14-17-7-4-12-19-17/h1-3,5-6,8-11,17,19H,4,7,12-14H2/t17-/m1/s1
DM1GCV3	CS	C1C[C@@H](NC1)COC2=CC=C(C=C2)CC3=CC=CC=C3
DM1GCV3	IK	NXNMORHGFGYRDN-QGZVFWFLSA-N
DM1GCV3	IU	(2R)-2-[(4-benzylphenoxy)methyl]pyrrolidine
DM1GCV3	DE	Discovery agent

DMR8E0G	ID	DMR8E0G
DMR8E0G	DN	(R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide
DMR8E0G	HS	Investigative
DMR8E0G	SN	CHEMBL190899; SCHEMBL13952025; Benzeneacetamide,N-methoxy-alpha-methyl-4-(2-methylpropyl)-,(alphaR)-
DMR8E0G	DT	Small molecular drug
DMR8E0G	PC	11322291
DMR8E0G	MW	235.32
DMR8E0G	FM	C14H21NO2
DMR8E0G	IC	InChI=1S/C14H21NO2/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-17-4/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
DMR8E0G	CS	C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NOC
DMR8E0G	IK	UOURTTOYLTUYKY-LLVKDONJSA-N
DMR8E0G	IU	(2R)-N-methoxy-2-[4-(2-methylpropyl)phenyl]propanamide
DMR8E0G	DE	Discovery agent

DMAD4JY	ID	DMAD4JY
DMAD4JY	DN	(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide
DMAD4JY	HS	Investigative
DMAD4JY	SN	AC1LGDRI; SCHEMBL4372856; CHEMBL190952; ZINC250026; (2R)-2-(4-Isobutylphenyl)-N-phenylpropionamide
DMAD4JY	DT	Small molecular drug
DMAD4JY	PC	769367
DMAD4JY	MW	281.4
DMAD4JY	FM	C19H23NO
DMAD4JY	IC	InChI=1S/C19H23NO/c1-14(2)13-16-9-11-17(12-10-16)15(3)19(21)20-18-7-5-4-6-8-18/h4-12,14-15H,13H2,1-3H3,(H,20,21)/t15-/m1/s1
DMAD4JY	CS	C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NC2=CC=CC=C2
DMAD4JY	IK	UHKIXOMKDZNTLI-OAHLLOKOSA-N
DMAD4JY	IU	(2R)-2-[4-(2-methylpropyl)phenyl]-N-phenylpropanamide
DMAD4JY	DE	Discovery agent

DMBQ0PR	ID	DMBQ0PR
DMBQ0PR	DN	(R)-2-(4-Isobutyl-phenyl)-propionamide
DMBQ0PR	HS	Investigative
DMBQ0PR	SN	UNII-LMA883899Q; LMA883899Q; 121839-78-9; (R)-Ibuprofenamide; (-)-Ibuprofenamide; Ibuprofenamide, (R)-; (R)-2-(4-(Isobutylphenyl)propanamide; AC1LEPBR; SCHEMBL1883571; CHEMBL190950; Benzeneacetamide, alpha-methyl-4-(2-methylpropyl)-, (R)-; Benzeneacetamide,alpha-methyl-4-(2-methylpropyl)-,(alphaR)-; ZINC112491; Benzeneacetamide, alpha-methyl-4-(2-methylpropyl)-, (alphaR)-; ZB003774; (R)-alpha-Methyl-4-isobutylbenzeneacetamide; (2R)-2-[4-(2-methylpropyl)phenyl]propanamide; UNII-74M0104F2J component REUQKCDCQVNKLW-SNVBAGLBSA-
DMBQ0PR	DT	Small molecular drug
DMBQ0PR	PC	715794
DMBQ0PR	MW	205.3
DMBQ0PR	FM	C13H19NO
DMBQ0PR	IC	InChI=1S/C13H19NO/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H2,14,15)/t10-/m1/s1
DMBQ0PR	CS	C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)N
DMBQ0PR	IK	REUQKCDCQVNKLW-SNVBAGLBSA-N
DMBQ0PR	IU	(2R)-2-[4-(2-methylpropyl)phenyl]propanamide
DMBQ0PR	CA	CAS 121839-78-9
DMBQ0PR	DE	Discovery agent

DMJVQN8	ID	DMJVQN8
DMJVQN8	DN	(R)-2-(Benzylamino-methyl)-chroman-7-ol
DMJVQN8	HS	Investigative
DMJVQN8	SN	CHEMBL64553; CHEMBL134807; BDBM50061669; ZINC13527706; (2R)-2-(Benzylaminomethyl)chroman-7-ol; (r)-2-[(benzylamino)methyl]chroman-7-ol
DMJVQN8	DT	Small molecular drug
DMJVQN8	PC	10378389
DMJVQN8	MW	269.34
DMJVQN8	FM	C17H19NO2
DMJVQN8	IC	InChI=1S/C17H19NO2/c19-15-8-6-14-7-9-16(20-17(14)10-15)12-18-11-13-4-2-1-3-5-13/h1-6,8,10,16,18-19H,7,9,11-12H2/t16-/m1/s1
DMJVQN8	CS	C1CC2=C(C=C(C=C2)O)O[C@H]1CNCC3=CC=CC=C3
DMJVQN8	IK	DWUAAOIZQFTYQP-MRXNPFEDSA-N
DMJVQN8	IU	(2R)-2-[(benzylamino)methyl]-3,4-dihydro-2H-chromen-7-ol
DMJVQN8	DE	Discovery agent

DM16JFS	ID	DM16JFS
DM16JFS	DN	(R)-2-(biphenyl-4-sulfonylamino)-propionic acid
DM16JFS	HS	Investigative
DM16JFS	SN	SCHEMBL4651862; CHEMBL198184; BDBM24034; biphenylsulfonamide carboxylate, 11; (2R)-2-[(4-phenylbenzene)sulfonamido]propanoic acid
DM16JFS	DT	Small molecular drug
DM16JFS	PC	24901481
DM16JFS	MW	305.4
DM16JFS	FM	C15H15NO4S
DM16JFS	IC	InChI=1S/C15H15NO4S/c1-11(15(17)18)16-21(19,20)14-9-7-13(8-10-14)12-5-3-2-4-6-12/h2-11,16H,1H3,(H,17,18)/t11-/m1/s1
DM16JFS	CS	C[C@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DM16JFS	IK	KXVXZFCETOKHTC-LLVKDONJSA-N
DM16JFS	IU	(2R)-2-[(4-phenylphenyl)sulfonylamino]propanoic acid
DM16JFS	DE	Discovery agent

DM70ZIF	ID	DM70ZIF
DM70ZIF	DN	(R)-2,11-Diaminoaporphine
DM70ZIF	HS	Investigative
DM70ZIF	SN	(R)-2,11-Diaminoaporphine; CHEMBL455051
DM70ZIF	DT	Small molecular drug
DM70ZIF	PC	44568534
DM70ZIF	MW	265.35
DM70ZIF	FM	C17H19N3
DM70ZIF	IC	InChI=1S/C17H19N3/c1-20-6-5-11-7-12(18)9-13-16-10(3-2-4-14(16)19)8-15(20)17(11)13/h2-4,7,9,15H,5-6,8,18-19H2,1H3/t15-/m1/s1
DM70ZIF	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)N)C(=CC=C4)N
DM70ZIF	IK	SBZULQRCMCHLCL-OAHLLOKOSA-N
DM70ZIF	IU	(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,11-diamine
DM70ZIF	DE	Discovery agent

DMRO9C7	ID	DMRO9C7
DMRO9C7	DN	(R)-2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol
DMRO9C7	HS	Investigative
DMRO9C7	SN	CHEMBL87169; (R)-2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol
DMRO9C7	DT	Small molecular drug
DMRO9C7	PC	44320078
DMRO9C7	MW	193.2
DMRO9C7	FM	C7H15NO5
DMRO9C7	IC	InChI=1S/C7H15NO5/c9-1-3-5(11)7(13)6(12)4(2-10)8-3/h3-13H,1-2H2/t3?,4?,5-,6?,7?/m1/s1
DMRO9C7	CS	C(C1[C@H](C(C(C(N1)CO)O)O)O)O
DMRO9C7	IK	CLVUFWXGNIFGNC-BQHSNLCNSA-N
DMRO9C7	IU	(3R)-2,6-bis(hydroxymethyl)piperidine-3,4,5-triol
DMRO9C7	DE	Discovery agent

DMZXT34	ID	DMZXT34
DMZXT34	DN	(R)-2-amino-3-(4-octylphenylamino)propan-1-ol
DMZXT34	HS	Investigative
DMZXT34	SN	CHEMBL572686; (R)-2-amino-3-(4-octylphenylamino)propan-1-ol; SCHEMBL1312243
DMZXT34	DT	Small molecular drug
DMZXT34	PC	45255203
DMZXT34	MW	278.4
DMZXT34	FM	C17H30N2O
DMZXT34	IC	InChI=1S/C17H30N2O/c1-2-3-4-5-6-7-8-15-9-11-17(12-10-15)19-13-16(18)14-20/h9-12,16,19-20H,2-8,13-14,18H2,1H3/t16-/m1/s1
DMZXT34	CS	CCCCCCCCC1=CC=C(C=C1)NC[C@H](CO)N
DMZXT34	IK	RCARSJSFSXRXLF-MRXNPFEDSA-N
DMZXT34	IU	(2R)-2-amino-3-(4-octylanilino)propan-1-ol
DMZXT34	DE	Discovery agent

DMA1EFL	ID	DMA1EFL
DMA1EFL	DN	(R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DMA1EFL	HS	Investigative
DMA1EFL	SN	CHEMBL572687; (R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide; SCHEMBL1312879; QJTVTVAQRCRXSM-QGZVFWFLSA-N
DMA1EFL	DT	Small molecular drug
DMA1EFL	PC	45254608
DMA1EFL	MW	306.4
DMA1EFL	FM	C18H30N2O2
DMA1EFL	IC	InChI=1S/C18H30N2O2/c1-2-3-4-5-6-7-8-15-9-11-16(12-10-15)20-18(22)17(19)13-14-21/h9-12,17,21H,2-8,13-14,19H2,1H3,(H,20,22)/t17-/m1/s1
DMA1EFL	CS	CCCCCCCCC1=CC=C(C=C1)NC(=O)[C@@H](CCO)N
DMA1EFL	IK	QJTVTVAQRCRXSM-QGZVFWFLSA-N
DMA1EFL	IU	(2R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DMA1EFL	DE	Discovery agent

DMSY4CK	ID	DMSY4CK
DMSY4CK	DN	(R)-2-Amino-5-phosphono-pentanoic acid
DMSY4CK	HS	Investigative
DMSY4CK	SN	76326-31-3; 5-Phosphononorvaline; DL-AP5; 2-Amino-5-phosphonopentanoic acid; 2-Amino-5-phosphovaleric acid; DL-2-Amino-5-phosphonopentanoic acid; 2-Amino-5-phosphopentanoic acid; 2-Amino-5-phosphonovaleric Acid; 2-AMINO-5-PHOSPHONOVALERATE; DL-2-Amino-5-phosphonovaleric acid; dl-APV; 2-Amino-5-phosphonopentanoate; AP-5; Norvaline, 5-phosphono-; 76726-92-6; CHEMBL28862; CHEBI:138644; 2-Amino-5-phosphono-pentanoic acid; (+/-)-Amino-5-phosphono-pentanoic acid; (+/-)-2-Amino-5-phosphonopentanoic acid; App acid; C5H12NO5P; Apv acid
DMSY4CK	DT	Small molecular drug
DMSY4CK	PC	1216
DMSY4CK	MW	197.13
DMSY4CK	FM	C5H12NO5P
DMSY4CK	IC	InChI=1S/C5H12NO5P/c6-4(5(7)8)2-1-3-12(9,10)11/h4H,1-3,6H2,(H,7,8)(H2,9,10,11)
DMSY4CK	CS	C(CC(C(=O)O)N)CP(=O)(O)O
DMSY4CK	IK	VOROEQBFPPIACJ-UHFFFAOYSA-N
DMSY4CK	IU	2-amino-5-phosphonopentanoic acid
DMSY4CK	CA	CAS 76326-31-3
DMSY4CK	CB	CHEBI:138644
DMSY4CK	DE	Discovery agent

DM4XEHR	ID	DM4XEHR
DM4XEHR	DN	(R)-2-Amino-7-phosphono-heptanoic acid
DM4XEHR	HS	Investigative
DM4XEHR	SN	81338-23-0; UNII-89FET0690I; (2R)-2-amino-7-phosphonoheptanoic acid; D(-)-2-Amino-7-phosphonoheptanoic acid; Heptanoic acid, 2-amino-7-phosphono-, (2R)-; CHEMBL302783; 89FET0690I; D-(-)-2-Amino-7-phosphonoheptanoic acid; (R)-AP7; D-(-)-2-Amino-7-phosphonoheptanoate; AC1LUTYN; Tocris-0164; Tocris-0104; Lopac-A-167; Lopac-A-5157; Lopac0_000157; SCHEMBL9848541; ZINC1856281; BDBM50017226; STL526509; BN0090; AKOS024456719; CCG-204252
DM4XEHR	DT	Small molecular drug
DM4XEHR	PC	1617430
DM4XEHR	MW	225.18
DM4XEHR	FM	C7H16NO5P
DM4XEHR	IC	InChI=1S/C7H16NO5P/c8-6(7(9)10)4-2-1-3-5-14(11,12)13/h6H,1-5,8H2,(H,9,10)(H2,11,12,13)/t6-/m1/s1
DM4XEHR	CS	C(CC[C@H](C(=O)O)N)CCP(=O)(O)O
DM4XEHR	IK	MYDMWESTDPJANS-ZCFIWIBFSA-N
DM4XEHR	IU	(2R)-2-amino-7-phosphonoheptanoic acid
DM4XEHR	CA	CAS 81338-23-0
DM4XEHR	DE	Discovery agent

DMT8HP1	ID	DMT8HP1
DMT8HP1	DN	(R)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine
DMT8HP1	HS	Investigative
DMT8HP1	SN	CHEMBL257915
DMT8HP1	DT	Small molecular drug
DMT8HP1	PC	44456132
DMT8HP1	MW	203.32
DMT8HP1	FM	C14H21N
DMT8HP1	IC	InChI=1S/C14H21N/c1-12-5-3-7-14(11-12)8-10-15-9-4-6-13(15)2/h3,5,7,11,13H,4,6,8-10H2,1-2H3/t13-/m1/s1
DMT8HP1	CS	C[C@@H]1CCCN1CCC2=CC=CC(=C2)C
DMT8HP1	IK	PXZKWHANTMQGIH-CYBMUJFWSA-N
DMT8HP1	IU	(2R)-2-methyl-1-[2-(3-methylphenyl)ethyl]pyrrolidine
DMT8HP1	DE	Discovery agent

DMA1FUH	ID	DMA1FUH
DMA1FUH	DN	(R)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine
DMA1FUH	HS	Investigative
DMA1FUH	SN	CHEMBL403052
DMA1FUH	DT	Small molecular drug
DMA1FUH	PC	44456127
DMA1FUH	MW	203.32
DMA1FUH	FM	C14H21N
DMA1FUH	IC	InChI=1S/C14H21N/c1-12-5-7-14(8-6-12)9-11-15-10-3-4-13(15)2/h5-8,13H,3-4,9-11H2,1-2H3/t13-/m1/s1
DMA1FUH	CS	C[C@@H]1CCCN1CCC2=CC=C(C=C2)C
DMA1FUH	IK	BFMXEUSPYLVDSY-CYBMUJFWSA-N
DMA1FUH	IU	(2R)-2-methyl-1-[2-(4-methylphenyl)ethyl]pyrrolidine
DMA1FUH	DE	Discovery agent

DMRZDM0	ID	DMRZDM0
DMRZDM0	DN	(R)-3-(1'-Adamantanecarbonyl)amino-caprolactam
DMRZDM0	HS	Investigative
DMRZDM0	SN	CHEMBL512094
DMRZDM0	DT	Small molecular drug
DMRZDM0	PC	44157844
DMRZDM0	MW	290.4
DMRZDM0	FM	C17H26N2O2
DMRZDM0	IC	InChI=1S/C17H26N2O2/c20-15-14(3-1-2-4-18-15)19-16(21)17-8-11-5-12(9-17)7-13(6-11)10-17/h11-14H,1-10H2,(H,18,20)(H,19,21)/t11?,12?,13?,14-,17?/m1/s1
DMRZDM0	CS	C1CCNC(=O)[C@@H](C1)NC(=O)C23CC4CC(C2)CC(C4)C3
DMRZDM0	IK	FRJOFURBYVCNEN-DLUQRMLASA-N
DMRZDM0	IU	N-[(3R)-2-oxoazepan-3-yl]adamantane-1-carboxamide
DMRZDM0	DE	Discovery agent

DMCSHI3	ID	DMCSHI3
DMCSHI3	DN	(R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate
DMCSHI3	HS	Investigative
DMCSHI3	SN	CHEMBL1080089; BDBM50311765; BDBM50074071; [(1R)-1-Methylpropyl]carbamic acid 3-(1H-imidazole-4-yl)propyl ester; ((R)-sec-Butyl)-carbamic acid 3-(1H-imidazol-4-yl)-propyl ester
DMCSHI3	DT	Small molecular drug
DMCSHI3	PC	10680721
DMCSHI3	MW	225.29
DMCSHI3	FM	C11H19N3O2
DMCSHI3	IC	InChI=1S/C11H19N3O2/c1-3-9(2)14-11(15)16-6-4-5-10-7-12-8-13-10/h7-9H,3-6H2,1-2H3,(H,12,13)(H,14,15)/t9-/m1/s1
DMCSHI3	CS	CC[C@@H](C)NC(=O)OCCCC1=CN=CN1
DMCSHI3	IK	RSHJCGZZSGNBHO-SECBINFHSA-N
DMCSHI3	IU	3-(1H-imidazol-5-yl)propyl N-[(2R)-butan-2-yl]carbamate
DMCSHI3	DE	Discovery agent

DMUFP7W	ID	DMUFP7W
DMUFP7W	DN	(R)-3-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DMUFP7W	HS	Investigative
DMUFP7W	SN	CHEMBL271226
DMUFP7W	DT	Small molecular drug
DMUFP7W	PC	44455920
DMUFP7W	MW	190.28
DMUFP7W	FM	C12H18N2
DMUFP7W	IC	InChI=1S/C12H18N2/c1-11-4-3-8-14(11)9-6-12-5-2-7-13-10-12/h2,5,7,10-11H,3-4,6,8-9H2,1H3/t11-/m1/s1
DMUFP7W	CS	C[C@@H]1CCCN1CCC2=CN=CC=C2
DMUFP7W	IK	WJLLZUXQRCOTAJ-LLVKDONJSA-N
DMUFP7W	IU	3-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DMUFP7W	DE	Discovery agent

DM5TH2W	ID	DM5TH2W
DM5TH2W	DN	(R)-3-(2-naphthamido)-4-m-tolylbutanoic acid
DM5TH2W	HS	Investigative
DM5TH2W	SN	CHEMBL1091065; (R)-3-(2-naphthamido)-4-m-tolylbutanoic acid
DM5TH2W	DT	Small molecular drug
DM5TH2W	PC	46884013
DM5TH2W	MW	347.4
DM5TH2W	FM	C22H21NO3
DM5TH2W	IC	InChI=1S/C22H21NO3/c1-15-5-4-6-16(11-15)12-20(14-21(24)25)23-22(26)19-10-9-17-7-2-3-8-18(17)13-19/h2-11,13,20H,12,14H2,1H3,(H,23,26)(H,24,25)/t20-/m1/s1
DM5TH2W	CS	CC1=CC(=CC=C1)C[C@H](CC(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DM5TH2W	IK	LDUFWTJAUGDLSR-HXUWFJFHSA-N
DM5TH2W	IU	(3R)-4-(3-methylphenyl)-3-(naphthalene-2-carbonylamino)butanoic acid
DM5TH2W	DE	Discovery agent

DMQ2KF8	ID	DMQ2KF8
DMQ2KF8	DN	(R)-3-(4-Isobutyl-phenyl)-butan-2-one
DMQ2KF8	HS	Investigative
DMQ2KF8	SN	2-Butanone,3-[4-(2-methylpropyl)phenyl]-,(3R)-; SCHEMBL4471196; CHEMBL371421; ZINC13646153
DMQ2KF8	DT	Small molecular drug
DMQ2KF8	PC	9794254
DMQ2KF8	MW	204.31
DMQ2KF8	FM	C14H20O
DMQ2KF8	IC	InChI=1S/C14H20O/c1-10(2)9-13-5-7-14(8-6-13)11(3)12(4)15/h5-8,10-11H,9H2,1-4H3/t11-/m0/s1
DMQ2KF8	CS	C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)C
DMQ2KF8	IK	VOYZJYGIHFRNAG-NSHDSACASA-N
DMQ2KF8	IU	(3R)-3-[4-(2-methylpropyl)phenyl]butan-2-one
DMQ2KF8	DE	Discovery agent

DMC73DY	ID	DMC73DY
DMC73DY	DN	(R)-3-(4-propylmorpholin-2-yl)phenol
DMC73DY	HS	Investigative
DMC73DY	SN	CHEMBL250403; 710654-74-3; pf-219061; (R)-3-(4-propylmorpholin-2-yl)phenol; SCHEMBL2078437; DTXSID90430791; ZINC26822913; BDBM50226008; KB-274981
DMC73DY	DT	Small molecular drug
DMC73DY	PC	9794475
DMC73DY	MW	221.29
DMC73DY	FM	C13H19NO2
DMC73DY	IC	InChI=1S/C13H19NO2/c1-2-6-14-7-8-16-13(10-14)11-4-3-5-12(15)9-11/h3-5,9,13,15H,2,6-8,10H2,1H3/t13-/m0/s1
DMC73DY	CS	CCCN1CCO[C@@H](C1)C2=CC(=CC=C2)O
DMC73DY	IK	WYEGTIGJSHGEID-ZDUSSCGKSA-N
DMC73DY	IU	3-[(2R)-4-propylmorpholin-2-yl]phenol
DMC73DY	CA	CAS 710654-74-3
DMC73DY	DE	Discovery agent

DM2DVNT	ID	DM2DVNT
DM2DVNT	DN	(R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM2DVNT	HS	Investigative
DM2DVNT	SN	CHEMBL377707; (R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid; SCHEMBL6382413
DM2DVNT	DT	Small molecular drug
DM2DVNT	PC	12985750
DM2DVNT	MW	183.2
DM2DVNT	FM	C9H13NO3
DM2DVNT	IC	InChI=1S/C9H13NO3/c10-6-7(5-9(11)12)4-8-2-1-3-13-8/h1-3,7H,4-6,10H2,(H,11,12)/t7-/m1/s1
DM2DVNT	CS	C1=COC(=C1)C[C@H](CC(=O)O)CN
DM2DVNT	IK	JASKMEUWYOXVFB-SSDOTTSWSA-N
DM2DVNT	IU	(3R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM2DVNT	DE	Discovery agent

DM94B12	ID	DM94B12
DM94B12	DN	(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12	HS	Investigative
DM94B12	SN	CHEMBL469809; (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12	DT	Small molecular drug
DM94B12	PC	44592119
DM94B12	MW	227.3
DM94B12	FM	C15H17NO
DM94B12	IC	InChI=1S/C15H17NO/c1-2-4-14-9-12(5-6-13(14)3-1)11-17-15-7-8-16-10-15/h1-6,9,15-16H,7-8,10-11H2/t15-/m1/s1
DM94B12	CS	C1CNC[C@@H]1OCC2=CC3=CC=CC=C3C=C2
DM94B12	IK	IQZVBBALTJFFCB-OAHLLOKOSA-N
DM94B12	IU	(3R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12	DE	Discovery agent

DM98L2X	ID	DM98L2X
DM98L2X	DN	(R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DM98L2X	HS	Investigative
DM98L2X	SN	(R)-3-Methyl-1,2,3,4-tetrahydroisoquinoline; 179893-97-1; CHEMBL293023; (3R)-3-methyl-1,2,3,4-tetrahydroisoquinoline; AC1OM1IT; (R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL1690519; Isoquinoline, 1,2,3,4-tetrahydro-3-methyl-, (3R)-; UEKQPSAKUNXFHL-MRVPVSSYSA-N; ZINC19928405; FCH952510; BDBM50052885; AKOS024259472; AJ-75700
DM98L2X	DT	Small molecular drug
DM98L2X	PC	7462300
DM98L2X	MW	147.22
DM98L2X	FM	C10H13N
DM98L2X	IC	InChI=1S/C10H13N/c1-8-6-9-4-2-3-5-10(9)7-11-8/h2-5,8,11H,6-7H2,1H3/t8-/m1/s1
DM98L2X	CS	C[C@@H]1CC2=CC=CC=C2CN1
DM98L2X	IK	UEKQPSAKUNXFHL-MRVPVSSYSA-N
DM98L2X	IU	(3R)-3-methyl-1,2,3,4-tetrahydroisoquinoline
DM98L2X	DE	Discovery agent

DMPEV2W	ID	DMPEV2W
DMPEV2W	DN	(R)-3-Prop-2-ynylamino-indan-5-ol
DMPEV2W	HS	Investigative
DMPEV2W	SN	5-Hydroxy-N-propargyl-1(R)-aminoindan; 5-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN; CHEMBL371428; 6-hydroxy-n-propargyl-1(r)-aminoindan; (3R)-3-(PROP-2-YNYLAMINO)INDAN-5-OL; (3R)-3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-ol; R-HPAI; AC1NRD0T; Aminoindan deriv (R)39u; SCHEMBL4188273; BDBM10799; 1H-Inden-5-ol, 2,3-dihydro-3-(2-propyn-1-ylamino)-, (3R)-; DB04307; 479206-03-6; 5-Hydroxy-N-Propargyl-1(R)-Aminoindan
DMPEV2W	DT	Small molecular drug
DMPEV2W	PC	5289289
DMPEV2W	MW	187.24
DMPEV2W	FM	C12H13NO
DMPEV2W	IC	InChI=1S/C12H13NO/c1-2-7-13-12-6-4-9-3-5-10(14)8-11(9)12/h1,3,5,8,12-14H,4,6-7H2/t12-/m1/s1
DMPEV2W	CS	C#CCN[C@@H]1CCC2=C1C=C(C=C2)O
DMPEV2W	IK	NRSDGDXUWMMUEV-GFCCVEGCSA-N
DMPEV2W	IU	(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-ol
DMPEV2W	DE	Discovery agent

DM1Y9MZ	ID	DM1Y9MZ
DM1Y9MZ	DN	(R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DM1Y9MZ	HS	Investigative
DM1Y9MZ	SN	CHEMBL186985; (R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DM1Y9MZ	DT	Small molecular drug
DM1Y9MZ	PC	15463450
DM1Y9MZ	MW	172.29
DM1Y9MZ	FM	C8H16N2S
DM1Y9MZ	IC	InChI=1S/C8H16N2S/c1-2-3-7-6-11-5-4-8(9)10-7/h7H,2-6H2,1H3,(H2,9,10)/t7-/m1/s1
DM1Y9MZ	CS	CCC[C@@H]1CSCCC(=N1)N
DM1Y9MZ	IK	SWOQAUBWIBZBLQ-SSDOTTSWSA-N
DM1Y9MZ	IU	(3R)-3-propyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DM1Y9MZ	DE	Discovery agent

DM5CL8B	ID	DM5CL8B
DM5CL8B	DN	(R)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DM5CL8B	HS	Investigative
DM5CL8B	SN	CHEMBL271722
DM5CL8B	DT	Small molecular drug
DM5CL8B	PC	44456501
DM5CL8B	MW	190.28
DM5CL8B	FM	C12H18N2
DM5CL8B	IC	InChI=1S/C12H18N2/c1-11-3-2-9-14(11)10-6-12-4-7-13-8-5-12/h4-5,7-8,11H,2-3,6,9-10H2,1H3/t11-/m1/s1
DM5CL8B	CS	C[C@@H]1CCCN1CCC2=CC=NC=C2
DM5CL8B	IK	HTPLEJUDOQHUSX-LLVKDONJSA-N
DM5CL8B	IU	4-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DM5CL8B	DE	Discovery agent

DMRVOLN	ID	DMRVOLN
DMRVOLN	DN	(R)-4-[2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl]piperidine-1-carboxylic acid amide (Ro-320-6206)
DMRVOLN	HS	Investigative
DMRVOLN	DE	Discovery agent

DM3F56O	ID	DM3F56O
DM3F56O	DN	(R)-4-amino-2-methylbutanoic acid
DM3F56O	HS	Investigative
DM3F56O	SN	CHEMBL257443; 96192-37-9; (2R)-4-amino-2-methylbutanoic acid; Butanoic acid, 4-amino-2-methyl-, (2R)-; AC1LIBFM; SCHEMBL14518787; CTK3G8616; ZINC518267; (R)-2-Methyl-4-aminobutyric acid; BDBM50374650; AKOS006341386
DM3F56O	DT	Small molecular drug
DM3F56O	PC	928194
DM3F56O	MW	117.15
DM3F56O	FM	C5H11NO2
DM3F56O	IC	InChI=1S/C5H11NO2/c1-4(2-3-6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1
DM3F56O	CS	C[C@H](CCN)C(=O)O
DM3F56O	IK	AEBRINKRALSWNY-SCSAIBSYSA-N
DM3F56O	IU	(2R)-4-amino-2-methylbutanoic acid
DM3F56O	DE	Discovery agent

DMW87OE	ID	DMW87OE
DMW87OE	DN	(R)-5-Amino-3-(4-chloro-phenyl)-pentanoic acid
DMW87OE	HS	Investigative
DMW87OE	SN	CHEMBL62361; (R)-Homobaclofen; (R)-5-Amino-3-(4-chloro-phenyl)-pentanoic acid
DMW87OE	DT	Small molecular drug
DMW87OE	PC	10491829
DMW87OE	MW	227.69
DMW87OE	FM	C11H14ClNO2
DMW87OE	IC	InChI=1S/C11H14ClNO2/c12-10-3-1-8(2-4-10)9(5-6-13)7-11(14)15/h1-4,9H,5-7,13H2,(H,14,15)/t9-/m1/s1
DMW87OE	CS	C1=CC(=CC=C1[C@H](CCN)CC(=O)O)Cl
DMW87OE	IK	QXAGSDSDBMVSQR-SECBINFHSA-N
DMW87OE	IU	(3R)-5-amino-3-(4-chlorophenyl)pentanoic acid
DMW87OE	DE	Discovery agent

DMOESL1	ID	DMOESL1
DMOESL1	DN	(R)-5-diphosphomevalonate
DMOESL1	HS	Investigative
DMOESL1	SN	mevalonate 5-diphosphate
DMOESL1	DT	Small molecular drug
DMOESL1	PC	439418
DMOESL1	MW	308.12
DMOESL1	FM	C6H14O10P2
DMOESL1	IC	InChI=1S/C6H14O10P2/c1-6(9,4-5(7)8)2-3-15-18(13,14)16-17(10,11)12/h9H,2-4H2,1H3,(H,7,8)(H,13,14)(H2,10,11,12)/t6-/m1/s1
DMOESL1	CS	C[C@@](CCOP(=O)(O)OP(=O)(O)O)(CC(=O)O)O
DMOESL1	IK	SIGQQUBJQXSAMW-ZCFIWIBFSA-N
DMOESL1	IU	(3R)-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid
DMOESL1	CA	CAS 4872-34-8
DMOESL1	CB	CHEBI:15899
DMOESL1	DE	Discovery agent

DM3LQFK	ID	DM3LQFK
DM3LQFK	DN	(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline
DM3LQFK	HS	Investigative
DM3LQFK	SN	CHEMBL1086032; (R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline
DM3LQFK	DT	Small molecular drug
DM3LQFK	PC	46890563
DM3LQFK	MW	240.34
DM3LQFK	FM	C16H20N2
DM3LQFK	IC	InChI=1S/C16H20N2/c1-13-4-3-10-18(13)11-8-14-6-7-16-15(12-14)5-2-9-17-16/h2,5-7,9,12-13H,3-4,8,10-11H2,1H3/t13-/m1/s1
DM3LQFK	CS	C[C@@H]1CCCN1CCC2=CC3=C(C=C2)N=CC=C3
DM3LQFK	IK	HUQYUKHHFHNJRR-CYBMUJFWSA-N
DM3LQFK	IU	6-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]quinoline
DM3LQFK	DE	Discovery agent

DM134UV	ID	DM134UV
DM134UV	DN	(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM134UV	HS	Investigative
DM134UV	SN	CHEMBL506397; (R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM134UV	DT	Small molecular drug
DM134UV	PC	44592199
DM134UV	MW	252.31
DM134UV	FM	C16H16N2O
DM134UV	IC	InChI=1S/C16H16N2O/c17-9-12-1-2-15-8-16(4-3-14(15)7-12)19-11-13-5-6-18-10-13/h1-4,7-8,13,18H,5-6,10-11H2/t13-/m1/s1
DM134UV	CS	C1CNC[C@@H]1COC2=CC3=C(C=C2)C=C(C=C3)C#N
DM134UV	IK	PYEILVKGQDUINV-CYBMUJFWSA-N
DM134UV	IU	6-[[(3R)-pyrrolidin-3-yl]methoxy]naphthalene-2-carbonitrile
DM134UV	DE	Discovery agent

DMCY76E	ID	DMCY76E
DMCY76E	DN	(R)-8-phenyl-N,N-dipropylchroman-3-amine
DMCY76E	HS	Investigative
DMCY76E	SN	CHEMBL186112; (R)-8-phenyl-N,N-dipropylchroman-3-amine; BDBM50150676
DMCY76E	DT	Small molecular drug
DMCY76E	PC	11267988
DMCY76E	MW	309.4
DMCY76E	FM	C21H27NO
DMCY76E	IC	InChI=1S/C21H27NO/c1-3-13-22(14-4-2)19-15-18-11-8-12-20(21(18)23-16-19)17-9-6-5-7-10-17/h5-12,19H,3-4,13-16H2,1-2H3/t19-/m1/s1
DMCY76E	CS	CCCN(CCC)[C@@H]1CC2=C(C(=CC=C2)C3=CC=CC=C3)OC1
DMCY76E	IK	OYEKUFKQGCYWCG-LJQANCHMSA-N
DMCY76E	IU	(3R)-8-phenyl-N,N-dipropyl-3,4-dihydro-2H-chromen-3-amine
DMCY76E	DE	Discovery agent

DMKAW4P	ID	DMKAW4P
DMKAW4P	DN	(R)-alpha-methylhistamine
DMKAW4P	HS	Investigative
DMKAW4P	SN	(R)-alpha-Methylhistamine; CHEBI:73337; r-alpha-methylhistamine; (R)alpha-Me-histamine; CHEMBL268229; (R)-(-)-alpha-methylhistamine; (2R)-1-(1H-imidazol-4-yl)propan-2-amine; 75614-87-8; 1H-Imidazole-4-ethanamine, alpha-methyl-, (alphaR)-; (R)-(-)-4-(2-aminopropyl)imidazole; (2R)-1-(3H-imidazol-4-yl)propan-2-amine; (2R)-1-(1H-imidazol-5-yl)propan-2-amine; Alpha-Methylhistamine-R; C6H11N3; [3H]-R-alpha-Methylhistamine; (R)-[3H]alpha-methylhistamine; [3H](R)-alpha-methylhistamine
DMKAW4P	DT	Small molecular drug
DMKAW4P	PC	156615
DMKAW4P	MW	125.17
DMKAW4P	FM	C6H11N3
DMKAW4P	IC	InChI=1S/C6H11N3/c1-5(7)2-6-3-8-4-9-6/h3-5H,2,7H2,1H3,(H,8,9)/t5-/m1/s1
DMKAW4P	CS	C[C@H](CC1=CN=CN1)N
DMKAW4P	IK	XNQIOISZPFVUFG-RXMQYKEDSA-N
DMKAW4P	IU	(2R)-1-(1H-imidazol-5-yl)propan-2-amine
DMKAW4P	CA	CAS 75614-87-8
DMKAW4P	CB	CHEBI:73337
DMKAW4P	DE	Discovery agent

DMECK7H	ID	DMECK7H
DMECK7H	DN	(R)-DULOXETINE
DMECK7H	HS	Investigative
DMECK7H	SN	(R)-duloxetine; Duloxetine, (R)-; 116539-60-7; UNII-TK9VOT90JQ; R-Duloxetine HCl; TK9VOT90JQ; CHEMBL336920; CHEBI:36797; (3R)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3R)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; Duloxetine impurity A; Ariclaim; Duloxetine hydrochloride impurity A [EP]; Duloxetine hydrochloride specified impurity A [EP]; SCHEMBL1200511; (r)-n-methyl-3-(1-naphthoxy)-3-(2-thienyl)propylamine; DTXSID40151424; ZINC1536780; PDSP1_000970
DMECK7H	DT	Small molecular drug
DMECK7H	PC	10334821
DMECK7H	MW	297.4
DMECK7H	FM	C18H19NOS
DMECK7H	IC	InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m1/s1
DMECK7H	CS	CNCC[C@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
DMECK7H	IK	ZEUITGRIYCTCEM-QGZVFWFLSA-N
DMECK7H	IU	(3R)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
DMECK7H	CA	CAS 116539-60-7
DMECK7H	CB	CHEBI:36797
DMECK7H	DE	Discovery agent

DM297MU	ID	DM297MU
DM297MU	DN	(R)-EF-1520
DM297MU	HS	Investigative
DM297MU	SN	(R)-EF-1520; GTPL6512
DM297MU	DT	Small molecular drug
DM297MU	PC	53321930
DM297MU	MW	414.6
DM297MU	FM	C22H26N2O2S2
DM297MU	IC	InChI=1S/C22H26N2O2S2/c1-14-9-12-27-20(14)16(21-15(2)10-13-28-21)6-5-11-24(3)17-7-4-8-18-19(17)22(25)23-26-18/h6,9-10,12-13,17H,4-5,7-8,11H2,1-3H3,(H,23,25)/t17-/m1/s1
DM297MU	CS	CC1=C(SC=C1)C(=CCCN(C)[C@@H]2CCCC3=C2C(=O)NO3)C4=C(C=CS4)C
DM297MU	IK	CUESOMOCKVRNIW-QGZVFWFLSA-N
DM297MU	IU	(4R)-4-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl-methylamino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-one
DM297MU	DE	Discovery agent

DM2KBOU	ID	DM2KBOU
DM2KBOU	DN	(R)-flurocarazolol
DM2KBOU	HS	Investigative
DM2KBOU	SN	(R)-flurocarazolol; GTPL65; CHEMBL418834; PDSP2_000795; PDSP1_000808
DM2KBOU	DT	Small molecular drug
DM2KBOU	PC	9995893
DM2KBOU	MW	316.4
DM2KBOU	FM	C18H21FN2O2
DM2KBOU	IC	InChI=1S/C18H21FN2O2/c1-12(9-19)20-10-13(22)11-23-17-8-4-7-16-18(17)14-5-2-3-6-15(14)21-16/h2-8,12-13,20-22H,9-11H2,1H3/t12?,13-/m1/s1
DM2KBOU	CS	CC(CF)NC[C@H](COC1=CC=CC2=C1C3=CC=CC=C3N2)O
DM2KBOU	IK	QHLGXPUIUKSADT-ZGTCLIOFSA-N
DM2KBOU	IU	(2R)-1-(9H-carbazol-4-yloxy)-3-(1-fluoropropan-2-ylamino)propan-2-ol
DM2KBOU	DE	Discovery agent

DMKFPMC	ID	DMKFPMC
DMKFPMC	DN	(R)-Indan-1-yl-methyl-prop-2-ynyl-amine
DMKFPMC	HS	Investigative
DMKFPMC	SN	Indan-1-yl-methyl-prop-2-ynyl-amine
DMKFPMC	DE	Discovery agent

DMEXLUR	ID	DMEXLUR
DMEXLUR	DN	(R)-Mevalonate
DMEXLUR	HS	Investigative
DMEXLUR	SN	(R)-mevalonate; mevalonate; mevalonic acid; (3R)-3,5-dihydroxy-3-methylpentanoate; AC1NRC4P; GTPL3042; CHEBI:36464; CTK4B1152; DTXSID50415347
DMEXLUR	DT	Small molecular drug
DMEXLUR	PC	5288798
DMEXLUR	MW	147.15
DMEXLUR	FM	C6H11O4-
DMEXLUR	IC	InChI=1S/C6H12O4/c1-6(10,2-3-7)4-5(8)9/h7,10H,2-4H2,1H3,(H,8,9)/p-1/t6-/m1/s1
DMEXLUR	CS	C[C@@](CCO)(CC(=O)[O-])O
DMEXLUR	IK	KJTLQQUUPVSXIM-ZCFIWIBFSA-M
DMEXLUR	IU	(3R)-3,5-dihydroxy-3-methylpentanoate
DMEXLUR	CB	CHEBI:36464
DMEXLUR	DE	Discovery agent

DMPKWIN	ID	DMPKWIN
DMPKWIN	DN	(R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide
DMPKWIN	HS	Investigative
DMPKWIN	SN	CHEMBL242835; (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide; SCHEMBL2185997
DMPKWIN	DT	Small molecular drug
DMPKWIN	PC	23625205
DMPKWIN	MW	318.8
DMPKWIN	FM	C17H19ClN2O2
DMPKWIN	IC	InChI=1S/C17H19ClN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m1/s1
DMPKWIN	CS	C[C@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)Cl
DMPKWIN	IK	JFADNUHMEURSIM-GFCCVEGCSA-N
DMPKWIN	IU	(2R)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]propanamide
DMPKWIN	DE	Discovery agent

DMEVM6G	ID	DMEVM6G
DMEVM6G	DN	(R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide
DMEVM6G	HS	Investigative
DMEVM6G	SN	CHEMBL244771; (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide; SCHEMBL2017087
DMEVM6G	DT	Small molecular drug
DMEVM6G	PC	11382066
DMEVM6G	MW	334.8
DMEVM6G	FM	C17H19ClN2O3
DMEVM6G	IC	InChI=1S/C17H19ClN2O3/c18-14-3-1-2-13(8-14)11-23-15-6-4-12(5-7-15)9-20-16(10-21)17(19)22/h1-8,16,20-21H,9-11H2,(H2,19,22)/t16-/m1/s1
DMEVM6G	CS	C1=CC(=CC(=C1)Cl)COC2=CC=C(C=C2)CN[C@H](CO)C(=O)N
DMEVM6G	IK	WYDCYPPIJUASJE-MRXNPFEDSA-N
DMEVM6G	IU	(2R)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide
DMEVM6G	DE	Discovery agent

DMU49JN	ID	DMU49JN
DMU49JN	DN	(R)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide
DMU49JN	HS	Investigative
DMU49JN	SN	CHEMBL82327; 174756-44-6; (R)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide; AC1NUPG0; SCHEMBL194169; CHEBI:94774; BDBM50080950; ZINC26506755; AKOS030631890; AN-31998; BRD-K84639753-066-01-9; (R)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide
DMU49JN	DT	Small molecular drug
DMU49JN	PC	5487407
DMU49JN	MW	302.34
DMU49JN	FM	C17H19FN2O2
DMU49JN	IC	InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m1/s1
DMU49JN	CS	C[C@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F
DMU49JN	IK	NEMGRZFTLSKBAP-GFCCVEGCSA-N
DMU49JN	IU	(2R)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DMU49JN	CB	CHEBI:94774
DMU49JN	DE	Discovery agent

DMM8TE0	ID	DMM8TE0
DMM8TE0	DN	(R)-N-benzyl-4-(pyrrolidin-2-ylmethoxy)aniline
DMM8TE0	HS	Investigative
DMM8TE0	SN	N-Benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline; N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline; CHEMBL570775; SCHEMBL4314176; HITMFLNAOQIZSN-QGZVFWFLSA-N; BDBM50294163; DB07260
DMM8TE0	DT	Small molecular drug
DMM8TE0	PC	44129620
DMM8TE0	MW	282.4
DMM8TE0	FM	C18H22N2O
DMM8TE0	IC	InChI=1S/C18H22N2O/c1-2-5-15(6-3-1)13-20-16-8-10-18(11-9-16)21-14-17-7-4-12-19-17/h1-3,5-6,8-11,17,19-20H,4,7,12-14H2/t17-/m1/s1
DMM8TE0	CS	C1C[C@@H](NC1)COC2=CC=C(C=C2)NCC3=CC=CC=C3
DMM8TE0	IK	HITMFLNAOQIZSN-QGZVFWFLSA-N
DMM8TE0	IU	N-benzyl-4-[[(2R)-pyrrolidin-2-yl]methoxy]aniline
DMM8TE0	DE	Discovery agent

DMWRIQG	ID	DMWRIQG
DMWRIQG	DN	(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide
DMWRIQG	HS	Investigative
DMWRIQG	SN	CHEMBL190266; ZINC5284667; UNII-O3LD16O96Z component BYPIURIATSUHDW-SNVBAGLBSA-N
DMWRIQG	DT	Small molecular drug
DMWRIQG	PC	11458696
DMWRIQG	MW	221.29
DMWRIQG	FM	C13H19NO2
DMWRIQG	IC	InChI=1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)/t10-/m1/s1
DMWRIQG	CS	C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NO
DMWRIQG	IK	BYPIURIATSUHDW-SNVBAGLBSA-N
DMWRIQG	IU	(2R)-N-hydroxy-2-[4-(2-methylpropyl)phenyl]propanamide
DMWRIQG	DE	Discovery agent

DMWGB40	ID	DMWGB40
DMWGB40	DN	(R)-nipecotic acid
DMWGB40	HS	Investigative
DMWGB40	SN	(R)-piperidine-3-carboxylic acid; 25137-00-2; (R)-(-)-Nipecotic acid; (3R)-piperidine-3-carboxylic acid; (R)-(-)-3-Piperidinecarboxylic acid; (-)-nipecotic acid; (3R)-nipecotic acid; (3R)-(-)-piperidine-3-carboxylic acid; D(-)-Nipecotic acid; r-(-)-3-piperidinecarboxylic acid; 3-Piperidinecarboxylic acid, (R)-; (R)-hexahydronicotinic acid; (R)-(-)-piperidine-3-carboxylic acid; (-)-hexahydronicotinic acid; (3R)-hexahydronicotinic acid; CHEMBL77575; (r)-3-piperidinecarboxylic acid
DMWGB40	DT	Small molecular drug
DMWGB40	PC	1796510
DMWGB40	MW	129.16
DMWGB40	FM	C6H11NO2
DMWGB40	IC	InChI=1S/C6H11NO2/c8-6(9)5-2-1-3-7-4-5/h5,7H,1-4H2,(H,8,9)/t5-/m1/s1
DMWGB40	CS	C1C[C@H](CNC1)C(=O)O
DMWGB40	IK	XJLSEXAGTJCILF-RXMQYKEDSA-N
DMWGB40	IU	(3R)-piperidine-3-carboxylic acid
DMWGB40	CA	CAS 25137-00-2
DMWGB40	CB	CHEBI:60120
DMWGB40	DE	Discovery agent

DMJFH97	ID	DMJFH97
DMJFH97	DN	(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMJFH97	HS	Investigative
DMJFH97	SN	CHEMBL577283; (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide; SCHEMBL6416013
DMJFH97	DT	Small molecular drug
DMJFH97	PC	11323940
DMJFH97	MW	296.4
DMJFH97	FM	C19H24N2O
DMJFH97	IC	InChI=1S/C19H24N2O/c1-14(2)13-21(18-9-10-20-12-18)19(22)17-8-7-15-5-3-4-6-16(15)11-17/h3-8,11,14,18,20H,9-10,12-13H2,1-2H3/t18-/m1/s1
DMJFH97	CS	CC(C)CN([C@@H]1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2
DMJFH97	IK	CEUJKSVEPJAVKD-GOSISDBHSA-N
DMJFH97	IU	N-(2-methylpropyl)-N-[(3R)-pyrrolidin-3-yl]naphthalene-2-carboxamide
DMJFH97	DE	Discovery agent

DMQIUOB	ID	DMQIUOB
DMQIUOB	DN	(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMQIUOB	HS	Investigative
DMQIUOB	SN	CHEMBL565639; (R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMQIUOB	DT	Small molecular drug
DMQIUOB	PC	45487774
DMQIUOB	MW	282.4
DMQIUOB	FM	C18H22N2O
DMQIUOB	IC	InChI=1S/C18H22N2O/c1-13(2)20(17-9-10-19-12-17)18(21)16-8-7-14-5-3-4-6-15(14)11-16/h3-8,11,13,17,19H,9-10,12H2,1-2H3/t17-/m1/s1
DMQIUOB	CS	CC(C)N([C@@H]1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2
DMQIUOB	IK	ZQHFQDYTXXQENI-QGZVFWFLSA-N
DMQIUOB	IU	N-propan-2-yl-N-[(3R)-pyrrolidin-3-yl]naphthalene-2-carboxamide
DMQIUOB	DE	Discovery agent

DMIHR14	ID	DMIHR14
DMIHR14	DN	(R)-N-oleoyltyrosinol
DMIHR14	HS	Investigative
DMIHR14	SN	(R)-N-oleoyltyrosinol; GTPL5720; 616884-63-0; ZINC95862771
DMIHR14	DT	Small molecular drug
DMIHR14	PC	73755147
DMIHR14	MW	431.7
DMIHR14	FM	C27H45NO3
DMIHR14	IC	InChI=1S/C27H45NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-27(31)28-25(23-29)22-24-18-20-26(30)21-19-24/h9-10,18-21,25,29-30H,2-8,11-17,22-23H2,1H3,(H,28,31)/b10-9+/t25-/m1/s1
DMIHR14	CS	CCCCCCCC/C=C/CCCCCCCC(=O)N[C@H](CC1=CC=C(C=C1)O)CO
DMIHR14	IK	ICDMLAQPOAVWNH-YHZGQTRVSA-N
DMIHR14	IU	(E)-N-[(2R)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide
DMIHR14	DE	Discovery agent

DMS30KU	ID	DMS30KU
DMS30KU	DN	(R)-Norfluoxetine
DMS30KU	HS	Investigative
DMS30KU	SN	130194-43-3; UNII-05UQ1299DN; (R)-3-Phenyl-3-(4-trifluoromethyl-phenoxy)-propylamine; CHEMBL446084; 05UQ1299DN; (R)-3-(4-Trifluoromethylphenoxy)-3-phenylpropylamine; Norfluoxetine, (R)-; (3r)-3-Phenyl-3-[4-(Trifluoromethyl)phenoxy]propan-1-Amine; R-Norfluoxetine; SCHEMBL3750512; CTK8E9557; MolPort-028-616-048; ZINC1645453; Benzenepropanamine, gamma-(4-(trifluoromethyl)phenoxy)-, (gammaR)-; BDBM50254791; 9049AH; AKOS027384575; NE64378; AJ-28674; RT-014016; FT-0673087; J-005760
DMS30KU	DT	Small molecular drug
DMS30KU	PC	9797657
DMS30KU	MW	295.3
DMS30KU	FM	C16H16F3NO
DMS30KU	IC	InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m1/s1
DMS30KU	CS	C1=CC=C(C=C1)[C@@H](CCN)OC2=CC=C(C=C2)C(F)(F)F
DMS30KU	IK	WIQRCHMSJFFONW-OAHLLOKOSA-N
DMS30KU	IU	(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
DMS30KU	CA	CAS 130194-43-3
DMS30KU	DE	Discovery agent

DMCYD8Q	ID	DMCYD8Q
DMCYD8Q	DN	(R)-ONDANSETRON
DMCYD8Q	HS	Investigative
DMCYD8Q	SN	Ondansetron, (3R)-; UNII-8KTH918W9P; CHEMBL428411; 8KTH918W9P; 99614-60-5; 3R-Ondansetron [MI]; Ondansetron (base and/or unspecified salts); AC1LDIAR; SCHEMBL848379; ZINC4448; DTXSID20244166; BDBM50241365; PDSP1_000036; PDSP2_000036; 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, (R)-; 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, (3R)-; UNII-4AF302ESOS component FELGMEQIXOGIFQ-CYBMUJFWSA-N
DMCYD8Q	DT	Small molecular drug
DMCYD8Q	PC	667538
DMCYD8Q	MW	293.4
DMCYD8Q	FM	C18H19N3O
DMCYD8Q	IC	InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3/t13-/m1/s1
DMCYD8Q	CS	CC1=NC=CN1C[C@H]2CCC3=C(C2=O)C4=CC=CC=C4N3C
DMCYD8Q	IK	FELGMEQIXOGIFQ-CYBMUJFWSA-N
DMCYD8Q	IU	(3R)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
DMCYD8Q	CA	CAS 99614-60-5
DMCYD8Q	DE	Discovery agent

DM03N5V	ID	DM03N5V
DM03N5V	DN	(R)PK-11195
DM03N5V	HS	Investigative
DM03N5V	SN	N-[(2r)-Butan-2-Yl]-1-(2-Chlorophenyl)-N-Methylisoquinoline-3-Carboxamide; CHEMBL416715; SCHEMBL3126094; ZINC3870481; BDBM50054139; (R)-PK11195; LS-85395; B6401; UNII-YNF83VN1RL component RAVIZVQZGXBOQO-CQSZACIVSA-N; (R)1-(2-Chloro-phenyl)-isoquinoline-3-carboxylic acid sec-butyl-methyl-amide
DM03N5V	DT	Small molecular drug
DM03N5V	PC	24839733
DM03N5V	MW	352.9
DM03N5V	FM	C21H21ClN2O
DM03N5V	IC	InChI=1S/C21H21ClN2O/c1-4-14(2)24(3)21(25)19-13-15-9-5-6-10-16(15)20(23-19)17-11-7-8-12-18(17)22/h5-14H,4H2,1-3H3/t14-/m1/s1
DM03N5V	CS	CC[C@@H](C)N(C)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC=CC=C3Cl
DM03N5V	IK	RAVIZVQZGXBOQO-CQSZACIVSA-N
DM03N5V	IU	N-[(2R)-butan-2-yl]-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide
DM03N5V	DE	Discovery agent

DM95Z4Q	ID	DM95Z4Q
DM95Z4Q	DN	(R)-Rolipram
DM95Z4Q	HS	Investigative
DM95Z4Q	SN	(R)-(-)-Rolipram; 85416-75-7; (R)-ROLIPRAM; (4R)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE; R-Rolipram; UNII-DPX51KUP08; DPX51KUP08; CHEMBL430893; CHEBI:40133; 1xmy; NCGC00016899-01; CAS-61413-54-5; Tocris-1349; Tocris-0905; Tocris-1350; PubChem18284; 1ro6; 3g4k; 1q9m; AC1L9LJS; Lopac-R-6520; SCHEMBL576805; ZINC4982; KS-00000QDB; MolPort-003-983-801; HMS3267P19; BCP14111
DM95Z4Q	DT	Small molecular drug
DM95Z4Q	PC	448055
DM95Z4Q	MW	275.34
DM95Z4Q	FM	C16H21NO3
DM95Z4Q	IC	InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)/t12-/m0/s1
DM95Z4Q	CS	COC1=C(C=C(C=C1)[C@H]2CC(=O)NC2)OC3CCCC3
DM95Z4Q	IK	HJORMJIFDVBMOB-LBPRGKRZSA-N
DM95Z4Q	IU	(4R)-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one
DM95Z4Q	CA	CAS 85416-75-7
DM95Z4Q	CB	CHEBI:40133
DM95Z4Q	DE	Discovery agent

DMV1IS8	ID	DMV1IS8
DMV1IS8	DN	(R)-sirtinol
DMV1IS8	HS	Investigative
DMV1IS8	DT	Small molecular drug
DMV1IS8	PC	1376646
DMV1IS8	MW	394.5
DMV1IS8	FM	C26H22N2O2
DMV1IS8	IC	InChI=1S/C26H22N2O2/c1-18(19-9-3-2-4-10-19)28-26(30)22-13-7-8-14-24(22)27-17-23-21-12-6-5-11-20(21)15-16-25(23)29/h2-18,29H,1H3,(H,28,30)/t18-/m1/s1
DMV1IS8	CS	C[C@H](C1=CC=CC=C1)NC(=O)C2=CC=CC=C2N=CC3=C(C=CC4=CC=CC=C43)O
DMV1IS8	IK	UXJFDYIHRJGPFS-GOSISDBHSA-N
DMV1IS8	IU	2-[(2-hydroxynaphthalen-1-yl)methylideneamino]-N-[(1R)-1-phenylethyl]benzamide
DMV1IS8	DE	Discovery agent

DMSFA2D	ID	DMSFA2D
DMSFA2D	DN	(R)-tacrine(10)-hupyridone
DMSFA2D	HS	Investigative
DMSFA2D	SN	(R)-TACRINE(10)-HUPYRIDONE; (5R)-5-{[10-(1,2,3,4-TETRAHYDROACRIDIN-9-YLAMINO)DECYL]AMINO}-5,6,7,8-TETRAHYDROQUINOLIN-2(1H)-ONE; A1E; 1zgb; AC1NS1ED; DB04614; (R)-N-9 -(1 ,2 ,3 ,4 -TETRAHYDROACRIDINYL)-N'-5 -[5 ,6 ,7 ,8 -TETRAHYDRO-2'(1'H)-QUINOLINONYL]-1,10-DIAMINODECANE; (5R)-5-[10-(1,2,3,4-Tetrahydroacridine-9-ylamino)decylamino]-1,2,5,6,7,8-hexahydroquinoline-2-one; (R)-N-9 -(1 ,2 ,3 ,4 -TETRAHYDROACRIDINYL)-N'-5 -[5 ,6 ,7 ,8 -TETRAHYDRO-2'(1'H)-QUINOLINONYL]-1,10-DIAMINODECANE; (R)-TACRINE(10)-HUPYRIDONE
DMSFA2D	DT	Small molecular drug
DMSFA2D	PC	5326966
DMSFA2D	MW	500.7
DMSFA2D	FM	C32H44N4O
DMSFA2D	IC	InChI=1S/C32H44N4O/c37-31-21-20-24-27(18-13-19-28(24)36-31)33-22-11-5-3-1-2-4-6-12-23-34-32-25-14-7-9-16-29(25)35-30-17-10-8-15-26(30)32/h7,9,14,16,20-21,27,33H,1-6,8,10-13,15,17-19,22-23H2,(H,34,35)(H,36,37)/t27-/m1/s1
DMSFA2D	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCCCCN[C@@H]4CCCC5=C4C=CC(=O)N5
DMSFA2D	IK	ROTFGKJJMRTWBD-HHHXNRCGSA-N
DMSFA2D	IU	(5R)-5-[10-(1,2,3,4-tetrahydroacridin-9-ylamino)decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMSFA2D	DE	Discovery agent

DMT6J51	ID	DMT6J51
DMT6J51	DN	(R)-zacopride
DMT6J51	HS	Investigative
DMT6J51	SN	CHEMBL27846; UNII-38126EQF7A; 38126EQF7A; ZACOPRIDE,S; r-zacopride; (R)ZACOPRIDE; (R)-(+)-Zacopride; ZINC848; GTPL2288; SCHEMBL5387843; BDBM50031475; PDSP2_001683; PDSP1_001700; UNII-9GN3OT4156 component FEROPKNOYKURCJ-ZDUSSCGKSA-N; 4-Amino-N-(R)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(8R)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide
DMT6J51	DT	Small molecular drug
DMT6J51	PC	9819593
DMT6J51	MW	309.79
DMT6J51	FM	C15H20ClN3O2
DMT6J51	IC	InChI=1S/C15H20ClN3O2/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20)/t13-/m0/s1
DMT6J51	CS	COC1=CC(=C(C=C1C(=O)N[C@H]2CN3CCC2CC3)Cl)N
DMT6J51	IK	FEROPKNOYKURCJ-ZDUSSCGKSA-N
DMT6J51	IU	4-amino-N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide
DMT6J51	CA	CAS 123441-85-0
DMT6J51	DE	Discovery agent

DMCW5A9	ID	DMCW5A9
DMCW5A9	DN	(R,)-2-(2-naphthamido)-5-phenylpent-4-enoic acid
DMCW5A9	HS	Investigative
DMCW5A9	SN	CHEMBL1090714; (2R,4E)-2-[(naphthalen-2-ylcarbonyl)amino]-5-phenylpent-4-enoic acid; (R,)-2-(2-naphthamido)-5-phenylpent-4-enoic acid; SCHEMBL16550527; SCHEMBL16550525; BDBM50314705
DMCW5A9	DT	Small molecular drug
DMCW5A9	PC	45100499
DMCW5A9	MW	345.4
DMCW5A9	FM	C22H19NO3
DMCW5A9	IC	InChI=1S/C22H19NO3/c24-21(19-14-13-17-10-4-5-11-18(17)15-19)23-20(22(25)26)12-6-9-16-7-2-1-3-8-16/h1-11,13-15,20H,12H2,(H,23,24)(H,25,26)/b9-6+/t20-/m1/s1
DMCW5A9	CS	C1=CC=C(C=C1)/C=C/C[C@H](C(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DMCW5A9	IK	OOTIJYFZZMIZHN-AQDCRGGLSA-N
DMCW5A9	IU	(E,2R)-2-(naphthalene-2-carbonylamino)-5-phenylpent-4-enoic acid
DMCW5A9	DE	Discovery agent

DM3FQYS	ID	DM3FQYS
DM3FQYS	DN	(R,R)-(-)-fenoterol
DM3FQYS	HS	Investigative
DM3FQYS	SN	UNII-5Z64M7W0JM; CHEMBL388570; 5Z64M7W0JM; R,R-Fenoterol; Fenoterol, R,R'-; Men 1191; Fenoterol [MI]; Fenoterol [INN]; (R,R)-Fenoterol; Fenoterol [USAN]; Fenoterol [VANDF]; Fenoterol [MART.]; (R,R')-Fenoterol; Fenoterol [WHO-DD]; AC1LEM52; 69421-37-0; SCHEMBL249376; ZINC57320; BDBM50213098; 130156-24-0; UNII-22M9P70OQ9 component LSLYOANBFKQKPT-DIFFPNOSSA-N; 5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DM3FQYS	DT	Small molecular drug
DM3FQYS	PC	688468
DM3FQYS	MW	303.35
DM3FQYS	FM	C17H21NO4
DM3FQYS	IC	InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3/t11-,17+/m1/s1
DM3FQYS	CS	C[C@H](CC1=CC=C(C=C1)O)NC[C@@H](C2=CC(=CC(=C2)O)O)O
DM3FQYS	IK	LSLYOANBFKQKPT-DIFFPNOSSA-N
DM3FQYS	IU	5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DM3FQYS	CA	CAS 69421-37-0
DM3FQYS	DE	Discovery agent

DMETQBI	ID	DMETQBI
DMETQBI	DN	(R,S)-(-)-fenoterol
DMETQBI	HS	Investigative
DMETQBI	SN	CHEMBL229476; (R,S)-(-)-fenoterol; (R,S)-Fenoterol; AC1LEM4Z; SCHEMBL9971022; ZINC57319; BDBM50213106; 5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DMETQBI	DT	Small molecular drug
DMETQBI	PC	688467
DMETQBI	MW	303.35
DMETQBI	FM	C17H21NO4
DMETQBI	IC	InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3/t11-,17-/m0/s1
DMETQBI	CS	C[C@@H](CC1=CC=C(C=C1)O)NC[C@@H](C2=CC(=CC(=C2)O)O)O
DMETQBI	IK	LSLYOANBFKQKPT-GTNSWQLSSA-N
DMETQBI	IU	5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DMETQBI	DE	Discovery agent

DMKZ4C6	ID	DMKZ4C6
DMKZ4C6	DN	(R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine
DMKZ4C6	HS	Investigative
DMKZ4C6	SN	CHEMBL276673; 1H-Indole-1-ethanamine, 5-bromo-alpha-methyl-; (R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine; SCHEMBL8959875; BDBM50321879; 169675-12-1
DMKZ4C6	DT	Small molecular drug
DMKZ4C6	PC	10753358
DMKZ4C6	MW	253.14
DMKZ4C6	FM	C11H13BrN2
DMKZ4C6	IC	InChI=1S/C11H13BrN2/c1-8(13)7-14-5-4-9-6-10(12)2-3-11(9)14/h2-6,8H,7,13H2,1H3
DMKZ4C6	CS	CC(CN1C=CC2=C1C=CC(=C2)Br)N
DMKZ4C6	IK	UOWVUNAMIYCETC-UHFFFAOYSA-N
DMKZ4C6	IU	1-(5-bromoindol-1-yl)propan-2-amine
DMKZ4C6	DE	Discovery agent

DMTZDAJ	ID	DMTZDAJ
DMTZDAJ	DN	(R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine
DMTZDAJ	HS	Investigative
DMTZDAJ	SN	CHEMBL328844; 1H-Indole-1-ethanamine, 5-chloro-alpha-methyl-; (R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine; SCHEMBL7092716; BDBM50321880; 169674-96-8
DMTZDAJ	DT	Small molecular drug
DMTZDAJ	PC	9855823
DMTZDAJ	MW	208.69
DMTZDAJ	FM	C11H13ClN2
DMTZDAJ	IC	InChI=1S/C11H13ClN2/c1-8(13)7-14-5-4-9-6-10(12)2-3-11(9)14/h2-6,8H,7,13H2,1H3
DMTZDAJ	CS	CC(CN1C=CC2=C1C=CC(=C2)Cl)N
DMTZDAJ	IK	XXCLNSYNUQMDML-UHFFFAOYSA-N
DMTZDAJ	IU	1-(5-chloroindol-1-yl)propan-2-amine
DMTZDAJ	DE	Discovery agent

DMAU1M5	ID	DMAU1M5
DMAU1M5	DN	(R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine
DMAU1M5	HS	Investigative
DMAU1M5	SN	CHEMBL96883; 1H-Indole-1-ethanamine, 5-fluoro-alpha-methyl-; (R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine; SCHEMBL7994160; BDBM50321881; 169674-98-0
DMAU1M5	DT	Small molecular drug
DMAU1M5	PC	9964324
DMAU1M5	MW	192.23
DMAU1M5	FM	C11H13FN2
DMAU1M5	IC	InChI=1S/C11H13FN2/c1-8(13)7-14-5-4-9-6-10(12)2-3-11(9)14/h2-6,8H,7,13H2,1H3
DMAU1M5	CS	CC(CN1C=CC2=C1C=CC(=C2)F)N
DMAU1M5	IK	DUUXOYARAAZWLV-UHFFFAOYSA-N
DMAU1M5	IU	1-(5-fluoroindol-1-yl)propan-2-amine
DMAU1M5	DE	Discovery agent

DMS2DI9	ID	DMS2DI9
DMS2DI9	DN	(R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine
DMS2DI9	HS	Investigative
DMS2DI9	SN	CHEMBL93850; (R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine; SCHEMBL9233990; BDBM50321882
DMS2DI9	DT	Small molecular drug
DMS2DI9	PC	10845306
DMS2DI9	MW	188.27
DMS2DI9	FM	C12H16N2
DMS2DI9	IC	InChI=1S/C12H16N2/c1-9-3-4-12-11(7-9)5-6-14(12)8-10(2)13/h3-7,10H,8,13H2,1-2H3
DMS2DI9	CS	CC1=CC2=C(C=C1)N(C=C2)CC(C)N
DMS2DI9	IK	WETMFNBRIOBNTK-UHFFFAOYSA-N
DMS2DI9	IU	1-(5-methylindol-1-yl)propan-2-amine
DMS2DI9	DE	Discovery agent

DM0YELX	ID	DM0YELX
DM0YELX	DN	(R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine
DM0YELX	HS	Investigative
DM0YELX	SN	1H-Indole-1-ethanamine, 6-fluoro-alpha-methyl-; CHEMBL92656; SCHEMBL8959596
DM0YELX	DT	Small molecular drug
DM0YELX	PC	10679289
DM0YELX	MW	192.23
DM0YELX	FM	C11H13FN2
DM0YELX	IC	InChI=1S/C11H13FN2/c1-8(13)7-14-5-4-9-2-3-10(12)6-11(9)14/h2-6,8H,7,13H2,1H3
DM0YELX	CS	CC(CN1C=CC2=C1C=C(C=C2)F)N
DM0YELX	IK	WZMZEXSQEAPONX-UHFFFAOYSA-N
DM0YELX	IU	1-(6-fluoroindol-1-yl)propan-2-amine
DM0YELX	DE	Discovery agent

DM7COSH	ID	DM7COSH
DM7COSH	DN	(R,S)-4-phosphonophenylglycine
DM7COSH	HS	Investigative
DM7COSH	SN	(RS)-PPG; 120667-15-4; 2-amino-2-(4-phosphonophenyl)acetic acid; CHEMBL277475; AC1ND7MS; (RS)PPG; (RS) PPG; C8H10NO5P; (RS)-4-Phosphonophenylglycine; GTPL1406; SCHEMBL9150881; CTK8F0597; (R,S)-4-PPG; MolPort-003-983-668; BN0429; BDBM50004881; AKOS015911887; Amino-(4-phosphono-phenyl)-acetic acid; NCGC00025051-02; RT-015313; V2034; Amino-(4-phosphono-phenyl)-acetic acid(RS-PPG); SR-01000597406; 667P154; L000025; SR-01000597406-1; J-004376
DM7COSH	DT	Small molecular drug
DM7COSH	PC	4545574
DM7COSH	MW	231.14
DM7COSH	FM	C8H10NO5P
DM7COSH	IC	InChI=1S/C8H10NO5P/c9-7(8(10)11)5-1-3-6(4-2-5)15(12,13)14/h1-4,7H,9H2,(H,10,11)(H2,12,13,14)
DM7COSH	CS	C1=CC(=CC=C1C(C(=O)O)N)P(=O)(O)O
DM7COSH	IK	JRQRKFDFHAPMGQ-UHFFFAOYSA-N
DM7COSH	IU	2-amino-2-(4-phosphonophenyl)acetic acid
DM7COSH	DE	Discovery agent

DMUG451	ID	DMUG451
DMUG451	DN	(R,S)-homoaromaline hydrochloride
DMUG451	HS	Investigative
DMUG451	SN	CHEMBL443953; (R,S)-Homoaromaline HCl
DMUG451	DT	Small molecular drug
DMUG451	PC	9851833
DMUG451	MW	608.7
DMUG451	FM	C37H40N2O6
DMUG451	IC	InChI=1S/C37H40N2O6/c1-38-14-12-24-19-31(42-4)33-21-27(24)28(38)17-23-8-11-30(41-3)32(18-23)44-26-9-6-22(7-10-26)16-29-35-25(13-15-39(29)2)20-34(43-5)36(40)37(35)45-33/h6-11,18-21,28-29,40H,12-17H2,1-5H3/t28-,29+/m0/s1
DMUG451	CS	CN1CCC2=CC(=C(C3=C2[C@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=CC(=C(C=C7CCN6C)OC)O3)OC)O)OC
DMUG451	IK	YJRWQNIRFXVBRB-URLMMPGGSA-N
DMUG451	IU	(1S,14R)-6,20,25-trimethoxy-15,30-dimethyl-8,23-dioxa-15,30-diazaheptacyclo[22.6.2.29,12.13,7.114,18.027,31.022,33]hexatriaconta-3(36),4,6,9(35),10,12(34),18,20,22(33),24,26,31-dodecaen-21-ol
DMUG451	DE	Discovery agent

DMPDO43	ID	DMPDO43
DMPDO43	DN	(R,S)-N-(R-phenylethyl)-1H-pyrrole-2-carboxamide
DMPDO43	HS	Investigative
DMPDO43	SN	N-(1-phenylethyl)-1H-pyrrole-2-carboxamide; pyrrole inhibitor 24; AC1MOG77; (R,S)-N-(R-phenylethyl)-1H-pyrrole-2-carboxamide; CHEMBL373648; SCHEMBL15771458; BDBM15599
DMPDO43	DT	Small molecular drug
DMPDO43	PC	3343155
DMPDO43	MW	214.26
DMPDO43	FM	C13H14N2O
DMPDO43	IC	InChI=1S/C13H14N2O/c1-10(11-6-3-2-4-7-11)15-13(16)12-8-5-9-14-12/h2-10,14H,1H3,(H,15,16)
DMPDO43	CS	CC(C1=CC=CC=C1)NC(=O)C2=CC=CN2
DMPDO43	IK	ZCDCLWRYDWKALM-UHFFFAOYSA-N
DMPDO43	IU	N-(1-phenylethyl)-1H-pyrrole-2-carboxamide
DMPDO43	DE	Discovery agent

DMQO71C	ID	DMQO71C
DMQO71C	DN	(R,S)-PHPNECA
DMQO71C	HS	Investigative
DMQO71C	SN	(R,S)-2-phenylhydroxypropynyl-NECA; 2-(3-hydroxy-3-phenyl)propyn-1-yladenosine-5'-N-ethyluronamide
DMQO71C	DT	Small molecular drug
DMQO71C	PC	91827339
DMQO71C	MW	438.4
DMQO71C	FM	C21H22N6O5
DMQO71C	IC	InChI=1S/C21H22N6O5/c1-2-23-20(31)17-15(29)16(30)21(32-17)27-10-24-14-18(22)25-13(26-19(14)27)9-8-12(28)11-6-4-3-5-7-11/h3-7,10,12,15-17,21,28-30H,2H2,1H3,(H,23,31)(H2,22,25,26)/t12?,15-,16+,17+,21-/m1/s1
DMQO71C	CS	CCNC(=O)[C@@H]1[C@@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)C#CC(C4=CC=CC=C4)O)N)O)O
DMQO71C	IK	WOAZCBPWCCREDO-CERUIEQFSA-N
DMQO71C	IU	(2S,3R,4S,5R)-5-[6-amino-2-(3-hydroxy-3-phenylprop-1-ynyl)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
DMQO71C	DE	Discovery agent

DM8I6MG	ID	DM8I6MG
DM8I6MG	DN	(R/R)BEFLOXATONE
DM8I6MG	HS	Investigative
DM8I6MG	SN	CHEMBL18101; (R/R)BEFLOXATONE; SCHEMBL9463614; BDBM50110715
DM8I6MG	DT	Small molecular drug
DM8I6MG	PC	18646248
DM8I6MG	MW	349.3
DM8I6MG	FM	C15H18F3NO5
DM8I6MG	IC	InChI=1S/C15H18F3NO5/c1-22-9-12-8-19(14(21)24-12)10-2-4-11(5-3-10)23-7-6-13(20)15(16,17)18/h2-5,12-13,20H,6-9H2,1H3/t12-,13-/m0/s1
DM8I6MG	CS	COC[C@@H]1CN(C(=O)O1)C2=CC=C(C=C2)OCC[C@@H](C(F)(F)F)O
DM8I6MG	IK	IALVDLPLCLFBCF-STQMWFEESA-N
DM8I6MG	IU	(5S)-5-(methoxymethyl)-3-[4-[(3S)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-1,3-oxazolidin-2-one
DM8I6MG	DE	Discovery agent

DMYDG27	ID	DMYDG27
DMYDG27	DN	(R/S) EF-1500
DMYDG27	HS	Investigative
DMYDG27	SN	(R/S) EF-1500; GTPL4583
DMYDG27	DT	Small molecular drug
DMYDG27	PC	53319290
DMYDG27	MW	400.6
DMYDG27	FM	C21H24N2O2S2
DMYDG27	IC	InChI=1S/C21H24N2O2S2/c1-13-8-11-26-19(13)15(20-14(2)9-12-27-20)5-4-10-22-16-6-3-7-17-18(16)21(24)23-25-17/h5,8-9,11-12,16,22H,3-4,6-7,10H2,1-2H3,(H,23,24)
DMYDG27	CS	CC1=C(SC=C1)C(=CCCNC2CCCC3=C2C(=O)NO3)C4=C(C=CS4)C
DMYDG27	IK	TYXWOLAOXRISSO-UHFFFAOYSA-N
DMYDG27	IU	4-[4,4-bis(3-methylthiophen-2-yl)but-3-enylamino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-one
DMYDG27	DE	Discovery agent

DM3MEQB	ID	DM3MEQB
DM3MEQB	DN	(R/S)-2-((4-benzylphenoxy)methyl)piperazine
DM3MEQB	HS	Investigative
DM3MEQB	SN	CHEMBL1098820; (R/S)-2-((4-benzylphenoxy)methyl)piperazine
DM3MEQB	DT	Small molecular drug
DM3MEQB	PC	46888243
DM3MEQB	MW	282.4
DM3MEQB	FM	C18H22N2O
DM3MEQB	IC	InChI=1S/C18H22N2O/c1-2-4-15(5-3-1)12-16-6-8-18(9-7-16)21-14-17-13-19-10-11-20-17/h1-9,17,19-20H,10-14H2
DM3MEQB	CS	C1CNC(CN1)COC2=CC=C(C=C2)CC3=CC=CC=C3
DM3MEQB	IK	NQEDMJQVVYPBBZ-UHFFFAOYSA-N
DM3MEQB	IU	2-[(4-benzylphenoxy)methyl]piperazine
DM3MEQB	DE	Discovery agent

DMRXD82	ID	DMRXD82
DMRXD82	DN	(R/S)-2-((4-benzylphenoxy)methyl)piperidine
DMRXD82	HS	Investigative
DMRXD82	SN	CHEMBL1098351; (R/S)-2-((4-benzylphenoxy)methyl)piperidine; SCHEMBL7332735; BDBM50317491
DMRXD82	DT	Small molecular drug
DMRXD82	PC	46888070
DMRXD82	MW	281.4
DMRXD82	FM	C19H23NO
DMRXD82	IC	InChI=1S/C19H23NO/c1-2-6-16(7-3-1)14-17-9-11-19(12-10-17)21-15-18-8-4-5-13-20-18/h1-3,6-7,9-12,18,20H,4-5,8,13-15H2
DMRXD82	CS	C1CCNC(C1)COC2=CC=C(C=C2)CC3=CC=CC=C3
DMRXD82	IK	YZRAMLLKPOGYCE-UHFFFAOYSA-N
DMRXD82	IU	2-[(4-benzylphenoxy)methyl]piperidine
DMRXD82	DE	Discovery agent

DMDA285	ID	DMDA285
DMDA285	DN	(R/S)-2-((4-phenoxyphenoxy)methyl)piperidine
DMDA285	HS	Investigative
DMDA285	SN	CHEMBL1097151; (R/S)-2-((4-phenoxyphenoxy)methyl)piperidine; SCHEMBL13809108; BDBM50317492
DMDA285	DT	Small molecular drug
DMDA285	PC	45253769
DMDA285	MW	283.4
DMDA285	FM	C18H21NO2
DMDA285	IC	InChI=1S/C18H21NO2/c1-2-7-17(8-3-1)21-18-11-9-16(10-12-18)20-14-15-6-4-5-13-19-15/h1-3,7-12,15,19H,4-6,13-14H2
DMDA285	CS	C1CCNC(C1)COC2=CC=C(C=C2)OC3=CC=CC=C3
DMDA285	IK	CSJNBXMUZIPBKQ-UHFFFAOYSA-N
DMDA285	IU	2-[(4-phenoxyphenoxy)methyl]piperidine
DMDA285	DE	Discovery agent

DMYZCRF	ID	DMYZCRF
DMYZCRF	DN	(RS)-(tetrazol-5-yl)glycine
DMYZCRF	HS	Investigative
DMYZCRF	SN	(RS)-(tetrazol-5-yl)glycine; 138199-51-6; Tet-glycine; Tetrazol-5-yl-gly; 5-Tetrazolyl-glycine; (Tetrazol-5-yl)glycine; Tetrazolylglycine; 2-amino-2-(1H-1,2,3,4-tetrazol-5-yl)acetic acid; 2-amino-2-(2H-tetrazol-5-yl)acetic acid; CHEBI:35003; alpha-tetrazolylglycine; LY 285 265; Biomol-NT_000191; C13738; AC1L2Q8Q; GTPL4068; BPBio1_001214; CHEMBL140784; SCHEMBL10231795; MolPort-023-275-877; HMS3266G07; AKOS006272482; AKOS024048687; NCGC00024531-02; RT-015857; 2-amino-2-(1H-tetrazol-5-yl)acetic acid; T-205
DMYZCRF	DT	Small molecular drug
DMYZCRF	PC	126383
DMYZCRF	MW	143.1
DMYZCRF	FM	C3H5N5O2
DMYZCRF	IC	InChI=1S/C3H5N5O2/c4-1(3(9)10)2-5-7-8-6-2/h1H,4H2,(H,9,10)(H,5,6,7,8)
DMYZCRF	CS	C1(=NNN=N1)C(C(=O)O)N
DMYZCRF	IK	UKBRUIZWQZHXFL-UHFFFAOYSA-N
DMYZCRF	IU	2-amino-2-(2H-tetrazol-5-yl)acetic acid
DMYZCRF	CA	CAS 138199-51-6
DMYZCRF	CB	CHEBI:35003
DMYZCRF	DE	Discovery agent

DMCPEBF	ID	DMCPEBF
DMCPEBF	DN	(RS)-5-diphosphomevalonate
DMCPEBF	HS	Investigative
DMCPEBF	SN	5-Diphosphomevalonic acid; (RS)-5-diphosphomevalonate; AC1L19ES; AC1Q6T4D; SCHEMBL183248; GTPL3055; CTK0I1968; 3-hydroxy-5-{[hydroxy(phosphonooxy)phosphoryl]oxy}-3-methylpentans; 1492-08-6; 4872-34-8; 5-(Phosphonooxyphosphonyloxy)-3-hydroxy-3-methylpentanoic acid; 3-hydroxy-5-(hydroxy-phosphonooxyphosphoryl)oxy-3-methylpentanoic acid; 3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid; 6,8-Dioxa-7,9-diphosphanonanoicacid, 3,7,9,9-tetrahydroxy-3-methyl-, 7,9-dioxide
DMCPEBF	DT	Small molecular drug
DMCPEBF	PC	516
DMCPEBF	MW	308.12
DMCPEBF	FM	C6H14O10P2
DMCPEBF	IC	InChI=1S/C6H14O10P2/c1-6(9,4-5(7)8)2-3-15-18(13,14)16-17(10,11)12/h9H,2-4H2,1H3,(H,7,8)(H,13,14)(H2,10,11,12)
DMCPEBF	CS	CC(CCOP(=O)(O)OP(=O)(O)O)(CC(=O)O)O
DMCPEBF	IK	SIGQQUBJQXSAMW-UHFFFAOYSA-N
DMCPEBF	IU	3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid
DMCPEBF	CA	CAS 1492-08-6
DMCPEBF	DE	Discovery agent

DMA8DEG	ID	DMA8DEG
DMA8DEG	DN	(RS)-PPCC
DMA8DEG	HS	Investigative
DMA8DEG	SN	CHEMBL222301; (RS)-PPCC; GTPL6676; SCHEMBL18261107; BDBM50206578; methyl 2-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl)cyclopropane-1-carboxylate; methyl (1R,2S/1S,2R)-2-[(4-hydroxy-4-phenylpiperidin-1-yl)-methyl]-1-(4-methylphenyl)cyclopropanecarboxylate
DMA8DEG	DT	Small molecular drug
DMA8DEG	PC	16726095
DMA8DEG	MW	379.5
DMA8DEG	FM	C24H29NO3
DMA8DEG	IC	InChI=1S/C24H29NO3/c1-18-8-10-20(11-9-18)24(22(26)28-2)16-21(24)17-25-14-12-23(27,13-15-25)19-6-4-3-5-7-19/h3-11,21,27H,12-17H2,1-2H3
DMA8DEG	CS	CC1=CC=C(C=C1)C2(CC2CN3CCC(CC3)(C4=CC=CC=C4)O)C(=O)OC
DMA8DEG	IK	BDSYECBSUUOPCT-UHFFFAOYSA-N
DMA8DEG	IU	methyl 2-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl)cyclopropane-1-carboxylate
DMA8DEG	DE	Discovery agent

DMCN6WR	ID	DMCN6WR
DMCN6WR	DN	(RS)-tacrine(10)-hupyridone
DMCN6WR	HS	Investigative
DMCN6WR	SN	(RS)-tacrine(10)-hupyridone; CHEMBL76658; BDBM50080157
DMCN6WR	DT	Small molecular drug
DMCN6WR	PC	10028957
DMCN6WR	MW	500.7
DMCN6WR	FM	C32H44N4O
DMCN6WR	IC	InChI=1S/C32H44N4O/c37-31-21-20-24-27(18-13-19-28(24)36-31)33-22-11-5-3-1-2-4-6-12-23-34-32-25-14-7-9-16-29(25)35-30-17-10-8-15-26(30)32/h7,9,14,16,20-21,27,33H,1-6,8,10-13,15,17-19,22-23H2,(H,34,35)(H,36,37)
DMCN6WR	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCCCCNC4CCCC5=C4C=CC(=O)N5
DMCN6WR	IK	ROTFGKJJMRTWBD-UHFFFAOYSA-N
DMCN6WR	IU	5-[10-(1,2,3,4-tetrahydroacridin-9-ylamino)decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMCN6WR	DE	Discovery agent

DM6EYQ2	ID	DM6EYQ2
DM6EYQ2	DN	(RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidine
DM6EYQ2	HS	Investigative
DM6EYQ2	SN	CHEMBL219649; (RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidine; BDBM50202396
DM6EYQ2	DT	Small molecular drug
DM6EYQ2	PC	16102764
DM6EYQ2	MW	286.2
DM6EYQ2	FM	C15H21Cl2N
DM6EYQ2	IC	InChI=1S/C15H21Cl2N/c1-2-5-12(15-6-3-4-9-18-15)11-7-8-13(16)14(17)10-11/h7-8,10,12,15,18H,2-6,9H2,1H3
DM6EYQ2	CS	CCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl
DM6EYQ2	IK	USGRALLMTYXJMV-UHFFFAOYSA-N
DM6EYQ2	IU	2-[1-(3,4-dichlorophenyl)butyl]piperidine
DM6EYQ2	DE	Discovery agent

DMGHWJ5	ID	DMGHWJ5
DMGHWJ5	DN	(RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidine
DMGHWJ5	HS	Investigative
DMGHWJ5	SN	CHEMBL218847; (RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidine
DMGHWJ5	DT	Small molecular drug
DMGHWJ5	PC	16102751
DMGHWJ5	MW	251.79
DMGHWJ5	FM	C15H22ClN
DMGHWJ5	IC	InChI=1S/C15H22ClN/c1-2-5-14(15-6-3-4-11-17-15)12-7-9-13(16)10-8-12/h7-10,14-15,17H,2-6,11H2,1H3
DMGHWJ5	CS	CCCC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMGHWJ5	IK	OICPVJMMZDEJMO-UHFFFAOYSA-N
DMGHWJ5	IU	2-[1-(4-chlorophenyl)butyl]piperidine
DMGHWJ5	DE	Discovery agent

DMAIGM2	ID	DMAIGM2
DMAIGM2	DN	(RS/SR)-2-[1-(4-chlorophenyl)ethyl]piperidine
DMAIGM2	HS	Investigative
DMAIGM2	SN	CHEMBL219224; (RS/SR)-2-[1-(4-chlorophenyl)ethyl]piperidine; BDBM50202385
DMAIGM2	DT	Small molecular drug
DMAIGM2	PC	16102749
DMAIGM2	MW	223.74
DMAIGM2	FM	C13H18ClN
DMAIGM2	IC	InChI=1S/C13H18ClN/c1-10(13-4-2-3-9-15-13)11-5-7-12(14)8-6-11/h5-8,10,13,15H,2-4,9H2,1H3
DMAIGM2	CS	CC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMAIGM2	IK	BMRJUXFHOOHDBF-UHFFFAOYSA-N
DMAIGM2	IU	2-[1-(4-chlorophenyl)ethyl]piperidine
DMAIGM2	DE	Discovery agent

DMDVMSP	ID	DMDVMSP
DMDVMSP	DN	(RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidine
DMDVMSP	HS	Investigative
DMDVMSP	SN	CHEMBL219703; (RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidine; BDBM50202394
DMDVMSP	DT	Small molecular drug
DMDVMSP	PC	16102754
DMDVMSP	MW	279.8
DMDVMSP	FM	C17H26ClN
DMDVMSP	IC	InChI=1S/C17H26ClN/c1-2-3-4-7-16(17-8-5-6-13-19-17)14-9-11-15(18)12-10-14/h9-12,16-17,19H,2-8,13H2,1H3
DMDVMSP	CS	CCCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMDVMSP	IK	PAZWPXLTYQROKI-UHFFFAOYSA-N
DMDVMSP	IU	2-[1-(4-chlorophenyl)hexyl]piperidine
DMDVMSP	DE	Discovery agent

DMMUV7R	ID	DMMUV7R
DMMUV7R	DN	(RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidine
DMMUV7R	HS	Investigative
DMMUV7R	SN	CHEMBL218849; (RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidine; BDBM50202388
DMMUV7R	DT	Small molecular drug
DMMUV7R	PC	16102753
DMMUV7R	MW	265.82
DMMUV7R	FM	C16H24ClN
DMMUV7R	IC	InChI=1S/C16H24ClN/c1-2-3-6-15(16-7-4-5-12-18-16)13-8-10-14(17)11-9-13/h8-11,15-16,18H,2-7,12H2,1H3
DMMUV7R	CS	CCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMMUV7R	IK	ZYPXTTXHMBCKFT-UHFFFAOYSA-N
DMMUV7R	IU	2-[1-(4-chlorophenyl)pentyl]piperidine
DMMUV7R	DE	Discovery agent

DMPQAGL	ID	DMPQAGL
DMPQAGL	DN	(RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidine
DMPQAGL	HS	Investigative
DMPQAGL	SN	CHEMBL376852; (RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidine; BDBM50202382
DMPQAGL	DT	Small molecular drug
DMPQAGL	PC	16102750
DMPQAGL	MW	237.77
DMPQAGL	FM	C14H20ClN
DMPQAGL	IC	InChI=1S/C14H20ClN/c1-2-13(14-5-3-4-10-16-14)11-6-8-12(15)9-7-11/h6-9,13-14,16H,2-5,10H2,1H3
DMPQAGL	CS	CCC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMPQAGL	IK	CJUVIUZOUUBMJB-UHFFFAOYSA-N
DMPQAGL	IU	2-[1-(4-chlorophenyl)propyl]piperidine
DMPQAGL	DE	Discovery agent

DML1GP5	ID	DML1GP5
DML1GP5	DN	(S-(2-oxo)pentadecyl-CoA)
DML1GP5	HS	Investigative
DML1GP5	SN	CHEMBL448516; Coenzyme A, S-(2-oxopentadecyl)-; (S-(2-oxo)pentadecyl-CoA); 121124-66-1; NSC618486; AC1L9QGK; S-(2-Oxopentadecyl) CoA; S-2-Ketopentadecyl Coenzyme A, Sodium Salt; BDBM50270015; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-[2-(2-oxopentadecylsulfanyl)ethylamino]propyl]amino]butyl] hydrogen phosphate
DML1GP5	DT	Small molecular drug
DML1GP5	PC	452663
DML1GP5	MW	991.9
DML1GP5	FM	C36H64N7O17P3S
DML1GP5	IC	InChI=1S/C36H64N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-25(44)21-64-19-18-38-27(45)16-17-39-34(48)31(47)36(2,3)22-57-63(54,55)60-62(52,53)56-20-26-30(59-61(49,50)51)29(46)35(58-26)43-24-42-28-32(37)40-23-41-33(28)43/h23-24,26,29-31,35,46-47H,4-22H2,1-3H3,(H,38,45)(H,39,48)(H,52,53)(H,54,55)(H2,37,40,41)(H2,49,50,51)/t26-,29-,30-,31?,35-/m1/s1
DML1GP5	CS	CCCCCCCCCCCCCC(=O)CSCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DML1GP5	IK	JKWHUJMJVNMKEF-DJEJIMQCSA-N
DML1GP5	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-[2-(2-oxopentadecylsulfanyl)ethylamino]propyl]amino]butyl] hydrogen phosphate
DML1GP5	DE	Discovery agent

DMUNQY7	ID	DMUNQY7
DMUNQY7	DN	(S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine
DMUNQY7	HS	Investigative
DMUNQY7	SN	CHEMBL211301; 890309-58-7; (S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine; CTK2I1397; DTXSID10467882; ZINC35569548; BDBM50190614; 1H-Indene-1-methanamine, 2,3-dihydro-4,5,6-trimethoxy-, (1S)-
DMUNQY7	DT	Small molecular drug
DMUNQY7	PC	11514605
DMUNQY7	MW	237.29
DMUNQY7	FM	C13H19NO3
DMUNQY7	IC	InChI=1S/C13H19NO3/c1-15-11-6-10-8(7-14)4-5-9(10)12(16-2)13(11)17-3/h6,8H,4-5,7,14H2,1-3H3/t8-/m1/s1
DMUNQY7	CS	COC1=C(C(=C2CC[C@@H](C2=C1)CN)OC)OC
DMUNQY7	IK	AFTIZGHFDCOQFS-MRVPVSSYSA-N
DMUNQY7	IU	[(1S)-4,5,6-trimethoxy-2,3-dihydro-1H-inden-1-yl]methanamine
DMUNQY7	CA	CAS 890309-58-7
DMUNQY7	DE	Discovery agent

DMC5Z2I	ID	DMC5Z2I
DMC5Z2I	DN	(S)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DMC5Z2I	HS	Investigative
DMC5Z2I	SN	CHEMBL598096; (S)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DMC5Z2I	DT	Small molecular drug
DMC5Z2I	PC	46232145
DMC5Z2I	MW	272.27
DMC5Z2I	FM	C16H13FO3
DMC5Z2I	IC	InChI=1S/C16H13FO3/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-8,15H,9H2,1H3/t15-/m0/s1
DMC5Z2I	CS	COC1=CC2=C(C=C1)C(=O)C[C@H](O2)C3=CC=C(C=C3)F
DMC5Z2I	IK	LIINIWOYEGBFDA-HNNXBMFYSA-N
DMC5Z2I	IU	(2S)-2-(4-fluorophenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMC5Z2I	DE	Discovery agent

DMILWE7	ID	DMILWE7
DMILWE7	DN	(S)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DMILWE7	HS	Investigative
DMILWE7	SN	CHEMBL601843; (S)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DMILWE7	DT	Small molecular drug
DMILWE7	PC	46232078
DMILWE7	MW	260.23
DMILWE7	FM	C15H10F2O2
DMILWE7	IC	InChI=1S/C15H10F2O2/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14H,8H2/t14-/m0/s1
DMILWE7	CS	C1[C@H](OC2=C(C1=O)C=CC(=C2)F)C3=CC=C(C=C3)F
DMILWE7	IK	YKJLGNVYFBPKJK-AWEZNQCLSA-N
DMILWE7	IU	(2S)-7-fluoro-2-(4-fluorophenyl)-2,3-dihydrochromen-4-one
DMILWE7	DE	Discovery agent

DMHR1IB	ID	DMHR1IB
DMHR1IB	DN	(S)(+)-7-fluoro-2-phenylchroman-4-one
DMHR1IB	HS	Investigative
DMHR1IB	SN	CHEMBL592764; (S)(+)-7-fluoro-2-phenylchroman-4-one
DMHR1IB	DT	Small molecular drug
DMHR1IB	PC	46232076
DMHR1IB	MW	242.24
DMHR1IB	FM	C15H11FO2
DMHR1IB	IC	InChI=1S/C15H11FO2/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14H,9H2/t14-/m0/s1
DMHR1IB	CS	C1[C@H](OC2=C(C1=O)C=CC(=C2)F)C3=CC=CC=C3
DMHR1IB	IK	SZNYRENOXQIQMR-AWEZNQCLSA-N
DMHR1IB	IU	(2S)-7-fluoro-2-phenyl-2,3-dihydrochromen-4-one
DMHR1IB	DE	Discovery agent

DMTFZBQ	ID	DMTFZBQ
DMTFZBQ	DN	(S)(+)-7-fluoro-2-p-tolylchroman-4-one
DMTFZBQ	HS	Investigative
DMTFZBQ	SN	CHEMBL597472; (S)(+)-7-fluoro-2-p-tolylchroman-4-one
DMTFZBQ	DT	Small molecular drug
DMTFZBQ	PC	46232080
DMTFZBQ	MW	256.269
DMTFZBQ	FM	C16H13FO2
DMTFZBQ	IC	InChI=1S/C16H13FO2/c1-10-2-4-11(5-3-10)15-9-14(18)13-7-6-12(17)8-16(13)19-15/h2-8,15H,9H2,1H3/t15-/m0/s1
DMTFZBQ	CS	CC1=CC=C(C=C1)[C@@H]2CC(=O)C3=C(O2)C=C(C=C3)F
DMTFZBQ	IK	QNQXLNDULBVXEX-HNNXBMFYSA-N
DMTFZBQ	IU	(2S)-7-fluoro-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMTFZBQ	DE	Discovery agent

DMBG4KN	ID	DMBG4KN
DMBG4KN	DN	(S)(+)-7-methyl-2-phenylchroman-4-one
DMBG4KN	HS	Investigative
DMBG4KN	SN	CHEMBL601205; (S)(+)-7-methyl-2-phenylchroman-4-one
DMBG4KN	DT	Small molecular drug
DMBG4KN	PC	46232141
DMBG4KN	MW	238.28
DMBG4KN	FM	C16H14O2
DMBG4KN	IC	InChI=1S/C16H14O2/c1-11-7-8-13-14(17)10-15(18-16(13)9-11)12-5-3-2-4-6-12/h2-9,15H,10H2,1H3/t15-/m0/s1
DMBG4KN	CS	CC1=CC2=C(C=C1)C(=O)C[C@H](O2)C3=CC=CC=C3
DMBG4KN	IK	FNOKOVWLKVWYRY-HNNXBMFYSA-N
DMBG4KN	IU	(2S)-7-methyl-2-phenyl-2,3-dihydrochromen-4-one
DMBG4KN	DE	Discovery agent

DMVBD6H	ID	DMVBD6H
DMVBD6H	DN	(S)(+)-7-methyl-2-p-tolylchroman-4-one
DMVBD6H	HS	Investigative
DMVBD6H	SN	CHEMBL600384; (S)(+)-7-methyl-2-p-tolylchroman-4-one
DMVBD6H	DT	Small molecular drug
DMVBD6H	PC	46232143
DMVBD6H	MW	252.31
DMVBD6H	FM	C17H16O2
DMVBD6H	IC	InChI=1S/C17H16O2/c1-11-3-6-13(7-4-11)16-10-15(18)14-8-5-12(2)9-17(14)19-16/h3-9,16H,10H2,1-2H3/t16-/m0/s1
DMVBD6H	CS	CC1=CC=C(C=C1)[C@@H]2CC(=O)C3=C(O2)C=C(C=C3)C
DMVBD6H	IK	MIEPNGHJBCGJAW-INIZCTEOSA-N
DMVBD6H	IU	(2S)-7-methyl-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMVBD6H	DE	Discovery agent

DMPDOY8	ID	DMPDOY8
DMPDOY8	DN	(S)-(+)-CBPG
DMPDOY8	HS	Investigative
DMPDOY8	SN	CBPG; 3-[(S)-amino(carboxy)methyl]bicyclo[1.1.1]pentane-1-carboxylic acid; 180465-02-5; (S)-3-(amino(carboxy)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; CHEMBL43412; S-(+)-CBPG; EN300-88066; (S)-(+)-CBPG; AC1NSJVN; AC1Q4UAL; SCHEMBL1308145; GTPL3421; (R)-3-(amino(carboxy)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; CTK7I3432; MolPort-044-812-180; MolPort-005-313-665; ZINC1485767; BDBM50052256; AKOS026740795; FCH4013584; AS-44366; OR312475; CS-0078773; KS-00000111; (s)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine
DMPDOY8	DT	Small molecular drug
DMPDOY8	PC	5311040
DMPDOY8	MW	185.18
DMPDOY8	FM	C8H11NO4
DMPDOY8	IC	InChI=1S/C8H11NO4/c9-4(5(10)11)7-1-8(2-7,3-7)6(12)13/h4H,1-3,9H2,(H,10,11)(H,12,13)/t4-,7?,8?/m1/s1
DMPDOY8	CS	C1C2(CC1(C2)C(=O)O)[C@@H](C(=O)O)N
DMPDOY8	IK	KNSHLWJBSDBBRH-XOJFDHPMSA-N
DMPDOY8	IU	3-[(S)-amino(carboxy)methyl]bicyclo[1.1.1]pentane-1-carboxylic acid
DMPDOY8	DE	Discovery agent

DMF2IY8	ID	DMF2IY8
DMF2IY8	DN	(S)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea
DMF2IY8	HS	Investigative
DMF2IY8	SN	indazole antagonist, (S)-16b; CHEMBL231392; BDBM20406
DMF2IY8	DT	Small molecular drug
DMF2IY8	PC	24768210
DMF2IY8	MW	294.35
DMF2IY8	FM	C17H18N4O
DMF2IY8	IC	InChI=1S/C17H18N4O/c1-11-6-8-13(9-7-11)12(2)19-17(22)20-15-4-3-5-16-14(15)10-18-21-16/h3-10,12H,1-2H3,(H,18,21)(H2,19,20,22)/t12-/m0/s1
DMF2IY8	CS	CC1=CC=C(C=C1)[C@H](C)NC(=O)NC2=CC=CC3=C2C=NN3
DMF2IY8	IK	SHOUDGQMQHLAFL-LBPRGKRZSA-N
DMF2IY8	IU	1-(1H-indazol-4-yl)-3-[(1S)-1-(4-methylphenyl)ethyl]urea
DMF2IY8	DE	Discovery agent

DMF9YLR	ID	DMF9YLR
DMF9YLR	DN	(S)-1-(2-methoxyphenethyl)-2-methylpyrrolidine
DMF9YLR	HS	Investigative
DMF9YLR	SN	CHEMBL404912
DMF9YLR	DT	Small molecular drug
DMF9YLR	PC	44456094
DMF9YLR	MW	219.32
DMF9YLR	FM	C14H21NO
DMF9YLR	IC	InChI=1S/C14H21NO/c1-12-6-5-10-15(12)11-9-13-7-3-4-8-14(13)16-2/h3-4,7-8,12H,5-6,9-11H2,1-2H3/t12-/m0/s1
DMF9YLR	CS	C[C@H]1CCCN1CCC2=CC=CC=C2OC
DMF9YLR	IK	KDVUGYDZNTZESD-LBPRGKRZSA-N
DMF9YLR	IU	(2S)-1-[2-(2-methoxyphenyl)ethyl]-2-methylpyrrolidine
DMF9YLR	DE	Discovery agent

DM8UWT9	ID	DM8UWT9
DM8UWT9	DN	(S)-1-(3-methoxyphenethyl)-2-methylpyrrolidine
DM8UWT9	HS	Investigative
DM8UWT9	SN	CHEMBL272306
DM8UWT9	DT	Small molecular drug
DM8UWT9	PC	44456090
DM8UWT9	MW	219.32
DM8UWT9	FM	C14H21NO
DM8UWT9	IC	InChI=1S/C14H21NO/c1-12-5-4-9-15(12)10-8-13-6-3-7-14(11-13)16-2/h3,6-7,11-12H,4-5,8-10H2,1-2H3/t12-/m0/s1
DM8UWT9	CS	C[C@H]1CCCN1CCC2=CC(=CC=C2)OC
DM8UWT9	IK	INKHQVYBVMGBHD-LBPRGKRZSA-N
DM8UWT9	IU	(2S)-1-[2-(3-methoxyphenyl)ethyl]-2-methylpyrrolidine
DM8UWT9	DE	Discovery agent

DMDBHY1	ID	DMDBHY1
DMDBHY1	DN	(S)-1-(4-methoxyphenethyl)-2-methylpyrrolidine
DMDBHY1	HS	Investigative
DMDBHY1	SN	CHEMBL404532
DMDBHY1	DT	Small molecular drug
DMDBHY1	PC	44456055
DMDBHY1	MW	219.32
DMDBHY1	FM	C14H21NO
DMDBHY1	IC	InChI=1S/C14H21NO/c1-12-4-3-10-15(12)11-9-13-5-7-14(16-2)8-6-13/h5-8,12H,3-4,9-11H2,1-2H3/t12-/m0/s1
DMDBHY1	CS	C[C@H]1CCCN1CCC2=CC=C(C=C2)OC
DMDBHY1	IK	NPUSLESRSBDEHN-LBPRGKRZSA-N
DMDBHY1	IU	(2S)-1-[2-(4-methoxyphenyl)ethyl]-2-methylpyrrolidine
DMDBHY1	DE	Discovery agent

DMG7XL5	ID	DMG7XL5
DMG7XL5	DN	(S)-1-(4-nitrophenethyl)-2-methylpyrrolidine
DMG7XL5	HS	Investigative
DMG7XL5	SN	CHEMBL257235
DMG7XL5	DT	Small molecular drug
DMG7XL5	PC	44456366
DMG7XL5	MW	234.29
DMG7XL5	FM	C13H18N2O2
DMG7XL5	IC	InChI=1S/C13H18N2O2/c1-11-3-2-9-14(11)10-8-12-4-6-13(7-5-12)15(16)17/h4-7,11H,2-3,8-10H2,1H3/t11-/m0/s1
DMG7XL5	CS	C[C@H]1CCCN1CCC2=CC=C(C=C2)[N+](=O)[O-]
DMG7XL5	IK	PFZYNGPCNCRLFU-NSHDSACASA-N
DMG7XL5	IU	(2S)-2-methyl-1-[2-(4-nitrophenyl)ethyl]pyrrolidine
DMG7XL5	DE	Discovery agent

DMEIB8F	ID	DMEIB8F
DMEIB8F	DN	(S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine
DMEIB8F	HS	Investigative
DMEIB8F	SN	CHEMBL40726; SCHEMBL8959516; (S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine; BDBM50108306; (S)-1-(5,6-Difluoro-1H-indol-1-yl)-2-propanamine
DMEIB8F	DT	Small molecular drug
DMEIB8F	PC	10330734
DMEIB8F	MW	210.22
DMEIB8F	FM	C11H12F2N2
DMEIB8F	IC	InChI=1S/C11H12F2N2/c1-7(14)6-15-3-2-8-4-9(12)10(13)5-11(8)15/h2-5,7H,6,14H2,1H3/t7-/m0/s1
DMEIB8F	CS	C[C@@H](CN1C=CC2=CC(=C(C=C21)F)F)N
DMEIB8F	IK	MYZDBEVPJGKIQS-ZETCQYMHSA-N
DMEIB8F	IU	(2S)-1-(5,6-difluoroindol-1-yl)propan-2-amine
DMEIB8F	DE	Discovery agent

DM1U7MC	ID	DM1U7MC
DM1U7MC	DN	(S)-1,7-Diphenyl-6(E)-hepten-3-ol
DM1U7MC	HS	Investigative
DM1U7MC	SN	CHEMBL461017; (S)-1,7-Diphenyl-6(E)-hepten-3-ol; (S)-1,7-diphenylhept-6-en-3-ol; BDBM50300189; (3S,6E)-1,7-Diphenyl-6-heptene-3-ol
DM1U7MC	DT	Small molecular drug
DM1U7MC	PC	44560846
DM1U7MC	MW	266.4
DM1U7MC	FM	C19H22O
DM1U7MC	IC	InChI=1S/C19H22O/c20-19(16-15-18-11-5-2-6-12-18)14-8-7-13-17-9-3-1-4-10-17/h1-7,9-13,19-20H,8,14-16H2/b13-7+/t19-/m0/s1
DM1U7MC	CS	C1=CC=C(C=C1)CC[C@H](CC/C=C/C2=CC=CC=C2)O
DM1U7MC	IK	DPRCKWANIKZGTF-KRSRXSRCSA-N
DM1U7MC	IU	(E,3S)-1,7-diphenylhept-6-en-3-ol
DM1U7MC	DE	Discovery agent

DMICUQK	ID	DMICUQK
DMICUQK	DN	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate
DMICUQK	HS	Investigative
DMICUQK	SN	CHEMBL117658; 1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE; 2auz; (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate; BDBM50148292; DB07593; 1-benzylcyclopentyl [(1S)-1-formylpentyl]carbamate; 1-benzylcyclopentyl N-[(2S)-1-oxohexan-2-yl]carbamate; ((S)-1-Formyl-pentyl)-carbamic acid 1-benzyl-cyclopentyl ester
DMICUQK	DT	Small molecular drug
DMICUQK	PC	10062714
DMICUQK	MW	317.4
DMICUQK	FM	C19H27NO3
DMICUQK	IC	InChI=1S/C19H27NO3/c1-2-3-11-17(15-21)20-18(22)23-19(12-7-8-13-19)14-16-9-5-4-6-10-16/h4-6,9-10,15,17H,2-3,7-8,11-14H2,1H3,(H,20,22)/t17-/m0/s1
DMICUQK	CS	CCCC[C@@H](C=O)NC(=O)OC1(CCCC1)CC2=CC=CC=C2
DMICUQK	IK	ONABDOMWRCXLPX-KRWDZBQOSA-N
DMICUQK	IU	(1-benzylcyclopentyl) N-[(2S)-1-oxohexan-2-yl]carbamate
DMICUQK	DE	Discovery agent

DM2VOAS	ID	DM2VOAS
DM2VOAS	DN	(S)-2-((4-phenoxyphenoxy)methyl)piperidine
DM2VOAS	HS	Investigative
DM2VOAS	SN	CHEMBL1099182; (S)-2-((4-phenoxyphenoxy)methyl)piperidine; SCHEMBL13809079
DM2VOAS	DT	Small molecular drug
DM2VOAS	PC	29293599
DM2VOAS	MW	283.4
DM2VOAS	FM	C18H21NO2
DM2VOAS	IC	InChI=1S/C18H21NO2/c1-2-7-17(8-3-1)21-18-11-9-16(10-12-18)20-14-15-6-4-5-13-19-15/h1-3,7-12,15,19H,4-6,13-14H2/t15-/m0/s1
DM2VOAS	CS	C1CCN[C@@H](C1)COC2=CC=C(C=C2)OC3=CC=CC=C3
DM2VOAS	IK	CSJNBXMUZIPBKQ-HNNXBMFYSA-N
DM2VOAS	IU	(2S)-2-[(4-phenoxyphenoxy)methyl]piperidine
DM2VOAS	DE	Discovery agent

DMQGCKX	ID	DMQGCKX
DMQGCKX	DN	(S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol
DMQGCKX	HS	Investigative
DMQGCKX	SN	CHEMBL408617
DMQGCKX	DT	Small molecular drug
DMQGCKX	PC	44456332
DMQGCKX	MW	205.3
DMQGCKX	FM	C13H19NO
DMQGCKX	IC	InChI=1S/C13H19NO/c1-11-5-4-9-14(11)10-8-12-6-2-3-7-13(12)15/h2-3,6-7,11,15H,4-5,8-10H2,1H3/t11-/m0/s1
DMQGCKX	CS	C[C@H]1CCCN1CCC2=CC=CC=C2O
DMQGCKX	IK	XLLMSPMZEFQVLD-NSHDSACASA-N
DMQGCKX	IU	2-[2-[(2S)-2-methylpyrrolidin-1-yl]ethyl]phenol
DMQGCKX	DE	Discovery agent

DMVKL84	ID	DMVKL84
DMVKL84	DN	(S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DMVKL84	HS	Investigative
DMVKL84	SN	CHEMBL429740
DMVKL84	DT	Small molecular drug
DMVKL84	PC	44455952
DMVKL84	MW	190.28
DMVKL84	FM	C12H18N2
DMVKL84	IC	InChI=1S/C12H18N2/c1-11-5-4-9-14(11)10-7-12-6-2-3-8-13-12/h2-3,6,8,11H,4-5,7,9-10H2,1H3/t11-/m0/s1
DMVKL84	CS	C[C@H]1CCCN1CCC2=CC=CC=N2
DMVKL84	IK	ICWSPDRNRGQWAB-NSHDSACASA-N
DMVKL84	IU	2-[2-[(2S)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DMVKL84	DE	Discovery agent

DMPQ53V	ID	DMPQ53V
DMPQ53V	DN	(S)-2-amino-1-(4-butylthiophenyl)-propane
DMPQ53V	HS	Investigative
DMPQ53V	SN	CHEMBL387778; (S)-2-amino-1-(4-butylthiophenyl)-propane
DMPQ53V	DT	Small molecular drug
DMPQ53V	PC	23661626
DMPQ53V	MW	223.38
DMPQ53V	FM	C13H21NS
DMPQ53V	IC	InChI=1S/C13H21NS/c1-3-4-9-15-13-7-5-12(6-8-13)10-11(2)14/h5-8,11H,3-4,9-10,14H2,1-2H3/t11-/m0/s1
DMPQ53V	CS	CCCCSC1=CC=C(C=C1)C[C@H](C)N
DMPQ53V	IK	RRHFSAVFMIWFCE-NSHDSACASA-N
DMPQ53V	IU	(2S)-1-(4-butylsulfanylphenyl)propan-2-amine
DMPQ53V	DE	Discovery agent

DMFK7O1	ID	DMFK7O1
DMFK7O1	DN	(S)-2-amino-1-(4-ethylthiophenyl)-propane
DMFK7O1	HS	Investigative
DMFK7O1	SN	CHEMBL387777; (S)-2-amino-1-(4-ethylthiophenyl)-propane; BDBM50213676
DMFK7O1	DT	Small molecular drug
DMFK7O1	PC	44424447
DMFK7O1	MW	195.33
DMFK7O1	FM	C11H17NS
DMFK7O1	IC	InChI=1S/C11H17NS/c1-3-13-11-6-4-10(5-7-11)8-9(2)12/h4-7,9H,3,8,12H2,1-2H3/t9-/m0/s1
DMFK7O1	CS	CCSC1=CC=C(C=C1)C[C@H](C)N
DMFK7O1	IK	WOBAXWXQKSIHCH-VIFPVBQESA-N
DMFK7O1	IU	(2S)-1-(4-ethylsulfanylphenyl)propan-2-amine
DMFK7O1	DE	Discovery agent

DM06NUM	ID	DM06NUM
DM06NUM	DN	(S)-2-amino-1-(4-methylthiophenyl)-propane
DM06NUM	HS	Investigative
DM06NUM	SN	CHEMBL439193; (S)-2-amino-1-(4-methylthiophenyl)-propane; ZINC6021007; BDBM50213675; (S)-alpha-Methyl-4-methylthiobenzeneethanamine; UNII-6JP2T8KXTR component OLEWMKVPSUCNLG-QMMMGPOBSA-N
DM06NUM	DT	Small molecular drug
DM06NUM	PC	44424446
DM06NUM	MW	181.3
DM06NUM	FM	C10H15NS
DM06NUM	IC	InChI=1S/C10H15NS/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3/t8-/m0/s1
DM06NUM	CS	C[C@@H](CC1=CC=C(C=C1)SC)N
DM06NUM	IK	OLEWMKVPSUCNLG-QMMMGPOBSA-N
DM06NUM	IU	(2S)-1-(4-methylsulfanylphenyl)propan-2-amine
DM06NUM	DE	Discovery agent

DMAN7YJ	ID	DMAN7YJ
DMAN7YJ	DN	(S)-2-amino-1-(4-propylthiophenyl)-propane
DMAN7YJ	HS	Investigative
DMAN7YJ	SN	CHEMBL229472; (S)-2-amino-1-(4-propylthiophenyl)-propane
DMAN7YJ	DT	Small molecular drug
DMAN7YJ	PC	44424448
DMAN7YJ	MW	209.35
DMAN7YJ	FM	C12H19NS
DMAN7YJ	IC	InChI=1S/C12H19NS/c1-3-8-14-12-6-4-11(5-7-12)9-10(2)13/h4-7,10H,3,8-9,13H2,1-2H3/t10-/m0/s1
DMAN7YJ	CS	CCCSC1=CC=C(C=C1)C[C@H](C)N
DMAN7YJ	IK	HIOIYGZUYPHUTC-JTQLQIEISA-N
DMAN7YJ	IU	(2S)-1-(4-propylsulfanylphenyl)propan-2-amine
DMAN7YJ	DE	Discovery agent

DMWBH9N	ID	DMWBH9N
DMWBH9N	DN	(S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone
DMWBH9N	HS	Investigative
DMWBH9N	SN	CHEMBL194258; (S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone
DMWBH9N	DT	Small molecular drug
DMWBH9N	PC	44403067
DMWBH9N	MW	196.29
DMWBH9N	FM	C11H20N2O
DMWBH9N	IC	InChI=1S/C11H20N2O/c12-10(9-5-2-1-3-6-9)11(14)13-7-4-8-13/h9-10H,1-8,12H2/t10-/m0/s1
DMWBH9N	CS	C1CCC(CC1)[C@@H](C(=O)N2CCC2)N
DMWBH9N	IK	ZFOKLNMBWVCMDT-JTQLQIEISA-N
DMWBH9N	IU	(2S)-2-amino-1-(azetidin-1-yl)-2-cyclohexylethanone
DMWBH9N	DE	Discovery agent

DMORFZE	ID	DMORFZE
DMORFZE	DN	(S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione
DMORFZE	HS	Investigative
DMORFZE	SN	CHEMBL318401; (S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione; BDBM50118934
DMORFZE	DT	Small molecular drug
DMORFZE	PC	44328273
DMORFZE	MW	176.3
DMORFZE	FM	C6H12N2S2
DMORFZE	IC	InChI=1S/C6H12N2S2/c1-5(7)6(9)8-2-3-10-4-8/h5H,2-4,7H2,1H3/t5-/m0/s1
DMORFZE	CS	C[C@@H](C(=S)N1CCSC1)N
DMORFZE	IK	NRUOPZCNSMPDPG-YFKPBYRVSA-N
DMORFZE	IU	(2S)-2-amino-1-(1,3-thiazolidin-3-yl)propane-1-thione
DMORFZE	DE	Discovery agent

DMVD05E	ID	DMVD05E
DMVD05E	DN	(S)-2-amino-2-cyclohexylacetic acid
DMVD05E	HS	Investigative
DMVD05E	SN	14328-51-9; h-chg-oh; l-alpha-cyclohexylglycine; L-Cyclohexylglycine; (S)-2-amino-2-cyclohexylacetic acid; h-cyclohexyl-gly-oh; L-(+)-2-Cyclohexylglycine; (2s)-amino(cyclohexyl)acetic acid; CYCLOHEXYLGLYCYL; 2-Cyclohexyl-L-glycine; (2S)-2-amino-2-cyclohexylacetic acid; CYCLOHEXYL-GLYCINE; l-cyclohexyl glycine; (s)-cyclohexylglycine; L-2-Cyclohexylglycine; h-cyclohexyl-d-gly-oh; CHEMBL382372; UNII-59Q5O5615E; (S)-Amino-cyclohexyl-acetic acid; (2S)-amino(cyclohexyl)ethanoic acid; MFCD01311679; 59Q5O5615E; l-(-)-cyclohexylglycine
DMVD05E	DT	Small molecular drug
DMVD05E	PC	736848
DMVD05E	MW	157.21
DMVD05E	FM	C8H15NO2
DMVD05E	IC	InChI=1S/C8H15NO2/c9-7(8(10)11)6-4-2-1-3-5-6/h6-7H,1-5,9H2,(H,10,11)/t7-/m0/s1
DMVD05E	CS	C1CCC(CC1)[C@@H](C(=O)O)N
DMVD05E	IK	WAMWSIDTKSNDCU-ZETCQYMHSA-N
DMVD05E	IU	(2S)-2-amino-2-cyclohexylacetic acid
DMVD05E	CA	CAS 14328-51-9
DMVD05E	DE	Discovery agent

DMG9KMN	ID	DMG9KMN
DMG9KMN	DN	(S)-2-amino-2-o-tolylacetic acid
DMG9KMN	HS	Investigative
DMG9KMN	SN	(S)-Amino-o-tolyl-acetic acid; 339274-33-8; CHEMBL204179; (S)-2-AMINO-2-(O-TOLYL)ACETIC ACID; (2S)-2-amino-2-(2-methylphenyl)acetic acid; (S)-2-amino-2-o-tolylacetic acid; 2-Methyl-L-phenylglycine; AC1LT3T3; SCHEMBL3611200; FLYIRERUSAMCDQ-QMMMGPOBSA-N; ZINC4202377; BDBM50179691; AKOS006284304; AB30505; SC-21704; AJ-48395; AB1006782
DMG9KMN	DT	Small molecular drug
DMG9KMN	PC	1501939
DMG9KMN	MW	165.19
DMG9KMN	FM	C9H11NO2
DMG9KMN	IC	InChI=1S/C9H11NO2/c1-6-4-2-3-5-7(6)8(10)9(11)12/h2-5,8H,10H2,1H3,(H,11,12)/t8-/m0/s1
DMG9KMN	CS	CC1=CC=CC=C1[C@@H](C(=O)O)N
DMG9KMN	IK	FLYIRERUSAMCDQ-QMMMGPOBSA-N
DMG9KMN	IU	(2S)-2-amino-2-(2-methylphenyl)acetic acid
DMG9KMN	DE	Discovery agent

DMFEGPX	ID	DMFEGPX
DMFEGPX	DN	(S)-2-Amino-2-phenyl-ethanethiol
DMFEGPX	HS	Investigative
DMFEGPX	SN	CHEMBL286865; (S)-2-Amino-2-phenyl-ethanethiol; BDBM50078138
DMFEGPX	DT	Small molecular drug
DMFEGPX	PC	44284631
DMFEGPX	MW	153.25
DMFEGPX	FM	C8H11NS
DMFEGPX	IC	InChI=1S/C8H11NS/c9-8(6-10)7-4-2-1-3-5-7/h1-5,8,10H,6,9H2/t8-/m1/s1
DMFEGPX	CS	C1=CC=C(C=C1)[C@@H](CS)N
DMFEGPX	IK	BYWNHDXZFZXBLV-MRVPVSSYSA-N
DMFEGPX	IU	(2S)-2-amino-2-phenylethanethiol
DMFEGPX	DE	Discovery agent

DM2104G	ID	DM2104G
DM2104G	DN	(S)-2-amino-2-phenylpropanoic acid
DM2104G	HS	Investigative
DM2104G	SN	13398-26-0; (S)-2-amino-2-phenylpropanoic acid; (2S)-2-amino-2-phenylpropanoic acid; (S)-2-AMINO-2-PHENYL-PROPIONIC ACID; Benzeneacetic acid, a-amino-a-methyl-, (aS)-; (S)-ALPHA-METHYL-PHENYLGLYCINE; 2-phenyl-d-alanine; 2-(s)-phenylalanine; AC1LGXHO; (+)-2-Phenyl-D-alanine; SCHEMBL222049; CHEMBL3085306; CTK4B8907; (S)-2-Methyl-2-phenyl glycine; HTCSFFGLRQDZDE-VIFPVBQESA-N; MolPort-021-795-057; ZINC8461952; KS-00001G1D; AKOS006287023; AB33354; SC-84682; AJ-57568; KB-04049; (+)-(2S)-2-amino-2-phenylpropionic acid; FT-0695117
DM2104G	DT	Small molecular drug
DM2104G	PC	853461
DM2104G	MW	165.19
DM2104G	FM	C9H11NO2
DM2104G	IC	InChI=1S/C9H11NO2/c1-9(10,8(11)12)7-5-3-2-4-6-7/h2-6H,10H2,1H3,(H,11,12)/t9-/m0/s1
DM2104G	CS	C[C@](C1=CC=CC=C1)(C(=O)O)N
DM2104G	IK	HTCSFFGLRQDZDE-VIFPVBQESA-N
DM2104G	IU	(2S)-2-amino-2-phenylpropanoic acid
DM2104G	DE	Discovery agent

DMCDZ8A	ID	DMCDZ8A
DMCDZ8A	DN	(S)-2-amino-2-p-tolylacetic acid
DMCDZ8A	HS	Investigative
DMCDZ8A	SN	119615-71-3; CHEMBL378582; (S)-2-Amino-2-(p-tolyl)acetic acid; (2S)-2-amino-2-(4-methylphenyl)acetic acid; (S)-2-amino-2-p-tolylacetic acid; AC1ODTRS; 4-Methyl-L-phenylglycine; (S)-Amino-p-tolyl-acetic acid; SCHEMBL11728987; DTXSID20427275; ZINC2567159; BENZENEACETIC ACID, ALPHA-AMINO-4-METHYL-, (ALPHAS)- (9CI); BDBM50179719; AKOS006275863; (2S)-Amino(4-methylphenyl)acetic acid; AJ-41354; KB-276738; AB1006787; Benzeneacetic acid, a-amino-4-methyl-, (aS)-
DMCDZ8A	DT	Small molecular drug
DMCDZ8A	PC	7020729
DMCDZ8A	MW	165.19
DMCDZ8A	FM	C9H11NO2
DMCDZ8A	IC	InChI=1S/C9H11NO2/c1-6-2-4-7(5-3-6)8(10)9(11)12/h2-5,8H,10H2,1H3,(H,11,12)/t8-/m0/s1
DMCDZ8A	CS	CC1=CC=C(C=C1)[C@@H](C(=O)O)N
DMCDZ8A	IK	RZRRCPHBUKHOEY-QMMMGPOBSA-N
DMCDZ8A	IU	(2S)-2-amino-2-(4-methylphenyl)acetic acid
DMCDZ8A	CA	CAS 119615-71-3
DMCDZ8A	DE	Discovery agent

DM6OUW0	ID	DM6OUW0
DM6OUW0	DN	(S)-2-amino-3-(benzylthio)propanoic acid
DM6OUW0	HS	Investigative
DM6OUW0	SN	H-D-Cys(Bzl)-OH; 23032-53-3; S-benzyl-D-cysteine; (S)-Benzyl-D-Cys; CHEMBL204162; CCRIS 1971; Alanine, 3-(benzylthio)-, L-; EINECS 221-273-4; (S)-2-AMINO-3-(S-BENZYLTHIO)PROPANOIC ACID; AC1Q5R1B; AC1L2QY5; SCHEMBL1927561; D-Cysteine, S-(phenylmethyl)-; CTK7D0951; MolPort-005-937-279; GHBAYRBVXCRIHT-SECBINFHSA-N; ZINC404299; BDBM50179697; AS-49045; AJ-22311; AX8012175; LS-188299
DM6OUW0	DT	Small molecular drug
DM6OUW0	PC	76454
DM6OUW0	MW	211.28
DM6OUW0	FM	C10H13NO2S
DM6OUW0	IC	InChI=1S/C10H13NO2S/c11-9(10(12)13)7-14-6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)/t9-/m1/s1
DM6OUW0	CS	C1=CC=C(C=C1)CSC[C@H](C(=O)O)N
DM6OUW0	IK	GHBAYRBVXCRIHT-SECBINFHSA-N
DM6OUW0	IU	(2S)-2-amino-3-benzylsulfanylpropanoic acid
DM6OUW0	DE	Discovery agent

DM1GBX8	ID	DM1GBX8
DM1GBX8	DN	(S)-2-amino-3-cyclohexylpropanoic acid
DM1GBX8	HS	Investigative
DM1GBX8	SN	27527-05-5; (S)-2-amino-3-cyclohexylpropanoic acid; L-Cyclohexylalanine; H-Cha-OH; (2S)-2-amino-3-cyclohexylpropanoic acid; 3-Cyclohexyl-L-alanine; L-3-Cyclohexylalanine; (S)-2-Amino-3-cyclohexylpropionic acid; BETA-CYCLOHEXYL-ALANINE; L-beta-Cyclohexylalanine; UNII-GYR4SF0FVQ; GYR4SF0FVQ; CHEMBL383208; Cyclohexanepropanoic acid, alpha-amino-, (alphaS)-; 2-AMINO-3-CYCLOHEXYL-PROPIONIC ACID; 3-cyclohexylalanine; b-cyclohexyl alanine; beta-cyclohexylalanine; PubChem5760; beta-cyclohexyl alanine; AC1LEHTM; AC1Q5QKA
DM1GBX8	DT	Small molecular drug
DM1GBX8	PC	712421
DM1GBX8	MW	171.24
DM1GBX8	FM	C9H17NO2
DM1GBX8	IC	InChI=1S/C9H17NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h7-8H,1-6,10H2,(H,11,12)/t8-/m0/s1
DM1GBX8	CS	C1CCC(CC1)C[C@@H](C(=O)O)N
DM1GBX8	IK	ORQXBVXKBGUSBA-QMMMGPOBSA-N
DM1GBX8	IU	(2S)-2-amino-3-cyclohexylpropanoic acid
DM1GBX8	CA	CAS 27527-05-5
DM1GBX8	DE	Discovery agent

DMMAUKO	ID	DMMAUKO
DMMAUKO	DN	(S)-2-Amino-3-phenyl-propane-1-thiol
DMMAUKO	HS	Investigative
DMMAUKO	SN	CHEMBL34907; 2-Amino-3-phenyl-propane-1-thiol; (S)-2-Amino-3-phenyl-propane-1-thiol; SCHEMBL6805553; BDBM50078129
DMMAUKO	DT	Small molecular drug
DMMAUKO	PC	44284634
DMMAUKO	MW	167.27
DMMAUKO	FM	C9H13NS
DMMAUKO	IC	InChI=1S/C9H13NS/c10-9(7-11)6-8-4-2-1-3-5-8/h1-5,9,11H,6-7,10H2/t9-/m0/s1
DMMAUKO	CS	C1=CC=C(C=C1)C[C@@H](CS)N
DMMAUKO	IK	BUAPSNKVPWEGPA-VIFPVBQESA-N
DMMAUKO	IU	(2S)-2-amino-3-phenylpropane-1-thiol
DMMAUKO	DE	Discovery agent

DMF8I2W	ID	DMF8I2W
DMF8I2W	DN	(S)-2-amino-4-(benzylthio)butanoic acid
DMF8I2W	HS	Investigative
DMF8I2W	SN	S-Benzyl-L-homocysteine; S-benzylhomocysteine; CHEMBL380911; 7689-60-3; (S)-2-amino-4-(benzylthio)butanoic acid; SCHEMBL2829688; S-(Phenylmethyl)-L-homocysteine; 2-Amino-4-benzylthiobutyric Acid; KIPDMPPOTUGMPW-JTQLQIEISA-N; ZINC2035154; BDBM50179713; NSC 206263; NSC 164657; L-2-Amino-4-(benzylthio)butyric Acid
DMF8I2W	DT	Small molecular drug
DMF8I2W	PC	11736265
DMF8I2W	MW	225.31
DMF8I2W	FM	C11H15NO2S
DMF8I2W	IC	InChI=1S/C11H15NO2S/c12-10(11(13)14)6-7-15-8-9-4-2-1-3-5-9/h1-5,10H,6-8,12H2,(H,13,14)/t10-/m0/s1
DMF8I2W	CS	C1=CC=C(C=C1)CSCC[C@@H](C(=O)O)N
DMF8I2W	IK	KIPDMPPOTUGMPW-JTQLQIEISA-N
DMF8I2W	IU	(2S)-2-amino-4-benzylsulfanylbutanoic acid
DMF8I2W	DE	Discovery agent

DM8A1HG	ID	DM8A1HG
DM8A1HG	DN	(S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DM8A1HG	HS	Investigative
DM8A1HG	SN	CHEMBL583979; (S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide; SCHEMBL1311702; QJTVTVAQRCRXSM-KRWDZBQOSA-N
DM8A1HG	DT	Small molecular drug
DM8A1HG	PC	45483175
DM8A1HG	MW	306.4
DM8A1HG	FM	C18H30N2O2
DM8A1HG	IC	InChI=1S/C18H30N2O2/c1-2-3-4-5-6-7-8-15-9-11-16(12-10-15)20-18(22)17(19)13-14-21/h9-12,17,21H,2-8,13-14,19H2,1H3,(H,20,22)/t17-/m0/s1
DM8A1HG	CS	CCCCCCCCC1=CC=C(C=C1)NC(=O)[C@H](CCO)N
DM8A1HG	IK	QJTVTVAQRCRXSM-KRWDZBQOSA-N
DM8A1HG	IU	(2S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DM8A1HG	DE	Discovery agent

DM96XYI	ID	DM96XYI
DM96XYI	DN	(S)-2-Amino-4-methyl-pentane-1-thiol
DM96XYI	HS	Investigative
DM96XYI	SN	CHEMBL448735; 88264-65-7; Leucinthiol; 2-Amino-4-methyl-pentane-1-thiol; L-LEUCINETHIOL; (S)-2-Amino-4-methyl-pentane-1-thiol; AC1L3ELJ; 1-Pentanethiol, 2-amino-4-methyl-, (2S)-; SCHEMBL2002339; GXEDNWSUKCJLLB-LURJTMIESA-N; ZINC403014; BDBM50078133; AKOS006342069; (S)-2-Amino-4-methyl-1-pentanethiol; (S)-2-Amino-4-methylpentane-1-thiol; (2S)-2-amino-4-methylpentane-1-thiol; 1-Pentanethiol, 2-amino-4-methyl-, (S)-; L-Leucinethiol, oxidized dihydrochloride, leucine aminopeptidase inhibitor
DM96XYI	DT	Small molecular drug
DM96XYI	PC	139311
DM96XYI	MW	133.26
DM96XYI	FM	C6H15NS
DM96XYI	IC	InChI=1S/C6H15NS/c1-5(2)3-6(7)4-8/h5-6,8H,3-4,7H2,1-2H3/t6-/m0/s1
DM96XYI	CS	CC(C)C[C@@H](CS)N
DM96XYI	IK	GXEDNWSUKCJLLB-LURJTMIESA-N
DM96XYI	IU	(2S)-2-amino-4-methylpentane-1-thiol
DM96XYI	CA	CAS 88264-65-7
DM96XYI	DE	Discovery agent

DMOVQ1T	ID	DMOVQ1T
DMOVQ1T	DN	(S)-2-Amino-4-methylsulfanyl-butane-1-thiol
DMOVQ1T	HS	Investigative
DMOVQ1T	SN	CHEMBL36661; (S)-2-Amino-4-methylsulfanyl-butane-1-thiol; 1-Butanethiol, 2-amino-4-(methylthio)-, (2S)-; SCHEMBL7164846; PC-18; BDBM50078128; 139428-86-7
DMOVQ1T	DT	Small molecular drug
DMOVQ1T	PC	22885599
DMOVQ1T	MW	151.3
DMOVQ1T	FM	C5H13NS2
DMOVQ1T	IC	InChI=1S/C5H13NS2/c1-8-3-2-5(6)4-7/h5,7H,2-4,6H2,1H3/t5-/m0/s1
DMOVQ1T	CS	CSCC[C@@H](CS)N
DMOVQ1T	IK	NSPBTQHSHXESOT-YFKPBYRVSA-N
DMOVQ1T	IU	(2S)-2-amino-4-methylsulfanylbutane-1-thiol
DMOVQ1T	DE	Discovery agent

DMJEGMI	ID	DMJEGMI
DMJEGMI	DN	(S)-2-Amino-4-phenyl-butane-1-thiol
DMJEGMI	HS	Investigative
DMJEGMI	SN	CHEMBL34963; (S)-2-Amino-4-phenyl-butane-1-thiol; BDBM50078121
DMJEGMI	DT	Small molecular drug
DMJEGMI	PC	44284635
DMJEGMI	MW	181.3
DMJEGMI	FM	C10H15NS
DMJEGMI	IC	InChI=1S/C10H15NS/c11-10(8-12)7-6-9-4-2-1-3-5-9/h1-5,10,12H,6-8,11H2/t10-/m0/s1
DMJEGMI	CS	C1=CC=C(C=C1)CC[C@@H](CS)N
DMJEGMI	IK	OMEJZTIVCZZOPI-JTQLQIEISA-N
DMJEGMI	IU	(2S)-2-amino-4-phenylbutane-1-thiol
DMJEGMI	DE	Discovery agent

DMZSWDM	ID	DMZSWDM
DMZSWDM	DN	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid
DMZSWDM	HS	Investigative
DMZSWDM	SN	delta-N-Methylarginine; N(5)-methyl-L-arginine; CHEMBL99636; N(5)-carbamimidoyl-N(5)-methyl-L-ornithine; CHEBI:21848; 77044-73-6; L-NMA; 6-monomethyl-l-arginine; AC1Q3XG3; AC1L5A8F; SCHEMBL2307076; DTXSID70227848; BDBM50049254; L-Ornithine, N(5)-(aminoiminomethyl)-N(5)-methyl-; (2S)-2-amino-5-[carbamimidoyl(methyl)amino]pentanoic acid; (2S)-2-amino-5-(carbamimidoyl-methylamino)pentanoic acid
DMZSWDM	DT	Small molecular drug
DMZSWDM	PC	173566
DMZSWDM	MW	188.23
DMZSWDM	FM	C7H16N4O2
DMZSWDM	IC	InChI=1S/C7H16N4O2/c1-11(7(9)10)4-2-3-5(8)6(12)13/h5H,2-4,8H2,1H3,(H3,9,10)(H,12,13)/t5-/m0/s1
DMZSWDM	CS	CN(CCC[C@@H](C(=O)O)N)C(=N)N
DMZSWDM	IK	XKCWNEVAXQCMGP-YFKPBYRVSA-N
DMZSWDM	IU	(2S)-2-amino-5-[carbamimidoyl(methyl)amino]pentanoic acid
DMZSWDM	CA	CAS 77044-73-6
DMZSWDM	CB	CHEBI:21848
DMZSWDM	DE	Discovery agent

DMRG80O	ID	DMRG80O
DMRG80O	DN	(S)-2-Amino-6-[(E)-ethylimino]-hexanoic acid
DMRG80O	HS	Investigative
DMRG80O	DT	Small molecular drug
DMRG80O	PC	44374166
DMRG80O	MW	172.22
DMRG80O	FM	C8H16N2O2
DMRG80O	IC	InChI=1S/C8H16N2O2/c1-2-10-6-4-3-5-7(9)8(11)12/h6-7H,2-5,9H2,1H3,(H,11,12)/t7-/m0/s1
DMRG80O	CS	CCN=CCCC[C@@H](C(=O)O)N
DMRG80O	IK	SWSFWCQRQUCVNB-ZETCQYMHSA-N
DMRG80O	IU	(2S)-2-amino-6-ethyliminohexanoic acid
DMRG80O	DE	Discovery agent

DMG0CSZ	ID	DMG0CSZ
DMG0CSZ	DN	(S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide
DMG0CSZ	HS	Investigative
DMG0CSZ	SN	CHEMBL568698; (S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide; SCHEMBL1311633; UKLIXHBQCDTKPU-IBGZPJMESA-N
DMG0CSZ	DT	Small molecular drug
DMG0CSZ	PC	45256207
DMG0CSZ	MW	334.5
DMG0CSZ	FM	C20H34N2O2
DMG0CSZ	IC	InChI=1S/C20H34N2O2/c1-2-3-4-5-6-7-10-17-12-14-18(15-13-17)22-20(24)19(21)11-8-9-16-23/h12-15,19,23H,2-11,16,21H2,1H3,(H,22,24)/t19-/m0/s1
DMG0CSZ	CS	CCCCCCCCC1=CC=C(C=C1)NC(=O)[C@H](CCCCO)N
DMG0CSZ	IK	UKLIXHBQCDTKPU-IBGZPJMESA-N
DMG0CSZ	IU	(2S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide
DMG0CSZ	DE	Discovery agent

DMN1G8L	ID	DMN1G8L
DMN1G8L	DN	(S)-2-amino-N-(1-cyano-2-phenylethyl)acetamide
DMN1G8L	HS	Investigative
DMN1G8L	SN	CHEMBL379542; (S)-2-amino-N-(1-cyano-2-phenylethyl)acetamide; Acetamide, 2-amino-N-[(1S)-1-cyano-2-phenylethyl]-; BDBM50186094
DMN1G8L	DT	Small molecular drug
DMN1G8L	PC	44413276
DMN1G8L	MW	203.24
DMN1G8L	FM	C11H13N3O
DMN1G8L	IC	InChI=1S/C11H13N3O/c12-7-10(14-11(15)8-13)6-9-4-2-1-3-5-9/h1-5,10H,6,8,13H2,(H,14,15)/t10-/m0/s1
DMN1G8L	CS	C1=CC=C(C=C1)C[C@@H](C#N)NC(=O)CN
DMN1G8L	IK	QLVGHFBUSGYCCG-JTQLQIEISA-N
DMN1G8L	IU	2-amino-N-[(1S)-1-cyano-2-phenylethyl]acetamide
DMN1G8L	DE	Discovery agent

DMDWFHV	ID	DMDWFHV
DMDWFHV	DN	(S)-2-Amino-N-cyclopentyl-7-mercaptoheptanamide
DMDWFHV	HS	Investigative
DMDWFHV	SN	thiolate analogue, 26a; CHEMBL235911; SCHEMBL16338810; BDBM19139
DMDWFHV	DT	Small molecular drug
DMDWFHV	PC	23634888
DMDWFHV	MW	244.4
DMDWFHV	FM	C12H24N2OS
DMDWFHV	IC	InChI=1S/C12H24N2OS/c13-11(8-2-1-5-9-16)12(15)14-10-6-3-4-7-10/h10-11,16H,1-9,13H2,(H,14,15)/t11-/m0/s1
DMDWFHV	CS	C1CCC(C1)NC(=O)[C@H](CCCCCS)N
DMDWFHV	IK	BNEXTTBMNDFSSZ-NSHDSACASA-N
DMDWFHV	IU	(2S)-2-amino-N-cyclopentyl-7-sulfanylheptanamide
DMDWFHV	DE	Discovery agent

DMYG8EV	ID	DMYG8EV
DMYG8EV	DN	(S)-2-Amino-propane-1-thiol
DMYG8EV	HS	Investigative
DMYG8EV	SN	CHEMBL37279; 2(R,S)-aminopropanethiol; (S)-2-Amino-propane-1-thiol; (S)-2-Aminopropane-1-thiol; ZINC5138737; BDBM50078126
DMYG8EV	DT	Small molecular drug
DMYG8EV	PC	18609630
DMYG8EV	MW	91.18
DMYG8EV	FM	C3H9NS
DMYG8EV	IC	InChI=1S/C3H9NS/c1-3(4)2-5/h3,5H,2,4H2,1H3/t3-/m0/s1
DMYG8EV	CS	C[C@@H](CS)N
DMYG8EV	IK	DJJIBYYAHJOUMY-VKHMYHEASA-N
DMYG8EV	IU	(2S)-2-aminopropane-1-thiol
DMYG8EV	DE	Discovery agent

DMQGCM3	ID	DMQGCM3
DMQGCM3	DN	(S)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine
DMQGCM3	HS	Investigative
DMQGCM3	SN	CHEMBL257914
DMQGCM3	DT	Small molecular drug
DMQGCM3	PC	44456131
DMQGCM3	MW	203.32
DMQGCM3	FM	C14H21N
DMQGCM3	IC	InChI=1S/C14H21N/c1-12-5-3-7-14(11-12)8-10-15-9-4-6-13(15)2/h3,5,7,11,13H,4,6,8-10H2,1-2H3/t13-/m0/s1
DMQGCM3	CS	C[C@H]1CCCN1CCC2=CC=CC(=C2)C
DMQGCM3	IK	PXZKWHANTMQGIH-ZDUSSCGKSA-N
DMQGCM3	IU	(2S)-2-methyl-1-[2-(3-methylphenyl)ethyl]pyrrolidine
DMQGCM3	DE	Discovery agent

DMJFI75	ID	DMJFI75
DMJFI75	DN	(S)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine
DMJFI75	HS	Investigative
DMJFI75	SN	CHEMBL257911
DMJFI75	DT	Small molecular drug
DMJFI75	PC	44456126
DMJFI75	MW	203.32
DMJFI75	FM	C14H21N
DMJFI75	IC	InChI=1S/C14H21N/c1-12-5-7-14(8-6-12)9-11-15-10-3-4-13(15)2/h5-8,13H,3-4,9-11H2,1-2H3/t13-/m0/s1
DMJFI75	CS	C[C@H]1CCCN1CCC2=CC=C(C=C2)C
DMJFI75	IK	BFMXEUSPYLVDSY-ZDUSSCGKSA-N
DMJFI75	IU	(2S)-2-methyl-1-[2-(4-methylphenyl)ethyl]pyrrolidine
DMJFI75	DE	Discovery agent

DMS5IHX	ID	DMS5IHX
DMS5IHX	DN	(S)-3-(1'-Adamantanecarbonyl)amino-caprolactam
DMS5IHX	HS	Investigative
DMS5IHX	SN	SCHEMBL195373
DMS5IHX	DT	Small molecular drug
DMS5IHX	PC	11659300
DMS5IHX	MW	290.4
DMS5IHX	FM	C17H26N2O2
DMS5IHX	IC	InChI=1S/C17H26N2O2/c20-15-14(3-1-2-4-18-15)19-16(21)17-8-11-5-12(9-17)7-13(6-11)10-17/h11-14H,1-10H2,(H,18,20)(H,19,21)/t11?,12?,13?,14-,17?/m0/s1
DMS5IHX	CS	C1CCNC(=O)[C@H](C1)NC(=O)C23CC4CC(C2)CC(C4)C3
DMS5IHX	IK	FRJOFURBYVCNEN-ZZTKBFGJSA-N
DMS5IHX	IU	N-[(3S)-2-oxoazepan-3-yl]adamantane-1-carboxamide
DMS5IHX	DE	Discovery agent

DM435QN	ID	DM435QN
DM435QN	DN	(S)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate
DM435QN	HS	Investigative
DM435QN	SN	CHEMBL1080090; BDBM50311766; BDBM50074077; [(1S)-1-Methylpropyl]carbamic acid 3-(1H-imidazole-4-yl)propyl ester; ((S)-sec-Butyl)-carbamic acid 3-(1H-imidazol-4-yl)-propyl ester
DM435QN	DT	Small molecular drug
DM435QN	PC	10489384
DM435QN	MW	225.29
DM435QN	FM	C11H19N3O2
DM435QN	IC	InChI=1S/C11H19N3O2/c1-3-9(2)14-11(15)16-6-4-5-10-7-12-8-13-10/h7-9H,3-6H2,1-2H3,(H,12,13)(H,14,15)/t9-/m0/s1
DM435QN	CS	CC[C@H](C)NC(=O)OCCCC1=CN=CN1
DM435QN	IK	RSHJCGZZSGNBHO-VIFPVBQESA-N
DM435QN	IU	3-(1H-imidazol-5-yl)propyl N-[(2S)-butan-2-yl]carbamate
DM435QN	DE	Discovery agent

DMANICH	ID	DMANICH
DMANICH	DN	(S)-3-(2',2'-Dimethyl-propionyl)amino-caprolactam
DMANICH	HS	Investigative
DMANICH	SN	CHEMBL512607
DMANICH	DT	Small molecular drug
DMANICH	PC	11735999
DMANICH	MW	212.29
DMANICH	FM	C11H20N2O2
DMANICH	IC	InChI=1S/C11H20N2O2/c1-11(2,3)10(15)13-8-6-4-5-7-12-9(8)14/h8H,4-7H2,1-3H3,(H,12,14)(H,13,15)/t8-/m0/s1
DMANICH	CS	CC(C)(C)C(=O)N[C@H]1CCCCNC1=O
DMANICH	IK	FAFRIRJGUOTURZ-QMMMGPOBSA-N
DMANICH	IU	2,2-dimethyl-N-[(3S)-2-oxoazepan-3-yl]propanamide
DMANICH	DE	Discovery agent

DMTBG57	ID	DMTBG57
DMTBG57	DN	(S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DMTBG57	HS	Investigative
DMTBG57	SN	CHEMBL208216; (S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid; SCHEMBL6375241
DMTBG57	DT	Small molecular drug
DMTBG57	PC	12985748
DMTBG57	MW	183.2
DMTBG57	FM	C9H13NO3
DMTBG57	IC	InChI=1S/C9H13NO3/c10-6-7(5-9(11)12)4-8-2-1-3-13-8/h1-3,7H,4-6,10H2,(H,11,12)/t7-/m0/s1
DMTBG57	CS	C1=COC(=C1)C[C@@H](CC(=O)O)CN
DMTBG57	IK	JASKMEUWYOXVFB-ZETCQYMHSA-N
DMTBG57	IU	(3S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DMTBG57	DE	Discovery agent

DMB9CQL	ID	DMB9CQL
DMB9CQL	DN	(S)-3-(azetidin-2-ylmethoxy)-2-fluoropyridine
DMB9CQL	HS	Investigative
DMB9CQL	SN	UNII-XY1C8J4WGF; XY1C8J4WGF; CHEMBL308538; 186588-98-7; F-A-85380; CHEMBL449437; F-A 85380 Tartrate; (S)-3-(azetidin-2-ylmethoxy)-2-fluoropyridine; 2-Fluoro-A 85380; 2-Fluoro-A-85380; A-85380, 2-fluoro; 2-Fluoro-3-(((2S)-2-azetidinyl)methoxy)pyridine; Pyridine, 3-[(2S)-2-azetidinylmethoxy]-2-fluoro-; SCHEMBL1220341; ZINC6525315; FCH858175; BDBM50066788; BDBM50263094; AKOS006285963; ACM209530938; J1.007.103H; 2-fluoro-3-(2(s)-azetidinylmethoxy)pyridine; 3-((S)-1-Azetidin-2-ylmethoxy)-2-fluoro-pyridine; Pyridine, 3-((2S)-2-azetidin
DMB9CQL	DT	Small molecular drug
DMB9CQL	PC	10241442
DMB9CQL	MW	182.19
DMB9CQL	FM	C9H11FN2O
DMB9CQL	IC	InChI=1S/C9H11FN2O/c10-9-8(2-1-4-12-9)13-6-7-3-5-11-7/h1-2,4,7,11H,3,5-6H2/t7-/m0/s1
DMB9CQL	CS	C1CN[C@@H]1COC2=C(N=CC=C2)F
DMB9CQL	IK	GVOOYVOZPRROMP-ZETCQYMHSA-N
DMB9CQL	IU	3-[[(2S)-azetidin-2-yl]methoxy]-2-fluoropyridine
DMB9CQL	CA	CAS 186588-98-7
DMB9CQL	DE	Discovery agent

DM5ILK1	ID	DM5ILK1
DM5ILK1	DN	(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1	HS	Investigative
DM5ILK1	SN	CHEMBL445794; (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1	DT	Small molecular drug
DM5ILK1	PC	44592118
DM5ILK1	MW	227.3
DM5ILK1	FM	C15H17NO
DM5ILK1	IC	InChI=1S/C15H17NO/c1-2-4-14-9-12(5-6-13(14)3-1)11-17-15-7-8-16-10-15/h1-6,9,15-16H,7-8,10-11H2/t15-/m0/s1
DM5ILK1	CS	C1CNC[C@H]1OCC2=CC3=CC=CC=C3C=C2
DM5ILK1	IK	IQZVBBALTJFFCB-HNNXBMFYSA-N
DM5ILK1	IU	(3S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1	CA	CAS 1159509-09-7
DM5ILK1	DE	Discovery agent

DMG5BUA	ID	DMG5BUA
DMG5BUA	DN	(S)-3,4-DCPG
DMG5BUA	HS	Investigative
DMG5BUA	SN	(S)-3,4-dicarboxylphenylglycine
DMG5BUA	DT	Small molecular drug
DMG5BUA	PC	16062593
DMG5BUA	MW	239.18
DMG5BUA	FM	C10H9NO6
DMG5BUA	IC	InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)/t7-/m0/s1
DMG5BUA	CS	C1=CC(=C(C=C1[C@@H](C(=O)O)N)C(=O)O)C(=O)O
DMG5BUA	IK	IJVMOGKBEVRBPP-ZETCQYMHSA-N
DMG5BUA	IU	4-[(S)-amino(carboxy)methyl]phthalic acid
DMG5BUA	CA	CAS 201730-11-2
DMG5BUA	DE	Discovery agent

DMQ0FVJ	ID	DMQ0FVJ
DMQ0FVJ	DN	(S)-3HPG
DMQ0FVJ	HS	Investigative
DMQ0FVJ	SN	3-hydroxyphenylglycine
DMQ0FVJ	DT	Small molecular drug
DMQ0FVJ	PC	6604712
DMQ0FVJ	MW	167.16
DMQ0FVJ	FM	C8H9NO3
DMQ0FVJ	IC	InChI=1S/C8H9NO3/c9-7(8(11)12)5-2-1-3-6(10)4-5/h1-4,7,10H,9H2,(H,11,12)/t7-/m0/s1
DMQ0FVJ	CS	C1=CC(=CC(=C1)O)[C@@H](C(=O)O)N
DMQ0FVJ	IK	DQLYTFPAEVJTFM-ZETCQYMHSA-N
DMQ0FVJ	IU	(2S)-2-amino-2-(3-hydroxyphenyl)acetic acid
DMQ0FVJ	DE	Discovery agent

DM3TW9V	ID	DM3TW9V
DM3TW9V	DN	(S)-3-hydroxy-3-methylglutaryl-CoA
DM3TW9V	HS	Investigative
DM3TW9V	SN	hydroxymethylglutaryl-CoA; 3-Hydroxy-3-methylglutaryl-CoA ; 3-hydroxy-3-methylglutaryl-coenzyme A; HMG-CoA
DM3TW9V	DT	Small molecular drug
DM3TW9V	PC	445127
DM3TW9V	MW	911.7
DM3TW9V	FM	C27H44N7O20P3S
DM3TW9V	IC	InChI=1S/C27H44N7O20P3S/c1-26(2,21(40)24(41)30-5-4-15(35)29-6-7-58-17(38)9-27(3,42)8-16(36)37)11-51-57(48,49)54-56(46,47)50-10-14-20(53-55(43,44)45)19(39)25(52-14)34-13-33-18-22(28)31-12-32-23(18)34/h12-14,19-21,25,39-40,42H,4-11H2,1-3H3,(H,29,35)(H,30,41)(H,36,37)(H,46,47)(H,48,49)(H2,28,31,32)(H2,43,44,45)/t14-,19-,20-,21+,25-,27+/m1/s1
DM3TW9V	CS	C[C@](CC(=O)O)(CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O
DM3TW9V	IK	CABVTRNMFUVUDM-VRHQGPGLSA-N
DM3TW9V	IU	(3S)-5-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-3-hydroxy-3-methyl-5-oxopentanoic acid
DM3TW9V	CA	CAS 1553-55-5
DM3TW9V	CB	CHEBI:15467
DM3TW9V	DE	Discovery agent

DMS4JAG	ID	DMS4JAG
DMS4JAG	DN	(S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMS4JAG	HS	Investigative
DMS4JAG	SN	(3S)-3-methyl-1,2,3,4-tetrahydroisoquinoline; CHEMBL294079; (s)-3-methyl-1,2,3,4-tetrahydroisoquinoline; 15547-43-0; J-501273; AC1OM1IZ; (S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL1690518; ZINC19928408; FCH855835; BDBM50052884; AKOS006286080; AB39365; AJ-75701; KB-31985; (3S)-1,2,3,4-tetrahydro-3-methyl-isoquinoline; Isoquinoline, 1,2,3,4-tetrahydro-3-methyl-, (3S)-
DMS4JAG	DT	Small molecular drug
DMS4JAG	PC	7462302
DMS4JAG	MW	147.22
DMS4JAG	FM	C10H13N
DMS4JAG	IC	InChI=1S/C10H13N/c1-8-6-9-4-2-3-5-10(9)7-11-8/h2-5,8,11H,6-7H2,1H3/t8-/m0/s1
DMS4JAG	CS	C[C@H]1CC2=CC=CC=C2CN1
DMS4JAG	IK	UEKQPSAKUNXFHL-QMMMGPOBSA-N
DMS4JAG	IU	(3S)-3-methyl-1,2,3,4-tetrahydroisoquinoline
DMS4JAG	DE	Discovery agent

DMIG9H3	ID	DMIG9H3
DMIG9H3	DN	(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DMIG9H3	HS	Investigative
DMIG9H3	SN	CHEMBL186431; (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7678842
DMIG9H3	DT	Small molecular drug
DMIG9H3	PC	10198539
DMIG9H3	MW	172.29
DMIG9H3	FM	C8H16N2S
DMIG9H3	IC	InChI=1S/C8H16N2S/c1-2-3-7-6-11-5-4-8(9)10-7/h7H,2-6H2,1H3,(H2,9,10)/t7-/m0/s1
DMIG9H3	CS	CCC[C@H]1CSCCC(=N1)N
DMIG9H3	IK	SWOQAUBWIBZBLQ-ZETCQYMHSA-N
DMIG9H3	IU	(3S)-3-propyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMIG9H3	DE	Discovery agent

DMLZBJT	ID	DMLZBJT
DMLZBJT	DN	(S)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DMLZBJT	HS	Investigative
DMLZBJT	SN	CHEMBL405069
DMLZBJT	DT	Small molecular drug
DMLZBJT	PC	44456500
DMLZBJT	MW	190.28
DMLZBJT	FM	C12H18N2
DMLZBJT	IC	InChI=1S/C12H18N2/c1-11-3-2-9-14(11)10-6-12-4-7-13-8-5-12/h4-5,7-8,11H,2-3,6,9-10H2,1H3/t11-/m0/s1
DMLZBJT	CS	C[C@H]1CCCN1CCC2=CC=NC=C2
DMLZBJT	IK	HTPLEJUDOQHUSX-NSHDSACASA-N
DMLZBJT	IU	4-[2-[(2S)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DMLZBJT	DE	Discovery agent

DMN9YXL	ID	DMN9YXL
DMN9YXL	DN	(S)-4-AHCP
DMN9YXL	HS	Investigative
DMN9YXL	SN	CHEMBL28472; 3-(3-HYDROXY-7,8-DIHYDRO-6H-CYCLOHEPTA[D]ISOXAZOL-4-YL)-L-ALANINE; 2-AMINO-3-(3-HYDROXY-7,8-DIHYDRO-6H-CYCLOHEPTA[D]-4-ISOXAZOLYL)PROPIONIC ACID; (2S)-2-amino-3-(3-oxo-7,8-dihydro-6H-cyclohepta[d][1,2]oxazol-4-yl)propanoic acid; (S)-4-AHCP; 1wvj; AC1NRBRE; GTPL4069; BDBM50126764; DB04152; (S)-2-Amino-3-[(3-hydroxy-7,8-dihydro-6H-cyclohept[d]isoxazol)-4-yl]propionic acid; (2S)-2-amino-3-{3-oxo-2H,6H,7H,8H-cyclohepta[d][1,2]oxazol-4-yl}propanoic acid
DMN9YXL	DT	Small molecular drug
DMN9YXL	PC	5288598
DMN9YXL	MW	238.24
DMN9YXL	FM	C11H14N2O4
DMN9YXL	IC	InChI=1S/C11H14N2O4/c12-7(11(15)16)5-6-3-1-2-4-8-9(6)10(14)13-17-8/h3,7H,1-2,4-5,12H2,(H,13,14)(H,15,16)/t7-/m0/s1
DMN9YXL	CS	C1CC=C(C2=C(C1)ONC2=O)C[C@@H](C(=O)O)N
DMN9YXL	IK	HJEPOXZLPHUVFE-ZETCQYMHSA-N
DMN9YXL	IU	(2S)-2-amino-3-(3-oxo-7,8-dihydro-6H-cyclohepta[d][1,2]oxazol-4-yl)propanoic acid
DMN9YXL	DE	Discovery agent

DMQK4I2	ID	DMQK4I2
DMQK4I2	DN	(S)-4C3HPG
DMQK4I2	HS	Investigative
DMQK4I2	SN	(S)-4-CARBOXY-3-HYDROXYPHENYLGLYCINE; 85148-82-9; (s)-4C3HPG; DFS3SIU1ME; UNII-DFS3SIU1ME; (S)-4-(amino(carboxy)methyl)-2-hydroxybenzoic acid; CHEMBL39372; (S)-4C3H-PG; Benzeneacetic acid, alpha-amino-4-carboxy-3-hydroxy-, (alphaS)-; 4-[(1S)-1-amino-2-hydroxy-2-oxoethyl]-2-hydroxybenzoic acid; 4C3HPG; Tocris-0320; 4-Carboxy-3-hydroxyphenylglycine, (S)-; AC1NSKO9; GTPL1374; SCHEMBL12648356; CTK8F2145; MolPort-003-983-491; ZINC2559031; PDSP1_001316; PDSP2_001300; BDBM50053585; 4-Carboxy-3-hydroxy-L-phenylglycine; BN0022
DMQK4I2	DT	Small molecular drug
DMQK4I2	PC	5311455
DMQK4I2	MW	211.17
DMQK4I2	FM	C9H9NO5
DMQK4I2	IC	InChI=1S/C9H9NO5/c10-7(9(14)15)4-1-2-5(8(12)13)6(11)3-4/h1-3,7,11H,10H2,(H,12,13)(H,14,15)/t7-/m0/s1
DMQK4I2	CS	C1=CC(=C(C=C1[C@@H](C(=O)O)N)O)C(=O)O
DMQK4I2	IK	GXZSAQLJWLCLOX-ZETCQYMHSA-N
DMQK4I2	IU	4-[(S)-amino(carboxy)methyl]-2-hydroxybenzoic acid
DMQK4I2	CA	CAS 85148-82-9
DMQK4I2	DE	Discovery agent

DMI12X9	ID	DMI12X9
DMI12X9	DN	(S)-4-CMTB
DMI12X9	HS	Investigative
DMI12X9	SN	CHEMBL594525; (S)-4-CMTB; GTPL3420; SCHEMBL16369612; BDBM50305980; (S)-2-(4-chlorophenyl)-N-(5-fluorothiazol-2-yl)-3-methylbutanamide
DMI12X9	DT	Small molecular drug
DMI12X9	PC	46226252
DMI12X9	MW	312.8
DMI12X9	FM	C14H14ClFN2OS
DMI12X9	IC	InChI=1S/C14H14ClFN2OS/c1-8(2)12(9-3-5-10(15)6-4-9)13(19)18-14-17-7-11(16)20-14/h3-8,12H,1-2H3,(H,17,18,19)/t12-/m0/s1
DMI12X9	CS	CC(C)[C@@H](C1=CC=C(C=C1)Cl)C(=O)NC2=NC=C(S2)F
DMI12X9	IK	VMELOMANPNYLFR-LBPRGKRZSA-N
DMI12X9	IU	(2S)-2-(4-chlorophenyl)-N-(5-fluoro-1,3-thiazol-2-yl)-3-methylbutanamide
DMI12X9	DE	Discovery agent

DMZ9UIL	ID	DMZ9UIL
DMZ9UIL	DN	(S)-4CPG
DMZ9UIL	HS	Investigative
DMZ9UIL	SN	(S)-4-carboxyphenylglycine
DMZ9UIL	DT	Small molecular drug
DMZ9UIL	PC	5311459
DMZ9UIL	MW	195.17
DMZ9UIL	FM	C9H9NO4
DMZ9UIL	IC	InChI=1S/C9H9NO4/c10-7(9(13)14)5-1-3-6(4-2-5)8(11)12/h1-4,7H,10H2,(H,11,12)(H,13,14)/t7-/m0/s1
DMZ9UIL	CS	C1=CC(=CC=C1[C@@H](C(=O)O)N)C(=O)O
DMZ9UIL	IK	VTMJKPGFERYGJF-ZETCQYMHSA-N
DMZ9UIL	IU	4-[(S)-amino(carboxy)methyl]benzoic acid
DMZ9UIL	DE	Discovery agent

DMCIZ7P	ID	DMCIZ7P
DMCIZ7P	DN	(S)-5-fluorowillardiine
DMCIZ7P	HS	Investigative
DMCIZ7P	SN	5-Fluorowillardiine; (S)-(-)-5-fluorowillardiine; 140187-23-1; FLUORO-WILLARDIINE; (S)-F-Willardiine; (S)-5-FLUOROWILLARDIINE; 2-AMINO-3-(5-FLUORO-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID; CHEMBL123132; CHEBI:42549; 3-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-L-alanine; (S)-alpha-Amino-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimmidinepropanoic acid; 3-(5-fluorouracil-1-yl)-L-alanine; (2S)-2-amino-3-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)propanoic acid; (S)-(-)-5-fluorowillardine
DMCIZ7P	DT	Small molecular drug
DMCIZ7P	PC	126569
DMCIZ7P	MW	217.15
DMCIZ7P	FM	C7H8FN3O4
DMCIZ7P	IC	InChI=1S/C7H8FN3O4/c8-3-1-11(2-4(9)6(13)14)7(15)10-5(3)12/h1,4H,2,9H2,(H,13,14)(H,10,12,15)/t4-/m0/s1
DMCIZ7P	CS	C1=C(C(=O)NC(=O)N1C[C@@H](C(=O)O)N)F
DMCIZ7P	IK	DBWPFHJYSTVBCZ-BYPYZUCNSA-N
DMCIZ7P	IU	(2S)-2-amino-3-(5-fluoro-2,4-dioxopyrimidin-1-yl)propanoic acid
DMCIZ7P	CA	CAS 140187-23-1
DMCIZ7P	CB	CHEBI:42549
DMCIZ7P	DE	Discovery agent

DM1DNRP	ID	DM1DNRP
DM1DNRP	DN	(S)-5-iodowillardiine
DM1DNRP	HS	Investigative
DM1DNRP	SN	IODO-WILLARDIINE; S-5-Iodowillardiine; (S)-(-)-5-IODOWILLARDIINE; (s)-5-iodowillardiine; 140187-25-3; CHEMBL121915; 2-AMINO-3-(5-IODO-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID; IWD; 5 Iodowillardine; 5-iodowillardiine; 1mqg; Tocris-0307; AC1L9KKQ; Lopac0_001239; SCHEMBL401659; GTPL4071; SCHEMBL13319969; DTXSID90332246; MolPort-006-069-040; ZINC2047688; BDBM50060627; AKOS024457411; DB02818; CCG-205313; NCGC00024529-01; NCGC00024529-02; EU-0101239; B6252; W-110; SR-01000597629; SR-01000075424; SR-01000075424-1; J-007367
DM1DNRP	DT	Small molecular drug
DM1DNRP	PC	447196
DM1DNRP	MW	325.06
DM1DNRP	FM	C7H8IN3O4
DM1DNRP	IC	InChI=1S/C7H8IN3O4/c8-3-1-11(2-4(9)6(13)14)7(15)10-5(3)12/h1,4H,2,9H2,(H,13,14)(H,10,12,15)/t4-/m0/s1
DM1DNRP	CS	C1=C(C(=O)NC(=O)N1C[C@@H](C(=O)O)N)I
DM1DNRP	IK	AXXYLTBQIQBTES-BYPYZUCNSA-N
DM1DNRP	IU	(2S)-2-amino-3-(5-iodo-2,4-dioxopyrimidin-1-yl)propanoic acid
DM1DNRP	CA	CAS 140187-25-3
DM1DNRP	DE	Discovery agent

DM32PJ5	ID	DM32PJ5
DM32PJ5	DN	(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM32PJ5	HS	Investigative
DM32PJ5	SN	CHEMBL469551; (S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM32PJ5	DT	Small molecular drug
DM32PJ5	PC	44592198
DM32PJ5	MW	252.31
DM32PJ5	FM	C16H16N2O
DM32PJ5	IC	InChI=1S/C16H16N2O/c17-9-12-1-2-15-8-16(4-3-14(15)7-12)19-11-13-5-6-18-10-13/h1-4,7-8,13,18H,5-6,10-11H2/t13-/m0/s1
DM32PJ5	CS	C1CNC[C@H]1COC2=CC3=C(C=C2)C=C(C=C3)C#N
DM32PJ5	IK	PYEILVKGQDUINV-ZDUSSCGKSA-N
DM32PJ5	IU	6-[[(3S)-pyrrolidin-3-yl]methoxy]naphthalene-2-carbonitrile
DM32PJ5	DE	Discovery agent

DMG58HM	ID	DMG58HM
DMG58HM	DN	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid
DMG58HM	HS	Investigative
DMG58HM	SN	iminoethyl-lysin
DMG58HM	DT	Small molecular drug
DMG58HM	PC	11446787
DMG58HM	MW	187.24
DMG58HM	FM	C8H17N3O2
DMG58HM	IC	InChI=1S/C8H17N3O2/c9-4-2-1-3-7(8(12)13)11-6-5-10/h5,7,10-11H,1-4,6,9H2,(H,12,13)/t7-/m0/s1
DMG58HM	CS	C(CCN)C[C@@H](C(=O)O)NCC=N
DMG58HM	IK	NNRMAICNBIUGOW-ZETCQYMHSA-N
DMG58HM	IU	(2S)-6-amino-2-(2-iminoethylamino)hexanoic acid
DMG58HM	DE	Discovery agent

DMTUZIN	ID	DMTUZIN
DMTUZIN	DN	(S)-alpha-methylhistamine
DMTUZIN	HS	Investigative
DMTUZIN	SN	(S)-alpha-MeHA
DMTUZIN	DT	Small molecular drug
DMTUZIN	PC	6603865
DMTUZIN	MW	125.17
DMTUZIN	FM	C6H11N3
DMTUZIN	IC	InChI=1S/C6H11N3/c1-5(7)2-6-3-8-4-9-6/h3-5H,2,7H2,1H3,(H,8,9)/t5-/m0/s1
DMTUZIN	CS	C[C@@H](CC1=CN=CN1)N
DMTUZIN	IK	XNQIOISZPFVUFG-YFKPBYRVSA-N
DMTUZIN	IU	(2S)-1-(1H-imidazol-5-yl)propan-2-amine
DMTUZIN	CA	CAS 75614-93-6
DMTUZIN	CB	CHEBI:125525
DMTUZIN	DE	Discovery agent

DMNJSTM	ID	DMNJSTM
DMNJSTM	DN	(S)-AMPA
DMNJSTM	HS	Investigative
DMNJSTM	SN	(S)-AMPA; 83643-88-3; (S)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; UNII-9280SC28GD; CHEMBL276815; 9280SC28GD; (S)-2-Amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)-propionic acid; AMPA, L-; AMQ; glutamate-AMPA; 1ftm; Tocris-0254; Tocris-0169; Tocris-1074; S-AMPA; 1p1q; L-AMPA; Lopac-G-017; AC1L4JUQ; Biomol-NT_000216; (S)-a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; SCHEMBL667915; BPBio1_001304; CTK7I3476; BDBM17662; BDBM85214; UUDAMDVQRQNNHZ-YFKPBYRVSA-N; MolPort-003-940-001; MolPort-003-983-512; HMS3266E09
DMNJSTM	DT	Small molecular drug
DMNJSTM	PC	158397
DMNJSTM	MW	186.17
DMNJSTM	FM	C7H10N2O4
DMNJSTM	IC	InChI=1S/C7H10N2O4/c1-3-4(6(10)9-13-3)2-5(8)7(11)12/h5H,2,8H2,1H3,(H,9,10)(H,11,12)/t5-/m0/s1
DMNJSTM	CS	CC1=C(C(=O)NO1)C[C@@H](C(=O)O)N
DMNJSTM	IK	UUDAMDVQRQNNHZ-YFKPBYRVSA-N
DMNJSTM	IU	(2S)-2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid
DMNJSTM	CA	CAS 83643-88-3
DMNJSTM	DE	Discovery agent

DMEKGIX	ID	DMEKGIX
DMEKGIX	DN	(S)APOMORPHINE
DMEKGIX	HS	Investigative
DMEKGIX	SN	S-(+)-apomorphine; S-apomorphine; UNII-LH812IV7LI; LH812IV7LI; CHEMBL416288; 39478-62-1; (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (S)-; S(+)-APOMORPHINE; (+)-10,11-Dihydroxyaporphine; Apomorphine, S-; AC1LEHBI; Lopac-A-4393; Oprea1_044402; SCHEMBL6922802; GTPL8285; CTK1C3986; cid_6852389; BDBM29643; DTXSID40192615; MolPort-002-507-063; (6as)-10,11-dihydroxyaporphine; ZINC155525; PDSP1_001504
DMEKGIX	DT	Small molecular drug
DMEKGIX	PC	736083
DMEKGIX	MW	267.32
DMEKGIX	FM	C17H17NO2
DMEKGIX	IC	InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m0/s1
DMEKGIX	CS	CN1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
DMEKGIX	IK	VMWNQDUVQKEIOC-ZDUSSCGKSA-N
DMEKGIX	IU	(6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMEKGIX	CA	CAS 39478-62-1
DMEKGIX	DE	Discovery agent

DMA43NY	ID	DMA43NY
DMA43NY	DN	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate
DMA43NY	HS	Investigative
DMA43NY	SN	Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-
DMA43NY	DT	Small molecular drug
DMA43NY	PC	5491980
DMA43NY	MW	255.7
DMA43NY	FM	C12H14ClNO3
DMA43NY	IC	InChI=1S/C12H14ClNO3/c1-9(11(15)7-13)14-12(16)17-8-10-5-3-2-4-6-10/h2-6,9H,7-8H2,1H3,(H,14,16)/t9-/m0/s1
DMA43NY	CS	C[C@@H](C(=O)CCl)NC(=O)OCC1=CC=CC=C1
DMA43NY	IK	ASDQMJAOUJQRCM-VIFPVBQESA-N
DMA43NY	IU	benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate
DMA43NY	CA	CAS 41036-43-5
DMA43NY	DE	Discovery agent

DMPI0AX	ID	DMPI0AX
DMPI0AX	DN	(S)-BULBOCAPNINE
DMPI0AX	HS	Investigative
DMPI0AX	SN	Bulbocapnine; 298-45-3; UNII-O0TGI865QO; Bulbokaprin; O0TGI865QO; CHEMBL157912; CHEBI:3211; (S)-BULBOCAPNINE; EINECS 206-061-1; Bulbocapnin; Buibocapnine hydrochloride; AC1L1ZLR; 632-47-3; ZINC103; SCHEMBL678694; 6a-alpha-APORPHIN-11-OL, 10-METHOXY-1,2-(METHYLENEDIOXY)-; AC1Q703Q; DTXSID20183940; BDBM50016018; 9126AF; PDSP2_000621; ACM298453; AKOS000276822; C09367; 11-Methoxy-7-methyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4'',5'':4,5]benzo[1,2,3-de]quinolin-12-ol (Bulbocapnine)
DMPI0AX	DT	Small molecular drug
DMPI0AX	PC	12441
DMPI0AX	MW	325.4
DMPI0AX	FM	C19H19NO4
DMPI0AX	IC	InChI=1S/C19H19NO4/c1-20-6-5-11-8-14-19(24-9-23-14)17-15(11)12(20)7-10-3-4-13(22-2)18(21)16(10)17/h3-4,8,12,21H,5-7,9H2,1-2H3/t12-/m0/s1
DMPI0AX	CS	CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=C4C(=C(C=C5)OC)O)OCO3
DMPI0AX	IK	LODGIKWNLDQZBM-LBPRGKRZSA-N
DMPI0AX	IU	(12S)-17-methoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14(19),15,17-hexaen-18-ol
DMPI0AX	CA	CAS 298-45-3
DMPI0AX	CB	CHEBI:3211
DMPI0AX	DE	Discovery agent

DMJN659	ID	DMJN659
DMJN659	DN	(S)-cetirizine
DMJN659	HS	Investigative
DMJN659	SN	UNII-V57G6B5I8Z; V57G6B5I8Z; 130018-76-7; (2-{4-[(S)-(4-Chlorophenyl)(Phenyl)methyl]piperazin-1-Yl}ethoxy)acetic Acid; Dextrocetirizine Dihydrochloride; 2-[2-[4-[(S)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid; Dextrocetirizine; (s)cetirizine; Cetirizine, (S)-; (S)-dextrocetirizine; Cetirizine (+) isomer; NCGC00016949-01; CAS-83881-52-1; GTPL1215; SCHEMBL5526985; AC1L44V3; (+)-Cetirizine Dihydrochloride; CHEMBL1334217; BDBM85029; (S)-(+)-DEXTROCETIRIZINE; ZINC19364229
DMJN659	DT	Small molecular drug
DMJN659	PC	150716
DMJN659	MW	388.9
DMJN659	FM	C21H25ClN2O3
DMJN659	IC	InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m0/s1
DMJN659	CS	C1CN(CCN1CCOCC(=O)O)[C@@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMJN659	IK	ZKLPARSLTMPFCP-NRFANRHFSA-N
DMJN659	IU	2-[2-[4-[(S)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMJN659	CA	CAS 130018-76-7
DMJN659	DE	Discovery agent

DMQSC21	ID	DMQSC21
DMQSC21	DN	(S)-DHPA
DMQSC21	HS	Investigative
DMQSC21	SN	S-Dihydroxypropyladenine; (S)-9-(2,3-Dihydroxypropyl)adenine; (S)-DHPA; 9-D-(2,3-Dihydroxypropyl)adenine; 54262-83-8; BRN 0990757; (2s)-3-(6-amino-9h-purin-9-yl)propane-1,2-diol; (2S)-3-(6-aminopurin-9-yl)propane-1,2-diol; (S)-3-(6-Amino-9H-purin-9-yl)-1,2-propanediol; 1,2-Propanediol, 3-(6-amino-9H-purin-9-yl)-, (S)-; 9-(S)-(2,3-Dihydroxypropyl)adenine; AC1Q4VGK; DHPA, (S)-DHPA; AC1L2JB5; 5-26-16-00201 (Beilstein Handbook Reference); SCHEMBL936286; CHEMBL494759; CTK5A0230; 9-(1,2-dihydroxypropyl)adenine; ZINC370772
DMQSC21	DT	Small molecular drug
DMQSC21	PC	73124
DMQSC21	MW	209.21
DMQSC21	FM	C8H11N5O2
DMQSC21	IC	InChI=1S/C8H11N5O2/c9-7-6-8(11-3-10-7)13(4-12-6)1-5(15)2-14/h3-5,14-15H,1-2H2,(H2,9,10,11)/t5-/m0/s1
DMQSC21	CS	C1=NC(=C2C(=N1)N(C=N2)C[C@@H](CO)O)N
DMQSC21	IK	GSLQFBVNOFBPRJ-YFKPBYRVSA-N
DMQSC21	IU	(2S)-3-(6-aminopurin-9-yl)propane-1,2-diol
DMQSC21	CA	CAS 54262-83-8
DMQSC21	DE	Discovery agent

DM0SEYN	ID	DM0SEYN
DM0SEYN	DN	(S)-dimethylenastron
DM0SEYN	HS	Investigative
DM0SEYN	SN	ZINC22309237
DM0SEYN	DT	Small molecular drug
DM0SEYN	PC	49863704
DM0SEYN	MW	302.4
DM0SEYN	FM	C16H18N2O2S
DM0SEYN	IC	InChI=1S/C16H18N2O2S/c1-16(2)7-11-13(12(20)8-16)14(18-15(21)17-11)9-4-3-5-10(19)6-9/h3-6,14,19H,7-8H2,1-2H3,(H2,17,18,21)/t14-/m0/s1
DM0SEYN	CS	CC1(CC2=C([C@@H](NC(=S)N2)C3=CC(=CC=C3)O)C(=O)C1)C
DM0SEYN	IK	RUOOPLOUUAYNPY-AWEZNQCLSA-N
DM0SEYN	IU	(4S)-4-(3-hydroxyphenyl)-7,7-dimethyl-2-sulfanylidene-3,4,6,8-tetrahydro-1H-quinazolin-5-one
DM0SEYN	DE	Discovery agent

DM0EQTM	ID	DM0EQTM
DM0EQTM	DN	(S)-EF-1520
DM0EQTM	HS	Investigative
DM0EQTM	SN	(S)-EF-1520; GTPL6513
DM0EQTM	DT	Small molecular drug
DM0EQTM	PC	53324619
DM0EQTM	MW	414.6
DM0EQTM	FM	C22H26N2O2S2
DM0EQTM	IC	InChI=1S/C22H26N2O2S2/c1-14-9-12-27-20(14)16(21-15(2)10-13-28-21)6-5-11-24(3)17-7-4-8-18-19(17)22(25)23-26-18/h6,9-10,12-13,17H,4-5,7-8,11H2,1-3H3,(H,23,25)/t17-/m0/s1
DM0EQTM	CS	CC1=C(SC=C1)C(=CCCN(C)[C@H]2CCCC3=C2C(=O)NO3)C4=C(C=CS4)C
DM0EQTM	IK	CUESOMOCKVRNIW-KRWDZBQOSA-N
DM0EQTM	IU	(4S)-4-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl-methylamino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-one
DM0EQTM	DE	Discovery agent

DMWNEA1	ID	DMWNEA1
DMWNEA1	DN	(S)-enastron
DMWNEA1	HS	Investigative
DMWNEA1	SN	AC1LFOER; 2x7c; ZINC2601603; (4S)-4-(3-hydroxyphenyl)-2-sulfanylidene-1,3,4,6,7,8-hexahydroquinazolin-5-one
DMWNEA1	DT	Small molecular drug
DMWNEA1	PC	757000
DMWNEA1	MW	274.34
DMWNEA1	FM	C14H14N2O2S
DMWNEA1	IC	InChI=1S/C14H14N2O2S/c17-9-4-1-3-8(7-9)13-12-10(15-14(19)16-13)5-2-6-11(12)18/h1,3-4,7,13,17H,2,5-6H2,(H2,15,16,19)/t13-/m0/s1
DMWNEA1	CS	C1CC2=C([C@@H](NC(=S)N2)C3=CC(=CC=C3)O)C(=O)C1
DMWNEA1	IK	BJTGVSGWTIUCSM-ZDUSSCGKSA-N
DMWNEA1	IU	(4S)-4-(3-hydroxyphenyl)-2-sulfanylidene-1,3,4,6,7,8-hexahydroquinazolin-5-one
DMWNEA1	DE	Discovery agent

DMFSXTJ	ID	DMFSXTJ
DMFSXTJ	DN	(S)-Ethyl 6-(2-oxohexadecanamido)decanoate
DMFSXTJ	HS	Investigative
DMFSXTJ	SN	CHEMBL462543
DMFSXTJ	DT	Small molecular drug
DMFSXTJ	PC	44562726
DMFSXTJ	MW	467.7
DMFSXTJ	FM	C28H53NO4
DMFSXTJ	IC	InChI=1S/C28H53NO4/c1-4-7-9-10-11-12-13-14-15-16-17-18-23-26(30)28(32)29-25(21-8-5-2)22-19-20-24-27(31)33-6-3/h25H,4-24H2,1-3H3,(H,29,32)/t25-/m0/s1
DMFSXTJ	CS	CCCCCCCCCCCCCCC(=O)C(=O)N[C@@H](CCCC)CCCCC(=O)OCC
DMFSXTJ	IK	HEZLMGZNPUCJHH-VWLOTQADSA-N
DMFSXTJ	IU	ethyl (6S)-6-(2-oxohexadecanoylamino)decanoate
DMFSXTJ	DE	Discovery agent

DM715AS	ID	DM715AS
DM715AS	DN	(S)-flurocarazolol
DM715AS	HS	Investigative
DM715AS	SN	(S)-flurocarazolol; GTPL66; CHEMBL326418; SCHEMBL14155316; PDSP2_000794; PDSP1_000807
DM715AS	DT	Small molecular drug
DM715AS	PC	10358392
DM715AS	MW	316.4
DM715AS	FM	C18H21FN2O2
DM715AS	IC	InChI=1S/C18H21FN2O2/c1-12(9-19)20-10-13(22)11-23-17-8-4-7-16-18(17)14-5-2-3-6-15(14)21-16/h2-8,12-13,20-22H,9-11H2,1H3/t12?,13-/m0/s1
DM715AS	CS	CC(CF)NC[C@@H](COC1=CC=CC2=C1C3=CC=CC=C3N2)O
DM715AS	IK	QHLGXPUIUKSADT-ABLWVSNPSA-N
DM715AS	IU	(2S)-1-(9H-carbazol-4-yloxy)-3-(1-fluoropropan-2-ylamino)propan-2-ol
DM715AS	DE	Discovery agent

DM5WETL	ID	DM5WETL
DM5WETL	DN	(S)-FTY720P
DM5WETL	HS	Investigative
DM5WETL	SN	CHEMBL1213480
DM5WETL	DT	Small molecular drug
DM5WETL	PC	11452022
DM5WETL	MW	387.5
DM5WETL	FM	C19H34NO5P
DM5WETL	IC	InChI=1S/C19H34NO5P/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-25-26(22,23)24/h9-12,21H,2-8,13-16,20H2,1H3,(H2,22,23,24)/t19-/m0/s1
DM5WETL	CS	CCCCCCCCC1=CC=C(C=C1)CC[C@](CO)(COP(=O)(O)O)N
DM5WETL	IK	LRFKWQGGENFBFO-IBGZPJMESA-N
DM5WETL	IU	[(2S)-2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl] dihydrogen phosphate
DM5WETL	CA	CAS 402616-26-6

DM8H0ND	ID	DM8H0ND
DM8H0ND	DN	(S)-Methyl 4-(2-oxohexadecanamido)octanoate
DM8H0ND	HS	Investigative
DM8H0ND	SN	CHEMBL462361
DM8H0ND	DT	Small molecular drug
DM8H0ND	PC	44562672
DM8H0ND	MW	425.6
DM8H0ND	FM	C25H47NO4
DM8H0ND	IC	InChI=1S/C25H47NO4/c1-4-6-8-9-10-11-12-13-14-15-16-17-19-23(27)25(29)26-22(18-7-5-2)20-21-24(28)30-3/h22H,4-21H2,1-3H3,(H,26,29)/t22-/m0/s1
DM8H0ND	CS	CCCCCCCCCCCCCCC(=O)C(=O)N[C@@H](CCCC)CCC(=O)OC
DM8H0ND	IK	RFWRXBDBLIGDAF-QFIPXVFZSA-N
DM8H0ND	IU	methyl (4S)-4-(2-oxohexadecanoylamino)octanoate
DM8H0ND	DE	Discovery agent

DMLR0N3	ID	DMLR0N3
DMLR0N3	DN	(S)-N-(1-phenylethyl)acetimidamide hydrobromide
DMLR0N3	HS	Investigative
DMLR0N3	SN	CHEMBL448703; 1-[(1-Phenylethyl)amino]ethaniminium bromide
DMLR0N3	DT	Small molecular drug
DMLR0N3	PC	25231669
DMLR0N3	MW	243.14
DMLR0N3	FM	C10H15BrN2
DMLR0N3	IC	InChI=1S/C10H14N2.BrH/c1-8(12-9(2)11)10-6-4-3-5-7-10;/h3-8H,1-2H3,(H2,11,12);1H/t8-;/m0./s1
DMLR0N3	CS	C[C@@H](C1=CC=CC=C1)N=C(C)N.Br
DMLR0N3	IK	SXSWEEJYFGUAON-QRPNPIFTSA-N
DMLR0N3	IU	N'-[(1S)-1-phenylethyl]ethanimidamide;hydrobromide
DMLR0N3	DE	Discovery agent

DMGFOQJ	ID	DMGFOQJ
DMGFOQJ	DN	(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide
DMGFOQJ	HS	Investigative
DMGFOQJ	SN	(S)-1 [PMID: 16904708]; compound 2 [PMID: 12852750]
DMGFOQJ	DT	Small molecular drug
DMGFOQJ	PC	9949648
DMGFOQJ	MW	336.4
DMGFOQJ	FM	C21H24N2O2
DMGFOQJ	IC	InChI=1S/C21H24N2O2/c1-17(22-21(24)11-10-18-6-3-2-4-7-18)19-8-5-9-20(16-19)23-12-14-25-15-13-23/h2-11,16-17H,12-15H2,1H3,(H,22,24)/b11-10+/t17-/m0/s1
DMGFOQJ	CS	C[C@@H](C1=CC(=CC=C1)N2CCOCC2)NC(=O)/C=C/C3=CC=CC=C3
DMGFOQJ	IK	QMIMHUDEVKGOTQ-DVQDXYAYSA-N
DMGFOQJ	IU	(E)-N-[(1S)-1-(3-morpholin-4-ylphenyl)ethyl]-3-phenylprop-2-enamide
DMGFOQJ	DE	Discovery agent

DMGMAPB	ID	DMGMAPB
DMGMAPB	DN	(S)-N2-[4-(benzyloxy)benzyl]alaninamide
DMGMAPB	HS	Investigative
DMGMAPB	SN	CHEMBL352004; (S)-N2-[4-(benzyloxy)benzyl]alaninamide; SCHEMBL4456855; BDBM50221295; (S)-2-(4-Benzyloxy-benzylamino)-propionamide
DMGMAPB	DT	Small molecular drug
DMGMAPB	PC	10517190
DMGMAPB	MW	284.35
DMGMAPB	FM	C17H20N2O2
DMGMAPB	IC	InChI=1S/C17H20N2O2/c1-13(17(18)20)19-11-14-7-9-16(10-8-14)21-12-15-5-3-2-4-6-15/h2-10,13,19H,11-12H2,1H3,(H2,18,20)/t13-/m0/s1
DMGMAPB	CS	C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2
DMGMAPB	IK	IEHDKRBHKAGVKZ-ZDUSSCGKSA-N
DMGMAPB	IU	(2S)-2-[(4-phenylmethoxyphenyl)methylamino]propanamide
DMGMAPB	DE	Discovery agent

DMW5ZK7	ID	DMW5ZK7
DMW5ZK7	DN	(S)-N2-[4-(benzyloxy)benzyl]serinamide
DMW5ZK7	HS	Investigative
DMW5ZK7	SN	CHEMBL243058; (S)-N2-[4-(benzyloxy)benzyl]serinamide; SCHEMBL7394895; ZINC28711471
DMW5ZK7	DT	Small molecular drug
DMW5ZK7	PC	10756633
DMW5ZK7	MW	300.35
DMW5ZK7	FM	C17H20N2O3
DMW5ZK7	IC	InChI=1S/C17H20N2O3/c18-17(21)16(11-20)19-10-13-6-8-15(9-7-13)22-12-14-4-2-1-3-5-14/h1-9,16,19-20H,10-12H2,(H2,18,21)/t16-/m0/s1
DMW5ZK7	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)CN[C@@H](CO)C(=O)N
DMW5ZK7	IK	JMIJOQDPXHRPOI-INIZCTEOSA-N
DMW5ZK7	IU	(2S)-3-hydroxy-2-[(4-phenylmethoxyphenyl)methylamino]propanamide
DMW5ZK7	DE	Discovery agent

DMKMJBL	ID	DMKMJBL
DMKMJBL	DN	(S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide
DMKMJBL	HS	Investigative
DMKMJBL	SN	CHEMBL242618; (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide; SCHEMBL2018555
DMKMJBL	DT	Small molecular drug
DMKMJBL	PC	10087289
DMKMJBL	MW	318.8
DMKMJBL	FM	C17H19ClN2O2
DMKMJBL	IC	InChI=1S/C17H19ClN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DMKMJBL	CS	C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)Cl
DMKMJBL	IK	JFADNUHMEURSIM-LBPRGKRZSA-N
DMKMJBL	IU	(2S)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]propanamide
DMKMJBL	DE	Discovery agent

DMINLCJ	ID	DMINLCJ
DMINLCJ	DN	(S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide
DMINLCJ	HS	Investigative
DMINLCJ	SN	CHEMBL394347; (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide; SCHEMBL2017824
DMINLCJ	DT	Small molecular drug
DMINLCJ	PC	23625507
DMINLCJ	MW	334.8
DMINLCJ	FM	C17H19ClN2O3
DMINLCJ	IC	InChI=1S/C17H19ClN2O3/c18-14-3-1-2-13(8-14)11-23-15-6-4-12(5-7-15)9-20-16(10-21)17(19)22/h1-8,16,20-21H,9-11H2,(H2,19,22)/t16-/m0/s1
DMINLCJ	CS	C1=CC(=CC(=C1)Cl)COC2=CC=C(C=C2)CN[C@@H](CO)C(=O)N
DMINLCJ	IK	WYDCYPPIJUASJE-INIZCTEOSA-N
DMINLCJ	IU	(2S)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide
DMINLCJ	DE	Discovery agent

DMSC8ZW	ID	DMSC8ZW
DMSC8ZW	DN	(S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide
DMSC8ZW	HS	Investigative
DMSC8ZW	SN	CHEMBL243059; (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide; SCHEMBL2014885
DMSC8ZW	DT	Small molecular drug
DMSC8ZW	PC	23625355
DMSC8ZW	MW	318.34
DMSC8ZW	FM	C17H19FN2O3
DMSC8ZW	IC	InChI=1S/C17H19FN2O3/c18-14-3-1-2-13(8-14)11-23-15-6-4-12(5-7-15)9-20-16(10-21)17(19)22/h1-8,16,20-21H,9-11H2,(H2,19,22)/t16-/m0/s1
DMSC8ZW	CS	C1=CC(=CC(=C1)F)COC2=CC=C(C=C2)CN[C@@H](CO)C(=O)N
DMSC8ZW	IK	UTIKAYGNKRMHTP-INIZCTEOSA-N
DMSC8ZW	IU	(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide
DMSC8ZW	DE	Discovery agent

DMU3F7H	ID	DMU3F7H
DMU3F7H	DN	(S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide
DMU3F7H	HS	Investigative
DMU3F7H	SN	CHEMBL397987; (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide
DMU3F7H	DT	Small molecular drug
DMU3F7H	PC	23625354
DMU3F7H	MW	318.8
DMU3F7H	FM	C17H19ClN2O2
DMU3F7H	IC	InChI=1S/C17H19ClN2O2/c1-12(17(19)21)20-10-13-4-8-16(9-5-13)22-11-14-2-6-15(18)7-3-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DMU3F7H	CS	C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=C(C=C2)Cl
DMU3F7H	IK	JAJNPDROJVQSPW-LBPRGKRZSA-N
DMU3F7H	IU	(2S)-2-[[4-[(4-chlorophenyl)methoxy]phenyl]methylamino]propanamide
DMU3F7H	DE	Discovery agent

DMLFOPV	ID	DMLFOPV
DMLFOPV	DN	(S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide
DMLFOPV	HS	Investigative
DMLFOPV	SN	CHEMBL243077; (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide
DMLFOPV	DT	Small molecular drug
DMLFOPV	PC	23625208
DMLFOPV	MW	334.8
DMLFOPV	FM	C17H19ClN2O3
DMLFOPV	IC	InChI=1S/C17H19ClN2O3/c18-14-5-1-13(2-6-14)11-23-15-7-3-12(4-8-15)9-20-16(10-21)17(19)22/h1-8,16,20-21H,9-11H2,(H2,19,22)/t16-/m0/s1
DMLFOPV	CS	C1=CC(=CC=C1CN[C@@H](CO)C(=O)N)OCC2=CC=C(C=C2)Cl
DMLFOPV	IK	NKJUZCSUSIWWQG-INIZCTEOSA-N
DMLFOPV	IU	(2S)-2-[[4-[(4-chlorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide
DMLFOPV	DE	Discovery agent

DMLP63J	ID	DMLP63J
DMLP63J	DN	(S)-N2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide
DMLP63J	HS	Investigative
DMLP63J	SN	CHEMBL243079; (S)-N2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide
DMLP63J	DT	Small molecular drug
DMLP63J	PC	23625356
DMLP63J	MW	345.3
DMLP63J	FM	C17H19N3O5
DMLP63J	IC	InChI=1S/C17H19N3O5/c18-17(22)16(10-21)19-9-12-3-7-15(8-4-12)25-11-13-1-5-14(6-2-13)20(23)24/h1-8,16,19,21H,9-11H2,(H2,18,22)/t16-/m0/s1
DMLP63J	CS	C1=CC(=CC=C1CN[C@@H](CO)C(=O)N)OCC2=CC=C(C=C2)[N+](=O)[O-]
DMLP63J	IK	XVFXQICJBNSYEW-INIZCTEOSA-N
DMLP63J	IU	(2S)-3-hydroxy-2-[[4-[(4-nitrophenyl)methoxy]phenyl]methylamino]propanamide
DMLP63J	DE	Discovery agent

DMUAYZJ	ID	DMUAYZJ
DMUAYZJ	DN	(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMUAYZJ	HS	Investigative
DMUAYZJ	SN	CHEMBL567932; (S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide; SCHEMBL4634335
DMUAYZJ	DT	Small molecular drug
DMUAYZJ	PC	11220185
DMUAYZJ	MW	296.4
DMUAYZJ	FM	C19H24N2O
DMUAYZJ	IC	InChI=1S/C19H24N2O/c1-14(2)13-21(18-9-10-20-12-18)19(22)17-8-7-15-5-3-4-6-16(15)11-17/h3-8,11,14,18,20H,9-10,12-13H2,1-2H3/t18-/m0/s1
DMUAYZJ	CS	CC(C)CN([C@H]1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2
DMUAYZJ	IK	CEUJKSVEPJAVKD-SFHVURJKSA-N
DMUAYZJ	IU	N-(2-methylpropyl)-N-[(3S)-pyrrolidin-3-yl]naphthalene-2-carboxamide
DMUAYZJ	DE	Discovery agent

DMNOWZ2	ID	DMNOWZ2
DMNOWZ2	DN	(S)-N-oleoyltyrosinol
DMNOWZ2	HS	Investigative
DMNOWZ2	SN	OMDM-1
DMNOWZ2	DT	Small molecular drug
DMNOWZ2	PC	10410511
DMNOWZ2	MW	431.7
DMNOWZ2	FM	C27H45NO3
DMNOWZ2	IC	InChI=1S/C27H45NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-27(31)28-25(23-29)22-24-18-20-26(30)21-19-24/h9-10,18-21,25,29-30H,2-8,11-17,22-23H2,1H3,(H,28,31)/b10-9-/t25-/m0/s1
DMNOWZ2	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)O)CO
DMNOWZ2	IK	ICDMLAQPOAVWNH-JRUKXMRZSA-N
DMNOWZ2	IU	(Z)-N-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide
DMNOWZ2	DE	Discovery agent

DMULFYA	ID	DMULFYA
DMULFYA	DN	(S)-NORDULOXETINE
DMULFYA	HS	Investigative
DMULFYA	SN	CHEMBL595063; (S)-NORDULOXETINE; SCHEMBL4573573; ZINC34220632; BDBM50304388; (S)-gamma-(1-Naphthyloxy)-2-thiophenepropan-1-amine
DMULFYA	DT	Small molecular drug
DMULFYA	PC	10107888
DMULFYA	MW	283.4
DMULFYA	FM	C17H17NOS
DMULFYA	IC	InChI=1S/C17H17NOS/c18-11-10-16(17-9-4-12-20-17)19-15-8-3-6-13-5-1-2-7-14(13)15/h1-9,12,16H,10-11,18H2/t16-/m0/s1
DMULFYA	CS	C1=CC=C2C(=C1)C=CC=C2O[C@@H](CCN)C3=CC=CS3
DMULFYA	IK	ZMXLKLOJDLMZFC-INIZCTEOSA-N
DMULFYA	IU	(3S)-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
DMULFYA	CA	CAS 178273-35-3
DMULFYA	DE	Discovery agent

DM8ZTPF	ID	DM8ZTPF
DM8ZTPF	DN	(S)-Norfluoxetine
DM8ZTPF	HS	Investigative
DM8ZTPF	SN	126924-38-7; SEPROXETINE; UNII-25CO3X0R31; (S)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE; CHEMBL465123; (3S)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; 25CO3X0R31; (S)-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Seproxetine [INN]; S-Norfluoxetine; AC1MHW5Z; SCHEMBL272873; ZINC4531; CTK8E9555; MolPort-005-941-621; 9173AH; BDBM50254790; AKOS027384574; DB06731; AJ-08214; RT-014029; FT-0673089; NFL_296.1257_14.5; J-005451
DM8ZTPF	DT	Small molecular drug
DM8ZTPF	PC	3058751
DM8ZTPF	MW	295.3
DM8ZTPF	FM	C16H16F3NO
DM8ZTPF	IC	InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m0/s1
DM8ZTPF	CS	C1=CC=C(C=C1)[C@H](CCN)OC2=CC=C(C=C2)C(F)(F)F
DM8ZTPF	IK	WIQRCHMSJFFONW-HNNXBMFYSA-N
DM8ZTPF	IU	(3S)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
DM8ZTPF	CA	CAS 126924-38-7
DM8ZTPF	DE	Discovery agent

DMAI1HU	ID	DMAI1HU
DMAI1HU	DN	(S)-phenylglycine
DMAI1HU	HS	Investigative
DMAI1HU	SN	2935-35-5; H-Phg-Oh; L-Phenylglycine; (S)-2-Amino-2-phenylacetic acid; L-(+)-alpha-Phenylglycine; L-2-Phenylglycine; (2S)-amino(phenyl)acetic acid; L-(+)-2-Phenylglycine; Phenylglycine; (2S)-2-amino-2-phenylacetic acid; L-(+)-alpha-Aminophenylacetic acid; UNII-3I753R0XI6; L-alpha-Phenylglycine; L(+)-alpha-Phenylglycine; (S)-(+)-2-Phenylglycine; CHEMBL378605; (2S)-amino(phenyl)ethanoic acid; CHEBI:439819; 3I753R0XI6; MFCD00064403; (alphaS)-alpha-aminobenzeneacetic acid
DMAI1HU	DT	Small molecular drug
DMAI1HU	PC	99291
DMAI1HU	MW	151.16
DMAI1HU	FM	C8H9NO2
DMAI1HU	IC	InChI=1S/C8H9NO2/c9-7(8(10)11)6-4-2-1-3-5-6/h1-5,7H,9H2,(H,10,11)/t7-/m0/s1
DMAI1HU	CS	C1=CC=C(C=C1)[C@@H](C(=O)O)N
DMAI1HU	IK	ZGUNAGUHMKGQNY-ZETCQYMHSA-N
DMAI1HU	IU	(2S)-2-amino-2-phenylacetic acid
DMAI1HU	CA	CAS 2935-35-5
DMAI1HU	CB	CHEBI:439819
DMAI1HU	DE	Discovery agent

DM04BHI	ID	DM04BHI
DM04BHI	DN	(S)-PIA
DM04BHI	HS	Investigative
DM04BHI	SN	CHEMBL420705; 38594-97-7; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(2S)-1-phenylpropan-2-yl]amino]purin-9-yl]oxolane-3,4-diol; S-PIA; N6-((S)-1-Methyl-2-phenylethyl)adenosine; AC1NSM10; GTPL415; SCHEMBL6762494; CTK1C3340; 2-Hydroxymethyl-5-[6-(1-methyl-2-phenyl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol; S(+)-N6-(2-PHENYLISOPROPYL)ADENOSINE (S( +)-PIA); N6-(D-2-Phenylisopropyl)adenosine; ZINC1320081; PDSP2_001015; PDSP1_000298; PDSP2_000296; PDSP1_001031; BDBM50080398
DM04BHI	DT	Small molecular drug
DM04BHI	PC	5312112
DM04BHI	MW	385.4
DM04BHI	FM	C19H23N5O4
DM04BHI	IC	InChI=1S/C19H23N5O4/c1-11(7-12-5-3-2-4-6-12)23-17-14-18(21-9-20-17)24(10-22-14)19-16(27)15(26)13(8-25)28-19/h2-6,9-11,13,15-16,19,25-27H,7-8H2,1H3,(H,20,21,23)/t11-,13+,15+,16+,19+/m0/s1
DM04BHI	CS	C[C@@H](CC1=CC=CC=C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DM04BHI	IK	RIRGCFBBHQEQQH-KFAHYOAQSA-N
DM04BHI	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(2S)-1-phenylpropan-2-yl]amino]purin-9-yl]oxolane-3,4-diol
DM04BHI	DE	Discovery agent

DMST89H	ID	DMST89H
DMST89H	DN	(S)-Piperidine-3-carboxylic acid
DMST89H	HS	Investigative
DMST89H	SN	59045-82-8; (S)-(+)-Nipecotic acid; (3S)-piperidine-3-carboxylic acid; (S)-nipecotic acid; (3S)-nipecotic acid; (S)-(+)-3-Piperidinecarboxylic acid; (S)-hexahydronicotinic acid; L(+)-NIPECOTIC ACID; (3S)-hexahydronicotinic acid; CHEBI:222169; (3S)-3-piperidinecarboxylic acid; 3-Piperidinecarboxylic acid, (3S)-; (S)-(+)-PIPERIDINE-3-CARBOXYLIC ACID; UNII-2635N2PS4Q; (3S)-(+)-piperidine-3-carboxylic acid; L-PIPERIDINE-3-CARBOXYLIC ACID
DMST89H	DT	Small molecular drug
DMST89H	PC	6575389
DMST89H	MW	129.16
DMST89H	FM	C6H11NO2
DMST89H	IC	InChI=1S/C6H11NO2/c8-6(9)5-2-1-3-7-4-5/h5,7H,1-4H2,(H,8,9)/t5-/m0/s1
DMST89H	CS	C1C[C@@H](CNC1)C(=O)O
DMST89H	IK	XJLSEXAGTJCILF-YFKPBYRVSA-N
DMST89H	IU	(3S)-piperidine-3-carboxylic acid
DMST89H	CA	CAS 59045-82-8
DMST89H	CB	CHEBI:222169
DMST89H	DE	Discovery agent

DMXVQJI	ID	DMXVQJI
DMXVQJI	DN	(S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone
DMXVQJI	HS	Investigative
DMXVQJI	SN	CHEMBL403882; L-Prolin-pyrrolidid; (S)-1-prolylpyrrolidine; 1-(L-Prolyl)pyrrolidine; (S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone; 41721-00-0; SCHEMBL1383434; HDLWINONZUFKQV-QMMMGPOBSA-N; ZINC11754367; BDBM50228295; AKOS022180332; AJ-60015; Pyrrolidine, 1-[(2S)-2-pyrrolidinylcarbonyl
DMXVQJI	DT	Small molecular drug
DMXVQJI	PC	13578534
DMXVQJI	MW	168.24
DMXVQJI	FM	C9H16N2O
DMXVQJI	IC	InChI=1S/C9H16N2O/c12-9(8-4-3-5-10-8)11-6-1-2-7-11/h8,10H,1-7H2/t8-/m0/s1
DMXVQJI	CS	C1CCN(C1)C(=O)[C@@H]2CCCN2
DMXVQJI	IK	HDLWINONZUFKQV-QMMMGPOBSA-N
DMXVQJI	IU	pyrrolidin-1-yl-[(2S)-pyrrolidin-2-yl]methanone
DMXVQJI	DE	Discovery agent

DM16N7Z	ID	DM16N7Z
DM16N7Z	DN	(S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone
DM16N7Z	HS	Investigative
DM16N7Z	SN	CHEMBL224435; (S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone; SCHEMBL2711156
DM16N7Z	DT	Small molecular drug
DM16N7Z	PC	44422449
DM16N7Z	MW	186.28
DM16N7Z	FM	C8H14N2OS
DM16N7Z	IC	InChI=1S/C8H14N2OS/c11-8(7-2-1-3-9-7)10-4-5-12-6-10/h7,9H,1-6H2/t7-/m0/s1
DM16N7Z	CS	C1C[C@H](NC1)C(=O)N2CCSC2
DM16N7Z	IK	GTTPYCGIEGLJPF-ZETCQYMHSA-N
DM16N7Z	IU	[(2S)-pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone
DM16N7Z	DE	Discovery agent

DM1SJZ3	ID	DM1SJZ3
DM1SJZ3	DN	(S)-Rolipram
DM1SJZ3	HS	Investigative
DM1SJZ3	SN	(S)-(+)-rolipram; 85416-73-5; S-(+)-Rolipram; (S)-ROLIPRAM; S- (+)-Rolipram; UNII-H6G4VMQ24K; H6G4VMQ24K; CHEMBL325795; CHEBI:59540; (4S)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE; (S)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one; (4S)-4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-pyrrolidin-2-one; S-rolipram; 1oyn; 1xn0; AC1L4KJV; MLS006011228; SCHEMBL5321568; CTK8G3018; DTXSID30234634; HJORMJIFDVBMOB-GFCCVEGCSA-N
DM1SJZ3	DT	Small molecular drug
DM1SJZ3	PC	158758
DM1SJZ3	MW	275.34
DM1SJZ3	FM	C16H21NO3
DM1SJZ3	IC	InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)/t12-/m1/s1
DM1SJZ3	CS	COC1=C(C=C(C=C1)[C@@H]2CC(=O)NC2)OC3CCCC3
DM1SJZ3	IK	HJORMJIFDVBMOB-GFCCVEGCSA-N
DM1SJZ3	IU	(4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one
DM1SJZ3	CA	CAS 85416-73-5
DM1SJZ3	CB	CHEBI:59540
DM1SJZ3	DE	Discovery agent

DMG4KIU	ID	DMG4KIU
DMG4KIU	DN	(S)-secoantioquine hydrochloride
DMG4KIU	HS	Investigative
DMG4KIU	SN	CHEMBL506299; (S)-Secoantioquine HCl
DMG4KIU	DT	Small molecular drug
DMG4KIU	PC	44584689
DMG4KIU	MW	675.2
DMG4KIU	FM	C37H39ClN2O8
DMG4KIU	IC	InChI=1S/C37H38N2O8.ClH/c1-38-12-11-24-18-33(46-5)35(42)36(47-32-19-25-23(17-31(32)45-4)10-13-39(2)37(25)43)34(24)28(38)16-21-7-9-30(44-3)27(14-21)26-15-22(20-40)6-8-29(26)41;/h6-9,14-15,17-20,28,41-42H,10-13,16H2,1-5H3;1H/t28-;/m0./s1
DMG4KIU	CS	CN1CCC2=CC(=C(C(=C2[C@@H]1CC3=CC(=C(C=C3)OC)C4=C(C=CC(=C4)C=O)O)OC5=C(C=C6CCN(C(=O)C6=C5)C)OC)O)OC.Cl
DMG4KIU	IK	UOCXQPQQPWZQIB-JCOPYZAKSA-N
DMG4KIU	IU	4-hydroxy-3-[5-[[(1S)-7-hydroxy-6-methoxy-8-[(6-methoxy-2-methyl-1-oxo-3,4-dihydroisoquinolin-7-yl)oxy]-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenyl]benzaldehyde;hydrochloride
DMG4KIU	DE	Discovery agent

DMS8WG3	ID	DMS8WG3
DMS8WG3	DN	(S)-sirtinol
DMS8WG3	HS	Investigative
DMS8WG3	DT	Small molecular drug
DMS8WG3	PC	1376645
DMS8WG3	MW	394.5
DMS8WG3	FM	C26H22N2O2
DMS8WG3	IC	InChI=1S/C26H22N2O2/c1-18(19-9-3-2-4-10-19)28-26(30)22-13-7-8-14-24(22)27-17-23-21-12-6-5-11-20(21)15-16-25(23)29/h2-18,29H,1H3,(H,28,30)/t18-/m0/s1
DMS8WG3	CS	C[C@@H](C1=CC=CC=C1)NC(=O)C2=CC=CC=C2N=CC3=C(C=CC4=CC=CC=C43)O
DMS8WG3	IK	UXJFDYIHRJGPFS-SFHVURJKSA-N
DMS8WG3	IU	2-[(2-hydroxynaphthalen-1-yl)methylideneamino]-N-[(1S)-1-phenylethyl]benzamide
DMS8WG3	DE	Discovery agent

DMH7QZ2	ID	DMH7QZ2
DMH7QZ2	DN	(S)-tacrine(10)-hupyridone
DMH7QZ2	HS	Investigative
DMH7QZ2	SN	(S)-TACRINE(10)-HUPYRIDONE; (5S)-5-{[10-(1,2,3,4-TETRAHYDROACRIDIN-9-YLAMINO)DECYL]AMINO}-5,6,7,8-TETRAHYDROQUINOLIN-2(1H)-ONE; AC1NS1EG; DB04615; (5S)-5-[10-(1,2,3,4-Tetrahydroacridine-9-ylamino)decylamino]-1,2,5,6,7,8-hexahydroquinoline-2-one; (S)-N-9 -(1 ,2 ,3 ,4 -TETRAHYDROACRIDINYL)-N'-5 -[5 ,6 ,7 ,8 -TETRAHYDRO-2'(1'H)-QUINOLINONYL]-1,10-DIAMINODECANE; (S)-TACRINE(10)-HUPYRIDONE; (S)-N-9 -(1 ,2 ,3 ,4 -TETRAHYDROACRIDINYL)-N'-5 -[5 ,6 ,7 ,8 -TETRAHYDRO-2'(1'H)-QUINOLINONYL]-1,10-DIAMINODECANE
DMH7QZ2	DT	Small molecular drug
DMH7QZ2	PC	5326967
DMH7QZ2	MW	500.7
DMH7QZ2	FM	C32H44N4O
DMH7QZ2	IC	InChI=1S/C32H44N4O/c37-31-21-20-24-27(18-13-19-28(24)36-31)33-22-11-5-3-1-2-4-6-12-23-34-32-25-14-7-9-16-29(25)35-30-17-10-8-15-26(30)32/h7,9,14,16,20-21,27,33H,1-6,8,10-13,15,17-19,22-23H2,(H,34,35)(H,36,37)/t27-/m0/s1
DMH7QZ2	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCCCCN[C@H]4CCCC5=C4C=CC(=O)N5
DMH7QZ2	IK	ROTFGKJJMRTWBD-MHZLTWQESA-N
DMH7QZ2	IU	(5S)-5-[10-(1,2,3,4-tetrahydroacridin-9-ylamino)decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMH7QZ2	DE	Discovery agent

DM68XFZ	ID	DM68XFZ
DM68XFZ	DN	(S)-TBPG
DM68XFZ	HS	Investigative
DM68XFZ	SN	S-TBPG
DM68XFZ	DT	Small molecular drug
DM68XFZ	PC	10058919
DM68XFZ	MW	209.21
DM68XFZ	FM	C8H11N5O2
DM68XFZ	IC	InChI=1S/C8H11N5O2/c9-4(5(14)15)7-1-8(2-7,3-7)6-10-12-13-11-6/h4H,1-3,9H2,(H,14,15)(H,10,11,12,13)/t4-,7?,8?/m1/s1
DM68XFZ	CS	C1C2(CC1(C2)[C@@H](C(=O)O)N)C3=NNN=N3
DM68XFZ	IK	XYCORZCGVTXZFU-XOJFDHPMSA-N
DM68XFZ	IU	(2S)-2-amino-2-[3-(2H-tetrazol-5-yl)-1-bicyclo[1.1.1]pentanyl]acetic acid
DM68XFZ	DE	Discovery agent

DMAQX4K	ID	DMAQX4K
DMAQX4K	DN	(S)-tert-butyl 1-oxohexan-2-ylcarbamate
DMAQX4K	HS	Investigative
DMAQX4K	SN	CHEMBL96875; ((S)-1-Formyl-pentyl)-carbamic acid tert-butyl ester; BML-244; (S)-tert-butyl 1-oxohexan-2-ylcarbamate; Carbamic acid, [(1S)-1-formylpentyl]-, 1,1-dimethylethyl ester; SCHEMBL3285479; CTK0G6629; OBMGXPJNZKYOQY-VIFPVBQESA-N; ZINC13588585; BDBM50137790; AKOS030572335; tert-butyl(1S)-1-formylpentylcarbamate; CCG-207873; 2(S)-(tert-Butoxycarbonylamino)hexanal; tert-butyl (1S)-1-formylpentylcarbamate; (2S)-2-(tert-Butoxycarbonylamino)hexanal; (S)-2-(tert-butoxycarbonylamino)-5-methylpentanal
DMAQX4K	DT	Small molecular drug
DMAQX4K	PC	10420833
DMAQX4K	MW	215.29
DMAQX4K	FM	C11H21NO3
DMAQX4K	IC	InChI=1S/C11H21NO3/c1-5-6-7-9(8-13)12-10(14)15-11(2,3)4/h8-9H,5-7H2,1-4H3,(H,12,14)/t9-/m0/s1
DMAQX4K	CS	CCCC[C@@H](C=O)NC(=O)OC(C)(C)C
DMAQX4K	IK	OBMGXPJNZKYOQY-VIFPVBQESA-N
DMAQX4K	IU	tert-butyl N-[(2S)-1-oxohexan-2-yl]carbamate
DMAQX4K	DE	Discovery agent

DMLG8Q2	ID	DMLG8Q2
DMLG8Q2	DN	(S)-tert-Butyl 4-(2-oxohexadecanamido)pentanoate
DMLG8Q2	HS	Investigative
DMLG8Q2	SN	CHEMBL462362
DMLG8Q2	DT	Small molecular drug
DMLG8Q2	PC	44562673
DMLG8Q2	MW	425.6
DMLG8Q2	FM	C25H47NO4
DMLG8Q2	IC	InChI=1S/C25H47NO4/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-22(27)24(29)26-21(2)19-20-23(28)30-25(3,4)5/h21H,6-20H2,1-5H3,(H,26,29)/t21-/m0/s1
DMLG8Q2	CS	CCCCCCCCCCCCCCC(=O)C(=O)N[C@@H](C)CCC(=O)OC(C)(C)C
DMLG8Q2	IK	MWODQGJPDWEORS-NRFANRHFSA-N
DMLG8Q2	IU	tert-butyl (4S)-4-(2-oxohexadecanoylamino)pentanoate
DMLG8Q2	DE	Discovery agent

DMR1HQ3	ID	DMR1HQ3
DMR1HQ3	DN	(S)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate
DMR1HQ3	HS	Investigative
DMR1HQ3	SN	58521-45-2; TERT-BUTYL (S)1-FORMYL-3-METHYLBUTYLCARBAMATE; Boc-Leucinal; N-t-butoxycarbonyl-L-leucinal; CHEMBL96823; N-Boc-2(S)-2-amino-4-methyl-pentanal; tert-butyl N-[(2S)-4-methyl-1-oxopentan-2-yl]carbamate; Boc-Leu-H; Boc--L--Leucinal; (S)-Boc-Leucinal; t-Boc-Leu-H; BOC-L-LEUCINAL; BOC-LEU-CHO; AC1L2WGL; N--BOC--L--leucinal; t-butoxycarbonyl-L-leucinal; tert-butyl (1S)-1-formyl-3-methylbutylcarbamate; tert-butyloxycarbonyl-leucinal; SCHEMBL739719; N-tert-butoxycarbonyl-L-leucinal; (t-Butyloxycarbonyl)-L-Leucinal
DMR1HQ3	DT	Small molecular drug
DMR1HQ3	PC	104275
DMR1HQ3	MW	215.29
DMR1HQ3	FM	C11H21NO3
DMR1HQ3	IC	InChI=1S/C11H21NO3/c1-8(2)6-9(7-13)12-10(14)15-11(3,4)5/h7-9H,6H2,1-5H3,(H,12,14)/t9-/m0/s1
DMR1HQ3	CS	CC(C)C[C@@H](C=O)NC(=O)OC(C)(C)C
DMR1HQ3	IK	RQSBRFZHUKLKNO-VIFPVBQESA-N
DMR1HQ3	IU	tert-butyl N-[(2S)-4-methyl-1-oxopentan-2-yl]carbamate
DMR1HQ3	DE	Discovery agent

DMXQ47M	ID	DMXQ47M
DMXQ47M	DN	(S)-WILLARDIINE
DMXQ47M	HS	Investigative
DMXQ47M	SN	(S)-WILLARDIINE; Willardiine; S(-)-Willardiine; 21416-43-3; 3-(Uracil-1-yl)-L-alanine; (-)-Willardiine; CHEMBL122005; CHEBI:15851; 3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-L-alanine; HWD; 2-AMINO-3-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID; 1mqj; 3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)alanine; AC1L98KY; Lopac0_001219; SCHEMBL401191; SCHEMBL13319907; BDBM17661; CTK5H8581; MolPort-003-959-938; ZINC901774; 96108-98-4; 2990AH; AKOS006281897; DB04129; CCG-205293; CS-3618; NCGC00094464-03; HY-12499; EU-0101219; C03584
DMXQ47M	DT	Small molecular drug
DMXQ47M	PC	440053
DMXQ47M	MW	199.16
DMXQ47M	FM	C7H9N3O4
DMXQ47M	IC	InChI=1S/C7H9N3O4/c8-4(6(12)13)3-10-2-1-5(11)9-7(10)14/h1-2,4H,3,8H2,(H,12,13)(H,9,11,14)/t4-/m0/s1
DMXQ47M	CS	C1=CN(C(=O)NC1=O)C[C@@H](C(=O)O)N
DMXQ47M	IK	FACUYWPMDKTVFU-BYPYZUCNSA-N
DMXQ47M	IU	(2S)-2-amino-3-(2,4-dioxopyrimidin-1-yl)propanoic acid
DMXQ47M	CA	CAS 21416-43-3
DMXQ47M	CB	CHEBI:15851
DMXQ47M	DE	Discovery agent

DM6BON2	ID	DM6BON2
DM6BON2	DN	(S)-zacopride
DM6BON2	HS	Investigative
DM6BON2	SN	CHEMBL28992; Tocris-1795; NCGC00025295-01; AC1O7H1O; SCHEMBL5373467; ZINC3961; GTPL2289; SCHEMBL16233195; PDSP2_001618; PDSP1_001634; BDBM50056419; UNII-9GN3OT4156 component FEROPKNOYKURCJ-CYBMUJFWSA-N; 4-Amino-N-(S)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide; 4-amino-N-[(8S)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide
DM6BON2	DT	Small molecular drug
DM6BON2	PC	6604914
DM6BON2	MW	309.79
DM6BON2	FM	C15H20ClN3O2
DM6BON2	IC	InChI=1S/C15H20ClN3O2/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20)/t13-/m1/s1
DM6BON2	CS	COC1=CC(=C(C=C1C(=O)N[C@@H]2CN3CCC2CC3)Cl)N
DM6BON2	IK	FEROPKNOYKURCJ-CYBMUJFWSA-N
DM6BON2	IU	4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide
DM6BON2	DE	Discovery agent

DMA30RW	ID	DMA30RW
DMA30RW	DN	(S,R)-(+)-fenoterol
DMA30RW	HS	Investigative
DMA30RW	SN	(S,R)-(+)-fenoterol; CHEMBL229477; (S,R)-Fenoterol; AC1LDIMM; SCHEMBL9971023; ZINC20252; BDBM50213103; 5-[(1S)-1-hydroxy-2-[[(2R)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DMA30RW	DT	Small molecular drug
DMA30RW	PC	667688
DMA30RW	MW	303.35
DMA30RW	FM	C17H21NO4
DMA30RW	IC	InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3/t11-,17-/m1/s1
DMA30RW	CS	C[C@H](CC1=CC=C(C=C1)O)NC[C@H](C2=CC(=CC(=C2)O)O)O
DMA30RW	IK	LSLYOANBFKQKPT-PIGZYNQJSA-N
DMA30RW	IU	5-[(1S)-1-hydroxy-2-[[(2R)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DMA30RW	DE	Discovery agent

DMIV0MT	ID	DMIV0MT
DMIV0MT	DN	(S,R)-antioquine hydrochloride
DMIV0MT	HS	Investigative
DMIV0MT	SN	CHEMBL446564; (S,R)-Antioquine HCl
DMIV0MT	DT	Small molecular drug
DMIV0MT	PC	44584687
DMIV0MT	MW	645.2
DMIV0MT	FM	C37H41ClN2O6
DMIV0MT	IC	InChI=1S/C37H40N2O6.ClH/c1-38-12-10-23-18-32(43-4)33-20-25(23)28(38)16-21-6-8-30(40)26(14-21)27-15-22(7-9-31(27)42-3)17-29-35-24(11-13-39(29)2)19-34(44-5)36(41)37(35)45-33;/h6-9,14-15,18-20,28-29,40-41H,10-13,16-17H2,1-5H3;1H/t28-,29+;/m1./s1
DMIV0MT	CS	CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC(=C(C=C4)O)C5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)O)OC)OC.Cl
DMIV0MT	IK	XMYUKGNJCHUIHP-XZVFQGBBSA-N
DMIV0MT	IU	(1R,14S)-9,20,25-trimethoxy-15,30-dimethyl-23-oxa-15,30-diazaheptacyclo[22.6.2.13,7.18,12.114,18.027,31.022,33]pentatriaconta-3(35),4,6,8,10,12(34),18,20,22(33),24,26,31-dodecaene-6,21-diol;hydrochloride
DMIV0MT	DE	Discovery agent

DMZV52W	ID	DMZV52W
DMZV52W	DN	(S,R)-isotetrandrine hydrochloride
DMZV52W	HS	Investigative
DMZV52W	SN	CHEMBL506025; (S,R)-Isotetrandrine HCl
DMZV52W	DT	Small molecular drug
DMZV52W	PC	44584681
DMZV52W	MW	659.2
DMZV52W	FM	C38H43ClN2O6
DMZV52W	IC	InChI=1S/C38H42N2O6.ClH/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34;/h7-12,19-22,29-30H,13-18H2,1-6H3;1H/t29-,30+;/m0./s1
DMZV52W	CS	CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC.Cl
DMZV52W	IK	RJAXUPVPTQWJKH-XCCPJCIBSA-N
DMZV52W	IU	(1S,14R)-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene;hydrochloride
DMZV52W	DE	Discovery agent

DMMRUVF	ID	DMMRUVF
DMMRUVF	DN	(S,R)-pseudoxandrine hydrochloride
DMMRUVF	HS	Investigative
DMMRUVF	SN	CHEMBL504303; (S,R)-Pseudoxandrine HCl
DMMRUVF	DT	Small molecular drug
DMMRUVF	PC	44584686
DMMRUVF	MW	622.7
DMMRUVF	FM	C37H38N2O7
DMMRUVF	IC	InChI=1S/C37H38N2O7/c1-38-12-10-21-17-30(44-4)31-19-24(21)27(38)15-20-6-9-29(43-3)26(14-20)25-16-23(7-8-28(25)40)35(41)34-33-22(11-13-39(34)2)18-32(45-5)36(42)37(33)46-31/h6-9,14,16-19,27,34,40,42H,10-13,15H2,1-5H3/t27-,34+/m1/s1
DMMRUVF	CS	CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC(=C(C=C4)OC)C5=C(C=CC(=C5)C(=O)[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)O)O)OC
DMMRUVF	IK	RUAKOEPLVVXTGN-YJNPBZNESA-N
DMMRUVF	IU	(1R,14S)-9,21-dihydroxy-6,20,25-trimethoxy-15,30-dimethyl-23-oxa-15,30-diazaheptacyclo[22.6.2.13,7.18,12.114,18.027,31.022,33]pentatriaconta-3(35),4,6,8,10,12(34),18,20,22(33),24,26,31-dodecaen-13-one
DMMRUVF	DE	Discovery agent

DMBR1JS	ID	DMBR1JS
DMBR1JS	DN	(S,S)-(-)-bis(10)-hupyridone
DMBR1JS	HS	Investigative
DMBR1JS	SN	E10; (s,s)-(-)-n,n'-di-5'-[5',6',7',8'-tetrahydro- 2'(1'h)-quinolynyl]-1,10-diaminodecane dihydrochloride; (S,S)-(-)-bis(10)-hupyridone; AC1L9IVU; CHEMBL483090; BDBM10439; 1h22; 5,5'-(1,10-Decanediylbisimino)bis[(5S)-5,6,7,8-tetrahydro-2(1H)-quinolinone]; (5S,5'S)-5,5'-(decane-1,10-diyldiimino)di(5,6,7,8-tetrahydroquinolin-2(1H)-one); (5S)-5-[10-[[(5S)-2-oxo-5,6,7,8-tetrahydro-1H-quinolin-5-yl]amino]decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMBR1JS	DT	Small molecular drug
DMBR1JS	PC	445974
DMBR1JS	MW	466.7
DMBR1JS	FM	C28H42N4O2
DMBR1JS	IC	InChI=1S/C28H42N4O2/c33-27-17-15-21-23(11-9-13-25(21)31-27)29-19-7-5-3-1-2-4-6-8-20-30-24-12-10-14-26-22(24)16-18-28(34)32-26/h15-18,23-24,29-30H,1-14,19-20H2,(H,31,33)(H,32,34)/t23-,24-/m0/s1
DMBR1JS	CS	C1C[C@@H](C2=C(C1)NC(=O)C=C2)NCCCCCCCCCCN[C@H]3CCCC4=C3C=CC(=O)N4
DMBR1JS	IK	CKFAWHBPSZAYLS-ZEQRLZLVSA-N
DMBR1JS	IU	(5S)-5-[10-[[(5S)-2-oxo-5,6,7,8-tetrahydro-1H-quinolin-5-yl]amino]decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMBR1JS	CA	CAS 286381-86-0
DMBR1JS	DE	Discovery agent

DM6PQ8D	ID	DM6PQ8D
DM6PQ8D	DN	(S,S)-(-)-bis(12)-hupyridone
DM6PQ8D	HS	Investigative
DM6PQ8D	SN	E12; (s,s)-(-)-n,n'-di-5'-[5',6',7',8'-tetrahydro- 2'(1'h)-quinolynyl]-1,12-diaminododecane dihydrochloride; (S,S)-(-)-bis(12)-hupyridone; AC1L9IVX; CHEMBL519154; BDBM10440; 1h23; 5,5'-(1,12-Dodecanediylbisimino)bis[(5S)-5,6,7,8-tetrahydro-2(1H)-quinolinone]; (5S,5'S)-5,5'-(dodecane-1,12-diyldiimino)di(5,6,7,8-tetrahydroquinolin-2(1H)-one); (5S)-5-[12-[[(5S)-2-oxo-5,6,7,8-tetrahydro-1H-quinolin-5-yl]amino]dodecylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DM6PQ8D	DT	Small molecular drug
DM6PQ8D	PC	445975
DM6PQ8D	MW	494.7
DM6PQ8D	FM	C30H46N4O2
DM6PQ8D	IC	InChI=1S/C30H46N4O2/c35-29-19-17-23-25(13-11-15-27(23)33-29)31-21-9-7-5-3-1-2-4-6-8-10-22-32-26-14-12-16-28-24(26)18-20-30(36)34-28/h17-20,25-26,31-32H,1-16,21-22H2,(H,33,35)(H,34,36)/t25-,26-/m0/s1
DM6PQ8D	CS	C1C[C@@H](C2=C(C1)NC(=O)C=C2)NCCCCCCCCCCCCN[C@H]3CCCC4=C3C=CC(=O)N4
DM6PQ8D	IK	VFFGYPZORQBRNM-UIOOFZCWSA-N
DM6PQ8D	IU	(5S)-5-[12-[[(5S)-2-oxo-5,6,7,8-tetrahydro-1H-quinolin-5-yl]amino]dodecylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DM6PQ8D	DE	Discovery agent

DMYDS6F	ID	DMYDS6F
DMYDS6F	DN	(S,S)-oxandrine hydrochloride
DMYDS6F	HS	Investigative
DMYDS6F	SN	CHEMBL445011; (S,S)-Oxandrine HCl
DMYDS6F	DT	Small molecular drug
DMYDS6F	PC	44584684
DMYDS6F	MW	622.7
DMYDS6F	FM	C37H38N2O7
DMYDS6F	IC	InChI=1S/C37H38N2O7/c1-38-12-11-22-18-32(45-5)36(42)37-33(22)27(38)15-20-6-9-29(43-3)26(14-20)25-16-23(7-8-28(25)40)35(41)34-24-19-31(46-37)30(44-4)17-21(24)10-13-39(34)2/h6-9,14,16-19,27,34,40,42H,10-13,15H2,1-5H3/t27-,34-/m0/s1
DMYDS6F	CS	CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C4)OC)C5=C(C=CC(=C5)C(=O)[C@@H]6C7=CC(=C(C=C7CCN6C)OC)O3)O)O)OC
DMYDS6F	IK	XCZPVAXCZZECDL-FOPBOCKXSA-N
DMYDS6F	IU	(1S,14S)-6,21-dihydroxy-9,20,25-trimethoxy-15,30-dimethyl-23-oxa-15,30-diazaheptacyclo[22.6.2.13,7.18,12.114,18.027,31.022,33]pentatriaconta-3(35),4,6,8,10,12(34),18,20,22(33),24,26,31-dodecaen-2-one
DMYDS6F	DE	Discovery agent

DMJL8SE	ID	DMJL8SE
DMJL8SE	DN	(Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K
DMJL8SE	HS	Investigative
DMJL8SE	SN	CHEMBL460706; (Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K
DMJL8SE	PC	44563953
DMJL8SE	MW	2029.5
DMJL8SE	FM	C98H161N23O23
DMJL8SE	IC	InChI=1S/C98H161N23O23/c1-11-12-13-14-15-16-17-36-80(126)105-44-27-23-34-69(88(133)111-67(85(103)130)31-20-24-41-99)113-89(134)68(32-21-25-42-100)112-90(135)70(33-22-26-43-101)114-96(141)77-35-28-45-121(77)82(128)54-108-87(132)71(46-57(2)3)115-91(136)72(47-58(4)5)116-93(138)74(49-62-37-39-64(124)40-38-62)110-81(127)53-107-86(131)60(8)109-95(140)76(56-122)119-94(139)75(51-79(102)125)117-92(137)73(48-59(6)7)118-98(143)84(61(9)123)120-97(142)78(144-83(129)55-104-10)50-63-52-106-66-30-19-18-29-65(63)66/h18-19,29-30,37-40,52,57-61,67-78,84,104,106,122-124H,11-17,20-28,31-36,41-51,53-56,99-101H2,1-10H3,(H2,102,125)(H2,103,130)(H,105,126)(H,107,131)(H,108,132)(H,109,140)(H,110,127)(H,111,133)(H,112,135)(H,113,134)(H,114,141)(H,115,136)(H,116,138)(H,117,137)(H,118,143)(H,119,139)(H,120,142)/t60-,61+,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,84-/m0/s1
DMJL8SE	CS	CCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMJL8SE	IK	PSJWDZZPEFDHOW-QSNPNBGOSA-N
DMJL8SE	IU	[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-(decanoylamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMJL8SE	DE	Discovery agent

DMPZHIE	ID	DMPZHIE
DMPZHIE	DN	(Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K
DMPZHIE	HS	Investigative
DMPZHIE	SN	CHEMBL507733; (Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K
DMPZHIE	PC	44563954
DMPZHIE	MW	2057.5
DMPZHIE	FM	C100H165N23O23
DMPZHIE	IC	InChI=1S/C100H165N23O23/c1-11-12-13-14-15-16-17-18-19-38-82(128)107-46-29-25-36-71(90(135)113-69(87(105)132)33-22-26-43-101)115-91(136)70(34-23-27-44-102)114-92(137)72(35-24-28-45-103)116-98(143)79-37-30-47-123(79)84(130)56-110-89(134)73(48-59(2)3)117-93(138)74(49-60(4)5)118-95(140)76(51-64-39-41-66(126)42-40-64)112-83(129)55-109-88(133)62(8)111-97(142)78(58-124)121-96(141)77(53-81(104)127)119-94(139)75(50-61(6)7)120-100(145)86(63(9)125)122-99(144)80(146-85(131)57-106-10)52-65-54-108-68-32-21-20-31-67(65)68/h20-21,31-32,39-42,54,59-63,69-80,86,106,108,124-126H,11-19,22-30,33-38,43-53,55-58,101-103H2,1-10H3,(H2,104,127)(H2,105,132)(H,107,128)(H,109,133)(H,110,134)(H,111,142)(H,112,129)(H,113,135)(H,114,137)(H,115,136)(H,116,143)(H,117,138)(H,118,140)(H,119,139)(H,120,145)(H,121,141)(H,122,144)/t62-,63+,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,86-/m0/s1
DMPZHIE	CS	CCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMPZHIE	IK	MNPLGRICQVXCSX-IUVNOECISA-N
DMPZHIE	IU	[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(dodecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMPZHIE	DE	Discovery agent

DMQIHZU	ID	DMQIHZU
DMQIHZU	DN	(Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K
DMQIHZU	HS	Investigative
DMQIHZU	SN	CHEMBL505299; (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K
DMQIHZU	PC	44563958
DMQIHZU	MW	2123.5
DMQIHZU	FM	C99H163N23O28
DMQIHZU	IC	InChI=1S/C99H163N23O28/c1-58(2)46-72(88(133)109-54-83(129)122-37-21-28-78(122)97(142)115-71(26-15-19-35-102)91(136)113-69(25-14-18-34-101)90(135)114-70(89(134)112-68(86(104)131)24-13-17-33-100)27-16-20-36-106-82(128)57-149-45-44-148-43-42-147-41-40-146-39-38-145-10)116-92(137)73(47-59(3)4)117-94(139)75(49-63-29-31-65(125)32-30-63)111-81(127)53-108-87(132)61(7)110-96(141)77(56-123)120-95(140)76(51-80(103)126)118-93(138)74(48-60(5)6)119-99(144)85(62(8)124)121-98(143)79(150-84(130)55-105-9)50-64-52-107-67-23-12-11-22-66(64)67/h11-12,22-23,29-32,52,58-62,68-79,85,105,107,123-125H,13-21,24-28,33-51,53-57,100-102H2,1-10H3,(H2,103,126)(H2,104,131)(H,106,128)(H,108,132)(H,109,133)(H,110,141)(H,111,127)(H,112,134)(H,113,136)(H,114,135)(H,115,142)(H,116,137)(H,117,139)(H,118,138)(H,119,144)(H,120,140)(H,121,143)/t61-,62+,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,85-/m0/s1
DMQIHZU	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCNC(=O)COCCOCCOCCOCCOC)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC)O
DMQIHZU	IK	MJZZQPFMLULOPB-UJNSRDRFSA-N
DMQIHZU	IU	[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-[[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]acetyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMQIHZU	DE	Discovery agent

DMVHDF4	ID	DMVHDF4
DMVHDF4	DN	(Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K
DMVHDF4	HS	Investigative
DMVHDF4	SN	CHEMBL524678; (Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K
DMVHDF4	PC	44563955
DMVHDF4	MW	2085.6
DMVHDF4	FM	C102H169N23O23
DMVHDF4	IC	InChI=1S/C102H169N23O23/c1-11-12-13-14-15-16-17-18-19-20-21-40-84(130)109-48-31-27-38-73(92(137)115-71(89(107)134)35-24-28-45-103)117-93(138)72(36-25-29-46-104)116-94(139)74(37-26-30-47-105)118-100(145)81-39-32-49-125(81)86(132)58-112-91(136)75(50-61(2)3)119-95(140)76(51-62(4)5)120-97(142)78(53-66-41-43-68(128)44-42-66)114-85(131)57-111-90(135)64(8)113-99(144)80(60-126)123-98(143)79(55-83(106)129)121-96(141)77(52-63(6)7)122-102(147)88(65(9)127)124-101(146)82(148-87(133)59-108-10)54-67-56-110-70-34-23-22-33-69(67)70/h22-23,33-34,41-44,56,61-65,71-82,88,108,110,126-128H,11-21,24-32,35-40,45-55,57-60,103-105H2,1-10H3,(H2,106,129)(H2,107,134)(H,109,130)(H,111,135)(H,112,136)(H,113,144)(H,114,131)(H,115,137)(H,116,139)(H,117,138)(H,118,145)(H,119,140)(H,120,142)(H,121,141)(H,122,147)(H,123,143)(H,124,146)/t64-,65+,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,88-/m0/s1
DMVHDF4	CS	CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMVHDF4	IK	KPRCBTZIVGRZHY-OPDXRYIWSA-N
DMVHDF4	IU	[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxo-6-(tetradecanoylamino)hexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMVHDF4	DE	Discovery agent

DMX3K4E	ID	DMX3K4E
DMX3K4E	DN	(Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K
DMX3K4E	HS	Investigative
DMX3K4E	SN	CHEMBL503900; (Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K
DMX3K4E	PC	44563952
DMX3K4E	MW	2001.4
DMX3K4E	FM	C96H157N23O23
DMX3K4E	IC	InChI=1S/C96H157N23O23/c1-11-12-13-14-15-34-78(124)103-42-25-21-32-67(86(131)109-65(83(101)128)29-18-22-39-97)111-87(132)66(30-19-23-40-98)110-88(133)68(31-20-24-41-99)112-94(139)75-33-26-43-119(75)80(126)52-106-85(130)69(44-55(2)3)113-89(134)70(45-56(4)5)114-91(136)72(47-60-35-37-62(122)38-36-60)108-79(125)51-105-84(129)58(8)107-93(138)74(54-120)117-92(137)73(49-77(100)123)115-90(135)71(46-57(6)7)116-96(141)82(59(9)121)118-95(140)76(142-81(127)53-102-10)48-61-50-104-64-28-17-16-27-63(61)64/h16-17,27-28,35-38,50,55-59,65-76,82,102,104,120-122H,11-15,18-26,29-34,39-49,51-54,97-99H2,1-10H3,(H2,100,123)(H2,101,128)(H,103,124)(H,105,129)(H,106,130)(H,107,138)(H,108,125)(H,109,131)(H,110,133)(H,111,132)(H,112,139)(H,113,134)(H,114,136)(H,115,135)(H,116,141)(H,117,137)(H,118,140)/t58-,59+,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,82-/m0/s1
DMX3K4E	CS	CCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMX3K4E	IK	XODIEYZRWNAUJL-MBNUXEJASA-N
DMX3K4E	IU	[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(octanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMX3K4E	DE	Discovery agent

DMSVMI8	ID	DMSVMI8
DMSVMI8	DN	(Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K
DMSVMI8	HS	Investigative
DMSVMI8	SN	CHEMBL507353; (Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K
DMSVMI8	PC	44563956
DMSVMI8	MW	2113.6
DMSVMI8	FM	C104H173N23O23
DMSVMI8	IC	InChI=1S/C104H173N23O23/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-86(132)111-50-33-29-40-75(94(139)117-73(91(109)136)37-26-30-47-105)119-95(140)74(38-27-31-48-106)118-96(141)76(39-28-32-49-107)120-102(147)83-41-34-51-127(83)88(134)60-114-93(138)77(52-63(2)3)121-97(142)78(53-64(4)5)122-99(144)80(55-68-43-45-70(130)46-44-68)116-87(133)59-113-92(137)66(8)115-101(146)82(62-128)125-100(145)81(57-85(108)131)123-98(143)79(54-65(6)7)124-104(149)90(67(9)129)126-103(148)84(150-89(135)61-110-10)56-69-58-112-72-36-25-24-35-71(69)72/h24-25,35-36,43-46,58,63-67,73-84,90,110,112,128-130H,11-23,26-34,37-42,47-57,59-62,105-107H2,1-10H3,(H2,108,131)(H2,109,136)(H,111,132)(H,113,137)(H,114,138)(H,115,146)(H,116,133)(H,117,139)(H,118,141)(H,119,140)(H,120,147)(H,121,142)(H,122,144)(H,123,143)(H,124,149)(H,125,145)(H,126,148)/t66-,67+,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,90-/m0/s1
DMSVMI8	CS	CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMSVMI8	IK	JPTGYQMVTVXYRV-CMDPNKGGSA-N
DMSVMI8	IU	[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMSVMI8	DE	Discovery agent

DMO6N7C	ID	DMO6N7C
DMO6N7C	DN	(Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K
DMO6N7C	HS	Investigative
DMO6N7C	SN	CHEMBL450827; (Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K
DMO6N7C	PC	44563957
DMO6N7C	MW	2141.7
DMO6N7C	FM	C106H177N23O23
DMO6N7C	IC	InChI=1S/C106H177N23O23/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-44-88(134)113-52-35-31-42-77(96(141)119-75(93(111)138)39-28-32-49-107)121-97(142)76(40-29-33-50-108)120-98(143)78(41-30-34-51-109)122-104(149)85-43-36-53-129(85)90(136)62-116-95(140)79(54-65(2)3)123-99(144)80(55-66(4)5)124-101(146)82(57-70-45-47-72(132)48-46-70)118-89(135)61-115-94(139)68(8)117-103(148)84(64-130)127-102(147)83(59-87(110)133)125-100(145)81(56-67(6)7)126-106(151)92(69(9)131)128-105(150)86(152-91(137)63-112-10)58-71-60-114-74-38-27-26-37-73(71)74/h26-27,37-38,45-48,60,65-69,75-86,92,112,114,130-132H,11-25,28-36,39-44,49-59,61-64,107-109H2,1-10H3,(H2,110,133)(H2,111,138)(H,113,134)(H,115,139)(H,116,140)(H,117,148)(H,118,135)(H,119,141)(H,120,143)(H,121,142)(H,122,149)(H,123,144)(H,124,146)(H,125,145)(H,126,151)(H,127,147)(H,128,150)/t68-,69+,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,92-/m0/s1
DMO6N7C	CS	CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMO6N7C	IK	IJKWJUNWQVNEKE-QPWLOKLFSA-N
DMO6N7C	IU	[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(octadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMO6N7C	DE	Discovery agent

DMT2NVG	ID	DMT2NVG
DMT2NVG	DN	(Sar)WTLNSAGYLLGPKKKK
DMT2NVG	HS	Investigative
DMT2NVG	SN	CHEMBL508036; (Sar)WTLNSAGYLLGPKKKK
DMT2NVG	PC	44563951
DMT2NVG	MW	1875.2
DMT2NVG	FM	C88H143N23O22
DMT2NVG	IC	InChI=1S/C88H143N23O22/c1-48(2)37-62(77(121)98-45-72(117)111-36-20-27-68(111)86(130)104-61(26-15-19-35-92)80(124)103-60(25-14-18-34-91)79(123)102-59(24-13-17-33-90)78(122)101-58(75(94)119)23-12-16-32-89)105-81(125)63(38-49(3)4)106-83(127)65(40-53-28-30-55(114)31-29-53)100-71(116)44-97-76(120)51(7)99-85(129)67(47-112)109-84(128)66(42-70(93)115)107-82(126)64(39-50(5)6)108-88(132)74(52(8)113)110-87(131)69(133-73(118)46-95-9)41-54-43-96-57-22-11-10-21-56(54)57/h10-11,21-22,28-31,43,48-52,58-69,74,95-96,112-114H,12-20,23-27,32-42,44-47,89-92H2,1-9H3,(H2,93,115)(H2,94,119)(H,97,120)(H,98,121)(H,99,129)(H,100,116)(H,101,122)(H,102,123)(H,103,124)(H,104,130)(H,105,125)(H,106,127)(H,107,126)(H,108,132)(H,109,128)(H,110,131)/t51-,52+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,74-/m0/s1
DMT2NVG	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC)O
DMT2NVG	IK	JTWAWYOTWKLDAO-GFUYWXIVSA-N
DMT2NVG	IU	[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMT2NVG	DE	Discovery agent

DMT3S72	ID	DMT3S72
DMT3S72	DN	(South)-Methanocarba-Thymidine
DMT3S72	HS	Investigative
DMT3S72	SN	(SOUTH)-METHANOCARBA-THYMIDINE; south-methanocarbathymidine; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hex-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; SCT; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]thymine; (1S,3S,4R,5S)-3-hydroxy-4-hydroxymethyl-1-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)bicyclo[3.1.0]hexane; [(S)-Methanocarba-T]; South-Methanocarba-thymine; AC1L9L1U; 2'-exo-Methanocarbathymidine; CHEBI:45586; XRMLXZVSFIBRRJ-PEFMBERDSA-N; DB02921
DMT3S72	DT	Small molecular drug
DMT3S72	PC	447628
DMT3S72	MW	252.27
DMT3S72	FM	C12H16N2O4
DMT3S72	IC	InChI=1S/C12H16N2O4/c1-6-4-14(11(18)13-10(6)17)12-2-8(12)7(5-15)9(16)3-12/h4,7-9,15-16H,2-3,5H2,1H3,(H,13,17,18)/t7-,8-,9-,12-/m0/s1
DMT3S72	CS	CC1=CN(C(=O)NC1=O)[C@]23C[C@H]2[C@@H]([C@H](C3)O)CO
DMT3S72	IK	XRMLXZVSFIBRRJ-PEFMBERDSA-N
DMT3S72	IU	1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)-1-bicyclo[3.1.0]hexanyl]-5-methylpyrimidine-2,4-dione
DMT3S72	CB	CHEBI:45586
DMT3S72	DE	Discovery agent

DMLW7TV	ID	DMLW7TV
DMLW7TV	DN	(Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine
DMLW7TV	HS	Investigative
DMLW7TV	SN	(TERT-BUTYLOXYCARBONYL)-ALANYL-ALANYL-AMINE; Boc-Ala-Ala-NH2; AC1NUZE3; SCHEMBL4327766; CTK5J1322; DB03757; 41036-24-2; N-(tert-butoxycarbonyl)-L-alanyl-L-alaninamide; tert-butyl N-[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamate
DMLW7TV	DT	Small molecular drug
DMLW7TV	PC	5497045
DMLW7TV	MW	259.3
DMLW7TV	FM	C11H21N3O4
DMLW7TV	IC	InChI=1S/C11H21N3O4/c1-6(8(12)15)13-9(16)7(2)14-10(17)18-11(3,4)5/h6-7H,1-5H3,(H2,12,15)(H,13,16)(H,14,17)/t6-,7-/m0/s1
DMLW7TV	CS	C[C@@H](C(=O)N)NC(=O)[C@H](C)NC(=O)OC(C)(C)C
DMLW7TV	IK	OAXZAMSRJZWMEV-BQBZGAKWSA-N
DMLW7TV	IU	tert-butyl N-[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamate
DMLW7TV	CA	CAS 41036-24-2
DMLW7TV	DE	Discovery agent

DMVZYNH	ID	DMVZYNH
DMVZYNH	DN	(Z)-1-(4-phenyloxazol-2-yl)octadec-9-en-1-one
DMVZYNH	HS	Investigative
DMVZYNH	SN	CHEMBL177471; (Z)-1-(4-phenyloxazol-2-yl)octadec-9-en-1-one; SCHEMBL3185614; BDBM50163160
DMVZYNH	DT	Small molecular drug
DMVZYNH	PC	10070106
DMVZYNH	MW	409.6
DMVZYNH	FM	C27H39NO2
DMVZYNH	IC	InChI=1S/C27H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-26(29)27-28-25(23-30-27)24-20-17-16-18-21-24/h9-10,16-18,20-21,23H,2-8,11-15,19,22H2,1H3/b10-9-
DMVZYNH	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC(=CO1)C2=CC=CC=C2
DMVZYNH	IK	KOOKQMBHKMEODJ-KTKRTIGZSA-N
DMVZYNH	IU	(Z)-1-(4-phenyl-1,3-oxazol-2-yl)octadec-9-en-1-one
DMVZYNH	DE	Discovery agent

DMNBDGH	ID	DMNBDGH
DMNBDGH	DN	(Z)-1-(benzo[d]oxazol-2-yl)octadec-9-en-1-one
DMNBDGH	HS	Investigative
DMNBDGH	SN	CHEMBL285678; (Z)-1-(benzo[d]oxazol-2-yl)octadec-9-en-1-one; SCHEMBL3964233; BDBM50100871; LS-97768; 1-Benzooxazol-2-yl-nonadec-10-en-2-one; (Z)-1-Benzooxazol-2-yl-octadec-9-en-1-one; (9Z)-1-(Benzoxazole-2-yl)-9-octadecene-1-one
DMNBDGH	DT	Small molecular drug
DMNBDGH	PC	10293363
DMNBDGH	MW	383.6
DMNBDGH	FM	C25H37NO2
DMNBDGH	IC	InChI=1S/C25H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-23(27)25-26-22-19-17-18-21-24(22)28-25/h9-10,17-19,21H,2-8,11-16,20H2,1H3/b10-9-
DMNBDGH	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC2=CC=CC=C2O1
DMNBDGH	IK	APIPEDDJLOMNRC-KTKRTIGZSA-N
DMNBDGH	IU	(Z)-1-(1,3-benzoxazol-2-yl)octadec-9-en-1-one
DMNBDGH	DE	Discovery agent

DMMTXKO	ID	DMMTXKO
DMMTXKO	DN	(Z)-1-(pyridazin-3-yl)octadec-9-en-1-one
DMMTXKO	HS	Investigative
DMMTXKO	SN	CHEMBL405089; SCHEMBL3967504; BDBM50374371; (9z)-1-pyridazin-3-yloctadec-9-en-1-one
DMMTXKO	DT	Small molecular drug
DMMTXKO	PC	12071714
DMMTXKO	MW	344.5
DMMTXKO	FM	C22H36N2O
DMMTXKO	IC	InChI=1S/C22H36N2O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-22(25)21-18-17-20-23-24-21/h9-10,17-18,20H,2-8,11-16,19H2,1H3/b10-9-
DMMTXKO	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NN=CC=C1
DMMTXKO	IK	REQRZXMTFPJHJQ-KTKRTIGZSA-N
DMMTXKO	IU	(Z)-1-pyridazin-3-yloctadec-9-en-1-one
DMMTXKO	DE	Discovery agent

DMSVBZO	ID	DMSVBZO
DMSVBZO	DN	(Z)-1,1,1,2,2,3,3-heptafluorohenicos-12-en-4-one
DMSVBZO	HS	Investigative
DMSVBZO	SN	CHEMBL1098397
DMSVBZO	DT	Small molecular drug
DMSVBZO	PC	25137229
DMSVBZO	MW	434.5
DMSVBZO	FM	C21H33F7O
DMSVBZO	IC	InChI=1S/C21H33F7O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(29)19(22,23)20(24,25)21(26,27)28/h9-10H,2-8,11-17H2,1H3/b10-9-
DMSVBZO	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C(C(C(F)(F)F)(F)F)(F)F
DMSVBZO	IK	CAINANTZOVVNLF-KTKRTIGZSA-N
DMSVBZO	IU	(Z)-1,1,1,2,2,3,3-heptafluorohenicos-12-en-4-one
DMSVBZO	DE	Discovery agent

DMBTMDG	ID	DMBTMDG
DMBTMDG	DN	(Z)-1,1,1-Trifluoro-nonadec-10-en-2-one
DMBTMDG	HS	Investigative
DMBTMDG	SN	CHEMBL422064; (Z)-1,1,1-Trifluoro-nonadec-10-en-2-one; SCHEMBL8059738; C19H33F3O; MolPort-009-018-697; HMS3649G07; BDBM50069273; 1964AH; ZINC34803437; LS-96805; (Z)-1,1,1-Trifluoro-10-nonadecen-2-one; (10z)-1,1,1-trifluorononadec-10-en-2-one; SR-01000946571; SR-01000946571-1
DMBTMDG	DT	Small molecular drug
DMBTMDG	PC	9840659
DMBTMDG	MW	334.5
DMBTMDG	FM	C19H33F3O
DMBTMDG	IC	InChI=1S/C19H33F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(23)19(20,21)22/h9-10H,2-8,11-17H2,1H3/b10-9-
DMBTMDG	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C(F)(F)F
DMBTMDG	IK	SOJGXPSMVNTNQL-KTKRTIGZSA-N
DMBTMDG	IU	(Z)-1,1,1-trifluorononadec-10-en-2-one
DMBTMDG	CA	CAS 177987-23-4
DMBTMDG	DE	Discovery agent

DMKQ679	ID	DMKQ679
DMKQ679	DN	(Z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMKQ679	HS	Investigative
DMKQ679	SN	CHEMBL493798; (Z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMKQ679	DT	Small molecular drug
DMKQ679	PC	44576974
DMKQ679	MW	329.4
DMKQ679	FM	C20H27NO3
DMKQ679	IC	InChI=1S/C20H27NO3/c1-2-3-4-5-6-7-8-11-14-21-18-13-10-9-12-16(18)17(20(21)24)15-19(22)23/h9-10,12-13,15H,2-8,11,14H2,1H3,(H,22,23)/b17-15-
DMKQ679	CS	CCCCCCCCCCN1C2=CC=CC=C2/C(=C/C(=O)O)/C1=O
DMKQ679	IK	LIUQXAWYSKFADK-ICFOKQHNSA-N
DMKQ679	IU	(2Z)-2-(1-decyl-2-oxoindol-3-ylidene)acetic acid
DMKQ679	DE	Discovery agent

DM2HZX8	ID	DM2HZX8
DM2HZX8	DN	(Z)-2,2-Dimethyl-1-oxazol-2-yl-octadec-9-en-1-one
DM2HZX8	HS	Investigative
DM2HZX8	SN	CHEMBL36655; (Z)-2,2-Dimethyl-1-oxazol-2-yl-octadec-9-en-1-one; BDBM50100875
DM2HZX8	DT	Small molecular drug
DM2HZX8	PC	11371880
DM2HZX8	MW	361.6
DM2HZX8	FM	C23H39NO2
DM2HZX8	IC	InChI=1S/C23H39NO2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(2,3)21(25)22-24-19-20-26-22/h11-12,19-20H,4-10,13-18H2,1-3H3/b12-11-
DM2HZX8	CS	CCCCCCCC/C=C\\CCCCCCC(C)(C)C(=O)C1=NC=CO1
DM2HZX8	IK	UIQYHSVDCXHKSQ-QXMHVHEDSA-N
DM2HZX8	IU	(Z)-2,2-dimethyl-1-(1,3-oxazol-2-yl)octadec-9-en-1-one
DM2HZX8	DE	Discovery agent

DMFLDPU	ID	DMFLDPU
DMFLDPU	DN	(Z)-2,6-diisopropyl-N-phenyloctadec-9-enamide
DMFLDPU	HS	Investigative
DMFLDPU	SN	CHEMBL272675
DMFLDPU	DT	Small molecular drug
DMFLDPU	PC	44457420
DMFLDPU	MW	441.7
DMFLDPU	FM	C30H51NO
DMFLDPU	IC	InChI=1S/C30H51NO/c1-6-7-8-9-10-11-12-13-14-16-20-27(25(2)3)21-19-24-29(26(4)5)30(32)31-28-22-17-15-18-23-28/h13-15,17-18,22-23,25-27,29H,6-12,16,19-21,24H2,1-5H3,(H,31,32)/b14-13-
DMFLDPU	CS	CCCCCCCC/C=C\\CCC(CCCC(C(C)C)C(=O)NC1=CC=CC=C1)C(C)C
DMFLDPU	IK	HUQXXTSZFWLRDE-YPKPFQOOSA-N
DMFLDPU	IU	(Z)-N-phenyl-2,6-di(propan-2-yl)octadec-9-enamide
DMFLDPU	DE	Discovery agent

DM0OEQJ	ID	DM0OEQJ
DM0OEQJ	DN	(Z)-2'-des-methyl sulindac sulfide
DM0OEQJ	HS	Investigative
DM0OEQJ	SN	CHEMBL561959; SCHEMBL2697270; BDBM50293599; ZINC43075511; (Z)-2''-des-methyl sulindac sulfide
DM0OEQJ	DT	Small molecular drug
DM0OEQJ	PC	44224199
DM0OEQJ	MW	326.4
DM0OEQJ	FM	C19H15FO2S
DM0OEQJ	IC	InChI=1S/C19H15FO2S/c1-23-16-5-2-12(3-6-16)8-13-9-14(10-19(21)22)18-11-15(20)4-7-17(13)18/h2-9,11H,10H2,1H3,(H,21,22)/b13-8-
DM0OEQJ	CS	CSC1=CC=C(C=C1)/C=C\\2/C=C(C3=C2C=CC(=C3)F)CC(=O)O
DM0OEQJ	IK	NEQPIGQSLNSVDO-JYRVWZFOSA-N
DM0OEQJ	IU	2-[(3Z)-6-fluoro-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid
DM0OEQJ	DE	Discovery agent

DMYH9BC	ID	DMYH9BC
DMYH9BC	DN	(Z)-2-Methyl-1-oxazol-2-yl-octadec-9-en-1-one
DMYH9BC	HS	Investigative
DMYH9BC	SN	CHEMBL37044; (Z)-2-Methyl-1-oxazol-2-yl-octadec-9-en-1-one; BDBM50100866
DMYH9BC	DT	Small molecular drug
DMYH9BC	PC	11221755
DMYH9BC	MW	347.5
DMYH9BC	FM	C22H37NO2
DMYH9BC	IC	InChI=1S/C22H37NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(2)21(24)22-23-18-19-25-22/h10-11,18-20H,3-9,12-17H2,1-2H3/b11-10-
DMYH9BC	CS	CCCCCCCC/C=C\\CCCCCCC(C)C(=O)C1=NC=CO1
DMYH9BC	IK	VNDQKKVLWCFNIJ-KHPPLWFESA-N
DMYH9BC	IU	(Z)-2-methyl-1-(1,3-oxazol-2-yl)octadec-9-en-1-one
DMYH9BC	DE	Discovery agent

DM18R6J	ID	DM18R6J
DM18R6J	DN	(Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid
DM18R6J	HS	Investigative
DM18R6J	SN	Chaetomellic acid A; CHEMBL103955; 148796-51-4; AC1MI36H; (Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid; ZINC14276303; BDBM50059863; (Z)-2-methyl-3-tetradecylbut-2-enedioic acid; 2-Butenedioic acid, 2-methyl-3-tetradecyl-, (Z)-
DM18R6J	DT	Small molecular drug
DM18R6J	PC	3037595
DM18R6J	MW	326.5
DM18R6J	FM	C19H34O4
DM18R6J	IC	InChI=1S/C19H34O4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-17(19(22)23)16(2)18(20)21/h3-15H2,1-2H3,(H,20,21)(H,22,23)/b17-16-
DM18R6J	CS	CCCCCCCCCCCCCC/C(=C(\\C)/C(=O)O)/C(=O)O
DM18R6J	IK	ULSDRNDLXFVDED-MSUUIHNZSA-N
DM18R6J	IU	(Z)-2-methyl-3-tetradecylbut-2-enedioic acid
DM18R6J	CA	CAS 148796-51-4
DM18R6J	DE	Discovery agent

DM27WDP	ID	DM27WDP
DM27WDP	DN	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one
DM27WDP	HS	Investigative
DM27WDP	SN	oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one; Oxindole I
DM27WDP	DT	Small molecular drug
DM27WDP	PC	5908088
DM27WDP	MW	210.23
DM27WDP	FM	C13H10N2O
DM27WDP	IC	InChI=1S/C13H10N2O/c16-13-11(8-9-4-3-7-14-9)10-5-1-2-6-12(10)15-13/h1-8,14H,(H,15,16)/b11-8-
DM27WDP	CS	C1=CC=C2C(=C1)/C(=C/C3=CC=CN3)/C(=O)N2
DM27WDP	IK	SEZFNTZQMWJIAI-FLIBITNWSA-N
DM27WDP	IU	(3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
DM27WDP	DE	Discovery agent

DMIQ14F	ID	DMIQ14F
DMIQ14F	DN	(Z)-3-[2-(9H-fluoren-2-yloxy)ethylidene]-quinuclidine hydrochloride 31
DMIQ14F	HS	Investigative
DMIQ14F	DT	Small molecular drug
DMIQ14F	PC	10313754
DMIQ14F	MW	317.4
DMIQ14F	FM	C22H23NO
DMIQ14F	IC	InChI=1S/C22H23NO/c1-2-4-21-17(3-1)13-19-14-20(5-6-22(19)21)24-12-9-18-15-23-10-7-16(18)8-11-23/h1-6,9,14,16H,7-8,10-13,15H2/b18-9+
DMIQ14F	CS	C1CN2CCC1/C(=C/COC3=CC4=C(C=C3)C5=CC=CC=C5C4)/C2
DMIQ14F	IK	VVZXRJARBWKUDG-GIJQJNRQSA-N
DMIQ14F	IU	(3Z)-3-[2-(9H-fluoren-2-yloxy)ethylidene]-1-azabicyclo[2.2.2]octane
DMIQ14F	DE	Discovery agent

DM30YQF	ID	DM30YQF
DM30YQF	DN	(Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid
DM30YQF	HS	Investigative
DM30YQF	SN	Substituted Acrylamide, 7b; CHEMBL235904; BDBM18847; (2Z)-3-[(4-hexylphenyl)carbamoyl]prop-2-enoic acid; (2z)-4-[(4-hexylphenyl)amino]-4-oxobut-2-enoic acid
DM30YQF	DT	Small molecular drug
DM30YQF	PC	23635730
DM30YQF	MW	275.34
DM30YQF	FM	C16H21NO3
DM30YQF	IC	InChI=1S/C16H21NO3/c1-2-3-4-5-6-13-7-9-14(10-8-13)17-15(18)11-12-16(19)20/h7-12H,2-6H2,1H3,(H,17,18)(H,19,20)/b12-11-
DM30YQF	CS	CCCCCCC1=CC=C(C=C1)NC(=O)/C=C\\C(=O)O
DM30YQF	IK	OOWYMHDWBQTCOX-QXMHVHEDSA-N
DM30YQF	IU	(Z)-4-(4-hexylanilino)-4-oxobut-2-enoic acid
DM30YQF	DE	Discovery agent

DMPJAKL	ID	DMPJAKL
DMPJAKL	DN	(Z)-5-Amino-3-(4-methoxybenzylidene)indolin-2-one
DMPJAKL	HS	Investigative
DMPJAKL	SN	CHEMBL591696; (3Z)-5-AMINO-3-[(4-METHOXYPHENYL)METHYLIDENE]-1,3-DIHYDRO-2H-INDOL-2-ONE; 2x2l; (Z)-5-Amino-3-(4-methoxybenzylidene)indolin-2-one
DMPJAKL	DT	Small molecular drug
DMPJAKL	PC	46233144
DMPJAKL	MW	266.29
DMPJAKL	FM	C16H14N2O2
DMPJAKL	IC	InChI=1S/C16H14N2O2/c1-20-12-5-2-10(3-6-12)8-14-13-9-11(17)4-7-15(13)18-16(14)19/h2-9H,17H2,1H3,(H,18,19)/b14-8-
DMPJAKL	CS	COC1=CC=C(C=C1)/C=C\\2/C3=C(C=CC(=C3)N)NC2=O
DMPJAKL	IK	DYCBCUFDDRQCID-ZSOIEALJSA-N
DMPJAKL	IU	(3Z)-5-amino-3-[(4-methoxyphenyl)methylidene]-1H-indol-2-one
DMPJAKL	DE	Discovery agent

DM3ALJD	ID	DM3ALJD
DM3ALJD	DN	(Z)-5-Benzylidene-2-thioxothiazolidin-4-one
DM3ALJD	HS	Investigative
DM3ALJD	SN	5-Benzylidenrodanin; 5-Benzylidenerhodanine; Rhodanine, 5-benzylidene-; NSC 43398; 5-Benzylidene-2-thioxo-4-thiazolidinone; CHEMBL305763; 5-(Phenylmethylene)-2-thioxo-4-thiazolidinone; (5Z)-5-benzylidene-2-sulfanyl-1,3-thiazol-4(5H)-one; 4-Thiazolidinone, 5-(phenylmethylene)-2-thioxo-; 3806-42-6; MLS002608541; 5-Benzyliden-rhodanin; AC1LOXMG; Rhodanine, 5-benzylidene; (Z)-5-Benzylidene-2-thioxothiazolidin-4-one; SCHEMBL3491175; MolPort-001-579-311; MolPort-000-420-057; HMS3087E14; HMS1786A04; ZINC1088586; 174813-23-1; STK441367
DM3ALJD	DT	Small molecular drug
DM3ALJD	PC	1273210
DM3ALJD	MW	221.3
DM3ALJD	FM	C10H7NOS2
DM3ALJD	IC	InChI=1S/C10H7NOS2/c12-9-8(14-10(13)11-9)6-7-4-2-1-3-5-7/h1-6H,(H,11,12,13)/b8-6-
DM3ALJD	CS	C1=CC=C(C=C1)/C=C\\2/C(=O)NC(=S)S2
DM3ALJD	IK	OONWCXLYKDWKOU-VURMDHGXSA-N
DM3ALJD	IU	(5Z)-5-benzylidene-2-sulfanylidene-1,3-thiazolidin-4-one
DM3ALJD	CA	CAS 3806-42-6
DM3ALJD	DE	Discovery agent

DMLRWAF	ID	DMLRWAF
DMLRWAF	DN	(Z)-5-Butylidene-2-thioxothiazolidin-4-one
DMLRWAF	HS	Investigative
DMLRWAF	DT	Small molecular drug
DMLRWAF	PC	91934927
DMLRWAF	MW	187.3
DMLRWAF	FM	C7H9NOS2
DMLRWAF	IC	InChI=1S/C7H9NOS2/c1-2-3-4-5-6(9)8-7(10)11-5/h3-4,9H,2H2,1H3,(H,8,10)/b4-3+
DMLRWAF	CS	CC/C=C/C1=C(NC(=S)S1)O
DMLRWAF	IK	KKMMHMVDVICNOR-ONEGZZNKSA-N
DMLRWAF	IU	5-[(E)-but-1-enyl]-4-hydroxy-3H-1,3-thiazole-2-thione
DMLRWAF	DE	Discovery agent

DM5U1M8	ID	DM5U1M8
DM5U1M8	DN	(Z)-5-Decylidene-2-thioxothiazolidin-4-one
DM5U1M8	HS	Investigative
DM5U1M8	DT	Small molecular drug
DM5U1M8	PC	91934932
DM5U1M8	MW	271.4
DM5U1M8	FM	C13H21NOS2
DM5U1M8	IC	InChI=1S/C13H21NOS2/c1-2-3-4-5-6-7-8-9-10-11-12(15)14-13(16)17-11/h9-10,15H,2-8H2,1H3,(H,14,16)/b10-9-
DM5U1M8	CS	CCCCCCCC/C=C\\C1=C(NC(=S)S1)O
DM5U1M8	IK	PVHZHDOPGHHBGQ-KTKRTIGZSA-N
DM5U1M8	IU	5-[(Z)-dec-1-enyl]-4-hydroxy-3H-1,3-thiazole-2-thione
DM5U1M8	DE	Discovery agent

DMV70YA	ID	DMV70YA
DMV70YA	DN	(Z)-5-Hexylidene-2-thioxothiazolidin-4-one
DMV70YA	HS	Investigative
DMV70YA	DT	Small molecular drug
DMV70YA	PC	91934930
DMV70YA	MW	215.3
DMV70YA	FM	C9H13NOS2
DMV70YA	IC	InChI=1S/C9H13NOS2/c1-2-3-4-5-6-7-8(11)10-9(12)13-7/h5-6,11H,2-4H2,1H3,(H,10,12)/b6-5-
DMV70YA	CS	CCCC/C=C\\C1=C(NC(=S)S1)O
DMV70YA	IK	NRLPFFHZVUFORL-WAYWQWQTSA-N
DMV70YA	IU	5-[(Z)-hex-1-enyl]-4-hydroxy-3H-1,3-thiazole-2-thione
DMV70YA	DE	Discovery agent

DM4X9GW	ID	DM4X9GW
DM4X9GW	DN	(Z)-5-octadecen-7,9-diynoic acid
DM4X9GW	HS	Investigative
DM4X9GW	SN	CHEMBL504781; 5Z-Octadecene-7,9-diynoic acid; (Z)-5-octadecen-7,9-diynoic acid; BDBM50292397
DM4X9GW	DT	Small molecular drug
DM4X9GW	PC	9543637
DM4X9GW	MW	274.4
DM4X9GW	FM	C18H26O2
DM4X9GW	IC	InChI=1S/C18H26O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h13-14H,2-8,15-17H2,1H3,(H,19,20)/b14-13-
DM4X9GW	CS	CCCCCCCCC#CC#C/C=C\\CCCC(=O)O
DM4X9GW	IK	IGVKWAAPMVVTFX-YPKPFQOOSA-N
DM4X9GW	IU	(Z)-octadec-5-en-7,9-diynoic acid
DM4X9GW	DE	Discovery agent

DMEJNFS	ID	DMEJNFS
DMEJNFS	DN	(Z)-5-Octylidene-2-thioxothiazolidin-4-one
DMEJNFS	HS	Investigative
DMEJNFS	DT	Small molecular drug
DMEJNFS	PC	91934931
DMEJNFS	MW	243.4
DMEJNFS	FM	C11H17NOS2
DMEJNFS	IC	InChI=1S/C11H17NOS2/c1-2-3-4-5-6-7-8-9-10(13)12-11(14)15-9/h7-8,13H,2-6H2,1H3,(H,12,14)/b8-7-
DMEJNFS	CS	CCCCCC/C=C\\C1=C(NC(=S)S1)O
DMEJNFS	IK	FMOVNYUOJKHVOR-FPLPWBNLSA-N
DMEJNFS	IU	4-hydroxy-5-[(Z)-oct-1-enyl]-3H-1,3-thiazole-2-thione
DMEJNFS	DE	Discovery agent

DMKWLSB	ID	DMKWLSB
DMKWLSB	DN	(Z)-7-octedecan-9-ynoic acid
DMKWLSB	HS	Investigative
DMKWLSB	SN	CHEMBL482601; (Z)-7-octedecan-9-ynoic acid; (Z)-7-Octadecene-9-ynoic acid
DMKWLSB	DT	Small molecular drug
DMKWLSB	PC	14309405
DMKWLSB	MW	278.4
DMKWLSB	FM	C18H30O2
DMKWLSB	IC	InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h11-12H,2-8,13-17H2,1H3,(H,19,20)/b12-11-
DMKWLSB	CS	CCCCCCCCC#C/C=C\\CCCCCC(=O)O
DMKWLSB	IK	BWSIKEZDJMZITO-QXMHVHEDSA-N
DMKWLSB	IU	(Z)-octadec-7-en-9-ynoic acid
DMKWLSB	DE	Discovery agent

DMOB9E4	ID	DMOB9E4
DMOB9E4	DN	(Z)-8-(3-chlorostyryl)caffeine
DMOB9E4	HS	Investigative
DMOB9E4	SN	CHEMBL483243; (Z)-8-(3-chlorostyryl)caffeine
DMOB9E4	DT	Small molecular drug
DMOB9E4	PC	44579921
DMOB9E4	MW	332.78
DMOB9E4	FM	C16H17ClN4O2
DMOB9E4	IC	InChI=1S/C16H17ClN4O2/c1-19-12(8-7-10-5-4-6-11(17)9-10)18-14-13(19)15(22)21(3)16(23)20(14)2/h4-9,13-14H,1-3H3/b8-7+
DMOB9E4	CS	CN1C2C(N=C1/C=C/C3=CC(=CC=C3)Cl)N(C(=O)N(C2=O)C)C
DMOB9E4	IK	SIKKJYKLUJCDNQ-BQYQJAHWSA-N
DMOB9E4	IU	8-[(E)-2-(3-chlorophenyl)ethenyl]-1,3,7-trimethyl-4,5-dihydropurine-2,6-dione
DMOB9E4	DE	Discovery agent

DMX0G7E	ID	DMX0G7E
DMX0G7E	DN	[(125)I] RB129
DMX0G7E	HS	Investigative
DMX0G7E	SN	GLYCYRRHETINIC ACID; Uralenic acid; 18-beta-Glycyrrhetinic acid; Arthrodont; Glycyrrhetin; Jintan; Rhetinic Acid; 18beta-Glycyrrhetinic acid; Biosone; alpha-Glycyrrhetinic acid; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; Enoxolonum [INN-Latin]; Enoxolona [INN-Spanish]; UNII-P540XA09DR; Enoxolone [INN:BAN:DCF]; CCRIS 3962; EINECS 207-444-6; NSC 35347; 3-Glycyrrhetinic acid; BRN 2229654; Glycyrrhetinate; MLS000028748; CHEMBL230006; P540XA09DR; Glycyrrhetinic acid
DMX0G7E	DT	Small molecular drug
DMX0G7E	DE	Discovery agent

DMG1ATX	ID	DMG1ATX
DMG1ATX	DN	[(1e)-4-Phenylbut-1-Enyl]Benzene
DMG1ATX	HS	Investigative
DMG1ATX	SN	[(1E)-4-PHENYLBUT-1-ENYL]BENZENE; 1,4-DIPHENYL-1-BUTENE; 14213-84-4; AC1NR9PT; (E)-1,4-Diphenyl-1-butene; [(E)-4-phenylbut-1-enyl]benzene; ZINC14880527; [(1E)-4-phenyl-1-butenyl]benzene; [(E)-4-phenyl-but-1-enyl]-benzene; 1,1'-(1E)-but-1-ene-1,4-diyldibenzene
DMG1ATX	DT	Small molecular drug
DMG1ATX	PC	5287453
DMG1ATX	MW	208.3
DMG1ATX	FM	C16H16
DMG1ATX	IC	InChI=1S/C16H16/c1-3-9-15(10-4-1)13-7-8-14-16-11-5-2-6-12-16/h1-7,9-13H,8,14H2/b13-7+
DMG1ATX	CS	C1=CC=C(C=C1)CC/C=C/C2=CC=CC=C2
DMG1ATX	IK	NJJOGKAVAWZLAU-NTUHNPAUSA-N
DMG1ATX	IU	[(E)-4-phenylbut-1-enyl]benzene
DMG1ATX	DE	Discovery agent

DM3WDOY	ID	DM3WDOY
DM3WDOY	DN	[(2-aminooxyethyl)methylamino]-5'-deoxyadenosine
DM3WDOY	HS	Investigative
DM3WDOY	SN	MAO; 5'-DEOXY-5'-[N-METHYL-N-(2-AMINOOXYETHYL) AMINO]ADENOSINE; 112621-39-3; AC1L9JAL; MAOEA, 5; SCHEMBL956861; Adenosine,5'-[[2-(aminooxy)ethyl]methylamino]-5'-deoxy- (9CI); CHEMBL461780; CTK4A7898; BDBM28431; AKOS030589585; 5'-[(2-Aminooxyethyl)methylamino]-5'-deoxyadenosine; 5'-{[2-(aminooxy)ethyl](methyl)amino}-5'-deoxyadenosine; (2R,3S,4R,5R)-2-[[2-aminooxyethyl(methyl)amino]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol
DM3WDOY	DT	Small molecular drug
DM3WDOY	PC	446204
DM3WDOY	MW	339.35
DM3WDOY	FM	C13H21N7O4
DM3WDOY	IC	InChI=1S/C13H21N7O4/c1-19(2-3-23-15)4-7-9(21)10(22)13(24-7)20-6-18-8-11(14)16-5-17-12(8)20/h5-7,9-10,13,21-22H,2-4,15H2,1H3,(H2,14,16,17)/t7-,9-,10-,13-/m1/s1
DM3WDOY	CS	CN(CCON)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DM3WDOY	IK	PPIPUCUVJJZYEK-QYVSTXNMSA-N
DM3WDOY	IU	(2R,3S,4R,5R)-2-[[2-aminooxyethyl(methyl)amino]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol
DM3WDOY	DE	Discovery agent

DMTK9V7	ID	DMTK9V7
DMTK9V7	DN	[(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone
DMTK9V7	HS	Investigative
DMTK9V7	SN	CHEMBL602092; [(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone
DMTK9V7	DT	Small molecular drug
DMTK9V7	PC	46232847
DMTK9V7	MW	348.3
DMTK9V7	FM	C15H14BrN3S
DMTK9V7	IC	InChI=1S/C15H14BrN3S/c1-10-4-2-5-11(8-10)14(18-19-15(17)20)12-6-3-7-13(16)9-12/h2-9H,1H3,(H3,17,19,20)/b18-14+
DMTK9V7	CS	CC1=CC(=CC=C1)/C(=N\\NC(=S)N)/C2=CC(=CC=C2)Br
DMTK9V7	IK	UUHYYCURIRMTND-NBVRZTHBSA-N
DMTK9V7	IU	[(E)-[(3-bromophenyl)-(3-methylphenyl)methylidene]amino]thiourea
DMTK9V7	DE	Discovery agent

DMZG7TH	ID	DMZG7TH
DMZG7TH	DN	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone
DMZG7TH	HS	Investigative
DMZG7TH	SN	CHEMBL590497; [(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone
DMZG7TH	DT	Small molecular drug
DMZG7TH	PC	46232967
DMZG7TH	MW	348.3
DMZG7TH	FM	C15H14BrN3S
DMZG7TH	IC	InChI=1S/C15H14BrN3S/c1-10-5-7-11(8-6-10)14(18-19-15(17)20)12-3-2-4-13(16)9-12/h2-9H,1H3,(H3,17,19,20)/b18-14+
DMZG7TH	CS	CC1=CC=C(C=C1)/C(=N\\NC(=S)N)/C2=CC(=CC=C2)Br
DMZG7TH	IK	IOXFIFMULNCUSH-NBVRZTHBSA-N
DMZG7TH	IU	[(E)-[(3-bromophenyl)-(4-methylphenyl)methylidene]amino]thiourea
DMZG7TH	DE	Discovery agent

DM9YHA7	ID	DM9YHA7
DM9YHA7	DN	[(40-OH) MeLeu]4-CsA derivatives
DM9YHA7	HS	Investigative
DM9YHA7	DE	Discovery agent

DM1ZM5R	ID	DM1ZM5R
DM1ZM5R	DN	[(40-OH)MeLeu]4-Cyclosporin A
DM1ZM5R	HS	Investigative
DM1ZM5R	SN	[(40-OH)MeLeu]4-Cyclosporin A; CHEMBL442519; AC1O51FB; [(4'-OH)MeLeu]4-CsA; SCHEMBL18736971; [.gamma.-Hydroxy-MeLeu]4-CsA; DFZMWWCBMPCKFD-DTLHCQOUSA-N; [gamma-hydroxy-MeLeu]4 -Ciclosporin; BDBM50136487; [.gamma.-Hydroxy-MeLeu]4-Ciclosporin; [.gamma.-Hydroxy-MeLeu]4-Cyclosporin
DM1ZM5R	PC	6475368
DM1ZM5R	MW	1218.6
DM1ZM5R	FM	C62H111N11O13
DM1ZM5R	IC	InChI=1S/C62H111N11O13/c1-25-27-28-39(13)51(75)50-55(79)65-42(26-2)57(81)67(18)33-47(74)68(19)46(32-62(16,17)86)54(78)66-48(37(9)10)60(84)69(20)43(29-34(3)4)53(77)63-40(14)52(76)64-41(15)56(80)70(21)44(30-35(5)6)58(82)71(22)45(31-36(7)8)59(83)72(23)49(38(11)12)61(85)73(50)24/h25,27,34-46,48-51,75,86H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t39-,40+,41-,42+,43+,44+,45+,46+,48+,49+,50?,51-/m1/s1
DM1ZM5R	CS	CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)(C)O)C)C
DM1ZM5R	IK	DFZMWWCBMPCKFD-DTLHCQOUSA-N
DM1ZM5R	IU	(3S,6S,9S,12R,15S,18S,21S,24S,30S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DM1ZM5R	DE	Discovery agent

DMV30N2	ID	DMV30N2
DMV30N2	DN	[(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A
DMV30N2	HS	Investigative
DMV30N2	SN	CHEMBL405301; [(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A
DMV30N2	PC	44358392
DMV30N2	MW	1248.6
DMV30N2	FM	C63H113N11O14
DMV30N2	IC	InChI=1S/C63H113N11O14/c1-25-27-28-39(13)51(76)50-55(80)66-42(26-2)57(82)72(22)47(33-75)60(85)71(21)46(32-63(16,17)88)54(79)67-48(37(9)10)61(86)68(18)43(29-34(3)4)53(78)64-40(14)52(77)65-41(15)56(81)69(19)44(30-35(5)6)58(83)70(20)45(31-36(7)8)59(84)73(23)49(38(11)12)62(87)74(50)24/h25,27,34-51,75-76,88H,26,28-33H2,1-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b27-25+/t39-,40+,41-,42+,43+,44+,45+,46+,47-,48+,49+,50?,51-/m1/s1
DMV30N2	CS	CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)(C)O)C)CO)C
DMV30N2	IK	XCXAXJCKONNWJE-HXEFTPTGSA-N
DMV30N2	IU	(3S,6S,9S,12R,15S,18S,21S,24S,27R,30S)-30-ethyl-27-(hydroxymethyl)-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMV30N2	DE	Discovery agent

DMVWCTL	ID	DMVWCTL
DMVWCTL	DN	[(N4-Bzdig)0,Nle14]BB(7-14)
DMVWCTL	HS	Investigative
DMVWCTL	SN	CHEMBL266079; [(N4-Bzdig)0,Nle14]BB(7-14)
DMVWCTL	PC	11434815
DMVWCTL	MW	1285.5
DMVWCTL	FM	C62H96N18O12
DMVWCTL	IC	InChI=1S/C62H96N18O12/c1-7-8-12-46(56(66)85)77-60(89)48(24-36(2)3)78-61(90)50(27-43-31-69-35-72-43)76-52(82)32-71-62(91)55(37(4)5)80-57(86)38(6)73-59(88)49(26-41-30-70-45-13-10-9-11-44(41)45)79-58(87)47(18-19-51(65)81)75-54(84)34-92-33-53(83)74-42-16-14-39(15-17-42)25-40(28-67-22-20-63)29-68-23-21-64/h9-11,13-17,30-31,35-38,40,46-50,55,67-68,70H,7-8,12,18-29,32-34,63-64H2,1-6H3,(H2,65,81)(H2,66,85)(H,69,72)(H,71,91)(H,73,88)(H,74,83)(H,75,84)(H,76,82)(H,77,89)(H,78,90)(H,79,87)(H,80,86)/t38-,46-,47-,48-,49-,50-,55-/m0/s1
DMVWCTL	CS	CCCC[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)COCC(=O)NC4=CC=C(C=C4)CC(CNCCN)CNCCN
DMVWCTL	IK	XDFRCEDKCPCBTG-KGOWMPLXSA-N
DMVWCTL	IU	(2S)-2-[[2-[2-[4-[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propyl]anilino]-2-oxoethoxy]acetyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMVWCTL	DE	Discovery agent

DMD4BSJ	ID	DMD4BSJ
DMD4BSJ	DN	[(N4-Bzdig)0]BB(7-14)
DMD4BSJ	HS	Investigative
DMD4BSJ	SN	CHEMBL414307; [(N4-Bzdig)0]BB(7-14)
DMD4BSJ	PC	11389266
DMD4BSJ	MW	1303.6
DMD4BSJ	FM	C61H94N18O12S
DMD4BSJ	IC	InChI=1S/C61H94N18O12S/c1-35(2)23-47(59(88)76-45(55(65)84)17-22-92-6)77-60(89)49(26-42-30-68-34-71-42)75-51(81)31-70-61(90)54(36(3)4)79-56(85)37(5)72-58(87)48(25-40-29-69-44-10-8-7-9-43(40)44)78-57(86)46(15-16-50(64)80)74-53(83)33-91-32-52(82)73-41-13-11-38(12-14-41)24-39(27-66-20-18-62)28-67-21-19-63/h7-14,29-30,34-37,39,45-49,54,66-67,69H,15-28,31-33,62-63H2,1-6H3,(H2,64,80)(H2,65,84)(H,68,71)(H,70,90)(H,72,87)(H,73,82)(H,74,83)(H,75,81)(H,76,88)(H,77,89)(H,78,86)(H,79,85)/t37-,45-,46-,47-,48-,49-,54-/m0/s1
DMD4BSJ	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)COCC(=O)NC4=CC=C(C=C4)CC(CNCCN)CNCCN
DMD4BSJ	IK	IKKYIPCELZIPRY-RNXDXMLZSA-N
DMD4BSJ	IU	(2S)-2-[[2-[2-[4-[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propyl]anilino]-2-oxoethoxy]acetyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMD4BSJ	DE	Discovery agent

DMPFUBE	ID	DMPFUBE
DMPFUBE	DN	[(R)-(+)-deoxytylophorinidine
DMPFUBE	HS	Investigative
DMPFUBE	SN	CHEMBL250474; [(R)-(+)-deoxytylophorinidine; BDBM50213932
DMPFUBE	DT	Small molecular drug
DMPFUBE	PC	44443385
DMPFUBE	MW	349.4
DMPFUBE	FM	C22H23NO3
DMPFUBE	IC	InChI=1S/C22H23NO3/c1-25-14-5-6-15-16-8-13-4-3-7-23(13)12-20(16)19-11-22(26-2)21(24)10-18(19)17(15)9-14/h5-6,9-11,13,24H,3-4,7-8,12H2,1-2H3/t13-/m1/s1
DMPFUBE	CS	COC1=CC2=C(C=C1)C3=C(CN4CCC[C@@H]4C3)C5=CC(=C(C=C52)O)OC
DMPFUBE	IK	DACRWRGHESRUQW-CYBMUJFWSA-N
DMPFUBE	IU	(13aR)-3,7-dimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[10,9-f]indolizin-6-ol
DMPFUBE	DE	Discovery agent

DMU9F2P	ID	DMU9F2P
DMU9F2P	DN	[[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
DMU9F2P	HS	Investigative
DMU9F2P	SN	[[4-(AMINOMETHYL)PHENYL]AMINO]OXO-ACETIC ACID,; 840454-25-3; LO1; Acetic acid, 2-[[4-(aminomethyl)phenyl]amino]-2-oxo-; 1wax; 2-[4-(aminomethyl)anilino]-2-oxoacetic acid; AC1L9MR9; SCHEMBL4317924; CHEMBL426815; CTK3D0907; DTXSID60332298; DB02420; {[4-(aminomethyl)phenyl]carbamoyl}formic acid; {[4-(aminomethyl)phenyl]amino}(oxo)acetic acid; Acetic acid, [[4-(aminomethyl)phenyl]amino]oxo-
DMU9F2P	DT	Small molecular drug
DMU9F2P	PC	449125
DMU9F2P	MW	194.19
DMU9F2P	FM	C9H10N2O3
DMU9F2P	IC	InChI=1S/C9H10N2O3/c10-5-6-1-3-7(4-2-6)11-8(12)9(13)14/h1-4H,5,10H2,(H,11,12)(H,13,14)
DMU9F2P	CS	C1=CC(=CC=C1CN)NC(=O)C(=O)O
DMU9F2P	IK	RKILOCCSAVHHJT-UHFFFAOYSA-N
DMU9F2P	IU	2-[4-(aminomethyl)anilino]-2-oxoacetic acid
DMU9F2P	CA	CAS 840454-25-3
DMU9F2P	DE	Discovery agent

DM86305	ID	DM86305
DM86305	DN	[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate
DM86305	HS	Investigative
DM86305	SN	[[n-(benzyloxycarbonyl)amino]methyl]phosphate; (BENZYLOXYCARBONYLAMINO)METHYLPHOSPHONIC ACID; ({[(benzyloxy)carbonyl]amino}methyl)phosphonic acid; AC1L1CL8; SCHEMBL5586441; CHEMBL1232804; CTK7G8496; WUNKRZNFNIYEPN-UHFFFAOYSA-N; DB02642; (N-carbobenzoxy-amino)methylphosphonic acid; phenylmethoxycarbonylaminomethylphosphonic acid
DM86305	DT	Small molecular drug
DM86305	PC	1950
DM86305	MW	245.17
DM86305	FM	C9H12NO5P
DM86305	IC	InChI=1S/C9H12NO5P/c11-9(10-7-16(12,13)14)15-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H,10,11)(H2,12,13,14)
DM86305	CS	C1=CC=C(C=C1)COC(=O)NCP(=O)(O)O
DM86305	IK	WUNKRZNFNIYEPN-UHFFFAOYSA-N
DM86305	IU	phenylmethoxycarbonylaminomethylphosphonic acid
DM86305	DE	Discovery agent

DMAGW3R	ID	DMAGW3R
DMAGW3R	DN	[1-(4-p-Tolyl-butyl)-piperidin-4-yl]-methanol
DMAGW3R	HS	Investigative
DMAGW3R	SN	CHEMBL570915
DMAGW3R	DT	Small molecular drug
DMAGW3R	PC	45485499
DMAGW3R	MW	261.399
DMAGW3R	FM	C17H27NO
DMAGW3R	IC	InChI=1S/C17H27NO/c1-15-5-7-16(8-6-15)4-2-3-11-18-12-9-17(14-19)10-13-18/h5-8,17,19H,2-4,9-14H2,1H3
DMAGW3R	CS	CC1=CC=C(C=C1)CCCCN2CCC(CC2)CO
DMAGW3R	IK	VTDHRHRPPVJGSU-UHFFFAOYSA-N
DMAGW3R	IU	[1-[4-(4-methylphenyl)butyl]piperidin-4-yl]methanol
DMAGW3R	DE	Discovery agent

DMVOY4D	ID	DMVOY4D
DMVOY4D	DN	[1,1':2',1'']-terphenyl-4,3'',5''-triol
DMVOY4D	HS	Investigative
DMVOY4D	SN	CHEMBL208098; BDBM50186757; ZINC35856323
DMVOY4D	DT	Small molecular drug
DMVOY4D	PC	11579996
DMVOY4D	MW	278.3
DMVOY4D	FM	C18H14O3
DMVOY4D	IC	InChI=1S/C18H14O3/c19-14-7-5-12(6-8-14)17-3-1-2-4-18(17)13-9-15(20)11-16(21)10-13/h1-11,19-21H
DMVOY4D	CS	C1=CC=C(C(=C1)C2=CC=C(C=C2)O)C3=CC(=CC(=C3)O)O
DMVOY4D	IK	UGGGRFWZAHTXBI-UHFFFAOYSA-N
DMVOY4D	IU	5-[2-(4-hydroxyphenyl)phenyl]benzene-1,3-diol
DMVOY4D	DE	Discovery agent

DMFXA8P	ID	DMFXA8P
DMFXA8P	DN	[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime
DMFXA8P	HS	Investigative
DMFXA8P	DT	Small molecular drug
DMFXA8P	PC	11780703
DMFXA8P	MW	273.3
DMFXA8P	FM	C19H15NO
DMFXA8P	IC	InChI=1S/C19H15NO/c21-20-14-15-11-12-18(16-7-3-1-4-8-16)19(13-15)17-9-5-2-6-10-17/h1-14,21H/b20-14+
DMFXA8P	CS	C1=CC=C(C=C1)C2=C(C=C(C=C2)/C=N/O)C3=CC=CC=C3
DMFXA8P	IK	XSIHFOOFJWBVHK-XSFVSMFZSA-N
DMFXA8P	IU	(NE)-N-[(3,4-diphenylphenyl)methylidene]hydroxylamine
DMFXA8P	DE	Discovery agent

DMPV0QN	ID	DMPV0QN
DMPV0QN	DN	[1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one
DMPV0QN	HS	Investigative
DMPV0QN	SN	[1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one; 150454-83-4; ACMC-1C8D4; CHEMBL365930; CTK0G9579; DTXSID10435607; AKOS027398551
DMPV0QN	DT	Small molecular drug
DMPV0QN	PC	10103893
DMPV0QN	MW	186.17
DMPV0QN	FM	C9H6N4O
DMPV0QN	IC	InChI=1S/C9H6N4O/c14-9-8-10-5-11-13(8)7-4-2-1-3-6(7)12-9/h1-5H,(H,12,14)
DMPV0QN	CS	C1=CC=C2C(=C1)NC(=O)C3=NC=NN23
DMPV0QN	IK	OEIMIUHARCZWJY-UHFFFAOYSA-N
DMPV0QN	IU	5H-[1,2,4]triazolo[1,5-a]quinoxalin-4-one
DMPV0QN	CA	CAS 150454-83-4
DMPV0QN	DE	Discovery agent

DMDX6W4	ID	DMDX6W4
DMDX6W4	DN	[1,3]Oxazinan-(2E)-ylideneamine
DMDX6W4	HS	Investigative
DMDX6W4	SN	5,6-dihydro-4h-1,3-oxazin-2-amine; CHEMBL161118; 1848-68-6; [1,3]Oxazinan-(2E)-ylideneamine; SCHEMBL31223; 2-iminotetrahydro-1,3-oxazine; MolPort-044-586-586; BDBM50049258; ZINC13746441; AKOS025312622; AKOS006338233; 2-amino-5,6-dihydro-4h-1,3-oxazine
DMDX6W4	DT	Small molecular drug
DMDX6W4	PC	23042899
DMDX6W4	MW	100.12
DMDX6W4	FM	C4H8N2O
DMDX6W4	IC	InChI=1S/C4H8N2O/c5-4-6-2-1-3-7-4/h1-3H2,(H2,5,6)
DMDX6W4	CS	C1CN=C(OC1)N
DMDX6W4	IK	VPVZSRIIAONGMU-UHFFFAOYSA-N
DMDX6W4	IU	5,6-dihydro-4H-1,3-oxazin-2-amine
DMDX6W4	DE	Discovery agent

DMOEIHC	ID	DMOEIHC
DMOEIHC	DN	[1,3]Thiazinan-(2E)-ylideneamine
DMOEIHC	HS	Investigative
DMOEIHC	SN	2-Amino-5,6-dihydro-4H-1,3-thiazine; 5,6-Dihydro-4H-1,3-thiazin-2-amine; 30480-64-9; CHEMBL306541; 2-Iminotetrahydro-1,3-thiazine; [1,3]Thiazinan-(2E)-ylideneamine; AC1Q4UKS; AC1L4O0Q; SCHEMBL30950; 2799-75-9 (hydrobromide); CTK4G5273; DTXSID60184552; [1,3]Thiazinan-(2Z)-ylideneamine; BDBM50049250; ZINC17744492; FCH991782; AKOS006347653; AKOS003362396; 4H-1,3-Thiazin-2-amine,5,6-dihydro-; EN300-203949; 3,4,5,6-Tetrahydro-2H-1,3-thiazin-2-imine
DMOEIHC	DT	Small molecular drug
DMOEIHC	PC	189081
DMOEIHC	MW	116.19
DMOEIHC	FM	C4H8N2S
DMOEIHC	IC	InChI=1S/C4H8N2S/c5-4-6-2-1-3-7-4/h1-3H2,(H2,5,6)
DMOEIHC	CS	C1CN=C(SC1)N
DMOEIHC	IK	PQXQEOIFIUJLIE-UHFFFAOYSA-N
DMOEIHC	IU	5,6-dihydro-4H-1,3-thiazin-2-amine
DMOEIHC	CA	CAS 30480-64-9
DMOEIHC	DE	Discovery agent

DMX58NK	ID	DMX58NK
DMX58NK	DN	[1,4]Oxazepan-(3E)-ylideneamine
DMX58NK	HS	Investigative
DMX58NK	SN	CHEMBL362772; [1,4]Oxazepan-(3E)-ylideneamine; SCHEMBL2593607; BDBM50155790
DMX58NK	DT	Small molecular drug
DMX58NK	PC	44396203
DMX58NK	MW	114.15
DMX58NK	FM	C5H10N2O
DMX58NK	IC	InChI=1S/C5H10N2O/c6-5-4-8-3-1-2-7-5/h1-4H2,(H2,6,7)
DMX58NK	CS	C1CN=C(COC1)N
DMX58NK	IK	WKPUJGILMQAMEH-UHFFFAOYSA-N
DMX58NK	IU	2,5,6,7-tetrahydro-1,4-oxazepin-3-amine
DMX58NK	DE	Discovery agent

DMMUZVS	ID	DMMUZVS
DMMUZVS	DN	[1,4]Oxazepan-(5E)-ylideneamine
DMMUZVS	HS	Investigative
DMMUZVS	SN	CHEMBL330548; [1,4]Oxazepan-(5E)-ylideneamine; SCHEMBL2590253; 5-Iminohexahydro-1,4-oxazepine; [1,4]Oxazepan-(5Z)-ylideneamine; BDBM50104659
DMMUZVS	DT	Small molecular drug
DMMUZVS	PC	15463448
DMMUZVS	MW	114.15
DMMUZVS	FM	C5H10N2O
DMMUZVS	IC	InChI=1S/C5H10N2O/c6-5-1-3-8-4-2-7-5/h1-4H2,(H2,6,7)
DMMUZVS	CS	C1COCCN=C1N
DMMUZVS	IK	IJBIVIJNRYYPRZ-UHFFFAOYSA-N
DMMUZVS	IU	2,3,6,7-tetrahydro-1,4-oxazepin-5-amine
DMMUZVS	DE	Discovery agent

DMCBFJQ	ID	DMCBFJQ
DMCBFJQ	DN	[1,4]Thiazepan-(3E)-ylideneamine
DMCBFJQ	HS	Investigative
DMCBFJQ	SN	CHEMBL186856; [1,4]Thiazepan-(3E)-ylideneamine; BDBM50155780
DMCBFJQ	DT	Small molecular drug
DMCBFJQ	PC	44396204
DMCBFJQ	MW	130.21
DMCBFJQ	FM	C5H10N2S
DMCBFJQ	IC	InChI=1S/C5H10N2S/c6-5-4-8-3-1-2-7-5/h1-4H2,(H2,6,7)
DMCBFJQ	CS	C1CN=C(CSC1)N
DMCBFJQ	IK	GMUCRJMNMMHHFX-UHFFFAOYSA-N
DMCBFJQ	IU	2,5,6,7-tetrahydro-1,4-thiazepin-3-amine
DMCBFJQ	DE	Discovery agent

DMFQ0Z4	ID	DMFQ0Z4
DMFQ0Z4	DN	[1,4]Thiazepan-(5E)-ylideneamine
DMFQ0Z4	HS	Investigative
DMFQ0Z4	SN	CHEMBL88308; [1,4]Thiazepan-(5E)-ylideneamine; SCHEMBL10239183; 5-Iminohexahydro-1,4-thiazepine; [1,4]Thiazepan-(5Z)-ylideneamine; BDBM50104653
DMFQ0Z4	DT	Small molecular drug
DMFQ0Z4	PC	15463447
DMFQ0Z4	MW	130.21
DMFQ0Z4	FM	C5H10N2S
DMFQ0Z4	IC	InChI=1S/C5H10N2S/c6-5-1-3-8-4-2-7-5/h1-4H2,(H2,6,7)
DMFQ0Z4	CS	C1CSCCN=C1N
DMFQ0Z4	IK	VXILVSMPTBRDEC-UHFFFAOYSA-N
DMFQ0Z4	IU	2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMFQ0Z4	CA	CAS 73028-68-9
DMFQ0Z4	DE	Discovery agent

DMF62JR	ID	DMF62JR
DMF62JR	DN	[1,5]Thiazocan-(4E)-ylideneamine
DMF62JR	HS	Investigative
DMF62JR	SN	CHEMBL92422; [1,5]Thiazocan-(4E)-ylideneamine; 4-Iminohexahydro-2H-1,5-thiazocine; BDBM50104658
DMF62JR	DT	Small molecular drug
DMF62JR	PC	44322961
DMF62JR	MW	144.24
DMF62JR	FM	C6H12N2S
DMF62JR	IC	InChI=1S/C6H12N2S/c7-6-2-5-9-4-1-3-8-6/h1-5H2,(H2,7,8)
DMF62JR	CS	C1CN=C(CCSC1)N
DMF62JR	IK	CMKCQRINBMEZKA-UHFFFAOYSA-N
DMF62JR	IU	3,4,7,8-tetrahydro-2H-1,5-thiazocin-6-amine
DMF62JR	DE	Discovery agent

DMMZUPX	ID	DMMZUPX
DMMZUPX	DN	[11C]AZ10419369
DMMZUPX	HS	Investigative
DMMZUPX	SN	[11C]AZ10419369 (PET ligand)
DMMZUPX	DT	Small molecular drug
DMMZUPX	PC	42608431
DMMZUPX	MW	461.5
DMMZUPX	FM	C26H30N4O4
DMMZUPX	IC	InChI=1S/C26H30N4O4/c1-18-3-8-21(30-11-9-28(2)10-12-30)25-24(18)22(31)17-23(34-25)26(32)27-19-4-6-20(7-5-19)29-13-15-33-16-14-29/h3-8,17H,9-16H2,1-2H3,(H,27,32)/i2-1
DMMZUPX	CS	CC1=C2C(=O)C=C(OC2=C(C=C1)N3CCN(CC3)[11CH3])C(=O)NC4=CC=C(C=C4)N5CCOCC5
DMMZUPX	IK	JKPWOPNZKYPRPZ-JVVVGQRLSA-N
DMMZUPX	IU	5-methyl-8-(4-(111C)methylpiperazin-1-yl)-N-(4-morpholin-4-ylphenyl)-4-oxochromene-2-carboxamide
DMMZUPX	DE	Discovery agent

DMQP03A	ID	DMQP03A
DMQP03A	DN	[11C]butylthio-TZTP
DMQP03A	HS	Investigative
DMQP03A	SN	[11C]butylthio-TZTP (PET ligand)
DMQP03A	DT	Small molecular drug
DMQP03A	PC	73755038
DMQP03A	MW	268.4
DMQP03A	FM	C12H19N3S2
DMQP03A	IC	InChI=1S/C12H19N3S2/c1-3-4-8-16-12-11(13-17-14-12)10-6-5-7-15(2)9-10/h6H,3-5,7-9H2,1-2H3/i1-1
DMQP03A	CS	CN1CCC=C(C1)C2=NSN=C2SCCC[11CH3]
DMQP03A	IK	SFXHHGRYNXLPKT-BJUDXGSMSA-N
DMQP03A	IU	3-(411C)butylsulfanyl-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DMQP03A	DE	Discovery agent

DM4ZANH	ID	DM4ZANH
DM4ZANH	DN	[11C]DTBZ
DM4ZANH	HS	Investigative
DM4ZANH	SN	[11C]-DTBZ ; [11C]-DTBZ (PET ligand); dihydrotetrabenazine
DM4ZANH	DT	Small molecular drug
DM4ZANH	PC	73755103
DM4ZANH	MW	332.5
DM4ZANH	FM	C20H31NO3
DM4ZANH	IC	InChI=1S/C20H31NO3/c1-13(2)8-15-12-21-7-6-14-9-18(23-4)19(24-5)10-16(14)20(21,3)11-17(15)22/h9-10,13,15,17,22H,6-8,11-12H2,1-5H3/t15-,17-,20-/m0/s1/i4-1
DM4ZANH	CS	CC(C)C[C@H]1CN2CCC3=CC(=C(C=C3[C@@]2(C[C@@H]1O)C)OC)O[11CH3]
DM4ZANH	IK	QJPLBORGTBURBF-VEFADGFBSA-N
DM4ZANH	IU	(2S,3S,11bS)-10-methoxy-9-(111C)methoxy-11b-methyl-3-(2-methylpropyl)-1,2,3,4,6,7-hexahydrobenzo[a]quinolizin-2-ol
DM4ZANH	DE	Discovery agent

DM5Q08F	ID	DM5Q08F
DM5Q08F	DN	[11C]GlySar
DM5Q08F	HS	Investigative
DM5Q08F	SN	[11C]-GlySar; [11C]glycylsarcosine
DM5Q08F	DT	Small molecular drug
DM5Q08F	PC	24971238
DM5Q08F	MW	145.15
DM5Q08F	FM	C5H10N2O3
DM5Q08F	IC	InChI=1S/C5H10N2O3/c1-7(3-5(9)10)4(8)2-6/h2-3,6H2,1H3,(H,9,10)/i1-1
DM5Q08F	CS	[11CH3]N(CC(=O)O)C(=O)CN
DM5Q08F	IK	VYAMLSCELQQRAE-BJUDXGSMSA-N
DM5Q08F	IU	2-[(2-aminoacetyl)-(111C)methylamino]acetic acid
DM5Q08F	DE	Discovery agent

DMQRSP7	ID	DMQRSP7
DMQRSP7	DN	[11C]MMTP
DMQRSP7	HS	Investigative
DMQRSP7	SN	[11C]MMTP; GTPL6212; CHEMBL1082810; Dimethylamino-3(4-[11C]methoxyphenyl)-3H-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one
DMQRSP7	DT	Small molecular drug
DMQRSP7	PC	46891047
DMQRSP7	MW	351.4
DMQRSP7	FM	C18H16N4O2S
DMQRSP7	IC	InChI=1S/C18H16N4O2S/c1-21(2)13-8-9-19-17-14(13)15-16(25-17)18(23)22(10-20-15)11-4-6-12(24-3)7-5-11/h4-10H,1-3H3/i3-1
DMQRSP7	CS	CN(C)C1=C2C3=C(C(=O)N(C=N3)C4=CC=C(C=C4)O[11CH3])SC2=NC=C1
DMQRSP7	IK	COQPVKMATNFNLG-KTXUZGJCSA-N
DMQRSP7	IU	13-(dimethylamino)-5-(4-(111C)methoxyphenyl)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMQRSP7	DE	Discovery agent

DMOZ8E3	ID	DMOZ8E3
DMOZ8E3	DN	[11C]SB207145
DMOZ8E3	HS	Investigative
DMOZ8E3	SN	[11C] SB207145 (PET ligand)
DMOZ8E3	DT	Small molecular drug
DMOZ8E3	PC	73755034
DMOZ8E3	MW	339.8
DMOZ8E3	FM	C16H21ClN2O4
DMOZ8E3	IC	InChI=1S/C16H21ClN2O4/c1-19-4-2-10(3-5-19)9-23-16(20)11-8-12(17)13(18)15-14(11)21-6-7-22-15/h8,10H,2-7,9,18H2,1H3/i1-1
DMOZ8E3	CS	[11CH3]N1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)Cl
DMOZ8E3	IK	FWDOTRBSNDBFMN-BJUDXGSMSA-N
DMOZ8E3	IU	(1-(111C)methylpiperidin-4-yl)methyl 5-amino-6-chloro-2,3-dihydro-1,4-benzodioxine-8-carboxylate
DMOZ8E3	DE	Discovery agent

DMCQTYW	ID	DMCQTYW
DMCQTYW	DN	[11C]volinanserin
DMCQTYW	HS	Investigative
DMCQTYW	SN	[11C]M100907 (PET ligand); [11C]MDL100907
DMCQTYW	DT	Small molecular drug
DMCQTYW	PC	449851
DMCQTYW	MW	372.5
DMCQTYW	FM	C22H28FNO3
DMCQTYW	IC	InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1/i1-1
DMCQTYW	CS	COC1=C(C=CC=C1O[11CH3])[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O
DMCQTYW	IK	HXTGXYRHXAGCFP-AVUPQLEMSA-N
DMCQTYW	IU	(R)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]-(2-methoxy-3-(111C)methoxyphenyl)methanol
DMCQTYW	CA	CAS 174792-03-1
DMCQTYW	DE	Discovery agent

DMXIEA1	ID	DMXIEA1
DMXIEA1	DN	[11C]WAY100635
DMXIEA1	HS	Investigative
DMXIEA1	SN	[11C]WAY100635 (PET ligand); [11C]WAY-100635
DMXIEA1	DT	Small molecular drug
DMXIEA1	PC	449645
DMXIEA1	MW	421.6
DMXIEA1	FM	C25H34N4O2
DMXIEA1	IC	InChI=1S/C25H34N4O2/c1-31-23-12-6-5-11-22(23)28-18-15-27(16-19-28)17-20-29(24-13-7-8-14-26-24)25(30)21-9-3-2-4-10-21/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3/i25-1
DMXIEA1	CS	COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)[11C](=O)C4CCCCC4
DMXIEA1	IK	SBPRIAGPYFYCRT-FNNGWQQSSA-N
DMXIEA1	IU	N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide
DMXIEA1	CA	CAS 162760-97-6
DMXIEA1	DE	Discovery agent

DM742L9	ID	DM742L9
DM742L9	DN	[11C]xanomeline
DM742L9	HS	Investigative
DM742L9	SN	[11C]xanomeline (PET ligand)
DM742L9	DT	Small molecular drug
DM742L9	PC	73755040
DM742L9	MW	280.42
DM742L9	FM	C14H23N3OS
DM742L9	IC	InChI=1S/C14H23N3OS/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12/h8H,3-7,9-11H2,1-2H3/i2-1
DM742L9	CS	CCCCCCOC1=NSN=C1C2=CCCN(C2)[11CH3]
DM742L9	IK	JOLJIIDDOBNFHW-JVVVGQRLSA-N
DM742L9	IU	3-hexoxy-4-(1-(111C)methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DM742L9	DE	Discovery agent

DMHWNOS	ID	DMHWNOS
DMHWNOS	DN	[123I] iodobenzoyl 12-Ex4
DMHWNOS	HS	Investigative
DMHWNOS	CP	Kyoto University
DMHWNOS	DE	Diabetic complication

DMCJQ0P	ID	DMCJQ0P
DMCJQ0P	DN	[123I]AM251
DMCJQ0P	HS	Investigative
DMCJQ0P	SN	[123I]AM251
DMCJQ0P	DT	Small molecular drug
DMCJQ0P	PC	10506880
DMCJQ0P	MW	551.2
DMCJQ0P	FM	C22H21Cl2IN4O
DMCJQ0P	IC	InChI=1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)/i25-4
DMCJQ0P	CS	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)[123I]
DMCJQ0P	IK	BUZAJRPLUGXRAB-VEFBWTBNSA-N
DMCJQ0P	IU	1-(2,4-dichlorophenyl)-5-(4-(123I)iodanylphenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMCJQ0P	DE	Discovery agent

DMOZGLM	ID	DMOZGLM
DMOZGLM	DN	[123I]iodobenzovesamicol
DMOZGLM	HS	Investigative
DMOZGLM	SN	[123I]-iodobenzovesamicol ; [123I]-IBVM
DMOZGLM	DT	Small molecular drug
DMOZGLM	PC	450460
DMOZGLM	MW	429.3
DMOZGLM	FM	C21H24INO
DMOZGLM	IC	InChI=1S/C21H24INO/c22-19-8-4-7-17-13-21(24)20(14-18(17)19)23-11-9-16(10-12-23)15-5-2-1-3-6-15/h1-8,16,20-21,24H,9-14H2/t20-,21-/m1/s1/i22-4
DMOZGLM	CS	C1CN(CCC1C2=CC=CC=C2)[C@@H]3CC4=C(C[C@H]3O)C=CC=C4[123I]
DMOZGLM	IK	FHYAUNJNVMGZQN-YKBXEZAISA-N
DMOZGLM	IU	(2R,3R)-5-(123I)iodanyl-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol
DMOZGLM	DE	Discovery agent

DM5SRT1	ID	DM5SRT1
DM5SRT1	DN	[123I]iodoproxyfan
DM5SRT1	HS	Investigative
DM5SRT1	DT	Small molecular drug
DM5SRT1	PC	449663
DM5SRT1	MW	338.18
DM5SRT1	FM	C13H15IN2O
DM5SRT1	IC	InChI=1S/C13H15IN2O/c14-12-5-3-11(4-6-12)9-17-7-1-2-13-8-15-10-16-13/h3-6,8,10H,1-2,7,9H2,(H,15,16)/i14-4
DM5SRT1	CS	C1=CC(=CC=C1COCCCC2=CN=CN2)[123I]
DM5SRT1	IK	DCQNAFOCXVCDLB-CKVWVWRJSA-N
DM5SRT1	IU	5-[3-[(4-(123I)iodanylphenyl)methoxy]propyl]-1H-imidazole
DM5SRT1	DE	Discovery agent

DMMG1TA	ID	DMMG1TA
DMMG1TA	DN	[123I]SB 207710
DMMG1TA	HS	Investigative
DMMG1TA	SN	[123I]SB 207710; GTPL3243; [123I]SB207710; (1-Butyl-4-piperidinylmethyl)-8-amino-7-[123I]iodo-1,4-benzodioxan-5-carboxylate; (1-butylpiperidin-4-yl)methyl 8-amino-7-(123I)iodo-2,3-dihydro-1,4-benzodioxine-5-carboxylate
DMMG1TA	DT	Small molecular drug
DMMG1TA	PC	32057519
DMMG1TA	MW	470.3
DMMG1TA	FM	C19H27IN2O4
DMMG1TA	IC	InChI=1S/C19H27IN2O4/c1-2-3-6-22-7-4-13(5-8-22)12-26-19(23)14-11-15(20)16(21)18-17(14)24-9-10-25-18/h11,13H,2-10,12,21H2,1H3/i20-4
DMMG1TA	CS	CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)[123I]
DMMG1TA	IK	FCKKCDRMGKXQDK-BMILMZPDSA-N
DMMG1TA	IU	(1-butylpiperidin-4-yl)methyl 5-amino-6-(123I)iodanyl-2,3-dihydro-1,4-benzodioxine-8-carboxylate
DMMG1TA	DE	Discovery agent

DMFT5N9	ID	DMFT5N9
DMFT5N9	DN	[125I]7-azido-8-iodoketanserine
DMFT5N9	HS	Investigative
DMFT5N9	SN	[125I]-7-azido-8-iodoketanserine (photoaffinity ligand); [125I]azidoiodoketanserin; [125I]AZIK
DMFT5N9	DT	Small molecular drug
DMFT5N9	PC	3037022
DMFT5N9	MW	560.3
DMFT5N9	FM	C22H20FIN6O3
DMFT5N9	IC	InChI=1S/C22H20FIN6O3/c23-15-3-1-13(2-4-15)20(31)14-7-9-29(10-8-14)11-12-30-21(32)16-5-6-17(27-28-25)18(24)19(16)26-22(30)33/h1-6,14H,7-12H2,(H,26,33)/i24-2
DMFT5N9	CS	C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=C(C(=C(C=C4)N=[N+]=[N-])[125I])NC3=O
DMFT5N9	IK	OALSEJAYBSRMHM-XXFZXMJFSA-N
DMFT5N9	IU	7-azido-3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-8-(125I)iodanyl-1H-quinazoline-2,4-dione
DMFT5N9	CA	CAS 136769-36-3
DMFT5N9	DE	Discovery agent

DM8EQFL	ID	DM8EQFL
DM8EQFL	DN	[125I]AB-MECA
DM8EQFL	HS	Investigative
DM8EQFL	SN	[125I]5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyl-oxolane-2-carboxamide; [125I]N(6)-(4-amino-3-iodobenzyl)adenosine-5'-N-methyluronamide; [125I]-AB-MECA
DM8EQFL	DT	Small molecular drug
DM8EQFL	PC	73754993
DM8EQFL	MW	523.299
DM8EQFL	FM	C18H20IN7O4
DM8EQFL	IC	InChI=1S/C18H20IN7O4/c1-21-17(29)14-12(27)13(28)18(30-14)26-7-25-11-15(23-6-24-16(11)26)22-5-8-2-3-10(20)9(19)4-8/h2-4,6-7,12-14,18,27-28H,5,20H2,1H3,(H,21,29)(H,22,23,24)/t12-,13+,14-,18+/m0/s1/i19-2
DM8EQFL	CS	CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=C(C=C4)N)[125I])O)O
DM8EQFL	IK	LOGOEBMHHXYBID-WBKNRDRNSA-N
DM8EQFL	IU	(2S,3S,4R,5R)-5-[6-[(4-amino-3-(125I)iodanylphenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
DM8EQFL	DE	Discovery agent

DMZBNK9	ID	DMZBNK9
DMZBNK9	DN	[125I]ABOPX
DMZBNK9	HS	Investigative
DMZBNK9	SN	[125I]3-(3,4-aminobenzyl)-8-(4-oxyacetate)phenyl-1-propyl-xanthine
DMZBNK9	DT	Small molecular drug
DMZBNK9	PC	14016348
DMZBNK9	MW	573.4
DMZBNK9	FM	C23H22IN5O5
DMZBNK9	IC	InChI=1S/C23H22IN5O5/c1-2-9-28-22(32)19-21(29(23(28)33)11-13-3-8-17(25)16(24)10-13)27-20(26-19)14-4-6-15(7-5-14)34-12-18(30)31/h3-8,10H,2,9,11-12,25H2,1H3,(H,26,27)(H,30,31)/i24-2
DMZBNK9	CS	CCCN1C(=O)C2=C(N=C(N2)C3=CC=C(C=C3)OCC(=O)O)N(C1=O)CC4=CC(=C(C=C4)N)[125I]
DMZBNK9	IK	DKJMGIXWGPEEFF-XXFZXMJFSA-N
DMZBNK9	IU	2-[4-[3-[(4-amino-3-(125I)iodanylphenyl)methyl]-2,6-dioxo-1-propyl-7H-purin-8-yl]phenoxy]acetic acid
DMZBNK9	DE	Discovery agent

DM95A4Z	ID	DM95A4Z
DM95A4Z	DN	[125I]APNEA
DM95A4Z	HS	Investigative
DM95A4Z	SN	CHEMBL326958; 2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; [3H]N6-2-(4-Aminophenyl)ethyladenosine; AC1L1I2P; AC1Q4Y3F; Lopac0_000118; GTPL417; GTPL462; ChEMBL_198532; SCHEMBL16585344; HMS3260G18; n-[2-(4-aminophenyl)ethyl]-9-pentofuranosyl-9h-purin-6-amine; Tox21_500118; BDBM50037785; LP00118; CCG-204213; NCGC00260803-01; NCGC00093612-03; NCGC00015017-04; NCGC00093612-02; NCGC00093612-01; NCGC00015017-05; NCGC00015017-03; NCGC00015017-02; [3H]N6-2-(4-aminophenyl)ethyladenosine
DM95A4Z	DT	Small molecular drug
DM95A4Z	PC	4397
DM95A4Z	MW	386.4
DM95A4Z	FM	C18H22N6O4
DM95A4Z	IC	InChI=1S/C18H22N6O4/c19-11-3-1-10(2-4-11)5-6-20-16-13-17(22-8-21-16)24(9-23-13)18-15(27)14(26)12(7-25)28-18/h1-4,8-9,12,14-15,18,25-27H,5-7,19H2,(H,20,21,22)
DM95A4Z	CS	C1=CC(=CC=C1CCNC2=C3C(=NC=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N
DM95A4Z	IK	XTPOZVLRZZIEBW-UHFFFAOYSA-N
DM95A4Z	IU	2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM95A4Z	DE	Discovery agent

DMYBQOG	ID	DMYBQOG
DMYBQOG	DN	[125I]-BDZ2
DMYBQOG	HS	Investigative
DMYBQOG	SN	CHEMBL515288; [125I]-BDZ2; GTPL6667
DMYBQOG	DT	Small molecular drug
DMYBQOG	PC	44572147
DMYBQOG	MW	508.3
DMYBQOG	FM	C23H19IN4O2
DMYBQOG	IC	InChI=1S/C23H19IN4O2/c1-28-19-13-6-5-12-18(19)20(15-8-3-2-4-9-15)26-21(22(28)29)27-23(30)25-17-11-7-10-16(24)14-17/h2-14,21H,1H3,(H2,25,27,30)/t21-/m0/s1/i24-2
DMYBQOG	CS	CN1C2=CC=CC=C2C(=N[C@H](C1=O)NC(=O)NC3=CC(=CC=C3)[125I])C4=CC=CC=C4
DMYBQOG	IK	VLKJKVMACAESPP-MRDSYVANSA-N
DMYBQOG	IU	1-(3-(125I)iodanylphenyl)-3-[(3R)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea
DMYBQOG	DE	Discovery agent

DM7GVYF	ID	DM7GVYF
DM7GVYF	DN	[125I]BE-2254
DM7GVYF	HS	Investigative
DM7GVYF	SN	HEAT; 2-{p-(4-hydroxy-3-[125I]iodophenyl)ethylaminomethyl}-tetralone; 2-[[2-(4-hydroxy-3-iodanylphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one
DM7GVYF	DT	Small molecular drug
DM7GVYF	PC	449744
DM7GVYF	MW	419.3
DM7GVYF	FM	C19H20INO2
DM7GVYF	IC	InChI=1S/C19H20INO2/c20-17-11-13(5-8-18(17)22)9-10-21-12-15-7-6-14-3-1-2-4-16(14)19(15)23/h1-5,8,11,15,21-22H,6-7,9-10,12H2/i20-2
DM7GVYF	CS	C1CC2=CC=CC=C2C(=O)C1CNCCC3=CC(=C(C=C3)O)[125I]
DM7GVYF	IK	DUOOAUBZMQZYLO-STTHPYEQSA-N
DM7GVYF	IU	2-[[2-(4-hydroxy-3-(125I)iodanylphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one
DM7GVYF	DE	Discovery agent

DMV6I7H	ID	DMV6I7H
DMV6I7H	DN	[125I]BOP
DMV6I7H	HS	Investigative
DMV6I7H	SN	[125I]-I-BOP
DMV6I7H	DT	Small molecular drug
DMV6I7H	PC	23986047
DMV6I7H	MW	510.4
DMV6I7H	FM	C23H29IO5
DMV6I7H	IC	InChI=1S/C23H29IO5/c24-16-7-10-18(11-8-16)28-15-17(25)9-12-20-19(21-13-14-22(20)29-21)5-3-1-2-4-6-23(26)27/h1,3,7-12,17,19-22,25H,2,4-6,13-15H2,(H,26,27)/b3-1+,12-9+/t17-,19-,20-,21+,22-/m1/s1/i24-2
DMV6I7H	CS	C1C[C@@H]2[C@@H]([C@H]([C@H]1O2)C/C=C/CCCC(=O)O)/C=C/[C@H](COC3=CC=C(C=C3)[125I])O
DMV6I7H	IK	UYFMSCHBODMWON-ZKBYQGIHSA-N
DMV6I7H	IU	(E)-7-[(1S,2R,3R,4R)-3-[(E,3R)-3-hydroxy-4-(4-(125I)iodanylphenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DMV6I7H	DE	Discovery agent

DM0X824	ID	DM0X824
DM0X824	DN	[125I]cetrorelix
DM0X824	HS	Investigative
DM0X824	SN	[125I]cetrorelix
DM0X824	DT	Small molecular drug
DM0X824	PC	73754999
DM0X824	MW	1520.5
DM0X824	FM	C70H92IN17O14
DM0X824	IC	InChI=1S/C70H92IN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1/i71-2
DM0X824	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)[125I])NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM0X824	IK	MVDPNTCYCFVFOX-SZENRQNHSA-N
DM0X824	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-(125I)iodanylphenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM0X824	DE	Discovery agent

DMIAO4V	ID	DMIAO4V
DMIAO4V	DN	[125I]CGP 64213
DMIAO4V	HS	Investigative
DMIAO4V	SN	[125I]CGP64213
DMIAO4V	DT	Small molecular drug
DMIAO4V	PC	53323294
DMIAO4V	MW	644.5
DMIAO4V	FM	C26H36IN2O7P
DMIAO4V	IC	InChI=1S/C26H36IN2O7P/c1-18(20-6-5-7-21(15-20)26(33)34)29-16-22(30)17-37(35,36)13-4-2-3-12-28-25(32)11-9-19-8-10-24(31)23(27)14-19/h5-8,10,14-15,18,22,29-31H,2-4,9,11-13,16-17H2,1H3,(H,28,32)(H,33,34)(H,35,36)/t18-,22+/m1/s1/i27-2
DMIAO4V	CS	C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CCCCCNC(=O)CCC2=CC(=C(C=C2)O)[125I])O)O
DMIAO4V	IK	RLYLJDJFHZHCTR-ZNAYHWKRSA-N
DMIAO4V	IU	3-[(1R)-1-[[(2S)-2-hydroxy-3-[hydroxy-[5-[3-(4-hydroxy-3-(125I)iodanylphenyl)propanoylamino]pentyl]phosphoryl]propyl]amino]ethyl]benzoic acid
DMIAO4V	DE	Discovery agent

DMQVW4E	ID	DMQVW4E
DMQVW4E	DN	[125I]CGP 71872
DMQVW4E	HS	Investigative
DMQVW4E	SN	[125I]CGP71872
DMQVW4E	DT	Small molecular drug
DMQVW4E	PC	53323295
DMQVW4E	MW	657.4
DMQVW4E	FM	C24H31IN5O7P
DMQVW4E	IC	InChI=1S/C24H31IN5O7P/c1-15(16-6-5-7-17(10-16)24(34)35)28-13-18(31)14-38(36,37)9-4-2-3-8-27-23(33)19-11-20(25)21(29-30-26)12-22(19)32/h5-7,10-12,15,18,28,31-32H,2-4,8-9,13-14H2,1H3,(H,27,33)(H,34,35)(H,36,37)/t15-,18+/m1/s1/i25-2
DMQVW4E	CS	C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CCCCCNC(=O)C2=CC(=C(C=C2O)N=[N+]=[N-])[125I])O)O
DMQVW4E	IK	IHFUJPDKHJTHGQ-DQPKGEOYSA-N
DMQVW4E	IU	3-[(1R)-1-[[(2S)-3-[5-[(4-azido-2-hydroxy-5-(125I)iodanylbenzoyl)amino]pentyl-hydroxyphosphoryl]-2-hydroxypropyl]amino]ethyl]benzoic acid
DMQVW4E	DE	Discovery agent

DM1NXDA	ID	DM1NXDA
DM1NXDA	DN	[125I]CGP42112
DM1NXDA	HS	Investigative
DM1NXDA	SN	UXGNARZDONUMMK-LRMQDCNJSA-N; Cgp-42112A; Cgp 42112; 127060-75-7; CGP 42112A; CGP-42112; Cgp 42112B; CGP42112A; Nicotinic acid-tyr-(N(sigma)-benzyloxycarbonyl-arg)lys-his-pro-ile-OH; Nicotinic acid-tyrosyl-(N(sigma)-benzyloxycarbonyl-arginyl)lysyl-histidyl-prolyl-isoleucine-OH; L-Isoleucine, N-(1-(N-(N6-(N2-((phenylmethoxy)carbonyl)-L-arginyl)-N2-(N-(3-pyridinylcarbonyl)-L-tyrosyl)-L-lysyl)-L-histidyl)-L-prolyl)-; CGP42112;  Cgp 42112B; [125I]-CGP42112
DM1NXDA	DT	Small molecular drug
DM1NXDA	PC	123794
DM1NXDA	MW	1052.2
DM1NXDA	FM	C52H69N13O11
DM1NXDA	IC	InChI=1S/C52H69N13O11/c1-3-32(2)43(50(73)74)64-48(71)42-17-11-25-65(42)49(72)41(27-36-29-56-31-59-36)62-46(69)39(60-47(70)40(26-33-18-20-37(66)21-19-33)61-44(67)35-14-9-22-55-28-35)15-7-8-23-57-45(68)38(16-10-24-58-51(53)54)63-52(75)76-30-34-12-5-4-6-13-34/h4-6,9,12-14,18-22,28-29,31-32,38-43,66H,3,7-8,10-11,15-17,23-27,30H2,1-2H3,(H,56,59)(H,57,68)(H,60,70)(H,61,67)(H,62,69)(H,63,75)(H,64,71)(H,73,74)(H4,53,54,58)/t32-,38-,39-,40-,41-,42-,43-/m0/s1
DM1NXDA	CS	CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCCNC(=O)[C@H](CCCN=C(N)N)NC(=O)OCC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)C5=CN=CC=C5
DM1NXDA	IK	UXGNARZDONUMMK-LRMQDCNJSA-N
DM1NXDA	IU	(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-6-[[(2S)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-2-[[(2S)-3-(4-hydroxyphenyl)-2-(pyridine-3-carbonylamino)propanoyl]amino]hexanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid
DM1NXDA	CA	CAS 127060-75-7
DM1NXDA	CB	CHEBI:147302
DM1NXDA	DE	Discovery agent

DMEPT8H	ID	DMEPT8H
DMEPT8H	DN	[125I]DIV880
DMEPT8H	HS	Investigative
DMEPT8H	SN	[125I]DIV880
DMEPT8H	DT	Small molecular drug
DMEPT8H	PC	86277837
DMEPT8H	MW	526.4
DMEPT8H	FM	C23H29IO6
DMEPT8H	IC	InChI=1S/C23H29IO6/c1-23(2,3)30-22(25)12-15-10-19(27-5)18(26-4)9-14(15)8-16-11-20(28-6)21(29-7)13-17(16)24/h9-11,13H,8,12H2,1-7H3/i24-2
DMEPT8H	CS	CC(C)(C)OC(=O)CC1=CC(=C(C=C1CC2=CC(=C(C=C2[125I])OC)OC)OC)OC
DMEPT8H	IK	UIYQREMVBQNPNM-XXFZXMJFSA-N
DMEPT8H	IU	tert-butyl 2-[2-[(2-(125I)iodanyl-4,5-dimethoxyphenyl)methyl]-4,5-dimethoxyphenyl]acetate
DMEPT8H	DE	Discovery agent

DMQUY08	ID	DMQUY08
DMQUY08	DN	[125I]DOI
DMQUY08	HS	Investigative
DMQUY08	SN	[125I]DOI
DMQUY08	DT	Small molecular drug
DMQUY08	PC	13547416
DMQUY08	MW	319.15
DMQUY08	FM	C11H16INO2
DMQUY08	IC	InChI=1S/C11H16INO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3/i12-2
DMQUY08	CS	CC(CC1=CC(=C(C=C1OC)[125I])OC)N
DMQUY08	IK	BGMZUEKZENQUJY-DACUFJSSSA-N
DMQUY08	IU	1-(4-(125I)iodanyl-2,5-dimethoxyphenyl)propan-2-amine
DMQUY08	DE	Discovery agent

DMZWQH3	ID	DMZWQH3
DMZWQH3	DN	[125I]epibatidine
DMZWQH3	HS	Investigative
DMZWQH3	SN	CHEMBL6623; NLPRAJRHRHZCQQ-UHFFFAOYSA-N; 140111-52-0; [3H]EPIBATIDINE; SR-01000597620; [125I]EPIBATIDINE; AC1Q3PYA; AC1L1AYB; 208/210 Epibatidine; KBioSS_000603; KBioGR_000603; BSPBio_001263; (R)-2-(6-Chloro-pyridin-3-yl)-7-aza-bicyclo[221]heptane; [3H]epibatidine
DMZWQH3	DT	Small molecular drug
DMZWQH3	PC	1204
DMZWQH3	MW	208.69
DMZWQH3	FM	C11H13ClN2
DMZWQH3	IC	InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2
DMZWQH3	CS	C1CC2C(CC1N2)C3=CN=C(C=C3)Cl
DMZWQH3	IK	NLPRAJRHRHZCQQ-UHFFFAOYSA-N
DMZWQH3	IU	2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane
DMZWQH3	CB	CHEBI:91678
DMZWQH3	DE	Discovery agent

DMEKGZS	ID	DMEKGZS
DMEKGZS	DN	[125I]EXP985
DMEKGZS	HS	Investigative
DMEKGZS	SN	[125I]-EXP985
DMEKGZS	DT	Small molecular drug
DMEKGZS	PC	73755063
DMEKGZS	MW	665.9
DMEKGZS	FM	C29H27ClIN7O2
DMEKGZS	IC	InChI=1S/C29H27ClIN7O2/c1-2-5-25-33-27(30)26(29(40)32-15-14-18-10-13-24(39)23(31)16-18)38(25)17-19-8-11-20(12-9-19)21-6-3-4-7-22(21)28-34-36-37-35-28/h3-4,6-13,16,39H,2,5,14-15,17H2,1H3,(H,32,40)(H,34,35,36,37)/i31-2
DMEKGZS	CS	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)NCCC5=CC(=C(C=C5)O)[125I])Cl
DMEKGZS	IK	WMCDNTWPKXBICS-DYSJZCPFSA-N
DMEKGZS	IU	5-chloro-N-[2-(4-hydroxy-3-(125I)iodanylphenyl)ethyl]-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxamide
DMEKGZS	DE	Discovery agent

DMFWE4H	ID	DMFWE4H
DMFWE4H	DN	[125I]GR231118
DMFWE4H	HS	Investigative
DMFWE4H	SN	[125I]1229U91; [125I]GW1229
DMFWE4H	DT	Small molecular drug
DMFWE4H	PC	56947140
DMFWE4H	MW	2352.7
DMFWE4H	FM	C110H170N34O24
DMFWE4H	IC	InChI=1S/C110H170N34O24/c1-9-59(7)87(111)103(165)133-73-39-41-85(149)127-55-81(99(161)139-79(53-63-27-35-67(147)36-28-63)97(159)131-71(19-13-45-125-109(119)120)93(155)137-77(49-57(3)4)95(157)129-69(17-11-43-123-107(115)116)91(153)135-75(89(113)151)51-61-23-31-65(145)32-24-61)142-102(164)84-22-16-48-144(84)106(168)74(134-104(166)88(112)60(8)10-2)40-42-86(150)128-56-82(141-101(163)83-21-15-47-143(83)105(73)167)100(162)140-80(54-64-29-37-68(148)38-30-64)98(160)132-72(20-14-46-126-110(121)122)94(156)138-78(50-58(5)6)96(158)130-70(18-12-44-124-108(117)118)92(154)136-76(90(114)152)52-62-25-33-66(146)34-26-62/h23-38,57-60,69-84,87-88,145-148H,9-22,39-56,111-112H2,1-8H3,(H2,113,151)(H2,114,152)(H,127,149)(H,128,150)(H,129,157)(H,130,158)(H,131,159)(H,132,160)(H,133,165)(H,134,166)(H,135,153)(H,136,154)(H,137,155)(H,138,156)(H,139,161)(H,140,162)(H,141,163)(H,142,164)(H4,115,116,123)(H4,117,118,124)(H4,119,120,125)(H4,121,122,126)/t59-,60-,69-,70-,71-,72-,73-,74+,75-,76-,77-,78-,79-,80-,81-,82+,83-,84-,87-,88-/m0/s1
DMFWE4H	CS	CC[C@H](C)[C@@H](C(=N[C@@H]1CCC(=NC[C@@H](N=C([C@@H]2CCCN2C(=O)[C@H](CCC(=NC[C@H](N=C([C@@H]3CCCN3C1=O)O)C(=N[C@@H](CC4=CC=C(C=C4)O)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CC(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CC5=CC=C(C=C5)O)C(=N)O)O)O)O)O)O)O)N=C([C@H]([C@@H](C)CC)N)O)O)C(=N[C@@H](CC6=CC=C(C=C6)O)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CC(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CC7=CC=C(C=C7)O)C(=N)O)O)O)O)O)O)O)O)N
DMFWE4H	IK	RJRBRCCJETZJLT-VHUVHYDGSA-N
DMFWE4H	IU	(3R,9R,12S,18S,24S,27S)-3,18-bis[[(2S,3S)-2-amino-1-hydroxy-3-methylpentylidene]amino]-9-N,24-N-bis[(2S)-1-[(2S)-5-carbamimidamido-1-[(2S)-1-[(2S)-5-carbamimidamido-1-hydroxy-1-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-iminopropan-2-yl]iminopentan-2-yl]imino-1-hydroxy-4-methylpentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]-6,11,21,26-tetrahydroxy-2,17-dioxo-1,7,10,16,22,25-hexazatricyclo[25.3.0.012,16]triaconta-6,10,21,25-tetraene-9,24-dicarboximidic acid
DMFWE4H	DE	Discovery agent

DMSYT5P	ID	DMSYT5P
DMSYT5P	DN	[125I]GTI
DMSYT5P	HS	Investigative
DMSYT5P	SN	serotonin-5-O-carboxymethyl-glycyl-(125I)tyrosinamide
DMSYT5P	DT	Small molecular drug
DMSYT5P	PC	73755035
DMSYT5P	MW	577.4
DMSYT5P	FM	C23H26IN5O5
DMSYT5P	IC	InChI=1S/C23H26IN5O5/c24-17-7-13(1-4-20(17)30)8-19(23(26)33)29-21(31)11-28-22(32)12-34-15-2-3-18-16(9-15)14(5-6-25)10-27-18/h1-4,7,9-10,19,27,30H,5-6,8,11-12,25H2,(H2,26,33)(H,28,32)(H,29,31)/t19-/m0/s1/i24-2
DMSYT5P	CS	C1=CC(=C(C=C1C[C@@H](C(=O)N)NC(=O)CNC(=O)COC2=CC3=C(C=C2)NC=C3CCN)[125I])O
DMSYT5P	IK	JVQSCVCNDUJMMW-BYWNROPASA-N
DMSYT5P	IU	(2S)-2-[[2-[[2-[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]amino]acetyl]amino]-3-(4-hydroxy-3-(125I)iodanylphenyl)propanamide
DMSYT5P	DE	Discovery agent

DMTFP5Q	ID	DMTFP5Q
DMTFP5Q	DN	[125I]HEAT
DMTFP5Q	HS	Investigative
DMTFP5Q	SN	[125I]-HEAT
DMTFP5Q	DT	Small molecular drug
DMTFP5Q	PC	73754995
DMTFP5Q	MW	419.3
DMTFP5Q	FM	C19H20INO2
DMTFP5Q	IC	InChI=1S/C19H20INO2/c20-18-11-16(22)8-7-14(18)9-10-21-12-15-6-5-13-3-1-2-4-17(13)19(15)23/h1-4,7-8,11,15,21-22H,5-6,9-10,12H2/i20-2
DMTFP5Q	CS	C1CC2=CC=CC=C2C(=O)C1CNCCC3=C(C=C(C=C3)O)[125I]
DMTFP5Q	IK	MIQRUWUVLIWVAW-STTHPYEQSA-N
DMTFP5Q	IU	2-[[2-(4-hydroxy-2-(125I)iodanylphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one
DMTFP5Q	DE	Discovery agent

DM3BQHO	ID	DM3BQHO
DM3BQHO	DN	[125I]ICYP
DM3BQHO	HS	Investigative
DM3BQHO	SN	[125I]iodocyanopindolol
DM3BQHO	DT	Small molecular drug
DM3BQHO	PC	73754996
DM3BQHO	MW	397.23
DM3BQHO	FM	C15H18IN3O2
DM3BQHO	IC	InChI=1S/C15H18IN3O2/c1-9(2)18-7-10(20)8-21-13-5-3-4-11-14(13)15(16)12(6-17)19-11/h3-5,9-10,18-20H,7-8H2,1-2H3/i16-2
DM3BQHO	CS	CC(C)NCC(COC1=CC=CC2=C1C(=C(N2)C#N)[125I])O
DM3BQHO	IK	WGSPBWSPJOBKNT-RFLHHMENSA-N
DM3BQHO	IU	4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3-(125I)iodanyl-1H-indole-2-carbonitrile
DM3BQHO	DE	Discovery agent

DMHJL58	ID	DMHJL58
DMHJL58	DN	[125I]iodoaminopotentidine
DMHJL58	HS	Investigative
DMHJL58	SN	[125I]APT; [125I]-iodoaminopotentidine
DMHJL58	DT	Small molecular drug
DMHJL58	PC	73755000
DMHJL58	MW	601.5
DMHJL58	FM	C26H34IN7O2
DMHJL58	IC	InChI=1S/C26H34IN7O2/c27-23-17-21(8-9-24(23)29)25(35)30-11-12-32-26(33-19-28)31-10-5-15-36-22-7-4-6-20(16-22)18-34-13-2-1-3-14-34/h4,6-9,16-17H,1-3,5,10-15,18,29H2,(H,30,35)(H2,31,32,33)/i27-2
DMHJL58	CS	C1CCN(CC1)CC2=CC(=CC=C2)OCCCN=C(NCCNC(=O)C3=CC(=C(C=C3)N)[125I])NC#N
DMHJL58	IK	VJTYCMQYDRXNNY-ALRLDUCRSA-N
DMHJL58	IU	4-amino-N-[2-[[N-cyano-N'-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]carbamimidoyl]amino]ethyl]-3-(125I)iodanylbenzamide
DMHJL58	DE	Discovery agent

DMN4ABU	ID	DMN4ABU
DMN4ABU	DN	[125I]iodophenpropit
DMN4ABU	HS	Investigative
DMN4ABU	SN	(1S)-1-[3-(3H-Imidazol-4-yl)propylsulfanyl]-N-[2-(4-iodophenyl)ethyl]methanediamine; (1S)-1-[3-(3H-imidazol-4-yl)propylsulfanyl]-N-[2-(4-iodophenyl)ethyl]methanediamine; [125I]IODOPHENPROPIT; AC1NSK68; GTPL3960; GTPL1266; IODOPHENPROPIT
DMN4ABU	DT	Small molecular drug
DMN4ABU	PC	5311186
DMN4ABU	MW	416.3
DMN4ABU	FM	C15H21IN4S
DMN4ABU	IC	InChI=1S/C15H21IN4S/c16-13-5-3-12(4-6-13)7-8-19-15(17)21-9-1-2-14-10-18-11-20-14/h3-6,10-11,15,19H,1-2,7-9,17H2,(H,18,20)/t15-/m0/s1
DMN4ABU	CS	C1=CC(=CC=C1CCN[C@H](N)SCCCC2=CN=CN2)I
DMN4ABU	IK	UWFACTDPNOOPFV-HNNXBMFYSA-N
DMN4ABU	IU	(1S)-1-[3-(1H-imidazol-5-yl)propylsulfanyl]-N'-[2-(4-iodophenyl)ethyl]methanediamine
DMN4ABU	DE	Discovery agent

DMVEHI7	ID	DMVEHI7
DMVEHI7	DN	[125I]IRL1620
DMVEHI7	HS	Investigative
DMVEHI7	SN	[125I]IRL 1620; [125I]-IRL1620
DMVEHI7	DT	Small molecular drug
DMVEHI7	PC	16130933
DMVEHI7	MW	1820.9
DMVEHI7	FM	C86H117N17O27
DMVEHI7	IC	InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1
DMVEHI7	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
DMVEHI7	IK	DXPHNGAMYPPTBJ-TZMIJSMNSA-N
DMVEHI7	IU	(4S)-4-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-(3-carboxypropanoylamino)propanoyl]amino]butanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMVEHI7	CA	CAS 142569-99-1
DMVEHI7	DE	Discovery agent

DMKSI80	ID	DMKSI80
DMKSI80	DN	[125I]L703,606
DMKSI80	HS	Investigative
DMKSI80	SN	[125I]L703606; [125I]-L703,606
DMKSI80	DT	Small molecular drug
DMKSI80	PC	53326807
DMKSI80	MW	506.4
DMKSI80	FM	C27H29IN2
DMKSI80	IC	InChI=1S/C27H29IN2/c28-24-14-8-7-13-23(24)19-29-26-22-15-17-30(18-16-22)27(26)25(20-9-3-1-4-10-20)21-11-5-2-6-12-21/h1-14,22,25-27,29H,15-19H2/t26-,27-/m1/s1/i28-2
DMKSI80	CS	C1CN2CCC1[C@H]([C@H]2C(C3=CC=CC=C3)C4=CC=CC=C4)NCC5=CC=CC=C5[125I]
DMKSI80	IK	WSLTYZVXORBNLB-BRXFWFLGSA-N
DMKSI80	IU	(2R,3R)-2-benzhydryl-N-[(2-(125I)iodanylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
DMKSI80	DE	Discovery agent

DMO7VRJ	ID	DMO7VRJ
DMO7VRJ	DN	[125I]L750667
DMO7VRJ	HS	Investigative
DMO7VRJ	SN	[125I]-L750667
DMO7VRJ	DT	Small molecular drug
DMO7VRJ	PC	5311214
DMO7VRJ	MW	416.3
DMO7VRJ	FM	C18H19IN4
DMO7VRJ	IC	InChI=1S/C18H19IN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)/i19-2
DMO7VRJ	CS	C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)[125I]
DMO7VRJ	IK	OOEUHRGMLFVKQO-GBVACIEGSA-N
DMO7VRJ	IU	3-[[4-(4-(125I)iodanylphenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine
DMO7VRJ	DE	Discovery agent

DMP69QG	ID	DMP69QG
DMP69QG	DN	[125I]LSD
DMP69QG	HS	Investigative
DMP69QG	SN	[125I]N,N-diethyllysergamide; [125I]lysergamid; [125I]lysergic acid diethylamide; [125I]lysergide
DMP69QG	DT	Small molecular drug
DMP69QG	PC	73754990
DMP69QG	MW	447.3
DMP69QG	FM	C20H24IN3O
DMP69QG	IC	InChI=1S/C20H24IN3O/c1-4-24(5-2)20(25)12-9-14-13-7-6-8-16-18(13)15(19(21)22-16)10-17(14)23(3)11-12/h6-9,12,17,22H,4-5,10-11H2,1-3H3/t12-,17-/m1/s1/i21-2
DMP69QG	CS	CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)[125I])C
DMP69QG	IK	OBCUQRYIGTWROI-YUPRZBKSSA-N
DMP69QG	IU	(6aR,9R)-N,N-diethyl-5-(125I)iodanyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMP69QG	DE	Discovery agent

DMEHK9M	ID	DMEHK9M
DMEHK9M	DN	[125I]PD142308
DMEHK9M	HS	Investigative
DMEHK9M	SN	(3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-(4-amino-3-iodophenyl)butanoic acid; [125I]PD142308
DMEHK9M	DT	Small molecular drug
DMEHK9M	PC	73755055
DMEHK9M	MW	696.6
DMEHK9M	FM	C33H39IN4O5
DMEHK9M	IC	InChI=1S/C33H39IN4O5/c1-33(16-23-17-36-28-5-3-2-4-25(23)28,38-32(42)43-30-21-9-19-8-20(11-21)12-22(30)10-19)31(41)37-24(15-29(39)40)13-18-6-7-27(35)26(34)14-18/h2-7,14,17,19-22,24,30,36H,8-13,15-16,35H2,1H3,(H,37,41)(H,38,42)(H,39,40)/t19?,20?,21?,22?,24-,30?,33+/m0/s1/i34-2
DMEHK9M	CS	C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@@H](CC3=CC(=C(C=C3)N)[125I])CC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMEHK9M	IK	YMNQSYWYYQDKJU-PDZULBFKSA-N
DMEHK9M	IU	(3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-(4-amino-3-(125I)iodanylphenyl)butanoic acid
DMEHK9M	DE	Discovery agent

DM4HLO5	ID	DM4HLO5
DM4HLO5	DN	[125I]PD151242
DM4HLO5	HS	Investigative
DM4HLO5	SN	[125I](N-[{hexahydro-1-azepinyl}carbonyl])Leu(1-Me)-DTrp-DTyr; [125I]-PD151242
DM4HLO5	DT	Small molecular drug
DM4HLO5	PC	132991
DM4HLO5	MW	619.7
DM4HLO5	FM	C34H45N5O6
DM4HLO5	IC	InChI=1S/C34H45N5O6/c1-22(2)18-27(37-34(45)39-16-8-4-5-9-17-39)31(41)35-28(20-24-21-38(3)30-11-7-6-10-26(24)30)32(42)36-29(33(43)44)19-23-12-14-25(40)15-13-23/h6-7,10-15,21-22,27-29,40H,4-5,8-9,16-20H2,1-3H3,(H,35,41)(H,36,42)(H,37,45)(H,43,44)/t27-,28+,29+/m0/s1
DM4HLO5	CS	CC(C)C[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C)C(=O)N[C@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)N4CCCCCC4
DM4HLO5	IK	JVILFANCFWZBFU-ZGIBFIJWSA-N
DM4HLO5	IU	(2R)-2-[[(2R)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-methylindol-3-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM4HLO5	CA	CAS 155561-67-4
DM4HLO5	DE	Discovery agent

DMROKJP	ID	DMROKJP
DMROKJP	DN	[125I]PTA-OH
DMROKJP	HS	Investigative
DMROKJP	SN	I-PTA-OH
DMROKJP	DT	Small molecular drug
DMROKJP	PC	73755023
DMROKJP	MW	539.5
DMROKJP	FM	C25H36INO4
DMROKJP	IC	InChI=1S/C25H36INO4/c1-25(2)17-13-20(25)19(7-5-3-4-6-8-24(30)31)22(14-17)27-15-18(28)11-16-9-10-23(29)21(26)12-16/h3,5,9-10,12,17-20,22,27-29H,4,6-8,11,13-15H2,1-2H3,(H,30,31)/b5-3+/i26-2
DMROKJP	CS	CC1(C2CC1C(C(C2)NCC(CC3=CC(=C(C=C3)O)[125I])O)C/C=C/CCCC(=O)O)C
DMROKJP	IK	RCPAWLXQBMAVGJ-WEGMHNBISA-N
DMROKJP	IU	(E)-7-[3-[[2-hydroxy-3-(4-hydroxy-3-(125I)iodanylphenyl)propyl]amino]-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DMROKJP	DE	Discovery agent

DMUD3A8	ID	DMUD3A8
DMUD3A8	DN	[125I]resiniferatoxin
DMUD3A8	HS	Investigative
DMUD3A8	SN	[125I]resiniferatoxin
DMUD3A8	DT	Small molecular drug
DMUD3A8	PC	73755027
DMUD3A8	MW	752.6
DMUD3A8	FM	C37H39IO9
DMUD3A8	IC	InChI=1S/C37H39IO9/c1-20(2)35-16-22(4)37-26(33(35)45-36(46-35,47-37)18-23-9-7-6-8-10-23)12-25(17-34(42)29(37)11-21(3)32(34)41)19-44-30(39)15-24-13-27(38)31(40)28(14-24)43-5/h6-14,22,26,29,33,40,42H,1,15-19H2,2-5H3/t22-,26+,29-,33-,34-,35-,36-,37-/m1/s1/i38-2
DMUD3A8	CS	C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5(CC(=C4)COC(=O)CC6=CC(=C(C(=C6)[125I])O)OC)O)C)O[C@](O3)(O2)CC7=CC=CC=C7)C(=C)C
DMUD3A8	IK	TZUJORCXGLGWDV-FOFZJNPASA-N
DMUD3A8	IU	[(1R,2R,6R,10S,11R,13S,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-(125I)iodanyl-5-methoxyphenyl)acetate
DMUD3A8	DE	Discovery agent

DMHC6KX	ID	DMHC6KX
DMHC6KX	DN	[125I]S70254
DMHC6KX	HS	Investigative
DMHC6KX	SN	[125I]S70254
DMHC6KX	DT	Small molecular drug
DMHC6KX	PC	86277839
DMHC6KX	MW	483.3
DMHC6KX	FM	C22H20IN3O2
DMHC6KX	IC	InChI=1S/C22H20IN3O2/c1-28-20-10-9-18-22(26-20)17(11-12-24-19(27)13-23)21(25-18)16-8-4-6-14-5-2-3-7-15(14)16/h2-10,25H,11-13H2,1H3,(H,24,27)/i23-2
DMHC6KX	CS	COC1=NC2=C(C=C1)NC(=C2CCNC(=O)C[125I])C3=CC=CC4=CC=CC=C43
DMHC6KX	IK	ZYVDSJZCXRMXGR-FOKFMTIASA-N
DMHC6KX	IU	2-(125I)iodanyl-N-[2-(5-methoxy-2-naphthalen-1-yl-1H-pyrrolo[3,2-b]pyridin-3-yl)ethyl]acetamide
DMHC6KX	DE	Discovery agent

DM1DXHG	ID	DM1DXHG
DM1DXHG	DN	[125I]SAP
DM1DXHG	HS	Investigative
DM1DXHG	SN	Isap acid; [125I]-SAP
DM1DXHG	DT	Small molecular drug
DM1DXHG	PC	73755024
DM1DXHG	MW	529.4
DM1DXHG	FM	C22H30INO4S
DM1DXHG	IC	InChI=1S/C22H30INO4S/c1-22(2)15-13-19(22)18(7-5-3-4-6-8-21(25)26)20(14-15)24-29(27,28)17-11-9-16(23)10-12-17/h3,5,9-12,15,18-20,24H,4,6-8,13-14H2,1-2H3,(H,25,26)/b5-3-/t15-,18-,19+,20-/m0/s1/i23-2
DM1DXHG	CS	CC1([C@H]2C[C@@H]1[C@@H]([C@H](C2)NS(=O)(=O)C3=CC=C(C=C3)[125I])C/C=C\\CCCC(=O)O)C
DM1DXHG	IK	SZNMERGTFJHNSM-NTVCQXSRSA-N
DM1DXHG	IU	(Z)-7-[(1R,2S,3S,5S)-3-[(4-(125I)iodanylphenyl)sulfonylamino]-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DM1DXHG	DE	Discovery agent

DM0XUPK	ID	DM0XUPK
DM0XUPK	DN	[125I]SB-236636
DM0XUPK	HS	Investigative
DM0XUPK	SN	[125I]SB-236636; GTPL2710; (2S)-3-(4-{2-[(1,3-benzoxazol-2-yl)(methyl)amino]ethoxy}-3-(125I)iodophenyl)-2-ethoxypropanoic acid
DM0XUPK	DT	Small molecular drug
DM0XUPK	PC	73755028
DM0XUPK	MW	508.3
DM0XUPK	FM	C21H23IN2O5
DM0XUPK	IC	InChI=1S/C21H23IN2O5/c1-3-27-19(20(25)26)13-14-8-9-17(15(22)12-14)28-11-10-24(2)21-23-16-6-4-5-7-18(16)29-21/h4-9,12,19H,3,10-11,13H2,1-2H3,(H,25,26)/t19-/m0/s1/i22-2
DM0XUPK	CS	CCO[C@@H](CC1=CC(=C(C=C1)OCCN(C)C2=NC3=CC=CC=C3O2)[125I])C(=O)O
DM0XUPK	IK	VMBRNDMISRCGGM-DYZOOXQFSA-N
DM0XUPK	IU	(2S)-3-[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]-3-(125I)iodanylphenyl]-2-ethoxypropanoic acid
DM0XUPK	DE	Discovery agent

DMXWZCB	ID	DMXWZCB
DMXWZCB	DN	[125I]SB-258585
DMXWZCB	HS	Investigative
DMXWZCB	SN	GTPL3245; SCHEMBL14113984
DMXWZCB	DT	Small molecular drug
DMXWZCB	PC	10743500
DMXWZCB	MW	485.4
DMXWZCB	FM	C18H22IN3O3S
DMXWZCB	IC	InChI=1S/C18H22IN3O3S/c1-21-9-11-22(12-10-21)17-13-15(5-8-18(17)25-2)20-26(23,24)16-6-3-14(19)4-7-16/h3-8,13,20H,9-12H2,1-2H3/i19-2
DMXWZCB	CS	CN1CCN(CC1)C2=C(C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)[125I])OC
DMXWZCB	IK	BDHMSYNBSBZCAF-GBVACIEGSA-N
DMXWZCB	IU	4-(125I)iodanyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide
DMXWZCB	DE	Discovery agent

DM06S9X	ID	DM06S9X
DM06S9X	DN	[125I]SCH23982
DM06S9X	HS	Investigative
DM06S9X	SN	[125I]-SCH23982
DM06S9X	DT	Small molecular drug
DM06S9X	PC	119353
DM06S9X	MW	377.23
DM06S9X	FM	C17H18INO
DM06S9X	IC	InChI=1S/C17H18INO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3/t15-/m1/s1/i18-2
DM06S9X	CS	CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC=C3)O)[125I]
DM06S9X	IK	JGBTWNOVLISURM-QFLNOARHSA-N
DM06S9X	IU	(5R)-8-(125I)iodanyl-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
DM06S9X	CA	CAS 116780-39-3
DM06S9X	DE	Discovery agent

DM285MQ	ID	DM285MQ
DM285MQ	DN	[125I]SD6
DM285MQ	HS	Investigative
DM285MQ	SN	[125I]SD6
DM285MQ	DT	Small molecular drug
DM285MQ	PC	86277836
DM285MQ	MW	356.17
DM285MQ	FM	C13H15IN2O2
DM285MQ	IC	InChI=1S/C13H15IN2O2/c1-18-10-2-3-12-11(6-10)9(8-16-12)4-5-15-13(17)7-14/h2-3,6,8,16H,4-5,7H2,1H3,(H,15,17)/i14-2
DM285MQ	CS	COC1=CC2=C(C=C1)NC=C2CCNC(=O)C[125I]
DM285MQ	IK	BCFPPJOYYKSYLA-XSBOKVBDSA-N
DM285MQ	IU	2-(125I)iodanyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
DM285MQ	DE	Discovery agent

DM0GKMA	ID	DM0GKMA
DM0GKMA	DN	[125I]SQ-29548
DM0GKMA	HS	Investigative
DM0GKMA	SN	[125I]SQ-29548; GTPL1983; (5Z)-7-[(1S,2R,3R,4R)-3-{[({[4-(125I)iodophenyl]carbamoyl}amino)amino]methyl}-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DM0GKMA	DT	Small molecular drug
DM0GKMA	PC	73755025
DM0GKMA	MW	511.4
DM0GKMA	FM	C21H28IN3O4
DM0GKMA	IC	InChI=1S/C21H28IN3O4/c22-14-7-9-15(10-8-14)24-21(28)25-23-13-17-16(18-11-12-19(17)29-18)5-3-1-2-4-6-20(26)27/h1,3,7-10,16-19,23H,2,4-6,11-13H2,(H,26,27)(H2,24,25,28)/b3-1-/t16-,17+,18+,19-/m1/s1/i22-2
DM0GKMA	CS	C1C[C@@H]2[C@H]([C@H]([C@H]1O2)C/C=C\\CCCC(=O)O)CNNC(=O)NC3=CC=C(C=C3)[125I]
DM0GKMA	IK	AMZRVJWBVXWSAC-BYMOSMHDSA-N
DM0GKMA	IU	(Z)-7-[(1S,2R,3R,4R)-3-[[2-[(4-(125I)iodanylphenyl)carbamoyl]hydrazinyl]methyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DM0GKMA	DE	Discovery agent

DME53D6	ID	DME53D6
DME53D6	DN	[125I]ZM-241385
DME53D6	HS	Investigative
DME53D6	SN	[125I]ZM-241385; GTPL430
DME53D6	DT	Small molecular drug
DME53D6	PC	73754992
DME53D6	MW	461.23
DME53D6	FM	C16H14IN7O2
DME53D6	IC	InChI=1S/C16H14IN7O2/c17-10-8-9(3-4-11(10)25)5-6-19-15-21-14(18)24-16(22-15)20-13(23-24)12-2-1-7-26-12/h1-4,7-8,25H,5-6H2,(H3,18,19,20,21,22,23)/i17-2
DME53D6	CS	C1=COC(=C1)C2=NN3C(=NC(=NC3=N2)NCCC4=CC(=C(C=C4)O)[125I])N
DME53D6	IK	RVECQPQWOUQTSZ-QZIRHQCUSA-N
DME53D6	IU	4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2-(125I)iodanylphenol
DME53D6	DE	Discovery agent

DM42B5D	ID	DM42B5D
DM42B5D	DN	[14C]acetylCoA
DM42B5D	HS	Investigative
DM42B5D	SN	[14C]-acetylCoA
DM42B5D	DT	Small molecular drug
DM42B5D	PC	73755097
DM42B5D	MW	811.6
DM42B5D	FM	C23H38N7O17P3S
DM42B5D	IC	InChI=1S/C23H38N7O17P3S/c1-12(31)51-7-6-25-14(32)4-5-26-21(35)18(34)23(2,3)9-44-50(41,42)47-49(39,40)43-8-13-17(46-48(36,37)38)16(33)22(45-13)30-11-29-15-19(24)27-10-28-20(15)30/h10-11,13,16-18,22,33-34H,4-9H2,1-3H3,(H,25,32)(H,26,35)(H,39,40)(H,41,42)(H2,24,27,28)(H2,36,37,38)/t13-,16-,17-,18+,22-/m1/s1/i12+2
DM42B5D	CS	C[14C](=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DM42B5D	IK	ZSLZBFCDCINBPY-YHBLMJDYSA-N
DM42B5D	IU	S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (114C)ethanethioate
DM42B5D	DE	Discovery agent

DMGLQ72	ID	DMGLQ72
DMGLQ72	DN	[14C]GlySar
DMGLQ72	HS	Investigative
DMGLQ72	SN	[14C]-GlySar; glycylsarcosine
DMGLQ72	DT	Small molecular drug
DMGLQ72	PC	73755101
DMGLQ72	MW	148.14
DMGLQ72	FM	C5H10N2O3
DMGLQ72	IC	InChI=1S/C5H10N2O3/c1-7(3-5(9)10)4(8)2-6/h2-3,6H2,1H3,(H,9,10)/i4+2
DMGLQ72	CS	CN(CC(=O)O)[14C](=O)CN
DMGLQ72	IK	VYAMLSCELQQRAE-DOMIDYPGSA-N
DMGLQ72	IU	2-[(2-aminoacetyl)-methylamino]acetic acid
DMGLQ72	DE	Discovery agent

DMVUF71	ID	DMVUF71
DMVUF71	DN	[14C]histidine
DMVUF71	HS	Investigative
DMVUF71	SN	[14C]-histidine
DMVUF71	DT	Small molecular drug
DMVUF71	PC	73755104
DMVUF71	MW	157.15
DMVUF71	FM	C6H9N3O2
DMVUF71	IC	InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1/i5+2
DMVUF71	CS	C1=C(NC=N1)C[14C@@H](C(=O)O)N
DMVUF71	IK	HNDVDQJCIGZPNO-YDUYVQCESA-N
DMVUF71	IU	(2S)-2-amino-3-(1H-imidazol-5-yl)(214C)propanoic acid
DMVUF71	DE	Discovery agent

DMRBZ3X	ID	DMRBZ3X
DMRBZ3X	DN	[14C]methylamine
DMRBZ3X	HS	Investigative
DMRBZ3X	SN	[14C]-methylamine
DMRBZ3X	DT	Small molecular drug
DMRBZ3X	PC	190331
DMRBZ3X	MW	33.05
DMRBZ3X	FM	CH5N
DMRBZ3X	IC	InChI=1S/CH5N/c1-2/h2H2,1H3/i1+2
DMRBZ3X	CS	[14CH3]N
DMRBZ3X	IK	BAVYZALUXZFZLV-NJFSPNSNSA-N
DMRBZ3X	IU	(114C)methanamine
DMRBZ3X	DE	Discovery agent

DMG17IU	ID	DMG17IU
DMG17IU	DN	[14C]MTEP
DMG17IU	HS	Investigative
DMG17IU	DT	Small molecular drug
DMG17IU	PC	9990429
DMG17IU	MW	202.25
DMG17IU	FM	C11H8N2S
DMG17IU	IC	InChI=1S/C11H8N2S/c1-9-13-11(8-14-9)5-4-10-3-2-6-12-7-10/h2-3,6-8H,1H3/i11+2
DMG17IU	CS	CC1=N[14C](=CS1)C#CC2=CN=CC=C2
DMG17IU	IK	NRBNGHCYDWUVLC-OZUIXNLOSA-N
DMG17IU	IU	2-methyl-4-(2-pyridin-3-ylethynyl)-(414C)1,3-thiazole
DMG17IU	DE	Discovery agent

DM6SFYH	ID	DM6SFYH
DM6SFYH	DN	[14C]TEA
DM6SFYH	HS	Investigative
DM6SFYH	SN	Tetraethylammonium; Tetrylammonium; TETRAETHYLAMMONIUM ION; Tetramon; tetraethylazanium; N,N,N-Triethylethanaminium; tetraethylamine; UNII-5AV7G7EIEE; Tetraetilammonio [Italian]; 66-40-0; 5AV7G7EIEE; BRN 1738225; CHEMBL9324; AMMONIUM, TETRAETHYL-; CHEBI:44296; C8H20N; Tetraetilammonio; [14C]-TEA; tetraethyl ammonium; AC1L1KAW; Lopac-T-2265; 77-98-5 (hydroxide); 71-91-0 (bromide); 56-34-8 (chloride); 68-05-3 (iodide); SCHEMBL16267; 4-04-00-00331 (Beilstein Handbook Reference); NEt4(+); GTPL4575; GTPL2343; Ethanaminium,;  [14C]-TEA ; tetraethylammonium
DM6SFYH	DT	Small molecular drug
DM6SFYH	PC	5413
DM6SFYH	MW	130.25
DM6SFYH	FM	C8H20N+
DM6SFYH	IC	InChI=1S/C8H20N/c1-5-9(6-2,7-3)8-4/h5-8H2,1-4H3/q+1
DM6SFYH	CS	CC[N+](CC)(CC)CC
DM6SFYH	IK	CBXCPBUEXACCNR-UHFFFAOYSA-N
DM6SFYH	IU	tetraethylazanium
DM6SFYH	CA	CAS 66-40-0
DM6SFYH	CB	CHEBI:44296
DM6SFYH	DE	Discovery agent

DMZJQC0	ID	DMZJQC0
DMZJQC0	DN	[18F](R,R)-quinuclidinyl-4-fluoromethyl-benzilate
DMZJQC0	HS	Investigative
DMZJQC0	SN	(R,R)-quinuclidinyl-4-[18F]-fluoromethyl-benzilate; (R,R)-quinuclidinyl-4-[18F]-fluoromethylbenzilate(PET ligand); [18F]-FMeQNB; (R,R)-[18F]-FMeQNB
DMZJQC0	DT	Small molecular drug
DMZJQC0	PC	73755039
DMZJQC0	MW	368.4
DMZJQC0	FM	C22H24FNO3
DMZJQC0	IC	InChI=1S/C22H24FNO3/c23-14-16-6-8-19(9-7-16)22(26,18-4-2-1-3-5-18)21(25)27-20-15-24-12-10-17(20)11-13-24/h1-9,17,20,26H,10-15H2/t20-,22+/m0/s1/i23-1
DMZJQC0	CS	C1CN2CCC1[C@H](C2)OC(=O)[C@@](C3=CC=CC=C3)(C4=CC=C(C=C4)C[18F])O
DMZJQC0	IK	WYNSCFORRAXQPA-IFWCHYDGSA-N
DMZJQC0	IU	[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-[4-((18F)fluoranylmethyl)phenyl]-2-hydroxy-2-phenylacetate
DMZJQC0	DE	Discovery agent

DM65BDN	ID	DM65BDN
DM65BDN	DN	[18F]altanserin
DM65BDN	HS	Investigative
DM65BDN	SN	[18F]altanserin (PET ligand)
DM65BDN	DT	Small molecular drug
DM65BDN	PC	5312287
DM65BDN	MW	410.5
DM65BDN	FM	C22H22FN3O2S
DM65BDN	IC	InChI=1S/C22H22FN3O2S/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)/i23-1
DM65BDN	CS	C1CN(CCC1C(=O)C2=CC=C(C=C2)[18F])CCN3C(=O)C4=CC=CC=C4NC3=S
DM65BDN	IK	SMYALUSCZJXWHG-VNRZBHCFSA-N
DM65BDN	IU	3-[2-[4-(4-(18F)fluoranylbenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one
DM65BDN	CA	CAS 139418-52-3
DM65BDN	DE	Discovery agent

DM4VQNE	ID	DM4VQNE
DM4VQNE	DN	[18F]FITM
DM4VQNE	HS	Investigative
DM4VQNE	SN	[18F]FITM; GTPL6213; CHEMBL1771389; 4-(18F)fluoro-N-methyl-N-(4-{6-[(propan-2-yl)amino]pyrimidin-4-yl}-1,3-thiazol-2-yl)benzamide
DM4VQNE	DT	Small molecular drug
DM4VQNE	PC	53233900
DM4VQNE	MW	370.4
DM4VQNE	FM	C18H18FN5OS
DM4VQNE	IC	InChI=1S/C18H18FN5OS/c1-11(2)22-16-8-14(20-10-21-16)15-9-26-18(23-15)24(3)17(25)12-4-6-13(19)7-5-12/h4-11H,1-3H3,(H,20,21,22)/i19-1
DM4VQNE	CS	CC(C)NC1=NC=NC(=C1)C2=CSC(=N2)N(C)C(=O)C3=CC=C(C=C3)[18F]
DM4VQNE	IK	WIVGIKIKQHUFOD-AWDFDDCISA-N
DM4VQNE	IU	4-(18F)fluoranyl-N-methyl-N-[4-[6-(propan-2-ylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]benzamide
DM4VQNE	DE	Discovery agent

DMPWART	ID	DMPWART
DMPWART	DN	[18F]fluoroethylflumazenil
DMPWART	HS	Investigative
DMPWART	SN	[18F]fluoroethylflumazenil (PET ligand)
DMPWART	DT	Small molecular drug
DMPWART	PC	126761
DMPWART	MW	334.31
DMPWART	FM	C16H15F2N3O3
DMPWART	IC	InChI=1S/C16H15F2N3O3/c1-2-24-16(23)14-13-8-20(6-5-17)15(22)11-7-10(18)3-4-12(11)21(13)9-19-14/h3-4,7,9H,2,5-6,8H2,1H3/i17-1
DMPWART	CS	CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)CC[18F]
DMPWART	IK	NRBIGDVWCXXFLI-SJPDSGJFSA-N
DMPWART	IU	ethyl 5-(2-(18F)fluoranylethyl)-8-fluoro-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMPWART	CA	CAS 143693-57-6
DMPWART	DE	Discovery agent

DMRQ6XD	ID	DMRQ6XD
DMRQ6XD	DN	[18F]FPIT
DMRQ6XD	HS	Investigative
DMRQ6XD	SN	[18F]FPIT; GTPL6392; 5-{1-[2-(18F)fluoropyridin-3-yl]-5-methyl-1H-1,2,3-triazol-4-yl}-2-(propan-2-yl)-2,3-dihydro-1H-isoindol-1-one
DMRQ6XD	DT	Small molecular drug
DMRQ6XD	PC	70702462
DMRQ6XD	MW	350.4
DMRQ6XD	FM	C19H18FN5O
DMRQ6XD	IC	InChI=1S/C19H18FN5O/c1-11(2)24-10-14-9-13(6-7-15(14)19(24)26)17-12(3)25(23-22-17)16-5-4-8-21-18(16)20/h4-9,11H,10H2,1-3H3/i20-1
DMRQ6XD	CS	CC1=C(N=NN1C2=C(N=CC=C2)[18F])C3=CC4=C(C=C3)C(=O)N(C4)C(C)C
DMRQ6XD	IK	ZUWMBBZBDLJVHD-LRFGSCOBSA-N
DMRQ6XD	IU	5-[1-(2-(18F)fluoranylpyridin-3-yl)-5-methyltriazol-4-yl]-2-propan-2-yl-3H-isoindol-1-one
DMRQ6XD	DE	Discovery agent

DMM2YU9	ID	DMM2YU9
DMM2YU9	DN	[18F]FP-TZTP
DMM2YU9	HS	Investigative
DMM2YU9	SN	[18F]FP-TZTP (PET ligand)
DMM2YU9	DT	Small molecular drug
DMM2YU9	PC	449812
DMM2YU9	MW	272.4
DMM2YU9	FM	C11H16FN3S2
DMM2YU9	IC	InChI=1S/C11H16FN3S2/c1-15-6-2-4-9(8-15)10-11(14-17-13-10)16-7-3-5-12/h4H,2-3,5-8H2,1H3/i12-1
DMM2YU9	CS	CN1CCC=C(C1)C2=NSN=C2SCCC[18F]
DMM2YU9	IK	NQKPPQNBFQLLIZ-DWSYCVKZSA-N
DMM2YU9	IU	3-(3-(18F)fluoranylpropylsulfanyl)-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DMM2YU9	CA	CAS 161395-77-3
DMM2YU9	DE	Discovery agent

DMQ6AR5	ID	DMQ6AR5
DMQ6AR5	DN	[18F]MK-1312
DMQ6AR5	HS	Investigative
DMQ6AR5	SN	CHEMBL1645349; GTPL6334; MK-1312
DMQ6AR5	DT	Small molecular drug
DMQ6AR5	PC	53316847
DMQ6AR5	MW	350.4
DMQ6AR5	FM	C19H18FN5O
DMQ6AR5	IC	InChI=1S/C19H18FN5O/c1-3-9-24-11-14-10-13(6-7-15(14)19(24)26)17-12(2)25(23-22-17)16-5-4-8-21-18(16)20/h4-8,10H,3,9,11H2,1-2H3/i20-1
DMQ6AR5	CS	CCCN1CC2=C(C1=O)C=CC(=C2)C3=C(N(N=N3)C4=C(N=CC=C4)[18F])C
DMQ6AR5	IK	NYDVTBHNZHBCKX-LRFGSCOBSA-N
DMQ6AR5	IU	5-[1-(2-(18F)fluoranylpyridin-3-yl)-5-methyltriazol-4-yl]-2-propyl-3H-isoindol-1-one
DMQ6AR5	DE	Discovery agent

DMXIO84	ID	DMXIO84
DMXIO84	DN	[18F]SPA-RQ
DMXIO84	HS	Investigative
DMXIO84	SN	[18F]-SPA-RQ
DMXIO84	DT	Small molecular drug
DMXIO84	PC	6914513
DMXIO84	MW	449.4
DMXIO84	FM	C21H22F4N6O
DMXIO84	IC	InChI=1S/C21H22F4N6O/c22-13-32-18-9-8-16(31-20(21(23,24)25)28-29-30-31)11-15(18)12-27-17-7-4-10-26-19(17)14-5-2-1-3-6-14/h1-3,5-6,8-9,11,17,19,26-27H,4,7,10,12-13H2/t17-,19-/m0/s1/i22-1
DMXIO84	CS	C1C[C@@H]([C@@H](NC1)C2=CC=CC=C2)NCC3=C(C=CC(=C3)N4C(=NN=N4)C(F)(F)F)OC[18F]
DMXIO84	IK	KSKJMSAKVZSMMV-LBXDGNDASA-N
DMXIO84	IU	(2S,3S)-N-[[2-((18F)fluoranylmethoxy)-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine
DMXIO84	CA	CAS 262598-99-2
DMXIO84	DE	Discovery agent

DMH3BG5	ID	DMH3BG5
DMH3BG5	DN	[1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine
DMH3BG5	HS	Investigative
DMH3BG5	SN	CHEMBL56173; [1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine; BDBM50030521; 1-Benzyl N-hexylquinolin-4(1H)-imine
DMH3BG5	DT	Small molecular drug
DMH3BG5	PC	44298928
DMH3BG5	MW	318.5
DMH3BG5	FM	C22H26N2
DMH3BG5	IC	InChI=1S/C22H26N2/c1-2-3-4-10-16-23-21-15-17-24(18-19-11-6-5-7-12-19)22-14-9-8-13-20(21)22/h5-9,11-15,17H,2-4,10,16,18H2,1H3
DMH3BG5	CS	CCCCCCN=C1C=CN(C2=CC=CC=C12)CC3=CC=CC=C3
DMH3BG5	IK	GRLRXFAGAKMYSQ-UHFFFAOYSA-N
DMH3BG5	IU	1-benzyl-N-hexylquinolin-4-imine
DMH3BG5	DE	Discovery agent

DMS1YN3	ID	DMS1YN3
DMS1YN3	DN	[1-bromo-(3S)-hydrox-4-(palmitoyloxy)butyl]phosphate
DMS1YN3	HS	Investigative
DMS1YN3	SN	[1-bromo-(3S)-hydrox-4-(palmitoyloxy)butyl]phosphate; GTPL6991; CHEMBL3621354
DMS1YN3	DT	Small molecular drug
DMS1YN3	PC	23682233
DMS1YN3	MW	509.4
DMS1YN3	FM	C20H39BrNaO6P
DMS1YN3	IC	InChI=1S/C20H40BrO6P.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20(23)27-17-18(22)16-19(21)28(24,25)26;/h18-19,22H,2-17H2,1H3,(H2,24,25,26);/q;+1/p-1/t18-,19?;/m0./s1
DMS1YN3	CS	CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)[O-])Br)O.[Na+]
DMS1YN3	IK	XCUPLWPVEJCIBO-HMEPSURWSA-M
DMS1YN3	IU	sodium;[(3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]-hydroxyphosphinate
DMS1YN3	DE	Discovery agent

DMSPMHE	ID	DMSPMHE
DMSPMHE	DN	[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine
DMSPMHE	HS	Investigative
DMSPMHE	SN	CHEMBL89420; [2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine; SCHEMBL8120489; BDBM50081111
DMSPMHE	DT	Small molecular drug
DMSPMHE	PC	9881815
DMSPMHE	MW	267.33
DMSPMHE	FM	C16H17N3O
DMSPMHE	IC	InChI=1S/C16H17N3O/c1-2-5-13(6-3-1)11-17-9-10-20-15-8-4-7-14-16(15)19-12-18-14/h1-8,12,17H,9-11H2,(H,18,19)
DMSPMHE	CS	C1=CC=C(C=C1)CNCCOC2=CC=CC3=C2N=CN3
DMSPMHE	IK	XQWCSGWUJUEAQM-UHFFFAOYSA-N
DMSPMHE	IU	2-(1H-benzimidazol-4-yloxy)-N-benzylethanamine
DMSPMHE	DE	Discovery agent

DMAJCVL	ID	DMAJCVL
DMAJCVL	DN	[2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine
DMAJCVL	HS	Investigative
DMAJCVL	SN	CHEMBL194174; [2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine
DMAJCVL	DT	Small molecular drug
DMAJCVL	PC	44401277
DMAJCVL	MW	263.4
DMAJCVL	FM	C19H21N
DMAJCVL	IC	InChI=1S/C19H21N/c1-20-12-11-16-14-17(13-15-7-3-2-4-8-15)19-10-6-5-9-18(16)19/h2-10,14,17,20H,11-13H2,1H3
DMAJCVL	CS	CNCCC1=CC(C2=CC=CC=C21)CC3=CC=CC=C3
DMAJCVL	IK	UHYPQIJLHJTNMK-UHFFFAOYSA-N
DMAJCVL	IU	2-(3-benzyl-3H-inden-1-yl)-N-methylethanamine
DMAJCVL	DE	Discovery agent

DMU5P8O	ID	DMU5P8O
DMU5P8O	DN	[2-(3-Benzyl-3H-indol-1-yl)-ethyl]-dimethyl-amine
DMU5P8O	HS	Investigative
DMU5P8O	DT	Small molecular drug
DMU5P8O	PC	44393544
DMU5P8O	MW	279.4
DMU5P8O	FM	C19H23N2+
DMU5P8O	IC	InChI=1S/C19H23N2/c1-20(2)12-13-21-15-17(14-16-8-4-3-5-9-16)18-10-6-7-11-19(18)21/h3-11,15,17H,12-14H2,1-2H3/q+1
DMU5P8O	CS	CN(C)CC[N+]1=CC(C2=CC=CC=C21)CC3=CC=CC=C3
DMU5P8O	IK	CEOWUNUFGJBATQ-UHFFFAOYSA-N
DMU5P8O	IU	2-(3-benzyl-3H-indol-1-ium-1-yl)-N,N-dimethylethanamine
DMU5P8O	DE	Discovery agent

DMBTRN6	ID	DMBTRN6
DMBTRN6	DN	[2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine
DMBTRN6	HS	Investigative
DMBTRN6	SN	CHEMBL186621; [2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine; SCHEMBL3328890
DMBTRN6	DT	Small molecular drug
DMBTRN6	PC	20722800
DMBTRN6	MW	278.4
DMBTRN6	FM	C19H22N2
DMBTRN6	IC	InChI=1S/C19H22N2/c1-20(2)12-13-21-15-17(14-16-8-4-3-5-9-16)18-10-6-7-11-19(18)21/h3-11,15H,12-14H2,1-2H3
DMBTRN6	CS	CN(C)CCN1C=C(C2=CC=CC=C21)CC3=CC=CC=C3
DMBTRN6	IK	OYHBRXFQPGMFDE-UHFFFAOYSA-N
DMBTRN6	IU	2-(3-benzylindol-1-yl)-N,N-dimethylethanamine
DMBTRN6	DE	Discovery agent

DM1RW4U	ID	DM1RW4U
DM1RW4U	DN	[2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine
DM1RW4U	HS	Investigative
DM1RW4U	SN	CHEMBL363035; [2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine
DM1RW4U	DT	Small molecular drug
DM1RW4U	PC	44393574
DM1RW4U	MW	189.28
DM1RW4U	FM	C12H17N2+
DM1RW4U	IC	InChI=1S/C12H17N2/c1-13(2)9-10-14-8-7-11-5-3-4-6-12(11)14/h3-6,8H,7,9-10H2,1-2H3/q+1
DM1RW4U	CS	CN(C)CC[N+]1=CCC2=CC=CC=C21
DM1RW4U	IK	YJCMFAZIOVDTLE-UHFFFAOYSA-N
DM1RW4U	IU	2-(3H-indol-1-ium-1-yl)-N,N-dimethylethanamine
DM1RW4U	DE	Discovery agent

DMDIH96	ID	DMDIH96
DMDIH96	DN	[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine
DMDIH96	HS	Investigative
DMDIH96	SN	CHEMBL197646; SCHEMBL6108769; [2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine; ISJZKVWGUWBUFG-UHFFFAOYSA-N; BDBM50171264; 1644-64-0; 4-fluoro-3-(dimethylaminoethyl)-1H-indole
DMDIH96	DT	Small molecular drug
DMDIH96	PC	11492162
DMDIH96	MW	206.26
DMDIH96	FM	C12H15FN2
DMDIH96	IC	InChI=1S/C12H15FN2/c1-15(2)7-6-9-8-14-11-5-3-4-10(13)12(9)11/h3-5,8,14H,6-7H2,1-2H3
DMDIH96	CS	CN(C)CCC1=CNC2=C1C(=CC=C2)F
DMDIH96	IK	ISJZKVWGUWBUFG-UHFFFAOYSA-N
DMDIH96	IU	2-(4-fluoro-1H-indol-3-yl)-N,N-dimethylethanamine
DMDIH96	DE	Discovery agent

DMOZ73L	ID	DMOZ73L
DMOZ73L	DN	[2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine
DMOZ73L	HS	Investigative
DMOZ73L	SN	CHEMBL50492; 171783-25-8; 5-Ethyl-DMT; [2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine; DTXSID30444736; BDBM50049099
DMOZ73L	DT	Small molecular drug
DMOZ73L	PC	10775128
DMOZ73L	MW	216.32
DMOZ73L	FM	C14H20N2
DMOZ73L	IC	InChI=1S/C14H20N2/c1-4-11-5-6-14-13(9-11)12(10-15-14)7-8-16(2)3/h5-6,9-10,15H,4,7-8H2,1-3H3
DMOZ73L	CS	CCC1=CC2=C(C=C1)NC=C2CCN(C)C
DMOZ73L	IK	ZEHXYLDGQMEYAX-UHFFFAOYSA-N
DMOZ73L	IU	2-(5-ethyl-1H-indol-3-yl)-N,N-dimethylethanamine
DMOZ73L	CA	CAS 171783-25-8
DMOZ73L	DE	Discovery agent

DM5LVIR	ID	DM5LVIR
DM5LVIR	DN	[2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid
DM5LVIR	HS	Investigative
DM5LVIR	SN	CHEMBL452354; [2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid; SCHEMBL3983260
DM5LVIR	DT	Small molecular drug
DM5LVIR	PC	25140321
DM5LVIR	MW	342.57
DM5LVIR	FM	C7H9ClN4O6P2
DM5LVIR	IC	InChI=1S/C7H9ClN4O6P2/c8-6-5-7(10-2-9-6)12(3-11-5)1-4(19(13,14)15)20(16,17)18/h2-4H,1H2,(H2,13,14,15)(H2,16,17,18)
DM5LVIR	CS	C1=NC2=C(C(=N1)Cl)N=CN2CC(P(=O)(O)O)P(=O)(O)O
DM5LVIR	IK	SCQIYVIHMOWGRK-UHFFFAOYSA-N
DM5LVIR	IU	[2-(6-chloropurin-9-yl)-1-phosphonoethyl]phosphonic acid
DM5LVIR	DE	Discovery agent

DMHPBQC	ID	DMHPBQC
DMHPBQC	DN	[2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine
DMHPBQC	HS	Investigative
DMHPBQC	SN	CHEMBL38742; [2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine; BDBM50108320; ZINC13586848
DMHPBQC	DT	Small molecular drug
DMHPBQC	PC	44287445
DMHPBQC	MW	218.29
DMHPBQC	FM	C13H18N2O
DMHPBQC	IC	InChI=1S/C13H18N2O/c1-14(2)8-9-15-7-6-11-4-5-12(16-3)10-13(11)15/h4-7,10H,8-9H2,1-3H3
DMHPBQC	CS	CN(C)CCN1C=CC2=C1C=C(C=C2)OC
DMHPBQC	IK	VIEWFQAHIRFETA-UHFFFAOYSA-N
DMHPBQC	IU	2-(6-methoxyindol-1-yl)-N,N-dimethylethanamine
DMHPBQC	DE	Discovery agent

DM98MXT	ID	DM98MXT
DM98MXT	DN	[2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid
DM98MXT	HS	Investigative
DM98MXT	SN	CHEMBL457423; AC1NQQY7; [2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid; [2-(benzoimidazol-1-yl)ethylidene]bisphosphonic acid; SCHEMBL20385726; BDBM50273716; 847738-31-2; [2-(benzimidazol-1-yl)-1-phosphonoethyl]phosphonic acid; Phosphonic acid, [2-(1H-benzimidazol-1-yl)ethylidene]bis-; [2-(benzimidazol-1-yl)-1-phosphono-ethyl]phosphonic acid
DM98MXT	DT	Small molecular drug
DM98MXT	PC	5277505
DM98MXT	MW	306.15
DM98MXT	FM	C9H12N2O6P2
DM98MXT	IC	InChI=1S/C9H12N2O6P2/c12-18(13,14)9(19(15,16)17)5-11-6-10-7-3-1-2-4-8(7)11/h1-4,6,9H,5H2,(H2,12,13,14)(H2,15,16,17)
DM98MXT	CS	C1=CC=C2C(=C1)N=CN2CC(P(=O)(O)O)P(=O)(O)O
DM98MXT	IK	ISSICOMKRRPVPD-UHFFFAOYSA-N
DM98MXT	IU	[2-(benzimidazol-1-yl)-1-phosphonoethyl]phosphonic acid
DM98MXT	DE	Discovery agent

DM37C25	ID	DM37C25
DM37C25	DN	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25	HS	Investigative
DM37C25	SN	CHEMBL573935; [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25	DT	Small molecular drug
DM37C25	PC	44479701
DM37C25	MW	352.4
DM37C25	FM	C20H16O4S
DM37C25	IC	InChI=1S/C20H16O4S/c21-20(22)14-17-8-4-5-9-19(17)25(23,24)18-12-10-16(11-13-18)15-6-2-1-3-7-15/h1-13H,14H2,(H,21,22)
DM37C25	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3CC(=O)O
DM37C25	IK	HGICQEUHJFERNR-UHFFFAOYSA-N
DM37C25	IU	2-[2-(4-phenylphenyl)sulfonylphenyl]acetic acid
DM37C25	DE	Discovery agent

DMQZUD9	ID	DMQZUD9
DMQZUD9	DN	[2-(Imidazol-1-yl)ethyl]-bisphosphonic acid
DMQZUD9	HS	Investigative
DMQZUD9	SN	CHEMBL446734; 1-deshydroxyzoledronate; [2-(Imidazol-1-yl)ethyl]-bisphosphonic acid; SCHEMBL515542; FBSQLNMIJFINOJ-UHFFFAOYSA-N; BDBM50273714; 2-(imidazol-1-yl)ethane-1,1-diphosphonic acid; 2-(1H-Imidazole-1-yl)ethylidenebisphosphonic acid
DMQZUD9	DT	Small molecular drug
DMQZUD9	PC	23043560
DMQZUD9	MW	256.089
DMQZUD9	FM	C5H10N2O6P2
DMQZUD9	IC	InChI=1S/C5H10N2O6P2/c8-14(9,10)5(15(11,12)13)3-7-2-1-6-4-7/h1-2,4-5H,3H2,(H2,8,9,10)(H2,11,12,13)
DMQZUD9	CS	C1=CN(C=N1)CC(P(=O)(O)O)P(=O)(O)O
DMQZUD9	IK	FBSQLNMIJFINOJ-UHFFFAOYSA-N
DMQZUD9	IU	(2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
DMQZUD9	DE	Discovery agent

DMBVDY5	ID	DMBVDY5
DMBVDY5	DN	[2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid
DMBVDY5	HS	Investigative
DMBVDY5	SN	CHEMBL504429; [2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid
DMBVDY5	DT	Small molecular drug
DMBVDY5	PC	25140170
DMBVDY5	MW	288.16
DMBVDY5	FM	C5H10N2O6P2S
DMBVDY5	IC	InChI=1S/C5H10N2O6P2S/c8-14(9,10)4(15(11,12)13)3-16-5-6-1-2-7-5/h1-2,4H,3H2,(H,6,7)(H2,8,9,10)(H2,11,12,13)
DMBVDY5	CS	C1=CN=C(N1)SCC(P(=O)(O)O)P(=O)(O)O
DMBVDY5	IK	KVMQBCIVXMEYRO-UHFFFAOYSA-N
DMBVDY5	IU	[2-(1H-imidazol-2-ylsulfanyl)-1-phosphonoethyl]phosphonic acid
DMBVDY5	DE	Discovery agent

DM3VT8M	ID	DM3VT8M
DM3VT8M	DN	[2-(Purin-9-yl)ethyl]-bisphosphonic acid
DM3VT8M	HS	Investigative
DM3VT8M	SN	CHEMBL457424; [2-(Purin-9-yl)ethyl]-bisphosphonic acid; SCHEMBL3976006
DM3VT8M	DT	Small molecular drug
DM3VT8M	PC	25140171
DM3VT8M	MW	308.13
DM3VT8M	FM	C7H10N4O6P2
DM3VT8M	IC	InChI=1S/C7H10N4O6P2/c12-18(13,14)6(19(15,16)17)2-11-4-10-5-1-8-3-9-7(5)11/h1,3-4,6H,2H2,(H2,12,13,14)(H2,15,16,17)
DM3VT8M	CS	C1=C2C(=NC=N1)N(C=N2)CC(P(=O)(O)O)P(=O)(O)O
DM3VT8M	IK	JGHPTTVGCUEGGI-UHFFFAOYSA-N
DM3VT8M	IU	(1-phosphono-2-purin-9-ylethyl)phosphonic acid
DM3VT8M	DE	Discovery agent

DMJN8XK	ID	DMJN8XK
DMJN8XK	DN	[2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid
DMJN8XK	HS	Investigative
DMJN8XK	SN	CHEMBL457069; 2-(pyrazol-1-yl)ethane-1,1-diphosphonic acid; [2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid; SCHEMBL10410288; UUGUSMHQBIUYKQ-UHFFFAOYSA-N; BDBM50273715
DMJN8XK	DT	Small molecular drug
DMJN8XK	PC	23043575
DMJN8XK	MW	256.089
DMJN8XK	FM	C5H10N2O6P2
DMJN8XK	IC	InChI=1S/C5H10N2O6P2/c8-14(9,10)5(15(11,12)13)4-7-3-1-2-6-7/h1-3,5H,4H2,(H2,8,9,10)(H2,11,12,13)
DMJN8XK	CS	C1=CN(N=C1)CC(P(=O)(O)O)P(=O)(O)O
DMJN8XK	IK	UUGUSMHQBIUYKQ-UHFFFAOYSA-N
DMJN8XK	IU	(1-phosphono-2-pyrazol-1-ylethyl)phosphonic acid
DMJN8XK	DE	Discovery agent

DMI9RLZ	ID	DMI9RLZ
DMI9RLZ	DN	[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
DMI9RLZ	HS	Investigative
DMI9RLZ	SN	[2(R,S)-2-Sulfanylheptanoyl]-phe-ala; [2(R,S)-2-SULFANYLHEPTANOYL]-PHE-ALA; TI1; AC1NRDCJ; 1qf1; DB02597; N-[(2S)-2-sulfanylheptanoyl]-L-phenylalanyl-L-alanine; N-[N-[(S)-2-Mercaptoheptanoyl]-L-phenylalanyl]-L-alanine; (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid; (2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic
DMI9RLZ	DT	Small molecular drug
DMI9RLZ	PC	5289469
DMI9RLZ	MW	380.5
DMI9RLZ	FM	C19H28N2O4S
DMI9RLZ	IC	InChI=1S/C19H28N2O4S/c1-3-4-6-11-16(26)18(23)21-15(12-14-9-7-5-8-10-14)17(22)20-13(2)19(24)25/h5,7-10,13,15-16,26H,3-4,6,11-12H2,1-2H3,(H,20,22)(H,21,23)(H,24,25)/t13-,15-,16-/m0/s1
DMI9RLZ	CS	CCCCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)O)S
DMI9RLZ	IK	GOIYKVXXGCPHQU-BPUTZDHNSA-N
DMI9RLZ	IU	(2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid
DMI9RLZ	DE	Discovery agent

DMRQC1F	ID	DMRQC1F
DMRQC1F	DN	[2,2':5',2'']Terthiophen-4-yl-methanol
DMRQC1F	HS	Investigative
DMRQC1F	SN	CHEMBL76100; BDBM50217032
DMRQC1F	DT	Small molecular drug
DMRQC1F	PC	44313272
DMRQC1F	MW	278.4
DMRQC1F	FM	C13H10OS3
DMRQC1F	IC	InChI=1S/C13H10OS3/c14-7-9-6-13(16-8-9)12-4-3-11(17-12)10-2-1-5-15-10/h1-6,8,14H,7H2
DMRQC1F	CS	C1=CSC(=C1)C2=CC=C(S2)C3=CC(=CS3)CO
DMRQC1F	IK	CTGDOERMEKYCRZ-UHFFFAOYSA-N
DMRQC1F	IU	[5-(5-thiophen-2-ylthiophen-2-yl)thiophen-3-yl]methanol
DMRQC1F	DE	Discovery agent

DMWDNLI	ID	DMWDNLI
DMWDNLI	DN	[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde
DMWDNLI	HS	Investigative
DMWDNLI	SN	CHEMBL74983; BDBM50217036
DMWDNLI	DT	Small molecular drug
DMWDNLI	PC	9972316
DMWDNLI	MW	304.4
DMWDNLI	FM	C14H8O2S3
DMWDNLI	IC	InChI=1S/C14H8O2S3/c15-6-9-5-14(17-8-9)13-4-3-12(19-13)11-2-1-10(7-16)18-11/h1-8H
DMWDNLI	CS	C1=C(SC(=C1)C2=CC=C(S2)C3=CC(=CS3)C=O)C=O
DMWDNLI	IK	PYABIFKTOKMEQD-UHFFFAOYSA-N
DMWDNLI	IU	5-[5-(4-formylthiophen-2-yl)thiophen-2-yl]thiophene-2-carbaldehyde
DMWDNLI	DE	Discovery agent

DM2S5EJ	ID	DM2S5EJ
DM2S5EJ	DN	[2,2':5',2'']Terthiophene-4-carbaldehyde
DM2S5EJ	HS	Investigative
DM2S5EJ	SN	CHEMBL73495; BDBM50217040
DM2S5EJ	DT	Small molecular drug
DM2S5EJ	PC	44313051
DM2S5EJ	MW	276.4
DM2S5EJ	FM	C13H8OS3
DM2S5EJ	IC	InChI=1S/C13H8OS3/c14-7-9-6-13(16-8-9)12-4-3-11(17-12)10-2-1-5-15-10/h1-8H
DM2S5EJ	CS	C1=CSC(=C1)C2=CC=C(S2)C3=CC(=CS3)C=O
DM2S5EJ	IK	IAQDUXQCKAZHSN-UHFFFAOYSA-N
DM2S5EJ	IU	5-(5-thiophen-2-ylthiophen-2-yl)thiophene-3-carbaldehyde
DM2S5EJ	DE	Discovery agent

DM4WXD2	ID	DM4WXD2
DM4WXD2	DN	[2-Phenylacetophenone]thiosemicarbazone
DM4WXD2	HS	Investigative
DM4WXD2	SN	CHEMBL1269810; [2-Phenylacetophenone]thiosemicarbazone
DM4WXD2	DT	Small molecular drug
DM4WXD2	PC	52945875
DM4WXD2	MW	269.4
DM4WXD2	FM	C15H15N3S
DM4WXD2	IC	InChI=1S/C15H15N3S/c16-15(19)18-17-14(13-9-5-2-6-10-13)11-12-7-3-1-4-8-12/h1-10H,11H2,(H3,16,18,19)/b17-14+
DM4WXD2	CS	C1=CC=C(C=C1)C/C(=N\\NC(=S)N)/C2=CC=CC=C2
DM4WXD2	IK	WHRFFXUXTGIZOH-SAPNQHFASA-N
DM4WXD2	IU	[(E)-1,2-diphenylethylideneamino]thiourea
DM4WXD2	DE	Discovery agent

DM4BYEQ	ID	DM4BYEQ
DM4BYEQ	DN	[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine
DM4BYEQ	HS	Investigative
DM4BYEQ	SN	CHEMBL296602; AC1L1GIZ; SCHEMBL11128740; BDBM50021226; 3-(3,4-Dichlorophenyl)-2,3-dihydro-N-methyl-1H-inden-1-amine
DM4BYEQ	DT	Small molecular drug
DM4BYEQ	PC	3703
DM4BYEQ	MW	292.2
DM4BYEQ	FM	C16H15Cl2N
DM4BYEQ	IC	InChI=1S/C16H15Cl2N/c1-19-16-9-13(11-4-2-3-5-12(11)16)10-6-7-14(17)15(18)8-10/h2-8,13,16,19H,9H2,1H3
DM4BYEQ	CS	CNC1CC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
DM4BYEQ	IK	SVFXPTLYMIXFRX-UHFFFAOYSA-N
DM4BYEQ	IU	3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine
DM4BYEQ	CA	CAS 86939-10-8
DM4BYEQ	DE	Discovery agent

DMGD487	ID	DMGD487
DMGD487	DN	[3-(4-Nonyl-benzylamino)-propyl]-phosphonic acid
DMGD487	HS	Investigative
DMGD487	SN	CHEMBL118860; 569684-50-0; [3-(4-Nonyl-benzylamino)-propyl]-phosphonic acid; SCHEMBL3846202; CTK1E1410; DTXSID10471181; IYOGKTIRIRHPOH-UHFFFAOYSA-N; BDBM50148394; N-(4-Nonylbenzyl)-3-aminopropylphosphonic acid; Phosphonic acid, [3-[[(4-nonylphenyl)methyl]amino]propyl]-
DMGD487	DT	Small molecular drug
DMGD487	PC	11725751
DMGD487	MW	355.5
DMGD487	FM	C19H34NO3P
DMGD487	IC	InChI=1S/C19H34NO3P/c1-2-3-4-5-6-7-8-10-18-11-13-19(14-12-18)17-20-15-9-16-24(21,22)23/h11-14,20H,2-10,15-17H2,1H3,(H2,21,22,23)
DMGD487	CS	CCCCCCCCCC1=CC=C(C=C1)CNCCCP(=O)(O)O
DMGD487	IK	IYOGKTIRIRHPOH-UHFFFAOYSA-N
DMGD487	IU	3-[(4-nonylphenyl)methylamino]propylphosphonic acid
DMGD487	CA	CAS 569684-50-0
DMGD487	DE	Discovery agent

DMD0LCU	ID	DMD0LCU
DMD0LCU	DN	[3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol
DMD0LCU	HS	Investigative
DMD0LCU	SN	3-(5-phenyl-oxazol-2-ylamino)phenylmethanol; 681002-56-2; [3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl]methanol; {3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}methanol; 2-Anilino-5-aryloxazole 12; AC1NS7RB; CHEMBL194113; BDBM5851; SCHEMBL5185668; ZINC13611262; KB-305372; N-(3-Hydroxymethylphenyl)-5-phenyl-1,3-oxazol-2-amine Hydrochloride
DMD0LCU	DT	Small molecular drug
DMD0LCU	PC	5329847
DMD0LCU	MW	266.29
DMD0LCU	FM	C16H14N2O2
DMD0LCU	IC	InChI=1S/C16H14N2O2/c19-11-12-5-4-8-14(9-12)18-16-17-10-15(20-16)13-6-2-1-3-7-13/h1-10,19H,11H2,(H,17,18)
DMD0LCU	CS	C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=CC(=C3)CO
DMD0LCU	IK	WTSNQZLKTLSHSD-UHFFFAOYSA-N
DMD0LCU	IU	[3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl]methanol
DMD0LCU	DE	Discovery agent

DMRBJ4V	ID	DMRBJ4V
DMRBJ4V	DN	[3-(Biphenyl-4-yloxy)-propyl]-dimethyl-amine
DMRBJ4V	HS	Investigative
DMRBJ4V	SN	CHEMBL132091; [3-(Biphenyl-4-yloxy)-propyl]-dimethyl-amine; N,N-dimethyl-3-(4-phenylphenoxy)propan-1-amine; AC1L9UWB; SCHEMBL10679594; ZINC4842179; BDBM50133286
DMRBJ4V	DT	Small molecular drug
DMRBJ4V	PC	501375
DMRBJ4V	MW	255.35
DMRBJ4V	FM	C17H21NO
DMRBJ4V	IC	InChI=1S/C17H21NO/c1-18(2)13-6-14-19-17-11-9-16(10-12-17)15-7-4-3-5-8-15/h3-5,7-12H,6,13-14H2,1-2H3
DMRBJ4V	CS	CN(C)CCCOC1=CC=C(C=C1)C2=CC=CC=C2
DMRBJ4V	IK	ITTYRYJIHNHJBL-UHFFFAOYSA-N
DMRBJ4V	IU	N,N-dimethyl-3-(4-phenylphenoxy)propan-1-amine
DMRBJ4V	DE	Discovery agent

DMHU4NS	ID	DMHU4NS
DMHU4NS	DN	[3,4''']biflavone
DMHU4NS	HS	Investigative
DMHU4NS	SN	CHEMBL204948; [3,4'''''']biflavone; BDBM50183244
DMHU4NS	DT	Small molecular drug
DMHU4NS	PC	44410505
DMHU4NS	MW	442.5
DMHU4NS	FM	C30H18O4
DMHU4NS	IC	InChI=1S/C30H18O4/c31-24-18-27(33-25-12-6-4-10-22(24)25)19-14-16-20(17-15-19)28-29(32)23-11-5-7-13-26(23)34-30(28)21-8-2-1-3-9-21/h1-18H
DMHU4NS	CS	C1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C3O2)C4=CC=C(C=C4)C5=CC(=O)C6=CC=CC=C6O5
DMHU4NS	IK	DKAAIRCEBVCHAT-UHFFFAOYSA-N
DMHU4NS	IU	3-[4-(4-oxochromen-2-yl)phenyl]-2-phenylchromen-4-one
DMHU4NS	DE	Discovery agent

DMEMVY5	ID	DMEMVY5
DMEMVY5	DN	[32P]MRS2500
DMEMVY5	HS	Investigative
DMEMVY5	SN	[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate
DMEMVY5	DT	Small molecular drug
DMEMVY5	PC	91827341
DMEMVY5	MW	562.16
DMEMVY5	FM	C13H18IN5O8P2
DMEMVY5	IC	InChI=1S/C13H18IN5O8P2/c1-15-10-9-11(18-12(14)17-10)19(5-16-9)7-2-8(27-29(23,24)25)13(3-6(7)13)4-26-28(20,21)22/h5-8H,2-4H2,1H3,(H,15,17,18)(H2,20,21,22)(H2,23,24,25)/t6-,7+,8+,13+/m1/s1/i28+1
DMEMVY5	CS	CNC1=C2C(=NC(=N1)I)N(C=N2)[C@H]3C[C@@H]([C@]4([C@@H]3C4)CO[32P](=O)(O)O)OP(=O)(O)O
DMEMVY5	IK	NMVWLEUONAKGCD-PNGSNQAVSA-N
DMEMVY5	IU	[(1R,2S,4S,5S)-1-((32P)dihydroxy(32P)phosphoryloxymethyl)-4-[2-iodo-6-(methylamino)purin-9-yl]-2-bicyclo[3.1.0]hexanyl] dihydrogen phosphate
DMEMVY5	DE	Discovery agent

DM218VZ	ID	DM218VZ
DM218VZ	DN	[33P]2MeSADP
DM218VZ	HS	Investigative
DM218VZ	SN	[33P]2-methylthio-ADP
DM218VZ	DT	Small molecular drug
DM218VZ	PC	73755009
DM218VZ	MW	477.29
DM218VZ	FM	C11H17N5O10P2S
DM218VZ	IC	InChI=1S/C11H17N5O10P2S/c1-29-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(25-10)2-24-28(22,23)26-27(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H,22,23)(H2,12,14,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1/i27+2,28+2
DM218VZ	CS	CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO[33P](=O)(O)O[33P](=O)(O)O)O)O)N
DM218VZ	IK	WLMZTKAZJUWXCB-JLOOSCHCSA-N
DM218VZ	IU	[(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydroxy(33P)phosphoryl hydrogen phosphate
DM218VZ	DE	Discovery agent

DMVUEYM	ID	DMVUEYM
DMVUEYM	DN	[35S]ACPPB
DMVUEYM	HS	Investigative
DMVUEYM	SN	[35S]-ACPPB
DMVUEYM	DT	Small molecular drug
DMVUEYM	PC	53321933
DMVUEYM	MW	466.9
DMVUEYM	FM	C23H30ClN3O3S
DMVUEYM	IC	InChI=1S/C23H30ClN3O3S/c1-3-16-31(29,30)27-14-12-23(13-15-27,18-8-5-4-6-9-18)17(2)26-22(28)21-19(24)10-7-11-20(21)25/h4-11,17H,3,12-16,25H2,1-2H3,(H,26,28)/t17-/m0/s1/i31+3
DMVUEYM	CS	CCC[35S](=O)(=O)N1CCC(CC1)(C2=CC=CC=C2)[C@H](C)NC(=O)C3=C(C=CC=C3Cl)N
DMVUEYM	IK	CPNFHRRINJHHNO-BMHXGNRYSA-N
DMVUEYM	IU	2-amino-6-chloro-N-[(1S)-1-(4-phenyl-1-propyl(35S)sulfonylpiperidin-4-yl)ethyl]benzamide
DMVUEYM	DE	Discovery agent

DMAYPTO	ID	DMAYPTO
DMAYPTO	DN	[35S]ADPbetaS
DMAYPTO	HS	Investigative
DMAYPTO	SN	[35S]ADPbetaS; GTPL3408; [({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](sulfanylidene)phosphonous acid
DMAYPTO	DT	Small molecular drug
DMAYPTO	PC	73755052
DMAYPTO	MW	446.17
DMAYPTO	FM	C10H15N5O9P2S
DMAYPTO	IC	InChI=1S/C10H15N5O9P2S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(23-10)1-22-25(18,19)24-26(20,21)27/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H2,11,12,13)(H2,20,21,27)/t4-,6-,7-,10-/m1/s1/i27+3
DMAYPTO	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=[35S])(O)O)O)O)N
DMAYPTO	IK	HCIKUKNAJRJFOW-JWNXZZODSA-N
DMAYPTO	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydroxy(35S)phosphinothioyl hydrogen phosphate
DMAYPTO	DE	Discovery agent

DMQ0NK8	ID	DMQ0NK8
DMQ0NK8	DN	[35S]ibutamoren
DMQ0NK8	HS	Investigative
DMQ0NK8	SN	[35S]MK-0677
DMQ0NK8	DT	Small molecular drug
DMQ0NK8	PC	10578170
DMQ0NK8	MW	531.6
DMQ0NK8	FM	C27H36N4O5S
DMQ0NK8	IC	InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1/i37+3
DMQ0NK8	CS	CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)[35S](=O)(=O)C)N
DMQ0NK8	IK	UMUPQWIGCOZEOY-KRTHATKOSA-N
DMQ0NK8	IU	2-amino-2-methyl-N-[(2R)-1-(1-methyl(35S)sulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
DMQ0NK8	DE	Discovery agent

DMSHOQ8	ID	DMSHOQ8
DMSHOQ8	DN	[35S]-non-peptide OT antagonist
DMSHOQ8	HS	Investigative
DMSHOQ8	SN	[35S]-non-peptide OT antagonist; GTPL3484; [35S]non-peptide OT antagonist
DMSHOQ8	DT	Small molecular drug
DMSHOQ8	PC	73755057
DMSHOQ8	MW	626.6
DMSHOQ8	FM	C30H36F3N3O6S
DMSHOQ8	IC	InChI=1S/C30H36F3N3O6S/c1-43(39,40)35-16-12-24(13-17-35)42-25-8-6-22(27(19-25)41-20-30(31,32)33)18-29(38)34-14-10-23(11-15-34)36-26-5-3-2-4-21(26)7-9-28(36)37/h2-6,8,19,23-24H,7,9-18,20H2,1H3/i43+3
DMSHOQ8	CS	C[35S](=O)(=O)N1CCC(CC1)OC2=CC(=C(C=C2)CC(=O)N3CCC(CC3)N4C(=O)CCC5=CC=CC=C54)OCC(F)(F)F
DMSHOQ8	IK	WGABGZOBUZZBRA-FFSUGBGASA-N
DMSHOQ8	IU	1-[1-[2-[4-(1-methyl(35S)sulfonylpiperidin-4-yl)oxy-2-(2,2,2-trifluoroethoxy)phenyl]acetyl]piperidin-4-yl]-3,4-dihydroquinolin-2-one
DMSHOQ8	DE	Discovery agent

DMSD51L	ID	DMSD51L
DMSD51L	DN	[35S]TBPS
DMSD51L	HS	Investigative
DMSD51L	SN	[35S]TBPS; 35S-TBPS; GTPL4369
DMSD51L	DT	Small molecular drug
DMSD51L	PC	59896759
DMSD51L	MW	225.15
DMSD51L	FM	C8H15O3PS
DMSD51L	IC	InChI=1S/C8H15O3PS/c1-7(2,3)8-4-9-12(13,10-5-8)11-6-8/h4-6H2,1-3H3/i13+3
DMSD51L	CS	CC(C)(C)C12COP(=[35S])(OC1)OC2
DMSD51L	IK	VTBHBNXGFPTBJL-DLSVHHIMSA-N
DMSD51L	IU	4-tert-butyl-1-(35S)sulfanylidene-2,6,7-trioxa-1lambda5-phosphabicyclo[2.2.2]octane
DMSD51L	DE	Discovery agent

DMN35BY	ID	DMN35BY
DMN35BY	DN	[3H](-)CGP 12177
DMN35BY	HS	Investigative
DMN35BY	SN	UNII-Z7YP8B158Q; CHEMBL36060; Z7YP8B158Q; 4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one; Tocris-1134; Lopac-C-125; AC1O7G0V; GTPL531; SCHEMBL12329633; ZINC3979132; BDBM50098668; NCGC00025024-01; NCGC00015184-01; NCGC00015184-02; CGP-12177, (S)-; (S)-(-)-CGP-12177; UNII-R89UMZ82MJ component UMQUQWCJKFOUGV-VIFPVBQESA-N; 4-(3-tert-Butylamino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one; 95840-76-9; 2H-Benzimidazol-2-one, 4-((2S)-3-((1,1-d
DMN35BY	DT	Small molecular drug
DMN35BY	PC	6603756
DMN35BY	MW	279.33
DMN35BY	FM	C14H21N3O3
DMN35BY	IC	InChI=1S/C14H21N3O3/c1-14(2,3)15-7-9(18)8-20-11-6-4-5-10-12(11)17-13(19)16-10/h4-6,9,15,18H,7-8H2,1-3H3,(H2,16,17,19)/t9-/m0/s1
DMN35BY	CS	CC(C)(C)NC[C@@H](COC1=CC=CC2=C1NC(=O)N2)O
DMN35BY	IK	UMQUQWCJKFOUGV-VIFPVBQESA-N
DMN35BY	IU	4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one
DMN35BY	CA	CAS 95840-76-9
DMN35BY	DE	Discovery agent

DM0KGHP	ID	DM0KGHP
DM0KGHP	DN	[3H](-)devapamil
DM0KGHP	HS	Investigative
DM0KGHP	SN	(-)-Desmethoxyverapamil; (-)-Devapamil; 4-Desmethoxyverapamil; UNII-99EAI85506; 99EAI85506; 93468-87-2; (2S)-2-(3,4-dimethoxyphenyl)-5-[2-(3-methoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; AC1L32ZZ; AC1Q4Q2Z; 4-DMV; (-)-H3-Desmethoxyverapamil; GTPL2515; GTPL2517; SCHEMBL10453636; 4-desmethoxyverapamil (4-DMV); ZINC2016058; PDSP2_001070; PDSP1_001086; benzeneacetonitrile, 3,4-dimethoxy-; A-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-; A-(1-methylethyl)-,(s)-; D888; D 888; D-888; (-)-D888; Desmethoxyverapamil
DM0KGHP	DT	Small molecular drug
DM0KGHP	PC	107928
DM0KGHP	MW	424.6
DM0KGHP	FM	C26H36N2O3
DM0KGHP	IC	InChI=1S/C26H36N2O3/c1-20(2)26(19-27,22-11-12-24(30-5)25(18-22)31-6)14-8-15-28(3)16-13-21-9-7-10-23(17-21)29-4/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t26-/m0/s1
DM0KGHP	CS	CC(C)[C@](CCCN(C)CCC1=CC(=CC=C1)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DM0KGHP	IK	VMVKIDPOEOLUFS-SANMLTNESA-N
DM0KGHP	IU	(2S)-2-(3,4-dimethoxyphenyl)-5-[2-(3-methoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DM0KGHP	CA	CAS 93468-87-2
DM0KGHP	DE	Discovery agent

DMP6XL9	ID	DMP6XL9
DMP6XL9	DN	[3H](+)-cis-diltiazem
DMP6XL9	HS	Investigative
DMP6XL9	SN	[3H]-(+)-cis-diltiazem
DMP6XL9	DT	Small molecular drug
DMP6XL9	PC	3076
DMP6XL9	MW	414.5
DMP6XL9	FM	C22H26N2O4S
DMP6XL9	IC	InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3
DMP6XL9	CS	CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DMP6XL9	IK	HSUGRBWQSSZJOP-UHFFFAOYSA-N
DMP6XL9	IU	[5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMP6XL9	CA	CAS 34933-06-7
DMP6XL9	CB	CHEBI:82814
DMP6XL9	DE	Discovery agent

DM7QE1J	ID	DM7QE1J
DM7QE1J	DN	[3H](+)-isradipine
DM7QE1J	HS	Investigative
DM7QE1J	SN	(+)-[3H]isradipine; (+)-[3H]O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 3H-(+)-PN 200-110
DM7QE1J	DT	Small molecular drug
DM7QE1J	PC	158617
DM7QE1J	MW	371.4
DM7QE1J	FM	C19H21N3O5
DM7QE1J	IC	InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3/t16-/m0/s1
DM7QE1J	CS	CC1=C([C@@H](C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC
DM7QE1J	IK	HMJIYCCIJYRONP-INIZCTEOSA-N
DM7QE1J	IU	3-O-methyl 5-O-propan-2-yl (4S)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM7QE1J	CA	CAS 84260-64-0
DM7QE1J	DE	Discovery agent

DMRPS2X	ID	DMRPS2X
DMRPS2X	DN	[3H](R)-NPTS
DMRPS2X	HS	Investigative
DMRPS2X	SN	[3H]-(R)-NPTS
DMRPS2X	DT	Small molecular drug
DMRPS2X	PC	45270374
DMRPS2X	MW	417.5
DMRPS2X	FM	C26H27NO4
DMRPS2X	IC	InChI=1S/C26H27NO4/c1-19-8-10-21(11-9-19)26(30)22-12-14-23(15-13-22)31-24(20-6-4-3-5-7-20)16-17-27(2)18-25(28)29/h3-15,24H,16-18H2,1-2H3,(H,28,29)/t24-/m1/s1
DMRPS2X	CS	CC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)O[C@H](CCN(C)CC(=O)O)C3=CC=CC=C3
DMRPS2X	IK	HNBKNDFZJLEZLZ-XMMPIXPASA-N
DMRPS2X	IU	2-[methyl-[(3R)-3-[4-(4-methylbenzoyl)phenoxy]-3-phenylpropyl]amino]acetic acid
DMRPS2X	DE	Discovery agent

DM0B54M	ID	DM0B54M
DM0B54M	DN	[3H](S)-zacopride
DM0B54M	HS	Investigative
DM0B54M	SN	[3H](S)-zacopride; GTPL4074
DM0B54M	DT	Small molecular drug
DM0B54M	PC	53321935
DM0B54M	MW	315.81
DM0B54M	FM	C15H20ClN3O2
DM0B54M	IC	InChI=1S/C15H20ClN3O2/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20)/t13-/m1/s1/i1T3
DM0B54M	CS	[3H]C([3H])([3H])OC1=CC(=C(C=C1C(=O)N[C@@H]2CN3CCC2CC3)Cl)N
DM0B54M	IK	FEROPKNOYKURCJ-RYASAWMLSA-N
DM0B54M	IU	4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-(tritritiomethoxy)benzamide
DM0B54M	DE	Discovery agent

DMQO8AF	ID	DMQO8AF
DMQO8AF	DN	[3H]2,2,2-TEMPS
DMQO8AF	HS	Investigative
DMQO8AF	SN	2,2,2-Trifluoro-N-(3-pentan-2-yloxyphenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide; CHEMBL105296; 2,2,2-trifluoro-N-(3-pentan-2-yloxyphenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide; [3H]-PAM; 2,2,2-TEMPS; SCHEMBL6735527; GTPL6329; GTPL6328; BDBM50147143; 2,2,2-Trifluoro-ethanesulfonic acid [3-(1-methyl-butoxy)-phenyl]-pyridin-3-ylmethyl-amide;  [3H]-PAM
DMQO8AF	DT	Small molecular drug
DMQO8AF	PC	11362035
DMQO8AF	MW	416.5
DMQO8AF	FM	C19H23F3N2O3S
DMQO8AF	IC	InChI=1S/C19H23F3N2O3S/c1-3-6-15(2)27-18-9-4-8-17(11-18)24(13-16-7-5-10-23-12-16)28(25,26)14-19(20,21)22/h4-5,7-12,15H,3,6,13-14H2,1-2H3
DMQO8AF	CS	CCCC(C)OC1=CC=CC(=C1)N(CC2=CN=CC=C2)S(=O)(=O)CC(F)(F)F
DMQO8AF	IK	ICFXZBZASBXILF-UHFFFAOYSA-N
DMQO8AF	IU	2,2,2-trifluoro-N-(3-pentan-2-yloxyphenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide
DMQO8AF	DE	Discovery agent

DM5SWI1	ID	DM5SWI1
DM5SWI1	DN	[3H]4NMPB
DM5SWI1	HS	Investigative
DM5SWI1	SN	[3H](1-methyl-4-piperidyl) 2-hydroxy-2,2-diphenyl-acetate; [3H]1-Methyl-4-piperidyl diphenylglycolate; [3H]enpiperate
DM5SWI1	DT	Small molecular drug
DM5SWI1	PC	77157
DM5SWI1	MW	325.4
DM5SWI1	FM	C20H23NO3
DM5SWI1	IC	InChI=1S/C20H23NO3/c1-21-14-12-18(13-15-21)24-19(22)20(23,16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18,23H,12-15H2,1H3
DM5SWI1	CS	CN1CCC(CC1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O
DM5SWI1	IK	UGYPGJCVNPPUPE-UHFFFAOYSA-N
DM5SWI1	IU	(1-methylpiperidin-4-yl) 2-hydroxy-2,2-diphenylacetate
DM5SWI1	CA	CAS 3608-67-1
DM5SWI1	DE	Discovery agent

DMEAHFZ	ID	DMEAHFZ
DMEAHFZ	DN	[3H]5-CT
DMEAHFZ	HS	Investigative
DMEAHFZ	SN	tritiated 5-carbamidotryptamine; [3H]5-carboxamidotryptamine
DMEAHFZ	DT	Small molecular drug
DMEAHFZ	PC	53324620
DMEAHFZ	MW	211.27
DMEAHFZ	FM	C11H13N3O
DMEAHFZ	IC	InChI=1S/C11H13N3O/c12-4-3-8-6-14-10-2-1-7(11(13)15)5-9(8)10/h1-2,5-6,14H,3-4,12H2,(H2,13,15)/i3T2,4T2
DMEAHFZ	CS	[3H]C([3H])(C1=CNC2=C1C=C(C=C2)C(=O)N)C([3H])([3H])N
DMEAHFZ	IK	WKZLNEWVIAGNAW-DOMYTETQSA-N
DMEAHFZ	IU	3-(2-amino-1,1,2,2-tetratritioethyl)-1H-indole-5-carboxamide
DMEAHFZ	DE	Discovery agent

DMYJXV7	ID	DMYJXV7
DMYJXV7	DN	[3H]5-HT
DMYJXV7	HS	Investigative
DMYJXV7	SN	[3H]-5-HT
DMYJXV7	DT	Small molecular drug
DMYJXV7	PC	53317992
DMYJXV7	MW	180.23
DMYJXV7	FM	C10H12N2O
DMYJXV7	IC	InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2/i3T,4T
DMYJXV7	CS	[3H]C(C1=CNC2=C1C=C(C=C2)O)C([3H])N
DMYJXV7	IK	QZAYGJVTTNCVMB-PZFLKRBQSA-N
DMYJXV7	IU	3-(2-amino-1,2-ditritioethyl)-1H-indol-5-ol
DMYJXV7	DE	Discovery agent

DM50WFM	ID	DM50WFM
DM50WFM	DN	[3H]5-oxo-ETE
DM50WFM	HS	Investigative
DM50WFM	SN	5-Oxo-ETE; 5-Oxoete; 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5-Kete; 5-Oxoeicosatetraenoic acid; 5-ketoeicosatetraenoic acid; CHEMBL18028; CHEBI:52449; (6E,8Z,11Z,14Z)-5-Oxoicosa-6,8,11,14-tetraenoic acid; 106154-18-1; 5-Oxo-eicosatetraenoate; 5-Oxoicosatetraenoic acid; [3H]-5-oxo-ETE; 5-Keto-6,8,11,14-eicosatetraenoic acid; 5-keto-ETE; ETE-5-Oxo; AC1NR1NN; BSPBio_001453; SCHEMBL139762; BML1-D12; GTPL3391; GTPL3416; MEASLHGILYBXFO-XTDASVJISA-N; HMS3402I15; HMS1791I15; HMS1989I15; HMS1361I15; ZINC4655377; LMFA03060011;  [3H]-5-oxo-ETE; 5-oxo-ETE
DM50WFM	DT	Small molecular drug
DM50WFM	PC	5283159
DM50WFM	MW	318.4
DM50WFM	FM	C20H30O3
DM50WFM	IC	InChI=1S/C20H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h6-7,9-10,12-14,16H,2-5,8,11,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,13-12-,16-14+
DM50WFM	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C=C\\C(=O)CCCC(=O)O
DM50WFM	IK	MEASLHGILYBXFO-XTDASVJISA-N
DM50WFM	IU	(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoic acid
DM50WFM	CA	CAS 106154-18-1
DM50WFM	CB	CHEBI:52449
DM50WFM	DE	Discovery agent

DM2PW8T	ID	DM2PW8T
DM2PW8T	DN	[3H]7-OH-DPAT
DM2PW8T	HS	Investigative
DM2PW8T	SN	7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol; 7-OH-DPAT; 7-Ohdpat; DP-7-AT; 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol; 7-Hydroxy-N,N-di-n-propyl-2-aminotetralin; 7-Hydroxy-2-N,N-dipropylaminotetralin; N,N-Di-n-propyl-7-hydroxy-2-aminotetralin; CHEMBL285755; 7-(Dipropylamino)-5,6,7,8-tetrahydro-2-naphthalenol; 2-Naphthalenol, 7-(dipropylamino)-5,6,7,8-tetrahydro-; 7-Hydroxy-DPAT hydrobromide; (+)-7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide; [3H]-7-OH-DPAT; (+)7-OH-DPAT; AC1Q7AGR; AC1L1AZK;  [3H]-7-OH-DPAT; (+/-)-7-hydroxy-2-(N,N-di-n-propylamino)tetralin
DM2PW8T	DT	Small molecular drug
DM2PW8T	PC	1219
DM2PW8T	MW	247.38
DM2PW8T	FM	C16H25NO
DM2PW8T	IC	InChI=1S/C16H25NO/c1-3-9-17(10-4-2)15-7-5-13-6-8-16(18)12-14(13)11-15/h6,8,12,15,18H,3-5,7,9-11H2,1-2H3
DM2PW8T	CS	CCCN(CCC)C1CCC2=C(C1)C=C(C=C2)O
DM2PW8T	IK	BLYMJBIZMIGWFK-UHFFFAOYSA-N
DM2PW8T	IU	7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol
DM2PW8T	CA	CAS 74938-11-7
DM2PW8T	CB	CHEBI:111176
DM2PW8T	DE	Discovery agent

DM4KCYU	ID	DM4KCYU
DM4KCYU	DN	[3H]8-OH-DPAT
DM4KCYU	HS	Investigative
DM4KCYU	SN	8-OH-Dpat; 78950-78-4; 8-HYDROXY-2-(DI-n-PROPYLAMINO)TETRALIN; 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol; 8-Hydroxy-DPAT; CHEMBL56; Ro-31-8220 in solution; CHEBI:73364; 1-Naphthalenol, 7-(dipropylamino)-5,6,7,8-tetrahydro-; S(-)-8-HYDROXY-DPAT HYDROBROMIDE PARTIAL  5-HT1A SECROT; (+/-)-8-HYDROXY-2-DIPROPYL-AMINOTETRALIN; [3H]-8-OH-DPAT; (+/-)-8-Hydroxy-DPAT hydrobromide; [3H]8-OH-DPAT; (+-)-8-OH-DPAT; S(-)-8-OH-DPAT HBr; S(-)-8-Hydroxy-DPAT hydrobromide; dl-8-Hydroxy-2-(dipropylamino)tetralin; GTPL7; 8OH-DPAT
DM4KCYU	DT	Small molecular drug
DM4KCYU	PC	1220
DM4KCYU	MW	247.38
DM4KCYU	FM	C16H25NO
DM4KCYU	IC	InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-9-8-13-6-5-7-16(18)15(13)12-14/h5-7,14,18H,3-4,8-12H2,1-2H3
DM4KCYU	CS	CCCN(CCC)C1CCC2=C(C1)C(=CC=C2)O
DM4KCYU	IK	ASXGJMSKWNBENU-UHFFFAOYSA-N
DM4KCYU	IU	7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
DM4KCYU	CA	CAS 78950-78-4
DM4KCYU	CB	CHEBI:73364
DM4KCYU	DE	Discovery agent

DMTBAXD	ID	DMTBAXD
DMTBAXD	DN	[3H]A317491
DMTBAXD	HS	Investigative
DMTBAXD	SN	A-317491; 475205-49-3; UNII-H327N08IPV; H327N08IPV; A 317491; 5-{[(3-phenoxyphenyl)methyl][(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl}benzene-1,2,4-tricarboxylic acid; A317491; VQGBOYBIENNKMI-LJAQVGFWSA-N; antagonist A-317491; [3H]A-317491; [3H]A 317491; SCHEMBL1160095; GTPL5407; GTPL4115; CHEMBL596234; CTK4J0070; BDBM86478; DTXSID40197185; MolPort-028-749-920; ZINC3990058; s8519; 475205-49-3 (free acid); AKOS030526820; CS-1250; NCGC00165956-01; 1,2,4-Benzenetricarboxylic acid,;  [3H]A-317491
DMTBAXD	DT	Small molecular drug
DMTBAXD	PC	9829395
DMTBAXD	MW	565.6
DMTBAXD	FM	C33H27NO8
DMTBAXD	IC	InChI=1S/C33H27NO8/c35-30(25-17-27(32(38)39)28(33(40)41)18-26(25)31(36)37)34(29-15-7-10-21-9-4-5-14-24(21)29)19-20-8-6-13-23(16-20)42-22-11-2-1-3-12-22/h1-6,8-9,11-14,16-18,29H,7,10,15,19H2,(H,36,37)(H,38,39)(H,40,41)/t29-/m0/s1
DMTBAXD	CS	C1C[C@@H](C2=CC=CC=C2C1)N(CC3=CC(=CC=C3)OC4=CC=CC=C4)C(=O)C5=CC(=C(C=C5C(=O)O)C(=O)O)C(=O)O
DMTBAXD	IK	VQGBOYBIENNKMI-LJAQVGFWSA-N
DMTBAXD	IU	5-[(3-phenoxyphenyl)methyl-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]benzene-1,2,4-tricarboxylic acid
DMTBAXD	CA	CAS 475205-49-3
DMTBAXD	DE	Discovery agent

DMSDY2Z	ID	DMSDY2Z
DMSDY2Z	DN	[3H]A-585539
DMSDY2Z	HS	Investigative
DMSDY2Z	SN	[3H]A-585539; GTPL3974; SCHEMBL18833113
DMSDY2Z	DT	Small molecular drug
DMSDY2Z	PC	23643135
DMSDY2Z	MW	281.38
DMSDY2Z	FM	C17H21N4+
DMSDY2Z	IC	InChI=1S/C17H21N4/c1-21(2)12-14-10-15(21)11-20(14)17-9-8-16(18-19-17)13-6-4-3-5-7-13/h3-9,14-15H,10-12H2,1-2H3/q+1
DMSDY2Z	CS	C[N+]1(CC2CC1CN2C3=NN=C(C=C3)C4=CC=CC=C4)C
DMSDY2Z	IK	AKMKIDQMKPFYDJ-UHFFFAOYSA-N
DMSDY2Z	IU	2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane
DMSDY2Z	DE	Discovery agent

DMVJKCH	ID	DMVJKCH
DMVJKCH	DN	[3H]A778317
DMVJKCH	HS	Investigative
DMVJKCH	SN	[3H]A778317; GTPL4076
DMVJKCH	DT	Small molecular drug
DMVJKCH	PC	53321936
DMVJKCH	MW	363.5
DMVJKCH	FM	C23H25N3O
DMVJKCH	IC	InChI=1S/C23H25N3O/c1-23(2,3)17-8-9-18-15(13-17)7-10-21(18)26-22(27)25-20-6-4-5-16-14-24-12-11-19(16)20/h4-6,8-9,11-14,21H,7,10H2,1-3H3,(H2,25,26,27)/t21-/m1/s1/i5T,6T
DMVJKCH	CS	[3H]C1=CC(=C(C2=C1C=NC=C2)NC(=O)N[C@@H]3CCC4=C3C=CC(=C4)C(C)(C)C)[3H]
DMVJKCH	IK	VPSCJCQPUGKRNC-ZVVBTKFUSA-N
DMVJKCH	IU	1-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-3-(6,8-ditritioisoquinolin-5-yl)urea
DMVJKCH	DE	Discovery agent

DMWV5C3	ID	DMWV5C3
DMWV5C3	DN	[3H]alphabeta-meATP
DMWV5C3	HS	Investigative
DMWV5C3	SN	Diphosphomethylphosphonic acid adenosyl ester; alpha,beta-Methylene ATP; alpha,beta-meATP; 7292-42-4; UNII-NYX13NT29D; diphosphomethylphosphonic acid adenosyl ester; alpha,beta-Methyleneadenosine 5'-triphosphate; EINECS 230-723-9; NYX13NT29D; ALPHA,BETA-METHYLENEADENOSINE-5'-TRIPHOSPHATE; CHEMBL132722; CHEBI:35056; 5'-O-(hydroxy{[hydroxy(phosphonooxy)phosphoryl]methyl}phosphoryl)adenosine; 5'-(Hydrogen((hydroxy(phosphonooxy)phosphinyl)methyl)phosphonate)adenosine; adenosine 5'-[alpha,beta-methylene]triphosphate; AMP-CPP; Adenosine 5'-(hydrogen; Alpha,Beta-Methyleneadenosine-5'-Triphosphate
DMWV5C3	DT	Small molecular drug
DMWV5C3	PC	91557
DMWV5C3	MW	505.21
DMWV5C3	FM	C11H18N5O12P3
DMWV5C3	IC	InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-29(19,20)4-30(21,22)28-31(23,24)25/h2-3,5,7-8,11,17-18H,1,4H2,(H,19,20)(H,21,22)(H2,12,13,14)(H2,23,24,25)/t5-,7-,8-,11-/m1/s1
DMWV5C3	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O)O)N
DMWV5C3	IK	CAWZRIXWFRFUQB-IOSLPCCCSA-N
DMWV5C3	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[hydroxy(phosphonooxy)phosphoryl]methyl]phosphinic acid
DMWV5C3	CA	CAS 7292-42-4
DMWV5C3	CB	CHEBI:35056
DMWV5C3	DE	Discovery agent

DMLF7SG	ID	DMLF7SG
DMLF7SG	DN	[3H]AMPA
DMLF7SG	HS	Investigative
DMLF7SG	SN	alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ampa; 74341-63-2; 77521-29-0; (RS)-AMPA; AMPA (pharmaceutical); CHEMBL13378; CHEBI:34018; 4-Isoxazolepropanoic acid, alpha-amino-2,3-dihydro-5-methyl-3-oxo-; gamma-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; dl-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; (+-)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; D,L-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; AMPA
DMLF7SG	DT	Small molecular drug
DMLF7SG	PC	1221
DMLF7SG	MW	186.17
DMLF7SG	FM	C7H10N2O4
DMLF7SG	IC	InChI=1S/C7H10N2O4/c1-3-4(6(10)9-13-3)2-5(8)7(11)12/h5H,2,8H2,1H3,(H,9,10)(H,11,12)
DMLF7SG	CS	CC1=C(C(=O)NO1)CC(C(=O)O)N
DMLF7SG	IK	UUDAMDVQRQNNHZ-UHFFFAOYSA-N
DMLF7SG	IU	2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid
DMLF7SG	CA	CAS 77521-29-0
DMLF7SG	CB	CHEBI:34018

DMPVG5Y	ID	DMPVG5Y
DMPVG5Y	DN	[3H]AZ11637326
DMPVG5Y	HS	Investigative
DMPVG5Y	SN	[3H]AZ11637326; GTPL3971
DMPVG5Y	DT	Small molecular drug
DMPVG5Y	PC	73755064
DMPVG5Y	MW	310.4
DMPVG5Y	FM	C19H19FN2O
DMPVG5Y	IC	InChI=1S/C19H19FN2O/c20-17-3-1-2-13(9-17)15-8-14-10-19(23-18(14)21-11-15)12-22-6-4-16(19)5-7-22/h1-3,8-9,11,16H,4-7,10,12H2/t19-/m0/s1
DMPVG5Y	CS	C1CN2CCC1[C@@]3(C2)CC4=C(O3)N=CC(=C4)C5=CC(=CC=C5)F
DMPVG5Y	IK	MRVNNESNVNUKCV-IBGZPJMESA-N
DMPVG5Y	IU	(3R)-5'-(3-fluorophenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3H-furo[2,3-b]pyridine]
DMPVG5Y	DE	Discovery agent

DMKL9X7	ID	DMKL9X7
DMKL9X7	DN	[3H]bag-2
DMKL9X7	HS	Investigative
DMKL9X7	SN	2-[4-[2-[5-(Cyclopentylmethyl)-1H-imidazol-2-yl]ethyl]phenyl]benzoic acid; Bag-2; CHEMBL1084942; 2-[4-[2-[5-(cyclopentylmethyl)-1H-imidazol-2-yl]ethyl]phenyl]benzoic acid; GTPL6189; SCHEMBL6982673; GTPL8506; BDBM50313741; 4''-(2-(5-(cyclopentylmethyl)-1H-imidazol-2-yl)ethyl)biphenyl-2-carboxylic acid; bag-2
DMKL9X7	DT	Small molecular drug
DMKL9X7	PC	25025654
DMKL9X7	MW	374.5
DMKL9X7	FM	C24H26N2O2
DMKL9X7	IC	InChI=1S/C24H26N2O2/c27-24(28)22-8-4-3-7-21(22)19-12-9-17(10-13-19)11-14-23-25-16-20(26-23)15-18-5-1-2-6-18/h3-4,7-10,12-13,16,18H,1-2,5-6,11,14-15H2,(H,25,26)(H,27,28)
DMKL9X7	CS	C1CCC(C1)CC2=CN=C(N2)CCC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O
DMKL9X7	IK	OENIXTHWZWFYIV-UHFFFAOYSA-N
DMKL9X7	IU	2-[4-[2-[5-(cyclopentylmethyl)-1H-imidazol-2-yl]ethyl]phenyl]benzoic acid
DMKL9X7	DE	Discovery agent

DMG8T3W	ID	DMG8T3W
DMG8T3W	DN	[3H]BQ123
DMG8T3W	HS	Investigative
DMG8T3W	SN	[3H]cyc(DTrp-DAsp-Pro-DVal-Leu; [3H]-BQ123
DMG8T3W	DT	Small molecular drug
DMG8T3W	PC	70686617
DMG8T3W	MW	612.7
DMG8T3W	FM	C31H42N6O7
DMG8T3W	IC	InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-,22+,23-,24-,26+/m0/s1/i14T/t14?,21-,22+,23-,24-,26+
DMG8T3W	CS	[3H]C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC3=CNC4=CC=CC=C43)CC(C)C)C(C)C)C(=O)O
DMG8T3W	IK	VYCMAAOURFJIHD-HCGDBENESA-N
DMG8T3W	IU	2-[(3S,6R,9S,12R,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-propan-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]-2-tritioacetic acid
DMG8T3W	DE	Discovery agent

DMZRQU7	ID	DMZRQU7
DMZRQU7	DN	[3H]cAMP
DMZRQU7	HS	Investigative
DMZRQU7	SN	Cyclic AMP; cAMP; 60-92-4; Adenosine 3',5'-cyclic monophosphate; 3',5'-cyclic AMP; Adenosine 3',5'-phosphate; Adenosine 3',5'-cyclophosphate; cyclic 3',5'-AMP; Adenosine cyclic monophosphate; cyclic 3',5'-Adenylic acid; Adenosine 3',5'-monophosphate; Adenosine-3',5'-cyclophosphate; Adenosine cyclophosphate; Cyclic Adenosine Monophosphate; cyclic Adenosine 3',5'-phosphate; Cyclic adenylic acid; Adenosine cyclic 3',5'-monophosphate; 3',5'-AMP; cyclic Adenosine 3',5'-monophosphate; Adenosine cyclic 3',5'-phosphate;  [3H]-cAMP
DMZRQU7	DT	Small molecular drug
DMZRQU7	PC	6076
DMZRQU7	MW	329.21
DMZRQU7	FM	C10H12N5O6P
DMZRQU7	IC	InChI=1S/C10H12N5O6P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(20-10)1-19-22(17,18)21-7/h2-4,6-7,10,16H,1H2,(H,17,18)(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
DMZRQU7	CS	C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O1)O
DMZRQU7	IK	IVOMOUWHDPKRLL-KQYNXXCUSA-N
DMZRQU7	IU	(4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol
DMZRQU7	CA	CAS 60-92-4
DMZRQU7	CB	CHEBI:17489
DMZRQU7	DE	Discovery agent

DMHDGB3	ID	DMHDGB3
DMHDGB3	DN	[3H]CCPA
DMHDGB3	HS	Investigative
DMHDGB3	SN	2-Chloro-N6-cyclopentyladenosine; CCPA; 37739-05-2; 2-CHLORO-N-CYCLOPENTYLADENOSINE; 2-chloro-N(6)cyclopentyladenosine; Adenosine, 2-chloro-N-cyclopentyl-; BRN 4888162; CHEMBL284969; (2R,3R,4S,5R)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 2-Chloro-N6-cyclopentyladenosine hemihydrate; C15H20ClN5O4; [3H]-CCPA; ccpa (biochemistry); AC1L3XBY; 2-Cl-CPA;  [3H]-CCPA; 2-chloro-N6-cyclopentyladenosine
DMHDGB3	DT	Small molecular drug
DMHDGB3	PC	123807
DMHDGB3	MW	369.8
DMHDGB3	FM	C15H20ClN5O4
DMHDGB3	IC	InChI=1S/C15H20ClN5O4/c16-15-19-12(18-7-3-1-2-4-7)9-13(20-15)21(6-17-9)14-11(24)10(23)8(5-22)25-14/h6-8,10-11,14,22-24H,1-5H2,(H,18,19,20)/t8-,10-,11-,14-/m1/s1
DMHDGB3	CS	C1CCC(C1)NC2=C3C(=NC(=N2)Cl)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMHDGB3	IK	XSMYYYQVWPZWIZ-IDTAVKCVSA-N
DMHDGB3	IU	(2R,3R,4S,5R)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMHDGB3	CA	CAS 37739-05-2
DMHDGB3	DE	Discovery agent

DMZN1A3	ID	DMZN1A3
DMZN1A3	DN	[3H]CGP12177
DMZN1A3	HS	Investigative
DMZN1A3	SN	4-(3-Tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one; Tbhpbo; 81047-99-6; 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one; CHEBI:73288; C14H19N3O3; 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one; 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one; 2H-Benzimidazol-2-one, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,3-dihydro-; (+/-)-CGP-12177A hydrochloride; Spectrum_001907; SpecPlus_000776; Spectrum4_000777; AC1Q6M3F
DMZN1A3	DT	Small molecular drug
DMZN1A3	PC	2687
DMZN1A3	MW	279.33
DMZN1A3	FM	C14H21N3O3
DMZN1A3	IC	InChI=1S/C14H21N3O3/c1-14(2,3)15-7-9(18)8-20-11-6-4-5-10-12(11)17-13(19)16-10/h4-6,9,15,18H,7-8H2,1-3H3,(H2,16,17,19)
DMZN1A3	CS	CC(C)(C)NCC(COC1=CC=CC2=C1NC(=O)N2)O
DMZN1A3	IK	UMQUQWCJKFOUGV-UHFFFAOYSA-N
DMZN1A3	IU	4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one
DMZN1A3	CA	CAS 81047-99-6
DMZN1A3	CB	CHEBI:73288
DMZN1A3	DE	Discovery agent

DMQTBRM	ID	DMQTBRM
DMQTBRM	DN	[3H]CGP27492
DMQTBRM	HS	Investigative
DMQTBRM	SN	3-Aminopropylphosphinic acid; 3-aminopropylphosphinic acid; 3-Aminopropanephosphinic acid; CGP-27492; Cgp 27492; 3-Aminopropylphosphonous acid; Phosphinic acid, (3-aminopropyl); 3-aminopropyl-hydroxy-oxophosphanium; CHEMBL112203; [3H]3-APPA; [3H]-3-APPA; Cgp 27 492; [3H]-CGP27492; AC1O3S7O; SCHEMBL341549; GTPL5381; GTPL1081; BDBM24184; CTK8G4752; (3-Amino-propyl)-phosphinic acid; ZTHNRNOOZGJLRR-UHFFFAOYSA-N; MolPort-019-939-257; CGP27492; 3-aminopropyl-hydroxy-oxo-phosphonium; BN0804; PDSP2_001468; PDSP1_001484; FCH933647; 3-aminopropylphosphinic;  [3H]-CGP27492
DMQTBRM	DT	Small molecular drug
DMQTBRM	PC	6335948
DMQTBRM	MW	122.08
DMQTBRM	FM	C3H9NO2P+
DMQTBRM	IC	InChI=1S/C3H8NO2P/c4-2-1-3-7(5)6/h1-4H2/p+1
DMQTBRM	CS	C(CN)C[P+](=O)O
DMQTBRM	IK	MQIWYGZSHIXQIU-UHFFFAOYSA-O
DMQTBRM	IU	3-aminopropyl-hydroxy-oxophosphanium
DMQTBRM	CA	CAS 103680-47-3
DMQTBRM	DE	Discovery agent

DMITR7A	ID	DMITR7A
DMITR7A	DN	[3H]CGP39653
DMITR7A	HS	Investigative
DMITR7A	SN	(E)-2-amino-4-(phosphonomethyl)hept-3-enoic acid; 132472-31-2; [3H]CGP39653; ACMC-20muiw; GTPL4078; CTK0H6852; 2-amino-4-(phosphonomethyl)hept-3-enoic acid
DMITR7A	DT	Small molecular drug
DMITR7A	PC	114756
DMITR7A	MW	237.19
DMITR7A	FM	C8H16NO5P
DMITR7A	IC	InChI=1S/C8H16NO5P/c1-2-3-6(5-15(12,13)14)4-7(9)8(10)11/h4,7H,2-3,5,9H2,1H3,(H,10,11)(H2,12,13,14)
DMITR7A	CS	CCCC(=CC(C(=O)O)N)CP(=O)(O)O
DMITR7A	IK	ZEFQYTSQDVUMEU-UHFFFAOYSA-N
DMITR7A	IU	2-amino-4-(phosphonomethyl)hept-3-enoic acid
DMITR7A	DE	Discovery agent

DM7H3JN	ID	DM7H3JN
DM7H3JN	DN	[3H]CGS19755
DM7H3JN	HS	Investigative
DM7H3JN	SN	ACMC-20mhnp; ACMC-20bxqj; 4-(phosphonomethyl)-2-piperidinecarboxylic acid; AC1N8SPX; SCHEMBL120235; 2-Piperidinecarboxylicacid, 4-(phosphonomethyl)-, (2R,4S)-rel-; GTPL4080; 113229-89-3; AKOS005066562; 4-phosphonomethyl-2-piperidinecarboxylic acid; A802182
DM7H3JN	DT	Small molecular drug
DM7H3JN	PC	4324257
DM7H3JN	MW	223.16
DM7H3JN	FM	C7H14NO5P
DM7H3JN	IC	InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)
DM7H3JN	CS	C1CNC(CC1CP(=O)(O)O)C(=O)O
DM7H3JN	IK	LPMRCCNDNGONCD-UHFFFAOYSA-N
DM7H3JN	IU	4-(phosphonomethyl)piperidine-2-carboxylic acid
DM7H3JN	CA	CAS 110347-85-8
DM7H3JN	DE	Discovery agent

DMLP68J	ID	DMLP68J
DMLP68J	DN	[3H]CGS8216
DMLP68J	HS	Investigative
DMLP68J	SN	2-Phenylpyrazolo(4,3-c)quinolin-3(5H)-one; Cgs 8216; CGS-8216; 77779-60-3; 2-phenylpyrazolo(4,3-c)quinolin-3(5H)-one; BRN 4257286; 2-phenyl-1,2-dihydro-3h-pyrazolo[4,3-c]quinolin-3-one; 2,5-Dihydro-2-phenyl-3H-pyrazolo(4,3-c)quinolin-3-one; 3H-Pyrazolo(4,3-c)quinolin-3-one, 2,5-dihydro-2-phenyl-; 2-phenyl-1H-pyrazolo[4,5-c]quinolin-3-one; 2,5-DIHYDRO-2-PHENYL-3H-PYRAZOLO[4,3-C]QUINOLIN-3-ONE; AC1Q6FQG; AC1Q6NJI; AC1L2XPQ; 2-phenyl-1H-pyrazolo[4,3-c]quinolin-3-one; 2-phenyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-one; GTPL4366; GTPL4156; SCHEMBL1466280
DMLP68J	DT	Small molecular drug
DMLP68J	PC	104916
DMLP68J	MW	261.279
DMLP68J	FM	C16H11N3O
DMLP68J	IC	InChI=1S/C16H11N3O/c20-16-13-10-17-14-9-5-4-8-12(14)15(13)18-19(16)11-6-2-1-3-7-11/h1-10,18H
DMLP68J	CS	C1=CC=C(C=C1)N2C(=O)C3=C(N2)C4=CC=CC=C4N=C3
DMLP68J	IK	XTYGFVVANLMBHE-UHFFFAOYSA-N
DMLP68J	IU	2-phenyl-1H-pyrazolo[4,3-c]quinolin-3-one
DMLP68J	CA	CAS 77779-60-3
DMLP68J	DE	Inflammation

DMIFKUX	ID	DMIFKUX
DMIFKUX	DN	[3H]CNQX
DMIFKUX	HS	Investigative
DMIFKUX	SN	6-Cyano-7-nitroquinoxaline-2,3-dione; CNQX; 115066-14-3; 6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; 7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile; UNII-6OTE87SCCW; FG 9065; 6OTE87SCCW; FG-9065; 6-Cyano-2,3-dihydroxy-7-nitroquinoxaline; CHEBI:34468; 1,4-dihydro-2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; 7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile; 6-Quinoxalinecarbonitrile, 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-; ST50405216; 2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; FG9065; AC1MWAKF; Tocris-0190; Biomol-NT_000200; 6-cyano-7-nitroquinoxaline-2,3-dione
DMIFKUX	DT	Small molecular drug
DMIFKUX	PC	3721046
DMIFKUX	MW	232.15
DMIFKUX	FM	C9H4N4O4
DMIFKUX	IC	InChI=1S/C9H4N4O4/c10-3-4-1-5-6(2-7(4)13(16)17)12-9(15)8(14)11-5/h1-2H,(H,11,14)(H,12,15)
DMIFKUX	CS	C1=C(C(=CC2=C1NC(=O)C(=O)N2)[N+](=O)[O-])C#N
DMIFKUX	IK	RPXVIAFEQBNEAX-UHFFFAOYSA-N
DMIFKUX	IU	7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile
DMIFKUX	CA	CAS 115066-14-3
DMIFKUX	CB	CHEBI:34468
DMIFKUX	DE	Discovery agent

DMU7FC5	ID	DMU7FC5
DMU7FC5	DN	[3H]CP55940
DMU7FC5	HS	Investigative
DMU7FC5	SN	5-(1,1-Dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol; CP55940; CP-55940; UNII-KFY70972J5; CP55,940; CP 55940; CP 55,940; KFY70972J5; 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol; 83002-04-4; CP-55,940; 83003-12-7; C24H40O3; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; Phenol, 5-(1,1-dimethylheptyl)-2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-, rel-
DMU7FC5	DT	Small molecular drug
DMU7FC5	PC	104895
DMU7FC5	MW	376.6
DMU7FC5	FM	C24H40O3
DMU7FC5	IC	InChI=1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3/t18-,20-,22-/m1/s1
DMU7FC5	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O)O
DMU7FC5	IK	YNZFFALZMRAPHQ-SYYKKAFVSA-N
DMU7FC5	IU	2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol
DMU7FC5	CA	CAS 83002-04-4
DMU7FC5	DE	Discovery agent

DMR5UBF	ID	DMR5UBF
DMR5UBF	DN	[3H]CPP
DMR5UBF	HS	Investigative
DMR5UBF	SN	100828-16-8; 4-(3-phosphonopropyl)piperazine-2-carboxylic acid; (RS)-CPP; 3-2-Cpp; CARBOXYPEPTIDASE P; 3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid; (+/-)-CPP; 4-(3-Phosphonopropyl)-2-piperazinecarboxylic acid; CHEMBL22304; DL-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphonic acid; 4-(3-Phosphono-propyl)-piperazine-2-carboxylic acid; 2-Piperazinecarboxylic acid, 4-(3-phosphonopropyl)-; (+)-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphoric Acid; 2-Piperazinecarboxylic acid, 4-(3-phosphonopropyl)-, (+-)-; 108549-42-4
DMR5UBF	DT	Small molecular drug
DMR5UBF	PC	1228
DMR5UBF	MW	252.2
DMR5UBF	FM	C8H17N2O5P
DMR5UBF	IC	InChI=1S/C8H17N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h7,9H,1-6H2,(H,11,12)(H2,13,14,15)
DMR5UBF	CS	C1CN(CC(N1)C(=O)O)CCCP(=O)(O)O
DMR5UBF	IK	CUVGUPIVTLGRGI-UHFFFAOYSA-N
DMR5UBF	IU	4-(3-phosphonopropyl)piperazine-2-carboxylic acid
DMR5UBF	CA	CAS 100828-16-8
DMR5UBF	DE	Discovery agent

DMVLRHW	ID	DMVLRHW
DMVLRHW	DN	[3H]cytisine
DMVLRHW	HS	Investigative
DMVLRHW	SN	[3H]CYTISINE
DMVLRHW	DT	Small molecular drug
DMVLRHW	PC	53321937
DMVLRHW	MW	194.26
DMVLRHW	FM	C11H14N2O
DMVLRHW	IC	InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1/i2T,3T
DMVLRHW	CS	[3H]C1=CC(=C2[C@@H]3C[C@@H](CNC3)CN2C1=O)[3H]
DMVLRHW	IK	ANJTVLIZGCUXLD-ZIAKYUPESA-N
DMVLRHW	IU	(1R,9S)-3,5-ditritio-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
DMVLRHW	DE	Discovery agent

DM4NXRO	ID	DM4NXRO
DM4NXRO	DN	[3H]devazepide
DM4NXRO	HS	Investigative
DM4NXRO	SN	N-(1-Methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide; Rac-Devazepide; CHEMBL39263; BRN 5156082; C25H20N4O2; N-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide; [3H]-devazepide; [3H]DEVAZEPIDE; AC1L1RVE; AC1Q5GGS; ACMC-20m69q; GTPL878; SCHEMBL4884074; GTPL3476; CTK8G4712; 1H-Indole-2-carboxamide,N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-; 103420-82-2; 1H-Indole-2-carboxamide, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, (S)-
DM4NXRO	DT	Small molecular drug
DM4NXRO	PC	59751
DM4NXRO	MW	408.5
DM4NXRO	FM	C25H20N4O2
DM4NXRO	IC	InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)
DM4NXRO	CS	CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=C5
DM4NXRO	IK	NFHRQQKPEBFUJK-UHFFFAOYSA-N
DM4NXRO	IU	N-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide
DM4NXRO	DE	Discovery agent

DMBWAIE	ID	DMBWAIE
DMBWAIE	DN	[3H]dimethyl-W84
DMBWAIE	HS	Investigative
DMBWAIE	SN	Dimethyl-W84; dimethyl-W84; 6-[dimethyl-[3-(4-methyl-1,3-dioxoisoindol-2-yl)propyl]azaniumyl]hexyl-dimethyl-[3-(4-methyl-1,3-dioxoisoindol-2-yl)propyl]azanium; Dimethyl-W-84; GTPL364
DMBWAIE	DT	Small molecular drug
DMBWAIE	PC	10350027
DMBWAIE	MW	576.8
DMBWAIE	FM	C34H48N4O4+2
DMBWAIE	IC	InChI=1S/C34H48N4O4/c1-25-15-11-17-27-29(25)33(41)35(31(27)39)19-13-23-37(3,4)21-9-7-8-10-22-38(5,6)24-14-20-36-32(40)28-18-12-16-26(2)30(28)34(36)42/h11-12,15-18H,7-10,13-14,19-24H2,1-6H3/q+2
DMBWAIE	CS	CC1=C2C(=CC=C1)C(=O)N(C2=O)CCC[N+](C)(C)CCCCCC[N+](C)(C)CCCN3C(=O)C4=CC=CC(=C4C3=O)C
DMBWAIE	IK	HMXRJKOINNJHNS-UHFFFAOYSA-N
DMBWAIE	IU	6-[dimethyl-[3-(4-methyl-1,3-dioxoisoindol-2-yl)propyl]azaniumyl]hexyl-dimethyl-[3-(4-methyl-1,3-dioxoisoindol-2-yl)propyl]azanium
DMBWAIE	DE	Discovery agent

DMBMS1U	ID	DMBMS1U
DMBMS1U	DN	[3H]diprenorphine
DMBMS1U	HS	Investigative
DMBMS1U	SN	[15,16-3H]diprenorphine
DMBMS1U	DT	Small molecular drug
DMBMS1U	PC	6858272
DMBMS1U	MW	429.6
DMBMS1U	FM	C26H35NO4
DMBMS1U	IC	InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1/i10T,11T/t10?,11?,18-,19-,22-,24-,25+,26-
DMBMS1U	CS	[3H]C1C(N([C@@H]2CC3=C4[C@@]15[C@@]26CC[C@]([C@@H]5OC4=C(C=C3)O)([C@H](C6)C(C)(C)O)OC)CC7CC7)[3H]
DMBMS1U	IK	OIJXLIIMXHRJJH-ZXJLXYCOSA-N
DMBMS1U	IU	(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxypropan-2-yl)-15-methoxy-3,4-ditritio-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMBMS1U	DE	Discovery agent

DMEC2PF	ID	DMEC2PF
DMEC2PF	DN	[3H]dizocilpine
DMEC2PF	HS	Investigative
DMEC2PF	SN	[3H]MK-801
DMEC2PF	DT	Small molecular drug
DMEC2PF	PC	1207
DMEC2PF	MW	221.3
DMEC2PF	FM	C16H15N
DMEC2PF	IC	InChI=1S/C16H15N/c1-16-13-8-4-2-6-11(13)10-15(17-16)12-7-3-5-9-14(12)16/h2-9,15,17H,10H2,1H3
DMEC2PF	CS	CC12C3=CC=CC=C3CC(N1)C4=CC=CC=C24
DMEC2PF	IK	LBOJYSIDWZQNJS-UHFFFAOYSA-N
DMEC2PF	IU	1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene
DMEC2PF	CA	CAS 70449-94-4
DMEC2PF	DE	Discovery agent

DM9GY7O	ID	DM9GY7O
DM9GY7O	DN	[3H]DPCPX
DM9GY7O	HS	Investigative
DM9GY7O	SN	[3H]-DPCPX
DM9GY7O	DT	Small molecular drug
DM9GY7O	PC	53319341
DM9GY7O	MW	312.42
DM9GY7O	FM	C16H24N4O2
DM9GY7O	IC	InChI=1S/C16H24N4O2/c1-3-9-19-14-12(15(21)20(10-4-2)16(19)22)17-13(18-14)11-7-5-6-8-11/h11H,3-10H2,1-2H3,(H,17,18)/i1T,2T,9T,10T
DM9GY7O	CS	[3H]CCC([3H])N1C2=C(C(=O)N(C1=O)C([3H])CC[3H])NC(=N2)C3CCCC3
DM9GY7O	IK	FFBDFADSZUINTG-LEZITTIZSA-N
DM9GY7O	IU	8-cyclopentyl-1,3-bis(1,3-ditritiopropyl)-7H-purine-2,6-dione
DM9GY7O	DE	Discovery agent

DMDTYRV	ID	DMDTYRV
DMDTYRV	DN	[3H]eletriptan
DMDTYRV	HS	Investigative
DMDTYRV	SN	[3H]eletriptan; GTPL118
DMDTYRV	DT	Small molecular drug
DMDTYRV	PC	53318014
DMDTYRV	MW	388.5
DMDTYRV	FM	C22H26N2O2S
DMDTYRV	IC	InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1/i1T3
DMDTYRV	CS	[3H]C([3H])([3H])N1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
DMDTYRV	IK	PWVXXGRKLHYWKM-YWMWWHSFSA-N
DMDTYRV	IU	5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-(tritritiomethyl)pyrrolidin-2-yl]methyl]-1H-indole
DMDTYRV	DE	Discovery agent

DMM1KBW	ID	DMM1KBW
DMM1KBW	DN	[3H]EM-TBPC
DMM1KBW	HS	Investigative
DMM1KBW	SN	1-Ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidine-5-carbonitrile; EM-TBPC; GTPL3363; GTPL1390; SCHEMBL6952709; E-165; 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidine-5-carbonitrile; 1-Ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile; 1-ethyl-2-methyl-6-oxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)-1,6-dihydropyrimidine-5-carbonitrile
DMM1KBW	DT	Small molecular drug
DMM1KBW	PC	9904703
DMM1KBW	MW	308.4
DMM1KBW	FM	C18H20N4O
DMM1KBW	IC	InChI=1S/C18H20N4O/c1-3-22-13(2)20-17(16(12-19)18(22)23)21-10-8-14-6-4-5-7-15(14)9-11-21/h4-7H,3,8-11H2,1-2H3
DMM1KBW	CS	CCN1C(=NC(=C(C1=O)C#N)N2CCC3=CC=CC=C3CC2)C
DMM1KBW	IK	QNUVWRAGDSGAKX-UHFFFAOYSA-N
DMM1KBW	IU	1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidine-5-carbonitrile
DMM1KBW	DE	Discovery agent

DM3KJ45	ID	DM3KJ45
DM3KJ45	DN	[3H]estradiol-17beta-glucuronide
DM3KJ45	HS	Investigative
DM3KJ45	SN	[3H]-estradiol-17beta-glucuronide
DM3KJ45	DT	Small molecular drug
DM3KJ45	PC	5281887
DM3KJ45	MW	448.5
DM3KJ45	FM	C24H32O8
DM3KJ45	IC	InChI=1S/C24H32O8/c1-24-9-8-14-13-5-3-12(25)10-11(13)2-4-15(14)16(24)6-7-17(24)31-23-20(28)18(26)19(27)21(32-23)22(29)30/h3,5,10,14-21,23,25-28H,2,4,6-9H2,1H3,(H,29,30)/t14-,15-,16+,17+,18+,19+,20-,21+,23-,24+/m1/s1
DM3KJ45	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)CCC5=C3C=CC(=C5)O
DM3KJ45	IK	MTKNDAQYHASLID-QXYWQCSFSA-N
DM3KJ45	IU	(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]oxy]oxane-2-carboxylic acid
DM3KJ45	CA	CAS 1806-98-0
DM3KJ45	CB	CHEBI:791
DM3KJ45	DE	Discovery agent

DMGPF0N	ID	DMGPF0N
DMGPF0N	DN	[3H]estrone-3-sulphate
DMGPF0N	HS	Investigative
DMGPF0N	SN	[3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate
DMGPF0N	DT	Small molecular drug
DMGPF0N	PC	3001028
DMGPF0N	MW	350.4
DMGPF0N	FM	C18H22O5S
DMGPF0N	IC	InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1
DMGPF0N	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O
DMGPF0N	IK	JKKFKPJIXZFSSB-CBZIJGRNSA-N
DMGPF0N	IU	[(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMGPF0N	CA	CAS 481-97-0
DMGPF0N	CB	CHEBI:17474
DMGPF0N	DE	Discovery agent

DMWGY61	ID	DMWGY61
DMWGY61	DN	[3H]ETB-TBOA
DMWGY61	HS	Investigative
DMWGY61	SN	[3H]-ETB-TBOA
DMWGY61	DT	Small molecular drug
DMWGY61	PC	73755093
DMWGY61	MW	390.4
DMWGY61	FM	C20H22N2O6
DMWGY61	IC	InChI=1S/C20H22N2O6/c1-2-12-6-8-14(9-7-12)18(23)22-15-5-3-4-13(10-15)11-28-17(20(26)27)16(21)19(24)25/h3-10,16-17H,2,11,21H2,1H3,(H,22,23)(H,24,25)(H,26,27)/t16-,17-/m0/s1/i1T,2T/t2?,16-,17-
DMWGY61	CS	[3H]CC([3H])C1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)CO[C@@H]([C@@H](C(=O)O)N)C(=O)O
DMWGY61	IK	GFSLJGCKUUCABJ-YQFXYRMXSA-N
DMWGY61	IU	(2S,3S)-2-amino-3-[[3-[[4-(1,2-ditritioethyl)benzoyl]amino]phenyl]methoxy]butanedioic acid
DMWGY61	DE	Discovery agent

DME0XHN	ID	DME0XHN
DME0XHN	DN	[3H]folinic acid
DME0XHN	HS	Investigative
DME0XHN	DT	Small molecular drug
DME0XHN	PC	135403648
DME0XHN	MW	473.4
DME0XHN	FM	C20H23N7O7
DME0XHN	IC	InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1
DME0XHN	CS	C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DME0XHN	IK	VVIAGPKUTFNRDU-ABLWVSNPSA-N
DME0XHN	IU	(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DME0XHN	CA	CAS 58-05-9
DME0XHN	CB	CHEBI:15640
DME0XHN	DE	Discovery agent

DMGQDLU	ID	DMGQDLU
DMGQDLU	DN	[3H]GBR12935
DMGQDLU	HS	Investigative
DMGQDLU	SN	1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine; Gbr 12935; 76778-22-8; GBR-12935; GBR12935; 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine; UNII-9J9974WIBA; CHEMBL26320; 9J9974WIBA; CHEBI:64093; 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine; 1-(2-(benzhydryloxy)ethyl)-4-(3-phenylpropyl)piperazine; Piperazine, 1-(2-(diphenylmethoxy)ethyl)-4-(3-phenylpropyl)-; Piperazine, 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-; 1-(2-(diphenylmethoxy)ethyl)-4-(3-phenylpropyl)piperazine; 1-(2-(Benzhydryloxy)ethyl)-4-(3-phenylpropyl)piperazine;  [3H]-GBR12935
DMGQDLU	DT	Small molecular drug
DMGQDLU	PC	3456
DMGQDLU	MW	414.6
DMGQDLU	FM	C28H34N2O
DMGQDLU	IC	InChI=1S/C28H34N2O/c1-4-11-25(12-5-1)13-10-18-29-19-21-30(22-20-29)23-24-31-28(26-14-6-2-7-15-26)27-16-8-3-9-17-27/h1-9,11-12,14-17,28H,10,13,18-24H2
DMGQDLU	CS	C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4
DMGQDLU	IK	RAQPOZGWANIDQT-UHFFFAOYSA-N
DMGQDLU	IU	1-(2-benzhydryloxyethyl)-4-(3-phenylpropyl)piperazine
DMGQDLU	CA	CAS 76778-22-8
DMGQDLU	CB	CHEBI:64093
DMGQDLU	DE	Discovery agent

DMFEYLS	ID	DMFEYLS
DMFEYLS	DN	[3H]GlySar
DMFEYLS	HS	Investigative
DMFEYLS	SN	[3H]-GlySar; tritiated glycylsarcosine
DMFEYLS	DT	Small molecular drug
DMFEYLS	PC	93131
DMFEYLS	MW	146.14
DMFEYLS	FM	C5H10N2O3
DMFEYLS	IC	InChI=1S/C5H10N2O3/c1-7(3-5(9)10)4(8)2-6/h2-3,6H2,1H3,(H,9,10)
DMFEYLS	CS	CN(CC(=O)O)C(=O)CN
DMFEYLS	IK	VYAMLSCELQQRAE-UHFFFAOYSA-N
DMFEYLS	IU	2-[(2-aminoacetyl)-methylamino]acetic acid
DMFEYLS	CA	CAS 29816-01-1
DMFEYLS	CB	CHEBI:155876
DMFEYLS	DE	Discovery agent

DM4URBO	ID	DM4URBO
DM4URBO	DN	[3H]GR 125,743
DM4URBO	HS	Investigative
DM4URBO	SN	[3H]GR125743
DM4URBO	DT	Small molecular drug
DM4URBO	PC	53321959
DM4URBO	MW	422.5
DM4URBO	FM	C25H28N4O2
DM4URBO	IC	InChI=1S/C25H28N4O2/c1-18-16-20(4-6-22(18)19-8-10-26-11-9-19)25(30)27-21-5-7-24(31-3)23(17-21)29-14-12-28(2)13-15-29/h4-11,16-17H,12-15H2,1-3H3,(H,27,30)/i2T3
DM4URBO	CS	[3H]C([3H])([3H])N1CCN(CC1)C2=C(C=CC(=C2)NC(=O)C3=CC(=C(C=C3)C4=CC=NC=C4)C)OC
DM4URBO	IK	GNOXPYACARZYMW-BHTRQJOGSA-N
DM4URBO	IU	N-[4-methoxy-3-[4-(tritritiomethyl)piperazin-1-yl]phenyl]-3-methyl-4-pyridin-4-ylbenzamide
DM4URBO	DE	Discovery agent

DMMHSYA	ID	DMMHSYA
DMMHSYA	DN	[3H]GR65630
DMMHSYA	HS	Investigative
DMMHSYA	SN	[3H]-GR65630
DMMHSYA	DT	Small molecular drug
DMMHSYA	PC	5311136
DMMHSYA	MW	267.33
DMMHSYA	FM	C16H17N3O
DMMHSYA	IC	InChI=1S/C16H17N3O/c1-11-14(18-10-17-11)7-8-16(20)13-9-19(2)15-6-4-3-5-12(13)15/h3-6,9-10H,7-8H2,1-2H3,(H,17,18)
DMMHSYA	CS	CC1=C(N=CN1)CCC(=O)C2=CN(C3=CC=CC=C32)C
DMMHSYA	IK	QZNZJWLUNDXZQA-UHFFFAOYSA-N
DMMHSYA	IU	3-(5-methyl-1H-imidazol-4-yl)-1-(1-methylindol-3-yl)propan-1-one
DMMHSYA	CB	CHEBI:87784
DMMHSYA	DE	Discovery agent

DMB9VGW	ID	DMB9VGW
DMB9VGW	DN	[3H]granisetron
DMB9VGW	HS	Investigative
DMB9VGW	SN	[3H]-granisetron; [3H]-BRL-43694
DMB9VGW	DT	Small molecular drug
DMB9VGW	PC	3510
DMB9VGW	MW	312.4
DMB9VGW	FM	C18H24N4O
DMB9VGW	IC	InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)
DMB9VGW	CS	CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
DMB9VGW	IK	MFWNKCLOYSRHCJ-UHFFFAOYSA-N
DMB9VGW	IU	1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide
DMB9VGW	CA	CAS 109889-09-0
DMB9VGW	DE	Discovery agent

DMU6A3W	ID	DMU6A3W
DMU6A3W	DN	[3H]GSK931145
DMU6A3W	HS	Investigative
DMU6A3W	SN	[3H]-GSK931145
DMU6A3W	DT	Small molecular drug
DMU6A3W	PC	73755091
DMU6A3W	MW	356.5
DMU6A3W	FM	C23H30N2O
DMU6A3W	IC	InChI=1S/C23H30N2O/c1-17-11-10-12-18(2)20(17)22(26)24-21(19-13-6-5-7-14-19)23(25(3)4)15-8-9-16-23/h5-7,10-14,21H,8-9,15-16H2,1-4H3,(H,24,26)/t21-/m0/s1/i3T3
DMU6A3W	CS	[3H]C([3H])([3H])N(C)C1(CCCC1)[C@H](C2=CC=CC=C2)NC(=O)C3=C(C=CC=C3C)C
DMU6A3W	IK	BMXRRRIDMAIEKX-IUNCQSRSSA-N
DMU6A3W	IU	2,6-dimethyl-N-[(S)-[1-[methyl(tritritiomethyl)amino]cyclopentyl]-phenylmethyl]benzamide
DMU6A3W	DE	Discovery agent

DMJT6D3	ID	DMJT6D3
DMJT6D3	DN	[3H]GW2331
DMJT6D3	HS	Investigative
DMJT6D3	SN	[3H]GW2331; GTPL2706; 2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid
DMJT6D3	DT	Small molecular drug
DMJT6D3	PC	10624977
DMJT6D3	MW	492.6
DMJT6D3	FM	C27H36F2N2O4
DMJT6D3	IC	InChI=1S/C27H36F2N2O4/c1-4-6-7-8-9-17-31(26(34)30-24-15-12-21(28)19-23(24)29)18-16-20-10-13-22(14-11-20)35-27(3,5-2)25(32)33/h10-15,19H,4-9,16-18H2,1-3H3,(H,30,34)(H,32,33)/i15T
DMJT6D3	CS	[3H]C1=CC(=CC(=C1NC(=O)N(CCCCCCC)CCC2=CC=C(C=C2)OC(C)(CC)C(=O)O)F)F
DMJT6D3	IK	VGSJXSLGVQINOL-BBSCNJGJSA-N
DMJT6D3	IU	2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid
DMJT6D3	DE	Discovery agent

DMEO6AH	ID	DMEO6AH
DMEO6AH	DN	[3H]HEMADO
DMEO6AH	HS	Investigative
DMEO6AH	SN	Hemado; HEMADO; CHEMBL260563; 403842-38-6; (2R,3R,4S,5R)-2-(2-hex-1-ynyl-6-methylaminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; SCHEMBL935096; GTPL5736; GTPL5599; MolPort-006-822-566; 2-(1-Hexynyl)-N-methyladenosine; 2-(1-Hexynyl)-N6-methyladenosine; ZINC3995955; BDBM50003273; AKOS024456680; HEMADO, &gt;=99% (HPLC), solid
DMEO6AH	DT	Small molecular drug
DMEO6AH	PC	10981286
DMEO6AH	MW	361.4
DMEO6AH	FM	C17H23N5O4
DMEO6AH	IC	InChI=1S/C17H23N5O4/c1-3-4-5-6-7-11-20-15(18-2)12-16(21-11)22(9-19-12)17-14(25)13(24)10(8-23)26-17/h9-10,13-14,17,23-25H,3-5,8H2,1-2H3,(H,18,20,21)/t10-,13-,14-,17-/m1/s1
DMEO6AH	CS	CCCCC#CC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NC
DMEO6AH	IK	KOCIMZNSNPOGOP-IWCJZZDYSA-N
DMEO6AH	IU	(2R,3R,4S,5R)-2-[2-hex-1-ynyl-6-(methylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMEO6AH	DE	Discovery agent

DM190QW	ID	DM190QW
DM190QW	DN	[3H]hemicholinium-3
DM190QW	HS	Investigative
DM190QW	SN	[3H]-HC-3 ; [3H]-hemicholinium-3; [3H]HC-3
DM190QW	DT	Small molecular drug
DM190QW	PC	9399
DM190QW	MW	574.3
DM190QW	FM	C24H34Br2N2O4
DM190QW	IC	InChI=1S/C24H34N2O4.2BrH/c1-25(2)13-15-29-23(27,17-25)21-9-5-19(6-10-21)20-7-11-22(12-8-20)24(28)18-26(3,4)14-16-30-24;;/h5-12,27-28H,13-18H2,1-4H3;2*1H/q+2;;/p-2
DM190QW	CS	C[N+]1(CCOC(C1)(C2=CC=C(C=C2)C3=CC=C(C=C3)C4(C[N+](CCO4)(C)C)O)O)C.[Br-].[Br-]
DM190QW	IK	OPYKHUMNFAMIBL-UHFFFAOYSA-L
DM190QW	IU	2-[4-[4-(2-hydroxy-4,4-dimethylmorpholin-4-ium-2-yl)phenyl]phenyl]-4,4-dimethylmorpholin-4-ium-2-ol;dibromide
DM190QW	CA	CAS 312-45-8

DMJ5BDQ	ID	DMJ5BDQ
DMJ5BDQ	DN	[3H]histidine
DMJ5BDQ	HS	Investigative
DMJ5BDQ	SN	[3H]-histidine
DMJ5BDQ	DT	Small molecular drug
DMJ5BDQ	PC	6274
DMJ5BDQ	MW	155.15
DMJ5BDQ	FM	C6H9N3O2
DMJ5BDQ	IC	InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1
DMJ5BDQ	CS	C1=C(NC=N1)C[C@@H](C(=O)O)N
DMJ5BDQ	IK	HNDVDQJCIGZPNO-YFKPBYRVSA-N
DMJ5BDQ	IU	(2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid
DMJ5BDQ	CA	CAS 71-00-1
DMJ5BDQ	CB	CHEBI:15971

DM8YUW6	ID	DM8YUW6
DM8YUW6	DN	[3H]HU-243
DM8YUW6	HS	Investigative
DM8YUW6	SN	140835-18-3; (3H)HU 243; (6aR,8S,9S,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol; AC1MIXOL; 3-Dimethylheptyl-11-hydroxyhexahydrocannabinol; BCP9000763; 6H-Dibenzo(b,d)pyran-8-t-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,8,9,10,10a-hexahydro-9-t-1-hydroxy-6,6-diemthyl-, (6aR-(6aalpha,8beta,9alpha,10abeta))-
DM8YUW6	DT	Small molecular drug
DM8YUW6	PC	73754997
DM8YUW6	MW	392.6
DM8YUW6	FM	C25H40O3
DM8YUW6	IC	InChI=1S/C25H40O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h14-15,17,19-20,26-27H,6-13,16H2,1-5H3/t17-,19-,20-/m1/s1/i10T,17T/t10?,17-,19-,20-
DM8YUW6	CS	[3H]C1C[C@@H]2[C@@H](C[C@]1([3H])CO)C3=C(C=C(C=C3OC2(C)C)C(C)(C)CCCCCC)O
DM8YUW6	IK	MVEVPDCVOXJVBD-AENGYHINSA-N
DM8YUW6	IU	(6aR,9R,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol
DM8YUW6	DE	Discovery agent

DMJCI2A	ID	DMJCI2A
DMJCI2A	DN	[3H]JB-93182
DMJCI2A	HS	Investigative
DMJCI2A	SN	CHEMBL14557; [3H]JB-93182; GTPL908; SCHEMBL7096084; BDBM50213845; JB-93182; 5-[[(2S)-2-[[6-(1-adamantylmethylcarbamoyl)1H-indole-5-carbonyl]amino]-3-phenylpropanoyl]amino]benzene-1,3-dicarboxylic acid
DMJCI2A	DT	Small molecular drug
DMJCI2A	PC	9939572
DMJCI2A	MW	662.7
DMJCI2A	FM	C38H38N4O7
DMJCI2A	IC	InChI=1S/C38H38N4O7/c43-33(40-20-38-17-22-8-23(18-38)10-24(9-22)19-38)30-16-31-25(6-7-39-31)15-29(30)34(44)42-32(11-21-4-2-1-3-5-21)35(45)41-28-13-26(36(46)47)12-27(14-28)37(48)49/h1-7,12-16,22-24,32,39H,8-11,17-20H2,(H,40,43)(H,41,45)(H,42,44)(H,46,47)(H,48,49)/t22?,23?,24?,32-,38?/m0/s1
DMJCI2A	CS	C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=C(C=C5C=CNC5=C4)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)NC7=CC(=CC(=C7)C(=O)O)C(=O)O
DMJCI2A	IK	DKYQJTXTKSMTHK-FGLZHOHTSA-N
DMJCI2A	IU	5-[[(2S)-2-[[6-(1-adamantylmethylcarbamoyl)-1H-indole-5-carbonyl]amino]-3-phenylpropanoyl]amino]benzene-1,3-dicarboxylic acid
DMJCI2A	DE	Discovery agent

DMZT8UD	ID	DMZT8UD
DMZT8UD	DN	[3H]JNJ 7777120
DMZT8UD	HS	Investigative
DMZT8UD	SN	1-[(5-Chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine; JNJ-7777120; 459168-41-3; JNJ7777120; JNJ 7777120; UNII-4H1AU2V37X; HUQJRYMLJBBEDO-UHFFFAOYSA-N; 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine; 4H1AU2V37X; CHEMBL129198; 1-[(5-CHLORO-1H-INDOL-2-YL)CARBONYL]-4-METHYL-PIPERAZINE; 1-((5-chloro-1H-indol-2-yl)carbonyl)-4-methylpiperazine; (5-chloro-1H-indol-2-yl)-(4-methylpiperazin-1-yl)methanone; (5-chloro-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone; METHANONE, (5-CHLORO-1H-INDOL-2-YL)(4-METHYL-1-PIPERAZINYL)-; STK175446; [3H]-JNJ7777120;  [3H]-JNJ7777120
DMZT8UD	DT	Small molecular drug
DMZT8UD	PC	4908365
DMZT8UD	MW	277.75
DMZT8UD	FM	C14H16ClN3O
DMZT8UD	IC	InChI=1S/C14H16ClN3O/c1-17-4-6-18(7-5-17)14(19)13-9-10-8-11(15)2-3-12(10)16-13/h2-3,8-9,16H,4-7H2,1H3
DMZT8UD	CS	CN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl
DMZT8UD	IK	HUQJRYMLJBBEDO-UHFFFAOYSA-N
DMZT8UD	IU	(5-chloro-1H-indol-2-yl)-(4-methylpiperazin-1-yl)methanone
DMZT8UD	CA	CAS 459168-41-3
DMZT8UD	DE	Inflammation

DMSE56B	ID	DMSE56B
DMSE56B	DN	[3H]JNJ-40068782
DMSE56B	HS	Investigative
DMSE56B	SN	RVRHQHDKALSKLY-UHFFFAOYSA-N; CHEMBL3337510; JNJ-40068782; SCHEMBL101802; GTPL6330; GTPL6331;  RVRHQHDKALSKLY-UHFFFAOYSA-N; BDBM50051571; 1-(cyclopropylmethyl)-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydropyridine-3-carbonitrile
DMSE56B	DT	Small molecular drug
DMSE56B	PC	59234231
DMSE56B	MW	333.4
DMSE56B	FM	C21H23N3O
DMSE56B	IC	InChI=1S/C21H23N3O/c22-14-19-20(10-13-24(21(19)25)15-16-6-7-16)23-11-8-18(9-12-23)17-4-2-1-3-5-17/h1-5,10,13,16,18H,6-9,11-12,15H2
DMSE56B	CS	C1CC1CN2C=CC(=C(C2=O)C#N)N3CCC(CC3)C4=CC=CC=C4
DMSE56B	IK	RVRHQHDKALSKLY-UHFFFAOYSA-N
DMSE56B	IU	1-(cyclopropylmethyl)-2-oxo-4-(4-phenylpiperidin-1-yl)pyridine-3-carbonitrile
DMSE56B	DE	Discovery agent

DMMK7XU	ID	DMMK7XU
DMMK7XU	DN	[3H]kainate
DMMK7XU	HS	Investigative
DMMK7XU	SN	(2S,3S,4S)-3-(Carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; (2S,3S,4S)-3-(carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; GTPL4231;  (2S,3S,4S)-3-(Carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; GTPL4085; KAINATE
DMMK7XU	DT	Small molecular drug
DMMK7XU	PC	73755076
DMMK7XU	MW	211.21
DMMK7XU	FM	C10H13NO4-2
DMMK7XU	IC	InChI=1S/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/p-2/t6-,7+,9-/m0/s1
DMMK7XU	CS	CC(=C)[C@H]1CN[C@@H]([C@H]1CC(=O)[O-])C(=O)[O-]
DMMK7XU	IK	VLSMHEGGTFMBBZ-OOZYFLPDSA-L
DMMK7XU	IU	(2S,3S,4S)-3-(carboxylatomethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylate
DMMK7XU	CB	CHEBI:156548
DMMK7XU	DE	Discovery agent

DMUZ9LX	ID	DMUZ9LX
DMUZ9LX	DN	[3H]L655708
DMUZ9LX	HS	Investigative
DMUZ9LX	SN	YKYOQIXTECBVBB-UHFFFAOYSA-N; ethyl 15-methoxy-12-oxo-2,4,11-triazatetracyclo[11400^{2,6}0^{7,11}]heptadeca-1(13),3,5,14,16-pentaene-5-carboxylate; AC1N5TG4; GTPL4363; GTPL4238; CHEBI:91920; HMS3267P07
DMUZ9LX	DT	Small molecular drug
DMUZ9LX	PC	4203080
DMUZ9LX	MW	341.4
DMUZ9LX	FM	C18H19N3O4
DMUZ9LX	IC	InChI=1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3
DMUZ9LX	CS	CCOC(=O)C1=C2C3CCCN3C(=O)C4=C(N2C=N1)C=CC(=C4)OC
DMUZ9LX	IK	YKYOQIXTECBVBB-UHFFFAOYSA-N
DMUZ9LX	IU	ethyl 15-methoxy-12-oxo-2,4,11-triazatetracyclo[11.4.0.02,6.07,11]heptadeca-1(17),3,5,13,15-pentaene-5-carboxylate
DMUZ9LX	CB	CHEBI:91920
DMUZ9LX	DE	Discovery agent

DM0YJHS	ID	DM0YJHS
DM0YJHS	DN	[3H]LSD
DM0YJHS	HS	Investigative
DM0YJHS	SN	[3H]N,N-diethyllysergamide; [3H]lysergic acid diethylamide; [3H]lysergide
DM0YJHS	DT	Small molecular drug
DM0YJHS	PC	44559100
DM0YJHS	MW	329.5
DM0YJHS	FM	C20H25N3O
DM0YJHS	IC	InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1/i3T3
DM0YJHS	CS	[3H]C([3H])([3H])N1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)N(CC)CC
DM0YJHS	IK	VAYOSLLFUXYJDT-QZGBZKRISA-N
DM0YJHS	IU	(6aR,9R)-N,N-diethyl-7-(tritritiomethyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM0YJHS	DE	Discovery agent

DMDOJVX	ID	DMDOJVX
DMDOJVX	DN	[3H]LTB4
DMDOJVX	HS	Investigative
DMDOJVX	SN	Delta(6)-trans,Delta(8)-cis-leukotriene B4; (6E,8Z)-LTB4; (5S,6E,8Z,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid; Delta(6)-trans,Delta(8)-cis-LTB4; 5(S),12(R)-dihydroxy-6(E),8(Z),10(E),14(Z)-icosatetraenoic acid; (5S,12R,6E,8Z,10E,14Z)-5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid; 5(S),12(R)-dihydroxy-6(E),8(Z),10(E),14(Z)-eicosatetraenoic acid; (5S,6E,8Z,10E,12R,14Z)-5,12-dihydroxyeicosa-6,8,10,14-tetraenoic acid; [3H]LTB4; SCHEMBL247274; GTPL3413; CHEBI:53027; ZINC27642911
DMDOJVX	DT	Small molecular drug
DMDOJVX	PC	9949656
DMDOJVX	MW	336.5
DMDOJVX	FM	C20H32O4
DMDOJVX	IC	InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7-,9-6-,14-10+,15-11+/t18-,19-/m1/s1
DMDOJVX	CS	CCCCC/C=C\\C[C@H](/C=C/C=C\\C=C\\[C@H](CCCC(=O)O)O)O
DMDOJVX	IK	VNYSSYRCGWBHLG-GEWAPNICSA-N
DMDOJVX	IU	(5S,6E,8Z,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid
DMDOJVX	CB	CHEBI:53027
DMDOJVX	DE	Discovery agent

DMD09BO	ID	DMD09BO
DMD09BO	DN	[3H]LTC4
DMD09BO	HS	Investigative
DMD09BO	SN	[3H]LTC4
DMD09BO	DT	Small molecular drug
DMD09BO	PC	73755045
DMD09BO	MW	481.6
DMD09BO	FM	C25H39NO6S
DMD09BO	IC	InChI=1S/C25H39NO6S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22(21(27)15-14-17-24(29)30)33-19-18-23(28)26-20-25(31)32/h6-7,9-13,16,21-22,27H,2-5,8,14-15,17-20H2,1H3,(H,26,28)(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t21-,22+/m0/s1
DMD09BO	CS	CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SCCC(=O)NCC(=O)O
DMD09BO	IK	SEOZZZSLGDJWJL-FSKXFZJASA-N
DMD09BO	IU	(5S,6R,7E,9E,11Z,14Z)-6-[3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
DMD09BO	DE	Discovery agent

DMGX0Y8	ID	DMGX0Y8
DMGX0Y8	DN	[3H]LY341495
DMGX0Y8	HS	Investigative
DMGX0Y8	SN	GTVQXKHWYDSDNM-JRHNIRLTSA-N; AC1O44IH; CTK8F0257; AN-16504; (1S,2S)-2-[(2S)-2-amino-3-(2,6-dioxo-3H-purin-9-yl)-1-hydroxy-1-oxopropan-2-yl]cyclopropane-1-carboxylic acid; (1S,2S)-2-[(1S)-1-amino-1-carboxy-2-(2,6-dioxo-3H-purin-9-yl)ethyl]cyclopropanecarboxylic;  [3H]alpha-9'-xantheylmethyl-2-(carboxycyclopropyl)glycine; LY341495
DMGX0Y8	DT	Small molecular drug
DMGX0Y8	PC	9819927
DMGX0Y8	MW	353.4
DMGX0Y8	FM	C20H19NO5
DMGX0Y8	IC	InChI=1S/C20H19NO5/c21-20(19(24)25,15-9-13(15)18(22)23)10-14-11-5-1-3-7-16(11)26-17-8-4-2-6-12(14)17/h1-8,13-15H,9-10,21H2,(H,22,23)(H,24,25)/t13-,15-,20-/m0/s1
DMGX0Y8	CS	C1[C@@H]([C@H]1[C@@](CC2C3=CC=CC=C3OC4=CC=CC=C24)(C(=O)O)N)C(=O)O
DMGX0Y8	IK	VLZBRVJVCCNPRJ-KPHUOKFYSA-N
DMGX0Y8	IU	(1S,2S)-2-[(1S)-1-amino-1-carboxy-2-(9H-xanthen-9-yl)ethyl]cyclopropane-1-carboxylic acid
DMGX0Y8	CA	CAS 201943-63-7
DMGX0Y8	CB	CHEBI:93224
DMGX0Y8	DE	Discovery agent

DMPKGHB	ID	DMPKGHB
DMPKGHB	DN	[3H]MDL105519
DMPKGHB	HS	Investigative
DMPKGHB	SN	AC1L1H8N; GTPL4088; CTK6G6780; CTK0I1827; HMS3370K17; (E)-3-(2-Carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid; 3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid; (Z)-3-(2-carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid; 1H-Indole-2-carboxylicacid, 3-[(1E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-
DMPKGHB	DT	Small molecular drug
DMPKGHB	PC	4023
DMPKGHB	MW	376.2
DMPKGHB	FM	C18H11Cl2NO4
DMPKGHB	IC	InChI=1S/C18H11Cl2NO4/c19-10-6-13(20)15-12(16(18(24)25)21-14(15)7-10)8-11(17(22)23)9-4-2-1-3-5-9/h1-8,21H,(H,22,23)(H,24,25)
DMPKGHB	CS	C1=CC=C(C=C1)C(=CC2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O)C(=O)O
DMPKGHB	IK	LPWVUDLZUVBQGP-UHFFFAOYSA-N
DMPKGHB	IU	3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid
DMPKGHB	DE	Discovery agent

DMEX6GT	ID	DMEX6GT
DMEX6GT	DN	[3H]meclinertant
DMEX6GT	HS	Investigative
DMEX6GT	SN	[3H]-SR48692; [3H]reminertant; [3H]SR-48692
DMEX6GT	DT	Small molecular drug
DMEX6GT	PC	53323315
DMEX6GT	MW	599.1
DMEX6GT	FM	C32H31ClN4O5
DMEX6GT	IC	InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)/i1T3,2T3
DMEX6GT	CS	[3H]C([3H])([3H])OC1=C(C(=CC=C1)OC([3H])([3H])[3H])C2=CC(=NN2C3=C4C=CC(=CC4=NC=C3)Cl)C(=O)NC5(C6CC7CC(C6)CC5C7)C(=O)O
DMEX6GT	IK	DYLJVOXRWLXDIG-VQBNBCTGSA-N
DMEX6GT	IU	2-[[5-[2,6-bis(tritritiomethoxy)phenyl]-1-(7-chloroquinolin-4-yl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
DMEX6GT	DE	Discovery agent

DM8K6VF	ID	DM8K6VF
DM8K6VF	DN	[3H]mesulergine
DM8K6VF	HS	Investigative
DM8K6VF	SN	[3H]mesulergine; AC1L1HDA; GTPL232; SCHEMBL11890532
DM8K6VF	DT	Small molecular drug
DM8K6VF	PC	4081
DM8K6VF	MW	361.5
DM8K6VF	FM	C19H27N3O2S
DM8K6VF	IC	InChI=1S/C19H27N3O2S/c1-20(2)25(23,24)12-13-8-16-15-6-5-7-17-19(15)14(11-22(17)4)9-18(16)21(3)10-13/h5-7,11,13,16,18H,8-10,12H2,1-4H3
DM8K6VF	CS	CN1CC(CC2C1CC3=CN(C4=CC=CC2=C34)C)CS(=O)(=O)N(C)C
DM8K6VF	IK	WYCMFCPHWDZHMR-UHFFFAOYSA-N
DM8K6VF	IU	1-(4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinolin-9-yl)-N,N-dimethylmethanesulfonamide
DM8K6VF	DE	Discovery agent

DMONI13	ID	DMONI13
DMONI13	DN	[3H]methoxymethyl-MTEP
DMONI13	HS	Investigative
DMONI13	SN	3-(Methoxymethyl)-5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; Pyridine, 3-(methoxymethyl)-5-[(2-methyl-4-thiazolyl)ethynyl]-; CHEMBL1169453; 3-(methoxymethyl)-5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; methoxymethyl-MTEP; 524924-75-2; [3H]-methoxymethyl-MTEP; CHEMBL420533; GTPL5394; GTPL3345; SCHEMBL5652003; CTK1E4453; DTXSID90438611; AWDRAHDWMICWJM-UHFFFAOYSA-N; BDBM50366853; 3-Methoxymethyl-5-(2-methyl-thiazol-4-ylethynyl)-pyridine; 3-(2-Methyl-4-thiazolylethynyl)-5-(methoxymethyl)pyridine;  [3H]-methoxymethyl-MTEP
DMONI13	DT	Small molecular drug
DMONI13	PC	10354477
DMONI13	MW	244.31
DMONI13	FM	C13H12N2OS
DMONI13	IC	InChI=1S/C13H12N2OS/c1-10-15-13(9-17-10)4-3-11-5-12(8-16-2)7-14-6-11/h5-7,9H,8H2,1-2H3
DMONI13	CS	CC1=NC(=CS1)C#CC2=CN=CC(=C2)COC
DMONI13	IK	AWDRAHDWMICWJM-UHFFFAOYSA-N
DMONI13	IU	4-[2-[5-(methoxymethyl)pyridin-3-yl]ethynyl]-2-methyl-1,3-thiazole
DMONI13	CA	CAS 524924-75-2
DMONI13	DE	Discovery agent

DMZ2R1O	ID	DMZ2R1O
DMZ2R1O	DN	[3H]methoxy-PEPy
DMZ2R1O	HS	Investigative
DMZ2R1O	SN	CHEMBL1169452; [3H]methoxy-PEPy; GTPL6425; SCHEMBL14573621
DMZ2R1O	DT	Small molecular drug
DMZ2R1O	PC	10910934
DMZ2R1O	MW	216.25
DMZ2R1O	FM	C13H10N2O
DMZ2R1O	IC	InChI=1S/C13H10N2O/c1-16-13-8-11(9-14-10-13)5-6-12-4-2-3-7-15-12/h2-4,7-10H,1H3/i1T3
DMZ2R1O	CS	[3H]C([3H])([3H])OC1=CN=CC(=C1)C#CC2=CC=CC=N2
DMZ2R1O	IK	VRTFKUFTEWQHDD-RLXJOQACSA-N
DMZ2R1O	IU	3-(2-pyridin-2-ylethynyl)-5-(tritritiomethoxy)pyridine
DMZ2R1O	CA	CAS 524924-80-9
DMZ2R1O	DE	Discovery agent

DMYWGCS	ID	DMYWGCS
DMYWGCS	DN	[3H]methyllycaconitine
DMYWGCS	HS	Investigative
DMYWGCS	SN	21019-30-7; MLK; 2byr; [(1S,2R,3R,4S,5R,6S,8R,9S,10S,13S,16S,17R,18S)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7721^{2,5}0^{1,10}0^{3,8}0^{13,17}]nonadecan-13-yl]methyl 2-[(3S)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate; GTPL3980; GTPL4005; ZINC24707797; BRD-K43192255-048-03-6; [(1beta,5alpha,6alpha,8alpha,9alpha,13alpha,14beta,16alpha)-20-ethyl-7,8-dihydroxy-1,6,14,16-tetramethoxyaconitan-4-yl]methyl
DMYWGCS	DT	Small molecular drug
DMYWGCS	PC	5288811
DMYWGCS	MW	682.8
DMYWGCS	FM	C37H50N2O10
DMYWGCS	IC	InChI=1S/C37H50N2O10/c1-7-38-17-34(18-49-32(42)20-10-8-9-11-23(20)39-26(40)14-19(2)31(39)41)13-12-25(46-4)36-22-15-21-24(45-3)16-35(43,27(22)28(21)47-5)37(44,33(36)38)30(48-6)29(34)36/h8-11,19,21-22,24-25,27-30,33,43-44H,7,12-18H2,1-6H3/t19-,21+,22+,24-,25-,27+,28-,29+,30-,33-,34-,35+,36-,37+/m0/s1
DMYWGCS	CS	CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@]([C@H]31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N8C(=O)C[C@@H](C8=O)C
DMYWGCS	IK	XLTANAWLDBYGFU-VTLKBQQISA-N
DMYWGCS	IU	[(1S,2R,3R,4S,5R,6S,8R,9S,10S,13S,16S,17R,18S)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-13-yl]methyl 2-[(3S)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate
DMYWGCS	CA	CAS 1356-60-1
DMYWGCS	DE	Discovery agent

DMTSGOW	ID	DMTSGOW
DMTSGOW	DN	[3H]methyltrienolone
DMTSGOW	HS	Investigative
DMTSGOW	SN	Methyltrienolone; METRIBOLONE; 965-93-5; R1881; Metribolona; 17alpha-Methyltrienolone; Metribolonum; RU 1881; Ru-1881; R 1881; UNII-2C323EGI97; 17beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; 17-beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; R-1881; R1881 (synthetic androgen); CHEBI:379896; 2C323EGI97; (17BETA)-17-HYDROXY-17-METHYLESTRA-4,9,11-TRIEN-3-ONE; 17-methyloestra-4,9,11-trien-3-one,17beta-ol; 17-beta-hydroxy-17-methylestra-4,9,11-trien-3-one (9CI); Estra-4,9,11-trien-3-one, 17-hydroxy-17-methyl-, (17b)-;  [3H]-R1881; [3H]R1881
DMTSGOW	DT	Small molecular drug
DMTSGOW	PC	261000
DMTSGOW	MW	284.4
DMTSGOW	FM	C19H24O2
DMTSGOW	IC	InChI=1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1
DMTSGOW	CS	C[C@@]1(CC[C@@H]2[C@@]1(C=CC3=C4CCC(=O)C=C4CC[C@@H]23)C)O
DMTSGOW	IK	CCCIJQPRIXGQOE-XWSJACJDSA-N
DMTSGOW	IU	(8S,13S,14S,17S)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMTSGOW	CA	CAS 965-93-5
DMTSGOW	CB	CHEBI:379896
DMTSGOW	DE	Discovery agent

DM6HDKQ	ID	DM6HDKQ
DM6HDKQ	DN	[3H]mibolerone
DM6HDKQ	HS	Investigative
DM6HDKQ	SN	Mibolerone; MIBOLERONE; 3704/9/4; Miboleronum; Mibolerona; Cheque; U-10,997; UNII-9OGY4BOR8D; NSC 72260; 9OGY4BOR8D; U 10997; Matenon; Miboleron; 17-beta-Hydroxy-7-alpha,17-dimethylestr-4-en-3-one; CHEBI:34849; U-10997; 17beta-Hydroxy-7alpha,17-dimethylestr-4-en-3-one; (7alpha,17beta)-17-hydroxy-7,17-dimethylestr-4-en-3-one; 7alpha-17alpha-dimethyl-19-nortestosterone; CDB 904; Cheque (Veterinary)
DM6HDKQ	DT	Small molecular drug
DM6HDKQ	PC	251636
DM6HDKQ	MW	302.5
DM6HDKQ	FM	C20H30O2
DM6HDKQ	IC	InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1
DM6HDKQ	CS	C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C)O
DM6HDKQ	IK	PTQMMNYJKCSPET-OMHQDGTGSA-N
DM6HDKQ	IU	(7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,13,17-trimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DM6HDKQ	CA	CAS 3704-09-4
DM6HDKQ	CB	CHEBI:34849
DM6HDKQ	DE	Discovery agent

DMO89N0	ID	DMO89N0
DMO89N0	DN	[3H]MK-912
DMO89N0	HS	Investigative
DMO89N0	SN	[3H]L-657,743
DMO89N0	DT	Small molecular drug
DMO89N0	PC	91827340
DMO89N0	MW	345.5
DMO89N0	FM	C20H25N3O2
DMO89N0	IC	InChI=1S/C20H25N3O2/c1-21-11-8-20(22(2)19(21)24)9-12-23-10-7-15-14-5-3-4-6-17(14)25-18(15)16(23)13-20/h3-6,16H,7-13H2,1-2H3/t16-,20+/m1/s1/i1T3
DMO89N0	CS	[3H]C([3H])([3H])N1CC[C@@]2(CCN3CCC4=C([C@H]3C2)OC5=CC=CC=C45)N(C1=O)C
DMO89N0	IK	JRDUBBHIPPPSLP-NFEZXYISSA-N
DMO89N0	IU	(2R,12bR)-3'-methyl-1'-(tritritiomethyl)spiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,4'-1,3-diazinane]-2'-one
DMO89N0	DE	Discovery agent

DM0THB9	ID	DM0THB9
DM0THB9	DN	[3H]N5-methylfolate
DM0THB9	HS	Investigative
DM0THB9	DT	Small molecular drug
DM0THB9	PC	135402010
DM0THB9	MW	459.5
DM0THB9	FM	C20H25N7O6
DM0THB9	IC	InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)
DM0THB9	CS	CN1C(CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DM0THB9	IK	ZNOVTXRBGFNYRX-UHFFFAOYSA-N
DM0THB9	IU	2-[[4-[(2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DM0THB9	CA	CAS 134-35-0
DM0THB9	DE	Discovery agent

DMQW3A9	ID	DMQW3A9
DMQW3A9	DN	[3H]naltrindole
DMQW3A9	HS	Investigative
DMQW3A9	SN	Naltrindole; UNII-G167Z38QA4; 111555-53-4; CHEBI:81528; G167Z38QA4; [3H]-naltrindole; 17-Cyclopropylmethyl-6,7-dehydro-4,5-epoxy-3,14-dihydroxy-6,7,2',3'-indolomorphinan; CHEMBL1237164; (4bs,8r,8as,14br)-7-(Cyclopropylmethyl)-5,6,7,8,14,14b-Hexahydro-4,8-Methano[1]benzofuro[2,3-A]pyrido[4,3-B]carbazole-1,8a(9h)-Diol; 4,8-Methanobenzofuro(2,3-a)pyrido(4,3-b)carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (8R-(4bS*,8alpha,8abeta,14bbeta))-; NTI; EJ4;  [3H]-naltrindole
DMQW3A9	DT	Small molecular drug
DMQW3A9	PC	5497186
DMQW3A9	MW	414.5
DMQW3A9	FM	C26H26N2O3
DMQW3A9	IC	InChI=1S/C26H26N2O3/c29-19-8-7-15-11-20-26(30)12-17-16-3-1-2-4-18(16)27-22(17)24-25(26,21(15)23(19)31-24)9-10-28(20)13-14-5-6-14/h1-4,7-8,14,20,24,27,29-30H,5-6,9-13H2/t20-,24+,25+,26-/m1/s1
DMQW3A9	CS	C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8N6
DMQW3A9	IK	WIYUZYBFCWCCQJ-IFKAHUTRSA-N
DMQW3A9	IU	(1S,2S,13R,21R)-22-(cyclopropylmethyl)-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol
DMQW3A9	CA	CAS 111555-53-4
DMQW3A9	CB	CHEBI:81528
DMQW3A9	DE	Discovery agent

DMAO9SH	ID	DMAO9SH
DMAO9SH	DN	[3H]NECA
DMAO9SH	HS	Investigative
DMAO9SH	SN	5'-N-Ethylcarboxamidoadenosine; NECA; 35920-39-9; Adenosine-5'-(N-ethylcarboxamide); N-ethyl-5'-carboxamidoadenosine; 1-(6-Amino-9H-purin-9-yl)-1-deoxy-N-ethyl-beta-D-ribofuranuronamide; N-ETHYL-5'-CARBOXAMIDO ADENOSINE; MLS000069759; CHEMBL464859; CHEBI:73284; 5'-N-ETHYLCARBOXAMIDO-ADENOSINE; SMR000058759; N-Ethylcarboxamidoadenosine; 5'-N(Sup 6)-Ethylcarboxamidoadenosine; (2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide;  [3H]adenosine-5'-(N-ethylcarboxamide)
DMAO9SH	DT	Small molecular drug
DMAO9SH	PC	448222
DMAO9SH	MW	308.29
DMAO9SH	FM	C12H16N6O4
DMAO9SH	IC	InChI=1S/C12H16N6O4/c1-2-14-11(21)8-6(19)7(20)12(22-8)18-4-17-5-9(13)15-3-16-10(5)18/h3-4,6-8,12,19-20H,2H2,1H3,(H,14,21)(H2,13,15,16)/t6-,7+,8-,12+/m0/s1
DMAO9SH	CS	CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMAO9SH	IK	JADDQZYHOWSFJD-FLNNQWSLSA-N
DMAO9SH	IU	(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
DMAO9SH	CA	CAS 35920-39-9
DMAO9SH	CB	CHEBI:73284
DMAO9SH	DE	Discovery agent

DM0163O	ID	DM0163O
DM0163O	DN	[3H]nelivaptan
DM0163O	HS	Investigative
DM0163O	SN	[3H]-SSR149415; [3H]SSR149415
DM0163O	DT	Small molecular drug
DM0163O	PC	70692936
DM0163O	MW	642.2
DM0163O	FM	C30H32ClN3O8S
DM0163O	IC	InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1/i3T3,5T3
DM0163O	CS	[3H]C([3H])([3H])OC1=CC(=C(C=C1)S(=O)(=O)N2C3=C(C=C(C=C3)Cl)[C@](C2=O)(C4=CC=CC=C4OC)N5C[C@@H](C[C@H]5C(=O)N(C)C)O)OC([3H])([3H])[3H]
DM0163O	IK	NJXZWIIMWNEOGJ-KGKCFUOPSA-N
DM0163O	IU	(2S,4R)-1-[(3R)-1-[2,4-bis(tritritiomethoxy)phenyl]sulfonyl-5-chloro-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide
DM0163O	DE	Discovery agent

DM6PO49	ID	DM6PO49
DM6PO49	DN	[3H]NFPS
DM6PO49	HS	Investigative
DM6PO49	SN	405225-21-0; CHEMBL26512; A1-01880; N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine; n-[3-([1,1-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-n-methylglycine; 2-((3-([1,1'-Biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl)(methyl)amino)acetic acid; [3H]-NFPS; AC1NSKCW; SCHEMBL427134; GTPL4620; GTPL4619; CTK8E8383; DTXSID30415522; MolPort-023-276-580; KS-000000NE; BCP21210; BCP17140; ( inverted exclamation
DM6PO49	DT	Small molecular drug
DM6PO49	PC	5311283
DM6PO49	MW	393.4
DM6PO49	FM	C24H24FNO3
DM6PO49	IC	InChI=1S/C24H24FNO3/c1-26(17-24(27)28)16-15-23(20-7-11-21(25)12-8-20)29-22-13-9-19(10-14-22)18-5-3-2-4-6-18/h2-14,23H,15-17H2,1H3,(H,27,28)
DM6PO49	CS	CN(CCC(C1=CC=C(C=C1)F)OC2=CC=C(C=C2)C3=CC=CC=C3)CC(=O)O
DM6PO49	IK	FDORQEIHOKEJNX-UHFFFAOYSA-N
DM6PO49	IU	2-[[3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid
DM6PO49	CA	CAS 405225-21-0
DM6PO49	DE	Discovery agent

DM9E2YI	ID	DM9E2YI
DM9E2YI	DN	[3H]nicotine
DM9E2YI	HS	Investigative
DM9E2YI	SN	3-(1-methylpyrrolidin-2-yl)pyridine; 22083-74-5; Nikotin; (R,S)-Nicotine; Black Leaf 40; Pyridine, 3-(1-methyl-2-pyrrolidinyl)-; Black leaf; Nicotine alkaloid; Nicotin; Nicocide; Tendust; (RS)-Nicotine; Nico-dust; Emo-nik; Nico-Fume; Mach-Nic; Nic-Sal; Nicotina; Nikotyna; CHEMBL440464; (+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine; NSC5065; SNICXCGAKADSCV-UHFFFAOYSA-N; BRN 0082111; 3-(1-Methyl-2-pyrrolidinyl)pyridine
DM9E2YI	DT	Small molecular drug
DM9E2YI	PC	942
DM9E2YI	MW	162.23
DM9E2YI	FM	C10H14N2
DM9E2YI	IC	InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3
DM9E2YI	CS	CN1CCCC1C2=CN=CC=C2
DM9E2YI	IK	SNICXCGAKADSCV-UHFFFAOYSA-N
DM9E2YI	IU	3-(1-methylpyrrolidin-2-yl)pyridine
DM9E2YI	CA	CAS 22083-74-5
DM9E2YI	CB	CHEBI:18723
DM9E2YI	DE	Discovery agent

DMS3WNG	ID	DMS3WNG
DMS3WNG	DN	[3H]nisoxetine
DMS3WNG	HS	Investigative
DMS3WNG	SN	[3H]-nisoxetine
DMS3WNG	DT	Small molecular drug
DMS3WNG	PC	53323310
DMS3WNG	MW	277.38
DMS3WNG	FM	C17H21NO2
DMS3WNG	IC	InChI=1S/C17H21NO2/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2/h3-11,15,18H,12-13H2,1-2H3/i1T3
DMS3WNG	CS	[3H]C([3H])([3H])NCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC
DMS3WNG	IK	ITJNARMNRKSWTA-RLXJOQACSA-N
DMS3WNG	IU	3-(2-methoxyphenoxy)-3-phenyl-N-(tritritiomethyl)propan-1-amine
DMS3WNG	DE	Discovery agent

DM5TDFQ	ID	DM5TDFQ
DM5TDFQ	DN	[3H]nitrobenzylmercaptopurine ribonucleoside
DM5TDFQ	HS	Investigative
DM5TDFQ	SN	[3H]NBTI; [3H]-NBTI; (2S,3R,4S,5R)-2-(6-hydroxy-9H-purin-9-yl)-5-(hydroxymethyl)-2-{[(2-nitrophenyl)methyl]sulfanyl}oxolane-3,4-diol; [3H]NBMPR; SCHEMBL290700; GTPL4511
DM5TDFQ	DT	Small molecular drug
DM5TDFQ	PC	135796589
DM5TDFQ	MW	435.4
DM5TDFQ	FM	C17H17N5O7S
DM5TDFQ	IC	InChI=1S/C17H17N5O7S/c23-5-11-13(24)14(25)17(29-11,21-8-20-12-15(21)18-7-19-16(12)26)30-6-9-3-1-2-4-10(9)22(27)28/h1-4,7-8,11,13-14,23-25H,5-6H2,(H,18,19,26)/t11-,13-,14-,17+/m1/s1
DM5TDFQ	CS	C1=CC=C(C(=C1)CS[C@@]2([C@@H]([C@@H]([C@H](O2)CO)O)O)N3C=NC4=C3N=CNC4=O)[N+](=O)[O-]
DM5TDFQ	IK	NVQXRTPYOZKYMZ-GDLHICMESA-N
DM5TDFQ	IU	9-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2-nitrophenyl)methylsulfanyl]oxolan-2-yl]-1H-purin-6-one
DM5TDFQ	DE	Discovery agent

DMG1TIV	ID	DMG1TIV
DMG1TIV	DN	[3H]NLX-112
DMG1TIV	HS	Investigative
DMG1TIV	SN	[3H]F13640
DMG1TIV	DT	Small molecular drug
DMG1TIV	PC	9865384
DMG1TIV	MW	393.9
DMG1TIV	FM	C20H22ClF2N3O
DMG1TIV	IC	InChI=1S/C20H22ClF2N3O/c1-14-2-4-16(25-11-14)12-24-13-20(23)6-8-26(9-7-20)19(27)15-3-5-18(22)17(21)10-15/h2-5,10-11,24H,6-9,12-13H2,1H3
DMG1TIV	CS	CC1=CN=C(C=C1)CNCC2(CCN(CC2)C(=O)C3=CC(=C(C=C3)F)Cl)F
DMG1TIV	IK	PKZXLMVXBZICTF-UHFFFAOYSA-N
DMG1TIV	IU	(3-chloro-4-fluorophenyl)-[4-fluoro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone
DMG1TIV	CA	CAS 208110-64-9
DMG1TIV	DE	Discovery agent

DM5176Y	ID	DM5176Y
DM5176Y	DN	[3H]N-methylspiperone
DM5176Y	HS	Investigative
DM5176Y	SN	3-N-Methylspiperone; N-Methylspiperone; N-Methylspiroperidol; 87539-19-3; UNII-5U54JM2T8G; 5U54JM2T8G; CHEMBL267932; 8-[4-(4-fluorophenyl)-4-oxobutyl]-3-methyl-1-phenyl-1,3,8-triazaspiro[45]decan-4-one; 8-(4-(4-Fluorophenyl)-4-oxobutyl)-3-methyl-1-phenyl-1,3,8-triazaspiro(45)decan-4-one; 1,3,8-Triazaspiro(45)decan-4-one, 8-(4-(4-fluorophenyl)-4-oxobutyl)-3-methyl-1-phenyl-; C24H28FN3O2; [3H]methylspiperone; Mespiperone;  [3H]methylspiperone; N-METHYLSPIPERONE
DM5176Y	DT	Small molecular drug
DM5176Y	PC	119146
DM5176Y	MW	409.5
DM5176Y	FM	C24H28FN3O2
DM5176Y	IC	InChI=1S/C24H28FN3O2/c1-26-18-28(21-6-3-2-4-7-21)24(23(26)30)13-16-27(17-14-24)15-5-8-22(29)19-9-11-20(25)12-10-19/h2-4,6-7,9-12H,5,8,13-18H2,1H3
DM5176Y	CS	CN1CN(C2(C1=O)CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4
DM5176Y	IK	QHJLPOSPWKZACG-UHFFFAOYSA-N
DM5176Y	IU	8-[4-(4-fluorophenyl)-4-oxobutyl]-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DM5176Y	CA	CAS 87539-19-3
DM5176Y	DE	Discovery agent

DMX4RJ8	ID	DMX4RJ8
DMX4RJ8	DN	[3H]N-methyl-SSR504734
DMX4RJ8	HS	Investigative
DMX4RJ8	SN	2-Chloro-N-[(S)-[(2S)-1-methylpiperidin-2-yl](phenyl)methyl]-3-(trifluoromethyl)benzamide; CHEMBL1939495; N-methyl-SSR504734; 2-chloro-N-[(S)-[(2S)-1-methylpiperidin-2-yl](phenyl)methyl]-3-(trifluoromethyl)benzamide; [3H]-N-methyl-SSR504734; SCHEMBL4245201; GTPL4603; GTPL4604;  [3H]-N-methyl-SSR504734
DMX4RJ8	DT	Small molecular drug
DMX4RJ8	PC	11704260
DMX4RJ8	MW	410.9
DMX4RJ8	FM	C21H22ClF3N2O
DMX4RJ8	IC	InChI=1S/C21H22ClF3N2O/c1-27-13-6-5-12-17(27)19(14-8-3-2-4-9-14)26-20(28)15-10-7-11-16(18(15)22)21(23,24)25/h2-4,7-11,17,19H,5-6,12-13H2,1H3,(H,26,28)/t17-,19-/m0/s1
DMX4RJ8	CS	CN1CCCC[C@H]1[C@H](C2=CC=CC=C2)NC(=O)C3=C(C(=CC=C3)C(F)(F)F)Cl
DMX4RJ8	IK	XPXKFXNVIAOBEI-HKUYNNGSSA-N
DMX4RJ8	IU	2-chloro-N-[(S)-[(2S)-1-methylpiperidin-2-yl]-phenylmethyl]-3-(trifluoromethyl)benzamide
DMX4RJ8	DE	Discovery agent

DM4BY5J	ID	DM4BY5J
DM4BY5J	DN	[3H]OSIP339391
DM4BY5J	HS	Investigative
DM4BY5J	SN	MIUCZFWBCFZKEU-UHFFFAOYSA-N; OSIP-339391; UCS15A; CHEMBL485862; N-[2-[[2-phenyl-6-[4-(3-phenylpropyl)piperazine-1-carbonyl]-7H-pyrrolo[3,2-e]pyrimidin-4-yl]amino]ethyl]acetamide; AC1NSJVQ; GTPL454; GTPL450; SCHEMBL2550652; OSIP339391; BDBM50268107; L000728; N-[2-[[2-phenyl-6-[4-(3-phenylpropyl)piperazine-1-carbonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]ethyl]acetamide; N-(2-{2-phenyl-6-[4-(3-phenylpropyl)-piperazine-1-carbonyl]-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino}ethyl)acetamide
DM4BY5J	DT	Small molecular drug
DM4BY5J	PC	5311041
DM4BY5J	MW	525.6
DM4BY5J	FM	C30H35N7O2
DM4BY5J	IC	InChI=1S/C30H35N7O2/c1-22(38)31-14-15-32-28-25-21-26(33-29(25)35-27(34-28)24-12-6-3-7-13-24)30(39)37-19-17-36(18-20-37)16-8-11-23-9-4-2-5-10-23/h2-7,9-10,12-13,21H,8,11,14-20H2,1H3,(H,31,38)(H2,32,33,34,35)
DM4BY5J	CS	CC(=O)NCCNC1=NC(=NC2=C1C=C(N2)C(=O)N3CCN(CC3)CCCC4=CC=CC=C4)C5=CC=CC=C5
DM4BY5J	IK	MIUCZFWBCFZKEU-UHFFFAOYSA-N
DM4BY5J	IU	N-[2-[[2-phenyl-6-[4-(3-phenylpropyl)piperazine-1-carbonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]ethyl]acetamide
DM4BY5J	DE	Discovery agent

DM5L7D3	ID	DM5L7D3
DM5L7D3	DN	[3H]oxotremorine-M
DM5L7D3	HS	Investigative
DM5L7D3	SN	Oxotremorine M; oxotremorine-M; CHEBI:38322; N,N,N-trimethyl-4-(2-oxopyrrolidin-1-yl)but-2-yn-1-aminium; 63939-65-1; trimethyl-[4-(2-oxopyrrolidin-1-yl)but-2-ynyl]azanium; N,N,N-Trimethyl-4-(2-oxo-1-pyrrolidinyl)-2-butyn-1-aminium; 2-Butyn-1-aminium, N,N,N-trimethyl-4-(2-oxo-1-pyrrolidinyl)-; CHEMBL23957; Tocris-1067; Spectrum_001982; OXO-M; Lopac-O-100; AC1L1ILG; AC1Q6FK0; Lopac0_000954; GTPL303; KBioSS_002548; CHEMBL44674; DivK1c_000379; SCHEMBL4542695; GTPL8595; KBio2_005107; KBio2_002539; KBio1_000379
DM5L7D3	DT	Small molecular drug
DM5L7D3	PC	4629
DM5L7D3	MW	195.28
DM5L7D3	FM	C11H19N2O+
DM5L7D3	IC	InChI=1S/C11H19N2O/c1-13(2,3)10-5-4-8-12-9-6-7-11(12)14/h6-10H2,1-3H3/q+1
DM5L7D3	CS	C[N+](C)(C)CC#CCN1CCCC1=O
DM5L7D3	IK	CANZROMYQDHYHR-UHFFFAOYSA-N
DM5L7D3	IU	trimethyl-[4-(2-oxopyrrolidin-1-yl)but-2-ynyl]azanium
DM5L7D3	CA	CAS 63939-65-1
DM5L7D3	CB	CHEBI:38322
DM5L7D3	DE	Discovery agent

DMK46C7	ID	DMK46C7
DMK46C7	DN	[3H]PBC-264
DMK46C7	HS	Investigative
DMK46C7	SN	[3H]propionyl-BC-264; [3H]-Propionyl-BC264; [3H]-Propionyl-BC-264
DMK46C7	DT	Small molecular drug
DMK46C7	PC	5748434
DMK46C7	MW	1072.2
DMK46C7	FM	C51H67N9O14S
DMK46C7	IC	InChI=1S/C51H67N9O14S/c1-5-8-18-37(52-4)46(65)57-41(28-45(63)64)47(66)56-39(25-31-15-11-10-12-16-31)49(68)60-50(69)40(27-33-29-53-36-19-14-13-17-35(33)36)58-51(70)42(61)30-54-43(20-9-6-2)59-48(67)38(55-44(62)7-3)26-32-21-23-34(24-22-32)74-75(71,72)73/h10-17,19,21-24,29,37-41,43,52-54H,5-9,18,20,25-28,30H2,1-4H3,(H,55,62)(H,56,66)(H,57,65)(H,58,70)(H,59,67)(H,63,64)(H,60,68,69)(H,71,72,73)/t37-,38-,39-,40-,41-,43-/m0/s1/i3T3,7T2
DMK46C7	CS	[3H]C([3H])([3H])C([3H])([3H])C(=O)N[C@@H](CC1=CC=C(C=C1)OS(=O)(=O)O)C(=O)N[C@@H](CCCC)NCC(=O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCC)NC
DMK46C7	IK	VNNMDTHCFFZSSJ-LWSGDBLMSA-N
DMK46C7	IU	(3S)-4-[[(2S)-1-[[(2S)-3-(1H-indol-3-yl)-2-[[2-oxo-3-[[(1S)-1-[[(2S)-2-(2,2,3,3,3-pentatritiopropanoylamino)-3-(4-sulfooxyphenyl)propanoyl]amino]pentyl]amino]propanoyl]amino]propanoyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-(methylamino)hexanoyl]amino]-4-oxobutanoic acid
DMK46C7	CA	CAS 125236-85-3
DMK46C7	DE	Discovery agent

DMWAT5S	ID	DMWAT5S
DMWAT5S	DN	[3H]PD140376
DMWAT5S	HS	Investigative
DMWAT5S	SN	[3H]PD 140376; [3H]-PD140,376
DMWAT5S	DT	Small molecular drug
DMWAT5S	PC	91827344
DMWAT5S	MW	576.7
DMWAT5S	FM	C33H40N4O5
DMWAT5S	IC	InChI=1S/C33H40N4O5/c1-33(17-24-18-35-28-5-3-2-4-27(24)28,31(40)36-26(16-29(38)39)15-19-6-8-25(34)9-7-19)37-32(41)42-30-22-11-20-10-21(13-22)14-23(30)12-20/h2-9,18,20-23,26,30,35H,10-17,34H2,1H3,(H,36,40)(H,37,41)(H,38,39)/t20?,21?,22?,23?,26-,30?,33+/m0/s1/i8T,9T
DMWAT5S	CS	[3H]C1=CC(=CC(=C1N)[3H])C[C@@H](CC(=O)O)NC(=O)[C@@](C)(CC2=CNC3=CC=CC=C32)NC(=O)OC4C5CC6CC(C5)CC4C6
DMWAT5S	IK	ADYHBZJCWPIGJS-CXVPADNPSA-N
DMWAT5S	IU	(3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-(4-amino-3,5-ditritiophenyl)butanoic acid
DMWAT5S	DE	Discovery agent

DMF4TWE	ID	DMF4TWE
DMF4TWE	DN	[3H]pentazocine
DMF4TWE	HS	Investigative
DMF4TWE	SN	(+)-[3H]-Pentazocine; [3H]-(+)-Pentazocine; CHEMBL2311194; [3H]pentazocine
DMF4TWE	DT	Small molecular drug
DMF4TWE	PC	71717297
DMF4TWE	MW	289.4
DMF4TWE	FM	C19H27NO
DMF4TWE	IC	InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m1/s1/i6T,12T
DMF4TWE	CS	[3H]C1=CC2=C(C(=C1O)[3H])[C@]3(CCN([C@@H](C2)[C@H]3C)CC=C(C)C)C
DMF4TWE	IK	VOKSWYLNZZRQPF-BXKNQVALSA-N
DMF4TWE	IU	(1S,9S,13S)-1,13-dimethyl-10-(3-methylbut-2-enyl)-3,5-ditritio-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMF4TWE	DE	Discovery agent

DMPE1B2	ID	DMPE1B2
DMPE1B2	DN	[3H]PGF2alpha
DMPE1B2	HS	Investigative
DMPE1B2	SN	[3H]dinoprost; [3H]prostaglandin F2alpha
DMPE1B2	DT	Small molecular drug
DMPE1B2	PC	10832988
DMPE1B2	MW	370.5
DMPE1B2	FM	C20H34O5
DMPE1B2	IC	InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1/i4T,7T,12T,15T,16T,17T,18T,19T
DMPE1B2	CS	[3H]/C(=C(\\[3H])/C[C@]1([C@@](C[C@@]([C@]1([3H])/C=C(\\[3H])/[C@]([3H])(CCCCC)O)([3H])O)([3H])O)[3H])/CCCC(=O)O
DMPE1B2	IK	PXGPLTODNUVGFL-WEMOGKSOSA-N
DMPE1B2	IU	(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-2,3-ditritiooct-1-enyl]-1,2,3,5-tetratritiocyclopentyl]-5,6-ditritiohept-5-enoic acid
DMPE1B2	DE	Discovery agent

DMAMD5H	ID	DMAMD5H
DMAMD5H	DN	[3H]pirenzepine
DMAMD5H	HS	Investigative
DMAMD5H	SN	[3H]PZ
DMAMD5H	DT	Small molecular drug
DMAMD5H	PC	53325462
DMAMD5H	MW	357.4
DMAMD5H	FM	C19H21N5O2
DMAMD5H	IC	InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)/i1T3
DMAMD5H	CS	[3H]C([3H])([3H])N1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMAMD5H	IK	RMHMFHUVIITRHF-RLXJOQACSA-N
DMAMD5H	IU	11-[2-[4-(tritritiomethyl)piperazin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMAMD5H	DE	Discovery agent

DM2LA9X	ID	DM2LA9X
DM2LA9X	DN	[3H]p-MPPF
DM2LA9X	HS	Investigative
DM2LA9X	SN	155204-26-5; p-MPPF; MPPF; CHEMBL286607; UNII-81KHI46E5L; 81KHI46E5L; 4-fluoro-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylbenzamide; 4-Fluoro-N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl)benzamide; 4-Fluoro-N-{2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-N-pyridin-2-yl-benzamide; [3H]p-MPPF; MPPF authentic; Lopac-M-226; GTPL81; AC1O7G4Q; Lopac0_000825; SCHEMBL4014204; CTK4C8576; DTXSID20424966; ZINC52542163; BDBM50035513; AKOS022184256; CCG-204909; FC-1062; NCGC00162265-01; NCGC00015641-03
DM2LA9X	DT	Small molecular drug
DM2LA9X	PC	6603915
DM2LA9X	MW	434.5
DM2LA9X	FM	C25H27FN4O2
DM2LA9X	IC	InChI=1S/C25H27FN4O2/c1-32-23-7-3-2-6-22(23)29-17-14-28(15-18-29)16-19-30(24-8-4-5-13-27-24)25(31)20-9-11-21(26)12-10-20/h2-13H,14-19H2,1H3
DM2LA9X	CS	COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4=CC=C(C=C4)F
DM2LA9X	IK	YJZYDPRMWYWYCG-UHFFFAOYSA-N
DM2LA9X	IU	4-fluoro-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylbenzamide
DM2LA9X	CA	CAS 155204-26-5
DM2LA9X	DE	Discovery agent

DMP98AQ	ID	DMP98AQ
DMP98AQ	DN	[3H]PSB-0413
DMP98AQ	HS	Investigative
DMP98AQ	SN	[3H]AR-C67085; [3H]AR-C67085MX
DMP98AQ	DT	Small molecular drug
DMP98AQ	PC	44405630
DMP98AQ	MW	658.3
DMP98AQ	FM	C14H22Cl2N5O12P3S
DMP98AQ	IC	InChI=1S/C14H22Cl2N5O12P3S/c1-2-3-37-13-19-10(17)7-11(20-13)21(5-18-7)12-9(23)8(22)6(32-12)4-31-36(29,30)33-35(27,28)14(15,16)34(24,25)26/h5-6,8-9,12,22-23H,2-4H2,1H3,(H,27,28)(H,29,30)(H2,17,19,20)(H2,24,25,26)/t6-,8-,9-,12-/m1/s1/i1T3,2T2
DMP98AQ	CS	[3H]C([3H])([3H])C([3H])([3H])CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)N
DMP98AQ	IK	ZLIAJZQKKBOFJR-WNJXVAICSA-N
DMP98AQ	IU	[[[[(2R,3S,4R,5R)-5-[6-amino-2-(2,2,3,3,3-pentatritiopropylsulfanyl)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-dichloromethyl]phosphonic acid
DMP98AQ	DE	Discovery agent

DMFDCJK	ID	DMFDCJK
DMFDCJK	DN	[3H]PSB-11
DMFDCJK	HS	Investigative
DMFDCJK	DT	Small molecular drug
DMFDCJK	PC	135921139
DMFDCJK	MW	295.34
DMFDCJK	FM	C16H17N5O
DMFDCJK	IC	InChI=1S/C16H17N5O/c1-3-11-9-21-15(17-11)12-14(20(2)16(21)22)19-13(18-12)10-7-5-4-6-8-10/h4-8,11,17H,3,9H2,1-2H3
DMFDCJK	CS	CCC1CN2C(=C3C(=NC(=N3)C4=CC=CC=C4)N(C2=O)C)N1
DMFDCJK	IK	XNWDEMWJNJVCBD-UHFFFAOYSA-N
DMFDCJK	IU	8-ethyl-4-methyl-2-phenyl-8,9-dihydro-7H-imidazo[2,1-f]purin-5-one
DMFDCJK	DE	Discovery agent

DMC1WHR	ID	DMC1WHR
DMC1WHR	DN	[3H]QNB
DMC1WHR	HS	Investigative
DMC1WHR	SN	3-Quinuclidinyl benzilate; 6581/6/2; 3-Chinuclidylbenzilate; 3-Quinuclidyl benzilate; 3-quinuclidinylbenzilate; 3-Quinuclidinol benzilate; Ro 2-3308; CHEMBL12980; Benzilic acid, 3-quinuclidinyl ester; (+/-)-QNB; NSC 173698; QNB; EA 2277; CS 4030; BZ; 1-Azabicyclo(222)octan-3-ol, benzilate; Buzz; Agent BZ; 1-azabicyclo[222]octan-3-yl 2-hydroxy-2,2-diphenylacetate; BZ [anticholinergic]; 4478-53-9; NSC170423; Benzilic acid, 3-quinuclidinyl ester, (+-)-; 3-quinuclidinyl-benzilate; [3H]quinuclidinylbenzilate; Benzeneacetic;  [3H]quinuclidinylbenzilate
DMC1WHR	DT	Small molecular drug
DMC1WHR	PC	23056
DMC1WHR	MW	337.4
DMC1WHR	FM	C21H23NO3
DMC1WHR	IC	InChI=1S/C21H23NO3/c23-20(25-19-15-22-13-11-16(19)12-14-22)21(24,17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-10,16,19,24H,11-15H2
DMC1WHR	CS	C1CN2CCC1C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMC1WHR	IK	HGMITUYOCPPQLE-UHFFFAOYSA-N
DMC1WHR	IU	1-azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2,2-diphenylacetate
DMC1WHR	CA	CAS 6581-06-2
DMC1WHR	DE	Discovery agent

DMDQBTX	ID	DMDQBTX
DMDQBTX	DN	[3H]quisqualate
DMDQBTX	HS	Investigative
DMDQBTX	SN	Quisqualic acid; QUISQUALIC ACID; Quisqualate; L-Quisqualic acid; 52809-07-1; (+)-Quisqualic acid; UNII-8OC22C1B99; C5H7N3O5; CHEBI:8734; CHEMBL279956; 8OC22C1B99; (2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid; 3-(3,5-Dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine; 2jbk; 1,2,4-Oxadiazolidine-2-propanoic acid, alpha-amino-3,5-dioxo-, (S)-; (S)-2-AMINO-3-(3,5-DIOXO-[1,2,4]OXADIAZOLIDIN-2-YL)-PROPIONIC ACID; 2or4; AC1ODZB5; (S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid; QUS; SR-01000075471; QUISQUALATE
DMDQBTX	DT	Small molecular drug
DMDQBTX	PC	40539
DMDQBTX	MW	189.13
DMDQBTX	FM	C5H7N3O5
DMDQBTX	IC	InChI=1S/C5H7N3O5/c6-2(3(9)10)1-8-4(11)7-5(12)13-8/h2H,1,6H2,(H,9,10)(H,7,11,12)/t2-/m0/s1
DMDQBTX	CS	C([C@@H](C(=O)O)N)N1C(=O)NC(=O)O1
DMDQBTX	IK	ASNFTDCKZKHJSW-REOHCLBHSA-N
DMDQBTX	IU	(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
DMDQBTX	CA	CAS 52809-07-1
DMDQBTX	CB	CHEBI:8734
DMDQBTX	DE	Discovery agent

DM21B46	ID	DM21B46
DM21B46	DN	[3H]ramosetron
DM21B46	HS	Investigative
DM21B46	SN	[3H]ramosetron
DM21B46	DT	Small molecular drug
DM21B46	PC	91827343
DM21B46	MW	285.36
DM21B46	FM	C17H17N3O
DM21B46	IC	InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1/i1T3
DM21B46	CS	[3H]C([3H])([3H])N1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
DM21B46	IK	NTHPAPBPFQJABD-WENCKANPSA-N
DM21B46	IU	[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]-[1-(tritritiomethyl)indol-3-yl]methanone
DM21B46	DE	Discovery agent

DMBQZ2H	ID	DMBQZ2H
DMBQZ2H	DN	[3H]rauwolscine
DMBQZ2H	HS	Investigative
DMBQZ2H	SN	Rauwolscine; alpha-Yohimbine; Mesoyohimbine; Isoyohimbine; Corynanthidine; 131-03-3; UNII-T4LJ7LU45W; Methyl (16beta,17alpha,20alpha)-17-hydroxyyohimban-16-carboxylate; T4LJ7LU45W; CHEMBL10347; CHEBI:48562; 17alpha-hydroxy-20alpha-yohimban-16beta-carboxylic acid methyl ester; NCGC00017260-05; methyl 17alpha-hydroxy-20alpha-yohimban-16beta-carboxylate; 17-alpha-Hydroxy-20-alpha-yohimban-16-beta-carboxylic acid methyl ester; EINECS 205-006-9; 20-alpha-Yohimban-16-beta-carboxylic acid, 17-alpha-hydroxy-, methyl ester
DMBQZ2H	DT	Small molecular drug
DMBQZ2H	PC	643606
DMBQZ2H	MW	354.4
DMBQZ2H	FM	C21H26N2O3
DMBQZ2H	IC	InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15+,17+,18+,19+/m1/s1
DMBQZ2H	CS	COC(=O)[C@@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O
DMBQZ2H	IK	BLGXFZZNTVWLAY-DIRVCLHFSA-N
DMBQZ2H	IU	methyl (1S,15S,18S,19S,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMBQZ2H	CA	CAS 131-03-3
DMBQZ2H	CB	CHEBI:48562
DMBQZ2H	DE	Discovery agent

DMFT0HU	ID	DMFT0HU
DMFT0HU	DN	[3H]resolvin D1
DMFT0HU	HS	Investigative
DMFT0HU	SN	OIWTWACQMDFHJG-LDOXQWQISA-N; RvD1; [3H]-RvD1; GTPL4356; GTPL3934; SCHEMBL13150511; (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic;  OIWTWACQMDFHJG-LDOXQWQISA-N; (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid; resolvin D1
DMFT0HU	DT	Small molecular drug
DMFT0HU	PC	73755062
DMFT0HU	MW	376.5
DMFT0HU	FM	C22H32O5
DMFT0HU	IC	InChI=1S/C22H32O5/c1-2-3-9-14-19(23)15-10-6-4-5-7-11-16-20(24)21(25)17-12-8-13-18-22(26)27/h3-12,15-16,19-21,23-25H,2,13-14,17-18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,12-8-,15-10+,16-11+/t19-,20-,21-/m0/s1
DMFT0HU	CS	CC/C=C\\C[C@@H](/C=C/C=C\\C=C\\C=C\\[C@@H]([C@H](C/C=C\\CCC(=O)O)O)O)O
DMFT0HU	IK	OIWTWACQMDFHJG-LDOXQWQISA-N
DMFT0HU	IU	(4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid
DMFT0HU	DE	Discovery agent

DMAMK3P	ID	DMAMK3P
DMAMK3P	DN	[3H]resolvin E1
DMAMK3P	HS	Investigative
DMAMK3P	SN	Resolvin E1; RvE1; 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid; UNII-GND3JH08JA; GND3JH08JA; 552830-51-0; resolvinE1; (5S,6Z,8E,10E,12R,14Z,16E,18R)-5,12,18-trihydroxyicosa-6,8,10,14,16-pentaenoic acid; 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-EPA; FA(20:5(OH3)); GTPL3333; SCHEMBL3321593; CHEBI:81559; ZINC56875015; LMFA03140003; DB13105; J2218407E; C18171; (5S,12R,18R)-trihydroxy-(6Z,8E,10E,14Z,16E)-eicosapentaenoic acid; (5S,12R,18R)-trihydroxy-(6Z,8E,10E,14Z,16E)-icosapentaenoic acid; [3H]RvE1; [(3)H]-labeled RvE1; resolvin E1
DMAMK3P	DT	Small molecular drug
DMAMK3P	PC	52921890
DMAMK3P	MW	350.4
DMAMK3P	FM	C20H30O5
DMAMK3P	IC	InChI=1S/C20H30O5/c1-2-17(21)11-8-5-9-14-18(22)12-6-3-4-7-13-19(23)15-10-16-20(24)25/h3-9,11-13,17-19,21-23H,2,10,14-16H2,1H3,(H,24,25)/b4-3+,9-5-,11-8+,12-6+,13-7-/t17-,18-,19+/m0/s1
DMAMK3P	CS	CC[C@@H](/C=C/C=C\\C[C@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O)O
DMAMK3P	IK	AOPOCGPBAIARAV-JJVMZPRHSA-N
DMAMK3P	IU	(5S,6Z,8E,10E,12R,14Z,16E,18S)-5,12,18-trihydroxyicosa-6,8,10,14,16-pentaenoic acid
DMAMK3P	CB	CHEBI:137038

DM5XSMN	ID	DM5XSMN
DM5XSMN	DN	[3H]Ro 63-0563
DM5XSMN	HS	Investigative
DM5XSMN	SN	4-Amino-N-[2,6-bis(methylamino)pyridin-4-yl]benzenesulfonamide; Ro-63-0563; Ro 63-0563; CHEMBL46071; 4-amino-N-[2,6-bis(methylamino)pyridin-4-yl]benzenesulfonamide; AC1NSM3I; GTPL275; SCHEMBL679027; GTPL3246; Ro630563; BDBM50090524; Ro-630563; L000518; 4-Amino-N-(2,6-diamino-pyridin-4-yl)-benzenesulfonamide; N-(2,6-bis(methylamino)pyridin-4-yl)-4-aminobenzenesulfonamide; 4-amino-N-(2,6 bis-methylamino-pyridin-4-yl)-benzene sulfonamide
DM5XSMN	DT	Small molecular drug
DM5XSMN	PC	5312144
DM5XSMN	MW	307.37
DM5XSMN	FM	C13H17N5O2S
DM5XSMN	IC	InChI=1S/C13H17N5O2S/c1-15-12-7-10(8-13(16-2)17-12)18-21(19,20)11-5-3-9(14)4-6-11/h3-8H,14H2,1-2H3,(H3,15,16,17,18)
DM5XSMN	CS	CNC1=CC(=CC(=N1)NC)NS(=O)(=O)C2=CC=C(C=C2)N
DM5XSMN	IK	PTFNKZLSFWJYFJ-UHFFFAOYSA-N
DM5XSMN	IU	4-amino-N-[2,6-bis(methylamino)pyridin-4-yl]benzenesulfonamide
DM5XSMN	DE	Discovery agent

DMMBWKL	ID	DMMBWKL
DMMBWKL	DN	[3H]Ro154513
DMMBWKL	HS	Investigative
DMMBWKL	SN	Ethyl 8-azido-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; Ro 15-4513; RO-154513; Ro15-4513; 91917-65-6; UNII-S5XGL82O5Y; S5XGL82O5Y; Ethyl-8-azido-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-1,4-benzodiazepine-3-carboxylate; ethyl 8-azido-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; Ethyl 8-azido-6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; Ethyl 8-azido-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate; Ro-154513
DMMBWKL	DT	Small molecular drug
DMMBWKL	PC	5081
DMMBWKL	MW	326.31
DMMBWKL	FM	C15H14N6O3
DMMBWKL	IC	InChI=1S/C15H14N6O3/c1-3-24-15(23)13-12-7-20(2)14(22)10-6-9(18-19-16)4-5-11(10)21(12)8-17-13/h4-6,8H,3,7H2,1-2H3
DMMBWKL	CS	CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)N=[N+]=[N-])C
DMMBWKL	IK	CFSOJZTUTOQNIA-UHFFFAOYSA-N
DMMBWKL	IU	ethyl 8-azido-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMMBWKL	CA	CAS 91917-65-6
DMMBWKL	CB	CHEBI:93452
DMMBWKL	DE	Discovery agent

DMK1TRG	ID	DMK1TRG
DMK1TRG	DN	[3H]robalzotan
DMK1TRG	HS	Investigative
DMK1TRG	SN	[3H]NAD-299; [3H]NAD 299
DMK1TRG	DT	Small molecular drug
DMK1TRG	PC	10591800
DMK1TRG	MW	320.4
DMK1TRG	FM	C18H23FN2O2
DMK1TRG	IC	InChI=1S/C18H23FN2O2/c19-16-8-7-14(18(20)22)15-9-13(10-23-17(15)16)21(11-3-1-4-11)12-5-2-6-12/h7-8,11-13H,1-6,9-10H2,(H2,20,22)/t13-/m1/s1/i7T
DMK1TRG	CS	[3H]C1=CC(=C2C(=C1C(=O)N)C[C@H](CO2)N(C3CCC3)C4CCC4)F
DMK1TRG	IK	MQTUXRKNJYPMCG-FZQCOGARSA-N
DMK1TRG	IU	(3R)-3-[di(cyclobutyl)amino]-8-fluoro-6-tritio-3,4-dihydro-2H-chromene-5-carboxamide
DMK1TRG	DE	Discovery agent

DM6IRN4	ID	DM6IRN4
DM6IRN4	DN	[3H]RX821002
DM6IRN4	HS	Investigative
DM6IRN4	SN	2-Methoxyidazoxan; RX-821002; RX 821002; 102575-24-6; RX821002; alpha-methoxyidazoxan; RX 821001; CHEMBL10332; CHEBI:73287; 2-(2,3-Dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; 1H-Imidazole, 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-; 2-[2-(2-methoxy-1,4-benzodioxanyl)]imidazoline; 2-(2-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; [3H]2-methoxyidazoxan; 2-(2-methoxy-3H-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; 2-ethoxy-idazoxan; PubChem2676; Spectrum_001808;  [3H]2-methoxyidazoxan
DM6IRN4	DT	Small molecular drug
DM6IRN4	PC	108094
DM6IRN4	MW	234.25
DM6IRN4	FM	C12H14N2O3
DM6IRN4	IC	InChI=1S/C12H14N2O3/c1-15-12(11-13-6-7-14-11)8-16-9-4-2-3-5-10(9)17-12/h2-5H,6-8H2,1H3,(H,13,14)
DM6IRN4	CS	COC1(COC2=CC=CC=C2O1)C3=NCCN3
DM6IRN4	IK	HQGWKNGAKBPTBX-UHFFFAOYSA-N
DM6IRN4	IU	2-(3-methoxy-2H-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole
DM6IRN4	CA	CAS 102575-24-6
DM6IRN4	CB	CHEBI:73287
DM6IRN4	DE	Discovery agent

DMJKWNY	ID	DMJKWNY
DMJKWNY	DN	[3H]RY80
DMJKWNY	HS	Investigative
DMJKWNY	SN	CHEMBL286594; ethyl 8-ethynyl-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; RY80; [3H]RY80; AC1NSKLC; SCHEMBL7454519; GTPL4364; BDBM25877; RY-80; PDSP2_001730; PDSP1_001747; RY-80, 1; LS-193636; ethyl 8-ethynyl-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; ethyl 12-ethynyl-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),3,5,10,12-pentaene-5-carboxylate
DMJKWNY	DT	Small molecular drug
DMJKWNY	PC	5311418
DMJKWNY	MW	309.32
DMJKWNY	FM	C17H15N3O3
DMJKWNY	IC	InChI=1S/C17H15N3O3/c1-4-11-6-7-13-12(8-11)16(21)19(3)9-14-15(17(22)23-5-2)18-10-20(13)14/h1,6-8,10H,5,9H2,2-3H3
DMJKWNY	CS	CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)C#C)C
DMJKWNY	IK	WDTNKNNGHGOKBH-UHFFFAOYSA-N
DMJKWNY	IU	ethyl 8-ethynyl-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMJKWNY	DE	Discovery agent

DM32IAB	ID	DM32IAB
DM32IAB	DN	[3H]S0139
DM32IAB	HS	Investigative
DM32IAB	SN	[3H]-S0139; [3H]S-0139
DM32IAB	DT	Small molecular drug
DM32IAB	PC	73755056
DM32IAB	MW	727.9
DM32IAB	FM	C43H53NO9-2
DM32IAB	IC	InChI=1S/C43H55NO9/c1-38(2)19-20-42(37(51)52)21-22-43(25-53-36(50)14-7-26-23-27(45)8-10-30(26)44-34(47)12-13-35(48)49)28(29(42)24-38)9-11-32-40(5)17-16-33(46)39(3,4)31(40)15-18-41(32,43)6/h7-10,12-14,23,29,31-32,45H,11,15-22,24-25H2,1-6H3,(H,44,47)(H,48,49)(H,51,52)/p-2/b13-12+,14-7+/t29-,31?,32?,40-,41+,42-,43-/m0/s1
DM32IAB	CS	C[C@]12CCC(=O)C(C1CC[C@@]3(C2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)[O-])COC(=O)/C=C/C6=C(C=CC(=C6)[O-])NC(=O)/C=C/C(=O)O)C)(C)C
DM32IAB	IK	NZCHLXQRTYIWRL-VDJOMVRUSA-L
DM32IAB	IU	(4aS,6aR,6bR,12aR,14bS)-6a-[[(E)-3-[2-[[(E)-3-carboxyprop-2-enoyl]amino]-5-oxidophenyl]prop-2-enoyl]oxymethyl]-2,2,6b,9,9,12a-hexamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-4a-carboxylate
DM32IAB	DE	Discovery agent

DMO9L38	ID	DMO9L38
DMO9L38	DN	[3H]SB-674042
DMO9L38	HS	Investigative
DMO9L38	SN	CHEMBL2413521; [3H]SB-674042; GTPL1706
DMO9L38	DT	Small molecular drug
DMO9L38	PC	73349109
DMO9L38	MW	452.5
DMO9L38	FM	C24H21FN4O2S
DMO9L38	IC	InChI=1S/C24H21FN4O2S/c1-15-26-21(22(32-15)18-11-5-6-12-19(18)25)24(30)29-13-7-10-17(29)14-20-27-28-23(31-20)16-8-3-2-4-9-16/h2-6,8-9,11-12,17H,7,10,13-14H2,1H3/t17-/m0/s1/i8T,9T
DMO9L38	CS	[3H]C1=C(C(=CC=C1)[3H])C2=NN=C(O2)C[C@@H]3CCCN3C(=O)C4=C(SC(=N4)C)C5=CC=CC=C5F
DMO9L38	IK	HYBZWVLPALMACV-JQGZANCBSA-N
DMO9L38	IU	[(2S)-2-[[5-(2,6-ditritiophenyl)-1,3,4-oxadiazol-2-yl]methyl]pyrrolidin-1-yl]-[5-(2-fluorophenyl)-2-methyl-1,3-thiazol-4-yl]methanone
DMO9L38	DE	Discovery agent

DMUS7EH	ID	DMUS7EH
DMUS7EH	DN	[3H]SB-733993
DMUS7EH	HS	Investigative
DMUS7EH	SN	[3H]-(2R)-3-[(2R,6S)-2,6-dimethylpiperidin-1-yl]-2-hydroxy-S-(naphthalen-1-yl)propane-1-sulfonamido ; [3H]-SB-733993
DMUS7EH	DT	Small molecular drug
DMUS7EH	PC	73755092
DMUS7EH	MW	378.5
DMUS7EH	FM	C20H28N2O3S
DMUS7EH	IC	InChI=1S/C20H28N2O3S/c1-15-7-5-8-16(2)22(15)14-18(23)13-21-26(24,25)20-12-6-10-17-9-3-4-11-19(17)20/h3-4,6,9-12,15-16,18,21,23H,5,7-8,13-14H2,1-2H3/t15-,16+,18-/m1/s1/i10T
DMUS7EH	CS	[3H]C1=CC=C(C2=CC=CC=C12)S(=O)(=O)NC[C@H](CN3[C@@H](CCC[C@@H]3C)C)O
DMUS7EH	IK	GJXFPIGLCXZHTN-LDHSEPLKSA-N
DMUS7EH	IU	N-[(2S)-3-[(2S,6R)-2,6-dimethylpiperidin-1-yl]-2-hydroxypropyl]-4-tritionaphthalene-1-sulfonamide
DMUS7EH	DE	Discovery agent

DM0MLU9	ID	DM0MLU9
DM0MLU9	DN	[3H]SNAP-7941
DM0MLU9	HS	Investigative
DM0MLU9	SN	387825-78-7; [3H]SNAP-7941; GTPL1318; ZINC65731246; KB-80596; methyl (6S)-6-(3,4-difluorophenyl)-4-(methoxymethyl)-2-oxo-1-[3-[4-[3-(propanoylamino)phenyl]piperidin-1-yl]propylcarbamoyl]-3,6-dihydropyrimidine-5-carboxylate
DM0MLU9	DT	Small molecular drug
DM0MLU9	PC	10121975
DM0MLU9	MW	627.7
DM0MLU9	FM	C32H39F2N5O6
DM0MLU9	IC	InChI=1S/C32H39F2N5O6/c1-4-27(40)36-23-8-5-7-21(17-23)20-11-15-38(16-12-20)14-6-13-35-31(42)39-29(22-9-10-24(33)25(34)18-22)28(30(41)45-3)26(19-44-2)37-32(39)43/h5,7-10,17-18,20,29H,4,6,11-16,19H2,1-3H3,(H,35,42)(H,36,40)(H,37,43)/t29-/m0/s1
DM0MLU9	CS	CCC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCNC(=O)N3[C@H](C(=C(NC3=O)COC)C(=O)OC)C4=CC(=C(C=C4)F)F
DM0MLU9	IK	PTSDBXLVMLZQHY-LJAQVGFWSA-N
DM0MLU9	IU	methyl (4S)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-3-[3-[4-[3-(propanoylamino)phenyl]piperidin-1-yl]propylcarbamoyl]-1,4-dihydropyrimidine-5-carboxylate
DM0MLU9	DE	Discovery agent

DMWHEV8	ID	DMWHEV8
DMWHEV8	DN	[3H]spiperone
DMWHEV8	HS	Investigative
DMWHEV8	SN	Spiperone; spiperone; Spiroperidol; Spiropitan; 749-02-0; Espiperona; Spiperonum; [3H]-spiperone; R 5147; Spiperonum [INN-Latin]; Espiperona [INN-Spanish]; E 525; UNII-4X6E73CJ0Q; NSC 170983; MLS000028615; Spiperone [USAN:INN:BAN:JAN]; 8-(3-(p-Fluorobenzoyl)propyl)-1-phenyl-1,3,8-triazaspiro(45)decan-4-one; 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[45]decan-4-one; 8-(3-p-Fluorobenzoyl-1-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decane; EINECS 212-024-0; BRN 0632204; SMR000058674;  [3H]-spiperone; SPIPERONE
DMWHEV8	DT	Small molecular drug
DMWHEV8	PC	5265
DMWHEV8	MW	395.5
DMWHEV8	FM	C23H26FN3O2
DMWHEV8	IC	InChI=1S/C23H26FN3O2/c24-19-10-8-18(9-11-19)21(28)7-4-14-26-15-12-23(13-16-26)22(29)25-17-27(23)20-5-2-1-3-6-20/h1-3,5-6,8-11H,4,7,12-17H2,(H,25,29)
DMWHEV8	CS	C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F
DMWHEV8	IK	DKGZKTPJOSAWFA-UHFFFAOYSA-N
DMWHEV8	IU	8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DMWHEV8	CA	CAS 749-02-0
DMWHEV8	CB	CHEBI:9233
DMWHEV8	DE	Discovery agent

DM0Y2SC	ID	DM0Y2SC
DM0Y2SC	DN	[3H]strychnine
DM0Y2SC	HS	Investigative
DM0Y2SC	SN	Strychnine; strychnine; 57-24-9; (-)-Strychnine; Strychnidin-10-one; Strychnin; UNII-H9Y79VD43J; Sanaseed; CHEBI:28973; Estricnina; Strychinos; Strychnos; Gopher-gitter; Gopher bait; Mouse-nots; Mole death; Boomer-rid; Mouse-rid; H9Y79VD43J; Mouse-tox; Kwik-kil; Hare-Rid; Dolco mouse cereal; Strychnin [German]; Stricnina [Italian]; Pied piper mouse seed; Caswell No 805; Strychnine [BSI:ISO]; RCRA waste number P108; (-)-Strychnine, 98%; HSDB 2001; NSC 5365; EINECS 200-319-7; UN1692; EPA Pesticide Chemical Code 076901; STRYCHNINE
DM0Y2SC	DT	Small molecular drug
DM0Y2SC	PC	441071
DM0Y2SC	MW	334.4
DM0Y2SC	FM	C21H22N2O2
DM0Y2SC	IC	InChI=1S/C21H22N2O2/c24-18-10-16-19-13-9-17-21(6-7-22(17)11-12(13)5-8-25-16)14-3-1-2-4-15(14)23(18)20(19)21/h1-5,13,16-17,19-20H,6-11H2/t13-,16-,17-,19-,20-,21+/m0/s1
DM0Y2SC	CS	C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75
DM0Y2SC	IK	QMGVPVSNSZLJIA-FVWCLLPLSA-N
DM0Y2SC	IU	(4aR,5aS,8aR,13aS,15aS,15bR)-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one
DM0Y2SC	CA	CAS 57-24-9
DM0Y2SC	CB	CHEBI:28973
DM0Y2SC	DE	Discovery agent

DM3MBGV	ID	DM3MBGV
DM3MBGV	DN	[3H]sumatriptan
DM3MBGV	HS	Investigative
DM3MBGV	SN	[3H]sumatriptan; GTPL119
DM3MBGV	DT	Small molecular drug
DM3MBGV	PC	53325948
DM3MBGV	MW	307.45
DM3MBGV	FM	C14H21N3O2S
DM3MBGV	IC	InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3/i2T3,3T3
DM3MBGV	CS	[3H]C([3H])([3H])N(CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)NC)C([3H])([3H])[3H]
DM3MBGV	IK	KQKPFRSPSRPDEB-KERYDJPLSA-N
DM3MBGV	IU	1-[3-[2-[bis(tritritiomethyl)amino]ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
DM3MBGV	DE	Discovery agent

DMSHW2E	ID	DMSHW2E
DMSHW2E	DN	[3H]thiamine
DMSHW2E	HS	Investigative
DMSHW2E	SN	thiamin; Aneurin; Antiberiberi factor; Thiadoxine; Betaxin; thiaminium; Vitaneuron; Biamine; Bequin; Bewon; Thiamine ion; thiamine(1+) ion; thiamine(1+); Clotiamina; Bethiazine; Vinothiam; Tiaminal; Thiaminal; Metabolin; Eskaphen; Bithiamin; Tiamidon; Thiavit; Benerva; Begiolan; Thiamol; Bivatin; Bevitine; Beatine; Slowten; Eskapen; Bevitex; Biuno; Berin; Bivita; Beuion; Bedome; Hybee; Apate drops; Lixa-beta; Vetalin S; Thiamin dichloride; [3H]-thiamine; [3H]vitamin B1
DMSHW2E	DT	Small molecular drug
DMSHW2E	PC	1130
DMSHW2E	MW	265.36
DMSHW2E	FM	C12H17N4OS+
DMSHW2E	IC	InChI=1S/C12H17N4OS/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15)/q+1
DMSHW2E	CS	CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO
DMSHW2E	IK	JZRWCGZRTZMZEH-UHFFFAOYSA-N
DMSHW2E	IU	2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol
DMSHW2E	CA	CAS 70-16-6
DMSHW2E	CB	CHEBI:18385
DMSHW2E	DE	Discovery agent

DM6RSZ9	ID	DM6RSZ9
DM6RSZ9	DN	[3H]U69593
DM6RSZ9	HS	Investigative
DM6RSZ9	SN	U-69593; U69593; 96744-75-1; U 69593; UNII-J5S4K6TKTG; U 69,593; J5S4K6TKTG; N-Methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)benzeneacetamide; CHEBI:73357; n-methyl-2-phenyl-n-[(5r,7s,8s)-7-(pyrrolidin-1-yl)-1-oxaspiro[45]dec-8-yl]acetamide; Benzeneacetamide, N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(45)dec-8-yl)-, (5alpha,7alpha,8beta)-(-)-; NCGC00163179-01; DSSTox_CID_26326; DSSTox_RID_81542; U69,593; DSSTox_GSID_46326; [3H]-U69593
DM6RSZ9	DT	Small molecular drug
DM6RSZ9	PC	105104
DM6RSZ9	MW	356.5
DM6RSZ9	FM	C22H32N2O2
DM6RSZ9	IC	InChI=1S/C22H32N2O2/c1-23(21(25)16-18-8-3-2-4-9-18)19-10-12-22(11-7-15-26-22)17-20(19)24-13-5-6-14-24/h2-4,8-9,19-20H,5-7,10-17H2,1H3/t19-,20-,22-/m0/s1
DM6RSZ9	CS	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC=CC=C4
DM6RSZ9	IK	PGZRDDYTKFZSFR-ONTIZHBOSA-N
DM6RSZ9	IU	N-methyl-2-phenyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
DM6RSZ9	CA	CAS 96744-75-1
DM6RSZ9	CB	CHEBI:73357
DM6RSZ9	DE	Discovery agent

DM3MK8S	ID	DM3MK8S
DM3MK8S	DN	[3H]vesamicol
DM3MK8S	HS	Investigative
DM3MK8S	SN	[3H]-vesamicol
DM3MK8S	DT	Small molecular drug
DM3MK8S	PC	54580503
DM3MK8S	MW	261.39
DM3MK8S	FM	C17H25NO
DM3MK8S	IC	InChI=1S/C17H25NO/c19-17-9-5-4-8-16(17)18-12-10-15(11-13-18)14-6-2-1-3-7-14/h1-3,6-7,15-17,19H,4-5,8-13H2/i19T
DM3MK8S	CS	[3H]OC1CCCCC1N2CCC(CC2)C3=CC=CC=C3
DM3MK8S	IK	YSSBJODGIYRAMI-SETVJMCQSA-N
DM3MK8S	IU	4-phenyl-1-(2-tritiooxycyclohexyl)piperidine
DM3MK8S	DE	Discovery agent

DMI8RU0	ID	DMI8RU0
DMI8RU0	DN	[3H]WIN35428
DMI8RU0	HS	Investigative
DMI8RU0	SN	beta-Cft; Win 35428; 2-Cmft; 50370-56-4; 2-CFT; WIN 35,428; 2-Carbomethoxy-3-(4-fluorophenyl)tropane; (3H)2-Carbomethoxy-3-(4-fluorophenyl)tropane; (1R,2S,3S,5S)-Methyl 3-(4-fluorophenyl)-8-methyl-8-azabicyclo[321]octane-2-carboxylate; 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane; WIN35428; methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[321]octane-2-carboxylate; [3H]WIN 35,428; (1R-(exo,exo))-3-(4-Fluorophenyl)-8-methyl-8-azabicyclo(321)octane-2-carboxylic acid, methyl ester;  [3H]-2beta-carboxymethy-3beta-(4-fluorophenyl)tropane ; [3H]-WIN35428 ; [3H]-beta-CFT; WIN_35428
DMI8RU0	DT	Small molecular drug
DMI8RU0	PC	105056
DMI8RU0	MW	277.33
DMI8RU0	FM	C16H20FNO2
DMI8RU0	IC	InChI=1S/C16H20FNO2/c1-18-12-7-8-14(18)15(16(19)20-2)13(9-12)10-3-5-11(17)6-4-10/h3-6,12-15H,7-9H2,1-2H3/t12-,13+,14+,15-/m0/s1
DMI8RU0	CS	CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC
DMI8RU0	IK	QUSLQENMLDRCTO-YJNKXOJESA-N
DMI8RU0	IU	methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
DMI8RU0	CA	CAS 50370-56-4
DMI8RU0	DE	Discovery agent

DM0TRAZ	ID	DM0TRAZ
DM0TRAZ	DN	[3H]WIN55212-2
DM0TRAZ	HS	Investigative
DM0TRAZ	SN	131513-18-3; (5-methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone; (5-Methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino-[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone; [5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](1-naphthyl)methanone; 134959-51-6; AC1Q5GBM; AC1L1KWZ; GTPL736; SCHEMBL3680086; CHEMBL283206; CTK4B9570; HQVHOQAKMCMIIM-UHFFFAOYSA-N
DM0TRAZ	DT	Small molecular drug
DM0TRAZ	PC	5689
DM0TRAZ	MW	426.5
DM0TRAZ	FM	C27H26N2O3
DM0TRAZ	IC	InChI=1S/C27H26N2O3/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28/h2-11,20H,12-17H2,1H3
DM0TRAZ	CS	CC1=C(C2=C3N1C(COC3=CC=C2)CN4CCOCC4)C(=O)C5=CC=CC6=CC=CC=C65
DM0TRAZ	IK	HQVHOQAKMCMIIM-UHFFFAOYSA-N
DM0TRAZ	IU	[2-methyl-11-(morpholin-4-ylmethyl)-9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraen-3-yl]-naphthalen-1-ylmethanone
DM0TRAZ	DE	Discovery agent

DMKU4YQ	ID	DMKU4YQ
DMKU4YQ	DN	[3H]ZM 241385
DMKU4YQ	HS	Investigative
DMKU4YQ	SN	[3H]-ZM241385
DMKU4YQ	DT	Small molecular drug
DMKU4YQ	PC	53316647
DMKU4YQ	MW	339.34
DMKU4YQ	FM	C16H15N7O2
DMKU4YQ	IC	InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22)/i5T
DMKU4YQ	CS	[3H]C1=CC(=CC=C1O)CCNC2=NC3=NC(=NN3C(=N2)N)C4=CC=CO4
DMKU4YQ	IK	PWTBZOIUWZOPFT-XHHURNKPSA-N
DMKU4YQ	IU	4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2-tritiophenol
DMKU4YQ	DE	Discovery agent

DMNCAE9	ID	DMNCAE9
DMNCAE9	DN	[4-(3-Adamantan-1-yl-ureido)-phenyl]-acetic acid
DMNCAE9	HS	Investigative
DMNCAE9	SN	CHEMBL478147; [4-(3-Adamantan-1-yl-ureido)-phenyl]-acetic acid; SCHEMBL12932182; BDBM50267207
DMNCAE9	DT	Small molecular drug
DMNCAE9	PC	44582486
DMNCAE9	MW	328.4
DMNCAE9	FM	C19H24N2O3
DMNCAE9	IC	InChI=1S/C19H24N2O3/c22-17(23)8-12-1-3-16(4-2-12)20-18(24)21-19-9-13-5-14(10-19)7-15(6-13)11-19/h1-4,13-15H,5-11H2,(H,22,23)(H2,20,21,24)
DMNCAE9	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=C(C=C4)CC(=O)O
DMNCAE9	IK	QDEKKGRIPYLLDK-UHFFFAOYSA-N
DMNCAE9	IU	2-[4-(1-adamantylcarbamoylamino)phenyl]acetic acid
DMNCAE9	DE	Discovery agent

DM7JSQL	ID	DM7JSQL
DM7JSQL	DN	[4',4''']-biflavone
DM7JSQL	HS	Investigative
DM7JSQL	SN	CHEMBL205219; [4'',4'''''']-biflavone; BDBM50183248
DM7JSQL	DT	Small molecular drug
DM7JSQL	PC	11962186
DM7JSQL	MW	442.5
DM7JSQL	FM	C30H18O4
DM7JSQL	IC	InChI=1S/C30H18O4/c31-25-17-29(33-27-7-3-1-5-23(25)27)21-13-9-19(10-14-21)20-11-15-22(16-12-20)30-18-26(32)24-6-2-4-8-28(24)34-30/h1-18H
DM7JSQL	CS	C1=CC=C2C(=C1)C(=O)C=C(O2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CC(=O)C6=CC=CC=C6O5
DM7JSQL	IK	HTPYEYLGDZAIRX-UHFFFAOYSA-N
DM7JSQL	IU	2-[4-[4-(4-oxochromen-2-yl)phenyl]phenyl]chromen-4-one
DM7JSQL	CA	CAS 1109-30-4
DM7JSQL	DE	Discovery agent

DM86Z4H	ID	DM86Z4H
DM86Z4H	DN	[4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix
DM86Z4H	HS	Investigative
DM86Z4H	SN	CHEMBL409044; [4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix
DM86Z4H	PC	16155593
DM86Z4H	MW	1768.4
DM86Z4H	FM	C88H119ClN18O19
DM86Z4H	IC	InChI=1S/C88H119ClN18O19/c1-53(2)44-68(78(112)99-67(17-10-11-35-93-54(3)4)86(120)107-37-13-18-75(107)85(119)95-55(5)77(90)111)100-80(114)71(47-59-24-31-66(32-25-59)98-87(91)121)102-82(116)72(48-58-22-29-65(30-23-58)97-76(110)33-38-124-40-42-126-43-41-125-39-36-94-88(122)106-123-7)104-84(118)74(52-108)105-83(117)73(50-61-14-12-34-92-51-61)103-81(115)70(46-57-20-27-64(89)28-21-57)101-79(113)69(96-56(6)109)49-60-19-26-62-15-8-9-16-63(62)45-60/h8-9,12,14-16,19-32,34,45,51,53-55,67-75,93,108H,10-11,13,17-18,33,35-44,46-50,52H2,1-7H3,(H2,90,111)(H,95,119)(H,96,109)(H,97,110)(H,99,112)(H,100,114)(H,101,113)(H,102,116)(H,103,115)(H,104,118)(H,105,117)(H3,91,98,121)(H2,94,106,122)/t55-,67+,68+,69-,70-,71-,72+,73-,74+,75+/m1/s1
DM86Z4H	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)CCOCCOCCOCCNC(=O)NOC)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM86Z4H	IK	UZNPTQUBATXHSV-POQOSWQFSA-N
DM86Z4H	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-[3-[2-[2-[2-(methoxycarbamoylamino)ethoxy]ethoxy]ethoxy]propanoylamino]phenyl]propanoyl]amino]-3-[4-(carbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM86Z4H	DE	Discovery agent

DM4IXJA	ID	DM4IXJA
DM4IXJA	DN	[4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix
DM4IXJA	HS	Investigative
DM4IXJA	SN	CHEMBL219532; [4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix
DM4IXJA	PC	16202050
DM4IXJA	MW	1651.3
DM4IXJA	FM	C84H112ClN17O16
DM4IXJA	IC	InChI=1S/C84H112ClN17O16/c1-8-117-39-40-118-38-36-90-84(116)94-63-32-25-56(26-33-63)45-69(78(110)98-68(44-55-23-30-62(31-24-55)93-83(87)115)76(108)96-65(41-50(2)3)74(106)95-64(18-11-12-35-89-51(4)5)82(114)102-37-14-19-72(102)81(113)91-52(6)73(86)105)100-80(112)71(49-103)101-79(111)70(47-58-15-13-34-88-48-58)99-77(109)67(43-54-21-28-61(85)29-22-54)97-75(107)66(92-53(7)104)46-57-20-27-59-16-9-10-17-60(59)42-57/h9-10,13,15-17,20-34,42,48,50-52,64-72,89,103H,8,11-12,14,18-19,35-41,43-47,49H2,1-7H3,(H2,86,105)(H,91,113)(H,92,104)(H,95,106)(H,96,108)(H,97,107)(H,98,110)(H,99,109)(H,100,112)(H,101,111)(H3,87,93,115)(H2,90,94,116)/t52-,64+,65+,66-,67-,68-,69+,70-,71+,72+/m1/s1
DM4IXJA	CS	CCOCCOCCNC(=O)NC1=CC=C(C=C1)C[C@@H](C(=O)N[C@H](CC2=CC=C(C=C2)NC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM4IXJA	IK	RTPDWFYCUSPDLA-CEUPRWEVSA-N
DM4IXJA	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-[2-(2-ethoxyethoxy)ethylcarbamoylamino]phenyl]propanoyl]amino]-3-[4-(carbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM4IXJA	DE	Discovery agent

DM57TIU	ID	DM57TIU
DM57TIU	DN	[4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix
DM57TIU	HS	Investigative
DM57TIU	SN	CHEMBL219061; [4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix
DM57TIU	PC	16156445
DM57TIU	MW	1595.2
DM57TIU	FM	C80H104ClN17O16
DM57TIU	IC	InChI=1S/C80H104ClN17O16/c1-46(2)37-61(70(102)89-60(18-11-12-35-84-47(3)4)78(110)98-36-14-19-68(98)77(109)85-48(5)69(82)101)90-72(104)64(40-51-23-30-58(31-24-51)87-79(111)96-113-7)92-74(106)65(41-52-25-32-59(33-26-52)88-80(112)97-114-8)94-76(108)67(45-99)95-75(107)66(43-54-15-13-34-83-44-54)93-73(105)63(39-50-21-28-57(81)29-22-50)91-71(103)62(86-49(6)100)42-53-20-27-55-16-9-10-17-56(55)38-53/h9-10,13,15-17,20-34,38,44,46-48,60-68,84,99H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,109)(H,86,100)(H,89,102)(H,90,104)(H,91,103)(H,92,106)(H,93,105)(H,94,108)(H,95,107)(H2,87,96,111)(H2,88,97,112)/t48-,60+,61+,62-,63-,64-,65+,66-,67+,68+/m1/s1
DM57TIU	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)NOC)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)NOC)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM57TIU	IK	MBXSPUXZEDANHS-KHEFCMSFSA-N
DM57TIU	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-(methoxycarbamoylamino)phenyl]propanoyl]amino]-3-[4-(methoxycarbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM57TIU	DE	Discovery agent

DM6C8K1	ID	DM6C8K1
DM6C8K1	DN	[4Aph(CO-NH-OCH3)5]degarelix
DM6C8K1	HS	Investigative
DM6C8K1	SN	CHEMBL407661; [4Aph(CO-NH-OCH3)5]degarelix
DM6C8K1	PC	16155587
DM6C8K1	MW	1565.2
DM6C8K1	FM	C79H102ClN17O15
DM6C8K1	IC	InChI=1S/C79H102ClN17O15/c1-45(2)36-60(69(101)89-59(17-10-11-34-84-46(3)4)77(109)97-35-13-18-67(97)76(108)85-47(5)68(81)100)90-71(103)63(39-50-22-29-57(30-23-50)87-78(82)110)92-73(105)64(40-51-24-31-58(32-25-51)88-79(111)96-112-7)94-75(107)66(44-98)95-74(106)65(42-53-14-12-33-83-43-53)93-72(104)62(38-49-20-27-56(80)28-21-49)91-70(102)61(86-48(6)99)41-52-19-26-54-15-8-9-16-55(54)37-52/h8-9,12,14-16,19-33,37,43,45-47,59-67,84,98H,10-11,13,17-18,34-36,38-42,44H2,1-7H3,(H2,81,100)(H,85,108)(H,86,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,107)(H,95,106)(H3,82,87,110)(H2,88,96,111)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+/m1/s1
DM6C8K1	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)NOC)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM6C8K1	IK	UXIBYNMMLXYZBN-PQAUVRRKSA-N
DM6C8K1	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-(methoxycarbamoylamino)phenyl]propanoyl]amino]-3-[4-(carbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM6C8K1	DE	Discovery agent

DMFMB31	ID	DMFMB31
DMFMB31	DN	[4Aph(CO-NH-OH)5]degarelix
DMFMB31	HS	Investigative
DMFMB31	SN	CHEMBL429527; [4Aph(CO-NH-OH)5]degarelix
DMFMB31	PC	16156634
DMFMB31	MW	1551.2
DMFMB31	FM	C78H100ClN17O15
DMFMB31	IC	InChI=1S/C78H100ClN17O15/c1-44(2)35-59(68(100)88-58(16-9-10-33-83-45(3)4)76(108)96-34-12-17-66(96)75(107)84-46(5)67(80)99)89-70(102)62(38-49-21-28-56(29-22-49)86-77(81)109)91-72(104)63(39-50-23-30-57(31-24-50)87-78(110)95-111)93-74(106)65(43-97)94-73(105)64(41-52-13-11-32-82-42-52)92-71(103)61(37-48-19-26-55(79)27-20-48)90-69(101)60(85-47(6)98)40-51-18-25-53-14-7-8-15-54(53)36-51/h7-8,11,13-15,18-32,36,42,44-46,58-66,83,97,111H,9-10,12,16-17,33-35,37-41,43H2,1-6H3,(H2,80,99)(H,84,107)(H,85,98)(H,88,100)(H,89,102)(H,90,101)(H,91,104)(H,92,103)(H,93,106)(H,94,105)(H3,81,86,109)(H2,87,95,110)/t46-,58+,59+,60-,61-,62-,63+,64-,65+,66+/m1/s1
DMFMB31	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)NO)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMFMB31	IK	WHBXYDIDMRDUDF-ZVSGBDDQSA-N
DMFMB31	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-(hydroxycarbamoylamino)phenyl]propanoyl]amino]-3-[4-(carbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMFMB31	DE	Discovery agent

DMA9PW7	ID	DMA9PW7
DMA9PW7	DN	[6,3''']biflavone
DMA9PW7	HS	Investigative
DMA9PW7	SN	CHEMBL383336; [6,3'''''']biflavone; BDBM50183246
DMA9PW7	DT	Small molecular drug
DMA9PW7	PC	23661736
DMA9PW7	MW	442.5
DMA9PW7	FM	C30H18O4
DMA9PW7	IC	InChI=1S/C30H18O4/c31-25-17-30(33-27-12-5-4-11-23(25)27)22-10-6-9-20(15-22)21-13-14-28-24(16-21)26(32)18-29(34-28)19-7-2-1-3-8-19/h1-18H
DMA9PW7	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC(=CC=C4)C5=CC(=O)C6=CC=CC=C6O5
DMA9PW7	IK	ATBFVHXRFRVXOQ-UHFFFAOYSA-N
DMA9PW7	IU	6-[3-(4-oxochromen-2-yl)phenyl]-2-phenylchromen-4-one
DMA9PW7	DE	Discovery agent

DMVOX4L	ID	DMVOX4L
DMVOX4L	DN	[6,4''']biflavone
DMVOX4L	HS	Investigative
DMVOX4L	SN	CHEMBL205326; [6,4'''''']biflavone; BDBM50183245
DMVOX4L	DT	Small molecular drug
DMVOX4L	PC	44410408
DMVOX4L	MW	442.5
DMVOX4L	FM	C30H18O4
DMVOX4L	IC	InChI=1S/C30H18O4/c31-25-17-30(33-27-9-5-4-8-23(25)27)21-12-10-19(11-13-21)22-14-15-28-24(16-22)26(32)18-29(34-28)20-6-2-1-3-7-20/h1-18H
DMVOX4L	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=C(C=C4)C5=CC(=O)C6=CC=CC=C6O5
DMVOX4L	IK	YQQFWTHRAHFRMC-UHFFFAOYSA-N
DMVOX4L	IU	6-[4-(4-oxochromen-2-yl)phenyl]-2-phenylchromen-4-one
DMVOX4L	DE	Discovery agent

DMUCAXT	ID	DMUCAXT
DMUCAXT	DN	[Aib7]OT
DMUCAXT	HS	Investigative
DMUCAXT	SN	CHEMBL395430; [Aib7]OT
DMUCAXT	DT	Small molecular drug
DMUCAXT	PC	16737793
DMUCAXT	MW	995.2
DMUCAXT	FM	C42H66N12O12S2
DMUCAXT	IC	InChI=1S/C42H66N12O12S2/c1-7-21(4)33-40(65)48-25(12-13-30(44)56)36(61)50-28(16-31(45)57)37(62)51-29(39(64)54-42(5,6)41(66)52-26(14-20(2)3)35(60)47-17-32(46)58)19-68-67-18-24(43)34(59)49-27(38(63)53-33)15-22-8-10-23(55)11-9-22/h8-11,20-21,24-29,33,55H,7,12-19,43H2,1-6H3,(H2,44,56)(H2,45,57)(H2,46,58)(H,47,60)(H,48,65)(H,49,59)(H,50,61)(H,51,62)(H,52,66)(H,53,63)(H,54,64)/t21-,24-,25-,26-,27-,28-,29-,33-/m0/s1
DMUCAXT	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMUCAXT	IK	VQOHKFLFXMHMBH-LQGOSMBMSA-N
DMUCAXT	IU	(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-N-[1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMUCAXT	DE	Discovery agent

DMHJEQL	ID	DMHJEQL
DMHJEQL	DN	[Asp6,Lys10]N/OFQ(1-13)NH2
DMHJEQL	HS	Investigative
DMHJEQL	SN	CHEMBL507269; [Asp6,Lys10]N/OFQ(1-13)NH2
DMHJEQL	PC	25084509
DMHJEQL	MW	1480.7
DMHJEQL	FM	C66H109N23O16
DMHJEQL	IC	InChI=1S/C66H109N23O16/c1-37(55(96)84-46(25-16-30-76-65(72)73)59(100)83-43(54(71)95)22-10-13-27-67)80-58(99)44(23-11-14-28-68)86-60(101)45(24-12-15-29-69)87-61(102)47(26-17-31-77-66(74)75)85-56(97)38(2)81-62(103)49(34-52(93)94)88-64(105)53(39(3)90)89-63(104)48(33-41-20-8-5-9-21-41)82-51(92)36-78-50(91)35-79-57(98)42(70)32-40-18-6-4-7-19-40/h4-9,18-21,37-39,42-49,53,90H,10-17,22-36,67-70H2,1-3H3,(H2,71,95)(H,78,91)(H,79,98)(H,80,99)(H,81,103)(H,82,92)(H,83,100)(H,84,96)(H,85,97)(H,86,101)(H,87,102)(H,88,105)(H,89,104)(H,93,94)(H4,72,73,76)(H4,74,75,77)/t37-,38-,39+,42-,43-,44-,45-,46-,47-,48-,49-,53-/m0/s1
DMHJEQL	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMHJEQL	IK	WSFUYLTYXFNGET-WYNMOEERSA-N
DMHJEQL	IU	(3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoic acid
DMHJEQL	DE	Discovery agent

DMN70VT	ID	DMN70VT
DMN70VT	DN	[Au(CN)2]-
DMN70VT	HS	Investigative
DMN70VT	PC	446142
DMN70VT	MW	249
DMN70VT	FM	C2AuN2-
DMN70VT	IC	InChI=1S/2CN.Au/c2*1-2;/q2*-1;+1
DMN70VT	CS	[C-]#N.[C-]#N.[Au+]
DMN70VT	IK	QGIPNVHDSSGMAA-UHFFFAOYSA-N
DMN70VT	IU	gold(1+);dicyanide
DMN70VT	CA	CAS 14950-87-9
DMN70VT	CB	CHEBI:49491
DMN70VT	DE	Discovery agent

DMB78GP	ID	DMB78GP
DMB78GP	DN	[Bpa1]AngII
DMB78GP	HS	Investigative
DMB78GP	SN	CHEMBL1076612; [Bpa1]AngII
DMB78GP	PC	46880540
DMB78GP	MW	1182.4
DMB78GP	FM	C62H79N13O11
DMB78GP	IC	InChI=1S/C62H79N13O11/c1-5-37(4)52(59(83)71-48(33-43-34-66-35-68-43)60(84)75-29-13-19-50(75)57(81)72-49(61(85)86)32-38-14-8-6-9-15-38)74-56(80)47(31-40-22-26-44(76)27-23-40)70-58(82)51(36(2)3)73-55(79)46(18-12-28-67-62(64)65)69-54(78)45(63)30-39-20-24-42(25-21-39)53(77)41-16-10-7-11-17-41/h6-11,14-17,20-27,34-37,45-52,76H,5,12-13,18-19,28-33,63H2,1-4H3,(H,66,68)(H,69,78)(H,70,82)(H,71,83)(H,72,81)(H,73,79)(H,74,80)(H,85,86)(H4,64,65,67)/t37-,45-,46-,47-,48-,49-,50-,51-,52-/m0/s1
DMB78GP	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CC=C(C=C5)C(=O)C6=CC=CC=C6)N
DMB78GP	IK	SSPYRQDCPZQEBX-LWJOARRHSA-N
DMB78GP	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-benzoylphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMB78GP	DE	Discovery agent

DMV6NP1	ID	DMV6NP1
DMV6NP1	DN	[Cu(CN)2]-
DMV6NP1	HS	Investigative
DMV6NP1	PC	60167587
DMV6NP1	MW	115.58
DMV6NP1	FM	C2CuN2-
DMV6NP1	IC	InChI=1S/2CN.Cu/c2*1-2;/q2*-1;+1
DMV6NP1	CS	[C-]#N.[C-]#N.[Cu+]
DMV6NP1	IK	FKUKJMKUXQUDHB-UHFFFAOYSA-N
DMV6NP1	IU	copper(1+);dicyanide
DMV6NP1	CA	CAS 18973-62-1
DMV6NP1	DE	Discovery agent

DMQ8CD3	ID	DMQ8CD3
DMQ8CD3	DN	[Cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid
DMQ8CD3	HS	Investigative
DMQ8CD3	SN	CHEMBL324703; [Cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid; BDBM50020839
DMQ8CD3	DT	Small molecular drug
DMQ8CD3	PC	44340887
DMQ8CD3	MW	292.29
DMQ8CD3	FM	C14H16N2O5
DMQ8CD3	IC	InChI=1S/C14H16N2O5/c17-13(18)9-15(10-5-1-2-6-10)14(19)11-7-3-4-8-12(11)16(20)21/h3-4,7-8,10H,1-2,5-6,9H2,(H,17,18)
DMQ8CD3	CS	C1CCC(C1)N(CC(=O)O)C(=O)C2=CC=CC=C2[N+](=O)[O-]
DMQ8CD3	IK	QLSOVPLMYSMOSO-UHFFFAOYSA-N
DMQ8CD3	IU	2-[cyclopentyl-(2-nitrobenzoyl)amino]acetic acid
DMQ8CD3	DE	Discovery agent

DMWFGBC	ID	DMWFGBC
DMWFGBC	DN	[Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMWFGBC	HS	Investigative
DMWFGBC	PC	16201387
DMWFGBC	MW	1760.1
DMWFGBC	FM	C80H118N28O14S2
DMWFGBC	IC	InChI=1S/C80H118N28O14S2/c1-3-13-55(69(115)101-59(21-11-33-95-79(89)90)73(119)105-61(65(83)111)35-43-23-27-47(109)28-24-43)99-71(117)57(19-9-31-93-77(85)86)103-75(121)63(37-45-39-97-53-17-7-5-15-49(45)53)107-67(113)51(81)41-123-124-42-52(82)68(114)108-64(38-46-40-98-54-18-8-6-16-50(46)54)76(122)104-58(20-10-32-94-78(87)88)72(118)100-56(14-4-2)70(116)102-60(22-12-34-96-80(91)92)74(120)106-62(66(84)112)36-44-25-29-48(110)30-26-44/h5-8,15-18,23-30,39-40,51-52,55-64,97-98,109-110H,3-4,9-14,19-22,31-38,41-42,81-82H2,1-2H3,(H2,83,111)(H2,84,112)(H,99,117)(H,100,118)(H,101,115)(H,102,116)(H,103,121)(H,104,122)(H,105,119)(H,106,120)(H,107,113)(H,108,114)(H4,85,86,93)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t51-,52-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1
DMWFGBC	CS	CCC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N)N)N
DMWFGBC	IK	QUIHYEFPGVPGCQ-HCHGDIHTSA-N
DMWFGBC	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-[[(2R)-2-amino-3-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]pentanoyl]amino]-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-5-carbamimidamidopentanamide
DMWFGBC	DE	Discovery agent

DMFKTJ8	ID	DMFKTJ8
DMFKTJ8	DN	[D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix
DMFKTJ8	HS	Investigative
DMFKTJ8	SN	CHEMBL438239; [D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix
DMFKTJ8	PC	16156573
DMFKTJ8	MW	1748.4
DMFKTJ8	FM	C88H115ClN18O18
DMFKTJ8	IC	InChI=1S/C88H115ClN18O18/c1-8-124-39-40-125-38-36-93-87(122)97-64-32-25-57(26-33-64)44-69(80(115)99-66(41-51(2)3)78(113)98-65(18-11-12-35-92-52(4)5)86(121)107-37-14-19-74(107)85(120)94-53(6)76(90)111)101-82(117)70(45-56-23-30-63(31-24-56)96-77(112)72-48-75(110)106-88(123)105-72)103-84(119)73(50-108)104-83(118)71(47-59-15-13-34-91-49-59)102-81(116)68(43-55-21-28-62(89)29-22-55)100-79(114)67(95-54(7)109)46-58-20-27-60-16-9-10-17-61(60)42-58/h9-10,13,15-17,20-34,42,49,51-53,65-74,92,108H,8,11-12,14,18-19,35-41,43-48,50H2,1-7H3,(H2,90,111)(H,94,120)(H,95,109)(H,96,112)(H,98,113)(H,99,115)(H,100,114)(H,101,117)(H,102,116)(H,103,119)(H,104,118)(H2,93,97,122)(H2,105,106,110,123)/t53-,65+,66+,67-,68-,69-,70+,71-,72+,73+,74+/m1/s1
DMFKTJ8	CS	CCOCCOCCNC(=O)NC1=CC=C(C=C1)C[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DMFKTJ8	IK	LXDBVFUKTKJYLL-UODKESISSA-N
DMFKTJ8	IU	(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-[2-(2-ethoxyethoxy)ethylcarbamoylamino]phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMFKTJ8	DE	Discovery agent

DMR7TEQ	ID	DMR7TEQ
DMR7TEQ	DN	[D-4Aph(CO-NH-OCH3)6]degarelix
DMR7TEQ	HS	Investigative
DMR7TEQ	SN	CHEMBL435141; [D-4Aph(CO-NH-OCH3)6]degarelix
DMR7TEQ	PC	16155709
DMR7TEQ	MW	1662.3
DMR7TEQ	FM	C83H105ClN18O17
DMR7TEQ	IC	InChI=1S/C83H105ClN18O17/c1-46(2)36-61(73(108)92-60(17-10-11-34-87-47(3)4)81(116)102-35-13-18-69(102)80(115)88-48(5)71(85)106)93-75(110)64(39-52-24-31-59(32-25-52)91-83(118)101-119-7)95-77(112)65(40-51-22-29-58(30-23-51)90-72(107)67-43-70(105)100-82(117)99-67)97-79(114)68(45-103)98-78(113)66(42-54-14-12-33-86-44-54)96-76(111)63(38-50-20-27-57(84)28-21-50)94-74(109)62(89-49(6)104)41-53-19-26-55-15-8-9-16-56(55)37-53/h8-9,12,14-16,19-33,37,44,46-48,60-69,87,103H,10-11,13,17-18,34-36,38-43,45H2,1-7H3,(H2,85,106)(H,88,115)(H,89,104)(H,90,107)(H,92,108)(H,93,110)(H,94,109)(H,95,112)(H,96,111)(H,97,114)(H,98,113)(H2,91,101,118)(H2,99,100,105,117)/t48-,60+,61+,62-,63-,64-,65+,66-,67+,68+,69+/m1/s1
DMR7TEQ	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)NOC)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DMR7TEQ	IK	GSLYUOBUEBSTPA-BWBLBVTNSA-N
DMR7TEQ	IU	(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(methoxycarbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMR7TEQ	DE	Discovery agent

DMMVIX7	ID	DMMVIX7
DMMVIX7	DN	[D-4Aph(CO-NH-OH)6]degarelix
DMMVIX7	HS	Investigative
DMMVIX7	SN	CHEMBL427976; [D-4Aph(CO-NH-OH)6]degarelix
DMMVIX7	PC	16156699
DMMVIX7	MW	1648.3
DMMVIX7	FM	C82H103ClN18O17
DMMVIX7	IC	InChI=1S/C82H103ClN18O17/c1-45(2)35-60(72(107)91-59(16-9-10-33-86-46(3)4)80(115)101-34-12-17-68(101)79(114)87-47(5)70(84)105)92-74(109)63(38-51-23-30-58(31-24-51)90-82(117)100-118)94-76(111)64(39-50-21-28-57(29-22-50)89-71(106)66-42-69(104)99-81(116)98-66)96-78(113)67(44-102)97-77(112)65(41-53-13-11-32-85-43-53)95-75(110)62(37-49-19-26-56(83)27-20-49)93-73(108)61(88-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,86,102,118H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,87,114)(H,88,103)(H,89,106)(H,91,107)(H,92,109)(H,93,108)(H,94,111)(H,95,110)(H,96,113)(H,97,112)(H2,90,100,117)(H2,98,99,104,116)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1
DMMVIX7	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)NO)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DMMVIX7	IK	ZYLCANLEJMKHHC-XYAYPHGZSA-N
DMMVIX7	IU	(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(hydroxycarbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMMVIX7	DE	Discovery agent

DM18ZNJ	ID	DM18ZNJ
DM18ZNJ	DN	[D-Ala2]Met-enkephalinamide
DM18ZNJ	HS	Investigative
DM18ZNJ	SN	CHEMBL287480
DM18ZNJ	DT	Small molecular drug
DM18ZNJ	PC	44280469
DM18ZNJ	MW	586.7
DM18ZNJ	FM	C28H38N6O6S
DM18ZNJ	IC	InChI=1S/C28H38N6O6S/c1-17(32-27(39)21(29)14-19-8-10-20(35)11-9-19)26(38)31-16-24(36)33-23(15-18-6-4-3-5-7-18)28(40)34-22(25(30)37)12-13-41-2/h3-11,17,21-23,35H,12-16,29H2,1-2H3,(H2,30,37)(H,31,38)(H,32,39)(H,33,36)(H,34,40)/t17-,21-,22-,23-/m0/s1
DM18ZNJ	CS	C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DM18ZNJ	IK	ANZXICRKKYOVMY-ZMVGRULKSA-N
DM18ZNJ	IU	(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide
DM18ZNJ	DE	Discovery agent

DMSGW51	ID	DMSGW51
DMSGW51	DN	[D-Asp7,Lys10]N/OFQ(1-13)NH2
DMSGW51	HS	Investigative
DMSGW51	SN	CHEMBL507653; [D-Asp7,Lys10]N/OFQ(1-13)NH2
DMSGW51	PC	25084510
DMSGW51	MW	1466.7
DMSGW51	FM	C65H107N23O16
DMSGW51	IC	InChI=1S/C65H107N23O16/c1-37(55(96)84-45(24-15-29-75-64(71)72)58(99)83-42(54(70)95)21-9-12-26-66)80-57(98)43(22-10-13-27-67)85-59(100)44(23-11-14-28-68)86-60(101)46(25-16-30-76-65(73)74)87-61(102)48(33-52(93)94)82-51(92)36-79-63(104)53(38(2)89)88-62(103)47(32-40-19-7-4-8-20-40)81-50(91)35-77-49(90)34-78-56(97)41(69)31-39-17-5-3-6-18-39/h3-8,17-20,37-38,41-48,53,89H,9-16,21-36,66-69H2,1-2H3,(H2,70,95)(H,77,90)(H,78,97)(H,79,104)(H,80,98)(H,81,91)(H,82,92)(H,83,99)(H,84,96)(H,85,100)(H,86,101)(H,87,102)(H,88,103)(H,93,94)(H4,71,72,75)(H4,73,74,76)/t37-,38+,41-,42-,43-,44-,45-,46-,47-,48+,53-/m0/s1
DMSGW51	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMSGW51	IK	RZSPAJQVMVZCJC-YRLNDPIWSA-N
DMSGW51	IU	(3R)-4-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMSGW51	DE	Discovery agent

DM23GCK	ID	DM23GCK
DM23GCK	DN	[Dcp1]Dyn A(1-11)-NH2
DM23GCK	HS	Investigative
DM23GCK	SN	CHEMBL412997; [Dcp1]Dyn A(1-11)-NH2
DM23GCK	PC	44415282
DM23GCK	MW	1564.9
DM23GCK	FM	C75H117N23O14
DM23GCK	IC	InChI=1S/C75H117N23O14/c1-7-43(4)62(71(111)95-54(22-15-33-87-75(83)84)72(112)98-34-16-23-58(98)70(110)92-51(64(78)104)19-11-12-30-76)97-67(107)53(21-14-32-86-74(81)82)93-66(106)52(20-13-31-85-73(79)80)94-68(108)55(35-42(2)3)96-69(109)57(38-46-17-9-8-10-18-46)91-61(102)41-88-60(101)40-89-65(105)56(39-47-24-26-49(99)27-25-47)90-59(100)29-28-50-44(5)36-48(63(77)103)37-45(50)6/h8-10,17-18,24-27,36-37,42-43,51-58,62,99H,7,11-16,19-23,28-35,38-41,76H2,1-6H3,(H2,77,103)(H2,78,104)(H,88,101)(H,89,105)(H,90,100)(H,91,102)(H,92,110)(H,93,106)(H,94,108)(H,95,111)(H,96,109)(H,97,107)(H4,79,80,85)(H4,81,82,86)(H4,83,84,87)/t43-,51-,52-,53-,54-,55-,56-,57-,58-,62-/m0/s1
DM23GCK	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)CCC4=C(C=C(C=C4C)C(=O)N)C
DM23GCK	IK	YPSMIMXFFGKHRC-DJQAJQEISA-N
DM23GCK	IU	(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[3-(4-carbamoyl-2,6-dimethylphenyl)propanoylamino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2S)-1,6-diamino-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
DM23GCK	DE	Discovery agent

DMEZKX0	ID	DMEZKX0
DMEZKX0	DN	[D-Dab(CO-NH-OCH3)3]degarelix
DMEZKX0	HS	Investigative
DMEZKX0	SN	CHEMBL411337; [D-Dab(CO-NH-OCH3)3]degarelix
DMEZKX0	PC	16155098
DMEZKX0	MW	1657.3
DMEZKX0	FM	C80H106ClN19O18
DMEZKX0	IC	InChI=1S/C80H106ClN19O18/c1-43(2)35-58(70(107)91-57(15-10-11-32-84-44(3)4)77(114)100-34-12-16-65(100)76(113)86-45(5)67(82)104)92-73(110)61(38-49-22-29-55(30-23-49)89-78(83)115)94-74(111)62(39-48-20-27-54(28-21-48)88-69(106)63-41-66(103)98-80(117)97-63)95-75(112)64(42-101)96-68(105)56(31-33-85-79(116)99-118-7)90-72(109)60(37-47-18-25-53(81)26-19-47)93-71(108)59(87-46(6)102)40-50-17-24-51-13-8-9-14-52(51)36-50/h8-9,13-14,17-30,36,43-45,56-65,84,101H,10-12,15-16,31-35,37-42H2,1-7H3,(H2,82,104)(H,86,113)(H,87,102)(H,88,106)(H,90,109)(H,91,107)(H,92,110)(H,93,108)(H,94,111)(H,95,112)(H,96,105)(H3,83,89,115)(H2,85,99,116)(H2,97,98,103,117)/t45-,56-,57+,58+,59-,60-,61-,62+,63+,64+,65+/m1/s1
DMEZKX0	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CCNC(=O)NOC)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMEZKX0	IK	DBLYRXMPBSXJDM-GOZSSGHVSA-N
DMEZKX0	IU	(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-4-(methoxycarbamoylamino)butanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMEZKX0	DE	Discovery agent

DMRVPN1	ID	DMRVPN1
DMRVPN1	DN	[D-Dab(CO-NH-OH)3]degarelix
DMRVPN1	HS	Investigative
DMRVPN1	SN	CHEMBL425813; [D-Dab(CO-NH-OH)3]degarelix
DMRVPN1	PC	16155654
DMRVPN1	MW	1643.2
DMRVPN1	FM	C79H104ClN19O18
DMRVPN1	IC	InChI=1S/C79H104ClN19O18/c1-42(2)34-57(69(106)90-56(14-9-10-31-83-43(3)4)76(113)99-33-11-15-64(99)75(112)85-44(5)66(81)103)91-72(109)60(37-48-21-28-54(29-22-48)88-77(82)114)93-73(110)61(38-47-19-26-53(27-20-47)87-68(105)62-40-65(102)97-79(116)96-62)94-74(111)63(41-100)95-67(104)55(30-32-84-78(115)98-117)89-71(108)59(36-46-17-24-52(80)25-18-46)92-70(107)58(86-45(6)101)39-49-16-23-50-12-7-8-13-51(50)35-49/h7-8,12-13,16-29,35,42-44,55-64,83,100,117H,9-11,14-15,30-34,36-41H2,1-6H3,(H2,81,103)(H,85,112)(H,86,101)(H,87,105)(H,89,108)(H,90,106)(H,91,109)(H,92,107)(H,93,110)(H,94,111)(H,95,104)(H3,82,88,114)(H2,84,98,115)(H2,96,97,102,116)/t44-,55-,56+,57+,58-,59-,60-,61+,62+,63+,64+/m1/s1
DMRVPN1	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CCNC(=O)NO)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMRVPN1	IK	GJGANCMMPWJOQC-UFLOVSMNSA-N
DMRVPN1	IU	(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-4-(hydroxycarbamoylamino)butanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMRVPN1	DE	Discovery agent

DM5ZR4S	ID	DM5ZR4S
DM5ZR4S	DN	[D-Dap(CO-NH-OCH3)3]degarelix
DM5ZR4S	HS	Investigative
DM5ZR4S	SN	CHEMBL411381; [D-Dap(CO-NH-OCH3)3]degarelix
DM5ZR4S	PC	16156517
DM5ZR4S	MW	1643.2
DM5ZR4S	FM	C79H104ClN19O18
DM5ZR4S	IC	InChI=1S/C79H104ClN19O18/c1-42(2)33-56(68(105)89-55(15-10-11-31-83-43(3)4)76(113)99-32-12-16-64(99)75(112)85-44(5)66(81)103)90-70(107)58(36-48-22-29-54(30-23-48)88-77(82)114)92-71(108)59(37-47-20-27-53(28-21-47)87-67(104)61-39-65(102)97-79(116)96-61)93-74(111)63(41-100)95-73(110)62(40-84-78(115)98-117-7)94-72(109)60(35-46-18-25-52(80)26-19-46)91-69(106)57(86-45(6)101)38-49-17-24-50-13-8-9-14-51(50)34-49/h8-9,13-14,17-30,34,42-44,55-64,83,100H,10-12,15-16,31-33,35-41H2,1-7H3,(H2,81,103)(H,85,112)(H,86,101)(H,87,104)(H,89,105)(H,90,107)(H,91,106)(H,92,108)(H,93,111)(H,94,109)(H,95,110)(H3,82,88,114)(H2,84,98,115)(H2,96,97,102,116)/t44-,55+,56+,57-,58-,59+,60-,61+,62-,63+,64+/m1/s1
DM5ZR4S	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CNC(=O)NOC)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM5ZR4S	IK	AJPARKCOZVUOMV-NOXGGNAKSA-N
DM5ZR4S	IU	(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(methoxycarbamoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DM5ZR4S	DE	Discovery agent

DMS0LFT	ID	DMS0LFT
DMS0LFT	DN	[D-Dap(CO-NH-OH)3]degarelix
DMS0LFT	HS	Investigative
DMS0LFT	SN	CHEMBL428484; [D-Dap(CO-NH-OH)3]degarelix
DMS0LFT	PC	16155218
DMS0LFT	MW	1629.2
DMS0LFT	FM	C78H102ClN19O18
DMS0LFT	IC	InChI=1S/C78H102ClN19O18/c1-41(2)32-55(67(104)88-54(14-9-10-30-82-42(3)4)75(112)98-31-11-15-63(98)74(111)84-43(5)65(80)102)89-69(106)57(35-47-21-28-53(29-22-47)87-76(81)113)91-70(107)58(36-46-19-26-52(27-20-46)86-66(103)60-38-64(101)96-78(115)95-60)92-73(110)62(40-99)94-72(109)61(39-83-77(114)97-116)93-71(108)59(34-45-17-24-51(79)25-18-45)90-68(105)56(85-44(6)100)37-48-16-23-49-12-7-8-13-50(49)33-48/h7-8,12-13,16-29,33,41-43,54-63,82,99,116H,9-11,14-15,30-32,34-40H2,1-6H3,(H2,80,102)(H,84,111)(H,85,100)(H,86,103)(H,88,104)(H,89,106)(H,90,105)(H,91,107)(H,92,110)(H,93,108)(H,94,109)(H3,81,87,113)(H2,83,97,114)(H2,95,96,101,115)/t43-,54+,55+,56-,57-,58+,59-,60+,61-,62+,63+/m1/s1
DMS0LFT	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CNC(=O)NO)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMS0LFT	IK	QJTXGVWJYSNZTE-PTPJWVMESA-N
DMS0LFT	IU	(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(hydroxycarbamoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMS0LFT	DE	Discovery agent

DMEL0SZ	ID	DMEL0SZ
DMEL0SZ	DN	[des-Arg9]bradykinin
DMEL0SZ	HS	Investigative
DMEL0SZ	SN	[des-Arg9]BK
DMEL0SZ	DT	Small molecular drug
DMEL0SZ	PC	5128451
DMEL0SZ	MW	904
DMEL0SZ	FM	C44H61N11O10
DMEL0SZ	IC	InChI=1S/C44H61N11O10/c45-29(15-7-19-48-44(46)47)40(61)55-22-10-18-35(55)42(63)54-21-8-16-33(54)38(59)49-25-36(57)50-30(23-27-11-3-1-4-12-27)37(58)52-32(26-56)41(62)53-20-9-17-34(53)39(60)51-31(43(64)65)24-28-13-5-2-6-14-28/h1-6,11-14,29-35,56H,7-10,15-26,45H2,(H,49,59)(H,50,57)(H,51,60)(H,52,58)(H,64,65)(H4,46,47,48)
DMEL0SZ	CS	C1CC(N(C1)C(=O)C2CCCN2C(=O)C(CCCN=C(N)N)N)C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CO)C(=O)N4CCCC4C(=O)NC(CC5=CC=CC=C5)C(=O)O
DMEL0SZ	IK	VCEHWDBVPZFHAG-UHFFFAOYSA-N
DMEL0SZ	IU	2-[[1-[2-[[2-[[2-[[1-[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMEL0SZ	DE	Discovery agent

DM1EPZB	ID	DM1EPZB
DM1EPZB	DN	[des-His1,Tyr5,Glu9,D-Ala10]glucagon-NH2
DM1EPZB	HS	Investigative
DM1EPZB	PC	44460671
DM1EPZB	MW	3328.6
DM1EPZB	FM	C147H219N41O46S
DM1EPZB	IC	InChI=1S/C147H219N41O46S/c1-70(2)54-95(131(220)172-94(49-53-235-11)130(219)180-102(61-111(153)200)140(229)187-117(75(9)193)119(154)208)175-135(224)101(60-81-64-161-86-29-19-18-28-84(81)86)179-129(218)92(43-47-110(152)199)173-144(233)116(72(5)6)186-138(227)99(56-77-24-14-12-15-25-77)178-136(225)103(62-114(204)205)181-128(217)91(42-46-109(151)198)166-120(209)73(7)163-124(213)88(31-22-51-159-146(155)156)168-126(215)89(32-23-52-160-147(157)158)170-142(231)106(68-191)184-137(226)104(63-115(206)207)182-132(221)96(55-71(3)4)174-134(223)98(59-80-35-39-83(196)40-36-80)176-127(216)87(30-20-21-50-148)169-141(230)105(67-190)183-121(210)74(8)164-125(214)93(44-48-113(202)203)171-143(232)107(69-192)185-145(234)118(76(10)194)188-139(228)100(57-78-26-16-13-17-27-78)177-133(222)97(58-79-33-37-82(195)38-34-79)165-112(201)65-162-123(212)90(41-45-108(150)197)167-122(211)85(149)66-189/h12-19,24-29,33-40,64,70-76,85,87-107,116-118,161,189-196H,20-23,30-32,41-63,65-69,148-149H2,1-11H3,(H2,150,197)(H2,151,198)(H2,152,199)(H2,153,200)(H2,154,208)(H,162,212)(H,163,213)(H,164,214)(H,165,201)(H,166,209)(H,167,211)(H,168,215)(H,169,230)(H,170,231)(H,171,232)(H,172,220)(H,173,233)(H,174,223)(H,175,224)(H,176,216)(H,177,222)(H,178,225)(H,179,218)(H,180,219)(H,181,217)(H,182,221)(H,183,210)(H,184,226)(H,185,234)(H,186,227)(H,187,229)(H,188,228)(H,202,203)(H,204,205)(H,206,207)(H4,155,156,159)(H4,157,158,160)/t73-,74-,75+,76+,85-,87-,88-,89-,90-,91-,92-,93+,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,116-,117-,118-/m0/s1
DM1EPZB	CS	C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)O
DM1EPZB	IK	PSHWUKAXGHEOPB-XGBCNKCESA-N
DM1EPZB	IU	(4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DM1EPZB	DE	Discovery agent

DM06Q2V	ID	DM06Q2V
DM06Q2V	DN	[des-His1,Tyr5,Glu9,D-Phe10]glucagon-NH2
DM06Q2V	HS	Investigative
DM06Q2V	PC	44460638
DM06Q2V	MW	3404.7
DM06Q2V	FM	C153H223N41O46S
DM06Q2V	IC	InChI=1S/C153H223N41O46S/c1-75(2)58-100(136(225)177-99(53-57-241-10)135(224)186-108(66-117(159)206)146(235)193-123(79(8)199)125(160)214)180-141(230)107(65-86-69-167-91-33-21-20-32-89(86)91)185-133(222)97(47-51-116(158)205)178-150(239)122(77(5)6)192-144(233)105(61-82-28-16-12-17-29-82)184-142(231)109(67-120(210)211)187-132(221)96(46-50-115(157)204)171-126(215)78(7)169-129(218)93(35-24-55-165-152(161)162)173-130(219)94(36-25-56-166-153(163)164)175-148(237)112(73-197)190-143(232)110(68-121(212)213)188-137(226)101(59-76(3)4)179-139(228)104(64-85-39-43-88(202)44-40-85)181-131(220)92(34-22-23-54-154)174-147(236)111(72-196)189-140(229)103(60-81-26-14-11-15-27-81)182-134(223)98(48-52-119(208)209)176-149(238)113(74-198)191-151(240)124(80(9)200)194-145(234)106(62-83-30-18-13-19-31-83)183-138(227)102(63-84-37-41-87(201)42-38-84)170-118(207)70-168-128(217)95(45-49-114(156)203)172-127(216)90(155)71-195/h11-21,26-33,37-44,69,75-80,90,92-113,122-124,167,195-202H,22-25,34-36,45-68,70-74,154-155H2,1-10H3,(H2,156,203)(H2,157,204)(H2,158,205)(H2,159,206)(H2,160,214)(H,168,217)(H,169,218)(H,170,207)(H,171,215)(H,172,216)(H,173,219)(H,174,236)(H,175,237)(H,176,238)(H,177,225)(H,178,239)(H,179,228)(H,180,230)(H,181,220)(H,182,223)(H,183,227)(H,184,231)(H,185,222)(H,186,224)(H,187,221)(H,188,226)(H,189,229)(H,190,232)(H,191,240)(H,192,233)(H,193,235)(H,194,234)(H,208,209)(H,210,211)(H,212,213)(H4,161,162,165)(H4,163,164,166)/t78-,79+,80+,90-,92-,93-,94-,95-,96-,97-,98+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-/m0/s1
DM06Q2V	CS	C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)O
DM06Q2V	IK	MBFPGOMXVAUTEP-VXJQVJGISA-N
DM06Q2V	IU	(4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DM06Q2V	DE	Discovery agent

DMFLVED	ID	DMFLVED
DMFLVED	DN	[des-His1,Tyr5,Glu9,D-Tyr10]glucagon-NH2
DMFLVED	HS	Investigative
DMFLVED	SN	CHEMBL413666
DMFLVED	PC	44461181
DMFLVED	MW	3420.7
DMFLVED	FM	C153H223N41O47S
DMFLVED	IC	InChI=1S/C153H223N41O47S/c1-74(2)57-100(136(226)177-99(52-56-242-10)135(225)186-108(65-117(159)207)146(236)193-123(78(8)199)125(160)215)180-141(231)107(64-85-68-167-91-28-18-17-27-89(85)91)185-133(223)97(46-50-116(158)206)178-150(240)122(76(5)6)192-144(234)105(59-80-23-13-11-14-24-80)184-142(232)109(66-120(211)212)187-132(222)96(45-49-115(157)205)171-126(216)77(7)169-129(219)93(30-21-54-165-152(161)162)173-130(220)94(31-22-55-166-153(163)164)175-148(238)112(72-197)190-143(233)110(67-121(213)214)188-137(227)101(58-75(3)4)179-139(229)103(62-83-34-40-87(202)41-35-83)181-131(221)92(29-19-20-53-154)174-147(237)111(71-196)189-140(230)104(63-84-36-42-88(203)43-37-84)182-134(224)98(47-51-119(209)210)176-149(239)113(73-198)191-151(241)124(79(9)200)194-145(235)106(60-81-25-15-12-16-26-81)183-138(228)102(61-82-32-38-86(201)39-33-82)170-118(208)69-168-128(218)95(44-48-114(156)204)172-127(217)90(155)70-195/h11-18,23-28,32-43,68,74-79,90,92-113,122-124,167,195-203H,19-22,29-31,44-67,69-73,154-155H2,1-10H3,(H2,156,204)(H2,157,205)(H2,158,206)(H2,159,207)(H2,160,215)(H,168,218)(H,169,219)(H,170,208)(H,171,216)(H,172,217)(H,173,220)(H,174,237)(H,175,238)(H,176,239)(H,177,226)(H,178,240)(H,179,229)(H,180,231)(H,181,221)(H,182,224)(H,183,228)(H,184,232)(H,185,223)(H,186,225)(H,187,222)(H,188,227)(H,189,230)(H,190,233)(H,191,241)(H,192,234)(H,193,236)(H,194,235)(H,209,210)(H,211,212)(H,213,214)(H4,161,162,165)(H4,163,164,166)/t77-,78+,79+,90-,92-,93-,94-,95-,96-,97-,98+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-/m0/s1
DMFLVED	CS	C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)O
DMFLVED	IK	SNCODYSDFYHLPQ-HYDYTQAJSA-N
DMFLVED	IU	(4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DMFLVED	DE	Discovery agent

DM93I0B	ID	DM93I0B
DM93I0B	DN	[des-His1,Tyr5,Glu9]glucagon-NH2
DM93I0B	HS	Investigative
DM93I0B	PC	44460796
DM93I0B	MW	3420.7
DM93I0B	FM	C153H223N41O47S
DM93I0B	IC	InChI=1S/C153H223N41O47S/c1-74(2)57-100(136(226)177-99(52-56-242-10)135(225)186-108(65-117(159)207)146(236)193-123(78(8)199)125(160)215)180-141(231)107(64-85-68-167-91-28-18-17-27-89(85)91)185-133(223)97(46-50-116(158)206)178-150(240)122(76(5)6)192-144(234)105(59-80-23-13-11-14-24-80)184-142(232)109(66-120(211)212)187-132(222)96(45-49-115(157)205)171-126(216)77(7)169-129(219)93(30-21-54-165-152(161)162)173-130(220)94(31-22-55-166-153(163)164)175-148(238)112(72-197)190-143(233)110(67-121(213)214)188-137(227)101(58-75(3)4)179-139(229)103(62-83-34-40-87(202)41-35-83)181-131(221)92(29-19-20-53-154)174-147(237)111(71-196)189-140(230)104(63-84-36-42-88(203)43-37-84)182-134(224)98(47-51-119(209)210)176-149(239)113(73-198)191-151(241)124(79(9)200)194-145(235)106(60-81-25-15-12-16-26-81)183-138(228)102(61-82-32-38-86(201)39-33-82)170-118(208)69-168-128(218)95(44-48-114(156)204)172-127(217)90(155)70-195/h11-18,23-28,32-43,68,74-79,90,92-113,122-124,167,195-203H,19-22,29-31,44-67,69-73,154-155H2,1-10H3,(H2,156,204)(H2,157,205)(H2,158,206)(H2,159,207)(H2,160,215)(H,168,218)(H,169,219)(H,170,208)(H,171,216)(H,172,217)(H,173,220)(H,174,237)(H,175,238)(H,176,239)(H,177,226)(H,178,240)(H,179,229)(H,180,231)(H,181,221)(H,182,224)(H,183,228)(H,184,232)(H,185,223)(H,186,225)(H,187,222)(H,188,227)(H,189,230)(H,190,233)(H,191,241)(H,192,234)(H,193,236)(H,194,235)(H,209,210)(H,211,212)(H,213,214)(H4,161,162,165)(H4,163,164,166)/t77-,78?,79+,90-,92-,93-,94-,95-,96-,97-,98+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-/m0/s1
DM93I0B	CS	C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)O)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)O
DM93I0B	IK	SNCODYSDFYHLPQ-MBYQMCMRSA-N
DM93I0B	IU	(4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DM93I0B	DE	Discovery agent

DMP1D7Q	ID	DMP1D7Q
DMP1D7Q	DN	[D-Gln3,D-Ncy(isopropyl)7]acyline
DMP1D7Q	HS	Investigative
DMP1D7Q	SN	CHEMBL428795; [D-Gln3,D-Ncy(isopropyl)7]acyline
DMP1D7Q	PC	16221613
DMP1D7Q	MW	1531.2
DMP1D7Q	FM	C76H100ClN15O15S
DMP1D7Q	IC	InChI=1S/C76H100ClN15O15S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(108-43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75-/m1/s1
DMP1D7Q	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)SC(C)C
DMP1D7Q	IK	JPMOBCPTBLZEAW-YSZAJMORSA-N
DMP1D7Q	IU	(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1R)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfanylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMP1D7Q	DE	Discovery agent

DMFAX1Q	ID	DMFAX1Q
DMFAX1Q	DN	[D-Gln3,D-Ncy(SO,isopropyl)7]acyline
DMFAX1Q	HS	Investigative
DMFAX1Q	SN	CHEMBL415380; [D-Gln3,D-Ncy(SO,isopropyl)7]acyline
DMFAX1Q	PC	16221379
DMFAX1Q	MW	1547.2
DMFAX1Q	FM	C76H100ClN15O16S
DMFAX1Q	IC	InChI=1S/C76H100ClN15O16S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(109(108)43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75-,109?/m1/s1
DMFAX1Q	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)S(=O)C(C)C
DMFAX1Q	IK	KYASUQFVWOOHIK-JKWOHFGQSA-N
DMFAX1Q	IU	(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1R)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfinylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMFAX1Q	DE	Discovery agent

DM3H0CX	ID	DM3H0CX
DM3H0CX	DN	[D-Gln3,D-Ncy(SO2,isopropyl)7]acyline
DM3H0CX	HS	Investigative
DM3H0CX	SN	CHEMBL373725; [D-Gln3,D-Ncy(SO2,isopropyl)7]acyline
DM3H0CX	PC	16221614
DM3H0CX	MW	1563.2
DM3H0CX	FM	C76H100ClN15O17S
DM3H0CX	IC	InChI=1S/C76H100ClN15O17S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(110(108,109)43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75-/m1/s1
DM3H0CX	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)S(=O)(=O)C(C)C
DM3H0CX	IK	FVPKWKBSMZRQEW-YSZAJMORSA-N
DM3H0CX	IU	(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1R)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfonylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DM3H0CX	DE	Discovery agent

DMMEQ3R	ID	DMMEQ3R
DMMEQ3R	DN	[D-Gln3,Ncy(isopropyl)7]acyline
DMMEQ3R	HS	Investigative
DMMEQ3R	SN	CHEMBL228197; [D-Gln3,Ncy(isopropyl)7]acyline
DMMEQ3R	PC	16221328
DMMEQ3R	MW	1531.2
DMMEQ3R	FM	C76H100ClN15O15S
DMMEQ3R	IC	InChI=1S/C76H100ClN15O15S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(108-43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75+/m1/s1
DMMEQ3R	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)SC(C)C
DMMEQ3R	IK	JPMOBCPTBLZEAW-RKSVTEAUSA-N
DMMEQ3R	IU	(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1S)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfanylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMMEQ3R	DE	Discovery agent

DM2QDXW	ID	DM2QDXW
DM2QDXW	DN	[D-Gln3,Ncy(SO,isopropyl)7]acyline
DM2QDXW	HS	Investigative
DM2QDXW	SN	CHEMBL425486; [D-Gln3,Ncy(SO,isopropyl)7]acyline
DM2QDXW	PC	16221557
DM2QDXW	MW	1547.2
DM2QDXW	FM	C76H100ClN15O16S
DM2QDXW	IC	InChI=1S/C76H100ClN15O16S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(109(108)43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75+,109?/m1/s1
DM2QDXW	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)S(=O)C(C)C
DM2QDXW	IK	KYASUQFVWOOHIK-WEDCXYFKSA-N
DM2QDXW	IU	(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1S)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfinylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DM2QDXW	DE	Discovery agent

DMJSCO7	ID	DMJSCO7
DMJSCO7	DN	[D-Gln3,Ncy(SO2,isopropyl)7]acyline
DMJSCO7	HS	Investigative
DMJSCO7	SN	CHEMBL373724; [D-Gln3,Ncy(SO2,isopropyl)7]acyline
DMJSCO7	PC	16221329
DMJSCO7	MW	1563.2
DMJSCO7	FM	C76H100ClN15O17S
DMJSCO7	IC	InChI=1S/C76H100ClN15O17S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(110(108,109)43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75+/m1/s1
DMJSCO7	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)S(=O)(=O)C(C)C
DMJSCO7	IK	FVPKWKBSMZRQEW-RKSVTEAUSA-N
DMJSCO7	IU	(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1S)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfonylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMJSCO7	DE	Discovery agent

DMAFNTL	ID	DMAFNTL
DMAFNTL	DN	[D-Ncy(2-naphthyl)1]acyline
DMAFNTL	HS	Investigative
DMAFNTL	SN	CHEMBL227861; [D-Ncy(2-naphthyl)1]acyline
DMAFNTL	PC	16221104
DMAFNTL	MW	1551.2
DMAFNTL	FM	C79H100ClN15O14S
DMAFNTL	IC	InChI=1S/C79H100ClN15O14S/c1-45(2)37-62(70(101)88-61(18-11-12-35-83-46(3)4)79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)89-71(102)63(39-52-22-29-58(30-23-52)85-48(6)97)90-72(103)64(40-53-24-31-59(32-25-53)86-49(7)98)92-75(106)67(44-96)94-74(105)66(41-54-15-13-34-82-43-54)91-73(104)65(38-51-20-27-57(80)28-21-51)93-77(108)78(87-50(8)99)110-60-33-26-55-16-9-10-17-56(55)42-60/h9-10,13,15-17,20-34,42-43,45-47,61-68,78,83,96H,11-12,14,18-19,35-41,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,101)(H,89,102)(H,90,103)(H,91,104)(H,92,106)(H,93,108)(H,94,105)/t47-,61+,62+,63-,64+,65-,66-,67+,68+,78-/m1/s1
DMAFNTL	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@H](NC(=O)C)SC6=CC7=CC=CC=C7C=C6
DMAFNTL	IK	JRWSZLDRIJBUBZ-GJCYDJOFSA-N
DMAFNTL	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-2-naphthalen-2-ylsulfanylacetyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMAFNTL	DE	Discovery agent

DMVBTAM	ID	DMVBTAM
DMVBTAM	DN	[D-Ncy(isopropyl)7]acyline
DMVBTAM	HS	Investigative
DMVBTAM	SN	CHEMBL227451; [D-Ncy(isopropyl)7]acyline
DMVBTAM	PC	16221495
DMVBTAM	MW	1551.2
DMVBTAM	FM	C79H100ClN15O14S
DMVBTAM	IC	InChI=1S/C79H100ClN15O14S/c1-45(2)83-35-12-11-18-61(79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)88-77(108)78(110-46(3)4)94-74(105)65(40-53-25-32-60(33-26-53)86-49(7)98)90-72(103)64(39-52-23-30-59(31-24-52)85-48(6)97)92-75(106)67(44-96)93-73(104)66(42-55-15-13-34-82-43-55)91-71(102)63(38-51-21-28-58(80)29-22-51)89-70(101)62(87-50(8)99)41-54-20-27-56-16-9-10-17-57(56)37-54/h9-10,13,15-17,20-34,37,43,45-47,61-68,78,83,96H,11-12,14,18-19,35-36,38-42,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,108)(H,89,101)(H,90,103)(H,91,102)(H,92,106)(H,93,104)(H,94,105)/t47-,61+,62-,63-,64+,65-,66-,67+,68+,78-/m1/s1
DMVBTAM	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)SC(C)C
DMVBTAM	IK	GFSHJVRBLLVKAZ-UQWNDQPVSA-N
DMVBTAM	IU	(2S)-1-[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-2-propan-2-ylsulfanylacetyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMVBTAM	DE	Discovery agent

DM9TORW	ID	DM9TORW
DM9TORW	DN	[D-Ncy(methyl)10] acyline
DM9TORW	HS	Investigative
DM9TORW	SN	CHEMBL387499; [D-Ncy(methyl)10] acyline
DM9TORW	PC	16221267
DM9TORW	MW	1565.3
DM9TORW	FM	C80H102ClN15O14S
DM9TORW	IC	InChI=1S/C80H102ClN15O14S/c1-46(2)37-62(71(102)88-61(18-11-12-35-84-47(3)4)80(110)96-36-14-19-69(96)78(109)95-79(111-8)70(82)101)89-73(104)65(40-52-23-30-59(31-24-52)85-48(5)98)91-75(106)66(41-53-25-32-60(33-26-53)86-49(6)99)93-77(108)68(45-97)94-76(107)67(43-55-15-13-34-83-44-55)92-74(105)64(39-51-21-28-58(81)29-22-51)90-72(103)63(87-50(7)100)42-54-20-27-56-16-9-10-17-57(56)38-54/h9-10,13,15-17,20-34,38,44,46-47,61-69,79,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,98)(H,86,99)(H,87,100)(H,88,102)(H,89,104)(H,90,103)(H,91,106)(H,92,105)(H,93,108)(H,94,107)(H,95,109)/t61-,62-,63+,64+,65+,66-,67+,68-,69-,79+/m0/s1
DM9TORW	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)SC)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM9TORW	IK	MNOHGPTZCIGJAF-NNRJBHNWSA-N
DM9TORW	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(1R)-2-amino-1-methylsulfanyl-2-oxoethyl]pyrrolidine-2-carboxamide
DM9TORW	DE	Discovery agent

DM63FN5	ID	DM63FN5
DM63FN5	DN	[D-Ncy(methyl)4]acyline
DM63FN5	HS	Investigative
DM63FN5	SN	CHEMBL268297; [D-Ncy(methyl)4]acyline
DM63FN5	PC	16221434
DM63FN5	MW	1549.3
DM63FN5	FM	C80H102ClN15O13S
DM63FN5	IC	InChI=1S/C80H102ClN15O13S/c1-46(2)38-63(71(101)89-62(19-12-13-36-84-47(3)4)80(109)96-37-15-20-69(96)77(107)85-48(5)70(82)100)90-73(103)66(41-53-24-31-60(32-25-53)86-49(6)97)92-75(105)67(42-54-26-33-61(34-27-54)87-50(7)98)94-78(108)79(110-9)95-76(106)68(44-56-16-14-35-83-45-56)93-74(104)65(40-52-22-29-59(81)30-23-52)91-72(102)64(88-51(8)99)43-55-21-28-57-17-10-11-18-58(57)39-55/h10-11,14,16-18,21-35,39,45-48,62-69,79,84H,12-13,15,19-20,36-38,40-44H2,1-9H3,(H2,82,100)(H,85,107)(H,86,97)(H,87,98)(H,88,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,108)(H,95,106)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,79-/m1/s1
DM63FN5	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)SC
DM63FN5	IK	HPTFWQIEIVLQOX-GHGJXBRZSA-N
DM63FN5	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-2-methylsulfanylacetyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM63FN5	DE	Discovery agent

DME9AN4	ID	DME9AN4
DME9AN4	DN	[D-Ncy(SO,isopropyl)7]acyline
DME9AN4	HS	Investigative
DME9AN4	SN	CHEMBL427269; [D-Ncy(SO,isopropyl)7]acyline
DME9AN4	PC	16221212
DME9AN4	MW	1567.2
DME9AN4	FM	C79H100ClN15O15S
DME9AN4	IC	InChI=1S/C79H100ClN15O15S/c1-45(2)83-35-12-11-18-61(79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)88-77(108)78(111(110)46(3)4)94-74(105)65(40-53-25-32-60(33-26-53)86-49(7)98)90-72(103)64(39-52-23-30-59(31-24-52)85-48(6)97)92-75(106)67(44-96)93-73(104)66(42-55-15-13-34-82-43-55)91-71(102)63(38-51-21-28-58(80)29-22-51)89-70(101)62(87-50(8)99)41-54-20-27-56-16-9-10-17-57(56)37-54/h9-10,13,15-17,20-34,37,43,45-47,61-68,78,83,96H,11-12,14,18-19,35-36,38-42,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,108)(H,89,101)(H,90,103)(H,91,102)(H,92,106)(H,93,104)(H,94,105)/t47-,61+,62-,63-,64+,65-,66-,67+,68+,78-,111?/m1/s1
DME9AN4	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)S(=O)C(C)C
DME9AN4	IK	KEFJIAHSOLWSII-JBSZQXIRSA-N
DME9AN4	IU	(2S)-1-[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-2-propan-2-ylsulfinylacetyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DME9AN4	DE	Discovery agent

DMT2X98	ID	DMT2X98
DMT2X98	DN	[D-Ncy(SO,methyl)10]acyline
DMT2X98	HS	Investigative
DMT2X98	SN	CHEMBL434371; [D-Ncy(SO,methyl)10]acyline
DMT2X98	PC	16221556
DMT2X98	MW	1581.3
DMT2X98	FM	C80H102ClN15O15S
DMT2X98	IC	InChI=1S/C80H102ClN15O15S/c1-46(2)37-62(71(102)88-61(18-11-12-35-84-47(3)4)80(110)96-36-14-19-69(96)78(109)95-79(70(82)101)112(8)111)89-73(104)65(40-52-23-30-59(31-24-52)85-48(5)98)91-75(106)66(41-53-25-32-60(33-26-53)86-49(6)99)93-77(108)68(45-97)94-76(107)67(43-55-15-13-34-83-44-55)92-74(105)64(39-51-21-28-58(81)29-22-51)90-72(103)63(87-50(7)100)42-54-20-27-56-16-9-10-17-57(56)38-54/h9-10,13,15-17,20-34,38,44,46-47,61-69,79,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,98)(H,86,99)(H,87,100)(H,88,102)(H,89,104)(H,90,103)(H,91,106)(H,92,105)(H,93,108)(H,94,107)(H,95,109)/t61-,62-,63+,64+,65+,66-,67+,68-,69-,79+,112?/m0/s1
DMT2X98	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)S(=O)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMT2X98	IK	SELUBVJEWYERMJ-PGGNZVFSSA-N
DMT2X98	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(1R)-2-amino-1-methylsulfinyl-2-oxoethyl]pyrrolidine-2-carboxamide
DMT2X98	DE	Discovery agent

DM6HEXG	ID	DM6HEXG
DM6HEXG	DN	[D-Ncy(SO,methyl)4]acyline
DM6HEXG	HS	Investigative
DM6HEXG	SN	CHEMBL389945; [D-Ncy(SO,methyl)4]acyline
DM6HEXG	PC	16221151
DM6HEXG	MW	1565.3
DM6HEXG	FM	C80H102ClN15O14S
DM6HEXG	IC	InChI=1S/C80H102ClN15O14S/c1-46(2)38-63(71(101)89-62(19-12-13-36-84-47(3)4)80(109)96-37-15-20-69(96)77(107)85-48(5)70(82)100)90-73(103)66(41-53-24-31-60(32-25-53)86-49(6)97)92-75(105)67(42-54-26-33-61(34-27-54)87-50(7)98)94-78(108)79(111(9)110)95-76(106)68(44-56-16-14-35-83-45-56)93-74(104)65(40-52-22-29-59(81)30-23-52)91-72(102)64(88-51(8)99)43-55-21-28-57-17-10-11-18-58(57)39-55/h10-11,14,16-18,21-35,39,45-48,62-69,79,84H,12-13,15,19-20,36-38,40-44H2,1-9H3,(H2,82,100)(H,85,107)(H,86,97)(H,87,98)(H,88,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,108)(H,95,106)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,79-,111?/m1/s1
DM6HEXG	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)S(=O)C
DM6HEXG	IK	VCYXYVFYPVPVGF-QUDAQTMVSA-N
DM6HEXG	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-2-methylsulfinylacetyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM6HEXG	DE	Discovery agent

DME8W3R	ID	DME8W3R
DME8W3R	DN	[D-Tic7]OT
DME8W3R	HS	Investigative
DME8W3R	SN	CHEMBL435159; [D-Tic7]OT
DME8W3R	PC	16738356
DME8W3R	MW	1069.3
DME8W3R	FM	C48H68N12O12S2
DME8W3R	IC	InChI=1S/C48H68N12O12S2/c1-5-25(4)40-47(71)54-31(14-15-37(50)62)43(67)56-34(19-38(51)63)44(68)58-35(23-74-73-22-30(49)41(65)55-33(45(69)59-40)17-26-10-12-29(61)13-11-26)48(72)60-21-28-9-7-6-8-27(28)18-36(60)46(70)57-32(16-24(2)3)42(66)53-20-39(52)64/h6-13,24-25,30-36,40,61H,5,14-23,49H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,66)(H,54,71)(H,55,65)(H,56,67)(H,57,70)(H,58,68)(H,59,69)/t25-,30-,31-,32-,33-,34-,35-,36+,40-/m0/s1
DME8W3R	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DME8W3R	IK	GJHLANNXTOQRKG-VLMAQVDPSA-N
DME8W3R	IU	(3R)-2-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DME8W3R	DE	Discovery agent

DMWGADP	ID	DMWGADP
DMWGADP	DN	[Fe(CN)6]4-
DMWGADP	HS	Investigative
DMWGADP	SN	FERROCYANIDE; Hexacyanoferrate(II); Hexacyanoferrate II; Hexazyanoferrat(II); hexacyanoferrate(4-); hexacyanidoferrate(II); hexacyanidoferrate(4-); [Fe(CN)6](4-); Iron-hexacyanide; Ferrocyanide salts; hexacyanoferrate(4)-; CHEBI:5032; ORXDSIPBTFAEKJ-UHFFFAOYSA-N; Hexakis(cyano-C)-(OC-6-11)-Ferrate(3-); C01913
DMWGADP	DT	Small molecular drug
DMWGADP	PC	9552077
DMWGADP	MW	211.95
DMWGADP	FM	C6FeN6-4
DMWGADP	IC	InChI=1S/6CN.Fe/c6*1-2;/q6*-1;+2
DMWGADP	CS	[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+2]
DMWGADP	IK	UETZVSHORCDDTH-UHFFFAOYSA-N
DMWGADP	IU	iron(2+);hexacyanide
DMWGADP	CA	CAS 13408-63-4
DMWGADP	CB	CHEBI:5032
DMWGADP	DE	Discovery agent

DMZM3GB	ID	DMZM3GB
DMZM3GB	DN	[Gly(But)7]OT
DMZM3GB	HS	Investigative
DMZM3GB	SN	CHEMBL234363; [Gly(But)7]OT
DMZM3GB	PC	44429264
DMZM3GB	MW	1023.2
DMZM3GB	FM	C44H70N12O12S2
DMZM3GB	IC	InChI=1S/C44H70N12O12S2/c1-8-22(4)34-42(67)50-26(13-14-31(46)58)38(63)52-29(17-32(47)59)39(64)54-30(20-70-69-19-25(45)36(61)51-28(40(65)55-34)16-23-9-11-24(57)12-10-23)41(66)56-35(44(5,6)7)43(68)53-27(15-21(2)3)37(62)49-18-33(48)60/h9-12,21-22,25-30,34-35,57H,8,13-20,45H2,1-7H3,(H2,46,58)(H2,47,59)(H2,48,60)(H,49,62)(H,50,67)(H,51,61)(H,52,63)(H,53,68)(H,54,64)(H,55,65)(H,56,66)/t22-,25-,26-,27-,28-,29-,30-,34-,35-/m0/s1
DMZM3GB	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)C(C)(C)C)CC(=O)N)CCC(=O)N
DMZM3GB	IK	ZQBKWQKQBINQEI-PJCZHVSHSA-N
DMZM3GB	IU	(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-N-[(2R)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMZM3GB	DE	Discovery agent

DM9SP2U	ID	DM9SP2U
DM9SP2U	DN	[Gly8, aib22]GLP-1(7-37)-NH2
DM9SP2U	HS	Investigative
DM9SP2U	PC	91935382
DM9SP2U	MW	3368.7
DM9SP2U	FM	C152H231N41O46
DM9SP2U	IC	InChI=1S/C152H231N41O46/c1-18-78(10)121(147(236)170-81(13)126(215)177-105(61-87-64-162-92-37-26-25-36-90(87)92)136(225)179-101(57-75(4)5)137(226)189-119(76(6)7)145(234)176-94(38-27-29-53-153)129(218)165-68-113(203)171-93(40-31-55-161-151(158)159)128(217)163-66-111(157)201)191-138(227)103(58-84-32-21-19-22-33-84)180-133(222)97(47-51-116(207)208)174-132(221)95(39-28-30-54-154)173-125(214)80(12)168-124(213)79(11)169-131(220)98(45-49-110(156)200)187-150(239)152(16,17)193-144(233)99(48-52-117(209)210)175-134(223)100(56-74(2)3)178-135(224)102(60-86-41-43-89(199)44-42-86)181-141(230)107(70-194)184-143(232)109(72-196)185-146(235)120(77(8)9)190-140(229)106(63-118(211)212)182-142(231)108(71-195)186-149(238)123(83(15)198)192-139(228)104(59-85-34-23-20-24-35-85)183-148(237)122(82(14)197)188-114(204)69-166-130(219)96(46-50-115(205)206)172-112(202)67-164-127(216)91(155)62-88-65-160-73-167-88/h19-26,32-37,41-44,64-65,73-83,91,93-109,119-123,162,194-199H,18,27-31,38-40,45-63,66-72,153-155H2,1-17H3,(H2,156,200)(H2,157,201)(H,160,167)(H,163,217)(H,164,216)(H,165,218)(H,166,219)(H,168,213)(H,169,220)(H,170,236)(H,171,203)(H,172,202)(H,173,214)(H,174,221)(H,175,223)(H,176,234)(H,177,215)(H,178,224)(H,179,225)(H,180,222)(H,181,230)(H,182,231)(H,183,237)(H,184,232)(H,185,235)(H,186,238)(H,187,239)(H,188,204)(H,189,226)(H,190,229)(H,191,227)(H,192,228)(H,193,233)(H,205,206)(H,207,208)(H,209,210)(H,211,212)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,119-,120-,121-,122-,123-/m0/s1
DM9SP2U	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DM9SP2U	IK	SNUALFGPRGVVPK-CCGBATFTSA-N
DM9SP2U	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM9SP2U	DE	Discovery agent

DMO8U3S	ID	DMO8U3S
DMO8U3S	DN	[Gly8,Glu22]GLP-1(7,37)-NH2
DMO8U3S	HS	Investigative
DMO8U3S	PC	77281783
DMO8U3S	MW	3413.7
DMO8U3S	FM	C153H230N40O49
DMO8U3S	IC	InChI=1S/C153H230N40O49/c1-16-78(10)123(150(240)170-81(13)128(218)179-106(61-87-64-162-92-35-24-23-34-90(87)92)140(230)181-102(57-75(4)5)141(231)190-121(76(6)7)148(238)178-94(36-25-27-53-154)131(221)164-67-113(202)171-93(38-29-55-161-153(158)159)130(220)166-69-120(214)215)192-142(232)104(58-84-30-19-17-20-31-84)182-137(227)100(47-52-118(210)211)175-134(224)95(37-26-28-54-155)173-127(217)80(12)168-126(216)79(11)169-133(223)97(43-48-111(157)200)174-135(225)98(45-50-116(206)207)176-136(226)99(46-51-117(208)209)177-138(228)101(56-74(2)3)180-139(229)103(60-86-39-41-89(199)42-40-86)183-145(235)108(70-194)186-147(237)110(72-196)187-149(239)122(77(8)9)191-144(234)107(63-119(212)213)184-146(236)109(71-195)188-152(242)125(83(15)198)193-143(233)105(59-85-32-21-18-22-33-85)185-151(241)124(82(14)197)189-114(203)68-165-132(222)96(44-49-115(204)205)172-112(201)66-163-129(219)91(156)62-88-65-160-73-167-88/h17-24,30-35,39-42,64-65,73-83,91,93-110,121-125,162,194-199H,16,25-29,36-38,43-63,66-72,154-156H2,1-15H3,(H2,157,200)(H,160,167)(H,163,219)(H,164,221)(H,165,222)(H,166,220)(H,168,216)(H,169,223)(H,170,240)(H,171,202)(H,172,201)(H,173,217)(H,174,225)(H,175,224)(H,176,226)(H,177,228)(H,178,238)(H,179,218)(H,180,229)(H,181,230)(H,182,227)(H,183,235)(H,184,236)(H,185,241)(H,186,237)(H,187,239)(H,188,242)(H,189,203)(H,190,231)(H,191,234)(H,192,232)(H,193,233)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H,214,215)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,121-,122-,123-,124-,125-/m0/s1
DMO8U3S	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DMO8U3S	IK	PDPPZBIGLPYQFY-KYYFCHEUSA-N
DMO8U3S	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMO8U3S	DE	Discovery agent

DM1SOT4	ID	DM1SOT4
DM1SOT4	DN	[Gly8]GLP-1(7-37)-NH2
DM1SOT4	HS	Investigative
DM1SOT4	PC	91935381
DM1SOT4	MW	3341.6
DM1SOT4	FM	C150H226N40O47
DM1SOT4	IC	InChI=1S/C150H226N40O47/c1-16-77(10)121(147(235)168-80(13)126(214)176-104(59-86-62-159-91-35-24-23-34-89(86)91)137(225)178-100(55-74(4)5)138(226)187-119(75(6)7)145(233)175-93(36-25-27-51-151)129(217)161-65-111(199)169-92(38-29-53-158-150(155)156)128(216)164-68-118(210)211)189-139(227)102(56-83-30-19-17-20-31-83)179-134(222)98(46-50-116(206)207)174-133(221)94(37-26-28-52-152)172-125(213)79(12)166-124(212)78(11)167-132(220)97(43-47-109(154)197)171-112(200)66-162-131(219)96(45-49-115(204)205)173-135(223)99(54-73(2)3)177-136(224)101(58-85-39-41-88(196)42-40-85)180-142(230)106(69-191)183-144(232)108(71-193)184-146(234)120(76(8)9)188-141(229)105(61-117(208)209)181-143(231)107(70-192)185-149(237)123(82(15)195)190-140(228)103(57-84-32-21-18-22-33-84)182-148(236)122(81(14)194)186-113(201)67-163-130(218)95(44-48-114(202)203)170-110(198)64-160-127(215)90(153)60-87-63-157-72-165-87/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,159,191-196H,16,25-29,36-38,43-61,64-71,151-153H2,1-15H3,(H2,154,197)(H,157,165)(H,160,215)(H,161,217)(H,162,219)(H,163,218)(H,164,216)(H,166,212)(H,167,220)(H,168,235)(H,169,199)(H,170,198)(H,171,200)(H,172,213)(H,173,223)(H,174,221)(H,175,233)(H,176,214)(H,177,224)(H,178,225)(H,179,222)(H,180,230)(H,181,231)(H,182,236)(H,183,232)(H,184,234)(H,185,237)(H,186,201)(H,187,226)(H,188,229)(H,189,227)(H,190,228)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,155,156,158)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
DM1SOT4	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DM1SOT4	IK	XXYMTCGQDUSUOO-RHBBJNDVSA-N
DM1SOT4	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM1SOT4	DE	Discovery agent

DMLZNK6	ID	DMLZNK6
DMLZNK6	DN	[HO1][Lys8(5/6C-Flu)]VT
DMLZNK6	HS	Investigative
DMLZNK6	PC	44320996
DMLZNK6	MW	1339.5
DMLZNK6	FM	C62H74N12O18S2
DMLZNK6	IC	InChI=1S/C62H74N12O18S2/c1-3-30(2)50-58(87)69-41(19-20-48(64)79)54(83)70-42(26-49(65)80)55(84)71-43(27-93-94-28-45(78)57(86)73-51(59(88)72-50)31-9-12-33(75)13-10-31)60(89)74-22-6-8-44(74)56(85)68-40(53(82)67-29-63)7-4-5-21-66-52(81)32-11-16-36-39(23-32)62(92-61(36)90)37-17-14-34(76)24-46(37)91-47-25-35(77)15-18-38(47)62/h9-18,23-25,30,40-45,50-51,75-78H,3-8,19-22,26-29,63H2,1-2H3,(H2,64,79)(H2,65,80)(H,66,81)(H,67,82)(H,68,85)(H,69,87)(H,70,83)(H,71,84)(H,72,88)(H,73,86)/t30?,40-,41+,42+,43+,44+,45?,50+,51-/m0/s1
DMLZNK6	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DMLZNK6	IK	UHOYWVNHWOKOQC-USAPJFQBSA-N
DMLZNK6	IU	(2R)-N-[(2S)-1-(aminomethylamino)-6-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxohexan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-19-hydroxy-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMLZNK6	DE	Discovery agent

DMFK9V5	ID	DMFK9V5
DMFK9V5	DN	[HO1][Orn8(5/6C-Flu)]VT
DMFK9V5	HS	Investigative
DMFK9V5	PC	44321041
DMFK9V5	MW	1325.4
DMFK9V5	FM	C61H72N12O18S2
DMFK9V5	IC	InChI=1S/C61H72N12O18S2/c1-3-29(2)49-57(86)68-40(18-19-47(63)78)53(82)69-41(25-48(64)79)54(83)70-42(26-92-93-27-44(77)56(85)72-50(58(87)71-49)30-8-11-32(74)12-9-30)59(88)73-21-5-7-43(73)55(84)67-39(52(81)66-28-62)6-4-20-65-51(80)31-10-15-35-38(22-31)61(91-60(35)89)36-16-13-33(75)23-45(36)90-46-24-34(76)14-17-37(46)61/h8-17,22-24,29,39-44,49-50,74-77H,3-7,18-21,25-28,62H2,1-2H3,(H2,63,78)(H2,64,79)(H,65,80)(H,66,81)(H,67,84)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,72,85)/t29?,39-,40+,41+,42+,43+,44?,49+,50-/m0/s1
DMFK9V5	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DMFK9V5	IK	AKOGSKPWCBYRCU-IRJYFLAISA-N
DMFK9V5	IU	(2R)-N-[(2S)-1-(aminomethylamino)-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-19-hydroxy-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMFK9V5	DE	Discovery agent

DM7COAM	ID	DM7COAM
DM7COAM	DN	[HO1][Orn8(5/6C-Rhm)]VT
DM7COAM	HS	Investigative
DM7COAM	PC	44321159
DM7COAM	MW	1382.6
DM7COAM	FM	C65H85N14O16S2+
DM7COAM	IC	InChI=1S/C65H84N14O16S2/c1-7-33(2)54-62(90)72-44(22-23-51(67)82)58(86)73-45(29-52(68)83)59(87)74-46(30-96-97-31-48(81)61(89)76-55(63(91)75-54)34-12-17-38(80)18-13-34)64(92)79-25-9-11-47(79)60(88)71-43(57(85)70-32-66)10-8-24-69-56(84)35-14-19-39(42(26-35)65(93)94)53-40-20-15-36(77(3)4)27-49(40)95-50-28-37(78(5)6)16-21-41(50)53/h12-21,26-28,33,40,43-48,50,54-55,81H,7-11,22-25,29-32,66H2,1-6H3,(H13-,67,68,69,70,71,72,73,74,75,76,80,82,83,84,85,86,87,88,89,90,91,93,94)/p+1/t33?,40?,43-,44+,45+,46+,47+,48?,50?,54+,55-/m0/s1
DM7COAM	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC(=C(C=C4)C5=C6C=CC(=CC6OC7=CC(=[N+](C)C)C=CC75)N(C)C)C(=O)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DM7COAM	IK	XSTBAVMTSHGRBE-CEBVGXOVSA-O
DM7COAM	IU	[9-[4-[[(4S)-5-(aminomethylamino)-4-[[(2R)-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-19-hydroxy-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carbonyl]amino]-5-oxopentyl]carbamoyl]-2-carboxyphenyl]-6-(dimethylamino)-9a,10a-dihydroxanthen-3-ylidene]-dimethylazanium
DM7COAM	DE	Discovery agent

DMT2UYR	ID	DMT2UYR
DMT2UYR	DN	[HO1][Thr4,Lys8(5/6C-Flu)]VT
DMT2UYR	HS	Investigative
DMT2UYR	PC	44321257
DMT2UYR	MW	1312.4
DMT2UYR	FM	C61H73N11O18S2
DMT2UYR	IC	InChI=1S/C61H73N11O18S2/c1-4-29(2)48-56(84)70-49(30(3)73)57(85)67-41(25-47(63)78)53(81)68-42(26-91-92-27-44(77)55(83)71-50(58(86)69-48)31-10-13-33(74)14-11-31)59(87)72-21-7-9-43(72)54(82)66-40(52(80)65-28-62)8-5-6-20-64-51(79)32-12-17-36-39(22-32)61(90-60(36)88)37-18-15-34(75)23-45(37)89-46-24-35(76)16-19-38(46)61/h10-19,22-24,29-30,40-44,48-50,73-77H,4-9,20-21,25-28,62H2,1-3H3,(H2,63,78)(H,64,79)(H,65,80)(H,66,82)(H,67,85)(H,68,81)(H,69,86)(H,70,84)(H,71,83)/t29?,30?,40-,41+,42+,43+,44?,48+,49+,50-/m0/s1
DMT2UYR	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)C(C)O
DMT2UYR	IK	FKCHDAOTEPJVRR-FBPATOIMSA-N
DMT2UYR	IU	(2R)-N-[(2S)-1-(aminomethylamino)-6-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxohexan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-13-butan-2-yl-19-hydroxy-10-(1-hydroxyethyl)-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMT2UYR	DE	Discovery agent

DM81B4W	ID	DM81B4W
DM81B4W	DN	[HO1][Thr4,Orn8(5/6C-Flu)]VT
DM81B4W	HS	Investigative
DM81B4W	PC	44321040
DM81B4W	MW	1298.4
DM81B4W	FM	C60H71N11O18S2
DM81B4W	IC	InChI=1S/C60H71N11O18S2/c1-4-28(2)47-55(83)69-48(29(3)72)56(84)66-40(24-46(62)77)52(80)67-41(25-90-91-26-43(76)54(82)70-49(57(85)68-47)30-9-12-32(73)13-10-30)58(86)71-20-6-8-42(71)53(81)65-39(51(79)64-27-61)7-5-19-63-50(78)31-11-16-35-38(21-31)60(89-59(35)87)36-17-14-33(74)22-44(36)88-45-23-34(75)15-18-37(45)60/h9-18,21-23,28-29,39-43,47-49,72-76H,4-8,19-20,24-27,61H2,1-3H3,(H2,62,77)(H,63,78)(H,64,79)(H,65,81)(H,66,84)(H,67,80)(H,68,85)(H,69,83)(H,70,82)/t28?,29?,39-,40+,41+,42+,43?,47+,48+,49-/m0/s1
DM81B4W	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)C(C)O
DM81B4W	IK	QZZVYFFNKFRZQH-NYIBOZPTSA-N
DM81B4W	IU	(2R)-N-[(2S)-1-(aminomethylamino)-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-13-butan-2-yl-19-hydroxy-10-(1-hydroxyethyl)-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM81B4W	DE	Discovery agent

DM7NXMB	ID	DM7NXMB
DM7NXMB	DN	[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL
DM7NXMB	HS	Investigative
DM7NXMB	SN	[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL; SB-485345; 2ai7; 2ai8; AC1NRD35; DB08523
DM7NXMB	DT	Small molecular drug
DM7NXMB	PC	5289329
DM7NXMB	MW	181.23
DM7NXMB	FM	C10H15NO2
DM7NXMB	IC	InChI=1S/C10H15NO2/c12-9-11(13)8-4-7-10-5-2-1-3-6-10/h1-3,5-6,12-13H,4,7-9H2
DM7NXMB	CS	C1=CC=C(C=C1)CCCN(CO)O
DM7NXMB	IK	GELOPWXSYZDPJT-UHFFFAOYSA-N
DM7NXMB	IU	[hydroxy(3-phenylpropyl)amino]methanol
DM7NXMB	DE	Discovery agent

DMXTY6L	ID	DMXTY6L
DMXTY6L	DN	[Leu13]motilin (human)
DMXTY6L	HS	Investigative
DMXTY6L	SN	[Leu13]-Motilin porcine; GTPL1453; 116283-54-6; [Leu13]-Motilin porcine, &gt
DMXTY6L	DT	Small molecular drug
DMXTY6L	PC	16198245
DMXTY6L	MW	2681
DMXTY6L	FM	C121H190N34O35
DMXTY6L	IC	InChI=1S/C121H190N34O35/c1-10-65(8)98(153-115(185)87-32-23-53-155(87)118(188)97(64(6)7)152-100(170)71(124)56-67-24-13-11-14-25-67)116(186)151-85(57-68-26-15-12-16-27-68)114(184)154-99(66(9)156)117(187)150-84(58-69-33-35-70(157)36-34-69)102(172)136-60-92(162)137-76(40-46-94(164)165)106(176)148-83(55-63(4)5)112(182)145-77(37-43-88(125)158)107(177)141-74(30-21-51-133-120(129)130)104(174)147-82(54-62(2)3)111(181)146-78(38-44-89(126)159)108(178)144-80(42-48-96(168)169)109(179)140-73(29-18-20-50-123)103(173)143-79(41-47-95(166)167)110(180)142-75(31-22-52-134-121(131)132)105(175)149-86(59-91(128)161)113(183)139-72(28-17-19-49-122)101(171)135-61-93(163)138-81(119(189)190)39-45-90(127)160/h11-16,24-27,33-36,62-66,71-87,97-99,156-157H,10,17-23,28-32,37-61,122-124H2,1-9H3,(H2,125,158)(H2,126,159)(H2,127,160)(H2,128,161)(H,135,171)(H,136,172)(H,137,162)(H,138,163)(H,139,183)(H,140,179)(H,141,177)(H,142,180)(H,143,173)(H,144,178)(H,145,182)(H,146,181)(H,147,174)(H,148,176)(H,149,175)(H,150,187)(H,151,186)(H,152,170)(H,153,185)(H,154,184)(H,164,165)(H,166,167)(H,168,169)(H,189,190)(H4,129,130,133)(H4,131,132,134)/t65-,66+,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,97-,98-,99-/m0/s1
DMXTY6L	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N
DMXTY6L	IK	GFOZQXMKARUPQI-HYOAWBISSA-N
DMXTY6L	IU	(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMXTY6L	CA	CAS 116283-54-6
DMXTY6L	DE	Discovery agent

DMA0N32	ID	DMA0N32
DMA0N32	DN	[Leu5]enkephalin
DMA0N32	HS	Investigative
DMA0N32	SN	[Leu5]-Enkephalin; 58822-25-6; Enkephalin; Enkephalin L; [Leu 5]enkephalin; UNII-RI01R707R6; [5-Leucine]Enkephalin; Tyr-Gly-Gly-Phe-Leu-OH; CHEMBL8234; H-Tyr-Gly-Gly-Phe-Leu-OH; CHEBI:89656; RI01R707R6; Enkephalins; L-Leucine, N-(N-(N-(N-L-tyrosylglycyl)glycyl)-L-phenylalanyl)-; Leucyl-enkephalin
DMA0N32	DT	Small molecular drug
DMA0N32	PC	9985128
DMA0N32	MW	554.6
DMA0N32	FM	C28H38N6O6
DMA0N32	IC	InChI=1S/C28H38N6O6/c1-17(2)12-22(26(30)38)34-28(40)23(14-18-6-4-3-5-7-18)33-25(37)16-31-24(36)15-32-27(39)21(29)13-19-8-10-20(35)11-9-19/h3-11,17,21-23,35H,12-16,29H2,1-2H3,(H2,30,38)(H,31,36)(H,32,39)(H,33,37)(H,34,40)/t21-,22-,23-/m0/s1
DMA0N32	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMA0N32	IK	YZXGODHVAJPXSG-VABKMULXSA-N
DMA0N32	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanamide
DMA0N32	DE	Discovery agent

DM3JHRC	ID	DM3JHRC
DM3JHRC	DN	[Leu8,des-Arg9]bradykinin
DM3JHRC	HS	Investigative
DM3JHRC	SN	8-Leu-9-des-arg-BK; 8-Leu-9-de-arg-bradykinin; Bradykinin, leu(8) (1-8); bradykinin, Leu(8)-des-Arg(9)-; Bradykinin, leucyl(8)-des-arginine(9)-; CHEMBL80472; 64695-06-3; Bradykinin, 8-L-leucine-9-de-L-arginine-; Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu; (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid
DM3JHRC	DT	Small molecular drug
DM3JHRC	PC	123884
DM3JHRC	MW	870
DM3JHRC	FM	C41H63N11O10
DM3JHRC	IC	InChI=1S/C41H63N11O10/c1-24(2)20-28(40(61)62)48-36(57)31-14-8-17-50(31)38(59)29(23-53)49-34(55)27(21-25-10-4-3-5-11-25)47-33(54)22-46-35(56)30-13-7-18-51(30)39(60)32-15-9-19-52(32)37(58)26(42)12-6-16-45-41(43)44/h3-5,10-11,24,26-32,53H,6-9,12-23,42H2,1-2H3,(H,46,56)(H,47,54)(H,48,57)(H,49,55)(H,61,62)(H4,43,44,45)/t26-,27-,28-,29-,30-,31-,32-/m0/s1
DM3JHRC	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DM3JHRC	IK	BGAPYBBQGHUQNM-YYGRSCHNSA-N
DM3JHRC	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid
DM3JHRC	CA	CAS 64695-06-3
DM3JHRC	DE	Discovery agent

DMHUMDR	ID	DMHUMDR
DMHUMDR	DN	[L-Tic7]OT
DMHUMDR	HS	Investigative
DMHUMDR	SN	CHEMBL397407; [L-Tic7]OT
DMHUMDR	PC	16738355
DMHUMDR	MW	1069.3
DMHUMDR	FM	C48H68N12O12S2
DMHUMDR	IC	InChI=1S/C48H68N12O12S2/c1-5-25(4)40-47(71)54-31(14-15-37(50)62)43(67)56-34(19-38(51)63)44(68)58-35(23-74-73-22-30(49)41(65)55-33(45(69)59-40)17-26-10-12-29(61)13-11-26)48(72)60-21-28-9-7-6-8-27(28)18-36(60)46(70)57-32(16-24(2)3)42(66)53-20-39(52)64/h6-13,24-25,30-36,40,61H,5,14-23,49H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,66)(H,54,71)(H,55,65)(H,56,67)(H,57,70)(H,58,68)(H,59,69)/t25-,30-,31-,32-,33-,34-,35-,36-,40-/m0/s1
DMHUMDR	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CC4=CC=CC=C4C[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMHUMDR	IK	GJHLANNXTOQRKG-FGTHJCBLSA-N
DMHUMDR	IU	(3S)-2-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMHUMDR	DE	Discovery agent

DM7STF6	ID	DM7STF6
DM7STF6	DN	[Lys8(Alexa 488) ]PVA
DM7STF6	HS	Investigative
DM7STF6	SN	CHEMBL1161978
DM7STF6	PC	44428107
DM7STF6	MW	2060.6
DM7STF6	FM	C94H122Cl3N17O23S3
DM7STF6	IC	InChI=1S/C94H122Cl3N17O23S3/c1-48-44-93(3,4)110-77-56(48)41-58-71(59-42-57-49(2)45-94(5,6)111-78(57)83(140(134,135)136)80(59)137-79(58)82(77)139(131,132)133)72-73(91(129)130)74(95)76(97)81(75(72)96)138-47-68(119)104-36-15-9-12-21-70(121)114(64(84(101)122)20-13-14-35-98)89(127)53-34-38-113(46-53)90(128)61(19-16-37-105-92(102)103)107-87(125)63(43-67(100)118)108-85(123)60(31-32-66(99)117)106-86(124)62(39-51-17-10-8-11-18-51)109-88(126)65(40-52-24-29-55(116)30-25-52)112(7)69(120)33-26-50-22-27-54(115)28-23-50/h8,10-11,17-18,22-25,27-30,41,48-49,53,57,60-65,80,83,110,115-116H,9,12-16,19-21,26,31-40,42-47,98H2,1-7H3,(H2,99,117)(H2,100,118)(H2,101,122)(H,104,119)(H,106,124)(H,107,125)(H,108,123)(H,109,126)(H,129,130)(H4,102,103,105)(H,131,132,133)(H,134,135,136)/t48?,49?,53-,57?,60-,61-,62-,63-,64-,65+,80?,83?/m0/s1
DM7STF6	CS	CC1CC(N=C2C1CC3=C(C4=C(C(=C5C(=C4)C(CC(N5)(C)C)C)S(=O)(=O)O)OC3C2S(=O)(=O)O)C6=C(C(=C(C(=C6Cl)SCC(=O)NCCCCCC(=O)N([C@@H](CCCCN)C(=O)N)C(=O)[C@H]7CCN(C7)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@@H](CC9=CC=C(C=C9)O)N(C)C(=O)CCC1=CC=C(C=C1)O)Cl)Cl)C(=O)O)(C)C
DM7STF6	IK	SVLGRIWNJNOFJU-CRAMPYNJSA-N
DM7STF6	IU	4-[2-[[6-[[(3S)-1-[(2S)-2-[[(2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2R)-3-(4-hydroxyphenyl)-2-[3-(4-hydroxyphenyl)propanoyl-methylamino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-3-carbonyl]-[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethyl]sulfanyl-2,3,5-trichloro-6-(7,7,9,17,19,19-hexamethyl-4,22-disulfo-2-oxa-6,20-diazapentacyclo[12.8.0.03,12.05,10.016,21]docosa-1(14),5,12,15,21-pentaen-13-yl)benzoic acid
DM7STF6	DE	Discovery agent

DM38L6U	ID	DM38L6U
DM38L6U	DN	[Lys8(Alexa 546) ]PVA
DM38L6U	HS	Investigative
DM38L6U	SN	CHEMBL1161979
DM38L6U	PC	44428109
DM38L6U	MW	1629.7
DM38L6U	FM	C75H88N16O22S2
DM38L6U	IC	InChI=1S/C75H88N16O22S2/c1-89(60(96)29-16-39-12-18-44(92)19-13-39)57(35-41-14-20-45(93)21-15-41)70(101)88-54(34-40-8-3-2-4-9-40)68(99)85-52(27-28-58(79)94)67(98)87-55(37-59(80)95)69(100)86-53(10-7-32-84-75(82)83)73(104)90-33-30-43(38-90)72(103)91(56(66(81)97)11-5-6-31-76)71(102)42-17-22-46(49(36-42)74(105)106)61-47-23-25-50(77)64(114(107,108)109)62(47)113-63-48(61)24-26-51(78)65(63)115(110,111)112/h2-4,8-9,12-15,17-26,36,43,52-57,77,92-93H,5-7,10-11,16,27-35,37-38,76,78H2,1H3,(H2,79,94)(H2,80,95)(H2,81,97)(H,85,99)(H,86,100)(H,87,98)(H,88,101)(H,105,106)(H4,82,83,84)(H,107,108,109)(H,110,111,112)/t43-,52-,53-,54-,55-,56-,57+/m0/s1
DM38L6U	CS	CN([C@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CC[C@@H](C3)C(=O)N([C@@H](CCCCN)C(=O)N)C(=O)C4=CC(=C(C=C4)C5=C6C=CC(=N)C(=C6OC7=C5C=CC(=C7S(=O)(=O)O)N)S(=O)(=O)O)C(=O)O)C(=O)CCC8=CC=C(C=C8)O
DM38L6U	IK	JTPJNKPWLHDAAT-RHFIIQKYSA-N
DM38L6U	IU	5-[[(3S)-1-[(2S)-2-[[(2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2R)-3-(4-hydroxyphenyl)-2-[3-(4-hydroxyphenyl)propanoyl-methylamino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-3-carbonyl]-[(2S)-1,6-diamino-1-oxohexan-2-yl]carbamoyl]-2-(3-amino-6-imino-4,5-disulfoxanthen-9-yl)benzoic acid
DM38L6U	DE	Discovery agent

DM27LNU	ID	DM27LNU
DM27LNU	DN	[Mpa1, D-Tic2, Aib7]OT
DM27LNU	HS	Investigative
DM27LNU	SN	CHEMBL394268; [Mpa1, D-Tic2, Aib7]OT
DM27LNU	DT	Small molecular drug
DM27LNU	PC	16736614
DM27LNU	MW	976.2
DM27LNU	FM	C43H65N11O11S2
DM27LNU	IC	InChI=1S/C43H65N11O11S2/c1-7-23(4)35-41(64)48-26(12-13-31(44)55)37(60)49-28(18-32(45)56)38(61)50-29(39(62)53-43(5,6)42(65)51-27(16-22(2)3)36(59)47-19-33(46)57)21-67-66-15-14-34(58)54-20-25-11-9-8-10-24(25)17-30(54)40(63)52-35/h8-11,22-23,26-30,35H,7,12-21H2,1-6H3,(H2,44,55)(H2,45,56)(H2,46,57)(H,47,59)(H,48,64)(H,49,60)(H,50,61)(H,51,65)(H,52,63)(H,53,62)/t23-,26-,27-,28-,29-,30+,35-/m0/s1
DM27LNU	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N2CC3=CC=CC=C3C[C@@H]2C(=O)N1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DM27LNU	IK	JBEGYQDVCITYKL-JEDRZNSQSA-N
DM27LNU	IU	(8R,11S,14S,17S,20R)-11-(2-amino-2-oxoethyl)-N-[1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-14-(3-amino-3-oxopropyl)-17-[(2S)-butan-2-yl]-2,10,13,16,19-pentaoxo-5,6-dithia-1,9,12,15,18-pentazatricyclo[18.8.0.022,27]octacosa-22,24,26-triene-8-carboxamide
DM27LNU	DE	Discovery agent

DMPT1ME	ID	DMPT1ME
DMPT1ME	DN	[Mpa1, D-Tic7]OT
DMPT1ME	HS	Investigative
DMPT1ME	SN	CHEMBL265630; [Mpa1, D-Tic7]OT
DMPT1ME	PC	16737618
DMPT1ME	MW	1054.2
DMPT1ME	FM	C48H67N11O12S2
DMPT1ME	IC	InChI=1S/C48H67N11O12S2/c1-5-26(4)41-47(70)54-31(14-15-37(49)61)43(66)55-34(21-38(50)62)44(67)57-35(24-73-72-17-16-40(64)53-33(45(68)58-41)19-27-10-12-30(60)13-11-27)48(71)59-23-29-9-7-6-8-28(29)20-36(59)46(69)56-32(18-25(2)3)42(65)52-22-39(51)63/h6-13,25-26,31-36,41,60H,5,14-24H2,1-4H3,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,64)(H,54,70)(H,55,66)(H,56,69)(H,57,67)(H,58,68)/t26-,31-,32-,33-,34-,35-,36+,41-/m0/s1
DMPT1ME	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMPT1ME	IK	BEKGLOSGJVQNHG-CKIXOVHCSA-N
DMPT1ME	IU	(3R)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMPT1ME	DE	Discovery agent

DMBPVSD	ID	DMBPVSD
DMBPVSD	DN	[Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT
DMBPVSD	HS	Investigative
DMBPVSD	SN	CHEMBL233080; [Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT
DMBPVSD	PC	44429304
DMBPVSD	MW	1062.3
DMBPVSD	FM	C48H75N11O12S2
DMBPVSD	IC	InChI=1S/C48H75N11O12S2/c1-8-27(5)39-45(68)53-30(17-18-36(49)60)41(64)54-32(24-37(50)61)42(65)55-34(25-73-72-21-19-38(62)52-31(43(66)57-39)23-28-13-15-29(16-14-28)71-9-2)44(67)58-48(6,7)47(70)56-33(22-26(3)4)46(69)59-20-11-10-12-35(59)40(51)63/h13-16,26-27,30-35,39H,8-12,17-25H2,1-7H3,(H2,49,60)(H2,50,61)(H2,51,63)(H,52,62)(H,53,68)(H,54,64)(H,55,65)(H,56,70)(H,57,66)(H,58,67)/t27-,30-,31-,32-,33-,34-,35+,39-/m0/s1
DMBPVSD	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)N3CCCC[C@@H]3C(=O)N)CC(=O)N)CCC(=O)N
DMBPVSD	IK	UMBCXADJMGHVRX-AYLPWDSMSA-N
DMBPVSD	IU	(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-N-[1-[[(2S)-1-[(2R)-2-carbamoylpiperidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMBPVSD	DE	Discovery agent

DMQSG6Y	ID	DMQSG6Y
DMQSG6Y	DN	[Mpa1, D-Tyr(Et)2, Aib7]OT
DMQSG6Y	HS	Investigative
DMQSG6Y	SN	CHEMBL393021; [Mpa1, D-Tyr(Et)2, Aib7]OT
DMQSG6Y	PC	44429303
DMQSG6Y	MW	1008.2
DMQSG6Y	FM	C44H69N11O12S2
DMQSG6Y	IC	InChI=1S/C44H69N11O12S2/c1-8-24(5)36-42(65)50-27(14-15-32(45)56)38(61)51-30(20-33(46)57)39(62)52-31(41(64)55-44(6,7)43(66)53-28(18-23(3)4)37(60)48-21-34(47)58)22-69-68-17-16-35(59)49-29(40(63)54-36)19-25-10-12-26(13-11-25)67-9-2/h10-13,23-24,27-31,36H,8-9,14-22H2,1-7H3,(H2,45,56)(H2,46,57)(H2,47,58)(H,48,60)(H,49,59)(H,50,65)(H,51,61)(H,52,62)(H,53,66)(H,54,63)(H,55,64)/t24-,27-,28-,29-,30-,31-,36-/m0/s1
DMQSG6Y	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMQSG6Y	IK	OGLIRWYQKYWIBI-YGTZAJLESA-N
DMQSG6Y	IU	(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-N-[1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMQSG6Y	DE	Discovery agent

DM5GSXC	ID	DM5GSXC
DM5GSXC	DN	[Mpa1, D-Tyr(Et)2, D-Tic7, Aib9]OT
DM5GSXC	HS	Investigative
DM5GSXC	SN	CHEMBL438849; [Mpa1, D-Tyr(Et)2, D-Tic7, Aib9]OT
DM5GSXC	PC	44429295
DM5GSXC	MW	1110.4
DM5GSXC	FM	C52H75N11O12S2
DM5GSXC	IC	InChI=1S/C52H75N11O12S2/c1-8-29(5)43-49(72)57-34(18-19-40(53)64)44(67)58-37(25-41(54)65)45(68)60-38(27-77-76-21-20-42(66)56-36(46(69)61-43)23-30-14-16-33(17-15-30)75-9-2)50(73)63-26-32-13-11-10-12-31(32)24-39(63)48(71)59-35(22-28(3)4)47(70)62-52(6,7)51(55)74/h10-17,28-29,34-39,43H,8-9,18-27H2,1-7H3,(H2,53,64)(H2,54,65)(H2,55,74)(H,56,66)(H,57,72)(H,58,67)(H,59,71)(H,60,68)(H,61,69)(H,62,70)/t29-,34-,35-,36-,37-,38-,39+,43-/m0/s1
DM5GSXC	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N)CC(=O)N)CCC(=O)N
DM5GSXC	IK	OKJBACYELSLYOC-QNDTVFEZSA-N
DM5GSXC	IU	(3R)-N-[(2S)-1-[(1-amino-2-methyl-1-oxopropan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM5GSXC	DE	Discovery agent

DMI9MBO	ID	DMI9MBO
DMI9MBO	DN	[Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT
DMI9MBO	HS	Investigative
DMI9MBO	SN	CHEMBL434193; [Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT
DMI9MBO	PC	44429294
DMI9MBO	MW	1184.4
DMI9MBO	FM	C58H77N11O12S2
DMI9MBO	IC	InChI=1S/C58H77N11O12S2/c1-6-33(5)50-56(78)63-40(20-21-47(59)70)52(74)64-42(28-48(60)71)53(75)66-44(31-83-82-23-22-49(72)62-41(54(76)67-50)25-34-16-18-39(19-17-34)81-7-2)58(80)69-30-38-15-11-9-13-36(38)27-46(69)55(77)65-43(24-32(3)4)57(79)68-29-37-14-10-8-12-35(37)26-45(68)51(61)73/h8-19,32-33,40-46,50H,6-7,20-31H2,1-5H3,(H2,59,70)(H2,60,71)(H2,61,73)(H,62,72)(H,63,78)(H,64,74)(H,65,77)(H,66,75)(H,67,76)/t33-,40-,41-,42-,43-,44-,45+,46+,50-/m0/s1
DMI9MBO	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)N5CC6=CC=CC=C6C[C@@H]5C(=O)N)CC(=O)N)CCC(=O)N
DMI9MBO	IK	WNQPWZVGNWMXJD-YJDWKIOXSA-N
DMI9MBO	IU	(3R)-2-[(2S)-2-[[(3R)-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-methylpentanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMI9MBO	DE	Discovery agent

DM3T4JF	ID	DM3T4JF
DM3T4JF	DN	[Mpa1, D-Tyr(Et)2, D-Tic7]OT
DM3T4JF	HS	Investigative
DM3T4JF	SN	CHEMBL233328; [Mpa1, D-Tyr(Et)2, D-Tic7]OT
DM3T4JF	PC	44429290
DM3T4JF	MW	1082.3
DM3T4JF	FM	C50H71N11O12S2
DM3T4JF	IC	InChI=1S/C50H71N11O12S2/c1-6-28(5)43-49(71)56-33(16-17-39(51)62)45(67)57-36(23-40(52)63)46(68)59-37(26-75-74-19-18-42(65)55-35(47(69)60-43)21-29-12-14-32(15-13-29)73-7-2)50(72)61-25-31-11-9-8-10-30(31)22-38(61)48(70)58-34(20-27(3)4)44(66)54-24-41(53)64/h8-15,27-28,33-38,43H,6-7,16-26H2,1-5H3,(H2,51,62)(H2,52,63)(H2,53,64)(H,54,66)(H,55,65)(H,56,71)(H,57,67)(H,58,70)(H,59,68)(H,60,69)/t28-,33-,34-,35-,36-,37-,38+,43-/m0/s1
DM3T4JF	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DM3T4JF	IK	XCBFBYRYXJOIRC-ABNDKVESSA-N
DM3T4JF	IU	(3R)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM3T4JF	DE	Discovery agent

DML8V4F	ID	DML8V4F
DML8V4F	DN	[Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT
DML8V4F	HS	Investigative
DML8V4F	SN	CHEMBL232501; [Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT
DML8V4F	PC	44429300
DML8V4F	MW	1036.3
DML8V4F	FM	C46H73N11O12S2
DML8V4F	IC	InChI=1S/C46H73N11O12S2/c1-10-69-26-13-11-25(12-14-26)20-29-41(65)56-36(45(4,5)6)43(67)52-27(15-16-32(47)58)39(63)53-30(21-33(48)59)40(64)55-31(23-71-70-18-17-35(61)51-29)42(66)57-37(46(7,8)9)44(68)54-28(19-24(2)3)38(62)50-22-34(49)60/h11-14,24,27-31,36-37H,10,15-23H2,1-9H3,(H2,47,58)(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,67)(H,53,63)(H,54,68)(H,55,64)(H,56,65)(H,57,66)/t27-,28-,29-,30-,31-,36+,37+/m0/s1
DML8V4F	CS	CCOC1=CC=C(C=C1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)C(C)(C)C)CC(=O)N)CCC(=O)N)C(C)(C)C
DML8V4F	IK	DUQYFIXOZDQOES-CQRJDLEJSA-N
DML8V4F	IU	(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-N-[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-10-(3-amino-3-oxopropyl)-13-tert-butyl-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DML8V4F	DE	Discovery agent

DMX2SU9	ID	DMX2SU9
DMX2SU9	DN	[Mpa1, D-Tyr(Et)2, Gly(But)7]OT
DMX2SU9	HS	Investigative
DMX2SU9	SN	CHEMBL441128; [Mpa1, D-Tyr(Et)2, Gly(But)7]OT
DMX2SU9	PC	44429299
DMX2SU9	MW	1036.3
DMX2SU9	FM	C46H73N11O12S2
DMX2SU9	IC	InChI=1S/C46H73N11O12S2/c1-9-25(5)37-44(67)52-28(15-16-33(47)58)40(63)53-31(21-34(48)59)41(64)55-32(43(66)57-38(46(6,7)8)45(68)54-29(19-24(3)4)39(62)50-22-35(49)60)23-71-70-18-17-36(61)51-30(42(65)56-37)20-26-11-13-27(14-12-26)69-10-2/h11-14,24-25,28-32,37-38H,9-10,15-23H2,1-8H3,(H2,47,58)(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,67)(H,53,63)(H,54,68)(H,55,64)(H,56,65)(H,57,66)/t25-,28-,29-,30-,31-,32-,37-,38+/m0/s1
DMX2SU9	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)C(C)(C)C)CC(=O)N)CCC(=O)N
DMX2SU9	IK	BTBKJAGQCVEVDA-GDQBDYHJSA-N
DMX2SU9	IU	(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-N-[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMX2SU9	DE	Discovery agent

DM0H3NV	ID	DM0H3NV
DM0H3NV	DN	[Mpa1, D-Tyr(Et)2, L-Tic7]OT
DM0H3NV	HS	Investigative
DM0H3NV	SN	CHEMBL234377; [Mpa1, D-Tyr(Et)2, L-Tic7]OT
DM0H3NV	PC	44429288
DM0H3NV	MW	1082.3
DM0H3NV	FM	C50H71N11O12S2
DM0H3NV	IC	InChI=1S/C50H71N11O12S2/c1-6-28(5)43-49(71)56-33(16-17-39(51)62)45(67)57-36(23-40(52)63)46(68)59-37(26-75-74-19-18-42(65)55-35(47(69)60-43)21-29-12-14-32(15-13-29)73-7-2)50(72)61-25-31-11-9-8-10-30(31)22-38(61)48(70)58-34(20-27(3)4)44(66)54-24-41(53)64/h8-15,27-28,33-38,43H,6-7,16-26H2,1-5H3,(H2,51,62)(H2,52,63)(H2,53,64)(H,54,66)(H,55,65)(H,56,71)(H,57,67)(H,58,70)(H,59,68)(H,60,69)/t28-,33-,34-,35-,36-,37-,38-,43-/m0/s1
DM0H3NV	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CC4=CC=CC=C4C[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DM0H3NV	IK	XCBFBYRYXJOIRC-SXXMFYQFSA-N
DM0H3NV	IU	(3S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM0H3NV	DE	Discovery agent

DM6W4LR	ID	DM6W4LR
DM6W4LR	DN	[Mpa1, D-Tyr(Et)2, Pip7]OT
DM6W4LR	HS	Investigative
DM6W4LR	SN	CHEMBL393020; [Mpa1, D-Tyr(Et)2, Pip7]OT
DM6W4LR	PC	44429298
DM6W4LR	MW	1034.3
DM6W4LR	FM	C46H71N11O12S2
DM6W4LR	IC	InChI=1S/C46H71N11O12S2/c1-6-26(5)39-45(67)52-29(15-16-35(47)58)41(63)53-32(22-36(48)59)42(64)55-33(24-71-70-19-17-38(61)51-31(43(65)56-39)21-27-11-13-28(14-12-27)69-7-2)46(68)57-18-9-8-10-34(57)44(66)54-30(20-25(3)4)40(62)50-23-37(49)60/h11-14,25-26,29-34,39H,6-10,15-24H2,1-5H3,(H2,47,58)(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,67)(H,53,63)(H,54,66)(H,55,64)(H,56,65)/t26-,29-,30-,31-,32-,33-,34-,39-/m0/s1
DM6W4LR	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DM6W4LR	IK	NMLWRIDSUBGNGP-IHJZLXGESA-N
DM6W4LR	IU	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]piperidine-2-carboxamide
DM6W4LR	DE	Discovery agent

DMB4J3N	ID	DMB4J3N
DMB4J3N	DN	[Mpa1, L-Tic7]OT
DMB4J3N	HS	Investigative
DMB4J3N	SN	CHEMBL415418; [Mpa1, L-Tic7]OT
DMB4J3N	PC	16737617
DMB4J3N	MW	1054.2
DMB4J3N	FM	C48H67N11O12S2
DMB4J3N	IC	InChI=1S/C48H67N11O12S2/c1-5-26(4)41-47(70)54-31(14-15-37(49)61)43(66)55-34(21-38(50)62)44(67)57-35(24-73-72-17-16-40(64)53-33(45(68)58-41)19-27-10-12-30(60)13-11-27)48(71)59-23-29-9-7-6-8-28(29)20-36(59)46(69)56-32(18-25(2)3)42(65)52-22-39(51)63/h6-13,25-26,31-36,41,60H,5,14-24H2,1-4H3,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,64)(H,54,70)(H,55,66)(H,56,69)(H,57,67)(H,58,68)/t26-,31-,32-,33-,34-,35-,36-,41-/m0/s1
DMB4J3N	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N3CC4=CC=CC=C4C[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMB4J3N	IK	BEKGLOSGJVQNHG-JSRVRBLWSA-N
DMB4J3N	IU	(3S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMB4J3N	DE	Discovery agent

DMW9AST	ID	DMW9AST
DMW9AST	DN	[N-[2-[(3'-N'-PROPYL-3''ALPHA-(BIS(4-FLUORORPHENYL)METHOXY)TROPANE-2''BETA-CARBOXYLIC ACID METHYL ESTER)(2-MERCAPTOETHYL)AMINO]ACETYL]-2-AMINOETHANETHIOLATO]RHENIUM(V) OXIDE (DIASTEREOMERIC MIX)
DMW9AST	HS	Investigative
DMW9AST	DE	Discovery agent

DM6EAHF	ID	DM6EAHF
DM6EAHF	DN	[N40,Pro1,Tyr4,Nle 14]BB
DM6EAHF	HS	Investigative
DM6EAHF	PC	91933168
DM6EAHF	MW	1838.1
DM6EAHF	FM	C84H132N28O19
DM6EAHF	IC	InChI=1S/C84H132N28O19/c1-7-8-9-16-55(71(90)119)104-78(126)59(33-45(2)3)108-79(127)62(36-51-41-95-44-100-51)102-69(118)43-99-82(130)70(46(4)5)111-72(120)47(6)101-77(125)61(35-49-40-97-54-15-11-10-14-53(49)54)110-76(124)57(23-25-65(87)114)106-80(128)63(37-67(89)116)103-68(117)42-98-73(121)60(34-48-19-21-52(113)22-20-48)109-74(122)56(17-12-29-96-84(91)92)105-75(123)58(24-26-66(88)115)107-81(129)64-18-13-32-112(64)83(131)50(38-93-30-27-85)39-94-31-28-86/h10-11,14-15,19-22,40-41,44-47,50,55-64,70,93-94,97,113H,7-9,12-13,16-18,23-39,42-43,85-86H2,1-6H3,(H2,87,114)(H2,88,115)(H2,89,116)(H2,90,119)(H,95,100)(H,98,121)(H,99,130)(H,101,125)(H,102,118)(H,103,117)(H,104,126)(H,105,123)(H,106,128)(H,107,129)(H,108,127)(H,109,122)(H,110,124)(H,111,120)(H4,91,92,96)/t47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64?,70-/m0/s1
DM6EAHF	CS	CCCCC[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C5CCCN5C(=O)C(CNCCN)CNCCN
DM6EAHF	IK	KQHZZRQJOXXKSD-LJBQZBCTSA-N
DM6EAHF	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxoheptan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[1-[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]pyrrolidine-2-carbonyl]amino]pentanediamide
DM6EAHF	DE	Discovery agent

DMVFHNM	ID	DMVFHNM
DMVFHNM	DN	[N40,Pro1,Tyr4]BB
DMVFHNM	HS	Investigative
DMVFHNM	PC	91933169
DMVFHNM	MW	1856.2
DMVFHNM	FM	C83H130N28O19S
DMVFHNM	IC	InChI=1S/C83H130N28O19S/c1-44(2)32-58(77(125)103-54(70(89)118)15-11-31-131-6)107-78(126)61(35-50-40-94-43-99-50)101-68(117)42-98-81(129)69(45(3)4)110-71(119)46(5)100-76(124)60(34-48-39-96-53-13-8-7-12-52(48)53)109-75(123)56(21-23-64(86)113)105-79(127)62(36-66(88)115)102-67(116)41-97-72(120)59(33-47-17-19-51(112)20-18-47)108-73(121)55(14-9-27-95-83(90)91)104-74(122)57(22-24-65(87)114)106-80(128)63-16-10-30-111(63)82(130)49(37-92-28-25-84)38-93-29-26-85/h7-8,12-13,17-20,39-40,43-46,49,54-63,69,92-93,96,112H,9-11,14-16,21-38,41-42,84-85H2,1-6H3,(H2,86,113)(H2,87,114)(H2,88,115)(H2,89,118)(H,94,99)(H,97,120)(H,98,129)(H,100,124)(H,101,117)(H,102,116)(H,103,125)(H,104,122)(H,105,127)(H,106,128)(H,107,126)(H,108,121)(H,109,123)(H,110,119)(H4,90,91,95)/t46-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63?,69-/m0/s1
DMVFHNM	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C5CCCN5C(=O)C(CNCCN)CNCCN
DMVFHNM	IK	WPAOEAXJLCSDBY-UKYQNQGLSA-N
DMVFHNM	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-methylsulfanyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[1-[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]pyrrolidine-2-carbonyl]amino]pentanediamide
DMVFHNM	DE	Discovery agent

DMW6LIJ	ID	DMW6LIJ
DMW6LIJ	DN	[N-Ac,des-Sar]Gal-B2
DMW6LIJ	HS	Investigative
DMW6LIJ	SN	CHEMBL578317; [N-Ac,des-Sar]Gal-B2
DMW6LIJ	PC	45104656
DMW6LIJ	MW	2083.6
DMW6LIJ	FM	C103H171N23O22
DMW6LIJ	IC	InChI=1S/C103H171N23O22/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-86(132)109-50-33-29-40-75(93(138)116-73(90(108)135)37-26-30-47-104)118-94(139)74(38-27-31-48-105)117-95(140)76(39-28-32-49-106)119-102(147)84-41-34-51-126(84)88(134)60-112-92(137)77(52-62(2)3)120-96(141)78(53-63(4)5)121-98(143)80(55-68-43-45-70(130)46-44-68)115-87(133)59-111-91(136)65(8)113-101(146)83(61-127)124-99(144)82(57-85(107)131)122-97(142)79(54-64(6)7)123-103(148)89(66(9)128)125-100(145)81(114-67(10)129)56-69-58-110-72-36-25-24-35-71(69)72/h24-25,35-36,43-46,58,62-66,73-84,89,110,127-128,130H,11-23,26-34,37-42,47-57,59-61,104-106H2,1-10H3,(H2,107,131)(H2,108,135)(H,109,132)(H,111,136)(H,112,137)(H,113,146)(H,114,129)(H,115,133)(H,116,138)(H,117,140)(H,118,139)(H,119,147)(H,120,141)(H,121,143)(H,122,142)(H,123,148)(H,124,144)(H,125,145)/t65-,66+,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,89-/m0/s1
DMW6LIJ	CS	CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)C
DMW6LIJ	IK	ODFVMHJVAFRRKO-QWBMYOKVSA-N
DMW6LIJ	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMW6LIJ	DE	Discovery agent

DME6LKY	ID	DME6LKY
DME6LKY	DN	[Ncy(2-naphthyl)1]acyline
DME6LKY	HS	Investigative
DME6LKY	SN	CHEMBL414344; [Ncy(2-naphthyl)1]acyline
DME6LKY	PC	16138575
DME6LKY	MW	1533.2
DME6LKY	FM	C80H102ClN15O14
DME6LKY	IC	InChI=1S/C80H102ClN15O14/c1-46(2)37-63(72(102)89-62(18-11-12-35-84-47(3)4)80(110)96-36-14-19-70(96)79(109)85-48(5)71(82)101)90-74(104)66(40-53-23-30-60(31-24-53)86-49(6)98)92-76(106)67(41-54-25-32-61(33-26-54)87-50(7)99)94-78(108)69(45-97)95-77(107)68(43-56-15-13-34-83-44-56)93-75(105)65(39-52-21-28-59(81)29-22-52)91-73(103)64(88-51(8)100)42-55-20-27-57-16-9-10-17-58(57)38-55/h9-10,13,15-17,20-34,38,44,46-48,62-70,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,109)(H,86,98)(H,87,99)(H,88,100)(H,89,102)(H,90,104)(H,91,103)(H,92,106)(H,93,105)(H,94,108)(H,95,107)/t48-,62+,63+,64+,65-,66-,67+,68-,69+,70+/m1/s1
DME6LKY	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DME6LKY	IK	ZWNUQDJANZGVFO-ITULWGTLSA-N
DME6LKY	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DME6LKY	DE	Discovery agent

DM5CS8U	ID	DM5CS8U
DM5CS8U	DN	[Ncy(isopropyl)7]acyline
DM5CS8U	HS	Investigative
DM5CS8U	SN	CHEMBL415659; [Ncy(isopropyl)7]acyline
DM5CS8U	PC	16221494
DM5CS8U	MW	1551.2
DM5CS8U	FM	C79H100ClN15O14S
DM5CS8U	IC	InChI=1S/C79H100ClN15O14S/c1-45(2)83-35-12-11-18-61(79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)88-77(108)78(110-46(3)4)94-74(105)65(40-53-25-32-60(33-26-53)86-49(7)98)90-72(103)64(39-52-23-30-59(31-24-52)85-48(6)97)92-75(106)67(44-96)93-73(104)66(42-55-15-13-34-82-43-55)91-71(102)63(38-51-21-28-58(80)29-22-51)89-70(101)62(87-50(8)99)41-54-20-27-56-16-9-10-17-57(56)37-54/h9-10,13,15-17,20-34,37,43,45-47,61-68,78,83,96H,11-12,14,18-19,35-36,38-42,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,108)(H,89,101)(H,90,103)(H,91,102)(H,92,106)(H,93,104)(H,94,105)/t47-,61+,62-,63-,64+,65-,66-,67+,68+,78+/m1/s1
DM5CS8U	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)SC(C)C
DM5CS8U	IK	GFSHJVRBLLVKAZ-FYZIRFIYSA-N
DM5CS8U	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-2-propan-2-ylsulfanylacetyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM5CS8U	DE	Discovery agent

DM9RC3O	ID	DM9RC3O
DM9RC3O	DN	[Ncy(methyl)10]acyline
DM9RC3O	HS	Investigative
DM9RC3O	SN	CHEMBL427438; [Ncy(methyl)10]acyline
DM9RC3O	PC	16221266
DM9RC3O	MW	1565.3
DM9RC3O	FM	C80H102ClN15O14S
DM9RC3O	IC	InChI=1S/C80H102ClN15O14S/c1-46(2)37-62(71(102)88-61(18-11-12-35-84-47(3)4)80(110)96-36-14-19-69(96)78(109)95-79(111-8)70(82)101)89-73(104)65(40-52-23-30-59(31-24-52)85-48(5)98)91-75(106)66(41-53-25-32-60(33-26-53)86-49(6)99)93-77(108)68(45-97)94-76(107)67(43-55-15-13-34-83-44-55)92-74(105)64(39-51-21-28-58(81)29-22-51)90-72(103)63(87-50(7)100)42-54-20-27-56-16-9-10-17-57(56)38-54/h9-10,13,15-17,20-34,38,44,46-47,61-69,79,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,98)(H,86,99)(H,87,100)(H,88,102)(H,89,104)(H,90,103)(H,91,106)(H,92,105)(H,93,108)(H,94,107)(H,95,109)/t61-,62-,63+,64+,65+,66-,67+,68-,69-,79-/m0/s1
DM9RC3O	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)SC)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM9RC3O	IK	MNOHGPTZCIGJAF-SLOMUXTRSA-N
DM9RC3O	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(1S)-2-amino-1-methylsulfanyl-2-oxoethyl]pyrrolidine-2-carboxamide
DM9RC3O	DE	Discovery agent

DMLK8YQ	ID	DMLK8YQ
DMLK8YQ	DN	[Ncy(methyl)4]acyline
DMLK8YQ	HS	Investigative
DMLK8YQ	SN	CHEMBL388369; [Ncy(methyl)4]acyline
DMLK8YQ	PC	16221433
DMLK8YQ	MW	1549.3
DMLK8YQ	FM	C80H102ClN15O13S
DMLK8YQ	IC	InChI=1S/C80H102ClN15O13S/c1-46(2)38-63(71(101)89-62(19-12-13-36-84-47(3)4)80(109)96-37-15-20-69(96)77(107)85-48(5)70(82)100)90-73(103)66(41-53-24-31-60(32-25-53)86-49(6)97)92-75(105)67(42-54-26-33-61(34-27-54)87-50(7)98)94-78(108)79(110-9)95-76(106)68(44-56-16-14-35-83-45-56)93-74(104)65(40-52-22-29-59(81)30-23-52)91-72(102)64(88-51(8)99)43-55-21-28-57-17-10-11-18-58(57)39-55/h10-11,14,16-18,21-35,39,45-48,62-69,79,84H,12-13,15,19-20,36-38,40-44H2,1-9H3,(H2,82,100)(H,85,107)(H,86,97)(H,87,98)(H,88,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,108)(H,95,106)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,79+/m1/s1
DMLK8YQ	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@@H](NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)SC
DMLK8YQ	IK	HPTFWQIEIVLQOX-CYCWPGSHSA-N
DMLK8YQ	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-2-methylsulfanylacetyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMLK8YQ	DE	Discovery agent

DMEFIQ9	ID	DMEFIQ9
DMEFIQ9	DN	[Ncy(SO,isopropyl)7]acyline
DMEFIQ9	HS	Investigative
DMEFIQ9	SN	CHEMBL441211; [Ncy(SO,isopropyl)7]acyline
DMEFIQ9	PC	16221211
DMEFIQ9	MW	1567.2
DMEFIQ9	FM	C79H100ClN15O15S
DMEFIQ9	IC	InChI=1S/C79H100ClN15O15S/c1-45(2)83-35-12-11-18-61(79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)88-77(108)78(111(110)46(3)4)94-74(105)65(40-53-25-32-60(33-26-53)86-49(7)98)90-72(103)64(39-52-23-30-59(31-24-52)85-48(6)97)92-75(106)67(44-96)93-73(104)66(42-55-15-13-34-82-43-55)91-71(102)63(38-51-21-28-58(80)29-22-51)89-70(101)62(87-50(8)99)41-54-20-27-56-16-9-10-17-57(56)37-54/h9-10,13,15-17,20-34,37,43,45-47,61-68,78,83,96H,11-12,14,18-19,35-36,38-42,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,108)(H,89,101)(H,90,103)(H,91,102)(H,92,106)(H,93,104)(H,94,105)/t47-,61+,62-,63-,64+,65-,66-,67+,68+,78+,111?/m1/s1
DMEFIQ9	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)S(=O)C(C)C
DMEFIQ9	IK	KEFJIAHSOLWSII-RUFKGVBESA-N
DMEFIQ9	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-2-propan-2-ylsulfinylacetyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMEFIQ9	DE	Discovery agent

DMT8X45	ID	DMT8X45
DMT8X45	DN	[Ncy(SO,methyl)10]acyline
DMT8X45	HS	Investigative
DMT8X45	SN	CHEMBL389248; [Ncy(SO,methyl)10]acyline
DMT8X45	PC	16221496
DMT8X45	MW	1581.3
DMT8X45	FM	C80H102ClN15O15S
DMT8X45	IC	InChI=1S/C80H102ClN15O15S/c1-46(2)37-62(71(102)88-61(18-11-12-35-84-47(3)4)80(110)96-36-14-19-69(96)78(109)95-79(70(82)101)112(8)111)89-73(104)65(40-52-23-30-59(31-24-52)85-48(5)98)91-75(106)66(41-53-25-32-60(33-26-53)86-49(6)99)93-77(108)68(45-97)94-76(107)67(43-55-15-13-34-83-44-55)92-74(105)64(39-51-21-28-58(81)29-22-51)90-72(103)63(87-50(7)100)42-54-20-27-56-16-9-10-17-57(56)38-54/h9-10,13,15-17,20-34,38,44,46-47,61-69,79,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,98)(H,86,99)(H,87,100)(H,88,102)(H,89,104)(H,90,103)(H,91,106)(H,92,105)(H,93,108)(H,94,107)(H,95,109)/t61-,62-,63+,64+,65+,66-,67+,68-,69-,79-,112?/m0/s1
DMT8X45	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)S(=O)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMT8X45	IK	SELUBVJEWYERMJ-DDPYUAONSA-N
DMT8X45	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(1S)-2-amino-1-methylsulfinyl-2-oxoethyl]pyrrolidine-2-carboxamide
DMT8X45	DE	Discovery agent

DM057MP	ID	DM057MP
DM057MP	DN	[Ncy(SO,methyl)4]acyline
DM057MP	HS	Investigative
DM057MP	SN	CHEMBL415432; [Ncy(SO,methyl)4]acyline
DM057MP	PC	16221150
DM057MP	MW	1565.3
DM057MP	FM	C80H102ClN15O14S
DM057MP	IC	InChI=1S/C80H102ClN15O14S/c1-46(2)38-63(71(101)89-62(19-12-13-36-84-47(3)4)80(109)96-37-15-20-69(96)77(107)85-48(5)70(82)100)90-73(103)66(41-53-24-31-60(32-25-53)86-49(6)97)92-75(105)67(42-54-26-33-61(34-27-54)87-50(7)98)94-78(108)79(111(9)110)95-76(106)68(44-56-16-14-35-83-45-56)93-74(104)65(40-52-22-29-59(81)30-23-52)91-72(102)64(88-51(8)99)43-55-21-28-57-17-10-11-18-58(57)39-55/h10-11,14,16-18,21-35,39,45-48,62-69,79,84H,12-13,15,19-20,36-38,40-44H2,1-9H3,(H2,82,100)(H,85,107)(H,86,97)(H,87,98)(H,88,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,108)(H,95,106)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,79+,111?/m1/s1
DM057MP	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@@H](NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)S(=O)C
DM057MP	IK	VCYXYVFYPVPVGF-SBGSYDNWSA-N
DM057MP	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-2-methylsulfinylacetyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM057MP	DE	Discovery agent

DM4XFOH	ID	DM4XFOH
DM4XFOH	DN	[N-Me,des-Sar]Gal-B2
DM4XFOH	HS	Investigative
DM4XFOH	SN	CHEMBL604991; [N-Me,des-Sar]Gal-B2
DM4XFOH	PC	45104657
DM4XFOH	MW	2055.6
DM4XFOH	FM	C102H171N23O21
DM4XFOH	IC	InChI=1S/C102H171N23O21/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-85(130)109-50-33-29-40-74(92(136)115-72(89(107)133)37-26-30-47-103)117-93(137)73(38-27-31-48-104)116-94(138)75(39-28-32-49-105)118-101(145)83-41-34-51-125(83)87(132)60-112-91(135)77(52-62(2)3)119-96(140)78(53-63(4)5)120-98(142)80(55-67-43-45-69(128)46-44-67)114-86(131)59-111-90(134)65(8)113-100(144)82(61-126)123-99(143)81(57-84(106)129)121-97(141)79(54-64(6)7)122-102(146)88(66(9)127)124-95(139)76(108-10)56-68-58-110-71-36-25-24-35-70(68)71/h24-25,35-36,43-46,58,62-66,72-83,88,108,110,126-128H,11-23,26-34,37-42,47-57,59-61,103-105H2,1-10H3,(H2,106,129)(H2,107,133)(H,109,130)(H,111,134)(H,112,135)(H,113,144)(H,114,131)(H,115,136)(H,116,138)(H,117,137)(H,118,145)(H,119,140)(H,120,142)(H,121,141)(H,122,146)(H,123,143)(H,124,139)/t65-,66+,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,88-/m0/s1
DM4XFOH	CS	CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC
DM4XFOH	IK	WZUYPFZMVKTBDB-CWYLLMHLSA-N
DM4XFOH	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S,3R)-3-hydroxy-2-[[(2S)-3-(1H-indol-3-yl)-2-(methylamino)propanoyl]amino]butanoyl]amino]-4-methylpentanoyl]amino]butanediamide
DM4XFOH	DE	Discovery agent

DMTG17Q	ID	DMTG17Q
DMTG17Q	DN	[Nphe(1)]-nociceptin (1-13)-NH(2)
DMTG17Q	HS	Investigative
DMTG17Q	DT	Small molecular drug
DMTG17Q	PC	24776433
DMTG17Q	MW	500.4
DMTG17Q	FM	C21H27F2N4O6P
DMTG17Q	IC	InChI=1S/C18H19F2N3O.C3H8NO5P/c1-23-9-14(16(22-23)17(19)20)18(24)21-15-5-3-2-4-11(15)13-8-12(13)10-6-7-10;5-3(6)1-4-2-10(7,8)9/h2-5,9-10,12-13,17H,6-8H2,1H3,(H,21,24);4H,1-2H2,(H,5,6)(H2,7,8,9)
DMTG17Q	CS	CN1C=C(C(=N1)C(F)F)C(=O)NC2=CC=CC=C2C3CC3C4CC4.C(C(=O)O)NCP(=O)(O)O
DMTG17Q	IK	ZLEQCJLOZSQAHT-UHFFFAOYSA-N
DMTG17Q	IU	N-[2-(2-cyclopropylcyclopropyl)phenyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide;2-(phosphonomethylamino)acetic acid
DMTG17Q	DE	Discovery agent

DMK18CS	ID	DMK18CS
DMK18CS	DN	[Phe3]OT
DMK18CS	HS	Investigative
DMK18CS	SN	[Phe3]oxytocin; oxypressin
DMK18CS	DT	Small molecular drug
DMK18CS	PC	164712
DMK18CS	MW	1041.2
DMK18CS	FM	C46H64N12O12S2
DMK18CS	IC	InChI=1S/C46H64N12O12S2/c1-24(2)17-30(40(64)51-21-38(50)62)56-45(69)35-9-6-16-58(35)46(70)34-23-72-71-22-28(47)39(63)53-31(19-26-10-12-27(59)13-11-26)43(67)54-32(18-25-7-4-3-5-8-25)42(66)52-29(14-15-36(48)60)41(65)55-33(20-37(49)61)44(68)57-34/h3-5,7-8,10-13,24,28-35,59H,6,9,14-23,47H2,1-2H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,63)(H,54,67)(H,55,65)(H,56,69)(H,57,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DMK18CS	CS	CC(C)C[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N
DMK18CS	IK	WTHKESHUHBGMGM-DZCXQCEKSA-N
DMK18CS	IU	(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMK18CS	CA	CAS 642-35-3
DMK18CS	DE	Discovery agent

DMXJDEA	ID	DMXJDEA
DMXJDEA	DN	[Pip7]OT
DMXJDEA	HS	Investigative
DMXJDEA	SN	CHEMBL395290; [Pip7]OT
DMXJDEA	PC	44429250
DMXJDEA	MW	1021.2
DMXJDEA	FM	C44H68N12O12S2
DMXJDEA	IC	InChI=1S/C44H68N12O12S2/c1-5-23(4)36-43(67)50-27(13-14-33(46)58)39(63)52-30(18-34(47)59)40(64)54-31(21-70-69-20-26(45)37(61)51-29(41(65)55-36)17-24-9-11-25(57)12-10-24)44(68)56-15-7-6-8-32(56)42(66)53-28(16-22(2)3)38(62)49-19-35(48)60/h9-12,22-23,26-32,36,57H,5-8,13-21,45H2,1-4H3,(H2,46,58)(H2,47,59)(H2,48,60)(H,49,62)(H,50,67)(H,51,61)(H,52,63)(H,53,66)(H,54,64)(H,55,65)/t23-,26-,27-,28-,29-,30-,31-,32-,36-/m0/s1
DMXJDEA	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMXJDEA	IK	AEGMQTAGVURKHK-CKNUHMDMSA-N
DMXJDEA	IU	(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]piperidine-2-carboxamide
DMXJDEA	DE	Discovery agent

DM4ZY79	ID	DM4ZY79
DM4ZY79	DN	[Pterin-6-Yl Methanyl]-Phosphonophosphate
DM4ZY79	HS	Investigative
DM4ZY79	DT	Small molecular drug
DM4ZY79	PC	135440058
DM4ZY79	MW	353.12
DM4ZY79	FM	C7H9N5O8P2
DM4ZY79	IC	InChI=1S/C7H9N5O8P2/c8-7-11-5-4(6(13)12-7)10-3(1-9-5)2-19-22(17,18)20-21(14,15)16/h1H,2H2,(H,17,18)(H2,14,15,16)(H3,8,9,11,12,13)
DM4ZY79	CS	C1=C(N=C2C(=O)NC(=NC2=N1)N)COP(=O)(O)OP(=O)(O)O
DM4ZY79	IK	AMDUVUKDRBIVAH-UHFFFAOYSA-N
DM4ZY79	IU	(2-amino-4-oxo-3H-pteridin-6-yl)methyl phosphono hydrogen phosphate
DM4ZY79	CA	CAS 6863-06-5
DM4ZY79	DE	Discovery agent

DM8YF3V	ID	DM8YF3V
DM8YF3V	DN	[R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether
DM8YF3V	HS	Investigative
DM8YF3V	SN	CHEMBL457275; BDBM50251328
DM8YF3V	DT	Small molecular drug
DM8YF3V	PC	44567595
DM8YF3V	MW	327.4
DM8YF3V	FM	C19H21NO4
DM8YF3V	IC	InChI=1S/C19H21NO4/c1-20-5-4-12-8-13(24-7-6-21)10-14-17(12)15(20)9-11-2-3-16(22)19(23)18(11)14/h2-3,8,10,15,21-23H,4-7,9H2,1H3/t15-/m1/s1
DM8YF3V	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OCCO)C(=C(C=C4)O)O
DM8YF3V	IK	MLSWBRKIYGJEGT-OAHLLOKOSA-N
DM8YF3V	IU	(6aR)-2-(2-hydroxyethoxy)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DM8YF3V	DE	Discovery agent

DMUF7DP	ID	DMUF7DP
DMUF7DP	DN	[Sar,D-Phe8,des-Arg9]bradykinin
DMUF7DP	HS	Investigative
DMUF7DP	SN	[N-methylglycine,D-Phe8,des-Arg9]bradykinin; [sarcosine,D-Phe8,des-Arg9]bradykinin; Sar[DPhe8][des-Arg9]BK
DMUF7DP	DT	Small molecular drug
DMUF7DP	PC	164234
DMUF7DP	MW	975.1
DMUF7DP	FM	C47H66N12O11
DMUF7DP	IC	InChI=1S/C47H66N12O11/c1-50-26-38(61)53-31(16-8-20-51-47(48)49)43(66)59-23-11-19-37(59)45(68)58-22-9-17-35(58)41(64)52-27-39(62)54-32(24-29-12-4-2-5-13-29)40(63)56-34(28-60)44(67)57-21-10-18-36(57)42(65)55-33(46(69)70)25-30-14-6-3-7-15-30/h2-7,12-15,31-37,50,60H,8-11,16-28H2,1H3,(H,52,64)(H,53,61)(H,54,62)(H,55,65)(H,56,63)(H,69,70)(H4,48,49,51)/t31-,32-,33+,34-,35-,36-,37-/m0/s1
DMUF7DP	CS	CNCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@H](CC5=CC=CC=C5)C(=O)O
DMUF7DP	IK	YIUBSFCQATYQJB-VCMDLEIESA-N
DMUF7DP	IU	(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMUF7DP	CA	CAS 126959-88-4
DMUF7DP	DE	Discovery agent

DM1HQ3D	ID	DM1HQ3D
DM1HQ3D	DN	[Sar1,Bpa2]AngII
DM1HQ3D	HS	Investigative
DM1HQ3D	SN	CHEMBL1076601; [Sar1,Bpa2]AngII
DM1HQ3D	PC	45140373
DM1HQ3D	MW	1097.3
DM1HQ3D	FM	C59H72N10O11
DM1HQ3D	IC	InChI=1S/C59H72N10O11/c1-6-36(4)51(57(77)65-46(31-42-32-61-34-62-42)58(78)69-27-13-18-48(69)55(75)66-47(59(79)80)30-37-14-9-7-10-15-37)68-54(74)45(29-39-21-25-43(70)26-22-39)64-56(76)50(35(2)3)67-53(73)44(63-49(71)33-60-5)28-38-19-23-41(24-20-38)52(72)40-16-11-8-12-17-40/h7-12,14-17,19-26,32,34-36,44-48,50-51,60,70H,6,13,18,27-31,33H2,1-5H3,(H,61,62)(H,63,71)(H,64,76)(H,65,77)(H,66,75)(H,67,73)(H,68,74)(H,79,80)/t36-,44-,45-,46-,47-,48-,50-,51-/m0/s1
DM1HQ3D	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)C(=O)C6=CC=CC=C6)NC(=O)CNC
DM1HQ3D	IK	BXRVAHMUUBZAPK-RUFDXANVSA-N
DM1HQ3D	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(4-benzoylphenyl)-2-[[2-(methylamino)acetyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DM1HQ3D	DE	Discovery agent

DMP64XH	ID	DMP64XH
DMP64XH	DN	[Sar1,Bpa3]AngII
DMP64XH	HS	Investigative
DMP64XH	SN	CHEMBL1076603; [Sar1,Bpa3]AngII
DMP64XH	PC	46880541
DMP64XH	MW	1154.3
DMP64XH	FM	C60H75N13O11
DMP64XH	IC	InChI=1S/C60H75N13O11/c1-4-36(2)51(57(81)70-47(32-42-33-64-35-66-42)58(82)73-28-12-18-49(73)56(80)71-48(59(83)84)31-37-13-7-5-8-14-37)72-55(79)46(30-39-21-25-43(74)26-22-39)69-54(78)45(29-38-19-23-41(24-20-38)52(76)40-15-9-6-10-16-40)68-53(77)44(67-50(75)34-63-3)17-11-27-65-60(61)62/h5-10,13-16,19-26,33,35-36,44-49,51,63,74H,4,11-12,17-18,27-32,34H2,1-3H3,(H,64,66)(H,67,75)(H,68,77)(H,69,78)(H,70,81)(H,71,80)(H,72,79)(H,83,84)(H4,61,62,65)/t36-,44-,45-,46-,47-,48-,49-,51-/m0/s1
DMP64XH	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=C(C=C5)C(=O)C6=CC=CC=C6)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMP64XH	IK	PXNIGPMZOUUXMA-FSKISDTGSA-N
DMP64XH	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-(4-benzoylphenyl)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMP64XH	DE	Discovery agent

DMWC10R	ID	DMWC10R
DMWC10R	DN	[Sar1,Bpa8]AngII
DMWC10R	HS	Investigative
DMWC10R	SN	CHEMBL1076632; [Sar1,Bpa8]AngII
DMWC10R	PC	46880544
DMWC10R	MW	1106.3
DMWC10R	FM	C56H75N13O11
DMWC10R	IC	InChI=1S/C56H75N13O11/c1-6-33(4)47(68-50(74)41(26-35-18-22-39(70)23-19-35)64-52(76)46(32(2)3)67-49(73)40(63-45(71)30-59-5)14-10-24-61-56(57)58)53(77)65-42(28-38-29-60-31-62-38)54(78)69-25-11-15-44(69)51(75)66-43(55(79)80)27-34-16-20-37(21-17-34)48(72)36-12-8-7-9-13-36/h7-9,12-13,16-23,29,31-33,40-44,46-47,59,70H,6,10-11,14-15,24-28,30H2,1-5H3,(H,60,62)(H,63,71)(H,64,76)(H,65,77)(H,66,75)(H,67,73)(H,68,74)(H,79,80)(H4,57,58,61)/t33-,40-,41-,42-,43-,44-,46-,47-/m0/s1
DMWC10R	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=C(C=C3)C(=O)C4=CC=CC=C4)C(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMWC10R	IK	CLBUUAFJDOTEBS-AAVPAQJNSA-N
DMWC10R	IU	(2S)-3-(4-benzoylphenyl)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid
DMWC10R	DE	Discovery agent

DM4AUFR	ID	DM4AUFR
DM4AUFR	DN	[Sar1,Tdf2]AngII
DM4AUFR	HS	Investigative
DM4AUFR	SN	CHEMBL1076602; [Sar1,Tdf2]AngII
DM4AUFR	PC	45140942
DM4AUFR	MW	1101.2
DM4AUFR	FM	C54H67F3N12O10
DM4AUFR	IC	InChI=1S/C54H67F3N12O10/c1-6-31(4)45(50(76)63-40(26-36-27-59-29-60-36)51(77)69-22-10-13-42(69)48(74)64-41(52(78)79)25-32-11-8-7-9-12-32)66-47(73)39(24-34-16-20-37(70)21-17-34)62-49(75)44(30(2)3)65-46(72)38(61-43(71)28-58-5)23-33-14-18-35(19-15-33)53(67-68-53)54(55,56)57/h7-9,11-12,14-21,27,29-31,38-42,44-45,58,70H,6,10,13,22-26,28H2,1-5H3,(H,59,60)(H,61,71)(H,62,75)(H,63,76)(H,64,74)(H,65,72)(H,66,73)(H,78,79)/t31-,38-,39-,40-,41-,42-,44-,45-/m0/s1
DM4AUFR	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)C6(N=N6)C(F)(F)F)NC(=O)CNC
DM4AUFR	IK	IANMQZMQGQLRSI-LTTXXCTBSA-N
DM4AUFR	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-3-methyl-2-[[(2S)-2-[[2-(methylamino)acetyl]amino]-3-[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl]propanoyl]amino]butanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DM4AUFR	DE	Discovery agent

DMWCS4Y	ID	DMWCS4Y
DMWCS4Y	DN	[Sar1,Tdf3]AngII
DMWCS4Y	HS	Investigative
DMWCS4Y	SN	CHEMBL1076604; [Sar1,Tdf3]AngII
DMWCS4Y	PC	45141142
DMWCS4Y	MW	1158.2
DMWCS4Y	FM	C55H70F3N15O10
DMWCS4Y	IC	InChI=1S/C55H70F3N15O10/c1-4-31(2)45(50(80)68-41(27-36-28-62-30-64-36)51(81)73-23-9-13-43(73)49(79)69-42(52(82)83)26-32-10-6-5-7-11-32)70-48(78)40(25-34-16-20-37(74)21-17-34)67-47(77)39(24-33-14-18-35(19-15-33)54(71-72-54)55(56,57)58)66-46(76)38(65-44(75)29-61-3)12-8-22-63-53(59)60/h5-7,10-11,14-21,28,30-31,38-43,45,61,74H,4,8-9,12-13,22-27,29H2,1-3H3,(H,62,64)(H,65,75)(H,66,76)(H,67,77)(H,68,80)(H,69,79)(H,70,78)(H,82,83)(H4,59,60,63)/t31-,38-,39-,40-,41-,42-,43-,45-/m0/s1
DMWCS4Y	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=C(C=C5)C6(N=N6)C(F)(F)F)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMWCS4Y	IK	SMLIEFKCEBMVHX-YUDJOFGFSA-N
DMWCS4Y	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMWCS4Y	DE	Discovery agent

DMTNGCW	ID	DMTNGCW
DMTNGCW	DN	[Sar1,Tdf8]AngII
DMTNGCW	HS	Investigative
DMTNGCW	SN	CHEMBL1076633; [Sar1,Tdf8]AngII
DMTNGCW	PC	46880545
DMTNGCW	MW	1110.2
DMTNGCW	FM	C51H70F3N15O10
DMTNGCW	IC	InChI=1S/C51H70F3N15O10/c1-6-28(4)41(66-43(73)35(21-30-13-17-33(70)18-14-30)62-45(75)40(27(2)3)65-42(72)34(61-39(71)25-57-5)9-7-19-59-49(55)56)46(76)63-36(23-32-24-58-26-60-32)47(77)69-20-8-10-38(69)44(74)64-37(48(78)79)22-29-11-15-31(16-12-29)50(67-68-50)51(52,53)54/h11-18,24,26-28,34-38,40-41,57,70H,6-10,19-23,25H2,1-5H3,(H,58,60)(H,61,71)(H,62,75)(H,63,76)(H,64,74)(H,65,72)(H,66,73)(H,78,79)(H4,55,56,59)/t28-,34-,35-,36-,37-,38-,40-,41-/m0/s1
DMTNGCW	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=C(C=C3)C4(N=N4)C(F)(F)F)C(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMTNGCW	IK	KSJIPXWEUUGTIY-LNEAKYCGSA-N
DMTNGCW	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl]propanoic acid
DMTNGCW	DE	Discovery agent

DMUD0LA	ID	DMUD0LA
DMUD0LA	DN	[Sar1Ala]GAL-B2
DMUD0LA	HS	Investigative
DMUD0LA	SN	CHEMBL578910; [Sar1Ala]GAL-B2
DMUD0LA	PC	45104655
DMUD0LA	MW	2112.6
DMUD0LA	FM	C104H174N24O22
DMUD0LA	IC	InChI=1S/C104H174N24O22/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-86(133)111-50-33-29-40-75(94(140)117-73(90(110)136)37-26-30-47-105)119-95(141)74(38-27-31-48-106)118-96(142)76(39-28-32-49-107)120-103(149)84-41-34-51-128(84)88(135)60-114-93(139)77(52-62(2)3)122-97(143)78(53-63(4)5)123-99(145)80(55-68-43-45-70(131)46-44-68)116-87(134)59-113-92(138)66(9)115-102(148)83(61-129)126-100(146)82(57-85(109)132)124-98(144)79(54-64(6)7)125-104(150)89(67(10)130)127-101(147)81(121-91(137)65(8)108)56-69-58-112-72-36-25-24-35-71(69)72/h24-25,35-36,43-46,58,62-67,73-84,89,112,129-131H,11-23,26-34,37-42,47-57,59-61,105-108H2,1-10H3,(H2,109,132)(H2,110,136)(H,111,133)(H,113,138)(H,114,139)(H,115,148)(H,116,134)(H,117,140)(H,118,142)(H,119,141)(H,120,149)(H,121,137)(H,122,143)(H,123,145)(H,124,144)(H,125,150)(H,126,146)(H,127,147)/t65-,66-,67+,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,89-/m0/s1
DMUD0LA	CS	CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](C)N
DMUD0LA	IK	SYZGVJVRSWLTDO-ZYVMWFDRSA-N
DMUD0LA	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]butanediamide
DMUD0LA	DE	Discovery agent

DMUI0XV	ID	DMUI0XV
DMUI0XV	DN	[Sar1Gly]GAL-B2
DMUI0XV	HS	Investigative
DMUI0XV	SN	CHEMBL499807; [Sar1Gly]GAL-B2
DMUI0XV	PC	25180489
DMUI0XV	MW	2098.6
DMUI0XV	FM	C103H172N24O22
DMUI0XV	IC	InChI=1S/C103H172N24O22/c1-10-11-12-13-14-15-16-17-18-19-20-21-22-41-85(132)110-49-32-28-39-74(93(139)117-72(90(109)136)36-25-29-46-104)119-94(140)73(37-26-30-47-105)118-95(141)75(38-27-31-48-106)120-102(148)83-40-33-50-127(83)88(135)60-113-92(138)76(51-62(2)3)121-96(142)77(52-63(4)5)122-98(144)79(54-67-42-44-69(130)45-43-67)116-87(134)59-112-91(137)65(8)114-101(147)82(61-128)125-99(145)81(56-84(108)131)123-97(143)78(53-64(6)7)124-103(149)89(66(9)129)126-100(146)80(115-86(133)57-107)55-68-58-111-71-35-24-23-34-70(68)71/h23-24,34-35,42-45,58,62-66,72-83,89,111,128-130H,10-22,25-33,36-41,46-57,59-61,104-107H2,1-9H3,(H2,108,131)(H2,109,136)(H,110,132)(H,112,137)(H,113,138)(H,114,147)(H,115,133)(H,116,134)(H,117,139)(H,118,141)(H,119,140)(H,120,148)(H,121,142)(H,122,144)(H,123,143)(H,124,149)(H,125,145)(H,126,146)/t65-,66+,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-/m0/s1
DMUI0XV	CS	CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CN
DMUI0XV	IK	FUVBWPLFMCRKPJ-RUUCUJBTSA-N
DMUI0XV	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMUI0XV	DE	Discovery agent

DMYF85Q	ID	DMYF85Q
DMYF85Q	DN	[Sar9,Met(O2)11]-SP
DMYF85Q	HS	Investigative
DMYF85Q	PC	44338651
DMYF85Q	MW	1393.7
DMYF85Q	FM	C64H100N18O15S
DMYF85Q	IC	InChI=1S/C64H100N18O15S/c1-37(2)34-46(58(90)74-42(53(69)85)28-33-98(4,96)97)78-54(86)38(3)73-57(89)47(35-39-16-7-5-8-17-39)80-59(91)48(36-40-18-9-6-10-19-40)79-56(88)43(24-26-51(67)83)75-55(87)44(25-27-52(68)84)76-60(92)50-23-15-32-82(50)63(95)45(21-11-12-29-65)77-61(93)49-22-14-31-81(49)62(94)41(66)20-13-30-72-64(70)71/h5-10,16-19,37-38,41-50H,11-15,20-36,65-66H2,1-4H3,(H2,67,83)(H2,68,84)(H2,69,85)(H,73,89)(H,74,90)(H,75,87)(H,76,92)(H,77,93)(H,78,86)(H,79,88)(H,80,91)(H4,70,71,72)/t38?,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMYF85Q	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)N)NC(=O)C(C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DMYF85Q	IK	VRAGPHDTXRPMRS-RGKHVPTMSA-N
DMYF85Q	IU	(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfonyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DMYF85Q	DE	Discovery agent

DMN0BT3	ID	DMN0BT3
DMN0BT3	DN	[Tdf1]AngII
DMN0BT3	HS	Investigative
DMN0BT3	SN	CHEMBL1076613; [Tdf1]AngII
DMN0BT3	PC	45140941
DMN0BT3	MW	1186.3
DMN0BT3	FM	C57H74F3N15O10
DMN0BT3	IC	InChI=1S/C57H74F3N15O10/c1-5-32(4)46(52(82)69-42(28-37-29-64-30-66-37)53(83)75-24-10-14-44(75)50(80)70-43(54(84)85)27-33-11-7-6-8-12-33)72-49(79)41(26-35-17-21-38(76)22-18-35)68-51(81)45(31(2)3)71-48(78)40(13-9-23-65-55(62)63)67-47(77)39(61)25-34-15-19-36(20-16-34)56(73-74-56)57(58,59)60/h6-8,11-12,15-22,29-32,39-46,76H,5,9-10,13-14,23-28,61H2,1-4H3,(H,64,66)(H,67,77)(H,68,81)(H,69,82)(H,70,80)(H,71,78)(H,72,79)(H,84,85)(H4,62,63,65)/t32-,39-,40-,41-,42-,43-,44-,45-,46-/m0/s1
DMN0BT3	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CC=C(C=C5)C6(N=N6)C(F)(F)F)N
DMN0BT3	IK	OGNWPDVTXMDCHR-PYRLQILWSA-N
DMN0BT3	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMN0BT3	DE	Discovery agent

DM7QAKB	ID	DM7QAKB
DM7QAKB	DN	[Thr4,Gly7]OT
DM7QAKB	HS	Investigative
DM7QAKB	SN	[Thr4,Gly7]oxytocin
DM7QAKB	DT	Small molecular drug
DM7QAKB	PC	3080871
DM7QAKB	MW	940.1
DM7QAKB	FM	C39H61N11O12S2
DM7QAKB	IC	InChI=1S/C39H61N11O12S2/c1-6-19(4)31(49-37(60)25(46-33(56)23(40)16-63)12-21-7-9-22(52)10-8-21)38(61)50-32(20(5)51)39(62)47-26(13-28(41)53)36(59)48-27(17-64)35(58)44-15-30(55)45-24(11-18(2)3)34(57)43-14-29(42)54/h7-10,16,18-20,23-27,31-32,51-52,64H,6,11-15,17,40H2,1-5H3,(H2,41,53)(H2,42,54)(H,43,57)(H,44,58)(H,45,55)(H,46,56)(H,47,62)(H,48,59)(H,49,60)(H,50,61)/t19-,20+,23-,24-,25-,26-,27-,31-,32-/m0/s1
DM7QAKB	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C=S)N
DM7QAKB	IK	SJRRTEZQOSELMP-IKNHWLCZSA-N
DM7QAKB	IU	(2S)-N-[(2R)-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylidenepropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]butanediamide
DM7QAKB	CA	CAS 60786-59-6
DM7QAKB	DE	Discovery agent

DMA6VNI	ID	DMA6VNI
DMA6VNI	DN	[Tyr4]Bombesin
DMA6VNI	HS	Investigative
DMA6VNI	PC	44388197
DMA6VNI	MW	1669.9
DMA6VNI	FM	C74H108N24O19S
DMA6VNI	IC	InChI=1S/C74H108N24O19S/c1-36(2)26-50(70(114)91-45(62(78)106)23-25-118-6)95-71(115)53(29-41-32-81-35-86-41)89-60(105)34-85-73(117)61(37(3)4)98-63(107)38(5)87-69(113)52(28-40-31-83-44-11-8-7-10-43(40)44)97-68(112)49(18-21-56(76)101)94-72(116)54(30-57(77)102)90-59(104)33-84-64(108)51(27-39-13-15-42(99)16-14-39)96-65(109)46(12-9-24-82-74(79)80)92-67(111)48(17-20-55(75)100)93-66(110)47-19-22-58(103)88-47/h7-8,10-11,13-16,31-32,35-38,45-54,61,83,99H,9,12,17-30,33-34H2,1-6H3,(H2,75,100)(H2,76,101)(H2,77,102)(H2,78,106)(H,81,86)(H,84,108)(H,85,117)(H,87,113)(H,88,103)(H,89,105)(H,90,104)(H,91,114)(H,92,111)(H,93,110)(H,94,116)(H,95,115)(H,96,109)(H,97,112)(H,98,107)(H4,79,80,82)/t38-,45-,46-,47?,48-,49-,50-,51-,52-,53-,54-,61-/m0/s1
DMA6VNI	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C5CCC(=O)N5
DMA6VNI	IK	QORXQELQSJVKIL-MOPZKQSYSA-N
DMA6VNI	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-2-[(5-oxopyrrolidine-2-carbonyl)amino]pentanediamide
DMA6VNI	DE	Discovery agent

DM61RG2	ID	DM61RG2
DM61RG2	DN	[Tyr-Pro-Phe-NH-]2
DM61RG2	HS	Investigative
DM61RG2	SN	CHEMBL179946; [Tyr-Pro-Phe-NH-]2
DM61RG2	DT	Small molecular drug
DM61RG2	PC	44390663
DM61RG2	MW	832
DM61RG2	FM	C46H53N7O8
DM61RG2	IC	InChI=1S/C46H53N7O8/c47-35(25-31-15-19-33(54)20-16-31)45(60)52-23-7-13-39(52)44(59)50-37(27-30-11-5-2-6-12-30)42(57)51-38(28-32-17-21-34(55)22-18-32)46(61)53-24-8-14-40(53)43(58)49-36(41(48)56)26-29-9-3-1-4-10-29/h1-6,9-12,15-22,35-40,54-55H,7-8,13-14,23-28,47H2,(H2,48,56)(H,49,58)(H,50,59)(H,51,57)/t35-,36-,37-,38-,39-,40-/m0/s1
DM61RG2	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N
DM61RG2	IK	PMYWZDRRZPJWHV-UNHORJANSA-N
DM61RG2	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM61RG2	DE	Discovery agent

DMZTRQ0	ID	DMZTRQ0
DMZTRQ0	DN	[Tyr-Pro-Phe-NH-CH2-]2
DMZTRQ0	HS	Investigative
DMZTRQ0	SN	CHEMBL180286; [Tyr-Pro-Phe-NH-CH2-]2
DMZTRQ0	DT	Small molecular drug
DMZTRQ0	PC	44390664
DMZTRQ0	MW	860
DMZTRQ0	FM	C48H57N7O8
DMZTRQ0	IC	InChI=1S/C48H57N7O8/c49-37(27-33-15-19-35(56)20-16-33)47(62)54-25-7-13-41(54)45(60)52-38(28-31-9-3-1-4-10-31)43(58)23-24-51-40(30-34-17-21-36(57)22-18-34)48(63)55-26-8-14-42(55)46(61)53-39(44(50)59)29-32-11-5-2-6-12-32/h1-6,9-12,15-22,37-42,51,56-57H,7-8,13-14,23-30,49H2,(H2,50,59)(H,52,60)(H,53,61)/t37-,38-,39-,40-,41-,42-/m0/s1
DMZTRQ0	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)CCN[C@@H](CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N
DMZTRQ0	IK	SDEZJRFUZMVTCN-UJKKYYSESA-N
DMZTRQ0	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-5-[[(2S)-1-[(2S)-2-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxo-1-phenylpentan-2-yl]pyrrolidine-2-carboxamide
DMZTRQ0	DE	Discovery agent

DME6TNL	ID	DME6TNL
DME6TNL	DN	[Tyr-Pro-Phe-Phe-NH-]2
DME6TNL	HS	Investigative
DME6TNL	SN	CHEMBL386887
DME6TNL	PC	44390628
DME6TNL	MW	1126.3
DME6TNL	FM	C64H71N9O10
DME6TNL	IC	InChI=1S/C64H71N9O10/c65-49(35-45-25-29-47(74)30-26-45)63(82)72-33-13-23-55(72)61(80)70-53(39-44-21-11-4-12-22-44)59(78)68-51(37-42-17-7-2-8-18-42)60(79)71-54(40-46-27-31-48(75)32-28-46)64(83)73-34-14-24-56(73)62(81)69-52(38-43-19-9-3-10-20-43)58(77)67-50(57(66)76)36-41-15-5-1-6-16-41/h1-12,15-22,25-32,49-56,74-75H,13-14,23-24,33-40,65H2,(H2,66,76)(H,67,77)(H,68,78)(H,69,81)(H,70,80)(H,71,79)/t49-,50-,51-,52-,53-,54-,55-,56-/m0/s1
DME6TNL	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N
DME6TNL	IK	DEEQOLBYTQLJHH-MENCHSDRSA-N
DME6TNL	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DME6TNL	DE	Discovery agent

DMFGO4W	ID	DMFGO4W
DMFGO4W	DN	[Tyr-Pro-Phe-Phe-NH-CH2-]2
DMFGO4W	HS	Investigative
DMFGO4W	SN	CHEMBL409336; [Tyr-Pro-Phe-Phe-NH-CH2-]2
DMFGO4W	PC	44390629
DMFGO4W	MW	1154.4
DMFGO4W	FM	C66H75N9O10
DMFGO4W	IC	InChI=1S/C66H75N9O10/c67-51(37-47-25-29-49(76)30-26-47)65(84)74-35-13-23-57(74)63(82)72-54(40-45-19-9-3-10-20-45)61(80)70-52(38-43-15-5-1-6-16-43)59(78)33-34-69-56(42-48-27-31-50(77)32-28-48)66(85)75-36-14-24-58(75)64(83)73-55(41-46-21-11-4-12-22-46)62(81)71-53(60(68)79)39-44-17-7-2-8-18-44/h1-12,15-22,25-32,51-58,69,76-77H,13-14,23-24,33-42,67H2,(H2,68,79)(H,70,80)(H,71,81)(H,72,82)(H,73,83)/t51-,52-,53-,54-,55-,56-,57-,58-/m0/s1
DMFGO4W	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)CCN[C@@H](CC5=CC=C(C=C5)O)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N
DMFGO4W	IK	YHWMMBKGEDGQFW-LEPIMFGVSA-N
DMFGO4W	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-5-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxo-1-phenylpentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMFGO4W	DE	Discovery agent

DMP3I6E	ID	DMP3I6E
DMP3I6E	DN	[U-13C]ascomycin
DMP3I6E	HS	Investigative
DMP3I6E	DE	Discovery agent

DMW82ZT	ID	DMW82ZT
DMW82ZT	DN	[Val4]AVP
DMW82ZT	HS	Investigative
DMW82ZT	SN	4-Val-argipressin
DMW82ZT	DT	Small molecular drug
DMW82ZT	PC	171113
DMW82ZT	MW	1055.2
DMW82ZT	FM	C46H66N14O11S2
DMW82ZT	IC	InChI=1S/C46H66N14O11S2/c1-24(2)37-44(70)57-32(20-35(48)62)41(67)58-33(45(71)60-17-7-11-34(60)43(69)54-29(10-6-16-52-46(50)51)39(65)53-21-36(49)63)23-73-72-22-28(47)38(64)55-30(19-26-12-14-27(61)15-13-26)40(66)56-31(42(68)59-37)18-25-8-4-3-5-9-25/h3-5,8-9,12-15,24,28-34,37,61H,6-7,10-11,16-23,47H2,1-2H3,(H2,48,62)(H2,49,63)(H,53,65)(H,54,69)(H,55,64)(H,56,66)(H,57,70)(H,58,67)(H,59,68)(H4,50,51,52)/t28-,29+,30-,31-,32-,33-,34-,37-/m0/s1
DMW82ZT	CS	CC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)N)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DMW82ZT	IK	JITASQOSGITBPR-FMCGBTBPSA-N
DMW82ZT	IU	(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMW82ZT	CA	CAS 52049-52-2
DMW82ZT	DE	Discovery agent

DMMB4US	ID	DMMB4US
DMMB4US	DN	{[(9Z)-octadec-9-en-1-yl]sulfamoyl}amine
DMMB4US	HS	Investigative
DMMB4US	SN	CHEMBL570566; {[(9Z)-octadec-9-en-1-yl]sulfamoyl}amine; SCHEMBL3117233
DMMB4US	DT	Small molecular drug
DMMB4US	PC	16103195
DMMB4US	MW	346.6
DMMB4US	FM	C18H38N2O2S
DMMB4US	IC	InChI=1S/C18H38N2O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-23(19,21)22/h9-10,20H,2-8,11-18H2,1H3,(H2,19,21,22)/b10-9-
DMMB4US	CS	CCCCCCCC/C=C\\CCCCCCCCNS(=O)(=O)N
DMMB4US	IK	VIGWMDIVSRLQST-KTKRTIGZSA-N
DMMB4US	IU	(Z)-1-(sulfamoylamino)octadec-9-ene
DMMB4US	DE	Discovery agent

DM3FBAZ	ID	DM3FBAZ
DM3FBAZ	DN	{2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine
DM3FBAZ	HS	Investigative
DM3FBAZ	SN	SCHEMBL3565077; CHEMBL608380; BDBM35240; 3-(phenylsulfonyl)-1H-indole, 18m
DM3FBAZ	DT	Small molecular drug
DM3FBAZ	PC	24861406
DM3FBAZ	MW	300.4
DM3FBAZ	FM	C16H16N2O2S
DM3FBAZ	IC	InChI=1S/C16H16N2O2S/c17-10-9-12-5-4-8-14-16(12)15(11-18-14)21(19,20)13-6-2-1-3-7-13/h1-8,11,18H,9-10,17H2
DM3FBAZ	CS	C1=CC=C(C=C1)S(=O)(=O)C2=CNC3=CC=CC(=C32)CCN
DM3FBAZ	IK	RSVUNKKDIROCQS-UHFFFAOYSA-N
DM3FBAZ	IU	2-[3-(benzenesulfonyl)-1H-indol-4-yl]ethanamine
DM3FBAZ	DE	Discovery agent

DMX53OY	ID	DMX53OY
DMX53OY	DN	{4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid
DMX53OY	HS	Investigative
DMX53OY	SN	CHEMBL201138; {4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid
DMX53OY	DT	Small molecular drug
DMX53OY	PC	11495248
DMX53OY	MW	411.2
DMX53OY	FM	C21H15BrO4
DMX53OY	IC	InChI=1S/C21H15BrO4/c22-17-7-11-19(12-8-17)26-18-9-5-16(6-10-18)21(25)15-3-1-14(2-4-15)13-20(23)24/h1-12H,13H2,(H,23,24)
DMX53OY	CS	C1=CC(=CC=C1CC(=O)O)C(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)Br
DMX53OY	IK	XVHMPUZJYISELN-UHFFFAOYSA-N
DMX53OY	IU	2-[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
DMX53OY	DE	Discovery agent

DMQEJVU	ID	DMQEJVU
DMQEJVU	DN	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
DMQEJVU	HS	Investigative
DMQEJVU	SN	1-((2-Chlorophenyl)diphenylmethyl)-1H-pyrazole; TRAM-34; 289905-88-0; Tram 34; 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole; AC1LCVHZ; CHEMBL498270; CHEBI:34990; 1-[(2-chlorophenyl)-diphenylmethyl]pyrazole; 1-(2-Chlorophenyl)diphenyl)methyl]-1H-pyrazole; SureCN41130; TRAM34; SCHEMBL41130; GTPL2336; KS-00000OJW; CTK0J1643; DTXSID70349650; MolPort-003-850-592; EX-A2316; BCP01324; ZINC3975392; BDBM50279107; ANW-72309; s1160; MFCD09842562; AKOS005146304; CS-1921; ACN-048484; MP-2041; API0000868; DS-2617; NCGC00165909-03; NCGC00165909-02
DMQEJVU	DT	Small molecular drug
DMQEJVU	PC	656734
DMQEJVU	MW	344.8
DMQEJVU	FM	C22H17ClN2
DMQEJVU	IC	InChI=1S/C22H17ClN2/c23-21-15-8-7-14-20(21)22(25-17-9-16-24-25,18-10-3-1-4-11-18)19-12-5-2-6-13-19/h1-17H
DMQEJVU	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CC=N4
DMQEJVU	IK	KBFUQFVFYYBHBT-UHFFFAOYSA-N
DMQEJVU	IU	1-[(2-chlorophenyl)-diphenylmethyl]pyrazole
DMQEJVU	CA	CAS 289905-88-0
DMQEJVU	CB	CHEBI:34990
DMQEJVU	DE	Conjunctival fibrosis

DMGRV8U	ID	DMGRV8U
DMGRV8U	DN	1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole
DMGRV8U	HS	Investigative
DMGRV8U	SN	CHEMBL501198; 1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole; SCHEMBL8609682; QOKBMECMKDLYIV-UHFFFAOYSA-N; BDBM50272209; 1-[1-(9H-Fluoren-2-yl)ethyl]-1H-imidazole; 1-[1-(9H-fluoren-2-yl) ethyl]-1H-imidazole
DMGRV8U	DT	Small molecular drug
DMGRV8U	PC	9861000
DMGRV8U	MW	260.3
DMGRV8U	FM	C18H16N2
DMGRV8U	IC	InChI=1S/C18H16N2/c1-13(20-9-8-19-12-20)14-6-7-18-16(10-14)11-15-4-2-3-5-17(15)18/h2-10,12-13H,11H2,1H3
DMGRV8U	CS	CC(C1=CC2=C(C=C1)C3=CC=CC=C3C2)N4C=CN=C4
DMGRV8U	IK	QOKBMECMKDLYIV-UHFFFAOYSA-N
DMGRV8U	IU	1-[1-(9H-fluoren-2-yl)ethyl]imidazole
DMGRV8U	DE	Discovery agent

DMPBJ9L	ID	DMPBJ9L
DMPBJ9L	DN	1-((9H-Fluoren-2-yl)methyl)-1H-imidazole
DMPBJ9L	HS	Investigative
DMPBJ9L	SN	CHEMBL502542; 1-((9H-Fluoren-2-yl)methyl)-1H-imidazole; SCHEMBL8607720
DMPBJ9L	DT	Small molecular drug
DMPBJ9L	PC	18976090
DMPBJ9L	MW	246.31
DMPBJ9L	FM	C17H14N2
DMPBJ9L	IC	InChI=1S/C17H14N2/c1-2-4-16-14(3-1)10-15-9-13(5-6-17(15)16)11-19-8-7-18-12-19/h1-9,12H,10-11H2
DMPBJ9L	CS	C1C2=CC=CC=C2C3=C1C=C(C=C3)CN4C=CN=C4
DMPBJ9L	IK	OLHTVPMFDRPUTG-UHFFFAOYSA-N
DMPBJ9L	IU	1-(9H-fluoren-2-ylmethyl)imidazole
DMPBJ9L	DE	Discovery agent

DM74R0E	ID	DM74R0E
DM74R0E	DN	1-((R)-2-aminopropyl)-1H-indazol-6-ol
DM74R0E	HS	Investigative
DM74R0E	DT	Small molecular drug
DM74R0E	PC	135399666
DM74R0E	MW	191.23
DM74R0E	FM	C10H13N3O
DM74R0E	IC	InChI=1S/C10H13N3O/c1-7(11)6-13-10-4-9(14)3-2-8(10)5-12-13/h2-5,7,14H,6,11H2,1H3/t7-/m1/s1
DM74R0E	CS	C[C@H](CN1C2=C(C=CC(=C2)O)C=N1)N
DM74R0E	IK	WBYHTZYHAFNBKW-SSDOTTSWSA-N
DM74R0E	IU	1-[(2R)-2-aminopropyl]indazol-6-ol
DM74R0E	DE	Discovery agent

DMU83KP	ID	DMU83KP
DMU83KP	DN	1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP	HS	Investigative
DMU83KP	DT	Small molecular drug
DMU83KP	PC	135453290
DMU83KP	MW	191.23
DMU83KP	FM	C10H13N3O
DMU83KP	IC	InChI=1S/C10H13N3O/c1-7(11)6-13-10-4-9(14)3-2-8(10)5-12-13/h2-5,7,14H,6,11H2,1H3/t7-/m0/s1
DMU83KP	CS	C[C@@H](CN1C2=C(C=CC(=C2)O)C=N1)N
DMU83KP	IK	WBYHTZYHAFNBKW-ZETCQYMHSA-N
DMU83KP	IU	1-[(2S)-2-aminopropyl]indazol-6-ol
DMU83KP	CA	CAS 210580-75-9
DMU83KP	DE	Discovery agent

DMRFJNC	ID	DMRFJNC
DMRFJNC	DN	1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol
DMRFJNC	HS	Investigative
DMRFJNC	DT	Small molecular drug
DMRFJNC	PC	135509961
DMRFJNC	MW	225.67
DMRFJNC	FM	C10H12ClN3O
DMRFJNC	IC	InChI=1S/C10H12ClN3O/c1-6(12)5-14-10-7(4-13-14)2-3-8(15)9(10)11/h2-4,6,15H,5,12H2,1H3/t6-/m0/s1
DMRFJNC	CS	C[C@@H](CN1C2=C(C=CC(=C2Cl)O)C=N1)N
DMRFJNC	IK	VCXUEWRCJZWCJB-LURJTMIESA-N
DMRFJNC	IU	1-[(2S)-2-aminopropyl]-7-chloroindazol-6-ol
DMRFJNC	DE	Discovery agent

DM76JVB	ID	DM76JVB
DM76JVB	DN	1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol
DM76JVB	HS	Investigative
DM76JVB	DT	Small molecular drug
DM76JVB	PC	135399866
DM76JVB	MW	209.22
DM76JVB	FM	C10H12FN3O
DM76JVB	IC	InChI=1S/C10H12FN3O/c1-6(12)5-14-10-7(4-13-14)2-3-8(15)9(10)11/h2-4,6,15H,5,12H2,1H3/t6-/m0/s1
DM76JVB	CS	C[C@@H](CN1C2=C(C=CC(=C2F)O)C=N1)N
DM76JVB	IK	TZBBLWXEAUOTGZ-LURJTMIESA-N
DM76JVB	IU	1-[(2S)-2-aminopropyl]-7-fluoroindazol-6-ol
DM76JVB	DE	Discovery agent

DMR2SXL	ID	DMR2SXL
DMR2SXL	DN	1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol
DMR2SXL	HS	Investigative
DMR2SXL	DT	Small molecular drug
DMR2SXL	PC	135427931
DMR2SXL	MW	317.13
DMR2SXL	FM	C10H12IN3O
DMR2SXL	IC	InChI=1S/C10H12IN3O/c1-6(12)5-14-10-7(4-13-14)2-3-8(15)9(10)11/h2-4,6,15H,5,12H2,1H3/t6-/m0/s1
DMR2SXL	CS	C[C@@H](CN1C2=C(C=CC(=C2I)O)C=N1)N
DMR2SXL	IK	NTWCUBZMEYKYQE-LURJTMIESA-N
DMR2SXL	IU	1-[(2S)-2-aminopropyl]-7-iodoindazol-6-ol
DMR2SXL	DE	Discovery agent

DM8MNZG	ID	DM8MNZG
DM8MNZG	DN	1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol
DM8MNZG	HS	Investigative
DM8MNZG	DT	Small molecular drug
DM8MNZG	PC	135414348
DM8MNZG	MW	205.26
DM8MNZG	FM	C11H15N3O
DM8MNZG	IC	InChI=1S/C11H15N3O/c1-7(12)6-14-11-8(2)10(15)4-3-9(11)5-13-14/h3-5,7,15H,6,12H2,1-2H3/t7-/m0/s1
DM8MNZG	CS	CC1=C(C=CC2=C1N(N=C2)C[C@H](C)N)O
DM8MNZG	IK	UFWMKRXWOOOKPI-ZETCQYMHSA-N
DM8MNZG	IU	1-[(2S)-2-aminopropyl]-7-methylindazol-6-ol
DM8MNZG	DE	Discovery agent

DMCSOAV	ID	DMCSOAV
DMCSOAV	DN	1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMCSOAV	HS	Investigative
DMCSOAV	SN	CHEMBL1083426; 1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX); SCHEMBL5443198; BDBM50319828; 1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine; (-)-1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine
DMCSOAV	DT	Small molecular drug
DMCSOAV	PC	46890492
DMCSOAV	MW	368.4
DMCSOAV	FM	C19H20F4N2O
DMCSOAV	IC	InChI=1S/C19H20F4N2O/c20-16-7-3-2-6-15(16)17(25-11-9-24-10-12-25)13-14-5-1-4-8-18(14)26-19(21,22)23/h1-8,17,24H,9-13H2
DMCSOAV	CS	C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=CC=C3F
DMCSOAV	IK	WARUECLCXNMKJR-UHFFFAOYSA-N
DMCSOAV	IU	1-[1-(2-fluorophenyl)-2-[2-(trifluoromethoxy)phenyl]ethyl]piperazine
DMCSOAV	DE	Discovery agent

DM0XNMP	ID	DM0XNMP
DM0XNMP	DN	1-(1-(3-nitrophenyl)propylidene)thiosemicarbazide
DM0XNMP	HS	Investigative
DM0XNMP	SN	CHEMBL373586; 1-(1-(3-nitrophenyl)propylidene)thiosemicarbazide; SCHEMBL6337198
DM0XNMP	DT	Small molecular drug
DM0XNMP	PC	25234549
DM0XNMP	MW	252.3
DM0XNMP	FM	C10H12N4O2S
DM0XNMP	IC	InChI=1S/C10H12N4O2S/c1-2-9(12-13-10(11)17)7-4-3-5-8(6-7)14(15)16/h3-6H,2H2,1H3,(H3,11,13,17)/b12-9+
DM0XNMP	CS	CC/C(=N\\NC(=S)N)/C1=CC(=CC=C1)[N+](=O)[O-]
DM0XNMP	IK	BTQZWQBDFKXQEG-FMIVXFBMSA-N
DM0XNMP	IU	[(E)-1-(3-nitrophenyl)propylideneamino]thiourea
DM0XNMP	DE	Discovery agent

DMXJ58Z	ID	DMXJ58Z
DMXJ58Z	DN	1-(1-(4-bromophenyl)ethylidene)thiosemicarbazide
DMXJ58Z	HS	Investigative
DMXJ58Z	SN	CHEMBL258261; NSC521067; AC1NSLKG; 16546-06-8; ZINC4709233; 4'-Bromoacetophenonethiosemicarbazone; BDBM50376212; AKOS002388584; AKOS008939483; NSC-521067
DMXJ58Z	DT	Small molecular drug
DMXJ58Z	PC	5365424
DMXJ58Z	MW	272.17
DMXJ58Z	FM	C9H10BrN3S
DMXJ58Z	IC	InChI=1S/C9H10BrN3S/c1-6(12-13-9(11)14)7-2-4-8(10)5-3-7/h2-5H,1H3,(H3,11,13,14)/b12-6-
DMXJ58Z	CS	C/C(=N/NC(=S)N)/C1=CC=C(C=C1)Br
DMXJ58Z	IK	OKNJXRBJRXAECS-SDQBBNPISA-N
DMXJ58Z	IU	[(Z)-1-(4-bromophenyl)ethylideneamino]thiourea
DMXJ58Z	CA	CAS 16546-06-8
DMXJ58Z	DE	Discovery agent

DMOQPKT	ID	DMOQPKT
DMOQPKT	DN	1-(1-(4'-Ethylbiphenyl-4-yl)propyl)-1H-imidazole
DMOQPKT	HS	Investigative
DMOQPKT	SN	CHEMBL496257; BDBM50272583
DMOQPKT	DT	Small molecular drug
DMOQPKT	PC	44587321
DMOQPKT	MW	290.4
DMOQPKT	FM	C20H22N2
DMOQPKT	IC	InChI=1S/C20H22N2/c1-3-16-5-7-17(8-6-16)18-9-11-19(12-10-18)20(4-2)22-14-13-21-15-22/h5-15,20H,3-4H2,1-2H3
DMOQPKT	CS	CCC1=CC=C(C=C1)C2=CC=C(C=C2)C(CC)N3C=CN=C3
DMOQPKT	IK	QQMBOZZNCNQCSN-UHFFFAOYSA-N
DMOQPKT	IU	1-[1-[4-(4-ethylphenyl)phenyl]propyl]imidazole
DMOQPKT	DE	Discovery agent

DMS9PZ7	ID	DMS9PZ7
DMS9PZ7	DN	1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMS9PZ7	HS	Investigative
DMS9PZ7	SN	CHEMBL1084033; 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX); SCHEMBL5447674; BDBM50319830; 1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine; (-)-1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine
DMS9PZ7	DT	Small molecular drug
DMS9PZ7	PC	46890532
DMS9PZ7	MW	368.4
DMS9PZ7	FM	C19H20F4N2O
DMS9PZ7	IC	InChI=1S/C19H20F4N2O/c20-16-7-5-14(6-8-16)17(25-11-9-24-10-12-25)13-15-3-1-2-4-18(15)26-19(21,22)23/h1-8,17,24H,9-13H2
DMS9PZ7	CS	C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=C(C=C3)F
DMS9PZ7	IK	SQSFWPVYWBTHEX-UHFFFAOYSA-N
DMS9PZ7	IU	1-[1-(4-fluorophenyl)-2-[2-(trifluoromethoxy)phenyl]ethyl]piperazine
DMS9PZ7	DE	Discovery agent

DMQBHGK	ID	DMQBHGK
DMQBHGK	DN	1-(1-(4-fluorophenyl)ethylidene)thiosemicarbazide
DMQBHGK	HS	Investigative
DMQBHGK	SN	CHEMBL429500; NSC118183; AC1NUA7B; BDBM50376208; ZINC12350299; AKOS008939384; NSC-118183; [(Z)-1-(4-fluorophenyl)ethylideneamino]thiourea; 1-[1-(4-Fluorophenyl)ethylidene]thiosemicarbazide
DMQBHGK	DT	Small molecular drug
DMQBHGK	PC	5397679
DMQBHGK	MW	211.26
DMQBHGK	FM	C9H10FN3S
DMQBHGK	IC	InChI=1S/C9H10FN3S/c1-6(12-13-9(11)14)7-2-4-8(10)5-3-7/h2-5H,1H3,(H3,11,13,14)/b12-6-
DMQBHGK	CS	C/C(=N/NC(=S)N)/C1=CC=C(C=C1)F
DMQBHGK	IK	JBOMIBNEKCISGH-SDQBBNPISA-N
DMQBHGK	IU	[(Z)-1-(4-fluorophenyl)ethylideneamino]thiourea
DMQBHGK	CA	CAS 777-16-2
DMQBHGK	DE	Discovery agent

DMEIH5N	ID	DMEIH5N
DMEIH5N	DN	1-(1-(4-thiophen-3-ylphenyl)ethyl)-1H-imidazole
DMEIH5N	HS	Investigative
DMEIH5N	SN	CHEMBL273191; SCHEMBL18770412
DMEIH5N	DT	Small molecular drug
DMEIH5N	PC	25099145
DMEIH5N	MW	254.4
DMEIH5N	FM	C15H14N2S
DMEIH5N	IC	InChI=1S/C15H14N2S/c1-12(17-8-7-16-11-17)13-2-4-14(5-3-13)15-6-9-18-10-15/h2-12H,1H3
DMEIH5N	CS	CC(C1=CC=C(C=C1)C2=CSC=C2)N3C=CN=C3
DMEIH5N	IK	CPEUHVZSVWFLMC-UHFFFAOYSA-N
DMEIH5N	IU	1-[1-(4-thiophen-3-ylphenyl)ethyl]imidazole
DMEIH5N	DE	Discovery agent

DMQF2N5	ID	DMQF2N5
DMQF2N5	DN	1-(1-(4-thiophen-3-yl-phenyl)propyl)-1Himidazole
DMQF2N5	HS	Investigative
DMQF2N5	SN	CHEMBL403475; SCHEMBL18770345
DMQF2N5	DT	Small molecular drug
DMQF2N5	PC	25099144
DMQF2N5	MW	268.4
DMQF2N5	FM	C16H16N2S
DMQF2N5	IC	InChI=1S/C16H16N2S/c1-2-16(18-9-8-17-12-18)14-5-3-13(4-6-14)15-7-10-19-11-15/h3-12,16H,2H2,1H3
DMQF2N5	CS	CCC(C1=CC=C(C=C1)C2=CSC=C2)N3C=CN=C3
DMQF2N5	IK	JCRCIQARESXRFA-UHFFFAOYSA-N
DMQF2N5	IU	1-[1-(4-thiophen-3-ylphenyl)propyl]imidazole
DMQF2N5	DE	Discovery agent

DMPGM0V	ID	DMPGM0V
DMPGM0V	DN	1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine
DMPGM0V	HS	Investigative
DMPGM0V	SN	BTCP; 112726-66-6; 1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine; 1-Btcp; GK 13; 1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine; 1-(1-Benzo(b)thien-2-ylcyclohexyl)piperidine; N-(1-(2-Benzo(b)thiophenyl)cyclohexyl)piperidine; GK-13; UNII-Q1WR6UP7MW; Q1WR6UP7MW; CHEMBL279556; CHEBI:64145; 1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine; Piperidine, 1-(1-benzo(b)thien-2-ylcyclohexyl)-; 1-(1-benzo[b]thien-2-ylcyclohexyl)Piperidine; Benocyclidine; C19H25NS; Tocris-0702; Lopac-B-138; Biomol-NT_000007; AC1L3X4G; Lopac0_000226
DMPGM0V	DT	Small molecular drug
DMPGM0V	PC	123692
DMPGM0V	MW	299.5
DMPGM0V	FM	C19H25NS
DMPGM0V	IC	InChI=1S/C19H25NS/c1-5-11-19(12-6-1,20-13-7-2-8-14-20)18-15-16-9-3-4-10-17(16)21-18/h3-4,9-10,15H,1-2,5-8,11-14H2
DMPGM0V	CS	C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4
DMPGM0V	IK	RGSVXQJPSWZXOP-UHFFFAOYSA-N
DMPGM0V	IU	1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine
DMPGM0V	CA	CAS 112726-66-6
DMPGM0V	CB	CHEBI:64145
DMPGM0V	DE	Discovery agent

DMLJ7WA	ID	DMLJ7WA
DMLJ7WA	DN	1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole
DMLJ7WA	HS	Investigative
DMLJ7WA	SN	CHEMBL443865; 1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole
DMLJ7WA	DT	Small molecular drug
DMLJ7WA	PC	44586827
DMLJ7WA	MW	260.3
DMLJ7WA	FM	C18H16N2
DMLJ7WA	IC	InChI=1S/C18H16N2/c1-2-18(20-13-12-19-14-20)17-10-8-16(9-11-17)15-6-4-3-5-7-15/h2-14,18H,1H2
DMLJ7WA	CS	C=CC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMLJ7WA	IK	VEPBIHWDSCDYJS-UHFFFAOYSA-N
DMLJ7WA	IU	1-[1-(4-phenylphenyl)prop-2-enyl]imidazole
DMLJ7WA	DE	Discovery agent

DM7WJOY	ID	DM7WJOY
DM7WJOY	DN	1-(1-(pyrazin-2-yl)ethylidene)thiosemicarbazide
DM7WJOY	HS	Investigative
DM7WJOY	SN	CHEMBL401556; AC1NT9J5; 142564-78-1; BDBM50376205; ZINC26974934; AKOS014545779; 1-(2-Pyrazinyl)ethanone thiosemicarbazone
DM7WJOY	DT	Small molecular drug
DM7WJOY	PC	5375406
DM7WJOY	MW	195.25
DM7WJOY	FM	C7H9N5S
DM7WJOY	IC	InChI=1S/C7H9N5S/c1-5(11-12-7(8)13)6-4-9-2-3-10-6/h2-4H,1H3,(H3,8,12,13)/b11-5-
DM7WJOY	CS	C/C(=N/NC(=S)N)/C1=NC=CN=C1
DM7WJOY	IK	LNRWBLGPWCJQEM-WZUFQYTHSA-N
DM7WJOY	IU	[(Z)-1-pyrazin-2-ylethylideneamino]thiourea
DM7WJOY	DE	Discovery agent

DMJ21XT	ID	DMJ21XT
DMJ21XT	DN	1-(1-(pyridin-3-yl)ethylidene)thiosemicarbazide
DMJ21XT	HS	Investigative
DMJ21XT	SN	CHEMBL272957; 3-Acetylpyridine thiosemicarbazone; AC1NT9I3; ZINC4535030; 13370-86-0; BDBM50376203; AKOS008939674
DMJ21XT	DT	Small molecular drug
DMJ21XT	PC	5375357
DMJ21XT	MW	194.26
DMJ21XT	FM	C8H10N4S
DMJ21XT	IC	InChI=1S/C8H10N4S/c1-6(11-12-8(9)13)7-3-2-4-10-5-7/h2-5H,1H3,(H3,9,12,13)/b11-6-
DMJ21XT	CS	C/C(=N/NC(=S)N)/C1=CN=CC=C1
DMJ21XT	IK	PFDWFNDHRREIDD-WDZFZDKYSA-N
DMJ21XT	IU	[(Z)-1-pyridin-3-ylethylideneamino]thiourea
DMJ21XT	DE	Discovery agent

DMQSEF6	ID	DMQSEF6
DMQSEF6	DN	1-(1-(thiophen-2-yl)ethylidene)thiosemicarbazide
DMQSEF6	HS	Investigative
DMQSEF6	SN	CHEMBL401925; 1-(2-thienyl)ethanone thiosemicarbazone; AC1NT9MW; ZINC4603414; BDBM50376204; AKOS006242416; AKOS002388583; 1-(2-Thienyl)ethanonethiosemicarbazone; [(Z)-1-thiophen-2-ylethylideneamino]thiourea
DMQSEF6	DT	Small molecular drug
DMQSEF6	PC	5375570
DMQSEF6	MW	199.3
DMQSEF6	FM	C7H9N3S2
DMQSEF6	IC	InChI=1S/C7H9N3S2/c1-5(9-10-7(8)11)6-3-2-4-12-6/h2-4H,1H3,(H3,8,10,11)/b9-5-
DMQSEF6	CS	C/C(=N/NC(=S)N)/C1=CC=CS1
DMQSEF6	IK	PJVHAJJEMJNPHN-UITAMQMPSA-N
DMQSEF6	IU	[(Z)-1-thiophen-2-ylethylideneamino]thiourea
DMQSEF6	DE	Discovery agent

DMPMLZF	ID	DMPMLZF
DMPMLZF	DN	1-(1,2,4-Oxadiazol-3-yl)-7-phenylheptan-1-one
DMPMLZF	HS	Investigative
DMPMLZF	SN	CHEMBL469050; 1-(1,2,4-Oxadiazol-3-yl)-7-phenylheptan-1-one; SCHEMBL2162025
DMPMLZF	DT	Small molecular drug
DMPMLZF	PC	24951006
DMPMLZF	MW	258.32
DMPMLZF	FM	C15H18N2O2
DMPMLZF	IC	InChI=1S/C15H18N2O2/c18-14(15-16-12-19-17-15)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMPMLZF	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NOC=N2
DMPMLZF	IK	YLPRJWHRSWGCQQ-UHFFFAOYSA-N
DMPMLZF	IU	1-(1,2,4-oxadiazol-3-yl)-7-phenylheptan-1-one
DMPMLZF	DE	Discovery agent

DMBS90M	ID	DMBS90M
DMBS90M	DN	1-(1,2,4-Oxadiazol-5-yl)-7-phenylheptan-1-one
DMBS90M	HS	Investigative
DMBS90M	SN	CHEMBL448922; 1-(1,2,4-Oxadiazol-5-yl)-7-phenylheptan-1-one; SCHEMBL2161958
DMBS90M	DT	Small molecular drug
DMBS90M	PC	24951000
DMBS90M	MW	258.32
DMBS90M	FM	C15H18N2O2
DMBS90M	IC	InChI=1S/C15H18N2O2/c18-14(15-16-12-17-19-15)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMBS90M	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=NO2
DMBS90M	IK	ZZEHRRGWKDFITC-UHFFFAOYSA-N
DMBS90M	IU	1-(1,2,4-oxadiazol-5-yl)-7-phenylheptan-1-one
DMBS90M	DE	Discovery agent

DMOR9EK	ID	DMOR9EK
DMOR9EK	DN	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK	HS	Investigative
DMOR9EK	SN	CHEMBL397945; 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK	DT	Small molecular drug
DMOR9EK	PC	44426814
DMOR9EK	MW	357.5
DMOR9EK	FM	C25H27NO
DMOR9EK	IC	InChI=1S/C25H27NO/c27-25(23-14-8-3-9-15-23)16-18-26(19-17-25)24(22-12-6-2-7-13-22)20-21-10-4-1-5-11-21/h1-15,24,27H,16-20H2
DMOR9EK	CS	C1CN(CCC1(C2=CC=CC=C2)O)C(CC3=CC=CC=C3)C4=CC=CC=C4
DMOR9EK	IK	FEOIETAFCTYQIE-UHFFFAOYSA-N
DMOR9EK	IU	1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK	DE	Discovery agent

DM0ARKB	ID	DM0ARKB
DM0ARKB	DN	1-(1,2-diphenylethyl)piperazine
DM0ARKB	HS	Investigative
DM0ARKB	SN	CHEMBL214237; 88144-93-8; 1-(1,2-diphenylethyl)piperazine; SCHEMBL6171525; CTK3B7060; N-(1,2-diphenylethyl)piperazine; DTXSID00483036; BDBM50188059; AKOS010287239; Piperazine, 1-(1,2-diphenylethyl)-
DM0ARKB	DT	Small molecular drug
DM0ARKB	PC	12263801
DM0ARKB	MW	266.4
DM0ARKB	FM	C18H22N2
DM0ARKB	IC	InChI=1S/C18H22N2/c1-3-7-16(8-4-1)15-18(17-9-5-2-6-10-17)20-13-11-19-12-14-20/h1-10,18-19H,11-15H2
DM0ARKB	CS	C1CN(CCN1)C(CC2=CC=CC=C2)C3=CC=CC=C3
DM0ARKB	IK	NIBIYLDNVMUKNB-UHFFFAOYSA-N
DM0ARKB	IU	1-(1,2-diphenylethyl)piperazine
DM0ARKB	CA	CAS 88144-93-8
DM0ARKB	DE	Discovery agent

DMHIYB3	ID	DMHIYB3
DMHIYB3	DN	1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one
DMHIYB3	HS	Investigative
DMHIYB3	SN	CHEMBL467796; 1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2161990
DMHIYB3	DT	Small molecular drug
DMHIYB3	PC	24950841
DMHIYB3	MW	258.32
DMHIYB3	FM	C15H18N2O2
DMHIYB3	IC	InChI=1S/C15H18N2O2/c18-14(15-17-16-12-19-15)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMHIYB3	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NN=CO2
DMHIYB3	IK	SRGOKBDAYNCSOV-UHFFFAOYSA-N
DMHIYB3	IU	1-(1,3,4-oxadiazol-2-yl)-7-phenylheptan-1-one
DMHIYB3	DE	Discovery agent

DMZ1GH0	ID	DMZ1GH0
DMZ1GH0	DN	1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one
DMZ1GH0	HS	Investigative
DMZ1GH0	SN	CHEMBL178791; 1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one; BDBM50161529; 1-[1,3,4]Oxadiazol-2-yl-octadec-9-en-1-one
DMZ1GH0	DT	Small molecular drug
DMZ1GH0	PC	44389962
DMZ1GH0	MW	334.5
DMZ1GH0	FM	C20H34N2O2
DMZ1GH0	IC	InChI=1S/C20H34N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(23)20-22-21-18-24-20/h9-10,18H,2-8,11-17H2,1H3/b10-9-
DMZ1GH0	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NN=CO1
DMZ1GH0	IK	JPZIIIRVMJASPM-KTKRTIGZSA-N
DMZ1GH0	IU	(Z)-1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one
DMZ1GH0	DE	Discovery agent

DM6B14Q	ID	DM6B14Q
DM6B14Q	DN	1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one
DM6B14Q	HS	Investigative
DM6B14Q	SN	CHEMBL467354; 1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one; SCHEMBL2162931; OGPJTMSGDUTXCW-KTKRTIGZSA-N; BDBM50262029
DM6B14Q	DT	Small molecular drug
DM6B14Q	PC	24950688
DM6B14Q	MW	350.6
DM6B14Q	FM	C20H34N2OS
DM6B14Q	IC	InChI=1S/C20H34N2OS/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(23)20-22-21-18-24-20/h9-10,18H,2-8,11-17H2,1H3/b10-9-
DM6B14Q	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NN=CS1
DM6B14Q	IK	OGPJTMSGDUTXCW-KTKRTIGZSA-N
DM6B14Q	IU	(Z)-1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one
DM6B14Q	DE	Discovery agent

DMTC98X	ID	DMTC98X
DMTC98X	DN	1-(1,3-diphenylpropyl)piperazine
DMTC98X	HS	Investigative
DMTC98X	SN	CHEMBL209707; 1-(1,3-diphenylpropyl)piperazine; SCHEMBL5444533
DMTC98X	DT	Small molecular drug
DMTC98X	PC	44414840
DMTC98X	MW	280.4
DMTC98X	FM	C19H24N2
DMTC98X	IC	InChI=1S/C19H24N2/c1-3-7-17(8-4-1)11-12-19(18-9-5-2-6-10-18)21-15-13-20-14-16-21/h1-10,19-20H,11-16H2
DMTC98X	CS	C1CN(CCN1)C(CCC2=CC=CC=C2)C3=CC=CC=C3
DMTC98X	IK	QKYQOSPSZVKFEL-UHFFFAOYSA-N
DMTC98X	IU	1-(1,3-diphenylpropyl)piperazine
DMTC98X	DE	Discovery agent

DMYI3F5	ID	DMYI3F5
DMYI3F5	DN	1-(1,3-diphenylpropylidene)thiosemicarbazide
DMYI3F5	HS	Investigative
DMYI3F5	SN	CHEMBL429858; BDBM50377591
DMYI3F5	DT	Small molecular drug
DMYI3F5	PC	44449925
DMYI3F5	MW	283.4
DMYI3F5	FM	C16H17N3S
DMYI3F5	IC	InChI=1S/C16H17N3S/c17-16(20)19-18-15(14-9-5-2-6-10-14)12-11-13-7-3-1-4-8-13/h1-10H,11-12H2,(H3,17,19,20)/b18-15-
DMYI3F5	CS	C1=CC=C(C=C1)CC/C(=N/NC(=S)N)/C2=CC=CC=C2
DMYI3F5	IK	AEHHXKHHRMBYLD-SDXDJHTJSA-N
DMYI3F5	IU	[(Z)-1,3-diphenylpropylideneamino]thiourea
DMYI3F5	DE	Discovery agent

DMHNOLA	ID	DMHNOLA
DMHNOLA	DN	1-(1,4-diacetylphenyl)dithiosemicarbazide
DMHNOLA	HS	Investigative
DMHNOLA	SN	CHEMBL256865; NSC627218; AC1NTSUI; ZINC5883102; BDBM50376201; [(Z)-1-[4-[(Z)-N-(carbamothioylamino)-C-methylcarbonimidoyl]phenyl]ethylideneamino]thiourea; Hydrazinecarbothioamide, 2,2'-[1,4-phenylenedi(1Z)ethylidyne]bis-, (2Z,2'Z)-
DMHNOLA	DT	Small molecular drug
DMHNOLA	PC	5387783
DMHNOLA	MW	308.4
DMHNOLA	FM	C12H16N6S2
DMHNOLA	IC	InChI=1S/C12H16N6S2/c1-7(15-17-11(13)19)9-3-5-10(6-4-9)8(2)16-18-12(14)20/h3-6H,1-2H3,(H3,13,17,19)(H3,14,18,20)/b15-7-,16-8-
DMHNOLA	CS	C/C(=N/NC(=S)N)/C1=CC=C(C=C1)/C(=N\\NC(=S)N)/C
DMHNOLA	IK	IFFLYNGBOLZAGJ-DUGOVBPYSA-N
DMHNOLA	IU	[(Z)-1-[4-[(Z)-N-(carbamothioylamino)-C-methylcarbonimidoyl]phenyl]ethylideneamino]thiourea
DMHNOLA	DE	Discovery agent

DM8Z1QU	ID	DM8Z1QU
DM8Z1QU	DN	1-(1,4-diphenylbutan-2-yl)piperazine
DM8Z1QU	HS	Investigative
DM8Z1QU	SN	CHEMBL384687; 1-(1,4-diphenylbutan-2-yl)piperazine
DM8Z1QU	DT	Small molecular drug
DM8Z1QU	PC	44414856
DM8Z1QU	MW	294.4
DM8Z1QU	FM	C20H26N2
DM8Z1QU	IC	InChI=1S/C20H26N2/c1-3-7-18(8-4-1)11-12-20(22-15-13-21-14-16-22)17-19-9-5-2-6-10-19/h1-10,20-21H,11-17H2
DM8Z1QU	CS	C1CN(CCN1)C(CCC2=CC=CC=C2)CC3=CC=CC=C3
DM8Z1QU	IK	OGFNNMZMCOBWPR-UHFFFAOYSA-N
DM8Z1QU	IU	1-(1,4-diphenylbutan-2-yl)piperazine
DM8Z1QU	DE	Discovery agent

DM2AEO0	ID	DM2AEO0
DM2AEO0	DN	1-(10-Bromoanthracen-9-yl)-2-aminopropane
DM2AEO0	HS	Investigative
DM2AEO0	SN	CHEMBL465525; 1-(10-Bromoanthracen-9-yl)-2-aminopropane
DM2AEO0	DT	Small molecular drug
DM2AEO0	PC	24939279
DM2AEO0	MW	314.2
DM2AEO0	FM	C17H16BrN
DM2AEO0	IC	InChI=1S/C17H16BrN/c1-11(19)10-16-12-6-2-4-8-14(12)17(18)15-9-5-3-7-13(15)16/h2-9,11H,10,19H2,1H3
DM2AEO0	CS	CC(CC1=C2C=CC=CC2=C(C3=CC=CC=C31)Br)N
DM2AEO0	IK	TUYLBDQSCRSJBH-UHFFFAOYSA-N
DM2AEO0	IU	1-(10-bromoanthracen-9-yl)propan-2-amine
DM2AEO0	DE	Discovery agent

DMKIWBT	ID	DMKIWBT
DMKIWBT	DN	1-(10H-phenothiazin-10-yl)-2-phenylbutan-1-one
DMKIWBT	HS	Investigative
DMKIWBT	SN	CHEMBL240261; 1-(10H-phenothiazin-10-yl)-2-phenylbutan-1-one
DMKIWBT	DT	Small molecular drug
DMKIWBT	PC	44435196
DMKIWBT	MW	345.5
DMKIWBT	FM	C22H19NOS
DMKIWBT	IC	InChI=1S/C22H19NOS/c1-2-17(16-10-4-3-5-11-16)22(24)23-18-12-6-8-14-20(18)25-21-15-9-7-13-19(21)23/h3-15,17H,2H2,1H3
DMKIWBT	CS	CCC(C1=CC=CC=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMKIWBT	IK	LASZSIUHSRRUPB-UHFFFAOYSA-N
DMKIWBT	IU	1-phenothiazin-10-yl-2-phenylbutan-1-one
DMKIWBT	DE	Discovery agent

DM5WBMY	ID	DM5WBMY
DM5WBMY	DN	1-(10H-phenothiazin-10-yl)-2-phenylethanone
DM5WBMY	HS	Investigative
DM5WBMY	SN	CHEMBL394753; AC1LODHB; 1-(10H-phenothiazin-10-yl)-2-phenylethanone; Oprea1_136899; SCHEMBL7966578; MolPort-019-780-057; ZINC1022328; BDBM50219227; 1-phenothiazin-10-yl-2-phenylethanone; 1-(10H-Phenothiazine-10-yl)-2-phenylethanone; 1-(10H-Phenothiazin-10-yl)-2-phenylethan-1-one
DM5WBMY	DT	Small molecular drug
DM5WBMY	PC	1238015
DM5WBMY	MW	317.4
DM5WBMY	FM	C20H15NOS
DM5WBMY	IC	InChI=1S/C20H15NOS/c22-20(14-15-8-2-1-3-9-15)21-16-10-4-6-12-18(16)23-19-13-7-5-11-17(19)21/h1-13H,14H2
DM5WBMY	CS	C1=CC=C(C=C1)CC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM5WBMY	IK	ODRJXAKDUXFICI-UHFFFAOYSA-N
DM5WBMY	IU	1-phenothiazin-10-yl-2-phenylethanone
DM5WBMY	DE	Discovery agent

DMYWG7D	ID	DMYWG7D
DMYWG7D	DN	1-(10H-phenothiazin-10-yl)-2-phenylpropan-1-one
DMYWG7D	HS	Investigative
DMYWG7D	SN	CHEMBL240045; 1-(10H-phenothiazin-10-yl)-2-phenylpropan-1-one
DMYWG7D	DT	Small molecular drug
DMYWG7D	PC	44435193
DMYWG7D	MW	331.4
DMYWG7D	FM	C21H17NOS
DMYWG7D	IC	InChI=1S/C21H17NOS/c1-15(16-9-3-2-4-10-16)21(23)22-17-11-5-7-13-19(17)24-20-14-8-6-12-18(20)22/h2-15H,1H3
DMYWG7D	CS	CC(C1=CC=CC=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMYWG7D	IK	JSTQBEJYZPIVJU-UHFFFAOYSA-N
DMYWG7D	IU	1-phenothiazin-10-yl-2-phenylpropan-1-one
DMYWG7D	DE	Discovery agent

DMZCPAQ	ID	DMZCPAQ
DMZCPAQ	DN	1-(10H-phenothiazin-10-yl)-3-phenylbutan-1-one
DMZCPAQ	HS	Investigative
DMZCPAQ	SN	CHEMBL240262; 1-(10H-phenothiazin-10-yl)-3-phenylbutan-1-one
DMZCPAQ	DT	Small molecular drug
DMZCPAQ	PC	44435197
DMZCPAQ	MW	345.5
DMZCPAQ	FM	C22H19NOS
DMZCPAQ	IC	InChI=1S/C22H19NOS/c1-16(17-9-3-2-4-10-17)15-22(24)23-18-11-5-7-13-20(18)25-21-14-8-6-12-19(21)23/h2-14,16H,15H2,1H3
DMZCPAQ	CS	CC(CC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31)C4=CC=CC=C4
DMZCPAQ	IK	WFXGFQNNLYOETN-UHFFFAOYSA-N
DMZCPAQ	IU	1-phenothiazin-10-yl-3-phenylbutan-1-one
DMZCPAQ	DE	Discovery agent

DMJQNLR	ID	DMJQNLR
DMJQNLR	DN	1-(10H-phenothiazin-10-yl)-3-phenylpropan-1-one
DMJQNLR	HS	Investigative
DMJQNLR	SN	1-(10H-phenothiazin-10-yl)-3-phenylpropan-1-one; CHEMBL240047; AC1LHUPA; 1-phenothiazin-10-yl-3-phenylpropan-1-one; MolPort-027-839-061; MolPort-002-255-240; ZINC469770; STL138828; BDBM50219214; AKOS005715472; MCULE-9350992214; 10-(3-phenylpropanoyl)-10H-phenothiazine; AO-365/41906550
DMJQNLR	DT	Small molecular drug
DMJQNLR	PC	893336
DMJQNLR	MW	331.4
DMJQNLR	FM	C21H17NOS
DMJQNLR	IC	InChI=1S/C21H17NOS/c23-21(15-14-16-8-2-1-3-9-16)22-17-10-4-6-12-19(17)24-20-13-7-5-11-18(20)22/h1-13H,14-15H2
DMJQNLR	CS	C1=CC=C(C=C1)CCC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMJQNLR	IK	UFAZLVHMPFPAHH-UHFFFAOYSA-N
DMJQNLR	IU	1-phenothiazin-10-yl-3-phenylpropan-1-one
DMJQNLR	DE	Discovery agent

DMGY32O	ID	DMGY32O
DMGY32O	DN	1-(10H-phenothiazin-10-yl)-4-phenylbutan-1-one
DMGY32O	HS	Investigative
DMGY32O	SN	CHEMBL394755; 1-(10H-phenothiazin-10-yl)-4-phenylbutan-1-one
DMGY32O	DT	Small molecular drug
DMGY32O	PC	44435200
DMGY32O	MW	345.5
DMGY32O	FM	C22H19NOS
DMGY32O	IC	InChI=1S/C22H19NOS/c24-22(16-8-11-17-9-2-1-3-10-17)23-18-12-4-6-14-20(18)25-21-15-7-5-13-19(21)23/h1-7,9-10,12-15H,8,11,16H2
DMGY32O	CS	C1=CC=C(C=C1)CCCC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMGY32O	IK	IDGMQHJPMVCZGQ-UHFFFAOYSA-N
DMGY32O	IU	1-phenothiazin-10-yl-4-phenylbutan-1-one
DMGY32O	DE	Discovery agent

DM7G2AB	ID	DM7G2AB
DM7G2AB	DN	1-(1-Adamantyl)-3-(1-propionylpiperidin-4-yl)urea
DM7G2AB	HS	Investigative
DM7G2AB	SN	CHEMBL214943; US8501783, 1163; SCHEMBL2731282; BDBM100426; BDBM100363; BDBM50191887
DM7G2AB	DT	Small molecular drug
DM7G2AB	PC	24849910
DM7G2AB	MW	333.5
DM7G2AB	FM	C19H31N3O2
DM7G2AB	IC	InChI=1S/C19H31N3O2/c1-2-17(23)22-5-3-16(4-6-22)20-18(24)21-19-10-13-7-14(11-19)9-15(8-13)12-19/h13-16H,2-12H2,1H3,(H2,20,21,24)
DM7G2AB	CS	CCC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DM7G2AB	IK	LFQPHKTUDTUJEA-UHFFFAOYSA-N
DM7G2AB	IU	1-(1-adamantyl)-3-(1-propanoylpiperidin-4-yl)urea
DM7G2AB	DE	Discovery agent

DM2T1CD	ID	DM2T1CD
DM2T1CD	DN	1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepane
DM2T1CD	HS	Investigative
DM2T1CD	SN	CHEMBL18190; 1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepane; BDBM50040196
DM2T1CD	DT	Small molecular drug
DM2T1CD	PC	14952700
DM2T1CD	MW	327.5
DM2T1CD	FM	C21H29NS
DM2T1CD	IC	InChI=1S/C21H29NS/c1-2-8-14-21(13-7-1,22-15-9-3-4-10-16-22)20-17-18-11-5-6-12-19(18)23-20/h5-6,11-12,17H,1-4,7-10,13-16H2
DM2T1CD	CS	C1CCCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCCC4
DM2T1CD	IK	SHYAOKYYAHMSCY-UHFFFAOYSA-N
DM2T1CD	IU	1-[1-(1-benzothiophen-2-yl)cycloheptyl]azepane
DM2T1CD	DE	Discovery agent

DMEFP15	ID	DMEFP15
DMEFP15	DN	1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepane
DMEFP15	HS	Investigative
DMEFP15	SN	CHEMBL17945; 1-[1-(1-benzothiophen-2-yl)cyclohexyl]azepane; NCI60_038332; AC1L9GGF; 1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepane; CTK5J7197; QDGRJLAJZNWVGV-UHFFFAOYSA-N; BDBM50040192; 1-[1-(1-Benzothien-2-yl)cyclohexyl]azepane #; Thionaphthene, 2-[1-(1-azacycloheptyl)cyclohexyl]-
DMEFP15	DT	Small molecular drug
DMEFP15	PC	398369
DMEFP15	MW	313.5
DMEFP15	FM	C20H27NS
DMEFP15	IC	InChI=1S/C20H27NS/c1-2-9-15-21(14-8-1)20(12-6-3-7-13-20)19-16-17-10-4-5-11-18(17)22-19/h4-5,10-11,16H,1-3,6-9,12-15H2
DMEFP15	CS	C1CCCN(CC1)C2(CCCCC2)C3=CC4=CC=CC=C4S3
DMEFP15	IK	QDGRJLAJZNWVGV-UHFFFAOYSA-N
DMEFP15	IU	1-[1-(1-benzothiophen-2-yl)cyclohexyl]azepane
DMEFP15	DE	Discovery agent

DM1Q36W	ID	DM1Q36W
DM1Q36W	DN	1-(1-Benzo[b]thiophen-2-yl-cyclopentyl)-azepane
DM1Q36W	HS	Investigative
DM1Q36W	SN	CHEMBL18025; AC1LCXWM; 1-(1-Benzo[b]thiophen-2-yl-cyclopentyl)-azepane; XZXHOFZYYWGLCJ-UHFFFAOYSA-N; BDBM50040198; 1-[1-(1-Benzothien-2-yl)cyclopentyl]azepane #; 1-[1-(1-benzothiophen-2-yl)cyclopentyl]azepane; Thionaphthene, 2-[1-(1-azacycloheptyl)cyclopentyl]-
DM1Q36W	DT	Small molecular drug
DM1Q36W	PC	608630
DM1Q36W	MW	299.5
DM1Q36W	FM	C19H25NS
DM1Q36W	IC	InChI=1S/C19H25NS/c1-2-8-14-20(13-7-1)19(11-5-6-12-19)18-15-16-9-3-4-10-17(16)21-18/h3-4,9-10,15H,1-2,5-8,11-14H2
DM1Q36W	CS	C1CCCN(CC1)C2(CCCC2)C3=CC4=CC=CC=C4S3
DM1Q36W	IK	XZXHOFZYYWGLCJ-UHFFFAOYSA-N
DM1Q36W	IU	1-[1-(1-benzothiophen-2-yl)cyclopentyl]azepane
DM1Q36W	DE	Discovery agent

DMLBCE5	ID	DMLBCE5
DMLBCE5	DN	1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole
DMLBCE5	HS	Investigative
DMLBCE5	SN	CHEMBL491222; AC1LAA5O; 1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole; BDBM50263812; 1-[1-benzyl-2-(4-phenylphenyl)ethyl]imidazole; 1-[1-phenyl-3-(4-phenylphenyl)propan-2-yl]imidazole; 1H-Imidazole, 1-[2-[1,1'-biphenyl]-4-yl-1-(phenylmethyl)ethyl]-
DMLBCE5	DT	Small molecular drug
DMLBCE5	PC	510040
DMLBCE5	MW	338.4
DMLBCE5	FM	C24H22N2
DMLBCE5	IC	InChI=1S/C24H22N2/c1-3-7-20(8-4-1)17-24(26-16-15-25-19-26)18-21-11-13-23(14-12-21)22-9-5-2-6-10-22/h1-16,19,24H,17-18H2
DMLBCE5	CS	C1=CC=C(C=C1)CC(CC2=CC=C(C=C2)C3=CC=CC=C3)N4C=CN=C4
DMLBCE5	IK	BHZGAVDQPKAVLD-UHFFFAOYSA-N
DMLBCE5	IU	1-[1-phenyl-3-(4-phenylphenyl)propan-2-yl]imidazole
DMLBCE5	DE	Discovery agent

DMPEIQT	ID	DMPEIQT
DMPEIQT	DN	1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole
DMPEIQT	HS	Investigative
DMPEIQT	SN	CHEMBL496468; 1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole
DMPEIQT	DT	Small molecular drug
DMPEIQT	PC	44587266
DMPEIQT	MW	276.4
DMPEIQT	FM	C19H20N2
DMPEIQT	IC	InChI=1S/C19H20N2/c1-15(2)19(21-13-12-20-14-21)18-10-8-17(9-11-18)16-6-4-3-5-7-16/h3-15,19H,1-2H3
DMPEIQT	CS	CC(C)C(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMPEIQT	IK	IYAQGZVBLONFOB-UHFFFAOYSA-N
DMPEIQT	IU	1-[2-methyl-1-(4-phenylphenyl)propyl]imidazole
DMPEIQT	DE	Discovery agent

DMCTF8X	ID	DMCTF8X
DMCTF8X	DN	1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole
DMCTF8X	HS	Investigative
DMCTF8X	SN	CHEMBL526293; 1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole
DMCTF8X	DT	Small molecular drug
DMCTF8X	PC	13416469
DMCTF8X	MW	324.4
DMCTF8X	FM	C23H20N2
DMCTF8X	IC	InChI=1S/C23H20N2/c1-3-7-19(8-4-1)17-23(25-16-15-24-18-25)22-13-11-21(12-14-22)20-9-5-2-6-10-20/h1-16,18,23H,17H2
DMCTF8X	CS	C1=CC=C(C=C1)CC(C2=CC=C(C=C2)C3=CC=CC=C3)N4C=CN=C4
DMCTF8X	IK	TVOGKVRUROHUOE-UHFFFAOYSA-N
DMCTF8X	IU	1-[2-phenyl-1-(4-phenylphenyl)ethyl]imidazole
DMCTF8X	DE	Discovery agent

DMWME7I	ID	DMWME7I
DMWME7I	DN	1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole
DMWME7I	HS	Investigative
DMWME7I	SN	CHEMBL497851; 1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole
DMWME7I	DT	Small molecular drug
DMWME7I	PC	44587268
DMWME7I	MW	290.4
DMWME7I	FM	C20H22N2
DMWME7I	IC	InChI=1S/C20H22N2/c1-16(2)14-20(22-13-12-21-15-22)19-10-8-18(9-11-19)17-6-4-3-5-7-17/h3-13,15-16,20H,14H2,1-2H3
DMWME7I	CS	CC(C)CC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMWME7I	IK	WLSWBXVWEUOVLV-UHFFFAOYSA-N
DMWME7I	IU	1-[3-methyl-1-(4-phenylphenyl)butyl]imidazole
DMWME7I	DE	Discovery agent

DM4XILF	ID	DM4XILF
DM4XILF	DN	1-(1-Biphenyl-4-yl-butyl)-1H-imidazole
DM4XILF	HS	Investigative
DM4XILF	SN	CHEMBL449343; 1-(1-Biphenyl-4-yl-butyl)-1H-imidazole
DM4XILF	DT	Small molecular drug
DM4XILF	PC	44587265
DM4XILF	MW	276.4
DM4XILF	FM	C19H20N2
DM4XILF	IC	InChI=1S/C19H20N2/c1-2-6-19(21-14-13-20-15-21)18-11-9-17(10-12-18)16-7-4-3-5-8-16/h3-5,7-15,19H,2,6H2,1H3
DM4XILF	CS	CCCC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DM4XILF	IK	SLKWPFBZPUBKHY-UHFFFAOYSA-N
DM4XILF	IU	1-[1-(4-phenylphenyl)butyl]imidazole
DM4XILF	DE	Discovery agent

DMW85CH	ID	DMW85CH
DMW85CH	DN	1-(1-Biphenyl-4-yl-ethyl)-1H-imidazole
DMW85CH	HS	Investigative
DMW85CH	SN	CHEMBL497499; 1-(1-Biphenyl-4-yl-ethyl)-1H-imidazole; SCHEMBL10649315; BDBM50272506
DMW85CH	DT	Small molecular drug
DMW85CH	PC	10354661
DMW85CH	MW	248.32
DMW85CH	FM	C17H16N2
DMW85CH	IC	InChI=1S/C17H16N2/c1-14(19-12-11-18-13-19)15-7-9-17(10-8-15)16-5-3-2-4-6-16/h2-14H,1H3
DMW85CH	CS	CC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMW85CH	IK	XGUZZPBTOANTPR-UHFFFAOYSA-N
DMW85CH	IU	1-[1-(4-phenylphenyl)ethyl]imidazole
DMW85CH	DE	Discovery agent

DM3AD7E	ID	DM3AD7E
DM3AD7E	DN	1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole
DM3AD7E	HS	Investigative
DM3AD7E	SN	CHEMBL498523; 1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole
DM3AD7E	DT	Small molecular drug
DM3AD7E	PC	44587267
DM3AD7E	MW	290.4
DM3AD7E	FM	C20H22N2
DM3AD7E	IC	InChI=1S/C20H22N2/c1-2-3-9-20(22-15-14-21-16-22)19-12-10-18(11-13-19)17-7-5-4-6-8-17/h4-8,10-16,20H,2-3,9H2,1H3
DM3AD7E	CS	CCCCC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DM3AD7E	IK	LJLOALSYDDARJF-UHFFFAOYSA-N
DM3AD7E	IU	1-[1-(4-phenylphenyl)pentyl]imidazole
DM3AD7E	DE	Discovery agent

DMGVE3F	ID	DMGVE3F
DMGVE3F	DN	1-(1-Biphenyl-4-yl-propyl)-1H-imidazole
DMGVE3F	HS	Investigative
DMGVE3F	SN	CHEMBL497500; 1-(1-Biphenyl-4-yl-propyl)-1H-imidazole
DMGVE3F	DT	Small molecular drug
DMGVE3F	PC	44587233
DMGVE3F	MW	262.3
DMGVE3F	FM	C18H18N2
DMGVE3F	IC	InChI=1S/C18H18N2/c1-2-18(20-13-12-19-14-20)17-10-8-16(9-11-17)15-6-4-3-5-7-15/h3-14,18H,2H2,1H3
DMGVE3F	CS	CCC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMGVE3F	IK	IGUCGOUQZFQHGU-UHFFFAOYSA-N
DMGVE3F	IU	1-[1-(4-phenylphenyl)propyl]imidazole
DMGVE3F	DE	Discovery agent

DM9MCAU	ID	DM9MCAU
DM9MCAU	DN	1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea
DM9MCAU	HS	Investigative
DM9MCAU	SN	Diarylurea deriv. 14a; AC1NS9HT; BDBM6656; CHEMBL143759; ZINC13471116; AKOS027814075; 3-1H-indazol-6-yl-1-pyridin-2-ylurea; 1-(1H-indazol-6-yl)-3-pyridin-2-ylurea; N-(1H-Indazol-6-yl)-N -pyridin-2-ylurea
DM9MCAU	DT	Small molecular drug
DM9MCAU	PC	5330597
DM9MCAU	MW	253.26
DM9MCAU	FM	C13H11N5O
DM9MCAU	IC	InChI=1S/C13H11N5O/c19-13(17-12-3-1-2-6-14-12)16-10-5-4-9-8-15-18-11(9)7-10/h1-8H,(H,15,18)(H2,14,16,17,19)
DM9MCAU	CS	C1=CC=NC(=C1)NC(=O)NC2=CC3=C(C=C2)C=NN3
DM9MCAU	IK	YGKMQQVUBKWTIJ-UHFFFAOYSA-N
DM9MCAU	IU	1-(1H-indazol-6-yl)-3-pyridin-2-ylurea
DM9MCAU	DE	Discovery agent

DMSUPCD	ID	DMSUPCD
DMSUPCD	DN	1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol
DMSUPCD	HS	Investigative
DMSUPCD	SN	CHEMBL37989
DMSUPCD	DT	Small molecular drug
DMSUPCD	PC	13626879
DMSUPCD	MW	310.4
DMSUPCD	FM	C19H22N2O2
DMSUPCD	IC	InChI=1S/C19H22N2O2/c22-16(13-20-11-9-15-5-2-1-3-6-15)14-23-19-8-4-7-18-17(19)10-12-21-18/h1-8,10,12,16,20-22H,9,11,13-14H2
DMSUPCD	CS	C1=CC=C(C=C1)CCNCC(COC2=CC=CC3=C2C=CN3)O
DMSUPCD	IK	MDPRLCKPDFRPJV-UHFFFAOYSA-N
DMSUPCD	IU	1-(1H-indol-4-yloxy)-3-(2-phenylethylamino)propan-2-ol
DMSUPCD	DE	Discovery agent

DM6X9J3	ID	DM6X9J3
DM6X9J3	DN	1-(1-Naphthyl)-2-aminopropane
DM6X9J3	HS	Investigative
DM6X9J3	SN	CHEMBL471838; 1-(1-Naphthyl)-2-aminopropane; 1-napthyl-2-aminopropane; SCHEMBL266931; AC1L96M0; 1-(1-Naphthyl)propane-2-amine; CTK6A7125; 1-naphthalen-1-ylpropan-2-amine; BDBM50276188; AKOS022488614; AKOS000151865; 12687-37-5; 1-(NAPHTHALEN-1-YL)PROPAN-2-AMINE
DM6X9J3	DT	Small molecular drug
DM6X9J3	PC	413939
DM6X9J3	MW	185.26
DM6X9J3	FM	C13H15N
DM6X9J3	IC	InChI=1S/C13H15N/c1-10(14)9-12-7-4-6-11-5-2-3-8-13(11)12/h2-8,10H,9,14H2,1H3
DM6X9J3	CS	CC(CC1=CC=CC2=CC=CC=C21)N
DM6X9J3	IK	ODTJDLMNBKMVGR-UHFFFAOYSA-N
DM6X9J3	IU	1-naphthalen-1-ylpropan-2-amine
DM6X9J3	CA	CAS 12687-37-5
DM6X9J3	DE	Discovery agent

DMSUC85	ID	DMSUC85
DMSUC85	DN	1-(1-phenyl-1H-tetrazol-5-ylthio)propan-2-one
DMSUC85	HS	Investigative
DMSUC85	SN	CHEMBL1082938; 1-(1-phenyl-1H-tetrazol-5-ylthio)propan-2-one
DMSUC85	DT	Small molecular drug
DMSUC85	PC	46890076
DMSUC85	MW	233.29
DMSUC85	FM	C11H11N3OS
DMSUC85	IC	InChI=1S/C11H11N3OS/c1-9(15)8-16-11-7-12-13-14(11)10-5-3-2-4-6-10/h2-7H,8H2,1H3
DMSUC85	CS	CC(=O)CSC1=CN=NN1C2=CC=CC=C2
DMSUC85	IK	ZEWXXPJFFAXSFB-UHFFFAOYSA-N
DMSUC85	IU	1-(3-phenyltriazol-4-yl)sulfanylpropan-2-one
DMSUC85	DE	Discovery agent

DM54ZKU	ID	DM54ZKU
DM54ZKU	DN	1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine
DM54ZKU	HS	Investigative
DM54ZKU	SN	CHEMBL213754; 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine; SCHEMBL5447617
DM54ZKU	DT	Small molecular drug
DM54ZKU	PC	44414723
DM54ZKU	MW	324.5
DM54ZKU	FM	C21H28N2O
DM54ZKU	IC	InChI=1S/C21H28N2O/c1-2-16-24-21-11-7-6-10-19(21)17-20(18-8-4-3-5-9-18)23-14-12-22-13-15-23/h3-11,20,22H,2,12-17H2,1H3
DM54ZKU	CS	CCCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DM54ZKU	IK	PSIGDYKJTYBHDY-UHFFFAOYSA-N
DM54ZKU	IU	1-[1-phenyl-2-(2-propoxyphenyl)ethyl]piperazine
DM54ZKU	DE	Discovery agent

DMIZBP6	ID	DMIZBP6
DMIZBP6	DN	1-(1-phenyl-2-(pyridin-2-yl)ethyl)piperazine
DMIZBP6	HS	Investigative
DMIZBP6	SN	CHEMBL376952; 1-(1-phenyl-2-(pyridin-2-yl)ethyl)piperazine
DMIZBP6	DT	Small molecular drug
DMIZBP6	PC	44414862
DMIZBP6	MW	267.37
DMIZBP6	FM	C17H21N3
DMIZBP6	IC	InChI=1S/C17H21N3/c1-2-6-15(7-3-1)17(20-12-10-18-11-13-20)14-16-8-4-5-9-19-16/h1-9,17-18H,10-14H2
DMIZBP6	CS	C1CN(CCN1)C(CC2=CC=CC=N2)C3=CC=CC=C3
DMIZBP6	IK	BAYDYCDSOWCJTI-UHFFFAOYSA-N
DMIZBP6	IU	1-(1-phenyl-2-pyridin-2-ylethyl)piperazine
DMIZBP6	DE	Discovery agent

DMTVPZC	ID	DMTVPZC
DMTVPZC	DN	1-(1-phenyl-2-(pyridin-4-yl)ethyl)piperazine
DMTVPZC	HS	Investigative
DMTVPZC	SN	CHEMBL214004; 1-(1-phenyl-2-(pyridin-4-yl)ethyl)piperazine; SCHEMBL7967173
DMTVPZC	DT	Small molecular drug
DMTVPZC	PC	44414874
DMTVPZC	MW	267.37
DMTVPZC	FM	C17H21N3
DMTVPZC	IC	InChI=1S/C17H21N3/c1-2-4-16(5-3-1)17(20-12-10-19-11-13-20)14-15-6-8-18-9-7-15/h1-9,17,19H,10-14H2
DMTVPZC	CS	C1CN(CCN1)C(CC2=CC=NC=C2)C3=CC=CC=C3
DMTVPZC	IK	QVONDVLKKQSPCH-UHFFFAOYSA-N
DMTVPZC	IU	1-(1-phenyl-2-pyridin-4-ylethyl)piperazine
DMTVPZC	DE	Discovery agent

DMZ6QX0	ID	DMZ6QX0
DMZ6QX0	DN	1-(1-phenyl-2-o-tolylethyl)piperazine
DMZ6QX0	HS	Investigative
DMZ6QX0	SN	CHEMBL210028; 1-(1-phenyl-2-o-tolylethyl)piperazine; SCHEMBL5453605
DMZ6QX0	DT	Small molecular drug
DMZ6QX0	PC	44414708
DMZ6QX0	MW	280.4
DMZ6QX0	FM	C19H24N2
DMZ6QX0	IC	InChI=1S/C19H24N2/c1-16-7-5-6-10-18(16)15-19(17-8-3-2-4-9-17)21-13-11-20-12-14-21/h2-10,19-20H,11-15H2,1H3
DMZ6QX0	CS	CC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DMZ6QX0	IK	XPYLNZBNFQMTKZ-UHFFFAOYSA-N
DMZ6QX0	IU	1-[2-(2-methylphenyl)-1-phenylethyl]piperazine
DMZ6QX0	DE	Discovery agent

DMN5SL6	ID	DMN5SL6
DMN5SL6	DN	1-(1-phenylethylidene)thiosemicarbazide
DMN5SL6	HS	Investigative
DMN5SL6	SN	CHEMBL256868; Acetophenone thiosemicarbazone; AC1NSE5V; SCHEMBL17666972; MolPort-000-248-706; ACETOPHENONE-THIOSEMICARBAZONE; BDBM50376200; ZINC13655939; AKOS002388568; AKOS002238721; [(Z)-1-phenylethylideneamino]thiourea; [(Z)-(1-phenylethylidene)amino]thiourea; KB-106912; ST50101590; (z)-2-(1-phenylethylidene)hydrazinecarbothioamide
DMN5SL6	DT	Small molecular drug
DMN5SL6	PC	5359703
DMN5SL6	MW	193.27
DMN5SL6	FM	C9H11N3S
DMN5SL6	IC	InChI=1S/C9H11N3S/c1-7(11-12-9(10)13)8-5-3-2-4-6-8/h2-6H,1H3,(H3,10,12,13)/b11-7-
DMN5SL6	CS	C/C(=N/NC(=S)N)/C1=CC=CC=C1
DMN5SL6	IK	JMULZUQMMLAALR-XFFZJAGNSA-N
DMN5SL6	IU	[(Z)-1-phenylethylideneamino]thiourea
DMN5SL6	DE	Discovery agent

DMER0IY	ID	DMER0IY
DMER0IY	DN	1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea
DMER0IY	HS	Investigative
DMER0IY	SN	CHEMBL151773; AC1MHEIH; 1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea; SCHEMBL6284442; BDBM50097039; 1-(1-phenylpropyl)-3-thiazol-2-yl-thiourea; N-(alpha-Ethylbenzyl]-N'-[2-(thiazolyl)]thiourea
DMER0IY	DT	Small molecular drug
DMER0IY	PC	3003038
DMER0IY	MW	277.4
DMER0IY	FM	C13H15N3S2
DMER0IY	IC	InChI=1S/C13H15N3S2/c1-2-11(10-6-4-3-5-7-10)15-12(17)16-13-14-8-9-18-13/h3-9,11H,2H2,1H3,(H2,14,15,16,17)
DMER0IY	CS	CCC(C1=CC=CC=C1)NC(=S)NC2=NC=CS2
DMER0IY	IK	PBDIRHCFDNJKQO-UHFFFAOYSA-N
DMER0IY	IU	1-(1-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea
DMER0IY	DE	Discovery agent

DMAZR9C	ID	DMAZR9C
DMAZR9C	DN	1-(1-Propionylpiperidin-4-yl)-3-m-tolylurea
DMAZR9C	HS	Investigative
DMAZR9C	SN	CHEMBL1257755; 1-(1-Propionylpiperidin-4-yl)-3-m-tolylurea; SCHEMBL2719775; BDBM50327819
DMAZR9C	DT	Small molecular drug
DMAZR9C	PC	49782798
DMAZR9C	MW	289.37
DMAZR9C	FM	C16H23N3O2
DMAZR9C	IC	InChI=1S/C16H23N3O2/c1-3-15(20)19-9-7-13(8-10-19)17-16(21)18-14-6-4-5-12(2)11-14/h4-6,11,13H,3,7-10H2,1-2H3,(H2,17,18,21)
DMAZR9C	CS	CCC(=O)N1CCC(CC1)NC(=O)NC2=CC=CC(=C2)C
DMAZR9C	IK	CWZWLJHZFNKFSC-UHFFFAOYSA-N
DMAZR9C	IU	1-(3-methylphenyl)-3-(1-propanoylpiperidin-4-yl)urea
DMAZR9C	DE	Discovery agent

DMUH59X	ID	DMUH59X
DMUH59X	DN	1-(1-Propionylpiperidin-4-yl)-3-o-tolylurea
DMUH59X	HS	Investigative
DMUH59X	SN	CHEMBL1257633; 1-(1-Propionylpiperidin-4-yl)-3-o-tolylurea; SCHEMBL2720137; BDBM50327838
DMUH59X	DT	Small molecular drug
DMUH59X	PC	49782797
DMUH59X	MW	289.37
DMUH59X	FM	C16H23N3O2
DMUH59X	IC	InChI=1S/C16H23N3O2/c1-3-15(20)19-10-8-13(9-11-19)17-16(21)18-14-7-5-4-6-12(14)2/h4-7,13H,3,8-11H2,1-2H3,(H2,17,18,21)
DMUH59X	CS	CCC(=O)N1CCC(CC1)NC(=O)NC2=CC=CC=C2C
DMUH59X	IK	CBKNSQNPJUKLHL-UHFFFAOYSA-N
DMUH59X	IU	1-(2-methylphenyl)-3-(1-propanoylpiperidin-4-yl)urea
DMUH59X	DE	Discovery agent

DMWUBI4	ID	DMWUBI4
DMWUBI4	DN	1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea
DMWUBI4	HS	Investigative
DMWUBI4	SN	CHEMBL1257756; 1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea; SCHEMBL2719286; BDBM50327828
DMWUBI4	DT	Small molecular drug
DMWUBI4	PC	49782799
DMWUBI4	MW	289.37
DMWUBI4	FM	C16H23N3O2
DMWUBI4	IC	InChI=1S/C16H23N3O2/c1-3-15(20)19-10-8-14(9-11-19)18-16(21)17-13-6-4-12(2)5-7-13/h4-7,14H,3,8-11H2,1-2H3,(H2,17,18,21)
DMWUBI4	CS	CCC(=O)N1CCC(CC1)NC(=O)NC2=CC=C(C=C2)C
DMWUBI4	IK	JYILGCQJFUIUHF-UHFFFAOYSA-N
DMWUBI4	IU	1-(4-methylphenyl)-3-(1-propanoylpiperidin-4-yl)urea
DMWUBI4	DE	Discovery agent

DM2PQFE	ID	DM2PQFE
DM2PQFE	DN	1-(1-p-tolylethylidene)thiosemicarbazide
DM2PQFE	HS	Investigative
DM2PQFE	SN	CHEMBL256866; 7410-54-0; NSC8380; AC1NS5IF; DTXSID70417787; MolPort-020-322-439; ZINC502706; 1-p-Tolylethanone thiosemicarbazone; NSC-8380; BDBM50376198; AKOS002388601; AKOS008939485
DM2PQFE	DT	Small molecular drug
DM2PQFE	PC	5354385
DM2PQFE	MW	207.3
DM2PQFE	FM	C10H13N3S
DM2PQFE	IC	InChI=1S/C10H13N3S/c1-7-3-5-9(6-4-7)8(2)12-13-10(11)14/h3-6H,1-2H3,(H3,11,13,14)/b12-8-
DM2PQFE	CS	CC1=CC=C(C=C1)/C(=N\\NC(=S)N)/C
DM2PQFE	IK	CLXMWTWYQLEKAI-WQLSENKSSA-N
DM2PQFE	IU	[(Z)-1-(4-methylphenyl)ethylideneamino]thiourea
DM2PQFE	CA	CAS 7410-54-0
DM2PQFE	DE	Discovery agent

DMJXKOF	ID	DMJXKOF
DMJXKOF	DN	1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine
DMJXKOF	HS	Investigative
DMJXKOF	SN	CHEMBL575700; 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine; SCHEMBL2191560
DMJXKOF	DT	Small molecular drug
DMJXKOF	PC	45483467
DMJXKOF	MW	286.34
DMJXKOF	FM	C17H19FN2O
DMJXKOF	IC	InChI=1S/C17H19FN2O/c18-15-5-3-6-16(12-15)21-13-14-4-1-2-7-17(14)20-10-8-19-9-11-20/h1-7,12,19H,8-11,13H2
DMJXKOF	CS	C1CN(CCN1)C2=CC=CC=C2COC3=CC(=CC=C3)F
DMJXKOF	IK	IGKKFJKUWPDJDR-UHFFFAOYSA-N
DMJXKOF	IU	1-[2-[(3-fluorophenoxy)methyl]phenyl]piperazine
DMJXKOF	DE	Discovery agent

DMUJ2WB	ID	DMUJ2WB
DMUJ2WB	DN	1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMUJ2WB	HS	Investigative
DMUJ2WB	SN	CHEMBL1083708; 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX); SCHEMBL5447686; BDBM50319818; 1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine; (-)-1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine
DMUJ2WB	DT	Small molecular drug
DMUJ2WB	PC	46890395
DMUJ2WB	MW	332.4
DMUJ2WB	FM	C19H22F2N2O
DMUJ2WB	IC	InChI=1S/C19H22F2N2O/c20-19(21)24-18-9-5-4-8-16(18)14-17(15-6-2-1-3-7-15)23-12-10-22-11-13-23/h1-9,17,19,22H,10-14H2
DMUJ2WB	CS	C1CN(CCN1)C(CC2=CC=CC=C2OC(F)F)C3=CC=CC=C3
DMUJ2WB	IK	VCVDPONUNCPTCQ-UHFFFAOYSA-N
DMUJ2WB	IU	1-[2-[2-(difluoromethoxy)phenyl]-1-phenylethyl]piperazine
DMUJ2WB	DE	Discovery agent

DMPRALC	ID	DMPRALC
DMPRALC	DN	1-(2-(2-bromophenyl)-1-phenylethyl)piperazine
DMPRALC	HS	Investigative
DMPRALC	SN	CHEMBL378418; 1-(2-(2-bromophenyl)-1-phenylethyl)piperazine; SCHEMBL5442011
DMPRALC	DT	Small molecular drug
DMPRALC	PC	44414750
DMPRALC	MW	345.3
DMPRALC	FM	C18H21BrN2
DMPRALC	IC	InChI=1S/C18H21BrN2/c19-17-9-5-4-8-16(17)14-18(15-6-2-1-3-7-15)21-12-10-20-11-13-21/h1-9,18,20H,10-14H2
DMPRALC	CS	C1CN(CCN1)C(CC2=CC=CC=C2Br)C3=CC=CC=C3
DMPRALC	IK	KVNXQYJMNFSXRE-UHFFFAOYSA-N
DMPRALC	IU	1-[2-(2-bromophenyl)-1-phenylethyl]piperazine
DMPRALC	DE	Discovery agent

DM9CVX5	ID	DM9CVX5
DM9CVX5	DN	1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine
DM9CVX5	HS	Investigative
DM9CVX5	SN	CHEMBL599593; 1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine
DM9CVX5	DT	Small molecular drug
DM9CVX5	PC	46230818
DM9CVX5	MW	289.76
DM9CVX5	FM	C15H16ClN3O
DM9CVX5	IC	InChI=1S/C15H16ClN3O/c16-12-4-1-2-6-14(12)20-15-13(5-3-7-18-15)19-10-8-17-9-11-19/h1-7,17H,8-11H2
DM9CVX5	CS	C1CN(CCN1)C2=C(N=CC=C2)OC3=CC=CC=C3Cl
DM9CVX5	IK	LVSZWRFDLAUNPF-UHFFFAOYSA-N
DM9CVX5	IU	1-[2-(2-chlorophenoxy)pyridin-3-yl]piperazine
DM9CVX5	DE	Discovery agent

DMUM4YQ	ID	DMUM4YQ
DMUM4YQ	DN	1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine
DMUM4YQ	HS	Investigative
DMUM4YQ	SN	CHEMBL213287; 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine; SCHEMBL5444180
DMUM4YQ	DT	Small molecular drug
DMUM4YQ	PC	44414719
DMUM4YQ	MW	300.8
DMUM4YQ	FM	C18H21ClN2
DMUM4YQ	IC	InChI=1S/C18H21ClN2/c19-17-9-5-4-8-16(17)14-18(15-6-2-1-3-7-15)21-12-10-20-11-13-21/h1-9,18,20H,10-14H2
DMUM4YQ	CS	C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=CC=C3
DMUM4YQ	IK	SDLVJPBOBLQFEW-UHFFFAOYSA-N
DMUM4YQ	IU	1-[2-(2-chlorophenyl)-1-phenylethyl]piperazine
DMUM4YQ	DE	Discovery agent

DMBRS3D	ID	DMBRS3D
DMBRS3D	DN	1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine
DMBRS3D	HS	Investigative
DMBRS3D	SN	CHEMBL386224; 1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine; SCHEMBL5450115
DMBRS3D	DT	Small molecular drug
DMBRS3D	PC	11289879
DMBRS3D	MW	310.4
DMBRS3D	FM	C20H26N2O
DMBRS3D	IC	InChI=1S/C20H26N2O/c1-2-23-20-11-7-6-10-18(20)16-19(17-8-4-3-5-9-17)22-14-12-21-13-15-22/h3-11,19,21H,2,12-16H2,1H3
DMBRS3D	CS	CCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DMBRS3D	IK	CVFBVSUFNWOPLD-UHFFFAOYSA-N
DMBRS3D	IU	1-[2-(2-ethoxyphenyl)-1-phenylethyl]piperazine
DMBRS3D	DE	Discovery agent

DMKWRCD	ID	DMKWRCD
DMKWRCD	DN	1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine
DMKWRCD	HS	Investigative
DMKWRCD	SN	CHEMBL210126; 1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine; SCHEMBL5458859
DMKWRCD	DT	Small molecular drug
DMKWRCD	PC	44414709
DMKWRCD	MW	294.4
DMKWRCD	FM	C20H26N2
DMKWRCD	IC	InChI=1S/C20H26N2/c1-2-17-8-6-7-11-19(17)16-20(18-9-4-3-5-10-18)22-14-12-21-13-15-22/h3-11,20-21H,2,12-16H2,1H3
DMKWRCD	CS	CCC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DMKWRCD	IK	USQDYFAONFKQLW-UHFFFAOYSA-N
DMKWRCD	IU	1-[2-(2-ethylphenyl)-1-phenylethyl]piperazine
DMKWRCD	DE	Discovery agent

DM6XCPV	ID	DM6XCPV
DM6XCPV	DN	1-(2-(2-fluorobenzyloxy)phenyl)piperazine
DM6XCPV	HS	Investigative
DM6XCPV	SN	CHEMBL575899; 1-(2-(2-fluorobenzyloxy)phenyl)piperazine; BDBM50299784
DM6XCPV	DT	Small molecular drug
DM6XCPV	PC	45483446
DM6XCPV	MW	286.34
DM6XCPV	FM	C17H19FN2O
DM6XCPV	IC	InChI=1S/C17H19FN2O/c18-15-6-2-1-5-14(15)13-21-17-8-4-3-7-16(17)20-11-9-19-10-12-20/h1-8,19H,9-13H2
DM6XCPV	CS	C1CN(CCN1)C2=CC=CC=C2OCC3=CC=CC=C3F
DM6XCPV	IK	XMQIWPUGABPALG-UHFFFAOYSA-N
DM6XCPV	IU	1-[2-[(2-fluorophenyl)methoxy]phenyl]piperazine
DM6XCPV	DE	Discovery agent

DM2H38V	ID	DM2H38V
DM2H38V	DN	1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine
DM2H38V	HS	Investigative
DM2H38V	SN	CHEMBL214335; 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine; SCHEMBL5440547; BDBM50188048; (-)-1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine
DM2H38V	DT	Small molecular drug
DM2H38V	PC	44414722
DM2H38V	MW	296.4
DM2H38V	FM	C19H24N2O
DM2H38V	IC	InChI=1S/C19H24N2O/c1-22-19-10-6-5-9-17(19)15-18(16-7-3-2-4-8-16)21-13-11-20-12-14-21/h2-10,18,20H,11-15H2,1H3
DM2H38V	CS	COC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DM2H38V	IK	PFTJCYRHNKTTTO-UHFFFAOYSA-N
DM2H38V	IU	1-[2-(2-methoxyphenyl)-1-phenylethyl]piperazine
DM2H38V	DE	Discovery agent

DM4WEGM	ID	DM4WEGM
DM4WEGM	DN	1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine
DM4WEGM	HS	Investigative
DM4WEGM	SN	CHEMBL214240; 1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine; SCHEMBL5448643
DM4WEGM	DT	Small molecular drug
DM4WEGM	PC	44414720
DM4WEGM	MW	300.8
DM4WEGM	FM	C18H21ClN2
DM4WEGM	IC	InChI=1S/C18H21ClN2/c19-17-8-4-5-15(13-17)14-18(16-6-2-1-3-7-16)21-11-9-20-10-12-21/h1-8,13,18,20H,9-12,14H2
DM4WEGM	CS	C1CN(CCN1)C(CC2=CC(=CC=C2)Cl)C3=CC=CC=C3
DM4WEGM	IK	LTKQGPSHVUGDKE-UHFFFAOYSA-N
DM4WEGM	IU	1-[2-(3-chlorophenyl)-1-phenylethyl]piperazine
DM4WEGM	DE	Discovery agent

DMXV2KQ	ID	DMXV2KQ
DMXV2KQ	DN	1-(2-(3-fluorophenoxy)phenyl)piperazine
DMXV2KQ	HS	Investigative
DMXV2KQ	SN	CHEMBL573973; 1-(2-(3-fluorophenoxy)phenyl)piperazine
DMXV2KQ	DT	Small molecular drug
DMXV2KQ	PC	45483432
DMXV2KQ	MW	272.32
DMXV2KQ	FM	C16H17FN2O
DMXV2KQ	IC	InChI=1S/C16H17FN2O/c17-13-4-3-5-14(12-13)20-16-7-2-1-6-15(16)19-10-8-18-9-11-19/h1-7,12,18H,8-11H2
DMXV2KQ	CS	C1CN(CCN1)C2=CC=CC=C2OC3=CC(=CC=C3)F
DMXV2KQ	IK	ZTEDPRVVBLHAKJ-UHFFFAOYSA-N
DMXV2KQ	IU	1-[2-(3-fluorophenoxy)phenyl]piperazine
DMXV2KQ	DE	Discovery agent

DM8V5IH	ID	DM8V5IH
DM8V5IH	DN	1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine
DM8V5IH	HS	Investigative
DM8V5IH	SN	CHEMBL212763; 1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine; 61311-72-6; 1-[2-(3-Methoxyphenyl)-1-phenylethyl]piperazine; SCHEMBL11504855; CTK2E2732; DTXSID40552210; BDBM50188044; Piperazine, 1-[2-(3-methoxyphenyl)-1-phenylethyl]-
DM8V5IH	DT	Small molecular drug
DM8V5IH	PC	13904719
DM8V5IH	MW	296.4
DM8V5IH	FM	C19H24N2O
DM8V5IH	IC	InChI=1S/C19H24N2O/c1-22-18-9-5-6-16(14-18)15-19(17-7-3-2-4-8-17)21-12-10-20-11-13-21/h2-9,14,19-20H,10-13,15H2,1H3
DM8V5IH	CS	COC1=CC=CC(=C1)CC(C2=CC=CC=C2)N3CCNCC3
DM8V5IH	IK	CTAHXNUPBZTDFO-UHFFFAOYSA-N
DM8V5IH	IU	1-[2-(3-methoxyphenyl)-1-phenylethyl]piperazine
DM8V5IH	CA	CAS 61311-72-6
DM8V5IH	DE	Discovery agent

DMU082P	ID	DMU082P
DMU082P	DN	1-(2-(4-fluorophenoxy)phenyl)piperazine
DMU082P	HS	Investigative
DMU082P	SN	CHEMBL573972; 1-(2-(4-fluorophenoxy)phenyl)piperazine
DMU082P	DT	Small molecular drug
DMU082P	PC	45483431
DMU082P	MW	272.32
DMU082P	FM	C16H17FN2O
DMU082P	IC	InChI=1S/C16H17FN2O/c17-13-5-7-14(8-6-13)20-16-4-2-1-3-15(16)19-11-9-18-10-12-19/h1-8,18H,9-12H2
DMU082P	CS	C1CN(CCN1)C2=CC=CC=C2OC3=CC=C(C=C3)F
DMU082P	IK	VWVYZCFGGWGOMP-UHFFFAOYSA-N
DMU082P	IU	1-[2-(4-fluorophenoxy)phenyl]piperazine
DMU082P	DE	Discovery agent

DMR4DJ1	ID	DMR4DJ1
DMR4DJ1	DN	1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine
DMR4DJ1	HS	Investigative
DMR4DJ1	SN	CHEMBL465515; 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine
DMR4DJ1	DT	Small molecular drug
DMR4DJ1	PC	44592244
DMR4DJ1	MW	258.329
DMR4DJ1	FM	C16H19FN2
DMR4DJ1	IC	InChI=1S/C16H19FN2/c17-16-4-3-14-11-13(1-2-15(14)12-16)5-8-19-9-6-18-7-10-19/h1-4,11-12,18H,5-10H2
DMR4DJ1	CS	C1CN(CCN1)CCC2=CC3=C(C=C2)C=C(C=C3)F
DMR4DJ1	IK	AVSJNVNTDDYDEP-UHFFFAOYSA-N
DMR4DJ1	IU	1-[2-(6-fluoronaphthalen-2-yl)ethyl]piperazine
DMR4DJ1	DE	Discovery agent

DMB3HI4	ID	DMB3HI4
DMB3HI4	DN	1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole
DMB3HI4	HS	Investigative
DMB3HI4	SN	CHEMBL460382; Benzo[b]thiophene 32; BDBM10038; ZINC13808220; 1-[2-(1-benzothiophen-4-yl)ethyl]-1H-imidazole; 4-[2-(1H-Imidazole-1-yl)ethyl]benzo[b]thiophene
DMB3HI4	DT	Small molecular drug
DMB3HI4	PC	10537337
DMB3HI4	MW	228.31
DMB3HI4	FM	C13H12N2S
DMB3HI4	IC	InChI=1S/C13H12N2S/c1-2-11(4-7-15-8-6-14-10-15)12-5-9-16-13(12)3-1/h1-3,5-6,8-10H,4,7H2
DMB3HI4	CS	C1=CC(=C2C=CSC2=C1)CCN3C=CN=C3
DMB3HI4	IK	ZEWHOUCPWZPPGK-UHFFFAOYSA-N
DMB3HI4	IU	1-[2-(1-benzothiophen-4-yl)ethyl]imidazole
DMB3HI4	DE	Discovery agent

DM0UZHL	ID	DM0UZHL
DM0UZHL	DN	1-(2-(benzyloxy)phenyl)piperazine
DM0UZHL	HS	Investigative
DM0UZHL	SN	1-(2-(benzyloxy)phenyl)piperazine; 96221-84-0; 1-(2-Benzyloxy-phenyl)-piperazine; CHEMBL582928; 1-[2-(benzyloxy)phenyl]piperazine; SCHEMBL4673484; 1-(2-benzyloxyphenyl)piperazine; CTK7D1689; ZINC2527252; BDBM50299797; 9395AH; AKOS010941582; AB19552; AJ-37911; DA-00144; BBV-33344054; KB-212806; AX8291986; FT-0752442; Z-7800
DM0UZHL	DT	Small molecular drug
DM0UZHL	PC	22615724
DM0UZHL	MW	268.35
DM0UZHL	FM	C17H20N2O
DM0UZHL	IC	InChI=1S/C17H20N2O/c1-2-6-15(7-3-1)14-20-17-9-5-4-8-16(17)19-12-10-18-11-13-19/h1-9,18H,10-14H2
DM0UZHL	CS	C1CN(CCN1)C2=CC=CC=C2OCC3=CC=CC=C3
DM0UZHL	IK	PPQUPQGZDGZYJI-UHFFFAOYSA-N
DM0UZHL	IU	1-(2-phenylmethoxyphenyl)piperazine
DM0UZHL	DE	Discovery agent

DMU5BOW	ID	DMU5BOW
DMU5BOW	DN	1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea
DMU5BOW	HS	Investigative
DMU5BOW	SN	CHEMBL305516; 1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea; BDBM50088469; 1-[2-(Diethylamino)-4-quinazolinyl]-3-phenylurea
DMU5BOW	DT	Small molecular drug
DMU5BOW	PC	10640536
DMU5BOW	MW	335.4
DMU5BOW	FM	C19H21N5O
DMU5BOW	IC	InChI=1S/C19H21N5O/c1-3-24(4-2)18-21-16-13-9-8-12-15(16)17(22-18)23-19(25)20-14-10-6-5-7-11-14/h5-13H,3-4H2,1-2H3,(H2,20,21,22,23,25)
DMU5BOW	CS	CCN(CC)C1=NC2=CC=CC=C2C(=N1)NC(=O)NC3=CC=CC=C3
DMU5BOW	IK	OACDZTWEJRHLMO-UHFFFAOYSA-N
DMU5BOW	IU	1-[2-(diethylamino)quinazolin-4-yl]-3-phenylurea
DMU5BOW	DE	Discovery agent

DMXL7Z5	ID	DMXL7Z5
DMXL7Z5	DN	1-(2-(naphthalen-1-yl)-1-phenylethyl)piperazine
DMXL7Z5	HS	Investigative
DMXL7Z5	SN	CHEMBL212878; 1-(2-(naphthalen-1-yl)-1-phenylethyl)piperazine
DMXL7Z5	DT	Small molecular drug
DMXL7Z5	PC	44414861
DMXL7Z5	MW	316.4
DMXL7Z5	FM	C22H24N2
DMXL7Z5	IC	InChI=1S/C22H24N2/c1-2-8-19(9-3-1)22(24-15-13-23-14-16-24)17-20-11-6-10-18-7-4-5-12-21(18)20/h1-12,22-23H,13-17H2
DMXL7Z5	CS	C1CN(CCN1)C(CC2=CC=CC3=CC=CC=C32)C4=CC=CC=C4
DMXL7Z5	IK	VWOWSEBOGHLBFX-UHFFFAOYSA-N
DMXL7Z5	IU	1-(2-naphthalen-1-yl-1-phenylethyl)piperazine
DMXL7Z5	DE	Discovery agent

DMTEBP0	ID	DMTEBP0
DMTEBP0	DN	1-(2-(naphthalen-2-yl)-1-phenylethyl)piperazine
DMTEBP0	HS	Investigative
DMTEBP0	SN	CHEMBL425961; 1-(2-(naphthalen-2-yl)-1-phenylethyl)piperazine
DMTEBP0	DT	Small molecular drug
DMTEBP0	PC	44414860
DMTEBP0	MW	316.4
DMTEBP0	FM	C22H24N2
DMTEBP0	IC	InChI=1S/C22H24N2/c1-2-7-20(8-3-1)22(24-14-12-23-13-15-24)17-18-10-11-19-6-4-5-9-21(19)16-18/h1-11,16,22-23H,12-15,17H2
DMTEBP0	CS	C1CN(CCN1)C(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4
DMTEBP0	IK	HSPJWADLPHSZQN-UHFFFAOYSA-N
DMTEBP0	IU	1-(2-naphthalen-2-yl-1-phenylethyl)piperazine
DMTEBP0	DE	Discovery agent

DMS7YF6	ID	DMS7YF6
DMS7YF6	DN	1-(2-(naphthalen-2-yl)ethyl)piperazine
DMS7YF6	HS	Investigative
DMS7YF6	SN	1-(2-(naphthalen-2-yl)ethyl)piperazine; CHEMBL503234; 194943-70-9; SCHEMBL8671948; BDBM50278561; ZINC40379086; AKOS011777831; DA-08636
DMS7YF6	DT	Small molecular drug
DMS7YF6	PC	44592243
DMS7YF6	MW	240.34
DMS7YF6	FM	C16H20N2
DMS7YF6	IC	InChI=1S/C16H20N2/c1-2-4-16-13-14(5-6-15(16)3-1)7-10-18-11-8-17-9-12-18/h1-6,13,17H,7-12H2
DMS7YF6	CS	C1CN(CCN1)CCC2=CC3=CC=CC=C3C=C2
DMS7YF6	IK	MXNHEKIHSVXJPG-UHFFFAOYSA-N
DMS7YF6	IU	1-(2-naphthalen-2-ylethyl)piperazine
DMS7YF6	DE	Discovery agent

DMYFKID	ID	DMYFKID
DMYFKID	DN	1-(2-(naphthalen-2-yl)ethyl)pyrrolidine
DMYFKID	HS	Investigative
DMYFKID	SN	CHEMBL270410
DMYFKID	DT	Small molecular drug
DMYFKID	PC	44455950
DMYFKID	MW	225.33
DMYFKID	FM	C16H19N
DMYFKID	IC	InChI=1S/C16H19N/c1-2-6-16-13-14(7-8-15(16)5-1)9-12-17-10-3-4-11-17/h1-2,5-8,13H,3-4,9-12H2
DMYFKID	CS	C1CCN(C1)CCC2=CC3=CC=CC=C3C=C2
DMYFKID	IK	BUFGWZZSSJWXIJ-UHFFFAOYSA-N
DMYFKID	IU	1-(2-naphthalen-2-ylethyl)pyrrolidine
DMYFKID	DE	Discovery agent

DM7Z19T	ID	DM7Z19T
DM7Z19T	DN	1-(2-(phenoxymethyl)phenyl)piperazine
DM7Z19T	HS	Investigative
DM7Z19T	SN	CHEMBL574127; 1-(2-(phenoxymethyl)phenyl)piperazine; SCHEMBL2189855
DM7Z19T	DT	Small molecular drug
DM7Z19T	PC	45483466
DM7Z19T	MW	268.35
DM7Z19T	FM	C17H20N2O
DM7Z19T	IC	InChI=1S/C17H20N2O/c1-2-7-16(8-3-1)20-14-15-6-4-5-9-17(15)19-12-10-18-11-13-19/h1-9,18H,10-14H2
DM7Z19T	CS	C1CN(CCN1)C2=CC=CC=C2COC3=CC=CC=C3
DM7Z19T	IK	WLIGTTARDYGFBV-UHFFFAOYSA-N
DM7Z19T	IU	1-[2-(phenoxymethyl)phenyl]piperazine
DM7Z19T	DE	Discovery agent

DMNX6CE	ID	DMNX6CE
DMNX6CE	DN	1-(2,2'-bithiophen-5-yl)methanamine
DMNX6CE	HS	Investigative
DMNX6CE	SN	4380-96-5; [2,2'-Bithiophen]-5-ylmethanamine; 2,2'-bithiophene-5-methylamine; 2,2'-bithiophen-5-ylmethanamine; [2,2'-Bithiophene]-5-methanamine; 1-(2,2'-bithiophen-5-yl)methanamine; 2,2-Bithiophene-5-methylamine; CHEMBL538940; (5-(2-thienyl)-2-thienyl)methylamine; [5-(Thiophen-2-Yl)Thiophen-2-Yl]Methanamine; SDCCGMLS-0065983.P001; AC1MCQYM; SCHEMBL2690127; CTK1D7717; DTXSID50380066; MolPort-000-142-515; FHYTVXBZSXZMGD-UHFFFAOYSA-N; ZINC158800; 2,2''-bithiophen-5-ylmethanamine; AC1Q5409; QC-966; SBB091920; BDBM50294164
DMNX6CE	DT	Small molecular drug
DMNX6CE	PC	2776424
DMNX6CE	MW	195.3
DMNX6CE	FM	C9H9NS2
DMNX6CE	IC	InChI=1S/C9H9NS2/c10-6-7-3-4-9(12-7)8-2-1-5-11-8/h1-5H,6,10H2
DMNX6CE	CS	C1=CSC(=C1)C2=CC=C(S2)CN
DMNX6CE	IK	FHYTVXBZSXZMGD-UHFFFAOYSA-N
DMNX6CE	IU	(5-thiophen-2-ylthiophen-2-yl)methanamine
DMNX6CE	CA	CAS 4380-96-5
DMNX6CE	DE	Discovery agent

DM1Q0TM	ID	DM1Q0TM
DM1Q0TM	DN	1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)
DM1Q0TM	HS	Investigative
DM1Q0TM	SN	CHEMBL1094208; 1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX); BDBM50316566; 1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol
DM1Q0TM	DT	Small molecular drug
DM1Q0TM	PC	46888467
DM1Q0TM	MW	455.2
DM1Q0TM	FM	C21H12Cl2F4N2O
DM1Q0TM	IC	InChI=1S/C21H12Cl2F4N2O/c22-17-3-1-2-16(19(17)23)20(30,21(25,26)27)13-4-9-18-12(10-13)11-28-29(18)15-7-5-14(24)6-8-15/h1-11,30H
DM1Q0TM	CS	C1=CC(=C(C(=C1)Cl)Cl)C(C2=CC3=C(C=C2)N(N=C3)C4=CC=C(C=C4)F)(C(F)(F)F)O
DM1Q0TM	IK	SGKVPHOMCZNDPT-UHFFFAOYSA-N
DM1Q0TM	IU	1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)indazol-5-yl]ethanol
DM1Q0TM	DE	Discovery agent

DM0URSE	ID	DM0URSE
DM0URSE	DN	1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine
DM0URSE	HS	Investigative
DM0URSE	SN	CHEMBL31171; 1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine; 1H-Indole-5-ethanamine, alpha-ethyl-2,3-dihydro-; BDBM50025077
DM0URSE	DT	Small molecular drug
DM0URSE	PC	13660291
DM0URSE	MW	190.28
DM0URSE	FM	C12H18N2
DM0URSE	IC	InChI=1S/C12H18N2/c1-2-11(13)8-9-3-4-12-10(7-9)5-6-14-12/h3-4,7,11,14H,2,5-6,8,13H2,1H3
DM0URSE	CS	CCC(CC1=CC2=C(C=C1)NCC2)N
DM0URSE	IK	WHXRWSJORCUAFO-UHFFFAOYSA-N
DM0URSE	IU	1-(2,3-dihydro-1H-indol-5-yl)butan-2-amine
DM0URSE	DE	Discovery agent

DM31CVR	ID	DM31CVR
DM31CVR	DN	1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine
DM31CVR	HS	Investigative
DM31CVR	SN	CHEMBL160344; ZINC27714862; BDBM50226210
DM31CVR	DT	Small molecular drug
DM31CVR	PC	13599004
DM31CVR	MW	236.31
DM31CVR	FM	C13H20N2O2
DM31CVR	IC	InChI=1S/C13H20N2O2/c1-10-8-13(17-3)11(9-12(10)16-2)15-6-4-14-5-7-15/h8-9,14H,4-7H2,1-3H3
DM31CVR	CS	CC1=CC(=C(C=C1OC)N2CCNCC2)OC
DM31CVR	IK	XJDJQRVAYJTBHO-UHFFFAOYSA-N
DM31CVR	IU	1-(2,5-dimethoxy-4-methylphenyl)piperazine
DM31CVR	DE	Discovery agent

DMNETHQ	ID	DMNETHQ
DMNETHQ	DN	1-(2,5-Dimethoxy-phenyl)-piperazine
DMNETHQ	HS	Investigative
DMNETHQ	SN	1-(2,5-dimethoxyphenyl)piperazine; 1-(2,5-Dimethoxy-phenyl)-piperazine; CHEMBL156216; 1019-06-3; Piperazine, 1-(2,5-dimethoxyphenyl)-; AC1MBY8N; Oprea1_560724; SCHEMBL2349863; CTK0G7924; DTXSID10374340; IZFHRJZAZNTUOI-UHFFFAOYSA-N; 4-[2,5-Dimethoxyphenyl]piperazine; ZINC11632569; BDBM50226212; MFCD03444397; AKOS003591177; DB-017049
DMNETHQ	DT	Small molecular drug
DMNETHQ	PC	2758473
DMNETHQ	MW	222.28
DMNETHQ	FM	C12H18N2O2
DMNETHQ	IC	InChI=1S/C12H18N2O2/c1-15-10-3-4-12(16-2)11(9-10)14-7-5-13-6-8-14/h3-4,9,13H,5-8H2,1-2H3
DMNETHQ	CS	COC1=CC(=C(C=C1)OC)N2CCNCC2
DMNETHQ	IK	IZFHRJZAZNTUOI-UHFFFAOYSA-N
DMNETHQ	IU	1-(2,5-dimethoxyphenyl)piperazine
DMNETHQ	CA	CAS 1019-06-3
DMNETHQ	DE	Discovery agent

DM043N8	ID	DM043N8
DM043N8	DN	1-(2,5-dimethoxyphenyl)propan-2-amine
DM043N8	HS	Investigative
DM043N8	SN	2-(2,5-Dimethoxy-phenyl)-1-methyl-ethylamine
DM043N8	DT	Small molecular drug
DM043N8	PC	62787
DM043N8	MW	195.26
DM043N8	FM	C11H17NO2
DM043N8	IC	InChI=1S/C11H17NO2/c1-8(12)6-9-7-10(13-2)4-5-11(9)14-3/h4-5,7-8H,6,12H2,1-3H3
DM043N8	CS	CC(CC1=C(C=CC(=C1)OC)OC)N
DM043N8	IK	LATVFYDIBMDBSY-UHFFFAOYSA-N
DM043N8	IU	1-(2,5-dimethoxyphenyl)propan-2-amine
DM043N8	CA	CAS 2801-68-5
DM043N8	DE	Discovery agent

DM3FHJK	ID	DM3FHJK
DM3FHJK	DN	1-(2,5-Dimethyl-1H-pyrrol-1-yl)thiourea
DM3FHJK	HS	Investigative
DM3FHJK	SN	1-(2,5-Dimethyl-1H-pyrrol-1-yl)thiourea; CHEMBL466982; 70436-68-9; BDBM50268203; ZINC40413177
DM3FHJK	DT	Small molecular drug
DM3FHJK	PC	42605400
DM3FHJK	MW	169.25
DM3FHJK	FM	C7H11N3S
DM3FHJK	IC	InChI=1S/C7H11N3S/c1-5-3-4-6(2)10(5)9-7(8)11/h3-4H,1-2H3,(H3,8,9,11)
DM3FHJK	CS	CC1=CC=C(N1NC(=S)N)C
DM3FHJK	IK	XNQJQAUTZJGWDW-UHFFFAOYSA-N
DM3FHJK	IU	(2,5-dimethylpyrrol-1-yl)thiourea
DM3FHJK	DE	Discovery agent

DMV0C6F	ID	DMV0C6F
DMV0C6F	DN	1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine
DMV0C6F	HS	Investigative
DMV0C6F	SN	1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine; CHEMBL293399; 80888-36-4; Psi-DOM; SCHEMBL2562975; DTXSID20548454; 2,6-dimethoxy-4-methylamphetamine; BDBM50115832; 2,6-Dimethoxy-alpha,4-dimethylbenzeneethanamine; Benzeneethanamine, 2,6-dimethoxy-alpha,4-dimethyl-
DMV0C6F	DT	Small molecular drug
DMV0C6F	PC	13753734
DMV0C6F	MW	209.28
DMV0C6F	FM	C12H19NO2
DMV0C6F	IC	InChI=1S/C12H19NO2/c1-8-5-11(14-3)10(7-9(2)13)12(6-8)15-4/h5-6,9H,7,13H2,1-4H3
DMV0C6F	CS	CC1=CC(=C(C(=C1)OC)CC(C)N)OC
DMV0C6F	IK	CFFJUEYUTHKVMQ-UHFFFAOYSA-N
DMV0C6F	IU	1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine
DMV0C6F	CA	CAS 80888-36-4
DMV0C6F	DE	Discovery agent

DMRHY2M	ID	DMRHY2M
DMRHY2M	DN	1-(2-adamantyl)-3-benzylpyrrolidin-2-one
DMRHY2M	HS	Investigative
DMRHY2M	SN	1-(2-adamantyl)-3-benzylpyrrolidin-2-one; CHEMBL218286; CHEMBL3085039; SCHEMBL13435191
DMRHY2M	DT	Small molecular drug
DMRHY2M	PC	44419251
DMRHY2M	MW	309.4
DMRHY2M	FM	C21H27NO
DMRHY2M	IC	InChI=1S/C21H27NO/c23-21-17(9-14-4-2-1-3-5-14)6-7-22(21)20-18-10-15-8-16(12-18)13-19(20)11-15/h1-5,15-20H,6-13H2
DMRHY2M	CS	C1CN(C(=O)C1CC2=CC=CC=C2)C3C4CC5CC(C4)CC3C5
DMRHY2M	IK	HAAVSDQVLBVURQ-UHFFFAOYSA-N
DMRHY2M	IU	1-(2-adamantyl)-3-benzylpyrrolidin-2-one
DMRHY2M	DE	Discovery agent

DMLV0PQ	ID	DMLV0PQ
DMLV0PQ	DN	1-(2-allylphenoxy)-3-morpholinopropan-2-ol
DMLV0PQ	HS	Investigative
DMLV0PQ	SN	CHEMBL1083667; 1-morpholin-4-yl-3-(2-prop-2-enylphenoxy)propan-2-ol; BAS 00134198; AC1MCHI5; 1-(2-allylphenoxy)-3-morpholinopropan-2-ol; Oprea1_670642; Oprea1_634560; MLS001143833; MolPort-001-916-053; HMS2803P24; STK843731; BDBM50318978; AKOS016050431; AKOS000525780; MCULE-7265762065; SMR000473272; ST50000343; EN300-241692; 1-(2-allylphenoxy)-3-morpholin-4-ylpropan-2-ol; 1-(2-Allyl-phenoxy)-3-morpholin-4-yl-propan-2-ol
DMLV0PQ	DT	Small molecular drug
DMLV0PQ	PC	2769774
DMLV0PQ	MW	277.36
DMLV0PQ	FM	C16H23NO3
DMLV0PQ	IC	InChI=1S/C16H23NO3/c1-2-5-14-6-3-4-7-16(14)20-13-15(18)12-17-8-10-19-11-9-17/h2-4,6-7,15,18H,1,5,8-13H2
DMLV0PQ	CS	C=CCC1=CC=CC=C1OCC(CN2CCOCC2)O
DMLV0PQ	IK	BKDPODVOOWQEGE-UHFFFAOYSA-N
DMLV0PQ	IU	1-morpholin-4-yl-3-(2-prop-2-enylphenoxy)propan-2-ol
DMLV0PQ	DE	Discovery agent

DMAE8BF	ID	DMAE8BF
DMAE8BF	DN	1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea
DMAE8BF	HS	Investigative
DMAE8BF	SN	CHEMBL397745; 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea
DMAE8BF	DT	Small molecular drug
DMAE8BF	PC	44430622
DMAE8BF	MW	252.4
DMAE8BF	FM	C10H12N4S2
DMAE8BF	IC	InChI=1S/C10H12N4S2/c1-2-15-9(11)13-6-3-4-8-7(5-6)14-10(12)16-8/h3-5H,2H2,1H3,(H2,11,13)(H2,12,14)
DMAE8BF	CS	CCSC(=NC1=CC2=C(C=C1)SC(=N2)N)N
DMAE8BF	IK	NXVMLACGHCLFBM-UHFFFAOYSA-N
DMAE8BF	IU	ethyl N'-(2-amino-1,3-benzothiazol-5-yl)carbamimidothioate
DMAE8BF	DE	Discovery agent

DMCSHRL	ID	DMCSHRL
DMCSHRL	DN	1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea
DMCSHRL	HS	Investigative
DMCSHRL	SN	CHEMBL233022; 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea; SCHEMBL6067873
DMCSHRL	DT	Small molecular drug
DMCSHRL	PC	10467406
DMCSHRL	MW	252.4
DMCSHRL	FM	C10H12N4S2
DMCSHRL	IC	InChI=1S/C10H12N4S2/c1-2-15-9(11)13-6-3-4-7-8(5-6)16-10(12)14-7/h3-5H,2H2,1H3,(H2,11,13)(H2,12,14)
DMCSHRL	CS	CCSC(=NC1=CC2=C(C=C1)N=C(S2)N)N
DMCSHRL	IK	ROUITZBECQQTSH-UHFFFAOYSA-N
DMCSHRL	IU	ethyl N'-(2-amino-1,3-benzothiazol-6-yl)carbamimidothioate
DMCSHRL	DE	Discovery agent

DMKWO6A	ID	DMKWO6A
DMKWO6A	DN	1-(2-aminoethyl)-1H-indazol-6-ol
DMKWO6A	HS	Investigative
DMKWO6A	DT	Small molecular drug
DMKWO6A	PC	135520431
DMKWO6A	MW	177.2
DMKWO6A	FM	C9H11N3O
DMKWO6A	IC	InChI=1S/C9H11N3O/c10-3-4-12-9-5-8(13)2-1-7(9)6-11-12/h1-2,5-6,13H,3-4,10H2
DMKWO6A	CS	C1=CC2=C(C=C1O)N(N=C2)CCN
DMKWO6A	IK	RVQKKYXTHSVLLB-UHFFFAOYSA-N
DMKWO6A	IU	1-(2-aminoethyl)indazol-6-ol
DMKWO6A	DE	Discovery agent

DMYF8ES	ID	DMYF8ES
DMYF8ES	DN	1-(2-bromoethyl)-1H-indole-2,3-dione
DMYF8ES	HS	Investigative
DMYF8ES	SN	1-(2-bromoethyl)-1H-indole-2,3-dione; 4290-78-2; 1-(2-Bromoethyl)indoline-2,3-dione; 1-(2-bromoethyl)-2,3-dihydro-1H-indole-2,3-dione; AC1MSZWL; 1-(2-bromoethyl)isatin; Isatin-based compound, 5; 1H-Indole-2,3-dione, 1-(2-bromoethyl)-; CHEMBL223000; SCHEMBL10685462; TOS-BB-0914; BDBM22785; CTK4I6774; DTXSID90393478; MolPort-000-453-141; SJALPCXFOSGNST-UHFFFAOYSA-N; ZINC2668691; 1-(2-bromoethyl)indole-2,3-dione; STK866424; BBL023389; 1-(2-bromoethyl)-indole-2,3-dione; AKOS000245669; MCULE-3160954506; KB-85508; AJ-44119
DMYF8ES	DT	Small molecular drug
DMYF8ES	PC	3542734
DMYF8ES	MW	254.08
DMYF8ES	FM	C10H8BrNO2
DMYF8ES	IC	InChI=1S/C10H8BrNO2/c11-5-6-12-8-4-2-1-3-7(8)9(13)10(12)14/h1-4H,5-6H2
DMYF8ES	CS	C1=CC=C2C(=C1)C(=O)C(=O)N2CCBr
DMYF8ES	IK	SJALPCXFOSGNST-UHFFFAOYSA-N
DMYF8ES	IU	1-(2-bromoethyl)indole-2,3-dione
DMYF8ES	CA	CAS 4290-78-2
DMYF8ES	DE	Discovery agent

DMUSEOW	ID	DMUSEOW
DMUSEOW	DN	1-(2-Bromo-phenyl)-3-(2,4-dihydroxy-phenyl)-urea
DMUSEOW	HS	Investigative
DMUSEOW	SN	CHEMBL184637; 1-(2-Bromo-phenyl)-3-(2,4-dihydroxy-phenyl)-urea
DMUSEOW	DT	Small molecular drug
DMUSEOW	PC	44393620
DMUSEOW	MW	323.14
DMUSEOW	FM	C13H11BrN2O3
DMUSEOW	IC	InChI=1S/C13H11BrN2O3/c14-9-3-1-2-4-10(9)15-13(19)16-11-6-5-8(17)7-12(11)18/h1-7,17-18H,(H2,15,16,19)
DMUSEOW	CS	C1=CC=C(C(=C1)NC(=O)NC2=C(C=C(C=C2)O)O)Br
DMUSEOW	IK	UUVQJGFAYHMNII-UHFFFAOYSA-N
DMUSEOW	IU	1-(2-bromophenyl)-3-(2,4-dihydroxyphenyl)urea
DMUSEOW	DE	Discovery agent

DMU9T3A	ID	DMU9T3A
DMU9T3A	DN	1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea
DMU9T3A	HS	Investigative
DMU9T3A	SN	CHEMBL27863; 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea; SCHEMBL3705632; ZINC13559608; BDBM50140796
DMU9T3A	DT	Small molecular drug
DMU9T3A	PC	9949456
DMU9T3A	MW	332.15
DMU9T3A	FM	C14H10BrN3O2
DMU9T3A	IC	InChI=1S/C14H10BrN3O2/c15-10-3-1-2-4-11(10)17-14(20)18-12-6-5-9(8-16)7-13(12)19/h1-7,19H,(H2,17,18,20)
DMU9T3A	CS	C1=CC=C(C(=C1)NC(=O)NC2=C(C=C(C=C2)C#N)O)Br
DMU9T3A	IK	VIKJECVSALYBJB-UHFFFAOYSA-N
DMU9T3A	IU	1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea
DMU9T3A	DE	Discovery agent

DMT5S2O	ID	DMT5S2O
DMT5S2O	DN	1-(2-Butoxy-phenyl)-piperazine
DMT5S2O	HS	Investigative
DMT5S2O	SN	CHEMBL9452; Piperazine, 1-(2-butoxyphenyl)-; 106476-37-3; 1-(2-Butoxy-phenyl)-piperazine; ACMC-20ma64; 1-(2-Butoxyphenyl)piperazine; SCHEMBL9319475; CTK0G3319; DTXSID60560817; ZINC25997855; BDBM50017460
DMT5S2O	DT	Small molecular drug
DMT5S2O	PC	14479837
DMT5S2O	MW	234.34
DMT5S2O	FM	C14H22N2O
DMT5S2O	IC	InChI=1S/C14H22N2O/c1-2-3-12-17-14-7-5-4-6-13(14)16-10-8-15-9-11-16/h4-7,15H,2-3,8-12H2,1H3
DMT5S2O	CS	CCCCOC1=CC=CC=C1N2CCNCC2
DMT5S2O	IK	YNPHKRWUIFAKLL-UHFFFAOYSA-N
DMT5S2O	IU	1-(2-butoxyphenyl)piperazine
DMT5S2O	CA	CAS 106476-37-3
DMT5S2O	DE	Discovery agent

DMGSKAO	ID	DMGSKAO
DMGSKAO	DN	1-(2-chlorophenyl)-3-(pyridin-2-yl)thiourea
DMGSKAO	HS	Investigative
DMGSKAO	SN	NSC695051; MLS000665964; 1-(2-chlorophenyl)-3-pyridin-2-ylthiourea; CHEMBL1253185; SMR000294655; 1-(2-chlorophenyl)-3-(2-pyridyl)thiourea; N-(2-chlorophenyl)-N'-2-pyridinylthiourea; 61966-21-0; 1-(2-chlorophenyl)-3-(pyridin-2-yl)thiourea; AC1LJD94; cid_972361; CTK2C9582; BDBM47541; DTXSID20359567; MolPort-001-585-178; HMS2680I19; ZINC5933945; STK164730; AKOS002331850; NSC-695051; MCULE-5727736228; NCI60_034026; Thiourea, N-(chlorophenyl)-N'-2-pyridinyl-; ST50765308; 1-(2-chlorophenyl)-3-(2-pyridinyl)thiourea
DMGSKAO	DT	Small molecular drug
DMGSKAO	PC	972361
DMGSKAO	MW	263.75
DMGSKAO	FM	C12H10ClN3S
DMGSKAO	IC	InChI=1S/C12H10ClN3S/c13-9-5-1-2-6-10(9)15-12(17)16-11-7-3-4-8-14-11/h1-8H,(H2,14,15,16,17)
DMGSKAO	CS	C1=CC=C(C(=C1)NC(=S)NC2=CC=CC=N2)Cl
DMGSKAO	IK	ZRDDWFAJQXEXAI-UHFFFAOYSA-N
DMGSKAO	IU	1-(2-chlorophenyl)-3-pyridin-2-ylthiourea
DMGSKAO	CA	CAS 61966-21-0
DMGSKAO	DE	Discovery agent

DMKTZSY	ID	DMKTZSY
DMKTZSY	DN	1-(2'-chlorophenyl)penta-1,4-dien-3-one
DMKTZSY	HS	Investigative
DMKTZSY	SN	CHEMBL224976; BDBM50177103; 1,4-Pentadien-3-one, 1-(2-chlorophenyl)-; 1-(2''-chlorophenyl)penta-1,4-dien-3-one
DMKTZSY	DT	Small molecular drug
DMKTZSY	PC	11665560
DMKTZSY	MW	192.64
DMKTZSY	FM	C11H9ClO
DMKTZSY	IC	InChI=1S/C11H9ClO/c1-2-10(13)8-7-9-5-3-4-6-11(9)12/h2-8H,1H2/b8-7+
DMKTZSY	CS	C=CC(=O)/C=C/C1=CC=CC=C1Cl
DMKTZSY	IK	DIYSCNLXRVKMMK-BQYQJAHWSA-N
DMKTZSY	IU	(1E)-1-(2-chlorophenyl)penta-1,4-dien-3-one
DMKTZSY	DE	Discovery agent

DM5RE71	ID	DM5RE71
DM5RE71	DN	1-(2-Chloro-phenyl)-piperazine
DM5RE71	HS	Investigative
DM5RE71	SN	1-(2-Chlorophenyl)piperazine; 39512-50-0; 1-(2-Chloro-phenyl)-piperazine; Piperazine, 1-(2-chlorophenyl)-; CHEMBL9841; 1-(2-chlorophenyl) piperazine; PWZDJIUQHUGFRJ-UHFFFAOYSA-N; 1-(o-CHLOROPHENYL)PIPERAZINE; (2-chlorophenyl)piperazine; Chlorphenylpiperazin; EINECS 254-480-3; PubChem14571; AC1Q3KEP; ACMC-1AIF1; ortho-chlorophenylpiperazine; AC1L9A0W; DSSTox_RID_97408; DSSTox_CID_31523; N-(o-Chlorophenyl)piperazine; DSSTox_GSID_57734; N-(2-Chlorophenyl)piperazine; KSC224M6P; SCHEMBL230424; N-(o-chlorophenyl)-piperazine
DM5RE71	DT	Small molecular drug
DM5RE71	PC	415628
DM5RE71	MW	196.67
DM5RE71	FM	C10H13ClN2
DM5RE71	IC	InChI=1S/C10H13ClN2/c11-9-3-1-2-4-10(9)13-7-5-12-6-8-13/h1-4,12H,5-8H2
DM5RE71	CS	C1CN(CCN1)C2=CC=CC=C2Cl
DM5RE71	IK	PWZDJIUQHUGFRJ-UHFFFAOYSA-N
DM5RE71	IU	1-(2-chlorophenyl)piperazine
DM5RE71	CA	CAS 39512-50-0
DM5RE71	DE	Discovery agent

DMM3LET	ID	DMM3LET
DMM3LET	DN	1-(2-Dimethylamino-ethyl)-1H-indol-4-ol
DMM3LET	HS	Investigative
DMM3LET	SN	CHEMBL194203; 1-(2-dimethylamino-ethyl)-indol-4-ol; 1-(2-Dimethylamino-ethyl)-1H-indol-4-ol; BDBM50171268
DMM3LET	DT	Small molecular drug
DMM3LET	PC	44404907
DMM3LET	MW	204.27
DMM3LET	FM	C12H16N2O
DMM3LET	IC	InChI=1S/C12H16N2O/c1-13(2)8-9-14-7-6-10-11(14)4-3-5-12(10)15/h3-7,15H,8-9H2,1-2H3
DMM3LET	CS	CN(C)CCN1C=CC2=C1C=CC=C2O
DMM3LET	IK	PKWAUGJGYFZHOE-UHFFFAOYSA-N
DMM3LET	IU	1-[2-(dimethylamino)ethyl]indol-4-ol
DMM3LET	DE	Discovery agent

DMV3FSH	ID	DMV3FSH
DMV3FSH	DN	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH	HS	Investigative
DMV3FSH	SN	CHEMBL228687; 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH	DT	Small molecular drug
DMV3FSH	PC	44426817
DMV3FSH	MW	325.4
DMV3FSH	FM	C21H27NO2
DMV3FSH	IC	InChI=1S/C21H27NO2/c1-2-24-17-20(18-9-5-3-6-10-18)22-15-13-21(23,14-16-22)19-11-7-4-8-12-19/h3-12,20,23H,2,13-17H2,1H3
DMV3FSH	CS	CCOCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMV3FSH	IK	ZZEVNYNMIVJANK-UHFFFAOYSA-N
DMV3FSH	IU	1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH	DE	Discovery agent

DM2P7YX	ID	DM2P7YX
DM2P7YX	DN	1-(2-Ethoxy-phenyl)-piperazine
DM2P7YX	HS	Investigative
DM2P7YX	SN	1-(2-Ethoxyphenyl)piperazine; 13339-01-0; 1-(2-Ethoxy-phenyl)-piperazine; CHEMBL273923; Piperazine,1-(2-ethoxyphenyl)-; FBQIUSDQWOLCNY-UHFFFAOYSA-N; 1-(2-Ethoxyphenyl)piperazinium chloride; ehoxyphenylpiperazine; EINECS 236-389-0; AC1Q57PR; AC1Q37ZC; Oprea1_356570; labotest-bb lt00233165; 4(2-eth-oxyphenyl)piperazine; SCHEMBL255189; 2-ethoxy-1-piperazinylbenzene; 1-(2-ehoxyphenyl)-piperazine; N-(2-ethoxyphenyl)-piperazine; AC1L359U; 1-(2-ethoxyphenyl)-piperazine; N-(2-ethyoxyphenyl)-piperazine; CTK4B8518
DM2P7YX	DT	Small molecular drug
DM2P7YX	PC	83357
DM2P7YX	MW	206.28
DM2P7YX	FM	C12H18N2O
DM2P7YX	IC	InChI=1S/C12H18N2O/c1-2-15-12-6-4-3-5-11(12)14-9-7-13-8-10-14/h3-6,13H,2,7-10H2,1H3
DM2P7YX	CS	CCOC1=CC=CC=C1N2CCNCC2
DM2P7YX	IK	FBQIUSDQWOLCNY-UHFFFAOYSA-N
DM2P7YX	IU	1-(2-ethoxyphenyl)piperazine
DM2P7YX	CA	CAS 13339-01-0
DM2P7YX	DE	Discovery agent

DM94LID	ID	DM94LID
DM94LID	DN	1-(2-Fluoro-phenyl)-piperazine
DM94LID	HS	Investigative
DM94LID	SN	1-(2-Fluorophenyl)piperazine; 1011-15-0; Piperazine, 1-(2-fluorophenyl)-; 1-(2-Fluorophenyl)-piperazine; 1-(2-Fluoro-phenyl)-piperazine; CHEMBL9429; IVTZRJKKXSKXKO-UHFFFAOYSA-N; 1-(2-Fluorophenyl)piperazine, 97%; MFCD00040726; (2-fluorophenyl)piperazine; EINECS 213-780-4; oFPP; PubChem8573; 1-(2-fluorophenyl)piperazinehydrochloride; 2-fluorophenylpiperazine; 2-Fluorophenyl piperazine; ACMC-1BX8H; ortho-fluorophenylpiperazine; 4-(fluorophenyl)piperazine; AC1Q4O5O; AC1Q4L3C; AC1L2EA5; 1-(2-flurophenyl)piperazine
DM94LID	DT	Small molecular drug
DM94LID	PC	70529
DM94LID	MW	180.22
DM94LID	FM	C10H13FN2
DM94LID	IC	InChI=1S/C10H13FN2/c11-9-3-1-2-4-10(9)13-7-5-12-6-8-13/h1-4,12H,5-8H2
DM94LID	CS	C1CN(CCN1)C2=CC=CC=C2F
DM94LID	IK	IVTZRJKKXSKXKO-UHFFFAOYSA-N
DM94LID	IU	1-(2-fluorophenyl)piperazine
DM94LID	CA	CAS 1011-15-0
DM94LID	DE	Discovery agent

DM0K2T1	ID	DM0K2T1
DM0K2T1	DN	1-(2-Furan-2-yl-ethyl)-3-thiazol-2-yl-thiourea
DM0K2T1	HS	Investigative
DM0K2T1	SN	172505-85-0; Thiourea, N-(2-(2-furanyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(2-furanyl)ethyl]-N'-2-thiazolyl-; PETT Analog 29; PETT Furyl deriv.; AC1MHDKI; CHEMBL359410; BDBM1922; 1-[2-(furan-2-yl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; DTXSID70169335; N-(2-(2-furyl)ethyl)-N-(2-thiazolyl)thiou; 1-[2-(2-furyl)ethyl]-3-thiazol-2-yl-thiourea; 1-(2-Thiazolyl)-3-[2-(furan-2-yl)ethyl]thiourea
DM0K2T1	DT	Small molecular drug
DM0K2T1	PC	3001099
DM0K2T1	MW	253.3
DM0K2T1	FM	C10H11N3OS2
DM0K2T1	IC	InChI=1S/C10H11N3OS2/c15-9(13-10-12-5-7-16-10)11-4-3-8-2-1-6-14-8/h1-2,5-7H,3-4H2,(H2,11,12,13,15)
DM0K2T1	CS	C1=COC(=C1)CCNC(=S)NC2=NC=CS2
DM0K2T1	IK	HSLMRTQANDUJDA-UHFFFAOYSA-N
DM0K2T1	IU	1-[2-(furan-2-yl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DM0K2T1	CA	CAS 172505-85-0
DM0K2T1	DE	Discovery agent

DM3WXET	ID	DM3WXET
DM3WXET	DN	1-(2-Hydroxy-3-nitro-phenyl)-3-phenyl-urea
DM3WXET	HS	Investigative
DM3WXET	SN	CHEMBL283736; 1-(2-hydroxy-3-nitro-phenyl)-3-phenyl-urea; SCHEMBL7491596; BDBM50140793
DM3WXET	DT	Small molecular drug
DM3WXET	PC	11414633
DM3WXET	MW	273.24
DM3WXET	FM	C13H11N3O4
DM3WXET	IC	InChI=1S/C13H11N3O4/c17-12-10(7-4-8-11(12)16(19)20)15-13(18)14-9-5-2-1-3-6-9/h1-8,17H,(H2,14,15,18)
DM3WXET	CS	C1=CC=C(C=C1)NC(=O)NC2=C(C(=CC=C2)[N+](=O)[O-])O
DM3WXET	IK	DZLCFOMBBDNYIQ-UHFFFAOYSA-N
DM3WXET	IU	1-(2-hydroxy-3-nitrophenyl)-3-phenylurea
DM3WXET	DE	Discovery agent

DMN4G7U	ID	DMN4G7U
DMN4G7U	DN	1-(2-hydroxy-4-nitrophenyl)-3-phenylurea
DMN4G7U	HS	Investigative
DMN4G7U	SN	1-(2-Hydroxy-4-nitrophenyl)-3-phenylurea; 80883-76-7; CHEMBL280711; NSC157449; AC1MUHEY; 1-(2-Hydroxy-4-nitro-phenyl)-3-phenyl-urea; SKampF 83589; GTPL834; SCHEMBL5595180; CTK9A5291; DTXSID00394355; ZINC3936851; BDBM50140794; AKOS024384917; NSC-157449; MCULE-1458670709; NSC 157449; N-(2-hydroxy-4-nitrophenyl)-N'-phenylurea; ST51035446; [(2-hydroxy-4-nitrophenyl)amino]-N-benzamide; N-(2-hydroxy-4-nitrophenyl)-N'-(phenyl);  1-(2-Hydroxy-4-nitro-phenyl)-3-phenyl-urea; SK&F 83589
DMN4G7U	DT	Small molecular drug
DMN4G7U	PC	3618472
DMN4G7U	MW	273.24
DMN4G7U	FM	C13H11N3O4
DMN4G7U	IC	InChI=1S/C13H11N3O4/c17-12-8-10(16(19)20)6-7-11(12)15-13(18)14-9-4-2-1-3-5-9/h1-8,17H,(H2,14,15,18)
DMN4G7U	CS	C1=CC=C(C=C1)NC(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])O
DMN4G7U	IK	SAUHQYBXEGARCC-UHFFFAOYSA-N
DMN4G7U	IU	1-(2-hydroxy-4-nitrophenyl)-3-phenylurea
DMN4G7U	CA	CAS 80883-76-7
DMN4G7U	DE	Discovery agent

DMPLHEY	ID	DMPLHEY
DMPLHEY	DN	1-(2-Hydroxy-5-nitro-phenyl)-3-phenyl-urea
DMPLHEY	HS	Investigative
DMPLHEY	SN	CHEMBL24912; 1-(2-hydroxy-5-nitro-phenyl)-3-phenyl-urea; SCHEMBL5595042; MHNNUSRLYWTBJF-UHFFFAOYSA-N; ZINC13559606; BDBM50140790; AKOS016618380; N-[5-nitro-2-hydroxyphenyl]-N'-phenylurea; N-[5-nitro-2-hydroxyphenyl]-N'-phenyl urea
DMPLHEY	DT	Small molecular drug
DMPLHEY	PC	11818139
DMPLHEY	MW	273.24
DMPLHEY	FM	C13H11N3O4
DMPLHEY	IC	InChI=1S/C13H11N3O4/c17-12-7-6-10(16(19)20)8-11(12)15-13(18)14-9-4-2-1-3-5-9/h1-8,17H,(H2,14,15,18)
DMPLHEY	CS	C1=CC=C(C=C1)NC(=O)NC2=C(C=CC(=C2)[N+](=O)[O-])O
DMPLHEY	IK	MHNNUSRLYWTBJF-UHFFFAOYSA-N
DMPLHEY	IU	1-(2-hydroxy-5-nitrophenyl)-3-phenylurea
DMPLHEY	DE	Discovery agent

DMAFS7J	ID	DMAFS7J
DMAFS7J	DN	1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one
DMAFS7J	HS	Investigative
DMAFS7J	SN	2'-Hydroxy-4-methylchalcone; 1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; AC1NTAGW; 2-Propen-1-one, 1-(2-hydroxyphenyl)-3-(4-methylphenyl)-; 4-Methyl-2'-hydroxychalcone; MLS000777737; CHEMBL476598; SCHEMBL2807968; MolPort-000-648-204; OOEWKJHFFYCQBM-ZHACJKMWSA-N; Chalcone, 2'-hydroxy-4-methyl-; HMS2760H03; ZX-AT026696; ZINC4252606; 2'-Hydroxy-4-methyl-trans-chalcone; STK530118; AKOS005463239; SMR000414122; ST098968; 2'-Hydroxy-4-methylchalcone, AldrichCPR
DMAFS7J	DT	Small molecular drug
DMAFS7J	PC	5376916
DMAFS7J	MW	238.28
DMAFS7J	FM	C16H14O2
DMAFS7J	IC	InChI=1S/C16H14O2/c1-12-6-8-13(9-7-12)10-11-16(18)14-4-2-3-5-15(14)17/h2-11,17H,1H3/b11-10+
DMAFS7J	CS	CC1=CC=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O
DMAFS7J	IK	OOEWKJHFFYCQBM-ZHACJKMWSA-N
DMAFS7J	IU	(E)-1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one
DMAFS7J	CA	CAS 16635-14-6
DMAFS7J	DE	Discovery agent

DM1MSAC	ID	DM1MSAC
DM1MSAC	DN	1-(2-iodoethyl)-1H-indole-2,3-dione
DM1MSAC	HS	Investigative
DM1MSAC	SN	1-(2-iodoethyl)indole-2,3-dione; AC1N4VNK; Isatin-based compound, 6; CHEMBL376518; BDBM22786; ZINC5738958; AKOS024343322; MCULE-9804545910; 1-(2-IODO-ETHYL)-1H-INDOLE-2,3-DIONE
DM1MSAC	DT	Small molecular drug
DM1MSAC	PC	4135273
DM1MSAC	MW	301.08
DM1MSAC	FM	C10H8INO2
DM1MSAC	IC	InChI=1S/C10H8INO2/c11-5-6-12-8-4-2-1-3-7(8)9(13)10(12)14/h1-4H,5-6H2
DM1MSAC	CS	C1=CC=C2C(=C1)C(=O)C(=O)N2CCI
DM1MSAC	IK	OBYVXAUONRVYHA-UHFFFAOYSA-N
DM1MSAC	IU	1-(2-iodoethyl)indole-2,3-dione
DM1MSAC	DE	Discovery agent

DM5KAH6	ID	DM5KAH6
DM5KAH6	DN	1-(2-Isopropoxy-phenyl)-piperazine
DM5KAH6	HS	Investigative
DM5KAH6	SN	1-(2-isopropoxyphenyl)piperazine; 1-(2-Isopropoxy-phenyl)-piperazine; CHEMBL9669; 54013-91-1; 2-isopropoxyphenyl piperazine; SCHEMBL3867980; CTK1F9762; DTXSID40449277; QJULELIONYLITF-UHFFFAOYSA-N; ZINC26001539; BDBM50017448; 1-[2-(methylethoxy)phenyl]piperazine; AKOS010941535; N-[2-(1-methylethoxy)phenyl]piperazine; 1-[2-(1-methylethoxy)phenyl]piperazine; DA-05081; BC4321135; Piperazine, 1-[2-(1-methylethoxy)phenyl]-; FT-0741526
DM5KAH6	DT	Small molecular drug
DM5KAH6	PC	10944016
DM5KAH6	MW	220.31
DM5KAH6	FM	C13H20N2O
DM5KAH6	IC	InChI=1S/C13H20N2O/c1-11(2)16-13-6-4-3-5-12(13)15-9-7-14-8-10-15/h3-6,11,14H,7-10H2,1-2H3
DM5KAH6	CS	CC(C)OC1=CC=CC=C1N2CCNCC2
DM5KAH6	IK	QJULELIONYLITF-UHFFFAOYSA-N
DM5KAH6	IU	1-(2-propan-2-yloxyphenyl)piperazine
DM5KAH6	CA	CAS 54013-91-1
DM5KAH6	DE	Discovery agent

DMK209P	ID	DMK209P
DMK209P	DN	1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol
DMK209P	HS	Investigative
DMK209P	SN	CHEMBL1083668; 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol; Oprea1_740178; AC1N31P0; 1-morpholin-4-yl-3-(2-propan-2-ylphenoxy)propan-2-ol; BDBM50318979
DMK209P	DT	Small molecular drug
DMK209P	PC	4080436
DMK209P	MW	279.37
DMK209P	FM	C16H25NO3
DMK209P	IC	InChI=1S/C16H25NO3/c1-13(2)15-5-3-4-6-16(15)20-12-14(18)11-17-7-9-19-10-8-17/h3-6,13-14,18H,7-12H2,1-2H3
DMK209P	CS	CC(C)C1=CC=CC=C1OCC(CN2CCOCC2)O
DMK209P	IK	OFEYQVJHAZFCJS-UHFFFAOYSA-N
DMK209P	IU	1-morpholin-4-yl-3-(2-propan-2-ylphenoxy)propan-2-ol
DMK209P	DE	Discovery agent

DMIPAMW	ID	DMIPAMW
DMIPAMW	DN	1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea
DMIPAMW	HS	Investigative
DMIPAMW	SN	CHEMBL459135; 1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea
DMIPAMW	DT	Small molecular drug
DMIPAMW	PC	44587908
DMIPAMW	MW	274.4
DMIPAMW	FM	C10H14N2O3S2
DMIPAMW	IC	InChI=1S/C10H14N2O3S2/c1-8-3-2-4-9(7-8)17(14,15)12-10(13)11-5-6-16/h2-4,7,16H,5-6H2,1H3,(H2,11,12,13)
DMIPAMW	CS	CC1=CC(=CC=C1)S(=O)(=O)NC(=O)NCCS
DMIPAMW	IK	CALOUQXNCIXXTN-UHFFFAOYSA-N
DMIPAMW	IU	1-(3-methylphenyl)sulfonyl-3-(2-sulfanylethyl)urea
DMIPAMW	DE	Discovery agent

DMDQVSU	ID	DMDQVSU
DMDQVSU	DN	1-(2-methoxyphenethyl)pyrrolidine
DMDQVSU	HS	Investigative
DMDQVSU	SN	CHEMBL257913; 2-(2-methoxyphenyl)-1-(pyrrolidin-1-yl)ethane; 123902-10-3; 1-(2-methoxyphenethyl)pyrrolidine; ZINC29130875; BDBM50372328
DMDQVSU	DT	Small molecular drug
DMDQVSU	PC	23061353
DMDQVSU	MW	205.3
DMDQVSU	FM	C13H19NO
DMDQVSU	IC	InChI=1S/C13H19NO/c1-15-13-7-3-2-6-12(13)8-11-14-9-4-5-10-14/h2-3,6-7H,4-5,8-11H2,1H3
DMDQVSU	CS	COC1=CC=CC=C1CCN2CCCC2
DMDQVSU	IK	YLUDJHIUYWQPKA-UHFFFAOYSA-N
DMDQVSU	IU	1-[2-(2-methoxyphenyl)ethyl]pyrrolidine
DMDQVSU	DE	Discovery agent

DM0EZSR	ID	DM0EZSR
DM0EZSR	DN	1-(2-methoxyphenyl)-4-pentylpiperazine
DM0EZSR	HS	Investigative
DM0EZSR	SN	CHEMBL1269289; 1-(2-methoxyphenyl)-4-pentylpiperazine; SCHEMBL13875119; BDBM50329677
DM0EZSR	DT	Small molecular drug
DM0EZSR	PC	10422832
DM0EZSR	MW	262.39
DM0EZSR	FM	C16H26N2O
DM0EZSR	IC	InChI=1S/C16H26N2O/c1-3-4-7-10-17-11-13-18(14-12-17)15-8-5-6-9-16(15)19-2/h5-6,8-9H,3-4,7,10-14H2,1-2H3
DM0EZSR	CS	CCCCCN1CCN(CC1)C2=CC=CC=C2OC
DM0EZSR	IK	KOQVTIBXMDYTOB-UHFFFAOYSA-N
DM0EZSR	IU	1-(2-methoxyphenyl)-4-pentylpiperazine
DM0EZSR	DE	Discovery agent

DMCADRI	ID	DMCADRI
DMCADRI	DN	1-(2-Methoxy-phenyl)-4-propyl-piperazine
DMCADRI	HS	Investigative
DMCADRI	SN	1-(2-methoxyphenyl)-4-propylpiperazine; CHEMBL92887; 1-(2-Methoxy-phenyl)-4-propyl-piperazine; AC1L8ZT0; Oprea1_562540; SCHEMBL3261221; MolPort-009-059-633; ZINC1663859; BDBM50039783; AKOS034319760; MCULE-3739556252; Z432755564
DMCADRI	DT	Small molecular drug
DMCADRI	PC	410747
DMCADRI	MW	234.34
DMCADRI	FM	C14H22N2O
DMCADRI	IC	InChI=1S/C14H22N2O/c1-3-8-15-9-11-16(12-10-15)13-6-4-5-7-14(13)17-2/h4-7H,3,8-12H2,1-2H3
DMCADRI	CS	CCCN1CCN(CC1)C2=CC=CC=C2OC
DMCADRI	IK	CXGGCNYHKKNQGW-UHFFFAOYSA-N
DMCADRI	IU	1-(2-methoxyphenyl)-4-propylpiperazine
DMCADRI	DE	Discovery agent

DM3M4RA	ID	DM3M4RA
DM3M4RA	DN	1-(2-Methoxy-phenyl)-piperazine
DM3M4RA	HS	Investigative
DM3M4RA	SN	1-(2-Methoxyphenyl)piperazine; 35386-24-4; 1-(o-Methoxyphenyl)piperazine; 1-(2-Methoxyphenyl)-piperazine; 2-MPP; UNII-81NJO1330A; N-(2-methoxyphenyl)piperazine; 1-(2-methoxy phenyl) piperazine; Piperazine, 1-(2-methoxyphenyl)-; 2-methoxyphenylpiperazine; 1-(2-METHOXYPHENYL) PIPERAZINE; CHEMBL9666; VNZLQLYBRIOLFZ-UHFFFAOYSA-N; 81NJO1330A; MFCD00005958; 1-(2-methoxyphenyl)piperazinehydrochloride; 2-methoxy-1-piperazinylbenzene; 1-(2-Methoxyphenyl)piperazine, 98+%; 1-(2-methoxyphenyl)piperazin
DM3M4RA	DT	Small molecular drug
DM3M4RA	PC	1346
DM3M4RA	MW	192.26
DM3M4RA	FM	C11H16N2O
DM3M4RA	IC	InChI=1S/C11H16N2O/c1-14-11-5-3-2-4-10(11)13-8-6-12-7-9-13/h2-5,12H,6-9H2,1H3
DM3M4RA	CS	COC1=CC=CC=C1N2CCNCC2
DM3M4RA	IK	VNZLQLYBRIOLFZ-UHFFFAOYSA-N
DM3M4RA	IU	1-(2-methoxyphenyl)piperazine
DM3M4RA	CA	CAS 35386-24-4
DM3M4RA	CB	CHEBI:104020
DM3M4RA	DE	Discovery agent

DMBWCOZ	ID	DMBWCOZ
DMBWCOZ	DN	1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBWCOZ	HS	Investigative
DMBWCOZ	SN	CHEMBL203403; 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4935428
DMBWCOZ	DT	Small molecular drug
DMBWCOZ	PC	11311147
DMBWCOZ	MW	245.36
DMBWCOZ	FM	C16H23NO
DMBWCOZ	IC	InChI=1S/C16H23NO/c1-3-8-15(17-11-6-7-12-17)16(18)14-10-5-4-9-13(14)2/h4-5,9-10,15H,3,6-8,11-12H2,1-2H3
DMBWCOZ	CS	CCCC(C(=O)C1=CC=CC=C1C)N2CCCC2
DMBWCOZ	IK	VVIVTDYOMWHKAE-UHFFFAOYSA-N
DMBWCOZ	IU	1-(2-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one
DMBWCOZ	DE	Discovery agent

DMZF0D3	ID	DMZF0D3
DMZF0D3	DN	1-(2-morpholinoethyl)-1H-indol-3-yl acetate
DMZF0D3	HS	Investigative
DMZF0D3	SN	CHEMBL495249
DMZF0D3	DT	Small molecular drug
DMZF0D3	PC	24851127
DMZF0D3	MW	288.34
DMZF0D3	FM	C16H20N2O3
DMZF0D3	IC	InChI=1S/C16H20N2O3/c1-13(19)21-16-12-18(15-5-3-2-4-14(15)16)7-6-17-8-10-20-11-9-17/h2-5,12H,6-11H2,1H3
DMZF0D3	CS	CC(=O)OC1=CN(C2=CC=CC=C21)CCN3CCOCC3
DMZF0D3	IK	WNJZFVIJUKGTLU-UHFFFAOYSA-N
DMZF0D3	IU	[1-(2-morpholin-4-ylethyl)indol-3-yl] acetate
DMZF0D3	DE	Discovery agent

DMKITY6	ID	DMKITY6
DMKITY6	DN	1-(2-m-tolyl-ethyl)-pyrrolidine
DMKITY6	HS	Investigative
DMKITY6	SN	CHEMBL257919; SCHEMBL14426311
DMKITY6	DT	Small molecular drug
DMKITY6	PC	44456174
DMKITY6	MW	189.3
DMKITY6	FM	C13H19N
DMKITY6	IC	InChI=1S/C13H19N/c1-12-5-4-6-13(11-12)7-10-14-8-2-3-9-14/h4-6,11H,2-3,7-10H2,1H3
DMKITY6	CS	CC1=CC(=CC=C1)CCN2CCCC2
DMKITY6	IK	AXQOVIUHTPHFNE-UHFFFAOYSA-N
DMKITY6	IU	1-[2-(3-methylphenyl)ethyl]pyrrolidine
DMKITY6	DE	Discovery agent

DMBNZKH	ID	DMBNZKH
DMBNZKH	DN	1-(2-Naphthyl)-2-aminopropane
DMBNZKH	HS	Investigative
DMBNZKH	SN	1-(naphthalen-2-yl)propan-2-amine; CHEMBL471839; 1-(2-Naphthyl)-2-aminopropane; AC1Q2BAX; SCHEMBL268036; 1-(2-naphthyl)propan-2-amine; 1-(2-Naphthyl)-2-propanamine; CTK6A7105; MolPort-004-323-272; BDBM50276189; AKOS022488613; AKOS000160972; MCULE-4757807613; NE51647; EN300-62738
DMBNZKH	DT	Small molecular drug
DMBNZKH	PC	10219723
DMBNZKH	MW	185.26
DMBNZKH	FM	C13H15N
DMBNZKH	IC	InChI=1S/C13H15N/c1-10(14)8-11-6-7-12-4-2-3-5-13(12)9-11/h2-7,9-10H,8,14H2,1H3
DMBNZKH	CS	CC(CC1=CC2=CC=CC=C2C=C1)N
DMBNZKH	IK	UPQSZFKXKRKCGZ-UHFFFAOYSA-N
DMBNZKH	IU	1-naphthalen-2-ylpropan-2-amine
DMBNZKH	CA	CAS 18085-03-5
DMBNZKH	DE	Discovery agent

DMR12KP	ID	DMR12KP
DMR12KP	DN	1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine
DMR12KP	HS	Investigative
DMR12KP	SN	CHEMBL540744; 1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine
DMR12KP	DT	Small molecular drug
DMR12KP	PC	45272467
DMR12KP	MW	267.28
DMR12KP	FM	C15H13N3O2
DMR12KP	IC	InChI=1S/C15H13N3O2/c19-18(20)14-5-2-1-4-12(14)7-10-17-11-8-13-15(17)6-3-9-16-13/h1-6,8-9,11H,7,10H2
DMR12KP	CS	C1=CC=C(C(=C1)CCN2C=CC3=C2C=CC=N3)[N+](=O)[O-]
DMR12KP	IK	CEHGVNIFTRLUOI-UHFFFAOYSA-N
DMR12KP	IU	1-[2-(2-nitrophenyl)ethyl]pyrrolo[3,2-b]pyridine
DMR12KP	DE	Discovery agent

DM69T3A	ID	DM69T3A
DM69T3A	DN	1-(2-Oxo-2-p-tolyl-ethyl)-1H-indole-2,3-dione
DM69T3A	HS	Investigative
DM69T3A	SN	CHEMBL84747; AKOS009237487
DM69T3A	DT	Small molecular drug
DM69T3A	PC	28476323
DM69T3A	MW	279.29
DM69T3A	FM	C17H13NO3
DM69T3A	IC	InChI=1S/C17H13NO3/c1-11-6-8-12(9-7-11)15(19)10-18-14-5-3-2-4-13(14)16(20)17(18)21/h2-9H,10H2,1H3
DM69T3A	CS	CC1=CC=C(C=C1)C(=O)CN2C3=CC=CC=C3C(=O)C2=O
DM69T3A	IK	PJQULSIUMHBSSF-UHFFFAOYSA-N
DM69T3A	IU	1-[2-(4-methylphenyl)-2-oxoethyl]indole-2,3-dione
DM69T3A	DE	Discovery agent

DMLY4ER	ID	DMLY4ER
DMLY4ER	DN	1-(2-phenoxybenzyl)-1H-imidazole
DMLY4ER	HS	Investigative
DMLY4ER	SN	CHEMBL1082760; 1-(2-phenoxybenzyl)-1H-imidazole; SCHEMBL11704850
DMLY4ER	DT	Small molecular drug
DMLY4ER	PC	46889432
DMLY4ER	MW	250.29
DMLY4ER	FM	C16H14N2O
DMLY4ER	IC	InChI=1S/C16H14N2O/c1-2-7-15(8-3-1)19-16-9-5-4-6-14(16)12-18-11-10-17-13-18/h1-11,13H,12H2
DMLY4ER	CS	C1=CC=C(C=C1)OC2=CC=CC=C2CN3C=CN=C3
DMLY4ER	IK	DFVDKHRBBOONAK-UHFFFAOYSA-N
DMLY4ER	IU	1-[(2-phenoxyphenyl)methyl]imidazole
DMLY4ER	DE	Discovery agent

DMOMAXJ	ID	DMOMAXJ
DMOMAXJ	DN	1-(2-Phenoxy-ethyl)-1H-imidazole
DMOMAXJ	HS	Investigative
DMOMAXJ	SN	CHEMBL284827; 1-(2-Phenoxy-ethyl)-1H-imidazole; 1H-Imidazole, 1-(2-phenoxyethyl)-; 1-(2-Phenoxyethyl)imidazole; SCHEMBL10370478; INUSBZKZIYQSRM-UHFFFAOYSA-N; ZINC26473891; BDBM50025988; AKOS002677376
DMOMAXJ	DT	Small molecular drug
DMOMAXJ	PC	13569172
DMOMAXJ	MW	188.23
DMOMAXJ	FM	C11H12N2O
DMOMAXJ	IC	InChI=1S/C11H12N2O/c1-2-4-11(5-3-1)14-9-8-13-7-6-12-10-13/h1-7,10H,8-9H2
DMOMAXJ	CS	C1=CC=C(C=C1)OCCN2C=CN=C2
DMOMAXJ	IK	INUSBZKZIYQSRM-UHFFFAOYSA-N
DMOMAXJ	IU	1-(2-phenoxyethyl)imidazole
DMOMAXJ	DE	Discovery agent

DMC1IKP	ID	DMC1IKP
DMC1IKP	DN	1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea
DMC1IKP	HS	Investigative
DMC1IKP	SN	CHEMBL345996; AC1MHEHQ; 1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea; BDBM50097040; 1-(2-phenoxyethyl)-3-thiazol-2-yl-thiourea; 1-(2-Phenoxyethyl)-3-(2-thiazolyl)thiourea; 1-(2-phenoxyethyl)-3-(1,3-thiazol-2-yl)thiourea
DMC1IKP	DT	Small molecular drug
DMC1IKP	PC	3003029
DMC1IKP	MW	279.4
DMC1IKP	FM	C12H13N3OS2
DMC1IKP	IC	InChI=1S/C12H13N3OS2/c17-11(15-12-14-7-9-18-12)13-6-8-16-10-4-2-1-3-5-10/h1-5,7,9H,6,8H2,(H2,13,14,15,17)
DMC1IKP	CS	C1=CC=C(C=C1)OCCNC(=S)NC2=NC=CS2
DMC1IKP	IK	MJPUUVIJLSCJEY-UHFFFAOYSA-N
DMC1IKP	IU	1-(2-phenoxyethyl)-3-(1,3-thiazol-2-yl)thiourea
DMC1IKP	DE	Discovery agent

DMWFCYN	ID	DMWFCYN
DMWFCYN	DN	1-(2-phenoxyphenyl)piperazine
DMWFCYN	HS	Investigative
DMWFCYN	SN	1-(2-phenoxyphenyl)piperazine; CHEMBL573532; SCHEMBL546735; VAXHGPCUAFNAQS-UHFFFAOYSA-N; 1-(2-Phenoxy-phenyl)-piperazine; ZINC37635596; BDBM50299785
DMWFCYN	DT	Small molecular drug
DMWFCYN	PC	12996705
DMWFCYN	MW	254.33
DMWFCYN	FM	C16H18N2O
DMWFCYN	IC	InChI=1S/C16H18N2O/c1-2-6-14(7-3-1)19-16-9-5-4-8-15(16)18-12-10-17-11-13-18/h1-9,17H,10-13H2
DMWFCYN	CS	C1CN(CCN1)C2=CC=CC=C2OC3=CC=CC=C3
DMWFCYN	IK	VAXHGPCUAFNAQS-UHFFFAOYSA-N
DMWFCYN	IU	1-(2-phenoxyphenyl)piperazine
DMWFCYN	DE	Discovery agent

DMXG10E	ID	DMXG10E
DMXG10E	DN	1-(2-Phenyl-propyl)-3-thiazol-2-yl-thiourea
DMXG10E	HS	Investigative
DMXG10E	SN	Thiourea, N-(2-phenylpropyl)-N'-2-thiazolyl-; 149486-09-9; PETT Analog 33; AC1MHDKK; BDBM1867; CHEMBL144136; 1-(2-phenylpropyl)-3-thiazol-2-yl-thiourea; 1-(beta-Methylphenethyl)-3-(2-thiazolyl)thiourea; 1-(2-phenylpropyl)-3-1,3-thiazol-2-ylthiourea; 1-(2-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea; N-(1-(2-Phenylpropyl))-N -(2-thiazolyl)thiourea
DMXG10E	DT	Small molecular drug
DMXG10E	PC	3001101
DMXG10E	MW	277.4
DMXG10E	FM	C13H15N3S2
DMXG10E	IC	InChI=1S/C13H15N3S2/c1-10(11-5-3-2-4-6-11)9-15-12(17)16-13-14-7-8-18-13/h2-8,10H,9H2,1H3,(H2,14,15,16,17)
DMXG10E	CS	CC(CNC(=S)NC1=NC=CS1)C2=CC=CC=C2
DMXG10E	IK	NQIQJPRBRMXGMW-UHFFFAOYSA-N
DMXG10E	IU	1-(2-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea
DMXG10E	CA	CAS 149486-09-9
DMXG10E	DE	Discovery agent

DMDLKPI	ID	DMDLKPI
DMDLKPI	DN	1-(2-p-tolyl-ethyl)-pyrrolidine
DMDLKPI	HS	Investigative
DMDLKPI	SN	CHEMBL257912; SCHEMBL13164030
DMDLKPI	DT	Small molecular drug
DMDLKPI	PC	44456128
DMDLKPI	MW	189.3
DMDLKPI	FM	C13H19N
DMDLKPI	IC	InChI=1S/C13H19N/c1-12-4-6-13(7-5-12)8-11-14-9-2-3-10-14/h4-7H,2-3,8-11H2,1H3
DMDLKPI	CS	CC1=CC=C(C=C1)CCN2CCCC2
DMDLKPI	IK	RLADTPQRCGVXDS-UHFFFAOYSA-N
DMDLKPI	IU	1-[2-(4-methylphenyl)ethyl]pyrrolidine
DMDLKPI	DE	Discovery agent

DM4B2EN	ID	DM4B2EN
DM4B2EN	DN	1-(2-Pyridin-2-yl-ethyl)-3-thiazol-2-yl-thiourea
DM4B2EN	HS	Investigative
DM4B2EN	SN	149486-07-7; Thiourea, N-(2-(2-pyridinyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(2-pyridinyl)ethyl]-N'-2-thiazolyl-; PETT Analog 25; AC1MHDKE; CHEMBL145709; SCHEMBL6956252; BDBM1918; DTXSID70164300; 1-(2-pyridin-2-ylethyl)-3-(1,3-thiazol-2-yl)thiourea; 1-[2-(2-pyridyl)ethyl]-3-thiazol-2-yl-thiourea; 1-(2-Thiazolyl)-3-[2-(2-pyridyl)ethyl]thiourea; N-(2-(2-Pyridylethyl))-N -(2-thiazolyl)thiourea
DM4B2EN	DT	Small molecular drug
DM4B2EN	PC	3001095
DM4B2EN	MW	264.4
DM4B2EN	FM	C11H12N4S2
DM4B2EN	IC	InChI=1S/C11H12N4S2/c16-10(15-11-14-7-8-17-11)13-6-4-9-3-1-2-5-12-9/h1-3,5,7-8H,4,6H2,(H2,13,14,15,16)
DM4B2EN	CS	C1=CC=NC(=C1)CCNC(=S)NC2=NC=CS2
DM4B2EN	IK	XNZLMIJCCHZKKA-UHFFFAOYSA-N
DM4B2EN	IU	1-(2-pyridin-2-ylethyl)-3-(1,3-thiazol-2-yl)thiourea
DM4B2EN	CA	CAS 149486-07-7
DM4B2EN	DE	Discovery agent

DMEDSLZ	ID	DMEDSLZ
DMEDSLZ	DN	1-(3-(2-(3-methoxyphenoxy)ethoxy)propyl)azepane
DMEDSLZ	HS	Investigative
DMEDSLZ	SN	CHEMBL476465; 1-(3-(2-(3-methoxyphenoxy)ethoxy)propyl)azepane
DMEDSLZ	DT	Small molecular drug
DMEDSLZ	PC	44582620
DMEDSLZ	MW	307.4
DMEDSLZ	FM	C18H29NO3
DMEDSLZ	IC	InChI=1S/C18H29NO3/c1-20-17-8-6-9-18(16-17)22-15-14-21-13-7-12-19-10-4-2-3-5-11-19/h6,8-9,16H,2-5,7,10-15H2,1H3
DMEDSLZ	CS	COC1=CC(=CC=C1)OCCOCCCN2CCCCCC2
DMEDSLZ	IK	CRNTZNDTRWBBPM-UHFFFAOYSA-N
DMEDSLZ	IU	1-[3-[2-(3-methoxyphenoxy)ethoxy]propyl]azepane
DMEDSLZ	DE	Discovery agent

DMD25N9	ID	DMD25N9
DMD25N9	DN	1-(3-(2-methylquinolin-7-yl)phenyl)ethanone
DMD25N9	HS	Investigative
DMD25N9	SN	CHEMBL233370; 1-(3-(2-methylquinolin-7-yl)phenyl)ethanone
DMD25N9	DT	Small molecular drug
DMD25N9	PC	44432663
DMD25N9	MW	261.3
DMD25N9	FM	C18H15NO
DMD25N9	IC	InChI=1S/C18H15NO/c1-12-6-7-14-8-9-17(11-18(14)19-12)16-5-3-4-15(10-16)13(2)20/h3-11H,1-2H3
DMD25N9	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)C(=O)C
DMD25N9	IK	RDDPBRGDKLSJLB-UHFFFAOYSA-N
DMD25N9	IU	1-[3-(2-methylquinolin-7-yl)phenyl]ethanone
DMD25N9	DE	Discovery agent

DM3EBFS	ID	DM3EBFS
DM3EBFS	DN	1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea
DM3EBFS	HS	Investigative
DM3EBFS	SN	CHEMBL540430; 1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea; SCHEMBL4263031; ANYYSWDTIHWUQV-UHFFFAOYSA-N
DM3EBFS	DT	Small molecular drug
DM3EBFS	PC	25015710
DM3EBFS	MW	355.4
DM3EBFS	FM	C20H25N3O3
DM3EBFS	IC	InChI=1S/C20H25N3O3/c24-20(21-17-6-2-1-3-7-17)22-18-8-4-9-19(16-18)26-13-5-10-23-11-14-25-15-12-23/h1-4,6-9,16H,5,10-15H2,(H2,21,22,24)
DM3EBFS	CS	C1COCCN1CCCOC2=CC=CC(=C2)NC(=O)NC3=CC=CC=C3
DM3EBFS	IK	ANYYSWDTIHWUQV-UHFFFAOYSA-N
DM3EBFS	IU	1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-phenylurea
DM3EBFS	DE	Discovery agent

DM3EYOL	ID	DM3EYOL
DM3EYOL	DN	1-(3-(3-phenylpropoxy)propyl)piperidine
DM3EYOL	HS	Investigative
DM3EYOL	SN	CHEMBL462606; 1-(3-(3-phenylpropoxy)propyl)piperidine; 1-[3-(3-phenylpropoxy)propyl]piperidine; SCHEMBL491655; UYLNHGRGPLPMFD-UHFFFAOYSA-N; BDBM50247055; 3-Phenylpropyl 3-piperidinopropyl ether
DM3EYOL	DT	Small molecular drug
DM3EYOL	PC	9903343
DM3EYOL	MW	261.399
DM3EYOL	FM	C17H27NO
DM3EYOL	IC	InChI=1S/C17H27NO/c1-3-9-17(10-4-1)11-7-15-19-16-8-14-18-12-5-2-6-13-18/h1,3-4,9-10H,2,5-8,11-16H2
DM3EYOL	CS	C1CCN(CC1)CCCOCCCC2=CC=CC=C2
DM3EYOL	IK	UYLNHGRGPLPMFD-UHFFFAOYSA-N
DM3EYOL	IU	1-[3-(3-phenylpropoxy)propyl]piperidine
DM3EYOL	DE	Discovery agent

DMHEIKQ	ID	DMHEIKQ
DMHEIKQ	DN	1-(3-(4-(2-fluoroethyl)phenoxy)propyl)piperidine
DMHEIKQ	HS	Investigative
DMHEIKQ	SN	CHEMBL449484; 1-(3-(4-(2-fluoroethyl)phenoxy)propyl)piperidine
DMHEIKQ	DT	Small molecular drug
DMHEIKQ	PC	44592097
DMHEIKQ	MW	265.37
DMHEIKQ	FM	C16H24FNO
DMHEIKQ	IC	InChI=1S/C16H24FNO/c17-10-9-15-5-7-16(8-6-15)19-14-4-13-18-11-2-1-3-12-18/h5-8H,1-4,9-14H2
DMHEIKQ	CS	C1CCN(CC1)CCCOC2=CC=C(C=C2)CCF
DMHEIKQ	IK	CKQQSVANJMAKBB-UHFFFAOYSA-N
DMHEIKQ	IU	1-[3-[4-(2-fluoroethyl)phenoxy]propyl]piperidine
DMHEIKQ	DE	Discovery agent

DMVXCPE	ID	DMVXCPE
DMVXCPE	DN	1-(3-(4-(fluoromethyl)phenoxy)propyl)piperidine
DMVXCPE	HS	Investigative
DMVXCPE	SN	CHEMBL469388; 1-(3-(4-(fluoromethyl)phenoxy)propyl)piperidine
DMVXCPE	DT	Small molecular drug
DMVXCPE	PC	44592096
DMVXCPE	MW	251.34
DMVXCPE	FM	C15H22FNO
DMVXCPE	IC	InChI=1S/C15H22FNO/c16-13-14-5-7-15(8-6-14)18-12-4-11-17-9-2-1-3-10-17/h5-8H,1-4,9-13H2
DMVXCPE	CS	C1CCN(CC1)CCCOC2=CC=C(C=C2)CF
DMVXCPE	IK	JRFMDYWVKRGBGL-UHFFFAOYSA-N
DMVXCPE	IU	1-[3-[4-(fluoromethyl)phenoxy]propyl]piperidine
DMVXCPE	DE	Discovery agent

DMM36DE	ID	DMM36DE
DMM36DE	DN	1-(3-(4-chlorobenzyl)quinoxalin-2-yl)hydrazine
DMM36DE	HS	Investigative
DMM36DE	SN	CHEMBL381487; 1-(3-(4-chlorobenzyl)quinoxalin-2-yl)hydrazine
DMM36DE	DT	Small molecular drug
DMM36DE	PC	44409445
DMM36DE	MW	284.74
DMM36DE	FM	C15H13ClN4
DMM36DE	IC	InChI=1S/C15H13ClN4/c16-11-7-5-10(6-8-11)9-14-15(20-17)19-13-4-2-1-3-12(13)18-14/h1-8H,9,17H2,(H,19,20)
DMM36DE	CS	C1=CC=C2C(=C1)N=C(C(=N2)NN)CC3=CC=C(C=C3)Cl
DMM36DE	IK	SMGDWLQUFKXCFA-UHFFFAOYSA-N
DMM36DE	IU	[3-[(4-chlorophenyl)methyl]quinoxalin-2-yl]hydrazine
DMM36DE	DE	Discovery agent

DMIFARP	ID	DMIFARP
DMIFARP	DN	1-(3-(4-chlorophenyl)propyl)-1H-imidazole
DMIFARP	HS	Investigative
DMIFARP	SN	CHEMBL213493; 1-(3-(4-chlorophenyl)propyl)-1H-imidazole; 1-[3-(4-Chlorophenyl)propyl]-1H-imidazole; 1H-Imidazole,1-[3-(4-chlorophenyl)propyl]-; SCHEMBL20570009; BDBM50191792
DMIFARP	DT	Small molecular drug
DMIFARP	PC	9991046
DMIFARP	MW	220.7
DMIFARP	FM	C12H13ClN2
DMIFARP	IC	InChI=1S/C12H13ClN2/c13-12-5-3-11(4-6-12)2-1-8-15-9-7-14-10-15/h3-7,9-10H,1-2,8H2
DMIFARP	CS	C1=CC(=CC=C1CCCN2C=CN=C2)Cl
DMIFARP	IK	CLJJKXWBLJQDDT-UHFFFAOYSA-N
DMIFARP	IU	1-[3-(4-chlorophenyl)propyl]imidazole
DMIFARP	DE	Discovery agent

DMWKXZ2	ID	DMWKXZ2
DMWKXZ2	DN	1-(3-(4-fluorophenyl)propyl)-1H-imidazole
DMWKXZ2	HS	Investigative
DMWKXZ2	SN	CHEMBL214932; 1-(3-(4-fluorophenyl)propyl)-1H-imidazole; 1-[3-(4-Fluorophenyl)propyl]-1H-imidazole
DMWKXZ2	DT	Small molecular drug
DMWKXZ2	PC	10081625
DMWKXZ2	MW	204.24
DMWKXZ2	FM	C12H13FN2
DMWKXZ2	IC	InChI=1S/C12H13FN2/c13-12-5-3-11(4-6-12)2-1-8-15-9-7-14-10-15/h3-7,9-10H,1-2,8H2
DMWKXZ2	CS	C1=CC(=CC=C1CCCN2C=CN=C2)F
DMWKXZ2	IK	BEKCOALNZLRGJA-UHFFFAOYSA-N
DMWKXZ2	IU	1-[3-(4-fluorophenyl)propyl]imidazole
DMWKXZ2	DE	Discovery agent

DMQ4MUF	ID	DMQ4MUF
DMQ4MUF	DN	1-(3-(benzyloxy)-2-methylphenyl)piperazine
DMQ4MUF	HS	Investigative
DMQ4MUF	SN	tolylpiperazine, 1; SCHEMBL4931607; CHEMBL483148; BDBM28584
DMQ4MUF	DT	Small molecular drug
DMQ4MUF	PC	25263303
DMQ4MUF	MW	282.4
DMQ4MUF	FM	C18H22N2O
DMQ4MUF	IC	InChI=1S/C18H22N2O/c1-15-17(20-12-10-19-11-13-20)8-5-9-18(15)21-14-16-6-3-2-4-7-16/h2-9,19H,10-14H2,1H3
DMQ4MUF	CS	CC1=C(C=CC=C1OCC2=CC=CC=C2)N3CCNCC3
DMQ4MUF	IK	LLKMJMQVKKJDAT-UHFFFAOYSA-N
DMQ4MUF	IU	1-(2-methyl-3-phenylmethoxyphenyl)piperazine
DMQ4MUF	DE	Discovery agent

DMX5N3V	ID	DMX5N3V
DMX5N3V	DN	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine
DMX5N3V	HS	Investigative
DMX5N3V	SN	CHEMBL239434
DMX5N3V	DT	Small molecular drug
DMX5N3V	PC	23643874
DMX5N3V	MW	261.26
DMX5N3V	FM	C9H12F5NS
DMX5N3V	IC	InChI=1S/C9H12F5NS/c1-7(15)5-8-3-2-4-9(6-8)16(10,11,12,13)14/h2-4,6-7H,5,15H2,1H3
DMX5N3V	CS	CC(CC1=CC(=CC=C1)S(F)(F)(F)(F)F)N
DMX5N3V	IK	YGBSUVPUXAMOTQ-UHFFFAOYSA-N
DMX5N3V	IU	1-[3-(pentafluoro-lambda6-sulfanyl)phenyl]propan-2-amine
DMX5N3V	DE	Discovery agent

DMXUNMW	ID	DMXUNMW
DMXUNMW	DN	1-(3-(phenylthio)propyl)-4-m-tolylpiperazine
DMXUNMW	HS	Investigative
DMXUNMW	SN	CHEMBL239159; 1-(3-(phenylthio)propyl)-4-m-tolylpiperazine
DMXUNMW	DT	Small molecular drug
DMXUNMW	PC	10245844
DMXUNMW	MW	326.5
DMXUNMW	FM	C20H26N2S
DMXUNMW	IC	InChI=1S/C20H26N2S/c1-18-7-5-8-19(17-18)22-14-12-21(13-15-22)11-6-16-23-20-9-3-2-4-10-20/h2-5,7-10,17H,6,11-16H2,1H3
DMXUNMW	CS	CC1=CC(=CC=C1)N2CCN(CC2)CCCSC3=CC=CC=C3
DMXUNMW	IK	ZHUHEUSMACZXIP-UHFFFAOYSA-N
DMXUNMW	IU	1-(3-methylphenyl)-4-(3-phenylsulfanylpropyl)piperazine
DMXUNMW	DE	Discovery agent

DMNZYWR	ID	DMNZYWR
DMNZYWR	DN	1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione
DMNZYWR	HS	Investigative
DMNZYWR	SN	1-(3,3-dimethyl-2-oxobutyl)-1H-indole-2,3-dione; 1-(3,3-dimethyl-2-oxobutyl)indole-2,3-dione; 214417-82-0; CHEMBL82686; AC1MU297; CTK7F3764; MolPort-003-013-041; ZINC3037941; ALBB-006420; STK506481; AKOS001570268; MCULE-7778783398; CCG-198354; TR-059060; SR-01000550574; 1-(2-Oxo-3,3-dimethylbutyl)-2,3-indolinedione
DMNZYWR	DT	Small molecular drug
DMNZYWR	PC	3659236
DMNZYWR	MW	245.27
DMNZYWR	FM	C14H15NO3
DMNZYWR	IC	InChI=1S/C14H15NO3/c1-14(2,3)11(16)8-15-10-7-5-4-6-9(10)12(17)13(15)18/h4-7H,8H2,1-3H3
DMNZYWR	CS	CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=O)C1=O
DMNZYWR	IK	GGQBSDZGSYIVQW-UHFFFAOYSA-N
DMNZYWR	IU	1-(3,3-dimethyl-2-oxobutyl)indole-2,3-dione
DMNZYWR	DE	Discovery agent

DM6RO2L	ID	DM6RO2L
DM6RO2L	DN	1-(3,3-Diphenyl-allyl)-3-m-tolyl-urea
DM6RO2L	HS	Investigative
DM6RO2L	SN	CHEMBL9312; 1-(3,3-Diphenyl-allyl)-3-m-tolyl-urea
DM6RO2L	DT	Small molecular drug
DM6RO2L	PC	44265928
DM6RO2L	MW	342.4
DM6RO2L	FM	C23H22N2O
DM6RO2L	IC	InChI=1S/C23H22N2O/c1-18-9-8-14-21(17-18)25-23(26)24-16-15-22(19-10-4-2-5-11-19)20-12-6-3-7-13-20/h2-15,17H,16H2,1H3,(H2,24,25,26)
DM6RO2L	CS	CC1=CC(=CC=C1)NC(=O)NCC=C(C2=CC=CC=C2)C3=CC=CC=C3
DM6RO2L	IK	AQCRRYHNTDGOLK-UHFFFAOYSA-N
DM6RO2L	IU	1-(3,3-diphenylprop-2-enyl)-3-(3-methylphenyl)urea
DM6RO2L	DE	Discovery agent

DMJDK7Z	ID	DMJDK7Z
DMJDK7Z	DN	1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol
DMJDK7Z	HS	Investigative
DMJDK7Z	SN	CHEMBL230033; 1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol
DMJDK7Z	DT	Small molecular drug
DMJDK7Z	PC	44426803
DMJDK7Z	MW	371.5
DMJDK7Z	FM	C26H29NO
DMJDK7Z	IC	InChI=1S/C26H29NO/c28-26(24-14-8-3-9-15-24)17-20-27(21-18-26)19-16-25(22-10-4-1-5-11-22)23-12-6-2-7-13-23/h1-15,25,28H,16-21H2
DMJDK7Z	CS	C1CN(CCC1(C2=CC=CC=C2)O)CCC(C3=CC=CC=C3)C4=CC=CC=C4
DMJDK7Z	IK	VJCUYHKRHUNZBN-UHFFFAOYSA-N
DMJDK7Z	IU	1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol
DMJDK7Z	DE	Discovery agent

DMX6PKO	ID	DMX6PKO
DMX6PKO	DN	1-(3,4-dichlorobenzyl)-1H-imidazole
DMX6PKO	HS	Investigative
DMX6PKO	SN	1-(3,4-dichlorobenzyl)-1H-imidazole; CHEMBL379436; 56643-72-2; 1-(3,4-Dichloro-benzyl)-1H-imidazole; 1-(3,4-Dichlorobenzyl)imidazole; BAS 11721008; AC1MGEX9; CTK1F4149; DTXSID40388096; MolPort-000-511-619; ZINC4385934; BDBM50188095; STK951804; AKOS000586982; [(3,4-dichlorophenyl)methyl]imidazole; MCULE-5938366655; 1-[(3,4-dichlorophenyl)methyl]imidazole; ST50162194; 1H-Imidazole, 1-[(3,4-dichlorophenyl)methyl]-; SR-01000301759
DMX6PKO	DT	Small molecular drug
DMX6PKO	PC	2985081
DMX6PKO	MW	227.09
DMX6PKO	FM	C10H8Cl2N2
DMX6PKO	IC	InChI=1S/C10H8Cl2N2/c11-9-2-1-8(5-10(9)12)6-14-4-3-13-7-14/h1-5,7H,6H2
DMX6PKO	CS	C1=CC(=C(C=C1CN2C=CN=C2)Cl)Cl
DMX6PKO	IK	AYZFQKPOALRPNQ-UHFFFAOYSA-N
DMX6PKO	IU	1-[(3,4-dichlorophenyl)methyl]imidazole
DMX6PKO	CA	CAS 56643-72-2
DMX6PKO	DE	Discovery agent

DMX71K9	ID	DMX71K9
DMX71K9	DN	1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione
DMX71K9	HS	Investigative
DMX71K9	SN	Apoptosis Activator 2; 79183-19-0; 1-(3,4-Dichlorobenzyl)-1H-indole-2,3-dione; Apoptosis Activator II; 1-(3,4-dichlorobenzyl)indoline-2,3-dione; MDK83190; 1-[(3,4-dichlorophenyl)methyl]indole-2,3-dione; J-503075; 1H-Indole-2,3-dione,1-[(3,4-dichlorophenyl)methyl]-; SR-01000411093; ApoptosisActivator2; AC1LYJSJ; Tocris-2098; AC1Q3JHQ; CBMicro_042945; Isatin-based compound, 16; CHEMBL375126; SCHEMBL5426477; BDBM22796; CHEBI:92273; KS-00001DBG; CTK5E6556; cid_1901244; DTXSID30365533; EX-A147; AOB2639; MolPort-002-181-853; HMS3651L12
DMX71K9	DT	Small molecular drug
DMX71K9	PC	1901244
DMX71K9	MW	306.1
DMX71K9	FM	C15H9Cl2NO2
DMX71K9	IC	InChI=1S/C15H9Cl2NO2/c16-11-6-5-9(7-12(11)17)8-18-13-4-2-1-3-10(13)14(19)15(18)20/h1-7H,8H2
DMX71K9	CS	C1=CC=C2C(=C1)C(=O)C(=O)N2CC3=CC(=C(C=C3)Cl)Cl
DMX71K9	IK	KGRJPLRFGLMQMV-UHFFFAOYSA-N
DMX71K9	IU	1-[(3,4-dichlorophenyl)methyl]indole-2,3-dione
DMX71K9	CA	CAS 79183-19-0
DMX71K9	CB	CHEBI:92273
DMX71K9	DE	Discovery agent

DM4YWEL	ID	DM4YWEL
DM4YWEL	DN	1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)ethanone
DM4YWEL	HS	Investigative
DM4YWEL	SN	CHEMBL238835; 1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)-1-ethanone; 344266-52-0; AC1LS77V; 1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)ethanone; MolPort-002-876-897; ZINC1396961; BDBM50212532; AKOS005097772; MCULE-8898035078; 7H-370S; KS-00001Z97; 2-(benzenesulfonyl)-1-(3,4-dichlorophenyl)ethanone
DM4YWEL	DT	Small molecular drug
DM4YWEL	PC	1483443
DM4YWEL	MW	329.2
DM4YWEL	FM	C14H10Cl2O3S
DM4YWEL	IC	InChI=1S/C14H10Cl2O3S/c15-12-7-6-10(8-13(12)16)14(17)9-20(18,19)11-4-2-1-3-5-11/h1-8H,9H2
DM4YWEL	CS	C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CC(=C(C=C2)Cl)Cl
DM4YWEL	IK	LZBIUNZNOUZDPA-UHFFFAOYSA-N
DM4YWEL	IU	2-(benzenesulfonyl)-1-(3,4-dichlorophenyl)ethanone
DM4YWEL	DE	Discovery agent

DMNOQ49	ID	DMNOQ49
DMNOQ49	DN	1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea
DMNOQ49	HS	Investigative
DMNOQ49	SN	CHEMBL255505; 1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea; AC1LKCSZ; CBMicro_019879; AC1Q3IF4; MolPort-000-644-777; ZINC639843; CCG-8060; 1-(3,4-DICHLORO-PHENYL)-3-(3,5-DICHLORO-PHENYL)-UREA; BDBM50373332; AKOS002934710; MCULE-5556566180; BIM-0020045.P001; ST50982277; SJ000146676
DMNOQ49	DT	Small molecular drug
DMNOQ49	PC	989142
DMNOQ49	MW	350
DMNOQ49	FM	C13H8Cl4N2O
DMNOQ49	IC	InChI=1S/C13H8Cl4N2O/c14-7-3-8(15)5-10(4-7)19-13(20)18-9-1-2-11(16)12(17)6-9/h1-6H,(H2,18,19,20)
DMNOQ49	CS	C1=CC(=C(C=C1NC(=O)NC2=CC(=CC(=C2)Cl)Cl)Cl)Cl
DMNOQ49	IK	IMDDDJBDFZQNJH-UHFFFAOYSA-N
DMNOQ49	IU	1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea
DMNOQ49	DE	Discovery agent

DMN4JU0	ID	DMN4JU0
DMN4JU0	DN	1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol
DMN4JU0	HS	Investigative
DMN4JU0	SN	CHEMBL315697; 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol
DMN4JU0	DT	Small molecular drug
DMN4JU0	PC	44322661
DMN4JU0	MW	350.3
DMN4JU0	FM	C19H21Cl2NO
DMN4JU0	IC	InChI=1S/C19H21Cl2NO/c1-3-22(4-2)19-11-15(12-5-8-17(20)18(21)9-12)14-7-6-13(23)10-16(14)19/h5-10,15,19,23H,3-4,11H2,1-2H3
DMN4JU0	CS	CCN(CC)C1CC(C2=C1C=C(C=C2)O)C3=CC(=C(C=C3)Cl)Cl
DMN4JU0	IK	NIIGXDSCJHJWSY-UHFFFAOYSA-N
DMN4JU0	IU	1-(3,4-dichlorophenyl)-3-(diethylamino)-2,3-dihydro-1H-inden-5-ol
DMN4JU0	DE	Discovery agent

DMVOJ7K	ID	DMVOJ7K
DMVOJ7K	DN	1-(3,4-dichlorophenyl)-3-hydroxyurea
DMVOJ7K	HS	Investigative
DMVOJ7K	SN	1-(3,4-Dichlorophenyl)-3-hydroxyurea; N-(3,4-Dichlorophenyl)-N'-hydroxyurea; 31225-17-9; Dichlorphenyloxyurea; Urea, N-(3,4-dichlorophenyl)-N'-hydroxy-; Urea, 1-(3,4-dichlorophenyl)-3-hydroxy-; EINECS 250-519-3; NSC125191; NSC 125191; BRN 2806578; AI3-63029; CHEMBL213348; AC1L3YKI; AC1Q3OJ7; SCHEMBL6791055; DTXSID8067602; CTK4G6577; Urea,4-dichlorophenyl)-3-hydroxy-; ZINC4809416; Urea,4-dichlorophenyl)-N'-hydroxy-; BDBM50188774; AKOS024368418; NSC-125191; MCULE-3584918333; 1-(3,4-dichlorophenyl)-3-hydroxy-urea; LS-159754
DMVOJ7K	DT	Small molecular drug
DMVOJ7K	PC	97463
DMVOJ7K	MW	221.04
DMVOJ7K	FM	C7H6Cl2N2O2
DMVOJ7K	IC	InChI=1S/C7H6Cl2N2O2/c8-5-2-1-4(3-6(5)9)10-7(12)11-13/h1-3,13H,(H2,10,11,12)
DMVOJ7K	CS	C1=CC(=C(C=C1NC(=O)NO)Cl)Cl
DMVOJ7K	IK	VKYZMAVGJARVPE-UHFFFAOYSA-N
DMVOJ7K	IU	1-(3,4-dichlorophenyl)-3-hydroxyurea
DMVOJ7K	CA	CAS 31225-17-9
DMVOJ7K	DE	Discovery agent

DMWIEDN	ID	DMWIEDN
DMWIEDN	DN	1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol
DMWIEDN	HS	Investigative
DMWIEDN	SN	CHEMBL301514; 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol
DMWIEDN	DT	Small molecular drug
DMWIEDN	PC	13543873
DMWIEDN	MW	308.2
DMWIEDN	FM	C16H15Cl2NO
DMWIEDN	IC	InChI=1S/C16H15Cl2NO/c1-19-16-8-12(9-2-5-14(17)15(18)6-9)11-4-3-10(20)7-13(11)16/h2-7,12,16,19-20H,8H2,1H3
DMWIEDN	CS	CNC1CC(C2=C1C=C(C=C2)O)C3=CC(=C(C=C3)Cl)Cl
DMWIEDN	IK	QAOIAICAGBDCEV-UHFFFAOYSA-N
DMWIEDN	IU	1-(3,4-dichlorophenyl)-3-(methylamino)-2,3-dihydro-1H-inden-5-ol
DMWIEDN	DE	Discovery agent

DMYZ548	ID	DMYZ548
DMYZ548	DN	1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMYZ548	HS	Investigative
DMYZ548	SN	SCHEMBL3194096; CHEMBL1173532; BDBM50322698; 1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX); rel-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane
DMYZ548	DT	Small molecular drug
DMYZ548	PC	24802842
DMYZ548	MW	286.2
DMYZ548	FM	C14H17Cl2NO
DMYZ548	IC	InChI=1S/C14H17Cl2NO/c1-18-9-13-7-14(13,4-5-17-8-13)10-2-3-11(15)12(16)6-10/h2-3,6,17H,4-5,7-9H2,1H3/t13-,14-/m1/s1
DMYZ548	CS	COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl
DMYZ548	IK	ICXJGCSEMJXNQF-ZIAGYGMSSA-N
DMYZ548	IU	(1R,6S)-6-(3,4-dichlorophenyl)-1-(methoxymethyl)-3-azabicyclo[4.1.0]heptane
DMYZ548	DE	Discovery agent

DMRXD2P	ID	DMRXD2P
DMRXD2P	DN	1-(3,4-difluorobenzyl)-1H-imidazole
DMRXD2P	HS	Investigative
DMRXD2P	SN	1-(3,4-difluorobenzyl)-1H-imidazole; 1-(3,4-Difluorobenzyl)imidazole; CHEMBL373588; 906478-71-5; ZINC36322898; BDBM50188090
DMRXD2P	DT	Small molecular drug
DMRXD2P	PC	44414157
DMRXD2P	MW	194.18
DMRXD2P	FM	C10H8F2N2
DMRXD2P	IC	InChI=1S/C10H8F2N2/c11-9-2-1-8(5-10(9)12)6-14-4-3-13-7-14/h1-5,7H,6H2
DMRXD2P	CS	C1=CC(=C(C=C1CN2C=CN=C2)F)F
DMRXD2P	IK	YOWSCWVTVGDNPQ-UHFFFAOYSA-N
DMRXD2P	IU	1-[(3,4-difluorophenyl)methyl]imidazole
DMRXD2P	DE	Discovery agent

DM5C7I8	ID	DM5C7I8
DM5C7I8	DN	1-(3,4-dihydronaphthalen-1-yl)ethanone
DM5C7I8	HS	Investigative
DM5C7I8	SN	CHEMBL378621; 1-(3,4-dihydro-naphthalen-1-yl)-ethanone; 67106-36-9; 1-(3,4-dihydronaphthalen-1-yl)ethanone; SCHEMBL6337844; 1-acetyl-3,4-dihydronaphthalene; CTK1J3902; DTXSID40447596; BDBM50189272; AKOS030597011; 1-(3,4-dihydro-1-naphthalenyl)ethanone; Ethanone, 1-(3,4-dihydro-1-naphthalenyl)-
DM5C7I8	DT	Small molecular drug
DM5C7I8	PC	10899142
DM5C7I8	MW	172.22
DM5C7I8	FM	C12H12O
DM5C7I8	IC	InChI=1S/C12H12O/c1-9(13)11-8-4-6-10-5-2-3-7-12(10)11/h2-3,5,7-8H,4,6H2,1H3
DM5C7I8	CS	CC(=O)C1=CCCC2=CC=CC=C21
DM5C7I8	IK	OUZPHFHCYBXKAY-UHFFFAOYSA-N
DM5C7I8	IU	1-(3,4-dihydronaphthalen-1-yl)ethanone
DM5C7I8	DE	Discovery agent

DMP93HZ	ID	DMP93HZ
DMP93HZ	DN	1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole
DMP93HZ	HS	Investigative
DMP93HZ	SN	BRN 4745179; 89781-63-5; 1H-Imidazole, 1-(3,4-dihydro-2-naphthalenyl)-; 1-(3,4-Dihydro-2-naphthalenyl)-1H-imidazole; 1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole; 1H-Imidazole,1-(3,4-dihydro-2-naphthalenyl)-; ACMC-20lqcl; Dihydronaphthalene 13; AC1MIBH1; SCHEMBL4513496; CHEMBL208471; BDBM8898; 1-(3,4-DIHYDRO-NAPHTHALEN-2-YL)-1H-IMIDAZOLE; CTK5G3471; DTXSID50237889; ZINC13684552; AKOS006279027; 1-(3,4-dihydronaphthalen-2-yl)imidazole; LS-78473
DMP93HZ	DT	Small molecular drug
DMP93HZ	PC	3021558
DMP93HZ	MW	196.25
DMP93HZ	FM	C13H12N2
DMP93HZ	IC	InChI=1S/C13H12N2/c1-2-4-12-9-13(6-5-11(12)3-1)15-8-7-14-10-15/h1-4,7-10H,5-6H2
DMP93HZ	CS	C1CC(=CC2=CC=CC=C21)N3C=CN=C3
DMP93HZ	IK	DHUCLDOIXQGVDQ-UHFFFAOYSA-N
DMP93HZ	IU	1-(3,4-dihydronaphthalen-2-yl)imidazole
DMP93HZ	CA	CAS 89781-63-5
DMP93HZ	DE	Discovery agent

DM9M5D1	ID	DM9M5D1
DM9M5D1	DN	1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone
DM9M5D1	HS	Investigative
DM9M5D1	SN	CHEMBL197115; 1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone; SCHEMBL7431618
DM9M5D1	DT	Small molecular drug
DM9M5D1	PC	9900163
DM9M5D1	MW	273.24
DM9M5D1	FM	C14H11NO5
DM9M5D1	IC	InChI=1S/C14H11NO5/c16-11-7-6-10(13(14(11)18)15(19)20)12(17)8-9-4-2-1-3-5-9/h1-7,16,18H,8H2
DM9M5D1	CS	C1=CC=C(C=C1)CC(=O)C2=C(C(=C(C=C2)O)O)[N+](=O)[O-]
DM9M5D1	IK	WQKGHRQZAOQUHW-UHFFFAOYSA-N
DM9M5D1	IU	1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone
DM9M5D1	DE	Discovery agent

DMKI719	ID	DMKI719
DMKI719	DN	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone
DMKI719	HS	Investigative
DMKI719	SN	CHEMBL374904; SCHEMBL7251537
DMKI719	DT	Small molecular drug
DMKI719	PC	9900598
DMKI719	MW	289.24
DMKI719	FM	C14H11NO6
DMKI719	IC	InChI=1S/C14H11NO6/c16-12-7-9(6-11(14(12)18)15(19)20)13(17)8-21-10-4-2-1-3-5-10/h1-7,16,18H,8H2
DMKI719	CS	C1=CC=C(C=C1)OCC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
DMKI719	IK	JFIYNCBDNTXFDN-UHFFFAOYSA-N
DMKI719	IU	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone
DMKI719	DE	Discovery agent

DMCHILK	ID	DMCHILK
DMCHILK	DN	1-(3,4-Dimethyl-phenyl)-2-phenyl-ethane-1,2-dione
DMCHILK	HS	Investigative
DMCHILK	SN	1-(3,4-dimethylphenyl)-2-phenylethane-1,2-dione; 59411-15-3; PubChem22503; AC1M6ONN; Benzil-based compound, 19; AC1Q2DS8; SCHEMBL2156354; CHEMBL193140; 1-(3,4-Dimethyl-phenyl)-2-phenyl-ethane-1,2-dione; CTK5A9919; BDBM22741; DTXSID20368619; MolPort-000-513-246; ZINC3311689; AKOS000118620; MCULE-1712710570; NE45262; AJ-44881; ST010102; KB-213539; J3.541.808C; EN300-11497
DMCHILK	DT	Small molecular drug
DMCHILK	PC	2427416
DMCHILK	MW	238.28
DMCHILK	FM	C16H14O2
DMCHILK	IC	InChI=1S/C16H14O2/c1-11-8-9-14(10-12(11)2)16(18)15(17)13-6-4-3-5-7-13/h3-10H,1-2H3
DMCHILK	CS	CC1=C(C=C(C=C1)C(=O)C(=O)C2=CC=CC=C2)C
DMCHILK	IK	UJARQLWFLLIFBN-UHFFFAOYSA-N
DMCHILK	IU	1-(3,4-dimethylphenyl)-2-phenylethane-1,2-dione
DMCHILK	CA	CAS 59411-15-3
DMCHILK	DE	Discovery agent

DM5WOK8	ID	DM5WOK8
DM5WOK8	DN	1-(3,5-bis(trifluoromethyl)benzyl)-1H-imidazole
DM5WOK8	HS	Investigative
DM5WOK8	SN	CHEMBL213596; 1-(3,5-bis(trifluoromethyl)benzyl)-1H-imidazole
DM5WOK8	DT	Small molecular drug
DM5WOK8	PC	44414156
DM5WOK8	MW	294.2
DM5WOK8	FM	C12H8F6N2
DM5WOK8	IC	InChI=1S/C12H8F6N2/c13-11(14,15)9-3-8(6-20-2-1-19-7-20)4-10(5-9)12(16,17)18/h1-5,7H,6H2
DM5WOK8	CS	C1=CN(C=N1)CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F
DM5WOK8	IK	XITLEILYHLIBPC-UHFFFAOYSA-N
DM5WOK8	IU	1-[[3,5-bis(trifluoromethyl)phenyl]methyl]imidazole
DM5WOK8	CA	CAS 906478-70-4
DM5WOK8	DE	Discovery agent

DMNRCM0	ID	DMNRCM0
DMNRCM0	DN	1-(3,5-dibromobenzyl)-1H-imidazole
DMNRCM0	HS	Investigative
DMNRCM0	SN	CHEMBL211276; 528543-94-4; 1-(3,5-dibromobenzyl)-1H-imidazole; CTK1G1925; DTXSID30658795; BDBM50188091; 1-[(3,5-Dibromophenyl)methyl]-1H-imidazole; 1H-Imidazole, 1-[(3,5-dibromophenyl)methyl]-
DMNRCM0	DT	Small molecular drug
DMNRCM0	PC	44414099
DMNRCM0	MW	315.99
DMNRCM0	FM	C10H8Br2N2
DMNRCM0	IC	InChI=1S/C10H8Br2N2/c11-9-3-8(4-10(12)5-9)6-14-2-1-13-7-14/h1-5,7H,6H2
DMNRCM0	CS	C1=CN(C=N1)CC2=CC(=CC(=C2)Br)Br
DMNRCM0	IK	QXITVPZFTOHIGY-UHFFFAOYSA-N
DMNRCM0	IU	1-[(3,5-dibromophenyl)methyl]imidazole
DMNRCM0	CA	CAS 528543-94-4
DMNRCM0	DE	Discovery agent

DMLSWHP	ID	DMLSWHP
DMLSWHP	DN	1-(3,5-dichlorobenzyl)-1H-imidazole
DMLSWHP	HS	Investigative
DMLSWHP	SN	CHEMBL210125; 1-(3,5-dichlorobenzyl)-1H-imidazole; SCHEMBL3980802
DMLSWHP	DT	Small molecular drug
DMLSWHP	PC	44414074
DMLSWHP	MW	227.09
DMLSWHP	FM	C10H8Cl2N2
DMLSWHP	IC	InChI=1S/C10H8Cl2N2/c11-9-3-8(4-10(12)5-9)6-14-2-1-13-7-14/h1-5,7H,6H2
DMLSWHP	CS	C1=CN(C=N1)CC2=CC(=CC(=C2)Cl)Cl
DMLSWHP	IK	RNVCIUBPHQDEID-UHFFFAOYSA-N
DMLSWHP	IU	1-[(3,5-dichlorophenyl)methyl]imidazole
DMLSWHP	DE	Discovery agent

DMEAI6V	ID	DMEAI6V
DMEAI6V	DN	1-(3,5-difluorobenzyl)-1H-imidazole
DMEAI6V	HS	Investigative
DMEAI6V	SN	1-(3,5-difluorobenzyl)-1H-imidazole; CHEMBL446946; 170166-01-5; SCHEMBL10518956; CTK0E4909; DTXSID20474067; 1-(3,5-Difluorobenzyl)imidazole; ZINC36466875; BDBM50188089; AKOS027391623; 1-[(3,5-difluorophenyl)methyl]-1H-imidazole; 1H-Imidazole, 1-[(3,5-difluorophenyl)methyl]-
DMEAI6V	DT	Small molecular drug
DMEAI6V	PC	11830301
DMEAI6V	MW	194.18
DMEAI6V	FM	C10H8F2N2
DMEAI6V	IC	InChI=1S/C10H8F2N2/c11-9-3-8(4-10(12)5-9)6-14-2-1-13-7-14/h1-5,7H,6H2
DMEAI6V	CS	C1=CN(C=N1)CC2=CC(=CC(=C2)F)F
DMEAI6V	IK	HGEAQRQBZSYPGD-UHFFFAOYSA-N
DMEAI6V	IU	1-[(3,5-difluorophenyl)methyl]imidazole
DMEAI6V	CA	CAS 170166-01-5
DMEAI6V	DE	Discovery agent

DMYJ4EG	ID	DMYJ4EG
DMYJ4EG	DN	1-(3,5-dimethylphenyl)-2-(phenylsulfonyl)ethanone
DMYJ4EG	HS	Investigative
DMYJ4EG	SN	CHEMBL239261; 1-(3,5-dimethylphenyl)-2-(phenylsulfonyl)ethanone; BDBM50212547
DMYJ4EG	DT	Small molecular drug
DMYJ4EG	PC	44437607
DMYJ4EG	MW	288.4
DMYJ4EG	FM	C16H16O3S
DMYJ4EG	IC	InChI=1S/C16H16O3S/c1-12-8-9-15(13(2)10-12)16(17)11-20(18,19)14-6-4-3-5-7-14/h3-10H,11H2,1-2H3
DMYJ4EG	CS	CC1=CC(=C(C=C1)C(=O)CS(=O)(=O)C2=CC=CC=C2)C
DMYJ4EG	IK	MYSKHEDYGIVTKV-UHFFFAOYSA-N
DMYJ4EG	IU	2-(benzenesulfonyl)-1-(2,4-dimethylphenyl)ethanone
DMYJ4EG	DE	Discovery agent

DMEJZAC	ID	DMEJZAC
DMEJZAC	DN	1-(3-Amino-benzyl)-1H-indole-5-carboxamidine
DMEJZAC	HS	Investigative
DMEJZAC	SN	CHEMBL319122; 1-(3-Amino-benzyl)-1H-indole-5-carboxamidine; ZINC26750418
DMEJZAC	DT	Small molecular drug
DMEJZAC	PC	44332077
DMEJZAC	MW	264.32
DMEJZAC	FM	C16H16N4
DMEJZAC	IC	InChI=1S/C16H16N4/c17-14-3-1-2-11(8-14)10-20-7-6-12-9-13(16(18)19)4-5-15(12)20/h1-9H,10,17H2,(H3,18,19)
DMEJZAC	CS	C1=CC(=CC(=C1)N)CN2C=CC3=C2C=CC(=C3)C(=N)N
DMEJZAC	IK	PHWLXNIGOXPBJT-UHFFFAOYSA-N
DMEJZAC	IU	1-[(3-aminophenyl)methyl]indole-5-carboximidamide
DMEJZAC	DE	Discovery agent

DMTY41F	ID	DMTY41F
DMTY41F	DN	1-(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine
DMTY41F	HS	Investigative
DMTY41F	SN	CHEMBL382886; 1-(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine
DMTY41F	DT	Small molecular drug
DMTY41F	PC	44409446
DMTY41F	MW	319.2
DMTY41F	FM	C15H12Cl2N4
DMTY41F	IC	InChI=1S/C15H12Cl2N4/c16-10-7-12-13(8-11(10)17)20-15(21-18)14(19-12)6-9-4-2-1-3-5-9/h1-5,7-8H,6,18H2,(H,20,21)
DMTY41F	CS	C1=CC=C(C=C1)CC2=NC3=CC(=C(C=C3N=C2NN)Cl)Cl
DMTY41F	IK	UMCSOEDKYUEPEK-UHFFFAOYSA-N
DMTY41F	IU	(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine
DMTY41F	DE	Discovery agent

DMDZAVU	ID	DMDZAVU
DMDZAVU	DN	1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea
DMDZAVU	HS	Investigative
DMDZAVU	SN	CHEMBL202880; 877458-90-7; 1-PHENYL-3-(3-(PHENYLMETHOXY)(2-PYRIDYL))UREA; 1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea; AC1MUB56; MolPort-006-755-114; KS-000029KK; ZINC13680188; BDBM50181486; AKOS016664347; MS-8514; 1-(3-benzyloxy-2-pyridyl)-3-phenyl-urea; 3-[3-(benzyloxy)pyridin-2-yl]-1-phenylurea; 1-phenyl-3-(3-phenylmethoxypyridin-2-yl)urea; Urea, N-(3-phenyl)-N'-[3-(phenylmethoxy)-2-pyridinyl]-
DMDZAVU	DT	Small molecular drug
DMDZAVU	PC	3663276
DMDZAVU	MW	319.4
DMDZAVU	FM	C19H17N3O2
DMDZAVU	IC	InChI=1S/C19H17N3O2/c23-19(21-16-10-5-2-6-11-16)22-18-17(12-7-13-20-18)24-14-15-8-3-1-4-9-15/h1-13H,14H2,(H2,20,21,22,23)
DMDZAVU	CS	C1=CC=C(C=C1)COC2=C(N=CC=C2)NC(=O)NC3=CC=CC=C3
DMDZAVU	IK	PFMMAQSZJDBKOE-UHFFFAOYSA-N
DMDZAVU	IU	1-phenyl-3-(3-phenylmethoxypyridin-2-yl)urea
DMDZAVU	DE	Discovery agent

DMJCVQN	ID	DMJCVQN
DMJCVQN	DN	1-(3-benzylquinoxalin-2-yl)hydrazine
DMJCVQN	HS	Investigative
DMJCVQN	SN	2-benzyl-3-hydrazinoquinoxaline; 223929-23-5; 2-benzyl-3-hydrazinylquinoxaline; CHEMBL379678; 1-(3-benzylquinoxalin-2-yl)hydrazine; AC1LAIMJ; benzylhydrazinoquinoxaline; SCHEMBL7628856; 3-benzyl-2-hydrazinoquinoxaline; KS-00001USU; CTK7F1811; 3-benzylquinoxaline-2-ylhydrazine; DTXSID80333186; MolPort-009-195-340; (3-benzylquinoxalin-2-yl)hydrazine; ZINC6580943; SBB100772; BDBM50179015; 7662AD; AKOS005070001; RTR-063098; RP14269; AJ-56391; TR-063098; 2R-0102
DMJCVQN	DT	Small molecular drug
DMJCVQN	PC	488815
DMJCVQN	MW	250.3
DMJCVQN	FM	C15H14N4
DMJCVQN	IC	InChI=1S/C15H14N4/c16-19-15-14(10-11-6-2-1-3-7-11)17-12-8-4-5-9-13(12)18-15/h1-9H,10,16H2,(H,18,19)
DMJCVQN	CS	C1=CC=C(C=C1)CC2=NC3=CC=CC=C3N=C2NN
DMJCVQN	IK	VVXTVQMXZGMAAH-UHFFFAOYSA-N
DMJCVQN	IU	(3-benzylquinoxalin-2-yl)hydrazine
DMJCVQN	CA	CAS 223929-23-5
DMJCVQN	DE	Discovery agent

DMA59TP	ID	DMA59TP
DMA59TP	DN	1-(3-Bromobenzyl)-1H-imidazole
DMA59TP	HS	Investigative
DMA59TP	SN	1-(3-Bromobenzyl)-1H-imidazole; 72459-47-3; 1-(3-bromobenzyl)imidazole; CHEMBL598391; 1H-Imidazole,1-[(3-bromophenyl)methyl]-; 1-[(3-bromophenyl)methyl]imidazole; SCHEMBL1848631; CTK5D6138; [(3-bromophenyl)methyl]imidazole; DTXSID00436926; BGYZLOIBJCHCTI-UHFFFAOYSA-N; MolPort-000-143-256; SBB098740; ZINC12370275; BDBM50307216; AKOS013124377; RP05747; KB-63888; 1-[(3-bromophenyl)methyl]-1H-imidazole; AJ-61784; DB-074567; ST24037191; Y9919; FT-0708606; 1-(3-bromobenzyl)-1H-imidazole, AldrichCPR; J-503102; Z1532751877
DMA59TP	DT	Small molecular drug
DMA59TP	PC	10220337
DMA59TP	MW	237.1
DMA59TP	FM	C10H9BrN2
DMA59TP	IC	InChI=1S/C10H9BrN2/c11-10-3-1-2-9(6-10)7-13-5-4-12-8-13/h1-6,8H,7H2
DMA59TP	CS	C1=CC(=CC(=C1)Br)CN2C=CN=C2
DMA59TP	IK	BGYZLOIBJCHCTI-UHFFFAOYSA-N
DMA59TP	IU	1-[(3-bromophenyl)methyl]imidazole
DMA59TP	CA	CAS 72459-47-3
DMA59TP	DE	Discovery agent

DM58S47	ID	DM58S47
DM58S47	DN	1-(3-Bromomethyl-phenyl)-2,2,2-trifluoro-ethanone
DM58S47	HS	Investigative
DM58S47	SN	3-Trifluoroacetylbenzyl bromide; 370104-05-5; 1-[3-(bromomethyl)phenyl]-2,2,2-trifluoroethan-1-one; CHEMBL322727; SCHEMBL19745468; BDBM10502; MolPort-039-241-133; ZINC13864123; 1-[3-(bromomethyl)phenyl]-2,2,2-trifluoroethanone; 1-[3-(bromomethyl)-phenyl]-2,2,2-trifluoro-ethanone
DM58S47	DT	Small molecular drug
DM58S47	PC	10858440
DM58S47	MW	267.04
DM58S47	FM	C9H6BrF3O
DM58S47	IC	InChI=1S/C9H6BrF3O/c10-5-6-2-1-3-7(4-6)8(14)9(11,12)13/h1-4H,5H2
DM58S47	CS	C1=CC(=CC(=C1)C(=O)C(F)(F)F)CBr
DM58S47	IK	PJBFZGACRBKRKV-UHFFFAOYSA-N
DM58S47	IU	1-[3-(bromomethyl)phenyl]-2,2,2-trifluoroethanone
DM58S47	CA	CAS 370104-05-5
DM58S47	DE	Discovery agent

DM2SEXH	ID	DM2SEXH
DM2SEXH	DN	1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one
DM2SEXH	HS	Investigative
DM2SEXH	SN	1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one; CHEMBL565396; AC1MHR9I; SCHEMBL769683; BDBM50302930
DM2SEXH	DT	Small molecular drug
DM2SEXH	PC	3031062
DM2SEXH	MW	284.19
DM2SEXH	FM	C13H18BrNO
DM2SEXH	IC	InChI=1S/C13H18BrNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
DM2SEXH	CS	CC(C(=O)C1=CC(=CC=C1)Br)NC(C)(C)C
DM2SEXH	IK	GIDJZDYNVHMFAH-UHFFFAOYSA-N
DM2SEXH	IU	1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one
DM2SEXH	DE	Discovery agent

DMJXOUK	ID	DMJXOUK
DMJXOUK	DN	1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)
DMJXOUK	HS	Investigative
DMJXOUK	SN	CHEMBL1094231; 1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX); SCHEMBL4285350; BDBM50316561; 1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol
DMJXOUK	DT	Small molecular drug
DMJXOUK	PC	46888441
DMJXOUK	MW	438.8
DMJXOUK	FM	C21H12ClF5N2O
DMJXOUK	IC	InChI=1S/C21H12ClF5N2O/c22-17-10-14(1-7-18(17)24)20(30,21(25,26)27)13-2-8-19-12(9-13)11-28-29(19)16-5-3-15(23)4-6-16/h1-11,30H
DMJXOUK	CS	C1=CC(=CC=C1N2C3=C(C=C(C=C3)C(C4=CC(=C(C=C4)F)Cl)(C(F)(F)F)O)C=N2)F
DMJXOUK	IK	DAXGWLCLIPNRDH-UHFFFAOYSA-N
DMJXOUK	IU	1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)indazol-5-yl]ethanol
DMJXOUK	DE	Discovery agent

DM3SQBH	ID	DM3SQBH
DM3SQBH	DN	1-(3-Chlorobenzyl)-1H-imidazole
DM3SQBH	HS	Investigative
DM3SQBH	SN	1-(3-Chlorobenzyl)-1H-imidazole; CHEMBL608437; 56643-68-6; 1-(3-Chlorobenzyl)imidazole; N-(3-chlorobenzyl)-imidazole; 1-(3-chlorobenzyl)-imidazole; SCHEMBL9661609; DARGVYVMURXBSO-UHFFFAOYSA-N; MolPort-008-647-602; BDBM50307215; ZINC35143438; AKOS003644458; MCULE-2532110476; 1-[(3-chlorophenyl)methyl]-1H-imidazole
DM3SQBH	DT	Small molecular drug
DM3SQBH	PC	12229386
DM3SQBH	MW	192.64
DM3SQBH	FM	C10H9ClN2
DM3SQBH	IC	InChI=1S/C10H9ClN2/c11-10-3-1-2-9(6-10)7-13-5-4-12-8-13/h1-6,8H,7H2
DM3SQBH	CS	C1=CC(=CC(=C1)Cl)CN2C=CN=C2
DM3SQBH	IK	DARGVYVMURXBSO-UHFFFAOYSA-N
DM3SQBH	IU	1-[(3-chlorophenyl)methyl]imidazole
DM3SQBH	DE	Discovery agent

DMFYJ5V	ID	DMFYJ5V
DMFYJ5V	DN	1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one
DMFYJ5V	HS	Investigative
DMFYJ5V	SN	CHEMBL566830; 2-(N,N-Dimethylamino)-3'-chloropropiophenone; 740079-95-2; 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one; SCHEMBL769582; BDBM50302908; AKOS009983839; 2-(N,N-Dimethylamino)-3''-chloropropiophenone
DMFYJ5V	DT	Small molecular drug
DMFYJ5V	PC	43794735
DMFYJ5V	MW	211.69
DMFYJ5V	FM	C11H14ClNO
DMFYJ5V	IC	InChI=1S/C11H14ClNO/c1-8(13(2)3)11(14)9-5-4-6-10(12)7-9/h4-8H,1-3H3
DMFYJ5V	CS	CC(C(=O)C1=CC(=CC=C1)Cl)N(C)C
DMFYJ5V	IK	UYZAXUWVJGHEFL-UHFFFAOYSA-N
DMFYJ5V	IU	1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one
DMFYJ5V	DE	Discovery agent

DMPOVUY	ID	DMPOVUY
DMPOVUY	DN	1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one
DMPOVUY	HS	Investigative
DMPOVUY	SN	2-Piperidino-3'-chloropropiophenone
DMPOVUY	PC	43227131
DMPOVUY	MW	251.75
DMPOVUY	FM	C14H18ClNO
DMPOVUY	IC	InChI=1S/C14H18ClNO/c1-11(16-8-3-2-4-9-16)14(17)12-6-5-7-13(15)10-12/h5-7,10-11H,2-4,8-9H2,1H3
DMPOVUY	CS	CC(C(=O)C1=CC(=CC=C1)Cl)N2CCCCC2
DMPOVUY	IK	LOWDJVQAZMFOLZ-UHFFFAOYSA-N
DMPOVUY	IU	1-(3-chlorophenyl)-2-piperidin-1-ylpropan-1-one
DMPOVUY	DE	Discovery agent

DMC5PI4	ID	DMC5PI4
DMC5PI4	DN	1-(3-Chloro-phenyl)-3-(4-hydroxy-decyl)-urea
DMC5PI4	HS	Investigative
DMC5PI4	SN	CHEMBL66498; 1-(3-Chloro-phenyl)-3-(4-hydroxy-decyl)-urea
DMC5PI4	DT	Small molecular drug
DMC5PI4	PC	11255879
DMC5PI4	MW	326.9
DMC5PI4	FM	C17H27ClN2O2
DMC5PI4	IC	InChI=1S/C17H27ClN2O2/c1-2-3-4-5-10-16(21)11-7-12-19-17(22)20-15-9-6-8-14(18)13-15/h6,8-9,13,16,21H,2-5,7,10-12H2,1H3,(H2,19,20,22)
DMC5PI4	CS	CCCCCCC(CCCNC(=O)NC1=CC(=CC=C1)Cl)O
DMC5PI4	IK	ZDFKGBJPFGFBQJ-UHFFFAOYSA-N
DMC5PI4	IU	1-(3-chlorophenyl)-3-(4-hydroxydecyl)urea
DMC5PI4	DE	Discovery agent

DM1VLMC	ID	DM1VLMC
DM1VLMC	DN	1-(3-Chloro-phenyl)-3-cyclohexyl-urea
DM1VLMC	HS	Investigative
DM1VLMC	SN	1-(3-chlorophenyl)-3-cyclohexylurea; CHEMBL192293; N-(3-chlorophenyl)-N'-cyclohexylurea; 72802-45-0; 1-(3-Chloro-phenyl)-3-cyclohexyl-urea; SMR000102236; AC1Q3IFF; AC1LFC0I; CBDivE_015961; MLS000105355; ARONIS24036; SCHEMBL12196175; REGID_for_CID_751320; DTXSID50353755; MolPort-001-819-362; ZINC201053; HMS2404F16; KS-000046HM; BDBM50167035; STK903181; 3-(3-chlorophenyl)-1-cyclohexylurea; AKOS002956586; MCULE-2109883694; 1-(3-chlorophenyl)-3-cyclohexyl-urea; KB-101580; ST45053223; N-(3-chlorophenyl)(cyclohexylamino)carboxamide
DM1VLMC	DT	Small molecular drug
DM1VLMC	PC	751320
DM1VLMC	MW	252.74
DM1VLMC	FM	C13H17ClN2O
DM1VLMC	IC	InChI=1S/C13H17ClN2O/c14-10-5-4-8-12(9-10)16-13(17)15-11-6-2-1-3-7-11/h4-5,8-9,11H,1-3,6-7H2,(H2,15,16,17)
DM1VLMC	CS	C1CCC(CC1)NC(=O)NC2=CC(=CC=C2)Cl
DM1VLMC	IK	WUPWWTKSYQSCFQ-UHFFFAOYSA-N
DM1VLMC	IU	1-(3-chlorophenyl)-3-cyclohexylurea
DM1VLMC	CA	CAS 72802-45-0
DM1VLMC	DE	Discovery agent

DM6LWR2	ID	DM6LWR2
DM6LWR2	DN	1-(3-chloropyridin-2-yl)-4-tosylpiperazine
DM6LWR2	HS	Investigative
DM6LWR2	SN	arylsulfonylpiperazine, 25; CHEMBL403685; SCHEMBL3217790; BDBM32553
DM6LWR2	DT	Small molecular drug
DM6LWR2	PC	44237028
DM6LWR2	MW	351.9
DM6LWR2	FM	C16H18ClN3O2S
DM6LWR2	IC	InChI=1S/C16H18ClN3O2S/c1-13-4-6-14(7-5-13)23(21,22)20-11-9-19(10-12-20)16-15(17)3-2-8-18-16/h2-8H,9-12H2,1H3
DM6LWR2	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=C(C=CC=N3)Cl
DM6LWR2	IK	DAJKQJMXMSAPCV-UHFFFAOYSA-N
DM6LWR2	IU	1-(3-chloropyridin-2-yl)-4-(4-methylphenyl)sulfonylpiperazine
DM6LWR2	DE	Discovery agent

DM8DR1B	ID	DM8DR1B
DM8DR1B	DN	1-(3-cyano-1-methyl-1H-indol-6-yl)-3-phenylurea
DM8DR1B	HS	Investigative
DM8DR1B	SN	CHEMBL333482; AC1LABSI; 1-(3-cyano-1-methyl-1H-indol-6-yl)-3-phenylurea; BDBM50133727; 1-(3-cyano-1-methylindol-6-yl)-3-phenylurea; 1-(3-Cyano-1-methyl-1H-indol-6-yl)-3-phenyl-urea
DM8DR1B	DT	Small molecular drug
DM8DR1B	PC	510913
DM8DR1B	MW	290.32
DM8DR1B	FM	C17H14N4O
DM8DR1B	IC	InChI=1S/C17H14N4O/c1-21-11-12(10-18)15-8-7-14(9-16(15)21)20-17(22)19-13-5-3-2-4-6-13/h2-9,11H,1H3,(H2,19,20,22)
DM8DR1B	CS	CN1C=C(C2=C1C=C(C=C2)NC(=O)NC3=CC=CC=C3)C#N
DM8DR1B	IK	DKHWZIZMXRFFLI-UHFFFAOYSA-N
DM8DR1B	IU	1-(3-cyano-1-methylindol-6-yl)-3-phenylurea
DM8DR1B	DE	Discovery agent

DM9KTH6	ID	DM9KTH6
DM9KTH6	DN	1-(3-cyano-2-hydroxyphenyl)-3-phenylurea
DM9KTH6	HS	Investigative
DM9KTH6	SN	CHEMBL239558; 1-(3-cyano-2-hydroxyphenyl)-3-phenylurea; SCHEMBL7488503
DM9KTH6	DT	Small molecular drug
DM9KTH6	PC	44439692
DM9KTH6	MW	253.26
DM9KTH6	FM	C14H11N3O2
DM9KTH6	IC	InChI=1S/C14H11N3O2/c15-9-10-5-4-8-12(13(10)18)17-14(19)16-11-6-2-1-3-7-11/h1-8,18H,(H2,16,17,19)
DM9KTH6	CS	C1=CC=C(C=C1)NC(=O)NC2=CC=CC(=C2O)C#N
DM9KTH6	IK	JFGPRCHQZYGZRH-UHFFFAOYSA-N
DM9KTH6	IU	1-(3-cyano-2-hydroxyphenyl)-3-phenylurea
DM9KTH6	DE	Discovery agent

DMVTCGP	ID	DMVTCGP
DMVTCGP	DN	1-(3-Cyano-phenyl)-1H-pyrazole-4-carboxylic acid
DMVTCGP	HS	Investigative
DMVTCGP	SN	CHEMBL169728; 1-(3-CYANOPHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID; 1-(3-Cyano-phenyl)-1H-pyrazole-4-carboxylic acid; SCHEMBL15579010; BDBM50098064; AKOS009563536
DMVTCGP	DT	Small molecular drug
DMVTCGP	PC	43542927
DMVTCGP	MW	213.19
DMVTCGP	FM	C11H7N3O2
DMVTCGP	IC	InChI=1S/C11H7N3O2/c12-5-8-2-1-3-10(4-8)14-7-9(6-13-14)11(15)16/h1-4,6-7H,(H,15,16)
DMVTCGP	CS	C1=CC(=CC(=C1)N2C=C(C=N2)C(=O)O)C#N
DMVTCGP	IK	FFNALGQEMPFZAF-UHFFFAOYSA-N
DMVTCGP	IU	1-(3-cyanophenyl)pyrazole-4-carboxylic acid
DMVTCGP	DE	Discovery agent

DM18DB3	ID	DM18DB3
DM18DB3	DN	1-(3-Fluorobenzyl)-1H-imidazole
DM18DB3	HS	Investigative
DM18DB3	SN	1-(3-Fluorobenzyl)-1H-imidazole; 109485-43-0; 1H-Imidazole, 1-[(3-fluorophenyl)methyl]-; CHEMBL598390; ACMC-20mcbr; 1-(3-Fluorobenzyl)imidazole; N-(3-fluorobenzyl)-imidazole; SCHEMBL9747422; CTK0D5768; DTXSID10601148; CJNXVRZKOSWWND-UHFFFAOYSA-N; BDBM50307214; ZINC41391477; AKOS009098433
DM18DB3	DT	Small molecular drug
DM18DB3	PC	19902087
DM18DB3	MW	176.19
DM18DB3	FM	C10H9FN2
DM18DB3	IC	InChI=1S/C10H9FN2/c11-10-3-1-2-9(6-10)7-13-5-4-12-8-13/h1-6,8H,7H2
DM18DB3	CS	C1=CC(=CC(=C1)F)CN2C=CN=C2
DM18DB3	IK	CJNXVRZKOSWWND-UHFFFAOYSA-N
DM18DB3	IU	1-[(3-fluorophenyl)methyl]imidazole
DM18DB3	CA	CAS 109485-43-0
DM18DB3	DE	Discovery agent

DM2SNR0	ID	DM2SNR0
DM2SNR0	DN	1-(3-Fluoro-phenyl)-piperazine
DM2SNR0	HS	Investigative
DM2SNR0	SN	1-(3-Fluorophenyl)piperazine; 3801-89-6; 1-(3-Fluoro-phenyl)-piperazine; Piperazine, 1-(3-fluorophenyl)-; 1-(3-fluorophenyl)-piperazine; CHEMBL269784; Piperazine,1-(3-fluorophenyl)-; EINECS 223-271-9; AC1Q4NBT; 3-fluorophenyl piperazine; (3-fluorophenyl)piperazine; AC1L2T0A; 4-(3-fluorophenyl)piperazine; N-(3-Fluorophenyl)piperazine; SCHEMBL315894; CTK4H9144; DTXSID40191426; MolPort-000-155-895; KIFCSMQTGWVMOD-UHFFFAOYSA-N; ZINC2529848; SBB089693; ANW-61692; 4877AB; BDBM50017455; AKOS000101159; FS-1513; KB-85106; AS-10296
DM2SNR0	DT	Small molecular drug
DM2SNR0	PC	77418
DM2SNR0	MW	180.22
DM2SNR0	FM	C10H13FN2
DM2SNR0	IC	InChI=1S/C10H13FN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2
DM2SNR0	CS	C1CN(CCN1)C2=CC(=CC=C2)F
DM2SNR0	IK	KIFCSMQTGWVMOD-UHFFFAOYSA-N
DM2SNR0	IU	1-(3-fluorophenyl)piperazine
DM2SNR0	CA	CAS 3801-89-6
DM2SNR0	DE	Discovery agent

DMWFU3T	ID	DMWFU3T
DMWFU3T	DN	1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine
DMWFU3T	HS	Investigative
DMWFU3T	SN	85386-90-9; 1-(3-fluoropyridin-2-yl)-4-methylpiperazine; CHEMBL280514; 1-Methyl-4-(3-fluoro-2-pyridinyl)piperazine; 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine; Piperazine, 1-(3-Fluoro-2-pyridinyl)-4-methyl- (9ci); SCHEMBL10964078; KZNJAAWCEFRAPW-UHFFFAOYSA-N; ZINC36237989; BDBM50026633; AKOS025286419; AM87258
DMWFU3T	DT	Small molecular drug
DMWFU3T	PC	13298530
DMWFU3T	MW	195.24
DMWFU3T	FM	C10H14FN3
DMWFU3T	IC	InChI=1S/C10H14FN3/c1-13-5-7-14(8-6-13)10-9(11)3-2-4-12-10/h2-4H,5-8H2,1H3
DMWFU3T	CS	CN1CCN(CC1)C2=C(C=CC=N2)F
DMWFU3T	IK	KZNJAAWCEFRAPW-UHFFFAOYSA-N
DMWFU3T	IU	1-(3-fluoropyridin-2-yl)-4-methylpiperazine
DMWFU3T	DE	Discovery agent

DMQHFOX	ID	DMQHFOX
DMQHFOX	DN	1-(3-Hydroxyphenyl)-4-propylpiperazine
DMQHFOX	HS	Investigative
DMQHFOX	SN	CHEMBL447809; 1-(3-Hydroxyphenyl)-4-propylpiperazine; SCHEMBL3453730; AWROKCIGUWAVRF-UHFFFAOYSA-N; 3-(4-Propyl-1-piperazinyl)phenol; BDBM50308023
DMQHFOX	DT	Small molecular drug
DMQHFOX	PC	22397846
DMQHFOX	MW	220.31
DMQHFOX	FM	C13H20N2O
DMQHFOX	IC	InChI=1S/C13H20N2O/c1-2-6-14-7-9-15(10-8-14)12-4-3-5-13(16)11-12/h3-5,11,16H,2,6-10H2,1H3
DMQHFOX	CS	CCCN1CCN(CC1)C2=CC(=CC=C2)O
DMQHFOX	IK	AWROKCIGUWAVRF-UHFFFAOYSA-N
DMQHFOX	IU	3-(4-propylpiperazin-1-yl)phenol
DMQHFOX	DE	Discovery agent

DMPEZ1V	ID	DMPEZ1V
DMPEZ1V	DN	1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPEZ1V	HS	Investigative
DMPEZ1V	SN	CHEMBL426304; 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4938442
DMPEZ1V	DT	Small molecular drug
DMPEZ1V	PC	11210506
DMPEZ1V	MW	357.23
DMPEZ1V	FM	C15H20INO
DMPEZ1V	IC	InChI=1S/C15H20INO/c1-2-6-14(17-9-3-4-10-17)15(18)12-7-5-8-13(16)11-12/h5,7-8,11,14H,2-4,6,9-10H2,1H3
DMPEZ1V	CS	CCCC(C(=O)C1=CC(=CC=C1)I)N2CCCC2
DMPEZ1V	IK	NYDUTEZMPZHSRY-UHFFFAOYSA-N
DMPEZ1V	IU	1-(3-iodophenyl)-2-pyrrolidin-1-ylpentan-1-one
DMPEZ1V	DE	Discovery agent

DM30M9H	ID	DM30M9H
DM30M9H	DN	1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione
DM30M9H	HS	Investigative
DM30M9H	SN	CHEMBL324722; 1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione; BDBM50133632; AKOS000245789; VU0238422-1; 1-(3-methoxybenzyl)-5-methylindoline-2,3-dione; 1-(3-methoxybenzyl)-5-methyl-1h-indole-2,3-dione
DM30M9H	DT	Small molecular drug
DM30M9H	PC	25798544
DM30M9H	MW	281.3
DM30M9H	FM	C17H15NO3
DM30M9H	IC	InChI=1S/C17H15NO3/c1-11-6-7-15-14(8-11)16(19)17(20)18(15)10-12-4-3-5-13(9-12)21-2/h3-9H,10H2,1-2H3
DM30M9H	CS	CC1=CC2=C(C=C1)N(C(=O)C2=O)CC3=CC(=CC=C3)OC
DM30M9H	IK	ZSPZSZMUOMBLFZ-UHFFFAOYSA-N
DM30M9H	IU	1-[(3-methoxyphenyl)methyl]-5-methylindole-2,3-dione
DM30M9H	DE	Discovery agent

DM16U5F	ID	DM16U5F
DM16U5F	DN	1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole
DM16U5F	HS	Investigative
DM16U5F	SN	1H-Imidazole, 1-(3-methoxy-2-naphthalenyl)-; 674309-81-0; CHEMBL194472; SCHEMBL4508354; BDBM8917; CTK1H7855; DTXSID70465102; Imidazole-substituted naphthalene 24; ZINC13674482; AKOS030619217; 1-(3-methoxy-2-naphthyl)-1h-imidazole
DM16U5F	DT	Small molecular drug
DM16U5F	PC	11413434
DM16U5F	MW	224.26
DM16U5F	FM	C14H12N2O
DM16U5F	IC	InChI=1S/C14H12N2O/c1-17-14-9-12-5-3-2-4-11(12)8-13(14)16-7-6-15-10-16/h2-10H,1H3
DM16U5F	CS	COC1=CC2=CC=CC=C2C=C1N3C=CN=C3
DM16U5F	IK	HDJQGQGNKJFUSV-UHFFFAOYSA-N
DM16U5F	IU	1-(3-methoxynaphthalen-2-yl)imidazole
DM16U5F	CA	CAS 674309-81-0
DM16U5F	DE	Discovery agent

DMGU7MO	ID	DMGU7MO
DMGU7MO	DN	1-(3-methoxyphenethyl)pyrrolidine
DMGU7MO	HS	Investigative
DMGU7MO	SN	CHEMBL404911; 1-(3-methoxyphenethyl)pyrrolidine; SCHEMBL10669091; JLMYWUJQHKXCOU-UHFFFAOYSA-N; 3-(2-pyrrolidin-1-ylethyl)anisole
DMGU7MO	DT	Small molecular drug
DMGU7MO	PC	18365007
DMGU7MO	MW	205.3
DMGU7MO	FM	C13H19NO
DMGU7MO	IC	InChI=1S/C13H19NO/c1-15-13-6-4-5-12(11-13)7-10-14-8-2-3-9-14/h4-6,11H,2-3,7-10H2,1H3
DMGU7MO	CS	COC1=CC=CC(=C1)CCN2CCCC2
DMGU7MO	IK	JLMYWUJQHKXCOU-UHFFFAOYSA-N
DMGU7MO	IU	1-[2-(3-methoxyphenyl)ethyl]pyrrolidine
DMGU7MO	DE	Discovery agent

DMR0ICB	ID	DMR0ICB
DMR0ICB	DN	1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone
DMR0ICB	HS	Investigative
DMR0ICB	SN	CHEMBL393079; 1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone; BDBM50212534
DMR0ICB	DT	Small molecular drug
DMR0ICB	PC	16750524
DMR0ICB	MW	290.3
DMR0ICB	FM	C15H14O4S
DMR0ICB	IC	InChI=1S/C15H14O4S/c1-19-13-7-5-6-12(10-13)15(16)11-20(17,18)14-8-3-2-4-9-14/h2-10H,11H2,1H3
DMR0ICB	CS	COC1=CC=CC(=C1)C(=O)CS(=O)(=O)C2=CC=CC=C2
DMR0ICB	IK	HHEJEAZSXBXRPO-UHFFFAOYSA-N
DMR0ICB	IU	2-(benzenesulfonyl)-1-(3-methoxyphenyl)ethanone
DMR0ICB	DE	Discovery agent

DMI15LJ	ID	DMI15LJ
DMI15LJ	DN	1-(3-Methylbutylidene)thiosemicarbazide
DMI15LJ	HS	Investigative
DMI15LJ	SN	CHEMBL467890; isobutyraldehyde-thiosemicarbazone; 1-(3-Methylbutylidene)thiosemicarbazide; AC1NYENJ; ZINC5452593; BDBM50268195; AKOS032954865
DMI15LJ	DT	Small molecular drug
DMI15LJ	PC	5828118
DMI15LJ	MW	145.23
DMI15LJ	FM	C5H11N3S
DMI15LJ	IC	InChI=1S/C5H11N3S/c1-4(2)3-7-8-5(6)9/h3-4H,1-2H3,(H3,6,8,9)/b7-3-
DMI15LJ	CS	CC(C)/C=N\\NC(=S)N
DMI15LJ	IK	ISGCVMPYARLSFM-CLTKARDFSA-N
DMI15LJ	IU	[(Z)-2-methylpropylideneamino]thiourea
DMI15LJ	DE	Discovery agent

DMB9T6F	ID	DMB9T6F
DMB9T6F	DN	1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMB9T6F	HS	Investigative
DMB9T6F	SN	CHEMBL204254; 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4939486
DMB9T6F	DT	Small molecular drug
DMB9T6F	PC	11470616
DMB9T6F	MW	245.36
DMB9T6F	FM	C16H23NO
DMB9T6F	IC	InChI=1S/C16H23NO/c1-3-7-15(17-10-4-5-11-17)16(18)14-9-6-8-13(2)12-14/h6,8-9,12,15H,3-5,7,10-11H2,1-2H3
DMB9T6F	CS	CCCC(C(=O)C1=CC=CC(=C1)C)N2CCCC2
DMB9T6F	IK	HHSYAWUBPBEDMP-UHFFFAOYSA-N
DMB9T6F	IU	1-(3-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one
DMB9T6F	DE	Discovery agent

DMYH9M0	ID	DMYH9M0
DMYH9M0	DN	1-(3-methylpyridin-2-yl)-4-tosylpiperazine
DMYH9M0	HS	Investigative
DMYH9M0	SN	arylsulfonylpiperazine, 24; CHEMBL257782
DMYH9M0	DT	Small molecular drug
DMYH9M0	PC	44237027
DMYH9M0	MW	331.4
DMYH9M0	FM	C17H21N3O2S
DMYH9M0	IC	InChI=1S/C17H21N3O2S/c1-14-5-7-16(8-6-14)23(21,22)20-12-10-19(11-13-20)17-15(2)4-3-9-18-17/h3-9H,10-13H2,1-2H3
DMYH9M0	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=C(C=CC=N3)C
DMYH9M0	IK	VJVLLYXNCKJIIY-UHFFFAOYSA-N
DMYH9M0	IU	1-(4-methylphenyl)sulfonyl-4-(3-methylpyridin-2-yl)piperazine
DMYH9M0	DE	Discovery agent

DM3RGLE	ID	DM3RGLE
DM3RGLE	DN	1-(3-Nitro-benzyl)-1H-indole-5-carboxamidine
DM3RGLE	HS	Investigative
DM3RGLE	SN	CHEMBL329730; 1-(3-Nitro-benzyl)-1H-indole-5-carboxamidine; BDBM50027293
DM3RGLE	DT	Small molecular drug
DM3RGLE	PC	44332057
DM3RGLE	MW	294.31
DM3RGLE	FM	C16H14N4O2
DM3RGLE	IC	InChI=1S/C16H14N4O2/c17-16(18)13-4-5-15-12(9-13)6-7-19(15)10-11-2-1-3-14(8-11)20(21)22/h1-9H,10H2,(H3,17,18)
DM3RGLE	CS	C1=CC(=CC(=C1)[N+](=O)[O-])CN2C=CC3=C2C=CC(=C3)C(=N)N
DM3RGLE	IK	SHTQZODGNRZEIP-UHFFFAOYSA-N
DM3RGLE	IU	1-[(3-nitrophenyl)methyl]indole-5-carboximidamide
DM3RGLE	DE	Discovery agent

DMMJC5E	ID	DMMJC5E
DMMJC5E	DN	1-(3-Nitro-phenyl)-piperazine
DMMJC5E	HS	Investigative
DMMJC5E	SN	1-(3-nitrophenyl)piperazine; 54054-85-2; 1-(3-Nitro-phenyl)-piperazine; 1-(3-nitrophenyl)-piperazine; CHEMBL267153; Piperazine, 1-(3-nitrophenyl)-; (3-nitrophenyl)piperazine; 3-nitrophenylpiperazine; AC1Q1X8X; AC1MC26R; SCHEMBL519878; Piperazine,1-(3-nitrophenyl)-; CTK4J9414; DTXSID20375060; MolPort-000-005-114; LHHZRIYUOZPKSG-UHFFFAOYSA-N; ZINC4244898; SBB055462; CN-052; BDBM50017449; ANW-49084; AKOS003587736; CS-W019388; MCULE-2930089958; BR-49879; AN-40610; KB-63925; AJ-49640; RT-006025; DB-024583; AB0025386; W6842; FT-0660276
DMMJC5E	DT	Small molecular drug
DMMJC5E	PC	2760216
DMMJC5E	MW	207.23
DMMJC5E	FM	C10H13N3O2
DMMJC5E	IC	InChI=1S/C10H13N3O2/c14-13(15)10-3-1-2-9(8-10)12-6-4-11-5-7-12/h1-3,8,11H,4-7H2
DMMJC5E	CS	C1CN(CCN1)C2=CC(=CC=C2)[N+](=O)[O-]
DMMJC5E	IK	LHHZRIYUOZPKSG-UHFFFAOYSA-N
DMMJC5E	IU	1-(3-nitrophenyl)piperazine
DMMJC5E	CA	CAS 54054-85-2
DMMJC5E	DE	Discovery agent

DM3FP6J	ID	DM3FP6J
DM3FP6J	DN	1-(3-nitropyridin-2-yl)-4-tosylpiperazine
DM3FP6J	HS	Investigative
DM3FP6J	SN	AC1PKJ5N; arylsulfonylpiperazine, 26; CHEMBL257825; BDBM32554; MolPort-005-603-659; 1-(4-methylphenyl)sulfonyl-4-(3-nitropyridin-2-yl)piperazine; ZINC24082236; AKOS034151568; MCULE-2914079043; AB00774122-01; Z31097365; 1-(4-methylbenzenesulfonyl)-4-(3-nitropyridin-2-yl)piperazine
DM3FP6J	DT	Small molecular drug
DM3FP6J	PC	9111347
DM3FP6J	MW	362.4
DM3FP6J	FM	C16H18N4O4S
DM3FP6J	IC	InChI=1S/C16H18N4O4S/c1-13-4-6-14(7-5-13)25(23,24)19-11-9-18(10-12-19)16-15(20(21)22)3-2-8-17-16/h2-8H,9-12H2,1H3
DM3FP6J	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=C(C=CC=N3)[N+](=O)[O-]
DM3FP6J	IK	JYSIWWVOXFISJK-UHFFFAOYSA-N
DM3FP6J	IU	1-(4-methylphenyl)sulfonyl-4-(3-nitropyridin-2-yl)piperazine
DM3FP6J	DE	Discovery agent

DMEMHIF	ID	DMEMHIF
DMEMHIF	DN	1-(3-Oxocyclohexylidene)thiosemicarbazide
DMEMHIF	HS	Investigative
DMEMHIF	DT	Small molecular drug
DMEMHIF	PC	91935109
DMEMHIF	MW	185.25
DMEMHIF	FM	C7H11N3OS
DMEMHIF	IC	InChI=1S/C7H11N3OS/c8-7(12)10-9-5-2-1-3-6(11)4-5/h4,9H,1-3H2,(H3,8,10,12)
DMEMHIF	CS	C1CC(=CC(=O)C1)NNC(=S)N
DMEMHIF	IK	DGPXORDYODTKDF-UHFFFAOYSA-N
DMEMHIF	IU	[(3-oxocyclohexen-1-yl)amino]thiourea
DMEMHIF	DE	Discovery agent

DMG8DLM	ID	DMG8DLM
DMG8DLM	DN	1-(3-phenoxypropyl)-4-(piperidin-1-yl)piperidine
DMG8DLM	HS	Investigative
DMG8DLM	SN	CHEMBL428756; 1-(3-phenoxypropyl)-4-(piperidin-1-yl)piperidine
DMG8DLM	DT	Small molecular drug
DMG8DLM	PC	24744901
DMG8DLM	MW	302.5
DMG8DLM	FM	C19H30N2O
DMG8DLM	IC	InChI=1S/C19H30N2O/c1-3-8-19(9-4-1)22-17-7-12-20-15-10-18(11-16-20)21-13-5-2-6-14-21/h1,3-4,8-9,18H,2,5-7,10-17H2
DMG8DLM	CS	C1CCN(CC1)C2CCN(CC2)CCCOC3=CC=CC=C3
DMG8DLM	IK	GCJKCPQHXFIKIF-UHFFFAOYSA-N
DMG8DLM	IU	1-(3-phenoxypropyl)-4-piperidin-1-ylpiperidine
DMG8DLM	DE	Discovery agent

DMFPUGV	ID	DMFPUGV
DMFPUGV	DN	1-(3-Phenylallylidene)thiosemicarbazide
DMFPUGV	HS	Investigative
DMFPUGV	SN	Cinnamaldehyde thiosemicarbazone; CHEMBL388025; 5351-70-2; 1-(3-Phenylallylidene)thiosemicarbazide; AC1NVG31; Cinnamaldehydethiosemicarbazone; 3-Phenylpropenalthiosemicarbazone; BDBM50241213; ZINC11536050; 3-phenylacrylaldehyde thiosemicarbazone; AKOS023092594; (Z)-1-((E)-3-phenylallylidene)thiosemicarbazide; AF-960/00472016; [(Z)-[(E)-3-phenylprop-2-enylidene]amino]thiourea; F3111-2831; N'-[(3-phenylprop-2-en-1-ylidene)amino]carbamimidothioic acid; (1Z,N'Z)-N'-((E)-3-phenylallylidene)carbamohydrazonothioic acid
DMFPUGV	DT	Small molecular drug
DMFPUGV	PC	5559203
DMFPUGV	MW	205.28
DMFPUGV	FM	C10H11N3S
DMFPUGV	IC	InChI=1S/C10H11N3S/c11-10(14)13-12-8-4-7-9-5-2-1-3-6-9/h1-8H,(H3,11,13,14)/b7-4+,12-8-
DMFPUGV	CS	C1=CC=C(C=C1)/C=C/C=N\\NC(=S)N
DMFPUGV	IK	SHUQFXIRXYXNOZ-JHLWKMQHSA-N
DMFPUGV	IU	[(Z)-[(E)-3-phenylprop-2-enylidene]amino]thiourea
DMFPUGV	DE	Discovery agent

DMPAWFJ	ID	DMPAWFJ
DMPAWFJ	DN	1-(3-phenylpropyl)-1H-imidazole
DMPAWFJ	HS	Investigative
DMPAWFJ	SN	1-(3-phenylpropyl)-1H-imidazole; CHEMBL380271; 1-(3-phenylpropyl)imidazole; 1H-Imidazole, 1-(3-phenylpropyl)-; SCHEMBL3160306; DDGQVFKVBFAACE-UHFFFAOYSA-N; BDBM50191796; AKOS009137296
DMPAWFJ	DT	Small molecular drug
DMPAWFJ	PC	9989980
DMPAWFJ	MW	186.25
DMPAWFJ	FM	C12H14N2
DMPAWFJ	IC	InChI=1S/C12H14N2/c1-2-5-12(6-3-1)7-4-9-14-10-8-13-11-14/h1-3,5-6,8,10-11H,4,7,9H2
DMPAWFJ	CS	C1=CC=C(C=C1)CCCN2C=CN=C2
DMPAWFJ	IK	DDGQVFKVBFAACE-UHFFFAOYSA-N
DMPAWFJ	IU	1-(3-phenylpropyl)imidazole
DMPAWFJ	CA	CAS 56643-92-6
DMPAWFJ	DE	Discovery agent

DM37RI9	ID	DM37RI9
DM37RI9	DN	1-(3-Phenyl-propyl)-3-thiazol-2-yl-thiourea
DM37RI9	HS	Investigative
DM37RI9	SN	Thiourea, N-(3-phenylpropyl)-N'-2-thiazolyl-; 149485-04-1; AC1MHDKJ; SCHEMBL6959149; CHEMBL145260; DTXSID10164283; AYXFDRTXLUHLOL-UHFFFAOYSA-N; ZINC12354016; AKOS030030954; N-(3-Phenylpropyl)-N'-(2-thiazolyl)thiourea; 1-(3-phenylpropyl)-3-thiazol-2-yl-thiourea; N-(3-Phenylpropyl)-N'-(2-thiazolyl) thiourea
DM37RI9	DT	Small molecular drug
DM37RI9	PC	3001100
DM37RI9	MW	277.4
DM37RI9	FM	C13H15N3S2
DM37RI9	IC	InChI=1S/C13H15N3S2/c17-12(16-13-15-9-10-18-13)14-8-4-7-11-5-2-1-3-6-11/h1-3,5-6,9-10H,4,7-8H2,(H2,14,15,16,17)
DM37RI9	CS	C1=CC=C(C=C1)CCCNC(=S)NC2=NC=CS2
DM37RI9	IK	AYXFDRTXLUHLOL-UHFFFAOYSA-N
DM37RI9	IU	1-(3-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea
DM37RI9	CA	CAS 149485-04-1
DM37RI9	DE	Discovery agent

DMZPJM4	ID	DMZPJM4
DMZPJM4	DN	1-(3-tritylaminopropyl)uracil
DMZPJM4	HS	Investigative
DMZPJM4	SN	CHEMBL211905; 1-(3-tritylaminopropyl)uracil; 1-[3-(tritylamino)propyl]pyrimidine-2,4-dione; SCHEMBL913253
DMZPJM4	DT	Small molecular drug
DMZPJM4	PC	11589642
DMZPJM4	MW	411.5
DMZPJM4	FM	C26H25N3O2
DMZPJM4	IC	InChI=1S/C26H25N3O2/c30-24-17-20-29(25(31)28-24)19-10-18-27-26(21-11-4-1-5-12-21,22-13-6-2-7-14-22)23-15-8-3-9-16-23/h1-9,11-17,20,27H,10,18-19H2,(H,28,30,31)
DMZPJM4	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)NCCCN4C=CC(=O)NC4=O
DMZPJM4	IK	FFJOPHQHIVRWNN-UHFFFAOYSA-N
DMZPJM4	IU	1-[3-(tritylamino)propyl]pyrimidine-2,4-dione
DMZPJM4	DE	Discovery agent

DMUDVRM	ID	DMUDVRM
DMUDVRM	DN	1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine
DMUDVRM	HS	Investigative
DMUDVRM	SN	CHEMBL210318; 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine; MolPort-009-381-113; ZINC12523427; BDBM50184798; AKOS033005282; MCULE-2217757517; Z104379906; 1-phenyl-4-{[4-(1H-pyrazol-1-yl)phenyl]methyl}piperazine
DMUDVRM	DT	Small molecular drug
DMUDVRM	PC	25333445
DMUDVRM	MW	318.4
DMUDVRM	FM	C20H22N4
DMUDVRM	IC	InChI=1S/C20H22N4/c1-2-5-19(6-3-1)23-15-13-22(14-16-23)17-18-7-9-20(10-8-18)24-12-4-11-21-24/h1-12H,13-17H2
DMUDVRM	CS	C1CN(CCN1CC2=CC=C(C=C2)N3C=CC=N3)C4=CC=CC=C4
DMUDVRM	IK	PKQSDHHTBMYENT-UHFFFAOYSA-N
DMUDVRM	IU	1-phenyl-4-[(4-pyrazol-1-ylphenyl)methyl]piperazine
DMUDVRM	DE	Discovery agent

DMYIK9W	ID	DMYIK9W
DMYIK9W	DN	1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea
DMYIK9W	HS	Investigative
DMYIK9W	SN	CHEMBL561382; 1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea; SCHEMBL4256144; HTAZKQMMJVVVSK-UHFFFAOYSA-N; BDBM50296222
DMYIK9W	DT	Small molecular drug
DMYIK9W	PC	25014697
DMYIK9W	MW	355.4
DMYIK9W	FM	C20H25N3O3
DMYIK9W	IC	InChI=1S/C20H25N3O3/c24-20(21-17-5-2-1-3-6-17)22-18-7-9-19(10-8-18)26-14-4-11-23-12-15-25-16-13-23/h1-3,5-10H,4,11-16H2,(H2,21,22,24)
DMYIK9W	CS	C1COCCN1CCCOC2=CC=C(C=C2)NC(=O)NC3=CC=CC=C3
DMYIK9W	IK	HTAZKQMMJVVVSK-UHFFFAOYSA-N
DMYIK9W	IU	1-[4-(3-morpholin-4-ylpropoxy)phenyl]-3-phenylurea
DMYIK9W	DE	Discovery agent

DMM18AQ	ID	DMM18AQ
DMM18AQ	DN	1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one
DMM18AQ	HS	Investigative
DMM18AQ	SN	CHEMBL394080; 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one; BDBM50216042; 1,3-Dihydro-1-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-2H-indole-2-one
DMM18AQ	DT	Small molecular drug
DMM18AQ	PC	10667433
DMM18AQ	MW	379.5
DMM18AQ	FM	C23H29N3O2
DMM18AQ	IC	InChI=1S/C23H29N3O2/c1-28-22-11-5-4-10-21(22)25-16-14-24(15-17-25)12-6-7-13-26-20-9-3-2-8-19(20)18-23(26)27/h2-5,8-11H,6-7,12-18H2,1H3
DMM18AQ	CS	COC1=CC=CC=C1N2CCN(CC2)CCCCN3C(=O)CC4=CC=CC=C43
DMM18AQ	IK	VJMHUOSOEAGNQW-UHFFFAOYSA-N
DMM18AQ	IU	1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-3H-indol-2-one
DMM18AQ	DE	Discovery agent

DMT3H0K	ID	DMT3H0K
DMT3H0K	DN	1-(4-(benzyloxy)phenethyl)pyrrolidine
DMT3H0K	HS	Investigative
DMT3H0K	SN	CHEMBL271661
DMT3H0K	DT	Small molecular drug
DMT3H0K	PC	44455916
DMT3H0K	MW	281.4
DMT3H0K	FM	C19H23NO
DMT3H0K	IC	InChI=1S/C19H23NO/c1-2-6-18(7-3-1)16-21-19-10-8-17(9-11-19)12-15-20-13-4-5-14-20/h1-3,6-11H,4-5,12-16H2
DMT3H0K	CS	C1CCN(C1)CCC2=CC=C(C=C2)OCC3=CC=CC=C3
DMT3H0K	IK	VREWPTOWOFJSKF-UHFFFAOYSA-N
DMT3H0K	IU	1-[2-(4-phenylmethoxyphenyl)ethyl]pyrrolidine
DMT3H0K	DE	Discovery agent

DM7FWK8	ID	DM7FWK8
DM7FWK8	DN	1-(4-(benzyloxy)phenyl)-3-hydroxyurea
DM7FWK8	HS	Investigative
DM7FWK8	SN	CHEMBL259768
DM7FWK8	DT	Small molecular drug
DM7FWK8	PC	11637459
DM7FWK8	MW	258.269
DM7FWK8	FM	C14H14N2O3
DM7FWK8	IC	InChI=1S/C14H14N2O3/c17-14(16-18)15-12-6-8-13(9-7-12)19-10-11-4-2-1-3-5-11/h1-9,18H,10H2,(H2,15,16,17)
DM7FWK8	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)NO
DM7FWK8	IK	PQXBDBGXKAZUEX-UHFFFAOYSA-N
DM7FWK8	IU	1-hydroxy-3-(4-phenylmethoxyphenyl)urea
DM7FWK8	DE	Discovery agent

DMT81N3	ID	DMT81N3
DMT81N3	DN	1-(4-(benzyloxy)phenyl)propan-2-amine
DMT81N3	HS	Investigative
DMT81N3	SN	4-Benzyloxyamphetamine; 1-(4-phenylmethoxyphenyl)propan-2-amine; CHEMBL456013; 7176-39-8; ZDZASCUBDMUTSR-UHFFFAOYSA-N; p-benzyloxyamphetamine; 1-(4-(benzyloxy)phenyl)propan-2-amine; Phenethylamine, p-(benzyloxy)-alpha-methyl-; alpha-Methyl-4-(phenylmethoxy)benzeneethanamine; AC1L34WV; Benzeneethanamine, alpha-methyl-4-(phenylmethoxy)-; SCHEMBL2750286; AC1Q56Y9; CTK2H7369; BDBM50276775; AKOS022489255; AKOS000152896; 1-(4-phenylmethoxyphenyl)-2-propanamine; 1-Methyl-2-(4-benzyloxyphenyl)ethanamine
DMT81N3	DT	Small molecular drug
DMT81N3	PC	134616
DMT81N3	MW	241.33
DMT81N3	FM	C16H19NO
DMT81N3	IC	InChI=1S/C16H19NO/c1-13(17)11-14-7-9-16(10-8-14)18-12-15-5-3-2-4-6-15/h2-10,13H,11-12,17H2,1H3
DMT81N3	CS	CC(CC1=CC=C(C=C1)OCC2=CC=CC=C2)N
DMT81N3	IK	ZDZASCUBDMUTSR-UHFFFAOYSA-N
DMT81N3	IU	1-(4-phenylmethoxyphenyl)propan-2-amine
DMT81N3	CA	CAS 7176-39-8
DMT81N3	DE	Discovery agent

DMLODAM	ID	DMLODAM
DMLODAM	DN	1-(4-(Hexyloxy)phenyl)-3-morpholinopropan-1-one
DMLODAM	HS	Investigative
DMLODAM	SN	CHEMBL561245; 1-(4-(Hexyloxy)phenyl)-3-morpholinopropan-1-one
DMLODAM	DT	Small molecular drug
DMLODAM	PC	24843916
DMLODAM	MW	319.4
DMLODAM	FM	C19H29NO3
DMLODAM	IC	InChI=1S/C19H29NO3/c1-2-3-4-5-14-23-18-8-6-17(7-9-18)19(21)10-11-20-12-15-22-16-13-20/h6-9H,2-5,10-16H2,1H3
DMLODAM	CS	CCCCCCOC1=CC=C(C=C1)C(=O)CCN2CCOCC2
DMLODAM	IK	VJZCZCUEZMGVCL-UHFFFAOYSA-N
DMLODAM	IU	1-(4-hexoxyphenyl)-3-morpholin-4-ylpropan-1-one
DMLODAM	DE	Discovery agent

DMCE7G0	ID	DMCE7G0
DMCE7G0	DN	1-(4-(methylsulfonyl)phenyl)-1H-indole
DMCE7G0	HS	Investigative
DMCE7G0	SN	CHEMBL1240964; 1-(4-(methylsulfonyl)phenyl)-1H-indole; 1-[4-(Methylsulfonyl)phenyl]-1H-indole; ZINC64475267
DMCE7G0	DT	Small molecular drug
DMCE7G0	PC	11958319
DMCE7G0	MW	271.3
DMCE7G0	FM	C15H13NO2S
DMCE7G0	IC	InChI=1S/C15H13NO2S/c1-19(17,18)14-8-6-13(7-9-14)16-11-10-12-4-2-3-5-15(12)16/h2-11H,1H3
DMCE7G0	CS	CS(=O)(=O)C1=CC=C(C=C1)N2C=CC3=CC=CC=C32
DMCE7G0	IK	XRGCFRFZQVGLLT-UHFFFAOYSA-N
DMCE7G0	IU	1-(4-methylsulfonylphenyl)indole
DMCE7G0	DE	Discovery agent

DMYFBRQ	ID	DMYFBRQ
DMYFBRQ	DN	1-(4-(methylsulfonyl)phenyl)-1H-pyrrole
DMYFBRQ	HS	Investigative
DMYFBRQ	SN	CHEMBL1240963; 1-(4-(methylsulfonyl)phenyl)-1H-pyrrole; 1-[4-(Methylsulfonyl)phenyl]-1H-pyrrole; ZINC35120168; BDBM50326521; AKOS008961779; 1-(4-methanesulfonylphenyl)-1H-pyrrole
DMYFBRQ	DT	Small molecular drug
DMYFBRQ	PC	22316981
DMYFBRQ	MW	221.28
DMYFBRQ	FM	C11H11NO2S
DMYFBRQ	IC	InChI=1S/C11H11NO2S/c1-15(13,14)11-6-4-10(5-7-11)12-8-2-3-9-12/h2-9H,1H3
DMYFBRQ	CS	CS(=O)(=O)C1=CC=C(C=C1)N2C=CC=C2
DMYFBRQ	IK	NIVLUABJSRHBFE-UHFFFAOYSA-N
DMYFBRQ	IU	1-(4-methylsulfonylphenyl)pyrrole
DMYFBRQ	DE	Discovery agent

DMH7RY0	ID	DMH7RY0
DMH7RY0	DN	1-(4-(methylsulfonyl)phenyl)-3-phenylurea
DMH7RY0	HS	Investigative
DMH7RY0	SN	CHEMBL252433; 1-(4-(methylsulfonyl)phenyl)-3-phenylurea; 1-[4-(methylsulfonyl)phenyl]-3-phenylurea; SCHEMBL9913187; MolPort-019-692-584; STL012316; ZINC29038894; BDBM50233182; AKOS005673001
DMH7RY0	DT	Small molecular drug
DMH7RY0	PC	44447099
DMH7RY0	MW	290.34
DMH7RY0	FM	C14H14N2O3S
DMH7RY0	IC	InChI=1S/C14H14N2O3S/c1-20(18,19)13-9-7-12(8-10-13)16-14(17)15-11-5-3-2-4-6-11/h2-10H,1H3,(H2,15,16,17)
DMH7RY0	CS	CS(=O)(=O)C1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2
DMH7RY0	IK	BNCVKEKVEUVIPN-UHFFFAOYSA-N
DMH7RY0	IU	1-(4-methylsulfonylphenyl)-3-phenylurea
DMH7RY0	DE	Discovery agent

DMMSQLC	ID	DMMSQLC
DMMSQLC	DN	1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea
DMMSQLC	HS	Investigative
DMMSQLC	SN	CHEMBL253402; 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea; SCHEMBL12793734
DMMSQLC	DT	Small molecular drug
DMMSQLC	PC	44447102
DMMSQLC	MW	304.4
DMMSQLC	FM	C15H16N2O3S
DMMSQLC	IC	InChI=1S/C15H16N2O3S/c1-11-3-5-12(6-4-11)16-15(18)17-13-7-9-14(10-8-13)21(2,19)20/h3-10H,1-2H3,(H2,16,17,18)
DMMSQLC	CS	CC1=CC=C(C=C1)NC(=O)NC2=CC=C(C=C2)S(=O)(=O)C
DMMSQLC	IK	ZWDYDUJTBVZZLR-UHFFFAOYSA-N
DMMSQLC	IU	1-(4-methylphenyl)-3-(4-methylsulfonylphenyl)urea
DMMSQLC	DE	Discovery agent

DM170BV	ID	DM170BV
DM170BV	DN	1-(4-acetyloxazol-2-yl)-7-phenylheptan-1-one
DM170BV	HS	Investigative
DM170BV	SN	CHEMBL461543; 1-(4-acetyloxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162586
DM170BV	DT	Small molecular drug
DM170BV	PC	44554446
DM170BV	MW	299.4
DM170BV	FM	C18H21NO3
DM170BV	IC	InChI=1S/C18H21NO3/c1-14(20)16-13-22-18(19-16)17(21)12-8-3-2-5-9-15-10-6-4-7-11-15/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DM170BV	CS	CC(=O)C1=COC(=N1)C(=O)CCCCCCC2=CC=CC=C2
DM170BV	IK	YLVGVXYZOJMUNJ-UHFFFAOYSA-N
DM170BV	IU	1-(4-acetyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DM170BV	DE	Discovery agent

DMOZAM6	ID	DMOZAM6
DMOZAM6	DN	1-(4-Aminobenzyl)-1H-imidazole
DMOZAM6	HS	Investigative
DMOZAM6	SN	56643-85-7; 4-Imidazol-1-ylmethylphenylamine; 4-(1H-imidazol-1-ylmethyl)aniline; 4-((1H-imidazol-1-yl)methyl)aniline; 4-(imidazol-1-ylmethyl)aniline; 4-[(1-Imidazolyl)methyl]aniline; 4-Imidazol-1-ylmethyl-phenylamine; 4-[(1H-Imidazol-1-yl)methyl]aniline; 1-(4-Aminobenzyl)imidazole; CHEMBL598389; 4-(imidazolylmethyl)phenylamine; Benzenamine, 4-(1H-imidazol-1-ylmethyl)-; 1-(4-Aminobenzyl)-1H-imidazole; BAS 06504682; AC1LOLP2; SCHEMBL77025; AC1Q520P; CTK5A5496; DTXSID40361425; 4-(imidazol-1-yl)methyl-aniline
DMOZAM6	DT	Small molecular drug
DMOZAM6	PC	1265319
DMOZAM6	MW	173.21
DMOZAM6	FM	C10H11N3
DMOZAM6	IC	InChI=1S/C10H11N3/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7,11H2
DMOZAM6	CS	C1=CC(=CC=C1CN2C=CN=C2)N
DMOZAM6	IK	DGHAOTHIDTUSJY-UHFFFAOYSA-N
DMOZAM6	IU	4-(imidazol-1-ylmethyl)aniline
DMOZAM6	CA	CAS 56643-85-7
DMOZAM6	DE	Discovery agent

DMMYT4W	ID	DMMYT4W
DMMYT4W	DN	1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone
DMMYT4W	HS	Investigative
DMMYT4W	SN	1-(4-aminophenyl)-2-(1h-imidazol-1-yl)ethanone; CHEMBL162431; AC1Q5E94; AC1L1F89; SCHEMBL9663730; BDBM50322067; AKOS022646799; 73932-42-0; 1-(4-aminophenyl)-2-imidazol-1-ylethanone; 1-(4-Amino-phenyl)-2-imidazol-1-yl-ethanone; alpha-(1H-Imidazole-1-yl)-4'-aminoacetophenone; Ethanone, 1-(4-aminophenyl)-2-(1H-imidazol-1-yl)-
DMMYT4W	DT	Small molecular drug
DMMYT4W	PC	53602
DMMYT4W	MW	201.22
DMMYT4W	FM	C11H11N3O
DMMYT4W	IC	InChI=1S/C11H11N3O/c12-10-3-1-9(2-4-10)11(15)7-14-6-5-13-8-14/h1-6,8H,7,12H2
DMMYT4W	CS	C1=CC(=CC=C1C(=O)CN2C=CN=C2)N
DMMYT4W	IK	QRMNVYHFJCGDDI-UHFFFAOYSA-N
DMMYT4W	IU	1-(4-aminophenyl)-2-imidazol-1-ylethanone
DMMYT4W	DE	Discovery agent

DMY7TDZ	ID	DMY7TDZ
DMY7TDZ	DN	1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMY7TDZ	HS	Investigative
DMY7TDZ	SN	CHEMBL555491; 1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMY7TDZ	DT	Small molecular drug
DMY7TDZ	PC	45268750
DMY7TDZ	MW	246.35
DMY7TDZ	FM	C15H22N2O
DMY7TDZ	IC	InChI=1S/C15H22N2O/c1-2-5-14(17-10-3-4-11-17)15(18)12-6-8-13(16)9-7-12/h6-9,14H,2-5,10-11,16H2,1H3
DMY7TDZ	CS	CCCC(C(=O)C1=CC=C(C=C1)N)N2CCCC2
DMY7TDZ	IK	DUNXFOYJTLLKNQ-UHFFFAOYSA-N
DMY7TDZ	IU	1-(4-aminophenyl)-2-pyrrolidin-1-ylpentan-1-one
DMY7TDZ	DE	Discovery agent

DM4G0NH	ID	DM4G0NH
DM4G0NH	DN	1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea
DM4G0NH	HS	Investigative
DM4G0NH	SN	CHEMBL497689; 4-Amino-N-[(2-Sulfanylethyl)carbamoyl]benzenesulfonamide; 1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea; BDBM50272611; DB08484; 1-(4-aminobenzenesulfonyl)-3-(2-sulfanylethyl)urea
DM4G0NH	DT	Small molecular drug
DM4G0NH	PC	24856357
DM4G0NH	MW	275.4
DM4G0NH	FM	C9H13N3O3S2
DM4G0NH	IC	InChI=1S/C9H13N3O3S2/c10-7-1-3-8(4-2-7)17(14,15)12-9(13)11-5-6-16/h1-4,16H,5-6,10H2,(H2,11,12,13)
DM4G0NH	CS	C1=CC(=CC=C1N)S(=O)(=O)NC(=O)NCCS
DM4G0NH	IK	LHVDNDIAMJOEKH-UHFFFAOYSA-N
DM4G0NH	IU	1-(4-aminophenyl)sulfonyl-3-(2-sulfanylethyl)urea
DM4G0NH	DE	Discovery agent

DMWA6G1	ID	DMWA6G1
DMWA6G1	DN	1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene
DMWA6G1	HS	Investigative
DMWA6G1	SN	CHEMBL265444
DMWA6G1	DT	Small molecular drug
DMWA6G1	PC	44452471
DMWA6G1	MW	258.3
DMWA6G1	FM	C13H10N2O2S
DMWA6G1	IC	InChI=1S/C13H10N2O2S/c14-18(16,17)13-8-5-11(6-9-13)4-7-12-3-1-2-10-15-12/h1-3,5-6,8-10H,(H2,14,16,17)
DMWA6G1	CS	C1=CC=NC(=C1)C#CC2=CC=C(C=C2)S(=O)(=O)N
DMWA6G1	IK	GZRBQSAJFPOMOT-UHFFFAOYSA-N
DMWA6G1	IU	4-(2-pyridin-2-ylethynyl)benzenesulfonamide
DMWA6G1	DE	Discovery agent

DMP93E2	ID	DMP93E2
DMP93E2	DN	1-(4-aminosulfonylphenyl)-2-(4-pyridyl)acetylene
DMP93E2	HS	Investigative
DMP93E2	SN	CHEMBL406989
DMP93E2	DT	Small molecular drug
DMP93E2	PC	44452472
DMP93E2	MW	258.3
DMP93E2	FM	C13H10N2O2S
DMP93E2	IC	InChI=1S/C13H10N2O2S/c14-18(16,17)13-5-3-11(4-6-13)1-2-12-7-9-15-10-8-12/h3-10H,(H2,14,16,17)
DMP93E2	CS	C1=CC(=CC=C1C#CC2=CC=NC=C2)S(=O)(=O)N
DMP93E2	IK	WAURLAKEIUZSMJ-UHFFFAOYSA-N
DMP93E2	IU	4-(2-pyridin-4-ylethynyl)benzenesulfonamide
DMP93E2	DE	Discovery agent

DMXV9S7	ID	DMXV9S7
DMXV9S7	DN	1-(4-Benzylsulfanyl-phenyl)-propylamine
DMXV9S7	HS	Investigative
DMXV9S7	SN	CHEMBL1079057; 1-(4-Benzylsulfanyl-phenyl)-propylamine; BDBM50310833
DMXV9S7	DT	Small molecular drug
DMXV9S7	PC	46882993
DMXV9S7	MW	257.399
DMXV9S7	FM	C16H19NS
DMXV9S7	IC	InChI=1S/C16H19NS/c1-13(17)11-14-7-9-16(10-8-14)18-12-15-5-3-2-4-6-15/h2-10,13H,11-12,17H2,1H3
DMXV9S7	CS	CC(CC1=CC=C(C=C1)SCC2=CC=CC=C2)N
DMXV9S7	IK	TXLRFCSLKMDOTM-UHFFFAOYSA-N
DMXV9S7	IU	1-(4-benzylsulfanylphenyl)propan-2-amine
DMXV9S7	DE	Discovery agent

DMMLCSG	ID	DMMLCSG
DMMLCSG	DN	1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane
DMMLCSG	HS	Investigative
DMMLCSG	SN	CHEMBL509461; 1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane
DMMLCSG	DT	Small molecular drug
DMMLCSG	PC	44567544
DMMLCSG	MW	250.08
DMMLCSG	FM	C9H10BrF2N
DMMLCSG	IC	InChI=1S/C9H10BrF2N/c1-5(13)2-6-3-9(12)7(10)4-8(6)11/h3-5H,2,13H2,1H3
DMMLCSG	CS	CC(CC1=CC(=C(C=C1F)Br)F)N
DMMLCSG	IK	TWIJKLXSGANTJL-UHFFFAOYSA-N
DMMLCSG	IU	1-(4-bromo-2,5-difluorophenyl)propan-2-amine
DMMLCSG	DE	Discovery agent

DMCH6R1	ID	DMCH6R1
DMCH6R1	DN	1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine
DMCH6R1	HS	Investigative
DMCH6R1	SN	CHEMBL348140; AC1NHEA9; 1-(2,5-dimethoxy-4-bromophenyl)piperazine; Oprea1_700068; BDBM50226218; AKOS003587698; 100939-87-5
DMCH6R1	DT	Small molecular drug
DMCH6R1	PC	4738744
DMCH6R1	MW	301.18
DMCH6R1	FM	C12H17BrN2O2
DMCH6R1	IC	InChI=1S/C12H17BrN2O2/c1-16-11-8-10(12(17-2)7-9(11)13)15-5-3-14-4-6-15/h7-8,14H,3-6H2,1-2H3
DMCH6R1	CS	COC1=CC(=C(C=C1N2CCNCC2)OC)Br
DMCH6R1	IK	JLAQUWGWRNMYGA-UHFFFAOYSA-N
DMCH6R1	IU	1-(4-bromo-2,5-dimethoxyphenyl)piperazine
DMCH6R1	DE	Discovery agent

DM2C7U0	ID	DM2C7U0
DM2C7U0	DN	1-(4-Bromobenzyl)-1H-imidazole
DM2C7U0	HS	Investigative
DM2C7U0	SN	1-(4-bromobenzyl)-1H-imidazole; 72459-46-2; 1-(4-bromobenzyl)imidazole; 1H-Imidazole, 1-[(4-bromophenyl)methyl]-; CHEMBL211207; 1-[(4-bromophenyl)methyl]imidazole; 1H-Imidazole,1-[(4-bromophenyl)methyl]-; [(4-bromophenyl)methyl]imidazole; AC1MGP7Q; SCHEMBL707075; 1-(4Bromobenzyl)-1H-imidazole; KS-00000LSK; CTK5D6137; DTXSID20388130; MZJSYLIOMLCYIS-UHFFFAOYSA-N; MolPort-000-143-261; 1-(4bromo-benzyl)-1H-imidazole; HMS1603K13; CS-D0078; ZINC4810192; STK951803; ANW-63041; CB-660; SBB098736; BDBM50188088; AKOS002272497; RP05746
DM2C7U0	DT	Small molecular drug
DM2C7U0	PC	2989557
DM2C7U0	MW	237.1
DM2C7U0	FM	C10H9BrN2
DM2C7U0	IC	InChI=1S/C10H9BrN2/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7H2
DM2C7U0	CS	C1=CC(=CC=C1CN2C=CN=C2)Br
DM2C7U0	IK	MZJSYLIOMLCYIS-UHFFFAOYSA-N
DM2C7U0	IU	1-[(4-bromophenyl)methyl]imidazole
DM2C7U0	CA	CAS 72459-46-2
DM2C7U0	DE	Discovery agent

DMTPD4R	ID	DMTPD4R
DMTPD4R	DN	1-(4-Bromo-benzyl)-3-quinazolin-8-yl-urea
DMTPD4R	HS	Investigative
DMTPD4R	SN	quinazoline deriv., 20b; CHEMBL175831; BDBM20420
DMTPD4R	DT	Small molecular drug
DMTPD4R	PC	11302766
DMTPD4R	MW	357.2
DMTPD4R	FM	C16H13BrN4O
DMTPD4R	IC	InChI=1S/C16H13BrN4O/c17-13-6-4-11(5-7-13)8-19-16(22)21-14-3-1-2-12-9-18-10-20-15(12)14/h1-7,9-10H,8H2,(H2,19,21,22)
DMTPD4R	CS	C1=CC2=CN=CN=C2C(=C1)NC(=O)NCC3=CC=C(C=C3)Br
DMTPD4R	IK	HUPXBWYDCNIXNH-UHFFFAOYSA-N
DMTPD4R	IU	1-[(4-bromophenyl)methyl]-3-quinazolin-8-ylurea
DMTPD4R	DE	Discovery agent

DMCW8RT	ID	DMCW8RT
DMCW8RT	DN	1-(4-Bromobenzyl)-5-phenyl-1H-imidazole
DMCW8RT	HS	Investigative
DMCW8RT	SN	CHEMBL597173; 1-(4-Bromobenzyl)-5-phenyl-1H-imidazole; SCHEMBL3822956
DMCW8RT	DT	Small molecular drug
DMCW8RT	PC	45103810
DMCW8RT	MW	313.19
DMCW8RT	FM	C16H13BrN2
DMCW8RT	IC	InChI=1S/C16H13BrN2/c17-15-8-6-13(7-9-15)11-19-12-18-10-16(19)14-4-2-1-3-5-14/h1-10,12H,11H2
DMCW8RT	CS	C1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)Br
DMCW8RT	IK	LHMVBZUXJAMAAP-UHFFFAOYSA-N
DMCW8RT	IU	1-[(4-bromophenyl)methyl]-5-phenylimidazole
DMCW8RT	DE	Discovery agent

DMUMNYZ	ID	DMUMNYZ
DMUMNYZ	DN	1-(4-bromooxazol-2-yl)-7-phenylheptan-1-one
DMUMNYZ	HS	Investigative
DMUMNYZ	SN	CHEMBL448688; 1-(4-bromooxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162450
DMUMNYZ	DT	Small molecular drug
DMUMNYZ	PC	44554272
DMUMNYZ	MW	336.22
DMUMNYZ	FM	C16H18BrNO2
DMUMNYZ	IC	InChI=1S/C16H18BrNO2/c17-15-12-20-16(18-15)14(19)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMUMNYZ	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)Br
DMUMNYZ	IK	PCSNCSLGTDBRDM-UHFFFAOYSA-N
DMUMNYZ	IU	1-(4-bromo-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMUMNYZ	DE	Discovery agent

DME8B15	ID	DME8B15
DME8B15	DN	1-(4-bromophenethyl)-1H-imidazole
DME8B15	HS	Investigative
DME8B15	SN	CHEMBL215320; 1-(4-bromophenethyl)-1H-imidazole; SCHEMBL6986190
DME8B15	DT	Small molecular drug
DME8B15	PC	19371551
DME8B15	MW	251.12
DME8B15	FM	C11H11BrN2
DME8B15	IC	InChI=1S/C11H11BrN2/c12-11-3-1-10(2-4-11)5-7-14-8-6-13-9-14/h1-4,6,8-9H,5,7H2
DME8B15	CS	C1=CC(=CC=C1CCN2C=CN=C2)Br
DME8B15	IK	PAYXPBIBNFYADE-UHFFFAOYSA-N
DME8B15	IU	1-[2-(4-bromophenyl)ethyl]imidazole
DME8B15	DE	Discovery agent

DMW6YDK	ID	DMW6YDK
DMW6YDK	DN	1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one
DMW6YDK	HS	Investigative
DMW6YDK	SN	CHEMBL566001; SCHEMBL770168; 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one; BDBM50302910; AKOS022330096
DMW6YDK	DT	Small molecular drug
DMW6YDK	PC	44542509
DMW6YDK	MW	284.19
DMW6YDK	FM	C13H18BrNO
DMW6YDK	IC	InChI=1S/C13H18BrNO/c1-9(15-13(2,3)4)12(16)10-5-7-11(14)8-6-10/h5-9,15H,1-4H3
DMW6YDK	CS	CC(C(=O)C1=CC=C(C=C1)Br)NC(C)(C)C
DMW6YDK	IK	QYLKSFXBRALDIS-UHFFFAOYSA-N
DMW6YDK	IU	1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one
DMW6YDK	DE	Discovery agent

DMPLEC0	ID	DMPLEC0
DMPLEC0	DN	1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPLEC0	HS	Investigative
DMPLEC0	SN	CHEMBL202420; 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one; 4-Bromo-alpha-pvp; SCHEMBL4937387; BDBM50182578; 4'-Bromo-alpha-pyrrolidinopentiophenone; 2-(Pyrrolidin-1-yl)-1-(4-bromophenyl)pentan-1-one; 1-Pentanone, 1-(4-bromophenyl)-2-(1-pyrrolidinyl)-; 1-(4-bromophenyl)-2-(pyrrolidin-1-yl)pentan-1-one
DMPLEC0	DT	Small molecular drug
DMPLEC0	PC	11220599
DMPLEC0	MW	310.23
DMPLEC0	FM	C15H20BrNO
DMPLEC0	IC	InChI=1S/C15H20BrNO/c1-2-5-14(17-10-3-4-11-17)15(18)12-6-8-13(16)9-7-12/h6-9,14H,2-5,10-11H2,1H3
DMPLEC0	CS	CCCC(C(=O)C1=CC=C(C=C1)Br)N2CCCC2
DMPLEC0	IK	RAHKQMUBMIJUFG-UHFFFAOYSA-N
DMPLEC0	IU	1-(4-bromophenyl)-2-pyrrolidin-1-ylpentan-1-one
DMPLEC0	CA	CAS 850352-59-9
DMPLEC0	DE	Discovery agent

DMEUHDL	ID	DMEUHDL
DMEUHDL	DN	1-(4-bromophenyl)-3-hydroxyurea
DMEUHDL	HS	Investigative
DMEUHDL	SN	1-(4-bromophenyl)-3-hydroxyurea; CHEMBL259767; 89677-50-9; AC1N5XPQ; AC1Q7DJ1; SCHEMBL5443582; QFELVVGTIKGYJL-UHFFFAOYSA-N; ZINC396739; N-(4-bromophenyl)-N'-hydroxyurea; BDBM50377111; AKOS024335516
DMEUHDL	DT	Small molecular drug
DMEUHDL	PC	4251126
DMEUHDL	MW	231.05
DMEUHDL	FM	C7H7BrN2O2
DMEUHDL	IC	InChI=1S/C7H7BrN2O2/c8-5-1-3-6(4-2-5)9-7(11)10-12/h1-4,12H,(H2,9,10,11)
DMEUHDL	CS	C1=CC(=CC=C1NC(=O)NO)Br
DMEUHDL	IK	QFELVVGTIKGYJL-UHFFFAOYSA-N
DMEUHDL	IU	1-(4-bromophenyl)-3-hydroxyurea
DMEUHDL	DE	Discovery agent

DMOEGZV	ID	DMOEGZV
DMOEGZV	DN	1-(4-Butoxy-phenyl)-1H-imidazole
DMOEGZV	HS	Investigative
DMOEGZV	SN	CHEMBL112532; 1-(4-Butoxy-phenyl)-1H-imidazole; SCHEMBL14129854; 1-(4-Butoxyphenyl)-1H-imidazole; ZINC13530153
DMOEGZV	DT	Small molecular drug
DMOEGZV	PC	11321889
DMOEGZV	MW	216.28
DMOEGZV	FM	C13H16N2O
DMOEGZV	IC	InChI=1S/C13H16N2O/c1-2-3-10-16-13-6-4-12(5-7-13)15-9-8-14-11-15/h4-9,11H,2-3,10H2,1H3
DMOEGZV	CS	CCCCOC1=CC=C(C=C1)N2C=CN=C2
DMOEGZV	IK	QJWFZZZHWWOBNM-UHFFFAOYSA-N
DMOEGZV	IU	1-(4-butoxyphenyl)imidazole
DMOEGZV	DE	Discovery agent

DM7GIZL	ID	DM7GIZL
DM7GIZL	DN	1-(4-butoxyphenyl)propan-2-amine
DM7GIZL	HS	Investigative
DM7GIZL	SN	CHEMBL456012; 1-(4-butoxyphenyl)propan-2-amine; BDBM50276774
DM7GIZL	DT	Small molecular drug
DM7GIZL	PC	21341306
DM7GIZL	MW	207.31
DM7GIZL	FM	C13H21NO
DM7GIZL	IC	InChI=1S/C13H21NO/c1-3-4-9-15-13-7-5-12(6-8-13)10-11(2)14/h5-8,11H,3-4,9-10,14H2,1-2H3
DM7GIZL	CS	CCCCOC1=CC=C(C=C1)CC(C)N
DM7GIZL	IK	XYGSKZYABPNAKO-UHFFFAOYSA-N
DM7GIZL	IU	1-(4-butoxyphenyl)propan-2-amine
DM7GIZL	DE	Discovery agent

DMIGDCK	ID	DMIGDCK
DMIGDCK	DN	1-(4-Butyl-thiazol-2-yl)-3-phenethyl-thiourea
DMIGDCK	HS	Investigative
DMIGDCK	SN	PETT Analog 41; AC1MHDKS; BDBM1874; CHEMBL254840; ZINC13744899; 1-(4-butylthiazol-2-yl)-3-phenethyl-thiourea; 1-(4-butyl-1,3-thiazol-2-yl)-3-phenethylthiourea; N-(2-Phenethyl)-N -(2-(4-butylthiazolyl))thiourea
DMIGDCK	DT	Small molecular drug
DMIGDCK	PC	3001109
DMIGDCK	MW	319.5
DMIGDCK	FM	C16H21N3S2
DMIGDCK	IC	InChI=1S/C16H21N3S2/c1-2-3-9-14-12-21-16(18-14)19-15(20)17-11-10-13-7-5-4-6-8-13/h4-8,12H,2-3,9-11H2,1H3,(H2,17,18,19,20)
DMIGDCK	CS	CCCCC1=CSC(=N1)NC(=S)NCCC2=CC=CC=C2
DMIGDCK	IK	SXKJLZJKVYKNHV-UHFFFAOYSA-N
DMIGDCK	IU	1-(4-butyl-1,3-thiazol-2-yl)-3-(2-phenylethyl)thiourea
DMIGDCK	DE	Discovery agent

DMBR9TQ	ID	DMBR9TQ
DMBR9TQ	DN	1-(4-chlorobenzyl)-1H-imidazole
DMBR9TQ	HS	Investigative
DMBR9TQ	SN	1-(4-chlorobenzyl)-1H-imidazole; 42032-27-9; CHEMBL441367; 1-[(4-chlorophenyl)methyl]imidazole; chlorbenzyl imidazole; AC1MCUZ8; 1H-Imidazole, 1-[(4-chlorophenyl)methyl]-; 1-(p-chlorobenzyl)imidazole; 1-(4-Chlorobenzyl)imidazole; SCHEMBL570342; CTK6H0128; MolPort-001-764-407; RPLWYOLCHGTNSX-UHFFFAOYSA-N; ZINC161401; BDBM50188097; AKOS002677375; MCULE-5157261929
DMBR9TQ	DT	Small molecular drug
DMBR9TQ	PC	2779191
DMBR9TQ	MW	192.64
DMBR9TQ	FM	C10H9ClN2
DMBR9TQ	IC	InChI=1S/C10H9ClN2/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7H2
DMBR9TQ	CS	C1=CC(=CC=C1CN2C=CN=C2)Cl
DMBR9TQ	IK	RPLWYOLCHGTNSX-UHFFFAOYSA-N
DMBR9TQ	IU	1-[(4-chlorophenyl)methyl]imidazole
DMBR9TQ	DE	Discovery agent

DMOUPNT	ID	DMOUPNT
DMOUPNT	DN	1-(4-chlorobenzyl)-1H-indole-2,3-dione
DMOUPNT	HS	Investigative
DMOUPNT	SN	1-(4-Chlorobenzyl)-1H-indole-2,3-dione; 26960-66-7; 1-(4-chloro-benzyl)-1h-indole-2,3-dione; 1-(4-Chlorobenzyl)indoline-2,3-dione; NSC127077; 1-[(4-chlorophenyl)methyl]-2,3-dihydro-1H-indole-2,3-dione; 1-[(4-chlorophenyl)methyl]indole-2,3-dione; 1-[(4-chlorophenyl)methyl]benzo[d]azolidine-2,3-dione; 4-chlorobenzylisatin; NSC 127077; AC1Q3JHP; AC1Q3NUX; AC1Q3JHO; CBMicro_042181; AC1L5N5R; Isatin-based compound, 15; Cambridge id 6046772; 1-(4-chlorobenzyl)-isatin; CHEMBL376291; SCHEMBL3027106; BDBM22795; CTK4F8812; KS-00001RNX
DMOUPNT	DT	Small molecular drug
DMOUPNT	PC	277990
DMOUPNT	MW	271.7
DMOUPNT	FM	C15H10ClNO2
DMOUPNT	IC	InChI=1S/C15H10ClNO2/c16-11-7-5-10(6-8-11)9-17-13-4-2-1-3-12(13)14(18)15(17)19/h1-8H,9H2
DMOUPNT	CS	C1=CC=C2C(=C1)C(=O)C(=O)N2CC3=CC=C(C=C3)Cl
DMOUPNT	IK	VEBLIIOSJXGVAW-UHFFFAOYSA-N
DMOUPNT	IU	1-[(4-chlorophenyl)methyl]indole-2,3-dione
DMOUPNT	CA	CAS 26960-66-7
DMOUPNT	DE	Discovery agent

DMASLUF	ID	DMASLUF
DMASLUF	DN	1-(4-Chlorobenzyl)-5-phenyl-1H-imidazole
DMASLUF	HS	Investigative
DMASLUF	SN	CHEMBL597101; 1-(4-Chlorobenzyl)-5-phenyl-1H-imidazole; SCHEMBL1949527
DMASLUF	DT	Small molecular drug
DMASLUF	PC	45103809
DMASLUF	MW	268.74
DMASLUF	FM	C16H13ClN2
DMASLUF	IC	InChI=1S/C16H13ClN2/c17-15-8-6-13(7-9-15)11-19-12-18-10-16(19)14-4-2-1-3-5-14/h1-10,12H,11H2
DMASLUF	CS	C1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)Cl
DMASLUF	IK	ILEPDNSLDAJTII-UHFFFAOYSA-N
DMASLUF	IU	1-[(4-chlorophenyl)methyl]-5-phenylimidazole
DMASLUF	DE	Discovery agent

DMXGB38	ID	DMXGB38
DMXGB38	DN	1-(4-chlorooxazol-2-yl)-7-phenylheptan-1-one
DMXGB38	HS	Investigative
DMXGB38	SN	CHEMBL462432; 1-(4-chlorooxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162562
DMXGB38	DT	Small molecular drug
DMXGB38	PC	44554440
DMXGB38	MW	291.77
DMXGB38	FM	C16H18ClNO2
DMXGB38	IC	InChI=1S/C16H18ClNO2/c17-15-12-20-16(18-15)14(19)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMXGB38	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)Cl
DMXGB38	IK	HEJGWGQTJYVGGY-UHFFFAOYSA-N
DMXGB38	IU	1-(4-chloro-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMXGB38	DE	Discovery agent

DM9MDZG	ID	DM9MDZG
DM9MDZG	DN	1-(4-chlorophenethyl)-1H-imidazole
DM9MDZG	HS	Investigative
DM9MDZG	SN	CHEMBL379290; 1-(4-chlorophenethyl)-1H-imidazole; 1H-Imidazole, 1-[2-(4-chlorophenyl)ethyl]-; BDBM50191793; 56643-90-4
DM9MDZG	DT	Small molecular drug
DM9MDZG	PC	10330640
DM9MDZG	MW	206.67
DM9MDZG	FM	C11H11ClN2
DM9MDZG	IC	InChI=1S/C11H11ClN2/c12-11-3-1-10(2-4-11)5-7-14-8-6-13-9-14/h1-4,6,8-9H,5,7H2
DM9MDZG	CS	C1=CC(=CC=C1CCN2C=CN=C2)Cl
DM9MDZG	IK	MOYFWXULYXUBOS-UHFFFAOYSA-N
DM9MDZG	IU	1-[2-(4-chlorophenyl)ethyl]imidazole
DM9MDZG	DE	Discovery agent

DMV8C7I	ID	DMV8C7I
DMV8C7I	DN	1-(4-CHLOROPHENYL)-2-(2,4-DICHLOROPHENYL)-5-(METHYLSULFINYL)-N-(PIPERIDIN-1-YL)-1H-IMIDAZOLE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DMV8C7I	HS	Investigative
DMV8C7I	SN	1-(4-CHLOROPHENYL)-2-(2,4-DICHLOROPHENYL)-5-(METHYLSULFINYL)-N-(PIPERIDIN-1-YL)-1H-IMIDAZOLE-4-CARBOXAMIDE (ENANTIOMERIC MIX); SCHEMBL675964; CHEMBL1088223; BDBM50378776
DMV8C7I	DT	Small molecular drug
DMV8C7I	PC	23654364
DMV8C7I	MW	511.8
DMV8C7I	FM	C22H21Cl3N4O2S
DMV8C7I	IC	InChI=1S/C22H21Cl3N4O2S/c1-32(31)22-19(21(30)27-28-11-3-2-4-12-28)26-20(17-10-7-15(24)13-18(17)25)29(22)16-8-5-14(23)6-9-16/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMV8C7I	CS	CS(=O)C1=C(N=C(N1C2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)Cl)Cl)C(=O)NN4CCCCC4
DMV8C7I	IK	XQPOHFLWEFPJAR-UHFFFAOYSA-N
DMV8C7I	IU	1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylsulfinyl-N-piperidin-1-ylimidazole-4-carboxamide
DMV8C7I	DE	Discovery agent

DMQHTR4	ID	DMQHTR4
DMQHTR4	DN	1-(4-chlorophenyl)-2-(phenylsulfonyl)ethanone
DMQHTR4	HS	Investigative
DMQHTR4	SN	1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethanone; 38488-19-6; CHEMBL238834; 1-(4-chlorophenyl)-2-(phenylsulfonyl)-1-ethanone; 4-Chlorophenacylphenyl sulfone; AC1LBPW5; SCHEMBL10931021; ZINC58239; CTK6G9147; MolPort-002-876-864; KZACHGLUJYSTGQ-UHFFFAOYSA-N; BDBM50212531; CCG-43075; AKOS003310153; MCULE-9299558448; 7H-330S; KS-00001Z91; ST50308734; Ethanone, 1-(4-chlorophenyl)-2-phenylsulfonyl-; 4'-CHLORO-2(PHENYL SULFONYL)ACETOPHENONE; 2-(benzenesulfonyl)-1-(4-chlorophenyl)ethanone; AF-731/00081054
DMQHTR4	DT	Small molecular drug
DMQHTR4	PC	586971
DMQHTR4	MW	294.8
DMQHTR4	FM	C14H11ClO3S
DMQHTR4	IC	InChI=1S/C14H11ClO3S/c15-12-8-6-11(7-9-12)14(16)10-19(17,18)13-4-2-1-3-5-13/h1-9H,10H2
DMQHTR4	CS	C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CC=C(C=C2)Cl
DMQHTR4	IK	KZACHGLUJYSTGQ-UHFFFAOYSA-N
DMQHTR4	IU	2-(benzenesulfonyl)-1-(4-chlorophenyl)ethanone
DMQHTR4	DE	Discovery agent

DMCDV1O	ID	DMCDV1O
DMCDV1O	DN	1-(4-Chloro-phenyl)-2-phenyl-ethane-1,2-dione
DMCDV1O	HS	Investigative
DMCDV1O	SN	4-Chlorobenzil; 22711-23-5; 1-(4-chlorophenyl)-2-phenylethane-1,2-dione; 4-Chlorodibenzoyl; (p-Chlorophenyl)phenylethanedione; QDCKVAZDINMMHO-UHFFFAOYSA-N; 1-(4-Chlorophenyl)-2-phenylethan-1,2-dione; 1-(4-Chlorophenyl)-2-phenyl-1,2-ethanedione; 1,2-Ethanedione,1-(4-chlorophenyl)-2-phenyl-; p-Chlorbenzil; EINECS 245-169-3; ACMC-20amkt; 1-(4-Chloro-phenyl)-2-phenyl-ethane; AC1L3IMU; Benzil-based compound, 15; SCHEMBL912515; CHEMBL192180; CTK4F0011; BDBM22737; DTXSID00177246; 4-Chlorobibenzyl-alpha,beta-dione; MolPort-001-763-274
DMCDV1O	DT	Small molecular drug
DMCDV1O	PC	89801
DMCDV1O	MW	244.67
DMCDV1O	FM	C14H9ClO2
DMCDV1O	IC	InChI=1S/C14H9ClO2/c15-12-8-6-11(7-9-12)14(17)13(16)10-4-2-1-3-5-10/h1-9H
DMCDV1O	CS	C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)Cl
DMCDV1O	IK	QDCKVAZDINMMHO-UHFFFAOYSA-N
DMCDV1O	IU	1-(4-chlorophenyl)-2-phenylethane-1,2-dione
DMCDV1O	CA	CAS 22711-23-5
DMCDV1O	DE	Discovery agent

DMOGVZ2	ID	DMOGVZ2
DMOGVZ2	DN	1-(4-Chloro-phenyl)-2-p-tolyl-ethane-1,2-dione
DMOGVZ2	HS	Investigative
DMOGVZ2	SN	86508-29-4; 1-(4-chlorophenyl)-2-(4-methylphenyl)ethane-1,2-dione; 1-(4-Chlorophenyl)-2-(p-tolyl)ethane-1,2-dione; 1-(4-Chlorophenyl)-2-(4-methylphenyl)-ethane-1,2-dione; 1,2-Ethanedione,1-(4-chlorophenyl)-2-(4-methylphenyl)-; AC1MCRLY; Benzil-based compound, 16; SCHEMBL2156105; CHEMBL192252; BDBM22738; CTK5F6872; DTXSID10380461; ZINC2510245; ZX-AT024772; SBB102088; 1010AF; AKOS025117220; KB-147233; FT-0605685; I14-93818; 1-(4-Chlorophenyl)-2-(4-methylphenyl)ethan-1,2-dione
DMOGVZ2	DT	Small molecular drug
DMOGVZ2	PC	2777298
DMOGVZ2	MW	258.7
DMOGVZ2	FM	C15H11ClO2
DMOGVZ2	IC	InChI=1S/C15H11ClO2/c1-10-2-4-11(5-3-10)14(17)15(18)12-6-8-13(16)9-7-12/h2-9H,1H3
DMOGVZ2	CS	CC1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)Cl
DMOGVZ2	IK	FKOYORNUXJRIQT-UHFFFAOYSA-N
DMOGVZ2	IU	1-(4-chlorophenyl)-2-(4-methylphenyl)ethane-1,2-dione
DMOGVZ2	CA	CAS 86508-29-4
DMOGVZ2	DE	Discovery agent

DM3YI5G	ID	DM3YI5G
DM3YI5G	DN	1-(4-Chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea
DM3YI5G	HS	Investigative
DM3YI5G	SN	CHEMBL9308; 1-(4-Chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea; BDBM50005456
DM3YI5G	DT	Small molecular drug
DM3YI5G	PC	44265973
DM3YI5G	MW	362.8
DM3YI5G	FM	C22H19ClN2O
DM3YI5G	IC	InChI=1S/C22H19ClN2O/c23-19-11-13-20(14-12-19)25-22(26)24-16-15-21(17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-15H,16H2,(H2,24,25,26)
DM3YI5G	CS	C1=CC=C(C=C1)C(=CCNC(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3
DM3YI5G	IK	BVFBYUIDPPDGCS-UHFFFAOYSA-N
DM3YI5G	IU	1-(4-chlorophenyl)-3-(3,3-diphenylprop-2-enyl)urea
DM3YI5G	DE	Discovery agent

DMUW1GI	ID	DMUW1GI
DMUW1GI	DN	1-(4-Chloro-phenyl)-3-(3-pentyl-oct-2-enyl)-urea
DMUW1GI	HS	Investigative
DMUW1GI	SN	CHEMBL422036; 1-(4-Chloro-phenyl)-3-(3-pentyl-oct-2-enyl)-urea; BDBM50005450
DMUW1GI	DT	Small molecular drug
DMUW1GI	PC	44265967
DMUW1GI	MW	350.9
DMUW1GI	FM	C20H31ClN2O
DMUW1GI	IC	InChI=1S/C20H31ClN2O/c1-3-5-7-9-17(10-8-6-4-2)15-16-22-20(24)23-19-13-11-18(21)12-14-19/h11-15H,3-10,16H2,1-2H3,(H2,22,23,24)
DMUW1GI	CS	CCCCCC(=CCNC(=O)NC1=CC=C(C=C1)Cl)CCCCC
DMUW1GI	IK	CIWRUSYLNXXOOQ-UHFFFAOYSA-N
DMUW1GI	IU	1-(4-chlorophenyl)-3-(3-pentyloct-2-enyl)urea
DMUW1GI	DE	Discovery agent

DMVCHSI	ID	DMVCHSI
DMVCHSI	DN	1-(4-chlorophenyl)-4-phenyl-1H-imidazole
DMVCHSI	HS	Investigative
DMVCHSI	SN	1-(4-chlorophenyl)-4-phenyl-1H-imidazole
DMVCHSI	DT	Small molecular drug
DMVCHSI	PC	12718449
DMVCHSI	MW	254.71
DMVCHSI	FM	C15H11ClN2
DMVCHSI	IC	InChI=1S/C15H11ClN2/c16-13-6-8-14(9-7-13)18-10-15(17-11-18)12-4-2-1-3-5-12/h1-11H
DMVCHSI	CS	C1=CC=C(C=C1)C2=CN(C=N2)C3=CC=C(C=C3)Cl
DMVCHSI	IK	CPDGQKJPYYDYQG-UHFFFAOYSA-N
DMVCHSI	IU	1-(4-chlorophenyl)-4-phenylimidazole
DMVCHSI	DE	Discovery agent

DMEJXWG	ID	DMEJXWG
DMEJXWG	DN	1-(4-chlorophenylsulfonyl)-4-phenylazepan-4-ol
DMEJXWG	HS	Investigative
DMEJXWG	SN	CHEMBL562534; 1-(4-chlorophenylsulfonyl)-4-phenylazepan-4-ol; SCHEMBL12550078
DMEJXWG	DT	Small molecular drug
DMEJXWG	PC	25192460
DMEJXWG	MW	365.9
DMEJXWG	FM	C18H20ClNO3S
DMEJXWG	IC	InChI=1S/C18H20ClNO3S/c19-16-7-9-17(10-8-16)24(22,23)20-13-4-11-18(21,12-14-20)15-5-2-1-3-6-15/h1-3,5-10,21H,4,11-14H2
DMEJXWG	CS	C1CC(CCN(C1)S(=O)(=O)C2=CC=C(C=C2)Cl)(C3=CC=CC=C3)O
DMEJXWG	IK	RVUCFBVJACHZFJ-UHFFFAOYSA-N
DMEJXWG	IU	1-(4-chlorophenyl)sulfonyl-4-phenylazepan-4-ol
DMEJXWG	DE	Discovery agent

DMIU3C8	ID	DMIU3C8
DMIU3C8	DN	1-(4-cyano-2-hydroxyphenyl)-3-phenylurea
DMIU3C8	HS	Investigative
DMIU3C8	SN	CHEMBL25573; 1-(4-cyano-2-hydroxyphenyl)-3-phenylurea; 1-(4-cyano-2-hydroxy-phenyl)-3-phenyl-urea; SCHEMBL7489930; ZINC13559607
DMIU3C8	DT	Small molecular drug
DMIU3C8	PC	11184341
DMIU3C8	MW	253.26
DMIU3C8	FM	C14H11N3O2
DMIU3C8	IC	InChI=1S/C14H11N3O2/c15-9-10-6-7-12(13(18)8-10)17-14(19)16-11-4-2-1-3-5-11/h1-8,18H,(H2,16,17,19)
DMIU3C8	CS	C1=CC=C(C=C1)NC(=O)NC2=C(C=C(C=C2)C#N)O
DMIU3C8	IK	XRZHCICQICNYCB-UHFFFAOYSA-N
DMIU3C8	IU	1-(4-cyano-2-hydroxyphenyl)-3-phenylurea
DMIU3C8	DE	Discovery agent

DMKDAJ2	ID	DMKDAJ2
DMKDAJ2	DN	1-(4-Cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole
DMKDAJ2	HS	Investigative
DMKDAJ2	SN	CHEMBL599603; 1-(4-Cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole; SCHEMBL3826070
DMKDAJ2	DT	Small molecular drug
DMKDAJ2	PC	45103912
DMKDAJ2	MW	277.29
DMKDAJ2	FM	C17H12FN3
DMKDAJ2	IC	InChI=1S/C17H12FN3/c18-16-4-2-1-3-15(16)17-10-20-12-21(17)11-14-7-5-13(9-19)6-8-14/h1-8,10,12H,11H2
DMKDAJ2	CS	C1=CC=C(C(=C1)C2=CN=CN2CC3=CC=C(C=C3)C#N)F
DMKDAJ2	IK	HPGUXAXJZVHMRJ-UHFFFAOYSA-N
DMKDAJ2	IU	4-[[5-(2-fluorophenyl)imidazol-1-yl]methyl]benzonitrile
DMKDAJ2	DE	Discovery agent

DMAJXYO	ID	DMAJXYO
DMAJXYO	DN	1-(4-Cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole
DMAJXYO	HS	Investigative
DMAJXYO	SN	CHEMBL610513; 1-(4-Cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole; SCHEMBL3822526
DMAJXYO	DT	Small molecular drug
DMAJXYO	PC	44187006
DMAJXYO	MW	273.3
DMAJXYO	FM	C18H15N3
DMAJXYO	IC	InChI=1S/C18H15N3/c1-14-4-2-3-5-17(14)18-11-20-13-21(18)12-16-8-6-15(10-19)7-9-16/h2-9,11,13H,12H2,1H3
DMAJXYO	CS	CC1=CC=CC=C1C2=CN=CN2CC3=CC=C(C=C3)C#N
DMAJXYO	IK	PMVNVHAWQMXUIC-UHFFFAOYSA-N
DMAJXYO	IU	4-[[5-(2-methylphenyl)imidazol-1-yl]methyl]benzonitrile
DMAJXYO	DE	Discovery agent

DMVS4D5	ID	DMVS4D5
DMVS4D5	DN	1-(4-Cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole
DMVS4D5	HS	Investigative
DMVS4D5	SN	CHEMBL598789; 1-(4-Cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole; SCHEMBL3828287
DMVS4D5	DT	Small molecular drug
DMVS4D5	PC	44206698
DMVS4D5	MW	277.29
DMVS4D5	FM	C17H12FN3
DMVS4D5	IC	InChI=1S/C17H12FN3/c18-16-3-1-2-15(8-16)17-10-20-12-21(17)11-14-6-4-13(9-19)5-7-14/h1-8,10,12H,11H2
DMVS4D5	CS	C1=CC(=CC(=C1)F)C2=CN=CN2CC3=CC=C(C=C3)C#N
DMVS4D5	IK	XBUPVQPMTRYFDV-UHFFFAOYSA-N
DMVS4D5	IU	4-[[5-(3-fluorophenyl)imidazol-1-yl]methyl]benzonitrile
DMVS4D5	DE	Discovery agent

DMI8UC7	ID	DMI8UC7
DMI8UC7	DN	1-(4-Cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole
DMI8UC7	HS	Investigative
DMI8UC7	SN	CHEMBL607862; 1-(4-Cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole
DMI8UC7	DT	Small molecular drug
DMI8UC7	PC	45103913
DMI8UC7	MW	273.3
DMI8UC7	FM	C18H15N3
DMI8UC7	IC	InChI=1S/C18H15N3/c1-14-3-2-4-17(9-14)18-11-20-13-21(18)12-16-7-5-15(10-19)6-8-16/h2-9,11,13H,12H2,1H3
DMI8UC7	CS	CC1=CC(=CC=C1)C2=CN=CN2CC3=CC=C(C=C3)C#N
DMI8UC7	IK	PLRIEAPRLTXNAI-UHFFFAOYSA-N
DMI8UC7	IU	4-[[5-(3-methylphenyl)imidazol-1-yl]methyl]benzonitrile
DMI8UC7	DE	Discovery agent

DM7C3VD	ID	DM7C3VD
DM7C3VD	DN	1-(4-Cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole
DM7C3VD	HS	Investigative
DM7C3VD	SN	CHEMBL598790; 1-(4-Cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole
DM7C3VD	DT	Small molecular drug
DM7C3VD	PC	45103914
DM7C3VD	MW	277.29
DM7C3VD	FM	C17H12FN3
DM7C3VD	IC	InChI=1S/C17H12FN3/c18-16-7-5-15(6-8-16)17-10-20-12-21(17)11-14-3-1-13(9-19)2-4-14/h1-8,10,12H,11H2
DM7C3VD	CS	C1=CC(=CC=C1CN2C=NC=C2C3=CC=C(C=C3)F)C#N
DM7C3VD	IK	KZBKCANQPHILBI-UHFFFAOYSA-N
DM7C3VD	IU	4-[[5-(4-fluorophenyl)imidazol-1-yl]methyl]benzonitrile
DM7C3VD	DE	Discovery agent

DMQX37R	ID	DMQX37R
DMQX37R	DN	1-(4-Cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole
DMQX37R	HS	Investigative
DMQX37R	SN	CHEMBL607567; 1-(4-Cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole
DMQX37R	DT	Small molecular drug
DMQX37R	PC	45103915
DMQX37R	MW	273.3
DMQX37R	FM	C18H15N3
DMQX37R	IC	InChI=1S/C18H15N3/c1-14-2-8-17(9-3-14)18-11-20-13-21(18)12-16-6-4-15(10-19)5-7-16/h2-9,11,13H,12H2,1H3
DMQX37R	CS	CC1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)C#N
DMQX37R	IK	DWILASUQXSLXIX-UHFFFAOYSA-N
DMQX37R	IU	4-[[5-(4-methylphenyl)imidazol-1-yl]methyl]benzonitrile
DMQX37R	DE	Discovery agent

DM372EG	ID	DM372EG
DM372EG	DN	1-(4-Cyanobenzyl)-5-(4-pyridyl)-1H-imidazole
DM372EG	HS	Investigative
DM372EG	SN	CHEMBL599602; 1-(4-Cyanobenzyl)-5-(4-pyridyl)-1H-imidazole
DM372EG	DT	Small molecular drug
DM372EG	PC	45103911
DM372EG	MW	260.29
DM372EG	FM	C16H12N4
DM372EG	IC	InChI=1S/C16H12N4/c17-9-13-1-3-14(4-2-13)11-20-12-19-10-16(20)15-5-7-18-8-6-15/h1-8,10,12H,11H2
DM372EG	CS	C1=CC(=CC=C1CN2C=NC=C2C3=CC=NC=C3)C#N
DM372EG	IK	JQIVWNYGSDPIRG-UHFFFAOYSA-N
DM372EG	IU	4-[(5-pyridin-4-ylimidazol-1-yl)methyl]benzonitrile
DM372EG	DE	Discovery agent

DMBUMDG	ID	DMBUMDG
DMBUMDG	DN	1-(4-Cyanobenzyl)-5-bromo-1H-imidazole
DMBUMDG	HS	Investigative
DMBUMDG	SN	1-(4-Cyanobenzyl)-5-bromo-1H-imidazole; CHEMBL599223; SCHEMBL3829392; BDBM50307238
DMBUMDG	DT	Small molecular drug
DMBUMDG	PC	45103910
DMBUMDG	MW	262.1
DMBUMDG	FM	C11H8BrN3
DMBUMDG	IC	InChI=1S/C11H8BrN3/c12-11-6-14-8-15(11)7-10-3-1-9(5-13)2-4-10/h1-4,6,8H,7H2
DMBUMDG	CS	C1=CC(=CC=C1CN2C=NC=C2Br)C#N
DMBUMDG	IK	MHDGKGCOBILXLM-UHFFFAOYSA-N
DMBUMDG	IU	4-[(5-bromoimidazol-1-yl)methyl]benzonitrile
DMBUMDG	DE	Discovery agent

DM2THVK	ID	DM2THVK
DM2THVK	DN	1-(4-Cyanobenzyl)-5-formyl-1H-imidazole
DM2THVK	HS	Investigative
DM2THVK	SN	183500-37-0; CHEMBL611680; 4-(5-formylimidazol-1-ylmethyl)benzonitrile; 4-[(5-formyl-1H-imidazol-1-yl)methyl]benzonitrile; 4-(5-FORMYL-IMIDAZOL-1-YLMETHYL)-BENZONITRILE; 4-((5-formyl-1h-imidazol-1-yl)methyl)benzonitrile; 1-(4-Cyanobenzyl)-5-formyl-1H-imidazole; SCHEMBL1064258; CTK4D8501; DTXSID30442752; AMUOEEKBBOOOCV-UHFFFAOYSA-N; ZINC39118604; BDBM50307239; 1-(4-cyanobenzyl)-5-formylimidazole; AKOS015911901; ACM183500370; SC-55448; KB-238611; FT-0714561; 1-(4-cyanobenzyl)-5-imidazolecarboxaldehyde
DM2THVK	DT	Small molecular drug
DM2THVK	PC	10632289
DM2THVK	MW	211.22
DM2THVK	FM	C12H9N3O
DM2THVK	IC	InChI=1S/C12H9N3O/c13-5-10-1-3-11(4-2-10)7-15-9-14-6-12(15)8-16/h1-4,6,8-9H,7H2
DM2THVK	CS	C1=CC(=CC=C1CN2C=NC=C2C=O)C#N
DM2THVK	IK	AMUOEEKBBOOOCV-UHFFFAOYSA-N
DM2THVK	IU	4-[(5-formylimidazol-1-yl)methyl]benzonitrile
DM2THVK	CA	CAS 183500-37-0
DM2THVK	DE	Discovery agent

DMCUE25	ID	DMCUE25
DMCUE25	DN	1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole
DMCUE25	HS	Investigative
DMCUE25	SN	183500-36-9; CHEMBL599601; 4-(5-HYDROXYMETHYLIMIDAZOL-1-YLMETHYL)BENZONITRILE; 1-(4-cyanobenzyl)-5-hydroxymethylimidazole; 1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole; SCHEMBL3630524; CTK4D8500; DTXSID40436662; ACFSBQWDVYWNRT-UHFFFAOYSA-N; ZINC45368822; BDBM50307240; ACM183500369; KB-238618; 1-(4-Cyanobenzyl)-5-Hydroxymethyl-imidazole; 1-(4-Cyanobenzyl)-5-(hydroxymethyl)imidazole; 1-(4-cyanobenzyl)-5-(hydroxymethyl) imidazole; 1-(4-cyanobenzyl)-5-(hydroxymethyl)-imidazole; 3-(4-cyanobenzyl)-3H-imidazol-4-ylmethyl alcohol
DMCUE25	DT	Small molecular drug
DMCUE25	PC	10198247
DMCUE25	MW	213.23
DMCUE25	FM	C12H11N3O
DMCUE25	IC	InChI=1S/C12H11N3O/c13-5-10-1-3-11(4-2-10)7-15-9-14-6-12(15)8-16/h1-4,6,9,16H,7-8H2
DMCUE25	CS	C1=CC(=CC=C1CN2C=NC=C2CO)C#N
DMCUE25	IK	ACFSBQWDVYWNRT-UHFFFAOYSA-N
DMCUE25	IU	4-[[5-(hydroxymethyl)imidazol-1-yl]methyl]benzonitrile
DMCUE25	CA	CAS 183500-36-9
DMCUE25	DE	Discovery agent

DMKC52N	ID	DMKC52N
DMKC52N	DN	1-(4-Cyanobenzyl)-5-methyl-1H-imidazole
DMKC52N	HS	Investigative
DMKC52N	SN	4-(5-Methyl-imidazol-1-ylmethyl)-benzonitrile
DMKC52N	PC	14231155
DMKC52N	MW	197.24
DMKC52N	FM	C12H11N3
DMKC52N	IC	InChI=1S/C12H11N3/c1-10-7-14-9-15(10)8-12-4-2-11(6-13)3-5-12/h2-5,7,9H,8H2,1H3
DMKC52N	CS	CC1=CN=CN1CC2=CC=C(C=C2)C#N
DMKC52N	IK	JYTDMONWVZXEMX-UHFFFAOYSA-N
DMKC52N	IU	4-[(5-methylimidazol-1-yl)methyl]benzonitrile
DMKC52N	DE	Discovery agent

DMQF8DY	ID	DMQF8DY
DMQF8DY	DN	1-(4-Cyanobenzyl)-5-phenyl-1H-imidazole
DMQF8DY	HS	Investigative
DMQF8DY	SN	CHEMBL597578; 1-(4-Cyanobenzyl)-5-phenyl-1H-imidazole; SCHEMBL1949482
DMQF8DY	DT	Small molecular drug
DMQF8DY	PC	44206482
DMQF8DY	MW	259.3
DMQF8DY	FM	C17H13N3
DMQF8DY	IC	InChI=1S/C17H13N3/c18-10-14-6-8-15(9-7-14)12-20-13-19-11-17(20)16-4-2-1-3-5-16/h1-9,11,13H,12H2
DMQF8DY	CS	C1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)C#N
DMQF8DY	IK	HPKNNFRLCPHIRD-UHFFFAOYSA-N
DMQF8DY	IU	4-[(5-phenylimidazol-1-yl)methyl]benzonitrile
DMQF8DY	DE	Discovery agent

DM9EK3T	ID	DM9EK3T
DM9EK3T	DN	1-(4-Cyano-thiazol-2-yl)-3-phenethyl-thiourea
DM9EK3T	HS	Investigative
DM9EK3T	SN	PETT CN deriv.; PETT Analog 42; AC1MHDKT; CHEMBL148106; BDBM1875; ZINC13744901; 1-(4-cyanothiazol-2-yl)-3-phenethyl-thiourea; 1-(4-cyano-1,3-thiazol-2-yl)-3-phenethylthiourea; N-(2-Phenethyl)-N -(2-(4-cyanothiazolyl))thiourea; N-(2-Phenylethyl)-N'-[2-(4-cyanothiazolyl)]thiourea
DM9EK3T	DT	Small molecular drug
DM9EK3T	PC	3001110
DM9EK3T	MW	288.4
DM9EK3T	FM	C13H12N4S2
DM9EK3T	IC	InChI=1S/C13H12N4S2/c14-8-11-9-19-13(16-11)17-12(18)15-7-6-10-4-2-1-3-5-10/h1-5,9H,6-7H2,(H2,15,16,17,18)
DM9EK3T	CS	C1=CC=C(C=C1)CCNC(=S)NC2=NC(=CS2)C#N
DM9EK3T	IK	BZAWZCHHJAFXDY-UHFFFAOYSA-N
DM9EK3T	IU	1-(4-cyano-1,3-thiazol-2-yl)-3-(2-phenylethyl)thiourea
DM9EK3T	DE	Discovery agent

DMZR94D	ID	DMZR94D
DMZR94D	DN	1-(4-ethoxyphenyl)propan-2-amine
DMZR94D	HS	Investigative
DMZR94D	SN	4-Ethoxyamphetamine; dl-p-Ethoxyamphetamine; 129476-58-0; 1-(4-ethoxyphenyl)propan-2-amine; CHEMBL161985; 135014-85-6; 1-(4-ethoxyphenyl)prop-2-ylamine; Para-Ethoxyamphetamine; Benzeneethanamine, 4-ethoxy-alpha-methyl-; AC1L2OHT; ACMC-1BZ3A; Benzeneethanamine, 4-ethoxy-alpha-methyl-, (+-)-; SCHEMBL2553013; CTK0H5621; CCAMEVFYMFXHEN-UHFFFAOYSA-N; BDBM50005270; AKOS016298265; AKOS017269155; AKOS000155579; 1-(4-Ethoxyphenyl)-2-propanamine #; 2-(4-Ethoxy-phenyl)-1-methyl-ethylamine
DMZR94D	DT	Small molecular drug
DMZR94D	PC	125379
DMZR94D	MW	179.26
DMZR94D	FM	C11H17NO
DMZR94D	IC	InChI=1S/C11H17NO/c1-3-13-11-6-4-10(5-7-11)8-9(2)12/h4-7,9H,3,8,12H2,1-2H3
DMZR94D	CS	CCOC1=CC=C(C=C1)CC(C)N
DMZR94D	IK	CCAMEVFYMFXHEN-UHFFFAOYSA-N
DMZR94D	IU	1-(4-ethoxyphenyl)propan-2-amine
DMZR94D	CA	CAS 129476-58-0
DMZR94D	DE	Discovery agent

DMIYLXU	ID	DMIYLXU
DMIYLXU	DN	1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine
DMIYLXU	HS	Investigative
DMIYLXU	SN	2,5-Dimethoxy-4-ethylamphetamine; 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine; 22004-32-6; DOET; CHEMBL8224; NCGC00247691-01; SCHEMBL1740704; DOET,(-); AC1L1D54; CTK4E8216; BDBM81965; HXJKWPGVENNMCC-UHFFFAOYSA-N; 4-Ethyl-2,5-dimethoxyamphetamine; PDSP2_000785; CAS_62066; PDSP1_001371; PDSP2_001355; PDSP1_000797; NSC_62066; DB01467; ACM22004326; 2,5-dimethoxy-4-ethylamphetamine (''DOEt''); L001150; Benzeneethanamine,4-ethyl-2,5-dimethoxy-a-methyl-; 1-(4-Ethyl-2,5-dimethoxyphenyl)-2-propanamine #; Phenethylamine, 4-ethyl-2,5-dimeth
DMIYLXU	DT	Small molecular drug
DMIYLXU	PC	27402
DMIYLXU	MW	223.31
DMIYLXU	FM	C13H21NO2
DMIYLXU	IC	InChI=1S/C13H21NO2/c1-5-10-7-13(16-4)11(6-9(2)14)8-12(10)15-3/h7-9H,5-6,14H2,1-4H3
DMIYLXU	CS	CCC1=CC(=C(C=C1OC)CC(C)N)OC
DMIYLXU	IK	HXJKWPGVENNMCC-UHFFFAOYSA-N
DMIYLXU	IU	1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine
DMIYLXU	CA	CAS 22004-32-6
DMIYLXU	DE	Discovery agent

DMXUIS2	ID	DMXUIS2
DMXUIS2	DN	1-(4-ethylphenylsulfonyl)-4-phenylazepan-4-ol
DMXUIS2	HS	Investigative
DMXUIS2	SN	CHEMBL562684; 1-(4-ethylphenylsulfonyl)-4-phenylazepan-4-ol; SCHEMBL12549978
DMXUIS2	DT	Small molecular drug
DMXUIS2	PC	25192457
DMXUIS2	MW	359.5
DMXUIS2	FM	C20H25NO3S
DMXUIS2	IC	InChI=1S/C20H25NO3S/c1-2-17-9-11-19(12-10-17)25(23,24)21-15-6-13-20(22,14-16-21)18-7-4-3-5-8-18/h3-5,7-12,22H,2,6,13-16H2,1H3
DMXUIS2	CS	CCC1=CC=C(C=C1)S(=O)(=O)N2CCCC(CC2)(C3=CC=CC=C3)O
DMXUIS2	IK	BUVJJRPTSWXSAA-UHFFFAOYSA-N
DMXUIS2	IU	1-(4-ethylphenyl)sulfonyl-4-phenylazepan-4-ol
DMXUIS2	DE	Discovery agent

DMRK0Z1	ID	DMRK0Z1
DMRK0Z1	DN	1-(4-ethylpiperazin-1-yl)-2-phenylethanone
DMRK0Z1	HS	Investigative
DMRK0Z1	SN	1-(4-ethylpiperazin-1-yl)-2-phenylethanone; CHEMBL439203; 1-ethyl-4-(phenylacetyl)piperazine; AC1MNIR9; SCHEMBL20353684; MolPort-019-032-483; ZINC23379273; BDBM50207797; AKOS003796844; MCULE-6061952446
DMRK0Z1	DT	Small molecular drug
DMRK0Z1	PC	3328378
DMRK0Z1	MW	232.32
DMRK0Z1	FM	C14H20N2O
DMRK0Z1	IC	InChI=1S/C14H20N2O/c1-2-15-8-10-16(11-9-15)14(17)12-13-6-4-3-5-7-13/h3-7H,2,8-12H2,1H3
DMRK0Z1	CS	CCN1CCN(CC1)C(=O)CC2=CC=CC=C2
DMRK0Z1	IK	ZKLSFAKJJJDQSA-UHFFFAOYSA-N
DMRK0Z1	IU	1-(4-ethylpiperazin-1-yl)-2-phenylethanone
DMRK0Z1	DE	Discovery agent

DMBJCGA	ID	DMBJCGA
DMBJCGA	DN	1-(4-fluorobenzyl)-1H-imidazole
DMBJCGA	HS	Investigative
DMBJCGA	SN	1-(4-fluorobenzyl)-1H-imidazole; CHEMBL377770; 56643-73-3; 1-(4-Fluorobenzyl)imidazole; SCHEMBL11082155; CTK1F4148; DTXSID90481445; ZINC5588657; BDBM50188085; AKOS003644474; 1H-Imidazole, 1-[(4-fluorophenyl)methyl]-
DMBJCGA	DT	Small molecular drug
DMBJCGA	PC	12229388
DMBJCGA	MW	176.19
DMBJCGA	FM	C10H9FN2
DMBJCGA	IC	InChI=1S/C10H9FN2/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7H2
DMBJCGA	CS	C1=CC(=CC=C1CN2C=CN=C2)F
DMBJCGA	IK	LOHJXVMUYVDWOW-UHFFFAOYSA-N
DMBJCGA	IU	1-[(4-fluorophenyl)methyl]imidazole
DMBJCGA	CA	CAS 56643-73-3
DMBJCGA	DE	Discovery agent

DMT2ZSV	ID	DMT2ZSV
DMT2ZSV	DN	1-(4-Fluorobenzyl)-5-phenyl-1H-imidazole
DMT2ZSV	HS	Investigative
DMT2ZSV	SN	CHEMBL610501; 1-(4-Fluorobenzyl)-5-phenyl-1H-imidazole; SCHEMBL3823466
DMT2ZSV	DT	Small molecular drug
DMT2ZSV	PC	45103808
DMT2ZSV	MW	252.29
DMT2ZSV	FM	C16H13FN2
DMT2ZSV	IC	InChI=1S/C16H13FN2/c17-15-8-6-13(7-9-15)11-19-12-18-10-16(19)14-4-2-1-3-5-14/h1-10,12H,11H2
DMT2ZSV	CS	C1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)F
DMT2ZSV	IK	OLGSJJAJXFNAKF-UHFFFAOYSA-N
DMT2ZSV	IU	1-[(4-fluorophenyl)methyl]-5-phenylimidazole
DMT2ZSV	DE	Discovery agent

DMZLNAP	ID	DMZLNAP
DMZLNAP	DN	1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone
DMZLNAP	HS	Investigative
DMZLNAP	SN	CHEMBL238832; 41024-58-2; Ethanone, 1-(4-fluorophenyl)-2-(phenylsulfonyl)-; 1-(4-fluorophenyl)-2-(phenylsulfonyl)-1-ethanone; 1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone; AC1LS74Y; CTK1D4107; DTXSID90363277; MolPort-002-876-867; ZINC1396918; BDBM50212525; AKOS005098035; MCULE-9386710722; 7H-334S; KS-00001Z92; 4'-Fluoro-alpha-(phenylsulfonyl)acetophenone; 2-(benzenesulfonyl)-1-(4-fluorophenyl)ethanone
DMZLNAP	DT	Small molecular drug
DMZLNAP	PC	1483401
DMZLNAP	MW	278.3
DMZLNAP	FM	C14H11FO3S
DMZLNAP	IC	InChI=1S/C14H11FO3S/c15-12-8-6-11(7-9-12)14(16)10-19(17,18)13-4-2-1-3-5-13/h1-9H,10H2
DMZLNAP	CS	C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CC=C(C=C2)F
DMZLNAP	IK	FCXNRTNBPQUTBL-UHFFFAOYSA-N
DMZLNAP	IU	2-(benzenesulfonyl)-1-(4-fluorophenyl)ethanone
DMZLNAP	CA	CAS 41024-58-2
DMZLNAP	DE	Discovery agent

DM6ARQF	ID	DM6ARQF
DM6ARQF	DN	1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DM6ARQF	HS	Investigative
DM6ARQF	SN	CHEMBL203640; 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one; 4-Fluoro-alpha-pvp; FPVP; SCHEMBL4938098; BDBM50182583; 4'-Fluoro-alpha-pyrrolidinopentiophenone; 1-(4-Fluorophenyl)-2-pyrrolizinopentane-1-one; 4-Fluoro-alpha-2-(1-pyrrolidinyl)-valerophenone; 1-(4-fluorophenyl)-2-(1-pyrrolidinyl)-1-pentanone; 2-(Pyrrolidin-1-yl)-1-(4-fluorophenyl)pentan-1-one; 1-Pentanone, 1-(4-fluorophenyl)-2-(1-pyrrolidinyl)-
DM6ARQF	DT	Small molecular drug
DM6ARQF	PC	11322641
DM6ARQF	MW	249.32
DM6ARQF	FM	C15H20FNO
DM6ARQF	IC	InChI=1S/C15H20FNO/c1-2-5-14(17-10-3-4-11-17)15(18)12-6-8-13(16)9-7-12/h6-9,14H,2-5,10-11H2,1H3
DM6ARQF	CS	CCCC(C(=O)C1=CC=C(C=C1)F)N2CCCC2
DM6ARQF	IK	BQLSUBYYRRZHRK-UHFFFAOYSA-N
DM6ARQF	IU	1-(4-fluorophenyl)-2-pyrrolidin-1-ylpentan-1-one
DM6ARQF	CA	CAS 850352-62-4
DM6ARQF	DE	Discovery agent

DMKATOJ	ID	DMKATOJ
DMKATOJ	DN	1-(4-fluorophenyl)-3-(phenylsulfonyl)propan-1-one
DMKATOJ	HS	Investigative
DMKATOJ	SN	CHEMBL397827; 1-(4-fluorophenyl)-3-(phenylsulfonyl)propan-1-one; ZINC28874847; BDBM50212549
DMKATOJ	DT	Small molecular drug
DMKATOJ	PC	44437632
DMKATOJ	MW	292.3
DMKATOJ	FM	C15H13FO3S
DMKATOJ	IC	InChI=1S/C15H13FO3S/c16-13-8-6-12(7-9-13)15(17)10-11-20(18,19)14-4-2-1-3-5-14/h1-9H,10-11H2
DMKATOJ	CS	C1=CC=C(C=C1)S(=O)(=O)CCC(=O)C2=CC=C(C=C2)F
DMKATOJ	IK	DMAMKPWVVZCTDR-UHFFFAOYSA-N
DMKATOJ	IU	3-(benzenesulfonyl)-1-(4-fluorophenyl)propan-1-one
DMKATOJ	DE	Discovery agent

DMIQ0VA	ID	DMIQ0VA
DMIQ0VA	DN	1-(4-heptylphenyl)prop-2-en-1-one
DMIQ0VA	HS	Investigative
DMIQ0VA	SN	CHEMBL237035
DMIQ0VA	DT	Small molecular drug
DMIQ0VA	PC	44435784
DMIQ0VA	MW	230.34
DMIQ0VA	FM	C16H22O
DMIQ0VA	IC	InChI=1S/C16H22O/c1-3-5-6-7-8-9-14-10-12-15(13-11-14)16(17)4-2/h4,10-13H,2-3,5-9H2,1H3
DMIQ0VA	CS	CCCCCCCC1=CC=C(C=C1)C(=O)C=C
DMIQ0VA	IK	WZQJNZZJSOSTIH-UHFFFAOYSA-N
DMIQ0VA	IU	1-(4-heptylphenyl)prop-2-en-1-one
DMIQ0VA	DE	Discovery agent

DM5QLGH	ID	DM5QLGH
DM5QLGH	DN	1-(4-hexylphenyl)-3-(propylamino)propan-1-one
DM5QLGH	HS	Investigative
DM5QLGH	SN	beta-Aminophenylketone, 3k; 1-(4-hexylphenyl)-3-(propylamino)propan-1-one; CHEMBL396873; BDBM18824
DM5QLGH	DT	Small molecular drug
DM5QLGH	PC	23635367
DM5QLGH	MW	275.4
DM5QLGH	FM	C18H29NO
DM5QLGH	IC	InChI=1S/C18H29NO/c1-3-5-6-7-8-16-9-11-17(12-10-16)18(20)13-15-19-14-4-2/h9-12,19H,3-8,13-15H2,1-2H3
DM5QLGH	CS	CCCCCCC1=CC=C(C=C1)C(=O)CCNCCC
DM5QLGH	IK	IHAKHGFZWJHPER-UHFFFAOYSA-N
DM5QLGH	IU	1-(4-hexylphenyl)-3-(propylamino)propan-1-one
DM5QLGH	DE	Discovery agent

DMFN8T6	ID	DMFN8T6
DMFN8T6	DN	1-(4-hexylphenyl)-3-morpholinopropan-1-one
DMFN8T6	HS	Investigative
DMFN8T6	SN	beta-Aminophenylketone, 3e; CHEMBL236132; BDBM18818; AKOS022274318
DMFN8T6	DT	Small molecular drug
DMFN8T6	PC	23635362
DMFN8T6	MW	303.4
DMFN8T6	FM	C19H29NO2
DMFN8T6	IC	InChI=1S/C19H29NO2/c1-2-3-4-5-6-17-7-9-18(10-8-17)19(21)11-12-20-13-15-22-16-14-20/h7-10H,2-6,11-16H2,1H3
DMFN8T6	CS	CCCCCCC1=CC=C(C=C1)C(=O)CCN2CCOCC2
DMFN8T6	IK	DRNLQHKMQJOYPM-UHFFFAOYSA-N
DMFN8T6	IU	1-(4-hexylphenyl)-3-morpholin-4-ylpropan-1-one
DMFN8T6	DE	Discovery agent

DMX7PJH	ID	DMX7PJH
DMX7PJH	DN	1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE
DMX7PJH	HS	Investigative
DMX7PJH	SN	1-(4-hexylphenyl)prop-2-en-1-one; 1-(4-Hexyphenyl)-2-propane-1-one; 131906-57-5; 1-(4-HEXYLPHENYL)-2-PROPEN-1-ONE; cpd L3; Enone, 1; L3 Antagonist TR-SIR-2; SCHEMBL2583757; CHEMBL237600; BDBM18825; DTXSID40565143; MFCD08702653; ZINC13829389; DB08085; NCGC00165805-01; NCGC00165805-02; KB-214837; J-006082; 1-(4-Hexyphenyl)-2-propane-1-one, &gt;=98% (HPLC), oil
DMX7PJH	DT	Small molecular drug
DMX7PJH	PC	14899645
DMX7PJH	MW	216.32
DMX7PJH	FM	C15H20O
DMX7PJH	IC	InChI=1S/C15H20O/c1-3-5-6-7-8-13-9-11-14(12-10-13)15(16)4-2/h4,9-12H,2-3,5-8H2,1H3
DMX7PJH	CS	CCCCCCC1=CC=C(C=C1)C(=O)C=C
DMX7PJH	IK	IINHTEWASPUCMH-UHFFFAOYSA-N
DMX7PJH	IU	1-(4-hexylphenyl)prop-2-en-1-one
DMX7PJH	CA	CAS 131906-57-5
DMX7PJH	DE	Discovery agent

DM145QS	ID	DM145QS
DM145QS	DN	1-(4-hydroxyphenyl)prop-2-en-1-one
DM145QS	HS	Investigative
DM145QS	SN	1-(4-hydroxyphenyl)prop-2-en-1-one; 4-acryloylphenol; CHEMBL378577; 95605-38-2; 4-hydroxyphenyl Vinyl Ketone; SCHEMBL2394894; GTPL8841; MolPort-007-991-476; NKPPNPJUBLEKAD-UHFFFAOYSA-N; ZINC28567957; BDBM50177407; AKOS005200150; FCH1599833; 1-(4-Hydroxyphenyl)-2-propene-1-one; EN300-246996
DM145QS	DT	Small molecular drug
DM145QS	PC	16036927
DM145QS	MW	148.16
DM145QS	FM	C9H8O2
DM145QS	IC	InChI=1S/C9H8O2/c1-2-9(11)7-3-5-8(10)6-4-7/h2-6,10H,1H2
DM145QS	CS	C=CC(=O)C1=CC=C(C=C1)O
DM145QS	IK	NKPPNPJUBLEKAD-UHFFFAOYSA-N
DM145QS	IU	1-(4-hydroxyphenyl)prop-2-en-1-one
DM145QS	DE	Discovery agent

DMM17I0	ID	DMM17I0
DMM17I0	DN	1-(4-iodobenzyl)-1H-imidazole
DMM17I0	HS	Investigative
DMM17I0	SN	4-Iodobenzyl Imidazole; CHEMBL427399; 1-(4-iodobenzyl)-1H-imidazole; SCHEMBL2393534; MolPort-023-162-403; WZKZRSOWLZKJCL-UHFFFAOYSA-N; 1-(4-Iodo-benzyl)-1H-imidazole; ZINC34849755; BDBM50188092; AKOS014827972; MCULE-7536799973; 1-[(4-iodophenyl)methyl]-1H-imidazole; 906478-69-1
DMM17I0	DT	Small molecular drug
DMM17I0	PC	15984072
DMM17I0	MW	284.1
DMM17I0	FM	C10H9IN2
DMM17I0	IC	InChI=1S/C10H9IN2/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7H2
DMM17I0	CS	C1=CC(=CC=C1CN2C=CN=C2)I
DMM17I0	IK	WZKZRSOWLZKJCL-UHFFFAOYSA-N
DMM17I0	IU	1-[(4-iodophenyl)methyl]imidazole
DMM17I0	DE	Discovery agent

DMDY93H	ID	DMDY93H
DMDY93H	DN	1-(4-iodooxazol-2-yl)-7-phenylheptan-1-one
DMDY93H	HS	Investigative
DMDY93H	SN	CHEMBL462302; 1-(4-iodooxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162540
DMDY93H	DT	Small molecular drug
DMDY93H	PC	44554441
DMDY93H	MW	383.22
DMDY93H	FM	C16H18INO2
DMDY93H	IC	InChI=1S/C16H18INO2/c17-15-12-20-16(18-15)14(19)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMDY93H	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)I
DMDY93H	IK	JCDUQBRWCLLJHF-UHFFFAOYSA-N
DMDY93H	IU	1-(4-iodo-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMDY93H	DE	Discovery agent

DMBV8PT	ID	DMBV8PT
DMBV8PT	DN	1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBV8PT	HS	Investigative
DMBV8PT	SN	CHEMBL202479; 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4933112
DMBV8PT	DT	Small molecular drug
DMBV8PT	PC	11152502
DMBV8PT	MW	357.23
DMBV8PT	FM	C15H20INO
DMBV8PT	IC	InChI=1S/C15H20INO/c1-2-5-14(17-10-3-4-11-17)15(18)12-6-8-13(16)9-7-12/h6-9,14H,2-5,10-11H2,1H3
DMBV8PT	CS	CCCC(C(=O)C1=CC=C(C=C1)I)N2CCCC2
DMBV8PT	IK	QXBWECFEEZMKTN-UHFFFAOYSA-N
DMBV8PT	IU	1-(4-iodophenyl)-2-pyrrolidin-1-ylpentan-1-one
DMBV8PT	DE	Discovery agent

DMZWRU7	ID	DMZWRU7
DMZWRU7	DN	1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol
DMZWRU7	HS	Investigative
DMZWRU7	SN	CHEMBL176319; 1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol; SCHEMBL7212147
DMZWRU7	DT	Small molecular drug
DMZWRU7	PC	15516781
DMZWRU7	MW	302.5
DMZWRU7	FM	C14H22O3S2
DMZWRU7	IC	InChI=1S/C14H22O3S2/c1-3-4-5-13(18)10-11-19(15,16)14-8-6-12(17-2)7-9-14/h6-9,13,18H,3-5,10-11H2,1-2H3
DMZWRU7	CS	CCCCC(CCS(=O)(=O)C1=CC=C(C=C1)OC)S
DMZWRU7	IK	XJUQEFFNMKAWSV-UHFFFAOYSA-N
DMZWRU7	IU	1-(4-methoxyphenyl)sulfonylheptane-3-thiol
DMZWRU7	DE	Discovery agent

DMSWJKZ	ID	DMSWJKZ
DMSWJKZ	DN	1-(4-Methoxybenzyl)-5-phenyl-1H-imidazole
DMSWJKZ	HS	Investigative
DMSWJKZ	SN	1-(4-Methoxybenzyl)-5-phenyl-1H-imidazole; 1192811-38-3; CHEMBL591697; SCHEMBL1950743; DTXSID90668214; ZINC45338026; BDBM50307235; AKOS016012754; KB-214961; AJ-110482; AX8249207
DMSWJKZ	DT	Small molecular drug
DMSWJKZ	PC	45103811
DMSWJKZ	MW	264.32
DMSWJKZ	FM	C17H16N2O
DMSWJKZ	IC	InChI=1S/C17H16N2O/c1-20-16-9-7-14(8-10-16)12-19-13-18-11-17(19)15-5-3-2-4-6-15/h2-11,13H,12H2,1H3
DMSWJKZ	CS	COC1=CC=C(C=C1)CN2C=NC=C2C3=CC=CC=C3
DMSWJKZ	IK	AZQFSYIIRUWICT-UHFFFAOYSA-N
DMSWJKZ	IU	1-[(4-methoxyphenyl)methyl]-5-phenylimidazole
DMSWJKZ	CA	CAS 1192811-38-3
DMSWJKZ	DE	Discovery agent

DMEPJRD	ID	DMEPJRD
DMEPJRD	DN	1-(4-methoxyoxazol-2-yl)-7-phenylheptan-1-one
DMEPJRD	HS	Investigative
DMEPJRD	SN	CHEMBL526161; 1-(4-methoxyoxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2163269
DMEPJRD	DT	Small molecular drug
DMEPJRD	PC	44554788
DMEPJRD	MW	287.35
DMEPJRD	FM	C17H21NO3
DMEPJRD	IC	InChI=1S/C17H21NO3/c1-20-16-13-21-17(18-16)15(19)12-8-3-2-5-9-14-10-6-4-7-11-14/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DMEPJRD	CS	COC1=COC(=N1)C(=O)CCCCCCC2=CC=CC=C2
DMEPJRD	IK	PLTPISAOEFIJFK-UHFFFAOYSA-N
DMEPJRD	IU	1-(4-methoxy-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMEPJRD	DE	Discovery agent

DMAW78K	ID	DMAW78K
DMAW78K	DN	1-(4-methoxyphenethyl)pyrrolidine
DMAW78K	HS	Investigative
DMAW78K	SN	CHEMBL272307; 1-(4-methoxyphenethyl)pyrrolidine
DMAW78K	DT	Small molecular drug
DMAW78K	PC	17805318
DMAW78K	MW	205.3
DMAW78K	FM	C13H19NO
DMAW78K	IC	InChI=1S/C13H19NO/c1-15-13-6-4-12(5-7-13)8-11-14-9-2-3-10-14/h4-7H,2-3,8-11H2,1H3
DMAW78K	CS	COC1=CC=C(C=C1)CCN2CCCC2
DMAW78K	IK	JMIPWGFKCQDIBK-UHFFFAOYSA-N
DMAW78K	IU	1-[2-(4-methoxyphenyl)ethyl]pyrrolidine
DMAW78K	DE	Discovery agent

DMRC7V8	ID	DMRC7V8
DMRC7V8	DN	1-(4-methoxyphenyl)-2-(phenylsulfonyl)ethanone
DMRC7V8	HS	Investigative
DMRC7V8	SN	CHEMBL238620; 27918-37-2; 1-(4-methoxyphenyl)-2-(phenylsulfonyl)ethanone; 1-(4-methoxyphenyl)-2-(phenylsulfonyl)-1-ethanone; AC1N74YZ; Oprea1_356612; 2-(benzenesulfonyl)-1-(4-methoxyphenyl)ethanone; SCHEMBL6203408; CTK0J2325; DTXSID00401432; MolPort-002-876-892; ZINC399878; KS-00003CN3; BDBM50212535; AKOS005097711; 7H-365S; MCULE-5138703884; 4'-Methoxy-alpha-(phenylsulfonyl)acetophenone; 4'-METHOXY-2-(PHENYLSULFONYL)ACETOPHENONE; Ethanone, 1-(4-methoxyphenyl)-2-(phenylsulfonyl)-
DMRC7V8	DT	Small molecular drug
DMRC7V8	PC	4271571
DMRC7V8	MW	290.3
DMRC7V8	FM	C15H14O4S
DMRC7V8	IC	InChI=1S/C15H14O4S/c1-19-13-9-7-12(8-10-13)15(16)11-20(17,18)14-5-3-2-4-6-14/h2-10H,11H2,1H3
DMRC7V8	CS	COC1=CC=C(C=C1)C(=O)CS(=O)(=O)C2=CC=CC=C2
DMRC7V8	IK	ZVVAUSXHYOKZSR-UHFFFAOYSA-N
DMRC7V8	IU	2-(benzenesulfonyl)-1-(4-methoxyphenyl)ethanone
DMRC7V8	CA	CAS 27918-37-2
DMRC7V8	DE	Discovery agent

DM5R8KU	ID	DM5R8KU
DM5R8KU	DN	1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione
DM5R8KU	HS	Investigative
DM5R8KU	SN	4-Methoxybenzil; p-Methoxybenzil; BENZIL, 4-METHOXY-; 22711-21-3; Ethanedione, (4-methoxyphenyl)phenyl-; NSC 39465; 1-(4-methoxyphenyl)-2-phenylethane-1,2-dione; BRN 2052507; NTINAJCDYRYMML-UHFFFAOYSA-N; NSC39465; Dibenzoyl, 4-methoxy; AC1L1LPW; Benzil-based compound, 20; 4-08-00-02532 (Beilstein Handbook Reference); SCHEMBL2156563; CHEMBL192474; BDBM22742; DTXSID40177245; MolPort-001-788-309; 4-Methoxybibenzyl-alpha,beta-dione; ZINC1671392; STK863335; NSC-39465; BBL023172; NSC602911; AKOS000298817; NSC-602911; MCULE-6173981634
DM5R8KU	DT	Small molecular drug
DM5R8KU	PC	31494
DM5R8KU	MW	240.25
DM5R8KU	FM	C15H12O3
DM5R8KU	IC	InChI=1S/C15H12O3/c1-18-13-9-7-12(8-10-13)15(17)14(16)11-5-3-2-4-6-11/h2-10H,1H3
DM5R8KU	CS	COC1=CC=C(C=C1)C(=O)C(=O)C2=CC=CC=C2
DM5R8KU	IK	NTINAJCDYRYMML-UHFFFAOYSA-N
DM5R8KU	IU	1-(4-methoxyphenyl)-2-phenylethane-1,2-dione
DM5R8KU	CA	CAS 22711-21-3
DM5R8KU	DE	Discovery agent

DMNJ2CS	ID	DMNJ2CS
DMNJ2CS	DN	1-(4-methoxyphenyl)-3-(1,3,4-thiadiazol-2-yl)urea
DMNJ2CS	HS	Investigative
DMNJ2CS	SN	CHEMBL389884; ZINC28225822
DMNJ2CS	DT	Small molecular drug
DMNJ2CS	PC	35523889
DMNJ2CS	MW	250.28
DMNJ2CS	FM	C10H10N4O2S
DMNJ2CS	IC	InChI=1S/C10H10N4O2S/c1-16-8-4-2-7(3-5-8)12-9(15)13-10-14-11-6-17-10/h2-6H,1H3,(H2,12,13,14,15)
DMNJ2CS	CS	COC1=CC=C(C=C1)NC(=O)NC2=NN=CS2
DMNJ2CS	IK	WRRMEHJVEKNTQJ-UHFFFAOYSA-N
DMNJ2CS	IU	1-(4-methoxyphenyl)-3-(1,3,4-thiadiazol-2-yl)urea
DMNJ2CS	DE	Discovery agent

DMYPC0W	ID	DMYPC0W
DMYPC0W	DN	1-(4-methoxyphenyl)-3-(4-methylthiazol-2-yl)urea
DMYPC0W	HS	Investigative
DMYPC0W	SN	CHEMBL375257
DMYPC0W	DT	Small molecular drug
DMYPC0W	PC	44423266
DMYPC0W	MW	263.32
DMYPC0W	FM	C12H13N3O2S
DMYPC0W	IC	InChI=1S/C12H13N3O2S/c1-8-7-18-12(13-8)15-11(16)14-9-3-5-10(17-2)6-4-9/h3-7H,1-2H3,(H2,13,14,15,16)
DMYPC0W	CS	CC1=CSC(=N1)NC(=O)NC2=CC=C(C=C2)OC
DMYPC0W	IK	DEHFWCRYQNJICK-UHFFFAOYSA-N
DMYPC0W	IU	1-(4-methoxyphenyl)-3-(4-methyl-1,3-thiazol-2-yl)urea
DMYPC0W	DE	Discovery agent

DMVWIE5	ID	DMVWIE5
DMVWIE5	DN	1-(4-methoxyphenyl)-3-(5-methylthiazol-2-yl)urea
DMVWIE5	HS	Investigative
DMVWIE5	SN	AC1LGH35; CHEMBL226324
DMVWIE5	DT	Small molecular drug
DMVWIE5	PC	771042
DMVWIE5	MW	263.32
DMVWIE5	FM	C12H13N3O2S
DMVWIE5	IC	InChI=1S/C12H13N3O2S/c1-8-7-13-12(18-8)15-11(16)14-9-3-5-10(17-2)6-4-9/h3-7H,1-2H3,(H2,13,14,15,16)
DMVWIE5	CS	CC1=CN=C(S1)NC(=O)NC2=CC=C(C=C2)OC
DMVWIE5	IK	OHPUNXDCCJNSEH-UHFFFAOYSA-N
DMVWIE5	IU	1-(4-methoxyphenyl)-3-(5-methyl-1,3-thiazol-2-yl)urea
DMVWIE5	DE	Discovery agent

DMG7PKA	ID	DMG7PKA
DMG7PKA	DN	1-(4-methoxyphenylsulfonyl)-4-phenylazepan-4-ol
DMG7PKA	HS	Investigative
DMG7PKA	SN	CHEMBL561076; 1-(4-methoxyphenylsulfonyl)-4-phenylazepan-4-ol; SCHEMBL12549973
DMG7PKA	DT	Small molecular drug
DMG7PKA	PC	25192455
DMG7PKA	MW	361.5
DMG7PKA	FM	C19H23NO4S
DMG7PKA	IC	InChI=1S/C19H23NO4S/c1-24-17-8-10-18(11-9-17)25(22,23)20-14-5-12-19(21,13-15-20)16-6-3-2-4-7-16/h2-4,6-11,21H,5,12-15H2,1H3
DMG7PKA	CS	COC1=CC=C(C=C1)S(=O)(=O)N2CCCC(CC2)(C3=CC=CC=C3)O
DMG7PKA	IK	CTMRNVLOBOSBEA-UHFFFAOYSA-N
DMG7PKA	IU	1-(4-methoxyphenyl)sulfonyl-4-phenylazepan-4-ol
DMG7PKA	DE	Discovery agent

DMNDJTL	ID	DMNDJTL
DMNDJTL	DN	1'-(4-Methyl-benzyl)-[1,4']bipiperidinyl
DMNDJTL	HS	Investigative
DMNDJTL	SN	CHEMBL399558; Tyrosinase Inhibitor, 4; BDBM50218211
DMNDJTL	DT	Small molecular drug
DMNDJTL	PC	23727896
DMNDJTL	MW	272.4
DMNDJTL	FM	C18H28N2
DMNDJTL	IC	InChI=1S/C18H28N2/c1-16-5-7-17(8-6-16)15-19-13-9-18(10-14-19)20-11-3-2-4-12-20/h5-8,18H,2-4,9-15H2,1H3
DMNDJTL	CS	CC1=CC=C(C=C1)CN2CCC(CC2)N3CCCCC3
DMNDJTL	IK	XJYLZLHTPACMIL-UHFFFAOYSA-N
DMNDJTL	IU	1-[(4-methylphenyl)methyl]-4-piperidin-1-ylpiperidine
DMNDJTL	DE	Discovery agent

DM48ISZ	ID	DM48ISZ
DM48ISZ	DN	1-(4-methyl-benzyl)-1H-imidazole
DM48ISZ	HS	Investigative
DM48ISZ	SN	1-(4-methylbenzyl)-1H-imidazole; CHEMBL212741; 18994-86-0; 1-(4-methyl-benzyl)-1H-imidazole; 1H-Imidazole, 1-[(4-methylphenyl)methyl]-; 1-(4-Methylbenzyl)imidazole; SCHEMBL171734; BDBM50188087; ZINC35143440
DM48ISZ	DT	Small molecular drug
DM48ISZ	PC	12229395
DM48ISZ	MW	172.23
DM48ISZ	FM	C11H12N2
DM48ISZ	IC	InChI=1S/C11H12N2/c1-10-2-4-11(5-3-10)8-13-7-6-12-9-13/h2-7,9H,8H2,1H3
DM48ISZ	CS	CC1=CC=C(C=C1)CN2C=CN=C2
DM48ISZ	IK	DQXGQHAFADWCKG-UHFFFAOYSA-N
DM48ISZ	IU	1-[(4-methylphenyl)methyl]imidazole
DM48ISZ	DE	Discovery agent

DMVI2PM	ID	DMVI2PM
DMVI2PM	DN	1-(4-methyloxazol-2-yl)-7-phenylheptan-1-one
DMVI2PM	HS	Investigative
DMVI2PM	SN	CHEMBL462405; 1-(4-methyloxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162404
DMVI2PM	DT	Small molecular drug
DMVI2PM	PC	44554442
DMVI2PM	MW	271.35
DMVI2PM	FM	C17H21NO2
DMVI2PM	IC	InChI=1S/C17H21NO2/c1-14-13-20-17(18-14)16(19)12-8-3-2-5-9-15-10-6-4-7-11-15/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DMVI2PM	CS	CC1=COC(=N1)C(=O)CCCCCCC2=CC=CC=C2
DMVI2PM	IK	UCOJBUIULZAIKB-UHFFFAOYSA-N
DMVI2PM	IU	1-(4-methyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMVI2PM	DE	Discovery agent

DM3NVLB	ID	DM3NVLB
DM3NVLB	DN	1-(4-Methylpent-3-en-2-ylidene)thiosemicarbazide
DM3NVLB	HS	Investigative
DM3NVLB	SN	CHEMBL444251; 1-(4-Methylpent-3-en-2-ylidene)thiosemicarbazide
DM3NVLB	DT	Small molecular drug
DM3NVLB	PC	44583134
DM3NVLB	MW	171.27
DM3NVLB	FM	C7H13N3S
DM3NVLB	IC	InChI=1S/C7H13N3S/c1-5(2)4-6(3)9-10-7(8)11/h4H,1-3H3,(H3,8,10,11)/b9-6-
DM3NVLB	CS	CC(=C/C(=N\\NC(=S)N)/C)C
DM3NVLB	IK	KSBSSDJKRMIXES-TWGQIWQCSA-N
DM3NVLB	IU	[(Z)-4-methylpent-3-en-2-ylideneamino]thiourea
DM3NVLB	DE	Discovery agent

DMSRBUE	ID	DMSRBUE
DMSRBUE	DN	1-(4-nitro-2-phenoxybenzyl)-1H-imidazole
DMSRBUE	HS	Investigative
DMSRBUE	SN	CHEMBL1083653; 1-(4-nitro-2-phenoxybenzyl)-1H-imidazole
DMSRBUE	DT	Small molecular drug
DMSRBUE	PC	46867546
DMSRBUE	MW	295.29
DMSRBUE	FM	C16H13N3O3
DMSRBUE	IC	InChI=1S/C16H13N3O3/c20-19(21)14-7-6-13(11-18-9-8-17-12-18)16(10-14)22-15-4-2-1-3-5-15/h1-10,12H,11H2
DMSRBUE	CS	C1=CC=C(C=C1)OC2=C(C=CC(=C2)[N+](=O)[O-])CN3C=CN=C3
DMSRBUE	IK	JIPGEBKJKOMJSL-UHFFFAOYSA-N
DMSRBUE	IU	1-[(4-nitro-2-phenoxyphenyl)methyl]imidazole
DMSRBUE	DE	Discovery agent

DMCP089	ID	DMCP089
DMCP089	DN	1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole
DMCP089	HS	Investigative
DMCP089	SN	CHEMBL1085936; 1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole
DMCP089	DT	Small molecular drug
DMCP089	PC	46867547
DMCP089	MW	311.4
DMCP089	FM	C16H13N3O2S
DMCP089	IC	InChI=1S/C16H13N3O2S/c20-19(21)14-7-6-13(11-18-9-8-17-12-18)16(10-14)22-15-4-2-1-3-5-15/h1-10,12H,11H2
DMCP089	CS	C1=CC=C(C=C1)SC2=C(C=CC(=C2)[N+](=O)[O-])CN3C=CN=C3
DMCP089	IK	FOCINXPGESCYHX-UHFFFAOYSA-N
DMCP089	IU	1-[(4-nitro-2-phenylsulfanylphenyl)methyl]imidazole
DMCP089	DE	Discovery agent

DMKT2MB	ID	DMKT2MB
DMKT2MB	DN	1-(4-nitrobenzyl)-1H-imidazole
DMKT2MB	HS	Investigative
DMKT2MB	SN	1-(4-Nitrobenzyl)-1H-imidazole; 18994-90-6; 1-(4-Nitrobenzyl)imidazole; 1-[(4-nitrophenyl)methyl]imidazole; Imidazole, 1-(4-nitrobenzyl)-; CHEMBL13784; 1H-Imidazole, 1-[(4-nitrophenyl)methyl]-; FLYGQJXMRPZYHQ-UHFFFAOYSA-N; 1-(4-Nitro-benzyl)-1H-imidazole; [(4-nitrophenyl)methyl]imidazole; AC1LBNLW; AC1Q1ZC3; ACMC-1C81T; SCHEMBL78081; CTK4E0266; DTXSID10342908; MolPort-001-494-965; KS-000024IG; ZINC1027711; ALBB-024046; CN-460; ANW-23472; STK149522; SBB093104; BDBM50188093; 1-(4-Nitrobenzyl)-1H-imidazole #; AKOS003266265; VI10027
DMKT2MB	DT	Small molecular drug
DMKT2MB	PC	585819
DMKT2MB	MW	203.2
DMKT2MB	FM	C10H9N3O2
DMKT2MB	IC	InChI=1S/C10H9N3O2/c14-13(15)10-3-1-9(2-4-10)7-12-6-5-11-8-12/h1-6,8H,7H2
DMKT2MB	CS	C1=CC(=CC=C1CN2C=CN=C2)[N+](=O)[O-]
DMKT2MB	IK	FLYGQJXMRPZYHQ-UHFFFAOYSA-N
DMKT2MB	IU	1-[(4-nitrophenyl)methyl]imidazole
DMKT2MB	CA	CAS 18994-90-6
DMKT2MB	DE	Discovery agent

DMKR8BI	ID	DMKR8BI
DMKR8BI	DN	1-(4-nitrophenethyl)pyrrolidine
DMKR8BI	HS	Investigative
DMKR8BI	SN	1-(4-nitrophenethyl)pyrrolidine; CHEMBL273004; 168897-19-6; Pyrrolidine, 1-[2-(4-nitrophenyl)ethyl]-; SCHEMBL3156895; CTK0E5156; DTXSID90441428; YFOCDNYNVHXLJE-UHFFFAOYSA-N; BDBM50372307; ZINC29131362; 1-[2-(4-nitrophenyl)-ethyl]-pyrrolidine
DMKR8BI	DT	Small molecular drug
DMKR8BI	PC	10536901
DMKR8BI	MW	220.27
DMKR8BI	FM	C12H16N2O2
DMKR8BI	IC	InChI=1S/C12H16N2O2/c15-14(16)12-5-3-11(4-6-12)7-10-13-8-1-2-9-13/h3-6H,1-2,7-10H2
DMKR8BI	CS	C1CCN(C1)CCC2=CC=C(C=C2)[N+](=O)[O-]
DMKR8BI	IK	YFOCDNYNVHXLJE-UHFFFAOYSA-N
DMKR8BI	IU	1-[2-(4-nitrophenyl)ethyl]pyrrolidine
DMKR8BI	CA	CAS 168897-19-6
DMKR8BI	DE	Discovery agent

DM1M67Q	ID	DM1M67Q
DM1M67Q	DN	1-(4-nitrophenyl)-2-(phenylsulfonyl)ethanone
DM1M67Q	HS	Investigative
DM1M67Q	SN	CHEMBL393284; 38488-17-4; 1-(4-nitrophenyl)-2-(phenylsulfonyl)ethanone; 4-Nitrophenacylphenyl sulfone; SCHEMBL6908652; CTK1B4829; DTXSID80456743; BDBM50212551; AKOS003309631; Ethanone, 1-(4-nitrophenyl)-2-(phenylsulfonyl)-
DM1M67Q	DT	Small molecular drug
DM1M67Q	PC	11141268
DM1M67Q	MW	305.31
DM1M67Q	FM	C14H11NO5S
DM1M67Q	IC	InChI=1S/C14H11NO5S/c16-14(11-6-8-12(9-7-11)15(17)18)10-21(19,20)13-4-2-1-3-5-13/h1-9H,10H2
DM1M67Q	CS	C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CC=C(C=C2)[N+](=O)[O-]
DM1M67Q	IK	GBLYERGOMLTORH-UHFFFAOYSA-N
DM1M67Q	IU	2-(benzenesulfonyl)-1-(4-nitrophenyl)ethanone
DM1M67Q	CA	CAS 38488-17-4
DM1M67Q	DE	Discovery agent

DMOC67J	ID	DMOC67J
DMOC67J	DN	1-(4-Nitro-phenyl)-2-phenyl-ethane-1,2-dione
DMOC67J	HS	Investigative
DMOC67J	SN	4-Nitrobenzil; 1-(4-nitrophenyl)-2-phenylethane-1,2-dione; 22711-24-6; Benzil, 4-nitro-; p-Nitrobenzil; Ethanedione, (4-nitrophenyl)phenyl-; NSC139153; Benzil-based compound, 27; AC1Q5B1C; AC1L5ZN0; SCHEMBL1370034; CHEMBL192589; BDBM22749; CTK4F0012; 4-Nitrobibenzyl-alpha,beta-dione; DTXSID10300826; GPDKREBNFFEDHW-UHFFFAOYSA-N; MolPort-000-146-024; ZX-AT021384; ZINC2555760; STK325617; SBB101571; AKOS004902243; OR28786; NSC-139153; MCULE-2855880102; ACM22711246; KB-147450; DB-045974; FT-0605764; ST51043016
DMOC67J	DT	Small molecular drug
DMOC67J	PC	283893
DMOC67J	MW	255.22
DMOC67J	FM	C14H9NO4
DMOC67J	IC	InChI=1S/C14H9NO4/c16-13(10-4-2-1-3-5-10)14(17)11-6-8-12(9-7-11)15(18)19/h1-9H
DMOC67J	CS	C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)[N+](=O)[O-]
DMOC67J	IK	GPDKREBNFFEDHW-UHFFFAOYSA-N
DMOC67J	IU	1-(4-nitrophenyl)-2-phenylethane-1,2-dione
DMOC67J	CA	CAS 22711-24-6
DMOC67J	DE	Discovery agent

DME435S	ID	DME435S
DME435S	DN	1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DME435S	HS	Investigative
DME435S	SN	CHEMBL379446; 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4938101
DME435S	DT	Small molecular drug
DME435S	PC	11357862
DME435S	MW	276.33
DME435S	FM	C15H20N2O3
DME435S	IC	InChI=1S/C15H20N2O3/c1-2-5-14(16-10-3-4-11-16)15(18)12-6-8-13(9-7-12)17(19)20/h6-9,14H,2-5,10-11H2,1H3
DME435S	CS	CCCC(C(=O)C1=CC=C(C=C1)[N+](=O)[O-])N2CCCC2
DME435S	IK	NAHZCGQMXZCULW-UHFFFAOYSA-N
DME435S	IU	1-(4-nitrophenyl)-2-pyrrolidin-1-ylpentan-1-one
DME435S	DE	Discovery agent

DMQKMCG	ID	DMQKMCG
DMQKMCG	DN	1-(4-nonylbenzyl)azetidine-3-carboxylic acid
DMQKMCG	HS	Investigative
DMQKMCG	SN	CHEMBL224623; 570423-68-6; 1-(4-nonylbenzyl)azetidine-3-carboxylic acid; SCHEMBL13271128; CTK1F3133; DTXSID30436176; BDBM50158342; AKOS030540874; 3-Azetidinecarboxylic acid, 1-[(4-nonylphenyl)methyl]-
DMQKMCG	DT	Small molecular drug
DMQKMCG	PC	10149721
DMQKMCG	MW	317.5
DMQKMCG	FM	C20H31NO2
DMQKMCG	IC	InChI=1S/C20H31NO2/c1-2-3-4-5-6-7-8-9-17-10-12-18(13-11-17)14-21-15-19(16-21)20(22)23/h10-13,19H,2-9,14-16H2,1H3,(H,22,23)
DMQKMCG	CS	CCCCCCCCCC1=CC=C(C=C1)CN2CC(C2)C(=O)O
DMQKMCG	IK	OVHZTRSKNATTNM-UHFFFAOYSA-N
DMQKMCG	IU	1-[(4-nonylphenyl)methyl]azetidine-3-carboxylic acid
DMQKMCG	CA	CAS 570423-68-6
DMQKMCG	DE	Discovery agent

DM8U2HP	ID	DM8U2HP
DM8U2HP	DN	1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid
DM8U2HP	HS	Investigative
DM8U2HP	SN	CHEMBL184349; 570423-38-0; 1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid; SCHEMBL13937997; CTK1F3135; DTXSID10437782; PRUUCTGBHIGGOH-UHFFFAOYSA-N; BDBM50152329; [1-(4-Nonyl-benzyl)-pyrrolidin-3-yl]-phosphonic acid; (r/s)-1-(4-nonylbenzyl)-pyrrolidin-3-ylphosphonic acid; Phosphonic acid, [1-[(4-nonylphenyl)methyl]-3-pyrrolidinyl]-
DM8U2HP	DT	Small molecular drug
DM8U2HP	PC	10287034
DM8U2HP	MW	367.5
DM8U2HP	FM	C20H34NO3P
DM8U2HP	IC	InChI=1S/C20H34NO3P/c1-2-3-4-5-6-7-8-9-18-10-12-19(13-11-18)16-21-15-14-20(17-21)25(22,23)24/h10-13,20H,2-9,14-17H2,1H3,(H2,22,23,24)
DM8U2HP	CS	CCCCCCCCCC1=CC=C(C=C1)CN2CCC(C2)P(=O)(O)O
DM8U2HP	IK	PRUUCTGBHIGGOH-UHFFFAOYSA-N
DM8U2HP	IU	[1-[(4-nonylphenyl)methyl]pyrrolidin-3-yl]phosphonic acid
DM8U2HP	CA	CAS 570423-38-0
DM8U2HP	DE	Discovery agent

DMAR39L	ID	DMAR39L
DMAR39L	DN	1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid
DMAR39L	HS	Investigative
DMAR39L	SN	CHEMBL224703; 570423-46-0; 1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid; SCHEMBL6179612; CTK1F3134; DTXSID10436795; BDBM50158343; AKOS030543683; 3-Pyrrolidinecarboxylic acid, 1-[(4-nonylphenyl)methyl]-
DMAR39L	DT	Small molecular drug
DMAR39L	PC	10215259
DMAR39L	MW	331.5
DMAR39L	FM	C21H33NO2
DMAR39L	IC	InChI=1S/C21H33NO2/c1-2-3-4-5-6-7-8-9-18-10-12-19(13-11-18)16-22-15-14-20(17-22)21(23)24/h10-13,20H,2-9,14-17H2,1H3,(H,23,24)
DMAR39L	CS	CCCCCCCCCC1=CC=C(C=C1)CN2CCC(C2)C(=O)O
DMAR39L	IK	JXGNTXCFTVWCAS-UHFFFAOYSA-N
DMAR39L	IU	1-[(4-nonylphenyl)methyl]pyrrolidine-3-carboxylic acid
DMAR39L	CA	CAS 570423-46-0
DMAR39L	DE	Discovery agent

DM9KVBJ	ID	DM9KVBJ
DM9KVBJ	DN	1-(4-octylphenyl)prop-2-en-1-one
DM9KVBJ	HS	Investigative
DM9KVBJ	SN	CHEMBL237241
DM9KVBJ	DT	Small molecular drug
DM9KVBJ	PC	44435785
DM9KVBJ	MW	244.37
DM9KVBJ	FM	C17H24O
DM9KVBJ	IC	InChI=1S/C17H24O/c1-3-5-6-7-8-9-10-15-11-13-16(14-12-15)17(18)4-2/h4,11-14H,2-3,5-10H2,1H3
DM9KVBJ	CS	CCCCCCCCC1=CC=C(C=C1)C(=O)C=C
DM9KVBJ	IK	GXBVBDUWTMDYAH-UHFFFAOYSA-N
DM9KVBJ	IU	1-(4-octylphenyl)prop-2-en-1-one
DM9KVBJ	DE	Discovery agent

DMVCM0I	ID	DMVCM0I
DMVCM0I	DN	1-(4-Phenoxyphenyl)piperazine
DMVCM0I	HS	Investigative
DMVCM0I	SN	1-(4-Phenoxyphenyl)piperazine; CHEMBL576512; 62755-61-7; EINECS 263-715-9; AC1MI4LW; Oprea1_372692; SCHEMBL2156502; 1-(4-phenoxylphenyl)piperazine; 1-(4-phenoxyphenyl)-piperazine; CEDIEUVYUSGIDQ-UHFFFAOYSA-N; Piperazine, 1-(4-phenoxyphenyl)-; BDBM50303652; ZINC11632570; AKOS000365585
DMVCM0I	DT	Small molecular drug
DMVCM0I	PC	3017356
DMVCM0I	MW	254.33
DMVCM0I	FM	C16H18N2O
DMVCM0I	IC	InChI=1S/C16H18N2O/c1-2-4-15(5-3-1)19-16-8-6-14(7-9-16)18-12-10-17-11-13-18/h1-9,17H,10-13H2
DMVCM0I	CS	C1CN(CCN1)C2=CC=C(C=C2)OC3=CC=CC=C3
DMVCM0I	IK	CEDIEUVYUSGIDQ-UHFFFAOYSA-N
DMVCM0I	IU	1-(4-phenoxyphenyl)piperazine
DMVCM0I	CA	CAS 62755-61-7
DMVCM0I	DE	Discovery agent

DMKNA5U	ID	DMKNA5U
DMKNA5U	DN	1-(4-propoxyphenyl)propan-2-amine
DMKNA5U	HS	Investigative
DMKNA5U	SN	1-(4-propoxyphenyl)propan-2-amine; CHEMBL455991; AC1MHJ8Q; BDBM50276773
DMKNA5U	DT	Small molecular drug
DMKNA5U	PC	3027265
DMKNA5U	MW	193.28
DMKNA5U	FM	C12H19NO
DMKNA5U	IC	InChI=1S/C12H19NO/c1-3-8-14-12-6-4-11(5-7-12)9-10(2)13/h4-7,10H,3,8-9,13H2,1-2H3
DMKNA5U	CS	CCCOC1=CC=C(C=C1)CC(C)N
DMKNA5U	IK	NVNUOGJMXPVHLF-UHFFFAOYSA-N
DMKNA5U	IU	1-(4-propoxyphenyl)propan-2-amine
DMKNA5U	DE	Discovery agent

DMFYK6T	ID	DMFYK6T
DMFYK6T	DN	1-(4-p-Tolyl-butyl)-piperidine
DMFYK6T	HS	Investigative
DMFYK6T	SN	CHEMBL571073; 1-(4-p-Tolyl-butyl)-piperidine
DMFYK6T	DT	Small molecular drug
DMFYK6T	PC	45485498
DMFYK6T	MW	231.38
DMFYK6T	FM	C16H25N
DMFYK6T	IC	InChI=1S/C16H25N/c1-15-8-10-16(11-9-15)7-3-6-14-17-12-4-2-5-13-17/h8-11H,2-7,12-14H2,1H3
DMFYK6T	CS	CC1=CC=C(C=C1)CCCCN2CCCCC2
DMFYK6T	IK	ZJZNOPQUDXUEDU-UHFFFAOYSA-N
DMFYK6T	IU	1-[4-(4-methylphenyl)butyl]piperidine
DMFYK6T	DE	Discovery agent

DMM7IJZ	ID	DMM7IJZ
DMM7IJZ	DN	1-(4-tert-butylphenylsulfonyl)-4-methoxyazepane
DMM7IJZ	HS	Investigative
DMM7IJZ	SN	CHEMBL560396; 1-(4-tert-butylphenylsulfonyl)-4-methoxyazepane; SCHEMBL12549992
DMM7IJZ	DT	Small molecular drug
DMM7IJZ	PC	25192606
DMM7IJZ	MW	325.5
DMM7IJZ	FM	C17H27NO3S
DMM7IJZ	IC	InChI=1S/C17H27NO3S/c1-17(2,3)14-7-9-16(10-8-14)22(19,20)18-12-5-6-15(21-4)11-13-18/h7-10,15H,5-6,11-13H2,1-4H3
DMM7IJZ	CS	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)N2CCCC(CC2)OC
DMM7IJZ	IK	XPMSNNNCHQEDRB-UHFFFAOYSA-N
DMM7IJZ	IU	1-(4-tert-butylphenyl)sulfonyl-4-methoxyazepane
DMM7IJZ	DE	Discovery agent

DMQECWT	ID	DMQECWT
DMQECWT	DN	1-(4-tert-butylphenylsulfonyl)azepan-4-ol
DMQECWT	HS	Investigative
DMQECWT	SN	CHEMBL539200; 1-(4-tert-butylphenylsulfonyl)azepan-4-ol; SCHEMBL12550392
DMQECWT	DT	Small molecular drug
DMQECWT	PC	25192605
DMQECWT	MW	311.4
DMQECWT	FM	C16H25NO3S
DMQECWT	IC	InChI=1S/C16H25NO3S/c1-16(2,3)13-6-8-15(9-7-13)21(19,20)17-11-4-5-14(18)10-12-17/h6-9,14,18H,4-5,10-12H2,1-3H3
DMQECWT	CS	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)N2CCCC(CC2)O
DMQECWT	IK	GHPTYGKGUJYMFW-UHFFFAOYSA-N
DMQECWT	IU	1-(4-tert-butylphenyl)sulfonylazepan-4-ol
DMQECWT	DE	Discovery agent

DMPL3UZ	ID	DMPL3UZ
DMPL3UZ	DN	1-(5-(furan-2-yl)oxazol-2-yl)octadec-9-en-1-one
DMPL3UZ	HS	Investigative
DMPL3UZ	SN	CHEMBL174048; 1-(5-(furan-2-yl)oxazol-2-yl)octadec-9-en-1-one; SCHEMBL3196395; BDBM50157127; (Z)-1-(5-Furan-2-yl-oxazol-2-yl)-octadec-9-en-1-one
DMPL3UZ	DT	Small molecular drug
DMPL3UZ	PC	11361560
DMPL3UZ	MW	399.6
DMPL3UZ	FM	C25H37NO3
DMPL3UZ	IC	InChI=1S/C25H37NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-22(27)25-26-21-24(29-25)23-19-17-20-28-23/h9-10,17,19-21H,2-8,11-16,18H2,1H3/b10-9-
DMPL3UZ	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC=C(O1)C2=CC=CO2
DMPL3UZ	IK	RZGSPAWMLKONHZ-KTKRTIGZSA-N
DMPL3UZ	IU	(Z)-1-[5-(furan-2-yl)-1,3-oxazol-2-yl]octadec-9-en-1-one
DMPL3UZ	DE	Discovery agent

DM4V9IB	ID	DM4V9IB
DM4V9IB	DN	1-(5-(pyridin-2-yl)oxazol-2-yl)dodecan-1-one
DM4V9IB	HS	Investigative
DM4V9IB	SN	CHEMBL177757; 1-(5-(pyridin-2-yl)oxazol-2-yl)dodecan-1-one; SCHEMBL3184225; VESZWTBYTDWAEO-UHFFFAOYSA-N; BDBM50163165
DM4V9IB	DT	Small molecular drug
DM4V9IB	PC	11450288
DM4V9IB	MW	328.4
DM4V9IB	FM	C20H28N2O2
DM4V9IB	IC	InChI=1S/C20H28N2O2/c1-2-3-4-5-6-7-8-9-10-14-18(23)20-22-16-19(24-20)17-13-11-12-15-21-17/h11-13,15-16H,2-10,14H2,1H3
DM4V9IB	CS	CCCCCCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DM4V9IB	IK	VESZWTBYTDWAEO-UHFFFAOYSA-N
DM4V9IB	IU	1-(5-pyridin-2-yl-1,3-oxazol-2-yl)dodecan-1-one
DM4V9IB	DE	Discovery agent

DMICZK0	ID	DMICZK0
DMICZK0	DN	1-(5-(pyridin-2-yl)oxazol-2-yl)octadec-9-en-1-one
DMICZK0	HS	Investigative
DMICZK0	SN	CHEMBL426230; SCHEMBL3193600; 1-(5-(pyridin-2-yl)oxazol-2-yl)octadec-9-en-1-one; 2-Oleoyl-5-(2-pyridyl)oxazole; BDBM50157122; AKOS030561894; 1-(5-Pyridin-2-yl-oxazol-2-yl)-nonadec-10-en-2-one; (Z)-1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-en-1-one
DMICZK0	DT	Small molecular drug
DMICZK0	PC	11327355
DMICZK0	MW	410.6
DMICZK0	FM	C26H38N2O2
DMICZK0	IC	InChI=1S/C26H38N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-24(29)26-28-22-25(30-26)23-19-17-18-21-27-23/h9-10,17-19,21-22H,2-8,11-16,20H2,1H3/b10-9-
DMICZK0	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DMICZK0	IK	MTEOAQVTLKPFRA-KTKRTIGZSA-N
DMICZK0	IU	(Z)-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)octadec-9-en-1-one
DMICZK0	CA	CAS 639819-38-8
DMICZK0	DE	Discovery agent

DMZNEIB	ID	DMZNEIB
DMZNEIB	DN	1-(5-(pyridin-2-yl)oxazol-2-yl)octan-1-one
DMZNEIB	HS	Investigative
DMZNEIB	SN	CHEMBL175021; 1-(5-(pyridin-2-yl)oxazol-2-yl)octan-1-one; SCHEMBL3197441; VLJKBQYNIDBQEJ-UHFFFAOYSA-N; BDBM50163176
DMZNEIB	DT	Small molecular drug
DMZNEIB	PC	11173328
DMZNEIB	MW	272.34
DMZNEIB	FM	C16H20N2O2
DMZNEIB	IC	InChI=1S/C16H20N2O2/c1-2-3-4-5-6-10-14(19)16-18-12-15(20-16)13-9-7-8-11-17-13/h7-9,11-12H,2-6,10H2,1H3
DMZNEIB	CS	CCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DMZNEIB	IK	VLJKBQYNIDBQEJ-UHFFFAOYSA-N
DMZNEIB	IU	1-(5-pyridin-2-yl-1,3-oxazol-2-yl)octan-1-one
DMZNEIB	DE	Discovery agent

DM6FDAY	ID	DM6FDAY
DM6FDAY	DN	1-(5-(pyridin-2-yl)oxazol-2-yl)pentan-1-one
DM6FDAY	HS	Investigative
DM6FDAY	SN	CHEMBL174951; 1-(5-(pyridin-2-yl)oxazol-2-yl)pentan-1-one; SCHEMBL3194478; BDBM50163189
DM6FDAY	DT	Small molecular drug
DM6FDAY	PC	11401957
DM6FDAY	MW	230.26
DM6FDAY	FM	C13H14N2O2
DM6FDAY	IC	InChI=1S/C13H14N2O2/c1-2-3-7-11(16)13-15-9-12(17-13)10-6-4-5-8-14-10/h4-6,8-9H,2-3,7H2,1H3
DM6FDAY	CS	CCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DM6FDAY	IK	ZGJFSRIJAXSNIH-UHFFFAOYSA-N
DM6FDAY	IU	1-(5-pyridin-2-yl-1,3-oxazol-2-yl)pentan-1-one
DM6FDAY	DE	Discovery agent

DMDTYAF	ID	DMDTYAF
DMDTYAF	DN	1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea
DMDTYAF	HS	Investigative
DMDTYAF	SN	CHEMBL430376; 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea; 117745-34-3; Urea, N-(5-chloro-2-hydroxy-4-nitrophenyl)-N'-phenyl-; ACMC-20mnej; AC1MXJKZ; SCHEMBL4241814; CTK0G0114; DTXSID10396461; MolPort-001-764-839; ZX-AT026392; ZINC3917497; BDBM50203018; AKOS024384929; MCULE-2402836101; ST51035461; 3-(5-chloro-2-hydroxy-4-nitrophenyl)-1-phenylurea
DMDTYAF	DT	Small molecular drug
DMDTYAF	PC	3791448
DMDTYAF	MW	307.69
DMDTYAF	FM	C13H10ClN3O4
DMDTYAF	IC	InChI=1S/C13H10ClN3O4/c14-9-6-10(12(18)7-11(9)17(20)21)16-13(19)15-8-4-2-1-3-5-8/h1-7,18H,(H2,15,16,19)
DMDTYAF	CS	C1=CC=C(C=C1)NC(=O)NC2=CC(=C(C=C2O)[N+](=O)[O-])Cl
DMDTYAF	IK	ASMCVDDUQQZBFK-UHFFFAOYSA-N
DMDTYAF	IU	1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea
DMDTYAF	CA	CAS 117745-34-3
DMDTYAF	DE	Discovery agent

DMD8IYZ	ID	DMD8IYZ
DMD8IYZ	DN	1-(5-fluorooxazol-2-yl)-7-phenylheptan-1-one
DMD8IYZ	HS	Investigative
DMD8IYZ	SN	CHEMBL373906; SCHEMBL3145274; BDBM50374375
DMD8IYZ	DT	Small molecular drug
DMD8IYZ	PC	11991891
DMD8IYZ	MW	275.32
DMD8IYZ	FM	C16H18FNO2
DMD8IYZ	IC	InChI=1S/C16H18FNO2/c17-15-12-18-16(20-15)14(19)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMD8IYZ	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=C(O2)F
DMD8IYZ	IK	KUKHXFUDITXZRG-UHFFFAOYSA-N
DMD8IYZ	IU	1-(5-fluoro-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMD8IYZ	DE	Discovery agent

DMWQ9ZP	ID	DMWQ9ZP
DMWQ9ZP	DN	1-(5-methyloxazol-2-yl)-7-phenylheptan-1-one
DMWQ9ZP	HS	Investigative
DMWQ9ZP	SN	CHEMBL220938; SCHEMBL3144951; BDBM50374374; 1-(5-Methyl-2-oxazolyl)-7-phenyl-1-heptanone
DMWQ9ZP	DT	Small molecular drug
DMWQ9ZP	PC	11991888
DMWQ9ZP	MW	271.35
DMWQ9ZP	FM	C17H21NO2
DMWQ9ZP	IC	InChI=1S/C17H21NO2/c1-14-13-18-17(20-14)16(19)12-8-3-2-5-9-15-10-6-4-7-11-15/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DMWQ9ZP	CS	CC1=CN=C(O1)C(=O)CCCCCCC2=CC=CC=C2
DMWQ9ZP	IK	PBGYMEUYJWSKDY-UHFFFAOYSA-N
DMWQ9ZP	IU	1-(5-methyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMWQ9ZP	DE	Discovery agent

DMRITHA	ID	DMRITHA
DMRITHA	DN	1-(5-phenyloxazol-2-yl)octadec-9-en-1-one
DMRITHA	HS	Investigative
DMRITHA	SN	CHEMBL426410; 2-Oleoyl-5-phenyloxazole; 1-(5-phenyloxazol-2-yl)octadec-9-en-1-one; SCHEMBL3205790; BDBM50161521; AKOS030561892; 1-(5-Phenyl-oxazol-2-yl)-nonadec-10-en-2-one; (Z)-1-(5-phenyloxazol-2-yl)octadec-9-en-1-one
DMRITHA	DT	Small molecular drug
DMRITHA	PC	11154099
DMRITHA	MW	409.6
DMRITHA	FM	C27H39NO2
DMRITHA	IC	InChI=1S/C27H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-25(29)27-28-23-26(30-27)24-20-17-16-18-21-24/h9-10,16-18,20-21,23H,2-8,11-15,19,22H2,1H3/b10-9-
DMRITHA	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=C2
DMRITHA	IK	JBJNKCWDUQMEEA-KTKRTIGZSA-N
DMRITHA	IU	(Z)-1-(5-phenyl-1,3-oxazol-2-yl)octadec-9-en-1-one
DMRITHA	CA	CAS 681135-40-0
DMRITHA	DE	Discovery agent

DM4IMON	ID	DM4IMON
DM4IMON	DN	1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-yn-1-one
DM4IMON	HS	Investigative
DM4IMON	SN	CHEMBL174397; SCHEMBL3202757; 1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-yn-1-one
DM4IMON	DT	Small molecular drug
DM4IMON	PC	11441196
DM4IMON	MW	408.6
DM4IMON	FM	C26H36N2O2
DM4IMON	IC	InChI=1S/C26H36N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-24(29)26-28-22-25(30-26)23-19-17-18-21-27-23/h17-19,21-22H,2-8,11-16,20H2,1H3
DM4IMON	CS	CCCCCCCCC#CCCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DM4IMON	IK	PFSWYEYBMPLGTD-UHFFFAOYSA-N
DM4IMON	IU	1-(5-pyridin-2-yl-1,3-oxazol-2-yl)octadec-9-yn-1-one
DM4IMON	DE	Discovery agent

DMUS9Z3	ID	DMUS9Z3
DMUS9Z3	DN	1-(6-Amino-4-methylpyridin-2-yl)propan-2-ol
DMUS9Z3	HS	Investigative
DMUS9Z3	SN	CHEMBL500364; 1-(6-Amino-4-methylpyridin-2-yl)propan-2-ol
DMUS9Z3	DT	Small molecular drug
DMUS9Z3	PC	42625616
DMUS9Z3	MW	166.22
DMUS9Z3	FM	C9H14N2O
DMUS9Z3	IC	InChI=1S/C9H14N2O/c1-6-3-8(5-7(2)12)11-9(10)4-6/h3-4,7,12H,5H2,1-2H3,(H2,10,11)
DMUS9Z3	CS	CC1=CC(=NC(=C1)N)CC(C)O
DMUS9Z3	IK	KSEWELLLEMDLDQ-UHFFFAOYSA-N
DMUS9Z3	IU	1-(6-amino-4-methylpyridin-2-yl)propan-2-ol
DMUS9Z3	DE	Discovery agent

DMEHK4F	ID	DMEHK4F
DMEHK4F	DN	1-(6-Methoxy-naphthalen-2-yl)-1H-imidazole
DMEHK4F	HS	Investigative
DMEHK4F	SN	BDBM8918; CHEMBL195629; SCHEMBL4499181; Imidazole-substituted naphthalene 25; ZINC13674484; 1-(6-methoxy-2-naphthyl)-1h-imidazole
DMEHK4F	DT	Small molecular drug
DMEHK4F	PC	11514098
DMEHK4F	MW	224.26
DMEHK4F	FM	C14H12N2O
DMEHK4F	IC	InChI=1S/C14H12N2O/c1-17-14-5-3-11-8-13(4-2-12(11)9-14)16-7-6-15-10-16/h2-10H,1H3
DMEHK4F	CS	COC1=CC2=C(C=C1)C=C(C=C2)N3C=CN=C3
DMEHK4F	IK	IARFMQDFBJWHDO-UHFFFAOYSA-N
DMEHK4F	IU	1-(6-methoxynaphthalen-2-yl)imidazole
DMEHK4F	DE	Discovery agent

DM7OGLI	ID	DM7OGLI
DM7OGLI	DN	1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea
DM7OGLI	HS	Investigative
DM7OGLI	SN	Diarylurea deriv. 14; AC1NS9HN; CHEMBL140624; BDBM6654; ZINC13471112; 1-(7-Hydroxy-1-naphthyl)-3-(2-pyridyl)urea; N-(7-Hydroxy-1-naphthyl)-N -pyridin-2-ylurea; 1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea
DM7OGLI	DT	Small molecular drug
DM7OGLI	PC	5330595
DM7OGLI	MW	279.29
DM7OGLI	FM	C16H13N3O2
DM7OGLI	IC	InChI=1S/C16H13N3O2/c20-12-8-7-11-4-3-5-14(13(11)10-12)18-16(21)19-15-6-1-2-9-17-15/h1-10,20H,(H2,17,18,19,21)
DM7OGLI	CS	C1=CC=NC(=C1)NC(=O)NC2=CC=CC3=C2C=C(C=C3)O
DM7OGLI	IK	PLKPAJOIRNQZMG-UHFFFAOYSA-N
DM7OGLI	IU	1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea
DM7OGLI	DE	Discovery agent

DMLHDE3	ID	DMLHDE3
DMLHDE3	DN	1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole
DMLHDE3	HS	Investigative
DMLHDE3	SN	CHEMBL95109; 1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole
DMLHDE3	DT	Small molecular drug
DMLHDE3	PC	10267149
DMLHDE3	MW	306.4
DMLHDE3	FM	C19H18N2O2
DMLHDE3	IC	InChI=1S/C19H18N2O2/c1-22-15-7-8-16-17(21-10-9-20-13-21)12-18(23-19(16)11-15)14-5-3-2-4-6-14/h2-11,13,17-18H,12H2,1H3
DMLHDE3	CS	COC1=CC2=C(C=C1)C(CC(O2)C3=CC=CC=C3)N4C=CN=C4
DMLHDE3	IK	JEQHTTKNYWNYDK-UHFFFAOYSA-N
DMLHDE3	IU	1-(7-methoxy-2-phenyl-3,4-dihydro-2H-chromen-4-yl)imidazole
DMLHDE3	DE	Discovery agent

DM1MJCE	ID	DM1MJCE
DM1MJCE	DN	1-(7-Methoxy-naphthalen-2-yl)-piperazine
DM1MJCE	HS	Investigative
DM1MJCE	SN	1-(7-methoxynaphthalen-2-yl)piperazine; CHEMBL129661; 1174207-86-3; 1-(7-Methoxy-naphthalen-2-yl)-piperazine; ZINC27313663; BDBM50061300; DA-15050
DM1MJCE	DT	Small molecular drug
DM1MJCE	PC	44351692
DM1MJCE	MW	242.32
DM1MJCE	FM	C15H18N2O
DM1MJCE	IC	InChI=1S/C15H18N2O/c1-18-15-5-3-12-2-4-14(10-13(12)11-15)17-8-6-16-7-9-17/h2-5,10-11,16H,6-9H2,1H3
DM1MJCE	CS	COC1=CC2=C(C=CC(=C2)N3CCNCC3)C=C1
DM1MJCE	IK	FRTFBUOBLXTGSL-UHFFFAOYSA-N
DM1MJCE	IU	1-(7-methoxynaphthalen-2-yl)piperazine
DM1MJCE	DE	Discovery agent

DMKHJBI	ID	DMKHJBI
DMKHJBI	DN	1-(7-methyl-9H-carbazol-3-yl)ethanone
DMKHJBI	HS	Investigative
DMKHJBI	SN	CHEMBL1173069; 1-(7-methyl-9H-carbazol-3-yl)ethanone
DMKHJBI	DT	Small molecular drug
DMKHJBI	PC	44191653
DMKHJBI	MW	223.27
DMKHJBI	FM	C15H13NO
DMKHJBI	IC	InChI=1S/C15H13NO/c1-9-3-5-12-13-8-11(10(2)17)4-6-14(13)16-15(12)7-9/h3-8,16H,1-2H3
DMKHJBI	CS	CC1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)C(=O)C
DMKHJBI	IK	YNKFXJJSPLSRRJ-UHFFFAOYSA-N
DMKHJBI	IU	1-(7-methyl-9H-carbazol-3-yl)ethanone
DMKHJBI	DE	Discovery agent

DMC3PYM	ID	DMC3PYM
DMC3PYM	DN	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
DMC3PYM	HS	Investigative
DMC3PYM	SN	PhiKan 083; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine
DMC3PYM	DT	Small molecular drug
DMC3PYM	PC	4722579
DMC3PYM	MW	238.33
DMC3PYM	FM	C16H18N2
DMC3PYM	IC	InChI=1S/C16H18N2/c1-3-18-15-7-5-4-6-13(15)14-10-12(11-17-2)8-9-16(14)18/h4-10,17H,3,11H2,1-2H3
DMC3PYM	CS	CCN1C2=C(C=C(C=C2)CNC)C3=CC=CC=C31
DMC3PYM	IK	LBPNOEAFWYTTEB-UHFFFAOYSA-N
DMC3PYM	IU	1-(9-ethylcarbazol-3-yl)-N-methylmethanamine
DMC3PYM	DE	Discovery agent

DMA96U5	ID	DMA96U5
DMA96U5	DN	1-(9H-beta-Carbolin-3-yl)-butan-1-one
DMA96U5	HS	Investigative
DMA96U5	SN	CHEMBL69719; AC1NFSYI; 1-(9H-beta-Carbolin-3-yl)-butan-1-one; 3-Butyryl-beta-carboline; CHEMBL510764; ZINC7260873; BDBM50001474
DMA96U5	DT	Small molecular drug
DMA96U5	PC	4713438
DMA96U5	MW	238.28
DMA96U5	FM	C15H14N2O
DMA96U5	IC	InChI=1S/C15H14N2O/c1-2-5-15(18)13-8-11-10-6-3-4-7-12(10)17-14(11)9-16-13/h3-4,6-9,17H,2,5H2,1H3
DMA96U5	CS	CCCC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMA96U5	IK	QIZPCEVRKTWHIE-UHFFFAOYSA-N
DMA96U5	IU	1-(9H-pyrido[3,4-b]indol-3-yl)butan-1-one
DMA96U5	DE	Discovery agent

DMFOD2L	ID	DMFOD2L
DMFOD2L	DN	1-(9H-beta-Carbolin-3-yl)-ethanone
DMFOD2L	HS	Investigative
DMFOD2L	SN	82596-93-8; 3-acetyl-beta-carboline; 1-(9H-pyrido[3,4-b]indol-3-yl)-ethanone; CHEMBL11863; SCHEMBL10857122; CTK3D8180; DTXSID90509895; MPLXFBXMWYMAFN-UHFFFAOYSA-N; ZINC26025316; AKOS030597437; 1-(9H-beta-Carbolin-3-yl)ethan-1-one; Ethanone, 1-(9H-pyrido[3,4-b]indol-3-yl)-
DMFOD2L	DT	Small molecular drug
DMFOD2L	PC	12789146
DMFOD2L	MW	210.23
DMFOD2L	FM	C13H10N2O
DMFOD2L	IC	InChI=1S/C13H10N2O/c1-8(16)12-6-10-9-4-2-3-5-11(9)15-13(10)7-14-12/h2-7,15H,1H3
DMFOD2L	CS	CC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMFOD2L	IK	MPLXFBXMWYMAFN-UHFFFAOYSA-N
DMFOD2L	IU	1-(9H-pyrido[3,4-b]indol-3-yl)ethanone
DMFOD2L	CA	CAS 82596-93-8
DMFOD2L	DE	Discovery agent

DMH49OD	ID	DMH49OD
DMH49OD	DN	1-(9H-fluoren-9-yl)-1H-imidazole
DMH49OD	HS	Investigative
DMH49OD	SN	1-(9H-fluoren-9-yl)-1H-imidazole; CHEMBL225447; 35214-35-8; Fluorenyl deriv. 13; AC1MY9SZ; SCHEMBL9633309; BDBM9464; 1-(9H-fluoren-9-yl)imidazole; MolPort-002-538-233; ZINC4645069; STL321422; AKOS022141595; MCULE-5499035128; DA-06525
DMH49OD	DT	Small molecular drug
DMH49OD	PC	3828439
DMH49OD	MW	232.28
DMH49OD	FM	C16H12N2
DMH49OD	IC	InChI=1S/C16H12N2/c1-3-7-14-12(5-1)13-6-2-4-8-15(13)16(14)18-10-9-17-11-18/h1-11,16H
DMH49OD	CS	C1=CC=C2C(=C1)C(C3=CC=CC=C32)N4C=CN=C4
DMH49OD	IK	TULIZIRHYBBLAI-UHFFFAOYSA-N
DMH49OD	IU	1-(9H-fluoren-9-yl)imidazole
DMH49OD	DE	Discovery agent

DM30FNL	ID	DM30FNL
DM30FNL	DN	1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea
DM30FNL	HS	Investigative
DM30FNL	SN	Diarylurea deriv. 15; AC1NS9HQ; BDBM6655; CHEMBL140589; SCHEMBL12856374; ZINC13471114; 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea; 3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea; 1-(9-Oxo-9H-fluorene-4-yl)-3-(2-pyridyl)urea; N-(9-Oxo-9H-fluoren-4-yl)-N -pyridin-2-ylurea
DM30FNL	DT	Small molecular drug
DM30FNL	PC	5330596
DM30FNL	MW	315.3
DM30FNL	FM	C19H13N3O2
DM30FNL	IC	InChI=1S/C19H13N3O2/c23-18-13-7-2-1-6-12(13)17-14(18)8-5-9-15(17)21-19(24)22-16-10-3-4-11-20-16/h1-11H,(H2,20,21,22,24)
DM30FNL	CS	C1=CC=C2C(=C1)C3=C(C2=O)C=CC=C3NC(=O)NC4=CC=CC=N4
DM30FNL	IK	XVVDNGPUSVDRAJ-UHFFFAOYSA-N
DM30FNL	IU	1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea
DM30FNL	DE	Discovery agent

DMVJZ0C	ID	DMVJZ0C
DMVJZ0C	DN	1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole
DMVJZ0C	HS	Investigative
DMVJZ0C	SN	CHEMBL376371; 1H-1,2,4-Triazole, 1-(9-phenyl-9H-fluoren-9-yl)-; 828265-51-6; Fluorenyl deriv. 17; BDBM9468; 1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole; CTK3D6011
DMVJZ0C	DT	Small molecular drug
DMVJZ0C	PC	11232117
DMVJZ0C	MW	309.4
DMVJZ0C	FM	C21H15N3
DMVJZ0C	IC	InChI=1S/C21H15N3/c1-2-8-16(9-3-1)21(24-15-22-14-23-24)19-12-6-4-10-17(19)18-11-5-7-13-20(18)21/h1-15H
DMVJZ0C	CS	C1=CC=C(C=C1)C2(C3=CC=CC=C3C4=CC=CC=C42)N5C=NC=N5
DMVJZ0C	IK	KVOFEYRUEAXEJQ-UHFFFAOYSA-N
DMVJZ0C	IU	1-(9-phenylfluoren-9-yl)-1,2,4-triazole
DMVJZ0C	CA	CAS 828265-51-6
DMVJZ0C	DE	Discovery agent

DMLIJYS	ID	DMLIJYS
DMLIJYS	DN	1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole
DMLIJYS	HS	Investigative
DMLIJYS	SN	CHEMBL223874; 1H-Imidazole, 1-(9-phenyl-9H-fluoren-9-yl)-; 27608-12-4; Fluorenyl deriv. 14; BDBM9465; CTK0J2505; DTXSID90432952
DMLIJYS	DT	Small molecular drug
DMLIJYS	PC	9926623
DMLIJYS	MW	308.4
DMLIJYS	FM	C22H16N2
DMLIJYS	IC	InChI=1S/C22H16N2/c1-2-8-17(9-3-1)22(24-15-14-23-16-24)20-12-6-4-10-18(20)19-11-5-7-13-21(19)22/h1-16H
DMLIJYS	CS	C1=CC=C(C=C1)C2(C3=CC=CC=C3C4=CC=CC=C42)N5C=CN=C5
DMLIJYS	IK	DNCKVRPGVMTVNH-UHFFFAOYSA-N
DMLIJYS	IU	1-(9-phenylfluoren-9-yl)imidazole
DMLIJYS	CA	CAS 27608-12-4
DMLIJYS	DE	Discovery agent

DMOTJWZ	ID	DMOTJWZ
DMOTJWZ	DN	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone
DMOTJWZ	HS	Investigative
DMOTJWZ	SN	1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone; CHEMBL493448; SCHEMBL10247513; CHEMBL1187207; BDBM50252801; DB07342; 1(adamantan1yl) 2(1himidazol1yl) ethanone; 1-(adamantan-1-yl)-2-(imidazol-1-yl)ethanone; 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone hydrochloride
DMOTJWZ	DT	Small molecular drug
DMOTJWZ	PC	20541332
DMOTJWZ	MW	244.33
DMOTJWZ	FM	C15H20N2O
DMOTJWZ	IC	InChI=1S/C15H20N2O/c18-14(9-17-2-1-16-10-17)15-6-11-3-12(7-15)5-13(4-11)8-15/h1-2,10-13H,3-9H2
DMOTJWZ	CS	C1C2CC3CC1CC(C2)(C3)C(=O)CN4C=CN=C4
DMOTJWZ	IK	BBCQJSMDKDHVKG-UHFFFAOYSA-N
DMOTJWZ	IU	1-(1-adamantyl)-2-imidazol-1-ylethanone
DMOTJWZ	DE	Discovery agent

DMOJC9Z	ID	DMOJC9Z
DMOJC9Z	DN	1-(Benzhydrylamino)ethaniminium bromide
DMOJC9Z	HS	Investigative
DMOJC9Z	SN	1-(Benzhydrylamino)ethaniminium bromide
DMOJC9Z	DT	Small molecular drug
DMOJC9Z	PC	50899558
DMOJC9Z	MW	305.21
DMOJC9Z	FM	C15H17BrN2
DMOJC9Z	IC	InChI=1S/C15H16N2.BrH/c1-12(16)17-15(13-8-4-2-5-9-13)14-10-6-3-7-11-14;/h2-11,15H,1H3,(H2,16,17);1H
DMOJC9Z	CS	CC(=NC(C1=CC=CC=C1)C2=CC=CC=C2)N.Br
DMOJC9Z	IK	SCBRUNBFSUXITM-UHFFFAOYSA-N
DMOJC9Z	IU	N'-benzhydrylethanimidamide;hydrobromide
DMOJC9Z	DE	Discovery agent

DMGNL2A	ID	DMGNL2A
DMGNL2A	DN	1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMGNL2A	HS	Investigative
DMGNL2A	SN	CHEMBL509158; 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMGNL2A	DT	Small molecular drug
DMGNL2A	PC	44561205
DMGNL2A	MW	199.25
DMGNL2A	FM	C13H13NO
DMGNL2A	IC	InChI=1S/C13H13NO/c1-2-4-11-9(3-1)5-12(15-11)13-6-10(13)7-14-8-13/h1-5,10,14H,6-8H2
DMGNL2A	CS	C1C2C1(CNC2)C3=CC4=CC=CC=C4O3
DMGNL2A	IK	FRXUZFQLSGFGPV-UHFFFAOYSA-N
DMGNL2A	IU	1-(1-benzofuran-2-yl)-3-azabicyclo[3.1.0]hexane
DMGNL2A	DE	Discovery agent

DMVSC3O	ID	DMVSC3O
DMVSC3O	DN	1-(benzyloxy)-2-(2-phenylethyl)benzene
DMVSC3O	HS	Investigative
DMVSC3O	SN	CHEMBL215010; 1-(benzyloxy)-2-(2-phenylethyl)benzene; SCHEMBL4183309; 1-(benzyloxy)-2-phenethylbenzene
DMVSC3O	DT	Small molecular drug
DMVSC3O	PC	11973811
DMVSC3O	MW	288.4
DMVSC3O	FM	C21H20O
DMVSC3O	IC	InChI=1S/C21H20O/c1-3-9-18(10-4-1)15-16-20-13-7-8-14-21(20)22-17-19-11-5-2-6-12-19/h1-14H,15-17H2
DMVSC3O	CS	C1=CC=C(C=C1)CCC2=CC=CC=C2OCC3=CC=CC=C3
DMVSC3O	IK	BMTUNIXXDMVUOW-UHFFFAOYSA-N
DMVSC3O	IU	1-(2-phenylethyl)-2-phenylmethoxybenzene
DMVSC3O	DE	Discovery agent

DMVB7P3	ID	DMVB7P3
DMVB7P3	DN	1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene
DMVB7P3	HS	Investigative
DMVB7P3	SN	CHEMBL214739; 1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene; BDBM50197201
DMVB7P3	DT	Small molecular drug
DMVB7P3	PC	11973927
DMVB7P3	MW	318.4
DMVB7P3	FM	C22H22O2
DMVB7P3	IC	InChI=1S/C22H22O2/c1-23-21-12-7-10-18(16-21)14-15-20-11-5-6-13-22(20)24-17-19-8-3-2-4-9-19/h2-13,16H,14-15,17H2,1H3
DMVB7P3	CS	COC1=CC=CC(=C1)CCC2=CC=CC=C2OCC3=CC=CC=C3
DMVB7P3	IK	SDDBNQDQBZPCGB-UHFFFAOYSA-N
DMVB7P3	IU	1-methoxy-3-[2-(2-phenylmethoxyphenyl)ethyl]benzene
DMVB7P3	DE	Discovery agent

DMA15X9	ID	DMA15X9
DMA15X9	DN	1(beta)-O-galloylpedunculagin
DMA15X9	HS	Investigative
DMA15X9	SN	Casuarictin; 1(beta)-O-Galloylpedunculagin; CHEMBL446979; CHEBI:3461; 79786-00-8; Sanguiin H 11; cuspinin; 1(.beta.)-O-Galloylpedunculagin; (10ar,11s,12ar,25ar,25bs)-2,3,4,5,6,7,17,18,19,20,21,22-dodecahydroxy-9,15,24,27-tetraoxo-9,10a,11,12a,13,15,24,25a,25b,27-decahydrodibenzo[g,i]dibenzo[6',7':8',9'][1,4]dioxecino[2',3':4,5]pyrano[3,2-b][1,5]dioxacycloundecin-11-yl 3,4,5-trihydroxybenzoate; AC1Q6P15; AC1L2K81; BDBM50250990; C10212; .beta.-D-Glucopyranose, cyclic 2,3:4,6-bis[(1S)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphen
DMA15X9	DT	Small molecular drug
DMA15X9	PC	73644
DMA15X9	MW	936.6
DMA15X9	FM	C41H28O26
DMA15X9	IC	InChI=1S/C41H28O26/c42-13-1-8(2-14(43)24(13)48)36(57)67-41-35-34(65-39(60)11-5-17(46)27(51)31(55)22(11)23-12(40(61)66-35)6-18(47)28(52)32(23)56)33-19(63-41)7-62-37(58)9-3-15(44)25(49)29(53)20(9)21-10(38(59)64-33)4-16(45)26(50)30(21)54/h1-6,19,33-35,41-56H,7H2/t19-,33-,34+,35-,41+/m1/s1
DMA15X9	CS	C1[C@@H]2[C@H]([C@H]3[C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5C6=C(C(=C(C=C6C(=O)O3)O)O)O)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O
DMA15X9	IK	SWRFKGRMQVLMKA-JIZJWZDPSA-N
DMA15X9	IU	[(1R,2S,19R,20S,22R)-7,8,9,12,13,14,28,29,30,33,34,35-dodecahydroxy-4,17,25,38-tetraoxo-3,18,21,24,39-pentaoxaheptacyclo[20.17.0.02,19.05,10.011,16.026,31.032,37]nonatriaconta-5,7,9,11,13,15,26,28,30,32,34,36-dodecaen-20-yl] 3,4,5-trihydroxybenzoate
DMA15X9	CA	CAS 79786-00-8
DMA15X9	CB	CHEBI:3461
DMA15X9	DE	Discovery agent

DMGVPMT	ID	DMGVPMT
DMGVPMT	DN	1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole
DMGVPMT	HS	Investigative
DMGVPMT	SN	CHEMBL598847; 1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole; SCHEMBL10172554
DMGVPMT	DT	Small molecular drug
DMGVPMT	PC	23585406
DMGVPMT	MW	235.28
DMGVPMT	FM	C15H13N3
DMGVPMT	IC	InChI=1S/C15H13N3/c1-2-6-14(7-3-1)15-8-4-5-13(9-15)10-18-12-16-11-17-18/h1-9,11-12H,10H2
DMGVPMT	CS	C1=CC=C(C=C1)C2=CC=CC(=C2)CN3C=NC=N3
DMGVPMT	IK	OZOOKYPKFWRQMO-UHFFFAOYSA-N
DMGVPMT	IU	1-[(3-phenylphenyl)methyl]-1,2,4-triazole
DMGVPMT	CA	CAS 942154-20-3
DMGVPMT	DE	Discovery agent

DM5KZ74	ID	DM5KZ74
DM5KZ74	DN	1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea
DM5KZ74	HS	Investigative
DM5KZ74	SN	CHEMBL1086332; 1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea; SCHEMBL13527422
DM5KZ74	DT	Small molecular drug
DM5KZ74	PC	46831055
DM5KZ74	MW	351.5
DM5KZ74	FM	C22H29N3O
DM5KZ74	IC	InChI=1S/C22H29N3O/c26-22(23-15-5-8-18-25-16-6-2-7-17-25)24-21-13-11-20(12-14-21)19-9-3-1-4-10-19/h1,3-4,9-14H,2,5-8,15-18H2,(H2,23,24,26)
DM5KZ74	CS	C1CCN(CC1)CCCCNC(=O)NC2=CC=C(C=C2)C3=CC=CC=C3
DM5KZ74	IK	MUIUUGJVKFYPIF-UHFFFAOYSA-N
DM5KZ74	IU	1-(4-phenylphenyl)-3-(4-piperidin-1-ylbutyl)urea
DM5KZ74	DE	Discovery agent

DMTZ71K	ID	DMTZ71K
DMTZ71K	DN	1-(bis(3-bromophenyl)methylene)thiosemicarbazide
DMTZ71K	HS	Investigative
DMTZ71K	SN	CHEMBL384296; 1-(bis(3-bromophenyl)methylene)thiosemicarbazide; SCHEMBL2675409; DLNPHAFNMNLYRY-UHFFFAOYSA-N; BDBM50189279; Bis(3-bromophenyl) ketone thiosemicarbazone
DMTZ71K	DT	Small molecular drug
DMTZ71K	PC	16061497
DMTZ71K	MW	413.1
DMTZ71K	FM	C14H11Br2N3S
DMTZ71K	IC	InChI=1S/C14H11Br2N3S/c15-11-5-1-3-9(7-11)13(18-19-14(17)20)10-4-2-6-12(16)8-10/h1-8H,(H3,17,19,20)
DMTZ71K	CS	C1=CC(=CC(=C1)Br)C(=NNC(=S)N)C2=CC(=CC=C2)Br
DMTZ71K	IK	DLNPHAFNMNLYRY-UHFFFAOYSA-N
DMTZ71K	IU	[bis(3-bromophenyl)methylideneamino]thiourea
DMTZ71K	DE	Discovery agent

DMYO8D3	ID	DMYO8D3
DMYO8D3	DN	1-(bis(4-bromophenyl)methyl)-3-phenylurea
DMYO8D3	HS	Investigative
DMYO8D3	SN	CHEMBL224748; 1-(bis(4-bromophenyl)methyl)-3-phenylurea
DMYO8D3	DT	Small molecular drug
DMYO8D3	PC	44421550
DMYO8D3	MW	460.2
DMYO8D3	FM	C20H16Br2N2O
DMYO8D3	IC	InChI=1S/C20H16Br2N2O/c21-16-10-6-14(7-11-16)19(15-8-12-17(22)13-9-15)24-20(25)23-18-4-2-1-3-5-18/h1-13,19H,(H2,23,24,25)
DMYO8D3	CS	C1=CC=C(C=C1)NC(=O)NC(C2=CC=C(C=C2)Br)C3=CC=C(C=C3)Br
DMYO8D3	IK	MNUYZVNTMQHNEW-UHFFFAOYSA-N
DMYO8D3	IU	1-[bis(4-bromophenyl)methyl]-3-phenylurea
DMYO8D3	DE	Discovery agent

DMTVNO3	ID	DMTVNO3
DMTVNO3	DN	1-(bis(4-chlorophenyl)methyl)-3-phenylurea
DMTVNO3	HS	Investigative
DMTVNO3	SN	CHEMBL375286; 1-(bis(4-chlorophenyl)methyl)-3-phenylurea; ZINC13676236
DMTVNO3	DT	Small molecular drug
DMTVNO3	PC	44421549
DMTVNO3	MW	371.3
DMTVNO3	FM	C20H16Cl2N2O
DMTVNO3	IC	InChI=1S/C20H16Cl2N2O/c21-16-10-6-14(7-11-16)19(15-8-12-17(22)13-9-15)24-20(25)23-18-4-2-1-3-5-18/h1-13,19H,(H2,23,24,25)
DMTVNO3	CS	C1=CC=C(C=C1)NC(=O)NC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMTVNO3	IK	VLXCCHGDBPKKAK-UHFFFAOYSA-N
DMTVNO3	IU	1-[bis(4-chlorophenyl)methyl]-3-phenylurea
DMTVNO3	DE	Discovery agent

DMF3D5R	ID	DMF3D5R
DMF3D5R	DN	1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole
DMF3D5R	HS	Investigative
DMF3D5R	SN	CHEMBL498534; 1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole; SCHEMBL11349905
DMF3D5R	DT	Small molecular drug
DMF3D5R	PC	20298212
DMF3D5R	MW	386.5
DMF3D5R	FM	C28H22N2
DMF3D5R	IC	InChI=1S/C28H22N2/c1-3-7-22(8-4-1)24-11-15-26(16-12-24)28(30-20-19-29-21-30)27-17-13-25(14-18-27)23-9-5-2-6-10-23/h1-21,28H
DMF3D5R	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=C(C=C3)C4=CC=CC=C4)N5C=CN=C5
DMF3D5R	IK	CKRNCVRILASGRW-UHFFFAOYSA-N
DMF3D5R	IU	1-[bis(4-phenylphenyl)methyl]imidazole
DMF3D5R	DE	Discovery agent

DMEULBF	ID	DMEULBF
DMEULBF	DN	1-(But-2-enylidene)thiosemicarbazide
DMEULBF	HS	Investigative
DMEULBF	SN	CHEMBL505588; 1-(But-2-enylidene)thiosemicarbazide; Crotonaldehyde thiosemicarbazone; 2-Butenal thiosemicarbazone; AC1O21BI; ZINC5179201; 22113-96-8; BDBM50268196
DMEULBF	DT	Small molecular drug
DMEULBF	PC	6188165
DMEULBF	MW	143.21
DMEULBF	FM	C5H9N3S
DMEULBF	IC	InChI=1S/C5H9N3S/c1-2-3-4-7-8-5(6)9/h2-4H,1H3,(H3,6,8,9)/b3-2+,7-4-
DMEULBF	CS	C/C=C/C=N\\NC(=S)N
DMEULBF	IK	OWTTWSQTSRNFHY-SWBALALESA-N
DMEULBF	IU	[(Z)-[(E)-but-2-enylidene]amino]thiourea
DMEULBF	DE	Discovery agent

DMTMZAJ	ID	DMTMZAJ
DMTMZAJ	DN	1-(but-2-ylamino)ethyl 1,I-bisphosphonic acid
DMTMZAJ	HS	Investigative
DMTMZAJ	SN	CHEMBL262598; BDBM50374761; [1-phosphono-2-(sec-butylamino)ethyl]phosphonic acid
DMTMZAJ	DT	Small molecular drug
DMTMZAJ	PC	44451344
DMTMZAJ	MW	261.149
DMTMZAJ	FM	C6H17NO6P2
DMTMZAJ	IC	InChI=1S/C6H17NO6P2/c1-3-5(2)7-4-6(14(8,9)10)15(11,12)13/h5-7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13)
DMTMZAJ	CS	CCC(C)NCC(P(=O)(O)O)P(=O)(O)O
DMTMZAJ	IK	BDBDLQIJTHDVGZ-UHFFFAOYSA-N
DMTMZAJ	IU	[2-(butan-2-ylamino)-1-phosphonoethyl]phosphonic acid
DMTMZAJ	DE	Discovery agent

DMXU1EF	ID	DMXU1EF
DMXU1EF	DN	1-(Butan-2-ylidene)thiosemicarbazide
DMXU1EF	HS	Investigative
DMXU1EF	SN	CHEMBL458405; 1752-40-5; AC1NSGXA; WLN: SUYZMNUY2&amp; 2-butanone thiosemicarbazone; NSC709; NSC-709; [(Z)-butan-2-ylideneamino]thiourea; ZINC13115335; BDBM50268198
DMXU1EF	DT	Small molecular drug
DMXU1EF	PC	5363036
DMXU1EF	MW	145.23
DMXU1EF	FM	C5H11N3S
DMXU1EF	IC	InChI=1S/C5H11N3S/c1-3-4(2)7-8-5(6)9/h3H2,1-2H3,(H3,6,8,9)/b7-4-
DMXU1EF	CS	CC/C(=N\\NC(=S)N)/C
DMXU1EF	IK	NCQXVINEPVAIDB-DAXSKMNVSA-N
DMXU1EF	IU	[(Z)-butan-2-ylideneamino]thiourea
DMXU1EF	CA	CAS 1752-40-5
DMXU1EF	DE	Discovery agent

DMS3XUC	ID	DMS3XUC
DMS3XUC	DN	1-(cyclohexyl)methyl-5'-O-tritylinosine
DMS3XUC	HS	Investigative
DMS3XUC	SN	CHEMBL211259; BDBM50194181
DMS3XUC	DT	Small molecular drug
DMS3XUC	PC	16082760
DMS3XUC	MW	606.7
DMS3XUC	FM	C36H38N4O5
DMS3XUC	IC	InChI=1S/C36H38N4O5/c41-31-29(22-44-36(26-15-7-2-8-16-26,27-17-9-3-10-18-27)28-19-11-4-12-20-28)45-35(32(31)42)40-24-37-30-33(40)38-23-39(34(30)43)21-25-13-5-1-6-14-25/h2-4,7-12,15-20,23-25,29,31-32,35,41-42H,1,5-6,13-14,21-22H2/t29-,31-,32-,35-/m1/s1
DMS3XUC	CS	C1CCC(CC1)CN2C=NC3=C(C2=O)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COC(C5=CC=CC=C5)(C6=CC=CC=C6)C7=CC=CC=C7)O)O
DMS3XUC	IK	CFSSQQKSMHGUJB-QSYCCZFCSA-N
DMS3XUC	IU	1-(cyclohexylmethyl)-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]purin-6-one
DMS3XUC	DE	Discovery agent

DMDU3X7	ID	DMDU3X7
DMDU3X7	DN	1-(cyclopropyl)methyl-5'-O-tritylinosine
DMDU3X7	HS	Investigative
DMDU3X7	SN	CHEMBL379981; BDBM50194179
DMDU3X7	DT	Small molecular drug
DMDU3X7	PC	16082776
DMDU3X7	MW	564.6
DMDU3X7	FM	C33H32N4O5
DMDU3X7	IC	InChI=1S/C33H32N4O5/c38-28-26(42-32(29(28)39)37-21-34-27-30(37)35-20-36(31(27)40)18-22-16-17-22)19-41-33(23-10-4-1-5-11-23,24-12-6-2-7-13-24)25-14-8-3-9-15-25/h1-15,20-22,26,28-29,32,38-39H,16-19H2/t26-,28-,29-,32-/m1/s1
DMDU3X7	CS	C1CC1CN2C=NC3=C(C2=O)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COC(C5=CC=CC=C5)(C6=CC=CC=C6)C7=CC=CC=C7)O)O
DMDU3X7	IK	UTXUWUTZGDAURC-DWCTZGTLSA-N
DMDU3X7	IU	1-(cyclopropylmethyl)-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]purin-6-one
DMDU3X7	DE	Discovery agent

DMLYO8P	ID	DMLYO8P
DMLYO8P	DN	1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol
DMLYO8P	HS	Investigative
DMLYO8P	SN	CHEMBL389665; 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol
DMLYO8P	DT	Small molecular drug
DMLYO8P	PC	9820782
DMLYO8P	MW	371.5
DMLYO8P	FM	C26H29NO
DMLYO8P	IC	InChI=1S/C26H29NO/c1-20-10-6-8-14-23(20)25(24-15-9-7-11-21(24)2)27-18-16-26(28,17-19-27)22-12-4-3-5-13-22/h3-15,25,28H,16-19H2,1-2H3
DMLYO8P	CS	CC1=CC=CC=C1C(C2=CC=CC=C2C)N3CCC(CC3)(C4=CC=CC=C4)O
DMLYO8P	IK	MHYKPRJMOSXVFG-UHFFFAOYSA-N
DMLYO8P	IU	1-[bis(2-methylphenyl)methyl]-4-phenylpiperidin-4-ol
DMLYO8P	DE	Discovery agent

DMBTLIJ	ID	DMBTLIJ
DMBTLIJ	DN	1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE
DMBTLIJ	HS	Investigative
DMBTLIJ	SN	8-(hydroxymethylamino)octan-1-ol; AC1NDZBQ; 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE; 8-[(hydroxymethyl)amino]octan-1-ol
DMBTLIJ	DT	Small molecular drug
DMBTLIJ	PC	4634038
DMBTLIJ	MW	175.27
DMBTLIJ	FM	C9H21NO2
DMBTLIJ	IC	InChI=1S/C9H21NO2/c11-8-6-4-2-1-3-5-7-10-9-12/h10-12H,1-9H2
DMBTLIJ	CS	C(CCCCO)CCCNCO
DMBTLIJ	IK	SJEVZMRZAJQYFZ-UHFFFAOYSA-N
DMBTLIJ	IU	8-(hydroxymethylamino)octan-1-ol
DMBTLIJ	DE	Discovery agent

DMOTICP	ID	DMOTICP
DMOTICP	DN	1-(isoquinolin-5-yl)-3-(1-phenylpropyl)urea
DMOTICP	HS	Investigative
DMOTICP	SN	isoquinoline antagonist, 5m; CHEMBL230772; BDBM20395
DMOTICP	DT	Small molecular drug
DMOTICP	PC	24768203
DMOTICP	MW	305.4
DMOTICP	FM	C19H19N3O
DMOTICP	IC	InChI=1S/C19H19N3O/c1-2-17(14-7-4-3-5-8-14)21-19(23)22-18-10-6-9-15-13-20-12-11-16(15)18/h3-13,17H,2H2,1H3,(H2,21,22,23)
DMOTICP	CS	CCC(C1=CC=CC=C1)NC(=O)NC2=CC=CC3=C2C=CN=C3
DMOTICP	IK	MDUZRJXYUICAEF-UHFFFAOYSA-N
DMOTICP	IU	1-isoquinolin-5-yl-3-(1-phenylpropyl)urea
DMOTICP	DE	Discovery agent

DMHWITR	ID	DMHWITR
DMHWITR	DN	1-(isoquinolin-5-yl)-3-(4-morpholinobenzyl)urea
DMHWITR	HS	Investigative
DMHWITR	SN	Isoquinoline Analogue, 35; CHEMBL231105; SCHEMBL4023640; BDBM20341; LAJBRLBYOVKUOY-UHFFFAOYSA-N; N-5-isoquinolinyl-N'-[4-(4-morpholinyl)benzyl]urea; N-isoquinolin-5-yl-N'-[(4-morpholin-4-ylphenyl)methyl]urea
DMHWITR	DT	Small molecular drug
DMHWITR	PC	10248092
DMHWITR	MW	362.4
DMHWITR	FM	C21H22N4O2
DMHWITR	IC	InChI=1S/C21H22N4O2/c26-21(24-20-3-1-2-17-15-22-9-8-19(17)20)23-14-16-4-6-18(7-5-16)25-10-12-27-13-11-25/h1-9,15H,10-14H2,(H2,23,24,26)
DMHWITR	CS	C1COCCN1C2=CC=C(C=C2)CNC(=O)NC3=CC=CC4=C3C=CN=C4
DMHWITR	IK	LAJBRLBYOVKUOY-UHFFFAOYSA-N
DMHWITR	IU	1-isoquinolin-5-yl-3-[(4-morpholin-4-ylphenyl)methyl]urea
DMHWITR	DE	Discovery agent

DMI479T	ID	DMI479T
DMI479T	DN	1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMI479T	HS	Investigative
DMI479T	SN	SCHEMBL3260073; CHEMBL1172744; BDBM50322697; 1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMI479T	DT	Small molecular drug
DMI479T	PC	24803184
DMI479T	MW	267.4
DMI479T	FM	C18H21NO
DMI479T	IC	InChI=1S/C18H21NO/c1-20-13-17-11-18(17,8-9-19-12-17)16-7-6-14-4-2-3-5-15(14)10-16/h2-7,10,19H,8-9,11-13H2,1H3/t17-,18-/m1/s1
DMI479T	CS	COC[C@]12C[C@]1(CCNC2)C3=CC4=CC=CC=C4C=C3
DMI479T	IK	KTJHVHZJTXJNIH-QZTJIDSGSA-N
DMI479T	IU	(1R,6S)-1-(methoxymethyl)-6-naphthalen-2-yl-3-azabicyclo[4.1.0]heptane
DMI479T	DE	Discovery agent

DMUEQC8	ID	DMUEQC8
DMUEQC8	DN	1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMUEQC8	HS	Investigative
DMUEQC8	SN	CHEMBL452045; 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane; SCHEMBL4177088; BDBM50243942; SY247368; MFCD28902249 (97%)
DMUEQC8	DT	Small molecular drug
DMUEQC8	PC	16068204
DMUEQC8	MW	209.29
DMUEQC8	FM	C15H15N
DMUEQC8	IC	InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2
DMUEQC8	CS	C1C2C1(CNC2)C3=CC4=CC=CC=C4C=C3
DMUEQC8	IK	HKHCSWPSUSWGLI-UHFFFAOYSA-N
DMUEQC8	IU	1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
DMUEQC8	DE	Discovery agent

DMXT2ZL	ID	DMXT2ZL
DMXT2ZL	DN	1-(oxazol-2-yl)-3-(4-phenoxyphenyl)propan-1-one
DMXT2ZL	HS	Investigative
DMXT2ZL	SN	CHEMBL441735
DMXT2ZL	DT	Small molecular drug
DMXT2ZL	PC	24799659
DMXT2ZL	MW	293.3
DMXT2ZL	FM	C18H15NO3
DMXT2ZL	IC	InChI=1S/C18H15NO3/c20-17(18-19-12-13-21-18)11-8-14-6-9-16(10-7-14)22-15-4-2-1-3-5-15/h1-7,9-10,12-13H,8,11H2
DMXT2ZL	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)CCC(=O)C3=NC=CO3
DMXT2ZL	IK	LLQSCQSWBWHWLL-UHFFFAOYSA-N
DMXT2ZL	IU	1-(1,3-oxazol-2-yl)-3-(4-phenoxyphenyl)propan-1-one
DMXT2ZL	DE	Discovery agent

DMEOS8P	ID	DMEOS8P
DMEOS8P	DN	1-(oxazol-2-yl)-4-(piperidin-4-yl)butan-1-one
DMEOS8P	HS	Investigative
DMEOS8P	SN	CHEMBL270404
DMEOS8P	DT	Small molecular drug
DMEOS8P	PC	44453945
DMEOS8P	MW	222.28
DMEOS8P	FM	C12H18N2O2
DMEOS8P	IC	InChI=1S/C12H18N2O2/c15-11(12-14-8-9-16-12)3-1-2-10-4-6-13-7-5-10/h8-10,13H,1-7H2
DMEOS8P	CS	C1CNCCC1CCCC(=O)C2=NC=CO2
DMEOS8P	IK	PKVYQZQOXHRPTR-UHFFFAOYSA-N
DMEOS8P	IU	1-(1,3-oxazol-2-yl)-4-piperidin-4-ylbutan-1-one
DMEOS8P	CA	CAS 938222-90-3
DMEOS8P	DE	Discovery agent

DMLKA5O	ID	DMLKA5O
DMLKA5O	DN	1-(oxazol-2-yl)-7-phenylheptan-1-one
DMLKA5O	HS	Investigative
DMLKA5O	SN	CHEMBL220125; 1-(oxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL12403823; BDBM50204493; ZINC34803651
DMLKA5O	DT	Small molecular drug
DMLKA5O	PC	11991808
DMLKA5O	MW	257.329
DMLKA5O	FM	C16H19NO2
DMLKA5O	IC	InChI=1S/C16H19NO2/c18-15(16-17-12-13-19-16)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,12-13H,1-2,4,7-8,11H2
DMLKA5O	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=CO2
DMLKA5O	IK	GWMQJJIAUUBGNE-UHFFFAOYSA-N
DMLKA5O	IU	1-(1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMLKA5O	DE	Discovery agent

DM1ATS3	ID	DM1ATS3
DM1ATS3	DN	1-(oxazol-2-yl)octadec-9-en-1-one
DM1ATS3	HS	Investigative
DM1ATS3	SN	CHEMBL39412; 1-(oxazol-2-yl)octadec-9-en-1-one; SCHEMBL13764125; BDBM50100864; AKOS030561890; 1-Oxazol-2-yl-nonadec-10-en-2-one; (Z)-1-Oxazol-2-yl-octadec-9-en-1-one; (Z)-1-(oxazol-2-yl)octadec-9-en-1-one; (9Z)-1-(2-Oxazolyl)-9-octadecene-1-one
DM1ATS3	DT	Small molecular drug
DM1ATS3	PC	44285344
DM1ATS3	MW	333.5
DM1ATS3	FM	C21H35NO2
DM1ATS3	IC	InChI=1S/C21H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-22-18-19-24-21/h9-10,18-19H,2-8,11-17H2,1H3/b10-9-
DM1ATS3	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC=CO1
DM1ATS3	IK	WWYUNXGFLPTVRR-KTKRTIGZSA-N
DM1ATS3	IU	(Z)-1-(1,3-oxazol-2-yl)octadec-9-en-1-one
DM1ATS3	CA	CAS 288862-40-8
DM1ATS3	DE	Discovery agent

DMT7P2Z	ID	DMT7P2Z
DMT7P2Z	DN	1-(oxazolo[4,5-b]pyridin-2-yl)dodecan-1-one
DMT7P2Z	HS	Investigative
DMT7P2Z	SN	1-OXAZOLO[4,5-B]PYRIDIN-2-YL-1-DODECANONE; 288862-73-7; CHEMBL257307; SCHEMBL3964457; MolPort-009-018-944; HMS3649B18; BDBM50350547; 1312AH; ZINC34803705; AKOS027301548; ACM288862737; SR-01000946699; 1-[1,3]oxazolo[4,5-b]pyridin-2-yldodecan-1-one
DMT7P2Z	DT	Small molecular drug
DMT7P2Z	PC	9972176
DMT7P2Z	MW	302.4
DMT7P2Z	FM	C18H26N2O2
DMT7P2Z	IC	InChI=1S/C18H26N2O2/c1-2-3-4-5-6-7-8-9-10-12-15(21)18-20-17-16(22-18)13-11-14-19-17/h11,13-14H,2-10,12H2,1H3
DMT7P2Z	CS	CCCCCCCCCCCC(=O)C1=NC2=C(O1)C=CC=N2
DMT7P2Z	IK	XUWBDQAPIZBSRY-UHFFFAOYSA-N
DMT7P2Z	IU	1-([1,3]oxazolo[4,5-b]pyridin-2-yl)dodecan-1-one
DMT7P2Z	DE	Discovery agent

DMFGUXZ	ID	DMFGUXZ
DMFGUXZ	DN	1-(oxazolo[4,5-b]pyridin-2-yl)octan-1-one
DMFGUXZ	HS	Investigative
DMFGUXZ	SN	CHEMBL257305; SCHEMBL3966136; BDBM50350545
DMFGUXZ	DT	Small molecular drug
DMFGUXZ	PC	22486174
DMFGUXZ	MW	246.3
DMFGUXZ	FM	C14H18N2O2
DMFGUXZ	IC	InChI=1S/C14H18N2O2/c1-2-3-4-5-6-8-11(17)14-16-13-12(18-14)9-7-10-15-13/h7,9-10H,2-6,8H2,1H3
DMFGUXZ	CS	CCCCCCCC(=O)C1=NC2=C(O1)C=CC=N2
DMFGUXZ	IK	HTWHWGPGIJSJQP-UHFFFAOYSA-N
DMFGUXZ	IU	1-([1,3]oxazolo[4,5-b]pyridin-2-yl)octan-1-one
DMFGUXZ	DE	Discovery agent

DMH2G13	ID	DMH2G13
DMH2G13	DN	1-(oxazolo[4,5-b]pyridin-2-yl)pentan-1-one
DMH2G13	HS	Investigative
DMH2G13	SN	CHEMBL402740; SCHEMBL3961770; BDBM50350542; 288862-78-2; 1-(oxazolo[4,5-b]pyridin-2-yl)-1-oxo-pentane
DMH2G13	DT	Small molecular drug
DMH2G13	PC	22486203
DMH2G13	MW	204.22
DMH2G13	FM	C11H12N2O2
DMH2G13	IC	InChI=1S/C11H12N2O2/c1-2-3-5-8(14)11-13-10-9(15-11)6-4-7-12-10/h4,6-7H,2-3,5H2,1H3
DMH2G13	CS	CCCCC(=O)C1=NC2=C(O1)C=CC=N2
DMH2G13	IK	FBFLUTUPSIYUIG-UHFFFAOYSA-N
DMH2G13	IU	1-([1,3]oxazolo[4,5-b]pyridin-2-yl)pentan-1-one
DMH2G13	DE	Discovery agent

DMJQ7T0	ID	DMJQ7T0
DMJQ7T0	DN	1-(pentyloxy)-4-phenoxybenzene
DMJQ7T0	HS	Investigative
DMJQ7T0	SN	CHEMBL472892; 1-(pentyloxy)-4-phenoxybenzene; SCHEMBL1335892
DMJQ7T0	DT	Small molecular drug
DMJQ7T0	PC	21883856
DMJQ7T0	MW	256.339
DMJQ7T0	FM	C17H20O2
DMJQ7T0	IC	InChI=1S/C17H20O2/c1-2-3-7-14-18-15-10-12-17(13-11-15)19-16-8-5-4-6-9-16/h4-6,8-13H,2-3,7,14H2,1H3
DMJQ7T0	CS	CCCCCOC1=CC=C(C=C1)OC2=CC=CC=C2
DMJQ7T0	IK	LFCVQUJWFGBKJK-UHFFFAOYSA-N
DMJQ7T0	IU	1-pentoxy-4-phenoxybenzene
DMJQ7T0	DE	Discovery agent

DMU10CY	ID	DMU10CY
DMU10CY	DN	1-(phenyl(p-tolyl)methylene)thiosemicarbazide
DMU10CY	HS	Investigative
DMU10CY	SN	CHEMBL402465; 1-(phenyl(p-tolyl)methylene)thiosemicarbazide
DMU10CY	DT	Small molecular drug
DMU10CY	PC	15722900
DMU10CY	MW	269.4
DMU10CY	FM	C15H15N3S
DMU10CY	IC	InChI=1S/C15H15N3S/c1-11-7-9-13(10-8-11)14(17-18-15(16)19)12-5-3-2-4-6-12/h2-10H,1H3,(H3,16,18,19)/b17-14+
DMU10CY	CS	CC1=CC=C(C=C1)/C(=N/NC(=S)N)/C2=CC=CC=C2
DMU10CY	IK	DZOZYORQEZEOCT-SAPNQHFASA-N
DMU10CY	IU	[(E)-[(4-methylphenyl)-phenylmethylidene]amino]thiourea
DMU10CY	DE	Discovery agent

DM8APLN	ID	DM8APLN
DM8APLN	DN	1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine
DM8APLN	HS	Investigative
DM8APLN	SN	1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; 1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225
DM8APLN	DT	Small molecular drug
DM8APLN	PC	45270766
DM8APLN	MW	258.3
DM8APLN	FM	C13H10N2O2S
DM8APLN	IC	InChI=1S/C13H10N2O2S/c16-18(17,11-5-2-1-3-6-11)15-10-8-12-13(15)7-4-9-14-12/h1-10H
DM8APLN	CS	C1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2C=CC=N3
DM8APLN	IK	HGOGRVVSSAWHTO-UHFFFAOYSA-N
DM8APLN	IU	1-(benzenesulfonyl)pyrrolo[3,2-b]pyridine
DM8APLN	DE	Discovery agent

DM7W25U	ID	DM7W25U
DM7W25U	DN	1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole
DM7W25U	HS	Investigative
DM7W25U	SN	CHEMBL370779; 1-(phenylsulfonyl)-4-(1-piperazinyl)-1h-indole; 1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole; 412049-71-9; 1-Benzenesulfonyl-4-piperazin-1-yl-1H-indole; SCHEMBL1136504; ZINC3210; DTXSID90436238; OPAMDWUUNKYGOR-UHFFFAOYSA-N; BDBM50174269; 1-(phenylsulfonyl)-4-piperazin-1-yl-indole; FT-0724295; 1-(benzenesulfonyl)-4-(1-piperazinyl)indole; 1-(phenylsulfonyl)-4-piperzin-1-yl-1H-indole; 1-(phenylsulfonyl)-4-piperazin-1-yl-1H-indole; 1-(phenylsulfonyl)-4-piperazin-1-y1-1H-indole
DM7W25U	DT	Small molecular drug
DM7W25U	PC	10154392
DM7W25U	MW	341.4
DM7W25U	FM	C18H19N3O2S
DM7W25U	IC	InChI=1S/C18H19N3O2S/c22-24(23,15-5-2-1-3-6-15)21-12-9-16-17(7-4-8-18(16)21)20-13-10-19-11-14-20/h1-9,12,19H,10-11,13-14H2
DM7W25U	CS	C1CN(CCN1)C2=CC=CC3=C2C=CN3S(=O)(=O)C4=CC=CC=C4
DM7W25U	IK	OPAMDWUUNKYGOR-UHFFFAOYSA-N
DM7W25U	IU	1-(benzenesulfonyl)-4-piperazin-1-ylindole
DM7W25U	CA	CAS 412049-71-9
DM7W25U	DE	Discovery agent

DMRGD8W	ID	DMRGD8W
DMRGD8W	DN	1-(phenylsulfonyl)butan-2-one
DMRGD8W	HS	Investigative
DMRGD8W	SN	CHEMBL240761; 1-(phenylsulfonyl)-2-butanone; 33597-94-3; 1-(phenylsulfonyl)butan-2-one; SCHEMBL12925480; CTK1B8309; DTXSID40452605; 2-Butanone, 1-(phenylsulfonyl)-; BDBM50212545
DMRGD8W	DT	Small molecular drug
DMRGD8W	PC	11031155
DMRGD8W	MW	212.27
DMRGD8W	FM	C10H12O3S
DMRGD8W	IC	InChI=1S/C10H12O3S/c1-2-9(11)8-14(12,13)10-6-4-3-5-7-10/h3-7H,2,8H2,1H3
DMRGD8W	CS	CCC(=O)CS(=O)(=O)C1=CC=CC=C1
DMRGD8W	IK	SMYSSDAIMUTBFY-UHFFFAOYSA-N
DMRGD8W	IU	1-(benzenesulfonyl)butan-2-one
DMRGD8W	CA	CAS 33597-94-3
DMRGD8W	DE	Discovery agent

DMEP80C	ID	DMEP80C
DMEP80C	DN	1-(piperazin-1-yl)isoquinoline
DMEP80C	HS	Investigative
DMEP80C	SN	1-(piperazin-1-yl)isoquinoline; 126653-00-7; 1-Piperazine-1-yl-isoquinoline; 1-Piperazin-1-yl-isoquinoline; 1-(1-isoquinolinyl)piperazine; 1-(1-piperazinyl)isoquinoline; CHEMBL595552; Isoquinoline,1-(1-piperazinyl)-; Isoquinoline, 1-(1-piperazinyl)-; W-205253; 1-[1-Piperazinyl]isoquinoline; PubChem8306; ACMC-209ymu; piperazinohydroisoquinoline; 1-piperazin-1-ylisoquinoline; 1-Pyperazin-1-yl-isoquinoline; SCHEMBL2076366; TPC-A003; 1-(Isoquinolin-1-yl)piperazine; CTK4B5291; KS-00000JYY; IDFYLSABDUMICK-UHFFFAOYSA-N
DMEP80C	DT	Small molecular drug
DMEP80C	PC	15887436
DMEP80C	MW	213.28
DMEP80C	FM	C13H15N3
DMEP80C	IC	InChI=1S/C13H15N3/c1-2-4-12-11(3-1)5-6-15-13(12)16-9-7-14-8-10-16/h1-6,14H,7-10H2
DMEP80C	CS	C1CN(CCN1)C2=NC=CC3=CC=CC=C32
DMEP80C	IK	IDFYLSABDUMICK-UHFFFAOYSA-N
DMEP80C	IU	1-piperazin-1-ylisoquinoline
DMEP80C	DE	Discovery agent

DMVRN0I	ID	DMVRN0I
DMVRN0I	DN	1-(piperidin-3-ylmethyl)pyridin-2(1H)-one
DMVRN0I	HS	Investigative
DMVRN0I	SN	1-(piperidin-3-ylmethyl)pyridin-2(1H)-one; 820231-74-1; 2(1H)-Pyridinone, 1-(3-piperidinylmethyl)-; CHEMBL205267; SCHEMBL2503319; CTK3E3069; DTXSID80658785; CRXGPVZZFUWGAF-UHFFFAOYSA-N; AKOS010944098; 1-Piperidin-3-ylmethyl-1H-pyridin-2-one; 1-[(Piperidin-3-yl)methyl]pyridin-2(1H)-one
DMVRN0I	DT	Small molecular drug
DMVRN0I	PC	44410533
DMVRN0I	MW	192.26
DMVRN0I	FM	C11H16N2O
DMVRN0I	IC	InChI=1S/C11H16N2O/c14-11-5-1-2-7-13(11)9-10-4-3-6-12-8-10/h1-2,5,7,10,12H,3-4,6,8-9H2
DMVRN0I	CS	C1CC(CNC1)CN2C=CC=CC2=O
DMVRN0I	IK	CRXGPVZZFUWGAF-UHFFFAOYSA-N
DMVRN0I	IU	1-(piperidin-3-ylmethyl)pyridin-2-one
DMVRN0I	CA	CAS 820231-74-1
DMVRN0I	DE	Discovery agent

DMKQZB7	ID	DMKQZB7
DMKQZB7	DN	1-(piperidin-4-ylmethyl)pyridin-2(1H)-one
DMKQZB7	HS	Investigative
DMKQZB7	SN	1-(piperidin-4-ylmethyl)pyridin-2(1H)-one; 2(1H)-Pyridinone, 1-(4-piperidinylmethyl)-; CHEMBL206887; SCHEMBL3217361; MolPort-008-735-437; ZINC13686304; AKOS010953288; 888729-52-0; 1-(piperidin-4-ylmethyl)-1,2-dihydropyridin-2-one
DMKQZB7	DT	Small molecular drug
DMKQZB7	PC	44410571
DMKQZB7	MW	192.26
DMKQZB7	FM	C11H16N2O
DMKQZB7	IC	InChI=1S/C11H16N2O/c14-11-3-1-2-8-13(11)9-10-4-6-12-7-5-10/h1-3,8,10,12H,4-7,9H2
DMKQZB7	CS	C1CNCCC1CN2C=CC=CC2=O
DMKQZB7	IK	WLPUWPRHPIZJQK-UHFFFAOYSA-N
DMKQZB7	IU	1-(piperidin-4-ylmethyl)pyridin-2-one
DMKQZB7	DE	Discovery agent

DMO10FD	ID	DMO10FD
DMO10FD	DN	1-(Propan-2-ylidene)thiosemicarbazide
DMO10FD	HS	Investigative
DMO10FD	SN	Acetone thiosemicarbazone; 1752-30-3; Thiosemicarbazone acetone; ACETONE THIOSEMICARBAZIDE; Acetone, thiosemicarbazone; Hydrazinecarbothioamide, 2-(1-methylethylidene)-; Acetonthiosemikarbazon; Acetonethiosemicarbazone; 2-(1-Methylethylidene)hydrazinecarbothioamide; NSC 711; Acetonthiosemikarbazon [Czech]; UNII-C3U604L47F; HSDB 6422; EINECS 217-137-9; (isopropylideneamino)thiourea; AI3-22961; CHEMBL500557; (propan-2-ylideneamino)thiourea; C3U604L47F; 2-(propan-2-ylidene)hydrazinecarbothioamide; WLN: SUYZMNUY1&amp; AC1MCI32
DMO10FD	DT	Small molecular drug
DMO10FD	PC	2770166
DMO10FD	MW	131.2
DMO10FD	FM	C4H9N3S
DMO10FD	IC	InChI=1S/C4H9N3S/c1-3(2)6-7-4(5)8/h1-2H3,(H3,5,7,8)
DMO10FD	CS	CC(=NNC(=S)N)C
DMO10FD	IK	FQUDPIIGGVBZEQ-UHFFFAOYSA-N
DMO10FD	IU	(propan-2-ylideneamino)thiourea
DMO10FD	CA	CAS 1752-30-3
DMO10FD	DE	Discovery agent

DMKE7FG	ID	DMKE7FG
DMKE7FG	DN	1-(pyridin-2-yl)piperazine
DMKE7FG	HS	Investigative
DMKE7FG	SN	1-Pyridin-2-yl-piperazine
DMKE7FG	DT	Small molecular drug
DMKE7FG	PC	94459
DMKE7FG	MW	163.22
DMKE7FG	FM	C9H13N3
DMKE7FG	IC	InChI=1S/C9H13N3/c1-2-4-11-9(3-1)12-7-5-10-6-8-12/h1-4,10H,5-8H2
DMKE7FG	CS	C1CN(CCN1)C2=CC=CC=N2
DMKE7FG	IK	GZRKXKUVVPSREJ-UHFFFAOYSA-N
DMKE7FG	IU	1-pyridin-2-ylpiperazine
DMKE7FG	CA	CAS 34803-66-2
DMKE7FG	DE	Discovery agent

DM78AJ1	ID	DM78AJ1
DM78AJ1	DN	1-(pyridin-4-yl)piperazine
DM78AJ1	HS	Investigative
DM78AJ1	SN	1-(4-Pyridyl)piperazine; 1008-91-9; 1-(pyridin-4-yl)piperazine; 1-Pyridin-4-yl-piperazine; 4-Piperazinopyridine; 1-(4-pyridyl)-piperazine; 4-pyridylpiperazine; 1-pyridin-4-ylpiperazine; 1-(4-pyridyl) piperazine; PIPERAZINE, 1-(4-PYRIDINYL)-; MFCD00040745; 4-(1-piperazino)pyridine; 1-(4-pyridinyl)piperazine; CHEMBL339069; 4-(1-PIPERAZINYL)PYRIDINE; 1-[4-pyridyl]piperazine; EINECS 213-764-7; 4-pyridyl piperazine; (4-pyridyl)piperazine; PubChem22899; l-(4-pyridyl)piperazine; AC1Q4WUQ; N-(4-Pyridyl)piperazine
DM78AJ1	DT	Small molecular drug
DM78AJ1	PC	70517
DM78AJ1	MW	163.22
DM78AJ1	FM	C9H13N3
DM78AJ1	IC	InChI=1S/C9H13N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h1-4,11H,5-8H2
DM78AJ1	CS	C1CN(CCN1)C2=CC=NC=C2
DM78AJ1	IK	OQZBAQXTXNIPRA-UHFFFAOYSA-N
DM78AJ1	IU	1-pyridin-4-ylpiperazine
DM78AJ1	CA	CAS 1008-91-9
DM78AJ1	DE	Discovery agent

DM6J1AK	ID	DM6J1AK
DM6J1AK	DN	1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DM6J1AK	HS	Investigative
DM6J1AK	SN	CHEMBL500739; 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DM6J1AK	DT	Small molecular drug
DM6J1AK	PC	44561207
DM6J1AK	MW	165.26
DM6J1AK	FM	C9H11NS
DM6J1AK	IC	InChI=1S/C9H11NS/c1-2-8(11-3-1)9-4-7(9)5-10-6-9/h1-3,7,10H,4-6H2
DM6J1AK	CS	C1C2C1(CNC2)C3=CC=CS3
DM6J1AK	IK	DMILNTFRFSJCOO-UHFFFAOYSA-N
DM6J1AK	IU	1-thiophen-2-yl-3-azabicyclo[3.1.0]hexane
DM6J1AK	DE	Discovery agent

DMD6CHB	ID	DMD6CHB
DMD6CHB	DN	1-(trifluoromethyl)-9H-carbazole
DMD6CHB	HS	Investigative
DMD6CHB	SN	CHEMBL1169609; 1-(trifluoromethyl)-9H-carbazole; SCHEMBL6961593
DMD6CHB	DT	Small molecular drug
DMD6CHB	PC	42611736
DMD6CHB	MW	235.2
DMD6CHB	FM	C13H8F3N
DMD6CHB	IC	InChI=1S/C13H8F3N/c14-13(15,16)10-6-3-5-9-8-4-1-2-7-11(8)17-12(9)10/h1-7,17H
DMD6CHB	CS	C1=CC=C2C(=C1)C3=C(N2)C(=CC=C3)C(F)(F)F
DMD6CHB	IK	RDMKBOMNZUKIDD-UHFFFAOYSA-N
DMD6CHB	IU	1-(trifluoromethyl)-9H-carbazole
DMD6CHB	DE	Discovery agent

DMWHN2J	ID	DMWHN2J
DMWHN2J	DN	1,1,1,2,2,3,3,5-octafluoro-8-phenyloctan-4-one
DMWHN2J	HS	Investigative
DMWHN2J	SN	SCHEMBL3487311
DMWHN2J	DT	Small molecular drug
DMWHN2J	PC	25060073
DMWHN2J	MW	348.23
DMWHN2J	FM	C14H12F8O
DMWHN2J	IC	InChI=1S/C14H12F8O/c15-10(8-4-7-9-5-2-1-3-6-9)11(23)12(16,17)13(18,19)14(20,21)22/h1-3,5-6,10H,4,7-8H2
DMWHN2J	CS	C1=CC=C(C=C1)CCCC(C(=O)C(C(C(F)(F)F)(F)F)(F)F)F
DMWHN2J	IK	MSCLPOMDBKAOHB-UHFFFAOYSA-N
DMWHN2J	IU	1,1,1,2,2,3,3,5-octafluoro-8-phenyloctan-4-one
DMWHN2J	DE	Discovery agent

DM45NF1	ID	DM45NF1
DM45NF1	DN	1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-ol
DM45NF1	HS	Investigative
DM45NF1	SN	SCHEMBL13498528
DM45NF1	DT	Small molecular drug
DM45NF1	PC	25137230
DM45NF1	MW	332.26
DM45NF1	FM	C14H15F7O
DM45NF1	IC	InChI=1S/C14H15F7O/c15-12(16,13(17,18)14(19,20)21)11(22)9-5-4-8-10-6-2-1-3-7-10/h1-3,6-7,11,22H,4-5,8-9H2
DM45NF1	CS	C1=CC=C(C=C1)CCCCC(C(C(C(F)(F)F)(F)F)(F)F)O
DM45NF1	IK	JTXDZUWPNVVKQF-UHFFFAOYSA-N
DM45NF1	IU	1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-ol
DM45NF1	DE	Discovery agent

DMN68K4	ID	DMN68K4
DMN68K4	DN	1,1,1,2,2,4-hexafluoro-7-phenylheptan-3-one
DMN68K4	HS	Investigative
DMN68K4	SN	CHEMBL1096057
DMN68K4	DT	Small molecular drug
DMN68K4	PC	25060074
DMN68K4	MW	298.22
DMN68K4	FM	C13H12F6O
DMN68K4	IC	InChI=1S/C13H12F6O/c14-10(11(20)12(15,16)13(17,18)19)8-4-7-9-5-2-1-3-6-9/h1-3,5-6,10H,4,7-8H2
DMN68K4	CS	C1=CC=C(C=C1)CCCC(C(=O)C(C(F)(F)F)(F)F)F
DMN68K4	IK	NOYVSSPMDRUWCC-UHFFFAOYSA-N
DMN68K4	IU	1,1,1,2,2,4-hexafluoro-7-phenylheptan-3-one
DMN68K4	DE	Discovery agent

DM7U8LD	ID	DM7U8LD
DM7U8LD	DN	1,1,1,2,2-Pentafluoro-8-phenyl-octan-3-one
DM7U8LD	HS	Investigative
DM7U8LD	SN	SCHEMBL3487432; CHEMBL462548
DM7U8LD	DT	Small molecular drug
DM7U8LD	PC	25059299
DM7U8LD	MW	294.26
DM7U8LD	FM	C14H15F5O
DM7U8LD	IC	InChI=1S/C14H15F5O/c15-13(16,14(17,18)19)12(20)10-6-2-5-9-11-7-3-1-4-8-11/h1,3-4,7-8H,2,5-6,9-10H2
DM7U8LD	CS	C1=CC=C(C=C1)CCCCCC(=O)C(C(F)(F)F)(F)F
DM7U8LD	IK	SZHLULFEEMJIQU-UHFFFAOYSA-N
DM7U8LD	IU	1,1,1,2,2-pentafluoro-8-phenyloctan-3-one
DM7U8LD	DE	Discovery agent

DMSEHNV	ID	DMSEHNV
DMSEHNV	DN	1,1,1,2,2-Pentafluoro-9-phenyl-nonan-3-one
DMSEHNV	HS	Investigative
DMSEHNV	SN	SCHEMBL3489036; CHEMBL500496
DMSEHNV	DT	Small molecular drug
DMSEHNV	PC	25059300
DMSEHNV	MW	308.29
DMSEHNV	FM	C15H17F5O
DMSEHNV	IC	InChI=1S/C15H17F5O/c16-14(17,15(18,19)20)13(21)11-7-2-1-4-8-12-9-5-3-6-10-12/h3,5-6,9-10H,1-2,4,7-8,11H2
DMSEHNV	CS	C1=CC=C(C=C1)CCCCCCC(=O)C(C(F)(F)F)(F)F
DMSEHNV	IK	DTHPBVZMSGVQFQ-UHFFFAOYSA-N
DMSEHNV	IU	1,1,1,2,2-pentafluoro-9-phenylnonan-3-one
DMSEHNV	DE	Discovery agent

DMLDH4Z	ID	DMLDH4Z
DMLDH4Z	DN	1,1,1,3-Tetrafluoro-6-phenylhexan-2-one
DMLDH4Z	HS	Investigative
DMLDH4Z	SN	1,1,1,3-Tetrafluoro-6-phenylhexan-2-one; 1071001-32-5; SCHEMBL3487610; CHEMBL1095335; ZJWMBXPFXFSELY-UHFFFAOYSA-N
DMLDH4Z	DT	Small molecular drug
DMLDH4Z	PC	25059820
DMLDH4Z	MW	248.22
DMLDH4Z	FM	C12H12F4O
DMLDH4Z	IC	InChI=1S/C12H12F4O/c13-10(11(17)12(14,15)16)8-4-7-9-5-2-1-3-6-9/h1-3,5-6,10H,4,7-8H2
DMLDH4Z	CS	C1=CC=C(C=C1)CCCC(C(=O)C(F)(F)F)F
DMLDH4Z	IK	ZJWMBXPFXFSELY-UHFFFAOYSA-N
DMLDH4Z	IU	1,1,1,3-tetrafluoro-6-phenylhexan-2-one
DMLDH4Z	DE	Discovery agent

DMV0CXN	ID	DMV0CXN
DMV0CXN	DN	1,1,1,3-Tetrafluoro-7-phenylheptan-2-one
DMV0CXN	HS	Investigative
DMV0CXN	SN	SCHEMBL3489536; CHEMBL1096056; NWIVHHJMCFVMET-UHFFFAOYSA-N; 1,1,1,3-Tetrafluoro-7-phenyl-2-heptanone
DMV0CXN	DT	Small molecular drug
DMV0CXN	PC	25059821
DMV0CXN	MW	262.24
DMV0CXN	FM	C13H14F4O
DMV0CXN	IC	InChI=1S/C13H14F4O/c14-11(12(18)13(15,16)17)9-5-4-8-10-6-2-1-3-7-10/h1-3,6-7,11H,4-5,8-9H2
DMV0CXN	CS	C1=CC=C(C=C1)CCCCC(C(=O)C(F)(F)F)F
DMV0CXN	IK	NWIVHHJMCFVMET-UHFFFAOYSA-N
DMV0CXN	IU	1,1,1,3-tetrafluoro-7-phenylheptan-2-one
DMV0CXN	DE	Discovery agent

DMD36WS	ID	DMD36WS
DMD36WS	DN	1,1,1,3-Tetrafluoro-heptadecan-2-one
DMD36WS	HS	Investigative
DMD36WS	SN	CHEMBL462389
DMD36WS	DT	Small molecular drug
DMD36WS	PC	25059819
DMD36WS	MW	326.4
DMD36WS	FM	C17H30F4O
DMD36WS	IC	InChI=1S/C17H30F4O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(18)16(22)17(19,20)21/h15H,2-14H2,1H3
DMD36WS	CS	CCCCCCCCCCCCCCC(C(=O)C(F)(F)F)F
DMD36WS	IK	HCIDRHZIAMIVIL-UHFFFAOYSA-N
DMD36WS	IU	1,1,1,3-tetrafluoroheptadecan-2-one
DMD36WS	DE	Discovery agent

DMJ0ZMT	ID	DMJ0ZMT
DMJ0ZMT	DN	1,1,1-trifluoro-3-(hexylsulfinyl)propan-2-one
DMJ0ZMT	HS	Investigative
DMJ0ZMT	SN	CHEMBL155396; 1,1,1-trifluoro-3-(hexane-1-sulfinyl)propane-2-one; 479669-33-5
DMJ0ZMT	DT	Small molecular drug
DMJ0ZMT	PC	11010182
DMJ0ZMT	MW	244.28
DMJ0ZMT	FM	C9H15F3O2S
DMJ0ZMT	IC	InChI=1S/C9H15F3O2S/c1-2-3-4-5-6-15(14)7-8(13)9(10,11)12/h2-7H2,1H3
DMJ0ZMT	CS	CCCCCCS(=O)CC(=O)C(F)(F)F
DMJ0ZMT	IK	LSJUTEXGKKBNFU-UHFFFAOYSA-N
DMJ0ZMT	IU	1,1,1-trifluoro-3-hexylsulfinylpropan-2-one
DMJ0ZMT	DE	Discovery agent

DMWDUCH	ID	DMWDUCH
DMWDUCH	DN	1,1,1-trifluoro-3-(hexylsulfonyl)propan-2-one
DMWDUCH	HS	Investigative
DMWDUCH	SN	CHEMBL155621
DMWDUCH	DT	Small molecular drug
DMWDUCH	PC	11821337
DMWDUCH	MW	260.279
DMWDUCH	FM	C9H15F3O3S
DMWDUCH	IC	InChI=1S/C9H15F3O3S/c1-2-3-4-5-6-16(14,15)7-8(13)9(10,11)12/h2-7H2,1H3
DMWDUCH	CS	CCCCCCS(=O)(=O)CC(=O)C(F)(F)F
DMWDUCH	IK	MAGOHNFKWBKUKQ-UHFFFAOYSA-N
DMWDUCH	IU	1,1,1-trifluoro-3-hexylsulfonylpropan-2-one
DMWDUCH	DE	Discovery agent

DMWGSP6	ID	DMWGSP6
DMWGSP6	DN	1,1,1-trifluoro-3-(hexylthio)propan-2-one
DMWGSP6	HS	Investigative
DMWGSP6	SN	CHEMBL440542; 133311-65-6; 1,1,1-trifluoro-3-hexylsulfanylpropan-2-one; 2-Propanone, 1,1,1-trifluoro-3-(hexylthio)-; ACMC-20muvv; CTK0C0416; DTXSID00434189
DMWGSP6	DT	Small molecular drug
DMWGSP6	PC	10013998
DMWGSP6	MW	228.28
DMWGSP6	FM	C9H15F3OS
DMWGSP6	IC	InChI=1S/C9H15F3OS/c1-2-3-4-5-6-14-7-8(13)9(10,11)12/h2-7H2,1H3
DMWGSP6	CS	CCCCCCSCC(=O)C(F)(F)F
DMWGSP6	IK	JKYLDTTWQQEIHX-UHFFFAOYSA-N
DMWGSP6	IU	1,1,1-trifluoro-3-hexylsulfanylpropan-2-one
DMWGSP6	CA	CAS 133311-65-6
DMWGSP6	DE	Discovery agent

DMLBT0E	ID	DMLBT0E
DMLBT0E	DN	1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one
DMLBT0E	HS	Investigative
DMLBT0E	SN	CHEMBL270373
DMLBT0E	DT	Small molecular drug
DMLBT0E	PC	44455866
DMLBT0E	MW	272.33
DMLBT0E	FM	C11H19F3O2S
DMLBT0E	IC	InChI=1S/C11H19F3O2S/c1-2-3-4-5-6-7-8-17(16)9-10(15)11(12,13)14/h2-9H2,1H3
DMLBT0E	CS	CCCCCCCCS(=O)CC(=O)C(F)(F)F
DMLBT0E	IK	WVDSELHSQAACKS-UHFFFAOYSA-N
DMLBT0E	IU	1,1,1-trifluoro-3-octylsulfinylpropan-2-one
DMLBT0E	DE	Discovery agent

DMT29SN	ID	DMT29SN
DMT29SN	DN	1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one
DMT29SN	HS	Investigative
DMT29SN	SN	CHEMBL273139
DMT29SN	DT	Small molecular drug
DMT29SN	PC	44455840
DMT29SN	MW	288.33
DMT29SN	FM	C11H19F3O3S
DMT29SN	IC	InChI=1S/C11H19F3O3S/c1-2-3-4-5-6-7-8-18(16,17)9-10(15)11(12,13)14/h2-9H2,1H3
DMT29SN	CS	CCCCCCCCS(=O)(=O)CC(=O)C(F)(F)F
DMT29SN	IK	LGBYSBJDEXOENJ-UHFFFAOYSA-N
DMT29SN	IU	1,1,1-trifluoro-3-octylsulfonylpropan-2-one
DMT29SN	DE	Discovery agent

DMU4EJW	ID	DMU4EJW
DMU4EJW	DN	1,1,1-trifluoro-3-(octylthio)propan-2-one
DMU4EJW	HS	Investigative
DMU4EJW	SN	89820-00-8; 3-Octylthio-1,1,1-trifluoro-2-propanone; CHEMBL89506; 2-Propanone,1,1,1-trifluoro-3-(octylthio)-; 1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE; 3-Octylthio-1,1,1-trifluoropropan-2-one; 2-Propanone, 1,1,1-trifluoro-3-(octylthio)-; 1,1,1-trifluoro-3-(octylsulfanyl)propan-2-one; 3-Otfp; 1,1,1-Trifluoro-3-octylsulfanyl-propan-2-one; OTFP; ACMC-20lqwm; AC1L3SIW; SCHEMBL4224604; CTK5G3533; DTXSID40237914; WMQHRXUKAYSPPK-UHFFFAOYSA-N; ZINC34803731; BDBM50371970; AKOS028111069; DB08612; 1,1,1-Trifluoro-3-(octylsulfanyl)acetone
DMU4EJW	DT	Small molecular drug
DMU4EJW	PC	146089
DMU4EJW	MW	256.329
DMU4EJW	FM	C11H19F3OS
DMU4EJW	IC	InChI=1S/C11H19F3OS/c1-2-3-4-5-6-7-8-16-9-10(15)11(12,13)14/h2-9H2,1H3
DMU4EJW	CS	CCCCCCCCSCC(=O)C(F)(F)F
DMU4EJW	IK	WMQHRXUKAYSPPK-UHFFFAOYSA-N
DMU4EJW	IU	1,1,1-trifluoro-3-octylsulfanylpropan-2-one
DMU4EJW	CA	CAS 89820-00-8
DMU4EJW	DE	Discovery agent

DMODCAM	ID	DMODCAM
DMODCAM	DN	1,1,1-Trifluoro-4-(4-hexyloxy-phenyl)-butan-2-one
DMODCAM	HS	Investigative
DMODCAM	SN	CHEMBL462596
DMODCAM	DT	Small molecular drug
DMODCAM	PC	25059817
DMODCAM	MW	302.33
DMODCAM	FM	C16H21F3O2
DMODCAM	IC	InChI=1S/C16H21F3O2/c1-2-3-4-5-12-21-14-9-6-13(7-10-14)8-11-15(20)16(17,18)19/h6-7,9-10H,2-5,8,11-12H2,1H3
DMODCAM	CS	CCCCCCOC1=CC=C(C=C1)CCC(=O)C(F)(F)F
DMODCAM	IK	UOOMUFUVLSIOFF-UHFFFAOYSA-N
DMODCAM	IU	1,1,1-trifluoro-4-(4-hexoxyphenyl)butan-2-one
DMODCAM	DE	Discovery agent

DMI2XWY	ID	DMI2XWY
DMI2XWY	DN	1,1,1-Trifluoro-5-(4-octylphenoxy)pentan-2-one
DMI2XWY	HS	Investigative
DMI2XWY	SN	SCHEMBL3490532
DMI2XWY	DT	Small molecular drug
DMI2XWY	PC	25059559
DMI2XWY	MW	344.4
DMI2XWY	FM	C19H27F3O2
DMI2XWY	IC	InChI=1S/C19H27F3O2/c1-2-3-4-5-6-7-9-16-11-13-17(14-12-16)24-15-8-10-18(23)19(20,21)22/h11-14H,2-10,15H2,1H3
DMI2XWY	CS	CCCCCCCCC1=CC=C(C=C1)OCCCC(=O)C(F)(F)F
DMI2XWY	IK	UMRJNULJIAZHAL-UHFFFAOYSA-N
DMI2XWY	IU	1,1,1-trifluoro-5-(4-octylphenoxy)pentan-2-one
DMI2XWY	DE	Discovery agent

DMCAQ5T	ID	DMCAQ5T
DMCAQ5T	DN	1,1,1-Trifluoro-6-(4-hexyloxy-phenyl)-hexan-2-one
DMCAQ5T	HS	Investigative
DMCAQ5T	SN	SCHEMBL3488416
DMCAQ5T	DT	Small molecular drug
DMCAQ5T	PC	25059556
DMCAQ5T	MW	330.4
DMCAQ5T	FM	C18H25F3O2
DMCAQ5T	IC	InChI=1S/C18H25F3O2/c1-2-3-4-7-14-23-16-12-10-15(11-13-16)8-5-6-9-17(22)18(19,20)21/h10-13H,2-9,14H2,1H3
DMCAQ5T	CS	CCCCCCOC1=CC=C(C=C1)CCCCC(=O)C(F)(F)F
DMCAQ5T	IK	AKKQOQJOIIZUSW-UHFFFAOYSA-N
DMCAQ5T	IU	1,1,1-trifluoro-6-(4-hexoxyphenyl)hexan-2-one
DMCAQ5T	DE	Discovery agent

DMZ2VE3	ID	DMZ2VE3
DMZ2VE3	DN	1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one
DMZ2VE3	HS	Investigative
DMZ2VE3	SN	FKGK18; 1071001-09-6; FKGK-18; SCHEMBL3489194; CHEMBL1095003; AOB4846; ZINC49114263; NCGC00402329-01
DMZ2VE3	DT	Small molecular drug
DMZ2VE3	PC	25060069
DMZ2VE3	MW	280.28
DMZ2VE3	FM	C16H15F3O
DMZ2VE3	IC	InChI=1S/C16H15F3O/c17-16(18,19)15(20)8-4-1-5-12-9-10-13-6-2-3-7-14(13)11-12/h2-3,6-7,9-11H,1,4-5,8H2
DMZ2VE3	CS	C1=CC=C2C=C(C=CC2=C1)CCCCC(=O)C(F)(F)F
DMZ2VE3	IK	VCWWTQMRNJSJGC-UHFFFAOYSA-N
DMZ2VE3	IU	1,1,1-trifluoro-6-naphthalen-2-ylhexan-2-one
DMZ2VE3	DE	Discovery agent

DMLHVWP	ID	DMLHVWP
DMLHVWP	DN	1,1,1-Trifluoro-7-phenylheptan-2-one
DMLHVWP	HS	Investigative
DMLHVWP	SN	1,1,1-Trifluoro-7-phenyl-heptan-2-one
DMLHVWP	DT	Small molecular drug
DMLHVWP	PC	9878121
DMLHVWP	MW	244.25
DMLHVWP	FM	C13H15F3O
DMLHVWP	IC	InChI=1S/C13H15F3O/c14-13(15,16)12(17)10-6-2-5-9-11-7-3-1-4-8-11/h1,3-4,7-8H,2,5-6,9-10H2
DMLHVWP	CS	C1=CC=C(C=C1)CCCCCC(=O)C(F)(F)F
DMLHVWP	IK	OYIOJJUJKLHWGM-UHFFFAOYSA-N
DMLHVWP	IU	1,1,1-trifluoro-7-phenylheptan-2-one
DMLHVWP	DE	Discovery agent

DM6GI4Z	ID	DM6GI4Z
DM6GI4Z	DN	1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one
DM6GI4Z	HS	Investigative
DM6GI4Z	SN	CHEMBL117916; SCHEMBL7366611; BDBM50217945
DM6GI4Z	DT	Small molecular drug
DM6GI4Z	PC	44342905
DM6GI4Z	MW	366.4
DM6GI4Z	FM	C20H21F3O3
DM6GI4Z	IC	InChI=1S/C20H21F3O3/c21-20(22,23)19(24)10-6-1-2-7-15-25-16-11-13-18(14-12-16)26-17-8-4-3-5-9-17/h3-5,8-9,11-14H,1-2,6-7,10,15H2
DM6GI4Z	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)OCCCCCCC(=O)C(F)(F)F
DM6GI4Z	IK	ZZPVOJAAHDFZNF-UHFFFAOYSA-N
DM6GI4Z	IU	1,1,1-trifluoro-8-(4-phenoxyphenoxy)octan-2-one
DM6GI4Z	DE	Discovery agent

DM41R2O	ID	DM41R2O
DM41R2O	DN	1,1,1-Trifluoro-8-phenoxy-octan-2-one
DM41R2O	HS	Investigative
DM41R2O	SN	CHEMBL114796; BDBM50217940
DM41R2O	DT	Small molecular drug
DM41R2O	PC	44342886
DM41R2O	MW	274.28
DM41R2O	FM	C14H17F3O2
DM41R2O	IC	InChI=1S/C14H17F3O2/c15-14(16,17)13(18)10-6-1-2-7-11-19-12-8-4-3-5-9-12/h3-5,8-9H,1-2,6-7,10-11H2
DM41R2O	CS	C1=CC=C(C=C1)OCCCCCCC(=O)C(F)(F)F
DM41R2O	IK	MSSNESMCPBOBIG-UHFFFAOYSA-N
DM41R2O	IU	1,1,1-trifluoro-8-phenoxyoctan-2-one
DM41R2O	DE	Discovery agent

DMYENI7	ID	DMYENI7
DMYENI7	DN	1,1,1-Trifluoro-8-phenyl-octan-2-one
DMYENI7	HS	Investigative
DMYENI7	SN	1,1,1-Trifluoro-8-phenyloctan-2-one
DMYENI7	PC	9813810
DMYENI7	MW	258.279
DMYENI7	FM	C14H17F3O
DMYENI7	IC	InChI=1S/C14H17F3O/c15-14(16,17)13(18)11-7-2-1-4-8-12-9-5-3-6-10-12/h3,5-6,9-10H,1-2,4,7-8,11H2
DMYENI7	CS	C1=CC=C(C=C1)CCCCCCC(=O)C(F)(F)F
DMYENI7	IK	LKXJGCHERZYPOU-UHFFFAOYSA-N
DMYENI7	IU	1,1,1-trifluoro-8-phenyloctan-2-one
DMYENI7	DE	Discovery agent

DM7DWVL	ID	DM7DWVL
DM7DWVL	DN	1,1,1-Trifluoro-9-phenyl-nonan-2-one
DM7DWVL	HS	Investigative
DM7DWVL	SN	CHEMBL91417; 1,1,1-trifluoro-9-phenyl-nonan-2-one; SCHEMBL5267943; BDBM50073987
DM7DWVL	DT	Small molecular drug
DM7DWVL	PC	9795477
DM7DWVL	MW	272.31
DM7DWVL	FM	C15H19F3O
DM7DWVL	IC	InChI=1S/C15H19F3O/c16-15(17,18)14(19)12-8-3-1-2-5-9-13-10-6-4-7-11-13/h4,6-7,10-11H,1-3,5,8-9,12H2
DM7DWVL	CS	C1=CC=C(C=C1)CCCCCCCC(=O)C(F)(F)F
DM7DWVL	IK	BAGRIDDIIFOCBK-UHFFFAOYSA-N
DM7DWVL	IU	1,1,1-trifluoro-9-phenylnonan-2-one
DM7DWVL	DE	Discovery agent

DMW6CQV	ID	DMW6CQV
DMW6CQV	DN	1,1,1-trifluorododecan-2-one
DMW6CQV	HS	Investigative
DMW6CQV	SN	1,1,1-trifluorododecan-2-one; CHEMBL86668; 26902-72-7; 2-Dodecanone, 1,1,1-trifluoro-; AC1L424F; 1,1,1-Trifluoro-2-dodecanone; BDBM50371959
DMW6CQV	DT	Small molecular drug
DMW6CQV	PC	176445
DMW6CQV	MW	238.29
DMW6CQV	FM	C12H21F3O
DMW6CQV	IC	InChI=1S/C12H21F3O/c1-2-3-4-5-6-7-8-9-10-11(16)12(13,14)15/h2-10H2,1H3
DMW6CQV	CS	CCCCCCCCCCC(=O)C(F)(F)F
DMW6CQV	IK	YXTBWTOMSMZIMA-UHFFFAOYSA-N
DMW6CQV	IU	1,1,1-trifluorododecan-2-one
DMW6CQV	CA	CAS 26902-72-7
DMW6CQV	DE	Discovery agent

DMB5U3P	ID	DMB5U3P
DMB5U3P	DN	1,1,1-trifluoroheptadecan-2-one
DMB5U3P	HS	Investigative
DMB5U3P	SN	PACOCF3; 1,1,1-trifluoroheptadecan-2-one; 141022-99-3; palmityl trifluoromethyl ketone; Palmitoyl Trifluoromethyl Ketone; CHEMBL99344; 1,1,1-Trifluoro-2-heptadecanone; SR-01000597566; Tocris-1460; AC1L1IOS; AC1Q4I4P; SCHEMBL4653611; Pentadecyl trifluoromethyl ketone; CTK4C2431; C17H31F3O; DTXSID00274441; MAHYXYTYTLCTQD-UHFFFAOYSA-N; MolPort-003-983-793; HMS3649G09; 1,1,1-Trifluoroheptadecen-2-one; HMS3267L18; ZINC8036041; IN1174; BS0141; HSCI1_000022; BDBM50085494; 1974AH; 1,1,1-Trifluoro-2-heptadecanone #; AKOS017343267
DMB5U3P	DT	Small molecular drug
DMB5U3P	PC	4670
DMB5U3P	MW	308.4
DMB5U3P	FM	C17H31F3O
DMB5U3P	IC	InChI=1S/C17H31F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(21)17(18,19)20/h2-15H2,1H3
DMB5U3P	CS	CCCCCCCCCCCCCCCC(=O)C(F)(F)F
DMB5U3P	IK	MAHYXYTYTLCTQD-UHFFFAOYSA-N
DMB5U3P	IU	1,1,1-trifluoroheptadecan-2-one
DMB5U3P	CA	CAS 141022-99-3
DMB5U3P	DE	Discovery agent

DM8TWY7	ID	DM8TWY7
DM8TWY7	DN	1,1,1-Trifluoro-nonadecan-2-one
DM8TWY7	HS	Investigative
DM8TWY7	SN	2-Nonadecanone, 1,1,1-trifluoro-; CHEMBL89946; 1,1,1-trifluorononadecan-2-one; 81124-01-8; 1,1,1-Trifluoro-nonadecan-2-one; AC1L4IKT; CTK5E8478; DTXSID90230910; 1,1,1-Trifluoro-2-nonadecanone; 2-Nonadecanone,1,1,1-trifluoro-
DM8TWY7	DT	Small molecular drug
DM8TWY7	PC	157730
DM8TWY7	MW	336.5
DM8TWY7	FM	C19H35F3O
DM8TWY7	IC	InChI=1S/C19H35F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(23)19(20,21)22/h2-17H2,1H3
DM8TWY7	CS	CCCCCCCCCCCCCCCCCC(=O)C(F)(F)F
DM8TWY7	IK	SYQIFPOSGNRRCM-UHFFFAOYSA-N
DM8TWY7	IU	1,1,1-trifluorononadecan-2-one
DM8TWY7	CA	CAS 81124-01-8
DM8TWY7	DE	Discovery agent

DM4CEQP	ID	DM4CEQP
DM4CEQP	DN	1,1,1-Trifluoro-tridecan-2-one
DM4CEQP	HS	Investigative
DM4CEQP	SN	1,1,1-trifluorotridecan-2-one; CHEMBL90308; 86571-23-5; 1,1,1-Trifluoro-tridecan-2-one; CTK2I3319; DTXSID20571888; 2-Tridecanone, 1,1,1-trifluoro-
DM4CEQP	DT	Small molecular drug
DM4CEQP	PC	15353606
DM4CEQP	MW	252.32
DM4CEQP	FM	C13H23F3O
DM4CEQP	IC	InChI=1S/C13H23F3O/c1-2-3-4-5-6-7-8-9-10-11-12(17)13(14,15)16/h2-11H2,1H3
DM4CEQP	CS	CCCCCCCCCCCC(=O)C(F)(F)F
DM4CEQP	IK	ZSPZNVMNSATHGF-UHFFFAOYSA-N
DM4CEQP	IU	1,1,1-trifluorotridecan-2-one
DM4CEQP	CA	CAS 86571-23-5
DM4CEQP	DE	Discovery agent

DMX2SFW	ID	DMX2SFW
DMX2SFW	DN	1,1,1-Trifluoro-undecan-2-one
DMX2SFW	HS	Investigative
DMX2SFW	SN	CHEMBL90258; 1,1,1-trifluoroundecan-2-one; 1,1,1-trifluoro-2-undecanone; 1,1,1-Trifluoro-undecan-2-one; BDBM50073985; AKOS012260318; 3-octyl-1,1,1-trifluoro-2-propanone; 3-Octyl-1,1,1-trifluoropropan-2-one
DMX2SFW	DT	Small molecular drug
DMX2SFW	PC	10609180
DMX2SFW	MW	224.26
DMX2SFW	FM	C11H19F3O
DMX2SFW	IC	InChI=1S/C11H19F3O/c1-2-3-4-5-6-7-8-9-10(15)11(12,13)14/h2-9H2,1H3
DMX2SFW	CS	CCCCCCCCCC(=O)C(F)(F)F
DMX2SFW	IK	ZKJPGCCWKBTIBE-UHFFFAOYSA-N
DMX2SFW	IU	1,1,1-trifluoroundecan-2-one
DMX2SFW	DE	Discovery agent

DMGHAC7	ID	DMGHAC7
DMGHAC7	DN	1,1':4',1''-terphenyl-3,3''-diol
DMGHAC7	HS	Investigative
DMGHAC7	SN	[1,1':4',1'']Terphenyl-3,3''-diol
DMGHAC7	DT	Small molecular drug
DMGHAC7	PC	44542195
DMGHAC7	MW	280.3
DMGHAC7	FM	C18H13FO2
DMGHAC7	IC	InChI=1S/C18H13FO2/c19-17-11-15(8-9-18(17)21)13-6-4-12(5-7-13)14-2-1-3-16(20)10-14/h1-11,20-21H
DMGHAC7	CS	C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC(=C(C=C3)O)F
DMGHAC7	IK	JNOWDEFWQPRYLB-UHFFFAOYSA-N
DMGHAC7	IU	2-fluoro-4-[4-(3-hydroxyphenyl)phenyl]phenol
DMGHAC7	DE	Discovery agent

DMA3LZ9	ID	DMA3LZ9
DMA3LZ9	DN	1,1':4',1''-terphenyl-3,4''-diol
DMA3LZ9	HS	Investigative
DMA3LZ9	SN	CHEMBL459976; SCHEMBL1180998; BDBM25864; RPJZTMNVHGSNCA-UHFFFAOYSA-N; ZINC40394061; hydroxyphenyl substituted benzene, 36; 3-[4-(4-hydroxyphenyl)phenyl]phenol
DMA3LZ9	DT	Small molecular drug
DMA3LZ9	PC	25093397
DMA3LZ9	MW	262.3
DMA3LZ9	FM	C18H14O2
DMA3LZ9	IC	InChI=1S/C18H14O2/c19-17-10-8-14(9-11-17)13-4-6-15(7-5-13)16-2-1-3-18(20)12-16/h1-12,19-20H
DMA3LZ9	CS	C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC=C(C=C3)O
DMA3LZ9	IK	RPJZTMNVHGSNCA-UHFFFAOYSA-N
DMA3LZ9	IU	3-[4-(4-hydroxyphenyl)phenyl]phenol
DMA3LZ9	DE	Discovery agent

DMYVBD2	ID	DMYVBD2
DMYVBD2	DN	1,10-(methylenedi-4,1-phenylene)bismaleimide
DMYVBD2	HS	Investigative
DMYVBD2	SN	Bismaleimide; 13676-54-5; Bismaleimide S; Bis(4-maleimidophenyl)methane; p,p'-Dimaleimidodiphenylmethane; Diphenylmethanebismaleimide; 4,4'-Methylenebis(N-phenylmaleimide); Bis(p-maleimidophenyl)methane; 4,4'-Diphenylmethanedimaleimide; 4,4'-Dimaleimidodiphenylmethane; 4,4'-Diphenylmethanebismaleimide; 4,4'-Biphenylmethanebismaleimide; 4,4'-Bismaleimidodiphenylmethane; 1H-Pyrrole-2,5-dione, 1,1'-(methylenedi-4,1-phenylene)bis-; 4,4'-Methylenebis(phenylmaleimide); p,p'-Methylenebis(N-phenylmaleimide)
DMYVBD2	DT	Small molecular drug
DMYVBD2	PC	83648
DMYVBD2	MW	358.3
DMYVBD2	FM	C21H14N2O4
DMYVBD2	IC	InChI=1S/C21H14N2O4/c24-18-9-10-19(25)22(18)16-5-1-14(2-6-16)13-15-3-7-17(8-4-15)23-20(26)11-12-21(23)27/h1-12H,13H2
DMYVBD2	CS	C1=CC(=CC=C1CC2=CC=C(C=C2)N3C(=O)C=CC3=O)N4C(=O)C=CC4=O
DMYVBD2	IK	XQUPVDVFXZDTLT-UHFFFAOYSA-N
DMYVBD2	IU	1-[4-[[4-(2,5-dioxopyrrol-1-yl)phenyl]methyl]phenyl]pyrrole-2,5-dione
DMYVBD2	CA	CAS 13676-54-5
DMYVBD2	DE	Discovery agent

DM9UGFQ	ID	DM9UGFQ
DM9UGFQ	DN	1,10-bis-(Dmt-Tic-amino)decane
DM9UGFQ	HS	Investigative
DM9UGFQ	SN	CHEMBL373192; 1,10-bis-(Dmt-Tic-amino)decane
DM9UGFQ	DT	Small molecular drug
DM9UGFQ	PC	44405160
DM9UGFQ	MW	873.1
DM9UGFQ	FM	C52H68N6O6
DM9UGFQ	IC	InChI=1S/C52H68N6O6/c1-33-23-41(59)24-34(2)43(33)29-45(53)51(63)57-31-39-19-13-11-17-37(39)27-47(57)49(61)55-21-15-9-7-5-6-8-10-16-22-56-50(62)48-28-38-18-12-14-20-40(38)32-58(48)52(64)46(54)30-44-35(3)25-42(60)26-36(44)4/h11-14,17-20,23-26,45-48,59-60H,5-10,15-16,21-22,27-32,53-54H2,1-4H3,(H,55,61)(H,56,62)/t45-,46-,47?,48?/m0/s1
DM9UGFQ	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCCCCCNC(=O)C4CC5=CC=CC=C5CN4C(=O)[C@H](CC6=C(C=C(C=C6C)O)C)N)N)C)O
DM9UGFQ	IK	WGSCXEFFOVZNEM-QCSGVJIWSA-N
DM9UGFQ	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[10-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]decyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM9UGFQ	DE	Discovery agent

DM6VCI3	ID	DM6VCI3
DM6VCI3	DN	1,10-bis(pyridinium)-decane dibromide
DM6VCI3	HS	Investigative
DM6VCI3	SN	P.M. 458; 1,1'-Decamethylenebis(pyridinium bromide); NSC 36864; 6266-40-6; G.L. 110; CHEMBL225689; 1-[10-(pyridin-1-ium-1-yl)decyl]pyridin-1-ium dibromide; Pyridinium, 1,1'-decamethylenebis-, dibromide; 1,10-bis(pyridinium)-decane dibromide; AC1L46P1; MolPort-023-233-174; 1,10-bis(pyridinium)decane dibromide; AKOS033332200; MCULE-1765937122; NE55775; LS-132391; 1,1'-decane-1,10-diyldipyridinium dibromide; Z1424831827; 1-(10-pyridin-1-ium-1-yldecyl)pyridin-1-ium dibromide
DM6VCI3	DT	Small molecular drug
DM6VCI3	PC	201563
DM6VCI3	MW	458.3
DM6VCI3	FM	C20H30Br2N2
DM6VCI3	IC	InChI=1S/C20H30N2.2BrH/c1(3-5-9-15-21-17-11-7-12-18-21)2-4-6-10-16-22-19-13-8-14-20-22;;/h7-8,11-14,17-20H,1-6,9-10,15-16H2;2*1H/q+2;;/p-2
DM6VCI3	CS	C1=CC=[N+](C=C1)CCCCCCCCCC[N+]2=CC=CC=C2.[Br-].[Br-]
DM6VCI3	IK	XZZPVHYTBRRMNM-UHFFFAOYSA-L
DM6VCI3	IU	1-(10-pyridin-1-ium-1-yldecyl)pyridin-1-ium;dibromide
DM6VCI3	CA	CAS 6266-40-6
DM6VCI3	DE	Discovery agent

DM5LVD2	ID	DM5LVD2
DM5LVD2	DN	1,10-phenanthroline-5,6-dione
DM5LVD2	HS	Investigative
DM5LVD2	SN	1,10-Phenanthroline-5,6-dione; 27318-90-7; [1,10]Phenanthroline-5,6-dione; UNII-8JD7KXA2W0; 8JD7KXA2W0; MLS003171048; KCALAFIVPCAXJI-UHFFFAOYSA-N; 1 10-Phenanthroline-5 6-Dione 97; AK-27690; J-400086; pyridino[3,2-h]quinoline-5,6-dione; 1,10-Phenanthroline-5,6-dione, 98%; Phen-5,6-dione; 1,10-Pad; NSC346882; NSC 346882; PubChem16755; ACMC-209gwd; AC1L2IPW; PHOX31; KSC204S8L; cid_72810; SCHEMBL460433; CHEMBL235504; AC1Q6N66; KS-00000LQX; CTK1A4985; BDBM22860; DTXSID60181763; MolPort-002-720-727; 1,2-Dione-Based Compound, 17; ZX-AT019110
DM5LVD2	DT	Small molecular drug
DM5LVD2	PC	72810
DM5LVD2	MW	210.19
DM5LVD2	FM	C12H6N2O2
DM5LVD2	IC	InChI=1S/C12H6N2O2/c15-11-7-3-1-5-13-9(7)10-8(12(11)16)4-2-6-14-10/h1-6H
DM5LVD2	CS	C1=CC2=C(C3=C(C=CC=N3)C(=O)C2=O)N=C1
DM5LVD2	IK	KCALAFIVPCAXJI-UHFFFAOYSA-N
DM5LVD2	IU	1,10-phenanthroline-5,6-dione
DM5LVD2	CA	CAS 27318-90-7
DM5LVD2	DE	Discovery agent

DMVXYZL	ID	DMVXYZL
DMVXYZL	DN	1,11-bis(pyridinium)-undecane dibromide
DMVXYZL	HS	Investigative
DMVXYZL	SN	1,11-bis(pyridinium)-undecane dibromide; CHEMBL430886; SCHEMBL6354341; RCBQYFFDMCXGIU-UHFFFAOYSA-L; N,N'-Undecane-1,11-diyl-bis-pyridinium Dibromide; 1,11-Di(1-Pyridiniumyl)Undecane With Dibromide Ions
DMVXYZL	DT	Small molecular drug
DMVXYZL	PC	11351920
DMVXYZL	MW	472.3
DMVXYZL	FM	C21H32Br2N2
DMVXYZL	IC	InChI=1S/C21H32N2.2BrH/c1(2-4-6-10-16-22-18-12-8-13-19-22)3-5-7-11-17-23-20-14-9-15-21-23;;/h8-9,12-15,18-21H,1-7,10-11,16-17H2;2*1H/q+2;;/p-2
DMVXYZL	CS	C1=CC=[N+](C=C1)CCCCCCCCCCC[N+]2=CC=CC=C2.[Br-].[Br-]
DMVXYZL	IK	RCBQYFFDMCXGIU-UHFFFAOYSA-L
DMVXYZL	IU	1-(11-pyridin-1-ium-1-ylundecyl)pyridin-1-ium;dibromide
DMVXYZL	DE	Discovery agent

DMG362U	ID	DMG362U
DMG362U	DN	1,1-bisphosphonate esters
DMG362U	HS	Investigative
DMG362U	DE	Discovery agent

DM9XTY7	ID	DM9XTY7
DM9XTY7	DN	1,1-Dimethyl-4-phenyl-piperazin-1-ium iodide
DM9XTY7	HS	Investigative
DM9XTY7	DE	Discovery agent

DMOGHRS	ID	DMOGHRS
DMOGHRS	DN	1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one
DMOGHRS	HS	Investigative
DMOGHRS	SN	5-Oxaspiro[2.4]heptan-4-one, 1,1-dimethyl-; 65652-09-7; CHEMBL97270
DMOGHRS	DT	Small molecular drug
DMOGHRS	PC	10464406
DMOGHRS	MW	140.18
DMOGHRS	FM	C8H12O2
DMOGHRS	IC	InChI=1S/C8H12O2/c1-7(2)5-8(7)3-4-10-6(8)9/h3-5H2,1-2H3
DMOGHRS	CS	CC1(CC12CCOC2=O)C
DMOGHRS	IK	KTGHZHGRFYRANW-UHFFFAOYSA-N
DMOGHRS	IU	2,2-dimethyl-5-oxaspiro[2.4]heptan-4-one
DMOGHRS	DE	Discovery agent

DMZDUSA	ID	DMZDUSA
DMZDUSA	DN	1,1-diphenyl-2-(3-tropanyl)ethanol
DMZDUSA	HS	Investigative
DMZDUSA	SN	1,1-diphenyl-2-(3-tropanyl)ethanol; CHEMBL558034; BDBM50345674; 2-(exo-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1,1-diphenylethanol
DMZDUSA	DT	Small molecular drug
DMZDUSA	PC	45271007
DMZDUSA	MW	321.5
DMZDUSA	FM	C22H27NO
DMZDUSA	IC	InChI=1S/C22H27NO/c1-23-20-12-13-21(23)15-17(14-20)16-22(24,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20-21,24H,12-16H2,1H3/t20-,21-/m1/s1
DMZDUSA	CS	CN1[C@@H]2CC[C@@H]1CC(C2)CC(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMZDUSA	IK	LAOBIJDCKIAALB-NHCUHLMSSA-N
DMZDUSA	IU	2-[(1R,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-1,1-diphenylethanol
DMZDUSA	DE	Discovery agent

DM7SQ4H	ID	DM7SQ4H
DM7SQ4H	DN	1,1-diphenyl-3-(phenylsulfonyl)propan-2-one
DM7SQ4H	HS	Investigative
DM7SQ4H	SN	CHEMBL239469; 1,1-diphenyl-3-(phenylsulfonyl)propan-2-one
DM7SQ4H	DT	Small molecular drug
DM7SQ4H	PC	44437611
DM7SQ4H	MW	350.4
DM7SQ4H	FM	C21H18O3S
DM7SQ4H	IC	InChI=1S/C21H18O3S/c22-20(16-25(23,24)19-14-8-3-9-15-19)21(17-10-4-1-5-11-17)18-12-6-2-7-13-18/h1-15,21H,16H2
DM7SQ4H	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)CS(=O)(=O)C3=CC=CC=C3
DM7SQ4H	IK	SKWQLTIDKRSBES-UHFFFAOYSA-N
DM7SQ4H	IU	3-(benzenesulfonyl)-1,1-diphenylpropan-2-one
DM7SQ4H	DE	Discovery agent

DMDYX7P	ID	DMDYX7P
DMDYX7P	DN	1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline
DMDYX7P	HS	Investigative
DMDYX7P	SN	CHEMBL133947; 1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline; 67728-01-2; SCHEMBL4107088; CTK1J3020; DTXSID80603290; BDBM50219331; AKOS023412127; 1,2,3,4,4a,5,10,10a-Octahydrobenzo[g]quinoline; Benzo[g]quinoline, 1,2,3,4,4a,5,10,10a-octahydro-
DMDYX7P	DT	Small molecular drug
DMDYX7P	PC	20186598
DMDYX7P	MW	187.28
DMDYX7P	FM	C13H17N
DMDYX7P	IC	InChI=1S/C13H17N/c1-2-5-11-9-13-12(6-3-7-14-13)8-10(11)4-1/h1-2,4-5,12-14H,3,6-9H2
DMDYX7P	CS	C1CC2CC3=CC=CC=C3CC2NC1
DMDYX7P	IK	PXDWMPVOPNRION-UHFFFAOYSA-N
DMDYX7P	IU	1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline
DMDYX7P	CA	CAS 67728-01-2
DMDYX7P	DE	Discovery agent

DM7JMCI	ID	DM7JMCI
DM7JMCI	DN	1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one
DM7JMCI	HS	Investigative
DM7JMCI	SN	CHEMBL84044; 7403-93-2; NSC403412; AC1L83AN; 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one; SCHEMBL6645911; DTXSID70323238; BDBM50131013; NSC-403412; 2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-one; 1,3,4,4a,5,10b-Hexahydro-2H-phenanthridin-6-one
DM7JMCI	DT	Small molecular drug
DM7JMCI	PC	345678
DM7JMCI	MW	201.26
DM7JMCI	FM	C13H15NO
DM7JMCI	IC	InChI=1S/C13H15NO/c15-13-11-7-2-1-5-9(11)10-6-3-4-8-12(10)14-13/h1-2,5,7,10,12H,3-4,6,8H2,(H,14,15)
DM7JMCI	CS	C1CCC2C(C1)C3=CC=CC=C3C(=O)N2
DM7JMCI	IK	CQQBPJQEIHYWQX-UHFFFAOYSA-N
DM7JMCI	IU	2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-one
DM7JMCI	CA	CAS 7403-93-2
DM7JMCI	DE	Discovery agent

DMVD702	ID	DMVD702
DMVD702	DN	1,2,3,4,5,6-hexabromocyclohexane
DMVD702	HS	Investigative
DMVD702	SN	1,2,3,4,5,6-Hexabromocyclohexane; 1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694
DMVD702	DT	Small molecular drug
DMVD702	PC	74603
DMVD702	MW	557.5
DMVD702	FM	C6H6Br6
DMVD702	IC	InChI=1S/C6H6Br6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H
DMVD702	CS	C1(C(C(C(C(C1Br)Br)Br)Br)Br)Br
DMVD702	IK	QFQZKISCBJKVHI-UHFFFAOYSA-N
DMVD702	IU	1,2,3,4,5,6-hexabromocyclohexane
DMVD702	CA	CAS 1837-91-8
DMVD702	CB	CHEBI:93940
DMVD702	DE	Liver cancer

DMTKYFE	ID	DMTKYFE
DMTKYFE	DN	1,2,3,4,5,6-Hexahydro-benzo[c]azocine
DMTKYFE	HS	Investigative
DMTKYFE	SN	1,2,3,4,5,6-Hexahydro-benzo[c]azocine; CHEMBL116945; SCHEMBL4503618; BDBM50052889; 7124-94-9; 1,2,3,4,5,6-hexahydro-2-benzazocine; 2-Benzazocine, 1,2,3,4,5,6-hexahydro-
DMTKYFE	DT	Small molecular drug
DMTKYFE	PC	13698159
DMTKYFE	MW	161.24
DMTKYFE	FM	C11H15N
DMTKYFE	IC	InChI=1S/C11H15N/c1-2-7-11-9-12-8-4-3-6-10(11)5-1/h1-2,5,7,12H,3-4,6,8-9H2
DMTKYFE	CS	C1CCNCC2=CC=CC=C2C1
DMTKYFE	IK	QLEFVMRRZCGFFA-UHFFFAOYSA-N
DMTKYFE	IU	1,2,3,4,5,6-hexahydro-2-benzazocine
DMTKYFE	DE	Discovery agent

DMTK650	ID	DMTK650
DMTK650	DN	1,2,3,4,6-penta-O-galloyl-beta-D-glucose
DMTK650	HS	Investigative
DMTK650	SN	Pentagalloyl glucose; Penta-O-galloyl-beta-glucoside
DMTK650	DT	Small molecular drug
DMTK650	PC	65238
DMTK650	MW	940.7
DMTK650	FM	C41H32O26
DMTK650	IC	InChI=1S/C41H32O26/c42-17-1-12(2-18(43)28(17)52)36(57)62-11-27-33(64-37(58)13-3-19(44)29(53)20(45)4-13)34(65-38(59)14-5-21(46)30(54)22(47)6-14)35(66-39(60)15-7-23(48)31(55)24(49)8-15)41(63-27)67-40(61)16-9-25(50)32(56)26(51)10-16/h1-10,27,33-35,41-56H,11H2/t27-,33-,34+,35-,41+/m1/s1
DMTK650	CS	C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)OC(=O)C6=CC(=C(C(=C6)O)O)O
DMTK650	IK	QJYNZEYHSMRWBK-NIKIMHBISA-N
DMTK650	IU	[(2R,3R,4S,5R,6S)-3,4,5,6-tetrakis[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate
DMTK650	CA	CAS 14937-32-7
DMTK650	CB	CHEBI:18082
DMTK650	DE	Discovery agent

DM9ICSA	ID	DM9ICSA
DM9ICSA	DN	1,2,3,4,6-penta-O-galloyl-D-glucopyranose
DM9ICSA	HS	Investigative
DM9ICSA	SN	D-Glucopyranose, pentakis(3,4,5-trihydroxybenzoate); 40410-94-4; 1,2,3,4,6-pentakis-o-(3,4,5-trihydroxybenzoyl)-d-glucopyranose; AC1L4RL6; SCHEMBL675693; AC1Q62I0; DTXSID00193426; 2,3,4,5,6-Pentagalloylglucose; BDBM175525; 3-O-Digalloyl-1,2,6-trigalloylglucose; 1,2,3,4,6-penta-O-galloyl--d-glucopyranose; US9120744, CDE-001 (or 073); 1-O,2-O,3-O,4-O,6-O-Pentagalloyl-D-glucopyranose; D-Glucose, 2,3,4,5,6-pentakis(3,4,5-trihydroxybenzoate); [(2R,3R,4S,5R)-3,4,5,6-tetrakis[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 3,4,5-
DM9ICSA	DT	Small molecular drug
DM9ICSA	PC	129651024
DM9ICSA	MW	945.7
DM9ICSA	FM	C41H32O26
DM9ICSA	IC	InChI=1S/C41H32O26/c42-17-1-12(2-18(43)28(17)52)36(57)62-11-27-33(64-37(58)13-3-19(44)29(53)20(45)4-13)34(65-38(59)14-5-21(46)30(54)22(47)6-14)35(66-39(60)15-7-23(48)31(55)24(49)8-15)41(63-27)67-40(61)16-9-25(50)32(56)26(51)10-16/h1-10,27,33-35,41-56H,11H2/t27-,33-,34+,35-,41?/m1/s1/i1D,3D,5D,7D,9D
DM9ICSA	CS	[2H]C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@H]([C@@H]([C@H](C(O2)OC(=O)C3=C(C(=C(C(=C3)O)O)O)[2H])OC(=O)C4=C(C(=C(C(=C4)O)O)O)[2H])OC(=O)C5=C(C(=C(C(=C5)O)O)O)[2H])OC(=O)C6=C(C(=C(C(=C6)O)O)O)[2H]
DM9ICSA	IK	QJYNZEYHSMRWBK-GYNONJAESA-N
DM9ICSA	IU	[(2R,3R,4S,5R)-3,4,5,6-tetrakis[(2-deuterio-3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 2-deuterio-3,4,5-trihydroxybenzoate
DM9ICSA	DE	Discovery agent

DMHKANE	ID	DMHKANE
DMHKANE	DN	1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol
DMHKANE	HS	Investigative
DMHKANE	SN	CHEMBL130744; 1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol; BDBM50061318; 1,2,3,4-Tetrahydrobenz[h]isoquinolin-8-ol
DMHKANE	DT	Small molecular drug
DMHKANE	PC	9990355
DMHKANE	MW	199.25
DMHKANE	FM	C13H13NO
DMHKANE	IC	InChI=1S/C13H13NO/c15-11-3-4-12-10(7-11)2-1-9-5-6-14-8-13(9)12/h1-4,7,14-15H,5-6,8H2
DMHKANE	CS	C1CNCC2=C1C=CC3=C2C=CC(=C3)O
DMHKANE	IK	MWWTWCVGHVVXBZ-UHFFFAOYSA-N
DMHKANE	IU	1,2,3,4-tetrahydrobenzo[h]isoquinolin-8-ol
DMHKANE	DE	Discovery agent

DM5VLIE	ID	DM5VLIE
DM5VLIE	DN	1,2,3,4-Tetrahydro-isoquinolin-7-ol
DM5VLIE	HS	Investigative
DM5VLIE	SN	1,2,3,4-tetrahydroisoquinolin-7-ol; 30798-64-2; 1,2,3,4-Tetrahydro-isoquinolin-7-ol; 1,2,3,4-Tetrahydro-7-isoquinolinol; 7-Hydroxy-1,2,3,4-tetrahydroisoquinoline; CHEMBL27730; RADQTHXRZJGDQI-UHFFFAOYSA-N; 7-Isoquinolinol, 1,2,3,4-tetrahydro-; 1,2,3,4-Tetrahydro-iosquinoline-7-ol; AC1L9HE2; 7-Hydroxytetrahydroisochinolin; SCHEMBL470826; AC1Q798F; DTXSID40329303; MolPort-005-312-666; ZINC3847389; BDBM50024826; ANW-75301; AKOS006222928; MB05747; RP21285; AC-9597; MCULE-2692939705; KB-74165; KB-64192; BS-13490; AJ-45863; TC-062003
DM5VLIE	DT	Small molecular drug
DM5VLIE	PC	419268
DM5VLIE	MW	149.19
DM5VLIE	FM	C9H11NO
DM5VLIE	IC	InChI=1S/C9H11NO/c11-9-2-1-7-3-4-10-6-8(7)5-9/h1-2,5,10-11H,3-4,6H2
DM5VLIE	CS	C1CNCC2=C1C=CC(=C2)O
DM5VLIE	IK	RADQTHXRZJGDQI-UHFFFAOYSA-N
DM5VLIE	IU	1,2,3,4-tetrahydroisoquinolin-7-ol
DM5VLIE	CA	CAS 30798-64-2
DM5VLIE	DE	Discovery agent

DMZGCEQ	ID	DMZGCEQ
DMZGCEQ	DN	1,2,3,4-tetrahydroisoquinoline
DMZGCEQ	HS	Investigative
DMZGCEQ	SN	1,2,3,4-Tetrahydroisoquinoline; 91-21-4; Tetrahydroisoquinoline; 1,2,3,4-Tetrahydro-isoquinoline; ISOQUINOLINE, 1,2,3,4-TETRAHYDRO-; 1,2,3,4-Tetrahydro isoquinoline; EINECS 202-050-0; NSC 15312; 1,2,3,4-Tetrahydro-2-isoquinoline; 1,2,3,4-Tetrahydro-2-azanaphthalene; BRN 0116156; UNII-56W89FBX3E; CHEMBL14346; AI3-15931; 56W89FBX3E; UWYZHKAOTLEWKK-UHFFFAOYSA-N; MFCD00006896; 1,2,3,4-Tetrahydroisoquinoline, 95%; 3,4-dihydro-1H-isoquinoline; tetrahydroisoquinolin; tetrahyroisoquinoline; tetrahydro-isoquinoline; PubChem7253; AC1L1NVS
DMZGCEQ	DT	Small molecular drug
DMZGCEQ	PC	7046
DMZGCEQ	MW	133.19
DMZGCEQ	FM	C9H11N
DMZGCEQ	IC	InChI=1S/C9H11N/c1-2-4-9-7-10-6-5-8(9)3-1/h1-4,10H,5-7H2
DMZGCEQ	CS	C1CNCC2=CC=CC=C21
DMZGCEQ	IK	UWYZHKAOTLEWKK-UHFFFAOYSA-N
DMZGCEQ	IU	1,2,3,4-tetrahydroisoquinoline
DMZGCEQ	CA	CAS 91-21-4
DMZGCEQ	CB	CHEBI:125498
DMZGCEQ	DE	Discovery agent

DMNXQ7Z	ID	DMNXQ7Z
DMNXQ7Z	DN	1,2,3,4-Tetrahydro-naphthalen-1-ylamine
DMNXQ7Z	HS	Investigative
DMNXQ7Z	SN	1,2,3,4-Tetrahydro-1-naphthylamine; 2217-40-5; 1,2,3,4-tetrahydronaphthalen-1-amine; 1-Aminotetralin; Aminotetralin; 1-Amino-1,2,3,4-tetrahydro-naphthalene; Aminotetralin [Czech]; 1,2,3,4-tetrahydronaphthylamine; JRZGPXSSNPTNMA-UHFFFAOYSA-N; EINECS 220-973-7; beta-1,2,3,4-Tetrahydronaphthylamine; Naphthalenamine, 1,2,3,4-tetrahydro-; BRN 1102357; 1-Amino-1,2,3,4-tetrahydronaphthalene; 1,2,3,4-tetrahydronaphthalen-1-ylamine; 1-Naphthalenamine, 1,2,3,4-tetrahydro-
DMNXQ7Z	DT	Small molecular drug
DMNXQ7Z	PC	18066
DMNXQ7Z	MW	147.22
DMNXQ7Z	FM	C10H13N
DMNXQ7Z	IC	InChI=1S/C10H13N/c11-10-7-3-5-8-4-1-2-6-9(8)10/h1-2,4,6,10H,3,5,7,11H2
DMNXQ7Z	CS	C1CC(C2=CC=CC=C2C1)N
DMNXQ7Z	IK	JRZGPXSSNPTNMA-UHFFFAOYSA-N
DMNXQ7Z	IU	1,2,3,4-tetrahydronaphthalen-1-amine
DMNXQ7Z	CA	CAS 2217-40-5
DMNXQ7Z	DE	Discovery agent

DMP4DLV	ID	DMP4DLV
DMP4DLV	DN	1,2,3,4-Tetrahydro-naphthalen-2-ylamine
DMP4DLV	HS	Investigative
DMP4DLV	SN	1,2,3,4-tetrahydronaphthalen-2-amine; 2954-50-9; 1,2,3,4-Tetrahydro-2-naphthylamine; 2-Aminotetralin; 2-Naphthalenamine, 1,2,3,4-tetrahydro-; 1,2,3,4-Tetrahydro-2-naphthalenamine; CHEMBL30294; LCGFVWKNXLRFIF-UHFFFAOYSA-N; 617700-25-1; 2-1,2,3,4-tetrahydronaphthylamine; 2-amino-tetralin; tetralin-2-amine; ACMC-20ac6z; AC1Q53DS; AC1L1S2C; SCHEMBL42952; .beta.-tetrahydronaphthylamine; BDBM23981; Tetrahydronaphthalen-2-amine, 3a; MolPort-001-779-767
DMP4DLV	DT	Small molecular drug
DMP4DLV	PC	34677
DMP4DLV	MW	147.22
DMP4DLV	FM	C10H13N
DMP4DLV	IC	InChI=1S/C10H13N/c11-10-6-5-8-3-1-2-4-9(8)7-10/h1-4,10H,5-7,11H2
DMP4DLV	CS	C1CC2=CC=CC=C2CC1N
DMP4DLV	IK	LCGFVWKNXLRFIF-UHFFFAOYSA-N
DMP4DLV	IU	1,2,3,4-tetrahydronaphthalen-2-amine
DMP4DLV	CA	CAS 2954-50-9
DMP4DLV	CB	CHEBI:125359
DMP4DLV	DE	Discovery agent

DM3JGVF	ID	DM3JGVF
DM3JGVF	DN	1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole
DM3JGVF	HS	Investigative
DM3JGVF	SN	1,2,3,4-tetrahydropyrazino[1,2-a]indole; 41838-39-5; 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole; CHEMBL6393; A1-02013; Pyrazino[1,2-a]indole, 1,2,3,4-tetrahydro-; SCHEMBL2356686; AEIDURNZWCNQIM-UHFFFAOYSA-N; MolPort-022-905-760; 2,3-dihydropyrazino[1,2-a]indole; ZINC13586839; STL290420; BDBM50108307; AKOS015996057; FCH1167619; OR70091; AJ-64212; AX8245433; KB-216229; FT-0682685; BB 0256492
DM3JGVF	DT	Small molecular drug
DM3JGVF	PC	14595509
DM3JGVF	MW	172.23
DM3JGVF	FM	C11H12N2
DM3JGVF	IC	InChI=1S/C11H12N2/c1-2-4-11-9(3-1)7-10-8-12-5-6-13(10)11/h1-4,7,12H,5-6,8H2
DM3JGVF	CS	C1CN2C(=CC3=CC=CC=C32)CN1
DM3JGVF	IK	AEIDURNZWCNQIM-UHFFFAOYSA-N
DM3JGVF	IU	1,2,3,4-tetrahydropyrazino[1,2-a]indole
DM3JGVF	CA	CAS 41838-39-5
DM3JGVF	DE	Discovery agent

DMFDK4N	ID	DMFDK4N
DMFDK4N	DN	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl
DMFDK4N	HS	Investigative
DMFDK4N	SN	1',2',3',6'-Tetrahydro-[2,4']bipyridinyl; 50461-51-3; CHEMBL278934; 1',2',3',6'-tetrahydro-2,4'-bipyridine; 2-(1,2,3,6-tetrahydropyridin-4-yl)pyridine; 2,4'-Bipyridine, 1',2',3',6'-tetrahydro-; SCHEMBL169400; CTK4J2646; DTXSID50569450; IVRPDZRVHKIBBG-UHFFFAOYSA-N; ZINC19811349; BDBM50026630; AKOS000205268
DMFDK4N	DT	Small molecular drug
DMFDK4N	PC	15166842
DMFDK4N	MW	160.22
DMFDK4N	FM	C10H12N2
DMFDK4N	IC	InChI=1S/C10H12N2/c1-2-6-12-10(3-1)9-4-7-11-8-5-9/h1-4,6,11H,5,7-8H2
DMFDK4N	CS	C1CNCC=C1C2=CC=CC=N2
DMFDK4N	IK	IVRPDZRVHKIBBG-UHFFFAOYSA-N
DMFDK4N	IU	2-(1,2,3,6-tetrahydropyridin-4-yl)pyridine
DMFDK4N	CA	CAS 50461-51-3
DMFDK4N	DE	Discovery agent

DMYDGAZ	ID	DMYDGAZ
DMYDGAZ	DN	1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol
DMYDGAZ	HS	Investigative
DMYDGAZ	SN	CHEMBL253530; 1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol
DMYDGAZ	DT	Small molecular drug
DMYDGAZ	PC	44448059
DMYDGAZ	MW	251.32
DMYDGAZ	FM	C17H17NO
DMYDGAZ	IC	InChI=1S/C17H17NO/c19-15-8-13-5-6-18-16-10-12-4-2-1-3-11(12)7-14(9-15)17(13)16/h1-4,8-9,16,18-19H,5-7,10H2
DMYDGAZ	CS	C1CNC2CC3=CC=CC=C3CC4=CC(=CC1=C24)O
DMYDGAZ	IK	ZCATUTKNMGBMKU-UHFFFAOYSA-N
DMYDGAZ	IU	11-azatetracyclo[8.7.1.03,8.014,18]octadeca-1(17),3,5,7,14(18),15-hexaen-16-ol
DMYDGAZ	DE	Discovery agent

DMAJ0B4	ID	DMAJ0B4
DMAJ0B4	DN	1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol
DMAJ0B4	HS	Investigative
DMAJ0B4	SN	CHEMBL253948; 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol
DMAJ0B4	DT	Small molecular drug
DMAJ0B4	PC	44448066
DMAJ0B4	MW	267.32
DMAJ0B4	FM	C17H17NO2
DMAJ0B4	IC	InChI=1S/C17H17NO2/c19-15-9-12-5-6-18-14-8-11-4-2-1-3-10(11)7-13(16(12)14)17(15)20/h1-4,9,14,18-20H,5-8H2
DMAJ0B4	CS	C1CNC2CC3=CC=CC=C3CC4=C2C1=CC(=C4O)O
DMAJ0B4	IK	SVRDMCXMTWERHI-UHFFFAOYSA-N
DMAJ0B4	IU	11-azatetracyclo[8.7.1.03,8.014,18]octadeca-1(18),3,5,7,14,16-hexaene-16,17-diol
DMAJ0B4	DE	Discovery agent

DMXL5R7	ID	DMXL5R7
DMXL5R7	DN	1,2,3-benzenetricarboxylic acid
DMXL5R7	HS	Investigative
DMXL5R7	SN	1,2,3-benzenetricarboxylate
DMXL5R7	DT	Small molecular drug
DMXL5R7	PC	11288
DMXL5R7	MW	210.14
DMXL5R7	FM	C9H6O6
DMXL5R7	IC	InChI=1S/C9H6O6/c10-7(11)4-2-1-3-5(8(12)13)6(4)9(14)15/h1-3H,(H,10,11)(H,12,13)(H,14,15)
DMXL5R7	CS	C1=CC(=C(C(=C1)C(=O)O)C(=O)O)C(=O)O
DMXL5R7	IK	UJMDYLWCYJJYMO-UHFFFAOYSA-N
DMXL5R7	IU	benzene-1,2,3-tricarboxylic acid
DMXL5R7	CA	CAS 569-51-7
DMXL5R7	DE	Discovery agent

DM73F5A	ID	DM73F5A
DM73F5A	DN	1,2,4-Triazole
DM73F5A	HS	Investigative
DM73F5A	SN	1H-1,2,4-Triazole; 1,2,4-TRIAZOLE; 288-88-0; 4H-1,2,4-triazole; Pyrrodiazole; s-Triazole; 1,2,4-1H-Triazole; 1H-1,2,4-triazol; UNII-10MS0Y1RDI; NSC 83128; 1,2,4 triazole; 1,2,4-triazol; 4H-1,2,4-Triazole (VAN); EINECS 206-022-9; 63598-71-0; 1H-[1,2,4]triazole; 10MS0Y1RDI; AI3-51031; CHEBI:46077; NSPMIYGKQJPBQR-UHFFFAOYSA-N; MFCD00005228; [1,2,4]-triazole; (1,2,4)-triazole; 1,2,4-1H-Triazole, 99.5%; InChI=1/C2H3N3/c1-3-2-5-4-1/h1-2H,(H,3,4,5; HSDB 7860; 1,4-Triazole; 1,2,4triazole; 1,3,4-triazole; 4H-1,4-Triazole; 1H-1,4-Triazole; 1,2, 4-
DM73F5A	DT	Small molecular drug
DM73F5A	PC	9257
DM73F5A	MW	69.07
DM73F5A	FM	C2H3N3
DM73F5A	IC	InChI=1S/C2H3N3/c1-3-2-5-4-1/h1-2H,(H,3,4,5)
DM73F5A	CS	C1=NC=NN1
DM73F5A	IK	NSPMIYGKQJPBQR-UHFFFAOYSA-N
DM73F5A	IU	1H-1,2,4-triazole
DM73F5A	CA	CAS 288-88-0
DM73F5A	CB	CHEBI:46077
DM73F5A	DE	Discovery agent

DMOXLHT	ID	DMOXLHT
DMOXLHT	DN	1,2,4-Triazole-Carboxamidine
DMOXLHT	HS	Investigative
DMOXLHT	SN	1,2,4-TRIAZOLE-CARBOXAMIDINE; AC1MPLO2; TZC; ZINC162503468; DB02048; CJ-13028; amino(1H-1,2,4-triazol-1-yl)methaniminium
DMOXLHT	DT	Small molecular drug
DMOXLHT	PC	3387240
DMOXLHT	MW	112.11
DMOXLHT	FM	C3H6N5+
DMOXLHT	IC	InChI=1S/C3H5N5/c4-3(5)8-2-6-1-7-8/h1-2H,(H3,4,5)/p+1
DMOXLHT	CS	C1=NN(C=N1)C(=[NH2+])N
DMOXLHT	IK	CDIOIIJXUJXYPB-UHFFFAOYSA-O
DMOXLHT	IU	[amino(1,2,4-triazol-1-yl)methylidene]azanium
DMOXLHT	DE	Discovery agent

DM7BAU2	ID	DM7BAU2
DM7BAU2	DN	1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one
DM7BAU2	HS	Investigative
DM7BAU2	SN	CHEMBL96006; 1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one; SCHEMBL6820047; ZINC22616; BDBM50072191; AKOS023799425; 1,2,5,6-Tetrahydro-3H-benzo[c]quinolizine-3-one
DM7BAU2	DT	Small molecular drug
DM7BAU2	PC	10081476
DM7BAU2	MW	199.25
DM7BAU2	FM	C13H13NO
DM7BAU2	IC	InChI=1S/C13H13NO/c15-12-7-8-14-11(9-12)6-5-10-3-1-2-4-13(10)14/h1-4,9H,5-8H2
DM7BAU2	CS	C1CC2=CC(=O)CCN2C3=CC=CC=C31
DM7BAU2	IK	OPJKPSOLCGGXEW-UHFFFAOYSA-N
DM7BAU2	IU	1,2,5,6-tetrahydrobenzo[f]quinolizin-3-one
DM7BAU2	DE	Discovery agent

DM9VYOI	ID	DM9VYOI
DM9VYOI	DN	1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
DM9VYOI	HS	Investigative
DM9VYOI	SN	NSC648146; 1,2,5-Thiadiazolidin-3-one 1,1-dioxide; 1,1-dioxo-1,2,5-thiadiazolidin-3-one; AC1Q6H1D; SCHEMBL630051; CHEMBL1996483; CTK7H4434; AC1L8566; NSC-648146; NCI60_016689; 1,5-Thiadiazolidin-3-one, 1,1-dioxide; 1,2,5-thiadiazolidine-3-one-1,1-dioxide; 1,2,5-Thiadiazolidine-3-one 1,1-dioxide; 1,2,5-Thiadiazolidin-3-one, 1,1-dioxide
DM9VYOI	DT	Small molecular drug
DM9VYOI	PC	4369452
DM9VYOI	MW	212.23
DM9VYOI	FM	C8H8N2O3S
DM9VYOI	IC	InChI=1S/C8H8N2O3S/c11-8-6-10(14(12,13)9-8)7-4-2-1-3-5-7/h1-5H,6H2,(H,9,11)
DM9VYOI	CS	C1C(=O)NS(=O)(=O)N1C2=CC=CC=C2
DM9VYOI	IK	LDCZCUKQWRZSDT-UHFFFAOYSA-N
DM9VYOI	IU	1,1-dioxo-5-phenyl-1,2,5-thiadiazolidin-3-one
DM9VYOI	DE	Discovery agent

DMWGN3F	ID	DMWGN3F
DMWGN3F	DN	1,2,6-tri-O-galloyl-beta-D-glucose
DMWGN3F	HS	Investigative
DMWGN3F	SN	AC1L3XRG; 1,2,6-Tri-O-galloyl-.beta.-D-glucose; 1,2,6-Tri-O-galloyl-.beta.-D-glucopyranose; .beta.-D-Glucopyranose, 1,2,6-tris(3,4,5-trihydroxybenzoate); [(5R)-4,5-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-4-[(3,4,5-trihydroxybenzoyl)oxymethyl]tetrahydrofuran-2-yl]methyl 3,4,5-trihydroxybenzoate; [(5R)-4,5-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-4-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxolan-2-yl]methyl 3,4,5-trihydroxybenzoate
DMWGN3F	DT	Small molecular drug
DMWGN3F	PC	124024
DMWGN3F	MW	636.5
DMWGN3F	FM	C27H24O18
DMWGN3F	IC	InChI=1S/C27H24O18/c28-12-1-9(2-13(29)19(12)34)23(37)42-7-18-22(45-25(39)11-5-16(32)21(36)17(33)6-11)27(41,26(40)44-18)8-43-24(38)10-3-14(30)20(35)15(31)4-10/h1-6,18,22,26,28-36,40-41H,7-8H2/t18?,22?,26-,27?/m1/s1
DMWGN3F	CS	C1=C(C=C(C(=C1O)O)O)C(=O)OCC2C(C([C@@H](O2)O)(COC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMWGN3F	IK	KCQFLGUEZXYOER-IPKUFKRGSA-N
DMWGN3F	IU	[(5R)-4,5-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-4-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxolan-2-yl]methyl 3,4,5-trihydroxybenzoate
DMWGN3F	CA	CAS 79886-49-0
DMWGN3F	DE	Discovery agent

DMZSL7H	ID	DMZSL7H
DMZSL7H	DN	1,2-bis(2,3,4-trifluorophenyl)-2-hydroxyethanone
DMZSL7H	HS	Investigative
DMZSL7H	SN	CHEMBL244631; 1,2-bis(2,3,4-trifluorophenyl)-2-hydroxyethanone
DMZSL7H	DT	Small molecular drug
DMZSL7H	PC	16745302
DMZSL7H	MW	320.19
DMZSL7H	FM	C14H6F6O2
DMZSL7H	IC	InChI=1S/C14H6F6O2/c15-7-3-1-5(9(17)11(7)19)13(21)14(22)6-2-4-8(16)12(20)10(6)18/h1-4,13,21H
DMZSL7H	CS	C1=CC(=C(C(=C1C(C(=O)C2=C(C(=C(C=C2)F)F)F)O)F)F)F
DMZSL7H	IK	ICSVRGYUGLAIDB-UHFFFAOYSA-N
DMZSL7H	IU	2-hydroxy-1,2-bis(2,3,4-trifluorophenyl)ethanone
DMZSL7H	DE	Discovery agent

DML5ECR	ID	DML5ECR
DML5ECR	DN	1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione
DML5ECR	HS	Investigative
DML5ECR	SN	CHEMBL242931; 1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione
DML5ECR	DT	Small molecular drug
DML5ECR	PC	44428841
DML5ECR	MW	318.17
DML5ECR	FM	C14H4F6O2
DML5ECR	IC	InChI=1S/C14H4F6O2/c15-7-3-1-5(9(17)11(7)19)13(21)14(22)6-2-4-8(16)12(20)10(6)18/h1-4H
DML5ECR	CS	C1=CC(=C(C(=C1C(=O)C(=O)C2=C(C(=C(C=C2)F)F)F)F)F)F
DML5ECR	IK	PWUSEBWVFQBDEQ-UHFFFAOYSA-N
DML5ECR	IU	1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione
DML5ECR	DE	Discovery agent

DMD9HP8	ID	DMD9HP8
DMD9HP8	DN	1,2-bis(2,3,5-trifluorophenyl)-2-hydroxyethanone
DMD9HP8	HS	Investigative
DMD9HP8	SN	CHEMBL244630; 1,2-bis(2,3,5-trifluorophenyl)-2-hydroxyethanone
DMD9HP8	DT	Small molecular drug
DMD9HP8	PC	44428834
DMD9HP8	MW	320.19
DMD9HP8	FM	C14H6F6O2
DMD9HP8	IC	InChI=1S/C14H6F6O2/c15-5-1-7(11(19)9(17)3-5)13(21)14(22)8-2-6(16)4-10(18)12(8)20/h1-4,13,21H
DMD9HP8	CS	C1=C(C=C(C(=C1C(C(=O)C2=C(C(=CC(=C2)F)F)F)O)F)F)F
DMD9HP8	IK	FWTYPBLNNIDCIZ-UHFFFAOYSA-N
DMD9HP8	IU	2-hydroxy-1,2-bis(2,3,5-trifluorophenyl)ethanone
DMD9HP8	DE	Discovery agent

DMZHWAV	ID	DMZHWAV
DMZHWAV	DN	1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione
DMZHWAV	HS	Investigative
DMZHWAV	SN	CHEMBL242930; 1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione
DMZHWAV	DT	Small molecular drug
DMZHWAV	PC	44428840
DMZHWAV	MW	318.17
DMZHWAV	FM	C14H4F6O2
DMZHWAV	IC	InChI=1S/C14H4F6O2/c15-5-1-7(11(19)9(17)3-5)13(21)14(22)8-2-6(16)4-10(18)12(8)20/h1-4H
DMZHWAV	CS	C1=C(C=C(C(=C1C(=O)C(=O)C2=C(C(=CC(=C2)F)F)F)F)F)F
DMZHWAV	IK	KLUCLGJNULKHIS-UHFFFAOYSA-N
DMZHWAV	IU	1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione
DMZHWAV	DE	Discovery agent

DMWS2HL	ID	DMWS2HL
DMWS2HL	DN	1,2-bis(2,3,6-trifluorophenyl)ethane-1,2-dione
DMWS2HL	HS	Investigative
DMWS2HL	SN	CHEMBL242722; 1,2-bis(2,3,6-trifluorophenyl)ethane-1,2-dione
DMWS2HL	DT	Small molecular drug
DMWS2HL	PC	44428839
DMWS2HL	MW	318.17
DMWS2HL	FM	C14H4F6O2
DMWS2HL	IC	InChI=1S/C14H4F6O2/c15-5-3-6(11(19)9(18)4-5)13(21)14(22)10-7(16)1-2-8(17)12(10)20/h1-4H
DMWS2HL	CS	C1=CC(=C(C(=C1F)C(=O)C(=O)C2=C(C(=CC(=C2)F)F)F)F)F
DMWS2HL	IK	NHBDBTHCQQXYBY-UHFFFAOYSA-N
DMWS2HL	IU	1-(2,3,5-trifluorophenyl)-2-(2,3,6-trifluorophenyl)ethane-1,2-dione
DMWS2HL	DE	Discovery agent

DMZ0D5W	ID	DMZ0D5W
DMZ0D5W	DN	1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone
DMZ0D5W	HS	Investigative
DMZ0D5W	SN	CHEMBL244427; 1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone
DMZ0D5W	DT	Small molecular drug
DMZ0D5W	PC	44428831
DMZ0D5W	MW	284.2
DMZ0D5W	FM	C14H8F4O2
DMZ0D5W	IC	InChI=1S/C14H8F4O2/c15-9-5-1-3-7(11(9)17)13(19)14(20)8-4-2-6-10(16)12(8)18/h1-6,13,19H
DMZ0D5W	CS	C1=CC(=C(C(=C1)F)F)C(C(=O)C2=C(C(=CC=C2)F)F)O
DMZ0D5W	IK	PYTAIIXDDDIUHU-UHFFFAOYSA-N
DMZ0D5W	IU	1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone
DMZ0D5W	DE	Discovery agent

DM9Z1NY	ID	DM9Z1NY
DM9Z1NY	DN	1,2-bis(2,3-fluorophenyl)ethane-1,2-dione
DM9Z1NY	HS	Investigative
DM9Z1NY	SN	CHEMBL395018; 1,2-bis(2,3-fluorophenyl)ethane-1,2-dione; SCHEMBL3184940
DM9Z1NY	DT	Small molecular drug
DM9Z1NY	PC	22574224
DM9Z1NY	MW	282.19
DM9Z1NY	FM	C14H6F4O2
DM9Z1NY	IC	InChI=1S/C14H6F4O2/c15-9-5-1-3-7(11(9)17)13(19)14(20)8-4-2-6-10(16)12(8)18/h1-6H
DM9Z1NY	CS	C1=CC(=C(C(=C1)F)F)C(=O)C(=O)C2=C(C(=CC=C2)F)F
DM9Z1NY	IK	LJRGNWLITYAYFC-UHFFFAOYSA-N
DM9Z1NY	IU	1,2-bis(2,3-difluorophenyl)ethane-1,2-dione
DM9Z1NY	DE	Discovery agent

DMLMCBW	ID	DMLMCBW
DMLMCBW	DN	1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone
DMLMCBW	HS	Investigative
DMLMCBW	SN	CHEMBL244425; 1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone
DMLMCBW	DT	Small molecular drug
DMLMCBW	PC	44428828
DMLMCBW	MW	284.2
DMLMCBW	FM	C14H8F4O2
DMLMCBW	IC	InChI=1S/C14H8F4O2/c15-7-1-3-9(11(17)5-7)13(19)14(20)10-4-2-8(16)6-12(10)18/h1-6,13,19H
DMLMCBW	CS	C1=CC(=C(C=C1F)F)C(C(=O)C2=C(C=C(C=C2)F)F)O
DMLMCBW	IK	MOZRQJUPHVESBZ-UHFFFAOYSA-N
DMLMCBW	IU	1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone
DMLMCBW	DE	Discovery agent

DMUZHPS	ID	DMUZHPS
DMUZHPS	DN	1,2-bis(2,4-difluorophenyl)ethane-1,2-dione
DMUZHPS	HS	Investigative
DMUZHPS	SN	CHEMBL242287; 1,2-bis(2,4-difluorophenyl)ethane-1,2-dione; SCHEMBL8070666
DMUZHPS	DT	Small molecular drug
DMUZHPS	PC	19377173
DMUZHPS	MW	282.19
DMUZHPS	FM	C14H6F4O2
DMUZHPS	IC	InChI=1S/C14H6F4O2/c15-7-1-3-9(11(17)5-7)13(19)14(20)10-4-2-8(16)6-12(10)18/h1-6H
DMUZHPS	CS	C1=CC(=C(C=C1F)F)C(=O)C(=O)C2=C(C=C(C=C2)F)F
DMUZHPS	IK	GMRRDQVLRFWXPQ-UHFFFAOYSA-N
DMUZHPS	IU	1,2-bis(2,4-difluorophenyl)ethane-1,2-dione
DMUZHPS	DE	Discovery agent

DM9EW2F	ID	DM9EW2F
DM9EW2F	DN	1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone
DM9EW2F	HS	Investigative
DM9EW2F	SN	CHEMBL244428; 1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone
DM9EW2F	DT	Small molecular drug
DM9EW2F	PC	44428832
DM9EW2F	MW	284.2
DM9EW2F	FM	C14H8F4O2
DM9EW2F	IC	InChI=1S/C14H8F4O2/c15-7-1-3-11(17)9(5-7)13(19)14(20)10-6-8(16)2-4-12(10)18/h1-6,13,19H
DM9EW2F	CS	C1=CC(=C(C=C1F)C(C(=O)C2=C(C=CC(=C2)F)F)O)F
DM9EW2F	IK	DMPZBXMNYCXAQZ-UHFFFAOYSA-N
DM9EW2F	IU	1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone
DM9EW2F	DE	Discovery agent

DMVLMBQ	ID	DMVLMBQ
DMVLMBQ	DN	1,2-bis(2,5-difluorophenyl)ethane-1,2-dione
DMVLMBQ	HS	Investigative
DMVLMBQ	SN	CHEMBL242721; 1,2-bis(2,5-difluorophenyl)ethane-1,2-dione; SCHEMBL3180092
DMVLMBQ	DT	Small molecular drug
DMVLMBQ	PC	22574258
DMVLMBQ	MW	282.19
DMVLMBQ	FM	C14H6F4O2
DMVLMBQ	IC	InChI=1S/C14H6F4O2/c15-7-1-3-11(17)9(5-7)13(19)14(20)10-6-8(16)2-4-12(10)18/h1-6H
DMVLMBQ	CS	C1=CC(=C(C=C1F)C(=O)C(=O)C2=C(C=CC(=C2)F)F)F
DMVLMBQ	IK	IWSRHXHMXUIXCZ-UHFFFAOYSA-N
DMVLMBQ	IU	1,2-bis(2,5-difluorophenyl)ethane-1,2-dione
DMVLMBQ	DE	Discovery agent

DMSMVCH	ID	DMSMVCH
DMSMVCH	DN	1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone
DMSMVCH	HS	Investigative
DMSMVCH	SN	CHEMBL244426; 1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone
DMSMVCH	DT	Small molecular drug
DMSMVCH	PC	44428829
DMSMVCH	MW	284.2
DMSMVCH	FM	C14H8F4O2
DMSMVCH	IC	InChI=1S/C14H8F4O2/c15-7-3-1-4-8(16)11(7)13(19)14(20)12-9(17)5-2-6-10(12)18/h1-6,13,19H
DMSMVCH	CS	C1=CC(=C(C(=C1)F)C(C(=O)C2=C(C=CC=C2F)F)O)F
DMSMVCH	IK	JVCMBBUYARXRIK-UHFFFAOYSA-N
DMSMVCH	IU	1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone
DMSMVCH	DE	Discovery agent

DM351EA	ID	DM351EA
DM351EA	DN	1,2-bis(2,6-difluorophenyl)ethane-1,2-dione
DM351EA	HS	Investigative
DM351EA	SN	CHEMBL242288; 1,2-bis(2,6-difluorophenyl)ethane-1,2-dione
DM351EA	DT	Small molecular drug
DM351EA	PC	44428837
DM351EA	MW	282.19
DM351EA	FM	C14H6F4O2
DM351EA	IC	InChI=1S/C14H6F4O2/c15-7-3-1-4-8(16)11(7)13(19)14(20)12-9(17)5-2-6-10(12)18/h1-6H
DM351EA	CS	C1=CC(=C(C(=C1)F)C(=O)C(=O)C2=C(C=CC=C2F)F)F
DM351EA	IK	ZQTHCEAXUHQYSG-UHFFFAOYSA-N
DM351EA	IU	1,2-bis(2,6-difluorophenyl)ethane-1,2-dione
DM351EA	DE	Discovery agent

DMZF4IC	ID	DMZF4IC
DMZF4IC	DN	1,2-Bis-(2-chloro-phenyl)-ethane-1,2-dione
DMZF4IC	HS	Investigative
DMZF4IC	SN	2,2'-Dichlorobenzil; 21854-95-5; 1,2-bis(2-chlorophenyl)ethane-1,2-dione; 2,2'-Dichlorodibenzoyl; Ethanedione, bis(2-chlorophenyl)-; Benzil, 2,2'-dichloro-; MFCD00018263; 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-; AE-562/43458948; NSC114829; Benzil,2'-dichloro-; ACMC-20aok0; AC1Q5FHJ; Benzil-based compound, 10; Bis(2-chlorophenyl) diketone; 2,2'-Dichlorobenzil, 97%; SCHEMBL2156567; CHEMBL365392; AC1L3H37; DTXSID1066736; CTK4E7789; BDBM22732; VOSNNSVWVJFJCR-UHFFFAOYSA-N; MolPort-003-915-120; ZINC1704748; Benzil, 2,2'-dichloro- (8CI)
DMZF4IC	DT	Small molecular drug
DMZF4IC	PC	89076
DMZF4IC	MW	279.1
DMZF4IC	FM	C14H8Cl2O2
DMZF4IC	IC	InChI=1S/C14H8Cl2O2/c15-11-7-3-1-5-9(11)13(17)14(18)10-6-2-4-8-12(10)16/h1-8H
DMZF4IC	CS	C1=CC=C(C(=C1)C(=O)C(=O)C2=CC=CC=C2Cl)Cl
DMZF4IC	IK	VOSNNSVWVJFJCR-UHFFFAOYSA-N
DMZF4IC	IU	1,2-bis(2-chlorophenyl)ethane-1,2-dione
DMZF4IC	CA	CAS 21854-95-5
DMZF4IC	DE	Discovery agent

DMNWM5S	ID	DMNWM5S
DMNWM5S	DN	1,2-bis(2-fluorophenyl)-2-hydroxyethanone
DMNWM5S	HS	Investigative
DMNWM5S	SN	CHEMBL242768; 1,2-bis(2-fluorophenyl)-2-hydroxyethanone; SCHEMBL7414865; XQFHNDNXOUWJPU-UHFFFAOYSA-N; BDBM50209403
DMNWM5S	DT	Small molecular drug
DMNWM5S	PC	19971657
DMNWM5S	MW	248.22
DMNWM5S	FM	C14H10F2O2
DMNWM5S	IC	InChI=1S/C14H10F2O2/c15-11-7-3-1-5-9(11)13(17)14(18)10-6-2-4-8-12(10)16/h1-8,13,17H
DMNWM5S	CS	C1=CC=C(C(=C1)C(C(=O)C2=CC=CC=C2F)O)F
DMNWM5S	IK	XQFHNDNXOUWJPU-UHFFFAOYSA-N
DMNWM5S	IU	1,2-bis(2-fluorophenyl)-2-hydroxyethanone
DMNWM5S	DE	Discovery agent

DM9FMUE	ID	DM9FMUE
DM9FMUE	DN	1,2-bis(2-fluorophenyl)ethane-1,2-dione
DM9FMUE	HS	Investigative
DM9FMUE	SN	1,2-bis(2-fluorophenyl)ethane-1,2-dione; CHEMBL244633; 573-43-3; Bis(2-fluorophenyl) diketone; SCHEMBL2156696; CTK1F2289; DTXSID60453098; Ethanedione, bis(2-fluorophenyl)-; ZINC28713881; BDBM50209423; AKOS030595584; 1,2-bis(2-fluorophenyl)-1,2-ethanedione
DM9FMUE	DT	Small molecular drug
DM9FMUE	PC	11043027
DM9FMUE	MW	246.21
DM9FMUE	FM	C14H8F2O2
DM9FMUE	IC	InChI=1S/C14H8F2O2/c15-11-7-3-1-5-9(11)13(17)14(18)10-6-2-4-8-12(10)16/h1-8H
DM9FMUE	CS	C1=CC=C(C(=C1)C(=O)C(=O)C2=CC=CC=C2F)F
DM9FMUE	IK	UWQCHLREAXYCBW-UHFFFAOYSA-N
DM9FMUE	IU	1,2-bis(2-fluorophenyl)ethane-1,2-dione
DM9FMUE	CA	CAS 573-43-3
DM9FMUE	DE	Discovery agent

DM0LWAV	ID	DM0LWAV
DM0LWAV	DN	1,2-bis(3,4,5-trifluorophenyl)-2-hydroxyethanone
DM0LWAV	HS	Investigative
DM0LWAV	SN	CHEMBL394806; 1,2-bis(3,4,5-trifluorophenyl)-2-hydroxyethanone
DM0LWAV	DT	Small molecular drug
DM0LWAV	PC	44428835
DM0LWAV	MW	320.19
DM0LWAV	FM	C14H6F6O2
DM0LWAV	IC	InChI=1S/C14H6F6O2/c15-7-1-5(2-8(16)11(7)19)13(21)14(22)6-3-9(17)12(20)10(18)4-6/h1-4,13,21H
DM0LWAV	CS	C1=C(C=C(C(=C1F)F)F)C(C(=O)C2=CC(=C(C(=C2)F)F)F)O
DM0LWAV	IK	BBOPAMQNZSQMGE-UHFFFAOYSA-N
DM0LWAV	IU	2-hydroxy-1,2-bis(3,4,5-trifluorophenyl)ethanone
DM0LWAV	DE	Discovery agent

DMPJT3V	ID	DMPJT3V
DMPJT3V	DN	1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione
DMPJT3V	HS	Investigative
DMPJT3V	SN	CHEMBL193180; 1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione; Benzil-based compound, 13; SCHEMBL2156255
DMPJT3V	DT	Small molecular drug
DMPJT3V	PC	11392969
DMPJT3V	MW	318.17
DMPJT3V	FM	C14H4F6O2
DMPJT3V	IC	InChI=1S/C14H4F6O2/c15-7-1-5(2-8(16)11(7)19)13(21)14(22)6-3-9(17)12(20)10(18)4-6/h1-4H
DMPJT3V	CS	C1=C(C=C(C(=C1F)F)F)C(=O)C(=O)C2=CC(=C(C(=C2)F)F)F
DMPJT3V	IK	FMFHXBPXDZLEKC-UHFFFAOYSA-N
DMPJT3V	IU	1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione
DMPJT3V	DE	Discovery agent

DMRCUKJ	ID	DMRCUKJ
DMRCUKJ	DN	1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone
DMRCUKJ	HS	Investigative
DMRCUKJ	SN	CHEMBL394557; 1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone
DMRCUKJ	DT	Small molecular drug
DMRCUKJ	PC	44428830
DMRCUKJ	MW	284.2
DMRCUKJ	FM	C14H8F4O2
DMRCUKJ	IC	InChI=1S/C14H8F4O2/c15-9-3-1-7(5-11(9)17)13(19)14(20)8-2-4-10(16)12(18)6-8/h1-6,13,19H
DMRCUKJ	CS	C1=CC(=C(C=C1C(C(=O)C2=CC(=C(C=C2)F)F)O)F)F
DMRCUKJ	IK	VPCIITRKAXBIRA-UHFFFAOYSA-N
DMRCUKJ	IU	1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone
DMRCUKJ	DE	Discovery agent

DMBZ5RN	ID	DMBZ5RN
DMBZ5RN	DN	1,2-bis(3,4-difluorophenyl)ethane-1,2-dione
DMBZ5RN	HS	Investigative
DMBZ5RN	SN	CHEMBL397739; 1,2-bis(3,4-difluorophenyl)ethane-1,2-dione; BDBM50209399
DMBZ5RN	DT	Small molecular drug
DMBZ5RN	PC	44428838
DMBZ5RN	MW	282.19
DMBZ5RN	FM	C14H6F4O2
DMBZ5RN	IC	InChI=1S/C14H6F4O2/c15-9-3-1-7(5-11(9)17)13(19)14(20)8-2-4-10(16)12(18)6-8/h1-6H
DMBZ5RN	CS	C1=CC(=C(C=C1C(=O)C(=O)C2=CC(=C(C=C2)F)F)F)F
DMBZ5RN	IK	IBDJXLAQEHPROM-UHFFFAOYSA-N
DMBZ5RN	IU	1,2-bis(3,4-difluorophenyl)ethane-1,2-dione
DMBZ5RN	DE	Discovery agent

DMQTPX2	ID	DMQTPX2
DMQTPX2	DN	1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone
DMQTPX2	HS	Investigative
DMQTPX2	SN	CHEMBL437373; 1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone
DMQTPX2	DT	Small molecular drug
DMQTPX2	PC	44428833
DMQTPX2	MW	284.2
DMQTPX2	FM	C14H8F4O2
DMQTPX2	IC	InChI=1S/C14H8F4O2/c15-9-1-7(2-10(16)5-9)13(19)14(20)8-3-11(17)6-12(18)4-8/h1-6,13,19H
DMQTPX2	CS	C1=C(C=C(C=C1F)F)C(C(=O)C2=CC(=CC(=C2)F)F)O
DMQTPX2	IK	RDAYGBPKZORYGI-UHFFFAOYSA-N
DMQTPX2	IU	1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone
DMQTPX2	DE	Discovery agent

DM3K5RI	ID	DM3K5RI
DM3K5RI	DN	1,2-bis(3,5-difluorophenyl)ethane-1,2-dione
DM3K5RI	HS	Investigative
DM3K5RI	SN	1,2-bis(3,5-difluorophenyl)ethane-1,2-dione; CHEMBL193229; 223707-22-0; Benzil-based compound, 12; SCHEMBL2156965; BDBM22734
DM3K5RI	DT	Small molecular drug
DM3K5RI	PC	11437501
DM3K5RI	MW	282.19
DM3K5RI	FM	C14H6F4O2
DM3K5RI	IC	InChI=1S/C14H6F4O2/c15-9-1-7(2-10(16)5-9)13(19)14(20)8-3-11(17)6-12(18)4-8/h1-6H
DM3K5RI	CS	C1=C(C=C(C=C1F)F)C(=O)C(=O)C2=CC(=CC(=C2)F)F
DM3K5RI	IK	ZDXXQKFXZDPNLI-UHFFFAOYSA-N
DM3K5RI	IU	1,2-bis(3,5-difluorophenyl)ethane-1,2-dione
DM3K5RI	DE	Discovery agent

DM8XGD0	ID	DM8XGD0
DM8XGD0	DN	1,2-bis(3-fluorophenyl)-2-hydroxyethanon
DM8XGD0	HS	Investigative
DM8XGD0	SN	CHEMBL396977; 1,2-bis(3-fluorophenyl)-2-hydroxyethanon; 1,2-bis(3-fluorophenyl)-2-hydroxy-ethanone; SCHEMBL11382156; BDBM50209422
DM8XGD0	DT	Small molecular drug
DM8XGD0	PC	10868634
DM8XGD0	MW	248.22
DM8XGD0	FM	C14H10F2O2
DM8XGD0	IC	InChI=1S/C14H10F2O2/c15-11-5-1-3-9(7-11)13(17)14(18)10-4-2-6-12(16)8-10/h1-8,13,17H
DM8XGD0	CS	C1=CC(=CC(=C1)F)C(C(=O)C2=CC(=CC=C2)F)O
DM8XGD0	IK	AELVPDSJUJGTJH-UHFFFAOYSA-N
DM8XGD0	IU	1,2-bis(3-fluorophenyl)-2-hydroxyethanone
DM8XGD0	DE	Discovery agent

DMM3I1P	ID	DMM3I1P
DMM3I1P	DN	1,2-bis(3-fluorophenyl)ethane-1,2-dione
DMM3I1P	HS	Investigative
DMM3I1P	SN	1,2-bis(3-fluorophenyl)ethane-1,2-dione; CHEMBL242067; 3,3'-Difluorobenzil; SCHEMBL3169331; NIOZEPOIIGVTTO-UHFFFAOYSA-N; BDBM50209414
DMM3I1P	DT	Small molecular drug
DMM3I1P	PC	22574214
DMM3I1P	MW	246.21
DMM3I1P	FM	C14H8F2O2
DMM3I1P	IC	InChI=1S/C14H8F2O2/c15-11-5-1-3-9(7-11)13(17)14(18)10-4-2-6-12(16)8-10/h1-8H
DMM3I1P	CS	C1=CC(=CC(=C1)F)C(=O)C(=O)C2=CC(=CC=C2)F
DMM3I1P	IK	NIOZEPOIIGVTTO-UHFFFAOYSA-N
DMM3I1P	IU	1,2-bis(3-fluorophenyl)ethane-1,2-dione
DMM3I1P	CA	CAS 70028-89-6
DMM3I1P	DE	Discovery agent

DMWY1QN	ID	DMWY1QN
DMWY1QN	DN	1,2-Bis-(3-methoxy-phenyl)-ethane-1,2-dione
DMWY1QN	HS	Investigative
DMWY1QN	SN	40101-17-5; 3,3'-Dimethoxybenzil; 1,2-bis(3-methoxyphenyl)ethane-1,2-dione; Ethanedione, bis(3-methoxyphenyl)-; 1,2-Ethanedione, 1,2-bis(3-methoxyphenyl)-; PJGXOGKIVAJFTE-UHFFFAOYSA-N; MFCD00038221; Bis(3-methoxyphenyl)ethanedione; EINECS 254-793-5; ACMC-20a2cz; 3,3'-dimethoxy benzil; AC1Q5BUM; AC1L3WPM; 3,3'-Dimethoxydibenzoyl; Bis(3-methoxyphenyl)glyoxal; Benzil-based compound, 22; CHEMBL435109; SCHEMBL2156482; 3,3'-Dimethoxybenzil, 99%; DTXSID7068213; BDBM22744; CTK4I2455; 3,3''-Dimethoxybenzil, 99+%; ZINC2168289; 5327AB
DMWY1QN	DT	Small molecular drug
DMWY1QN	PC	123493
DMWY1QN	MW	270.28
DMWY1QN	FM	C16H14O4
DMWY1QN	IC	InChI=1S/C16H14O4/c1-19-13-7-3-5-11(9-13)15(17)16(18)12-6-4-8-14(10-12)20-2/h3-10H,1-2H3
DMWY1QN	CS	COC1=CC=CC(=C1)C(=O)C(=O)C2=CC(=CC=C2)OC
DMWY1QN	IK	PJGXOGKIVAJFTE-UHFFFAOYSA-N
DMWY1QN	IU	1,2-bis(3-methoxyphenyl)ethane-1,2-dione
DMWY1QN	CA	CAS 40101-17-5
DMWY1QN	DE	Discovery agent

DMGSTKZ	ID	DMGSTKZ
DMGSTKZ	DN	1,2-Bis-(3-nitro-phenyl)-ethane-1,2-dione
DMGSTKZ	HS	Investigative
DMGSTKZ	SN	3,3'-Dinitrobenzil; 3,5'-Dinitrobenzil; Benzil, 3,5'-dinitro-; Bis(m-nitrophenyl)ethanedione; 1,2-bis(3-nitrophenyl)ethane-1,2-dione; 5913-06-4; Ethanedione, bis(3-nitrophenyl)-; NSC 408976; BRN 2003620; 1,2-bis{3-nitrophenyl}-1,2-ethanedione; AI3-61771; NSC408976; Benzil,5'-dinitro-; AC1L2QPJ; Bis-(m,m'-nitrobenzil); Benzil-based compound, 29; AC1Q5B0Z; SCHEMBL2156825; CHEMBL191796; BDBM22751; CTK7F3460; DTXSID90207869; MolPort-003-803-953; ZINC1601014; NSC-408976; 1,2-Bis(m-nitrophenyl)ethane-1,2-dione; LS-32448; Ethanedione, bis(3
DMGSTKZ	DT	Small molecular drug
DMGSTKZ	PC	101375
DMGSTKZ	MW	300.22
DMGSTKZ	FM	C14H8N2O6
DMGSTKZ	IC	InChI=1S/C14H8N2O6/c17-13(9-3-1-5-11(7-9)15(19)20)14(18)10-4-2-6-12(8-10)16(21)22/h1-8H
DMGSTKZ	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)C(=O)C2=CC(=CC=C2)[N+](=O)[O-]
DMGSTKZ	IK	SGKVXDKTNJHBCA-UHFFFAOYSA-N
DMGSTKZ	IU	1,2-bis(3-nitrophenyl)ethane-1,2-dione
DMGSTKZ	CA	CAS 5913-06-4
DMGSTKZ	DE	Discovery agent

DMUW2EJ	ID	DMUW2EJ
DMUW2EJ	DN	1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione
DMUW2EJ	HS	Investigative
DMUW2EJ	SN	4,4'-Dibromobenzil; 35578-47-3; Ethanedione, bis(4-bromophenyl)-; p,p'-Dibromobenzil; 1,2-bis(4-bromophenyl)ethane-1,2-dione; Benzyl, 4,4'-dibromo-; UNII-O4TXV8A656; Bis(4-bromophenyl)ethanedione; 4,4'-Dibromodibenzoyl; O4TXV8A656; 1,2-Ethanedione, 1,2-bis(4-bromophenyl)-; NYCBYBDDECLFPE-UHFFFAOYSA-N; MFCD00000104; W-110862; NSC74075; EINECS 252-628-1; NSC 74075; Benzyl,4'-dibromo-; 4,4'-dibromo-benzil; ACMC-209ihu; AI3-25040; AC1L3WFW; 1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione; Benzil-based compound, 11; NCIOpen2_008898
DMUW2EJ	DT	Small molecular drug
DMUW2EJ	PC	96430
DMUW2EJ	MW	368.02
DMUW2EJ	FM	C14H8Br2O2
DMUW2EJ	IC	InChI=1S/C14H8Br2O2/c15-11-5-1-9(2-6-11)13(17)14(18)10-3-7-12(16)8-4-10/h1-8H
DMUW2EJ	CS	C1=CC(=CC=C1C(=O)C(=O)C2=CC=C(C=C2)Br)Br
DMUW2EJ	IK	NYCBYBDDECLFPE-UHFFFAOYSA-N
DMUW2EJ	IU	1,2-bis(4-bromophenyl)ethane-1,2-dione
DMUW2EJ	CA	CAS 35578-47-3
DMUW2EJ	DE	Discovery agent

DM0E5FH	ID	DM0E5FH
DM0E5FH	DN	1,2-Bis-(4-chloro-phenyl)-ethane-1,2-dione
DM0E5FH	HS	Investigative
DM0E5FH	SN	4,4'-Dichlorobenzil; 3457-46-3; 1,2-bis(4-chlorophenyl)ethane-1,2-dione; 4,4'-Dichlorodibenzoyl; BIS(4-CHLOROPHENYL)ETHANEDIONE; 1,2-Bis-(4-chloro-phenyl)-ethane-1,2-dione; Ethanedione, bis(4-chlorophenyl)-; Bis(p-chlorophenyl)ethanedione; 1,2-bis(4-chlorophenyl)-1,2-ethanedione; bis(4-chlorophenyl)ethane-1,2-dione; 88372-92-3; 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-; Benzil, 4,4'-dichloro-; dichlorbenzil; C14H8Cl2O2; NSC274; NSC 274; EINECS 222-387-7; PubChem3923; p-p'-Dichloro-benzil; Benzil,4'-dichloro-; 4,4'-Dichloro benz
DM0E5FH	DT	Small molecular drug
DM0E5FH	PC	18946
DM0E5FH	MW	279.1
DM0E5FH	FM	C14H8Cl2O2
DM0E5FH	IC	InChI=1S/C14H8Cl2O2/c15-11-5-1-9(2-6-11)13(17)14(18)10-3-7-12(16)8-4-10/h1-8H
DM0E5FH	CS	C1=CC(=CC=C1C(=O)C(=O)C2=CC=C(C=C2)Cl)Cl
DM0E5FH	IK	XMAWUPHYEABFDR-UHFFFAOYSA-N
DM0E5FH	IU	1,2-bis(4-chlorophenyl)ethane-1,2-dione
DM0E5FH	CA	CAS 3457-46-3
DM0E5FH	DE	Discovery agent

DM38Q7W	ID	DM38Q7W
DM38Q7W	DN	1,2-bis(4-fluorophenyl)ethane-1,2-dione
DM38Q7W	HS	Investigative
DM38Q7W	SN	4,4'-Difluorobenzil; 579-39-5; 1,2-bis(4-fluorophenyl)ethane-1,2-dione; Ethanedione, bis(4-fluorophenyl)-; 4,4'-Difluorodibenzoyl; CHEMBL192410; 1,2-Ethanedione, 1,2-bis(4-fluorophenyl)-; BRKULQOUSCHDGS-UHFFFAOYSA-N; MFCD00134541; 1,2-Bis(4-fluorophenyl)-1,2-ethanedione; difluorobenzil; C14H8F2O2; 4,4'difluorobenzil; PubChem7683; ACMC-1AYLX; 4,4'-Difluorobibenzoyl; AC1L3VST; Benzil-based compound, 8; AC1Q5E6G; SCHEMBL716295; 4,4'-Difluorobenzil, 98%; DTXSID3060374; BDBM22730; MolPort-000-154-273; ZX-AP007762; ZINC2504724
DM38Q7W	DT	Small molecular drug
DM38Q7W	PC	123072
DM38Q7W	MW	246.21
DM38Q7W	FM	C14H8F2O2
DM38Q7W	IC	InChI=1S/C14H8F2O2/c15-11-5-1-9(2-6-11)13(17)14(18)10-3-7-12(16)8-4-10/h1-8H
DM38Q7W	CS	C1=CC(=CC=C1C(=O)C(=O)C2=CC=C(C=C2)F)F
DM38Q7W	IK	BRKULQOUSCHDGS-UHFFFAOYSA-N
DM38Q7W	IU	1,2-bis(4-fluorophenyl)ethane-1,2-dione
DM38Q7W	CA	CAS 579-39-5
DM38Q7W	DE	Discovery agent

DM9RF1T	ID	DM9RF1T
DM9RF1T	DN	1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol
DM9RF1T	HS	Investigative
DM9RF1T	SN	CHEMBL26865; 1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol
DM9RF1T	DT	Small molecular drug
DM9RF1T	PC	11638264
DM9RF1T	MW	316.3
DM9RF1T	FM	C21H16O3
DM9RF1T	IC	InChI=1S/C21H16O3/c22-16-5-1-13(2-6-16)20-12-15-11-18(24)9-10-19(15)21(20)14-3-7-17(23)8-4-14/h1-11,22-24H,12H2
DM9RF1T	CS	C1C2=C(C=CC(=C2)O)C(=C1C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
DM9RF1T	IK	PTZCIKOPLAEWTE-UHFFFAOYSA-N
DM9RF1T	IU	1,2-bis(4-hydroxyphenyl)-3H-inden-5-ol
DM9RF1T	DE	Discovery agent

DMCGRV7	ID	DMCGRV7
DMCGRV7	DN	1,2-Bis-(4-methoxy-phenyl)-ethane-1,2-dione
DMCGRV7	HS	Investigative
DMCGRV7	SN	4,4'-Dimethoxybenzil; 1226-42-2; p-Anisil; Anisil; 1,2-bis(4-methoxyphenyl)ethane-1,2-dione; Bis(4-methoxyphenyl)ethanedione; Ethanedione, bis(4-methoxyphenyl)-; Di-p-anisoyl; p,p'-Dimethoxybenzil; 1,2-ethanedione, 1,2-bis(4-methoxyphenyl)-; YNANGXWUZWWFKX-UHFFFAOYSA-N; MFCD00008405; 1,2-Bis(4-methoxyphenyl)-1,2-ethanedione; 1,2-bis(4-methoxyphenyl)-ethane-1,2-dione; AE-641/01115007; W-108428; 4,4'-Dimethoxybenzil, 99+%; EINECS 214-960-5; NSC 19218; ACMC-1BZIL; p-Anisil; Di-p-anisoyl; 4,4\'-Dimethoxybenzil
DMCGRV7	DT	Small molecular drug
DMCGRV7	PC	71043
DMCGRV7	MW	270.28
DMCGRV7	FM	C16H14O4
DMCGRV7	IC	InChI=1S/C16H14O4/c1-19-13-7-3-11(4-8-13)15(17)16(18)12-5-9-14(20-2)10-6-12/h3-10H,1-2H3
DMCGRV7	CS	COC1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)OC
DMCGRV7	IK	YNANGXWUZWWFKX-UHFFFAOYSA-N
DMCGRV7	IU	1,2-bis(4-methoxyphenyl)ethane-1,2-dione
DMCGRV7	CA	CAS 1226-42-2
DMCGRV7	DE	Discovery agent

DM9ENXO	ID	DM9ENXO
DM9ENXO	DN	1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane
DM9ENXO	HS	Investigative
DM9ENXO	SN	CHEMBL442926; BDBM50251330
DM9ENXO	DT	Small molecular drug
DM9ENXO	PC	44567597
DM9ENXO	MW	592.7
DM9ENXO	FM	C36H36N2O6
DM9ENXO	IC	InChI=1S/C36H36N2O6/c1-37-9-7-21-13-23(17-25-31(21)27(37)15-19-3-5-29(39)35(41)33(19)25)43-11-12-44-24-14-22-8-10-38(2)28-16-20-4-6-30(40)36(42)34(20)26(18-24)32(22)28/h3-6,13-14,17-18,27-28,39-42H,7-12,15-16H2,1-2H3/t27-,28-/m1/s1
DM9ENXO	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OCCOC5=CC6=C7[C@@H](CC8=C(C7=C5)C(=C(C=C8)O)O)N(CC6)C)C(=C(C=C4)O)O
DM9ENXO	IK	KWKONXOZQQYOJW-VSGBNLITSA-N
DM9ENXO	IU	(6aR)-2-[2-[[(6aR)-10,11-dihydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-2-yl]oxy]ethoxy]-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DM9ENXO	DE	Discovery agent

DMJAK0E	ID	DMJAK0E
DMJAK0E	DN	1,2-di(10H-phenothiazin-10-yl)ethane-1,2-dione
DMJAK0E	HS	Investigative
DMJAK0E	SN	1,2-ethanedione, 1,2-di-10h-phenothiazin-10-yl-; CHEMBL391727; 6283-46-1; NSC7508; AC1L5BDH; 1,2-di(phenothiazin-10-yl)ethane-1,2-dione; AC1Q5KI6; 1,2-di(10H-phenothiazin-10-yl)ethane-1,2-dione; CTK5B6284; DTXSID40278468; NSC-7508
DMJAK0E	DT	Small molecular drug
DMJAK0E	PC	222149
DMJAK0E	MW	452.6
DMJAK0E	FM	C26H16N2O2S2
DMJAK0E	IC	InChI=1S/C26H16N2O2S2/c29-25(27-17-9-1-5-13-21(17)31-22-14-6-2-10-18(22)27)26(30)28-19-11-3-7-15-23(19)32-24-16-8-4-12-20(24)28/h1-16H
DMJAK0E	CS	C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)C(=O)N4C5=CC=CC=C5SC6=CC=CC=C64
DMJAK0E	IK	LWNPJAXCRSELQF-UHFFFAOYSA-N
DMJAK0E	IU	1,2-di(phenothiazin-10-yl)ethane-1,2-dione
DMJAK0E	CA	CAS 6283-46-1
DMJAK0E	DE	Discovery agent

DM7S1D5	ID	DM7S1D5
DM7S1D5	DN	1,2-Di(berberine-9-O-yl)ethane dibromide
DM7S1D5	HS	Investigative
DM7S1D5	SN	CHEMBL1163560
DM7S1D5	DT	Small molecular drug
DM7S1D5	PC	46906937
DM7S1D5	MW	670.7
DM7S1D5	FM	C40H34N2O8+2
DM7S1D5	IC	InChI=1S/C40H34N2O8/c1-43-33-5-3-23-13-31-27-17-37-35(47-21-49-37)15-25(27)7-9-41(31)19-29(23)39(33)45-11-12-46-40-30-20-42-10-8-26-16-36-38(50-22-48-36)18-28(26)32(42)14-24(30)4-6-34(40)44-2/h3-6,13-20H,7-12,21-22H2,1-2H3/q+2
DM7S1D5	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCOC6=C(C=CC7=CC8=[N+](CCC9=CC1=C(C=C98)OCO1)C=C76)OC
DM7S1D5	IK	KHTZNQPZFCEMGU-UHFFFAOYSA-N
DM7S1D5	IU	17-methoxy-16-[2-[(17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-yl)oxy]ethoxy]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM7S1D5	DE	Discovery agent

DMBAX2L	ID	DMBAX2L
DMBAX2L	DN	1,2-Diacetoxylycorine
DMBAX2L	HS	Investigative
DMBAX2L	SN	1,2-Diacetoxylycorine; 1,2-Diacetyllycorine; CHEMBL465295; Lycorin diacetate; LYCORINE DIACETATE; 1,2-Di-O-acetyllycorine; SCHEMBL12319317; BDBM50293602; (1S,17S,18S,19S)-17-(acetyloxy)-5,7-dioxa-12-azapentacyclo[10.6.1.0^{2,10}.0^{4,8}.0^{15,19}]nonadeca-2,4(8),9,15-tetraen-18-yl acetate
DMBAX2L	DT	Small molecular drug
DMBAX2L	PC	10429288
DMBAX2L	MW	371.4
DMBAX2L	FM	C20H21NO6
DMBAX2L	IC	InChI=1S/C20H21NO6/c1-10(22)26-17-5-12-3-4-21-8-13-6-15-16(25-9-24-15)7-14(13)18(19(12)21)20(17)27-11(2)23/h5-7,17-20H,3-4,8-9H2,1-2H3/t17-,18-,19+,20+/m0/s1
DMBAX2L	CS	CC(=O)O[C@H]1C=C2CCN3[C@H]2[C@@H]([C@@H]1OC(=O)C)C4=CC5=C(C=C4C3)OCO5
DMBAX2L	IK	LMZHAKUXAHOCST-VNTMZGSJSA-N
DMBAX2L	IU	[(1S,17S,18S,19S)-18-acetyloxy-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraen-17-yl] acetate
DMBAX2L	DE	Discovery agent

DMDJYHK	ID	DMDJYHK
DMDJYHK	DN	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane
DMDJYHK	HS	Investigative
DMDJYHK	SN	1,2-DIBROMO-4-(1,2-DIBROMOETHYL)CYCLOHEXANE; 3322-93-8; Citex BCL 462; Saytex BCL 462; Cyclohexane, 1,2-dibromo-4-(1,2-dibromoethyl)-; 1-(1,2-Dibromoethyl)-3,4-dibromocyclohexane; Vinylcyclohexene tetrabromide; 1,2-DIBROMO-4-(1,2-DIBROMOETHYL)-CYCLOHEXANE; 4-(1,2-Dibromoethyl)-1,2-dibromocyclohexane; CCRIS 3743; HSDB 6146; EINECS 222-036-8; BRN 1927455; CHEMBL375107; AK-78933; C8H12Br4; TBECH; AC1L2COC; DSSTox_CID_4947; DSSTox_RID_77594; DSSTox_GSID_24947; MLS002454355; 3-05-00-00093 (Beilstein Handbook Reference); SCHEMBL332771
DMDJYHK	DT	Small molecular drug
DMDJYHK	PC	18728
DMDJYHK	MW	427.8
DMDJYHK	FM	C8H12Br4
DMDJYHK	IC	InChI=1S/C8H12Br4/c9-4-8(12)5-1-2-6(10)7(11)3-5/h5-8H,1-4H2
DMDJYHK	CS	C1CC(C(CC1C(CBr)Br)Br)Br
DMDJYHK	IK	PQRRSJBLKOPVJV-UHFFFAOYSA-N
DMDJYHK	IU	1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane
DMDJYHK	CA	CAS 3322-93-8
DMDJYHK	DE	Discovery agent

DM75OR8	ID	DM75OR8
DM75OR8	DN	1,2-dicyclohexylethane-1,2-dione
DM75OR8	HS	Investigative
DM75OR8	SN	Ethanedione, dicyclohexyl-; 951-88-2; 1,2-dicyclohexylethane-1,2-dione; 1,2-Dicyclohexylethanedione; SCHEMBL3071715; CHEMBL235287; 1,2-Dione-Based Compound, 7; BDBM22850; CTK3G8986; DTXSID40473153; 1,2-dicyclohexyl-1,2-ethanedione; 1,2-dicyclohexyl-ethane-1,2-dione
DM75OR8	DT	Small molecular drug
DM75OR8	PC	11806279
DM75OR8	MW	222.32
DM75OR8	FM	C14H22O2
DM75OR8	IC	InChI=1S/C14H22O2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h11-12H,1-10H2
DM75OR8	CS	C1CCC(CC1)C(=O)C(=O)C2CCCCC2
DM75OR8	IK	ZWDFMOMBVDVEHE-UHFFFAOYSA-N
DM75OR8	IU	1,2-dicyclohexylethane-1,2-dione
DM75OR8	CA	CAS 951-88-2
DM75OR8	DE	Discovery agent

DM542I9	ID	DM542I9
DM542I9	DN	1,2-dihydro-2-oxoquinazoline-4-carboxyanilide
DM542I9	HS	Investigative
DM542I9	SN	CHEMBL279403; 1,2-dihydro-2-oxoquinazoline-4-carboxyanilide; BDBM50228374; AKOS027611184
DM542I9	DT	Small molecular drug
DM542I9	PC	24749598
DM542I9	MW	265.27
DM542I9	FM	C15H11N3O2
DM542I9	IC	InChI=1S/C15H11N3O2/c19-14(16-10-6-2-1-3-7-10)13-11-8-4-5-9-12(11)17-15(20)18-13/h1-9H,(H,16,19)(H,17,18,20)
DM542I9	CS	C1=CC=C(C=C1)NC(=O)C2=NC(=O)NC3=CC=CC=C32
DM542I9	IK	IBKXBRUBWALIOJ-UHFFFAOYSA-N
DM542I9	IU	2-oxo-N-phenyl-1H-quinazoline-4-carboxamide
DM542I9	DE	Discovery agent

DMST60D	ID	DMST60D
DMST60D	DN	1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene
DMST60D	HS	Investigative
DMST60D	SN	CHEMBL229245; 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene
DMST60D	DT	Small molecular drug
DMST60D	PC	44424402
DMST60D	MW	296.4
DMST60D	FM	C19H20O3
DMST60D	IC	InChI=1S/C19H20O3/c1-20-17-11-10-16(18(21-2)19(17)22-3)15-9-8-13-6-4-5-7-14(13)12-15/h4-7,10-12H,8-9H2,1-3H3
DMST60D	CS	COC1=C(C(=C(C=C1)C2=CC3=CC=CC=C3CC2)OC)OC
DMST60D	IK	WOSGVZBVAWUJJN-UHFFFAOYSA-N
DMST60D	IU	3-(2,3,4-trimethoxyphenyl)-1,2-dihydronaphthalene
DMST60D	DE	Discovery agent

DM9G7DT	ID	DM9G7DT
DM9G7DT	DN	1,2-Dihydro-indazol-3-one
DM9G7DT	HS	Investigative
DM9G7DT	SN	1H-Indazol-3-ol; 3-Indazolinone; 7364-25-2; 1H-indazol-3(2H)-one; 100922-96-1; Indazolinone; 3-Hydroxy-1H-indazole; 3-Hydroxyindazole; 1,2-dihydroindazol-3-one; 1,2-Dihydro-3H-indazol-3-one; 3-Oxo-1,2-indazole; 3H-Indazol-3-one, 1,2-dihydro-; 3-Indazolone; 2H-Indazol-3-ol; hydroxyindazole; 2,3-Dihydro-1H-indazol-3-one; NSC 9352; UNII-8E254S9S1R; CCRIS 6800; EINECS 230-904-2; CHEMBL276725; SWEICGMKXPNXNU-UHFFFAOYSA-N; 8E254S9S1R; MFCD00005685; 1H-2-hydroindazol-3-one; benzopyrazolone; 1,2-Dihydro-indazol-3-one; 3-Oxoindazoline
DM9G7DT	DT	Small molecular drug
DM9G7DT	PC	81829
DM9G7DT	MW	134.14
DM9G7DT	FM	C7H6N2O
DM9G7DT	IC	InChI=1S/C7H6N2O/c10-7-5-3-1-2-4-6(5)8-9-7/h1-4H,(H2,8,9,10)
DM9G7DT	CS	C1=CC=C2C(=C1)C(=O)NN2
DM9G7DT	IK	SWEICGMKXPNXNU-UHFFFAOYSA-N
DM9G7DT	IU	1,2-dihydroindazol-3-one
DM9G7DT	CA	CAS 7364-25-2
DM9G7DT	DE	Discovery agent

DMASC8K	ID	DMASC8K
DMASC8K	DN	1,2-Dihydroxy-10H-anthracen-9-one
DMASC8K	HS	Investigative
DMASC8K	SN	CHEMBL123692; 1,2-Dihydroxy-10H-anthracen-9-one; 1,2-Dihydroxy-9-anthron; SCHEMBL6418805; ZINC13606491; BDBM50060891
DMASC8K	DT	Small molecular drug
DMASC8K	PC	15259267
DMASC8K	MW	226.23
DMASC8K	FM	C14H10O3
DMASC8K	IC	InChI=1S/C14H10O3/c15-11-6-5-9-7-8-3-1-2-4-10(8)13(16)12(9)14(11)17/h1-6,15,17H,7H2
DMASC8K	CS	C1C2=C(C(=C(C=C2)O)O)C(=O)C3=CC=CC=C31
DMASC8K	IK	VQTRJTVHFJIZMI-UHFFFAOYSA-N
DMASC8K	IU	1,2-dihydroxy-10H-anthracen-9-one
DMASC8K	DE	Discovery agent

DMGXMF0	ID	DMGXMF0
DMGXMF0	DN	1,2-Di-naphthalen-2-yl-ethane-1,2-dione
DMGXMF0	HS	Investigative
DMGXMF0	SN	CHEMBL189162; 1,2-dinaphthalen-2-ylethane-1,2-dione; Bis(2-naphthyl)glyoxal; AC1MN9RI; 1,2-Di-naphthalen-2-yl-ethane-1,2-dione; SCHEMBL7220072; MolPort-003-808-637; ZINC5705162; BDBM50171924
DMGXMF0	DT	Small molecular drug
DMGXMF0	PC	3274712
DMGXMF0	MW	310.3
DMGXMF0	FM	C22H14O2
DMGXMF0	IC	InChI=1S/C22H14O2/c23-21(19-11-9-15-5-1-3-7-17(15)13-19)22(24)20-12-10-16-6-2-4-8-18(16)14-20/h1-14H
DMGXMF0	CS	C1=CC=C2C=C(C=CC2=C1)C(=O)C(=O)C3=CC4=CC=CC=C4C=C3
DMGXMF0	IK	CUUMQBIJNWGQLU-UHFFFAOYSA-N
DMGXMF0	IU	1,2-dinaphthalen-2-ylethane-1,2-dione
DMGXMF0	DE	Discovery agent

DMEAB03	ID	DMEAB03
DMEAB03	DN	1,2-dioctanoyl-sn-glycerol
DMEAB03	HS	Investigative
DMEAB03	SN	60514-48-9; Dicaprylglyceride; sn-1,2-Dioctanoylglycerol; (S)-3-Hydroxypropane-1,2-diyl dioctanoate; 1,2-Dicapryloyl-sn-glycerol; D-alpha,beta-Dicaprylin; BRN 1714754; CHEMBL55267; CHEBI:76979; Octanoic acid, 1-(hydroxymethyl)-1,2-ethanediyl ester, (S)-; DG(8:0/8:0/0:0); sn-1,2-dicaprilin; A-Dicaprylin; AC1L3XZK; 1,2-octanoyl-sn-diglyceride; CBiol_001868; KBioGR_000011; BSPBio_001291; KBioSS_000011; 4-02-00-00990 (Beilstein Handbook Reference); SCHEMBL466152
DMEAB03	DT	Small molecular drug
DMEAB03	PC	148879
DMEAB03	MW	344.5
DMEAB03	FM	C19H36O5
DMEAB03	IC	InChI=1S/C19H36O5/c1-3-5-7-9-11-13-18(21)23-16-17(15-20)24-19(22)14-12-10-8-6-4-2/h17,20H,3-16H2,1-2H3/t17-/m0/s1
DMEAB03	CS	CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC
DMEAB03	IK	ZQBULZYTDGUSSK-KRWDZBQOSA-N
DMEAB03	IU	[(2S)-3-hydroxy-2-octanoyloxypropyl] octanoate
DMEAB03	CA	CAS 60514-48-9
DMEAB03	CB	CHEBI:76979
DMEAB03	DE	Discovery agent

DMFXB21	ID	DMFXB21
DMFXB21	DN	1,2-Di-p-tolyl-ethane-1,2-dione
DMFXB21	HS	Investigative
DMFXB21	SN	4,4'-Dimethylbenzil; 3457-48-5; 1,2-Di-p-tolylethane-1,2-dione; p-Tolil; 1,2-bis(4-methylphenyl)ethane-1,2-dione; Ethanedione, bis(4-methylphenyl)-; 4,4'-Dimethyldibenzoyl; Ethandione, bis(p-tolyl)-; 1,2-dip-tolylethane-1,2-dione; BCWCEHMHCDCJAD-UHFFFAOYSA-N; MFCD00008554; AK105959; 1,2-Bis(4-methylphenyl)-1,2-ethanedione; AE-562/06268025; Di-p-tolylethanedione; EINECS 222-388-2; AC1Q5DTX; ACMC-209i8d; AC1L2S4L; Benzil-based compound, 18; SCHEMBL167254; 4,4'-Dimethylbenzil, 97%; CHEMBL192625; BDBM22740; DTXSID60188116
DMFXB21	DT	Small molecular drug
DMFXB21	PC	76996
DMFXB21	MW	238.28
DMFXB21	FM	C16H14O2
DMFXB21	IC	InChI=1S/C16H14O2/c1-11-3-7-13(8-4-11)15(17)16(18)14-9-5-12(2)6-10-14/h3-10H,1-2H3
DMFXB21	CS	CC1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)C
DMFXB21	IK	BCWCEHMHCDCJAD-UHFFFAOYSA-N
DMFXB21	IU	1,2-bis(4-methylphenyl)ethane-1,2-dione
DMFXB21	CA	CAS 3457-48-5
DMFXB21	DE	Discovery agent

DMV275G	ID	DMV275G
DMV275G	DN	1,2-indanedione
DMV275G	HS	Investigative
DMV275G	SN	16214-27-0; 1H-Indene-1,2(3H)-dione; 1,2-Indanedione; Indan-1,2-dione; 1,2-Indandione; Indandione; 3H-indene-1,2-dione; 2,3-dihydro-1H-indene-1,2-dione; indane dione; NSC62555; indane-1,2-dione; ACMC-20a7vb; AI3-25041; AC1L3WEO; AC1Q6K5I; 1,2-Indanedione, 95%; Indan-1,2-dione, 97%; 1H-Indene-1,2(3H)dione; SCHEMBL669542; CHEMBL235288; 1,2-Dione-Based Compound, 9; CTK0I2756; BDBM22852; DTXSID50167314; 1,2-IND; MolPort-000-004-392; WFFZGYRTVIPBFN-UHFFFAOYSA-N; ZINC1691218; KS-00000C3N; NSC-62555; BBL103322; 8216AA; STL557132; ANW-61125
DMV275G	DT	Small molecular drug
DMV275G	PC	123358
DMV275G	MW	146.14
DMV275G	FM	C9H6O2
DMV275G	IC	InChI=1S/C9H6O2/c10-8-5-6-3-1-2-4-7(6)9(8)11/h1-4H,5H2
DMV275G	CS	C1C2=CC=CC=C2C(=O)C1=O
DMV275G	IK	WFFZGYRTVIPBFN-UHFFFAOYSA-N
DMV275G	IU	3H-indene-1,2-dione
DMV275G	CA	CAS 16214-27-0
DMV275G	DE	Discovery agent

DMYXELH	ID	DMYXELH
DMYXELH	DN	1,2-NAPHTHOQUINONE
DMYXELH	HS	Investigative
DMYXELH	SN	1,2-NAPHTHOQUINONE; 524-42-5; 1,2-Naphthalenedione; naphthalene-1,2-dione; o-Naphthoquinone; beta-Naphthoquinone; 1,2-Naphthaquinone; 1,2-Naftochinon; .beta.-Naphthoquinone; 1,2-Naftochinon [Czech]; CCRIS 1558; UNII-804K62F61Q; HSDB 2036; 1,2-dihydronaphthalene-1,2-dione; NSC 9831; EINECS 208-360-2; 1,2-Dihydro-1,2-diketo-naphthalene; BRN 0606546; CHEMBL52347; MLS000069467; AI3-14930; CHEBI:34055; C10H6O2; KETQAJRQOHHATG-UHFFFAOYSA-N; 804K62F61Q; SMR000059112; 1,2-Naphthoquinone, 95%, tech.; NAPHTHALENEDIONE; b-naphthoquinone
DMYXELH	DT	Small molecular drug
DMYXELH	PC	10667
DMYXELH	MW	158.15
DMYXELH	FM	C10H6O2
DMYXELH	IC	InChI=1S/C10H6O2/c11-9-6-5-7-3-1-2-4-8(7)10(9)12/h1-6H
DMYXELH	CS	C1=CC=C2C(=C1)C=CC(=O)C2=O
DMYXELH	IK	KETQAJRQOHHATG-UHFFFAOYSA-N
DMYXELH	IU	naphthalene-1,2-dione
DMYXELH	CA	CAS 524-42-5
DMYXELH	CB	CHEBI:34055
DMYXELH	DE	Discovery agent

DMNCWXZ	ID	DMNCWXZ
DMNCWXZ	DN	1,3,5-BENZENETRICARBOXYLIC ACID
DMNCWXZ	HS	Investigative
DMNCWXZ	SN	Trimesic acid; 554-95-0; 1,3,5-BENZENETRICARBOXYLIC ACID; benzene-1,3,5-tricarboxylic acid; Trimesinic acid; Trimesitinic acid; 5-Carboxyisophthalic acid; 1,3,5-Benzene tricarboxylic acid; 1,3,5-Tricarboxybenzene; UNII-OU36OO5MTN; NSC 3998; EINECS 209-077-7; OU36OO5MTN; CHEMBL77562; AI3-06468; CHEBI:46032; QMKYBPDZANOJGF-UHFFFAOYSA-N; MFCD00002517; Trimesicacid; 1,3,5-Benzenetricarboxylic acid, 98%; 1.3.5-Benzenetricarboxylic Acid; H3BTCt; Trimesic acid, 95%; 1,5-Tricarboxybenzene; PubChem18615; H3TMA; AC1Q1GOL; DSSTox_CID_1488
DMNCWXZ	DT	Small molecular drug
DMNCWXZ	PC	11138
DMNCWXZ	MW	210.14
DMNCWXZ	FM	C9H6O6
DMNCWXZ	IC	InChI=1S/C9H6O6/c10-7(11)4-1-5(8(12)13)3-6(2-4)9(14)15/h1-3H,(H,10,11)(H,12,13)(H,14,15)
DMNCWXZ	CS	C1=C(C=C(C=C1C(=O)O)C(=O)O)C(=O)O
DMNCWXZ	IK	QMKYBPDZANOJGF-UHFFFAOYSA-N
DMNCWXZ	IU	benzene-1,3,5-tricarboxylic acid
DMNCWXZ	CA	CAS 554-95-0
DMNCWXZ	CB	CHEBI:46032
DMNCWXZ	DE	Discovery agent

DM7U6S0	ID	DM7U6S0
DM7U6S0	DN	1,3,5-triphenylimidazolidine-2,4-dione
DM7U6S0	HS	Investigative
DM7U6S0	SN	CHEMBL381136; 61505-60-0; SCHEMBL2791034; CTK2D8602; DTXSID10469422; 1,3,5-triphenylimidazoline-2,4-dione; 2,4-Imidazolidinedione, 1,3,5-triphenyl-
DM7U6S0	DT	Small molecular drug
DM7U6S0	PC	11609579
DM7U6S0	MW	328.4
DM7U6S0	FM	C21H16N2O2
DM7U6S0	IC	InChI=1S/C21H16N2O2/c24-20-19(16-10-4-1-5-11-16)22(17-12-6-2-7-13-17)21(25)23(20)18-14-8-3-9-15-18/h1-15,19H
DM7U6S0	CS	C1=CC=C(C=C1)C2C(=O)N(C(=O)N2C3=CC=CC=C3)C4=CC=CC=C4
DM7U6S0	IK	YEGAYNNVHYHYEO-UHFFFAOYSA-N
DM7U6S0	IU	1,3,5-triphenylimidazolidine-2,4-dione
DM7U6S0	CA	CAS 61505-60-0
DM7U6S0	DE	Discovery agent

DMDNM05	ID	DMDNM05
DMDNM05	DN	1,3,5-tris(4-chlorophenyl)imidazolidine-2,4-dione
DMDNM05	HS	Investigative
DMDNM05	DT	Small molecular drug
DMDNM05	PC	91936518
DMDNM05	MW	431.7
DMDNM05	FM	C21H13Cl3N2O2
DMDNM05	IC	InChI=1S/C21H13Cl3N2O2/c22-14-3-1-13(2-4-14)19-20(27)26(18-11-7-16(24)8-12-18)21(28)25(19)17-9-5-15(23)6-10-17/h1-12,27H
DMDNM05	CS	C1=CC(=CC=C1C2=C(N(C(=O)N2C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)O)Cl
DMDNM05	IK	FXRARDZLGGDTOS-UHFFFAOYSA-N
DMDNM05	IU	1,3,4-tris(4-chlorophenyl)-5-hydroxyimidazol-2-one
DMDNM05	DE	Discovery agent

DMFA8CW	ID	DMFA8CW
DMFA8CW	DN	1,3,7-trihydroxyacridone
DMFA8CW	HS	Investigative
DMFA8CW	DE	Discovery agent

DMNCJ5R	ID	DMNCJ5R
DMNCJ5R	DN	1,3,7-Tripropyl-3,7-dihydro-purine-2,6-dione
DMNCJ5R	HS	Investigative
DMNCJ5R	SN	1,3,7-Tripropylxanthine; CHEMBL417834; 1,3,7-Tripropyl-3,7-dihydro-purine-2,6-dione; SCHEMBL316171
DMNCJ5R	DT	Small molecular drug
DMNCJ5R	PC	11492842
DMNCJ5R	MW	278.35
DMNCJ5R	FM	C14H22N4O2
DMNCJ5R	IC	InChI=1S/C14H22N4O2/c1-4-7-16-10-15-12-11(16)13(19)18(9-6-3)14(20)17(12)8-5-2/h10H,4-9H2,1-3H3
DMNCJ5R	CS	CCCN1C=NC2=C1C(=O)N(C(=O)N2CCC)CCC
DMNCJ5R	IK	PMJKNRZFAZJNRA-UHFFFAOYSA-N
DMNCJ5R	IU	1,3,7-tripropylpurine-2,6-dione
DMNCJ5R	DE	Discovery agent

DMRP03X	ID	DMRP03X
DMRP03X	DN	1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one
DMRP03X	HS	Investigative
DMRP03X	SN	Emodin anthrone; Emodinanthrone; 491-60-1; 1,3,8-Trihydroxy-6-methylanthrone; 1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one; UNII-77C500W1A2; 2,4,5-trihydroxy-7-methylanthracen-10(9H)-one; CHEMBL122192; 77C500W1A2; 1,6,8-trihydroxy-3-methyl-10-hydroanthracen-9-one; 9(10H)-Anthracenone, 1,3,8-trihydroxy-6-methyl-; Emodinanthranol; Emodinol; Protophyscihydrone; Frangulaemodinanthrone; Frangulaemodinanthranol; Frangula emodin anthrone; AC1L3UZ6; SCHEMBL6046328; DTXSID80197684; LAJSXCAVRQXZIO-UHFFFAOYSA-N; ZINC6070245; BCP29231
DMRP03X	DT	Small molecular drug
DMRP03X	PC	122635
DMRP03X	MW	256.25
DMRP03X	FM	C15H12O4
DMRP03X	IC	InChI=1S/C15H12O4/c1-7-2-8-4-9-5-10(16)6-12(18)14(9)15(19)13(8)11(17)3-7/h2-3,5-6,16-18H,4H2,1H3
DMRP03X	CS	CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2)C=C(C=C3O)O
DMRP03X	IK	LAJSXCAVRQXZIO-UHFFFAOYSA-N
DMRP03X	IU	1,3,8-trihydroxy-6-methyl-10H-anthracen-9-one
DMRP03X	CA	CAS 491-60-1
DMRP03X	CB	CHEBI:150013
DMRP03X	DE	Discovery agent

DMOZEKU	ID	DMOZEKU
DMOZEKU	DN	1,3,8-Trimethyl-3,7-dihydro-purine-2,6-dione
DMOZEKU	HS	Investigative
DMOZEKU	SN	830-65-9; 8-Methyltheophylline; 1,3,8-Trimethyl-1H-purine-2,6(3H,7H)-dione; Theophylline, 8-methyl-; Xanthine, 1,3,8-trimethyl-; 1,3,8-Trimethyl-2,6-dioxopurine; 1,3,8-trimethylxanthine; NSC 14289; 1,3,8-trimethyl-3,9-dihydro-1h-purine-2,6-dione; CHEMBL89062; 3,7-Dihydro-1,3,8-trimethyl-1H-purine-2,6-dione; 1,3,8-trimethyl-2,3,6,9-tetrahydro-1H-purine-2,6-dione; 8-methyltheophyllin; NSC14289; 8-Methyltheophyline; AC1Q6LAN; AC1L3TFC; Xanthine,3,8-trimethyl-; 1,3,8-Trimethyl-3,7-dihydro-purine-2,6-dione; SCHEMBL461786
DMOZEKU	DT	Small molecular drug
DMOZEKU	PC	95030
DMOZEKU	MW	194.19
DMOZEKU	FM	C8H10N4O2
DMOZEKU	IC	InChI=1S/C8H10N4O2/c1-4-9-5-6(10-4)11(2)8(14)12(3)7(5)13/h1-3H3,(H,9,10)
DMOZEKU	CS	CC1=NC2=C(N1)C(=O)N(C(=O)N2C)C
DMOZEKU	IK	WZBKGWBHAPBSBF-UHFFFAOYSA-N
DMOZEKU	IU	1,3,8-trimethyl-7H-purine-2,6-dione
DMOZEKU	CA	CAS 830-65-9
DMOZEKU	DE	Discovery agent

DM7U31Q	ID	DM7U31Q
DM7U31Q	DN	1,3,9,9a-Tetrahydro-imidazo[4,5-b]quinolin-2-one
DM7U31Q	HS	Investigative
DM7U31Q	DT	Small molecular drug
DM7U31Q	PC	20200511
DM7U31Q	DE	Discovery agent

DMP86R3	ID	DMP86R3
DMP86R3	DN	1,3-bis(1,3-benzothiazol-2-ylthio)acetone
DMP86R3	HS	Investigative
DMP86R3	SN	1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one; MLS000533100; AC1LOHTK; 1,3-bis(1,3-benzothiazol-2-ylthio)acetone; CBMicro_026328; CHEMBL1526448; MolPort-002-158-967; HMS2496A11; ZINC1029672; 1,3-dibenzothiazol-2-ylthioacetone; STK733322; AKOS001750462; MCULE-2850305009; ST006263; SMR000140538; BIM-0026345.P001; 1,3-bis(benzo[d]thiazol-2-ylthio)propan-2-one; SR-01000535355; SR-01000535355-1; 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propane-2-one; F1563-0006; A2660/0113409
DMP86R3	DT	Small molecular drug
DMP86R3	PC	1240423
DMP86R3	MW	388.6
DMP86R3	FM	C17H12N2OS4
DMP86R3	IC	InChI=1S/C17H12N2OS4/c20-11(9-21-16-18-12-5-1-3-7-14(12)23-16)10-22-17-19-13-6-2-4-8-15(13)24-17/h1-8H,9-10H2
DMP86R3	CS	C1=CC=C2C(=C1)N=C(S2)SCC(=O)CSC3=NC4=CC=CC=C4S3
DMP86R3	IK	BWTBZOLHOSVREZ-UHFFFAOYSA-N
DMP86R3	IU	1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one
DMP86R3	DE	Glioma; Melanoma

DMELSV1	ID	DMELSV1
DMELSV1	DN	1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one
DMELSV1	HS	Investigative
DMELSV1	SN	CHEMBL225618; 3,3',4,4'-tetrahydroxychalcone; 1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one; SCHEMBL109015; BDBM50157562; 3,3'',4,4''-tetrahydroxychalcone; ZINC13541162
DMELSV1	DT	Small molecular drug
DMELSV1	PC	10038861
DMELSV1	MW	272.25
DMELSV1	FM	C15H12O5
DMELSV1	IC	InChI=1S/C15H12O5/c16-11(10-3-6-13(18)15(20)8-10)4-1-9-2-5-12(17)14(19)7-9/h1-8,17-20H/b4-1+
DMELSV1	CS	C1=CC(=C(C=C1/C=C/C(=O)C2=CC(=C(C=C2)O)O)O)O
DMELSV1	IK	DOWSJIIZLUFMFM-DAFODLJHSA-N
DMELSV1	IU	(E)-1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one
DMELSV1	DE	Discovery agent

DM78UPQ	ID	DM78UPQ
DM78UPQ	DN	1,3-Bis-(3-imidazolidin-2-yl-phenyl)-urea
DM78UPQ	HS	Investigative
DM78UPQ	SN	Imidocarb; 27885-92-3; Imidocarbum; Imidocarbe; Imidocarbo; 1,3-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]urea; Imidocarb [INN:BAN]; UNII-8USS3K0VDH; Imidocarbum [INN-Latin]; Imidocarbe [INN-French]; Imidocarbo [INN-Spanish]; 1,3-Bis(3-(2-imidazolin-2-yl)phenyl)urea; 1,3-Bis(3-(2-imidazolin-2-yl)phenyl)harnstoff; C19H20N6O; TCMDC-124304; N,N'-Bis(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)urea; EINECS 248-711-7; 8USS3K0VDH; CARBANILIDE, 3,3'-DI-2-IMIDAZOLIN-2-YL-; BRN 0964732; CHEMBL427342; NSC 51189; Urea, N,N'-bis[3-(4,5-dihydro-
DM78UPQ	DT	Small molecular drug
DM78UPQ	PC	21389
DM78UPQ	MW	348.4
DM78UPQ	FM	C19H20N6O
DM78UPQ	IC	InChI=1S/C19H20N6O/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26)
DM78UPQ	CS	C1CN=C(N1)C2=CC(=CC=C2)NC(=O)NC3=CC=CC(=C3)C4=NCCN4
DM78UPQ	IK	SCEVFJUWLLRELN-UHFFFAOYSA-N
DM78UPQ	IU	1,3-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]urea
DM78UPQ	CA	CAS 27885-92-3
DM78UPQ	CB	CHEBI:51804
DM78UPQ	DE	Discovery agent

DMIK7XV	ID	DMIK7XV
DMIK7XV	DN	1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate
DMIK7XV	HS	Investigative
DMIK7XV	SN	CHEMBL467905; 1,3-dinitrooxy-2-propyl 2-acetoxybenzoate; 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate; SCHEMBL8318285; BDBM50258493
DMIK7XV	DT	Small molecular drug
DMIK7XV	PC	44219619
DMIK7XV	MW	344.23
DMIK7XV	FM	C12H12N2O10
DMIK7XV	IC	InChI=1S/C12H12N2O10/c1-8(15)23-11-5-3-2-4-10(11)12(16)24-9(6-21-13(17)18)7-22-14(19)20/h2-5,9H,6-7H2,1H3
DMIK7XV	CS	CC(=O)OC1=CC=CC=C1C(=O)OC(CO[N+](=O)[O-])CO[N+](=O)[O-]
DMIK7XV	IK	KDHWEMULLOVCEH-UHFFFAOYSA-N
DMIK7XV	IU	1,3-dinitrooxypropan-2-yl 2-acetyloxybenzoate
DMIK7XV	DE	Discovery agent

DMZKUOX	ID	DMZKUOX
DMZKUOX	DN	1,3-Di(berberine-9-O-yl)ethane dibromide
DMZKUOX	HS	Investigative
DMZKUOX	SN	CHEMBL1163253
DMZKUOX	DT	Small molecular drug
DMZKUOX	PC	11643451
DMZKUOX	MW	684.7
DMZKUOX	FM	C41H36N2O8+2
DMZKUOX	IC	InChI=1S/C41H36N2O8/c1-44-34-6-4-24-14-32-28-18-38-36(48-22-50-38)16-26(28)8-10-42(32)20-30(24)40(34)46-12-3-13-47-41-31-21-43-11-9-27-17-37-39(51-23-49-37)19-29(27)33(43)15-25(31)5-7-35(41)45-2/h4-7,14-21H,3,8-13,22-23H2,1-2H3/q+2
DMZKUOX	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCOC6=C(C=CC7=CC8=[N+](CCC9=CC1=C(C=C98)OCO1)C=C76)OC
DMZKUOX	IK	AOMDJTYUICYNJP-UHFFFAOYSA-N
DMZKUOX	IU	17-methoxy-16-[3-[(17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-yl)oxy]propoxy]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMZKUOX	DE	Discovery agent

DMEV8G2	ID	DMEV8G2
DMEV8G2	DN	1,3-Diallyl-3,7-dihydro-purine-2,6-dione
DMEV8G2	HS	Investigative
DMEV8G2	SN	CHEMBL286785; 1.3-Diallylxanthin; 1,3-Diallyl-3,7-dihydro-purine-2,6-dione; SCHEMBL516503; 1H-Purine-2,6-dione, 3,9-dihydro-1,3-di-2-propen-1-yl-; BDBM50022725; 31542-64-0
DMEV8G2	DT	Small molecular drug
DMEV8G2	PC	22995178
DMEV8G2	MW	232.24
DMEV8G2	FM	C11H12N4O2
DMEV8G2	IC	InChI=1S/C11H12N4O2/c1-3-5-14-9-8(12-7-13-9)10(16)15(6-4-2)11(14)17/h3-4,7H,1-2,5-6H2,(H,12,13)
DMEV8G2	CS	C=CCN1C2=C(C(=O)N(C1=O)CC=C)NC=N2
DMEV8G2	IK	NUZFZZOVBJUJQN-UHFFFAOYSA-N
DMEV8G2	IU	1,3-bis(prop-2-enyl)-7H-purine-2,6-dione
DMEV8G2	DE	Discovery agent

DM4G2IE	ID	DM4G2IE
DM4G2IE	DN	1,3-Diallyl-7-methyl-3,7-dihydro-purine-2,6-dione
DM4G2IE	HS	Investigative
DM4G2IE	SN	CHEMBL26406; 1,3-diallyl-7-methylxanthine; 1,3-Diallyl-7-methyl-3,7-dihydro-purine-2,6-dione; BDBM50025574; 1,3-Di(2-propenyl)-7-methylxanthine
DM4G2IE	DT	Small molecular drug
DM4G2IE	PC	44459941
DM4G2IE	MW	246.27
DM4G2IE	FM	C12H14N4O2
DM4G2IE	IC	InChI=1S/C12H14N4O2/c1-4-6-15-10-9(14(3)8-13-10)11(17)16(7-5-2)12(15)18/h4-5,8H,1-2,6-7H2,3H3
DM4G2IE	CS	CN1C=NC2=C1C(=O)N(C(=O)N2CC=C)CC=C
DM4G2IE	IK	YAUBCZNTZIWFJS-UHFFFAOYSA-N
DM4G2IE	IU	7-methyl-1,3-bis(prop-2-enyl)purine-2,6-dione
DM4G2IE	CA	CAS 102284-65-1
DM4G2IE	DE	Discovery agent

DMMOBPN	ID	DMMOBPN
DMMOBPN	DN	1,3-dibenzyl urea
DMMOBPN	HS	Investigative
DMMOBPN	SN	1,3-Dibenzylurea; N,N'-Dibenzylurea; 1466-67-7; sym-Dibenzylurea; Urea, N,N'-bis(phenylmethyl)-; 1,3-dibenzyl urea; 1,3-Dibenzyl-urea; CHEMBL504463; KATOLVAXCGIBLO-UHFFFAOYSA-N; N-benzyl[benzylamino]carboxamide; dibenzylurea; EINECS 215-984-9; NSC408007; NSC 408007; N,N'-Dibenzylharnstoff; AI3-19855; AC1Q5OY5; AC1L2IW5; Oprea1_448978; Urea,N'-bis(phenylmethyl)-; SCHEMBL714625; Urea,N,N'-bis(phenylmethyl)-; DTXSID3061710; ZINC84096; KS-00001BSB; CTK4C5047; MolPort-000-421-383; HMS1697A06; STK008269; BDBM50248768; SBB023417; CCG-48904
DMMOBPN	DT	Small molecular drug
DMMOBPN	PC	72889
DMMOBPN	MW	240.3
DMMOBPN	FM	C15H16N2O
DMMOBPN	IC	InChI=1S/C15H16N2O/c18-15(16-11-13-7-3-1-4-8-13)17-12-14-9-5-2-6-10-14/h1-10H,11-12H2,(H2,16,17,18)
DMMOBPN	CS	C1=CC=C(C=C1)CNC(=O)NCC2=CC=CC=C2
DMMOBPN	IK	KATOLVAXCGIBLO-UHFFFAOYSA-N
DMMOBPN	IU	1,3-dibenzylurea
DMMOBPN	CA	CAS 1466-67-7
DMMOBPN	DE	Discovery agent

DM8NARQ	ID	DM8NARQ
DM8NARQ	DN	1,3-Dibenzyl-[1,3]diazetidine-2,4-dione
DM8NARQ	HS	Investigative
DM8NARQ	SN	CHEMBL47394; 1,3-dibenzyl-1,3-diazetidine-2,4-dione; GTPL6542; BDBM50101132; compound 1 [PMID: 11425539]
DM8NARQ	DT	Small molecular drug
DM8NARQ	PC	10038543
DM8NARQ	MW	266.29
DM8NARQ	FM	C16H14N2O2
DM8NARQ	IC	InChI=1S/C16H14N2O2/c19-15-17(11-13-7-3-1-4-8-13)16(20)18(15)12-14-9-5-2-6-10-14/h1-10H,11-12H2
DM8NARQ	CS	C1=CC=C(C=C1)CN2C(=O)N(C2=O)CC3=CC=CC=C3
DM8NARQ	IK	PGIXYPNBNAOYHW-UHFFFAOYSA-N
DM8NARQ	IU	1,3-dibenzyl-1,3-diazetidine-2,4-dione
DM8NARQ	DE	Discovery agent

DM2WSG5	ID	DM2WSG5
DM2WSG5	DN	1,3-Dibenzyl-3,7-dihydro-purine-2,6-dione
DM2WSG5	HS	Investigative
DM2WSG5	SN	1,3-dibenzyl-3,7-dihydro-1h-purine-2,6-dione; CHEMBL24774; 31542-68-4; NSC70563; AC1Q6LGR; 1,3-Dibenzyl-3,7-dihydro-purine-2,6-dione; 1,3-Dibenzyl-1H-purine-2,6(3H,7H)-dione; AC1L5IF2; SCHEMBL3107001; CTK4G7326; NSC-70563; BDBM50025573; 1,3-dibenzyl-7H-purine-2,6-dione
DM2WSG5	DT	Small molecular drug
DM2WSG5	PC	250782
DM2WSG5	MW	332.4
DM2WSG5	FM	C19H16N4O2
DM2WSG5	IC	InChI=1S/C19H16N4O2/c24-18-16-17(21-13-20-16)22(11-14-7-3-1-4-8-14)19(25)23(18)12-15-9-5-2-6-10-15/h1-10,13H,11-12H2,(H,20,21)
DM2WSG5	CS	C1=CC=C(C=C1)CN2C3=C(C(=O)N(C2=O)CC4=CC=CC=C4)NC=N3
DM2WSG5	IK	NHCLZKKZQJJXER-UHFFFAOYSA-N
DM2WSG5	IU	1,3-dibenzyl-7H-purine-2,6-dione
DM2WSG5	CA	CAS 31542-68-4
DM2WSG5	DE	Discovery agent

DMKYE16	ID	DMKYE16
DMKYE16	DN	1,3-Diethyl-3,7-dihydro-purine-2,6-dione
DMKYE16	HS	Investigative
DMKYE16	SN	1,3-Diethylxanthine; SC 2079; 5169-95-9; 1,3-diethyl-3,9-dihydro-1h-purine-2,6-dione; CHEMBL416013; UNII-4550Q64O79; 4550Q64O79; 1,3-Diethylxantine; Xanthine,3-diethyl-; NSC 515479; 1,3-diethyl-xanthine; AC1L2QSV; AC1Q6LGQ; 1,3-diethyl-1H-purine-2,6(3H,7H)-dione; SCHEMBL515564; BDBM82021; CTK8I9744; CTK8D7769; DTXSID40199644; 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro- (9CI); GIMNFISWKTZFKJ-UHFFFAOYSA-N; Xanthine, 1,3-diethyl- (8CI); NSC515479; 1,3-diethyl-7H-purine-2,6-dione; AKOS030616954; NSC_101420; NSC-515479; CAS_101420
DMKYE16	DT	Small molecular drug
DMKYE16	PC	101420
DMKYE16	MW	208.22
DMKYE16	FM	C9H12N4O2
DMKYE16	IC	InChI=1S/C9H12N4O2/c1-3-12-7-6(10-5-11-7)8(14)13(4-2)9(12)15/h5H,3-4H2,1-2H3,(H,10,11)
DMKYE16	CS	CCN1C2=C(C(=O)N(C1=O)CC)NC=N2
DMKYE16	IK	GIMNFISWKTZFKJ-UHFFFAOYSA-N
DMKYE16	IU	1,3-diethyl-7H-purine-2,6-dione
DMKYE16	CA	CAS 5169-95-9
DMKYE16	DE	Discovery agent

DMB9XR5	ID	DMB9XR5
DMB9XR5	DN	1,3-Dihydro-imidazo[4,5-b]quinolin-2-one
DMB9XR5	HS	Investigative
DMB9XR5	SN	CHEMBL98604; 1,3-Dihydro-imidazo[4,5-b]quinolin-2-one; SCHEMBL2014813; BDBM50007220; 1H-Imidazo[4,5-b]quinolin-2(3H)-one
DMB9XR5	DT	Small molecular drug
DMB9XR5	PC	10867033
DMB9XR5	MW	185.18
DMB9XR5	FM	C10H7N3O
DMB9XR5	IC	InChI=1S/C10H7N3O/c14-10-12-8-5-6-3-1-2-4-7(6)11-9(8)13-10/h1-5H,(H2,11,12,13,14)
DMB9XR5	CS	C1=CC=C2C(=C1)C=C3C(=N2)NC(=O)N3
DMB9XR5	IK	BINWKEIURMBREF-UHFFFAOYSA-N
DMB9XR5	IU	1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMB9XR5	DE	Discovery agent

DM8CYOP	ID	DM8CYOP
DM8CYOP	DN	1,3-Dihydro-naphtho[2,3-d]imidazol-2-one
DM8CYOP	HS	Investigative
DM8CYOP	SN	1H-Naphtho[2,3-d]imidazol-2(3H)-one; 5649-76-3; CHEMBL316599; 1,3-Dihydro-naphtho[2,3-d]imidazol-2-one; SCHEMBL17206226; SCHEMBL11357960; ZINC13824637; BDBM50007236; FCH995480; AKOS024262366; 1H-Naphth[2,3-d]imidazol-2(3H)-one; AJ-64431; AX8292028; 1,3-Dihydro-2H-naphth[2,3-d]imidazol-2-one
DM8CYOP	DT	Small molecular drug
DM8CYOP	PC	13724742
DM8CYOP	MW	184.19
DM8CYOP	FM	C11H8N2O
DM8CYOP	IC	InChI=1S/C11H8N2O/c14-11-12-9-5-7-3-1-2-4-8(7)6-10(9)13-11/h1-6H,(H2,12,13,14)
DM8CYOP	CS	C1=CC=C2C=C3C(=CC2=C1)NC(=O)N3
DM8CYOP	IK	HUOPXZLFTBYAML-UHFFFAOYSA-N
DM8CYOP	IU	1,3-dihydrobenzo[f]benzimidazol-2-one
DM8CYOP	DE	Discovery agent

DMZ80CT	ID	DMZ80CT
DMZ80CT	DN	1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione
DMZ80CT	HS	Investigative
DMZ80CT	SN	1,3-Diisobutylxanthine; Xanthine, 1,3-diisobutyl-; BRN 1143460; CHEMBL26350; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-bis(2-methylpropyl)-; 3,7-Dihydro-1,3-bis(2-methylpropyl)-1H-purine-2,6-dione; 63908-24-7; AC1MIMT3; 1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione; DTXSID70213605; BDBM50022731; LS-126573
DMZ80CT	DT	Small molecular drug
DMZ80CT	PC	3048504
DMZ80CT	MW	264.32
DMZ80CT	FM	C13H20N4O2
DMZ80CT	IC	InChI=1S/C13H20N4O2/c1-8(2)5-16-11-10(14-7-15-11)12(18)17(13(16)19)6-9(3)4/h7-9H,5-6H2,1-4H3,(H,14,15)
DMZ80CT	CS	CC(C)CN1C2=C(C(=O)N(C1=O)CC(C)C)NC=N2
DMZ80CT	IK	IPUAJXHKDUKOCH-UHFFFAOYSA-N
DMZ80CT	IU	1,3-bis(2-methylpropyl)-7H-purine-2,6-dione
DMZ80CT	CA	CAS 63908-24-7
DMZ80CT	DE	Discovery agent

DM1KND6	ID	DM1KND6
DM1KND6	DN	1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one
DM1KND6	HS	Investigative
DM1KND6	SN	100008-84-2; [1]Benzopyrano[4,3-c]pyrazol-4(1H)-one, 1,3-diphenyl-; ACMC-20m32m; CHEMBL99633; CTK0G9179; DTXSID70541117; AKOS030534409; J3.620.041C; 1,3-Diphenyl[1]benzopyrano[4,3-c]pyrazole-4(1H)-one
DM1KND6	DT	Small molecular drug
DM1KND6	PC	13448492
DM1KND6	MW	338.4
DM1KND6	FM	C22H14N2O2
DM1KND6	IC	InChI=1S/C22H14N2O2/c25-22-19-20(15-9-3-1-4-10-15)23-24(16-11-5-2-6-12-16)21(19)17-13-7-8-14-18(17)26-22/h1-14H
DM1KND6	CS	C1=CC=C(C=C1)C2=NN(C3=C2C(=O)OC4=CC=CC=C43)C5=CC=CC=C5
DM1KND6	IK	ZPXTZMAWXDLUOO-UHFFFAOYSA-N
DM1KND6	IU	1,3-diphenylchromeno[4,3-c]pyrazol-4-one
DM1KND6	CA	CAS 100008-84-2
DM1KND6	DE	Discovery agent

DMI4H05	ID	DMI4H05
DMI4H05	DN	1,3-DIPHENYLUREA
DMI4H05	HS	Investigative
DMI4H05	SN	1,3-Diphenylurea; 102-07-8; N,N'-Diphenylurea; CARBANILIDE; Diphenylurea; Diphenylcarbamide; Urea, N,N'-diphenyl-; s-Diphenylurea; sym-Diphenylurea; Acardite I; Acardite; N-Phenyl-N'-phenylurea; 1,3-Diphenylcarbamide; Karbanilid; N,N'-Difenylmocovina; USAF EK-534; Urea, 1,3-diphenyl-; Karbanilid [Czech]; 1,3-diphenyl-urea; AD 30; UNII-94YD8RMX5B; NSC 227401; N,N'-Difenylmocovina [Czech]; CCRIS 4634; HSDB 2757; Urea-based compound, 7; EINECS 203-003-7; BRN 0782650; 94YD8RMX5B; AI3-52320; CHEBI:41320; GWEHVDNNLFDJLR-UHFFFAOYSA-N
DMI4H05	DT	Small molecular drug
DMI4H05	PC	7595
DMI4H05	MW	212.25
DMI4H05	FM	C13H12N2O
DMI4H05	IC	InChI=1S/C13H12N2O/c16-13(14-11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h1-10H,(H2,14,15,16)
DMI4H05	CS	C1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2
DMI4H05	IK	GWEHVDNNLFDJLR-UHFFFAOYSA-N
DMI4H05	IU	1,3-diphenylurea
DMI4H05	CA	CAS 102-07-8
DMI4H05	CB	CHEBI:41320
DMI4H05	DE	Discovery agent

DMUL2B3	ID	DMUL2B3
DMUL2B3	DN	1,3-Dipropyl-3,7-dihydro-purine-2,6-dione
DMUL2B3	HS	Investigative
DMUL2B3	SN	1,3-Dipropylxanthine; 31542-62-8; 1,3-Dipropyl-1H-purine-2,6(3H,7H)-dione; UNII-Z02T66W92D; CHEMBL157655; Z02T66W92D; 1,3-dipropyl-7H-purine-2,6-dione; 1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione; 1,3-dipropyl-xanthine; AC1Q6LGS; 1,3-di-n-propylxanthine; AC1L53IX; GTPL427; SCHEMBL515771; 1H-Purine-2,6-dione, 3,9-dihydro-1,3-dipropyl-; BDBM82032; CTK4G7324; DTXSID00185447; MJVIGUCNSRXAFO-UHFFFAOYSA-N; ZINC4654890; PDSP2_000967; PDSP1_000983; PDSP1_000328; PDSP2_001217; BDBM50227331
DMUL2B3	DT	Small molecular drug
DMUL2B3	PC	169317
DMUL2B3	MW	236.27
DMUL2B3	FM	C11H16N4O2
DMUL2B3	IC	InChI=1S/C11H16N4O2/c1-3-5-14-9-8(12-7-13-9)10(16)15(6-4-2)11(14)17/h7H,3-6H2,1-2H3,(H,12,13)
DMUL2B3	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC=N2
DMUL2B3	IK	MJVIGUCNSRXAFO-UHFFFAOYSA-N
DMUL2B3	IU	1,3-dipropyl-7H-purine-2,6-dione
DMUL2B3	CA	CAS 31542-62-8
DMUL2B3	DE	Discovery agent

DMHNUWG	ID	DMHNUWG
DMHNUWG	DN	1,3-Di-p-tolyl-[1,3]diazetidine-2,4-dione
DMHNUWG	HS	Investigative
DMHNUWG	SN	CHEMBL296771; 1,3-bis(4-methylphenyl)-1,3-diazetidine-2,4-dione; 1,3-Di-p-tolyl-[1,3]diazetidine-2,4-dione; AC1MRG54; SCHEMBL19214040
DMHNUWG	DT	Small molecular drug
DMHNUWG	PC	3492365
DMHNUWG	MW	266.29
DMHNUWG	FM	C16H14N2O2
DMHNUWG	IC	InChI=1S/C16H14N2O2/c1-11-3-7-13(8-4-11)17-15(19)18(16(17)20)14-9-5-12(2)6-10-14/h3-10H,1-2H3
DMHNUWG	CS	CC1=CC=C(C=C1)N2C(=O)N(C2=O)C3=CC=C(C=C3)C
DMHNUWG	IK	AZZFGWWOGRBVOV-UHFFFAOYSA-N
DMHNUWG	IU	1,3-bis(4-methylphenyl)-1,3-diazetidine-2,4-dione
DMHNUWG	DE	Discovery agent

DM04KS1	ID	DM04KS1
DM04KS1	DN	1,3-ditolylguanidine
DM04KS1	HS	Investigative
DM04KS1	SN	1,3-Di-o-tolylguanidine; 97-39-2; Di-o-tolylguanidine; DOTG; Vulkacite DOTG; 1,3-Ditolylguanidine; Vulkacit DOTG; Eveite DOTG; ditolylguanidine; Vulkacit dotg/C; Nocceler DT; Sanceler DT; DOTG accelerator; Soxinol DT; Akrochem DOTG; Vulcafor DOTG; 1,3-Bis(o-tolyl)guanidine; Guanidine, N,N'-bis(2-methylphenyl)-; Diorthotolylguanidine; 1,3-Di-o-tolyguanidine; N,N'-Di-o-tolylguanidine; Guanidine, 1,3-di-o-tolyl-; USAF A-6598; NSC 473; CNS 1001; N,N'-Di-o-tolueylguanidine; UNII-LL2P01I17O; 1,3-di-(2-tolyl)guanidine; NSC 132023; [3H]-di-o-tolylguanidine; DITOLYLGUANIDINE
DM04KS1	DT	Small molecular drug
DM04KS1	PC	7333
DM04KS1	MW	239.32
DM04KS1	FM	C15H17N3
DM04KS1	IC	InChI=1S/C15H17N3/c1-11-7-3-5-9-13(11)17-15(16)18-14-10-6-4-8-12(14)2/h3-10H,1-2H3,(H3,16,17,18)
DM04KS1	CS	CC1=CC=CC=C1NC(=NC2=CC=CC=C2C)N
DM04KS1	IK	OPNUROKCUBTKLF-UHFFFAOYSA-N
DM04KS1	IU	1,2-bis(2-methylphenyl)guanidine
DM04KS1	CA	CAS 97-39-2
DM04KS1	CB	CHEBI:92585
DM04KS1	DE	Discovery agent

DMVBI2C	ID	DMVBI2C
DMVBI2C	DN	1,3-propanediphosphonic acid
DMVBI2C	HS	Investigative
DMVBI2C	SN	1,3-Propylenediphosphonic Acid; 1,3-propanediphosphonic acid; Propane-1,3-Diylbis(Phosphonic Acid); 3-phosphonopropylphosphonic acid; CHEMBL1230579; 7702-51-4; AC1L92ZA; SCHEMBL182326; propane-1,3-diphosphonic acid; CTK2H9782; 1,3-Propanediylbisphosphonic acid; ZINC31962397; BDBM50326711; AKOS025402728; P2304; I04-10331
DMVBI2C	DT	Small molecular drug
DMVBI2C	PC	437081
DMVBI2C	MW	204.06
DMVBI2C	FM	C3H10O6P2
DMVBI2C	IC	InChI=1S/C3H10O6P2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H2,4,5,6)(H2,7,8,9)
DMVBI2C	CS	C(CP(=O)(O)O)CP(=O)(O)O
DMVBI2C	IK	PUVMVPFLXCHEOY-UHFFFAOYSA-N
DMVBI2C	IU	3-phosphonopropylphosphonic acid
DMVBI2C	DE	Discovery agent

DMLBHXN	ID	DMLBHXN
DMLBHXN	DN	1,4-bis-(Dmt-Tic-amino)butane
DMLBHXN	HS	Investigative
DMLBHXN	SN	CHEMBL370197; 1,4-bis-(Dmt-Tic-amino)butane
DMLBHXN	DT	Small molecular drug
DMLBHXN	PC	44405158
DMLBHXN	MW	789
DMLBHXN	FM	C46H56N6O6
DMLBHXN	IC	InChI=1S/C46H56N6O6/c1-27-17-35(53)18-28(2)37(27)23-39(47)45(57)51-25-33-13-7-5-11-31(33)21-41(51)43(55)49-15-9-10-16-50-44(56)42-22-32-12-6-8-14-34(32)26-52(42)46(58)40(48)24-38-29(3)19-36(54)20-30(38)4/h5-8,11-14,17-20,39-42,53-54H,9-10,15-16,21-26,47-48H2,1-4H3,(H,49,55)(H,50,56)/t39-,40-,41?,42?/m0/s1
DMLBHXN	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCNC(=O)C4CC5=CC=CC=C5CN4C(=O)[C@H](CC6=C(C=C(C=C6C)O)C)N)N)C)O
DMLBHXN	IK	JSRJJBASKHLXAZ-YZNAZWRISA-N
DMLBHXN	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[4-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]butyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMLBHXN	DE	Discovery agent

DMC4LMT	ID	DMC4LMT
DMC4LMT	DN	1,4-bis(malimido)xylene
DMC4LMT	HS	Investigative
DMC4LMT	SN	1,4-bis(malimido)xylene; CHEMBL565711; SCHEMBL146412; BDBM50300349
DMC4LMT	DT	Small molecular drug
DMC4LMT	PC	22022556
DMC4LMT	MW	296.28
DMC4LMT	FM	C16H12N2O4
DMC4LMT	IC	InChI=1S/C16H12N2O4/c19-13-5-6-14(20)17(13)9-11-1-2-12(4-3-11)10-18-15(21)7-8-16(18)22/h1-8H,9-10H2
DMC4LMT	CS	C1=CC(=CC=C1CN2C(=O)C=CC2=O)CN3C(=O)C=CC3=O
DMC4LMT	IK	XFRPTDABLAIJMY-UHFFFAOYSA-N
DMC4LMT	IU	1-[[4-[(2,5-dioxopyrrol-1-yl)methyl]phenyl]methyl]pyrrole-2,5-dione
DMC4LMT	DE	Discovery agent

DMVHKZT	ID	DMVHKZT
DMVHKZT	DN	1,4-Butanediol
DMVHKZT	HS	Investigative
DMVHKZT	SN	1,4-BUTANEDIOL; Butane-1,4-diol; 110-63-4; 1,4-Butylene glycol; Tetramethylene glycol; 1,4-Dihydroxybutane; 1,4-Tetramethylene glycol; Tetramethylene 1,4-diol; Sucol B; 1,4-BD; DIOL 14B; Agrisynth B1D; UNII-7XOO2LE6G3; HO(CH2)4OH; NSC 406696; CCRIS 5984; 1,4-Dihdyroxybutane; HSDB 1112; EINECS 203-786-5; HOCH2CH2CH2CH2OH; BRN 1633445; 7XOO2LE6G3; AI3-07553; CHEBI:41189; WERYXYBDKMZEQL-UHFFFAOYSA-N; MFCD00002968; DSSTox_CID_4666; DSSTox_RID_77492; DSSTox_GSID_24666; BDO; CAS-110-63-4; BU1; 1,4-Butanediol, homopolymer; 4-hydroxybutanol
DMVHKZT	DT	Small molecular drug
DMVHKZT	PC	8064
DMVHKZT	MW	90.12
DMVHKZT	FM	C4H10O2
DMVHKZT	IC	InChI=1S/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2
DMVHKZT	CS	C(CCO)CO
DMVHKZT	IK	WERYXYBDKMZEQL-UHFFFAOYSA-N
DMVHKZT	IU	butane-1,4-diol
DMVHKZT	CA	CAS 110-63-4
DMVHKZT	CB	CHEBI:41189
DMVHKZT	DE	Discovery agent

DM87MWN	ID	DM87MWN
DM87MWN	DN	1,4-Di(berberine-9-O-yl)ethane dibromide
DM87MWN	HS	Investigative
DM87MWN	SN	CHEMBL1165194
DM87MWN	DT	Small molecular drug
DM87MWN	PC	44400818
DM87MWN	MW	698.8
DM87MWN	FM	C42H38N2O8+2
DM87MWN	IC	InChI=1S/C42H38N2O8/c1-45-35-7-5-25-15-33-29-19-39-37(49-23-51-39)17-27(29)9-11-43(33)21-31(25)41(35)47-13-3-4-14-48-42-32-22-44-12-10-28-18-38-40(52-24-50-38)20-30(28)34(44)16-26(32)6-8-36(42)46-2/h5-8,15-22H,3-4,9-14,23-24H2,1-2H3/q+2
DM87MWN	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=C(C=CC7=CC8=[N+](CCC9=CC1=C(C=C98)OCO1)C=C76)OC
DM87MWN	IK	SJALLAIALHPUMH-UHFFFAOYSA-N
DM87MWN	IU	17-methoxy-16-[4-[(17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-yl)oxy]butoxy]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM87MWN	DE	Discovery agent

DMIHYKG	ID	DMIHYKG
DMIHYKG	DN	1,4-diaminoanthracene-9,10-dione
DMIHYKG	HS	Investigative
DMIHYKG	SN	1,4-Diaminoanthraquinone; 128-95-0; 1,4-diaminoanthracene-9,10-dione; Disperse violet 1; Krisolamine; 1,4-Diamino anthraquinone; Grasol Violet R; Seacyl Violet R; Acetate Red Violet R; 9,10-Anthracenedione, 1,4-diamino-; Setacyl Violet R; Oil Violet R; Disperse Violet K; Resiren Violet TR; Oracet Violet 2R; Gracet Violet 2R; Setile Violet 3R; Duranol Violet 2R; Nacelan Violet 4R; Cibacet Violet 2R; Amacel heliotrope R; Dispersive Violet K; Solvent Violet 11; Cibacete Violet 2R; Perliton Violet 3R; Nyloquinone Violet R; Artisil Viole
DMIHYKG	DT	Small molecular drug
DMIHYKG	PC	31420
DMIHYKG	MW	238.24
DMIHYKG	FM	C14H10N2O2
DMIHYKG	IC	InChI=1S/C14H10N2O2/c15-9-5-6-10(16)12-11(9)13(17)7-3-1-2-4-8(7)14(12)18/h1-6H,15-16H2
DMIHYKG	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)N)N
DMIHYKG	IK	FBMQNRKSAWNXBT-UHFFFAOYSA-N
DMIHYKG	IU	1,4-diaminoanthracene-9,10-dione
DMIHYKG	CA	CAS 128-95-0
DMIHYKG	DE	Discovery agent

DMB5VQK	ID	DMB5VQK
DMB5VQK	DN	1,4-dideoxy-1,4-imino-D-arabinito
DMB5VQK	HS	Investigative
DMB5VQK	SN	1,4-dideoxy-1,4-imino-d-arabinitol; imino-D-arabinitol; CHEMBL80254; 3,4-Pyrrolidinediol, 2-(hydroxymethyl-14C)-, (2R,3R,4R)-; (2R,3R,4R)-2-(hydroxymethyl)pyrrolidine-3,4-diol; 259140-24-4; (2R,3R,4R)-2-Hydroxymethyl-pyrrolidine-3,4-diol; BDBM50031485; AC1L9PZY; 100937-52-8; DAB-1; Lopac0_000366; MLS002153179; SCHEMBL143519; CHEMBL305131; DTXSID10180589; OQEBIHBLFRADNM-UOWFLXDJSA-N; HMS2233K17; ZINC1492250; 1,4-Dideoxy-1,4-imino-arabinitol; BDBM50016703
DMB5VQK	DT	Small molecular drug
DMB5VQK	PC	451991
DMB5VQK	MW	133.15
DMB5VQK	FM	C5H11NO3
DMB5VQK	IC	InChI=1S/C5H11NO3/c7-2-3-5(9)4(8)1-6-3/h3-9H,1-2H2/t3-,4-,5-/m1/s1
DMB5VQK	CS	C1[C@H]([C@@H]([C@H](N1)CO)O)O
DMB5VQK	IK	OQEBIHBLFRADNM-UOWFLXDJSA-N
DMB5VQK	IU	(2R,3R,4R)-2-(hydroxymethyl)pyrrolidine-3,4-diol
DMB5VQK	CA	CAS 259140-24-4
DMB5VQK	DE	Discovery agent

DM4RD2S	ID	DM4RD2S
DM4RD2S	DN	1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
DM4RD2S	HS	Investigative
DM4RD2S	SN	AC1NRDG1; (3S,4S)-4-hydroxy-3-sulfooxy-3,4-dihydro-2H-pyran-6-carboxylic acid
DM4RD2S	DT	Small molecular drug
DM4RD2S	PC	46936854
DM4RD2S	MW	240.19
DM4RD2S	FM	C6H8O8S
DM4RD2S	IC	InChI=1S/C6H8O8S/c7-3-1-4(6(8)9)13-2-5(3)14-15(10,11)12/h1,3,5,7H,2H2,(H,8,9)(H,10,11,12)/t3-,5-/m1/s1
DM4RD2S	CS	C1[C@H]([C@@H](C=C(O1)C(=O)O)O)OS(=O)(=O)O
DM4RD2S	IK	SLBOXLMLDIGNGG-NQXXGFSBSA-N
DM4RD2S	IU	(3R,4R)-4-hydroxy-3-sulfooxy-3,4-dihydro-2H-pyran-6-carboxylic acid
DM4RD2S	DE	Discovery agent

DM9KUQZ	ID	DM9KUQZ
DM9KUQZ	DN	1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
DM9KUQZ	HS	Investigative
DM9KUQZ	SN	AC1NRBS8; (2R,4S,5S)-4-hydroxy-5-sulfooxyoxane-2-carboxylic acid
DM9KUQZ	DT	Small molecular drug
DM9KUQZ	PC	46936835
DM9KUQZ	MW	242.21
DM9KUQZ	FM	C6H10O8S
DM9KUQZ	IC	InChI=1S/C6H10O8S/c7-3-1-4(6(8)9)13-2-5(3)14-15(10,11)12/h3-5,7H,1-2H2,(H,8,9)(H,10,11,12)/t3-,4-,5-/m1/s1
DM9KUQZ	CS	C1[C@H]([C@@H](CO[C@H]1C(=O)O)OS(=O)(=O)O)O
DM9KUQZ	IK	IRTONBQROPNEJZ-UOWFLXDJSA-N
DM9KUQZ	IU	(2R,4R,5R)-4-hydroxy-5-sulfooxyoxane-2-carboxylic acid
DM9KUQZ	DE	Discovery agent

DMI36WC	ID	DMI36WC
DMI36WC	DN	1,4-Diethylene Dioxide
DMI36WC	HS	Investigative
DMI36WC	SN	1,4-DIOXANE; Dioxane; 123-91-1; p-Dioxane; 1,4-Diethylene dioxide; Diethylene ether; Dioxan; 1,4-Dioxacyclohexane; Dioxanne; Tetrahydro-p-dioxin; Di(ethylene oxide); Tetrahydro-1,4-dioxin; Dioxane-1,4; Diethylene dioxide; Glycol ethylene ether; 1,4-Dioxan; p-Dioxan; Dioxan-1,4; Dioxyethylene ether; Dioksan; Diokan; para-Dioxane; Tetrahydro-para-dioxin; Diossano-1,4; Dioxaan-1,4; p-Dioxin, tetrahydro-; Glycolethylenether; Dioksan [Polish]; Dioxanne [French]; RCRA waste number U108; p-Dioxan [Czech]; 1,4-Dioxanne; NCI-C03689
DMI36WC	DT	Small molecular drug
DMI36WC	PC	31275
DMI36WC	MW	88.11
DMI36WC	FM	C4H8O2
DMI36WC	IC	InChI=1S/C4H8O2/c1-2-6-4-3-5-1/h1-4H2
DMI36WC	CS	C1COCCO1
DMI36WC	IK	RYHBNJHYFVUHQT-UHFFFAOYSA-N
DMI36WC	IU	1,4-dioxane
DMI36WC	CA	CAS 123-91-1
DMI36WC	CB	CHEBI:47032
DMI36WC	DE	Discovery agent

DMNHGVD	ID	DMNHGVD
DMNHGVD	DN	1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide
DMNHGVD	HS	Investigative
DMNHGVD	SN	CHEMBL1240572; 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide; 182556-18-9; SCHEMBL8320257; BDBM50326118; ZINC39054006; NSC744701; AKOS027401058; NSC-744701; KB-184852; 1,4-Dihydro-1-methyl-4-oxopyridine-3-sulfonamide
DMNHGVD	DT	Small molecular drug
DMNHGVD	PC	45028895
DMNHGVD	MW	188.21
DMNHGVD	FM	C6H8N2O3S
DMNHGVD	IC	InChI=1S/C6H8N2O3S/c1-8-3-2-5(9)6(4-8)12(7,10)11/h2-4H,1H3,(H2,7,10,11)
DMNHGVD	CS	CN1C=CC(=O)C(=C1)S(=O)(=O)N
DMNHGVD	IK	HTPSIFNKXNIAJZ-UHFFFAOYSA-N
DMNHGVD	IU	1-methyl-4-oxopyridine-3-sulfonamide
DMNHGVD	CA	CAS 182556-18-9
DMNHGVD	DE	Discovery agent

DMMGP9X	ID	DMMGP9X
DMMGP9X	DN	1,4-dihydroindeno[1,2-c]-pyrazole
DMMGP9X	HS	Investigative
DMMGP9X	SN	CHEMBL218957; SCHEMBL14746942; BDBM50176977
DMMGP9X	DT	Small molecular drug
DMMGP9X	PC	44418727
DMMGP9X	MW	461.8
DMMGP9X	FM	C22H19Cl3N4O
DMMGP9X	IC	InChI=1S/C22H19Cl3N4O/c23-14-4-6-16-13(10-14)11-17-20(22(30)27-28-8-2-1-3-9-28)26-29(21(16)17)19-7-5-15(24)12-18(19)25/h4-7,10,12H,1-3,8-9,11H2,(H,27,30)
DMMGP9X	CS	C1CCN(CC1)NC(=O)C2=NN(C3=C2CC4=C3C=CC(=C4)Cl)C5=C(C=C(C=C5)Cl)Cl
DMMGP9X	IK	AOONPZHOPMGIMM-UHFFFAOYSA-N
DMMGP9X	IU	6-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4H-indeno[1,2-c]pyrazole-3-carboxamide
DMMGP9X	DE	Discovery agent

DMRT13B	ID	DMRT13B
DMRT13B	DN	1,4-Dimethylquinolin-2(1H)-one
DMRT13B	HS	Investigative
DMRT13B	SN	1,4-dimethylquinolin-2(1h)-one; 2584-47-6; 2(1H)-Quinolinone, 1,4-dimethyl-; 1,4-Dimethyl-2(1H)-quinolinone; 1,4-dimethyl-1,2-dihydroquinolin-2-one; UNII-6WT6AG3ZQJ; 6WT6AG3ZQJ; 1,4-dimethyl-2-quinolone; 1,4-dimethylquinolin-2-one; ST019653; Q-101237; 2(1H)-quinolinone,1,4-dimethyl-; NSC108420; NSC 108420; 1,4-DIMETHYL-2(1H)-QUINOLONE; casimiroin analogue, 1d; 1,4-dimethylcarbostyril; 4-methyl-n-methylquinolone; AC1Q6I1L; AC1L3Y4F; KSC497K0B; MLS000764269; CHEMBL60376; SCHEMBL436564; ZINC32147; CTK3J7500; BDBM29215
DMRT13B	DT	Small molecular drug
DMRT13B	PC	97252
DMRT13B	MW	173.21
DMRT13B	FM	C11H11NO
DMRT13B	IC	InChI=1S/C11H11NO/c1-8-7-11(13)12(2)10-6-4-3-5-9(8)10/h3-7H,1-2H3
DMRT13B	CS	CC1=CC(=O)N(C2=CC=CC=C12)C
DMRT13B	IK	CEONKCOBRZOYJS-UHFFFAOYSA-N
DMRT13B	IU	1,4-dimethylquinolin-2-one
DMRT13B	CA	CAS 2584-47-6
DMRT13B	DE	Discovery agent

DMFY3VS	ID	DMFY3VS
DMFY3VS	DN	1,4-diphenyl-(1E,3E)-1,3-butadiene
DMFY3VS	HS	Investigative
DMFY3VS	SN	Bistyryl; 1,4-Diphenyl-1,3-butadiene; 1,4-Diphenylbutadiene; trans,trans-1,4-Diphenyl-1,3-butadiene; 538-81-8; 1,4-Diphenylerythrene; Distyryl; trans,trans-1,4-Diphenylbuta-1,3-diene; (1E,3E)-1,4-Diphenylbuta-1,3-diene; 886-65-7; NSC 122702; 1,4-Diphenylbuta-1,3-diene; UNII-R7P15V6543; 1,1'-(1E,3E)-buta-1,3-diene-1,4-diyldibenzene; 1,3-Butadiene, 1,4-diphenyl-; EINECS 212-952-6; CHEMBL198810; CHEBI:35100; JFLKFZNIIQFQBS-FNCQTZNRSA-N; (4-phenyl-1,3-butadienyl)benzene; R7P15V6543; 1,1'-buta-1,3-diene-1,4-diyldibenzene
DMFY3VS	DT	Small molecular drug
DMFY3VS	PC	641683
DMFY3VS	MW	206.28
DMFY3VS	FM	C16H14
DMFY3VS	IC	InChI=1S/C16H14/c1-3-9-15(10-4-1)13-7-8-14-16-11-5-2-6-12-16/h1-14H/b13-7+,14-8+
DMFY3VS	CS	C1=CC=C(C=C1)/C=C/C=C/C2=CC=CC=C2
DMFY3VS	IK	JFLKFZNIIQFQBS-FNCQTZNRSA-N
DMFY3VS	IU	[(1E,3E)-4-phenylbuta-1,3-dienyl]benzene
DMFY3VS	CA	CAS 538-81-8
DMFY3VS	CB	CHEBI:35100
DMFY3VS	DE	Discovery agent

DMIFOXE	ID	DMIFOXE
DMIFOXE	DN	1,4-Dithiothreitol
DMIFOXE	HS	Investigative
DMIFOXE	SN	Cleland's reagent; Dithiothreitol; 1,4-Dithiothreitol; Dithiotreitol; 1,4-Dimercaptobutane-2,3-diol; dl-Dithiothreitol; rac-Dithiothreitol; Cleland reagent; 7634-42-6; 1,4-disulfanylbutane-2,3-diol; Clelands reagent; Sputolysin; DL-threo-1,4-Dimercapto-2,3-butanediol; 1,4-dimercapto-2,3-butanediol; 3483-12-3; 2,3-Butanediol, 1,4-dimercapto-; Threitol, 1,4-dithio-; 1,4-bis(sulfanyl)butane-2,3-diol; trans-1,4-Dimercaptobutane-2,3-diol; L-1,4-Dithiothreitol; L-Dithiothreitol; CHEBI:18320; 1,4-Bissulfanylbutane-2,3-diol
DMIFOXE	DT	Small molecular drug
DMIFOXE	PC	19001
DMIFOXE	MW	154.3
DMIFOXE	FM	C4H10O2S2
DMIFOXE	IC	InChI=1S/C4H10O2S2/c5-3(1-7)4(6)2-8/h3-8H,1-2H2
DMIFOXE	CS	C(C(C(CS)O)O)S
DMIFOXE	IK	VHJLVAABSRFDPM-UHFFFAOYSA-N
DMIFOXE	IU	1,4-bis(sulfanyl)butane-2,3-diol
DMIFOXE	CA	CAS 7634-42-6
DMIFOXE	CB	CHEBI:18320
DMIFOXE	DE	Discovery agent

DMTCMH7	ID	DMTCMH7
DMTCMH7	DN	1,4-Naphthoquinone
DMTCMH7	HS	Investigative
DMTCMH7	SN	1,4-NAPHTHOQUINONE; 130-15-4; naphthalene-1,4-dione; p-Naphthoquinone; NAPHTHOQUINONE; alpha-Naphthoquinone; 1,4-Naphthylquinone; USAF CY-10; 1,4-dihydronaphthalene-1,4-dione; 1,4-Dihydro-1,4-diketonaphthalene; 1,4-Naftochinon; RCRA waste number U166; UNII-RBF5ZU7R7K; NSC 9583; 1,4-Naftochinon [Czech]; 1,4-Naphthaquinone; CCRIS 5424; HSDB 2037; EINECS 204-977-6; RBF5ZU7R7K; RCRA waste no U166; CHEMBL55934; AI3-24292; NQ-1; CHEBI:27418; NSC9583; FRASJONUBLZVQX-UHFFFAOYSA-N; MFCD00001676; 1,4-naphtho-quinone
DMTCMH7	DT	Small molecular drug
DMTCMH7	PC	8530
DMTCMH7	MW	158.15
DMTCMH7	FM	C10H6O2
DMTCMH7	IC	InChI=1S/C10H6O2/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6H
DMTCMH7	CS	C1=CC=C2C(=O)C=CC(=O)C2=C1
DMTCMH7	IK	FRASJONUBLZVQX-UHFFFAOYSA-N
DMTCMH7	IU	naphthalene-1,4-dione
DMTCMH7	CA	CAS 130-15-4
DMTCMH7	CB	CHEBI:27418
DMTCMH7	DE	Discovery agent

DMEDBO2	ID	DMEDBO2
DMEDBO2	DN	1,4-phenylene disulfamate
DMEDBO2	HS	Investigative
DMEDBO2	SN	1,4-phenylene disulfamate; CHEMBL461964
DMEDBO2	DT	Small molecular drug
DMEDBO2	PC	44564283
DMEDBO2	MW	268.3
DMEDBO2	FM	C6H8N2O6S2
DMEDBO2	IC	InChI=1S/C6H8N2O6S2/c7-15(9,10)13-5-1-2-6(4-3-5)14-16(8,11)12/h1-4H,(H2,7,9,10)(H2,8,11,12)
DMEDBO2	CS	C1=CC(=CC=C1OS(=O)(=O)N)OS(=O)(=O)N
DMEDBO2	IK	BPEJBYDTMVTZIA-UHFFFAOYSA-N
DMEDBO2	IU	(4-sulfamoyloxyphenyl) sulfamate
DMEDBO2	DE	Discovery agent

DMF0RXK	ID	DMF0RXK
DMF0RXK	DN	1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole
DMF0RXK	HS	Investigative
DMF0RXK	SN	CHEMBL503677; 1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole
DMF0RXK	DT	Small molecular drug
DMF0RXK	PC	44572111
DMF0RXK	MW	290.1
DMF0RXK	FM	C14H9Cl2N3
DMF0RXK	IC	InChI=1S/C14H9Cl2N3/c15-11-3-1-10(2-4-11)14-9-17-18-19(14)13-7-5-12(16)6-8-13/h1-9H
DMF0RXK	CS	C1=CC(=CC=C1C2=CN=NN2C3=CC=C(C=C3)Cl)Cl
DMF0RXK	IK	RXDUBIUDBWNEMF-UHFFFAOYSA-N
DMF0RXK	IU	1,5-bis(4-chlorophenyl)triazole
DMF0RXK	DE	Discovery agent

DMPOAB7	ID	DMPOAB7
DMPOAB7	DN	1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one
DMPOAB7	HS	Investigative
DMPOAB7	SN	3654-49-7; (1E,4E)-1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one; 1,5-Bis(4-hydroxyphenyl)penta-1,4-dien-3-one; Bis-1,5-(4-Hydroxyphenyl)-1,4-Pentadien-3-one; 1,5-Bis-(4-hydroxyphenyl)-1,4-pentadien-3-one; CHEMBL129134; EINECS 222-896-4; AC1O5NFJ; 1,5-Di(p-hydroxyphenyl)-1,4-pentadien-3-one; 1,5-BIS(4-HYDROXYPHENYL)-1,4-PENTADIEN-3-ONE; 4,4'-Dihydroxydistyrylketon; ZINC6092599; BDBM50067044; AKOS015962226; CD-1056; M064; CC-03405; AC-16155; A823289; C-35230; 654B497; 1,5-Bis-(4-hydroxy-phenyl)-penta-1,4-dien-3-one; W-106603
DMPOAB7	DT	Small molecular drug
DMPOAB7	PC	6437306
DMPOAB7	MW	266.29
DMPOAB7	FM	C17H14O3
DMPOAB7	IC	InChI=1S/C17H14O3/c18-15-7-1-13(2-8-15)5-11-17(20)12-6-14-3-9-16(19)10-4-14/h1-12,18-19H/b11-5+,12-6+
DMPOAB7	CS	C1=CC(=CC=C1/C=C/C(=O)/C=C/C2=CC=C(C=C2)O)O
DMPOAB7	IK	FTEGUKWEUQPKIS-YDWXAUTNSA-N
DMPOAB7	IU	(1E,4E)-1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one
DMPOAB7	CA	CAS 3654-49-7
DMPOAB7	DE	Discovery agent

DMZU1GD	ID	DMZU1GD
DMZU1GD	DN	1,5-Dideoxy-1,5-imino-D-xylitol
DMZU1GD	HS	Investigative
DMZU1GD	SN	PIPERIDINE-3,4,5-TRIOL; (3R,4r,5S)-piperidine-3,4,5-triol; CHEMBL110830; 13042-55-2; 1,5-dideoxy-1,5-imino-xylitol; XYLOSE-DERIVED 1-DEOXY-NOJIRIMYCIN; XDN; dideoxyiminoxylitol; 1,5-Dideoxy-1,5-imino-D-xylitol; AC1L9IA9; SCHEMBL955713; SCHEMBL2435095; SCHEMBL2435099; 1,5-dideoxy-1,5-iminoxylitol; MolPort-042-605-431; 172588-13-5; 3alpha,4beta,5alpha-Piperidinetriol; FCH951710; 3alpha,4alpha,5alpha-Piperidinetriol; BDBM50182798; (3S,5R)-piperidine-3,4,5-triol; AKOS006351347; ZINC104595290; ZINC100872034; AKOS006294154
DMZU1GD	DT	Small molecular drug
DMZU1GD	PC	445612
DMZU1GD	MW	133.15
DMZU1GD	FM	C5H11NO3
DMZU1GD	IC	InChI=1S/C5H11NO3/c7-3-1-6-2-4(8)5(3)9/h3-9H,1-2H2/t3-,4+,5?
DMZU1GD	CS	C1[C@H](C([C@H](CN1)O)O)O
DMZU1GD	IK	RMCNETIHECSPMZ-NGQZWQHPSA-N
DMZU1GD	IU	(3S,5R)-piperidine-3,4,5-triol
DMZU1GD	DE	Discovery agent

DMYA25G	ID	DMYA25G
DMYA25G	DN	1,5-Dihydro-imidazo[2,1-b]quinazolin-2-one
DMYA25G	HS	Investigative
DMYA25G	DT	Small molecular drug
DMYA25G	PC	10130278
DMYA25G	DE	Discovery agent

DMC7FLT	ID	DMC7FLT
DMC7FLT	DN	1,5-Dihydroxy-10H-anthracen-9-one
DMC7FLT	HS	Investigative
DMC7FLT	SN	1,5-dihydroxyanthrone; CHEMBL333452; 1,5-Dihydroxy-10H-anthracen-9-one; SCHEMBL8756171; MYYRAEQRSBLQQO-UHFFFAOYSA-N; ZINC13606493; BDBM50060873
DMC7FLT	DT	Small molecular drug
DMC7FLT	PC	13486778
DMC7FLT	MW	226.23
DMC7FLT	FM	C14H10O3
DMC7FLT	IC	InChI=1S/C14H10O3/c15-11-5-2-4-9-10(11)7-8-3-1-6-12(16)13(8)14(9)17/h1-6,15-16H,7H2
DMC7FLT	CS	C1C2=C(C(=CC=C2)O)C(=O)C3=C1C(=CC=C3)O
DMC7FLT	IK	MYYRAEQRSBLQQO-UHFFFAOYSA-N
DMC7FLT	IU	1,5-dihydroxy-10H-anthracen-9-one
DMC7FLT	DE	Discovery agent

DMDFU6S	ID	DMDFU6S
DMDFU6S	DN	1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane
DMDFU6S	HS	Investigative
DMDFU6S	SN	CHEMBL1171823; 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane; SCHEMBL4525555
DMDFU6S	DT	Small molecular drug
DMDFU6S	PC	11641429
DMDFU6S	MW	475.5
DMDFU6S	FM	C26H36Cl2N4
DMDFU6S	IC	InChI=1S/C26H36Cl2N4/c27-23-7-5-9-25(21-23)31-17-13-29(14-18-31)11-3-1-2-4-12-30-15-19-32(20-16-30)26-10-6-8-24(28)22-26/h5-10,21-22H,1-4,11-20H2
DMDFU6S	CS	C1CN(CCN1CCCCCCN2CCN(CC2)C3=CC(=CC=C3)Cl)C4=CC(=CC=C4)Cl
DMDFU6S	IK	YWGRWBCJUGEEBA-UHFFFAOYSA-N
DMDFU6S	IU	1-(3-chlorophenyl)-4-[6-[4-(3-chlorophenyl)piperazin-1-yl]hexyl]piperazine
DMDFU6S	DE	Discovery agent

DMNLUKS	ID	DMNLUKS
DMNLUKS	DN	1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane
DMNLUKS	HS	Investigative
DMNLUKS	SN	CHEMBL1172206; 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane; SCHEMBL4525293
DMNLUKS	DT	Small molecular drug
DMNLUKS	PC	11568942
DMNLUKS	MW	466.7
DMNLUKS	FM	C28H42N4O2
DMNLUKS	IC	InChI=1S/C28H42N4O2/c1-33-27-11-7-9-25(23-27)31-19-15-29(16-20-31)13-5-3-4-6-14-30-17-21-32(22-18-30)26-10-8-12-28(24-26)34-2/h7-12,23-24H,3-6,13-22H2,1-2H3
DMNLUKS	CS	COC1=CC=CC(=C1)N2CCN(CC2)CCCCCCN3CCN(CC3)C4=CC(=CC=C4)OC
DMNLUKS	IK	IMWNCWRNMUKPGO-UHFFFAOYSA-N
DMNLUKS	IU	1-(3-methoxyphenyl)-4-[6-[4-(3-methoxyphenyl)piperazin-1-yl]hexyl]piperazine
DMNLUKS	DE	Discovery agent

DM0GRMD	ID	DM0GRMD
DM0GRMD	DN	1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane
DM0GRMD	HS	Investigative
DM0GRMD	SN	CHEMBL1171644; 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane; SCHEMBL4519313
DM0GRMD	DT	Small molecular drug
DM0GRMD	PC	11524350
DM0GRMD	MW	408.6
DM0GRMD	FM	C24H36N6
DM0GRMD	IC	InChI=1S/C24H36N6/c1(7-13-27-15-19-29(20-16-27)23-9-3-5-11-25-23)2-8-14-28-17-21-30(22-18-28)24-10-4-6-12-26-24/h3-6,9-12H,1-2,7-8,13-22H2
DM0GRMD	CS	C1CN(CCN1CCCCCCN2CCN(CC2)C3=CC=CC=N3)C4=CC=CC=N4
DM0GRMD	IK	OSEVIYJKDQCRJK-UHFFFAOYSA-N
DM0GRMD	IU	1-pyridin-2-yl-4-[6-(4-pyridin-2-ylpiperazin-1-yl)hexyl]piperazine
DM0GRMD	DE	Discovery agent

DM70ODN	ID	DM70ODN
DM70ODN	DN	1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene
DM70ODN	HS	Investigative
DM70ODN	SN	CHEMBL208456; SCHEMBL9750157; ZINC13686481; BDBM50185992
DM70ODN	DT	Small molecular drug
DM70ODN	PC	11507217
DM70ODN	MW	262.3
DM70ODN	FM	C18H18N2
DM70ODN	IC	InChI=1S/C18H18N2/c19-17-11-7-15(8-12-17)5-3-1-2-4-6-16-9-13-18(20)14-10-16/h1-14H,19-20H2/b2-1+,5-3+,6-4+
DM70ODN	CS	C1=CC(=CC=C1/C=C/C=C/C=C/C2=CC=C(C=C2)N)N
DM70ODN	IK	IZOOKGZEMKOBQA-CRQXNEITSA-N
DM70ODN	IU	4-[(1E,3E,5E)-6-(4-aminophenyl)hexa-1,3,5-trienyl]aniline
DM70ODN	DE	Discovery agent

DMBCU6W	ID	DMBCU6W
DMBCU6W	DN	1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene
DMBCU6W	HS	Investigative
DMBCU6W	SN	CHEMBL377929; BDBM50185990; 1,6-Bis[4-(dimethylamino)phenyl]-1,3,5-hexatriene; 1,6-bis(4''-dimethylaminophenyl)-hexa-1,3,5-triene
DMBCU6W	DT	Small molecular drug
DMBCU6W	PC	11537013
DMBCU6W	MW	318.5
DMBCU6W	FM	C22H26N2
DMBCU6W	IC	InChI=1S/C22H26N2/c1-23(2)21-15-11-19(12-16-21)9-7-5-6-8-10-20-13-17-22(18-14-20)24(3)4/h5-18H,1-4H3/b6-5+,9-7+,10-8+
DMBCU6W	CS	CN(C1=CC=C(C=C1)/C=C/C=C/C=C/C2=CC=C(C=C2)N(C)C)C
DMBCU6W	IK	JGQHLETVKDCCET-NRIIQWGUSA-N
DMBCU6W	IU	4-[(1E,3E,5E)-6-[4-(dimethylamino)phenyl]hexa-1,3,5-trienyl]-N,N-dimethylaniline
DMBCU6W	DE	Discovery agent

DMEU3MN	ID	DMEU3MN
DMEU3MN	DN	1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene
DMEU3MN	HS	Investigative
DMEU3MN	SN	CHEMBL381731; ZINC13686478; BDBM50185986; 4,4'-(1,3,5-Hexatriene-1,6-diyl)bisphenol
DMEU3MN	DT	Small molecular drug
DMEU3MN	PC	11587026
DMEU3MN	MW	264.3
DMEU3MN	FM	C18H16O2
DMEU3MN	IC	InChI=1S/C18H16O2/c19-17-11-7-15(8-12-17)5-3-1-2-4-6-16-9-13-18(20)14-10-16/h1-14,19-20H/b2-1+,5-3+,6-4+
DMEU3MN	CS	C1=CC(=CC=C1/C=C/C=C/C=C/C2=CC=C(C=C2)O)O
DMEU3MN	IK	FXGYAFMJWIVHGO-CRQXNEITSA-N
DMEU3MN	IU	4-[(1E,3E,5E)-6-(4-hydroxyphenyl)hexa-1,3,5-trienyl]phenol
DMEU3MN	DE	Discovery agent

DM0D6JN	ID	DM0D6JN
DM0D6JN	DN	1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene
DM0D6JN	HS	Investigative
DM0D6JN	SN	CHEMBL208457; ZINC13686485; BDBM50185991
DM0D6JN	DT	Small molecular drug
DM0D6JN	PC	11608986
DM0D6JN	MW	290.4
DM0D6JN	FM	C20H22N2
DM0D6JN	IC	InChI=1S/C20H22N2/c1-21-19-13-9-17(10-14-19)7-5-3-4-6-8-18-11-15-20(22-2)16-12-18/h3-16,21-22H,1-2H3/b4-3+,7-5+,8-6+
DM0D6JN	CS	CNC1=CC=C(C=C1)/C=C/C=C/C=C/C2=CC=C(C=C2)NC
DM0D6JN	IK	SWZSFUMMCHKHMM-OKWWDJPNSA-N
DM0D6JN	IU	N-methyl-4-[(1E,3E,5E)-6-[4-(methylamino)phenyl]hexa-1,3,5-trienyl]aniline
DM0D6JN	DE	Discovery agent

DM5Z6XG	ID	DM5Z6XG
DM5Z6XG	DN	1,6-bis(4-m-tolylpiperazin-1-yl)hexane
DM5Z6XG	HS	Investigative
DM5Z6XG	SN	CHEMBL1172204; 1,6-bis(4-m-tolylpiperazin-1-yl)hexane; SCHEMBL4519876
DM5Z6XG	DT	Small molecular drug
DM5Z6XG	PC	11669239
DM5Z6XG	MW	434.7
DM5Z6XG	FM	C28H42N4
DM5Z6XG	IC	InChI=1S/C28H42N4/c1-25-9-7-11-27(23-25)31-19-15-29(16-20-31)13-5-3-4-6-14-30-17-21-32(22-18-30)28-12-8-10-26(2)24-28/h7-12,23-24H,3-6,13-22H2,1-2H3
DM5Z6XG	CS	CC1=CC(=CC=C1)N2CCN(CC2)CCCCCCN3CCN(CC3)C4=CC=CC(=C4)C
DM5Z6XG	IK	CQEUVRXXXLSTIL-UHFFFAOYSA-N
DM5Z6XG	IU	1-(3-methylphenyl)-4-[6-[4-(3-methylphenyl)piperazin-1-yl]hexyl]piperazine
DM5Z6XG	DE	Discovery agent

DMQY75B	ID	DMQY75B
DMQY75B	DN	1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene
DMQY75B	HS	Investigative
DMQY75B	SN	CHEMBL205899; 1,6-Bis(4-nitrophenyl)-1,3,5-hexatriene; AC1O1Q5Y; SCHEMBL9750443; ZINC3080662; BDBM50185989; AKOS024339803; 1,6-bis(4''-nitrophenyl)-hexa-1,3,5-triene; (1E,3E,5E)-1,6-Bis(4-nitrophenyl)-1,3,5-hexatriene
DMQY75B	DT	Small molecular drug
DMQY75B	PC	6177872
DMQY75B	MW	322.3
DMQY75B	FM	C18H14N2O4
DMQY75B	IC	InChI=1S/C18H14N2O4/c21-19(22)17-11-7-15(8-12-17)5-3-1-2-4-6-16-9-13-18(14-10-16)20(23)24/h1-14H/b2-1+,5-3+,6-4+
DMQY75B	CS	C1=CC(=CC=C1/C=C/C=C/C=C/C2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-]
DMQY75B	IK	OYPMHQIMQGZDHK-CRQXNEITSA-N
DMQY75B	IU	1-nitro-4-[(1E,3E,5E)-6-(4-nitrophenyl)hexa-1,3,5-trienyl]benzene
DMQY75B	DE	Discovery agent

DMD3EUI	ID	DMD3EUI
DMD3EUI	DN	1,6-bis(4-phenylpiperazin-1-yl)hexane
DMD3EUI	HS	Investigative
DMD3EUI	SN	CHEMBL1172205; 1,6-bis(4-phenylpiperazin-1-yl)hexane; SCHEMBL4528457
DMD3EUI	DT	Small molecular drug
DMD3EUI	PC	11567667
DMD3EUI	MW	406.6
DMD3EUI	FM	C26H38N4
DMD3EUI	IC	InChI=1S/C26H38N4/c1(9-15-27-17-21-29(22-18-27)25-11-5-3-6-12-25)2-10-16-28-19-23-30(24-20-28)26-13-7-4-8-14-26/h3-8,11-14H,1-2,9-10,15-24H2
DMD3EUI	CS	C1CN(CCN1CCCCCCN2CCN(CC2)C3=CC=CC=C3)C4=CC=CC=C4
DMD3EUI	IK	ORESESSHUCUUFK-UHFFFAOYSA-N
DMD3EUI	IU	1-phenyl-4-[6-(4-phenylpiperazin-1-yl)hexyl]piperazine
DMD3EUI	DE	Discovery agent

DMRG2CU	ID	DMRG2CU
DMRG2CU	DN	1,6-bis-(Dmt-Tic-amino)hexane
DMRG2CU	HS	Investigative
DMRG2CU	SN	CHEMBL197185; 1,6-bis-(Dmt-Tic-amino)hexane
DMRG2CU	DT	Small molecular drug
DMRG2CU	PC	44405159
DMRG2CU	MW	817
DMRG2CU	FM	C48H60N6O6
DMRG2CU	IC	InChI=1S/C48H60N6O6/c1-29-19-37(55)20-30(2)39(29)25-41(49)47(59)53-27-35-15-9-7-13-33(35)23-43(53)45(57)51-17-11-5-6-12-18-52-46(58)44-24-34-14-8-10-16-36(34)28-54(44)48(60)42(50)26-40-31(3)21-38(56)22-32(40)4/h7-10,13-16,19-22,41-44,55-56H,5-6,11-12,17-18,23-28,49-50H2,1-4H3,(H,51,57)(H,52,58)/t41-,42-,43?,44?/m0/s1
DMRG2CU	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCNC(=O)C4CC5=CC=CC=C5CN4C(=O)[C@H](CC6=C(C=C(C=C6C)O)C)N)N)C)O
DMRG2CU	IK	VJIXEMXKNBJTQB-GCGBLBKRSA-N
DMRG2CU	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMRG2CU	DE	Discovery agent

DMMUZK9	ID	DMMUZK9
DMMUZK9	DN	1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane
DMMUZK9	HS	Investigative
DMMUZK9	SN	CHEMBL370399; 1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane
DMMUZK9	DT	Small molecular drug
DMMUZK9	PC	44405153
DMMUZK9	MW	873.1
DMMUZK9	FM	C52H68N6O6
DMMUZK9	IC	InChI=1S/C52H68N6O6/c1-33-23-41(59)24-34(2)43(33)29-47(55(5)6)51(63)57-31-39-19-13-11-17-37(39)27-45(57)49(61)53-21-15-9-10-16-22-54-50(62)46-28-38-18-12-14-20-40(38)32-58(46)52(64)48(56(7)8)30-44-35(3)25-42(60)26-36(44)4/h11-14,17-20,23-26,45-48,59-60H,9-10,15-16,21-22,27-32H2,1-8H3,(H,53,61)(H,54,62)/t45?,46?,47-,48-/m0/s1
DMMUZK9	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCNC(=O)C4CC5=CC=CC=C5CN4C(=O)[C@H](CC6=C(C=C(C=C6C)O)C)N(C)C)N(C)C)C)O
DMMUZK9	IK	WQLMNYRHCQXDKA-QYXCYUBVSA-N
DMMUZK9	IU	2-[(2S)-2-(dimethylamino)-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-[[2-[(2S)-2-(dimethylamino)-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMMUZK9	DE	Discovery agent

DMLB3RT	ID	DMLB3RT
DMLB3RT	DN	1,6-hexamethylene diisocyanate
DMLB3RT	HS	Investigative
DMLB3RT	SN	HMDI; HDI
DMLB3RT	DT	Small molecular drug
DMLB3RT	PC	13192
DMLB3RT	MW	168.19
DMLB3RT	FM	C8H12N2O2
DMLB3RT	IC	InChI=1S/C8H12N2O2/c11-7-9-5-3-1-2-4-6-10-8-12/h1-6H2
DMLB3RT	CS	C(CCCN=C=O)CCN=C=O
DMLB3RT	IK	RRAMGCGOFNQTLD-UHFFFAOYSA-N
DMLB3RT	IU	1,6-diisocyanatohexane
DMLB3RT	CA	CAS 822-06-0
DMLB3RT	CB	CHEBI:53578
DMLB3RT	DE	Discovery agent

DMBU796	ID	DMBU796
DMBU796	DN	1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione
DMBU796	HS	Investigative
DMBU796	SN	CHEMBL201907; 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione; SCHEMBL2086780; ZINC28569089
DMBU796	DT	Small molecular drug
DMBU796	PC	11506860
DMBU796	MW	226.23
DMBU796	FM	C13H10N2O2
DMBU796	IC	InChI=1S/C13H10N2O2/c16-12-9-6-2-1-3-7(6)11-8(4-5-14-11)10(9)13(17)15-12/h4-5,14H,1-3H2,(H,15,16,17)
DMBU796	CS	C1CC2=C3C(=C4C=CNC4=C2C1)C(=O)NC3=O
DMBU796	IK	NMFHMHLMLQVGMW-UHFFFAOYSA-N
DMBU796	IU	3,9-diazatetracyclo[10.3.0.02,6.07,11]pentadeca-1,4,6,11-tetraene-8,10-dione
DMBU796	DE	Discovery agent

DMVHE1P	ID	DMVHE1P
DMVHE1P	DN	1,8,9-Trimethoxy-9,10-dihydro-anthracene
DMVHE1P	HS	Investigative
DMVHE1P	SN	CHEMBL125328; 1,8,9-Trimethoxy-9,10-dihydro-anthracene
DMVHE1P	DT	Small molecular drug
DMVHE1P	PC	44348682
DMVHE1P	MW	270.32
DMVHE1P	FM	C17H18O3
DMVHE1P	IC	InChI=1S/C17H18O3/c1-18-13-8-4-6-11-10-12-7-5-9-14(19-2)16(12)17(20-3)15(11)13/h4-9,17H,10H2,1-3H3
DMVHE1P	CS	COC1C2=C(CC3=C1C(=CC=C3)OC)C=CC=C2OC
DMVHE1P	IK	SEFFBCQMWOLCMQ-UHFFFAOYSA-N
DMVHE1P	IU	1,8,9-trimethoxy-9,10-dihydroanthracene
DMVHE1P	DE	Discovery agent

DMKJGTH	ID	DMKJGTH
DMKJGTH	DN	1,8-bis-maleimidodiethyleneglycol
DMKJGTH	HS	Investigative
DMKJGTH	SN	115597-84-7; UNII-R20U86RE9F; 1,8-bis-maleimidodiethyleneglycol; 1,8-Bis(maleimido)-3,6-dioxaoctane; CHEMBL575383; R20U86RE9F; 2,2'-(Ethylenedioxy)bis(ethylmaleimide); Liqwd; 1H-Pyrrole-2,5-dione, 1,1'-(1,2-ethanediylbis(oxy-2,1-ethanediyl))bis-; Bis-(maleimidoethoxy) ethane; BM(peg)2; 1,1'-[ethane-1,2-Diylbis(Oxyethane-2,1-Diyl)]bis(1h-Pyrrole-2,5-Dione); 1H-Pyrrole-2,5-dione, 1,1'-[1,2-ethanediylbis(oxy-2,1-ethanediyl)]bis-; 1,2-bis(2-maleimidoethoxy)ethane; Bis-(maleimidoethoxy) ethane [INCI]; AC1MVX1G; SCHEMBL349749
DMKJGTH	DT	Small molecular drug
DMKJGTH	PC	3690297
DMKJGTH	MW	308.29
DMKJGTH	FM	C14H16N2O6
DMKJGTH	IC	InChI=1S/C14H16N2O6/c17-11-1-2-12(18)15(11)5-7-21-9-10-22-8-6-16-13(19)3-4-14(16)20/h1-4H,5-10H2
DMKJGTH	CS	C1=CC(=O)N(C1=O)CCOCCOCCN2C(=O)C=CC2=O
DMKJGTH	IK	FERLGYOHRKHQJP-UHFFFAOYSA-N
DMKJGTH	IU	1-[2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethyl]pyrrole-2,5-dione
DMKJGTH	CA	CAS 115597-84-7
DMKJGTH	DE	Discovery agent

DMZK4DL	ID	DMZK4DL
DMZK4DL	DN	1,8-Dichloro-10H-anthracen-9-one
DMZK4DL	HS	Investigative
DMZK4DL	SN	1,8-Dichloro-10H-anthracen-9-one; CHEMBL122022; 50259-93-3; NSC162539; 1,8-Dichloroanthrone; AC1Q3KGA; AC1L9O6M; SCHEMBL7103871; CTK1H2907; DTXSID70329816; ZINC393214; BDBM50060867; AKOS024331862; NSC-162539; MCULE-9362278595
DMZK4DL	DT	Small molecular drug
DMZK4DL	PC	424114
DMZK4DL	MW	263.1
DMZK4DL	FM	C14H8Cl2O
DMZK4DL	IC	InChI=1S/C14H8Cl2O/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-6H,7H2
DMZK4DL	CS	C1C2=C(C(=CC=C2)Cl)C(=O)C3=C1C=CC=C3Cl
DMZK4DL	IK	AYDNUUZHQKPRKA-UHFFFAOYSA-N
DMZK4DL	IU	1,8-dichloro-10H-anthracen-9-one
DMZK4DL	CA	CAS 50259-93-3
DMZK4DL	DE	Discovery agent

DMKJBRZ	ID	DMKJBRZ
DMKJBRZ	DN	1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMKJBRZ	HS	Investigative
DMKJBRZ	SN	CHEMBL192876; 1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL4456831; YTFVBUBYMJJWQZ-UHFFFAOYSA-N; ZINC13645103; BDBM50168322
DMKJBRZ	DT	Small molecular drug
DMKJBRZ	PC	10149584
DMKJBRZ	MW	305.2
DMKJBRZ	FM	C16H10Cl2O2
DMKJBRZ	IC	InChI=1S/C16H10Cl2O2/c17-13-8-11(9-1-4-12(19)5-2-9)7-10-3-6-14(20)16(18)15(10)13/h1-8,19-20H
DMKJBRZ	CS	C1=CC(=CC=C1C2=CC(=C3C(=C2)C=CC(=C3Cl)O)Cl)O
DMKJBRZ	IK	YTFVBUBYMJJWQZ-UHFFFAOYSA-N
DMKJBRZ	IU	1,8-dichloro-6-(4-hydroxyphenyl)naphthalen-2-ol
DMKJBRZ	DE	Discovery agent

DMDFBSX	ID	DMDFBSX
DMDFBSX	DN	1,8-Dihydroxy-2-propionyl-10H-anthracen-9-one
DMDFBSX	HS	Investigative
DMDFBSX	SN	CHEMBL126057; 1,8-Dihydroxy-2-propionyl-10H-anthracen-9-one; BDBM50060901
DMDFBSX	DT	Small molecular drug
DMDFBSX	PC	10779243
DMDFBSX	MW	282.29
DMDFBSX	FM	C17H14O4
DMDFBSX	IC	InChI=1S/C17H14O4/c1-2-12(18)11-7-6-10-8-9-4-3-5-13(19)14(9)17(21)15(10)16(11)20/h3-7,19-20H,2,8H2,1H3
DMDFBSX	CS	CCC(=O)C1=C(C2=C(CC3=C(C2=O)C(=CC=C3)O)C=C1)O
DMDFBSX	IK	KGAHUIIBPUKUER-UHFFFAOYSA-N
DMDFBSX	IU	1,8-dihydroxy-2-propanoyl-10H-anthracen-9-one
DMDFBSX	DE	Discovery agent

DMWC7QE	ID	DMWC7QE
DMWC7QE	DN	1,9-bis(pyridinium)-nonane dibromide
DMWC7QE	HS	Investigative
DMWC7QE	SN	1,9-bis(pyridinium)-nonane dibromide; CHEMBL105742; SCHEMBL3591238; UOOOOWOODBZUKX-UHFFFAOYSA-L; N,N'-Nonane-1,9-diyl-bis-pyridinium Dibromide; 1,9-Di(1-Pyridiniumyl)Nonane With Dibromide Ions
DMWC7QE	DT	Small molecular drug
DMWC7QE	PC	11408144
DMWC7QE	MW	444.2
DMWC7QE	FM	C19H28Br2N2
DMWC7QE	IC	InChI=1S/C19H28N2.2BrH/c1(2-4-8-14-20-16-10-6-11-17-20)3-5-9-15-21-18-12-7-13-19-21;;/h6-7,10-13,16-19H,1-5,8-9,14-15H2;2*1H/q+2;;/p-2
DMWC7QE	CS	C1=CC=[N+](C=C1)CCCCCCCCC[N+]2=CC=CC=C2.[Br-].[Br-]
DMWC7QE	IK	UOOOOWOODBZUKX-UHFFFAOYSA-L
DMWC7QE	IU	1-(9-pyridin-1-ium-1-ylnonyl)pyridin-1-ium;dibromide
DMWC7QE	DE	Discovery agent

DMW613U	ID	DMW613U
DMW613U	DN	1,9-dideoxyforskolin
DMW613U	HS	Investigative
DMW613U	SN	1,9-DIDEOXYFORSKOLIN; UNII-OAW710HWIX; 64657-18-7; OAW710HWIX; CHEBI:50295; (3R,4aS,5S,6S,6aS,10aS,10bR)-3-ethenyl-6-hydroxy-3,4a,7,7,10a-pentamethyl-1-oxododecahydro-1H-benzo[f]chromen-5-yl acetate; 7beta-acetoxy-8,13-epoxy-6beta-hydroxylabd-14-en-11-one; (3R,4aS,5S,6S,6aS,10aS,10bR)-5-(acetyloxy)-3-ethenyldodecahydro-6-hydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho(2,1-b)pyran-1-one
DMW613U	DT	Small molecular drug
DMW613U	PC	107948
DMW613U	MW	378.5
DMW613U	FM	C22H34O5
DMW613U	IC	InChI=1S/C22H34O5/c1-8-20(5)12-14(24)16-21(6)11-9-10-19(3,4)17(21)15(25)18(26-13(2)23)22(16,7)27-20/h8,15-18,25H,1,9-12H2,2-7H3/t15-,16+,17-,18-,20-,21+,22-/m0/s1
DMW613U	CS	CC(=O)O[C@H]1[C@H]([C@@H]2[C@](CCCC2(C)C)([C@@H]3[C@@]1(O[C@@](CC3=O)(C)C=C)C)C)O
DMW613U	IK	ZKZMDXUDDJYAIB-SUCLLAFCSA-N
DMW613U	IU	[(3R,4aS,5S,6S,6aS,10aS,10bR)-3-ethenyl-6-hydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-2,5,6,6a,8,9,10,10b-octahydrobenzo[f]chromen-5-yl] acetate
DMW613U	CA	CAS 64657-18-7
DMW613U	CB	CHEBI:50295
DMW613U	DE	Discovery agent

DM7U0XW	ID	DM7U0XW
DM7U0XW	DN	1-[(3-Methoxybenzyl)amino]ethaniminium chloride
DM7U0XW	HS	Investigative
DM7U0XW	SN	1-[(3-Methoxybenzyl)amino]ethaniminium chloride
DM7U0XW	DT	Small molecular drug
DM7U0XW	PC	52940828
DM7U0XW	MW	214.69
DM7U0XW	FM	C10H15ClN2O
DM7U0XW	IC	InChI=1S/C10H14N2O.ClH/c1-8(11)12-7-9-4-3-5-10(6-9)13-2;/h3-6H,7H2,1-2H3,(H2,11,12);1H
DM7U0XW	CS	CC(=NCC1=CC(=CC=C1)OC)N.Cl
DM7U0XW	IK	KAHXLIVOQBJXSB-UHFFFAOYSA-N
DM7U0XW	IU	N'-[(3-methoxyphenyl)methyl]ethanimidamide;hydrochloride
DM7U0XW	DE	Discovery agent

DM3UHDW	ID	DM3UHDW
DM3UHDW	DN	1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene
DM3UHDW	HS	Investigative
DM3UHDW	DT	Small molecular drug
DM3UHDW	PC	11973921
DM3UHDW	MW	318.4
DM3UHDW	FM	C22H22O2
DM3UHDW	IC	InChI=1S/C22H22O2/c1-23-21-12-7-10-19(16-21)17-24-22-13-6-5-11-20(22)15-14-18-8-3-2-4-9-18/h2-13,16H,14-15,17H2,1H3
DM3UHDW	CS	COC1=CC=CC(=C1)COC2=CC=CC=C2CCC3=CC=CC=C3
DM3UHDW	IK	GYSNUAVEYIUVBT-UHFFFAOYSA-N
DM3UHDW	IU	1-methoxy-3-[[2-(2-phenylethyl)phenoxy]methyl]benzene
DM3UHDW	DE	Discovery agent

DMNJMGK	ID	DMNJMGK
DMNJMGK	DN	1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole
DMNJMGK	HS	Investigative
DMNJMGK	SN	CHEMBL1098424; 1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole
DMNJMGK	DT	Small molecular drug
DMNJMGK	PC	46887506
DMNJMGK	MW	226.25
DMNJMGK	FM	C14H11FN2
DMNJMGK	IC	InChI=1S/C14H11FN2/c15-14-4-3-12-2-1-11(7-13(12)8-14)9-17-6-5-16-10-17/h1-8,10H,9H2
DMNJMGK	CS	C1=CC(=CC2=C1C=CC(=C2)F)CN3C=CN=C3
DMNJMGK	IK	SFBANCVOUQRQEX-UHFFFAOYSA-N
DMNJMGK	IU	1-[(7-fluoronaphthalen-2-yl)methyl]imidazole
DMNJMGK	DE	Discovery agent

DM1JQPW	ID	DM1JQPW
DM1JQPW	DN	1-[(cyclohexylamino)ethyl]-1,1-bisphosphonicacid
DM1JQPW	HS	Investigative
DM1JQPW	SN	CHEMBL261432; [2-(Cyclohexylamino)ethane-1,1-Diyl]bisphosphonic Acid; 2-(cyclohexylamino)ethylidene-1,1-bisphosphonic acid; SCHEMBL9564518; BDBM50374762; 146829-50-7; [2-(cyclohexylamino)-1-phosphono-ethyl]phosphonic acid
DM1JQPW	DT	Small molecular drug
DM1JQPW	PC	21803454
DM1JQPW	MW	287.19
DM1JQPW	FM	C8H19NO6P2
DM1JQPW	IC	InChI=1S/C8H19NO6P2/c10-16(11,12)8(17(13,14)15)6-9-7-4-2-1-3-5-7/h7-9H,1-6H2,(H2,10,11,12)(H2,13,14,15)
DM1JQPW	CS	C1CCC(CC1)NCC(P(=O)(O)O)P(=O)(O)O
DM1JQPW	IK	OAHUDYBQKIUBMC-UHFFFAOYSA-N
DM1JQPW	IU	[2-(cyclohexylamino)-1-phosphonoethyl]phosphonic acid
DM1JQPW	DE	Discovery agent

DMQPFT3	ID	DMQPFT3
DMQPFT3	DN	1-[(Furan-2(5H)-one)-4-methyl]-desloratadine
DMQPFT3	HS	Investigative
DMQPFT3	SN	CHEMBL597381
DMQPFT3	DT	Small molecular drug
DMQPFT3	PC	46233181
DMQPFT3	MW	406.9
DMQPFT3	FM	C24H23ClN2O2
DMQPFT3	IC	InChI=1S/C24H23ClN2O2/c25-20-5-6-21-19(13-20)4-3-18-2-1-9-26-24(18)23(21)17-7-10-27(11-8-17)14-16-12-22(28)29-15-16/h1-2,5-6,9,12-13H,3-4,7-8,10-11,14-15H2
DMQPFT3	CS	C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)CC4=CC(=O)OC4)C5=C1C=CC=N5
DMQPFT3	IK	CHEQBNZJRBHHQT-UHFFFAOYSA-N
DMQPFT3	IU	3-[[4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidin-1-yl]methyl]-2H-furan-5-one
DMQPFT3	DE	Discovery agent

DM8VNYA	ID	DM8VNYA
DM8VNYA	DN	1-[(n-but-1-ylamino)ethyl]-1,1-bisphosphonic acid
DM8VNYA	HS	Investigative
DM8VNYA	SN	CHEMBL406087; SCHEMBL7538729; BDBM50374767; [2-(Butylamino)ethylidene]bisphosphonic acid; [2-(butylamino)-1-phosphono-ethyl]phosphonic acid
DM8VNYA	DT	Small molecular drug
DM8VNYA	PC	15390275
DM8VNYA	MW	261.149
DM8VNYA	FM	C6H17NO6P2
DM8VNYA	IC	InChI=1S/C6H17NO6P2/c1-2-3-4-7-5-6(14(8,9)10)15(11,12)13/h6-7H,2-5H2,1H3,(H2,8,9,10)(H2,11,12,13)
DM8VNYA	CS	CCCCNCC(P(=O)(O)O)P(=O)(O)O
DM8VNYA	IK	HFKAJGBERMPCOS-UHFFFAOYSA-N
DM8VNYA	IU	[2-(butylamino)-1-phosphonoethyl]phosphonic acid
DM8VNYA	DE	Discovery agent

DM4ABTN	ID	DM4ABTN
DM4ABTN	DN	1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid
DM4ABTN	HS	Investigative
DM4ABTN	SN	CHEMBL259192; [2-(Hexylamino)ethane-1,1-Diyl]bis(Phosphonic Acid); 1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid; SCHEMBL8674064; BDBM50341917; 2-(hexylamino)ethane-1,1-diyldiphosphonic acid; [2-(hexylamino)-1-phosphono-ethyl]phosphonic acid
DM4ABTN	DT	Small molecular drug
DM4ABTN	PC	19689034
DM4ABTN	MW	289.2
DM4ABTN	FM	C8H21NO6P2
DM4ABTN	IC	InChI=1S/C8H21NO6P2/c1-2-3-4-5-6-9-7-8(16(10,11)12)17(13,14)15/h8-9H,2-7H2,1H3,(H2,10,11,12)(H2,13,14,15)
DM4ABTN	CS	CCCCCCNCC(P(=O)(O)O)P(=O)(O)O
DM4ABTN	IK	QDLXIUDMSHZYCG-UHFFFAOYSA-N
DM4ABTN	IU	[2-(hexylamino)-1-phosphonoethyl]phosphonic acid
DM4ABTN	DE	Discovery agent

DM9ZK0D	ID	DM9ZK0D
DM9ZK0D	DN	1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid
DM9ZK0D	HS	Investigative
DM9ZK0D	SN	CHEMBL260601; 1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid; SCHEMBL11418940; BDBM50341916; 2-(octylamino)ethane-1,1-diyldiphosphonic acid; [2-(octylamino)-1-phosphono-ethyl]phosphonic acid
DM9ZK0D	DT	Small molecular drug
DM9ZK0D	PC	44451417
DM9ZK0D	MW	317.26
DM9ZK0D	FM	C10H25NO6P2
DM9ZK0D	IC	InChI=1S/C10H25NO6P2/c1-2-3-4-5-6-7-8-11-9-10(18(12,13)14)19(15,16)17/h10-11H,2-9H2,1H3,(H2,12,13,14)(H2,15,16,17)
DM9ZK0D	CS	CCCCCCCCNCC(P(=O)(O)O)P(=O)(O)O
DM9ZK0D	IK	NTUHKTMOLKDMDP-UHFFFAOYSA-N
DM9ZK0D	IU	[2-(octylamino)-1-phosphonoethyl]phosphonic acid
DM9ZK0D	DE	Discovery agent

DMCRHVI	ID	DMCRHVI
DMCRHVI	DN	1-[(prop-1-ylamino)ethyl]-1,1-bisphosphonic acid
DMCRHVI	HS	Investigative
DMCRHVI	SN	CHEMBL408745; [2-(Propylamino)ethane-1,1-Diyl]bis(Phosphonic Acid); SCHEMBL7074253; BDBM50374757; [2-(Propylamino)ethylidene]bisphosphonic acid; [1-phosphono-2-(propylamino)ethyl]phosphonic acid
DMCRHVI	DT	Small molecular drug
DMCRHVI	PC	15390273
DMCRHVI	MW	247.12
DMCRHVI	FM	C5H15NO6P2
DMCRHVI	IC	InChI=1S/C5H15NO6P2/c1-2-3-6-4-5(13(7,8)9)14(10,11)12/h5-6H,2-4H2,1H3,(H2,7,8,9)(H2,10,11,12)
DMCRHVI	CS	CCCNCC(P(=O)(O)O)P(=O)(O)O
DMCRHVI	IK	YFFJUBPLIKXHAO-UHFFFAOYSA-N
DMCRHVI	IU	[1-phosphono-2-(propylamino)ethyl]phosphonic acid
DMCRHVI	DE	Discovery agent

DMSCN8J	ID	DMSCN8J
DMSCN8J	DN	1-[(prop-2-ylamino)ethyl]-1,1-bisphosphonicacid
DMSCN8J	HS	Investigative
DMSCN8J	SN	CHEMBL407221; SCHEMBL8675602; BDBM50374764; [2-(isopropylamino)-1-phosphono-ethyl]phosphonic acid
DMSCN8J	DT	Small molecular drug
DMSCN8J	PC	19689020
DMSCN8J	MW	247.12
DMSCN8J	FM	C5H15NO6P2
DMSCN8J	IC	InChI=1S/C5H15NO6P2/c1-4(2)6-3-5(13(7,8)9)14(10,11)12/h4-6H,3H2,1-2H3,(H2,7,8,9)(H2,10,11,12)
DMSCN8J	CS	CC(C)NCC(P(=O)(O)O)P(=O)(O)O
DMSCN8J	IK	XUKNZUJYUAFJQJ-UHFFFAOYSA-N
DMSCN8J	IU	[1-phosphono-2-(propan-2-ylamino)ethyl]phosphonic acid
DMSCN8J	DE	Discovery agent

DMLDY3H	ID	DMLDY3H
DMLDY3H	DN	1-[(tert-butylamino)ethyl]-1,1-bisphosphonicacid
DMLDY3H	HS	Investigative
DMLDY3H	SN	CHEMBL405827; SCHEMBL8677583; BDBM50374763; [2-(tert-butylamino)-1-phosphono-ethyl]phosphonic acid
DMLDY3H	DT	Small molecular drug
DMLDY3H	PC	19689018
DMLDY3H	MW	261.149
DMLDY3H	FM	C6H17NO6P2
DMLDY3H	IC	InChI=1S/C6H17NO6P2/c1-6(2,3)7-4-5(14(8,9)10)15(11,12)13/h5,7H,4H2,1-3H3,(H2,8,9,10)(H2,11,12,13)
DMLDY3H	CS	CC(C)(C)NCC(P(=O)(O)O)P(=O)(O)O
DMLDY3H	IK	XGRIOZQTBVXIFW-UHFFFAOYSA-N
DMLDY3H	IU	[2-(tert-butylamino)-1-phosphonoethyl]phosphonic acid
DMLDY3H	DE	Discovery agent

DMU3VWA	ID	DMU3VWA
DMU3VWA	DN	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine
DMU3VWA	HS	Investigative
DMU3VWA	SN	CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione
DMU3VWA	DT	Small molecular drug
DMU3VWA	PC	6477686
DMU3VWA	MW	438.5
DMU3VWA	FM	C28H26N2O3
DMU3VWA	IC	InChI=1S/C28H26N2O3/c1-22-21-30(27(32)29-26(22)31)19-11-12-20-33-28(23-13-5-2-6-14-23,24-15-7-3-8-16-24)25-17-9-4-10-18-25/h2-18,21H,19-20H2,1H3,(H,29,31,32)/b12-11-
DMU3VWA	CS	CC1=CN(C(=O)NC1=O)C/C=C\\COC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMU3VWA	IK	BHMZJUVAVWRNLN-QXMHVHEDSA-N
DMU3VWA	IU	5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione
DMU3VWA	DE	Discovery agent

DMIHBFO	ID	DMIHBFO
DMIHBFO	DN	1-[(Z)-4-trityloxy-2-butenyl]uracil
DMIHBFO	HS	Investigative
DMIHBFO	SN	CHEMBL377199; 1-[(Z)-4-trityloxy-2-butenyl]uracil; SCHEMBL12268304
DMIHBFO	DT	Small molecular drug
DMIHBFO	PC	11704530
DMIHBFO	MW	424.5
DMIHBFO	FM	C27H24N2O3
DMIHBFO	IC	InChI=1S/C27H24N2O3/c30-25-18-20-29(26(31)28-25)19-10-11-21-32-27(22-12-4-1-5-13-22,23-14-6-2-7-15-23)24-16-8-3-9-17-24/h1-18,20H,19,21H2,(H,28,30,31)/b11-10-
DMIHBFO	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC/C=C\\CN4C=CC(=O)NC4=O
DMIHBFO	IK	ISRBLVQOVMVNRK-KHPPLWFESA-N
DMIHBFO	IU	1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione
DMIHBFO	DE	Discovery agent

DMEHP8M	ID	DMEHP8M
DMEHP8M	DN	1-[2-(2,4,6-trimethyl-phenyl)-ethyl]-pyrrolidine
DMEHP8M	HS	Investigative
DMEHP8M	SN	CHEMBL272140
DMEHP8M	DT	Small molecular drug
DMEHP8M	PC	44456331
DMEHP8M	MW	217.35
DMEHP8M	FM	C15H23N
DMEHP8M	IC	InChI=1S/C15H23N/c1-12-10-13(2)15(14(3)11-12)6-9-16-7-4-5-8-16/h10-11H,4-9H2,1-3H3
DMEHP8M	CS	CC1=CC(=C(C(=C1)C)CCN2CCCC2)C
DMEHP8M	IK	IYOUBSBBWJSRIG-UHFFFAOYSA-N
DMEHP8M	IU	1-[2-(2,4,6-trimethylphenyl)ethyl]pyrrolidine
DMEHP8M	DE	Discovery agent

DMTNRG7	ID	DMTNRG7
DMTNRG7	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine
DMTNRG7	HS	Investigative
DMTNRG7	SN	CHEMBL364565; 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine; SCHEMBL8773745; BDBM50151048
DMTNRG7	DT	Small molecular drug
DMTNRG7	PC	44396220
DMTNRG7	MW	295.4
DMTNRG7	FM	C20H25NO
DMTNRG7	IC	InChI=1S/C20H25NO/c1-3-9-18(10-4-1)17-19-11-5-6-12-20(19)22-16-15-21-13-7-2-8-14-21/h1,3-6,9-12H,2,7-8,13-17H2
DMTNRG7	CS	C1CCN(CC1)CCOC2=CC=CC=C2CC3=CC=CC=C3
DMTNRG7	IK	QKRCVHKKBOUVNT-UHFFFAOYSA-N
DMTNRG7	IU	1-[2-(2-benzylphenoxy)ethyl]piperidine
DMTNRG7	DE	Discovery agent

DMLSU30	ID	DMLSU30
DMLSU30	DN	1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine
DMLSU30	HS	Investigative
DMLSU30	SN	CHEMBL435505; 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine; BDBM50151045
DMLSU30	DT	Small molecular drug
DMLSU30	PC	44396235
DMLSU30	MW	281.4
DMLSU30	FM	C19H23NO
DMLSU30	IC	InChI=1S/C19H23NO/c1-2-8-17(9-3-1)16-18-10-4-5-11-19(18)21-15-14-20-12-6-7-13-20/h1-5,8-11H,6-7,12-16H2
DMLSU30	CS	C1CCN(C1)CCOC2=CC=CC=C2CC3=CC=CC=C3
DMLSU30	IK	MNZXCYDDVWTITD-UHFFFAOYSA-N
DMLSU30	IU	1-[2-(2-benzylphenoxy)ethyl]pyrrolidine
DMLSU30	DE	Discovery agent

DMDZA83	ID	DMDZA83
DMDZA83	DN	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine
DMDZA83	HS	Investigative
DMDZA83	SN	CHEMBL219905; 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine
DMDZA83	DT	Small molecular drug
DMDZA83	PC	16098875
DMDZA83	MW	456.5
DMDZA83	FM	C28H28N2O4
DMDZA83	IC	InChI=1S/C28H28N2O4/c1-22-21-30(27(32)29-26(22)31)17-18-33-19-20-34-28(23-11-5-2-6-12-23,24-13-7-3-8-14-24)25-15-9-4-10-16-25/h2-16,21H,17-20H2,1H3,(H,29,31,32)
DMDZA83	CS	CC1=CN(C(=O)NC1=O)CCOCCOC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMDZA83	IK	XTVPTIAFWYQSSW-UHFFFAOYSA-N
DMDZA83	IU	5-methyl-1-[2-(2-trityloxyethoxy)ethyl]pyrimidine-2,4-dione
DMDZA83	DE	Discovery agent

DM98F0U	ID	DM98F0U
DM98F0U	DN	1-[2-(trityloxy)ethoxymethyl]uracil
DM98F0U	HS	Investigative
DM98F0U	SN	1-[2-(trityloxy)ethoxymethyl]uracil; CHEMBL424704; SCHEMBL912787; US8530490, Comparative 1; QEKAGWDUKXATPZ-UHFFFAOYSA-N; BDBM50190553
DM98F0U	DT	Small molecular drug
DM98F0U	PC	11750725
DM98F0U	MW	428.5
DM98F0U	FM	C26H24N2O4
DM98F0U	IC	InChI=1S/C26H24N2O4/c29-24-16-17-28(25(30)27-24)20-31-18-19-32-26(21-10-4-1-5-11-21,22-12-6-2-7-13-22)23-14-8-3-9-15-23/h1-17H,18-20H2,(H,27,29,30)
DM98F0U	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCCOCN4C=CC(=O)NC4=O
DM98F0U	IK	QEKAGWDUKXATPZ-UHFFFAOYSA-N
DM98F0U	IU	1-(2-trityloxyethoxymethyl)pyrimidine-2,4-dione
DM98F0U	DE	Discovery agent

DMD2NXL	ID	DMD2NXL
DMD2NXL	DN	1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine
DMD2NXL	HS	Investigative
DMD2NXL	SN	CHEMBL187367; 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine; ZINC13581632
DMD2NXL	DT	Small molecular drug
DMD2NXL	PC	11335419
DMD2NXL	MW	295.4
DMD2NXL	FM	C20H25NO
DMD2NXL	IC	InChI=1S/C20H25NO/c1-2-9-18(10-3-1)17-19-11-4-5-12-20(19)22-16-8-15-21-13-6-7-14-21/h1-5,9-12H,6-8,13-17H2
DMD2NXL	CS	C1CCN(C1)CCCOC2=CC=CC=C2CC3=CC=CC=C3
DMD2NXL	IK	SECXHJRGBAZUCO-UHFFFAOYSA-N
DMD2NXL	IU	1-[3-(2-benzylphenoxy)propyl]pyrrolidine
DMD2NXL	DE	Discovery agent

DMLRS8I	ID	DMLRS8I
DMLRS8I	DN	1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMLRS8I	HS	Investigative
DMLRS8I	SN	CHEMBL212743; SCHEMBL14506371; 1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMLRS8I	DT	Small molecular drug
DMLRS8I	PC	11580459
DMLRS8I	MW	313.4
DMLRS8I	FM	C20H15N3O
DMLRS8I	IC	InChI=1S/C20H15N3O/c24-19-11-5-10-18(13-19)23-14-21-22-20(23)17-9-4-8-16(12-17)15-6-2-1-3-7-15/h1-14,24H
DMLRS8I	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)C3=NN=CN3C4=CC(=CC=C4)O
DMLRS8I	IK	XGXZTGGFJHBJDN-UHFFFAOYSA-N
DMLRS8I	IU	3-[3-(3-phenylphenyl)-1,2,4-triazol-4-yl]phenol
DMLRS8I	DE	Discovery agent

DMB1NF0	ID	DMB1NF0
DMB1NF0	DN	1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMB1NF0	HS	Investigative
DMB1NF0	SN	CHEMBL208801; 1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMB1NF0	DT	Small molecular drug
DMB1NF0	PC	11645313
DMB1NF0	MW	313.4
DMB1NF0	FM	C20H15N3O
DMB1NF0	IC	InChI=1S/C20H15N3O/c24-19-8-4-7-18(13-19)23-14-21-22-20(23)17-11-9-16(10-12-17)15-5-2-1-3-6-15/h1-14,24H
DMB1NF0	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C3=NN=CN3C4=CC(=CC=C4)O
DMB1NF0	IK	MENDTFDIUWAVMQ-UHFFFAOYSA-N
DMB1NF0	IU	3-[3-(4-phenylphenyl)-1,2,4-triazol-4-yl]phenol
DMB1NF0	DE	Discovery agent

DMS192I	ID	DMS192I
DMS192I	DN	1-[3-(Methylsulfonyl)phenyl]-4-propylpiperazine
DMS192I	HS	Investigative
DMS192I	SN	CHEMBL596801; 1-[3-(Methylsulfonyl)phenyl]-4-propylpiperazine; SCHEMBL3453749; IIFAQXPNYXJBMU-UHFFFAOYSA-N; BDBM50308027
DMS192I	DT	Small molecular drug
DMS192I	PC	11529282
DMS192I	MW	282.4
DMS192I	FM	C14H22N2O2S
DMS192I	IC	InChI=1S/C14H22N2O2S/c1-3-7-15-8-10-16(11-9-15)13-5-4-6-14(12-13)19(2,17)18/h4-6,12H,3,7-11H2,1-2H3
DMS192I	CS	CCCN1CCN(CC1)C2=CC(=CC=C2)S(=O)(=O)C
DMS192I	IK	IIFAQXPNYXJBMU-UHFFFAOYSA-N
DMS192I	IU	1-(3-methylsulfonylphenyl)-4-propylpiperazine
DMS192I	DE	Discovery agent

DME1R96	ID	DME1R96
DME1R96	DN	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine
DME1R96	HS	Investigative
DME1R96	SN	1-[4-(2-Oxo-2-Phenylethyl)phenyl]guanidine; SCHEMBL20553177; DB07122
DME1R96	DT	Small molecular drug
DME1R96	PC	16758228
DME1R96	MW	253.3
DME1R96	FM	C15H15N3O
DME1R96	IC	InChI=1S/C15H15N3O/c16-15(17)18-13-8-6-11(7-9-13)10-14(19)12-4-2-1-3-5-12/h1-9H,10H2,(H4,16,17,18)
DME1R96	CS	C1=CC=C(C=C1)C(=O)CC2=CC=C(C=C2)N=C(N)N
DME1R96	IK	MERNPSIIBFTCAI-UHFFFAOYSA-N
DME1R96	IU	2-(4-phenacylphenyl)guanidine
DME1R96	DE	Discovery agent

DM0I2RH	ID	DM0I2RH
DM0I2RH	DN	1-[4-(4-Iodophenoxy)phenyl]piperazine
DM0I2RH	HS	Investigative
DM0I2RH	SN	CHEMBL567267; 1-[4-(4-Iodophenoxy)phenyl]piperazine; SCHEMBL13234979
DM0I2RH	DT	Small molecular drug
DM0I2RH	PC	16039611
DM0I2RH	MW	380.22
DM0I2RH	FM	C16H17IN2O
DM0I2RH	IC	InChI=1S/C16H17IN2O/c17-13-1-5-15(6-2-13)20-16-7-3-14(4-8-16)19-11-9-18-10-12-19/h1-8,18H,9-12H2
DM0I2RH	CS	C1CN(CCN1)C2=CC=C(C=C2)OC3=CC=C(C=C3)I
DM0I2RH	IK	AFIBQMXKOKSOEJ-UHFFFAOYSA-N
DM0I2RH	IU	1-[4-(4-iodophenoxy)phenyl]piperazine
DM0I2RH	DE	Discovery agent

DM4F1GJ	ID	DM4F1GJ
DM4F1GJ	DN	1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-ol
DM4F1GJ	HS	Investigative
DM4F1GJ	SN	Benzthiazole compound, 33e; CHEMBL479752; SCHEMBL4692452; BDBM24232
DM4F1GJ	DT	Small molecular drug
DM4F1GJ	PC	11473281
DM4F1GJ	MW	340.4
DM4F1GJ	FM	C19H20N2O2S
DM4F1GJ	IC	InChI=1S/C19H20N2O2S/c22-15-9-11-21(12-10-15)13-14-5-7-16(8-6-14)23-19-20-17-3-1-2-4-18(17)24-19/h1-8,15,22H,9-13H2
DM4F1GJ	CS	C1CN(CCC1O)CC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3
DM4F1GJ	IK	CFTXJKKITUELKJ-UHFFFAOYSA-N
DM4F1GJ	IU	1-[[4-(1,3-benzothiazol-2-yloxy)phenyl]methyl]piperidin-4-ol
DM4F1GJ	DE	Discovery agent

DMHXAMR	ID	DMHXAMR
DMHXAMR	DN	1-[4-hydroxy-3-(tritylaminomethyl)butyl]uracil
DMHXAMR	HS	Investigative
DMHXAMR	SN	CHEMBL378101; 1-[4-hydroxy-3-(tritylaminomethyl)butyl]uracil; SCHEMBL913211
DMHXAMR	DT	Small molecular drug
DMHXAMR	PC	11683928
DMHXAMR	MW	455.5
DMHXAMR	FM	C28H29N3O3
DMHXAMR	IC	InChI=1S/C28H29N3O3/c32-21-22(16-18-31-19-17-26(33)30-27(31)34)20-29-28(23-10-4-1-5-11-23,24-12-6-2-7-13-24)25-14-8-3-9-15-25/h1-15,17,19,22,29,32H,16,18,20-21H2,(H,30,33,34)
DMHXAMR	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)NCC(CCN4C=CC(=O)NC4=O)CO
DMHXAMR	IK	AROLDFLIRWDCKX-UHFFFAOYSA-N
DMHXAMR	IU	1-[3-(hydroxymethyl)-4-(tritylamino)butyl]pyrimidine-2,4-dione
DMHXAMR	DE	Discovery agent

DM8NMAV	ID	DM8NMAV
DM8NMAV	DN	1-[5-(4-Chlorophenyl)-2-furoyl]piperazine
DM8NMAV	HS	Investigative
DM8NMAV	SN	CHEMBL521211; 1-[5-(4-Chlorophenyl)-2-furoyl]piperazine; BDBM50270649
DM8NMAV	DT	Small molecular drug
DM8NMAV	PC	24857857
DM8NMAV	MW	290.74
DM8NMAV	FM	C15H15ClN2O2
DM8NMAV	IC	InChI=1S/C15H15ClN2O2/c16-12-3-1-11(2-4-12)13-5-6-14(20-13)15(19)18-9-7-17-8-10-18/h1-6,17H,7-10H2
DM8NMAV	CS	C1CN(CCN1)C(=O)C2=CC=C(O2)C3=CC=C(C=C3)Cl
DM8NMAV	IK	FSVUGYFGMKVKHY-UHFFFAOYSA-N
DM8NMAV	IU	[5-(4-chlorophenyl)furan-2-yl]-piperazin-1-ylmethanone
DM8NMAV	DE	Discovery agent

DMFHBJM	ID	DMFHBJM
DMFHBJM	DN	1-[5-(triphenylmethoxy)pentyl]thymine
DMFHBJM	HS	Investigative
DMFHBJM	SN	1-[5-(triphenylmethoxy)pentyl]thymine; CHEMBL216997; 921587-92-0; CTK3G1845; DTXSID10582665; BDBM50201001; 5-Methyl-1-[5-(triphenylmethoxy)pentyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[5-(triphenylmethoxy)pentyl]-
DMFHBJM	DT	Small molecular drug
DMFHBJM	PC	16098859
DMFHBJM	MW	454.6
DMFHBJM	FM	C29H30N2O3
DMFHBJM	IC	InChI=1S/C29H30N2O3/c1-23-22-31(28(33)30-27(23)32)20-12-5-13-21-34-29(24-14-6-2-7-15-24,25-16-8-3-9-17-25)26-18-10-4-11-19-26/h2-4,6-11,14-19,22H,5,12-13,20-21H2,1H3,(H,30,32,33)
DMFHBJM	CS	CC1=CN(C(=O)NC1=O)CCCCCOC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMFHBJM	IK	SLJLMYFAIDHROH-UHFFFAOYSA-N
DMFHBJM	IU	5-methyl-1-(5-trityloxypentyl)pyrimidine-2,4-dione
DMFHBJM	CA	CAS 921587-92-0
DMFHBJM	DE	Discovery agent

DM5NVHO	ID	DM5NVHO
DM5NVHO	DN	1-[6-(triphenylmethoxy)hexyl]thymine
DM5NVHO	HS	Investigative
DM5NVHO	SN	1-[6-(triphenylmethoxy)hexyl]thymine; CHEMBL216998; 921587-93-1; CTK3G1844; DTXSID00658828; BDBM50200990; 5-Methyl-1-[6-(triphenylmethoxy)hexyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[6-(triphenylmethoxy)hexyl]-
DM5NVHO	DT	Small molecular drug
DM5NVHO	PC	44418795
DM5NVHO	MW	468.6
DM5NVHO	FM	C30H32N2O3
DM5NVHO	IC	InChI=1S/C30H32N2O3/c1-24-23-32(29(34)31-28(24)33)21-13-2-3-14-22-35-30(25-15-7-4-8-16-25,26-17-9-5-10-18-26)27-19-11-6-12-20-27/h4-12,15-20,23H,2-3,13-14,21-22H2,1H3,(H,31,33,34)
DM5NVHO	CS	CC1=CN(C(=O)NC1=O)CCCCCCOC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DM5NVHO	IK	POQKPOUSJVGFHD-UHFFFAOYSA-N
DM5NVHO	IU	5-methyl-1-(6-trityloxyhexyl)pyrimidine-2,4-dione
DM5NVHO	CA	CAS 921587-93-1
DM5NVHO	DE	Discovery agent

DMQ05F2	ID	DMQ05F2
DMQ05F2	DN	1-[7-(triphenylmethoxy)heptyl]thymine
DMQ05F2	HS	Investigative
DMQ05F2	SN	1-[7-(triphenylmethoxy)heptyl]thymine; CHEMBL219367; 921587-94-2; CTK3G1843; DTXSID20582671; BDBM50200997; 5-Methyl-1-[7-(triphenylmethoxy)heptyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[7-(triphenylmethoxy)heptyl]-
DMQ05F2	DT	Small molecular drug
DMQ05F2	PC	16098874
DMQ05F2	MW	482.6
DMQ05F2	FM	C31H34N2O3
DMQ05F2	IC	InChI=1S/C31H34N2O3/c1-25-24-33(30(35)32-29(25)34)22-14-3-2-4-15-23-36-31(26-16-8-5-9-17-26,27-18-10-6-11-19-27)28-20-12-7-13-21-28/h5-13,16-21,24H,2-4,14-15,22-23H2,1H3,(H,32,34,35)
DMQ05F2	CS	CC1=CN(C(=O)NC1=O)CCCCCCCOC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMQ05F2	IK	MYFJLJCVSVNEDV-UHFFFAOYSA-N
DMQ05F2	IU	5-methyl-1-(7-trityloxyheptyl)pyrimidine-2,4-dione
DMQ05F2	CA	CAS 921587-94-2
DMQ05F2	DE	Discovery agent

DM13D4E	ID	DM13D4E
DM13D4E	DN	1-[bis(4-bromophenyl)methyl]-3-phenylthiourea
DM13D4E	HS	Investigative
DM13D4E	SN	CHEMBL224904; 1-[bis(4-bromophenyl)methyl]-3-phenylthiourea
DM13D4E	DT	Small molecular drug
DM13D4E	PC	11576518
DM13D4E	MW	476.2
DM13D4E	FM	C20H16Br2N2S
DM13D4E	IC	InChI=1S/C20H16Br2N2S/c21-16-10-6-14(7-11-16)19(15-8-12-17(22)13-9-15)24-20(25)23-18-4-2-1-3-5-18/h1-13,19H,(H2,23,24,25)
DM13D4E	CS	C1=CC=C(C=C1)NC(=S)NC(C2=CC=C(C=C2)Br)C3=CC=C(C=C3)Br
DM13D4E	IK	JQWBRSQRBYVWFQ-UHFFFAOYSA-N
DM13D4E	IU	1-[bis(4-bromophenyl)methyl]-3-phenylthiourea
DM13D4E	DE	Discovery agent

DMN2LHM	ID	DMN2LHM
DMN2LHM	DN	1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-
DMN2LHM	HS	Investigative
DMN2LHM	SN	CHEMBL224113; 1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-; ZINC13676240
DMN2LHM	DT	Small molecular drug
DMN2LHM	PC	11524275
DMN2LHM	MW	405.7
DMN2LHM	FM	C20H15Cl3N2O
DMN2LHM	IC	InChI=1S/C20H15Cl3N2O/c21-15-5-1-13(2-6-15)19(14-3-7-16(22)8-4-14)25-20(26)24-18-11-9-17(23)10-12-18/h1-12,19H,(H2,24,25,26)
DMN2LHM	CS	C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)NC(=O)NC3=CC=C(C=C3)Cl)Cl
DMN2LHM	IK	IQLQNNIZPSPERD-UHFFFAOYSA-N
DMN2LHM	IU	1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)urea
DMN2LHM	DE	Discovery agent

DMFMR2N	ID	DMFMR2N
DMFMR2N	DN	1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea
DMFMR2N	HS	Investigative
DMFMR2N	SN	CHEMBL391003; 1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea; ZINC13676247
DMFMR2N	DT	Small molecular drug
DMFMR2N	PC	11552795
DMFMR2N	MW	387.3
DMFMR2N	FM	C20H16Cl2N2S
DMFMR2N	IC	InChI=1S/C20H16Cl2N2S/c21-16-10-6-14(7-11-16)19(15-8-12-17(22)13-9-15)24-20(25)23-18-4-2-1-3-5-18/h1-13,19H,(H2,23,24,25)
DMFMR2N	CS	C1=CC=C(C=C1)NC(=S)NC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMFMR2N	IK	SYUQZYSPZLUEIG-UHFFFAOYSA-N
DMFMR2N	IU	1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea
DMFMR2N	DE	Discovery agent

DMJT7VI	ID	DMJT7VI
DMJT7VI	DN	1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea
DMJT7VI	HS	Investigative
DMJT7VI	SN	CHEMBL388398; 1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea
DMJT7VI	DT	Small molecular drug
DMJT7VI	PC	11498260
DMJT7VI	MW	633.1
DMJT7VI	FM	C20H15BrI2N2O
DMJT7VI	IC	InChI=1S/C20H15BrI2N2O/c21-15-5-11-18(12-6-15)24-20(26)25-19(13-1-7-16(22)8-2-13)14-3-9-17(23)10-4-14/h1-12,19H,(H2,24,25,26)
DMJT7VI	CS	C1=CC(=CC=C1C(C2=CC=C(C=C2)I)NC(=O)NC3=CC=C(C=C3)Br)I
DMJT7VI	IK	ALTGZVPJBKOZHG-UHFFFAOYSA-N
DMJT7VI	IU	1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea
DMJT7VI	DE	Discovery agent

DML745Y	ID	DML745Y
DML745Y	DN	10,10-difluoro TXA2
DML745Y	HS	Investigative
DML745Y	SN	10,10-difluoro TXA2; GTPL6069; (Z)-7-[(1S,3R,4R,5R)-7,7-difluoro-3-[(E,3S)-3-hydroxyoct-1-enyl]-6-oxabicyclo[3.1.1]heptan-4-yl]hept-5-enoic acid
DML745Y	DT	Small molecular drug
DML745Y	PC	73755171
DML745Y	MW	386.5
DML745Y	FM	C21H32F2O4
DML745Y	IC	InChI=1S/C21H32F2O4/c1-2-3-6-9-16(24)13-12-15-14-18-21(22,23)20(27-18)17(15)10-7-4-5-8-11-19(25)26/h4,7,12-13,15-18,20,24H,2-3,5-6,8-11,14H2,1H3,(H,25,26)/b7-4-,13-12+/t15-,16-,17+,18-,20+/m0/s1
DML745Y	CS	CCCCC[C@@H](/C=C/[C@H]1C[C@H]2C([C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O2)(F)F)O
DML745Y	IK	CIYZUODQUHAGKZ-SCVXEUJASA-N
DML745Y	IU	(Z)-7-[(1R,2R,3R,5S)-7,7-difluoro-3-[(E,3S)-3-hydroxyoct-1-enyl]-6-oxabicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid
DML745Y	DE	Discovery agent

DMS5ICY	ID	DMS5ICY
DMS5ICY	DN	10,11-dihydro-5H-dibenzo[b,f]azepine
DMS5ICY	HS	Investigative
DMS5ICY	SN	Iminodibenzyl; 494-19-9; 10,11-Dihydro-5H-dibenzo[b,f]azepine; 10,11-Dihydro-5H-dibenz[b,f]azepine; Iminobibenzyl; 2,2'-Iminodibenzyl; 2,2'-Iminobibenzyl; 5H-Dibenz[b,f]azepine, 10,11-dihydro-; RP 23669; UNII-262BX7OE3U; NSC 72110; 10,11-Dihydro-5-dibenz(b,f)azepine; 6,11-dihydro-5H-benzo[b][1]benzazepine; 10,11-Dihydrodibenz(b,f)azepine; EINECS 207-787-1; 10,11-Dihydro-5H-dibenz(b,f)azepine; BRN 0152732; CHEMBL63054; 5H-Dibenz(b,f)azepine, 10,11-dihydro-; AI3-39165; 262BX7OE3U; ZSMRRZONCYIFNB-UHFFFAOYSA-N
DMS5ICY	DT	Small molecular drug
DMS5ICY	PC	10308
DMS5ICY	MW	195.26
DMS5ICY	FM	C14H13N
DMS5ICY	IC	InChI=1S/C14H13N/c1-3-7-13-11(5-1)9-10-12-6-2-4-8-14(12)15-13/h1-8,15H,9-10H2
DMS5ICY	CS	C1CC2=CC=CC=C2NC3=CC=CC=C31
DMS5ICY	IK	ZSMRRZONCYIFNB-UHFFFAOYSA-N
DMS5ICY	IU	6,11-dihydro-5H-benzo[b][1]benzazepine
DMS5ICY	CA	CAS 494-19-9
DMS5ICY	DE	Discovery agent

DM5BUXZ	ID	DM5BUXZ
DM5BUXZ	DN	10-Acetyl-1,8-dihydroxy-10H-anthracen-9-one
DM5BUXZ	HS	Investigative
DM5BUXZ	SN	10-Acetyl dithranol; CCRIS 2039; CHEMBL339332; 3022-61-5; 10-Acetyl-1,8-dihydroxy-10H-anthracen-9-one; 9(10H)-Anthracenone, 10-acetyl-1,8-dihydroxy-; 10-Acetylanthraline; AC1MIVB6; SCHEMBL10630399; DTXSID30184322; 1,8-Dihydroxy-10-acetylanthrone; JLVFGQSHNYEUIN-UHFFFAOYSA-N; 1,8-dihydroxy-10-acetyl anthrone; ZINC13606543; BDBM50060870
DM5BUXZ	DT	Small molecular drug
DM5BUXZ	PC	3080591
DM5BUXZ	MW	268.26
DM5BUXZ	FM	C16H12O4
DM5BUXZ	IC	InChI=1S/C16H12O4/c1-8(17)13-9-4-2-6-11(18)14(9)16(20)15-10(13)5-3-7-12(15)19/h2-7,13,18-19H,1H3
DM5BUXZ	CS	CC(=O)C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=CC=C3O
DM5BUXZ	IK	JLVFGQSHNYEUIN-UHFFFAOYSA-N
DM5BUXZ	IU	10-acetyl-1,8-dihydroxy-10H-anthracen-9-one
DM5BUXZ	CA	CAS 3022-61-5
DM5BUXZ	DE	Discovery agent

DM1JLUV	ID	DM1JLUV
DM1JLUV	DN	10-Allyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DM1JLUV	HS	Investigative
DM1JLUV	SN	10Allyl-DBOA-11one; 10-Ally-dibenz(b,f)(1,4)oxazepin-11-(10H)-one; 135810-46-7; 10-Ally-dibenz[b,f][1,4]oxazepin-11-(10H)-one; Dibenzoxazepinone 11; AC1L9R9L; CHEMBL301443; BDBM1972; DTXSID50159537; 5-allylbenzo[b][1,4]benzoxazepin-6-one; 5-prop-2-enylbenzo[b][1,4]benzoxazepin-6-one; 10-(2-Propenyl)dibenz[b,f][1,4]oxazepin-11(10H)-one
DM1JLUV	DT	Small molecular drug
DM1JLUV	PC	453916
DM1JLUV	MW	251.28
DM1JLUV	FM	C16H13NO2
DM1JLUV	IC	InChI=1S/C16H13NO2/c1-2-11-17-13-8-4-6-10-15(13)19-14-9-5-3-7-12(14)16(17)18/h2-10H,1,11H2
DM1JLUV	CS	C=CCN1C2=CC=CC=C2OC3=CC=CC=C3C1=O
DM1JLUV	IK	QANXXCPLBYYJSG-UHFFFAOYSA-N
DM1JLUV	IU	5-prop-2-enylbenzo[b][1,4]benzoxazepin-6-one
DM1JLUV	CA	CAS 135810-46-7
DM1JLUV	DE	Discovery agent

DM4M2VU	ID	DM4M2VU
DM4M2VU	DN	10-Benzoyl-1,8-dihydroxy-10H-anthracen-9-one
DM4M2VU	HS	Investigative
DM4M2VU	SN	CHEMBL123724; 10-benzoyl-1,8-dihydroxy-10H-anthracen-9-one; BDBM50060881
DM4M2VU	DT	Small molecular drug
DM4M2VU	PC	10592514
DM4M2VU	MW	330.3
DM4M2VU	FM	C21H14O4
DM4M2VU	IC	InChI=1S/C21H14O4/c22-15-10-4-8-13-17(20(24)12-6-2-1-3-7-12)14-9-5-11-16(23)19(14)21(25)18(13)15/h1-11,17,22-23H
DM4M2VU	CS	C1=CC=C(C=C1)C(=O)C2C3=C(C(=CC=C3)O)C(=O)C4=C2C=CC=C4O
DM4M2VU	IK	ZIWVGWPZACHOMW-UHFFFAOYSA-N
DM4M2VU	IU	10-benzoyl-1,8-dihydroxy-10H-anthracen-9-one
DM4M2VU	DE	Discovery agent

DMQOUJ7	ID	DMQOUJ7
DMQOUJ7	DN	10-CF3C(OH)2-DDACTHF
DMQOUJ7	HS	Investigative
DMQOUJ7	SN	Hydrolyzed Form of 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid
DMQOUJ7	DT	Small molecular drug
DMQOUJ7	PC	46936711
DMQOUJ7	MW	549.5
DMQOUJ7	FM	C22H30F3N5O8
DMQOUJ7	IC	InChI=1S/C22H30F3N5O8/c23-22(24,25)21(37,38)13(3-1-2-12-16(26)29-20(27)30-18(12)34)10-4-6-11(7-5-10)17(33)28-14(19(35)36)8-9-15(31)32/h4-7,12-14,16,20,29,37-38H,1-3,8-9,26-27H2,(H,28,33)(H,30,34)(H,31,32)(H,35,36)/t12-,13+,14-,16+,20-/m1/s1
DMQOUJ7	CS	C1=CC(=CC=C1[C@H](CCC[C@@H]2[C@H](N[C@H](NC2=O)N)N)C(C(F)(F)F)(O)O)C(=O)N[C@H](CCC(=O)O)C(=O)O
DMQOUJ7	IK	KOLDLUFBEMUZIM-WUAYEBGVSA-N
DMQOUJ7	IU	(2R)-2-[[4-[(3S)-6-[(2R,4S,5R)-2,4-diamino-6-oxo-1,3-diazinan-5-yl]-1,1,1-trifluoro-2,2-dihydroxyhexan-3-yl]benzoyl]amino]pentanedioic acid
DMQOUJ7	DE	Discovery agent

DMDQ7Z9	ID	DMDQ7Z9
DMDQ7Z9	DN	10-EPI-8-DEOXY-CUMAMBRIN B
DMDQ7Z9	HS	Investigative
DMDQ7Z9	SN	10-Epi-8-deoxy-cumambrin B; CHEMBL1099308
DMDQ7Z9	DT	Small molecular drug
DMDQ7Z9	PC	46887018
DMDQ7Z9	MW	218.29
DMDQ7Z9	FM	C14H18O2
DMDQ7Z9	IC	InChI=1S/C14H18O2/c1-8-6-7-10-4-3-5-11-9(2)14(15)16-13(11)12(8)10/h6,10-13H,2-5,7H2,1H3/t10-,11+,12+,13+/m1/s1
DMDQ7Z9	CS	CC1=CC[C@@H]2[C@H]1[C@@H]3[C@@H](CCC2)C(=C)C(=O)O3
DMDQ7Z9	IK	PFGQZVWFUUWHOT-VOAKCMCISA-N
DMDQ7Z9	IU	(3aS,6aR,9aR,9bS)-9-methyl-3-methylidene-3a,4,5,6,6a,7,9a,9b-octahydroazuleno[4,5-b]furan-2-one
DMDQ7Z9	DE	Discovery agent

DMGT82V	ID	DMGT82V
DMGT82V	DN	10-Ethyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DMGT82V	HS	Investigative
DMGT82V	SN	10Et-DBOA-11one; 10-Ethyl-dibenz(b,f)(1,4)oxazepin-11-(10H)-one; 17296-50-3; 5-ethylbenzo[b][1,4]benzoxazepin-6-one; 10-Ethyl-dibenz[b,f][1,4]oxazepin-11-(10H)-one; Dibenzoxazepinone 10; AC1L9R9K; CHEMBL299710; BDBM1971; SCHEMBL8401275; DTXSID20169441; ZINC6385234; 10-Ethyldibenz[b,f][1,4]oxazepin-11(10H)-one
DMGT82V	DT	Small molecular drug
DMGT82V	PC	453915
DMGT82V	MW	239.27
DMGT82V	FM	C15H13NO2
DMGT82V	IC	InChI=1S/C15H13NO2/c1-2-16-12-8-4-6-10-14(12)18-13-9-5-3-7-11(13)15(16)17/h3-10H,2H2,1H3
DMGT82V	CS	CCN1C2=CC=CC=C2OC3=CC=CC=C3C1=O
DMGT82V	IK	MRBRHCRUXKHKKI-UHFFFAOYSA-N
DMGT82V	IU	5-ethylbenzo[b][1,4]benzoxazepin-6-one
DMGT82V	CA	CAS 17296-50-3
DMGT82V	DE	Discovery agent

DMEBHML	ID	DMEBHML
DMEBHML	DN	10-Formyl-5,8,10-Trideazafolic Acid
DMEBHML	HS	Investigative
DMEBHML	SN	10-formyl-5,8,10-trideazafolic
DMEBHML	DT	Small molecular drug
DMEBHML	PC	135460967
DMEBHML	MW	482.4
DMEBHML	FM	C23H22N4O8
DMEBHML	IC	InChI=1S/C23H22N4O8/c24-23-26-16-6-1-11(10-15(16)20(31)27-23)9-14(21(32)33)12-2-4-13(5-3-12)19(30)25-17(22(34)35)7-8-18(28)29/h1-6,10,14,17H,7-9H2,(H,25,30)(H,28,29)(H,32,33)(H,34,35)(H3,24,26,27,31)/t14-,17-/m0/s1
DMEBHML	CS	C1=CC(=CC=C1[C@H](CC2=CC3=C(C=C2)N=C(NC3=O)N)C(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMEBHML	IK	DAOQLLQRJAXMGY-YOEHRIQHSA-N
DMEBHML	IU	(2S)-2-[[4-[(1S)-2-(2-amino-4-oxo-3H-quinazolin-6-yl)-1-carboxyethyl]benzoyl]amino]pentanedioic acid
DMEBHML	DE	Discovery agent

DM4R7X8	ID	DM4R7X8
DM4R7X8	DN	10-hydroxy-18-methoxybetaenone
DM4R7X8	HS	Investigative
DM4R7X8	SN	CHEMBL498247; 10-hydroxy-18-methoxybetaenone; BDBM50269144
DM4R7X8	DT	Small molecular drug
DM4R7X8	PC	10644450
DM4R7X8	MW	396.5
DM4R7X8	FM	C22H36O6
DM4R7X8	IC	InChI=1S/C22H36O6/c1-8-13(2)16-20(5,15(23)9-10-28-7)17-14(3)11-19(4,25)12-22(17,27)18(24)21(16,6)26/h9-10,13-14,16-17,25-27H,8,11-12H2,1-7H3/b10-9+/t13?,14-,16-,17-,19-,20-,21+,22-/m1/s1
DM4R7X8	CS	CCC(C)[C@@H]1[C@@]([C@H]2[C@@H](C[C@@](C[C@@]2(C(=O)[C@@]1(C)O)O)(C)O)C)(C)C(=O)/C=C/OC
DM4R7X8	IK	ONZDNBGTAVEQQN-FJXLOMMUSA-N
DM4R7X8	IU	(2S,3R,4R,4aR,5R,7R,8aR)-3-butan-2-yl-2,7,8a-trihydroxy-4-[(E)-3-methoxyprop-2-enoyl]-2,4,5,7-tetramethyl-4a,5,6,8-tetrahydro-3H-naphthalen-1-one
DM4R7X8	DE	Discovery agent

DM9WLN4	ID	DM9WLN4
DM9WLN4	DN	10-hydroxycamptothecin
DM9WLN4	HS	Investigative
DM9WLN4	SN	10-Hydroxycamptothecin; 19685-09-7; (S)-10-Hydroxycamptothecin; Hydroxycamptothecin; 10-hydroxycamptothecine; 10-Hydroxy camptothecin; Hydroxycamptothecine; Camptothecin, hydroxy-; 10-Hydroxy-Camptothecin; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; Camptothecin, 10-hydroxy-; Camptothecine, 10-hydroxy-; UNII-9Z01632KRV; NSC 107124; HCPT; (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-Hydroxycamptothecin hydrate; NSC107124
DM9WLN4	DT	Small molecular drug
DM9WLN4	PC	97226
DM9WLN4	MW	364.4
DM9WLN4	FM	C20H16N2O5
DM9WLN4	IC	InChI=1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3/t20-/m0/s1
DM9WLN4	CS	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=CC5=C4)O)O
DM9WLN4	IK	HAWSQZCWOQZXHI-FQEVSTJZSA-N
DM9WLN4	IU	(19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
DM9WLN4	CA	CAS 19685-09-7
DM9WLN4	CB	CHEBI:81395
DM9WLN4	DE	Discovery agent

DM5H73W	ID	DM5H73W
DM5H73W	DN	10-Hydroxy-infractopicrin
DM5H73W	HS	Investigative
DM5H73W	SN	10-Hydroxy-infractopicrin
DM5H73W	DT	Small molecular drug
DM5H73W	PC	46228997
DM5H73W	MW	312.7
DM5H73W	FM	C17H13ClN2O2
DM5H73W	IC	InChI=1S/C17H12N2O2.ClH/c20-11-3-4-14-13(9-11)12-5-7-18-6-1-2-10-8-15(21)19(14)17(12)16(10)18;/h3-5,7-9H,1-2,6H2;1H
DM5H73W	CS	C1CC2=CC(=O)N3C4=C(C=C(C=C4)O)C5=C3C2=[N+](C1)C=C5.[Cl-]
DM5H73W	IK	NTHWONPMICHNIA-UHFFFAOYSA-N
DM5H73W	IU	5-hydroxy-1-aza-11-azoniapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2(7),3,5,8(18),9,11(19),15-heptaen-17-one;chloride
DM5H73W	DE	Discovery agent

DMCXA1Y	ID	DMCXA1Y
DMCXA1Y	DN	10-Isopropyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DMCXA1Y	HS	Investigative
DMCXA1Y	SN	10iPr-DBOA-11one; 10-Isopropyl-dibenz(b,f)(1,4)oxazepin-11-(10H)-one; 135810-42-3; 10-Isopropyl-dibenz[b,f][1,4]oxazepin-11-(10H)-one; Dibenzoxazepinone 12; AC1L9R9N; CHEMBL56567; SCHEMBL7955434; BDBM1974; DTXSID10159533; ACJZSMFIMMQNTP-UHFFFAOYSA-N; 5-isopropylbenzo[b][1,4]benzoxazepin-6-one; 5-propan-2-ylbenzo[b][1,4]benzoxazepin-6-one; 10-Isopropyldibenz[b,f][1,4]oxazepin-11(10H)-one; 10-isopropyl-10H-dibenz[b,f][1,4]oxazepin-11-one
DMCXA1Y	DT	Small molecular drug
DMCXA1Y	PC	453918
DMCXA1Y	MW	253.29
DMCXA1Y	FM	C16H15NO2
DMCXA1Y	IC	InChI=1S/C16H15NO2/c1-11(2)17-13-8-4-6-10-15(13)19-14-9-5-3-7-12(14)16(17)18/h3-11H,1-2H3
DMCXA1Y	CS	CC(C)N1C2=CC=CC=C2OC3=CC=CC=C3C1=O
DMCXA1Y	IK	ACJZSMFIMMQNTP-UHFFFAOYSA-N
DMCXA1Y	IU	5-propan-2-ylbenzo[b][1,4]benzoxazepin-6-one
DMCXA1Y	CA	CAS 135810-42-3
DMCXA1Y	DE	Discovery agent

DM2H6KD	ID	DM2H6KD
DM2H6KD	DN	10-methoxy-ginkgolide C
DM2H6KD	HS	Investigative
DM2H6KD	SN	10-methoxy-ginkgolide C; CHEMBL221823
DM2H6KD	DT	Small molecular drug
DM2H6KD	PC	44420890
DM2H6KD	MW	454.4
DM2H6KD	FM	C21H26O11
DM2H6KD	IC	InChI=1S/C21H26O11/c1-6-13(24)29-11-10(23)19-7-8(22)9(17(2,3)4)18(19)12(28-5)15(26)30-16(18)32-21(19,20(6,11)27)31-14(7)25/h6-12,16,22-23,27H,1-5H3/t6-,7+,8+,9+,10+,11+,12+,16+,18+,19+,20-,21+/m1/s1
DM2H6KD	CS	C[C@@H]1C(=O)O[C@@H]2[C@]1([C@]34[C@]5([C@H]2O)[C@@H]([C@@H]([C@H]([C@@]56[C@H](C(=O)O[C@H]6O3)OC)C(C)(C)C)O)C(=O)O4)O
DM2H6KD	IK	RYOIKJMKJWXJLR-XWGAEZTCSA-N
DM2H6KD	IU	(1R,3R,6R,7S,8S,9R,10S,11R,12R,13S,16S,17R)-8-tert-butyl-9,12,17-trihydroxy-6-methoxy-16-methyl-2,4,14,18-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,19-trione
DM2H6KD	DE	Discovery agent

DMJW25X	ID	DMJW25X
DMJW25X	DN	10-methoxy-N(1)-methylburnamine-17-O-veratrate
DMJW25X	HS	Investigative
DMJW25X	SN	CHEMBL592603; 10-methoxy-N(1)-methylburnamine-17-O-veratrate
DMJW25X	DT	Small molecular drug
DMJW25X	PC	46229075
DMJW25X	MW	576.6
DMJW25X	FM	C32H36N2O8
DMJW25X	IC	InChI=1S/C32H36N2O8/c1-7-18-16-34-26-14-21(18)30(29(36)40-6,17-41-28(35)19-8-11-24(38-4)25(12-19)39-5)31-15-27(34)42-32(26,31)33(2)23-10-9-20(37-3)13-22(23)31/h7-13,21,26-27H,14-17H2,1-6H3/b18-7-/t21-,26-,27-,30-,31-,32-/m0/s1
DMJW25X	CS	C/C=C\\1/CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(N(C6=C4C=C(C=C6)OC)C)O[C@H]2C5)(COC(=O)C7=CC(=C(C=C7)OC)OC)C(=O)OC
DMJW25X	IK	DTINADCHYFZWSG-BUVDGYSPSA-N
DMJW25X	IU	methyl (1R,9S,11S,14E,15S,17S,19R)-19-[(3,4-dimethoxybenzoyl)oxymethyl]-14-ethylidene-6-methoxy-2-methyl-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3(8),4,6-triene-19-carboxylate
DMJW25X	DE	Discovery agent

DMM9GEA	ID	DMM9GEA
DMM9GEA	DN	10-OBn-7alpha-F-gingkolide B
DMM9GEA	HS	Investigative
DMM9GEA	SN	compound 17 [PMID: 12570381]
DMM9GEA	DT	Small molecular drug
DMM9GEA	PC	73755010
DMM9GEA	MW	532.5
DMM9GEA	FM	C27H29FO10
DMM9GEA	IC	InChI=1S/C27H29FO10/c1-11-19(30)35-17-15(29)25-16-13(28)14(23(2,3)4)24(25)18(34-10-12-8-6-5-7-9-12)20(31)37-22(24)38-27(25,21(32)36-16)26(11,17)33/h5-9,11,13-18,22,29,33H,10H2,1-4H3/t11?,13-,14?,15?,16?,17-,18-,22?,24?,25?,26+,27-/m0/s1
DMM9GEA	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)OCC7=CC=CC=C7)C([C@@H]5F)C(C)(C)C)O
DMM9GEA	IK	LFVHCLPCEWRXME-CLNXZACASA-N
DMM9GEA	IU	(1S,6R,9S,13S,17R)-8-tert-butyl-9-fluoro-12,17-dihydroxy-16-methyl-6-phenylmethoxy-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMM9GEA	DE	Discovery agent

DMAM5WJ	ID	DMAM5WJ
DMAM5WJ	DN	10-OBn-epi-ginkgolide C
DMAM5WJ	HS	Investigative
DMAM5WJ	SN	10-OBn-epi-ginkgolide C; 10-OBn-epi-GC
DMAM5WJ	DT	Small molecular drug
DMAM5WJ	PC	73755013
DMAM5WJ	MW	530.5
DMAM5WJ	FM	C27H30O11
DMAM5WJ	IC	InChI=1S/C27H30O11/c1-11-19(30)35-17-15(29)25-16-13(28)14(23(2,3)4)24(25)18(34-10-12-8-6-5-7-9-12)20(31)37-22(24)38-27(25,21(32)36-16)26(11,17)33/h5-9,11,13-18,22,28-29,33H,10H2,1-4H3/t11?,13-,14?,15?,16?,17-,18-,22?,24?,25?,26+,27-/m0/s1
DMAM5WJ	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)OCC7=CC=CC=C7)C([C@@H]5O)C(C)(C)C)O
DMAM5WJ	IK	YPOMAFCMSAKBRX-CLNXZACASA-N
DMAM5WJ	IU	(1S,6R,9S,13S,17R)-8-tert-butyl-9,12,17-trihydroxy-16-methyl-6-phenylmethoxy-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMAM5WJ	DE	Discovery agent

DMS0I5V	ID	DMS0I5V
DMS0I5V	DN	10-OBn-ginkgolide B
DMS0I5V	HS	Investigative
DMS0I5V	SN	10-OBn-ginkgolide B; 10-OBn-GB
DMS0I5V	DT	Small molecular drug
DMS0I5V	PC	73755011
DMS0I5V	MW	514.5
DMS0I5V	FM	C27H30O10
DMS0I5V	IC	InChI=1S/C27H30O10/c1-12-19(29)35-17-16(28)25-15-10-14(23(2,3)4)24(25)18(33-11-13-8-6-5-7-9-13)20(30)36-22(24)37-27(25,21(31)34-15)26(12,17)32/h5-9,12,14-18,22,28,32H,10-11H2,1-4H3/t12?,14?,15?,16?,17-,18-,22?,24?,25?,26+,27-/m0/s1
DMS0I5V	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)OCC7=CC=CC=C7)C(C5)C(C)(C)C)O
DMS0I5V	IK	PHJOWQWLQBFEEM-ZTPSGWAGSA-N
DMS0I5V	IU	(1S,6R,13S,17R)-8-tert-butyl-12,17-dihydroxy-16-methyl-6-phenylmethoxy-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMS0I5V	DE	Discovery agent

DMOXKLH	ID	DMOXKLH
DMOXKLH	DN	10-OBn-ginkgolide C
DMOXKLH	HS	Investigative
DMOXKLH	SN	10-OBn-ginkgolide C; 10-OBn-GC
DMOXKLH	DT	Small molecular drug
DMOXKLH	PC	73755012
DMOXKLH	MW	530.5
DMOXKLH	FM	C27H30O11
DMOXKLH	IC	InChI=1S/C27H30O11/c1-11-19(30)35-17-15(29)25-16-13(28)14(23(2,3)4)24(25)18(34-10-12-8-6-5-7-9-12)20(31)37-22(24)38-27(25,21(32)36-16)26(11,17)33/h5-9,11,13-18,22,28-29,33H,10H2,1-4H3/t11?,13-,14?,15?,16?,17+,18+,22?,24?,25?,26-,27+/m1/s1
DMOXKLH	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)OCC7=CC=CC=C7)C([C@H]5O)C(C)(C)C)O
DMOXKLH	IK	YPOMAFCMSAKBRX-WULOTIIESA-N
DMOXKLH	IU	(1S,6R,9R,13S,17R)-8-tert-butyl-9,12,17-trihydroxy-16-methyl-6-phenylmethoxy-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMOXKLH	DE	Discovery agent

DMR3A5N	ID	DMR3A5N
DMR3A5N	DN	10-Propargyl-5,8-Dideazafolic Acid
DMR3A5N	HS	Investigative
DMR3A5N	DT	Small molecular drug
DMR3A5N	PC	135438608
DMR3A5N	MW	477.5
DMR3A5N	FM	C24H23N5O6
DMR3A5N	IC	InChI=1S/C24H23N5O6/c1-2-11-29(13-14-3-8-18-17(12-14)22(33)28-24(25)27-18)16-6-4-15(5-7-16)21(32)26-19(23(34)35)9-10-20(30)31/h1,3-8,12,19H,9-11,13H2,(H,26,32)(H,30,31)(H,34,35)(H3,25,27,28,33)/t19-/m0/s1
DMR3A5N	CS	C#CCN(CC1=CC2=C(C=C1)N=C(NC2=O)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMR3A5N	IK	LTKHPMDRMUCUEB-IBGZPJMESA-N
DMR3A5N	IU	(2S)-2-[[4-[(2-amino-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]benzoyl]amino]pentanedioic acid
DMR3A5N	CA	CAS 76849-19-9
DMR3A5N	CB	CHEBI:3258

DMD1258	ID	DMD1258
DMD1258	DN	10-Propyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DMD1258	HS	Investigative
DMD1258	SN	10Pr-DBOA-11one; 10-Propyl-dibenz(b,f)(1,4)oxazepin-11-(10H)-one; 135810-41-2; 5-propylbenzo[b][1,4]benzoxazepin-6-one; 10-Propyl-dibenz[b,f][1,4]oxazepin-11-(10H)-one; Dibenzoxazepinone 1; AC1L9R9M; CHEMBL56451; SCHEMBL9004262; BDBM1973; DTXSID50159532; OGPOBJPKGVLINB-UHFFFAOYSA-N; 10-propyl-10H-dibenz[b,f][1.4]oxazepin-11-one; 10-Propyldibenz[b,f][1,4]oxazepin-11(10H)-one
DMD1258	DT	Small molecular drug
DMD1258	PC	453917
DMD1258	MW	253.29
DMD1258	FM	C16H15NO2
DMD1258	IC	InChI=1S/C16H15NO2/c1-2-11-17-13-8-4-6-10-15(13)19-14-9-5-3-7-12(14)16(17)18/h3-10H,2,11H2,1H3
DMD1258	CS	CCCN1C2=CC=CC=C2OC3=CC=CC=C3C1=O
DMD1258	IK	OGPOBJPKGVLINB-UHFFFAOYSA-N
DMD1258	IU	5-propylbenzo[b][1,4]benzoxazepin-6-one
DMD1258	CA	CAS 135810-41-2
DMD1258	DE	Discovery agent

DMZ3N8A	ID	DMZ3N8A
DMZ3N8A	DN	10-Propyl-10H-dibenzo[b,f][1,4]thiazepin-11-one
DMZ3N8A	HS	Investigative
DMZ3N8A	SN	10Pr-DBTA-11one; 10-Propyl-dibenz(b,f)(1,4)thiazepin-11-(10H)-one; 135810-44-5; 5-propylbenzo[b][1,4]benzothiazepin-6-one; 10-Propyl-dibenz[b,f][1,4]thiazepin-11-(10H)-one; Dibenzoxazepinone 5; AC1L9R9G; CHEMBL55258; BDBM1994; SCHEMBL9004259; DTXSID30159535; ARJSKRFEYLKXQL-UHFFFAOYSA-N; 10-Propyldibenzo[b,f][1,4]thiazepin-11(10H)-one; 10-n-propyl-dibenz[b,f][1,4]thiazepin-11(10H)-one
DMZ3N8A	DT	Small molecular drug
DMZ3N8A	PC	453911
DMZ3N8A	MW	269.4
DMZ3N8A	FM	C16H15NOS
DMZ3N8A	IC	InChI=1S/C16H15NOS/c1-2-11-17-13-8-4-6-10-15(13)19-14-9-5-3-7-12(14)16(17)18/h3-10H,2,11H2,1H3
DMZ3N8A	CS	CCCN1C2=CC=CC=C2SC3=CC=CC=C3C1=O
DMZ3N8A	IK	ARJSKRFEYLKXQL-UHFFFAOYSA-N
DMZ3N8A	IU	5-propylbenzo[b][1,4]benzothiazepin-6-one
DMZ3N8A	CA	CAS 135810-44-5
DMZ3N8A	DE	Discovery agent

DM8XRCT	ID	DM8XRCT
DM8XRCT	DN	10R-hydroxylobel-7-ene
DM8XRCT	HS	Investigative
DM8XRCT	SN	CHEMBL217815; 10R-hydroxylobel-7-ene
DM8XRCT	DT	Small molecular drug
DM8XRCT	PC	44416422
DM8XRCT	MW	321.5
DM8XRCT	FM	C22H27NO
DM8XRCT	IC	InChI=1S/C22H27NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,15-16,20-22,24H,8,13-14,17H2,1H3/b16-15+/t20-,21+,22-/m1/s1
DM8XRCT	CS	CN1[C@@H](CCC[C@@H]1/C=C/C2=CC=CC=C2)C[C@H](C3=CC=CC=C3)O
DM8XRCT	IK	IKYXUFYHDWVXST-LRGONLHBSA-N
DM8XRCT	IU	(1R)-2-[(2S,6R)-1-methyl-6-[(E)-2-phenylethenyl]piperidin-2-yl]-1-phenylethanol
DM8XRCT	DE	Discovery agent

DMN93QT	ID	DMN93QT
DMN93QT	DN	10R-hydroxylobelane
DMN93QT	HS	Investigative
DMN93QT	SN	10R-hydroxylobelane; CHEMBL213148
DMN93QT	DT	Small molecular drug
DMN93QT	PC	44416453
DMN93QT	MW	323.5
DMN93QT	FM	C22H29NO
DMN93QT	IC	InChI=1S/C22H29NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,20-22,24H,8,13-17H2,1H3/t20-,21+,22-/m1/s1
DMN93QT	CS	CN1[C@H](CCC[C@H]1C[C@H](C2=CC=CC=C2)O)CCC3=CC=CC=C3
DMN93QT	IK	MUSFCRGEWKAWEE-BHIFYINESA-N
DMN93QT	IU	(1R)-2-[(2S,6R)-1-methyl-6-(2-phenylethyl)piperidin-2-yl]-1-phenylethanol
DMN93QT	DE	Discovery agent

DMN1YQ6	ID	DMN1YQ6
DMN1YQ6	DN	10S-hydroxylobel-7-ene
DMN1YQ6	HS	Investigative
DMN1YQ6	SN	CHEMBL124219; 10S-hydroxylobel-7-ene; SCHEMBL14178950; BDBM50080826; (S)-1-Phenyl-2-(1-methyl-6alpha-trans-styryl-2alpha-piperidinyl)ethanol
DMN1YQ6	DT	Small molecular drug
DMN1YQ6	PC	10687251
DMN1YQ6	MW	321.5
DMN1YQ6	FM	C22H27NO
DMN1YQ6	IC	InChI=1S/C22H27NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,15-16,20-22,24H,8,13-14,17H2,1H3/b16-15+/t20-,21+,22+/m1/s1
DMN1YQ6	CS	CN1[C@@H](CCC[C@@H]1/C=C/C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O
DMN1YQ6	IK	IKYXUFYHDWVXST-XIGZGLEXSA-N
DMN1YQ6	IU	(1S)-2-[(2S,6R)-1-methyl-6-[(E)-2-phenylethenyl]piperidin-2-yl]-1-phenylethanol
DMN1YQ6	DE	Discovery agent

DM54AKV	ID	DM54AKV
DM54AKV	DN	10S-hydroxylobelane
DM54AKV	HS	Investigative
DM54AKV	SN	10S-hydroxylobelane; CHEMBL122317; SCHEMBL14178961; BDBM50080814; (S)-2-((2S,6R)-1-Methyl-6-phenethyl-piperidin-2-yl)-1-phenyl-ethanol
DM54AKV	DT	Small molecular drug
DM54AKV	PC	10782199
DM54AKV	MW	323.5
DM54AKV	FM	C22H29NO
DM54AKV	IC	InChI=1S/C22H29NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,20-22,24H,8,13-17H2,1H3/t20-,21+,22+/m1/s1
DM54AKV	CS	CN1[C@H](CCC[C@H]1C[C@@H](C2=CC=CC=C2)O)CCC3=CC=CC=C3
DM54AKV	IK	MUSFCRGEWKAWEE-FSSWDIPSSA-N
DM54AKV	IU	(1S)-2-[(2S,6R)-1-methyl-6-(2-phenylethyl)piperidin-2-yl]-1-phenylethanol
DM54AKV	DE	Discovery agent

DMEAGI6	ID	DMEAGI6
DMEAGI6	DN	10-trifluoroacetyl-DDACTHF
DMEAGI6	HS	Investigative
DMEAGI6	DT	Small molecular drug
DMEAGI6	PC	135929093
DMEAGI6	MW	527.4
DMEAGI6	FM	C22H24F3N5O7
DMEAGI6	IC	InChI=1S/C22H24F3N5O7/c23-22(24,25)16(33)12(2-1-3-13-17(26)29-21(27)30-19(13)35)10-4-6-11(7-5-10)18(34)28-14(20(36)37)8-9-15(31)32/h4-7,12,14H,1-3,8-9H2,(H,28,34)(H,31,32)(H,36,37)(H5,26,27,29,30,35)
DMEAGI6	CS	C1=CC(=CC=C1C(CCCC2=C(N=C(NC2=O)N)N)C(=O)C(F)(F)F)C(=O)NC(CCC(=O)O)C(=O)O
DMEAGI6	IK	GMLVQBYTPQKEQF-UHFFFAOYSA-N
DMEAGI6	IU	2-[[4-[6-(2,4-diamino-6-oxo-1H-pyrimidin-5-yl)-1,1,1-trifluoro-2-oxohexan-3-yl]benzoyl]amino]pentanedioic acid
DMEAGI6	DE	Discovery agent

DMIRSA5	ID	DMIRSA5
DMIRSA5	DN	10Z-Hymenialdisine
DMIRSA5	HS	Investigative
DMIRSA5	SN	Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173
DMIRSA5	DT	Small molecular drug
DMIRSA5	PC	135413546
DMIRSA5	MW	324.13
DMIRSA5	FM	C11H10BrN5O2
DMIRSA5	IC	InChI=1S/C11H10BrN5O2/c12-6-3-5-4(7-10(19)17-11(13)16-7)1-2-14-9(18)8(5)15-6/h3,15H,1-2H2,(H,14,18)(H3,13,16,17,19)/b7-4-
DMIRSA5	CS	C\\1CNC(=O)C2=C(/C1=C\\3/C(=O)NC(=N3)N)C=C(N2)Br
DMIRSA5	IK	ATBAETXFFCOZOY-DAXSKMNVSA-N
DMIRSA5	IU	(4Z)-4-(2-amino-5-oxo-1H-imidazol-4-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one
DMIRSA5	CA	CAS 82005-12-7
DMIRSA5	DE	Discovery agent

DME0OGM	ID	DME0OGM
DME0OGM	DN	11,12-dihydro-dibenzo[a,e]cyclooctene-5,6-dione
DME0OGM	HS	Investigative
DME0OGM	SN	AC1MBM6T; CHEMBL235931; SCHEMBL13712393; ZINC3848035; AKOS004901956
DME0OGM	DT	Small molecular drug
DME0OGM	PC	2752926
DME0OGM	MW	236.26
DME0OGM	FM	C16H12O2
DME0OGM	IC	InChI=1S/C16H12O2/c17-15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)16(15)18/h1-8H,9-10H2
DME0OGM	CS	C1CC2=CC=CC=C2C(=O)C(=O)C3=CC=CC=C31
DME0OGM	IK	FBFVXHNJGVOZPS-UHFFFAOYSA-N
DME0OGM	IU	tricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaene-2,3-dione
DME0OGM	DE	Discovery agent

DMFVP6K	ID	DMFVP6K
DMFVP6K	DN	11A1
DMFVP6K	HS	Investigative
DMFVP6K	CP	Tokyo Metropolitan Institute of Gerontology
DMFVP6K	DT	Antibody
DMFVP6K	DE	Alzheimer disease

DM0EPJT	ID	DM0EPJT
DM0EPJT	DN	11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B
DM0EPJT	HS	Investigative
DM0EPJT	SN	CHEMBL1097371; 11beta,13-Dihydro-10-epi-8-deoxycumam-brin B; BDBM50318411; LS-23585; 11betaH,13-Dihydro-10-epi-8-deoxycumambrin B
DM0EPJT	DT	Small molecular drug
DM0EPJT	PC	10354739
DM0EPJT	MW	250.33
DM0EPJT	FM	C15H22O3
DM0EPJT	IC	InChI=1S/C15H22O3/c1-8-4-5-11-12(8)13-10(6-7-15(11,3)17)9(2)14(16)18-13/h4,9-13,17H,5-7H2,1-3H3/t9-,10-,11+,12-,13-,15-/m0/s1
DM0EPJT	CS	C[C@H]1[C@@H]2CC[C@]([C@@H]3CC=C([C@@H]3[C@H]2OC1=O)C)(C)O
DM0EPJT	IK	CWACFPQPFUIHTR-WBSYEDSCSA-N
DM0EPJT	IU	(3S,3aS,6S,6aR,9aR,9bS)-6-hydroxy-3,6,9-trimethyl-3,3a,4,5,6a,7,9a,9b-octahydroazuleno[4,5-b]furan-2-one
DM0EPJT	DE	Discovery agent

DMH5QEA	ID	DMH5QEA
DMH5QEA	DN	11-Butyryloxy-N-n-propylnoraporphine
DMH5QEA	HS	Investigative
DMH5QEA	SN	CHEMBL478671; 11-Butyryloxy-N-n-propylnoraporphine
DMH5QEA	DT	Small molecular drug
DMH5QEA	PC	25141414
DMH5QEA	MW	349.5
DMH5QEA	FM	C23H27NO2
DMH5QEA	IC	InChI=1S/C23H27NO2/c1-3-7-21(25)26-20-11-6-9-17-15-19-22-16(12-14-24(19)13-4-2)8-5-10-18(22)23(17)20/h5-6,8-11,19H,3-4,7,12-15H2,1-2H3/t19-/m1/s1
DMH5QEA	CS	CCCC(=O)OC1=CC=CC2=C1C3=CC=CC4=C3[C@@H](C2)N(CC4)CCC
DMH5QEA	IK	PSFOXKHONDMYHK-LJQANCHMSA-N
DMH5QEA	IU	[(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] butanoate
DMH5QEA	DE	Discovery agent

DMYGE3K	ID	DMYGE3K
DMYGE3K	DN	11C-PBR-170
DMYGE3K	HS	Investigative
DMYGE3K	SN	Radiolabeled peripheral benzodiazepine receptor ligand, Royal Prince Alfred Hospital; PRB-170-[11C]; Carbon-11-PBR-170
DMYGE3K	CP	Royal Prince Alfred Hospital
DMYGE3K	DE	Discovery agent

DM1ERJC	ID	DM1ERJC
DM1ERJC	DN	11-deoxy-PGE1
DM1ERJC	HS	Investigative
DM1ERJC	SN	11-deoxyprostaglandin E1; doproston
DM1ERJC	DT	Small molecular drug
DM1ERJC	PC	5283055
DM1ERJC	MW	338.5
DM1ERJC	FM	C20H34O4
DM1ERJC	IC	InChI=1S/C20H34O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h12,14,16-18,21H,2-11,13,15H2,1H3,(H,23,24)/b14-12+/t16-,17-,18+/m0/s1
DM1ERJC	CS	CCCCC[C@@H](/C=C/[C@H]1CCC(=O)[C@@H]1CCCCCCC(=O)O)O
DM1ERJC	IK	DPNOTBLPQOITGU-LDDQNKHRSA-N
DM1ERJC	IU	7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
DM1ERJC	CA	CAS 37786-00-8
DM1ERJC	DE	Discovery agent

DMXLWOK	ID	DMXLWOK
DMXLWOK	DN	11-deoxy-PGE2
DMXLWOK	HS	Investigative
DMXLWOK	SN	11-deoxy-PGE2; 11-deoxy Prostaglandin E2; 9-oxo-15S-hydroxy-5Z,13E-prostadienoic acid; (Z)-7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 11-Deoxyprostaglandin E2; 35536-53-9; LMFA03010061; AC1NR1FV; 11-deoxy-Prostaglandin E2; SCHEMBL9247000; GTPL1945; MolPort-039-138-850; HMS3648H09; ZINC27640133; 1151AH; SR-01000946427
DMXLWOK	DT	Small molecular drug
DMXLWOK	PC	5283062
DMXLWOK	MW	336.5
DMXLWOK	FM	C20H32O4
DMXLWOK	IC	InChI=1S/C20H32O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h4,7,12,14,16-18,21H,2-3,5-6,8-11,13,15H2,1H3,(H,23,24)/b7-4-,14-12+/t16-,17-,18+/m0/s1
DMXLWOK	CS	CCCCC[C@@H](/C=C/[C@H]1CCC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O
DMXLWOK	IK	CTHZICXYLKQMKI-FOSBLDSVSA-N
DMXLWOK	IU	(Z)-7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMXLWOK	CA	CAS 35536-53-9
DMXLWOK	CB	CHEBI:165301
DMXLWOK	DE	Discovery agent

DMK41DJ	ID	DMK41DJ
DMK41DJ	DN	11H-benzo[a]carbazole
DMK41DJ	HS	Investigative
DMK41DJ	SN	11H-Benzo[a]carbazole; Benzocarbazole; 239-01-0; 1,2-Benzocarbazole; 1,2-Benzcarbazole; 11-Azachrysofluorene; Benzo[a]carbazole; 11H-Benzo(a)carbazole; BENZO(A)CARBAZOLE; UNII-3Y3SPE26QX; EINECS 205-945-4; NSC 403640; BRN 0155940; 3Y3SPE26QX; CHEMBL1173622; MYKQKWIPLZEVOW-UHFFFAOYSA-N; 67526-84-5; WLN: T D6 B566 CMJ; benzo[3,4]carbazole; benzo[1,2]carbazole; 1,2-Benzo-carbazole; AC1L1SJA; AC1Q4W1R; AC1Q1IZ3; SCHEMBL70791; 5-20-08-00456 (Beilstein Handbook Reference); CTK1A2947; MolPort-001-815-051; ZINC1690207; NSC60421; NSC403640
DMK41DJ	DT	Small molecular drug
DMK41DJ	PC	9196
DMK41DJ	MW	217.26
DMK41DJ	FM	C16H11N
DMK41DJ	IC	InChI=1S/C16H11N/c1-2-6-12-11(5-1)9-10-14-13-7-3-4-8-15(13)17-16(12)14/h1-10,17H
DMK41DJ	CS	C1=CC=C2C(=C1)C=CC3=C2NC4=CC=CC=C34
DMK41DJ	IK	MYKQKWIPLZEVOW-UHFFFAOYSA-N
DMK41DJ	IU	11H-benzo[a]carbazole
DMK41DJ	CA	CAS 239-01-0
DMK41DJ	DE	Discovery agent

DMX4I9D	ID	DMX4I9D
DMX4I9D	DN	11-Heptanoyloxy-N-n-propylnoraporphine
DMX4I9D	HS	Investigative
DMX4I9D	SN	CHEMBL516580; 11-Heptanoyloxy-N-n-propylnoraporphine
DMX4I9D	DT	Small molecular drug
DMX4I9D	PC	44579031
DMX4I9D	MW	391.5
DMX4I9D	FM	C26H33NO2
DMX4I9D	IC	InChI=1S/C26H33NO2/c1-3-5-6-7-14-24(28)29-23-13-9-11-20-18-22-25-19(15-17-27(22)16-4-2)10-8-12-21(25)26(20)23/h8-13,22H,3-7,14-18H2,1-2H3/t22-/m1/s1
DMX4I9D	CS	CCCCCCC(=O)OC1=CC=CC2=C1C3=CC=CC4=C3[C@@H](C2)N(CC4)CCC
DMX4I9D	IK	KWMUKPVHQQVHLC-JOCHJYFZSA-N
DMX4I9D	IU	[(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] heptanoate
DMX4I9D	DE	Discovery agent

DMRYV9E	ID	DMRYV9E
DMRYV9E	DN	11-Hexanoyloxy-N-n-propylnoraporphine
DMRYV9E	HS	Investigative
DMRYV9E	SN	CHEMBL515342; 11-Hexanoyloxy-N-n-propylnoraporphine
DMRYV9E	DT	Small molecular drug
DMRYV9E	PC	44579030
DMRYV9E	MW	377.5
DMRYV9E	FM	C25H31NO2
DMRYV9E	IC	InChI=1S/C25H31NO2/c1-3-5-6-13-23(27)28-22-12-8-10-19-17-21-24-18(14-16-26(21)15-4-2)9-7-11-20(24)25(19)22/h7-12,21H,3-6,13-17H2,1-2H3/t21-/m1/s1
DMRYV9E	CS	CCCCCC(=O)OC1=CC=CC2=C1C3=CC=CC4=C3[C@@H](C2)N(CC4)CCC
DMRYV9E	IK	IHDFATFMTYOPPY-OAQYLSRUSA-N
DMRYV9E	IU	[(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] hexanoate
DMRYV9E	DE	Discovery agent

DMM6CJI	ID	DMM6CJI
DMM6CJI	DN	11-keto-beta-boswellicacid
DMM6CJI	HS	Investigative
DMM6CJI	SN	11-Keto-beta-boswellic acid; UNII-0S3BIF6H0Q; 11-Keto Boswellic Acid; 0S3BIF6H0Q; 17019-92-0; CHEMBL437964; 11-Oxo-beta-boswellic acid; (4R)-3alpha-hydroxy-11-oxo-urs-12-en-23-oic acid; Keto-b-boswellic acid; 3alpha-Hydroxy-11-oxours-12-en-24-oic acid; 11-Oxo-; 11-Keto-; BETA-BOSWELLIC ACID,11-KETO; A-Hydroxy-11-oxours-12-en-24-oic acid; 11-Oxo-b-boswellic acid; 11-Keto-b-boswellic acid; SCHEMBL4388405; (3alpha,4beta)-3-Hydroxy-11-oxours-12-en-23-oic acid
DMM6CJI	DT	Small molecular drug
DMM6CJI	PC	9847548
DMM6CJI	MW	470.7
DMM6CJI	FM	C30H46O4
DMM6CJI	IC	InChI=1S/C30H46O4/c1-17-8-11-26(3)14-15-28(5)19(23(26)18(17)2)16-20(31)24-27(4)12-10-22(32)30(7,25(33)34)21(27)9-13-29(24,28)6/h16-18,21-24,32H,8-15H2,1-7H3,(H,33,34)/t17-,18+,21-,22-,23+,24-,26-,27+,28-,29-,30-/m1/s1
DMM6CJI	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@H]([C@]5(C)C(=O)O)O)C)C)[C@@H]2[C@H]1C)C)C
DMM6CJI	IK	YIMHGPSYDOGBPI-YZCVQEKWSA-N
DMM6CJI	IU	(3R,4R,4aR,6aR,6bS,8aR,11R,12S,12aR,14aR,14bS)-3-hydroxy-4,6a,6b,8a,11,12,14b-heptamethyl-14-oxo-1,2,3,4a,5,6,7,8,9,10,11,12,12a,14a-tetradecahydropicene-4-carboxylic acid
DMM6CJI	CA	CAS 17019-92-0
DMM6CJI	DE	Discovery agent

DM1WPE3	ID	DM1WPE3
DM1WPE3	DN	11-keto-ursolic acid
DM1WPE3	HS	Investigative
DM1WPE3	SN	11-keto-ursolic acid; Obtusilin; CHEMBL603710; 105870-59-5; MolPort-039-339-172; ZINC45385190; BDBM50307108; AKOS016036263; 3beta-Hydroxy-11-oxours-12-en-28-oic acid
DM1WPE3	DT	Small molecular drug
DM1WPE3	PC	21671982
DM1WPE3	MW	470.7
DM1WPE3	FM	C30H46O4
DM1WPE3	IC	InChI=1S/C30H46O4/c1-17-8-13-30(25(33)34)15-14-28(6)19(23(30)18(17)2)16-20(31)24-27(5)11-10-22(32)26(3,4)21(27)9-12-29(24,28)7/h16-18,21-24,32H,8-15H2,1-7H3,(H,33,34)/t17-,18+,21+,22+,23+,24-,27+,28-,29-,30+/m1/s1
DM1WPE3	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DM1WPE3	IK	MDQJVSLVPQYJLP-HUWCOUCRSA-N
DM1WPE3	IU	(1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,5,6,6a,7,8,8a,10,11,12,14b-tetradecahydropicene-4a-carboxylic acid
DM1WPE3	DE	Discovery agent

DM9IHFY	ID	DM9IHFY
DM9IHFY	DN	11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol
DM9IHFY	HS	Investigative
DM9IHFY	SN	CHEMBL207706; 11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol
DM9IHFY	DT	Small molecular drug
DM9IHFY	PC	44411876
DM9IHFY	MW	249.31
DM9IHFY	FM	C17H15NO
DM9IHFY	IC	InChI=1S/C17H15NO/c1-18-16-10-12(19)7-9-14(16)15-8-6-11-4-2-3-5-13(11)17(15)18/h2-5,7,9-10,19H,6,8H2,1H3
DM9IHFY	CS	CN1C2=C(C=CC(=C2)O)C3=C1C4=CC=CC=C4CC3
DM9IHFY	IK	MZXLONQJNNQZJT-UHFFFAOYSA-N
DM9IHFY	IU	11-methyl-5,6-dihydrobenzo[a]carbazol-9-ol
DM9IHFY	DE	Discovery agent

DM62FEH	ID	DM62FEH
DM62FEH	DN	11-Propionyloxy-N-n-propylnoraporphine
DM62FEH	HS	Investigative
DM62FEH	SN	CHEMBL515187; 11-Propionyloxy-N-n-propylnoraporphine
DM62FEH	DT	Small molecular drug
DM62FEH	PC	44578927
DM62FEH	MW	335.4
DM62FEH	FM	C22H25NO2
DM62FEH	IC	InChI=1S/C22H25NO2/c1-3-12-23-13-11-15-7-5-9-17-21(15)18(23)14-16-8-6-10-19(22(16)17)25-20(24)4-2/h5-10,18H,3-4,11-14H2,1-2H3/t18-/m1/s1
DM62FEH	CS	CCCN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=CC=C4)OC(=O)CC
DM62FEH	IK	FKAOLIWLWAYCIA-GOSISDBHSA-N
DM62FEH	IU	[(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] propanoate
DM62FEH	DE	Discovery agent

DMM91WE	ID	DMM91WE
DMM91WE	DN	11-valeryloxynoraporphine
DMM91WE	HS	Investigative
DMM91WE	SN	11-valeryloxynoraporphine; CHEMBL403550; BDBM50202292; pentanoic acid (R)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl ester
DMM91WE	DT	Small molecular drug
DMM91WE	PC	44447998
DMM91WE	MW	363.5
DMM91WE	FM	C24H29NO2
DMM91WE	IC	InChI=1S/C24H29NO2/c1-3-5-12-22(26)27-21-11-7-9-18-16-20-23-17(13-15-25(20)14-4-2)8-6-10-19(23)24(18)21/h6-11,20H,3-5,12-16H2,1-2H3/t20-/m1/s1
DMM91WE	CS	CCCCC(=O)OC1=CC=CC2=C1C3=CC=CC4=C3[C@@H](C2)N(CC4)CCC
DMM91WE	IK	JGCVBGVDWQJTDF-HXUWFJFHSA-N
DMM91WE	IU	[(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] pentanoate
DMM91WE	DE	Discovery agent

DM84YCI	ID	DM84YCI
DM84YCI	DN	12-(3-Adamantan-1-yl-ureido)-dodeca noic acid
DM84YCI	HS	Investigative
DM84YCI	SN	AUDA; 479413-70-2; CHEMBL215387; Urea-based compound, 18; 12-[(adamantan-1-ylcarbamoyl)amino]dodecanoic acid; MLS002415562; SCHEMBL120588; CTK8F0781; BDBM25737; DTXSID20435153; HMS3650M09; HMS2204E15; HMS3332K06; AUDA, &gt; ZINC27645646; MFCD12912267; 1631AH; SMR001339077; ACM479413702; RT-011342; 12-(3-adamantan-1-yl-ureido)-dodecanoic acid; SR-01000860315; SR-01000860315-2; 12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid
DM84YCI	DT	Small molecular drug
DM84YCI	PC	10069117
DM84YCI	MW	392.6
DM84YCI	FM	C23H40N2O3
DM84YCI	IC	InChI=1S/C23H40N2O3/c26-21(27)10-8-6-4-2-1-3-5-7-9-11-24-22(28)25-23-15-18-12-19(16-23)14-20(13-18)17-23/h18-20H,1-17H2,(H,26,27)(H2,24,25,28)
DM84YCI	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCCCCCCCCC(=O)O
DM84YCI	IK	XLGSEOAVLVTJDH-UHFFFAOYSA-N
DM84YCI	IU	12-(1-adamantylcarbamoylamino)dodecanoic acid
DM84YCI	CA	CAS 479413-70-2
DM84YCI	DE	Discovery agent

DM0F3SR	ID	DM0F3SR
DM0F3SR	DN	12-(3-n-Hexylureido)dodec-8(Z)-enoic acid
DM0F3SR	HS	Investigative
DM0F3SR	SN	CHEMBL560029; 12-(3-n-Hexylureido)dodec-8(Z)-enoic acid
DM0F3SR	DT	Small molecular drug
DM0F3SR	PC	44234914
DM0F3SR	MW	340.5
DM0F3SR	FM	C19H36N2O3
DM0F3SR	IC	InChI=1S/C19H36N2O3/c1-2-3-4-13-16-20-19(24)21-17-14-11-9-7-5-6-8-10-12-15-18(22)23/h7,9H,2-6,8,10-17H2,1H3,(H,22,23)(H2,20,21,24)/b9-7-
DM0F3SR	CS	CCCCCCNC(=O)NCCC/C=C\\CCCCCCC(=O)O
DM0F3SR	IK	CQPDPYBIHJYCBO-CLFYSBASSA-N
DM0F3SR	IU	(Z)-12-(hexylcarbamoylamino)dodec-8-enoic acid
DM0F3SR	DE	Discovery agent

DMAFNXZ	ID	DMAFNXZ
DMAFNXZ	DN	12-(3-n-Pentylureidooxy)dodec-8(Z)-enoic acid
DMAFNXZ	HS	Investigative
DMAFNXZ	SN	CHEMBL560419; 12-(3-n-Pentylureidooxy)dodec-8(Z)-enoic acid
DMAFNXZ	DT	Small molecular drug
DMAFNXZ	PC	44234917
DMAFNXZ	MW	342.5
DMAFNXZ	FM	C18H34N2O4
DMAFNXZ	IC	InChI=1S/C18H34N2O4/c1-2-3-12-15-19-18(23)20-24-16-13-10-8-6-4-5-7-9-11-14-17(21)22/h6,8H,2-5,7,9-16H2,1H3,(H,21,22)(H2,19,20,23)/b8-6-
DMAFNXZ	CS	CCCCCNC(=O)NOCCC/C=C\\CCCCCCC(=O)O
DMAFNXZ	IK	QHNVLXQJNGLGOO-VURMDHGXSA-N
DMAFNXZ	IU	(Z)-12-(pentylcarbamoylamino)oxydodec-8-enoic acid
DMAFNXZ	DE	Discovery agent

DMVP39I	ID	DMVP39I
DMVP39I	DN	12,13-DEHYDRO-8-O-ACETYLMANZAMINE A
DMVP39I	HS	Investigative
DMVP39I	SN	12,13-dehydro-8-O-acetylmanzamine A; CHEMBL252520
DMVP39I	DT	Small molecular drug
DMVP39I	PC	23643836
DMVP39I	MW	588.8
DMVP39I	FM	C38H44N4O2
DMVP39I	IC	InChI=1S/C38H44N4O2/c1-26(43)44-33-16-12-15-29-30-17-19-39-35(36(30)40-34(29)33)31-23-27-13-8-4-2-3-6-10-20-41-22-18-32(31)38(25-41)24-28-14-9-5-7-11-21-42(28)37(27)38/h2,4,9,12-17,19,23,28,32,37,40H,3,5-8,10-11,18,20-22,24-25H2,1H3/b4-2-,14-9-,27-13-/t28-,32?,37-,38-/m0/s1
DMVP39I	CS	CC(=O)OC1=CC=CC2=C1NC3=C2C=CN=C3C4=C/C/5=C/C/C=C\\CCCCN6CCC4[C@]7(C6)[C@H]5N8CCCC/C=C\\[C@H]8C7
DMVP39I	IK	XANHIHHFYZZCBY-CVNPAURDSA-N
DMVP39I	IU	[1-[(2R,4R,5Z,12S,13Z,16Z)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,13,16,25-tetraen-25-yl]-9H-pyrido[3,4-b]indol-8-yl] acetate
DMVP39I	DE	Discovery agent

DM8XAWU	ID	DM8XAWU
DM8XAWU	DN	12,13-DEHYDROMANZAMINE A
DM8XAWU	HS	Investigative
DM8XAWU	SN	12,13-dehydromanzamine A; CHEMBL268202
DM8XAWU	DT	Small molecular drug
DM8XAWU	PC	23643835
DM8XAWU	MW	530.7
DM8XAWU	FM	C36H42N4
DM8XAWU	IC	InChI=1S/C36H42N4/c1-2-5-11-20-39-22-18-31-30(33-34-29(17-19-37-33)28-15-9-10-16-32(28)38-34)23-26(13-7-3-1)35-36(31,25-39)24-27-14-8-4-6-12-21-40(27)35/h1,3,8-10,13-17,19,23,27,31,35,38H,2,4-7,11-12,18,20-22,24-25H2/b3-1-,14-8-,26-13-/t27-,31?,35-,36-/m0/s1
DM8XAWU	CS	C1CCN2CCC3C(=C/C(=C/C/C=C\\C1)/[C@H]4[C@]3(C2)C[C@H]/5N4CCCC/C=C5)C6=NC=CC7=C6NC8=CC=CC=C78
DM8XAWU	IK	XJPQQKQCGFEXKO-SGYLFFKUSA-N
DM8XAWU	IU	(2R,4R,5Z,12S,13Z,16Z)-25-(9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,13,16,25-tetraene
DM8XAWU	DE	Discovery agent

DMAUPQR	ID	DMAUPQR
DMAUPQR	DN	12,17-dehydroxyriccardin C
DMAUPQR	HS	Investigative
DMAUPQR	SN	12,17-dehydroxyriccardin C; Riccardin C derivative, 20e; CHEMBL429324; BDBM23852
DMAUPQR	DT	Small molecular drug
DMAUPQR	PC	24860514
DMAUPQR	MW	392.5
DMAUPQR	FM	C28H24O2
DMAUPQR	IC	InChI=1S/C28H24O2/c29-27-18-12-22-6-5-20-8-14-24(15-9-20)26-4-2-1-3-23(26)13-7-21-10-16-25(17-11-21)30-28(27)19-22/h1-4,8-12,14-19,29H,5-7,13H2
DMAUPQR	CS	C1CC2=CC(=C(C=C2)O)OC3=CC=C(CCC4=CC=CC=C4C5=CC=C1C=C5)C=C3
DMAUPQR	IK	CTGIBRGBEVEPID-UHFFFAOYSA-N
DMAUPQR	IU	14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2,4,6,10(29),11,13(28),15,17,19(27),22,25-dodecaen-16-ol
DMAUPQR	DE	Discovery agent

DMW172Q	ID	DMW172Q
DMW172Q	DN	123I-DRM-106
DMW172Q	HS	Investigative
DMW172Q	SN	DRM-106-[123I]; Iodine-123-DRM-106; SPECT diagnostic (Alzheimer's disease), Fujifilm RI Pharma Co Ltd
DMW172Q	CP	FUJIFILM Corp
DMW172Q	DT	Small molecular drug
DMW172Q	PC	49801966
DMW172Q	MW	382.19
DMW172Q	FM	C16H11IN4
DMW172Q	IC	InChI=1S/C16H11IN4/c17-13-5-6-16-19-15(10-21(16)9-13)12-3-1-11(2-4-12)14-7-8-18-20-14/h1-10H,(H,18,20)/i17-4
DMW172Q	CS	C1=CC(=CC=C1C2=CC=NN2)C3=CN4C=C(C=CC4=N3)[123I]
DMW172Q	IK	OLFQWTDIJLVADS-HHRLKWFBSA-N
DMW172Q	IU	6-(123I)iodanyl-2-[4-(1H-pyrazol-5-yl)phenyl]imidazo[1,2-a]pyridine
DMW172Q	DE	Alzheimer disease

DMTOSXF	ID	DMTOSXF
DMTOSXF	DN	12-dehydroxyriccardin C
DMTOSXF	HS	Investigative
DMTOSXF	SN	12-dehydroxyriccardin C; Riccardin C derivative, 20c; CHEMBL260632; BDBM23850; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-4'-ol
DMTOSXF	DT	Small molecular drug
DMTOSXF	PC	24860512
DMTOSXF	MW	408.5
DMTOSXF	FM	C28H24O3
DMTOSXF	IC	InChI=1S/C28H24O3/c29-24-12-15-26-22-9-3-19(4-10-22)1-2-21-8-16-27(30)28(17-21)31-25-13-6-20(7-14-25)5-11-23(26)18-24/h3-4,6-10,12-18,29-30H,1-2,5,11H2
DMTOSXF	CS	C1CC2=CC(=C(C=C2)O)OC3=CC=C(CCC4=C(C=CC(=C4)O)C5=CC=C1C=C5)C=C3
DMTOSXF	IK	VSXIMYQGZUVRSK-UHFFFAOYSA-N
DMTOSXF	IU	14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2(7),3,5,10(29),11,13(28),15,17,19(27),22,25-dodecaene-5,16-diol
DMTOSXF	DE	Discovery agent

DM9JI8C	ID	DM9JI8C
DM9JI8C	DN	12-epi LTB4
DM9JI8C	HS	Investigative
DM9JI8C	SN	12(S)-Leukotriene B4
DM9JI8C	DT	Small molecular drug
DM9JI8C	PC	5283130
DM9JI8C	MW	336.5
DM9JI8C	FM	C20H32O4
DM9JI8C	IC	InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11-/t18-,19+/m0/s1
DM9JI8C	CS	CCCCC/C=C\\C[C@@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O
DM9JI8C	IK	VNYSSYRCGWBHLG-CBBLYLIKSA-N
DM9JI8C	IU	(5S,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid
DM9JI8C	CA	CAS 83709-73-3
DM9JI8C	CB	CHEBI:72795
DM9JI8C	DE	Discovery agent

DMZ9PW3	ID	DMZ9PW3
DMZ9PW3	DN	12-EPI-SALVINORIN A
DMZ9PW3	HS	Investigative
DMZ9PW3	SN	12-epi-Salvinorin A; CHEMBL458235; SCHEMBL10071862; OBSYBRPAKCASQB-KWMFLVSKSA-N
DMZ9PW3	DT	Small molecular drug
DMZ9PW3	PC	25242485
DMZ9PW3	MW	432.5
DMZ9PW3	FM	C23H28O8
DMZ9PW3	IC	InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17+,19-,22-,23-/m0/s1
DMZ9PW3	CS	CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DMZ9PW3	IK	OBSYBRPAKCASQB-KWMFLVSKSA-N
DMZ9PW3	IU	methyl (2R,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMZ9PW3	DE	Discovery agent

DMA2EIK	ID	DMA2EIK
DMA2EIK	DN	12-hydroxyheptadecatrienoic acid
DMA2EIK	HS	Investigative
DMA2EIK	SN	12S-HHTrE
DMA2EIK	DT	Small molecular drug
DMA2EIK	PC	5283141
DMA2EIK	MW	280.4
DMA2EIK	FM	C17H28O3
DMA2EIK	IC	InChI=1S/C17H28O3/c1-2-3-10-13-16(18)14-11-8-6-4-5-7-9-12-15-17(19)20/h5-8,11,14,16,18H,2-4,9-10,12-13,15H2,1H3,(H,19,20)/b7-5-,8-6+,14-11+/t16-/m0/s1
DMA2EIK	CS	CCCCC[C@@H](/C=C/C=C/C/C=C\\CCCC(=O)O)O
DMA2EIK	IK	KUKJHGXXZWHSBG-WBGSEQOASA-N
DMA2EIK	IU	(5Z,8E,10E,12S)-12-hydroxyheptadeca-5,8,10-trienoic acid
DMA2EIK	CA	CAS 54397-84-1
DMA2EIK	CB	CHEBI:63977
DMA2EIK	DE	Discovery agent

DMKH0OC	ID	DMKH0OC
DMKH0OC	DN	12-O-deacetyl-12-epi-19-deoxy-21-hydroxyscalarin
DMKH0OC	HS	Investigative
DMKH0OC	SN	CHEMBL251695; CHEBI:68038; 12-O-deacetyl-12-epi-19-deoxy-21-hydroxyscalarin; BDBM50226460
DMKH0OC	DT	Small molecular drug
DMKH0OC	PC	24178658
DMKH0OC	MW	402.6
DMKH0OC	FM	C25H38O4
DMKH0OC	IC	InChI=1S/C25H38O4/c1-22(14-26)9-5-10-23(2)17(22)8-11-24(3)18-7-6-15-16(13-29-21(15)28)25(18,4)20(27)12-19(23)24/h6,16-20,26-27H,5,7-14H2,1-4H3/t16-,17-,18-,19+,20+,22-,23-,24-,25+/m0/s1
DMKH0OC	CS	C[C@]1(CCC[C@]2([C@H]1CC[C@@]3([C@@H]2C[C@H]([C@]4([C@H]3CC=C5[C@@H]4COC5=O)C)O)C)C)CO
DMKH0OC	IK	LXWMXTKOJPFGPW-NFXGRNOLSA-N
DMKH0OC	IU	(5aS,5bR,7aR,8R,11aR,11bR,13R,13aS,13bR)-13-hydroxy-8-(hydroxymethyl)-5b,8,11a,13a-tetramethyl-5,5a,6,7,7a,9,10,11,11b,12,13,13b-dodecahydro-1H-phenanthro[2,1-e][2]benzofuran-3-one
DMKH0OC	CA	CAS 957131-96-3
DMKH0OC	CB	CHEBI:68038
DMKH0OC	DE	Discovery agent

DMLR2FB	ID	DMLR2FB
DMLR2FB	DN	12-Phenylheme
DMLR2FB	HS	Investigative
DMLR2FB	DT	Small molecular drug
DMLR2FB	PC	5287448
DMLR2FB	MW	694.6
DMLR2FB	FM	C40H38FeN4O4
DMLR2FB	IC	InChI=1S/C40H40N4O4.Fe/c1-7-26-24(6)39-38(25-12-10-9-11-13-25)40-27(8-2)21(3)32(43-40)18-30-22(4)28(14-16-36(45)46)34(41-30)20-35-29(15-17-37(47)48)23(5)31(42-35)19-33(26)44-39;/h7-13,18-20,24,26H,1-2,14-17H2,3-6H3,(H4,41,42,43,44,45,46,47,48);/q;+2/p-2
DMLR2FB	CS	CC1C(C2=NC1=C(C3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=C2)[N-]5)C)CCC(=O)O)CCC(=O)O)C)C)C=C)C6=CC=CC=C6)C=C.[Fe+2]
DMLR2FB	IK	ODMHOWCUYFSODS-UHFFFAOYSA-L
DMLR2FB	IU	3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethyl-10-phenyl-7,8-dihydroporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)
DMLR2FB	DE	Discovery agent

DMK0GJ3	ID	DMK0GJ3
DMK0GJ3	DN	12R-HETE
DMK0GJ3	HS	Investigative
DMK0GJ3	SN	12r-HETE
DMK0GJ3	DT	Small molecular drug
DMK0GJ3	PC	5283156
DMK0GJ3	MW	320.5
DMK0GJ3	FM	C20H32O3
DMK0GJ3	IC	InChI=1S/C20H32O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h7-11,13-14,17,19,21H,2-6,12,15-16,18H2,1H3,(H,22,23)/b9-7-,11-8-,13-10-,17-14+/t19-/m1/s1
DMK0GJ3	CS	CCCCC/C=C\\C[C@H](/C=C/C=C\\C/C=C\\CCCC(=O)O)O
DMK0GJ3	IK	ZNHVWPKMFKADKW-ZYBDYUKJSA-N
DMK0GJ3	IU	(5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid
DMK0GJ3	CA	CAS 82337-46-0
DMK0GJ3	CB	CHEBI:34144
DMK0GJ3	DE	Discovery agent

DMBEZ09	ID	DMBEZ09
DMBEZ09	DN	12S-HETE
DMBEZ09	HS	Investigative
DMBEZ09	SN	12S-Hete; 12(S)-HETE; 54397-83-0; 12(S)-Hydroxyeicosatetraenoic acid; CHEBI:34146; 12-Hete; (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid; 12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid; 12-Hydroxyeicosatetraenoic acid; 12(S)-Hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoic acid; (5Z,8Z,10E,14Z)-(12S)-12-Hydroxyicosa-5,8,10,14-tetraenoic acid; (5Z,8Z,10E,14Z)-(12S)-12-Hydroxyeicosa-5,8,10,14-tetraenoic acid; (S)-12-HETE; 12S-[3H]HETE; 12 hete; 12-L-Hydroxy-5,8,10,14-eicosatetraenoic acid; AC1NR1NB;  12(S)-hydroxyeicosatetraenoic acid
DMBEZ09	DT	Small molecular drug
DMBEZ09	PC	5283155
DMBEZ09	MW	320.5
DMBEZ09	FM	C20H32O3
DMBEZ09	IC	InChI=1S/C20H32O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h7-11,13-14,17,19,21H,2-6,12,15-16,18H2,1H3,(H,22,23)/b9-7-,11-8-,13-10-,17-14+/t19-/m0/s1
DMBEZ09	CS	CCCCC/C=C\\C[C@@H](/C=C/C=C\\C/C=C\\CCCC(=O)O)O
DMBEZ09	IK	ZNHVWPKMFKADKW-LQWMCKPYSA-N
DMBEZ09	IU	(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid
DMBEZ09	CA	CAS 54397-83-0
DMBEZ09	CB	CHEBI:34146
DMBEZ09	DE	Discovery agent

DM6ZX1O	ID	DM6ZX1O
DM6ZX1O	DN	12S-HPETE
DM6ZX1O	HS	Investigative
DM6ZX1O	SN	12-(S)-hydroperoxyeicosatetraenoic acid; 12-(S)-HPETE
DM6ZX1O	DT	Small molecular drug
DM6ZX1O	PC	5280892
DM6ZX1O	MW	336.5
DM6ZX1O	FM	C20H32O4
DM6ZX1O	IC	InChI=1S/C20H32O4/c1-2-3-4-5-10-13-16-19(24-23)17-14-11-8-6-7-9-12-15-18-20(21)22/h7-11,13-14,17,19,23H,2-6,12,15-16,18H2,1H3,(H,21,22)/b9-7-,11-8-,13-10-,17-14+/t19-/m0/s1
DM6ZX1O	CS	CCCCC/C=C\\C[C@@H](/C=C/C=C\\C/C=C\\CCCC(=O)O)OO
DM6ZX1O	IK	ZIOZYRSDNLNNNJ-LQWMCKPYSA-N
DM6ZX1O	IU	(5Z,8Z,10E,12S,14Z)-12-hydroperoxyicosa-5,8,10,14-tetraenoic acid
DM6ZX1O	CA	CAS 71774-10-2
DM6ZX1O	CB	CHEBI:15626
DM6ZX1O	DE	Discovery agent

DMRO1IU	ID	DMRO1IU
DMRO1IU	DN	1-3 Sugar Ring of Pentamannosyl 6-Phosphate
DMRO1IU	HS	Investigative
DMRO1IU	SN	1-3 SUGAR RING OF PENTAMANNOSYL 6-PHOSPHATE; P3M; AC1L9GSL; DB02755; WURCS=2.0/2,3,2/[a1122h-1a_1-5][a1122h-1a_1-5_6*OPO/3O/3=O]/1-1-2/a3-b1_b3-c1; 6-O-phosphono-alpha-D-mannopyranosyl-(1-&gt;3)-alpha-D-mannopyranosyl-(1-&gt;3)-alpha-D-mannopyranose; [(2R,3S,4S,5S,6R)-6-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2S,3S,4S,5R,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-4-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMRO1IU	DT	Small molecular drug
DMRO1IU	PC	444727
DMRO1IU	MW	584.4
DMRO1IU	FM	C18H33O19P
DMRO1IU	IC	InChI=1S/C18H33O19P/c19-1-4-8(22)14(12(26)16(28)33-4)36-18-13(27)15(9(23)5(2-20)34-18)37-17-11(25)10(24)7(21)6(35-17)3-32-38(29,30)31/h4-28H,1-3H2,(H2,29,30,31)/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16+,17-,18-/m1/s1
DMRO1IU	CS	C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)O[C@@H]2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)O)O)O)O
DMRO1IU	IK	HDQMHAJOIVYOIP-NAVBLJQLSA-N
DMRO1IU	IU	[(2R,3S,4S,5S,6R)-6-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2S,3S,4S,5R,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-4-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMRO1IU	DE	Discovery agent

DMIY9DB	ID	DMIY9DB
DMIY9DB	DN	13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid
DMIY9DB	HS	Investigative
DMIY9DB	SN	CHEMBL551158; 13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid
DMIY9DB	DT	Small molecular drug
DMIY9DB	PC	44234660
DMIY9DB	MW	356.6
DMIY9DB	FM	C19H36N2O2S
DMIY9DB	IC	InChI=1S/C19H36N2O2S/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h5,7H,2-4,6,8-17H2,1H3,(H,22,23)(H2,20,21,24)/b7-5-
DMIY9DB	CS	CCCCCNC(=S)NCCCC/C=C\\CCCCCCC(=O)O
DMIY9DB	IK	XZCDMUCBAMBZQK-ALCCZGGFSA-N
DMIY9DB	IU	(Z)-13-(pentylcarbamothioylamino)tridec-8-enoic acid
DMIY9DB	DE	Discovery agent

DM0NRJG	ID	DM0NRJG
DM0NRJG	DN	13-(3-n-Pentylureido)tridec-5(Z)-enoic acid
DM0NRJG	HS	Investigative
DM0NRJG	SN	CHEMBL551162; 13-(3-n-Pentylureido)tridec-5(Z)-enoic acid
DM0NRJG	DT	Small molecular drug
DM0NRJG	PC	44234912
DM0NRJG	MW	340.5
DM0NRJG	FM	C19H36N2O3
DM0NRJG	IC	InChI=1S/C19H36N2O3/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h6,8H,2-5,7,9-17H2,1H3,(H,22,23)(H2,20,21,24)/b8-6-
DM0NRJG	CS	CCCCCNC(=O)NCCCCCCC/C=C\\CCCC(=O)O
DM0NRJG	IK	YUYHEPLRNYDYLU-VURMDHGXSA-N
DM0NRJG	IU	(Z)-13-(pentylcarbamoylamino)tridec-5-enoic acid
DM0NRJG	DE	Discovery agent

DM17DY6	ID	DM17DY6
DM17DY6	DN	13-(3-n-Pentylureido)tridec-8(E)-enoic acid
DM17DY6	HS	Investigative
DM17DY6	SN	CHEMBL559573; 13-(3-n-Pentylureido)tridec-8(E)-enoic acid
DM17DY6	DT	Small molecular drug
DM17DY6	PC	44234663
DM17DY6	MW	340.5
DM17DY6	FM	C19H36N2O3
DM17DY6	IC	InChI=1S/C19H36N2O3/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h5,7H,2-4,6,8-17H2,1H3,(H,22,23)(H2,20,21,24)/b7-5+
DM17DY6	CS	CCCCCNC(=O)NCCCC/C=C/CCCCCCC(=O)O
DM17DY6	IK	CVIWLKCFJOISPD-FNORWQNLSA-N
DM17DY6	IU	(E)-13-(pentylcarbamoylamino)tridec-8-enoic acid
DM17DY6	DE	Discovery agent

DM9VDOG	ID	DM9VDOG
DM9VDOG	DN	13-(3-n-Pentylureido)tridec-8-ynoic acid
DM9VDOG	HS	Investigative
DM9VDOG	SN	CHEMBL551161; 13-(3-n-Pentylureido)tridec-8-ynoic acid
DM9VDOG	DT	Small molecular drug
DM9VDOG	PC	44234911
DM9VDOG	MW	338.5
DM9VDOG	FM	C19H34N2O3
DM9VDOG	IC	InChI=1S/C19H34N2O3/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h2-4,6,8-17H2,1H3,(H,22,23)(H2,20,21,24)
DM9VDOG	CS	CCCCCNC(=O)NCCCCC#CCCCCCCC(=O)O
DM9VDOG	IK	CFQZBGUYWSZYQK-UHFFFAOYSA-N
DM9VDOG	IU	13-(pentylcarbamoylamino)tridec-8-ynoic acid
DM9VDOG	DE	Discovery agent

DM3I6PS	ID	DM3I6PS
DM3I6PS	DN	13-(3-Pentyluredo)tridec-8(Z)-enoic acid
DM3I6PS	HS	Investigative
DM3I6PS	SN	CHEMBL558097; 13-(3-Pentyluredo)tridec-8(Z)-enoic acid; SCHEMBL13193158
DM3I6PS	DT	Small molecular drug
DM3I6PS	PC	44234656
DM3I6PS	MW	340.5
DM3I6PS	FM	C19H36N2O3
DM3I6PS	IC	InChI=1S/C19H36N2O3/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h5,7H,2-4,6,8-17H2,1H3,(H,22,23)(H2,20,21,24)/b7-5-
DM3I6PS	CS	CCCCCNC(=O)NCCCC/C=C\\CCCCCCC(=O)O
DM3I6PS	IK	CVIWLKCFJOISPD-ALCCZGGFSA-N
DM3I6PS	IU	(Z)-13-(pentylcarbamoylamino)tridec-8-enoic acid
DM3I6PS	DE	Discovery agent

DM8HRTC	ID	DM8HRTC
DM8HRTC	DN	13-(5-n-Pentylfuran-2-yl)tridec-8(Z)-enoic acid
DM8HRTC	HS	Investigative
DM8HRTC	SN	CHEMBL559279; 13-(5-n-Pentylfuran-2-yl)tridec-8(Z)-enoic acid
DM8HRTC	DT	Small molecular drug
DM8HRTC	PC	44235412
DM8HRTC	MW	348.5
DM8HRTC	FM	C22H36O3
DM8HRTC	IC	InChI=1S/C22H36O3/c1-2-3-12-15-20-18-19-21(25-20)16-13-10-8-6-4-5-7-9-11-14-17-22(23)24/h4,6,18-19H,2-3,5,7-17H2,1H3,(H,23,24)/b6-4-
DM8HRTC	CS	CCCCCC1=CC=C(O1)CCCC/C=C\\CCCCCCC(=O)O
DM8HRTC	IK	SJFMNLQBZCGDPV-XQRVVYSFSA-N
DM8HRTC	IU	(Z)-13-(5-pentylfuran-2-yl)tridec-8-enoic acid
DM8HRTC	DE	Discovery agent

DMXK6D2	ID	DMXK6D2
DMXK6D2	DN	13-(N-Isopropylheptanamido)tridec-8(Z)-enoic acid
DMXK6D2	HS	Investigative
DMXK6D2	SN	CHEMBL560026; 13-(N-Isopropylheptanamido)tridec-8(Z)-enoic acid; SCHEMBL15645552
DMXK6D2	DT	Small molecular drug
DMXK6D2	PC	44235173
DMXK6D2	MW	381.6
DMXK6D2	FM	C23H43NO3
DMXK6D2	IC	InChI=1S/C23H43NO3/c1-4-5-6-15-18-22(25)24(21(2)3)20-17-14-12-10-8-7-9-11-13-16-19-23(26)27/h8,10,21H,4-7,9,11-20H2,1-3H3,(H,26,27)/b10-8-
DMXK6D2	CS	CCCCCCC(=O)N(CCCC/C=C\\CCCCCCC(=O)O)C(C)C
DMXK6D2	IK	SWWIYFCSVNBILX-NTMALXAHSA-N
DMXK6D2	IU	(Z)-13-[heptanoyl(propan-2-yl)amino]tridec-8-enoic acid
DMXK6D2	DE	Discovery agent

DM689TH	ID	DM689TH
DM689TH	DN	13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid
DM689TH	HS	Investigative
DM689TH	SN	CHEMBL559454; 13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid
DM689TH	DT	Small molecular drug
DM689TH	PC	44235172
DM689TH	MW	353.5
DM689TH	FM	C21H39NO3
DM689TH	IC	InChI=1S/C21H39NO3/c1-3-4-5-14-17-20(23)22(2)19-16-13-11-9-7-6-8-10-12-15-18-21(24)25/h7,9H,3-6,8,10-19H2,1-2H3,(H,24,25)/b9-7-
DM689TH	CS	CCCCCCC(=O)N(C)CCCC/C=C\\CCCCCCC(=O)O
DM689TH	IK	CJHOGNAQWWHHBN-CLFYSBASSA-N
DM689TH	IU	(Z)-13-[heptanoyl(methyl)amino]tridec-8-enoic acid
DM689TH	DE	Discovery agent

DMSF3C8	ID	DMSF3C8
DMSF3C8	DN	13-(n-Pentylcarbamoyloxy)tridec-8(Z)-enoic acid
DMSF3C8	HS	Investigative
DMSF3C8	SN	CHEMBL558485; 13-(n-Pentylcarbamoyloxy)tridec-8(Z)-enoic acid
DMSF3C8	DT	Small molecular drug
DMSF3C8	PC	44234662
DMSF3C8	MW	341.5
DMSF3C8	FM	C19H35NO4
DMSF3C8	IC	InChI=1S/C19H35NO4/c1-2-3-13-16-20-19(23)24-17-14-11-9-7-5-4-6-8-10-12-15-18(21)22/h5,7H,2-4,6,8-17H2,1H3,(H,20,23)(H,21,22)/b7-5-
DMSF3C8	CS	CCCCCNC(=O)OCCCC/C=C\\CCCCCCC(=O)O
DMSF3C8	IK	MSASWGXYEFVTGT-ALCCZGGFSA-N
DMSF3C8	IU	(Z)-13-(pentylcarbamoyloxy)tridec-8-enoic acid
DMSF3C8	DE	Discovery agent

DMZVWCG	ID	DMZVWCG
DMZVWCG	DN	13,14-dihydro-15-keto-PGD2
DMZVWCG	HS	Investigative
DMZVWCG	SN	13,14-dihydro-15-keto-prostaglandin D2; 13,14-dihydro-15-ketoprostaglandin D2; DK-PGD2; 13,14-dihydro-15-oxo PGD2
DMZVWCG	DT	Small molecular drug
DMZVWCG	PC	5283036
DMZVWCG	MW	352.5
DMZVWCG	FM	C20H32O5
DMZVWCG	IC	InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-18,22H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,18+/m1/s1
DMZVWCG	CS	CCCCCC(=O)CC[C@@H]1[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O
DMZVWCG	IK	VSRXYLYXIXYEST-KZTWKYQFSA-N
DMZVWCG	IU	(Z)-7-[(1R,2R,5S)-5-hydroxy-3-oxo-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid
DMZVWCG	CA	CAS 59894-07-4
DMZVWCG	CB	CHEBI:72603
DMZVWCG	DE	Discovery agent

DMNT1XI	ID	DMNT1XI
DMNT1XI	DN	13,14-dihydro-15-keto-PGF2alpha
DMNT1XI	HS	Investigative
DMNT1XI	SN	Dhk-pgf2alpha
DMNT1XI	DT	Small molecular drug
DMNT1XI	PC	5283039
DMNT1XI	MW	354.5
DMNT1XI	FM	C20H34O5
DMNT1XI	IC	InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-19,22-23H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,18+,19-/m1/s1
DMNT1XI	CS	CCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O
DMNT1XI	IK	VKTIONYPMSCHQI-XAGFEHLVSA-N
DMNT1XI	IU	(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid
DMNT1XI	CA	CAS 27376-76-7
DMNT1XI	CB	CHEBI:63976
DMNT1XI	DE	Discovery agent

DMNRMTX	ID	DMNRMTX
DMNRMTX	DN	13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha
DMNRMTX	HS	Investigative
DMNRMTX	SN	CHEMBL36041; 7-[(1R,2R,3R,5S)-2-[(3R)-4-(3-chlorophenoxy)-3-hydroxybutyl]-3,5-dihydroxycyclopentyl]heptanoic acid; AC1NSKAB; GTPL1955; 13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha; 13,14-Dihydro-16-m-Chlorophenoxy-Omega-Tetranor PGF-1alpha; BDBM50085911; 7-{2-[4-(3-Chloro-phenoxy)-3-hydroxy-butyl]-3,5-dihydroxy-cyclopentyl}-heptanoic acid; 7-[(1R)-2beta-[(3R)-3-Hydroxy-4-(3-chlorophenoxy)butyl]-3alpha,5alpha-dihydroxycyclopentane-1alpha-yl]heptanoic acid
DMNRMTX	DT	Small molecular drug
DMNRMTX	PC	5311240
DMNRMTX	MW	428.9
DMNRMTX	FM	C22H33ClO6
DMNRMTX	IC	InChI=1S/C22H33ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h5-7,12,16,18-21,24-26H,1-4,8-11,13-14H2,(H,27,28)/t16-,18-,19-,20+,21-/m1/s1
DMNRMTX	CS	C1[C@@H]([C@@H]([C@H]([C@@H]1O)CC[C@H](COC2=CC(=CC=C2)Cl)O)CCCCCCC(=O)O)O
DMNRMTX	IK	XECZBZWECQIBDA-LELZANKISA-N
DMNRMTX	IU	7-[(1R,2R,3R,5S)-2-[(3R)-4-(3-chlorophenoxy)-3-hydroxybutyl]-3,5-dihydroxycyclopentyl]heptanoic acid
DMNRMTX	DE	Discovery agent

DMTEACQ	ID	DMTEACQ
DMTEACQ	DN	13,14-dihydro-PGE1
DMTEACQ	HS	Investigative
DMTEACQ	SN	13,14-dihydro-prostaglandin E1
DMTEACQ	DT	Small molecular drug
DMTEACQ	PC	161273
DMTEACQ	MW	356.5
DMTEACQ	FM	C20H36O5
DMTEACQ	IC	InChI=1S/C20H36O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h15-17,19,21,23H,2-14H2,1H3,(H,24,25)/t15-,16+,17+,19+/m0/s1
DMTEACQ	CS	CCCCC[C@@H](CC[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O
DMTEACQ	IK	DPOINJQWXDTOSF-DODZYUBVSA-N
DMTEACQ	IU	7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid
DMTEACQ	CA	CAS 19313-28-1
DMTEACQ	CB	CHEBI:89310
DMTEACQ	DE	Discovery agent

DMMTPK3	ID	DMMTPK3
DMMTPK3	DN	135PAM1
DMMTPK3	HS	Investigative
DMMTPK3	SN	135PAM1; GTPL8343; 3-[3,5-bis(trifluoromethyl)phenyl]-1-[(3,4-dichlorophenyl)methyl]-1-[2-(5-methoxy-1H-indol-3-yl)ethyl]urea
DMMTPK3	DT	Small molecular drug
DMMTPK3	PC	56953333
DMMTPK3	MW	604.4
DMMTPK3	FM	C27H21Cl2F6N3O2
DMMTPK3	IC	InChI=1S/C27H21Cl2F6N3O2/c1-40-20-3-5-24-21(12-20)16(13-36-24)6-7-38(14-15-2-4-22(28)23(29)8-15)25(39)37-19-10-17(26(30,31)32)9-18(11-19)27(33,34)35/h2-5,8-13,36H,6-7,14H2,1H3,(H,37,39)
DMMTPK3	CS	COC1=CC2=C(C=C1)NC=C2CCN(CC3=CC(=C(C=C3)Cl)Cl)C(=O)NC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMMTPK3	IK	FAXDMTURZKFXIY-UHFFFAOYSA-N
DMMTPK3	IU	3-[3,5-bis(trifluoromethyl)phenyl]-1-[(3,4-dichlorophenyl)methyl]-1-[2-(5-methoxy-1H-indol-3-yl)ethyl]urea
DMMTPK3	DE	Discovery agent

DMJ2T7P	ID	DMJ2T7P
DMJ2T7P	DN	13-Acetylphorbol
DMJ2T7P	HS	Investigative
DMJ2T7P	SN	Phorbol 13-acetate; 13-Acetylphorbol; Phorbol-13-acetate; Phorbol 13-monoacetate; 32752-29-7; CHEBI:45127; Phorbol13-acetate; (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9-trihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulen-9a-yl acetate; PRB; 5H-Cyclopropa(3,4)benz(1,2-e)azulen-5-one, 1,1a-alpha,1b-beta,4,4a,7a-alpha,7b,8,9,9a-decahydro-4a-alpha,7b-alpha,9-beta,9a-alpha-tetrahydroxy-3-hydroxymethyl-1,1,6,8-alpha-tetramethyl-, 9a-acetate
DMJ2T7P	DT	Small molecular drug
DMJ2T7P	PC	499953
DMJ2T7P	MW	406.5
DMJ2T7P	FM	C22H30O7
DMJ2T7P	IC	InChI=1S/C22H30O7/c1-10-6-15-20(27,17(10)25)8-13(9-23)7-14-16-19(4,5)22(16,29-12(3)24)18(26)11(2)21(14,15)28/h6-7,11,14-16,18,23,26-28H,8-9H2,1-5H3/t11-,14+,15-,16-,18-,20-,21-,22-/m1/s1
DMJ2T7P	CS	C[C@@H]1[C@H]([C@@]2([C@@H](C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)CO)O)C)O)OC(=O)C)O
DMJ2T7P	IK	SDSVJYOOAPRSDA-RPCQODIISA-N
DMJ2T7P	IU	[(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] acetate
DMJ2T7P	CA	CAS 32752-29-7
DMJ2T7P	CB	CHEBI:45127
DMJ2T7P	DE	Discovery agent

DMRVQCB	ID	DMRVQCB
DMRVQCB	DN	13-n-Heptanamidotridec-5-ynoic acid
DMRVQCB	HS	Investigative
DMRVQCB	SN	CHEMBL550898; 13-n-Heptanamidotridec-5-ynoic acid
DMRVQCB	DT	Small molecular drug
DMRVQCB	PC	44235174
DMRVQCB	MW	337.5
DMRVQCB	FM	C20H35NO3
DMRVQCB	IC	InChI=1S/C20H35NO3/c1-2-3-4-13-16-19(22)21-18-15-12-10-8-6-5-7-9-11-14-17-20(23)24/h2-6,8,10-18H2,1H3,(H,21,22)(H,23,24)
DMRVQCB	CS	CCCCCCC(=O)NCCCCCCCC#CCCCC(=O)O
DMRVQCB	IK	UGVCHIUURWYSNO-UHFFFAOYSA-N
DMRVQCB	IU	13-(heptanoylamino)tridec-5-ynoic acid
DMRVQCB	DE	Discovery agent

DM0LGWJ	ID	DM0LGWJ
DM0LGWJ	DN	13-n-Heptanamidotridec-8(Z)-enoic acid
DM0LGWJ	HS	Investigative
DM0LGWJ	SN	CHEMBL560420; 13-n-Heptanamidotridec-8(Z)-enoic acid
DM0LGWJ	DT	Small molecular drug
DM0LGWJ	PC	44235171
DM0LGWJ	MW	339.5
DM0LGWJ	FM	C20H37NO3
DM0LGWJ	IC	InChI=1S/C20H37NO3/c1-2-3-4-13-16-19(22)21-18-15-12-10-8-6-5-7-9-11-14-17-20(23)24/h6,8H,2-5,7,9-18H2,1H3,(H,21,22)(H,23,24)/b8-6-
DM0LGWJ	CS	CCCCCCC(=O)NCCCC/C=C\\CCCCCCC(=O)O
DM0LGWJ	IK	QCBRCTHDMJHJJU-VURMDHGXSA-N
DM0LGWJ	IU	(Z)-13-(heptanoylamino)tridec-8-enoic acid
DM0LGWJ	DE	Discovery agent

DM5NFB6	ID	DM5NFB6
DM5NFB6	DN	14-(n-Hexylamino)-14-oxotetradec-8(Z)-enoic acid
DM5NFB6	HS	Investigative
DM5NFB6	SN	CHEMBL561706; 14-(n-Hexylamino)-14-oxotetradec-8(Z)-enoic acid
DM5NFB6	DT	Small molecular drug
DM5NFB6	PC	44235175
DM5NFB6	MW	339.5
DM5NFB6	FM	C20H37NO3
DM5NFB6	IC	InChI=1S/C20H37NO3/c1-2-3-4-15-18-21-19(22)16-13-11-9-7-5-6-8-10-12-14-17-20(23)24/h5,7H,2-4,6,8-18H2,1H3,(H,21,22)(H,23,24)/b7-5-
DM5NFB6	CS	CCCCCCNC(=O)CCCC/C=C\\CCCCCCC(=O)O
DM5NFB6	IK	RDDSCWVCGRBWBZ-ALCCZGGFSA-N
DM5NFB6	IU	(Z)-14-(hexylamino)-14-oxotetradec-8-enoic acid
DM5NFB6	DE	Discovery agent

DMLZT64	ID	DMLZT64
DMLZT64	DN	1400W
DMLZT64	HS	Investigative
DMLZT64	SN	N-(3-(Aminomethyl)benzyl)acetamidine; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; 180001-34-7; N-(3-(aminomethyl)benzyl)-acetamidine; n-[3-(aminomethyl)benzyl]ethanimidamide; CHEMBL107251; CHEBI:90721; N-{[3-(aminomethyl)phenyl]methyl}ethanimidamide; RODUKNYOEVZQPR-UHFFFAOYSA-N; n-[3-(aminomethyl)benzyl]acetamidine; N-(3-(aminomethyl)benzyl)acetimidamide; N-(3-Aminomethyl-benzyl)-acetamidine; CHEMBL544788; 14W; N-[[3-(Aminomethyl)phenyl]methyl]ethanimidamide; Bio1_001405; Tocris-1415; AC1Q4SXP; AC1L1BGT; Lopac-W-4262; W 1400; SCHEMBL4467; Lopac0_001258;  W 1400; N-(3-(Aminomethyl)Benzyl)Acetamidine; N-(3-(aminomethyl)-benzyl)acetamidine
DMLZT64	DT	Small molecular drug
DMLZT64	PC	1433
DMLZT64	MW	177.25
DMLZT64	FM	C10H15N3
DMLZT64	IC	InChI=1S/C10H15N3/c1-8(12)13-7-10-4-2-3-9(5-10)6-11/h2-5H,6-7,11H2,1H3,(H2,12,13)
DMLZT64	CS	CC(=NCC1=CC=CC(=C1)CN)N
DMLZT64	IK	RODUKNYOEVZQPR-UHFFFAOYSA-N
DMLZT64	IU	N'-[[3-(aminomethyl)phenyl]methyl]ethanimidamide
DMLZT64	CA	CAS 180001-34-7
DMLZT64	CB	CHEBI:90721
DMLZT64	DE	Discovery agent

DMI7LXH	ID	DMI7LXH
DMI7LXH	DN	14-O-phenylpropylnaltrexone
DMI7LXH	HS	Investigative
DMI7LXH	SN	14-O-phenylpropylnaltrexone; CHEMBL514774; SCHEMBL3167650; BDBM50249017
DMI7LXH	DT	Small molecular drug
DMI7LXH	PC	44565511
DMI7LXH	MW	459.6
DMI7LXH	FM	C29H33NO4
DMI7LXH	IC	InChI=1S/C29H33NO4/c31-22-11-10-21-17-24-29(33-16-4-7-19-5-2-1-3-6-19)13-12-23(32)27-28(29,25(21)26(22)34-27)14-15-30(24)18-20-8-9-20/h1-3,5-6,10-11,20,24,27,31H,4,7-9,12-18H2/t24-,27+,28+,29-/m1/s1
DMI7LXH	CS	C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)OCCCC7=CC=CC=C7
DMI7LXH	IK	KOXWKZKLXNZQAO-ZLPBPMGLSA-N
DMI7LXH	IU	(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-9-hydroxy-4a-(3-phenylpropoxy)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMI7LXH	DE	Discovery agent

DMY9ZT8	ID	DMY9ZT8
DMY9ZT8	DN	15(R)-15-methyl-PGD2
DMY9ZT8	HS	Investigative
DMY9ZT8	SN	15R-15-methyl PGD2
DMY9ZT8	DT	Small molecular drug
DMY9ZT8	PC	5283097
DMY9ZT8	MW	366.5
DMY9ZT8	FM	C21H34O5
DMY9ZT8	IC	InChI=1S/C21H34O5/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25/h5,7,12,14,16-18,22,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25)/b7-5-,14-12+/t16-,17-,18+,21-/m1/s1
DMY9ZT8	CS	CCCCC[C@](C)(/C=C/[C@@H]1[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O)O
DMY9ZT8	IK	CTXLUMAOXBULOZ-BKVRKCTKSA-N
DMY9ZT8	IU	(Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(E,3R)-3-hydroxy-3-methyloct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid
DMY9ZT8	CA	CAS 210978-26-0
DMY9ZT8	DE	Discovery agent

DMG273T	ID	DMG273T
DMG273T	DN	15(S)-15-methyl-PGD2
DMG273T	HS	Investigative
DMG273T	SN	BRN 5989341
DMG273T	DT	Small molecular drug
DMG273T	PC	5283051
DMG273T	MW	366.5
DMG273T	FM	C21H34O5
DMG273T	IC	InChI=1S/C21H34O5/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25/h5,7,12,14,16-18,22,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25)/b7-5-,14-12+/t16-,17-,18+,21+/m1/s1
DMG273T	CS	CCCCC[C@@](C)(/C=C/[C@@H]1[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O)O
DMG273T	IK	CTXLUMAOXBULOZ-QEQARHSSSA-N
DMG273T	IU	(Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid
DMG273T	CA	CAS 85280-90-6
DMG273T	DE	Discovery agent

DMLSZW2	ID	DMLSZW2
DMLSZW2	DN	15-ACETOXY-EREMANTHOLIDE B
DMLSZW2	HS	Investigative
DMLSZW2	SN	15-acetoxy-eremantholide B
DMLSZW2	DT	Small molecular drug
DMLSZW2	PC	44398297
DMLSZW2	MW	420.5
DMLSZW2	FM	C22H28O8
DMLSZW2	IC	InChI=1S/C22H28O8/c1-6-11(2)22(26)21(5)18-15(28-19(21)25)7-13(10-27-12(3)23)14-8-17(24)20(4,29-14)9-16(18)30-22/h7-8,11,15-16,18,26H,6,9-10H2,1-5H3/b13-7-/t11-,15-,16+,18?,20-,21-,22-/m1/s1
DMLSZW2	CS	CC[C@@H](C)[C@@]1([C@@]2(C3[C@@H](O1)C[C@@]4(C(=O)C=C(O4)/C(=C\\[C@H]3OC2=O)/COC(=O)C)C)C)O
DMLSZW2	IK	UNFGCPCUYMXWDG-MRPVOENGSA-N
DMLSZW2	IU	[(1S,3R,7Z,9R,12S,13R)-13-[(2R)-butan-2-yl]-13-hydroxy-3,12-dimethyl-4,11-dioxo-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-dien-7-yl]methyl acetate
DMLSZW2	DE	Discovery agent

DMJC0NQ	ID	DMJC0NQ
DMJC0NQ	DN	15-DEOXYBUDLEIN A
DMJC0NQ	HS	Investigative
DMJC0NQ	SN	15-deoxybudlein A; Atripliciolide angelate
DMJC0NQ	DT	Small molecular drug
DMJC0NQ	PC	14314511
DMJC0NQ	MW	358.4
DMJC0NQ	FM	C20H22O6
DMJC0NQ	IC	InChI=1S/C20H22O6/c1-6-10(2)18(22)25-15-9-20(5)16(21)8-13(26-20)11(3)7-14-17(15)12(4)19(23)24-14/h6-8,14-15,17H,4,9H2,1-3,5H3/b10-6-,11-7-/t14-,15-,17+,20-/m1/s1
DMJC0NQ	CS	C/C=C(/C)\\C(=O)O[C@@H]1C[C@@]2(C(=O)C=C(O2)/C(=C\\[C@@H]3[C@@H]1C(=C)C(=O)O3)/C)C
DMJC0NQ	IK	QATUWZPYBIHFFR-JWHLFBEVSA-N
DMJC0NQ	IU	[(2Z,4R,8R,9R,11R)-2,11-dimethyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (Z)-2-methylbut-2-enoate
DMJC0NQ	DE	Discovery agent

DM8VUX3	ID	DM8VUX3
DM8VUX3	DN	15-deoxy-Delta(12, 14)-prostaglandin J(2)
DM8VUX3	HS	Investigative
DM8VUX3	SN	15d-PGJ2; 15-Deoxy-PGJ2; 15-Deoxy-delta-12,14-prostaglandin J2; 15-deoxy-delta12,14-prostaglandin J2; delta12,14-PGJ 2; UNII-ALI977775J; 87893-55-8; CHEMBL482477; CHEBI:34159; (5Z,12E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid; ALI977775J; delta-12,14-15-Deoxy-PGJ2; 15-Deoxy-delta12,14-prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J2; Prostaglandin J2, 15-Deoxy-Delta12,14; 15-Deoxy-delta 12, 14-Prostaglandin J2
DM8VUX3	DT	Small molecular drug
DM8VUX3	PC	5311211
DM8VUX3	MW	316.4
DM8VUX3	FM	C20H28O3
DM8VUX3	IC	InChI=1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7-,10-6+,18-13+/t17-/m0/s1
DM8VUX3	CS	CCCCC/C=C/C=C/1\\[C@H](C=CC1=O)C/C=C\\CCCC(=O)O
DM8VUX3	IK	VHRUMKCAEVRUBK-GODQJPCRSA-N
DM8VUX3	IU	(Z)-7-[(1S,5E)-5-[(E)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
DM8VUX3	CA	CAS 87893-55-8
DM8VUX3	CB	CHEBI:34159
DM8VUX3	DE	Discovery agent

DMJ27QT	ID	DMJ27QT
DMJ27QT	DN	15-deoxy-Delta12,14-PGD2
DMJ27QT	HS	Investigative
DMJ27QT	SN	15-deoxy-Delta12,14-prostaglandin D2; 15d-Delta12,14-PGD2
DMJ27QT	DT	Small molecular drug
DMJ27QT	PC	5283052
DMJ27QT	MW	334.4
DMJ27QT	FM	C20H30O4
DMJ27QT	IC	InChI=1S/C20H30O4/c1-2-3-4-5-6-9-12-16-17(19(22)15-18(16)21)13-10-7-8-11-14-20(23)24/h6-7,9-10,12,17,19,22H,2-5,8,11,13-15H2,1H3,(H,23,24)/b9-6+,10-7-,16-12+/t17-,19+/m1/s1
DMJ27QT	CS	CCCCC/C=C/C=C/1\\[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O
DMJ27QT	IK	QUGBPWLPAUHDTI-PLGLXCLHSA-N
DMJ27QT	IU	(Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(E)-oct-2-enylidene]-3-oxocyclopentyl]hept-5-enoic acid
DMJ27QT	CA	CAS 85235-11-6
DMJ27QT	DE	Discovery agent

DMNDECA	ID	DMNDECA
DMNDECA	DN	15-deoxy-Delta12,14-PGJ2
DMNDECA	HS	Investigative
DMNDECA	SN	15d-Delta12,14-PGJ2; LS-125843
DMNDECA	DT	Small molecular drug
DMNDECA	PC	5283035
DMNDECA	MW	316.4
DMNDECA	FM	C20H28O3
DMNDECA	IC	InChI=1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7-,10-6-,18-13+/t17-/m0/s1
DMNDECA	CS	CCCCC/C=C\\C=C\\1/[C@H](C=CC1=O)C/C=C\\CCCC(=O)O
DMNDECA	IK	VHRUMKCAEVRUBK-WKELIDJCSA-N
DMNDECA	IU	(Z)-7-[(1S,5E)-5-[(Z)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
DMNDECA	CA	CAS 87893-55-8
DMNDECA	DE	Discovery agent

DMR9SFM	ID	DMR9SFM
DMR9SFM	DN	15-deoxygoiazensolide
DMR9SFM	HS	Investigative
DMR9SFM	SN	Calaxin; CHEBI:3302; 15-deoxygoiazensolide; 30412-86-3; C09353; CHEMBL189790; 2-Propenoic acid, 2-methyl-, 2,3,3a,4,5,6,7,11a-octahydro-6,10-dimethyl-3-methylene-2,7-dioxo-6,9-epoxycyclodeca(b)furan-4-yl ester, (3aR-(3aR*,4R*,6R*,10Z,11aR*))-
DMR9SFM	DT	Small molecular drug
DMR9SFM	PC	5281431
DMR9SFM	MW	344.4
DMR9SFM	FM	C19H20O6
DMR9SFM	IC	InChI=1S/C19H20O6/c1-9(2)17(21)24-14-8-19(5)15(20)7-12(25-19)10(3)6-13-16(14)11(4)18(22)23-13/h6-7,13-14,16H,1,4,8H2,2-3,5H3/b10-6-/t13-,14-,16+,19-/m1/s1
DMR9SFM	CS	C/C/1=C/[C@@H]2[C@@H]([C@@H](C[C@@]3(C(=O)C=C1O3)C)OC(=O)C(=C)C)C(=C)C(=O)O2
DMR9SFM	IK	RYBHZNMPMHOBAR-IRNKKCRZSA-N
DMR9SFM	IU	[(2Z,4R,8R,9R,11R)-2,11-dimethyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] 2-methylprop-2-enoate
DMR9SFM	CA	CAS 30412-86-3
DMR9SFM	CB	CHEBI:3302
DMR9SFM	DE	Discovery agent

DMEML8B	ID	DMEML8B
DMEML8B	DN	15-hydroxyeicosatetraenoic acid
DMEML8B	HS	Investigative
DMEML8B	SN	15-Hydroxyeicosatetraenoic acid; Eicosatetraenoic acid, 15-hydroxy-; AC1O5OKC; SCHEMBL462602; LS-63796; (2E,4E,6E,8E)-15-hydroxyicosa-2,4,6,8-tetraenoic acid
DMEML8B	DT	Small molecular drug
DMEML8B	PC	6437873
DMEML8B	MW	320.5
DMEML8B	FM	C20H32O3
DMEML8B	IC	InChI=1S/C20H32O3/c1-2-3-13-16-19(21)17-14-11-9-7-5-4-6-8-10-12-15-18-20(22)23/h4-6,8,10,12,15,18-19,21H,2-3,7,9,11,13-14,16-17H2,1H3,(H,22,23)/b5-4+,8-6+,12-10+,18-15+
DMEML8B	CS	CCCCCC(CCCCC/C=C/C=C/C=C/C=C/C(=O)O)O
DMEML8B	IK	GQHZVWMHPQXBIA-QYANQBPOSA-N
DMEML8B	IU	(2E,4E,6E,8E)-15-hydroxyicosa-2,4,6,8-tetraenoic acid
DMEML8B	CA	CAS 73180-00-4
DMEML8B	DE	Discovery agent

DMQCRUG	ID	DMQCRUG
DMQCRUG	DN	15-isobutyrylmiguanin
DMQCRUG	HS	Investigative
DMQCRUG	SN	15-isobutyrylmiguanin
DMQCRUG	DT	Small molecular drug
DMQCRUG	PC	12039267
DMQCRUG	MW	348.4
DMQCRUG	FM	C19H24O6
DMQCRUG	IC	InChI=1S/C19H24O6/c1-11(2)18(22)24-10-13-5-4-6-14(9-20)16(21)8-15-12(3)19(23)25-17(15)7-13/h6-7,11,15,17,20H,3-5,8-10H2,1-2H3/b13-7-,14-6+/t15-,17+/m0/s1
DMQCRUG	CS	CC(C)C(=O)OC/C/1=C\\[C@@H]2[C@@H](CC(=O)/C(=C/CC1)/CO)C(=C)C(=O)O2
DMQCRUG	IK	TXZUNEFLWSLHBF-UZBZFLIQSA-N
DMQCRUG	IU	[(3aS,6E,10Z,11aR)-6-(hydroxymethyl)-3-methylidene-2,5-dioxo-4,8,9,11a-tetrahydro-3aH-cyclodeca[b]furan-10-yl]methyl 2-methylpropanoate
DMQCRUG	DE	Discovery agent

DMDKFGX	ID	DMDKFGX
DMDKFGX	DN	15-nor-18-Methoxycornaridine
DMDKFGX	HS	Investigative
DMDKFGX	SN	CHEMBL607096
DMDKFGX	DT	Small molecular drug
DMDKFGX	PC	46877891
DMDKFGX	MW	354.4
DMDKFGX	FM	C21H26N2O3
DMDKFGX	IC	InChI=1S/C21H26N2O3/c1-25-10-8-14-13-11-21(20(24)26-2)18-16(7-9-23(12-13)19(14)21)15-5-3-4-6-17(15)22-18/h3-6,13-14,19,22H,7-12H2,1-2H3/t13?,14?,19-,21+/m0/s1
DMDKFGX	CS	COCCC1[C@H]2[C@]3(CC1CN2CCC4=C3NC5=CC=CC=C45)C(=O)OC
DMDKFGX	IK	VNPGFSWKZRZJCI-XZKBRSTLSA-N
DMDKFGX	IU	methyl (1S,17S)-16-(2-methoxyethyl)-3,13-diazapentacyclo[13.2.1.02,10.04,9.013,17]octadeca-2(10),4,6,8-tetraene-1-carboxylate
DMDKFGX	DE	Discovery agent

DM41LV6	ID	DM41LV6
DM41LV6	DN	15S-HPETE
DM41LV6	HS	Investigative
DM41LV6	SN	15(S)-HPETE; 15-(S)-hydroperoxyeicosatetraenoic acid
DM41LV6	DT	Small molecular drug
DM41LV6	PC	5280893
DM41LV6	MW	336.5
DM41LV6	FM	C20H32O4
DM41LV6	IC	InChI=1S/C20H32O4/c1-2-3-13-16-19(24-23)17-14-11-9-7-5-4-6-8-10-12-15-18-20(21)22/h4-5,8-11,14,17,19,23H,2-3,6-7,12-13,15-16,18H2,1H3,(H,21,22)/b5-4-,10-8-,11-9-,17-14+/t19-/m0/s1
DM41LV6	CS	CCCCC[C@@H](/C=C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O)OO
DM41LV6	IK	BFWYTORDSFIVKP-VAEKSGALSA-N
DM41LV6	IU	(5Z,8Z,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid
DM41LV6	CA	CAS 70981-96-3
DM41LV6	CB	CHEBI:15628
DM41LV6	DE	Discovery agent

DMK4N2F	ID	DMK4N2F
DMK4N2F	DN	16-(2',2'-Dimethyl)-propylidene-estradiol
DMK4N2F	HS	Investigative
DMK4N2F	SN	SCHEMBL12379675
DMK4N2F	DT	Small molecular drug
DMK4N2F	PC	44407372
DMK4N2F	MW	340.5
DMK4N2F	FM	C23H32O2
DMK4N2F	IC	InChI=1S/C23H32O2/c1-22(2,3)13-15-12-20-19-7-5-14-11-16(24)6-8-17(14)18(19)9-10-23(20,4)21(15)25/h6,8,11,13,18-21,24-25H,5,7,9-10,12H2,1-4H3/b15-13+/t18?,19?,20?,21-,23-/m0/s1
DMK4N2F	CS	C[C@]12CCC3C(C1C/C(=C\\C(C)(C)C)/[C@@H]2O)CCC4=C3C=CC(=C4)O
DMK4N2F	IK	GJYCOULXILNZBK-LBIHAFKNSA-N
DMK4N2F	IU	(13S,16E,17S)-16-(2,2-dimethylpropylidene)-13-methyl-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMK4N2F	DE	Discovery agent

DMQYJB1	ID	DMQYJB1
DMQYJB1	DN	16-(2',2'-Dimethyl)-propylidene-estrone
DMQYJB1	HS	Investigative
DMQYJB1	SN	SCHEMBL12379631
DMQYJB1	DT	Small molecular drug
DMQYJB1	PC	44407482
DMQYJB1	MW	338.5
DMQYJB1	FM	C23H30O2
DMQYJB1	IC	InChI=1S/C23H30O2/c1-22(2,3)13-15-12-20-19-7-5-14-11-16(24)6-8-17(14)18(19)9-10-23(20,4)21(15)25/h6,8,11,13,18-20,24H,5,7,9-10,12H2,1-4H3/b15-13+/t18?,19?,20?,23-/m0/s1
DMQYJB1	CS	C[C@]12CCC3C(C1C/C(=C\\C(C)(C)C)/C2=O)CCC4=C3C=CC(=C4)O
DMQYJB1	IK	FSXMOAXUKSPGCO-MIWZRYNRSA-N
DMQYJB1	IU	(13S,16E)-16-(2,2-dimethylpropylidene)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one
DMQYJB1	DE	Discovery agent

DMCHMNF	ID	DMCHMNF
DMCHMNF	DN	16-(3-Ethylureido)hexadec-11(Z)-enoic acid
DMCHMNF	HS	Investigative
DMCHMNF	SN	CHEMBL560030; 16-(3-Ethylureido)hexadec-11(Z)-enoic acid; SCHEMBL3702468; BDBM50295084
DMCHMNF	DT	Small molecular drug
DMCHMNF	PC	44234916
DMCHMNF	MW	340.5
DMCHMNF	FM	C19H36N2O3
DMCHMNF	IC	InChI=1S/C19H36N2O3/c1-2-20-19(24)21-17-15-13-11-9-7-5-3-4-6-8-10-12-14-16-18(22)23/h7,9H,2-6,8,10-17H2,1H3,(H,22,23)(H2,20,21,24)/b9-7-
DMCHMNF	CS	CCNC(=O)NCCCC/C=C\\CCCCCCCCCC(=O)O
DMCHMNF	IK	OUFBVXMGWWCVFO-CLFYSBASSA-N
DMCHMNF	IU	(Z)-16-(ethylcarbamoylamino)hexadec-11-enoic acid
DMCHMNF	DE	Discovery agent

DMTAXZI	ID	DMTAXZI
DMTAXZI	DN	16-(4-cyano-benzylidene)-estradiol
DMTAXZI	HS	Investigative
DMTAXZI	SN	SCHEMBL12379740
DMTAXZI	DT	Small molecular drug
DMTAXZI	PC	44407411
DMTAXZI	MW	385.5
DMTAXZI	FM	C26H27NO2
DMTAXZI	IC	InChI=1S/C26H27NO2/c1-26-11-10-22-21-9-7-20(28)13-18(21)6-8-23(22)24(26)14-19(25(26)29)12-16-2-4-17(15-27)5-3-16/h2-5,7,9,12-13,22-25,28-29H,6,8,10-11,14H2,1H3/b19-12+/t22?,23?,24?,25-,26-/m0/s1
DMTAXZI	CS	C[C@]12CCC3C(C1C/C(=C\\C4=CC=C(C=C4)C#N)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMTAXZI	IK	RMEMBAHSFFEOKG-HNTYVEMZSA-N
DMTAXZI	IU	4-[(E)-[(13S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthren-16-ylidene]methyl]benzonitrile
DMTAXZI	DE	Discovery agent

DMEH8I0	ID	DMEH8I0
DMEH8I0	DN	16-(4-dimethylamino-benzylidene)-estradiol
DMEH8I0	HS	Investigative
DMEH8I0	SN	SCHEMBL12379373
DMEH8I0	DT	Small molecular drug
DMEH8I0	PC	44407495
DMEH8I0	MW	403.6
DMEH8I0	FM	C27H33NO2
DMEH8I0	IC	InChI=1S/C27H33NO2/c1-27-13-12-23-22-11-9-21(29)15-18(22)6-10-24(23)25(27)16-19(26(27)30)14-17-4-7-20(8-5-17)28(2)3/h4-5,7-9,11,14-15,23-26,29-30H,6,10,12-13,16H2,1-3H3/b19-14+/t23?,24?,25?,26-,27-/m0/s1
DMEH8I0	CS	C[C@]12CCC3C(C1C/C(=C\\C4=CC=C(C=C4)N(C)C)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMEH8I0	IK	HUZDSTZYTXBRMO-BACVCVEMSA-N
DMEH8I0	IU	(13S,16E,17S)-16-[[4-(dimethylamino)phenyl]methylidene]-13-methyl-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMEH8I0	DE	Discovery agent

DMX8YCK	ID	DMX8YCK
DMX8YCK	DN	16-(4-dimethylamino-benzylidene)-estrone
DMX8YCK	HS	Investigative
DMX8YCK	SN	SCHEMBL12379372
DMX8YCK	DT	Small molecular drug
DMX8YCK	PC	44407477
DMX8YCK	MW	401.5
DMX8YCK	FM	C27H31NO2
DMX8YCK	IC	InChI=1S/C27H31NO2/c1-27-13-12-23-22-11-9-21(29)15-18(22)6-10-24(23)25(27)16-19(26(27)30)14-17-4-7-20(8-5-17)28(2)3/h4-5,7-9,11,14-15,23-25,29H,6,10,12-13,16H2,1-3H3/b19-14+/t23?,24?,25?,27-/m0/s1
DMX8YCK	CS	C[C@]12CCC3C(C1C/C(=C\\C4=CC=C(C=C4)N(C)C)/C2=O)CCC5=C3C=CC(=C5)O
DMX8YCK	IK	ZDWWQQXXGWLFMH-IMNIJDOTSA-N
DMX8YCK	IU	(13S,16E)-16-[[4-(dimethylamino)phenyl]methylidene]-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one
DMX8YCK	DE	Discovery agent

DMIC0OU	ID	DMIC0OU
DMIC0OU	DN	16-(pyridin-2-yl)methylene-estradiol
DMIC0OU	HS	Investigative
DMIC0OU	SN	SCHEMBL12379723
DMIC0OU	DT	Small molecular drug
DMIC0OU	PC	44407498
DMIC0OU	MW	361.5
DMIC0OU	FM	C24H27NO2
DMIC0OU	IC	InChI=1S/C24H27NO2/c1-24-10-9-20-19-8-6-18(26)13-15(19)5-7-21(20)22(24)14-16(23(24)27)12-17-4-2-3-11-25-17/h2-4,6,8,11-13,20-23,26-27H,5,7,9-10,14H2,1H3/b16-12+/t20?,21?,22?,23-,24-/m0/s1
DMIC0OU	CS	C[C@]12CCC3C(C1C/C(=C\\C4=CC=CC=N4)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMIC0OU	IK	NEJZGGCMSBCPLE-NSLXHHGFSA-N
DMIC0OU	IU	(13S,16E,17S)-13-methyl-16-(pyridin-2-ylmethylidene)-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMIC0OU	DE	Discovery agent

DMSXFG0	ID	DMSXFG0
DMSXFG0	DN	16-(pyridin-2-yl)methyl-estradiol
DMSXFG0	HS	Investigative
DMSXFG0	DT	Small molecular drug
DMSXFG0	PC	44407461
DMSXFG0	MW	363.5
DMSXFG0	FM	C24H29NO2
DMSXFG0	IC	InChI=1S/C24H29NO2/c1-24-10-9-20-19-8-6-18(26)13-15(19)5-7-21(20)22(24)14-16(23(24)27)12-17-4-2-3-11-25-17/h2-4,6,8,11,13,16,20-23,26-27H,5,7,9-10,12,14H2,1H3/t16-,20?,21?,22?,23-,24-/m0/s1
DMSXFG0	CS	C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)CC4=CC=CC=N4)CCC5=C3C=CC(=C5)O
DMSXFG0	IK	SJHBYTOZADGQDY-CCXBEIMISA-N
DMSXFG0	IU	(13S,16R,17S)-13-methyl-16-(pyridin-2-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMSXFG0	DE	Discovery agent

DMIMZ21	ID	DMIMZ21
DMIMZ21	DN	16-(pyridin-3-yl)methylene-estradiol
DMIMZ21	HS	Investigative
DMIMZ21	SN	SCHEMBL12379725
DMIMZ21	DT	Small molecular drug
DMIMZ21	PC	44407494
DMIMZ21	MW	361.5
DMIMZ21	FM	C24H27NO2
DMIMZ21	IC	InChI=1S/C24H27NO2/c1-24-9-8-20-19-7-5-18(26)12-16(19)4-6-21(20)22(24)13-17(23(24)27)11-15-3-2-10-25-14-15/h2-3,5,7,10-12,14,20-23,26-27H,4,6,8-9,13H2,1H3/b17-11+/t20?,21?,22?,23-,24-/m0/s1
DMIMZ21	CS	C[C@]12CCC3C(C1C/C(=C\\C4=CN=CC=C4)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMIMZ21	IK	FCVLVYMOBDNAMK-PLNMCULSSA-N
DMIMZ21	IU	(13S,16E,17S)-13-methyl-16-(pyridin-3-ylmethylidene)-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMIMZ21	DE	Discovery agent

DMTD5AO	ID	DMTD5AO
DMTD5AO	DN	16-(pyridin-3-yl)methyl-estradiol
DMTD5AO	HS	Investigative
DMTD5AO	DT	Small molecular drug
DMTD5AO	PC	44407419
DMTD5AO	MW	363.5
DMTD5AO	FM	C24H29NO2
DMTD5AO	IC	InChI=1S/C24H29NO2/c1-24-9-8-20-19-7-5-18(26)12-16(19)4-6-21(20)22(24)13-17(23(24)27)11-15-3-2-10-25-14-15/h2-3,5,7,10,12,14,17,20-23,26-27H,4,6,8-9,11,13H2,1H3/t17-,20?,21?,22?,23-,24-/m0/s1
DMTD5AO	CS	C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)CC4=CN=CC=C4)CCC5=C3C=CC(=C5)O
DMTD5AO	IK	QLYAKILKANOLBC-ZCTINNFXSA-N
DMTD5AO	IU	(13S,16R,17S)-13-methyl-16-(pyridin-3-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMTD5AO	DE	Discovery agent

DMOTNPC	ID	DMOTNPC
DMOTNPC	DN	16-(pyridin-4-yl)methylene-estradiol
DMOTNPC	HS	Investigative
DMOTNPC	SN	SCHEMBL12379722
DMOTNPC	DT	Small molecular drug
DMOTNPC	PC	44407490
DMOTNPC	MW	361.5
DMOTNPC	FM	C24H27NO2
DMOTNPC	IC	InChI=1S/C24H27NO2/c1-24-9-6-20-19-5-3-18(26)13-16(19)2-4-21(20)22(24)14-17(23(24)27)12-15-7-10-25-11-8-15/h3,5,7-8,10-13,20-23,26-27H,2,4,6,9,14H2,1H3/b17-12+/t20?,21?,22?,23-,24-/m0/s1
DMOTNPC	CS	C[C@]12CCC3C(C1C/C(=C\\C4=CC=NC=C4)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMOTNPC	IK	SOWVSBMETYFGLF-PHKWELIGSA-N
DMOTNPC	IU	(13S,16E,17S)-13-methyl-16-(pyridin-4-ylmethylidene)-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMOTNPC	DE	Discovery agent

DM7NSRI	ID	DM7NSRI
DM7NSRI	DN	16-(pyridin-4-yl)methyl-estradiol
DM7NSRI	HS	Investigative
DM7NSRI	DT	Small molecular drug
DM7NSRI	PC	44407464
DM7NSRI	MW	363.5
DM7NSRI	FM	C24H29NO2
DM7NSRI	IC	InChI=1S/C24H29NO2/c1-24-9-6-20-19-5-3-18(26)13-16(19)2-4-21(20)22(24)14-17(23(24)27)12-15-7-10-25-11-8-15/h3,5,7-8,10-11,13,17,20-23,26-27H,2,4,6,9,12,14H2,1H3/t17-,20?,21?,22?,23-,24-/m0/s1
DM7NSRI	CS	C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)CC4=CC=NC=C4)CCC5=C3C=CC(=C5)O
DM7NSRI	IK	HTDAGQQNWZEQOG-ZCTINNFXSA-N
DM7NSRI	IU	(13S,16R,17S)-13-methyl-16-(pyridin-4-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DM7NSRI	DE	Discovery agent

DME3XS4	ID	DME3XS4
DME3XS4	DN	16-(thiophen-2-yl)methylene-estrone
DME3XS4	HS	Investigative
DME3XS4	SN	SCHEMBL12379730
DME3XS4	DT	Small molecular drug
DME3XS4	PC	44407400
DME3XS4	MW	364.5
DME3XS4	FM	C23H24O2S
DME3XS4	IC	InChI=1S/C23H24O2S/c1-23-9-8-19-18-7-5-16(24)11-14(18)4-6-20(19)21(23)13-15(22(23)25)12-17-3-2-10-26-17/h2-3,5,7,10-12,19-21,24H,4,6,8-9,13H2,1H3/b15-12+/t19?,20?,21?,23-/m0/s1
DME3XS4	CS	C[C@]12CCC3C(C1C/C(=C\\C4=CC=CS4)/C2=O)CCC5=C3C=CC(=C5)O
DME3XS4	IK	NTDFYDJSLAOTRY-LUYQZUMISA-N
DME3XS4	IU	(13S,16E)-3-hydroxy-13-methyl-16-(thiophen-2-ylmethylidene)-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one
DME3XS4	DE	Discovery agent

DMI49D0	ID	DMI49D0
DMI49D0	DN	16-alphaH,17-isovaleryloxy-ent-kauran-19-oic acid
DMI49D0	HS	Investigative
DMI49D0	SN	16-alphaH,17-isovaleryloxy-ent-kauran-19-oic acid; CHEMBL379581; CHEMBL2373418
DMI49D0	DT	Small molecular drug
DMI49D0	PC	44411588
DMI49D0	MW	404.6
DMI49D0	FM	C25H40O4
DMI49D0	IC	InChI=1S/C25H40O4/c1-16(2)12-21(26)29-15-18-14-25-11-8-19-23(3,20(25)7-6-17(18)13-25)9-5-10-24(19,4)22(27)28/h16-20H,5-15H2,1-4H3,(H,27,28)/t17-,18-,19?,20?,23-,24-,25+/m1/s1
DMI49D0	CS	CC(C)CC(=O)OC[C@H]1C[C@@]23CCC4[C@](C2CC[C@@H]1C3)(CCC[C@@]4(C)C(=O)O)C
DMI49D0	IK	ZOILZTWSQHWPGH-SLLFEXPVSA-N
DMI49D0	IU	(1S,5R,9S,13R,14S)-5,9-dimethyl-14-(3-methylbutanoyloxymethyl)tetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid
DMI49D0	DE	Discovery agent

DMCMP9B	ID	DMCMP9B
DMCMP9B	DN	16beta-cyano-estradiol
DMCMP9B	HS	Investigative
DMCMP9B	DT	Small molecular drug
DMCMP9B	PC	53322423
DMCMP9B	MW	297.4
DMCMP9B	FM	C19H23NO2
DMCMP9B	IC	InChI=1S/C19H23NO2/c1-19-7-6-15-14-5-3-13(21)8-11(14)2-4-16(15)17(19)9-12(10-20)18(19)22/h3,5,8,12,15-18,21-22H,2,4,6-7,9H2,1H3/t12-,15-,16-,17+,18+,19+/m1/s1
DMCMP9B	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@@H]([C@@H]2O)C#N)CCC4=C3C=CC(=C4)O
DMCMP9B	IK	IWVYOPUBSXDPSW-IEQBIMPXSA-N
DMCMP9B	IU	(8R,9S,13S,14S,16R,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carbonitrile
DMCMP9B	DE	Discovery agent

DMWJNV5	ID	DMWJNV5
DMWJNV5	DN	16-beta-ethoxymethyl-estrone
DMWJNV5	HS	Investigative
DMWJNV5	DT	Small molecular drug
DMWJNV5	PC	44407402
DMWJNV5	MW	328.4
DMWJNV5	FM	C21H28O3
DMWJNV5	IC	InChI=1S/C21H28O3/c1-3-24-12-14-11-19-18-6-4-13-10-15(22)5-7-16(13)17(18)8-9-21(19,2)20(14)23/h5,7,10,14,17-19,22H,3-4,6,8-9,11-12H2,1-2H3/t14-,17?,18?,19?,21+/m1/s1
DMWJNV5	CS	CCOC[C@H]1CC2C3CCC4=C(C3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMWJNV5	IK	UOFWRCJSMZKWLE-NCHCSYJDSA-N
DMWJNV5	IU	(13S,16R)-16-(ethoxymethyl)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
DMWJNV5	DE	Discovery agent

DMUW07J	ID	DMUW07J
DMUW07J	DN	16-beta-hydroxymethyl-estradiol
DMUW07J	HS	Investigative
DMUW07J	DT	Small molecular drug
DMUW07J	PC	44407401
DMUW07J	MW	302.4
DMUW07J	FM	C19H26O3
DMUW07J	IC	InChI=1S/C19H26O3/c1-19-7-6-15-14-5-3-13(21)8-11(14)2-4-16(15)17(19)9-12(10-20)18(19)22/h3,5,8,12,15-18,20-22H,2,4,6-7,9-10H2,1H3/t12-,15?,16?,17?,18+,19+/m1/s1
DMUW07J	CS	C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)CO)CCC4=C3C=CC(=C4)O
DMUW07J	IK	MWYASXMURYJSCR-CMYKETFCSA-N
DMUW07J	IU	(13S,16R,17S)-16-(hydroxymethyl)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMUW07J	DE	Discovery agent

DMTZG68	ID	DMTZG68
DMTZG68	DN	16-isobutylidene-estradiol
DMTZG68	HS	Investigative
DMTZG68	SN	SCHEMBL12379628
DMTZG68	DT	Small molecular drug
DMTZG68	PC	53322980
DMTZG68	MW	326.5
DMTZG68	FM	C22H30O2
DMTZG68	IC	InChI=1S/C22H30O2/c1-13(2)10-15-12-20-19-6-4-14-11-16(23)5-7-17(14)18(19)8-9-22(20,3)21(15)24/h5,7,10-11,13,18-21,23-24H,4,6,8-9,12H2,1-3H3/b15-10+/t18-,19-,20+,21+,22+/m1/s1
DMTZG68	CS	CC(C)/C=C/1\\C[C@H]2[C@@H]3CCC4=C([C@H]3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DMTZG68	IK	NOFDRMUQQIVAPE-PIEVVZFUSA-N
DMTZG68	IU	(8R,9S,13S,14S,16E,17S)-13-methyl-16-(2-methylpropylidene)-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMTZG68	DE	Discovery agent

DMS7PL3	ID	DMS7PL3
DMS7PL3	DN	16-isobutylidene-estrone
DMS7PL3	HS	Investigative
DMS7PL3	SN	16-isobutylidene-estrone
DMS7PL3	DT	Small molecular drug
DMS7PL3	PC	11493555
DMS7PL3	MW	324.5
DMS7PL3	FM	C22H28O2
DMS7PL3	IC	InChI=1S/C22H28O2/c1-13(2)10-15-12-20-19-6-4-14-11-16(23)5-7-17(14)18(19)8-9-22(20,3)21(15)24/h5,7,10-11,13,18-20,23H,4,6,8-9,12H2,1-3H3/b15-10+/t18-,19-,20+,22+/m1/s1
DMS7PL3	CS	CC(C)/C=C/1\\C[C@H]2[C@@H]3CCC4=C([C@H]3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMS7PL3	IK	PTANBYHUNIXKEU-HDLVZFDGSA-N
DMS7PL3	IU	(8R,9S,13S,14S,16E)-3-hydroxy-13-methyl-16-(2-methylpropylidene)-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one
DMS7PL3	DE	Discovery agent

DMDR1M6	ID	DMDR1M6
DMDR1M6	DN	17 beta-N,N-diethylcarbamoyl-4-aza-5 alpha-androstan-3-one (4MA)
DMDR1M6	HS	Investigative
DMDR1M6	DE	Discovery agent

DMUQWPZ	ID	DMUQWPZ
DMUQWPZ	DN	17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine
DMUQWPZ	HS	Investigative
DMUQWPZ	SN	CHEMBL570225; 17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine
DMUQWPZ	DT	Small molecular drug
DMUQWPZ	PC	44627903
DMUQWPZ	MW	386.6
DMUQWPZ	FM	C27H34N2
DMUQWPZ	IC	InChI=1S/C27H34N2/c1-2-9-22(10-3-1)28-23-13-12-21-17-26-24-11-4-5-14-27(24,25(21)18-23)15-16-29(26)19-20-7-6-8-20/h1-3,9-10,12-13,18,20,24,26,28H,4-8,11,14-17,19H2/t24-,26+,27+/m0/s1
DMUQWPZ	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NC5=CC=CC=C5)CC6CCC6
DMUQWPZ	IK	JXXVPNRGUCGAEU-WYMJOSIYSA-N
DMUQWPZ	IU	(1R,9R,10R)-17-(cyclobutylmethyl)-N-phenyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DMUQWPZ	DE	Discovery agent

DM174HN	ID	DM174HN
DM174HN	DN	17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine
DM174HN	HS	Investigative
DM174HN	SN	CHEMBL568757; 17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine
DM174HN	DT	Small molecular drug
DM174HN	PC	44627900
DM174HN	MW	372.5
DM174HN	FM	C26H32N2
DM174HN	IC	InChI=1S/C26H32N2/c1-2-6-21(7-3-1)27-22-12-11-20-16-25-23-8-4-5-13-26(23,24(20)17-22)14-15-28(25)18-19-9-10-19/h1-3,6-7,11-12,17,19,23,25,27H,4-5,8-10,13-16,18H2/t23-,25+,26+/m0/s1
DM174HN	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NC5=CC=CC=C5)CC6CC6
DM174HN	IK	UVUFQEMGPJPSIS-SKBVVQJISA-N
DM174HN	IU	(1R,9R,10R)-17-(cyclopropylmethyl)-N-phenyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DM174HN	DE	Discovery agent

DMLC2VE	ID	DMLC2VE
DMLC2VE	DN	177Lu-labelled RM2
DMLC2VE	HS	Investigative
DMLC2VE	CP	ABX GmbH
DMLC2VE	DT	Radiopharmaceutical therapy agent
DMLC2VE	DE	Solid tumour/cancer

DMT2EPG	ID	DMT2EPG
DMT2EPG	DN	17alpha-hydroxypregnenolone
DMT2EPG	HS	Investigative
DMT2EPG	SN	17alpha hydroxypregnenolone; 17-OH-pregnenolone; 17-hydroxypregnenolone
DMT2EPG	DT	Small molecular drug
DMT2EPG	PC	91451
DMT2EPG	MW	332.5
DMT2EPG	FM	C21H32O3
DMT2EPG	IC	InChI=1S/C21H32O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h4,15-18,23-24H,5-12H2,1-3H3/t15-,16+,17-,18-,19-,20-,21-/m0/s1
DMT2EPG	CS	CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)O
DMT2EPG	IK	JERGUCIJOXJXHF-TVWVXWENSA-N
DMT2EPG	IU	1-[(3S,8R,9S,10R,13S,14S,17R)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone
DMT2EPG	CA	CAS 387-79-1
DMT2EPG	CB	CHEBI:28750
DMT2EPG	DE	Discovery agent

DM7UHJS	ID	DM7UHJS
DM7UHJS	DN	17-dehydroxyriccardin C
DM7UHJS	HS	Investigative
DM7UHJS	SN	17-dehydroxyriccardin C; Riccardin C derivative, 20b; CHEMBL409652; BDBM23849; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-2-ol
DM7UHJS	DT	Small molecular drug
DM7UHJS	PC	24860511
DM7UHJS	MW	408.5
DM7UHJS	FM	C28H24O3
DM7UHJS	IC	InChI=1S/C28H24O3/c29-26-16-11-21-6-5-20-10-15-25(27(30)17-20)24-4-2-1-3-22(24)12-7-19-8-13-23(14-9-19)31-28(26)18-21/h1-4,8-11,13-18,29-30H,5-7,12H2
DM7UHJS	CS	C1CC2=CC=CC=C2C3=C(C=C(CCC4=CC(=C(C=C4)O)OC5=CC=C1C=C5)C=C3)O
DM7UHJS	IK	OAEVJFPPXJHCKV-UHFFFAOYSA-N
DM7UHJS	IU	14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2,4,6,10(29),11,13(28),15,17,19(27),22,25-dodecaene-16,24-diol
DM7UHJS	DE	Discovery agent

DMCALYO	ID	DMCALYO
DMCALYO	DN	17-desmethoxy-17-aminogeldanamycin
DMCALYO	HS	Investigative
DMCALYO	SN	UNII-SLQ1AJG3VB; SLQ1AJG3VB; 17-Aminogeldanamycin; 17-Amino-17-demethoxygeldanamycin; Geldanamycin, 17-amino-17-demethoxy-; 17-Amino Geldanamycin; SCHEMBL8250568; SCHEMBL16226317; XYFFWTYOFPSZRM-TWNAANEASA-N; DB13023; 1174669-94-3
DMCALYO	DT	Small molecular drug
DMCALYO	PC	91929099
DMCALYO	MW	545.6
DMCALYO	FM	C28H39N3O8
DMCALYO	IC	InChI=1S/C28H39N3O8/c1-14-10-18-23(29)20(32)13-19(25(18)34)31-27(35)15(2)8-7-9-21(37-5)26(39-28(30)36)17(4)12-16(3)24(33)22(11-14)38-6/h7-10,12-13,16,21-22,24,26,32-34H,11,29H2,1-6H3,(H2,30,36)(H,31,35)/b9-7-,14-10-,15-8+,17-12+/t16-,21-,22-,24+,26-/m0/s1
DMCALYO	CS	C[C@H]1/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=C(C(=C2O)/C=C(\\C[C@@H]([C@@H]1O)OC)/C)N)O)/C)OC)OC(=O)N)\\C
DMCALYO	IK	VWTYNHIROMEOBP-PQMSMOMXSA-N
DMCALYO	IU	[(4E,6Z,8S,9S,10E,12S,13R,14S,16Z)-19-amino-13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,16,18(22),19-heptaen-9-yl] carbamate
DMCALYO	DE	Discovery agent

DMKUGH1	ID	DMKUGH1
DMKUGH1	DN	17-METHYL-17-ALPHA-DIHYDROEQUILENIN
DMKUGH1	HS	Investigative
DMKUGH1	SN	17-Methyl-17-Alpha-Dihydroequilenin; 2b1z; ZINC5048688; DB06871; 17beta-Methyl-17alpha-dihydroequilenin; 17M; (13alpha,17beta)-17-methylestra-1(10),2,4,6,8-pentaene-3,17-diol
DMKUGH1	DT	Small molecular drug
DMKUGH1	PC	9549180
DMKUGH1	MW	282.4
DMKUGH1	FM	C19H22O2
DMKUGH1	IC	InChI=1S/C19H22O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h3-6,11,17,20-21H,7-10H2,1-2H3/t17-,18-,19+/m0/s1
DMKUGH1	CS	C[C@]12CCC3=C([C@@H]1CC[C@@]2(C)O)C=CC4=C3C=CC(=C4)O
DMKUGH1	IK	FQMQOMRDADWGJJ-GBESFXJTSA-N
DMKUGH1	IU	(13S,14S,17R)-13,17-dimethyl-12,14,15,16-tetrahydro-11H-cyclopenta[a]phenanthrene-3,17-diol
DMKUGH1	CA	CAS 1011733-40-6
DMKUGH1	DE	Discovery agent

DMMEB64	ID	DMMEB64
DMMEB64	DN	17-methyl-4'-methyldihydromorphinone
DMMEB64	HS	Investigative
DMMEB64	SN	CHEMBL607018
DMMEB64	DT	Small molecular drug
DMMEB64	PC	44415081
DMMEB64	MW	444.5
DMMEB64	FM	C27H28N2O4
DMMEB64	IC	InChI=1S/C27H28N2O4/c1-16-3-5-17(6-4-16)7-10-22(32)28-27-12-11-20(31)25-26(27)13-14-29(2)21(27)15-18-8-9-19(30)24(33-25)23(18)26/h3-10,21,25,30H,11-15H2,1-2H3,(H,28,32)/b10-7+/t21?,25-,26-,27+/m0/s1
DMMEB64	CS	CC1=CC=C(C=C1)/C=C/C(=O)N[C@@]23CCC(=O)[C@H]4[C@@]25CCN(C3CC6=C5C(=C(C=C6)O)O4)C
DMMEB64	IK	JRFZMFGBYRTYRZ-KPAXYDNFSA-N
DMMEB64	IU	(E)-N-[(4aS,7aR,12bR)-9-hydroxy-3-methyl-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-methylphenyl)prop-2-enamide
DMMEB64	DE	Discovery agent

DMI4WCQ	ID	DMI4WCQ
DMI4WCQ	DN	17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate
DMI4WCQ	HS	Investigative
DMI4WCQ	SN	CHEMBL568989; 17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate
DMI4WCQ	DT	Small molecular drug
DMI4WCQ	PC	44627904
DMI4WCQ	MW	502.4
DMI4WCQ	FM	C24H27IN2O2
DMI4WCQ	IC	InChI=1S/C24H27IN2O2/c1-27-13-12-24-11-3-2-4-20(24)22(27)14-16-5-10-19(15-21(16)24)29-23(28)26-18-8-6-17(25)7-9-18/h5-10,15,20,22H,2-4,11-14H2,1H3,(H,26,28)/t20-,22+,24+/m0/s1
DMI4WCQ	CS	CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)OC(=O)NC5=CC=C(C=C5)I
DMI4WCQ	IK	YGDGBZQTGCWFHN-BGWNEDDSSA-N
DMI4WCQ	IU	[(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-(4-iodophenyl)carbamate
DMI4WCQ	DE	Discovery agent

DM9OMI3	ID	DM9OMI3
DM9OMI3	DN	17-phenyl-omega-trinor-PGE2
DM9OMI3	HS	Investigative
DM9OMI3	SN	17-phenyl-omega-trinor-prostaglandin E2; 17-phenyl-trinor-PGE2; 17-Ph-omega-trinor-PGE2; 17-phenyl-PGE2
DM9OMI3	DT	Small molecular drug
DM9OMI3	PC	5283068
DM9OMI3	MW	386.5
DM9OMI3	FM	C23H30O5
DM9OMI3	IC	InChI=1S/C23H30O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,14-15,18-20,22,24,26H,2,7,10-13,16H2,(H,27,28)/b6-1-,15-14+/t18-,19+,20+,22+/m0/s1
DM9OMI3	CS	C1[C@H]([C@@H]([C@H](C1=O)C/C=C\\CCCC(=O)O)/C=C/[C@H](CCC2=CC=CC=C2)O)O
DM9OMI3	IK	FOBVMYJQWZOGGJ-XYRJXBATSA-N
DM9OMI3	IU	(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DM9OMI3	CA	CAS 38315-43-4
DM9OMI3	CB	CHEBI:87820
DM9OMI3	DE	Discovery agent

DMYS6DB	ID	DMYS6DB
DMYS6DB	DN	18alpha-Glycyrrhetic acid
DMYS6DB	HS	Investigative
DMYS6DB	SN	18a-Glycyrrhetic acid; 18a-glycyrrhetinic acid; 1449-05-4; CHEMBL378653; 18ss -Glycyrrhetinic acid; SCHEMBL18539; MolPort-027-835-537; BDBM50185128; AKOS016009638; DS-5150; 3A-Hydroxy-11-oxo-18ss20ss -olean-12-en-29-oic acid
DMYS6DB	DT	Small molecular drug
DMYS6DB	PC	12193680
DMYS6DB	MW	470.7
DMYS6DB	FM	C30H46O4
DMYS6DB	IC	InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21?,22+,23-,26-,27+,28+,29-,30-/m1/s1
DMYS6DB	CS	C[C@]12CC[C@](C[C@@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C(C5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O
DMYS6DB	IK	MPDGHEJMBKOTSU-NFYGSHHYSA-N
DMYS6DB	IU	(2S,4aS,6aR,6aS,6bR,10S,12aS,14bS)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid
DMYS6DB	CA	CAS 471-53-4
DMYS6DB	DE	Discovery agent

DMFMRN8	ID	DMFMRN8
DMFMRN8	DN	18beta-Glycyrrhetic acid
DMFMRN8	HS	Investigative
DMFMRN8	SN	18b-Glycyrrhetic acid; CHEMBL208873; 18b-Glycyrrhetinic acid; Glycyrrhetinic Acid, 8; 18; A-Glycyrrhetintic Acid; SCHEMBL231125; BDBM23195; pentacyclic triterpene compound 8; MolPort-023-220-126; AKOS016009607; cent-GLYCYRRHETINTIC ACID; AS-11631; SC-17800; (2S,4aS,6aS,6bR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
DMFMRN8	DT	Small molecular drug
DMFMRN8	PC	10114
DMFMRN8	MW	470.7
DMFMRN8	FM	C30H46O4
DMFMRN8	IC	InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1
DMFMRN8	CS	C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O
DMFMRN8	IK	MPDGHEJMBKOTSU-YKLVYJNSSA-N
DMFMRN8	IU	(2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid
DMFMRN8	CA	CAS 471-53-4
DMFMRN8	CB	CHEBI:30853
DMFMRN8	DE	Discovery agent

DM0JEQ6	ID	DM0JEQ6
DM0JEQ6	DN	18-Dimethylaminocoronaridine
DM0JEQ6	HS	Investigative
DM0JEQ6	SN	18-Dimethylaminocoronaridine
DM0JEQ6	DT	Small molecular drug
DM0JEQ6	PC	46877893
DM0JEQ6	MW	381.5
DM0JEQ6	FM	C23H31N3O2
DM0JEQ6	IC	InChI=1S/C23H31N3O2/c1-25(2)10-8-16-12-15-13-23(22(27)28-3)20-18(9-11-26(14-15)21(16)23)17-6-4-5-7-19(17)24-20/h4-7,15-16,21,24H,8-14H2,1-3H3/t15?,16-,21-,23+/m0/s1
DM0JEQ6	CS	CN(C)CC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC
DM0JEQ6	IK	WUYGHHRQOSQDIC-NVVKDKPXSA-N
DM0JEQ6	IU	methyl (1S,17R,18S)-17-[2-(dimethylamino)ethyl]-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DM0JEQ6	DE	Discovery agent

DMAPI2G	ID	DMAPI2G
DMAPI2G	DN	18F-AV-45 dimer
DMAPI2G	HS	Investigative
DMAPI2G	SN	AV-45 dimer
DMAPI2G	CP	Avid Radiopharmaceuticals Inc
DMAPI2G	DE	Cerebral amyloid angiopathy

DM2VZMC	ID	DM2VZMC
DM2VZMC	DN	18F-SMIBR-K5
DM2VZMC	HS	Investigative
DM2VZMC	SN	SMIBR-K5; RGD-K5-[18F]; Fluorine-18-SMIBR-K5; Cyclic triazole bearing RGD peptide integrin alpha-v beta-3 imaging agent (cancer), Siemens; 18F-RGD-K5
DM2VZMC	CP	Siemens Medical Solutions Molecular Imaging
DM2VZMC	DE	Solid tumour/cancer

DMBG9Z3	ID	DMBG9Z3
DMBG9Z3	DN	18-methoxycoronaridinate 2-Hydroxyethylamide
DMBG9Z3	HS	Investigative
DMBG9Z3	SN	18-methoxycoronaridinate 2-Hydroxyethylamide
DMBG9Z3	DT	Small molecular drug
DMBG9Z3	PC	46877897
DMBG9Z3	MW	397.5
DMBG9Z3	FM	C23H31N3O3
DMBG9Z3	IC	InChI=1S/C23H31N3O3/c1-29-11-7-16-12-15-13-23(22(28)24-8-10-27)20-18(6-9-26(14-15)21(16)23)17-4-2-3-5-19(17)25-20/h2-5,15-16,21,25,27H,6-14H2,1H3,(H,24,28)/t15?,16-,21-,23+/m0/s1
DMBG9Z3	CS	COCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)NCCO
DMBG9Z3	IK	RPYHLEHPZWHJIE-NVVKDKPXSA-N
DMBG9Z3	IU	(1S,17R,18S)-N-(2-hydroxyethyl)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxamide
DMBG9Z3	DE	Discovery agent

DMSBAC0	ID	DMSBAC0
DMSBAC0	DN	18-methoxycoronaridinate 2-methoxyethylamide
DMSBAC0	HS	Investigative
DMSBAC0	SN	18-methoxycoronaridinate 2-methoxyethylamide
DMSBAC0	DT	Small molecular drug
DMSBAC0	PC	46877896
DMSBAC0	MW	411.5
DMSBAC0	FM	C24H33N3O3
DMSBAC0	IC	InChI=1S/C24H33N3O3/c1-29-11-8-17-13-16-14-24(23(28)25-9-12-30-2)21-19(7-10-27(15-16)22(17)24)18-5-3-4-6-20(18)26-21/h3-6,16-17,22,26H,7-15H2,1-2H3,(H,25,28)/t16?,17-,22-,24+/m0/s1
DMSBAC0	CS	COCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)NCCOC
DMSBAC0	IK	OLGJSZRDLAADNK-SAJNPJMVSA-N
DMSBAC0	IU	(1S,17R,18S)-N,17-bis(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxamide
DMSBAC0	DE	Discovery agent

DMTJ384	ID	DMTJ384
DMTJ384	DN	18-Methoxycoronaridine
DMTJ384	HS	Investigative
DMTJ384	SN	18-methoxycoronaridine; 308123-60-6; DTXSID40437331
DMTJ384	DT	Small molecular drug
DMTJ384	PC	15479177
DMTJ384	MW	368.5
DMTJ384	FM	C22H28N2O3
DMTJ384	IC	InChI=1S/C22H28N2O3/c1-26-10-8-15-11-14-12-22(21(25)27-2)19-17(7-9-24(13-14)20(15)22)16-5-3-4-6-18(16)23-19/h3-6,14-15,20,23H,7-13H2,1-2H3/t14-,15+,20+,22-/m1/s1
DMTJ384	CS	COCC[C@H]1C[C@@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC
DMTJ384	IK	DTJQBBHYRQYDEG-SVBQBFEESA-N
DMTJ384	IU	methyl (1S,15R,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMTJ384	CA	CAS 308123-60-6
DMTJ384	DE	Drug abuse

DMOYC0U	ID	DMOYC0U
DMOYC0U	DN	18-Methylaminocoronaridine
DMOYC0U	HS	Investigative
DMOYC0U	SN	18-Methylaminocoronaridine
DMOYC0U	DT	Small molecular drug
DMOYC0U	PC	46877894
DMOYC0U	MW	367.5
DMOYC0U	FM	C22H29N3O2
DMOYC0U	IC	InChI=1S/C22H29N3O2/c1-23-9-7-15-11-14-12-22(21(26)27-2)19-17(8-10-25(13-14)20(15)22)16-5-3-4-6-18(16)24-19/h3-6,14-15,20,23-24H,7-13H2,1-2H3/t14?,15-,20-,22+/m0/s1
DMOYC0U	CS	CNCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC
DMOYC0U	IK	YKMOJVPLIUXEIP-JNBMDGLNSA-N
DMOYC0U	IU	methyl (1S,17R,18S)-17-[2-(methylamino)ethyl]-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMOYC0U	DE	Discovery agent

DMGUKCF	ID	DMGUKCF
DMGUKCF	DN	19(R)-OH-PGE2
DMGUKCF	HS	Investigative
DMGUKCF	SN	19(R)-hydroxy-PGE2; 19R-(OH)-PGE2
DMGUKCF	DT	Small molecular drug
DMGUKCF	PC	5283038
DMGUKCF	MW	368.5
DMGUKCF	FM	C20H32O6
DMGUKCF	IC	InChI=1S/C20H32O6/c1-14(21)7-6-8-15(22)11-12-17-16(18(23)13-19(17)24)9-4-2-3-5-10-20(25)26/h2,4,11-12,14-17,19,21-22,24H,3,5-10,13H2,1H3,(H,25,26)/b4-2-,12-11+/t14-,15+,16-,17-,19-/m1/s1
DMGUKCF	CS	C[C@H](CCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O)O
DMGUKCF	IK	WTJYDBMHYPQFNJ-ZUVVJKHESA-N
DMGUKCF	IU	(Z)-7-[(1R,2R,3R)-2-[(E,3S,7R)-3,7-dihydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoic acid
DMGUKCF	CA	CAS 64625-54-3
DMGUKCF	CB	CHEBI:165313
DMGUKCF	DE	Discovery agent

DMP168O	ID	DMP168O
DMP168O	DN	19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid
DMP168O	HS	Investigative
DMP168O	SN	CHEMBL494111; 19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid; BDBM50253117; 3-Oxo-19,24-dihydroxyurs-12-ene-28-oic acid
DMP168O	DT	Small molecular drug
DMP168O	PC	10600994
DMP168O	MW	486.7
DMP168O	FM	C30H46O5
DMP168O	IC	InChI=1S/C30H46O5/c1-18-9-14-30(24(33)34)16-15-27(4)19(23(30)29(18,6)35)7-8-21-25(2)12-11-22(32)26(3,17-31)20(25)10-13-28(21,27)5/h7,18,20-21,23,31,35H,8-17H2,1-6H3,(H,33,34)/t18-,20-,21-,23-,25+,26-,27-,28-,29-,30+/m1/s1
DMP168O	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CCC(=O)[C@]5(C)CO)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O
DMP168O	IK	DICFMPCEXYENLE-OGHVSZAPSA-N
DMP168O	IU	(1R,2R,4aS,6aR,6aS,6bR,8aR,9S,12aR,14bS)-1-hydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-2H-picene-4a-carboxylic acid
DMP168O	DE	Discovery agent

DM92ZCU	ID	DM92ZCU
DM92ZCU	DN	1-acetamido-5-sulfonamidoindane
DM92ZCU	HS	Investigative
DM92ZCU	SN	N-(5-Sulfamoyl-indan-1-yl)-acetamide
DM92ZCU	PC	11680415
DM92ZCU	MW	254.31
DM92ZCU	FM	C11H14N2O3S
DM92ZCU	IC	InChI=1S/C11H14N2O3S/c1-7(14)13-11-5-2-8-6-9(17(12,15)16)3-4-10(8)11/h3-4,6,11H,2,5H2,1H3,(H,13,14)(H2,12,15,16)
DM92ZCU	CS	CC(=O)NC1CCC2=C1C=CC(=C2)S(=O)(=O)N
DM92ZCU	IK	RUUYVLNZHGCPRP-UHFFFAOYSA-N
DM92ZCU	IU	N-(5-sulfamoyl-2,3-dihydro-1H-inden-1-yl)acetamide
DM92ZCU	DE	Discovery agent

DM7DL03	ID	DM7DL03
DM7DL03	DN	1-Acetoxy-2-tert-butyldimethylsilyl-oxylycorine
DM7DL03	HS	Investigative
DM7DL03	SN	CHEMBL564408; 1-Acetoxy-2-tert-butyldimethylsilyl-oxylycorine; 1-Acetoxy-2-TBS-lycorine; BDBM50293601; (1S,2S,3a1S,12bS)-2-(tert-butyldimethylsilyloxy)-2,3a1,4,5,7,12b-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-1-yl acetate
DM7DL03	DT	Small molecular drug
DM7DL03	PC	44191463
DM7DL03	MW	443.6
DM7DL03	FM	C24H33NO5Si
DM7DL03	IC	InChI=1S/C24H33NO5Si/c1-14(26)29-23-20(30-31(5,6)24(2,3)4)9-15-7-8-25-12-16-10-18-19(28-13-27-18)11-17(16)21(23)22(15)25/h9-11,20-23H,7-8,12-13H2,1-6H3/t20-,21-,22+,23+/m0/s1
DM7DL03	CS	CC(=O)O[C@@H]1[C@H](C=C2CCN3[C@H]2[C@@H]1C4=CC5=C(C=C4C3)OCO5)O[Si](C)(C)C(C)(C)C
DM7DL03	IK	IQOBLYMQXROOIM-MYDTUXCISA-N
DM7DL03	IU	[(1S,17S,18S,19S)-17-[tert-butyl(dimethyl)silyl]oxy-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraen-18-yl] acetate
DM7DL03	DE	Discovery agent

DMMP7HU	ID	DMMP7HU
DMMP7HU	DN	1'-acetoxychavicol acetate
DMMP7HU	HS	Investigative
DMMP7HU	SN	1'-Acetoxychavicol acetate; 52946-22-2; 1'-Acetoxychavicol; UNII-SQV3080A20; CHEBI:469; 1'S-1'-Acetoxychavicol acetate; SQV3080A20; (alphaS)-4-(Acetyloxy)-alpha-ethenylbenzenemethanol; [4-[(1S)-1-acetyloxyprop-2-enyl]phenyl] acetate; Galangal acetate; (1S)-1-[4-(acetyloxy)phenyl]prop-2-en-1-yl acetate; Benzenemethanol, 4-(acetyloxy)-.alpha.-ethenyl-, acetate, (.alpha.S)-; CCRIS 7708; 1'-Acethoxychavicol; AC1Q60ZN; AC1L3O7Q; GTPL6298; CHEMBL323727; SCHEMBL17454871; (S)-1'-Acetoxychavicol Acetate; benzenemethanol, 4-(acetyloxy)-
DMMP7HU	DT	Small molecular drug
DMMP7HU	PC	119104
DMMP7HU	MW	234.25
DMMP7HU	FM	C13H14O4
DMMP7HU	IC	InChI=1S/C13H14O4/c1-4-13(17-10(3)15)11-5-7-12(8-6-11)16-9(2)14/h4-8,13H,1H2,2-3H3/t13-/m0/s1
DMMP7HU	CS	CC(=O)OC1=CC=C(C=C1)[C@H](C=C)OC(=O)C
DMMP7HU	IK	JAMQIUWGGBSIKZ-ZDUSSCGKSA-N
DMMP7HU	IU	[4-[(1S)-1-acetyloxyprop-2-enyl]phenyl] acetate
DMMP7HU	CA	CAS 52946-22-2
DMMP7HU	CB	CHEBI:469
DMMP7HU	DE	Discovery agent

DMQH1MS	ID	DMQH1MS
DMQH1MS	DN	1-Acetoxylycorine
DMQH1MS	HS	Investigative
DMQH1MS	SN	1-O-Acetyllycorine; 1-Acetoxylycorine; 1-Acetyllycorine; CHEMBL251077; CHEBI:31045; C12166; AC1L9EZ8; SCHEMBL12319390; BDBM50221063; acetic acid (1S,2S,12bS,12cS)-2-hydroxy-1,2,4,5,12b,12c-hexahydro-7H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-1-yl ester; (1S,2S,12bS,12cS)-1,2-Diol-2,4,5,7, 12b,12c-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1-acetate
DMQH1MS	DT	Small molecular drug
DMQH1MS	PC	443672
DMQH1MS	MW	329.3
DMQH1MS	FM	C18H19NO5
DMQH1MS	IC	InChI=1S/C18H19NO5/c1-9(20)24-18-13(21)4-10-2-3-19-7-11-5-14-15(23-8-22-14)6-12(11)16(18)17(10)19/h4-6,13,16-18,21H,2-3,7-8H2,1H3/t13-,16-,17+,18+/m0/s1
DMQH1MS	CS	CC(=O)O[C@@H]1[C@H](C=C2CCN3[C@H]2[C@@H]1C4=CC5=C(C=C4C3)OCO5)O
DMQH1MS	IK	BIGUPJIJZYZJMV-VIBAHUMZSA-N
DMQH1MS	IU	[(1S,17S,18S,19S)-17-hydroxy-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraen-18-yl] acetate
DMQH1MS	CB	CHEBI:31045
DMQH1MS	DE	Discovery agent

DMRJSG7	ID	DMRJSG7
DMRJSG7	DN	1-adamantan-1-yl-3-((R)-1-phenyl-ethyl)-urea
DMRJSG7	HS	Investigative
DMRJSG7	SN	CHEMBL222080; 1-adamantan-1-yl-3-((R)-1-phenyl-ethyl)-urea
DMRJSG7	DT	Small molecular drug
DMRJSG7	PC	44419692
DMRJSG7	MW	298.4
DMRJSG7	FM	C19H26N2O
DMRJSG7	IC	InChI=1S/C19H26N2O/c1-13(17-5-3-2-4-6-17)20-18(22)21-19-10-14-7-15(11-19)9-16(8-14)12-19/h2-6,13-16H,7-12H2,1H3,(H2,20,21,22)/t13-,14?,15?,16?,19?/m1/s1
DMRJSG7	CS	C[C@H](C1=CC=CC=C1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMRJSG7	IK	ODVZFEPLOWORBJ-PGBRGIIUSA-N
DMRJSG7	IU	1-(1-adamantyl)-3-[(1R)-1-phenylethyl]urea
DMRJSG7	DE	Discovery agent

DMNXU1O	ID	DMNXU1O
DMNXU1O	DN	1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea
DMNXU1O	HS	Investigative
DMNXU1O	SN	CHEMBL387034; AC1MG4WB; 1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea; SCHEMBL4349264; MolPort-001-589-466; BDBM100357; ZINC5041294; STK455719; BDBM50191877; AKOS003332205; MCULE-1433138775; ST50939640; SR-01000276706; 1-(1-adamantyl)-3-(1-benzylpiperidin-4-yl)urea; US8501783, 1158; SR-01000276706-1; N-adamantanyl{[1-benzyl(4-piperidyl)]amino}carboxamide
DMNXU1O	DT	Small molecular drug
DMNXU1O	PC	2955557
DMNXU1O	MW	367.5
DMNXU1O	FM	C23H33N3O
DMNXU1O	IC	InChI=1S/C23H33N3O/c27-22(25-23-13-18-10-19(14-23)12-20(11-18)15-23)24-21-6-8-26(9-7-21)16-17-4-2-1-3-5-17/h1-5,18-21H,6-16H2,(H2,24,25,27)
DMNXU1O	CS	C1CN(CCC1NC(=O)NC23CC4CC(C2)CC(C4)C3)CC5=CC=CC=C5
DMNXU1O	IK	SZCGIFNKYJVHTL-UHFFFAOYSA-N
DMNXU1O	IU	1-(1-adamantyl)-3-(1-benzylpiperidin-4-yl)urea
DMNXU1O	DE	Discovery agent

DMAJC42	ID	DMAJC42
DMAJC42	DN	1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea
DMAJC42	HS	Investigative
DMAJC42	SN	CHEMBL386820; 1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea; SCHEMBL5144023; BDBM100356; BDBM50191894; US8501783, 1160
DMAJC42	DT	Small molecular drug
DMAJC42	PC	24849868
DMAJC42	MW	333.5
DMAJC42	FM	C20H35N3O
DMAJC42	IC	InChI=1S/C20H35N3O/c1-2-3-6-23-7-4-18(5-8-23)21-19(24)22-20-12-15-9-16(13-20)11-17(10-15)14-20/h15-18H,2-14H2,1H3,(H2,21,22,24)
DMAJC42	CS	CCCCN1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMAJC42	IK	FTNAVCVMGWLLJE-UHFFFAOYSA-N
DMAJC42	IU	1-(1-adamantyl)-3-(1-butylpiperidin-4-yl)urea
DMAJC42	DE	Discovery agent

DMY1Z2X	ID	DMY1Z2X
DMY1Z2X	DN	1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea
DMY1Z2X	HS	Investigative
DMY1Z2X	SN	CHEMBL214534; 1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea; SCHEMBL5146577
DMY1Z2X	DT	Small molecular drug
DMY1Z2X	PC	44416958
DMY1Z2X	MW	305.5
DMY1Z2X	FM	C18H31N3O
DMY1Z2X	IC	InChI=1S/C18H31N3O/c1-2-21-5-3-16(4-6-21)19-17(22)20-18-10-13-7-14(11-18)9-15(8-13)12-18/h13-16H,2-12H2,1H3,(H2,19,20,22)
DMY1Z2X	CS	CCN1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMY1Z2X	IK	SMBXAXBAAIGIAK-UHFFFAOYSA-N
DMY1Z2X	IU	1-(1-adamantyl)-3-(1-ethylpiperidin-4-yl)urea
DMY1Z2X	DE	Discovery agent

DM2K7TX	ID	DM2K7TX
DM2K7TX	DN	1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea
DM2K7TX	HS	Investigative
DM2K7TX	SN	CHEMBL215168; 1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea; SCHEMBL5144236; MolPort-028-759-082; BDBM100355; BDBM50191872; ZINC36330629; AKOS034496458; MCULE-1016100156; US8501783, 1155; 1-(adamantan-1-yl)-3-(1-propylpiperidin-4-yl)urea; Z642063290
DM2K7TX	DT	Small molecular drug
DM2K7TX	PC	24849867
DM2K7TX	MW	319.5
DM2K7TX	FM	C19H33N3O
DM2K7TX	IC	InChI=1S/C19H33N3O/c1-2-5-22-6-3-17(4-7-22)20-18(23)21-19-11-14-8-15(12-19)10-16(9-14)13-19/h14-17H,2-13H2,1H3,(H2,20,21,23)
DM2K7TX	CS	CCCN1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DM2K7TX	IK	OYDLKUZQSIKGSE-UHFFFAOYSA-N
DM2K7TX	IU	1-(1-adamantyl)-3-(1-propylpiperidin-4-yl)urea
DM2K7TX	DE	Discovery agent

DMRIYX9	ID	DMRIYX9
DMRIYX9	DN	1-adamantan-1-yl-3-(2-heptyloxyethyl)urea
DMRIYX9	HS	Investigative
DMRIYX9	SN	CHEMBL388004; 1-adamantan-1-yl-3-(2-heptyloxyethyl)urea; SCHEMBL12931851
DMRIYX9	DT	Small molecular drug
DMRIYX9	PC	23631474
DMRIYX9	MW	336.5
DMRIYX9	FM	C20H36N2O2
DMRIYX9	IC	InChI=1S/C20H36N2O2/c1-2-3-4-5-6-8-24-9-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DMRIYX9	CS	CCCCCCCOCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMRIYX9	IK	ADHBJDWCKMOLCA-UHFFFAOYSA-N
DMRIYX9	IU	1-(1-adamantyl)-3-(2-heptoxyethyl)urea
DMRIYX9	DE	Discovery agent

DMDO9YM	ID	DMDO9YM
DMDO9YM	DN	1-adamantan-1-yl-3-(2-hydroxyethyl)urea
DMDO9YM	HS	Investigative
DMDO9YM	SN	1-adamantan-1-yl-3-(2-hydroxyethyl)urea; CHEMBL398166; 120615-92-1; NSC98656; 1-(1-adamantyl)-3-(2-hydroxyethyl)urea; AC1L6ASW; Oprea1_805585; CTK8A5210; MolPort-000-709-916; HMS1608K05; ZINC1643992; STK862338; BDBM50223393; IMED57309943; NSC-98656; AKOS023552817; AKOS001482962; MCULE-6824900815; N-1-adamantyl-N'-(2-hydroxyethyl)urea; EN300-234857; SR-01000396891; SR-01000396891-1; F0266-0451
DMDO9YM	DT	Small molecular drug
DMDO9YM	PC	263942
DMDO9YM	MW	238.33
DMDO9YM	FM	C13H22N2O2
DMDO9YM	IC	InChI=1S/C13H22N2O2/c16-2-1-14-12(17)15-13-6-9-3-10(7-13)5-11(4-9)8-13/h9-11,16H,1-8H2,(H2,14,15,17)
DMDO9YM	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NCCO
DMDO9YM	IK	BBHYFNMMUBVBEX-UHFFFAOYSA-N
DMDO9YM	IU	1-(1-adamantyl)-3-(2-hydroxyethyl)urea
DMDO9YM	DE	Discovery agent

DMJ8ZS6	ID	DMJ8ZS6
DMJ8ZS6	DN	1-Adamantan-1-yl-3-(2-hydroxy-phenyl)-urea
DMJ8ZS6	HS	Investigative
DMJ8ZS6	SN	CHEMBL477670; 1-Adamantan-1-yl-3-(2-hydroxy-phenyl)-urea; SCHEMBL6565549; BDBM50267092
DMJ8ZS6	DT	Small molecular drug
DMJ8ZS6	PC	22932333
DMJ8ZS6	MW	286.37
DMJ8ZS6	FM	C17H22N2O2
DMJ8ZS6	IC	InChI=1S/C17H22N2O2/c20-15-4-2-1-3-14(15)18-16(21)19-17-8-11-5-12(9-17)7-13(6-11)10-17/h1-4,11-13,20H,5-10H2,(H2,18,19,21)
DMJ8ZS6	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=CC=C4O
DMJ8ZS6	IK	LYHYUDXVHBEHPM-UHFFFAOYSA-N
DMJ8ZS6	IU	1-(1-adamantyl)-3-(2-hydroxyphenyl)urea
DMJ8ZS6	DE	Discovery agent

DMRBVFO	ID	DMRBVFO
DMRBVFO	DN	1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea
DMRBVFO	HS	Investigative
DMRBVFO	SN	CHEMBL445531; 1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea; Oprea1_425301; Oprea1_433459; MolPort-001-590-368; ZINC5676460; STL504055; BDBM50267095; AKOS003326568; MCULE-4523135214; 1-(1-adamantyl)-3-(2-methoxyphenyl)urea; ST50933621; N-adamantanyl[(2-methoxyphenyl)amino]carboxamide
DMRBVFO	DT	Small molecular drug
DMRBVFO	PC	17375075
DMRBVFO	MW	300.4
DMRBVFO	FM	C18H24N2O2
DMRBVFO	IC	InChI=1S/C18H24N2O2/c1-22-16-5-3-2-4-15(16)19-17(21)20-18-9-12-6-13(10-18)8-14(7-12)11-18/h2-5,12-14H,6-11H2,1H3,(H2,19,20,21)
DMRBVFO	CS	COC1=CC=CC=C1NC(=O)NC23CC4CC(C2)CC(C4)C3
DMRBVFO	IK	KVPRHLDYUVRHBP-UHFFFAOYSA-N
DMRBVFO	IU	1-(1-adamantyl)-3-(2-methoxyphenyl)urea
DMRBVFO	DE	Discovery agent

DMGEXOZ	ID	DMGEXOZ
DMGEXOZ	DN	1-adamantan-1-yl-3-(3-hexyloxypropyl)urea
DMGEXOZ	HS	Investigative
DMGEXOZ	SN	CHEMBL245127; 1-adamantan-1-yl-3-(3-hexyloxypropyl)urea; SCHEMBL12931853
DMGEXOZ	DT	Small molecular drug
DMGEXOZ	PC	23631475
DMGEXOZ	MW	336.5
DMGEXOZ	FM	C20H36N2O2
DMGEXOZ	IC	InChI=1S/C20H36N2O2/c1-2-3-4-5-8-24-9-6-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DMGEXOZ	CS	CCCCCCOCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMGEXOZ	IK	XMBHPHYTFZFYFH-UHFFFAOYSA-N
DMGEXOZ	IU	1-(1-adamantyl)-3-(3-hexoxypropyl)urea
DMGEXOZ	DE	Discovery agent

DM8SEJP	ID	DM8SEJP
DM8SEJP	DN	1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea
DM8SEJP	HS	Investigative
DM8SEJP	SN	CHEMBL477671; 1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea; SCHEMBL6568488; BDBM50267093
DM8SEJP	DT	Small molecular drug
DM8SEJP	PC	22932424
DM8SEJP	MW	286.37
DM8SEJP	FM	C17H22N2O2
DM8SEJP	IC	InChI=1S/C17H22N2O2/c20-15-3-1-2-14(7-15)18-16(21)19-17-8-11-4-12(9-17)6-13(5-11)10-17/h1-3,7,11-13,20H,4-6,8-10H2,(H2,18,19,21)
DM8SEJP	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC(=CC=C4)O
DM8SEJP	IK	FBTNUWJYRWKVCD-UHFFFAOYSA-N
DM8SEJP	IU	1-(1-adamantyl)-3-(3-hydroxyphenyl)urea
DM8SEJP	DE	Discovery agent

DMZX72E	ID	DMZX72E
DMZX72E	DN	1-adamantan-1-yl-3-(3-hydroxypropyl)urea
DMZX72E	HS	Investigative
DMZX72E	SN	CHEMBL242592; SMR000144635; 1-adamantan-1-yl-3-(3-hydroxypropyl)urea; AC1M3CD5; MLS000538598; MolPort-001-628-514; HMS2462I06; ZINC2882943; 1-(3-hydroxypropyl)-3-tricyclo[3.3.1.1~3,7~]dec-1-ylurea; STK207014; BDBM50223385; AKOS016321670; AKOS003366277; AKOS002318484; MCULE-4878985284; N-1-adamantyl-N'-(3-hydroxypropyl)urea; 1-(1-adamantyl)-3-(3-hydroxypropyl)urea; ST50766260
DMZX72E	DT	Small molecular drug
DMZX72E	PC	2235217
DMZX72E	MW	252.35
DMZX72E	FM	C14H24N2O2
DMZX72E	IC	InChI=1S/C14H24N2O2/c17-3-1-2-15-13(18)16-14-7-10-4-11(8-14)6-12(5-10)9-14/h10-12,17H,1-9H2,(H2,15,16,18)
DMZX72E	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCO
DMZX72E	IK	QADGUCFKHPQVSD-UHFFFAOYSA-N
DMZX72E	IU	1-(1-adamantyl)-3-(3-hydroxypropyl)urea
DMZX72E	DE	Discovery agent

DMHAS3G	ID	DMHAS3G
DMHAS3G	DN	1-Adamantan-1-yl-3-(3-methoxy-phenyl)-urea
DMHAS3G	HS	Investigative
DMHAS3G	SN	CHEMBL516890; 1-Adamantan-1-yl-3-(3-methoxy-phenyl)-urea; ZINC8167942; BDBM50267096
DMHAS3G	DT	Small molecular drug
DMHAS3G	PC	44582391
DMHAS3G	MW	300.4
DMHAS3G	FM	C18H24N2O2
DMHAS3G	IC	InChI=1S/C18H24N2O2/c1-22-16-4-2-3-15(8-16)19-17(21)20-18-9-12-5-13(10-18)7-14(6-12)11-18/h2-4,8,12-14H,5-7,9-11H2,1H3,(H2,19,20,21)
DMHAS3G	CS	COC1=CC=CC(=C1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMHAS3G	IK	QPAGLMBLMPXYKJ-UHFFFAOYSA-N
DMHAS3G	IU	1-(1-adamantyl)-3-(3-methoxyphenyl)urea
DMHAS3G	DE	Discovery agent

DM53G1V	ID	DM53G1V
DM53G1V	DN	1-adamantan-1-yl-3-(4-hydroxybutyl)urea
DM53G1V	HS	Investigative
DM53G1V	SN	CHEMBL397197; 1-adamantan-1-yl-3-(4-hydroxybutyl)urea
DM53G1V	DT	Small molecular drug
DM53G1V	PC	16756510
DM53G1V	MW	266.38
DM53G1V	FM	C15H26N2O2
DM53G1V	IC	InChI=1S/C15H26N2O2/c18-4-2-1-3-16-14(19)17-15-8-11-5-12(9-15)7-13(6-11)10-15/h11-13,18H,1-10H2,(H2,16,17,19)
DM53G1V	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCO
DM53G1V	IK	GVVAZSZYNJNYGI-UHFFFAOYSA-N
DM53G1V	IU	1-(1-adamantyl)-3-(4-hydroxybutyl)urea
DM53G1V	DE	Discovery agent

DMHKG89	ID	DMHKG89
DMHKG89	DN	1-Adamantan-1-yl-3-(4-hydroxy-decyl)-urea
DMHKG89	HS	Investigative
DMHKG89	SN	CHEMBL195796; 1-Adamantan-1-yl-3-(4-hydroxy-decyl)-urea
DMHKG89	DT	Small molecular drug
DMHKG89	PC	11772500
DMHKG89	MW	350.5
DMHKG89	FM	C21H38N2O2
DMHKG89	IC	InChI=1S/C21H38N2O2/c1-2-3-4-5-7-19(24)8-6-9-22-20(25)23-21-13-16-10-17(14-21)12-18(11-16)15-21/h16-19,24H,2-15H2,1H3,(H2,22,23,25)
DMHKG89	CS	CCCCCCC(CCCNC(=O)NC12CC3CC(C1)CC(C3)C2)O
DMHKG89	IK	BQABXUIGNYSGOR-UHFFFAOYSA-N
DMHKG89	IU	1-(1-adamantyl)-3-(4-hydroxydecyl)urea
DMHKG89	DE	Discovery agent

DMUPAR1	ID	DMUPAR1
DMUPAR1	DN	1-Adamantan-1-yl-3-(4-hydroxy-phenyl)-urea
DMUPAR1	HS	Investigative
DMUPAR1	SN	CHEMBL477872; 1-Adamantan-1-yl-3-(4-hydroxy-phenyl)-urea; SCHEMBL12932185; BDBM50267094; AKOS009210324
DMUPAR1	DT	Small molecular drug
DMUPAR1	PC	28787671
DMUPAR1	MW	286.37
DMUPAR1	FM	C17H22N2O2
DMUPAR1	IC	InChI=1S/C17H22N2O2/c20-15-3-1-14(2-4-15)18-16(21)19-17-8-11-5-12(9-17)7-13(6-11)10-17/h1-4,11-13,20H,5-10H2,(H2,18,19,21)
DMUPAR1	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=C(C=C4)O
DMUPAR1	IK	NGFXIFJXNYMTPD-UHFFFAOYSA-N
DMUPAR1	IU	1-(1-adamantyl)-3-(4-hydroxyphenyl)urea
DMUPAR1	DE	Discovery agent

DMMBYOD	ID	DMMBYOD
DMMBYOD	DN	1-Adamantan-1-yl-3-(4-methoxy-phenyl)-urea
DMMBYOD	HS	Investigative
DMMBYOD	SN	1-(1-adamantyl)-3-(4-methoxyphenyl)urea; CHEMBL477067; AC1MT5QX; 1-Adamantan-1-yl-3-(4-methoxy-phenyl)-urea; Oprea1_591947; BDBM50267097
DMMBYOD	DT	Small molecular drug
DMMBYOD	PC	3545369
DMMBYOD	MW	300.4
DMMBYOD	FM	C18H24N2O2
DMMBYOD	IC	InChI=1S/C18H24N2O2/c1-22-16-4-2-15(3-5-16)19-17(21)20-18-9-12-6-13(10-18)8-14(7-12)11-18/h2-5,12-14H,6-11H2,1H3,(H2,19,20,21)
DMMBYOD	CS	COC1=CC=C(C=C1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMMBYOD	IK	SITQZMUGNIFVIS-UHFFFAOYSA-N
DMMBYOD	IU	1-(1-adamantyl)-3-(4-methoxyphenyl)urea
DMMBYOD	DE	Discovery agent

DM3RE2D	ID	DM3RE2D
DM3RE2D	DN	1-adamantan-1-yl-3-(4-pentyloxybutyl)urea
DM3RE2D	HS	Investigative
DM3RE2D	SN	CHEMBL191767; 1-adamantan-1-yl-3-(4-pentyloxybutyl)urea; SCHEMBL12931855; BDBM50167050
DM3RE2D	DT	Small molecular drug
DM3RE2D	PC	11186744
DM3RE2D	MW	336.5
DM3RE2D	FM	C20H36N2O2
DM3RE2D	IC	InChI=1S/C20H36N2O2/c1-2-3-5-8-24-9-6-4-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DM3RE2D	CS	CCCCCOCCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DM3RE2D	IK	UCGGVDAPMCFWNI-UHFFFAOYSA-N
DM3RE2D	IU	1-(1-adamantyl)-3-(4-pentoxybutyl)urea
DM3RE2D	DE	Discovery agent

DMUZ3OS	ID	DMUZ3OS
DMUZ3OS	DN	1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea
DMUZ3OS	HS	Investigative
DMUZ3OS	SN	CHEMBL439577; CHEMBL2031926; 1-(1-adamantyl)-3-(4-pentoxycyclohexyl)urea; 1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea; SCHEMBL3178050; BDBM50383478
DMUZ3OS	DT	Small molecular drug
DMUZ3OS	PC	11417158
DMUZ3OS	MW	362.5
DMUZ3OS	FM	C22H38N2O2
DMUZ3OS	IC	InChI=1S/C22H38N2O2/c1-2-3-4-9-26-20-7-5-19(6-8-20)23-21(25)24-22-13-16-10-17(14-22)12-18(11-16)15-22/h16-20H,2-15H2,1H3,(H2,23,24,25)
DMUZ3OS	CS	CCCCCOC1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMUZ3OS	IK	VIWCJPKZDQYQRJ-UHFFFAOYSA-N
DMUZ3OS	IU	1-(1-adamantyl)-3-(4-pentoxycyclohexyl)urea
DMUZ3OS	DE	Discovery agent

DMEDQVX	ID	DMEDQVX
DMEDQVX	DN	1-adamantan-1-yl-3-(5-butoxypentyl)urea
DMEDQVX	HS	Investigative
DMEDQVX	SN	CHEMBL245142; 1-adamantan-1-yl-3-(5-butoxypentyl)urea; SCHEMBL2050549
DMEDQVX	DT	Small molecular drug
DMEDQVX	PC	23631476
DMEDQVX	MW	336.5
DMEDQVX	FM	C20H36N2O2
DMEDQVX	IC	InChI=1S/C20H36N2O2/c1-2-3-8-24-9-6-4-5-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DMEDQVX	CS	CCCCOCCCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMEDQVX	IK	KBTVUXWBRNQXPI-UHFFFAOYSA-N
DMEDQVX	IU	1-(1-adamantyl)-3-(5-butoxypentyl)urea
DMEDQVX	DE	Discovery agent

DMV6824	ID	DMV6824
DMV6824	DN	1-adamantan-1-yl-3-(5-hydroxypentyl)urea
DMV6824	HS	Investigative
DMV6824	SN	CHEMBL245141; 1-adamantan-1-yl-3-(5-hydroxypentyl)urea; BDBM50223381
DMV6824	DT	Small molecular drug
DMV6824	PC	23631733
DMV6824	MW	280.41
DMV6824	FM	C16H28N2O2
DMV6824	IC	InChI=1S/C16H28N2O2/c19-5-3-1-2-4-17-15(20)18-16-9-12-6-13(10-16)8-14(7-12)11-16/h12-14,19H,1-11H2,(H2,17,18,20)
DMV6824	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCCO
DMV6824	IK	MMIRJMPACJKTFC-UHFFFAOYSA-N
DMV6824	IU	1-(1-adamantyl)-3-(5-hydroxypentyl)urea
DMV6824	DE	Discovery agent

DMOX5MC	ID	DMOX5MC
DMOX5MC	DN	1-adamantan-1-yl-3-(6-hydroxyhexyl)urea
DMOX5MC	HS	Investigative
DMOX5MC	SN	CHEMBL245143; 1-adamantan-1-yl-3-(6-hydroxyhexyl)urea
DMOX5MC	DT	Small molecular drug
DMOX5MC	PC	23631734
DMOX5MC	MW	294.4
DMOX5MC	FM	C17H30N2O2
DMOX5MC	IC	InChI=1S/C17H30N2O2/c20-6-4-2-1-3-5-18-16(21)19-17-10-13-7-14(11-17)9-15(8-13)12-17/h13-15,20H,1-12H2,(H2,18,19,21)
DMOX5MC	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCCCO
DMOX5MC	IK	FUMIBHNYGFMWPI-UHFFFAOYSA-N
DMOX5MC	IU	1-(1-adamantyl)-3-(6-hydroxyhexyl)urea
DMOX5MC	DE	Discovery agent

DMO1L3I	ID	DMO1L3I
DMO1L3I	DN	1-adamantan-1-yl-3-(6-propyloxyhexyl)urea
DMO1L3I	HS	Investigative
DMO1L3I	SN	CHEMBL245144; 1-adamantan-1-yl-3-(6-propyloxyhexyl)urea; SCHEMBL12931856
DMO1L3I	DT	Small molecular drug
DMO1L3I	PC	9927748
DMO1L3I	MW	336.5
DMO1L3I	FM	C20H36N2O2
DMO1L3I	IC	InChI=1S/C20H36N2O2/c1-2-8-24-9-6-4-3-5-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DMO1L3I	CS	CCCOCCCCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMO1L3I	IK	GXOBIXGHFWBEMM-UHFFFAOYSA-N
DMO1L3I	IU	1-(1-adamantyl)-3-(6-propoxyhexyl)urea
DMO1L3I	DE	Discovery agent

DMXRHKQ	ID	DMXRHKQ
DMXRHKQ	DN	1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea
DMXRHKQ	HS	Investigative
DMXRHKQ	SN	CHEMBL387810; 1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea; BDBM50217475
DMXRHKQ	DT	Small molecular drug
DMXRHKQ	PC	16756389
DMXRHKQ	MW	360.5
DMXRHKQ	FM	C21H29FN2O2
DMXRHKQ	IC	InChI=1S/C21H29FN2O2/c22-18-3-5-19(6-4-18)26-8-2-1-7-23-20(25)24-21-12-15-9-16(13-21)11-17(10-15)14-21/h3-6,15-17H,1-2,7-14H2,(H2,23,24,25)
DMXRHKQ	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCOC4=CC=C(C=C4)F
DMXRHKQ	IK	PVCKSZSZTVYJKW-UHFFFAOYSA-N
DMXRHKQ	IU	1-(1-adamantyl)-3-[4-(4-fluorophenoxy)butyl]urea
DMXRHKQ	DE	Discovery agent

DMLD2G3	ID	DMLD2G3
DMLD2G3	DN	1-Adamantan-1-yl-3-decyl-urea
DMLD2G3	HS	Investigative
DMLD2G3	SN	CHEMBL69663; 1-Adamantan-1-yl-3-decyl-urea; SCHEMBL4445372
DMLD2G3	DT	Small molecular drug
DMLD2G3	PC	11151795
DMLD2G3	MW	334.5
DMLD2G3	FM	C21H38N2O
DMLD2G3	IC	InChI=1S/C21H38N2O/c1-2-3-4-5-6-7-8-9-10-22-20(24)23-21-14-17-11-18(15-21)13-19(12-17)16-21/h17-19H,2-16H2,1H3,(H2,22,23,24)
DMLD2G3	CS	CCCCCCCCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMLD2G3	IK	KDYRDODPBAFNHJ-UHFFFAOYSA-N
DMLD2G3	IU	1-(1-adamantyl)-3-decylurea
DMLD2G3	DE	Discovery agent

DMCFKX0	ID	DMCFKX0
DMCFKX0	DN	1-Adamantan-1-yl-3-phenyl-urea
DMCFKX0	HS	Investigative
DMCFKX0	SN	1-Adamantan-1-yl-3-phenyl-urea; CHEMBL516415; AC1MJEST; BAS 00102691; AC1Q5LN2; Oprea1_605405; Oprea1_553434; SCHEMBL1420838; IFLab1_001789; 1-(1-adamantyl)-3-phenylurea; 1-adamantan-1-yl-3-phenylurea; N-(1-adamantyl)-N'-phenylurea; 1-(1-adamantyl)-3-phenyl-urea; BOKJLWGPHOTBQZ-UHFFFAOYSA-N; MolPort-000-434-175; HMS1417B07; 3-(adamantan-1-yl)-1-phenylurea; ZINC6645734; N-adamantanyl(phenylamino)carboxamide; STL263876; BDBM50267067; AKOS003625202; AKOS001215839; MCULE-9094796377; UPCMLD0ENAT5533559:001; ST50049182; SR-01000363562
DMCFKX0	DT	Small molecular drug
DMCFKX0	PC	3090774
DMCFKX0	MW	270.37
DMCFKX0	FM	C17H22N2O
DMCFKX0	IC	InChI=1S/C17H22N2O/c20-16(18-15-4-2-1-3-5-15)19-17-9-12-6-13(10-17)8-14(7-12)11-17/h1-5,12-14H,6-11H2,(H2,18,19,20)
DMCFKX0	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=CC=C4
DMCFKX0	IK	BOKJLWGPHOTBQZ-UHFFFAOYSA-N
DMCFKX0	IU	1-(1-adamantyl)-3-phenylurea
DMCFKX0	DE	Discovery agent

DMGPIL0	ID	DMGPIL0
DMGPIL0	DN	1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea
DMGPIL0	HS	Investigative
DMGPIL0	SN	CHEMBL216287; 1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea; SCHEMBL8925408; BDBM50191866
DMGPIL0	DT	Small molecular drug
DMGPIL0	PC	14322900
DMGPIL0	MW	291.4
DMGPIL0	FM	C17H29N3O
DMGPIL0	IC	InChI=1S/C17H29N3O/c21-16(19-11-12-1-3-18-4-2-12)20-17-8-13-5-14(9-17)7-15(6-13)10-17/h12-15,18H,1-11H2,(H2,19,20,21)
DMGPIL0	CS	C1CNCCC1CNC(=O)NC23CC4CC(C2)CC(C4)C3
DMGPIL0	IK	ZQMNKAGVCNSSIW-UHFFFAOYSA-N
DMGPIL0	IU	1-(1-adamantyl)-3-(piperidin-4-ylmethyl)urea
DMGPIL0	DE	Discovery agent

DMTNPBH	ID	DMTNPBH
DMTNPBH	DN	1-adamantan-1-yl-3-piperidin-4-yl-urea
DMTNPBH	HS	Investigative
DMTNPBH	SN	ASN 06482309; 1-Adamantan-1-yl-3-piperidin-4-yl-urea; CHEMBL215356; AC1MLKMS; SCHEMBL8234307; BDBM50191891; AKOS000794965
DMTNPBH	DT	Small molecular drug
DMTNPBH	PC	3221297
DMTNPBH	MW	277.4
DMTNPBH	FM	C16H27N3O
DMTNPBH	IC	InChI=1S/C16H27N3O/c20-15(18-14-1-3-17-4-2-14)19-16-8-11-5-12(9-16)7-13(6-11)10-16/h11-14,17H,1-10H2,(H2,18,19,20)
DMTNPBH	CS	C1CNCCC1NC(=O)NC23CC4CC(C2)CC(C4)C3
DMTNPBH	IK	NWWZZPCDHOXVSZ-UHFFFAOYSA-N
DMTNPBH	IU	1-(1-adamantyl)-3-piperidin-4-ylurea
DMTNPBH	DE	Discovery agent

DM60Y8M	ID	DM60Y8M
DM60Y8M	DN	1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea
DM60Y8M	HS	Investigative
DM60Y8M	SN	CHEMBL149161; AC1MHEHW; 1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea; SCHEMBL6281905; PHI-535; BDBM50097038; 1-(1-adamantylmethyl)-3-thiazol-2-yl-thiourea; 1-(1-Adamantylmethyl)-3-(2-thiazolyl)thiourea; 1-(1-adamantylmethyl)-3-(1,3-thiazol-2-yl)thiourea
DM60Y8M	DT	Small molecular drug
DM60Y8M	PC	3003031
DM60Y8M	MW	307.5
DM60Y8M	FM	C15H21N3S2
DM60Y8M	IC	InChI=1S/C15H21N3S2/c19-13(18-14-16-1-2-20-14)17-9-15-6-10-3-11(7-15)5-12(4-10)8-15/h1-2,10-12H,3-9H2,(H2,16,17,18,19)
DM60Y8M	CS	C1C2CC3CC1CC(C2)(C3)CNC(=S)NC4=NC=CS4
DM60Y8M	IK	YVDWMGNODCFVJL-UHFFFAOYSA-N
DM60Y8M	IU	1-(1-adamantylmethyl)-3-(1,3-thiazol-2-yl)thiourea
DM60Y8M	DE	Discovery agent

DMQJ9RZ	ID	DMQJ9RZ
DMQJ9RZ	DN	1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole
DMQJ9RZ	HS	Investigative
DMQJ9RZ	SN	1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole; GTPL3136; SCHEMBL8249304
DMQJ9RZ	DT	Small molecular drug
DMQJ9RZ	PC	9949081
DMQJ9RZ	MW	322.4
DMQJ9RZ	FM	C21H26N2O
DMQJ9RZ	IC	InChI=1S/C21H26N2O/c1-4-8-18-20(24-14-7-13-22-15(2)3)12-11-17-16-9-5-6-10-19(16)23-21(17)18/h4-6,9-12,15,22-23H,1,7-8,13-14H2,2-3H3
DMQJ9RZ	CS	CC(C)NCCCOC1=C(C2=C(C=C1)C3=CC=CC=C3N2)CC=C
DMQJ9RZ	IK	UQDMMPHZGIOABI-UHFFFAOYSA-N
DMQJ9RZ	IU	N-propan-2-yl-3-[(1-prop-2-enyl-9H-carbazol-2-yl)oxy]propan-1-amine
DMQJ9RZ	DE	Discovery agent

DMNDW4J	ID	DMNDW4J
DMNDW4J	DN	1-allyl-2-[3-(isopropylamino)propoxy]-9H-xanthen-9-one
DMNDW4J	HS	Investigative
DMNDW4J	SN	GTPL3135; SCHEMBL16792026; 1-allyl-2-[3-(isopropylamino)propoxy]-9H-xanthen-9-one
DMNDW4J	DT	Small molecular drug
DMNDW4J	PC	56947004
DMNDW4J	MW	351.4
DMNDW4J	FM	C22H25NO3
DMNDW4J	IC	InChI=1S/C22H25NO3/c1-4-8-16-18(25-14-7-13-23-15(2)3)11-12-20-21(16)22(24)17-9-5-6-10-19(17)26-20/h4-6,9-12,15,23H,1,7-8,13-14H2,2-3H3
DMNDW4J	CS	CC(C)NCCCOC1=C(C2=C(C=C1)OC3=CC=CC=C3C2=O)CC=C
DMNDW4J	IK	NZEPLPVSYIYMMM-UHFFFAOYSA-N
DMNDW4J	IU	2-[3-(propan-2-ylamino)propoxy]-1-prop-2-enylxanthen-9-one
DMNDW4J	DE	Discovery agent

DML54H2	ID	DML54H2
DML54H2	DN	1-Allyl-3,7-dihydro-purine-2,6-dione
DML54H2	HS	Investigative
DML54H2	SN	CHEMBL66899; 1H-Purine-2,6-dione, 3,9-dihydro-1-(2-propen-1-yl)-; 146830-80-0; 1-allylxanthine; 1-Allyl-3,7-dihydro-purine-2,6-dione; SCHEMBL6464355; BDBM50042206
DML54H2	DT	Small molecular drug
DML54H2	PC	14969716
DML54H2	MW	192.17
DML54H2	FM	C8H8N4O2
DML54H2	IC	InChI=1S/C8H8N4O2/c1-2-3-12-7(13)5-6(10-4-9-5)11-8(12)14/h2,4H,1,3H2,(H,9,10)(H,11,14)
DML54H2	CS	C=CCN1C(=O)C2=C(NC1=O)N=CN2
DML54H2	IK	IPKIKTHDWDXHPU-UHFFFAOYSA-N
DML54H2	IU	1-prop-2-enyl-3,7-dihydropurine-2,6-dione
DML54H2	DE	Discovery agent

DMZE5GX	ID	DMZE5GX
DMZE5GX	DN	1-Allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione
DMZE5GX	HS	Investigative
DMZE5GX	SN	Allyltheobromine; 1-Allyltheobromine; Theobromine, 1-allyl-; UNII-4JG7O04XYX; 2530-99-6; 4JG7O04XYX; CHEMBL25427; 1-Allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione; Allyltheobromin; NSC40882; AC1L5YRZ; 3,7-dimethyl-1-prop-2-enylpurine-2,6-dione; AC1Q6LF9; SCHEMBL8435386; CTK4F5434; MolPort-001-981-271; HMS1586E14; ZINC349954; NSC-40882; BDBM50025568; STL378446; AKOS002340304; MCULE-9142254572; BAS 02549760; WLN: T56 BN DN FNVNVJ B1 F1 H1U2; 1H-Purine-2, 3,7-dihydro-3,7-dimethyl-1-(2-propenyl)-
DMZE5GX	DT	Small molecular drug
DMZE5GX	PC	237430
DMZE5GX	MW	220.23
DMZE5GX	FM	C10H12N4O2
DMZE5GX	IC	InChI=1S/C10H12N4O2/c1-4-5-14-9(15)7-8(11-6-12(7)2)13(3)10(14)16/h4,6H,1,5H2,2-3H3
DMZE5GX	CS	CN1C=NC2=C1C(=O)N(C(=O)N2C)CC=C
DMZE5GX	IK	BTFHIKZOEZREBX-UHFFFAOYSA-N
DMZE5GX	IU	3,7-dimethyl-1-prop-2-enylpurine-2,6-dione
DMZE5GX	CA	CAS 2530-99-6
DMZE5GX	DE	Discovery agent

DM2J5WH	ID	DM2J5WH
DM2J5WH	DN	1-allyl-5'-O-tritylinosine
DM2J5WH	HS	Investigative
DM2J5WH	SN	CHEMBL213891; 1-allyl-5''-O-tritylinosine
DM2J5WH	DT	Small molecular drug
DM2J5WH	PC	16082759
DM2J5WH	MW	550.6
DM2J5WH	FM	C32H30N4O5
DM2J5WH	IC	InChI=1S/C32H30N4O5/c1-2-18-35-20-34-29-26(30(35)39)33-21-36(29)31-28(38)27(37)25(41-31)19-40-32(22-12-6-3-7-13-22,23-14-8-4-9-15-23)24-16-10-5-11-17-24/h2-17,20-21,25,27-28,31,37-38H,1,18-19H2/t25-,27-,28-,31-/m1/s1
DM2J5WH	CS	C=CCN1C=NC2=C(C1=O)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COC(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)O)O
DM2J5WH	IK	WUKAFOPIIOGNJA-QWOIFIOOSA-N
DM2J5WH	IU	9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]-1-prop-2-enylpurin-6-one
DM2J5WH	DE	Discovery agent

DMRAN9T	ID	DMRAN9T
DMRAN9T	DN	1-amino-2,4-bis(phenylthio)anthracene-9,10-dione
DMRAN9T	HS	Investigative
DMRAN9T	SN	CHEMBL600009; ChemDiv1_000050; AC1MZ0W8; 1-amino-2,4-bis(phenylthio)anthracene-9,10-dione; SCHEMBL13944330; HMS587C06; MolPort-003-717-430; ZINC4421222; BDBM50306772; AKOS001588262; MCULE-8570323585; 1-amino-2,4-bis(phenylthio)anthra-9,10-quinone
DMRAN9T	DT	Small molecular drug
DMRAN9T	PC	3890693
DMRAN9T	MW	439.6
DMRAN9T	FM	C26H17NO2S2
DMRAN9T	IC	InChI=1S/C26H17NO2S2/c27-24-21(31-17-11-5-2-6-12-17)15-20(30-16-9-3-1-4-10-16)22-23(24)26(29)19-14-8-7-13-18(19)25(22)28/h1-15H,27H2
DMRAN9T	CS	C1=CC=C(C=C1)SC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)SC5=CC=CC=C5
DMRAN9T	IK	XAJKSCYRAOFPAT-UHFFFAOYSA-N
DMRAN9T	IU	1-amino-2,4-bis(phenylsulfanyl)anthracene-9,10-dione
DMRAN9T	DE	Discovery agent

DMWCXM4	ID	DMWCXM4
DMWCXM4	DN	1-amino-2-phenoxyanthracene-9,10-dione
DMWCXM4	HS	Investigative
DMWCXM4	SN	1-amino-2-phenoxyanthracene-9,10-dione; CHEMBL601856; AC1MDASQ; 1-Amino-2-phenoxy-anthraquinone; MolPort-001-914-416; ZINC3878658; BDBM50306773; AKOS000668569; MCULE-3398092458; BAS 00096273
DMWCXM4	DT	Small molecular drug
DMWCXM4	PC	2833773
DMWCXM4	MW	315.3
DMWCXM4	FM	C20H13NO3
DMWCXM4	IC	InChI=1S/C20H13NO3/c21-18-16(24-12-6-2-1-3-7-12)11-10-15-17(18)20(23)14-9-5-4-8-13(14)19(15)22/h1-11H,21H2
DMWCXM4	CS	C1=CC=C(C=C1)OC2=C(C3=C(C=C2)C(=O)C4=CC=CC=C4C3=O)N
DMWCXM4	IK	LTBODPBDLZJCLH-UHFFFAOYSA-N
DMWCXM4	IU	1-amino-2-phenoxyanthracene-9,10-dione
DMWCXM4	DE	Discovery agent

DMOAQC4	ID	DMOAQC4
DMOAQC4	DN	1-Amino-3-(aminoxy)-2-propanol Dihydrochloride
DMOAQC4	HS	Investigative
DMOAQC4	SN	CHEMBL1209777
DMOAQC4	DT	Small molecular drug
DMOAQC4	PC	49862726
DMOAQC4	MW	142.58
DMOAQC4	FM	C3H11ClN2O2
DMOAQC4	IC	InChI=1S/C3H10N2O2.ClH/c4-1-3(6)2-7-5;/h3,6H,1-2,4-5H2;1H
DMOAQC4	CS	C(C(CON)O)N.Cl
DMOAQC4	IK	CDNYZQKHCXXBPH-UHFFFAOYSA-N
DMOAQC4	IU	1-amino-3-aminooxypropan-2-ol;hydrochloride
DMOAQC4	DE	Discovery agent

DMJMDNX	ID	DMJMDNX
DMJMDNX	DN	1-amino-4-chloroanthracene-9,10-dione
DMJMDNX	HS	Investigative
DMJMDNX	SN	1-Amino-4-chloroanthraquinone; 1-amino-4-chloroanthracene-9,10-dione; 2872-47-1; 4-Chloro-1-aminoanthraquinone; 4-Amino-4-chloroanthraquinone; ANTHRAQUINONE, 1-AMINO-4-CHLORO-; C.I. 62805; NSC 39927; BRN 0916373; 1-Amino-4-chloro-9,10-anthracenedione; 9,10-Anthracenedione, 1-amino-4-chloro-; CHEMBL603094; NSC39927; AC1L2AVQ; 9, 1-amino-4-chloro-; 4-14-00-00440 (Beilstein Handbook Reference); SCHEMBL5109323; CTK4G1984; DTXSID50182880; MolPort-000-643-769; AWACQBFBMROGQC-UHFFFAOYSA-N; ZINC4792024; NSC-39927; BDBM50306769; STK238272
DMJMDNX	DT	Small molecular drug
DMJMDNX	PC	17884
DMJMDNX	MW	257.67
DMJMDNX	FM	C14H8ClNO2
DMJMDNX	IC	InChI=1S/C14H8ClNO2/c15-9-5-6-10(16)12-11(9)13(17)7-3-1-2-4-8(7)14(12)18/h1-6H,16H2
DMJMDNX	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)Cl)N
DMJMDNX	IK	AWACQBFBMROGQC-UHFFFAOYSA-N
DMJMDNX	IU	1-amino-4-chloroanthracene-9,10-dione
DMJMDNX	CA	CAS 2872-47-1
DMJMDNX	DE	Discovery agent

DM7X5BP	ID	DM7X5BP
DM7X5BP	DN	1-amino-4-methoxyanthracene-9,10-dione
DM7X5BP	HS	Investigative
DM7X5BP	SN	1-Amino-4-methoxyanthraquinone; 1-amino-4-methoxyanthracene-9,10-dione; 116-83-6; 4-Methoxy-1-anthraquinonylamine; 1-Amino-4-methoxy-9,10-anthraquinone; UNII-BCH9T82ZKZ; NSC 84162; BCH9T82ZKZ; BRN 2218945; ANTHRAQUINONE, 1-AMINO-4-METHOXY-; CHEMBL600008; 9,10-Anthracenedione, 1-amino-4-methoxy- (9CI); NSC84162; AC1L1QQQ; cid_8321; 9, 1-amino-4-methoxy-; MLS000585344; 1-Methoxy-4-aminoanthraquinone; SCHEMBL2303569; CTK4A9995; DTXSID40151262; KXOGXZAXERYOTC-UHFFFAOYSA-N; HMS2536C23; ZINC3874026; NSC-84162; BDBM50306771; AKOS001666411
DM7X5BP	DT	Small molecular drug
DM7X5BP	PC	8321
DM7X5BP	MW	253.25
DM7X5BP	FM	C15H11NO3
DM7X5BP	IC	InChI=1S/C15H11NO3/c1-19-11-7-6-10(16)12-13(11)15(18)9-5-3-2-4-8(9)14(12)17/h2-7H,16H2,1H3
DM7X5BP	CS	COC1=C2C(=C(C=C1)N)C(=O)C3=CC=CC=C3C2=O
DM7X5BP	IK	KXOGXZAXERYOTC-UHFFFAOYSA-N
DM7X5BP	IU	1-amino-4-methoxyanthracene-9,10-dione
DM7X5BP	CA	CAS 116-83-6
DM7X5BP	DE	Discovery agent

DM6AV2S	ID	DM6AV2S
DM6AV2S	DN	1-Amino-6-Cyclohex-3-Enylmethyloxypurine
DM6AV2S	HS	Investigative
DM6AV2S	SN	1-AMINO-6-CYCLOHEX-3-ENYLMETHYLOXYPURINE; 872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-
DM6AV2S	DT	Small molecular drug
DM6AV2S	PC	445967
DM6AV2S	MW	246.31
DM6AV2S	FM	C13H18N4O
DM6AV2S	IC	InChI=1S/C13H18N4O/c14-11-6-10-12(16-8-15-10)13(17-11)18-7-9-4-2-1-3-5-9/h6,8-9H,1-5,7H2,(H2,14,17)(H,15,16)
DM6AV2S	CS	C1CCC(CC1)COC2=C3C(=CC(=N2)N)NC=N3
DM6AV2S	IK	VPUIDVRYMVIXGO-UHFFFAOYSA-N
DM6AV2S	IU	4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine
DM6AV2S	CA	CAS 872556-74-6
DM6AV2S	DE	Discovery agent

DMGU76I	ID	DMGU76I
DMGU76I	DN	1-aminoanthracene-9,10-dione
DMGU76I	HS	Investigative
DMGU76I	SN	1-AMINOANTHRAQUINONE; 82-45-1; 1-aminoanthracene-9,10-dione; Diazo Fast Red AL; 1-Amino anthraquinone; Anthraquinone, 1-amino-; 1-Aminoanthrachinon; 1-Amino-anthraquinone; 9,10-Anthracenedione, 1-amino-; alpha-Aminoanthraquinone; 1-Amino-9,10-anthraquinone; C.I. 37275; 1-Amino-9,10-anthracenedione; alpha-Anthraquinonylamine; UNII-N5YYY1NEUI; NSC 458; 1-Aminoquinone; .alpha.-Aminoanthraquinone; NSC 30415; 1-Aminoanthrachinon [Czech]; 9,10-Anthracenedione, amino-; N5YYY1NEUI; EINECS 201-423-5; .alpha.-Anthraquinonylamine; BRN 039636
DMGU76I	DT	Small molecular drug
DMGU76I	PC	6710
DMGU76I	MW	223.23
DMGU76I	FM	C14H9NO2
DMGU76I	IC	InChI=1S/C14H9NO2/c15-11-7-3-6-10-12(11)14(17)9-5-2-1-4-8(9)13(10)16/h1-7H,15H2
DMGU76I	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)N
DMGU76I	IK	KHUFHLFHOQVFGB-UHFFFAOYSA-N
DMGU76I	IU	1-aminoanthracene-9,10-dione
DMGU76I	CA	CAS 82-45-1
DMGU76I	DE	Discovery agent

DM4TFN6	ID	DM4TFN6
DM4TFN6	DN	1-aminobutylphosphonic acid
DM4TFN6	HS	Investigative
DM4TFN6	SN	(1-aminobutyl)phosphonic acid; 1-aminobutylphosphonic acid; 13138-36-8; Phosphonic acid, (1-aminobutyl)-; NSC-117799; CHEMBL1089898; Phosphonic acid,P-(1-aminobutyl)-; alpha-Aminobutanephosphonic acid; DL-(1-Aminobutyl)phosphonic acid; Phosphonic acid, P-(1-aminobutyl)-; NSC117799; (+/-)-(1-Aminobutyl)phosphonic acid; J441.089K; AC1Q6RLK; AC1L6SK2; SCHEMBL745916; alpha-aminobutylphosphonic acid; CTK4B7247; BDBM50316029; AKOS015854597; FCH1112358; TRA0100955; KB-00224; TR-032039; DB-042023; FT-0636808; C-51169
DM4TFN6	DT	Small molecular drug
DM4TFN6	PC	272986
DM4TFN6	MW	153.12
DM4TFN6	FM	C4H12NO3P
DM4TFN6	IC	InChI=1S/C4H12NO3P/c1-2-3-4(5)9(6,7)8/h4H,2-3,5H2,1H3,(H2,6,7,8)
DM4TFN6	CS	CCCC(N)P(=O)(O)O
DM4TFN6	IK	UAEPDDGDPAPPHZ-UHFFFAOYSA-N
DM4TFN6	IU	1-aminobutylphosphonic acid
DM4TFN6	CA	CAS 13138-36-8
DM4TFN6	DE	Discovery agent

DMFUABI	ID	DMFUABI
DMFUABI	DN	1-aminohexylphosphonic acid
DMFUABI	HS	Investigative
DMFUABI	SN	(1-Aminohexyl)phosphonic acid; 1-aminohexylphosphonic Acid; 63207-60-3; CHEMBL40508; 109638-78-0; ACMC-20mcgx; AC1MC01Z; SCHEMBL625939; CTK6D6935; DTXSID70370060; 1-AMINOHEXYL PHOSPHONIC ACID; Phosphonic acid, P-(1-aminohexyl)-; AKOS015892987; DB-054431; FT-0640877
DMFUABI	DT	Small molecular drug
DMFUABI	PC	2733961
DMFUABI	MW	181.17
DMFUABI	FM	C6H16NO3P
DMFUABI	IC	InChI=1S/C6H16NO3P/c1-2-3-4-5-6(7)11(8,9)10/h6H,2-5,7H2,1H3,(H2,8,9,10)
DMFUABI	CS	CCCCCC(N)P(=O)(O)O
DMFUABI	IK	ODMTWOKJHVPSLP-UHFFFAOYSA-N
DMFUABI	IU	1-aminohexylphosphonic acid
DMFUABI	CA	CAS 109638-78-0
DMFUABI	DE	Discovery agent

DML6UJM	ID	DML6UJM
DML6UJM	DN	1-aminohexylphosphonic acid monophenyl ester
DML6UJM	HS	Investigative
DML6UJM	SN	1-aminohexylphosphonic acid monophenyl ester; CHEMBL1093531
DML6UJM	DT	Small molecular drug
DML6UJM	PC	46886335
DML6UJM	MW	257.269
DML6UJM	FM	C12H20NO3P
DML6UJM	IC	InChI=1S/C12H20NO3P/c1-2-3-5-10-12(13)17(14,15)16-11-8-6-4-7-9-11/h4,6-9,12H,2-3,5,10,13H2,1H3,(H,14,15)
DML6UJM	CS	CCCCCC(N)P(=O)(O)OC1=CC=CC=C1
DML6UJM	IK	DHJINNDLWRRCRC-UHFFFAOYSA-N
DML6UJM	IU	1-aminohexyl(phenoxy)phosphinic acid
DML6UJM	DE	Discovery agent

DMBWNL6	ID	DMBWNL6
DMBWNL6	DN	1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol
DMBWNL6	HS	Investigative
DMBWNL6	SN	CHEMBL100572; 1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol; SCHEMBL10380336; BDBM50008832
DMBWNL6	DT	Small molecular drug
DMBWNL6	PC	15696466
DMBWNL6	MW	277.36
DMBWNL6	FM	C16H23NO3
DMBWNL6	IC	InChI=1S/C16H23NO3/c17-9-15-11-6-7-13(18)16(19)12(11)8-14(20-15)10-4-2-1-3-5-10/h6-7,10,14-15,18-19H,1-5,8-9,17H2/t14-,15-/m0/s1
DMBWNL6	CS	C1CCC(CC1)[C@@H]2CC3=C(C=CC(=C3O)O)[C@@H](O2)CN
DMBWNL6	IK	BOKASTZDGGZFET-GJZGRUSLSA-N
DMBWNL6	IU	(1R,3S)-1-(aminomethyl)-3-cyclohexyl-3,4-dihydro-1H-isochromene-5,6-diol
DMBWNL6	DE	Discovery agent

DMJNG8A	ID	DMJNG8A
DMJNG8A	DN	1-Aminomethyl-3-phenyl-isochroman-5,6-diol
DMJNG8A	HS	Investigative
DMJNG8A	SN	CHEMBL83080; SCHEMBL7447363; SUHGRZPINGKYNV-HUUCEWRRSA-N; ZINC4637270; BDBM50007136; AJ-51787; [1S,3R]1-aminomethyl-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran
DMJNG8A	DT	Small molecular drug
DMJNG8A	PC	14809026
DMJNG8A	MW	271.31
DMJNG8A	FM	C16H17NO3
DMJNG8A	IC	InChI=1S/C16H17NO3/c17-9-15-11-6-7-13(18)16(19)12(11)8-14(20-15)10-4-2-1-3-5-10/h1-7,14-15,18-19H,8-9,17H2/t14-,15-/m1/s1
DMJNG8A	CS	C1[C@@H](O[C@@H](C2=C1C(=C(C=C2)O)O)CN)C3=CC=CC=C3
DMJNG8A	IK	SUHGRZPINGKYNV-HUUCEWRRSA-N
DMJNG8A	IU	(1S,3R)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1H-isochromene-5,6-diol
DMJNG8A	DE	Discovery agent

DM50GS7	ID	DM50GS7
DM50GS7	DN	1-Aminomethyl-isochroman-5,6-diol
DM50GS7	HS	Investigative
DM50GS7	SN	CHEMBL99361; SCHEMBL8726506; 1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-; BDBM50010891; 83694-56-8; 1-Aminomethyl-3,4-dihydro-1H-2-benzopyran-5,6-diol
DM50GS7	DT	Small molecular drug
DM50GS7	PC	13864381
DM50GS7	MW	195.21
DM50GS7	FM	C10H13NO3
DM50GS7	IC	InChI=1S/C10H13NO3/c11-5-9-6-1-2-8(12)10(13)7(6)3-4-14-9/h1-2,9,12-13H,3-5,11H2
DM50GS7	CS	C1COC(C2=C1C(=C(C=C2)O)O)CN
DM50GS7	IK	JBSRTZUQAXYSQB-UHFFFAOYSA-N
DM50GS7	IU	1-(aminomethyl)-3,4-dihydro-1H-isochromene-5,6-diol
DM50GS7	DE	Discovery agent

DMMV30B	ID	DMMV30B
DMMV30B	DN	1-aminopentylphosphonic acid monophenyl ester
DMMV30B	HS	Investigative
DMMV30B	SN	CHEMBL1090367; 1-aminopentylphosphonic acid monophenyl ester
DMMV30B	DT	Small molecular drug
DMMV30B	PC	46886334
DMMV30B	MW	243.24
DMMV30B	FM	C11H18NO3P
DMMV30B	IC	InChI=1S/C11H18NO3P/c1-2-3-9-11(12)16(13,14)15-10-7-5-4-6-8-10/h4-8,11H,2-3,9,12H2,1H3,(H,13,14)
DMMV30B	CS	CCCCC(N)P(=O)(O)OC1=CC=CC=C1
DMMV30B	IK	WRTBDONQGQRUNP-UHFFFAOYSA-N
DMMV30B	IU	1-aminopentyl(phenoxy)phosphinic acid
DMMV30B	DE	Discovery agent

DMPYCK5	ID	DMPYCK5
DMPYCK5	DN	1-Aminopropane-1,2,3-tricarboxylic acid
DMPYCK5	HS	Investigative
DMPYCK5	SN	1-Aminopropane-1,2,3-tricarboxylic acid; 2393-15-9; NSC206248; AC1L7BSJ; SCHEMBL2774681; CHEMBL1190722
DMPYCK5	DT	Small molecular drug
DMPYCK5	PC	307919
DMPYCK5	MW	191.14
DMPYCK5	FM	C6H9NO6
DMPYCK5	IC	InChI=1S/C6H9NO6/c7-4(6(12)13)2(5(10)11)1-3(8)9/h2,4H,1,7H2,(H,8,9)(H,10,11)(H,12,13)
DMPYCK5	CS	C(C(C(C(=O)O)N)C(=O)O)C(=O)O
DMPYCK5	IK	BZJZJZZWFXEMRG-UHFFFAOYSA-N
DMPYCK5	IU	1-aminopropane-1,2,3-tricarboxylic acid
DMPYCK5	DE	Discovery agent

DMNGY0E	ID	DMNGY0E
DMNGY0E	DN	1-anilinonaphthalene-8-sulfonic acid
DMNGY0E	HS	Investigative
DMNGY0E	SN	CHEMBL471741; SCHEMBL3327539; BDBM50243721; 8-(Phenylamino)naphthalene-1-ol sulfate
DMNGY0E	DT	Small molecular drug
DMNGY0E	PC	1369
DMNGY0E	MW	299.3
DMNGY0E	FM	C16H13NO3S
DMNGY0E	IC	InChI=1S/C16H13NO3S/c18-21(19,20)15-11-5-7-12-6-4-10-14(16(12)15)17-13-8-2-1-3-9-13/h1-11,17H,(H,18,19,20)
DMNGY0E	CS	C1=CC=C(C=C1)NC2=CC=CC3=C2C(=CC=C3)S(=O)(=O)O
DMNGY0E	IK	FWEOQOXTVHGIFQ-UHFFFAOYSA-N
DMNGY0E	IU	8-anilinonaphthalene-1-sulfonic acid
DMNGY0E	CA	CAS 82-76-8
DMNGY0E	CB	CHEBI:39708

DMJD1QF	ID	DMJD1QF
DMJD1QF	DN	1-arylmethylpyrrolidin-2-yl ethanol amine
DMJD1QF	HS	Investigative
DMJD1QF	SN	compound 26a [PMID: 16216508]
DMJD1QF	DT	Small molecular drug
DMJD1QF	PC	44405854
DMJD1QF	MW	433.6
DMJD1QF	FM	C26H31N3OS
DMJD1QF	IC	InChI=1S/C26H31N3OS/c1-26(2,15-22-14-21-9-3-4-11-25(21)31-22)28-17-24(30)23-10-6-12-29(23)18-20-8-5-7-19(13-20)16-27/h3-5,7-9,11,13-14,23-24,28,30H,6,10,12,15,17-18H2,1-2H3/t23-,24-/m1/s1
DMJD1QF	CS	CC(C)(CC1=CC2=CC=CC=C2S1)NC[C@H]([C@H]3CCCN3CC4=CC(=CC=C4)C#N)O
DMJD1QF	IK	HCLQARMRCPEALF-DNQXCXABSA-N
DMJD1QF	IU	3-[[(2R)-2-[(1R)-2-[[1-(1-benzothiophen-2-yl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]pyrrolidin-1-yl]methyl]benzonitrile
DMJD1QF	DE	Discovery agent

DMQ1EVT	ID	DMQ1EVT
DMQ1EVT	DN	1-benzene sulfonyl-cis-2,6-dimethyl piperidine
DMQ1EVT	HS	Investigative
DMQ1EVT	SN	CHEMBL575619; AC1LDWTF; 1-benzene sulfonyl-cis-2,6-dimethyl piperidine; BDBM50298422; ZINC12417747
DMQ1EVT	DT	Small molecular drug
DMQ1EVT	PC	726586
DMQ1EVT	MW	253.36
DMQ1EVT	FM	C13H19NO2S
DMQ1EVT	IC	InChI=1S/C13H19NO2S/c1-11-7-6-8-12(2)14(11)17(15,16)13-9-4-3-5-10-13/h3-5,9-12H,6-8H2,1-2H3/t11-,12+
DMQ1EVT	CS	C[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=CC=C2)C
DMQ1EVT	IK	JINDARNDFYFWDT-TXEJJXNPSA-N
DMQ1EVT	IU	(2S,6R)-1-(benzenesulfonyl)-2,6-dimethylpiperidine
DMQ1EVT	DE	Discovery agent

DM781L6	ID	DM781L6
DM781L6	DN	1-Benzenesulfonyl-2-nitro-benzene
DM781L6	HS	Investigative
DM781L6	SN	31515-43-2; 2-Nitrophenyl phenyl sulfone; 1-Nitro-2-(phenylsulfonyl)benzene; 2-Nitrodiphenyl Sulfone; 2-Nitro diphenyl sulfone; Benzene, 1-nitro-2-(phenylsulfonyl)-; 2'-Nitrophenylphenylsulfone; 1-(benzenesulfonyl)-2-nitrobenzene; 1-Nitro-2-(phenylsulphonyl)benzene; 2NO2Ph-SO2-Ph; NSC-624231; NSC624231; NSC 624231; 144113-81-5; W-106894; SMR000554655; o-Nitrophenyl phenyl sulfone; Sulfone, o-nitrophenyl phenyl; EINECS 250-672-6; 2-Nitrodiphenylsulfone; PubChem10856; 2-nitrophenylphenylsulfone; ACMC-209hn5; AC1L22CT; MLS001074875
DM781L6	DT	Small molecular drug
DM781L6	PC	64984
DM781L6	MW	263.27
DM781L6	FM	C12H9NO4S
DM781L6	IC	InChI=1S/C12H9NO4S/c14-13(15)11-8-4-5-9-12(11)18(16,17)10-6-2-1-3-7-10/h1-9H
DM781L6	CS	C1=CC=C(C=C1)S(=O)(=O)C2=CC=CC=C2[N+](=O)[O-]
DM781L6	IK	GKNMUCPEXSCGKC-UHFFFAOYSA-N
DM781L6	IU	1-(benzenesulfonyl)-2-nitrobenzene
DM781L6	CA	CAS 31515-43-2
DM781L6	DE	Discovery agent

DM1N4LK	ID	DM1N4LK
DM1N4LK	DN	1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole
DM1N4LK	HS	Investigative
DM1N4LK	SN	CHEMBL371292; piperidinylindole, 7; 1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole; SCHEMBL5251020; BDBM34148
DM1N4LK	DT	Small molecular drug
DM1N4LK	PC	9902533
DM1N4LK	MW	340.4
DM1N4LK	FM	C19H20N2O2S
DM1N4LK	IC	InChI=1S/C19H20N2O2S/c22-24(23,16-8-2-1-3-9-16)21-14-18(15-7-6-12-20-13-15)17-10-4-5-11-19(17)21/h1-5,8-11,14-15,20H,6-7,12-13H2
DM1N4LK	CS	C1CC(CNC1)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DM1N4LK	IK	QUUSSZWUXRDTJG-UHFFFAOYSA-N
DM1N4LK	IU	1-(benzenesulfonyl)-3-piperidin-3-ylindole
DM1N4LK	DE	Discovery agent

DMRA9VG	ID	DMRA9VG
DMRA9VG	DN	1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole
DMRA9VG	HS	Investigative
DMRA9VG	SN	CHEMBL180826; 1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole
DMRA9VG	DT	Small molecular drug
DMRA9VG	PC	44388931
DMRA9VG	MW	340.4
DMRA9VG	FM	C19H20N2O2S
DMRA9VG	IC	InChI=1S/C19H20N2O2S/c22-24(23,16-6-2-1-3-7-16)21-14-18(15-10-12-20-13-11-15)17-8-4-5-9-19(17)21/h1-9,14-15,20H,10-13H2
DMRA9VG	CS	C1CNCCC1C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DMRA9VG	IK	CACLUIQWYMWMBO-UHFFFAOYSA-N
DMRA9VG	IU	1-(benzenesulfonyl)-3-piperidin-4-ylindole
DMRA9VG	DE	Discovery agent

DMQSK3H	ID	DMQSK3H
DMQSK3H	DN	1-benzhydryl-3-(isoquinolin-5-yl)urea
DMQSK3H	HS	Investigative
DMQSK3H	SN	isoquinoline antagonist, 5h; SCHEMBL4026073; CHEMBL397897; BDBM20390
DMQSK3H	DT	Small molecular drug
DMQSK3H	PC	10473280
DMQSK3H	MW	353.4
DMQSK3H	FM	C23H19N3O
DMQSK3H	IC	InChI=1S/C23H19N3O/c27-23(25-21-13-7-12-19-16-24-15-14-20(19)21)26-22(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-16,22H,(H2,25,26,27)
DMQSK3H	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)NC(=O)NC3=CC=CC4=C3C=CN=C4
DMQSK3H	IK	ZBZSZXCYOYRLKL-UHFFFAOYSA-N
DMQSK3H	IU	1-benzhydryl-3-isoquinolin-5-ylurea
DMQSK3H	DE	Discovery agent

DMBAZG3	ID	DMBAZG3
DMBAZG3	DN	1-benzhydryl-3-butylpiperidin-4-amine
DMBAZG3	HS	Investigative
DMBAZG3	SN	CHEMBL234414; 1-benzhydryl-3-butylpiperidin-4-amine
DMBAZG3	DT	Small molecular drug
DMBAZG3	PC	11674875
DMBAZG3	MW	322.5
DMBAZG3	FM	C22H30N2
DMBAZG3	IC	InChI=1S/C22H30N2/c1-2-3-10-20-17-24(16-15-21(20)23)22(18-11-6-4-7-12-18)19-13-8-5-9-14-19/h4-9,11-14,20-22H,2-3,10,15-17,23H2,1H3
DMBAZG3	CS	CCCCC1CN(CCC1N)C(C2=CC=CC=C2)C3=CC=CC=C3
DMBAZG3	IK	OJLIZWWFCLNTKT-UHFFFAOYSA-N
DMBAZG3	IU	1-benzhydryl-3-butylpiperidin-4-amine
DMBAZG3	DE	Discovery agent

DMTANPG	ID	DMTANPG
DMTANPG	DN	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG	HS	Investigative
DMTANPG	SN	CHEMBL232476; 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG	DT	Small molecular drug
DMTANPG	PC	44430007
DMTANPG	MW	361.5
DMTANPG	FM	C24H24FNO
DMTANPG	IC	InChI=1S/C24H24FNO/c25-22-14-8-7-13-21(22)24(27)15-17-26(18-16-24)23(19-9-3-1-4-10-19)20-11-5-2-6-12-20/h1-14,23,27H,15-18H2
DMTANPG	CS	C1CN(CCC1(C2=CC=CC=C2F)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMTANPG	IK	RGFPDLNQIQLMPK-UHFFFAOYSA-N
DMTANPG	IU	1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG	DE	Discovery agent

DMWHMNY	ID	DMWHMNY
DMWHMNY	DN	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY	HS	Investigative
DMWHMNY	SN	CHEMBL233493; 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY	DT	Small molecular drug
DMWHMNY	PC	44430016
DMWHMNY	MW	373.5
DMWHMNY	FM	C25H27NO2
DMWHMNY	IC	InChI=1S/C25H27NO2/c1-28-23-15-9-8-14-22(23)25(27)16-18-26(19-17-25)24(20-10-4-2-5-11-20)21-12-6-3-7-13-21/h2-15,24,27H,16-19H2,1H3
DMWHMNY	CS	COC1=CC=CC=C1C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMWHMNY	IK	MMHFMRZIXGSYBY-UHFFFAOYSA-N
DMWHMNY	IU	1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY	DE	Discovery agent

DMTYKMR	ID	DMTYKMR
DMTYKMR	DN	1-benzhydryl-4-(3,3-diphenylpropyl)piperazine
DMTYKMR	HS	Investigative
DMTYKMR	SN	CHEMBL1081018
DMTYKMR	DT	Small molecular drug
DMTYKMR	PC	44756847
DMTYKMR	MW	446.6
DMTYKMR	FM	C32H34N2
DMTYKMR	IC	InChI=1S/C32H34N2/c1-5-13-27(14-6-1)31(28-15-7-2-8-16-28)21-22-33-23-25-34(26-24-33)32(29-17-9-3-10-18-29)30-19-11-4-12-20-30/h1-20,31-32H,21-26H2
DMTYKMR	CS	C1CN(CCN1CCC(C2=CC=CC=C2)C3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5
DMTYKMR	IK	CLZJJBZJUIWHJT-UHFFFAOYSA-N
DMTYKMR	IU	1-benzhydryl-4-(3,3-diphenylpropyl)piperazine
DMTYKMR	DE	Discovery agent

DMXZFPB	ID	DMXZFPB
DMXZFPB	DN	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB	HS	Investigative
DMXZFPB	SN	CHEMBL395838; 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB	DT	Small molecular drug
DMXZFPB	PC	44430008
DMXZFPB	MW	361.5
DMXZFPB	FM	C24H24FNO
DMXZFPB	IC	InChI=1S/C24H24FNO/c25-22-13-7-12-21(18-22)24(27)14-16-26(17-15-24)23(19-8-3-1-4-9-19)20-10-5-2-6-11-20/h1-13,18,23,27H,14-17H2
DMXZFPB	CS	C1CN(CCC1(C2=CC(=CC=C2)F)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMXZFPB	IK	AXBTYZPRVDTMRF-UHFFFAOYSA-N
DMXZFPB	IU	1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB	DE	Discovery agent

DM1QYS8	ID	DM1QYS8
DM1QYS8	DN	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8	HS	Investigative
DM1QYS8	SN	CHEMBL233494; 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8	DT	Small molecular drug
DM1QYS8	PC	44430018
DM1QYS8	MW	373.5
DM1QYS8	FM	C25H27NO2
DM1QYS8	IC	InChI=1S/C25H27NO2/c1-28-23-14-8-13-22(19-23)25(27)15-17-26(18-16-25)24(20-9-4-2-5-10-20)21-11-6-3-7-12-21/h2-14,19,24,27H,15-18H2,1H3
DM1QYS8	CS	COC1=CC=CC(=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DM1QYS8	IK	KFPUCANOYSPKNM-UHFFFAOYSA-N
DM1QYS8	IU	1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8	DE	Discovery agent

DMIT7SH	ID	DMIT7SH
DMIT7SH	DN	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH	HS	Investigative
DMIT7SH	SN	CHEMBL231664; 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH	DT	Small molecular drug
DMIT7SH	PC	44430029
DMIT7SH	MW	385.5
DMIT7SH	FM	C27H31NO
DMIT7SH	IC	InChI=1S/C27H31NO/c29-27(18-10-13-23-11-4-1-5-12-23)19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-9,11-12,14-17,26,29H,10,13,18-22H2
DMIT7SH	CS	C1CN(CCC1(CCCC2=CC=CC=C2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMIT7SH	IK	LBCGIDHKEKGBGS-UHFFFAOYSA-N
DMIT7SH	IU	1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH	DE	Discovery agent

DM5SWL7	ID	DM5SWL7
DM5SWL7	DN	1-benzhydryl-4-(4,4-diphenylbutyl)piperazine
DM5SWL7	HS	Investigative
DM5SWL7	SN	CHEMBL1081016
DM5SWL7	DT	Small molecular drug
DM5SWL7	PC	46879832
DM5SWL7	MW	460.7
DM5SWL7	FM	C33H36N2
DM5SWL7	IC	InChI=1S/C33H36N2/c1-5-14-28(15-6-1)32(29-16-7-2-8-17-29)22-13-23-34-24-26-35(27-25-34)33(30-18-9-3-10-19-30)31-20-11-4-12-21-31/h1-12,14-21,32-33H,13,22-27H2
DM5SWL7	CS	C1CN(CCN1CCCC(C2=CC=CC=C2)C3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5
DM5SWL7	IK	MICPQZJRSOUTGV-UHFFFAOYSA-N
DM5SWL7	IU	1-benzhydryl-4-(4,4-diphenylbutyl)piperazine
DM5SWL7	DE	Discovery agent

DM0BQYX	ID	DM0BQYX
DM0BQYX	DN	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol
DM0BQYX	HS	Investigative
DM0BQYX	SN	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol; CHEMBL232067; BDBM50210228
DM0BQYX	DT	Small molecular drug
DM0BQYX	PC	10093682
DM0BQYX	MW	422.4
DM0BQYX	FM	C24H24BrNO
DM0BQYX	IC	InChI=1S/C24H24BrNO/c25-22-13-11-21(12-14-22)24(27)15-17-26(18-16-24)23(19-7-3-1-4-8-19)20-9-5-2-6-10-20/h1-14,23,27H,15-18H2
DM0BQYX	CS	C1CN(CCC1(C2=CC=C(C=C2)Br)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DM0BQYX	IK	FIHWNAAGEWTLGW-UHFFFAOYSA-N
DM0BQYX	IU	1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol
DM0BQYX	DE	Discovery agent

DMMAJW9	ID	DMMAJW9
DMMAJW9	DN	1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol
DMMAJW9	HS	Investigative
DMMAJW9	SN	CHEMBL233287; 1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol
DMMAJW9	DT	Small molecular drug
DMMAJW9	PC	44430014
DMMAJW9	MW	399.6
DMMAJW9	FM	C28H33NO
DMMAJW9	IC	InChI=1S/C28H33NO/c1-2-3-10-23-15-17-26(18-16-23)28(30)19-21-29(22-20-28)27(24-11-6-4-7-12-24)25-13-8-5-9-14-25/h4-9,11-18,27,30H,2-3,10,19-22H2,1H3
DMMAJW9	CS	CCCCC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMMAJW9	IK	RVNGGHXLYIZGKP-UHFFFAOYSA-N
DMMAJW9	IU	1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol
DMMAJW9	DE	Discovery agent

DMWYG8K	ID	DMWYG8K
DMWYG8K	DN	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K	HS	Investigative
DMWYG8K	SN	CHEMBL392753; 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K	DT	Small molecular drug
DMWYG8K	PC	10091033
DMWYG8K	MW	377.9
DMWYG8K	FM	C24H24ClNO
DMWYG8K	IC	InChI=1S/C24H24ClNO/c25-22-13-11-21(12-14-22)24(27)15-17-26(18-16-24)23(19-7-3-1-4-8-19)20-9-5-2-6-10-20/h1-14,23,27H,15-18H2
DMWYG8K	CS	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMWYG8K	IK	LTTPWCPNNZPPLF-UHFFFAOYSA-N
DMWYG8K	IU	1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K	DE	Discovery agent

DME0BJD	ID	DME0BJD
DME0BJD	DN	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol
DME0BJD	HS	Investigative
DME0BJD	SN	CHEMBL234543; 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol
DME0BJD	DT	Small molecular drug
DME0BJD	PC	44430012
DME0BJD	MW	371.5
DME0BJD	FM	C26H29NO
DME0BJD	IC	InChI=1S/C26H29NO/c1-2-21-13-15-24(16-14-21)26(28)17-19-27(20-18-26)25(22-9-5-3-6-10-22)23-11-7-4-8-12-23/h3-16,25,28H,2,17-20H2,1H3
DME0BJD	CS	CCC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DME0BJD	IK	JHTQREMVHFRWEJ-UHFFFAOYSA-N
DME0BJD	IU	1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol
DME0BJD	DE	Discovery agent

DMRNZD6	ID	DMRNZD6
DMRNZD6	DN	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6	HS	Investigative
DMRNZD6	SN	CHEMBL232066; 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6	DT	Small molecular drug
DMRNZD6	PC	10089987
DMRNZD6	MW	361.5
DMRNZD6	FM	C24H24FNO
DMRNZD6	IC	InChI=1S/C24H24FNO/c25-22-13-11-21(12-14-22)24(27)15-17-26(18-16-24)23(19-7-3-1-4-8-19)20-9-5-2-6-10-20/h1-14,23,27H,15-18H2
DMRNZD6	CS	C1CN(CCC1(C2=CC=C(C=C2)F)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMRNZD6	IK	WBNMPDBWSUFASE-UHFFFAOYSA-N
DMRNZD6	IU	1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6	DE	Discovery agent

DMXT894	ID	DMXT894
DMXT894	DN	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894	HS	Investigative
DMXT894	SN	CHEMBL401234; 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894	DT	Small molecular drug
DMXT894	PC	10384734
DMXT894	MW	373.5
DMXT894	FM	C25H27NO2
DMXT894	IC	InChI=1S/C25H27NO2/c1-28-23-14-12-22(13-15-23)25(27)16-18-26(19-17-25)24(20-8-4-2-5-9-20)21-10-6-3-7-11-21/h2-15,24,27H,16-19H2,1H3
DMXT894	CS	COC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMXT894	IK	UWUHHENFQBTZCW-UHFFFAOYSA-N
DMXT894	IU	1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894	DE	Discovery agent

DMJDUM5	ID	DMJDUM5
DMJDUM5	DN	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol
DMJDUM5	HS	Investigative
DMJDUM5	SN	CHEMBL393675; 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol
DMJDUM5	DT	Small molecular drug
DMJDUM5	PC	44430013
DMJDUM5	MW	385.5
DMJDUM5	FM	C27H31NO
DMJDUM5	IC	InChI=1S/C27H31NO/c1-2-9-22-14-16-25(17-15-22)27(29)18-20-28(21-19-27)26(23-10-5-3-6-11-23)24-12-7-4-8-13-24/h3-8,10-17,26,29H,2,9,18-21H2,1H3
DMJDUM5	CS	CCCC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMJDUM5	IK	BVRSNRCGJVPHBA-UHFFFAOYSA-N
DMJDUM5	IU	1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol
DMJDUM5	DE	Discovery agent

DMDRUBL	ID	DMDRUBL
DMDRUBL	DN	1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine
DMDRUBL	HS	Investigative
DMDRUBL	SN	CHEMBL229018; 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine
DMDRUBL	DT	Small molecular drug
DMDRUBL	PC	10388166
DMDRUBL	MW	433.6
DMDRUBL	FM	C31H31NO
DMDRUBL	IC	InChI=1S/C31H31NO/c1-5-13-26(14-6-1)25-33-31(29-19-11-4-12-20-29)21-23-32(24-22-31)30(27-15-7-2-8-16-27)28-17-9-3-10-18-28/h1-20,30H,21-25H2
DMDRUBL	CS	C1CN(CCC1(C2=CC=CC=C2)OCC3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5
DMDRUBL	IK	KSNUQMXXRSKFOM-UHFFFAOYSA-N
DMDRUBL	IU	1-benzhydryl-4-phenyl-4-phenylmethoxypiperidine
DMDRUBL	DE	Discovery agent

DMMB2GV	ID	DMMB2GV
DMMB2GV	DN	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV	HS	Investigative
DMMB2GV	SN	CHEMBL231874; 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV	DT	Small molecular drug
DMMB2GV	PC	10336926
DMMB2GV	MW	333.4
DMMB2GV	FM	C22H23NO2
DMMB2GV	IC	InChI=1S/C22H23NO2/c24-22(20-12-7-17-25-20)13-15-23(16-14-22)21(18-8-3-1-4-9-18)19-10-5-2-6-11-19/h1-12,17,21,24H,13-16H2
DMMB2GV	CS	C1CN(CCC1(C2=CC=CO2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMMB2GV	IK	RANYWKODIKNHDB-UHFFFAOYSA-N
DMMB2GV	IU	1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV	DE	Discovery agent

DMJ8F60	ID	DMJ8F60
DMJ8F60	DN	1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol
DMJ8F60	HS	Investigative
DMJ8F60	SN	CHEMBL393971; 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol
DMJ8F60	DT	Small molecular drug
DMJ8F60	PC	10427620
DMJ8F60	MW	344.4
DMJ8F60	FM	C23H24N2O
DMJ8F60	IC	InChI=1S/C23H24N2O/c26-23(21-13-7-8-16-24-21)14-17-25(18-15-23)22(19-9-3-1-4-10-19)20-11-5-2-6-12-20/h1-13,16,22,26H,14-15,17-18H2
DMJ8F60	CS	C1CN(CCC1(C2=CC=CC=N2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMJ8F60	IK	RQPLUPANAPAMMF-UHFFFAOYSA-N
DMJ8F60	IU	1-benzhydryl-4-pyridin-2-ylpiperidin-4-ol
DMJ8F60	DE	Discovery agent

DMNOZR2	ID	DMNOZR2
DMNOZR2	DN	1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol
DMNOZR2	HS	Investigative
DMNOZR2	SN	CHEMBL233323; 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol
DMNOZR2	DT	Small molecular drug
DMNOZR2	PC	10315818
DMNOZR2	MW	349.5
DMNOZR2	FM	C22H23NOS
DMNOZR2	IC	InChI=1S/C22H23NOS/c24-22(20-12-7-17-25-20)13-15-23(16-14-22)21(18-8-3-1-4-9-18)19-10-5-2-6-11-19/h1-12,17,21,24H,13-16H2
DMNOZR2	CS	C1CN(CCC1(C2=CC=CS2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMNOZR2	IK	LBJDYBPTWNSHBS-UHFFFAOYSA-N
DMNOZR2	IU	1-benzhydryl-4-thiophen-2-ylpiperidin-4-ol
DMNOZR2	DE	Discovery agent

DMVBR36	ID	DMVBR36
DMVBR36	DN	1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36	HS	Investigative
DMVBR36	SN	CHEMBL231661; 1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36	DT	Small molecular drug
DMVBR36	PC	44430028
DMVBR36	MW	357.5
DMVBR36	FM	C25H27NO
DMVBR36	IC	InChI=1S/C25H27NO/c27-25(20-21-10-4-1-5-11-21)16-18-26(19-17-25)24(22-12-6-2-7-13-22)23-14-8-3-9-15-23/h1-15,24,27H,16-20H2
DMVBR36	CS	C1CN(CCC1(CC2=CC=CC=C2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMVBR36	IK	DJXDWBRLMRAPJG-UHFFFAOYSA-N
DMVBR36	IU	1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36	DE	Discovery agent

DMRN7SC	ID	DMRN7SC
DMRN7SC	DN	1-benzhydryl-4-butylpiperidin-4-ol
DMRN7SC	HS	Investigative
DMRN7SC	SN	CHEMBL397761; 1-benzhydryl-4-butylpiperidin-4-ol; SCHEMBL13597038
DMRN7SC	DT	Small molecular drug
DMRN7SC	PC	22970051
DMRN7SC	MW	323.5
DMRN7SC	FM	C22H29NO
DMRN7SC	IC	InChI=1S/C22H29NO/c1-2-3-14-22(24)15-17-23(18-16-22)21(19-10-6-4-7-11-19)20-12-8-5-9-13-20/h4-13,21,24H,2-3,14-18H2,1H3
DMRN7SC	CS	CCCCC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)O
DMRN7SC	IK	REUKRNAMFNVGPA-UHFFFAOYSA-N
DMRN7SC	IU	1-benzhydryl-4-butylpiperidin-4-ol
DMRN7SC	DE	Discovery agent

DMZVSYD	ID	DMZVSYD
DMZVSYD	DN	1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD	HS	Investigative
DMZVSYD	SN	CHEMBL394695; 1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD	DT	Small molecular drug
DMZVSYD	PC	10043439
DMZVSYD	MW	349.5
DMZVSYD	FM	C24H31NO
DMZVSYD	IC	InChI=1S/C24H31NO/c26-24(22-14-8-3-9-15-22)16-18-25(19-17-24)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-2,4-7,10-13,22-23,26H,3,8-9,14-19H2
DMZVSYD	CS	C1CCC(CC1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMZVSYD	IK	RJWCOGYISGJIPN-UHFFFAOYSA-N
DMZVSYD	IU	1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD	DE	Discovery agent

DMM94Y2	ID	DMM94Y2
DMM94Y2	DN	1-benzhydryl-4-cyclopropylpiperidin-4-ol
DMM94Y2	HS	Investigative
DMM94Y2	SN	CHEMBL398039; 1-benzhydryl-4-cyclopropylpiperidin-4-ol
DMM94Y2	DT	Small molecular drug
DMM94Y2	PC	44430024
DMM94Y2	MW	307.4
DMM94Y2	FM	C21H25NO
DMM94Y2	IC	InChI=1S/C21H25NO/c23-21(19-11-12-19)13-15-22(16-14-21)20(17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-10,19-20,23H,11-16H2
DMM94Y2	CS	C1CC1C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMM94Y2	IK	DWUKNKDABPWVAE-UHFFFAOYSA-N
DMM94Y2	IU	1-benzhydryl-4-cyclopropylpiperidin-4-ol
DMM94Y2	DE	Discovery agent

DM6PIL2	ID	DM6PIL2
DM6PIL2	DN	1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2	HS	Investigative
DM6PIL2	SN	CHEMBL229016; 1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2	DT	Small molecular drug
DM6PIL2	PC	10022129
DM6PIL2	MW	371.5
DM6PIL2	FM	C26H29NO
DM6PIL2	IC	InChI=1S/C26H29NO/c1-2-28-26(24-16-10-5-11-17-24)18-20-27(21-19-26)25(22-12-6-3-7-13-22)23-14-8-4-9-15-23/h3-17,25H,2,18-21H2,1H3
DM6PIL2	CS	CCOC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DM6PIL2	IK	HFALMYBPBZADRA-UHFFFAOYSA-N
DM6PIL2	IU	1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2	DE	Discovery agent

DMUK95S	ID	DMUK95S
DMUK95S	DN	1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S	HS	Investigative
DMUK95S	SN	CHEMBL234773; 1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S	DT	Small molecular drug
DMUK95S	PC	44430026
DMUK95S	MW	351.5
DMUK95S	FM	C24H33NO
DMUK95S	IC	InChI=1S/C24H33NO/c1-2-3-4-11-16-24(26)17-19-25(20-18-24)23(21-12-7-5-8-13-21)22-14-9-6-10-15-22/h5-10,12-15,23,26H,2-4,11,16-20H2,1H3
DMUK95S	CS	CCCCCCC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)O
DMUK95S	IK	MJJFIAIFQWXWHK-UHFFFAOYSA-N
DMUK95S	IU	1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S	DE	Discovery agent

DMGYCQ3	ID	DMGYCQ3
DMGYCQ3	DN	1-benzhydryl-4-isopropylpiperidin-4-ol
DMGYCQ3	HS	Investigative
DMGYCQ3	SN	CHEMBL233721; 1-benzhydryl-4-isopropylpiperidin-4-ol
DMGYCQ3	DT	Small molecular drug
DMGYCQ3	PC	44430025
DMGYCQ3	MW	309.4
DMGYCQ3	FM	C21H27NO
DMGYCQ3	IC	InChI=1S/C21H27NO/c1-17(2)21(23)13-15-22(16-14-21)20(18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3-12,17,20,23H,13-16H2,1-2H3
DMGYCQ3	CS	CC(C)C1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)O
DMGYCQ3	IK	BOIJUJOJZXIYHU-UHFFFAOYSA-N
DMGYCQ3	IU	1-benzhydryl-4-propan-2-ylpiperidin-4-ol
DMGYCQ3	DE	Discovery agent

DMBG0N8	ID	DMBG0N8
DMBG0N8	DN	1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8	HS	Investigative
DMBG0N8	SN	CHEMBL228965; 1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8	DT	Small molecular drug
DMBG0N8	PC	10043898
DMBG0N8	MW	357.5
DMBG0N8	FM	C25H27NO
DMBG0N8	IC	InChI=1S/C25H27NO/c1-27-25(23-15-9-4-10-16-23)17-19-26(20-18-25)24(21-11-5-2-6-12-21)22-13-7-3-8-14-22/h2-16,24H,17-20H2,1H3
DMBG0N8	CS	COC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMBG0N8	IK	ULOWZIQCEGBTDH-UHFFFAOYSA-N
DMBG0N8	IU	1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8	DE	Discovery agent

DMVJH1S	ID	DMVJH1S
DMVJH1S	DN	1-benzhydryl-4-m-tolylpiperidin-4-ol
DMVJH1S	HS	Investigative
DMVJH1S	SN	CHEMBL437380; 1-benzhydryl-4-m-tolylpiperidin-4-ol
DMVJH1S	DT	Small molecular drug
DMVJH1S	PC	44430009
DMVJH1S	MW	357.5
DMVJH1S	FM	C25H27NO
DMVJH1S	IC	InChI=1S/C25H27NO/c1-20-9-8-14-23(19-20)25(27)15-17-26(18-16-25)24(21-10-4-2-5-11-21)22-12-6-3-7-13-22/h2-14,19,24,27H,15-18H2,1H3
DMVJH1S	CS	CC1=CC(=CC=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMVJH1S	IK	IFEJQGWUIGIJPD-UHFFFAOYSA-N
DMVJH1S	IU	1-benzhydryl-4-(3-methylphenyl)piperidin-4-ol
DMVJH1S	DE	Discovery agent

DMVUMSF	ID	DMVUMSF
DMVUMSF	DN	1-benzhydryl-4-o-tolylpiperidin-4-ol
DMVUMSF	HS	Investigative
DMVUMSF	SN	CHEMBL232273; 1-benzhydryl-4-o-tolylpiperidin-4-ol
DMVUMSF	DT	Small molecular drug
DMVUMSF	PC	20481138
DMVUMSF	MW	357.5
DMVUMSF	FM	C25H27NO
DMVUMSF	IC	InChI=1S/C25H27NO/c1-20-10-8-9-15-23(20)25(27)16-18-26(19-17-25)24(21-11-4-2-5-12-21)22-13-6-3-7-14-22/h2-15,24,27H,16-19H2,1H3
DMVUMSF	CS	CC1=CC=CC=C1C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMVUMSF	IK	WOOXDHAITFKPDQ-UHFFFAOYSA-N
DMVUMSF	IU	1-benzhydryl-4-(2-methylphenyl)piperidin-4-ol
DMVUMSF	DE	Discovery agent

DMEB968	ID	DMEB968
DMEB968	DN	1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968	HS	Investigative
DMEB968	SN	CHEMBL229017; 1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968	DT	Small molecular drug
DMEB968	PC	10317947
DMEB968	MW	385.5
DMEB968	FM	C27H31NO
DMEB968	IC	InChI=1S/C27H31NO/c1-2-22-29-27(25-16-10-5-11-17-25)18-20-28(21-19-27)26(23-12-6-3-7-13-23)24-14-8-4-9-15-24/h3-17,26H,2,18-22H2,1H3
DMEB968	CS	CCCOC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMEB968	IK	RCNHZINTASPDKK-UHFFFAOYSA-N
DMEB968	IU	1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968	DE	Discovery agent

DM7KU1X	ID	DM7KU1X
DM7KU1X	DN	1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X	HS	Investigative
DM7KU1X	SN	CHEMBL228690; 1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X	DT	Small molecular drug
DM7KU1X	PC	10269001
DM7KU1X	MW	343.5
DM7KU1X	FM	C24H25NO
DM7KU1X	IC	InChI=1S/C24H25NO/c26-24(22-14-8-3-9-15-22)16-18-25(19-17-24)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-15,23,26H,16-19H2
DM7KU1X	CS	C1CN(CCC1(C2=CC=CC=C2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DM7KU1X	IK	PMLFKOKTRMHUPA-UHFFFAOYSA-N
DM7KU1X	IU	1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X	DE	Discovery agent

DM679RC	ID	DM679RC
DM679RC	DN	1-benzhydryl-4-p-tolylpiperidin-4-ol
DM679RC	HS	Investigative
DM679RC	SN	CHEMBL393985; 1-benzhydryl-4-p-tolylpiperidin-4-ol
DM679RC	DT	Small molecular drug
DM679RC	PC	9924923
DM679RC	MW	357.5
DM679RC	FM	C25H27NO
DM679RC	IC	InChI=1S/C25H27NO/c1-20-12-14-23(15-13-20)25(27)16-18-26(19-17-25)24(21-8-4-2-5-9-21)22-10-6-3-7-11-22/h2-15,24,27H,16-19H2,1H3
DM679RC	CS	CC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DM679RC	IK	ZDADQNJEUZQHKH-UHFFFAOYSA-N
DM679RC	IU	1-benzhydryl-4-(4-methylphenyl)piperidin-4-ol
DM679RC	DE	Discovery agent

DMM5DTF	ID	DMM5DTF
DMM5DTF	DN	1-benzhydryl-4-tert-butylpiperidin-4-ol
DMM5DTF	HS	Investigative
DMM5DTF	SN	CHEMBL234771; 1-benzhydryl-4-tert-butylpiperidin-4-ol
DMM5DTF	DT	Small molecular drug
DMM5DTF	PC	10314141
DMM5DTF	MW	323.5
DMM5DTF	FM	C22H29NO
DMM5DTF	IC	InChI=1S/C22H29NO/c1-21(2,3)22(24)14-16-23(17-15-22)20(18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13,20,24H,14-17H2,1-3H3
DMM5DTF	CS	CC(C)(C)C1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)O
DMM5DTF	IK	CSHMHUZYEYOBPL-UHFFFAOYSA-N
DMM5DTF	IU	1-benzhydryl-4-tert-butylpiperidin-4-ol
DMM5DTF	DE	Discovery agent

DMMN5TA	ID	DMMN5TA
DMMN5TA	DN	1-Benzo[b]thiophen-2-yl-cycloheptylamine
DMMN5TA	HS	Investigative
DMMN5TA	SN	CHEMBL18811; NCI60_038329; 1-Benzo[b]thiophen-2-yl-cycloheptylamine; AC1L9GG6; CTK7D5124; ZINC1657601; BDBM50040194; 1-(benzothiophen-2-yl)cycloheptan-1-amine; 1-(1-benzothiophen-2-yl)cycloheptan-1-amine
DMMN5TA	DT	Small molecular drug
DMMN5TA	PC	398365
DMMN5TA	MW	245.4
DMMN5TA	FM	C15H19NS
DMMN5TA	IC	InChI=1S/C15H19NS/c16-15(9-5-1-2-6-10-15)14-11-12-7-3-4-8-13(12)17-14/h3-4,7-8,11H,1-2,5-6,9-10,16H2
DMMN5TA	CS	C1CCCC(CC1)(C2=CC3=CC=CC=C3S2)N
DMMN5TA	IK	BCBMINBNEZGMJJ-UHFFFAOYSA-N
DMMN5TA	IU	1-(1-benzothiophen-2-yl)cycloheptan-1-amine
DMMN5TA	DE	Discovery agent

DMR97FU	ID	DMR97FU
DMR97FU	DN	1-Benzo[b]thiophen-2-yl-cyclohexylamine
DMR97FU	HS	Investigative
DMR97FU	SN	Cyclohexanamine, 1-benzo[b]thien-2-yl-; CHEMBL18556; 143603-26-3; NSC708121; ACMC-20bbzv; 1-Benzo[b]thiophen-2-yl-cyclohexylamine; AC1L9GJR; SCHEMBL7095248; CTK0B4318; DTXSID80327969; HYVMNAZTYJDWIZ-UHFFFAOYSA-N; ZINC1657638; BDBM50040190; AKOS030613260; NSC-708121; 1-(1-Benzothien-2-yl)cyclohexanamine #; Thionaphthene, 2-[1-aminocyclohex-1-yl]-; 1-(1-benzothiophen-2-yl)cyclohexan-1-amine
DMR97FU	DT	Small molecular drug
DMR97FU	PC	398415
DMR97FU	MW	231.36
DMR97FU	FM	C14H17NS
DMR97FU	IC	InChI=1S/C14H17NS/c15-14(8-4-1-5-9-14)13-10-11-6-2-3-7-12(11)16-13/h2-3,6-7,10H,1,4-5,8-9,15H2
DMR97FU	CS	C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N
DMR97FU	IK	HYVMNAZTYJDWIZ-UHFFFAOYSA-N
DMR97FU	IU	1-(1-benzothiophen-2-yl)cyclohexan-1-amine
DMR97FU	CA	CAS 143603-26-3
DMR97FU	DE	Discovery agent

DM6EF1L	ID	DM6EF1L
DM6EF1L	DN	1-Benzo[b]thiophen-2-yl-cyclopentylamine
DM6EF1L	HS	Investigative
DM6EF1L	SN	CHEMBL18502; NCI60_038335; 1-Benzo[b]thiophen-2-yl-cyclopentylamine; AC1L9GGU; CTK7D5118; ZINC1657608; BDBM50040195; 1-(benzothiophen-2-yl)cyclopentan-1-amine; 1-(1-benzothiophen-2-yl)cyclopentan-1-amine
DM6EF1L	DT	Small molecular drug
DM6EF1L	PC	398376
DM6EF1L	MW	217.33
DM6EF1L	FM	C13H15NS
DM6EF1L	IC	InChI=1S/C13H15NS/c14-13(7-3-4-8-13)12-9-10-5-1-2-6-11(10)15-12/h1-2,5-6,9H,3-4,7-8,14H2
DM6EF1L	CS	C1CCC(C1)(C2=CC3=CC=CC=C3S2)N
DM6EF1L	IK	CHUXWBUYFQVPQD-UHFFFAOYSA-N
DM6EF1L	IU	1-(1-benzothiophen-2-yl)cyclopentan-1-amine
DM6EF1L	DE	Discovery agent

DM153Y8	ID	DM153Y8
DM153Y8	DN	1-Benzooxazol-2-yl-6-phenyl-hexan-1-one
DM153Y8	HS	Investigative
DM153Y8	SN	CHEMBL366907; 1-Benzooxazol-2-yl-6-phenyl-hexan-1-one
DM153Y8	DT	Small molecular drug
DM153Y8	PC	44387731
DM153Y8	MW	293.4
DM153Y8	FM	C19H19NO2
DM153Y8	IC	InChI=1S/C19H19NO2/c21-17(19-20-16-12-7-8-14-18(16)22-19)13-6-2-5-11-15-9-3-1-4-10-15/h1,3-4,7-10,12,14H,2,5-6,11,13H2
DM153Y8	CS	C1=CC=C(C=C1)CCCCCC(=O)C2=NC3=CC=CC=C3O2
DM153Y8	IK	PCLBCMUYLOBYMW-UHFFFAOYSA-N
DM153Y8	IU	1-(1,3-benzoxazol-2-yl)-6-phenylhexan-1-one
DM153Y8	DE	Discovery agent

DMEZPC8	ID	DMEZPC8
DMEZPC8	DN	1-Benzothiazol-2-yl-3-phenethyl-thiourea
DMEZPC8	HS	Investigative
DMEZPC8	SN	Thiourea, N-2-benzothiazolyl-N'-(2-phenylethyl)-; 149485-21-2; PETT Analog 54; PETT Bzthiazol deriv.; AC1MHDL2; SCHEMBL6951823; CHEMBL147099; BDBM1887; DTXSID30164285; ZINC13744911; 1-Phenethyl-3-(benzothiazol-2-yl)thiourea; N-(2-Phenethyl)-N -(2-benzothiazolyl)thiourea; 1-(1,3-benzothiazol-2-yl)-3-phenethylthiourea; 1-(1,3-benzothiazol-2-yl)-3-phenethyl-thiourea
DMEZPC8	DT	Small molecular drug
DMEZPC8	PC	3001119
DMEZPC8	MW	313.4
DMEZPC8	FM	C16H15N3S2
DMEZPC8	IC	InChI=1S/C16H15N3S2/c20-15(17-11-10-12-6-2-1-3-7-12)19-16-18-13-8-4-5-9-14(13)21-16/h1-9H,10-11H2,(H2,17,18,19,20)
DMEZPC8	CS	C1=CC=C(C=C1)CCNC(=S)NC2=NC3=CC=CC=C3S2
DMEZPC8	IK	PKNPAMNXDLTPNX-UHFFFAOYSA-N
DMEZPC8	IU	1-(1,3-benzothiazol-2-yl)-3-(2-phenylethyl)thiourea
DMEZPC8	CA	CAS 149485-21-2
DMEZPC8	DE	Discovery agent

DMF9X2T	ID	DMF9X2T
DMF9X2T	DN	1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one
DMF9X2T	HS	Investigative
DMF9X2T	SN	CHEMBL379434; 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one
DMF9X2T	DT	Small molecular drug
DMF9X2T	PC	16037828
DMF9X2T	MW	291.3
DMF9X2T	FM	C19H17NO2
DMF9X2T	IC	InChI=1S/C19H17NO2/c21-18-12-7-13-20(19(22)16-10-5-2-6-11-16)17(18)14-15-8-3-1-4-9-15/h1-12,17H,13-14H2
DMF9X2T	CS	C1C=CC(=O)C(N1C(=O)C2=CC=CC=C2)CC3=CC=CC=C3
DMF9X2T	IK	CKNOOIXBZFVOCF-UHFFFAOYSA-N
DMF9X2T	IU	1-benzoyl-2-benzyl-2,6-dihydropyridin-3-one
DMF9X2T	DE	Discovery agent

DMG5MNZ	ID	DMG5MNZ
DMG5MNZ	DN	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide
DMG5MNZ	HS	Investigative
DMG5MNZ	SN	AC1LERN1; 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide; TimTec1_001906; Oprea1_174326; N-Benzoylpyrazole deriv., 6; CHEMBL388239; BDBM23704; MolPort-001-664-680; ZINC115253; HMS1539G14; STK398485; AKOS003748858; MCULE-1390939767; 1-benzoyl-N-phenylpyrazole-3-carboxamide; ST025783; N-phenyl[1-(phenylcarbonyl)pyrazol-3-yl]carboxamide
DMG5MNZ	DT	Small molecular drug
DMG5MNZ	PC	716930
DMG5MNZ	MW	291.3
DMG5MNZ	FM	C17H13N3O2
DMG5MNZ	IC	InChI=1S/C17H13N3O2/c21-16(18-14-9-5-2-6-10-14)15-11-12-20(19-15)17(22)13-7-3-1-4-8-13/h1-12H,(H,18,21)
DMG5MNZ	CS	C1=CC=C(C=C1)C(=O)N2C=CC(=N2)C(=O)NC3=CC=CC=C3
DMG5MNZ	IK	ZYYMCOZRPAHLRN-UHFFFAOYSA-N
DMG5MNZ	IU	1-benzoyl-N-phenylpyrazole-3-carboxamide
DMG5MNZ	DE	Discovery agent

DM17TIX	ID	DM17TIX
DM17TIX	DN	1-Benzyl-1,2-dihydro-indazol-3-one
DM17TIX	HS	Investigative
DM17TIX	SN	1-Benzyl-3-hydroxy-1H-indazole; 2215-63-6; 1-Benzyl-1H-indazol-3-ol; 1-Benzyl-1,2-dihydro-3H-indazol-3-one; 1-benzyl-2H-indazol-3-one; 1-Benzyl-1,2-dihydro-indazol-3-one; 1-benzylindazol-3-ol; CHEMBL8612; SXPJFDSMKWLOAB-UHFFFAOYSA-N; 3H-Indazol-3-one, 1,2-dihydro-1-(phenylmethyl)-; 1-Benzyl-2,3-dihydroindazol-3-one; CBMicro_007258; EINECS 218-680-4; 5-Hydroxybenzydamine; AC1Q6GZH; ACMC-1CR7T; ChemDiv2_000492; 1-Benzyl-3-hydroxyindazole; AC1Q6K7E; AC1L2O7R; Oprea1_591436; Oprea1_122894; MLS001211149; SCHEMBL376005
DM17TIX	DT	Small molecular drug
DM17TIX	PC	75181
DM17TIX	MW	224.26
DM17TIX	FM	C14H12N2O
DM17TIX	IC	InChI=1S/C14H12N2O/c17-14-12-8-4-5-9-13(12)16(15-14)10-11-6-2-1-3-7-11/h1-9H,10H2,(H,15,17)
DM17TIX	CS	C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=O)N2
DM17TIX	IK	SXPJFDSMKWLOAB-UHFFFAOYSA-N
DM17TIX	IU	1-benzyl-2H-indazol-3-one
DM17TIX	CA	CAS 2215-63-6
DM17TIX	DE	Discovery agent

DMUXSH5	ID	DMUXSH5
DMUXSH5	DN	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide
DMUXSH5	HS	Investigative
DMUXSH5	SN	1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide; CHEMBL1240573; 182556-28-1
DMUXSH5	DT	Small molecular drug
DMUXSH5	PC	46933593
DMUXSH5	MW	264.3
DMUXSH5	FM	C12H12N2O3S
DMUXSH5	IC	InChI=1S/C12H12N2O3S/c13-18(16,17)12-9-14(7-6-11(12)15)8-10-4-2-1-3-5-10/h1-7,9H,8H2,(H2,13,16,17)
DMUXSH5	CS	C1=CC=C(C=C1)CN2C=CC(=O)C(=C2)S(=O)(=O)N
DMUXSH5	IK	WIIFYOJVUKTZDG-UHFFFAOYSA-N
DMUXSH5	IU	1-benzyl-4-oxopyridine-3-sulfonamide
DMUXSH5	DE	Discovery agent

DMYGZ8V	ID	DMYGZ8V
DMYGZ8V	DN	1-Benzyl-1H-1,3,4b,9-tetraaza-fluorene-2,4-dione
DMYGZ8V	HS	Investigative
DMYGZ8V	SN	CHEMBL112256; 1-Benzyl-1H-1,3,4b,9-tetraaza-fluorene-2,4-dione
DMYGZ8V	DT	Small molecular drug
DMYGZ8V	PC	21604934
DMYGZ8V	MW	292.29
DMYGZ8V	FM	C16H12N4O2
DMYGZ8V	IC	InChI=1S/C16H12N4O2/c21-15-13-14(17-12-8-4-5-9-19(12)13)20(16(22)18-15)10-11-6-2-1-3-7-11/h1-9H,10H2,(H,18,21,22)
DMYGZ8V	CS	C1=CC=C(C=C1)CN2C3=C(C(=O)NC2=O)N4C=CC=CC4=N3
DMYGZ8V	IK	JHTRSVKUCQEETB-UHFFFAOYSA-N
DMYGZ8V	IU	1-benzylpurino[7,8-a]pyridine-2,4-dione
DMYGZ8V	DE	Discovery agent

DM2UFXE	ID	DM2UFXE
DM2UFXE	DN	1-benzyl-1H-indole-2,3-dione
DM2UFXE	HS	Investigative
DM2UFXE	SN	1-Benzyl-1H-indole-2,3-dione; 1217-89-6; 1-benzylisatin; 1-benzylindole-2,3-dione; 1-benzyl-2,3-dihydro-1H-indole-2,3-dione; 1-benzylindoline-2,3-dione; 1-Benzyl-2,3-indolinedione; 1H-indole-2,3-dione, 1-(phenylmethyl)-; 1H-Indole-2,3-dione,1-(phenylmethyl)-; benzylisatin; N-benzylisatin; N-benzyl isatin; 4kwf; NSC100000; AC1Q6FLI; AC1Q6FLG; AC1L6CGC; Isatin-based compound, 14; AC1Q6K6Z; N1-benzyl-indole-2,3-dione; CHEMBL115581; SCHEMBL2087729; BDBM22794; CTK4B2748; DTXSID30295164; SIISFRLGYDVIRG-UHFFFAOYSA-N; MolPort-000-322-417
DM2UFXE	DT	Small molecular drug
DM2UFXE	PC	264734
DM2UFXE	MW	237.25
DM2UFXE	FM	C15H11NO2
DM2UFXE	IC	InChI=1S/C15H11NO2/c17-14-12-8-4-5-9-13(12)16(15(14)18)10-11-6-2-1-3-7-11/h1-9H,10H2
DM2UFXE	CS	C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=O)C2=O
DM2UFXE	IK	SIISFRLGYDVIRG-UHFFFAOYSA-N
DM2UFXE	IU	1-benzylindole-2,3-dione
DM2UFXE	CA	CAS 1217-89-6
DM2UFXE	DE	Discovery agent

DMW0Y92	ID	DMW0Y92
DMW0Y92	DN	1-Benzyl-1H-indole-5-carboxamidine
DMW0Y92	HS	Investigative
DMW0Y92	SN	CHEMBL101343; 1-Benzyl-1H-indole-5-carboxamidine; BDBM50027286
DMW0Y92	DT	Small molecular drug
DMW0Y92	PC	29012033
DMW0Y92	MW	249.31
DMW0Y92	FM	C16H15N3
DMW0Y92	IC	InChI=1S/C16H15N3/c17-16(18)14-6-7-15-13(10-14)8-9-19(15)11-12-4-2-1-3-5-12/h1-10H,11H2,(H3,17,18)
DMW0Y92	CS	C1=CC=C(C=C1)CN2C=CC3=C2C=CC(=C3)C(=N)N
DMW0Y92	IK	LHXHNJWJHADGSJ-UHFFFAOYSA-N
DMW0Y92	IU	1-benzylindole-5-carboximidamide
DMW0Y92	DE	Discovery agent

DMEVSFY	ID	DMEVSFY
DMEVSFY	DN	1-benzyl-1H-pyrrolo[3,2-b]pyridine
DMEVSFY	HS	Investigative
DMEVSFY	SN	1-benzyl-1H-pyrrolo[3,2-b]pyridine; CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2
DMEVSFY	DT	Small molecular drug
DMEVSFY	PC	45267314
DMEVSFY	MW	208.26
DMEVSFY	FM	C14H12N2
DMEVSFY	IC	InChI=1S/C14H12N2/c1-2-5-12(6-3-1)11-16-10-8-13-14(16)7-4-9-15-13/h1-10H,11H2
DMEVSFY	CS	C1=CC=C(C=C1)CN2C=CC3=C2C=CC=N3
DMEVSFY	IK	LOGFFHFLSCMKJF-UHFFFAOYSA-N
DMEVSFY	IU	1-benzylpyrrolo[3,2-b]pyridine
DMEVSFY	DE	Discovery agent

DMQFS2D	ID	DMQFS2D
DMQFS2D	DN	1-benzyl-2,3-dimethyl-1H-indole-7-carboxylic acid
DMQFS2D	HS	Investigative
DMQFS2D	SN	CHEMBL515599; 1-benzyl-2,3-dimethyl-1H-indole-7-carboxylic acid; SCHEMBL6686678
DMQFS2D	DT	Small molecular drug
DMQFS2D	PC	44564825
DMQFS2D	MW	279.3
DMQFS2D	FM	C18H17NO2
DMQFS2D	IC	InChI=1S/C18H17NO2/c1-12-13(2)19(11-14-7-4-3-5-8-14)17-15(12)9-6-10-16(17)18(20)21/h3-10H,11H2,1-2H3,(H,20,21)
DMQFS2D	CS	CC1=C(N(C2=C1C=CC=C2C(=O)O)CC3=CC=CC=C3)C
DMQFS2D	IK	NSKDMNCONIAVGH-UHFFFAOYSA-N
DMQFS2D	IU	1-benzyl-2,3-dimethylindole-7-carboxylic acid
DMQFS2D	DE	Discovery agent

DMEVO6M	ID	DMEVO6M
DMEVO6M	DN	1-Benzyl-2-methyl-1H-imidazole
DMEVO6M	HS	Investigative
DMEVO6M	SN	1-Benzyl-2-methyl-1H-imidazole; 1-Benzyl-2-methylimidazole; 13750-62-4; N-Benzyl-2-methylimidazole; Imidazole, 1-benzyl-2-methyl-; 1H-Imidazole, 2-methyl-1-(phenylmethyl)-; EINECS 237-333-8; 1H-Imidazole, methyl(phenylmethyl)-; 2-methyl-1-benzylimidazole; PubChem9442; ACMC-209ccp; SCHEMBL81625; 1-benzyl-2-methyl imidazole; labotest-bb lt00455538; KSC427M1B; MLS001074953; BDBM7885; AC1Q4X69; AC1L35Z6; CHEMBL1269154; DTXSID4065604; FBHPRUXJQNWTEW-UHFFFAOYSA-N; MolPort-003-931-164; HMS3372N18; ZINC156633; HMS2231D21; SBB058028
DMEVO6M	DT	Small molecular drug
DMEVO6M	PC	83699
DMEVO6M	MW	172.23
DMEVO6M	FM	C11H12N2
DMEVO6M	IC	InChI=1S/C11H12N2/c1-10-12-7-8-13(10)9-11-5-3-2-4-6-11/h2-8H,9H2,1H3
DMEVO6M	CS	CC1=NC=CN1CC2=CC=CC=C2
DMEVO6M	IK	FBHPRUXJQNWTEW-UHFFFAOYSA-N
DMEVO6M	IU	1-benzyl-2-methylimidazole
DMEVO6M	CA	CAS 13750-62-4
DMEVO6M	DE	Discovery agent

DMPTMKU	ID	DMPTMKU
DMPTMKU	DN	1-benzyl-3,3-diethylazetidine-2,4-dione
DMPTMKU	HS	Investigative
DMPTMKU	SN	CHEMBL271819; 1-benzyl-3,3-diethylazetidine-2,4-dione
DMPTMKU	DT	Small molecular drug
DMPTMKU	PC	24823606
DMPTMKU	MW	231.29
DMPTMKU	FM	C14H17NO2
DMPTMKU	IC	InChI=1S/C14H17NO2/c1-3-14(4-2)12(16)15(13(14)17)10-11-8-6-5-7-9-11/h5-9H,3-4,10H2,1-2H3
DMPTMKU	CS	CCC1(C(=O)N(C1=O)CC2=CC=CC=C2)CC
DMPTMKU	IK	FWKVKYCYDHDEBH-UHFFFAOYSA-N
DMPTMKU	IU	1-benzyl-3,3-diethylazetidine-2,4-dione
DMPTMKU	DE	Discovery agent

DMW59XA	ID	DMW59XA
DMW59XA	DN	1-benzyl-3,3-dimethylazetidine-2,4-dione
DMW59XA	HS	Investigative
DMW59XA	SN	1-benzyl-3,3-dimethylazetidine-2,4-dione; CHEMBL556728
DMW59XA	DT	Small molecular drug
DMW59XA	PC	24823444
DMW59XA	MW	203.24
DMW59XA	FM	C12H13NO2
DMW59XA	IC	InChI=1S/C12H13NO2/c1-12(2)10(14)13(11(12)15)8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3
DMW59XA	CS	CC1(C(=O)N(C1=O)CC2=CC=CC=C2)C
DMW59XA	IK	LGZSEGMYAOALQU-UHFFFAOYSA-N
DMW59XA	IU	1-benzyl-3,3-dimethylazetidine-2,4-dione
DMW59XA	DE	Discovery agent

DMMRV21	ID	DMMRV21
DMMRV21	DN	1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione
DMMRV21	HS	Investigative
DMMRV21	SN	CHEMBL63944; 120642-81-1; 1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-1-(phenylmethyl)-; phenyltheophylline; ACMC-20mp1i; 1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione; SCHEMBL7453870; CTK0C3768; DTXSID50473801
DMMRV21	DT	Small molecular drug
DMMRV21	PC	11821203
DMMRV21	MW	256.26
DMMRV21	FM	C13H12N4O2
DMMRV21	IC	InChI=1S/C13H12N4O2/c1-16-11-10(14-8-15-11)12(18)17(13(16)19)7-9-5-3-2-4-6-9/h2-6,8H,7H2,1H3,(H,14,15)
DMMRV21	CS	CN1C2=C(C(=O)N(C1=O)CC3=CC=CC=C3)NC=N2
DMMRV21	IK	YAYRUHPCXIPTID-UHFFFAOYSA-N
DMMRV21	IU	1-benzyl-3-methyl-7H-purine-2,6-dione
DMMRV21	CA	CAS 120642-81-1
DMMRV21	DE	Discovery agent

DMMNH4K	ID	DMMNH4K
DMMNH4K	DN	1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione
DMMNH4K	HS	Investigative
DMMNH4K	SN	Benzetimidum; 14051-33-3; Benzetimide [INN]; 5633-14-7; CHEMBL10272; Benzetimide (INN); NCGC00160474-01; 2-(1-Benzyl-4-piperidyl)-2-phenylglutarimide; Dexbenzetimide; 119391-55-8; Dextrobenzetimide; Benzezimida; Benzetimidum [INN-Latin]; 2-[1-BENZYL-4-PIPERIDYL]-2-PHENYLGLUTARIMIDE; Benzezimida [INN-Spanish]; [3,4'-Bipiperidine]-2,6-dione, 3-phenyl-1'-(phenylmethyl)-, (S)-; Benzetimide(hydrochloride); 1''-Benzyl-3-phenyl-[3,4'']bipiperidinyl-2,6-dione; AC1L2J7P; DSSTox_RID_81404; DSSTox_CID_26173
DMMNH4K	DT	Small molecular drug
DMMNH4K	PC	21847
DMMNH4K	MW	362.5
DMMNH4K	FM	C23H26N2O2
DMMNH4K	IC	InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)
DMMNH4K	CS	C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4
DMMNH4K	IK	LQQIVYSCPWCSSD-UHFFFAOYSA-N
DMMNH4K	IU	3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione
DMMNH4K	CA	CAS 14051-33-3
DMMNH4K	DE	Discovery agent

DMV7UC0	ID	DMV7UC0
DMV7UC0	DN	1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione
DMV7UC0	HS	Investigative
DMV7UC0	SN	CHEMBL520083; 1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione; ZINC9926727; BDBM50251699
DMV7UC0	DT	Small molecular drug
DMV7UC0	PC	17132382
DMV7UC0	MW	328.4
DMV7UC0	FM	C21H16N2O2
DMV7UC0	IC	InChI=1S/C21H16N2O2/c24-20-18-13-7-8-14-19(18)22(15-16-9-3-1-4-10-16)21(25)23(20)17-11-5-2-6-12-17/h1-14H,15H2
DMV7UC0	CS	C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=O)N(C2=O)C4=CC=CC=C4
DMV7UC0	IK	CUMHESHKEAHQDE-UHFFFAOYSA-N
DMV7UC0	IU	1-benzyl-3-phenylquinazoline-2,4-dione
DMV7UC0	DE	Discovery agent

DMNWGOE	ID	DMNWGOE
DMNWGOE	DN	1-Benzyl-3-thiazol-2-yl-thiourea
DMNWGOE	HS	Investigative
DMNWGOE	SN	1-Benzyl-3-thiazol-2-yl-thiourea; Thiourea, N-(phenylmethyl)-N'-2-thiazolyl-; 51623-90-6; BAS 00581141; 1-benzyl-3-(1,3-thiazol-2-yl)thiourea; PETT Bz deriv.; PETT Analog 30; AC1LDT48; MLS001208035; BDBM1923; SCHEMBL5455503; CHEMBL145897; REGID_for_CID_700723; CTK1G4420; ZINC80959; DTXSID90351457; PDHMEDMWKUZUAB-UHFFFAOYSA-N; MolPort-000-656-277; N-(benzyl)-N'-[2-thiazolyl]thiourea; AKOS000533873; 1-benzyl-3-1,3-thiazol-2-ylthiourea; MCULE-4774117095; N-(benzyl)-N'-[2-thiazolyl] thiourea; SMR000514687
DMNWGOE	DT	Small molecular drug
DMNWGOE	PC	700723
DMNWGOE	MW	249.4
DMNWGOE	FM	C11H11N3S2
DMNWGOE	IC	InChI=1S/C11H11N3S2/c15-10(14-11-12-6-7-16-11)13-8-9-4-2-1-3-5-9/h1-7H,8H2,(H2,12,13,14,15)
DMNWGOE	CS	C1=CC=C(C=C1)CNC(=S)NC2=NC=CS2
DMNWGOE	IK	PDHMEDMWKUZUAB-UHFFFAOYSA-N
DMNWGOE	IU	1-benzyl-3-(1,3-thiazol-2-yl)thiourea
DMNWGOE	CA	CAS 51623-90-6
DMNWGOE	DE	Discovery agent

DMGDY4X	ID	DMGDY4X
DMGDY4X	DN	1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine
DMGDY4X	HS	Investigative
DMGDY4X	SN	1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine; CHEMBL395208
DMGDY4X	DT	Small molecular drug
DMGDY4X	PC	44440618
DMGDY4X	MW	321.2
DMGDY4X	FM	C17H18Cl2N2
DMGDY4X	IC	InChI=1S/C17H18Cl2N2/c18-13-6-7-14(16(19)8-13)15-10-21(11-17(15)20)9-12-4-2-1-3-5-12/h1-8,15,17H,9-11,20H2
DMGDY4X	CS	C1C(C(CN1CC2=CC=CC=C2)N)C3=C(C=C(C=C3)Cl)Cl
DMGDY4X	IK	OHYGBKLWBNYXTE-UHFFFAOYSA-N
DMGDY4X	IU	1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine
DMGDY4X	DE	Discovery agent

DMF0GXD	ID	DMF0GXD
DMF0GXD	DN	1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine
DMF0GXD	HS	Investigative
DMF0GXD	SN	CHEMBL325104; 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine; BDBM50082164
DMF0GXD	DT	Small molecular drug
DMF0GXD	PC	15508240
DMF0GXD	MW	264.4
DMF0GXD	FM	C18H20N2
DMF0GXD	IC	InChI=1S/C18H20N2/c1-2-17-9-6-12-20(17)18-10-13-19(14-11-18)15-16-7-4-3-5-8-16/h1,3-9,12,18H,10-11,13-15H2
DMF0GXD	CS	C#CC1=CC=CN1C2CCN(CC2)CC3=CC=CC=C3
DMF0GXD	IK	CNGQSMFIQRDDKI-UHFFFAOYSA-N
DMF0GXD	IU	1-benzyl-4-(2-ethynylpyrrol-1-yl)piperidine
DMF0GXD	DE	Discovery agent

DMBRJ5S	ID	DMBRJ5S
DMBRJ5S	DN	1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine
DMBRJ5S	HS	Investigative
DMBRJ5S	SN	1-Benzyl-4-(2-iodo-1H-pyrrol-1-yl)piperidine; CHEMBL106635; 254115-95-2; 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine; CTK7C3535; BDBM50082171; ZINC20358060; SBB054419; AKOS027449108; 4-(2-iodopyrrolyl)-1-benzylpiperidine
DMBRJ5S	DT	Small molecular drug
DMBRJ5S	PC	15508243
DMBRJ5S	MW	366.24
DMBRJ5S	FM	C16H19IN2
DMBRJ5S	IC	InChI=1S/C16H19IN2/c17-16-7-4-10-19(16)15-8-11-18(12-9-15)13-14-5-2-1-3-6-14/h1-7,10,15H,8-9,11-13H2
DMBRJ5S	CS	C1CN(CCC1N2C=CC=C2I)CC3=CC=CC=C3
DMBRJ5S	IK	LZMIVAWAFVXKJL-UHFFFAOYSA-N
DMBRJ5S	IU	1-benzyl-4-(2-iodopyrrol-1-yl)piperidine
DMBRJ5S	DE	Discovery agent

DMSBNY8	ID	DMSBNY8
DMSBNY8	DN	1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMSBNY8	HS	Investigative
DMSBNY8	SN	CHEMBL104453; 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine; BDBM50082166
DMSBNY8	DT	Small molecular drug
DMSBNY8	PC	10357869
DMSBNY8	MW	307.4
DMSBNY8	FM	C19H21N3O
DMSBNY8	IC	InChI=1S/C19H21N3O/c1-2-5-16(6-3-1)14-21-11-8-17(9-12-21)22-10-4-7-18(22)19-13-20-15-23-19/h1-7,10,13,15,17H,8-9,11-12,14H2
DMSBNY8	CS	C1CN(CCC1N2C=CC=C2C3=CN=CO3)CC4=CC=CC=C4
DMSBNY8	IK	JTHXHSNJAJMWTQ-UHFFFAOYSA-N
DMSBNY8	IU	5-[1-(1-benzylpiperidin-4-yl)pyrrol-2-yl]-1,3-oxazole
DMSBNY8	DE	Discovery agent

DMCO0JU	ID	DMCO0JU
DMCO0JU	DN	1-Benzyl-4-(3-hydroxyphenyl)piperidine
DMCO0JU	HS	Investigative
DMCO0JU	SN	CHEMBL592377; 1-Benzyl-4-(3-hydroxyphenyl)piperidine; SCHEMBL4826023
DMCO0JU	DT	Small molecular drug
DMCO0JU	PC	22397839
DMCO0JU	MW	267.4
DMCO0JU	FM	C18H21NO
DMCO0JU	IC	InChI=1S/C18H21NO/c20-18-8-4-7-17(13-18)16-9-11-19(12-10-16)14-15-5-2-1-3-6-15/h1-8,13,16,20H,9-12,14H2
DMCO0JU	CS	C1CN(CCC1C2=CC(=CC=C2)O)CC3=CC=CC=C3
DMCO0JU	IK	BPNZNQGAIFMNES-UHFFFAOYSA-N
DMCO0JU	IU	3-(1-benzylpiperidin-4-yl)phenol
DMCO0JU	DE	Discovery agent

DMCJZVA	ID	DMCJZVA
DMCJZVA	DN	1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMCJZVA	HS	Investigative
DMCJZVA	SN	CHEMBL107529; 1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine; BDBM50082170
DMCJZVA	DT	Small molecular drug
DMCJZVA	PC	9995378
DMCJZVA	MW	307.4
DMCJZVA	FM	C19H21N3O
DMCJZVA	IC	InChI=1S/C19H21N3O/c1-2-4-16(5-3-1)13-21-9-7-18(8-10-21)22-11-6-17(14-22)19-12-20-15-23-19/h1-6,11-12,14-15,18H,7-10,13H2
DMCJZVA	CS	C1CN(CCC1N2C=CC(=C2)C3=CN=CO3)CC4=CC=CC=C4
DMCJZVA	IK	ASGPPKHUWWRTLM-UHFFFAOYSA-N
DMCJZVA	IU	5-[1-(1-benzylpiperidin-4-yl)pyrrol-3-yl]-1,3-oxazole
DMCJZVA	DE	Discovery agent

DM4NGUL	ID	DM4NGUL
DM4NGUL	DN	1-Benzyl-4-(4-phenylpiperazin-1-yl)phthalazine
DM4NGUL	HS	Investigative
DM4NGUL	SN	1-Benzyl-4-(4-phenylpiperazin-1-yl)phthalazine; CHEMBL496013; 1-benzyl-4-(4-phenylpiperazino)phthalazine; 320418-04-0; AC1O4EAW; Oprea1_653246; SCHEMBL13444952; KS-000031YH; ZINC1393434; BDBM50269040; AKOS005082019
DM4NGUL	DT	Small molecular drug
DM4NGUL	PC	6404568
DM4NGUL	MW	380.5
DM4NGUL	FM	C25H24N4
DM4NGUL	IC	InChI=1S/C25H24N4/c1-3-9-20(10-4-1)19-24-22-13-7-8-14-23(22)25(27-26-24)29-17-15-28(16-18-29)21-11-5-2-6-12-21/h1-14H,15-19H2
DM4NGUL	CS	C1CN(CCN1C2=CC=CC=C2)C3=NN=C(C4=CC=CC=C43)CC5=CC=CC=C5
DM4NGUL	IK	PMNLMFUHSIYHHB-UHFFFAOYSA-N
DM4NGUL	IU	1-benzyl-4-(4-phenylpiperazin-1-yl)phthalazine
DM4NGUL	CA	CAS 320418-04-0
DM4NGUL	DE	Discovery agent

DMOF07G	ID	DMOF07G
DMOF07G	DN	1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperazine
DMOF07G	HS	Investigative
DMOF07G	SN	CHEMBL597413; 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperazine
DMOF07G	DT	Small molecular drug
DMOF07G	PC	45380179
DMOF07G	MW	330.4
DMOF07G	FM	C18H22N2O2S
DMOF07G	IC	InChI=1S/C18H22N2O2S/c1-23(21,22)18-9-5-8-17(14-18)20-12-10-19(11-13-20)15-16-6-3-2-4-7-16/h2-9,14H,10-13,15H2,1H3
DMOF07G	CS	CS(=O)(=O)C1=CC=CC(=C1)N2CCN(CC2)CC3=CC=CC=C3
DMOF07G	IK	DABGEKAEKHHGFN-UHFFFAOYSA-N
DMOF07G	IU	1-benzyl-4-(3-methylsulfonylphenyl)piperazine
DMOF07G	DE	Discovery agent

DME0MDL	ID	DME0MDL
DME0MDL	DN	1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperidine
DME0MDL	HS	Investigative
DME0MDL	SN	CHEMBL596800; 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperidine; SCHEMBL4825273
DME0MDL	DT	Small molecular drug
DME0MDL	PC	22397829
DME0MDL	MW	329.5
DME0MDL	FM	C19H23NO2S
DME0MDL	IC	InChI=1S/C19H23NO2S/c1-23(21,22)19-9-5-8-18(14-19)17-10-12-20(13-11-17)15-16-6-3-2-4-7-16/h2-9,14,17H,10-13,15H2,1H3
DME0MDL	CS	CS(=O)(=O)C1=CC=CC(=C1)C2CCN(CC2)CC3=CC=CC=C3
DME0MDL	IK	KOPPWFMKOOMORI-UHFFFAOYSA-N
DME0MDL	IU	1-benzyl-4-(3-methylsulfonylphenyl)piperidine
DME0MDL	DE	Discovery agent

DMAQSBV	ID	DMAQSBV
DMAQSBV	DN	1-Benzyl-4-chroman-2-ylmethyl-piperazine
DMAQSBV	HS	Investigative
DMAQSBV	SN	CHEMBL179648; 1-Benzyl-4-chroman-2-ylmethyl-piperazine; SCHEMBL8031431; AJZBPCAHQHCXMX-UHFFFAOYSA-N; BDBM50159018; 1-[(chroman-2-yl)methyl]-4-benzylpiperazine
DMAQSBV	DT	Small molecular drug
DMAQSBV	PC	10758200
DMAQSBV	MW	322.4
DMAQSBV	FM	C21H26N2O
DMAQSBV	IC	InChI=1S/C21H26N2O/c1-2-6-18(7-3-1)16-22-12-14-23(15-13-22)17-20-11-10-19-8-4-5-9-21(19)24-20/h1-9,20H,10-17H2
DMAQSBV	CS	C1CC2=CC=CC=C2OC1CN3CCN(CC3)CC4=CC=CC=C4
DMAQSBV	IK	AJZBPCAHQHCXMX-UHFFFAOYSA-N
DMAQSBV	IU	1-benzyl-4-(3,4-dihydro-2H-chromen-2-ylmethyl)piperazine
DMAQSBV	DE	Discovery agent

DMETDQC	ID	DMETDQC
DMETDQC	DN	1-Benzyl-4-methyl-piperazine
DMETDQC	HS	Investigative
DMETDQC	SN	1-benzyl-4-methylpiperazine; 62226-74-8; 1-benzyl-4-methyl-piperazine; CHEMBL363603; Piperazine, 1-methyl-4-(phenylmethyl)-; 4-Benzyl-1-methylpiperazine; 1-Benzyl-4-methylpiperazinehydrochloride; PubChem10987; AC1LG1B6; Cambridge id 5263722; N-benzyl-N'-methylpiperazine; SCHEMBL221139; Methyl piperazine, polymer-bound; CTK2C4522; DTXSID90354100; Methyl piperazinomethyl polystyrene; MolPort-000-882-836; MLJOKPBESJWYGL-UHFFFAOYSA-N; HMS1579O15; BCP22253; MFCD00976530; ZINC19536830; STK115879; BDBM50174044
DMETDQC	DT	Small molecular drug
DMETDQC	PC	763557
DMETDQC	MW	190.28
DMETDQC	FM	C12H18N2
DMETDQC	IC	InChI=1S/C12H18N2/c1-13-7-9-14(10-8-13)11-12-5-3-2-4-6-12/h2-6H,7-11H2,1H3
DMETDQC	CS	CN1CCN(CC1)CC2=CC=CC=C2
DMETDQC	IK	MLJOKPBESJWYGL-UHFFFAOYSA-N
DMETDQC	IU	1-benzyl-4-methylpiperazine
DMETDQC	CA	CAS 62226-74-8
DMETDQC	DE	Discovery agent

DMNTELW	ID	DMNTELW
DMNTELW	DN	1-benzyl-4-phenylpiperidin-4-ol
DMNTELW	HS	Investigative
DMNTELW	SN	1-Benzyl-4-phenylpiperidin-4-ol; 63843-83-4; 1-Benzyl-4-phenyl-4-piperidinol; 4-Piperidinol, 1-benzyl-4-phenyl-; 1-Benzyl-4-phenyl-piperidin-4-ol; EINECS 264-512-8; 1-benzyl-4-hydroxy-4-phenylpiperidine; 1-benzyl-4-hydroxy-4-phenyl piperidine; BRN 0235839; CHEMBL230141; F1446-0078; NSC116051; AC1L3YAO; Oprea1_213406; Oprea1_173104; SCHEMBL1411499; AC1Q7B56; CTK5B9985; DTXSID60213290; MolPort-001-954-320; FCLMXEAPEVBCKQ-UHFFFAOYSA-N; ZINC320034; HMS1672E06; BCP13431; ANW-45516; BDBM50210409; STK081775; AKOS000541462
DMNTELW	DT	Small molecular drug
DMNTELW	PC	97333
DMNTELW	MW	267.4
DMNTELW	FM	C18H21NO
DMNTELW	IC	InChI=1S/C18H21NO/c20-18(17-9-5-2-6-10-17)11-13-19(14-12-18)15-16-7-3-1-4-8-16/h1-10,20H,11-15H2
DMNTELW	CS	C1CN(CCC1(C2=CC=CC=C2)O)CC3=CC=CC=C3
DMNTELW	IK	FCLMXEAPEVBCKQ-UHFFFAOYSA-N
DMNTELW	IU	1-benzyl-4-phenylpiperidin-4-ol
DMNTELW	CA	CAS 63843-83-4
DMNTELW	DE	Discovery agent

DMNWEC9	ID	DMNWEC9
DMNWEC9	DN	1-Benzyl-4-pyrrol-1-yl-piperidine
DMNWEC9	HS	Investigative
DMNWEC9	SN	1-benzyl-4-(1H-pyrrol-1-yl)piperidine; 254115-91-8; CHEMBL326877; 1-(phenylmethyl)-4-pyrrol-1-yl-piperidine; 1-benzyl-4-pyrrolylpiperidine; 1-benzyl-4-pyrrol-1-yl-piperidine; AC1MCV5B; AC1Q28X7; CTK5J6306; KS-00003TOT; MolPort-001-764-445; ZINC161500; 1-benzyl-4-pyrrol-1-ylpiperidine; BDBM50082169; SBB056067; 1-benzyl-4-(pyrrol-1-yl)piperidine; AKOS008965823; NE54439; MCULE-3402690429; TS-03355; 1-Benzyl-4-(1H-pyrrole-1-yl)piperidine; KB-152224; ST50950067; EN300-52430; Z56618096
DMNWEC9	DT	Small molecular drug
DMNWEC9	PC	2779264
DMNWEC9	MW	240.34
DMNWEC9	FM	C16H20N2
DMNWEC9	IC	InChI=1S/C16H20N2/c1-2-6-15(7-3-1)14-17-12-8-16(9-13-17)18-10-4-5-11-18/h1-7,10-11,16H,8-9,12-14H2
DMNWEC9	CS	C1CN(CCC1N2C=CC=C2)CC3=CC=CC=C3
DMNWEC9	IK	UPRFZLANTXURKF-UHFFFAOYSA-N
DMNWEC9	IU	1-benzyl-4-pyrrol-1-ylpiperidine
DMNWEC9	DE	Discovery agent

DMH0ZVR	ID	DMH0ZVR
DMH0ZVR	DN	1-benzyl-5'-O-tritylinosine
DMH0ZVR	HS	Investigative
DMH0ZVR	SN	CHEMBL441540; 5'-O-trityl-1-benzylinosine; 1-benzyl-5''-O-tritylinosine; AUYLAWYEMLZGBM-QSYCCZFCSA-N
DMH0ZVR	DT	Small molecular drug
DMH0ZVR	PC	16082777
DMH0ZVR	MW	600.7
DMH0ZVR	FM	C36H32N4O5
DMH0ZVR	IC	InChI=1S/C36H32N4O5/c41-31-29(22-44-36(26-15-7-2-8-16-26,27-17-9-3-10-18-27)28-19-11-4-12-20-28)45-35(32(31)42)40-24-37-30-33(40)38-23-39(34(30)43)21-25-13-5-1-6-14-25/h1-20,23-24,29,31-32,35,41-42H,21-22H2/t29-,31-,32-,35-/m1/s1
DMH0ZVR	CS	C1=CC=C(C=C1)CN2C=NC3=C(C2=O)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COC(C5=CC=CC=C5)(C6=CC=CC=C6)C7=CC=CC=C7)O)O
DMH0ZVR	IK	AUYLAWYEMLZGBM-QSYCCZFCSA-N
DMH0ZVR	IU	1-benzyl-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]purin-6-one
DMH0ZVR	DE	Discovery agent

DM8GUN9	ID	DM8GUN9
DM8GUN9	DN	1-Benzyl-5-phenyl-1H-imidazole
DM8GUN9	HS	Investigative
DM8GUN9	SN	1-benzyl-5-phenyl-1H-imidazole; 53704-79-3; 1-benzyl-5-phenylimidazole; SCHEMBL1501929; CHEMBL463582; CTK1G0360; BDBM24655; DTXSID30440036; AWZYHJQWJWUOHS-UHFFFAOYSA-N; AKOS015905520; 4-phenylimidazole (4-PI) derivative, 27; 1H-Imidazole, 5-phenyl-1-(phenylmethyl)-
DM8GUN9	DT	Small molecular drug
DM8GUN9	PC	10444038
DM8GUN9	MW	234.29
DM8GUN9	FM	C16H14N2
DM8GUN9	IC	InChI=1S/C16H14N2/c1-3-7-14(8-4-1)12-18-13-17-11-16(18)15-9-5-2-6-10-15/h1-11,13H,12H2
DM8GUN9	CS	C1=CC=C(C=C1)CN2C=NC=C2C3=CC=CC=C3
DM8GUN9	IK	AWZYHJQWJWUOHS-UHFFFAOYSA-N
DM8GUN9	IU	1-benzyl-5-phenylimidazole
DM8GUN9	CA	CAS 53704-79-3
DM8GUN9	DE	Discovery agent

DMCX3N1	ID	DMCX3N1
DMCX3N1	DN	1-Benzyl-7-chloro-4-hexyloxy-quinolinium
DMCX3N1	HS	Investigative
DMCX3N1	DT	Small molecular drug
DMCX3N1	PC	10433084
DMCX3N1	MW	434.8
DMCX3N1	FM	C22H25BrClNO
DMCX3N1	IC	InChI=1S/C22H25ClNO.BrH/c1-2-3-4-8-15-25-22-13-14-24(17-18-9-6-5-7-10-18)21-16-19(23)11-12-20(21)22;/h5-7,9-14,16H,2-4,8,15,17H2,1H3;1H/q+1;/p-1
DMCX3N1	CS	CCCCCCOC1=C2C=CC(=CC2=[N+](C=C1)CC3=CC=CC=C3)Cl.[Br-]
DMCX3N1	IK	RZJKFYPDZZJFFA-UHFFFAOYSA-M
DMCX3N1	IU	1-benzyl-7-chloro-4-hexoxyquinolin-1-ium;bromide
DMCX3N1	DE	Discovery agent

DMJHXMY	ID	DMJHXMY
DMJHXMY	DN	1-benzyl-APDC
DMJHXMY	HS	Investigative
DMJHXMY	SN	CHEMBL60238; 171336-76-8; (2R,4R)-1-BENZYL-4-AMINO-PYRROLIDINE-2,4-DIcarboxylic acid; GTPL1436; SCHEMBL8061968; CTK0A8043; DTXSID60573467; ZINC39952128; BDBM50071161; DB-064818; AJ-101168; FT-0772028; 4-amino-1-(phenylmethyl)pyrrolidine-2,4-dicarboxylic acid; (2R,4R)-4-amino-1-benzylpyrrolidine-2,4-dicarboxylic acid; (2R,4R)-4-Amino-1-benzyl-pyrrolidine-2,4-dicarboxylic acid; (2R)-1-Benzyl-4-aminopyrrolidine-2beta,4alpha-dicarboxylic acid; 4-Amino-1-benzyl-pyrrolidine-2,4-dicarboxylic acid(1-benzyl-APDC)
DMJHXMY	DT	Small molecular drug
DMJHXMY	PC	15508178
DMJHXMY	MW	264.28
DMJHXMY	FM	C13H16N2O4
DMJHXMY	IC	InChI=1S/C13H16N2O4/c14-13(12(18)19)6-10(11(16)17)15(8-13)7-9-4-2-1-3-5-9/h1-5,10H,6-8,14H2,(H,16,17)(H,18,19)/t10-,13-/m1/s1
DMJHXMY	CS	C1[C@@H](N(C[C@]1(C(=O)O)N)CC2=CC=CC=C2)C(=O)O
DMJHXMY	IK	LYCSUAGKQMUTBR-ZWNOBZJWSA-N
DMJHXMY	IU	(2R,4R)-4-amino-1-benzylpyrrolidine-2,4-dicarboxylic acid
DMJHXMY	CA	CAS 171336-76-8
DMJHXMY	DE	Discovery agent

DM7GDEK	ID	DM7GDEK
DM7GDEK	DN	1-benzylpiperidine hydrochloride
DM7GDEK	HS	Investigative
DM7GDEK	SN	1-Benzylpiperidine hydrochloride; 6295-81-4; Piperidine, 1-benzyl-, hydrochloride; 1-Benzyl-Piperidine HCl; Piperidine, 1-(phenylmethyl)-, hydrochloride; AC1L46RA; benzylpiperidine hydrochloride; CHEMBL555311; SCHEMBL7409551; 2905-56-8 (Parent); DTXSID70212153; NSC49527; NSC-49527; LS-114289; KB-218184
DM7GDEK	DT	Small molecular drug
DM7GDEK	PC	201590
DM7GDEK	MW	211.73
DM7GDEK	FM	C12H18ClN
DM7GDEK	IC	InChI=1S/C12H17N.ClH/c1-3-7-12(8-4-1)11-13-9-5-2-6-10-13;/h1,3-4,7-8H,2,5-6,9-11H2;1H
DM7GDEK	CS	C1CCN(CC1)CC2=CC=CC=C2.Cl
DM7GDEK	IK	MPPIBJJDFLONMO-UHFFFAOYSA-N
DM7GDEK	IU	1-benzylpiperidine;hydrochloride
DM7GDEK	CA	CAS 6295-81-4
DM7GDEK	DE	Discovery agent

DMHR90S	ID	DMHR90S
DMHR90S	DN	1beta-methoxy-miller-9Z-enolide
DMHR90S	HS	Investigative
DMHR90S	SN	CHEMBL425948
DMHR90S	DT	Small molecular drug
DMHR90S	PC	44409505
DMHR90S	MW	376.4
DMHR90S	FM	C20H24O7
DMHR90S	IC	InChI=1S/C20H24O7/c1-10(2)19(23)26-15-8-13(9-21)14(25-5)7-6-11(3)17(22)18-16(15)12(4)20(24)27-18/h8-9,14-18,22H,1,3-4,6-7H2,2,5H3/b13-8+/t14-,15-,16-,17+,18+/m1/s1
DMHR90S	CS	CC(=C)C(=O)O[C@@H]1/C=C(/[C@@H](CCC(=C)[C@@H]([C@@H]2[C@@H]1C(=C)C(=O)O2)O)OC)\\C=O
DMHR90S	IK	JYJDQGQWAQKPAO-FLTPFCGOSA-N
DMHR90S	IU	[(3aR,4R,5Z,7R,11S,11aS)-6-formyl-11-hydroxy-7-methoxy-3,10-dimethylidene-2-oxo-4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DMHR90S	DE	Discovery agent

DMKJYCU	ID	DMKJYCU
DMKJYCU	DN	1-biphenyl-2-ylmethanamine
DMKJYCU	HS	Investigative
DMKJYCU	SN	2-Phenylbenzylamine; 1924-77-2; [1,1'-biphenyl]-2-ylmethanamine; 1-Biphenyl-2-Ylmethanamine; [1,1'-Biphenyl]-2-methanamine; (2-phenylphenyl)methanamine; biphenyl-2-methanamine; CHEMBL257036; (2-phenylphenyl)methylamine; 1-(biphenyl-2-yl)methanamine; biphenyl-2-ylmethanamine hydrochloride; NSC97774; 2-phenylbenzyl amine; 2-aminomethylbiphenyl; biphenyl-2-ylmethylamine; biphenyl-2-ylmethanamine; AC1Q1IHD; (2-biphenylylmethyl)amine; 2-phenylbenzylamine ,98%; 2-phenyl-phenylmethyl amine; c-biphenyl-2-yl-methylamine; SCHEMBL469051
DMKJYCU	DT	Small molecular drug
DMKJYCU	PC	263366
DMKJYCU	MW	183.25
DMKJYCU	FM	C13H13N
DMKJYCU	IC	InChI=1S/C13H13N/c14-10-12-8-4-5-9-13(12)11-6-2-1-3-7-11/h1-9H,10,14H2
DMKJYCU	CS	C1=CC=C(C=C1)C2=CC=CC=C2CN
DMKJYCU	IK	YHXKXVFQHWJYOD-UHFFFAOYSA-N
DMKJYCU	IU	(2-phenylphenyl)methanamine
DMKJYCU	CA	CAS 1924-77-2
DMKJYCU	DE	Discovery agent

DM6E7TA	ID	DM6E7TA
DM6E7TA	DN	1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane
DM6E7TA	HS	Investigative
DM6E7TA	SN	CHEMBL505313; 86225-52-7; 1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane; SCHEMBL4713453; CTK2I3607; DTXSID40534177; BDBM50243943; 1-([1,1'-Biphenyl]-4-yl)-3-azabicyclo[3.1.0]hexane; 3-Azabicyclo[3.1.0]hexane, 1-[1,1'-biphenyl]-4-yl-
DM6E7TA	DT	Small molecular drug
DM6E7TA	PC	13279027
DM6E7TA	MW	235.32
DM6E7TA	FM	C17H17N
DM6E7TA	IC	InChI=1S/C17H17N/c1-2-4-13(5-3-1)14-6-8-15(9-7-14)17-10-16(17)11-18-12-17/h1-9,16,18H,10-12H2
DM6E7TA	CS	C1C2C1(CNC2)C3=CC=C(C=C3)C4=CC=CC=C4
DM6E7TA	IK	FKKPHPHBDNQCCQ-UHFFFAOYSA-N
DM6E7TA	IU	1-(4-phenylphenyl)-3-azabicyclo[3.1.0]hexane
DM6E7TA	CA	CAS 86225-52-7
DM6E7TA	DE	Discovery agent

DM9QTWB	ID	DM9QTWB
DM9QTWB	DN	1-Biphenyl-4-ylmaleimide
DM9QTWB	HS	Investigative
DM9QTWB	SN	N-(4-Biphenylyl)maleimide; MALEIMIDE, N-4-BIPHENYLYL-; BRN 0183921; 58609-75-9; AI3-02979; CHEMBL567545; 1-(4-phenylphenyl)pyrrole-2,5-dione; 1H-Pyrrole-2,5-dione, 1-(1,1'-biphenyl)-4-yl-; 1-Biphenyl-4-ylmaleimide; Cyto6B10; Maybridge3_004857; AC1L28LA; CBDivE_004932; 4-21-00-04634 (Beilstein Handbook Reference); SCHEMBL9719419; DTXSID30207328; MolPort-000-929-072; HMS1444M17; ZINC186459; STK003872; BDBM50300341; AKOS000296044; MCULE-5728148499; IDI1_016244; LS-88673
DM9QTWB	DT	Small molecular drug
DM9QTWB	PC	42797
DM9QTWB	MW	249.26
DM9QTWB	FM	C16H11NO2
DM9QTWB	IC	InChI=1S/C16H11NO2/c18-15-10-11-16(19)17(15)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-11H
DM9QTWB	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)N3C(=O)C=CC3=O
DM9QTWB	IK	RXWKCYQPTDVVSI-UHFFFAOYSA-N
DM9QTWB	IU	1-(4-phenylphenyl)pyrrole-2,5-dione
DM9QTWB	CA	CAS 58609-75-9
DM9QTWB	DE	Discovery agent

DMKL201	ID	DMKL201
DMKL201	DN	1-Biphenyl-4-ylmethylmaleimide
DMKL201	HS	Investigative
DMKL201	SN	CHEMBL576859; 1-Biphenyl-4-ylmethylmaleimide
DMKL201	DT	Small molecular drug
DMKL201	PC	45483984
DMKL201	MW	263.29
DMKL201	FM	C17H13NO2
DMKL201	IC	InChI=1S/C17H13NO2/c19-16-10-11-17(20)18(16)12-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-11H,12H2
DMKL201	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CN3C(=O)C=CC3=O
DMKL201	IK	LMMOMHSYMJTOJF-UHFFFAOYSA-N
DMKL201	IU	1-[(4-phenylphenyl)methyl]pyrrole-2,5-dione
DMKL201	CA	CAS 913733-40-1
DMKL201	DE	Discovery agent

DMGL4MJ	ID	DMGL4MJ
DMGL4MJ	DN	1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one
DMGL4MJ	HS	Investigative
DMGL4MJ	SN	CHEMBL421829; 1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one; BDBM50097367; 4-((1H-imidazol-1-yl)methyl)-1-bromo-9H-xanthen-9-one
DMGL4MJ	DT	Small molecular drug
DMGL4MJ	PC	10546089
DMGL4MJ	MW	355.2
DMGL4MJ	FM	C17H11BrN2O2
DMGL4MJ	IC	InChI=1S/C17H11BrN2O2/c18-13-6-5-11(9-20-8-7-19-10-20)17-15(13)16(21)12-3-1-2-4-14(12)22-17/h1-8,10H,9H2
DMGL4MJ	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3O2)CN4C=CN=C4)Br
DMGL4MJ	IK	DPCAMTPMSZHJLT-UHFFFAOYSA-N
DMGL4MJ	IU	1-bromo-4-(imidazol-1-ylmethyl)xanthen-9-one
DMGL4MJ	DE	Discovery agent

DMU2PSQ	ID	DMU2PSQ
DMU2PSQ	DN	1-Bromo-6-(3-hydroxyphenyl)-2-naphthol
DMU2PSQ	HS	Investigative
DMU2PSQ	SN	CHEMBL467151; 1-Bromo-6-(3-hydroxyphenyl)-2-naphthol; SCHEMBL3009237; WIVQIQQCUPQEGH-UHFFFAOYSA-N; ZINC40876206; BDBM50261887; 1-bromo-6-(3-hydroxyphenyl)naphthalene-2-ol
DMU2PSQ	DT	Small molecular drug
DMU2PSQ	PC	24950391
DMU2PSQ	MW	315.16
DMU2PSQ	FM	C16H11BrO2
DMU2PSQ	IC	InChI=1S/C16H11BrO2/c17-16-14-6-4-11(8-12(14)5-7-15(16)19)10-2-1-3-13(18)9-10/h1-9,18-19H
DMU2PSQ	CS	C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)Br
DMU2PSQ	IK	WIVQIQQCUPQEGH-UHFFFAOYSA-N
DMU2PSQ	IU	1-bromo-6-(3-hydroxyphenyl)naphthalen-2-ol
DMU2PSQ	DE	Discovery agent

DM2T4NL	ID	DM2T4NL
DM2T4NL	DN	1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DM2T4NL	HS	Investigative
DM2T4NL	SN	CHEMBL194936; 1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3936480; IPBYYNRPJBGKET-UHFFFAOYSA-N; ZINC13645011; BDBM50168334
DM2T4NL	DT	Small molecular drug
DM2T4NL	PC	10149684
DM2T4NL	MW	315.16
DM2T4NL	FM	C16H11BrO2
DM2T4NL	IC	InChI=1S/C16H11BrO2/c17-16-14-7-3-11(9-12(14)4-8-15(16)19)10-1-5-13(18)6-2-10/h1-9,18-19H
DM2T4NL	CS	C1=CC(=CC=C1C2=CC3=C(C=C2)C(=C(C=C3)O)Br)O
DM2T4NL	IK	IPBYYNRPJBGKET-UHFFFAOYSA-N
DM2T4NL	IU	1-bromo-6-(4-hydroxyphenyl)naphthalen-2-ol
DM2T4NL	DE	Discovery agent

DMXMATS	ID	DMXMATS
DMXMATS	DN	1-butoxy-4-phenoxybenzene
DMXMATS	HS	Investigative
DMXMATS	SN	CHEMBL475731; 1-butoxy-4-phenoxybenzene; 4-Butoxydiphenyl ether; SCHEMBL13545912; BDBM50246008
DMXMATS	DT	Small molecular drug
DMXMATS	PC	44562812
DMXMATS	MW	242.31
DMXMATS	FM	C16H18O2
DMXMATS	IC	InChI=1S/C16H18O2/c1-2-3-13-17-14-9-11-16(12-10-14)18-15-7-5-4-6-8-15/h4-12H,2-3,13H2,1H3
DMXMATS	CS	CCCCOC1=CC=C(C=C1)OC2=CC=CC=C2
DMXMATS	IK	NSCFOXCKETUFMF-UHFFFAOYSA-N
DMXMATS	IU	1-butoxy-4-phenoxybenzene
DMXMATS	DE	Discovery agent

DMO7NXE	ID	DMO7NXE
DMO7NXE	DN	1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol
DMO7NXE	HS	Investigative
DMO7NXE	SN	CHEMBL198124; 1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol
DMO7NXE	DT	Small molecular drug
DMO7NXE	PC	44404886
DMO7NXE	MW	260.37
DMO7NXE	FM	C16H24N2O
DMO7NXE	IC	InChI=1S/C16H24N2O/c1-4-5-10-18-12-13(9-11-17(2)3)16-14(18)7-6-8-15(16)19/h6-8,12,19H,4-5,9-11H2,1-3H3
DMO7NXE	CS	CCCCN1C=C(C2=C1C=CC=C2O)CCN(C)C
DMO7NXE	IK	HVOYRIYIBILDHN-UHFFFAOYSA-N
DMO7NXE	IU	1-butyl-3-[2-(dimethylamino)ethyl]indol-4-ol
DMO7NXE	DE	Discovery agent

DMOE2ZV	ID	DMOE2ZV
DMOE2ZV	DN	1-Butyl-3,7-dihydro-purine-2,6-dione
DMOE2ZV	HS	Investigative
DMOE2ZV	SN	1-Butylxanthine; CHEMBL68278; 1-Butyl-3,7-dihydro-purine-2,6-dione; SCHEMBL6233166
DMOE2ZV	DT	Small molecular drug
DMOE2ZV	PC	14969715
DMOE2ZV	MW	208.22
DMOE2ZV	FM	C9H12N4O2
DMOE2ZV	IC	InChI=1S/C9H12N4O2/c1-2-3-4-13-8(14)6-7(11-5-10-6)12-9(13)15/h5H,2-4H2,1H3,(H,10,11)(H,12,15)
DMOE2ZV	CS	CCCCN1C(=O)C2=C(NC1=O)N=CN2
DMOE2ZV	IK	HZPVRRDNEDXPAJ-UHFFFAOYSA-N
DMOE2ZV	IU	1-butyl-3,7-dihydropurine-2,6-dione
DMOE2ZV	CA	CAS 60942-22-5
DMOE2ZV	DE	Discovery agent

DM9GRN8	ID	DM9GRN8
DM9GRN8	DN	1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione
DM9GRN8	HS	Investigative
DM9GRN8	SN	CHEMBL130503; 1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione; SCHEMBL7109948; 1H-Purine-2,6-dione, 1-butyl-3,9-dihydro-3-methyl-; XT-56; BDBM50001494
DM9GRN8	DT	Small molecular drug
DM9GRN8	PC	12905389
DM9GRN8	MW	222.24
DM9GRN8	FM	C10H14N4O2
DM9GRN8	IC	InChI=1S/C10H14N4O2/c1-3-4-5-14-9(15)7-8(12-6-11-7)13(2)10(14)16/h6H,3-5H2,1-2H3,(H,11,12)
DM9GRN8	CS	CCCCN1C(=O)C2=C(N=CN2)N(C1=O)C
DM9GRN8	IK	GDRIWEXJHHARCU-UHFFFAOYSA-N
DM9GRN8	IU	1-butyl-3-methyl-7H-purine-2,6-dione
DM9GRN8	DE	Discovery agent

DM6QULO	ID	DM6QULO
DM6QULO	DN	1-Butyl-4-(2-methoxy-phenyl)-piperazine
DM6QULO	HS	Investigative
DM6QULO	SN	CHEMBL26789; 1-Butyl-4-(2-methoxy-phenyl)-piperazine; Oprea1_525926; SCHEMBL10414460; ZINC13738286; BDBM50039791; AKOS008298691
DM6QULO	DT	Small molecular drug
DM6QULO	PC	10354670
DM6QULO	MW	248.36
DM6QULO	FM	C15H24N2O
DM6QULO	IC	InChI=1S/C15H24N2O/c1-3-4-9-16-10-12-17(13-11-16)14-7-5-6-8-15(14)18-2/h5-8H,3-4,9-13H2,1-2H3
DM6QULO	CS	CCCCN1CCN(CC1)C2=CC=CC=C2OC
DM6QULO	IK	DCFYVNHQUVKFKK-UHFFFAOYSA-N
DM6QULO	IU	1-butyl-4-(2-methoxyphenyl)piperazine
DM6QULO	DE	Discovery agent

DMSNK98	ID	DMSNK98
DMSNK98	DN	1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSNK98	HS	Investigative
DMSNK98	SN	CHEMBL8789; 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSNK98	DT	Small molecular drug
DMSNK98	PC	11781054
DMSNK98	MW	284.31
DMSNK98	FM	C15H16N4O2
DMSNK98	IC	InChI=1S/C15H16N4O2/c1-2-3-9-19-14(20)11-13(18-15(19)21)17-12(16-11)10-7-5-4-6-8-10/h4-8H,2-3,9H2,1H3,(H,16,17)(H,18,21)
DMSNK98	CS	CCCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=CC=C3
DMSNK98	IK	UGAWDWCYTZJBPQ-UHFFFAOYSA-N
DMSNK98	IU	1-butyl-8-phenyl-3,7-dihydropurine-2,6-dione
DMSNK98	DE	Discovery agent

DMVFCLO	ID	DMVFCLO
DMVFCLO	DN	1-butyryl-1H-indole-2,3-dione
DMVFCLO	HS	Investigative
DMVFCLO	SN	1-butyryl-1H-indole-2,3-dione; 92675-59-7; Butyrylisatin; AC1MXQ1S; Isatin-based compound, 10; 1-butanoylindole-2,3-dione; CHEMBL374970; BDBM22790; MolPort-002-322-431; 1-butanoyl-1H-indole-2,3-dione; ZINC3160706; STK370040; AKOS001849110; MCULE-5909492944; CCG-139393; 1-butanoylbenzo[d]azolidine-2,3-dione; ST50561436
DMVFCLO	DT	Small molecular drug
DMVFCLO	PC	3794313
DMVFCLO	MW	217.22
DMVFCLO	FM	C12H11NO3
DMVFCLO	IC	InChI=1S/C12H11NO3/c1-2-5-10(14)13-9-7-4-3-6-8(9)11(15)12(13)16/h3-4,6-7H,2,5H2,1H3
DMVFCLO	CS	CCCC(=O)N1C2=CC=CC=C2C(=O)C1=O
DMVFCLO	IK	LYWOFWNKZLWLPZ-UHFFFAOYSA-N
DMVFCLO	IU	1-butanoylindole-2,3-dione
DMVFCLO	DE	Discovery agent

DM13HGN	ID	DM13HGN
DM13HGN	DN	1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene
DM13HGN	HS	Investigative
DM13HGN	SN	CHEMBL191195; 1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene
DM13HGN	DT	Small molecular drug
DM13HGN	PC	44400752
DM13HGN	MW	334.9
DM13HGN	FM	C18H19ClO2S
DM13HGN	IC	InChI=1S/C18H19ClO2S/c19-16-9-11-17(12-10-16)22(20,21)18(13-5-2-6-14-18)15-7-3-1-4-8-15/h1,3-4,7-12H,2,5-6,13-14H2
DM13HGN	CS	C1CCC(CC1)(C2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)Cl
DM13HGN	IK	XMYNJSLMUBGZIQ-UHFFFAOYSA-N
DM13HGN	IU	1-chloro-4-(1-phenylcyclohexyl)sulfonylbenzene
DM13HGN	DE	Discovery agent

DM0MGFQ	ID	DM0MGFQ
DM0MGFQ	DN	1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
DM0MGFQ	HS	Investigative
DM0MGFQ	SN	1-Chloro-6-(4-hydroxyphenyl)-2-naphthol; CHEMBL364092; 1-chloro-6-(4-hydroxyphenyl)naphthalen-2-ol; 4NA; 1yy4; AC1O0UUG; 1-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3933824; YHEHVRSGKUYDON-UHFFFAOYSA-N; ZINC13645009; BDBM50168323
DM0MGFQ	DT	Small molecular drug
DM0MGFQ	PC	6102690
DM0MGFQ	MW	270.71
DM0MGFQ	FM	C16H11ClO2
DM0MGFQ	IC	InChI=1S/C16H11ClO2/c17-16-14-7-3-11(9-12(14)4-8-15(16)19)10-1-5-13(18)6-2-10/h1-9,18-19H
DM0MGFQ	CS	C1=CC(=CC=C1C2=CC3=C(C=C2)C(=C(C=C3)O)Cl)O
DM0MGFQ	IK	YHEHVRSGKUYDON-UHFFFAOYSA-N
DM0MGFQ	IU	1-chloro-6-(4-hydroxyphenyl)naphthalen-2-ol
DM0MGFQ	DE	Discovery agent

DMA2607	ID	DMA2607
DMA2607	DN	1-Cycloheptyl-3-(1-propionylpiperidin-4-yl)urea
DMA2607	HS	Investigative
DMA2607	SN	CHEMBL1257632; 1-Cycloheptyl-3-(1-propionylpiperidin-4-yl)urea; SCHEMBL2719520
DMA2607	DT	Small molecular drug
DMA2607	PC	49782569
DMA2607	MW	295.42
DMA2607	FM	C16H29N3O2
DMA2607	IC	InChI=1S/C16H29N3O2/c1-2-15(20)19-11-9-14(10-12-19)18-16(21)17-13-7-5-3-4-6-8-13/h13-14H,2-12H2,1H3,(H2,17,18,21)
DMA2607	CS	CCC(=O)N1CCC(CC1)NC(=O)NC2CCCCCC2
DMA2607	IK	VEXSVFHEOLIFHA-UHFFFAOYSA-N
DMA2607	IU	1-cycloheptyl-3-(1-propanoylpiperidin-4-yl)urea
DMA2607	DE	Discovery agent

DMS10LE	ID	DMS10LE
DMS10LE	DN	1-cyclohexyl-1-isopropyl-3,3-dimethylselenourea
DMS10LE	HS	Investigative
DMS10LE	SN	CHEMBL399930; 1-cyclohexyl-1-isopropyl-3,3-dimethylselenourea
DMS10LE	DT	Small molecular drug
DMS10LE	PC	24776961
DMS10LE	MW	275.3
DMS10LE	FM	C12H24N2Se
DMS10LE	IC	InChI=1S/C12H24N2Se/c1-10(2)14(12(15)13(3)4)11-8-6-5-7-9-11/h10-11H,5-9H2,1-4H3
DMS10LE	CS	CC(C)N(C1CCCCC1)C(=[Se])N(C)C
DMS10LE	IK	WEFWDSQOLMAXHJ-UHFFFAOYSA-N
DMS10LE	IU	1-cyclohexyl-3,3-dimethyl-1-propan-2-ylselenourea
DMS10LE	DE	Discovery agent

DMAZYCD	ID	DMAZYCD
DMAZYCD	DN	1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea
DMAZYCD	HS	Investigative
DMAZYCD	SN	CHEMBL1256164; 1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea; SCHEMBL2730613; BDBM50327823
DMAZYCD	DT	Small molecular drug
DMAZYCD	PC	47379736
DMAZYCD	MW	281.39
DMAZYCD	FM	C15H27N3O2
DMAZYCD	IC	InChI=1S/C15H27N3O2/c1-2-14(19)18-10-8-13(9-11-18)17-15(20)16-12-6-4-3-5-7-12/h12-13H,2-11H2,1H3,(H2,16,17,20)
DMAZYCD	CS	CCC(=O)N1CCC(CC1)NC(=O)NC2CCCCC2
DMAZYCD	IK	VZLSZVQSSZTJPS-UHFFFAOYSA-N
DMAZYCD	IU	1-cyclohexyl-3-(1-propanoylpiperidin-4-yl)urea
DMAZYCD	DE	Discovery agent

DMESUD7	ID	DMESUD7
DMESUD7	DN	1-Cyclohexyl-3-(4-methoxy-phenyl)-urea
DMESUD7	HS	Investigative
DMESUD7	SN	1-cyclohexyl-3-(4-methoxyphenyl)urea; CHEMBL191968; N-cyclohexyl-N'-(4-methoxyphenyl)urea; 148806-87-5; Urea, N-cyclohexyl-N'-(4-methoxyphenyl)-; 1-Cyclohexyl-3-(4-methoxy-phenyl)-urea; AC1MQ7FX; ACMC-20n5j8; AC1Q4DC4; SCHEMBL12196154; CTK0E8825; DTXSID20392116; ZINC395455; STL268801; BDBM50167053; AKOS003408864; N-(4-Methoxyphenyl)-N'-cyclohexylurea; MCULE-4247297698; KB-104482; US8815951, 67
DMESUD7	DT	Small molecular drug
DMESUD7	PC	3397178
DMESUD7	MW	248.32
DMESUD7	FM	C14H20N2O2
DMESUD7	IC	InChI=1S/C14H20N2O2/c1-18-13-9-7-12(8-10-13)16-14(17)15-11-5-3-2-4-6-11/h7-11H,2-6H2,1H3,(H2,15,16,17)
DMESUD7	CS	COC1=CC=C(C=C1)NC(=O)NC2CCCCC2
DMESUD7	IK	KZOFCHITIRGEGY-UHFFFAOYSA-N
DMESUD7	IU	1-cyclohexyl-3-(4-methoxyphenyl)urea
DMESUD7	CA	CAS 148806-87-5
DMESUD7	DE	Discovery agent

DMH9O6V	ID	DMH9O6V
DMH9O6V	DN	1-Cyclohexyl-3-phenethyl-urea
DMH9O6V	HS	Investigative
DMH9O6V	SN	N-cyclohexyl-N'-(2-phenylethyl)urea; 1-cyclohexyl-3-phenethylurea; CHEMBL193888; MLS000061067; 1-Cyclohexyl-3-phenethyl-urea; AC1LEVP0; AC1Q5P4E; Cambridge id 5402894; Oprea1_499442; SCHEMBL12196137; CHEBI:108334; MolPort-001-839-964; ZINC182146; HMS2444C08; HMS1582O21; 1-cyclohexyl-3-(2-phenylethyl)urea; 3-cyclohexyl-1-(2-phenylethyl)urea; BDBM50167058; AKOS001026537; MCULE-2992993146; SMR000069580; US8815951, 36; AB00084095-01; Z44585920
DMH9O6V	DT	Small molecular drug
DMH9O6V	PC	742677
DMH9O6V	MW	246.35
DMH9O6V	FM	C15H22N2O
DMH9O6V	IC	InChI=1S/C15H22N2O/c18-15(17-14-9-5-2-6-10-14)16-12-11-13-7-3-1-4-8-13/h1,3-4,7-8,14H,2,5-6,9-12H2,(H2,16,17,18)
DMH9O6V	CS	C1CCC(CC1)NC(=O)NCCC2=CC=CC=C2
DMH9O6V	IK	YJAMPQZPTKVFIU-UHFFFAOYSA-N
DMH9O6V	IU	1-cyclohexyl-3-(2-phenylethyl)urea
DMH9O6V	CB	CHEBI:108334
DMH9O6V	DE	Discovery agent

DM9K8HA	ID	DM9K8HA
DM9K8HA	DN	1-Cyclohexyl-3-phenyl-urea
DM9K8HA	HS	Investigative
DM9K8HA	SN	1-cyclohexyl-3-phenylurea; N-CYCLOHEXYL-N'-PHENYLUREA; CHEMBL365939; Urea, N-cyclohexyl-N'-phenyl-; 886-59-9; WPLYTRWMCWBZEN-UHFFFAOYSA-N; (cyclohexylamino)-N-benzamide; 1-Cyclohexyl-3-phenyl-urea; NSC80588; CBMicro_019203; 3-cyclohexyl-1-phenylurea; 1-phenyl-3-cyclohexylurea; Cambridge id 5353538; AC1Q5NF9; 1-cyclohexyl 3-phenyl urea; MLS000532450; SCHEMBL812273; N-Cyclohexyl-N'-phenylurea #; AC1L21R9; ZINC65313; MolPort-001-837-644; HMS3323I20; HMS2169M05; HMS1775L19; CCG-7124; NSC-80588; SBB056567; BDBM50167056; AKOS001021945
DM9K8HA	DT	Small molecular drug
DM9K8HA	PC	13451
DM9K8HA	MW	218.29
DM9K8HA	FM	C13H18N2O
DM9K8HA	IC	InChI=1S/C13H18N2O/c16-13(14-11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h1,3-4,7-8,12H,2,5-6,9-10H2,(H2,14,15,16)
DM9K8HA	CS	C1CCC(CC1)NC(=O)NC2=CC=CC=C2
DM9K8HA	IK	WPLYTRWMCWBZEN-UHFFFAOYSA-N
DM9K8HA	IU	1-cyclohexyl-3-phenylurea
DM9K8HA	CA	CAS 886-59-9
DM9K8HA	DE	Discovery agent

DMFPQME	ID	DMFPQME
DMFPQME	DN	1-cyclohexylamido-5-sulfonamidoindane
DMFPQME	HS	Investigative
DMFPQME	SN	CHEMBL206830; 1-cyclohexylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 11b; BDBM11032
DMFPQME	DT	Small molecular drug
DMFPQME	PC	11659798
DMFPQME	MW	322.4
DMFPQME	FM	C16H22N2O3S
DMFPQME	IC	InChI=1S/C16H22N2O3S/c17-22(20,21)13-7-8-14-12(10-13)6-9-15(14)18-16(19)11-4-2-1-3-5-11/h7-8,10-11,15H,1-6,9H2,(H,18,19)(H2,17,20,21)
DMFPQME	CS	C1CCC(CC1)C(=O)NC2CCC3=C2C=CC(=C3)S(=O)(=O)N
DMFPQME	IK	XUDBTOFDMYBQSW-UHFFFAOYSA-N
DMFPQME	IU	N-(5-sulfamoyl-2,3-dihydro-1H-inden-1-yl)cyclohexanecarboxamide
DMFPQME	DE	Discovery agent

DM7A50Z	ID	DM7A50Z
DM7A50Z	DN	1-Cyclohexylidenethiosemicarbazide
DM7A50Z	HS	Investigative
DM7A50Z	SN	(cyclohexylideneamino)thiourea; Cyclohexanone thiosemicarbazone; 5351-77-9; Cyclohexanone, thiosemicarbazone; 1-Cyclohexylidenethiosemicarbazide; 2-cyclohexylidenehydrazinecarbothioamide; Hydrazinecarbothioamide, 2-cyclohexylidene-; CHEMBL510328; amino[(cyclohexylideneazamethyl)amino]methane-1-thione; AC1MD1GF; Thiosemicarbazonecyclohexanone; SCHEMBL941085; Thiosemicarbazone, cyclohexanone; NSC717; CTK1H1977; DTXSID20385240; NSC-717; MolPort-000-248-718; GYRDZVHNPFBIST-UHFFFAOYSA-N; HMS1577F04; ZINC5413245; SBB041170
DM7A50Z	DT	Small molecular drug
DM7A50Z	PC	2829394
DM7A50Z	MW	171.27
DM7A50Z	FM	C7H13N3S
DM7A50Z	IC	InChI=1S/C7H13N3S/c8-7(11)10-9-6-4-2-1-3-5-6/h1-5H2,(H3,8,10,11)
DM7A50Z	CS	C1CCC(=NNC(=S)N)CC1
DM7A50Z	IK	GYRDZVHNPFBIST-UHFFFAOYSA-N
DM7A50Z	IU	(cyclohexylideneamino)thiourea
DM7A50Z	CA	CAS 5351-77-9
DM7A50Z	DE	Discovery agent

DMEMQFH	ID	DMEMQFH
DMEMQFH	DN	1-Cyclopentyl-3,7-dihydro-purine-2,6-dione
DMEMQFH	HS	Investigative
DMEMQFH	SN	CHEMBL302344; cyclopentylxanthine; 1-Cyclopentyl-3,7-dihydro-purine-2,6-dione; SCHEMBL2520260; BDBM50042198
DMEMQFH	DT	Small molecular drug
DMEMQFH	PC	10998551
DMEMQFH	MW	220.23
DMEMQFH	FM	C10H12N4O2
DMEMQFH	IC	InChI=1S/C10H12N4O2/c15-9-7-8(12-5-11-7)13-10(16)14(9)6-3-1-2-4-6/h5-6H,1-4H2,(H,11,12)(H,13,16)
DMEMQFH	CS	C1CCC(C1)N2C(=O)C3=C(NC2=O)N=CN3
DMEMQFH	IK	IBCDFVYWAHQNAA-UHFFFAOYSA-N
DMEMQFH	IU	1-cyclopentyl-3,7-dihydropurine-2,6-dione
DMEMQFH	DE	Discovery agent

DMDGWAY	ID	DMDGWAY
DMDGWAY	DN	1-Cyclopentylidenethiosemicarbazide
DMDGWAY	HS	Investigative
DMDGWAY	SN	cyclopentanone thiosemicarbazone; 7283-39-8; Hydrazinecarbothioamide, 2-cyclopentylidene-; (cyclopentylideneamino)thiourea; Cyclopentanone, thiosemicarbazone; 1-Cyclopentylidenethiosemicarbazide; 2-cyclopentylidenehydrazinecarbothioamide; CHEMBL483262; PKHFATUAFMXAKP-UHFFFAOYSA-N; amino[(cyclopentylideneazamethyl)amino]methane-1-thione; NSC8269; AC1Q7EGW; AC1LEPE5; SCHEMBL4100479; MolPort-000-248-728; KS-000027YL; NSC-8269; STK391362; BDBM50268200; SBB041172; ZINC17730060; AKOS000269515; MCULE-1053883982
DMDGWAY	DT	Small molecular drug
DMDGWAY	PC	690102
DMDGWAY	MW	157.24
DMDGWAY	FM	C6H11N3S
DMDGWAY	IC	InChI=1S/C6H11N3S/c7-6(10)9-8-5-3-1-2-4-5/h1-4H2,(H3,7,9,10)
DMDGWAY	CS	C1CCC(=NNC(=S)N)C1
DMDGWAY	IK	PKHFATUAFMXAKP-UHFFFAOYSA-N
DMDGWAY	IU	(cyclopentylideneamino)thiourea
DMDGWAY	CA	CAS 7283-39-8
DMDGWAY	DE	Discovery agent

DMGSQTK	ID	DMGSQTK
DMGSQTK	DN	1D05
DMGSQTK	HS	Investigative
DMGSQTK	SN	Humanized monoclonal antibody (coronary heart disease), Merck
DMGSQTK	CP	Merck & Co Inc
DMGSQTK	DT	Antibody
DMGSQTK	DE	Coronary artery disease

DMG0VN6	ID	DMG0VN6
DMG0VN6	DN	1-Deaza-Adenosine
DMG0VN6	HS	Investigative
DMG0VN6	SN	1-Deazaadenosine; 1-deaza-adenosine; 14432-09-8; CHEMBL115824; 1DA; 1add; 1-Deaza-A; AC1L4ME8; AC1Q4XY1; adenosine-N,1,3-15N3; SCHEMBL18490353; A-d-ribofuranosyl)-3h-imidazo[4,5-b]pyridin-7-amine; MolPort-023-278-902; 3H-Imidazo(4,5-b)pyridin-7-amine, 3-beta-D-ribofuranosyl-; ZINC3814313; PDSP1_001078; BDBM50060165; PDSP2_001062; AKOS024458188; DB04218; NCGC00163308-01; 3- -D-Ribofuranosyl-3H-imidazo[4,5-b]pyridin-7-amine; 3-beta-D-ribofuranosyl-3H-imidazo[4,5-b]pyridin-7-amine; 3H-Imidazo[4,5-B]Pyridine, 7-Amino-3-ss-D-Ribof
DMG0VN6	DT	Small molecular drug
DMG0VN6	PC	159738
DMG0VN6	MW	266.25
DMG0VN6	FM	C11H14N4O4
DMG0VN6	IC	InChI=1S/C11H14N4O4/c12-5-1-2-13-10-7(5)14-4-15(10)11-9(18)8(17)6(3-16)19-11/h1-2,4,6,8-9,11,16-18H,3H2,(H2,12,13)/t6-,8-,9-,11-/m1/s1
DMG0VN6	CS	C1=CN=C2C(=C1N)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMG0VN6	IK	NVUDDRWKCUAERS-PNHWDRBUSA-N
DMG0VN6	IU	(2R,3R,4S,5R)-2-(7-aminoimidazo[4,5-b]pyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMG0VN6	CA	CAS 14432-09-8
DMG0VN6	DE	Discovery agent

DMOEQDP	ID	DMOEQDP
DMOEQDP	DN	1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose
DMOEQDP	HS	Investigative
DMOEQDP	SN	1-DEOXY-1-METHOXYCARBAMIDO-BETA-D-GLUCOPYRANOSE; CHEMBL134529; CR1; AC1L9IGO; Carbamic acid, N-beta-D-glucopyranosyl-, methyl ester; BDBM50363873; DB03657; 188679-87-0; N-(methoxycarbonyl)-beta-D-glucopyranosylamine; methyl N-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamate
DMOEQDP	DT	Small molecular drug
DMOEQDP	PC	445722
DMOEQDP	MW	237.21
DMOEQDP	FM	C8H15NO7
DMOEQDP	IC	InChI=1S/C8H15NO7/c1-15-8(14)9-7-6(13)5(12)4(11)3(2-10)16-7/h3-7,10-13H,2H2,1H3,(H,9,14)/t3-,4-,5+,6-,7-/m1/s1
DMOEQDP	CS	COC(=O)N[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMOEQDP	IK	IZZJOGWXTFEDLL-XUUWZHRGSA-N
DMOEQDP	IU	methyl N-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamate
DMOEQDP	CA	CAS 188679-87-0
DMOEQDP	DE	Discovery agent

DMAEWHB	ID	DMAEWHB
DMAEWHB	DN	1-Deoxy-1-Thio-Heptaethylene Glycol
DMAEWHB	HS	Investigative
DMAEWHB	SN	1-DEOXY-1-THIO-HEPTAETHYLENE GLYCOL; PE7; 20-sulfanyl-3,6,9,12,15,18-hexaoxaicosan-1-ol; AC1L9JR2; MolPort-006-168-364; ZINC5828797; DB02404; 3,6,9,12,15,18-Hexaoxa-20-mercaptoicosane-1-ol
DMAEWHB	DT	Small molecular drug
DMAEWHB	PC	446506
DMAEWHB	MW	342.45
DMAEWHB	FM	C14H30O7S
DMAEWHB	IC	InChI=1S/C14H30O7S/c15-1-2-16-3-4-17-5-6-18-7-8-19-9-10-20-11-12-21-13-14-22/h15,22H,1-14H2
DMAEWHB	CS	C(COCCOCCOCCOCCOCCOCCS)O
DMAEWHB	IK	ACMBXVJDKVNCGH-UHFFFAOYSA-N
DMAEWHB	IU	2-[2-[2-[2-[2-[2-(2-sulfanylethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
DMAEWHB	DE	Discovery agent

DMCSPU4	ID	DMCSPU4
DMCSPU4	DN	1-Deoxy-D-Xylulose-5-Phosphate
DMCSPU4	HS	Investigative
DMCSPU4	SN	1-Deoxy-xylulose 5-phosphate; deoxyxylulose-5-phosphate; D-1-deoxyxylulose-5-P; 1-deoxy-D-threo-pentulose 5-phosphate; DXP; CHEBI:57792; 1-deoxy-5-O-phosphonato-D-xylulose; 1-deoxy-D-xylulose 5-phosphate(2-); 1-deoxy-D-xylulose 5-phosphate dianion
DMCSPU4	DT	Small molecular drug
DMCSPU4	PC	443201
DMCSPU4	MW	214.11
DMCSPU4	FM	C5H11O7P
DMCSPU4	IC	InChI=1S/C5H11O7P/c1-3(6)5(8)4(7)2-12-13(9,10)11/h4-5,7-8H,2H2,1H3,(H2,9,10,11)/t4-,5-/m1/s1
DMCSPU4	CS	CC(=O)[C@H]([C@@H](COP(=O)(O)O)O)O
DMCSPU4	IK	AJPADPZSRRUGHI-RFZPGFLSSA-N
DMCSPU4	IU	[(2R,3S)-2,3-dihydroxy-4-oxopentyl] dihydrogen phosphate
DMCSPU4	CA	CAS 190079-18-6
DMCSPU4	CB	CHEBI:16493
DMCSPU4	DE	Discovery agent

DMH9WFD	ID	DMH9WFD
DMH9WFD	DN	1-Deoxy-Ribofuranose-5'-Phosphate
DMH9WFD	HS	Investigative
DMH9WFD	SN	1-DEOXY-RIBOFURANOSE-5'-PHOSPHATE; AC1NRD1H; DB03936; [(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMH9WFD	DT	Small molecular drug
DMH9WFD	PC	5289299
DMH9WFD	MW	214.11
DMH9WFD	FM	C5H11O7P
DMH9WFD	IC	InChI=1S/C5H11O7P/c6-3-1-11-4(5(3)7)2-12-13(8,9)10/h3-7H,1-2H2,(H2,8,9,10)/t3-,4+,5+/m0/s1
DMH9WFD	CS	C1[C@@H]([C@H]([C@H](O1)COP(=O)(O)O)O)O
DMH9WFD	IK	CYZZKTRFOOKUMT-VPENINKCSA-N
DMH9WFD	IU	[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMH9WFD	DE	Discovery agent

DM4NBUH	ID	DM4NBUH
DM4NBUH	DN	1-D-glucopyranosyl cytosine
DM4NBUH	HS	Investigative
DM4NBUH	SN	1-D-glucopyranosyl cytosine; CHEMBL1096136; 4-Amino-1-Beta-D-Glucopyranosylpyrimidin-2(1h)-One; 1-D-glucopyranosyl-cytosine; SCHEMBL7520145; 1-beta-D-Glucopyranosylcytosine; BDBM50316588
DM4NBUH	DT	Small molecular drug
DM4NBUH	PC	21678292
DM4NBUH	MW	273.24
DM4NBUH	FM	C10H15N3O6
DM4NBUH	IC	InChI=1S/C10H15N3O6/c11-5-1-2-13(10(18)12-5)9-8(17)7(16)6(15)4(3-14)19-9/h1-2,4,6-9,14-17H,3H2,(H2,11,12,18)/t4-,6-,7+,8-,9-/m1/s1
DM4NBUH	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM4NBUH	IK	YYUQXKHCNLFJNF-DDIGBBAMSA-N
DM4NBUH	IU	4-amino-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]pyrimidin-2-one
DM4NBUH	DE	Discovery agent

DM90ULM	ID	DM90ULM
DM90ULM	DN	1-D-glucopyranosyl uracil
DM90ULM	HS	Investigative
DM90ULM	SN	1-D-glucopyranosyl uracil; CHEMBL1096135; 1-Beta-D-Glucopyranosylpyrimidine-2,4(1h,3h)-Dione; 3bcs; CJB; 3t3d; 1-D-glucopyranosyl-uracil; SCHEMBL8712423; BDBM50316587
DM90ULM	DT	Small molecular drug
DM90ULM	PC	15042826
DM90ULM	MW	274.23
DM90ULM	FM	C10H14N2O7
DM90ULM	IC	InChI=1S/C10H14N2O7/c13-3-4-6(15)7(16)8(17)9(19-4)12-2-1-5(14)11-10(12)18/h1-2,4,6-9,13,15-17H,3H2,(H,11,14,18)/t4-,6-,7+,8-,9-/m1/s1
DM90ULM	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM90ULM	IK	PBGBADORVLQASN-DDIGBBAMSA-N
DM90ULM	IU	1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]pyrimidine-2,4-dione
DM90ULM	DE	Discovery agent

DMOL2Y0	ID	DMOL2Y0
DMOL2Y0	DN	1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine
DMOL2Y0	HS	Investigative
DMOL2Y0	SN	RMI 60947; CHEMBL89970; piperazine, 1-dibenz[b,f]oxepin-10-yl-4-methyl-; Piperazine, 1-dibenz(b,f)oxepin-10-yl-4-methyl-; BRN 0624016; 1-Dibenz(b,f)oxepin-10-yl-4-methylpiperazine; 22012-06-2; AC1L4PU3; 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine; AC1Q70N4; CTK8D8624; DTXSID60176452; ZINC26648468; BDBM50028598; AKOS005065368; 11-(4-Methylpiperazino)dibenz[b,f]oxepin; LS-111456; 1-benzo[b][1]benzoxepin-5-yl-4-methylpiperazine; 5-23-02-00446 (Beilstein Handbook Reference)
DMOL2Y0	DT	Small molecular drug
DMOL2Y0	PC	210956
DMOL2Y0	MW	292.4
DMOL2Y0	FM	C19H20N2O
DMOL2Y0	IC	InChI=1S/C19H20N2O/c1-20-10-12-21(13-11-20)17-14-15-6-2-4-8-18(15)22-19-9-5-3-7-16(17)19/h2-9,14H,10-13H2,1H3
DMOL2Y0	CS	CN1CCN(CC1)C2=CC3=CC=CC=C3OC4=CC=CC=C42
DMOL2Y0	IK	ZCCUIFWJESTQQQ-UHFFFAOYSA-N
DMOL2Y0	IU	1-benzo[b][1]benzoxepin-5-yl-4-methylpiperazine
DMOL2Y0	CA	CAS 22012-06-2
DMOL2Y0	DE	Discovery agent

DMOSRET	ID	DMOSRET
DMOSRET	DN	1DMe
DMOSRET	HS	Investigative
DMOSRET	SN	[D.Tyr1,(N.Me)Phe3]NPFF; [D-Tyr1,(NMe)Phe3]neuropeptide FF
DMOSRET	DT	Small molecular drug
DMOSRET	PC	132709
DMOSRET	MW	1111.3
DMOSRET	FM	C55H78N14O11
DMOSRET	IC	InChI=1S/C55H78N14O11/c1-32(2)28-44(68(3)53(79)37(56)29-35-18-20-36(70)21-19-35)52(78)67-42(31-34-14-8-5-9-15-34)50(76)65-40(23-25-46(58)72)54(80)69-27-11-17-43(69)51(77)64-39(22-24-45(57)71)49(75)63-38(16-10-26-62-55(60)61)48(74)66-41(47(59)73)30-33-12-6-4-7-13-33/h4-9,12-15,18-21,32,37-44,70H,10-11,16-17,22-31,56H2,1-3H3,(H2,57,71)(H2,58,72)(H2,59,73)(H,63,75)(H,64,77)(H,65,76)(H,66,74)(H,67,78)(H4,60,61,62)/t37-,38-,39-,40-,41-,42-,43-,44-/m0/s1
DMOSRET	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)N(C)C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMOSRET	IK	UQGBICZACVFETI-YTAGXALCSA-N
DMOSRET	IU	(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-methylamino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMOSRET	CA	CAS 145274-94-8
DMOSRET	DE	Discovery agent

DM7P3N5	ID	DM7P3N5
DM7P3N5	DN	1-DODECANOL
DM7P3N5	HS	Investigative
DM7P3N5	SN	1-DODECANOL; Dodecyl alcohol; Dodecan-1-ol; Lauryl alcohol; Dodecanol; 112-53-8; n-Dodecyl alcohol; Lauric alcohol; Laurinic alcohol; Undecyl carbinol; Dodecylalcohol; Pisol; 1-Dodecyl alcohol; n-Dodecan-1-ol; Duodecyl alcohol; 1-Hydroxydodecane; Siponol L5; Karukoru 20; Siponol 25; Lorol 7; Lorol 5; n-Dodecanol; Lauryl 24; Alcohol C-12; Sipol L12; Lorol 11; Alfol 12; Siponol L2; Dytol J-68; Cachalot L-50; Cachalot L-90; Lauroyl alcohol; n-Lauryl alcohol; C12 alcohol; Hainol 12SS; Hydroxydodecane; Conol 20P; Lorol; Conol 20PP; Dodecyl alcoho
DM7P3N5	DT	Small molecular drug
DM7P3N5	PC	8193
DM7P3N5	MW	186.33
DM7P3N5	FM	C12H26O
DM7P3N5	IC	InChI=1S/C12H26O/c1-2-3-4-5-6-7-8-9-10-11-12-13/h13H,2-12H2,1H3
DM7P3N5	CS	CCCCCCCCCCCCO
DM7P3N5	IK	LQZZUXJYWNFBMV-UHFFFAOYSA-N
DM7P3N5	IU	dodecan-1-ol
DM7P3N5	CA	CAS 112-53-8
DM7P3N5	CB	CHEBI:28878
DM7P3N5	DE	Discovery agent

DMK6BWV	ID	DMK6BWV
DMK6BWV	DN	1-dodecyl-1H-indole-2,3-dione
DMK6BWV	HS	Investigative
DMK6BWV	SN	1-dodecylindoline-2,3-dione
DMK6BWV	DT	Small molecular drug
DMK6BWV	PC	1897797
DMK6BWV	MW	315.4
DMK6BWV	FM	C20H29NO2
DMK6BWV	IC	InChI=1S/C20H29NO2/c1-2-3-4-5-6-7-8-9-10-13-16-21-18-15-12-11-14-17(18)19(22)20(21)23/h11-12,14-15H,2-10,13,16H2,1H3
DMK6BWV	CS	CCCCCCCCCCCCN1C2=CC=CC=C2C(=O)C1=O
DMK6BWV	IK	GQEQKTGRIPEAKW-UHFFFAOYSA-N
DMK6BWV	IU	1-dodecylindole-2,3-dione
DMK6BWV	DE	Discovery agent

DMJBFN0	ID	DMJBFN0
DMJBFN0	DN	1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE
DMJBFN0	HS	Investigative
DMJBFN0	SN	2-Ethoxyethyl ether; DIETHYLENE GLYCOL DIETHYL ETHER; 112-36-7; Diethyl carbitol; 1-Ethoxy-2-(2-ethoxyethoxy)ethane; Ethyl diglyme; Bis(2-ethoxyethyl) ether; Diethyldiethylene glycol; 3,6,9-Trioxaundecane; DEGDEE; Ether, bis(2-ethoxyethyl); Ethane, 1,1'-oxybis[2-ethoxy-; 2-(2-Ethoxyethoxy)-1-ethoxyethane; Diethylether diethylenglykolu; HSDB 68; UNII-ZH086O935Z; Ethanol, 2,2'-oxybis-, diethyl ether; Ethane, 1,1'-oxybis(2-ethoxy-; Glycol, diethylene-, diethyl ether; EINECS 203-963-7; Diethylether diethylenglykolu [Czech]
DMJBFN0	DT	Small molecular drug
DMJBFN0	PC	8179
DMJBFN0	MW	162.23
DMJBFN0	FM	C8H18O3
DMJBFN0	IC	InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3
DMJBFN0	CS	CCOCCOCCOCC
DMJBFN0	IK	RRQYJINTUHWNHW-UHFFFAOYSA-N
DMJBFN0	IU	1-ethoxy-2-(2-ethoxyethoxy)ethane
DMJBFN0	CA	CAS 112-36-7
DMJBFN0	CB	CHEBI:44664
DMJBFN0	DE	Discovery agent

DM5UWH9	ID	DM5UWH9
DM5UWH9	DN	1-Ethyl-3-imidazol-1-ylmethyl-1H-indole
DM5UWH9	HS	Investigative
DM5UWH9	SN	CHEMBL115899; 72818-64-5; 1-Ethyl-3-imidazol-1-ylmethyl-1H-indole; SCHEMBL11496228; CTK2G2099; DTXSID10438234; BDBM50022117; ZINC27096766; 1-Ethyl-3-[(1H-imidazol-1-yl)methyl]-1H-indole; 1H-Indole, 1-ethyl-3-(1H-imidazol-1-ylmethyl)-
DM5UWH9	DT	Small molecular drug
DM5UWH9	PC	10331244
DM5UWH9	MW	225.29
DM5UWH9	FM	C14H15N3
DM5UWH9	IC	InChI=1S/C14H15N3/c1-2-17-10-12(9-16-8-7-15-11-16)13-5-3-4-6-14(13)17/h3-8,10-11H,2,9H2,1H3
DM5UWH9	CS	CCN1C=C(C2=CC=CC=C21)CN3C=CN=C3
DM5UWH9	IK	KIIFZBAPVHIJQJ-UHFFFAOYSA-N
DM5UWH9	IU	1-ethyl-3-(imidazol-1-ylmethyl)indole
DM5UWH9	CA	CAS 72818-64-5
DM5UWH9	DE	Discovery agent

DMSFINY	ID	DMSFINY
DMSFINY	DN	1-Ethyl-3-methyl-3,7-dihydro-purine-2,6-dione
DMSFINY	HS	Investigative
DMSFINY	SN	1-Ethyl-3-methylxanthine; CHEMBL24107; 1-ethyl-3,7-dihydro-3-methyl-1H-purine-2,6-dione; 37102-58-2; 1-Ethyl-3-methyl-3,7-dihydro-purine-2,6-dione; SCHEMBL7016029; KVSRUALMCYFLEP-UHFFFAOYSA-N
DMSFINY	DT	Small molecular drug
DMSFINY	PC	12905388
DMSFINY	MW	194.19
DMSFINY	FM	C8H10N4O2
DMSFINY	IC	InChI=1S/C8H10N4O2/c1-3-12-7(13)5-6(10-4-9-5)11(2)8(12)14/h4H,3H2,1-2H3,(H,9,10)
DMSFINY	CS	CCN1C(=O)C2=C(N=CN2)N(C1=O)C
DMSFINY	IK	KVSRUALMCYFLEP-UHFFFAOYSA-N
DMSFINY	IU	1-ethyl-3-methyl-7H-purine-2,6-dione
DMSFINY	DE	Discovery agent

DMGKP9Y	ID	DMGKP9Y
DMGKP9Y	DN	1-Ethyl-4-(2-methoxy-phenyl)-piperazine
DMGKP9Y	HS	Investigative
DMGKP9Y	SN	CHEMBL91689; 1-ethyl-4-(2-methoxyphenyl)piperazine; 1-Ethyl-4-(2-methoxy-phenyl)-piperazine; SCHEMBL4617829; ZINC13738285; BDBM50039788
DMGKP9Y	DT	Small molecular drug
DMGKP9Y	PC	10376185
DMGKP9Y	MW	220.31
DMGKP9Y	FM	C13H20N2O
DMGKP9Y	IC	InChI=1S/C13H20N2O/c1-3-14-8-10-15(11-9-14)12-6-4-5-7-13(12)16-2/h4-7H,3,8-11H2,1-2H3
DMGKP9Y	CS	CCN1CCN(CC1)C2=CC=CC=C2OC
DMGKP9Y	IK	VLKJSRWSKNCNBI-UHFFFAOYSA-N
DMGKP9Y	IU	1-ethyl-4-(2-methoxyphenyl)piperazine
DMGKP9Y	DE	Discovery agent

DMUOSJG	ID	DMUOSJG
DMUOSJG	DN	1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole
DMUOSJG	HS	Investigative
DMUOSJG	SN	CHEMBL112074; 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole
DMUOSJG	DT	Small molecular drug
DMUOSJG	PC	44341253
DMUOSJG	MW	301.4
DMUOSJG	FM	C20H19N3
DMUOSJG	IC	InChI=1S/C20H19N3/c1-2-22-12-10-17-14-18(8-9-19(17)22)20(23-13-11-21-15-23)16-6-4-3-5-7-16/h3-15,20H,2H2,1H3
DMUOSJG	CS	CCN1C=CC2=C1C=CC(=C2)C(C3=CC=CC=C3)N4C=CN=C4
DMUOSJG	IK	WUILDCCEKAPXPV-UHFFFAOYSA-N
DMUOSJG	IU	1-ethyl-5-[imidazol-1-yl(phenyl)methyl]indole
DMUOSJG	DE	Discovery agent

DMQRKZO	ID	DMQRKZO
DMQRKZO	DN	1-Ethylidenethiosemicarbazide
DMQRKZO	HS	Investigative
DMQRKZO	SN	1-Ethylidenethiosemicarbazide; CHEMBL449882; Ethanone thiosemicarbazone; AC1NUX6Z; [(Z)-ethylideneamino]thiourea; SCHEMBL3066172; ZINC38825875
DMQRKZO	DT	Small molecular drug
DMQRKZO	PC	5463036
DMQRKZO	MW	117.18
DMQRKZO	FM	C3H7N3S
DMQRKZO	IC	InChI=1S/C3H7N3S/c1-2-5-6-3(4)7/h2H,1H3,(H3,4,6,7)/b5-2-
DMQRKZO	CS	C/C=N\\NC(=S)N
DMQRKZO	IK	OOPAKHKIEGNKDU-DJWKRKHSSA-N
DMQRKZO	IU	[(Z)-ethylideneamino]thiourea
DMQRKZO	DE	Discovery agent

DM0Q46C	ID	DM0Q46C
DM0Q46C	DN	1-fluoro-5-phenyl-3-aza-bicyclo[3.1.0]hexane
DM0Q46C	HS	Investigative
DM0Q46C	SN	CHEMBL519717; 1-fluoro-5-phenyl-3-aza-bicyclo[3.1.0]hexane
DM0Q46C	DT	Small molecular drug
DM0Q46C	PC	44561133
DM0Q46C	MW	177.22
DM0Q46C	FM	C11H12FN
DM0Q46C	IC	InChI=1S/C11H12FN/c12-11-6-10(11,7-13-8-11)9-4-2-1-3-5-9/h1-5,13H,6-8H2
DM0Q46C	CS	C1C2(C1(CNC2)F)C3=CC=CC=C3
DM0Q46C	IK	OSYUYUPNSGSVAL-UHFFFAOYSA-N
DM0Q46C	IU	1-fluoro-5-phenyl-3-azabicyclo[3.1.0]hexane
DM0Q46C	DE	Discovery agent

DM8BC1M	ID	DM8BC1M
DM8BC1M	DN	1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DM8BC1M	HS	Investigative
DM8BC1M	SN	CHEMBL192782; 1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3925203; VQATUPWMFYRKSD-UHFFFAOYSA-N; BDBM50168380; ZINC13645014
DM8BC1M	DT	Small molecular drug
DM8BC1M	PC	10214633
DM8BC1M	MW	254.25
DM8BC1M	FM	C16H11FO2
DM8BC1M	IC	InChI=1S/C16H11FO2/c17-16-14-7-3-11(9-12(14)4-8-15(16)19)10-1-5-13(18)6-2-10/h1-9,18-19H
DM8BC1M	CS	C1=CC(=CC=C1C2=CC3=C(C=C2)C(=C(C=C3)O)F)O
DM8BC1M	IK	VQATUPWMFYRKSD-UHFFFAOYSA-N
DM8BC1M	IU	1-fluoro-6-(4-hydroxyphenyl)naphthalen-2-ol
DM8BC1M	DE	Discovery agent

DM7UK56	ID	DM7UK56
DM7UK56	DN	1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3)
DM7UK56	HS	Investigative
DM7UK56	SN	FPP 028; 86969-15-5; BRN 5552278; 4-Ethyl-4,7-dihydro-2-phenylpyrazolo(1,5-a)pyrimidin-7-one; FPP-028; 4-Ethyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7(4H)-one; 4,7-Dihydro-4-ethyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7-one; Pyrazolo(1,5-a)pyrimidin-7(4H)-one, 4-ethyl-2-phenyl-; AC1Q6I4H; CHEMBL45806; AC1L375B; 4-ethyl-2-phenylpyrazolo[1,5-a]pyrimidin-7(4h)-one; CTK5F7460; DTXSID70236016; ZINC5957034; LS-129307; 4-ethyl-2-phenylpyrazolo[1,5-a]pyrimidin-7-one
DM7UK56	DT	Small molecular drug
DM7UK56	PC	135819
DM7UK56	MW	239.27
DM7UK56	FM	C14H13N3O
DM7UK56	IC	InChI=1S/C14H13N3O/c1-2-16-9-8-14(18)17-13(16)10-12(15-17)11-6-4-3-5-7-11/h3-10H,2H2,1H3
DM7UK56	CS	CCN1C=CC(=O)N2C1=CC(=N2)C3=CC=CC=C3
DM7UK56	IK	JEWOUZIOCRUZPT-UHFFFAOYSA-N
DM7UK56	IU	4-ethyl-2-phenylpyrazolo[1,5-a]pyrimidin-7-one
DM7UK56	CA	CAS 86969-15-5
DM7UK56	DE	Discovery agent

DMF4BCP	ID	DMF4BCP
DMF4BCP	DN	1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea
DMF4BCP	HS	Investigative
DMF4BCP	SN	CHEMBL148698; AC1MHEHZ; 1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea; PHI-536; BDBM50097046; AKOS030027701; 1-(2-furylmethyl)-3-thiazol-2-yl-thiourea; 1-(2-Furanylmethyl)-3-(2-thiazolyl)thiourea; 1-(furan-2-ylmethyl)-3-(1,3-thiazol-2-yl)thiourea
DMF4BCP	DT	Small molecular drug
DMF4BCP	PC	3003032
DMF4BCP	MW	239.3
DMF4BCP	FM	C9H9N3OS2
DMF4BCP	IC	InChI=1S/C9H9N3OS2/c14-8(12-9-10-3-5-15-9)11-6-7-2-1-4-13-7/h1-5H,6H2,(H2,10,11,12,14)
DMF4BCP	CS	C1=COC(=C1)CNC(=S)NC2=NC=CS2
DMF4BCP	IK	OLLCKULTVXOISU-UHFFFAOYSA-N
DMF4BCP	IU	1-(furan-2-ylmethyl)-3-(1,3-thiazol-2-yl)thiourea
DMF4BCP	DE	Discovery agent

DMEB8CG	ID	DMEB8CG
DMEB8CG	DN	1G244
DMEB8CG	HS	Investigative
DMEB8CG	SN	1G244; CHEMBL1814633; (2~{S})-2-azanyl-4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-(1,3-dihydroisoindol-2-yl)butane-1,4-dione; GTPL8551; SCHEMBL19350285; C29H30N4O2F2; ZINC14949370; BDBM50350169; AKOS030528223; 847928-32-9; (S)-2-amino-4-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-1-(isoindolin-2-yl)butane-1,4-dione; Y0432
DMEB8CG	DT	Small molecular drug
DMEB8CG	PC	56658139
DMEB8CG	MW	504.6
DMEB8CG	FM	C29H30F2N4O2
DMEB8CG	IC	InChI=1S/C29H30F2N4O2/c30-24-9-5-20(6-10-24)28(21-7-11-25(31)12-8-21)34-15-13-33(14-16-34)27(36)17-26(32)29(37)35-18-22-3-1-2-4-23(22)19-35/h1-12,26,28H,13-19,32H2/t26-/m0/s1
DMEB8CG	CS	C1CN(CCN1C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)C[C@@H](C(=O)N4CC5=CC=CC=C5C4)N
DMEB8CG	IK	ZKIQFLSGMMYCGS-SANMLTNESA-N
DMEB8CG	IU	(2S)-2-amino-4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-(1,3-dihydroisoindol-2-yl)butane-1,4-dione
DMEB8CG	DE	Discovery agent

DM42IY7	ID	DM42IY7
DM42IY7	DN	1-Guanidinium-7-Aminoheptane
DM42IY7	HS	Investigative
DM42IY7	SN	1-Guanidinium-7-aminoheptane; 1-GUANIDINIUM-7-AMINOHEPTANE; AC1NRBDQ; N-(7-aminoheptyl)methanetriamine; N"-(7-aminoheptyl)methanetriamine; GC7
DM42IY7	DT	Small molecular drug
DM42IY7	PC	5288371
DM42IY7	MW	174.29
DM42IY7	FM	C8H22N4
DM42IY7	IC	InChI=1S/C8H22N4/c9-6-4-2-1-3-5-7-12-8(10)11/h8,12H,1-7,9-11H2
DM42IY7	CS	C(CCCN)CCCNC(N)N
DM42IY7	IK	SKGAVCHIFDRDTK-UHFFFAOYSA-N
DM42IY7	IU	N'-(7-aminoheptyl)methanetriamine
DM42IY7	DE	Discovery agent

DM48TIN	ID	DM48TIN
DM48TIN	DN	1-guanidino-7-isoquinolinesulphonamide
DM48TIN	HS	Investigative
DM48TIN	SN	SCHEMBL6436143; CHEMBL227583; 7-Isoquinolinesulfonamide, 1-[(aminoiminomethyl)amino]-; BDBM16130; NRVVFOKWKSWIIV-UHFFFAOYSA-N; 1-Guanidino-7-sulphamoylisoquinoline; 1-guanidino-7-sulfonamidoisoquinoline 4; 2-(7-sulfamoylisoquinolin-1-yl)guanidine
DM48TIN	DT	Small molecular drug
DM48TIN	PC	16658352
DM48TIN	MW	265.29
DM48TIN	FM	C10H11N5O2S
DM48TIN	IC	InChI=1S/C10H11N5O2S/c11-10(12)15-9-8-5-7(18(13,16)17)2-1-6(8)3-4-14-9/h1-5H,(H2,13,16,17)(H4,11,12,14,15)
DM48TIN	CS	C1=CC(=CC2=C1C=CN=C2N=C(N)N)S(=O)(=O)N
DM48TIN	IK	NRVVFOKWKSWIIV-UHFFFAOYSA-N
DM48TIN	IU	2-(7-sulfamoylisoquinolin-1-yl)guanidine
DM48TIN	DE	Discovery agent

DMTF1HL	ID	DMTF1HL
DMTF1HL	DN	1-guanidino-N-phenyl-7-isoquinolinesulphonamide
DMTF1HL	HS	Investigative
DMTF1HL	SN	SCHEMBL6435184; CHEMBL227781; BDBM16131; NNEJXIJKGKRBBF-UHFFFAOYSA-N; 1-guanidino-7-sulfonamidoisoquinoline 5; 1-guanidino-7-phenylsulphamoylisoquinoline
DMTF1HL	DT	Small molecular drug
DMTF1HL	PC	16658631
DMTF1HL	MW	341.4
DMTF1HL	FM	C16H15N5O2S
DMTF1HL	IC	InChI=1S/C16H15N5O2S/c17-16(18)20-15-14-10-13(7-6-11(14)8-9-19-15)24(22,23)21-12-4-2-1-3-5-12/h1-10,21H,(H4,17,18,19,20)
DMTF1HL	CS	C1=CC=C(C=C1)NS(=O)(=O)C2=CC3=C(C=C2)C=CN=C3N=C(N)N
DMTF1HL	IK	NNEJXIJKGKRBBF-UHFFFAOYSA-N
DMTF1HL	IU	2-[7-(phenylsulfamoyl)isoquinolin-1-yl]guanidine
DMTF1HL	DE	Discovery agent

DM9KAI5	ID	DM9KAI5
DM9KAI5	DN	1H-1,2,3-benzotriazol-1-amine
DM9KAI5	HS	Investigative
DM9KAI5	SN	1-aminobenzotriazole; 1614-12-6; 1H-Benzotriazol-1-amine; 1H-benzo[d][1,2,3]triazol-1-amine; 1-Benzotriazolamine; benzotriazol-1-amine; 1H-1,2,3-Benzotriazol-1-amine; 1-Abtz; 1H-1,2,3-Benzotriazol-1-ylamine; UNII-9EFF75BJ1O; NSC 114498; 9EFF75BJ1O; CHEMBL101168; benzotriazolylamine; MFCD00132902; NSC656987; 1-Aminobenzotriazole, 98%; AK-830/25033013; Q-102063; 1-benzotriazolylamine; benzotriazol-1-ylamine; PubChem19954; rarechem aq nn 0550; ACMC-1BVFA; AC1L1BBK; timtec-bb sbb004208; Lopac-A-3940; ABT; 1-Benzotriazolamine
DM9KAI5	DT	Small molecular drug
DM9KAI5	PC	1367
DM9KAI5	MW	134.14
DM9KAI5	FM	C6H6N4
DM9KAI5	IC	InChI=1S/C6H6N4/c7-10-6-4-2-1-3-5(6)8-9-10/h1-4H,7H2
DM9KAI5	CS	C1=CC=C2C(=C1)N=NN2N
DM9KAI5	IK	JCXKHYLLVKZPKE-UHFFFAOYSA-N
DM9KAI5	IU	benzotriazol-1-amine
DM9KAI5	CA	CAS 1614-12-6
DM9KAI5	DE	Discovery agent

DMNZAVE	ID	DMNZAVE
DMNZAVE	DN	1h-Benoximidazole-2-Carboxylic Acid
DMNZAVE	HS	Investigative
DMNZAVE	SN	1H-Benzimidazole-2-carboxylic acid; 2849-93-6; 2-Benzimidazolecarboxylic acid; 1H-benzo[d]imidazole-2-carboxylic acid; Benzimidazole-2-carboxylic acid; 1H-Benzoimidazole-2-carboxylic acid; 1H-1,3-benzodiazole-2-carboxylic acid; Benzoimidazole-2-carboxylic acid; benzimidazole-2-yl-carboxylic acid; 1H-BENOXIMIDAZOLE-2-CARBOXYLIC ACID; 1h-1,3-benzimidazole-2-carboxylic acid; RHXSYTACTOMVLJ-UHFFFAOYSA-N; PubChem8062; AC1L5PLZ; benzimidazolecarboxylic acid; AC1Q1HJ4; benzimidazole carboxylic acid; 2-Carboxy-1H-benzimidazole
DMNZAVE	DT	Small molecular drug
DMNZAVE	PC	233240
DMNZAVE	MW	162.15
DMNZAVE	FM	C8H6N2O2
DMNZAVE	IC	InChI=1S/C8H6N2O2/c11-8(12)7-9-5-3-1-2-4-6(5)10-7/h1-4H,(H,9,10)(H,11,12)
DMNZAVE	CS	C1=CC=C2C(=C1)NC(=N2)C(=O)O
DMNZAVE	IK	RHXSYTACTOMVLJ-UHFFFAOYSA-N
DMNZAVE	IU	1H-benzimidazole-2-carboxylic acid
DMNZAVE	CA	CAS 2849-93-6
DMNZAVE	CB	CHEBI:46117
DMNZAVE	DE	Discovery agent

DM4OWM6	ID	DM4OWM6
DM4OWM6	DN	1-hexadecyl-1H-indole-2,3-dione
DM4OWM6	HS	Investigative
DM4OWM6	SN	1-hexadecyl-1H-indole-2,3-dione; C24H37NO2; 1-hexadecylindole-2,3-dione; AC1MXWVN; Isatin-based compound, 63; CHEMBL221512; BDBM22843; MolPort-000-704-286; STK527744; ZINC14979621; AKOS005460820; MCULE-4252873887; 28035-35-0
DM4OWM6	DT	Small molecular drug
DM4OWM6	PC	3772674
DM4OWM6	MW	371.6
DM4OWM6	FM	C24H37NO2
DM4OWM6	IC	InChI=1S/C24H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-20-25-22-19-16-15-18-21(22)23(26)24(25)27/h15-16,18-19H,2-14,17,20H2,1H3
DM4OWM6	CS	CCCCCCCCCCCCCCCCN1C2=CC=CC=C2C(=O)C1=O
DM4OWM6	IK	JLUGWHXZCKLPBY-UHFFFAOYSA-N
DM4OWM6	IU	1-hexadecylindole-2,3-dione
DM4OWM6	DE	Discovery agent

DMME09C	ID	DMME09C
DMME09C	DN	1H-Imidazo[4,5-c]quinolin-4-ylamine HCl
DMME09C	HS	Investigative
DMME09C	SN	3H-imidazo[4,5-c]quinolin-4-amine; 1H-Imidazo[4,5-c]quinolin-4-amine; CHEMBL19191; 4-amino-1h-imidazo[4,5-c]quinoline; 132207-04-6; SCHEMBL482926; SCHEMBL212131; imidazo[4,5-c]quinolin-4-amine; imidazo(4,5-c)quinolin 4-amine; WUUCVVFSWNXYRD-UHFFFAOYSA-N; HQBUPOAKJGJGCD-UHFFFAOYSA-N; CS-B1117; BDBM50011593; ZINC28222586; AKOS027322300; 1h-imidazo-[4,5-c]quinolin-4-amine; SB22857; 1H-Imidazo[4,5-c]quinolin-4-ylamine
DMME09C	DT	Small molecular drug
DMME09C	PC	14896613
DMME09C	MW	184.2
DMME09C	FM	C10H8N4
DMME09C	IC	InChI=1S/C10H8N4/c11-10-9-8(12-5-13-9)6-3-1-2-4-7(6)14-10/h1-5H,(H2,11,14)(H,12,13)
DMME09C	CS	C1=CC=C2C(=C1)C3=C(C(=N2)N)NC=N3
DMME09C	IK	HQBUPOAKJGJGCD-UHFFFAOYSA-N
DMME09C	IU	3H-imidazo[4,5-c]quinolin-4-amine
DMME09C	DE	Discovery agent

DMOZ91H	ID	DMOZ91H
DMOZ91H	DN	1H-Indole-2,3-dione
DMOZ91H	HS	Investigative
DMOZ91H	SN	Isatin; 91-56-5; Indoline-2,3-dione; 2,3-Indolinedione; INDOLE-2,3-DIONE; 2,3-Dioxoindoline; Isatine; Pseudoisatin; Isatic acid lactam; Tribulin; Isotin; 2,3-Diketoindoline; Isatinic acid anhydride; 2,3-Ketoindoline; o-Aminobenzoylformic anhydride; 2,3-Dioxo-2,3-dihydroindole; 2,3-dihydro-1H-indole-2,3-dione; NSC 9262; UNII-82X95S7M06; EINECS 202-077-8; BRN 0383659; AI3-03111; CHEMBL326294; 2,3-dihydroindole-2,3-dione; CHEBI:27539; JXDYKVIHCLTXOP-UHFFFAOYSA-N; MFCD00005718; 82X95S7M06; 84788-92-1; Isatin, 98%
DMOZ91H	DT	Small molecular drug
DMOZ91H	PC	7054
DMOZ91H	MW	147.13
DMOZ91H	FM	C8H5NO2
DMOZ91H	IC	InChI=1S/C8H5NO2/c10-7-5-3-1-2-4-6(5)9-8(7)11/h1-4H,(H,9,10,11)
DMOZ91H	CS	C1=CC=C2C(=C1)C(=O)C(=O)N2
DMOZ91H	IK	JXDYKVIHCLTXOP-UHFFFAOYSA-N
DMOZ91H	IU	1H-indole-2,3-dione
DMOZ91H	CA	CAS 91-56-5
DMOZ91H	CB	CHEBI:27539
DMOZ91H	DE	Discovery agent

DMNDVMH	ID	DMNDVMH
DMNDVMH	DN	1H-indole-4,7-dione
DMNDVMH	HS	Investigative
DMNDVMH	SN	Indole-4,7-dione; 1H-Indole-4,7-dione; 20342-64-7; indole-4,7-quinone; CHEBI:51637; Indolequinone, 19; AC1L483C; CHEMBL500863; SCHEMBL1650480; CTK1A3633; BDBM21979; DTXSID20174252; ZINC6091591; 4,7-dihydro-1H-indole-4,7-dione; AKOS006347266
DMNDVMH	DT	Small molecular drug
DMNDVMH	PC	152300
DMNDVMH	MW	147.13
DMNDVMH	FM	C8H5NO2
DMNDVMH	IC	InChI=1S/C8H5NO2/c10-6-1-2-7(11)8-5(6)3-4-9-8/h1-4,9H
DMNDVMH	CS	C1=CC(=O)C2=C(C1=O)C=CN2
DMNDVMH	IK	QMRIWYCCTCNABA-UHFFFAOYSA-N
DMNDVMH	IU	1H-indole-4,7-dione
DMNDVMH	CA	CAS 20342-64-7
DMNDVMH	CB	CHEBI:51637
DMNDVMH	DE	Discovery agent

DM4V6JE	ID	DM4V6JE
DM4V6JE	DN	1H-Pyrazole-3-carboxylic acid
DM4V6JE	HS	Investigative
DM4V6JE	SN	1H-Pyrazole-3-carboxylic acid; 1621-91-6; Pyrazole-3-carboxylic acid; 1H-Pyrazole-5-carboxylic acid; 2H-PYRAZOLE-3-CARBOXYLIC ACID; 5-Pyrazolecarboxylic acid; 3-Pyrazolecarboxylic acid; 797027-83-9; 3-carboxy-1h-pyrazole; Pyrazolic acid; CHEMBL128679; KOPFEFZSAMLEHK-UHFFFAOYSA-N; pyrazolecarboxylic; 3-Carboxypyrazole; 2H-PYRAZOLE-3-CARBOXYLICACID; zlchem 656; pyrazolecarboxylic acid; pyrazole-5-carboxylic; PubChem12935; AC1Q5UBI; AC1LCCJ7; 3-pyrazole carboxylic acid; pyrazole 3-carboxylic acid; ACMC-209z0p; Pyrazole-5-carboxylic a
DM4V6JE	DT	Small molecular drug
DM4V6JE	PC	574310
DM4V6JE	MW	112.09
DM4V6JE	FM	C4H4N2O2
DM4V6JE	IC	InChI=1S/C4H4N2O2/c7-4(8)3-1-2-5-6-3/h1-2H,(H,5,6)(H,7,8)
DM4V6JE	CS	C1=C(NN=C1)C(=O)O
DM4V6JE	IK	KOPFEFZSAMLEHK-UHFFFAOYSA-N
DM4V6JE	IU	1H-pyrazole-5-carboxylic acid
DM4V6JE	CA	CAS 1621-91-6
DM4V6JE	DE	Discovery agent

DM235CQ	ID	DM235CQ
DM235CQ	DN	1-Hydroxy-10H-anthracen-9-one
DM235CQ	HS	Investigative
DM235CQ	SN	1-Hydroxyanthrone; 1-Hydroxy-9-anthrone; 1715-81-7; 1-Hydroxy-10H-anthracen-9-one; 9-Anthrone, 1-hydroxy-; 9-Anthronol; BRN 3530761; CHEMBL123161; 1-HYDROXY-9,10-DIHYDROANTHRACEN-9-ONE; hydroxyanthrone; AC1L45BO; SCHEMBL1204733; CTK4D3980; DTXSID10169112; 1-Hydroxyanthracen-9(10H)-one; MolPort-022-384-226; 9(10H)-Anthracenone,1-hydroxy-; ZINC6117388; BDBM50060879; AKOS022650101; LS-20754
DM235CQ	DT	Small molecular drug
DM235CQ	PC	150937
DM235CQ	MW	210.23
DM235CQ	FM	C14H10O2
DM235CQ	IC	InChI=1S/C14H10O2/c15-12-7-3-5-10-8-9-4-1-2-6-11(9)14(16)13(10)12/h1-7,15H,8H2
DM235CQ	CS	C1C2=C(C(=CC=C2)O)C(=O)C3=CC=CC=C31
DM235CQ	IK	AXHRXVXCOMMNLG-UHFFFAOYSA-N
DM235CQ	IU	1-hydroxy-10H-anthracen-9-one
DM235CQ	CA	CAS 1715-81-7
DM235CQ	DE	Discovery agent

DMIOTQ8	ID	DMIOTQ8
DMIOTQ8	DN	1-Hydroxy-1-Thio-Glycerol
DMIOTQ8	HS	Investigative
DMIOTQ8	SN	1-HYDROXY-1-THIO-GLYCEROL; SGL; AC1NRD54; SCHEMBL5003699; DB01684; (2R)-3-hydroxysulfanylpropane-1,2-diol; (2R)-2,3-dihydroxypropane-1-sulfenic acid
DMIOTQ8	DT	Small molecular drug
DMIOTQ8	PC	5289354
DMIOTQ8	MW	124.16
DMIOTQ8	FM	C3H8O3S
DMIOTQ8	IC	InChI=1S/C3H8O3S/c4-1-3(5)2-7-6/h3-6H,1-2H2/t3-/m1/s1
DMIOTQ8	CS	C([C@H](CSO)O)O
DMIOTQ8	IK	DLQCXFUWHQZWJQ-GSVOUGTGSA-N
DMIOTQ8	IU	(2R)-3-hydroxysulfanylpropane-1,2-diol
DMIOTQ8	DE	Discovery agent

DM9EWN8	ID	DM9EWN8
DM9EWN8	DN	1-Hydroxy-2-Amino-3-Cyclohexylpropane
DM9EWN8	HS	Investigative
DM9EWN8	SN	(S)-2-Amino-3-cyclohexylpropan-1-ol; 131288-67-0; (S)-2-Amino-3-cyclohexyl-propan-1-ol; 1-Hydroxy-2-Amino-3-Cyclohexylpropane; CHEMBL1231778; (S)-2-AMINO-3-CYCLOHEXYL-1-PROPANOL; (2S)-2-Amino-3-Cyclohexylpropan-1-Ol Hydrochloride; 205445-49-4; (2S)-2-amino-3-cyclohexylpropan-1-ol; AC1L9GJG; AC1Q4UB7; SCHEMBL82667; S-2-Amino-3-cyclohexylpropanol; KS-00000LNV; QWDRYURVUDZKSG-VIFPVBQESA-N; MolPort-000-000-987; ZINC154757; ZX-CM013052; (S)-cyclohexylalaninol, AldrichCPR; BDBM50367060; FCH835925; AKOS022180681; MB00862; DB04387
DM9EWN8	DT	Small molecular drug
DM9EWN8	PC	444569
DM9EWN8	MW	157.25
DM9EWN8	FM	C9H19NO
DM9EWN8	IC	InChI=1S/C9H19NO/c10-9(7-11)6-8-4-2-1-3-5-8/h8-9,11H,1-7,10H2/t9-/m0/s1
DM9EWN8	CS	C1CCC(CC1)C[C@@H](CO)N
DM9EWN8	IK	QWDRYURVUDZKSG-VIFPVBQESA-N
DM9EWN8	IU	(2S)-2-amino-3-cyclohexylpropan-1-ol
DM9EWN8	CA	CAS 205445-49-4
DM9EWN8	DE	Discovery agent

DMGBSWP	ID	DMGBSWP
DMGBSWP	DN	1-hydroxy-2-dodecyl-4(1H)quinolone
DMGBSWP	HS	Investigative
DMGBSWP	SN	1-hydroxy-2-dodecyl-4(1H)quinolone; CHEMBL224182; AC1LCHH0; SCHEMBL8535434; 2-dodecyl-1-hydroxyquinolin-4-one; 2-dodecyl-1-hydroxy-quinolin-4-one; BDBM50203194; 1-Hydroxy-2-dodecyl-4(1H)quinoline; 1-hydroxy-2-dodecyl-4-(1H)quinoline; (1-Hydroxy-2-dodecyl-4(1H)quinolone); 1-Hydroxy-2-dodecylquinoline-4(1H)-one; 2-dodecyl-1-oxidanidyl-quinolin-1-ium-4-ol; 2-dodecyl -4-HYDROXY QUINOLINE N-OXIDE
DMGBSWP	DT	Small molecular drug
DMGBSWP	PC	600305
DMGBSWP	MW	329.5
DMGBSWP	FM	C21H31NO2
DMGBSWP	IC	InChI=1S/C21H31NO2/c1-2-3-4-5-6-7-8-9-10-11-14-18-17-21(23)19-15-12-13-16-20(19)22(18)24/h12-13,15-17,24H,2-11,14H2,1H3
DMGBSWP	CS	CCCCCCCCCCCCC1=CC(=O)C2=CC=CC=C2N1O
DMGBSWP	IK	SBALADRDZPFHLM-UHFFFAOYSA-N
DMGBSWP	IU	2-dodecyl-1-hydroxyquinolin-4-one
DMGBSWP	DE	Discovery agent

DMGNVEF	ID	DMGNVEF
DMGNVEF	DN	1-hydroxy-3-(4-(trifluoromethyl)phenyl)urea
DMGNVEF	HS	Investigative
DMGNVEF	SN	CHEMBL260172; SCHEMBL12491371
DMGNVEF	DT	Small molecular drug
DMGNVEF	PC	11651456
DMGNVEF	MW	220.15
DMGNVEF	FM	C8H7F3N2O2
DMGNVEF	IC	InChI=1S/C8H7F3N2O2/c9-8(10,11)5-1-3-6(4-2-5)12-7(14)13-15/h1-4,15H,(H2,12,13,14)
DMGNVEF	CS	C1=CC(=CC=C1C(F)(F)F)NC(=O)NO
DMGNVEF	IK	DRFSQRMYIQLAMQ-UHFFFAOYSA-N
DMGNVEF	IU	1-hydroxy-3-[4-(trifluoromethyl)phenyl]urea
DMGNVEF	DE	Discovery agent

DMZ7GUP	ID	DMZ7GUP
DMZ7GUP	DN	1-hydroxy-3-(4-nitrophenyl)urea
DMZ7GUP	HS	Investigative
DMZ7GUP	SN	1-hydroxy-3-(4-nitrophenyl)urea; CHEMBL259979; 53731-88-7; NSC163567; AC1NQIZ7; SCHEMBL16005844; CTK1H3407; DTXSID10411168; BDBM50377113
DMZ7GUP	DT	Small molecular drug
DMZ7GUP	PC	5222748
DMZ7GUP	MW	197.15
DMZ7GUP	FM	C7H7N3O4
DMZ7GUP	IC	InChI=1S/C7H7N3O4/c11-7(9-12)8-5-1-3-6(4-2-5)10(13)14/h1-4,12H,(H2,8,9,11)
DMZ7GUP	CS	C1=CC(=CC=C1NC(=O)NO)[N+](=O)[O-]
DMZ7GUP	IK	DXBVARSUKIUCDK-UHFFFAOYSA-N
DMZ7GUP	IU	1-hydroxy-3-(4-nitrophenyl)urea
DMZ7GUP	CA	CAS 53731-88-7
DMZ7GUP	DE	Discovery agent

DMZ8IL9	ID	DMZ8IL9
DMZ8IL9	DN	1-Hydroxy-3-Methylbutane
DMZ8IL9	HS	Investigative
DMZ8IL9	SN	3-Methyl-1-butanol; Isoamyl alcohol; Isopentyl alcohol; 3-Methylbutan-1-ol; Isopentanol; 123-51-3; 3-Methylbutanol; 1-Butanol, 3-methyl-; Isoamylol; Isobutylcarbinol; Fusel Oil; Iso-amylalkohol; Isobutyl carbinol; Iso-amyl alcohol; 2-Methyl-4-butanol; ISOAMYLALCOHOL; Alcool isoamylique; Fermentation amyl alcohol; Isoamyl alkohol; Amylowy alkohol; Alcool amilico; i-Amyl Alcohol; Primary isoamyl alcohol; 3-Metil-butanolo; isopentan-1-ol; Isoamyl alcohol (natural); 1-Hydroxy-3-Methylbutane; Isoamyl alcohol, primary; FEMA Number 2057
DMZ8IL9	DT	Small molecular drug
DMZ8IL9	PC	31260
DMZ8IL9	MW	88.15
DMZ8IL9	FM	C5H12O
DMZ8IL9	IC	InChI=1S/C5H12O/c1-5(2)3-4-6/h5-6H,3-4H2,1-2H3
DMZ8IL9	CS	CC(C)CCO
DMZ8IL9	IK	PHTQWCKDNZKARW-UHFFFAOYSA-N
DMZ8IL9	IU	3-methylbutan-1-ol
DMZ8IL9	CA	CAS 123-51-3
DMZ8IL9	CB	CHEBI:15837
DMZ8IL9	DE	Discovery agent

DM4TSVC	ID	DM4TSVC
DM4TSVC	DN	1-hydroxy-3-phenylurea
DM4TSVC	HS	Investigative
DM4TSVC	SN	1-hydroxy-3-phenylurea; Urea, N-hydroxy-N'-phenyl-; Urea, 1-hydroxy-3-phenyl-; 7335-35-5; CHEMBL125955; NSC52953; NSC 52953; WLN: QMVMR; AI3-63229; AC1Q5NHR; SCHEMBL676383; AC1L322W; DTXSID20223597; MolPort-003-699-942; ZINC161805; BDBM50377106; NSC-52953; AKOS024336836
DM4TSVC	DT	Small molecular drug
DM4TSVC	PC	81786
DM4TSVC	MW	152.15
DM4TSVC	FM	C7H8N2O2
DM4TSVC	IC	InChI=1S/C7H8N2O2/c10-7(9-11)8-6-4-2-1-3-5-6/h1-5,11H,(H2,8,9,10)
DM4TSVC	CS	C1=CC=C(C=C1)NC(=O)NO
DM4TSVC	IK	AAVSQBMWOCNSDL-UHFFFAOYSA-N
DM4TSVC	IU	1-hydroxy-3-phenylurea
DM4TSVC	CA	CAS 7335-35-5
DM4TSVC	DE	Discovery agent

DMRNO5U	ID	DMRNO5U
DMRNO5U	DN	1-Hydroxy-8-methoxy-10H-anthracen-9-one
DMRNO5U	HS	Investigative
DMRNO5U	SN	CHEMBL125592; 9(10H)-Anthracenone, 1-hydroxy-8-methoxy-; 138591-01-2; ACMC-20mxto; 1-Hydroxy-8-methoxy-10H-anthracen-9-one; 1-Hydroxy-8-methoxyanthrone; SCHEMBL12775753; CTK0B8005; DTXSID10568303; ZINC13366515; BDBM50060886; AKOS030561671
DMRNO5U	DT	Small molecular drug
DMRNO5U	PC	15107209
DMRNO5U	MW	240.25
DMRNO5U	FM	C15H12O3
DMRNO5U	IC	InChI=1S/C15H12O3/c1-18-12-7-3-5-10-8-9-4-2-6-11(16)13(9)15(17)14(10)12/h2-7,16H,8H2,1H3
DMRNO5U	CS	COC1=CC=CC2=C1C(=O)C3=C(C2)C=CC=C3O
DMRNO5U	IK	KXNCIFRRMSGNPW-UHFFFAOYSA-N
DMRNO5U	IU	1-hydroxy-8-methoxy-10H-anthracen-9-one
DMRNO5U	CA	CAS 138591-01-2
DMRNO5U	DE	Discovery agent

DM6FLXW	ID	DM6FLXW
DM6FLXW	DN	1-Hydroxyamine-2-Isobutylmalonic Acid
DM6FLXW	HS	Investigative
DM6FLXW	SN	1-HYDROXYAMINE-2-ISOBUTYLMALONIC ACID; (2R)-2-(hydroxycarbamoyl)-4-methylpentanoic acid; AC1O43QE; DB02326
DM6FLXW	DT	Small molecular drug
DM6FLXW	PC	6323374
DM6FLXW	MW	175.18
DM6FLXW	FM	C7H13NO4
DM6FLXW	IC	InChI=1S/C7H13NO4/c1-4(2)3-5(7(10)11)6(9)8-12/h4-5,12H,3H2,1-2H3,(H,8,9)(H,10,11)/t5-/m1/s1
DM6FLXW	CS	CC(C)C[C@H](C(=O)NO)C(=O)O
DM6FLXW	IK	CINIOMOBGSHXRK-RXMQYKEDSA-N
DM6FLXW	IU	(2R)-2-(hydroxycarbamoyl)-4-methylpentanoic acid
DM6FLXW	DE	Discovery agent

DM3JHVL	ID	DM3JHVL
DM3JHVL	DN	1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one
DM3JHVL	HS	Investigative
DM3JHVL	SN	CHEMBL598974; 1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one
DM3JHVL	DT	Small molecular drug
DM3JHVL	PC	46230393
DM3JHVL	MW	328.4
DM3JHVL	FM	C20H28N2O2
DM3JHVL	IC	InChI=1S/C20H28N2O2/c1-2-3-4-5-6-7-8-18-9-11-20(12-10-18)24-16-19(23)15-22-14-13-21-17-22/h9-14,17H,2-8,15-16H2,1H3
DM3JHVL	CS	CCCCCCCCC1=CC=C(C=C1)OCC(=O)CN2C=CN=C2
DM3JHVL	IK	CGVPWFIJGMBNPP-UHFFFAOYSA-N
DM3JHVL	IU	1-imidazol-1-yl-3-(4-octylphenoxy)propan-2-one
DM3JHVL	DE	Discovery agent

DMN7KHS	ID	DMN7KHS
DMN7KHS	DN	1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one
DMN7KHS	HS	Investigative
DMN7KHS	SN	CHEMBL307160; 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one; BDBM50097363; 1-(imidazol-1-ylmethyl)-4-nitro-9h-9-xanthenone; 4-Nitro-1-(1H-imidazole-1-ylmethyl)-9H-xanthene-9-one
DMN7KHS	DT	Small molecular drug
DMN7KHS	PC	10853186
DMN7KHS	MW	321.29
DMN7KHS	FM	C17H11N3O4
DMN7KHS	IC	InChI=1S/C17H11N3O4/c21-16-12-3-1-2-4-14(12)24-17-13(20(22)23)6-5-11(15(16)17)9-19-8-7-18-10-19/h1-8,10H,9H2
DMN7KHS	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3O2)[N+](=O)[O-])CN4C=CN=C4
DMN7KHS	IK	VKGUMSNSPMTJMS-UHFFFAOYSA-N
DMN7KHS	IU	1-(imidazol-1-ylmethyl)-4-nitroxanthen-9-one
DMN7KHS	DE	Discovery agent

DMIDX7P	ID	DMIDX7P
DMIDX7P	DN	1-Imidazol-1-ylmethylxanthen-9-one
DMIDX7P	HS	Investigative
DMIDX7P	SN	CHEMBL1083652; 1-Imidazol-1-ylmethylxanthen-9-one
DMIDX7P	DT	Small molecular drug
DMIDX7P	PC	46867545
DMIDX7P	MW	276.29
DMIDX7P	FM	C17H12N2O2
DMIDX7P	IC	InChI=1S/C17H12N2O2/c20-17-13-5-1-2-6-14(13)21-15-7-3-4-12(16(15)17)10-19-9-8-18-11-19/h1-9,11H,10H2
DMIDX7P	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC=C3O2)CN4C=CN=C4
DMIDX7P	IK	FJYGKMHQKKRCON-UHFFFAOYSA-N
DMIDX7P	IU	1-(imidazol-1-ylmethyl)xanthen-9-one
DMIDX7P	DE	Discovery agent

DMYIQDE	ID	DMYIQDE
DMYIQDE	DN	1-Iodyl-3-nitro-benzene
DMYIQDE	HS	Investigative
DMYIQDE	SN	Benzene, 1-iodyl-3-nitro-; CHEMBL118998; 16825-78-8; 1-iodyl-3-nitro-benzene; 1-iodoxy-3-nitrobenzene; SCHEMBL2217800; CTK0E5266; DTXSID30438317
DMYIQDE	DT	Small molecular drug
DMYIQDE	PC	10333896
DMYIQDE	MW	281
DMYIQDE	FM	C6H4INO4
DMYIQDE	IC	InChI=1S/C6H4INO4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4H
DMYIQDE	CS	C1=CC(=CC(=C1)I(=O)=O)[N+](=O)[O-]
DMYIQDE	IK	PSLSYWRHLJIBMS-UHFFFAOYSA-N
DMYIQDE	IU	1-iodyl-3-nitrobenzene
DMYIQDE	CA	CAS 16825-78-8
DMYIQDE	DE	Discovery agent

DMF1WA6	ID	DMF1WA6
DMF1WA6	DN	1-Iodyl-4-nitro-benzene
DMF1WA6	HS	Investigative
DMF1WA6	SN	CHEMBL118424; 1-iodyl-4-nitro-benzene; p-Iodoxynitrobenzene; 1-Iodoxy-4-nitrobenzene; SCHEMBL1572451; BDBM50075023
DMF1WA6	DT	Small molecular drug
DMF1WA6	PC	10107739
DMF1WA6	MW	281
DMF1WA6	FM	C6H4INO4
DMF1WA6	IC	InChI=1S/C6H4INO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4H
DMF1WA6	CS	C1=CC(=CC=C1[N+](=O)[O-])I(=O)=O
DMF1WA6	IK	BMXXYWBYOJKMLW-UHFFFAOYSA-N
DMF1WA6	IU	1-iodyl-4-nitrobenzene
DMF1WA6	DE	Discovery agent

DMD7WNV	ID	DMD7WNV
DMD7WNV	DN	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
DMD7WNV	HS	Investigative
DMD7WNV	SN	Triglyme; 2,5,8,11-TETRAOXADODECANE; 112-49-2; Triethylene glycol dimethyl ether; 1,2-Bis(2-methoxyethoxy)ethane; Glyme 4; Ansul ether 161; Glyme-3; TEGDME; TEGDIME; 1-METHOXY-2-[2-(2-METHOXY-ETHOXY]-ETHANE; UNII-32YXG88KK0; Ethane, 1,2-bis(2-methoxyethoxy)-; NSC 66400; 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane; Dimethyl ether of triethylene glycol; EINECS 203-977-3; Glycol, triethylene-, dimethyl ether; BRN 1700630; AI3-28582; triethyleneglycol dimethyl ether; 32YXG88KK0; CHEBI:44842; YFNKIDBQEZZDLK-UHFFFAOYSA-N; Triethylene 
DMD7WNV	DT	Small molecular drug
DMD7WNV	PC	8189
DMD7WNV	MW	178.23
DMD7WNV	FM	C8H18O4
DMD7WNV	IC	InChI=1S/C8H18O4/c1-9-3-5-11-7-8-12-6-4-10-2/h3-8H2,1-2H3
DMD7WNV	CS	COCCOCCOCCOC
DMD7WNV	IK	YFNKIDBQEZZDLK-UHFFFAOYSA-N
DMD7WNV	IU	1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane
DMD7WNV	CA	CAS 112-49-2
DMD7WNV	CB	CHEBI:44842
DMD7WNV	DE	Discovery agent

DM7DTRM	ID	DM7DTRM
DM7DTRM	DN	1-methoxy-3-(3-(pyridin-4-yl)-1H-indol-6-yl)urea
DM7DTRM	HS	Investigative
DM7DTRM	SN	CHEMBL205218; 1-methoxy-3-(3-(pyridin-4-yl)-1H-indol-6-yl)urea
DM7DTRM	DT	Small molecular drug
DM7DTRM	PC	44410473
DM7DTRM	MW	282.3
DM7DTRM	FM	C15H14N4O2
DM7DTRM	IC	InChI=1S/C15H14N4O2/c1-21-19-15(20)18-11-2-3-12-13(9-17-14(12)8-11)10-4-6-16-7-5-10/h2-9,17H,1H3,(H2,18,19,20)
DM7DTRM	CS	CONC(=O)NC1=CC2=C(C=C1)C(=CN2)C3=CC=NC=C3
DM7DTRM	IK	XYNMCCVGHHUPIU-UHFFFAOYSA-N
DM7DTRM	IU	1-methoxy-3-(3-pyridin-4-yl-1H-indol-6-yl)urea
DM7DTRM	DE	Discovery agent

DMFVSBK	ID	DMFVSBK
DMFVSBK	DN	1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one
DMFVSBK	HS	Investigative
DMFVSBK	SN	1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one; CHEMBL1242450; SCHEMBL11029477
DMFVSBK	DT	Small molecular drug
DMFVSBK	PC	46932895
DMFVSBK	MW	298.29
DMFVSBK	FM	C17H14O5
DMFVSBK	IC	InChI=1S/C17H14O5/c1-19-14-6-10(20-8-11-9-21-11)7-15-16(14)17(18)12-4-2-3-5-13(12)22-15/h2-7,11H,8-9H2,1H3
DMFVSBK	CS	COC1=CC(=CC2=C1C(=O)C3=CC=CC=C3O2)OCC4CO4
DMFVSBK	IK	DTYOZZZAYPACPN-UHFFFAOYSA-N
DMFVSBK	IU	1-methoxy-3-(oxiran-2-ylmethoxy)xanthen-9-one
DMFVSBK	DE	Discovery agent

DM8YQ2O	ID	DM8YQ2O
DM8YQ2O	DN	1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine
DM8YQ2O	HS	Investigative
DM8YQ2O	SN	CHEMBL292721; 1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine; SCHEMBL7234473; MVULNNIYAGEMCC-UHFFFAOYSA-N; BDBM50144165
DM8YQ2O	DT	Small molecular drug
DM8YQ2O	PC	18189209
DM8YQ2O	MW	303.4
DM8YQ2O	FM	C20H17NO2
DM8YQ2O	IC	InChI=1S/C20H17NO2/c1-22-17-8-5-9-18-19(17)15-11-10-14(21)12-16(15)20(23-18)13-6-3-2-4-7-13/h2-12,20H,21H2,1H3
DM8YQ2O	CS	COC1=CC=CC2=C1C3=C(C=C(C=C3)N)C(O2)C4=CC=CC=C4
DM8YQ2O	IK	MVULNNIYAGEMCC-UHFFFAOYSA-N
DM8YQ2O	IU	1-methoxy-6-phenyl-6H-benzo[c]chromen-8-amine
DM8YQ2O	DE	Discovery agent

DM2D5HB	ID	DM2D5HB
DM2D5HB	DN	1-Methoxy-6-phenyl-6H-benzo[c]chromene
DM2D5HB	HS	Investigative
DM2D5HB	SN	CHEMBL63422; 1-Methoxy-6-phenyl-6H-benzo[c]chromene
DM2D5HB	DT	Small molecular drug
DM2D5HB	PC	44305900
DM2D5HB	MW	288.3
DM2D5HB	FM	C20H16O2
DM2D5HB	IC	InChI=1S/C20H16O2/c1-21-17-12-7-13-18-19(17)15-10-5-6-11-16(15)20(22-18)14-8-3-2-4-9-14/h2-13,20H,1H3
DM2D5HB	CS	COC1=CC=CC2=C1C3=CC=CC=C3C(O2)C4=CC=CC=C4
DM2D5HB	IK	SZYXTCHBPGBQPM-UHFFFAOYSA-N
DM2D5HB	IU	1-methoxy-6-phenyl-6H-benzo[c]chromene
DM2D5HB	DE	Discovery agent

DMAUZHJ	ID	DMAUZHJ
DMAUZHJ	DN	1-methoxy-9-aminomethyl-9,10-dihydroanthracene
DMAUZHJ	HS	Investigative
DMAUZHJ	SN	CHEMBL497156; 1-methoxy-9-aminomethyl-9,10-dihydroanthracene; BDBM50264948
DMAUZHJ	DT	Small molecular drug
DMAUZHJ	PC	44580316
DMAUZHJ	MW	239.31
DMAUZHJ	FM	C16H17NO
DMAUZHJ	IC	InChI=1S/C16H17NO/c1-18-15-8-4-6-12-9-11-5-2-3-7-13(11)14(10-17)16(12)15/h2-8,14H,9-10,17H2,1H3
DMAUZHJ	CS	COC1=CC=CC2=C1C(C3=CC=CC=C3C2)CN
DMAUZHJ	IK	MVQHAVPXHRGPMI-UHFFFAOYSA-N
DMAUZHJ	IU	(1-methoxy-9,10-dihydroanthracen-9-yl)methanamine
DMAUZHJ	DE	Discovery agent

DM9KCXI	ID	DM9KCXI
DM9KCXI	DN	1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea
DM9KCXI	HS	Investigative
DM9KCXI	SN	CHEMBL110018; 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea; BDBM50004732
DM9KCXI	DT	Small molecular drug
DM9KCXI	PC	15669672
DM9KCXI	MW	195.26
DM9KCXI	FM	C10H17N3O
DM9KCXI	IC	InChI=1S/C10H17N3O/c1-12(10(11)14)6-2-3-7-13-8-4-5-9-13/h4-9H2,1H3,(H2,11,14)
DM9KCXI	CS	CN(CC#CCN1CCCC1)C(=O)N
DM9KCXI	IK	NSYYEAWIQXWYBA-UHFFFAOYSA-N
DM9KCXI	IU	1-methyl-1-(4-pyrrolidin-1-ylbut-2-ynyl)urea
DM9KCXI	DE	Discovery agent

DMI6P91	ID	DMI6P91
DMI6P91	DN	1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol
DMI6P91	HS	Investigative
DMI6P91	SN	1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol; 525-72-4; (+/-) Salsolinol; CHEMBL416732; 1-Methyl-6,7-dihydroxytetrahydroisoquinoline; CHEBI:88801; (R)-Salsolinol; IBRKLUSXDYATLG-UHFFFAOYSA-N; 1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol; 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-methyl-; 1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; Sasolinol; (+)-Salsolinol; (R)-(+)-Salsolinol; (+)-(R)-Salsolinol; AC1L1H1L; Oprea1_470083; SCHEMBL1627427; CTK4J6115; 1,2,3,4-TETRAHYDRO-1-METHYL-6,7-ISOQUINOLINEDIOL
DMI6P91	DT	Small molecular drug
DMI6P91	PC	54456
DMI6P91	MW	179.22
DMI6P91	FM	C10H13NO2
DMI6P91	IC	InChI=1S/C10H13NO2/c1-6-8-5-10(13)9(12)4-7(8)2-3-11-6/h4-6,11-13H,2-3H2,1H3
DMI6P91	CS	CC1C2=CC(=C(C=C2CCN1)O)O
DMI6P91	IK	IBRKLUSXDYATLG-UHFFFAOYSA-N
DMI6P91	IU	1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol
DMI6P91	CA	CAS 525-72-4
DMI6P91	CB	CHEBI:88801
DMI6P91	DE	Discovery agent

DM1BGQN	ID	DM1BGQN
DM1BGQN	DN	1-Methyl-1,2-dihydro-indazol-3-one
DM1BGQN	HS	Investigative
DM1BGQN	SN	1006-19-5; 1-METHYL-1H-INDAZOL-3(2H)-ONE; 1H-Indazol-3-ol, 1-methyl-; 1,2-dihydro-1-methyl-3H-indazol-3-one; CHEMBL412905; 3H-Indazol-3-one, 1,2-dihydro-1-methyl-; 100922-97-2; 1-methyl-2,3-dihydro-1H-indazol-3-one; N-methylindazolone; 1,2-dihydro-1-methylindazol-3-one; NSC512755; 1-Methyl-1,2-dihydro-indazol-3-one; ACMC-1BUMW; AC1L6WKF; 1-methyl-3-hydroxyindazole; 1-methyl-2H-indazol-3-one; 1-Methyl-1H-indazole-3-ol; SCHEMBL2270654; SCHEMBL12998307; CTK0D9874; KS-00000SDI; ONNIFDMRZCMQQM-UHFFFAOYSA-N; MolPort-035-688-834
DM1BGQN	DT	Small molecular drug
DM1BGQN	PC	350589
DM1BGQN	MW	148.16
DM1BGQN	FM	C8H8N2O
DM1BGQN	IC	InChI=1S/C8H8N2O/c1-10-7-5-3-2-4-6(7)8(11)9-10/h2-5H,1H3,(H,9,11)
DM1BGQN	CS	CN1C2=CC=CC=C2C(=O)N1
DM1BGQN	IK	ONNIFDMRZCMQQM-UHFFFAOYSA-N
DM1BGQN	IU	1-methyl-2H-indazol-3-one
DM1BGQN	CA	CAS 100922-97-2
DM1BGQN	DE	Discovery agent

DMMX7V8	ID	DMMX7V8
DMMX7V8	DN	1-Methyl-1,3-dihydro-indol-2-one
DMMX7V8	HS	Investigative
DMMX7V8	PC	6096
DMMX7V8	MW	147.17
DMMX7V8	FM	C9H9NO
DMMX7V8	IC	InChI=1S/C9H9NO/c1-10-8-5-3-2-4-7(8)6-9(10)11/h2-5H,6H2,1H3
DMMX7V8	CS	CN1C(=O)CC2=CC=CC=C21
DMMX7V8	IK	RSQUAQMIGSMNNE-UHFFFAOYSA-N
DMMX7V8	IU	1-methyl-3H-indol-2-one
DMMX7V8	CA	CAS 61-70-1
DMMX7V8	DE	Discovery agent

DMPW75L	ID	DMPW75L
DMPW75L	DN	1-methyl-1H-indole-2,3-dione
DMPW75L	HS	Investigative
DMPW75L	SN	N-Methylisatin; 2058-74-4; 1-Methylisatin; 1-methylindoline-2,3-dione; 1-Methyl-1H-indole-2,3-dione; 1-methylindole-2,3-dione; 1H-Indole-2,3-dione, 1-methyl-; 1-Methyl-indole-2,3-dione; NSC 42449; 1 methylisatine; OL-57; 1-methyl-2,3-dihydro-1H-indole-2,3-dione; 1-Methyl-2,3-indolinedione; INDOLE-2,3-DIONE, 1-METHYL-; EINECS 218-164-9; N-methylindol-2,3-dione; BRN 0128280; N-Methylindoline-2,3-dione; 1-Methyl-2,3-dihydroindole-2,3-dione; CHEMBL60569; VCYBVWFTGAZHGH-UHFFFAOYSA-N; MFCD00005812; 1-Methylisatin, 98%
DMPW75L	DT	Small molecular drug
DMPW75L	PC	16358
DMPW75L	MW	161.16
DMPW75L	FM	C9H7NO2
DMPW75L	IC	InChI=1S/C9H7NO2/c1-10-7-5-3-2-4-6(7)8(11)9(10)12/h2-5H,1H3
DMPW75L	CS	CN1C2=CC=CC=C2C(=O)C1=O
DMPW75L	IK	VCYBVWFTGAZHGH-UHFFFAOYSA-N
DMPW75L	IU	1-methylindole-2,3-dione
DMPW75L	CA	CAS 2058-74-4
DMPW75L	DE	Discovery agent

DMDZ1FR	ID	DMDZ1FR
DMDZ1FR	DN	1-methyl-1H-indole-3-carbaldehyde
DMDZ1FR	HS	Investigative
DMDZ1FR	SN	1-Methyl-1H-indole-3-carbaldehyde; 19012-03-4; 1-Methylindole-3-carboxaldehyde; 1-methylindole-3-carbaldehyde; 3-Formyl-1-methylindole; 1-Methyl-indole-3-carbaldehyde; 1H-Indole-3-carboxaldehyde, 1-methyl-; 1-Methyl-3-formylindole; N-Methyl-3-formylindole; Indole-3-carboxaldehyde, 1-methyl-; 3-Formyl-1-methyl-1H-indole; CHEMBL210779; N-Methyl-3-indolecarboxaldehyde; KXYBYRKRRGSZCX-UHFFFAOYSA-N; MFCD00014570; 1-Methylindole-3-carboxaldehyde, 97%; NSC83042; EINECS 242-750-3; PubChem7503; AI3-51477; AC1L3EMK; AC1Q6QCU; AC1Q3YTB
DMDZ1FR	DT	Small molecular drug
DMDZ1FR	PC	87894
DMDZ1FR	MW	159.18
DMDZ1FR	FM	C10H9NO
DMDZ1FR	IC	InChI=1S/C10H9NO/c1-11-6-8(7-12)9-4-2-3-5-10(9)11/h2-7H,1H3
DMDZ1FR	CS	CN1C=C(C2=CC=CC=C21)C=O
DMDZ1FR	IK	KXYBYRKRRGSZCX-UHFFFAOYSA-N
DMDZ1FR	IU	1-methylindole-3-carbaldehyde
DMDZ1FR	CA	CAS 19012-03-4
DMDZ1FR	DE	Discovery agent

DML5FQT	ID	DML5FQT
DML5FQT	DN	1-methyl-1H-indole-3-carbonitrile
DML5FQT	HS	Investigative
DML5FQT	SN	1-Methyl-1H-indole-3-carbonitrile; 24662-37-1; 1-methylindole-3-carbonitrile; 3-Cyano-1-methylindole; 1H-Indole-3-carbonitrile, 1-methyl-; 1H-Indole-3-carbonitrile,1-methyl-; CHEMBL205035; F9995-1129; AC1M4H5X; SCHEMBL1778037; 3-Cyano(1-methyl-1H-indole); CTK4F4137; FBAXZPMXGBNBPE-UHFFFAOYSA-; DTXSID30367996; MolPort-000-002-609; FBAXZPMXGBNBPE-UHFFFAOYSA-N; HMS1753J21; ZINC3165608; BDBM50182877; STK386450; MFCD00466602; AKOS001015339; MCULE-7170650231; AS-9400; AJ-44684; KB-12784; DA-07730; ST50875554; AM20040004; FT-0719960
DML5FQT	DT	Small molecular drug
DML5FQT	PC	2307681
DML5FQT	MW	156.18
DML5FQT	FM	C10H8N2
DML5FQT	IC	InChI=1S/C10H8N2/c1-12-7-8(6-11)9-4-2-3-5-10(9)12/h2-5,7H,1H3
DML5FQT	CS	CN1C=C(C2=CC=CC=C21)C#N
DML5FQT	IK	FBAXZPMXGBNBPE-UHFFFAOYSA-N
DML5FQT	IU	1-methylindole-3-carbonitrile
DML5FQT	CA	CAS 24662-37-1
DML5FQT	DE	Discovery agent

DMUKAH6	ID	DMUKAH6
DMUKAH6	DN	1-methyl-1H-indole-3-carboxamide
DMUKAH6	HS	Investigative
DMUKAH6	SN	1-methyl-1H-indole-3-carboxamide; 118959-44-7; 1H-Indole-3-carboxamide, 1-methyl-; 1-methylindole-3-carboxamide; CHEMBL382602; AC1LGL0W; ACMC-20mo37; MLS001049055; SCHEMBL2174829; CTK0F9691; DTXSID00356397; MolPort-002-560-820; UHQHFXKJFJHBAE-UHFFFAOYSA-N; HMS2271M13; ZINC341025; BDBM50427552; STK721948; AKOS009024585; MCULE-8790085472; AS-9399; SMR000386893; AJ-19941; KB-219182; FT-0721669
DMUKAH6	DT	Small molecular drug
DMUKAH6	PC	823187
DMUKAH6	MW	174.2
DMUKAH6	FM	C10H10N2O
DMUKAH6	IC	InChI=1S/C10H10N2O/c1-12-6-8(10(11)13)7-4-2-3-5-9(7)12/h2-6H,1H3,(H2,11,13)
DMUKAH6	CS	CN1C=C(C2=CC=CC=C21)C(=O)N
DMUKAH6	IK	UHQHFXKJFJHBAE-UHFFFAOYSA-N
DMUKAH6	IU	1-methylindole-3-carboxamide
DMUKAH6	CA	CAS 118959-44-7
DMUKAH6	DE	Discovery agent

DMYU348	ID	DMYU348
DMYU348	DN	1-Methyl-2-(4-phenylsulfanyl-phenyl)-ethylamine
DMYU348	HS	Investigative
DMYU348	SN	CHEMBL1078716; 1-Methyl-2-(4-phenylsulfanyl-phenyl)-ethylamine; BDBM50310835
DMYU348	DT	Small molecular drug
DMYU348	PC	44613329
DMYU348	MW	243.4
DMYU348	FM	C15H17NS
DMYU348	IC	InChI=1S/C15H17NS/c1-12(16)11-13-7-9-15(10-8-13)17-14-5-3-2-4-6-14/h2-10,12H,11,16H2,1H3
DMYU348	CS	CC(CC1=CC=C(C=C1)SC2=CC=CC=C2)N
DMYU348	IK	FPOOXERVBCKPAG-UHFFFAOYSA-N
DMYU348	IU	1-(4-phenylsulfanylphenyl)propan-2-amine
DMYU348	DE	Discovery agent

DM5GELS	ID	DM5GELS
DM5GELS	DN	1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine
DM5GELS	HS	Investigative
DM5GELS	SN	1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine; 1,5,5-trimethylpyrrolidin-2-one; 119715-71-8; AC1L9GJJ; SCHEMBL4329315; 1,5,5-trimethylpyrrolid-2one; CHEBI:43533; 1,5,5-Trimethyl-2-pyrrolidone; 1,5,5-trimethylpyrrolid-2-one; YARDEGUIPATLSG-UHFFFAOYSA-N; 1,5,5-trimethyl-pyrrolidin-2-one; 2-Pyrrolidinone, 1,5,5-trimethyl-; DB03968
DM5GELS	DT	Small molecular drug
DM5GELS	PC	444570
DM5GELS	MW	127.18
DM5GELS	FM	C7H13NO
DM5GELS	IC	InChI=1S/C7H13NO/c1-7(2)5-4-6(9)8(7)3/h4-5H2,1-3H3
DM5GELS	CS	CC1(CCC(=O)N1C)C
DM5GELS	IK	YARDEGUIPATLSG-UHFFFAOYSA-N
DM5GELS	IU	1,5,5-trimethylpyrrolidin-2-one
DM5GELS	CA	CAS 119715-71-8
DM5GELS	CB	CHEBI:43533
DM5GELS	DE	Discovery agent

DMC3IGK	ID	DMC3IGK
DMC3IGK	DN	1-methyl-3-(phenylcarbamoyloxy)pyridinium bromide
DMC3IGK	HS	Investigative
DMC3IGK	SN	CHEMBL1173603
DMC3IGK	DT	Small molecular drug
DMC3IGK	PC	49799304
DMC3IGK	MW	229.25
DMC3IGK	FM	C13H13N2O2+
DMC3IGK	IC	InChI=1S/C13H12N2O2/c1-15-9-5-8-12(10-15)17-13(16)14-11-6-3-2-4-7-11/h2-10H,1H3/p+1
DMC3IGK	CS	C[N+]1=CC=CC(=C1)OC(=O)NC2=CC=CC=C2
DMC3IGK	IK	HFCGFRPAGMNQAZ-UHFFFAOYSA-O
DMC3IGK	IU	(1-methylpyridin-1-ium-3-yl) N-phenylcarbamate
DMC3IGK	DE	Discovery agent

DMICQWN	ID	DMICQWN
DMICQWN	DN	1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
DMICQWN	HS	Investigative
DMICQWN	SN	1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID; (2-METHYL-5-PHENYL-2H-PYRAZOL-3-YL)-SULFAMIC ACID; UN3; AC1NS1QY; SULFAMIC ACID Analog 13; BDBM13529; DB04800; (2-methyl-5-phenylpyrazol-3-yl)sulfamic acid; N-(2-methyl-5-phenylpyrazol-3-yl)sulfamic acid; (1-methyl-3-phenyl-1H-pyrazol-5-yl)sulfamic acid; N-(1-methyl-3-phenyl-1H-pyrazol-5-yl)sulfamic acid
DMICQWN	DT	Small molecular drug
DMICQWN	PC	5327154
DMICQWN	MW	253.28
DMICQWN	FM	C10H11N3O3S
DMICQWN	IC	InChI=1S/C10H11N3O3S/c1-13-10(12-17(14,15)16)7-9(11-13)8-5-3-2-4-6-8/h2-7,12H,1H3,(H,14,15,16)
DMICQWN	CS	CN1C(=CC(=N1)C2=CC=CC=C2)NS(=O)(=O)O
DMICQWN	IK	OTZLVSGSRPNRFT-UHFFFAOYSA-N
DMICQWN	IU	(2-methyl-5-phenylpyrazol-3-yl)sulfamic acid
DMICQWN	DE	Discovery agent

DM90LWT	ID	DM90LWT
DM90LWT	DN	1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione
DM90LWT	HS	Investigative
DM90LWT	SN	Xanthine, 1-methyl-3-propyl-; 1-methyl-3-propyl-7H-purine-2,6-dione; CHEMBL286976; 118024-67-2; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-propyl-; 1H-Purine-2,6-dione,3,9-dihydro-3-methyl-1-propyl-; AC1L3BCB; 1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione; SCHEMBL9765669; CTK5D5561; ZINC4770328; BDBM50001509; AKOS030229248
DM90LWT	DT	Small molecular drug
DM90LWT	PC	86344
DM90LWT	MW	208.22
DM90LWT	FM	C9H12N4O2
DM90LWT	IC	InChI=1S/C9H12N4O2/c1-3-4-13-7-6(10-5-11-7)8(14)12(2)9(13)15/h5H,3-4H2,1-2H3,(H,10,11)
DM90LWT	CS	CCCN1C2=C(C(=O)N(C1=O)C)NC=N2
DM90LWT	IK	MCPROACZLSAAPY-UHFFFAOYSA-N
DM90LWT	IU	1-methyl-3-propyl-7H-purine-2,6-dione
DM90LWT	CA	CAS 118024-67-2
DM90LWT	CB	CHEBI:145517
DM90LWT	DE	Discovery agent

DMBWSCR	ID	DMBWSCR
DMBWSCR	DN	1-Methyl-4-(1-phenyl-ethyl)-piperazine
DMBWSCR	HS	Investigative
DMBWSCR	SN	CHEMBL195009; 1-Methyl-4-(1-phenyl-ethyl)-piperazine; SCHEMBL2625061; BDBM50174064
DMBWSCR	DT	Small molecular drug
DMBWSCR	PC	14364677
DMBWSCR	MW	204.31
DMBWSCR	FM	C13H20N2
DMBWSCR	IC	InChI=1S/C13H20N2/c1-12(13-6-4-3-5-7-13)15-10-8-14(2)9-11-15/h3-7,12H,8-11H2,1-2H3
DMBWSCR	CS	CC(C1=CC=CC=C1)N2CCN(CC2)C
DMBWSCR	IK	CQTKDGNXBCFBTR-UHFFFAOYSA-N
DMBWSCR	IU	1-methyl-4-(1-phenylethyl)piperazine
DMBWSCR	DE	Discovery agent

DMPWB8G	ID	DMPWB8G
DMPWB8G	DN	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
DMPWB8G	HS	Investigative
DMPWB8G	SN	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPTP; 28289-54-5; CCRIS 2186; 1,2,3,6-Tetrahydro-1-methyl-4-phenylpyridine; HSDB 6942; PYRIDINE, 1,2,3,6-TETRAHYDRO-1-METHYL-4-PHENYL-; 1-METHYL-4-PHENYL-PIPERIDINE-3-EN; UNII-9P21XSP91P; N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NSC 139654; EINECS 248-939-7; 1-Methyl-4-phenyl-1,2,3,6-tetrahydroxpyridine; BRN 0133712; CHEMBL24172; 9P21XSP91P; 1-methyl-4-phenyl-3,6-dihydro-2H-pyridine; CHEBI:17963; 1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine; PLRACCBDVIHHLZ-UHFFFAOYSA-N
DMPWB8G	DT	Small molecular drug
DMPWB8G	PC	1388
DMPWB8G	MW	173.25
DMPWB8G	FM	C12H15N
DMPWB8G	IC	InChI=1S/C12H15N/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11/h2-7H,8-10H2,1H3
DMPWB8G	CS	CN1CCC(=CC1)C2=CC=CC=C2
DMPWB8G	IK	PLRACCBDVIHHLZ-UHFFFAOYSA-N
DMPWB8G	IU	1-methyl-4-phenyl-3,6-dihydro-2H-pyridine
DMPWB8G	CA	CAS 28289-54-5
DMPWB8G	CB	CHEBI:17963
DMPWB8G	DE	Discovery agent

DM6XFMT	ID	DM6XFMT
DM6XFMT	DN	1-Methyl-4-p-tolyl-piperidine-4-carbonitrile
DM6XFMT	HS	Investigative
DM6XFMT	SN	CHEMBL111498; 1-Methyl-4-p-tolyl-piperidine-4-carbonitrile; 1-methyl-4-(4-methylphenyl)piperidine-4-carbonitrile; ZINC13610036; BDBM50083527
DM6XFMT	DT	Small molecular drug
DM6XFMT	PC	11184286
DM6XFMT	MW	214.31
DM6XFMT	FM	C14H18N2
DM6XFMT	IC	InChI=1S/C14H18N2/c1-12-3-5-13(6-4-12)14(11-15)7-9-16(2)10-8-14/h3-6H,7-10H2,1-2H3
DM6XFMT	CS	CC1=CC=C(C=C1)C2(CCN(CC2)C)C#N
DM6XFMT	IK	UWFQWENRHDTJQQ-UHFFFAOYSA-N
DM6XFMT	IU	1-methyl-4-(4-methylphenyl)piperidine-4-carbonitrile
DM6XFMT	DE	Discovery agent

DM4HS92	ID	DM4HS92
DM4HS92	DN	1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one
DM4HS92	HS	Investigative
DM4HS92	SN	CHEMBL56908; 1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one; BDBM50091710; 1-Methyl-5-[(E)-azobenzene-4-yl]piperidine-2-one
DM4HS92	DT	Small molecular drug
DM4HS92	PC	10017278
DM4HS92	MW	293.4
DM4HS92	FM	C18H19N3O
DM4HS92	IC	InChI=1S/C18H19N3O/c1-21-13-15(9-12-18(21)22)14-7-10-17(11-8-14)20-19-16-5-3-2-4-6-16/h2-8,10-11,15H,9,12-13H2,1H3
DM4HS92	CS	CN1CC(CCC1=O)C2=CC=C(C=C2)N=NC3=CC=CC=C3
DM4HS92	IK	GUDNFCRTZUCEOP-UHFFFAOYSA-N
DM4HS92	IU	1-methyl-5-(4-phenyldiazenylphenyl)piperidin-2-one
DM4HS92	DE	Discovery agent

DMX2FWN	ID	DMX2FWN
DMX2FWN	DN	1-Methyl-5-oxa-spiro[2.4]heptan-4-one
DMX2FWN	HS	Investigative
DMX2FWN	SN	SCHEMBL19526372
DMX2FWN	DT	Small molecular drug
DMX2FWN	PC	12421856
DMX2FWN	MW	126.15
DMX2FWN	FM	C7H10O2
DMX2FWN	IC	InChI=1S/C7H10O2/c1-5-4-7(5)2-3-9-6(7)8/h5H,2-4H2,1H3
DMX2FWN	CS	CC1CC12CCOC2=O
DMX2FWN	IK	FQIBVSQKGHYUKI-UHFFFAOYSA-N
DMX2FWN	IU	2-methyl-5-oxaspiro[2.4]heptan-4-one
DMX2FWN	DE	Discovery agent

DMB3JO2	ID	DMB3JO2
DMB3JO2	DN	1-Methyl-5-phenyl-piperidin-2-one
DMB3JO2	HS	Investigative
DMB3JO2	SN	1-Methyl-5-phenyl-piperidin-2-one; CHEMBL55261; SCHEMBL16591470; 1-Methyl-5-phenylpiperidine-2-one; BDBM50091702
DMB3JO2	DT	Small molecular drug
DMB3JO2	PC	12012176
DMB3JO2	MW	189.25
DMB3JO2	FM	C12H15NO
DMB3JO2	IC	InChI=1S/C12H15NO/c1-13-9-11(7-8-12(13)14)10-5-3-2-4-6-10/h2-6,11H,7-9H2,1H3
DMB3JO2	CS	CN1CC(CCC1=O)C2=CC=CC=C2
DMB3JO2	IK	ASTTXNJRFSDNDJ-UHFFFAOYSA-N
DMB3JO2	IU	1-methyl-5-phenylpiperidin-2-one
DMB3JO2	DE	Discovery agent

DMSTH24	ID	DMSTH24
DMSTH24	DN	1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSTH24	HS	Investigative
DMSTH24	SN	2850-37-5; CHEMBL9069; 1-methyl-8-phenylxanthine; NSC282736; CBMicro_029762; Cambridge id 5733876; AC1L88FA; Oprea1_619029; Oprea1_215826; 1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione; SCHEMBL515920; 1-methyl-8-phenyl-3,9-dihydro-1H-purine-2,6-dione; SCHEMBL13977442; CTK8I0059; DTXSID40314411; MolPort-002-516-863; MolPort-000-816-326; STK169388; ZINC18270697; BDBM50018157; AKOS005409446; NSC-282736; MCULE-2769568078; BIM-0029837.P001; 1-methyl-8-phenyl-3,7-dihydropurine-2,6-dione; 1-methyl-8-phenyl-1H-purine-2,6(3H,9H)-dione
DMSTH24	DT	Small molecular drug
DMSTH24	PC	323342
DMSTH24	MW	242.23
DMSTH24	FM	C12H10N4O2
DMSTH24	IC	InChI=1S/C12H10N4O2/c1-16-11(17)8-10(15-12(16)18)14-9(13-8)7-5-3-2-4-6-7/h2-6H,1H3,(H,13,14)(H,15,18)
DMSTH24	CS	CN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=CC=C3
DMSTH24	IK	UOOOWRVLSKCKGJ-UHFFFAOYSA-N
DMSTH24	IU	1-methyl-8-phenyl-3,7-dihydropurine-2,6-dione
DMSTH24	CA	CAS 2850-37-5
DMSTH24	DE	Discovery agent

DMDIH07	ID	DMDIH07
DMDIH07	DN	1-methylcyclopropanecarboxylic acid
DMDIH07	HS	Investigative
DMDIH07	SN	1-Methylcyclopropane-1-carboxylic acid; 6914-76-7; 1-Methylcyclopropanecarboxylic acid; 1-Methyl-cyclopropanecarboxylic acid; Cyclopropanecarboxylic acid, 1-methyl-; DIZKLZKLNKQFGB-UHFFFAOYSA-N; Cyclopropanecarboxylicacid, 1-methyl-; 1-Methylcyclopropanecarboxylic acid, 98%; EINECS 230-020-7; PubChem16037; AC1Q5TAN; AC1Q2CXA; 1-methylcyclopropanoic acid; ACMC-209o6g; SCHEMBL113962; 1-Carboxy-1-methylcyclopropane; GTPL6500; DIZKLZKLNKQFGB-UHFFFAOYSA-; CTK2F4732; Methyl-cyclopropanecarboxylic acid; DTXSID50219201
DMDIH07	DT	Small molecular drug
DMDIH07	PC	81326
DMDIH07	MW	100.12
DMDIH07	FM	C5H8O2
DMDIH07	IC	InChI=1S/C5H8O2/c1-5(2-3-5)4(6)7/h2-3H2,1H3,(H,6,7)
DMDIH07	CS	CC1(CC1)C(=O)O
DMDIH07	IK	DIZKLZKLNKQFGB-UHFFFAOYSA-N
DMDIH07	IU	1-methylcyclopropane-1-carboxylic acid
DMDIH07	CA	CAS 6914-76-7
DMDIH07	DE	Discovery agent

DMFR7JW	ID	DMFR7JW
DMFR7JW	DN	1-Methyloxy-4-Sulfone-Benzene
DMFR7JW	HS	Investigative
DMFR7JW	SN	1-METHYLOXY-4-SULFONE-BENZENE; 4-methoxybenzenesulfinate; AC1MZTZ7; SCHEMBL13838953; YVZWQPOTHRMEQW-UHFFFAOYSA-M; SBB082464; 1-(dioxidosulfanyl)-4-methoxybenzene; ZINC150339282; AKOS004898433; DB03033
DMFR7JW	DT	Small molecular drug
DMFR7JW	PC	3952261
DMFR7JW	MW	171.2
DMFR7JW	FM	C7H7O3S-
DMFR7JW	IC	InChI=1S/C7H8O3S/c1-10-6-2-4-7(5-3-6)11(8)9/h2-5H,1H3,(H,8,9)/p-1
DMFR7JW	CS	COC1=CC=C(C=C1)S(=O)[O-]
DMFR7JW	IK	YVZWQPOTHRMEQW-UHFFFAOYSA-M
DMFR7JW	IU	4-methoxybenzenesulfinate
DMFR7JW	DE	Discovery agent

DM2WQ1E	ID	DM2WQ1E
DM2WQ1E	DN	1-METHYLXANTHINE
DM2WQ1E	HS	Investigative
DM2WQ1E	SN	1-Methylxanthine; 6136-37-4; 1-Methyl-3,7-dihydro-purine-2,6-dione; 1-Methyl-1H-purine-2,6(3H,7H)-dione; Methylxanthine; Xanthine, 1-methyl-; UNII-7EE8WCA32U; 2,6-Dihydroxy-1-methylpurine; CCRIS 5816; 1-methyl-7H-xanthine; EINECS 228-108-5; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-; 7EE8WCA32U; CHEMBL1250; 2,6 Dihydroxy-1-methylpurine; CHEBI:68444; 3,7-Dihydro-1-methyl-1H-purine-2,6-dione; MVOYJPOZRLFTCP-UHFFFAOYSA-N; 1-methyl-3,7-dihydropurine-2,6-dione; 1-methyl-3,9-dihydropurine-2,6-dione
DM2WQ1E	DT	Small molecular drug
DM2WQ1E	PC	80220
DM2WQ1E	MW	166.14
DM2WQ1E	FM	C6H6N4O2
DM2WQ1E	IC	InChI=1S/C6H6N4O2/c1-10-5(11)3-4(8-2-7-3)9-6(10)12/h2H,1H3,(H,7,8)(H,9,12)
DM2WQ1E	CS	CN1C(=O)C2=C(NC1=O)N=CN2
DM2WQ1E	IK	MVOYJPOZRLFTCP-UHFFFAOYSA-N
DM2WQ1E	IU	1-methyl-3,7-dihydropurine-2,6-dione
DM2WQ1E	CA	CAS 6136-37-4
DM2WQ1E	CB	CHEBI:68444
DM2WQ1E	DE	Discovery agent

DMYOJ01	ID	DMYOJ01
DMYOJ01	DN	1-Morpholin-4-yl-benzo[f]chromen-3-one
DMYOJ01	HS	Investigative
DMYOJ01	SN	CHEMBL178969; 1-Morpholin-4-yl-benzo[f]chromen-3-one
DMYOJ01	DT	Small molecular drug
DMYOJ01	PC	11277489
DMYOJ01	MW	281.3
DMYOJ01	FM	C17H15NO3
DMYOJ01	IC	InChI=1S/C17H15NO3/c19-16-11-14(18-7-9-20-10-8-18)17-13-4-2-1-3-12(13)5-6-15(17)21-16/h1-6,11H,7-10H2
DMYOJ01	CS	C1COCCN1C2=CC(=O)OC3=C2C4=CC=CC=C4C=C3
DMYOJ01	IK	BYCFTTKUJHROAO-UHFFFAOYSA-N
DMYOJ01	IU	1-morpholin-4-ylbenzo[f]chromen-3-one
DMYOJ01	DE	Discovery agent

DM0A1YI	ID	DM0A1YI
DM0A1YI	DN	1na
DM0A1YI	HS	Investigative
DM0A1YI	SN	3946-01-8; Methyl 2-acetamido-2-deoxy-beta-D-glucopyranoside; N-((2R,3R,4R,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3-yl)acetamide; Alpha-Methyl-N-Acetyl-D-Glucosamine; Beta-Methyl-N-Acetyl-D-Glucosamine; Methyl 2-acetamido-2-deoxy-b-D-glucopyranoside; AC1L9IIR; SCHEMBL1673962; ZEVOCXOZYFLVKN-JGKVKWKGSA-N; MolPort-000-189-911; ZINC5234411; methyl n-acetyl-beta-d-glucosaminide; AKOS002687842; N-ACETYL-O-METHYL-D-GLUCOSAMINE; DB04426; N-acetyl-1-O-methyl-beta-d-glucosamine
DM0A1YI	DT	Small molecular drug
DM0A1YI	PC	445750
DM0A1YI	MW	235.23
DM0A1YI	FM	C9H17NO6
DM0A1YI	IC	InChI=1S/C9H17NO6/c1-4(12)10-6-8(14)7(13)5(3-11)16-9(6)15-2/h5-9,11,13-14H,3H2,1-2H3,(H,10,12)/t5-,6-,7-,8-,9-/m1/s1
DM0A1YI	CS	CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC)CO)O)O
DM0A1YI	IK	ZEVOCXOZYFLVKN-JGKVKWKGSA-N
DM0A1YI	IU	N-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide
DM0A1YI	DE	Discovery agent

DMF87Z5	ID	DMF87Z5
DMF87Z5	DN	1-N-Acetyl-Beta-D-Glucosamine
DMF87Z5	HS	Investigative
DMF87Z5	SN	1-N-ACETYL-BETA-D-GLUCOSAMINE; N-Acetyl-beta-D-glucopyranosylamine; CHEMBL335315; N-beta-D-Glucopyranosylacetamide; NBG; 6983-36-4; Acetamide, N-beta-D-glucopyranosyl-; 2prj; AC1L9HVU; SCHEMBL4388634; n-acetyl-b-d-glucopyranosylamine; BDBM50240802; DB02320; N-(3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yl)-acetamide; N-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide
DMF87Z5	DT	Small molecular drug
DMF87Z5	PC	445382
DMF87Z5	MW	221.21
DMF87Z5	FM	C8H15NO6
DMF87Z5	IC	InChI=1S/C8H15NO6/c1-3(11)9-8-7(14)6(13)5(12)4(2-10)15-8/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6+,7-,8-/m1/s1
DMF87Z5	CS	CC(=O)N[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMF87Z5	IK	IBONACLSSOLHFU-JAJWTYFOSA-N
DMF87Z5	IU	N-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide
DMF87Z5	CA	CAS 6983-36-4
DMF87Z5	DE	Discovery agent

DMTBZJL	ID	DMTBZJL
DMTBZJL	DN	1-Naphthalen-2-yl-1H-imidazole
DMTBZJL	HS	Investigative
DMTBZJL	SN	1-(naphthalen-2-yl)-1H-imidazole; 1-(2-naphthyl)-1h-imidazole; 25372-01-4; 1H-Imidazole, 1-(2-naphthalenyl)-; SCHEMBL2071832; CHEMBL195996; BDBM8916; MolPort-009-323-053; Imidazole-substituted naphthalene 23; ZINC13674480; AKOS034336039; MCULE-9753314459
DMTBZJL	DT	Small molecular drug
DMTBZJL	PC	23644748
DMTBZJL	MW	194.23
DMTBZJL	FM	C13H10N2
DMTBZJL	IC	InChI=1S/C13H10N2/c1-2-4-12-9-13(6-5-11(12)3-1)15-8-7-14-10-15/h1-10H
DMTBZJL	CS	C1=CC=C2C=C(C=CC2=C1)N3C=CN=C3
DMTBZJL	IK	LHAAPZJTEBPKBJ-UHFFFAOYSA-N
DMTBZJL	IU	1-naphthalen-2-ylimidazole
DMTBZJL	DE	Discovery agent

DMU04ZQ	ID	DMU04ZQ
DMU04ZQ	DN	1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one
DMU04ZQ	HS	Investigative
DMU04ZQ	SN	naphyrone; 1-(Naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one; 850352-11-3; 850352-53-3; Naphyrone (O-2482); CHEMBL204759; naphthylpyrovalerone; beta-Naphyrone; O-2482; 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4939526; DEA No. 1258; CTK8C0838; ACT06821; BDBM50182546; ANW-65341; AKOS015898953; KB-215797; AX8234386; AB1004335; TC-154086; I14-12001; 1-Pentanone, 1-(2-naphthalenyl)-2-(1-pyrrolidinyl)-; 850352-53-3,850352-11-3(HCl); 1-(1-(naphthalen-2-yl)-1-oxopentan-2-yl)pyrrolidinium chloride
DMU04ZQ	DT	Small molecular drug
DMU04ZQ	PC	11243002
DMU04ZQ	MW	281.4
DMU04ZQ	FM	C19H23NO
DMU04ZQ	IC	InChI=1S/C19H23NO/c1-2-7-18(20-12-5-6-13-20)19(21)17-11-10-15-8-3-4-9-16(15)14-17/h3-4,8-11,14,18H,2,5-7,12-13H2,1H3
DMU04ZQ	CS	CCCC(C(=O)C1=CC2=CC=CC=C2C=C1)N3CCCC3
DMU04ZQ	IK	DTNUPBSOODGRKW-UHFFFAOYSA-N
DMU04ZQ	IU	1-naphthalen-2-yl-2-pyrrolidin-1-ylpentan-1-one
DMU04ZQ	CA	CAS 850352-53-3
DMU04ZQ	DE	Discovery agent

DMJK0MF	ID	DMJK0MF
DMJK0MF	DN	1-Naphthalen-2-yl-piperazine
DMJK0MF	HS	Investigative
DMJK0MF	SN	1-(naphthalen-2-yl)piperazine; 57536-91-1; 1-Naphthalen-2-yl-piperazine; 1-(2-NAPHTHYL)PIPERAZINE; CHEMBL278509; 1-naphthalen-2-ylpiperazine; Oprea1_405543; AC1MC234; SCHEMBL3138664; LWLBVIFUVSUSAY-UHFFFAOYSA-N; ZINC3716177; SBB076290; BDBM50007411; AKOS003591179; MCULE-5668438904
DMJK0MF	DT	Small molecular drug
DMJK0MF	PC	2760172
DMJK0MF	MW	212.29
DMJK0MF	FM	C14H16N2
DMJK0MF	IC	InChI=1S/C14H16N2/c1-2-4-13-11-14(6-5-12(13)3-1)16-9-7-15-8-10-16/h1-6,11,15H,7-10H2
DMJK0MF	CS	C1CN(CCN1)C2=CC3=CC=CC=C3C=C2
DMJK0MF	IK	LWLBVIFUVSUSAY-UHFFFAOYSA-N
DMJK0MF	IU	1-naphthalen-2-ylpiperazine
DMJK0MF	DE	Discovery agent

DM6BIWK	ID	DM6BIWK
DM6BIWK	DN	1-naphthylpiperazine
DM6BIWK	HS	Investigative
DM6BIWK	SN	1-(1-Naphthyl)piperazine; 1-Naphthylpiperazine; 57536-86-4; 1-(naphthalen-1-yl)piperazine; 1-naphthalen-1-ylpiperazine; 1-Naphthalen-1-yl-piperazine; CHEMBL277120; Piperazine, 1-(1-naphthalenyl)-; Piperazine,1-(1-naphthalenyl)-; 4-(naphth-1-yl)piperazine; Naphthylpiperazine; GTPL3; Lopac-S-003; AC1Q1INU; N-(1-naphthyl)piperazine; 4-(1-naphthyl)piperazine; Biomol-NT_000100; N-(1- naphthyl)piperazine; N-(1-naphthyl)-piperazine; N-(1-naphthyl) piperazine; AC1L1B9K; 4-(1-naphthyl) piperazine; 1-(naphth-1-yl)piperazine; Oprea1_621306;  1-NP
DM6BIWK	DT	Small molecular drug
DM6BIWK	PC	1342
DM6BIWK	MW	212.29
DM6BIWK	FM	C14H16N2
DM6BIWK	IC	InChI=1S/C14H16N2/c1-2-6-13-12(4-1)5-3-7-14(13)16-10-8-15-9-11-16/h1-7,15H,8-11H2
DM6BIWK	CS	C1CN(CCN1)C2=CC=CC3=CC=CC=C32
DM6BIWK	IK	VNICFCQJUVFULD-UHFFFAOYSA-N
DM6BIWK	IU	1-naphthalen-1-ylpiperazine
DM6BIWK	CA	CAS 57536-86-4
DM6BIWK	CB	CHEBI:108599
DM6BIWK	DE	Discovery agent

DMP6VOK	ID	DMP6VOK
DMP6VOK	DN	1-nitro-2-(2-nitrophenylsulfonyl)benzene
DMP6VOK	HS	Investigative
DMP6VOK	SN	Bis(2-nitrophenyl)sulfone; NSC633001; 14665-52-2; Benzene, 1,1'-sulfonylbis[2-nitro-; NSC-633001; 1-nitro-2-[(2-nitrophenyl)sulfonyl]benzene; Bis(2NO2Ph)SO2; AC1Q6URW; AC1L7QPG; NCIMech_000590; MLS001196654; SCHEMBL2039879; BDBM1780; CHEMBL415959; CTK0E9275; DTXSID40327122; MolPort-006-834-474; Benzene,1'-sulfonylbis(2-nitro-; HMS2872L23; ZINC1622822; CCG-35737; AKOS001662347; MCULE-4947941526; 1-nitro-2-(2-nitrophenyl)sulfonylbenzene; 2-Amino-6-arylthiobenzonitrile deriv. 4b; SMR000556031; NCI60_010909
DMP6VOK	DT	Small molecular drug
DMP6VOK	PC	365388
DMP6VOK	MW	308.27
DMP6VOK	FM	C12H8N2O6S
DMP6VOK	IC	InChI=1S/C12H8N2O6S/c15-13(16)9-5-1-3-7-11(9)21(19,20)12-8-4-2-6-10(12)14(17)18/h1-8H
DMP6VOK	CS	C1=CC=C(C(=C1)[N+](=O)[O-])S(=O)(=O)C2=CC=CC=C2[N+](=O)[O-]
DMP6VOK	IK	IHZVFZOUXUNSPQ-UHFFFAOYSA-N
DMP6VOK	IU	1-nitro-2-(2-nitrophenyl)sulfonylbenzene
DMP6VOK	CA	CAS 14665-52-2
DMP6VOK	DE	Discovery agent

DM9OJ7T	ID	DM9OJ7T
DM9OJ7T	DN	1-Octyl-3-(1-propionylpiperidin-4-yl)urea
DM9OJ7T	HS	Investigative
DM9OJ7T	SN	CHEMBL1257514; 1-Octyl-3-(1-propionylpiperidin-4-yl)urea; SCHEMBL2721029
DM9OJ7T	DT	Small molecular drug
DM9OJ7T	PC	49782570
DM9OJ7T	MW	311.5
DM9OJ7T	FM	C17H33N3O2
DM9OJ7T	IC	InChI=1S/C17H33N3O2/c1-3-5-6-7-8-9-12-18-17(22)19-15-10-13-20(14-11-15)16(21)4-2/h15H,3-14H2,1-2H3,(H2,18,19,22)
DM9OJ7T	CS	CCCCCCCCNC(=O)NC1CCN(CC1)C(=O)CC
DM9OJ7T	IK	QCBCCMKAGKJZIU-UHFFFAOYSA-N
DM9OJ7T	IU	1-octyl-3-(1-propanoylpiperidin-4-yl)urea
DM9OJ7T	DE	Discovery agent

DMYHMEK	ID	DMYHMEK
DMYHMEK	DN	1-OH-PGE1
DMYHMEK	HS	Investigative
DMYHMEK	SN	19-hydroxy-PGE1; 19-hydroxyprostaglandin E1; 19-OH PGE1
DMYHMEK	DT	Small molecular drug
DMYHMEK	PC	6438402
DMYHMEK	MW	370.5
DMYHMEK	FM	C20H34O6
DMYHMEK	IC	InChI=1S/C20H34O6/c1-14(21)7-6-8-15(22)11-12-17-16(18(23)13-19(17)24)9-4-2-3-5-10-20(25)26/h11-12,14-17,19,21-22,24H,2-10,13H2,1H3,(H,25,26)/b12-11+/t14?,15-,16+,17+,19+/m0/s1
DMYHMEK	CS	CC(CCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O)O
DMYHMEK	IK	QVVXWHIDRKRPMO-LXCOYWBSSA-N
DMYHMEK	IU	7-[(1R,2R,3R)-2-[(E,3S)-3,7-dihydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]heptanoic acid
DMYHMEK	CA	CAS 55123-67-6
DMYHMEK	DE	Discovery agent

DM5KU8S	ID	DM5KU8S
DM5KU8S	DN	1-oleoyl glycerol
DM5KU8S	HS	Investigative
DM5KU8S	SN	2,3-Dihydroxypropyl oleate; Monoolein; Glyceryl monooleate; 1-Monoolein; 111-03-5; 1-Oleoylglycerol; Glyceryl oleate; 1-Oleoyl-rac-glycerol; 1-Glyceryl oleate; 1-Monooleoylglycerol; Glycerol 1-monooleate; rac-1-Monoolein; Aldo MO; Aldo HMO; Danisco MO 90; 1-Monooleoyl-rac-glycerol; Glycerin 1-monooleate; Monooleoylglycerol; Oleic monoglyceride; rac-1-Monooleoylglycerol; Olein, 1-mono-; Oleoylglycerol; Olicine; Peceol; Supeol; alpha-Monoolein; Sinnoester ogc; Oleylmonoglyceride; Emalsy MO; Emalsy OL; Dimodan LSQK; Glycerol alpha-monooleat
DM5KU8S	DT	Small molecular drug
DM5KU8S	PC	5283468
DM5KU8S	MW	356.5
DM5KU8S	FM	C21H40O4
DM5KU8S	IC	InChI=1S/C21H40O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h9-10,20,22-23H,2-8,11-19H2,1H3/b10-9-
DM5KU8S	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OCC(CO)O
DM5KU8S	IK	RZRNAYUHWVFMIP-KTKRTIGZSA-N
DM5KU8S	IU	2,3-dihydroxypropyl (Z)-octadec-9-enoate
DM5KU8S	CA	CAS 111-03-5
DM5KU8S	CB	CHEBI:75342
DM5KU8S	DE	Discovery agent

DMPMGLO	ID	DMPMGLO
DMPMGLO	DN	1-Oxazolo[4,5-b]pyridin-2-yl-6-phenyl-hexan-1-one
DMPMGLO	HS	Investigative
DMPMGLO	SN	PHOP; 288862-83-9; CHEMBL175854; 1-(oxazolo[4,5-b]pyridin-2-yl)-6-phenylhexan-1-one; 1-Oxazolo[4,5-b]pyridin-2-yl-6-phenyl-hexan-1-one; SCHEMBL3964367; CTK8E9849; LEI-104; DTXSID10435440; MolPort-009-018-760; HMS3649E22; ZINC13611906; BDBM50161518; ACM288862839; RT-015038; SR-01000946606; J-017316; SR-01000946606-1
DMPMGLO	DT	Small molecular drug
DMPMGLO	PC	10085812
DMPMGLO	MW	294.3
DMPMGLO	FM	C18H18N2O2
DMPMGLO	IC	InChI=1S/C18H18N2O2/c21-15(18-20-17-16(22-18)12-7-13-19-17)11-6-2-5-10-14-8-3-1-4-9-14/h1,3-4,7-9,12-13H,2,5-6,10-11H2
DMPMGLO	CS	C1=CC=C(C=C1)CCCCCC(=O)C2=NC3=C(O2)C=CC=N3
DMPMGLO	IK	VPZHQLPAKFVGKX-UHFFFAOYSA-N
DMPMGLO	IU	1-([1,3]oxazolo[4,5-b]pyridin-2-yl)-6-phenylhexan-1-one
DMPMGLO	CA	CAS 288862-83-9
DMPMGLO	DE	Discovery agent

DM9BY8D	ID	DM9BY8D
DM9BY8D	DN	1-Oxazolo[4,5-b]pyridin-2-yl-octadec-9-yn-1-one
DM9BY8D	HS	Investigative
DM9BY8D	SN	1-oxazolo[4,5-b]pyridin-2-yl-9-octadecyn-1-one; 288862-89-5; CHEMBL175580; 1-Oxazolo[4,5-b]pyridin-2-yl-octadec-9-yn-1-one; SCHEMBL1811297; CTK8E3290; DTXSID50433602; HMS3649E20; BDBM50163152; ZINC34803574; ACM288862895; RT-006406; SR-01000946605; SR-01000946605-1; J-017317
DM9BY8D	DT	Small molecular drug
DM9BY8D	PC	9977214
DM9BY8D	MW	382.5
DM9BY8D	FM	C24H34N2O2
DM9BY8D	IC	InChI=1S/C24H34N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-21(27)24-26-23-22(28-24)19-17-20-25-23/h17,19-20H,2-8,11-16,18H2,1H3
DM9BY8D	CS	CCCCCCCCC#CCCCCCCCC(=O)C1=NC2=C(O1)C=CC=N2
DM9BY8D	IK	DBMKKVSGBYKSFI-UHFFFAOYSA-N
DM9BY8D	IU	1-([1,3]oxazolo[4,5-b]pyridin-2-yl)octadec-9-yn-1-one
DM9BY8D	CA	CAS 288862-89-5
DM9BY8D	DE	Discovery agent

DM9ZK0M	ID	DM9ZK0M
DM9ZK0M	DN	1-palmitoyl-lysophosphatidylcholine
DM9ZK0M	HS	Investigative
DM9ZK0M	SN	lysophosphatidylcholine(16:0); LPC 16:0
DM9ZK0M	DT	Small molecular drug
DM9ZK0M	PC	10097314
DM9ZK0M	MW	495.6
DM9ZK0M	FM	C24H50NO7P
DM9ZK0M	IC	InChI=1S/C24H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24(27)30-21-23(26)22-32-33(28,29)31-20-19-25(2,3)4/h23,26H,5-22H2,1-4H3/t23-/m0/s1
DM9ZK0M	CS	CCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)([O-])OCC[N+](C)(C)C)O
DM9ZK0M	IK	ASWBNKHCZGQVJV-QHCPKHFHSA-N
DM9ZK0M	IU	[(2S)-3-hexadecanoyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DM9ZK0M	DE	Discovery agent

DM9PNTQ	ID	DM9PNTQ
DM9PNTQ	DN	1-pentafluorophenylamido-5-sulfonamidoindane
DM9PNTQ	HS	Investigative
DM9PNTQ	SN	CHEMBL205867; 1-pentafluorophenylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 11c; BDBM11034
DM9PNTQ	DT	Small molecular drug
DM9PNTQ	PC	11640067
DM9PNTQ	MW	406.3
DM9PNTQ	FM	C16H11F5N2O3S
DM9PNTQ	IC	InChI=1S/C16H11F5N2O3S/c17-11-10(12(18)14(20)15(21)13(11)19)16(24)23-9-4-1-6-5-7(27(22,25)26)2-3-8(6)9/h2-3,5,9H,1,4H2,(H,23,24)(H2,22,25,26)
DM9PNTQ	CS	C1CC2=C(C1NC(=O)C3=C(C(=C(C(=C3F)F)F)F)F)C=CC(=C2)S(=O)(=O)N
DM9PNTQ	IK	GSDOCCQCQXIOCL-UHFFFAOYSA-N
DM9PNTQ	IU	2,3,4,5,6-pentafluoro-N-(5-sulfamoyl-2,3-dihydro-1H-inden-1-yl)benzamide
DM9PNTQ	DE	Discovery agent

DMNUAB9	ID	DMNUAB9
DMNUAB9	DN	1-pentenyl-4-(aminosulfonyl)benzoate
DMNUAB9	HS	Investigative
DMNUAB9	SN	CHEMBL200074; 1-pentenyl-4-(aminosulfonyl)benzoate
DMNUAB9	DT	Small molecular drug
DMNUAB9	PC	11630396
DMNUAB9	MW	269.32
DMNUAB9	FM	C12H15NO4S
DMNUAB9	IC	InChI=1S/C12H15NO4S/c1-2-3-4-9-17-12(14)10-5-7-11(8-6-10)18(13,15)16/h2,5-8H,1,3-4,9H2,(H2,13,15,16)
DMNUAB9	CS	C=CCCCOC(=O)C1=CC=C(C=C1)S(=O)(=O)N
DMNUAB9	IK	IEMQKTRDDVFPKZ-UHFFFAOYSA-N
DMNUAB9	IU	pent-4-enyl 4-sulfamoylbenzoate
DMNUAB9	DE	Discovery agent

DMA29SX	ID	DMA29SX
DMA29SX	DN	1-Phenethyl-3,7-dihydro-purine-2,6-dione
DMA29SX	HS	Investigative
DMA29SX	SN	CHEMBL67949; 1-Phenethyl-3,7-dihydro-purine-2,6-dione; BDBM50042215
DMA29SX	DT	Small molecular drug
DMA29SX	PC	14969717
DMA29SX	MW	256.26
DMA29SX	FM	C13H12N4O2
DMA29SX	IC	InChI=1S/C13H12N4O2/c18-12-10-11(15-8-14-10)16-13(19)17(12)7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H,14,15)(H,16,19)
DMA29SX	CS	C1=CC=C(C=C1)CCN2C(=O)C3=C(NC2=O)N=CN3
DMA29SX	IK	WZIAGOQSFXTMAJ-UHFFFAOYSA-N
DMA29SX	IU	1-(2-phenylethyl)-3,7-dihydropurine-2,6-dione
DMA29SX	DE	Discovery agent

DM32WSM	ID	DM32WSM
DM32WSM	DN	1-Phenethyl-3-[1,3,4]thiadiazol-2-yl-thiourea
DM32WSM	HS	Investigative
DM32WSM	SN	Thiourea, N-(2-phenylethyl)-N'-1,3,4-thiadiazol-2-yl-; 149484-90-2; 1-phenethyl-3-(1,3,4-thiadiazol-2-yl)thiourea; PETT Analog 48; AC1MHDKZ; PETT Thiadiazol deriv.; SCHEMBL8886004; BDBM1881; CHEMBL144420; DTXSID90164281; 1-(2-phenylethyl)-3-1,3,4-thiadiazol-2-ylthiourea; N-(2-Phenethyl)-N -(2-(1,3,4-thiadiazolyl))thiourea
DM32WSM	DT	Small molecular drug
DM32WSM	PC	3001116
DM32WSM	MW	264.4
DM32WSM	FM	C11H12N4S2
DM32WSM	IC	InChI=1S/C11H12N4S2/c16-10(14-11-15-13-8-17-11)12-7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H2,12,14,15,16)
DM32WSM	CS	C1=CC=C(C=C1)CCNC(=S)NC2=NN=CS2
DM32WSM	IK	CKSSUWZTRWMHOY-UHFFFAOYSA-N
DM32WSM	IU	1-(2-phenylethyl)-3-(1,3,4-thiadiazol-2-yl)thiourea
DM32WSM	CA	CAS 149484-90-2
DM32WSM	DE	Discovery agent

DM0DH98	ID	DM0DH98
DM0DH98	DN	1-phenyl-1-(piperidin-2-yl)propan-2-one
DM0DH98	HS	Investigative
DM0DH98	SN	CHEMBL219540; 1-phenyl-1-(piperidin-2-yl)propan-2-one
DM0DH98	DT	Small molecular drug
DM0DH98	PC	16102777
DM0DH98	MW	217.31
DM0DH98	FM	C14H19NO
DM0DH98	IC	InChI=1S/C14H19NO/c1-11(16)14(12-7-3-2-4-8-12)13-9-5-6-10-15-13/h2-4,7-8,13-15H,5-6,9-10H2,1H3
DM0DH98	CS	CC(=O)C(C1CCCCN1)C2=CC=CC=C2
DM0DH98	IK	IYNBYQDXVFMDGE-UHFFFAOYSA-N
DM0DH98	IU	1-phenyl-1-piperidin-2-ylpropan-2-one
DM0DH98	DE	Discovery agent

DMGV6BI	ID	DMGV6BI
DMGV6BI	DN	1-Phenyl-1H-benzoimidazol-5-ol
DMGV6BI	HS	Investigative
DMGV6BI	SN	1-Phenyl-5-hydroxybenzimidazole; 1-phenyl-1H-Benzimidazol-5-ol; 69445-45-0; 1-Phenylbenzimidazole deriv. 65; AC1LDIKP; 1-phenylbenzimidazol-5-ol; CHEMBL80873; SCHEMBL4280861; BDBM3848; 5-hydroxy-1-phenylbenzimidazole; CTK5C9901; ZINC17525; DTXSID70349872; 1-Phenyl-1H-benzimidazole-5-ol; 1H-Benzimidazol-5-ol,1-phenyl-; OQAPWZCMAFFBBL-UHFFFAOYSA-N; 1-phenyl-1H-1,3-benzodiazol-5-ol; AKOS022650144; 5-Substituted 1-Phenylbenzimidazole 5; DA-04176; KB-219704; FT-0734974
DMGV6BI	DT	Small molecular drug
DMGV6BI	PC	667662
DMGV6BI	MW	210.23
DMGV6BI	FM	C13H10N2O
DMGV6BI	IC	InChI=1S/C13H10N2O/c16-11-6-7-13-12(8-11)14-9-15(13)10-4-2-1-3-5-10/h1-9,16H
DMGV6BI	CS	C1=CC=C(C=C1)N2C=NC3=C2C=CC(=C3)O
DMGV6BI	IK	OQAPWZCMAFFBBL-UHFFFAOYSA-N
DMGV6BI	IU	1-phenylbenzimidazol-5-ol
DMGV6BI	CA	CAS 69445-45-0
DMGV6BI	DE	Discovery agent

DM8YPH0	ID	DM8YPH0
DM8YPH0	DN	1-Phenyl-1H-benzoimidazole
DM8YPH0	HS	Investigative
DM8YPH0	SN	1-Phenyl-1H-benzoimidazole; 2622-60-8; 1-phenyl-1H-benzo[d]imidazole; 1-phenylbenzimidazole; 1-Phenyl-1H-benzimidazole; 97542-80-8; 1H-Benzimidazole,1-phenyl-; BAS 00350928; 1H-Benzimidazole, 1-phenyl-; XNCMQRWVMWLODV-UHFFFAOYSA-N; 1-PHENYL-1H-1,3-BENZODIAZOLE; AK123264; AC1LCTXI; PubChem19972; 1-Phenyl benzoimidazole; 1-Phenylbenzimidazole 3; phenyl-1H- Benzimidazole; 1-phenyl-1,3-benzodiazole; MLS000765952; SCHEMBL157265; 1-Phenyl-1H-benzimidazole #; CHEMBL310080; BDBM3794; CTK4F7433; DTXSID10345732; 1-Phenylbenzimidazole deriv. 
DM8YPH0	DT	Small molecular drug
DM8YPH0	PC	606669
DM8YPH0	MW	194.23
DM8YPH0	FM	C13H10N2
DM8YPH0	IC	InChI=1S/C13H10N2/c1-2-6-11(7-3-1)15-10-14-12-8-4-5-9-13(12)15/h1-10H
DM8YPH0	CS	C1=CC=C(C=C1)N2C=NC3=CC=CC=C32
DM8YPH0	IK	XNCMQRWVMWLODV-UHFFFAOYSA-N
DM8YPH0	IU	1-phenylbenzimidazole
DM8YPH0	CA	CAS 2622-60-8
DM8YPH0	DE	Discovery agent

DM74RMP	ID	DM74RMP
DM74RMP	DN	1-phenyl-1H-indole-2,3-dione
DM74RMP	HS	Investigative
DM74RMP	SN	1-Phenylisatin; 723-89-7; 1-Phenylindoline-2,3-dione; 1-Phenyl-1H-indole-2,3-dione; 1-phenylindole-2,3-dione; 1H-Indole-2,3-dione, 1-phenyl-; 1-Phenyl-indole-2,3-dione; INDOLE-2,3-DIONE, 1-PHENYL-; NSC 100013; BRN 0164531; 1H-Indole-2,3-dione, 1-phenyl- (9CI); 1-phenyl-2,3-dihydro-1H-indole-2,3-dione; UWCPWBIMRYXUOU-UHFFFAOYSA-N; AE-641/30401023; N-Phenylisatin; SMR000131753; phenylisatin; phenylindoledione; Phenyl Isatin; N-phenyl isatin; 1-phenyl isatin; NSC100013; 1-Phenylisatin,98%; 1-Phenylisatin, 97%; Isatin-based compound, 
DM74RMP	DT	Small molecular drug
DM74RMP	PC	12884
DM74RMP	MW	223.23
DM74RMP	FM	C14H9NO2
DM74RMP	IC	InChI=1S/C14H9NO2/c16-13-11-8-4-5-9-12(11)15(14(13)17)10-6-2-1-3-7-10/h1-9H
DM74RMP	CS	C1=CC=C(C=C1)N2C3=CC=CC=C3C(=O)C2=O
DM74RMP	IK	UWCPWBIMRYXUOU-UHFFFAOYSA-N
DM74RMP	IU	1-phenylindole-2,3-dione
DM74RMP	CA	CAS 723-89-7
DM74RMP	DE	Discovery agent

DMZM9AI	ID	DMZM9AI
DMZM9AI	DN	1-phenyl-2-(1-phenyl-1H-tetrazol-5-yloxy)ethanone
DMZM9AI	HS	Investigative
DMZM9AI	SN	CHEMBL1082497; 1-phenyl-2-(1-phenyl-1H-tetrazol-5-yloxy)ethanone
DMZM9AI	DT	Small molecular drug
DMZM9AI	PC	46890243
DMZM9AI	MW	279.29
DMZM9AI	FM	C16H13N3O2
DMZM9AI	IC	InChI=1S/C16H13N3O2/c20-15(13-7-3-1-4-8-13)12-21-16-11-17-18-19(16)14-9-5-2-6-10-14/h1-11H,12H2
DMZM9AI	CS	C1=CC=C(C=C1)C(=O)COC2=CN=NN2C3=CC=CC=C3
DMZM9AI	IK	NFBZAZXCZDAVSL-UHFFFAOYSA-N
DMZM9AI	IU	1-phenyl-2-(3-phenyltriazol-4-yl)oxyethanone
DMZM9AI	DE	Discovery agent

DMW9CRT	ID	DMW9CRT
DMW9CRT	DN	1-Phenyl-2-p-tolyl-ethane-1,2-dione
DMW9CRT	HS	Investigative
DMW9CRT	SN	p-Methylbenzil; 4-Methylbenzil; 2431-00-7; Ethanedione, (4-methylphenyl)phenyl-; 1-(4-methylphenyl)-2-phenylethane-1,2-dione; 1-(4-methylphenyl)-2-phenyl-ethane-1,2-dione; ethanedione,(4-methylphenyl)phenyl-; EINECS 219-396-3; 1-Phenyl-2-(p-tolyl)ethane-1,2-dione; AC1Q5DTY; AC1L2OX0; Benzil-based compound, 17; SCHEMBL2157002; CHEMBL371858; CTK1A7291; BDBM22739; (4-Methylphenyl)phenylethanedione; DTXSID80179046; QKFICTUTRIMBEX-UHFFFAOYSA-N; ZINC1841234; 1-Phenyl-2-p-tolylethane-1,2-dione; AKOS023905136
DMW9CRT	DT	Small molecular drug
DMW9CRT	PC	75511
DMW9CRT	MW	224.25
DMW9CRT	FM	C15H12O2
DMW9CRT	IC	InChI=1S/C15H12O2/c1-11-7-9-13(10-8-11)15(17)14(16)12-5-3-2-4-6-12/h2-10H,1H3
DMW9CRT	CS	CC1=CC=C(C=C1)C(=O)C(=O)C2=CC=CC=C2
DMW9CRT	IK	QKFICTUTRIMBEX-UHFFFAOYSA-N
DMW9CRT	IU	1-(4-methylphenyl)-2-phenylethane-1,2-dione
DMW9CRT	CA	CAS 2431-00-7
DMW9CRT	DE	Discovery agent

DM8EDI7	ID	DM8EDI7
DM8EDI7	DN	1-Phenyl-2-pyridin-3-yl-propan-1-one
DM8EDI7	HS	Investigative
DM8EDI7	SN	CHEMBL53248; 62144-16-5; 1-phenyl-2-pyridin-3-yl-propan-1-one; alpha-(3-Pyridyl)propiophenone; SCHEMBL4810062; CTK2C6291; DTXSID40463372; BDBM50028159; 1-phenyl-2-(3-pyridinyl)-1-propanone; 1-Propanone, 1-phenyl-2-(3-pyridinyl)-
DM8EDI7	DT	Small molecular drug
DM8EDI7	PC	11356288
DM8EDI7	MW	211.26
DM8EDI7	FM	C14H13NO
DM8EDI7	IC	InChI=1S/C14H13NO/c1-11(13-8-5-9-15-10-13)14(16)12-6-3-2-4-7-12/h2-11H,1H3
DM8EDI7	CS	CC(C1=CN=CC=C1)C(=O)C2=CC=CC=C2
DM8EDI7	IK	NFHIPZYAYZPXJE-UHFFFAOYSA-N
DM8EDI7	IU	1-phenyl-2-pyridin-3-ylpropan-1-one
DM8EDI7	CA	CAS 62144-16-5
DM8EDI7	DE	Discovery agent

DM6QU5B	ID	DM6QU5B
DM6QU5B	DN	1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea
DM6QU5B	HS	Investigative
DM6QU5B	SN	1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea; CHEMBL1253381; AC1LHWR1; SCHEMBL13779380; MolPort-002-153-004; ZINC436272; BDBM50326573; AKOS000986880; MCULE-5997854144; SDCCGMLS-0064737.P001; ST50980881; AB00086777-01; SR-01000210707; SR-01000210707-1; Z56753795; (phenylamino)(1,3,4-thiadiazol-2-ylamino)methane-1-thione
DM6QU5B	DT	Small molecular drug
DM6QU5B	PC	870537
DM6QU5B	MW	236.3
DM6QU5B	FM	C9H8N4S2
DM6QU5B	IC	InChI=1S/C9H8N4S2/c14-8(12-9-13-10-6-15-9)11-7-4-2-1-3-5-7/h1-6H,(H2,11,12,13,14)
DM6QU5B	CS	C1=CC=C(C=C1)NC(=S)NC2=NN=CS2
DM6QU5B	IK	CSUHGRXUQXQHRB-UHFFFAOYSA-N
DM6QU5B	IU	1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea
DM6QU5B	DE	Discovery agent

DMCHOFK	ID	DMCHOFK
DMCHOFK	DN	1-Phenyl-3-(1-propionylpiperidin-4-yl)urea
DMCHOFK	HS	Investigative
DMCHOFK	SN	CHEMBL1256163; 1-Phenyl-3-(1-propionylpiperidin-4-yl)urea; SCHEMBL2729525; BDBM50327829
DMCHOFK	DT	Small molecular drug
DMCHOFK	PC	47379737
DMCHOFK	MW	275.35
DMCHOFK	FM	C15H21N3O2
DMCHOFK	IC	InChI=1S/C15H21N3O2/c1-2-14(19)18-10-8-13(9-11-18)17-15(20)16-12-6-4-3-5-7-12/h3-7,13H,2,8-11H2,1H3,(H2,16,17,20)
DMCHOFK	CS	CCC(=O)N1CCC(CC1)NC(=O)NC2=CC=CC=C2
DMCHOFK	IK	XOEKGIBLQVJFBB-UHFFFAOYSA-N
DMCHOFK	IU	1-phenyl-3-(1-propanoylpiperidin-4-yl)urea
DMCHOFK	DE	Discovery agent

DM9SKYC	ID	DM9SKYC
DM9SKYC	DN	1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea
DM9SKYC	HS	Investigative
DM9SKYC	SN	CHEMBL423311; 1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea; BDBM50088476; 1-[2-(2-Pyridyl)-4-quinazolinyl]-3-phenylurea
DM9SKYC	DT	Small molecular drug
DM9SKYC	PC	10712256
DM9SKYC	MW	341.4
DM9SKYC	FM	C20H15N5O
DM9SKYC	IC	InChI=1S/C20H15N5O/c26-20(22-14-8-2-1-3-9-14)25-18-15-10-4-5-11-16(15)23-19(24-18)17-12-6-7-13-21-17/h1-13H,(H2,22,23,24,25,26)
DM9SKYC	CS	C1=CC=C(C=C1)NC(=O)NC2=NC(=NC3=CC=CC=C32)C4=CC=CC=N4
DM9SKYC	IK	XZUXPDFYRHJJLN-UHFFFAOYSA-N
DM9SKYC	IU	1-phenyl-3-(2-pyridin-2-ylquinazolin-4-yl)urea
DM9SKYC	DE	Discovery agent

DMQKB6W	ID	DMQKB6W
DMQKB6W	DN	1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea
DMQKB6W	HS	Investigative
DMQKB6W	SN	CHEMBL305512; 1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea; BDBM50088462; 1-[2-(3-Pyridyl)-4-quinazolinyl]-3-phenylurea
DMQKB6W	DT	Small molecular drug
DMQKB6W	PC	10688595
DMQKB6W	MW	341.4
DMQKB6W	FM	C20H15N5O
DMQKB6W	IC	InChI=1S/C20H15N5O/c26-20(22-15-8-2-1-3-9-15)25-19-16-10-4-5-11-17(16)23-18(24-19)14-7-6-12-21-13-14/h1-13H,(H2,22,23,24,25,26)
DMQKB6W	CS	C1=CC=C(C=C1)NC(=O)NC2=NC(=NC3=CC=CC=C32)C4=CN=CC=C4
DMQKB6W	IK	GDOLLVJHBJTNPM-UHFFFAOYSA-N
DMQKB6W	IU	1-phenyl-3-(2-pyridin-3-ylquinazolin-4-yl)urea
DMQKB6W	DE	Discovery agent

DMJVITG	ID	DMJVITG
DMJVITG	DN	1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea
DMJVITG	HS	Investigative
DMJVITG	SN	acyclic urea, 1; CHEMBL392228; BDBM20816
DMJVITG	DT	Small molecular drug
DMJVITG	PC	24768279
DMJVITG	MW	296.3
DMJVITG	FM	C15H12N4OS
DMJVITG	IC	InChI=1S/C15H12N4OS/c20-15(17-12-4-2-1-3-5-12)19-13-10-21-14(18-13)11-6-8-16-9-7-11/h1-10H,(H2,17,19,20)
DMJVITG	CS	C1=CC=C(C=C1)NC(=O)NC2=CSC(=N2)C3=CC=NC=C3
DMJVITG	IK	AXDWPTZOIRLDDO-UHFFFAOYSA-N
DMJVITG	IU	1-phenyl-3-(2-pyridin-4-yl-1,3-thiazol-4-yl)urea
DMJVITG	DE	Discovery agent

DMJNAX5	ID	DMJNAX5
DMJNAX5	DN	1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea
DMJNAX5	HS	Investigative
DMJNAX5	SN	CHEMBL70553; 1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea; BDBM50088465; 1-Phenyl-3-[3-(2-pyridyl)-1-isoquinolyl]urea
DMJNAX5	DT	Small molecular drug
DMJNAX5	PC	10640891
DMJNAX5	MW	340.4
DMJNAX5	FM	C21H16N4O
DMJNAX5	IC	InChI=1S/C21H16N4O/c26-21(23-16-9-2-1-3-10-16)25-20-17-11-5-4-8-15(17)14-19(24-20)18-12-6-7-13-22-18/h1-14H,(H2,23,24,25,26)
DMJNAX5	CS	C1=CC=C(C=C1)NC(=O)NC2=NC(=CC3=CC=CC=C32)C4=CC=CC=N4
DMJNAX5	IK	IJXVHHOSRPNGFG-UHFFFAOYSA-N
DMJNAX5	IU	1-phenyl-3-(3-pyridin-2-ylisoquinolin-1-yl)urea
DMJNAX5	DE	Discovery agent

DMJ723D	ID	DMJ723D
DMJ723D	DN	1-Phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea
DMJ723D	HS	Investigative
DMJ723D	SN	CHEMBL164422; 1-Phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea; TCMDC-143133; BDBM50097425; AKOS028168115; 1-Phenyl-3-[4-(2-pyridyl)-2-thiazolyl]urea
DMJ723D	DT	Small molecular drug
DMJ723D	PC	10590030
DMJ723D	MW	296.3
DMJ723D	FM	C15H12N4OS
DMJ723D	IC	InChI=1S/C15H12N4OS/c20-14(17-11-6-2-1-3-7-11)19-15-18-13(10-21-15)12-8-4-5-9-16-12/h1-10H,(H2,17,18,19,20)
DMJ723D	CS	C1=CC=C(C=C1)NC(=O)NC2=NC(=CS2)C3=CC=CC=N3
DMJ723D	IK	SDGJJDKFCDDMKK-UHFFFAOYSA-N
DMJ723D	IU	1-phenyl-3-(4-pyridin-2-yl-1,3-thiazol-2-yl)urea
DMJ723D	DE	Discovery agent

DM8ZBHF	ID	DM8ZBHF
DM8ZBHF	DN	1-phenyl-3-(phenylsulfonyl)propan-1-one
DM8ZBHF	HS	Investigative
DM8ZBHF	SN	1-phenyl-3-(phenylsulfonyl)propan-1-one; CHEMBL240292; ZINC28874843
DM8ZBHF	DT	Small molecular drug
DM8ZBHF	PC	44437631
DM8ZBHF	MW	274.3
DM8ZBHF	FM	C15H14O3S
DM8ZBHF	IC	InChI=1S/C15H14O3S/c16-15(13-7-3-1-4-8-13)11-12-19(17,18)14-9-5-2-6-10-14/h1-10H,11-12H2
DM8ZBHF	CS	C1=CC=C(C=C1)C(=O)CCS(=O)(=O)C2=CC=CC=C2
DM8ZBHF	IK	IOTOILGYCOMTGK-UHFFFAOYSA-N
DM8ZBHF	IU	3-(benzenesulfonyl)-1-phenylpropan-1-one
DM8ZBHF	CA	CAS 65885-28-1
DM8ZBHF	DE	Discovery agent

DMZOEQY	ID	DMZOEQY
DMZOEQY	DN	1-phenyl-3-(quinazolin-4-yl)urea
DMZOEQY	HS	Investigative
DMZOEQY	SN	CHEMBL309974; 1-phenyl-3-(quinazolin-4-yl)urea; SCHEMBL4689838; 1-Phenyl-3-quinazolin-4-yl-urea; 1-(4-Quinazolinyl)-3-phenylurea; BDBM50088472
DMZOEQY	DT	Small molecular drug
DMZOEQY	PC	10563562
DMZOEQY	MW	264.28
DMZOEQY	FM	C15H12N4O
DMZOEQY	IC	InChI=1S/C15H12N4O/c20-15(18-11-6-2-1-3-7-11)19-14-12-8-4-5-9-13(12)16-10-17-14/h1-10H,(H2,16,17,18,19,20)
DMZOEQY	CS	C1=CC=C(C=C1)NC(=O)NC2=NC=NC3=CC=CC=C32
DMZOEQY	IK	IYKBZJSFOBYNTL-UHFFFAOYSA-N
DMZOEQY	IU	1-phenyl-3-quinazolin-4-ylurea
DMZOEQY	DE	Discovery agent

DMUA72F	ID	DMUA72F
DMUA72F	DN	1-phenyl-3-aza-bicyclo[3.1.0]hexane
DMUA72F	HS	Investigative
DMUA72F	SN	1-phenyl-3-azabicyclo[3.1.0]hexane; 67644-21-7; 1-phenyl-3-aza-bicyclo[3.1.0]hexane; CHEMBL503383; 1-PHENYL-3-AZABICYCLO(3.1.0)HEXANE; 66505-14-4; SCHEMBL4557697; CTK5C4827; HYXPTPHIWQWOQF-UHFFFAOYSA-N; BDBM50243891; AKOS006370964; 1-phenyl-3-azabicyclo-[3.1.0]hexane; 1-phenyl-3-azabicyclo[3.1.0]-hexane
DMUA72F	DT	Small molecular drug
DMUA72F	PC	10130094
DMUA72F	MW	159.23
DMUA72F	FM	C11H13N
DMUA72F	IC	InChI=1S/C11H13N/c1-2-4-9(5-3-1)11-6-10(11)7-12-8-11/h1-5,10,12H,6-8H2
DMUA72F	CS	C1C2C1(CNC2)C3=CC=CC=C3
DMUA72F	IK	HYXPTPHIWQWOQF-UHFFFAOYSA-N
DMUA72F	IU	1-phenyl-3-azabicyclo[3.1.0]hexane
DMUA72F	DE	Discovery agent

DMKV17L	ID	DMKV17L
DMKV17L	DN	1-phenyl-4-(1-phenyl-1H-tetrazol-5-yl)butan-2-one
DMKV17L	HS	Investigative
DMKV17L	SN	CHEMBL1083423; 1-phenyl-4-(1-phenyl-1H-tetrazol-5-yl)butan-2-one
DMKV17L	DT	Small molecular drug
DMKV17L	PC	46890339
DMKV17L	MW	292.33
DMKV17L	FM	C17H16N4O
DMKV17L	IC	InChI=1S/C17H16N4O/c22-16(13-14-7-3-1-4-8-14)11-12-17-18-19-20-21(17)15-9-5-2-6-10-15/h1-10H,11-13H2
DMKV17L	CS	C1=CC=C(C=C1)CC(=O)CCC2=NN=NN2C3=CC=CC=C3
DMKV17L	IK	FPYZSRILLJGVMX-UHFFFAOYSA-N
DMKV17L	IU	1-phenyl-4-(1-phenyltetrazol-5-yl)butan-2-one
DMKV17L	DE	Discovery agent

DMA4XGL	ID	DMA4XGL
DMA4XGL	DN	1-phenylbiguanide
DMA4XGL	HS	Investigative
DMA4XGL	SN	phenylbiguanide; 1-Phenylbiguanide; Phenyl biguanide; 102-02-3; Phenyldiguanide; Phenylguanide; phenyl diguanide; N-Phenyl-N'-guanylguanidine; N-phenylimidodicarbonimidic diamide; Biguanide, phenyl-; Imidodicarbonimidic diamide, N-phenyl-; UNII-W8PKA3T2I3; BIGUANIDE, 1-PHENYL-; C8H11N5; N-Phenyl-imidocarbonimidic diamide; EINECS 202-998-5; W8PKA3T2I3; CHEMBL13791; CHEBI:75377; P 1426; Imidodicarbonimidicdiamide, N-phenyl-; 1-(diaminomethylidene)-2-phenylguanidine; SR-01000075565; N-phenylbiguanide; N'-phenylbiguanide
DMA4XGL	DT	Small molecular drug
DMA4XGL	PC	4780
DMA4XGL	MW	177.21
DMA4XGL	FM	C8H11N5
DMA4XGL	IC	InChI=1S/C8H11N5/c9-7(10)13-8(11)12-6-4-2-1-3-5-6/h1-5H,(H6,9,10,11,12,13)
DMA4XGL	CS	C1=CC=C(C=C1)N=C(N)N=C(N)N
DMA4XGL	IK	CUQCMXFWIMOWRP-UHFFFAOYSA-N
DMA4XGL	IU	1-(diaminomethylidene)-2-phenylguanidine
DMA4XGL	CA	CAS 102-02-3
DMA4XGL	CB	CHEBI:75377
DMA4XGL	DE	Discovery agent

DM04SWY	ID	DM04SWY
DM04SWY	DN	1-Phenyl-propane-1,2-dione
DM04SWY	HS	Investigative
DM04SWY	SN	1-PHENYL-1,2-PROPANEDIONE; 1-Phenylpropane-1,2-dione; 579-07-7; Acetylbenzoyl; Acetyl benzoyl; Benzoylacetyl; 1,2-Propanedione, 1-phenyl-; Methylphenylglyoxal; Pyruvophenone; Phenylmethyldiketone; Benzoyl methyl ketone; Methyl phenyl diketone; 3-Phenyl-2,3-propanedione; Methyl phenyl glyoxal; Phenyl methyl diketone; UNII-ZB5XA3GD0I; 1-phenyl-1,2-propandione; 1-Phenyl-propane-1,2-dione; FEMA No. 3226; CCRIS 6297; NSC 7643; EINECS 209-435-2; ZB5XA3GD0I; AI3-23868; CHEBI:63552; BVQVLAIMHVDZEL-UHFFFAOYSA-N; 1-Phenyl-1,2-propanedione, 98
DM04SWY	DT	Small molecular drug
DM04SWY	PC	11363
DM04SWY	MW	148.16
DM04SWY	FM	C9H8O2
DM04SWY	IC	InChI=1S/C9H8O2/c1-7(10)9(11)8-5-3-2-4-6-8/h2-6H,1H3
DM04SWY	CS	CC(=O)C(=O)C1=CC=CC=C1
DM04SWY	IK	BVQVLAIMHVDZEL-UHFFFAOYSA-N
DM04SWY	IU	1-phenylpropane-1,2-dione
DM04SWY	CA	CAS 579-07-7
DM04SWY	CB	CHEBI:63552
DM04SWY	DE	Discovery agent

DM5REQ9	ID	DM5REQ9
DM5REQ9	DN	1-phenylthio-N,N-dimethyltryptamine
DM5REQ9	HS	Investigative
DM5REQ9	SN	CHEMBL253397; 1-phenylthio-N,N-dimethyltryptamine
DM5REQ9	DT	Small molecular drug
DM5REQ9	PC	24776941
DM5REQ9	MW	296.4
DM5REQ9	FM	C18H20N2S
DM5REQ9	IC	InChI=1S/C18H20N2S/c1-19(2)13-12-15-14-20(18-11-7-6-10-17(15)18)21-16-8-4-3-5-9-16/h3-11,14H,12-13H2,1-2H3
DM5REQ9	CS	CN(C)CCC1=CN(C2=CC=CC=C21)SC3=CC=CC=C3
DM5REQ9	IK	APYJLIWKKMRCGM-UHFFFAOYSA-N
DM5REQ9	IU	N,N-dimethyl-2-(1-phenylsulfanylindol-3-yl)ethanamine
DM5REQ9	DE	Discovery agent

DMCBX7R	ID	DMCBX7R
DMCBX7R	DN	1-Prop-2-ynyl-3,7-dihydro-purine-2,6-dione
DMCBX7R	HS	Investigative
DMCBX7R	SN	CHEMBL67415; 1H-Purine-2,6-dione, 3,9-dihydro-1-(2-propyn-1-yl)-; 146830-81-1; 1-propargylxanthine; 1-Prop-2-ynyl-3,7-dihydro-purine-2,6-dione; SCHEMBL3423318; BDBM50042217
DMCBX7R	DT	Small molecular drug
DMCBX7R	PC	10219753
DMCBX7R	MW	190.16
DMCBX7R	FM	C8H6N4O2
DMCBX7R	IC	InChI=1S/C8H6N4O2/c1-2-3-12-7(13)5-6(10-4-9-5)11-8(12)14/h1,4H,3H2,(H,9,10)(H,11,14)
DMCBX7R	CS	C#CCN1C(=O)C2=C(NC1=O)N=CN2
DMCBX7R	IK	HJYAFKKSAAYVHQ-UHFFFAOYSA-N
DMCBX7R	IU	1-prop-2-ynyl-3,7-dihydropurine-2,6-dione
DMCBX7R	DE	Discovery agent

DM1TNWG	ID	DM1TNWG
DM1TNWG	DN	1-propionyl-1H-indole-2,3-dione
DM1TNWG	HS	Investigative
DM1TNWG	SN	1-Propionyl-1H-indole-2,3-dione; 17529-69-0; 1-propanoyl-2,3-dihydro-1H-indole-2,3-dione; Propionylisatin; Isatin-based compound, 9; AC1LBV75; 1-propanoylindole-2,3-dione; CHEMBL386000; BDBM22789; MolPort-002-488-122; IHNYAHBLLCMRCD-UHFFFAOYSA-N; ZINC3086180; ZX-AN080727; ALBB-029917; AKOS001849000; 1-Propionyl-1H-indole-2,3-dione #; MCULE-1099895518; CCG-139392; 1H-Indole-2,3-dione, 1-(1-oxopropyl)-; EU-0084456; 1H-Isoindole-2,3(2H)-dione, 1-propionyl-; SR-01000512691
DM1TNWG	DT	Small molecular drug
DM1TNWG	PC	589576
DM1TNWG	MW	203.19
DM1TNWG	FM	C11H9NO3
DM1TNWG	IC	InChI=1S/C11H9NO3/c1-2-9(13)12-8-6-4-3-5-7(8)10(14)11(12)15/h3-6H,2H2,1H3
DM1TNWG	CS	CCC(=O)N1C2=CC=CC=C2C(=O)C1=O
DM1TNWG	IK	IHNYAHBLLCMRCD-UHFFFAOYSA-N
DM1TNWG	IU	1-propanoylindole-2,3-dione
DM1TNWG	DE	Discovery agent

DMOCAUL	ID	DMOCAUL
DMOCAUL	DN	1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine
DMOCAUL	HS	Investigative
DMOCAUL	SN	CHEMBL310607; 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine
DMOCAUL	DT	Small molecular drug
DMOCAUL	PC	44460502
DMOCAUL	MW	257.29
DMOCAUL	FM	C14H18F3N
DMOCAUL	IC	InChI=1S/C14H18F3N/c1-2-7-18-8-6-12(10-18)11-4-3-5-13(9-11)14(15,16)17/h3-5,9,12H,2,6-8,10H2,1H3
DMOCAUL	CS	CCCN1CCC(C1)C2=CC(=CC=C2)C(F)(F)F
DMOCAUL	IK	YATKXAPVZGTXAR-UHFFFAOYSA-N
DMOCAUL	IU	1-propyl-3-[3-(trifluoromethyl)phenyl]pyrrolidine
DMOCAUL	DE	Discovery agent

DML5J94	ID	DML5J94
DML5J94	DN	1-Propyl-3,7-dihydro-purine-2,6-dione
DML5J94	HS	Investigative
DML5J94	SN	1-Propylxanthine; 104285-82-7; CHEMBL39986; 1H-Purine-2,6-dione,3,9-dihydro-1-propyl-; 1-Propyl-3,7-dihydro-purine-2,6-dione; ACMC-1BNN6; AC1L2TY0; SCHEMBL4423680; SCHEMBL8930198; CTK4A2909; DTXSID10146367; IWBONKMODGBEOX-UHFFFAOYSA-N; BDBM50001490; 1-propyl-3,7-dihydropurine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-1-propyl-
DML5J94	DT	Small molecular drug
DML5J94	PC	128525
DML5J94	MW	194.19
DML5J94	FM	C8H10N4O2
DML5J94	IC	InChI=1S/C8H10N4O2/c1-2-3-12-7(13)5-6(10-4-9-5)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,14)
DML5J94	CS	CCCN1C(=O)C2=C(NC1=O)N=CN2
DML5J94	IK	IWBONKMODGBEOX-UHFFFAOYSA-N
DML5J94	IU	1-propyl-3,7-dihydropurine-2,6-dione
DML5J94	CA	CAS 104285-82-7
DML5J94	DE	Discovery agent

DM1387P	ID	DM1387P
DM1387P	DN	1-Propyl-3-m-tolyl-piperidine hydrochloride
DM1387P	HS	Investigative
DM1387P	DE	Discovery agent

DM1O6KQ	ID	DM1O6KQ
DM1O6KQ	DN	1-Propyl-3-o-tolyl-piperidine hydrochloride
DM1O6KQ	HS	Investigative
DM1O6KQ	DE	Discovery agent

DMPMIN9	ID	DMPMIN9
DMPMIN9	DN	1-Propyl-3-p-tolyl-piperidine hydrochloride
DMPMIN9	HS	Investigative
DMPMIN9	DE	Discovery agent

DM5P01L	ID	DM5P01L
DM5P01L	DN	1-propyl-5'-O-tritylinosine
DM5P01L	HS	Investigative
DM5P01L	SN	CHEMBL213890; 1-propyl-5''-O-tritylinosine
DM5P01L	DT	Small molecular drug
DM5P01L	PC	16082758
DM5P01L	MW	552.6
DM5P01L	FM	C32H32N4O5
DM5P01L	IC	InChI=1S/C32H32N4O5/c1-2-18-35-20-34-29-26(30(35)39)33-21-36(29)31-28(38)27(37)25(41-31)19-40-32(22-12-6-3-7-13-22,23-14-8-4-9-15-23)24-16-10-5-11-17-24/h3-17,20-21,25,27-28,31,37-38H,2,18-19H2,1H3/t25-,27-,28-,31-/m1/s1
DM5P01L	CS	CCCN1C=NC2=C(C1=O)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COC(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)O)O
DM5P01L	IK	GTLQVJJXEZWWMS-QWOIFIOOSA-N
DM5P01L	IU	9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]-1-propylpurin-6-one
DM5P01L	DE	Discovery agent

DMXOUFI	ID	DMXOUFI
DMXOUFI	DN	1-Propylidenethiosemicarbazide
DMXOUFI	HS	Investigative
DMXOUFI	SN	1-Propylidenethiosemicarbazide; CHEMBL452107; [(Z)-propylideneamino]thiourea; propionaldehyde thiosemicarbazone; AC1O0DHJ; 22042-87-1; ZINC5447671; BDBM50268175
DMXOUFI	DT	Small molecular drug
DMXOUFI	PC	6036901
DMXOUFI	MW	131.2
DMXOUFI	FM	C4H9N3S
DMXOUFI	IC	InChI=1S/C4H9N3S/c1-2-3-6-7-4(5)8/h3H,2H2,1H3,(H3,5,7,8)/b6-3-
DMXOUFI	CS	CC/C=N\\NC(=S)N
DMXOUFI	IK	SREKQYKLPZJBJG-UTCJRWHESA-N
DMXOUFI	IU	[(Z)-propylideneamino]thiourea
DMXOUFI	DE	Discovery agent

DMTMXN4	ID	DMTMXN4
DMTMXN4	DN	1-Pyridin-2-yl-3-quinolin-5-yl-urea
DMTMXN4	HS	Investigative
DMTMXN4	SN	Diarylurea deriv. 14b; AC1NS9HW; BDBM6657; CHEMBL143704; ZINC13471117; 1-pyridin-2-yl-3-quinolin-5-ylurea; 3-pyridin-2-yl-1-quinolin-5-ylurea; 1-(5-Quinolyl)-3-(2-pyridyl)urea; N-Pyridin-2-yl-N -quinolin-5-ylurea
DMTMXN4	DT	Small molecular drug
DMTMXN4	PC	5330598
DMTMXN4	MW	264.28
DMTMXN4	FM	C15H12N4O
DMTMXN4	IC	InChI=1S/C15H12N4O/c20-15(19-14-8-1-2-9-17-14)18-13-7-3-6-12-11(13)5-4-10-16-12/h1-10H,(H2,17,18,19,20)
DMTMXN4	CS	C1=CC=NC(=C1)NC(=O)NC2=CC=CC3=C2C=CC=N3
DMTMXN4	IK	XJYQTPJBOGSWBE-UHFFFAOYSA-N
DMTMXN4	IU	1-pyridin-2-yl-3-quinolin-5-ylurea
DMTMXN4	DE	Discovery agent

DM7Y5AN	ID	DM7Y5AN
DM7Y5AN	DN	1S,2R-milnacipran
DM7Y5AN	HS	Investigative
DM7Y5AN	SN	CHEMBL471001; AC1MHWCG; SCHEMBL1707471; ZINC5649654; BDBM50275771; NCGC00165825-02; AJ-54473; FT-0696627; cyclopropanecarboxamide,2-(aminomethyl)-n,n-diethyl-1-phenyl-, (1r,2s)-; N,N-Diethyl-1-phenyl-2alpha-(aminomethyl)cyclopropane-1beta-carboxamide
DM7Y5AN	DT	Small molecular drug
DM7Y5AN	PC	3033806
DM7Y5AN	MW	246.35
DM7Y5AN	FM	C15H22N2O
DM7Y5AN	IC	InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15-/m0/s1
DM7Y5AN	CS	CCN(CC)C(=O)[C@@]1(C[C@H]1CN)C2=CC=CC=C2
DM7Y5AN	IK	GJJFMKBJSRMPLA-ZFWWWQNUSA-N
DM7Y5AN	IU	(1R,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DM7Y5AN	DE	Discovery agent

DM7K0B3	ID	DM7K0B3
DM7K0B3	DN	1-stearoyl-lysophosphatidylcholine
DM7K0B3	HS	Investigative
DM7K0B3	SN	LPC 18:0; lysophosphatidylcholine (18:0); stearoyl alpha-lysolecithin
DM7K0B3	DT	Small molecular drug
DM7K0B3	PC	497299
DM7K0B3	MW	523.7
DM7K0B3	FM	C26H54NO7P
DM7K0B3	IC	InChI=1S/C26H54NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-26(29)32-23-25(28)24-34-35(30,31)33-22-21-27(2,3)4/h25,28H,5-24H2,1-4H3/t25-/m1/s1
DM7K0B3	CS	CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)O
DM7K0B3	IK	IHNKQIMGVNPMTC-RUZDIDTESA-N
DM7K0B3	IU	[(2R)-2-hydroxy-3-octadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DM7K0B3	CA	CAS 19420-57-6
DM7K0B3	CB	CHEBI:73858
DM7K0B3	DE	Discovery agent

DMPSM4O	ID	DMPSM4O
DMPSM4O	DN	1-tert-butyl-9H-carbazole
DMPSM4O	HS	Investigative
DMPSM4O	SN	1-tert-butyl-9H-carbazole; CHEMBL1172393; t-butyl carbazole; SCHEMBL3866477
DMPSM4O	DT	Small molecular drug
DMPSM4O	PC	18504802
DMPSM4O	MW	223.31
DMPSM4O	FM	C16H17N
DMPSM4O	IC	InChI=1S/C16H17N/c1-16(2,3)13-9-6-8-12-11-7-4-5-10-14(11)17-15(12)13/h4-10,17H,1-3H3
DMPSM4O	CS	CC(C)(C)C1=CC=CC2=C1NC3=CC=CC=C23
DMPSM4O	IK	BKPDQETYXNGMRE-UHFFFAOYSA-N
DMPSM4O	IU	1-tert-butyl-9H-carbazole
DMPSM4O	DE	Discovery agent

DMAQKO1	ID	DMAQKO1
DMAQKO1	DN	1-Thiazol-2-yl-3-(2-o-tolyl-ethyl)-thiourea
DMAQKO1	HS	Investigative
DMAQKO1	SN	Thiourea, N-(2-(2-methylphenyl)ethyl)-N'-2-thiazolyl-; 149486-23-7; PETT Analog 8; Thiourea, N-[2-(2-methylphenyl)ethyl]-N'-2-thiazolyl-; AC1MHDME; BDBM1901; CHEMBL254207; SCHEMBL6955476; DTXSID90164302; ZINC13744851; AKOS030030934; 1-[2-(o-tolyl)ethyl]-3-thiazol-2-yl-thiourea; 1-(2-Thiazolyl)-3-[2-methylphenethyl]thiourea; N-(2-(2-Methylphenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(2-methylphenyl)ethyl]-3-1,3-thiazol-2-ylthiourea
DMAQKO1	DT	Small molecular drug
DMAQKO1	PC	3001167
DMAQKO1	MW	277.4
DMAQKO1	FM	C13H15N3S2
DMAQKO1	IC	InChI=1S/C13H15N3S2/c1-10-4-2-3-5-11(10)6-7-14-12(17)16-13-15-8-9-18-13/h2-5,8-9H,6-7H2,1H3,(H2,14,15,16,17)
DMAQKO1	CS	CC1=CC=CC=C1CCNC(=S)NC2=NC=CS2
DMAQKO1	IK	VTSYVNSWDAGAAS-UHFFFAOYSA-N
DMAQKO1	IU	1-[2-(2-methylphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMAQKO1	CA	CAS 149486-23-7
DMAQKO1	DE	Discovery agent

DMCIA40	ID	DMCIA40
DMCIA40	DN	1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea
DMCIA40	HS	Investigative
DMCIA40	SN	CHEMBL149100; 149484-92-4; Thiourea, N-[2-(4-methylphenyl)ethyl]-N'-2-thiazolyl-; AC1MHEHT; ACMC-20n5ps; 1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea; SCHEMBL6284717; CTK0B1828; DTXSID70388246; BDBM50097037; AKOS030030944; 1-[2-(p-tolyl)ethyl]-3-thiazol-2-yl-thiourea; 1-(4-Methylphenethyl)-3-(2-thiazolyl)thiourea; [2-(4-Methylphenyl)ethyl]-N''-[2-(thiazolyl)]thiourea
DMCIA40	DT	Small molecular drug
DMCIA40	PC	3003030
DMCIA40	MW	277.4
DMCIA40	FM	C13H15N3S2
DMCIA40	IC	InChI=1S/C13H15N3S2/c1-10-2-4-11(5-3-10)6-7-14-12(17)16-13-15-8-9-18-13/h2-5,8-9H,6-7H2,1H3,(H2,14,15,16,17)
DMCIA40	CS	CC1=CC=C(C=C1)CCNC(=S)NC2=NC=CS2
DMCIA40	IK	SIJMMWOYIWBAFY-UHFFFAOYSA-N
DMCIA40	IU	1-[2-(4-methylphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMCIA40	CA	CAS 149484-92-4
DMCIA40	DE	Discovery agent

DM9SYEP	ID	DM9SYEP
DM9SYEP	DN	1'-tosylspiro[indene-1,4'-piperidine]
DM9SYEP	HS	Investigative
DM9SYEP	SN	CHEMBL341490; SCHEMBL7381332; VRVIZJNFYYAUKC-UHFFFAOYSA-N; ZINC13728182; BDBM50001405; L-342643; 1'-((4-Methylphenyl)sulfonyl)spiro(1H-indene-1,4'-piperidine)
DM9SYEP	DT	Small molecular drug
DM9SYEP	PC	9797987
DM9SYEP	MW	339.5
DM9SYEP	FM	C20H21NO2S
DM9SYEP	IC	InChI=1S/C20H21NO2S/c1-16-6-8-18(9-7-16)24(22,23)21-14-12-20(13-15-21)11-10-17-4-2-3-5-19(17)20/h2-11H,12-15H2,1H3
DM9SYEP	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCC3(CC2)C=CC4=CC=CC=C34
DM9SYEP	IK	VRVIZJNFYYAUKC-UHFFFAOYSA-N
DM9SYEP	IU	1'-(4-methylphenyl)sulfonylspiro[indene-1,4'-piperidine]
DM9SYEP	DE	Discovery agent

DM9ZRU2	ID	DM9ZRU2
DM9ZRU2	DN	1-valproylamido-5-sulfonamidoindane
DM9ZRU2	HS	Investigative
DM9ZRU2	SN	CHEMBL204941; 1-valproylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 11a; BDBM11030
DM9ZRU2	DT	Small molecular drug
DM9ZRU2	PC	11638641
DM9ZRU2	MW	338.5
DM9ZRU2	FM	C17H26N2O3S
DM9ZRU2	IC	InChI=1S/C17H26N2O3S/c1-3-5-12(6-4-2)17(20)19-16-10-7-13-11-14(23(18,21)22)8-9-15(13)16/h8-9,11-12,16H,3-7,10H2,1-2H3,(H,19,20)(H2,18,21,22)
DM9ZRU2	CS	CCCC(CCC)C(=O)NC1CCC2=C1C=CC(=C2)S(=O)(=O)N
DM9ZRU2	IK	FCGKZIRRZCVIGR-UHFFFAOYSA-N
DM9ZRU2	IU	2-propyl-N-(5-sulfamoyl-2,3-dihydro-1H-inden-1-yl)pentanamide
DM9ZRU2	DE	Discovery agent

DM1TK45	ID	DM1TK45
DM1TK45	DN	2-((1H-imidazol-4-yl)methyl)pyridine
DM1TK45	HS	Investigative
DM1TK45	SN	CHEMBL81644; 2-((1H-imidazol-4-yl)methyl)pyridine; BDBM50326296
DM1TK45	DT	Small molecular drug
DM1TK45	PC	9877454
DM1TK45	MW	159.19
DM1TK45	FM	C9H9N3
DM1TK45	IC	InChI=1S/C9H9N3/c1-2-4-11-8(3-1)5-9-6-10-7-12-9/h1-4,6-7H,5H2,(H,10,12)
DM1TK45	CS	C1=CC=NC(=C1)CC2=CN=CN2
DM1TK45	IK	YSOIYRCVNZBHGT-UHFFFAOYSA-N
DM1TK45	IU	2-(1H-imidazol-5-ylmethyl)pyridine
DM1TK45	CA	CAS 87976-01-0
DM1TK45	DE	Discovery agent

DM91PA5	ID	DM91PA5
DM91PA5	DN	2-((2-ethoxyphenoxy)methyl)-4-isopropylmorpholine
DM91PA5	HS	Investigative
DM91PA5	SN	CHEMBL495543; 2-((2-ethoxyphenoxy)methyl)-4-isopropylmorpholine
DM91PA5	DT	Small molecular drug
DM91PA5	PC	12226576
DM91PA5	MW	279.37
DM91PA5	FM	C16H25NO3
DM91PA5	IC	InChI=1S/C16H25NO3/c1-4-18-15-7-5-6-8-16(15)20-12-14-11-17(13(2)3)9-10-19-14/h5-8,13-14H,4,9-12H2,1-3H3
DM91PA5	CS	CCOC1=CC=CC=C1OCC2CN(CCO2)C(C)C
DM91PA5	IK	YIUUQQVMBNHWQV-UHFFFAOYSA-N
DM91PA5	IU	2-[(2-ethoxyphenoxy)methyl]-4-propan-2-ylmorpholine
DM91PA5	DE	Discovery agent

DMS1AOK	ID	DMS1AOK
DMS1AOK	DN	2-((2-iodophenoxy)(phenyl)methyl)morpholine
DMS1AOK	HS	Investigative
DMS1AOK	SN	CHEMBL396328; 2-((2-iodophenoxy)(phenyl)methyl)morpholine
DMS1AOK	DT	Small molecular drug
DMS1AOK	PC	44438550
DMS1AOK	MW	395.23
DMS1AOK	FM	C17H18INO2
DMS1AOK	IC	InChI=1S/C17H18INO2/c18-14-8-4-5-9-15(14)21-17(13-6-2-1-3-7-13)16-12-19-10-11-20-16/h1-9,16-17,19H,10-12H2
DMS1AOK	CS	C1COC(CN1)C(C2=CC=CC=C2)OC3=CC=CC=C3I
DMS1AOK	IK	BHMLFPOTZYRDKA-UHFFFAOYSA-N
DMS1AOK	IU	2-[(2-iodophenoxy)-phenylmethyl]morpholine
DMS1AOK	DE	Discovery agent

DM1BI65	ID	DM1BI65
DM1BI65	DN	2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DM1BI65	HS	Investigative
DM1BI65	DT	Small molecular drug
DM1BI65	PC	44417638
DM1BI65	DE	Discovery agent

DMS21CR	ID	DMS21CR
DMS21CR	DN	2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine
DMS21CR	HS	Investigative
DMS21CR	SN	CHEMBL439030; 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine
DMS21CR	DT	Small molecular drug
DMS21CR	PC	44438489
DMS21CR	MW	409.3
DMS21CR	FM	C18H20INO2
DMS21CR	IC	InChI=1S/C18H20INO2/c1-13-5-2-3-8-16(13)22-18(17-12-20-9-10-21-17)14-6-4-7-15(19)11-14/h2-8,11,17-18,20H,9-10,12H2,1H3
DMS21CR	CS	CC1=CC=CC=C1OC(C2CNCCO2)C3=CC(=CC=C3)I
DMS21CR	IK	GUJGIDDFMFZKIV-UHFFFAOYSA-N
DMS21CR	IU	2-[(3-iodophenyl)-(2-methylphenoxy)methyl]morpholine
DMS21CR	DE	Discovery agent

DMFXDY3	ID	DMFXDY3
DMFXDY3	DN	2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid
DMFXDY3	HS	Investigative
DMFXDY3	SN	CHEMBL602385; 2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid
DMFXDY3	DT	Small molecular drug
DMFXDY3	PC	46227565
DMFXDY3	MW	213.32
DMFXDY3	FM	C12H23NO2
DMFXDY3	IC	InChI=1S/C12H23NO2/c1-2-3-4-10-5-6-12(7-10,9-13)8-11(14)15/h10H,2-9,13H2,1H3,(H,14,15)
DMFXDY3	CS	CCCCC1CCC(C1)(CC(=O)O)CN
DMFXDY3	IK	USZXKKPNEFLRDV-UHFFFAOYSA-N
DMFXDY3	IU	2-[1-(aminomethyl)-3-butylcyclopentyl]acetic acid
DMFXDY3	DE	Discovery agent

DM1ASK6	ID	DM1ASK6
DM1ASK6	DN	2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid
DM1ASK6	HS	Investigative
DM1ASK6	SN	CHEMBL594478; 2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid; SCHEMBL5433016; BDBM50304693
DM1ASK6	DT	Small molecular drug
DM1ASK6	PC	21879702
DM1ASK6	MW	185.26
DM1ASK6	FM	C10H19NO2
DM1ASK6	IC	InChI=1S/C10H19NO2/c1-2-8-3-4-10(5-8,7-11)6-9(12)13/h8H,2-7,11H2,1H3,(H,12,13)
DM1ASK6	CS	CCC1CCC(C1)(CC(=O)O)CN
DM1ASK6	IK	JUNVYYPZXPVIAH-UHFFFAOYSA-N
DM1ASK6	IU	2-[1-(aminomethyl)-3-ethylcyclopentyl]acetic acid
DM1ASK6	DE	Discovery agent

DM3D8WI	ID	DM3D8WI
DM3D8WI	DN	2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine
DM3D8WI	HS	Investigative
DM3D8WI	SN	CHEMBL363275; SCHEMBL1357126; BDBM21341; N1-Phenylsulfonyltryptamine, 11a
DM3D8WI	DT	Small molecular drug
DM3D8WI	PC	21071574
DM3D8WI	MW	300.4
DM3D8WI	FM	C16H16N2O2S
DM3D8WI	IC	InChI=1S/C16H16N2O2S/c17-11-10-13-12-18(16-9-5-4-8-15(13)16)21(19,20)14-6-2-1-3-7-14/h1-9,12H,10-11,17H2
DM3D8WI	CS	C1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=CC=CC=C32)CCN
DM3D8WI	IK	GSOZASAZEKGFMK-UHFFFAOYSA-N
DM3D8WI	IU	2-[1-(benzenesulfonyl)indol-3-yl]ethanamine
DM3D8WI	DE	Discovery agent

DMUE0D6	ID	DMUE0D6
DMUE0D6	DN	2-(1,1'-Biphenyl-4-Yl)Propanoic Acid
DMUE0D6	HS	Investigative
DMUE0D6	SN	alpha-Methyl-4-biphenylacetic acid; 6341-72-6; BPPA; NSC 16300; Ly 71130; 2-(p-Biphenyl)propionic acid; 2-(4-phenylphenyl)propanoic acid; 4-BIPHENYLACETIC ACID, alpha-METHYL-; CHEMBL317434; 2-Biphenyl-4-yl-propionic acid; Biprofen; 2-(4-Biphenylyl)propionic Acid; (1,1'-Biphenyl)-4-acetic acid, alpha-methyl-; 2-[1,1'-biphenyl]-4-ylpropanoic acid; [1,1'-Biphenyl]-4-aceticacid, a-methyl-; [1,1'-Biphenyl]-4-acetic acid, alpha-methyl-; alpha-Methyl-4-biphenyl-acetic acid; p-Phenylhydratropic Acid; 2-(4-Biphenyl)propionic acid,; Alpha-Methyl-4-biphenyl-acetic acid
DMUE0D6	DT	Small molecular drug
DMUE0D6	PC	448006
DMUE0D6	MW	226.27
DMUE0D6	FM	C15H14O2
DMUE0D6	IC	InChI=1S/C15H14O2/c1-11(15(16)17)12-7-9-14(10-8-12)13-5-3-2-4-6-13/h2-11H,1H3,(H,16,17)/t11-/m0/s1
DMUE0D6	CS	C[C@@H](C1=CC=C(C=C1)C2=CC=CC=C2)C(=O)O
DMUE0D6	IK	JALUUBQFLPUJMY-NSHDSACASA-N
DMUE0D6	IU	(2S)-2-(4-phenylphenyl)propanoic acid
DMUE0D6	CA	CAS 10532-14-6
DMUE0D6	DE	Discovery agent

DMZ83G9	ID	DMZ83G9
DMZ83G9	DN	2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridine
DMZ83G9	HS	Investigative
DMZ83G9	SN	CHEMBL583693; SCHEMBL12041243; BDBM50299006
DMZ83G9	DT	Small molecular drug
DMZ83G9	PC	45482707
DMZ83G9	MW	302.4
DMZ83G9	FM	C16H22N4S
DMZ83G9	IC	InChI=1S/C16H22N4S/c1-2-9-19(10-3-1)13-6-11-20(12-7-13)16-18-15-14(21-16)5-4-8-17-15/h4-5,8,13H,1-3,6-7,9-12H2
DMZ83G9	CS	C1CCN(CC1)C2CCN(CC2)C3=NC4=C(S3)C=CC=N4
DMZ83G9	IK	LHPSMXXBNXLHOD-UHFFFAOYSA-N
DMZ83G9	IU	2-(4-piperidin-1-ylpiperidin-1-yl)-[1,3]thiazolo[4,5-b]pyridine
DMZ83G9	DE	Discovery agent

DMEKSAZ	ID	DMEKSAZ
DMEKSAZ	DN	2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridine
DMEKSAZ	HS	Investigative
DMEKSAZ	SN	CHEMBL574615; SCHEMBL12041449; BDBM50299011
DMEKSAZ	DT	Small molecular drug
DMEKSAZ	PC	45482781
DMEKSAZ	MW	302.4
DMEKSAZ	FM	C16H22N4S
DMEKSAZ	IC	InChI=1S/C16H22N4S/c1-2-8-19(9-3-1)13-5-10-20(11-6-13)16-18-14-12-17-7-4-15(14)21-16/h4,7,12-13H,1-3,5-6,8-11H2
DMEKSAZ	CS	C1CCN(CC1)C2CCN(CC2)C3=NC4=C(S3)C=CN=C4
DMEKSAZ	IK	CYASDRJNADLAFT-UHFFFAOYSA-N
DMEKSAZ	IU	2-(4-piperidin-1-ylpiperidin-1-yl)-[1,3]thiazolo[4,5-c]pyridine
DMEKSAZ	DE	Discovery agent

DMVXN01	ID	DMVXN01
DMVXN01	DN	2-(10-Imidazol-1-yl-decyl)-isoindole-1,3-dione
DMVXN01	HS	Investigative
DMVXN01	SN	CHEMBL166731; 2-(10-Imidazol-1-yl-decyl)-isoindole-1,3-dione; SCHEMBL10655149; DOVKNTJKHQSOTE-UHFFFAOYSA-N; BDBM50024103; 2[10-(1H-imidazol-1-yl)decyl]-1H-isoindole-1,3(2H)dione
DMVXN01	DT	Small molecular drug
DMVXN01	PC	13588977
DMVXN01	MW	353.5
DMVXN01	FM	C21H27N3O2
DMVXN01	IC	InChI=1S/C21H27N3O2/c25-20-18-11-7-8-12-19(18)21(26)24(20)15-10-6-4-2-1-3-5-9-14-23-16-13-22-17-23/h7-8,11-13,16-17H,1-6,9-10,14-15H2
DMVXN01	CS	C1=CC=C2C(=C1)C(=O)N(C2=O)CCCCCCCCCCN3C=CN=C3
DMVXN01	IK	DOVKNTJKHQSOTE-UHFFFAOYSA-N
DMVXN01	IU	2-(10-imidazol-1-yldecyl)isoindole-1,3-dione
DMVXN01	DE	Discovery agent

DM05OJD	ID	DM05OJD
DM05OJD	DN	2-(1-adamantyl) piperidine
DM05OJD	HS	Investigative
DM05OJD	SN	2-(1-adamantyl)piperidine; 2-adamantanylpiperidine; 2-Adamantan-1-yl-piperidine; AC1LAFGW; Oprea1_303203; MLS000121957; SCHEMBL587889; 2-(adamantan-1-yl)piperidine; CHEMBL294443; CTK5J6774; MolPort-002-006-546; HMS2382E07; STL326117; AKOS016346316; AKOS000201213; MCULE-8550112936; BAS 06744019; SMR000119379; ST50340078; J3.628.419F
DM05OJD	DT	Small molecular drug
DM05OJD	PC	467461
DM05OJD	MW	219.37
DM05OJD	FM	C15H25N
DM05OJD	IC	InChI=1S/C15H25N/c1-2-4-16-14(3-1)15-8-11-5-12(9-15)7-13(6-11)10-15/h11-14,16H,1-10H2
DM05OJD	CS	C1CCNC(C1)C23CC4CC(C2)CC(C4)C3
DM05OJD	IK	CGRWFWOAXCFBRF-UHFFFAOYSA-N
DM05OJD	IU	2-(1-adamantyl)piperidine
DM05OJD	DE	Discovery agent

DMMSFEU	ID	DMMSFEU
DMMSFEU	DN	2-(1-adamantyl) pyrrolidine
DMMSFEU	HS	Investigative
DMMSFEU	SN	2-(1-adamantyl)pyrrolidine; 2-(adamantan-1-yl)pyrrolidine; 180258-96-2; 2-Adamantan-1-yl-pyrrolidine; 2-(tricyclo[3.3.1.1~3,7~]dec-1-yl)pyrrolidine; AC1LADDP; SCHEMBL587943; CHEMBL323901; CTK5J7450; YVRRAISBZUMEJB-UHFFFAOYSA-N; MolPort-004-320-513; ALBB-007403; ZX-AN006941; BBL022461; STK504519; AKOS016345558; AKOS000157977; RTR-059731; MCULE-4533332464; ACM180258962; TR-059731; W-9623; Pyrrolidine, 2-tricyclo[3.3.1.1~3,7~]dec-1-yl-, (2S)-
DMMSFEU	DT	Small molecular drug
DMMSFEU	PC	511811
DMMSFEU	MW	205.34
DMMSFEU	FM	C14H23N
DMMSFEU	IC	InChI=1S/C14H23N/c1-2-13(15-3-1)14-7-10-4-11(8-14)6-12(5-10)9-14/h10-13,15H,1-9H2
DMMSFEU	CS	C1CC(NC1)C23CC4CC(C2)CC(C4)C3
DMMSFEU	IK	YVRRAISBZUMEJB-UHFFFAOYSA-N
DMMSFEU	IU	2-(1-adamantyl)pyrrolidine
DMMSFEU	DE	Discovery agent

DMIGRMV	ID	DMIGRMV
DMIGRMV	DN	2-(1-adamantyl)-2-methyl-pyrrolidine
DMIGRMV	HS	Investigative
DMIGRMV	SN	SCHEMBL588363
DMIGRMV	DT	Small molecular drug
DMIGRMV	PC	11964505
DMIGRMV	MW	219.37
DMIGRMV	FM	C15H25N
DMIGRMV	IC	InChI=1S/C15H25N/c1-14(3-2-4-16-14)15-8-11-5-12(9-15)7-13(6-11)10-15/h11-13,16H,2-10H2,1H3
DMIGRMV	CS	CC1(CCCN1)C23CC4CC(C2)CC(C4)C3
DMIGRMV	IK	JQQSEBALQVRCLA-UHFFFAOYSA-N
DMIGRMV	IU	2-(1-adamantyl)-2-methylpyrrolidine
DMIGRMV	DE	Discovery agent

DMB5LHA	ID	DMB5LHA
DMB5LHA	DN	2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine
DMB5LHA	HS	Investigative
DMB5LHA	SN	CHEMBL457351; 2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine; SCHEMBL3320417
DMB5LHA	DT	Small molecular drug
DMB5LHA	PC	11818252
DMB5LHA	MW	277.4
DMB5LHA	FM	C20H23N
DMB5LHA	IC	InChI=1S/C20H23N/c1-21(2)13-12-17-15-18(14-16-8-4-3-5-9-16)20-11-7-6-10-19(17)20/h3-11,15,18H,12-14H2,1-2H3
DMB5LHA	CS	CN(C)CCC1=CC(C2=CC=CC=C21)CC3=CC=CC=C3
DMB5LHA	IK	CKYIFJXFLBXUQQ-UHFFFAOYSA-N
DMB5LHA	IU	2-(3-benzyl-3H-inden-1-yl)-N,N-dimethylethanamine
DMB5LHA	DE	Discovery agent

DMML3XI	ID	DMML3XI
DMML3XI	DN	2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine
DMML3XI	HS	Investigative
DMML3XI	SN	CHEMBL188144; 2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine; BDBM50164758
DMML3XI	DT	Small molecular drug
DMML3XI	PC	44397102
DMML3XI	MW	278.4
DMML3XI	FM	C19H22N2
DMML3XI	IC	InChI=1S/C19H22N2/c1-20(2)13-12-17-15-21(14-16-8-4-3-5-9-16)19-11-7-6-10-18(17)19/h3-11,15H,12-14H2,1-2H3
DMML3XI	CS	CN(C)CCC1=CN(C2=CC=CC=C21)CC3=CC=CC=C3
DMML3XI	IK	QBWKAYAFIXQNCU-UHFFFAOYSA-N
DMML3XI	IU	2-(1-benzylindol-3-yl)-N,N-dimethylethanamine
DMML3XI	DE	Discovery agent

DMF2XHZ	ID	DMF2XHZ
DMF2XHZ	DN	2-(1-dodecyl-1H-indol-3-yl)acetic acid
DMF2XHZ	HS	Investigative
DMF2XHZ	SN	CHEMBL521836; 2-(1-dodecyl-1H-indol-3-yl)acetic acid
DMF2XHZ	DT	Small molecular drug
DMF2XHZ	PC	44577010
DMF2XHZ	MW	343.5
DMF2XHZ	FM	C22H33NO2
DMF2XHZ	IC	InChI=1S/C22H33NO2/c1-2-3-4-5-6-7-8-9-10-13-16-23-18-19(17-22(24)25)20-14-11-12-15-21(20)23/h11-12,14-15,18H,2-10,13,16-17H2,1H3,(H,24,25)
DMF2XHZ	CS	CCCCCCCCCCCCN1C=C(C2=CC=CC=C21)CC(=O)O
DMF2XHZ	IK	BFCFBVXYQIIZAF-UHFFFAOYSA-N
DMF2XHZ	IU	2-(1-dodecylindol-3-yl)acetic acid
DMF2XHZ	DE	Discovery agent

DM0Y2P1	ID	DM0Y2P1
DM0Y2P1	DN	2-(1H-benzo[d]imidazol-2-yl)quinoxaline
DM0Y2P1	HS	Investigative
DM0Y2P1	SN	CHEMBL200636; benzimidazolylquinoxaline; benzimidazole-quinoxaline, C1; BDBM21215; 2-(1H-benzimidazol-2-yl)quinoxaline; 2-(1H-Benzoimidazole-2-yl)quinoxaline
DM0Y2P1	DT	Small molecular drug
DM0Y2P1	PC	11658819
DM0Y2P1	MW	246.27
DM0Y2P1	FM	C15H10N4
DM0Y2P1	IC	InChI=1S/C15H10N4/c1-2-6-11-10(5-1)16-9-14(17-11)15-18-12-7-3-4-8-13(12)19-15/h1-9H,(H,18,19)
DM0Y2P1	CS	C1=CC=C2C(=C1)NC(=N2)C3=NC4=CC=CC=C4N=C3
DM0Y2P1	IK	AYFBMQMYJRNGIM-UHFFFAOYSA-N
DM0Y2P1	IU	2-(1H-benzimidazol-2-yl)quinoxaline
DM0Y2P1	DE	Discovery agent

DMXA20E	ID	DMXA20E
DMXA20E	DN	2-(1H-imidazo[4,5-c]pyridin-2-yl)quinoxaline
DMXA20E	HS	Investigative
DMXA20E	SN	CHEMBL380770; 2-(1H-imidazo[4,5-c]pyridin-2-yl)quinoxaline; ZINC13678127
DMXA20E	DT	Small molecular drug
DMXA20E	PC	11536096
DMXA20E	MW	247.25
DMXA20E	FM	C14H9N5
DMXA20E	IC	InChI=1S/C14H9N5/c1-2-4-10-9(3-1)16-8-13(17-10)14-18-11-5-6-15-7-12(11)19-14/h1-8H,(H,18,19)
DMXA20E	CS	C1=CC=C2C(=C1)N=CC(=N2)C3=NC4=C(N3)C=NC=C4
DMXA20E	IK	UYUCQGUDIHPICB-UHFFFAOYSA-N
DMXA20E	IU	2-(3H-imidazo[4,5-c]pyridin-2-yl)quinoxaline
DMXA20E	DE	Discovery agent

DMFK9GA	ID	DMFK9GA
DMFK9GA	DN	2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone
DMFK9GA	HS	Investigative
DMFK9GA	SN	37910-79-5; n-(4-nitrophenacyl)imidazole; CHEMBL162549; 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone; Ethanone, 2-(1H-imidazol-1-yl)-1-(4-nitrophenyl)-; AC1Q5DPC; 2-imidazol-1-yl-1-(4-nitrophenyl)ethanone; AC1Q1XG1; SCHEMBL5730977; AC1L1F83; CTK1A9243; DTXSID00275594; BDBM50240895; ZINC19595447; AKOS009984680; 2-Imidazol-1-yl-1-(4-nitro-phenyl)-ethanone; I90114; alpha-(1H-Imidazole-1-yl)-4'-nitroacetophenone; 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)-ethanone
DMFK9GA	DT	Small molecular drug
DMFK9GA	PC	53600
DMFK9GA	MW	231.21
DMFK9GA	FM	C11H9N3O3
DMFK9GA	IC	InChI=1S/C11H9N3O3/c15-11(7-13-6-5-12-8-13)9-1-3-10(4-2-9)14(16)17/h1-6,8H,7H2
DMFK9GA	CS	C1=CC(=CC=C1C(=O)CN2C=CN=C2)[N+](=O)[O-]
DMFK9GA	IK	SBPGWXSTCFNGPY-UHFFFAOYSA-N
DMFK9GA	IU	2-imidazol-1-yl-1-(4-nitrophenyl)ethanone
DMFK9GA	CA	CAS 37910-79-5
DMFK9GA	DE	Discovery agent

DM2PZ1B	ID	DM2PZ1B
DM2PZ1B	DN	2-(1H-Imidazol-4-yl)benzene-1,3-diol
DM2PZ1B	HS	Investigative
DM2PZ1B	SN	2-(1H-Imidazol-4-yl)benzene-1,3-diol; 1048983-14-7; CHEMBL509549; SCHEMBL1502239; BDBM24664; 2-(1H-imidazol-4-yl)benzene-1,3-diol, 11
DM2PZ1B	DT	Small molecular drug
DM2PZ1B	PC	24971326
DM2PZ1B	MW	176.17
DM2PZ1B	FM	C9H8N2O2
DM2PZ1B	IC	InChI=1S/C9H8N2O2/c12-7-2-1-3-8(13)9(7)6-4-10-5-11-6/h1-5,12-13H,(H,10,11)
DM2PZ1B	CS	C1=CC(=C(C(=C1)O)C2=CN=CN2)O
DM2PZ1B	IK	VMNQZTQDHXFNPD-UHFFFAOYSA-N
DM2PZ1B	IU	2-(1H-imidazol-5-yl)benzene-1,3-diol
DM2PZ1B	DE	Discovery agent

DM6MR82	ID	DM6MR82
DM6MR82	DN	2-(1H-Imidazol-4-yl)phenol
DM6MR82	HS	Investigative
DM6MR82	SN	2-(1H-Imidazol-4-yl)phenol; 19170-74-2; 2-(1H-Imidazol-5-yl)-phenol; 2-(1H-Imidazol-5-yl)phenol; CHEMBL457063; SCHEMBL1502109; BDBM24663; 2-(1H-imidazol-4-yl)phenol, 1
DM6MR82	DT	Small molecular drug
DM6MR82	PC	10307884
DM6MR82	MW	160.17
DM6MR82	FM	C9H8N2O
DM6MR82	IC	InChI=1S/C9H8N2O/c12-9-4-2-1-3-7(9)8-5-10-6-11-8/h1-6,12H,(H,10,11)
DM6MR82	CS	C1=CC=C(C(=C1)C2=CN=CN2)O
DM6MR82	IK	BYAAMOMNSVKNMA-UHFFFAOYSA-N
DM6MR82	IU	2-(1H-imidazol-5-yl)phenol
DM6MR82	DE	Discovery agent

DMCG1HE	ID	DMCG1HE
DMCG1HE	DN	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole
DMCG1HE	HS	Investigative
DMCG1HE	SN	CHEMBL289060; 2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole; BDBM50014174
DMCG1HE	DT	Small molecular drug
DMCG1HE	PC	14742545
DMCG1HE	MW	241.31
DMCG1HE	FM	C13H11N3S
DMCG1HE	IC	InChI=1S/C13H11N3S/c1-2-4-10(5-3-1)12-8-17-13(16-12)6-11-7-14-9-15-11/h1-5,7-9H,6H2,(H,14,15)
DMCG1HE	CS	C1=CC=C(C=C1)C2=CSC(=N2)CC3=CN=CN3
DMCG1HE	IK	TVRYIDIUBFYXFE-UHFFFAOYSA-N
DMCG1HE	IU	2-(1H-imidazol-5-ylmethyl)-4-phenyl-1,3-thiazole
DMCG1HE	DE	Discovery agent

DM0CSH8	ID	DM0CSH8
DM0CSH8	DN	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole
DM0CSH8	HS	Investigative
DM0CSH8	SN	3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE; CHEMBL383990; 3-(1H-1,3-benzodiazol-2-yl)-2H-indazole; 2-(2H-indazol-3-yl)-1H-1,3-benzodiazole; IDZ; 1097816-83-5; Indazole Compound 2; 2c3l; AC1Q4XAS; AC1NS1P1; SCHEMBL311148; BDBM16590; 3-benzimidazol-2-yl-1h-indazole; JTKFRFMSUBOCIQ-UHFFFAOYSA-N; MolPort-016-542-829; ZINC14961821; AKOS009356321; NE25942; MCULE-6782886882; DB07959; 2-(1H-indazol-3-yl)-1H-benzimidazole; 3-(1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-Indazole-3-yl)-1H-benzoimidazole; EN300-70692
DM0CSH8	DT	Small molecular drug
DM0CSH8	PC	135464491
DM0CSH8	MW	234.26
DM0CSH8	FM	C14H10N4
DM0CSH8	IC	InChI=1S/C14H10N4/c1-2-6-10-9(5-1)13(18-17-10)14-15-11-7-3-4-8-12(11)16-14/h1-8H,(H,15,16)(H,17,18)
DM0CSH8	CS	C1=CC=C2C(=C1)C(=NN2)C3=NC4=CC=CC=C4N3
DM0CSH8	IK	JTKFRFMSUBOCIQ-UHFFFAOYSA-N
DM0CSH8	IU	2-(1H-indazol-3-yl)-1H-benzimidazole
DM0CSH8	DE	Discovery agent

DMFAME4	ID	DMFAME4
DMFAME4	DN	2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide
DMFAME4	HS	Investigative
DMFAME4	SN	2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide; USGVPHMVQJFJJD-UHFFFAOYSA-N; 2-(1H-indol-3-yl)-2-oxo-N-(2-phenylethyl)acetamide; 2-(1H-Indol-3-yl)-2-oxo-N-[2-phenylethyl]acetamide; AC1M2UTB; MLS001212145; CHEMBL68442; SCHEMBL4760802; MolPort-000-249-097; HMS3430C11; ZINC2815535; STK710826; AKOS000530675; MCULE-7691246998; 94209-12-8; BAS 04280191; SMR000518992; ST4091858; MLS-0351990.0002; 2-(1H-indol-3-yl)-2-oxo-N-phenethylacetamide; 2-indol-3-yl-2-oxo-N-(2-phenylethyl)acetamide; Acetamide, 2-(1H-indol-3-yl)-2-oxo-N-phenethyl-
DMFAME4	DT	Small molecular drug
DMFAME4	PC	2176767
DMFAME4	MW	292.3
DMFAME4	FM	C18H16N2O2
DMFAME4	IC	InChI=1S/C18H16N2O2/c21-17(15-12-20-16-9-5-4-8-14(15)16)18(22)19-11-10-13-6-2-1-3-7-13/h1-9,12,20H,10-11H2,(H,19,22)
DMFAME4	CS	C1=CC=C(C=C1)CCNC(=O)C(=O)C2=CNC3=CC=CC=C32
DMFAME4	IK	USGVPHMVQJFJJD-UHFFFAOYSA-N
DMFAME4	IU	2-(1H-indol-3-yl)-2-oxo-N-(2-phenylethyl)acetamide
DMFAME4	DE	Discovery agent

DMR9Q4Y	ID	DMR9Q4Y
DMR9Q4Y	DN	2-(1H-indol-3-yl)-N,N-dimethylethanamine
DMR9Q4Y	HS	Investigative
DMR9Q4Y	SN	N,N-Dimethyltryptamine; N,N-DIMETHYLTRYPTAMINE; DIMETHYLTRYPTAMINE; 61-50-7; 3-(2-Dimethylaminoethyl)indole; 2-(3-Indolyl)ethyldimethylamine; N,N-Dimethyl-1H-indole-3-ethylamine; 2-(1H-Indol-3-yl)-N,N-dimethylethanamine; 1H-Indole-3-ethanamine, N,N-dimethyl-; DMT (psychogenic); (psychogenic); UNII-WUB601BHAA; 3-[2-(dimethylamino)ethyl]indole; EINECS 200-508-4; NSC 63795; WUB601BHAA; N,N-dimethyl-1H-Indole-3-ethanamine; BRN 0138259; CHEMBL12420; DEA No 7435; CHEBI:28969; DMULVCHRPCFFGV-UHFFFAOYSA-N; (2-Indol-3-ylethyl)dimethylamine; Indole,; Dimethyltryptamine
DMR9Q4Y	DT	Small molecular drug
DMR9Q4Y	PC	6089
DMR9Q4Y	MW	188.27
DMR9Q4Y	FM	C12H16N2
DMR9Q4Y	IC	InChI=1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3
DMR9Q4Y	CS	CN(C)CCC1=CNC2=CC=CC=C21
DMR9Q4Y	IK	DMULVCHRPCFFGV-UHFFFAOYSA-N
DMR9Q4Y	IU	2-(1H-indol-3-yl)-N,N-dimethylethanamine
DMR9Q4Y	CA	CAS 61-50-7
DMR9Q4Y	CB	CHEBI:28969
DMR9Q4Y	DE	Discovery agent

DMB7AU5	ID	DMB7AU5
DMB7AU5	DN	2-(1H-Indol-3-ylmethyl)-1,2-dihydro-indazol-3-one
DMB7AU5	HS	Investigative
DMB7AU5	SN	CHEMBL3144574; CHEMBL8374; 2-(1H-Indol-3-ylmethyl)-1,2-dihydro-indazol-3-one; BDBM50009014
DMB7AU5	DT	Small molecular drug
DMB7AU5	PC	44265197
DMB7AU5	MW	263.29
DMB7AU5	FM	C16H13N3O
DMB7AU5	IC	InChI=1S/C16H13N3O/c20-16-13-6-2-4-8-15(13)18-19(16)10-11-9-17-14-7-3-1-5-12(11)14/h1-9,17-18H,10H2
DMB7AU5	CS	C1=CC=C2C(=C1)C(=CN2)CN3C(=O)C4=CC=CC=C4N3
DMB7AU5	IK	IAJFPXRONWWXNK-UHFFFAOYSA-N
DMB7AU5	IU	2-(1H-indol-3-ylmethyl)-1H-indazol-3-one
DMB7AU5	DE	Discovery agent

DMZNML4	ID	DMZNML4
DMZNML4	DN	2-(1H-indol-5-yl)-6-morpholino-4H-pyran-4-one
DMZNML4	HS	Investigative
DMZNML4	SN	CHEMBL222745; 2-(1H-indol-5-yl)-6-morpholino-4H-pyran-4-one
DMZNML4	DT	Small molecular drug
DMZNML4	PC	16203946
DMZNML4	MW	296.32
DMZNML4	FM	C17H16N2O3
DMZNML4	IC	InChI=1S/C17H16N2O3/c20-14-10-16(13-1-2-15-12(9-13)3-4-18-15)22-17(11-14)19-5-7-21-8-6-19/h1-4,9-11,18H,5-8H2
DMZNML4	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC4=C(C=C3)NC=C4
DMZNML4	IK	AWODDYAKSFDGCI-UHFFFAOYSA-N
DMZNML4	IU	2-(1H-indol-5-yl)-6-morpholin-4-ylpyran-4-one
DMZNML4	DE	Discovery agent

DMHSORL	ID	DMHSORL
DMHSORL	DN	2-(1H-pyrazol-3-yl)-1H-benzimidazole
DMHSORL	HS	Investigative
DMHSORL	DT	Small molecular drug
DMHSORL	PC	763936
DMHSORL	MW	184.2
DMHSORL	FM	C10H8N4
DMHSORL	IC	InChI=1S/C10H8N4/c1-2-4-8-7(3-1)12-10(13-8)9-5-6-11-14-9/h1-6H,(H,11,14)(H,12,13)
DMHSORL	CS	C1=CC=C2C(=C1)NC(=N2)C3=CC=NN3
DMHSORL	IK	IYTGPPNUOLLGBE-UHFFFAOYSA-N
DMHSORL	IU	2-(1H-pyrazol-5-yl)-1H-benzimidazole
DMHSORL	DE	Discovery agent

DMUY75A	ID	DMUY75A
DMUY75A	DN	2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
DMUY75A	HS	Investigative
DMUY75A	SN	2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol; 1-(2,4,6-trihydroxybenzoyl)pyrrole; 288839-58-7; 3eko; CHEMBL513225; DB08443; 2-(1-Pyrrolylcarbonyl)benzene-1,3,5-triol; 2-(pyrrole-1-carbonyl)benzene-1,3,5-triol
DMUY75A	DT	Small molecular drug
DMUY75A	PC	11160307
DMUY75A	MW	219.19
DMUY75A	FM	C11H9NO4
DMUY75A	IC	InChI=1S/C11H9NO4/c13-7-5-8(14)10(9(15)6-7)11(16)12-3-1-2-4-12/h1-6,13-15H
DMUY75A	CS	C1=CN(C=C1)C(=O)C2=C(C=C(C=C2O)O)O
DMUY75A	IK	RYGSNHBTZDYVSS-UHFFFAOYSA-N
DMUY75A	IU	pyrrol-1-yl-(2,4,6-trihydroxyphenyl)methanone
DMUY75A	DE	Discovery agent

DM4MIXK	ID	DM4MIXK
DM4MIXK	DN	2-(1-Imidazol-1-yl-ethyl)-9H-carbazole
DM4MIXK	HS	Investigative
DM4MIXK	SN	CHEMBL499882; 2-(1-Imidazol-1-yl-ethyl)-9H-carbazole; SCHEMBL9020993; VCFYTQOGKYSBGI-UHFFFAOYSA-N; BDBM50272211; YM 55208; 2-[1-(1H-imidazol-1-yl) ethyl]carbazole
DM4MIXK	DT	Small molecular drug
DM4MIXK	PC	18976091
DM4MIXK	MW	261.32
DM4MIXK	FM	C17H15N3
DM4MIXK	IC	InChI=1S/C17H15N3/c1-12(20-9-8-18-11-20)13-6-7-15-14-4-2-3-5-16(14)19-17(15)10-13/h2-12,19H,1H3
DM4MIXK	CS	CC(C1=CC2=C(C=C1)C3=CC=CC=C3N2)N4C=CN=C4
DM4MIXK	IK	VCFYTQOGKYSBGI-UHFFFAOYSA-N
DM4MIXK	IU	2-(1-imidazol-1-ylethyl)-9H-carbazole
DM4MIXK	DE	Discovery agent

DMY35HG	ID	DMY35HG
DMY35HG	DN	2-(1-o-tolyl-1H-pyrrol-3-yl)ethanamine
DMY35HG	HS	Investigative
DMY35HG	SN	CHEMBL232994
DMY35HG	DT	Small molecular drug
DMY35HG	PC	44431707
DMY35HG	MW	200.28
DMY35HG	FM	C13H16N2
DMY35HG	IC	InChI=1S/C13H16N2/c1-11-4-2-3-5-13(11)15-9-7-12(10-15)6-8-14/h2-5,7,9-10H,6,8,14H2,1H3
DMY35HG	CS	CC1=CC=CC=C1N2C=CC(=C2)CCN
DMY35HG	IK	MQJFADBSJHNKPK-UHFFFAOYSA-N
DMY35HG	IU	2-[1-(2-methylphenyl)pyrrol-3-yl]ethanamine
DMY35HG	DE	Discovery agent

DMR0HDF	ID	DMR0HDF
DMR0HDF	DN	2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole
DMR0HDF	HS	Investigative
DMR0HDF	SN	CHEMBL119494; SCHEMBL4814520
DMR0HDF	DT	Small molecular drug
DMR0HDF	PC	9944114
DMR0HDF	MW	298.5
DMR0HDF	FM	C20H30N2
DMR0HDF	IC	InChI=1S/C20H30N2/c1-3-5-8-14-18(15-9-6-4-2)20-21-16-19(22-20)17-12-10-7-11-13-17/h7,10-13,16,18H,3-6,8-9,14-15H2,1-2H3,(H,21,22)
DMR0HDF	CS	CCCCCC(CCCCC)C1=NC=C(N1)C2=CC=CC=C2
DMR0HDF	IK	XYWGMJFQZHLYDO-UHFFFAOYSA-N
DMR0HDF	IU	5-phenyl-2-undecan-6-yl-1H-imidazole
DMR0HDF	DE	Discovery agent

DMXCID6	ID	DMXCID6
DMXCID6	DN	2-(1-tosyl-1H-indol-3-yl)ethanamine
DMXCID6	HS	Investigative
DMXCID6	SN	CHEMBL394303; SCHEMBL15250049; BDBM21349; 1-Tosyl-1H-indole-3-ethaneamine; Substituted phenylsulfonyltryptamine, 11h
DMXCID6	DT	Small molecular drug
DMXCID6	PC	14571158
DMXCID6	MW	314.4
DMXCID6	FM	C17H18N2O2S
DMXCID6	IC	InChI=1S/C17H18N2O2S/c1-13-6-8-15(9-7-13)22(20,21)19-12-14(10-11-18)16-4-2-3-5-17(16)19/h2-9,12H,10-11,18H2,1H3
DMXCID6	CS	CC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=CC=CC=C32)CCN
DMXCID6	IK	XKKWGBDMWUAPLE-UHFFFAOYSA-N
DMXCID6	IU	2-[1-(4-methylphenyl)sulfonylindol-3-yl]ethanamine
DMXCID6	DE	Discovery agent

DMGZKCT	ID	DMGZKCT
DMGZKCT	DN	2-(2-((benzylamino)methyl)phenoxy)-5-chlorophenol
DMGZKCT	HS	Investigative
DMGZKCT	DE	Discovery agent

DM54M6C	ID	DM54M6C
DM54M6C	DN	2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid
DM54M6C	HS	Investigative
DM54M6C	SN	CHEMBL77981; 2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid; SCHEMBL7166052; JSJQNYIFLKCXRE-UHFFFAOYSA-N; ZINC13809288; BDBM50090679; 2-(2,5-Dichloroanilino)benzeneacetic acid; 2-[(2,5-dichlorophenyl)amino]phenylacetic acid; [2-(2,5-Dichloro-phenylamino)-phenyl]-acetic acid
DM54M6C	DT	Small molecular drug
DM54M6C	PC	14076674
DM54M6C	MW	296.1
DM54M6C	FM	C14H11Cl2NO2
DM54M6C	IC	InChI=1S/C14H11Cl2NO2/c15-10-5-6-11(16)13(8-10)17-12-4-2-1-3-9(12)7-14(18)19/h1-6,8,17H,7H2,(H,18,19)
DM54M6C	CS	C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC(=C2)Cl)Cl
DM54M6C	IK	JSJQNYIFLKCXRE-UHFFFAOYSA-N
DM54M6C	IU	2-[2-(2,5-dichloroanilino)phenyl]acetic acid
DM54M6C	DE	Discovery agent

DMJ2DE4	ID	DMJ2DE4
DMJ2DE4	DN	2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid
DMJ2DE4	HS	Investigative
DMJ2DE4	SN	CHEMBL76154; SCHEMBL6239733; CTK8H7205; ICJTVRXTYOYEOT-UHFFFAOYSA-N; BDBM50375601; ZINC26399260; 2-(2,6-Dimethylanilino)benzeneacetic acid; 2-[(2,6-dimethylphenyl]amino]phenylacetic acid; 2-[(2,6-dimethylphenyl] amino] phenylacetic acid
DMJ2DE4	DT	Small molecular drug
DMJ2DE4	PC	14762941
DMJ2DE4	MW	255.31
DMJ2DE4	FM	C16H17NO2
DMJ2DE4	IC	InChI=1S/C16H17NO2/c1-11-6-5-7-12(2)16(11)17-14-9-4-3-8-13(14)10-15(18)19/h3-9,17H,10H2,1-2H3,(H,18,19)
DMJ2DE4	CS	CC1=C(C(=CC=C1)C)NC2=CC=CC=C2CC(=O)O
DMJ2DE4	IK	ICJTVRXTYOYEOT-UHFFFAOYSA-N
DMJ2DE4	IU	2-[2-(2,6-dimethylanilino)phenyl]acetic acid
DMJ2DE4	DE	Discovery agent

DMBP1TQ	ID	DMBP1TQ
DMBP1TQ	DN	2-(2-(2-chlorophenoxy)phenyl)acetic acid
DMBP1TQ	HS	Investigative
DMBP1TQ	SN	CHEMBL30038; 2-(2-(2-chlorophenoxy)phenyl)acetic acid; BDBM50295282; ZINC28766380; [2-(2-Chloro-phenoxy)-phenyl]-acetic acid
DMBP1TQ	DT	Small molecular drug
DMBP1TQ	PC	15581854
DMBP1TQ	MW	262.69
DMBP1TQ	FM	C14H11ClO3
DMBP1TQ	IC	InChI=1S/C14H11ClO3/c15-11-6-2-4-8-13(11)18-12-7-3-1-5-10(12)9-14(16)17/h1-8H,9H2,(H,16,17)
DMBP1TQ	CS	C1=CC=C(C(=C1)CC(=O)O)OC2=CC=CC=C2Cl
DMBP1TQ	IK	SYANOAWCBFRXNL-UHFFFAOYSA-N
DMBP1TQ	IU	2-[2-(2-chlorophenoxy)phenyl]acetic acid
DMBP1TQ	CA	CAS 81682-40-8
DMBP1TQ	DE	Discovery agent

DMPLV3A	ID	DMPLV3A
DMPLV3A	DN	2-(2-(2-chlorophenylamino)phenyl)acetic acid
DMPLV3A	HS	Investigative
DMPLV3A	SN	CHEMBL77823; 488862-17-5; 2-(2-(2-chlorophenylamino)phenyl)acetic acid; SCHEMBL6243911; CTK1D1110; DTXSID00548437; RXRLPBIKRNGLJD-UHFFFAOYSA-N; ZINC26400000; BDBM50295275; AKOS030583290; [2-(2-Chloroanilino)phenyl]acetic acid; 2-(2-Chlorophenylamino)benzeneacetic acid; 2-[(2-chlorophenyl)amino]phenylacetic acid; Benzeneacetic acid, 2-[(chlorophenyl)amino]-; [2-(2-Chloro-phenylamino)-phenyl]-acetic acid
DMPLV3A	DT	Small molecular drug
DMPLV3A	PC	13752584
DMPLV3A	MW	261.7
DMPLV3A	FM	C14H12ClNO2
DMPLV3A	IC	InChI=1S/C14H12ClNO2/c15-11-6-2-4-8-13(11)16-12-7-3-1-5-10(12)9-14(17)18/h1-8,16H,9H2,(H,17,18)
DMPLV3A	CS	C1=CC=C(C(=C1)CC(=O)O)NC2=CC=CC=C2Cl
DMPLV3A	IK	RXRLPBIKRNGLJD-UHFFFAOYSA-N
DMPLV3A	IU	2-[2-(2-chloroanilino)phenyl]acetic acid
DMPLV3A	CA	CAS 488862-17-5
DMPLV3A	DE	Discovery agent

DMDSUR2	ID	DMDSUR2
DMDSUR2	DN	2-(2-(2-fluorophenoxy)phenyl)acetic acid
DMDSUR2	HS	Investigative
DMDSUR2	SN	CHEMBL29804; 2-(2-(2-fluorophenoxy)phenyl)acetic acid; BDBM50295281; ZINC28767088; AKOS022663030; [2-(2-Fluoro-phenoxy)-phenyl]-acetic acid
DMDSUR2	DT	Small molecular drug
DMDSUR2	PC	13409348
DMDSUR2	MW	246.23
DMDSUR2	FM	C14H11FO3
DMDSUR2	IC	InChI=1S/C14H11FO3/c15-11-6-2-4-8-13(11)18-12-7-3-1-5-10(12)9-14(16)17/h1-8H,9H2,(H,16,17)
DMDSUR2	CS	C1=CC=C(C(=C1)CC(=O)O)OC2=CC=CC=C2F
DMDSUR2	IK	LAVKHAMQQVBXLL-UHFFFAOYSA-N
DMDSUR2	IU	2-[2-(2-fluorophenoxy)phenyl]acetic acid
DMDSUR2	DE	Discovery agent

DMVQ68F	ID	DMVQ68F
DMVQ68F	DN	2-(2-(2-fluorophenylamino)phenyl)acetic acid
DMVQ68F	HS	Investigative
DMVQ68F	SN	CHEMBL427739; 2-(2-(2-fluorophenylamino)phenyl)acetic acid; SCHEMBL7165042; DWKOQWOOVUATNI-UHFFFAOYSA-N; BDBM50295276; 2-[(2-fluorophenyl)amino]phenylacetic acid
DMVQ68F	DT	Small molecular drug
DMVQ68F	PC	18546352
DMVQ68F	MW	245.25
DMVQ68F	FM	C14H12FNO2
DMVQ68F	IC	InChI=1S/C14H12FNO2/c15-11-6-2-4-8-13(11)16-12-7-3-1-5-10(12)9-14(17)18/h1-8,16H,9H2,(H,17,18)
DMVQ68F	CS	C1=CC=C(C(=C1)CC(=O)O)NC2=CC=CC=C2F
DMVQ68F	IK	DWKOQWOOVUATNI-UHFFFAOYSA-N
DMVQ68F	IU	2-[2-(2-fluoroanilino)phenyl]acetic acid
DMVQ68F	DE	Discovery agent

DMKT51Z	ID	DMKT51Z
DMKT51Z	DN	2-(2-(4-tert-butylphenoxy)acetamido)benzoic acid
DMKT51Z	HS	Investigative
DMKT51Z	SN	CHEMBL443733; Oprea1_160526; 2-(2-(4-tert-butylphenoxy)acetamido)benzoic acid; SCHEMBL3987191; 2-[[2-(4-tert-butylphenoxy)acetyl]amino]benzoic Acid; MolPort-001-494-161; ZINC4546761; AC1N7082; STK000456; BDBM50264188; AKOS002944005; MCULE-2716737007; 2-{[(4-tert-butylphenoxy)acetyl]amino}benzoic acid
DMKT51Z	DT	Small molecular drug
DMKT51Z	PC	4268702
DMKT51Z	MW	327.4
DMKT51Z	FM	C19H21NO4
DMKT51Z	IC	InChI=1S/C19H21NO4/c1-19(2,3)13-8-10-14(11-9-13)24-12-17(21)20-16-7-5-4-6-15(16)18(22)23/h4-11H,12H2,1-3H3,(H,20,21)(H,22,23)
DMKT51Z	CS	CC(C)(C)C1=CC=C(C=C1)OCC(=O)NC2=CC=CC=C2C(=O)O
DMKT51Z	IK	RZQIBGXCHZEONC-UHFFFAOYSA-N
DMKT51Z	IU	2-[[2-(4-tert-butylphenoxy)acetyl]amino]benzoic acid
DMKT51Z	DE	Discovery agent

DMZVBPG	ID	DMZVBPG
DMZVBPG	DN	2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole
DMZVBPG	HS	Investigative
DMZVBPG	SN	4-(2-(4-tert-butylphenylthio)ethyl)-1H-imidazole; 4-(2-(40-tert-butylphenylthio)ethyl)-1H-imidazole
DMZVBPG	PC	46222048
DMZVBPG	MW	260.399
DMZVBPG	FM	C15H20N2S
DMZVBPG	IC	InChI=1S/C15H20N2S/c1-15(2,3)12-4-6-14(7-5-12)18-9-8-13-10-16-11-17-13/h4-7,10-11H,8-9H2,1-3H3,(H,16,17)
DMZVBPG	CS	CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2
DMZVBPG	IK	PQPVHIHIJVIEQG-UHFFFAOYSA-N
DMZVBPG	IU	5-[2-(4-tert-butylphenyl)sulfanylethyl]-1H-imidazole
DMZVBPG	DE	Discovery agent

DMDR50V	ID	DMDR50V
DMDR50V	DN	2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid
DMDR50V	HS	Investigative
DMDR50V	SN	CHEMBL572947; 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid
DMDR50V	DT	Small molecular drug
DMDR50V	PC	21496278
DMDR50V	MW	288.4
DMDR50V	FM	C16H16O3S
DMDR50V	IC	InChI=1S/C16H16O3S/c17-16(18)12-20(19)11-10-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-9H,10-12H2,(H,17,18)
DMDR50V	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCS(=O)CC(=O)O
DMDR50V	IK	JPUWBNMOSGBVRW-UHFFFAOYSA-N
DMDR50V	IU	2-[2-(4-phenylphenyl)ethylsulfinyl]acetic acid
DMDR50V	DE	Discovery agent

DM95B4J	ID	DM95B4J
DM95B4J	DN	2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid
DM95B4J	HS	Investigative
DM95B4J	SN	CHEMBL566511; 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid
DM95B4J	DT	Small molecular drug
DM95B4J	PC	45483015
DM95B4J	MW	304.4
DM95B4J	FM	C16H16O4S
DM95B4J	IC	InChI=1S/C16H16O4S/c17-16(18)12-21(19,20)11-10-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-9H,10-12H2,(H,17,18)
DM95B4J	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCS(=O)(=O)CC(=O)O
DM95B4J	IK	PPYPHJNYICUMPA-UHFFFAOYSA-N
DM95B4J	IU	2-[2-(4-phenylphenyl)ethylsulfonyl]acetic acid
DM95B4J	DE	Discovery agent

DMBZIUC	ID	DMBZIUC
DMBZIUC	DN	2-(2-(biphenyl-4-yl)ethylthio)acetic acid
DMBZIUC	HS	Investigative
DMBZIUC	SN	CHEMBL572980; 2-(2-(biphenyl-4-yl)ethylthio)acetic acid
DMBZIUC	DT	Small molecular drug
DMBZIUC	PC	20348772
DMBZIUC	MW	272.4
DMBZIUC	FM	C16H16O2S
DMBZIUC	IC	InChI=1S/C16H16O2S/c17-16(18)12-19-11-10-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-9H,10-12H2,(H,17,18)
DMBZIUC	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCSCC(=O)O
DMBZIUC	IK	VNCUHIXOCDBZGU-UHFFFAOYSA-N
DMBZIUC	IU	2-[2-(4-phenylphenyl)ethylsulfanyl]acetic acid
DMBZIUC	DE	Discovery agent

DMZA8M7	ID	DMZA8M7
DMZA8M7	DN	2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid
DMZA8M7	HS	Investigative
DMZA8M7	SN	4-anilinopyrimidine 7a; CHEMBL394869; BDBM15986; AKOS029246132; 2-{[2-(butylamino)pyrimidin-4-yl]amino}benzoic acid
DMZA8M7	DT	Small molecular drug
DMZA8M7	PC	23647246
DMZA8M7	MW	286.33
DMZA8M7	FM	C15H18N4O2
DMZA8M7	IC	InChI=1S/C15H18N4O2/c1-2-3-9-16-15-17-10-8-13(19-15)18-12-7-5-4-6-11(12)14(20)21/h4-8,10H,2-3,9H2,1H3,(H,20,21)(H2,16,17,18,19)
DMZA8M7	CS	CCCCNC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DMZA8M7	IK	FSZJHCURVIQYSG-UHFFFAOYSA-N
DMZA8M7	IU	2-[[2-(butylamino)pyrimidin-4-yl]amino]benzoic acid
DMZA8M7	DE	Discovery agent

DM4KS27	ID	DM4KS27
DM4KS27	DN	2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid
DM4KS27	HS	Investigative
DM4KS27	SN	4-anilinopyrimidine 6c; CHEMBL242701; BDBM15981; 2-{[2-(pentyloxy)pyrimidin-4-yl]amino}benzoic acid
DM4KS27	DT	Small molecular drug
DM4KS27	PC	23647241
DM4KS27	MW	301.34
DM4KS27	FM	C16H19N3O3
DM4KS27	IC	InChI=1S/C16H19N3O3/c1-2-3-6-11-22-16-17-10-9-14(19-16)18-13-8-5-4-7-12(13)15(20)21/h4-5,7-10H,2-3,6,11H2,1H3,(H,20,21)(H,17,18,19)
DM4KS27	CS	CCCCCOC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DM4KS27	IK	QOFCYNIGWDGPEN-UHFFFAOYSA-N
DM4KS27	IU	2-[(2-pentoxypyrimidin-4-yl)amino]benzoic acid
DM4KS27	DE	Discovery agent

DM5GAOZ	ID	DM5GAOZ
DM5GAOZ	DN	2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide
DM5GAOZ	HS	Investigative
DM5GAOZ	SN	4-anilinopyrimidine 2a; CHEMBL428213; BDBM15995
DM5GAOZ	DT	Small molecular drug
DM5GAOZ	PC	23647253
DM5GAOZ	MW	305.33
DM5GAOZ	FM	C17H15N5O
DM5GAOZ	IC	InChI=1S/C17H15N5O/c18-16(23)13-8-4-5-9-14(13)21-15-10-11-19-17(22-15)20-12-6-2-1-3-7-12/h1-11H,(H2,18,23)(H2,19,20,21,22)
DM5GAOZ	CS	C1=CC=C(C=C1)NC2=NC=CC(=N2)NC3=CC=CC=C3C(=O)N
DM5GAOZ	IK	TVKTVNQGZQPCAT-UHFFFAOYSA-N
DM5GAOZ	IU	2-[(2-anilinopyrimidin-4-yl)amino]benzamide
DM5GAOZ	DE	Discovery agent

DMCHZ8J	ID	DMCHZ8J
DMCHZ8J	DN	2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole
DMCHZ8J	HS	Investigative
DMCHZ8J	SN	CHEMBL271899
DMCHZ8J	DT	Small molecular drug
DMCHZ8J	PC	44456057
DMCHZ8J	MW	214.31
DMCHZ8J	FM	C14H18N2
DMCHZ8J	IC	InChI=1S/C14H18N2/c1-2-6-14-12(5-1)11-13(15-14)7-10-16-8-3-4-9-16/h1-2,5-6,11,15H,3-4,7-10H2
DMCHZ8J	CS	C1CCN(C1)CCC2=CC3=CC=CC=C3N2
DMCHZ8J	IK	IVJNJVNKYYOCPC-UHFFFAOYSA-N
DMCHZ8J	IU	2-(2-pyrrolidin-1-ylethyl)-1H-indole
DMCHZ8J	DE	Discovery agent

DMQ0WKA	ID	DMQ0WKA
DMQ0WKA	DN	2-(2-(pyrrolidin-1-yl)ethyl)phenol
DMQ0WKA	HS	Investigative
DMQ0WKA	SN	CHEMBL273002
DMQ0WKA	DT	Small molecular drug
DMQ0WKA	PC	44456361
DMQ0WKA	MW	191.27
DMQ0WKA	FM	C12H17NO
DMQ0WKA	IC	InChI=1S/C12H17NO/c14-12-6-2-1-5-11(12)7-10-13-8-3-4-9-13/h1-2,5-6,14H,3-4,7-10H2
DMQ0WKA	CS	C1CCN(C1)CCC2=CC=CC=C2O
DMQ0WKA	IK	MCYUAYDQGCYEGH-UHFFFAOYSA-N
DMQ0WKA	IU	2-(2-pyrrolidin-1-ylethyl)phenol
DMQ0WKA	DE	Discovery agent

DMGQC2F	ID	DMGQC2F
DMGQC2F	DN	2-(2-(pyrrolidin-1-yl)ethyl)pyridine
DMGQC2F	HS	Investigative
DMGQC2F	SN	2-(2-Pyrrolidinoethyl)Pyridine; 6311-90-6; CHEMBL270595; 2-[2-(Pyrrolidin-1-yl)ethyl]pyridine; N-(2-(2-pyridyl)ethyl)pyrrolidine; NSC42644; 2-[2-(1-Pyrrolidinyl)ethyl]pyridine; AC1Q4VNT; AC1L60PK; AC1Q28PR; SCHEMBL868571; 2-(2-Pyrrolizinoethyl)pyridine; CTK5B7636; DTXSID60285694; OXEFHEYEQUISKC-UHFFFAOYSA-N; ZINC393798; NSC-42644; 2-(2-pyrrolidin-1-ylethyl)pyridine; BDBM50372289; AKOS006243249; MCULE-8128571557; 2-(2-Pyrrolidin-1-yl-ethyl)-pyridine; Pyridine,2-[2-(1-pyrrolidinyl)ethyl]-; 2-[2-(1-Pyrrolidinyl)ethyl]pyridine #
DMGQC2F	DT	Small molecular drug
DMGQC2F	PC	238317
DMGQC2F	MW	176.26
DMGQC2F	FM	C11H16N2
DMGQC2F	IC	InChI=1S/C11H16N2/c1-2-7-12-11(5-1)6-10-13-8-3-4-9-13/h1-2,5,7H,3-4,6,8-10H2
DMGQC2F	CS	C1CCN(C1)CCC2=CC=CC=N2
DMGQC2F	IK	OXEFHEYEQUISKC-UHFFFAOYSA-N
DMGQC2F	IU	2-(2-pyrrolidin-1-ylethyl)pyridine
DMGQC2F	CA	CAS 6311-90-6
DMGQC2F	DE	Discovery agent

DMFU1PK	ID	DMFU1PK
DMFU1PK	DN	2-(2,3,4-trimethoxyphenyl)-1H-indene
DMFU1PK	HS	Investigative
DMFU1PK	SN	CHEMBL228561; 2-(2,3,4-trimethoxyphenyl)-1H-indene
DMFU1PK	DT	Small molecular drug
DMFU1PK	PC	23627032
DMFU1PK	MW	282.3
DMFU1PK	FM	C18H18O3
DMFU1PK	IC	InChI=1S/C18H18O3/c1-19-16-9-8-15(17(20-2)18(16)21-3)14-10-12-6-4-5-7-13(12)11-14/h4-10H,11H2,1-3H3
DMFU1PK	CS	COC1=C(C(=C(C=C1)C2=CC3=CC=CC=C3C2)OC)OC
DMFU1PK	IK	ULQHBVJHLIJHLL-UHFFFAOYSA-N
DMFU1PK	IU	2-(2,3,4-trimethoxyphenyl)-1H-indene
DMFU1PK	DE	Discovery agent

DM1T8IP	ID	DM1T8IP
DM1T8IP	DN	2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid
DM1T8IP	HS	Investigative
DM1T8IP	SN	CHEMBL212860; 2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid; SCHEMBL5664165; JDODANGOYUAOQT-UHFFFAOYSA-N; BDBM50192463; 2,3-bis[(2-chlorophenyl)methoxy]benzeneacetic acid
DM1T8IP	DT	Small molecular drug
DM1T8IP	PC	10126984
DM1T8IP	MW	417.3
DM1T8IP	FM	C22H18Cl2O4
DM1T8IP	IC	InChI=1S/C22H18Cl2O4/c23-18-9-3-1-6-16(18)13-27-20-11-5-8-15(12-21(25)26)22(20)28-14-17-7-2-4-10-19(17)24/h1-11H,12-14H2,(H,25,26)
DM1T8IP	CS	C1=CC=C(C(=C1)COC2=CC=CC(=C2OCC3=CC=CC=C3Cl)CC(=O)O)Cl
DM1T8IP	IK	JDODANGOYUAOQT-UHFFFAOYSA-N
DM1T8IP	IU	2-[2,3-bis[(2-chlorophenyl)methoxy]phenyl]acetic acid
DM1T8IP	DE	Discovery agent

DM56NK4	ID	DM56NK4
DM56NK4	DN	2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine
DM56NK4	HS	Investigative
DM56NK4	SN	CHEMBL32958; 1H-Indole-5-ethanamine, 2,3-dihydro-alpha-methyl-; 2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine; BDBM50025081
DM56NK4	DT	Small molecular drug
DM56NK4	PC	13660281
DM56NK4	MW	176.26
DM56NK4	FM	C11H16N2
DM56NK4	IC	InChI=1S/C11H16N2/c1-8(12)6-9-2-3-11-10(7-9)4-5-13-11/h2-3,7-8,13H,4-6,12H2,1H3
DM56NK4	CS	CC(CC1=CC2=C(C=C1)NCC2)N
DM56NK4	IK	YAVKNEHUAXPRSK-UHFFFAOYSA-N
DM56NK4	IU	1-(2,3-dihydro-1H-indol-5-yl)propan-2-amine
DM56NK4	DE	Discovery agent

DM4XL8Z	ID	DM4XL8Z
DM4XL8Z	DN	2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol
DM4XL8Z	HS	Investigative
DM4XL8Z	SN	CHEMBL259403; 2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol; Triclosan derivative, 12; BDBM25411
DM4XL8Z	DT	Small molecular drug
DM4XL8Z	PC	25023962
DM4XL8Z	MW	325.2
DM4XL8Z	FM	C17H18Cl2O2
DM4XL8Z	IC	InChI=1S/C17H18Cl2O2/c1-3-11(2)8-12-4-6-17(15(20)9-12)21-16-7-5-13(18)10-14(16)19/h4-7,9-11,20H,3,8H2,1-2H3
DM4XL8Z	CS	CCC(C)CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DM4XL8Z	IK	LHFFQFRAOUEGEB-UHFFFAOYSA-N
DM4XL8Z	IU	2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol
DM4XL8Z	DE	Discovery agent

DME3FUD	ID	DME3FUD
DME3FUD	DN	2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol
DME3FUD	HS	Investigative
DME3FUD	SN	2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol; JPN; Triclosan derivative, 22; CHEMBL259880; BDBM25421; 6760-EP2316452A1; 6760-EP2311801A1; 6760-EP2311797A1; 6760-EP2311455A1; 6760-EP2301536A1; 6760-EP2298767A1; 6760-EP2281818A1; 6760-EP2311798A1; 6760-EP2308509A1; 6760-EP2305250A1; 6760-EP2301627A1; 6760-EP2301538A1; 6760-EP2298734A2; 6760-EP2295053A1; 6760-EP2292614A1; 6760-EP2287155A1; 6760-EP2277876A1; 6760-EP1441224A2; 6760-EP2314587A1; 6760-EP2311831A1; 6760-EP2311799A1; 6760-EP2308874A1; 6760-EP2308873A1; 6760-EP2305653A1
DME3FUD	DT	Small molecular drug
DME3FUD	PC	16220126
DME3FUD	MW	373.3
DME3FUD	FM	C21H18Cl2O2
DME3FUD	IC	InChI=1S/C21H18Cl2O2/c22-17-10-12-20(18(23)14-17)25-21-11-9-16(13-19(21)24)8-4-7-15-5-2-1-3-6-15/h1-3,5-6,9-14,24H,4,7-8H2
DME3FUD	CS	C1=CC=C(C=C1)CCCC2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DME3FUD	IK	MJRPBNSOVIMDHN-UHFFFAOYSA-N
DME3FUD	IU	2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol
DME3FUD	DE	Discovery agent

DMPSR1O	ID	DMPSR1O
DMPSR1O	DN	2-(2,4-dichlorophenoxy)-5-ethylphenol
DMPSR1O	HS	Investigative
DMPSR1O	SN	Triclosan derivative, 8; CHEMBL260753; BDBM25407; 2-(2,4-dichlorophenoxy)-5-ethyl-phenol; ethylphenol (11)
DMPSR1O	DT	Small molecular drug
DMPSR1O	PC	25023958
DMPSR1O	MW	283.1
DMPSR1O	FM	C14H12Cl2O2
DMPSR1O	IC	InChI=1S/C14H12Cl2O2/c1-2-9-3-5-14(12(17)7-9)18-13-6-4-10(15)8-11(13)16/h3-8,17H,2H2,1H3
DMPSR1O	CS	CCC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DMPSR1O	IK	UUSUFMSMUYHSBH-UHFFFAOYSA-N
DMPSR1O	IU	2-(2,4-dichlorophenoxy)-5-ethylphenol
DMPSR1O	DE	Discovery agent

DMKOFRE	ID	DMKOFRE
DMKOFRE	DN	2-(2,4-dichlorophenoxy)-5-isobutylphenol
DMKOFRE	HS	Investigative
DMKOFRE	SN	Triclosan derivative, 11; CHEMBL261521; BDBM25410
DMKOFRE	DT	Small molecular drug
DMKOFRE	PC	25023961
DMKOFRE	MW	311.2
DMKOFRE	FM	C16H16Cl2O2
DMKOFRE	IC	InChI=1S/C16H16Cl2O2/c1-10(2)7-11-3-5-16(14(19)8-11)20-15-6-4-12(17)9-13(15)18/h3-6,8-10,19H,7H2,1-2H3
DMKOFRE	CS	CC(C)CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DMKOFRE	IK	ZPZSZEVICIKUBD-UHFFFAOYSA-N
DMKOFRE	IU	2-(2,4-dichlorophenoxy)-5-(2-methylpropyl)phenol
DMKOFRE	DE	Discovery agent

DME0LZ2	ID	DME0LZ2
DME0LZ2	DN	2-(2,4-dichlorophenoxy)-5-isopentylphenol
DME0LZ2	HS	Investigative
DME0LZ2	SN	Triclosan derivative, 13; CHEMBL261144; BDBM25412; 2-(2,4-dichlorophenoxy)-5-isopentyl-phenol
DME0LZ2	DT	Small molecular drug
DME0LZ2	PC	25023963
DME0LZ2	MW	325.2
DME0LZ2	FM	C17H18Cl2O2
DME0LZ2	IC	InChI=1S/C17H18Cl2O2/c1-11(2)3-4-12-5-7-17(15(20)9-12)21-16-8-6-13(18)10-14(16)19/h5-11,20H,3-4H2,1-2H3
DME0LZ2	CS	CC(C)CCC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DME0LZ2	IK	CODNLKSZUDXSLW-UHFFFAOYSA-N
DME0LZ2	IU	2-(2,4-dichlorophenoxy)-5-(3-methylbutyl)phenol
DME0LZ2	DE	Discovery agent

DM1L3US	ID	DM1L3US
DM1L3US	DN	2-(2,4-dichlorophenoxy)-5-methylphenol
DM1L3US	HS	Investigative
DM1L3US	SN	2-(2,4-dichlorophenoxy)-5-methylphenol; Triclosan derivative, 2; CHEMBL258569; SCHEMBL12286177; BDBM25401
DM1L3US	DT	Small molecular drug
DM1L3US	PC	22947105
DM1L3US	MW	269.12
DM1L3US	FM	C13H10Cl2O2
DM1L3US	IC	InChI=1S/C13H10Cl2O2/c1-8-2-4-13(11(16)6-8)17-12-5-3-9(14)7-10(12)15/h2-7,16H,1H3
DM1L3US	CS	CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DM1L3US	IK	FHTKTADYDYDEMS-UHFFFAOYSA-N
DM1L3US	IU	2-(2,4-dichlorophenoxy)-5-methylphenol
DM1L3US	DE	Discovery agent

DM6ZNR3	ID	DM6ZNR3
DM6ZNR3	DN	2-(2,4-dichlorophenoxy)-5-phenethylphenol
DM6ZNR3	HS	Investigative
DM6ZNR3	SN	2-(2,4-Dichlorophenoxy)-5-(2-Phenylethyl)phenol; JPJ; Triclosan derivative, 21; CHEMBL260061; BDBM25420
DM6ZNR3	DT	Small molecular drug
DM6ZNR3	PC	16220128
DM6ZNR3	MW	359.2
DM6ZNR3	FM	C20H16Cl2O2
DM6ZNR3	IC	InChI=1S/C20H16Cl2O2/c21-16-9-11-19(17(22)13-16)24-20-10-8-15(12-18(20)23)7-6-14-4-2-1-3-5-14/h1-5,8-13,23H,6-7H2
DM6ZNR3	CS	C1=CC=C(C=C1)CCC2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DM6ZNR3	IK	SOSAEWQXZFTNAQ-UHFFFAOYSA-N
DM6ZNR3	IU	2-(2,4-dichlorophenoxy)-5-(2-phenylethyl)phenol
DM6ZNR3	DE	Discovery agent

DMKP974	ID	DMKP974
DMKP974	DN	2-(2,4-dichlorophenoxy)-5-propylphenol
DMKP974	HS	Investigative
DMKP974	SN	2-(2,4-dichlorophenoxy)-5-propylphenol; Triclosan derivative, 9; CHEMBL263896; BDBM25408
DMKP974	DT	Small molecular drug
DMKP974	PC	25023959
DMKP974	MW	297.2
DMKP974	FM	C15H14Cl2O2
DMKP974	IC	InChI=1S/C15H14Cl2O2/c1-2-3-10-4-6-15(13(18)8-10)19-14-7-5-11(16)9-12(14)17/h4-9,18H,2-3H2,1H3
DMKP974	CS	CCCC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DMKP974	IK	ILBQDZVPNAVUMD-UHFFFAOYSA-N
DMKP974	IU	2-(2,4-dichlorophenoxy)-5-propylphenol
DMKP974	DE	Discovery agent

DMDUF21	ID	DMDUF21
DMDUF21	DN	2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole
DMDUF21	HS	Investigative
DMDUF21	SN	2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole; CHEMBL489080; 61033-72-5; 2-(2,4-dichlorophenyl)-2-imidazoline; CTK2E8089; DTXSID20492004; BDBM50266030; ZINC40976675; AKOS027869670; DB-072897; FT-0720309; 1H-Imidazole, 2-(2,4-dichlorophenyl)-4,5-dihydro-
DMDUF21	DT	Small molecular drug
DMDUF21	PC	12341497
DMDUF21	MW	215.08
DMDUF21	FM	C9H8Cl2N2
DMDUF21	IC	InChI=1S/C9H8Cl2N2/c10-6-1-2-7(8(11)5-6)9-12-3-4-13-9/h1-2,5H,3-4H2,(H,12,13)
DMDUF21	CS	C1CN=C(N1)C2=C(C=C(C=C2)Cl)Cl
DMDUF21	IK	DSQMJENLNWSEMO-UHFFFAOYSA-N
DMDUF21	IU	2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole
DMDUF21	CA	CAS 61033-72-5
DMDUF21	DE	Discovery agent

DMSND8U	ID	DMSND8U
DMSND8U	DN	2-(2,4-difluorophenyl)-2,2-diphenylacetamide
DMSND8U	HS	Investigative
DMSND8U	SN	CHEMBL270913; SCHEMBL14437488
DMSND8U	DT	Small molecular drug
DMSND8U	PC	20684853
DMSND8U	MW	323.3
DMSND8U	FM	C20H15F2NO
DMSND8U	IC	InChI=1S/C20H15F2NO/c21-16-11-12-17(18(22)13-16)20(19(23)24,14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-13H,(H2,23,24)
DMSND8U	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=C(C=C(C=C3)F)F)C(=O)N
DMSND8U	IK	GASORINMDZETOC-UHFFFAOYSA-N
DMSND8U	IU	2-(2,4-difluorophenyl)-2,2-diphenylacetamide
DMSND8U	DE	Discovery agent

DMG49N2	ID	DMG49N2
DMG49N2	DN	2-(2,4-diphenylthiazol-5-yl)acetic acid
DMG49N2	HS	Investigative
DMG49N2	SN	2-(2,4-diphenyl-1,3-thiazol-5-yl)acetic acid; 21256-15-5; 2-(2,4-diphenylthiazol-5-yl)acetic acid; CHEMBL592001; SMR000168586; diphenylthiazolylaceticacid; Bionet2_000936; AC1MC90U; Oprea1_148343; MLS000327963; SCHEMBL4497493; CTK4E6215; DTXSID40377203; MolPort-002-345-061; ZINC169124; HMS2377A22; HMS1366K12; KS-00001A6R; 7213AD; SBB077302; BDBM50309445; AKOS005070458; RP15938; MCULE-6578968783; 4K-539S; (diphenyl-1,3-thiazol-5-yl)acetic acid; AM803507; AJ-17064; KB-220568; TR-009976; CS-0039039; FT-0680367; I04-4316; J-505484
DMG49N2	DT	Small molecular drug
DMG49N2	PC	2763923
DMG49N2	MW	295.4
DMG49N2	FM	C17H13NO2S
DMG49N2	IC	InChI=1S/C17H13NO2S/c19-15(20)11-14-16(12-7-3-1-4-8-12)18-17(21-14)13-9-5-2-6-10-13/h1-10H,11H2,(H,19,20)
DMG49N2	CS	C1=CC=C(C=C1)C2=C(SC(=N2)C3=CC=CC=C3)CC(=O)O
DMG49N2	IK	WNGOHXAHAKLKAR-UHFFFAOYSA-N
DMG49N2	IU	2-(2,4-diphenyl-1,3-thiazol-5-yl)acetic acid
DMG49N2	CA	CAS 21256-15-5
DMG49N2	DE	Discovery agent

DM7JUK0	ID	DM7JUK0
DM7JUK0	DN	2-(2,6-Dimethyl-benzyl)-4,5-dihydro-1H-imidazole
DM7JUK0	HS	Investigative
DM7JUK0	SN	CHEMBL71033; SCHEMBL953521; 2-(2,6-Dimethyl-benzyl)-4,5-dihydro-1H-imidazole; 1H-Imidazole, 2-[(2,6-dimethylphenyl)methyl]-4,5-dihydro-; BDBM50064817; 2-(2,6-Dimethylbenzyl)-2-imidazoline
DM7JUK0	DT	Small molecular drug
DM7JUK0	PC	24782016
DM7JUK0	MW	188.27
DM7JUK0	FM	C12H16N2
DM7JUK0	IC	InChI=1S/C12H16N2/c1-9-4-3-5-10(2)11(9)8-12-13-6-7-14-12/h3-5H,6-8H2,1-2H3,(H,13,14)
DM7JUK0	CS	CC1=C(C(=CC=C1)C)CC2=NCCN2
DM7JUK0	IK	GPUVYOKQAJEFBO-UHFFFAOYSA-N
DM7JUK0	IU	2-[(2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
DM7JUK0	DE	Discovery agent

DMITKZY	ID	DMITKZY
DMITKZY	DN	2-(2-acetyl-4-bromophenoxy)acetic acid
DMITKZY	HS	Investigative
DMITKZY	SN	2-(2-acetyl-4-bromophenoxy)acetic acid; 34849-51-9; CHEMBL384130; SCHEMBL789387; ZPKLKLLENLTZEX-UHFFFAOYSA-N; MolPort-035-831-033; 2-Acetyl-4-bromophenoxyacetic acid; BDBM50200252; ZINC36127031; AKOS005215962; (2-Acetyl-4-bromophenoxy)acetic acid; AS-30410; SY028375; [(2-acetyl-4-bromophenyl)oxy]acetic Acid; Aceticacid,2-(2-acetyl-4-bromophenoxy)-; Acetic acid, (2-acetyl-4-bromophenoxy)-; MFCD27949767 (95%)
DMITKZY	DT	Small molecular drug
DMITKZY	PC	19261363
DMITKZY	MW	273.08
DMITKZY	FM	C10H9BrO4
DMITKZY	IC	InChI=1S/C10H9BrO4/c1-6(12)8-4-7(11)2-3-9(8)15-5-10(13)14/h2-4H,5H2,1H3,(H,13,14)
DMITKZY	CS	CC(=O)C1=C(C=CC(=C1)Br)OCC(=O)O
DMITKZY	IK	ZPKLKLLENLTZEX-UHFFFAOYSA-N
DMITKZY	IU	2-(2-acetyl-4-bromophenoxy)acetic acid
DMITKZY	DE	Discovery agent

DMP1KZW	ID	DMP1KZW
DMP1KZW	DN	2-(2-adamantyl) piperidine
DMP1KZW	HS	Investigative
DMP1KZW	SN	2-(2-Adamantyl)piperidine; AC1LADJJ; SCHEMBL587506; 2-(adamantan-2-yl)piperidine; CHEMBL117334
DMP1KZW	DT	Small molecular drug
DMP1KZW	PC	511919
DMP1KZW	MW	219.37
DMP1KZW	FM	C15H25N
DMP1KZW	IC	InChI=1S/C15H25N/c1-2-4-16-14(3-1)15-12-6-10-5-11(8-12)9-13(15)7-10/h10-16H,1-9H2
DMP1KZW	CS	C1CCNC(C1)C2C3CC4CC(C3)CC2C4
DMP1KZW	IK	XNMHSNFFGAZILT-UHFFFAOYSA-N
DMP1KZW	IU	2-(2-adamantyl)piperidine
DMP1KZW	DE	Discovery agent

DMXDGEF	ID	DMXDGEF
DMXDGEF	DN	2-(2-allyl-4-chlorophenoxy)acetic acid
DMXDGEF	HS	Investigative
DMXDGEF	SN	CHEMBL245707; 6964-26-7; (2-allyl-4-chloro-phenoxy)-acetic acid; NSC66309; [4-chloro-2-(prop-2-en-1-yl)phenoxy]acetic acid; 2-(2-allyl-4-chlorophenoxy)acetic acid; AC1Q3LUZ; 2-(4-chloro-2-prop-2-enylphenoxy)acetic acid; AC1L6N6K; SCHEMBL4879038; CTK5D0709; DTXSID60290061; NSC-66309; BDBM50213925; AKOS005352797; Acetic acid,2-[4-chloro-2-(2-propen-1-yl)phenoxy]-
DMXDGEF	DT	Small molecular drug
DMXDGEF	PC	248828
DMXDGEF	MW	226.65
DMXDGEF	FM	C11H11ClO3
DMXDGEF	IC	InChI=1S/C11H11ClO3/c1-2-3-8-6-9(12)4-5-10(8)15-7-11(13)14/h2,4-6H,1,3,7H2,(H,13,14)
DMXDGEF	CS	C=CCC1=C(C=CC(=C1)Cl)OCC(=O)O
DMXDGEF	IK	SUGLMNNOLUZPQE-UHFFFAOYSA-N
DMXDGEF	IU	2-(4-chloro-2-prop-2-enylphenoxy)acetic acid
DMXDGEF	CA	CAS 6964-26-7
DMXDGEF	DE	Discovery agent

DMVTD1F	ID	DMVTD1F
DMVTD1F	DN	2-(2'-Aminoethyl)-5-benzyltetrahydrofuran
DMVTD1F	HS	Investigative
DMVTD1F	SN	CHEMBL448912; SCHEMBL2691374; BDBM50276507
DMVTD1F	DT	Small molecular drug
DMVTD1F	PC	11672904
DMVTD1F	MW	205.3
DMVTD1F	FM	C13H19NO
DMVTD1F	IC	InChI=1S/C13H19NO/c14-9-8-12-6-7-13(15-12)10-11-4-2-1-3-5-11/h1-5,12-13H,6-10,14H2
DMVTD1F	CS	C1CC(OC1CCN)CC2=CC=CC=C2
DMVTD1F	IK	FZRYLYZNENTFJM-UHFFFAOYSA-N
DMVTD1F	IU	2-(5-benzyloxolan-2-yl)ethanamine
DMVTD1F	DE	Discovery agent

DM3JM7V	ID	DM3JM7V
DM3JM7V	DN	2-(2-Amino-ethyl)-7-imino-azepane
DM3JM7V	HS	Investigative
DM3JM7V	SN	CHEMBL92475; 2-(2-Amino-ethyl)-7-imino-azepane; SCHEMBL6976741; BDBM50104654
DM3JM7V	DT	Small molecular drug
DM3JM7V	PC	9995251
DM3JM7V	MW	155.24
DM3JM7V	FM	C8H17N3
DM3JM7V	IC	InChI=1S/C8H17N3/c9-6-5-7-3-1-2-4-8(10)11-7/h7H,1-6,9H2,(H2,10,11)
DM3JM7V	CS	C1CCC(=NC(C1)CCN)N
DM3JM7V	IK	KENFUNZIVHXJNM-UHFFFAOYSA-N
DM3JM7V	IU	2-(2-aminoethyl)-3,4,5,6-tetrahydro-2H-azepin-7-amine
DM3JM7V	DE	Discovery agent

DMDFYJR	ID	DMDFYJR
DMDFYJR	DN	2-(2-Aminoethyl)anthra[1,9-cd]pyrazol-6(2H)-one
DMDFYJR	HS	Investigative
DMDFYJR	SN	CHEMBL1163331
DMDFYJR	DT	Small molecular drug
DMDFYJR	PC	46907250
DMDFYJR	MW	263.29
DMDFYJR	FM	C16H13N3O
DMDFYJR	IC	InChI=1S/C16H13N3O/c17-8-9-19-13-7-3-6-12-14(13)15(18-19)10-4-1-2-5-11(10)16(12)20/h1-7H,8-9,17H2
DMDFYJR	CS	C1=CC=C2C(=C1)C3=NN(C4=CC=CC(=C43)C2=O)CCN
DMDFYJR	IK	BELLEOUYTCSNAZ-UHFFFAOYSA-N
DMDFYJR	IU	14-(2-aminoethyl)-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one
DMDFYJR	DE	Discovery agent

DMM9A8G	ID	DMM9A8G
DMM9A8G	DN	2-(2-aminophenoxy)-5-hexylphenol
DMM9A8G	HS	Investigative
DMM9A8G	SN	CHEMBL264434; 2-(2-Azanylphenoxy)-5-Hexyl-Phenol; 2-(2-aminophenoxy)-5-hexylphenol; PT13; BDBM50373348
DMM9A8G	DT	Small molecular drug
DMM9A8G	PC	44450094
DMM9A8G	MW	285.4
DMM9A8G	FM	C18H23NO2
DMM9A8G	IC	InChI=1S/C18H23NO2/c1-2-3-4-5-8-14-11-12-18(16(20)13-14)21-17-10-7-6-9-15(17)19/h6-7,9-13,20H,2-5,8,19H2,1H3
DMM9A8G	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2N)O
DMM9A8G	IK	UGZFBZMADDXZRA-UHFFFAOYSA-N
DMM9A8G	IU	2-(2-aminophenoxy)-5-hexylphenol
DMM9A8G	DE	Discovery agent

DM0CWHT	ID	DM0CWHT
DM0CWHT	DN	2-(2-Amino-phenyl)-6-methyl-chromen-4-one
DM0CWHT	HS	Investigative
DM0CWHT	SN	CHEMBL132035
DM0CWHT	DT	Small molecular drug
DM0CWHT	PC	11107795
DM0CWHT	MW	251.28
DM0CWHT	FM	C16H13NO2
DM0CWHT	IC	InChI=1S/C16H13NO2/c1-10-6-7-15-12(8-10)14(18)9-16(19-15)11-4-2-3-5-13(11)17/h2-9H,17H2,1H3
DM0CWHT	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3N
DM0CWHT	IK	FGXFHSSFMRVHFP-UHFFFAOYSA-N
DM0CWHT	IU	2-(2-aminophenyl)-6-methylchromen-4-one
DM0CWHT	DE	Discovery agent

DMCLSJZ	ID	DMCLSJZ
DMCLSJZ	DN	2-(2-aminophenyl)-6-morpholino-4H-pyran-4-one
DMCLSJZ	HS	Investigative
DMCLSJZ	SN	CHEMBL375346; 2-(2-aminophenyl)-6-morpholino-4H-pyran-4-one
DMCLSJZ	DT	Small molecular drug
DMCLSJZ	PC	16203354
DMCLSJZ	MW	272.3
DMCLSJZ	FM	C15H16N2O3
DMCLSJZ	IC	InChI=1S/C15H16N2O3/c16-13-4-2-1-3-12(13)14-9-11(18)10-15(20-14)17-5-7-19-8-6-17/h1-4,9-10H,5-8,16H2
DMCLSJZ	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC=C3N
DMCLSJZ	IK	SGCZGVONFZVNLU-UHFFFAOYSA-N
DMCLSJZ	IU	2-(2-aminophenyl)-6-morpholin-4-ylpyran-4-one
DMCLSJZ	DE	Discovery agent

DMZNRFG	ID	DMZNRFG
DMZNRFG	DN	2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol
DMZNRFG	HS	Investigative
DMZNRFG	SN	CHEMBL61002; Phenol, 2-(2-aminopropyl)-5-bromo-4-methoxy-; BDBM50226139
DMZNRFG	DT	Small molecular drug
DMZNRFG	PC	13547424
DMZNRFG	MW	260.13
DMZNRFG	FM	C10H14BrNO2
DMZNRFG	IC	InChI=1S/C10H14BrNO2/c1-6(12)3-7-4-10(14-2)8(11)5-9(7)13/h4-6,13H,3,12H2,1-2H3
DMZNRFG	CS	CC(CC1=CC(=C(C=C1O)Br)OC)N
DMZNRFG	IK	YMEPEWSDHUFKSX-UHFFFAOYSA-N
DMZNRFG	IU	2-(2-aminopropyl)-5-bromo-4-methoxyphenol
DMZNRFG	DE	Discovery agent

DMN6IV2	ID	DMN6IV2
DMN6IV2	DN	2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid
DMN6IV2	HS	Investigative
DMN6IV2	SN	CHEMBL603459; 2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid; SCHEMBL5056681; BDBM50309282
DMN6IV2	DT	Small molecular drug
DMN6IV2	PC	46230226
DMN6IV2	MW	385.5
DMN6IV2	FM	C24H19NO2S
DMN6IV2	IC	InChI=1S/C24H19NO2S/c26-21(27)16-20-23(19-14-8-3-9-15-19)25-24(28-20)22(17-10-4-1-5-11-17)18-12-6-2-7-13-18/h1-15,22H,16H2,(H,26,27)
DMN6IV2	CS	C1=CC=C(C=C1)C2=C(SC(=N2)C(C3=CC=CC=C3)C4=CC=CC=C4)CC(=O)O
DMN6IV2	IK	GSFLUFCQJVKCFD-UHFFFAOYSA-N
DMN6IV2	IU	2-(2-benzhydryl-4-phenyl-1,3-thiazol-5-yl)acetic acid
DMN6IV2	DE	Discovery agent

DMLOD2Y	ID	DMLOD2Y
DMLOD2Y	DN	2-(2-benzoyl-4-bromophenoxy)acetic acid
DMLOD2Y	HS	Investigative
DMLOD2Y	SN	CHEMBL217591; 2-(2-benzoyl-4-bromophenoxy)acetic acid
DMLOD2Y	DT	Small molecular drug
DMLOD2Y	PC	44417452
DMLOD2Y	MW	335.15
DMLOD2Y	FM	C15H11BrO4
DMLOD2Y	IC	InChI=1S/C15H11BrO4/c16-11-6-7-13(20-9-14(17)18)12(8-11)15(19)10-4-2-1-3-5-10/h1-8H,9H2,(H,17,18)
DMLOD2Y	CS	C1=CC=C(C=C1)C(=O)C2=C(C=CC(=C2)Br)OCC(=O)O
DMLOD2Y	IK	QCXHRPLPQPZWKP-UHFFFAOYSA-N
DMLOD2Y	IU	2-(2-benzoyl-4-bromophenoxy)acetic acid
DMLOD2Y	DE	Discovery agent

DMFK0GM	ID	DMFK0GM
DMFK0GM	DN	2-(2-bromo-2-naphthamido)benzoic acid
DMFK0GM	HS	Investigative
DMFK0GM	SN	CHEMBL199574; SCHEMBL18120563; BDBM16096; 2-[(6-bromonaphthalene-2-)amido]benzoic acid; 2-{[(6-bromonaphthalen-2-yl)carbonyl]amino}benzoic acid
DMFK0GM	DT	Small molecular drug
DMFK0GM	PC	23647297
DMFK0GM	MW	370.2
DMFK0GM	FM	C18H12BrNO3
DMFK0GM	IC	InChI=1S/C18H12BrNO3/c19-14-8-7-11-9-13(6-5-12(11)10-14)17(21)20-16-4-2-1-3-15(16)18(22)23/h1-10H,(H,20,21)(H,22,23)
DMFK0GM	CS	C1=CC=C(C(=C1)C(=O)O)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)Br
DMFK0GM	IK	KNVPXLPBRSRJCV-UHFFFAOYSA-N
DMFK0GM	IU	2-[(6-bromonaphthalene-2-carbonyl)amino]benzoic acid
DMFK0GM	DE	Discovery agent

DM3VH7F	ID	DM3VH7F
DM3VH7F	DN	2-(2-Bromo-benzoyl)-cyclohexane-1,3-dione
DM3VH7F	HS	Investigative
DM3VH7F	SN	2-(2-Bromobenzoyl)cyclohexane-1,3-dione; CHEMBL168906; 88562-08-7; 1,3-Cyclohexanedione, 2-(2-bromobenzoyl)-; ACMC-20lbdp; 2-(2-Bromo-benzoyl)-cyclohexane-1,3-dione; CTK3A9588; DTXSID70558700
DM3VH7F	DT	Small molecular drug
DM3VH7F	PC	14301627
DM3VH7F	MW	295.13
DM3VH7F	FM	C13H11BrO3
DM3VH7F	IC	InChI=1S/C13H11BrO3/c14-9-5-2-1-4-8(9)13(17)12-10(15)6-3-7-11(12)16/h1-2,4-5,12H,3,6-7H2
DM3VH7F	CS	C1CC(=O)C(C(=O)C1)C(=O)C2=CC=CC=C2Br
DM3VH7F	IK	XECQPEVQAQFNOX-UHFFFAOYSA-N
DM3VH7F	IU	2-(2-bromobenzoyl)cyclohexane-1,3-dione
DM3VH7F	CA	CAS 88562-08-7
DM3VH7F	DE	Discovery agent

DMHBE0X	ID	DMHBE0X
DMHBE0X	DN	2-(2-Bromophenoxy)-N,N-dimethylethanamine
DMHBE0X	HS	Investigative
DMHBE0X	SN	886851-37-2; 2-(2-Dimethylaminoethoxy)-bromobenzene; 2-(2-Bromophenoxy)-N,N-dimethylethanamine; CHEMBL599818; [2-(2-bromophenoxy)ethyl]dimethylamine; AC1LHJHJ; SCHEMBL1857526; DTXSID50358341; MolPort-004-331-572; ZINC4914895; KS-000000PE; BDBM50307492; 2-(2-dimethylaminoethoxy)bromobenzene; AKOS000170274; MCULE-8721188188; AM87375; AS-44355; AJ-52607; KB-323008; Y-0778
DMHBE0X	DT	Small molecular drug
DMHBE0X	PC	888311
DMHBE0X	MW	244.13
DMHBE0X	FM	C10H14BrNO
DMHBE0X	IC	InChI=1S/C10H14BrNO/c1-12(2)7-8-13-10-6-4-3-5-9(10)11/h3-6H,7-8H2,1-2H3
DMHBE0X	CS	CN(C)CCOC1=CC=CC=C1Br
DMHBE0X	IK	OUWAXRLVNYTZJK-UHFFFAOYSA-N
DMHBE0X	IU	2-(2-bromophenoxy)-N,N-dimethylethanamine
DMHBE0X	CA	CAS 886851-37-2
DMHBE0X	DE	Discovery agent

DMHJMUX	ID	DMHJMUX
DMHJMUX	DN	2-(2-Bromophenylthio)-N,N-dimethylethanamine
DMHJMUX	HS	Investigative
DMHJMUX	SN	2-(2-Bromophenylthio)-N,N-dimethylethanamine; CHEMBL610515; 1222866-87-6; BDBM50307491
DMHJMUX	DT	Small molecular drug
DMHJMUX	PC	46233353
DMHJMUX	MW	260.2
DMHJMUX	FM	C10H14BrNS
DMHJMUX	IC	InChI=1S/C10H14BrNS/c1-12(2)7-8-13-10-6-4-3-5-9(10)11/h3-6H,7-8H2,1-2H3
DMHJMUX	CS	CN(C)CCSC1=CC=CC=C1Br
DMHJMUX	IK	WXAWOWHEHSIUMN-UHFFFAOYSA-N
DMHJMUX	IU	2-(2-bromophenyl)sulfanyl-N,N-dimethylethanamine
DMHJMUX	DE	Discovery agent

DMLTU3J	ID	DMLTU3J
DMLTU3J	DN	2-(2-butoxypyrimidin-4-ylamino)benzoic acid
DMLTU3J	HS	Investigative
DMLTU3J	SN	2-[(2-butoxypyrimidin-4-yl)amino]benzoic Acid; 4-anilinopyrimidine 1; AC1LZD2G; CHEMBL242488; BDBM15977; MolPort-002-549-430; ZINC2272106; STL297947; AKOS003630983; MCULE-6330252818
DMLTU3J	DT	Small molecular drug
DMLTU3J	PC	1897784
DMLTU3J	MW	287.31
DMLTU3J	FM	C15H17N3O3
DMLTU3J	IC	InChI=1S/C15H17N3O3/c1-2-3-10-21-15-16-9-8-13(18-15)17-12-7-5-4-6-11(12)14(19)20/h4-9H,2-3,10H2,1H3,(H,19,20)(H,16,17,18)
DMLTU3J	CS	CCCCOC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DMLTU3J	IK	YTFVMUTWNFDKIY-UHFFFAOYSA-N
DMLTU3J	IU	2-[(2-butoxypyrimidin-4-yl)amino]benzoic acid
DMLTU3J	DE	Discovery agent

DMEGY0T	ID	DMEGY0T
DMEGY0T	DN	2-(2-carboxy-5-mercaptopentyl)benzoic acid
DMEGY0T	HS	Investigative
DMEGY0T	SN	Thiol-Based Inhibitor, 6b; SCHEMBL5053172; CHEMBL207314; CTK8A8856; BDBM17761; AKOS015966159; 2-(2-CARBOXY-5-MERCAPTO-PENTYL)-BENZOIC ACID; 2-[2-carboxy-2-(3-sulfanylpropyl)ethyl]benzoic acid
DMEGY0T	DT	Small molecular drug
DMEGY0T	PC	9921539
DMEGY0T	MW	268.33
DMEGY0T	FM	C13H16O4S
DMEGY0T	IC	InChI=1S/C13H16O4S/c14-12(15)10(5-3-7-18)8-9-4-1-2-6-11(9)13(16)17/h1-2,4,6,10,18H,3,5,7-8H2,(H,14,15)(H,16,17)
DMEGY0T	CS	C1=CC=C(C(=C1)CC(CCCS)C(=O)O)C(=O)O
DMEGY0T	IK	AJRYUIBEXXWDCQ-UHFFFAOYSA-N
DMEGY0T	IU	2-(2-carboxy-5-sulfanylpentyl)benzoic acid
DMEGY0T	DE	Discovery agent

DMR98ML	ID	DMR98ML
DMR98ML	DN	2-(2-carboxy-7-mercaptoheptyl)benzoic acid
DMR98ML	HS	Investigative
DMR98ML	SN	CHEMBL206804
DMR98ML	DT	Small molecular drug
DMR98ML	PC	44410794
DMR98ML	MW	296.4
DMR98ML	FM	C15H20O4S
DMR98ML	IC	InChI=1S/C15H20O4S/c16-14(17)12(7-2-1-5-9-20)10-11-6-3-4-8-13(11)15(18)19/h3-4,6,8,12,20H,1-2,5,7,9-10H2,(H,16,17)(H,18,19)
DMR98ML	CS	C1=CC=C(C(=C1)CC(CCCCCS)C(=O)O)C(=O)O
DMR98ML	IK	MLFBNUWBZSWDEZ-UHFFFAOYSA-N
DMR98ML	IU	2-(2-carboxy-7-sulfanylheptyl)benzoic acid
DMR98ML	DE	Discovery agent

DMWDV71	ID	DMWDV71
DMWDV71	DN	2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMWDV71	HS	Investigative
DMWDV71	DT	Small molecular drug
DMWDV71	PC	135528624
DMWDV71	MW	261.66
DMWDV71	FM	C13H8ClNO3
DMWDV71	IC	InChI=1S/C13H8ClNO3/c14-10-5-7(16)1-3-9(10)13-15-11-6-8(17)2-4-12(11)18-13/h1-6,16-17H
DMWDV71	CS	C1=CC(=C(C=C1O)Cl)C2=NC3=C(O2)C=CC(=C3)O
DMWDV71	IK	RDNJWPGDJWLTPJ-UHFFFAOYSA-N
DMWDV71	IU	2-(2-chloro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMWDV71	DE	Discovery agent

DMG6ABE	ID	DMG6ABE
DMG6ABE	DN	2-(2-Chloro-benzoyl)-cyclohexane-1,3-dione
DMG6ABE	HS	Investigative
DMG6ABE	SN	2-(2-Chlorobenzoyl)cyclohexane-1,3-dione; CHEMBL166951; 88562-09-8; 1,3-Cyclohexanedione, 2-(2-chlorobenzoyl)-; ACMC-20lbdq; 2-(2-Chloro-benzoyl)-cyclohexane-1,3-dione; SCHEMBL10192439; CTK3A9587; DTXSID30558701
DMG6ABE	DT	Small molecular drug
DMG6ABE	PC	14301628
DMG6ABE	MW	250.68
DMG6ABE	FM	C13H11ClO3
DMG6ABE	IC	InChI=1S/C13H11ClO3/c14-9-5-2-1-4-8(9)13(17)12-10(15)6-3-7-11(12)16/h1-2,4-5,12H,3,6-7H2
DMG6ABE	CS	C1CC(=O)C(C(=O)C1)C(=O)C2=CC=CC=C2Cl
DMG6ABE	IK	TYJXBELAFWQDPT-UHFFFAOYSA-N
DMG6ABE	IU	2-(2-chlorobenzoyl)cyclohexane-1,3-dione
DMG6ABE	CA	CAS 88562-09-8
DMG6ABE	DE	Discovery agent

DM1ULEX	ID	DM1ULEX
DM1ULEX	DN	2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine
DM1ULEX	HS	Investigative
DM1ULEX	SN	CHEMBL609904; 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine; SCHEMBL13769617
DM1ULEX	DT	Small molecular drug
DM1ULEX	PC	44133853
DM1ULEX	MW	288.77
DM1ULEX	FM	C16H17ClN2O
DM1ULEX	IC	InChI=1S/C16H17ClN2O/c17-14-5-1-2-6-15(14)20-16-13(4-3-9-19-16)12-7-10-18-11-8-12/h1-6,9,12,18H,7-8,10-11H2
DM1ULEX	CS	C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3Cl
DM1ULEX	IK	OLCRHPXGKWMFIP-UHFFFAOYSA-N
DM1ULEX	IU	2-(2-chlorophenoxy)-3-piperidin-4-ylpyridine
DM1ULEX	DE	Discovery agent

DM60RWZ	ID	DM60RWZ
DM60RWZ	DN	2-(2-chlorophenyl)-2,2-diphenylethanamide
DM60RWZ	HS	Investigative
DM60RWZ	SN	CHEMBL406683; AC1NNFGO; Amino-2-chlorotrityl resin; SCHEMBL1001586; 2-Chlorotriphenylmethyl amine resin; (2-chlorophenyl)-diphenylmethanamine; 2-Chlorotrityl amine, polymer-bound; BDBM50371377; 2-Chlorotrityl amine, polymer-bound, 100-200 mesh, extent of labeling: 1.3-1.8 mmol/g loading, 1 % cross-linked
DM60RWZ	DT	Small molecular drug
DM60RWZ	PC	5068018
DM60RWZ	MW	293.8
DM60RWZ	FM	C19H16ClN
DM60RWZ	IC	InChI=1S/C19H16ClN/c20-18-14-8-7-13-17(18)19(21,15-9-3-1-4-10-15)16-11-5-2-6-12-16/h1-14H,21H2
DM60RWZ	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N
DM60RWZ	IK	AXCRTHNDHLRNOA-UHFFFAOYSA-N
DM60RWZ	IU	(2-chlorophenyl)-diphenylmethanamine
DM60RWZ	CA	CAS 42074-69-1
DM60RWZ	DE	Discovery agent

DMTYDX2	ID	DMTYDX2
DMTYDX2	DN	2-(2-Chlorophenyl)-2H-indazole-7-carboxamide
DMTYDX2	HS	Investigative
DMTYDX2	SN	CHEMBL1094952; 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2265265
DMTYDX2	DT	Small molecular drug
DMTYDX2	PC	44549373
DMTYDX2	MW	271.7
DMTYDX2	FM	C14H10ClN3O
DMTYDX2	IC	InChI=1S/C14H10ClN3O/c15-11-6-1-2-7-12(11)18-8-9-4-3-5-10(14(16)19)13(9)17-18/h1-8H,(H2,16,19)
DMTYDX2	CS	C1=CC=C(C(=C1)N2C=C3C=CC=C(C3=N2)C(=O)N)Cl
DMTYDX2	IK	CYJGVBUKZAGGCY-UHFFFAOYSA-N
DMTYDX2	IU	2-(2-chlorophenyl)indazole-7-carboxamide
DMTYDX2	DE	Discovery agent

DMFG2S5	ID	DMFG2S5
DMFG2S5	DN	2-(2-chlorophenyl)-2-morpholinoethanamine
DMFG2S5	HS	Investigative
DMFG2S5	SN	866782-01-6; 2-(2-Chlorophenyl)-2-morpholin-4-ylethylamine; 2-(2-chlorophenyl)-2-(morpholin-4-yl)ethan-1-amine; 2-(2-chlorophenyl)-2-morpholinoethanamine; CHEMBL382382; 4-Morpholineethanamine,b-(2-chlorophenyl)-; 2-(2-chlorophenyl)-2-morpholin-4-ylethanamine; 2-(2-Chlorophenyl)-2-morpholinoethylamine; 2-(2-Chlorophenyl)-2-(morpholin-4-yl)ethylamine; beta-phenethylamine 6; AC1MZFUY; AC1Q53NI; SCHEMBL8276869; CTK5F7083; BDBM11556; DCA-S02-0; DTXSID90397254; MolPort-001-760-150; KS-000029ZH; 4759AH; SBB073200; AR3509
DMFG2S5	DT	Small molecular drug
DMFG2S5	PC	3847395
DMFG2S5	MW	240.73
DMFG2S5	FM	C12H17ClN2O
DMFG2S5	IC	InChI=1S/C12H17ClN2O/c13-11-4-2-1-3-10(11)12(9-14)15-5-7-16-8-6-15/h1-4,12H,5-9,14H2
DMFG2S5	CS	C1COCCN1C(CN)C2=CC=CC=C2Cl
DMFG2S5	IK	OJHPTRVTZGOWAO-UHFFFAOYSA-N
DMFG2S5	IU	2-(2-chlorophenyl)-2-morpholin-4-ylethanamine
DMFG2S5	CA	CAS 866782-01-6
DMFG2S5	DE	Discovery agent

DMJ38LE	ID	DMJ38LE
DMJ38LE	DN	2-(2-chlorophenylamino)-5-methylthiazol-4(5H)-one
DMJ38LE	HS	Investigative
DMJ38LE	DT	Small molecular drug
DMJ38LE	PC	91181036
DMJ38LE	MW	240.71
DMJ38LE	FM	C10H9ClN2OS
DMJ38LE	IC	InChI=1S/C10H9ClN2OS/c1-6-9(14)13-10(15-6)12-8-5-3-2-4-7(8)11/h2-5,14H,1H3,(H,12,13)
DMJ38LE	CS	CC1=C(N=C(S1)NC2=CC=CC=C2Cl)O
DMJ38LE	IK	JVRHHSAVCUJPIO-UHFFFAOYSA-N
DMJ38LE	IU	2-(2-chloroanilino)-5-methyl-1,3-thiazol-4-ol
DMJ38LE	DE	Discovery agent

DM187UQ	ID	DM187UQ
DM187UQ	DN	2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole
DM187UQ	HS	Investigative
DM187UQ	SN	CHEMBL248050; 2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole; AC1NRV52; BDBM50326635; Cycloheptanone, (4-phenyl-2-thiazolyl)hydrazone; N-(cycloheptylideneamino)-4-phenyl-thiazol-2-amine; 1-cycloheptylidene-2-(4-phenylthiazol-2-yl)hydrazine
DM187UQ	DT	Small molecular drug
DM187UQ	PC	5273551
DM187UQ	MW	285.4
DM187UQ	FM	C16H19N3S
DM187UQ	IC	InChI=1S/C16H19N3S/c1-2-7-11-14(10-6-1)18-19-16-17-15(12-20-16)13-8-4-3-5-9-13/h3-5,8-9,12H,1-2,6-7,10-11H2,(H,17,19)
DM187UQ	CS	C1CCCC(=NNC2=NC(=CS2)C3=CC=CC=C3)CC1
DM187UQ	IK	HFWROKPXAPGNOY-UHFFFAOYSA-N
DM187UQ	IU	N-(cycloheptylideneamino)-4-phenyl-1,3-thiazol-2-amine
DM187UQ	DE	Discovery agent

DMUN2CS	ID	DMUN2CS
DMUN2CS	DN	2-(2-cyclohexyl-4-fluorophenoxy)acetic acid
DMUN2CS	HS	Investigative
DMUN2CS	SN	CHEMBL246312; 2-(2-cyclohexyl-4-fluorophenoxy)acetic acid; SCHEMBL4886140
DMUN2CS	DT	Small molecular drug
DMUN2CS	PC	44441190
DMUN2CS	MW	252.28
DMUN2CS	FM	C14H17FO3
DMUN2CS	IC	InChI=1S/C14H17FO3/c15-11-6-7-13(18-9-14(16)17)12(8-11)10-4-2-1-3-5-10/h6-8,10H,1-5,9H2,(H,16,17)
DMUN2CS	CS	C1CCC(CC1)C2=C(C=CC(=C2)F)OCC(=O)O
DMUN2CS	IK	QBBFFBYIFRGECW-UHFFFAOYSA-N
DMUN2CS	IU	2-(2-cyclohexyl-4-fluorophenoxy)acetic acid
DMUN2CS	DE	Discovery agent

DMSI07M	ID	DMSI07M
DMSI07M	DN	2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid
DMSI07M	HS	Investigative
DMSI07M	SN	CHEMBL245701; (2-Cyclohexyl-4-methoxyphenoxy)acetic acid; 2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid; SCHEMBL4885675; BDBM50213921
DMSI07M	DT	Small molecular drug
DMSI07M	PC	11587023
DMSI07M	MW	264.32
DMSI07M	FM	C15H20O4
DMSI07M	IC	InChI=1S/C15H20O4/c1-18-12-7-8-14(19-10-15(16)17)13(9-12)11-5-3-2-4-6-11/h7-9,11H,2-6,10H2,1H3,(H,16,17)
DMSI07M	CS	COC1=CC(=C(C=C1)OCC(=O)O)C2CCCCC2
DMSI07M	IK	PJEFVLZYUWCSGF-UHFFFAOYSA-N
DMSI07M	IU	2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid
DMSI07M	DE	Discovery agent

DMVCY42	ID	DMVCY42
DMVCY42	DN	2-(2-cyclohexyl-4-methylphenoxy)acetic acid
DMVCY42	HS	Investigative
DMVCY42	SN	CHEMBL397651; 2-(2-cyclohexyl-4-methylphenoxy)acetic acid; SCHEMBL4883828
DMVCY42	DT	Small molecular drug
DMVCY42	PC	44441192
DMVCY42	MW	248.32
DMVCY42	FM	C15H20O3
DMVCY42	IC	InChI=1S/C15H20O3/c1-11-7-8-14(18-10-15(16)17)13(9-11)12-5-3-2-4-6-12/h7-9,12H,2-6,10H2,1H3,(H,16,17)
DMVCY42	CS	CC1=CC(=C(C=C1)OCC(=O)O)C2CCCCC2
DMVCY42	IK	QMGSFVNEZAIRGD-UHFFFAOYSA-N
DMVCY42	IU	2-(2-cyclohexyl-4-methylphenoxy)acetic acid
DMVCY42	DE	Discovery agent

DMPNGXE	ID	DMPNGXE
DMPNGXE	DN	2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole
DMPNGXE	HS	Investigative
DMPNGXE	SN	CHEMBL220495; 2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole; AC1P6Q43; SCHEMBL19017688; ZINC7350105; BDBM50326652; AKOS005139675; ST51067929; N-(cyclohexylideneamino)-4-phenyl-thiazol-2-amine; 1-cyclohexylidene-2-(4-phenylthiazol-2-yl)hydrazine; N-(cyclohexylideneamino)-4-phenyl-1,3-thiazol-2-amine
DMPNGXE	DT	Small molecular drug
DMPNGXE	PC	8443728
DMPNGXE	MW	271.4
DMPNGXE	FM	C15H17N3S
DMPNGXE	IC	InChI=1S/C15H17N3S/c1-3-7-12(8-4-1)14-11-19-15(16-14)18-17-13-9-5-2-6-10-13/h1,3-4,7-8,11H,2,5-6,9-10H2,(H,16,18)
DMPNGXE	CS	C1CCC(=NNC2=NC(=CS2)C3=CC=CC=C3)CC1
DMPNGXE	IK	RQMWJSWLKXHIEZ-UHFFFAOYSA-N
DMPNGXE	IU	N-(cyclohexylideneamino)-4-phenyl-1,3-thiazol-2-amine
DMPNGXE	DE	Discovery agent

DMTFWAQ	ID	DMTFWAQ
DMTFWAQ	DN	2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole
DMTFWAQ	HS	Investigative
DMTFWAQ	SN	CHEMBL1253700; 2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole; BDBM50326648; ZINC54362881; AKOS005139686; ST51067932
DMTFWAQ	DT	Small molecular drug
DMTFWAQ	PC	50876172
DMTFWAQ	MW	285.4
DMTFWAQ	FM	C16H19N3S
DMTFWAQ	IC	InChI=1S/C16H19N3S/c1-12-7-9-13(10-8-12)15-11-20-16(17-15)19-18-14-5-3-2-4-6-14/h7-11H,2-6H2,1H3,(H,17,19)
DMTFWAQ	CS	CC1=CC=C(C=C1)C2=CSC(=N2)NN=C3CCCCC3
DMTFWAQ	IK	KHLVZVWWHKJADP-UHFFFAOYSA-N
DMTFWAQ	IU	N-(cyclohexylideneamino)-4-(4-methylphenyl)-1,3-thiazol-2-amine
DMTFWAQ	DE	Discovery agent

DM81WJK	ID	DM81WJK
DM81WJK	DN	2-(2-cyclohexylphenoxy)acetic acid
DM81WJK	HS	Investigative
DM81WJK	SN	2-(2-cyclohexylphenoxy)acetic acid; CHEMBL247739; 82506-00-1; NSC405039; SCHEMBL4883839; AC1L85O4; DTXSID50323877; ZINC1597753; BDBM50213918
DM81WJK	DT	Small molecular drug
DM81WJK	PC	346737
DM81WJK	MW	234.29
DM81WJK	FM	C14H18O3
DM81WJK	IC	InChI=1S/C14H18O3/c15-14(16)10-17-13-9-5-4-8-12(13)11-6-2-1-3-7-11/h4-5,8-9,11H,1-3,6-7,10H2,(H,15,16)
DM81WJK	CS	C1CCC(CC1)C2=CC=CC=C2OCC(=O)O
DM81WJK	IK	SIYNBMWECIIUOX-UHFFFAOYSA-N
DM81WJK	IU	2-(2-cyclohexylphenoxy)acetic acid
DM81WJK	CA	CAS 82506-00-1
DM81WJK	DE	Discovery agent

DMH1VCE	ID	DMH1VCE
DMH1VCE	DN	2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole
DMH1VCE	HS	Investigative
DMH1VCE	SN	CHEMBL386941; AC1LBKTO; 2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole; SCHEMBL18998987; WUSIIHCESPBBHG-UHFFFAOYSA-N; MolPort-002-698-743; ZINC7350034; BDBM50326626; STK673148; AKOS005593088; MCULE-7323011972; Cyclopentanone, (4-phenyl-2-thiazolyl)hydrazone; N-(cyclopentylideneamino)-4-phenyl-thiazol-2-amine; 1-cyclopentylidene-2-(4-phenylthiazol-2-yl)hydrazine; N-(cyclopentylideneamino)-4-phenyl-1,3-thiazol-2-amine; A1355/0061138; Cyclopentanone ((2Z)-4-phenyl-1,3-thiazol-2(3H)-ylidene)hydrazone #
DMH1VCE	DT	Small molecular drug
DMH1VCE	PC	584447
DMH1VCE	MW	257.36
DMH1VCE	FM	C14H15N3S
DMH1VCE	IC	InChI=1S/C14H15N3S/c1-2-6-11(7-3-1)13-10-18-14(15-13)17-16-12-8-4-5-9-12/h1-3,6-7,10H,4-5,8-9H2,(H,15,17)
DMH1VCE	CS	C1CCC(=NNC2=NC(=CS2)C3=CC=CC=C3)C1
DMH1VCE	IK	WUSIIHCESPBBHG-UHFFFAOYSA-N
DMH1VCE	IU	N-(cyclopentylideneamino)-4-phenyl-1,3-thiazol-2-amine
DMH1VCE	DE	Discovery agent

DM1SN37	ID	DM1SN37
DM1SN37	DN	2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine
DM1SN37	HS	Investigative
DM1SN37	SN	CHEMBL597530; 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine; SCHEMBL13769759
DM1SN37	DT	Small molecular drug
DM1SN37	PC	44133851
DM1SN37	MW	272.32
DM1SN37	FM	C16H17FN2O
DM1SN37	IC	InChI=1S/C16H17FN2O/c17-14-5-1-2-6-15(14)20-16-13(4-3-9-19-16)12-7-10-18-11-8-12/h1-6,9,12,18H,7-8,10-11H2
DM1SN37	CS	C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3F
DM1SN37	IK	OTTUCFBNHXCUBH-UHFFFAOYSA-N
DM1SN37	IU	2-(2-fluorophenoxy)-3-piperidin-4-ylpyridine
DM1SN37	DE	Discovery agent

DMDUG9M	ID	DMDUG9M
DMDUG9M	DN	2-(2-Fluoro-phenyl)-benzo[h]chromen-4-one
DMDUG9M	HS	Investigative
DMDUG9M	SN	CHEMBL361608; 2-(2-Fluoro-phenyl)-benzo[h]chromen-4-one
DMDUG9M	DT	Small molecular drug
DMDUG9M	PC	11415057
DMDUG9M	MW	290.3
DMDUG9M	FM	C19H11FO2
DMDUG9M	IC	InChI=1S/C19H11FO2/c20-16-8-4-3-7-14(16)18-11-17(21)15-10-9-12-5-1-2-6-13(12)19(15)22-18/h1-11H
DMDUG9M	CS	C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CC=CC=C4F
DMDUG9M	IK	PBCBXDLSTLVGDE-UHFFFAOYSA-N
DMDUG9M	IU	2-(2-fluorophenyl)benzo[h]chromen-4-one
DMDUG9M	DE	Discovery agent

DMMEBH3	ID	DMMEBH3
DMMEBH3	DN	2-(2-formylphenoxy)acetic acid
DMMEBH3	HS	Investigative
DMMEBH3	SN	2-Formylphenoxyacetic acid; 2-(2-Formylphenoxy)acetic acid; 6280-80-4; (2-Formylphenoxy)acetic acid; o-Formylphenoxyacetic acid; Acetic acid, (2-formylphenoxy)-; 2-Carboxymethoxybenzaldehyde; ortho-Formylphenoxyacetic acid; Acetic acid, (o-formylphenoxy)-; 2-Formylphenoxyaceticacid; Acetic acid, 2-(2-formylphenoxy)-; CHEMBL384289; ANWMNLAAFDCKMT-UHFFFAOYSA-N; NSC 6140; EINECS 228-480-9; NSC 133590; o-Formyphenoxyacetic acid; o-formyl phenoxyacetic acid; AC1L2G6R; 2-formyl phenoxyacetic acid; 2-monoformylphenoxyacetic acid
DMMEBH3	DT	Small molecular drug
DMMEBH3	PC	46533
DMMEBH3	MW	180.16
DMMEBH3	FM	C9H8O4
DMMEBH3	IC	InChI=1S/C9H8O4/c10-5-7-3-1-2-4-8(7)13-6-9(11)12/h1-5H,6H2,(H,11,12)
DMMEBH3	CS	C1=CC=C(C(=C1)C=O)OCC(=O)O
DMMEBH3	IK	ANWMNLAAFDCKMT-UHFFFAOYSA-N
DMMEBH3	IU	2-(2-formylphenoxy)acetic acid
DMMEBH3	CA	CAS 6280-80-4
DMMEBH3	DE	Discovery agent

DMXGWOT	ID	DMXGWOT
DMXGWOT	DN	2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine
DMXGWOT	HS	Investigative
DMXGWOT	SN	CHEMBL399529; 2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine; 2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-ylamine; 856171-18-1; SCHEMBL1489577; SSPIGFDAVQVRCH-UHFFFAOYSA-N; BDBM50232155
DMXGWOT	DT	Small molecular drug
DMXGWOT	PC	11424684
DMXGWOT	MW	227.22
DMXGWOT	FM	C11H9N5O
DMXGWOT	IC	InChI=1S/C11H9N5O/c12-9-7-10(16-5-2-4-13-16)15-11(14-9)8-3-1-6-17-8/h1-7H,(H2,12,14,15)
DMXGWOT	CS	C1=CN(N=C1)C2=NC(=NC(=C2)N)C3=CC=CO3
DMXGWOT	IK	SSPIGFDAVQVRCH-UHFFFAOYSA-N
DMXGWOT	IU	2-(furan-2-yl)-6-pyrazol-1-ylpyrimidin-4-amine
DMXGWOT	DE	Discovery agent

DMSI41E	ID	DMSI41E
DMSI41E	DN	2-(2-hexylphenyl)isoindoline-1,3-dione
DMSI41E	HS	Investigative
DMSI41E	SN	CHEMBL245943; PP60; BDBM23841
DMSI41E	DT	Small molecular drug
DMSI41E	PC	10638446
DMSI41E	MW	307.4
DMSI41E	FM	C20H21NO2
DMSI41E	IC	InChI=1S/C20H21NO2/c1-2-3-4-5-10-15-11-6-9-14-18(15)21-19(22)16-12-7-8-13-17(16)20(21)23/h6-9,11-14H,2-5,10H2,1H3
DMSI41E	CS	CCCCCCC1=CC=CC=C1N2C(=O)C3=CC=CC=C3C2=O
DMSI41E	IK	USXHUJLIZBGCGH-UHFFFAOYSA-N
DMSI41E	IU	2-(2-hexylphenyl)isoindole-1,3-dione
DMSI41E	DE	Discovery agent

DMMEL39	ID	DMMEL39
DMMEL39	DN	2-(2-Hydroxycarbamoyl-ethyl)-pentanedioic acid
DMMEL39	HS	Investigative
DMMEL39	SN	CHEMBL63454; 475653-52-2; 2-(2-Hydroxycarbamoyl-ethyl)-pentanedioic acid; SCHEMBL13996820; CTK1C7211; DTXSID40609753; BDBM50129195; 2-[3-Oxo-3-(hydroxyamino)propyl]pentanedioic acid; 2-[3-(Hydroxyamino)-3-oxopropyl]pentanedioic acid; Pentanedioic acid, 2-[3-(hydroxyamino)-3-oxopropyl]-
DMMEL39	DT	Small molecular drug
DMMEL39	PC	20778197
DMMEL39	MW	219.19
DMMEL39	FM	C8H13NO6
DMMEL39	IC	InChI=1S/C8H13NO6/c10-6(9-15)3-1-5(8(13)14)2-4-7(11)12/h5,15H,1-4H2,(H,9,10)(H,11,12)(H,13,14)
DMMEL39	CS	C(CC(=O)NO)C(CCC(=O)O)C(=O)O
DMMEL39	IK	HTZIUDNKEYUDDE-UHFFFAOYSA-N
DMMEL39	IU	2-[3-(hydroxyamino)-3-oxopropyl]pentanedioic acid
DMMEL39	CA	CAS 475653-52-2
DMMEL39	DE	Discovery agent

DMRPCL7	ID	DMRPCL7
DMRPCL7	DN	2-(2-Hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one
DMRPCL7	HS	Investigative
DMRPCL7	SN	SCHEMBL11120339
DMRPCL7	DT	Small molecular drug
DMRPCL7	PC	46907248
DMRPCL7	MW	264.28
DMRPCL7	FM	C16H12N2O2
DMRPCL7	IC	InChI=1S/C16H12N2O2/c19-9-8-18-13-7-3-6-12-14(13)15(17-18)10-4-1-2-5-11(10)16(12)20/h1-7,19H,8-9H2
DMRPCL7	CS	C1=CC=C2C(=C1)C3=NN(C4=CC=CC(=C43)C2=O)CCO
DMRPCL7	IK	IWTWHJYONHLOQB-UHFFFAOYSA-N
DMRPCL7	IU	14-(2-hydroxyethyl)-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one
DMRPCL7	DE	Discovery agent

DM3UMYD	ID	DM3UMYD
DM3UMYD	DN	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine
DM3UMYD	HS	Investigative
DM3UMYD	SN	2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine; amino[2-(2-hydroxyphenyl)-1H-indol-5-yl]methaniminium; AC1L1BMI; BDBM13942; CTK8A0256; APC-8328; DB02463; [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium
DM3UMYD	DT	Small molecular drug
DM3UMYD	PC	1507
DM3UMYD	MW	252.29
DM3UMYD	FM	C15H14N3O+
DM3UMYD	IC	InChI=1S/C15H13N3O/c16-15(17)9-5-6-12-10(7-9)8-13(18-12)11-3-1-2-4-14(11)19/h1-8,18-19H,(H3,16,17)/p+1
DM3UMYD	CS	C1=CC=C(C(=C1)C2=CC3=C(N2)C=CC(=C3)C(=[NH2+])N)O
DM3UMYD	IK	JPGNPKIYCTXJPG-UHFFFAOYSA-O
DM3UMYD	IU	[amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium
DM3UMYD	DE	Discovery agent

DMOANXP	ID	DMOANXP
DMOANXP	DN	2-(2-Hydroxy-phenyl)-6-methyl-chromen-4-one
DMOANXP	HS	Investigative
DMOANXP	SN	CHEMBL134408
DMOANXP	DT	Small molecular drug
DMOANXP	PC	11032345
DMOANXP	MW	252.26
DMOANXP	FM	C16H12O3
DMOANXP	IC	InChI=1S/C16H12O3/c1-10-6-7-15-12(8-10)14(18)9-16(19-15)11-4-2-3-5-13(11)17/h2-9,17H,1H3
DMOANXP	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3O
DMOANXP	IK	JWTNDTDENSEMQI-UHFFFAOYSA-N
DMOANXP	IU	2-(2-hydroxyphenyl)-6-methylchromen-4-one
DMOANXP	DE	Discovery agent

DMCLIN8	ID	DMCLIN8
DMCLIN8	DN	2-(2''-indolylethyloxy)adenosine
DMCLIN8	HS	Investigative
DMCLIN8	SN	CHEMBL374461; SCHEMBL4234414; 2-(2'-Indolylethyloxy)Adenosine; BDBM50208812
DMCLIN8	DT	Small molecular drug
DMCLIN8	PC	16203431
DMCLIN8	MW	426.4
DMCLIN8	FM	C20H22N6O5
DMCLIN8	IC	InChI=1S/C20H22N6O5/c21-17-14-18(26(9-22-14)19-16(29)15(28)13(8-27)31-19)25-20(24-17)30-6-5-11-7-10-3-1-2-4-12(10)23-11/h1-4,7,9,13,15-16,19,23,27-29H,5-6,8H2,(H2,21,24,25)/t13-,15-,16-,19-/m1/s1
DMCLIN8	CS	C1=CC=C2C(=C1)C=C(N2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMCLIN8	IK	VWETWISDPZSJHC-NVQRDWNXSA-N
DMCLIN8	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(1H-indol-2-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMCLIN8	DE	Discovery agent

DMSVHU9	ID	DMSVHU9
DMSVHU9	DN	2-(2-Iodo-benzoyl)-cyclohexane-1,3-dione
DMSVHU9	HS	Investigative
DMSVHU9	SN	2-(2-Iodobenzoyl)cyclohexane-1,3-dione; CHEMBL165937; 88562-10-1; 1,3-Cyclohexanedione, 2-(2-iodobenzoyl)-; ACMC-20lbdr; 2-(2-Iodo-benzoyl)-cyclohexane-1,3-dione; CTK3A9586; DTXSID90558702
DMSVHU9	DT	Small molecular drug
DMSVHU9	PC	14301629
DMSVHU9	MW	342.13
DMSVHU9	FM	C13H11IO3
DMSVHU9	IC	InChI=1S/C13H11IO3/c14-9-5-2-1-4-8(9)13(17)12-10(15)6-3-7-11(12)16/h1-2,4-5,12H,3,6-7H2
DMSVHU9	CS	C1CC(=O)C(C(=O)C1)C(=O)C2=CC=CC=C2I
DMSVHU9	IK	OGHGLYVCKWVCJJ-UHFFFAOYSA-N
DMSVHU9	IU	2-(2-iodobenzoyl)cyclohexane-1,3-dione
DMSVHU9	CA	CAS 88562-10-1
DMSVHU9	DE	Discovery agent

DMPA4S0	ID	DMPA4S0
DMPA4S0	DN	2-(2-Iodo-phenyl)-benzo[d][1,3]oxazin-4-one
DMPA4S0	HS	Investigative
DMPA4S0	SN	CHEMBL10378; NSC165772; AC1L6PF7; 2-(2-Iodo-phenyl)-benzo[d][1,3]oxazin-4-one; SCHEMBL913450; BDBM50063703; NSC-165772; 2-(2-iodophenyl)-3,1-benzoxazin-4-one
DMPA4S0	DT	Small molecular drug
DMPA4S0	PC	296008
DMPA4S0	MW	349.12
DMPA4S0	FM	C14H8INO2
DMPA4S0	IC	InChI=1S/C14H8INO2/c15-11-7-3-1-5-9(11)13-16-12-8-4-2-6-10(12)14(17)18-13/h1-8H
DMPA4S0	CS	C1=CC=C2C(=C1)C(=O)OC(=N2)C3=CC=CC=C3I
DMPA4S0	IK	VEBIXPCJYGGBAF-UHFFFAOYSA-N
DMPA4S0	IU	2-(2-iodophenyl)-3,1-benzoxazin-4-one
DMPA4S0	DE	Discovery agent

DMGELY0	ID	DMGELY0
DMGELY0	DN	2-(2-Mercapto-ethyl)-pentanedioic acid
DMGELY0	HS	Investigative
DMGELY0	SN	2-(2-sulfanylethyl)pentanedioic Acid; CHEMBL292562; 254737-18-3; Pentanedioic acid, 2-(2-mercaptoethyl)-; 2-(2-Mercapto-ethyl)-pentanedioic acid; SCHEMBL2058227; CTK0J4031; DTXSID80430765; SMGZBRVSYVJHCB-UHFFFAOYSA-N
DMGELY0	DT	Small molecular drug
DMGELY0	PC	9794137
DMGELY0	MW	192.24
DMGELY0	FM	C7H12O4S
DMGELY0	IC	InChI=1S/C7H12O4S/c8-6(9)2-1-5(3-4-12)7(10)11/h5,12H,1-4H2,(H,8,9)(H,10,11)
DMGELY0	CS	C(CC(=O)O)C(CCS)C(=O)O
DMGELY0	IK	SMGZBRVSYVJHCB-UHFFFAOYSA-N
DMGELY0	IU	2-(2-sulfanylethyl)pentanedioic acid
DMGELY0	CA	CAS 254737-18-3
DMGELY0	DE	Discovery agent

DMESMBO	ID	DMESMBO
DMESMBO	DN	2-(2-Methoxy-benzoyl)-cyclohexane-1,3-dione
DMESMBO	HS	Investigative
DMESMBO	SN	CHEMBL167062; 2-(2-Methoxybenzoyl)cyclohexane-1,3-dione; 2-(2-Methoxy-benzoyl)-cyclohexane-1,3-dione; SCHEMBL10192397
DMESMBO	DT	Small molecular drug
DMESMBO	PC	12723197
DMESMBO	MW	246.26
DMESMBO	FM	C14H14O4
DMESMBO	IC	InChI=1S/C14H14O4/c1-18-12-8-3-2-5-9(12)14(17)13-10(15)6-4-7-11(13)16/h2-3,5,8,13H,4,6-7H2,1H3
DMESMBO	CS	COC1=CC=CC=C1C(=O)C2C(=O)CCCC2=O
DMESMBO	IK	ADJLOHOSFKJYEC-UHFFFAOYSA-N
DMESMBO	IU	2-(2-methoxybenzoyl)cyclohexane-1,3-dione
DMESMBO	DE	Discovery agent

DM9Z8V5	ID	DM9Z8V5
DM9Z8V5	DN	2-(2-Methoxybenzyl)-3H-benzo[f]chromen-3-one
DM9Z8V5	HS	Investigative
DM9Z8V5	SN	CHEMBL469340; 2-(2-Methoxybenzyl)-3H-benzo[f]chromen-3-one
DM9Z8V5	DT	Small molecular drug
DM9Z8V5	PC	44592011
DM9Z8V5	MW	316.3
DM9Z8V5	FM	C21H16O3
DM9Z8V5	IC	InChI=1S/C21H16O3/c1-23-19-9-5-3-7-15(19)12-16-13-18-17-8-4-2-6-14(17)10-11-20(18)24-21(16)22/h2-11,13H,12H2,1H3
DM9Z8V5	CS	COC1=CC=CC=C1CC2=CC3=C(C=CC4=CC=CC=C43)OC2=O
DM9Z8V5	IK	VCXYTPBLXWPGOC-UHFFFAOYSA-N
DM9Z8V5	IU	2-[(2-methoxyphenyl)methyl]benzo[f]chromen-3-one
DM9Z8V5	DE	Discovery agent

DMYVDJQ	ID	DMYVDJQ
DMYVDJQ	DN	2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine
DMYVDJQ	HS	Investigative
DMYVDJQ	SN	CHEMBL597531; 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine
DMYVDJQ	DT	Small molecular drug
DMYVDJQ	PC	44133674
DMYVDJQ	MW	284.35
DMYVDJQ	FM	C17H20N2O2
DMYVDJQ	IC	InChI=1S/C17H20N2O2/c1-20-15-6-2-3-7-16(15)21-17-14(5-4-10-19-17)13-8-11-18-12-9-13/h2-7,10,13,18H,8-9,11-12H2,1H3
DMYVDJQ	CS	COC1=CC=CC=C1OC2=C(C=CC=N2)C3CCNCC3
DMYVDJQ	IK	GZJLFOYGSNAXDK-UHFFFAOYSA-N
DMYVDJQ	IU	2-(2-methoxyphenoxy)-3-piperidin-4-ylpyridine
DMYVDJQ	DE	Discovery agent

DMXFYN8	ID	DMXFYN8
DMXFYN8	DN	2-(2-methoxyphenyl)-1H-indene
DMXFYN8	HS	Investigative
DMXFYN8	SN	CHEMBL376583; 2-(2-methoxyphenyl)-1H-indene; 2-(o-Methoxyphenyl)-1H-indene; SCHEMBL16621596
DMXFYN8	DT	Small molecular drug
DMXFYN8	PC	44424412
DMXFYN8	MW	222.28
DMXFYN8	FM	C16H14O
DMXFYN8	IC	InChI=1S/C16H14O/c1-17-16-9-5-4-8-15(16)14-10-12-6-2-3-7-13(12)11-14/h2-10H,11H2,1H3
DMXFYN8	CS	COC1=CC=CC=C1C2=CC3=CC=CC=C3C2
DMXFYN8	IK	APOFCYAJMPJCJI-UHFFFAOYSA-N
DMXFYN8	IU	2-(2-methoxyphenyl)-1H-indene
DMXFYN8	DE	Discovery agent

DMDI98B	ID	DMDI98B
DMDI98B	DN	2-(2-Methoxy-phenyl)-1-methyl-ethylamine
DMDI98B	HS	Investigative
DMDI98B	SN	1-(2-methoxyphenyl)propan-2-amine; 15402-84-3; N-Desmethylmethoxyphenamine; 2-Methoxyamphetamine; o-Methoxyamphetamine; NDMP; 2-(2-Methoxy-phenyl)-1-methyl-ethylamine; CHEMBL16451; Benzeneethanamine, 2-methoxy-alpha-methyl-; Benzeneethanamine,2-methoxy--methyl-; 1-(2-METHOXYPHENYL)-2-PROPYLAMINE; AC1L4MFB; AC1Q57OA; AC1Q45CZ; (d,l)-2-Methoxyamphetamine; Methoxyphenamine, N-desmethyl; SCHEMBL266563; o-Methoxy(phenylisopropyl)amine; AMBZ0414; AC1Q45D0; 2-Methoxy(phenylisopropyl)amine; o-Methoxy-a-methylphenethylamine
DMDI98B	DT	Small molecular drug
DMDI98B	PC	159755
DMDI98B	MW	165.23
DMDI98B	FM	C10H15NO
DMDI98B	IC	InChI=1S/C10H15NO/c1-8(11)7-9-5-3-4-6-10(9)12-2/h3-6,8H,7,11H2,1-2H3
DMDI98B	CS	CC(CC1=CC=CC=C1OC)N
DMDI98B	IK	VBAHFEPKESUPDE-UHFFFAOYSA-N
DMDI98B	IU	1-(2-methoxyphenyl)propan-2-amine
DMDI98B	CA	CAS 15402-84-3
DMDI98B	DE	Discovery agent

DMPVCDN	ID	DMPVCDN
DMPVCDN	DN	2-(2-Methoxy-phenyl)-6-methyl-chromen-4-one
DMPVCDN	HS	Investigative
DMPVCDN	SN	89112-85-6; 2-(2-methoxyphenyl)-6-methyl-4H-chromen-4-one; CHEMBL334355; 2-(2-methoxyphenyl)-6-methylchromen-4-one; 4H-1-Benzopyran-4-one, 2-(2-methoxyphenyl)-6-methyl-; F3139-0622; ACMC-20lhvv; AC1LIFWU; 2'-Methoxy-6-methylflavone; CTK3A1211; DTXSID40358996; QEIHFNZSIRWEBX-UHFFFAOYSA-N; MolPort-000-450-861; ZINC521727; STK788037; AKOS002182005; MCULE-9515838114; NCGC00339312-01; ST4146766
DMPVCDN	DT	Small molecular drug
DMPVCDN	PC	930492
DMPVCDN	MW	266.29
DMPVCDN	FM	C17H14O3
DMPVCDN	IC	InChI=1S/C17H14O3/c1-11-7-8-16-13(9-11)14(18)10-17(20-16)12-5-3-4-6-15(12)19-2/h3-10H,1-2H3
DMPVCDN	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3OC
DMPVCDN	IK	QEIHFNZSIRWEBX-UHFFFAOYSA-N
DMPVCDN	IU	2-(2-methoxyphenyl)-6-methylchromen-4-one
DMPVCDN	CA	CAS 89112-85-6
DMPVCDN	DE	Discovery agent

DMXVCL0	ID	DMXVCL0
DMXVCL0	DN	2-(2-methoxyphenyl)-6-morpholino-4H-pyran-4-one
DMXVCL0	HS	Investigative
DMXVCL0	SN	CHEMBL105256; 2-(2-methoxyphenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3538816; BDBM50132363; 2-Morpholino-6-(2-methoxyphenyl)-4H-pyran-4-one
DMXVCL0	DT	Small molecular drug
DMXVCL0	PC	21106400
DMXVCL0	MW	287.31
DMXVCL0	FM	C16H17NO4
DMXVCL0	IC	InChI=1S/C16H17NO4/c1-19-14-5-3-2-4-13(14)15-10-12(18)11-16(21-15)17-6-8-20-9-7-17/h2-5,10-11H,6-9H2,1H3
DMXVCL0	CS	COC1=CC=CC=C1C2=CC(=O)C=C(O2)N3CCOCC3
DMXVCL0	IK	ZDNMYLJFYAXNHH-UHFFFAOYSA-N
DMXVCL0	IU	2-(2-methoxyphenyl)-6-morpholin-4-ylpyran-4-one
DMXVCL0	CA	CAS 155906-26-6
DMXVCL0	DE	Discovery agent

DM4GN0E	ID	DM4GN0E
DM4GN0E	DN	2-(2-Methyl-benzoyl)-cyclohexane-1,3-dione
DM4GN0E	HS	Investigative
DM4GN0E	SN	CHEMBL355470; 2-(2-Methylbenzoyl)cyclohexane-1,3-dione; 2-(2-Methyl-benzoyl)-cyclohexane-1,3-dione; SCHEMBL10191381
DM4GN0E	DT	Small molecular drug
DM4GN0E	PC	14301714
DM4GN0E	MW	230.26
DM4GN0E	FM	C14H14O3
DM4GN0E	IC	InChI=1S/C14H14O3/c1-9-5-2-3-6-10(9)14(17)13-11(15)7-4-8-12(13)16/h2-3,5-6,13H,4,7-8H2,1H3
DM4GN0E	CS	CC1=CC=CC=C1C(=O)C2C(=O)CCCC2=O
DM4GN0E	IK	ZGPNNJNODAAWSM-UHFFFAOYSA-N
DM4GN0E	IU	2-(2-methylbenzoyl)cyclohexane-1,3-dione
DM4GN0E	DE	Discovery agent

DM7HN4Z	ID	DM7HN4Z
DM7HN4Z	DN	2-(2'-methyl-biphenyl-3-yl)-ethylamine
DM7HN4Z	HS	Investigative
DM7HN4Z	SN	CHEMBL234885; ZINC28821767; BDBM50210124; AKOS022255130; 2-(2''-methyl-biphenyl-3-yl)-ethylamine
DM7HN4Z	DT	Small molecular drug
DM7HN4Z	PC	35985234
DM7HN4Z	MW	211.3
DM7HN4Z	FM	C15H17N
DM7HN4Z	IC	InChI=1S/C15H17N/c1-12-5-2-3-8-15(12)14-7-4-6-13(11-14)9-10-16/h2-8,11H,9-10,16H2,1H3
DM7HN4Z	CS	CC1=CC=CC=C1C2=CC=CC(=C2)CCN
DM7HN4Z	IK	KQRAKUVQYREATE-UHFFFAOYSA-N
DM7HN4Z	IU	2-[3-(2-methylphenyl)phenyl]ethanamine
DM7HN4Z	DE	Discovery agent

DMAHZR9	ID	DMAHZR9
DMAHZR9	DN	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one
DMAHZR9	HS	Investigative
DMAHZR9	SN	CHEMBL435507; 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one; SCHEMBL3545107
DMAHZR9	DT	Small molecular drug
DMAHZR9	PC	10017389
DMAHZR9	MW	295.3
DMAHZR9	FM	C18H17NO3
DMAHZR9	IC	InChI=1S/C18H17NO3/c1-12-11-19(8-9-21-12)17-10-16(20)15-7-6-13-4-2-3-5-14(13)18(15)22-17/h2-7,10,12H,8-9,11H2,1H3
DMAHZR9	CS	CC1CN(CCO1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMAHZR9	IK	RFWCIJWQGHFULK-UHFFFAOYSA-N
DMAHZR9	IU	2-(2-methylmorpholin-4-yl)benzo[h]chromen-4-one
DMAHZR9	DE	Discovery agent

DMPH63G	ID	DMPH63G
DMPH63G	DN	2-(2-Methylpropanoyl)-1,3,5-benzenetriol
DMPH63G	HS	Investigative
DMPH63G	SN	Phlorisobutyrophenone; 35458-21-0; 2-(2-Methylpropanoyl)-1,3,5-benzenetriol; 1-Propanone, 2-methyl-1-(2,4,6-trihydroxyphenyl)-; CHEMBL20038; 2-methyl-1-(2,4,6-trihydroxyphenyl)propan-1-one; 2-Methyl-1-(2,4,6-trihydroxyphenyl)-1-propanone; phlorisobutanophenone; phloroisobutyrophenone; AC1NS0BJ; 2-isobutyrylphloroglucinol; 2-isobutanoylphloroglucinol; SCHEMBL2150396; CTK1B6928; DTXSID60416108; MolPort-022-379-188; BNEBXEZRBLYBCZ-UHFFFAOYSA-N; CHEBI:133419; ZINC13650343; BDBM50005639; 1-isobutyryl-2,4,6-trihydroxybenzene
DMPH63G	DT	Small molecular drug
DMPH63G	PC	5326317
DMPH63G	MW	196.2
DMPH63G	FM	C10H12O4
DMPH63G	IC	InChI=1S/C10H12O4/c1-5(2)10(14)9-7(12)3-6(11)4-8(9)13/h3-5,11-13H,1-2H3
DMPH63G	CS	CC(C)C(=O)C1=C(C=C(C=C1O)O)O
DMPH63G	IK	BNEBXEZRBLYBCZ-UHFFFAOYSA-N
DMPH63G	IU	2-methyl-1-(2,4,6-trihydroxyphenyl)propan-1-one
DMPH63G	CA	CAS 35458-21-0
DMPH63G	CB	CHEBI:133419
DMPH63G	DE	Discovery agent

DMW75IF	ID	DMW75IF
DMW75IF	DN	2-(2-methylquinolin-4-ylamino)-N-phenylacetamide
DMW75IF	HS	Investigative
DMW75IF	SN	CHEMBL594511; 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide
DMW75IF	DT	Small molecular drug
DMW75IF	PC	44596230
DMW75IF	MW	291.3
DMW75IF	FM	C18H17N3O
DMW75IF	IC	InChI=1S/C18H17N3O/c1-13-11-17(15-9-5-6-10-16(15)20-13)19-12-18(22)21-14-7-3-2-4-8-14/h2-11H,12H2,1H3,(H,19,20)(H,21,22)
DMW75IF	CS	CC1=NC2=CC=CC=C2C(=C1)NCC(=O)NC3=CC=CC=C3
DMW75IF	IK	HRXVDSHQRNNGBO-UHFFFAOYSA-N
DMW75IF	IU	2-[(2-methylquinolin-4-yl)amino]-N-phenylacetamide
DMW75IF	DE	Discovery agent

DMENUIH	ID	DMENUIH
DMENUIH	DN	2-(2-methylquinolin-7-yl)benzonitrile
DMENUIH	HS	Investigative
DMENUIH	SN	CHEMBL434585; 2-(2-methylquinolin-7-yl)benzonitrile
DMENUIH	DT	Small molecular drug
DMENUIH	PC	44432671
DMENUIH	MW	244.29
DMENUIH	FM	C17H12N2
DMENUIH	IC	InChI=1S/C17H12N2/c1-12-6-7-13-8-9-14(10-17(13)19-12)16-5-3-2-4-15(16)11-18/h2-10H,1H3
DMENUIH	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC=C3C#N
DMENUIH	IK	MUNVAMLSVBEAIR-UHFFFAOYSA-N
DMENUIH	IU	2-(2-methylquinolin-7-yl)benzonitrile
DMENUIH	DE	Discovery agent

DMIHTL0	ID	DMIHTL0
DMIHTL0	DN	2-(2-Methyl-thiazol-4-ylethynyl)-pyridine
DMIHTL0	HS	Investigative
DMIHTL0	SN	CHEMBL65022; 2-(2-Methyl-thiazol-4-ylethynyl)-pyridine; SCHEMBL15049682; BDBM50122757
DMIHTL0	DT	Small molecular drug
DMIHTL0	PC	11063448
DMIHTL0	MW	200.26
DMIHTL0	FM	C11H8N2S
DMIHTL0	IC	InChI=1S/C11H8N2S/c1-9-13-11(8-14-9)6-5-10-4-2-3-7-12-10/h2-4,7-8H,1H3
DMIHTL0	CS	CC1=NC(=CS1)C#CC2=CC=CC=N2
DMIHTL0	IK	BQDSXKBRSCMFRW-UHFFFAOYSA-N
DMIHTL0	IU	2-methyl-4-(2-pyridin-2-ylethynyl)-1,3-thiazole
DMIHTL0	DE	Discovery agent

DMN176Y	ID	DMN176Y
DMN176Y	DN	2-(2-naphthamido)benzoic acid
DMN176Y	HS	Investigative
DMN176Y	SN	2-(2-naphthamido)benzoic acid; SCHEMBL8044197; CHEMBL200536; BDBM16098; 2-(naphthalene-2-amido)benzoic acid; AKOS000132452; 2-[(naphthalen-2-ylcarbonyl)amino]benzoic acid
DMN176Y	DT	Small molecular drug
DMN176Y	PC	13707619
DMN176Y	MW	291.3
DMN176Y	FM	C18H13NO3
DMN176Y	IC	InChI=1S/C18H13NO3/c20-17(19-16-8-4-3-7-15(16)18(21)22)14-10-9-12-5-1-2-6-13(12)11-14/h1-11H,(H,19,20)(H,21,22)
DMN176Y	CS	C1=CC=C2C=C(C=CC2=C1)C(=O)NC3=CC=CC=C3C(=O)O
DMN176Y	IK	BBJZKXXWFJLNRR-UHFFFAOYSA-N
DMN176Y	IU	2-(naphthalene-2-carbonylamino)benzoic acid
DMN176Y	DE	Discovery agent

DMUJQX1	ID	DMUJQX1
DMUJQX1	DN	2-(2-Nitro-benzoyl)-cyclohexane-1,3-dione
DMUJQX1	HS	Investigative
DMUJQX1	SN	CHEMBL169696; 2-(2-nitrobenzoyl)cyclohexane-1,3-dione; 1,3-Cyclohexanedione, 2-(2-nitrobenzoyl)-; 104206-60-2; 2-(2-Nitro-benzoyl)-cyclohexane-1,3-dione; ACMC-20m705; SCHEMBL7275303; CTK0G6513; DTXSID90553792; ZZJZBPYZTKGWTD-UHFFFAOYSA-N; 2-nitrobenzoylcyclohexane-1,3-dione; BDBM50088793; 2-(2-nitrobenzoyl)-1 ,3-cyclohexanedione
DMUJQX1	DT	Small molecular drug
DMUJQX1	PC	13983070
DMUJQX1	MW	261.23
DMUJQX1	FM	C13H11NO5
DMUJQX1	IC	InChI=1S/C13H11NO5/c15-10-6-3-7-11(16)12(10)13(17)8-4-1-2-5-9(8)14(18)19/h1-2,4-5,12H,3,6-7H2
DMUJQX1	CS	C1CC(=O)C(C(=O)C1)C(=O)C2=CC=CC=C2[N+](=O)[O-]
DMUJQX1	IK	ZZJZBPYZTKGWTD-UHFFFAOYSA-N
DMUJQX1	IU	2-(2-nitrobenzoyl)cyclohexane-1,3-dione
DMUJQX1	CA	CAS 104206-60-2
DMUJQX1	DE	Discovery agent

DM5NLQE	ID	DM5NLQE
DM5NLQE	DN	2-(2-phenethylphenyl)isoindoline-1,3-dione
DM5NLQE	HS	Investigative
DM5NLQE	SN	CHEMBL246144; PP2P; SCHEMBL2464969; BDBM23840; N-(2-Phenethylphenyl)phthalimide
DM5NLQE	DT	Small molecular drug
DM5NLQE	PC	10616182
DM5NLQE	MW	327.4
DM5NLQE	FM	C22H17NO2
DM5NLQE	IC	InChI=1S/C22H17NO2/c24-21-18-11-5-6-12-19(18)22(25)23(21)20-13-7-4-10-17(20)15-14-16-8-2-1-3-9-16/h1-13H,14-15H2
DM5NLQE	CS	C1=CC=C(C=C1)CCC2=CC=CC=C2N3C(=O)C4=CC=CC=C4C3=O
DM5NLQE	IK	XGSWAPNRKGOSKD-UHFFFAOYSA-N
DM5NLQE	IU	2-[2-(2-phenylethyl)phenyl]isoindole-1,3-dione
DM5NLQE	DE	Discovery agent

DME0HPA	ID	DME0HPA
DME0HPA	DN	2-(2-phenoxypyrimidin-4-ylamino)benzoic acid
DME0HPA	HS	Investigative
DME0HPA	SN	4-anilinopyrimidine 6g; CHEMBL244626; BDBM15985; 2-[(2-phenoxypyrimidin-4-yl)amino]benzoic acid
DME0HPA	DT	Small molecular drug
DME0HPA	PC	23647245
DME0HPA	MW	307.3
DME0HPA	FM	C17H13N3O3
DME0HPA	IC	InChI=1S/C17H13N3O3/c21-16(22)13-8-4-5-9-14(13)19-15-10-11-18-17(20-15)23-12-6-2-1-3-7-12/h1-11H,(H,21,22)(H,18,19,20)
DME0HPA	CS	C1=CC=C(C=C1)OC2=NC=CC(=N2)NC3=CC=CC=C3C(=O)O
DME0HPA	IK	MQQUMLXYIRSXSZ-UHFFFAOYSA-N
DME0HPA	IU	2-[(2-phenoxypyrimidin-4-yl)amino]benzoic acid
DME0HPA	DE	Discovery agent

DM1K0U5	ID	DM1K0U5
DM1K0U5	DN	2-(2-Phenyl-1H-indol-3-yl)-N,N-dipropyl-acetamide
DM1K0U5	HS	Investigative
DM1K0U5	SN	CHEMBL327286; 2-(2-phenyl-1H-indol-3-yl)-N,N-dipropyl-acetamide; BDBM50045857
DM1K0U5	DT	Small molecular drug
DM1K0U5	PC	10449567
DM1K0U5	MW	334.5
DM1K0U5	FM	C22H26N2O
DM1K0U5	IC	InChI=1S/C22H26N2O/c1-3-14-24(15-4-2)21(25)16-19-18-12-8-9-13-20(18)23-22(19)17-10-6-5-7-11-17/h5-13,23H,3-4,14-16H2,1-2H3
DM1K0U5	CS	CCCN(CCC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DM1K0U5	IK	VEAFPKIMCGYMFZ-UHFFFAOYSA-N
DM1K0U5	IU	2-(2-phenyl-1H-indol-3-yl)-N,N-dipropylacetamide
DM1K0U5	DE	Discovery agent

DMO9SP1	ID	DMO9SP1
DMO9SP1	DN	2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DMO9SP1	HS	Investigative
DMO9SP1	SN	CHEMBL213035; 2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DMO9SP1	DT	Small molecular drug
DMO9SP1	PC	44414735
DMO9SP1	MW	291.4
DMO9SP1	FM	C19H21N3
DMO9SP1	IC	InChI=1S/C19H21N3/c20-15-18-9-5-4-8-17(18)14-19(16-6-2-1-3-7-16)22-12-10-21-11-13-22/h1-9,19,21H,10-14H2
DMO9SP1	CS	C1CN(CCN1)C(CC2=CC=CC=C2C#N)C3=CC=CC=C3
DMO9SP1	IK	FCHUPCOGZXEFDS-UHFFFAOYSA-N
DMO9SP1	IU	2-(2-phenyl-2-piperazin-1-ylethyl)benzonitrile
DMO9SP1	DE	Discovery agent

DMQM6IA	ID	DMQM6IA
DMQM6IA	DN	2-(2-Phosphonooxy-ethyl)-pentanedioic acid
DMQM6IA	HS	Investigative
DMQM6IA	SN	CHEMBL58232; 2-(2-Phosphonooxy-ethyl)-pentanedioic acid; SCHEMBL8060048
DMQM6IA	DT	Small molecular drug
DMQM6IA	PC	10879227
DMQM6IA	MW	240.15
DMQM6IA	FM	C7H13O7P
DMQM6IA	IC	InChI=1S/C7H13O7P/c8-6(9)2-1-5(7(10)11)3-4-15(12,13)14/h5H,1-4H2,(H,8,9)(H,10,11)(H2,12,13,14)
DMQM6IA	CS	C(CC(=O)O)C(CCP(=O)(O)O)C(=O)O
DMQM6IA	IK	NKKKETAADLKALP-UHFFFAOYSA-N
DMQM6IA	IU	2-(2-phosphonoethyl)pentanedioic acid
DMQM6IA	DE	Discovery agent

DMGVCKZ	ID	DMGVCKZ
DMGVCKZ	DN	2-(2-propoxypyrimidin-4-ylamino)benzoic acid
DMGVCKZ	HS	Investigative
DMGVCKZ	SN	4-anilinopyrimidine 6b; CHEMBL242489; BDBM15980; 2-[(2-propoxypyrimidin-4-yl)amino]benzoic acid
DMGVCKZ	DT	Small molecular drug
DMGVCKZ	PC	23647240
DMGVCKZ	MW	273.29
DMGVCKZ	FM	C14H15N3O3
DMGVCKZ	IC	InChI=1S/C14H15N3O3/c1-2-9-20-14-15-8-7-12(17-14)16-11-6-4-3-5-10(11)13(18)19/h3-8H,2,9H2,1H3,(H,18,19)(H,15,16,17)
DMGVCKZ	CS	CCCOC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DMGVCKZ	IK	NZLCVQSIEXQTHO-UHFFFAOYSA-N
DMGVCKZ	IU	2-[(2-propoxypyrimidin-4-yl)amino]benzoic acid
DMGVCKZ	DE	Discovery agent

DMB4W68	ID	DMB4W68
DMB4W68	DN	2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid
DMB4W68	HS	Investigative
DMB4W68	SN	CHEMBL242702
DMB4W68	DT	Small molecular drug
DMB4W68	PC	44427133
DMB4W68	MW	287.31
DMB4W68	FM	C15H17N3O3
DMB4W68	IC	InChI=1S/C15H17N3O3/c1-3-10(2)21-15-16-9-8-13(18-15)17-12-7-5-4-6-11(12)14(19)20/h4-10H,3H2,1-2H3,(H,19,20)(H,16,17,18)
DMB4W68	CS	CCC(C)OC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DMB4W68	IK	XCPPZXZCQFKXQJ-UHFFFAOYSA-N
DMB4W68	IU	2-[(2-butan-2-yloxypyrimidin-4-yl)amino]benzoic acid
DMB4W68	DE	Discovery agent

DMRL65E	ID	DMRL65E
DMRL65E	DN	2-(2-thiazolyl)ethanamine
DMRL65E	HS	Investigative
DMRL65E	SN	2-thiazoleethanamine; 2-thiazolylethylamine; 2-(2-aminoethyl)thiazole
DMRL65E	DT	Small molecular drug
DMRL65E	PC	87653
DMRL65E	MW	128.199
DMRL65E	FM	C5H8N2S
DMRL65E	IC	InChI=1S/C5H8N2S/c6-2-1-5-7-3-4-8-5/h3-4H,1-2,6H2
DMRL65E	CS	C1=CSC(=N1)CCN
DMRL65E	IK	TWZOYAWHWDRMEZ-UHFFFAOYSA-N
DMRL65E	IU	2-(1,3-thiazol-2-yl)ethanamine
DMRL65E	CA	CAS 18453-07-1
DMRL65E	CB	CHEBI:81388
DMRL65E	DE	Discovery agent

DMLJH92	ID	DMLJH92
DMLJH92	DN	2-(3-(2-methylquinolin-7-yl)phenyl)acetonitrile
DMLJH92	HS	Investigative
DMLJH92	SN	CHEMBL267839; 2-(3-(2-methylquinolin-7-yl)phenyl)acetonitrile
DMLJH92	DT	Small molecular drug
DMLJH92	PC	44432658
DMLJH92	MW	258.3
DMLJH92	FM	C18H14N2
DMLJH92	IC	InChI=1S/C18H14N2/c1-13-5-6-15-7-8-17(12-18(15)20-13)16-4-2-3-14(11-16)9-10-19/h2-8,11-12H,9H2,1H3
DMLJH92	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC(=C3)CC#N
DMLJH92	IK	XNAOGJHXZYYKMV-UHFFFAOYSA-N
DMLJH92	IU	2-[3-(2-methylquinolin-7-yl)phenyl]acetonitrile
DMLJH92	DE	Discovery agent

DMM9WB0	ID	DMM9WB0
DMM9WB0	DN	2-(3-(3,5-dichlorophenyl)ureido)benzoic acid
DMM9WB0	HS	Investigative
DMM9WB0	SN	CHEMBL1088742; 2-{[(3,5-dichlorophenyl)carbamoyl]amino}benzoic acid; 2-(3-(3,5-dichlorophenyl)ureido)benzoic acid; SCHEMBL11983339; MolPort-011-309-281; BDBM50313600; AKOS012857299
DMM9WB0	DT	Small molecular drug
DMM9WB0	PC	44631845
DMM9WB0	MW	325.1
DMM9WB0	FM	C14H10Cl2N2O3
DMM9WB0	IC	InChI=1S/C14H10Cl2N2O3/c15-8-5-9(16)7-10(6-8)17-14(21)18-12-4-2-1-3-11(12)13(19)20/h1-7H,(H,19,20)(H2,17,18,21)
DMM9WB0	CS	C1=CC=C(C(=C1)C(=O)O)NC(=O)NC2=CC(=CC(=C2)Cl)Cl
DMM9WB0	IK	PIWYMPXOKMFVER-UHFFFAOYSA-N
DMM9WB0	IU	2-[(3,5-dichlorophenyl)carbamoylamino]benzoic acid
DMM9WB0	DE	Discovery agent

DMRX4HM	ID	DMRX4HM
DMRX4HM	DN	2-(3-(3-bromophenyl)ureido)-4-chlorobenzoic acid
DMRX4HM	HS	Investigative
DMRX4HM	SN	CHEMBL154700; 2-(3-(3-bromophenyl)ureido)-4-chlorobenzoic acid; SCHEMBL6431740; ZINC1491954; BDBM50137125; AKOS012857302; 2-[3-(3-Bromo-phenyl)-ureido]-4-chloro-benzoic acid
DMRX4HM	DT	Small molecular drug
DMRX4HM	PC	9799478
DMRX4HM	MW	369.6
DMRX4HM	FM	C14H10BrClN2O3
DMRX4HM	IC	InChI=1S/C14H10BrClN2O3/c15-8-2-1-3-10(6-8)17-14(21)18-12-7-9(16)4-5-11(12)13(19)20/h1-7H,(H,19,20)(H2,17,18,21)
DMRX4HM	CS	C1=CC(=CC(=C1)Br)NC(=O)NC2=C(C=CC(=C2)Cl)C(=O)O
DMRX4HM	IK	QRRARWFCZGWJJY-UHFFFAOYSA-N
DMRX4HM	IU	2-[(3-bromophenyl)carbamoylamino]-4-chlorobenzoic acid
DMRX4HM	DE	Discovery agent

DM1VSOK	ID	DM1VSOK
DM1VSOK	DN	2-(3-(3-methoxyphenoxy)prop-1-ynyl)pyridine
DM1VSOK	HS	Investigative
DM1VSOK	SN	CHEMBL212018; 2-(3-(3-methoxyphenoxy)prop-1-ynyl)pyridine; SCHEMBL5698315
DM1VSOK	DT	Small molecular drug
DM1VSOK	PC	11299421
DM1VSOK	MW	239.27
DM1VSOK	FM	C15H13NO2
DM1VSOK	IC	InChI=1S/C15H13NO2/c1-17-14-8-4-9-15(12-14)18-11-5-7-13-6-2-3-10-16-13/h2-4,6,8-10,12H,11H2,1H3
DM1VSOK	CS	COC1=CC(=CC=C1)OCC#CC2=CC=CC=N2
DM1VSOK	IK	NUGIZDIFZXSZAH-UHFFFAOYSA-N
DM1VSOK	IU	2-[3-(3-methoxyphenoxy)prop-1-ynyl]pyridine
DM1VSOK	DE	Discovery agent

DMXRHOY	ID	DMXRHOY
DMXRHOY	DN	2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine
DMXRHOY	HS	Investigative
DMXRHOY	SN	CHEMBL434377; BDBM50208797
DMXRHOY	DT	Small molecular drug
DMXRHOY	PC	16203543
DMXRHOY	MW	505.3
DMXRHOY	FM	C20H21BrN6O5
DMXRHOY	IC	InChI=1S/C20H21BrN6O5/c21-10-2-1-3-11-13(10)9(6-23-11)4-5-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)12(7-28)32-19/h1-3,6,8,12,15-16,19,23,28-30H,4-5,7H2,(H2,22,25,26)/t12-,15-,16-,19-/m1/s1
DMXRHOY	CS	C1=CC2=C(C(=C1)Br)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMXRHOY	IK	GBCVNJCVWVIDED-BGIGGGFGSA-N
DMXRHOY	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(4-bromo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMXRHOY	DE	Discovery agent

DMR8PGZ	ID	DMR8PGZ
DMR8PGZ	DN	2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine
DMR8PGZ	HS	Investigative
DMR8PGZ	SN	CHEMBL222194; MRS-3854; BDBM50208783; 2-(3''''-(5''''-bromo-indolyl)ethyloxy)adenosine
DMR8PGZ	DT	Small molecular drug
DMR8PGZ	PC	16203540
DMR8PGZ	MW	505.3
DMR8PGZ	FM	C20H21BrN6O5
DMR8PGZ	IC	InChI=1S/C20H21BrN6O5/c21-10-1-2-12-11(5-10)9(6-23-12)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DMR8PGZ	CS	C1=CC2=C(C=C1Br)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMR8PGZ	IK	ZUYSJPWNKBPSJB-NVQRDWNXSA-N
DMR8PGZ	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(5-bromo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMR8PGZ	DE	Discovery agent

DMD8Q3E	ID	DMD8Q3E
DMD8Q3E	DN	2-(3''(5''-chloro-indolyl)ethyloxy)adenosine
DMD8Q3E	HS	Investigative
DMD8Q3E	SN	CHEMBL222442; BDBM50208782; 2-(3''''(5''''-chloro-indolyl)ethyloxy)adenosine
DMD8Q3E	DT	Small molecular drug
DMD8Q3E	PC	16202725
DMD8Q3E	MW	460.9
DMD8Q3E	FM	C20H21ClN6O5
DMD8Q3E	IC	InChI=1S/C20H21ClN6O5/c21-10-1-2-12-11(5-10)9(6-23-12)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DMD8Q3E	CS	C1=CC2=C(C=C1Cl)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMD8Q3E	IK	RBLGZQGAVZQMSY-NVQRDWNXSA-N
DMD8Q3E	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(5-chloro-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMD8Q3E	DE	Discovery agent

DME3IN1	ID	DME3IN1
DME3IN1	DN	2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine
DME3IN1	HS	Investigative
DME3IN1	SN	CHEMBL373478; BDBM50208809; 2-(3''''-(5''''-fluoro-indolyl)ethyloxy)adenosine
DME3IN1	DT	Small molecular drug
DME3IN1	PC	16203539
DME3IN1	MW	444.4
DME3IN1	FM	C20H21FN6O5
DME3IN1	IC	InChI=1S/C20H21FN6O5/c21-10-1-2-12-11(5-10)9(6-23-12)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DME3IN1	CS	C1=CC2=C(C=C1F)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DME3IN1	IK	VEJNLHIDLOHNST-NVQRDWNXSA-N
DME3IN1	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(5-fluoro-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DME3IN1	DE	Discovery agent

DM6BIOP	ID	DM6BIOP
DM6BIOP	DN	2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine
DM6BIOP	HS	Investigative
DM6BIOP	SN	CHEMBL222500; BDBM50208785; 2-(3''''-(5''''-hydroxyindolyl)ethyloxy)adenosine
DM6BIOP	DT	Small molecular drug
DM6BIOP	PC	16202841
DM6BIOP	MW	442.4
DM6BIOP	FM	C20H22N6O6
DM6BIOP	IC	InChI=1S/C20H22N6O6/c21-17-14-18(26(8-23-14)19-16(30)15(29)13(7-27)32-19)25-20(24-17)31-4-3-9-6-22-12-2-1-10(28)5-11(9)12/h1-2,5-6,8,13,15-16,19,22,27-30H,3-4,7H2,(H2,21,24,25)/t13-,15-,16-,19-/m1/s1
DM6BIOP	CS	C1=CC2=C(C=C1O)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DM6BIOP	IK	CPKNPTKTLVLFFU-NVQRDWNXSA-N
DM6BIOP	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(5-hydroxy-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM6BIOP	DE	Discovery agent

DMFP0IW	ID	DMFP0IW
DMFP0IW	DN	2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine
DMFP0IW	HS	Investigative
DMFP0IW	SN	CHEMBL222748; BDBM50208791; 2-(3''''-(5''''-iodo-indolyl)ethyloxy)adenosine
DMFP0IW	DT	Small molecular drug
DMFP0IW	PC	16202726
DMFP0IW	MW	552.3
DMFP0IW	FM	C20H21IN6O5
DMFP0IW	IC	InChI=1S/C20H21IN6O5/c21-10-1-2-12-11(5-10)9(6-23-12)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DMFP0IW	CS	C1=CC2=C(C=C1I)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMFP0IW	IK	RPHVWFYWABZLPJ-NVQRDWNXSA-N
DMFP0IW	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(5-iodo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMFP0IW	DE	Discovery agent

DMWA0MN	ID	DMWA0MN
DMWA0MN	DN	2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine
DMWA0MN	HS	Investigative
DMWA0MN	SN	CHEMBL374028; BDBM50208796; 2-(3''''-(5''''-methoxy-indolyl)ethyloxy)adenosine
DMWA0MN	DT	Small molecular drug
DMWA0MN	PC	16203665
DMWA0MN	MW	456.5
DMWA0MN	FM	C21H24N6O6
DMWA0MN	IC	InChI=1S/C21H24N6O6/c1-31-11-2-3-13-12(6-11)10(7-23-13)4-5-32-21-25-18(22)15-19(26-21)27(9-24-15)20-17(30)16(29)14(8-28)33-20/h2-3,6-7,9,14,16-17,20,23,28-30H,4-5,8H2,1H3,(H2,22,25,26)/t14-,16-,17-,20-/m1/s1
DMWA0MN	CS	COC1=CC2=C(C=C1)NC=C2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMWA0MN	IK	HIDGDYNRSPJOMR-WVSUBDOOSA-N
DMWA0MN	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(5-methoxy-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMWA0MN	DE	Discovery agent

DMGRC24	ID	DMGRC24
DMGRC24	DN	2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine
DMGRC24	HS	Investigative
DMGRC24	SN	CHEMBL225459; MRS-3997; BDBM50208794; 2-(3''''-(6''''-bromo-indolyl)ethyloxy)adenosine
DMGRC24	DT	Small molecular drug
DMGRC24	PC	16203542
DMGRC24	MW	505.3
DMGRC24	FM	C20H21BrN6O5
DMGRC24	IC	InChI=1S/C20H21BrN6O5/c21-10-1-2-11-9(6-23-12(11)5-10)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DMGRC24	CS	C1=CC2=C(C=C1Br)NC=C2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMGRC24	IK	OXLUZSPXALFOBX-NVQRDWNXSA-N
DMGRC24	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(6-bromo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMGRC24	DE	Discovery agent

DML39UW	ID	DML39UW
DML39UW	DN	2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine
DML39UW	HS	Investigative
DML39UW	SN	CHEMBL222907; BDBM50208786; 2-(3''''-(6''''-chloro-indolyl)ethyloxy)adenosine
DML39UW	DT	Small molecular drug
DML39UW	PC	16202727
DML39UW	MW	460.9
DML39UW	FM	C20H21ClN6O5
DML39UW	IC	InChI=1S/C20H21ClN6O5/c21-10-1-2-11-9(6-23-12(11)5-10)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DML39UW	CS	C1=CC2=C(C=C1Cl)NC=C2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DML39UW	IK	QEBJMUICJFPGLR-NVQRDWNXSA-N
DML39UW	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(6-chloro-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DML39UW	DE	Discovery agent

DMITEND	ID	DMITEND
DMITEND	DN	2-(3''(7''-bromo-indolyl)ethyloxy)adenosine
DMITEND	HS	Investigative
DMITEND	SN	CHEMBL223729; BDBM50208814
DMITEND	DT	Small molecular drug
DMITEND	PC	16202728
DMITEND	MW	505.3
DMITEND	FM	C20H21BrN6O5
DMITEND	IC	InChI=1S/C20H21BrN6O5/c21-11-3-1-2-10-9(6-23-13(10)11)4-5-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)12(7-28)32-19/h1-3,6,8,12,15-16,19,23,28-30H,4-5,7H2,(H2,22,25,26)/t12-,15-,16-,19-/m1/s1
DMITEND	CS	C1=CC2=C(C(=C1)Br)NC=C2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMITEND	IK	DKKUXTZYGGOBFU-BGIGGGFGSA-N
DMITEND	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(7-bromo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMITEND	DE	Discovery agent

DMLDOH6	ID	DMLDOH6
DMLDOH6	DN	2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine
DMLDOH6	HS	Investigative
DMLDOH6	SN	CHEMBL221363; BDBM50208818
DMLDOH6	DT	Small molecular drug
DMLDOH6	PC	16203666
DMLDOH6	MW	427.4
DMLDOH6	FM	C19H21N7O5
DMLDOH6	IC	InChI=1S/C19H21N7O5/c20-16-13-17(26(9-22-13)18-15(29)14(28)12(7-27)31-18)24-19(23-16)30-6-5-25-8-21-10-3-1-2-4-11(10)25/h1-4,8-9,12,14-15,18,27-29H,5-7H2,(H2,20,23,24)/t12-,14-,15-,18-/m1/s1
DMLDOH6	CS	C1=CC=C2C(=C1)N=CN2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMLDOH6	IK	KTEOQJBVVWABJA-SCFUHWHPSA-N
DMLDOH6	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(benzimidazol-1-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMLDOH6	DE	Discovery agent

DM1KCUV	ID	DM1KCUV
DM1KCUV	DN	2-(3''-(benzotriazole-1''-yl)ethyloxy)adenosine
DM1KCUV	HS	Investigative
DM1KCUV	SN	CHEMBL374737; BDBM50208808
DM1KCUV	DT	Small molecular drug
DM1KCUV	PC	16202842
DM1KCUV	MW	428.4
DM1KCUV	FM	C18H20N8O5
DM1KCUV	IC	InChI=1S/C18H20N8O5/c19-15-12-16(25(8-20-12)17-14(29)13(28)11(7-27)31-17)22-18(21-15)30-6-5-26-10-4-2-1-3-9(10)23-24-26/h1-4,8,11,13-14,17,27-29H,5-7H2,(H2,19,21,22)/t11-,13-,14-,17-/m1/s1
DM1KCUV	CS	C1=CC=C2C(=C1)N=NN2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DM1KCUV	IK	DNLYYBHYIBDUCX-LSCFUAHRSA-N
DM1KCUV	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(benzotriazol-1-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM1KCUV	DE	Discovery agent

DM0R5U6	ID	DM0R5U6
DM0R5U6	DN	2-(3-(benzyloxy)phenyl)isoindoline-1,3-dione
DM0R5U6	HS	Investigative
DM0R5U6	SN	CHEMBL205391; N-(3-BENZYLOXYPHENYL)PHTHALIMIDE; 2-(3-phenylmethoxyphenyl)isoindole-1,3-dione; 2-(3-(benzyloxy)phenyl)isoindoline-1,3-dione; AC1MO1I5; ZINC4826839; BDBM50181082; AKOS003508151
DM0R5U6	DT	Small molecular drug
DM0R5U6	PC	3361967
DM0R5U6	MW	329.3
DM0R5U6	FM	C21H15NO3
DM0R5U6	IC	InChI=1S/C21H15NO3/c23-20-18-11-4-5-12-19(18)21(24)22(20)16-9-6-10-17(13-16)25-14-15-7-2-1-3-8-15/h1-13H,14H2
DM0R5U6	CS	C1=CC=C(C=C1)COC2=CC=CC(=C2)N3C(=O)C4=CC=CC=C4C3=O
DM0R5U6	IK	KEXVEOJPANROJT-UHFFFAOYSA-N
DM0R5U6	IU	2-(3-phenylmethoxyphenyl)isoindole-1,3-dione
DM0R5U6	DE	Discovery agent

DMKEY9V	ID	DMKEY9V
DMKEY9V	DN	2-(3-(naphthalen-2-yl)propanamido)benzoic acid
DMKEY9V	HS	Investigative
DMKEY9V	SN	CHEMBL235740; SCHEMBL5623042; BDBM23518; Biaryl Anthranilide Analogue, 1b; TUCHRHOVXUFQLY-UHFFFAOYSA-N; 2-[3-(naphthalen-2-yl)propanamido]benzoic acid; 2-{[3-(2-naphthalenyl)propanoyl]amino}benzoic acid
DMKEY9V	DT	Small molecular drug
DMKEY9V	PC	11594881
DMKEY9V	MW	319.4
DMKEY9V	FM	C20H17NO3
DMKEY9V	IC	InChI=1S/C20H17NO3/c22-19(21-18-8-4-3-7-17(18)20(23)24)12-10-14-9-11-15-5-1-2-6-16(15)13-14/h1-9,11,13H,10,12H2,(H,21,22)(H,23,24)
DMKEY9V	CS	C1=CC=C2C=C(C=CC2=C1)CCC(=O)NC3=CC=CC=C3C(=O)O
DMKEY9V	IK	TUCHRHOVXUFQLY-UHFFFAOYSA-N
DMKEY9V	IU	2-(3-naphthalen-2-ylpropanoylamino)benzoic acid
DMKEY9V	DE	Discovery agent

DM94B7N	ID	DM94B7N
DM94B7N	DN	2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine
DM94B7N	HS	Investigative
DM94B7N	SN	CHEMBL188182; 2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine; SCHEMBL5787166; BDBM50155140
DM94B7N	DT	Small molecular drug
DM94B7N	PC	10017687
DM94B7N	MW	300.4
DM94B7N	FM	C16H16N2O2S
DM94B7N	IC	InChI=1S/C16H16N2O2S/c17-10-11-18-12-16(14-8-4-5-9-15(14)18)21(19,20)13-6-2-1-3-7-13/h1-9,12H,10-11,17H2
DM94B7N	CS	C1=CC=C(C=C1)S(=O)(=O)C2=CN(C3=CC=CC=C32)CCN
DM94B7N	IK	AIHYRVVMMSIZRM-UHFFFAOYSA-N
DM94B7N	IU	2-[3-(benzenesulfonyl)indol-1-yl]ethanamine
DM94B7N	DE	Discovery agent

DM1I6SO	ID	DM1I6SO
DM1I6SO	DN	2-(3,4,5-Trihydroxy-benzylidene)-malononitrile
DM1I6SO	HS	Investigative
DM1I6SO	SN	Tyrphostin A25; Tyrphostin 25; 118409-58-8; Tyrphostin-25; (3,4,5-Trihydroxybenzylidene)-malononitrile; NSC 676484; 2-(3,4,5-Trihydroxybenzylidene)malononitrile; alpha-Cyano-(3,4,5-trihydroxy)cinnamonitrile; AG 82; ((3,4,5-Trihydroxyphenyl)methylene)propanedinitrile; NSC676484; 2-[(3,4,5-trihydroxyphenyl)methylidene]propanedinitrile; NCGC00016046-02; RG-50875; 158129-55-6; Propanedinitrile, ((3,4,5-trihydroxyphenyl)methylene)-; Propanedinitrile,2-[(3,4,5-trihydroxyphenyl)methylene]-; Tyrphostin A 25
DM1I6SO	DT	Small molecular drug
DM1I6SO	PC	2061
DM1I6SO	MW	202.17
DM1I6SO	FM	C10H6N2O3
DM1I6SO	IC	InChI=1S/C10H6N2O3/c11-4-7(5-12)1-6-2-8(13)10(15)9(14)3-6/h1-3,13-15H
DM1I6SO	CS	C1=C(C=C(C(=C1O)O)O)C=C(C#N)C#N
DM1I6SO	IK	YZOFLYUAQDJWKV-UHFFFAOYSA-N
DM1I6SO	IU	2-[(3,4,5-trihydroxyphenyl)methylidene]propanedinitrile
DM1I6SO	CA	CAS 118409-58-8
DM1I6SO	CB	CHEBI:92063
DM1I6SO	DE	Discovery agent

DMJKVZ3	ID	DMJKVZ3
DMJKVZ3	DN	2-(3,4-Difluorophenyl)-2,2-diphenylacetamide
DMJKVZ3	HS	Investigative
DMJKVZ3	SN	CHEMBL272040; SCHEMBL14437487
DMJKVZ3	DT	Small molecular drug
DMJKVZ3	PC	20684857
DMJKVZ3	MW	323.3
DMJKVZ3	FM	C20H15F2NO
DMJKVZ3	IC	InChI=1S/C20H15F2NO/c21-17-12-11-16(13-18(17)22)20(19(23)24,14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-13H,(H2,23,24)
DMJKVZ3	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC(=C(C=C3)F)F)C(=O)N
DMJKVZ3	IK	ADMJNOLCZZLSIA-UHFFFAOYSA-N
DMJKVZ3	IU	2-(3,4-difluorophenyl)-2,2-diphenylacetamide
DMJKVZ3	DE	Discovery agent

DMAOD0K	ID	DMAOD0K
DMAOD0K	DN	2-(3,4-Dihydroxy-benzyl)-7-hydroxy-chromen-4-one
DMAOD0K	HS	Investigative
DMAOD0K	SN	CHEMBL56890; 2-(3,4-Dihydroxy-benzyl)-7-hydroxy-chromen-4-one; ZINC13797584; BDBM50077314
DMAOD0K	DT	Small molecular drug
DMAOD0K	PC	10636768
DMAOD0K	MW	284.26
DMAOD0K	FM	C16H12O5
DMAOD0K	IC	InChI=1S/C16H12O5/c17-10-2-3-12-14(19)8-11(21-16(12)7-10)5-9-1-4-13(18)15(20)6-9/h1-4,6-8,17-18,20H,5H2
DMAOD0K	CS	C1=CC(=C(C=C1CC2=CC(=O)C3=C(O2)C=C(C=C3)O)O)O
DMAOD0K	IK	AERADEZJMNEWMZ-UHFFFAOYSA-N
DMAOD0K	IU	2-[(3,4-dihydroxyphenyl)methyl]-7-hydroxychromen-4-one
DMAOD0K	DE	Discovery agent

DM5MKEI	ID	DM5MKEI
DM5MKEI	DN	2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one
DM5MKEI	HS	Investigative
DM5MKEI	SN	7,3',4'-Trihydroxyflavone; 2150-11-0; 2-(3,4-dihydroxyphenyl)-7-hydroxy-4H-chromen-4-one; 3',4',7-Trihydroxyflavone; BRN 0253031; CHEMBL301624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-hydroxy-; Flavone, 7,3',4'-trihydroxy-; 2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-7-hydroxy-4H-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one; Q-100553; 4hlf; AC1NT15U; 3',4',7-Trihydroxyflavon; SCHEMBL34405; 7, 3',4'-Trihydroxyflavone; 3'',4'',7-trihydroxyflavon; trihydroxyflavone, 7
DM5MKEI	DT	Small molecular drug
DM5MKEI	PC	5322065
DM5MKEI	MW	270.24
DM5MKEI	FM	C15H10O5
DM5MKEI	IC	InChI=1S/C15H10O5/c16-9-2-3-10-12(18)7-14(20-15(10)6-9)8-1-4-11(17)13(19)5-8/h1-7,16-17,19H
DM5MKEI	CS	C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C=C(C=C3)O)O)O
DM5MKEI	IK	PVFGJHYLIHMCQD-UHFFFAOYSA-N
DM5MKEI	IU	2-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one
DM5MKEI	CA	CAS 2150-11-0
DM5MKEI	DE	Discovery agent

DMSZ0H9	ID	DMSZ0H9
DMSZ0H9	DN	2-(3,4-Dihydroxyphenyl)Acetic Acid
DMSZ0H9	HS	Investigative
DMSZ0H9	SN	3,4-Dihydroxyphenylacetic acid; 102-32-9; Dopac; Homoprotocatechuic acid; 2-(3,4-DIHYDROXYPHENYL)ACETIC ACID; Dopacetic acid; Benzeneacetic acid, 3,4-dihydroxy-; 3,4-Dihydroxybenzeneacetic acid; Dihydroxyphenylacetic acid; 4-Carboxymethylcatechol; (3,4-DIHYDROXYPHENYL)ACETIC ACID; Homoprotocatechuate; 3,4-Dihydroxy-phenylacetic acid; Acetic acid, (3,4-dihydroxyphenyl)-; BA 2773; UNII-KEX5N0R4N5; CCRIS 3765; 3,4-dihydroxyphenylacetate; Lopac-D-9128; EINECS 203-024-1; NSC 73191; BRN 2211017; KEX5N0R4N5; 3,4-DHPOP; MLS001056737
DMSZ0H9	DT	Small molecular drug
DMSZ0H9	PC	547
DMSZ0H9	MW	168.15
DMSZ0H9	FM	C8H8O4
DMSZ0H9	IC	InChI=1S/C8H8O4/c9-6-2-1-5(3-7(6)10)4-8(11)12/h1-3,9-10H,4H2,(H,11,12)
DMSZ0H9	CS	C1=CC(=C(C=C1CC(=O)O)O)O
DMSZ0H9	IK	CFFZDZCDUFSOFZ-UHFFFAOYSA-N
DMSZ0H9	IU	2-(3,4-dihydroxyphenyl)acetic acid
DMSZ0H9	CA	CAS 102-32-9
DMSZ0H9	CB	CHEBI:41941
DMSZ0H9	DE	Discovery agent

DM3S26I	ID	DM3S26I
DM3S26I	DN	2-(3,4-dimethoxybenzamido)thiophene-3-carboxamide
DM3S26I	HS	Investigative
DM3S26I	SN	2-(3,4-dimethoxybenzamido)thiophene-3-carboxamide; CHEMBL210622; MolPort-003-062-950; ZINC4275736; AC1N3474; BDBM50185082; AKOS024605336; MCULE-1480938066; SR-01000011723; SR-01000011723-1; F1358-0295; 2-[(3,4-dimethoxybenzoyl)amino]thiophene-3-carboxamide
DM3S26I	DT	Small molecular drug
DM3S26I	PC	4106590
DM3S26I	MW	306.34
DM3S26I	FM	C14H14N2O4S
DM3S26I	IC	InChI=1S/C14H14N2O4S/c1-19-10-4-3-8(7-11(10)20-2)13(18)16-14-9(12(15)17)5-6-21-14/h3-7H,1-2H3,(H2,15,17)(H,16,18)
DM3S26I	CS	COC1=C(C=C(C=C1)C(=O)NC2=C(C=CS2)C(=O)N)OC
DM3S26I	IK	LORRZRFBMUDPOE-UHFFFAOYSA-N
DM3S26I	IU	2-[(3,4-dimethoxybenzoyl)amino]thiophene-3-carboxamide
DM3S26I	DE	Discovery agent

DMLOX0Y	ID	DMLOX0Y
DMLOX0Y	DN	2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole
DMLOX0Y	HS	Investigative
DMLOX0Y	SN	2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole; CHEMBL503049; 192988-59-3; SCHEMBL9575182; DTXSID80571566; BDBM50265991; ZINC34530543; AKOS022491775; 2-(3,4-Dimethoxyphenyl)-2-imidazoline
DMLOX0Y	DT	Small molecular drug
DMLOX0Y	PC	15327588
DMLOX0Y	MW	206.24
DMLOX0Y	FM	C11H14N2O2
DMLOX0Y	IC	InChI=1S/C11H14N2O2/c1-14-9-4-3-8(7-10(9)15-2)11-12-5-6-13-11/h3-4,7H,5-6H2,1-2H3,(H,12,13)
DMLOX0Y	CS	COC1=C(C=C(C=C1)C2=NCCN2)OC
DMLOX0Y	IK	NXHHUAOYFMCRFK-UHFFFAOYSA-N
DMLOX0Y	IU	2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole
DMLOX0Y	CA	CAS 192988-59-3
DMLOX0Y	DE	Discovery agent

DMDGRWM	ID	DMDGRWM
DMDGRWM	DN	2-(3,4-dimethylphenyl)-1,8-naphthyridine
DMDGRWM	HS	Investigative
DMDGRWM	SN	CHEMBL235398; 2-(3,4-dimethylphenyl)-1,8-naphthyridine
DMDGRWM	DT	Small molecular drug
DMDGRWM	PC	44434720
DMDGRWM	MW	234.29
DMDGRWM	FM	C16H14N2
DMDGRWM	IC	InChI=1S/C16H14N2/c1-11-5-6-14(10-12(11)2)15-8-7-13-4-3-9-17-16(13)18-15/h3-10H,1-2H3
DMDGRWM	CS	CC1=C(C=C(C=C1)C2=NC3=C(C=CC=N3)C=C2)C
DMDGRWM	IK	HNJUUHIKQMSRFO-UHFFFAOYSA-N
DMDGRWM	IU	2-(3,4-dimethylphenyl)-1,8-naphthyridine
DMDGRWM	DE	Discovery agent

DM8KM1Q	ID	DM8KM1Q
DM8KM1Q	DN	2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine
DM8KM1Q	HS	Investigative
DM8KM1Q	SN	CHEMBL393049; 2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine
DM8KM1Q	DT	Small molecular drug
DM8KM1Q	PC	44435041
DM8KM1Q	MW	276.12
DM8KM1Q	FM	C13H7Cl2N3
DM8KM1Q	IC	InChI=1S/C13H7Cl2N3/c14-10-4-9(5-11(15)6-10)13-17-7-8-2-1-3-16-12(8)18-13/h1-7H
DM8KM1Q	CS	C1=CC2=CN=C(N=C2N=C1)C3=CC(=CC(=C3)Cl)Cl
DM8KM1Q	IK	UDWGFUUPZLVQFW-UHFFFAOYSA-N
DM8KM1Q	IU	2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine
DM8KM1Q	DE	Discovery agent

DMGJPYO	ID	DMGJPYO
DMGJPYO	DN	2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine
DMGJPYO	HS	Investigative
DMGJPYO	SN	CHEMBL235838; 2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine
DMGJPYO	DT	Small molecular drug
DMGJPYO	PC	44434736
DMGJPYO	MW	256.25
DMGJPYO	FM	C15H10F2N2
DMGJPYO	IC	InChI=1S/C15H10F2N2/c1-9-2-3-10-4-5-14(19-15(10)18-9)11-6-12(16)8-13(17)7-11/h2-8H,1H3
DMGJPYO	CS	CC1=NC2=C(C=C1)C=CC(=N2)C3=CC(=CC(=C3)F)F
DMGJPYO	IK	ODEYWYKLTXXLRT-UHFFFAOYSA-N
DMGJPYO	IU	2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine
DMGJPYO	DE	Discovery agent

DMIEB8R	ID	DMIEB8R
DMIEB8R	DN	2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine
DMIEB8R	HS	Investigative
DMIEB8R	SN	CHEMBL465866; 207740-42-9; Phenescaline; 2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine; DTXSID00659517; BDBM50251265
DMIEB8R	DT	Small molecular drug
DMIEB8R	PC	44567543
DMIEB8R	MW	301.4
DMIEB8R	FM	C18H23NO3
DMIEB8R	IC	InChI=1S/C18H23NO3/c1-20-16-12-15(8-10-19)13-17(21-2)18(16)22-11-9-14-6-4-3-5-7-14/h3-7,12-13H,8-11,19H2,1-2H3
DMIEB8R	CS	COC1=CC(=CC(=C1OCCC2=CC=CC=C2)OC)CCN
DMIEB8R	IK	FKXBCTFKCKEDNI-UHFFFAOYSA-N
DMIEB8R	IU	2-[3,5-dimethoxy-4-(2-phenylethoxy)phenyl]ethanamine
DMIEB8R	CA	CAS 207740-42-9
DMIEB8R	DE	Discovery agent

DMKND0T	ID	DMKND0T
DMKND0T	DN	2-(3,5-dimethoxyphenyl)-1,8-naphthyridine
DMKND0T	HS	Investigative
DMKND0T	SN	CHEMBL391755; 2-(3,5-dimethoxyphenyl)-1,8-naphthyridine
DMKND0T	DT	Small molecular drug
DMKND0T	PC	44434719
DMKND0T	MW	266.29
DMKND0T	FM	C16H14N2O2
DMKND0T	IC	InChI=1S/C16H14N2O2/c1-19-13-8-12(9-14(10-13)20-2)15-6-5-11-4-3-7-17-16(11)18-15/h3-10H,1-2H3
DMKND0T	CS	COC1=CC(=CC(=C1)C2=NC3=C(C=CC=N3)C=C2)OC
DMKND0T	IK	JUMXQELSAJZAIP-UHFFFAOYSA-N
DMKND0T	IU	2-(3,5-dimethoxyphenyl)-1,8-naphthyridine
DMKND0T	DE	Discovery agent

DMJ2NPY	ID	DMJ2NPY
DMJ2NPY	DN	2-(3-acetylphenyl)-6-morpholino-4H-pyran-4-one
DMJ2NPY	HS	Investigative
DMJ2NPY	SN	CHEMBL223436; 2-(3-acetylphenyl)-6-morpholino-4H-pyran-4-one
DMJ2NPY	DT	Small molecular drug
DMJ2NPY	PC	16203469
DMJ2NPY	MW	299.32
DMJ2NPY	FM	C17H17NO4
DMJ2NPY	IC	InChI=1S/C17H17NO4/c1-12(19)13-3-2-4-14(9-13)16-10-15(20)11-17(22-16)18-5-7-21-8-6-18/h2-4,9-11H,5-8H2,1H3
DMJ2NPY	CS	CC(=O)C1=CC=CC(=C1)C2=CC(=O)C=C(O2)N3CCOCC3
DMJ2NPY	IK	MUGFHNCVHGYLEQ-UHFFFAOYSA-N
DMJ2NPY	IU	2-(3-acetylphenyl)-6-morpholin-4-ylpyran-4-one
DMJ2NPY	DE	Discovery agent

DMAGFUH	ID	DMAGFUH
DMAGFUH	DN	2-(3'-Allyl-biphenyl-4-yl)-propionic acid
DMAGFUH	HS	Investigative
DMAGFUH	SN	CHEMBL325787; BDBM50074936; 2-(3''-Allyl-biphenyl-4-yl)-propionic acid
DMAGFUH	DT	Small molecular drug
DMAGFUH	PC	44336367
DMAGFUH	MW	266.3
DMAGFUH	FM	C18H18O2
DMAGFUH	IC	InChI=1S/C18H18O2/c1-3-5-14-6-4-7-17(12-14)16-10-8-15(9-11-16)13(2)18(19)20/h3-4,6-13H,1,5H2,2H3,(H,19,20)
DMAGFUH	CS	CC(C1=CC=C(C=C1)C2=CC=CC(=C2)CC=C)C(=O)O
DMAGFUH	IK	NOUUHOHFFJKTMS-UHFFFAOYSA-N
DMAGFUH	IU	2-[4-(3-prop-2-enylphenyl)phenyl]propanoic acid
DMAGFUH	DE	Discovery agent

DMC6E8R	ID	DMC6E8R
DMC6E8R	DN	2-(3-aminophenoxy)-5-hexylphenol
DMC6E8R	HS	Investigative
DMC6E8R	SN	CHEMBL404984
DMC6E8R	DT	Small molecular drug
DMC6E8R	PC	44450095
DMC6E8R	MW	285.4
DMC6E8R	FM	C18H23NO2
DMC6E8R	IC	InChI=1S/C18H23NO2/c1-2-3-4-5-7-14-10-11-18(17(20)12-14)21-16-9-6-8-15(19)13-16/h6,8-13,20H,2-5,7,19H2,1H3
DMC6E8R	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=CC(=C2)N)O
DMC6E8R	IK	ZRRRBQYWHBBQGE-UHFFFAOYSA-N
DMC6E8R	IU	2-(3-aminophenoxy)-5-hexylphenol
DMC6E8R	DE	Discovery agent

DMQB9SC	ID	DMQB9SC
DMQB9SC	DN	2-(3-aminophenyl)-3-mercaptopropanoic acid
DMQB9SC	HS	Investigative
DMQB9SC	SN	2-(3-aminophenyl)-3-mercaptopropanoic acid; CHEMBL246595; 607832-91-7; SCHEMBL2352530; BDBM50201431
DMQB9SC	DT	Small molecular drug
DMQB9SC	PC	10214451
DMQB9SC	MW	197.26
DMQB9SC	FM	C9H11NO2S
DMQB9SC	IC	InChI=1S/C9H11NO2S/c10-7-3-1-2-6(4-7)8(5-13)9(11)12/h1-4,8,13H,5,10H2,(H,11,12)
DMQB9SC	CS	C1=CC(=CC(=C1)N)C(CS)C(=O)O
DMQB9SC	IK	WOYCAJIRNXWVLG-UHFFFAOYSA-N
DMQB9SC	IU	2-(3-aminophenyl)-3-sulfanylpropanoic acid
DMQB9SC	DE	Discovery agent

DMAP37I	ID	DMAP37I
DMAP37I	DN	2-(3-Amino-phenyl)-6-methyl-chromen-4-one
DMAP37I	HS	Investigative
DMAP37I	SN	CHEMBL132423; ZINC13491189; AKOS022269929; 468060-72-2; KB-191922
DMAP37I	DT	Small molecular drug
DMAP37I	PC	10977911
DMAP37I	MW	251.28
DMAP37I	FM	C16H13NO2
DMAP37I	IC	InChI=1S/C16H13NO2/c1-10-5-6-15-13(7-10)14(18)9-16(19-15)11-3-2-4-12(17)8-11/h2-9H,17H2,1H3
DMAP37I	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC(=CC=C3)N
DMAP37I	IK	JDDRGOPANADJMA-UHFFFAOYSA-N
DMAP37I	IU	2-(3-aminophenyl)-6-methylchromen-4-one
DMAP37I	DE	Discovery agent

DM3FBLT	ID	DM3FBLT
DM3FBLT	DN	2-(3-benzenesulfonyl)phenyl-1-aminoethane
DM3FBLT	HS	Investigative
DM3FBLT	SN	CHEMBL209383; 2-(3-benzenesulfonyl)phenyl-1-aminoethane; ZINC36093365
DM3FBLT	DT	Small molecular drug
DM3FBLT	PC	11849199
DM3FBLT	MW	261.339
DM3FBLT	FM	C14H15NO2S
DM3FBLT	IC	InChI=1S/C14H15NO2S/c15-10-9-12-5-4-8-14(11-12)18(16,17)13-6-2-1-3-7-13/h1-8,11H,9-10,15H2
DM3FBLT	CS	C1=CC=C(C=C1)S(=O)(=O)C2=CC=CC(=C2)CCN
DM3FBLT	IK	PXOKRWBUDGQCDL-UHFFFAOYSA-N
DM3FBLT	IU	2-[3-(benzenesulfonyl)phenyl]ethanamine
DM3FBLT	DE	Discovery agent

DMDB4LZ	ID	DMDB4LZ
DMDB4LZ	DN	2-(3-benzoyl-1H-pyrrol-1-yl)acetic acid
DMDB4LZ	HS	Investigative
DMDB4LZ	SN	CHEMBL93723; 2-(3-benzoyl-1H-pyrrol-1-yl)acetic acid; 3-benzoylpyrrole-1-acetic acid; BDBM50146187; 3-Benzoyl-1H-pyrrole-1-acetic acid; (3-Benzoyl-pyrrol-1-yl)-acetic acid
DMDB4LZ	DT	Small molecular drug
DMDB4LZ	PC	10398922
DMDB4LZ	MW	229.23
DMDB4LZ	FM	C13H11NO3
DMDB4LZ	IC	InChI=1S/C13H11NO3/c15-12(16)9-14-7-6-11(8-14)13(17)10-4-2-1-3-5-10/h1-8H,9H2,(H,15,16)
DMDB4LZ	CS	C1=CC=C(C=C1)C(=O)C2=CN(C=C2)CC(=O)O
DMDB4LZ	IK	NFEXRSVGIRNYEZ-UHFFFAOYSA-N
DMDB4LZ	IU	2-(3-benzoylpyrrol-1-yl)acetic acid
DMDB4LZ	DE	Discovery agent

DMWMFTJ	ID	DMWMFTJ
DMWMFTJ	DN	2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE
DMWMFTJ	HS	Investigative
DMWMFTJ	SN	SB-543668; 2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE; N-[2-(3-benzoylphenoxy)ethyl]-N-hydroxyformamide; SB8; AC1NRD38; SCHEMBL6245513; BDBM21684; DB08524
DMWMFTJ	DT	Small molecular drug
DMWMFTJ	PC	5289330
DMWMFTJ	MW	285.29
DMWMFTJ	FM	C16H15NO4
DMWMFTJ	IC	InChI=1S/C16H15NO4/c18-12-17(20)9-10-21-15-8-4-7-14(11-15)16(19)13-5-2-1-3-6-13/h1-8,11-12,20H,9-10H2
DMWMFTJ	CS	C1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)OCCN(C=O)O
DMWMFTJ	IK	ZHFKBNAHHTUQBH-UHFFFAOYSA-N
DMWMFTJ	IU	N-[2-(3-benzoylphenoxy)ethyl]-N-hydroxyformamide
DMWMFTJ	DE	Discovery agent

DM6V91D	ID	DM6V91D
DM6V91D	DN	2-(3-benzylquinoxalin-2-ylamino)ethanol
DM6V91D	HS	Investigative
DM6V91D	SN	CHEMBL203892; 2-(3-benzylquinoxalin-2-ylamino)ethanol
DM6V91D	DT	Small molecular drug
DM6V91D	PC	44409443
DM6V91D	MW	279.34
DM6V91D	FM	C17H17N3O
DM6V91D	IC	InChI=1S/C17H17N3O/c21-11-10-18-17-16(12-13-6-2-1-3-7-13)19-14-8-4-5-9-15(14)20-17/h1-9,21H,10-12H2,(H,18,20)
DM6V91D	CS	C1=CC=C(C=C1)CC2=NC3=CC=CC=C3N=C2NCCO
DM6V91D	IK	SNVOYVYEVPVVNG-UHFFFAOYSA-N
DM6V91D	IU	2-[(3-benzylquinoxalin-2-yl)amino]ethanol
DM6V91D	DE	Discovery agent

DMY60K3	ID	DMY60K3
DMY60K3	DN	2-(3-biphenyl-4-yl-propionylamino)-benzoic acid
DMY60K3	HS	Investigative
DMY60K3	SN	CHEMBL235741; SCHEMBL12671515; BDBM23519; Biaryl Anthranilide Analogue, 1c; 2-[3-(4-phenylphenyl)propanamido]benzoic acid
DMY60K3	DT	Small molecular drug
DMY60K3	PC	11617151
DMY60K3	MW	345.4
DMY60K3	FM	C22H19NO3
DMY60K3	IC	InChI=1S/C22H19NO3/c24-21(23-20-9-5-4-8-19(20)22(25)26)15-12-16-10-13-18(14-11-16)17-6-2-1-3-7-17/h1-11,13-14H,12,15H2,(H,23,24)(H,25,26)
DMY60K3	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCC(=O)NC3=CC=CC=C3C(=O)O
DMY60K3	IK	CAYOKBAXZPGNTO-UHFFFAOYSA-N
DMY60K3	IU	2-[3-(4-phenylphenyl)propanoylamino]benzoic acid
DMY60K3	DE	Discovery agent

DMX4DUR	ID	DMX4DUR
DMX4DUR	DN	2-(3-bromobenzoylamino)-4-chlorobenzoic acid
DMX4DUR	HS	Investigative
DMX4DUR	SN	827325-60-0; 2-[(3-bromobenzoyl)amino]-4-chlorobenzoic acid; CHEMBL225612; 2-(3-Bromobenzamido)-4-chlorobenzoic acid; Benzoic acid, 2-[(3-bromobenzoyl)amino]-4-chloro-; 2-(3-bromobenzoylamino)-4-chlorobenzoic acid; AC1N8QX1; SCHEMBL14075271; CTK3D6918; KS-00003MRF; DTXSID50401927; MolPort-002-885-931; ZINC4104976; ZX-AN021268; ALBB-022752; BDBM50158557; AKOS005107642; MCULE-7998531013; MS-0095; R4909; SR-01000309735; SR-01000309735-1; 2-[(3-bromobenzoyl)amino]-4-chlorobenzenecarboxylic acid
DMX4DUR	DT	Small molecular drug
DMX4DUR	PC	4323128
DMX4DUR	MW	354.58
DMX4DUR	FM	C14H9BrClNO3
DMX4DUR	IC	InChI=1S/C14H9BrClNO3/c15-9-3-1-2-8(6-9)13(18)17-12-7-10(16)4-5-11(12)14(19)20/h1-7H,(H,17,18)(H,19,20)
DMX4DUR	CS	C1=CC(=CC(=C1)Br)C(=O)NC2=C(C=CC(=C2)Cl)C(=O)O
DMX4DUR	IK	NKUSVNRZDILGSG-UHFFFAOYSA-N
DMX4DUR	IU	2-[(3-bromobenzoyl)amino]-4-chlorobenzoic acid
DMX4DUR	CA	CAS 827325-60-0
DMX4DUR	DE	Discovery agent

DM9G7B6	ID	DM9G7B6
DM9G7B6	DN	2-(3-Bromo-phenyl)-6-methyl-chromen-4-one
DM9G7B6	HS	Investigative
DM9G7B6	SN	CHEMBL334427; 2-(3-Bromo-phenyl)-6-methyl-chromen-4-one; AC1LFCVT; BAS 01121887; 3'-Bromo-6-methylflavone; 6-Methyl-3''-bromoflavone; Oprea1_370713; Oprea1_120869; MolPort-001-955-842; ZINC265292; BDBM50118406; AKOS000603553
DM9G7B6	DT	Small molecular drug
DM9G7B6	PC	776059
DM9G7B6	MW	315.16
DM9G7B6	FM	C16H11BrO2
DM9G7B6	IC	InChI=1S/C16H11BrO2/c1-10-5-6-15-13(7-10)14(18)9-16(19-15)11-3-2-4-12(17)8-11/h2-9H,1H3
DM9G7B6	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC(=CC=C3)Br
DM9G7B6	IK	NGKYRJKVRCEDNG-UHFFFAOYSA-N
DM9G7B6	IU	2-(3-bromophenyl)-6-methylchromen-4-one
DM9G7B6	DE	Discovery agent

DM9RAYC	ID	DM9RAYC
DM9RAYC	DN	2-(3-Bromo-phenyl)-6-nitro-chromen-4-one
DM9RAYC	HS	Investigative
DM9RAYC	SN	CHEMBL64792; 3'-Bromo-6-nitroflavone
DM9RAYC	DT	Small molecular drug
DM9RAYC	PC	9841153
DM9RAYC	MW	346.13
DM9RAYC	FM	C15H8BrNO4
DM9RAYC	IC	InChI=1S/C15H8BrNO4/c16-10-3-1-2-9(6-10)15-8-13(18)12-7-11(17(19)20)4-5-14(12)21-15/h1-8H
DM9RAYC	CS	C1=CC(=CC(=C1)Br)C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-]
DM9RAYC	IK	IOYFMBZXVIRMNX-UHFFFAOYSA-N
DM9RAYC	IU	2-(3-bromophenyl)-6-nitrochromen-4-one
DM9RAYC	DE	Discovery agent

DMYSM9L	ID	DMYSM9L
DMYSM9L	DN	2-(3-bromophenyl)-7-methyl-1,8-naphthyridine
DMYSM9L	HS	Investigative
DMYSM9L	SN	CHEMBL237906; 2-(3-bromophenyl)-7-methyl-1,8-naphthyridine
DMYSM9L	DT	Small molecular drug
DMYSM9L	PC	44434745
DMYSM9L	MW	299.16
DMYSM9L	FM	C15H11BrN2
DMYSM9L	IC	InChI=1S/C15H11BrN2/c1-10-5-6-11-7-8-14(18-15(11)17-10)12-3-2-4-13(16)9-12/h2-9H,1H3
DMYSM9L	CS	CC1=NC2=C(C=C1)C=CC(=N2)C3=CC(=CC=C3)Br
DMYSM9L	IK	YAOUIVOXDAAEBA-UHFFFAOYSA-N
DMYSM9L	IU	2-(3-bromophenyl)-7-methyl-1,8-naphthyridine
DMYSM9L	DE	Discovery agent

DMANS5X	ID	DMANS5X
DMANS5X	DN	2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine
DMANS5X	HS	Investigative
DMANS5X	SN	CHEMBL396346; 2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine
DMANS5X	DT	Small molecular drug
DMANS5X	PC	44435028
DMANS5X	MW	300.15
DMANS5X	FM	C14H10BrN3
DMANS5X	IC	InChI=1S/C14H10BrN3/c1-9-5-6-11-8-16-13(18-14(11)17-9)10-3-2-4-12(15)7-10/h2-8H,1H3
DMANS5X	CS	CC1=NC2=NC(=NC=C2C=C1)C3=CC(=CC=C3)Br
DMANS5X	IK	QTHPZWOJWWROSA-UHFFFAOYSA-N
DMANS5X	IU	2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine
DMANS5X	DE	Discovery agent

DM7XDLO	ID	DM7XDLO
DM7XDLO	DN	2-(3-Bromo-phenyl)-chromen-4-one
DM7XDLO	HS	Investigative
DM7XDLO	SN	3'-Bromoflavone; CHEMBL55148; 2-(3-bromophenyl)chromen-4-one; 2-(3-Bromo-phenyl)-chromen-4-one; AC1LAQPY; SCHEMBL6654321; MolPort-001-904-025; ZINC265291; AKOS000603552; BAS 01121885; 4H-1-Benzopyran-4-one, 2-(3-bromophenyl)-
DM7XDLO	DT	Small molecular drug
DM7XDLO	PC	493373
DM7XDLO	MW	301.13
DM7XDLO	FM	C15H9BrO2
DM7XDLO	IC	InChI=1S/C15H9BrO2/c16-11-5-3-4-10(8-11)15-9-13(17)12-6-1-2-7-14(12)18-15/h1-9H
DM7XDLO	CS	C1=CC=C2C(=C1)C(=O)C=C(O2)C3=CC(=CC=C3)Br
DM7XDLO	IK	YFEZLTPSCJWVHI-UHFFFAOYSA-N
DM7XDLO	IU	2-(3-bromophenyl)chromen-4-one
DM7XDLO	DE	Discovery agent

DM260RG	ID	DM260RG
DM260RG	DN	2-(3-bromophenyl)histamine
DM260RG	HS	Investigative
DM260RG	SN	2-(3-Bromophenyl)histamine; CHEMBL26116; GTPL1194; SCHEMBL15974857; BDBM22863; PDSP2_001292; PDSP1_001308; AKOS022562838; AKOS023977997; 2-(3-Bromophenyl)-1H-imidazole-4-(ethanamine); 2-[2-(3-bromophenyl)-3H-imidazol-4-yl]ethanamine
DM260RG	DT	Small molecular drug
DM260RG	PC	23786499
DM260RG	MW	266.14
DM260RG	FM	C11H12BrN3
DM260RG	IC	InChI=1S/C11H12BrN3/c12-9-3-1-2-8(6-9)11-14-7-10(15-11)4-5-13/h1-3,6-7H,4-5,13H2,(H,14,15)
DM260RG	CS	C1=CC(=CC(=C1)Br)C2=NC=C(N2)CCN
DM260RG	IK	VSKJPAMQPJDPLL-UHFFFAOYSA-N
DM260RG	IU	2-[2-(3-bromophenyl)-1H-imidazol-5-yl]ethanamine
DM260RG	DE	Discovery agent

DMVA4XC	ID	DMVA4XC
DMVA4XC	DN	2-(3-bromophenyl)pyrido[2,3-d]pyrimidine
DMVA4XC	HS	Investigative
DMVA4XC	SN	CHEMBL239197; 2-(3-bromophenyl)pyrido[2,3-d]pyrimidine
DMVA4XC	DT	Small molecular drug
DMVA4XC	PC	44435039
DMVA4XC	MW	286.13
DMVA4XC	FM	C13H8BrN3
DMVA4XC	IC	InChI=1S/C13H8BrN3/c14-11-5-1-3-9(7-11)12-16-8-10-4-2-6-15-13(10)17-12/h1-8H
DMVA4XC	CS	C1=CC(=CC(=C1)Br)C2=NC=C3C=CC=NC3=N2
DMVA4XC	IK	KOBJRMNXIZSOES-UHFFFAOYSA-N
DMVA4XC	IU	2-(3-bromophenyl)pyrido[2,3-d]pyrimidine
DMVA4XC	DE	Discovery agent

DMFETRH	ID	DMFETRH
DMFETRH	DN	2-(3-Bromophenylthio)-N,N-dimethylethanamine
DMFETRH	HS	Investigative
DMFETRH	SN	2-(3-Bromophenylthio)-N,N-dimethylethanamine; CHEMBL609323; 144085-61-0; BDBM50307505
DMFETRH	DT	Small molecular drug
DMFETRH	PC	46233484
DMFETRH	MW	260.2
DMFETRH	FM	C10H14BrNS
DMFETRH	IC	InChI=1S/C10H14BrNS/c1-12(2)6-7-13-10-5-3-4-9(11)8-10/h3-5,8H,6-7H2,1-2H3
DMFETRH	CS	CN(C)CCSC1=CC(=CC=C1)Br
DMFETRH	IK	LIEFSMJAVJRLBQ-UHFFFAOYSA-N
DMFETRH	IU	2-(3-bromophenyl)sulfanyl-N,N-dimethylethanamine
DMFETRH	DE	Discovery agent

DMJM5VW	ID	DMJM5VW
DMJM5VW	DN	2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol
DMJM5VW	HS	Investigative
DMJM5VW	DT	Small molecular drug
DMJM5VW	PC	135454786
DMJM5VW	MW	299.32
DMJM5VW	FM	C17H17NO4
DMJM5VW	IC	InChI=1S/C17H17NO4/c1-2-3-8-21-16-9-11(4-7-14(16)20)17-18-13-6-5-12(19)10-15(13)22-17/h4-7,9-10,19-20H,2-3,8H2,1H3
DMJM5VW	CS	CCCCOC1=C(C=CC(=C1)C2=NC3=C(O2)C=C(C=C3)O)O
DMJM5VW	IK	BJVMSZRSXULFSB-UHFFFAOYSA-N
DMJM5VW	IU	2-(3-butoxy-4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DMJM5VW	DE	Discovery agent

DMSZT9G	ID	DMSZT9G
DMSZT9G	DN	2-(3-Butoxy-phenyl)-6-methyl-chromen-4-one
DMSZT9G	HS	Investigative
DMSZT9G	SN	CHEMBL131928
DMSZT9G	DT	Small molecular drug
DMSZT9G	PC	11012278
DMSZT9G	MW	308.4
DMSZT9G	FM	C20H20O3
DMSZT9G	IC	InChI=1S/C20H20O3/c1-3-4-10-22-16-7-5-6-15(12-16)20-13-18(21)17-11-14(2)8-9-19(17)23-20/h5-9,11-13H,3-4,10H2,1-2H3
DMSZT9G	CS	CCCCOC1=CC=CC(=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)C
DMSZT9G	IK	CFRCJBWAEQSCHB-UHFFFAOYSA-N
DMSZT9G	IU	2-(3-butoxyphenyl)-6-methylchromen-4-one
DMSZT9G	DE	Discovery agent

DMHXVNZ	ID	DMHXVNZ
DMHXVNZ	DN	2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
DMHXVNZ	HS	Investigative
DMHXVNZ	SN	Thiol-Based Inhibitor, 20; CHEMBL206885; BDBM17773; 2-[(3-carbamoylphenyl)methyl]-5-sulfanylpentanoic acid
DMHXVNZ	DT	Small molecular drug
DMHXVNZ	PC	11601420
DMHXVNZ	MW	267.35
DMHXVNZ	FM	C13H17NO3S
DMHXVNZ	IC	InChI=1S/C13H17NO3S/c14-12(15)10-4-1-3-9(7-10)8-11(13(16)17)5-2-6-18/h1,3-4,7,11,18H,2,5-6,8H2,(H2,14,15)(H,16,17)
DMHXVNZ	CS	C1=CC(=CC(=C1)C(=O)N)CC(CCCS)C(=O)O
DMHXVNZ	IK	AGWUXZTVEYUITF-UHFFFAOYSA-N
DMHXVNZ	IU	2-[(3-carbamoylphenyl)methyl]-5-sulfanylpentanoic acid
DMHXVNZ	DE	Discovery agent

DMI6AZ5	ID	DMI6AZ5
DMI6AZ5	DN	2-(3-carboxybenzyl)succinic acid
DMI6AZ5	HS	Investigative
DMI6AZ5	SN	2-(3-carboxybenzyl)succinic acid; carboxylate, 39; 2-[(3-carboxyphenyl)methyl]butanedioic Acid; Butanedioic acid, 2-[(3-carboxyphenyl)methyl]-; CHEMBL209190; BDBM17782
DMI6AZ5	DT	Small molecular drug
DMI6AZ5	PC	11499788
DMI6AZ5	MW	252.22
DMI6AZ5	FM	C12H12O6
DMI6AZ5	IC	InChI=1S/C12H12O6/c13-10(14)6-9(12(17)18)5-7-2-1-3-8(4-7)11(15)16/h1-4,9H,5-6H2,(H,13,14)(H,15,16)(H,17,18)
DMI6AZ5	CS	C1=CC(=CC(=C1)C(=O)O)CC(CC(=O)O)C(=O)O
DMI6AZ5	IK	WCLWDNBZTFVGIR-UHFFFAOYSA-N
DMI6AZ5	IU	2-[(3-carboxyphenyl)methyl]butanedioic acid
DMI6AZ5	DE	Discovery agent

DMBONUV	ID	DMBONUV
DMBONUV	DN	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMBONUV	HS	Investigative
DMBONUV	DT	Small molecular drug
DMBONUV	PC	135443280
DMBONUV	MW	261.66
DMBONUV	FM	C13H8ClNO3
DMBONUV	IC	InChI=1S/C13H8ClNO3/c14-9-5-7(1-3-11(9)17)13-15-10-6-8(16)2-4-12(10)18-13/h1-6,16-17H
DMBONUV	CS	C1=CC(=C(C=C1C2=NC3=C(O2)C=CC(=C3)O)Cl)O
DMBONUV	IK	XCJCSWQYKSCDIH-UHFFFAOYSA-N
DMBONUV	IU	2-(3-chloro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMBONUV	DE	Discovery agent

DM3B6IN	ID	DM3B6IN
DM3B6IN	DN	2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol
DM3B6IN	HS	Investigative
DM3B6IN	DT	Small molecular drug
DM3B6IN	PC	135496133
DM3B6IN	MW	261.66
DM3B6IN	FM	C13H8ClNO3
DM3B6IN	IC	InChI=1S/C13H8ClNO3/c14-9-5-7(1-4-11(9)17)13-15-10-3-2-8(16)6-12(10)18-13/h1-6,16-17H
DM3B6IN	CS	C1=CC(=C(C=C1C2=NC3=C(O2)C=C(C=C3)O)Cl)O
DM3B6IN	IK	YWMCWMCSJCYHBX-UHFFFAOYSA-N
DM3B6IN	IU	2-(3-chloro-4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DM3B6IN	DE	Discovery agent

DM1VDC3	ID	DM1VDC3
DM1VDC3	DN	2-(3-chlorobenzyloxy)-6-chloroisonicotinonitrile
DM1VDC3	HS	Investigative
DM1VDC3	SN	CHEMBL202908; 2-(3-chlorobenzyloxy)-6-chloroisonicotinonitrile; SCHEMBL4292772; BDBM50181075
DM1VDC3	DT	Small molecular drug
DM1VDC3	PC	44409846
DM1VDC3	MW	279.12
DM1VDC3	FM	C13H8Cl2N2O
DM1VDC3	IC	InChI=1S/C13H8Cl2N2O/c14-11-3-1-2-9(4-11)8-18-13-6-10(7-16)5-12(15)17-13/h1-6H,8H2
DM1VDC3	CS	C1=CC(=CC(=C1)Cl)COC2=NC(=CC(=C2)C#N)Cl
DM1VDC3	IK	MGYAMTJNJZZLMV-UHFFFAOYSA-N
DM1VDC3	IU	2-chloro-6-[(3-chlorophenyl)methoxy]pyridine-4-carbonitrile
DM1VDC3	DE	Discovery agent

DMK6CD9	ID	DMK6CD9
DMK6CD9	DN	2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one
DMK6CD9	HS	Investigative
DMK6CD9	SN	CHEMBL45677; NSC679034; AC1L8S0S; 1, 2-(3-chlorophenyl)-; 2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one; SCHEMBL7920166; CTK8C9853; ZINC5541496; BDBM50059959; NSC-679034; NCI60_028233; 2-(3-chlorophenyl)-1H-1,8-naphthyridin-4-one; 2-(3-Chlorophenyl)-1,8-naphthyridin-4(1H)-one; 1,8-Naphthyridin-4(1H)-one, 2-(3-chlorophenyl)-
DMK6CD9	DT	Small molecular drug
DMK6CD9	PC	386586
DMK6CD9	MW	256.68
DMK6CD9	FM	C14H9ClN2O
DMK6CD9	IC	InChI=1S/C14H9ClN2O/c15-10-4-1-3-9(7-10)12-8-13(18)11-5-2-6-16-14(11)17-12/h1-8H,(H,16,17,18)
DMK6CD9	CS	C1=CC(=CC(=C1)Cl)C2=CC(=O)C3=C(N2)N=CC=C3
DMK6CD9	IK	HZSAAZXBYZMFJN-UHFFFAOYSA-N
DMK6CD9	IU	2-(3-chlorophenyl)-1H-1,8-naphthyridin-4-one
DMK6CD9	DE	Discovery agent

DMYQBSV	ID	DMYQBSV
DMYQBSV	DN	2-(3-Chlorophenyl)-2H-indazole-7-carboxamide
DMYQBSV	HS	Investigative
DMYQBSV	SN	CHEMBL1094953; 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2265628
DMYQBSV	DT	Small molecular drug
DMYQBSV	PC	44549374
DMYQBSV	MW	271.7
DMYQBSV	FM	C14H10ClN3O
DMYQBSV	IC	InChI=1S/C14H10ClN3O/c15-10-4-2-5-11(7-10)18-8-9-3-1-6-12(14(16)19)13(9)17-18/h1-8H,(H2,16,19)
DMYQBSV	CS	C1=CC(=CC(=C1)Cl)N2C=C3C=CC=C(C3=N2)C(=O)N
DMYQBSV	IK	HWNODZACISEDHJ-UHFFFAOYSA-N
DMYQBSV	IU	2-(3-chlorophenyl)indazole-7-carboxamide
DMYQBSV	DE	Discovery agent

DM7BC50	ID	DM7BC50
DM7BC50	DN	2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine
DM7BC50	HS	Investigative
DM7BC50	SN	CHEMBL397551; 2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine
DM7BC50	DT	Small molecular drug
DM7BC50	PC	44434741
DM7BC50	MW	254.71
DM7BC50	FM	C15H11ClN2
DM7BC50	IC	InChI=1S/C15H11ClN2/c1-10-5-6-11-7-8-14(18-15(11)17-10)12-3-2-4-13(16)9-12/h2-9H,1H3
DM7BC50	CS	CC1=NC2=C(C=C1)C=CC(=N2)C3=CC(=CC=C3)Cl
DM7BC50	IK	LLSDDUWUZVPZOE-UHFFFAOYSA-N
DM7BC50	IU	2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine
DM7BC50	DE	Discovery agent

DML83DM	ID	DML83DM
DML83DM	DN	2-(3-Chloro-phenyl)-chromen-4-one
DML83DM	HS	Investigative
DML83DM	SN	CHEMBL56414; 2-(3-chlorophenyl)chromen-4-one; 1849-61-2; 4h-1-benzopyran-4-one,2-(3-chlorophenyl)-; AC1LAD8B; 2-(3-CHLOROPHENYL)-4H-CHROMEN-4-ONE; SCHEMBL6655676; ZINC6583548; MB10491; 2-(3'-chlorophenyl)-4h-chromen-4-one
DML83DM	DT	Small molecular drug
DML83DM	PC	466272
DML83DM	MW	256.68
DML83DM	FM	C15H9ClO2
DML83DM	IC	InChI=1S/C15H9ClO2/c16-11-5-3-4-10(8-11)15-9-13(17)12-6-1-2-7-14(12)18-15/h1-9H
DML83DM	CS	C1=CC=C2C(=C1)C(=O)C=C(O2)C3=CC(=CC=C3)Cl
DML83DM	IK	JWTQJUQJIRWZLA-UHFFFAOYSA-N
DML83DM	IU	2-(3-chlorophenyl)chromen-4-one
DML83DM	DE	Discovery agent

DMO0Y79	ID	DMO0Y79
DMO0Y79	DN	2-(3-chlorophenyl)histamine
DMO0Y79	HS	Investigative
DMO0Y79	SN	2-(3-chlorophenyl)histamine; 2-(3-chlorophenyl)-histamine; SCHEMBL3028276; GTPL1195; CHEMBL287052; BDBM86172; PDSP1_001307; PDSP2_001291; AKOS022543464; AKOS023903196; 133118-40-8
DMO0Y79	DT	Small molecular drug
DMO0Y79	PC	14827778
DMO0Y79	MW	221.68
DMO0Y79	FM	C11H12ClN3
DMO0Y79	IC	InChI=1S/C11H12ClN3/c12-9-3-1-2-8(6-9)11-14-7-10(15-11)4-5-13/h1-3,6-7H,4-5,13H2,(H,14,15)
DMO0Y79	CS	C1=CC(=CC(=C1)Cl)C2=NC=C(N2)CCN
DMO0Y79	IK	DHGUFKPZDMQBED-UHFFFAOYSA-N
DMO0Y79	IU	2-[2-(3-chlorophenyl)-1H-imidazol-5-yl]ethanamine
DMO0Y79	DE	Discovery agent

DMVB5U0	ID	DMVB5U0
DMVB5U0	DN	2-(3-cyanobenzyl)-5-mercaptopentanoic acid
DMVB5U0	HS	Investigative
DMVB5U0	SN	Thiol-Based Inhibitor, 22; CHEMBL207899; BDBM17774; 2-[(3-cyanophenyl)methyl]-5-sulfanylpentanoic acid
DMVB5U0	DT	Small molecular drug
DMVB5U0	PC	11715765
DMVB5U0	MW	249.33
DMVB5U0	FM	C13H15NO2S
DMVB5U0	IC	InChI=1S/C13H15NO2S/c14-9-11-4-1-3-10(7-11)8-12(13(15)16)5-2-6-17/h1,3-4,7,12,17H,2,5-6,8H2,(H,15,16)
DMVB5U0	CS	C1=CC(=CC(=C1)C#N)CC(CCCS)C(=O)O
DMVB5U0	IK	PCFBGUNMCCWACH-UHFFFAOYSA-N
DMVB5U0	IU	2-[(3-cyanophenyl)methyl]-5-sulfanylpentanoic acid
DMVB5U0	DE	Discovery agent

DMPLN58	ID	DMPLN58
DMPLN58	DN	2-(3'-Ethyl-biphenyl-4-yl)-propionic acid
DMPLN58	HS	Investigative
DMPLN58	SN	CHEMBL106203; BDBM50074929; 2-(3'-Ethyl-4-biphenylyl)propanoic acid; 2-(3''-Ethyl-biphenyl-4-yl)-propionic acid
DMPLN58	DT	Small molecular drug
DMPLN58	PC	44336344
DMPLN58	MW	254.32
DMPLN58	FM	C17H18O2
DMPLN58	IC	InChI=1S/C17H18O2/c1-3-13-5-4-6-16(11-13)15-9-7-14(8-10-15)12(2)17(18)19/h4-12H,3H2,1-2H3,(H,18,19)
DMPLN58	CS	CCC1=CC(=CC=C1)C2=CC=C(C=C2)C(C)C(=O)O
DMPLN58	IK	NXNPVWSOBXWFAA-UHFFFAOYSA-N
DMPLN58	IU	2-[4-(3-ethylphenyl)phenyl]propanoic acid
DMPLN58	DE	Discovery agent

DMPGYDA	ID	DMPGYDA
DMPGYDA	DN	2-(3'-Ethylsulfanyl-biphenyl-4-yl)-propionic acid
DMPGYDA	HS	Investigative
DMPGYDA	SN	CHEMBL107938; BDBM50074924; 2-(3'-Ethylthio-4-biphenylyl)propanoic acid; 2-(3''-Ethylsulfanyl-biphenyl-4-yl)-propionic acid
DMPGYDA	DT	Small molecular drug
DMPGYDA	PC	9817355
DMPGYDA	MW	286.4
DMPGYDA	FM	C17H18O2S
DMPGYDA	IC	InChI=1S/C17H18O2S/c1-3-20-16-6-4-5-15(11-16)14-9-7-13(8-10-14)12(2)17(18)19/h4-12H,3H2,1-2H3,(H,18,19)
DMPGYDA	CS	CCSC1=CC=CC(=C1)C2=CC=C(C=C2)C(C)C(=O)O
DMPGYDA	IK	QGKUCOODYMVNGO-UHFFFAOYSA-N
DMPGYDA	IU	2-[4-(3-ethylsulfanylphenyl)phenyl]propanoic acid
DMPGYDA	DE	Discovery agent

DMNTHK5	ID	DMNTHK5
DMNTHK5	DN	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMNTHK5	HS	Investigative
DMNTHK5	DT	Small molecular drug
DMNTHK5	PC	135528620
DMNTHK5	MW	245.21
DMNTHK5	FM	C13H8FNO3
DMNTHK5	IC	InChI=1S/C13H8FNO3/c14-9-5-7(1-3-11(9)17)13-15-10-6-8(16)2-4-12(10)18-13/h1-6,16-17H
DMNTHK5	CS	C1=CC(=C(C=C1C2=NC3=C(O2)C=CC(=C3)O)F)O
DMNTHK5	IK	GOGMBKCQZDIOLM-UHFFFAOYSA-N
DMNTHK5	IU	2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMNTHK5	DE	Discovery agent

DM50FW1	ID	DM50FW1
DM50FW1	DN	2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol
DM50FW1	HS	Investigative
DM50FW1	DT	Small molecular drug
DM50FW1	PC	135528621
DM50FW1	MW	245.21
DM50FW1	FM	C13H8FNO3
DM50FW1	IC	InChI=1S/C13H8FNO3/c14-9-5-7(1-4-11(9)17)13-15-10-3-2-8(16)6-12(10)18-13/h1-6,16-17H
DM50FW1	CS	C1=CC(=C(C=C1C2=NC3=C(O2)C=C(C=C3)O)F)O
DM50FW1	IK	LMARQOUQPBAFEB-UHFFFAOYSA-N
DM50FW1	IU	2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DM50FW1	DE	Discovery agent

DMNYWAT	ID	DMNYWAT
DMNYWAT	DN	2-(3-Fluoro-phenyl)-benzo[h]chromen-4-one
DMNYWAT	HS	Investigative
DMNYWAT	SN	CHEMBL436080; 652138-30-2; 2-(3-Fluoro-phenyl)-benzo[h]chromen-4-one; CTK1J8219; DTXSID70467020; BDBM50159673; 4H-Naphtho[1,2-b]pyran-4-one, 2-(3-fluorophenyl)-
DMNYWAT	DT	Small molecular drug
DMNYWAT	PC	11471812
DMNYWAT	MW	290.3
DMNYWAT	FM	C19H11FO2
DMNYWAT	IC	InChI=1S/C19H11FO2/c20-14-6-3-5-13(10-14)18-11-17(21)16-9-8-12-4-1-2-7-15(12)19(16)22-18/h1-11H
DMNYWAT	CS	C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CC(=CC=C4)F
DMNYWAT	IK	PJCRQJRMDLDKLR-UHFFFAOYSA-N
DMNYWAT	IU	2-(3-fluorophenyl)benzo[h]chromen-4-one
DMNYWAT	CA	CAS 652138-30-2
DMNYWAT	DE	Discovery agent

DMZX2GE	ID	DMZX2GE
DMZX2GE	DN	2-(3-guanidinophenyl)-3-mercaptopropanoic acid
DMZX2GE	HS	Investigative
DMZX2GE	SN	2-(3-GUANIDINOPHENYL)-3-MERCAPTOPROPANOIC ACID; (2R)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-SULFANYLPROPANOIC ACID; L98; AC1NA0C3; ZINC16051731; DB04723; (2R)-2-(3-carbamimidamidophenyl)-3-sulfanylpropanoic acid; (2R)-2-[3-(diaminomethylideneamino)phenyl]-3-sulfanylpropanoic acid; (2R)-2-{3-[(diaminomethylidene)amino]phenyl}-3-sulfanylpropanoic acid
DMZX2GE	DT	Small molecular drug
DMZX2GE	PC	4369579
DMZX2GE	MW	239.3
DMZX2GE	FM	C10H13N3O2S
DMZX2GE	IC	InChI=1S/C10H13N3O2S/c11-10(12)13-7-3-1-2-6(4-7)8(5-16)9(14)15/h1-4,8,16H,5H2,(H,14,15)(H4,11,12,13)/t8-/m1/s1
DMZX2GE	CS	C1=CC(=CC(=C1)N=C(N)N)[C@@H](CS)C(=O)O
DMZX2GE	IK	YHBCRXAIIVZWEW-MRVPVSSYSA-N
DMZX2GE	IU	(2R)-2-[3-(diaminomethylideneamino)phenyl]-3-sulfanylpropanoic acid
DMZX2GE	DE	Discovery agent

DMFVITM	ID	DMFVITM
DMFVITM	DN	2-(3-Hydroxycarbamoyl-propyl)-pentanedioic acid
DMFVITM	HS	Investigative
DMFVITM	SN	CHEMBL433298; 2-(3-Hydroxycarbamoyl-propyl)-pentanedioic acid; SCHEMBL13996819; BDBM50129199; 2-[4-Oxo-4-(hydroxyamino)butyl]pentanedioic acid
DMFVITM	DT	Small molecular drug
DMFVITM	PC	20778204
DMFVITM	MW	233.22
DMFVITM	FM	C9H15NO6
DMFVITM	IC	InChI=1S/C9H15NO6/c11-7(10-16)3-1-2-6(9(14)15)4-5-8(12)13/h6,16H,1-5H2,(H,10,11)(H,12,13)(H,14,15)
DMFVITM	CS	C(CC(CCC(=O)O)C(=O)O)CC(=O)NO
DMFVITM	IK	SFUVFBUNWNKLJH-UHFFFAOYSA-N
DMFVITM	IU	2-[4-(hydroxyamino)-4-oxobutyl]pentanedioic acid
DMFVITM	DE	Discovery agent

DMZCE18	ID	DMZCE18
DMZCE18	DN	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol
DMZCE18	HS	Investigative
DMZCE18	SN	CHEMBL24950; SCHEMBL6286195; BDBM50123206; 2-(3-hydroxyphenyl)-1,2''-spirobi[1H-indene]-5-ol
DMZCE18	DT	Small molecular drug
DMZCE18	PC	9901869
DMZCE18	MW	326.4
DMZCE18	FM	C23H18O2
DMZCE18	IC	InChI=1S/C23H18O2/c24-19-7-3-6-15(10-19)22-12-18-11-20(25)8-9-21(18)23(22)13-16-4-1-2-5-17(16)14-23/h1-12,24-25H,13-14H2
DMZCE18	CS	C1C2=CC=CC=C2CC13C4=C(C=C(C=C4)O)C=C3C5=CC(=CC=C5)O
DMZCE18	IK	NBNSBPOETAKHET-UHFFFAOYSA-N
DMZCE18	IU	2'-(3-hydroxyphenyl)spiro[1,3-dihydroindene-2,1'-indene]-5'-ol
DMZCE18	DE	Discovery agent

DMIGXRJ	ID	DMIGXRJ
DMIGXRJ	DN	2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol
DMIGXRJ	HS	Investigative
DMIGXRJ	SN	CHEMBL144431; SCHEMBL6283932; BDBM50123207; 2-(3-hydroxyphenyl)-1,2''-spirobi[1H-indene]-6-ol
DMIGXRJ	DT	Small molecular drug
DMIGXRJ	PC	10131379
DMIGXRJ	MW	326.4
DMIGXRJ	FM	C23H18O2
DMIGXRJ	IC	InChI=1S/C23H18O2/c24-19-7-3-6-15(10-19)21-11-16-8-9-20(25)12-22(16)23(21)13-17-4-1-2-5-18(17)14-23/h1-12,24-25H,13-14H2
DMIGXRJ	CS	C1C2=CC=CC=C2CC13C(=CC4=C3C=C(C=C4)O)C5=CC(=CC=C5)O
DMIGXRJ	IK	GWRXSPPQGAVBCP-UHFFFAOYSA-N
DMIGXRJ	IU	2'-(3-hydroxyphenyl)spiro[1,3-dihydroindene-2,3'-indene]-5'-ol
DMIGXRJ	DE	Discovery agent

DM40RS3	ID	DM40RS3
DM40RS3	DN	2-(3-Hydroxy-phenyl)-6-methyl-chromen-4-one
DM40RS3	HS	Investigative
DM40RS3	SN	3'-HYDROXY-6-METHYLFLAVONE; 468060-75-5; SCHEMBL5424662; CHEMBL336559; CTK6C0232; BNOQFZSTTRNHCN-UHFFFAOYSA-N; ZINC13491192; 3'-hydroxy-6-methylflavone, AldrichCPR; RT-008155; 4H-1-Benzopyran-4-one, 2-(3-hydroxyphenyl)-6-methyl-
DM40RS3	DT	Small molecular drug
DM40RS3	PC	11075942
DM40RS3	MW	252.26
DM40RS3	FM	C16H12O3
DM40RS3	IC	InChI=1S/C16H12O3/c1-10-5-6-15-13(7-10)14(18)9-16(19-15)11-3-2-4-12(17)8-11/h2-9,17H,1H3
DM40RS3	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC(=CC=C3)O
DM40RS3	IK	BNOQFZSTTRNHCN-UHFFFAOYSA-N
DM40RS3	IU	2-(3-hydroxyphenyl)-6-methylchromen-4-one
DM40RS3	DE	Discovery agent

DMAH0ZG	ID	DMAH0ZG
DMAH0ZG	DN	2-(3-hydroxyphenyl)-7-methoxychroman-4-one
DMAH0ZG	HS	Investigative
DMAH0ZG	SN	CHEMBL256407; 32274-72-9; CTK1B9323; DTXSID30438650; BDBM50374258; AKOS030552772; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(3-hydroxyphenyl)-7-methoxy-
DMAH0ZG	DT	Small molecular drug
DMAH0ZG	PC	10355761
DMAH0ZG	MW	270.28
DMAH0ZG	FM	C16H14O4
DMAH0ZG	IC	InChI=1S/C16H14O4/c1-19-12-5-6-13-14(18)9-15(20-16(13)8-12)10-3-2-4-11(17)7-10/h2-8,15,17H,9H2,1H3
DMAH0ZG	CS	COC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC(=CC=C3)O
DMAH0ZG	IK	YETISVQJYRETIF-UHFFFAOYSA-N
DMAH0ZG	IU	2-(3-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMAH0ZG	CA	CAS 32274-72-9
DMAH0ZG	DE	Discovery agent

DMV9M57	ID	DMV9M57
DMV9M57	DN	2-(3-hydroxyphenyl)quinolin-6-ol
DMV9M57	HS	Investigative
DMV9M57	SN	2-(3-hydroxyphenyl)quinolin-6-ol; CHEMBL260459; SCHEMBL3007819
DMV9M57	DT	Small molecular drug
DMV9M57	PC	25069444
DMV9M57	MW	237.25
DMV9M57	FM	C15H11NO2
DMV9M57	IC	InChI=1S/C15H11NO2/c17-12-3-1-2-10(8-12)14-6-4-11-9-13(18)5-7-15(11)16-14/h1-9,17-18H
DMV9M57	CS	C1=CC(=CC(=C1)O)C2=NC3=C(C=C2)C=C(C=C3)O
DMV9M57	IK	KVSLALXAPWSPAG-UHFFFAOYSA-N
DMV9M57	IU	2-(3-hydroxyphenyl)quinolin-6-ol
DMV9M57	CA	CAS 87741-96-6
DMV9M57	DE	Discovery agent

DMXRAE3	ID	DMXRAE3
DMXRAE3	DN	2-(3''-indolylethyloxy)adenosine
DMXRAE3	HS	Investigative
DMXRAE3	SN	CHEMBL223366; SCHEMBL8111144; 2-(3'-Indolylethyloxy)Adenosine; BDBM50208804; 2-(3''''-indolylethyloxy)adenosine; 2-[2-(1H-Indol-3-yl)ethoxy]adenosine
DMXRAE3	DT	Small molecular drug
DMXRAE3	PC	16203429
DMXRAE3	MW	426.4
DMXRAE3	FM	C20H22N6O5
DMXRAE3	IC	InChI=1S/C20H22N6O5/c21-17-14-18(26(9-23-14)19-16(29)15(28)13(8-27)31-19)25-20(24-17)30-6-5-10-7-22-12-4-2-1-3-11(10)12/h1-4,7,9,13,15-16,19,22,27-29H,5-6,8H2,(H2,21,24,25)/t13-,15-,16-,19-/m1/s1
DMXRAE3	CS	C1=CC=C2C(=C1)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMXRAE3	IK	UIPASAROPWUJRQ-NVQRDWNXSA-N
DMXRAE3	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMXRAE3	DE	Discovery agent

DMML0VP	ID	DMML0VP
DMML0VP	DN	2-(3-iodophenyl)histamine
DMML0VP	HS	Investigative
DMML0VP	SN	2-(3-iodophenyl)histamine; 2-[2-(3-iodophenyl)-3H-imidazol-4-yl]ethanamine; CHEMBL287367; GTPL1196; BDBM86173; PDSP2_001293; PDSP1_001309
DMML0VP	DT	Small molecular drug
DMML0VP	PC	10245039
DMML0VP	MW	313.14
DMML0VP	FM	C11H12IN3
DMML0VP	IC	InChI=1S/C11H12IN3/c12-9-3-1-2-8(6-9)11-14-7-10(15-11)4-5-13/h1-3,6-7H,4-5,13H2,(H,14,15)
DMML0VP	CS	C1=CC(=CC(=C1)I)C2=NC=C(N2)CCN
DMML0VP	IK	OPICWPJAKDPOOB-UHFFFAOYSA-N
DMML0VP	IU	2-[2-(3-iodophenyl)-1H-imidazol-5-yl]ethanamine
DMML0VP	DE	Discovery agent

DM59VBG	ID	DM59VBG
DM59VBG	DN	2-(3-Isobutyl-phenyl)-propionic acid
DM59VBG	HS	Investigative
DM59VBG	SN	66622-47-7; 2-(3-isobutylphenyl)propanoic acid; m-Isobutyl Ibuprofen; 2-[3-(2-methylpropyl)phenyl]propanoic Acid; 2-(3-Isobutylphenyl)propionic Acid; (2RS)-2-(3-(2-Methylpropyl)phenyl)propanoic acid; (2RS)-2-[3-(2-Methylpropyl)phenyl]propanoic Acid; Ibuprofen specified impurity A [EP]; Ibuprofen Impurity A; alpha-(3-Isobutylphenyl)propionic acid; SCHEMBL66534; alpha-Methyl-3-(2-methylpropyl)phenylacetic acid; CHEMBL187556; Benzeneacetic acid, alpha-methyl-3-(2-methylpropyl)-; CTK5C4963; MolPort-029-294-062; AKOS023890981
DM59VBG	DT	Small molecular drug
DM59VBG	PC	11424295
DM59VBG	MW	206.28
DM59VBG	FM	C13H18O2
DM59VBG	IC	InChI=1S/C13H18O2/c1-9(2)7-11-5-4-6-12(8-11)10(3)13(14)15/h4-6,8-10H,7H2,1-3H3,(H,14,15)
DM59VBG	CS	CC(C)CC1=CC(=CC=C1)C(C)C(=O)O
DM59VBG	IK	SFVKLYXPBKITCE-UHFFFAOYSA-N
DM59VBG	IU	2-[3-(2-methylpropyl)phenyl]propanoic acid
DM59VBG	CA	CAS 66622-47-7
DM59VBG	DE	Discovery agent

DMUOWNE	ID	DMUOWNE
DMUOWNE	DN	2-(3-Isopropyl-phenyl)-propionic acid
DMUOWNE	HS	Investigative
DMUOWNE	SN	Benzeneacetic acid, alpha-methyl-3-(1-methylethyl)-; CHEMBL191103; SCHEMBL1345333; DHFSUPPYOBITGY-UHFFFAOYSA-N; 2-(3-isopropylphenyl)propanoic acid; AKOS022699991; 2-[(3'-isopropyl)phenyl]propionic acid
DMUOWNE	DT	Small molecular drug
DMUOWNE	PC	10307922
DMUOWNE	MW	192.25
DMUOWNE	FM	C12H16O2
DMUOWNE	IC	InChI=1S/C12H16O2/c1-8(2)10-5-4-6-11(7-10)9(3)12(13)14/h4-9H,1-3H3,(H,13,14)
DMUOWNE	CS	CC(C)C1=CC(=CC=C1)C(C)C(=O)O
DMUOWNE	IK	DHFSUPPYOBITGY-UHFFFAOYSA-N
DMUOWNE	IU	2-(3-propan-2-ylphenyl)propanoic acid
DMUOWNE	DE	Discovery agent

DMMDNA8	ID	DMMDNA8
DMMDNA8	DN	2-(3-Mercapto-propyl)-pentanedioic acid
DMMDNA8	HS	Investigative
DMMDNA8	SN	2-(3-mercaptopropyl)pentanedioic acid; 2-MPPA; 2-(3-sulfanylpropyl)pentanedioic Acid; 254737-29-6; CHEMBL303352; Pentanedioic acid, 2-(3-mercaptopropyl)-; 2-[3-mercaptopropyl]pentanedioic acid; GPI 5693; SCHEMBL787800; CTK0J4030; BDBM17755; FNLNSQHJKVQCBP-UHFFFAOYSA-N; MolPort-035-765-922; pentanedioic acid analogue, (RS)-3; AKOS024458465
DMMDNA8	DT	Small molecular drug
DMMDNA8	PC	10198171
DMMDNA8	MW	206.26
DMMDNA8	FM	C8H14O4S
DMMDNA8	IC	InChI=1S/C8H14O4S/c9-7(10)4-3-6(8(11)12)2-1-5-13/h6,13H,1-5H2,(H,9,10)(H,11,12)
DMMDNA8	CS	C(CC(CCC(=O)O)C(=O)O)CS
DMMDNA8	IK	FNLNSQHJKVQCBP-UHFFFAOYSA-N
DMMDNA8	IU	2-(3-sulfanylpropyl)pentanedioic acid
DMMDNA8	CA	CAS 254737-29-6
DMMDNA8	DE	Discovery agent

DM21MAU	ID	DM21MAU
DM21MAU	DN	2-(3-methoxybenzylthio)-2-phenylacetic acid
DM21MAU	HS	Investigative
DM21MAU	SN	MLS003115376; 2-(3-methoxybenzylthio)-2-phenylacetic acid; CHEMBL493464; 7037-33-4; NSC268685; AC1L82IK; 2-[(3-methoxyphenyl)methylsulfanyl]-2-phenylacetic acid; DTXSID20313306; BDBM50253013; NSC-268685
DM21MAU	DT	Small molecular drug
DM21MAU	PC	320577
DM21MAU	MW	288.4
DM21MAU	FM	C16H16O3S
DM21MAU	IC	InChI=1S/C16H16O3S/c1-19-14-9-5-6-12(10-14)11-20-15(16(17)18)13-7-3-2-4-8-13/h2-10,15H,11H2,1H3,(H,17,18)
DM21MAU	CS	COC1=CC=CC(=C1)CSC(C2=CC=CC=C2)C(=O)O
DM21MAU	IK	DCWDBUYRVFMPPL-UHFFFAOYSA-N
DM21MAU	IU	2-[(3-methoxyphenyl)methylsulfanyl]-2-phenylacetic acid
DM21MAU	CA	CAS 7037-33-4
DM21MAU	DE	Discovery agent

DMCDGAU	ID	DMCDGAU
DMCDGAU	DN	2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
DMCDGAU	HS	Investigative
DMCDGAU	SN	2-(3'-methoxyphenyl) benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide; CHEMBL134022; BZC; 1efy; AC1L1BMO; SCHEMBL4321727; CTK7A9229; NVVWVYYHTKCIAE-UHFFFAOYSA-N; ZINC11565446; BDBM50093373; DB04010; 2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide; 2-(3''-METHOXYPHENYL) BENZIMIDAZOLE-4-CARBOXAMIDE; 2-(3-Methoxy-phenyl)-1H-benzoimidazole-4-carboxylic acid amide
DMCDGAU	DT	Small molecular drug
DMCDGAU	PC	1511
DMCDGAU	MW	267.28
DMCDGAU	FM	C15H13N3O2
DMCDGAU	IC	InChI=1S/C15H13N3O2/c1-20-10-5-2-4-9(8-10)15-17-12-7-3-6-11(14(16)19)13(12)18-15/h2-8H,1H3,(H2,16,19)(H,17,18)
DMCDGAU	CS	COC1=CC=CC(=C1)C2=NC3=C(C=CC=C3N2)C(=O)N
DMCDGAU	IK	NVVWVYYHTKCIAE-UHFFFAOYSA-N
DMCDGAU	IU	2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide
DMCDGAU	DE	Discovery agent

DM4C9H2	ID	DM4C9H2
DM4C9H2	DN	2-(3-Methoxy-phenyl)-1-methyl-ethylamine
DM4C9H2	HS	Investigative
DM4C9H2	SN	3-Methoxyamphetamine; 1-(3-methoxyphenyl)propan-2-amine; 17862-85-0; Benzeneethanamine, 3-methoxy-alpha-methyl-; CHEMBL16247; VEJWNIYARKAHFI-UHFFFAOYSA-N; 2-(3-Methoxyphenyl)-1-methylethylamine; 17862-91-8; meta-Methoxyamphetamine; 3-methoxyamphetamine -; 2-(3-Methoxy-phenyl)-1-methyl-ethylamine; AC1L47YE; NCIOpen2_006073; SCHEMBL269071; CTK0H8604; 1-(3-methoxyphenyl)-2-propylamine; BDBM50024211; AKOS000157039; AKOS022196418; MCULE-6670391418; MB01562; 1-(3-Methoxyphenyl)-2-propanamine #; NCI60_042089
DM4C9H2	DT	Small molecular drug
DM4C9H2	PC	152234
DM4C9H2	MW	165.23
DM4C9H2	FM	C10H15NO
DM4C9H2	IC	InChI=1S/C10H15NO/c1-8(11)6-9-4-3-5-10(7-9)12-2/h3-5,7-8H,6,11H2,1-2H3
DM4C9H2	CS	CC(CC1=CC(=CC=C1)OC)N
DM4C9H2	IK	VEJWNIYARKAHFI-UHFFFAOYSA-N
DM4C9H2	IU	1-(3-methoxyphenyl)propan-2-amine
DM4C9H2	CA	CAS 17862-85-0
DM4C9H2	DE	Discovery agent

DMBGVEK	ID	DMBGVEK
DMBGVEK	DN	2-(3-Methoxy-phenyl)-6-methyl-chromen-4-one
DMBGVEK	HS	Investigative
DMBGVEK	SN	3'-METHOXY-6-METHYLFLAVONE; CHEMBL131632; 4H-1-Benzopyran-4-one, 2-(3-methoxyphenyl)-6-methyl-; 88952-72-1; ACMC-20lfb9; AC1LVOZ6; CTK3A4546; DTXSID50364725; GPLWNAUILJELBH-UHFFFAOYSA-N; ZINC1933195; AKOS002387234; MB03835; 3'-methoxy-6-methylflavone, AldrichCPR
DMBGVEK	DT	Small molecular drug
DMBGVEK	PC	1659443
DMBGVEK	MW	266.29
DMBGVEK	FM	C17H14O3
DMBGVEK	IC	InChI=1S/C17H14O3/c1-11-6-7-16-14(8-11)15(18)10-17(20-16)12-4-3-5-13(9-12)19-2/h3-10H,1-2H3
DMBGVEK	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC(=CC=C3)OC
DMBGVEK	IK	GPLWNAUILJELBH-UHFFFAOYSA-N
DMBGVEK	IU	2-(3-methoxyphenyl)-6-methylchromen-4-one
DMBGVEK	CA	CAS 88952-72-1
DMBGVEK	DE	Discovery agent

DMASH36	ID	DMASH36
DMASH36	DN	2-(3-methoxyphenyl)-6-morpholino-4H-pyran-4-one
DMASH36	HS	Investigative
DMASH36	SN	CHEMBL106543; 2-(3-methoxyphenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3538409; BDBM50132356; 2-Morpholino-6-(3-methoxyphenyl)-4H-pyran-4-one
DMASH36	DT	Small molecular drug
DMASH36	PC	21106405
DMASH36	MW	287.31
DMASH36	FM	C16H17NO4
DMASH36	IC	InChI=1S/C16H17NO4/c1-19-14-4-2-3-12(9-14)15-10-13(18)11-16(21-15)17-5-7-20-8-6-17/h2-4,9-11H,5-8H2,1H3
DMASH36	CS	COC1=CC=CC(=C1)C2=CC(=O)C=C(O2)N3CCOCC3
DMASH36	IK	OLIONIBTYZDPMY-UHFFFAOYSA-N
DMASH36	IU	2-(3-methoxyphenyl)-6-morpholin-4-ylpyran-4-one
DMASH36	DE	Discovery agent

DME09J2	ID	DME09J2
DME09J2	DN	2-(3-Methyl-3H-imidazol-4-yl)-ethylamine
DME09J2	HS	Investigative
DME09J2	SN	3-Methylhistamine; Tau-methylhistamine; 644-42-8; Imidazole, 5-(2-aminoethyl)-1-methyl-; L-histamine deriv. 1; 2-(1-methyl-1H-imidazol-5-yl)ethan-1-amine; 1H-Imidazole-5-ethanamine, 1-methyl-; CHEMBL14722; 2-(1-methyl-1H-imidazol-5-yl)ethanamine; CPAGZVLINCPJEH-UHFFFAOYSA-N; 2-(3-methylimidazol-4-yl)ethanamine; 3-Methyl Histamine Dihydrochloride; (r)-a-methylhistamine; AC1Q4WNL; SCHEMBL946729; BDBM7967; AC1L2C25; CTK5C1256; DTXSID10214651; ZINC403074; AKOS006340201; 1H-Imidazole-5-ethanamine,1-methyl-
DME09J2	DT	Small molecular drug
DME09J2	PC	69520
DME09J2	MW	125.17
DME09J2	FM	C6H11N3
DME09J2	IC	InChI=1S/C6H11N3/c1-9-5-8-4-6(9)2-3-7/h4-5H,2-3,7H2,1H3
DME09J2	CS	CN1C=NC=C1CCN
DME09J2	IK	CPAGZVLINCPJEH-UHFFFAOYSA-N
DME09J2	IU	2-(3-methylimidazol-4-yl)ethanamine
DME09J2	CA	CAS 644-42-8
DME09J2	DE	Discovery agent

DMFOA6R	ID	DMFOA6R
DMFOA6R	DN	2-(3-Methyl-indole-1-sulfonyl)-benzoic acid
DMFOA6R	HS	Investigative
DMFOA6R	SN	CHEMBL361251; 2-(3-Methyl-indole-1-sulfonyl)-benzoic acid
DMFOA6R	DT	Small molecular drug
DMFOA6R	PC	44393556
DMFOA6R	MW	315.3
DMFOA6R	FM	C16H13NO4S
DMFOA6R	IC	InChI=1S/C16H13NO4S/c1-11-10-17(14-8-4-2-6-12(11)14)22(20,21)15-9-5-3-7-13(15)16(18)19/h2-10H,1H3,(H,18,19)
DMFOA6R	CS	CC1=CN(C2=CC=CC=C12)S(=O)(=O)C3=CC=CC=C3C(=O)O
DMFOA6R	IK	FBAOKNXTXGWCMO-UHFFFAOYSA-N
DMFOA6R	IU	2-(3-methylindol-1-yl)sulfonylbenzoic acid
DMFOA6R	DE	Discovery agent

DM1J4MT	ID	DM1J4MT
DM1J4MT	DN	2-(3-Methyl-piperazin-1-yl)-6-nitro-quinoline
DM1J4MT	HS	Investigative
DM1J4MT	SN	CHEMBL43526; 2-(3-Methyl-piperazin-1-yl)-6-nitro-quinoline; Quinoline,2-(3-methyl-1-piperazinyl)-6-nitro-; SCHEMBL6365197; WIRIBEHWECMIRC-UHFFFAOYSA-N; BDBM50090211; AKOS011768382; 2-(3-Methylpiperazino)-6-nitroquinoline; 296759-20-1
DM1J4MT	DT	Small molecular drug
DM1J4MT	PC	44286607
DM1J4MT	MW	272.3
DM1J4MT	FM	C14H16N4O2
DM1J4MT	IC	InChI=1S/C14H16N4O2/c1-10-9-17(7-6-15-10)14-5-2-11-8-12(18(19)20)3-4-13(11)16-14/h2-5,8,10,15H,6-7,9H2,1H3
DM1J4MT	CS	CC1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)[N+](=O)[O-]
DM1J4MT	IK	WIRIBEHWECMIRC-UHFFFAOYSA-N
DM1J4MT	IU	2-(3-methylpiperazin-1-yl)-6-nitroquinoline
DM1J4MT	DE	Discovery agent

DM4D1UT	ID	DM4D1UT
DM4D1UT	DN	2-(3-Methylsulfanyl-propyl)-pentanedioic acid
DM4D1UT	HS	Investigative
DM4D1UT	SN	CHEMBL61882; 2-(3-Methylsulfanyl-propyl)-pentanedioic acid
DM4D1UT	DT	Small molecular drug
DM4D1UT	PC	11790725
DM4D1UT	MW	220.29
DM4D1UT	FM	C9H16O4S
DM4D1UT	IC	InChI=1S/C9H16O4S/c1-14-6-2-3-7(9(12)13)4-5-8(10)11/h7H,2-6H2,1H3,(H,10,11)(H,12,13)
DM4D1UT	CS	CSCCCC(CCC(=O)O)C(=O)O
DM4D1UT	IK	AXRGKFNGKGNVEI-UHFFFAOYSA-N
DM4D1UT	IU	2-(3-methylsulfanylpropyl)pentanedioic acid
DM4D1UT	DE	Discovery agent

DMMYQ9R	ID	DMMYQ9R
DMMYQ9R	DN	2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole
DMMYQ9R	HS	Investigative
DMMYQ9R	SN	2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole; 31659-42-4; 1h-imidazole, 4,5-dihydro-2-(3-nitrophenyl)-; CHEMBL457101; 4,5-Dihydro-2-(3-nitrophenyl)-1H-imidazole; EINECS 250-754-1; AC1LEYVJ; AC1Q1ZUC; 2-(m-nitrophenyl)imidazoline; IMI021; SCHEMBL12643294; CTK4G7541; DTXSID30185551; MolPort-006-126-327; ZINC121568; 2-(3-Nitrophenyl)-2-imidazoline; STK367845; BDBM50266032; BBL001160; AKOS005444754; MCULE-9494328291; T7684
DMMYQ9R	DT	Small molecular drug
DMMYQ9R	PC	720241
DMMYQ9R	MW	191.19
DMMYQ9R	FM	C9H9N3O2
DMMYQ9R	IC	InChI=1S/C9H9N3O2/c13-12(14)8-3-1-2-7(6-8)9-10-4-5-11-9/h1-3,6H,4-5H2,(H,10,11)
DMMYQ9R	CS	C1CN=C(N1)C2=CC(=CC=C2)[N+](=O)[O-]
DMMYQ9R	IK	YSCJJOXSVFNSPY-UHFFFAOYSA-N
DMMYQ9R	IU	2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole
DMMYQ9R	CA	CAS 31659-42-4
DMMYQ9R	DE	Discovery agent

DM6GLEA	ID	DM6GLEA
DM6GLEA	DN	2-(3-Phenoxy-benzoylamino)-benzoic acid
DM6GLEA	HS	Investigative
DM6GLEA	SN	CHEMBL178465; BDBM23579; 2-(3-Phenoxybenzamido)Benzoic Acid; 2-(3-phenoxybenzoylamino)benzoic acid; 2-[(3-phenoxybenzene)amido]benzoic acid; (3-Phenoxybenzoylamino)benzoic acid deriv., 15
DM6GLEA	DT	Small molecular drug
DM6GLEA	PC	11325072
DM6GLEA	MW	333.3
DM6GLEA	FM	C20H15NO4
DM6GLEA	IC	InChI=1S/C20H15NO4/c22-19(21-18-12-5-4-11-17(18)20(23)24)14-7-6-10-16(13-14)25-15-8-2-1-3-9-15/h1-13H,(H,21,22)(H,23,24)
DM6GLEA	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)NC3=CC=CC=C3C(=O)O
DM6GLEA	IK	MIKJQLWATXBRIP-UHFFFAOYSA-N
DM6GLEA	IU	2-[(3-phenoxybenzoyl)amino]benzoic acid
DM6GLEA	DE	Discovery agent

DMIQBXD	ID	DMIQBXD
DMIQBXD	DN	2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one
DMIQBXD	HS	Investigative
DMIQBXD	SN	CHEMBL3144578; CHEMBL8053; 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one; BDBM50009009; ZINC138045856
DMIQBXD	DT	Small molecular drug
DMIQBXD	PC	14898717
DMIQBXD	MW	252.31
DMIQBXD	FM	C16H16N2O
DMIQBXD	IC	InChI=1S/C16H16N2O/c19-16-14-10-4-5-11-15(14)17-18(16)12-6-9-13-7-2-1-3-8-13/h1-5,7-8,10-11,17H,6,9,12H2
DMIQBXD	CS	C1=CC=C(C=C1)CCCN2C(=O)C3=CC=CC=C3N2
DMIQBXD	IK	ZTUNGCGUHQENHO-UHFFFAOYSA-N
DMIQBXD	IU	2-(3-phenylpropyl)-1H-indazol-3-one
DMIQBXD	DE	Discovery agent

DM4WOT6	ID	DM4WOT6
DM4WOT6	DN	2-(3-phenylthio)phenyl)-1-aminoethane
DM4WOT6	HS	Investigative
DM4WOT6	SN	CHEMBL211688; 2-(3-phenylthio)phenyl)-1-aminoethane; 2-(3-(Phenylthio)Phenyl)Ethanamine; BDBM50193470
DM4WOT6	DT	Small molecular drug
DM4WOT6	PC	11849796
DM4WOT6	MW	229.34
DM4WOT6	FM	C14H15NS
DM4WOT6	IC	InChI=1S/C14H15NS/c15-10-9-12-5-4-8-14(11-12)16-13-6-2-1-3-7-13/h1-8,11H,9-10,15H2
DM4WOT6	CS	C1=CC=C(C=C1)SC2=CC=CC(=C2)CCN
DM4WOT6	IK	FJLQSSVQBNJTEU-UHFFFAOYSA-N
DM4WOT6	IU	2-(3-phenylsulfanylphenyl)ethanamine
DM4WOT6	DE	Discovery agent

DMZ5H8O	ID	DMZ5H8O
DMZ5H8O	DN	2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one
DMZ5H8O	HS	Investigative
DMZ5H8O	DT	Small molecular drug
DMZ5H8O	PC	135508369
DMZ5H8O	MW	271.36
DMZ5H8O	FM	C16H21N3O
DMZ5H8O	IC	InChI=1S/C16H21N3O/c20-16-13-7-2-3-8-14(13)17-15(18-16)9-6-12-19-10-4-1-5-11-19/h2-3,7-8H,1,4-6,9-12H2,(H,17,18,20)
DMZ5H8O	CS	C1CCN(CC1)CCCC2=NC3=CC=CC=C3C(=O)N2
DMZ5H8O	IK	HDVNQQSSIKDDKS-UHFFFAOYSA-N
DMZ5H8O	IU	2-(3-piperidin-1-ylpropyl)-3H-quinazolin-4-one
DMZ5H8O	DE	Discovery agent

DMNCP8Y	ID	DMNCP8Y
DMNCP8Y	DN	2-(3''-pyrrolylethyloxy)adenosine
DMNCP8Y	HS	Investigative
DMNCP8Y	SN	CHEMBL222945; 2-(3'-Pyrrolylethyloxy)Adenosine; BDBM50208806; 2-(3''''-pyrrolylethyloxy)adenosine
DMNCP8Y	DT	Small molecular drug
DMNCP8Y	PC	16204411
DMNCP8Y	MW	376.37
DMNCP8Y	FM	C16H20N6O5
DMNCP8Y	IC	InChI=1S/C16H20N6O5/c17-13-10-14(21-16(20-13)26-4-2-8-1-3-18-5-8)22(7-19-10)15-12(25)11(24)9(6-23)27-15/h1,3,5,7,9,11-12,15,18,23-25H,2,4,6H2,(H2,17,20,21)/t9-,11-,12-,15-/m1/s1
DMNCP8Y	CS	C1=CNC=C1CCOC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DMNCP8Y	IK	OBDCLFIHFXHMSJ-SDBHATRESA-N
DMNCP8Y	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(1H-pyrrol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMNCP8Y	DE	Discovery agent

DM7NGV1	ID	DM7NGV1
DM7NGV1	DN	2-(3'-Vinyl-biphenyl-4-yl)-propionic acid
DM7NGV1	HS	Investigative
DM7NGV1	SN	CHEMBL432782; BDBM50074925; 2-(3'-Vinyl-4-biphenylyl)propanoic acid; 2-(3''-Vinyl-biphenyl-4-yl)-propionic acid
DM7NGV1	DT	Small molecular drug
DM7NGV1	PC	44336157
DM7NGV1	MW	252.31
DM7NGV1	FM	C17H16O2
DM7NGV1	IC	InChI=1S/C17H16O2/c1-3-13-5-4-6-16(11-13)15-9-7-14(8-10-15)12(2)17(18)19/h3-12H,1H2,2H3,(H,18,19)
DM7NGV1	CS	CC(C1=CC=C(C=C1)C2=CC=CC(=C2)C=C)C(=O)O
DM7NGV1	IK	VRFXYYPKWQXDFK-UHFFFAOYSA-N
DM7NGV1	IU	2-[4-(3-ethenylphenyl)phenyl]propanoic acid
DM7NGV1	DE	Discovery agent

DM27CQJ	ID	DM27CQJ
DM27CQJ	DN	2-(4-(3-chlorophenyl)but-1-ynyl)-6-methylpyridine
DM27CQJ	HS	Investigative
DM27CQJ	SN	CHEMBL213001; 2-(4-(3-chlorophenyl)but-1-ynyl)-6-methylpyridine; SCHEMBL4293064; 2-[4-(3-chlorophenyl)but-1-yn-1-yl]-6-methylpyridine; BDBM50191127
DM27CQJ	DT	Small molecular drug
DM27CQJ	PC	11379837
DM27CQJ	MW	255.74
DM27CQJ	FM	C16H14ClN
DM27CQJ	IC	InChI=1S/C16H14ClN/c1-13-6-4-11-16(18-13)10-3-2-7-14-8-5-9-15(17)12-14/h4-6,8-9,11-12H,2,7H2,1H3
DM27CQJ	CS	CC1=NC(=CC=C1)C#CCCC2=CC(=CC=C2)Cl
DM27CQJ	IK	PLDMRMLBISIHNX-UHFFFAOYSA-N
DM27CQJ	IU	2-[4-(3-chlorophenyl)but-1-ynyl]-6-methylpyridine
DM27CQJ	DE	Discovery agent

DMOYT8I	ID	DMOYT8I
DMOYT8I	DN	2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol
DMOYT8I	HS	Investigative
DMOYT8I	SN	CHEMBL551839; 2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol
DMOYT8I	DT	Small molecular drug
DMOYT8I	PC	45270433
DMOYT8I	MW	284.3
DMOYT8I	FM	C15H12N2O2S
DMOYT8I	IC	InChI=1S/C15H12N2O2S/c18-11-7-5-10(6-8-11)13-9-20-15(17-13)16-12-3-1-2-4-14(12)19/h1-9,18-19H,(H,16,17)
DMOYT8I	CS	C1=CC=C(C(=C1)NC2=NC(=CS2)C3=CC=C(C=C3)O)O
DMOYT8I	IK	HXSHJTRADFDFMA-UHFFFAOYSA-N
DMOYT8I	IU	2-[[4-(4-hydroxyphenyl)-1,3-thiazol-2-yl]amino]phenol
DMOYT8I	DE	Discovery agent

DMDAO5T	ID	DMDAO5T
DMDAO5T	DN	2-(4-(benzenesulfonyl)phenyl)-1-aminoethane
DMDAO5T	HS	Investigative
DMDAO5T	SN	CHEMBL213589; 2-(4-(benzenesulfonyl)phenyl)-1-aminoethane; BDBM50193459
DMDAO5T	DT	Small molecular drug
DMDAO5T	PC	44414681
DMDAO5T	MW	261.339
DMDAO5T	FM	C14H15NO2S
DMDAO5T	IC	InChI=1S/C14H15NO2S/c15-11-10-12-6-8-14(9-7-12)18(16,17)13-4-2-1-3-5-13/h1-9H,10-11,15H2
DMDAO5T	CS	C1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)CCN
DMDAO5T	IK	YNFGKNGJUDQMQL-UHFFFAOYSA-N
DMDAO5T	IU	2-[4-(benzenesulfonyl)phenyl]ethanamine
DMDAO5T	DE	Discovery agent

DMFNQZS	ID	DMFNQZS
DMFNQZS	DN	2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol
DMFNQZS	HS	Investigative
DMFNQZS	SN	2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol; 566169-93-5; UNII-K6396E6G8G; CHEMBL93124; K6396E6G8G; AK-87409; 2-[4'-(methylamino)phenyl]-6-hydroxybenzothiazole; Pittsburgh compound B unlabelled; 2-(4'-methylaminophenyl)-6-hydroxybenzothiazole; SCHEMBL912744; ZQAQXZBSGZUUNL-UHFFFAOYSA-N; MolPort-028-616-384; ZINC3816332; BDBM50129793; AKOS022184240; FC-3012; 4-methylamino-phenyl)-benzothiazol-6-ol; AJ-45711; PIB authentic (6-OH-BTA-1) free base; 2-(4-Methylamino-phenyl)-benzothiazol-6-ol
DMFNQZS	DT	Small molecular drug
DMFNQZS	PC	10171487
DMFNQZS	MW	256.32
DMFNQZS	FM	C14H12N2OS
DMFNQZS	IC	InChI=1S/C14H12N2OS/c1-15-10-4-2-9(3-5-10)14-16-12-7-6-11(17)8-13(12)18-14/h2-8,15,17H,1H3
DMFNQZS	CS	CNC1=CC=C(C=C1)C2=NC3=C(S2)C=C(C=C3)O
DMFNQZS	IK	ZQAQXZBSGZUUNL-UHFFFAOYSA-N
DMFNQZS	IU	2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
DMFNQZS	CA	CAS 566169-93-5
DMFNQZS	DE	Discovery agent

DMVD6HE	ID	DMVD6HE
DMVD6HE	DN	2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline
DMVD6HE	HS	Investigative
DMVD6HE	SN	CHEMBL598330; 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline
DMVD6HE	DT	Small molecular drug
DMVD6HE	PC	46232132
DMVD6HE	MW	359.4
DMVD6HE	FM	C22H17NO2S
DMVD6HE	IC	InChI=1S/C22H17NO2S/c1-26(24,25)19-13-11-17(12-14-19)22-20(16-7-3-2-4-8-16)15-18-9-5-6-10-21(18)23-22/h2-15H,1H3
DMVD6HE	CS	CS(=O)(=O)C1=CC=C(C=C1)C2=NC3=CC=CC=C3C=C2C4=CC=CC=C4
DMVD6HE	IK	OPLJPOZQZWTQDV-UHFFFAOYSA-N
DMVD6HE	IU	2-(4-methylsulfonylphenyl)-3-phenylquinoline
DMVD6HE	DE	Discovery agent

DM1TZNK	ID	DM1TZNK
DM1TZNK	DN	2-(4-(methylsulfonyl)phenyl)pyridine
DM1TZNK	HS	Investigative
DM1TZNK	SN	2-(4-(methylsulfonyl)phenyl)pyridine; CHEMBL1240924; 2-[4-(Methylsulfonyl)phenyl]pyridine; SCHEMBL8229590
DM1TZNK	DT	Small molecular drug
DM1TZNK	PC	46937403
DM1TZNK	MW	233.29
DM1TZNK	FM	C12H11NO2S
DM1TZNK	IC	InChI=1S/C12H11NO2S/c1-16(14,15)11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3
DM1TZNK	CS	CS(=O)(=O)C1=CC=C(C=C1)C2=CC=CC=N2
DM1TZNK	IK	PCRZBBOIGHSIEX-UHFFFAOYSA-N
DM1TZNK	IU	2-(4-methylsulfonylphenyl)pyridine
DM1TZNK	DE	Discovery agent

DM4X0SJ	ID	DM4X0SJ
DM4X0SJ	DN	2-(4,5-dihydro-1H-imidazol-2-yl)quinoline
DM4X0SJ	HS	Investigative
DM4X0SJ	SN	BU 224; 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline; CHEMBL13698; 2-(4,5-Dihydroimidaz-2-yl)-Quinoline; BU-224; NCGC00015130-01; Tocris-0725; Lopac-B-154; AC1L1DPZ; Lopac0_000167; SCHEMBL1526637; CHEBI:92967; CTK5J7405; ZINC2565858; BDBM50240365; CCG-204262; NCGC00024750-02; NCGC00015130-02; NCGC00024750-01; NCGC00015130-03; NCGC00015130-04; 2-(4,5-Dihydro-1H-imidazol-2-yl)-quinoline
DM4X0SJ	DT	Small molecular drug
DM4X0SJ	PC	2457
DM4X0SJ	MW	197.24
DM4X0SJ	FM	C12H11N3
DM4X0SJ	IC	InChI=1S/C12H11N3/c1-2-4-10-9(3-1)5-6-11(15-10)12-13-7-8-14-12/h1-6H,7-8H2,(H,13,14)
DM4X0SJ	CS	C1CN=C(N1)C2=NC3=CC=CC=C3C=C2
DM4X0SJ	IK	OSUVWJGCKQEMHK-UHFFFAOYSA-N
DM4X0SJ	IU	2-(4,5-dihydro-1H-imidazol-2-yl)quinoline
DM4X0SJ	CA	CAS 187173-05-3
DM4X0SJ	CB	CHEBI:92967
DM4X0SJ	DE	Discovery agent

DM4BFHR	ID	DM4BFHR
DM4BFHR	DN	2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile
DM4BFHR	HS	Investigative
DM4BFHR	SN	(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile
DM4BFHR	DT	Small molecular drug
DM4BFHR	PC	5328755
DM4BFHR	MW	212.2
DM4BFHR	FM	C12H8N2O2
DM4BFHR	IC	InChI=1S/C12H8N2O2/c13-5-7(6-14)8-1-2-10-9(8)3-4-11(15)12(10)16/h3-4,15-16H,1-2H2
DM4BFHR	CS	C1CC(=C(C#N)C#N)C2=C1C(=C(C=C2)O)O
DM4BFHR	IK	QNMCUDUCYPYEQM-UHFFFAOYSA-N
DM4BFHR	IU	2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile
DM4BFHR	DE	Discovery agent

DM1UBGQ	ID	DM1UBGQ
DM1UBGQ	DN	2-(4,6-dimethoxypyrimidin-2-yloxy)-5-hexylphenol
DM1UBGQ	HS	Investigative
DM1UBGQ	SN	CHEMBL258933
DM1UBGQ	DT	Small molecular drug
DM1UBGQ	PC	44450157
DM1UBGQ	MW	332.4
DM1UBGQ	FM	C18H24N2O4
DM1UBGQ	IC	InChI=1S/C18H24N2O4/c1-4-5-6-7-8-13-9-10-15(14(21)11-13)24-18-19-16(22-2)12-17(20-18)23-3/h9-12,21H,4-8H2,1-3H3
DM1UBGQ	CS	CCCCCCC1=CC(=C(C=C1)OC2=NC(=CC(=N2)OC)OC)O
DM1UBGQ	IK	YNAUOGCPBHCMDN-UHFFFAOYSA-N
DM1UBGQ	IU	2-(4,6-dimethoxypyrimidin-2-yl)oxy-5-hexylphenol
DM1UBGQ	DE	Discovery agent

DMUANX1	ID	DMUANX1
DMUANX1	DN	2-(4-amino-2-chlorophenoxy)-5-chlorophenol
DMUANX1	HS	Investigative
DMUANX1	SN	2-(4-AMINO-2-CHLOROPHENOXY)-5-CHLOROPHENOL; CHEMBL383166; TN5; AC1OA9T5
DMUANX1	DT	Small molecular drug
DMUANX1	PC	6852148
DMUANX1	MW	270.11
DMUANX1	FM	C12H9Cl2NO2
DMUANX1	IC	InChI=1S/C12H9Cl2NO2/c13-7-1-3-12(10(16)5-7)17-11-4-2-8(15)6-9(11)14/h1-6,16H,15H2
DMUANX1	CS	C1=CC(=C(C=C1N)Cl)OC2=C(C=C(C=C2)Cl)O
DMUANX1	IK	MCYCMAVHVQGDNE-UHFFFAOYSA-N
DMUANX1	IU	2-(4-amino-2-chlorophenoxy)-5-chlorophenol
DMUANX1	DE	Discovery agent

DMSHPCW	ID	DMSHPCW
DMSHPCW	DN	2-(4-Amino-3'-chloro-biphenyl-3-yl)-propan-2-ol
DMSHPCW	HS	Investigative
DMSHPCW	SN	CHEMBL350283; SCHEMBL6770087; ITEDDYPYHIHWHC-UHFFFAOYSA-N; BDBM50110507; 2-[2-Amino-5-(3-chlorophenyl)phenyl]-2-propanol; (4-amino-3'-chloro-biphenyl-3-yl)-dimethyl-methanol; 2-(4-Amino-3''-chloro-biphenyl-3-yl)-propan-2-ol
DMSHPCW	DT	Small molecular drug
DMSHPCW	PC	15908132
DMSHPCW	MW	261.74
DMSHPCW	FM	C15H16ClNO
DMSHPCW	IC	InChI=1S/C15H16ClNO/c1-15(2,18)13-9-11(6-7-14(13)17)10-4-3-5-12(16)8-10/h3-9,18H,17H2,1-2H3
DMSHPCW	CS	CC(C)(C1=C(C=CC(=C1)C2=CC(=CC=C2)Cl)N)O
DMSHPCW	IK	ITEDDYPYHIHWHC-UHFFFAOYSA-N
DMSHPCW	IU	2-[2-amino-5-(3-chlorophenyl)phenyl]propan-2-ol
DMSHPCW	DE	Discovery agent

DMP0GI8	ID	DMP0GI8
DMP0GI8	DN	2-(4-aminophenoxy)-5-hexylphenol
DMP0GI8	HS	Investigative
DMP0GI8	SN	CHEMBL264175
DMP0GI8	DT	Small molecular drug
DMP0GI8	PC	44450091
DMP0GI8	MW	285.4
DMP0GI8	FM	C18H23NO2
DMP0GI8	IC	InChI=1S/C18H23NO2/c1-2-3-4-5-6-14-7-12-18(17(20)13-14)21-16-10-8-15(19)9-11-16/h7-13,20H,2-6,19H2,1H3
DMP0GI8	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=C(C=C2)N)O
DMP0GI8	IK	ZURCHSRLJXKILX-UHFFFAOYSA-N
DMP0GI8	IU	2-(4-aminophenoxy)-5-hexylphenol
DMP0GI8	DE	Discovery agent

DMGQHBU	ID	DMGQHBU
DMGQHBU	DN	2-(4-Amino-phenyl)-6-methyl-chromen-4-one
DMGQHBU	HS	Investigative
DMGQHBU	SN	CHEMBL132422; 468060-73-3; CTK1D1882; DTXSID00451376; ZINC13491190; AKOS022269882; KB-191927; 4h-1-benzopyran-4-one,2-(4-aminophenyl)-6-methyl-; 4H-1-Benzopyran-4-one, 2-(4-aminophenyl)-6-methyl-
DMGQHBU	DT	Small molecular drug
DMGQHBU	PC	10999496
DMGQHBU	MW	251.28
DMGQHBU	FM	C16H13NO2
DMGQHBU	IC	InChI=1S/C16H13NO2/c1-10-2-7-15-13(8-10)14(18)9-16(19-15)11-3-5-12(17)6-4-11/h2-9H,17H2,1H3
DMGQHBU	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=C(C=C3)N
DMGQHBU	IK	BCMMIAHCWHQZDZ-UHFFFAOYSA-N
DMGQHBU	IU	2-(4-aminophenyl)-6-methylchromen-4-one
DMGQHBU	CA	CAS 468060-73-3
DMGQHBU	DE	Discovery agent

DM7LBEG	ID	DM7LBEG
DM7LBEG	DN	2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one
DM7LBEG	HS	Investigative
DM7LBEG	DT	Small molecular drug
DM7LBEG	PC	135471356
DM7LBEG	MW	253.26
DM7LBEG	FM	C14H11N3O2
DM7LBEG	IC	InChI=1S/C14H11N3O2/c15-9-6-4-8(5-7-9)13-16-12-10(14(19)17-13)2-1-3-11(12)18/h1-7,18H,15H2,(H,16,17,19)
DM7LBEG	CS	C1=CC2=C(C(=C1)O)N=C(NC2=O)C3=CC=C(C=C3)N
DM7LBEG	IK	FNYTYXJFOSRUTI-UHFFFAOYSA-N
DM7LBEG	IU	2-(4-aminophenyl)-8-hydroxy-3H-quinazolin-4-one
DM7LBEG	DE	Discovery agent

DMJRDAQ	ID	DMJRDAQ
DMJRDAQ	DN	2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one
DMJRDAQ	HS	Investigative
DMJRDAQ	DT	Small molecular drug
DMJRDAQ	PC	135463623
DMJRDAQ	MW	251.28
DMJRDAQ	FM	C15H13N3O
DMJRDAQ	IC	InChI=1S/C15H13N3O/c1-9-3-2-4-12-13(9)17-14(18-15(12)19)10-5-7-11(16)8-6-10/h2-8H,16H2,1H3,(H,17,18,19)
DMJRDAQ	CS	CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=C(C=C3)N
DMJRDAQ	IK	RFMIZKCQNUDSTO-UHFFFAOYSA-N
DMJRDAQ	IU	2-(4-aminophenyl)-8-methyl-3H-quinazolin-4-one
DMJRDAQ	DE	Discovery agent

DM2P9L5	ID	DM2P9L5
DM2P9L5	DN	2-(4-Amino-phenyl)-benzo[h]chromen-4-one
DM2P9L5	HS	Investigative
DM2P9L5	SN	CHEMBL179276; 2-(4-Amino-phenyl)-benzo[h]chromen-4-one; BDBM50159660
DM2P9L5	DT	Small molecular drug
DM2P9L5	PC	11471732
DM2P9L5	MW	287.3
DM2P9L5	FM	C19H13NO2
DM2P9L5	IC	InChI=1S/C19H13NO2/c20-14-8-5-13(6-9-14)18-11-17(21)16-10-7-12-3-1-2-4-15(12)19(16)22-18/h1-11H,20H2
DM2P9L5	CS	C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CC=C(C=C4)N
DM2P9L5	IK	JXHKSKYNJHBJDZ-UHFFFAOYSA-N
DM2P9L5	IU	2-(4-aminophenyl)benzo[h]chromen-4-one
DM2P9L5	DE	Discovery agent

DMMU2BZ	ID	DMMU2BZ
DMMU2BZ	DN	2-(4-aminophenylsulfonamido)acetic acid
DMMU2BZ	HS	Investigative
DMMU2BZ	SN	5616-30-8; (4-Amino-benzenesulfonylamino)-acetic acid; 2-(4-aminophenylsulfonamido)acetic acid; 2-[(4-aminophenyl)sulfonylamino]acetic acid; CHEMBL285053; (4-aminophenylsulfonylamino)acetic acid; Glycine, N-[(4-aminophenyl)sulfonyl]-; 2-(4-aminobenzenesulfonylamino)ethanoic acid; Sulfanilamidoacetic acid; 2-(4-aminophenylsulfonamido)aceticacid; AC1L92ZE; SCHEMBL1228868; N-4-aminobenzenesulfonyl glycine; CTK1F5176; DTXSID30328582; ((4-aminophenyl)sulfonyl)glycine; BPJUMYMTQYMSFZ-UHFFFAOYSA-N; ZINC1670307
DMMU2BZ	DT	Small molecular drug
DMMU2BZ	PC	412201
DMMU2BZ	MW	230.24
DMMU2BZ	FM	C8H10N2O4S
DMMU2BZ	IC	InChI=1S/C8H10N2O4S/c9-6-1-3-7(4-2-6)15(13,14)10-5-8(11)12/h1-4,10H,5,9H2,(H,11,12)
DMMU2BZ	CS	C1=CC(=CC=C1N)S(=O)(=O)NCC(=O)O
DMMU2BZ	IK	BPJUMYMTQYMSFZ-UHFFFAOYSA-N
DMMU2BZ	IU	2-[(4-aminophenyl)sulfonylamino]acetic acid
DMMU2BZ	CA	CAS 5616-30-8
DMMU2BZ	DE	Discovery agent

DM2JG49	ID	DM2JG49
DM2JG49	DN	2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one
DM2JG49	HS	Investigative
DM2JG49	DT	Small molecular drug
DM2JG49	PC	135547083
DM2JG49	MW	293.28
DM2JG49	FM	C15H11N5O2
DM2JG49	IC	InChI=1S/C15H11N5O2/c1-22-12-4-2-3-11-13(12)17-14(18-15(11)21)9-5-7-10(8-6-9)19-20-16/h2-8H,1H3,(H,17,18,21)
DM2JG49	CS	COC1=CC=CC2=C1N=C(NC2=O)C3=CC=C(C=C3)N=[N+]=[N-]
DM2JG49	IK	BLVUCZJFMHXSJA-UHFFFAOYSA-N
DM2JG49	IU	2-(4-azidophenyl)-8-methoxy-3H-quinazolin-4-one
DM2JG49	DE	Discovery agent

DMJA5Y4	ID	DMJA5Y4
DMJA5Y4	DN	2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide
DMJA5Y4	HS	Investigative
DMJA5Y4	SN	CHEMBL568131; 2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide
DMJA5Y4	DT	Small molecular drug
DMJA5Y4	PC	45487374
DMJA5Y4	MW	316.4
DMJA5Y4	FM	C15H16N4O2S
DMJA5Y4	IC	InChI=1S/C15H16N4O2S/c16-13(20)12-10-17-15(22-12)19-8-6-18(7-9-19)14(21)11-4-2-1-3-5-11/h1-5,10H,6-9H2,(H2,16,20)
DMJA5Y4	CS	C1CN(CCN1C2=NC=C(S2)C(=O)N)C(=O)C3=CC=CC=C3
DMJA5Y4	IK	NYHCFTYRFCRXPO-UHFFFAOYSA-N
DMJA5Y4	IU	2-(4-benzoylpiperazin-1-yl)-1,3-thiazole-5-carboxamide
DMJA5Y4	DE	Discovery agent

DMGMZV9	ID	DMGMZV9
DMGMZV9	DN	2-(4-benzoylpiperidine-1-carbonyl)benzoic acid
DMGMZV9	HS	Investigative
DMGMZV9	SN	CHEMBL571233; 2-(4-benzoylpiperidine-1-carbonyl)benzoic acid; ASN 06584077; AC1LSF7A; HMS1695L15; ZINC1336805; BDBM50296427; AKOS000753095; SR-01000350200; 2-(4-Benzoyl-piperidine-1-carbonyl)-benzoic acid
DMGMZV9	DT	Small molecular drug
DMGMZV9	PC	1438175
DMGMZV9	MW	337.4
DMGMZV9	FM	C20H19NO4
DMGMZV9	IC	InChI=1S/C20H19NO4/c22-18(14-6-2-1-3-7-14)15-10-12-21(13-11-15)19(23)16-8-4-5-9-17(16)20(24)25/h1-9,15H,10-13H2,(H,24,25)
DMGMZV9	CS	C1CN(CCC1C(=O)C2=CC=CC=C2)C(=O)C3=CC=CC=C3C(=O)O
DMGMZV9	IK	JLSQZICREOKKAN-UHFFFAOYSA-N
DMGMZV9	IU	2-(4-benzoylpiperidine-1-carbonyl)benzoic acid
DMGMZV9	DE	Discovery agent

DM6R4MG	ID	DM6R4MG
DM6R4MG	DN	2-(4-benzylphenoxy)ethanamine
DM6R4MG	HS	Investigative
DM6R4MG	SN	2-(4-benzylphenoxy)ethanamine; CHEMBL163807; 2-(4-benzylphenoxy)ethylamine; SCHEMBL7138354; MJTXDDKAEQAMNA-UHFFFAOYSA-N; 2-(4-Benzyl-phenoxy)-ethylamine; BDBM50085290
DM6R4MG	DT	Small molecular drug
DM6R4MG	PC	10609349
DM6R4MG	MW	227.3
DM6R4MG	FM	C15H17NO
DM6R4MG	IC	InChI=1S/C15H17NO/c16-10-11-17-15-8-6-14(7-9-15)12-13-4-2-1-3-5-13/h1-9H,10-12,16H2
DM6R4MG	CS	C1=CC=C(C=C1)CC2=CC=C(C=C2)OCCN
DM6R4MG	IK	MJTXDDKAEQAMNA-UHFFFAOYSA-N
DM6R4MG	IU	2-(4-benzylphenoxy)ethanamine
DM6R4MG	DE	Discovery agent

DM1V7EF	ID	DM1V7EF
DM1V7EF	DN	2-(4-Benzyl-piperazin-1-yl)-benzothiazole
DM1V7EF	HS	Investigative
DM1V7EF	SN	2-(4-benzylpiperazin-1-yl)-1,3-benzothiazole; CHEMBL282234; 2-(4-benzylpiperazino)-1,3-benzothiazole; 35463-75-3; AC1LSALZ; 2-(4-Benzyl-piperazin-1-yl)-benzothiazole; Oprea1_030694; MLS001166194; SCHEMBL7760900; KS-00003DHQ; MolPort-002-878-239; HMS2852D05; ZINC20405012; BDBM50041381; AKOS005101332; MCULE-9582396226; 7P-339S; 1-(2-Benzothiazolyl)-4-benzylpiperazine; SMR000550026; 2-(4-benzylpiperazin-1-yl)benzo[d]thiazole; Z86230191
DM1V7EF	DT	Small molecular drug
DM1V7EF	PC	1484933
DM1V7EF	MW	309.4
DM1V7EF	FM	C18H19N3S
DM1V7EF	IC	InChI=1S/C18H19N3S/c1-2-6-15(7-3-1)14-20-10-12-21(13-11-20)18-19-16-8-4-5-9-17(16)22-18/h1-9H,10-14H2
DM1V7EF	CS	C1CN(CCN1CC2=CC=CC=C2)C3=NC4=CC=CC=C4S3
DM1V7EF	IK	SNRZSONRAFJJSB-UHFFFAOYSA-N
DM1V7EF	IU	2-(4-benzylpiperazin-1-yl)-1,3-benzothiazole
DM1V7EF	CA	CAS 35463-75-3
DM1V7EF	DE	Discovery agent

DMFGCS1	ID	DMFGCS1
DMFGCS1	DN	2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol
DMFGCS1	HS	Investigative
DMFGCS1	SN	CHEMBL220775; 2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol
DMFGCS1	DT	Small molecular drug
DMFGCS1	PC	16110268
DMFGCS1	MW	320.4
DMFGCS1	FM	C21H24N2O
DMFGCS1	IC	InChI=1S/C21H24N2O/c24-20-7-6-18-13-19(22-21(18)14-20)15-23-10-8-17(9-11-23)12-16-4-2-1-3-5-16/h1-7,13-14,17,22,24H,8-12,15H2
DMFGCS1	CS	C1CN(CCC1CC2=CC=CC=C2)CC3=CC4=C(N3)C=C(C=C4)O
DMFGCS1	IK	XCBFDMFJYYJHAL-UHFFFAOYSA-N
DMFGCS1	IU	2-[(4-benzylpiperidin-1-yl)methyl]-1H-indol-6-ol
DMFGCS1	CA	CAS 933474-38-5
DMFGCS1	DE	Discovery agent

DMID9YA	ID	DMID9YA
DMID9YA	DN	2-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMID9YA	HS	Investigative
DMID9YA	SN	CHEMBL179397; 2-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMID9YA	DT	Small molecular drug
DMID9YA	PC	11245709
DMID9YA	MW	335.4
DMID9YA	FM	C22H25NO2
DMID9YA	IC	InChI=1S/C22H25NO2/c24-21-15-19(25-22-9-5-4-8-20(21)22)16-23-12-10-18(11-13-23)14-17-6-2-1-3-7-17/h1-9,18-19H,10-16H2
DMID9YA	CS	C1CN(CCC1CC2=CC=CC=C2)CC3CC(=O)C4=CC=CC=C4O3
DMID9YA	IK	SVALPNADURCFPN-UHFFFAOYSA-N
DMID9YA	IU	2-[(4-benzylpiperidin-1-yl)methyl]-2,3-dihydrochromen-4-one
DMID9YA	DE	Discovery agent

DM7QK5C	ID	DM7QK5C
DM7QK5C	DN	2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid
DM7QK5C	HS	Investigative
DM7QK5C	SN	CHEMBL214655; 2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid; 2-[4-bromo-2-(hydroxymethyl)phenoxy]acetic acid; AC1LHWL0; AH-487/41804565; SCHEMBL3201339; MolPort-002-091-532; ZINC470785; HMS1590C02; BDBM50200250; MCULE-6729250214; SR-01000266540
DM7QK5C	DT	Small molecular drug
DM7QK5C	PC	894151
DM7QK5C	MW	261.07
DM7QK5C	FM	C9H9BrO4
DM7QK5C	IC	InChI=1S/C9H9BrO4/c10-7-1-2-8(6(3-7)4-11)14-5-9(12)13/h1-3,11H,4-5H2,(H,12,13)
DM7QK5C	CS	C1=CC(=C(C=C1Br)CO)OCC(=O)O
DM7QK5C	IK	QMNTWAAGYOSTJK-UHFFFAOYSA-N
DM7QK5C	IU	2-[4-bromo-2-(hydroxymethyl)phenoxy]acetic acid
DM7QK5C	DE	Discovery agent

DM6I1NQ	ID	DM6I1NQ
DM6I1NQ	DN	2-(4-bromo-2-cyclohexylphenoxy)acetic acid
DM6I1NQ	HS	Investigative
DM6I1NQ	SN	CHEMBL246311; (4-bromo-2-cyclohexylphenoxy)acetic acid; 2-(4-bromo-2-cyclohexylphenoxy)acetic acid; SCHEMBL4882946; BDBM50213922
DM6I1NQ	DT	Small molecular drug
DM6I1NQ	PC	11500603
DM6I1NQ	MW	313.19
DM6I1NQ	FM	C14H17BrO3
DM6I1NQ	IC	InChI=1S/C14H17BrO3/c15-11-6-7-13(18-9-14(16)17)12(8-11)10-4-2-1-3-5-10/h6-8,10H,1-5,9H2,(H,16,17)
DM6I1NQ	CS	C1CCC(CC1)C2=C(C=CC(=C2)Br)OCC(=O)O
DM6I1NQ	IK	ZWQTTYNQLIMKNE-UHFFFAOYSA-N
DM6I1NQ	IU	2-(4-bromo-2-cyclohexylphenoxy)acetic acid
DM6I1NQ	DE	Discovery agent

DMQVUZP	ID	DMQVUZP
DMQVUZP	DN	2-(4-bromo-2-formylphenoxy)acetic acid
DMQVUZP	HS	Investigative
DMQVUZP	SN	2-(4-bromo-2-formylphenoxy)acetic acid; 24589-89-7; (4-bromo-2-formylphenoxy)acetic acid; CHEMBL385009; AC1LJ5IQ; bromoformylphenoxyaceticacid; Oprea1_723931; AC1Q764A; SCHEMBL2879909; KS-00000LHU; CTK1A1564; DTXSID80359528; MolPort-000-886-040; KXRYNWDCFUKVNN-UHFFFAOYSA-N; ZINC586295; SP656; 4-bromo-2-formylphenoxyacetic acid; ALBB-007850; 4-bromo-2-formylphenoxy acetic acid; 2-formyl-4-bromophenoxy acetic acid; STK201324; SBB020100; BDBM50200251; BBL023190; 8265AD; AKOS000113320; MCULE-3263948503; AC-0818; RP14657; ACN-052850
DMQVUZP	DT	Small molecular drug
DMQVUZP	PC	968879
DMQVUZP	MW	259.05
DMQVUZP	FM	C9H7BrO4
DMQVUZP	IC	InChI=1S/C9H7BrO4/c10-7-1-2-8(6(3-7)4-11)14-5-9(12)13/h1-4H,5H2,(H,12,13)
DMQVUZP	CS	C1=CC(=C(C=C1Br)C=O)OCC(=O)O
DMQVUZP	IK	KXRYNWDCFUKVNN-UHFFFAOYSA-N
DMQVUZP	IU	2-(4-bromo-2-formylphenoxy)acetic acid
DMQVUZP	CA	CAS 24589-89-7
DMQVUZP	DE	Discovery agent

DM79JVK	ID	DM79JVK
DM79JVK	DN	2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine
DM79JVK	HS	Investigative
DM79JVK	SN	CHEMBL60146; 99632-51-6; 2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine; Benzeneethanamine, 4-bromo-2-methoxy-alpha-methyl-; BDBM50005262; AKOS023456739
DM79JVK	DT	Small molecular drug
DM79JVK	PC	13547422
DM79JVK	MW	244.13
DM79JVK	FM	C10H14BrNO
DM79JVK	IC	InChI=1S/C10H14BrNO/c1-7(12)5-8-3-4-9(11)6-10(8)13-2/h3-4,6-7H,5,12H2,1-2H3
DM79JVK	CS	CC(CC1=C(C=C(C=C1)Br)OC)N
DM79JVK	IK	YWONMRKCBJPFCM-UHFFFAOYSA-N
DM79JVK	IU	1-(4-bromo-2-methoxyphenyl)propan-2-amine
DM79JVK	DE	Discovery agent

DMXAQZ0	ID	DMXAQZ0
DMXAQZ0	DN	2-(4-bromo-2-tert-butylphenoxy)acetic acid
DMXAQZ0	HS	Investigative
DMXAQZ0	SN	2-[4-BROMO-2-(TERT-BUTYL)PHENOXY]ACETIC ACID; 425372-86-7; 2-(4-bromo-2-tert-butylphenoxy)acetic acid; (4-bromo-2-tert-butylphenoxy)acetic acid; CHEMBL386348; 2-(4-bromo-2-(tert-butyl)phenoxy)acetic acid; 2-[2-(tert-butyl)-4-bromophenoxy]acetic acid; CBMicro_046462; AC1LEXUE; Oprea1_645612; Oprea1_576852; ARONIS011292; SCHEMBL12478128; CTK7J5471; BBB/316; MolPort-000-651-933; GCBNGPDJYUPSBS-UHFFFAOYSA-N; ZINC120478; KS-000042GS; ZX-AS003555; ZX-AL002245; SBB043460; STK948100; BDBM50200269; 3158AE; AKOS000273807; MCULE-9342897788
DMXAQZ0	DT	Small molecular drug
DMXAQZ0	PC	719761
DMXAQZ0	MW	287.15
DMXAQZ0	FM	C12H15BrO3
DMXAQZ0	IC	InChI=1S/C12H15BrO3/c1-12(2,3)9-6-8(13)4-5-10(9)16-7-11(14)15/h4-6H,7H2,1-3H3,(H,14,15)
DMXAQZ0	CS	CC(C)(C)C1=C(C=CC(=C1)Br)OCC(=O)O
DMXAQZ0	IK	GCBNGPDJYUPSBS-UHFFFAOYSA-N
DMXAQZ0	IU	2-(4-bromo-2-tert-butylphenoxy)acetic acid
DMXAQZ0	DE	Discovery agent

DMY8GZP	ID	DMY8GZP
DMY8GZP	DN	2-(4-Bromo-3-phenoxy-benzoylamino)-benzoic acid
DMY8GZP	HS	Investigative
DMY8GZP	SN	CHEMBL178585; BDBM23581; 2-(4-bromo-3-phenoxybenzoylamino)benzoic acid; 2-[(4-bromo-3-phenoxybenzene)amido]benzoic acid; (3-Phenoxybenzoylamino)benzoic acid deriv., 23b
DMY8GZP	DT	Small molecular drug
DMY8GZP	PC	11441298
DMY8GZP	MW	412.2
DMY8GZP	FM	C20H14BrNO4
DMY8GZP	IC	InChI=1S/C20H14BrNO4/c21-16-11-10-13(12-18(16)26-14-6-2-1-3-7-14)19(23)22-17-9-5-4-8-15(17)20(24)25/h1-12H,(H,22,23)(H,24,25)
DMY8GZP	CS	C1=CC=C(C=C1)OC2=C(C=CC(=C2)C(=O)NC3=CC=CC=C3C(=O)O)Br
DMY8GZP	IK	XOENRMSDPFHAEO-UHFFFAOYSA-N
DMY8GZP	IU	2-[(4-bromo-3-phenoxybenzoyl)amino]benzoic acid
DMY8GZP	DE	Discovery agent

DMB49UP	ID	DMB49UP
DMB49UP	DN	2-(4-Bromo-phenyl)-1-methyl-ethylamine
DMB49UP	HS	Investigative
DMB49UP	SN	1-(4-bromophenyl)propan-2-amine; 13235-83-1; 4-bromoamphetamine; Para-Bromoamphetamine; BRN 3240553; Benzeneethanamine, 4-bromo-alpha-methyl-, (+-)-; 2-(4-Bromo-phenyl)-1-methyl-ethylamine; CHEMBL61355; (+-)-4-Bromo-alpha-methylbenzeneethanamine; 18455-37-3; 1-(4-Bromobenzyl)ethylamine; 4-Ba; AC1L4F4G; 3-12-00-02675 (Beilstein Handbook Reference); SCHEMBL164716; CTK0I1684; SMNXUMMCCOZPPN-UHFFFAOYSA-N; 1-(4-bromophenyl)propane-2-amine; BDBM50005252; AKOS022180693; AKOS000160383; 1-Methyl-2-(4-bromophenyl)ethanamine
DMB49UP	DT	Small molecular drug
DMB49UP	PC	205668
DMB49UP	MW	214.1
DMB49UP	FM	C9H12BrN
DMB49UP	IC	InChI=1S/C9H12BrN/c1-7(11)6-8-2-4-9(10)5-3-8/h2-5,7H,6,11H2,1H3
DMB49UP	CS	CC(CC1=CC=C(C=C1)Br)N
DMB49UP	IK	SMNXUMMCCOZPPN-UHFFFAOYSA-N
DMB49UP	IU	1-(4-bromophenyl)propan-2-amine
DMB49UP	CA	CAS 13235-83-1
DMB49UP	DE	Discovery agent

DMY5STK	ID	DMY5STK
DMY5STK	DN	2-(4-bromophenylsulfonamido)-N-hydroxyacetamide
DMY5STK	HS	Investigative
DMY5STK	SN	2-(4-bromophenylsulfonamido)-N-hydroxyacetamide; CHEMBL1090283; 1218922-39-4; SCHEMBL7413923
DMY5STK	DT	Small molecular drug
DMY5STK	PC	22004198
DMY5STK	MW	309.14
DMY5STK	FM	C8H9BrN2O4S
DMY5STK	IC	InChI=1S/C8H9BrN2O4S/c9-6-1-3-7(4-2-6)16(14,15)10-5-8(12)11-13/h1-4,10,13H,5H2,(H,11,12)
DMY5STK	CS	C1=CC(=CC=C1S(=O)(=O)NCC(=O)NO)Br
DMY5STK	IK	AKOBMMAQXVKOJR-UHFFFAOYSA-N
DMY5STK	IU	2-[(4-bromophenyl)sulfonylamino]-N-hydroxyacetamide
DMY5STK	DE	Discovery agent

DMG32HQ	ID	DMG32HQ
DMG32HQ	DN	2-(4-Butoxy-phenoxy)-N-hydroxy-acetamide
DMG32HQ	HS	Investigative
DMG32HQ	SN	CHEMBL175410; 2-(4-Butoxy-phenoxy)-N-hydroxy-acetamide; Acetamide, 2-(4-butoxyphenoxy)-N-hydroxy-; BDBM50015105
DMG32HQ	DT	Small molecular drug
DMG32HQ	PC	44387190
DMG32HQ	MW	239.27
DMG32HQ	FM	C12H17NO4
DMG32HQ	IC	InChI=1S/C12H17NO4/c1-2-3-8-16-10-4-6-11(7-5-10)17-9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
DMG32HQ	CS	CCCCOC1=CC=C(C=C1)OCC(=O)NO
DMG32HQ	IK	UJAGRYRJVJSNJC-UHFFFAOYSA-N
DMG32HQ	IU	2-(4-butoxyphenoxy)-N-hydroxyacetamide
DMG32HQ	DE	Discovery agent

DMEKNZW	ID	DMEKNZW
DMEKNZW	DN	2-(4-Butoxy-phenoxy)-N-hydroxy-N-methyl-acetamide
DMEKNZW	HS	Investigative
DMEKNZW	SN	CHEMBL178065; 2-(4-Butoxy-phenoxy)-N-hydroxy-N-methyl-acetamide
DMEKNZW	DT	Small molecular drug
DMEKNZW	PC	44386556
DMEKNZW	MW	253.29
DMEKNZW	FM	C13H19NO4
DMEKNZW	IC	InChI=1S/C13H19NO4/c1-3-4-9-17-11-5-7-12(8-6-11)18-10-13(15)14(2)16/h5-8,16H,3-4,9-10H2,1-2H3
DMEKNZW	CS	CCCCOC1=CC=C(C=C1)OCC(=O)N(C)O
DMEKNZW	IK	QJXRKNPTYVKBQZ-UHFFFAOYSA-N
DMEKNZW	IU	2-(4-butoxyphenoxy)-N-hydroxy-N-methylacetamide
DMEKNZW	DE	Discovery agent

DMO5IM0	ID	DMO5IM0
DMO5IM0	DN	2-(4-Butoxy-phenoxy)-N-hydroxy-propionamide
DMO5IM0	HS	Investigative
DMO5IM0	SN	CHEMBL177422; 2-(4-Butoxy-phenoxy)-N-hydroxy-propionamide
DMO5IM0	DT	Small molecular drug
DMO5IM0	PC	44386557
DMO5IM0	MW	253.29
DMO5IM0	FM	C13H19NO4
DMO5IM0	IC	InChI=1S/C13H19NO4/c1-3-4-9-17-11-5-7-12(8-6-11)18-10(2)13(15)14-16/h5-8,10,16H,3-4,9H2,1-2H3,(H,14,15)
DMO5IM0	CS	CCCCOC1=CC=C(C=C1)OC(C)C(=O)NO
DMO5IM0	IK	PBEZWGMLOHXFDA-UHFFFAOYSA-N
DMO5IM0	IU	2-(4-butoxyphenoxy)-N-hydroxypropanamide
DMO5IM0	DE	Discovery agent

DMP7CF8	ID	DMP7CF8
DMP7CF8	DN	2-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acetamide
DMP7CF8	HS	Investigative
DMP7CF8	SN	CHEMBL368604; 2-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acetamide; KUC110092N; ZINC28096255; BDBM50015186; KSC-229-6-1
DMP7CF8	DT	Small molecular drug
DMP7CF8	PC	44386193
DMP7CF8	MW	237.29
DMP7CF8	FM	C13H19NO3
DMP7CF8	IC	InChI=1S/C13H19NO3/c1-3-4-9-17-12-7-5-11(6-8-12)10-13(15)14(2)16/h5-8,16H,3-4,9-10H2,1-2H3
DMP7CF8	CS	CCCCOC1=CC=C(C=C1)CC(=O)N(C)O
DMP7CF8	IK	JGCLGKCTJPLHOR-UHFFFAOYSA-N
DMP7CF8	IU	2-(4-butoxyphenyl)-N-hydroxy-N-methylacetamide
DMP7CF8	DE	Discovery agent

DM2XFGJ	ID	DM2XFGJ
DM2XFGJ	DN	2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
DM2XFGJ	HS	Investigative
DM2XFGJ	SN	2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE; DB08192; 5-isopropyl-2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]-1,3-thiazole-4-carboxylic acid; 5-(1-methylethyl)-2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]-1,3-thiazole-4-carboxylic acid
DM2XFGJ	DT	Small molecular drug
DM2XFGJ	PC	46937131
DM2XFGJ	MW	302.4
DM2XFGJ	FM	C16H18N2O2S
DM2XFGJ	IC	InChI=1S/C16H18N2O2S/c1-9(2)14-13(16(19)20)18-15(21-14)12-7-10-5-3-4-6-11(10)8-17-12/h3-6,9,12,17H,7-8H2,1-2H3,(H,19,20)/t12-/m0/s1
DM2XFGJ	CS	CC(C)C1=C(N=C(S1)[C@@H]2CC3=CC=CC=C3CN2)C(=O)O
DM2XFGJ	IK	HCUGCUQZFBURHR-LBPRGKRZSA-N
DM2XFGJ	IU	5-propan-2-yl-2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]-1,3-thiazole-4-carboxylic acid
DM2XFGJ	DE	Discovery agent

DM7BHYS	ID	DM7BHYS
DM7BHYS	DN	2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM7BHYS	HS	Investigative
DM7BHYS	SN	CHEMBL426297; 2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM7BHYS	DT	Small molecular drug
DM7BHYS	PC	11500124
DM7BHYS	MW	280.71
DM7BHYS	FM	C15H9ClN4
DM7BHYS	IC	InChI=1S/C15H9ClN4/c16-9-4-3-7-12-14(9)20-15(19-12)13-8-17-10-5-1-2-6-11(10)18-13/h1-8H,(H,19,20)
DM7BHYS	CS	C1=CC=C2C(=C1)N=CC(=N2)C3=NC4=C(N3)C=CC=C4Cl
DM7BHYS	IK	KBVMQLRZERGALQ-UHFFFAOYSA-N
DM7BHYS	IU	2-(4-chloro-1H-benzimidazol-2-yl)quinoxaline
DM7BHYS	DE	Discovery agent

DM15YM7	ID	DM15YM7
DM15YM7	DN	2-(4-chloro-2-cycloheptylphenoxy)acetic acid
DM15YM7	HS	Investigative
DM15YM7	SN	CHEMBL398126; 2-(4-chloro-2-cycloheptylphenoxy)acetic acid; SCHEMBL4875122; JEPDINCGXLHLDF-UHFFFAOYSA-N; BDBM50213919; (4-Chloro-2-cycloheptylphenoxy)acetic acid
DM15YM7	DT	Small molecular drug
DM15YM7	PC	11514705
DM15YM7	MW	282.76
DM15YM7	FM	C15H19ClO3
DM15YM7	IC	InChI=1S/C15H19ClO3/c16-12-7-8-14(19-10-15(17)18)13(9-12)11-5-3-1-2-4-6-11/h7-9,11H,1-6,10H2,(H,17,18)
DM15YM7	CS	C1CCCC(CC1)C2=C(C=CC(=C2)Cl)OCC(=O)O
DM15YM7	IK	JEPDINCGXLHLDF-UHFFFAOYSA-N
DM15YM7	IU	2-(4-chloro-2-cycloheptylphenoxy)acetic acid
DM15YM7	DE	Discovery agent

DMGYZ8D	ID	DMGYZ8D
DMGYZ8D	DN	2-(4-chloro-2-cyclohexylphenoxy)acetic acid
DMGYZ8D	HS	Investigative
DMGYZ8D	SN	2-(4-chloro-2-cyclohexylphenoxy)acetic acid; (4-chloro-2-cyclohexylphenoxy)acetic acid; 19774-97-1; MLS002639096; CHEMBL245908; NSC26127; AC1L5KDG; AC1Q3LV0; SCHEMBL4888054; CTK7J5481; DTXSID10282496; MolPort-004-296-406; HMS3089F12; ZINC1628222; AC1Q7647; BDBM50213909; NSC-26127; AKOS000132678; NE44164; MCULE-7136939287; AS-9826; 4-chloro-2-cyclohexylphenoxy-acetic acid; SMR001548547
DMGYZ8D	DT	Small molecular drug
DMGYZ8D	PC	230826
DMGYZ8D	MW	268.73
DMGYZ8D	FM	C14H17ClO3
DMGYZ8D	IC	InChI=1S/C14H17ClO3/c15-11-6-7-13(18-9-14(16)17)12(8-11)10-4-2-1-3-5-10/h6-8,10H,1-5,9H2,(H,16,17)
DMGYZ8D	CS	C1CCC(CC1)C2=C(C=CC(=C2)Cl)OCC(=O)O
DMGYZ8D	IK	OGVODSDQXYUSDP-UHFFFAOYSA-N
DMGYZ8D	IU	2-(4-chloro-2-cyclohexylphenoxy)acetic acid
DMGYZ8D	CA	CAS 19774-97-1
DMGYZ8D	DE	Discovery agent

DMA6KQU	ID	DMA6KQU
DMA6KQU	DN	2-(4-chloro-2-cyclopentylphenoxy)acetic acid
DMA6KQU	HS	Investigative
DMA6KQU	SN	CHEMBL397842; 2-(4-chloro-2-cyclopentylphenoxy)acetic acid; SCHEMBL4879219
DMA6KQU	DT	Small molecular drug
DMA6KQU	PC	44441193
DMA6KQU	MW	254.71
DMA6KQU	FM	C13H15ClO3
DMA6KQU	IC	InChI=1S/C13H15ClO3/c14-10-5-6-12(17-8-13(15)16)11(7-10)9-3-1-2-4-9/h5-7,9H,1-4,8H2,(H,15,16)
DMA6KQU	CS	C1CCC(C1)C2=C(C=CC(=C2)Cl)OCC(=O)O
DMA6KQU	IK	GOFMJZFPLZWDOU-UHFFFAOYSA-N
DMA6KQU	IU	2-(4-chloro-2-cyclopentylphenoxy)acetic acid
DMA6KQU	DE	Discovery agent

DMBHFIM	ID	DMBHFIM
DMBHFIM	DN	2-(4-chloro-2-hydroxyphenoxy)benzenaminium
DMBHFIM	HS	Investigative
DMBHFIM	SN	2-(2-aminophenoxy)-5-chlorophenol; CHEMBL206178; 832734-14-2; 2-(4-chloro-2-hydroxyphenoxy)benzenaminium; CTK3D3158; DTXSID60658783; BDBM50182380; Phenol, 2-(2-aminophenoxy)-5-chloro-
DMBHFIM	DT	Small molecular drug
DMBHFIM	PC	44410251
DMBHFIM	MW	235.66
DMBHFIM	FM	C12H10ClNO2
DMBHFIM	IC	InChI=1S/C12H10ClNO2/c13-8-5-6-12(10(15)7-8)16-11-4-2-1-3-9(11)14/h1-7,15H,14H2
DMBHFIM	CS	C1=CC=C(C(=C1)N)OC2=C(C=C(C=C2)Cl)O
DMBHFIM	IK	HJXYQHRZHJFAGC-UHFFFAOYSA-N
DMBHFIM	IU	2-(2-aminophenoxy)-5-chlorophenol
DMBHFIM	CA	CAS 832734-14-2
DMBHFIM	DE	Discovery agent

DMOH2YC	ID	DMOH2YC
DMOH2YC	DN	2-(4-Chlorobenzylidene)cyclopentanone
DMOH2YC	HS	Investigative
DMOH2YC	SN	CHEMBL562352; 2-(4-Chlorobenzylidene)cyclopentanone; E-2-(4-chlorobenzylidene)cyclopentanone; BDBM50293435; AKOS027461656; 134791-44-9; (E)-2-(4-Chlorobenzylidene)cyclopentanone
DMOH2YC	DT	Small molecular drug
DMOH2YC	PC	11009103
DMOH2YC	MW	206.67
DMOH2YC	FM	C12H11ClO
DMOH2YC	IC	InChI=1S/C12H11ClO/c13-11-6-4-9(5-7-11)8-10-2-1-3-12(10)14/h4-8H,1-3H2/b10-8+
DMOH2YC	CS	C1C/C(=C\\C2=CC=C(C=C2)Cl)/C(=O)C1
DMOH2YC	IK	WUMOJUUCPXEEQL-CSKARUKUSA-N
DMOH2YC	IU	(2E)-2-[(4-chlorophenyl)methylidene]cyclopentan-1-one
DMOH2YC	DE	Discovery agent

DMFE93N	ID	DMFE93N
DMFE93N	DN	2-(4-chlorobenzylidene)cyclopentyl ethyl ether
DMFE93N	HS	Investigative
DMFE93N	SN	CHEMBL538612; 2-(4-chlorobenzylidene)cyclopentyl ethyl ether
DMFE93N	DT	Small molecular drug
DMFE93N	PC	44126813
DMFE93N	MW	236.73
DMFE93N	FM	C14H17ClO
DMFE93N	IC	InChI=1S/C14H17ClO/c1-2-16-14-5-3-4-12(14)10-11-6-8-13(15)9-7-11/h6-10,14H,2-5H2,1H3/b12-10+
DMFE93N	CS	CCOC\\1CCC/C1=C\\C2=CC=C(C=C2)Cl
DMFE93N	IK	VORGMCXCJIDOMV-ZRDIBKRKSA-N
DMFE93N	IU	1-chloro-4-[(E)-(2-ethoxycyclopentylidene)methyl]benzene
DMFE93N	DE	Discovery agent

DMTW9B7	ID	DMTW9B7
DMTW9B7	DN	2-(4-chlorobenzylidene)cyclopentylmethyl ether
DMTW9B7	HS	Investigative
DMTW9B7	SN	CHEMBL540746; 2-(4-chlorobenzylidene)cyclopentylmethyl ether
DMTW9B7	DT	Small molecular drug
DMTW9B7	PC	44126812
DMTW9B7	MW	222.71
DMTW9B7	FM	C13H15ClO
DMTW9B7	IC	InChI=1S/C13H15ClO/c1-15-13-4-2-3-11(13)9-10-5-7-12(14)8-6-10/h5-9,13H,2-4H2,1H3/b11-9+
DMTW9B7	CS	COC\\1CCC/C1=C\\C2=CC=C(C=C2)Cl
DMTW9B7	IK	HTHFNFRVDYWDQC-PKNBQFBNSA-N
DMTW9B7	IU	1-chloro-4-[(E)-(2-methoxycyclopentylidene)methyl]benzene
DMTW9B7	DE	Discovery agent

DM1JKWL	ID	DM1JKWL
DM1JKWL	DN	2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide
DM1JKWL	HS	Investigative
DM1JKWL	SN	CHEMBL227566; 2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide
DM1JKWL	DT	Small molecular drug
DM1JKWL	PC	44423684
DM1JKWL	MW	230.65
DM1JKWL	FM	C9H11ClN2O3
DM1JKWL	IC	InChI=1S/C9H11ClN2O3/c10-8-3-1-7(2-4-8)6-15-11-5-9(13)12-14/h1-4,11,14H,5-6H2,(H,12,13)
DM1JKWL	CS	C1=CC(=CC=C1CONCC(=O)NO)Cl
DM1JKWL	IK	DSHAKCWOEUEDGY-UHFFFAOYSA-N
DM1JKWL	IU	2-[(4-chlorophenyl)methoxyamino]-N-hydroxyacetamide
DM1JKWL	DE	Discovery agent

DMFGQ7K	ID	DMFGQ7K
DMFGQ7K	DN	2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide
DMFGQ7K	HS	Investigative
DMFGQ7K	SN	CHEMBL388309; 2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide
DMFGQ7K	DT	Small molecular drug
DMFGQ7K	PC	44423687
DMFGQ7K	MW	286.75
DMFGQ7K	FM	C13H19ClN2O3
DMFGQ7K	IC	InChI=1S/C13H19ClN2O3/c1-2-3-4-12(13(17)15-18)16-19-9-10-5-7-11(14)8-6-10/h5-8,12,16,18H,2-4,9H2,1H3,(H,15,17)
DMFGQ7K	CS	CCCCC(C(=O)NO)NOCC1=CC=C(C=C1)Cl
DMFGQ7K	IK	SUZRJMQBDIHWSQ-UHFFFAOYSA-N
DMFGQ7K	IU	2-[(4-chlorophenyl)methoxyamino]-N-hydroxyhexanamide
DMFGQ7K	DE	Discovery agent

DMRADWB	ID	DMRADWB
DMRADWB	DN	2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide
DMRADWB	HS	Investigative
DMRADWB	SN	CHEMBL228229; 2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide
DMRADWB	DT	Small molecular drug
DMRADWB	PC	44423685
DMRADWB	MW	244.67
DMRADWB	FM	C10H13ClN2O3
DMRADWB	IC	InChI=1S/C10H13ClN2O3/c1-7(10(14)12-15)13-16-6-8-2-4-9(11)5-3-8/h2-5,7,13,15H,6H2,1H3,(H,12,14)
DMRADWB	CS	CC(C(=O)NO)NOCC1=CC=C(C=C1)Cl
DMRADWB	IK	JNDVWCINXNIDOF-UHFFFAOYSA-N
DMRADWB	IU	2-[(4-chlorophenyl)methoxyamino]-N-hydroxypropanamide
DMRADWB	DE	Discovery agent

DMQAVM4	ID	DMQAVM4
DMQAVM4	DN	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid
DMQAVM4	HS	Investigative
DMQAVM4	SN	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid
DMQAVM4	DT	Small molecular drug
DMQAVM4	PC	44411812
DMQAVM4	MW	352.8
DMQAVM4	FM	C17H17ClO4S
DMQAVM4	IC	InChI=1S/C17H17ClO4S/c1-2-3-16(17(19)20)23(21,22)15-10-6-13(7-11-15)12-4-8-14(18)9-5-12/h4-11,16H,2-3H2,1H3,(H,19,20)
DMQAVM4	CS	CCCC(C(=O)O)S(=O)(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)Cl
DMQAVM4	IK	JGNJABZIGHTRNB-UHFFFAOYSA-N
DMQAVM4	IU	2-[4-(4-chlorophenyl)phenyl]sulfonylpentanoic acid
DMQAVM4	DE	Discovery agent

DM6Z9U4	ID	DM6Z9U4
DM6Z9U4	DN	2-(4-Chlorophenyl)-2H-indazole-7-carboxamide
DM6Z9U4	HS	Investigative
DM6Z9U4	SN	CHEMBL1099295; 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2264064
DM6Z9U4	DT	Small molecular drug
DM6Z9U4	PC	44549375
DM6Z9U4	MW	271.7
DM6Z9U4	FM	C14H10ClN3O
DM6Z9U4	IC	InChI=1S/C14H10ClN3O/c15-10-4-6-11(7-5-10)18-8-9-2-1-3-12(14(16)19)13(9)17-18/h1-8H,(H2,16,19)
DM6Z9U4	CS	C1=CC2=CN(N=C2C(=C1)C(=O)N)C3=CC=C(C=C3)Cl
DM6Z9U4	IK	ZUUTWXXAMVQOFT-UHFFFAOYSA-N
DM6Z9U4	IU	2-(4-chlorophenyl)indazole-7-carboxamide
DM6Z9U4	DE	Discovery agent

DMSB0JA	ID	DMSB0JA
DMSB0JA	DN	2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline
DMSB0JA	HS	Investigative
DMSB0JA	SN	CHEMBL316782; SCHEMBL10771178; ZINC13756970
DMSB0JA	DT	Small molecular drug
DMSB0JA	PC	10540663
DMSB0JA	MW	279.72
DMSB0JA	FM	C16H10ClN3
DMSB0JA	IC	InChI=1S/C16H10ClN3/c17-11-7-5-10(6-8-11)16-19-14-9-18-13-4-2-1-3-12(13)15(14)20-16/h1-9H,(H,19,20)
DMSB0JA	CS	C1=CC=C2C(=C1)C3=C(C=N2)NC(=N3)C4=CC=C(C=C4)Cl
DMSB0JA	IK	CGBRMMMHBXSYHH-UHFFFAOYSA-N
DMSB0JA	IU	2-(4-chlorophenyl)-3H-imidazo[4,5-c]quinoline
DMSB0JA	DE	Discovery agent

DMFQI4C	ID	DMFQI4C
DMFQI4C	DN	2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole
DMFQI4C	HS	Investigative
DMFQI4C	SN	2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole; 13623-52-4; CHEMBL448710; 1H-Imidazole,2-(4-chlorophenyl)-4,5-dihydro-; NSC129258; AC1L5PGD; AC1Q3R0Q; AC1Q3IU9; 1h-imidazole, 2-(4-chlorophenyl)-4,5-dihydro-; SCHEMBL523059; CTK4C0220; DTXSID90299300; XUMWMBLBTZAVLW-UHFFFAOYSA-N; MolPort-005-311-522; ZINC608390; 2-(4-chlorophenyl)-2-imidazoline; 2-(4-Chlorophenyl)-1-imidazoline; BDBM50266028; STK367850; AKOS005444786; NE32890; NSC-129258; MCULE-4125153952; 2-Imidazoline, 2-(p-chloro-phenyl)-; DB-063124; FT-0766187; EN300-29599
DMFQI4C	DT	Small molecular drug
DMFQI4C	PC	279088
DMFQI4C	MW	180.63
DMFQI4C	FM	C9H9ClN2
DMFQI4C	IC	InChI=1S/C9H9ClN2/c10-8-3-1-7(2-4-8)9-11-5-6-12-9/h1-4H,5-6H2,(H,11,12)
DMFQI4C	CS	C1CN=C(N1)C2=CC=C(C=C2)Cl
DMFQI4C	IK	XUMWMBLBTZAVLW-UHFFFAOYSA-N
DMFQI4C	IU	2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole
DMFQI4C	CA	CAS 13623-52-4
DMFQI4C	DE	Discovery agent

DMYGRS9	ID	DMYGRS9
DMYGRS9	DN	2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one
DMYGRS9	HS	Investigative
DMYGRS9	SN	CHEMBL203853
DMYGRS9	DT	Small molecular drug
DMYGRS9	PC	11543610
DMYGRS9	MW	271.7
DMYGRS9	FM	C15H10ClNO2
DMYGRS9	IC	InChI=1S/C15H10ClNO2/c16-12-6-8-13(9-7-12)17-15(18)10-14(19-17)11-4-2-1-3-5-11/h1-10H
DMYGRS9	CS	C1=CC=C(C=C1)C2=CC(=O)N(O2)C3=CC=C(C=C3)Cl
DMYGRS9	IK	DWRJXWOCTFGHCE-UHFFFAOYSA-N
DMYGRS9	IU	2-(4-chlorophenyl)-5-phenyl-1,2-oxazol-3-one
DMYGRS9	DE	Discovery agent

DM9SGBO	ID	DM9SGBO
DM9SGBO	DN	2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
DM9SGBO	HS	Investigative
DM9SGBO	SN	3-(4-CHLOROPHENYL)QUINOXALINE-5-CARBOXAMIDE; 2-(4-CHLOROPHENYL)-5-QUINOXALINECARBOXAMIDE; 4tju; 1wok; AC1LCVX7; quinoxaline analogue, 3b; SCHEMBL424209; 3-(4-chloro-phenyl)-quinoxaline-5-carboxylic acid amide; CTK8F4675; BDBM27720; ZINC1489510; DB03509; 489457-67-2
DM9SGBO	DT	Small molecular drug
DM9SGBO	PC	657038
DM9SGBO	MW	283.71
DM9SGBO	FM	C15H10ClN3O
DM9SGBO	IC	InChI=1S/C15H10ClN3O/c16-10-6-4-9(5-7-10)13-8-18-12-3-1-2-11(15(17)20)14(12)19-13/h1-8H,(H2,17,20)
DM9SGBO	CS	C1=CC(=C2C(=C1)N=CC(=N2)C3=CC=C(C=C3)Cl)C(=O)N
DM9SGBO	IK	FLYGLPYJEQPCFY-UHFFFAOYSA-N
DM9SGBO	IU	3-(4-chlorophenyl)quinoxaline-5-carboxamide
DM9SGBO	DE	Discovery agent

DM7EUOX	ID	DM7EUOX
DM7EUOX	DN	2-(4-chlorophenyl)-6-morpholino-4H-pyran-4-one
DM7EUOX	HS	Investigative
DM7EUOX	SN	CHEMBL105612; 2-(4-chlorophenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3535601; BDBM50132355; 2-Morpholino-6-(4-chlorophenyl)-4H-pyran-4-one
DM7EUOX	DT	Small molecular drug
DM7EUOX	PC	10062895
DM7EUOX	MW	291.73
DM7EUOX	FM	C15H14ClNO3
DM7EUOX	IC	InChI=1S/C15H14ClNO3/c16-12-3-1-11(2-4-12)14-9-13(18)10-15(20-14)17-5-7-19-8-6-17/h1-4,9-10H,5-8H2
DM7EUOX	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=C(C=C3)Cl
DM7EUOX	IK	VYDDKZSYMMZLQU-UHFFFAOYSA-N
DM7EUOX	IU	2-(4-chlorophenyl)-6-morpholin-4-ylpyran-4-one
DM7EUOX	DE	Discovery agent

DMAPWNR	ID	DMAPWNR
DMAPWNR	DN	2-(4-chlorophenyl)-6-phenyl-9H-purine
DMAPWNR	HS	Investigative
DMAPWNR	SN	CHEMBL205586; 2-(4-chlorophenyl)-6-phenyl-9H-purine
DMAPWNR	DT	Small molecular drug
DMAPWNR	PC	11529627
DMAPWNR	MW	306.7
DMAPWNR	FM	C17H11ClN4
DMAPWNR	IC	InChI=1S/C17H11ClN4/c18-13-8-6-12(7-9-13)16-21-14(11-4-2-1-3-5-11)15-17(22-16)20-10-19-15/h1-10H,(H,19,20,21,22)
DMAPWNR	CS	C1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=C(C=C4)Cl)N=CN3
DMAPWNR	IK	FPWZFVSRIINTRB-UHFFFAOYSA-N
DMAPWNR	IU	2-(4-chlorophenyl)-6-phenyl-7H-purine
DMAPWNR	DE	Discovery agent

DMJORCV	ID	DMJORCV
DMJORCV	DN	2-(4-chlorophenylsulfonyl)naphthalene-1,4-diol
DMJORCV	HS	Investigative
DMJORCV	SN	CHEMBL460104; 2-(4-chlorophenylsulfonyl)naphthalene-1,4-diol
DMJORCV	DT	Small molecular drug
DMJORCV	PC	25154759
DMJORCV	MW	334.8
DMJORCV	FM	C16H11ClO4S
DMJORCV	IC	InChI=1S/C16H11ClO4S/c17-10-5-7-11(8-6-10)22(20,21)15-9-14(18)12-3-1-2-4-13(12)16(15)19/h1-9,18-19H
DMJORCV	CS	C1=CC=C2C(=C1)C(=CC(=C2O)S(=O)(=O)C3=CC=C(C=C3)Cl)O
DMJORCV	IK	SXWUEZFUYNUEML-UHFFFAOYSA-N
DMJORCV	IU	2-(4-chlorophenyl)sulfonylnaphthalene-1,4-diol
DMJORCV	DE	Discovery agent

DM4XFJI	ID	DM4XFJI
DM4XFJI	DN	2-(4-cyano-2-cyclohexylphenoxy)acetic acid
DM4XFJI	HS	Investigative
DM4XFJI	SN	CHEMBL245700; (4-Cyano-2-cyclohexylphenoxy)acetic acid; 2-(4-cyano-2-cyclohexylphenoxy)acetic acid; SCHEMBL4881986; BDBM50213915
DM4XFJI	DT	Small molecular drug
DM4XFJI	PC	11586961
DM4XFJI	MW	259.3
DM4XFJI	FM	C15H17NO3
DM4XFJI	IC	InChI=1S/C15H17NO3/c16-9-11-6-7-14(19-10-15(17)18)13(8-11)12-4-2-1-3-5-12/h6-8,12H,1-5,10H2,(H,17,18)
DM4XFJI	CS	C1CCC(CC1)C2=C(C=CC(=C2)C#N)OCC(=O)O
DM4XFJI	IK	YLYPWLBTNPRZEM-UHFFFAOYSA-N
DM4XFJI	IU	2-(4-cyano-2-cyclohexylphenoxy)acetic acid
DM4XFJI	DE	Discovery agent

DMOH46C	ID	DMOH46C
DMOH46C	DN	2-(4-cyclohexylthiosemicarbazono)methyl-phenol
DMOH46C	HS	Investigative
DMOH46C	DT	Small molecular drug
DMOH46C	PC	135676207
DMOH46C	MW	277.39
DMOH46C	FM	C14H19N3OS
DMOH46C	IC	InChI=1S/C14H19N3OS/c18-13-9-5-4-6-11(13)10-15-17-14(19)16-12-7-2-1-3-8-12/h4-6,9-10,12,18H,1-3,7-8H2,(H2,16,17,19)/b15-10+
DMOH46C	CS	C1CCC(CC1)NC(=S)N/N=C/C2=CC=CC=C2O
DMOH46C	IK	QEQOERHFAIIFBC-XNTDXEJSSA-N
DMOH46C	IU	1-cyclohexyl-3-[(E)-(2-hydroxyphenyl)methylideneamino]thiourea
DMOH46C	DE	Discovery agent

DM6VQEO	ID	DM6VQEO
DM6VQEO	DN	2-(4-Cyclopentyl-piperazin-1-yl)-quinoline
DM6VQEO	HS	Investigative
DM6VQEO	SN	CHEMBL178608; 2-(4-Cyclopentyl-piperazin-1-yl)-quinoline; SCHEMBL3970736
DM6VQEO	DT	Small molecular drug
DM6VQEO	PC	11337173
DM6VQEO	MW	281.4
DM6VQEO	FM	C18H23N3
DM6VQEO	IC	InChI=1S/C18H23N3/c1-4-8-17-15(5-1)9-10-18(19-17)21-13-11-20(12-14-21)16-6-2-3-7-16/h1,4-5,8-10,16H,2-3,6-7,11-14H2
DM6VQEO	CS	C1CCC(C1)N2CCN(CC2)C3=NC4=CC=CC=C4C=C3
DM6VQEO	IK	JGCMOVVEQUHZRT-UHFFFAOYSA-N
DM6VQEO	IU	2-(4-cyclopentylpiperazin-1-yl)quinoline
DM6VQEO	DE	Discovery agent

DMPU90E	ID	DMPU90E
DMPU90E	DN	2-(4-Cyclopropyl-piperazin-1-yl)-quinoline
DMPU90E	HS	Investigative
DMPU90E	SN	CHEMBL179578; 2-(4-Cyclopropyl-piperazin-1-yl)-quinoline; SCHEMBL13648831; BDBM50159109
DMPU90E	DT	Small molecular drug
DMPU90E	PC	11324846
DMPU90E	MW	253.34
DMPU90E	FM	C16H19N3
DMPU90E	IC	InChI=1S/C16H19N3/c1-2-4-15-13(3-1)5-8-16(17-15)19-11-9-18(10-12-19)14-6-7-14/h1-5,8,14H,6-7,9-12H2
DMPU90E	CS	C1CC1N2CCN(CC2)C3=NC4=CC=CC=C4C=C3
DMPU90E	IK	HOMYCGKCEABFJF-UHFFFAOYSA-N
DMPU90E	IU	2-(4-cyclopropylpiperazin-1-yl)quinoline
DMPU90E	DE	Discovery agent

DM823CD	ID	DM823CD
DM823CD	DN	2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione
DM823CD	HS	Investigative
DM823CD	SN	CHEMBL176400; F2147-1072; 7351-91-9; 2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione; SCHEMBL14676513; MolPort-023-212-106; DEWGBLHKQDVWLX-UHFFFAOYSA-N; BDBM50291598; ZINC28090831; AKOS024627738; MCULE-2799628954; 2-(4-(diethylamino)but-2-yn-1-yl)isoindoline-1,3-dione
DM823CD	DT	Small molecular drug
DM823CD	PC	44385509
DM823CD	MW	270.33
DM823CD	FM	C16H18N2O2
DM823CD	IC	InChI=1S/C16H18N2O2/c1-3-17(4-2)11-7-8-12-18-15(19)13-9-5-6-10-14(13)16(18)20/h5-6,9-10H,3-4,11-12H2,1-2H3
DM823CD	CS	CCN(CC)CC#CCN1C(=O)C2=CC=CC=C2C1=O
DM823CD	IK	DEWGBLHKQDVWLX-UHFFFAOYSA-N
DM823CD	IU	2-[4-(diethylamino)but-2-ynyl]isoindole-1,3-dione
DM823CD	DE	Discovery agent

DMXH0FO	ID	DMXH0FO
DMXH0FO	DN	2-(4-Dipropylamino-cyclohexylidene)-malononitrile
DMXH0FO	HS	Investigative
DMXH0FO	SN	CHEMBL164950; 2-(4-Dipropylamino-cyclohexylidene)-malononitrile; ZINC13805533
DMXH0FO	DT	Small molecular drug
DMXH0FO	PC	10705550
DMXH0FO	MW	245.36
DMXH0FO	FM	C15H23N3
DMXH0FO	IC	InChI=1S/C15H23N3/c1-3-9-18(10-4-2)15-7-5-13(6-8-15)14(11-16)12-17/h15H,3-10H2,1-2H3
DMXH0FO	CS	CCCN(CCC)C1CCC(=C(C#N)C#N)CC1
DMXH0FO	IK	FGVSZVRUGNMGKP-UHFFFAOYSA-N
DMXH0FO	IU	2-[4-(dipropylamino)cyclohexylidene]propanedinitrile
DMXH0FO	DE	Discovery agent

DMTAVU5	ID	DMTAVU5
DMTAVU5	DN	2-(4-ethylthiobenzimidazol-2-yl)quinoxaline
DMTAVU5	HS	Investigative
DMTAVU5	SN	CHEMBL198008; benzimidazole-quinoxaline, C2; BDBM21216; 2-[4-(ethylsulfanyl)-1H-benzimidazol-2-yl]quinoxaline
DMTAVU5	DT	Small molecular drug
DMTAVU5	PC	11688103
DMTAVU5	MW	306.4
DMTAVU5	FM	C17H14N4S
DMTAVU5	IC	InChI=1S/C17H14N4S/c1-2-22-15-9-5-8-13-16(15)21-17(20-13)14-10-18-11-6-3-4-7-12(11)19-14/h3-10H,2H2,1H3,(H,20,21)
DMTAVU5	CS	CCSC1=CC=CC2=C1N=C(N2)C3=NC4=CC=CC=C4N=C3
DMTAVU5	IK	IHVQPVYBIZVMSJ-UHFFFAOYSA-N
DMTAVU5	IU	2-(4-ethylsulfanyl-1H-benzimidazol-2-yl)quinoxaline
DMTAVU5	DE	Discovery agent

DMGLEX5	ID	DMGLEX5
DMGLEX5	DN	2-(4-Fluoro-3-phenoxy-benzoylamino)-benzoic acid
DMGLEX5	HS	Investigative
DMGLEX5	SN	CHEMBL180428; BDBM23580; 2-(4-fluoro-3-phenoxybenzoylamino)benzoic acid; (3-Phenoxybenzoylamino)benzoic acid deriv., 23a; 2-[(4-fluoro-3-phenoxybenzene)amido]benzoic acid
DMGLEX5	DT	Small molecular drug
DMGLEX5	PC	11233439
DMGLEX5	MW	351.3
DMGLEX5	FM	C20H14FNO4
DMGLEX5	IC	InChI=1S/C20H14FNO4/c21-16-11-10-13(12-18(16)26-14-6-2-1-3-7-14)19(23)22-17-9-5-4-8-15(17)20(24)25/h1-12H,(H,22,23)(H,24,25)
DMGLEX5	CS	C1=CC=C(C=C1)OC2=C(C=CC(=C2)C(=O)NC3=CC=CC=C3C(=O)O)F
DMGLEX5	IK	OPLSSBDEHIIFAG-UHFFFAOYSA-N
DMGLEX5	IU	2-[(4-fluoro-3-phenoxybenzoyl)amino]benzoic acid
DMGLEX5	DE	Discovery agent

DMZSHDR	ID	DMZSHDR
DMZSHDR	DN	2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione
DMZSHDR	HS	Investigative
DMZSHDR	SN	2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione; CHEMBL203552; SCHEMBL13442861; Isoquinoline-1,3,4-trione 2f; CTK7C0409; BDBM10253; AKOS015966191; 2-(4-FLUORO-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE
DMZSHDR	DT	Small molecular drug
DMZSHDR	PC	11680763
DMZSHDR	MW	283.25
DMZSHDR	FM	C16H10FNO3
DMZSHDR	IC	InChI=1S/C16H10FNO3/c17-11-7-5-10(6-8-11)9-18-15(20)13-4-2-1-3-12(13)14(19)16(18)21/h1-8H,9H2
DMZSHDR	CS	C1=CC=C2C(=C1)C(=O)C(=O)N(C2=O)CC3=CC=C(C=C3)F
DMZSHDR	IK	XFTAXSAPJPVWNZ-UHFFFAOYSA-N
DMZSHDR	IU	2-[(4-fluorophenyl)methyl]isoquinoline-1,3,4-trione
DMZSHDR	DE	Discovery agent

DMKFIEY	ID	DMKFIEY
DMKFIEY	DN	2-(4-Fluoro-indole-1-sulfonyl)-benzoic acid
DMKFIEY	HS	Investigative
DMKFIEY	SN	CHEMBL362888; 2-(4-Fluoro-indole-1-sulfonyl)-benzoic acid
DMKFIEY	DT	Small molecular drug
DMKFIEY	PC	44393638
DMKFIEY	MW	319.3
DMKFIEY	FM	C15H10FNO4S
DMKFIEY	IC	InChI=1S/C15H10FNO4S/c16-12-5-3-6-13-10(12)8-9-17(13)22(20,21)14-7-2-1-4-11(14)15(18)19/h1-9H,(H,18,19)
DMKFIEY	CS	C1=CC=C(C(=C1)C(=O)O)S(=O)(=O)N2C=CC3=C2C=CC=C3F
DMKFIEY	IK	YQOPLEXTOUMMNP-UHFFFAOYSA-N
DMKFIEY	IU	2-(4-fluoroindol-1-yl)sulfonylbenzoic acid
DMKFIEY	DE	Discovery agent

DMECX8S	ID	DMECX8S
DMECX8S	DN	2-(4-fluorophenyl)-6-morpholino-4H-pyran-4-one
DMECX8S	HS	Investigative
DMECX8S	SN	CHEMBL105521; 2-(4-fluorophenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3537099; BDBM50132370; 2-Morpholino-6-(4-fluorophenyl)-4H-pyran-4-one
DMECX8S	DT	Small molecular drug
DMECX8S	PC	10912743
DMECX8S	MW	275.27
DMECX8S	FM	C15H14FNO3
DMECX8S	IC	InChI=1S/C15H14FNO3/c16-12-3-1-11(2-4-12)14-9-13(18)10-15(20-14)17-5-7-19-8-6-17/h1-4,9-10H,5-8H2
DMECX8S	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=C(C=C3)F
DMECX8S	IK	PERAFXFTWFWDNO-UHFFFAOYSA-N
DMECX8S	IU	2-(4-fluorophenyl)-6-morpholin-4-ylpyran-4-one
DMECX8S	DE	Discovery agent

DMZDGB3	ID	DMZDGB3
DMZDGB3	DN	2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one
DMZDGB3	HS	Investigative
DMZDGB3	SN	CHEMBL344504; 4'-Fluoro-7-methoxyflavone; 2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one; SCHEMBL9142214; ZINC27557271; BDBM50310198
DMZDGB3	DT	Small molecular drug
DMZDGB3	PC	10378415
DMZDGB3	MW	270.25
DMZDGB3	FM	C16H11FO3
DMZDGB3	IC	InChI=1S/C16H11FO3/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-9H,1H3
DMZDGB3	CS	COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=C(C=C3)F
DMZDGB3	IK	FQRUARKLFVTIIK-UHFFFAOYSA-N
DMZDGB3	IU	2-(4-fluorophenyl)-7-methoxychromen-4-one
DMZDGB3	DE	Discovery agent

DM0CDRP	ID	DM0CDRP
DM0CDRP	DN	2-(4-fluorophenylsulfonamido)-1-naphthoic acid
DM0CDRP	HS	Investigative
DM0CDRP	SN	sulfonamide compound, 10; CHEMBL212006; SCHEMBL3982656; BDBM17604; 2-[(4-fluorobenzene)sulfonamido]naphthalene-1-carboxylic acid
DM0CDRP	DT	Small molecular drug
DM0CDRP	PC	10427648
DM0CDRP	MW	345.3
DM0CDRP	FM	C17H12FNO4S
DM0CDRP	IC	InChI=1S/C17H12FNO4S/c18-12-6-8-13(9-7-12)24(22,23)19-15-10-5-11-3-1-2-4-14(11)16(15)17(20)21/h1-10,19H,(H,20,21)
DM0CDRP	CS	C1=CC=C2C(=C1)C=CC(=C2C(=O)O)NS(=O)(=O)C3=CC=C(C=C3)F
DM0CDRP	IK	KIYWIXCUCALPGQ-UHFFFAOYSA-N
DM0CDRP	IU	2-[(4-fluorophenyl)sulfonylamino]naphthalene-1-carboxylic acid
DM0CDRP	DE	Discovery agent

DM05HBC	ID	DM05HBC
DM05HBC	DN	2-(4-hexyl-2-methoxyphenoxy)pyrimidine
DM05HBC	HS	Investigative
DM05HBC	SN	CHEMBL429332
DM05HBC	DT	Small molecular drug
DM05HBC	PC	44450125
DM05HBC	MW	286.37
DM05HBC	FM	C17H22N2O2
DM05HBC	IC	InChI=1S/C17H22N2O2/c1-3-4-5-6-8-14-9-10-15(16(13-14)20-2)21-17-18-11-7-12-19-17/h7,9-13H,3-6,8H2,1-2H3
DM05HBC	CS	CCCCCCC1=CC(=C(C=C1)OC2=NC=CC=N2)OC
DM05HBC	IK	UIFANQCPIJLKBV-UHFFFAOYSA-N
DM05HBC	IU	2-(4-hexyl-2-methoxyphenoxy)pyrimidine
DM05HBC	DE	Discovery agent

DMCPN7V	ID	DMCPN7V
DMCPN7V	DN	2-(4-hydroxybenzylideneamino)ethanesulfonamide
DMCPN7V	HS	Investigative
DMCPN7V	DT	Small molecular drug
DMCPN7V	PC	136123546
DMCPN7V	MW	228.27
DMCPN7V	FM	C9H12N2O3S
DMCPN7V	IC	InChI=1S/C9H12N2O3S/c10-15(13,14)6-5-11-7-8-1-3-9(12)4-2-8/h1-4,7,12H,5-6H2,(H2,10,13,14)
DMCPN7V	CS	C1=CC(=CC=C1C=NCCS(=O)(=O)N)O
DMCPN7V	IK	IDKQYIBAMQLGRT-UHFFFAOYSA-N
DMCPN7V	IU	2-[(4-hydroxyphenyl)methylideneamino]ethanesulfonamide
DMCPN7V	DE	Discovery agent

DMM4S1R	ID	DMM4S1R
DMM4S1R	DN	2-(4-hydroxylphenyl)-3-(3,5-dihydroxylphenyl) propenoic acid (NNU-hdpa)
DMM4S1R	HS	Investigative
DMM4S1R	SN	ZINC34018202; (E)-alpha-(4-Hydroxyphenyl)-3,5-dihydroxycinnamic acid
DMM4S1R	DT	Small molecular drug
DMM4S1R	PC	9900145
DMM4S1R	MW	272.25
DMM4S1R	FM	C15H12O5
DMM4S1R	IC	InChI=1S/C15H12O5/c16-11-3-1-10(2-4-11)14(15(19)20)7-9-5-12(17)8-13(18)6-9/h1-8,16-18H,(H,19,20)/b14-7+
DMM4S1R	CS	C1=CC(=CC=C1/C(=C\\C2=CC(=CC(=C2)O)O)/C(=O)O)O
DMM4S1R	IK	LGVSCQYCQUYTOK-VGOFMYFVSA-N
DMM4S1R	IU	(E)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)prop-2-enoic acid
DMM4S1R	DE	Discovery agent

DMUGHF6	ID	DMUGHF6
DMUGHF6	DN	2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DMUGHF6	HS	Investigative
DMUGHF6	DT	Small molecular drug
DMUGHF6	PC	135503567
DMUGHF6	MW	277.27
DMUGHF6	FM	C17H11NO3
DMUGHF6	IC	InChI=1S/C17H11NO3/c19-10-5-7-14-16(9-10)21-17(18-14)13-6-8-15(20)12-4-2-1-3-11(12)13/h1-9,19-20H
DMUGHF6	CS	C1=CC=C2C(=C1)C(=CC=C2O)C3=NC4=C(O3)C=C(C=C4)O
DMUGHF6	IK	JOCGYNKOMBFRII-UHFFFAOYSA-N
DMUGHF6	IU	2-(4-hydroxynaphthalen-1-yl)-1,3-benzoxazol-6-ol
DMUGHF6	DE	Discovery agent

DM1C864	ID	DM1C864
DM1C864	DN	2-(4-hydroxypent-1-yl)-N6-methoxyadenosine
DM1C864	HS	Investigative
DM1C864	SN	CHEMBL219888; 2-(4-hydroxypent-1-yl)-N6-methoxyadenosine; SCHEMBL4381152
DM1C864	DT	Small molecular drug
DM1C864	PC	11740439
DM1C864	MW	379.37
DM1C864	FM	C16H21N5O6
DM1C864	IC	InChI=1S/C16H21N5O6/c1-8(23)4-3-5-10-18-14(20-26-2)11-15(19-10)21(7-17-11)16-13(25)12(24)9(6-22)27-16/h7-9,12-13,16,22-25H,4,6H2,1-2H3,(H,18,19,20)/t8?,9-,12-,13-,16-/m1/s1
DM1C864	CS	CC(CC#CC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NOC)O
DM1C864	IK	MVQXWIPZMVHVNF-WTBWQYLWSA-N
DM1C864	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[2-(4-hydroxypent-1-ynyl)-6-(methoxyamino)purin-9-yl]oxolane-3,4-diol
DM1C864	DE	Discovery agent

DMW6L38	ID	DMW6L38
DMW6L38	DN	2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol
DMW6L38	HS	Investigative
DMW6L38	SN	CHEMBL281499; SCHEMBL6286186; BDBM50123205; 2-(4-hydroxyphenyl)-1,2''-spirobi[1H-indene]-5-ol
DMW6L38	DT	Small molecular drug
DMW6L38	PC	9945207
DMW6L38	MW	326.4
DMW6L38	FM	C23H18O2
DMW6L38	IC	InChI=1S/C23H18O2/c24-19-7-5-15(6-8-19)22-12-18-11-20(25)9-10-21(18)23(22)13-16-3-1-2-4-17(16)14-23/h1-12,24-25H,13-14H2
DMW6L38	CS	C1C2=CC=CC=C2CC13C4=C(C=C(C=C4)O)C=C3C5=CC=C(C=C5)O
DMW6L38	IK	NRJDKQAGGSKGKV-UHFFFAOYSA-N
DMW6L38	IU	2'-(4-hydroxyphenyl)spiro[1,3-dihydroindene-2,1'-indene]-5'-ol
DMW6L38	DE	Discovery agent

DMBIV8F	ID	DMBIV8F
DMBIV8F	DN	2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol
DMBIV8F	HS	Investigative
DMBIV8F	SN	CHEMBL197188; 2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol
DMBIV8F	DT	Small molecular drug
DMBIV8F	PC	11716633
DMBIV8F	MW	314.4
DMBIV8F	FM	C22H18O2
DMBIV8F	IC	InChI=1S/C22H18O2/c1-14-2-4-16(5-3-14)22-20-11-10-19(24)12-17(20)13-21(22)15-6-8-18(23)9-7-15/h2-12,23-24H,13H2,1H3
DMBIV8F	CS	CC1=CC=C(C=C1)C2=C(CC3=C2C=CC(=C3)O)C4=CC=C(C=C4)O
DMBIV8F	IK	YIFNILRPNDYIBP-UHFFFAOYSA-N
DMBIV8F	IU	2-(4-hydroxyphenyl)-1-(4-methylphenyl)-3H-inden-5-ol
DMBIV8F	DE	Discovery agent

DMNGW1A	ID	DMNGW1A
DMNGW1A	DN	2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile
DMNGW1A	HS	Investigative
DMNGW1A	SN	CHEMBL305128
DMNGW1A	DT	Small molecular drug
DMNGW1A	PC	14537253
DMNGW1A	MW	297.3
DMNGW1A	FM	C21H15NO
DMNGW1A	IC	InChI=1S/C21H15NO/c22-15-20(16-11-13-19(23)14-12-16)21(17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-14,23H
DMNGW1A	CS	C1=CC=C(C=C1)C(=C(C#N)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMNGW1A	IK	IMMSDZNZGPJVRN-UHFFFAOYSA-N
DMNGW1A	IU	2-(4-hydroxyphenyl)-3,3-diphenylprop-2-enenitrile
DMNGW1A	DE	Discovery agent

DM4N0LB	ID	DM4N0LB
DM4N0LB	DN	2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol
DM4N0LB	HS	Investigative
DM4N0LB	DT	Small molecular drug
DM4N0LB	PC	135424609
DM4N0LB	MW	267.28
DM4N0LB	FM	C16H13NO3
DM4N0LB	IC	InChI=1S/C16H13NO3/c1-20-16-9-15(10-2-4-11(18)5-3-10)17-14-7-6-12(19)8-13(14)16/h2-9,18-19H,1H3
DM4N0LB	CS	COC1=CC(=NC2=C1C=C(C=C2)O)C3=CC=C(C=C3)O
DM4N0LB	IK	IOTUBGYZUXLZPC-UHFFFAOYSA-N
DM4N0LB	IU	2-(4-hydroxyphenyl)-4-methoxyquinolin-6-ol
DM4N0LB	DE	Discovery agent

DM81G2U	ID	DM81G2U
DM81G2U	DN	2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol
DM81G2U	HS	Investigative
DM81G2U	SN	2-(4-hydroxyphenyl)-4-vinylquinolin-6-ol
DM81G2U	PC	135409729
DM81G2U	MW	263.29
DM81G2U	FM	C17H13NO2
DM81G2U	IC	InChI=1S/C17H13NO2/c1-2-11-9-17(12-3-5-13(19)6-4-12)18-16-8-7-14(20)10-15(11)16/h2-10,19-20H,1H2
DM81G2U	CS	C=CC1=CC(=NC2=C1C=C(C=C2)O)C3=CC=C(C=C3)O
DM81G2U	IK	MPGOJACGGLDRIE-UHFFFAOYSA-N
DM81G2U	IU	4-ethenyl-2-(4-hydroxyphenyl)quinolin-6-ol
DM81G2U	DE	Discovery agent

DMFWOMY	ID	DMFWOMY
DMFWOMY	DN	2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol
DMFWOMY	HS	Investigative
DMFWOMY	DT	Small molecular drug
DMFWOMY	PC	135442595
DMFWOMY	MW	269.29
DMFWOMY	FM	C16H15NO3
DMFWOMY	IC	InChI=1S/C16H15NO3/c1-9(2)13-7-12(19)8-14-15(13)20-16(17-14)10-3-5-11(18)6-4-10/h3-9,18-19H,1-2H3
DMFWOMY	CS	CC(C)C1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMFWOMY	IK	XMPVRZGJAQOXGV-UHFFFAOYSA-N
DMFWOMY	IU	2-(4-hydroxyphenyl)-7-propan-2-yl-1,3-benzoxazol-5-ol
DMFWOMY	DE	Discovery agent

DMY0I8P	ID	DMY0I8P
DMY0I8P	DN	2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol
DMY0I8P	HS	Investigative
DMY0I8P	SN	CHEMBL361226; 2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol; SCHEMBL3928011; KEWMBPCQWDVBAS-UHFFFAOYSA-N
DMY0I8P	DT	Small molecular drug
DMY0I8P	PC	10286022
DMY0I8P	MW	256.25
DMY0I8P	FM	C15H12O4
DMY0I8P	IC	InChI=1S/C15H12O4/c1-18-14-8-12(17)6-10-7-13(19-15(10)14)9-2-4-11(16)5-3-9/h2-8,16-17H,1H3
DMY0I8P	CS	COC1=C2C(=CC(=C1)O)C=C(O2)C3=CC=C(C=C3)O
DMY0I8P	IK	KEWMBPCQWDVBAS-UHFFFAOYSA-N
DMY0I8P	IU	2-(4-hydroxyphenyl)-7-methoxy-1-benzofuran-5-ol
DMY0I8P	DE	Discovery agent

DMCNITS	ID	DMCNITS
DMCNITS	DN	2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol
DMCNITS	HS	Investigative
DMCNITS	DT	Small molecular drug
DMCNITS	PC	135409725
DMCNITS	MW	257.24
DMCNITS	FM	C14H11NO4
DMCNITS	IC	InChI=1S/C14H11NO4/c1-18-12-7-10(17)6-11-13(12)19-14(15-11)8-2-4-9(16)5-3-8/h2-7,16-17H,1H3
DMCNITS	CS	COC1=CC(=CC2=C1OC(=N2)C3=CC=C(C=C3)O)O
DMCNITS	IK	RJJQKEPGOIGNSZ-UHFFFAOYSA-N
DMCNITS	IU	2-(4-hydroxyphenyl)-7-methoxy-1,3-benzoxazol-5-ol
DMCNITS	DE	Discovery agent

DMT847Y	ID	DMT847Y
DMT847Y	DN	2-(4-hydroxyphenyl)-7-methoxychroman-4-one
DMT847Y	HS	Investigative
DMT847Y	SN	Methyl-liquiritigenin; CHEMBL402970; 4'-hydroxy-7-methoxyflavanone; 32274-71-8; 7-Methylliquiritigenin; CTK1B9324; DTXSID80437613; LMPK12140062; BDBM50374257; AKOS030552775; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(4-hydroxyphenyl)-7-methoxy-
DMT847Y	DT	Small molecular drug
DMT847Y	PC	10265122
DMT847Y	MW	270.28
DMT847Y	FM	C16H14O4
DMT847Y	IC	InChI=1S/C16H14O4/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-8,15,17H,9H2,1H3
DMT847Y	CS	COC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=C(C=C3)O
DMT847Y	IK	OJOSVTQXBSSCMQ-UHFFFAOYSA-N
DMT847Y	IU	2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMT847Y	CA	CAS 32274-71-8
DMT847Y	DE	Discovery agent

DMQ2KPI	ID	DMQ2KPI
DMQ2KPI	DN	2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol
DMQ2KPI	HS	Investigative
DMQ2KPI	SN	CHEMBL365290; 2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol; SCHEMBL1119325; FUWUZPRNKPGRGX-UHFFFAOYSA-N
DMQ2KPI	DT	Small molecular drug
DMQ2KPI	PC	10285954
DMQ2KPI	MW	240.25
DMQ2KPI	FM	C15H12O3
DMQ2KPI	IC	InChI=1S/C15H12O3/c1-9-6-13(17)7-11-8-14(18-15(9)11)10-2-4-12(16)5-3-10/h2-8,16-17H,1H3
DMQ2KPI	CS	CC1=CC(=CC2=C1OC(=C2)C3=CC=C(C=C3)O)O
DMQ2KPI	IK	FUWUZPRNKPGRGX-UHFFFAOYSA-N
DMQ2KPI	IU	2-(4-hydroxyphenyl)-7-methyl-1-benzofuran-5-ol
DMQ2KPI	DE	Discovery agent

DMUB7KH	ID	DMUB7KH
DMUB7KH	DN	2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol
DMUB7KH	HS	Investigative
DMUB7KH	DT	Small molecular drug
DMUB7KH	PC	135409756
DMUB7KH	MW	303.3
DMUB7KH	FM	C19H13NO3
DMUB7KH	IC	InChI=1S/C19H13NO3/c21-14-8-6-13(7-9-14)19-20-17-11-15(22)10-16(18(17)23-19)12-4-2-1-3-5-12/h1-11,21-22H
DMUB7KH	CS	C1=CC=C(C=C1)C2=C3C(=CC(=C2)O)N=C(O3)C4=CC=C(C=C4)O
DMUB7KH	IK	OMOPCSHWHZVQPY-UHFFFAOYSA-N
DMUB7KH	IU	2-(4-hydroxyphenyl)-7-phenyl-1,3-benzoxazol-5-ol
DMUB7KH	DE	Discovery agent

DMND63Z	ID	DMND63Z
DMND63Z	DN	2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol
DMND63Z	HS	Investigative
DMND63Z	DT	Small molecular drug
DMND63Z	PC	136048731
DMND63Z	MW	267.28
DMND63Z	FM	C16H13NO3
DMND63Z	IC	InChI=1S/C16H13NO3/c1-2-3-11-8-13(19)9-14-15(11)20-16(17-14)10-4-6-12(18)7-5-10/h2-9,18-19H,1H3/b3-2-
DMND63Z	CS	C/C=C\\C1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMND63Z	IK	GBNLUWROABYNBX-IHWYPQMZSA-N
DMND63Z	IU	2-(4-hydroxyphenyl)-7-[(Z)-prop-1-enyl]-1,3-benzoxazol-5-ol
DMND63Z	DE	Discovery agent

DMONT2D	ID	DMONT2D
DMONT2D	DN	2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol
DMONT2D	HS	Investigative
DMONT2D	DT	Small molecular drug
DMONT2D	PC	135519317
DMONT2D	MW	269.29
DMONT2D	FM	C16H15NO3
DMONT2D	IC	InChI=1S/C16H15NO3/c1-2-3-11-8-13(19)9-14-15(11)20-16(17-14)10-4-6-12(18)7-5-10/h4-9,18-19H,2-3H2,1H3
DMONT2D	CS	CCCC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMONT2D	IK	VHUQNFQIHPMAAE-UHFFFAOYSA-N
DMONT2D	IU	2-(4-hydroxyphenyl)-7-propyl-1,3-benzoxazol-5-ol
DMONT2D	DE	Discovery agent

DM2F6U3	ID	DM2F6U3
DM2F6U3	DN	2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol
DM2F6U3	HS	Investigative
DM2F6U3	DT	Small molecular drug
DM2F6U3	PC	135494488
DM2F6U3	MW	253.25
DM2F6U3	FM	C15H11NO3
DM2F6U3	IC	InChI=1S/C15H11NO3/c1-2-9-7-12(18)8-13-14(9)19-15(16-13)10-3-5-11(17)6-4-10/h2-8,17-18H,1H2
DM2F6U3	CS	C=CC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DM2F6U3	IK	DNOMWUYUDHLCAY-UHFFFAOYSA-N
DM2F6U3	IU	7-ethenyl-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DM2F6U3	DE	Discovery agent

DMVHQM9	ID	DMVHQM9
DMVHQM9	DN	2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one
DMVHQM9	HS	Investigative
DMVHQM9	DT	Small molecular drug
DMVHQM9	PC	135471354
DMVHQM9	MW	252.27
DMVHQM9	FM	C15H12N2O2
DMVHQM9	IC	InChI=1S/C15H12N2O2/c1-9-3-2-4-12-13(9)16-14(17-15(12)19)10-5-7-11(18)8-6-10/h2-8,18H,1H3,(H,16,17,19)
DMVHQM9	CS	CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=C(C=C3)O
DMVHQM9	IK	NIPIEXNSQBQPML-UHFFFAOYSA-N
DMVHQM9	IU	2-(4-hydroxyphenyl)-8-methyl-3H-quinazolin-4-one
DMVHQM9	DE	Discovery agent

DMN6S3F	ID	DMN6S3F
DMN6S3F	DN	2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL
DMN6S3F	HS	Investigative
DMN6S3F	SN	2-(4-Hydroxy-phenyl)benzofuran-5-OL; 2-(4-Hydroxy-phenyl)-benzofuran-5-ol; 2-(4-hydroxyphenyl)-1-benzofuran-5-ol; CHEMBL367588; 52814-86-5; 2-(4-Hydroxyphenyl)benzofuran-5-ol; AC1LCVQT; 1u9e; SCHEMBL3922677; CTK1G1983; DTXSID60349669; SNNNDCMXZYWCCI-UHFFFAOYSA-N; ZINC3816519; BDBM50152627; SBB096959; AKOS030555876; DB07032; 2-(4-hydroxyphenyl)benzo[b]furan-5-ol; 5-Benzofuranol,
DMN6S3F	DT	Small molecular drug
DMN6S3F	PC	656936
DMN6S3F	MW	226.23
DMN6S3F	FM	C14H10O3
DMN6S3F	IC	InChI=1S/C14H10O3/c15-11-3-1-9(2-4-11)14-8-10-7-12(16)5-6-13(10)17-14/h1-8,15-16H
DMN6S3F	CS	C1=CC(=CC=C1C2=CC3=C(O2)C=CC(=C3)O)O
DMN6S3F	IK	SNNNDCMXZYWCCI-UHFFFAOYSA-N
DMN6S3F	IU	2-(4-hydroxyphenyl)-1-benzofuran-5-ol
DMN6S3F	CA	CAS 52814-86-5
DMN6S3F	DE	Discovery agent

DMMUNA7	ID	DMMUNA7
DMMUNA7	DN	2-(4-Hydroxy-phenyl)-benzooxazol-5-ol
DMMUNA7	HS	Investigative
DMMUNA7	DT	Small molecular drug
DMMUNA7	PC	135405741
DMMUNA7	MW	227.21
DMMUNA7	FM	C13H9NO3
DMMUNA7	IC	InChI=1S/C13H9NO3/c15-9-3-1-8(2-4-9)13-14-11-7-10(16)5-6-12(11)17-13/h1-7,15-16H
DMMUNA7	CS	C1=CC(=CC=C1C2=NC3=C(O2)C=CC(=C3)O)O
DMMUNA7	IK	DPAMLAKLEWYMGF-UHFFFAOYSA-N
DMMUNA7	IU	2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMMUNA7	CA	CAS 142629-43-4
DMMUNA7	DE	Discovery agent

DM31MY0	ID	DM31MY0
DM31MY0	DN	2-(4-Hydroxy-phenyl)-benzooxazol-6-ol
DM31MY0	HS	Investigative
DM31MY0	DT	Small molecular drug
DM31MY0	PC	135471161
DM31MY0	MW	227.21
DM31MY0	FM	C13H9NO3
DM31MY0	IC	InChI=1S/C13H9NO3/c15-9-3-1-8(2-4-9)13-14-11-6-5-10(16)7-12(11)17-13/h1-7,15-16H
DM31MY0	CS	C1=CC(=CC=C1C2=NC3=C(O2)C=C(C=C3)O)O
DM31MY0	IK	PDCFEVXISBNCNF-UHFFFAOYSA-N
DM31MY0	IU	2-(4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DM31MY0	DE	Discovery agent

DMCWFUZ	ID	DMCWFUZ
DMCWFUZ	DN	2-(4-Hydroxy-phenyl)-quinolin-6-ol
DMCWFUZ	HS	Investigative
DMCWFUZ	DT	Small molecular drug
DMCWFUZ	PC	135987619
DMCWFUZ	MW	237.25
DMCWFUZ	FM	C15H11NO2
DMCWFUZ	IC	InChI=1S/C15H11NO2/c17-12-4-1-10(2-5-12)14-7-3-11-9-13(18)6-8-15(11)16-14/h1-9,17-18H
DMCWFUZ	CS	C1=CC(=CC=C1C2=NC3=C(C=C2)C=C(C=C3)O)O
DMCWFUZ	IK	SEKOFPJLRLFURL-UHFFFAOYSA-N
DMCWFUZ	IU	2-(4-hydroxyphenyl)quinolin-6-ol
DMCWFUZ	DE	Discovery agent

DM8GBH4	ID	DM8GBH4
DM8GBH4	DN	2-(4-hydroxystyryl)quinolin-8-ol
DM8GBH4	HS	Investigative
DM8GBH4	DT	Small molecular drug
DM8GBH4	PC	135500760
DM8GBH4	MW	263.29
DM8GBH4	FM	C17H13NO2
DM8GBH4	IC	InChI=1S/C17H13NO2/c19-15-10-5-12(6-11-15)4-8-14-9-7-13-2-1-3-16(20)17(13)18-14/h1-11,19-20H/b8-4+
DM8GBH4	CS	C1=CC2=C(C(=C1)O)N=C(C=C2)/C=C/C3=CC=C(C=C3)O
DM8GBH4	IK	YMSHSKJZBZKCOR-XBXARRHUSA-N
DM8GBH4	IU	2-[(E)-2-(4-hydroxyphenyl)ethenyl]quinolin-8-ol
DM8GBH4	DE	Discovery agent

DMUIVS9	ID	DMUIVS9
DMUIVS9	DN	2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine
DMUIVS9	HS	Investigative
DMUIVS9	SN	CHEMBL112592; 2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine; SCHEMBL14129997; BDBM50138232
DMUIVS9	DT	Small molecular drug
DMUIVS9	PC	44341428
DMUIVS9	MW	251.28
DMUIVS9	FM	C15H13N3O
DMUIVS9	IC	InChI=1S/C15H13N3O/c1-2-8-17-13(3-1)11-19-15-6-4-14(5-7-15)18-10-9-16-12-18/h1-10,12H,11H2
DMUIVS9	CS	C1=CC=NC(=C1)COC2=CC=C(C=C2)N3C=CN=C3
DMUIVS9	IK	IMJROXJEYNKELD-UHFFFAOYSA-N
DMUIVS9	IU	2-[(4-imidazol-1-ylphenoxy)methyl]pyridine
DMUIVS9	DE	Discovery agent

DMSH4WP	ID	DMSH4WP
DMSH4WP	DN	2-(4-Isopropyl-piperazin-1-yl)-quinoline
DMSH4WP	HS	Investigative
DMSH4WP	SN	CHEMBL360253; 2-(4-Isopropyl-piperazin-1-yl)-quinoline; SCHEMBL13648771
DMSH4WP	DT	Small molecular drug
DMSH4WP	PC	11393294
DMSH4WP	MW	255.36
DMSH4WP	FM	C16H21N3
DMSH4WP	IC	InChI=1S/C16H21N3/c1-13(2)18-9-11-19(12-10-18)16-8-7-14-5-3-4-6-15(14)17-16/h3-8,13H,9-12H2,1-2H3
DMSH4WP	CS	CC(C)N1CCN(CC1)C2=NC3=CC=CC=C3C=C2
DMSH4WP	IK	WICRMWNIFYTKBK-UHFFFAOYSA-N
DMSH4WP	IU	2-(4-propan-2-ylpiperazin-1-yl)quinoline
DMSH4WP	DE	Discovery agent

DMXPJF3	ID	DMXPJF3
DMXPJF3	DN	2-(4-Mercapto-butyl)-pentanedioic acid
DMXPJF3	HS	Investigative
DMXPJF3	SN	CHEMBL60317; 2-(4-Mercapto-butyl)-pentanedioic acid; SCHEMBL6383425
DMXPJF3	DT	Small molecular drug
DMXPJF3	PC	10130679
DMXPJF3	MW	220.29
DMXPJF3	FM	C9H16O4S
DMXPJF3	IC	InChI=1S/C9H16O4S/c10-8(11)5-4-7(9(12)13)3-1-2-6-14/h7,14H,1-6H2,(H,10,11)(H,12,13)
DMXPJF3	CS	C(CCS)CC(CCC(=O)O)C(=O)O
DMXPJF3	IK	QFKHEJQVTSTWPJ-UHFFFAOYSA-N
DMXPJF3	IU	2-(4-sulfanylbutyl)pentanedioic acid
DMXPJF3	DE	Discovery agent

DMHAE31	ID	DMHAE31
DMHAE31	DN	2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione
DMHAE31	HS	Investigative
DMHAE31	SN	2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione; CHEMBL205983; SCHEMBL13442854; Isoquinoline-1,3,4-trione 2e; CTK7A3832; BDBM10252; AKOS015966190; 2-(4-METHOXY-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE
DMHAE31	DT	Small molecular drug
DMHAE31	PC	11522185
DMHAE31	MW	295.29
DMHAE31	FM	C17H13NO4
DMHAE31	IC	InChI=1S/C17H13NO4/c1-22-12-8-6-11(7-9-12)10-18-16(20)14-5-3-2-4-13(14)15(19)17(18)21/h2-9H,10H2,1H3
DMHAE31	CS	COC1=CC=C(C=C1)CN2C(=O)C3=CC=CC=C3C(=O)C2=O
DMHAE31	IK	UJBONJNKVPTSPR-UHFFFAOYSA-N
DMHAE31	IU	2-[(4-methoxyphenyl)methyl]isoquinoline-1,3,4-trione
DMHAE31	DE	Discovery agent

DMZNPMQ	ID	DMZNPMQ
DMZNPMQ	DN	2-(4-methoxybenzylthio)-6-methylpyrimidin-4-ol
DMZNPMQ	HS	Investigative
DMZNPMQ	DT	Small molecular drug
DMZNPMQ	PC	716696
DMZNPMQ	DE	Discovery agent

DMTEQU8	ID	DMTEQU8
DMTEQU8	DN	2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde
DMTEQU8	HS	Investigative
DMTEQU8	SN	2-(4-methoxyphenyl)-1H-indole-3-carbaldehyde; 76195-80-7; AC1MY4K3; CHEMBL144222; SCHEMBL15332438; CTK2G8075; DTXSID90396949; MolPort-006-701-191; IAL-1620; ZX-BK002979; ZINC3675784; KM5032; STK894724; BBL022005; AKOS005143919; MCULE-1940549514; 1H-Indole-3-carboxaldehyde, 2-(4-methoxyphenyl)-
DMTEQU8	DT	Small molecular drug
DMTEQU8	PC	3826063
DMTEQU8	MW	251.28
DMTEQU8	FM	C16H13NO2
DMTEQU8	IC	InChI=1S/C16H13NO2/c1-19-12-8-6-11(7-9-12)16-14(10-18)13-4-2-3-5-15(13)17-16/h2-10,17H,1H3
DMTEQU8	CS	COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=O
DMTEQU8	IK	QIMWZVMNUAWWSJ-UHFFFAOYSA-N
DMTEQU8	IU	2-(4-methoxyphenyl)-1H-indole-3-carbaldehyde
DMTEQU8	CA	CAS 76195-80-7
DMTEQU8	DE	Discovery agent

DM0KUMX	ID	DM0KUMX
DM0KUMX	DN	2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole
DM0KUMX	HS	Investigative
DM0KUMX	SN	2-(4-Methoxyphenyl)-4,5-dihydro-1H-imidazole; 6302-84-7; 4,5-Dihydro-2-(4-methoxyphenyl)-1H-Imidazole; 2-Imidazoline, 2-(p-methoxyphenyl)-; 1H-Imidazole, 4,5-dihydro-2-(4-methoxyphenyl)-; CHEMBL13633; NSC41538; AC1L5ZGN; 2-(p-Anisyl)-1-imidazoline; SCHEMBL9575256; AC1Q580G; CTK5B7166; DTXSID40285359; LPRQSQCAHSRGRZ-UHFFFAOYSA-N; ZINC1672770; BDBM50240364; NSC-41538; AKOS022491172; MCULE-4518622050; 1-(2-imidazolin-2-yl)-4-methoxybenzene; 2-(P-METHOXY-PHENYL)-IMIDAZOLINE; DB-073247; KB-222983; ST50998435; FT-0712566
DM0KUMX	DT	Small molecular drug
DM0KUMX	PC	237746
DM0KUMX	MW	176.21
DM0KUMX	FM	C10H12N2O
DM0KUMX	IC	InChI=1S/C10H12N2O/c1-13-9-4-2-8(3-5-9)10-11-6-7-12-10/h2-5H,6-7H2,1H3,(H,11,12)
DM0KUMX	CS	COC1=CC=C(C=C1)C2=NCCN2
DM0KUMX	IK	LPRQSQCAHSRGRZ-UHFFFAOYSA-N
DM0KUMX	IU	2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole
DM0KUMX	CA	CAS 6302-84-7
DM0KUMX	DE	Discovery agent

DMIDXTR	ID	DMIDXTR
DMIDXTR	DN	2-(4-methoxyphenyl)-4H-chromene-4-thione
DMIDXTR	HS	Investigative
DMIDXTR	SN	CHEMBL607571; 2-(4-methoxyphenyl)chromene-4-thione; AC1LO0PS; 2-(4-methoxyphenyl)-4H-chromene-4-thione; MolPort-019-767-607; ZINC1011200; BDBM50310182
DMIDXTR	DT	Small molecular drug
DMIDXTR	PC	1231330
DMIDXTR	MW	268.3
DMIDXTR	FM	C16H12O2S
DMIDXTR	IC	InChI=1S/C16H12O2S/c1-17-12-8-6-11(7-9-12)15-10-16(19)13-4-2-3-5-14(13)18-15/h2-10H,1H3
DMIDXTR	CS	COC1=CC=C(C=C1)C2=CC(=S)C3=CC=CC=C3O2
DMIDXTR	IK	VNYCDMLKRQOQKQ-UHFFFAOYSA-N
DMIDXTR	IU	2-(4-methoxyphenyl)chromene-4-thione
DMIDXTR	DE	Discovery agent

DMZ9A6U	ID	DMZ9A6U
DMZ9A6U	DN	2-(4-Methoxy-phenyl)-5-phenyl-thiazol-4-ol
DMZ9A6U	HS	Investigative
DMZ9A6U	SN	CHEMBL65940; 2-(4-Methoxyphenyl)-5-phenylthiazol-4-ol; 2-(4-Methoxy-phenyl)-5-phenyl-thiazol-4-ol; Oprea1_607545; SCHEMBL9629437; YQAKORGQQCUKEJ-UHFFFAOYSA-N; BDBM50012392
DMZ9A6U	DT	Small molecular drug
DMZ9A6U	PC	14425906
DMZ9A6U	MW	283.3
DMZ9A6U	FM	C16H13NO2S
DMZ9A6U	IC	InChI=1S/C16H13NO2S/c1-19-13-9-7-12(8-10-13)16-17-15(18)14(20-16)11-5-3-2-4-6-11/h2-10,18H,1H3
DMZ9A6U	CS	COC1=CC=C(C=C1)C2=NC(=C(S2)C3=CC=CC=C3)O
DMZ9A6U	IK	YQAKORGQQCUKEJ-UHFFFAOYSA-N
DMZ9A6U	IU	2-(4-methoxyphenyl)-5-phenyl-1,3-thiazol-4-ol
DMZ9A6U	DE	Discovery agent

DMVQU1M	ID	DMVQU1M
DMVQU1M	DN	2-(4-methoxyphenyl)-6-morpholino-4H-pyran-4-one
DMVQU1M	HS	Investigative
DMVQU1M	SN	CHEMBL319261; 2-(4-methoxyphenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3545199; BDBM50132361; 2-(4-methoxyphenyl)-6-morpholin-4-ylpyran-4-one; 2-Morpholino-6-(4-methoxyphenyl)-4H-pyran-4-one; 2-(4-Methoxy-phenyl)-6-morpholin-4-yl-pyran-4-one
DMVQU1M	DT	Small molecular drug
DMVQU1M	PC	16745325
DMVQU1M	MW	287.31
DMVQU1M	FM	C16H17NO4
DMVQU1M	IC	InChI=1S/C16H17NO4/c1-19-14-4-2-12(3-5-14)15-10-13(18)11-16(21-15)17-6-8-20-9-7-17/h2-5,10-11H,6-9H2,1H3
DMVQU1M	CS	COC1=CC=C(C=C1)C2=CC(=O)C=C(O2)N3CCOCC3
DMVQU1M	IK	QJIHTEXMXZZXDS-UHFFFAOYSA-N
DMVQU1M	IU	2-(4-methoxyphenyl)-6-morpholin-4-ylpyran-4-one
DMVQU1M	DE	Discovery agent

DMXTHOV	ID	DMXTHOV
DMXTHOV	DN	2-(4-methoxyphenyl)-6-phenyl-9H-purine
DMXTHOV	HS	Investigative
DMXTHOV	SN	CHEMBL207760; 2-(4-methoxyphenyl)-6-phenyl-9H-purine
DMXTHOV	DT	Small molecular drug
DMXTHOV	PC	11536774
DMXTHOV	MW	302.3
DMXTHOV	FM	C18H14N4O
DMXTHOV	IC	InChI=1S/C18H14N4O/c1-23-14-9-7-13(8-10-14)17-21-15(12-5-3-2-4-6-12)16-18(22-17)20-11-19-16/h2-11H,1H3,(H,19,20,21,22)
DMXTHOV	CS	COC1=CC=C(C=C1)C2=NC(=C3C(=N2)N=CN3)C4=CC=CC=C4
DMXTHOV	IK	COPIEKYOHOQDKK-UHFFFAOYSA-N
DMXTHOV	IU	2-(4-methoxyphenyl)-6-phenyl-7H-purine
DMXTHOV	DE	Discovery agent

DMS572H	ID	DMS572H
DMS572H	DN	2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one
DMS572H	HS	Investigative
DMS572H	DT	Small molecular drug
DMS572H	PC	135407310
DMS572H	MW	266.29
DMS572H	FM	C16H14N2O2
DMS572H	IC	InChI=1S/C16H14N2O2/c1-10-4-3-5-13-14(10)17-15(18-16(13)19)11-6-8-12(20-2)9-7-11/h3-9H,1-2H3,(H,17,18,19)
DMS572H	CS	CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=C(C=C3)OC
DMS572H	IK	HTLUBFSSIMOABR-UHFFFAOYSA-N
DMS572H	IU	2-(4-methoxyphenyl)-8-methyl-3H-quinazolin-4-one
DMS572H	DE	Discovery agent

DM1N08O	ID	DM1N08O
DM1N08O	DN	2-(4-methoxyphenyl)-N-(thiazol-2-yl)acetamide
DM1N08O	HS	Investigative
DM1N08O	SN	2-(4-methoxyphenyl)-N-(1,3-thiazol-2-yl)acetamide; AC1LGGXP; Cambridge id 5286247; Oprea1_702537; Oprea1_294245; CHEMBL227898; MolPort-001-026-371; ZINC253385; STL503574; AKOS000673322; MCULE-3731631352; BAS 00626097; KB-115460; ST50912475; 2-(4-Methoxy-phenyl)-N-thiazol-2-yl-acetamide; 2-(4-methoxyphenyl)-N-1,3-thiazol-2-ylacetamide; Z28173731
DM1N08O	DT	Small molecular drug
DM1N08O	PC	770967
DM1N08O	MW	248.3
DM1N08O	FM	C12H12N2O2S
DM1N08O	IC	InChI=1S/C12H12N2O2S/c1-16-10-4-2-9(3-5-10)8-11(15)14-12-13-6-7-17-12/h2-7H,8H2,1H3,(H,13,14,15)
DM1N08O	CS	COC1=CC=C(C=C1)CC(=O)NC2=NC=CS2
DM1N08O	IK	SPAPWVUPZKTBMH-UHFFFAOYSA-N
DM1N08O	IU	2-(4-methoxyphenyl)-N-(1,3-thiazol-2-yl)acetamide
DM1N08O	DE	Discovery agent

DMBRETS	ID	DMBRETS
DMBRETS	DN	2-(4-methoxyphenyl)quinoline-8-carboxamide
DMBRETS	HS	Investigative
DMBRETS	SN	2-(4-methoxyphenyl)quinoline-8-carboxamide; CHEMBL481591; 655222-47-2; CTK1J6622; DTXSID70649086; BDBM50255383; AKOS030560276; 8-Quinolinecarboxamide, 2-(4-methoxyphenyl)-
DMBRETS	DT	Small molecular drug
DMBRETS	PC	25209058
DMBRETS	MW	278.3
DMBRETS	FM	C17H14N2O2
DMBRETS	IC	InChI=1S/C17H14N2O2/c1-21-13-8-5-11(6-9-13)15-10-7-12-3-2-4-14(17(18)20)16(12)19-15/h2-10H,1H3,(H2,18,20)
DMBRETS	CS	COC1=CC=C(C=C1)C2=NC3=C(C=CC=C3C(=O)N)C=C2
DMBRETS	IK	HJJCORRFLXJIBM-UHFFFAOYSA-N
DMBRETS	IU	2-(4-methoxyphenyl)quinoline-8-carboxamide
DMBRETS	CA	CAS 655222-47-2
DMBRETS	DE	Discovery agent

DMDXIN1	ID	DMDXIN1
DMDXIN1	DN	2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline
DMDXIN1	HS	Investigative
DMDXIN1	SN	CHEMBL198779; benzimidazole-quinoxaline, C3; SCHEMBL12834347; BDBM21217; ZINC13678106
DMDXIN1	DT	Small molecular drug
DMDXIN1	PC	11521761
DMDXIN1	MW	260.29
DMDXIN1	FM	C16H12N4
DMDXIN1	IC	InChI=1S/C16H12N4/c1-10-5-4-8-13-15(10)20-16(19-13)14-9-17-11-6-2-3-7-12(11)18-14/h2-9H,1H3,(H,19,20)
DMDXIN1	CS	CC1=C2C(=CC=C1)NC(=N2)C3=NC4=CC=CC=C4N=C3
DMDXIN1	IK	HQNVISKJTIKRQJ-UHFFFAOYSA-N
DMDXIN1	IU	2-(4-methyl-1H-benzimidazol-2-yl)quinoxaline
DMDXIN1	DE	Discovery agent

DM943YL	ID	DM943YL
DM943YL	DN	2-(4-Methyl-indole-1-sulfonyl)-benzoic acid
DM943YL	HS	Investigative
DM943YL	SN	CHEMBL184195; 2-(4-Methyl-indole-1-sulfonyl)-benzoic acid
DM943YL	DT	Small molecular drug
DM943YL	PC	44393606
DM943YL	MW	315.3
DM943YL	FM	C16H13NO4S
DM943YL	IC	InChI=1S/C16H13NO4S/c1-11-5-4-7-14-12(11)9-10-17(14)22(20,21)15-8-3-2-6-13(15)16(18)19/h2-10H,1H3,(H,18,19)
DM943YL	CS	CC1=C2C=CN(C2=CC=C1)S(=O)(=O)C3=CC=CC=C3C(=O)O
DM943YL	IK	FSVUAMOXCTUQEP-UHFFFAOYSA-N
DM943YL	IU	2-(4-methylindol-1-yl)sulfonylbenzoic acid
DM943YL	DE	Discovery agent

DMDHFU9	ID	DMDHFU9
DMDHFU9	DN	2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine
DMDHFU9	HS	Investigative
DMDHFU9	SN	CHEMBL45158; 159692-85-0; 2-(4-methylpiperazin-1-yl)-4-phenylpyrimidine; 2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine; SCHEMBL1275203; CTK0B0099; DTXSID80438281; QHOBPFOGFURKFZ-UHFFFAOYSA-N; BDBM50289600; 1-(4-Phenylpyrimidin-2-yl)-4-methylpiperazine; Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-phenyl-
DMDHFU9	DT	Small molecular drug
DMDHFU9	PC	10332554
DMDHFU9	MW	254.33
DMDHFU9	FM	C15H18N4
DMDHFU9	IC	InChI=1S/C15H18N4/c1-18-9-11-19(12-10-18)15-16-8-7-14(17-15)13-5-3-2-4-6-13/h2-8H,9-12H2,1H3
DMDHFU9	CS	CN1CCN(CC1)C2=NC=CC(=N2)C3=CC=CC=C3
DMDHFU9	IK	QHOBPFOGFURKFZ-UHFFFAOYSA-N
DMDHFU9	IU	2-(4-methylpiperazin-1-yl)-4-phenylpyrimidine
DMDHFU9	CA	CAS 159692-85-0
DMDHFU9	DE	Discovery agent

DMB8OY6	ID	DMB8OY6
DMB8OY6	DN	2-(4-Methyl-piperazin-1-yl)-quinoline
DMB8OY6	HS	Investigative
DMB8OY6	SN	N-methylquipazine; 2-(4-methylpiperazin-1-yl)quinoline; UNII-0YV1ZIR6S0; 0YV1ZIR6S0; CHEMBL288591; CHEBI:64164; quinoline, 2-(4-methyl-1-piperazinyl)-; 2-(4-Methyl-piperazin-1-yl)-quinoline; Tocris-0566; Lopac-Q-107; Biomol-NT_000084; AC1L1JF3; Oprea1_654246; Lopac0_001000; SCHEMBL606721; BPBio1_001081; DTXSID8043731; CTK6I3065; HOMWNUXPSJQSSU-UHFFFAOYSA-N; MolPort-006-384-975; ZINC403653; 2-(4-Methylpiperazinyl)-quinoline; 1-(2-Quinolyl)-4-methylpiperazine; STK362919; BDBM50053631; AKOS005453926; MCULE-4786527390; CCG-205080
DMB8OY6	DT	Small molecular drug
DMB8OY6	PC	5013
DMB8OY6	MW	227.3
DMB8OY6	FM	C14H17N3
DMB8OY6	IC	InChI=1S/C14H17N3/c1-16-8-10-17(11-9-16)14-7-6-12-4-2-3-5-13(12)15-14/h2-7H,8-11H2,1H3
DMB8OY6	CS	CN1CCN(CC1)C2=NC3=CC=CC=C3C=C2
DMB8OY6	IK	HOMWNUXPSJQSSU-UHFFFAOYSA-N
DMB8OY6	IU	2-(4-methylpiperazin-1-yl)quinoline
DMB8OY6	CA	CAS 28614-26-8
DMB8OY6	CB	CHEBI:64164
DMB8OY6	DE	Discovery agent

DMBJICP	ID	DMBJICP
DMBJICP	DN	2-(4-nitro-1H-benzo[d]imidazol-2-yl)quinoxaline
DMBJICP	HS	Investigative
DMBJICP	SN	CHEMBL198060; 2-(4-nitro-1H-benzo[d]imidazol-2-yl)quinoxaline
DMBJICP	DT	Small molecular drug
DMBJICP	PC	11565524
DMBJICP	MW	291.26
DMBJICP	FM	C15H9N5O2
DMBJICP	IC	InChI=1S/C15H9N5O2/c21-20(22)13-7-3-6-11-14(13)19-15(18-11)12-8-16-9-4-1-2-5-10(9)17-12/h1-8H,(H,18,19)
DMBJICP	CS	C1=CC=C2C(=C1)N=CC(=N2)C3=NC4=C(N3)C=CC=C4[N+](=O)[O-]
DMBJICP	IK	RDSFCGCNTCJZOD-UHFFFAOYSA-N
DMBJICP	IU	2-(4-nitro-1H-benzimidazol-2-yl)quinoxaline
DMBJICP	DE	Discovery agent

DMX8U32	ID	DMX8U32
DMX8U32	DN	2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene
DMX8U32	HS	Investigative
DMX8U32	SN	CHEMBL205403; 2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene
DMX8U32	DT	Small molecular drug
DMX8U32	PC	10425576
DMX8U32	MW	311.4
DMX8U32	FM	C17H13NO3S
DMX8U32	IC	InChI=1S/C17H13NO3S/c1-21-15-8-4-13(5-9-15)17-11-10-16(22-17)12-2-6-14(7-3-12)18(19)20/h2-11H,1H3
DMX8U32	CS	COC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)[N+](=O)[O-]
DMX8U32	IK	JNOACYJDBPZIMJ-UHFFFAOYSA-N
DMX8U32	IU	2-(4-methoxyphenyl)-5-(4-nitrophenyl)thiophene
DMX8U32	DE	Discovery agent

DMR54SW	ID	DMR54SW
DMR54SW	DN	2-(4-pentylphenyl)-N-(pyridin-3-yl)acetamide
DMR54SW	HS	Investigative
DMR54SW	SN	CHEMBL260464
DMR54SW	DT	Small molecular drug
DMR54SW	PC	44450365
DMR54SW	MW	282.4
DMR54SW	FM	C18H22N2O
DMR54SW	IC	InChI=1S/C18H22N2O/c1-2-3-4-6-15-8-10-16(11-9-15)13-18(21)20-17-7-5-12-19-14-17/h5,7-12,14H,2-4,6,13H2,1H3,(H,20,21)
DMR54SW	CS	CCCCCC1=CC=C(C=C1)CC(=O)NC2=CN=CC=C2
DMR54SW	IK	VYJQGHFNPZKVTQ-UHFFFAOYSA-N
DMR54SW	IU	2-(4-pentylphenyl)-N-pyridin-3-ylacetamide
DMR54SW	DE	Discovery agent

DM65IF1	ID	DM65IF1
DM65IF1	DN	2-(4-Phenoxy-benzyl)-1H-benzoimidazole
DM65IF1	HS	Investigative
DM65IF1	SN	CHEMBL67249; SCHEMBL7510229
DM65IF1	DT	Small molecular drug
DM65IF1	PC	9817808
DM65IF1	MW	300.4
DM65IF1	FM	C20H16N2O
DM65IF1	IC	InChI=1S/C20H16N2O/c1-2-6-16(7-3-1)23-17-12-10-15(11-13-17)14-20-21-18-8-4-5-9-19(18)22-20/h1-13H,14H2,(H,21,22)
DM65IF1	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=CC=CC=C4N3
DM65IF1	IK	HWTRVTWTEQIXOY-UHFFFAOYSA-N
DM65IF1	IU	2-[(4-phenoxyphenyl)methyl]-1H-benzimidazole
DM65IF1	DE	Discovery agent

DM3HANW	ID	DM3HANW
DM3HANW	DN	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol
DM3HANW	HS	Investigative
DM3HANW	SN	CHEMBL63924
DM3HANW	DT	Small molecular drug
DM3HANW	PC	9796984
DM3HANW	MW	316.4
DM3HANW	FM	C20H16N2O2
DM3HANW	IC	InChI=1S/C20H16N2O2/c23-18-8-4-7-17-20(18)22-19(21-17)13-14-9-11-16(12-10-14)24-15-5-2-1-3-6-15/h1-12,23H,13H2,(H,21,22)
DM3HANW	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=C(N3)C=CC=C4O
DM3HANW	IK	MRBKMMZUVLPGTA-UHFFFAOYSA-N
DM3HANW	IU	2-[(4-phenoxyphenyl)methyl]-1H-benzimidazol-4-ol
DM3HANW	DE	Discovery agent

DMFO19B	ID	DMFO19B
DMFO19B	DN	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol
DMFO19B	HS	Investigative
DMFO19B	SN	CHEMBL63200; SCHEMBL7453649
DMFO19B	DT	Small molecular drug
DMFO19B	PC	9839919
DMFO19B	MW	316.4
DMFO19B	FM	C20H16N2O2
DMFO19B	IC	InChI=1S/C20H16N2O2/c23-15-8-11-18-19(13-15)22-20(21-18)12-14-6-9-17(10-7-14)24-16-4-2-1-3-5-16/h1-11,13,23H,12H2,(H,21,22)
DMFO19B	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=C(N3)C=C(C=C4)O
DMFO19B	IK	LVCCXJOSNNQODU-UHFFFAOYSA-N
DMFO19B	IU	2-[(4-phenoxyphenyl)methyl]-3H-benzimidazol-5-ol
DMFO19B	DE	Discovery agent

DMJSBFU	ID	DMJSBFU
DMJSBFU	DN	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine
DMJSBFU	HS	Investigative
DMJSBFU	SN	CHEMBL65119
DMJSBFU	DT	Small molecular drug
DMJSBFU	PC	9883372
DMJSBFU	MW	315.4
DMJSBFU	FM	C20H17N3O
DMJSBFU	IC	InChI=1S/C20H17N3O/c21-15-8-11-18-19(13-15)23-20(22-18)12-14-6-9-17(10-7-14)24-16-4-2-1-3-5-16/h1-11,13H,12,21H2,(H,22,23)
DMJSBFU	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=C(N3)C=C(C=C4)N
DMJSBFU	IK	KVTYWLATLSZWKO-UHFFFAOYSA-N
DMJSBFU	IU	2-[(4-phenoxyphenyl)methyl]-3H-benzimidazol-5-amine
DMJSBFU	DE	Discovery agent

DM7TBUJ	ID	DM7TBUJ
DM7TBUJ	DN	2-(4-phenoxyphenoxy)ethanamine
DM7TBUJ	HS	Investigative
DM7TBUJ	SN	2-(4-phenoxyphenoxy)ethanamine; CHEMBL472386; 2-(4-Phenoxyphenoxy)Ethylamine; 72490-14-3; SCHEMBL9486899; SCHEMBL4653229; CTK2H2396; DTXSID40452640; FBLANPWAVFBRNS-UHFFFAOYSA-N; 2-[(p-phenoxy)phenoxy]ethylamine; Ethanamine, 2-(4-phenoxyphenoxy)-; ZINC11945831; BDBM50246062
DM7TBUJ	DT	Small molecular drug
DM7TBUJ	PC	11031651
DM7TBUJ	MW	229.27
DM7TBUJ	FM	C14H15NO2
DM7TBUJ	IC	InChI=1S/C14H15NO2/c15-10-11-16-12-6-8-14(9-7-12)17-13-4-2-1-3-5-13/h1-9H,10-11,15H2
DM7TBUJ	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)OCCN
DM7TBUJ	IK	FBLANPWAVFBRNS-UHFFFAOYSA-N
DM7TBUJ	IU	2-(4-phenoxyphenoxy)ethanamine
DM7TBUJ	CA	CAS 72490-14-3
DM7TBUJ	DE	Discovery agent

DMSPOAT	ID	DMSPOAT
DMSPOAT	DN	2-(4-Phenoxy-phenyl)-1H-benzoimidazol-5-ylamine
DMSPOAT	HS	Investigative
DMSPOAT	SN	CHEMBL179383; 2-(4-Phenoxy-phenyl)-1H-benzoimidazol-5-ylamine
DMSPOAT	DT	Small molecular drug
DMSPOAT	PC	11407345
DMSPOAT	MW	301.3
DMSPOAT	FM	C19H15N3O
DMSPOAT	IC	InChI=1S/C19H15N3O/c20-14-8-11-17-18(12-14)22-19(21-17)13-6-9-16(10-7-13)23-15-4-2-1-3-5-15/h1-12H,20H2,(H,21,22)
DMSPOAT	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=NC4=C(N3)C=C(C=C4)N
DMSPOAT	IK	YDXHPXOLZYGIGV-UHFFFAOYSA-N
DMSPOAT	IU	2-(4-phenoxyphenyl)-3H-benzimidazol-5-amine
DMSPOAT	DE	Discovery agent

DMEQ063	ID	DMEQ063
DMEQ063	DN	2-(4-Phenyl-butyl)-1,2-dihydro-indazol-3-one
DMEQ063	HS	Investigative
DMEQ063	SN	CHEMBL3144714; 2-(4-Phenyl-butyl)-1,2-dihydro-indazol-3-one; CHEMBL269654; BDBM50009016
DMEQ063	DT	Small molecular drug
DMEQ063	PC	14898718
DMEQ063	MW	266.34
DMEQ063	FM	C17H18N2O
DMEQ063	IC	InChI=1S/C17H18N2O/c20-17-15-11-4-5-12-16(15)18-19(17)13-7-6-10-14-8-2-1-3-9-14/h1-5,8-9,11-12,18H,6-7,10,13H2
DMEQ063	CS	C1=CC=C(C=C1)CCCCN2C(=O)C3=CC=CC=C3N2
DMEQ063	IK	VMGHZFARQGLROM-UHFFFAOYSA-N
DMEQ063	IU	2-(4-phenylbutyl)-1H-indazol-3-one
DMEQ063	DE	Discovery agent

DMNJAV1	ID	DMNJAV1
DMNJAV1	DN	2-(4-phenylbutyl)pyrido[2,3-d]pyrimidin-4(3H)-one
DMNJAV1	HS	Investigative
DMNJAV1	DT	Small molecular drug
DMNJAV1	PC	135899247
DMNJAV1	MW	279.34
DMNJAV1	FM	C17H17N3O
DMNJAV1	IC	InChI=1S/C17H17N3O/c21-17-14-10-6-12-18-16(14)19-15(20-17)11-5-4-9-13-7-2-1-3-8-13/h1-3,6-8,10,12H,4-5,9,11H2,(H,18,19,20,21)
DMNJAV1	CS	C1=CC=C(C=C1)CCCCC2=NC3=C(C=CC=N3)C(=O)N2
DMNJAV1	IK	KGCFTSWBCFAQQI-UHFFFAOYSA-N
DMNJAV1	IU	2-(4-phenylbutyl)-3H-pyrido[2,3-d]pyrimidin-4-one
DMNJAV1	DE	Discovery agent

DM98WVL	ID	DM98WVL
DM98WVL	DN	2-(4-Piperidin-1-ylmethylphenoxy)benzothiazole
DM98WVL	HS	Investigative
DM98WVL	SN	Benzthiazole compound, 33b; SCHEMBL4689016; CHEMBL454760; BDBM24231
DM98WVL	DT	Small molecular drug
DM98WVL	PC	11472798
DM98WVL	MW	324.4
DM98WVL	FM	C19H20N2OS
DM98WVL	IC	InChI=1S/C19H20N2OS/c1-4-12-21(13-5-1)14-15-8-10-16(11-9-15)22-19-20-17-6-2-3-7-18(17)23-19/h2-3,6-11H,1,4-5,12-14H2
DM98WVL	CS	C1CCN(CC1)CC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3
DM98WVL	IK	JNKRNJIZLGLIJG-UHFFFAOYSA-N
DM98WVL	IU	2-[4-(piperidin-1-ylmethyl)phenoxy]-1,3-benzothiazole
DM98WVL	DE	Discovery agent

DMXC20R	ID	DMXC20R
DMXC20R	DN	2-(4-propylphenylsulfonyl)naphthalene-1,4-diol
DMXC20R	HS	Investigative
DMXC20R	SN	CHEMBL445555; 2-(4-propylphenylsulfonyl)naphthalene-1,4-diol; BDBM50245880; J3.494.437G
DMXC20R	DT	Small molecular drug
DMXC20R	PC	44562692
DMXC20R	MW	342.4
DMXC20R	FM	C19H18O4S
DMXC20R	IC	InChI=1S/C19H18O4S/c1-2-5-13-8-10-14(11-9-13)24(22,23)18-12-17(20)15-6-3-4-7-16(15)19(18)21/h3-4,6-12,20-21H,2,5H2,1H3
DMXC20R	CS	CCCC1=CC=C(C=C1)S(=O)(=O)C2=C(C3=CC=CC=C3C(=C2)O)O
DMXC20R	IK	BCECDLBGKYFWCS-UHFFFAOYSA-N
DMXC20R	IU	2-(4-propylphenyl)sulfonylnaphthalene-1,4-diol
DMXC20R	DE	Discovery agent

DMWPM9L	ID	DMWPM9L
DMWPM9L	DN	2-(4-Propyl-piperazin-1-yl)-quinoline
DMWPM9L	HS	Investigative
DMWPM9L	SN	CHEMBL180478; 2-(4-Propyl-piperazin-1-yl)-quinoline; Oprea1_188953; SCHEMBL3970431; 2-(4-Ethylpiperazino)quinoline; HEWVIFVVKWCRML-UHFFFAOYSA-N; BDBM50159120
DMWPM9L	DT	Small molecular drug
DMWPM9L	PC	11370427
DMWPM9L	MW	241.33
DMWPM9L	FM	C15H19N3
DMWPM9L	IC	InChI=1S/C15H19N3/c1-2-17-9-11-18(12-10-17)15-8-7-13-5-3-4-6-14(13)16-15/h3-8H,2,9-12H2,1H3
DMWPM9L	CS	CCN1CCN(CC1)C2=NC3=CC=CC=C3C=C2
DMWPM9L	IK	HEWVIFVVKWCRML-UHFFFAOYSA-N
DMWPM9L	IU	2-(4-ethylpiperazin-1-yl)quinoline
DMWPM9L	DE	Discovery agent

DMIOW3D	ID	DMIOW3D
DMIOW3D	DN	2-(4-tert-butylbenzylideneamino)ethanesulfonamide
DMIOW3D	HS	Investigative
DMIOW3D	SN	CHEMBL575785; 2-(4-tert-butylbenzylideneamino)ethanesulfonamide
DMIOW3D	DT	Small molecular drug
DMIOW3D	PC	45483187
DMIOW3D	MW	268.38
DMIOW3D	FM	C13H20N2O2S
DMIOW3D	IC	InChI=1S/C13H20N2O2S/c1-13(2,3)12-6-4-11(5-7-12)10-15-8-9-18(14,16)17/h4-7,10H,8-9H2,1-3H3,(H2,14,16,17)
DMIOW3D	CS	CC(C)(C)C1=CC=C(C=C1)C=NCCS(=O)(=O)N
DMIOW3D	IK	KYYQVPLISNAOAE-UHFFFAOYSA-N
DMIOW3D	IU	2-[(4-tert-butylphenyl)methylideneamino]ethanesulfonamide
DMIOW3D	DE	Discovery agent

DM1A4BS	ID	DM1A4BS
DM1A4BS	DN	2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole
DM1A4BS	HS	Investigative
DM1A4BS	SN	CHEMBL276868; 67277-66-1; 2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole; SCHEMBL8229695; CTK1J3678; DTXSID50658095; ZINC13806045; BDBM50151704; AKOS022538449; 2-(4-tert-Butylphenyl)-4,5-dihydro-1H-imidazole; 1H-Imidazole, 2-[4-(1,1-dimethylethyl)phenyl]-4,5-dihydro-
DM1A4BS	DT	Small molecular drug
DM1A4BS	PC	44269078
DM1A4BS	MW	202.3
DM1A4BS	FM	C13H18N2
DM1A4BS	IC	InChI=1S/C13H18N2/c1-13(2,3)11-6-4-10(5-7-11)12-14-8-9-15-12/h4-7H,8-9H2,1-3H3,(H,14,15)
DM1A4BS	CS	CC(C)(C)C1=CC=C(C=C1)C2=NCCN2
DM1A4BS	IK	JRUYKUSXUFPDNO-UHFFFAOYSA-N
DM1A4BS	IU	2-(4-tert-butylphenyl)-4,5-dihydro-1H-imidazole
DM1A4BS	CA	CAS 67277-66-1
DM1A4BS	DE	Discovery agent

DMED9FL	ID	DMED9FL
DMED9FL	DN	2-(4-tosylpiperazin-1-yl)nicotinonitrile
DMED9FL	HS	Investigative
DMED9FL	SN	arylsulfonylpiperazine, 27; CHEMBL404148; BDBM32555; MolPort-005-568-142; ZINC23996035; AKOS029603555; MCULE-2636718919; AB00772161-01; Z31097483; 2-[4-(4-methylbenzenesulfonyl)piperazin-1-yl]pyridine-3-carbonitrile
DMED9FL	DT	Small molecular drug
DMED9FL	PC	16267445
DMED9FL	MW	342.4
DMED9FL	FM	C17H18N4O2S
DMED9FL	IC	InChI=1S/C17H18N4O2S/c1-14-4-6-16(7-5-14)24(22,23)21-11-9-20(10-12-21)17-15(13-18)3-2-8-19-17/h2-8H,9-12H2,1H3
DMED9FL	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=C(C=CC=N3)C#N
DMED9FL	IK	NYLACAAEFWBUQQ-UHFFFAOYSA-N
DMED9FL	IU	2-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]pyridine-3-carbonitrile
DMED9FL	DE	Discovery agent

DMTC5Y9	ID	DMTC5Y9
DMTC5Y9	DN	2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile
DMTC5Y9	HS	Investigative
DMTC5Y9	SN	133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile
DMTC5Y9	DT	Small molecular drug
DMTC5Y9	PC	5328753
DMTC5Y9	MW	212.2
DMTC5Y9	FM	C12H8N2O2
DMTC5Y9	IC	InChI=1S/C12H8N2O2/c13-5-8(6-14)9-2-1-7-3-11(15)12(16)4-10(7)9/h3-4,15-16H,1-2H2
DMTC5Y9	CS	C1CC(=C(C#N)C#N)C2=CC(=C(C=C21)O)O
DMTC5Y9	IK	CDYLNUVNFDZTEB-UHFFFAOYSA-N
DMTC5Y9	IU	2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile
DMTC5Y9	CA	CAS 133550-11-5
DMTC5Y9	DE	Discovery agent

DMXRYDL	ID	DMXRYDL
DMXRYDL	DN	2-(5-Bromo-indole-1-sulfonyl)-benzoic acid
DMXRYDL	HS	Investigative
DMXRYDL	SN	CHEMBL184005; 2-(5-Bromo-indole-1-sulfonyl)-benzoic acid
DMXRYDL	DT	Small molecular drug
DMXRYDL	PC	44393643
DMXRYDL	MW	380.2
DMXRYDL	FM	C15H10BrNO4S
DMXRYDL	IC	InChI=1S/C15H10BrNO4S/c16-11-5-6-13-10(9-11)7-8-17(13)22(20,21)14-4-2-1-3-12(14)15(18)19/h1-9H,(H,18,19)
DMXRYDL	CS	C1=CC=C(C(=C1)C(=O)O)S(=O)(=O)N2C=CC3=C2C=CC(=C3)Br
DMXRYDL	IK	RGZDWZUMVMDEAG-UHFFFAOYSA-N
DMXRYDL	IU	2-(5-bromoindol-1-yl)sulfonylbenzoic acid
DMXRYDL	DE	Discovery agent

DM0ZB89	ID	DM0ZB89
DM0ZB89	DN	2-(5-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM0ZB89	HS	Investigative
DM0ZB89	SN	CHEMBL198673; 2-(5-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM0ZB89	DT	Small molecular drug
DM0ZB89	PC	11652061
DM0ZB89	MW	280.71
DM0ZB89	FM	C15H9ClN4
DM0ZB89	IC	InChI=1S/C15H9ClN4/c16-9-5-6-12-13(7-9)20-15(19-12)14-8-17-10-3-1-2-4-11(10)18-14/h1-8H,(H,19,20)
DM0ZB89	CS	C1=CC=C2C(=C1)N=CC(=N2)C3=NC4=C(N3)C=C(C=C4)Cl
DM0ZB89	IK	SOUPHJBGFDZRAD-UHFFFAOYSA-N
DM0ZB89	IU	2-(6-chloro-1H-benzimidazol-2-yl)quinoxaline
DM0ZB89	DE	Discovery agent

DMSIJ17	ID	DMSIJ17
DMSIJ17	DN	2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine
DMSIJ17	HS	Investigative
DMSIJ17	SN	CHEMBL375619; 2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine
DMSIJ17	DT	Small molecular drug
DMSIJ17	PC	16115752
DMSIJ17	MW	388.4
DMSIJ17	FM	C17H20N6O5
DMSIJ17	IC	InChI=1S/C17H20N6O5/c1-27-22-15-12-16(21-11(20-15)6-4-2-3-5-7-18)23(9-19-12)17-14(26)13(25)10(8-24)28-17/h9-10,13-14,17,24-26H,2-3,5,8H2,1H3,(H,20,21,22)/t10-,13-,14-,17-/m1/s1
DMSIJ17	CS	CONC1=C2C(=NC(=N1)C#CCCCC#N)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMSIJ17	IK	SNWMEUXNYSKHNP-IWCJZZDYSA-N
DMSIJ17	IU	6-[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methoxyamino)purin-2-yl]hex-5-ynenitrile
DMSIJ17	DE	Discovery agent

DMHW5FT	ID	DMHW5FT
DMHW5FT	DN	2-(5-fluoro-1H-indol-3-yl)ethanamine
DMHW5FT	HS	Investigative
DMHW5FT	SN	5-Fluorotryptamine; 576-16-9; 3-(2-Aminoethyl)-5-fluoro-1H-indole; 1H-Indole-3-ethanamine, 5-fluoro-; 2-(5-FLUORO-1H-INDOL-3-YL)ETHAN-1-AMINE; 2-(5-Fluoro-1H-indol-3-yl)ethylamine; CHEMBL275628; 2-(5-Fluoro-1H-indol-3-yl)-ethylamine; 2-(5-fluoroindol-3-yl)ethylamine; PubChem1926; PubChem13384; ChemDiv2_003993; AC1L4V8Y; AC1Q4NE7; Oprea1_696214; GTPL146; SCHEMBL387663; 5-fluorotryptamine, AldrichCPR; cid_197774; CTK5A7173; ZINC77278; BDBM30853; DTXSID20206229; ZKIORVIXEWIOGB-UHFFFAOYSA-N; 5-fluorotryptamine
DMHW5FT	DT	Small molecular drug
DMHW5FT	PC	164682
DMHW5FT	MW	178.21
DMHW5FT	FM	C10H11FN2
DMHW5FT	IC	InChI=1S/C10H11FN2/c11-8-1-2-10-9(5-8)7(3-4-12)6-13-10/h1-2,5-6,13H,3-4,12H2
DMHW5FT	CS	C1=CC2=C(C=C1F)C(=CN2)CCN
DMHW5FT	IK	ZKIORVIXEWIOGB-UHFFFAOYSA-N
DMHW5FT	IU	2-(5-fluoro-1H-indol-3-yl)ethanamine
DMHW5FT	CA	CAS 576-16-9
DMHW5FT	DE	Discovery agent

DMB3JG0	ID	DMB3JG0
DMB3JG0	DN	2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DMB3JG0	HS	Investigative
DMB3JG0	DT	Small molecular drug
DMB3JG0	PC	4369550
DMB3JG0	MW	277.27
DMB3JG0	FM	C17H11NO3
DMB3JG0	IC	InChI=1S/C17H11NO3/c19-10-7-8-14-16(9-10)21-17(18-14)13-5-1-4-12-11(13)3-2-6-15(12)20/h1-9,19-20H
DMB3JG0	CS	C1=CC2=C(C=CC=C2O)C(=C1)C3=NC4=C(O3)C=C(C=C4)O
DMB3JG0	IK	JHOZVRGNIYFYHE-UHFFFAOYSA-N
DMB3JG0	IU	2-(5-hydroxynaphthalen-1-yl)-1,3-benzoxazol-6-ol
DMB3JG0	DE	Discovery agent

DM0P6A3	ID	DM0P6A3
DM0P6A3	DN	2-(5-Mercapto-pentyl)-pentanedioic acid
DM0P6A3	HS	Investigative
DM0P6A3	SN	CHEMBL61067; 2-(5-Mercapto-pentyl)-pentanedioic acid; Pentanedioic acid, 2-(5-mercaptopentyl)-; BDBM50127621
DM0P6A3	DT	Small molecular drug
DM0P6A3	PC	10955499
DM0P6A3	MW	234.31
DM0P6A3	FM	C10H18O4S
DM0P6A3	IC	InChI=1S/C10H18O4S/c11-9(12)6-5-8(10(13)14)4-2-1-3-7-15/h8,15H,1-7H2,(H,11,12)(H,13,14)
DM0P6A3	CS	C(CCC(CCC(=O)O)C(=O)O)CCS
DM0P6A3	IK	RHHNRXAIWMGSRF-UHFFFAOYSA-N
DM0P6A3	IU	2-(5-sulfanylpentyl)pentanedioic acid
DM0P6A3	DE	Discovery agent

DM1O0JD	ID	DM1O0JD
DM1O0JD	DN	2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine
DM1O0JD	HS	Investigative
DM1O0JD	SN	5-methoxy-alpha-methyltryptamine
DM1O0JD	PC	36906
DM1O0JD	MW	204.27
DM1O0JD	FM	C12H16N2O
DM1O0JD	IC	InChI=1S/C12H16N2O/c1-8(13)5-9-7-14-12-4-3-10(15-2)6-11(9)12/h3-4,6-8,14H,5,13H2,1-2H3
DM1O0JD	CS	CC(CC1=CNC2=C1C=C(C=C2)OC)N
DM1O0JD	IK	OGNJZVNNKBZFRM-UHFFFAOYSA-N
DM1O0JD	IU	1-(5-methoxy-1H-indol-3-yl)propan-2-amine
DM1O0JD	CA	CAS 1137-04-8
DM1O0JD	CB	CHEBI:125422
DM1O0JD	DE	Discovery agent

DM2TU6W	ID	DM2TU6W
DM2TU6W	DN	2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine
DM2TU6W	HS	Investigative
DM2TU6W	SN	5-Nonyloxytryptamine; 5-(Nonyloxy)tryptamine; O-nonylserotonin; 5-(Nonyloxy)-1H-indole-3-ethanamine; 157798-12-4; 2-(5-nonoxy-1H-indol-3-yl)ethanamine; CHEMBL97450; CHEBI:64149; 3-(2-aminoethyl)-5-nonyloxyindole; 1H-Indole-3-ethanamine,5-(nonyloxy)-; 2-[5-(nonyloxy)-1H-indol-3-yl]ethanamine; 5-(Nonyloxy)-tryptamine; Tocris-0901; NCGC00024858-01; Biomol-NT_000115; AC1L1C9C; GTPL106; SCHEMBL2335932; BPBio1_000133; AC1Q56M5; DTXSID4058653; CTK4C9475; ZINC1541570; BDBM50039947; AKOS030238973; 5-(nonyloxy)-tryptamine
DM2TU6W	DT	Small molecular drug
DM2TU6W	PC	1797
DM2TU6W	MW	302.5
DM2TU6W	FM	C19H30N2O
DM2TU6W	IC	InChI=1S/C19H30N2O/c1-2-3-4-5-6-7-8-13-22-17-9-10-19-18(14-17)16(11-12-20)15-21-19/h9-10,14-15,21H,2-8,11-13,20H2,1H3
DM2TU6W	CS	CCCCCCCCCOC1=CC2=C(C=C1)NC=C2CCN
DM2TU6W	IK	YHSMSRREJYOGQJ-UHFFFAOYSA-N
DM2TU6W	IU	2-(5-nonoxy-1H-indol-3-yl)ethanamine
DM2TU6W	CA	CAS 157798-12-4
DM2TU6W	CB	CHEBI:64149
DM2TU6W	DE	Discovery agent

DMDZ9RK	ID	DMDZ9RK
DMDZ9RK	DN	2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole
DMDZ9RK	HS	Investigative
DMDZ9RK	SN	furaline; CHEMBL213439; SCHEMBL11783413
DMDZ9RK	DT	Small molecular drug
DMDZ9RK	PC	16082793
DMDZ9RK	MW	212.25
DMDZ9RK	FM	C13H12N2O
DMDZ9RK	IC	InChI=1S/C13H12N2O/c1-2-4-10(5-3-1)11-6-7-12(16-11)13-14-8-9-15-13/h1-7H,8-9H2,(H,14,15)
DMDZ9RK	CS	C1CN=C(N1)C2=CC=C(O2)C3=CC=CC=C3
DMDZ9RK	IK	HNPLGLAMYJQFOS-UHFFFAOYSA-N
DMDZ9RK	IU	2-(5-phenylfuran-2-yl)-4,5-dihydro-1H-imidazole
DMDZ9RK	DE	Discovery agent

DMX6QMT	ID	DMX6QMT
DMX6QMT	DN	2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMX6QMT	HS	Investigative
DMX6QMT	SN	2-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile; 2-Anilino-5-aryloxazole 8; AC1NS7QZ; CHEMBL193912; BDBM5847; N-(2-Cyanophenyl)-5-phenyl-1,3-oxazol-2-amine Hydrochloride
DMX6QMT	DT	Small molecular drug
DMX6QMT	PC	5329843
DMX6QMT	MW	261.279
DMX6QMT	FM	C16H11N3O
DMX6QMT	IC	InChI=1S/C16H11N3O/c17-10-13-8-4-5-9-14(13)19-16-18-11-15(20-16)12-6-2-1-3-7-12/h1-9,11H,(H,18,19)
DMX6QMT	CS	C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=CC=C3C#N
DMX6QMT	IK	FPMCYJLZCOBPEC-UHFFFAOYSA-N
DMX6QMT	IU	2-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile
DMX6QMT	DE	Discovery agent

DM1AEK4	ID	DM1AEK4
DM1AEK4	DN	2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine
DM1AEK4	HS	Investigative
DM1AEK4	SN	CHEMBL355517; 2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine; SCHEMBL8686120; BDBM50088863; AKOS022550938; 3-(2-Aminoethyl)-5-(2-thienyl)-1H-indole
DM1AEK4	DT	Small molecular drug
DM1AEK4	PC	10198700
DM1AEK4	MW	242.34
DM1AEK4	FM	C14H14N2S
DM1AEK4	IC	InChI=1S/C14H14N2S/c15-6-5-11-9-16-13-4-3-10(8-12(11)13)14-2-1-7-17-14/h1-4,7-9,16H,5-6,15H2
DM1AEK4	CS	C1=CSC(=C1)C2=CC3=C(C=C2)NC=C3CCN
DM1AEK4	IK	KULFBKTWESBCBG-UHFFFAOYSA-N
DM1AEK4	IU	2-(5-thiophen-2-yl-1H-indol-3-yl)ethanamine
DM1AEK4	DE	Discovery agent

DMRBX1D	ID	DMRBX1D
DMRBX1D	DN	2-(6-amino-8-bromo-9H-purin-9-yl)ethanol
DMRBX1D	HS	Investigative
DMRBX1D	SN	CHEMBL474058; 43047-77-4; 8-Bromo-9-(2-hydroxyethyl)-9H-adenine; 2-(6-amino-8-bromo-9H-purin-9-yl)ethanol; SCHEMBL987368; CTK1C8207; DTXSID50659527; HPCQLQBYCLLETI-UHFFFAOYSA-N; BDBM50257051; AKOS030562477; 9H-Purine-9-ethanol, 6-amino-8-bromo-; 2-(6-amino-8-bromo-purin-9-yl)ethanol; 6-amino-8-bromo-9-(2-hydroxyethyl)-9H-purine
DMRBX1D	DT	Small molecular drug
DMRBX1D	PC	44572469
DMRBX1D	MW	258.079
DMRBX1D	FM	C7H8BrN5O
DMRBX1D	IC	InChI=1S/C7H8BrN5O/c8-7-12-4-5(9)10-3-11-6(4)13(7)1-2-14/h3,14H,1-2H2,(H2,9,10,11)
DMRBX1D	CS	C1=NC(=C2C(=N1)N(C(=N2)Br)CCO)N
DMRBX1D	IK	HPCQLQBYCLLETI-UHFFFAOYSA-N
DMRBX1D	IU	2-(6-amino-8-bromopurin-9-yl)ethanol
DMRBX1D	CA	CAS 43047-77-4
DMRBX1D	DE	Discovery agent

DMTI1VO	ID	DMTI1VO
DMTI1VO	DN	2-(6-Cyclopentylamino-purin-9-yl)-ethanol
DMTI1VO	HS	Investigative
DMTI1VO	SN	CHEMBL320370; 2-(6-Cyclopentylamino-purin-9-yl)-ethanol; BDBM50009691
DMTI1VO	DT	Small molecular drug
DMTI1VO	PC	15693950
DMTI1VO	MW	247.3
DMTI1VO	FM	C12H17N5O
DMTI1VO	IC	InChI=1S/C12H17N5O/c18-6-5-17-8-15-10-11(13-7-14-12(10)17)16-9-3-1-2-4-9/h7-9,18H,1-6H2,(H,13,14,16)
DMTI1VO	CS	C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)CCO
DMTI1VO	IK	XVKHXAUTWLZBQD-UHFFFAOYSA-N
DMTI1VO	IU	2-[6-(cyclopentylamino)purin-9-yl]ethanol
DMTI1VO	DE	Discovery agent

DMXAVHT	ID	DMXAVHT
DMXAVHT	DN	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol
DMXAVHT	HS	Investigative
DMXAVHT	SN	CHEMBL183367; 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol; SCHEMBL3933889; GLVGKXBQPYTMGJ-UHFFFAOYSA-N; ZINC3817709; BDBM50154056; 2-(6-hydroxynaphthalen-1-yl)benzo[d]oxazol-5-ol
DMXAVHT	DT	Small molecular drug
DMXAVHT	PC	9993627
DMXAVHT	MW	277.27
DMXAVHT	FM	C17H11NO3
DMXAVHT	IC	InChI=1S/C17H11NO3/c19-11-4-6-13-10(8-11)2-1-3-14(13)17-18-15-9-12(20)5-7-16(15)21-17/h1-9,19-20H
DMXAVHT	CS	C1=CC2=C(C=CC(=C2)O)C(=C1)C3=NC4=C(O3)C=CC(=C4)O
DMXAVHT	IK	GLVGKXBQPYTMGJ-UHFFFAOYSA-N
DMXAVHT	IU	2-(6-hydroxynaphthalen-1-yl)-1,3-benzoxazol-5-ol
DMXAVHT	DE	Discovery agent

DM3GQN2	ID	DM3GQN2
DM3GQN2	DN	2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DM3GQN2	HS	Investigative
DM3GQN2	SN	CHEMBL189077; 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol; 2-(6-hydroxynaphthalen-1-yl)benzo[d]oxazol-6-ol; SCHEMBL3926798; ZRGCERZQAHMXNC-UHFFFAOYSA-N; BDBM50154135; 595566-69-1; 6-Benzoxazolol,2-(6-hydroxy-1-naphthalenyl)-
DM3GQN2	DT	Small molecular drug
DM3GQN2	PC	10062042
DM3GQN2	MW	277.27
DM3GQN2	FM	C17H11NO3
DM3GQN2	IC	InChI=1S/C17H11NO3/c19-11-4-6-13-10(8-11)2-1-3-14(13)17-18-15-7-5-12(20)9-16(15)21-17/h1-9,19-20H
DM3GQN2	CS	C1=CC2=C(C=CC(=C2)O)C(=C1)C3=NC4=C(O3)C=C(C=C4)O
DM3GQN2	IK	ZRGCERZQAHMXNC-UHFFFAOYSA-N
DM3GQN2	IU	2-(6-hydroxynaphthalen-1-yl)-1,3-benzoxazol-6-ol
DM3GQN2	DE	Discovery agent

DM715EC	ID	DM715EC
DM715EC	DN	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol
DM715EC	HS	Investigative
DM715EC	DT	Small molecular drug
DM715EC	PC	135492380
DM715EC	MW	277.27
DM715EC	FM	C17H11NO3
DM715EC	IC	InChI=1S/C17H11NO3/c19-13-4-3-10-7-12(2-1-11(10)8-13)17-18-15-9-14(20)5-6-16(15)21-17/h1-9,19-20H
DM715EC	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=NC4=C(O3)C=CC(=C4)O
DM715EC	IK	PRBSKPRGLMJEEA-UHFFFAOYSA-N
DM715EC	IU	2-(6-hydroxynaphthalen-2-yl)-1,3-benzoxazol-5-ol
DM715EC	DE	Discovery agent

DMANHOT	ID	DMANHOT
DMANHOT	DN	2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol
DMANHOT	HS	Investigative
DMANHOT	DT	Small molecular drug
DMANHOT	PC	135449109
DMANHOT	MW	277.27
DMANHOT	FM	C17H11NO3
DMANHOT	IC	InChI=1S/C17H11NO3/c19-13-4-3-10-7-12(2-1-11(10)8-13)17-18-15-6-5-14(20)9-16(15)21-17/h1-9,19-20H
DMANHOT	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=NC4=C(O3)C=C(C=C4)O
DMANHOT	IK	PZIKVWJRAOMJDU-UHFFFAOYSA-N
DMANHOT	IU	2-(6-hydroxynaphthalen-2-yl)-1,3-benzoxazol-6-ol
DMANHOT	CA	CAS 595566-71-5
DMANHOT	DE	Discovery agent

DMKI6GQ	ID	DMKI6GQ
DMKI6GQ	DN	2-(6-Imidazol-1-yl-hexyl)-isoindole-1,3-dione
DMKI6GQ	HS	Investigative
DMKI6GQ	SN	CHEMBL167372; 2-(6-Imidazol-1-yl-hexyl)-isoindole-1,3-dione
DMKI6GQ	DT	Small molecular drug
DMKI6GQ	PC	13580026
DMKI6GQ	MW	297.35
DMKI6GQ	FM	C17H19N3O2
DMKI6GQ	IC	InChI=1S/C17H19N3O2/c21-16-14-7-3-4-8-15(14)17(22)20(16)11-6-2-1-5-10-19-12-9-18-13-19/h3-4,7-9,12-13H,1-2,5-6,10-11H2
DMKI6GQ	CS	C1=CC=C2C(=C1)C(=O)N(C2=O)CCCCCCN3C=CN=C3
DMKI6GQ	IK	CGDDIOSGLRENCV-UHFFFAOYSA-N
DMKI6GQ	IU	2-(6-imidazol-1-ylhexyl)isoindole-1,3-dione
DMKI6GQ	DE	Discovery agent

DM41UYN	ID	DM41UYN
DM41UYN	DN	2-(6-Methoxy-indole-1-sulfonyl)-benzoic acid
DM41UYN	HS	Investigative
DM41UYN	SN	CHEMBL365508; 2-(6-Methoxy-indole-1-sulfonyl)-benzoic acid
DM41UYN	DT	Small molecular drug
DM41UYN	PC	44393683
DM41UYN	MW	331.3
DM41UYN	FM	C16H13NO5S
DM41UYN	IC	InChI=1S/C16H13NO5S/c1-22-12-7-6-11-8-9-17(14(11)10-12)23(20,21)15-5-3-2-4-13(15)16(18)19/h2-10H,1H3,(H,18,19)
DM41UYN	CS	COC1=CC2=C(C=C1)C=CN2S(=O)(=O)C3=CC=CC=C3C(=O)O
DM41UYN	IK	HQQRNJVZOJLXOO-UHFFFAOYSA-N
DM41UYN	IU	2-(6-methoxyindol-1-yl)sulfonylbenzoic acid
DM41UYN	DE	Discovery agent

DMZDNHQ	ID	DMZDNHQ
DMZDNHQ	DN	2-(6-morpholino-9H-purin-2-yl)phenol
DMZDNHQ	HS	Investigative
DMZDNHQ	DT	Small molecular drug
DMZDNHQ	PC	135955185
DMZDNHQ	MW	297.31
DMZDNHQ	FM	C15H15N5O2
DMZDNHQ	IC	InChI=1S/C15H15N5O2/c21-11-4-2-1-3-10(11)13-18-14-12(16-9-17-14)15(19-13)20-5-7-22-8-6-20/h1-4,9,21H,5-8H2,(H,16,17,18,19)
DMZDNHQ	CS	C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC=CC=C4O
DMZDNHQ	IK	SWYYAXGUDZLFKO-UHFFFAOYSA-N
DMZDNHQ	IU	2-(6-morpholin-4-yl-7H-purin-2-yl)phenol
DMZDNHQ	DE	Discovery agent

DMR3Z1D	ID	DMR3Z1D
DMR3Z1D	DN	2-(6-phenylhexyl)pyrido[2,3-d]pyrimidin-4(3H)-one
DMR3Z1D	HS	Investigative
DMR3Z1D	DT	Small molecular drug
DMR3Z1D	PC	135899263
DMR3Z1D	MW	307.4
DMR3Z1D	FM	C19H21N3O
DMR3Z1D	IC	InChI=1S/C19H21N3O/c23-19-16-12-8-14-20-18(16)21-17(22-19)13-7-2-1-4-9-15-10-5-3-6-11-15/h3,5-6,8,10-12,14H,1-2,4,7,9,13H2,(H,20,21,22,23)
DMR3Z1D	CS	C1=CC=C(C=C1)CCCCCCC2=NC3=C(C=CC=N3)C(=O)N2
DMR3Z1D	IK	WWIOUCLIAKKTPW-UHFFFAOYSA-N
DMR3Z1D	IU	2-(6-phenylhexyl)-3H-pyrido[2,3-d]pyrimidin-4-one
DMR3Z1D	DE	Discovery agent

DMD2QVO	ID	DMD2QVO
DMD2QVO	DN	2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine
DMD2QVO	HS	Investigative
DMD2QVO	SN	7-Benzyloxytryptamine; 31677-75-5; 2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine; CHEMBL460302; 2-[7-(benzyloxy)-1h-indol-3-yl]ethanamine; JOYGWYISRWPUIM-UHFFFAOYSA-N; 3-(2-AMINOETHYL)-7-BENZYLOXYINDOLE; 1H-Indole-3-ethanamine,7-(phenylmethoxy)-; B-2160; NSC92541; 7-Benzyloxytriptamine; AC1Q57HL; SCHEMBL5167328; AC1L63X1; CTK4G7564; ZINC39096; 7-Benzyloxytryptamine, free base; DTXSID60293835; 6038AH; NSC-92541; BDBM50247069; AKOS024282335; 7-(Benzyloxy)-1H-indole-3-ethanamine; MCULE-8072963757; ACM31677755; ST055630
DMD2QVO	DT	Small molecular drug
DMD2QVO	PC	260806
DMD2QVO	MW	266.34
DMD2QVO	FM	C17H18N2O
DMD2QVO	IC	InChI=1S/C17H18N2O/c18-10-9-14-11-19-17-15(14)7-4-8-16(17)20-12-13-5-2-1-3-6-13/h1-8,11,19H,9-10,12,18H2
DMD2QVO	CS	C1=CC=C(C=C1)COC2=CC=CC3=C2NC=C3CCN
DMD2QVO	IK	JOYGWYISRWPUIM-UHFFFAOYSA-N
DMD2QVO	IU	2-(7-phenylmethoxy-1H-indol-3-yl)ethanamine
DMD2QVO	CA	CAS 31677-75-5
DMD2QVO	DE	Discovery agent

DMJAEZ8	ID	DMJAEZ8
DMJAEZ8	DN	2-(7-phenylheptanoyl)oxazole-4-carbaldehyde
DMJAEZ8	HS	Investigative
DMJAEZ8	SN	CHEMBL461315; 2-(7-phenylheptanoyl)oxazole-4-carbaldehyde; SCHEMBL2162538
DMJAEZ8	DT	Small molecular drug
DMJAEZ8	PC	44554445
DMJAEZ8	MW	285.34
DMJAEZ8	FM	C17H19NO3
DMJAEZ8	IC	InChI=1S/C17H19NO3/c19-12-15-13-21-17(18-15)16(20)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,12-13H,1-2,4,7-8,11H2
DMJAEZ8	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C=O
DMJAEZ8	IK	CLWIISIKUDVYMX-UHFFFAOYSA-N
DMJAEZ8	IU	2-(7-phenylheptanoyl)-1,3-oxazole-4-carbaldehyde
DMJAEZ8	DE	Discovery agent

DMVSL49	ID	DMVSL49
DMVSL49	DN	2-(7-phenylheptanoyl)oxazole-4-carbonitrile
DMVSL49	HS	Investigative
DMVSL49	SN	CHEMBL462423; 2-(7-phenylheptanoyl)oxazole-4-carbonitrile; SCHEMBL2162448; IGDLMZPDBOKHRJ-UHFFFAOYSA-N
DMVSL49	DT	Small molecular drug
DMVSL49	PC	25147546
DMVSL49	MW	282.34
DMVSL49	FM	C17H18N2O2
DMVSL49	IC	InChI=1S/C17H18N2O2/c18-12-15-13-21-17(19-15)16(20)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,13H,1-2,4,7-8,11H2
DMVSL49	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C#N
DMVSL49	IK	IGDLMZPDBOKHRJ-UHFFFAOYSA-N
DMVSL49	IU	2-(7-phenylheptanoyl)-1,3-oxazole-4-carbonitrile
DMVSL49	DE	Discovery agent

DM9JMF2	ID	DM9JMF2
DM9JMF2	DN	2-(7-phenylheptanoyl)oxazole-4-carboxamide
DM9JMF2	HS	Investigative
DM9JMF2	SN	2-(7-phenylheptanoyl)oxazole-4-carboxamide; CHEMBL460492; SCHEMBL2162480; ZOLDFPZCQMAAPD-UHFFFAOYSA-N
DM9JMF2	DT	Small molecular drug
DM9JMF2	PC	44554616
DM9JMF2	MW	300.35
DM9JMF2	FM	C17H20N2O3
DM9JMF2	IC	InChI=1S/C17H20N2O3/c18-16(21)14-12-22-17(19-14)15(20)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2,(H2,18,21)
DM9JMF2	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C(=O)N
DM9JMF2	IK	ZOLDFPZCQMAAPD-UHFFFAOYSA-N
DM9JMF2	IU	2-(7-phenylheptanoyl)-1,3-oxazole-4-carboxamide
DM9JMF2	DE	Discovery agent

DM9BE2S	ID	DM9BE2S
DM9BE2S	DN	2-(7-phenylheptanoyl)oxazole-4-carboxylic acid
DM9BE2S	HS	Investigative
DM9BE2S	SN	CHEMBL460317; 2-(7-phenylheptanoyl)oxazole-4-carboxylic acid; SCHEMBL2162839; UJGLCAJZAMDFHN-UHFFFAOYSA-N
DM9BE2S	DT	Small molecular drug
DM9BE2S	PC	44554615
DM9BE2S	MW	301.34
DM9BE2S	FM	C17H19NO4
DM9BE2S	IC	InChI=1S/C17H19NO4/c19-15(16-18-14(12-22-16)17(20)21)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2,(H,20,21)
DM9BE2S	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C(=O)O
DM9BE2S	IK	UJGLCAJZAMDFHN-UHFFFAOYSA-N
DM9BE2S	IU	2-(7-phenylheptanoyl)-1,3-oxazole-4-carboxylic acid
DM9BE2S	DE	Discovery agent

DM89RYN	ID	DM89RYN
DM89RYN	DN	2-(7-phenylheptanoyl)oxazole-5-carbonitrile
DM89RYN	HS	Investigative
DM89RYN	SN	CHEMBL220770; 2-(7-phenylheptanoyl)oxazole-5-carbonitrile; 2-(7-phenylheptanoyl)-1,3-oxazole-5-carbonitrile; SCHEMBL3144301; JOWNZAGZZQQDKI-UHFFFAOYSA-N
DM89RYN	DT	Small molecular drug
DM89RYN	PC	11991895
DM89RYN	MW	282.34
DM89RYN	FM	C17H18N2O2
DM89RYN	IC	InChI=1S/C17H18N2O2/c18-12-15-13-19-17(21-15)16(20)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,13H,1-2,4,7-8,11H2
DM89RYN	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=C(O2)C#N
DM89RYN	IK	JOWNZAGZZQQDKI-UHFFFAOYSA-N
DM89RYN	IU	2-(7-phenylheptanoyl)-1,3-oxazole-5-carbonitrile
DM89RYN	DE	Discovery agent

DMB53ML	ID	DMB53ML
DMB53ML	DN	2-(7-phenylheptanoyl)oxazole-5-carboxylic acid
DMB53ML	HS	Investigative
DMB53ML	SN	CHEMBL220729; 2-(7-phenylheptanoyl)oxazole-5-carboxylic acid; SCHEMBL1471352; 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylic Acid; YYZORCCDLMGZTQ-UHFFFAOYSA-N
DMB53ML	DT	Small molecular drug
DMB53ML	PC	11991892
DMB53ML	MW	301.34
DMB53ML	FM	C17H19NO4
DMB53ML	IC	InChI=1S/C17H19NO4/c19-14(16-18-12-15(22-16)17(20)21)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2,(H,20,21)
DMB53ML	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=C(O2)C(=O)O
DMB53ML	IK	YYZORCCDLMGZTQ-UHFFFAOYSA-N
DMB53ML	IU	2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylic acid
DMB53ML	DE	Discovery agent

DMLQ9WD	ID	DMLQ9WD
DMLQ9WD	DN	2-(8-Imidazol-1-yl-octyl)-isoindole-1,3-dione
DMLQ9WD	HS	Investigative
DMLQ9WD	SN	CHEMBL166834; 2-(8-Imidazol-1-yl-octyl)-isoindole-1,3-dione; SCHEMBL10839307; UYNFUMGZMJRXFD-UHFFFAOYSA-N; BDBM50024111
DMLQ9WD	DT	Small molecular drug
DMLQ9WD	PC	13580028
DMLQ9WD	MW	325.4
DMLQ9WD	FM	C19H23N3O2
DMLQ9WD	IC	InChI=1S/C19H23N3O2/c23-18-16-9-5-6-10-17(16)19(24)22(18)13-8-4-2-1-3-7-12-21-14-11-20-15-21/h5-6,9-11,14-15H,1-4,7-8,12-13H2
DMLQ9WD	CS	C1=CC=C2C(=C1)C(=O)N(C2=O)CCCCCCCCN3C=CN=C3
DMLQ9WD	IK	UYNFUMGZMJRXFD-UHFFFAOYSA-N
DMLQ9WD	IU	2-(8-imidazol-1-yloctyl)isoindole-1,3-dione
DMLQ9WD	DE	Discovery agent

DMRW475	ID	DMRW475
DMRW475	DN	2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine
DMRW475	HS	Investigative
DMRW475	SN	CHEMBL595158; BDBM35924; 9,10-dihydroanthracene(DHA), 2b
DMRW475	DT	Small molecular drug
DMRW475	PC	44521012
DMRW475	MW	237.34
DMRW475	FM	C17H19N
DMRW475	IC	InChI=1S/C17H19N/c1-18-11-10-17-15-8-4-2-6-13(15)12-14-7-3-5-9-16(14)17/h2-9,17-18H,10-12H2,1H3
DMRW475	CS	CNCCC1C2=CC=CC=C2CC3=CC=CC=C13
DMRW475	IK	PVWQFOKNAQZORV-UHFFFAOYSA-N
DMRW475	IU	2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine
DMRW475	DE	Discovery agent

DMPJ0O6	ID	DMPJ0O6
DMPJ0O6	DN	2-(9-Benzyl-9H-purin-6-ylamino)-ethanol
DMPJ0O6	HS	Investigative
DMPJ0O6	SN	MLS000083858; AC1LDHLL; CHEMBL7291; MolPort-002-645-925; HMS2407L21; ZINC2352774; STL140995; AKOS005714812; MCULE-9452123598; 2-[(9-benzylpurin-6-yl)amino]ethanol; SMR000048556; 112089-01-7
DMPJ0O6	DT	Small molecular drug
DMPJ0O6	PC	667207
DMPJ0O6	MW	269.3
DMPJ0O6	FM	C14H15N5O
DMPJ0O6	IC	InChI=1S/C14H15N5O/c20-7-6-15-13-12-14(17-9-16-13)19(10-18-12)8-11-4-2-1-3-5-11/h1-5,9-10,20H,6-8H2,(H,15,16,17)
DMPJ0O6	CS	C1=CC=C(C=C1)CN2C=NC3=C(N=CN=C32)NCCO
DMPJ0O6	IK	ZOVSVHTVIDXQPS-UHFFFAOYSA-N
DMPJ0O6	IU	2-[(9-benzylpurin-6-yl)amino]ethanol
DMPJ0O6	DE	Discovery agent

DMOUG6Y	ID	DMOUG6Y
DMOUG6Y	DN	2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose
DMOUG6Y	HS	Investigative
DMOUG6Y	SN	Beta-N-Acetylglucosamine; betaGlcNAc; GlcNAc-beta; CHEBI:28009; UNII-8P59336F68; 2-Acetamido-2-deoxy-beta-D-glucose; AI3-51898; 8P59336F68; N-[(2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]acetamide; Cheon shim bo yun
DMOUG6Y	DT	Small molecular drug
DMOUG6Y	PC	82313
DMOUG6Y	MW	221.21
DMOUG6Y	FM	C8H15NO6
DMOUG6Y	IC	InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8+/m1/s1
DMOUG6Y	CS	CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O
DMOUG6Y	IK	OVRNDRQMDRJTHS-PVFLNQBWSA-N
DMOUG6Y	IU	N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DMOUG6Y	CA	CAS 10036-64-3
DMOUG6Y	CB	CHEBI:44278
DMOUG6Y	DE	Discovery agent

DMB3YXG	ID	DMB3YXG
DMB3YXG	DN	2-(adamantan-1-ylamino)-5,5-diethyl-oxazol-4-one
DMB3YXG	HS	Investigative
DMB3YXG	DT	Small molecular drug
DMB3YXG	PC	135950102
DMB3YXG	MW	290.4
DMB3YXG	FM	C17H26N2O2
DMB3YXG	IC	InChI=1S/C17H26N2O2/c1-3-17(4-2)14(20)18-15(21-17)19-16-8-11-5-12(9-16)7-13(6-11)10-16/h11-13H,3-10H2,1-2H3,(H,18,19,20)
DMB3YXG	CS	CCC1(C(=O)NC(=NC23CC4CC(C2)CC(C4)C3)O1)CC
DMB3YXG	IK	RHBIZJSBQCBDJJ-UHFFFAOYSA-N
DMB3YXG	IU	2-(1-adamantylimino)-5,5-diethyl-1,3-oxazolidin-4-one
DMB3YXG	DE	Discovery agent

DM6P20R	ID	DM6P20R
DM6P20R	DN	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide
DM6P20R	HS	Investigative
DM6P20R	SN	CHEMBL402719; 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide; SCHEMBL8150833
DM6P20R	DT	Small molecular drug
DM6P20R	PC	25065931
DM6P20R	MW	320.4
DM6P20R	FM	C17H24N2O4
DM6P20R	IC	InChI=1S/C17H24N2O4/c1-2-13-23-15(11-7-4-8-12-16(20)19-22)17(21)18-14-9-5-3-6-10-14/h2-3,5-6,9-10,15,22H,1,4,7-8,11-13H2,(H,18,21)(H,19,20)
DM6P20R	CS	C=CCOC(CCCCCC(=O)NO)C(=O)NC1=CC=CC=C1
DM6P20R	IK	KPKWEJNZWZGOID-UHFFFAOYSA-N
DM6P20R	IU	N'-hydroxy-N-phenyl-2-prop-2-enoxyoctanediamide
DM6P20R	DE	Discovery agent

DMU4MIC	ID	DMU4MIC
DMU4MIC	DN	2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran
DMU4MIC	HS	Investigative
DMU4MIC	SN	CHEMBL511163; SCHEMBL4615998; BDBM50276460
DMU4MIC	DT	Small molecular drug
DMU4MIC	PC	11514389
DMU4MIC	MW	255.35
DMU4MIC	FM	C17H21NO
DMU4MIC	IC	InChI=1S/C17H21NO/c18-12-16-11-10-15(19-16)9-8-14-6-3-5-13-4-1-2-7-17(13)14/h1-7,15-16H,8-12,18H2
DMU4MIC	CS	C1CC(OC1CCC2=CC=CC3=CC=CC=C32)CN
DMU4MIC	IK	QLXIMJBRAWACSR-UHFFFAOYSA-N
DMU4MIC	IU	[5-(2-naphthalen-1-ylethyl)oxolan-2-yl]methanamine
DMU4MIC	DE	Discovery agent

DMCUTY9	ID	DMCUTY9
DMCUTY9	DN	2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran
DMCUTY9	HS	Investigative
DMCUTY9	SN	CHEMBL456638; SCHEMBL2689095; BDBM50276458
DMCUTY9	DT	Small molecular drug
DMCUTY9	PC	11572135
DMCUTY9	MW	227.3
DMCUTY9	FM	C15H17NO
DMCUTY9	IC	InChI=1S/C15H17NO/c16-10-12-8-9-15(17-12)14-7-3-5-11-4-1-2-6-13(11)14/h1-7,12,15H,8-10,16H2
DMCUTY9	CS	C1CC(OC1CN)C2=CC=CC3=CC=CC=C32
DMCUTY9	IK	HDLNQDARKJUPIY-UHFFFAOYSA-N
DMCUTY9	IU	(5-naphthalen-1-yloxolan-2-yl)methanamine
DMCUTY9	DE	Discovery agent

DM157SO	ID	DM157SO
DM157SO	DN	2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran
DM157SO	HS	Investigative
DM157SO	SN	CHEMBL504028; SCHEMBL2690271; BDBM50276457
DM157SO	DT	Small molecular drug
DM157SO	PC	11637187
DM157SO	MW	227.3
DM157SO	FM	C15H17NO
DM157SO	IC	InChI=1S/C15H17NO/c16-10-14-7-8-15(17-14)13-6-5-11-3-1-2-4-12(11)9-13/h1-6,9,14-15H,7-8,10,16H2
DM157SO	CS	C1CC(OC1CN)C2=CC3=CC=CC=C3C=C2
DM157SO	IK	BVTKYAZPIRQNNS-UHFFFAOYSA-N
DM157SO	IU	(5-naphthalen-2-yloxolan-2-yl)methanamine
DM157SO	DE	Discovery agent

DMEZ7O2	ID	DMEZ7O2
DMEZ7O2	DN	2-(Aminomethyl)-5-phenethyltetrahydrofuran
DMEZ7O2	HS	Investigative
DMEZ7O2	SN	CHEMBL456639; 2-(Aminomethyl)-5-phenethyltetrahydrofuran; SCHEMBL2691411
DMEZ7O2	DT	Small molecular drug
DMEZ7O2	PC	11506691
DMEZ7O2	MW	205.3
DMEZ7O2	FM	C13H19NO
DMEZ7O2	IC	InChI=1S/C13H19NO/c14-10-13-9-8-12(15-13)7-6-11-4-2-1-3-5-11/h1-5,12-13H,6-10,14H2
DMEZ7O2	CS	C1CC(OC1CCC2=CC=CC=C2)CN
DMEZ7O2	IK	LKTJWDXCFJJUGY-UHFFFAOYSA-N
DMEZ7O2	IU	[5-(2-phenylethyl)oxolan-2-yl]methanamine
DMEZ7O2	DE	Discovery agent

DMO3G6Q	ID	DMO3G6Q
DMO3G6Q	DN	2-(benzofuran-2-yl)-6-morpholino-4H-pyran-4-one
DMO3G6Q	HS	Investigative
DMO3G6Q	SN	CHEMBL222545; 2-(benzofuran-2-yl)-6-morpholino-4H-pyran-4-one
DMO3G6Q	DT	Small molecular drug
DMO3G6Q	PC	16204045
DMO3G6Q	MW	297.3
DMO3G6Q	FM	C17H15NO4
DMO3G6Q	IC	InChI=1S/C17H15NO4/c19-13-10-16(15-9-12-3-1-2-4-14(12)21-15)22-17(11-13)18-5-7-20-8-6-18/h1-4,9-11H,5-8H2
DMO3G6Q	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC4=CC=CC=C4O3
DMO3G6Q	IK	FFDIMOCTDZWGJB-UHFFFAOYSA-N
DMO3G6Q	IU	2-(1-benzofuran-2-yl)-6-morpholin-4-ylpyran-4-one
DMO3G6Q	DE	Discovery agent

DMW27AC	ID	DMW27AC
DMW27AC	DN	2-(benzylamino)-5,5-diethyloxazol-4(5H)-one
DMW27AC	HS	Investigative
DMW27AC	DT	Small molecular drug
DMW27AC	PC	135950109
DMW27AC	MW	246.3
DMW27AC	FM	C14H18N2O2
DMW27AC	IC	InChI=1S/C14H18N2O2/c1-3-14(4-2)12(17)16-13(18-14)15-10-11-8-6-5-7-9-11/h5-9H,3-4,10H2,1-2H3,(H,15,16,17)
DMW27AC	CS	CCC1(C(=O)NC(=NCC2=CC=CC=C2)O1)CC
DMW27AC	IK	UYIBORRFWIVHQJ-UHFFFAOYSA-N
DMW27AC	IU	2-benzylimino-5,5-diethyl-1,3-oxazolidin-4-one
DMW27AC	DE	Discovery agent

DM4X6I9	ID	DM4X6I9
DM4X6I9	DN	2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine
DM4X6I9	HS	Investigative
DM4X6I9	SN	CHEMBL199800; 2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine
DM4X6I9	DT	Small molecular drug
DM4X6I9	PC	11631107
DM4X6I9	MW	318.4
DM4X6I9	FM	C19H18N4O
DM4X6I9	IC	InChI=1S/C19H18N4O/c1-14(24)22-17-9-5-8-16(10-17)18-12-20-13-19(23-18)21-11-15-6-3-2-4-7-15/h2-10,12-13H,11H2,1H3,(H,21,23)(H,22,24)
DM4X6I9	CS	CC(=O)NC1=CC=CC(=C1)C2=CN=CC(=N2)NCC3=CC=CC=C3
DM4X6I9	IK	APNYMHFAZCCZRG-UHFFFAOYSA-N
DM4X6I9	IU	N-[3-[6-(benzylamino)pyrazin-2-yl]phenyl]acetamide
DM4X6I9	DE	Discovery agent

DM3VJLZ	ID	DM3VJLZ
DM3VJLZ	DN	2-(benzylideneamino)ethanesulfonamide
DM3VJLZ	HS	Investigative
DM3VJLZ	SN	2-(benzylideneamino)ethanesulfonamide; CHEMBL574337
DM3VJLZ	DT	Small molecular drug
DM3VJLZ	PC	45483186
DM3VJLZ	MW	212.27
DM3VJLZ	FM	C9H12N2O2S
DM3VJLZ	IC	InChI=1S/C9H12N2O2S/c10-14(12,13)7-6-11-8-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H2,10,12,13)
DM3VJLZ	CS	C1=CC=C(C=C1)C=NCCS(=O)(=O)N
DM3VJLZ	IK	TZIDZFKPPIWVBP-UHFFFAOYSA-N
DM3VJLZ	IU	2-(benzylideneamino)ethanesulfonamide
DM3VJLZ	DE	Discovery agent

DM48C7G	ID	DM48C7G
DM48C7G	DN	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide
DM48C7G	HS	Investigative
DM48C7G	SN	CHEMBL402718; 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide; SCHEMBL8152458
DM48C7G	DT	Small molecular drug
DM48C7G	PC	25065925
DM48C7G	MW	356.4
DM48C7G	FM	C20H24N2O4
DM48C7G	IC	InChI=1S/C20H24N2O4/c23-19(22-25)14-8-7-13-18(26-15-16-9-3-1-4-10-16)20(24)21-17-11-5-2-6-12-17/h1-6,9-12,18,25H,7-8,13-15H2,(H,21,24)(H,22,23)
DM48C7G	CS	C1=CC=C(C=C1)COC(CCCCC(=O)NO)C(=O)NC2=CC=CC=C2
DM48C7G	IK	DGQYQVJKMZAQBV-UHFFFAOYSA-N
DM48C7G	IU	N'-hydroxy-N-phenyl-2-phenylmethoxyheptanediamide
DM48C7G	DE	Discovery agent

DME50RZ	ID	DME50RZ
DME50RZ	DN	2-(benzyloxy)naphthalene
DME50RZ	HS	Investigative
DME50RZ	SN	Benzyl 2-naphthyl ether; 613-62-7; 2-(benzyloxy)naphthalene; 2-Benzyloxynaphthalene; Naphthalene, 2-(phenylmethoxy)-; 2-(phenylmethoxy)naphthalene; 2-Benzyloxy-naphthalene; 2-phenylmethoxynaphthalene; CHEMBL146439; Q-200695; 2-(Phenylmethoxy)-naphthalene; Benzyl2-naphthylether; 2-Phenylmethoxy naphthalenen; b-naphthylbenzyl ether; ss-Naphtholbenzylaether; benzyl-2-naphthylether; ACMC-209mru; AI3-00945; AC1L3VTE; beta-naphthyl benzyl ether; EC 405-490-3; SCHEMBL51460; KSC493E6R; CTK3J3268; DTXSID80210201; MolPort-002-476-516
DME50RZ	DT	Small molecular drug
DME50RZ	PC	123080
DME50RZ	MW	234.29
DME50RZ	FM	C17H14O
DME50RZ	IC	InChI=1S/C17H14O/c1-2-6-14(7-3-1)13-18-17-11-10-15-8-4-5-9-16(15)12-17/h1-12H,13H2
DME50RZ	CS	C1=CC=C(C=C1)COC2=CC3=CC=CC=C3C=C2
DME50RZ	IK	WLTCCDHHWYAMCG-UHFFFAOYSA-N
DME50RZ	IU	2-phenylmethoxynaphthalene
DME50RZ	CA	CAS 613-62-7
DME50RZ	DE	Discovery agent

DMSNCOW	ID	DMSNCOW
DMSNCOW	DN	2-(benzyloxyamino)-N-hydroxy-3-methylpentanamide
DMSNCOW	HS	Investigative
DMSNCOW	SN	CHEMBL228231; 2-(benzyloxyamino)-N-hydroxy-3-methylpentanamide
DMSNCOW	DT	Small molecular drug
DMSNCOW	PC	16721024
DMSNCOW	MW	252.31
DMSNCOW	FM	C13H20N2O3
DMSNCOW	IC	InChI=1S/C13H20N2O3/c1-3-10(2)12(13(16)14-17)15-18-9-11-7-5-4-6-8-11/h4-8,10,12,15,17H,3,9H2,1-2H3,(H,14,16)
DMSNCOW	CS	CCC(C)C(C(=O)NO)NOCC1=CC=CC=C1
DMSNCOW	IK	OISVGEVVTLNTBZ-UHFFFAOYSA-N
DMSNCOW	IU	N-hydroxy-3-methyl-2-(phenylmethoxyamino)pentanamide
DMSNCOW	DE	Discovery agent

DMHZJXG	ID	DMHZJXG
DMHZJXG	DN	2-(benzyloxyamino)-N-hydroxyacetamide
DMHZJXG	HS	Investigative
DMHZJXG	SN	CHEMBL226149; 2-(benzyloxyamino)-N-hydroxyacetamide
DMHZJXG	DT	Small molecular drug
DMHZJXG	PC	44423683
DMHZJXG	MW	196.2
DMHZJXG	FM	C9H12N2O3
DMHZJXG	IC	InChI=1S/C9H12N2O3/c12-9(11-13)6-10-14-7-8-4-2-1-3-5-8/h1-5,10,13H,6-7H2,(H,11,12)
DMHZJXG	CS	C1=CC=C(C=C1)CONCC(=O)NO
DMHZJXG	IK	PMVJGZGFFBJYLQ-UHFFFAOYSA-N
DMHZJXG	IU	N-hydroxy-2-(phenylmethoxyamino)acetamide
DMHZJXG	DE	Discovery agent

DMOUKTH	ID	DMOUKTH
DMOUKTH	DN	2-(benzyloxyamino)-N-hydroxyhexanamide
DMOUKTH	HS	Investigative
DMOUKTH	SN	CHEMBL228230; 2-(benzyloxyamino)-N-hydroxyhexanamide
DMOUKTH	DT	Small molecular drug
DMOUKTH	PC	44423686
DMOUKTH	MW	252.31
DMOUKTH	FM	C13H20N2O3
DMOUKTH	IC	InChI=1S/C13H20N2O3/c1-2-3-9-12(13(16)14-17)15-18-10-11-7-5-4-6-8-11/h4-8,12,15,17H,2-3,9-10H2,1H3,(H,14,16)
DMOUKTH	CS	CCCCC(C(=O)NO)NOCC1=CC=CC=C1
DMOUKTH	IK	MTXWGHZYBWXADO-UHFFFAOYSA-N
DMOUKTH	IU	N-hydroxy-2-(phenylmethoxyamino)hexanamide
DMOUKTH	DE	Discovery agent

DM0C5O3	ID	DM0C5O3
DM0C5O3	DN	2-(Biphenyl-2-yloxy)-N,N-dimethylethanamine
DM0C5O3	HS	Investigative
DM0C5O3	SN	CHEMBL20666; N,N-dimethyl-2-(2-phenylphenoxy)ethanamine; 2-(Biphenyl-2-yloxy)-N,N-dimethylethanamine; AC1LHJ83; ZINC4913607; BDBM50307494; MCULE-6428005896
DM0C5O3	DT	Small molecular drug
DM0C5O3	PC	888197
DM0C5O3	MW	241.33
DM0C5O3	FM	C16H19NO
DM0C5O3	IC	InChI=1S/C16H19NO/c1-17(2)12-13-18-16-11-7-6-10-15(16)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3
DM0C5O3	CS	CN(C)CCOC1=CC=CC=C1C2=CC=CC=C2
DM0C5O3	IK	HEGXUUYKFGNKJB-UHFFFAOYSA-N
DM0C5O3	IU	N,N-dimethyl-2-(2-phenylphenoxy)ethanamine
DM0C5O3	DE	Discovery agent

DM9XZSC	ID	DM9XZSC
DM9XZSC	DN	2-(Biphenyl-2-ylthio)-N,N-dimethylethanamine
DM9XZSC	HS	Investigative
DM9XZSC	SN	CHEMBL607584; 2-(Biphenyl-2-ylthio)-N,N-dimethylethanamine; ZINC45387798
DM9XZSC	DT	Small molecular drug
DM9XZSC	PC	46233381
DM9XZSC	MW	257.399
DM9XZSC	FM	C16H19NS
DM9XZSC	IC	InChI=1S/C16H19NS/c1-17(2)12-13-18-16-11-7-6-10-15(16)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3
DM9XZSC	CS	CN(C)CCSC1=CC=CC=C1C2=CC=CC=C2
DM9XZSC	IK	CIOXNSHCQPHJOE-UHFFFAOYSA-N
DM9XZSC	IU	N,N-dimethyl-2-(2-phenylphenyl)sulfanylethanamine
DM9XZSC	DE	Discovery agent

DMU0GDY	ID	DMU0GDY
DMU0GDY	DN	2-(Biphenyl-3-ylthio)-N,N-dimethylethanamine
DMU0GDY	HS	Investigative
DMU0GDY	SN	CHEMBL597981; 2-(Biphenyl-3-ylthio)-N,N-dimethylethanamine
DMU0GDY	DT	Small molecular drug
DMU0GDY	PC	46233485
DMU0GDY	MW	257.399
DMU0GDY	FM	C16H19NS
DMU0GDY	IC	InChI=1S/C16H19NS/c1-17(2)11-12-18-16-10-6-9-15(13-16)14-7-4-3-5-8-14/h3-10,13H,11-12H2,1-2H3
DMU0GDY	CS	CN(C)CCSC1=CC=CC(=C1)C2=CC=CC=C2
DMU0GDY	IK	NDJKJLMJAGRKRK-UHFFFAOYSA-N
DMU0GDY	IU	N,N-dimethyl-2-(3-phenylphenyl)sulfanylethanamine
DMU0GDY	DE	Discovery agent

DMRQOKB	ID	DMRQOKB
DMRQOKB	DN	2-(biphenyl-4-yl)vinylboronic acid
DMRQOKB	HS	Investigative
DMRQOKB	SN	352530-23-5; trans-2-(4-Biphenyl)vinylboronic acid; (2-([1,1'-Biphenyl]-4-yl)vinyl)boronic acid; (E)-(2-([1,1'-Biphenyl]-4-yl)vinyl)boronic acid; AC1O0CFW; Alkenylboronic Acid, 22; 4-Phenylstyrylboronic acid; CHEMBL453758; SCHEMBL2910475; SCHEMBL12260418; C14H13BO2; BDBM26143; DTXSID30421729; ZINC169870786; AKOS015893176; FCH5518572; AB21449; RTR-014581; KB-61854; BBV-43957496; ACM352530235; OR360465; AX8240126; [(E)-2-(4-phenylphenyl)ethenyl]boranediol; V5431; [(E)-2-(4-phenylphenyl)ethenyl]boronic acid; B-4710; I04-2357
DMRQOKB	DT	Small molecular drug
DMRQOKB	PC	6011033
DMRQOKB	MW	224.06
DMRQOKB	FM	C14H13BO2
DMRQOKB	IC	InChI=1S/C14H13BO2/c16-15(17)11-10-12-6-8-14(9-7-12)13-4-2-1-3-5-13/h1-11,16-17H/b11-10+
DMRQOKB	CS	B(/C=C/C1=CC=C(C=C1)C2=CC=CC=C2)(O)O
DMRQOKB	IK	NTRGFVQIGQYKIL-ZHACJKMWSA-N
DMRQOKB	IU	[(E)-2-(4-phenylphenyl)ethenyl]boronic acid
DMRQOKB	CA	CAS 352530-23-5
DMRQOKB	DE	Discovery agent

DM3PWK7	ID	DM3PWK7
DM3PWK7	DN	2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide
DM3PWK7	HS	Investigative
DM3PWK7	SN	CHEMBL550148; 2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide; 3f17; BDBM50294120
DM3PWK7	DT	Small molecular drug
DM3PWK7	PC	25049753
DM3PWK7	MW	306.34
DM3PWK7	FM	C14H14N2O4S
DM3PWK7	IC	InChI=1S/C14H14N2O4S/c17-14(16-18)10-15-21(19,20)13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-9,15,18H,10H2,(H,16,17)
DM3PWK7	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NCC(=O)NO
DM3PWK7	IK	NKGRTRASISLCCZ-UHFFFAOYSA-N
DM3PWK7	IU	N-hydroxy-2-[(4-phenylphenyl)sulfonylamino]acetamide
DM3PWK7	DE	Discovery agent

DMH3YBR	ID	DMH3YBR
DMH3YBR	DN	2-(biphenyl-4-ylsulfonamido)pentanedioic acid
DMH3YBR	HS	Investigative
DMH3YBR	SN	CHEMBL475540; 2-(Biphenyl-4-sulfonylamino)-pentanedioic acid; SR-01000365325; BAS 07869980; AC1LD9LY; 2-(biphenyl-4-ylsulfonamido)pentanedioic acid; MLS000075919; CHEBI:91838; HMS2373B21; ML034; BDBM50247207; AKOS000737926; AKOS024284065; MCULE-3770968562; ST072428; SMR000014780; 2-[(4-phenylphenyl)sulfonylamino]pentanedioic acid; SR-01000365325-1; SR-01000365325-3; 2-{[(4-phenylphenyl)sulfonyl]amino}pentanedioic acid
DMH3YBR	DT	Small molecular drug
DMH3YBR	PC	644601
DMH3YBR	MW	363.4
DMH3YBR	FM	C17H17NO6S
DMH3YBR	IC	InChI=1S/C17H17NO6S/c19-16(20)11-10-15(17(21)22)18-25(23,24)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9,15,18H,10-11H2,(H,19,20)(H,21,22)
DMH3YBR	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NC(CCC(=O)O)C(=O)O
DMH3YBR	IK	IQGHPUPMOUUHPP-UHFFFAOYSA-N
DMH3YBR	IU	2-[(4-phenylphenyl)sulfonylamino]pentanedioic acid
DMH3YBR	CA	CAS 193808-18-3
DMH3YBR	CB	CHEBI:91838
DMH3YBR	DE	Discovery agent

DMCNV5J	ID	DMCNV5J
DMCNV5J	DN	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J	HS	Investigative
DMCNV5J	SN	CHEMBL574589; 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J	DT	Small molecular drug
DMCNV5J	PC	44478925
DMCNV5J	MW	353.4
DMCNV5J	FM	C19H15NO4S
DMCNV5J	IC	InChI=1S/C19H15NO4S/c21-19(20-22)17-8-4-5-9-18(17)25(23,24)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13,22H,(H,20,21)
DMCNV5J	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3C(=O)NO
DMCNV5J	IK	WQRJSSRVHCJAKB-UHFFFAOYSA-N
DMCNV5J	IU	N-hydroxy-2-(4-phenylphenyl)sulfonylbenzamide
DMCNV5J	DE	Discovery agent

DMFO7CH	ID	DMFO7CH
DMFO7CH	DN	2-(butylthiomethyl)-5-hydroxy-4H-pyran-4-one
DMFO7CH	HS	Investigative
DMFO7CH	SN	CHEMBL1269398; 204503-10-6; 2-(butylthiomethyl)-5-hydroxy-4H-pyran-4-one; CTK0J0428; DTXSID10680655; BDBM50330110; AKOS030554091; 4H-Pyran-4-one, 2-[(butylthio)methyl]-5-hydroxy-
DMFO7CH	DT	Small molecular drug
DMFO7CH	PC	52943048
DMFO7CH	MW	214.28
DMFO7CH	FM	C10H14O3S
DMFO7CH	IC	InChI=1S/C10H14O3S/c1-2-3-4-14-7-8-5-9(11)10(12)6-13-8/h5-6,12H,2-4,7H2,1H3
DMFO7CH	CS	CCCCSCC1=CC(=O)C(=CO1)O
DMFO7CH	IK	PJEUFTMKXABORH-UHFFFAOYSA-N
DMFO7CH	IU	2-(butylsulfanylmethyl)-5-hydroxypyran-4-one
DMFO7CH	CA	CAS 204503-10-6
DMFO7CH	DE	Discovery agent

DMA6P4J	ID	DMA6P4J
DMA6P4J	DN	2-(Carbazole-9-sulfonyl)-benzoic acid
DMA6P4J	HS	Investigative
DMA6P4J	SN	CHEMBL364141; 2-(Carbazole-9-sulfonyl)-benzoic acid
DMA6P4J	DT	Small molecular drug
DMA6P4J	PC	44393734
DMA6P4J	MW	351.4
DMA6P4J	FM	C19H13NO4S
DMA6P4J	IC	InChI=1S/C19H13NO4S/c21-19(22)15-9-3-6-12-18(15)25(23,24)20-16-10-4-1-7-13(16)14-8-2-5-11-17(14)20/h1-12H,(H,21,22)
DMA6P4J	CS	C1=CC=C2C(=C1)C3=CC=CC=C3N2S(=O)(=O)C4=CC=CC=C4C(=O)O
DMA6P4J	IK	WVHKYPINALNKJJ-UHFFFAOYSA-N
DMA6P4J	IU	2-carbazol-9-ylsulfonylbenzoic acid
DMA6P4J	DE	Discovery agent

DMQ2SNL	ID	DMQ2SNL
DMQ2SNL	DN	2-(carboxymethylamino)-2-oxoacetic acid
DMQ2SNL	HS	Investigative
DMQ2SNL	SN	N-Oxalylglycine; 5262-39-5; Oxalylglycine; Oxaloglycine; 2-((Carboxymethyl)amino)-2-oxoacetic acid; UNII-VVW38EB8YS; N-(carboxycarbonyl)glycine; N-OXALYOLGLYCINE; VVW38EB8YS; 2-oxo-3-azaglutaric acid; CHEMBL90852; Glycine, N-(carboxycarbonyl)-; CHEBI:44482; OGA; C4H5NO5; 4idz; 4nrp; 2xml; 3hqr; N-oxalyl glycine, 1a; 2oq6; 1h2k; AC1MIVD0; Glycine,N-(carboxycarbonyl)-; SCHEMBL435820; BDBM26106; CTK8F0807; DTXSID20200601; MolPort-000-141-021; ZINC1534133; N-Oxalylglycine, &gt; 4958AE
DMQ2SNL	DT	Small molecular drug
DMQ2SNL	PC	3080614
DMQ2SNL	MW	147.09
DMQ2SNL	FM	C4H5NO5
DMQ2SNL	IC	InChI=1S/C4H5NO5/c6-2(7)1-5-3(8)4(9)10/h1H2,(H,5,8)(H,6,7)(H,9,10)
DMQ2SNL	CS	C(C(=O)O)NC(=O)C(=O)O
DMQ2SNL	IK	BIMZLRFONYSTPT-UHFFFAOYSA-N
DMQ2SNL	IU	2-(carboxymethylamino)-2-oxoacetic acid
DMQ2SNL	CA	CAS 5262-39-5
DMQ2SNL	CB	CHEBI:44482
DMQ2SNL	DE	Discovery agent

DM0PA6I	ID	DM0PA6I
DM0PA6I	DN	2-(cinnamyloxy)pyrido[2,3-d]pyrimidin-4(3H)-one
DM0PA6I	HS	Investigative
DM0PA6I	DT	Small molecular drug
DM0PA6I	PC	136127015
DM0PA6I	MW	279.29
DM0PA6I	FM	C16H13N3O2
DM0PA6I	IC	InChI=1S/C16H13N3O2/c20-15-13-9-4-10-17-14(13)18-16(19-15)21-11-5-8-12-6-2-1-3-7-12/h1-10H,11H2,(H,17,18,19,20)/b8-5+
DM0PA6I	CS	C1=CC=C(C=C1)/C=C/COC2=NC3=C(C=CC=N3)C(=O)N2
DM0PA6I	IK	FROKBSNKSJMXTH-VMPITWQZSA-N
DM0PA6I	IU	2-[(E)-3-phenylprop-2-enoxy]-3H-pyrido[2,3-d]pyrimidin-4-one
DM0PA6I	DE	Discovery agent

DMQ9ODG	ID	DMQ9ODG
DMQ9ODG	DN	2-(cycloheptylamino)-2-oxoethyl 2-aminonicotinate
DMQ9ODG	HS	Investigative
DMQ9ODG	SN	CHEMBL550694; AC1P0KT3; MLS002166893; 2-(cycloheptylamino)-2-oxoethyl 2-aminonicotinate; MolPort-004-113-473; HMS3049I09; ZINC25561600; BDBM50295159; AKOS033614947; MCULE-1392821852; SMR001249231; SR-01000074735; SR-01000074735-1; Z18385694; (cycloheptylcarbamoyl)methyl 2-aminopyridine-3-carboxylate; [2-(cycloheptylamino)-2-oxoethyl] 2-aminopyridine-3-carboxylate
DMQ9ODG	DT	Small molecular drug
DMQ9ODG	PC	8147464
DMQ9ODG	MW	291.35
DMQ9ODG	FM	C15H21N3O3
DMQ9ODG	IC	InChI=1S/C15H21N3O3/c16-14-12(8-5-9-17-14)15(20)21-10-13(19)18-11-6-3-1-2-4-7-11/h5,8-9,11H,1-4,6-7,10H2,(H2,16,17)(H,18,19)
DMQ9ODG	CS	C1CCCC(CC1)NC(=O)COC(=O)C2=C(N=CC=C2)N
DMQ9ODG	IK	YLZFUORCIVHHHD-UHFFFAOYSA-N
DMQ9ODG	IU	[2-(cycloheptylamino)-2-oxoethyl] 2-aminopyridine-3-carboxylate
DMQ9ODG	DE	Discovery agent

DMPT0MB	ID	DMPT0MB
DMPT0MB	DN	2-(cyclohexylamino)benzoic acid
DMPT0MB	HS	Investigative
DMPT0MB	SN	2-(cyclohexylamino)benzoic acid; 10286-53-0; 2-CYCLOHEXYLAMINO-BENZOIC ACID; Oprea1_006076; SCHEMBL3274851; DTXSID60600368; MolPort-005-940-199; KS-00003TL8; ZINC21999434; AKOS009313819; DB07038; TS-03143; AJ-80046; Z1945984208
DMPT0MB	DT	Small molecular drug
DMPT0MB	PC	19826721
DMPT0MB	MW	219.28
DMPT0MB	FM	C13H17NO2
DMPT0MB	IC	InChI=1S/C13H17NO2/c15-13(16)11-8-4-5-9-12(11)14-10-6-2-1-3-7-10/h4-5,8-10,14H,1-3,6-7H2,(H,15,16)
DMPT0MB	CS	C1CCC(CC1)NC2=CC=CC=C2C(=O)O
DMPT0MB	IK	JSXMFCCPQQJLCR-UHFFFAOYSA-N
DMPT0MB	IU	2-(cyclohexylamino)benzoic acid
DMPT0MB	CA	CAS 10286-53-0
DMPT0MB	DE	Discovery agent

DM2CAI1	ID	DM2CAI1
DM2CAI1	DN	2-(cyclohexylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM2CAI1	HS	Investigative
DM2CAI1	SN	CHEMBL1269426; 2-(cyclohexylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM2CAI1	DT	Small molecular drug
DM2CAI1	PC	23274383
DM2CAI1	MW	240.32
DM2CAI1	FM	C12H16O3S
DM2CAI1	IC	InChI=1S/C12H16O3S/c13-11-6-9(15-7-12(11)14)8-16-10-4-2-1-3-5-10/h6-7,10,14H,1-5,8H2
DM2CAI1	CS	C1CCC(CC1)SCC2=CC(=O)C(=CO2)O
DM2CAI1	IK	QOQLSVLZCVJKQA-UHFFFAOYSA-N
DM2CAI1	IU	2-(cyclohexylsulfanylmethyl)-5-hydroxypyran-4-one
DM2CAI1	DE	Discovery agent

DMAPW5K	ID	DMAPW5K
DMAPW5K	DN	2-(cyclooctylamino)-5,5-diethyloxazol-4(5H)-one
DMAPW5K	HS	Investigative
DMAPW5K	DT	Small molecular drug
DMAPW5K	PC	135950111
DMAPW5K	MW	266.38
DMAPW5K	FM	C15H26N2O2
DMAPW5K	IC	InChI=1S/C15H26N2O2/c1-3-15(4-2)13(18)17-14(19-15)16-12-10-8-6-5-7-9-11-12/h12H,3-11H2,1-2H3,(H,16,17,18)
DMAPW5K	CS	CCC1(C(=O)NC(=NC2CCCCCCC2)O1)CC
DMAPW5K	IK	RCJPILQMNSKTFG-UHFFFAOYSA-N
DMAPW5K	IU	2-cyclooctylimino-5,5-diethyl-1,3-oxazolidin-4-one
DMAPW5K	DE	Discovery agent

DMZVMDO	ID	DMZVMDO
DMZVMDO	DN	2-(difluoromethyl)-9H-carbazole
DMZVMDO	HS	Investigative
DMZVMDO	SN	CHEMBL1170284; 2-(difluoromethyl)-9H-carbazole
DMZVMDO	DT	Small molecular drug
DMZVMDO	PC	46855212
DMZVMDO	MW	217.21
DMZVMDO	FM	C13H9F2N
DMZVMDO	IC	InChI=1S/C13H9F2N/c14-13(15)8-5-6-10-9-3-1-2-4-11(9)16-12(10)7-8/h1-7,13,16H
DMZVMDO	CS	C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)C(F)F
DMZVMDO	IK	JHTSEXLNQMISRI-UHFFFAOYSA-N
DMZVMDO	IU	2-(difluoromethyl)-9H-carbazole
DMZVMDO	DE	Discovery agent

DMS7WQD	ID	DMS7WQD
DMS7WQD	DN	2-(ethoxycarbonyl)-1H-indole-5-carboxylic acid
DMS7WQD	HS	Investigative
DMS7WQD	SN	2-(ethoxycarbonyl)-1H-indole-5-carboxylic acid; 138731-14-3; 2-(ethoxycarbonyl)indole-5-carboxylic acid; 1H-INDOLE-2,5-DICARBOXYLIC ACID 2-ETHYL ESTER; CHEMBL503643; CAVYPAYXEMVXMS-UHFFFAOYSA-N; 2-ETHOXYCABONYL-5-INDOLE CARBOXYLIC ACID; 2-ethoxycarbonyl-1H-indole-5-carboxylic acid; SCHEMBL1306748; AC1Q34A5; CTK6F6093; DTXSID70592508; MolPort-004-323-750; KS-00000BY1; STK695496; SBB019411; 1264AJ; ZINC14985904; BDBM50268451; AKOS000161198; MCULE-3298585220; AB49136; NCGC00341253-01; BS-14093; SY043081; AJ-66467
DMS7WQD	DT	Small molecular drug
DMS7WQD	PC	18071365
DMS7WQD	MW	233.22
DMS7WQD	FM	C12H11NO4
DMS7WQD	IC	InChI=1S/C12H11NO4/c1-2-17-12(16)10-6-8-5-7(11(14)15)3-4-9(8)13-10/h3-6,13H,2H2,1H3,(H,14,15)
DMS7WQD	CS	CCOC(=O)C1=CC2=C(N1)C=CC(=C2)C(=O)O
DMS7WQD	IK	CAVYPAYXEMVXMS-UHFFFAOYSA-N
DMS7WQD	IU	2-ethoxycarbonyl-1H-indole-5-carboxylic acid
DMS7WQD	CA	CAS 138731-14-3
DMS7WQD	DE	Discovery agent

DM8GJCU	ID	DM8GJCU
DM8GJCU	DN	2-(ethylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM8GJCU	HS	Investigative
DM8GJCU	SN	CHEMBL1269349; 2-(ethylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM8GJCU	DT	Small molecular drug
DM8GJCU	PC	52944229
DM8GJCU	MW	186.23
DM8GJCU	FM	C8H10O3S
DM8GJCU	IC	InChI=1S/C8H10O3S/c1-2-12-5-6-3-7(9)8(10)4-11-6/h3-4,10H,2,5H2,1H3
DM8GJCU	CS	CCSCC1=CC(=O)C(=CO1)O
DM8GJCU	IK	BOZGBIVLELURMD-UHFFFAOYSA-N
DM8GJCU	IU	2-(ethylsulfanylmethyl)-5-hydroxypyran-4-one
DM8GJCU	DE	Discovery agent

DM6BHUF	ID	DM6BHUF
DM6BHUF	DN	2-(furan-2-yl)-6-morpholino-4H-pyran-4-one
DM6BHUF	HS	Investigative
DM6BHUF	SN	CHEMBL223775; 2-(furan-2-yl)-6-morpholino-4H-pyran-4-one
DM6BHUF	DT	Small molecular drug
DM6BHUF	PC	16203943
DM6BHUF	MW	247.25
DM6BHUF	FM	C13H13NO4
DM6BHUF	IC	InChI=1S/C13H13NO4/c15-10-8-12(11-2-1-5-17-11)18-13(9-10)14-3-6-16-7-4-14/h1-2,5,8-9H,3-4,6-7H2
DM6BHUF	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CO3
DM6BHUF	IK	AHAIOLWQJGMAQA-UHFFFAOYSA-N
DM6BHUF	IU	2-(furan-2-yl)-6-morpholin-4-ylpyran-4-one
DM6BHUF	DE	Discovery agent

DM490BL	ID	DM490BL
DM490BL	DN	2-(heptylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM490BL	HS	Investigative
DM490BL	SN	CHEMBL1269401; 2-(heptylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM490BL	DT	Small molecular drug
DM490BL	PC	52949129
DM490BL	MW	256.36
DM490BL	FM	C13H20O3S
DM490BL	IC	InChI=1S/C13H20O3S/c1-2-3-4-5-6-7-17-10-11-8-12(14)13(15)9-16-11/h8-9,15H,2-7,10H2,1H3
DM490BL	CS	CCCCCCCSCC1=CC(=O)C(=CO1)O
DM490BL	IK	ZRHZWPMLQKIVHQ-UHFFFAOYSA-N
DM490BL	IU	2-(heptylsulfanylmethyl)-5-hydroxypyran-4-one
DM490BL	DE	Discovery agent

DM7YLTS	ID	DM7YLTS
DM7YLTS	DN	2-(hex-1-ynyl)-N6-methoxyadenosine
DM7YLTS	HS	Investigative
DM7YLTS	SN	CHEMBL220889; 2-(hex-1-ynyl)-N6-methoxyadenosine; SCHEMBL4384408
DM7YLTS	DT	Small molecular drug
DM7YLTS	PC	10045125
DM7YLTS	MW	377.4
DM7YLTS	FM	C17H23N5O5
DM7YLTS	IC	InChI=1S/C17H23N5O5/c1-3-4-5-6-7-11-19-15(21-26-2)12-16(20-11)22(9-18-12)17-14(25)13(24)10(8-23)27-17/h9-10,13-14,17,23-25H,3-5,8H2,1-2H3,(H,19,20,21)/t10-,13-,14-,17-/m1/s1
DM7YLTS	CS	CCCCC#CC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NOC
DM7YLTS	IK	NIZLYCJGSQRCLN-IWCJZZDYSA-N
DM7YLTS	IU	(2R,3R,4S,5R)-2-[2-hex-1-ynyl-6-(methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM7YLTS	DE	Discovery agent

DM235Q4	ID	DM235Q4
DM235Q4	DN	2-(hexylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM235Q4	HS	Investigative
DM235Q4	SN	2-(hexylthiomethyl)-5-hydroxy-4H-pyran-4-one; CHEMBL1269400; 1257846-10-8
DM235Q4	DT	Small molecular drug
DM235Q4	PC	50899743
DM235Q4	MW	242.34
DM235Q4	FM	C12H18O3S
DM235Q4	IC	InChI=1S/C12H18O3S/c1-2-3-4-5-6-16-9-10-7-11(13)12(14)8-15-10/h7-8,14H,2-6,9H2,1H3
DM235Q4	CS	CCCCCCSCC1=CC(=O)C(=CO1)O
DM235Q4	IK	TWEMRPGKBWBOSQ-UHFFFAOYSA-N
DM235Q4	IU	2-(hexylsulfanylmethyl)-5-hydroxypyran-4-one
DM235Q4	DE	Discovery agent

DMOVYXT	ID	DMOVYXT
DMOVYXT	DN	2-(indolin-1yl)-melatonin
DMOVYXT	HS	Investigative
DMOVYXT	SN	CHEMBL514415; 2-(indolin-1yl)-melatonin; GTPL7782; BDBM50266430; N-(2-{5-Methoxy-2-[(2,3-dihydro-1H-indol-1yl)methyl)]-1H-indol-3-yl}ethyl)acetamide
DMOVYXT	DT	Small molecular drug
DMOVYXT	PC	25210130
DMOVYXT	MW	363.5
DMOVYXT	FM	C22H25N3O2
DMOVYXT	IC	InChI=1S/C22H25N3O2/c1-15(26)23-11-9-18-19-13-17(27-2)7-8-20(19)24-21(18)14-25-12-10-16-5-3-4-6-22(16)25/h3-8,13,24H,9-12,14H2,1-2H3,(H,23,26)
DMOVYXT	CS	CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)CN3CCC4=CC=CC=C43
DMOVYXT	IK	WPMBIMXWTHXWHN-UHFFFAOYSA-N
DMOVYXT	IU	N-[2-[2-(2,3-dihydroindol-1-ylmethyl)-5-methoxy-1H-indol-3-yl]ethyl]acetamide
DMOVYXT	DE	Discovery agent

DM1SIQD	ID	DM1SIQD
DM1SIQD	DN	2-(methylsulfonyl)naphthalene-1,4-diol
DM1SIQD	HS	Investigative
DM1SIQD	SN	CHEMBL491752; 2-(methylsulfonyl)naphthalene-1,4-diol
DM1SIQD	DT	Small molecular drug
DM1SIQD	PC	44562639
DM1SIQD	MW	238.26
DM1SIQD	FM	C11H10O4S
DM1SIQD	IC	InChI=1S/C11H10O4S/c1-16(14,15)10-6-9(12)7-4-2-3-5-8(7)11(10)13/h2-6,12-13H,1H3
DM1SIQD	CS	CS(=O)(=O)C1=C(C2=CC=CC=C2C(=C1)O)O
DM1SIQD	IK	LDKPKJBNGZYJSR-UHFFFAOYSA-N
DM1SIQD	IU	2-methylsulfonylnaphthalene-1,4-diol
DM1SIQD	DE	Discovery agent

DMM52D3	ID	DMM52D3
DMM52D3	DN	2-(methylsulfonylthio)ethyl 2-propylpentanoate
DMM52D3	HS	Investigative
DMM52D3	SN	CHEMBL271677; 2-(methylsulfonylthio)ethyl 2-propylpentanoate; SCHEMBL4156413
DMM52D3	DT	Small molecular drug
DMM52D3	PC	24759251
DMM52D3	MW	282.4
DMM52D3	FM	C11H22O4S2
DMM52D3	IC	InChI=1S/C11H22O4S2/c1-4-6-10(7-5-2)11(12)15-8-9-16-17(3,13)14/h10H,4-9H2,1-3H3
DMM52D3	CS	CCCC(CCC)C(=O)OCCSS(=O)(=O)C
DMM52D3	IK	ZHKBCGORMGLCBI-UHFFFAOYSA-N
DMM52D3	IU	2-methylsulfonylsulfanylethyl 2-propylpentanoate
DMM52D3	DE	Discovery agent

DM15BA7	ID	DM15BA7
DM15BA7	DN	2-(m-tolylethynyl)pyrimidine
DM15BA7	HS	Investigative
DM15BA7	SN	2-(m-tolylethynyl)pyrimidine; CHEMBL496882
DM15BA7	DT	Small molecular drug
DM15BA7	PC	44190040
DM15BA7	MW	194.23
DM15BA7	FM	C13H10N2
DM15BA7	IC	InChI=1S/C13H10N2/c1-11-4-2-5-12(10-11)6-7-13-14-8-3-9-15-13/h2-5,8-10H,1H3
DM15BA7	CS	CC1=CC(=CC=C1)C#CC2=NC=CC=N2
DM15BA7	IK	GHGMWMJKRGZKMW-UHFFFAOYSA-N
DM15BA7	IU	2-[2-(3-methylphenyl)ethynyl]pyrimidine
DM15BA7	DE	Discovery agent

DMRNOM6	ID	DMRNOM6
DMRNOM6	DN	2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid
DMRNOM6	HS	Investigative
DMRNOM6	SN	CHEMBL398087; 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid
DMRNOM6	DT	Small molecular drug
DMRNOM6	PC	44434501
DMRNOM6	MW	219.21
DMRNOM6	FM	C12H10FNO2
DMRNOM6	IC	InChI=1S/C12H10FNO2/c13-10-3-1-2-4-11(10)14-6-5-9(8-14)7-12(15)16/h1-6,8H,7H2,(H,15,16)
DMRNOM6	CS	C1=CC=C(C(=C1)N2C=CC(=C2)CC(=O)O)F
DMRNOM6	IK	FBDSYHLMZKXXBC-UHFFFAOYSA-N
DMRNOM6	IU	2-[1-(2-fluorophenyl)pyrrol-3-yl]acetic acid
DMRNOM6	DE	Discovery agent

DMCL9E6	ID	DMCL9E6
DMCL9E6	DN	2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid
DMCL9E6	HS	Investigative
DMCL9E6	SN	CHEMBL236238; 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid; BDBM50213563
DMCL9E6	DT	Small molecular drug
DMCL9E6	PC	44434500
DMCL9E6	MW	219.21
DMCL9E6	FM	C12H10FNO2
DMCL9E6	IC	InChI=1S/C12H10FNO2/c13-10-5-1-2-6-11(10)14-7-3-4-9(14)8-12(15)16/h1-7H,8H2,(H,15,16)
DMCL9E6	CS	C1=CC=C(C(=C1)N2C=CC=C2CC(=O)O)F
DMCL9E6	IK	XOJPIEDVJHMQEJ-UHFFFAOYSA-N
DMCL9E6	IU	2-[1-(2-fluorophenyl)pyrrol-2-yl]acetic acid
DMCL9E6	DE	Discovery agent

DMVR248	ID	DMVR248
DMVR248	DN	2-(N,N-Diethylamino)-3'-chloropropiophenone
DMVR248	HS	Investigative
DMVR248	SN	CHEMBL578815; SCHEMBL634022; BDBM50302915; AKOS009048034
DMVR248	DT	Small molecular drug
DMVR248	PC	43227726
DMVR248	MW	239.74
DMVR248	FM	C13H18ClNO
DMVR248	IC	InChI=1S/C13H18ClNO/c1-4-15(5-2)10(3)13(16)11-7-6-8-12(14)9-11/h6-10H,4-5H2,1-3H3
DMVR248	CS	CCN(CC)C(C)C(=O)C1=CC(=CC=C1)Cl
DMVR248	IK	TZRAZPTWNAPWGU-UHFFFAOYSA-N
DMVR248	IU	1-(3-chlorophenyl)-2-(diethylamino)propan-1-one
DMVR248	DE	Discovery agent

DMHYKR8	ID	DMHYKR8
DMHYKR8	DN	2-(N''-Acetyl-hydrazino)-benzenesulfonamide
DMHYKR8	HS	Investigative
DMHYKR8	SN	hydrazide deriv. 19; CHEMBL175652; BDBM12164; 2-acetohydrazidobenzene-1-sulfonamide
DMHYKR8	DT	Small molecular drug
DMHYKR8	PC	11160546
DMHYKR8	MW	229.26
DMHYKR8	FM	C8H11N3O3S
DMHYKR8	IC	InChI=1S/C8H11N3O3S/c1-6(12)10-11-7-4-2-3-5-8(7)15(9,13)14/h2-5,11H,1H3,(H,10,12)(H2,9,13,14)
DMHYKR8	CS	CC(=O)NNC1=CC=CC=C1S(=O)(=O)N
DMHYKR8	IK	NGNPYNHOTNXXJP-UHFFFAOYSA-N
DMHYKR8	IU	2-(2-acetylhydrazinyl)benzenesulfonamide
DMHYKR8	DE	Discovery agent

DMKY71Z	ID	DMKY71Z
DMKY71Z	DN	2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole
DMKY71Z	HS	Investigative
DMKY71Z	SN	CHEMBL266155; 2-(2-Naphthyl)-1-imidazoline; 2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole; 2-naphthalen-2-yl-4,5-dihydro-1H-imidazole; 113698-36-5; SCHEMBL9575180; DTXSID8048442; BGWRJAXPPYHIRG-UHFFFAOYSA-N; ZINC13805903
DMKY71Z	DT	Small molecular drug
DMKY71Z	PC	11769428
DMKY71Z	MW	196.25
DMKY71Z	FM	C13H12N2
DMKY71Z	IC	InChI=1S/C13H12N2/c1-2-4-11-9-12(6-5-10(11)3-1)13-14-7-8-15-13/h1-6,9H,7-8H2,(H,14,15)
DMKY71Z	CS	C1CN=C(N1)C2=CC3=CC=CC=C3C=C2
DMKY71Z	IK	BGWRJAXPPYHIRG-UHFFFAOYSA-N
DMKY71Z	IU	2-naphthalen-2-yl-4,5-dihydro-1H-imidazole
DMKY71Z	DE	Discovery agent

DMEXBUF	ID	DMEXBUF
DMEXBUF	DN	2-(naphthalen-2-ylsulfonyl)naphthalene-1,4-diol
DMEXBUF	HS	Investigative
DMEXBUF	SN	CHEMBL462374; 2-(naphthalen-2-ylsulfonyl)naphthalene-1,4-diol
DMEXBUF	DT	Small molecular drug
DMEXBUF	PC	44562747
DMEXBUF	MW	350.4
DMEXBUF	FM	C20H14O4S
DMEXBUF	IC	InChI=1S/C20H14O4S/c21-18-12-19(20(22)17-8-4-3-7-16(17)18)25(23,24)15-10-9-13-5-1-2-6-14(13)11-15/h1-12,21-22H
DMEXBUF	CS	C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)C3=C(C4=CC=CC=C4C(=C3)O)O
DMEXBUF	IK	NEXUTBMTXKQNMP-UHFFFAOYSA-N
DMEXBUF	IU	2-naphthalen-2-ylsulfonylnaphthalene-1,4-diol
DMEXBUF	DE	Discovery agent

DML4GHA	ID	DML4GHA
DML4GHA	DN	2-(N-Cyclopentylamino)-3'-bromopropiophenone
DML4GHA	HS	Investigative
DML4GHA	SN	CHEMBL599846; BDBM50308113
DML4GHA	DT	Small molecular drug
DML4GHA	PC	45141380
DML4GHA	MW	296.2
DML4GHA	FM	C14H18BrNO
DML4GHA	IC	InChI=1S/C14H18BrNO/c1-10(16-13-7-2-3-8-13)14(17)11-5-4-6-12(15)9-11/h4-6,9-10,13,16H,2-3,7-8H2,1H3
DML4GHA	CS	CC(C(=O)C1=CC(=CC=C1)Br)NC2CCCC2
DML4GHA	IK	ZZWUEOYQVWAKCJ-UHFFFAOYSA-N
DML4GHA	IU	1-(3-bromophenyl)-2-(cyclopentylamino)propan-1-one
DML4GHA	DE	Discovery agent

DMP68CE	ID	DMP68CE
DMP68CE	DN	2-(N-Cyclopentylamino)-3'-chloropropiophenone
DMP68CE	HS	Investigative
DMP68CE	SN	CHEMBL566618; SCHEMBL633829; BDBM50302916; 2-(N-Cyclopentylamino)-3''-chloropropiophenone
DMP68CE	DT	Small molecular drug
DMP68CE	PC	44543272
DMP68CE	MW	251.75
DMP68CE	FM	C14H18ClNO
DMP68CE	IC	InChI=1S/C14H18ClNO/c1-10(16-13-7-2-3-8-13)14(17)11-5-4-6-12(15)9-11/h4-6,9-10,13,16H,2-3,7-8H2,1H3
DMP68CE	CS	CC(C(=O)C1=CC(=CC=C1)Cl)NC2CCCC2
DMP68CE	IK	RPHSTODYKZLNFU-UHFFFAOYSA-N
DMP68CE	IU	1-(3-chlorophenyl)-2-(cyclopentylamino)propan-1-one
DMP68CE	DE	Discovery agent

DMH6FKX	ID	DMH6FKX
DMH6FKX	DN	2-(N-Cyclopentylamino)-3'-fluoropropiophenone
DMH6FKX	HS	Investigative
DMH6FKX	SN	CHEMBL605501; BDBM50308112
DMH6FKX	DT	Small molecular drug
DMH6FKX	PC	45141379
DMH6FKX	MW	235.3
DMH6FKX	FM	C14H18FNO
DMH6FKX	IC	InChI=1S/C14H18FNO/c1-10(16-13-7-2-3-8-13)14(17)11-5-4-6-12(15)9-11/h4-6,9-10,13,16H,2-3,7-8H2,1H3
DMH6FKX	CS	CC(C(=O)C1=CC(=CC=C1)F)NC2CCCC2
DMH6FKX	IK	CFVHNYYHCCJXDK-UHFFFAOYSA-N
DMH6FKX	IU	2-(cyclopentylamino)-1-(3-fluorophenyl)propan-1-one
DMH6FKX	DE	Discovery agent

DMVN1UI	ID	DMVN1UI
DMVN1UI	DN	2-(N-Cyclopentylamino)-3'-methoxypropiophenone
DMVN1UI	HS	Investigative
DMVN1UI	SN	CHEMBL589250; BDBM50308121
DMVN1UI	DT	Small molecular drug
DMVN1UI	PC	45141608
DMVN1UI	MW	247.33
DMVN1UI	FM	C15H21NO2
DMVN1UI	IC	InChI=1S/C15H21NO2/c1-11(16-13-7-3-4-8-13)15(17)12-6-5-9-14(10-12)18-2/h5-6,9-11,13,16H,3-4,7-8H2,1-2H3
DMVN1UI	CS	CC(C(=O)C1=CC(=CC=C1)OC)NC2CCCC2
DMVN1UI	IK	ZMRXSORFBXMBCB-UHFFFAOYSA-N
DMVN1UI	IU	2-(cyclopentylamino)-1-(3-methoxyphenyl)propan-1-one
DMVN1UI	DE	Discovery agent

DMG87RK	ID	DMG87RK
DMG87RK	DN	2-(N-Cyclopentylamino)-3'-methylpropiophenone
DMG87RK	HS	Investigative
DMG87RK	SN	CHEMBL592854; BDBM50308114
DMG87RK	DT	Small molecular drug
DMG87RK	PC	45141381
DMG87RK	MW	231.33
DMG87RK	FM	C15H21NO
DMG87RK	IC	InChI=1S/C15H21NO/c1-11-6-5-7-13(10-11)15(17)12(2)16-14-8-3-4-9-14/h5-7,10,12,14,16H,3-4,8-9H2,1-2H3
DMG87RK	CS	CC1=CC(=CC=C1)C(=O)C(C)NC2CCCC2
DMG87RK	IK	VLLKJTHFWNJPCE-UHFFFAOYSA-N
DMG87RK	IU	2-(cyclopentylamino)-1-(3-methylphenyl)propan-1-one
DMG87RK	DE	Discovery agent

DMNMES3	ID	DMNMES3
DMNMES3	DN	2-(N-Cyclopropylamino)-3-chloropropiophenone
DMNMES3	HS	Investigative
DMNMES3	SN	CHEMBL569700; 2-(N-Cyclopropylamino)-3-chloropropiophenone; 2-(N-cyclopropylamino)-3'-chloropropiophenone; SCHEMBL634169; BDBM50302907
DMNMES3	DT	Small molecular drug
DMNMES3	PC	44543271
DMNMES3	MW	223.7
DMNMES3	FM	C12H14ClNO
DMNMES3	IC	InChI=1S/C12H14ClNO/c1-8(14-11-5-6-11)12(15)9-3-2-4-10(13)7-9/h2-4,7-8,11,14H,5-6H2,1H3
DMNMES3	CS	CC(C(=O)C1=CC(=CC=C1)Cl)NC2CC2
DMNMES3	IK	YKOZIWZLLJVPPD-UHFFFAOYSA-N
DMNMES3	IU	1-(3-chlorophenyl)-2-(cyclopropylamino)propan-1-one
DMNMES3	DE	Discovery agent

DMCK7SV	ID	DMCK7SV
DMCK7SV	DN	2-(N-Isopropylamino)-3'-chloropropiophenone
DMCK7SV	HS	Investigative
DMCK7SV	SN	CHEMBL565397; 2-(N-Isopropylamino)-3'-chloropropiophenone; 130839-36-0; AC1MHRAR; SCHEMBL770155; 1-(3-chlorophenyl)-2-(propan-2-ylamino)propan-1-one; BDBM50302920
DMCK7SV	DT	Small molecular drug
DMCK7SV	PC	3031077
DMCK7SV	MW	225.71
DMCK7SV	FM	C12H16ClNO
DMCK7SV	IC	InChI=1S/C12H16ClNO/c1-8(2)14-9(3)12(15)10-5-4-6-11(13)7-10/h4-9,14H,1-3H3
DMCK7SV	CS	CC(C)NC(C)C(=O)C1=CC(=CC=C1)Cl
DMCK7SV	IK	WHPARCHZPIKXEX-UHFFFAOYSA-N
DMCK7SV	IU	1-(3-chlorophenyl)-2-(propan-2-ylamino)propan-1-one
DMCK7SV	DE	Discovery agent

DMZVHSB	ID	DMZVHSB
DMZVHSB	DN	2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB	HS	Investigative
DMZVHSB	SN	Jsp003925
DMZVHSB	DT	Small molecular drug
DMZVHSB	PC	4478249
DMZVHSB	MW	195.24
DMZVHSB	FM	C6H13NO4S
DMZVHSB	IC	InChI=1S/C6H13NO4S/c8-12(9,10)6-3-7-1-4-11-5-2-7/h1-6H2,(H,8,9,10)
DMZVHSB	CS	C1COCC[NH+]1CCS(=O)(=O)[O-]
DMZVHSB	IK	SXGZJKUKBWWHRA-UHFFFAOYSA-N
DMZVHSB	IU	2-morpholin-4-ium-4-ylethanesulfonate
DMZVHSB	CA	CAS 4432-31-9
DMZVHSB	CB	CHEBI:39408
DMZVHSB	DE	Discovery agent

DM85ZCW	ID	DM85ZCW
DM85ZCW	DN	2-(N-Pyrrolidinyl)-3'-bromopropiophenone
DM85ZCW	HS	Investigative
DM85ZCW	SN	CHEMBL599230; BDBM50308117
DM85ZCW	DT	Small molecular drug
DM85ZCW	PC	45141806
DM85ZCW	MW	296.2
DM85ZCW	FM	C14H18BrNO
DM85ZCW	IC	InChI=1S/C14H18BrNO/c1-11(16-8-3-2-4-9-16)14(17)12-6-5-7-13(15)10-12/h5-7,10-11H,2-4,8-9H2,1H3
DM85ZCW	CS	CC(C(=O)C1=CC(=CC=C1)Br)N2CCCCC2
DM85ZCW	IK	DNVMLFGJFSQQDE-UHFFFAOYSA-N
DM85ZCW	IU	1-(3-bromophenyl)-2-piperidin-1-ylpropan-1-one
DM85ZCW	DE	Discovery agent

DMYPOC5	ID	DMYPOC5
DMYPOC5	DN	2-(N-Pyrrolidinyl)-3'-fluoropropiophenone
DMYPOC5	HS	Investigative
DMYPOC5	SN	CHEMBL599028; BDBM50308116
DMYPOC5	DT	Small molecular drug
DMYPOC5	PC	45141805
DMYPOC5	MW	235.3
DMYPOC5	FM	C14H18FNO
DMYPOC5	IC	InChI=1S/C14H18FNO/c1-11(16-8-3-2-4-9-16)14(17)12-6-5-7-13(15)10-12/h5-7,10-11H,2-4,8-9H2,1H3
DMYPOC5	CS	CC(C(=O)C1=CC(=CC=C1)F)N2CCCCC2
DMYPOC5	IK	UDGISDAHRCDXMV-UHFFFAOYSA-N
DMYPOC5	IU	1-(3-fluorophenyl)-2-piperidin-1-ylpropan-1-one
DMYPOC5	DE	Discovery agent

DM1W3L9	ID	DM1W3L9
DM1W3L9	DN	2-(N-Pyrrolidinyl)-3'-methoxypropiophenone
DM1W3L9	HS	Investigative
DM1W3L9	SN	CHEMBL580143; BDBM50308119
DM1W3L9	DT	Small molecular drug
DM1W3L9	PC	45141808
DM1W3L9	MW	247.33
DM1W3L9	FM	C15H21NO2
DM1W3L9	IC	InChI=1S/C15H21NO2/c1-12(16-9-4-3-5-10-16)15(17)13-7-6-8-14(11-13)18-2/h6-8,11-12H,3-5,9-10H2,1-2H3
DM1W3L9	CS	CC(C(=O)C1=CC(=CC=C1)OC)N2CCCCC2
DM1W3L9	IK	VIWKHXNVEIOPSC-UHFFFAOYSA-N
DM1W3L9	IU	1-(3-methoxyphenyl)-2-piperidin-1-ylpropan-1-one
DM1W3L9	DE	Discovery agent

DMGKXOI	ID	DMGKXOI
DMGKXOI	DN	2-(N-Pyrrolidinyl)-3'-methylpropiophenone
DMGKXOI	HS	Investigative
DMGKXOI	SN	CHEMBL589494; BDBM50308118
DMGKXOI	DT	Small molecular drug
DMGKXOI	PC	45141807
DMGKXOI	MW	231.33
DMGKXOI	FM	C15H21NO
DMGKXOI	IC	InChI=1S/C15H21NO/c1-12-7-6-8-14(11-12)15(17)13(2)16-9-4-3-5-10-16/h6-8,11,13H,3-5,9-10H2,1-2H3
DMGKXOI	CS	CC1=CC(=CC=C1)C(=O)C(C)N2CCCCC2
DMGKXOI	IK	VMEDIUSDIYRUSA-UHFFFAOYSA-N
DMGKXOI	IU	1-(3-methylphenyl)-2-piperidin-1-ylpropan-1-one
DMGKXOI	DE	Discovery agent

DM1I9LQ	ID	DM1I9LQ
DM1I9LQ	DN	2-(N-Pyrrolidinyl)-3'-nitropropiophenone
DM1I9LQ	HS	Investigative
DM1I9LQ	SN	CHEMBL599233; SCHEMBL6055564; BDBM50308120
DM1I9LQ	DT	Small molecular drug
DM1I9LQ	PC	45141809
DM1I9LQ	MW	262.3
DM1I9LQ	FM	C14H18N2O3
DM1I9LQ	IC	InChI=1S/C14H18N2O3/c1-11(15-8-3-2-4-9-15)14(17)12-6-5-7-13(10-12)16(18)19/h5-7,10-11H,2-4,8-9H2,1H3
DM1I9LQ	CS	CC(C(=O)C1=CC(=CC=C1)[N+](=O)[O-])N2CCCCC2
DM1I9LQ	IK	LTLFRBMKBHQUTH-UHFFFAOYSA-N
DM1I9LQ	IU	1-(3-nitrophenyl)-2-piperidin-1-ylpropan-1-one
DM1I9LQ	DE	Discovery agent

DMKIEVP	ID	DMKIEVP
DMKIEVP	DN	2-(N-tert-Butylamino)-3',4'-dichloropropiophenone
DMKIEVP	HS	Investigative
DMKIEVP	SN	CHEMBL568140; SCHEMBL770039; BDBM50302918; AKOS022330446; 2-(N-tert-Butylamino)-3'',4''-dichloropropiophenone
DMKIEVP	DT	Small molecular drug
DMKIEVP	PC	45487890
DMKIEVP	MW	274.18
DMKIEVP	FM	C13H17Cl2NO
DMKIEVP	IC	InChI=1S/C13H17Cl2NO/c1-8(16-13(2,3)4)12(17)9-5-6-10(14)11(15)7-9/h5-8,16H,1-4H3
DMKIEVP	CS	CC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C
DMKIEVP	IK	MXUDEADPGZWZCH-UHFFFAOYSA-N
DMKIEVP	IU	2-(tert-butylamino)-1-(3,4-dichlorophenyl)propan-1-one
DMKIEVP	CA	CAS 1193779-34-8
DMKIEVP	DE	Discovery agent

DMY2PBO	ID	DMY2PBO
DMY2PBO	DN	2-(N-tert-Butylamino)-3'-chloroheptanophenone
DMY2PBO	HS	Investigative
DMY2PBO	SN	CHEMBL565382; SCHEMBL769133; BDBM50302921
DMY2PBO	DT	Small molecular drug
DMY2PBO	PC	44542656
DMY2PBO	MW	295.8
DMY2PBO	FM	C17H26ClNO
DMY2PBO	IC	InChI=1S/C17H26ClNO/c1-5-6-7-11-15(19-17(2,3)4)16(20)13-9-8-10-14(18)12-13/h8-10,12,15,19H,5-7,11H2,1-4H3
DMY2PBO	CS	CCCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMY2PBO	IK	OROOSQVGDDDAFY-UHFFFAOYSA-N
DMY2PBO	IU	2-(tert-butylamino)-1-(3-chlorophenyl)heptan-1-one
DMY2PBO	DE	Discovery agent

DMPO3CJ	ID	DMPO3CJ
DMPO3CJ	DN	2-(N-tert-Butylamino)-3'-chlorohexanophenone
DMPO3CJ	HS	Investigative
DMPO3CJ	SN	CHEMBL576622; SCHEMBL634045; BDBM50302931
DMPO3CJ	DT	Small molecular drug
DMPO3CJ	PC	44543267
DMPO3CJ	MW	281.82
DMPO3CJ	FM	C16H24ClNO
DMPO3CJ	IC	InChI=1S/C16H24ClNO/c1-5-6-10-14(18-16(2,3)4)15(19)12-8-7-9-13(17)11-12/h7-9,11,14,18H,5-6,10H2,1-4H3
DMPO3CJ	CS	CCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMPO3CJ	IK	WSLDIWPVDFGUNH-UHFFFAOYSA-N
DMPO3CJ	IU	2-(tert-butylamino)-1-(3-chlorophenyl)hexan-1-one
DMPO3CJ	DE	Discovery agent

DMW47VA	ID	DMW47VA
DMW47VA	DN	2-(N-tert-Butylamino)-3'-chlorooctanophenone
DMW47VA	HS	Investigative
DMW47VA	SN	CHEMBL565593; 2-(N-tert-Butylamino)-3'-chlorooctanophenone; SCHEMBL633368; HHZNTCLXZVSLGW-UHFFFAOYSA-N; BDBM50302909
DMW47VA	DT	Small molecular drug
DMW47VA	PC	44543268
DMW47VA	MW	309.9
DMW47VA	FM	C18H28ClNO
DMW47VA	IC	InChI=1S/C18H28ClNO/c1-5-6-7-8-12-16(20-18(2,3)4)17(21)14-10-9-11-15(19)13-14/h9-11,13,16,20H,5-8,12H2,1-4H3
DMW47VA	CS	CCCCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMW47VA	IK	HHZNTCLXZVSLGW-UHFFFAOYSA-N
DMW47VA	IU	2-(tert-butylamino)-1-(3-chlorophenyl)octan-1-one
DMW47VA	DE	Discovery agent

DMTZ540	ID	DMTZ540
DMTZ540	DN	2-(N-tert-Butylamino)-3'-chloropentanophenone
DMTZ540	HS	Investigative
DMTZ540	SN	CHEMBL569465; 2-(tert-butylamino)-1-(3-chlorophenyl)pentan-1-one; AC1MHOFP; SCHEMBL769847; BDBM50302927
DMTZ540	DT	Small molecular drug
DMTZ540	PC	3029724
DMTZ540	MW	267.79
DMTZ540	FM	C15H22ClNO
DMTZ540	IC	InChI=1S/C15H22ClNO/c1-5-7-13(17-15(2,3)4)14(18)11-8-6-9-12(16)10-11/h6,8-10,13,17H,5,7H2,1-4H3
DMTZ540	CS	CCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMTZ540	IK	PREYWAJYVTVVPE-UHFFFAOYSA-N
DMTZ540	IU	2-(tert-butylamino)-1-(3-chlorophenyl)pentan-1-one
DMTZ540	DE	Discovery agent

DME1SP4	ID	DME1SP4
DME1SP4	DN	2-(N-tert-Butylamino)-4'-chloropropiophenone
DME1SP4	HS	Investigative
DME1SP4	SN	CHEMBL566000; 2-(tert-butylamino)-1-(4-chlorophenyl)propan-1-one; AC1MHR9U; SCHEMBL770391; BDBM50302911; AKOS022330116; 4'-Chloro-alpha-(tert-butylamino)propiophenone
DME1SP4	DT	Small molecular drug
DME1SP4	PC	3031066
DME1SP4	MW	239.74
DME1SP4	FM	C13H18ClNO
DME1SP4	IC	InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-5-7-11(14)8-6-10/h5-9,15H,1-4H3
DME1SP4	CS	CC(C(=O)C1=CC=C(C=C1)Cl)NC(C)(C)C
DME1SP4	IK	IELBAACIVCODPI-UHFFFAOYSA-N
DME1SP4	IU	2-(tert-butylamino)-1-(4-chlorophenyl)propan-1-one
DME1SP4	DE	Discovery agent

DM9E5LT	ID	DM9E5LT
DM9E5LT	DN	2-(N-tert-Butylamino)propiophenone
DM9E5LT	HS	Investigative
DM9E5LT	SN	2-(N-tert-Butylamino)propiophenone; CHEMBL569699; AC1MIL82; SCHEMBL769768; JQNSRSIGKZYQAA-UHFFFAOYSA-N; alpha-(tert-Butylamino)propiophenone; BDBM50302912; AKOS022329747
DM9E5LT	DT	Small molecular drug
DM9E5LT	PC	3047299
DM9E5LT	MW	205.3
DM9E5LT	FM	C13H19NO
DM9E5LT	IC	InChI=1S/C13H19NO/c1-10(14-13(2,3)4)12(15)11-8-6-5-7-9-11/h5-10,14H,1-4H3
DM9E5LT	CS	CC(C(=O)C1=CC=CC=C1)NC(C)(C)C
DM9E5LT	IK	JQNSRSIGKZYQAA-UHFFFAOYSA-N
DM9E5LT	IU	2-(tert-butylamino)-1-phenylpropan-1-one
DM9E5LT	CA	CAS 34509-36-9
DM9E5LT	DE	Discovery agent

DM3RCA9	ID	DM3RCA9
DM3RCA9	DN	2-(o-toluidino)-5-ethylthiazol-4(5H)-one
DM3RCA9	HS	Investigative
DM3RCA9	DT	Small molecular drug
DM3RCA9	PC	135450677
DM3RCA9	MW	234.32
DM3RCA9	FM	C12H14N2OS
DM3RCA9	IC	InChI=1S/C12H14N2OS/c1-3-10-11(15)14-12(16-10)13-9-7-5-4-6-8(9)2/h4-7,10H,3H2,1-2H3,(H,13,14,15)
DM3RCA9	CS	CCC1C(=O)NC(=NC2=CC=CC=C2C)S1
DM3RCA9	IK	CWOSTWNWVJUZID-UHFFFAOYSA-N
DM3RCA9	IU	5-ethyl-2-(2-methylphenyl)imino-1,3-thiazolidin-4-one
DM3RCA9	DE	Discovery agent

DMYTJX4	ID	DMYTJX4
DMYTJX4	DN	2-(o-toluidino)-5-isopropylthiazol-4(5H)-one
DMYTJX4	HS	Investigative
DMYTJX4	DT	Small molecular drug
DMYTJX4	PC	91253621
DMYTJX4	MW	248.35
DMYTJX4	FM	C13H16N2OS
DMYTJX4	IC	InChI=1S/C13H16N2OS/c1-8(2)11-12(16)15-13(17-11)14-10-7-5-4-6-9(10)3/h4-8,16H,1-3H3,(H,14,15)
DMYTJX4	CS	CC1=CC=CC=C1NC2=NC(=C(S2)C(C)C)O
DMYTJX4	IK	CSOPFNOFIZHDML-UHFFFAOYSA-N
DMYTJX4	IU	2-(2-methylanilino)-5-propan-2-yl-1,3-thiazol-4-ol
DMYTJX4	DE	Discovery agent

DM7LOHK	ID	DM7LOHK
DM7LOHK	DN	2-(Oxalyl-Amino)-Benzoic Acid
DM7LOHK	HS	Investigative
DM7LOHK	SN	2-(oxaloamino)benzoic acid; 2-(OXALYL-AMINO)-BENZOIC ACID; CHEMBL139050; CHEBI:44493; 2-[(carboxycarbonyl)amino]benzoic acid; OBA; 2-oxaloaminobenzoic acid; AC1L9GUO; SCHEMBL4315667; 2-(Carboxyformamido)Benzoic Acid; 1c85; ZINC2007905; BDBM50118789; AKOS022649621; DB02622; SC-57508; 5651-01-4; BENZOIC ACID,2[(CARBOXYCARBONYL)AMINO]-
DM7LOHK	DT	Small molecular drug
DM7LOHK	PC	444764
DM7LOHK	MW	209.16
DM7LOHK	FM	C9H7NO5
DM7LOHK	IC	InChI=1S/C9H7NO5/c11-7(9(14)15)10-6-4-2-1-3-5(6)8(12)13/h1-4H,(H,10,11)(H,12,13)(H,14,15)
DM7LOHK	CS	C1=CC=C(C(=C1)C(=O)O)NC(=O)C(=O)O
DM7LOHK	IK	QBYNNSFEMMNINN-UHFFFAOYSA-N
DM7LOHK	IU	2-(oxaloamino)benzoic acid
DM7LOHK	CB	CHEBI:44493
DM7LOHK	DE	Discovery agent

DMPUARE	ID	DMPUARE
DMPUARE	DN	2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine
DMPUARE	HS	Investigative
DMPUARE	SN	CHEMBL425576; 2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine; SCHEMBL1122285
DMPUARE	DT	Small molecular drug
DMPUARE	PC	11515006
DMPUARE	MW	304.3
DMPUARE	FM	C18H16N4O
DMPUARE	IC	InChI=1S/C18H16N4O/c1-13(23)20-16-9-5-6-14(10-16)17-11-19-12-18(22-17)21-15-7-3-2-4-8-15/h2-12H,1H3,(H,20,23)(H,21,22)
DMPUARE	CS	CC(=O)NC1=CC=CC(=C1)C2=CN=CC(=N2)NC3=CC=CC=C3
DMPUARE	IK	MKRMZWIJCMWBDU-UHFFFAOYSA-N
DMPUARE	IU	N-[3-(6-anilinopyrazin-2-yl)phenyl]acetamide
DMPUARE	DE	Discovery agent

DMRIFCW	ID	DMRIFCW
DMRIFCW	DN	2-(phenylethynyl)pyrimidine
DMRIFCW	HS	Investigative
DMRIFCW	SN	2-(phenylethynyl)pyrimidine; CHEMBL450465; phenylethynylpyrimidine; SCHEMBL13841597; ZINC39236614; BDBM50278929
DMRIFCW	DT	Small molecular drug
DMRIFCW	PC	12490583
DMRIFCW	MW	180.2
DMRIFCW	FM	C12H8N2
DMRIFCW	IC	InChI=1S/C12H8N2/c1-2-5-11(6-3-1)7-8-12-13-9-4-10-14-12/h1-6,9-10H
DMRIFCW	CS	C1=CC=C(C=C1)C#CC2=NC=CC=N2
DMRIFCW	IK	JGGFEZRQOSIEGG-UHFFFAOYSA-N
DMRIFCW	IU	2-(2-phenylethynyl)pyrimidine
DMRIFCW	DE	Discovery agent

DMFBTM2	ID	DMFBTM2
DMFBTM2	DN	2-(phenylsulfonamido)-1-naphthoic acid
DMFBTM2	HS	Investigative
DMFBTM2	SN	1-Naphthalenecarboxylic acid, 2-[(phenylsulfonyl)amino]-; 677290-81-2; sulfonamide compound, 9; SCHEMBL3986500; CHEMBL377198; CTK1H6801; BDBM17603; DTXSID20471157; CXPIFTCBANXJNX-UHFFFAOYSA-N; AKOS030618475; 2-[(phenylsulfonyl)amino]-1-naphthoic acid; 2-benzenesulfonamidonaphthalene-1-carboxylic acid
DMFBTM2	DT	Small molecular drug
DMFBTM2	PC	11723962
DMFBTM2	MW	327.4
DMFBTM2	FM	C17H13NO4S
DMFBTM2	IC	InChI=1S/C17H13NO4S/c19-17(20)16-14-9-5-4-6-12(14)10-11-15(16)18-23(21,22)13-7-2-1-3-8-13/h1-11,18H,(H,19,20)
DMFBTM2	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=C(C3=CC=CC=C3C=C2)C(=O)O
DMFBTM2	IK	CXPIFTCBANXJNX-UHFFFAOYSA-N
DMFBTM2	IU	2-(benzenesulfonamido)naphthalene-1-carboxylic acid
DMFBTM2	CA	CAS 677290-81-2
DMFBTM2	DE	Discovery agent

DMDGAHO	ID	DMDGAHO
DMDGAHO	DN	2-(phenylsulfonamido)-5-propylbenzoic acid
DMDGAHO	HS	Investigative
DMDGAHO	SN	2-benzenesulfonamido-5-propylbenzoic acid; sulfonamide compound, 7; SCHEMBL3984242; CHEMBL209071; BDBM17601; MolPort-009-343-156; ZINC14965014; AKOS034553679; MCULE-3140792066; Z738155172
DMDGAHO	DT	Small molecular drug
DMDGAHO	PC	10018850
DMDGAHO	MW	319.4
DMDGAHO	FM	C16H17NO4S
DMDGAHO	IC	InChI=1S/C16H17NO4S/c1-2-6-12-9-10-15(14(11-12)16(18)19)17-22(20,21)13-7-4-3-5-8-13/h3-5,7-11,17H,2,6H2,1H3,(H,18,19)
DMDGAHO	CS	CCCC1=CC(=C(C=C1)NS(=O)(=O)C2=CC=CC=C2)C(=O)O
DMDGAHO	IK	LZDCSXYOKAIIJO-UHFFFAOYSA-N
DMDGAHO	IU	2-(benzenesulfonamido)-5-propylbenzoic acid
DMDGAHO	DE	Discovery agent

DMMSI67	ID	DMMSI67
DMMSI67	DN	2-(Phenylsulfonamido)acetic Acid
DMMSI67	HS	Investigative
DMMSI67	SN	2-(Phenylsulfonamido)acetic Acid; 5398-96-9; Benzenesulfonylamino-acetic acid; n-(phenylsulfonyl)glycine; 2-benzenesulfonamidoacetic acid; CHEMBL37054; 2-(benzenesulfonamido)acetic acid; 2-[(phenylsulfonyl)amino]acetic acid; n-benzenesulfonylglycine; N-benzenesulfonyl-glycine; ChemDiv3_006100; CBChromo1_000178; AC1Q6W5M; Oprea1_227014; Oprea1_645532; CBDivE_002981; SCHEMBL359770; AC1Q763K; NSC3682; MolPort-000-182-647; WTSZSAHZIMPSDM-UHFFFAOYSA-N; ZINC187388; HMS1490F06; NSC-3682; AC1L5954; NSC121986; STL477593; SBB015317
DMMSI67	DT	Small molecular drug
DMMSI67	PC	220662
DMMSI67	MW	215.23
DMMSI67	FM	C8H9NO4S
DMMSI67	IC	InChI=1S/C8H9NO4S/c10-8(11)6-9-14(12,13)7-4-2-1-3-5-7/h1-5,9H,6H2,(H,10,11)
DMMSI67	CS	C1=CC=C(C=C1)S(=O)(=O)NCC(=O)O
DMMSI67	IK	WTSZSAHZIMPSDM-UHFFFAOYSA-N
DMMSI67	IU	2-(benzenesulfonamido)acetic acid
DMMSI67	CA	CAS 5398-96-9
DMMSI67	DE	Discovery agent

DMCF75U	ID	DMCF75U
DMCF75U	DN	2-(phenylsulfonyl)-1-(thiophen-3-yl)ethanone
DMCF75U	HS	Investigative
DMCF75U	SN	CHEMBL238851; 2-(phenylsulfonyl)-1-(thiophen-3-yl)ethanone; BDBM50212533
DMCF75U	DT	Small molecular drug
DMCF75U	PC	44437618
DMCF75U	MW	266.3
DMCF75U	FM	C12H10O3S2
DMCF75U	IC	InChI=1S/C12H10O3S2/c13-12(10-6-7-16-8-10)9-17(14,15)11-4-2-1-3-5-11/h1-8H,9H2
DMCF75U	CS	C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CSC=C2
DMCF75U	IK	CBJGWEVSYFKKBK-UHFFFAOYSA-N
DMCF75U	IU	2-(benzenesulfonyl)-1-thiophen-3-ylethanone
DMCF75U	DE	Discovery agent

DM93XJT	ID	DM93XJT
DM93XJT	DN	2-(phenylsulfonyl)-1-p-tolylethanone
DM93XJT	HS	Investigative
DM93XJT	SN	38488-14-1; CHEMBL392808; Ethanone, 1-(4-methylphenyl)-2-(phenylsulfonyl)-; 2-(phenylsulfonyl)-1-p-tolylethanone; 4-Methylphenacylphenyl sulfone; SCHEMBL6202982; CTK1A8876; DTXSID20575987; BDBM50212530; ZINC28874639; AKOS008967833; 1-p-Tolyl-2-(phenylsulphonyl)ethanone; 1-(4-methylphenyl)-2-(phenylsulfonyl)ethanone; 2-(Benzenesulfonyl)-1-(4-methylphenyl)ethan-1-one
DM93XJT	DT	Small molecular drug
DM93XJT	PC	15627039
DM93XJT	MW	274.3
DM93XJT	FM	C15H14O3S
DM93XJT	IC	InChI=1S/C15H14O3S/c1-12-7-9-13(10-8-12)15(16)11-19(17,18)14-5-3-2-4-6-14/h2-10H,11H2,1H3
DM93XJT	CS	CC1=CC=C(C=C1)C(=O)CS(=O)(=O)C2=CC=CC=C2
DM93XJT	IK	DITVWQPTRBYVRP-UHFFFAOYSA-N
DM93XJT	IU	2-(benzenesulfonyl)-1-(4-methylphenyl)ethanone
DM93XJT	CA	CAS 38488-14-1
DM93XJT	DE	Discovery agent

DMAKR2E	ID	DMAKR2E
DMAKR2E	DN	2-(phenylsulfonyl)naphthalene-1,4-diol
DMAKR2E	HS	Investigative
DMAKR2E	SN	2-(phenylsulfonyl)naphthalene-1,4-diol; CHEMBL462205; SCHEMBL9717678; YEDZIHZPRGSAMI-UHFFFAOYSA-N; BDBM50245877
DMAKR2E	DT	Small molecular drug
DMAKR2E	PC	15657226
DMAKR2E	MW	300.3
DMAKR2E	FM	C16H12O4S
DMAKR2E	IC	InChI=1S/C16H12O4S/c17-14-10-15(16(18)13-9-5-4-8-12(13)14)21(19,20)11-6-2-1-3-7-11/h1-10,17-18H
DMAKR2E	CS	C1=CC=C(C=C1)S(=O)(=O)C2=C(C3=CC=CC=C3C(=C2)O)O
DMAKR2E	IK	YEDZIHZPRGSAMI-UHFFFAOYSA-N
DMAKR2E	IU	2-(benzenesulfonyl)naphthalene-1,4-diol
DMAKR2E	DE	Discovery agent

DM4V2ZO	ID	DM4V2ZO
DM4V2ZO	DN	2-(Phosphonooxy)Butanoic Acid
DM4V2ZO	HS	Investigative
DM4V2ZO	SN	2-(PHOSPHONOOXY)BUTANOIC ACID; AC1NRCQI; 2-phosphonooxybutanoic acid; SCHEMBL4318695; (2R)-2-(phosphonooxy)butanoic acid
DM4V2ZO	DT	Small molecular drug
DM4V2ZO	PC	17754119
DM4V2ZO	MW	184.08
DM4V2ZO	FM	C4H9O6P
DM4V2ZO	IC	InChI=1S/C4H9O6P/c1-2-3(4(5)6)10-11(7,8)9/h3H,2H2,1H3,(H,5,6)(H2,7,8,9)/t3-/m1/s1
DM4V2ZO	CS	CC[C@H](C(=O)O)OP(=O)(O)O
DM4V2ZO	IK	OETAGSCBSKODFW-GSVOUGTGSA-N
DM4V2ZO	IU	(2R)-2-phosphonooxybutanoic acid
DM4V2ZO	DE	Discovery agent

DML6HSE	ID	DML6HSE
DML6HSE	DN	2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline
DML6HSE	HS	Investigative
DML6HSE	SN	2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline; CHEMBL593547; 1207671-23-5; ZINC45354604; BDBM50304820; AKOS023594147
DML6HSE	DT	Small molecular drug
DML6HSE	PC	46228433
DML6HSE	MW	217.31
DML6HSE	FM	C13H19N3
DML6HSE	IC	InChI=1S/C13H19N3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h5-6,14H,1-4,7-10H2
DML6HSE	CS	C1CCC2=C(C1)C=CC(=N2)N3CCNCC3
DML6HSE	IK	OHJFBSROVXQKFQ-UHFFFAOYSA-N
DML6HSE	IU	2-piperazin-1-yl-5,6,7,8-tetrahydroquinoline
DML6HSE	DE	Discovery agent

DMGQX1I	ID	DMGQX1I
DMGQX1I	DN	2-(piperidin-1-yl)-4H-benzo[h]chromen-4-one
DMGQX1I	HS	Investigative
DMGQX1I	SN	K 12212; BRN 0415699; 4H-Naphtho(1,2-b)pyran-4-one, 2-(1-piperidinyl)-; CHEMBL367468; 2-(1-Piperidinyl)-4H-naphtho(1,2-b)pyran-4-one; 2-(N-Piperidil)-4-oxo-4H-nafto(1,2-b)pirano [Italian]; 61035-05-0; AC1MIJ0F; 2-(piperidin-1-yl)-4H-benzo[h]chromen-4-one; 2-(N-Piperidil)-4-oxo-4H-nafto(1,2-b)pirano; SCHEMBL3538224; DTXSID60209911; BDBM50159645; 2-piperidin-1-ylbenzo[h]chromen-4-one; LS-95581
DMGQX1I	DT	Small molecular drug
DMGQX1I	PC	3045697
DMGQX1I	MW	279.3
DMGQX1I	FM	C18H17NO2
DMGQX1I	IC	InChI=1S/C18H17NO2/c20-16-12-17(19-10-4-1-5-11-19)21-18-14-7-3-2-6-13(14)8-9-15(16)18/h2-3,6-9,12H,1,4-5,10-11H2
DMGQX1I	CS	C1CCN(CC1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMGQX1I	IK	MAIHLQWUOLIOEP-UHFFFAOYSA-N
DMGQX1I	IU	2-piperidin-1-ylbenzo[h]chromen-4-one
DMGQX1I	CA	CAS 61035-05-0
DMGQX1I	DE	Discovery agent

DMLT635	ID	DMLT635
DMLT635	DN	2-(p-Methylsulfonylbenzoyl)furan
DMLT635	HS	Investigative
DMLT635	SN	2-(p-Methylsulfonylbenzoyl)furan; CHEMBL1240887; SCHEMBL7814046; BDBM50326535
DMLT635	DT	Small molecular drug
DMLT635	PC	12701751
DMLT635	MW	250.27
DMLT635	FM	C12H10O4S
DMLT635	IC	InChI=1S/C12H10O4S/c1-17(14,15)10-6-4-9(5-7-10)12(13)11-3-2-8-16-11/h2-8H,1H3
DMLT635	CS	CS(=O)(=O)C1=CC=C(C=C1)C(=O)C2=CC=CO2
DMLT635	IK	CWRZECMEZICAFW-UHFFFAOYSA-N
DMLT635	IU	furan-2-yl-(4-methylsulfonylphenyl)methanone
DMLT635	DE	Discovery agent

DM27YTF	ID	DM27YTF
DM27YTF	DN	2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile
DM27YTF	HS	Investigative
DM27YTF	SN	CHEMBL233874; 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile
DM27YTF	DT	Small molecular drug
DM27YTF	PC	44430881
DM27YTF	MW	286.3
DM27YTF	FM	C18H14N4
DM27YTF	IC	InChI=1S/C18H14N4/c1-13-7-9-16(10-8-13)21-18-20-12-15(11-19)17(22-18)14-5-3-2-4-6-14/h2-10,12H,1H3,(H,20,21,22)
DM27YTF	CS	CC1=CC=C(C=C1)NC2=NC=C(C(=N2)C3=CC=CC=C3)C#N
DM27YTF	IK	OBWJJSHWDHTFAP-UHFFFAOYSA-N
DM27YTF	IU	2-(4-methylanilino)-4-phenylpyrimidine-5-carbonitrile
DM27YTF	DE	Discovery agent

DMON1A5	ID	DMON1A5
DMON1A5	DN	2-(p-tolylthio)naphthalene-1,4-dione
DMON1A5	HS	Investigative
DMON1A5	SN	CHEMBL501551; 89478-03-5; 1,4-Naphthalenedione, 2-[(4-methylphenyl)thio]-; 2-(p-tolylthio)naphthalene-1,4-dione; ACMC-20lmns; CTK2J5214; DTXSID70567231; BDBM50245831; AKOS030617287; 2-(4-Methylphenylthio)-1,4-naphthoquinone
DMON1A5	DT	Small molecular drug
DMON1A5	PC	15032092
DMON1A5	MW	280.3
DMON1A5	FM	C17H12O2S
DMON1A5	IC	InChI=1S/C17H12O2S/c1-11-6-8-12(9-7-11)20-16-10-15(18)13-4-2-3-5-14(13)17(16)19/h2-10H,1H3
DMON1A5	CS	CC1=CC=C(C=C1)SC2=CC(=O)C3=CC=CC=C3C2=O
DMON1A5	IK	IHRGUZGBIGODSC-UHFFFAOYSA-N
DMON1A5	IU	2-(4-methylphenyl)sulfanylnaphthalene-1,4-dione
DMON1A5	CA	CAS 89478-03-5
DMON1A5	DE	Discovery agent

DMST2LX	ID	DMST2LX
DMST2LX	DN	2-(pyridin-2-yl)-1H-benzo[d]imidazol-5-amine
DMST2LX	HS	Investigative
DMST2LX	SN	55396-63-9; CHEMBL199925; 2-(pyridin-2-yl)-1H-1,3-benzodiazol-5-amine; MLS000528495; 2-Pyridin-2-yl-1H-benzoimidazol-5-ylamine; 2-(pyridin-2-yl)-1H-benzo[d]imidazol-5-amine; ITFXYBZUPPBWEC-UHFFFAOYSA-N; SMR000121070; 2-pyridin-2-yl-3H-benzimidazol-5-amine; 1H-Benzimidazol-5-amine, 2-(2-pyridinyl)-; 2-(Pyridin-2-yl)-1H-1,3-benzodiazol-6-amine; AC1LBVAV; 1H-Benzimidazol-6-amine, 2-(2-pyridinyl)-; AC1Q52EP; SCHEMBL8556415; SCHEMBL4371835; cid_542828; BDBM62926; CTK1F6864; DTXSID50337459; MolPort-006-709-925; MolPort-001-815-306
DMST2LX	DT	Small molecular drug
DMST2LX	PC	542828
DMST2LX	MW	210.23
DMST2LX	FM	C12H10N4
DMST2LX	IC	InChI=1S/C12H10N4/c13-8-4-5-9-11(7-8)16-12(15-9)10-3-1-2-6-14-10/h1-7H,13H2,(H,15,16)
DMST2LX	CS	C1=CC=NC(=C1)C2=NC3=C(N2)C=C(C=C3)N
DMST2LX	IK	ITFXYBZUPPBWEC-UHFFFAOYSA-N
DMST2LX	IU	2-pyridin-2-yl-3H-benzimidazol-5-amine
DMST2LX	CA	CAS 55396-63-9
DMST2LX	DE	Discovery agent

DMRUTDY	ID	DMRUTDY
DMRUTDY	DN	2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMRUTDY	HS	Investigative
DMRUTDY	SN	2-(2-Pyridyl)benzimidazole; 1137-68-4; 2-(pyridin-2-yl)-1H-benzo[d]imidazole; 2-pyridin-2-yl-1H-benzimidazole; 2-Pyridin-2-yl-1H-benzoimidazole; 2-(pyridin-2-yl)-1H-benzimidazole; NSC 32814; NSC 110942; CHEMBL72683; YNFBMDWHEHETJW-UHFFFAOYSA-N; 1H-Benzimidazole, 2-(pyridinyl)-; 1H-Benzimidazole, 2-(2-pyridinyl)-; 2-(pyridin-2-yl)-1H-1,3-benzodiazole; 2-(2-Pyridyl)benzimidazole, 99%; EINECS 214-508-7; ACMC-20aime; AC1L2EXP; 2(2-Pyridyl)benzimidazole; 2-(2'-Pyrido)benzimidazole; MLS000554415; 2-(2-pyridyl) benzimidazole
DMRUTDY	DT	Small molecular drug
DMRUTDY	PC	70821
DMRUTDY	MW	195.22
DMRUTDY	FM	C12H9N3
DMRUTDY	IC	InChI=1S/C12H9N3/c1-2-6-10-9(5-1)14-12(15-10)11-7-3-4-8-13-11/h1-8H,(H,14,15)
DMRUTDY	CS	C1=CC=C2C(=C1)NC(=N2)C3=CC=CC=N3
DMRUTDY	IK	YNFBMDWHEHETJW-UHFFFAOYSA-N
DMRUTDY	IU	2-pyridin-2-yl-1H-benzimidazole
DMRUTDY	CA	CAS 1137-68-4
DMRUTDY	DE	Discovery agent

DMHFGMQ	ID	DMHFGMQ
DMHFGMQ	DN	2-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine
DMHFGMQ	HS	Investigative
DMHFGMQ	SN	CHEMBL202826; 14060-62-9; 2-(2-Pyridinyl)-1H-imidazo[4,5-c]pyridine; AC1LJB5G; 2-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine; 3H-Imidazo[4,5-c]pyridine, 2-(2-pyridinyl)-; Oprea1_672867; SCHEMBL11397558; 2-pyridylimidazo[4,5-c]pyridine; MolPort-002-623-631; ZINC5819379; BDBM50180747; STL346357; AKOS022141602; AKOS012572462; MCULE-6118149650; NCGC00375714-01; NCGC00375714-02; 2-pyridin-2-yl-3H-imidazo[4,5-c]pyridine
DMHFGMQ	DT	Small molecular drug
DMHFGMQ	PC	947740
DMHFGMQ	MW	196.21
DMHFGMQ	FM	C11H8N4
DMHFGMQ	IC	InChI=1S/C11H8N4/c1-2-5-13-9(3-1)11-14-8-4-6-12-7-10(8)15-11/h1-7H,(H,14,15)
DMHFGMQ	CS	C1=CC=NC(=C1)C2=NC3=C(N2)C=NC=C3
DMHFGMQ	IK	RCQLXXHLXWNHOU-UHFFFAOYSA-N
DMHFGMQ	IU	2-pyridin-2-yl-3H-imidazo[4,5-c]pyridine
DMHFGMQ	DE	Discovery agent

DM3EBYD	ID	DM3EBYD
DM3EBYD	DN	2-(pyridin-2-yl)-4-(m-tolylthio)pyrimidine
DM3EBYD	HS	Investigative
DM3EBYD	SN	2-(pyridin-2-yl)-4-(m-tolylthio)pyrimidine; CHEMBL208730; SCHEMBL6512812; BDBM50182815
DM3EBYD	DT	Small molecular drug
DM3EBYD	PC	11460152
DM3EBYD	MW	279.4
DM3EBYD	FM	C16H13N3S
DM3EBYD	IC	InChI=1S/C16H13N3S/c1-12-5-4-6-13(11-12)20-15-8-10-18-16(19-15)14-7-2-3-9-17-14/h2-11H,1H3
DM3EBYD	CS	CC1=CC(=CC=C1)SC2=NC(=NC=C2)C3=CC=CC=N3
DM3EBYD	IK	LUFGLBRBPWCPQS-UHFFFAOYSA-N
DM3EBYD	IU	4-(3-methylphenyl)sulfanyl-2-pyridin-2-ylpyrimidine
DM3EBYD	DE	Discovery agent

DMET46L	ID	DMET46L
DMET46L	DN	2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile
DMET46L	HS	Investigative
DMET46L	SN	CHEMBL202748; 2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile; SCHEMBL5889065
DMET46L	DT	Small molecular drug
DMET46L	PC	21934605
DMET46L	MW	203.23
DMET46L	FM	C8H5N5S
DMET46L	IC	InChI=1S/C8H5N5S/c9-3-6-4-11-8(14-6)13-7-1-2-10-5-12-7/h1-2,4-5H,(H,10,11,12,13)
DMET46L	CS	C1=CN=CN=C1NC2=NC=C(S2)C#N
DMET46L	IK	SMNGUXOKYVUIRA-UHFFFAOYSA-N
DMET46L	IU	2-(pyrimidin-4-ylamino)-1,3-thiazole-5-carbonitrile
DMET46L	CA	CAS 436852-19-6
DMET46L	DE	Discovery agent

DM5CEG8	ID	DM5CEG8
DM5CEG8	DN	2-(Sulfanylmethyl)phenylphosphonic acid
DM5CEG8	HS	Investigative
DM5CEG8	SN	2-(Sulfanylmethyl)phenylphosphonic acid; CHEMBL1173338
DM5CEG8	DT	Small molecular drug
DM5CEG8	PC	46855907
DM5CEG8	MW	204.19
DM5CEG8	FM	C7H9O3PS
DM5CEG8	IC	InChI=1S/C7H9O3PS/c8-11(9,10)7-4-2-1-3-6(7)5-12/h1-4,12H,5H2,(H2,8,9,10)
DM5CEG8	CS	C1=CC=C(C(=C1)CS)P(=O)(O)O
DM5CEG8	IK	MVLYXNMBKWWFNE-UHFFFAOYSA-N
DM5CEG8	IU	[2-(sulfanylmethyl)phenyl]phosphonic acid
DM5CEG8	DE	Discovery agent

DMI457Y	ID	DMI457Y
DMI457Y	DN	2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one
DMI457Y	HS	Investigative
DMI457Y	SN	CHEMBL566886; 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one; AC1MHKA5; SCHEMBL770048; BDBM50302929
DMI457Y	DT	Small molecular drug
DMI457Y	PC	3027752
DMI457Y	MW	253.77
DMI457Y	FM	C14H20ClNO
DMI457Y	IC	InChI=1S/C14H20ClNO/c1-5-12(16-14(2,3)4)13(17)10-7-6-8-11(15)9-10/h6-9,12,16H,5H2,1-4H3
DMI457Y	CS	CCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMI457Y	IK	PGTPXIBBHIHMQS-UHFFFAOYSA-N
DMI457Y	IU	2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one
DMI457Y	DE	Discovery agent

DM6PV4W	ID	DM6PV4W
DM6PV4W	DN	2-(tert-butylamino)-1-m-tolylpropan-1-one
DM6PV4W	HS	Investigative
DM6PV4W	SN	CHEMBL566832; 2-(tert-butylamino)-1-m-tolylpropan-1-one; SCHEMBL769882; BDBM50302942
DM6PV4W	DT	Small molecular drug
DM6PV4W	PC	44543118
DM6PV4W	MW	219.32
DM6PV4W	FM	C14H21NO
DM6PV4W	IC	InChI=1S/C14H21NO/c1-10-7-6-8-12(9-10)13(16)11(2)15-14(3,4)5/h6-9,11,15H,1-5H3
DM6PV4W	CS	CC1=CC(=CC=C1)C(=O)C(C)NC(C)(C)C
DM6PV4W	IK	YDGOUEKZXBLUDG-UHFFFAOYSA-N
DM6PV4W	IU	2-(tert-butylamino)-1-(3-methylphenyl)propan-1-one
DM6PV4W	DE	Discovery agent

DMYFQDT	ID	DMYFQDT
DMYFQDT	DN	2-(tert-butylamino)-1-p-tolylpropan-1-one
DMYFQDT	HS	Investigative
DMYFQDT	SN	CHEMBL566207; 2-(tert-butylamino)-1-p-tolylpropan-1-one; SCHEMBL769850; BDBM50302941; AKOS022329818; 4'-Methyl-alpha-(tert-butylamino)propiophenone
DMYFQDT	DT	Small molecular drug
DMYFQDT	PC	45487941
DMYFQDT	MW	219.32
DMYFQDT	FM	C14H21NO
DMYFQDT	IC	InChI=1S/C14H21NO/c1-10-6-8-12(9-7-10)13(16)11(2)15-14(3,4)5/h6-9,11,15H,1-5H3
DMYFQDT	CS	CC1=CC=C(C=C1)C(=O)C(C)NC(C)(C)C
DMYFQDT	IK	BMWDQBTXNBGORC-UHFFFAOYSA-N
DMYFQDT	IU	2-(tert-butylamino)-1-(4-methylphenyl)propan-1-one
DMYFQDT	DE	Discovery agent

DMOJK8Y	ID	DMOJK8Y
DMOJK8Y	DN	2-(tert-Butylamino)-3',4'-dichlorobutyrophenone
DMOJK8Y	HS	Investigative
DMOJK8Y	SN	CHEMBL566208; SCHEMBL634229; BDBM50302914; 2-(tert-Butylamino)-3'',4''-dichlorobutyrophenone
DMOJK8Y	DT	Small molecular drug
DMOJK8Y	PC	44542809
DMOJK8Y	MW	288.2
DMOJK8Y	FM	C14H19Cl2NO
DMOJK8Y	IC	InChI=1S/C14H19Cl2NO/c1-5-12(17-14(2,3)4)13(18)9-6-7-10(15)11(16)8-9/h6-8,12,17H,5H2,1-4H3
DMOJK8Y	CS	CCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C
DMOJK8Y	IK	JYBXLCIZWPNCMU-UHFFFAOYSA-N
DMOJK8Y	IU	2-(tert-butylamino)-1-(3,4-dichlorophenyl)butan-1-one
DMOJK8Y	DE	Discovery agent

DMMUDQ7	ID	DMMUDQ7
DMMUDQ7	DN	2-(tert-Butylamino)-3',4'-dichloropentanophenone
DMMUDQ7	HS	Investigative
DMMUDQ7	SN	CHEMBL566050; SCHEMBL769423; BDBM50302924; J3.628.916C; 3',4'-Dichloro-alpha-(tert-butylamino)valerophenone; 2-(tert-Butylamino)-3'',4''-dichloropentanophenone
DMMUDQ7	DT	Small molecular drug
DMMUDQ7	PC	44543273
DMMUDQ7	MW	302.2
DMMUDQ7	FM	C15H21Cl2NO
DMMUDQ7	IC	InChI=1S/C15H21Cl2NO/c1-5-6-13(18-15(2,3)4)14(19)10-7-8-11(16)12(17)9-10/h7-9,13,18H,5-6H2,1-4H3
DMMUDQ7	CS	CCCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C
DMMUDQ7	IK	VBQDZZHUUPHQGQ-UHFFFAOYSA-N
DMMUDQ7	IU	2-(tert-butylamino)-1-(3,4-dichlorophenyl)pentan-1-one
DMMUDQ7	DE	Discovery agent

DMH3QLF	ID	DMH3QLF
DMH3QLF	DN	2-(tert-Butylamino)-3',5'-difluoropropiophenone
DMH3QLF	HS	Investigative
DMH3QLF	SN	CHEMBL577501; SCHEMBL634113; BDBM50302939
DMH3QLF	DT	Small molecular drug
DMH3QLF	PC	44543266
DMH3QLF	MW	241.28
DMH3QLF	FM	C13H17F2NO
DMH3QLF	IC	InChI=1S/C13H17F2NO/c1-8(16-13(2,3)4)12(17)9-5-10(14)7-11(15)6-9/h5-8,16H,1-4H3
DMH3QLF	CS	CC(C(=O)C1=CC(=CC(=C1)F)F)NC(C)(C)C
DMH3QLF	IK	CXFKXPAAWKFBPJ-UHFFFAOYSA-N
DMH3QLF	IU	2-(tert-butylamino)-1-(3,5-difluorophenyl)propan-1-one
DMH3QLF	DE	Discovery agent

DM5YJP3	ID	DM5YJP3
DM5YJP3	DN	2-(tert-Butylamino)-3'-fluoropropiophenone
DM5YJP3	HS	Investigative
DM5YJP3	SN	2-(tert-butylamino)-1-(3-fluorophenyl)propan-1-one; CHEMBL576063; AC1Q5DGH; AC1L4Y0Z; 2-(tert-butylamino)-1-(3-fluorphenyl)propan-1-on; 34841-40-2; SCHEMBL770228; CTK8I3431; BDBM50302925; TL8002592
DM5YJP3	DT	Small molecular drug
DM5YJP3	PC	215051
DM5YJP3	MW	223.29
DM5YJP3	FM	C13H18FNO
DM5YJP3	IC	InChI=1S/C13H18FNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
DM5YJP3	CS	CC(C(=O)C1=CC(=CC=C1)F)NC(C)(C)C
DM5YJP3	IK	CCGVLNAUEKVICK-UHFFFAOYSA-N
DM5YJP3	IU	2-(tert-butylamino)-1-(3-fluorophenyl)propan-1-one
DM5YJP3	DE	Discovery agent

DMH4IRP	ID	DMH4IRP
DMH4IRP	DN	2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine
DMH4IRP	HS	Investigative
DMH4IRP	SN	1H-Benzimidazol-5-amine, 2-(4-thiazolyl)-; CHEMBL370420; 25893-06-5; 5-Aminothiabendazole; 5-amino-2-(thiazol-4-yl)-1H-benzimidazole; 2-(4-Thiazolyl)-1H-benzimidazol-5-amine; AC1Q4XVD; 2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine; AC1L35H8; SCHEMBL4367564; CTK7D8516; CUDHOGCHOXYXRZ-UHFFFAOYSA-N; MolPort-004-293-518; ZINC13679482; BDBM50180749; AKOS000129404; MCULE-2929987645; 5-amino-2-thiazol-4-yl-1H-benzoimidazole; 2-Thiazol-4-yl-3H-benzoimidazol-5-ylamine; 2-(1,3-thiazol-4-yl)-3H-benzimidazol-5-amine
DMH4IRP	DT	Small molecular drug
DMH4IRP	PC	134912
DMH4IRP	MW	216.26
DMH4IRP	FM	C10H8N4S
DMH4IRP	IC	InChI=1S/C10H8N4S/c11-6-1-2-7-8(3-6)14-10(13-7)9-4-15-5-12-9/h1-5H,11H2,(H,13,14)
DMH4IRP	CS	C1=CC2=C(C=C1N)NC(=N2)C3=CSC=N3
DMH4IRP	IK	CUDHOGCHOXYXRZ-UHFFFAOYSA-N
DMH4IRP	IU	2-(1,3-thiazol-4-yl)-3H-benzimidazol-5-amine
DMH4IRP	CA	CAS 25893-06-5
DMH4IRP	DE	Discovery agent

DMDL8KY	ID	DMDL8KY
DMDL8KY	DN	2-(trifluoromethoxy)-9H-carbazole
DMDL8KY	HS	Investigative
DMDL8KY	SN	CHEMBL1171980; 2-(trifluoromethoxy)-9H-carbazole
DMDL8KY	DT	Small molecular drug
DMDL8KY	PC	46855213
DMDL8KY	MW	251.2
DMDL8KY	FM	C13H8F3NO
DMDL8KY	IC	InChI=1S/C13H8F3NO/c14-13(15,16)18-8-5-6-10-9-3-1-2-4-11(9)17-12(10)7-8/h1-7,17H
DMDL8KY	CS	C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)OC(F)(F)F
DMDL8KY	IK	AKPHYUFLAWJLFA-UHFFFAOYSA-N
DMDL8KY	IU	2-(trifluoromethoxy)-9H-carbazole
DMDL8KY	DE	Discovery agent

DM7M6T3	ID	DM7M6T3
DM7M6T3	DN	2-(trifluoromethyl)-9H-carbazole
DM7M6T3	HS	Investigative
DM7M6T3	SN	2-(trifluoromethyl)-9H-carbazole; 2285-35-0; CHEMBL1173704; 2-TRIFLUOROMETHYL-9H-CARBAZOLE; SCHEMBL4126997; C13H8F3N; CTK4F0330; DTXSID40479099; HWUDQSLQFQHKSV-UHFFFAOYSA-N; 9H-Carbazole,2-(trifluoromethyl)-; BDBM50322579; 9H-Carbazole, 2-(trifluoromethyl)-; ZINC22003772; AKOS015967072; ACM2285350
DM7M6T3	DT	Small molecular drug
DM7M6T3	PC	12169809
DM7M6T3	MW	235.2
DM7M6T3	FM	C13H8F3N
DM7M6T3	IC	InChI=1S/C13H8F3N/c14-13(15,16)8-5-6-10-9-3-1-2-4-11(9)17-12(10)7-8/h1-7,17H
DM7M6T3	CS	C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)C(F)(F)F
DM7M6T3	IK	HWUDQSLQFQHKSV-UHFFFAOYSA-N
DM7M6T3	IU	2-(trifluoromethyl)-9H-carbazole
DM7M6T3	CA	CAS 2285-35-0
DM7M6T3	DE	Discovery agent

DMWAKFM	ID	DMWAKFM
DMWAKFM	DN	2-(trifluoromethyl)benzaldehyde thiosemicarbazone
DMWAKFM	HS	Investigative
DMWAKFM	SN	3-Bromobenzaldehyde thiosemicarbazone; CHEMBL91844; (E)-2-(3-bromobenzylidene)hydrazinecarbothioamide; 1346145-39-8; [(E)-(3-bromophenyl)methylideneamino]thiourea; AC1OR2L9; MLS000679007; SCHEMBL8443935; MolPort-000-665-235; MolPort-000-517-617; FGGWIXJNLRDBPW-VZUCSPMQSA-N; MolPort-020-322-421; HMS1608D07; STK409371; SBB015558; ITH000389; BDBM50114665; AKOS002349799; AKOS000304365; 3-Bromobenzaldehyde thiosemicarbazone #; FCH4917890; FCH3689419; SMR000323398; BBV-39869959; [(E)-(3-bromophenyl)methyleneamino]thiourea; ST50169421
DMWAKFM	DT	Small molecular drug
DMWAKFM	PC	5561401
DMWAKFM	MW	247.24
DMWAKFM	FM	C9H8F3N3S
DMWAKFM	IC	InChI=1S/C9H8F3N3S/c10-9(11,12)7-4-2-1-3-6(7)5-14-15-8(13)16/h1-5H,(H3,13,15,16)/b14-5-
DMWAKFM	CS	C1=CC=C(C(=C1)/C=N\\NC(=S)N)C(F)(F)F
DMWAKFM	IK	IVJQRNPGHXNEJE-RZNTYIFUSA-N
DMWAKFM	IU	[(Z)-[2-(trifluoromethyl)phenyl]methylideneamino]thiourea
DMWAKFM	DE	Discovery agent

DMBLXOG	ID	DMBLXOG
DMBLXOG	DN	2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX)
DMBLXOG	HS	Investigative
DMBLXOG	SN	SCHEMBL4280142; CHEMBL1095541; BDBM50316555; 2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX); 2,2,2-trifluoro-1-(4-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethan-1-ol
DMBLXOG	DT	Small molecular drug
DMBLXOG	PC	46888391
DMBLXOG	MW	404.3
DMBLXOG	FM	C21H13F5N2O
DMBLXOG	IC	InChI=1S/C21H13F5N2O/c22-16-4-1-14(2-5-16)20(29,21(24,25)26)15-3-10-19-13(11-15)12-27-28(19)18-8-6-17(23)7-9-18/h1-12,29H
DMBLXOG	CS	C1=CC(=CC=C1C(C2=CC3=C(C=C2)N(N=C3)C4=CC=C(C=C4)F)(C(F)(F)F)O)F
DMBLXOG	IK	KMBFENZTPAWDBF-UHFFFAOYSA-N
DMBLXOG	IU	2,2,2-trifluoro-1-(4-fluorophenyl)-1-[1-(4-fluorophenyl)indazol-5-yl]ethanol
DMBLXOG	DE	Discovery agent

DMG4ITB	ID	DMG4ITB
DMG4ITB	DN	2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide
DMG4ITB	HS	Investigative
DMG4ITB	SN	2,2,2-trifluoro-N-(4-sulfamoylphenyl)acetamide; CHEMBL417648; NSC36432; AC1L5TZB; AC1Q6VD0; N-[4-(aminosulfonyl)phenyl]-2,2,2-trifluoroacetamide; aromatic sulfonamide compound 9; SCHEMBL16057183; BDBM16644; acetamide, n-[4-(aminosulfonyl)phenyl]-2,2,2-trifluoro-; MolPort-001-023-586; KYCGMLPXHVMDAN-UHFFFAOYSA-N; ZINC993502; HMS1580F07; STK413007; NSC-36432; 4-Trifluoroacetamido-benzenesulfonamide; AKOS001720753; MCULE-7425586358; SDCCGMLS-0064722.P001; ST45139606; EU-0050996; AB00079123-01; SR-01000408197; AK-968/10112031
DMG4ITB	DT	Small molecular drug
DMG4ITB	PC	235259
DMG4ITB	MW	268.22
DMG4ITB	FM	C8H7F3N2O3S
DMG4ITB	IC	InChI=1S/C8H7F3N2O3S/c9-8(10,11)7(14)13-5-1-3-6(4-2-5)17(12,15)16/h1-4H,(H,13,14)(H2,12,15,16)
DMG4ITB	CS	C1=CC(=CC=C1NC(=O)C(F)(F)F)S(=O)(=O)N
DMG4ITB	IK	KYCGMLPXHVMDAN-UHFFFAOYSA-N
DMG4ITB	IU	2,2,2-trifluoro-N-(4-sulfamoylphenyl)acetamide
DMG4ITB	CA	CAS 6275-99-6
DMG4ITB	DE	Discovery agent

DMJXAF7	ID	DMJXAF7
DMJXAF7	DN	2,2,2-tris-(3-fluorophenyl)-acetamide
DMJXAF7	HS	Investigative
DMJXAF7	SN	CHEMBL260736; SCHEMBL13950949
DMJXAF7	DT	Small molecular drug
DMJXAF7	PC	20684851
DMJXAF7	MW	341.3
DMJXAF7	FM	C20H14F3NO
DMJXAF7	IC	InChI=1S/C20H14F3NO/c21-16-7-1-4-13(10-16)20(19(24)25,14-5-2-8-17(22)11-14)15-6-3-9-18(23)12-15/h1-12H,(H2,24,25)
DMJXAF7	CS	C1=CC(=CC(=C1)F)C(C2=CC(=CC=C2)F)(C3=CC(=CC=C3)F)C(=O)N
DMJXAF7	IK	NYTZBODQYAXXMZ-UHFFFAOYSA-N
DMJXAF7	IU	2,2,2-tris(3-fluorophenyl)acetamide
DMJXAF7	DE	Discovery agent

DMCZHEN	ID	DMCZHEN
DMCZHEN	DN	2,2,2-tris-(4-fluorophenyl)-acetamide
DMCZHEN	HS	Investigative
DMCZHEN	SN	CHEMBL270704; 2,2,2-tris(4-fluorophenyl)acetamide; SCHEMBL2338402
DMCZHEN	DT	Small molecular drug
DMCZHEN	PC	9884397
DMCZHEN	MW	341.3
DMCZHEN	FM	C20H14F3NO
DMCZHEN	IC	InChI=1S/C20H14F3NO/c21-16-7-1-13(2-8-16)20(19(24)25,14-3-9-17(22)10-4-14)15-5-11-18(23)12-6-15/h1-12H,(H2,24,25)
DMCZHEN	CS	C1=CC(=CC=C1C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N)F
DMCZHEN	IK	NEYVEJOLUVXNDA-UHFFFAOYSA-N
DMCZHEN	IU	2,2,2-tris(4-fluorophenyl)acetamide
DMCZHEN	DE	Discovery agent

DMG7EPF	ID	DMG7EPF
DMG7EPF	DN	2,2',3-Tribromo-4,4',5,5'-tetrahydroxybibenzyl
DMG7EPF	HS	Investigative
DMG7EPF	SN	CHEMBL1270043; SCHEMBL15511567; BDBM50329699; 2,2'',3-Tribromo-4,4'',5,5''-tetrahydroxybibenzyl
DMG7EPF	DT	Small molecular drug
DMG7EPF	PC	52945885
DMG7EPF	MW	482.95
DMG7EPF	FM	C14H11Br3O4
DMG7EPF	IC	InChI=1S/C14H11Br3O4/c15-8-5-10(19)9(18)3-6(8)1-2-7-4-11(20)14(21)13(17)12(7)16/h3-5,18-21H,1-2H2
DMG7EPF	CS	C1=C(C(=CC(=C1O)O)Br)CCC2=CC(=C(C(=C2Br)Br)O)O
DMG7EPF	IK	NFQMJMJFBMIAAK-UHFFFAOYSA-N
DMG7EPF	IU	3,4-dibromo-5-[2-(2-bromo-4,5-dihydroxyphenyl)ethyl]benzene-1,2-diol
DMG7EPF	DE	Discovery agent

DMAYXUR	ID	DMAYXUR
DMAYXUR	DN	2,2',4,4',6'-pentahydroxychalcone
DMAYXUR	HS	Investigative
DMAYXUR	SN	CHEMBL244249; 2,2',4,4',6'-pentahydroxychalcone; BDBM50203986
DMAYXUR	DT	Small molecular drug
DMAYXUR	PC	16721049
DMAYXUR	MW	288.25
DMAYXUR	FM	C15H12O6
DMAYXUR	IC	InChI=1S/C15H12O6/c16-9-3-1-8(12(19)5-9)2-4-11(18)15-13(20)6-10(17)7-14(15)21/h1-7,16-17,19-21H/b4-2+
DMAYXUR	CS	C1=CC(=C(C=C1O)O)/C=C/C(=O)C2=C(C=C(C=C2O)O)O
DMAYXUR	IK	MDRJIGPMMMALHB-DUXPYHPUSA-N
DMAYXUR	IU	(E)-3-(2,4-dihydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one
DMAYXUR	DE	Discovery agent

DMMJ613	ID	DMMJ613
DMMJ613	DN	2,2',4,4'-tetrahydroxy-6'-methoxychalcone
DMMJ613	HS	Investigative
DMMJ613	SN	CHEMBL244248; BDBM50203987
DMMJ613	DT	Small molecular drug
DMMJ613	PC	44428616
DMMJ613	MW	302.28
DMMJ613	FM	C16H14O6
DMMJ613	IC	InChI=1S/C16H14O6/c1-22-15-8-11(18)7-14(21)16(15)12(19)5-3-9-2-4-10(17)6-13(9)20/h2-8,17-18,20-21H,1H3/b5-3+
DMMJ613	CS	COC1=CC(=CC(=C1C(=O)/C=C/C2=C(C=C(C=C2)O)O)O)O
DMMJ613	IK	NNOIQNQJIKZQCN-HWKANZROSA-N
DMMJ613	IU	(E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-(2,4-dihydroxyphenyl)prop-2-en-1-one
DMMJ613	DE	Discovery agent

DMM6KBD	ID	DMM6KBD
DMM6KBD	DN	2,2',4,4'-tetrahydroxychalcone
DMM6KBD	HS	Investigative
DMM6KBD	SN	2,4,2',4'-Tetrahydroxychalcone; 2,2',4,4'-tetrahydroxychalcone; CHEMBL394855; SCHEMBL675094; 2,4,2'',4''-tetrahydroxychalcone; LMPK12120128; 2,2'',4,4''-tetrahydroxychalcone; BDBM50203985
DMM6KBD	DT	Small molecular drug
DMM6KBD	PC	10107266
DMM6KBD	MW	272.25
DMM6KBD	FM	C15H12O5
DMM6KBD	IC	InChI=1S/C15H12O5/c16-10-3-1-9(14(19)7-10)2-6-13(18)12-5-4-11(17)8-15(12)20/h1-8,16-17,19-20H/b6-2+
DMM6KBD	CS	C1=CC(=C(C=C1O)O)/C=C/C(=O)C2=C(C=C(C=C2)O)O
DMM6KBD	IK	ZWTDXYUDJYDHJR-QHHAFSJGSA-N
DMM6KBD	IU	(E)-1,3-bis(2,4-dihydroxyphenyl)prop-2-en-1-one
DMM6KBD	DE	Discovery agent

DMP9ECK	ID	DMP9ECK
DMP9ECK	DN	2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline
DMP9ECK	HS	Investigative
DMP9ECK	SN	Santoflex B; UNII-UT9B2V4JD4; USAF B-29; 2,2,4-Trimethyl-6-phenyl-1,2-dihydroquinoline; 3562-69-4; BRN 0185528; UT9B2V4JD4; CHEMBL93463; 6-Phenyl-2,2,4-trimethyldihydroquinoline; 1,2-Dihydro-2,2,4-trimethyl-6-phenylquinoline; Quinoline, 1,2-dihydro-2,2,4-trimethyl-6-phenyl-; 2,2,4-trimethyl-6-phenyl-1H-quinoline; AC1L2SCX; 2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline; 4-20-00-04116 (Beilstein Handbook Reference); SCHEMBL311413; DTXSID30189094; ZINC5315096; BDBM50066527; ACM3562694; LS-141859
DMP9ECK	DT	Small molecular drug
DMP9ECK	PC	77098
DMP9ECK	MW	249.3
DMP9ECK	FM	C18H19N
DMP9ECK	IC	InChI=1S/C18H19N/c1-13-12-18(2,3)19-17-10-9-15(11-16(13)17)14-7-5-4-6-8-14/h4-12,19H,1-3H3
DMP9ECK	CS	CC1=CC(NC2=C1C=C(C=C2)C3=CC=CC=C3)(C)C
DMP9ECK	IK	XKBGEVHKVFIMLY-UHFFFAOYSA-N
DMP9ECK	IU	2,2,4-trimethyl-6-phenyl-1H-quinoline
DMP9ECK	CA	CAS 3562-69-4
DMP9ECK	DE	Discovery agent

DMPMOHQ	ID	DMPMOHQ
DMPMOHQ	DN	2,2'-bi(1,3,4-thiadiazole)-5,5'(4H,4'H)-dithione
DMPMOHQ	HS	Investigative
DMPMOHQ	SN	CHEMBL1163927; BDBM50320719
DMPMOHQ	DT	Small molecular drug
DMPMOHQ	PC	21790441
DMPMOHQ	MW	234.4
DMPMOHQ	FM	C4H2N4S4
DMPMOHQ	IC	InChI=1S/C4H2N4S4/c9-3-7-5-1(11-3)2-6-8-4(10)12-2/h(H,7,9)(H,8,10)
DMPMOHQ	CS	C1(=NNC(=S)S1)C2=NNC(=S)S2
DMPMOHQ	IK	DAHNZAVSTBXUBS-UHFFFAOYSA-N
DMPMOHQ	IU	5-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)-3H-1,3,4-thiadiazole-2-thione
DMPMOHQ	DE	Discovery agent

DMDIX40	ID	DMDIX40
DMDIX40	DN	2,2-bis-(2-fluorophenyl)-2-phenylacetamide
DMDIX40	HS	Investigative
DMDIX40	SN	CHEMBL261606; SCHEMBL2332073
DMDIX40	DT	Small molecular drug
DMDIX40	PC	9880246
DMDIX40	MW	323.3
DMDIX40	FM	C20H15F2NO
DMDIX40	IC	InChI=1S/C20H15F2NO/c21-17-12-6-4-10-15(17)20(19(23)24,14-8-2-1-3-9-14)16-11-5-7-13-18(16)22/h1-13H,(H2,23,24)
DMDIX40	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2F)(C3=CC=CC=C3F)C(=O)N
DMDIX40	IK	JYLGTXBPFRKVJO-UHFFFAOYSA-N
DMDIX40	IU	2,2-bis(2-fluorophenyl)-2-phenylacetamide
DMDIX40	DE	Discovery agent

DM6ICRJ	ID	DM6ICRJ
DM6ICRJ	DN	2,2-bis-(3-fluorophenyl)-2-phenylacetamide
DM6ICRJ	HS	Investigative
DM6ICRJ	SN	CHEMBL261828; SCHEMBL13950934
DM6ICRJ	DT	Small molecular drug
DM6ICRJ	PC	20684855
DM6ICRJ	MW	323.3
DM6ICRJ	FM	C20H15F2NO
DM6ICRJ	IC	InChI=1S/C20H15F2NO/c21-17-10-4-8-15(12-17)20(19(23)24,14-6-2-1-3-7-14)16-9-5-11-18(22)13-16/h1-13H,(H2,23,24)
DM6ICRJ	CS	C1=CC=C(C=C1)C(C2=CC(=CC=C2)F)(C3=CC(=CC=C3)F)C(=O)N
DM6ICRJ	IK	WBCHZEIUTRPOCM-UHFFFAOYSA-N
DM6ICRJ	IU	2,2-bis(3-fluorophenyl)-2-phenylacetamide
DM6ICRJ	DE	Discovery agent

DMTODR2	ID	DMTODR2
DMTODR2	DN	2,2-bis(3-fluorophenyl)-N-hydroxyacetamide
DMTODR2	HS	Investigative
DMTODR2	SN	CHEMBL574594; 2,2-bis(3-fluorophenyl)-N-hydroxyacetamide; SCHEMBL4536216
DMTODR2	DT	Small molecular drug
DMTODR2	PC	45482630
DMTODR2	MW	263.24
DMTODR2	FM	C14H11F2NO2
DMTODR2	IC	InChI=1S/C14H11F2NO2/c15-11-5-1-3-9(7-11)13(14(18)17-19)10-4-2-6-12(16)8-10/h1-8,13,19H,(H,17,18)
DMTODR2	CS	C1=CC(=CC(=C1)F)C(C2=CC(=CC=C2)F)C(=O)NO
DMTODR2	IK	OCJJUBQJPOHGBE-UHFFFAOYSA-N
DMTODR2	IU	2,2-bis(3-fluorophenyl)-N-hydroxyacetamide
DMTODR2	DE	Discovery agent

DM2RKD6	ID	DM2RKD6
DM2RKD6	DN	2,2-bis(4-chlorophenyl)-N-hydroxyacetamide
DM2RKD6	HS	Investigative
DM2RKD6	SN	CHEMBL572805; 2,2-bis(4-chlorophenyl)-N-hydroxyacetamide; SCHEMBL2848402
DM2RKD6	DT	Small molecular drug
DM2RKD6	PC	45482643
DM2RKD6	MW	296.1
DM2RKD6	FM	C14H11Cl2NO2
DM2RKD6	IC	InChI=1S/C14H11Cl2NO2/c15-11-5-1-9(2-6-11)13(14(18)17-19)10-3-7-12(16)8-4-10/h1-8,13,19H,(H,17,18)
DM2RKD6	CS	C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(=O)NO)Cl
DM2RKD6	IK	MITRLTIJDHOUFN-UHFFFAOYSA-N
DM2RKD6	IU	2,2-bis(4-chlorophenyl)-N-hydroxyacetamide
DM2RKD6	DE	Discovery agent

DM5PWQM	ID	DM5PWQM
DM5PWQM	DN	2,2-bis(4-fluorophenyl)-N-hydroxyacetamide
DM5PWQM	HS	Investigative
DM5PWQM	SN	CHEMBL573190; 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide; SCHEMBL2841871
DM5PWQM	DT	Small molecular drug
DM5PWQM	PC	45482672
DM5PWQM	MW	263.24
DM5PWQM	FM	C14H11F2NO2
DM5PWQM	IC	InChI=1S/C14H11F2NO2/c15-11-5-1-9(2-6-11)13(14(18)17-19)10-3-7-12(16)8-4-10/h1-8,13,19H,(H,17,18)
DM5PWQM	CS	C1=CC(=CC=C1C(C2=CC=C(C=C2)F)C(=O)NO)F
DM5PWQM	IK	HHJNWMNXSDYVHL-UHFFFAOYSA-N
DM5PWQM	IU	2,2-bis(4-fluorophenyl)-N-hydroxyacetamide
DM5PWQM	DE	Discovery agent

DMFPYU8	ID	DMFPYU8
DMFPYU8	DN	2,2-Dibenzylcyclopentanol
DMFPYU8	HS	Investigative
DMFPYU8	SN	2,2-Dibenzylcyclopentanol
DMFPYU8	DT	Small molecular drug
DMFPYU8	PC	10468150
DMFPYU8	MW	266.4
DMFPYU8	FM	C19H22O
DMFPYU8	IC	InChI=1S/C19H22O/c20-18-12-7-13-19(18,14-16-8-3-1-4-9-16)15-17-10-5-2-6-11-17/h1-6,8-11,18,20H,7,12-15H2
DMFPYU8	CS	C1CC(C(C1)(CC2=CC=CC=C2)CC3=CC=CC=C3)O
DMFPYU8	IK	MSJGQZXPPBXPBA-UHFFFAOYSA-N
DMFPYU8	IU	2,2-dibenzylcyclopentan-1-ol
DMFPYU8	DE	Discovery agent

DMKXFDA	ID	DMKXFDA
DMKXFDA	DN	2,2-difluoromevalonate 5-diphosphate
DMKXFDA	HS	Investigative
DMKXFDA	SN	2,2-difluoromevalonate 5-diphosphate; GTPL3213; CHEMBL1162018; 2,2-difluoro-3-hydroxy-5-(hydroxy-phosphonooxyphosphoryl)oxy-3-methylpentanoic acid
DMKXFDA	DT	Small molecular drug
DMKXFDA	PC	24779755
DMKXFDA	MW	344.1
DMKXFDA	FM	C6H12F2O10P2
DMKXFDA	IC	InChI=1S/C6H12F2O10P2/c1-5(11,6(7,8)4(9)10)2-3-17-20(15,16)18-19(12,13)14/h11H,2-3H2,1H3,(H,9,10)(H,15,16)(H2,12,13,14)
DMKXFDA	CS	CC(CCOP(=O)(O)OP(=O)(O)O)(C(C(=O)O)(F)F)O
DMKXFDA	IK	TYAGFMDNISQMRJ-UHFFFAOYSA-N
DMKXFDA	IU	2,2-difluoro-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid
DMKXFDA	DE	Discovery agent

DMPX642	ID	DMPX642
DMPX642	DN	2,2-diMeBut-RYYRIK-NH2
DMPX642	HS	Investigative
DMPX642	SN	CHEMBL403588
DMPX642	DT	Small molecular drug
DMPX642	PC	44456216
DMPX642	MW	979.2
DMPX642	FM	C48H78N14O8
DMPX642	IC	InChI=1S/C48H78N14O8/c1-6-29(3)38(44(69)57-33(39(50)64)17-11-12-24-49)62-41(66)34(18-13-25-55-46(51)52)58-42(67)37(28-31-20-22-32(63)23-21-31)60-43(68)36(27-30-15-9-8-10-16-30)59-40(65)35(19-14-26-56-47(53)54)61-45(70)48(4,5)7-2/h8-10,15-16,20-23,29,33-38,63H,6-7,11-14,17-19,24-28,49H2,1-5H3,(H2,50,64)(H,57,69)(H,58,67)(H,59,65)(H,60,68)(H,61,70)(H,62,66)(H4,51,52,55)(H4,53,54,56)/t29-,33-,34-,35-,36-,37-,38-/m0/s1
DMPX642	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(C)(C)CC
DMPX642	IK	JOZALXQUIMQHHA-AVTNSMPVSA-N
DMPX642	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2,2-dimethylbutanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMPX642	DE	Discovery agent

DM34IX5	ID	DM34IX5
DM34IX5	DN	2,2-Dimethoxy-1,2-diphenyl-ethanone
DM34IX5	HS	Investigative
DM34IX5	SN	24650-42-8; 2,2-Dimethoxy-2-phenylacetophenone; 2,2-Dimethoxy-1,2-diphenylethanone; Benzil dimethyl ketal; Kayacure BDMK; Irgacure 651; Ethanone, 2,2-dimethoxy-1,2-diphenyl-; Lucirin BDK; Photomer 51; Esacure KB 1; Irgacure 641; Irgacure 621; Irgacure I 651; Irgacure E 651; Benzil Dimethylketal; Irgacure 951; Benzil mono(dimethyl ketal); 2,2-Dimethoxy-1,2-diphenylethan-1-one; Benzil mono(dimethyl acetal); Benzil dimethyl acetal; alpha,alpha-Dimethoxy-alpha-phenylacetophenone; KB 1; 2,2-Dimethoxy-1,2-diphenyl-ethanone
DM34IX5	DT	Small molecular drug
DM34IX5	PC	90571
DM34IX5	MW	256.3
DM34IX5	FM	C16H16O3
DM34IX5	IC	InChI=1S/C16H16O3/c1-18-16(19-2,14-11-7-4-8-12-14)15(17)13-9-5-3-6-10-13/h3-12H,1-2H3
DM34IX5	CS	COC(C1=CC=CC=C1)(C(=O)C2=CC=CC=C2)OC
DM34IX5	IK	KWVGIHKZDCUPEU-UHFFFAOYSA-N
DM34IX5	IU	2,2-dimethoxy-1,2-diphenylethanone
DM34IX5	CA	CAS 24650-42-8
DM34IX5	DE	Discovery agent

DMQYCFI	ID	DMQYCFI
DMQYCFI	DN	2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
DMQYCFI	HS	Investigative
DMQYCFI	SN	Xyloidone; Dehydro-alpha-lapachone; 15297-92-4; Dehydrolapachone; DEHYDROPLAPACHONE; Dehydro-.alpha.-lapachol; Dehydro-.alpha.-lapacone; NSC106453; NSC629748; 2,2-Dimethyl-2H-benzo[g]chromene-5,10-dione; Dehydro-.alpha.-lapachone; NSC 629748; NSC 106453; UNII-305WY61CUF; .alpha.-Lapachone, dehydro-; 2H-Naphtho[2,3-b]pyran-5,10-dione, 2,2-dimethyl-; 305WY61CUF; 2,2-dimethylbenzo[g]chromene-5,10-dione; 2H-Naphtho[2,3-b]pyran-5,10-dione,2,2-dimethyl-; 2,2-dimethyl-2H,5H,10H-benzo[g]chromene-5,10-dione; Xyloidone (VAN)
DMQYCFI	DT	Small molecular drug
DMQYCFI	PC	72734
DMQYCFI	MW	240.25
DMQYCFI	FM	C15H12O3
DMQYCFI	IC	InChI=1S/C15H12O3/c1-15(2)8-7-11-12(16)9-5-3-4-6-10(9)13(17)14(11)18-15/h3-8H,1-2H3
DMQYCFI	CS	CC1(C=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O)C
DMQYCFI	IK	OWFHAMHRUCUSRM-UHFFFAOYSA-N
DMQYCFI	IU	2,2-dimethylbenzo[g]chromene-5,10-dione
DMQYCFI	CA	CAS 15297-92-4
DMQYCFI	DE	Discovery agent

DM7BL04	ID	DM7BL04
DM7BL04	DN	2,2-dimethyl-3-methyleneheptadecane
DM7BL04	HS	Investigative
DM7BL04	SN	CHEMBL270375; 2-Propanone, 3-(dodecylthio)-1,1,1-trifluoro-; 92682-28-5; ACMC-20lwey; CTK3F7670; DTXSID90467547; BDBM50371972
DM7BL04	DT	Small molecular drug
DM7BL04	PC	11493344
DM7BL04	MW	312.4
DM7BL04	FM	C15H27F3OS
DM7BL04	IC	InChI=1S/C15H27F3OS/c1-2-3-4-5-6-7-8-9-10-11-12-20-13-14(19)15(16,17)18/h2-13H2,1H3
DM7BL04	CS	CCCCCCCCCCCCSCC(=O)C(F)(F)F
DM7BL04	IK	NACMLRDTSWENRZ-UHFFFAOYSA-N
DM7BL04	IU	3-dodecylsulfanyl-1,1,1-trifluoropropan-2-one
DM7BL04	CA	CAS 92682-28-5
DM7BL04	DE	Discovery agent

DMATB8H	ID	DMATB8H
DMATB8H	DN	2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide
DMATB8H	HS	Investigative
DMATB8H	SN	CHEMBL23285; 2,2-dimethyl-N-(4-sulfamoylphenyl)propanamide; 103826-87-5; AC1MBHEI; Oprea1_396828; p-pivaloylaminobenzenesulfonamide; Propanamide, N-[4-(aminosulfonyl)phenyl]-2,2-dimethyl-; N-(4-Sulfamoylphenyl)Pivalamide; SCHEMBL10603454; ZINC73524; BDBM16649; aromatic sulfonamide compound 14; CCG-916; KGBTVIQRHXYTRQ-UHFFFAOYSA-N; 4-Pivaloylamido-benzenesulfonamide; MolPort-002-912-681; AKOS003441276; MCULE-2674794031; BRD-K77020128-001-01-6
DMATB8H	DT	Small molecular drug
DMATB8H	PC	2725651
DMATB8H	MW	256.32
DMATB8H	FM	C11H16N2O3S
DMATB8H	IC	InChI=1S/C11H16N2O3S/c1-11(2,3)10(14)13-8-4-6-9(7-5-8)17(12,15)16/h4-7H,1-3H3,(H,13,14)(H2,12,15,16)
DMATB8H	CS	CC(C)(C)C(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DMATB8H	IK	KGBTVIQRHXYTRQ-UHFFFAOYSA-N
DMATB8H	IU	2,2-dimethyl-N-(4-sulfamoylphenyl)propanamide
DMATB8H	DE	Discovery agent

DMTBAUG	ID	DMTBAUG
DMTBAUG	DN	2,2-Diphenyl-ethylamine
DMTBAUG	HS	Investigative
DMTBAUG	SN	2,2-Diphenylethylamine; 3963-62-0; 2,2-Diphenylethanamine; 2,2-Diphenyl-ethylamine; 1-Amino-2,2-diphenylethane; 2,2-Diphenylethan-1-Amine; CHEMBL10780; 2,2-Diphenylethylamine, 96%; RXMTUVIKZRXSSM-UHFFFAOYSA-N; NSC27209; EINECS 223-565-7; PubChem7986; ACMC-1CSWZ; 2,2-diphenylethyl-amine; 2,2- diphenylethylamine; AC1L2TCM; beta-phenylbenzeneethanamine; 2,2-diphenyl-ethyl-amine; 2,2-diphenyl ethyl amine; 2,2-di(phenyl)ethanamine; 2,2-Diphenylethanamine #; 2,2-bis-phenyl-ethylamine; AC1Q53LU; Benzeneethanamine, b-phenyl-
DMTBAUG	DT	Small molecular drug
DMTBAUG	PC	77575
DMTBAUG	MW	197.27
DMTBAUG	FM	C14H15N
DMTBAUG	IC	InChI=1S/C14H15N/c15-11-14(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,14H,11,15H2
DMTBAUG	CS	C1=CC=C(C=C1)C(CN)C2=CC=CC=C2
DMTBAUG	IK	RXMTUVIKZRXSSM-UHFFFAOYSA-N
DMTBAUG	IU	2,2-diphenylethanamine
DMTBAUG	CA	CAS 3963-62-0
DMTBAUG	DE	Discovery agent

DMOQDBA	ID	DMOQDBA
DMOQDBA	DN	2,2'-pyridylisatogen tosylate
DMOQDBA	HS	Investigative
DMOQDBA	SN	2,2'-Pyridylisatogen tosylate; 56583-49-4; PIT; 2-(2-pyridinyl)-(3h)-indol-3-one-1-oxide 4-methylbenzenesulfonate; 4-methylbenzenesulfonic acid; 1-oxido-2-pyridin-2-ylindol-1-ium-3-one; Tocris-1682; AC1L3Y9P; AC1Q6WM2; GTPL1729; CHEMBL1364808; CTK1H0971; MolPort-023-276-189; HMS3268O03; AKOS024456745; 2-(pyridin-2-yl)-3h-indol-3-one 1-oxide 4-methylbenzenesulfonate(1:1); NCGC00025378-01; KB-221271; B6827; SR-01000597767; SR-01000597767-1; 4-methylbenzenesulfonic acid
DMOQDBA	DT	Small molecular drug
DMOQDBA	PC	124333
DMOQDBA	MW	396.4
DMOQDBA	FM	C20H16N2O5S
DMOQDBA	IC	InChI=1S/C13H8N2O2.C7H8O3S/c16-13-9-5-1-2-7-11(9)15(17)12(13)10-6-3-4-8-14-10;1-6-2-4-7(5-3-6)11(8,9)10/h1-8H;2-5H,1H3,(H,8,9,10)
DMOQDBA	CS	CC1=CC=C(C=C1)S(=O)(=O)O.C1=CC=C2C(=C1)C(=O)C(=[N+]2[O-])C3=CC=CC=N3
DMOQDBA	IK	MMPTYEXNPWSTOR-UHFFFAOYSA-N
DMOQDBA	IU	4-methylbenzenesulfonic acid;1-oxido-2-pyridin-2-ylindol-1-ium-3-one
DMOQDBA	DE	Discovery agent

DM7H34U	ID	DM7H34U
DM7H34U	DN	2,3,3-Triphenyl-acrylonitrile
DM7H34U	HS	Investigative
DM7H34U	SN	Triphenylacrylonitrile; 2,3,3-Triphenylacrylonitrile; Triphenylcyanoethylene; 6304-33-2; Acrylonitrile, triphenyl-; 2,3,3-triphenylprop-2-enenitrile; 2,3,3-Triphenyl-acrylonitrile; alpha,beta-Diphenylcinnamonitrile; ACRYLONITRILE, 2,3,3-TRIPHENYL-; EINECS 228-610-4; NSC 42900; 2,3,3-Trifenylakrylonitril [Czech]; BRN 1980289; alpha-(Diphenylmethylene)benzeneacetic acid; AI3-63069; MLS002608486; CHEBI:34217; Benzeneacetic acid, alpha-(diphenylmethylene)-; NSC42900; Benzeneacetonitrile, .alpha.-(diphenylmethylene)-
DM7H34U	DT	Small molecular drug
DM7H34U	PC	22743
DM7H34U	MW	281.3
DM7H34U	FM	C21H15N
DM7H34U	IC	InChI=1S/C21H15N/c22-16-20(17-10-4-1-5-11-17)21(18-12-6-2-7-13-18)19-14-8-3-9-15-19/h1-15H
DM7H34U	CS	C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)C3=CC=CC=C3)C#N
DM7H34U	IK	OPACMJHTQWVSKW-UHFFFAOYSA-N
DM7H34U	IU	2,3,3-triphenylprop-2-enenitrile
DM7H34U	CA	CAS 6304-33-2
DM7H34U	CB	CHEBI:34217
DM7H34U	DE	Discovery agent

DMV1CX0	ID	DMV1CX0
DMV1CX0	DN	2,3,4,11-tetrahydro-1H-benzo[a]carbazole
DMV1CX0	HS	Investigative
DMV1CX0	SN	CHEMBL1173621; Tetrahydrobenzcarbazol; 2,3,4,11-tetrahydro-1H-benzo[a]carbazole; SCHEMBL17775042; BDBM50322598
DMV1CX0	DT	Small molecular drug
DMV1CX0	PC	11593764
DMV1CX0	MW	221.3
DMV1CX0	FM	C16H15N
DMV1CX0	IC	InChI=1S/C16H15N/c1-2-6-12-11(5-1)9-10-14-13-7-3-4-8-15(13)17-16(12)14/h3-4,7-10,17H,1-2,5-6H2
DMV1CX0	CS	C1CCC2=C(C1)C=CC3=C2NC4=CC=CC=C34
DMV1CX0	IK	OOCBASGHISDDOY-UHFFFAOYSA-N
DMV1CX0	IU	2,3,4,11-tetrahydro-1H-benzo[a]carbazole
DMV1CX0	DE	Discovery agent

DMK4LTB	ID	DMK4LTB
DMK4LTB	DN	2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol
DMK4LTB	HS	Investigative
DMK4LTB	SN	CHEMBL362761; Phenol, 2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)-; 111863-67-3; ACMC-20meye; 2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol; 2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol; CTK0G1675; DTXSID50433647; BDBM50150785; 2,2',3,4,4',5-Hexabromo-6-hydroxydiphenyl ether; 2,3,4,5-tetrabromo-6-(2',4'-dibromophenoxy)phenol; 2-(2'',4''-dibromophenoxy-3,4,5,6-tetrabromophenol
DMK4LTB	DT	Small molecular drug
DMK4LTB	PC	9986835
DMK4LTB	MW	659.6
DMK4LTB	FM	C12H4Br6O2
DMK4LTB	IC	InChI=1S/C12H4Br6O2/c13-4-1-2-6(5(14)3-4)20-12-10(18)8(16)7(15)9(17)11(12)19/h1-3,19H
DMK4LTB	CS	C1=CC(=C(C=C1Br)Br)OC2=C(C(=C(C(=C2Br)Br)Br)Br)O
DMK4LTB	IK	LDMKXEGTHGJWLG-UHFFFAOYSA-N
DMK4LTB	IU	2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
DMK4LTB	CA	CAS 111863-67-3
DMK4LTB	DE	Discovery agent

DMGQE4B	ID	DMGQE4B
DMGQE4B	DN	2,3,4,5-Tetrafluoro-6-pentafluorophenylazo-phenol
DMGQE4B	HS	Investigative
DMGQE4B	DT	Small molecular drug
DMGQE4B	PC	125381
DMGQE4B	MW	360.13
DMGQE4B	FM	C12HF9N2O
DMGQE4B	IC	InChI=1S/C12HF9N2O/c13-1-2(14)6(18)10(7(19)3(1)15)22-23-11-8(20)4(16)5(17)9(21)12(11)24/h24H
DMGQE4B	CS	C1(=C(C(=C(C(=C1F)F)F)F)O)N=NC2=C(C(=C(C(=C2F)F)F)F)F
DMGQE4B	IK	VNLIKHWBADHUKM-UHFFFAOYSA-N
DMGQE4B	IU	2,3,4,5-tetrafluoro-6-[(2,3,4,5,6-pentafluorophenyl)diazenyl]phenol
DMGQE4B	CA	CAS 129520-55-4
DMGQE4B	DE	Discovery agent

DM1RE9Q	ID	DM1RE9Q
DM1RE9Q	DN	2,3,4,5-Tetrahydro-1H-benzo[c]azepine
DM1RE9Q	HS	Investigative
DM1RE9Q	SN	2,3,4,5-Tetrahydro-1H-benzo[c]azepine; 7216-22-0; 2,3,4,5-tetrahydro-1H-2-benzazepine; 1H-2-Benzazepine, 2,3,4,5-tetrahydro-; CHEMBL118310; SCHEMBL233066; ARK042; CTK2H2810; DTXSID00440260; SIQBPWRTJNBBER-UHFFFAOYSA-N; MolPort-020-016-004; BDBM50052883; ANW-49031; ZINC13516868; AKOS005264678; MCULE-2809792553; AB49623; 2,3,4,5-tetrahydro 1H-2-benzazepine; BS-13541; BR-76361; AJ-64016; TC-137776; DB-074526; W8089; ST24021451; FT-0707305; 4CH-000440; S-5095; 2,3,4,5-tetrahydro-1H-benzo[c]azepine, AldrichCPR
DM1RE9Q	DT	Small molecular drug
DM1RE9Q	PC	10464472
DM1RE9Q	MW	147.22
DM1RE9Q	FM	C10H13N
DM1RE9Q	IC	InChI=1S/C10H13N/c1-2-5-10-8-11-7-3-6-9(10)4-1/h1-2,4-5,11H,3,6-8H2
DM1RE9Q	CS	C1CC2=CC=CC=C2CNC1
DM1RE9Q	IK	SIQBPWRTJNBBER-UHFFFAOYSA-N
DM1RE9Q	IU	2,3,4,5-tetrahydro-1H-2-benzazepine
DM1RE9Q	CA	CAS 7216-22-0
DM1RE9Q	DE	Discovery agent

DM4EZOB	ID	DM4EZOB
DM4EZOB	DN	2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine
DM4EZOB	HS	Investigative
DM4EZOB	SN	2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine; 5946-39-4; 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine; CHEMBL323692; 1H-1,4-Benzodiazepine, 2,3,4,5-tetrahydro-; 2,3,4,5-tetrahydro-(1h)-1,4-benzodiazepine; 2,3,4,5-tetrahydro-1h benzo[e][1,4]diazepine; AC1MCKFZ; PubChem14772; ACMC-1ANOK; tetrahydrobenzo[1,4]diazepine; SCHEMBL379799; BEN206; BEN025; AC1Q1I93; KS-00001OTC; CTK1G9067; DTXSID20378071; MolPort-000-006-540; MLXBHOCKBUILHN-UHFFFAOYSA-N; ZINC2511438; STL554215; CT-889; BDBM50052888; MFCD03789577; BBL100421; AKOS005254212
DM4EZOB	DT	Small molecular drug
DM4EZOB	PC	2771762
DM4EZOB	MW	148.2
DM4EZOB	FM	C9H12N2
DM4EZOB	IC	InChI=1S/C9H12N2/c1-2-4-9-8(3-1)7-10-5-6-11-9/h1-4,10-11H,5-7H2
DM4EZOB	CS	C1CNC2=CC=CC=C2CN1
DM4EZOB	IK	MLXBHOCKBUILHN-UHFFFAOYSA-N
DM4EZOB	IU	2,3,4,5-tetrahydro-1H-1,4-benzodiazepine
DM4EZOB	CA	CAS 5946-39-4
DM4EZOB	DE	Discovery agent

DMX8NYD	ID	DMX8NYD
DMX8NYD	DN	2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole
DMX8NYD	HS	Investigative
DMX8NYD	SN	2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole; 6208-60-2; 2,3,4,5-Tetrahydro-1h-pyrido[4,3,b]indole; 1H,2H,3H,4H,5H-pyrido[4,3-b]indole; 1H-Pyrido[4,3-b]indole, 2,3,4,5-tetrahydro-; MLS001198355; 1,2,3,4-tetrahydropyridino[4,3-b]indole; SMR000559186; SR-01000530765; PubChem2433; BAS 00107381; AC1Q1GJA; AC1LF5C1; Oprea1_367545; SCHEMBL169954; CHEMBL269074; AC1Q1H88; CTK5B4311; BDBM73071; DTXSID50352329; cid_11572011; MolPort-000-928-989; RPROHCOBMVQVIV-UHFFFAOYSA-N; ALBB-007677; KS-00000E6L; STK500458; BBL010407; ANW-57714; ZINC19228212
DMX8NYD	DT	Small molecular drug
DMX8NYD	PC	723230
DMX8NYD	MW	172.23
DMX8NYD	FM	C11H12N2
DMX8NYD	IC	InChI=1S/C11H12N2/c1-2-4-10-8(3-1)9-7-12-6-5-11(9)13-10/h1-4,12-13H,5-7H2
DMX8NYD	CS	C1CNCC2=C1NC3=CC=CC=C23
DMX8NYD	IK	RPROHCOBMVQVIV-UHFFFAOYSA-N
DMX8NYD	IU	2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
DMX8NYD	CA	CAS 6208-60-2
DMX8NYD	DE	Discovery agent

DMOFG4M	ID	DMOFG4M
DMOFG4M	DN	2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine
DMOFG4M	HS	Investigative
DMOFG4M	SN	17775-01-8; 2,3,4,5-Tetrahydrobenzo[f][1,4]oxazepine; 2,3,4,5-tetrahydro-1,4-benzoxazepine; 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine; CHEMBL118420; 1,4-Benzoxazepine, 2,3,4,5-tetrahydro-; 2.3.4.5-tetrahydro-benzo[f][1,4]oxazepine; 1,4-Benzoxazepine, 2,3,4,5-tetrahydro-, hydrochloride; AC1Q1IB5; AC1Q1IB6; SCHEMBL400964; CTK4D6590; DTXSID90619367; HDVHFHONOKCUHQ-UHFFFAOYSA-N; MolPort-001-792-633; KS-00000I8M; ALBB-011885; CT-115; BDBM50052890; ZINC11802711; ANW-65610; STK897763; AKOS005173482; MCULE-4987146186; CS-W007152; BS-12101
DMOFG4M	DT	Small molecular drug
DMOFG4M	PC	21882775
DMOFG4M	MW	149.19
DMOFG4M	FM	C9H11NO
DMOFG4M	IC	InChI=1S/C9H11NO/c1-2-4-9-8(3-1)7-10-5-6-11-9/h1-4,10H,5-7H2
DMOFG4M	CS	C1COC2=CC=CC=C2CN1
DMOFG4M	IK	HDVHFHONOKCUHQ-UHFFFAOYSA-N
DMOFG4M	IU	2,3,4,5-tetrahydro-1,4-benzoxazepine
DMOFG4M	CA	CAS 17775-01-8
DMOFG4M	DE	Discovery agent

DMXAS25	ID	DMXAS25
DMXAS25	DN	2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
DMXAS25	HS	Investigative
DMXAS25	SN	2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-
DMXAS25	DT	Small molecular drug
DMXAS25	PC	4262314
DMXAS25	MW	214.26
DMXAS25	FM	C13H14N2O
DMXAS25	IC	InChI=1S/C13H14N2O/c14-13(16)10-6-3-5-9-8-4-1-2-7-11(8)15-12(9)10/h1-2,4,7,10,15H,3,5-6H2,(H2,14,16)
DMXAS25	CS	C1CC(C2=C(C1)C3=CC=CC=C3N2)C(=O)N
DMXAS25	IK	YMLOFDJHJSQCSN-UHFFFAOYSA-N
DMXAS25	IU	2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
DMXAS25	CA	CAS 352549-39-4
DMXAS25	DE	Discovery agent

DMQYEZP	ID	DMQYEZP
DMQYEZP	DN	2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol
DMQYEZP	HS	Investigative
DMQYEZP	SN	CHEMBL462942; 80246-24-8; 2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol; SCHEMBL5531128; CTK3E5867; DTXSID70475089; 2-OH-BDE-123; ZINC44386786; BDBM50292444; 2-hydroxy-2',3,4,4',5-pentabromodiphenyl ether; Phenol, 2,3,4-tribromo-6-(2,4-dibromophenoxy)-
DMQYEZP	DT	Small molecular drug
DMQYEZP	PC	11978695
DMQYEZP	MW	580.7
DMQYEZP	FM	C12H5Br5O2
DMQYEZP	IC	InChI=1S/C12H5Br5O2/c13-5-1-2-8(6(14)3-5)19-9-4-7(15)10(16)11(17)12(9)18/h1-4,18H
DMQYEZP	CS	C1=CC(=C(C=C1Br)Br)OC2=CC(=C(C(=C2O)Br)Br)Br
DMQYEZP	IK	FSIJSYKTNOYMTQ-UHFFFAOYSA-N
DMQYEZP	IU	2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol
DMQYEZP	CA	CAS 80246-24-8
DMQYEZP	DE	Discovery agent

DMCAZ32	ID	DMCAZ32
DMCAZ32	DN	2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide
DMCAZ32	HS	Investigative
DMCAZ32	SN	CHEMBL214839; 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide; BDBM50196033
DMCAZ32	DT	Small molecular drug
DMCAZ32	PC	16090303
DMCAZ32	MW	287.31
DMCAZ32	FM	C16H17NO4
DMCAZ32	IC	InChI=1S/C16H17NO4/c1-9(2)11-8-12(14(19)15(20)13(11)18)16(21)17-10-6-4-3-5-7-10/h3-9,18-20H,1-2H3,(H,17,21)
DMCAZ32	CS	CC(C)C1=CC(=C(C(=C1O)O)O)C(=O)NC2=CC=CC=C2
DMCAZ32	IK	HMVKMSUSFWLQLX-UHFFFAOYSA-N
DMCAZ32	IU	2,3,4-trihydroxy-N-phenyl-5-propan-2-ylbenzamide
DMCAZ32	DE	Discovery agent

DMWHK35	ID	DMWHK35
DMWHK35	DN	2,3,4-trihydroxybenzoic acid
DMWHK35	HS	Investigative
DMWHK35	SN	2,3,4-TRIHYDROXYBENZOIC ACID; 610-02-6; 4-Pyrogallolcarboxylic acid; Pyrogallolcarboxylic acid; 2,3,4-Trihydroxybenzoate; Pyrogallol-4-carboxylic acid; UNII-AD1ID2JF5O; Benzoic acid, trihydroxy-; Benzoic acid, 2,3,4-trihydroxy-; 2,3,4-Trihydroxybenzene carboxylic acid; EINECS 210-205-9; NSC 27436; AD1ID2JF5O; BRN 2210807; CHEMBL220779; CHEBI:88714; 2,3,4-Trihydroxybenzoic acid, 97%; AK-94172; W-105210; pyrogallolcarboxylate; trihydroxybenzoic acid; 2,4-Trihydroxybenzoate; AC1L1YC0; 2,4-Trihydroxybenzoic acid; Oprea1_870375
DMWHK35	DT	Small molecular drug
DMWHK35	PC	11874
DMWHK35	MW	170.12
DMWHK35	FM	C7H6O5
DMWHK35	IC	InChI=1S/C7H6O5/c8-4-2-1-3(7(11)12)5(9)6(4)10/h1-2,8-10H,(H,11,12)
DMWHK35	CS	C1=CC(=C(C(=C1C(=O)O)O)O)O
DMWHK35	IK	BRRSNXCXLSVPFC-UHFFFAOYSA-N
DMWHK35	IU	2,3,4-trihydroxybenzoic acid
DMWHK35	CA	CAS 610-02-6
DMWHK35	CB	CHEBI:88714
DMWHK35	DE	Discovery agent

DMPRF1X	ID	DMPRF1X
DMPRF1X	DN	2,3,4-Trimethoxy-4'-amino-trans-stilbene
DMPRF1X	HS	Investigative
DMPRF1X	SN	CHEMBL1173067; BDBM50322053
DMPRF1X	DT	Small molecular drug
DMPRF1X	PC	49799652
DMPRF1X	MW	285.34
DMPRF1X	FM	C17H19NO3
DMPRF1X	IC	InChI=1S/C17H19NO3/c1-19-15-11-8-13(16(20-2)17(15)21-3)7-4-12-5-9-14(18)10-6-12/h4-11H,18H2,1-3H3/b7-4+
DMPRF1X	CS	COC1=C(C(=C(C=C1)/C=C/C2=CC=C(C=C2)N)OC)OC
DMPRF1X	IK	YLCPSZLMRABQDV-QPJJXVBHSA-N
DMPRF1X	IU	4-[(E)-2-(2,3,4-trimethoxyphenyl)ethenyl]aniline
DMPRF1X	DE	Discovery agent

DM592YS	ID	DM592YS
DM592YS	DN	2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide
DM592YS	HS	Investigative
DM592YS	SN	2,3,5,6-TETRAFLUORO-4-METHOXY-BENZAMIDE; 2,3,5,6-tetrafluoro-4-methoxybenzamide; C8H5F4NO2; BEK; AC1LCVZS; SCHEMBL1002032; ZINC12501151; AKOS000299242
DM592YS	DT	Small molecular drug
DM592YS	PC	657081
DM592YS	MW	223.12
DM592YS	FM	C8H5F4NO2
DM592YS	IC	InChI=1S/C8H5F4NO2/c1-15-7-5(11)3(9)2(8(13)14)4(10)6(7)12/h1H3,(H2,13,14)
DM592YS	CS	COC1=C(C(=C(C(=C1F)F)C(=O)N)F)F
DM592YS	IK	JTXPTSGPUNTKSM-UHFFFAOYSA-N
DM592YS	IU	2,3,5,6-tetrafluoro-4-methoxybenzamide
DM592YS	DE	Discovery agent

DMRVYKQ	ID	DMRVYKQ
DMRVYKQ	DN	2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol
DMRVYKQ	HS	Investigative
DMRVYKQ	DT	Small molecular drug
DMRVYKQ	PC	168394
DMRVYKQ	MW	360.13
DMRVYKQ	FM	C12HF9N2O
DMRVYKQ	IC	InChI=1S/C12HF9N2O/c13-1-2(14)4(16)10(5(17)3(1)15)22-23-11-6(18)8(20)12(24)9(21)7(11)19/h24H
DMRVYKQ	CS	C1(=C(C(=C(C(=C1F)F)O)F)F)N=NC2=C(C(=C(C(=C2F)F)F)F)F
DMRVYKQ	IK	JYNSAKFWNZEUTH-UHFFFAOYSA-N
DMRVYKQ	IU	2,3,5,6-tetrafluoro-4-[(2,3,4,5,6-pentafluorophenyl)diazenyl]phenol
DMRVYKQ	CA	CAS 25593-03-7
DMRVYKQ	DE	Discovery agent

DMLI5UT	ID	DMLI5UT
DMLI5UT	DN	2,3,5-Trimethoxy-4'-amino-trans-stilbene
DMLI5UT	HS	Investigative
DMLI5UT	SN	CHEMBL1170663; BDBM50322054
DMLI5UT	DT	Small molecular drug
DMLI5UT	PC	49799657
DMLI5UT	MW	285.34
DMLI5UT	FM	C17H19NO3
DMLI5UT	IC	InChI=1S/C17H19NO3/c1-19-15-10-13(17(21-3)16(11-15)20-2)7-4-12-5-8-14(18)9-6-12/h4-11H,18H2,1-3H3/b7-4+
DMLI5UT	CS	COC1=CC(=C(C(=C1)OC)OC)/C=C/C2=CC=C(C=C2)N
DMLI5UT	IK	SRZFJBWGNUYOJJ-QPJJXVBHSA-N
DMLI5UT	IU	4-[(E)-2-(2,3,5-trimethoxyphenyl)ethenyl]aniline
DMLI5UT	DE	Discovery agent

DMCKO6T	ID	DMCKO6T
DMCKO6T	DN	2,3,7-trichloro-5-nitroquinoxaline (TNQX)
DMCKO6T	HS	Investigative
DMCKO6T	SN	5-nitro-2,3,7-trichloroquinoxaline; 72558-70-4; 2,3,7-trichloro-5-nitroquinoxaline
DMCKO6T	DT	Small molecular drug
DMCKO6T	PC	10378848
DMCKO6T	MW	278.5
DMCKO6T	FM	C8H2Cl3N3O2
DMCKO6T	IC	InChI=1S/C8H2Cl3N3O2/c9-3-1-4-6(5(2-3)14(15)16)13-8(11)7(10)12-4/h1-2H
DMCKO6T	CS	C1=C(C=C(C2=C1N=C(C(=N2)Cl)Cl)[N+](=O)[O-])Cl
DMCKO6T	IK	DUBINERALUDRHX-UHFFFAOYSA-N
DMCKO6T	IU	2,3,7-trichloro-5-nitroquinoxaline
DMCKO6T	DE	Discovery agent

DMOB7P6	ID	DMOB7P6
DMOB7P6	DN	2',3'-ddATP
DMOB7P6	HS	Investigative
DMOB7P6	SN	2',3'-Dideoxyadenosine triphosphate; ddATP; UNII-9MCI2H1EJ6; 2',3'-dideoxyadenosine-5'-triphosphate; 24027-80-3; dideoxyadenosine triphosphate; CHEMBL1383; 9MCI2H1EJ6; 2',3'-DIDEOXYADENOSINE 5'-TRIPHOSPHATE; Adenosine 5'-(tetrahydrogen triphosphate), 2',3'-dideoxy-; 2',3'-Dideoxy-ATP; ddA-TP; ATP,2',3'-dideoxy; SCHEMBL79815; GTPL1709; AC1L230G; DTXSID90178767; MolPort-044-561-436; ZINC12501706; BDBM50164644; AKOS030589611; 2'',3''-dideoxyadenosine triphosphate; DB02189; 2',3'-Dideoxyadenosine-5-triphosphate; 2',3'-Dideoxyadenosine Triphosphate (Ddatp)
DMOB7P6	DT	Small molecular drug
DMOB7P6	PC	65304
DMOB7P6	MW	475.18
DMOB7P6	FM	C10H16N5O11P3
DMOB7P6	IC	InChI=1S/C10H16N5O11P3/c11-9-8-10(13-4-12-9)15(5-14-8)7-2-1-6(24-7)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h4-7H,1-3H2,(H,19,20)(H,21,22)(H2,11,12,13)(H2,16,17,18)/t6-,7+/m0/s1
DMOB7P6	CS	C1C[C@@H](O[C@@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N2C=NC3=C(N=CN=C32)N
DMOB7P6	IK	OAKPWEUQDVLTCN-NKWVEPMBSA-N
DMOB7P6	IU	[[(2S,5R)-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMOB7P6	CA	CAS 24027-80-3
DMOB7P6	DE	Discovery agent

DM2UWDR	ID	DM2UWDR
DM2UWDR	DN	2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene
DM2UWDR	HS	Investigative
DM2UWDR	SN	SCHEMBL4220471
DM2UWDR	DT	Small molecular drug
DM2UWDR	PC	16090839
DM2UWDR	MW	330.4
DM2UWDR	FM	C18H22N2O4
DM2UWDR	IC	InChI=1S/C18H22N2O4/c1-21-14-8-6-11(9-13(14)19)5-7-12-10-15(22-2)17(23-3)18(24-4)16(12)20/h5-10H,19-20H2,1-4H3/b7-5-
DM2UWDR	CS	COC1=C(C=C(C=C1)/C=C\\C2=CC(=C(C(=C2N)OC)OC)OC)N
DM2UWDR	IK	ONFPNROXTUMLBU-ALCCZGGFSA-N
DM2UWDR	IU	6-[(Z)-2-(3-amino-4-methoxyphenyl)ethenyl]-2,3,4-trimethoxyaniline
DM2UWDR	DE	Discovery agent

DMPCGSD	ID	DMPCGSD
DMPCGSD	DN	2,3-dichloro-1,4-naphthoquinone
DMPCGSD	HS	Investigative
DMPCGSD	SN	2,3-Dichloro-1,4-naphthoquinone; 117-80-6; DICHLONE; 2,3-dichloronaphthalene-1,4-dione; Diclone; 2,3-Dichloronaphthoquinone; Phygon; Uniroyal; Sanquinon; Algistat; Phygon paste; Dichloronaphthoquinone; Phygon XL; Quintar; Compound 604; 1,4-Naphthalenedione, 2,3-dichloro-; Phygon seed protectant; U.s. rubber 604; Quintar 540F; Dichlon; USR 604; 2,3-Dichloro-1,4-naphthaquinone; 2,3-Dichloro-1,4-naphthalenedione; Caswell No. 298; ENT 3,776; 1,4-Naphthoquinone, 2,3-dichloro-; US Rubber 604; Latka 604; Dichlone [BSI:ISO]; Latka 604 [Czech]
DMPCGSD	DT	Small molecular drug
DMPCGSD	PC	8342
DMPCGSD	MW	227.04
DMPCGSD	FM	C10H4Cl2O2
DMPCGSD	IC	InChI=1S/C10H4Cl2O2/c11-7-8(12)10(14)6-4-2-1-3-5(6)9(7)13/h1-4H
DMPCGSD	CS	C1=CC=C2C(=C1)C(=O)C(=C(C2=O)Cl)Cl
DMPCGSD	IK	SVPKNMBRVBMTLB-UHFFFAOYSA-N
DMPCGSD	IU	2,3-dichloronaphthalene-1,4-dione
DMPCGSD	CA	CAS 117-80-6
DMPCGSD	DE	Discovery agent

DM6SBPI	ID	DM6SBPI
DM6SBPI	DN	2,3-Didehydroalanine
DM6SBPI	HS	Investigative
DM6SBPI	SN	dehydroalanine; 2-aminoacrylic acid; 2-Aminoacrylate; 2,3-DIDEHYDROALANINE; 1948-56-7; alpha,beta-Dehydroalanine; alpha-Aminoacrylate; 2-aminoprop-2-enoic acid; 2-aminoprop-2-enoate; UNII-98RA387EKY; 2-AMINO-ACRYLIC ACID; 98RA387EKY; a-b-di-dehydroalanine; 2-ammonioprop-2-enoate; AC1L3XOY; alpha-beta-di-dehydroalanine; 2-Propenoic acid,2-amino-; 2-Propenoic acid, 2-amino-; CHEBI:76565; CHEBI:17123; CTK4E1639; DTXSID90173131; UQBOJOOOTLPNST-UHFFFAOYSA-N; (alpha)-(beta)-di-dehydroalanine; anhydroserine 2-aminopropenoic acid
DM6SBPI	DT	Small molecular drug
DM6SBPI	PC	123991
DM6SBPI	MW	87.08
DM6SBPI	FM	C3H5NO2
DM6SBPI	IC	InChI=1S/C3H5NO2/c1-2(4)3(5)6/h1,4H2,(H,5,6)
DM6SBPI	CS	C=C(C(=O)O)N
DM6SBPI	IK	UQBOJOOOTLPNST-UHFFFAOYSA-N
DM6SBPI	IU	2-aminoprop-2-enoic acid
DM6SBPI	CA	CAS 1948-56-7
DM6SBPI	CB	CHEBI:17123
DM6SBPI	DE	Discovery agent

DMCXR4M	ID	DMCXR4M
DMCXR4M	DN	2',3'-Dideoxycytidine-5'-Monophosphate
DMCXR4M	HS	Investigative
DMCXR4M	SN	104086-76-2; ((2S,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl dihydrogen phosphate; 5'-Cytidylic acid, 2',3'-dideoxy-; ddCMP; 2',3'-DIDEOXYCYTIDINE-5'-MONOPHOSPHATE; BRN 0556994; 2',3'-Dideoxycytidine 5'-monophosphate; CHEMBL1232305; C9H14N3O6P; [(2S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate; AC1L9JZG; SCHEMBL454264; dideoxycytidine 5'-monophosphate; ZINC1611080; 0954AA; BDBM50349537; AKOS016009455; DB02883; LS-59086; AJ-28234; AK112219; KB-204945; AX8123167
DMCXR4M	DT	Small molecular drug
DMCXR4M	PC	446696
DMCXR4M	MW	291.2
DMCXR4M	FM	C9H14N3O6P
DMCXR4M	IC	InChI=1S/C9H14N3O6P/c10-7-3-4-12(9(13)11-7)8-2-1-6(18-8)5-17-19(14,15)16/h3-4,6,8H,1-2,5H2,(H2,10,11,13)(H2,14,15,16)/t6-,8+/m0/s1
DMCXR4M	CS	C1C[C@@H](O[C@@H]1COP(=O)(O)O)N2C=CC(=NC2=O)N
DMCXR4M	IK	RAJMXAZJKUGYGW-POYBYMJQSA-N
DMCXR4M	IU	[(2S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMCXR4M	CA	CAS 104086-76-2
DMCXR4M	DE	Discovery agent

DMEQXUD	ID	DMEQXUD
DMEQXUD	DN	2',3'-Dideoxythymidine-5'-Monophosphate
DMEQXUD	HS	Investigative
DMEQXUD	SN	ddTMP; 5'-Thymidylic acid, 3'-deoxy-; 2',3'-DIDEOXYTHYMIDINE-5'-MONOPHOSPHATE; 3'-DEOXYTHYMIDINE-5'-MONOPHOSPHATE; [(2s,5r)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate; 3715-64-8; 2DT; 3'-Deoxy-5'-thymidylic acid; AC1Q69EO; AC1L4W6C; 3-Deoxy-5-thymidylic acid; SCHEMBL8883; deoxy-thymidine monophosphate; CHEMBL1229914; CTK4H7825; DTXSID20190634; ZINC1610269; DB03150; 2',3'-Dideoxythymidine-5'-monophosphate disodium salt
DMEQXUD	DT	Small molecular drug
DMEQXUD	PC	165151
DMEQXUD	MW	306.21
DMEQXUD	FM	C10H15N2O7P
DMEQXUD	IC	InChI=1S/C10H15N2O7P/c1-6-4-12(10(14)11-9(6)13)8-3-2-7(19-8)5-18-20(15,16)17/h4,7-8H,2-3,5H2,1H3,(H,11,13,14)(H2,15,16,17)/t7-,8+/m0/s1
DMEQXUD	CS	CC1=CN(C(=O)NC1=O)[C@H]2CC[C@H](O2)COP(=O)(O)O
DMEQXUD	IK	WVNRRNJFRREKAR-JGVFFNPUSA-N
DMEQXUD	IU	[(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMEQXUD	CA	CAS 3715-64-8
DMEQXUD	DE	Discovery agent

DMJB7W1	ID	DMJB7W1
DMJB7W1	DN	2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide
DMJB7W1	HS	Investigative
DMJB7W1	SN	2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide; GTPL3486; SCHEMBL10948770; 5,6-Dihydro-1,4-dithiin-1,1,4,4-tetraoxide; 2,3-dihydro-1,4-dithiine 1,1,4,4-tetraoxide
DMJB7W1	DT	Small molecular drug
DMJB7W1	PC	20549618
DMJB7W1	MW	182.2
DMJB7W1	FM	C4H6O4S2
DMJB7W1	IC	InChI=1S/C4H6O4S2/c5-9(6)1-2-10(7,8)4-3-9/h1-2H,3-4H2
DMJB7W1	CS	C1CS(=O)(=O)C=CS1(=O)=O
DMJB7W1	IK	YNEKVCMDWXAQGQ-UHFFFAOYSA-N
DMJB7W1	IU	2,3-dihydro-1,4-dithiine 1,1,4,4-tetraoxide
DMJB7W1	DE	Discovery agent

DMB3WI8	ID	DMB3WI8
DMB3WI8	DN	2,3-dihydro-1H-benzo[de]isoquinolin-1-one
DMB3WI8	HS	Investigative
DMB3WI8	SN	CHEMBL594596; 2,3-dihydro-benzo[de]isoquinolin-1-one; 2,3-dihydro-1H-benzo[de]isoquinolin-1-one; SCHEMBL832168; ZINC24216; BDBM50306285; FCH1866210
DMB3WI8	DT	Small molecular drug
DMB3WI8	PC	10130246
DMB3WI8	MW	183.21
DMB3WI8	FM	C12H9NO
DMB3WI8	IC	InChI=1S/C12H9NO/c14-12-10-6-2-4-8-3-1-5-9(7-13-12)11(8)10/h1-6H,7H2,(H,13,14)
DMB3WI8	CS	C1C2=CC=CC3=C2C(=CC=C3)C(=O)N1
DMB3WI8	IK	QGJHNXPHHOCUAH-UHFFFAOYSA-N
DMB3WI8	IU	2,3-dihydrobenzo[de]isoquinolin-1-one
DMB3WI8	DE	Discovery agent

DM46MKY	ID	DM46MKY
DM46MKY	DN	2,3-dihydro-1H-indene-5-sulfonamide
DM46MKY	HS	Investigative
DM46MKY	SN	Indane-5-sulfonamide; indane-5-sulfonamide; 35203-93-1; Indan-5-sulphonamide; Indan-5-sulfonic acid amide; 5-Indansulfonamide; CHEMBL364869; 2,3-dihydro-5-indenylsulfonamide; 2qoa; 5-indanesulfonamide; NSC91508; EINECS 252-432-6; indan-5-sulfonamide; AC1L3XER; AC1Q6UJV; AC1Q55FD; AC1Q55FC; SCHEMBL2011443; CTK7F2159; DTXSID40188710; MolPort-001-845-197; XVQJTFMKKZBBSX-UHFFFAOYSA-N; ZINC394620; HMS3604H17; 1295AE; NSC-91508; BDBM50155556; AKOS000141119; AS-8808; MCULE-2518558267; DB08165; NE29982;  Indan-5-sulfonic acid amide
DM46MKY	DT	Small molecular drug
DM46MKY	PC	96876
DM46MKY	MW	197.26
DM46MKY	FM	C9H11NO2S
DM46MKY	IC	InChI=1S/C9H11NO2S/c10-13(11,12)9-5-4-7-2-1-3-8(7)6-9/h4-6H,1-3H2,(H2,10,11,12)
DM46MKY	CS	C1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DM46MKY	IK	XVQJTFMKKZBBSX-UHFFFAOYSA-N
DM46MKY	IU	2,3-dihydro-1H-indene-5-sulfonamide
DM46MKY	CA	CAS 35203-93-1
DM46MKY	DE	Discovery agent

DM3URJG	ID	DM3URJG
DM3URJG	DN	2,3-Dihydro-1H-indol-5-ol
DM3URJG	HS	Investigative
DM3URJG	SN	Indolin-5-ol; 172078-33-0; 2,3-dihydro-1H-indol-5-ol; 2,3-Dihydroindol-5-ol; 1H-Indol-5-ol,2,3-dihydro-; CHEMBL19331; AK-60844; 5-Indolinol; 5-hydroxyindoline; SCHEMBL59263; 2,3-Dihydro-1H-indole-5-ol; 2,3-dihydro-1 H-indol-5-ol; CTK4D4118; DTXSID40434426; MolPort-000-003-182; MPCXQPXCYDDJSR-UHFFFAOYSA-N; 1H-Indol-5-ol, 2,3-dihydro-; 5-hydroxy-2,3-dihydro-1H-indole; KS-00000ML8; ZINC13462664; FCH845722; 8845AA; BDBM50291681; ANW-58857; AKOS006279674; CS-W007244; CHM0007709; AJ-63836; SC-26235; 1H-INDOL-5-OL,2,3-DIHYDRO-,; KB-12380
DM3URJG	DT	Small molecular drug
DM3URJG	PC	10034684
DM3URJG	MW	135.16
DM3URJG	FM	C8H9NO
DM3URJG	IC	InChI=1S/C8H9NO/c10-7-1-2-8-6(5-7)3-4-9-8/h1-2,5,9-10H,3-4H2
DM3URJG	CS	C1CNC2=C1C=C(C=C2)O
DM3URJG	IK	MPCXQPXCYDDJSR-UHFFFAOYSA-N
DM3URJG	IU	2,3-dihydro-1H-indol-5-ol
DM3URJG	CA	CAS 172078-33-0
DM3URJG	DE	Discovery agent

DMWI9XS	ID	DMWI9XS
DMWI9XS	DN	2,3-Dihydro-1H-isoindole
DMWI9XS	HS	Investigative
DMWI9XS	SN	Isoindoline; 496-12-8; 2,3-dihydro-1H-isoindole; 1H-Isoindole, 2,3-dihydro-; Isoindoline, 97%; CHEMBL118475; GWVMLCQWXVFZCN-UHFFFAOYSA-N; iso-indoline; 2-Azaindan; 1,3-dihydroisoindole; 1,2-dihydroisoindole; PubChem16248; ACMC-1AM9E; AC1Q1IE0; AC1L9MF9; 1,3-dihydro-2H-isoindole; SCHEMBL10612; KSC222C5F; SCHEMBL2764305; CTK1C2152; MolPort-000-165-448; KS-000013BD; BCP01139; ACN-S003606; ZINC4111883; ACN-S001460; ANW-30800; STK077165; BDBM50052887; AN-716; BBL000565; AKOS000283835; TRA0077123; RTC-060566; CM10320; MB01342
DMWI9XS	DT	Small molecular drug
DMWI9XS	PC	422478
DMWI9XS	MW	119.16
DMWI9XS	FM	C8H9N
DMWI9XS	IC	InChI=1S/C8H9N/c1-2-4-8-6-9-5-7(8)3-1/h1-4,9H,5-6H2
DMWI9XS	CS	C1C2=CC=CC=C2CN1
DMWI9XS	IK	GWVMLCQWXVFZCN-UHFFFAOYSA-N
DMWI9XS	IU	2,3-dihydro-1H-isoindole
DMWI9XS	CA	CAS 496-12-8
DMWI9XS	DE	Discovery agent

DMUW94S	ID	DMUW94S
DMUW94S	DN	2,3-dihydrobenzo[d]thiazole-2-thiol
DMUW94S	HS	Investigative
DMUW94S	SN	CHEMBL570797; 2,3-dihydrobenzothiazole-2-thiol; 2,3-dihydrobenzo[d]thiazole-2-thiol; 2,3-dihydro-1,3-benzothiazole-2-thiol; AC1MMT8Q; 2-benzo[d]thiazolinethiol; 2(3H)-Benzothiazolethiol; SCHEMBL1405549; BDBM50303907; AKOS006278847; 94495-79-1
DMUW94S	DT	Small molecular drug
DMUW94S	PC	3266369
DMUW94S	MW	169.3
DMUW94S	FM	C7H7NS2
DMUW94S	IC	InChI=1S/C7H7NS2/c9-7-8-5-3-1-2-4-6(5)10-7/h1-4,7-9H
DMUW94S	CS	C1=CC=C2C(=C1)NC(S2)S
DMUW94S	IK	PYVUUPVBIDIYPY-UHFFFAOYSA-N
DMUW94S	IU	2,3-dihydro-1,3-benzothiazole-2-thiol
DMUW94S	DE	Discovery agent

DMYHFUO	ID	DMYHFUO
DMYHFUO	DN	2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine
DMYHFUO	HS	Investigative
DMYHFUO	SN	CHEMBL214856; 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine; SCHEMBL3385589; Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 2,3-dihydro-; BDBM50194096; 745837-16-5
DMYHFUO	DT	Small molecular drug
DMYHFUO	PC	21094663
DMYHFUO	MW	185.22
DMYHFUO	FM	C11H11N3
DMYHFUO	IC	InChI=1S/C11H11N3/c12-11-8-4-1-2-5-9(8)13-10-6-3-7-14(10)11/h1-2,4-5,12H,3,6-7H2
DMYHFUO	CS	C1CC2=NC3=CC=CC=C3C(=N)N2C1
DMYHFUO	IK	AOSPPBURKIEYRC-UHFFFAOYSA-N
DMYHFUO	IU	2,3-dihydro-1H-pyrrolo[2,1-b]quinazolin-9-imine
DMYHFUO	DE	Discovery agent

DMOWNB4	ID	DMOWNB4
DMOWNB4	DN	2,3-dihydroxypropanal
DMOWNB4	HS	Investigative
DMOWNB4	SN	DL-Glyceraldehyde; glyceraldehyde; 2,3-Dihydroxypropanal; Glyceric aldehyde; Glycerose; Glycerinaldehyde; Glycerinformal; 56-82-6; Propanal, 2,3-dihydroxy-; 2,3-Dihydroxypropionaldehyde; DL-GLYC; Aldotriose; alpha,beta-dihydroxypropionaldehyde; 367-47-5; Glyceraldehyde, (+-)-; Propionaldehyde, 2,3-dihydroxy-; aldose; U 1188; D,L-glyceraldehyde; NSC 67934; BRN 0635844; AI3-24475; (+/-)-Glyceraldehyde; EINECS 206-695-9; EINECS 200-290-0; DLG; .alpha.,.beta.-Dihydroxypropionaldehyde; 2,3-dihydroxy-propionaldehyde; CHEBI:5445
DMOWNB4	DT	Small molecular drug
DMOWNB4	PC	751
DMOWNB4	MW	90.08
DMOWNB4	FM	C3H6O3
DMOWNB4	IC	InChI=1S/C3H6O3/c4-1-3(6)2-5/h1,3,5-6H,2H2
DMOWNB4	CS	C(C(C=O)O)O
DMOWNB4	IK	MNQZXJOMYWMBOU-UHFFFAOYSA-N
DMOWNB4	IU	2,3-dihydroxypropanal
DMOWNB4	CA	CAS 56-82-6
DMOWNB4	CB	CHEBI:5445
DMOWNB4	DE	Discovery agent

DML92OK	ID	DML92OK
DML92OK	DN	2,3-dimethoxy-2'-hydroxychalcone
DML92OK	HS	Investigative
DML92OK	SN	2'-HYDROXY-2,3-DIMETHOXYCHALCONE; AC1NQ7LG; CTK4I5873; CTK1B1409; 3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; MCULE-6103350400; FT-0772376; 2-Propen-1-one, 3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)-, (2E)-
DML92OK	DT	Small molecular drug
DML92OK	PC	6296545
DML92OK	MW	284.31
DML92OK	FM	C17H16O4
DML92OK	IC	InChI=1S/C17H16O4/c1-20-16-9-5-6-12(17(16)21-2)10-11-15(19)13-7-3-4-8-14(13)18/h3-11,18H,1-2H3/b11-10+
DML92OK	CS	COC1=CC=CC(=C1OC)/C=C/C(=O)C2=CC=CC=C2O
DML92OK	IK	HKKXNGSRSNONCJ-ZHACJKMWSA-N
DML92OK	IU	(E)-3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
DML92OK	DE	Discovery agent

DM9C0YZ	ID	DM9C0YZ
DM9C0YZ	DN	2,3-Dimethoxy-4'-amino-trans-stilbene
DM9C0YZ	HS	Investigative
DM9C0YZ	SN	CHEMBL1173700; BDBM50322050
DM9C0YZ	DT	Small molecular drug
DM9C0YZ	PC	49799640
DM9C0YZ	MW	255.31
DM9C0YZ	FM	C16H17NO2
DM9C0YZ	IC	InChI=1S/C16H17NO2/c1-18-15-5-3-4-13(16(15)19-2)9-6-12-7-10-14(17)11-8-12/h3-11H,17H2,1-2H3/b9-6+
DM9C0YZ	CS	COC1=CC=CC(=C1OC)/C=C/C2=CC=C(C=C2)N
DM9C0YZ	IK	WSPBGPLITZFWJL-RMKNXTFCSA-N
DM9C0YZ	IU	4-[(E)-2-(2,3-dimethoxyphenyl)ethenyl]aniline
DM9C0YZ	DE	Discovery agent

DMEB47J	ID	DMEB47J
DMEB47J	DN	2,3-Dimethoxybenzo[i]phenanthridines
DMEB47J	HS	Investigative
DMEB47J	DT	Small molecular drug
DMEB47J	PC	56603740
DMEB47J	DE	Discovery agent

DMGXVBA	ID	DMGXVBA
DMGXVBA	DN	2,3-DIMETHYL-1,4-NAPHTHOQUINONE
DMGXVBA	HS	Investigative
DMGXVBA	SN	2,3-Dimethyl-1,4-naphthoquinone; 2,3-Dimethylnaphthoquinone; USAF SN-29; 2197-57-1; 1,4-Naphthalenedione, 2,3-dimethyl-; 2,3-dimethylnaphthalene-1,4-dione; UNII-SY9IO0B44O; SY9IO0B44O; 1,4-NAPHTHOQUINONE, 2,3-DIMETHYL-; NSC 36460; BRN 2044697; AI3-16112; 2,3-dimethyl-1,4-dihydronaphthalene-1,4-dione; AC1L28BU; AC1Q2DM1; SCHEMBL571026; CHEMBL354201; CTK4E8092; DTXSID50176380; MolPort-001-817-681; LGFDNUSAWCHVJN-UHFFFAOYSA-N; HMS1666O12; NSC36460; ZINC3063275; WLN: L66 BV EVJ C1 D1; 2,3-Dimethyl-[1,4]naphthoquinone; NSC-36460
DMGXVBA	DT	Small molecular drug
DMGXVBA	PC	16615
DMGXVBA	MW	186.21
DMGXVBA	FM	C12H10O2
DMGXVBA	IC	InChI=1S/C12H10O2/c1-7-8(2)12(14)10-6-4-3-5-9(10)11(7)13/h3-6H,1-2H3
DMGXVBA	CS	CC1=C(C(=O)C2=CC=CC=C2C1=O)C
DMGXVBA	IK	LGFDNUSAWCHVJN-UHFFFAOYSA-N
DMGXVBA	IU	2,3-dimethylnaphthalene-1,4-dione
DMGXVBA	CA	CAS 2197-57-1
DMGXVBA	DE	Discovery agent

DMKV9EZ	ID	DMKV9EZ
DMKV9EZ	DN	2,3-Dimethylnaphtho[2,3-f]quinoxaline-7,12-dione
DMKV9EZ	HS	Investigative
DMKV9EZ	SN	2,3-Dimethylnaphtho[2,3-f]quinoxaline-7,12-dione; 89986-91-4; Naphtho[2,3-f]quinoxaline-7,12-dione, 2,3-dimethyl-; ACMC-20lsfz; SCHEMBL3505034; CHEMBL604342; CTK2I7956; DTXSID80658048
DMKV9EZ	DT	Small molecular drug
DMKV9EZ	PC	44251290
DMKV9EZ	MW	288.3
DMKV9EZ	FM	C18H12N2O2
DMKV9EZ	IC	InChI=1S/C18H12N2O2/c1-9-10(2)20-16-14(19-9)8-7-13-15(16)18(22)12-6-4-3-5-11(12)17(13)21/h3-8H,1-2H3
DMKV9EZ	CS	CC1=C(N=C2C(=N1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O)C
DMKV9EZ	IK	WDHCRURNPCZZII-UHFFFAOYSA-N
DMKV9EZ	IU	2,3-dimethylnaphtho[3,2-f]quinoxaline-7,12-dione
DMKV9EZ	CA	CAS 89986-91-4
DMKV9EZ	DE	Discovery agent

DM8C43L	ID	DM8C43L
DM8C43L	DN	2,3-dioxoindoline-7-carboxylic acid
DM8C43L	HS	Investigative
DM8C43L	SN	2,3-dioxoindoline-7-carboxylic acid; 25128-35-2; Isatin-7-carboxylic acid; 2,3-DIOXO-2,3-DIHYDRO-1H-INDOLE-7-CARBOXYLIC ACID; 2,3-dioxo-1H-indole-7-carboxylic Acid; CHEMBL375078; 1H-INDOLE-7-CARBOXYLIC ACID, 2,3-DIHYDRO-2,3-DIOXO-; 2,3-dioxo-1H-benzo[d]azolidine-7-carboxylic acid; 2,3-Dioxoindoline-7-carboxylicacid; 7-isatincarboxylic acid; PubChem24310; AC1MCVF6; Isatin-based compound, 46; AC1Q72QN; SCHEMBL1742133; BDBM22826; CTK1A1532; DTXSID00381427; ROODQCZSWXEDJL-UHFFFAOYSA-N; MolPort-000-144-864; ZINC2496760; KS-00000FO0
DM8C43L	DT	Small molecular drug
DM8C43L	PC	2779383
DM8C43L	MW	191.14
DM8C43L	FM	C9H5NO4
DM8C43L	IC	InChI=1S/C9H5NO4/c11-7-4-2-1-3-5(9(13)14)6(4)10-8(7)12/h1-3H,(H,13,14)(H,10,11,12)
DM8C43L	CS	C1=CC2=C(C(=C1)C(=O)O)NC(=O)C2=O
DM8C43L	IK	ROODQCZSWXEDJL-UHFFFAOYSA-N
DM8C43L	IU	2,3-dioxo-1H-indole-7-carboxylic acid
DM8C43L	CA	CAS 25128-35-2
DM8C43L	DE	Discovery agent

DMC3UYH	ID	DMC3UYH
DMC3UYH	DN	2,3-diphenyl-1H-indole
DMC3UYH	HS	Investigative
DMC3UYH	SN	2,3-Diphenylindole; 2,3-Diphenyl-1H-indole; 3469-20-3; 1H-Indole, 2,3-diphenyl-; CHEMBL200719; GYGKJNGSQQORRG-UHFFFAOYSA-N; Indole, 2,3-diphenyl-; NSC17363; EINECS 222-432-0; Indole,3-diphenyl-; Cyto5A2; AC1Q1HUE; 1H-Indole,3-diphenyl-; AC1Q4W1P; AC1L2S6L; Oprea1_738570; 2,3-Diphenyl-1H-indole #; SCHEMBL3864662; CTK1C3291; KS-00000FNK; DTXSID50188241; MolPort-001-804-408; ZINC1036850; STK080838; BDBM50175411; RW3400; NSC-17363; CCG-46312; AKOS001022174; ACM3469203; MCULE-8938765915; VI30149; ACN-036136; 7J-655S; QC-2111; CC-07034; AK-81890
DMC3UYH	DT	Small molecular drug
DMC3UYH	PC	77020
DMC3UYH	MW	269.3
DMC3UYH	FM	C20H15N
DMC3UYH	IC	InChI=1S/C20H15N/c1-3-9-15(10-4-1)19-17-13-7-8-14-18(17)21-20(19)16-11-5-2-6-12-16/h1-14,21H
DMC3UYH	CS	C1=CC=C(C=C1)C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DMC3UYH	IK	GYGKJNGSQQORRG-UHFFFAOYSA-N
DMC3UYH	IU	2,3-diphenyl-1H-indole
DMC3UYH	CA	CAS 3469-20-3
DMC3UYH	DE	Discovery agent

DMI2PY7	ID	DMI2PY7
DMI2PY7	DN	2,4,3',5'-tetrahydroxybibenzyl
DMI2PY7	HS	Investigative
DMI2PY7	SN	CHEMBL221291; 2,4,3',5'-tetrahydroxybibenzyl; SCHEMBL19433107; BDBM50193667; 2,4,3'',5''-tetrahydroxybibenzyl; 4-[2-(3,5-dihydroxyphenyl)ethyl]benzene-1,3-diol
DMI2PY7	DT	Small molecular drug
DMI2PY7	PC	16126762
DMI2PY7	MW	246.26
DMI2PY7	FM	C14H14O4
DMI2PY7	IC	InChI=1S/C14H14O4/c15-11-4-3-10(14(18)8-11)2-1-9-5-12(16)7-13(17)6-9/h3-8,15-18H,1-2H2
DMI2PY7	CS	C1=CC(=C(C=C1O)O)CCC2=CC(=CC(=C2)O)O
DMI2PY7	IK	IEOZKGCYMAJAHS-UHFFFAOYSA-N
DMI2PY7	IU	4-[2-(3,5-dihydroxyphenyl)ethyl]benzene-1,3-diol
DMI2PY7	DE	Discovery agent

DMS8I1E	ID	DMS8I1E
DMS8I1E	DN	2,4,4-triphenylimidazoline
DMS8I1E	HS	Investigative
DMS8I1E	SN	2,4,4-triphenylimidazoline; CHEMBL493970; SCHEMBL4463957; BDBM50257786
DMS8I1E	DT	Small molecular drug
DMS8I1E	PC	22054806
DMS8I1E	MW	298.4
DMS8I1E	FM	C21H18N2
DMS8I1E	IC	InChI=1S/C21H18N2/c1-4-10-17(11-5-1)20-22-16-21(23-20,18-12-6-2-7-13-18)19-14-8-3-9-15-19/h1-15H,16H2,(H,22,23)
DMS8I1E	CS	C1C(NC(=N1)C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMS8I1E	IK	KXSXOHNHKQJMNF-UHFFFAOYSA-N
DMS8I1E	IU	2,5,5-triphenyl-1,4-dihydroimidazole
DMS8I1E	DE	Discovery agent

DMSJBEH	ID	DMSJBEH
DMSJBEH	DN	2,4,5-Triarylimidazole analogue
DMSJBEH	HS	Investigative
DMSJBEH	SN	CHEMBL16925; 2,4,5-Triarylimidazole analogue; SCHEMBL5137478; JVMAHSCWJIZBJE-UHFFFAOYSA-N; BDBM50284516; N-Hydroxy-N-[1-[4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1H-imidazol-2-yl]phenyl]ethyl]urea
DMSJBEH	DT	Small molecular drug
DMSJBEH	PC	18771543
DMSJBEH	MW	417.4
DMSJBEH	FM	C23H20FN5O2
DMSJBEH	IC	InChI=1S/C23H20FN5O2/c1-14(29(31)23(25)30)15-2-4-18(5-3-15)22-27-20(16-6-8-19(24)9-7-16)21(28-22)17-10-12-26-13-11-17/h2-14,31H,1H3,(H2,25,30)(H,27,28)
DMSJBEH	CS	CC(C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)N(C(=O)N)O
DMSJBEH	IK	JVMAHSCWJIZBJE-UHFFFAOYSA-N
DMSJBEH	IU	1-[1-[4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenyl]ethyl]-1-hydroxyurea
DMSJBEH	DE	Discovery agent

DMTA152	ID	DMTA152
DMTA152	DN	2,4,6 trinitrobenzene sulfonate 1,3-bis (2-chlorethyl)-1-nitrosourea
DMTA152	HS	Investigative
DMTA152	DT	Small molecular drug
DMTA152	PC	56603741
DMTA152	MW	507.2
DMTA152	FM	C11H12Cl2N6O11S
DMTA152	IC	InChI=1S/C6H3N3O9S.C5H9Cl2N3O2/c10-7(11)3-1-4(8(12)13)6(19(16,17)18)5(2-3)9(14)15;6-1-3-8-5(11)10(9-12)4-2-7/h1-2H,(H,16,17,18);1-4H2,(H,8,11)
DMTA152	CS	C1=C(C=C(C(=C1[N+](=O)[O-])S(=O)(=O)[O-])[N+](=O)[O-])[N+](=O)[O-].C(CCl)[NH2+]C(=O)N(CCCl)N=O
DMTA152	IK	LMBKFJAIRIBNHB-UHFFFAOYSA-N
DMTA152	IU	2-chloroethyl-[2-chloroethyl(nitroso)carbamoyl]azanium;2,4,6-trinitrobenzenesulfonate
DMTA152	DE	Discovery agent

DMTVL9N	ID	DMTVL9N
DMTVL9N	DN	2,4,6-Trihydroxy-3-nitro-N-tridecyl-benzamide
DMTVL9N	HS	Investigative
DMTVL9N	SN	CHEMBL175532; 2,4,6-Trihydroxy-3-nitro-N-tridecyl-benzamide; Benzamide, 2,4,6-trihydroxy-3-nitro-N-tridecyl-; 126395-25-3; ACMC-20mryy; RD34082; AC1LA66U; SCHEMBL12902000; CTK0F6648; DTXSID50333097; BDBM50158817; AKOS030576830; RD-3-4082
DMTVL9N	DT	Small molecular drug
DMTVL9N	PC	482191
DMTVL9N	MW	396.5
DMTVL9N	FM	C20H32N2O6
DMTVL9N	IC	InChI=1S/C20H32N2O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-21-20(26)17-15(23)14-16(24)18(19(17)25)22(27)28/h14,23-25H,2-13H2,1H3,(H,21,26)
DMTVL9N	CS	CCCCCCCCCCCCCNC(=O)C1=C(C(=C(C=C1O)O)[N+](=O)[O-])O
DMTVL9N	IK	MSWMANFKQVMQAR-UHFFFAOYSA-N
DMTVL9N	IU	2,4,6-trihydroxy-3-nitro-N-tridecylbenzamide
DMTVL9N	CA	CAS 126395-25-3
DMTVL9N	DE	Discovery agent

DM90TSI	ID	DM90TSI
DM90TSI	DN	2,4-bis-docosanoylamino-benzenesulfonate
DM90TSI	HS	Investigative
DM90TSI	SN	CHEMBL96329
DM90TSI	DT	Small molecular drug
DM90TSI	PC	44327149
DM90TSI	MW	855.3
DM90TSI	FM	C50H91N2NaO5S
DM90TSI	IC	InChI=1S/C50H92N2O5S.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39-41-49(53)51-46-43-44-48(58(55,56)57)47(45-46)52-50(54)42-40-38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h43-45H,3-42H2,1-2H3,(H,51,53)(H,52,54)(H,55,56,57);/q;+1/p-1
DM90TSI	CS	CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=CC(=C(C=C1)S(=O)(=O)[O-])NC(=O)CCCCCCCCCCCCCCCCCCCCC.[Na+]
DM90TSI	IK	IXCBRSKAYDVLLF-UHFFFAOYSA-M
DM90TSI	IU	sodium;2,4-bis(docosanoylamino)benzenesulfonate
DM90TSI	DE	Discovery agent

DMZO0EI	ID	DMZO0EI
DMZO0EI	DN	2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid
DMZO0EI	HS	Investigative
DMZO0EI	SN	2,4-DEOXY-4-GUANIDINO-5-N-ACETYL-NEURAMINIC ACID; AC1NRBJW; 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid; 5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-erythro-L-manno-nononic acid; (4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMZO0EI	DT	Small molecular drug
DMZO0EI	PC	46936668
DMZO0EI	MW	334.33
DMZO0EI	FM	C12H22N4O7
DMZO0EI	IC	InChI=1S/C12H22N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h5-10,17,19-20H,2-3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,7-,8+,9-,10-/m1/s1
DMZO0EI	CS	CC(=O)N[C@H]1[C@@H](C[C@@H](O[C@H]1[C@@H]([C@H](CO)O)O)C(=O)O)N=C(N)N
DMZO0EI	IK	DAAUVSVERFXBSX-WHSUVHHGSA-N
DMZO0EI	IU	(2R,4R,5S,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2S)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMZO0EI	DE	Discovery agent

DMVPWML	ID	DMVPWML
DMVPWML	DN	2,4'-Diacetoxy-5,3'-di-(2-propenyl)-biphenyl
DMVPWML	HS	Investigative
DMVPWML	SN	CHEMBL570311; Diacetylhonokiol; SCHEMBL18313888; BDBM50295922
DMVPWML	DT	Small molecular drug
DMVPWML	PC	45269978
DMVPWML	MW	350.4
DMVPWML	FM	C22H22O4
DMVPWML	IC	InChI=1S/C22H22O4/c1-5-7-17-9-11-22(26-16(4)24)20(13-17)18-10-12-21(25-15(3)23)19(14-18)8-6-2/h5-6,9-14H,1-2,7-8H2,3-4H3
DMVPWML	CS	CC(=O)OC1=C(C=C(C=C1)C2=C(C=CC(=C2)CC=C)OC(=O)C)CC=C
DMVPWML	IK	XNFZWGDLKCJOLJ-UHFFFAOYSA-N
DMVPWML	IU	[4-(2-acetyloxy-5-prop-2-enylphenyl)-2-prop-2-enylphenyl] acetate
DMVPWML	DE	Discovery agent

DMQPKWM	ID	DMQPKWM
DMQPKWM	DN	2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
DMQPKWM	HS	Investigative
DMQPKWM	SN	2,4-diamino-6-phenyl-5,6,7,8,-tetrahydropteridine; (6R)-6-phenyl-5,6,7,8-tetrahydropteridine-2,4-diamine; AC1L9HFU
DMQPKWM	DT	Small molecular drug
DMQPKWM	PC	445109
DMQPKWM	MW	242.28
DMQPKWM	FM	C12H14N6
DMQPKWM	IC	InChI=1S/C12H14N6/c13-10-9-11(18-12(14)17-10)15-6-8(16-9)7-4-2-1-3-5-7/h1-5,8,16H,6H2,(H5,13,14,15,17,18)/t8-/m0/s1
DMQPKWM	CS	C1[C@H](NC2=C(N=C(N=C2N1)N)N)C3=CC=CC=C3
DMQPKWM	IK	VEKRIXRQADJFAG-QMMMGPOBSA-N
DMQPKWM	IU	(6R)-6-phenyl-5,6,7,8-tetrahydropteridine-2,4-diamine
DMQPKWM	DE	Discovery agent

DMAOGBP	ID	DMAOGBP
DMAOGBP	DN	2,4-Diamino-butyric acid(GABA)
DMAOGBP	HS	Investigative
DMAOGBP	SN	2,4-Diaminobutanoic acid; 2,4-Diaminobutyric acid; 305-62-4; 2,4-Diamino-butyric acid; alpha,gamma-Diaminobutyric acid; 2,4-diamino-butanoic acid; DL-2,4-Diaminobutyric acid; Butanoic acid, 2,4-diamino-; CHEBI:64307; EINECS 206-166-2; Butyric acid, 2,4-diamino-; CHEMBL307931; OGNSCSPNOLGXSM-UHFFFAOYSA-N; Butanoic acid, 2,4-diamino-, (+)-; Butanoic acid, 2,4-diamino-, dihydrochloride; 6970-28-1; 2,4-Diaminobutyrate; 2,4-Diaminobutanoate; NSC41117; 2,4-diamino-butanoate; DL-2,4-Diaminobutanoate; AC1Q28UL; SCHEMBL34705
DMAOGBP	DT	Small molecular drug
DMAOGBP	PC	470
DMAOGBP	MW	118.13
DMAOGBP	FM	C4H10N2O2
DMAOGBP	IC	InChI=1S/C4H10N2O2/c5-2-1-3(6)4(7)8/h3H,1-2,5-6H2,(H,7,8)
DMAOGBP	CS	C(CN)C(C(=O)O)N
DMAOGBP	IK	OGNSCSPNOLGXSM-UHFFFAOYSA-N
DMAOGBP	IU	2,4-diaminobutanoic acid
DMAOGBP	CA	CAS 305-62-4
DMAOGBP	CB	CHEBI:64307
DMAOGBP	DE	Discovery agent

DMS1YXL	ID	DMS1YXL
DMS1YXL	DN	2,4-diaminoquinozalines and quinoxaline-2,3-diones
DMS1YXL	HS	Investigative
DMS1YXL	DE	Discovery agent

DMQ385U	ID	DMQ385U
DMQ385U	DN	2,4-Dibenzylamino-6-isopentylpyrimidine
DMQ385U	HS	Investigative
DMQ385U	SN	CHEMBL494121; 2,4-Dibenzylamino-6-isopentylpyrimidine
DMQ385U	DT	Small molecular drug
DMQ385U	PC	25128804
DMQ385U	MW	360.5
DMQ385U	FM	C23H28N4
DMQ385U	IC	InChI=1S/C23H28N4/c1-18(2)13-14-21-15-22(24-16-19-9-5-3-6-10-19)27-23(26-21)25-17-20-11-7-4-8-12-20/h3-12,15,18H,13-14,16-17H2,1-2H3,(H2,24,25,26,27)
DMQ385U	CS	CC(C)CCC1=CC(=NC(=N1)NCC2=CC=CC=C2)NCC3=CC=CC=C3
DMQ385U	IK	HEIDJEFGBUXABK-UHFFFAOYSA-N
DMQ385U	IU	2-N,4-N-dibenzyl-6-(3-methylbutyl)pyrimidine-2,4-diamine
DMQ385U	DE	Discovery agent

DM4EY5S	ID	DM4EY5S
DM4EY5S	DN	2,4-dichloro-5-sulfamoylbenzoic acid
DM4EY5S	HS	Investigative
DM4EY5S	SN	2,4-Dichloro-5-sulfamoylbenzoic acid; 2736-23-4; Lasamide; 5-(Aminosulfonyl)-2,4-dichlorobenzoic acid; 2,4-Dichloro-5-sulfamoyl-benzoic acid; 2,4-Dichloro-5-sulphamoylbenzoic acid; UNII-LEG53TF0SN; 2,4-Dichloro-5-sulfamylbenzoic acid; Benzoic acid, 5-(aminosulfonyl)-2,4-dichloro-; EINECS 220-358-3; LEG53TF0SN; 3-Sulfamoyl-4,6-dichlorobenzoic acid; BENZOIC ACID, 2,4-DICHLORO-5-SULFAMOYL-; BRN 2219046; 5-Carboxy-2,4-dichlorobenzenesulfonamide; 5-Aminosulfonyl-2,4-dichlorobenzoic acid; M 12325
DM4EY5S	DT	Small molecular drug
DM4EY5S	PC	17655
DM4EY5S	MW	270.09
DM4EY5S	FM	C7H5Cl2NO4S
DM4EY5S	IC	InChI=1S/C7H5Cl2NO4S/c8-4-2-5(9)6(15(10,13)14)1-3(4)7(11)12/h1-2H,(H,11,12)(H2,10,13,14)
DM4EY5S	CS	C1=C(C(=CC(=C1S(=O)(=O)N)Cl)Cl)C(=O)O
DM4EY5S	IK	ZSHHRBYVHTVRFK-UHFFFAOYSA-N
DM4EY5S	IU	2,4-dichloro-5-sulfamoylbenzoic acid
DM4EY5S	CA	CAS 2736-23-4
DM4EY5S	DE	Discovery agent

DMR5DYK	ID	DMR5DYK
DMR5DYK	DN	2,4-Dichlorobenzenemethanethiol
DMR5DYK	HS	Investigative
DMR5DYK	SN	2,4-Dichlorobenzyl mercaptan; 59293-67-3; (2,4-Dichlorophenyl)methanethiol; 2,4-Dichlorobenzylmercaptan; 2,4-dichlorophenylmethanethiol; 2,4-Dichlorobenzenemethanethiol; 2,4-Dichloro-alpha-toluenethiol; 2,4-Dichlorotoluene-alpha-thiol; Benzenemethanethiol, 2,4-dichloro-; CHEMBL1224561; ZSPXTTVUJDSRNJ-UHFFFAOYSA-N; NSC33218; EINECS 261-687-2; AI3-31458; AC1Q3MDQ; ACMC-1B9KZ; AC1L3V0Z; SCHEMBL1802752; 2,4-Dichlorothiobenzyl Alcohol; ZSPXTTVUJDSRNJ-UHFFFAOYSA-; CTK5A9733; DTXSID70208016; MolPort-004-354-551
DMR5DYK	DT	Small molecular drug
DMR5DYK	PC	95756
DMR5DYK	MW	193.09
DMR5DYK	FM	C7H6Cl2S
DMR5DYK	IC	InChI=1S/C7H6Cl2S/c8-6-2-1-5(4-10)7(9)3-6/h1-3,10H,4H2
DMR5DYK	CS	C1=CC(=C(C=C1Cl)Cl)CS
DMR5DYK	IK	ZSPXTTVUJDSRNJ-UHFFFAOYSA-N
DMR5DYK	IU	(2,4-dichlorophenyl)methanethiol
DMR5DYK	CA	CAS 59293-67-3
DMR5DYK	DE	Discovery agent

DMO4FSH	ID	DMO4FSH
DMO4FSH	DN	2,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMO4FSH	HS	Investigative
DMO4FSH	SN	CHEMBL61381; 2,4-Dichloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; 260790-88-3; (Z)-2,4-dichloro-N-(4-phenylthiazol-2(3H)-ylidene)benzamide; 5307-12-0; AC1LCD3F; CBMicro_016815; Oprea1_161519; 2,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide; ARONIS019647; KS-00004BJV; DTXSID00344799; MolPort-001-620-431; MWSDOEQEOIKHRL-UHFFFAOYSA-N; MolPort-003-009-221; ZINC4696587; CCG-5657; STK048438; BDBM50101786; AKOS000486711; AKOS024573981; MCULE-1720813827; ST036566; BIM-0016665.P001; N-(4-Phenyl-2-thiazolyl)-2,4-dichlorobenzamide
DMO4FSH	DT	Small molecular drug
DMO4FSH	PC	599553
DMO4FSH	MW	349.2
DMO4FSH	FM	C16H10Cl2N2OS
DMO4FSH	IC	InChI=1S/C16H10Cl2N2OS/c17-11-6-7-12(13(18)8-11)15(21)20-16-19-14(9-22-16)10-4-2-1-3-5-10/h1-9H,(H,19,20,21)
DMO4FSH	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=C(C=C(C=C3)Cl)Cl
DMO4FSH	IK	MWSDOEQEOIKHRL-UHFFFAOYSA-N
DMO4FSH	IU	2,4-dichloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMO4FSH	CA	CAS 5307-12-0
DMO4FSH	DE	Discovery agent

DM4QDZV	ID	DM4QDZV
DM4QDZV	DN	2',4'-dicyanobiphenyl-4-yl sulfamate
DM4QDZV	HS	Investigative
DM4QDZV	SN	CHEMBL592320; SCHEMBL4667745; BDBM50307888; 2'',4''-dicyanobiphenyl-4-yl sulfamate
DM4QDZV	DT	Small molecular drug
DM4QDZV	PC	9861093
DM4QDZV	MW	299.31
DM4QDZV	FM	C14H9N3O3S
DM4QDZV	IC	InChI=1S/C14H9N3O3S/c15-8-10-1-6-14(12(7-10)9-16)11-2-4-13(5-3-11)20-21(17,18)19/h1-7H,(H2,17,18,19)
DM4QDZV	CS	C1=CC(=CC=C1C2=C(C=C(C=C2)C#N)C#N)OS(=O)(=O)N
DM4QDZV	IK	VQTYXLRQENRZOV-UHFFFAOYSA-N
DM4QDZV	IU	[4-(2,4-dicyanophenyl)phenyl] sulfamate
DM4QDZV	DE	Discovery agent

DM75TJ1	ID	DM75TJ1
DM75TJ1	DN	2,4-difluorophenyl 4-butoxybenzylcarbamate
DM75TJ1	HS	Investigative
DM75TJ1	SN	2,4-difluorophenyl 4-butoxybenzylcarbamate; CHEMBL596875; SCHEMBL5222747
DM75TJ1	DT	Small molecular drug
DM75TJ1	PC	20872684
DM75TJ1	MW	335.3
DM75TJ1	FM	C18H19F2NO3
DM75TJ1	IC	InChI=1S/C18H19F2NO3/c1-2-3-10-23-15-7-4-13(5-8-15)12-21-18(22)24-17-9-6-14(19)11-16(17)20/h4-9,11H,2-3,10,12H2,1H3,(H,21,22)
DM75TJ1	CS	CCCCOC1=CC=C(C=C1)CNC(=O)OC2=C(C=C(C=C2)F)F
DM75TJ1	IK	OHKUODJKULFCPB-UHFFFAOYSA-N
DM75TJ1	IU	(2,4-difluorophenyl) N-[(4-butoxyphenyl)methyl]carbamate
DM75TJ1	DE	Discovery agent

DM0URFY	ID	DM0URFY
DM0URFY	DN	2,4-diisobutylamino-6-isopentylpyrimidine
DM0URFY	HS	Investigative
DM0URFY	SN	CHEMBL347927; 2,4-diisobutylamino-6-isopentylpyrimidine; ZINC13559143; BDBM50138886
DM0URFY	DT	Small molecular drug
DM0URFY	PC	9994500
DM0URFY	MW	292.5
DM0URFY	FM	C17H32N4
DM0URFY	IC	InChI=1S/C17H32N4/c1-12(2)7-8-15-9-16(18-10-13(3)4)21-17(20-15)19-11-14(5)6/h9,12-14H,7-8,10-11H2,1-6H3,(H2,18,19,20,21)
DM0URFY	CS	CC(C)CCC1=CC(=NC(=N1)NCC(C)C)NCC(C)C
DM0URFY	IK	FELVKNQXOFEZOY-UHFFFAOYSA-N
DM0URFY	IU	6-(3-methylbutyl)-2-N,4-N-bis(2-methylpropyl)pyrimidine-2,4-diamine
DM0URFY	DE	Discovery agent

DMP9BZU	ID	DMP9BZU
DMP9BZU	DN	2,4-dimethoxy-2'-hydroxychalcone
DMP9BZU	HS	Investigative
DMP9BZU	SN	3-(2,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; 36685-63-9; AC1L5NE0; NCIOpen2_004691; CTK1C4388
DMP9BZU	DT	Small molecular drug
DMP9BZU	PC	6041429
DMP9BZU	MW	284.31
DMP9BZU	FM	C17H16O4
DMP9BZU	IC	InChI=1S/C17H16O4/c1-20-13-9-7-12(17(11-13)21-2)8-10-16(19)14-5-3-4-6-15(14)18/h3-11,18H,1-2H3/b10-8+
DMP9BZU	CS	COC1=CC(=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O)OC
DMP9BZU	IK	ORIBPRISLKRPRQ-CSKARUKUSA-N
DMP9BZU	IU	(E)-3-(2,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
DMP9BZU	DE	Discovery agent

DMHSLXI	ID	DMHSLXI
DMHSLXI	DN	2,4-Dimethoxy-3'-amino-trans-stilbene
DMHSLXI	HS	Investigative
DMHSLXI	SN	CHEMBL1173641; BDBM50322048
DMHSLXI	DT	Small molecular drug
DMHSLXI	PC	49799639
DMHSLXI	MW	255.31
DMHSLXI	FM	C16H17NO2
DMHSLXI	IC	InChI=1S/C16H17NO2/c1-18-15-9-8-13(16(11-15)19-2)7-6-12-4-3-5-14(17)10-12/h3-11H,17H2,1-2H3/b7-6+
DMHSLXI	CS	COC1=CC(=C(C=C1)/C=C/C2=CC(=CC=C2)N)OC
DMHSLXI	IK	YTHARJUESQVNDD-VOTSOKGWSA-N
DMHSLXI	IU	3-[(E)-2-(2,4-dimethoxyphenyl)ethenyl]aniline
DMHSLXI	DE	Discovery agent

DMMZ643	ID	DMMZ643
DMMZ643	DN	2,4-Dimethoxy-4'-amino-trans-stilbene
DMMZ643	HS	Investigative
DMMZ643	SN	CHEMBL1170662; BDBM50322047
DMMZ643	DT	Small molecular drug
DMMZ643	PC	49799655
DMMZ643	MW	255.31
DMMZ643	FM	C16H17NO2
DMMZ643	IC	InChI=1S/C16H17NO2/c1-18-15-10-7-13(16(11-15)19-2)6-3-12-4-8-14(17)9-5-12/h3-11H,17H2,1-2H3/b6-3+
DMMZ643	CS	COC1=CC(=C(C=C1)/C=C/C2=CC=C(C=C2)N)OC
DMMZ643	IK	CPBHGSOSBBDXHN-ZZXKWVIFSA-N
DMMZ643	IU	4-[(E)-2-(2,4-dimethoxyphenyl)ethenyl]aniline
DMMZ643	DE	Discovery agent

DMWNJ84	ID	DMWNJ84
DMWNJ84	DN	2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl
DMWNJ84	HS	Investigative
DMWNJ84	SN	CHEMBL89828; 68592-18-7; NSC293102; AC1L6VMD; HONOKIOL DIMETHYL ETHER; SCHEMBL13978616; CTK2F6825; DTXSID00315202; ZINC1566148; BDBM50295927; 3',5-diallyl-2,4'-dimethoxybiphenyl; NSC-293102; 5,3''-Diallyl-2,4''-dimethoxy-biphenyl; 3,3'-Diallyl-4',6-dimethoxy-1,1'-biphenyl; 2,4''-Dimethoxy-5,3''-di-(2-propenyl)-biphenyl; 1-methoxy-2-(4-methoxy-3-prop-2-enylphenyl)-4-prop-2-enylbenzene
DMWNJ84	DT	Small molecular drug
DMWNJ84	PC	325144
DMWNJ84	MW	294.4
DMWNJ84	FM	C20H22O2
DMWNJ84	IC	InChI=1S/C20H22O2/c1-5-7-15-9-11-20(22-4)18(13-15)16-10-12-19(21-3)17(14-16)8-6-2/h5-6,9-14H,1-2,7-8H2,3-4H3
DMWNJ84	CS	COC1=C(C=C(C=C1)C2=C(C=CC(=C2)CC=C)OC)CC=C
DMWNJ84	IK	GDCJELDNRAWYTE-UHFFFAOYSA-N
DMWNJ84	IU	1-methoxy-2-(4-methoxy-3-prop-2-enylphenyl)-4-prop-2-enylbenzene
DMWNJ84	CA	CAS 68592-18-7
DMWNJ84	DE	Discovery agent

DM94NM7	ID	DM94NM7
DM94NM7	DN	2,4'-Dimethoxy-5,3'-dipropyl-biphenyl
DM94NM7	HS	Investigative
DM94NM7	SN	CHEMBL560262; BDBM50295928
DM94NM7	DT	Small molecular drug
DM94NM7	PC	45267390
DM94NM7	MW	298.4
DM94NM7	FM	C20H26O2
DM94NM7	IC	InChI=1S/C20H26O2/c1-5-7-15-9-11-20(22-4)18(13-15)16-10-12-19(21-3)17(14-16)8-6-2/h9-14H,5-8H2,1-4H3
DM94NM7	CS	CCCC1=CC(=C(C=C1)OC)C2=CC(=C(C=C2)OC)CCC
DM94NM7	IK	GLDMMYBVNSMLGE-UHFFFAOYSA-N
DM94NM7	IU	1-methoxy-2-(4-methoxy-3-propylphenyl)-4-propylbenzene
DM94NM7	DE	Discovery agent

DM2AW0Z	ID	DM2AW0Z
DM2AW0Z	DN	2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z	HS	Investigative
DM2AW0Z	SN	654-62-6; 4-Amino-6-(trifluoromethyl)benzene-1,3-disulfonamide; 2-amino-4-trifluoromethyl-1,5-benzendisulfonamide; 2,4-Disulfamyl-5-trifluoromethylaniline; UNII-YBN90877RI; CHEMBL418; YBN90877RI; 1,3-Benzenedisulfonamide, 4-amino-6-(trifluoromethyl)-; 5-Amino-alpha,alpha,alpha-trifluorotoluene-2,4-disulfonamide; 5-Amino-alpha,alpha,alpha-trifluorotoluene-2,4-disulphonamide; C7H8F3N3O4S2; 2pow; EINECS 211-506-8; NSC 44625; 2,4-DISULFAMYLTRIFLUOROMETHYLANILINE; AC1Q6TRC; AC1L2C5H; SCHEMBL3863705; BDBM10866; CTK5C2741
DM2AW0Z	DT	Small molecular drug
DM2AW0Z	PC	69561
DM2AW0Z	MW	319.3
DM2AW0Z	FM	C7H8F3N3O4S2
DM2AW0Z	IC	InChI=1S/C7H8F3N3O4S2/c8-7(9,10)3-1-4(11)6(19(13,16)17)2-5(3)18(12,14)15/h1-2H,11H2,(H2,12,14,15)(H2,13,16,17)
DM2AW0Z	CS	C1=C(C(=CC(=C1N)S(=O)(=O)N)S(=O)(=O)N)C(F)(F)F
DM2AW0Z	IK	KRVABEGPNKGLOT-UHFFFAOYSA-N
DM2AW0Z	IU	4-amino-6-(trifluoromethyl)benzene-1,3-disulfonamide
DM2AW0Z	CA	CAS 654-62-6
DM2AW0Z	DE	Discovery agent

DMZRY0Q	ID	DMZRY0Q
DMZRY0Q	DN	2,4-epi-neodysiherbaine
DMZRY0Q	HS	Investigative
DMZRY0Q	SN	2,4-epi-neoDH
DMZRY0Q	DT	Small molecular drug
DMZRY0Q	PC	73755077
DMZRY0Q	MW	290.25
DMZRY0Q	FM	C11H16NO8-
DMZRY0Q	IC	InChI=1S/C11H17NO8/c12-4(9(15)16)1-11(10(17)18)2-6-8(20-11)7(14)5(13)3-19-6/h4-8,13-14H,1-3,12H2,(H,15,16)(H,17,18)/p-1/t4-,5+,6?,7+,8?,11-/m1/s1
DMZRY0Q	CS	C1[C@@H]([C@@H](C2C(O1)C[C@](O2)(C[C@H](C(=O)[O-])[NH3+])C(=O)[O-])O)O
DMZRY0Q	IK	NRTJEXLNSCGBJU-LUHIGIFZSA-M
DMZRY0Q	IU	(2R,6S,7S)-2-[(2R)-2-azaniumyl-2-carboxylatoethyl]-6,7-dihydroxy-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-carboxylate
DMZRY0Q	DE	Discovery agent

DMLDHMB	ID	DMLDHMB
DMLDHMB	DN	2,5-Anhydroglucitol-1,6-Biphosphate
DMLDHMB	HS	Investigative
DMLDHMB	SN	2,5-Anhydroglucitol-1,6-Biphosphate; 2,5-Anhydro-D-glucitol-1,6-diphosphate; 2,5-Anhydro-D-glucitol 1,6-diphosphate; 4429-47-4; AHG; 2,5-Anhydroglucitol 1,6-Bisphosphate; AC1L9I6X; SCHEMBL20154711; ZINC3870733; AKOS032954084; DB02778; 2,5-anhydro-1,6-di-O-phosphono-D-glucitol; 2,5-Anhydro-D-glucitol 1,6-bisphosphoric acid; W-202770; [(2R,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]methyl dihydrogen phosphate
DMLDHMB	DT	Small molecular drug
DMLDHMB	PC	445555
DMLDHMB	MW	324.12
DMLDHMB	FM	C6H14O11P2
DMLDHMB	IC	InChI=1S/C6H14O11P2/c7-5-3(1-15-18(9,10)11)17-4(6(5)8)2-16-19(12,13)14/h3-8H,1-2H2,(H2,9,10,11)(H2,12,13,14)/t3-,4+,5-,6-/m1/s1
DMLDHMB	CS	C([C@@H]1[C@H]([C@@H]([C@@H](O1)COP(=O)(O)O)O)O)OP(=O)(O)O
DMLDHMB	IK	WSMBXSQDFPTODV-JGWLITMVSA-N
DMLDHMB	IU	[(2R,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]methyl dihydrogen phosphate
DMLDHMB	DE	Discovery agent

DMU5GKN	ID	DMU5GKN
DMU5GKN	DN	2,5-bis(2-methoxyphenyl)thiophene
DMU5GKN	HS	Investigative
DMU5GKN	SN	2,5-bis(2-methoxyphenyl)thiophene; CHEMBL204873; SCHEMBL12973253
DMU5GKN	DT	Small molecular drug
DMU5GKN	PC	44408693
DMU5GKN	MW	296.4
DMU5GKN	FM	C18H16O2S
DMU5GKN	IC	InChI=1S/C18H16O2S/c1-19-15-9-5-3-7-13(15)17-11-12-18(21-17)14-8-4-6-10-16(14)20-2/h3-12H,1-2H3
DMU5GKN	CS	COC1=CC=CC=C1C2=CC=C(S2)C3=CC=CC=C3OC
DMU5GKN	IK	VXQDFBRKMXPIGY-UHFFFAOYSA-N
DMU5GKN	IU	2,5-bis(2-methoxyphenyl)thiophene
DMU5GKN	DE	Discovery agent

DMH6RDL	ID	DMH6RDL
DMH6RDL	DN	2,5-Bis-(3,4-dimethoxy-phenyl)-furan
DMH6RDL	HS	Investigative
DMH6RDL	SN	CHEMBL110937; 2,5-Bis-(3,4-dimethoxy-phenyl)-furan
DMH6RDL	DT	Small molecular drug
DMH6RDL	PC	16038022
DMH6RDL	MW	340.4
DMH6RDL	FM	C20H20O5
DMH6RDL	IC	InChI=1S/C20H20O5/c1-21-17-7-5-13(11-19(17)23-3)15-9-10-16(25-15)14-6-8-18(22-2)20(12-14)24-4/h5-12H,1-4H3
DMH6RDL	CS	COC1=C(C=C(C=C1)C2=CC=C(O2)C3=CC(=C(C=C3)OC)OC)OC
DMH6RDL	IK	ZESHRVUYCRWWFA-UHFFFAOYSA-N
DMH6RDL	IU	2,5-bis(3,4-dimethoxyphenyl)furan
DMH6RDL	DE	Discovery agent

DM28GQS	ID	DM28GQS
DM28GQS	DN	2,5-Bis-(3-cyclopentyloxy-4-methoxy-phenyl)-furan
DM28GQS	HS	Investigative
DM28GQS	SN	CHEMBL111506; 2,5-Bis-(3-cyclopentyloxy-4-methoxy-phenyl)-furan
DM28GQS	DT	Small molecular drug
DM28GQS	PC	44339586
DM28GQS	MW	448.5
DM28GQS	FM	C28H32O5
DM28GQS	IC	InChI=1S/C28H32O5/c1-29-25-13-11-19(17-27(25)31-21-7-3-4-8-21)23-15-16-24(33-23)20-12-14-26(30-2)28(18-20)32-22-9-5-6-10-22/h11-18,21-22H,3-10H2,1-2H3
DM28GQS	CS	COC1=C(C=C(C=C1)C2=CC=C(O2)C3=CC(=C(C=C3)OC)OC4CCCC4)OC5CCCC5
DM28GQS	IK	VJENKFARFHFXFG-UHFFFAOYSA-N
DM28GQS	IU	2,5-bis(3-cyclopentyloxy-4-methoxyphenyl)furan
DM28GQS	DE	Discovery agent

DMOQPHK	ID	DMOQPHK
DMOQPHK	DN	2,5-bis(4-hydroxybenzylidene)cyclopentanone
DMOQPHK	HS	Investigative
DMOQPHK	SN	2,5-Bis(4-hydroxybenzylidene)cyclopentanone; NSC666766; CHEMBL452101; AC1LVVMV; SCHEMBL14473242; MolPort-000-640-539; ZINC5955757; BDBM50264922; AKOS001331259; NSC-666766; 2,5-Bis[(E)-4-hydroxybenzylidene]cyclopentanone; (2E,5E)-2,5-bis[(4-hydroxyphenyl)methylene]cyclopentanone
DMOQPHK	DT	Small molecular drug
DMOQPHK	PC	1712706
DMOQPHK	MW	292.3
DMOQPHK	FM	C19H16O3
DMOQPHK	IC	InChI=1S/C19H16O3/c20-17-7-1-13(2-8-17)11-15-5-6-16(19(15)22)12-14-3-9-18(21)10-4-14/h1-4,7-12,20-21H,5-6H2/b15-11+,16-12+
DMOQPHK	CS	C1/C(=C\\C2=CC=C(C=C2)O)/C(=O)/C(=C/C3=CC=C(C=C3)O)/C1
DMOQPHK	IK	YSEMBYWAAKOCKW-JOBJLJCHSA-N
DMOQPHK	IU	(2E,5E)-2,5-bis[(4-hydroxyphenyl)methylidene]cyclopentan-1-one
DMOQPHK	DE	Discovery agent

DMNQIGZ	ID	DMNQIGZ
DMNQIGZ	DN	2,5-bis(4-Hydroxyphenyl)thiophene
DMNQIGZ	HS	Investigative
DMNQIGZ	SN	CHEMBL204010; 2,5-bis(4-Hydroxyphenyl)thiophene; SCHEMBL1181642; BDBM25849; ZINC28571224; 4,4'-(Thiophene-2,5-diyl)bisphenol; hydroxyphenyl substituted thiophene, 21
DMNQIGZ	DT	Small molecular drug
DMNQIGZ	PC	14905189
DMNQIGZ	MW	268.3
DMNQIGZ	FM	C16H12O2S
DMNQIGZ	IC	InChI=1S/C16H12O2S/c17-13-5-1-11(2-6-13)15-9-10-16(19-15)12-3-7-14(18)8-4-12/h1-10,17-18H
DMNQIGZ	CS	C1=CC(=CC=C1C2=CC=C(S2)C3=CC=C(C=C3)O)O
DMNQIGZ	IK	KZMOBYGIRBRCFV-UHFFFAOYSA-N
DMNQIGZ	IU	4-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMNQIGZ	DE	Discovery agent

DM30RNY	ID	DM30RNY
DM30RNY	DN	2,5-bis(4-methoxyphenyl)thiophene
DM30RNY	HS	Investigative
DM30RNY	SN	2,5-bis(4-methoxyphenyl)thiophene; CHEMBL378797; 55827-09-3; AC1MS3AA; SCHEMBL1181273; CTK1F5890; DTXSID30393578; SNVBIBDQUGLRIV-UHFFFAOYSA-N; ZINC405078; BDBM50178543; AKOS024342405; MCULE-5357210093; Thiophene, 2,5-bis(4-methoxyphenyl)-
DM30RNY	DT	Small molecular drug
DM30RNY	PC	3552928
DM30RNY	MW	296.4
DM30RNY	FM	C18H16O2S
DM30RNY	IC	InChI=1S/C18H16O2S/c1-19-15-7-3-13(4-8-15)17-11-12-18(21-17)14-5-9-16(20-2)10-6-14/h3-12H,1-2H3
DM30RNY	CS	COC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)OC
DM30RNY	IK	SNVBIBDQUGLRIV-UHFFFAOYSA-N
DM30RNY	IU	2,5-bis(4-methoxyphenyl)thiophene
DM30RNY	CA	CAS 55827-09-3
DM30RNY	DE	Discovery agent

DM3USOR	ID	DM3USOR
DM3USOR	DN	2,5-bis(4-nitrophenyl)thiophene
DM3USOR	HS	Investigative
DM3USOR	SN	2,5-bis(4-nitrophenyl)thiophene; CHEMBL202898; AC1NA972; SCHEMBL12491620; ZINC3107517; BDBM50178545; 70010-47-8
DM3USOR	DT	Small molecular drug
DM3USOR	PC	4373578
DM3USOR	MW	326.3
DM3USOR	FM	C16H10N2O4S
DM3USOR	IC	InChI=1S/C16H10N2O4S/c19-17(20)13-5-1-11(2-6-13)15-9-10-16(23-15)12-3-7-14(8-4-12)18(21)22/h1-10H
DM3USOR	CS	C1=CC(=CC=C1C2=CC=C(S2)C3=CC=C(C=C3)[N+](=O)[O-])[N+](=O)[O-]
DM3USOR	IK	FBNOZEYGTWFASC-UHFFFAOYSA-N
DM3USOR	IU	2,5-bis(4-nitrophenyl)thiophene
DM3USOR	DE	Discovery agent

DMMESIU	ID	DMMESIU
DMMESIU	DN	2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine
DMMESIU	HS	Investigative
DMMESIU	SN	CHEMBL477445; BDBM50267394; 2,5''-dichloro-5''-deoxy-N6-cyclopentyladenosine
DMMESIU	DT	Small molecular drug
DMMESIU	PC	44582613
DMMESIU	MW	388.2
DMMESIU	FM	C15H19Cl2N5O3
DMMESIU	IC	InChI=1S/C15H19Cl2N5O3/c16-5-8-10(23)11(24)14(25-8)22-6-18-9-12(19-7-3-1-2-4-7)20-15(17)21-13(9)22/h6-8,10-11,14,23-24H,1-5H2,(H,19,20,21)/t8-,10-,11-,14-/m1/s1
DMMESIU	CS	C1CCC(C1)NC2=C3C(=NC(=N2)Cl)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CCl)O)O
DMMESIU	IK	GWUOJELSUSGGDU-IDTAVKCVSA-N
DMMESIU	IU	(2R,3R,4S,5S)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol
DMMESIU	DE	Discovery agent

DM9PK1R	ID	DM9PK1R
DM9PK1R	DN	2,5-dichloro-N-phenylthiophene-3-sulfonamide
DM9PK1R	HS	Investigative
DM9PK1R	SN	CHEMBL1171971; 2,5-dichloro-N-phenylthiophene-3-sulfonamide; SCHEMBL7579927; BDBM50321450
DM9PK1R	DT	Small molecular drug
DM9PK1R	PC	29098931
DM9PK1R	MW	308.2
DM9PK1R	FM	C10H7Cl2NO2S2
DM9PK1R	IC	InChI=1S/C10H7Cl2NO2S2/c11-9-6-8(10(12)16-9)17(14,15)13-7-4-2-1-3-5-7/h1-6,13H
DM9PK1R	CS	C1=CC=C(C=C1)NS(=O)(=O)C2=C(SC(=C2)Cl)Cl
DM9PK1R	IK	ILXABJHIVUDACG-UHFFFAOYSA-N
DM9PK1R	IU	2,5-dichloro-N-phenylthiophene-3-sulfonamide
DM9PK1R	DE	Discovery agent

DMU5J8Y	ID	DMU5J8Y
DMU5J8Y	DN	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide
DMU5J8Y	HS	Investigative
DMU5J8Y	SN	CHEMBL1171972; 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide
DMU5J8Y	DT	Small molecular drug
DMU5J8Y	PC	49798484
DMU5J8Y	MW	322.2
DMU5J8Y	FM	C11H9Cl2NO2S2
DMU5J8Y	IC	InChI=1S/C11H9Cl2NO2S2/c1-7-2-4-8(5-3-7)14-18(15,16)9-6-10(12)17-11(9)13/h2-6,14H,1H3
DMU5J8Y	CS	CC1=CC=C(C=C1)NS(=O)(=O)C2=C(SC(=C2)Cl)Cl
DMU5J8Y	IK	OQWXAWNHXDPWGS-UHFFFAOYSA-N
DMU5J8Y	IU	2,5-dichloro-N-(4-methylphenyl)thiophene-3-sulfonamide
DMU5J8Y	DE	Discovery agent

DMI1O54	ID	DMI1O54
DMI1O54	DN	2,5-dideoxy-2,5-imino-D-altritol
DMI1O54	HS	Investigative
DMI1O54	SN	CHEMBL469844; 172823-15-3; CHEMBL10437; SCHEMBL2435520; CTK0A7803; DTXSID40437432; ZINC5766623; 2,5-Imino-2,5-dideoxy-D-altritol; BDBM50241865; BDBM50099008; (2R,3S,4S)-2,5-Bis-hydroxymethyl-pyrrolidine-3,4-diol; 2,5-Pyrrolidinedimethanol, 3,4-dihydroxy-, (2R,3R,4S,5R)-
DMI1O54	DT	Small molecular drug
DMI1O54	PC	10261406
DMI1O54	MW	163.17
DMI1O54	FM	C6H13NO4
DMI1O54	IC	InChI=1S/C6H13NO4/c8-1-3-5(10)6(11)4(2-9)7-3/h3-11H,1-2H2/t3-,4-,5-,6+/m1/s1
DMI1O54	CS	C([C@@H]1[C@H]([C@H]([C@H](N1)CO)O)O)O
DMI1O54	IK	PFYHYHZGDNWFIF-KAZBKCHUSA-N
DMI1O54	IU	(2R,3S,4R,5R)-2,5-bis(hydroxymethyl)pyrrolidine-3,4-diol
DMI1O54	CA	CAS 172823-15-3
DMI1O54	DE	Discovery agent

DMKP7O0	ID	DMKP7O0
DMKP7O0	DN	2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol
DMKP7O0	HS	Investigative
DMKP7O0	SN	CHEMBL456077; 2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol; 2,5-dideoxy-2,5-imino-D-glycero-D-manno-heptitol; SCHEMBL5851667; BDBM50242071
DMKP7O0	DT	Small molecular drug
DMKP7O0	PC	13005892
DMKP7O0	MW	193.2
DMKP7O0	FM	C7H15NO5
DMKP7O0	IC	InChI=1S/C7H15NO5/c9-1-3-6(12)7(13)5(8-3)4(11)2-10/h3-13H,1-2H2/t3-,4?,5-,6-,7-/m1/s1
DMKP7O0	CS	C([C@@H]1[C@H]([C@@H]([C@H](N1)C(CO)O)O)O)O
DMKP7O0	IK	ZJRUOSSQTZGFJV-UHEPRFFZSA-N
DMKP7O0	IU	(2R,3R,4R,5R)-2-(1,2-dihydroxyethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
DMKP7O0	DE	Discovery agent

DMGQVF5	ID	DMGQVF5
DMGQVF5	DN	2,5-Dideoxy-2,5-imino-D-mannitol
DMGQVF5	HS	Investigative
DMGQVF5	SN	59920-31-9; (2R,3R,4R,5R)-2,5-bis(hydroxymethyl)pyrrolidine-3,4-diol; 2,5-Dihydroxymethyl-3,4-dihydroxypyrrolidine; CHEBI:4289; CHEMBL312653; NSC624987; NSC613239; 2(r),5(r)-bis(hydroxymethyl)-3(r),4(r)-dihydroxypyrrolidine; 2,5-Anhydro-2,5-imino-D-mannitol; DQQ; 2,5-dideoxy-2,5-imino-L-mannitol; NSC 624987; AC1L3YWM; AC1Q59GS; SCHEMBL466574; ZINC1492230; 2,5-Pyrrolidinedimethanol, 3,4-dihydroxy-, (2R,3R,4R,5R)-
DMGQVF5	DT	Small molecular drug
DMGQVF5	PC	124702
DMGQVF5	MW	163.17
DMGQVF5	FM	C6H13NO4
DMGQVF5	IC	InChI=1S/C6H13NO4/c8-1-3-5(10)6(11)4(2-9)7-3/h3-11H,1-2H2/t3-,4-,5-,6-/m1/s1
DMGQVF5	CS	C([C@@H]1[C@H]([C@@H]([C@H](N1)CO)O)O)O
DMGQVF5	IK	PFYHYHZGDNWFIF-KVTDHHQDSA-N
DMGQVF5	IU	(2R,3R,4R,5R)-2,5-bis(hydroxymethyl)pyrrolidine-3,4-diol
DMGQVF5	CA	CAS 59920-31-9
DMGQVF5	CB	CHEBI:4289
DMGQVF5	DE	Discovery agent

DM5OYWF	ID	DM5OYWF
DM5OYWF	DN	2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE
DM5OYWF	HS	Investigative
DM5OYWF	SN	2',5'-dideoxy-adenosine 3'-monophosphate; 2',5'-Dideoxyadenosine 3'-monophosphate; AC1L9H2O; SCHEMBL1920523; CTK8E3534; 2',5'-dideoxy-3'-adenylic acid; 2,5-Dideoxyadenosine 3-monophosphate; AKOS025394264; DB06843; 121878-11-3; RT-018381; 2',5'-Dideoxyadenosine 3'-phosphoric acid; [(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl]oxyphosphonic acid; [(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl] dihydrogen phosphate
DM5OYWF	DT	Small molecular drug
DM5OYWF	PC	444894
DM5OYWF	MW	315.22
DM5OYWF	FM	C10H14N5O5P
DM5OYWF	IC	InChI=1S/C10H14N5O5P/c1-5-6(20-21(16,17)18)2-7(19-5)15-4-14-8-9(11)12-3-13-10(8)15/h3-7H,2H2,1H3,(H2,11,12,13)(H2,16,17,18)/t5-,6+,7-/m1/s1
DM5OYWF	CS	C[C@@H]1[C@H](C[C@@H](O1)N2C=NC3=C(N=CN=C32)N)OP(=O)(O)O
DM5OYWF	IK	NFGZMOICZSFFLB-DSYKOEDSSA-N
DM5OYWF	IU	[(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl] dihydrogen phosphate
DM5OYWF	DE	Discovery agent

DM5CWM0	ID	DM5CWM0
DM5CWM0	DN	2,5-didesoxy-3-ATP
DM5CWM0	HS	Investigative
DM5CWM0	SN	2',5'-DD-3'-ATP; 2',5'-Dideoxyadenosine 3'-(Tetrahydrogen Triphosphate); ZDA; SCHEMBL375553; CHEMBL1162355; ZINC13829365; 2',5'-Dideoxyadenosine 3'-triphosphate; 2',5'-Dideoxyadenosine 3'-triphosphoric acid; (2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-2-methyltetrahydrofuran-3-yl tetrahydrogen triphosphate
DM5CWM0	DT	Small molecular drug
DM5CWM0	PC	9934622
DM5CWM0	MW	475.18
DM5CWM0	FM	C10H16N5O11P3
DM5CWM0	IC	InChI=1S/C10H16N5O11P3/c1-5-6(24-28(19,20)26-29(21,22)25-27(16,17)18)2-7(23-5)15-4-14-8-9(11)12-3-13-10(8)15/h3-7H,2H2,1H3,(H,19,20)(H,21,22)(H2,11,12,13)(H2,16,17,18)/t5-,6+,7-/m1/s1
DM5CWM0	CS	C[C@@H]1[C@H](C[C@@H](O1)N2C=NC3=C(N=CN=C32)N)OP(=O)(O)OP(=O)(O)OP(=O)(O)O
DM5CWM0	IK	ZJGUOEYCABTFNH-DSYKOEDSSA-N
DM5CWM0	IU	[(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl] [hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate
DM5CWM0	DE	Discovery agent

DMIGFX6	ID	DMIGFX6
DMIGFX6	DN	2,5-difluorophenol
DMIGFX6	HS	Investigative
DMIGFX6	SN	2,5-Difluorophenol; 2713-31-7; Phenol, 2,5-difluoro-; 1,4-Difluoro-2-hydroxybenzene; Phenol,2,5-difluoro-; INXKVYFOWNAVMU-UHFFFAOYSA-N; 2,5-difluorphenol; MFCD00042501; 2,5-Difluorophenol;2,5-Difluorophenol;; NSC10288; PubChem3464; phenol derivative, 5; 2,5-difluoro-phenol; 2,5-difluoro phenol; ACMC-209gva; 2,5-Difluorophenol 97%; AC1Q78DB; SCHEMBL70273; 2,5-Difluorophenol, 95%; KSC493C1H; CHEMBL261219; AC1L3T96; INXKVYFOWNAVMU-UHFFFAOYSA-; BDBM26191; CTK3J3113; DTXSID90181594; MolPort-000-154-447; ZINC409280; CS-D1368; JRD-0251
DMIGFX6	DT	Small molecular drug
DMIGFX6	PC	94952
DMIGFX6	MW	130.09
DMIGFX6	FM	C6H4F2O
DMIGFX6	IC	InChI=1S/C6H4F2O/c7-4-1-2-5(8)6(9)3-4/h1-3,9H
DMIGFX6	CS	C1=CC(=C(C=C1F)O)F
DMIGFX6	IK	INXKVYFOWNAVMU-UHFFFAOYSA-N
DMIGFX6	IU	2,5-difluorophenol
DMIGFX6	CA	CAS 2713-31-7
DMIGFX6	DE	Discovery agent

DMV0UIR	ID	DMV0UIR
DMV0UIR	DN	2,5-Dimethoxy-4'-amino-trans-stilbene
DMV0UIR	HS	Investigative
DMV0UIR	SN	BRN 2855929; 4-(2,5-Dimethoxy)stilbenamine; 4'-Stilbenamine, 2,5-dimethoxy-; 4-(2,5-Dimethoxyphenethyl)aniline; 2,5-Dimethoxy-4'-aminostilbene(trans); 4'-AMINO-2,5-DIMETHOXY STILBENE; CHEMBL1173699; 4-(2-(2,5-Dimethoxyphenyl)ethyl)benzenamine; Stilbenamine, 2',5'-dimethoxy-; 2',5'-Dimethoxy-4-stilbenamine; 23435-31-6; 4-[(E)-2-(2,5-Dimethoxyphenyl)ethenyl]aniline; 32180-65-7; 4-[2-(2,5-dimethoxyphenyl)vinyl]aniline; 4-[2-(2,5-dimethoxyphenyl)ethenyl]aniline; 2,5-Dimethoxy-4'-aminostilbene; 5803-51-0; DMBAS; AC1NTB1S
DMV0UIR	DT	Small molecular drug
DMV0UIR	PC	5377410
DMV0UIR	MW	255.31
DMV0UIR	FM	C16H17NO2
DMV0UIR	IC	InChI=1S/C16H17NO2/c1-18-15-9-10-16(19-2)13(11-15)6-3-12-4-7-14(17)8-5-12/h3-11H,17H2,1-2H3/b6-3+
DMV0UIR	CS	COC1=CC(=C(C=C1)OC)/C=C/C2=CC=C(C=C2)N
DMV0UIR	IK	OZGXSMOLBWHIQA-ZZXKWVIFSA-N
DMV0UIR	IU	4-[(E)-2-(2,5-dimethoxyphenyl)ethenyl]aniline
DMV0UIR	CA	CAS 23435-31-6
DMV0UIR	DE	Discovery agent

DM50ZQP	ID	DM50ZQP
DM50ZQP	DN	2,5-dimethoxy-4-bromophenethylamine
DM50ZQP	HS	Investigative
DM50ZQP	SN	2,5-Dimethoxy-4-bromophenethylamine; 4-Bromo-2,5-dimethoxyphenethylamine; 66142-81-2; BDMPEA; 2-(4-Bromo-2,5-dimethoxyphenyl)ethylamine; 2C-B; 2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine; Nexus; 4-Bromo-2,5-dimethoxyphenylethylamine; UNII-V77772N32H; Benzeneethanamine, 4-bromo-2,5-dimethoxy-; CHEMBL292821; 2-CB; CHEBI:189669; V77772N32H; Eros [Street Name]; Venus [Street Name]; Nexus [Street Name]; Nexus (pharmaceutical); Spectrum [Street Name]; NCGC00168259-02; Toonies [Street Name]dd; DEA No. 7392
DM50ZQP	DT	Small molecular drug
DM50ZQP	PC	98527
DM50ZQP	MW	260.13
DM50ZQP	FM	C10H14BrNO2
DM50ZQP	IC	InChI=1S/C10H14BrNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3
DM50ZQP	CS	COC1=CC(=C(C=C1CCN)OC)Br
DM50ZQP	IK	YMHOBZXQZVXHBM-UHFFFAOYSA-N
DM50ZQP	IU	2-(4-bromo-2,5-dimethoxyphenyl)ethanamine
DM50ZQP	CA	CAS 66142-81-2
DM50ZQP	CB	CHEBI:189669
DM50ZQP	DE	Discovery agent

DM5IJSW	ID	DM5IJSW
DM5IJSW	DN	2,5-imino-2,5,6-trideoxy-D-manno-heptitol
DM5IJSW	HS	Investigative
DM5IJSW	SN	CHEMBL407337; 6-deoxyhomoDMDP; 2,5-imino-2,5,6-trideoxy-D-manno-heptitol; SCHEMBL2437378; BDBM50234571; 2alpha-Hydroxymethyl-3beta,4alpha-dihydroxypyrrolidine 5beta-ethanol
DM5IJSW	DT	Small molecular drug
DM5IJSW	PC	10374978
DM5IJSW	MW	177.2
DM5IJSW	FM	C7H15NO4
DM5IJSW	IC	InChI=1S/C7H15NO4/c9-2-1-4-6(11)7(12)5(3-10)8-4/h4-12H,1-3H2/t4-,5-,6-,7-/m1/s1
DM5IJSW	CS	C(CO)[C@@H]1[C@H]([C@@H]([C@H](N1)CO)O)O
DM5IJSW	IK	AGFACLQFIYFFOI-DBRKOABJSA-N
DM5IJSW	IU	(2R,3R,4R,5R)-2-(2-hydroxyethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
DM5IJSW	DE	Discovery agent

DM4IFPQ	ID	DM4IFPQ
DM4IFPQ	DN	2,6,8-triphenyl-9H-purine
DM4IFPQ	HS	Investigative
DM4IFPQ	SN	CHEMBL378959; 2,6,8-triphenyl-9H-purine
DM4IFPQ	DT	Small molecular drug
DM4IFPQ	PC	11462181
DM4IFPQ	MW	348.4
DM4IFPQ	FM	C23H16N4
DM4IFPQ	IC	InChI=1S/C23H16N4/c1-4-10-16(11-5-1)19-20-23(26-21(24-19)17-12-6-2-7-13-17)27-22(25-20)18-14-8-3-9-15-18/h1-15H,(H,24,25,26,27)
DM4IFPQ	CS	C1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=CC=C4)N=C(N3)C5=CC=CC=C5
DM4IFPQ	IK	UHWGSYGCZUMSMO-UHFFFAOYSA-N
DM4IFPQ	IU	2,6,8-triphenyl-7H-purine
DM4IFPQ	DE	Discovery agent

DMYQNK0	ID	DMYQNK0
DMYQNK0	DN	2,6-bis(4-chlorophenyl)-9H-purine
DMYQNK0	HS	Investigative
DMYQNK0	SN	CHEMBL426497; 2,6-bis(4-chlorophenyl)-9H-purine
DMYQNK0	DT	Small molecular drug
DMYQNK0	PC	11660141
DMYQNK0	MW	341.2
DMYQNK0	FM	C17H10Cl2N4
DMYQNK0	IC	InChI=1S/C17H10Cl2N4/c18-12-5-1-10(2-6-12)14-15-17(21-9-20-15)23-16(22-14)11-3-7-13(19)8-4-11/h1-9H,(H,20,21,22,23)
DMYQNK0	CS	C1=CC(=CC=C1C2=C3C(=NC(=N2)C4=CC=C(C=C4)Cl)N=CN3)Cl
DMYQNK0	IK	WDBFJNSPOHEOFN-UHFFFAOYSA-N
DMYQNK0	IU	2,6-bis(4-chlorophenyl)-7H-purine
DMYQNK0	DE	Discovery agent

DMC2N80	ID	DMC2N80
DMC2N80	DN	2,6-bis(4-methoxyphenyl)-9H-purine
DMC2N80	HS	Investigative
DMC2N80	SN	CHEMBL437123; 889673-61-4; 2,6-bis(4-methoxyphenyl)-9H-purine; CTK3A4136; DTXSID00467553; BDBM50186600; 1H-Purine, 2,6-bis(4-methoxyphenyl)-
DMC2N80	DT	Small molecular drug
DMC2N80	PC	11493677
DMC2N80	MW	332.4
DMC2N80	FM	C19H16N4O2
DMC2N80	IC	InChI=1S/C19H16N4O2/c1-24-14-7-3-12(4-8-14)16-17-19(21-11-20-17)23-18(22-16)13-5-9-15(25-2)10-6-13/h3-11H,1-2H3,(H,20,21,22,23)
DMC2N80	CS	COC1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=C(C=C4)OC)N=CN3
DMC2N80	IK	ZGJSQGNKCRURQW-UHFFFAOYSA-N
DMC2N80	IU	2,6-bis(4-methoxyphenyl)-7H-purine
DMC2N80	CA	CAS 889673-61-4
DMC2N80	DE	Discovery agent

DM41RZX	ID	DM41RZX
DM41RZX	DN	2,6-bis(4-tolyl)-9H-purine
DM41RZX	HS	Investigative
DM41RZX	SN	CHEMBL205192; 2,6-bis(4-tolyl)-9H-purine; BDBM50186598
DM41RZX	DT	Small molecular drug
DM41RZX	PC	11709210
DM41RZX	MW	300.4
DM41RZX	FM	C19H16N4
DM41RZX	IC	InChI=1S/C19H16N4/c1-12-3-7-14(8-4-12)16-17-19(21-11-20-17)23-18(22-16)15-9-5-13(2)6-10-15/h3-11H,1-2H3,(H,20,21,22,23)
DM41RZX	CS	CC1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=C(C=C4)C)N=CN3
DM41RZX	IK	DEIRTPFLGXETKT-UHFFFAOYSA-N
DM41RZX	IU	2,6-bis(4-methylphenyl)-7H-purine
DM41RZX	DE	Discovery agent

DMREF31	ID	DMREF31
DMREF31	DN	2,6-diamino-5-nitropyrimidin-4(3H)-one
DMREF31	HS	Investigative
DMREF31	DT	Small molecular drug
DMREF31	PC	135461662
DMREF31	MW	171.11
DMREF31	FM	C4H5N5O3
DMREF31	IC	InChI=1S/C4H5N5O3/c5-2-1(9(11)12)3(10)8-4(6)7-2/h(H5,5,6,7,8,10)
DMREF31	CS	C1(=C(N=C(NC1=O)N)N)[N+](=O)[O-]
DMREF31	IK	XNFGVBWYGFPSDN-UHFFFAOYSA-N
DMREF31	IU	2,4-diamino-5-nitro-1H-pyrimidin-6-one
DMREF31	CA	CAS 3346-23-4
DMREF31	DE	Discovery agent

DM4RS9N	ID	DM4RS9N
DM4RS9N	DN	2,6-diamino-5-nitrosopyrimidin-4(3H)-one
DM4RS9N	HS	Investigative
DM4RS9N	DT	Small molecular drug
DM4RS9N	PC	135408762
DM4RS9N	MW	155.12
DM4RS9N	FM	C4H5N5O2
DM4RS9N	IC	InChI=1S/C4H5N5O2/c5-2-1(9-11)3(10)8-4(6)7-2/h(H5,5,6,7,8,10)
DM4RS9N	CS	C1(=C(N=C(NC1=O)N)N)N=O
DM4RS9N	IK	HVMRLFSFHWCUCG-UHFFFAOYSA-N
DM4RS9N	IU	2,4-diamino-5-nitroso-1H-pyrimidin-6-one
DM4RS9N	CA	CAS 2387-48-6
DM4RS9N	DE	Discovery agent

DM8JFNU	ID	DM8JFNU
DM8JFNU	DN	2,6-DICARBOXYNAPHTHALENE
DM8JFNU	HS	Investigative
DM8JFNU	SN	2,6-Naphthalenedicarboxylic acid; naphthalene-2,6-dicarboxylic acid; 1141-38-4; 2,6-NAPHTHALIC ACID; 2,6-DICARBOXYNAPHTHALENE; UNII-K3C4DYZ29O; 2,6-naphthalene dicarboxylic acid; EINECS 214-527-0; NSC 96410; K3C4DYZ29O; CHEBI:44460; RXOHFPCZGPKIRD-UHFFFAOYSA-N; MFCD00004105; FR-1318; W-108606; DSSTox_CID_9211; ACMC-2099kj; AC1Q73RL; NCIOpen2_007124; DSSTox_RID_78711; DSSTox_GSID_29211; SCHEMBL18758; AC1L23O7; 2,6-Naphthalenedicarboxylicacid; 2,6-Naphthalendicarboxylic acid; Jsp001070; CHEMBL1205452; DTXSID5029211; CTK0H6341
DM8JFNU	DT	Small molecular drug
DM8JFNU	PC	14357
DM8JFNU	MW	216.19
DM8JFNU	FM	C12H8O4
DM8JFNU	IC	InChI=1S/C12H8O4/c13-11(14)9-3-1-7-5-10(12(15)16)4-2-8(7)6-9/h1-6H,(H,13,14)(H,15,16)
DM8JFNU	CS	C1=CC2=C(C=CC(=C2)C(=O)O)C=C1C(=O)O
DM8JFNU	IK	RXOHFPCZGPKIRD-UHFFFAOYSA-N
DM8JFNU	IU	naphthalene-2,6-dicarboxylic acid
DM8JFNU	CA	CAS 1141-38-4
DM8JFNU	CB	CHEBI:44460
DM8JFNU	DE	Discovery agent

DMGEYAK	ID	DMGEYAK
DMGEYAK	DN	2,6-Difluorobenzenesulfonamide
DMGEYAK	HS	Investigative
DMGEYAK	SN	2,6-DIFLUOROBENZENESULFONAMIDE; 60230-37-7; 2,6-difluorobenzenesulphonamide; 2,6-difluorobenzene-1-sulfonamide; Benzenesulfonamide, 2,6-difluoro-; FBT; 2,6-Difluorophenylsulphonylamide; PubChem11779; ACMC-209vki; AC1L9JF9; KSC495S1R; SCHEMBL677588; 2,6-difluorobenzenesulfon-amide; 2,6-difluoro-benzenesulfonamide; CTK3J5918; CHEBI:42429; DTXSID60332218; MolPort-000-154-262; RVVVGGCOFWWDEL-UHFFFAOYSA-N; ZINC404039; KS-000010UU; WT2099; STL554304; SBB091559; WT1897; BBL100510; ANW-45184; 2,6-Difluorobenzenesulfonamide, 97%
DMGEYAK	DT	Small molecular drug
DMGEYAK	PC	446274
DMGEYAK	MW	193.17
DMGEYAK	FM	C6H5F2NO2S
DMGEYAK	IC	InChI=1S/C6H5F2NO2S/c7-4-2-1-3-5(8)6(4)12(9,10)11/h1-3H,(H2,9,10,11)
DMGEYAK	CS	C1=CC(=C(C(=C1)F)S(=O)(=O)N)F
DMGEYAK	IK	RVVVGGCOFWWDEL-UHFFFAOYSA-N
DMGEYAK	IU	2,6-difluorobenzenesulfonamide
DMGEYAK	CA	CAS 60230-37-7
DMGEYAK	CB	CHEBI:42429
DMGEYAK	DE	Discovery agent

DMDN12L	ID	DMDN12L
DMDN12L	DN	2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
DMDN12L	HS	Investigative
DMDN12L	SN	Anthra[1,9-cd]pyrazol-6(2H)-one; 129-56-6; 1,9-Pyrazoloanthrone; SP600125; Pyrazolanthrone; Dibenzo[cd,g]indazol-6(2H)-one; Pyrazoleanthrone; SP 600125; Anthra-1,9-pyrazol-6-none; SP-600125; CI 70300; 2H-Dibenzo[cd,g]indazol-6-one; JNK Inhibitor II; SAPK Inhibitor II; NSC 75890; UNII-1TW30Y2766; ANTHRA(1,9-cd)PYRAZOL-6(2H)-ONE; EINECS 204-955-6; 2,6-DIHYDROANTHRA/1,9-CD/PYRAZOL-6-ONE; BRN 0746890; CHEMBL7064; MLS002693964; CHEBI:90695; ACPOUJIDANTYHO-UHFFFAOYSA-N; 1TW30Y2766
DMDN12L	DT	Small molecular drug
DMDN12L	PC	8515
DMDN12L	MW	220.23
DMDN12L	FM	C14H8N2O
DMDN12L	IC	InChI=1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)
DMDN12L	CS	C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O
DMDN12L	IK	ACPOUJIDANTYHO-UHFFFAOYSA-N
DMDN12L	IU	14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one
DMDN12L	CA	CAS 129-56-6
DMDN12L	CB	CHEBI:90695
DMDN12L	DE	Discovery agent

DM5QEUC	ID	DM5QEUC
DM5QEUC	DN	2,6-dihydroxy-1,7-dimethoxyxanthone
DM5QEUC	HS	Investigative
DM5QEUC	SN	calophymembranol A; 2,6-dihydroxy-1,7-dimethoxyxanthone; CHEMBL463769; AC1NRZXJ; BDBM50269644; 2,6-dihydroxy-1,7-dimethoxyxanthen-9-one
DM5QEUC	DT	Small molecular drug
DM5QEUC	PC	5326145
DM5QEUC	MW	288.25
DM5QEUC	FM	C15H12O6
DM5QEUC	IC	InChI=1S/C15H12O6/c1-19-12-5-7-11(6-9(12)17)21-10-4-3-8(16)15(20-2)13(10)14(7)18/h3-6,16-17H,1-2H3
DM5QEUC	CS	COC1=C(C=C2C(=C1)C(=O)C3=C(O2)C=CC(=C3OC)O)O
DM5QEUC	IK	SROSPGQNFCAFNO-UHFFFAOYSA-N
DM5QEUC	IU	2,6-dihydroxy-1,7-dimethoxyxanthen-9-one
DM5QEUC	DE	Discovery agent

DMD51I4	ID	DMD51I4
DMD51I4	DN	2,6-Diisopropyl-4-nitro-phenol
DMD51I4	HS	Investigative
DMD51I4	SN	2,6-Diisopropyl-4-nitrophenol; 4-Nitro Propofol; 1576-14-3; Phenol, 2,6-bis(1-methylethyl)-4-nitro-; 4-Nitro-2,6-diisopropylphenol; SCHEMBL6978784; CHEMBL299111; DTXSID20443430; BDOVQBSHXBPOLJ-UHFFFAOYSA-N; ZINC13779578; 2,6-bis(1-methylethyl)-4-nitrophenol; 2,6-Bis(1-methylethyl)-4-nitro-phenol; FT-0672927
DMD51I4	DT	Small molecular drug
DMD51I4	PC	10680603
DMD51I4	MW	223.27
DMD51I4	FM	C12H17NO3
DMD51I4	IC	InChI=1S/C12H17NO3/c1-7(2)10-5-9(13(15)16)6-11(8(3)4)12(10)14/h5-8,14H,1-4H3
DMD51I4	CS	CC(C)C1=CC(=CC(=C1O)C(C)C)[N+](=O)[O-]
DMD51I4	IK	BDOVQBSHXBPOLJ-UHFFFAOYSA-N
DMD51I4	IU	4-nitro-2,6-di(propan-2-yl)phenol
DMD51I4	CA	CAS 1576-14-3
DMD51I4	DE	Discovery agent

DMRZJU5	ID	DMRZJU5
DMRZJU5	DN	2,6-dimethyl-8-ethyl-1-deazapurine
DMRZJU5	HS	Investigative
DMRZJU5	SN	133240-06-9; 2-Ethyl-5,7-dimethyl-1H-imidazo[4,5-b]pyridine; 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine; CHEMBL221579; 3H-Imidazo[4,5-b]pyridine,2-ethyl-5,7-dimethyl-; 5,7-Dimethyl-2-ethylimidazo[4,5-b]pyridine; 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-; 2,6-dimethyl-8-ethyl-1-deazapurine; ACMC-20dzbe; SCHEMBL1918476; CTK4B8431; DTXSID40431137; XWWJWZJOSWSJQV-UHFFFAOYSA-N; ZINC22058897; BDBM50205288; ANW-72022; AKOS000278272; AKOS015904384; RTX-011778; FCH1411209; AM803160; SC-21701; KB-23752; AJ-80864; TC-160767
DMRZJU5	DT	Small molecular drug
DMRZJU5	PC	9815374
DMRZJU5	MW	175.23
DMRZJU5	FM	C10H13N3
DMRZJU5	IC	InChI=1S/C10H13N3/c1-4-8-12-9-6(2)5-7(3)11-10(9)13-8/h5H,4H2,1-3H3,(H,11,12,13)
DMRZJU5	CS	CCC1=NC2=C(N1)C(=CC(=N2)C)C
DMRZJU5	IK	XWWJWZJOSWSJQV-UHFFFAOYSA-N
DMRZJU5	IU	2-ethyl-5,7-dimethyl-1H-imidazo[4,5-b]pyridine
DMRZJU5	CA	CAS 133240-06-9
DMRZJU5	DE	Discovery agent

DMW2VZ1	ID	DMW2VZ1
DMW2VZ1	DN	2,6-diphenyl-1-deazapurine
DMW2VZ1	HS	Investigative
DMW2VZ1	SN	CHEMBL220535; 2,6-diphenyl-1-deazapurine; ZINC34800849
DMW2VZ1	DT	Small molecular drug
DMW2VZ1	PC	16109423
DMW2VZ1	MW	271.3
DMW2VZ1	FM	C18H13N3
DMW2VZ1	IC	InChI=1S/C18H13N3/c1-3-7-13(8-4-1)15-11-16(14-9-5-2-6-10-14)21-18-17(15)19-12-20-18/h1-12H,(H,19,20,21)
DMW2VZ1	CS	C1=CC=C(C=C1)C2=CC(=NC3=C2NC=N3)C4=CC=CC=C4
DMW2VZ1	IK	JRQCVLBKLGJDMI-UHFFFAOYSA-N
DMW2VZ1	IU	5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMW2VZ1	DE	Discovery agent

DMY3C78	ID	DMY3C78
DMY3C78	DN	2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine
DMY3C78	HS	Investigative
DMY3C78	SN	CHEMBL385109; 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine
DMY3C78	DT	Small molecular drug
DMY3C78	PC	16109429
DMY3C78	MW	341.4
DMY3C78	FM	C23H23N3
DMY3C78	IC	InChI=1S/C23H23N3/c1-3-16(4-2)22-25-21-19(17-11-7-5-8-12-17)15-20(24-23(21)26-22)18-13-9-6-10-14-18/h5-16H,3-4H2,1-2H3,(H,24,25,26)
DMY3C78	CS	CCC(CC)C1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DMY3C78	IK	GPQRSDCKVYJMOH-UHFFFAOYSA-N
DMY3C78	IU	2-pentan-3-yl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMY3C78	DE	Discovery agent

DM0C8BW	ID	DM0C8BW
DM0C8BW	DN	2,6-diphenyl-8-ethyl-1-deazapurine
DM0C8BW	HS	Investigative
DM0C8BW	SN	CHEMBL222130; 2,6-diphenyl-8-ethyl-1-deazapurine
DM0C8BW	DT	Small molecular drug
DM0C8BW	PC	16109432
DM0C8BW	MW	299.4
DM0C8BW	FM	C20H17N3
DM0C8BW	IC	InChI=1S/C20H17N3/c1-2-18-22-19-16(14-9-5-3-6-10-14)13-17(21-20(19)23-18)15-11-7-4-8-12-15/h3-13H,2H2,1H3,(H,21,22,23)
DM0C8BW	CS	CCC1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DM0C8BW	IK	PMDYRFYZMJGDQY-UHFFFAOYSA-N
DM0C8BW	IU	2-ethyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DM0C8BW	DE	Discovery agent

DMI79FV	ID	DMI79FV
DMI79FV	DN	2,6-diphenyl-8-methyl-1-deazapurine
DMI79FV	HS	Investigative
DMI79FV	SN	CHEMBL220587; 2,6-diphenyl-8-methyl-1-deazapurine
DMI79FV	DT	Small molecular drug
DMI79FV	PC	16109426
DMI79FV	MW	285.3
DMI79FV	FM	C19H15N3
DMI79FV	IC	InChI=1S/C19H15N3/c1-13-20-18-16(14-8-4-2-5-9-14)12-17(22-19(18)21-13)15-10-6-3-7-11-15/h2-12H,1H3,(H,20,21,22)
DMI79FV	CS	CC1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DMI79FV	IK	HKDKOLLILMBGNN-UHFFFAOYSA-N
DMI79FV	IU	2-methyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMI79FV	DE	Discovery agent

DM6D1BQ	ID	DM6D1BQ
DM6D1BQ	DN	2,6-diphenyl-8-tButyl-1-deazapurine
DM6D1BQ	HS	Investigative
DM6D1BQ	SN	CHEMBL220053; 2,6-diphenyl-8-tButyl-1-deazapurine
DM6D1BQ	DT	Small molecular drug
DM6D1BQ	PC	16109434
DM6D1BQ	MW	327.4
DM6D1BQ	FM	C22H21N3
DM6D1BQ	IC	InChI=1S/C22H21N3/c1-22(2,3)21-24-19-17(15-10-6-4-7-11-15)14-18(23-20(19)25-21)16-12-8-5-9-13-16/h4-14H,1-3H3,(H,23,24,25)
DM6D1BQ	CS	CC(C)(C)C1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DM6D1BQ	IK	LYZUCUIUVUYBJL-UHFFFAOYSA-N
DM6D1BQ	IU	2-tert-butyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DM6D1BQ	DE	Discovery agent

DM5SXYI	ID	DM5SXYI
DM5SXYI	DN	2,6-diphenyl-9H-purine
DM5SXYI	HS	Investigative
DM5SXYI	SN	2,6-diphenyl-9H-purine; 1H-Purine, 2,6-diphenyl-; CHEMBL381729; 889673-58-9; CTK3A4137; DTXSID90468791
DM5SXYI	DT	Small molecular drug
DM5SXYI	PC	11572592
DM5SXYI	MW	272.3
DM5SXYI	FM	C17H12N4
DM5SXYI	IC	InChI=1S/C17H12N4/c1-3-7-12(8-4-1)14-15-17(19-11-18-15)21-16(20-14)13-9-5-2-6-10-13/h1-11H,(H,18,19,20,21)
DM5SXYI	CS	C1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=CC=C4)N=CN3
DM5SXYI	IK	WNVFFQZYOFELQA-UHFFFAOYSA-N
DM5SXYI	IU	2,6-diphenyl-7H-purine
DM5SXYI	CA	CAS 889673-58-9
DM5SXYI	DE	Discovery agent

DM3JURW	ID	DM3JURW
DM3JURW	DN	2,6-Diphenyl-pyrimidin-4-ylamine
DM3JURW	HS	Investigative
DM3JURW	SN	4-Amino-2,6-diphenylpyrimidine; 2,6-diphenylpyrimidin-4-amine; CHEMBL406788; PLXFRDQUOPPVHF-UHFFFAOYSA-N; 2,6-Diphenyl-4-pyrimidinamine; AC1LDIB7; SCHEMBL1490059; 2,6-Diphenyl-4-pyrimidinamine #; ZINC29062470; BDBM50375487; AKOS011055092; (2,6-diphenyl-pyrimidin-4-yl)-amine
DM3JURW	DT	Small molecular drug
DM3JURW	PC	619020
DM3JURW	MW	247.29
DM3JURW	FM	C16H13N3
DM3JURW	IC	InChI=1S/C16H13N3/c17-15-11-14(12-7-3-1-4-8-12)18-16(19-15)13-9-5-2-6-10-13/h1-11H,(H2,17,18,19)
DM3JURW	CS	C1=CC=C(C=C1)C2=CC(=NC(=N2)C3=CC=CC=C3)N
DM3JURW	IK	PLXFRDQUOPPVHF-UHFFFAOYSA-N
DM3JURW	IU	2,6-diphenylpyrimidin-4-amine
DM3JURW	DE	Discovery agent

DMY8LDT	ID	DMY8LDT
DMY8LDT	DN	2,6-di-t-butylphenol
DMY8LDT	HS	Investigative
DMY8LDT	SN	2,6-DI-TERT-BUTYLPHENOL; 128-39-2; 2,6-Di-t-butylphenol; 2,6-Bis(tert-butyl)phenol; 2,6-Bis(1,1-dimethylethyl)phenol; Phenol, 2,6-bis(1,1-dimethylethyl)-; 2,6-ditert-butylphenol; 2,6 Di-tert-butylphenol; Ethanox 701; Isonox 103; Ethyl 701; Ethyl AN 701; Hitec 4701; Phenol, 2,6-di-tert-butyl-; 2,6-Bis(t-butyl)phenol; NSC 49175; AN 701; CCRIS 5828; UNII-21294V58PF; HSDB 5616; 2,6-(1,1-Dimethylethyl)phenol; EINECS 204-884-0; MFCD00008820; 2,6-di-tert.-butylphenol; 2,6-Di-tert-butyl-phenol; AI3-26293; CHEMBL281071
DMY8LDT	DT	Small molecular drug
DMY8LDT	PC	31405
DMY8LDT	MW	206.32
DMY8LDT	FM	C14H22O
DMY8LDT	IC	InChI=1S/C14H22O/c1-13(2,3)10-8-7-9-11(12(10)15)14(4,5)6/h7-9,15H,1-6H3
DMY8LDT	CS	CC(C)(C)C1=C(C(=CC=C1)C(C)(C)C)O
DMY8LDT	IK	DKCPKDPYUFEZCP-UHFFFAOYSA-N
DMY8LDT	IU	2,6-ditert-butylphenol
DMY8LDT	CA	CAS 128-39-2
DMY8LDT	CB	CHEBI:131421
DMY8LDT	DE	Discovery agent

DMFO1H2	ID	DMFO1H2
DMFO1H2	DN	2,6-di-tert-butyl-4-methoxyphenol
DMFO1H2	HS	Investigative
DMFO1H2	SN	2,6-DI-TERT-BUTYL-4-METHOXYPHENOL; 489-01-0; 3,5-Di-tert-butyl-4-hydroxyanisole; Topanol 354; Phenol, 2,6-bis(1,1-dimethylethyl)-4-methoxy-; 3,5-di-t-Butyl-4-hydroxyanisole; UNII-616072TMXY; CCRIS 5219; 2,6-Bis(1,1-dimethylethyl)-4-methoxyphenol; EINECS 207-693-0; NSC 14451; Phenol, 2,6-di-tert-butyl-4-methoxy-; CHEMBL98253; 2,6-di-t-butyl-4-methoxyphenol; SLUKQUGVTITNSY-UHFFFAOYSA-N; 2,6-ditert-butyl-4-methoxyphenol; 616072TMXY; 2,6-bis(tert-butyl)-4-methoxyphenol; 2,6-Di-tert-butyl-4-methoxyphenol, 97%; DTBHA; ACMC-1ALDH
DMFO1H2	DT	Small molecular drug
DMFO1H2	PC	10269
DMFO1H2	MW	236.35
DMFO1H2	FM	C15H24O2
DMFO1H2	IC	InChI=1S/C15H24O2/c1-14(2,3)11-8-10(17-7)9-12(13(11)16)15(4,5)6/h8-9,16H,1-7H3
DMFO1H2	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)OC
DMFO1H2	IK	SLUKQUGVTITNSY-UHFFFAOYSA-N
DMFO1H2	IU	2,6-ditert-butyl-4-methoxyphenol
DMFO1H2	CA	CAS 489-01-0
DMFO1H2	DE	Discovery agent

DM8F9KO	ID	DM8F9KO
DM8F9KO	DN	2,6-dphenyl-8-propyl-1-deazapurine
DM8F9KO	HS	Investigative
DM8F9KO	SN	CHEMBL376648; 2,6-dphenyl-8-propyl-1-deazapurine
DM8F9KO	DT	Small molecular drug
DM8F9KO	PC	16109427
DM8F9KO	MW	313.4
DM8F9KO	FM	C21H19N3
DM8F9KO	IC	InChI=1S/C21H19N3/c1-2-9-19-23-20-17(15-10-5-3-6-11-15)14-18(22-21(20)24-19)16-12-7-4-8-13-16/h3-8,10-14H,2,9H2,1H3,(H,22,23,24)
DM8F9KO	CS	CCCC1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DM8F9KO	IK	DBBRCPJIWFJBPI-UHFFFAOYSA-N
DM8F9KO	IU	5,7-diphenyl-2-propyl-1H-imidazo[4,5-b]pyridine
DM8F9KO	DE	Discovery agent

DMT9JHV	ID	DMT9JHV
DMT9JHV	DN	2,7-Bis(3-chloropropionamido)anthraquinone
DMT9JHV	HS	Investigative
DMT9JHV	SN	2,7-Bis(3-chloropropionamido)anthraquinone; SCHEMBL4294857; CHEMBL494457
DMT9JHV	DT	Small molecular drug
DMT9JHV	PC	10669736
DMT9JHV	MW	419.3
DMT9JHV	FM	C20H16Cl2N2O4
DMT9JHV	IC	InChI=1S/C20H16Cl2N2O4/c21-7-5-17(25)23-11-1-3-13-15(9-11)20(28)16-10-12(24-18(26)6-8-22)2-4-14(16)19(13)27/h1-4,9-10H,5-8H2,(H,23,25)(H,24,26)
DMT9JHV	CS	C1=CC2=C(C=C1NC(=O)CCCl)C(=O)C3=C(C2=O)C=CC(=C3)NC(=O)CCCl
DMT9JHV	IK	ZOTZWUALAZOEAF-UHFFFAOYSA-N
DMT9JHV	IU	3-chloro-N-[7-(3-chloropropanoylamino)-9,10-dioxoanthracen-2-yl]propanamide
DMT9JHV	DE	Discovery agent

DM8VWQ2	ID	DM8VWQ2
DM8VWQ2	DN	2,7-Bis(4-chlorobutyramido)anthraquinone
DM8VWQ2	HS	Investigative
DM8VWQ2	SN	2,7-Bis(4-chlorobutyramido)anthraquinone; SCHEMBL4293006
DM8VWQ2	DT	Small molecular drug
DM8VWQ2	PC	44242844
DM8VWQ2	MW	447.3
DM8VWQ2	FM	C22H20Cl2N2O4
DM8VWQ2	IC	InChI=1S/C22H20Cl2N2O4/c23-9-1-3-19(27)25-13-5-7-15-17(11-13)22(30)18-12-14(6-8-16(18)21(15)29)26-20(28)4-2-10-24/h5-8,11-12H,1-4,9-10H2,(H,25,27)(H,26,28)
DM8VWQ2	CS	C1=CC2=C(C=C1NC(=O)CCCCl)C(=O)C3=C(C2=O)C=CC(=C3)NC(=O)CCCCl
DM8VWQ2	IK	OWZXQHSZHVLBPE-UHFFFAOYSA-N
DM8VWQ2	IU	4-chloro-N-[7-(4-chlorobutanoylamino)-9,10-dioxoanthracen-2-yl]butanamide
DM8VWQ2	DE	Discovery agent

DM2EPM4	ID	DM2EPM4
DM2EPM4	DN	2,7-Bis(acetamido)anthraquinone
DM2EPM4	HS	Investigative
DM2EPM4	SN	2,7-Bis(acetamido)anthraquinone; CHEMBL481175; SCHEMBL4291944
DM2EPM4	DT	Small molecular drug
DM2EPM4	PC	44568336
DM2EPM4	MW	322.3
DM2EPM4	FM	C18H14N2O4
DM2EPM4	IC	InChI=1S/C18H14N2O4/c1-9(21)19-11-3-5-13-15(7-11)18(24)16-8-12(20-10(2)22)4-6-14(16)17(13)23/h3-8H,1-2H3,(H,19,21)(H,20,22)
DM2EPM4	CS	CC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)C
DM2EPM4	IK	SNSGXIQBZKNIJT-UHFFFAOYSA-N
DM2EPM4	IU	N-(7-acetamido-9,10-dioxoanthracen-2-yl)acetamide
DM2EPM4	DE	Discovery agent

DMEQC4X	ID	DMEQC4X
DMEQC4X	DN	2,7-Bis(benzoamido)anthraquinone
DMEQC4X	HS	Investigative
DMEQC4X	SN	2,7-Bis(benzoamido)anthraquinone; SCHEMBL4289564
DMEQC4X	DT	Small molecular drug
DMEQC4X	PC	44243461
DMEQC4X	MW	446.5
DMEQC4X	FM	C28H18N2O4
DMEQC4X	IC	InChI=1S/C28H18N2O4/c31-25-21-13-11-19(29-27(33)17-7-3-1-4-8-17)15-23(21)26(32)24-16-20(12-14-22(24)25)30-28(34)18-9-5-2-6-10-18/h1-16H,(H,29,33)(H,30,34)
DMEQC4X	CS	C1=CC=C(C=C1)C(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)C5=CC=CC=C5
DMEQC4X	IK	IJKYLKHKCJTQGH-UHFFFAOYSA-N
DMEQC4X	IU	N-(7-benzamido-9,10-dioxoanthracen-2-yl)benzamide
DMEQC4X	DE	Discovery agent

DM9S8LY	ID	DM9S8LY
DM9S8LY	DN	2,7-Bis(butyramido)anthraquinone
DM9S8LY	HS	Investigative
DM9S8LY	SN	2,7-Bis(butyramido)anthraquinone; SCHEMBL4298269; CHEMBL480780
DM9S8LY	DT	Small molecular drug
DM9S8LY	PC	44243462
DM9S8LY	MW	378.4
DM9S8LY	FM	C22H22N2O4
DM9S8LY	IC	InChI=1S/C22H22N2O4/c1-3-5-19(25)23-13-7-9-15-17(11-13)22(28)18-12-14(24-20(26)6-4-2)8-10-16(18)21(15)27/h7-12H,3-6H2,1-2H3,(H,23,25)(H,24,26)
DM9S8LY	CS	CCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCC
DM9S8LY	IK	WKZCLVUWGOTILL-UHFFFAOYSA-N
DM9S8LY	IU	N-[7-(butanoylamino)-9,10-dioxoanthracen-2-yl]butanamide
DM9S8LY	DE	Discovery agent

DM4MYAR	ID	DM4MYAR
DM4MYAR	DN	2,7-Bis(chloroacetamido)anthraquinone
DM4MYAR	HS	Investigative
DM4MYAR	SN	2,7-Bis(chloroacetamido)anthraquinone; SCHEMBL4294197; CHEMBL492429
DM4MYAR	DT	Small molecular drug
DM4MYAR	PC	44243423
DM4MYAR	MW	391.2
DM4MYAR	FM	C18H12Cl2N2O4
DM4MYAR	IC	InChI=1S/C18H12Cl2N2O4/c19-7-15(23)21-9-1-3-11-13(5-9)18(26)14-6-10(22-16(24)8-20)2-4-12(14)17(11)25/h1-6H,7-8H2,(H,21,23)(H,22,24)
DM4MYAR	CS	C1=CC2=C(C=C1NC(=O)CCl)C(=O)C3=C(C2=O)C=CC(=C3)NC(=O)CCl
DM4MYAR	IK	MKVRAGYBTIZOIV-UHFFFAOYSA-N
DM4MYAR	IU	2-chloro-N-[7-[(2-chloroacetyl)amino]-9,10-dioxoanthracen-2-yl]acetamide
DM4MYAR	DE	Discovery agent

DMTPZ8D	ID	DMTPZ8D
DMTPZ8D	DN	2,7-Bis(cyclohexanecarbonamido)anthraquinone
DMTPZ8D	HS	Investigative
DMTPZ8D	SN	2,7-Bis(cyclohexanecarbonamido)anthraquinone; CHEMBL479981
DMTPZ8D	DT	Small molecular drug
DMTPZ8D	PC	44243425
DMTPZ8D	MW	458.5
DMTPZ8D	FM	C28H30N2O4
DMTPZ8D	IC	InChI=1S/C28H30N2O4/c31-25-21-13-11-19(29-27(33)17-7-3-1-4-8-17)15-23(21)26(32)24-16-20(12-14-22(24)25)30-28(34)18-9-5-2-6-10-18/h11-18H,1-10H2,(H,29,33)(H,30,34)
DMTPZ8D	CS	C1CCC(CC1)C(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)C5CCCCC5
DMTPZ8D	IK	ISUCEGSINPVOBA-UHFFFAOYSA-N
DMTPZ8D	IU	N-[7-(cyclohexanecarbonylamino)-9,10-dioxoanthracen-2-yl]cyclohexanecarboxamide
DMTPZ8D	DE	Discovery agent

DMP3EZ8	ID	DMP3EZ8
DMP3EZ8	DN	2,7-Bis(cyclopentanecarbonamido)anthraquinone
DMP3EZ8	HS	Investigative
DMP3EZ8	SN	2,7-Bis(cyclopentanecarbonamido)anthraquinone; CHEMBL480939; SCHEMBL4293737
DMP3EZ8	DT	Small molecular drug
DMP3EZ8	PC	44568364
DMP3EZ8	MW	430.5
DMP3EZ8	FM	C26H26N2O4
DMP3EZ8	IC	InChI=1S/C26H26N2O4/c29-23-19-11-9-17(27-25(31)15-5-1-2-6-15)13-21(19)24(30)22-14-18(10-12-20(22)23)28-26(32)16-7-3-4-8-16/h9-16H,1-8H2,(H,27,31)(H,28,32)
DMP3EZ8	CS	C1CCC(C1)C(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)C5CCCC5
DMP3EZ8	IK	IYTIDEOSIOFBPE-UHFFFAOYSA-N
DMP3EZ8	IU	N-[7-(cyclopentanecarbonylamino)-9,10-dioxoanthracen-2-yl]cyclopentanecarboxamide
DMP3EZ8	DE	Discovery agent

DMY3V2B	ID	DMY3V2B
DMY3V2B	DN	2,7-Bis(cyclopropanecarbonamido)anthraquinone
DMY3V2B	HS	Investigative
DMY3V2B	SN	2,7-Bis(cyclopropanecarbonamido)anthraquinone; CHEMBL520920; SCHEMBL4296357
DMY3V2B	DT	Small molecular drug
DMY3V2B	PC	44243459
DMY3V2B	MW	374.4
DMY3V2B	FM	C22H18N2O4
DMY3V2B	IC	InChI=1S/C22H18N2O4/c25-19-15-7-5-13(23-21(27)11-1-2-11)9-17(15)20(26)18-10-14(6-8-16(18)19)24-22(28)12-3-4-12/h5-12H,1-4H2,(H,23,27)(H,24,28)
DMY3V2B	CS	C1CC1C(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)C5CC5
DMY3V2B	IK	SCYQIQINYUMLPD-UHFFFAOYSA-N
DMY3V2B	IU	N-[7-(cyclopropanecarbonylamino)-9,10-dioxoanthracen-2-yl]cyclopropanecarboxamide
DMY3V2B	DE	Discovery agent

DMEVIBT	ID	DMEVIBT
DMEVIBT	DN	2,7-Bis(phenylacetamido)anthraquinone
DMEVIBT	HS	Investigative
DMEVIBT	SN	2,7-Bis(phenylacetamido)anthraquinone; CHEMBL480771
DMEVIBT	DT	Small molecular drug
DMEVIBT	PC	44232525
DMEVIBT	MW	474.5
DMEVIBT	FM	C30H22N2O4
DMEVIBT	IC	InChI=1S/C30H22N2O4/c33-27(15-19-7-3-1-4-8-19)31-21-11-13-23-25(17-21)30(36)26-18-22(12-14-24(26)29(23)35)32-28(34)16-20-9-5-2-6-10-20/h1-14,17-18H,15-16H2,(H,31,33)(H,32,34)
DMEVIBT	CS	C1=CC=C(C=C1)CC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CC5=CC=CC=C5
DMEVIBT	IK	YFLLPGICLQVMIU-UHFFFAOYSA-N
DMEVIBT	IU	N-[9,10-dioxo-7-[(2-phenylacetyl)amino]anthracen-2-yl]-2-phenylacetamide
DMEVIBT	DE	Discovery agent

DMDKXEY	ID	DMDKXEY
DMDKXEY	DN	2,7-Bis(phenylpropionamido)anthraquinone
DMDKXEY	HS	Investigative
DMDKXEY	SN	2,7-Bis(phenylpropionamido)anthraquinone; SCHEMBL4296330
DMDKXEY	DT	Small molecular drug
DMDKXEY	PC	44243460
DMDKXEY	MW	502.6
DMDKXEY	FM	C32H26N2O4
DMDKXEY	IC	InChI=1S/C32H26N2O4/c35-29(17-11-21-7-3-1-4-8-21)33-23-13-15-25-27(19-23)32(38)28-20-24(14-16-26(28)31(25)37)34-30(36)18-12-22-9-5-2-6-10-22/h1-10,13-16,19-20H,11-12,17-18H2,(H,33,35)(H,34,36)
DMDKXEY	CS	C1=CC=C(C=C1)CCC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CCC5=CC=CC=C5
DMDKXEY	IK	SZRGPNHLVDLPHX-UHFFFAOYSA-N
DMDKXEY	IU	N-[9,10-dioxo-7-(3-phenylpropanoylamino)anthracen-2-yl]-3-phenylpropanamide
DMDKXEY	DE	Discovery agent

DM2D1EJ	ID	DM2D1EJ
DM2D1EJ	DN	2,7-Bis(propionamido)anthraquinone
DM2D1EJ	HS	Investigative
DM2D1EJ	SN	2,7-Bis(propionamido)anthraquinone; SCHEMBL4299908; CHEMBL481176
DM2D1EJ	DT	Small molecular drug
DM2D1EJ	PC	44568337
DM2D1EJ	MW	350.4
DM2D1EJ	FM	C20H18N2O4
DM2D1EJ	IC	InChI=1S/C20H18N2O4/c1-3-17(23)21-11-5-7-13-15(9-11)20(26)16-10-12(22-18(24)4-2)6-8-14(16)19(13)25/h5-10H,3-4H2,1-2H3,(H,21,23)(H,22,24)
DM2D1EJ	CS	CCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CC
DM2D1EJ	IK	FNUQOQZYSRMGQN-UHFFFAOYSA-N
DM2D1EJ	IU	N-[9,10-dioxo-7-(propanoylamino)anthracen-2-yl]propanamide
DM2D1EJ	DE	Discovery agent

DM3GTV0	ID	DM3GTV0
DM3GTV0	DN	2,7-Bis[2-(butylamino)acetamido]anthraquinone
DM3GTV0	HS	Investigative
DM3GTV0	SN	2,7-Bis[2-(butylamino)acetamido]anthraquinone; SCHEMBL4294896; CHEMBL494076
DM3GTV0	DT	Small molecular drug
DM3GTV0	PC	44568666
DM3GTV0	MW	464.6
DM3GTV0	FM	C26H32N4O4
DM3GTV0	IC	InChI=1S/C26H32N4O4/c1-3-5-11-27-15-23(31)29-17-7-9-19-21(13-17)26(34)22-14-18(8-10-20(22)25(19)33)30-24(32)16-28-12-6-4-2/h7-10,13-14,27-28H,3-6,11-12,15-16H2,1-2H3,(H,29,31)(H,30,32)
DM3GTV0	CS	CCCCNCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNCCCC
DM3GTV0	IK	FYPZVYMKSUFNRS-UHFFFAOYSA-N
DM3GTV0	IU	2-(butylamino)-N-[7-[[2-(butylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DM3GTV0	DE	Discovery agent

DMKDSGE	ID	DMKDSGE
DMKDSGE	DN	2,7-Bis[2-(diethylamino)acetamido]anthraquinone
DMKDSGE	HS	Investigative
DMKDSGE	SN	2,7-Bis[2-(diethylamino)acetamido]anthraquinone; SCHEMBL4305307; CHEMBL493878
DMKDSGE	DT	Small molecular drug
DMKDSGE	PC	44243424
DMKDSGE	MW	464.6
DMKDSGE	FM	C26H32N4O4
DMKDSGE	IC	InChI=1S/C26H32N4O4/c1-5-29(6-2)15-23(31)27-17-9-11-19-21(13-17)26(34)22-14-18(10-12-20(22)25(19)33)28-24(32)16-30(7-3)8-4/h9-14H,5-8,15-16H2,1-4H3,(H,27,31)(H,28,32)
DMKDSGE	CS	CCN(CC)CC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CN(CC)CC
DMKDSGE	IK	ZNVJTQUBGZVROG-UHFFFAOYSA-N
DMKDSGE	IU	2-(diethylamino)-N-[7-[[2-(diethylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DMKDSGE	DE	Discovery agent

DMNW5PL	ID	DMNW5PL
DMNW5PL	DN	2,7-Bis[2-(dimethylamino)acetamido]anthraquinone
DMNW5PL	HS	Investigative
DMNW5PL	SN	2,7-Bis[2-(dimethylamino)acetamido]anthraquinone; SCHEMBL4291524; CHEMBL494283; BQUQDCVNESTXAU-UHFFFAOYSA-N
DMNW5PL	DT	Small molecular drug
DMNW5PL	PC	44568710
DMNW5PL	MW	408.4
DMNW5PL	FM	C22H24N4O4
DMNW5PL	IC	InChI=1S/C22H24N4O4/c1-25(2)11-19(27)23-13-5-7-15-17(9-13)22(30)18-10-14(6-8-16(18)21(15)29)24-20(28)12-26(3)4/h5-10H,11-12H2,1-4H3,(H,23,27)(H,24,28)
DMNW5PL	CS	CN(C)CC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CN(C)C
DMNW5PL	IK	BQUQDCVNESTXAU-UHFFFAOYSA-N
DMNW5PL	IU	2-(dimethylamino)-N-[7-[[2-(dimethylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DMNW5PL	DE	Discovery agent

DMZ7EAC	ID	DMZ7EAC
DMZ7EAC	DN	2,7-Bis[2-(ethylamino)acetamido]anthraquinone
DMZ7EAC	HS	Investigative
DMZ7EAC	SN	2,7-Bis[2-(ethylamino)acetamido]anthraquinone; SCHEMBL4291481; CHEMBL494482
DMZ7EAC	DT	Small molecular drug
DMZ7EAC	PC	44568712
DMZ7EAC	MW	408.4
DMZ7EAC	FM	C22H24N4O4
DMZ7EAC	IC	InChI=1S/C22H24N4O4/c1-3-23-11-19(27)25-13-5-7-15-17(9-13)22(30)18-10-14(6-8-16(18)21(15)29)26-20(28)12-24-4-2/h5-10,23-24H,3-4,11-12H2,1-2H3,(H,25,27)(H,26,28)
DMZ7EAC	CS	CCNCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNCC
DMZ7EAC	IK	DJJHCFWUEPEODX-UHFFFAOYSA-N
DMZ7EAC	IU	2-(ethylamino)-N-[7-[[2-(ethylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DMZ7EAC	DE	Discovery agent

DMM4T1Q	ID	DMM4T1Q
DMM4T1Q	DN	2,7-Bis[2-(isobutylamino)acetamido]anthraquinone
DMM4T1Q	HS	Investigative
DMM4T1Q	SN	2,7-Bis[2-(isobutylamino)acetamido]anthraquinone; SCHEMBL4298304; CHEMBL494456
DMM4T1Q	DT	Small molecular drug
DMM4T1Q	PC	44568765
DMM4T1Q	MW	464.6
DMM4T1Q	FM	C26H32N4O4
DMM4T1Q	IC	InChI=1S/C26H32N4O4/c1-15(2)11-27-13-23(31)29-17-5-7-19-21(9-17)26(34)22-10-18(6-8-20(22)25(19)33)30-24(32)14-28-12-16(3)4/h5-10,15-16,27-28H,11-14H2,1-4H3,(H,29,31)(H,30,32)
DMM4T1Q	CS	CC(C)CNCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNCC(C)C
DMM4T1Q	IK	BTABHVPIAAKKHL-UHFFFAOYSA-N
DMM4T1Q	IU	2-(2-methylpropylamino)-N-[7-[[2-(2-methylpropylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DMM4T1Q	DE	Discovery agent

DMRQGWX	ID	DMRQGWX
DMRQGWX	DN	2,7-Bis[2-(isopropylamino)acetamido]anthraquinone
DMRQGWX	HS	Investigative
DMRQGWX	SN	2,7-Bis[2-(isopropylamino)acetamido]anthraquinone; SCHEMBL4300462; CHEMBL494259
DMRQGWX	DT	Small molecular drug
DMRQGWX	PC	44568764
DMRQGWX	MW	436.5
DMRQGWX	FM	C24H28N4O4
DMRQGWX	IC	InChI=1S/C24H28N4O4/c1-13(2)25-11-21(29)27-15-5-7-17-19(9-15)24(32)20-10-16(6-8-18(20)23(17)31)28-22(30)12-26-14(3)4/h5-10,13-14,25-26H,11-12H2,1-4H3,(H,27,29)(H,28,30)
DMRQGWX	CS	CC(C)NCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNC(C)C
DMRQGWX	IK	DKNQCGLIKICHPF-UHFFFAOYSA-N
DMRQGWX	IU	N-[9,10-dioxo-7-[[2-(propan-2-ylamino)acetyl]amino]anthracen-2-yl]-2-(propan-2-ylamino)acetamide
DMRQGWX	DE	Discovery agent

DMPE8GX	ID	DMPE8GX
DMPE8GX	DN	2,7-Bis[2-(piperazino)acetamido]anthraquinone
DMPE8GX	HS	Investigative
DMPE8GX	SN	2,7-Bis[2-(piperazino)acetamido]anthraquinone; SCHEMBL4291737; CHEMBL495308
DMPE8GX	DT	Small molecular drug
DMPE8GX	PC	44568763
DMPE8GX	MW	490.6
DMPE8GX	FM	C26H30N6O4
DMPE8GX	IC	InChI=1S/C26H30N6O4/c33-23(15-31-9-5-27-6-10-31)29-17-1-3-19-21(13-17)26(36)22-14-18(2-4-20(22)25(19)35)30-24(34)16-32-11-7-28-8-12-32/h1-4,13-14,27-28H,5-12,15-16H2,(H,29,33)(H,30,34)
DMPE8GX	CS	C1CN(CCN1)CC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CN5CCNCC5
DMPE8GX	IK	OBWFXMCXHJYGRS-UHFFFAOYSA-N
DMPE8GX	IU	N-[9,10-dioxo-7-[(2-piperazin-1-ylacetyl)amino]anthracen-2-yl]-2-piperazin-1-ylacetamide
DMPE8GX	DE	Discovery agent

DMITF0P	ID	DMITF0P
DMITF0P	DN	2,7-Bis[2-(piperidino)acetamido]anthraquinone
DMITF0P	HS	Investigative
DMITF0P	SN	2,7-Bis[2-(piperidino)acetamido]anthraquinone; SCHEMBL4299285; CHEMBL492640
DMITF0P	DT	Small molecular drug
DMITF0P	PC	44568668
DMITF0P	MW	488.6
DMITF0P	FM	C28H32N4O4
DMITF0P	IC	InChI=1S/C28H32N4O4/c33-25(17-31-11-3-1-4-12-31)29-19-7-9-21-23(15-19)28(36)24-16-20(8-10-22(24)27(21)35)30-26(34)18-32-13-5-2-6-14-32/h7-10,15-16H,1-6,11-14,17-18H2,(H,29,33)(H,30,34)
DMITF0P	CS	C1CCN(CC1)CC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CN5CCCCC5
DMITF0P	IK	IOHQNFPYEZQWLH-UHFFFAOYSA-N
DMITF0P	IU	N-[9,10-dioxo-7-[(2-piperidin-1-ylacetyl)amino]anthracen-2-yl]-2-piperidin-1-ylacetamide
DMITF0P	DE	Discovery agent

DMH89TO	ID	DMH89TO
DMH89TO	DN	2,7-Bis[2-(propylamino)acetamido]anthraquinone
DMH89TO	HS	Investigative
DMH89TO	SN	2,7-Bis[2-(propylamino)acetamido]anthraquinone; SCHEMBL4297885; CHEMBL494284
DMH89TO	DT	Small molecular drug
DMH89TO	PC	44568711
DMH89TO	MW	436.5
DMH89TO	FM	C24H28N4O4
DMH89TO	IC	InChI=1S/C24H28N4O4/c1-3-9-25-13-21(29)27-15-5-7-17-19(11-15)24(32)20-12-16(6-8-18(20)23(17)31)28-22(30)14-26-10-4-2/h5-8,11-12,25-26H,3-4,9-10,13-14H2,1-2H3,(H,27,29)(H,28,30)
DMH89TO	CS	CCCNCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNCCC
DMH89TO	IK	OBGMWZLARFADCF-UHFFFAOYSA-N
DMH89TO	IU	N-[9,10-dioxo-7-[[2-(propylamino)acetyl]amino]anthracen-2-yl]-2-(propylamino)acetamide
DMH89TO	DE	Discovery agent

DMHVKIJ	ID	DMHVKIJ
DMHVKIJ	DN	2,7-Bis[2-(pyrrolidino)acetamido]anthraquinone
DMHVKIJ	HS	Investigative
DMHVKIJ	SN	2,7-Bis[2-(pyrrolidino)acetamido]anthraquinone; SCHEMBL4297878; CHEMBL522685
DMHVKIJ	DT	Small molecular drug
DMHVKIJ	PC	44568667
DMHVKIJ	MW	460.5
DMHVKIJ	FM	C26H28N4O4
DMHVKIJ	IC	InChI=1S/C26H28N4O4/c31-23(15-29-9-1-2-10-29)27-17-5-7-19-21(13-17)26(34)22-14-18(6-8-20(22)25(19)33)28-24(32)16-30-11-3-4-12-30/h5-8,13-14H,1-4,9-12,15-16H2,(H,27,31)(H,28,32)
DMHVKIJ	CS	C1CCN(C1)CC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CN5CCCC5
DMHVKIJ	IK	CJLKYQVGOOCWAC-UHFFFAOYSA-N
DMHVKIJ	IU	N-[9,10-dioxo-7-[(2-pyrrolidin-1-ylacetyl)amino]anthracen-2-yl]-2-pyrrolidin-1-ylacetamide
DMHVKIJ	DE	Discovery agent

DM4V63W	ID	DM4V63W
DM4V63W	DN	2,7-Bis[3-(butylamino)propionamido]anthraquinone
DM4V63W	HS	Investigative
DM4V63W	SN	2,7-Bis[3-(butylamino)propionamido]anthraquinone; SCHEMBL4289808; CHEMBL479984
DM4V63W	DT	Small molecular drug
DM4V63W	PC	44568189
DM4V63W	MW	492.6
DM4V63W	FM	C28H36N4O4
DM4V63W	IC	InChI=1S/C28H36N4O4/c1-3-5-13-29-15-11-25(33)31-19-7-9-21-23(17-19)28(36)24-18-20(8-10-22(24)27(21)35)32-26(34)12-16-30-14-6-4-2/h7-10,17-18,29-30H,3-6,11-16H2,1-2H3,(H,31,33)(H,32,34)
DM4V63W	CS	CCCCNCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCNCCCC
DM4V63W	IK	WKRXVGOZDDYFGG-UHFFFAOYSA-N
DM4V63W	IU	3-(butylamino)-N-[7-[3-(butylamino)propanoylamino]-9,10-dioxoanthracen-2-yl]propanamide
DM4V63W	DE	Discovery agent

DMC537F	ID	DMC537F
DMC537F	DN	2,7-Bis[3-(ethylamino)propionamido]anthraquinone
DMC537F	HS	Investigative
DMC537F	SN	2,7-Bis[3-(ethylamino)propionamido]anthraquinone; CHEMBL481161; SCHEMBL4291487
DMC537F	DT	Small molecular drug
DMC537F	PC	44242847
DMC537F	MW	436.5
DMC537F	FM	C24H28N4O4
DMC537F	IC	InChI=1S/C24H28N4O4/c1-3-25-11-9-21(29)27-15-5-7-17-19(13-15)24(32)20-14-16(6-8-18(20)23(17)31)28-22(30)10-12-26-4-2/h5-8,13-14,25-26H,3-4,9-12H2,1-2H3,(H,27,29)(H,28,30)
DMC537F	CS	CCNCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCNCC
DMC537F	IK	HJVRZEPJBMFCNQ-UHFFFAOYSA-N
DMC537F	IU	3-(ethylamino)-N-[7-[3-(ethylamino)propanoylamino]-9,10-dioxoanthracen-2-yl]propanamide
DMC537F	DE	Discovery agent

DMOZEKQ	ID	DMOZEKQ
DMOZEKQ	DN	2,7-Bis[3-(piperazino)propionamido]anthraquinone
DMOZEKQ	HS	Investigative
DMOZEKQ	SN	2,7-Bis[3-(piperazino)propionamido]anthraquinone; SCHEMBL4302435; CHEMBL520095
DMOZEKQ	DT	Small molecular drug
DMOZEKQ	PC	44242845
DMOZEKQ	MW	518.6
DMOZEKQ	FM	C28H34N6O4
DMOZEKQ	IC	InChI=1S/C28H34N6O4/c35-25(5-11-33-13-7-29-8-14-33)31-19-1-3-21-23(17-19)28(38)24-18-20(2-4-22(24)27(21)37)32-26(36)6-12-34-15-9-30-10-16-34/h1-4,17-18,29-30H,5-16H2,(H,31,35)(H,32,36)
DMOZEKQ	CS	C1CN(CCN1)CCC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CCN5CCNCC5
DMOZEKQ	IK	NXAKQSOMJQXBST-UHFFFAOYSA-N
DMOZEKQ	IU	N-[9,10-dioxo-7-(3-piperazin-1-ylpropanoylamino)anthracen-2-yl]-3-piperazin-1-ylpropanamide
DMOZEKQ	DE	Discovery agent

DMET693	ID	DMET693
DMET693	DN	2,7-Bis[3-(piperidino)propionamido]anthraquinone
DMET693	HS	Investigative
DMET693	SN	2,7-Bis[3-(piperidino)propionamido]anthraquinone; CHEMBL89250; SCHEMBL4300594; OFUHVIUIKBRCMP-UHFFFAOYSA-N; BDBM50068321
DMET693	DT	Small molecular drug
DMET693	PC	9809446
DMET693	MW	516.6
DMET693	FM	C30H36N4O4
DMET693	IC	InChI=1S/C30H36N4O4/c35-27(11-17-33-13-3-1-4-14-33)31-21-7-9-23-25(19-21)30(38)26-20-22(8-10-24(26)29(23)37)32-28(36)12-18-34-15-5-2-6-16-34/h7-10,19-20H,1-6,11-18H2,(H,31,35)(H,32,36)
DMET693	CS	C1CCN(CC1)CCC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CCN5CCCCC5
DMET693	IK	OFUHVIUIKBRCMP-UHFFFAOYSA-N
DMET693	IU	N-[9,10-dioxo-7-(3-piperidin-1-ylpropanoylamino)anthracen-2-yl]-3-piperidin-1-ylpropanamide
DMET693	DE	Discovery agent

DM6I90F	ID	DM6I90F
DM6I90F	DN	2,7-Bis[3-(propylamino)propionamido]anthraquinone
DM6I90F	HS	Investigative
DM6I90F	SN	2,7-Bis[3-(propylamino)propionamido]anthraquinone; SCHEMBL4298186; CHEMBL481160
DM6I90F	DT	Small molecular drug
DM6I90F	PC	44242848
DM6I90F	MW	464.6
DM6I90F	FM	C26H32N4O4
DM6I90F	IC	InChI=1S/C26H32N4O4/c1-3-11-27-13-9-23(31)29-17-5-7-19-21(15-17)26(34)22-16-18(6-8-20(22)25(19)33)30-24(32)10-14-28-12-4-2/h5-8,15-16,27-28H,3-4,9-14H2,1-2H3,(H,29,31)(H,30,32)
DM6I90F	CS	CCCNCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCNCCC
DM6I90F	IK	JELVSCOBEUHNBV-UHFFFAOYSA-N
DM6I90F	IU	N-[9,10-dioxo-7-[3-(propylamino)propanoylamino]anthracen-2-yl]-3-(propylamino)propanamide
DM6I90F	DE	Discovery agent

DMD6ZV5	ID	DMD6ZV5
DMD6ZV5	DN	2,7-Bis[3-(pyrrolidino)propionamido]anthraquinone
DMD6ZV5	HS	Investigative
DMD6ZV5	SN	2,7-Bis[3-(pyrrolidino)propionamido]anthraquinone; CHEMBL144757; SCHEMBL4298492; CUZAYOMYKDAXQR-UHFFFAOYSA-N; BDBM50068320; N,N'-(9,10-Dihydro-9,10-dioxoanthracene-2,7-diyl)bis[3-(pyrrolidine-1-yl)propanamide]
DMD6ZV5	DT	Small molecular drug
DMD6ZV5	PC	10719801
DMD6ZV5	MW	488.6
DMD6ZV5	FM	C28H32N4O4
DMD6ZV5	IC	InChI=1S/C28H32N4O4/c33-25(9-15-31-11-1-2-12-31)29-19-5-7-21-23(17-19)28(36)24-18-20(6-8-22(24)27(21)35)30-26(34)10-16-32-13-3-4-14-32/h5-8,17-18H,1-4,9-16H2,(H,29,33)(H,30,34)
DMD6ZV5	CS	C1CCN(C1)CCC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CCN5CCCC5
DMD6ZV5	IK	CUZAYOMYKDAXQR-UHFFFAOYSA-N
DMD6ZV5	IU	N-[9,10-dioxo-7-(3-pyrrolidin-1-ylpropanoylamino)anthracen-2-yl]-3-pyrrolidin-1-ylpropanamide
DMD6ZV5	DE	Discovery agent

DME0TZU	ID	DME0TZU
DME0TZU	DN	2,7-diaminoanthraquinone
DME0TZU	HS	Investigative
DME0TZU	SN	2,7-Diaminoanthraquinone; 2,7-Diaminoanthrachinon; BRN 2809381; 605-44-7; 2,7-Diaminoanthrachinon [Czech]; 2,7-diaminoanthracene-9,10-dione; 9,10-Anthracenedione, 2,7-diamino- (9CI); ANTHRAQUINONE, 2,7-DIAMINO-; 9,10-Anthracenedione, 2,7-diamino-; AC1L1Y5O; SCHEMBL3135129; CHEMBL454957; CTK5B1667; DTXSID20209235; KJNHYKBXQOSFJR-UHFFFAOYSA-N; ZINC31483469; 9,10-Anthracenedione,2,7-diamino-; AKOS030561506
DME0TZU	DT	Small molecular drug
DME0TZU	PC	11798
DME0TZU	MW	238.24
DME0TZU	FM	C14H10N2O2
DME0TZU	IC	InChI=1S/C14H10N2O2/c15-7-1-3-9-11(5-7)14(18)12-6-8(16)2-4-10(12)13(9)17/h1-6H,15-16H2
DME0TZU	CS	C1=CC2=C(C=C1N)C(=O)C3=C(C2=O)C=CC(=C3)N
DME0TZU	IK	KJNHYKBXQOSFJR-UHFFFAOYSA-N
DME0TZU	IU	2,7-diaminoanthracene-9,10-dione
DME0TZU	CA	CAS 605-44-7
DME0TZU	DE	Discovery agent

DMN56VM	ID	DMN56VM
DMN56VM	DN	2,7-Dinitroantraquinone
DMN56VM	HS	Investigative
DMN56VM	SN	2,7-Dinitroanthraquinone; 605-28-7; 2,7-Dinitroantraquinone; EINECS 210-084-2; 2,7-dinitro-9,10-anthraquinone; 2,7- Dinitroanthrachinon; AC1L2B0Y; SCHEMBL2772220; CHEMBL493255; AC1Q21I1; CTK5B1648; DTXSID00209233; XFLONXIGNOXKCG-UHFFFAOYSA-N; ZINC5845160; 2,7-dinitroanthracene-9,10-dione
DMN56VM	DT	Small molecular drug
DMN56VM	PC	69057
DMN56VM	MW	298.21
DMN56VM	FM	C14H6N2O6
DMN56VM	IC	InChI=1S/C14H6N2O6/c17-13-9-3-1-7(15(19)20)5-11(9)14(18)12-6-8(16(21)22)2-4-10(12)13/h1-6H
DMN56VM	CS	C1=CC2=C(C=C1[N+](=O)[O-])C(=O)C3=C(C2=O)C=CC(=C3)[N+](=O)[O-]
DMN56VM	IK	XFLONXIGNOXKCG-UHFFFAOYSA-N
DMN56VM	IU	2,7-dinitroanthracene-9,10-dione
DMN56VM	CA	CAS 605-28-7
DMN56VM	DE	Discovery agent

DMAKZ43	ID	DMAKZ43
DMAKZ43	DN	2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one
DMAKZ43	HS	Investigative
DMAKZ43	SN	2,8-dimethyl-1-oxa-8-azaspiro[4.5]decan-3-one; CHEMBL40121; 123319-03-9; ARL-14995; 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one; SCHEMBL1326512; 1-Oxa-8-azaspiro[4.5]decan-3-one, 2,8-dimethyl-; MolPort-039-242-339; OODDNJQTVFMGCF-UHFFFAOYSA-N; BDBM50034651; AKOS033633463; 2,8-dimethyl-1-oxa-8-azaspiro[4,5]decan-3-one; L010200; 2,8-dimethyl-1-oxa-8-azaspiro[4.5]-decan-3-one; 2,8-dimethyl-1-oxa-8-azaspiro[4,5]-decan-3-one
DMAKZ43	DT	Small molecular drug
DMAKZ43	PC	10176401
DMAKZ43	MW	183.25
DMAKZ43	FM	C10H17NO2
DMAKZ43	IC	InChI=1S/C10H17NO2/c1-8-9(12)7-10(13-8)3-5-11(2)6-4-10/h8H,3-7H2,1-2H3
DMAKZ43	CS	CC1C(=O)CC2(O1)CCN(CC2)C
DMAKZ43	IK	OODDNJQTVFMGCF-UHFFFAOYSA-N
DMAKZ43	IU	2,8-dimethyl-1-oxa-8-azaspiro[4.5]decan-3-one
DMAKZ43	DE	Discovery agent

DMU2EFH	ID	DMU2EFH
DMU2EFH	DN	2,8-Dimethyl-3H-quinazolin-4-one
DMU2EFH	HS	Investigative
DMU2EFH	DT	Small molecular drug
DMU2EFH	PC	135463574
DMU2EFH	MW	174.2
DMU2EFH	FM	C10H10N2O
DMU2EFH	IC	InChI=1S/C10H10N2O/c1-6-4-3-5-8-9(6)11-7(2)12-10(8)13/h3-5H,1-2H3,(H,11,12,13)
DMU2EFH	CS	CC1=C2C(=CC=C1)C(=O)NC(=N2)C
DMU2EFH	IK	CJXMJXBJIWEHRP-UHFFFAOYSA-N
DMU2EFH	IU	2,8-dimethyl-3H-quinazolin-4-one
DMU2EFH	CA	CAS 172462-90-7
DMU2EFH	DE	Discovery agent

DMVSTG7	ID	DMVSTG7
DMVSTG7	DN	2-[(2,2-diphenylacetyl)amino]benzoic acid
DMVSTG7	HS	Investigative
DMVSTG7	SN	2-[(2,2-diphenylacetyl)amino]benzoic Acid; CHEMBL196755; 2-[(diphenylacetyl)amino]benzoic acid; Oprea1_593830; Oprea1_339985; MLS001143352; AC1N2C22; MolPort-001-015-645; HMS2781B19; ZINC3466236; BDBM50174204; STK004896; AKOS003244646; MCULE-3235692188; 2-(2,2-diphenylacetylamino)benzoic acid; SMR000473187
DMVSTG7	DT	Small molecular drug
DMVSTG7	PC	4044373
DMVSTG7	MW	331.4
DMVSTG7	FM	C21H17NO3
DMVSTG7	IC	InChI=1S/C21H17NO3/c23-20(22-18-14-8-7-13-17(18)21(24)25)19(15-9-3-1-4-10-15)16-11-5-2-6-12-16/h1-14,19H,(H,22,23)(H,24,25)
DMVSTG7	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC3=CC=CC=C3C(=O)O
DMVSTG7	IK	NDZQPXFPOCTXEF-UHFFFAOYSA-N
DMVSTG7	IU	2-[(2,2-diphenylacetyl)amino]benzoic acid
DMVSTG7	DE	Discovery agent

DMR4LJY	ID	DMR4LJY
DMR4LJY	DN	2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL
DMR4LJY	HS	Investigative
DMR4LJY	SN	TF5
DMR4LJY	DT	Small molecular drug
DMR4LJY	PC	46937163
DMR4LJY	MW	268.23
DMR4LJY	FM	C14H11F3O2
DMR4LJY	IC	InChI=1S/C14H11F3O2/c15-11-6-5-10(13(16)14(11)17)9-3-1-2-4-12(9)19-8-7-18/h1-6,18H,7-8H2
DMR4LJY	CS	C1=CC=C(C(=C1)C2=C(C(=C(C=C2)F)F)F)OCCO
DMR4LJY	IK	AGXPXFPIOHNDAN-UHFFFAOYSA-N
DMR4LJY	IU	2-[2-(2,3,4-trifluorophenyl)phenoxy]ethanol
DMR4LJY	DE	Discovery agent

DMXA1LK	ID	DMXA1LK
DMXA1LK	DN	2-[(2-methoxy-5-methylphenoxy)methyl]pyridine
DMXA1LK	HS	Investigative
DMXA1LK	SN	2-[(2-methoxy-5-methylphenoxy)methyl]pyridine; SCHEMBL12409072; DB07427
DMXA1LK	DT	Small molecular drug
DMXA1LK	PC	44129642
DMXA1LK	MW	229.27
DMXA1LK	FM	C14H15NO2
DMXA1LK	IC	InChI=1S/C14H15NO2/c1-11-6-7-13(16-2)14(9-11)17-10-12-5-3-4-8-15-12/h3-9H,10H2,1-2H3
DMXA1LK	CS	CC1=CC(=C(C=C1)OC)OCC2=CC=CC=N2
DMXA1LK	IK	AVXQTLSOXWQOHO-UHFFFAOYSA-N
DMXA1LK	IU	2-[(2-methoxy-5-methylphenoxy)methyl]pyridine
DMXA1LK	DE	Discovery agent

DM75WN4	ID	DM75WN4
DM75WN4	DN	2-[(2-methyl-4-thiazolyl)ethynyl]pyrazine
DM75WN4	HS	Investigative
DM75WN4	SN	CHEMBL371884; 2-[(2-methyl-4-thiazolyl)ethynyl]pyrazine; SCHEMBL4154142
DM75WN4	DT	Small molecular drug
DM75WN4	PC	11608117
DM75WN4	MW	201.25
DM75WN4	FM	C10H7N3S
DM75WN4	IC	InChI=1S/C10H7N3S/c1-8-13-10(7-14-8)3-2-9-6-11-4-5-12-9/h4-7H,1H3
DM75WN4	CS	CC1=NC(=CS1)C#CC2=NC=CN=C2
DM75WN4	IK	TZWSJNFDGNIKAZ-UHFFFAOYSA-N
DM75WN4	IU	2-methyl-4-(2-pyrazin-2-ylethynyl)-1,3-thiazole
DM75WN4	DE	Discovery agent

DMKC1GI	ID	DMKC1GI
DMKC1GI	DN	2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine
DMKC1GI	HS	Investigative
DMKC1GI	SN	CHEMBL385770; 2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine; SCHEMBL4383259
DMKC1GI	DT	Small molecular drug
DMKC1GI	PC	11743895
DMKC1GI	MW	439.4
DMKC1GI	FM	C21H21N5O6
DMKC1GI	IC	InChI=1S/C21H21N5O6/c1-11(28)13-6-3-12(4-7-13)5-8-15-23-19(25-31-2)16-20(24-15)26(10-22-16)21-18(30)17(29)14(9-27)32-21/h3-4,6-7,10,14,17-18,21,27,29-30H,9H2,1-2H3,(H,23,24,25)/t14-,17-,18-,21-/m1/s1
DMKC1GI	CS	CC(=O)C1=CC=C(C=C1)C#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)NOC
DMKC1GI	IK	MPFGTODTMYCUJG-HAXDFEGKSA-N
DMKC1GI	IU	1-[4-[2-[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methoxyamino)purin-2-yl]ethynyl]phenyl]ethanone
DMKC1GI	DE	Discovery agent

DMTNQZU	ID	DMTNQZU
DMTNQZU	DN	2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine
DMTNQZU	HS	Investigative
DMTNQZU	SN	CHEMBL223739; 2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine; SCHEMBL4381150
DMTNQZU	DT	Small molecular drug
DMTNQZU	PC	10454501
DMTNQZU	MW	415.4
DMTNQZU	FM	C19H18FN5O5
DMTNQZU	IC	InChI=1S/C19H18FN5O5/c1-29-24-17-14-18(23-13(22-17)7-4-10-2-5-11(20)6-3-10)25(9-21-14)19-16(28)15(27)12(8-26)30-19/h2-3,5-6,9,12,15-16,19,26-28H,8H2,1H3,(H,22,23,24)/t12-,15-,16-,19-/m1/s1
DMTNQZU	CS	CONC1=C2C(=NC(=N1)C#CC3=CC=C(C=C3)F)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMTNQZU	IK	IEVVENMHWBPFQV-BGIGGGFGSA-N
DMTNQZU	IU	(2R,3R,4S,5R)-2-[2-[2-(4-fluorophenyl)ethynyl]-6-(methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMTNQZU	DE	Discovery agent

DMDT7SK	ID	DMDT7SK
DMDT7SK	DN	2-[(biphenyl-4-carbonyl)-amino]-benzoic acid
DMDT7SK	HS	Investigative
DMDT7SK	SN	2-[(biphenyl-4-ylcarbonyl)amino]benzoic acid; 94578-69-5; AC1LIZYF; 2-[(4-phenylbenzoyl)amino]benzoic Acid; Oprea1_107922; CHEMBL370865; SCHEMBL14075233; BDBM16094; MolPort-000-468-692; ZINC499675; STK068761; BBL015607; AKOS002229873; MCULE-9626131737; 2-[(4-phenylbenzene)amido]benzoic acid; ST50103720; H3372; 2-[(4-phenylphenyl)carbonylamino]benzoic acid
DMDT7SK	DT	Small molecular drug
DMDT7SK	PC	914489
DMDT7SK	MW	317.3
DMDT7SK	FM	C20H15NO3
DMDT7SK	IC	InChI=1S/C20H15NO3/c22-19(21-18-9-5-4-8-17(18)20(23)24)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13H,(H,21,22)(H,23,24)
DMDT7SK	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NC3=CC=CC=C3C(=O)O
DMDT7SK	IK	WXLRBDMDGLLZRS-UHFFFAOYSA-N
DMDT7SK	IU	2-[(4-phenylbenzoyl)amino]benzoic acid
DMDT7SK	DE	Discovery agent

DMVSI6R	ID	DMVSI6R
DMVSI6R	DN	2-[(Dioxidophosphino)Oxy]Benzoate
DMVSI6R	HS	Investigative
DMVSI6R	SN	2-[(DIOXIDOPHOSPHINO)OXY]BENZOATE; 2-phosphooxybenzoate; 2-(phosphooxy)benzoate; AC1NR9RL; AC1O4QG1; 2-oxidophosphonoyloxybenzoate; 2-[(dioxidophosphanyl)oxy]benzoate; 2-[(Dioxidophosphoranyl)oxy]benzoate
DMVSI6R	DT	Small molecular drug
DMVSI6R	PC	6398365
DMVSI6R	MW	199.08
DMVSI6R	FM	C7H4O5P-
DMVSI6R	IC	InChI=1S/C7H5O5P/c8-7(9)5-3-1-2-4-6(5)12-13(10)11/h1-4H,(H,8,9)/p-1
DMVSI6R	CS	C1=CC=C(C(=C1)C(=O)[O-])OP(=O)=O
DMVSI6R	IK	CEHNRTFNHMGQGW-UHFFFAOYSA-M
DMVSI6R	DE	Discovery agent

DMSW89U	ID	DMSW89U
DMSW89U	DN	2-[1-(2-Chloro-phenyl)-1H-pyrrol-2-yl]-ethylamine
DMSW89U	HS	Investigative
DMSW89U	SN	CHEMBL360277
DMSW89U	DT	Small molecular drug
DMSW89U	PC	44388886
DMSW89U	MW	220.7
DMSW89U	FM	C12H13ClN2
DMSW89U	IC	InChI=1S/C12H13ClN2/c13-11-5-1-2-6-12(11)15-9-3-4-10(15)7-8-14/h1-6,9H,7-8,14H2
DMSW89U	CS	C1=CC=C(C(=C1)N2C=CC=C2CCN)Cl
DMSW89U	IK	QDZRUXBRYDSOHU-UHFFFAOYSA-N
DMSW89U	IU	2-[1-(2-chlorophenyl)pyrrol-2-yl]ethanamine
DMSW89U	DE	Discovery agent

DMUZDSC	ID	DMUZDSC
DMUZDSC	DN	2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL
DMUZDSC	HS	Investigative
DMUZDSC	SN	2-[1-(4-chlorophenyl)ethyl]-4,6-dinitrophenol; DNP-19; AC1MRP5X; CHEBI:74325; 2-[1-(p-chlorophenyl)ethyl]-4,6-dinitrophenol; 2-[1-(p-chlorophenyl)ethyl] 4,6-dinitrophenol
DMUZDSC	DT	Small molecular drug
DMUZDSC	PC	446716
DMUZDSC	MW	322.7
DMUZDSC	FM	C14H11ClN2O5
DMUZDSC	IC	InChI=1S/C14H11ClN2O5/c1-8(9-2-4-10(15)5-3-9)12-6-11(16(19)20)7-13(14(12)18)17(21)22/h2-8,18H,1H3/t8-/m1/s1
DMUZDSC	CS	C[C@H](C1=CC=C(C=C1)Cl)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O
DMUZDSC	IK	MOZUMFSUQQHSCO-MRVPVSSYSA-N
DMUZDSC	IU	2-[(1R)-1-(4-chlorophenyl)ethyl]-4,6-dinitrophenol
DMUZDSC	DE	Discovery agent

DMEA2SR	ID	DMEA2SR
DMEA2SR	DN	2-[1,4]Diazepan-1-yl-6-nitro-quinoline
DMEA2SR	HS	Investigative
DMEA2SR	SN	CHEMBL43139; 2-[1,4]Diazepan-1-yl-6-nitro-quinoline; BDBM50090215; AKOS009510173
DMEA2SR	DT	Small molecular drug
DMEA2SR	PC	10445930
DMEA2SR	MW	272.3
DMEA2SR	FM	C14H16N4O2
DMEA2SR	IC	InChI=1S/C14H16N4O2/c19-18(20)12-3-4-13-11(10-12)2-5-14(16-13)17-8-1-6-15-7-9-17/h2-5,10,15H,1,6-9H2
DMEA2SR	CS	C1CNCCN(C1)C2=NC3=C(C=C2)C=C(C=C3)[N+](=O)[O-]
DMEA2SR	IK	DKLQZCAIKFJPKG-UHFFFAOYSA-N
DMEA2SR	IU	2-(1,4-diazepan-1-yl)-6-nitroquinoline
DMEA2SR	DE	Discovery agent

DMC8IEM	ID	DMC8IEM
DMC8IEM	DN	2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one
DMC8IEM	HS	Investigative
DMC8IEM	SN	CHEMBL367141; 2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one
DMC8IEM	DT	Small molecular drug
DMC8IEM	PC	11208656
DMC8IEM	MW	295.3
DMC8IEM	FM	C18H17NO3
DMC8IEM	IC	InChI=1S/C18H17NO3/c20-16-12-17(19-8-3-10-21-11-9-19)22-18-14-5-2-1-4-13(14)6-7-15(16)18/h1-2,4-7,12H,3,8-11H2
DMC8IEM	CS	C1CN(CCOC1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMC8IEM	IK	NVGTWFCMXLHRJF-UHFFFAOYSA-N
DMC8IEM	IU	2-(1,4-oxazepan-4-yl)benzo[h]chromen-4-one
DMC8IEM	DE	Discovery agent

DMFJOHG	ID	DMFJOHG
DMFJOHG	DN	2-[125I]melatonin
DMFJOHG	HS	Investigative
DMFJOHG	SN	2-(125I)Iodomelatonin; 2[125I]iodomelatonin; 2-iodo-[125I]-melatonin
DMFJOHG	DT	Small molecular drug
DMFJOHG	PC	644212
DMFJOHG	MW	356.17
DMFJOHG	FM	C13H15IN2O2
DMFJOHG	IC	InChI=1S/C13H15IN2O2/c1-8(17)15-6-5-10-11-7-9(18-2)3-4-12(11)16-13(10)14/h3-4,7,16H,5-6H2,1-2H3,(H,15,17)/i14-2
DMFJOHG	CS	CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)[125I]
DMFJOHG	IK	FJDDSMSDZHURBJ-XSBOKVBDSA-N
DMFJOHG	IU	N-[2-(2-(125I)iodanyl-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMFJOHG	CA	CAS 140671-15-4
DMFJOHG	DE	Discovery agent

DMKEZ5G	ID	DMKEZ5G
DMKEZ5G	DN	2-[2-(1H-Imidazol-4-yl)-cyclopropyl]-ethylamine
DMKEZ5G	HS	Investigative
DMKEZ5G	SN	CHEMBL60716; 2-[2-(1H-Imidazol-4-yl)-cyclopropyl]-ethylamine; SCHEMBL1443461; BDBM50127610; AKOS027413644; (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane
DMKEZ5G	DT	Small molecular drug
DMKEZ5G	PC	10154137
DMKEZ5G	MW	151.21
DMKEZ5G	FM	C8H13N3
DMKEZ5G	IC	InChI=1S/C8H13N3/c9-2-1-6-3-7(6)8-4-10-5-11-8/h4-7H,1-3,9H2,(H,10,11)/t6-,7+/m1/s1
DMKEZ5G	CS	C1[C@H]([C@H]1C2=CN=CN2)CCN
DMKEZ5G	IK	OTBYLNCJHFPRTL-RQJHMYQMSA-N
DMKEZ5G	IU	2-[(1S,2S)-2-(1H-imidazol-5-yl)cyclopropyl]ethanamine
DMKEZ5G	DE	Discovery agent

DMX1TIU	ID	DMX1TIU
DMX1TIU	DN	2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene
DMX1TIU	HS	Investigative
DMX1TIU	SN	CHEMBL42428; 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene; SCHEMBL7042974; SCHEMBL7042968; ZINC13471769; BDBM50108048; AKOS015967551; (E)-2-(3,5-dimethoxystyryl)thiophene; 2-[(E)-3,5-Dimethoxystyryl]thiophene
DMX1TIU	DT	Small molecular drug
DMX1TIU	PC	9834747
DMX1TIU	MW	246.33
DMX1TIU	FM	C14H14O2S
DMX1TIU	IC	InChI=1S/C14H14O2S/c1-15-12-8-11(9-13(10-12)16-2)5-6-14-4-3-7-17-14/h3-10H,1-2H3/b6-5+
DMX1TIU	CS	COC1=CC(=CC(=C1)/C=C/C2=CC=CS2)OC
DMX1TIU	IK	URRYDXXEGGXDQJ-AATRIKPKSA-N
DMX1TIU	IU	2-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]thiophene
DMX1TIU	DE	Discovery agent

DMDT9KG	ID	DMDT9KG
DMDT9KG	DN	2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid
DMDT9KG	HS	Investigative
DMDT9KG	SN	SCHEMBL1345633; CHEMBL189037; Benzeneacetic acid, 3-(1-hydroxypropyl)-alpha-methyl-; AKOS023891992
DMDT9KG	DT	Small molecular drug
DMDT9KG	PC	9964424
DMDT9KG	MW	208.25
DMDT9KG	FM	C12H16O3
DMDT9KG	IC	InChI=1S/C12H16O3/c1-3-11(13)10-6-4-5-9(7-10)8(2)12(14)15/h4-8,11,13H,3H2,1-2H3,(H,14,15)
DMDT9KG	CS	CCC(C1=CC=CC(=C1)C(C)C(=O)O)O
DMDT9KG	IK	HTWFANVWNDWYRH-UHFFFAOYSA-N
DMDT9KG	IU	2-[3-(1-hydroxypropyl)phenyl]propanoic acid
DMDT9KG	DE	Discovery agent

DMWIUR0	ID	DMWIUR0
DMWIUR0	DN	2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid
DMWIUR0	HS	Investigative
DMWIUR0	SN	SCHEMBL3630168
DMWIUR0	DT	Small molecular drug
DMWIUR0	PC	11299790
DMWIUR0	MW	254.32
DMWIUR0	FM	C17H18O2
DMWIUR0	IC	InChI=1S/C17H18O2/c1-12(14-7-4-3-5-8-14)15-9-6-10-16(11-15)13(2)17(18)19/h3-13H,1-2H3,(H,18,19)
DMWIUR0	CS	CC(C1=CC=CC=C1)C2=CC(=CC=C2)C(C)C(=O)O
DMWIUR0	IK	WHCCIVDFHWZGFN-UHFFFAOYSA-N
DMWIUR0	IU	2-[3-(1-phenylethyl)phenyl]propanoic acid
DMWIUR0	DE	Discovery agent

DMKSDT4	ID	DMKSDT4
DMKSDT4	DN	2-[3-(2-Methyl-butyl)-phenyl]-propionic acid
DMKSDT4	HS	Investigative
DMKSDT4	SN	CHEMBL190956
DMKSDT4	DT	Small molecular drug
DMKSDT4	PC	44398456
DMKSDT4	MW	220.31
DMKSDT4	FM	C14H20O2
DMKSDT4	IC	InChI=1S/C14H20O2/c1-4-10(2)8-12-6-5-7-13(9-12)11(3)14(15)16/h5-7,9-11H,4,8H2,1-3H3,(H,15,16)
DMKSDT4	CS	CCC(C)CC1=CC(=CC=C1)C(C)C(=O)O
DMKSDT4	IK	MKEVMCJZLHDVPO-UHFFFAOYSA-N
DMKSDT4	IU	2-[3-(2-methylbutyl)phenyl]propanoic acid
DMKSDT4	DE	Discovery agent

DM8A3NI	ID	DM8A3NI
DM8A3NI	DN	2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DM8A3NI	HS	Investigative
DM8A3NI	SN	CHEMBL115876; 2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine; SCHEMBL14129965; BDBM50138233
DM8A3NI	DT	Small molecular drug
DM8A3NI	PC	44341234
DM8A3NI	MW	279.34
DM8A3NI	FM	C17H17N3O
DM8A3NI	IC	InChI=1S/C17H17N3O/c1-2-10-19-15(4-1)5-3-13-21-17-8-6-16(7-9-17)20-12-11-18-14-20/h1-2,4,6-12,14H,3,5,13H2
DM8A3NI	CS	C1=CC=NC(=C1)CCCOC2=CC=C(C=C2)N3C=CN=C3
DM8A3NI	IK	UGLPVHLKYTWQRV-UHFFFAOYSA-N
DM8A3NI	IU	2-[3-(4-imidazol-1-ylphenoxy)propyl]pyridine
DM8A3NI	DE	Discovery agent

DM5ETL9	ID	DM5ETL9
DM5ETL9	DN	2-[3-(Pyridin-4-yloxy)-benzoylamino]-benzoic acid
DM5ETL9	HS	Investigative
DM5ETL9	SN	2-[3-(Pyridin-4-yloxy)benzoylamino]benzoic acid; CHEMBL438975; BDBM23613; 2-benzoylamino benzoic acid deriv., 28g; 2-{[3-(pyridin-4-yloxy)benzene]amido}benzoic acid
DM5ETL9	DT	Small molecular drug
DM5ETL9	PC	11209825
DM5ETL9	MW	334.3
DM5ETL9	FM	C19H14N2O4
DM5ETL9	IC	InChI=1S/C19H14N2O4/c22-18(21-17-7-2-1-6-16(17)19(23)24)13-4-3-5-15(12-13)25-14-8-10-20-11-9-14/h1-12H,(H,21,22)(H,23,24)
DM5ETL9	CS	C1=CC=C(C(=C1)C(=O)O)NC(=O)C2=CC(=CC=C2)OC3=CC=NC=C3
DM5ETL9	IK	YATZGUOENCNURV-UHFFFAOYSA-N
DM5ETL9	IU	2-[(3-pyridin-4-yloxybenzoyl)amino]benzoic acid
DM5ETL9	DE	Discovery agent

DMUH526	ID	DMUH526
DMUH526	DN	2-[4-(1-Ethyl-propyl)-piperazin-1-yl]-quinoline
DMUH526	HS	Investigative
DMUH526	SN	CHEMBL360156; 2-[4-(1-Ethyl-propyl)-piperazin-1-yl]-quinoline; SCHEMBL3971032
DMUH526	DT	Small molecular drug
DMUH526	PC	11314275
DMUH526	MW	283.4
DMUH526	FM	C18H25N3
DMUH526	IC	InChI=1S/C18H25N3/c1-3-16(4-2)20-11-13-21(14-12-20)18-10-9-15-7-5-6-8-17(15)19-18/h5-10,16H,3-4,11-14H2,1-2H3
DMUH526	CS	CCC(CC)N1CCN(CC1)C2=NC3=CC=CC=C3C=C2
DMUH526	IK	FNSKLNDKQPXTIL-UHFFFAOYSA-N
DMUH526	IU	2-(4-pentan-3-ylpiperazin-1-yl)quinoline
DMUH526	DE	Discovery agent

DMUHECR	ID	DMUHECR
DMUHECR	DN	2-[4-(1H-Indol-5-yl)-phenyl]-propionic acid
DMUHECR	HS	Investigative
DMUHECR	SN	CHEMBL104592; 2-[4-(1H-Indol-5-yl)-phenyl]-propionic acid; BDBM50074934; 2-[4-(1H-Indole-5-yl)phenyl]propanoic acid
DMUHECR	DT	Small molecular drug
DMUHECR	PC	44336354
DMUHECR	MW	265.31
DMUHECR	FM	C17H15NO2
DMUHECR	IC	InChI=1S/C17H15NO2/c1-11(17(19)20)12-2-4-13(5-3-12)14-6-7-16-15(10-14)8-9-18-16/h2-11,18H,1H3,(H,19,20)
DMUHECR	CS	CC(C1=CC=C(C=C1)C2=CC3=C(C=C2)NC=C3)C(=O)O
DMUHECR	IK	NSKFZVRZALCZND-UHFFFAOYSA-N
DMUHECR	IU	2-[4-(1H-indol-5-yl)phenyl]propanoic acid
DMUHECR	DE	Discovery agent

DMWXI06	ID	DMWXI06
DMWXI06	DN	2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid
DMWXI06	HS	Investigative
DMWXI06	SN	Diclofop; 40843-25-2; Diclofop acid; DICHLORFOP ACID; Caswell No. 328B; 2-(4-(2,4-Dichlorophenoxy)phenoxy)propanoic acid; Diclofop [ANSI:BSI:ISO]; 2-[4-(2,4-Dichlorophenoxy)phenoxy]propanoic acid; HOE 21079; BRN 2338390; CHEBI:81909; OOLBCHYXZDXLDS-UHFFFAOYSA-N; Methyl 2-(4-(2,4-Dichlorophenyoxy)phenoxy)propanoate; HOE-021079; (RS)-2-(4-(2,4-Dichlorophenoxy)phenoxy)propionic acid; Methyl (RS)-2-(4-(2,4-Dichlorophenoxy)phenoxy)propionate; Propanoic acid, 2-(4-(2,4-dichlorophenoxy)phenoxy)-; Propanoic acid, 2-[4-(2,4-dichloro
DMWXI06	DT	Small molecular drug
DMWXI06	PC	38687
DMWXI06	MW	327.2
DMWXI06	FM	C15H12Cl2O4
DMWXI06	IC	InChI=1S/C15H12Cl2O4/c1-9(15(18)19)20-11-3-5-12(6-4-11)21-14-7-2-10(16)8-13(14)17/h2-9H,1H3,(H,18,19)
DMWXI06	CS	CC(C(=O)O)OC1=CC=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl
DMWXI06	IK	OOLBCHYXZDXLDS-UHFFFAOYSA-N
DMWXI06	IU	2-[4-(2,4-dichlorophenoxy)phenoxy]propanoic acid
DMWXI06	CA	CAS 40843-25-2
DMWXI06	CB	CHEBI:81909
DMWXI06	DE	Discovery agent

DMDMK5V	ID	DMDMK5V
DMDMK5V	DN	2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzooxazole
DMDMK5V	HS	Investigative
DMDMK5V	SN	Benzoxazole compound, 10c; SCHEMBL2168424; CHEMBL482254; BDBM24206; ZINC40919149
DMDMK5V	DT	Small molecular drug
DMDMK5V	PC	11416868
DMDMK5V	MW	352.4
DMDMK5V	FM	C21H24N2O3
DMDMK5V	IC	InChI=1S/C21H24N2O3/c1-2-6-14-23(13-5-1)15-16-24-17-9-11-18(12-10-17)25-21-22-19-7-3-4-8-20(19)26-21/h3-4,7-12H,1-2,5-6,13-16H2
DMDMK5V	CS	C1CCCN(CC1)CCOC2=CC=C(C=C2)OC3=NC4=CC=CC=C4O3
DMDMK5V	IK	RUOSQGLZVMYCMI-UHFFFAOYSA-N
DMDMK5V	IU	2-[4-[2-(azepan-1-yl)ethoxy]phenoxy]-1,3-benzoxazole
DMDMK5V	DE	Discovery agent

DM923WK	ID	DM923WK
DM923WK	DN	2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzothiazole
DM923WK	HS	Investigative
DM923WK	SN	Benzthiazole compound, 11c; SCHEMBL2168218; CHEMBL520120; BDBM24207; ZINC40919150
DM923WK	DT	Small molecular drug
DM923WK	PC	11257168
DM923WK	MW	368.5
DM923WK	FM	C21H24N2O2S
DM923WK	IC	InChI=1S/C21H24N2O2S/c1-2-6-14-23(13-5-1)15-16-24-17-9-11-18(12-10-17)25-21-22-19-7-3-4-8-20(19)26-21/h3-4,7-12H,1-2,5-6,13-16H2
DM923WK	CS	C1CCCN(CC1)CCOC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3
DM923WK	IK	JDZUDVCYJPNUKO-UHFFFAOYSA-N
DM923WK	IU	2-[4-[2-(azepan-1-yl)ethoxy]phenoxy]-1,3-benzothiazole
DM923WK	DE	Discovery agent

DMECQB4	ID	DMECQB4
DMECQB4	DN	2-[4-(2-Morpholin-4-ylethoxy)phenoxy]benzooxazole
DMECQB4	HS	Investigative
DMECQB4	SN	Benzoxazole compound, 10d; SCHEMBL2168507; CHEMBL482256; BDBM24209
DMECQB4	DT	Small molecular drug
DMECQB4	PC	24901582
DMECQB4	MW	340.4
DMECQB4	FM	C19H20N2O4
DMECQB4	IC	InChI=1S/C19H20N2O4/c1-2-4-18-17(3-1)20-19(25-18)24-16-7-5-15(6-8-16)23-14-11-21-9-12-22-13-10-21/h1-8H,9-14H2
DMECQB4	CS	C1COCCN1CCOC2=CC=C(C=C2)OC3=NC4=CC=CC=C4O3
DMECQB4	IK	NVSWCWWHQRVUDU-UHFFFAOYSA-N
DMECQB4	IU	2-[4-(2-morpholin-4-ylethoxy)phenoxy]-1,3-benzoxazole
DMECQB4	DE	Discovery agent

DMMYJ3R	ID	DMMYJ3R
DMMYJ3R	DN	2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole
DMMYJ3R	HS	Investigative
DMMYJ3R	SN	Benzthiazole compound, 27b; SCHEMBL2168381; CHEMBL470753; BDBM24223
DMMYJ3R	DT	Small molecular drug
DMMYJ3R	PC	11427736
DMMYJ3R	MW	338.5
DMMYJ3R	FM	C20H22N2OS
DMMYJ3R	IC	InChI=1S/C20H22N2OS/c1-4-13-22(14-5-1)15-12-16-8-10-17(11-9-16)23-20-21-18-6-2-3-7-19(18)24-20/h2-3,6-11H,1,4-5,12-15H2
DMMYJ3R	CS	C1CCN(CC1)CCC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3
DMMYJ3R	IK	DHHMVJVCMLXZBO-UHFFFAOYSA-N
DMMYJ3R	IU	2-[4-(2-piperidin-1-ylethyl)phenoxy]-1,3-benzothiazole
DMMYJ3R	DE	Discovery agent

DM6R1XH	ID	DM6R1XH
DM6R1XH	DN	2-[4-(2-Thienyl)phenyl]-4-methylmorpholin-2-ol
DM6R1XH	HS	Investigative
DM6R1XH	SN	CHEMBL449619; GTPL3081; BDBM50253901; compound 5 [PMID: 18754614]
DM6R1XH	DT	Small molecular drug
DM6R1XH	PC	25108103
DM6R1XH	MW	275.4
DM6R1XH	FM	C15H17NO2S
DM6R1XH	IC	InChI=1S/C15H17NO2S/c1-16-8-9-18-15(17,11-16)13-6-4-12(5-7-13)14-3-2-10-19-14/h2-7,10,17H,8-9,11H2,1H3
DM6R1XH	CS	CN1CCOC(C1)(C2=CC=C(C=C2)C3=CC=CS3)O
DM6R1XH	IK	KXFMAIULBLABNA-UHFFFAOYSA-N
DM6R1XH	IU	4-methyl-2-(4-thiophen-2-ylphenyl)morpholin-2-ol
DM6R1XH	DE	Discovery agent

DMZFKDW	ID	DMZFKDW
DMZFKDW	DN	2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
DMZFKDW	HS	Investigative
DMZFKDW	SN	CHEMBL574419; 2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
DMZFKDW	DT	Small molecular drug
DMZFKDW	PC	44541904
DMZFKDW	MW	309.3
DMZFKDW	FM	C18H15NO4
DMZFKDW	IC	InChI=1S/C18H15NO4/c19-17(20)8-13-9-18(21)23-16-10-14(6-7-15(13)16)22-11-12-4-2-1-3-5-12/h1-7,9-10H,8,11H2,(H2,19,20)
DMZFKDW	CS	C1=CC=C(C=C1)COC2=CC3=C(C=C2)C(=CC(=O)O3)CC(=O)N
DMZFKDW	IK	XAUATGLGKLEUAX-UHFFFAOYSA-N
DMZFKDW	IU	2-(2-oxo-7-phenylmethoxychromen-4-yl)acetamide
DMZFKDW	DE	Discovery agent

DM1PSRQ	ID	DM1PSRQ
DM1PSRQ	DN	2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DM1PSRQ	HS	Investigative
DM1PSRQ	SN	CHEMBL216198; 2-((2-phenethylphenoxy)methyl)pyridine; 2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DM1PSRQ	DT	Small molecular drug
DM1PSRQ	PC	11973809
DM1PSRQ	MW	289.4
DM1PSRQ	FM	C20H19NO
DM1PSRQ	IC	InChI=1S/C20H19NO/c1-2-8-17(9-3-1)13-14-18-10-4-5-12-20(18)22-16-19-11-6-7-15-21-19/h1-12,15H,13-14,16H2
DM1PSRQ	CS	C1=CC=C(C=C1)CCC2=CC=CC=C2OCC3=CC=CC=N3
DM1PSRQ	IK	XVQTWFFAIBVICX-UHFFFAOYSA-N
DM1PSRQ	IU	2-[[2-(2-phenylethyl)phenoxy]methyl]pyridine
DM1PSRQ	DE	Discovery agent

DM9TCWA	ID	DM9TCWA
DM9TCWA	DN	2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol
DM9TCWA	HS	Investigative
DM9TCWA	SN	CHEMBL516151; BDBM50251329
DM9TCWA	DT	Small molecular drug
DM9TCWA	PC	44567596
DM9TCWA	MW	371.4
DM9TCWA	FM	C21H25NO5
DM9TCWA	IC	InChI=1S/C21H25NO5/c1-22-5-4-14-10-15(27-9-8-26-7-6-23)12-16-19(14)17(22)11-13-2-3-18(24)21(25)20(13)16/h2-3,10,12,17,23-25H,4-9,11H2,1H3/t17-/m1/s1
DM9TCWA	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OCCOCCO)C(=C(C=C4)O)O
DM9TCWA	IK	LUIRUBNQVJTQKP-QGZVFWFLSA-N
DM9TCWA	IU	(6aR)-2-[2-(2-hydroxyethoxy)ethoxy]-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DM9TCWA	DE	Discovery agent

DM5BAJ9	ID	DM5BAJ9
DM5BAJ9	DN	20-HETE
DM5BAJ9	HS	Investigative
DM5BAJ9	SN	20-hydroxyeicosatetraenoic acid
DM5BAJ9	DT	Small molecular drug
DM5BAJ9	PC	5283157
DM5BAJ9	MW	320.5
DM5BAJ9	FM	C20H32O3
DM5BAJ9	IC	InChI=1S/C20H32O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6-7,9-10,12,21H,2,5,8,11,13-19H2,(H,22,23)/b3-1-,6-4-,9-7-,12-10-
DM5BAJ9	CS	C(CC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O)CCO
DM5BAJ9	IK	NNDIXBJHNLFJJP-DTLRTWKJSA-N
DM5BAJ9	IU	(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoic acid
DM5BAJ9	CA	CAS 79551-86-3
DM5BAJ9	CB	CHEBI:34306
DM5BAJ9	DE	Discovery agent

DM84GAQ	ID	DM84GAQ
DM84GAQ	DN	20-hydroxy-LTB4
DM84GAQ	HS	Investigative
DM84GAQ	SN	20-Hydroxy-leukotriene B4; 20-hydroxy-LTB4; 20-hydroxy LTB4; 20-OH-LTB4; 20-OH-Leukotriene B4; (5S,6Z,8E,10E,12R,14Z)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoic acid; CHEBI:15646; 79516-82-8; 5S,12R,20-trihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid; 20-hydroxyleukotriene B4; (5S,12R)-5,12,20-Trihydroxy-(6Z,8E,10E,14Z)-eicosatetraenoic acid; (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoate; (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyeicosa-6,8,10,14-tetraenoate; 5,12,20-Trihete; w-Hydroxy-LTB4
DM84GAQ	DT	Small molecular drug
DM84GAQ	PC	5280745
DM84GAQ	MW	352.5
DM84GAQ	FM	C20H32O5
DM84GAQ	IC	InChI=1S/C20H32O5/c21-17-10-6-2-1-3-7-12-18(22)13-8-4-5-9-14-19(23)15-11-16-20(24)25/h3-5,7-9,13-14,18-19,21-23H,1-2,6,10-12,15-17H2,(H,24,25)/b5-4+,7-3-,13-8+,14-9-/t18-,19-/m1/s1
DM84GAQ	CS	C(CC/C=C\\C[C@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O)CCO
DM84GAQ	IK	PTJFJXLGRSTECQ-PSPARDEHSA-N
DM84GAQ	IU	(5S,6Z,8E,10E,12R,14Z)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoic acid
DM84GAQ	CA	CAS 79516-82-8
DM84GAQ	CB	CHEBI:15646
DM84GAQ	DE	Discovery agent

DMHJM0F	ID	DMHJM0F
DMHJM0F	DN	227Th-rituximab
DMHJM0F	HS	Investigative
DMHJM0F	SN	Thorium-227-rituximab (cancer), Algeta
DMHJM0F	CP	Algeta ASA
DMHJM0F	DT	Antibody
DMHJM0F	DE	Solid tumour/cancer

DME8273	ID	DME8273
DME8273	DN	22R-hydroxycholesterol
DME8273	HS	Investigative
DME8273	SN	22beta-hydroxycholesterol; 22R-OHC
DME8273	DT	Small molecular drug
DME8273	PC	167685
DME8273	MW	402.7
DME8273	FM	C27H46O2
DME8273	IC	InChI=1S/C27H46O2/c1-17(2)6-11-25(29)18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20-,21-,22+,23-,24-,25+,26-,27+/m0/s1
DME8273	CS	C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)[C@@H](CCC(C)C)O
DME8273	IK	RZPAXNJLEKLXNO-GFKLAVDKSA-N
DME8273	IU	(3S,8S,9S,10R,13S,14S,17R)-17-[(2S,3R)-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DME8273	CA	CAS 17954-98-2
DME8273	CB	CHEBI:67237
DME8273	DE	Discovery agent

DM74X5O	ID	DM74X5O
DM74X5O	DN	2'-3'-dideoxy-7-deaza-guaninetriphosphate
DM74X5O	HS	Investigative
DM74X5O	SN	CHEMBL195111; BDBM50164639
DM74X5O	DT	Small molecular drug
DM74X5O	PC	44400853
DM74X5O	MW	490.19
DM74X5O	FM	C11H17N4O12P3
DM74X5O	IC	InChI=1S/C11H17N4O12P3/c12-11-10(16)9-7(3-13-11)15(5-14-9)8-2-1-6(25-8)4-24-29(20,21)27-30(22,23)26-28(17,18)19/h5-6,8H,1-4H2,(H2,12,13)(H,20,21)(H,22,23)(H2,17,18,19)/t6-,8+/m0/s1
DM74X5O	CS	C1C[C@@H](O[C@@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N2C=NC3=C2CN=C(C3=O)N
DM74X5O	IK	UOKJOXGBXPVQIX-POYBYMJQSA-N
DM74X5O	IU	[[(2S,5R)-5-(6-amino-7-oxo-4H-imidazo[4,5-c]pyridin-3-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM74X5O	DE	Discovery agent

DM27GH0	ID	DM27GH0
DM27GH0	DN	23-hydroxybetulinic acid
DM27GH0	HS	Investigative
DM27GH0	SN	85999-40-2; CHEBI:69580; 3,23-dihydroxy-20(29)-lupen-28-oic acid; Anemosapogenin; 23-Hydroxybetulinicacid; 23-hydroxy betulic acid; CHEMBL251308; 23-Hydroxybetulinic Acid, 25; BDBM23209; MolPort-039-338-114; HXWLKAXCQLXHML-WGOZWDAUSA-N; HY-N0566; EBD870843; ZINC14980302; AKOS032944876; CS-5686; SC-72875; 23-Hydroxybetulinic acid, &gt; 3I(2),23-dihydroxylup-20(29)-en-28-oic acid
DM27GH0	DT	Small molecular drug
DM27GH0	PC	21672692
DM27GH0	MW	472.7
DM27GH0	FM	C30H48O4
DM27GH0	IC	InChI=1S/C30H48O4/c1-18(2)19-9-14-30(25(33)34)16-15-28(5)20(24(19)30)7-8-22-26(3)12-11-23(32)27(4,17-31)21(26)10-13-29(22,28)6/h19-24,31-32H,1,7-17H2,2-6H3,(H,33,34)/t19-,20+,21+,22+,23-,24+,26-,27-,28+,29+,30-/m0/s1
DM27GH0	CS	CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H]([C@@]([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)CO)O)C)C(=O)O
DM27GH0	IK	HXWLKAXCQLXHML-WGOZWDAUSA-N
DM27GH0	IU	(1R,3aS,5aR,5bR,7aR,8R,9S,11aR,11bR,13aR,13bR)-9-hydroxy-8-(hydroxymethyl)-5a,5b,8,11a-tetramethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
DM27GH0	CA	CAS 85999-40-2
DM27GH0	CB	CHEBI:69580
DM27GH0	DE	Discovery agent

DMW2KI5	ID	DMW2KI5
DMW2KI5	DN	24(S), 25-epoxycholesterol
DMW2KI5	HS	Investigative
DMW2KI5	SN	24,25-epoxy-cholesterol
DMW2KI5	DT	Small molecular drug
DMW2KI5	PC	3247059
DMW2KI5	MW	400.6
DMW2KI5	FM	C27H44O2
DMW2KI5	IC	InChI=1S/C27H44O2/c1-17(6-11-24-25(2,3)29-24)21-9-10-22-20-8-7-18-16-19(28)12-14-26(18,4)23(20)13-15-27(21,22)5/h7,17,19-24,28H,6,8-16H2,1-5H3/t17-,19+,20+,21-,22+,23+,24+,26+,27-/m1/s1
DMW2KI5	CS	C[C@H](CC[C@H]1C(O1)(C)C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O)C)C
DMW2KI5	IK	OSENKJZWYQXHBN-XVYZBDJZSA-N
DMW2KI5	IU	(3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-4-[(2S)-3,3-dimethyloxiran-2-yl]butan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMW2KI5	CA	CAS 77058-74-3
DMW2KI5	CB	CHEBI:41633
DMW2KI5	DE	Discovery agent

DMGMWA6	ID	DMGMWA6
DMGMWA6	DN	24(S)-hydroxycholesterol
DMGMWA6	HS	Investigative
DMGMWA6	SN	24s-OHC
DMGMWA6	DT	Small molecular drug
DMGMWA6	PC	121948
DMGMWA6	MW	402.7
DMGMWA6	FM	C27H46O2
DMGMWA6	IC	InChI=1S/C27H46O2/c1-17(2)25(29)11-6-18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20+,21+,22-,23+,24+,25+,26+,27-/m1/s1
DMGMWA6	CS	C[C@H](CC[C@@H](C(C)C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DMGMWA6	IK	IOWMKBFJCNLRTC-XWXSNNQWSA-N
DMGMWA6	IU	(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5S)-5-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMGMWA6	CA	CAS 474-73-7
DMGMWA6	CB	CHEBI:34310
DMGMWA6	DE	Discovery agent

DMZIQ56	ID	DMZIQ56
DMZIQ56	DN	24-ethylcholest-6-ene-3,5-diol
DMZIQ56	HS	Investigative
DMZIQ56	SN	CHEMBL201866; 24-ethylcholest-6-ene-3,5-diol
DMZIQ56	DT	Small molecular drug
DMZIQ56	PC	44407138
DMZIQ56	MW	430.7
DMZIQ56	FM	C29H50O2
DMZIQ56	IC	InChI=1S/C29H50O2/c1-7-21(19(2)3)9-8-20(4)24-10-11-25-23-13-17-29(31)18-22(30)12-16-28(29,6)26(23)14-15-27(24,25)5/h13,17,19-26,30-31H,7-12,14-16,18H2,1-6H3/t20-,21?,22+,23+,24-,25+,26+,27-,28-,29?/m1/s1
DMZIQ56	CS	CCC(CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=CC4([C@@]3(CC[C@@H](C4)O)C)O)C)C(C)C
DMZIQ56	IK	CIZGZRCBMJRIFK-VRGDKWBFSA-N
DMZIQ56	IU	(3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-3,5-diol
DMZIQ56	DE	Discovery agent

DMQSTYZ	ID	DMQSTYZ
DMQSTYZ	DN	24-ethyl-cholest-7-ene-3,5,6-triol
DMQSTYZ	HS	Investigative
DMQSTYZ	SN	CHEMBL201951; 24-ethyl-cholest-7-ene-3,5,6-triol
DMQSTYZ	DT	Small molecular drug
DMQSTYZ	PC	44407137
DMQSTYZ	MW	446.7
DMQSTYZ	FM	C29H50O3
DMQSTYZ	IC	InChI=1S/C29H50O3/c1-7-20(18(2)3)9-8-19(4)23-10-11-24-22-16-26(31)29(32)17-21(30)12-15-28(29,6)25(22)13-14-27(23,24)5/h16,18-21,23-26,30-32H,7-15,17H2,1-6H3/t19-,20?,21+,23-,24+,25+,26?,27-,28-,29?/m1/s1
DMQSTYZ	CS	CCC(CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC(C4([C@@]3(CC[C@@H](C4)O)C)O)O)C)C(C)C
DMQSTYZ	IK	OZIAZQBXQMKSLA-XMWGPCPVSA-N
DMQSTYZ	IU	(3S,9S,10R,13R,14R,17R)-17-[(2R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,6,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-3,5,6-triol
DMQSTYZ	DE	Discovery agent

DMVY271	ID	DMVY271
DMVY271	DN	24-hydroxyursolic acid
DMVY271	HS	Investigative
DMVY271	SN	24-hydroxyursolic acid; CHEMBL522373; BDBM50253075; 3beta,24-Dihydroxyurs-12-en-28-oic acid
DMVY271	DT	Small molecular drug
DMVY271	PC	44568920
DMVY271	MW	472.7
DMVY271	FM	C30H48O4
DMVY271	IC	InChI=1S/C30H48O4/c1-18-9-14-30(25(33)34)16-15-28(5)20(24(30)19(18)2)7-8-22-26(3)12-11-23(32)27(4,17-31)21(26)10-13-29(22,28)6/h7,18-19,21-24,31-32H,8-17H2,1-6H3,(H,33,34)/t18-,19+,21-,22-,23+,24+,26+,27-,28-,29-,30+/m1/s1
DMVY271	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H]([C@]5(C)CO)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMVY271	IK	NZCULBURCGAPSF-OQCQIIONSA-N
DMVY271	IU	(1S,2R,4aS,6aR,6aS,6bR,8aR,9S,10S,12aR,14bS)-10-hydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMVY271	DE	Discovery agent

DM90IRW	ID	DM90IRW
DM90IRW	DN	24-thiacycloartanol
DM90IRW	HS	Investigative
DM90IRW	SN	CHEMBL238349; 24-thiacycloartanol
DM90IRW	DT	Small molecular drug
DM90IRW	PC	44434253
DM90IRW	MW	446.8
DM90IRW	FM	C29H50OS
DM90IRW	IC	InChI=1S/C29H50OS/c1-19(2)31-17-12-20(3)21-10-13-27(7)23-9-8-22-25(4,5)24(30)11-14-28(22)18-29(23,28)16-15-26(21,27)6/h19-24,30H,8-18H2,1-7H3/t20-,21-,22+,23+,24+,26-,27+,28?,29?/m1/s1
DM90IRW	CS	C[C@H](CCSC(C)C)[C@H]1CC[C@@]2([C@@]1(CCC34[C@H]2CC[C@@H]5C3(C4)CC[C@@H](C5(C)C)O)C)C
DM90IRW	IK	RCCUSRZZXQUAQP-VMZLNZKESA-N
DM90IRW	IU	(6S,8R,11S,12S,15R,16R)-7,7,12,16-tetramethyl-15-[(2R)-4-propan-2-ylsulfanylbutan-2-yl]pentacyclo[9.7.0.01,3.03,8.012,16]octadecan-6-ol
DM90IRW	DE	Discovery agent

DM6P3Z8	ID	DM6P3Z8
DM6P3Z8	DN	2'-5'dideoxyuridine
DM6P3Z8	HS	Investigative
DM6P3Z8	SN	2',5'-Dideoxyuridine; 2'-5'dideoxyuridine; 35959-50-3; AC1L9G4G; Uridine, 2',5'-dideoxy-; SCHEMBL2919639; CTK1C1122; DTXSID00332151; FDCFKLBIAIKUKB-GKROBHDKSA-N; ZINC3870698; DB03274
DM6P3Z8	DT	Small molecular drug
DM6P3Z8	PC	444320
DM6P3Z8	MW	212.2
DM6P3Z8	FM	C9H12N2O4
DM6P3Z8	IC	InChI=1S/C9H12N2O4/c1-5-6(12)4-8(15-5)11-3-2-7(13)10-9(11)14/h2-3,5-6,8,12H,4H2,1H3,(H,10,13,14)/t5-,6+,8-/m1/s1
DM6P3Z8	CS	C[C@@H]1[C@H](C[C@@H](O1)N2C=CC(=O)NC2=O)O
DM6P3Z8	IK	FDCFKLBIAIKUKB-GKROBHDKSA-N
DM6P3Z8	IU	1-[(2R,4S,5R)-4-hydroxy-5-methyloxolan-2-yl]pyrimidine-2,4-dione
DM6P3Z8	CA	CAS 35959-50-3
DM6P3Z8	DE	Discovery agent

DMCHAQ7	ID	DMCHAQ7
DMCHAQ7	DN	25-hydroxycholesterol
DMCHAQ7	HS	Investigative
DMCHAQ7	SN	25-OHC
DMCHAQ7	DT	Small molecular drug
DMCHAQ7	PC	65094
DMCHAQ7	MW	402.7
DMCHAQ7	FM	C27H46O2
DMCHAQ7	IC	InChI=1S/C27H46O2/c1-18(7-6-14-25(2,3)29)22-10-11-23-21-9-8-19-17-20(28)12-15-26(19,4)24(21)13-16-27(22,23)5/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t18-,20+,21+,22-,23+,24+,26+,27-/m1/s1
DMCHAQ7	CS	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DMCHAQ7	IK	INBGSXNNRGWLJU-ZHHJOTBYSA-N
DMCHAQ7	IU	(3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMCHAQ7	CA	CAS 2140-46-7
DMCHAQ7	CB	CHEBI:42977
DMCHAQ7	DE	Discovery agent

DM2L6OZ	ID	DM2L6OZ
DM2L6OZ	DN	27-hydroxycholesterol
DM2L6OZ	HS	Investigative
DM2L6OZ	SN	27-OHC; 26-hydroxycholesterol
DM2L6OZ	DT	Small molecular drug
DM2L6OZ	PC	123976
DM2L6OZ	MW	402.7
DM2L6OZ	FM	C27H46O2
DM2L6OZ	IC	InChI=1S/C27H46O2/c1-18(17-28)6-5-7-19(2)23-10-11-24-22-9-8-20-16-21(29)12-14-26(20,3)25(22)13-15-27(23,24)4/h8,18-19,21-25,28-29H,5-7,9-17H2,1-4H3/t18-,19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DM2L6OZ	CS	C[C@H](CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)CO
DM2L6OZ	IK	FYHRJWMENCALJY-YSQMORBQSA-N
DM2L6OZ	IU	(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM2L6OZ	CA	CAS 20380-11-4
DM2L6OZ	CB	CHEBI:76591
DM2L6OZ	DE	Discovery agent

DMUQAP7	ID	DMUQAP7
DMUQAP7	DN	29-methylidene-2,3-oxidosqualene
DMUQAP7	HS	Investigative
DMUQAP7	SN	29-Mos; 29-Methylidene-2,3-oxidosqualene; 2,2-dimethyl-3-[(3E,7E,11E,15E,19Z)-3,7,12-trimethyl-16-prop-2-enylhenicosa-3,7,11,15,19-pentaenyl]oxirane; AC1O5QC1; (3H)29-Mos; GTPL6719; Oxirane, 3-(16-ethenyl-3,7,12,20-tetramethyl-3,7,11,15,19-heneicosapentaenyl)-2,2-dimethyl-, (S-(all-E))-
DMUQAP7	DT	Small molecular drug
DMUQAP7	PC	6438780
DMUQAP7	MW	438.7
DMUQAP7	FM	C31H50O
DMUQAP7	IC	InChI=1S/C31H50O/c1-8-10-11-22-29(16-9-2)23-15-21-27(4)18-13-12-17-26(3)19-14-20-28(5)24-25-30-31(6,7)32-30/h8-10,17-18,20,23,30H,2,11-16,19,21-22,24-25H2,1,3-7H3/b10-8-,26-17+,27-18+,28-20+,29-23-
DMUQAP7	CS	C/C=C\\CC/C(=C\\CC/C(=C/CC/C=C(\\C)/CC/C=C(\\C)/CCC1C(O1)(C)C)/C)/CC=C
DMUQAP7	IK	DOTTUEYUTNVWMJ-KSTFQPQISA-N
DMUQAP7	IU	2,2-dimethyl-3-[(3E,7E,11E,15E,19Z)-3,7,12-trimethyl-16-prop-2-enylhenicosa-3,7,11,15,19-pentaenyl]oxirane
DMUQAP7	CA	CAS 145919-42-2
DMUQAP7	DE	Discovery agent

DMIQM4O	ID	DMIQM4O
DMIQM4O	DN	2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid
DMIQM4O	HS	Investigative
DMIQM4O	SN	CHEMBL454461; CHEMBL363489; BDBM50155551; 2-Acetylamino-indan-5-sulfonic acid
DMIQM4O	DT	Small molecular drug
DMIQM4O	PC	44395768
DMIQM4O	MW	255.29
DMIQM4O	FM	C11H13NO4S
DMIQM4O	IC	InChI=1S/C11H13NO4S/c1-7(13)12-10-4-8-2-3-11(17(14,15)16)6-9(8)5-10/h2-3,6,10H,4-5H2,1H3,(H,12,13)(H,14,15,16)
DMIQM4O	CS	CC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)O
DMIQM4O	IK	YEEWPYLDOKFULS-UHFFFAOYSA-N
DMIQM4O	IU	2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid
DMIQM4O	DE	Discovery agent

DMPKBVR	ID	DMPKBVR
DMPKBVR	DN	2-acetamido-5-sulfonamidoindane
DMPKBVR	HS	Investigative
DMPKBVR	SN	CHEMBL184674; N-(5-Sulfamoyl-indan-2-yl)-acetamide; 2-acetamido-5-sulfonamidoindane; Indanesulfonamide Derivative 6; SCHEMBL1971499; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)acetamide; BDBM11029; CTK6A0685; RVPDXKXWYPPTAL-UHFFFAOYSA-N; N-acetyl-5-sulfamyl-2-indanamine; Acetamide, N-[5-(aminosulfonyl)-2,3-dihydro-1H-inden-2-yl]-; AKOS015966079; 74124-93-9
DMPKBVR	DT	Small molecular drug
DMPKBVR	PC	11414131
DMPKBVR	MW	254.31
DMPKBVR	FM	C11H14N2O3S
DMPKBVR	IC	InChI=1S/C11H14N2O3S/c1-7(14)13-10-4-8-2-3-11(17(12,15)16)6-9(8)5-10/h2-3,6,10H,4-5H2,1H3,(H,13,14)(H2,12,15,16)
DMPKBVR	CS	CC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DMPKBVR	IK	RVPDXKXWYPPTAL-UHFFFAOYSA-N
DMPKBVR	IU	N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)acetamide
DMPKBVR	CA	CAS 74124-93-9
DMPKBVR	DE	Discovery agent

DMRKYD6	ID	DMRKYD6
DMRKYD6	DN	2-acetyl-3-hydroxycyclohex-2-enone
DMRKYD6	HS	Investigative
DMRKYD6	SN	CHEMBL73025; 37514-00-4; SCHEMBL5628771; CTK1B5605; DTXSID50472617; YKOOMGHHVDVJAY-UHFFFAOYSA-N; 2-Acetyl-3-hydroxy-cyclohex-2-enone; 2-Acetyl-3-hydroxy-2-cyclohexen-1-one; 2-Cyclohexen-1-one, 2-acetyl-3-hydroxy-
DMRKYD6	DT	Small molecular drug
DMRKYD6	PC	11788412
DMRKYD6	MW	154.16
DMRKYD6	FM	C8H10O3
DMRKYD6	IC	InChI=1S/C8H10O3/c1-5(9)8-6(10)3-2-4-7(8)11/h10H,2-4H2,1H3
DMRKYD6	CS	CC(=O)C1=C(CCCC1=O)O
DMRKYD6	IK	YKOOMGHHVDVJAY-UHFFFAOYSA-N
DMRKYD6	IU	2-acetyl-3-hydroxycyclohex-2-en-1-one
DMRKYD6	CA	CAS 37514-00-4
DMRKYD6	DE	Discovery agent

DM9ZOX4	ID	DM9ZOX4
DM9ZOX4	DN	2-Acetylaminoethyl 18-methoxycoronaridinate
DM9ZOX4	HS	Investigative
DM9ZOX4	SN	2-Acetylaminoethyl 18-methoxycoronaridinate
DM9ZOX4	DT	Small molecular drug
DM9ZOX4	PC	46877890
DM9ZOX4	MW	439.5
DM9ZOX4	FM	C25H33N3O4
DM9ZOX4	IC	InChI=1S/C25H33N3O4/c1-16(29)26-9-12-32-24(30)25-14-17-13-18(8-11-31-2)23(25)28(15-17)10-7-20-19-5-3-4-6-21(19)27-22(20)25/h3-6,17-18,23,27H,7-15H2,1-2H3,(H,26,29)/t17?,18-,23-,25+/m0/s1
DM9ZOX4	CS	CC(=O)NCCOC(=O)[C@@]12CC3C[C@@H]([C@@H]1N(C3)CCC4=C2NC5=CC=CC=C45)CCOC
DM9ZOX4	IK	PIPDTENSRZRDNA-BJASRFDRSA-N
DM9ZOX4	IU	2-acetamidoethyl (1S,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DM9ZOX4	DE	Discovery agent

DMEQKIU	ID	DMEQKIU
DMEQKIU	DN	2-Acetylamino-indan-5-sulfonic acid hydrate
DMEQKIU	HS	Investigative
DMEQKIU	DE	Discovery agent

DM0NJYZ	ID	DM0NJYZ
DM0NJYZ	DN	2-acetylaminoquinazoline-4-carboxyanilide
DM0NJYZ	HS	Investigative
DM0NJYZ	SN	CHEMBL239193; 2-acetylaminoquinazoline-4-carboxyanilide
DM0NJYZ	DT	Small molecular drug
DM0NJYZ	PC	24749707
DM0NJYZ	MW	306.32
DM0NJYZ	FM	C17H14N4O2
DM0NJYZ	IC	InChI=1S/C17H14N4O2/c1-11(22)18-17-20-14-10-6-5-9-13(14)15(21-17)16(23)19-12-7-3-2-4-8-12/h2-10H,1H3,(H,19,23)(H,18,20,21,22)
DM0NJYZ	CS	CC(=O)NC1=NC2=CC=CC=C2C(=N1)C(=O)NC3=CC=CC=C3
DM0NJYZ	IK	BQZOPXKHGPNWQR-UHFFFAOYSA-N
DM0NJYZ	IU	2-acetamido-N-phenylquinazoline-4-carboxamide
DM0NJYZ	DE	Discovery agent

DMN8TVB	ID	DMN8TVB
DMN8TVB	DN	2-Acetyl-cyclohexane-1,3-dione
DMN8TVB	HS	Investigative
DMN8TVB	SN	2-Acetyl-1,3-cyclohexanedione; 4056-73-9; 2-acetylcyclohexane-1,3-dione; 2-Acetyl-cyclohexane-1,3-dione; 1,3-Cyclohexanedione, 2-acetyl-; CHEMBL167675; CHNXDYRMRBQOEF-UHFFFAOYSA-N; ACMC-1CTSA; AC1L3C2Y; 2-acetyl1,3-cyclohexanedione; 2-acetyl-1,3-cyclohexadione; SCHEMBL170644; 1-acetyl-2,6-dioxocyclohexane; CTK4I3348; 1,3-Cyclohexanedione,2-acetyl-; DTXSID50193577; BDBM50088797; AKOS015906528; ZINC100068139; 2-Acetyl-1,3-cyclohexanedione, 98%; MCULE-5567869384; TC-171004; ST50997553; X3265; CS-0060856; Z-8544
DMN8TVB	DT	Small molecular drug
DMN8TVB	PC	138104
DMN8TVB	MW	154.16
DMN8TVB	FM	C8H10O3
DMN8TVB	IC	InChI=1S/C8H10O3/c1-5(9)8-6(10)3-2-4-7(8)11/h8H,2-4H2,1H3
DMN8TVB	CS	CC(=O)C1C(=O)CCCC1=O
DMN8TVB	IK	CHNXDYRMRBQOEF-UHFFFAOYSA-N
DMN8TVB	IU	2-acetylcyclohexane-1,3-dione
DMN8TVB	CA	CAS 4056-73-9
DMN8TVB	DE	Discovery agent

DMJAUH0	ID	DMJAUH0
DMJAUH0	DN	2-Adamantan-1-yl-N-decyl-acetamide
DMJAUH0	HS	Investigative
DMJAUH0	SN	CHEMBL192549; 2-Adamantan-1-yl-N-decyl-acetamide; SCHEMBL12931880
DMJAUH0	DT	Small molecular drug
DMJAUH0	PC	11382033
DMJAUH0	MW	333.6
DMJAUH0	FM	C22H39NO
DMJAUH0	IC	InChI=1S/C22H39NO/c1-2-3-4-5-6-7-8-9-10-23-21(24)17-22-14-18-11-19(15-22)13-20(12-18)16-22/h18-20H,2-17H2,1H3,(H,23,24)
DMJAUH0	CS	CCCCCCCCCCNC(=O)CC12CC3CC(C1)CC(C3)C2
DMJAUH0	IK	CIOJRKYNUJJCLZ-UHFFFAOYSA-N
DMJAUH0	IU	2-(1-adamantyl)-N-decylacetamide
DMJAUH0	DE	Discovery agent

DMXG029	ID	DMXG029
DMXG029	DN	2-Adamantan-2-ylidenemethyl-benzooxazol-6-ol
DMXG029	HS	Investigative
DMXG029	SN	CHEMBL187900
DMXG029	DT	Small molecular drug
DMXG029	PC	22733402
DMXG029	MW	281.3
DMXG029	FM	C18H19NO2
DMXG029	IC	InChI=1S/C18H19NO2/c20-14-1-2-16-17(8-14)21-18(19-16)9-15-12-4-10-3-11(6-12)7-13(15)5-10/h1-2,8-13,20H,3-7H2
DMXG029	CS	C1C2CC3CC1CC(C2)C3=CC4=NC5=C(O4)C=C(C=C5)O
DMXG029	IK	CEAARYLECHJRSD-UHFFFAOYSA-N
DMXG029	IU	2-(2-adamantylidenemethyl)-1,3-benzoxazol-6-ol
DMXG029	DE	Discovery agent

DM3DE9Z	ID	DM3DE9Z
DM3DE9Z	DN	2-allylisoquinoline-1,3,4-trione
DM3DE9Z	HS	Investigative
DM3DE9Z	SN	807334-89-0; 1,3,4(2H)-Isoquinolinetrione, 2-(2-propenyl)-; 2-allylisoquinoline-1,3,4-trione; CHEMBL381777; Isoquinoline-1,3,4-trione 2b; SCHEMBL13442855; CTK2I7309; BDBM10249; DTXSID20469711; ZINC13683126; AKOS015966148
DM3DE9Z	DT	Small molecular drug
DM3DE9Z	PC	11629882
DM3DE9Z	MW	215.2
DM3DE9Z	FM	C12H9NO3
DM3DE9Z	IC	InChI=1S/C12H9NO3/c1-2-7-13-11(15)9-6-4-3-5-8(9)10(14)12(13)16/h2-6H,1,7H2
DM3DE9Z	CS	C=CCN1C(=O)C2=CC=CC=C2C(=O)C1=O
DM3DE9Z	IK	RFPACNBGGYBCGT-UHFFFAOYSA-N
DM3DE9Z	IU	2-prop-2-enylisoquinoline-1,3,4-trione
DM3DE9Z	CA	CAS 807334-89-0
DM3DE9Z	DE	Discovery agent

DMTO1EJ	ID	DMTO1EJ
DMTO1EJ	DN	2-Allylthio-3-benzyl-6-nitro-quinazolin-4(3H)-one
DMTO1EJ	HS	Investigative
DMTO1EJ	SN	CHEMBL1092451; 2-Allylthio-3-benzyl-6-nitro-quinazolin-4(3H)-one
DMTO1EJ	DT	Small molecular drug
DMTO1EJ	PC	46886486
DMTO1EJ	MW	353.4
DMTO1EJ	FM	C18H15N3O3S
DMTO1EJ	IC	InChI=1S/C18H15N3O3S/c1-2-10-25-18-19-16-9-8-14(21(23)24)11-15(16)17(22)20(18)12-13-6-4-3-5-7-13/h2-9,11H,1,10,12H2
DMTO1EJ	CS	C=CCSC1=NC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)N1CC3=CC=CC=C3
DMTO1EJ	IK	BDDASWRESYMCMC-UHFFFAOYSA-N
DMTO1EJ	IU	3-benzyl-6-nitro-2-prop-2-enylsulfanylquinazolin-4-one
DMTO1EJ	DE	Discovery agent

DMBWGCX	ID	DMBWGCX
DMBWGCX	DN	2-Allylthio-6-amino-3-benzyl-quinazolin-4(3H)-one
DMBWGCX	HS	Investigative
DMBWGCX	SN	CHEMBL1093491; 2-Allylthio-6-amino-3-benzyl-quinazolin-4(3H)-one
DMBWGCX	DT	Small molecular drug
DMBWGCX	PC	46886512
DMBWGCX	MW	323.4
DMBWGCX	FM	C18H17N3OS
DMBWGCX	IC	InChI=1S/C18H17N3OS/c1-2-10-23-18-20-16-9-8-14(19)11-15(16)17(22)21(18)12-13-6-4-3-5-7-13/h2-9,11H,1,10,12,19H2
DMBWGCX	CS	C=CCSC1=NC2=C(C=C(C=C2)N)C(=O)N1CC3=CC=CC=C3
DMBWGCX	IK	FKQLYAVUAISVGO-UHFFFAOYSA-N
DMBWGCX	IU	6-amino-3-benzyl-2-prop-2-enylsulfanylquinazolin-4-one
DMBWGCX	DE	Discovery agent

DMHY2RA	ID	DMHY2RA
DMHY2RA	DN	2alpha-Hydroxyolean-12-en-28-oic acid
DMHY2RA	HS	Investigative
DMHY2RA	SN	CHEMBL1077726; 2alpha-Hydroxyolean-12-en-28-oic acid; BDBM50310519; 2alpha-Hydroxyoleana-12-ene-28-oic acid
DMHY2RA	DT	Small molecular drug
DMHY2RA	PC	44254077
DMHY2RA	MW	456.7
DMHY2RA	FM	C30H48O3
DMHY2RA	IC	InChI=1S/C30H48O3/c1-25(2)12-14-30(24(32)33)15-13-28(6)20(21(30)18-25)8-9-23-27(5)17-19(31)16-26(3,4)22(27)10-11-29(23,28)7/h8,19,21-23,31H,9-18H2,1-7H3,(H,32,33)/t19-,21-,22-,23+,27-,28+,29+,30-/m0/s1
DMHY2RA	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H](CC3(C)C)O)C
DMHY2RA	IK	UODITNOILLXLOO-DBWGAYEVSA-N
DMHY2RA	IU	(4aS,6aR,6aS,6bR,8aS,11S,12aS,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMHY2RA	DE	Discovery agent

DM1RSCP	ID	DM1RSCP
DM1RSCP	DN	2alpha-Hydroxyurs-12-en-28-oic acid
DM1RSCP	HS	Investigative
DM1RSCP	SN	CHEMBL1078844; 2alpha-Hydroxyurs-12-en-28-oic acid
DM1RSCP	DT	Small molecular drug
DM1RSCP	PC	44254078
DM1RSCP	MW	456.7
DM1RSCP	FM	C30H48O3
DM1RSCP	IC	InChI=1S/C30H48O3/c1-18-10-13-30(25(32)33)15-14-28(6)21(24(30)19(18)2)8-9-23-27(5)17-20(31)16-26(3,4)22(27)11-12-29(23,28)7/h8,18-20,22-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,20+,22+,23-,24+,27+,28-,29-,30+/m1/s1
DM1RSCP	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H](CC5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DM1RSCP	IK	DDHYEJNMSYDDTH-ZWHPGZRZSA-N
DM1RSCP	IU	(1S,2R,4aS,6aR,6aS,6bR,8aS,11S,12aS,14bS)-11-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DM1RSCP	DE	Discovery agent

DM73FWA	ID	DM73FWA
DM73FWA	DN	2-Amino-1-(4-ethylthiophenyl)butane
DM73FWA	HS	Investigative
DM73FWA	SN	2-Amino-1-(4-ethylthiophenyl)butane; CHEMBL1077883; 1204749-31-4; BDBM50310840
DM73FWA	DT	Small molecular drug
DM73FWA	PC	44613455
DM73FWA	MW	209.35
DM73FWA	FM	C12H19NS
DM73FWA	IC	InChI=1S/C12H19NS/c1-3-11(13)9-10-5-7-12(8-6-10)14-4-2/h5-8,11H,3-4,9,13H2,1-2H3
DM73FWA	CS	CCC(CC1=CC=C(C=C1)SCC)N
DM73FWA	IK	PCPVEGXNPCSDGS-UHFFFAOYSA-N
DM73FWA	IU	1-(4-ethylsulfanylphenyl)butan-2-amine
DM73FWA	DE	Discovery agent

DMS5LKR	ID	DMS5LKR
DMS5LKR	DN	2-Amino-1-(4-ethylthiophenyl)propane
DMS5LKR	HS	Investigative
DMS5LKR	SN	CHEMBL193309; 2-Amino-1-(4-ethylthiophenyl)propane; 4-ethylthioamphetamine; BDBM50164327; AKOS013148908
DMS5LKR	DT	Small molecular drug
DMS5LKR	PC	44399737
DMS5LKR	MW	195.33
DMS5LKR	FM	C11H17NS
DMS5LKR	IC	InChI=1S/C11H17NS/c1-3-13-11-6-4-10(5-7-11)8-9(2)12/h4-7,9H,3,8,12H2,1-2H3
DMS5LKR	CS	CCSC1=CC=C(C=C1)CC(C)N
DMS5LKR	IK	WOBAXWXQKSIHCH-UHFFFAOYSA-N
DMS5LKR	IU	1-(4-ethylsulfanylphenyl)propan-2-amine
DMS5LKR	DE	Discovery agent

DMW7N3H	ID	DMW7N3H
DMW7N3H	DN	2-Amino-1-(4-methylthiophenyl)butane
DMW7N3H	HS	Investigative
DMW7N3H	SN	2-Amino-1-(4-methylthiophenyl)butane; CHEMBL1078352; 634607-37-7; BDBM50310844
DMW7N3H	DT	Small molecular drug
DMW7N3H	PC	43565977
DMW7N3H	MW	195.33
DMW7N3H	FM	C11H17NS
DMW7N3H	IC	InChI=1S/C11H17NS/c1-3-10(12)8-9-4-6-11(13-2)7-5-9/h4-7,10H,3,8,12H2,1-2H3
DMW7N3H	CS	CCC(CC1=CC=C(C=C1)SC)N
DMW7N3H	IK	DTEDVKORISMLCH-UHFFFAOYSA-N
DMW7N3H	IU	1-(4-methylsulfanylphenyl)butan-2-amine
DMW7N3H	DE	Discovery agent

DMJ2Z9G	ID	DMJ2Z9G
DMJ2Z9G	DN	2-Amino-1-(4-methylthiophenyl)propane
DMJ2Z9G	HS	Investigative
DMJ2Z9G	SN	1-(6-(methylthio)naphthalen-2-yl)propan-2-amine
DMJ2Z9G	DT	Small molecular drug
DMJ2Z9G	PC	151900
DMJ2Z9G	MW	181.3
DMJ2Z9G	FM	C10H15NS
DMJ2Z9G	IC	InChI=1S/C10H15NS/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3
DMJ2Z9G	CS	CC(CC1=CC=C(C=C1)SC)N
DMJ2Z9G	IK	OLEWMKVPSUCNLG-UHFFFAOYSA-N
DMJ2Z9G	IU	1-(4-methylsulfanylphenyl)propan-2-amine
DMJ2Z9G	CA	CAS 14116-06-4
DMJ2Z9G	DE	Discovery agent

DMNQL17	ID	DMNQL17
DMNQL17	DN	2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
DMNQL17	HS	Investigative
DMNQL17	SN	PhIP; 105650-23-5; 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; 1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2-amine; 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; UNII-909C6UN66T; CHEBI:76290; 909C6UN66T; 1-Methyl-6-phenyl-1H-imidazo(4,5-b)pyridin-2-amine; PIQ; 2-AMINO-1-METHYL-6-PHENYL-IMIDAZO [4,5-b] PYRIDINE; 1H-Imidazo(4,5-b)pyridin-2-amine, 1-methyl-6-phenyl- (9CI); CCRIS 2954; HSDB 7768; BRN 5951264; ACMC-1BRGI; AC1Q4WMI; (3H)PhIP; AC1L1BO3; SCHEMBL151718; CHEMBL1213271; DTXSID3037628; CTK0I0185
DMNQL17	DT	Small molecular drug
DMNQL17	PC	1530
DMNQL17	MW	224.26
DMNQL17	FM	C13H12N4
DMNQL17	IC	InChI=1S/C13H12N4/c1-17-11-7-10(9-5-3-2-4-6-9)8-15-12(11)16-13(17)14/h2-8H,1H3,(H2,14,15,16)
DMNQL17	CS	CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N
DMNQL17	IK	UQVKZNNCIHJZLS-UHFFFAOYSA-N
DMNQL17	IU	1-methyl-6-phenylimidazo[4,5-b]pyridin-2-amine
DMNQL17	CA	CAS 105650-23-5
DMNQL17	CB	CHEBI:76290
DMNQL17	DE	Discovery agent

DMWDENZ	ID	DMWDENZ
DMWDENZ	DN	2-amino-2-(2,3-difluorophenyl)acetic acid
DMWDENZ	HS	Investigative
DMWDENZ	SN	2-amino-2-(2,3-difluorophenyl)acetic Acid; 237424-16-7; 2,3-Difluoro-DL-phenylglycine; 2,3-DIFLUOR-DL-PHENYLGLYCINE; CHEMBL204804; AC1MC6PF; MolPort-000-165-847; JRD-0494; SBB090537; BDBM50179717; amino(2,3-difluorophenyl)acetic acid; AKOS012977999; AB26703; PS-11465; alpha-Amino-2,3-difluoro-benzeneacetic acid
DMWDENZ	DT	Small molecular drug
DMWDENZ	PC	2737049
DMWDENZ	MW	187.14
DMWDENZ	FM	C8H7F2NO2
DMWDENZ	IC	InChI=1S/C8H7F2NO2/c9-5-3-1-2-4(6(5)10)7(11)8(12)13/h1-3,7H,11H2,(H,12,13)
DMWDENZ	CS	C1=CC(=C(C(=C1)F)F)C(C(=O)O)N
DMWDENZ	IK	DNWOZEQWCCXGRU-UHFFFAOYSA-N
DMWDENZ	IU	2-amino-2-(2,3-difluorophenyl)acetic acid
DMWDENZ	DE	Discovery agent

DMSAFUK	ID	DMSAFUK
DMSAFUK	DN	2-amino-2-(2,4-difluorophenyl)acetic acid
DMSAFUK	HS	Investigative
DMSAFUK	SN	2-amino-2-(2,4-difluorophenyl)acetic Acid; 240409-02-3; 2,4-DIFLUORO-DL-PHENYLGLYCINE; amino(2,4-difluorophenyl)acetic acid; CHEMBL382622; Amino-(2,4-difluoro-phenyl)-acetic acid; alpha-Amino-2,4-difluorobenzeneacetic acid; AC1MC6PH; SCHEMBL1115280; CTK7I4174; DTXSID70371799; MolPort-000-165-848; COIWYFIMAXMSKX-UHFFFAOYSA-N; AC1Q5058; KS-00003QV7; BDBM50179695; SBB090539; AKOS016051288; AKOS000170674; PS-6697; QC-3701; AB11996; RP03495; SC-59456; FT-0691426; BB 0249675; 2-aMino-2-(2;4-difluorophenyl)acetic acid; Y8397; EN300-88022
DMSAFUK	DT	Small molecular drug
DMSAFUK	PC	2737050
DMSAFUK	MW	187.14
DMSAFUK	FM	C8H7F2NO2
DMSAFUK	IC	InChI=1S/C8H7F2NO2/c9-4-1-2-5(6(10)3-4)7(11)8(12)13/h1-3,7H,11H2,(H,12,13)
DMSAFUK	CS	C1=CC(=C(C=C1F)F)C(C(=O)O)N
DMSAFUK	IK	COIWYFIMAXMSKX-UHFFFAOYSA-N
DMSAFUK	IU	2-amino-2-(2,4-difluorophenyl)acetic acid
DMSAFUK	CA	CAS 240409-02-3
DMSAFUK	DE	Discovery agent

DMLXOHE	ID	DMLXOHE
DMLXOHE	DN	2-amino-2-(2-fluorophenyl)acetic acid
DMLXOHE	HS	Investigative
DMLXOHE	SN	84145-28-8; Amino(2-fluorophenyl)acetic acid; Amino-(2-fluoro-phenyl)-acetic acid; 2-(2-FLUOROPHENYL)GLYCINE; CHEMBL383715; DL-2-FLUOROPHENYLGLYCINE; CGNMJIBUVDGMIY-UHFFFAOYSA-N; Bionet2_000821; dl-O-Fluorophenylglycine; AC1LBC1Z; 2-fluoro-dl-phenylglycine; 2-(o-fluorophenyl)glycine; AC1Q4O3E; dl-(2-Fluorophenyl)-glycine; 2-fluoro-dl-; SCHEMBL2628067; AC1Q505A; 2-Fluoro-dl-alpha-phenylglycine; CTK8D0864; MolPort-000-000-424; HMS1366F07; 2-Fluoro-dl-.alpha.-phenylglycine
DMLXOHE	DT	Small molecular drug
DMLXOHE	PC	580073
DMLXOHE	MW	169.15
DMLXOHE	FM	C8H8FNO2
DMLXOHE	IC	InChI=1S/C8H8FNO2/c9-6-4-2-1-3-5(6)7(10)8(11)12/h1-4,7H,10H2,(H,11,12)
DMLXOHE	CS	C1=CC=C(C(=C1)C(C(=O)O)N)F
DMLXOHE	IK	CGNMJIBUVDGMIY-UHFFFAOYSA-N
DMLXOHE	IU	2-amino-2-(2-fluorophenyl)acetic acid
DMLXOHE	CA	CAS 84145-28-8
DMLXOHE	DE	Discovery agent

DMEX6AM	ID	DMEX6AM
DMEX6AM	DN	2-amino-2-(3-bromophenyl)acetic acid
DMEX6AM	HS	Investigative
DMEX6AM	SN	2-amino-2-(3-bromophenyl)acetic Acid; 79422-73-4; Amino(3-bromophenyl)acetic acid; 3-Bromo-DL-phenylglycine; CHEMBL382371; 150174-93-9; Amino-(3-bromo-phenyl)-acetic acid; Benzeneacetic acid, a-amino-3-bromo-; 3-Bromo-L-phenylglycine; (+)-2-Amino-2-(3-bromophenyl)acetic acid; (S)-2-(3-BROMOPHENYL)GLYCINE; AC1MXE2V; 2-(3-Bromophenyl)glycine; SCHEMBL2927725; AMGLY00125; AC1Q505E; CTK5E6784; KS-00000MGC; DTXSID80396791; MolPort-000-000-540; MJPMYLPJAVQUQA-UHFFFAOYSA-N; N-(3-BROMOPHENYL)-GLYCINE; ANW-43657; MFCD00665358; BDBM50179696
DMEX6AM	DT	Small molecular drug
DMEX6AM	PC	3814142
DMEX6AM	MW	230.06
DMEX6AM	FM	C8H8BrNO2
DMEX6AM	IC	InChI=1S/C8H8BrNO2/c9-6-3-1-2-5(4-6)7(10)8(11)12/h1-4,7H,10H2,(H,11,12)
DMEX6AM	CS	C1=CC(=CC(=C1)Br)C(C(=O)O)N
DMEX6AM	IK	MJPMYLPJAVQUQA-UHFFFAOYSA-N
DMEX6AM	IU	2-amino-2-(3-bromophenyl)acetic acid
DMEX6AM	CA	CAS 79422-73-4
DMEX6AM	DE	Discovery agent

DMMU1CQ	ID	DMMU1CQ
DMMU1CQ	DN	2-amino-2-(3-chloro-4-fluorophenyl)acetic acid
DMMU1CQ	HS	Investigative
DMMU1CQ	SN	261762-99-6; 2-amino-2-(3-chloro-4-fluorophenyl)acetic acid; 3-Chloro-4-fluoro-DL-phenylglycine; C8H7ClFNO2; CHEMBL203905; amino(3-chloro-4-fluorophenyl)acetic acid; AC1MCND8; SCHEMBL8196588; KS-00000ZXX; CTK8F0591; DTXSID40378674; MolPort-000-153-073; JRD-1093; SBB093187; BDBM50179692; 8653AD; 2-(3-Chloro-4-fluorophenyl)glycine; MFCD01631397; AKOS032962888; AKOS015907725; MCULE-4108995551; RTR-011871; PS-6305; SY044823; TR-011871; ST51041478; FT-0676194; MFCD01631397 (95%); C-5924
DMMU1CQ	DT	Small molecular drug
DMMU1CQ	PC	2773727
DMMU1CQ	MW	203.6
DMMU1CQ	FM	C8H7ClFNO2
DMMU1CQ	IC	InChI=1S/C8H7ClFNO2/c9-5-3-4(1-2-6(5)10)7(11)8(12)13/h1-3,7H,11H2,(H,12,13)
DMMU1CQ	CS	C1=CC(=C(C=C1C(C(=O)O)N)Cl)F
DMMU1CQ	IK	DVSWHHQDQJPPBH-UHFFFAOYSA-N
DMMU1CQ	IU	2-amino-2-(3-chloro-4-fluorophenyl)acetic acid
DMMU1CQ	CA	CAS 261762-99-6
DMMU1CQ	DE	Discovery agent

DMPZX8U	ID	DMPZX8U
DMPZX8U	DN	2-amino-2-(3-chlorophenyl)acetic acid
DMPZX8U	HS	Investigative
DMPZX8U	SN	7292-71-9; 2-amino-2-(3-chlorophenyl)acetic acid; Amino-(3-chloro-phenyl)-acetic acid; amino(3-chlorophenyl)acetic acid; dl-3-chlorophenylglycine; 3-chlorophenylglycine; amino-(3-chlorophenyl)acetic acid; DL-(3-Chlorophenyl)glycine; DL-2-(3-Chlorophenyl)glycine; CHEMBL204655; amino(3-chloro-phenyl)acetic acid; (R)-2-(3-Chlorophenyl)glycine; NSC154922; Benzeneacetic acid, a-amino-3-chloro-, (aS)-; PubChem20741; ACMC-20en3l; (3-chlorophenyl)glycine; AC1L6EDK; 3-Chloro-DL-phenylglycine; AC1Q3M3E; 2-(3-Chlorophenyl)glycine
DMPZX8U	DT	Small molecular drug
DMPZX8U	PC	290730
DMPZX8U	MW	185.61
DMPZX8U	FM	C8H8ClNO2
DMPZX8U	IC	InChI=1S/C8H8ClNO2/c9-6-3-1-2-5(4-6)7(10)8(11)12/h1-4,7H,10H2,(H,11,12)
DMPZX8U	CS	C1=CC(=CC(=C1)Cl)C(C(=O)O)N
DMPZX8U	IK	MGOUENCSVMAGSE-UHFFFAOYSA-N
DMPZX8U	IU	2-amino-2-(3-chlorophenyl)acetic acid
DMPZX8U	CA	CAS 29884-14-8
DMPZX8U	DE	Discovery agent

DMHQNZD	ID	DMHQNZD
DMHQNZD	DN	2-amino-2-(thiophen-2-yl)acetic acid
DMHQNZD	HS	Investigative
DMHQNZD	SN	21124-40-3; AMINO-THIOPHEN-2-YL-ACETIC ACID; 2-amino-2-(thiophen-2-yl)acetic acid; Amino(2-thienyl)acetic acid; DL-alpha-Amino-2-thiopheneacetic acid; 2-(2-thienyl)glycine; 4052-59-9; 2-amino-2-(2-thienyl)acetic acid; CHEMBL382570; amino(thiophen-2-yl)acetic acid; 2-Thiopheneacetic acid, alpha-amino-, (-)-; XLMSKXASROPJNG-UHFFFAOYSA-N; (-)-2-Thienylglycine; EINECS 223-758-6; ACMC-20altb; (-)-alpha-Amino-2-thiopheneacetic acid; alpha-(2-Thienyl)glycine; DL-2-(2-Thienyl)glycine; AC1Q5S3H; 2-(Thiophen-2-yl)glycine; AC1L3HV3
DMHQNZD	DT	Small molecular drug
DMHQNZD	PC	89435
DMHQNZD	MW	157.19
DMHQNZD	FM	C6H7NO2S
DMHQNZD	IC	InChI=1S/C6H7NO2S/c7-5(6(8)9)4-2-1-3-10-4/h1-3,5H,7H2,(H,8,9)
DMHQNZD	CS	C1=CSC(=C1)C(C(=O)O)N
DMHQNZD	IK	XLMSKXASROPJNG-UHFFFAOYSA-N
DMHQNZD	IU	2-amino-2-thiophen-2-ylacetic acid
DMHQNZD	CA	CAS 21124-40-3
DMHQNZD	DE	Discovery agent

DMQOCAY	ID	DMQOCAY
DMQOCAY	DN	2-amino-2,3-dihydro-1H-indene-5-sulfonamide
DMQOCAY	HS	Investigative
DMQOCAY	SN	CHEMBL457996; CHEMBL559179; 5-sulfamyl-2-indanamine; 2-amino-2,3-dihydro-1H-indene-5-sulfonamide; SCHEMBL11452177; FVWXUWAWIYLUJG-UHFFFAOYSA-N; BDBM50155553; 2-Amino-indan-5-sulfonic acid amide; AKOS015921614; 52069-27-9; 2-Amino-indan-5-sulfonic acid amide
DMQOCAY	DT	Small molecular drug
DMQOCAY	PC	20347846
DMQOCAY	MW	212.27
DMQOCAY	FM	C9H12N2O2S
DMQOCAY	IC	InChI=1S/C9H12N2O2S/c10-8-3-6-1-2-9(14(11,12)13)5-7(6)4-8/h1-2,5,8H,3-4,10H2,(H2,11,12,13)
DMQOCAY	CS	C1C(CC2=C1C=CC(=C2)S(=O)(=O)N)N
DMQOCAY	IK	FVWXUWAWIYLUJG-UHFFFAOYSA-N
DMQOCAY	IU	2-amino-2,3-dihydro-1H-indene-5-sulfonamide
DMQOCAY	DE	Discovery agent

DM14HCY	ID	DM14HCY
DM14HCY	DN	2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol
DM14HCY	HS	Investigative
DM14HCY	SN	CHEMBL1090816; 2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol
DM14HCY	DT	Small molecular drug
DM14HCY	PC	46885586
DM14HCY	MW	291.3
DM14HCY	FM	C18H17N3O
DM14HCY	IC	InChI=1S/C18H17N3O/c19-17(14-6-2-1-3-7-14)18(22,15-8-4-10-20-12-15)16-9-5-11-21-13-16/h1-13,17,22H,19H2
DM14HCY	CS	C1=CC=C(C=C1)C(C(C2=CN=CC=C2)(C3=CN=CC=C3)O)N
DM14HCY	IK	BBACDJSPZTWBIB-UHFFFAOYSA-N
DM14HCY	IU	2-amino-2-phenyl-1,1-dipyridin-3-ylethanol
DM14HCY	DE	Discovery agent

DMQKGL3	ID	DMQKGL3
DMQKGL3	DN	2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX)
DMQKGL3	HS	Investigative
DMQKGL3	SN	CHEMBL1094129; BDBM50318264
DMQKGL3	DT	Small molecular drug
DMQKGL3	PC	46237944
DMQKGL3	MW	173.13
DMQKGL3	FM	C5H7N3O4
DMQKGL3	IC	InChI=1S/C5H7N3O4/c6-2(5(10)11)1-3-4(9)8-12-7-3/h2H,1,6H2,(H,8,9)(H,10,11)
DMQKGL3	CS	C(C1=NONC1=O)C(C(=O)O)N
DMQKGL3	IK	LSAPTLMISILBOS-UHFFFAOYSA-N
DMQKGL3	IU	2-amino-3-(4-oxo-1,2,5-oxadiazol-3-yl)propanoic acid
DMQKGL3	DE	Discovery agent

DM2GJZE	ID	DM2GJZE
DM2GJZE	DN	2-amino-3-(m-tolylamino)naphthalene-1,4-dione
DM2GJZE	HS	Investigative
DM2GJZE	SN	CHEMBL598551; 2-amino-3-(m-tolylamino)naphthalene-1,4-dione; MolPort-007-563-584; ZINC27548840; BDBM50306786; AKOS001660486; MCULE-4833073664; EU-0076855
DM2GJZE	DT	Small molecular drug
DM2GJZE	PC	11976150
DM2GJZE	MW	278.3
DM2GJZE	FM	C17H14N2O2
DM2GJZE	IC	InChI=1S/C17H14N2O2/c1-10-5-4-6-11(9-10)19-15-14(18)16(20)12-7-2-3-8-13(12)17(15)21/h2-9,19H,18H2,1H3
DM2GJZE	CS	CC1=CC(=CC=C1)NC2=C(C(=O)C3=CC=CC=C3C2=O)N
DM2GJZE	IK	REWOWOXSGLQOHC-UHFFFAOYSA-N
DM2GJZE	IU	2-amino-3-(3-methylanilino)naphthalene-1,4-dione
DM2GJZE	DE	Discovery agent

DMUYZA8	ID	DMUYZA8
DMUYZA8	DN	2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene
DMUYZA8	HS	Investigative
DMUYZA8	SN	CHEMBL217041; SCHEMBL5071915; ZINC38145012; BDBM50147364; J3.552.112G
DMUYZA8	DT	Small molecular drug
DMUYZA8	PC	11988330
DMUYZA8	MW	315.4
DMUYZA8	FM	C18H21NO4
DMUYZA8	IC	InChI=1S/C18H21NO4/c1-20-14-8-7-13(15(19)11-14)6-5-12-9-16(21-2)18(23-4)17(10-12)22-3/h5-11H,19H2,1-4H3/b6-5-
DMUYZA8	CS	COC1=CC(=C(C=C1)/C=C\\C2=CC(=C(C(=C2)OC)OC)OC)N
DMUYZA8	IK	XMMNPPLYAJJFPL-WAYWQWQTSA-N
DMUYZA8	IU	5-methoxy-2-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline
DMUYZA8	DE	Discovery agent

DMMZ2LI	ID	DMMZ2LI
DMMZ2LI	DN	2-amino-3,4',5-trimethoxy-(Z)-stillbene
DMMZ2LI	HS	Investigative
DMMZ2LI	SN	CHEMBL216433; SCHEMBL4224804
DMMZ2LI	DT	Small molecular drug
DMMZ2LI	PC	16090836
DMMZ2LI	MW	285.34
DMMZ2LI	FM	C17H19NO3
DMMZ2LI	IC	InChI=1S/C17H19NO3/c1-19-14-8-5-12(6-9-14)4-7-13-10-15(20-2)11-16(21-3)17(13)18/h4-11H,18H2,1-3H3/b7-4-
DMMZ2LI	CS	COC1=CC=C(C=C1)/C=C\\C2=C(C(=CC(=C2)OC)OC)N
DMMZ2LI	IK	WCORNZIRKFTEOF-DAXSKMNVSA-N
DMMZ2LI	IU	2,4-dimethoxy-6-[(Z)-2-(4-methoxyphenyl)ethenyl]aniline
DMMZ2LI	DE	Discovery agent

DM6AYDL	ID	DM6AYDL
DM6AYDL	DN	2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One
DM6AYDL	HS	Investigative
DM6AYDL	SN	CHEMBL16709; 54124-67-3; AC1NBNWM; 2-amino-3-methyl-1-(1-pyrrolidinyl)-1-Butanone; SCHEMBL1951493; CTK8J1465; MolPort-004-338-106; ALBB-022686; BDBM50118952; AKOS016347010; AKOS000180650; 1-Pyrrolizino-2-amino-3-methyl-1-butanone; DB-071796; FT-0723537; 2-amino-3-methyl-1-pyrrolidin-1-ylbutan-1-one; F2147-1598; [(1S)-2-methyl-1-(pyrrolidin-1-ylcarbonyl)propyl]amine; 3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-amine hydrochloride; [2-Methyl-1-(pyrrolidin-1-ylcarbonyl)propyl]amine hydrochloride
DM6AYDL	DT	Small molecular drug
DM6AYDL	PC	447256
DM6AYDL	MW	170.25
DM6AYDL	FM	C9H18N2O
DM6AYDL	IC	InChI=1S/C9H18N2O/c1-7(2)8(10)9(12)11-5-3-4-6-11/h7-8H,3-6,10H2,1-2H3/t8-/m0/s1
DM6AYDL	CS	CC(C)[C@@H](C(=O)N1CCCC1)N
DM6AYDL	IK	IHBAVXVTGLANPI-QMMMGPOBSA-N
DM6AYDL	IU	(2S)-2-amino-3-methyl-1-pyrrolidin-1-ylbutan-1-one
DM6AYDL	CA	CAS 54164-07-7
DM6AYDL	DE	Discovery agent

DMXLZUA	ID	DMXLZUA
DMXLZUA	DN	2-Amino-3-Oxo-4-Sulfo-Butyric Acid
DMXLZUA	HS	Investigative
DMXLZUA	DT	Small molecular drug
DMXLZUA	PC	46936475
DMXLZUA	MW	199.14
DMXLZUA	FM	C3H5NO7S
DMXLZUA	IC	InChI=1S/C3H5NO7S/c4-1(2(5)6)3(7)11-12(8,9)10/h1H,4H2,(H,5,6)(H,8,9,10)/t1-/m0/s1
DMXLZUA	CS	[C@H](C(=O)O)(C(=O)OS(=O)(=O)O)N
DMXLZUA	IK	RZIKAUMRZOEFET-SFOWXEAESA-N
DMXLZUA	IU	(2S)-2-amino-3-oxo-3-sulfooxypropanoic acid
DMXLZUA	DE	Discovery agent

DMTP3LD	ID	DMTP3LD
DMTP3LD	DN	2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMTP3LD	HS	Investigative
DMTP3LD	SN	CHEMBL234897; BDBM50213173
DMTP3LD	DT	Small molecular drug
DMTP3LD	PC	44431964
DMTP3LD	MW	311.5
DMTP3LD	FM	C21H29NO
DMTP3LD	IC	InChI=1S/C21H29NO/c1-4-5-6-9-14-21(2,3)16-12-13-18(20(23)15-16)17-10-7-8-11-19(17)22/h7-8,10-13,15,23H,4-6,9,14,22H2,1-3H3
DMTP3LD	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC=CC=C2N)O
DMTP3LD	IK	QCCUOHALIFFEGL-UHFFFAOYSA-N
DMTP3LD	IU	2-(2-aminophenyl)-5-(2-methyloctan-2-yl)phenol
DMTP3LD	DE	Discovery agent

DMULSNQ	ID	DMULSNQ
DMULSNQ	DN	2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid
DMULSNQ	HS	Investigative
DMULSNQ	SN	CHEMBL203743; 2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid; BDBM50179732
DMULSNQ	DT	Small molecular drug
DMULSNQ	PC	44408323
DMULSNQ	MW	239.34
DMULSNQ	FM	C12H17NO2S
DMULSNQ	IC	InChI=1S/C12H17NO2S/c1-9-4-2-3-5-10(9)8-16-7-6-11(13)12(14)15/h2-5,11H,6-8,13H2,1H3,(H,14,15)
DMULSNQ	CS	CC1=CC=CC=C1CSCCC(C(=O)O)N
DMULSNQ	IK	FWEMQWXSSVUTGP-UHFFFAOYSA-N
DMULSNQ	IU	2-amino-4-[(2-methylphenyl)methylsulfanyl]butanoic acid
DMULSNQ	DE	Discovery agent

DMVN0EC	ID	DMVN0EC
DMVN0EC	DN	2-Amino-4,6-di-furan-2-yl-nicotinonitrile
DMVN0EC	HS	Investigative
DMVN0EC	SN	CHEMBL506250; AC1MDUVT; 2-Amino-4,6-di-furan-2-yl-nicotinonitrile; SCHEMBL6252357; MolPort-002-903-619; ZINC20432232; BDBM50262441; MCULE-1490383880; SR-01000003798; SR-01000003798-1
DMVN0EC	DT	Small molecular drug
DMVN0EC	PC	2817165
DMVN0EC	MW	251.24
DMVN0EC	FM	C14H9N3O2
DMVN0EC	IC	InChI=1S/C14H9N3O2/c15-8-10-9(12-3-1-5-18-12)7-11(17-14(10)16)13-4-2-6-19-13/h1-7H,(H2,16,17)
DMVN0EC	CS	C1=COC(=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CO3
DMVN0EC	IK	BDULELAUBSFJFH-UHFFFAOYSA-N
DMVN0EC	IU	2-amino-4,6-bis(furan-2-yl)pyridine-3-carbonitrile
DMVN0EC	DE	Discovery agent

DMVJXQ9	ID	DMVJXQ9
DMVJXQ9	DN	2-amino-4,6-dimethylpyridine
DMVJXQ9	HS	Investigative
DMVJXQ9	SN	2-AMINO-4,6-DIMETHYLPYRIDINE; 5407-87-4; 4,6-dimethylpyridin-2-amine; 6-Amino-2,4-lutidine; 2-Pyridinamine, 4,6-dimethyl-; 4,6-Dimethyl-2-pyridinamine; 4,6-Dimethyl-2-pyridylamine; Pyridine, 2-amino-4,6-dimethyl-; 2,4-Lutidine, 6-amino-; NSC 10731; 2-Amino-4,6-dimehtylpyridine; EINECS 226-470-9; UNII-7NVZ9DW9Q5; BRN 0002048; 7NVZ9DW9Q5; CHEMBL59925; 4,6-Dimethyl-2-aminopyridine; 2-amino-4,6-dimethyl pyridine; 4,6-Dimethyl-pyridin-2-ylamine; BRBUBVKGJRPRRD-UHFFFAOYSA-N; 2-Amino-4,6-dimethylpyridine, 99%; PubChem19956; AC1Q2ICQ
DMVJXQ9	DT	Small molecular drug
DMVJXQ9	PC	21507
DMVJXQ9	MW	122.17
DMVJXQ9	FM	C7H10N2
DMVJXQ9	IC	InChI=1S/C7H10N2/c1-5-3-6(2)9-7(8)4-5/h3-4H,1-2H3,(H2,8,9)
DMVJXQ9	CS	CC1=CC(=NC(=C1)N)C
DMVJXQ9	IK	BRBUBVKGJRPRRD-UHFFFAOYSA-N
DMVJXQ9	IU	4,6-dimethylpyridin-2-amine
DMVJXQ9	CA	CAS 5407-87-4
DMVJXQ9	DE	Discovery agent

DMO69TS	ID	DMO69TS
DMO69TS	DN	2-Amino-4,6-diphenyl-nicotinonitrile
DMO69TS	HS	Investigative
DMO69TS	SN	2-amino-4,6-diphenylpyridine-3-carbonitrile; 2-Amino-4,6-diphenyl-nicotinonitrile; CHEMBL467387; 4604-06-2; CBDivE_000439; AC1LDJG4; TimTec1_000178; SCHEMBL4911494; CTK1D2047; DTXSID70349897; YFQVSTNNJZZYLY-UHFFFAOYSA-N; MolPort-000-994-643; HMS1534I02; C18H13N3; 2-amino-4,6-diphenylnicotinonitrile; ZINC18995588; STK831928; BDBM50262323; AKOS000286699; MCULE-4409959472; NCGC00175390-01; ST001238; EU-0034185; 2-Amino-4,6-diphenyl-3-pyridinecarbonitrile; 3-Pyridinecarbonitrile, 2-amino-4,6-diphenyl-; SR-01000395192; SR-01000395192-1
DMO69TS	DT	Small molecular drug
DMO69TS	PC	668105
DMO69TS	MW	271.3
DMO69TS	FM	C18H13N3
DMO69TS	IC	InChI=1S/C18H13N3/c19-12-16-15(13-7-3-1-4-8-13)11-17(21-18(16)20)14-9-5-2-6-10-14/h1-11H,(H2,20,21)
DMO69TS	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CC=C3
DMO69TS	IK	YFQVSTNNJZZYLY-UHFFFAOYSA-N
DMO69TS	IU	2-amino-4,6-diphenylpyridine-3-carbonitrile
DMO69TS	CA	CAS 4604-06-2
DMO69TS	DE	Discovery agent

DM1MOB9	ID	DM1MOB9
DM1MOB9	DN	2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile
DM1MOB9	HS	Investigative
DM1MOB9	SN	CHEMBL259736; SCHEMBL6440910; JMXZSEAMWCKILY-UHFFFAOYSA-N; ZINC29063803; BDBM50375505; 2-amino-4,6-diphenylpyrimidine-5-carbonitrile
DM1MOB9	DT	Small molecular drug
DM1MOB9	PC	18507264
DM1MOB9	MW	272.3
DM1MOB9	FM	C17H12N4
DM1MOB9	IC	InChI=1S/C17H12N4/c18-11-14-15(12-7-3-1-4-8-12)20-17(19)21-16(14)13-9-5-2-6-10-13/h1-10H,(H2,19,20,21)
DM1MOB9	CS	C1=CC=C(C=C1)C2=C(C(=NC(=N2)N)C3=CC=CC=C3)C#N
DM1MOB9	IK	JMXZSEAMWCKILY-UHFFFAOYSA-N
DM1MOB9	IU	2-amino-4,6-diphenylpyrimidine-5-carbonitrile
DM1MOB9	DE	Discovery agent

DMI9YGU	ID	DMI9YGU
DMI9YGU	DN	2-Amino-4,6-diphenyl-pyrimidine
DMI9YGU	HS	Investigative
DMI9YGU	SN	4,6-diphenylpyrimidin-2-amine; 40230-24-8; 2-Amino-4,6-diphenylpyrimidine; 4,6-diphenyl-2- Pyrimidinamine; 4,6-Diphenyl-2-pyrimidinamine; CHEMBL261185; KZUCBEYDRUCBCS-UHFFFAOYSA-N; 2-Pyrimidinamine, 4,6-diphenyl-; AK136264; AC1LDIBD; Cambridge id 5109412; AC1Q52JN; CBDivE_006411; MLS001162904; SCHEMBL4904514; 4,6-Diphenylpyrimidine-2-amine; CTK1D4711; DTXSID20347207; MolPort-001-847-654; HMS2833A20; HMS1577A06; 4,6-Diphenyl-2-pyrimidinamine #; ZINC295268; KS-00001N3D; BDBM50375490; AKOS010263933; (4,6-diphenyl-pyrimidin-2-yl)-amine
DMI9YGU	DT	Small molecular drug
DMI9YGU	PC	619024
DMI9YGU	MW	247.29
DMI9YGU	FM	C16H13N3
DMI9YGU	IC	InChI=1S/C16H13N3/c17-16-18-14(12-7-3-1-4-8-12)11-15(19-16)13-9-5-2-6-10-13/h1-11H,(H2,17,18,19)
DMI9YGU	CS	C1=CC=C(C=C1)C2=CC(=NC(=N2)N)C3=CC=CC=C3
DMI9YGU	IK	KZUCBEYDRUCBCS-UHFFFAOYSA-N
DMI9YGU	IU	4,6-diphenylpyrimidin-2-amine
DMI9YGU	CA	CAS 40230-24-8
DMI9YGU	DE	Discovery agent

DM53T8Q	ID	DM53T8Q
DM53T8Q	DN	2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile
DM53T8Q	HS	Investigative
DM53T8Q	SN	CHEMBL455264; 2-amino-4,6-di(2-thienyl)nicotinonitrile; AC1MDUJS; Maybridge3_002859; 2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile; AK-245/12665006; MolPort-002-818-186; HMS1439B21; CCG-51878; BDBM50262435; ZINC19815853; MCULE-1768454862; IDI1_014246; SR-01000003726; SR-01000003726-1; 2-amino-4,6-dithiophen-2-ylpyridine-3-carbonitrile; SR-01000003726-2
DM53T8Q	DT	Small molecular drug
DM53T8Q	PC	2817024
DM53T8Q	MW	283.4
DM53T8Q	FM	C14H9N3S2
DM53T8Q	IC	InChI=1S/C14H9N3S2/c15-8-10-9(12-3-1-5-18-12)7-11(17-14(10)16)13-4-2-6-19-13/h1-7H,(H2,16,17)
DM53T8Q	CS	C1=CSC(=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CS3
DM53T8Q	IK	NMMNXFUCSNOZLW-UHFFFAOYSA-N
DM53T8Q	IU	2-amino-4,6-dithiophen-2-ylpyridine-3-carbonitrile
DM53T8Q	DE	Discovery agent

DMP4NHD	ID	DMP4NHD
DMP4NHD	DN	2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile
DMP4NHD	HS	Investigative
DMP4NHD	SN	CHEMBL447192; 2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile; 2-amino-4-(furan-2-yl)-6-phenylpyridine-3-carbonitrile; BAS 02565128; AC1LEWZ0; Oprea1_555020; SCHEMBL6250225; MolPort-001-022-735; HMS1617K16; STL308426; ZINC19608452; BDBM50262388; AKOS000670186; MCULE-4659467081; ST50302441; 2-amino-4-(2-furyl)-6-phenylnicotinonitrile; 2-amino-4-(2-furyl)-6-phenylpyridine-3-carbonitrile
DMP4NHD	DT	Small molecular drug
DMP4NHD	PC	743242
DMP4NHD	MW	261.279
DMP4NHD	FM	C16H11N3O
DMP4NHD	IC	InChI=1S/C16H11N3O/c17-10-13-12(15-7-4-8-20-15)9-14(19-16(13)18)11-5-2-1-3-6-11/h1-9H,(H2,18,19)
DMP4NHD	CS	C1=CC=C(C=C1)C2=NC(=C(C(=C2)C3=CC=CO3)C#N)N
DMP4NHD	IK	UPNSGUUFOFSFEZ-UHFFFAOYSA-N
DMP4NHD	IU	2-amino-4-(furan-2-yl)-6-phenylpyridine-3-carbonitrile
DMP4NHD	DE	Discovery agent

DM1OED2	ID	DM1OED2
DM1OED2	DN	2-amino-4-methylpyridine
DM1OED2	HS	Investigative
DM1OED2	SN	2-Amino-4-methylpyridine; 4-METHYLPYRIDIN-2-AMINE; 695-34-1; 2-Amino-4-picoline; Ascensil; 2-Pyridinamine, 4-methyl-; 4-Methyl-2-pyridinamine; 4-Methyl-2-aminopyridine; 4-Methyl-2-pyridylamine; W 45 Raschig; 4-PICOLINE, 2-AMINO-; Methyl-4 amino-2-pyridine; 4M2AP; Pyridine, 2-amino-4-methyl-; 4-methylpyridin-2-ylamine; 2-amino-4-methyl pyridine; RA 1226; alpha-Amino-gamma-picoline; NSC 6972; NSC 1490; VMI 20-4; UNII-394N1Z644H; EINECS 211-780-9; 4-Methyl-pyridin-2-ylamine; BRN 0107066; W 45; CHEMBL40833; AI3-23984; C6H8N2; 4-methylpyridin-2-amine
DM1OED2	DT	Small molecular drug
DM1OED2	PC	1533
DM1OED2	MW	108.14
DM1OED2	FM	C6H8N2
DM1OED2	IC	InChI=1S/C6H8N2/c1-5-2-3-8-6(7)4-5/h2-4H,1H3,(H2,7,8)
DM1OED2	CS	CC1=CC(=NC=C1)N
DM1OED2	IK	ORLGLBZRQYOWNA-UHFFFAOYSA-N
DM1OED2	IU	4-methylpyridin-2-amine
DM1OED2	CA	CAS 695-34-1
DM1OED2	DE	Discovery agent

DMRVTJ1	ID	DMRVTJ1
DMRVTJ1	DN	2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile
DMRVTJ1	HS	Investigative
DMRVTJ1	SN	CHEMBL476308; 2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile; SCHEMBL6251249
DMRVTJ1	DT	Small molecular drug
DMRVTJ1	PC	10423637
DMRVTJ1	MW	277.3
DMRVTJ1	FM	C16H11N3S
DMRVTJ1	IC	InChI=1S/C16H11N3S/c17-10-13-12(11-5-2-1-3-6-11)9-14(19-16(13)18)15-7-4-8-20-15/h1-9H,(H2,18,19)
DMRVTJ1	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CS3
DMRVTJ1	IK	CMOAUWPKTBSUQT-UHFFFAOYSA-N
DMRVTJ1	IU	2-amino-4-phenyl-6-thiophen-2-ylpyridine-3-carbonitrile
DMRVTJ1	DE	Discovery agent

DMOIZY1	ID	DMOIZY1
DMOIZY1	DN	2-Amino-4-phosphono-butyric acid
DMOIZY1	HS	Investigative
DMOIZY1	SN	2-amino-4-phosphonobutanoic acid; 6323-99-5; DL-AP4; 20263-07-4; DL-2-Amino-4-phosphonobutyric acid; Butanoic acid, 2-amino-4-phosphono-; BRN 5255932; CHEMBL285843; BUTYRIC ACID, 2-AMINO-4-PHOSPHONO-; MFCD00013999; L-2-amino-4-phosphonobutyrate; Abu(P); SR-01000075414; L-2-amino-4-phosphobutyric acid; L-AP4 cpd, butyric; AC1Q6RPJ; 4-Amino Phosphonobutyrate
DMOIZY1	DT	Small molecular drug
DMOIZY1	PC	2207
DMOIZY1	MW	183.1
DMOIZY1	FM	C4H10NO5P
DMOIZY1	IC	InChI=1S/C4H10NO5P/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H2,8,9,10)
DMOIZY1	CS	C(CP(=O)(O)O)C(C(=O)O)N
DMOIZY1	IK	DDOQBQRIEWHWBT-UHFFFAOYSA-N
DMOIZY1	IU	2-amino-4-phosphonobutanoic acid
DMOIZY1	CA	CAS 6323-99-5
DMOIZY1	DE	Discovery agent

DMDUZ2H	ID	DMDUZ2H
DMDUZ2H	DN	2-Amino-5-(N-nitro-guanidino)-pentanoic acid
DMDUZ2H	HS	Investigative
DMDUZ2H	SN	CHEMBL353794; N-nitro-l-arg; KSC911C9L; SCHEMBL5271958; CTK8B1195; BDBM50049252; ANW-24471; ZINC27740002
DMDUZ2H	DT	Small molecular drug
DMDUZ2H	PC	10198326
DMDUZ2H	MW	219.2
DMDUZ2H	FM	C6H13N5O4
DMDUZ2H	IC	InChI=1S/C6H13N5O4/c7-4(5(12)13)2-1-3-10(6(8)9)11(14)15/h4H,1-3,7H2,(H3,8,9)(H,12,13)/t4-/m0/s1
DMDUZ2H	CS	C(C[C@@H](C(=O)O)N)CN(C(=N)N)[N+](=O)[O-]
DMDUZ2H	IK	ZXGQUZOHXHNDPE-BYPYZUCNSA-N
DMDUZ2H	IU	(2S)-2-amino-5-[carbamimidoyl(nitro)amino]pentanoic acid
DMDUZ2H	DE	Discovery agent

DMA7ZOW	ID	DMA7ZOW
DMA7ZOW	DN	2-Amino-5-Hydroxy-Benzimidazole
DMA7ZOW	HS	Investigative
DMA7ZOW	DT	Small molecular drug
DMA7ZOW	PC	162636
DMA7ZOW	MW	149.15
DMA7ZOW	FM	C7H7N3O
DMA7ZOW	IC	InChI=1S/C7H7N3O/c8-7-9-5-2-1-4(11)3-6(5)10-7/h1-3,11H,(H3,8,9,10)
DMA7ZOW	CS	C1=CC2=C(C=C1O)NC(=N2)N
DMA7ZOW	IK	FNSYWIPPPFVBAV-UHFFFAOYSA-N
DMA7ZOW	IU	2-amino-3H-benzimidazol-5-ol
DMA7ZOW	CA	CAS 51276-85-8
DMA7ZOW	DE	Discovery agent

DMOQ2R8	ID	DMOQ2R8
DMOQ2R8	DN	2-amino-5-phenylthiophene-3-carboxamide
DMOQ2R8	HS	Investigative
DMOQ2R8	SN	2-amino-5-phenylthiophene-3-carboxamide; 4815-35-4; 2-Amino-5-phenyl-thiophene-3-carboxylic acid amide; CHEMBL382565; 2-AMINO-5-PHENYL-3-THIOPHENECARBOXAMIDE; EN300-04586; AC1LDZKQ; ACMC-209kch; 3-thiophenecarboxamide, 2-amino-5-phenyl-; AC1Q5DNT; CBMicro_037044; Cambridge id 5914467; AC1Q4Z6N; Oprea1_326775; Oprea1_445444; SCHEMBL3510525; ZINC87504; CTK4J0691; DTXSID60351580; UHEGYTDIDBFUJD-UHFFFAOYSA-N; MolPort-000-223-057; HMS1757A19; ZX-AL001522; ANW-30639; STK346852; SBB015475; BDBM50186655; AKOS000274130; ACM4815354
DMOQ2R8	DT	Small molecular drug
DMOQ2R8	PC	703965
DMOQ2R8	MW	218.28
DMOQ2R8	FM	C11H10N2OS
DMOQ2R8	IC	InChI=1S/C11H10N2OS/c12-10(14)8-6-9(15-11(8)13)7-4-2-1-3-5-7/h1-6H,13H2,(H2,12,14)
DMOQ2R8	CS	C1=CC=C(C=C1)C2=CC(=C(S2)N)C(=O)N
DMOQ2R8	IK	UHEGYTDIDBFUJD-UHFFFAOYSA-N
DMOQ2R8	IU	2-amino-5-phenylthiophene-3-carboxamide
DMOQ2R8	CA	CAS 4815-35-4
DMOQ2R8	DE	Discovery agent

DM3VJEZ	ID	DM3VJEZ
DM3VJEZ	DN	2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile
DM3VJEZ	HS	Investigative
DM3VJEZ	SN	AC1LA8EL; 2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile; BDBM1791; CHEMBL293780; CTK7C6578; ZINC5933963; 2-Amino-6-arylthiobenzonitrile deriv. 3k; 2-(2-Bromophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-bromophenyl)sulfonylbenzonitrile; 2-amino-6-(2-bromophenyl)sulfonyl-benzonitrile; 2-amino-6-[(2-bromophenyl)sulfonyl]benzonitrile
DM3VJEZ	DT	Small molecular drug
DM3VJEZ	PC	483455
DM3VJEZ	MW	337.19
DM3VJEZ	FM	C13H9BrN2O2S
DM3VJEZ	IC	InChI=1S/C13H9BrN2O2S/c14-10-4-1-2-6-13(10)19(17,18)12-7-3-5-11(16)9(12)8-15/h1-7H,16H2
DM3VJEZ	CS	C1=CC=C(C(=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N)Br
DM3VJEZ	IK	WBNCALTXWWEQQV-UHFFFAOYSA-N
DM3VJEZ	IU	2-amino-6-(2-bromophenyl)sulfonylbenzonitrile
DM3VJEZ	DE	Discovery agent

DMFW9D3	ID	DMFW9D3
DMFW9D3	DN	2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile
DMFW9D3	HS	Investigative
DMFW9D3	SN	AC1LA8EC; 2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile; BDBM1788; CHEMBL301086; CTK7C6580; ZINC5933964; 2-Amino-6-arylthiobenzonitrile deriv. 3h; 2-amino-6-(2-chlorophenyl)sulfonylbenzonitrile; 2-(2-Chlorophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-chlorophenyl)sulfonyl-benzonitrile; 2-amino-6-[(2-chlorophenyl)sulfonyl]benzonitrile
DMFW9D3	DT	Small molecular drug
DMFW9D3	PC	483452
DMFW9D3	MW	292.74
DMFW9D3	FM	C13H9ClN2O2S
DMFW9D3	IC	InChI=1S/C13H9ClN2O2S/c14-10-4-1-2-6-13(10)19(17,18)12-7-3-5-11(16)9(12)8-15/h1-7H,16H2
DMFW9D3	CS	C1=CC=C(C(=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N)Cl
DMFW9D3	IK	NXUSIYJXPBRFJT-UHFFFAOYSA-N
DMFW9D3	IU	2-amino-6-(2-chlorophenyl)sulfonylbenzonitrile
DMFW9D3	DE	Discovery agent

DM7391H	ID	DM7391H
DM7391H	DN	2-Amino-6-(2-chloro-phenylsulfanyl)-benzonitrile
DM7391H	HS	Investigative
DM7391H	SN	6-Amino-2-(2-chlorophenylthio)benzenecarbonitrile; AC1LAE0H; CHEMBL300757; BDBM1738; CTK7C6441; ZINC5933966; 2-Amino-6-arylthiobenzonitrile deriv. 1h; 2-Amino-6-[(2-chlorophenyl)thio]benzonitrile; 2-amino-6-(2-chlorophenyl)sulfanylbenzonitrile; 2-amino-6-(2-chlorophenyl)sulfanyl-benzonitrile
DM7391H	DT	Small molecular drug
DM7391H	PC	486313
DM7391H	MW	260.74
DM7391H	FM	C13H9ClN2S
DM7391H	IC	InChI=1S/C13H9ClN2S/c14-10-4-1-2-6-13(10)17-12-7-3-5-11(16)9(12)8-15/h1-7H,16H2
DM7391H	CS	C1=CC=C(C(=C1)SC2=CC=CC(=C2C#N)N)Cl
DM7391H	IK	ICAGMNDXSMYTTM-UHFFFAOYSA-N
DM7391H	IU	2-amino-6-(2-chlorophenyl)sulfanylbenzonitrile
DM7391H	DE	Discovery agent

DM8O6AC	ID	DM8O6AC
DM8O6AC	DN	2-Amino-6-(2-cyano-benzenesulfinyl)-benzonitrile
DM8O6AC	HS	Investigative
DM8O6AC	SN	CHEMBL294212; 6-Amino-2-[(2-cyanophenyl)sulfinyl]benzenecarbonitrile; AC1LAE2N; BDBM1765; CTK7C8877; 6-Amino[2,2'-sulfinylbisbenzonitrile]; 2-Amino-6-arylthiobenzonitrile deriv. 2j; 2-amino-6-(2-cyanophenyl)sulfinylbenzonitrile; 2-amino-6-(2-cyanophenyl)sulfinyl-benzonitrile
DM8O6AC	DT	Small molecular drug
DM8O6AC	PC	486339
DM8O6AC	MW	267.31
DM8O6AC	FM	C14H9N3OS
DM8O6AC	IC	InChI=1S/C14H9N3OS/c15-8-10-4-1-2-6-13(10)19(18)14-7-3-5-12(17)11(14)9-16/h1-7H,17H2
DM8O6AC	CS	C1=CC=C(C(=C1)C#N)S(=O)C2=CC=CC(=C2C#N)N
DM8O6AC	IK	SAAMTBNDGHUYAE-UHFFFAOYSA-N
DM8O6AC	IU	2-amino-6-(2-cyanophenyl)sulfinylbenzonitrile
DM8O6AC	DE	Discovery agent

DMRKQLV	ID	DMRKQLV
DMRKQLV	DN	2-Amino-6-(2-cyano-benzenesulfonyl)-benzonitrile
DMRKQLV	HS	Investigative
DMRKQLV	SN	6-Amino-2-[(2-cyanophenyl)sulfonyl]benzenecarbonitrile; AC1LA8F0; CHEMBL298823; BDBM1796; CTK7C8868; ZINC5933865; 2-Amino-6-arylthiobenzonitrile deriv. 3p; 2-amino-6-(2-cyanophenyl)sulfonylbenzonitrile; 2-(2-Cyanophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-cyanophenyl)sulfonyl-benzonitrile
DMRKQLV	DT	Small molecular drug
DMRKQLV	PC	483460
DMRKQLV	MW	283.31
DMRKQLV	FM	C14H9N3O2S
DMRKQLV	IC	InChI=1S/C14H9N3O2S/c15-8-10-4-1-2-6-13(10)20(18,19)14-7-3-5-12(17)11(14)9-16/h1-7H,17H2
DMRKQLV	CS	C1=CC=C(C(=C1)C#N)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMRKQLV	IK	QVEQBYNJIDMTHN-UHFFFAOYSA-N
DMRKQLV	IU	2-amino-6-(2-cyanophenyl)sulfonylbenzonitrile
DMRKQLV	DE	Discovery agent

DM8UQD5	ID	DM8UQD5
DM8UQD5	DN	2-Amino-6-(2-cyano-phenylsulfanyl)-benzonitrile
DM8UQD5	HS	Investigative
DM8UQD5	SN	6-Amino-2-(2-cyanophenylthio)benzenecarbonitrile; AC1LAE0Z; CHEMBL59586; BDBM1744; CTK7C8878; ZINC5933866; 2-Amino-6-arylthiobenzonitrile deriv. 1n; 2-amino-6-(2-cyanophenyl)sulfanylbenzonitrile; 2-amino-6-(2-cyanophenyl)sulfanyl-benzonitrile
DM8UQD5	DT	Small molecular drug
DM8UQD5	PC	486319
DM8UQD5	MW	251.31
DM8UQD5	FM	C14H9N3S
DM8UQD5	IC	InChI=1S/C14H9N3S/c15-8-10-4-1-2-6-13(10)18-14-7-3-5-12(17)11(14)9-16/h1-7H,17H2
DM8UQD5	CS	C1=CC=C(C(=C1)C#N)SC2=CC=CC(=C2C#N)N
DM8UQD5	IK	HZXBXUYNSPXXOH-UHFFFAOYSA-N
DM8UQD5	IU	2-amino-6-(2-cyanophenyl)sulfanylbenzonitrile
DM8UQD5	DE	Discovery agent

DMBMK8S	ID	DMBMK8S
DMBMK8S	DN	2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile
DMBMK8S	HS	Investigative
DMBMK8S	SN	AC1LA8EU; 2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile; CHEMBL53684; BDBM1794; CTK7C6581; ZINC5933932; 2-Amino-6-arylthiobenzonitrile deriv. 3n; 2-(2-Fluorophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-fluorophenyl)sulfonylbenzonitrile; 2-amino-6-(2-fluorophenyl)sulfonyl-benzonitrile; 2-amino-6-[(2-fluorophenyl)sulfonyl]benzonitrile
DMBMK8S	DT	Small molecular drug
DMBMK8S	PC	483458
DMBMK8S	MW	276.29
DMBMK8S	FM	C13H9FN2O2S
DMBMK8S	IC	InChI=1S/C13H9FN2O2S/c14-10-4-1-2-6-13(10)19(17,18)12-7-3-5-11(16)9(12)8-15/h1-7H,16H2
DMBMK8S	CS	C1=CC=C(C(=C1)F)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMBMK8S	IK	MBHOZDSUDFTYGO-UHFFFAOYSA-N
DMBMK8S	IU	2-amino-6-(2-fluorophenyl)sulfonylbenzonitrile
DMBMK8S	DE	Discovery agent

DM0N5J4	ID	DM0N5J4
DM0N5J4	DN	2-Amino-6-(2-methoxy-phenylsulfanyl)-benzonitrile
DM0N5J4	HS	Investigative
DM0N5J4	SN	6-Amino-2-(2-methoxyphenylthio)benzenecarbonitrile; AC1LADZB; BDBM1732; CHEMBL292464; CTK7B1781; ZINC5929241; 2-Amino-6-arylthiobenzonitrile deriv. 1b; 2-Amino-6-[(2-methoxyphenyl)thio]benzonitrile; 2-amino-6-(2-methoxyphenyl)sulfanylbenzonitrile; 2-amino-6-[(2-methoxyphenyl)sulfanyl]benzonitrile
DM0N5J4	DT	Small molecular drug
DM0N5J4	PC	486297
DM0N5J4	MW	256.32
DM0N5J4	FM	C14H12N2OS
DM0N5J4	IC	InChI=1S/C14H12N2OS/c1-17-12-6-2-3-7-14(12)18-13-8-4-5-11(16)10(13)9-15/h2-8H,16H2,1H3
DM0N5J4	CS	COC1=CC=CC=C1SC2=CC=CC(=C2C#N)N
DM0N5J4	IK	NZXQIIPHDSINPY-UHFFFAOYSA-N
DM0N5J4	IU	2-amino-6-(2-methoxyphenyl)sulfanylbenzonitrile
DM0N5J4	DE	Discovery agent

DM6R98Y	ID	DM6R98Y
DM6R98Y	DN	2-Amino-6-(3-bromo-benzenesulfinyl)-benzonitrile
DM6R98Y	HS	Investigative
DM6R98Y	SN	CHEMBL55998; 6-Amino-2-[(3-bromophenyl)sulfinyl]benzenecarbonitrile; AC1LAE2H; BDBM1763; CTK7C6587; 2-Amino-6-arylthiobenzonitrile deriv. 2h; 2-amino-6-(3-bromophenyl)sulfinylbenzonitrile; 2-amino-6-(3-bromophenyl)sulfinyl-benzonitrile
DM6R98Y	DT	Small molecular drug
DM6R98Y	PC	486337
DM6R98Y	MW	321.19
DM6R98Y	FM	C13H9BrN2OS
DM6R98Y	IC	InChI=1S/C13H9BrN2OS/c14-9-3-1-4-10(7-9)18(17)13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DM6R98Y	CS	C1=CC(=CC(=C1)Br)S(=O)C2=CC=CC(=C2C#N)N
DM6R98Y	IK	JNNOSSLVLGASPM-UHFFFAOYSA-N
DM6R98Y	IU	2-amino-6-(3-bromophenyl)sulfinylbenzonitrile
DM6R98Y	DE	Discovery agent

DMTUM78	ID	DMTUM78
DMTUM78	DN	2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile
DMTUM78	HS	Investigative
DMTUM78	SN	AC1LA8EO; 2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile; CHEMBL293989; SCHEMBL2641656; BDBM1792; CTK7C6572; ZINC20483; 2-Amino-6-arylthiobenzonitrile deriv. 3l; 2-amino-6-(3-bromophenyl)sulfonylbenzonitrile; 2-(3-Bromophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(3-bromophenyl)sulfonyl-benzonitrile; 2-amino-6-[(3-bromophenyl)sulfonyl]benzonitrile
DMTUM78	DT	Small molecular drug
DMTUM78	PC	483456
DMTUM78	MW	337.19
DMTUM78	FM	C13H9BrN2O2S
DMTUM78	IC	InChI=1S/C13H9BrN2O2S/c14-9-3-1-4-10(7-9)19(17,18)13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DMTUM78	CS	C1=CC(=CC(=C1)Br)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMTUM78	IK	YZHGYTBCSXZBDO-UHFFFAOYSA-N
DMTUM78	IU	2-amino-6-(3-bromophenyl)sulfonylbenzonitrile
DMTUM78	DE	Discovery agent

DMH4TRD	ID	DMH4TRD
DMH4TRD	DN	2-Amino-6-(3-bromo-phenylsulfanyl)-benzonitrile
DMH4TRD	HS	Investigative
DMH4TRD	SN	6-Amino-2-(3-bromophenylthio)benzenecarbonitrile; AC1LAE0T; CHEMBL56465; BDBM1742; SCHEMBL2638192; ZINC20478; CTK7C6433; 2-Amino-6-arylthiobenzonitrile deriv. 1l; 2-amino-6-(3-bromophenyl)sulfanylbenzonitrile; 2-amino-6-(3-bromophenyl)sulfanyl-benzonitrile
DMH4TRD	DT	Small molecular drug
DMH4TRD	PC	486317
DMH4TRD	MW	305.19
DMH4TRD	FM	C13H9BrN2S
DMH4TRD	IC	InChI=1S/C13H9BrN2S/c14-9-3-1-4-10(7-9)17-13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DMH4TRD	CS	C1=CC(=CC(=C1)Br)SC2=CC=CC(=C2C#N)N
DMH4TRD	IK	DAHSRCREKZVLOW-UHFFFAOYSA-N
DMH4TRD	IU	2-amino-6-(3-bromophenyl)sulfanylbenzonitrile
DMH4TRD	DE	Discovery agent

DM9XKJQ	ID	DM9XKJQ
DM9XKJQ	DN	2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile
DM9XKJQ	HS	Investigative
DM9XKJQ	SN	AC1LA8EF; 2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile; BDBM1789; CHEMBL291532; CTK7C6575; ZINC5933077; 2-Amino-6-arylthiobenzonitrile deriv. 3i; 2-amino-6-(3-chlorophenyl)sulfonylbenzonitrile; 2-(3-Chlorophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(3-chlorophenyl)sulfonyl-benzonitrile; 2-amino-6-[(3-chlorophenyl)sulfonyl]benzonitrile
DM9XKJQ	DT	Small molecular drug
DM9XKJQ	PC	483453
DM9XKJQ	MW	292.74
DM9XKJQ	FM	C13H9ClN2O2S
DM9XKJQ	IC	InChI=1S/C13H9ClN2O2S/c14-9-3-1-4-10(7-9)19(17,18)13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DM9XKJQ	CS	C1=CC(=CC(=C1)Cl)S(=O)(=O)C2=CC=CC(=C2C#N)N
DM9XKJQ	IK	AJPMQLQIJVLDJP-UHFFFAOYSA-N
DM9XKJQ	IU	2-amino-6-(3-chlorophenyl)sulfonylbenzonitrile
DM9XKJQ	DE	Discovery agent

DMT3KP0	ID	DMT3KP0
DMT3KP0	DN	2-Amino-6-(3-chloro-phenylsulfanyl)-benzonitrile
DMT3KP0	HS	Investigative
DMT3KP0	SN	6-Amino-2-(3-chlorophenylthio)benzenecarbonitrile; AC1LAE0K; CHEMBL55599; SCHEMBL2637932; BDBM1739; ZINC20476; CTK7C6436; 2-Amino-6-arylthiobenzonitrile deriv. 1i; 2-amino-6-(3-chlorophenyl)sulfanylbenzonitrile; 2-amino-6-(3-chlorophenyl)sulfanyl-benzonitrile
DMT3KP0	DT	Small molecular drug
DMT3KP0	PC	486314
DMT3KP0	MW	260.74
DMT3KP0	FM	C13H9ClN2S
DMT3KP0	IC	InChI=1S/C13H9ClN2S/c14-9-3-1-4-10(7-9)17-13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DMT3KP0	CS	C1=CC(=CC(=C1)Cl)SC2=CC=CC(=C2C#N)N
DMT3KP0	IK	IQGAOZOACGWEAI-UHFFFAOYSA-N
DMT3KP0	IU	2-amino-6-(3-chlorophenyl)sulfanylbenzonitrile
DMT3KP0	DE	Discovery agent

DM9GQ1U	ID	DM9GQ1U
DM9GQ1U	DN	2-Amino-6-(3-cyano-benzenesulfonyl)-benzonitrile
DM9GQ1U	HS	Investigative
DM9GQ1U	SN	6-Amino-2-[(3-cyanophenyl)sulfonyl]benzenecarbonitrile; AC1LA8F3; CHEMBL299271; BDBM1797; CTK7C8628; ZINC5933126; 2-Amino-6-arylthiobenzonitrile deriv. 3q; 2-amino-6-(3-cyanophenyl)sulfonylbenzonitrile; 2-(3-Cyanophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(3-cyanophenyl)sulfonyl-benzonitrile
DM9GQ1U	DT	Small molecular drug
DM9GQ1U	PC	483461
DM9GQ1U	MW	283.31
DM9GQ1U	FM	C14H9N3O2S
DM9GQ1U	IC	InChI=1S/C14H9N3O2S/c15-8-10-3-1-4-11(7-10)20(18,19)14-6-2-5-13(17)12(14)9-16/h1-7H,17H2
DM9GQ1U	CS	C1=CC(=CC(=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N)C#N
DM9GQ1U	IK	PZWWWGPTXCTXOT-UHFFFAOYSA-N
DM9GQ1U	IU	2-amino-6-(3-cyanophenyl)sulfonylbenzonitrile
DM9GQ1U	DE	Discovery agent

DM2MCK1	ID	DM2MCK1
DM2MCK1	DN	2-Amino-6-(3-cyano-phenylsulfanyl)-benzonitrile
DM2MCK1	HS	Investigative
DM2MCK1	SN	6-Amino-2-(3-cyanophenylthio)benzenecarbonitrile; AC1LAE12; BDBM1745; CHEMBL293806; CTK7C8632; ZINC5933129; 6-Amino[2,3'-thiobisbenzonitrile]; 2-Amino-6-arylthiobenzonitrile deriv. 1o; 2-amino-6-(3-cyanophenyl)sulfanylbenzonitrile; 2-amino-6-(3-cyanophenyl)sulfanyl-benzonitrile
DM2MCK1	DT	Small molecular drug
DM2MCK1	PC	486320
DM2MCK1	MW	251.31
DM2MCK1	FM	C14H9N3S
DM2MCK1	IC	InChI=1S/C14H9N3S/c15-8-10-3-1-4-11(7-10)18-14-6-2-5-13(17)12(14)9-16/h1-7H,17H2
DM2MCK1	CS	C1=CC(=CC(=C1)SC2=CC=CC(=C2C#N)N)C#N
DM2MCK1	IK	LZFWQHZSIBNMAA-UHFFFAOYSA-N
DM2MCK1	IU	2-amino-6-(3-cyanophenyl)sulfanylbenzonitrile
DM2MCK1	DE	Discovery agent

DMG7HP2	ID	DMG7HP2
DMG7HP2	DN	2-Amino-6-(3-fluoro-phenylsulfanyl)-benzonitrile
DMG7HP2	HS	Investigative
DMG7HP2	SN	6-Amino-2-(3-fluorophenylthio)benzenecarbonitrile; AC1LAE0W; SCHEMBL2639266; BDBM1743; CHEMBL449041; CTK7C6437; ZINC20475; 2-Amino-6-arylthiobenzonitrile deriv. 1m; 2-amino-6-(3-fluorophenyl)sulfanylbenzonitrile; 2-amino-6-(3-fluorophenyl)sulfanyl-benzonitrile
DMG7HP2	DT	Small molecular drug
DMG7HP2	PC	486318
DMG7HP2	MW	244.29
DMG7HP2	FM	C13H9FN2S
DMG7HP2	IC	InChI=1S/C13H9FN2S/c14-9-3-1-4-10(7-9)17-13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DMG7HP2	CS	C1=CC(=CC(=C1)SC2=CC=CC(=C2C#N)N)F
DMG7HP2	IK	ZJXCBXBCZFLMTP-UHFFFAOYSA-N
DMG7HP2	IU	2-amino-6-(3-fluorophenyl)sulfanylbenzonitrile
DMG7HP2	DE	Discovery agent

DMACYWZ	ID	DMACYWZ
DMACYWZ	DN	2-Amino-6-(3-methoxy-phenylsulfanyl)-benzonitrile
DMACYWZ	HS	Investigative
DMACYWZ	SN	6-Amino-2-(3-methoxyphenylthio)benzenecarbonitrile; AC1LAE02; CHEMBL51738; BDBM1733; SCHEMBL8640275; ZINC20465; CTK7A9945; 2-Amino-6-arylthiobenzonitrile deriv. 1c; 2-amino-6-(3-methoxyphenyl)sulfanylbenzonitrile; 2-amino-6-(3-methoxyphenyl)sulfanyl-benzonitrile
DMACYWZ	DT	Small molecular drug
DMACYWZ	PC	486308
DMACYWZ	MW	256.32
DMACYWZ	FM	C14H12N2OS
DMACYWZ	IC	InChI=1S/C14H12N2OS/c1-17-10-4-2-5-11(8-10)18-14-7-3-6-13(16)12(14)9-15/h2-8H,16H2,1H3
DMACYWZ	CS	COC1=CC(=CC=C1)SC2=CC=CC(=C2C#N)N
DMACYWZ	IK	SHCOEGYZJNZDIW-UHFFFAOYSA-N
DMACYWZ	IU	2-amino-6-(3-methoxyphenyl)sulfanylbenzonitrile
DMACYWZ	DE	Discovery agent

DML6EFV	ID	DML6EFV
DML6EFV	DN	2-Amino-6-(4-chloro-phenylsulfanyl)-benzonitrile
DML6EFV	HS	Investigative
DML6EFV	SN	6-Amino-2-(4-chlorophenylthio)benzenecarbonitrile; AC1LAE0N; CHEMBL55747; BDBM1740; CTK7C6432; ZINC5932913; 2-Amino-6-arylthiobenzonitrile deriv. 1j; 2-amino-6-(4-chlorophenyl)sulfanylbenzonitrile; 2-amino-6-(4-chlorophenyl)sulfanyl-benzonitrile
DML6EFV	DT	Small molecular drug
DML6EFV	PC	486315
DML6EFV	MW	260.74
DML6EFV	FM	C13H9ClN2S
DML6EFV	IC	InChI=1S/C13H9ClN2S/c14-9-4-6-10(7-5-9)17-13-3-1-2-12(16)11(13)8-15/h1-7H,16H2
DML6EFV	CS	C1=CC(=C(C(=C1)SC2=CC=C(C=C2)Cl)C#N)N
DML6EFV	IK	GYICYNRXLTUTRB-UHFFFAOYSA-N
DML6EFV	IU	2-amino-6-(4-chlorophenyl)sulfanylbenzonitrile
DML6EFV	DE	Discovery agent

DMECHD0	ID	DMECHD0
DMECHD0	DN	2-Amino-6-(indan-5-ylamino)-3H-pyrimidin-4-one
DMECHD0	HS	Investigative
DMECHD0	DT	Small molecular drug
DMECHD0	PC	136044111
DMECHD0	MW	242.28
DMECHD0	FM	C13H14N4O
DMECHD0	IC	InChI=1S/C13H14N4O/c14-13-16-11(7-12(18)17-13)15-10-5-4-8-2-1-3-9(8)6-10/h4-7H,1-3H2,(H4,14,15,16,17,18)
DMECHD0	CS	C1CC2=C(C1)C=C(C=C2)NC3=CC(=O)NC(=N3)N
DMECHD0	IK	YUPQFUXJUXRXOG-UHFFFAOYSA-N
DMECHD0	IU	2-amino-4-(2,3-dihydro-1H-inden-5-ylamino)-1H-pyrimidin-6-one
DMECHD0	DE	Discovery agent

DMXPWHF	ID	DMXPWHF
DMXPWHF	DN	2-Amino-6-(naphthalene-1-sulfonyl)-benzonitrile
DMXPWHF	HS	Investigative
DMXPWHF	SN	CHEMBL297956; BDBM50422688; ZINC12354034
DMXPWHF	DT	Small molecular drug
DMXPWHF	PC	10852315
DMXPWHF	MW	308.4
DMXPWHF	FM	C17H12N2O2S
DMXPWHF	IC	InChI=1S/C17H12N2O2S/c18-11-14-15(19)8-4-10-17(14)22(20,21)16-9-3-6-12-5-1-2-7-13(12)16/h1-10H,19H2
DMXPWHF	CS	C1=CC=C2C(=C1)C=CC=C2S(=O)(=O)C3=CC=CC(=C3C#N)N
DMXPWHF	IK	BMSIRAVUGDDUKN-UHFFFAOYSA-N
DMXPWHF	IU	2-amino-6-naphthalen-1-ylsulfonylbenzonitrile
DMXPWHF	DE	Discovery agent

DMMKJYG	ID	DMMKJYG
DMMKJYG	DN	2-Amino-6-(naphthalene-2-sulfonyl)-benzonitrile
DMMKJYG	HS	Investigative
DMMKJYG	SN	2-Amino-6-arylthiobenzonitrile deriv. 3ff; AC1NS2PK; CHEMBL53043; BDBM1778; ZINC12354040; 2-(2-Naphthylsulfonyl)-6-aminobenzonitrile; 2-amino-6-naphthalen-2-ylsulfonylbenzonitrile
DMMKJYG	DT	Small molecular drug
DMMKJYG	PC	5327619
DMMKJYG	MW	308.4
DMMKJYG	FM	C17H12N2O2S
DMMKJYG	IC	InChI=1S/C17H12N2O2S/c18-11-15-16(19)6-3-7-17(15)22(20,21)14-9-8-12-4-1-2-5-13(12)10-14/h1-10H,19H2
DMMKJYG	CS	C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)C3=CC=CC(=C3C#N)N
DMMKJYG	IK	SSBDRFPTUIJDHD-UHFFFAOYSA-N
DMMKJYG	IU	2-amino-6-naphthalen-2-ylsulfonylbenzonitrile
DMMKJYG	DE	Discovery agent

DMWGE3U	ID	DMWGE3U
DMWGE3U	DN	2-Amino-6-(toluene-2-sulfonyl)-benzonitrile
DMWGE3U	HS	Investigative
DMWGE3U	SN	AC1LA8DU; 2-Amino-6-(toluene-2-sulfonyl)-benzonitrile; CHEMBL54444; BDBM1785; CTK7C6579; ZINC5931403; 2-amino-6-(o-tolylsulfonyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 3e; 2-(2-Methylphenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-methylphenyl)sulfonylbenzonitrile; 2-amino-6-[(2-methylbenzene)sulfonyl]benzonitrile
DMWGE3U	DT	Small molecular drug
DMWGE3U	PC	483446
DMWGE3U	MW	272.32
DMWGE3U	FM	C14H12N2O2S
DMWGE3U	IC	InChI=1S/C14H12N2O2S/c1-10-5-2-3-7-13(10)19(17,18)14-8-4-6-12(16)11(14)9-15/h2-8H,16H2,1H3
DMWGE3U	CS	CC1=CC=CC=C1S(=O)(=O)C2=CC=CC(=C2C#N)N
DMWGE3U	IK	YJZJHTMOZPILRK-UHFFFAOYSA-N
DMWGE3U	IU	2-amino-6-(2-methylphenyl)sulfonylbenzonitrile
DMWGE3U	DE	Discovery agent

DMJXWH0	ID	DMJXWH0
DMJXWH0	DN	2-Amino-6-(toluene-3-sulfinyl)-benzonitrile
DMJXWH0	HS	Investigative
DMJXWH0	SN	CHEMBL53893; 6-Amino-2-[(3-methylphenyl)sulfinyl]benzenecarbonitrile; AC1LAE28; BDBM1760; CTK7C6588; 2-amino-6-(m-tolylsulfinyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 2e; 2-amino-6-(3-methylphenyl)sulfinylbenzonitrile
DMJXWH0	DT	Small molecular drug
DMJXWH0	PC	486334
DMJXWH0	MW	256.32
DMJXWH0	FM	C14H12N2OS
DMJXWH0	IC	InChI=1S/C14H12N2OS/c1-10-4-2-5-11(8-10)18(17)14-7-3-6-13(16)12(14)9-15/h2-8H,16H2,1H3
DMJXWH0	CS	CC1=CC(=CC=C1)S(=O)C2=CC=CC(=C2C#N)N
DMJXWH0	IK	VIFDNSNSPURBMX-UHFFFAOYSA-N
DMJXWH0	IU	2-amino-6-(3-methylphenyl)sulfinylbenzonitrile
DMJXWH0	DE	Discovery agent

DM1EGP9	ID	DM1EGP9
DM1EGP9	DN	2-Amino-6-(toluene-3-sulfonyl)-benzonitrile
DM1EGP9	HS	Investigative
DM1EGP9	SN	AC1LA8DX; 2-Amino-6-(toluene-3-sulfonyl)-benzonitrile; CHEMBL54600; BDBM1786; CTK7C6573; ZINC5931254; 2-amino-6-(m-tolylsulfonyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 3f; 2-amino-6-(3-methylphenyl)sulfonylbenzonitrile; 2-(3-Methylphenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-[(3-methylphenyl)sulfonyl]benzonitrile
DM1EGP9	DT	Small molecular drug
DM1EGP9	PC	483447
DM1EGP9	MW	272.32
DM1EGP9	FM	C14H12N2O2S
DM1EGP9	IC	InChI=1S/C14H12N2O2S/c1-10-4-2-5-11(8-10)19(17,18)14-7-3-6-13(16)12(14)9-15/h2-8H,16H2,1H3
DM1EGP9	CS	CC1=CC(=CC=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N
DM1EGP9	IK	KWHGWXMLBAGGOE-UHFFFAOYSA-N
DM1EGP9	IU	2-amino-6-(3-methylphenyl)sulfonylbenzonitrile
DM1EGP9	DE	Discovery agent

DMB7415	ID	DMB7415
DMB7415	DN	2-Amino-6-(toluene-4-sulfonyl)-benzonitrile
DMB7415	HS	Investigative
DMB7415	SN	2-Amino-6-(toluene-4-sulfonyl)-benzonitrile; AC1LA8E0; CHEMBL53896; BDBM1787; CTK7C6568; ZINC5930941; 2-amino-6-(p-tolylsulfonyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 3g; 2-amino-6-(4-methylphenyl)sulfonylbenzonitrile; 2-(4-Methylphenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-[(4-methylbenzene)sulfonyl]benzonitrile
DMB7415	DT	Small molecular drug
DMB7415	PC	483448
DMB7415	MW	272.32
DMB7415	FM	C14H12N2O2S
DMB7415	IC	InChI=1S/C14H12N2O2S/c1-10-5-7-11(8-6-10)19(17,18)14-4-2-3-13(16)12(14)9-15/h2-8H,16H2,1H3
DMB7415	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMB7415	IK	RDGYQSLTDBICQU-UHFFFAOYSA-N
DMB7415	IU	2-amino-6-(4-methylphenyl)sulfonylbenzonitrile
DMB7415	DE	Discovery agent

DMJ4H9F	ID	DMJ4H9F
DMJ4H9F	DN	2-Amino-6-benzenesulfonyl-benzonitrile
DMJ4H9F	HS	Investigative
DMJ4H9F	SN	2-amino-6-(benzenesulfonyl)benzonitrile; 6-Amino-2-(phenylsulfonyl)benzenecarbonitrile; AC1LAE3B; CHEMBL55271; BDBM1781; CTK7C6577; ZINC5939149; 2-(Phenylsulfonyl)-6-aminobenzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 3a
DMJ4H9F	DT	Small molecular drug
DMJ4H9F	PC	486347
DMJ4H9F	MW	258.3
DMJ4H9F	FM	C13H10N2O2S
DMJ4H9F	IC	InChI=1S/C13H10N2O2S/c14-9-11-12(15)7-4-8-13(11)18(16,17)10-5-2-1-3-6-10/h1-8H,15H2
DMJ4H9F	CS	C1=CC=C(C=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMJ4H9F	IK	HVMPJKPAYPLWJZ-UHFFFAOYSA-N
DMJ4H9F	IU	2-amino-6-(benzenesulfonyl)benzonitrile
DMJ4H9F	DE	Discovery agent

DMJVG30	ID	DMJVG30
DMJVG30	DN	2-Amino-6-Chloropyrazine
DMJVG30	HS	Investigative
DMJVG30	SN	2-AMINO-6-CHLOROPYRAZINE; 33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115
DMJVG30	DT	Small molecular drug
DMJVG30	PC	118458
DMJVG30	MW	129.55
DMJVG30	FM	C4H4ClN3
DMJVG30	IC	InChI=1S/C4H4ClN3/c5-3-1-7-2-4(6)8-3/h1-2H,(H2,6,8)
DMJVG30	CS	C1=C(N=C(C=N1)Cl)N
DMJVG30	IK	JTPXVCKCLBROOJ-UHFFFAOYSA-N
DMJVG30	IU	6-chloropyrazin-2-amine
DMJVG30	CA	CAS 33332-28-4
DMJVG30	DE	Discovery agent

DMUYTXS	ID	DMUYTXS
DMUYTXS	DN	2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile
DMUYTXS	HS	Investigative
DMUYTXS	SN	CHEMBL468370; 2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile; SCHEMBL6254165
DMUYTXS	DT	Small molecular drug
DMUYTXS	PC	24950370
DMUYTXS	MW	261.279
DMUYTXS	FM	C16H11N3O
DMUYTXS	IC	InChI=1S/C16H11N3O/c17-10-13-12(11-5-2-1-3-6-11)9-14(19-16(13)18)15-7-4-8-20-15/h1-9H,(H2,18,19)
DMUYTXS	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CO3
DMUYTXS	IK	ABFMBAYHWWNULS-UHFFFAOYSA-N
DMUYTXS	IU	2-amino-6-(furan-2-yl)-4-phenylpyridine-3-carbonitrile
DMUYTXS	DE	Discovery agent

DMQF9H1	ID	DMQF9H1
DMQF9H1	DN	2-Amino-6-m-tolylsulfanyl-benzonitrile
DMQF9H1	HS	Investigative
DMQF9H1	SN	6-Amino-2-(3-methylphenylthio)benzenecarbonitrile; AC1LAE0B; CHEMBL296376; BDBM1736; SCHEMBL8641894; CTK7C6434; ZINC20466; 2-amino-6-(m-tolylsulfanyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 1f; 2-amino-6-(3-methylphenyl)sulfanylbenzonitrile
DMQF9H1	DT	Small molecular drug
DMQF9H1	PC	486311
DMQF9H1	MW	240.33
DMQF9H1	FM	C14H12N2S
DMQF9H1	IC	InChI=1S/C14H12N2S/c1-10-4-2-5-11(8-10)17-14-7-3-6-13(16)12(14)9-15/h2-8H,16H2,1H3
DMQF9H1	CS	CC1=CC(=CC=C1)SC2=CC=CC(=C2C#N)N
DMQF9H1	IK	VGPLRZAJQWYFDD-UHFFFAOYSA-N
DMQF9H1	IU	2-amino-6-(3-methylphenyl)sulfanylbenzonitrile
DMQF9H1	DE	Discovery agent

DMAXESK	ID	DMAXESK
DMAXESK	DN	2-amino-6-phenyl-4-p-tolylnicotinonitrile
DMAXESK	HS	Investigative
DMAXESK	SN	CHEMBL376920; 2-amino-4-(4-methylphenyl)-6-phenylpyridine-3-carbonitrile; AC1LEZMJ; BAS 00789881; 2-amino-6-phenyl-4-p-tolylnicotinonitrile; MolPort-000-994-656; ZINC19818501; STK696423; BDBM50194811; AKOS000286711; MCULE-7406561707; ST4039142; 2-Amino-6-phenyl-4-p-tolyl-nicotinonitrile; SR-01000520248; SR-01000520248-1; 2-amino-3-cyano-4-(4-methylphenyl)-6-phenylpyridine; 2-amino-4-(4-methylphenyl)-6-phenyl-3-pyridyl cyanide; A1811/0076551
DMAXESK	DT	Small molecular drug
DMAXESK	PC	695136
DMAXESK	MW	285.3
DMAXESK	FM	C19H15N3
DMAXESK	IC	InChI=1S/C19H15N3/c1-13-7-9-14(10-8-13)16-11-18(15-5-3-2-4-6-15)22-19(21)17(16)12-20/h2-11H,1H3,(H2,21,22)
DMAXESK	CS	CC1=CC=C(C=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CC=C3
DMAXESK	IK	ADSZRHDJWBZORK-UHFFFAOYSA-N
DMAXESK	IU	2-amino-4-(4-methylphenyl)-6-phenylpyridine-3-carbonitrile
DMAXESK	DE	Discovery agent

DM7M9CL	ID	DM7M9CL
DM7M9CL	DN	2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile
DM7M9CL	HS	Investigative
DM7M9CL	SN	CHEMBL476298; AC1MNMTO; 2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile; ZINC33468133; BDBM50262440; AKOS000286735
DM7M9CL	DT	Small molecular drug
DM7M9CL	PC	3355253
DM7M9CL	MW	277.3
DM7M9CL	FM	C16H11N3S
DM7M9CL	IC	InChI=1S/C16H11N3S/c17-10-13-12(15-7-4-8-20-15)9-14(19-16(13)18)11-5-2-1-3-6-11/h1-9H,(H2,18,19)
DM7M9CL	CS	C1=CC=C(C=C1)C2=NC(=C(C(=C2)C3=CC=CS3)C#N)N
DM7M9CL	IK	WFWGQLLRRFDTHC-UHFFFAOYSA-N
DM7M9CL	IU	2-amino-6-phenyl-4-thiophen-2-ylpyridine-3-carbonitrile
DM7M9CL	DE	Discovery agent

DMMBGK0	ID	DMMBGK0
DMMBGK0	DN	2-Amino-6-phenylsulfanyl-benzonitrile
DMMBGK0	HS	Investigative
DMMBGK0	SN	Benzonitrile, 2-amino-6-(phenylthio)-; 123241-49-6; 2-amino-6-phenylsulfanylbenzonitrile; 2-Amino-6-phenylsulfanyl-benzonitrile; AC1LADY2; ACMC-20b9p7; CHEMBL52068; SCHEMBL1772509; BDBM1731; CTK0C2943; DTXSID80333141; MPKFSGFZCBOCIQ-UHFFFAOYSA-N; ZINC5939158; 2-Amino-6-(phenylthio)benzonitrile; 6-Amino-2-phenylthiobenzenecarbonitrile; 2-amino-6-(phenylsulfanyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 1a
DMMBGK0	DT	Small molecular drug
DMMBGK0	PC	486276
DMMBGK0	MW	226.3
DMMBGK0	FM	C13H10N2S
DMMBGK0	IC	InChI=1S/C13H10N2S/c14-9-11-12(15)7-4-8-13(11)16-10-5-2-1-3-6-10/h1-8H,15H2
DMMBGK0	CS	C1=CC=C(C=C1)SC2=CC=CC(=C2C#N)N
DMMBGK0	IK	MPKFSGFZCBOCIQ-UHFFFAOYSA-N
DMMBGK0	IU	2-amino-6-phenylsulfanylbenzonitrile
DMMBGK0	CA	CAS 123241-49-6
DMMBGK0	DE	Discovery agent

DM4BQ1W	ID	DM4BQ1W
DM4BQ1W	DN	2-Amino-6-p-tolylsulfanyl-benzonitrile
DM4BQ1W	HS	Investigative
DM4BQ1W	SN	Benzonitrile, 2-amino-6-[(4-methylphenyl)thio]-; 168910-27-8; AC1LAE0E; 2-amino-6-(4-methylphenyl)sulfanylbenzonitrile; CHEMBL51912; BDBM1737; CTK0A8438; DTXSID00333143; ZINC5930943; 2-Amino-6-(p-tolylthio)benzonitrile; 2-amino-6-(p-tolylsulfanyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 1g; 2-amino-6-[(4-methylphenyl)sulfanyl]benzonitrile
DM4BQ1W	DT	Small molecular drug
DM4BQ1W	PC	486312
DM4BQ1W	MW	240.33
DM4BQ1W	FM	C14H12N2S
DM4BQ1W	IC	InChI=1S/C14H12N2S/c1-10-5-7-11(8-6-10)17-14-4-2-3-13(16)12(14)9-15/h2-8H,16H2,1H3
DM4BQ1W	CS	CC1=CC=C(C=C1)SC2=CC=CC(=C2C#N)N
DM4BQ1W	IK	NLGYCJNCIXKPHK-UHFFFAOYSA-N
DM4BQ1W	IU	2-amino-6-(4-methylphenyl)sulfanylbenzonitrile
DM4BQ1W	CA	CAS 168910-27-8
DM4BQ1W	DE	Discovery agent

DMRSGC5	ID	DMRSGC5
DMRSGC5	DN	2-amino-8-methyl-7,8-dihydropteridin-4(3H)-one
DMRSGC5	HS	Investigative
DMRSGC5	DE	Discovery agent

DMEMANH	ID	DMEMANH
DMEMANH	DN	2-Amino-benzenesulfonamide
DMEMANH	HS	Investigative
DMEMANH	SN	2-aminobenzenesulfonamide
DMEMANH	DT	Small molecular drug
DMEMANH	PC	72894
DMEMANH	MW	172.21
DMEMANH	FM	C6H8N2O2S
DMEMANH	IC	InChI=1S/C6H8N2O2S/c7-5-3-1-2-4-6(5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
DMEMANH	CS	C1=CC=C(C(=C1)N)S(=O)(=O)N
DMEMANH	IK	YAZSBRQTAHVVGE-UHFFFAOYSA-N
DMEMANH	IU	2-aminobenzenesulfonamide
DMEMANH	CA	CAS 3306-62-5
DMEMANH	CB	CHEBI:94579
DMEMANH	DE	Discovery agent

DM2OE1W	ID	DM2OE1W
DM2OE1W	DN	2-Aminoethanimidic Acid
DM2OE1W	HS	Investigative
DM2OE1W	SN	2-AMINOETHANIMIDIC ACID; 2-iminoethanamine; 2-aminoethylimine; 2-Aminoethanimine; AC1NBQ0B; (2E)-2-iminoethanamine; AKOS006363845
DM2OE1W	DT	Small molecular drug
DM2OE1W	PC	4471892
DM2OE1W	MW	58.08
DM2OE1W	FM	C2H6N2
DM2OE1W	IC	InChI=1S/C2H6N2/c3-1-2-4/h1,3H,2,4H2
DM2OE1W	CS	C(C=N)N
DM2OE1W	IK	AXQVKDQRBAXYBP-UHFFFAOYSA-N
DM2OE1W	IU	2-iminoethanamine
DM2OE1W	DE	Discovery agent

DMUJC2E	ID	DMUJC2E
DMUJC2E	DN	2'-aminoimidazolylmethyluracils
DMUJC2E	HS	Investigative
DMUJC2E	DT	Small molecular drug
DMUJC2E	PC	56603742
DMUJC2E	MW	243.65
DMUJC2E	FM	C8H10ClN5O2
DMUJC2E	IC	InChI=1S/C8H10ClN5O2/c9-5-4(12-8(16)13-6(5)15)3-14-2-1-11-7(14)10/h1-2,7,11H,3,10H2,(H2,12,13,15,16)
DMUJC2E	CS	C1=CN(C(N1)N)CC2=C(C(=O)NC(=O)N2)Cl
DMUJC2E	IK	VDNGDZIPDSUEKT-UHFFFAOYSA-N
DMUJC2E	IU	6-[(2-amino-1,2-dihydroimidazol-3-yl)methyl]-5-chloro-1H-pyrimidine-2,4-dione
DMUJC2E	DE	Discovery agent

DMCUSH1	ID	DMCUSH1
DMCUSH1	DN	2-Amino-indan-5-sulfonic acid
DMCUSH1	HS	Investigative
DMCUSH1	SN	2-amino-2,3-dihydro-1H-indene-5-sulfonic acid
DMCUSH1	PC	44395769
DMCUSH1	MW	213.26
DMCUSH1	FM	C9H11NO3S
DMCUSH1	IC	InChI=1S/C9H11NO3S/c10-8-3-6-1-2-9(14(11,12)13)5-7(6)4-8/h1-2,5,8H,3-4,10H2,(H,11,12,13)
DMCUSH1	CS	C1C(CC2=C1C=CC(=C2)S(=O)(=O)O)N
DMCUSH1	IK	NVRZETXANFNFEF-UHFFFAOYSA-N
DMCUSH1	IU	2-amino-2,3-dihydro-1H-indene-5-sulfonic acid
DMCUSH1	DE	Discovery agent

DMCJUWK	ID	DMCJUWK
DMCJUWK	DN	2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran
DMCJUWK	HS	Investigative
DMCJUWK	SN	CHEMBL461268; 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran; SCHEMBL2689197
DMCJUWK	DT	Small molecular drug
DMCJUWK	PC	11644566
DMCJUWK	MW	256.14
DMCJUWK	FM	C11H14BrNO
DMCJUWK	IC	InChI=1S/C11H14BrNO/c12-9-3-1-8(2-4-9)11-6-5-10(7-13)14-11/h1-4,10-11H,5-7,13H2
DMCJUWK	CS	C1CC(OC1CN)C2=CC=C(C=C2)Br
DMCJUWK	IK	NZCDMSTWUUULEH-UHFFFAOYSA-N
DMCJUWK	IU	[5-(4-bromophenyl)oxolan-2-yl]methanamine
DMCJUWK	DE	Discovery agent

DM3OTZY	ID	DM3OTZY
DM3OTZY	DN	2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran
DM3OTZY	HS	Investigative
DM3OTZY	SN	CHEMBL447825; [5-(4-chlorophenyl)oxolan-2-yl]methanamine; 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran; SCHEMBL2689896
DM3OTZY	DT	Small molecular drug
DM3OTZY	PC	11506733
DM3OTZY	MW	211.69
DM3OTZY	FM	C11H14ClNO
DM3OTZY	IC	InChI=1S/C11H14ClNO/c12-9-3-1-8(2-4-9)11-6-5-10(7-13)14-11/h1-4,10-11H,5-7,13H2
DM3OTZY	CS	C1CC(OC1CN)C2=CC=C(C=C2)Cl
DM3OTZY	IK	KHKLNHSDQIKVSU-UHFFFAOYSA-N
DM3OTZY	IU	[5-(4-chlorophenyl)oxolan-2-yl]methanamine
DM3OTZY	DE	Discovery agent

DM413ZB	ID	DM413ZB
DM413ZB	DN	2-Aminomethyl-5-(phenyl)tetrahydrofuran
DM413ZB	HS	Investigative
DM413ZB	SN	(5-phenyloxolan-2-yl)methanamine; CHEMBL458639; 878661-56-4; 2-Aminomethyl-5-(phenyl)tetrahydrofuran; SCHEMBL2690113; MolPort-035-929-309
DM413ZB	DT	Small molecular drug
DM413ZB	PC	11571886
DM413ZB	MW	177.24
DM413ZB	FM	C11H15NO
DM413ZB	IC	InChI=1S/C11H15NO/c12-8-10-6-7-11(13-10)9-4-2-1-3-5-9/h1-5,10-11H,6-8,12H2
DM413ZB	CS	C1CC(OC1CN)C2=CC=CC=C2
DM413ZB	IK	IAIACGGIZWXQIK-UHFFFAOYSA-N
DM413ZB	IU	(5-phenyloxolan-2-yl)methanamine
DM413ZB	DE	Discovery agent

DMDG8FL	ID	DMDG8FL
DMDG8FL	DN	2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran
DMDG8FL	HS	Investigative
DMDG8FL	SN	CHEMBL451652; 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran; SCHEMBL2689310
DMDG8FL	DT	Small molecular drug
DMDG8FL	PC	11658526
DMDG8FL	MW	207.27
DMDG8FL	FM	C12H17NO2
DMDG8FL	IC	InChI=1S/C12H17NO2/c1-14-10-4-2-9(3-5-10)12-7-6-11(8-13)15-12/h2-5,11-12H,6-8,13H2,1H3
DMDG8FL	CS	COC1=CC=C(C=C1)C2CCC(O2)CN
DMDG8FL	IK	SUAFTJAVJHXARK-UHFFFAOYSA-N
DMDG8FL	IU	[5-(4-methoxyphenyl)oxolan-2-yl]methanamine
DMDG8FL	DE	Discovery agent

DME4P7K	ID	DME4P7K
DME4P7K	DN	2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran
DME4P7K	HS	Investigative
DME4P7K	SN	CHEMBL447750; 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran; SCHEMBL2690807
DME4P7K	DT	Small molecular drug
DME4P7K	PC	11651575
DME4P7K	MW	233.35
DME4P7K	FM	C15H23NO
DME4P7K	IC	InChI=1S/C15H23NO/c1-15(2,3)12-6-4-11(5-7-12)14-9-8-13(10-16)17-14/h4-7,13-14H,8-10,16H2,1-3H3
DME4P7K	CS	CC(C)(C)C1=CC=C(C=C1)C2CCC(O2)CN
DME4P7K	IK	OOZOQFAQHUVOAM-UHFFFAOYSA-N
DME4P7K	IU	[5-(4-tert-butylphenyl)oxolan-2-yl]methanamine
DME4P7K	DE	Discovery agent

DMAN8EH	ID	DMAN8EH
DMAN8EH	DN	2-Aminomethyl-pyrrolidine-3,4-diol
DMAN8EH	HS	Investigative
DMAN8EH	SN	CHEMBL79727; 2-Aminomethyl-pyrrolidine-3,4-diol
DMAN8EH	DT	Small molecular drug
DMAN8EH	PC	11852460
DMAN8EH	MW	132.16
DMAN8EH	FM	C5H12N2O2
DMAN8EH	IC	InChI=1S/C5H12N2O2/c6-1-3-5(9)4(8)2-7-3/h3-5,7-9H,1-2,6H2
DMAN8EH	CS	C1C(C(C(N1)CN)O)O
DMAN8EH	IK	PTUICKYMXFZVGV-UHFFFAOYSA-N
DMAN8EH	IU	2-(aminomethyl)pyrrolidine-3,4-diol
DMAN8EH	DE	Discovery agent

DMESFTW	ID	DMESFTW
DMESFTW	DN	2-amino-N-(quinolin-8-yl)benzenesulfonamide
DMESFTW	HS	Investigative
DMESFTW	SN	2-Amino-N-quinolin-8-yl-benzenesulfonamide; 16082-64-7; CHEMBL256062; QBS; 2-amino-N-quinolin-8-ylbenzenesulfonamide; AC1LLN9A; Cambridge id 5175136; Oprea1_584159; CBDivE_007127; SCHEMBL460773; CTK4D0607; DTXSID90360049; NIOOKXAMJQVDGB-UHFFFAOYSA-N; ZINC758699; DNDI1417207; CCG-15219; BDBM50372507; MFCD00168987; AKOS000154013; NCGC00161683-02; NCGC00161683-01; NCGC00161683-04; NCGC00161683-03; 2-amino-n-quinoline-8-yl-benzenesulfonamide; AB00074880-01; 2-AMINO-N-QUINOLINE-8-YL-BENZENESULFONAM
DMESFTW	DT	Small molecular drug
DMESFTW	PC	1070159
DMESFTW	MW	299.3
DMESFTW	FM	C15H13N3O2S
DMESFTW	IC	InChI=1S/C15H13N3O2S/c16-12-7-1-2-9-14(12)21(19,20)18-13-8-3-5-11-6-4-10-17-15(11)13/h1-10,18H,16H2
DMESFTW	CS	C1=CC=C(C(=C1)N)S(=O)(=O)NC2=CC=CC3=C2N=CC=C3
DMESFTW	IK	NIOOKXAMJQVDGB-UHFFFAOYSA-N
DMESFTW	IU	2-amino-N-quinolin-8-ylbenzenesulfonamide
DMESFTW	CA	CAS 16082-64-7
DMESFTW	DE	Discovery agent

DM3YI9P	ID	DM3YI9P
DM3YI9P	DN	2-Amino-N,3,3-Trimethylbutanamide
DM3YI9P	HS	Investigative
DM3YI9P	SN	2-AMINO-N,3,3-TRIMETHYLBUTANAMIDE; AC1MRP6C; SCHEMBL343358; DTXSID30393038; BPKJNEIOHOEWLO-UHFFFAOYSA-N; 2-amino-N,3,3-trimethyl-butanamide; 2-azanyl-N,3,3-trimethyl-butanamide; AKOS022475747; AN-25241
DM3YI9P	DT	Small molecular drug
DM3YI9P	PC	3496445
DM3YI9P	MW	144.21
DM3YI9P	FM	C7H16N2O
DM3YI9P	IC	InChI=1S/C7H16N2O/c1-7(2,3)5(8)6(10)9-4/h5H,8H2,1-4H3,(H,9,10)
DM3YI9P	CS	CC(C)(C)C(C(=O)NC)N
DM3YI9P	IK	BPKJNEIOHOEWLO-UHFFFAOYSA-N
DM3YI9P	IU	2-amino-N,3,3-trimethylbutanamide
DM3YI9P	CA	CAS 515140-27-9
DM3YI9P	DE	Discovery agent

DMRY06D	ID	DMRY06D
DMRY06D	DN	2-Amino-N-[4-(phenylmethoxy)phenyl]-acetamide
DMRY06D	HS	Investigative
DMRY06D	SN	N-[4-(Benzyloxy)phenyl]glycinamide; N-[4-(benzyloxy)phenyl]glycinamide; CHEMBL479960; Amino acid analog, 2; BDBM24243; MolPort-003-787-576; HMS3604F07; ZINC11957004; STL183976; BBL019466; AKOS008945725; DB07099; 2-amino-N-[4-(benzyloxy)phenyl]acetamide; 2-Amino-N-(4-benzyloxy-phenyl)-acetamide; T8777; 347A389
DMRY06D	DT	Small molecular drug
DMRY06D	PC	22690393
DMRY06D	MW	256.3
DMRY06D	FM	C15H16N2O2
DMRY06D	IC	InChI=1S/C15H16N2O2/c16-10-15(18)17-13-6-8-14(9-7-13)19-11-12-4-2-1-3-5-12/h1-9H,10-11,16H2,(H,17,18)
DMRY06D	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CN
DMRY06D	IK	YJPUATSIKWOSST-UHFFFAOYSA-N
DMRY06D	IU	2-amino-N-(4-phenylmethoxyphenyl)acetamide
DMRY06D	DE	Discovery agent

DMQ30UY	ID	DMQ30UY
DMQ30UY	DN	2-amino-N1-benzyl-N3-hydroxymalonamide
DMQ30UY	HS	Investigative
DMQ30UY	SN	CHEMBL219940
DMQ30UY	DT	Small molecular drug
DMQ30UY	PC	16115628
DMQ30UY	MW	223.23
DMQ30UY	FM	C10H13N3O3
DMQ30UY	IC	InChI=1S/C10H13N3O3/c11-8(10(15)13-16)9(14)12-6-7-4-2-1-3-5-7/h1-5,8,16H,6,11H2,(H,12,14)(H,13,15)
DMQ30UY	CS	C1=CC=C(C=C1)CNC(=O)C(C(=O)NO)N
DMQ30UY	IK	HVTWOBIOCPYSGH-UHFFFAOYSA-N
DMQ30UY	IU	2-amino-N-benzyl-N'-hydroxypropanediamide
DMQ30UY	DE	Discovery agent

DM320RW	ID	DM320RW
DM320RW	DN	2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide
DM320RW	HS	Investigative
DM320RW	SN	CHEMBL259164
DM320RW	DT	Small molecular drug
DM320RW	PC	44449523
DM320RW	MW	344.4
DM320RW	FM	C19H16N6O
DM320RW	IC	InChI=1S/C19H16N6O/c20-18-23-15(14-9-5-2-6-10-14)16-17(24-18)25(12-22-16)19(26)21-11-13-7-3-1-4-8-13/h1-10,12H,11H2,(H,21,26)(H2,20,23,24)
DM320RW	CS	C1=CC=C(C=C1)CNC(=O)N2C=NC3=C(N=C(N=C32)N)C4=CC=CC=C4
DM320RW	IK	MNONTGDJIJLFPU-UHFFFAOYSA-N
DM320RW	IU	2-amino-N-benzyl-6-phenylpurine-9-carboxamide
DM320RW	DE	Discovery agent

DMBVGAO	ID	DMBVGAO
DMBVGAO	DN	2-aminophenoxazine-3-one
DMBVGAO	HS	Investigative
DMBVGAO	SN	Questiomycin A; 2-Amino-3H-phenoxazin-3-one; 2-Aminophenoxazin-3-one; 1916-59-2; 2-Aminophenoxazon; 2-Aminophenoxazone; 3-Aminophenoxazone; 2-Amino-3-phenoxazone; 3H-Phenoxazin-3-one, 2-amino-; Isophenoxazine; 2-amino-phenoxazin-3-one; NSC 94945; MLS000736964; CHEBI:17293; SMR000528446; BRN 0014215; Questinomycine A; 3H-Phenoxazin-3-one,2-amino-; AV toxin C; 2-Aminophenoxazinone; Phx-3 cpd; Phx-3; 2-amino-3-phenoxazinone; 2-azanylphenoxazin-3-one; Acrospermum viticola toxin C; NCIOpen2_006212; 4-27-00-05519 (Beilstein Handbook Reference); cid_72725; CHEMBL146710; SCHEMBL2609261; BDBM76155; DTXSID60172691; HMS2270F19; NSC94945; ZINC4095812; MFCD00207317; NSC-94945; 2-acetylamino-(3h)-phenoxazin-3-one; AKOS027339724; NCGC00246903-01; AS-47041; C02161; J-012388; BRD-K66640612-001-05-8; Q15424786
DMBVGAO	DT	Small molecular drug
DMBVGAO	PC	72725
DMBVGAO	MW	212.2
DMBVGAO	FM	C12H8N2O2
DMBVGAO	IC	InChI=1S/C12H8N2O2/c13-7-5-9-12(6-10(7)15)16-11-4-2-1-3-8(11)14-9/h1-6H,13H2
DMBVGAO	CS	C1=CC=C2C(=C1)N=C3C=C(C(=O)C=C3O2)N
DMBVGAO	IK	RDJXPXHQENRCNG-UHFFFAOYSA-N
DMBVGAO	IU	2-aminophenoxazin-3-one
DMBVGAO	CA	CAS 1916-59-2
DMBVGAO	CB	CHEBI:17293
DMBVGAO	DE	T-cell leukaemia

DMQIC3L	ID	DMQIC3L
DMQIC3L	DN	2-aminopyridine
DMQIC3L	HS	Investigative
DMQIC3L	SN	2-AMINOPYRIDINE; 504-29-0; pyridin-2-amine; 2-Pyridinamine; 2-Pyridylamine; Aminopyridine; Pyridinamine; o-Aminopyridine; 2-aminopyridin; 2-Aminopryidine; Amino-2 pyridine; Pyridine, 2-amino-; 1,2-Dihydro-2-iminopyridine; alpha-Pyridylamine; alpha-Pyridinamine; 2-Pyridinylnitrene; alpha-Aminopyridine; Pyridin-2-ylamine; NSC 431; UNII-WSX981HEWU; 2-pyridinylamine; 2-amino pyridine; Pyridine, amino-; pyridin-2-yl-amine; .beta.-Pyridylamine; .alpha.-Pyridylamine; .alpha.-Pyridinamine; CCRIS 4747; .alpha.-Aminopyridine; 26445-05-6; HSDB 206
DMQIC3L	DT	Small molecular drug
DMQIC3L	PC	10439
DMQIC3L	MW	94.11
DMQIC3L	FM	C5H6N2
DMQIC3L	IC	InChI=1S/C5H6N2/c6-5-3-1-2-4-7-5/h1-4H,(H2,6,7)
DMQIC3L	CS	C1=CC=NC(=C1)N
DMQIC3L	IK	ICSNLGPSRYBMBD-UHFFFAOYSA-N
DMQIC3L	IU	pyridin-2-amine
DMQIC3L	CA	CAS 504-29-0
DMQIC3L	DE	Discovery agent

DMJW4CS	ID	DMJW4CS
DMJW4CS	DN	2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide
DMJW4CS	HS	Investigative
DMJW4CS	SN	CHEMBL235988; 2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide
DMJW4CS	DT	Small molecular drug
DMJW4CS	PC	24749595
DMJW4CS	MW	343.18
DMJW4CS	FM	C15H11BrN4O
DMJW4CS	IC	InChI=1S/C15H11BrN4O/c16-9-5-7-10(8-6-9)18-14(21)13-11-3-1-2-4-12(11)19-15(17)20-13/h1-8H,(H,18,21)(H2,17,19,20)
DMJW4CS	CS	C1=CC=C2C(=C1)C(=NC(=N2)N)C(=O)NC3=CC=C(C=C3)Br
DMJW4CS	IK	DYTZVUGMYADHJM-UHFFFAOYSA-N
DMJW4CS	IU	2-amino-N-(4-bromophenyl)quinazoline-4-carboxamide
DMJW4CS	DE	Discovery agent

DMQJYX7	ID	DMQJYX7
DMQJYX7	DN	2-aminoquinazoline-4-carboxyanilide
DMQJYX7	HS	Investigative
DMQJYX7	SN	CHEMBL238091; 2-aminoquinazoline-4-carboxyanilide; SCHEMBL3086622
DMQJYX7	DT	Small molecular drug
DMQJYX7	PC	24749831
DMQJYX7	MW	264.28
DMQJYX7	FM	C15H12N4O
DMQJYX7	IC	InChI=1S/C15H12N4O/c16-15-18-12-9-5-4-8-11(12)13(19-15)14(20)17-10-6-2-1-3-7-10/h1-9H,(H,17,20)(H2,16,18,19)
DMQJYX7	CS	C1=CC=C(C=C1)NC(=O)C2=NC(=NC3=CC=CC=C32)N
DMQJYX7	IK	FXATZDLBKVHWOG-UHFFFAOYSA-N
DMQJYX7	IU	2-amino-N-phenylquinazoline-4-carboxamide
DMQJYX7	DE	Discovery agent

DME4856	ID	DME4856
DME4856	DN	2-amino-quinoline-3-carboxylic acid amide
DME4856	HS	Investigative
DME4856	SN	2-aminoquinoline-3-carboxamide; 31407-28-0; 3-Quinolinecarboxamide, 2-amino-; 2-amino-quinoline-3-carboxylic acid amide; 2-amino-3-quinolinecarboxamide; CHEMBL206956; GXZOXGRLLFZVGF-UHFFFAOYSA-N; ZERO/004541; AC1NP94V; SCHEMBL30837; CTK7D2638; MolPort-002-742-881; ZX-AN021879; ALBB-023365; STK735522; BDBM50186621; SBB012747; ZINC19890815; FCH854771; AKOS003368785; MCULE-6676169786; NCGC00340196-01; 2-Aminoquinoline-3-carboxylic acid amide; OR346178; KB-118564; 2-amino-3-quinolinecarboxamide, AldrichCPR; ST4128359; R9463
DME4856	DT	Small molecular drug
DME4856	PC	5200228
DME4856	MW	187.2
DME4856	FM	C10H9N3O
DME4856	IC	InChI=1S/C10H9N3O/c11-9-7(10(12)14)5-6-3-1-2-4-8(6)13-9/h1-5H,(H2,11,13)(H2,12,14)
DME4856	CS	C1=CC=C2C(=C1)C=C(C(=N2)N)C(=O)N
DME4856	IK	GXZOXGRLLFZVGF-UHFFFAOYSA-N
DME4856	IU	2-aminoquinoline-3-carboxamide
DME4856	CA	CAS 31407-28-0
DME4856	DE	Discovery agent

DM9YCAH	ID	DM9YCAH
DM9YCAH	DN	2-Aminothiazoline
DM9YCAH	HS	Investigative
DM9YCAH	SN	2-Amino-2-thiazoline; 1779-81-3; 4,5-dihydrothiazol-2-amine; 2-Iminothiazolidine; 2-Thiazolidinimine; 2-Thiazolamine, 4,5-dihydro-; 2-Amino-4,5-dihydrothiazole; 2-Thiazoline, 2-amino-; 4,5-Dihydro-1,3-thiazol-2-amine; USAF PD-57; 2-Amino-4,5-dihydrothiazoline; 4,5-DIHYDRO-2-THIAZOLAMINE; 2-Thiazolin-2-ylamine; 2-Aminothiazoline (VAN); UNII-5JC2YZG56Q; NSC 3110; NSC 24626; Thiazolidin-(2E)-ylideneamine; 2-Amino-DELTA2-thiazoline; EINECS 217-224-1; 5JC2YZG56Q; CHEMBL362148; 2-Amino-2-thiazoline, 97%
DM9YCAH	DT	Small molecular drug
DM9YCAH	PC	15689
DM9YCAH	MW	102.16
DM9YCAH	FM	C3H6N2S
DM9YCAH	IC	InChI=1S/C3H6N2S/c4-3-5-1-2-6-3/h1-2H2,(H2,4,5)
DM9YCAH	CS	C1CSC(=N1)N
DM9YCAH	IK	REGFWZVTTFGQOJ-UHFFFAOYSA-N
DM9YCAH	IU	4,5-dihydro-1,3-thiazol-2-amine
DM9YCAH	CA	CAS 1779-81-3
DM9YCAH	CB	CHEBI:40889
DM9YCAH	DE	Discovery agent

DMO792L	ID	DMO792L
DMO792L	DN	2-amino-uridine-5'-monophosphate
DMO792L	HS	Investigative
DMO792L	SN	iso-CMP; compound 13g [PMID: 21417463]
DMO792L	DT	Small molecular drug
DMO792L	PC	49867142
DMO792L	MW	323.2
DMO792L	FM	C9H14N3O8P
DMO792L	IC	InChI=1S/C9H14N3O8P/c10-9-11-5(13)1-2-12(9)8-7(15)6(14)4(20-8)3-19-21(16,17)18/h1-2,4,6-8,14-15H,3H2,(H2,10,11,13)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DMO792L	CS	C1=CN(C(=NC1=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O
DMO792L	IK	ONSQLDCEJIIUJS-XVFCMESISA-N
DMO792L	IU	[(2R,3S,4R,5R)-5-(2-amino-4-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMO792L	DE	Discovery agent

DMFNEZW	ID	DMFNEZW
DMFNEZW	DN	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
DMFNEZW	HS	Investigative
DMFNEZW	SN	2-Anilino-6-cyclohexylmethoxypurine; 2-anilino-6-cyclohexylmethoxypurine; 6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,
DMFNEZW	DT	Small molecular drug
DMFNEZW	PC	1540
DMFNEZW	MW	323.4
DMFNEZW	FM	C18H21N5O
DMFNEZW	IC	InChI=1S/C18H21N5O/c1-3-7-13(8-4-1)11-24-17-15-16(20-12-19-15)22-18(23-17)21-14-9-5-2-6-10-14/h2,5-6,9-10,12-13H,1,3-4,7-8,11H2,(H2,19,20,21,22,23)
DMFNEZW	CS	C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)NC4=CC=CC=C4
DMFNEZW	IK	XWWRLKIBRPJQJX-UHFFFAOYSA-N
DMFNEZW	IU	6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine
DMFNEZW	CA	CAS 444722-80-9
DMFNEZW	DE	Discovery agent

DM9AKVR	ID	DM9AKVR
DM9AKVR	DN	2-APB
DM9AKVR	HS	Investigative
DM9AKVR	SN	2-aminoethoxydiphenyl borate; 2-aminoethoxydiphenylborane
DM9AKVR	DT	Small molecular drug
DM9AKVR	PC	1598
DM9AKVR	MW	225.1
DM9AKVR	FM	C14H16BNO
DM9AKVR	IC	InChI=1S/C14H16BNO/c16-11-12-17-15(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10H,11-12,16H2
DM9AKVR	CS	B(C1=CC=CC=C1)(C2=CC=CC=C2)OCCN
DM9AKVR	IK	BLZVCIGGICSWIG-UHFFFAOYSA-N
DM9AKVR	IU	2-diphenylboranyloxyethanamine
DM9AKVR	CA	CAS 524-95-8
DM9AKVR	CB	CHEBI:131184
DM9AKVR	DE	Discovery agent

DMM0KOJ	ID	DMM0KOJ
DMM0KOJ	DN	2-arachidonoylglycerol
DMM0KOJ	HS	Investigative
DMM0KOJ	SN	2-arachidonoylglycerol; 2-AG; 2-Arachidonylglycerol; 2-Arachidonyl-glycerol; 53847-30-6; 2-Arachidonoyl-glycerol; 2-Arachidonoyl Glycerol; 2-Ara-Gl; 2-Monoarachidonoylglycerol; UNII-8D239QDW64; 1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate; CHEMBL122972; CHEBI:52392; RCRCTBLIHCHWDZ-DOFZRALJSA-N; 8D239QDW64; MG(20:4); MG(0:0/20:4(5Z,8Z,11Z,14Z)/0:0); 5,8,11,14-Eicosatetraenoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester, (5Z,8Z,11Z,14Z)-; 5,8,11,14-Eicosatetraenoic acid, 2-hydroxy-1-(hydroxymethyl)ethy
DMM0KOJ	DT	Small molecular drug
DMM0KOJ	PC	5282280
DMM0KOJ	MW	378.5
DMM0KOJ	FM	C23H38O4
DMM0KOJ	IC	InChI=1S/C23H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)27-22(20-24)21-25/h6-7,9-10,12-13,15-16,22,24-25H,2-5,8,11,14,17-21H2,1H3/b7-6-,10-9-,13-12-,16-15-
DMM0KOJ	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)OC(CO)CO
DMM0KOJ	IK	RCRCTBLIHCHWDZ-DOFZRALJSA-N
DMM0KOJ	IU	1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
DMM0KOJ	CA	CAS 53847-30-6
DMM0KOJ	CB	CHEBI:52392
DMM0KOJ	DE	Discovery agent

DMICOL3	ID	DMICOL3
DMICOL3	DN	2-arachidonoylglycerolphosphoinositol
DMICOL3	HS	Investigative
DMICOL3	SN	2-arachidonoyl-glycerol-phosphoinositol; arachidonoyl LPI
DMICOL3	DT	Small molecular drug
DMICOL3	PC	73755068
DMICOL3	MW	619.7
DMICOL3	FM	C29H48O12P-
DMICOL3	IC	InChI=1S/C29H49O12P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(31)40-22(20-30)21-39-42(37,38)41-29-27(35)25(33)24(32)26(34)28(29)36/h6-7,9-10,12-13,15-16,22,24-30,32-36H,2-5,8,11,14,17-21H2,1H3,(H,37,38)/p-1/b7-6-,10-9-,13-12-,16-15-
DMICOL3	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)OC(CO)COP(=O)([O-])OC1C(C(C(C(C1O)O)O)O)O
DMICOL3	IK	OKEQUIXTUXJQNT-DOFZRALJSA-M
DMICOL3	IU	[3-hydroxy-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]oxypropyl] (2,3,4,5,6-pentahydroxycyclohexyl) phosphate
DMICOL3	DE	Discovery agent

DM2H8TV	ID	DM2H8TV
DM2H8TV	DN	2-arachidonyl glyceryl ether
DM2H8TV	HS	Investigative
DM2H8TV	SN	Noladin ether; HU 310; 2-AG ether; 2-arachidonylglyceryl ether
DM2H8TV	DT	Small molecular drug
DM2H8TV	PC	6483057
DM2H8TV	MW	364.6
DM2H8TV	FM	C23H40O3
DM2H8TV	IC	InChI=1S/C23H40O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-26-23(21-24)22-25/h6-7,9-10,12-13,15-16,23-25H,2-5,8,11,14,17-22H2,1H3/b7-6-,10-9-,13-12-,16-15-
DM2H8TV	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCOC(CO)CO
DM2H8TV	IK	CUJUUWXZAQHCNC-DOFZRALJSA-N
DM2H8TV	IU	2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoxy]propane-1,3-diol
DM2H8TV	CA	CAS 222723-55-9
DM2H8TV	CB	CHEBI:75913
DM2H8TV	DE	Discovery agent

DMBSDIV	ID	DMBSDIV
DMBSDIV	DN	2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine
DMBSDIV	HS	Investigative
DMBSDIV	SN	CHEMBL384425; 2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine
DMBSDIV	DT	Small molecular drug
DMBSDIV	PC	16094571
DMBSDIV	MW	322.28
DMBSDIV	FM	C11H14N8O4
DMBSDIV	IC	InChI=1S/C11H14N8O4/c1-13-8-5-9(16-11(15-8)17-18-12)19(3-14-5)10-7(22)6(21)4(2-20)23-10/h3-4,6-7,10,20-22H,2H2,1H3,(H,13,15,16)/t4-,6-,7-,10-/m1/s1
DMBSDIV	CS	CNC1=C2C(=NC(=N1)N=[N+]=[N-])N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMBSDIV	IK	CAQREKOGAXNCLL-KQYNXXCUSA-N
DMBSDIV	IU	(2R,3R,4S,5R)-2-[2-azido-6-(methylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMBSDIV	DE	Discovery agent

DMXZ1HL	ID	DMXZ1HL
DMXZ1HL	DN	2-Benzhydryl-7-hydroxy-chromen-4-one
DMXZ1HL	HS	Investigative
DMXZ1HL	SN	CHEMBL292697; 2-benzhydryl-7-hydroxy-chromen-4-one; 2-Benzhydryl-7-hydroxychromone
DMXZ1HL	DT	Small molecular drug
DMXZ1HL	PC	10711364
DMXZ1HL	MW	328.4
DMXZ1HL	FM	C22H16O3
DMXZ1HL	IC	InChI=1S/C22H16O3/c23-17-11-12-18-19(24)14-21(25-20(18)13-17)22(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-14,22-23H
DMXZ1HL	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC(=O)C4=C(O3)C=C(C=C4)O
DMXZ1HL	IK	VVMXRAGTHNZYRJ-UHFFFAOYSA-N
DMXZ1HL	IU	2-benzhydryl-7-hydroxychromen-4-one
DMXZ1HL	DE	Discovery agent

DMQX9PD	ID	DMQX9PD
DMQX9PD	DN	2-Benzoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMQX9PD	HS	Investigative
DMQX9PD	SN	CHEMBL1098228; 2-Benzoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMQX9PD	DT	Small molecular drug
DMQX9PD	PC	46888005
DMQX9PD	MW	350.4
DMQX9PD	FM	C24H18N2O
DMQX9PD	IC	InChI=1S/C24H18N2O/c1-17-7-8-19-9-10-21(14-23(19)26-17)20-11-12-24(22(13-20)15-25)27-16-18-5-3-2-4-6-18/h2-14H,16H2,1H3
DMQX9PD	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=C(C=C3)OCC4=CC=CC=C4)C#N
DMQX9PD	IK	INOCIGKWKFGOCI-UHFFFAOYSA-N
DMQX9PD	IU	5-(2-methylquinolin-7-yl)-2-phenylmethoxybenzonitrile
DMQX9PD	DE	Discovery agent

DMO97FR	ID	DMO97FR
DMO97FR	DN	2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile
DMO97FR	HS	Investigative
DMO97FR	SN	Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
DMO97FR	DT	Small molecular drug
DMO97FR	PC	5328763
DMO97FR	MW	265.26
DMO97FR	FM	C16H11NO3
DMO97FR	IC	InChI=1S/C16H11NO3/c17-10-13(16(20)12-4-2-1-3-5-12)8-11-6-7-14(18)15(19)9-11/h1-9,18-19H/b13-8+
DMO97FR	CS	C1=CC=C(C=C1)C(=O)/C(=C/C2=CC(=C(C=C2)O)O)/C#N
DMO97FR	IK	QBKFKKGORMOFFU-MDWZMJQESA-N
DMO97FR	IU	(E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
DMO97FR	DE	Discovery agent

DMGEFQP	ID	DMGEFQP
DMGEFQP	DN	2-benzoylaminoquinazoline-4-carboxyanilide
DMGEFQP	HS	Investigative
DMGEFQP	SN	CHEMBL239194; 2-benzoylaminoquinazoline-4-carboxyanilide
DMGEFQP	DT	Small molecular drug
DMGEFQP	PC	24749708
DMGEFQP	MW	368.4
DMGEFQP	FM	C22H16N4O2
DMGEFQP	IC	InChI=1S/C22H16N4O2/c27-20(15-9-3-1-4-10-15)26-22-24-18-14-8-7-13-17(18)19(25-22)21(28)23-16-11-5-2-6-12-16/h1-14H,(H,23,28)(H,24,25,26,27)
DMGEFQP	CS	C1=CC=C(C=C1)C(=O)NC2=NC3=CC=CC=C3C(=N2)C(=O)NC4=CC=CC=C4
DMGEFQP	IK	RQQPFMNLXURQFV-UHFFFAOYSA-N
DMGEFQP	IU	2-benzamido-N-phenylquinazoline-4-carboxamide
DMGEFQP	DE	Discovery agent

DM1CB5J	ID	DM1CB5J
DM1CB5J	DN	2-Benzyl-1,2-dihydro-indazol-3-one
DM1CB5J	HS	Investigative
DM1CB5J	SN	2-Benzyl-1,2-dihydro-indazol-3-one; 1848-46-0; CHEMBL1984519; NSC34822; 2-benzyl-1H-indazol-3-one; SCHEMBL9645952; CHEMBL267523; AC1L91I6; CTK4D8835; DTXSID40328538; 2-Benzyl-1H-indazol-3(2H)-one; ZINC1667231; NSC-34822; BDBM50009000; AKOS015963502; FCH2821694; ACM1848460; NCI60_003094
DM1CB5J	DT	Small molecular drug
DM1CB5J	PC	411523
DM1CB5J	MW	224.26
DM1CB5J	FM	C14H12N2O
DM1CB5J	IC	InChI=1S/C14H12N2O/c17-14-12-8-4-5-9-13(12)15-16(14)10-11-6-2-1-3-7-11/h1-9,15H,10H2
DM1CB5J	CS	C1=CC=C(C=C1)CN2C(=O)C3=CC=CC=C3N2
DM1CB5J	IK	IBMDKBAGSDBZIJ-UHFFFAOYSA-N
DM1CB5J	IU	2-benzyl-1H-indazol-3-one
DM1CB5J	CA	CAS 1848-46-0
DM1CB5J	DE	Discovery agent

DMV7IWE	ID	DMV7IWE
DMV7IWE	DN	2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one
DMV7IWE	HS	Investigative
DMV7IWE	SN	CHEMBL573922
DMV7IWE	DT	Small molecular drug
DMV7IWE	PC	54736441
DMV7IWE	MW	306.4
DMV7IWE	FM	C20H18O3
DMV7IWE	IC	InChI=1S/C20H18O3/c21-19-16(12-13-6-2-1-3-7-13)20(22)23-17-11-10-14-8-4-5-9-15(14)18(17)19/h1-3,6-7,10-11,21H,4-5,8-9,12H2
DMV7IWE	CS	C1CCC2=C(C1)C=CC3=C2C(=C(C(=O)O3)CC4=CC=CC=C4)O
DMV7IWE	IK	VVGMGNIOZFKXQQ-UHFFFAOYSA-N
DMV7IWE	IU	2-benzyl-1-hydroxy-7,8,9,10-tetrahydrobenzo[f]chromen-3-one
DMV7IWE	DE	Discovery agent

DMPYB93	ID	DMPYB93
DMPYB93	DN	2-Benzyl-2H-indazole-7-carboxamide
DMPYB93	HS	Investigative
DMPYB93	SN	CHEMBL1094951; 2-Benzyl-2H-indazole-7-carboxamide; SCHEMBL2268172
DMPYB93	DT	Small molecular drug
DMPYB93	PC	44549372
DMPYB93	MW	251.28
DMPYB93	FM	C15H13N3O
DMPYB93	IC	InChI=1S/C15H13N3O/c16-15(19)13-8-4-7-12-10-18(17-14(12)13)9-11-5-2-1-3-6-11/h1-8,10H,9H2,(H2,16,19)
DMPYB93	CS	C1=CC=C(C=C1)CN2C=C3C=CC=C(C3=N2)C(=O)N
DMPYB93	IK	FCHCPSCDAOGWGQ-UHFFFAOYSA-N
DMPYB93	IU	2-benzylindazole-7-carboxamide
DMPYB93	DE	Discovery agent

DM6E04T	ID	DM6E04T
DM6E04T	DN	2-benzyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM6E04T	HS	Investigative
DM6E04T	SN	CHEMBL242205; 2-benzyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM6E04T	DT	Small molecular drug
DM6E04T	PC	10636110
DM6E04T	MW	275.3
DM6E04T	FM	C17H13N3O
DM6E04T	IC	InChI=1S/C17H13N3O/c21-17-16-14(13-8-4-5-9-15(13)18-17)11-20(19-16)10-12-6-2-1-3-7-12/h1-9,11H,10H2,(H,18,21)
DM6E04T	CS	C1=CC=C(C=C1)CN2C=C3C4=CC=CC=C4NC(=O)C3=N2
DM6E04T	IK	XJRYZVBNFXKWFF-UHFFFAOYSA-N
DM6E04T	IU	2-benzyl-5H-pyrazolo[3,4-c]quinolin-4-one
DM6E04T	DE	Discovery agent

DMANTCY	ID	DMANTCY
DMANTCY	DN	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole
DMANTCY	HS	Investigative
DMANTCY	SN	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole; SCHEMBL1407219; CHEMBL464189; BDBM26064; LGRUCHCYEMOENE-UHFFFAOYSA-N; 2-benzyl-3-aryl-7-trifluoromethylindazole, 5
DMANTCY	DT	Small molecular drug
DMANTCY	PC	25137977
DMANTCY	MW	352.4
DMANTCY	FM	C21H15F3N2
DMANTCY	IC	InChI=1S/C21H15F3N2/c22-21(23,24)18-13-7-12-17-19(18)25-26(14-15-8-3-1-4-9-15)20(17)16-10-5-2-6-11-16/h1-13H,14H2
DMANTCY	CS	C1=CC=C(C=C1)CN2C(=C3C=CC=C(C3=N2)C(F)(F)F)C4=CC=CC=C4
DMANTCY	IK	LGRUCHCYEMOENE-UHFFFAOYSA-N
DMANTCY	IU	2-benzyl-3-phenyl-7-(trifluoromethyl)indazole
DMANTCY	DE	Discovery agent

DMH76SO	ID	DMH76SO
DMH76SO	DN	2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione
DMH76SO	HS	Investigative
DMH76SO	SN	CHEMBL11516; 63586-13-0; 2-Benzyl-4,5,6,7-tetrachloro-isoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloro-1H-isoindole-1,3(2H)-dione; AC1LK1ZO; Oprea1_023833; 2-benzyl-4,5,6,7-tetrachloroisoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione; SCHEMBL10675358; CTK2A8819; DTXSID60359687; MolPort-001-020-850; ZINC630019; STK246502; BDBM50088678; AKOS003243470; MCULE-7798575308; N-Benzyl-3,4,5,6-tetrachlorophthalimide; ST50854964; AK-918/11423009; 4,5,6,7-tetrachloro-2-benzylbenzo[c]azolidine-1,3-dione
DMH76SO	DT	Small molecular drug
DMH76SO	PC	983732
DMH76SO	MW	375
DMH76SO	FM	C15H7Cl4NO2
DMH76SO	IC	InChI=1S/C15H7Cl4NO2/c16-10-8-9(11(17)13(19)12(10)18)15(22)20(14(8)21)6-7-4-2-1-3-5-7/h1-5H,6H2
DMH76SO	CS	C1=CC=C(C=C1)CN2C(=O)C3=C(C2=O)C(=C(C(=C3Cl)Cl)Cl)Cl
DMH76SO	IK	MQFQHWBPMPPVNJ-UHFFFAOYSA-N
DMH76SO	IU	2-benzyl-4,5,6,7-tetrachloroisoindole-1,3-dione
DMH76SO	CA	CAS 63586-13-0
DMH76SO	DE	Discovery agent

DMYGKW5	ID	DMYGKW5
DMYGKW5	DN	2-Benzyl-4-piperazin-1-yl-1H-benzimidazole
DMYGKW5	HS	Investigative
DMYGKW5	SN	CHEMBL578411; 2-Benzyl-4-piperazin-1-yl-1H-benzimidazole
DMYGKW5	DT	Small molecular drug
DMYGKW5	PC	45488131
DMYGKW5	MW	292.4
DMYGKW5	FM	C18H20N4
DMYGKW5	IC	InChI=1S/C18H20N4/c1-2-5-14(6-3-1)13-17-20-15-7-4-8-16(18(15)21-17)22-11-9-19-10-12-22/h1-8,19H,9-13H2,(H,20,21)
DMYGKW5	CS	C1CN(CCN1)C2=CC=CC3=C2N=C(N3)CC4=CC=CC=C4
DMYGKW5	IK	YTVICZASURPPDE-UHFFFAOYSA-N
DMYGKW5	IU	2-benzyl-4-piperazin-1-yl-1H-benzimidazole
DMYGKW5	DE	Discovery agent

DM3I7EL	ID	DM3I7EL
DM3I7EL	DN	2-benzyl-5-mercaptopentanoic acid
DM3I7EL	HS	Investigative
DM3I7EL	SN	Thiol-Based Inhibitor, 6a; Benzenepropanoic acid, alpha-(3-mercaptopropyl)-; CHEMBL383676; SCHEMBL5054359; CTK8A8855; BDBM17760; 2-benzyl-5-sulfanylpentanoic acid; AKOS015966158; 378242-19-4; 2-BENZYL-5-MERCAPTO-PENTANOIC ACID
DM3I7EL	DT	Small molecular drug
DM3I7EL	PC	9920926
DM3I7EL	MW	224.32
DM3I7EL	FM	C12H16O2S
DM3I7EL	IC	InChI=1S/C12H16O2S/c13-12(14)11(7-4-8-15)9-10-5-2-1-3-6-10/h1-3,5-6,11,15H,4,7-9H2,(H,13,14)
DM3I7EL	CS	C1=CC=C(C=C1)CC(CCCS)C(=O)O
DM3I7EL	IK	QTCRNIDSGWSKLN-UHFFFAOYSA-N
DM3I7EL	IU	2-benzyl-5-sulfanylpentanoic acid
DM3I7EL	DE	Discovery agent

DMGWRID	ID	DMGWRID
DMGWRID	DN	2-Benzyl-6-methoxy-5-oxazol-5-yl-1H-indole
DMGWRID	HS	Investigative
DMGWRID	SN	CHEMBL281635; 2-Benzyl-6-methoxy-5-oxazol-5-yl-1H-indole; SCHEMBL5831606; BDBM50126015
DMGWRID	DT	Small molecular drug
DMGWRID	PC	22238481
DMGWRID	MW	304.3
DMGWRID	FM	C19H16N2O2
DMGWRID	IC	InChI=1S/C19H16N2O2/c1-22-18-10-17-14(9-16(18)19-11-20-12-23-19)8-15(21-17)7-13-5-3-2-4-6-13/h2-6,8-12,21H,7H2,1H3
DMGWRID	CS	COC1=C(C=C2C=C(NC2=C1)CC3=CC=CC=C3)C4=CN=CO4
DMGWRID	IK	HWRLJNBXLQMWKB-UHFFFAOYSA-N
DMGWRID	IU	5-(2-benzyl-6-methoxy-1H-indol-5-yl)-1,3-oxazole
DMGWRID	DE	Discovery agent

DMAX5TC	ID	DMAX5TC
DMAX5TC	DN	2-Benzyl-7-hydroxy-chromen-4-one
DMAX5TC	HS	Investigative
DMAX5TC	SN	2-benzyl-7-hydroxy-chromen-4-one; CHEMBL56346; 2-Benzyl-7-hydroxychromone; ZINC12343959
DMAX5TC	DT	Small molecular drug
DMAX5TC	PC	10705949
DMAX5TC	MW	252.26
DMAX5TC	FM	C16H12O3
DMAX5TC	IC	InChI=1S/C16H12O3/c17-12-6-7-14-15(18)10-13(19-16(14)9-12)8-11-4-2-1-3-5-11/h1-7,9-10,17H,8H2
DMAX5TC	CS	C1=CC=C(C=C1)CC2=CC(=O)C3=C(O2)C=C(C=C3)O
DMAX5TC	IK	BQFDTKDYOCJBGZ-UHFFFAOYSA-N
DMAX5TC	IU	2-benzyl-7-hydroxychromen-4-one
DMAX5TC	DE	Discovery agent

DM6EMGJ	ID	DM6EMGJ
DM6EMGJ	DN	2-Benzylaminomethyl-3-hydroxymorphinan
DM6EMGJ	HS	Investigative
DM6EMGJ	SN	CHEMBL578173; 2-Benzylaminomethyl-3-hydroxymorphinan
DM6EMGJ	DT	Small molecular drug
DM6EMGJ	PC	44626544
DM6EMGJ	MW	376.5
DM6EMGJ	FM	C25H32N2O
DM6EMGJ	IC	InChI=1S/C25H32N2O/c1-27-12-11-25-10-6-5-9-21(25)23(27)14-19-13-20(24(28)15-22(19)25)17-26-16-18-7-3-2-4-8-18/h2-4,7-8,13,15,21,23,26,28H,5-6,9-12,14,16-17H2,1H3/t21-,23+,25+/m0/s1
DM6EMGJ	CS	CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=CC(=C(C=C34)O)CNCC5=CC=CC=C5
DM6EMGJ	IK	BGGKLNVUQJUZIE-QQKQFIJSSA-N
DM6EMGJ	IU	(1R,9R,10R)-5-[(benzylamino)methyl]-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-4-ol
DM6EMGJ	DE	Discovery agent

DMM48L6	ID	DMM48L6
DMM48L6	DN	2-Benzylbenzo[f]chromen-3-one
DMM48L6	HS	Investigative
DMM48L6	SN	CHEMBL513763; 2-Benzylbenzo[f]chromen-3-one; SCHEMBL15398169; BDBM50278257
DMM48L6	DT	Small molecular drug
DMM48L6	PC	10731937
DMM48L6	MW	286.3
DMM48L6	FM	C20H14O2
DMM48L6	IC	InChI=1S/C20H14O2/c21-20-16(12-14-6-2-1-3-7-14)13-18-17-9-5-4-8-15(17)10-11-19(18)22-20/h1-11,13H,12H2
DMM48L6	CS	C1=CC=C(C=C1)CC2=CC3=C(C=CC4=CC=CC=C43)OC2=O
DMM48L6	IK	OOALWLFUSOVWMV-UHFFFAOYSA-N
DMM48L6	IU	2-benzylbenzo[f]chromen-3-one
DMM48L6	DE	Discovery agent

DME7SAV	ID	DME7SAV
DME7SAV	DN	2-benzylisoquinoline-1,3,4-trione
DME7SAV	HS	Investigative
DME7SAV	SN	21640-35-7; 2-benzylisoquinoline-1,3,4-trione; 2-BENZYL-ISOQUINOLINE-1,3,4-TRIONE; CHEMBL382859; SCHEMBL13442853; Isoquinoline-1,3,4-trione 2c; BDBM10250; CTK4E7388; DTXSID80463477; ZINC13683129; AKOS015966149; FCH2821819; ACM21640357; 2-Benzylisoquinoline-1,3,4(2H)-trione; 2-Benzylisoquinoline-1,3,4(2H,4H)-trione; 1,3,4(2H)-Isoquinolinetrione,2-(phenylmethyl)-
DME7SAV	DT	Small molecular drug
DME7SAV	PC	11357566
DME7SAV	MW	265.26
DME7SAV	FM	C16H11NO3
DME7SAV	IC	InChI=1S/C16H11NO3/c18-14-12-8-4-5-9-13(12)15(19)17(16(14)20)10-11-6-2-1-3-7-11/h1-9H,10H2
DME7SAV	CS	C1=CC=C(C=C1)CN2C(=O)C3=CC=CC=C3C(=O)C2=O
DME7SAV	IK	MCRWFXGWJMDFON-UHFFFAOYSA-N
DME7SAV	IU	2-benzylisoquinoline-1,3,4-trione
DME7SAV	CA	CAS 21640-35-7
DME7SAV	DE	Discovery agent

DMF5MGQ	ID	DMF5MGQ
DMF5MGQ	DN	2-benzyl-N1-hydroxy-N3-(3-phenylpropyl)malonamide
DMF5MGQ	HS	Investigative
DMF5MGQ	SN	CHEMBL331784; 2-benzyl-N1-hydroxy-N3-(3-phenylpropyl)malonamide; SCHEMBL7357043; BDBM50062453
DMF5MGQ	DT	Small molecular drug
DMF5MGQ	PC	10592233
DMF5MGQ	MW	326.4
DMF5MGQ	FM	C19H22N2O3
DMF5MGQ	IC	InChI=1S/C19H22N2O3/c22-18(20-13-7-12-15-8-3-1-4-9-15)17(19(23)21-24)14-16-10-5-2-6-11-16/h1-6,8-11,17,24H,7,12-14H2,(H,20,22)(H,21,23)
DMF5MGQ	CS	C1=CC=C(C=C1)CCCNC(=O)C(CC2=CC=CC=C2)C(=O)NO
DMF5MGQ	IK	CQGGQNFRJIAPHA-UHFFFAOYSA-N
DMF5MGQ	IU	2-benzyl-N-hydroxy-N'-(3-phenylpropyl)propanediamide
DMF5MGQ	DE	Discovery agent

DMRVA94	ID	DMRVA94
DMRVA94	DN	2-benzyl-N1-hydroxy-N3-(4-phenylbutyl)malonamide
DMRVA94	HS	Investigative
DMRVA94	SN	CHEMBL220996; 2-benzyl-N1-hydroxy-N3-(4-phenylbutyl)malonamide; BDBM50197497
DMRVA94	DT	Small molecular drug
DMRVA94	PC	16115012
DMRVA94	MW	340.4
DMRVA94	FM	C20H24N2O3
DMRVA94	IC	InChI=1S/C20H24N2O3/c23-19(21-14-8-7-11-16-9-3-1-4-10-16)18(20(24)22-25)15-17-12-5-2-6-13-17/h1-6,9-10,12-13,18,25H,7-8,11,14-15H2,(H,21,23)(H,22,24)
DMRVA94	CS	C1=CC=C(C=C1)CCCCNC(=O)C(CC2=CC=CC=C2)C(=O)NO
DMRVA94	IK	WBIXUIDQAJRMSZ-UHFFFAOYSA-N
DMRVA94	IU	2-benzyl-N-hydroxy-N'-(4-phenylbutyl)propanediamide
DMRVA94	DE	Discovery agent

DM2BPIN	ID	DM2BPIN
DM2BPIN	DN	2-benzyl-N1-hydroxy-N3-phenethylmalonamide
DM2BPIN	HS	Investigative
DM2BPIN	SN	CHEMBL220434; 2-benzyl-N1-hydroxy-N3-phenethylmalonamide; BDBM50206544
DM2BPIN	DT	Small molecular drug
DM2BPIN	PC	16114889
DM2BPIN	MW	312.4
DM2BPIN	FM	C18H20N2O3
DM2BPIN	IC	InChI=1S/C18H20N2O3/c21-17(19-12-11-14-7-3-1-4-8-14)16(18(22)20-23)13-15-9-5-2-6-10-15/h1-10,16,23H,11-13H2,(H,19,21)(H,20,22)
DM2BPIN	CS	C1=CC=C(C=C1)CCNC(=O)C(CC2=CC=CC=C2)C(=O)NO
DM2BPIN	IK	GJBWQDWUWPUOOP-UHFFFAOYSA-N
DM2BPIN	IU	2-benzyl-N-hydroxy-N'-(2-phenylethyl)propanediamide
DM2BPIN	DE	Discovery agent

DMCLAXG	ID	DMCLAXG
DMCLAXG	DN	2-benzyloxy-7,8-dihydro-6H-quinolin-5-one
DMCLAXG	HS	Investigative
DMCLAXG	SN	CHEMBL400104; 2-benzyloxy-7,8-dihydro-6H-quinolin-5-one; SCHEMBL4275594; 2-(BENZYLOXY)-7,8-DIHYDROQUINOLIN-5(6H)-ONE; VGMBEUFDLPGOMH-UHFFFAOYSA-N; BDBM50231740; ZINC28967402; AB68928; 143232-64-8; 2-Benzyloxy-7,8-dihydroquinolin-5(6H)-one; 5,6,7,8-tetrahydro-2-(phenylmethoxy)-5-oxoquinoline; 5,6,7,8-Tetrahydro-5-oxo-2-(phenylmethoxy)quinoline
DMCLAXG	DT	Small molecular drug
DMCLAXG	PC	10444977
DMCLAXG	MW	253.29
DMCLAXG	FM	C16H15NO2
DMCLAXG	IC	InChI=1S/C16H15NO2/c18-15-8-4-7-14-13(15)9-10-16(17-14)19-11-12-5-2-1-3-6-12/h1-3,5-6,9-10H,4,7-8,11H2
DMCLAXG	CS	C1CC2=C(C=CC(=N2)OCC3=CC=CC=C3)C(=O)C1
DMCLAXG	IK	VGMBEUFDLPGOMH-UHFFFAOYSA-N
DMCLAXG	IU	2-phenylmethoxy-7,8-dihydro-6H-quinolin-5-one
DMCLAXG	CA	CAS 143232-64-8
DMCLAXG	DE	Discovery agent

DM6F0C4	ID	DM6F0C4
DM6F0C4	DN	2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine
DM6F0C4	HS	Investigative
DM6F0C4	SN	4-Amino-2-(benzylthio)-6-chloropyrimidine; 99983-92-3; CHEMBL124578; U-31,355; 2-benzylmercapto-4-amino-6-chloropyrimidine; 2-(benzylthio)-6-chloropyrimidin-4-amine; 2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine; AC1Q3RY2; AC1L3VC9; U 31355; SCHEMBL489860; 4-Pyrimidinamine, 6-chloro-2-((phenylmethyl)thio)-; U 31,355; CTK5I0853; ZINC21246; DTXSID20244368; LGTXUPUULSWTNA-UHFFFAOYSA-N; BDBM50066933; AKOS030548304; KB-239927; 2-benzylsulfanyl-6-chloropyrimidin-4-amine; 2-benzylsulfanyl-6-chloro-pyrimidin-4-amine
DM6F0C4	DT	Small molecular drug
DM6F0C4	PC	122830
DM6F0C4	MW	251.74
DM6F0C4	FM	C11H10ClN3S
DM6F0C4	IC	InChI=1S/C11H10ClN3S/c12-9-6-10(13)15-11(14-9)16-7-8-4-2-1-3-5-8/h1-6H,7H2,(H2,13,14,15)
DM6F0C4	CS	C1=CC=C(C=C1)CSC2=NC(=CC(=N2)Cl)N
DM6F0C4	IK	LGTXUPUULSWTNA-UHFFFAOYSA-N
DM6F0C4	IU	2-benzylsulfanyl-6-chloropyrimidin-4-amine
DM6F0C4	CA	CAS 99983-92-3
DM6F0C4	DE	Discovery agent

DMV4OY2	ID	DMV4OY2
DMV4OY2	DN	2beta,3alpha-dihydroxyolean-12-en-28-oic acid
DMV4OY2	HS	Investigative
DMV4OY2	SN	bredemolic acid; CHEMBL577380; 5957-40-4; ZINC8952016; BDBM50346696
DMV4OY2	DT	Small molecular drug
DMV4OY2	PC	25156878
DMV4OY2	MW	472.7
DMV4OY2	FM	C30H48O4
DMV4OY2	IC	InChI=1S/C30H48O4/c1-25(2)12-14-30(24(33)34)15-13-28(6)18(19(30)16-25)8-9-22-27(5)17-20(31)23(32)26(3,4)21(27)10-11-29(22,28)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20-,21-,22+,23+,27-,28+,29+,30-/m0/s1
DMV4OY2	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H]([C@H](C3(C)C)O)O)C
DMV4OY2	IK	MDZKJHQSJHYOHJ-SXISEVPCSA-N
DMV4OY2	IU	(4aS,6aR,6aS,6bR,8aR,10S,11S,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMV4OY2	DE	Discovery agent

DMU4Q8C	ID	DMU4Q8C
DMU4Q8C	DN	2beta,3alpha-dihydroxyurs-12-en-28-oic acid
DMU4Q8C	HS	Investigative
DMU4Q8C	SN	CHEMBL574993; SCHEMBL4456541; (2beta,3alpha)-2,3-Dihydroxy-urs-12-en-28-oic acid; BDBM50346702; ZINC49708319; 856012-03-8; 2beta,3alpha-Dihydroxyurs-12-ene-28-oic acid; 012A038; Adbeta,3a)-2,3-dihydroxy-urs-12-en-28-oic acid
DMU4Q8C	DT	Small molecular drug
DMU4Q8C	PC	45481653
DMU4Q8C	MW	472.7
DMU4Q8C	FM	C30H48O4
DMU4Q8C	IC	InChI=1S/C30H48O4/c1-17-10-13-30(25(33)34)15-14-28(6)19(23(30)18(17)2)8-9-22-27(5)16-20(31)24(32)26(3,4)21(27)11-12-29(22,28)7/h8,17-18,20-24,31-32H,9-16H2,1-7H3,(H,33,34)/t17-,18+,20+,21+,22-,23+,24-,27+,28-,29-,30+/m1/s1
DMU4Q8C	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H]([C@H](C5(C)C)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMU4Q8C	IK	HFGSQOYIOKBQOW-FEZPFBHMSA-N
DMU4Q8C	IU	(1S,2R,4aS,6aR,6aS,6bR,8aR,10S,11S,12aR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMU4Q8C	DE	Discovery agent

DMWZ4KN	ID	DMWZ4KN
DMWZ4KN	DN	2beta-methoxy-2-deethoxyphantomolin
DMWZ4KN	HS	Investigative
DMWZ4KN	DT	Small molecular drug
DMWZ4KN	PC	70697849
DMWZ4KN	MW	360.4
DMWZ4KN	FM	C20H24O6
DMWZ4KN	IC	InChI=1S/C20H24O6/c1-10(2)18(21)24-14-7-11(3)8-20(23-6)9-12(4)16(26-20)17-15(14)13(5)19(22)25-17/h8-9,14-17H,1,5,7H2,2-4,6H3/b11-8+/t14-,15+,16-,17-,20-/m0/s1
DMWZ4KN	CS	C/C/1=C\\[C@]2(C=C([C@H](O2)[C@@H]3[C@@H]([C@H](C1)OC(=O)C(=C)C)C(=C)C(=O)O3)C)OC
DMWZ4KN	IK	CSIBMGLPBAXXSG-FWTBDAJASA-N
DMWZ4KN	IU	[(1S,2S,6R,7S,9E,11S)-11-methoxy-9,13-dimethyl-5-methylidene-4-oxo-3,14-dioxatricyclo[9.2.1.02,6]tetradeca-9,12-dien-7-yl] 2-methylprop-2-enoate
DMWZ4KN	CB	CHEBI:65835
DMWZ4KN	DE	Discovery agent

DMFAW4R	ID	DMFAW4R
DMFAW4R	DN	2-BFi
DMFAW4R	HS	Investigative
DMFAW4R	SN	2-Benzofuran-2-yl-4,5-dihydro-1H-imidazole
DMFAW4R	DT	Small molecular drug
DMFAW4R	PC	3080926
DMFAW4R	MW	186.21
DMFAW4R	FM	C11H10N2O
DMFAW4R	IC	InChI=1S/C11H10N2O/c1-2-4-9-8(3-1)7-10(14-9)11-12-5-6-13-11/h1-4,7H,5-6H2,(H,12,13)
DMFAW4R	CS	C1CN=C(N1)C2=CC3=CC=CC=C3O2
DMFAW4R	IK	YTJOHEUHUVBKSB-UHFFFAOYSA-N
DMFAW4R	IU	2-(1-benzofuran-2-yl)-4,5-dihydro-1H-imidazole
DMFAW4R	CA	CAS 72583-92-7
DMFAW4R	CB	CHEBI:103964
DMFAW4R	DE	Discovery agent

DMHS3N6	ID	DMHS3N6
DMHS3N6	DN	2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone
DMHS3N6	HS	Investigative
DMHS3N6	SN	CHEMBL240469; 2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone
DMHS3N6	DT	Small molecular drug
DMHS3N6	PC	44435201
DMHS3N6	MW	393.5
DMHS3N6	FM	C26H19NOS
DMHS3N6	IC	InChI=1S/C26H19NOS/c28-26(18-19-14-16-21(17-15-19)20-8-2-1-3-9-20)27-22-10-4-6-12-24(22)29-25-13-7-5-11-23(25)27/h1-17H,18H2
DMHS3N6	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DMHS3N6	IK	HQYQYXMOSDNQPG-UHFFFAOYSA-N
DMHS3N6	IU	1-phenothiazin-10-yl-2-(4-phenylphenyl)ethanone
DMHS3N6	DE	Discovery agent

DML1W5Z	ID	DML1W5Z
DML1W5Z	DN	2-biphenyl-4-yl-6-morpholin-4-yl-pyran-4-one
DML1W5Z	HS	Investigative
DML1W5Z	SN	CHEMBL426894; 2-biphenyl-4-yl-6-morpholin-4-yl-pyran-4-one
DML1W5Z	DT	Small molecular drug
DML1W5Z	PC	16203714
DML1W5Z	MW	333.4
DML1W5Z	FM	C21H19NO3
DML1W5Z	IC	InChI=1S/C21H19NO3/c23-19-14-20(25-21(15-19)22-10-12-24-13-11-22)18-8-6-17(7-9-18)16-4-2-1-3-5-16/h1-9,14-15H,10-13H2
DML1W5Z	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=C(C=C3)C4=CC=CC=C4
DML1W5Z	IK	MIZPDLBPZZKHCN-UHFFFAOYSA-N
DML1W5Z	IU	2-morpholin-4-yl-6-(4-phenylphenyl)pyran-4-one
DML1W5Z	DE	Discovery agent

DMWOJ5N	ID	DMWOJ5N
DMWOJ5N	DN	2-Biphenyl-4-yl-N-hydroxy-N-methyl-acetamide
DMWOJ5N	HS	Investigative
DMWOJ5N	SN	CHEMBL174051; 2-Biphenyl-4-yl-N-hydroxy-N-methyl-acetamide; BDBM50015169
DMWOJ5N	DT	Small molecular drug
DMWOJ5N	PC	13670400
DMWOJ5N	MW	241.28
DMWOJ5N	FM	C15H15NO2
DMWOJ5N	IC	InChI=1S/C15H15NO2/c1-16(18)15(17)11-12-7-9-14(10-8-12)13-5-3-2-4-6-13/h2-10,18H,11H2,1H3
DMWOJ5N	CS	CN(C(=O)CC1=CC=C(C=C1)C2=CC=CC=C2)O
DMWOJ5N	IK	OKCNSKAFTYDWAP-UHFFFAOYSA-N
DMWOJ5N	IU	N-hydroxy-N-methyl-2-(4-phenylphenyl)acetamide
DMWOJ5N	DE	Discovery agent

DMCM01R	ID	DMCM01R
DMCM01R	DN	2-bromo-4-(3-fluorophenylethynyl)thiazole
DMCM01R	HS	Investigative
DMCM01R	SN	2-bromo-4-(3-fluorophenylethynyl)thiazole; CHEMBL382491; 878018-74-7; SCHEMBL4145773; CTK2I2017; DTXSID80468225; ZINC13680939; BDBM50181781; AKOS015965444; KB-228728; Thiazole, 2-bromo-4-[(3-fluorophenyl)ethynyl]-
DMCM01R	DT	Small molecular drug
DMCM01R	PC	11536470
DMCM01R	MW	282.13
DMCM01R	FM	C11H5BrFNS
DMCM01R	IC	InChI=1S/C11H5BrFNS/c12-11-14-10(7-15-11)5-4-8-2-1-3-9(13)6-8/h1-3,6-7H
DMCM01R	CS	C1=CC(=CC(=C1)F)C#CC2=CSC(=N2)Br
DMCM01R	IK	XPOUXVRKZDTDJY-UHFFFAOYSA-N
DMCM01R	IU	2-bromo-4-[2-(3-fluorophenyl)ethynyl]-1,3-thiazole
DMCM01R	CA	CAS 878018-74-7
DMCM01R	DE	Discovery agent

DMJ0368	ID	DMJ0368
DMJ0368	DN	2-bromo-4-methylphenyl 2-nitrobenzoate
DMJ0368	HS	Investigative
DMJ0368	SN	2-bromo-4-methylphenyl 2-nitrobenzoate; CHEMBL549456; AC1LDUV8; Oprea1_572597; Oprea1_573870; ARONIS001613; ZINC38499; MolPort-001-525-391; KS-00003V1E; STK096466; BDBM50297528; AKOS000491705; MCULE-5867447196; ST054603; (2-bromo-4-methylphenyl) 2-nitrobenzoate
DMJ0368	DT	Small molecular drug
DMJ0368	PC	675658
DMJ0368	MW	336.14
DMJ0368	FM	C14H10BrNO4
DMJ0368	IC	InChI=1S/C14H10BrNO4/c1-9-6-7-13(11(15)8-9)20-14(17)10-4-2-3-5-12(10)16(18)19/h2-8H,1H3
DMJ0368	CS	CC1=CC(=C(C=C1)OC(=O)C2=CC=CC=C2[N+](=O)[O-])Br
DMJ0368	IK	GWWHSLCVPYBDPI-UHFFFAOYSA-N
DMJ0368	IU	(2-bromo-4-methylphenyl) 2-nitrobenzoate
DMJ0368	DE	Discovery agent

DMIHJSA	ID	DMIHJSA
DMIHJSA	DN	2-Bromoacetyl Group
DMIHJSA	HS	Investigative
DMIHJSA	SN	BROMOACETIC ACID; 2-Bromoacetic acid; 79-08-3; Monobromoacetic acid; Bromoethanoic acid; Acetic acid, bromo-; To NTU; Bromoacetate ion; Acide bromacetique; 2-bromoethanoic acid; 2-Bromoacetyl Group; Monobromessigsaeure; Acetic acid, 2-bromo-; Bromo-acetic acid; Kyselina bromoctova; alpha-Bromoacetic acid; Caswell No. 112A; NSC 141; .alpha.-Bromoacetic acid; Acide bromacetique [French]; Kyselina bromoctova [Czech]; Monobromessigsaeure [German]; CCRIS 7886; UNII-2B3HS32431; Acetic acid, bromo-, (solution); alpha-Bromoethanoic acid
DMIHJSA	DT	Small molecular drug
DMIHJSA	PC	6227
DMIHJSA	MW	138.95
DMIHJSA	FM	C2H3BrO2
DMIHJSA	IC	InChI=1S/C2H3BrO2/c3-1-2(4)5/h1H2,(H,4,5)
DMIHJSA	CS	C(C(=O)O)Br
DMIHJSA	IK	KDPAWGWELVVRCH-UHFFFAOYSA-N
DMIHJSA	IU	2-bromoacetic acid
DMIHJSA	CA	CAS 79-08-3
DMIHJSA	DE	Discovery agent

DMOYCWU	ID	DMOYCWU
DMOYCWU	DN	2-bromo-LSD
DMOYCWU	HS	Investigative
DMOYCWU	SN	2-bromolysergic acid diethylamide; 2-br-LSD; bromolysergide
DMOYCWU	DT	Small molecular drug
DMOYCWU	PC	10171
DMOYCWU	MW	402.3
DMOYCWU	FM	C20H24BrN3O
DMOYCWU	IC	InChI=1S/C20H24BrN3O/c1-4-24(5-2)20(25)12-9-14-13-7-6-8-16-18(13)15(19(21)22-16)10-17(14)23(3)11-12/h6-9,12,17,22H,4-5,10-11H2,1-3H3/t12-,17-/m1/s1
DMOYCWU	CS	CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)Br)C
DMOYCWU	IK	VKRAXSZEDRWLAG-SJKOYZFVSA-N
DMOYCWU	IU	(6aR,9R)-5-bromo-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMOYCWU	CA	CAS 478-84-2
DMOYCWU	DE	Discovery agent

DMYCENM	ID	DMYCENM
DMYCENM	DN	2-Bromo-N-(2-morpholinoethyl)nicotinamide
DMYCENM	HS	Investigative
DMYCENM	SN	2-Bromo-N-(2-morpholinoethyl)nicotinamide; CHEMBL607864; BDBM50307208
DMYCENM	DT	Small molecular drug
DMYCENM	PC	46233338
DMYCENM	MW	314.18
DMYCENM	FM	C12H16BrN3O2
DMYCENM	IC	InChI=1S/C12H16BrN3O2/c13-11-10(2-1-3-14-11)12(17)15-4-5-16-6-8-18-9-7-16/h1-3H,4-9H2,(H,15,17)
DMYCENM	CS	C1COCCN1CCNC(=O)C2=C(N=CC=C2)Br
DMYCENM	IK	FKGFLJZEVNCAEZ-UHFFFAOYSA-N
DMYCENM	IU	2-bromo-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMYCENM	DE	Discovery agent

DM9NMIO	ID	DM9NMIO
DM9NMIO	DN	2-Bromo-N-(3-morpholinopropyl)nicotinamide
DM9NMIO	HS	Investigative
DM9NMIO	SN	CHEMBL598373; 2-Bromo-N-(3-morpholinopropyl)nicotinamide
DM9NMIO	DT	Small molecular drug
DM9NMIO	PC	46233404
DM9NMIO	MW	328.2
DM9NMIO	FM	C13H18BrN3O2
DM9NMIO	IC	InChI=1S/C13H18BrN3O2/c14-12-11(3-1-4-15-12)13(18)16-5-2-6-17-7-9-19-10-8-17/h1,3-4H,2,5-10H2,(H,16,18)
DM9NMIO	CS	C1COCCN1CCCNC(=O)C2=C(N=CC=C2)Br
DM9NMIO	IK	ZMORGFKKKAMCBI-UHFFFAOYSA-N
DM9NMIO	IU	2-bromo-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DM9NMIO	DE	Discovery agent

DM6JDIY	ID	DM6JDIY
DM6JDIY	DN	2-bromophenol
DM6JDIY	HS	Investigative
DM6JDIY	SN	2-BROMOPHENOL; 95-56-7; o-Bromophenol; Phenol, 2-bromo-; BROMOPHENOL; 2-Bromfenol; 2-Bromo-phenol; Phenol, o-bromo-; o-bromo-phenol; 2-bromo phenol; Phenol, bromo-; 2-Bromfenol [Czech]; NSC 6970; bromophenol, 2-; UNII-A0UB206YF0; 2-Bromophenol, 98%; EINECS 202-432-7; 1-Bromo-2-hydroxybenzene; BRN 1905115; CHEMBL186007; A0UB206YF0; 2-BROMO-1-HYDROXYBENZENE; VADKRMSMGWJZCF-UHFFFAOYSA-N; MFCD00002146; 32762-51-9; ortho-bromophenol; 2BR; bromphenol; bromo-phenol; bromo phenol; 2-bromanylphenol; HSDB 7648; ortho-bromo-phenol; EINECS 251-200-1
DM6JDIY	DT	Small molecular drug
DM6JDIY	PC	7244
DM6JDIY	MW	173.01
DM6JDIY	FM	C6H5BrO
DM6JDIY	IC	InChI=1S/C6H5BrO/c7-5-3-1-2-4-6(5)8/h1-4,8H
DM6JDIY	CS	C1=CC=C(C(=C1)O)Br
DM6JDIY	IK	VADKRMSMGWJZCF-UHFFFAOYSA-N
DM6JDIY	IU	2-bromophenol
DM6JDIY	CA	CAS 95-56-7
DM6JDIY	CB	CHEBI:34264
DM6JDIY	DE	Discovery agent

DMY7RM8	ID	DMY7RM8
DMY7RM8	DN	2-Butyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione
DMY7RM8	HS	Investigative
DMY7RM8	SN	CHEMBL593752
DMY7RM8	DT	Small molecular drug
DMY7RM8	PC	44251145
DMY7RM8	MW	304.3
DMY7RM8	FM	C19H16N2O2
DMY7RM8	IC	InChI=1S/C19H16N2O2/c1-2-3-8-15-20-14-10-9-13-16(17(14)21-15)19(23)12-7-5-4-6-11(12)18(13)22/h4-7,9-10H,2-3,8H2,1H3,(H,20,21)
DMY7RM8	CS	CCCCC1=NC2=C(N1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O
DMY7RM8	IK	DSPOAQONKLYCKM-UHFFFAOYSA-N
DMY7RM8	IU	2-butyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMY7RM8	DE	Discovery agent

DML9MCU	ID	DML9MCU
DML9MCU	DN	2-butylamido-5-sulfonamidoindane
DML9MCU	HS	Investigative
DML9MCU	SN	CHEMBL208531; 2-butylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 12f; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)pentanamide
DML9MCU	DT	Small molecular drug
DML9MCU	PC	11529486
DML9MCU	MW	296.39
DML9MCU	FM	C14H20N2O3S
DML9MCU	IC	InChI=1S/C14H20N2O3S/c1-2-3-4-14(17)16-12-7-10-5-6-13(20(15,18)19)9-11(10)8-12/h5-6,9,12H,2-4,7-8H2,1H3,(H,16,17)(H2,15,18,19)
DML9MCU	CS	CCCCC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DML9MCU	IK	VPKYLHQTQYEJLJ-UHFFFAOYSA-N
DML9MCU	IU	N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)pentanamide
DML9MCU	DE	Discovery agent

DMG5SAQ	ID	DMG5SAQ
DMG5SAQ	DN	2-chloro-1-(5-(pyridin-2-yl)oxazol-2-yl)ethanone
DMG5SAQ	HS	Investigative
DMG5SAQ	SN	2-chloro-1-(5-(pyridin-2-yl)oxazol-2-yl)ethanone; 945414-11-9; alpha-ketooxazole, 14f; SCHEMBL710273; CHEMBL229323; BDBM23135; MKVLXIACPLGLLP-UHFFFAOYSA-N; ZINC14980143; DA-40252; FT-0713758
DMG5SAQ	DT	Small molecular drug
DMG5SAQ	PC	16735859
DMG5SAQ	MW	222.63
DMG5SAQ	FM	C10H7ClN2O2
DMG5SAQ	IC	InChI=1S/C10H7ClN2O2/c11-5-8(14)10-13-6-9(15-10)7-3-1-2-4-12-7/h1-4,6H,5H2
DMG5SAQ	CS	C1=CC=NC(=C1)C2=CN=C(O2)C(=O)CCl
DMG5SAQ	IK	MKVLXIACPLGLLP-UHFFFAOYSA-N
DMG5SAQ	IU	2-chloro-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)ethanone
DMG5SAQ	DE	Discovery agent

DMD3ZNP	ID	DMD3ZNP
DMD3ZNP	DN	2-chloro-2'-C-methyl-tecadenoson
DMD3ZNP	HS	Investigative
DMD3ZNP	SN	CHEMBL400782; 2-chloro-2''-C-methyl-tecadenoson
DMD3ZNP	DT	Small molecular drug
DMD3ZNP	PC	44447548
DMD3ZNP	MW	385.8
DMD3ZNP	FM	C15H20ClN5O5
DMD3ZNP	IC	InChI=1S/C15H20ClN5O5/c1-15(24)10(23)8(4-22)26-13(15)21-6-17-9-11(18-7-2-3-25-5-7)19-14(16)20-12(9)21/h6-8,10,13,22-24H,2-5H2,1H3,(H,18,19,20)/t7-,8-,10-,13-,15-/m1/s1
DMD3ZNP	CS	C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N[C@@H]4CCOC4)CO)O)O
DMD3ZNP	IK	PKAKDOUFCOQHOJ-RAPCHXAISA-N
DMD3ZNP	IU	(2R,3R,4R,5R)-2-[2-chloro-6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
DMD3ZNP	DE	Discovery agent

DMTPKU8	ID	DMTPKU8
DMTPKU8	DN	2-chloro-4-(o-tolyloxy)benzonitrile
DMTPKU8	HS	Investigative
DMTPKU8	SN	CHEMBL470204; 2-chloro-4-(o-tolyloxy)benzonitrile; SCHEMBL4175953; BDBM50278226
DMTPKU8	DT	Small molecular drug
DMTPKU8	PC	11507014
DMTPKU8	MW	243.69
DMTPKU8	FM	C14H10ClNO
DMTPKU8	IC	InChI=1S/C14H10ClNO/c1-10-4-2-3-5-14(10)17-12-7-6-11(9-16)13(15)8-12/h2-8H,1H3
DMTPKU8	CS	CC1=CC=CC=C1OC2=CC(=C(C=C2)C#N)Cl
DMTPKU8	IK	NOLQETBWRAYXMF-UHFFFAOYSA-N
DMTPKU8	IU	2-chloro-4-(2-methylphenoxy)benzonitrile
DMTPKU8	DE	Discovery agent

DMPCRLY	ID	DMPCRLY
DMPCRLY	DN	2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMPCRLY	HS	Investigative
DMPCRLY	SN	CHEMBL260773; 2-Chloro-4-(2-thiazolyl)thieno[3,2-d]pyrimidine; 443148-15-0; SCHEMBL3679573; GWBPGRWRSLAHEX-UHFFFAOYSA-N
DMPCRLY	DT	Small molecular drug
DMPCRLY	PC	44449565
DMPCRLY	MW	253.7
DMPCRLY	FM	C9H4ClN3S2
DMPCRLY	IC	InChI=1S/C9H4ClN3S2/c10-9-12-5-1-3-14-7(5)6(13-9)8-11-2-4-15-8/h1-4H
DMPCRLY	CS	C1=CSC2=C1N=C(N=C2C3=NC=CS3)Cl
DMPCRLY	IK	GWBPGRWRSLAHEX-UHFFFAOYSA-N
DMPCRLY	IU	2-chloro-4-(1,3-thiazol-2-yl)thieno[3,2-d]pyrimidine
DMPCRLY	DE	Discovery agent

DMC5OQ3	ID	DMC5OQ3
DMC5OQ3	DN	2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine
DMC5OQ3	HS	Investigative
DMC5OQ3	SN	CHEMBL253753; Thieno[3,2-d]pyrimidine, 2-chloro-4-(2-thienyl)-; SCHEMBL3682427; BDBM50377508
DMC5OQ3	DT	Small molecular drug
DMC5OQ3	PC	44449257
DMC5OQ3	MW	252.7
DMC5OQ3	FM	C10H5ClN2S2
DMC5OQ3	IC	InChI=1S/C10H5ClN2S2/c11-10-12-6-3-5-15-9(6)8(13-10)7-2-1-4-14-7/h1-5H
DMC5OQ3	CS	C1=CSC(=C1)C2=NC(=NC3=C2SC=C3)Cl
DMC5OQ3	IK	GFDPXLUZWJSHBL-UHFFFAOYSA-N
DMC5OQ3	IU	2-chloro-4-thiophen-2-ylthieno[3,2-d]pyrimidine
DMC5OQ3	DE	Discovery agent

DM5KR4B	ID	DM5KR4B
DM5KR4B	DN	2-Chloro-5-(2-methylquinolin-7-yl)nicotinonitrile
DM5KR4B	HS	Investigative
DM5KR4B	SN	CHEMBL1096196; 2-Chloro-5-(2-methylquinolin-7-yl)nicotinonitrile
DM5KR4B	DT	Small molecular drug
DM5KR4B	PC	46888088
DM5KR4B	MW	279.72
DM5KR4B	FM	C16H10ClN3
DM5KR4B	IC	InChI=1S/C16H10ClN3/c1-10-2-3-11-4-5-12(7-15(11)20-10)14-6-13(8-18)16(17)19-9-14/h2-7,9H,1H3
DM5KR4B	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=C(N=C3)Cl)C#N
DM5KR4B	IK	FCXAJLFDBPZDJD-UHFFFAOYSA-N
DM5KR4B	IU	2-chloro-5-(2-methylquinolin-7-yl)pyridine-3-carbonitrile
DM5KR4B	DE	Discovery agent

DMUGQIV	ID	DMUGQIV
DMUGQIV	DN	2-chloro-5-nitro-N-phenylbenzamide
DMUGQIV	HS	Investigative
DMUGQIV	SN	2-Chloro-5-nitro-N-phenylbenzamide; GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213
DMUGQIV	DT	Small molecular drug
DMUGQIV	PC	644213
DMUGQIV	MW	276.67
DMUGQIV	FM	C13H9ClN2O3
DMUGQIV	IC	InChI=1S/C13H9ClN2O3/c14-12-7-6-10(16(18)19)8-11(12)13(17)15-9-4-2-1-3-5-9/h1-8H,(H,15,17)
DMUGQIV	CS	C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])Cl
DMUGQIV	IK	DNTSIBUQMRRYIU-UHFFFAOYSA-N
DMUGQIV	IU	2-chloro-5-nitro-N-phenylbenzamide
DMUGQIV	CA	CAS 22978-25-2
DMUGQIV	CB	CHEBI:79993
DMUGQIV	DE	Discovery agent

DML0S8M	ID	DML0S8M
DML0S8M	DN	2-chloro-6(methylamino)purine
DML0S8M	HS	Investigative
DML0S8M	SN	2-Chloro-6(methylamino)purine; 82499-02-3; 2-CHLORO-N-METHYL-9H-PURIN-6-AMINE; 2-chloro-N-methyl-7H-purin-6-amine; CHEMBL446449; 2-Chloro-6-(methylamino)purine; 2-CHLORO-6-(N-METHYLAMINO)-9H-PURINE; ACMC-20anyt; PubChem9784; 2-chloro-6-methylaminopurine; SCHEMBL130696; AC1NE105; CTK5E9746; DTXSID00404544; RIAVUEFUPHOGJY-UHFFFAOYSA-N; 2-Chloro-6-methylamino-9H-purine; NSC15416; ZINC4429067; NSC-15416; BDBM50208873; AKOS006283488; AKOS015894684; 2-Chloro-6(methylamino)purine, 97%; AB44277; TC-170732
DML0S8M	DT	Small molecular drug
DML0S8M	PC	4584789
DML0S8M	MW	183.6
DML0S8M	FM	C6H6ClN5
DML0S8M	IC	InChI=1S/C6H6ClN5/c1-8-4-3-5(10-2-9-3)12-6(7)11-4/h2H,1H3,(H2,8,9,10,11,12)
DML0S8M	CS	CNC1=NC(=NC2=C1NC=N2)Cl
DML0S8M	IK	RIAVUEFUPHOGJY-UHFFFAOYSA-N
DML0S8M	IU	2-chloro-N-methyl-7H-purin-6-amine
DML0S8M	CA	CAS 82499-02-3
DML0S8M	DE	Discovery agent

DMYPQEW	ID	DMYPQEW
DMYPQEW	DN	2-chloroadenosine
DMYPQEW	HS	Investigative
DMYPQEW	SN	2Cl-Ado; CADO
DMYPQEW	DT	Small molecular drug
DMYPQEW	PC	8974
DMYPQEW	MW	301.69
DMYPQEW	FM	C10H12ClN5O4
DMYPQEW	IC	InChI=1S/C10H12ClN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6-,9-/m1/s1
DMYPQEW	CS	C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)Cl)N
DMYPQEW	IK	BIXYYZIIJIXVFW-UUOKFMHZSA-N
DMYPQEW	IU	(2R,3R,4S,5R)-2-(6-amino-2-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMYPQEW	CA	CAS 146-77-0
DMYPQEW	CB	CHEBI:125640
DMYPQEW	DE	Discovery agent

DMQUDA9	ID	DMQUDA9
DMQUDA9	DN	2-chloroadenosine-5-triphosphate
DMQUDA9	HS	Investigative
DMQUDA9	SN	2-chloro-ATP
DMQUDA9	DT	Small molecular drug
DMQUDA9	PC	162565
DMQUDA9	MW	541.62
DMQUDA9	FM	C10H15ClN5O13P3
DMQUDA9	IC	InChI=1S/C10H15ClN5O13P3/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(27-9)1-26-31(22,23)29-32(24,25)28-30(19,20)21/h2-3,5-6,9,17-18H,1H2,(H,22,23)(H,24,25)(H2,12,14,15)(H2,19,20,21)/t3-,5-,6-,9-/m1/s1
DMQUDA9	CS	C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)Cl)N
DMQUDA9	IK	RNGCVFCOKZEZFL-UUOKFMHZSA-N
DMQUDA9	IU	[[(2R,3S,4R,5R)-5-(6-amino-2-chloropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMQUDA9	CA	CAS 49564-60-5
DMQUDA9	DE	Discovery agent

DMI89RL	ID	DMI89RL
DMI89RL	DN	2-Chlorobenzenemethanethiol
DMI89RL	HS	Investigative
DMI89RL	SN	2-Chlorobenzenemethanethiol; 39718-00-8; (2-Chlorophenyl)methanethiol; 2-Chlorobenzyl mercaptan; 2-Chlorobenzylmercaptan; 2-Chloro benzyl mercaptan; Benzenemethanethiol, 2-chloro-; CHEMBL1224556; WWFIIZLHSNBNTC-UHFFFAOYSA-N; 2-Chlorobenzyl mercaptan, 98%; o-chlorobenzylmercaptan; PubChem6836; AC1Q3PHW; AC1LBDF6; 2-chlorophenylmethanethiol; 2-chlorophenyl-methanethiol; 2-chloro-alpha-toluenethiol; ACMC-1CT33; SCHEMBL646102; (2-Chlorophenyl)methanethiol #; o-chlorotoluene-&amp;#x3B1;-thiol; CTK3J1402
DMI89RL	DT	Small molecular drug
DMI89RL	PC	580759
DMI89RL	MW	158.65
DMI89RL	FM	C7H7ClS
DMI89RL	IC	InChI=1S/C7H7ClS/c8-7-4-2-1-3-6(7)5-9/h1-4,9H,5H2
DMI89RL	CS	C1=CC=C(C(=C1)CS)Cl
DMI89RL	IK	WWFIIZLHSNBNTC-UHFFFAOYSA-N
DMI89RL	IU	(2-chlorophenyl)methanethiol
DMI89RL	CA	CAS 39718-00-8
DMI89RL	DE	Discovery agent

DMR8M36	ID	DMR8M36
DMR8M36	DN	2-Chloro-N-(2-morpholinoethyl)nicotinamide
DMR8M36	HS	Investigative
DMR8M36	SN	2-Chloro-N-(2-morpholinoethyl)nicotinamide; CHEMBL598814; 551901-48-5; 2-CHLORO-N-[2-(MORPHOLIN-4-YL)ETHYL]PYRIDINE-3-CARBOXAMIDE; AC1MRDK5; CTK7F9629; 2-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide; MolPort-003-989-877; ZINC19387520; BDBM50307207; AKOS000160265
DMR8M36	DT	Small molecular drug
DMR8M36	PC	3466480
DMR8M36	MW	269.73
DMR8M36	FM	C12H16ClN3O2
DMR8M36	IC	InChI=1S/C12H16ClN3O2/c13-11-10(2-1-3-14-11)12(17)15-4-5-16-6-8-18-9-7-16/h1-3H,4-9H2,(H,15,17)
DMR8M36	CS	C1COCCN1CCNC(=O)C2=C(N=CC=C2)Cl
DMR8M36	IK	DSNJJTFFMQNNPE-UHFFFAOYSA-N
DMR8M36	IU	2-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMR8M36	DE	Discovery agent

DM2W71L	ID	DM2W71L
DM2W71L	DN	2-chloro-N-(3-(3-chlorobenzamido)phenyl)benzamide
DM2W71L	HS	Investigative
DM2W71L	SN	CHEMBL1088311; 2-chloro-N-(3-(3-chlorobenzamido)phenyl)benzamide
DM2W71L	DT	Small molecular drug
DM2W71L	PC	45375908
DM2W71L	MW	385.2
DM2W71L	FM	C20H14Cl2N2O2
DM2W71L	IC	InChI=1S/C20H14Cl2N2O2/c21-14-6-3-5-13(11-14)19(25)23-15-7-4-8-16(12-15)24-20(26)17-9-1-2-10-18(17)22/h1-12H,(H,23,25)(H,24,26)
DM2W71L	CS	C1=CC=C(C(=C1)C(=O)NC2=CC=CC(=C2)NC(=O)C3=CC(=CC=C3)Cl)Cl
DM2W71L	IK	IKCXGGCLQZZTJZ-UHFFFAOYSA-N
DM2W71L	IU	2-chloro-N-[3-[(3-chlorobenzoyl)amino]phenyl]benzamide
DM2W71L	DE	Discovery agent

DM5S1DW	ID	DM5S1DW
DM5S1DW	DN	2-Chloro-N-(3-morpholinopropyl)nicotinamide
DM5S1DW	HS	Investigative
DM5S1DW	SN	CHEMBL608436; 2-Chloro-N-(3-morpholinopropyl)nicotinamide; AC1N46O7; 2-chloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide; ZINC23379340; BDBM50307194; AKOS003849609; KB-120077
DM5S1DW	DT	Small molecular drug
DM5S1DW	PC	4124566
DM5S1DW	MW	283.75
DM5S1DW	FM	C13H18ClN3O2
DM5S1DW	IC	InChI=1S/C13H18ClN3O2/c14-12-11(3-1-4-15-12)13(18)16-5-2-6-17-7-9-19-10-8-17/h1,3-4H,2,5-10H2,(H,16,18)
DM5S1DW	CS	C1COCCN1CCCNC(=O)C2=C(N=CC=C2)Cl
DM5S1DW	IK	YLZONZBOTGMALV-UHFFFAOYSA-N
DM5S1DW	IU	2-chloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DM5S1DW	DE	Discovery agent

DMBKVM4	ID	DMBKVM4
DMBKVM4	DN	2-chloro-N-(6-cyanopyridin-3-yl)propanamide
DMBKVM4	HS	Investigative
DMBKVM4	SN	2-chloro-N-(6-cyanopyridin-3-yl)propanamide; 1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N
DMBKVM4	DT	Small molecular drug
DMBKVM4	PC	25141337
DMBKVM4	MW	209.63
DMBKVM4	FM	C9H8ClN3O
DMBKVM4	IC	InChI=1S/C9H8ClN3O/c1-6(10)9(14)13-8-3-2-7(4-11)12-5-8/h2-3,5-6H,1H3,(H,13,14)
DMBKVM4	CS	CC(C(=O)NC1=CN=C(C=C1)C#N)Cl
DMBKVM4	IK	VFOLQYOVUCHHET-UHFFFAOYSA-N
DMBKVM4	IU	2-chloro-N-(6-cyanopyridin-3-yl)propanamide
DMBKVM4	DE	Discovery agent

DMLDQ6I	ID	DMLDQ6I
DMLDQ6I	DN	2-chloro-N-(o-tolylcarbamoyl)benzamide
DMLDQ6I	HS	Investigative
DMLDQ6I	SN	CHEMBL1169825; 2-chloro-N-(o-tolylcarbamoyl)benzamide
DMLDQ6I	DT	Small molecular drug
DMLDQ6I	PC	15740307
DMLDQ6I	MW	288.73
DMLDQ6I	FM	C15H13ClN2O2
DMLDQ6I	IC	InChI=1S/C15H13ClN2O2/c1-10-6-2-5-9-13(10)17-15(20)18-14(19)11-7-3-4-8-12(11)16/h2-9H,1H3,(H2,17,18,19,20)
DMLDQ6I	CS	CC1=CC=CC=C1NC(=O)NC(=O)C2=CC=CC=C2Cl
DMLDQ6I	IK	BXURYJIVZUMNBL-UHFFFAOYSA-N
DMLDQ6I	IU	2-chloro-N-[(2-methylphenyl)carbamoyl]benzamide
DMLDQ6I	DE	Discovery agent

DM2E3X5	ID	DM2E3X5
DM2E3X5	DN	2-Chlorophenol
DM2E3X5	HS	Investigative
DM2E3X5	SN	2-CHLOROPHENOL; o-Chlorophenol; 95-57-8; Phenol, 2-chloro-; 2-Hydroxychlorobenzene; o-Chlorphenol; o-Chlorophenic acid; Phenol, o-chloro-; 2-Chloro-1-hydroxybenzene; CHLOROPHENOL; Septi-Kleen; 2-chloro-phenol; RCRA waste number U048; Pine-O Disinfectant; Caswell No. 203; o-Chlorphenol [German]; UNII-K9KAV4K6BN; Phenol, chloro-; NSC 2870; CCRIS 640; HSDB 1415; EINECS 202-433-2; K9KAV4K6BN; RCRA waste no. U048; 1-Chloro-2-hydroxybenzene; EPA Pesticide Chemical Code 062204; AI3-09060; CHEBI:47083; ISPYQTSUDJAMAB-UHFFFAOYSA-N
DM2E3X5	DT	Small molecular drug
DM2E3X5	PC	7245
DM2E3X5	MW	128.55
DM2E3X5	FM	C6H5ClO
DM2E3X5	IC	InChI=1S/C6H5ClO/c7-5-3-1-2-4-6(5)8/h1-4,8H
DM2E3X5	CS	C1=CC=C(C(=C1)O)Cl
DM2E3X5	IK	ISPYQTSUDJAMAB-UHFFFAOYSA-N
DM2E3X5	IU	2-chlorophenol
DM2E3X5	CA	CAS 95-57-8
DM2E3X5	CB	CHEBI:47083
DM2E3X5	DE	Discovery agent

DMXYTGU	ID	DMXYTGU
DMXYTGU	DN	2-Cinnamamido-N1-hydroxy-N4-octylsuccinamide
DMXYTGU	HS	Investigative
DMXYTGU	SN	CHEMBL594848; 2-Cinnamamido-N1-hydroxy-N4-octylsuccinamide
DMXYTGU	DT	Small molecular drug
DMXYTGU	PC	46228282
DMXYTGU	MW	389.5
DMXYTGU	FM	C21H31N3O4
DMXYTGU	IC	InChI=1S/C21H31N3O4/c1-2-3-4-5-6-10-15-22-20(26)16-18(21(27)24-28)23-19(25)14-13-17-11-8-7-9-12-17/h7-9,11-14,18,28H,2-6,10,15-16H2,1H3,(H,22,26)(H,23,25)(H,24,27)/b14-13+/t18-/m1/s1
DMXYTGU	CS	CCCCCCCCNC(=O)C[C@H](C(=O)NO)NC(=O)/C=C/C1=CC=CC=C1
DMXYTGU	IK	TYVAVCSSCPJBHI-KAUXGEHWSA-N
DMXYTGU	IU	(2R)-N-hydroxy-N'-octyl-2-[[(E)-3-phenylprop-2-enoyl]amino]butanediamide
DMXYTGU	DE	Discovery agent

DMI6FZN	ID	DMI6FZN
DMI6FZN	DN	2-Cinnamamido-N1-hydroxy-N4-pentylsuccinamide
DMI6FZN	HS	Investigative
DMI6FZN	SN	CHEMBL596560; 2-Cinnamamido-N1-hydroxy-N4-pentylsuccinamide
DMI6FZN	DT	Small molecular drug
DMI6FZN	PC	45257111
DMI6FZN	MW	347.4
DMI6FZN	FM	C18H25N3O4
DMI6FZN	IC	InChI=1S/C18H25N3O4/c1-2-3-7-12-19-17(23)13-15(18(24)21-25)20-16(22)11-10-14-8-5-4-6-9-14/h4-6,8-11,15,25H,2-3,7,12-13H2,1H3,(H,19,23)(H,20,22)(H,21,24)/b11-10+/t15-/m1/s1
DMI6FZN	CS	CCCCCNC(=O)C[C@H](C(=O)NO)NC(=O)/C=C/C1=CC=CC=C1
DMI6FZN	IK	GEWJSTSZXRZGCY-AUECHBEKSA-N
DMI6FZN	IU	(2R)-N-hydroxy-N'-pentyl-2-[[(E)-3-phenylprop-2-enoyl]amino]butanediamide
DMI6FZN	DE	Discovery agent

DMRNGK7	ID	DMRNGK7
DMRNGK7	DN	2-Cinnamamido-N4-hexyl-N1-hydroxysuccinamide
DMRNGK7	HS	Investigative
DMRNGK7	SN	CHEMBL595209; 2-Cinnamamido-N4-hexyl-N1-hydroxysuccinamide
DMRNGK7	DT	Small molecular drug
DMRNGK7	PC	46228278
DMRNGK7	MW	361.4
DMRNGK7	FM	C19H27N3O4
DMRNGK7	IC	InChI=1S/C19H27N3O4/c1-2-3-4-8-13-20-18(24)14-16(19(25)22-26)21-17(23)12-11-15-9-6-5-7-10-15/h5-7,9-12,16,26H,2-4,8,13-14H2,1H3,(H,20,24)(H,21,23)(H,22,25)/b12-11+/t16-/m1/s1
DMRNGK7	CS	CCCCCCNC(=O)C[C@H](C(=O)NO)NC(=O)/C=C/C1=CC=CC=C1
DMRNGK7	IK	AOIMNHYQILMKAB-LPQFERQCSA-N
DMRNGK7	IU	(2R)-N'-hexyl-N-hydroxy-2-[[(E)-3-phenylprop-2-enoyl]amino]butanediamide
DMRNGK7	DE	Discovery agent

DM4235F	ID	DM4235F
DM4235F	DN	2-Cl-ADP(alpha-BH3)
DM4235F	HS	Investigative
DM4235F	SN	2-Cl-ADP(alpha-BH3); GTPL8447; CHEMBL2386491; BDBM50435011
DM4235F	DT	Small molecular drug
DM4235F	PC	71733822
DM4235F	MW	455.45
DM4235F	FM	C10H13BClN5O9P2-
DM4235F	IC	InChI=1S/C10H13BClN5O9P2/c11-27(20,26-28(21,22)23)24-1-3-5(18)6(19)9(25-3)17-2-14-4-7(13)15-10(12)16-8(4)17/h2-3,5-6,9,18-19H,1H2,(H2,13,15,16)(H2,21,22,23)/q-1/t3-,5-,6-,9-,27-/m1/s1
DM4235F	CS	[B-][P@@](=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)N)O)O)OP(=O)(O)O
DM4235F	IK	XLTJNJOUVKOQCW-MWZJDIDNSA-N
DM4235F	DE	Discovery agent

DMCN6PY	ID	DMCN6PY
DMCN6PY	DN	2-cyano-3-(3,4-dihydroxyphenyl)acrylamide
DMCN6PY	HS	Investigative
DMCN6PY	SN	Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR
DMCN6PY	DT	Small molecular drug
DMCN6PY	PC	5328768
DMCN6PY	MW	204.18
DMCN6PY	FM	C10H8N2O3
DMCN6PY	IC	InChI=1S/C10H8N2O3/c11-5-7(10(12)15)3-6-1-2-8(13)9(14)4-6/h1-4,13-14H,(H2,12,15)/b7-3+
DMCN6PY	CS	C1=CC(=C(C=C1/C=C(\\C#N)/C(=O)N)O)O
DMCN6PY	IK	USOXQZNJFMKTKJ-XVNBXDOJSA-N
DMCN6PY	IU	(E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
DMCN6PY	CA	CAS 118409-59-9
DMCN6PY	DE	Discovery agent

DM2U1N5	ID	DM2U1N5
DM2U1N5	DN	2-Cyclohex-1-enylethynyl-pyridine
DM2U1N5	HS	Investigative
DM2U1N5	SN	CHEMBL196643; 2-Cyclohex-1-enylethynyl-pyridine; 2-(1-Cyclohexenyl)ethynylpyridine
DM2U1N5	DT	Small molecular drug
DM2U1N5	PC	12811063
DM2U1N5	MW	183.25
DM2U1N5	FM	C13H13N
DM2U1N5	IC	InChI=1S/C13H13N/c1-2-6-12(7-3-1)9-10-13-8-4-5-11-14-13/h4-6,8,11H,1-3,7H2
DM2U1N5	CS	C1CCC(=CC1)C#CC2=CC=CC=N2
DM2U1N5	IK	ZWQFPYQWWDBORG-UHFFFAOYSA-N
DM2U1N5	IU	2-[2-(cyclohexen-1-yl)ethynyl]pyridine
DM2U1N5	DE	Discovery agent

DMS1T0V	ID	DMS1T0V
DMS1T0V	DN	2-Cyclohexylacetic acidbiphenyl-3-yl ester
DMS1T0V	HS	Investigative
DMS1T0V	SN	CHEMBL505895; 2-Cyclohexylacetic acidbiphenyl-3-yl ester
DMS1T0V	DT	Small molecular drug
DMS1T0V	PC	24881867
DMS1T0V	MW	294.4
DMS1T0V	FM	C20H22O2
DMS1T0V	IC	InChI=1S/C20H22O2/c21-20(14-16-8-3-1-4-9-16)22-19-13-7-12-18(15-19)17-10-5-2-6-11-17/h2,5-7,10-13,15-16H,1,3-4,8-9,14H2
DMS1T0V	CS	C1CCC(CC1)CC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMS1T0V	IK	VBMZBWIWRKLCHP-UHFFFAOYSA-N
DMS1T0V	IU	(3-phenylphenyl) 2-cyclohexylacetate
DMS1T0V	DE	Discovery agent

DMFBD3K	ID	DMFBD3K
DMFBD3K	DN	2-cyclohexylamido-5-sulfonamidoindane
DMFBD3K	HS	Investigative
DMFBD3K	SN	CHEMBL204990; 2-cyclohexylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 12b; BDBM11033
DMFBD3K	DT	Small molecular drug
DMFBD3K	PC	11623958
DMFBD3K	MW	322.4
DMFBD3K	FM	C16H22N2O3S
DMFBD3K	IC	InChI=1S/C16H22N2O3S/c17-22(20,21)15-7-6-12-8-14(9-13(12)10-15)18-16(19)11-4-2-1-3-5-11/h6-7,10-11,14H,1-5,8-9H2,(H,18,19)(H2,17,20,21)
DMFBD3K	CS	C1CCC(CC1)C(=O)NC2CC3=C(C2)C=C(C=C3)S(=O)(=O)N
DMFBD3K	IK	PUAFUZDTMVHXBP-UHFFFAOYSA-N
DMFBD3K	IU	N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)cyclohexanecarboxamide
DMFBD3K	DE	Discovery agent

DMFMZRB	ID	DMFMZRB
DMFMZRB	DN	2-cyclohexylamino-pyridine-2-carbonitrile
DMFMZRB	HS	Investigative
DMFMZRB	SN	2-Cyano-pyridine, 8; 2-Pyridinecarbonitrile, 6-(cyclohexylamino)-; CHEMBL218522; BDBM19747; AKOS013783092; 927176-95-2
DMFMZRB	DT	Small molecular drug
DMFMZRB	PC	16108897
DMFMZRB	MW	201.27
DMFMZRB	FM	C12H15N3
DMFMZRB	IC	InChI=1S/C12H15N3/c13-9-11-7-4-8-12(15-11)14-10-5-2-1-3-6-10/h4,7-8,10H,1-3,5-6H2,(H,14,15)
DMFMZRB	CS	C1CCC(CC1)NC2=CC=CC(=N2)C#N
DMFMZRB	IK	IBXQOGXYFIMECI-UHFFFAOYSA-N
DMFMZRB	IU	6-(cyclohexylamino)pyridine-2-carbonitrile
DMFMZRB	DE	Discovery agent

DMMIGXO	ID	DMMIGXO
DMMIGXO	DN	2-cyclohexylamino-pyrimidine-4-carbonitrile
DMMIGXO	HS	Investigative
DMMIGXO	SN	4-Cyano-pyrimidine, 9; 2-(cyclohexylamino)pyrimidine-4-carbonitrile; CHEMBL221804; BDBM19748; 927176-96-3; 4-Pyrimidinecarbonitrile, 2-(cyclohexylamino)-
DMMIGXO	DT	Small molecular drug
DMMIGXO	PC	16108885
DMMIGXO	MW	202.26
DMMIGXO	FM	C11H14N4
DMMIGXO	IC	InChI=1S/C11H14N4/c12-8-10-6-7-13-11(15-10)14-9-4-2-1-3-5-9/h6-7,9H,1-5H2,(H,13,14,15)
DMMIGXO	CS	C1CCC(CC1)NC2=NC=CC(=N2)C#N
DMMIGXO	IK	SOIZAJGZULPDSF-UHFFFAOYSA-N
DMMIGXO	IU	2-(cyclohexylamino)pyrimidine-4-carbonitrile
DMMIGXO	DE	Discovery agent

DM2JZ84	ID	DM2JZ84
DM2JZ84	DN	2-Cyclohexylethynyl-pyridine
DM2JZ84	HS	Investigative
DM2JZ84	SN	2-Cyclohexylethynyl-pyridine; CHEMBL195965; 2-(Cyclohexylethynyl)pyridine
DM2JZ84	DT	Small molecular drug
DM2JZ84	PC	44403640
DM2JZ84	MW	185.26
DM2JZ84	FM	C13H15N
DM2JZ84	IC	InChI=1S/C13H15N/c1-2-6-12(7-3-1)9-10-13-8-4-5-11-14-13/h4-5,8,11-12H,1-3,6-7H2
DM2JZ84	CS	C1CCC(CC1)C#CC2=CC=CC=N2
DM2JZ84	IK	WDQDPHLOSGNFKP-UHFFFAOYSA-N
DM2JZ84	IU	2-(2-cyclohexylethynyl)pyridine
DM2JZ84	DE	Discovery agent

DMF6PMU	ID	DMF6PMU
DMF6PMU	DN	2-Cyclohexyl-N-(4-methoxy-phenyl)-acetamide
DMF6PMU	HS	Investigative
DMF6PMU	SN	CHEMBL192523; 2-cyclohexyl-N-(4-methoxyphenyl)acetamide; CBMicro_031991; AC1LH2YD; 2-Cyclohexyl-N-(4-methoxy-phenyl)-acetamide; Oprea1_584438; SCHEMBL12931990; MolPort-002-194-789; ZINC451523; STL384380; BDBM50167041; AKOS001067578; MCULE-9916735458; BIM-0031907.P001; SR-01000232787
DMF6PMU	DT	Small molecular drug
DMF6PMU	PC	880925
DMF6PMU	MW	247.33
DMF6PMU	FM	C15H21NO2
DMF6PMU	IC	InChI=1S/C15H21NO2/c1-18-14-9-7-13(8-10-14)16-15(17)11-12-5-3-2-4-6-12/h7-10,12H,2-6,11H2,1H3,(H,16,17)
DMF6PMU	CS	COC1=CC=C(C=C1)NC(=O)CC2CCCCC2
DMF6PMU	IK	SCFJMQSXUCFKPS-UHFFFAOYSA-N
DMF6PMU	IU	2-cyclohexyl-N-(4-methoxyphenyl)acetamide
DMF6PMU	DE	Discovery agent

DM89CLH	ID	DM89CLH
DM89CLH	DN	2-Cyclohexyl-N-phenethyl-acetamide
DM89CLH	HS	Investigative
DM89CLH	SN	CHEMBL193019; 2-cyclohexyl-N-phenethyl-acetamide; AC1LM26R; Oprea1_260865; SCHEMBL12932020; 2-cyclohexyl-N-phenethylacetamide; MolPort-002-220-431; ZINC858629; STK222764; BDBM50167042; AKOS003337086; MCULE-6211391975
DM89CLH	DT	Small molecular drug
DM89CLH	PC	1121089
DM89CLH	MW	245.36
DM89CLH	FM	C16H23NO
DM89CLH	IC	InChI=1S/C16H23NO/c18-16(13-15-9-5-2-6-10-15)17-12-11-14-7-3-1-4-8-14/h1,3-4,7-8,15H,2,5-6,9-13H2,(H,17,18)
DM89CLH	CS	C1CCC(CC1)CC(=O)NCCC2=CC=CC=C2
DM89CLH	IK	BDWDBZQULOREPW-UHFFFAOYSA-N
DM89CLH	IU	2-cyclohexyl-N-(2-phenylethyl)acetamide
DM89CLH	DE	Discovery agent

DMBJUP5	ID	DMBJUP5
DMBJUP5	DN	2-Cyclohexyl-N-phenyl-acetamide
DMBJUP5	HS	Investigative
DMBJUP5	SN	2-cyclohexyl-N-phenylacetamide; CHEMBL191663; 2-Cyclohexyl-N-phenyl-acetamide; 4-Cyclohexylacetanilide; CBMicro_047799; AC1LH2Y4; Cambridge id 6369179; SCHEMBL3822162; WIFWWZGKYZCASF-UHFFFAOYSA-N; MolPort-002-194-779; ZINC451519; BDBM50167040; STL384376; AKOS008916535; BIM-0047893.P001; SR-01000232777
DMBJUP5	DT	Small molecular drug
DMBJUP5	PC	880922
DMBJUP5	MW	217.31
DMBJUP5	FM	C14H19NO
DMBJUP5	IC	InChI=1S/C14H19NO/c16-14(11-12-7-3-1-4-8-12)15-13-9-5-2-6-10-13/h2,5-6,9-10,12H,1,3-4,7-8,11H2,(H,15,16)
DMBJUP5	CS	C1CCC(CC1)CC(=O)NC2=CC=CC=C2
DMBJUP5	IK	WIFWWZGKYZCASF-UHFFFAOYSA-N
DMBJUP5	IU	2-cyclohexyl-N-phenylacetamide
DMBJUP5	DE	Discovery agent

DMVP6CW	ID	DMVP6CW
DMVP6CW	DN	2-Cyclopent-1-enylethynyl-pyridine
DMVP6CW	HS	Investigative
DMVP6CW	SN	CHEMBL443487; 2-Cyclopent-1-enylethynyl-pyridine; 2-(cyclopent-1-enyl-ethynyl)-pyridine; BDBM50172132
DMVP6CW	DT	Small molecular drug
DMVP6CW	PC	12811064
DMVP6CW	MW	169.22
DMVP6CW	FM	C12H11N
DMVP6CW	IC	InChI=1S/C12H11N/c1-2-6-11(5-1)8-9-12-7-3-4-10-13-12/h3-5,7,10H,1-2,6H2
DMVP6CW	CS	C1CC=C(C1)C#CC2=CC=CC=N2
DMVP6CW	IK	PJMNINJICZHJJV-UHFFFAOYSA-N
DMVP6CW	IU	2-[2-(cyclopenten-1-yl)ethynyl]pyridine
DMVP6CW	DE	Discovery agent

DM6CZAN	ID	DM6CZAN
DM6CZAN	DN	2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DM6CZAN	HS	Investigative
DM6CZAN	SN	CHEMBL19970; 2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine; ZINC13821060; BDBM50011595
DM6CZAN	DT	Small molecular drug
DM6CZAN	PC	14896621
DM6CZAN	MW	252.31
DM6CZAN	FM	C15H16N4
DM6CZAN	IC	InChI=1S/C15H16N4/c16-14-13-12(10-7-3-4-8-11(10)17-14)18-15(19-13)9-5-1-2-6-9/h3-4,7-9H,1-2,5-6H2,(H2,16,17)(H,18,19)
DM6CZAN	CS	C1CCC(C1)C2=NC3=C(N2)C(=NC4=CC=CC=C43)N
DM6CZAN	IK	KPONPDGMNFNBFA-UHFFFAOYSA-N
DM6CZAN	IU	2-cyclopentyl-3H-imidazo[4,5-c]quinolin-4-amine
DM6CZAN	DE	Discovery agent

DMS947W	ID	DMS947W
DMS947W	DN	2-Cyclopentylaminomethyl-pyrrolidine-3,4-diol
DMS947W	HS	Investigative
DMS947W	SN	CHEMBL84940; 2-Cyclopentylaminomethyl-pyrrolidine-3,4-diol
DMS947W	DT	Small molecular drug
DMS947W	PC	44462095
DMS947W	MW	200.28
DMS947W	FM	C10H20N2O2
DMS947W	IC	InChI=1S/C10H20N2O2/c13-9-6-12-8(10(9)14)5-11-7-3-1-2-4-7/h7-14H,1-6H2
DMS947W	CS	C1CCC(C1)NCC2C(C(CN2)O)O
DMS947W	IK	CAYLVMUUXWDLQS-UHFFFAOYSA-N
DMS947W	IU	2-[(cyclopentylamino)methyl]pyrrolidine-3,4-diol
DMS947W	DE	Discovery agent

DMRS6LH	ID	DMRS6LH
DMRS6LH	DN	2-Cyclopropanecarbonyl-cyclohexane-1,3-dione
DMRS6LH	HS	Investigative
DMRS6LH	SN	CHEMBL355709; 288258-62-8; 2-Cyclopropanecarbonyl-cyclohexane-1,3-dione; 1,3-Cyclohexanedione, 2-(cyclopropylcarbonyl)-; SCHEMBL10192859; BDBM50088792; 2-cyclopropanecarbonylcyclohexane-1,3-dione
DMRS6LH	DT	Small molecular drug
DMRS6LH	PC	44380695
DMRS6LH	MW	180.2
DMRS6LH	FM	C10H12O3
DMRS6LH	IC	InChI=1S/C10H12O3/c11-7-2-1-3-8(12)9(7)10(13)6-4-5-6/h6,9H,1-5H2
DMRS6LH	CS	C1CC(=O)C(C(=O)C1)C(=O)C2CC2
DMRS6LH	IK	DYVQTUZCXQZYGL-UHFFFAOYSA-N
DMRS6LH	IU	2-(cyclopropanecarbonyl)cyclohexane-1,3-dione
DMRS6LH	DE	Discovery agent

DM0W2QB	ID	DM0W2QB
DM0W2QB	DN	2-Cyclopropylmethylenepropanal
DM0W2QB	HS	Investigative
DM0W2QB	SN	2-Cyclopropylmethylenepropanal; AC1NRALT; (2S)-3-cyclopropyl-2-methylpropanal
DM0W2QB	DT	Small molecular drug
DM0W2QB	PC	5287974
DM0W2QB	MW	112.17
DM0W2QB	FM	C7H12O
DM0W2QB	IC	InChI=1S/C7H12O/c1-6(5-8)4-7-2-3-7/h5-7H,2-4H2,1H3/t6-/m0/s1
DM0W2QB	CS	C[C@@H](CC1CC1)C=O
DM0W2QB	IK	NOQCSSAEKDLHCI-LURJTMIESA-N
DM0W2QB	IU	(2S)-3-cyclopropyl-2-methylpropanal
DM0W2QB	DE	Discovery agent

DMIAM5L	ID	DMIAM5L
DMIAM5L	DN	2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid
DMIAM5L	HS	Investigative
DMIAM5L	SN	24967-27-9; Neu5Ac2en; 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid; N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid; 2-deoxy-2,3-dehydro-n-acetyl-neuraminic acid; 2,3-Dehydro-2-deoxy-N-acetylneuraminic acid; N-Acetyl-2,3-didehydro-2-deoxyneuraminic acid; EINECS 246-550-7; CHEMBL96712; CHEBI:28062; C11H17NO8; (2R,3R,4S)-3-acetamido-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 1,3-Dehydro-2-deoxy-N-acetylneuraminic acid
DMIAM5L	DT	Small molecular drug
DMIAM5L	PC	65309
DMIAM5L	MW	291.25
DMIAM5L	FM	C11H17NO8
DMIAM5L	IC	InChI=1S/C11H17NO8/c1-4(14)12-8-5(15)2-7(11(18)19)20-10(8)9(17)6(16)3-13/h2,5-6,8-10,13,15-17H,3H2,1H3,(H,12,14)(H,18,19)/t5-,6+,8+,9+,10+/m0/s1
DMIAM5L	CS	CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)O
DMIAM5L	IK	JINJZWSZQKHCIP-UFGQHTETSA-N
DMIAM5L	IU	(2R,3R,4S)-3-acetamido-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DMIAM5L	CA	CAS 24967-27-9
DMIAM5L	CB	CHEBI:28062

DMBMK4T	ID	DMBMK4T
DMBMK4T	DN	2-Deoxy-2-Amino Glucitol-6-Phosphate
DMBMK4T	HS	Investigative
DMBMK4T	SN	2-Deoxy-2-Amino Glucitol-6-Phosphate; AGP; 2-amino-2-deoxy-D-glucitol 6-phosphate; 2-amino-2-deoxy-6-O-phosphono-D-glucitol; AC1L9J4R; SCHEMBL2847976; CHEMBL396380; DB02445; 2-amino-2-deoxy-d-glucitol-6-phosphate; D-Glucitol, 2-amino-2-deoxy-, 6-(dihydrogen phosphate); [(2R,3S,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexyl] dihydrogen phosphate; [(2R,3S,4R,5S)-5-amino-2,3,4,6-tetrahydroxy-hexyl] dihydrogen phosphate
DMBMK4T	DT	Small molecular drug
DMBMK4T	PC	446113
DMBMK4T	MW	261.17
DMBMK4T	FM	C6H16NO8P
DMBMK4T	IC	InChI=1S/C6H16NO8P/c7-3(1-8)5(10)6(11)4(9)2-15-16(12,13)14/h3-6,8-11H,1-2,7H2,(H2,12,13,14)/t3-,4+,5+,6+/m0/s1
DMBMK4T	CS	C([C@@H]([C@H]([C@@H]([C@@H](COP(=O)(O)O)O)O)O)N)O
DMBMK4T	IK	LBNVXZROMBUNNQ-SLPGGIOYSA-N
DMBMK4T	IU	[(2R,3S,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexyl] dihydrogen phosphate
DMBMK4T	DE	Discovery agent

DMMC8IG	ID	DMMC8IG
DMMC8IG	DN	2-Deoxy-2fluoro-Glucose
DMMC8IG	HS	Investigative
DMMC8IG	SN	2-deoxy-2-fluoro-beta-D-glucopyranose; 2-DEOXY-2FLUORO-GLUCOSE; UNII-41XAV5II5H; 41XAV5II5H; CHEBI:49128; 2-deoxy-2-fluoro-beta-D-glucose; NSC-240588; AC1NRBA5; beta-D-Fludeoxyglucopyranose; SCHEMBL4323343; CHEMBL1235932; ZINC4329335; G2F; 2-Fluoro-2-deoxy-beta-D-glucopyranose; beta-D-Glucopyranose, 2-deoxy-2-fluoro-; WURCS=2.0/1,1,0/[a2122h-1b_1-5_2*F]/1/
DMMC8IG	DT	Small molecular drug
DMMC8IG	PC	5288324
DMMC8IG	MW	182.15
DMMC8IG	FM	C6H11FO5
DMMC8IG	IC	InChI=1S/C6H11FO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1H2/t2-,3-,4-,5-,6-/m1/s1
DMMC8IG	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)F)O)O)O
DMMC8IG	IK	ZCXUVYAZINUVJD-QZABAPFNSA-N
DMMC8IG	IU	(2R,3R,4S,5S,6R)-3-fluoro-6-(hydroxymethyl)oxane-2,4,5-triol
DMMC8IG	CA	CAS 38711-37-4
DMMC8IG	CB	CHEBI:49128
DMMC8IG	DE	Discovery agent

DMG7CAU	ID	DMG7CAU
DMG7CAU	DN	2'-Deoxycytidine-5'-Monophosphate
DMG7CAU	HS	Investigative
DMG7CAU	SN	1032-65-1; dCMP; deoxycytidylic acid; 2'-Deoxycytidine-5'-monophosphoric acid; deoxycytidine monophosphate; 2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE; 5'-Cytidylic acid, 2'-deoxy-; 2'-Deoxycytidine 5'-monophosphate; Deoxycytidine-5'-monophosphoric acid; Deoxycytidylate; Polydeoxycytidylic acid; UNII-W7A9174XQL; 2'-deoxy-5'-cytidylic acid; W7A9174XQL; CHEBI:15918; NCMVOABPESMRCP-SHYZEUOFSA-N; deoxycytidine-phosphate; 2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE FREE ACID
DMG7CAU	DT	Small molecular drug
DMG7CAU	PC	13945
DMG7CAU	MW	307.2
DMG7CAU	FM	C9H14N3O7P
DMG7CAU	IC	InChI=1S/C9H14N3O7P/c10-7-1-2-12(9(14)11-7)8-3-5(13)6(19-8)4-18-20(15,16)17/h1-2,5-6,8,13H,3-4H2,(H2,10,11,14)(H2,15,16,17)/t5-,6+,8+/m0/s1
DMG7CAU	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O)O
DMG7CAU	IK	NCMVOABPESMRCP-SHYZEUOFSA-N
DMG7CAU	IU	[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMG7CAU	CA	CAS 1032-65-1
DMG7CAU	CB	CHEBI:15918
DMG7CAU	DE	Discovery agent

DMMPL3D	ID	DMMPL3D
DMMPL3D	DN	2-Deoxy-Glucose-6-Phosphate
DMMPL3D	HS	Investigative
DMMPL3D	SN	D6G; 2-Deoxy-6-O-Phosphono-Alpha-D-Arabino-Hexopyranose; 2pri; AC1L9N1X; ZINC4097095; 2-deoxy-alpha-D-glucopyranose 6-phosphate; [(2R,3S,4R,6S)-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMMPL3D	DT	Small molecular drug
DMMPL3D	PC	46936435
DMMPL3D	MW	244.14
DMMPL3D	FM	C6H13O8P
DMMPL3D	IC	InChI=1S/C6H13O8P/c7-3-1-5(8)14-4(6(3)9)2-13-15(10,11)12/h3-9H,1-2H2,(H2,10,11,12)/t3-,4-,5-,6+/m1/s1
DMMPL3D	CS	C1[C@H]([C@@H]([C@H](O[C@H]1O)COP(=O)(O)O)O)O
DMMPL3D	IK	UQJFZAAGZAYVKZ-KAZBKCHUSA-N
DMMPL3D	IU	[(2R,3S,4R,6R)-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMMPL3D	DE	Discovery agent

DMY9FDT	ID	DMY9FDT
DMY9FDT	DN	2'-Deoxyguanosine-5'-Monophosphate
DMY9FDT	HS	Investigative
DMY9FDT	SN	Deoxyguanylic acid; Deoxy-GMP; 2'-Deoxyguanylic acid; Deoxyguanylate; Deoxyguanosine 5'-monophosphate; dGMP; 2'-Deoxy-GMP; 2'-dGMP; Deoxyguanosine monophosphate; Deoxyguanosine 5'-phosphate; 2'-Deoxyguanosine 5'-phosphate; 2'-Deoxy-5'-guanylic acid; 2'-deoxyguanosine 5'-monophosphate; 5'-DGMP; 5'-Deoxyguanylic acid; Deoxy GMP; 2'-Deoxyguanosine 5'MP; 902-04-5; deoxyguanosine-phosphate; 5'-Guanylic acid, 2'-deoxy-; 2'-dG-5'-MP; 2'-Deoxy-5'-GMP; UNII-7EAM4TG712; 2'-Deoxyguanosine 5'-phosphoric; 5'-dGMP
DMY9FDT	DT	Small molecular drug
DMY9FDT	PC	135398597
DMY9FDT	MW	347.22
DMY9FDT	FM	C10H14N5O7P
DMY9FDT	IC	InChI=1S/C10H14N5O7P/c11-10-13-8-7(9(17)14-10)12-3-15(8)6-1-4(16)5(22-6)2-21-23(18,19)20/h3-6,16H,1-2H2,(H2,18,19,20)(H3,11,13,14,17)/t4-,5+,6+/m0/s1
DMY9FDT	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)O)O
DMY9FDT	IK	LTFMZDNNPPEQNG-KVQBGUIXSA-N
DMY9FDT	IU	[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMY9FDT	CA	CAS 902-04-5
DMY9FDT	CB	CHEBI:16192
DMY9FDT	DE	Discovery agent

DM9OEJT	ID	DM9OEJT
DM9OEJT	DN	2'-deoxythymidine triphosphate
DM9OEJT	HS	Investigative
DM9OEJT	SN	Thymidine-5'-triphosphate; dTTP; thymidine 5'-triphosphate; Deoxy-TTP; Deoxythymidine 5'-triphosphate; 2'-Deoxythymidine triphosphate; 5'-TTP; THYMIDINE-5'-TRIPHOSPHATE; thymidine 5'-(tetrahydrogen triphosphate); TTP (nucleotide); thymidine triphosphate; pppdT; TTP; UNII-QOP4K539MU; 5-Methyl-dUTP; dThd5'PPP; CHEBI:18077; EINECS 206-669-7; QOP4K539MU; CHEMBL363559; 2'-Deoxythymidine 5'-triphosphate; 18423-43-3; [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate; DEOXYTHYMIDINE_TRIPHOSPHATE; Thymidine-5'-Triphosphate
DM9OEJT	DT	Small molecular drug
DM9OEJT	PC	64968
DM9OEJT	MW	482.17
DM9OEJT	FM	C10H17N2O14P3
DM9OEJT	IC	InChI=1S/C10H17N2O14P3/c1-5-3-12(10(15)11-9(5)14)8-2-6(13)7(24-8)4-23-28(19,20)26-29(21,22)25-27(16,17)18/h3,6-8,13H,2,4H2,1H3,(H,19,20)(H,21,22)(H,11,14,15)(H2,16,17,18)/t6-,7+,8+/m0/s1
DM9OEJT	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O
DM9OEJT	IK	NHVNXKFIZYSCEB-XLPZGREQSA-N
DM9OEJT	IU	[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate
DM9OEJT	CA	CAS 365-08-2
DM9OEJT	CB	CHEBI:18077
DM9OEJT	DE	Discovery agent

DM1HMWA	ID	DM1HMWA
DM1HMWA	DN	2'-Deoxyuridine
DM1HMWA	HS	Investigative
DM1HMWA	SN	2'-DEOXYURIDINE; 951-78-0; deoxyuridine; Uracil deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2-Deoxyuridine; Deoxyribose uracil; 2'-Desoxyuridine; UNII-W78I7AY22C; CCRIS 2832; dURD; EINECS 213-455-7; BRN 0024433; 1-(2-Deoxy-beta-D-ribofuranosyl)uracil; W78I7AY22C; CHEBI:16450; 2 -Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; MFCD00006527; AK-54658; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; NSC 23615; DEOXYURIDINE
DM1HMWA	DT	Small molecular drug
DM1HMWA	PC	13712
DM1HMWA	MW	228.2
DM1HMWA	FM	C9H12N2O5
DM1HMWA	IC	InChI=1S/C9H12N2O5/c12-4-6-5(13)3-8(16-6)11-2-1-7(14)10-9(11)15/h1-2,5-6,8,12-13H,3-4H2,(H,10,14,15)/t5-,6+,8+/m0/s1
DM1HMWA	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)O
DM1HMWA	IK	MXHRCPNRJAMMIM-SHYZEUOFSA-N
DM1HMWA	IU	1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DM1HMWA	CA	CAS 951-78-0
DM1HMWA	CB	CHEBI:16450
DM1HMWA	DE	Discovery agent

DMXV27U	ID	DMXV27U
DMXV27U	DN	2'-deoxyuridine 5'-alpha,beta-imido-diphosphate
DMXV27U	HS	Investigative
DMXV27U	SN	2'-DEOXYURIDINE 5'-ALPHA,BETA-IMIDO-DIPHOSPHATE; DUN; AC1L9MQ3; 2,4(1H,3H)-PYRIMIDINEDIONE, 1-[2-DEOXY-5-O-[HYDROXY(PHOSPHONOAMINO)PHOSPHINYL]-BETA-D-ERYTHRO-PENTOFURANOSYL]-; DB03641; [(2'-Deoxy-5'-uridylyl)amino]phosphonic acid; 2'-deoxy-5'-O-[(R)-hydroxy(phosphonoamino)phosphoryl]uridine; 1-[2-DEOXY-5-O-[HYDROXY(PHOSPHONOAMINO)PHOSPHINYL]-BETA-D-ERYTHRO-PENTOFURANOSYL]-; [[[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]amino]phosphonic acid
DMXV27U	DT	Small molecular drug
DMXV27U	PC	449098
DMXV27U	MW	387.18
DMXV27U	FM	C9H15N3O10P2
DMXV27U	IC	InChI=1S/C9H15N3O10P2/c13-5-3-8(12-2-1-7(14)10-9(12)15)22-6(5)4-21-24(19,20)11-23(16,17)18/h1-2,5-6,8,13H,3-4H2,(H,10,14,15)(H4,11,16,17,18,19,20)/t5-,6+,8+/m0/s1
DMXV27U	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(NP(=O)(O)O)O)O
DMXV27U	IK	COFNIXBQVWFHTR-SHYZEUOFSA-N
DMXV27U	IU	[[[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]amino]phosphonic acid
DMXV27U	CA	CAS 178809-71-7
DMXV27U	DE	Discovery agent

DMOHABR	ID	DMOHABR
DMOHABR	DN	2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate
DMOHABR	HS	Investigative
DMOHABR	SN	2'-DEOXYURIDINE 5'-ALPHA,BETA-IMIDO-TRIPHOSPHATE; CHEMBL1232397; DUP; alpha,beta-Imino-dUTP; AC1L9LWH; BDBM50386619; DB01965; 2'-deoxy-5'-O-[(S)-hydroxy{[(R)-hydroxy(phosphonooxy)phosphoryl]amino}phosphoryl]uridine; [(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-N-[hydroxy(phosphonooxy)phosphoryl]phosphonamidic acid
DMOHABR	DT	Small molecular drug
DMOHABR	PC	448381
DMOHABR	MW	467.16
DMOHABR	FM	C9H16N3O13P3
DMOHABR	IC	InChI=1S/C9H16N3O13P3/c13-5-3-8(12-2-1-7(14)10-9(12)15)24-6(5)4-23-26(16,17)11-27(18,19)25-28(20,21)22/h1-2,5-6,8,13H,3-4H2,(H,10,14,15)(H2,20,21,22)(H3,11,16,17,18,19)/t5-,6+,8+/m0/s1
DMOHABR	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(NP(=O)(O)OP(=O)(O)O)O)O
DMOHABR	IK	XZLLMTSKYYYJLH-SHYZEUOFSA-N
DMOHABR	IU	[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-N-[hydroxy(phosphonooxy)phosphoryl]phosphonamidic acid
DMOHABR	DE	Discovery agent

DMPV1LU	ID	DMPV1LU
DMPV1LU	DN	2'-deoxyuridylic acid
DMPV1LU	HS	Investigative
DMPV1LU	SN	dUMP; 2'-deoxyuridylic acid; Deoxyuridine monophosphate; Deoxyuridylic acid; 2'-Deoxyuridine 5'-monophosphate; 2'-deoxy-5'-uridylic acid; Deoxyuridine 5'-phosphate; 2'-Deoxyuridine 5'-phosphate; Deoxy-UMP; 2'-Deoxyuridylate; 964-26-1; 2'-DEOXYURIDINE-5'-MONOPHOSPHATE; Deoxyuridine 5'-monophosphate; 5'-Uridylic acid, 2'-deoxy-; deoxyuridylate; Uridine, 2'-deoxy-, 5'-phosphate; EINECS 213-518-9; Uridine, 2'-deoxy-, 5'-(dihydrogen phosphate); BRN 0042143; CHEMBL211312; CHEBI:17622; JSRLJPSBLDHEIO-SHYZEUOFSA-N; 42155-08-8; 1tsy; 1tsv
DMPV1LU	DT	Small molecular drug
DMPV1LU	PC	65063
DMPV1LU	MW	308.18
DMPV1LU	FM	C9H13N2O8P
DMPV1LU	IC	InChI=1S/C9H13N2O8P/c12-5-3-8(11-2-1-7(13)10-9(11)14)19-6(5)4-18-20(15,16)17/h1-2,5-6,8,12H,3-4H2,(H,10,13,14)(H2,15,16,17)/t5-,6+,8+/m0/s1
DMPV1LU	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(O)O)O
DMPV1LU	IK	JSRLJPSBLDHEIO-SHYZEUOFSA-N
DMPV1LU	IU	[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMPV1LU	CA	CAS 964-26-1
DMPV1LU	CB	CHEBI:17622
DMPV1LU	DE	Discovery agent

DM4A527	ID	DM4A527
DM4A527	DN	2-dibenzofuran-4-yl-6-morpholin-4-yl-pyran-4-one
DM4A527	HS	Investigative
DM4A527	SN	CHEMBL373979; 2-dibenzofuran-4-yl-6-morpholin-4-yl-pyran-4-one; SCHEMBL13113941
DM4A527	DT	Small molecular drug
DM4A527	PC	16204050
DM4A527	MW	347.4
DM4A527	FM	C21H17NO4
DM4A527	IC	InChI=1S/C21H17NO4/c23-14-12-19(25-20(13-14)22-8-10-24-11-9-22)17-6-3-5-16-15-4-1-2-7-18(15)26-21(16)17/h1-7,12-13H,8-11H2
DM4A527	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC4=C3OC5=CC=CC=C45
DM4A527	IK	YREPYLIFIQVESI-UHFFFAOYSA-N
DM4A527	IU	2-dibenzofuran-4-yl-6-morpholin-4-ylpyran-4-one
DM4A527	DE	Discovery agent

DMF50YH	ID	DMF50YH
DMF50YH	DN	2-Dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol
DMF50YH	HS	Investigative
DMF50YH	SN	CHEMBL62297; 2-Dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol
DMF50YH	DT	Small molecular drug
DMF50YH	PC	44304339
DMF50YH	MW	297.4
DMF50YH	FM	C20H27NO
DMF50YH	IC	InChI=1S/C20H27NO/c1-3-11-21(12-4-2)17-10-9-16-13-15-7-5-6-8-18(15)20(22)19(16)14-17/h5-8,13,17,22H,3-4,9-12,14H2,1-2H3
DMF50YH	CS	CCCN(CCC)C1CCC2=CC3=CC=CC=C3C(=C2C1)O
DMF50YH	IK	TXKDLYBWCJNMHU-UHFFFAOYSA-N
DMF50YH	IU	2-(dipropylamino)-1,2,3,4-tetrahydroanthracen-9-ol
DMF50YH	DE	Discovery agent

DM2PDGO	ID	DM2PDGO
DM2PDGO	DN	2-EPI-2-THIOSALVINORIN A
DM2PDGO	HS	Investigative
DM2PDGO	SN	2-epi-2-thiosalvinorin A; CHEMBL231537
DM2PDGO	DT	Small molecular drug
DM2PDGO	PC	44425462
DM2PDGO	MW	448.5
DM2PDGO	FM	C23H28O7S
DM2PDGO	IC	InChI=1S/C23H28O7S/c1-12(24)31-17-9-15(20(26)28-4)22(2)7-5-14-21(27)30-16(13-6-8-29-11-13)10-23(14,3)19(22)18(17)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17+,19-,22-,23-/m0/s1
DM2PDGO	CS	CC(=O)S[C@@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DM2PDGO	IK	SIUXIXPAKGOVLQ-KWMFLVSKSA-N
DM2PDGO	IU	methyl (2S,4aR,6aR,7R,9R,10aS,10bR)-9-acetylsulfanyl-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM2PDGO	DE	Discovery agent

DMZXIW0	ID	DMZXIW0
DMZXIW0	DN	2-EPI-2-THIOSALVINORIN B
DMZXIW0	HS	Investigative
DMZXIW0	SN	2-epi-2-thiosalvinorin B; CHEMBL231638
DMZXIW0	DT	Small molecular drug
DMZXIW0	PC	44425463
DMZXIW0	MW	406.5
DMZXIW0	FM	C21H26O6S
DMZXIW0	IC	InChI=1S/C21H26O6S/c1-20-6-4-12-19(24)27-14(11-5-7-26-10-11)9-21(12,2)17(20)16(22)15(28)8-13(20)18(23)25-3/h5,7,10,12-15,17,28H,4,6,8-9H2,1-3H3/t12-,13-,14-,15+,17-,20-,21-/m0/s1
DMZXIW0	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@@H](C[C@H]2C(=O)OC)S)C)C4=COC=C4
DMZXIW0	IK	NGNBKFTYZQINBO-ZNKMMSAYSA-N
DMZXIW0	IU	methyl (2S,4aR,6aR,7R,9R,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-sulfanyl-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMZXIW0	DE	Discovery agent

DMNVJY0	ID	DMNVJY0
DMNVJY0	DN	2'-epi-guianin
DMNVJY0	HS	Investigative
DMNVJY0	SN	CHEMBL570978; 2'-epi-guianin; 2''-epi-guianin
DMNVJY0	DT	Small molecular drug
DMNVJY0	PC	45487149
DMNVJY0	MW	352.4
DMNVJY0	FM	C22H24O4
DMNVJY0	IC	InChI=1S/C22H24O4/c1-4-6-15-11-22(9-5-2)13(3)18(19(20(15)23)21(22)24)14-7-8-16-17(10-14)26-12-25-16/h4-5,7-8,10-11,13,18-19,21,24H,1-2,6,9,12H2,3H3/t13-,18+,19?,21+,22+/m1/s1
DMNVJY0	CS	C[C@@H]1[C@H](C2[C@@H]([C@]1(C=C(C2=O)CC=C)CC=C)O)C3=CC4=C(C=C3)OCO4
DMNVJY0	IK	IELYWLBCFOCUNW-KUXMWZRESA-N
DMNVJY0	IU	(5R,6R,7R,8S)-7-(1,3-benzodioxol-5-yl)-8-hydroxy-6-methyl-3,5-bis(prop-2-enyl)bicyclo[3.2.1]oct-3-en-2-one
DMNVJY0	DE	Discovery agent

DMGRA3T	ID	DMGRA3T
DMGRA3T	DN	2-ethoxy-5-(m-tolylethynyl)pyrimidine
DMGRA3T	HS	Investigative
DMGRA3T	SN	CHEMBL496874; 2-ethoxy-5-(m-tolylethynyl)pyrimidine; Pyrimidine,2-ethoxy-5-[2-(3-methylphenyl)ethynyl]-; BDBM50278923
DMGRA3T	DT	Small molecular drug
DMGRA3T	PC	44190034
DMGRA3T	MW	238.28
DMGRA3T	FM	C15H14N2O
DMGRA3T	IC	InChI=1S/C15H14N2O/c1-3-18-15-16-10-14(11-17-15)8-7-13-6-4-5-12(2)9-13/h4-6,9-11H,3H2,1-2H3
DMGRA3T	CS	CCOC1=NC=C(C=N1)C#CC2=CC=CC(=C2)C
DMGRA3T	IK	LZJPKUYOMGXTBK-UHFFFAOYSA-N
DMGRA3T	IU	2-ethoxy-5-[2-(3-methylphenyl)ethynyl]pyrimidine
DMGRA3T	DE	Discovery agent

DM0BHKM	ID	DM0BHKM
DM0BHKM	DN	2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine
DM0BHKM	HS	Investigative
DM0BHKM	SN	CHEMBL265695; SCHEMBL3677848
DM0BHKM	DT	Small molecular drug
DM0BHKM	PC	44449741
DM0BHKM	MW	230.29
DM0BHKM	FM	C12H10N2OS
DM0BHKM	IC	InChI=1S/C12H10N2OS/c1-2-10-13-8-5-7-16-12(8)11(14-10)9-4-3-6-15-9/h3-7H,2H2,1H3
DM0BHKM	CS	CCC1=NC2=C(C(=N1)C3=CC=CO3)SC=C2
DM0BHKM	IK	UPHUXPVSRYTEBO-UHFFFAOYSA-N
DM0BHKM	IU	2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine
DM0BHKM	DE	Discovery agent

DMR0IEK	ID	DMR0IEK
DMR0IEK	DN	2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine
DMR0IEK	HS	Investigative
DMR0IEK	SN	CHEMBL259338; SCHEMBL3684676
DMR0IEK	DT	Small molecular drug
DMR0IEK	PC	44449709
DMR0IEK	MW	230.29
DMR0IEK	FM	C12H10N2OS
DMR0IEK	IC	InChI=1S/C12H10N2OS/c1-2-10-13-9-4-6-16-12(9)11(14-10)8-3-5-15-7-8/h3-7H,2H2,1H3
DMR0IEK	CS	CCC1=NC2=C(C(=N1)C3=COC=C3)SC=C2
DMR0IEK	IK	XVRNMWQROQLUBA-UHFFFAOYSA-N
DMR0IEK	IU	2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine
DMR0IEK	DE	Discovery agent

DMWFR16	ID	DMWFR16
DMWFR16	DN	2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine
DMWFR16	HS	Investigative
DMWFR16	SN	CHEMBL259337; SCHEMBL3684919
DMWFR16	DT	Small molecular drug
DMWFR16	PC	9964781
DMWFR16	MW	241.31
DMWFR16	FM	C13H11N3S
DMWFR16	IC	InChI=1S/C13H11N3S/c1-2-11-15-10-6-8-17-13(10)12(16-11)9-5-3-4-7-14-9/h3-8H,2H2,1H3
DMWFR16	CS	CCC1=NC2=C(C(=N1)C3=CC=CC=N3)SC=C2
DMWFR16	IK	RJLBQJZGTPMDPY-UHFFFAOYSA-N
DMWFR16	IU	2-ethyl-4-pyridin-2-ylthieno[3,2-d]pyrimidine
DMWFR16	DE	Discovery agent

DMWCGE8	ID	DMWCGE8
DMWCGE8	DN	2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMWCGE8	HS	Investigative
DMWCGE8	SN	CHEMBL407650; 2-ethyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine; 443148-33-2; SCHEMBL3674131
DMWCGE8	DT	Small molecular drug
DMWCGE8	PC	9834769
DMWCGE8	MW	247.3
DMWCGE8	FM	C11H9N3S2
DMWCGE8	IC	InChI=1S/C11H9N3S2/c1-2-8-13-7-3-5-15-10(7)9(14-8)11-12-4-6-16-11/h3-6H,2H2,1H3
DMWCGE8	CS	CCC1=NC2=C(C(=N1)C3=NC=CS3)SC=C2
DMWCGE8	IK	YNBYJWXOQPYWEM-UHFFFAOYSA-N
DMWCGE8	IU	2-ethyl-4-(1,3-thiazol-2-yl)thieno[3,2-d]pyrimidine
DMWCGE8	DE	Discovery agent

DMIRSQO	ID	DMIRSQO
DMIRSQO	DN	2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine
DMIRSQO	HS	Investigative
DMIRSQO	SN	CHEMBL402817; SCHEMBL3677642
DMIRSQO	DT	Small molecular drug
DMIRSQO	PC	44449258
DMIRSQO	MW	246.4
DMIRSQO	FM	C12H10N2S2
DMIRSQO	IC	InChI=1S/C12H10N2S2/c1-2-10-13-8-5-7-16-12(8)11(14-10)9-4-3-6-15-9/h3-7H,2H2,1H3
DMIRSQO	CS	CCC1=NC2=C(C(=N1)C3=CC=CS3)SC=C2
DMIRSQO	IK	HTDFKCHXFHIXPU-UHFFFAOYSA-N
DMIRSQO	IU	2-ethyl-4-thiophen-2-ylthieno[3,2-d]pyrimidine
DMIRSQO	DE	Discovery agent

DMLC8OB	ID	DMLC8OB
DMLC8OB	DN	2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole
DMLC8OB	HS	Investigative
DMLC8OB	SN	CHEMBL194412; 1h-indole,2-ethyl-5-methoxy-3-(4-piperidinyl)-; 866404-90-2; 2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole; ZINC28526364; BDBM50171247
DMLC8OB	DT	Small molecular drug
DMLC8OB	PC	44403334
DMLC8OB	MW	258.36
DMLC8OB	FM	C16H22N2O
DMLC8OB	IC	InChI=1S/C16H22N2O/c1-3-14-16(11-6-8-17-9-7-11)13-10-12(19-2)4-5-15(13)18-14/h4-5,10-11,17-18H,3,6-9H2,1-2H3
DMLC8OB	CS	CCC1=C(C2=C(N1)C=CC(=C2)OC)C3CCNCC3
DMLC8OB	IK	UMTBQNCFQQORNJ-UHFFFAOYSA-N
DMLC8OB	IU	2-ethyl-5-methoxy-3-piperidin-4-yl-1H-indole
DMLC8OB	DE	Discovery agent

DMN8W1H	ID	DMN8W1H
DMN8W1H	DN	2-ethyl-9H-carbazole
DMN8W1H	HS	Investigative
DMN8W1H	SN	2-ethyl-9H-carbazole; 9H-Carbazole, 2-ethyl-; CHEMBL1171435; 106551-62-6; SCHEMBL278610; AC1L3D11; BDBM50322582
DMN8W1H	DT	Small molecular drug
DMN8W1H	PC	138537
DMN8W1H	MW	195.26
DMN8W1H	FM	C14H13N
DMN8W1H	IC	InChI=1S/C14H13N/c1-2-10-7-8-12-11-5-3-4-6-13(11)15-14(12)9-10/h3-9,15H,2H2,1H3
DMN8W1H	CS	CCC1=CC2=C(C=C1)C3=CC=CC=C3N2
DMN8W1H	IK	MLTJHZTUKWUPTG-UHFFFAOYSA-N
DMN8W1H	IU	2-ethyl-9H-carbazole
DMN8W1H	CA	CAS 5599-49-5
DMN8W1H	DE	Discovery agent

DMDY3JQ	ID	DMDY3JQ
DMDY3JQ	DN	2-ethylamido-5-sulfonamidoindane
DMDY3JQ	HS	Investigative
DMDY3JQ	SN	CHEMBL204740; 2-ethylamido-5-sulfonamidoindane; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)propanamide; Indanesulfonamide Derivative 12d
DMDY3JQ	DT	Small molecular drug
DMDY3JQ	PC	11543564
DMDY3JQ	MW	268.33
DMDY3JQ	FM	C12H16N2O3S
DMDY3JQ	IC	InChI=1S/C12H16N2O3S/c1-2-12(15)14-10-5-8-3-4-11(18(13,16)17)7-9(8)6-10/h3-4,7,10H,2,5-6H2,1H3,(H,14,15)(H2,13,16,17)
DMDY3JQ	CS	CCC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DMDY3JQ	IK	PFHQSNAQKZORAY-UHFFFAOYSA-N
DMDY3JQ	IU	N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)propanamide
DMDY3JQ	DE	Discovery agent

DMC10DR	ID	DMC10DR
DMC10DR	DN	2-ethylestradiol 3,17-O,O-bis-sulfamate
DMC10DR	HS	Investigative
DMC10DR	SN	2-ethylestradiol-3,17-O,O-bis-sulfamate; CHEMBL425287; (9beta,13alpha,14beta,17alpha)-2-Ethylestra-1(10),2,4-Triene-3,17-Diyl Disulfamate; 2-ethyloestradiol-bis-sulfamate; 3oik; WZB; 2x7t; 2-EbM; SCHEMBL3690812; BDBM50200941; LS-193106; 2-Ethyl-3,17beta-bis(sulfamoyloxy)estra-1,3,5(10)-triene; Estra-1,3,5(10)-triene-3,17-diol, 2-ethyl-, disulfamate, (17beta)-
DMC10DR	DT	Small molecular drug
DMC10DR	PC	11583423
DMC10DR	MW	458.6
DMC10DR	FM	C20H30N2O6S2
DMC10DR	IC	InChI=1S/C20H30N2O6S2/c1-3-12-10-16-13(11-18(12)27-29(21,23)24)4-5-15-14(16)8-9-20(2)17(15)6-7-19(20)28-30(22,25)26/h10-11,14-15,17,19H,3-9H2,1-2H3,(H2,21,23,24)(H2,22,25,26)/t14-,15+,17-,19-,20-/m0/s1
DMC10DR	CS	CCC1=C(C=C2CC[C@@H]3[C@@H](C2=C1)CC[C@]4([C@H]3CC[C@@H]4OS(=O)(=O)N)C)OS(=O)(=O)N
DMC10DR	IK	LDOGEZTUWBORPG-SSGANFLRSA-N
DMC10DR	IU	[(8R,9S,13S,14S,17S)-2-ethyl-13-methyl-3-sulfamoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMC10DR	CA	CAS 556813-12-8
DMC10DR	DE	Discovery agent

DMKR47X	ID	DMKR47X
DMKR47X	DN	2-ethylquinoline-8-carboxamide
DMKR47X	HS	Investigative
DMKR47X	SN	CHEMBL526128; 2-ethylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 2-ethyl-; BDBM50255330
DMKR47X	DT	Small molecular drug
DMKR47X	PC	25208752
DMKR47X	MW	200.24
DMKR47X	FM	C12H12N2O
DMKR47X	IC	InChI=1S/C12H12N2O/c1-2-9-7-6-8-4-3-5-10(12(13)15)11(8)14-9/h3-7H,2H2,1H3,(H2,13,15)
DMKR47X	CS	CCC1=NC2=C(C=CC=C2C(=O)N)C=C1
DMKR47X	IK	DFEARBGMUARFKD-UHFFFAOYSA-N
DMKR47X	IU	2-ethylquinoline-8-carboxamide
DMKR47X	DE	Discovery agent

DME6VKS	ID	DME6VKS
DME6VKS	DN	2-ethynyl-4-(3-fluorophenylethynyl)thiazole
DME6VKS	HS	Investigative
DME6VKS	SN	CHEMBL201939; 2-ethynyl-4-(3-fluorophenylethynyl)thiazole; SCHEMBL4138461; Thiazole, 2-ethynyl-4-[2-(3-fluorophenyl)ethynyl]-; BDBM50181773
DME6VKS	DT	Small molecular drug
DME6VKS	PC	11550377
DME6VKS	MW	227.26
DME6VKS	FM	C13H6FNS
DME6VKS	IC	InChI=1S/C13H6FNS/c1-2-13-15-12(9-16-13)7-6-10-4-3-5-11(14)8-10/h1,3-5,8-9H
DME6VKS	CS	C#CC1=NC(=CS1)C#CC2=CC(=CC=C2)F
DME6VKS	IK	SECGPKGEFXVRQQ-UHFFFAOYSA-N
DME6VKS	IU	2-ethynyl-4-[2-(3-fluorophenyl)ethynyl]-1,3-thiazole
DME6VKS	DE	Discovery agent

DM2D78W	ID	DM2D78W
DM2D78W	DN	2-ethynyl-N6-methoxyadenosine
DM2D78W	HS	Investigative
DM2D78W	SN	CHEMBL374019; 2-ethynyl-N6-methoxyadenosine; SCHEMBL4389749
DM2D78W	DT	Small molecular drug
DM2D78W	PC	16115754
DM2D78W	MW	321.29
DM2D78W	FM	C13H15N5O5
DM2D78W	IC	InChI=1S/C13H15N5O5/c1-3-7-15-11(17-22-2)8-12(16-7)18(5-14-8)13-10(21)9(20)6(4-19)23-13/h1,5-6,9-10,13,19-21H,4H2,2H3,(H,15,16,17)/t6-,9-,10-,13-/m1/s1
DM2D78W	CS	CONC1=C2C(=NC(=N1)C#C)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DM2D78W	IK	DPDYWTZJFUXIEE-ZRFIDHNTSA-N
DM2D78W	IU	(2R,3R,4S,5R)-2-[2-ethynyl-6-(methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM2D78W	DE	Discovery agent

DMNOAJG	ID	DMNOAJG
DMNOAJG	DN	2ewy
DMNOAJG	HS	Investigative
DMNOAJG	SN	2ewy; N-{(1s,2r)-1-Benzyl-2-Hydroxy-3-[(3-Methylbenzyl)amino]propyl}dibenzo[b,F]oxepine-10-Carboxamide; GTPL8688; DBO; hydroxyethylamine transition-state inhibitor 1; N-[(2S,3R)-3-hydroxy-4-[(3-methylphenyl)methylamino]-1-phenylbutan-2-yl]benzo[b][1]benzoxepine-6-carboxamide
DMNOAJG	DT	Small molecular drug
DMNOAJG	PC	11963503
DMNOAJG	MW	504.6
DMNOAJG	FM	C33H32N2O3
DMNOAJG	IC	InChI=1S/C33H32N2O3/c1-23-10-9-13-25(18-23)21-34-22-30(36)29(19-24-11-3-2-4-12-24)35-33(37)28-20-26-14-5-7-16-31(26)38-32-17-8-6-15-27(28)32/h2-18,20,29-30,34,36H,19,21-22H2,1H3,(H,35,37)/t29-,30+/m0/s1
DMNOAJG	CS	CC1=CC(=CC=C1)CNC[C@H]([C@H](CC2=CC=CC=C2)NC(=O)C3=CC4=CC=CC=C4OC5=CC=CC=C53)O
DMNOAJG	IK	BNWZCXDHHPBQOX-XZWHSSHBSA-N
DMNOAJG	IU	N-[(2S,3R)-3-hydroxy-4-[(3-methylphenyl)methylamino]-1-phenylbutan-2-yl]benzo[b][1]benzoxepine-5-carboxamide
DMNOAJG	DE	Discovery agent

DMUGAT8	ID	DMUGAT8
DMUGAT8	DN	2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol
DMUGAT8	HS	Investigative
DMUGAT8	SN	CHEMBL577338; 2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol; SCHEMBL1180589
DMUGAT8	DT	Small molecular drug
DMUGAT8	PC	25192477
DMUGAT8	MW	286.3
DMUGAT8	FM	C16H11FO2S
DMUGAT8	IC	InChI=1S/C16H11FO2S/c17-13-9-11(4-5-14(13)19)16-7-6-15(20-16)10-2-1-3-12(18)8-10/h1-9,18-19H
DMUGAT8	CS	C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=C(C=C3)O)F
DMUGAT8	IK	NRSWHXCLBQLBRC-UHFFFAOYSA-N
DMUGAT8	IU	2-fluoro-4-[5-(3-hydroxyphenyl)thiophen-2-yl]phenol
DMUGAT8	DE	Discovery agent

DMGBEFY	ID	DMGBEFY
DMGBEFY	DN	2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol
DMGBEFY	HS	Investigative
DMGBEFY	SN	CHEMBL570110; 2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol
DMGBEFY	DT	Small molecular drug
DMGBEFY	PC	44543255
DMGBEFY	MW	286.3
DMGBEFY	FM	C16H11FO2S
DMGBEFY	IC	InChI=1S/C16H11FO2S/c17-14-7-10(4-5-15(14)19)12-8-16(20-9-12)11-2-1-3-13(18)6-11/h1-9,18-19H
DMGBEFY	CS	C1=CC(=CC(=C1)O)C2=CC(=CS2)C3=CC(=C(C=C3)O)F
DMGBEFY	IK	MOBQDOLSPUFHFF-UHFFFAOYSA-N
DMGBEFY	IU	2-fluoro-4-[5-(3-hydroxyphenyl)thiophen-3-yl]phenol
DMGBEFY	DE	Discovery agent

DMCGI1S	ID	DMCGI1S
DMCGI1S	DN	2-fluoro-5-(3-methylthiophen-2-yl)pyridine
DMCGI1S	HS	Investigative
DMCGI1S	SN	2-fluoro-5-(3-methylthiophen-2-yl)pyridine; CHEMBL179621; 837376-37-1; Pyridine, 2-fluoro-5-(3-methyl-2-thienyl)-; SCHEMBL957977; BDBM12354; CTK3D1374; DTXSID90456895; RYGQGRAICBWYPW-UHFFFAOYSA-N; nicotine 3-heteroaromatic analogue 7; US8609708,10
DMCGI1S	DT	Small molecular drug
DMCGI1S	PC	11148236
DMCGI1S	MW	193.24
DMCGI1S	FM	C10H8FNS
DMCGI1S	IC	InChI=1S/C10H8FNS/c1-7-4-5-13-10(7)8-2-3-9(11)12-6-8/h2-6H,1H3
DMCGI1S	CS	CC1=C(SC=C1)C2=CN=C(C=C2)F
DMCGI1S	IK	RYGQGRAICBWYPW-UHFFFAOYSA-N
DMCGI1S	IU	2-fluoro-5-(3-methylthiophen-2-yl)pyridine
DMCGI1S	CA	CAS 837376-37-1
DMCGI1S	DE	Discovery agent

DMKOUCM	ID	DMKOUCM
DMKOUCM	DN	2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMKOUCM	HS	Investigative
DMKOUCM	SN	CHEMBL570595; 2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMKOUCM	DT	Small molecular drug
DMKOUCM	PC	44542049
DMKOUCM	MW	286.3
DMKOUCM	FM	C16H11FO2S
DMKOUCM	IC	InChI=1S/C16H11FO2S/c17-13-6-3-11(9-14(13)19)16-8-7-15(20-16)10-1-4-12(18)5-2-10/h1-9,18-19H
DMKOUCM	CS	C1=CC(=CC=C1C2=CC=C(S2)C3=CC(=C(C=C3)F)O)O
DMKOUCM	IK	QFKIHVDWWIPQTB-UHFFFAOYSA-N
DMKOUCM	IU	2-fluoro-5-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMKOUCM	DE	Discovery agent

DMP8OXL	ID	DMP8OXL
DMP8OXL	DN	2-Fluoro-6-(3-phenoxy-benzoylamino)-benzoic acid
DMP8OXL	HS	Investigative
DMP8OXL	SN	CHEMBL426645; BDBM23611; 3-Phenoxybenzoylamino deriv., 28e; 2-fluoro-6-(3-phenoxybenzoylamino)benzoic acid; 2-fluoro-6-[(3-phenoxybenzene)amido]benzoic acid
DMP8OXL	DT	Small molecular drug
DMP8OXL	PC	11772508
DMP8OXL	MW	351.3
DMP8OXL	FM	C20H14FNO4
DMP8OXL	IC	InChI=1S/C20H14FNO4/c21-16-10-5-11-17(18(16)20(24)25)22-19(23)13-6-4-9-15(12-13)26-14-7-2-1-3-8-14/h1-12H,(H,22,23)(H,24,25)
DMP8OXL	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)NC3=C(C(=CC=C3)F)C(=O)O
DMP8OXL	IK	MUCVEZAGZUMXAG-UHFFFAOYSA-N
DMP8OXL	IU	2-fluoro-6-[(3-phenoxybenzoyl)amino]benzoic acid
DMP8OXL	DE	Discovery agent

DMEQRHY	ID	DMEQRHY
DMEQRHY	DN	2-fluoromevalonate 5-diphosphate
DMEQRHY	HS	Investigative
DMEQRHY	SN	2-fluoromevalonate 5-diphosphate; GTPL3204; 2-fluoro-3-hydroxy-5-{[hydroxy(phosphonooxy)phosphoryl]oxy}-3-methylpentanoic acid
DMEQRHY	DT	Small molecular drug
DMEQRHY	PC	56947015
DMEQRHY	MW	326.11
DMEQRHY	FM	C6H13FO10P2
DMEQRHY	IC	InChI=1S/C6H13FO10P2/c1-6(10,4(7)5(8)9)2-3-16-19(14,15)17-18(11,12)13/h4,10H,2-3H2,1H3,(H,8,9)(H,14,15)(H2,11,12,13)
DMEQRHY	CS	CC(CCOP(=O)(O)OP(=O)(O)O)(C(C(=O)O)F)O
DMEQRHY	IK	WPXHWHACORBSDS-UHFFFAOYSA-N
DMEQRHY	IU	2-fluoro-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid
DMEQRHY	DE	Discovery agent

DMX34TL	ID	DMX34TL
DMX34TL	DN	2-fluoronorepinehprine
DMX34TL	HS	Investigative
DMX34TL	SN	CHEMBL40317; Lopac-B-012; AC1O7G01; CTK2G6131; BDBM50087513; NCGC00015118-01; 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-5-fluoro-; 4-[(1R)-2-amino-1-hydroxyethyl]-5-fluorobenzene-1,2-diol; (R)4-(2-Amino-1-hydroxy-ethyl)-5-fluoro-benzene-1,2-diol
DMX34TL	DT	Small molecular drug
DMX34TL	PC	6603724
DMX34TL	MW	187.17
DMX34TL	FM	C8H10FNO3
DMX34TL	IC	InChI=1S/C8H10FNO3/c9-5-2-7(12)6(11)1-4(5)8(13)3-10/h1-2,8,11-13H,3,10H2/t8-/m0/s1
DMX34TL	CS	C1=C(C(=CC(=C1O)O)F)[C@H](CN)O
DMX34TL	IK	SBUQBFTXTZSRMH-QMMMGPOBSA-N
DMX34TL	IU	4-[(1R)-2-amino-1-hydroxyethyl]-5-fluorobenzene-1,2-diol
DMX34TL	DE	Discovery agent

DM5OW91	ID	DM5OW91
DM5OW91	DN	2-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate
DM5OW91	HS	Investigative
DM5OW91	SN	CHEMBL597030; 2-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate; SCHEMBL5216198
DM5OW91	DT	Small molecular drug
DM5OW91	PC	20872688
DM5OW91	MW	345.4
DM5OW91	FM	C20H24FNO3
DM5OW91	IC	InChI=1S/C20H24FNO3/c1-3-5-14-24-16-12-10-15(11-13-16)18(4-2)22-20(23)25-19-9-7-6-8-17(19)21/h6-13,18H,3-5,14H2,1-2H3,(H,22,23)
DM5OW91	CS	CCCCOC1=CC=C(C=C1)C(CC)NC(=O)OC2=CC=CC=C2F
DM5OW91	IK	GDLJXVIFSNBWKP-UHFFFAOYSA-N
DM5OW91	IU	(2-fluorophenyl) N-[1-(4-butoxyphenyl)propyl]carbamate
DM5OW91	DE	Discovery agent

DMSFQAZ	ID	DMSFQAZ
DMSFQAZ	DN	2-fluorophenyl 4-(decyloxy)phenylcarbamate
DMSFQAZ	HS	Investigative
DMSFQAZ	SN	2-fluorophenyl 4-(decyloxy)phenylcarbamate; CHEMBL591825; SCHEMBL5218224
DMSFQAZ	DT	Small molecular drug
DMSFQAZ	PC	20872692
DMSFQAZ	MW	387.5
DMSFQAZ	FM	C23H30FNO3
DMSFQAZ	IC	InChI=1S/C23H30FNO3/c1-2-3-4-5-6-7-8-11-18-27-20-16-14-19(15-17-20)25-23(26)28-22-13-10-9-12-21(22)24/h9-10,12-17H,2-8,11,18H2,1H3,(H,25,26)
DMSFQAZ	CS	CCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMSFQAZ	IK	PWZMFAZZDZNTOQ-UHFFFAOYSA-N
DMSFQAZ	IU	(2-fluorophenyl) N-(4-decoxyphenyl)carbamate
DMSFQAZ	DE	Discovery agent

DMCEGZU	ID	DMCEGZU
DMCEGZU	DN	2-fluorophenyl 4-(dodecyloxy)phenylcarbamate
DMCEGZU	HS	Investigative
DMCEGZU	SN	CHEMBL599488; 2-fluorophenyl 4-(dodecyloxy)phenylcarbamate
DMCEGZU	DT	Small molecular drug
DMCEGZU	PC	20872693
DMCEGZU	MW	415.5
DMCEGZU	FM	C25H34FNO3
DMCEGZU	IC	InChI=1S/C25H34FNO3/c1-2-3-4-5-6-7-8-9-10-13-20-29-22-18-16-21(17-19-22)27-25(28)30-24-15-12-11-14-23(24)26/h11-12,14-19H,2-10,13,20H2,1H3,(H,27,28)
DMCEGZU	CS	CCCCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMCEGZU	IK	WEDCHEHVZVVAIL-UHFFFAOYSA-N
DMCEGZU	IU	(2-fluorophenyl) N-(4-dodecoxyphenyl)carbamate
DMCEGZU	DE	Discovery agent

DMLM2WU	ID	DMLM2WU
DMLM2WU	DN	2-fluorophenyl 4-(heptyloxy)phenylcarbamate
DMLM2WU	HS	Investigative
DMLM2WU	SN	2-fluorophenyl 4-(heptyloxy)phenylcarbamate; CHEMBL610774
DMLM2WU	DT	Small molecular drug
DMLM2WU	PC	20872694
DMLM2WU	MW	345.4
DMLM2WU	FM	C20H24FNO3
DMLM2WU	IC	InChI=1S/C20H24FNO3/c1-2-3-4-5-8-15-24-17-13-11-16(12-14-17)22-20(23)25-19-10-7-6-9-18(19)21/h6-7,9-14H,2-5,8,15H2,1H3,(H,22,23)
DMLM2WU	CS	CCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMLM2WU	IK	SHLSOZYYUDUBRA-UHFFFAOYSA-N
DMLM2WU	IU	(2-fluorophenyl) N-(4-heptoxyphenyl)carbamate
DMLM2WU	DE	Discovery agent

DM854ED	ID	DM854ED
DM854ED	DN	2-fluorophenyl 4-(hexyloxy)phenylcarbamate
DM854ED	HS	Investigative
DM854ED	SN	2-fluorophenyl 4-(hexyloxy)phenylcarbamate; CHEMBL590243
DM854ED	DT	Small molecular drug
DM854ED	PC	20872695
DM854ED	MW	331.4
DM854ED	FM	C19H22FNO3
DM854ED	IC	InChI=1S/C19H22FNO3/c1-2-3-4-7-14-23-16-12-10-15(11-13-16)21-19(22)24-18-9-6-5-8-17(18)20/h5-6,8-13H,2-4,7,14H2,1H3,(H,21,22)
DM854ED	CS	CCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DM854ED	IK	ASBZIVYPMZQHBL-UHFFFAOYSA-N
DM854ED	IU	(2-fluorophenyl) N-(4-hexoxyphenyl)carbamate
DM854ED	DE	Discovery agent

DM81J0O	ID	DM81J0O
DM81J0O	DN	2-fluorophenyl 4-(octyloxy)phenylcarbamate
DM81J0O	HS	Investigative
DM81J0O	SN	2-fluorophenyl 4-(octyloxy)phenylcarbamate; CHEMBL597029; SCHEMBL5216564
DM81J0O	DT	Small molecular drug
DM81J0O	PC	20872696
DM81J0O	MW	359.4
DM81J0O	FM	C21H26FNO3
DM81J0O	IC	InChI=1S/C21H26FNO3/c1-2-3-4-5-6-9-16-25-18-14-12-17(13-15-18)23-21(24)26-20-11-8-7-10-19(20)22/h7-8,10-15H,2-6,9,16H2,1H3,(H,23,24)
DM81J0O	CS	CCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DM81J0O	IK	PHBVHSXINCCZDW-UHFFFAOYSA-N
DM81J0O	IU	(2-fluorophenyl) N-(4-octoxyphenyl)carbamate
DM81J0O	DE	Discovery agent

DMTYX5G	ID	DMTYX5G
DMTYX5G	DN	2-fluorophenyl 4-(undecyloxy)phenylcarbamate
DMTYX5G	HS	Investigative
DMTYX5G	SN	CHEMBL609024; 2-fluorophenyl 4-(undecyloxy)phenylcarbamate
DMTYX5G	DT	Small molecular drug
DMTYX5G	PC	20872698
DMTYX5G	MW	401.5
DMTYX5G	FM	C24H32FNO3
DMTYX5G	IC	InChI=1S/C24H32FNO3/c1-2-3-4-5-6-7-8-9-12-19-28-21-17-15-20(16-18-21)26-24(27)29-23-14-11-10-13-22(23)25/h10-11,13-18H,2-9,12,19H2,1H3,(H,26,27)
DMTYX5G	CS	CCCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMTYX5G	IK	PDDXKUNCGFODGC-UHFFFAOYSA-N
DMTYX5G	IU	(2-fluorophenyl) N-(4-undecoxyphenyl)carbamate
DMTYX5G	DE	Discovery agent

DM4EIQ3	ID	DM4EIQ3
DM4EIQ3	DN	2-fluorophenyl 4-butoxybenzylcarbamate
DM4EIQ3	HS	Investigative
DM4EIQ3	SN	2-fluorophenyl 4-butoxybenzylcarbamate; CHEMBL596876; SCHEMBL5223902
DM4EIQ3	DT	Small molecular drug
DM4EIQ3	PC	20872691
DM4EIQ3	MW	317.4
DM4EIQ3	FM	C18H20FNO3
DM4EIQ3	IC	InChI=1S/C18H20FNO3/c1-2-3-12-22-15-10-8-14(9-11-15)13-20-18(21)23-17-7-5-4-6-16(17)19/h4-11H,2-3,12-13H2,1H3,(H,20,21)
DM4EIQ3	CS	CCCCOC1=CC=C(C=C1)CNC(=O)OC2=CC=CC=C2F
DM4EIQ3	IK	XSSVFUMMMRTXER-UHFFFAOYSA-N
DM4EIQ3	IU	(2-fluorophenyl) N-[(4-butoxyphenyl)methyl]carbamate
DM4EIQ3	DE	Discovery agent

DMYJ1M4	ID	DMYJ1M4
DMYJ1M4	DN	2-fluorophenyl 4-butoxyphenylcarbamate
DMYJ1M4	HS	Investigative
DMYJ1M4	SN	2-fluorophenyl 4-butoxyphenylcarbamate; CHEMBL597924
DMYJ1M4	DT	Small molecular drug
DMYJ1M4	PC	20872690
DMYJ1M4	MW	303.33
DMYJ1M4	FM	C17H18FNO3
DMYJ1M4	IC	InChI=1S/C17H18FNO3/c1-2-3-12-21-14-10-8-13(9-11-14)19-17(20)22-16-7-5-4-6-15(16)18/h4-11H,2-3,12H2,1H3,(H,19,20)
DMYJ1M4	CS	CCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMYJ1M4	IK	IDOBASBUNMSFTC-UHFFFAOYSA-N
DMYJ1M4	IU	(2-fluorophenyl) N-(4-butoxyphenyl)carbamate
DMYJ1M4	DE	Discovery agent

DMGIKWA	ID	DMGIKWA
DMGIKWA	DN	2-fluorophenyl 4'-ethylbiphenyl-4-ylcarbamate
DMGIKWA	HS	Investigative
DMGIKWA	SN	CHEMBL599180; BDBM50309731; 2-fluorophenyl 4''-ethylbiphenyl-4-ylcarbamate
DMGIKWA	DT	Small molecular drug
DMGIKWA	PC	20872689
DMGIKWA	MW	335.4
DMGIKWA	FM	C21H18FNO2
DMGIKWA	IC	InChI=1S/C21H18FNO2/c1-2-15-7-9-16(10-8-15)17-11-13-18(14-12-17)23-21(24)25-20-6-4-3-5-19(20)22/h3-14H,2H2,1H3,(H,23,24)
DMGIKWA	CS	CCC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)OC3=CC=CC=C3F
DMGIKWA	IK	XHWBLLJZJZYEES-UHFFFAOYSA-N
DMGIKWA	IU	(2-fluorophenyl) N-[4-(4-ethylphenyl)phenyl]carbamate
DMGIKWA	DE	Discovery agent

DMSMDQC	ID	DMSMDQC
DMSMDQC	DN	2-fluorophenyl 4-phenoxyphenylcarbamate
DMSMDQC	HS	Investigative
DMSMDQC	SN	2-fluorophenyl 4-phenoxyphenylcarbamate; CHEMBL599179; BDBM50309730
DMSMDQC	DT	Small molecular drug
DMSMDQC	PC	20872697
DMSMDQC	MW	323.3
DMSMDQC	FM	C19H14FNO3
DMSMDQC	IC	InChI=1S/C19H14FNO3/c20-17-8-4-5-9-18(17)24-19(22)21-14-10-12-16(13-11-14)23-15-6-2-1-3-7-15/h1-13H,(H,21,22)
DMSMDQC	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)OC3=CC=CC=C3F
DMSMDQC	IK	KFKCZSDVVBTNPG-UHFFFAOYSA-N
DMSMDQC	IU	(2-fluorophenyl) N-(4-phenoxyphenyl)carbamate
DMSMDQC	DE	Discovery agent

DMNPGXA	ID	DMNPGXA
DMNPGXA	DN	2-fluorophenyl-2,2-diphenylacetamide
DMNPGXA	HS	Investigative
DMNPGXA	SN	CHEMBL270071; SCHEMBL1784375
DMNPGXA	DT	Small molecular drug
DMNPGXA	PC	9814995
DMNPGXA	MW	305.3
DMNPGXA	FM	C20H16FNO
DMNPGXA	IC	InChI=1S/C20H16FNO/c21-18-14-8-7-13-17(18)20(19(22)23,15-9-3-1-4-10-15)16-11-5-2-6-12-16/h1-14H,(H2,22,23)
DMNPGXA	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3F)C(=O)N
DMNPGXA	IK	YDVJKRJJBXTMCW-UHFFFAOYSA-N
DMNPGXA	IU	2-(2-fluorophenyl)-2,2-diphenylacetamide
DMNPGXA	DE	Discovery agent

DMXPFYZ	ID	DMXPFYZ
DMXPFYZ	DN	2-fluorophenylboronic acid
DMXPFYZ	HS	Investigative
DMXPFYZ	SN	2-Fluorophenylboronic acid; 1993-03-9; (2-fluorophenyl)boronic acid; 2-Fluorobenzeneboronic Acid; (2-fluorophenyl)boranediol; Boronic acid, B-(2-fluorophenyl)-; o-fluorophenylboronic acid; 2-fluorophenyl boronic acid; 2-fluoro-phenyl-boronic acid; BORONIC ACID, (2-FLUOROPHENYL)-; MFCD00674013; 2-Fluorophenylboronic acid, 98%; 34-03-7; PubChem1856; 2-Fluorophenylboronicacid; o-fluorobenzeneboronic acid; ACMC-1BR1I; o -Fluorophenylboronic acid; 2-fluoro-phenylboronic acid; AC1MC0Y0; 2-fluoro phenylboronic acid
DMXPFYZ	DT	Small molecular drug
DMXPFYZ	PC	2734354
DMXPFYZ	MW	139.92
DMXPFYZ	FM	C6H6BFO2
DMXPFYZ	IC	InChI=1S/C6H6BFO2/c8-6-4-2-1-3-5(6)7(9)10/h1-4,9-10H
DMXPFYZ	CS	B(C1=CC=CC=C1F)(O)O
DMXPFYZ	IK	QCSLIRFWJPOENV-UHFFFAOYSA-N
DMXPFYZ	IU	(2-fluorophenyl)boronic acid
DMXPFYZ	DE	Discovery agent

DM28XTE	ID	DM28XTE
DM28XTE	DN	2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one
DM28XTE	HS	Investigative
DM28XTE	SN	CHEMBL180336; 2-(furan-2-yl)-3-phenethylquinazolin-4-one; AC1LEB94; 2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one; Oprea1_070906; 2-(2-furyl)-3-(2-phenylethyl)-4(3H)-quinazolinone; ZINC49416; NPS-53574; BDBM50162542; STK674065; AKOS005593239; MCULE-4160039246; ST008066; J3.621.250K; 2-(2-furyl)-3-phenethyl-4(3H)-quinazolinone; AG-205/11559428; SR-01000416527; SR-01000416527-1; 2-(2-furyl)-3-(2-phenylethyl)-3-hydroquinazolin-4-one; 2-(furan-2-yl)-3-(2-phenylethyl)quinazolin-4(3H)-one; A1715/0073151
DM28XTE	DT	Small molecular drug
DM28XTE	PC	683379
DM28XTE	MW	316.4
DM28XTE	FM	C20H16N2O2
DM28XTE	IC	InChI=1S/C20H16N2O2/c23-20-16-9-4-5-10-17(16)21-19(18-11-6-14-24-18)22(20)13-12-15-7-2-1-3-8-15/h1-11,14H,12-13H2
DM28XTE	CS	C1=CC=C(C=C1)CCN2C(=NC3=CC=CC=C3C2=O)C4=CC=CO4
DM28XTE	IK	ZFIMKOHGGKYLGR-UHFFFAOYSA-N
DM28XTE	IU	2-(furan-2-yl)-3-(2-phenylethyl)quinazolin-4-one
DM28XTE	DE	Discovery agent

DMQIFJ9	ID	DMQIFJ9
DMQIFJ9	DN	2-Furan-2-yl-4,5-dihydro-1H-imidazole
DMQIFJ9	HS	Investigative
DMQIFJ9	SN	2-Furan-2-yl-4,5-dihydro-1H-imidazole; 2-(furan-2-yl)-4,5-dihydro-1H-imidazole; 40029-93-4; CHEMBL14410; 2-(2-furyl)-4,5-dihydro-1H-imidazole; AC1LHNFC; BAS 00087895; 2-(2-furyl)imidazoline; 2-(2-imidazolin-2-yl)furan; 2-(1-Imidazoline-2-yl)furan; CTK5J7407; DTXSID40357040; MolPort-001-914-212; HMS1698J05; ZINC4992560; BDBM50138501; 2536AE; AKOS000301450; MCULE-8474767921; ST072486; TR-043590
DMQIFJ9	DT	Small molecular drug
DMQIFJ9	PC	840808
DMQIFJ9	MW	136.15
DMQIFJ9	FM	C7H8N2O
DMQIFJ9	IC	InChI=1S/C7H8N2O/c1-2-6(10-5-1)7-8-3-4-9-7/h1-2,5H,3-4H2,(H,8,9)
DMQIFJ9	CS	C1CN=C(N1)C2=CC=CO2
DMQIFJ9	IK	IOTMYJAUZMRWCJ-UHFFFAOYSA-N
DMQIFJ9	IU	2-(furan-2-yl)-4,5-dihydro-1H-imidazole
DMQIFJ9	CA	CAS 40029-93-4
DMQIFJ9	DE	Discovery agent

DMHT80R	ID	DMHT80R
DMHT80R	DN	2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMHT80R	HS	Investigative
DMHT80R	DT	Small molecular drug
DMHT80R	PC	135511822
DMHT80R	MW	251.24
DMHT80R	FM	C14H9N3O2
DMHT80R	IC	InChI=1S/C14H9N3O2/c18-14-15-10-5-2-1-4-9(10)12-8-11(16-17(12)14)13-6-3-7-19-13/h1-8H,(H,15,18)
DMHT80R	CS	C1=CC=C2C(=C1)C3=CC(=NN3C(=O)N2)C4=CC=CO4
DMHT80R	IK	HWHAANIZIAJOCF-UHFFFAOYSA-N
DMHT80R	IU	2-(furan-2-yl)-6H-pyrazolo[1,5-c]quinazolin-5-one
DMHT80R	DE	Discovery agent

DMD8ZUH	ID	DMD8ZUH
DMD8ZUH	DN	2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one
DMD8ZUH	HS	Investigative
DMD8ZUH	SN	9008-02-0; CHEMBL130391
DMD8ZUH	DT	Small molecular drug
DMD8ZUH	PC	13285535
DMD8ZUH	MW	226.23
DMD8ZUH	FM	C13H10N2O2
DMD8ZUH	IC	InChI=1S/C13H10N2O2/c1-8-4-5-9-11(16)7-10(15-13(9)14-8)12-3-2-6-17-12/h2-7H,1H3,(H,14,15,16)
DMD8ZUH	CS	CC1=NC2=C(C=C1)C(=O)C=C(N2)C3=CC=CO3
DMD8ZUH	IK	INGWEZCOABYORO-UHFFFAOYSA-N
DMD8ZUH	IU	2-(furan-2-yl)-7-methyl-1H-1,8-naphthyridin-4-one
DMD8ZUH	CA	CAS 9008-02-0
DMD8ZUH	DE	Discovery agent

DMQIRY7	ID	DMQIRY7
DMQIRY7	DN	2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one
DMQIRY7	HS	Investigative
DMQIRY7	SN	CHEMBL3144716; 1,2-dihydro-2-(2-furylmethyl)-3H-indazol-3-one; 120273-74-7; 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL268738; BDBM50009008; AKOS023543910
DMQIRY7	DT	Small molecular drug
DMQIRY7	PC	14898715
DMQIRY7	MW	214.22
DMQIRY7	FM	C12H10N2O2
DMQIRY7	IC	InChI=1S/C12H10N2O2/c15-12-10-5-1-2-6-11(10)13-14(12)8-9-4-3-7-16-9/h1-7,13H,8H2
DMQIRY7	CS	C1=CC=C2C(=C1)C(=O)N(N2)CC3=CC=CO3
DMQIRY7	IK	FFYKZUMLEJLSIN-UHFFFAOYSA-N
DMQIRY7	IU	2-(furan-2-ylmethyl)-1H-indazol-3-one
DMQIRY7	DE	Discovery agent

DMET6FO	ID	DMET6FO
DMET6FO	DN	2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione
DMET6FO	HS	Investigative
DMET6FO	SN	CHEMBL611665; 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)
DMET6FO	DT	Small molecular drug
DMET6FO	PC	1403654
DMET6FO	MW	214.18
DMET6FO	FM	C11H6N2O3
DMET6FO	IC	InChI=1S/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)
DMET6FO	CS	C1=CC=C2C(=C1)C=C3C(=O)NC(=O)N=C3O2
DMET6FO	IK	BFMCRAXOACCPEL-UHFFFAOYSA-N
DMET6FO	IU	chromeno[2,3-d]pyrimidine-2,4-dione
DMET6FO	DE	Discovery agent

DMX45WE	ID	DMX45WE
DMX45WE	DN	2-Heptyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione
DMX45WE	HS	Investigative
DMX45WE	SN	CHEMBL596063
DMX45WE	DT	Small molecular drug
DMX45WE	PC	44251211
DMX45WE	MW	346.4
DMX45WE	FM	C22H22N2O2
DMX45WE	IC	InChI=1S/C22H22N2O2/c1-2-3-4-5-6-11-18-23-17-13-12-16-19(20(17)24-18)22(26)15-10-8-7-9-14(15)21(16)25/h7-10,12-13H,2-6,11H2,1H3,(H,23,24)
DMX45WE	CS	CCCCCCCC1=NC2=C(N1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O
DMX45WE	IK	VJUQZYULXGTXCN-UHFFFAOYSA-N
DMX45WE	IU	2-heptyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMX45WE	DE	Discovery agent

DMJ3ATL	ID	DMJ3ATL
DMJ3ATL	DN	2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE
DMJ3ATL	HS	Investigative
DMJ3ATL	SN	HQNO; HOQNO; 2-heptyl-4-hydroxyquinoline n-oxide; 341-88-8; 2-heptylquinolin-4-ol 1-oxide; 2-Heptyl-4-quinolinol 1-oxide; 2-HEPTYL-4-HYDROXYQUINOLINE-1-OXIDE; 2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE; 2-(n-Heptyl)-4-hydroxyquinoline N-oxide; CHEBI:28362; 2-Heptyl-4-hydroxyquinoline-N-oxide; 2-n-heptyl-4-hydroxyquinoline-N-oxide; 2-HEPTYL-1-OXY-QUINOLIN-4-OL; Pyo II; UNII-1FU5S5CG6A; 2-Heptyl-4-hydroxyquinoline oxide; KF 8940; BRN 1466419; AC1L1BQL; 1FU5S5CG6A; SCHEMBL429766; CHEMBL1233401; 1-hydroxy-2-heptyl-4-quinolone; CTK4H1880
DMJ3ATL	DT	Small molecular drug
DMJ3ATL	PC	1561
DMJ3ATL	MW	259.339
DMJ3ATL	FM	C16H21NO2
DMJ3ATL	IC	InChI=1S/C16H21NO2/c1-2-3-4-5-6-9-13-12-16(18)14-10-7-8-11-15(14)17(13)19/h7-8,10-12,19H,2-6,9H2,1H3
DMJ3ATL	CS	CCCCCCCC1=CC(=O)C2=CC=CC=C2N1O
DMJ3ATL	IK	ICTVCUOZYWNYHM-UHFFFAOYSA-N
DMJ3ATL	IU	2-heptyl-1-hydroxyquinolin-4-one
DMJ3ATL	CA	CAS 341-88-8
DMJ3ATL	CB	CHEBI:28362
DMJ3ATL	DE	Discovery agent

DMRXW3U	ID	DMRXW3U
DMRXW3U	DN	2-Hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole
DMRXW3U	HS	Investigative
DMRXW3U	SN	CHEMBL14196; 2-Hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole; AC1LBGT2; 2-(1-Non-8-enyl)-5-(1-hex-5-enyl)-pyrroline; CTK5J4228; JRNMZRPLKGPMHB-UHFFFAOYSA-N; BDBM50284426; 2-(5-Hexenyl)-5-(8-nonenyl)-3,4-dihydro-2H-pyrrole #; 2-(1-Non-8-enyl)-5-(1-hex-5-enyl).delta.1--pyrroline
DMRXW3U	DT	Small molecular drug
DMRXW3U	PC	557705
DMRXW3U	MW	275.5
DMRXW3U	FM	C19H33N
DMRXW3U	IC	InChI=1S/C19H33N/c1-3-5-7-9-10-11-13-15-19-17-16-18(20-19)14-12-8-6-4-2/h3-4,18H,1-2,5-17H2
DMRXW3U	CS	C=CCCCCCCCC1=NC(CC1)CCCCC=C
DMRXW3U	IK	JRNMZRPLKGPMHB-UHFFFAOYSA-N
DMRXW3U	IU	2-hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole
DMRXW3U	DE	Discovery agent

DM7KDQV	ID	DM7KDQV
DM7KDQV	DN	2-Hex-5-enyl-5-non-8-enyl-pyrrolidine
DM7KDQV	HS	Investigative
DM7KDQV	SN	2-Hex-5-enyl-5-non-8-enyl-pyrrolidine; CHEMBL14599; 2-(5-Hexenyl)-5-(8-nonenyl)pyrrolidine; 100594-86-3; 2-Hex-5-enyl-5-non-8-enylpyr; ACMC-20m3ob; Pyrrolidine, 2-(5-hexenyl)-5-(8-nonenyl)-; CTK0I4208; YCQNSAJAZIVRFR-UHFFFAOYSA-N; AC1L4819; BDBM50284428
DM7KDQV	DT	Small molecular drug
DM7KDQV	PC	180889
DM7KDQV	MW	277.5
DM7KDQV	FM	C19H35N
DM7KDQV	IC	InChI=1S/C19H35N/c1-3-5-7-9-10-11-13-15-19-17-16-18(20-19)14-12-8-6-4-2/h3-4,18-20H,1-2,5-17H2
DM7KDQV	CS	C=CCCCCCCCC1CCC(N1)CCCCC=C
DM7KDQV	IK	YCQNSAJAZIVRFR-UHFFFAOYSA-N
DM7KDQV	IU	2-hex-5-enyl-5-non-8-enylpyrrolidine
DM7KDQV	CA	CAS 100594-86-3
DM7KDQV	DE	Discovery agent

DMIBRYM	ID	DMIBRYM
DMIBRYM	DN	2-Hex-5-enyl-5-nonyl-pyrrolidine
DMIBRYM	HS	Investigative
DMIBRYM	SN	2-hex-5-enyl-5-nonylpyrrolidine; CHEMBL417618; 100594-88-5; 2-hex-5-enyl-5-nonyl-pyrrolidine; Pyrrolidine, 2-(5-hexenyl)-5-nonyl-; AC1L481F; 2-(5-hexenyl)-5-nonylpyrrolidine; BDBM50284429
DMIBRYM	DT	Small molecular drug
DMIBRYM	PC	180891
DMIBRYM	MW	279.5
DMIBRYM	FM	C19H37N
DMIBRYM	IC	InChI=1S/C19H37N/c1-3-5-7-9-10-11-13-15-19-17-16-18(20-19)14-12-8-6-4-2/h4,18-20H,2-3,5-17H2,1H3
DMIBRYM	CS	CCCCCCCCCC1CCC(N1)CCCCC=C
DMIBRYM	IK	VJYHAIYEEJOCLT-UHFFFAOYSA-N
DMIBRYM	IU	2-hex-5-enyl-5-nonylpyrrolidine
DMIBRYM	CA	CAS 100594-88-5
DMIBRYM	DE	Discovery agent

DMTFIPZ	ID	DMTFIPZ
DMTFIPZ	DN	2-Hexadecynoic acid
DMTFIPZ	HS	Investigative
DMTFIPZ	SN	2-Hexadecynoic acid; hexadec-2-ynoic acid; 2834-03-9; 2-Hexadecynoate; N-2-Hexadecynoic acid; AC1L45K9; SCHEMBL2818253; CTK4G1266; DTXSID00182577; MECFGCCEVOFCNS-UHFFFAOYSA-N; NSC289580; LMFA01030494
DMTFIPZ	DT	Small molecular drug
DMTFIPZ	PC	151047
DMTFIPZ	MW	252.39
DMTFIPZ	FM	C16H28O2
DMTFIPZ	IC	InChI=1S/C16H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-13H2,1H3,(H,17,18)
DMTFIPZ	CS	CCCCCCCCCCCCCC#CC(=O)O
DMTFIPZ	IK	MECFGCCEVOFCNS-UHFFFAOYSA-N
DMTFIPZ	IU	hexadec-2-ynoic acid
DMTFIPZ	CA	CAS 2834-03-9
DMTFIPZ	DE	Discovery agent

DM94PBL	ID	DM94PBL
DM94PBL	DN	2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole
DM94PBL	HS	Investigative
DM94PBL	SN	CHEMBL331942; SCHEMBL4812369
DM94PBL	DT	Small molecular drug
DM94PBL	PC	9795821
DM94PBL	MW	284.4
DM94PBL	FM	C19H28N2
DM94PBL	IC	InChI=1S/C19H28N2/c1-4-5-6-7-8-19-20-14-18(21-19)17-11-9-16(10-12-17)13-15(2)3/h9-12,14-15H,4-8,13H2,1-3H3,(H,20,21)
DM94PBL	CS	CCCCCCC1=NC=C(N1)C2=CC=C(C=C2)CC(C)C
DM94PBL	IK	DJDWXDSQUIVYCH-UHFFFAOYSA-N
DM94PBL	IU	2-hexyl-5-[4-(2-methylpropyl)phenyl]-1H-imidazole
DM94PBL	CA	CAS 478869-61-3
DM94PBL	DE	Discovery agent

DMKORTS	ID	DMKORTS
DMKORTS	DN	2-Hexyloxy-5-imidazol-1-yl-pyridine
DMKORTS	HS	Investigative
DMKORTS	SN	CHEMBL320105; 2-Hexyloxy-5-imidazol-1-yl-pyridine; SCHEMBL14129948; BDBM50138236
DMKORTS	DT	Small molecular drug
DMKORTS	PC	44341439
DMKORTS	MW	245.32
DMKORTS	FM	C14H19N3O
DMKORTS	IC	InChI=1S/C14H19N3O/c1-2-3-4-5-10-18-14-7-6-13(11-16-14)17-9-8-15-12-17/h6-9,11-12H,2-5,10H2,1H3
DMKORTS	CS	CCCCCCOC1=NC=C(C=C1)N2C=CN=C2
DMKORTS	IK	DCDHWTNKKCKJLQ-UHFFFAOYSA-N
DMKORTS	IU	2-hexoxy-5-imidazol-1-ylpyridine
DMKORTS	DE	Discovery agent

DMTD0IG	ID	DMTD0IG
DMTD0IG	DN	2-hexylphenyl acrylate
DMTD0IG	HS	Investigative
DMTD0IG	SN	2-hexylphenyl acrylate; SCHEMBL4475068
DMTD0IG	DT	Small molecular drug
DMTD0IG	PC	44435789
DMTD0IG	MW	232.32
DMTD0IG	FM	C15H20O2
DMTD0IG	IC	InChI=1S/C15H20O2/c1-3-5-6-7-10-13-11-8-9-12-14(13)17-15(16)4-2/h4,8-9,11-12H,2-3,5-7,10H2,1H3
DMTD0IG	CS	CCCCCCC1=CC=CC=C1OC(=O)C=C
DMTD0IG	IK	MADYBBZSBQFZRP-UHFFFAOYSA-N
DMTD0IG	IU	(2-hexylphenyl) prop-2-enoate
DMTD0IG	DE	Discovery agent

DMHR1UE	ID	DMHR1UE
DMHR1UE	DN	2H-Isoquinolin-1-one
DMHR1UE	HS	Investigative
DMHR1UE	SN	1-Hydroxyisoquinoline; 491-30-5; Isoquinolin-1(2H)-one; isoquinolin-1-ol; 1-Isoquinolinol; 2H-Isoquinolin-1-one; Isocarbostyril; 1(2H)-ISOQUINOLINONE; Isoquinolin-1-one; 489453-23-8; 1(2H)-Isoquinolone; 1,2-dihydroisoquinolin-1-one; 1-hydroxyisoquinolin; isoquinolinol; 87602-67-3; 1(2H)-ISOQUINILONE; Isocarbostyril, 98%; UNII-95EG3HGG1P; 95EG3HGG1P; Isoquinolinone; CHEMBL339695; CHEBI:18350; VDBNYAPERZTOOF-UHFFFAOYSA-N; 1-isoquinolone; oxidoisoquinolinium; EINECS 207-732-1; Isocarbostyril(1-hydroxyisoquinoline); NSC 27273
DMHR1UE	DT	Small molecular drug
DMHR1UE	PC	10284
DMHR1UE	MW	145.16
DMHR1UE	FM	C9H7NO
DMHR1UE	IC	InChI=1S/C9H7NO/c11-9-8-4-2-1-3-7(8)5-6-10-9/h1-6H,(H,10,11)
DMHR1UE	CS	C1=CC=C2C(=C1)C=CNC2=O
DMHR1UE	IK	VDBNYAPERZTOOF-UHFFFAOYSA-N
DMHR1UE	IU	2H-isoquinolin-1-one
DMHR1UE	CA	CAS 491-30-5
DMHR1UE	CB	CHEBI:18350
DMHR1UE	DE	Discovery agent

DMOT1LQ	ID	DMOT1LQ
DMOT1LQ	DN	2-Hydrazino-3-methyl-4(3H)-quinazolinone
DMOT1LQ	HS	Investigative
DMOT1LQ	SN	2-hydrazino-3-methylquinazolin-4(3H)-one; 61507-80-0; 2-Hydrazino-3-methyl-3H-quinazolin-4-one; 2-Hydrazino-3-methyl-4(3H)-quinazolinone; NSC657432; CHEMBL503552; 2-hydrazinyl-3-methylquinazolin-4(3H)-one; 2-hydrazinyl-3-methylquinazolin-4-one; BAS 00718750; 4(3H)-Quinazolinone,2-hydrazinyl-3-methyl-; 2-hydrazinyl-3-methyl-3,4-dihydroquinazolin-4-one; 2-hydrazino-3-methyl-3-hydroquinazolin-4-one; AC1Q6DRE; AC1L8CIY; AC1Q3XQM; 2-Hydrazino-3-methyl-3 H -quinazolin-4-one; Oprea1_318278; Oprea1_401830; MLS000713036; CTK5B3345
DMOT1LQ	DT	Small molecular drug
DMOT1LQ	PC	376484
DMOT1LQ	MW	190.2
DMOT1LQ	FM	C9H10N4O
DMOT1LQ	IC	InChI=1S/C9H10N4O/c1-13-8(14)6-4-2-3-5-7(6)11-9(13)12-10/h2-5H,10H2,1H3,(H,11,12)
DMOT1LQ	CS	CN1C(=O)C2=CC=CC=C2N=C1NN
DMOT1LQ	IK	BQDOAXFBKRUNTF-UHFFFAOYSA-N
DMOT1LQ	IU	2-hydrazinyl-3-methylquinazolin-4-one
DMOT1LQ	CA	CAS 61507-80-0
DMOT1LQ	DE	Discovery agent

DMG78U2	ID	DMG78U2
DMG78U2	DN	2-Hydrazinocarbonyl-benzenesulfonamide
DMG78U2	HS	Investigative
DMG78U2	SN	102169-52-8; 2-(hydrazinecarbonyl)benzenesulfonamide; 2-(hydrazinocarbonyl)benzenesulfonamide; 2-Hydrazinocarbonyl-benzenesulfonamide; 2-(hydrazinecarbonyl)benzene-1-sulfonamide; Benzoic acid,2-(aminosulfonyl)-, hydrazide; hydrazide deriv. 6; AC1M8OJR; ACMC-1BW2D; AC1Q54UM; Oprea1_607731; CHEMBL361191; CTK4A0755; BDBM12153; DTXSID30368807; HMS1788K01; ZX-AN012798; ZINC3372954; ALBB-014056; 7604AC; STL301522; AKOS000116142; FCH1317207; MCULE-6758898279; 2-(hydrazinylcarbonyl)benzenesulfonamide; BBV-40193034; Benzoic acid, 2-(aminosul
DMG78U2	DT	Small molecular drug
DMG78U2	PC	2490720
DMG78U2	MW	215.23
DMG78U2	FM	C7H9N3O3S
DMG78U2	IC	InChI=1S/C7H9N3O3S/c8-10-7(11)5-3-1-2-4-6(5)14(9,12)13/h1-4H,8H2,(H,10,11)(H2,9,12,13)
DMG78U2	CS	C1=CC=C(C(=C1)C(=O)NN)S(=O)(=O)N
DMG78U2	IK	YWPOXIABDFDDSR-UHFFFAOYSA-N
DMG78U2	IU	2-(hydrazinecarbonyl)benzenesulfonamide
DMG78U2	CA	CAS 102169-52-8
DMG78U2	DE	Discovery agent

DMCNXZM	ID	DMCNXZM
DMCNXZM	DN	2-hydrazinylbenzenesulfonamide
DMCNXZM	HS	Investigative
DMCNXZM	SN	2-Hydrazino-benzenesulfonamide
DMCNXZM	DT	Small molecular drug
DMCNXZM	PC	11206245
DMCNXZM	MW	187.22
DMCNXZM	FM	C6H9N3O2S
DMCNXZM	IC	InChI=1S/C6H9N3O2S/c7-9-5-3-1-2-4-6(5)12(8,10)11/h1-4,9H,7H2,(H2,8,10,11)
DMCNXZM	CS	C1=CC=C(C(=C1)NN)S(=O)(=O)N
DMCNXZM	IK	CTEZEDIMFASQNI-UHFFFAOYSA-N
DMCNXZM	IU	2-hydrazinylbenzenesulfonamide
DMCNXZM	CA	CAS 90824-33-2
DMCNXZM	DE	Discovery agent

DMJAN52	ID	DMJAN52
DMJAN52	DN	2-hydroxy capric acid
DMJAN52	HS	Investigative
DMJAN52	SN	2-hydroxy-decanoic acid; 2-OH-C10
DMJAN52	DT	Small molecular drug
DMJAN52	PC	21488
DMJAN52	MW	188.26
DMJAN52	FM	C10H20O3
DMJAN52	IC	InChI=1S/C10H20O3/c1-2-3-4-5-6-7-8-9(11)10(12)13/h9,11H,2-8H2,1H3,(H,12,13)
DMJAN52	CS	CCCCCCCCC(C(=O)O)O
DMJAN52	IK	GHPVDCPCKSNJDR-UHFFFAOYSA-N
DMJAN52	IU	2-hydroxydecanoic acid
DMJAN52	CA	CAS 5393-81-7
DMJAN52	CB	CHEBI:133172
DMJAN52	DE	Discovery agent

DMM9Z0B	ID	DMM9Z0B
DMM9Z0B	DN	2-hydroxy-17beta-estradiol
DMM9Z0B	HS	Investigative
DMM9Z0B	SN	2-Hydroxyestradiol; 2-OH-Estradiol; 362-05-0; 2-hydroxy-estradiol; 2-OH-E2; (17beta)-Estra-1,3,5(10)-triene-2,3,17-triol; UNII-AYU2L67YUU; Estra-1,3,5(10)-triene-2,3,17beta-triol; CHEBI:28744; NSC 61711; AYU2L67YUU; 2-Hydroxy-17; MLS000069506; CHEMBL467987; DILDHNKDVHLEQB-XSSYPUMDSA-N; ESTRA-1,3,5(10)-TRIENE-2,3,17-beta-TRIOL; SMR000058615; ECS; CCRIS 8709; 2bw7
DMM9Z0B	DT	Small molecular drug
DMM9Z0B	PC	247304
DMM9Z0B	MW	288.4
DMM9Z0B	FM	C18H24O3
DMM9Z0B	IC	InChI=1S/C18H24O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,17,19-21H,2-7H2,1H3/t11-,12+,14-,17-,18-/m0/s1
DMM9Z0B	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)O)O
DMM9Z0B	IK	DILDHNKDVHLEQB-XSSYPUMDSA-N
DMM9Z0B	IU	(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,17-triol
DMM9Z0B	CA	CAS 362-05-0
DMM9Z0B	CB	CHEBI:28744
DMM9Z0B	DE	Discovery agent

DM2GPF6	ID	DM2GPF6
DM2GPF6	DN	2-Hydroxy-2-phenyl-nonanoic acid amide
DM2GPF6	HS	Investigative
DM2GPF6	SN	CHEMBL287713
DM2GPF6	DT	Small molecular drug
DM2GPF6	PC	10131164
DM2GPF6	MW	249.35
DM2GPF6	FM	C15H23NO2
DM2GPF6	IC	InChI=1S/C15H23NO2/c1-2-3-4-5-9-12-15(18,14(16)17)13-10-7-6-8-11-13/h6-8,10-11,18H,2-5,9,12H2,1H3,(H2,16,17)
DM2GPF6	CS	CCCCCCCC(C1=CC=CC=C1)(C(=O)N)O
DM2GPF6	IK	FXKCDILPUXRDAT-UHFFFAOYSA-N
DM2GPF6	IU	2-hydroxy-2-phenylnonanamide
DM2GPF6	DE	Discovery agent

DM5ACNU	ID	DM5ACNU
DM5ACNU	DN	2'-hydroxy-3,4,5-trimethoxychalcone
DM5ACNU	HS	Investigative
DM5ACNU	SN	Crotaoprostrin; 2'-hydroxy-3,4,5-trimethoxychalcone; CHEMBL521653; 2'-Hydroxy-3,4,5-methoxychalcone; (E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; 59817-22-0; 142955-68-8; NSC331924; AC1NWOUH; MLS001049027; SCHEMBL5423339; MolPort-000-450-785; SRSBUHVXNLHWHU-CMDGGOBGSA-N; HMS2268N22; ZINC4042476; ZX-AT026929; LMPK12120198; STK888527; BDBM50257726; AKOS002181958; NSC-331924; NSC 331924; 2''-hydroxy-3,4,5-trimethoxychalcone; SMR000387055
DM5ACNU	DT	Small molecular drug
DM5ACNU	PC	5709436
DM5ACNU	MW	314.3
DM5ACNU	FM	C18H18O5
DM5ACNU	IC	InChI=1S/C18H18O5/c1-21-16-10-12(11-17(22-2)18(16)23-3)8-9-15(20)13-6-4-5-7-14(13)19/h4-11,19H,1-3H3/b9-8+
DM5ACNU	CS	COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)C2=CC=CC=C2O
DM5ACNU	IK	SRSBUHVXNLHWHU-CMDGGOBGSA-N
DM5ACNU	IU	(E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
DM5ACNU	CA	CAS 59817-22-0
DM5ACNU	DE	Discovery agent

DMDOHRF	ID	DMDOHRF
DMDOHRF	DN	2-HYDROXY-3,5-DIIODOBENZOIC ACID
DMDOHRF	HS	Investigative
DMDOHRF	SN	3,5-DIIODOSALICYLIC ACID; 133-91-5; 2-Hydroxy-3,5-diiodobenzoic acid; 3,5-Diiodo-2-hydroxybenzoic acid; Benzoic acid, 2-hydroxy-3,5-diiodo-; 2-Hydroxy-3,5-diiodobenzoate; 3,5-Diiodosalicylate; 2-Hydroxy-3,5-diiodobenzenecarboxylic acid; 2-HYDROXY-3,5-DIIODO-BENZOIC ACID; Salicylic acid, 3,5-diiodo-; NSC 6303; Benzoic acid, 3,5-diiodo-2-hydroxy-; UNII-1496OH15B6; 3,5-Diiodosalicylicacid; EINECS 205-124-0; BRN 2615358; AI3-33355; NSC6303; DHZVWQPHNWDCFS-UHFFFAOYSA-N; MFCD00002444; 1496OH15B6; DIU; rarechem al be 0656; ACMC-1BPSO
DMDOHRF	DT	Small molecular drug
DMDOHRF	PC	8631
DMDOHRF	MW	389.91
DMDOHRF	FM	C7H4I2O3
DMDOHRF	IC	InChI=1S/C7H4I2O3/c8-3-1-4(7(11)12)6(10)5(9)2-3/h1-2,10H,(H,11,12)
DMDOHRF	CS	C1=C(C=C(C(=C1C(=O)O)O)I)I
DMDOHRF	IK	DHZVWQPHNWDCFS-UHFFFAOYSA-N
DMDOHRF	IU	2-hydroxy-3,5-diiodobenzoic acid
DMDOHRF	CA	CAS 133-91-5
DMDOHRF	DE	Discovery agent

DMK8WUR	ID	DMK8WUR
DMK8WUR	DN	2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one
DMK8WUR	HS	Investigative
DMK8WUR	SN	2,4,6-Cycloheptatrien-1-one, 2-hydroxy-3-(1-methylethyl)-; 1946-74-3; CHEMBL1275969; a-thujaplicine; thujaplicin; .alpha.-Thujaplicin; AC1Q6BZY; SCHEMBL355645; 2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one; AC1L2Z64; CTK1B5134; DTXSID70173098; TUFYVOCKVJOUIR-UHFFFAOYSA-N; ZINC2041733; BDBM50330793; AKOS025402371; AC-8489; LS-56188; 2-hydroxy-3-isopropyl-cyclohepta-2,4,6-trien-1-one; 2-hydroxy-3-propan-2-ylcyclohepta-2,4,6-trien-1-one; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy(1-methylethyl)-; 38094-79-0
DMK8WUR	DT	Small molecular drug
DMK8WUR	PC	80297
DMK8WUR	MW	164.2
DMK8WUR	FM	C10H12O2
DMK8WUR	IC	InChI=1S/C10H12O2/c1-7(2)8-5-3-4-6-9(11)10(8)12/h3-7H,1-2H3,(H,11,12)
DMK8WUR	CS	CC(C)C1=C(C(=O)C=CC=C1)O
DMK8WUR	IK	TUFYVOCKVJOUIR-UHFFFAOYSA-N
DMK8WUR	IU	2-hydroxy-3-propan-2-ylcyclohepta-2,4,6-trien-1-one
DMK8WUR	CA	CAS 1946-74-3
DMK8WUR	DE	Discovery agent

DM5QV19	ID	DM5QV19
DM5QV19	DN	2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile
DM5QV19	HS	Investigative
DM5QV19	SN	diarylphenol, 5b; CHEMBL503575; BDBM25431
DM5QV19	DT	Small molecular drug
DM5QV19	PC	25093227
DM5QV19	MW	225.24
DM5QV19	FM	C14H11NO2
DM5QV19	IC	InChI=1S/C14H11NO2/c1-17-14-8-10(6-7-11(14)9-15)12-4-2-3-5-13(12)16/h2-8,16H,1H3
DM5QV19	CS	COC1=C(C=CC(=C1)C2=CC=CC=C2O)C#N
DM5QV19	IK	LZGNSWNEFCSNST-UHFFFAOYSA-N
DM5QV19	IU	4-(2-hydroxyphenyl)-2-methoxybenzonitrile
DM5QV19	DE	Discovery agent

DMSDYZQ	ID	DMSDYZQ
DMSDYZQ	DN	2-hydroxy-5-isopropyl-2,4,6-cycloheptatrien-1-one
DMSDYZQ	HS	Investigative
DMSDYZQ	SN	gamma-Thujaplicin; 5-Isopropyltropolone; 672-76-4; gamma-Thujaplicine; THUJAPLICIN, ALPHA; .gamma.-Thujaplicin; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-5-(1-methylethyl)-; NSC43338; .gamma.-Thujaplicine; 2-Hydroxy-5-isopropyl-2,4,6-cycloheptatrien-1-one; NSC402794; NSC 43338; NSC 18805; NSC 402794; BRN 2044323; AI3-28399; MLS002608534; MLS002702822; CHEMBL1275999; CHEBI:10578; NSC18805; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-5-isopropyl-; 2-hydroxy-5-isopropyl-cyclohepta-2,4,6-trien-1-one; WLN: L7VJ BQ EY1&amp; SMR001527281
DMSDYZQ	DT	Small molecular drug
DMSDYZQ	PC	12649
DMSDYZQ	MW	164.2
DMSDYZQ	FM	C10H12O2
DMSDYZQ	IC	InChI=1S/C10H12O2/c1-7(2)8-3-5-9(11)10(12)6-4-8/h3-7H,1-2H3,(H,11,12)
DMSDYZQ	CS	CC(C)C1=CC=C(C(=O)C=C1)O
DMSDYZQ	IK	WKEWHSLZDDZONF-UHFFFAOYSA-N
DMSDYZQ	IU	2-hydroxy-5-propan-2-ylcyclohepta-2,4,6-trien-1-one
DMSDYZQ	CA	CAS 672-76-4
DMSDYZQ	CB	CHEBI:10578
DMSDYZQ	DE	Discovery agent

DMB3Y8H	ID	DMB3Y8H
DMB3Y8H	DN	2-Hydroxy-6-(3-phenoxy-benzoylamino)-benzoic acid
DMB3Y8H	HS	Investigative
DMB3Y8H	SN	CHEMBL193840; BDBM23612; 3-Phenoxybenzoylamino deriv., 28f; 2-hydroxy-6-(3-phenoxybenzoylamino)benzoic acid; 2-hydroxy-6-[(3-phenoxybenzene)amido]benzoic acid
DMB3Y8H	DT	Small molecular drug
DMB3Y8H	PC	11302521
DMB3Y8H	MW	349.3
DMB3Y8H	FM	C20H15NO5
DMB3Y8H	IC	InChI=1S/C20H15NO5/c22-17-11-5-10-16(18(17)20(24)25)21-19(23)13-6-4-9-15(12-13)26-14-7-2-1-3-8-14/h1-12,22H,(H,21,23)(H,24,25)
DMB3Y8H	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)NC3=C(C(=CC=C3)O)C(=O)O
DMB3Y8H	IK	QXBHJJXXAXXUEZ-UHFFFAOYSA-N
DMB3Y8H	IU	2-hydroxy-6-[(3-phenoxybenzoyl)amino]benzoic acid
DMB3Y8H	DE	Discovery agent

DMOT6V7	ID	DMOT6V7
DMOT6V7	DN	2-HYDROXYCARBAMOYL-4-METHYL-PENTANOIC ACID
DMOT6V7	HS	Investigative
DMOT6V7	SN	AC1L1BQO; SCHEMBL1458463; CINIOMOBGSHXRK-UHFFFAOYSA-N
DMOT6V7	DT	Small molecular drug
DMOT6V7	PC	1562
DMOT6V7	MW	175.18
DMOT6V7	FM	C7H13NO4
DMOT6V7	IC	InChI=1S/C7H13NO4/c1-4(2)3-5(7(10)11)6(9)8-12/h4-5,12H,3H2,1-2H3,(H,8,9)(H,10,11)
DMOT6V7	CS	CC(C)CC(C(=O)NO)C(=O)O
DMOT6V7	IK	CINIOMOBGSHXRK-UHFFFAOYSA-N
DMOT6V7	IU	2-(hydroxycarbamoyl)-4-methylpentanoic acid
DMOT6V7	DE	Discovery agent

DMA8DZT	ID	DMA8DZT
DMA8DZT	DN	2-Hydroxycarbamoylmethyl-pentanedioic acid
DMA8DZT	HS	Investigative
DMA8DZT	SN	CHEMBL65043; hydroxamate, 41; 2-Hydroxycarbamoylmethyl-pentanedioic acid; SCHEMBL1373534; BDBM17779; 2-[(hydroxycarbamoyl)methyl]pentanedioic acid; 2-[2-Oxo-2-(hydroxyamino)ethyl]pentanedioic acid
DMA8DZT	DT	Small molecular drug
DMA8DZT	PC	10219893
DMA8DZT	MW	205.17
DMA8DZT	FM	C7H11NO6
DMA8DZT	IC	InChI=1S/C7H11NO6/c9-5(8-14)3-4(7(12)13)1-2-6(10)11/h4,14H,1-3H2,(H,8,9)(H,10,11)(H,12,13)
DMA8DZT	CS	C(CC(=O)O)C(CC(=O)NO)C(=O)O
DMA8DZT	IK	PILHIJIJVLWKNF-UHFFFAOYSA-N
DMA8DZT	IU	2-[2-(hydroxyamino)-2-oxoethyl]pentanedioic acid
DMA8DZT	DE	Discovery agent

DM412RI	ID	DM412RI
DM412RI	DN	2-Hydroxycarbamoyl-pentanedioic acid
DM412RI	HS	Investigative
DM412RI	SN	2-Hydroxycarbamoyl-pentanedioic acid; CHEMBL432726; SCHEMBL13996815; BDBM50129193; 2-(Hydroxycarbamoyl)pentanedioic acid
DM412RI	DT	Small molecular drug
DM412RI	PC	20778210
DM412RI	MW	191.14
DM412RI	FM	C6H9NO6
DM412RI	IC	InChI=1S/C6H9NO6/c8-4(9)2-1-3(6(11)12)5(10)7-13/h3,13H,1-2H2,(H,7,10)(H,8,9)(H,11,12)
DM412RI	CS	C(CC(=O)O)C(C(=O)NO)C(=O)O
DM412RI	IK	FSDICXJFWIWOEV-UHFFFAOYSA-N
DM412RI	IU	2-(hydroxycarbamoyl)pentanedioic acid
DM412RI	DE	Discovery agent

DM8RTBS	ID	DM8RTBS
DM8RTBS	DN	2'-Hydroxychalcone
DM8RTBS	HS	Investigative
DM8RTBS	SN	6'-hydroxychalcone; ACMC-1BLFY; 2-HYDROXY CHALCONE; 2-Propen-1-one, 1-(hydroxyphenyl)-3-phenyl-; SCHEMBL126857; CHEMBL1867065; CTK1E5803; CTK4B2371; MolPort-006-109-326; AETKQQBRKSELEL-UHFFFAOYSA-N; AC1L2476; ACT07806; CMLD2_000189; ANW-17633; MCULE-2929659613; TRA0032483; AN-6742; NCGC00017803-05; NCGC00017803-04; DB-021203; FT-0669974; FT-0612588; 2-Propen-1-one,1-(2-hydroxyphenyl)-3-phenyl-; 1-(2-hydroxyphenyl)-3-phenyl-prop-2-en-1-one
DM8RTBS	DT	Small molecular drug
DM8RTBS	PC	638276
DM8RTBS	MW	224.25
DM8RTBS	FM	C15H12O2
DM8RTBS	IC	InChI=1S/C15H12O2/c16-14-9-5-4-8-13(14)15(17)11-10-12-6-2-1-3-7-12/h1-11,16H/b11-10+
DM8RTBS	CS	C1=CC=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O
DM8RTBS	IK	AETKQQBRKSELEL-ZHACJKMWSA-N
DM8RTBS	IU	(E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one
DM8RTBS	CA	CAS 888-12-0
DM8RTBS	CB	CHEBI:27916
DM8RTBS	DE	Discovery agent

DM86HTZ	ID	DM86HTZ
DM86HTZ	DN	2-Hydroxycinnamic acid
DM86HTZ	HS	Investigative
DM86HTZ	SN	2-Hydroxy Cinnamic Acid; 3-(2-hydroxyphenyl)prop-2-enoic acid; Orthocumarsaure; ACMC-1BBQC; AC1L1YJR; 2-HYDROXYCINNAMICACID; CTK1F7842; CTK1H2007; CTK1B5135; PMOWTIHVNWZYFI-UHFFFAOYSA-N; MolPort-006-109-312; HMS3604C08; KS-00000X9C; EINECS 209-500-5; AKOS026677434; MCULE-7485332494; SY048367; FT-0612592; FT-0612591; MFCD00004379 (97%); 2-Propenoic acid, 3-(hydroxyphenyl)-, (Z)-; 2-Propenoic acid, 3-(hydroxyphenyl)-, (2E)-; 38094-41-6
DM86HTZ	DT	Small molecular drug
DM86HTZ	PC	637540
DM86HTZ	MW	164.16
DM86HTZ	FM	C9H8O3
DM86HTZ	IC	InChI=1S/C9H8O3/c10-8-4-2-1-3-7(8)5-6-9(11)12/h1-6,10H,(H,11,12)/b6-5+
DM86HTZ	CS	C1=CC=C(C(=C1)/C=C/C(=O)O)O
DM86HTZ	IK	PMOWTIHVNWZYFI-AATRIKPKSA-N
DM86HTZ	IU	(E)-3-(2-hydroxyphenyl)prop-2-enoic acid
DM86HTZ	CA	CAS 614-60-8
DM86HTZ	CB	CHEBI:18125
DM86HTZ	DE	Discovery agent

DMT6APV	ID	DMT6APV
DMT6APV	DN	2-Hydroxyethyl 18-methoxycoronaridinate
DMT6APV	HS	Investigative
DMT6APV	SN	2-Hydroxyethyl 18-methoxycoronaridinate
DMT6APV	DT	Small molecular drug
DMT6APV	PC	46877886
DMT6APV	MW	398.5
DMT6APV	FM	C23H30N2O4
DMT6APV	IC	InChI=1S/C23H30N2O4/c1-28-10-7-16-12-15-13-23(22(27)29-11-9-26)20-18(6-8-25(14-15)21(16)23)17-4-2-3-5-19(17)24-20/h2-5,15-16,21,24,26H,6-14H2,1H3/t15?,16-,21-,23+/m0/s1
DMT6APV	CS	COCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OCCO
DMT6APV	IK	VOCSICAFSPBNRT-NVVKDKPXSA-N
DMT6APV	IU	2-hydroxyethyl (1S,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMT6APV	DE	Discovery agent

DM5E1DC	ID	DM5E1DC
DM5E1DC	DN	2-hydroxygarveatin E
DM5E1DC	HS	Investigative
DM5E1DC	SN	2-hydroxygarveatin E
DM5E1DC	DT	Small molecular drug
DM5E1DC	PC	16091656
DM5E1DC	MW	356.4
DM5E1DC	FM	C20H20O6
DM5E1DC	IC	InChI=1S/C20H20O6/c1-6-9-8(2)14(21)10-7-11-13(16(23)12(10)15(9)22)17(24)20(5,26)18(25)19(11,3)4/h7,23,26H,6H2,1-5H3
DM5E1DC	CS	CCC1=C(C(=O)C2=CC3=C(C(=C2C1=O)O)C(=O)C(C(=O)C3(C)C)(C)O)C
DM5E1DC	IK	MEDXQZJJCUKMBX-UHFFFAOYSA-N
DM5E1DC	IU	7-ethyl-2,9-dihydroxy-2,4,4,6-tetramethylanthracene-1,3,5,8-tetrone
DM5E1DC	DE	Discovery agent

DMK96BL	ID	DMK96BL
DMK96BL	DN	2-HYDROXYGARVIN A
DMK96BL	HS	Investigative
DMK96BL	SN	2-hydroxygarvin A; CHEMBL465623; SCHEMBL3076542
DMK96BL	DT	Small molecular drug
DMK96BL	PC	21609882
DMK96BL	MW	414.4
DMK96BL	FM	C23H26O7
DMK96BL	IC	InChI=1S/C23H26O7/c1-7-8-12-15-11(10-14(29-5)16(12)20(26)30-6)9-13-17(18(15)24)19(25)23(4,28)21(27)22(13,2)3/h9-10,24,28H,7-8H2,1-6H3
DMK96BL	CS	CCCC1=C(C(=CC2=CC3=C(C(=C21)O)C(=O)C(C(=O)C3(C)C)(C)O)OC)C(=O)OC
DMK96BL	IK	PRAZMVBMBFPZFN-UHFFFAOYSA-N
DMK96BL	IU	methyl 7,9-dihydroxy-3-methoxy-5,5,7-trimethyl-6,8-dioxo-1-propylanthracene-2-carboxylate
DMK96BL	DE	Discovery agent

DMNXV2I	ID	DMNXV2I
DMNXV2I	DN	2-Hydroxyiminoolean-12-en-28-oic acid
DMNXV2I	HS	Investigative
DMNXV2I	DT	Small molecular drug
DMNXV2I	PC	91937014
DMNXV2I	MW	469.7
DMNXV2I	FM	C30H47NO3
DMNXV2I	IC	InChI=1S/C30H47NO3/c1-25(2)12-14-30(24(32)33)15-13-28(6)20(21(30)18-25)8-9-23-27(5)17-19(31-34)16-26(3,4)22(27)10-11-29(23,28)7/h8,19,21-23H,9-18H2,1-7H3,(H,32,33)/t19?,21-,22-,23+,27-,28+,29+,30-/m0/s1
DMNXV2I	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(CC(CC3(C)C)N=O)C
DMNXV2I	IK	XTPUMPBRCGZOFP-VVLRTUPLSA-N
DMNXV2I	IU	(4aS,6aR,6aS,6bR,8aS,12aS,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-11-nitroso-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMNXV2I	DE	Discovery agent

DMDKF03	ID	DMDKF03
DMDKF03	DN	2-Hydroxyiminours-12-en-28-oic acid
DMDKF03	HS	Investigative
DMDKF03	SN	2-(Hydroxyimino)-19beta-methyl-30-noroleana-12-ene-28-oic acid
DMDKF03	DT	Small molecular drug
DMDKF03	PC	91937016
DMDKF03	MW	469.7
DMDKF03	FM	C30H47NO3
DMDKF03	IC	InChI=1S/C30H47NO3/c1-18-10-13-30(25(32)33)15-14-28(6)21(24(30)19(18)2)8-9-23-27(5)17-20(31-34)16-26(3,4)22(27)11-12-29(23,28)7/h8,18-20,22-24H,9-17H2,1-7H3,(H,32,33)/t18-,19+,20?,22+,23-,24+,27+,28-,29-,30+/m1/s1
DMDKF03	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC(CC5(C)C)N=O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMDKF03	IK	YUEQLEDAPGIQNH-POPBXVHQSA-N
DMDKF03	IU	(1S,2R,4aS,6aR,6aS,6bR,8aS,12aS,14bS)-1,2,6a,6b,9,9,12a-heptamethyl-11-nitroso-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMDKF03	DE	Discovery agent

DMTLYDS	ID	DMTLYDS
DMTLYDS	DN	2-hydroxyisoquinoline-1,3(2H,4H)-dione
DMTLYDS	HS	Investigative
DMTLYDS	SN	2-hydroxyisoquinoline-1,3(2H,4H)-dione; 6890-08-0; CHEMBL16755; 2-Hydroxy-4H-isoquinoline-1,3-dione; 1,3(2H,4H)-Isoquinolinedione, 2-hydroxy-; 2-hydroxy-1,2,3,4-tetrahydroisoquinoline-1,3-dione; 0N7; AC1LAHYL; N-hydroxyisoquinolinedione, 2; SCHEMBL3358267; BDBM33410; DTXSID70333610; ZINC3626195; 0637AC; AKOS016011468; FCH1154656; ACN-049309; AJ-45130; 2-Hydroxy-1,3(2H,4H)-isoquinolinedione; KB-230940; AX8246098
DMTLYDS	DT	Small molecular drug
DMTLYDS	PC	514100
DMTLYDS	MW	177.16
DMTLYDS	FM	C9H7NO3
DMTLYDS	IC	InChI=1S/C9H7NO3/c11-8-5-6-3-1-2-4-7(6)9(12)10(8)13/h1-4,13H,5H2
DMTLYDS	CS	C1C2=CC=CC=C2C(=O)N(C1=O)O
DMTLYDS	IK	ZXAICCBFIBBVAR-UHFFFAOYSA-N
DMTLYDS	IU	2-hydroxy-4H-isoquinoline-1,3-dione
DMTLYDS	CA	CAS 6890-08-0
DMTLYDS	DE	Discovery agent

DMCNW3M	ID	DMCNW3M
DMCNW3M	DN	2-hydroxylauric acid
DMCNW3M	HS	Investigative
DMCNW3M	SN	2-OH-C12; 2-hydroxy lauric acid
DMCNW3M	DT	Small molecular drug
DMCNW3M	PC	97783
DMCNW3M	MW	216.32
DMCNW3M	FM	C12H24O3
DMCNW3M	IC	InChI=1S/C12H24O3/c1-2-3-4-5-6-7-8-9-10-11(13)12(14)15/h11,13H,2-10H2,1H3,(H,14,15)
DMCNW3M	CS	CCCCCCCCCCC(C(=O)O)O
DMCNW3M	IK	YDZIJQXINJLRLL-UHFFFAOYSA-N
DMCNW3M	IU	2-hydroxydodecanoic acid
DMCNW3M	CB	CHEBI:36211
DMCNW3M	DE	Discovery agent

DM4LMPD	ID	DM4LMPD
DM4LMPD	DN	2-Hydroxymethyl-3-hydroxymorphinan
DM4LMPD	HS	Investigative
DM4LMPD	SN	CHEMBL570449; 2-Hydroxymethyl-3-hydroxymorphinan
DM4LMPD	DT	Small molecular drug
DM4LMPD	PC	44626540
DM4LMPD	MW	287.4
DM4LMPD	FM	C18H25NO2
DM4LMPD	IC	InChI=1S/C18H25NO2/c1-19-7-6-18-5-3-2-4-14(18)16(19)9-12-8-13(11-20)17(21)10-15(12)18/h8,10,14,16,20-21H,2-7,9,11H2,1H3/t14-,16+,18+/m0/s1
DM4LMPD	CS	CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=CC(=C(C=C34)O)CO
DM4LMPD	IK	BPBSRBFSNMZXSP-YXJHDRRASA-N
DM4LMPD	IU	(1R,9R,10R)-5-(hydroxymethyl)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-4-ol
DM4LMPD	DE	Discovery agent

DM7MUZ1	ID	DM7MUZ1
DM7MUZ1	DN	2-Hydroxymethyl-Pyrrolidine-3,4-Diol
DM7MUZ1	HS	Investigative
DM7MUZ1	SN	2-(Hydroxymethyl)-[2R-(2a,3b,4b)]-3,4-Pyrrolidinediol; 2-(Hydroxymethyl)-(2R-(2a,3b,4b))-3,4-Pyrrolidinediol; ACMC-20m9e3; ACMC-20m1d3; ACMC-20m9e4; 3,4-Pyrrolidinediol,2-(hydroxymethyl)-, (2S,3S,4R)-; 3,4-Pyrrolidinediol,2-(hydroxymethyl)-, (2R,3R,4S)-; AC1L1B8Z; 3,4-Pyrrolidinediol, 2-(hydroxymethyl)-, (2R,3S,4S)-; SCHEMBL981088; CTK8A3364; 1,4-dideoxy-1,4-iminopentitol; OQEBIHBLFRADNM-UHFFFAOYSA-N; HMS3373I18; IMR; 97058-12-3
DM7MUZ1	DT	Small molecular drug
DM7MUZ1	PC	127716
DM7MUZ1	MW	133.15
DM7MUZ1	FM	C5H11NO3
DM7MUZ1	IC	InChI=1S/C5H11NO3/c7-2-3-5(9)4(8)1-6-3/h3-9H,1-2H2/t3-,4-,5-/m0/s1
DM7MUZ1	CS	C1[C@@H]([C@H]([C@@H](N1)CO)O)O
DM7MUZ1	IK	OQEBIHBLFRADNM-YUPRTTJUSA-N
DM7MUZ1	IU	(2S,3S,4S)-2-(hydroxymethyl)pyrrolidine-3,4-diol
DM7MUZ1	CA	CAS 100937-53-9
DM7MUZ1	DE	Discovery agent

DMWSR13	ID	DMWSR13
DMWSR13	DN	2-Hydroxy-N-(3-phenyl-propyl)-benzamide
DMWSR13	HS	Investigative
DMWSR13	SN	2-hydroxy-N-(3-phenylpropyl)benzamide; CHEMBL290426; 153810-66-3; MLS000112389; 2-Hydroxy-N-(3-phenyl-propyl)-benzamide; AC1M4REE; Cambridge id 6816004; cid_2287872; MolPort-001-028-867; HMS2472G06; ZINC2989649; AC1Q7881; BDBM50282105; AKOS008913729; NE30179; MCULE-4556826159; JJ-3297; ST069062; SMR000108303; EN300-70444; AB00120250-01; (2-hydroxyphenyl)-N-(3-phenylpropyl)carboxamide; SR-01000522099; SR-01000522099-1
DMWSR13	DT	Small molecular drug
DMWSR13	PC	2287872
DMWSR13	MW	255.31
DMWSR13	FM	C16H17NO2
DMWSR13	IC	InChI=1S/C16H17NO2/c18-15-11-5-4-10-14(15)16(19)17-12-6-9-13-7-2-1-3-8-13/h1-5,7-8,10-11,18H,6,9,12H2,(H,17,19)
DMWSR13	CS	C1=CC=C(C=C1)CCCNC(=O)C2=CC=CC=C2O
DMWSR13	IK	NCGDIICSZWHCQX-UHFFFAOYSA-N
DMWSR13	IU	2-hydroxy-N-(3-phenylpropyl)benzamide
DMWSR13	DE	Discovery agent

DMQ0F96	ID	DMQ0F96
DMQ0F96	DN	2-Hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide
DMQ0F96	HS	Investigative
DMQ0F96	SN	2-Hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide; SCHEMBL3009043; CHEMBL511606
DMQ0F96	DT	Small molecular drug
DMQ0F96	PC	24950386
DMQ0F96	MW	371.4
DMQ0F96	FM	C23H17NO4
DMQ0F96	IC	InChI=1S/C23H17NO4/c25-18-5-1-3-14(12-18)15-7-9-20-16(11-15)8-10-21(27)22(20)23(28)24-17-4-2-6-19(26)13-17/h1-13,25-27H,(H,24,28)
DMQ0F96	CS	C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)C(=O)NC4=CC(=CC=C4)O
DMQ0F96	IK	JFOMBBOIWCMHKV-UHFFFAOYSA-N
DMQ0F96	IU	2-hydroxy-N,6-bis(3-hydroxyphenyl)naphthalene-1-carboxamide
DMQ0F96	DE	Discovery agent

DMMILJS	ID	DMMILJS
DMMILJS	DN	2-hydroxyoctanoic acid
DMMILJS	HS	Investigative
DMMILJS	SN	2-Hydroxyoctanoic acid; 617-73-2; 2-Hydroxycaprylic acid; 2-Hydroxy-n-octanoic Acid; hydroxycaprylic acid; 2-hydroxy caprylic acid; Hydroxyoctanoate; 2-hydroxy-octanoic acid; Octanoic acid, hydroxy-; alpha-Hydroxycaprylic acid; 2-Hydroxyoctanoate; alpha-Hydroxyoctanoic acid; (+/-)-2-Hydroxyoctanoic acid; JKRDADVRIYVCCY-UHFFFAOYSA-N; MFCD00014410; 2-Hydroxycaprylate; alpha-Hydroxyoctanoate; alpha-Hydroxycaprylate; 2-hydroxyoctans; Octanoic acid, 2-hydroxy-; a-Hydroxycaprylate; a-Hydroxyoctanoate; EINECS 210-524-3; NSC 189703
DMMILJS	DT	Small molecular drug
DMMILJS	PC	94180
DMMILJS	MW	160.21
DMMILJS	FM	C8H16O3
DMMILJS	IC	InChI=1S/C8H16O3/c1-2-3-4-5-6-7(9)8(10)11/h7,9H,2-6H2,1H3,(H,10,11)
DMMILJS	CS	CCCCCCC(C(=O)O)O
DMMILJS	IK	JKRDADVRIYVCCY-UHFFFAOYSA-N
DMMILJS	IU	2-hydroxyoctanoic acid
DMMILJS	CA	CAS 617-73-2
DMMILJS	CB	CHEBI:86543
DMMILJS	DE	Discovery agent

DMHK2NQ	ID	DMHK2NQ
DMHK2NQ	DN	2-hydroxyphenethyl 3,4,5-trihydroxybenzoate
DMHK2NQ	HS	Investigative
DMHK2NQ	SN	CHEMBL399354; 2-hydroxyphenethyl 3,4,5-trihydroxybenzoate; Gallic acid 2-hydroxyphenethyl ester
DMHK2NQ	DT	Small molecular drug
DMHK2NQ	PC	24180556
DMHK2NQ	MW	290.27
DMHK2NQ	FM	C15H14O6
DMHK2NQ	IC	InChI=1S/C15H14O6/c16-11-4-2-1-3-9(11)5-6-21-15(20)10-7-12(17)14(19)13(18)8-10/h1-4,7-8,16-19H,5-6H2
DMHK2NQ	CS	C1=CC=C(C(=C1)CCOC(=O)C2=CC(=C(C(=C2)O)O)O)O
DMHK2NQ	IK	BFCLPURLRKZMCC-UHFFFAOYSA-N
DMHK2NQ	IU	2-(2-hydroxyphenyl)ethyl 3,4,5-trihydroxybenzoate
DMHK2NQ	DE	Discovery agent

DMHO8KQ	ID	DMHO8KQ
DMHO8KQ	DN	2-hydroxy-saclofen
DMHO8KQ	HS	Investigative
DMHO8KQ	SN	 2-hydroxy-s-(-)-saclofen; 2-OH-saclofen; 2-hydroxysaclofen
DMHO8KQ	DT	Small molecular drug
DMHO8KQ	PC	1564
DMHO8KQ	MW	265.71
DMHO8KQ	FM	C9H12ClNO4S
DMHO8KQ	IC	InChI=1S/C9H12ClNO4S/c10-8-3-1-7(2-4-8)9(12,5-11)6-16(13,14)15/h1-4,12H,5-6,11H2,(H,13,14,15)
DMHO8KQ	CS	C1=CC(=CC=C1C(CN)(CS(=O)(=O)O)O)Cl
DMHO8KQ	IK	WBSMZVIMANOCNX-UHFFFAOYSA-N
DMHO8KQ	IU	3-amino-2-(4-chlorophenyl)-2-hydroxypropane-1-sulfonic acid
DMHO8KQ	CA	CAS 117354-64-0
DMHO8KQ	CB	CHEBI:111179
DMHO8KQ	DE	Discovery agent

DM261B0	ID	DM261B0
DM261B0	DN	2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one
DM261B0	HS	Investigative
DM261B0	SN	CHEMBL192306; azole isoflavone analog 2a; BDBM9891; 2-(1H-imidazol-1-yl)-7-methoxy-3-phenyl-4H-chromen-4-one; 2-(1H-Imidazol-1-yl)-7-methoxy-3-phenyl-4H-1-benzopyran4-one; 2-(1h-imidazol-1-yl)-7-methoxy-3-phenyl-4h-1-benzo pyran-4-one
DM261B0	DT	Small molecular drug
DM261B0	PC	23644623
DM261B0	MW	318.3
DM261B0	FM	C19H14N2O3
DM261B0	IC	InChI=1S/C19H14N2O3/c1-23-14-7-8-15-16(11-14)24-19(21-10-9-20-12-21)17(18(15)22)13-5-3-2-4-6-13/h2-12H,1H3
DM261B0	CS	COC1=CC2=C(C=C1)C(=O)C(=C(O2)N3C=CN=C3)C4=CC=CC=C4
DM261B0	IK	XDJIKPUCOXIQTJ-UHFFFAOYSA-N
DM261B0	IU	2-imidazol-1-yl-7-methoxy-3-phenylchromen-4-one
DM261B0	DE	Discovery agent

DM2GUDZ	ID	DM2GUDZ
DM2GUDZ	DN	2-Imidazol-1-ylmethylxanthen-9-one
DM2GUDZ	HS	Investigative
DM2GUDZ	SN	CHEMBL1083354; 2-Imidazol-1-ylmethylxanthen-9-one
DM2GUDZ	DT	Small molecular drug
DM2GUDZ	PC	46867544
DM2GUDZ	MW	276.29
DM2GUDZ	FM	C17H12N2O2
DM2GUDZ	IC	InChI=1S/C17H12N2O2/c20-17-13-3-1-2-4-15(13)21-16-6-5-12(9-14(16)17)10-19-8-7-18-11-19/h1-9,11H,10H2
DM2GUDZ	CS	C1=CC=C2C(=C1)C(=O)C3=C(O2)C=CC(=C3)CN4C=CN=C4
DM2GUDZ	IK	FWPREHSGJHCERR-UHFFFAOYSA-N
DM2GUDZ	IU	2-(imidazol-1-ylmethyl)xanthen-9-one
DM2GUDZ	DE	Discovery agent

DMSEIUP	ID	DMSEIUP
DMSEIUP	DN	2-iodo-melatonin
DMSEIUP	HS	Investigative
DMSEIUP	SN	2-Iodomelatonin; 93515-00-5; n-[2-(2-iodo-5-methoxy-1h-indol-3-yl)ethyl]acetamide; CHEMBL289233; N-(2-(2-Iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide; acetamide,n-[2-(2-iodo-5-methoxy-1h-indol-3-yl)ethyl]-; Acetamide, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)-, (3beta)-; Acetamide, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)-; SR-01000075935; 2-I-MLT; Melatonin,2-Iodo; ML2; Tocris-0737; Lopac-I-1899; AC1L3GZ8; AC1Q5P6Z; Lopac0_000610; SCHEMBL163451; GTPL1343; BDBM29611; CTK8F4316; DTXSID30239462;  2-iodomelatonin; IODOMELATONIN
DMSEIUP	DT	Small molecular drug
DMSEIUP	PC	115348
DMSEIUP	MW	358.17
DMSEIUP	FM	C13H15IN2O2
DMSEIUP	IC	InChI=1S/C13H15IN2O2/c1-8(17)15-6-5-10-11-7-9(18-2)3-4-12(11)16-13(10)14/h3-4,7,16H,5-6H2,1-2H3,(H,15,17)
DMSEIUP	CS	CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)I
DMSEIUP	IK	FJDDSMSDZHURBJ-UHFFFAOYSA-N
DMSEIUP	IU	N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMSEIUP	CA	CAS 93515-00-5
DMSEIUP	CB	CHEBI:109558
DMSEIUP	DE	Discovery agent

DMOVRX7	ID	DMOVRX7
DMOVRX7	DN	2-isooleanolic acid
DMOVRX7	HS	Investigative
DMOVRX7	SN	2-isooleanolic acid; CHEMBL1080965; BDBM50310507; 2beta-Hydroxyoleana-12-ene-28-oic acid
DMOVRX7	DT	Small molecular drug
DMOVRX7	PC	46883487
DMOVRX7	MW	456.7
DMOVRX7	FM	C30H48O3
DMOVRX7	IC	InChI=1S/C30H48O3/c1-25(2)12-14-30(24(32)33)15-13-28(6)20(21(30)18-25)8-9-23-27(5)17-19(31)16-26(3,4)22(27)10-11-29(23,28)7/h8,19,21-23,31H,9-18H2,1-7H3,(H,32,33)/t19-,21+,22+,23-,27+,28-,29-,30+/m1/s1
DMOVRX7	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H](CC3(C)C)O)C
DMOVRX7	IK	UODITNOILLXLOO-VGWDZYRESA-N
DMOVRX7	IU	(4aS,6aR,6aS,6bR,8aS,11R,12aS,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMOVRX7	DE	Discovery agent

DMSLMAN	ID	DMSLMAN
DMSLMAN	DN	2-isopropyl-9H-carbazole
DMSLMAN	HS	Investigative
DMSLMAN	SN	2-isopropyl-9H-carbazole; CHEMBL1170460; SCHEMBL10892550
DMSLMAN	DT	Small molecular drug
DMSLMAN	PC	20228010
DMSLMAN	MW	209.29
DMSLMAN	FM	C15H15N
DMSLMAN	IC	InChI=1S/C15H15N/c1-10(2)11-7-8-13-12-5-3-4-6-14(12)16-15(13)9-11/h3-10,16H,1-2H3
DMSLMAN	CS	CC(C)C1=CC2=C(C=C1)C3=CC=CC=C3N2
DMSLMAN	IK	AMSCTVXMVALTQJ-UHFFFAOYSA-N
DMSLMAN	IU	2-propan-2-yl-9H-carbazole
DMSLMAN	DE	Discovery agent

DMEZFKS	ID	DMEZFKS
DMEZFKS	DN	2-isoursolic acid
DMEZFKS	HS	Investigative
DMEZFKS	SN	2-isoursolic acid; CHEMBL1080966
DMEZFKS	DT	Small molecular drug
DMEZFKS	PC	46883488
DMEZFKS	MW	456.7
DMEZFKS	FM	C30H48O3
DMEZFKS	IC	InChI=1S/C30H48O3/c1-18-10-13-30(25(32)33)15-14-28(6)21(24(30)19(18)2)8-9-23-27(5)17-20(31)16-26(3,4)22(27)11-12-29(23,28)7/h8,18-20,22-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19-,20+,22-,23+,24-,27-,28+,29+,30-/m0/s1
DMEZFKS	CS	C[C@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H](CC5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMEZFKS	IK	DDHYEJNMSYDDTH-JJKIWFBPSA-N
DMEZFKS	IU	(1S,2S,4aS,6aR,6aS,6bR,8aS,11R,12aS,14bS)-11-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMEZFKS	DE	Discovery agent

DM1F4TN	ID	DM1F4TN
DM1F4TN	DN	2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline
DM1F4TN	HS	Investigative
DM1F4TN	DT	Small molecular drug
DM1F4TN	PC	10561772
DM1F4TN	DE	Discovery agent

DMD2ZNA	ID	DMD2ZNA
DMD2ZNA	DN	2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline
DMD2ZNA	HS	Investigative
DMD2ZNA	DT	Small molecular drug
DMD2ZNA	PC	10513958
DMD2ZNA	DE	Discovery agent

DMZD348	ID	DMZD348
DMZD348	DN	2LM20-4
DMZD348	HS	Investigative
DMZD348	SN	Anti-CD20 SMIP (autoimmune disease), Pfizer; Anti-CD20 small modular immunopharmaceutical (autoimmune disease), Pfizer
DMZD348	CP	Pfizer Inc
DMZD348	DE	Autoimmune diabetes

DMPJT1C	ID	DMPJT1C
DMPJT1C	DN	2MD
DMPJT1C	HS	Investigative
DMPJT1C	SN	VDZ; 2-methylene-19-nor-(20S)-1 alpha,25-dihydroxy-vitamin D3
DMPJT1C	DT	Small molecular drug
DMPJT1C	PC	5289549
DMPJT1C	MW	416.6
DMPJT1C	FM	C27H44O3
DMPJT1C	IC	InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)22-12-13-23-21(9-7-15-27(22,23)5)11-10-20-16-24(28)19(2)25(29)17-20/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b21-11+/t18-,22+,23-,24+,25+,27+/m0/s1
DMPJT1C	CS	C[C@@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C(=C)[C@@H](C3)O)O)C
DMPJT1C	IK	UHMPCVGLSKFXHR-NAQZCRMNSA-N
DMPJT1C	IU	(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2S)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol
DMPJT1C	DE	Discovery agent

DMDFPGB	ID	DMDFPGB
DMDFPGB	DN	2'-Me-CCPA
DMDFPGB	HS	Investigative
DMDFPGB	SN	2'methyl-2-chloro-N6-cyclopentyladenosine
DMDFPGB	DT	Small molecular drug
DMDFPGB	PC	10475082
DMDFPGB	MW	383.8
DMDFPGB	FM	C16H22ClN5O4
DMDFPGB	IC	InChI=1S/C16H22ClN5O4/c1-16(25)11(24)9(6-23)26-14(16)22-7-18-10-12(19-8-4-2-3-5-8)20-15(17)21-13(10)22/h7-9,11,14,23-25H,2-6H2,1H3,(H,19,20,21)/t9-,11-,14-,16-/m1/s1
DMDFPGB	CS	C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)NC4CCCC4)CO)O)O
DMDFPGB	IK	MMPAUXMIDJWGFO-ROMFRFKVSA-N
DMDFPGB	IU	(2R,3R,4R,5R)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
DMDFPGB	CA	CAS 205171-12-6
DMDFPGB	DE	Discovery agent

DMDZTU3	ID	DMDZTU3
DMDZTU3	DN	2-MePen-RYYRIK-NH2
DMDZTU3	HS	Investigative
DMDZTU3	SN	CHEMBL437601
DMDZTU3	DT	Small molecular drug
DMDZTU3	PC	44456298
DMDZTU3	MW	979.2
DMDZTU3	FM	C48H78N14O8
DMDZTU3	IC	InChI=1S/C48H78N14O8/c1-5-14-30(4)41(65)58-35(18-12-25-55-47(51)52)42(66)60-37(27-31-15-8-7-9-16-31)45(69)61-38(28-32-20-22-33(63)23-21-32)44(68)59-36(19-13-26-56-48(53)54)43(67)62-39(29(3)6-2)46(70)57-34(40(50)64)17-10-11-24-49/h7-9,15-16,20-23,29-30,34-39,63H,5-6,10-14,17-19,24-28,49H2,1-4H3,(H2,50,64)(H,57,70)(H,58,65)(H,59,68)(H,60,66)(H,61,69)(H,62,67)(H4,51,52,55)(H4,53,54,56)/t29-,30?,34-,35-,36-,37-,38-,39-/m0/s1
DMDZTU3	CS	CCCC(C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N
DMDZTU3	IK	TYNKFZNKNQQZMB-GUICQBDJSA-N
DMDZTU3	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2-methylpentanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMDZTU3	DE	Discovery agent

DMHK25N	ID	DMHK25N
DMHK25N	DN	2-Mercaptomethyl-pentanedioic acid
DMHK25N	HS	Investigative
DMHK25N	SN	2-Mercaptomethylglutaric acid; 2-Mercaptomethyl-pentanedioic acid; CHEMBL60941; 106146-19-4; Pentanedioic acid,2-(mercaptomethyl)-; 2-Mmga; 2-(sulfanylmethyl)pentanedioic acid; ACMC-1BUG7; AC1L2VT3; 2-mer-captomethylglutaric acid; SCHEMBL1278279; CTK4A4424; Glutaric acid, 2-mercaptomethyl-; LDFDXRPEWZHIML-UHFFFAOYSA-N; NSC613827; BDBM50127614
DMHK25N	DT	Small molecular drug
DMHK25N	PC	129558
DMHK25N	MW	178.21
DMHK25N	FM	C6H10O4S
DMHK25N	IC	InChI=1S/C6H10O4S/c7-5(8)2-1-4(3-11)6(9)10/h4,11H,1-3H2,(H,7,8)(H,9,10)
DMHK25N	CS	C(CC(=O)O)C(CS)C(=O)O
DMHK25N	IK	LDFDXRPEWZHIML-UHFFFAOYSA-N
DMHK25N	IU	2-(sulfanylmethyl)pentanedioic acid
DMHK25N	CA	CAS 109333-27-9
DMHK25N	DE	Discovery agent

DMXEUDM	ID	DMXEUDM
DMXEUDM	DN	2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide
DMXEUDM	HS	Investigative
DMXEUDM	SN	N-[4-(Aminosulfonyl)phenyl]-2-Mercaptobenzamide; N-(4-sulfamoylphenyl)-2-sulfanylbenzamide; CHEMBL386049; reduced thio H5a; 2hd6; AC1LA75B; SCHEMBL6227210; BDBM11053; reduced monomeric thio of compound 5a; DB07476; BOS; N-(4-sulfamoylphenyl)-2-sulfanyl-benzamide; 4-(2-mercaptophenylcarboxamido)benzenesulfonamide; N-[4-(AMINOSULFONYL)PHENYL]-2-MERCAPTOBENZAMIDE
DMXEUDM	DT	Small molecular drug
DMXEUDM	PC	462919
DMXEUDM	MW	308.4
DMXEUDM	FM	C13H12N2O3S2
DMXEUDM	IC	InChI=1S/C13H12N2O3S2/c14-20(17,18)10-7-5-9(6-8-10)15-13(16)11-3-1-2-4-12(11)19/h1-8,19H,(H,15,16)(H2,14,17,18)
DMXEUDM	CS	C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)N)S
DMXEUDM	IK	MRLVIVXGUGNENL-UHFFFAOYSA-N
DMXEUDM	IU	N-(4-sulfamoylphenyl)-2-sulfanylbenzamide
DMXEUDM	DE	Discovery agent

DMRVBCI	ID	DMRVBCI
DMRVBCI	DN	2-Mercapto-pentanedioic acid
DMRVBCI	HS	Investigative
DMRVBCI	SN	Pentanedioic acid, 2-mercapto-; 2-Mercapto-pentanedioic acid; CHEMBL304885; 36303-63-6; 2-Mercaptoglutaric acid; SCHEMBL1204501; CTK1B0110; DTXSID20436307
DMRVBCI	DT	Small molecular drug
DMRVBCI	PC	10171263
DMRVBCI	MW	164.18
DMRVBCI	FM	C5H8O4S
DMRVBCI	IC	InChI=1S/C5H8O4S/c6-4(7)2-1-3(10)5(8)9/h3,10H,1-2H2,(H,6,7)(H,8,9)
DMRVBCI	CS	C(CC(=O)O)C(C(=O)O)S
DMRVBCI	IK	HWPIVZNZHAFMNA-UHFFFAOYSA-N
DMRVBCI	IU	2-sulfanylpentanedioic acid
DMRVBCI	CA	CAS 36303-63-6
DMRVBCI	DE	Discovery agent

DM8HSBT	ID	DM8HSBT
DM8HSBT	DN	2-mercaptophenylphosphonic acid
DM8HSBT	HS	Investigative
DM8HSBT	SN	2-mercaptophenylphosphonic acid; CHEMBL1173336; SCHEMBL108541; (2-Mercaptophenyl)phosphonic acid
DM8HSBT	DT	Small molecular drug
DM8HSBT	PC	15738646
DM8HSBT	MW	190.16
DM8HSBT	FM	C6H7O3PS
DM8HSBT	IC	InChI=1S/C6H7O3PS/c7-10(8,9)5-3-1-2-4-6(5)11/h1-4,11H,(H2,7,8,9)
DM8HSBT	CS	C1=CC=C(C(=C1)P(=O)(O)O)S
DM8HSBT	IK	XUDMIKRWJYMQKD-UHFFFAOYSA-N
DM8HSBT	IU	(2-sulfanylphenyl)phosphonic acid
DM8HSBT	DE	Discovery agent

DMGADQ1	ID	DMGADQ1
DMGADQ1	DN	2MeSADP
DMGADQ1	HS	Investigative
DMGADQ1	SN	2-Methylthio-adenosine-5'-diphosphate; 2-MeSADP; 2-methylthio-ADP; 2-Mes-ADP; 2-methylthio-adenosine-5'-diphosphate; CHEMBL435402; 2-(methylsulfanyl)adenosine 5'-(trihydrogen diphosphate); methylthio-ADP; [(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate; 2-(Methylthio)adenosine 5'-diphosphate; [3H]2-methylthio-ADP; [3H]2MeSADP; (3H)2-Mes-ADP; AC1L3TRY; SCHEMBL195864; GTPL1763; GTPL1710; AC1Q6S18; adenosine, 2-(methylthio)-, 5'-(trihydrogen diphosphate); 2-(Methylthio)-Adenosinediphosphate;  2-methylthio-ADP
DMGADQ1	DT	Small molecular drug
DMGADQ1	PC	121990
DMGADQ1	MW	473.3
DMGADQ1	FM	C11H17N5O10P2S
DMGADQ1	IC	InChI=1S/C11H17N5O10P2S/c1-29-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(25-10)2-24-28(22,23)26-27(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H,22,23)(H2,12,14,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1
DMGADQ1	CS	CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N
DMGADQ1	IK	WLMZTKAZJUWXCB-KQYNXXCUSA-N
DMGADQ1	IU	[(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMGADQ1	CA	CAS 34983-48-7
DMGADQ1	DE	Discovery agent

DMBO2DC	ID	DMBO2DC
DMBO2DC	DN	2MeSAMP
DMBO2DC	HS	Investigative
DMBO2DC	SN	2-methylthio-AMP; poly(2'-methylthioadenylic acid)
DMBO2DC	DT	Small molecular drug
DMBO2DC	PC	189762
DMBO2DC	MW	393.32
DMBO2DC	FM	C11H16N5O7PS
DMBO2DC	IC	InChI=1S/C11H16N5O7PS/c1-25-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(23-10)2-22-24(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H2,12,14,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1
DMBO2DC	CS	CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N
DMBO2DC	IK	XVTFTCNRRAQHEQ-KQYNXXCUSA-N
DMBO2DC	IU	[(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMBO2DC	CA	CAS 70804-88-5
DMBO2DC	DE	Discovery agent

DMUE0W6	ID	DMUE0W6
DMUE0W6	DN	2MeSATP
DMUE0W6	HS	Investigative
DMUE0W6	SN	2-methylthio-ATP; 2-MeSATP; 2-methylthio-adenosine-5'-triphosphate
DMUE0W6	DT	Small molecular drug
DMUE0W6	PC	5310983
DMUE0W6	MW	553.28
DMUE0W6	FM	C11H18N5O13P3S
DMUE0W6	IC	InChI=1S/C11H18N5O13P3S/c1-33-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(27-10)2-26-31(22,23)29-32(24,25)28-30(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H,22,23)(H,24,25)(H2,12,14,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1
DMUE0W6	CS	CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N
DMUE0W6	IK	XNOBOKJVOTYSJV-KQYNXXCUSA-N
DMUE0W6	IU	[[(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMUE0W6	CA	CAS 43170-89-4
DMUE0W6	DE	Discovery agent

DMY2GXT	ID	DMY2GXT
DMY2GXT	DN	2'-Me-tecadenoson
DMY2GXT	HS	Investigative
DMY2GXT	SN	CHEMBL400190; 2'-Me-tecadenoson; 2''-Me-tecadenoson
DMY2GXT	DT	Small molecular drug
DMY2GXT	PC	44447542
DMY2GXT	MW	351.36
DMY2GXT	FM	C15H21N5O5
DMY2GXT	IC	InChI=1S/C15H21N5O5/c1-15(23)11(22)9(4-21)25-14(15)20-7-18-10-12(16-6-17-13(10)20)19-8-2-3-24-5-8/h6-9,11,14,21-23H,2-5H2,1H3,(H,16,17,19)/t8-,9-,11-,14-,15-/m1/s1
DMY2GXT	CS	C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N[C@@H]4CCOC4)CO)O)O
DMY2GXT	IK	BPEIIXZHZSYVFH-LVSZHXFLSA-N
DMY2GXT	IU	(2R,3R,4R,5R)-5-(hydroxymethyl)-3-methyl-2-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol
DMY2GXT	DE	Discovery agent

DMA5Q4T	ID	DMA5Q4T
DMA5Q4T	DN	2-methoxy-1,4-naphthoquinone
DMA5Q4T	HS	Investigative
DMA5Q4T	SN	2-Methoxy-1,4-naphthoquinone; 2348-82-5; 2-Methoxynaphthoquinone; 2-methoxynaphthalene-1,4-dione; 2-Methoxy-p-naphthoquinone; 1,4-Naphthalenedione, 2-methoxy-; 1,4-NAPHTHOQUINONE, 2-METHOXY-; UNII-39020BUT1D; 2-Methoxy-1,4-naphthalenedione; NSC 31530; AI3-17893; CHEMBL106562; 2-Methoxy-[1,4]naphthoquinone; CHEBI:69522; OBGBGHKYJAOXRR-UHFFFAOYSA-N; 39020BUT1D; 2-methoxy-1,4-dihydronaphthalene-1,4-dione; ACMC-20ans6; AC1L28UU; MLS002472995; 2-methoxy-1,4-napthoquinone; SCHEMBL571061; AC1Q483I; DTXSID1062338; CTK4F1565
DMA5Q4T	DT	Small molecular drug
DMA5Q4T	PC	16871
DMA5Q4T	MW	188.18
DMA5Q4T	FM	C11H8O3
DMA5Q4T	IC	InChI=1S/C11H8O3/c1-14-10-6-9(12)7-4-2-3-5-8(7)11(10)13/h2-6H,1H3
DMA5Q4T	CS	COC1=CC(=O)C2=CC=CC=C2C1=O
DMA5Q4T	IK	OBGBGHKYJAOXRR-UHFFFAOYSA-N
DMA5Q4T	IU	2-methoxynaphthalene-1,4-dione
DMA5Q4T	CA	CAS 2348-82-5
DMA5Q4T	CB	CHEBI:69522
DMA5Q4T	DE	Discovery agent

DMH76C5	ID	DMH76C5
DMH76C5	DN	2-methoxy-1-naphthaldehyde thiosemicarbazone
DMH76C5	HS	Investigative
DMH76C5	SN	CHEMBL90867; 2-methoxy-1-naphthaldehyde thiosemicarbazone; 65110-22-7; NSC525522; AC1OBL0Z; ARONIS022059; SCHEMBL13954727; DTXSID80425959; MolPort-009-657-950; MolPort-001-023-825; ZINC4483101; BDBM50114597; STK028739; AKOS000488676; NSC-525522; KB-94431; ST035230; BB0276319; AN-329/40200631; [(E)-(2-methoxynaphthalen-1-yl)methylideneamino]thiourea; {[(1E)-2-(2-methoxynaphthyl)-1-azavinyl]amino}aminomethane-1-thione
DMH76C5	DT	Small molecular drug
DMH76C5	PC	6875577
DMH76C5	MW	259.329
DMH76C5	FM	C13H13N3OS
DMH76C5	IC	InChI=1S/C13H13N3OS/c1-17-12-7-6-9-4-2-3-5-10(9)11(12)8-15-16-13(14)18/h2-8H,1H3,(H3,14,16,18)/b15-8+
DMH76C5	CS	COC1=C(C2=CC=CC=C2C=C1)/C=N/NC(=S)N
DMH76C5	IK	DXTYDDVJOBCCHE-OVCLIPMQSA-N
DMH76C5	IU	[(E)-(2-methoxynaphthalen-1-yl)methylideneamino]thiourea
DMH76C5	CA	CAS 65110-22-7
DMH76C5	DE	Discovery agent

DM93DYT	ID	DM93DYT
DM93DYT	DN	2-methoxy-3,4-methylenedioxybenzophenone
DM93DYT	HS	Investigative
DM93DYT	SN	872881-74-8; (4-methoxybenzo[d][1,3]dioxol-5-yl)(phenyl)methanone; 2-methoxy-3,4-methylenedioxybenzophenone; CHEMBL497717; CTK3C4926; SUKAEERDMQPLMM-UHFFFAOYSA-; DTXSID20475539; AKOS027335527; 4-Methoxy-5-benzoyl-1,3-benzodioxole; Methanone, (4-methoxy-1,3-benzodioxol-5-yl)phenyl-
DM93DYT	DT	Small molecular drug
DM93DYT	PC	11999967
DM93DYT	MW	256.25
DM93DYT	FM	C15H12O4
DM93DYT	IC	InChI=1S/C15H12O4/c1-17-14-11(7-8-12-15(14)19-9-18-12)13(16)10-5-3-2-4-6-10/h2-8H,9H2,1H3
DM93DYT	CS	COC1=C(C=CC2=C1OCO2)C(=O)C3=CC=CC=C3
DM93DYT	IK	SUKAEERDMQPLMM-UHFFFAOYSA-N
DM93DYT	IU	(4-methoxy-1,3-benzodioxol-5-yl)-phenylmethanone
DM93DYT	CA	CAS 872881-74-8
DM93DYT	DE	Discovery agent

DMF8E5L	ID	DMF8E5L
DMF8E5L	DN	2-methoxy-4-(2-methoxyphenylthio)benzonitrile
DMF8E5L	HS	Investigative
DMF8E5L	SN	CHEMBL510145; 2-methoxy-4-(2-methoxyphenylthio)benzonitrile
DMF8E5L	DT	Small molecular drug
DMF8E5L	PC	44565206
DMF8E5L	MW	271.3
DMF8E5L	FM	C15H13NO2S
DMF8E5L	IC	InChI=1S/C15H13NO2S/c1-17-13-5-3-4-6-15(13)19-12-8-7-11(10-16)14(9-12)18-2/h3-9H,1-2H3
DMF8E5L	CS	COC1=CC=CC=C1SC2=CC(=C(C=C2)C#N)OC
DMF8E5L	IK	WQGGJJSMEMAVIF-UHFFFAOYSA-N
DMF8E5L	IU	2-methoxy-4-(2-methoxyphenyl)sulfanylbenzonitrile
DMF8E5L	DE	Discovery agent

DMEAVD2	ID	DMEAVD2
DMEAVD2	DN	2-methoxy-4-(2-nitrovinyl)phenol
DMEAVD2	HS	Investigative
DMEAVD2	SN	2-methoxy-4-(2-nitrovinyl)phenol; 6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924
DMEAVD2	DT	Small molecular drug
DMEAVD2	PC	638439
DMEAVD2	MW	195.17
DMEAVD2	FM	C9H9NO4
DMEAVD2	IC	InChI=1S/C9H9NO4/c1-14-9-6-7(2-3-8(9)11)4-5-10(12)13/h2-6,11H,1H3/b5-4+
DMEAVD2	CS	COC1=C(C=CC(=C1)/C=C/[N+](=O)[O-])O
DMEAVD2	IK	XVXCSPJSXIUNQJ-SNAWJCMRSA-N
DMEAVD2	IU	2-methoxy-4-[(E)-2-nitroethenyl]phenol
DMEAVD2	CA	CAS 22568-51-0
DMEAVD2	DE	Discovery agent

DM1MGQ6	ID	DM1MGQ6
DM1MGQ6	DN	2-methoxy-4-(m-tolyloxy)benzonitrile
DM1MGQ6	HS	Investigative
DM1MGQ6	SN	CHEMBL490957; 2-methoxy-4-(m-tolyloxy)benzonitrile
DM1MGQ6	DT	Small molecular drug
DM1MGQ6	PC	44565104
DM1MGQ6	MW	239.27
DM1MGQ6	FM	C15H13NO2
DM1MGQ6	IC	InChI=1S/C15H13NO2/c1-11-4-3-5-13(8-11)18-14-7-6-12(10-16)15(9-14)17-2/h3-9H,1-2H3
DM1MGQ6	CS	CC1=CC(=CC=C1)OC2=CC(=C(C=C2)C#N)OC
DM1MGQ6	IK	NXORRFHUCGSBOI-UHFFFAOYSA-N
DM1MGQ6	IU	2-methoxy-4-(3-methylphenoxy)benzonitrile
DM1MGQ6	DE	Discovery agent

DMT7YR3	ID	DMT7YR3
DMT7YR3	DN	2-methoxy-4-(o-tolyloxy)benzonitrile
DMT7YR3	HS	Investigative
DMT7YR3	SN	CHEMBL491493; 2-methoxy-4-(o-tolyloxy)benzonitrile; SCHEMBL4178171
DMT7YR3	DT	Small molecular drug
DMT7YR3	PC	11715659
DMT7YR3	MW	239.27
DMT7YR3	FM	C15H13NO2
DMT7YR3	IC	InChI=1S/C15H13NO2/c1-11-5-3-4-6-14(11)18-13-8-7-12(10-16)15(9-13)17-2/h3-9H,1-2H3
DMT7YR3	CS	CC1=CC=CC=C1OC2=CC(=C(C=C2)C#N)OC
DMT7YR3	IK	QZFFCZYDLZAYFR-UHFFFAOYSA-N
DMT7YR3	IU	2-methoxy-4-(2-methylphenoxy)benzonitrile
DMT7YR3	DE	Discovery agent

DMXGP2I	ID	DMXGP2I
DMXGP2I	DN	2-methoxy-4-(propylthio)benzonitrile
DMXGP2I	HS	Investigative
DMXGP2I	SN	CHEMBL443970; 2-methoxy-4-(propylthio)benzonitrile
DMXGP2I	DT	Small molecular drug
DMXGP2I	PC	44564581
DMXGP2I	MW	207.29
DMXGP2I	FM	C11H13NOS
DMXGP2I	IC	InChI=1S/C11H13NOS/c1-3-6-14-10-5-4-9(8-12)11(7-10)13-2/h4-5,7H,3,6H2,1-2H3
DMXGP2I	CS	CCCSC1=CC(=C(C=C1)C#N)OC
DMXGP2I	IK	SYEDQZDHJDTUDG-UHFFFAOYSA-N
DMXGP2I	IU	2-methoxy-4-propylsulfanylbenzonitrile
DMXGP2I	DE	Discovery agent

DMR5YZG	ID	DMR5YZG
DMR5YZG	DN	2-methoxy-4-(p-tolyloxy)benzonitrile
DMR5YZG	HS	Investigative
DMR5YZG	SN	CHEMBL501649; 2-methoxy-4-(p-tolyloxy)benzonitrile; SCHEMBL17354615
DMR5YZG	DT	Small molecular drug
DMR5YZG	PC	44565150
DMR5YZG	MW	239.27
DMR5YZG	FM	C15H13NO2
DMR5YZG	IC	InChI=1S/C15H13NO2/c1-11-3-6-13(7-4-11)18-14-8-5-12(10-16)15(9-14)17-2/h3-9H,1-2H3
DMR5YZG	CS	CC1=CC=C(C=C1)OC2=CC(=C(C=C2)C#N)OC
DMR5YZG	IK	UIOZKPIEPDRGOC-UHFFFAOYSA-N
DMR5YZG	IU	2-methoxy-4-(4-methylphenoxy)benzonitrile
DMR5YZG	DE	Discovery agent

DMCGID6	ID	DMCGID6
DMCGID6	DN	2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol
DMCGID6	HS	Investigative
DMCGID6	SN	CHEMBL10121; 2-methoxy-5-(3,4,5-trimethoxybenzyl)phenol; NSC648581; Neuro_000355; AC1Q56F6; AC1L85N6; CTK6J6605; ZINC1630963; BDBM50212289; NSC-648581; NCI60_016862
DMCGID6	DT	Small molecular drug
DMCGID6	PC	372869
DMCGID6	MW	304.34
DMCGID6	FM	C17H20O5
DMCGID6	IC	InChI=1S/C17H20O5/c1-19-14-6-5-11(8-13(14)18)7-12-9-15(20-2)17(22-4)16(10-12)21-3/h5-6,8-10,18H,7H2,1-4H3
DMCGID6	CS	COC1=C(C=C(C=C1)CC2=CC(=C(C(=C2)OC)OC)OC)O
DMCGID6	IK	JFZDWXGLUXEEAY-UHFFFAOYSA-N
DMCGID6	IU	2-methoxy-5-[(3,4,5-trimethoxyphenyl)methyl]phenol
DMCGID6	DE	Discovery agent

DM6CAYV	ID	DM6CAYV
DM6CAYV	DN	2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol
DM6CAYV	HS	Investigative
DM6CAYV	SN	CHEMBL356370; 2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol; BDBM50095326
DM6CAYV	DT	Small molecular drug
DM6CAYV	PC	44367275
DM6CAYV	MW	306.31
DM6CAYV	FM	C16H18O6
DM6CAYV	IC	InChI=1S/C16H18O6/c1-18-13-6-5-10(7-12(13)17)22-11-8-14(19-2)16(21-4)15(9-11)20-3/h5-9,17H,1-4H3
DM6CAYV	CS	COC1=C(C=C(C=C1)OC2=CC(=C(C(=C2)OC)OC)OC)O
DM6CAYV	IK	OJRSPUQFMNDPAN-UHFFFAOYSA-N
DM6CAYV	IU	2-methoxy-5-(3,4,5-trimethoxyphenoxy)phenol
DM6CAYV	DE	Discovery agent

DM9LY0Z	ID	DM9LY0Z
DM9LY0Z	DN	2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol
DM9LY0Z	HS	Investigative
DM9LY0Z	SN	CHEMBL131684
DM9LY0Z	DT	Small molecular drug
DM9LY0Z	PC	10336746
DM9LY0Z	MW	330.4
DM9LY0Z	FM	C19H22O5
DM9LY0Z	IC	InChI=1S/C19H22O5/c1-21-15-8-6-11(9-14(15)20)13-7-5-12-10-16(22-2)18(23-3)19(24-4)17(12)13/h6,8-10,13,20H,5,7H2,1-4H3
DM9LY0Z	CS	COC1=C(C=C(C=C1)C2CCC3=CC(=C(C(=C23)OC)OC)OC)O
DM9LY0Z	IK	QYUAUFKQRRPTIK-UHFFFAOYSA-N
DM9LY0Z	IU	2-methoxy-5-(5,6,7-trimethoxy-2,3-dihydro-1H-inden-1-yl)phenol
DM9LY0Z	DE	Discovery agent

DMXCAKO	ID	DMXCAKO
DMXCAKO	DN	2-methoxy-9-aminomethyl-9,10-dihydroanthracene
DMXCAKO	HS	Investigative
DMXCAKO	SN	CHEMBL497157; 2-methoxy-9-aminomethyl-9,10-dihydroanthracene; BDBM50264949
DMXCAKO	DT	Small molecular drug
DMXCAKO	PC	44580317
DMXCAKO	MW	239.31
DMXCAKO	FM	C16H17NO
DMXCAKO	IC	InChI=1S/C16H17NO/c1-18-13-7-6-12-8-11-4-2-3-5-14(11)16(10-17)15(12)9-13/h2-7,9,16H,8,10,17H2,1H3
DMXCAKO	CS	COC1=CC2=C(CC3=CC=CC=C3C2CN)C=C1
DMXCAKO	IK	UKAGNBPAZOMJAO-UHFFFAOYSA-N
DMXCAKO	IU	(2-methoxy-9,10-dihydroanthracen-9-yl)methanamine
DMXCAKO	DE	Discovery agent

DM4G3FS	ID	DM4G3FS
DM4G3FS	DN	2-methoxy-alpha,beta-didehydro-agomelatine
DM4G3FS	HS	Investigative
DM4G3FS	SN	CHEMBL2314259; 2-methoxy-alpha,beta-didehydro-agomelatine; GTPL7775; BDBM50425202
DM4G3FS	DT	Small molecular drug
DM4G3FS	PC	71533431
DM4G3FS	MW	271.31
DM4G3FS	FM	C16H17NO3
DM4G3FS	IC	InChI=1S/C16H17NO3/c1-11(18)17-9-8-14-15-10-13(19-2)6-4-12(15)5-7-16(14)20-3/h4-10H,1-3H3,(H,17,18)/b9-8+
DM4G3FS	CS	CC(=O)N/C=C/C1=C(C=CC2=C1C=C(C=C2)OC)OC
DM4G3FS	IK	HMYFXYOFPXZULT-CMDGGOBGSA-N
DM4G3FS	IU	N-[(E)-2-(2,7-dimethoxynaphthalen-1-yl)ethenyl]acetamide
DM4G3FS	DE	Discovery agent

DMPG0V7	ID	DMPG0V7
DMPG0V7	DN	2-methoxyapomorphine
DMPG0V7	HS	Investigative
DMPG0V7	SN	2-Methoxyapomorphine; CHEMBL53445; 126874-79-1; (6ar)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol; SCHEMBL8097389; AC1L503G; (R)-(-)-2-methoxyapomorphine; CTK4B5400; 4H-Dibenzo[de,g]quinoline-10,11-diol,5,6,6a,7-tetrahydro-2-methoxy-6-methyl-, (6aR)-; 2-Methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; AC1Q5802; BDBM50010697; (R)-2-Methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; (6aR)-5,6,6abeta,7-Tetrahydro-2-methoxy-6-methyl 4H-dibenzo
DMPG0V7	DT	Small molecular drug
DMPG0V7	PC	195499
DMPG0V7	MW	297.3
DMPG0V7	FM	C18H19NO3
DMPG0V7	IC	InChI=1S/C18H19NO3/c1-19-6-5-11-7-12(22-2)9-13-16(11)14(19)8-10-3-4-15(20)18(21)17(10)13/h3-4,7,9,14,20-21H,5-6,8H2,1-2H3/t14-/m1/s1
DMPG0V7	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=C(C=C4)O)O
DMPG0V7	IK	QGJWYJSOGNAUCY-CQSZACIVSA-N
DMPG0V7	IU	(6aR)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMPG0V7	CA	CAS 126874-79-1
DMPG0V7	DE	Discovery agent

DMIBKNZ	ID	DMIBKNZ
DMIBKNZ	DN	2-methoxyestradiol-17-O-sulfamate
DMIBKNZ	HS	Investigative
DMIBKNZ	SN	CHEMBL374721; 2-methoxyestradiol 17-O-sulfamate; (13alpha,14beta,17alpha)-3-Hydroxy-2-Methoxyestra-1,3,5(10)-Trien-17-Yl Sulfamate; 2-methoxyestradiol-17-O-sulfamate; 2x7s; BDBM50200940
DMIBKNZ	DT	Small molecular drug
DMIBKNZ	PC	16098578
DMIBKNZ	MW	381.5
DMIBKNZ	FM	C19H27NO5S
DMIBKNZ	IC	InChI=1S/C19H27NO5S/c1-19-8-7-12-13(15(19)5-6-18(19)25-26(20,22)23)4-3-11-9-16(21)17(24-2)10-14(11)12/h9-10,12-13,15,18,21H,3-8H2,1-2H3,(H2,20,22,23)/t12-,13+,15-,18-,19-/m0/s1
DMIBKNZ	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=CC(=C(C=C34)OC)O
DMIBKNZ	IK	AOEHUXLJSHGXHN-SSTWWWIQSA-N
DMIBKNZ	IU	[(8R,9S,13S,14S,17S)-3-hydroxy-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMIBKNZ	DE	Discovery agent

DMD6L7C	ID	DMD6L7C
DMD6L7C	DN	2-methoxyestrrone-3-O-sulfamate
DMD6L7C	HS	Investigative
DMD6L7C	SN	CHEMBL372231; 2-MeOEMATE; 2-methoxyestrrone-3-O-sulfamate; 2-methoxyestrone sulfamate; SCHEMBL307890; BTQHAWWINOTNQQ-QPWUGHHJSA-N; BDBM50171450; 2-methoxy-17-oxo-estra-1,3,5(10)-trien-3-yl sulfamate; (8R,9S,13S,14S)-2-Methoxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3-sulfonic acid amide
DMD6L7C	DT	Small molecular drug
DMD6L7C	PC	9842809
DMD6L7C	MW	379.5
DMD6L7C	FM	C19H25NO5S
DMD6L7C	IC	InChI=1S/C19H25NO5S/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-17(25-26(20,22)23)16(24-2)10-14(11)12/h9-10,12-13,15H,3-8H2,1-2H3,(H2,20,22,23)/t12-,13+,15-,19-/m0/s1
DMD6L7C	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=C(C=C34)OC)OS(=O)(=O)N
DMD6L7C	IK	BTQHAWWINOTNQQ-QPWUGHHJSA-N
DMD6L7C	IU	[(8R,9S,13S,14S)-2-methoxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfamate
DMD6L7C	DE	Discovery agent

DM6X8GN	ID	DM6X8GN
DM6X8GN	DN	2-Methoxyethyl 18-methoxycoronaridinate
DM6X8GN	HS	Investigative
DM6X8GN	SN	CHEMBL607152; 2-Methoxyethyl 18-methoxycoronaridinate
DM6X8GN	DT	Small molecular drug
DM6X8GN	PC	46877895
DM6X8GN	MW	412.5
DM6X8GN	FM	C24H32N2O4
DM6X8GN	IC	InChI=1S/C24H32N2O4/c1-28-10-8-17-13-16-14-24(23(27)30-12-11-29-2)21-19(7-9-26(15-16)22(17)24)18-5-3-4-6-20(18)25-21/h3-6,16-17,22,25H,7-15H2,1-2H3/t16?,17-,22-,24+/m0/s1
DM6X8GN	CS	COCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OCCOC
DM6X8GN	IK	OLFXZBDPKBSIPG-SAJNPJMVSA-N
DM6X8GN	IU	2-methoxyethyl (1S,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DM6X8GN	DE	Discovery agent

DM31E6J	ID	DM31E6J
DM31E6J	DN	2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide
DM31E6J	HS	Investigative
DM31E6J	SN	CHEMBL16450; 2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide
DM31E6J	DT	Small molecular drug
DM31E6J	PC	44270882
DM31E6J	MW	297.4
DM31E6J	FM	C19H23NO2
DM31E6J	IC	InChI=1S/C19H23NO2/c1-14(2)17(15-9-5-4-6-10-15)13-20-19(21)16-11-7-8-12-18(16)22-3/h4-12,14,17H,13H2,1-3H3,(H,20,21)
DM31E6J	CS	CC(C)C(CNC(=O)C1=CC=CC=C1OC)C2=CC=CC=C2
DM31E6J	IK	XVFLGHVOMBWJAC-UHFFFAOYSA-N
DM31E6J	IU	2-methoxy-N-(3-methyl-2-phenylbutyl)benzamide
DM31E6J	DE	Discovery agent

DMQS8VE	ID	DMQS8VE
DMQS8VE	DN	2-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMQS8VE	HS	Investigative
DMQS8VE	SN	CHEMBL481525; 2-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMQS8VE	DT	Small molecular drug
DMQS8VE	PC	24905595
DMQS8VE	MW	349.4
DMQS8VE	FM	C20H15NO3S
DMQS8VE	IC	InChI=1S/C20H15NO3S/c1-23-16-10-4-5-11-17(16)24-20(22)21-14-8-2-6-12-18(14)25-19-13-7-3-9-15(19)21/h2-13H,1H3
DMQS8VE	CS	COC1=CC=CC=C1OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMQS8VE	IK	KQZJYFLCWHHHIK-UHFFFAOYSA-N
DMQS8VE	IU	(2-methoxyphenyl) phenothiazine-10-carboxylate
DMQS8VE	DE	Discovery agent

DML5PE9	ID	DML5PE9
DML5PE9	DN	2-methoxyphenylboronic acid
DML5PE9	HS	Investigative
DML5PE9	SN	2-Methoxyphenylboronic acid; 5720-06-9; 2-Methoxybenzeneboronic acid; (2-methoxyphenyl)boronic Acid; 2-methoxyphenyl boronic acid; o-Methoxyphenylboronic acid; 2-boronoanisole; (2-methoxyphenyl)boranediol; MFCD00236047; o-methoxyphenyl boronic acid; 2-methoxy phenylboronic acid; 2-methoxybenzene boronic acid; Boronic acid, (2-methoxyphenyl)-; 2-methoxypenylboronic acid; 2-Methoxybenzeneboronicacid; PubChem1865; ACMC-1AZDE; 2-methoxypbenylboronic acid; AC1Q44YL; AC1MC01Q; 2-methyoxyphenylboronic acid; 2-methoxyphenyl-boronic aci
DML5PE9	DT	Small molecular drug
DML5PE9	PC	2733958
DML5PE9	MW	151.96
DML5PE9	FM	C7H9BO3
DML5PE9	IC	InChI=1S/C7H9BO3/c1-11-7-5-3-2-4-6(7)8(9)10/h2-5,9-10H,1H3
DML5PE9	CS	B(C1=CC=CC=C1OC)(O)O
DML5PE9	IK	ROEQGIFOWRQYHD-UHFFFAOYSA-N
DML5PE9	IU	(2-methoxyphenyl)boronic acid
DML5PE9	CA	CAS 5720-06-9
DML5PE9	DE	Discovery agent

DMX1IC4	ID	DMX1IC4
DMX1IC4	DN	2-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMX1IC4	HS	Investigative
DMX1IC4	SN	CHEMBL187008; 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine; BDBM50155783
DMX1IC4	DT	Small molecular drug
DMX1IC4	PC	18721719
DMX1IC4	MW	144.24
DMX1IC4	FM	C6H12N2S
DMX1IC4	IC	InChI=1S/C6H12N2S/c1-5-4-8-6(7)2-3-9-5/h5H,2-4H2,1H3,(H2,7,8)
DMX1IC4	CS	CC1CN=C(CCS1)N
DMX1IC4	IK	FACIWFABQIDLEA-UHFFFAOYSA-N
DMX1IC4	IU	2-methyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMX1IC4	DE	Discovery agent

DMKTQB2	ID	DMKTQB2
DMKTQB2	DN	2-Methyl-1(3)H-anthrasimidazole-6,11-dione
DMKTQB2	HS	Investigative
DMKTQB2	SN	AC1MZY8L; CHEMBL594892; SCHEMBL17702673; MolPort-002-517-242; MolPort-000-752-121; ZINC9353066; AKOS030496241; MCULE-7367469235; 2-methyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMKTQB2	DT	Small molecular drug
DMKTQB2	PC	3908369
DMKTQB2	MW	262.26
DMKTQB2	FM	C16H10N2O2
DMKTQB2	IC	InChI=1S/C16H10N2O2/c1-8-17-12-7-6-11-13(14(12)18-8)16(20)10-5-3-2-4-9(10)15(11)19/h2-7H,1H3,(H,17,18)
DMKTQB2	CS	CC1=NC2=C(N1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O
DMKTQB2	IK	IXPPRTBZHPTQCM-UHFFFAOYSA-N
DMKTQB2	IU	2-methyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMKTQB2	DE	Discovery agent

DMRWOQH	ID	DMRWOQH
DMRWOQH	DN	2-methyl-1-(pyridin-3-yl)pent-1-en-3-one oxime
DMRWOQH	HS	Investigative
DMRWOQH	SN	SCHEMBL4299298
DMRWOQH	DT	Small molecular drug
DMRWOQH	PC	91933437
DMRWOQH	MW	190.24
DMRWOQH	FM	C11H14N2O
DMRWOQH	IC	InChI=1S/C11H14N2O/c1-3-11(13-14)9(2)7-10-5-4-6-12-8-10/h4-8,11H,3H2,1-2H3/b9-7+
DMRWOQH	CS	CCC(/C(=C/C1=CN=CC=C1)/C)N=O
DMRWOQH	IK	ZJNKUZQXZJOGMM-VQHVLOKHSA-N
DMRWOQH	IU	3-[(E)-2-methyl-3-nitrosopent-1-enyl]pyridine
DMRWOQH	DE	Discovery agent

DMTQ4FV	ID	DMTQ4FV
DMTQ4FV	DN	2-methyl-1-(pyridin-4-yl)pent-1-en-3-one oxime
DMTQ4FV	HS	Investigative
DMTQ4FV	DT	Small molecular drug
DMTQ4FV	PC	91933438
DMTQ4FV	MW	190.24
DMTQ4FV	FM	C11H14N2O
DMTQ4FV	IC	InChI=1S/C11H14N2O/c1-3-11(13-14)9(2)8-10-4-6-12-7-5-10/h4-8,11H,3H2,1-2H3/b9-8+
DMTQ4FV	CS	CCC(/C(=C/C1=CC=NC=C1)/C)N=O
DMTQ4FV	IK	GOJJWAOCMJUGEU-CMDGGOBGSA-N
DMTQ4FV	IU	4-[(E)-2-methyl-3-nitrosopent-1-enyl]pyridine
DMTQ4FV	DE	Discovery agent

DMLTJDR	ID	DMLTJDR
DMLTJDR	DN	2-methyl-1-(thiophen-2-yl)pent-1-en-3-one oxime
DMLTJDR	HS	Investigative
DMLTJDR	SN	SCHEMBL4299802
DMLTJDR	DT	Small molecular drug
DMLTJDR	PC	91933434
DMLTJDR	MW	195.28
DMLTJDR	FM	C10H13NOS
DMLTJDR	IC	InChI=1S/C10H13NOS/c1-3-10(11-12)8(2)7-9-5-4-6-13-9/h4-7,10H,3H2,1-2H3/b8-7+
DMLTJDR	CS	CCC(/C(=C/C1=CC=CS1)/C)N=O
DMLTJDR	IK	KWDFITPUCBENQZ-BQYQJAHWSA-N
DMLTJDR	IU	2-[(E)-2-methyl-3-nitrosopent-1-enyl]thiophene
DMLTJDR	DE	Discovery agent

DMQJKSV	ID	DMQJKSV
DMQJKSV	DN	2-methyl-1-(thiophen-3-yl)pent-1-en-3-one oxime
DMQJKSV	HS	Investigative
DMQJKSV	SN	SCHEMBL3671471
DMQJKSV	DT	Small molecular drug
DMQJKSV	PC	91933436
DMQJKSV	MW	195.28
DMQJKSV	FM	C10H13NOS
DMQJKSV	IC	InChI=1S/C10H13NOS/c1-3-10(11-12)8(2)6-9-4-5-13-7-9/h4-7,10H,3H2,1-2H3/b8-6+
DMQJKSV	CS	CCC(/C(=C/C1=CSC=C1)/C)N=O
DMQJKSV	IK	MTERIVIYUVDTBU-SOFGYWHQSA-N
DMQJKSV	IU	3-[(E)-2-methyl-3-nitrosopent-1-enyl]thiophene
DMQJKSV	DE	Discovery agent

DMDJHFQ	ID	DMDJHFQ
DMDJHFQ	DN	2-Methyl-1,2-dihydro-indazol-3-one
DMDJHFQ	HS	Investigative
DMDJHFQ	SN	1848-40-4; 1,2-Dihydro-2-methyl-3H-indazol-3-one; 2-methyl-1H-indazol-3(2H)-one; 3H-Indazol-3-one, 1,2-dihydro-2-methyl-; CHEMBL3144583; FPNXGZRMUROVNY-UHFFFAOYSA-N; 2-methyl-1,2-dihydroindazol-3-one; 3-Indazolinone, 2-methyl-; 2-methyl-1H-indazol-3-one; 2-Methyl-1,2-dihydro-indazol-3-one; AC1LBX43; CHEMBL8364; SCHEMBL2673327; CTK0E2434; DTXSID30343553; MolPort-028-748-594; BDBM50009002; ZINC13820683; AKOS023543896; MB14910; CM10169; 2-Methyl-1,2-dihydro-3H-indazol-3-one #; 2-METHYL-2,3-DIHYDRO-1H-INDAZOL-3-ONE; INDAZOL-3-ONE, 1,
DMDJHFQ	DT	Small molecular drug
DMDJHFQ	PC	590513
DMDJHFQ	MW	148.16
DMDJHFQ	FM	C8H8N2O
DMDJHFQ	IC	InChI=1S/C8H8N2O/c1-10-8(11)6-4-2-3-5-7(6)9-10/h2-5,9H,1H3
DMDJHFQ	CS	CN1C(=O)C2=CC=CC=C2N1
DMDJHFQ	IK	FPNXGZRMUROVNY-UHFFFAOYSA-N
DMDJHFQ	IU	2-methyl-1H-indazol-3-one
DMDJHFQ	CA	CAS 1848-40-4
DMDJHFQ	DE	Discovery agent

DMIWX21	ID	DMIWX21
DMIWX21	DN	2-Methyl-1,2-di-pyridin-3-yl-1-methoxypropane
DMIWX21	HS	Investigative
DMIWX21	SN	CHEMBL55488; 87372-73-4; 2-Methyl-1,2-di-pyridin-3-yl-1-methoxypropane; CTK3C4531; DTXSID00658227; BDBM50028161; 3,3'-(1-Methoxy-2-methylpropane-1,2-diyl)dipyridine; Pyridine, 3,3'-(2-methoxy-1,1-dimethyl-1,2-ethanediyl)bis-
DMIWX21	DT	Small molecular drug
DMIWX21	PC	44299128
DMIWX21	MW	242.32
DMIWX21	FM	C15H18N2O
DMIWX21	IC	InChI=1S/C15H18N2O/c1-15(2,13-7-5-9-17-11-13)14(18-3)12-6-4-8-16-10-12/h4-11,14H,1-3H3
DMIWX21	CS	CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)OC
DMIWX21	IK	NIZJKWCUCWIETQ-UHFFFAOYSA-N
DMIWX21	IU	3-(1-methoxy-2-methyl-1-pyridin-3-ylpropan-2-yl)pyridine
DMIWX21	CA	CAS 87372-73-4
DMIWX21	DE	Discovery agent

DMB0NEL	ID	DMB0NEL
DMB0NEL	DN	2-Methyl-1,2-di-pyridin-3-yl-propan-1-one oxime
DMB0NEL	HS	Investigative
DMB0NEL	DT	Small molecular drug
DMB0NEL	PC	53724392
DMB0NEL	MW	241.29
DMB0NEL	FM	C14H15N3O
DMB0NEL	IC	InChI=1S/C14H15N3O/c1-14(2,12-6-4-8-16-10-12)13(17-18)11-5-3-7-15-9-11/h3-10,13H,1-2H3
DMB0NEL	CS	CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)N=O
DMB0NEL	IK	CJLBATLINTYVRN-UHFFFAOYSA-N
DMB0NEL	IU	3-(2-methyl-1-nitroso-1-pyridin-3-ylpropan-2-yl)pyridine
DMB0NEL	DE	Discovery agent

DMC3ET2	ID	DMC3ET2
DMC3ET2	DN	2-Methyl-1,2-di-pyridin-3-yl-propane
DMC3ET2	HS	Investigative
DMC3ET2	SN	CHEMBL54171; 87372-71-2; 2-Methyl-1,2-di-pyridin-3-yl-propane; CTK3C4533; DTXSID60658228; ZINC29551986; BDBM50028165; 3,3'-(2-Methylpropane-1,2-diyl)dipyridine; Pyridine, 3,3'-(1,1-dimethyl-1,2-ethanediyl)bis-
DMC3ET2	DT	Small molecular drug
DMC3ET2	PC	44299129
DMC3ET2	MW	212.29
DMC3ET2	FM	C14H16N2
DMC3ET2	IC	InChI=1S/C14H16N2/c1-14(2,13-6-4-8-16-11-13)9-12-5-3-7-15-10-12/h3-8,10-11H,9H2,1-2H3
DMC3ET2	CS	CC(C)(CC1=CN=CC=C1)C2=CN=CC=C2
DMC3ET2	IK	PKJNPGGSGKBGGS-UHFFFAOYSA-N
DMC3ET2	IU	3-(2-methyl-1-pyridin-3-ylpropan-2-yl)pyridine
DMC3ET2	CA	CAS 87372-71-2
DMC3ET2	DE	Discovery agent

DMQHM7R	ID	DMQHM7R
DMQHM7R	DN	2-Methyl-1,2-di-pyridin-3-yl-propylchloride
DMQHM7R	HS	Investigative
DMQHM7R	SN	CHEMBL300127; 87372-70-1; 2-Methyl-1,2-di-pyridin-3-yl-propylchloride; CTK3C4534; DTXSID60658223; BDBM50028167; 3,3'-(1-Chloro-2-methylpropane-1,2-diyl)dipyridine; Pyridine, 3,3'-(2-chloro-1,1-dimethyl-1,2-ethanediyl)bis-
DMQHM7R	DT	Small molecular drug
DMQHM7R	PC	44299093
DMQHM7R	MW	246.73
DMQHM7R	FM	C14H15ClN2
DMQHM7R	IC	InChI=1S/C14H15ClN2/c1-14(2,12-6-4-8-17-10-12)13(15)11-5-3-7-16-9-11/h3-10,13H,1-2H3
DMQHM7R	CS	CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)Cl
DMQHM7R	IK	VVJXUKVBHKTNGD-UHFFFAOYSA-N
DMQHM7R	IU	3-(1-chloro-2-methyl-1-pyridin-3-ylpropan-2-yl)pyridine
DMQHM7R	CA	CAS 87372-70-1
DMQHM7R	DE	Discovery agent

DM561MH	ID	DM561MH
DM561MH	DN	2-Methyl-1,2-di-pyridin-3-yl-propyliodide
DM561MH	HS	Investigative
DM561MH	SN	CHEMBL55678; 87372-72-3; 2-Methyl-1,2-di-pyridin-3-yl-propyliodide; CTK3C4532; DTXSID20658224; BDBM50028168; 3,3'-(1-Iodo-2-methylpropane-1,2-diyl)dipyridine; Pyridine, 3,3'-(2-iodo-1,1-dimethyl-1,2-ethanediyl)bis-
DM561MH	DT	Small molecular drug
DM561MH	PC	44299094
DM561MH	MW	338.19
DM561MH	FM	C14H15IN2
DM561MH	IC	InChI=1S/C14H15IN2/c1-14(2,12-6-4-8-17-10-12)13(15)11-5-3-7-16-9-11/h3-10,13H,1-2H3
DM561MH	CS	CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)I
DM561MH	IK	BPACVLBDZBTCAO-UHFFFAOYSA-N
DM561MH	IU	3-(1-iodo-2-methyl-1-pyridin-3-ylpropan-2-yl)pyridine
DM561MH	CA	CAS 87372-72-3
DM561MH	DE	Discovery agent

DMLX9RG	ID	DMLX9RG
DMLX9RG	DN	2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol
DMLX9RG	HS	Investigative
DMLX9RG	SN	CHEMBL55378; 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol
DMLX9RG	DT	Small molecular drug
DMLX9RG	PC	44299143
DMLX9RG	MW	227.3
DMLX9RG	FM	C15H17NO
DMLX9RG	IC	InChI=1S/C15H17NO/c1-15(2,13-9-6-10-16-11-13)14(17)12-7-4-3-5-8-12/h3-11,14,17H,1-2H3
DMLX9RG	CS	CC(C)(C1=CN=CC=C1)C(C2=CC=CC=C2)O
DMLX9RG	IK	LCRMYPGRORRMNU-UHFFFAOYSA-N
DMLX9RG	IU	2-methyl-1-phenyl-2-pyridin-3-ylpropan-1-ol
DMLX9RG	DE	Discovery agent

DMZY72I	ID	DMZY72I
DMZY72I	DN	2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-one
DMZY72I	HS	Investigative
DMZY72I	SN	87372-75-6; 2-Methyl-1-phenyl-2-(3-pyridinyl)-1-propanone; CHEMBL294460; 2-Mppp; 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-one; AC1L37C5; SCHEMBL12260655; CTK5F8302; DTXSID50236312; ZINC5138212; BDBM50028170; KB-231336; 2-methyl-1-phenyl-2-pyridin-3-ylpropan-1-one
DMZY72I	DT	Small molecular drug
DMZY72I	PC	135918
DMZY72I	MW	225.28
DMZY72I	FM	C15H15NO
DMZY72I	IC	InChI=1S/C15H15NO/c1-15(2,13-9-6-10-16-11-13)14(17)12-7-4-3-5-8-12/h3-11H,1-2H3
DMZY72I	CS	CC(C)(C1=CN=CC=C1)C(=O)C2=CC=CC=C2
DMZY72I	IK	GWWVZTFGCNLAOV-UHFFFAOYSA-N
DMZY72I	IU	2-methyl-1-phenyl-2-pyridin-3-ylpropan-1-one
DMZY72I	CA	CAS 87372-75-6
DMZY72I	DE	Discovery agent

DMD45CU	ID	DMD45CU
DMD45CU	DN	2-Methyl-2,4-Pentanediol
DMD45CU	HS	Investigative
DMD45CU	SN	2-METHYL-2,4-PENTANEDIOL; 107-41-5; 2-Methylpentane-2,4-diol; Pinakon; 2,4-Dihydroxy-2-methylpentane; 2,4-Pentanediol, 2-methyl-; Diolane; Isol; 4-Methyl-2,4-pentanediol; 1,1,3-Trimethyltrimethylenediol; 2-Methyl pentane-2,4-diol; 2-Methyl-2,4-pentandiol; Caswell No. 574; alpha,alpha,alpha'-Trimethyltrimethylene glycol; 1,3-dimethyl-3-hydroxybutanol; Hexylene glycol [NF]; HSDB 1126; 1,3,3-trimethyl-1,3-propanediol; (+-)-2-Methyl-2,4-pentanediol; NSC 8098; EINECS 203-489-0; EPA Pesticide Chemical Code 068601; BRN
DMD45CU	DT	Small molecular drug
DMD45CU	PC	7870
DMD45CU	MW	118.17
DMD45CU	FM	C6H14O2
DMD45CU	IC	InChI=1S/C6H14O2/c1-5(7)4-6(2,3)8/h5,7-8H,4H2,1-3H3
DMD45CU	CS	CC(CC(C)(C)O)O
DMD45CU	IK	SVTBMSDMJJWYQN-UHFFFAOYSA-N
DMD45CU	IU	2-methylpentane-2,4-diol
DMD45CU	CA	CAS 107-41-5
DMD45CU	CB	CHEBI:62995
DMD45CU	DE	Discovery agent

DMHM5GJ	ID	DMHM5GJ
DMHM5GJ	DN	2-Methyl-2-Propanol
DMHM5GJ	HS	Investigative
DMHM5GJ	SN	tert-Butanol; tert-Butyl alcohol; 2-Methyl-2-propanol; 2-Methylpropan-2-ol; 75-65-0; t-Butanol; t-Butyl hydroxide; 1,1-Dimethylethanol; Trimethylcarbinol; Trimethyl methanol; 2-Propanol, 2-methyl-; Tertiary-Butyl Alcohol; T-BUTYL ALCOHOL; Trimethylmethanol; tert-butylalcohol; Butanol tertiaire; Trimethyl carbinol; Dimethylethanol; tertiary-Butanol; Alcool butylique tertiaire; Methanol, trimethyl-; Arconol; tertiary Butyl Alcohol; tert.-butanol; tert- butyl alcohol; Caswell No. 124A; t-butylalcohol; tertiary butanol; NCI-C55367; tBuOH
DMHM5GJ	DT	Small molecular drug
DMHM5GJ	PC	6386
DMHM5GJ	MW	74.12
DMHM5GJ	FM	C4H10O
DMHM5GJ	IC	InChI=1S/C4H10O/c1-4(2,3)5/h5H,1-3H3
DMHM5GJ	CS	CC(C)(C)O
DMHM5GJ	IK	DKGAVHZHDRPRBM-UHFFFAOYSA-N
DMHM5GJ	IU	2-methylpropan-2-ol
DMHM5GJ	CA	CAS 75-65-0
DMHM5GJ	CB	CHEBI:45895
DMHM5GJ	DE	Discovery agent

DM3DNFQ	ID	DM3DNFQ
DM3DNFQ	DN	2-Methyl-3-(2-Aminothiazolo)Propanal
DM3DNFQ	HS	Investigative
DM3DNFQ	SN	2-Methyl-3-(2-Aminothiazolo)propanal; (2S)-3-(2-amino-1,3-thiazol-4-yl)-2-methylpropanal; AC1NRBOT; DB03024
DM3DNFQ	DT	Small molecular drug
DM3DNFQ	PC	5288557
DM3DNFQ	MW	170.23
DM3DNFQ	FM	C7H10N2OS
DM3DNFQ	IC	InChI=1S/C7H10N2OS/c1-5(3-10)2-6-4-11-7(8)9-6/h3-5H,2H2,1H3,(H2,8,9)/t5-/m0/s1
DM3DNFQ	CS	C[C@@H](CC1=CSC(=N1)N)C=O
DM3DNFQ	IK	KFMAJVLZSDMFBV-YFKPBYRVSA-N
DM3DNFQ	IU	(2S)-3-(2-amino-1,3-thiazol-4-yl)-2-methylpropanal
DM3DNFQ	DE	Discovery agent

DMV8YIZ	ID	DMV8YIZ
DMV8YIZ	DN	2-methyl-3-(pyridin-4-yl)-1H-indol-6-amine
DMV8YIZ	HS	Investigative
DMV8YIZ	SN	CHEMBL207502; 2-methyl-3-(pyridin-4-yl)-1H-indol-6-amine
DMV8YIZ	DT	Small molecular drug
DMV8YIZ	PC	44410708
DMV8YIZ	MW	223.27
DMV8YIZ	FM	C14H13N3
DMV8YIZ	IC	InChI=1S/C14H13N3/c1-9-14(10-4-6-16-7-5-10)12-3-2-11(15)8-13(12)17-9/h2-8,17H,15H2,1H3
DMV8YIZ	CS	CC1=C(C2=C(N1)C=C(C=C2)N)C3=CC=NC=C3
DMV8YIZ	IK	AAIHLDQORIUJKB-UHFFFAOYSA-N
DMV8YIZ	IU	2-methyl-3-pyridin-4-yl-1H-indol-6-amine
DMV8YIZ	DE	Discovery agent

DM8N54C	ID	DM8N54C
DM8N54C	DN	2-methyl-3-(pyridin-4-yl)-1H-indole
DM8N54C	HS	Investigative
DM8N54C	SN	CHEMBL207501; 2-methyl-3-(pyridin-4-yl)-1H-indole; ZINC36338566
DM8N54C	DT	Small molecular drug
DM8N54C	PC	11962095
DM8N54C	MW	208.26
DM8N54C	FM	C14H12N2
DM8N54C	IC	InChI=1S/C14H12N2/c1-10-14(11-6-8-15-9-7-11)12-4-2-3-5-13(12)16-10/h2-9,16H,1H3
DM8N54C	CS	CC1=C(C2=CC=CC=C2N1)C3=CC=NC=C3
DM8N54C	IK	NMPHKIHQOKMIKF-UHFFFAOYSA-N
DM8N54C	IU	2-methyl-3-pyridin-4-yl-1H-indole
DM8N54C	DE	Discovery agent

DMHYA7G	ID	DMHYA7G
DMHYA7G	DN	2-methyl-3-phenethyl-3H-pyrimidin-4-one
DMHYA7G	HS	Investigative
DMHYA7G	SN	compound 2H [PMID: 15863312]
DMHYA7G	DT	Small molecular drug
DMHYA7G	PC	135515453
DMHYA7G	MW	352.4
DMHYA7G	FM	C21H21FN2O2
DMHYA7G	IC	InChI=1S/C21H21FN2O2/c1-3-16-14(2)23-20(17-9-5-7-11-19(17)25)24(21(16)26)13-12-15-8-4-6-10-18(15)22/h4-11,25H,3,12-13H2,1-2H3
DMHYA7G	CS	CCC1=C(N=C(N(C1=O)CCC2=CC=CC=C2F)C3=CC=CC=C3O)C
DMHYA7G	IK	JYFJNCCRKBBRKZ-UHFFFAOYSA-N
DMHYA7G	IU	5-ethyl-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methylpyrimidin-4-one
DMHYA7G	DE	Discovery agent

DMAFPE7	ID	DMAFPE7
DMAFPE7	DN	2-methyl-4-(2-thienylethynyl)thiazole
DMAFPE7	HS	Investigative
DMAFPE7	SN	CHEMBL202331; 2-methyl-4-(2-thienylethynyl)thiazole; Thiazole, 2-methyl-4-[2-(2-thienyl)ethynyl]-; SCHEMBL4151041; BDBM50181768; 878018-56-5
DMAFPE7	DT	Small molecular drug
DMAFPE7	PC	11535796
DMAFPE7	MW	205.3
DMAFPE7	FM	C10H7NS2
DMAFPE7	IC	InChI=1S/C10H7NS2/c1-8-11-9(7-13-8)4-5-10-3-2-6-12-10/h2-3,6-7H,1H3
DMAFPE7	CS	CC1=NC(=CS1)C#CC2=CC=CS2
DMAFPE7	IK	SSSIEHWNKPXIHQ-UHFFFAOYSA-N
DMAFPE7	IU	2-methyl-4-(2-thiophen-2-ylethynyl)-1,3-thiazole
DMAFPE7	DE	Discovery agent

DMK4A0J	ID	DMK4A0J
DMK4A0J	DN	2-methyl-4-(3-thienylethynyl)thiazole
DMK4A0J	HS	Investigative
DMK4A0J	SN	CHEMBL202610; 2-methyl-4-(3-thienylethynyl)thiazole; Thiazole, 2-methyl-4-[2-(3-thienyl)ethynyl]-; SCHEMBL4144709; BDBM50181788
DMK4A0J	DT	Small molecular drug
DMK4A0J	PC	11658509
DMK4A0J	MW	205.3
DMK4A0J	FM	C10H7NS2
DMK4A0J	IC	InChI=1S/C10H7NS2/c1-8-11-10(7-13-8)3-2-9-4-5-12-6-9/h4-7H,1H3
DMK4A0J	CS	CC1=NC(=CS1)C#CC2=CSC=C2
DMK4A0J	IK	DWHLLFJNQYENJN-UHFFFAOYSA-N
DMK4A0J	IU	2-methyl-4-(2-thiophen-3-ylethynyl)-1,3-thiazole
DMK4A0J	DE	Discovery agent

DM4P3CW	ID	DM4P3CW
DM4P3CW	DN	2-methyl-4-(m-tolylethynyl)thiazole
DM4P3CW	HS	Investigative
DM4P3CW	SN	CHEMBL182950; 2-methyl-4-(m-tolylethynyl)thiazole; SCHEMBL4150883; 2-Methyl-4-m-tolylethynyl-thiazole; ZINC13680880
DM4P3CW	DT	Small molecular drug
DM4P3CW	PC	11579392
DM4P3CW	MW	213.3
DM4P3CW	FM	C13H11NS
DM4P3CW	IC	InChI=1S/C13H11NS/c1-10-4-3-5-12(8-10)6-7-13-9-15-11(2)14-13/h3-5,8-9H,1-2H3
DM4P3CW	CS	CC1=CC(=CC=C1)C#CC2=CSC(=N2)C
DM4P3CW	IK	LYHRSGPNRBPYDG-UHFFFAOYSA-N
DM4P3CW	IU	2-methyl-4-[2-(3-methylphenyl)ethynyl]-1,3-thiazole
DM4P3CW	DE	Discovery agent

DMKFBVS	ID	DMKFBVS
DMKFBVS	DN	2-Methyl-4-o-tolylethynyl-thiazole
DMKFBVS	HS	Investigative
DMKFBVS	SN	CHEMBL181915; 2-Methyl-4-o-tolylethynyl-thiazole; Thiazole, 2-methyl-4-[2-(2-methylphenyl)ethynyl]-; BDBM50149797
DMKFBVS	DT	Small molecular drug
DMKFBVS	PC	44393020
DMKFBVS	MW	213.3
DMKFBVS	FM	C13H11NS
DMKFBVS	IC	InChI=1S/C13H11NS/c1-10-5-3-4-6-12(10)7-8-13-9-15-11(2)14-13/h3-6,9H,1-2H3
DMKFBVS	CS	CC1=CC=CC=C1C#CC2=CSC(=N2)C
DMKFBVS	IK	XDQBEOSJZSBVGG-UHFFFAOYSA-N
DMKFBVS	IU	2-methyl-4-[2-(2-methylphenyl)ethynyl]-1,3-thiazole
DMKFBVS	DE	Discovery agent

DMRC60A	ID	DMRC60A
DMRC60A	DN	2-Methyl-4-phenylethynyl-thiazole
DMRC60A	HS	Investigative
DMRC60A	SN	CHEMBL63042; 2-Methyl-4-phenylethynyl-thiazole; Thiazole, 2-methyl-4-(2-phenylethynyl)-; SCHEMBL5653485; NZHWBWVBWDOSJY-UHFFFAOYSA-N; 2-Methyl-4-(phenylethynyl)thiazole; BDBM50122759; 329203-01-2
DMRC60A	DT	Small molecular drug
DMRC60A	PC	10921526
DMRC60A	MW	199.27
DMRC60A	FM	C12H9NS
DMRC60A	IC	InChI=1S/C12H9NS/c1-10-13-12(9-14-10)8-7-11-5-3-2-4-6-11/h2-6,9H,1H3
DMRC60A	CS	CC1=NC(=CS1)C#CC2=CC=CC=C2
DMRC60A	IK	NZHWBWVBWDOSJY-UHFFFAOYSA-N
DMRC60A	IU	2-methyl-4-(2-phenylethynyl)-1,3-thiazole
DMRC60A	DE	Discovery agent

DMWRCFY	ID	DMWRCFY
DMWRCFY	DN	2-Methyl-4-p-tolylethynyl-thiazole
DMWRCFY	HS	Investigative
DMWRCFY	SN	CHEMBL185813; 2-Methyl-4-p-tolylethynyl-thiazole; Thiazole, 2-methyl-4-[2-(4-methylphenyl)ethynyl]-; SCHEMBL4456131; BDBM50149803
DMWRCFY	DT	Small molecular drug
DMWRCFY	PC	44393040
DMWRCFY	MW	213.3
DMWRCFY	FM	C13H11NS
DMWRCFY	IC	InChI=1S/C13H11NS/c1-10-3-5-12(6-4-10)7-8-13-9-15-11(2)14-13/h3-6,9H,1-2H3
DMWRCFY	CS	CC1=CC=C(C=C1)C#CC2=CSC(=N2)C
DMWRCFY	IK	AIMMPGMZHVMWCT-UHFFFAOYSA-N
DMWRCFY	IU	2-methyl-4-[2-(4-methylphenyl)ethynyl]-1,3-thiazole
DMWRCFY	DE	Discovery agent

DM1S5CB	ID	DM1S5CB
DM1S5CB	DN	2-methyl-5-HT
DM1S5CB	HS	Investigative
DM1S5CB	SN	2-methyl-5-hydroxytryptamine; 2-Me-5-HT; 2-methylserotonin
DM1S5CB	DT	Small molecular drug
DM1S5CB	PC	1574
DM1S5CB	MW	190.24
DM1S5CB	FM	C11H14N2O
DM1S5CB	IC	InChI=1S/C11H14N2O/c1-7-9(4-5-12)10-6-8(14)2-3-11(10)13-7/h2-3,6,13-14H,4-5,12H2,1H3
DM1S5CB	CS	CC1=C(C2=C(N1)C=CC(=C2)O)CCN
DM1S5CB	IK	WYWNEDARFVJQSG-UHFFFAOYSA-N
DM1S5CB	IU	3-(2-aminoethyl)-2-methyl-1H-indol-5-ol
DM1S5CB	CA	CAS 78263-90-8
DM1S5CB	CB	CHEBI:31085

DM536IA	ID	DM536IA
DM536IA	DN	2-methyl-6-(3-(phenylthio)prop-1-ynyl)pyridine
DM536IA	HS	Investigative
DM536IA	SN	CHEMBL214874; 2-methyl-6-(3-(phenylthio)prop-1-ynyl)pyridine; 2-methyl-6-[3-(phenylthio)prop-1-yn-1-yl]pyridine; SCHEMBL5703368; BDBM50191120
DM536IA	DT	Small molecular drug
DM536IA	PC	11333903
DM536IA	MW	239.3
DM536IA	FM	C15H13NS
DM536IA	IC	InChI=1S/C15H13NS/c1-13-7-5-8-14(16-13)9-6-12-17-15-10-3-2-4-11-15/h2-5,7-8,10-11H,12H2,1H3
DM536IA	CS	CC1=NC(=CC=C1)C#CCSC2=CC=CC=C2
DM536IA	IK	QPGKAVMWBQPWGX-UHFFFAOYSA-N
DM536IA	IU	2-methyl-6-(3-phenylsulfanylprop-1-ynyl)pyridine
DM536IA	DE	Discovery agent

DMGPDYE	ID	DMGPDYE
DMGPDYE	DN	2-methyl-6-(3-(p-tolyloxy)prop-1-ynyl)pyridine
DMGPDYE	HS	Investigative
DMGPDYE	SN	CHEMBL212130; 2-methyl-6-(3-p-tolyloxy-prop-1-ynyl)pyridine; 2-methyl-6-(3-(p-tolyloxy)prop-1-ynyl)pyridine; SCHEMBL5698271; BDBM50191151
DMGPDYE	DT	Small molecular drug
DMGPDYE	PC	11481793
DMGPDYE	MW	237.3
DMGPDYE	FM	C16H15NO
DMGPDYE	IC	InChI=1S/C16H15NO/c1-13-8-10-16(11-9-13)18-12-4-7-15-6-3-5-14(2)17-15/h3,5-6,8-11H,12H2,1-2H3
DMGPDYE	CS	CC1=CC=C(C=C1)OCC#CC2=CC=CC(=N2)C
DMGPDYE	IK	GMIZGDGVYPBQCS-UHFFFAOYSA-N
DMGPDYE	IU	2-methyl-6-[3-(4-methylphenoxy)prop-1-ynyl]pyridine
DMGPDYE	DE	Discovery agent

DM1YK7M	ID	DM1YK7M
DM1YK7M	DN	2-methyl-6-(4-phenylbut-1-ynyl)pyridine
DM1YK7M	HS	Investigative
DM1YK7M	SN	CHEMBL214542; 2-methyl-6-(4-phenylbut-1-ynyl)pyridine; 2-methyl-6-(4-phenylbut-1-yn-1-yl)pyridine; SCHEMBL5703352; BDBM50191117
DM1YK7M	DT	Small molecular drug
DM1YK7M	PC	11424570
DM1YK7M	MW	221.3
DM1YK7M	FM	C16H15N
DM1YK7M	IC	InChI=1S/C16H15N/c1-14-8-7-13-16(17-14)12-6-5-11-15-9-3-2-4-10-15/h2-4,7-10,13H,5,11H2,1H3
DM1YK7M	CS	CC1=NC(=CC=C1)C#CCCC2=CC=CC=C2
DM1YK7M	IK	YWQJYKCSHSTIRB-UHFFFAOYSA-N
DM1YK7M	IU	2-methyl-6-(4-phenylbut-1-ynyl)pyridine
DM1YK7M	DE	Discovery agent

DM0UNM1	ID	DM0UNM1
DM0UNM1	DN	2-methyl-6-(4-phenylpent-1-ynyl)pyridine
DM0UNM1	HS	Investigative
DM0UNM1	SN	CHEMBL212834; 2-methyl-6-(4-phenylpent-1-ynyl)pyridine; 2-methyl-6-(4-phenylpent-1-yn-1-yl)pyridine; SCHEMBL5703254; BDBM50191124
DM0UNM1	DT	Small molecular drug
DM0UNM1	PC	11736483
DM0UNM1	MW	235.32
DM0UNM1	FM	C17H17N
DM0UNM1	IC	InChI=1S/C17H17N/c1-14(16-10-4-3-5-11-16)8-6-12-17-13-7-9-15(2)18-17/h3-5,7,9-11,13-14H,8H2,1-2H3
DM0UNM1	CS	CC1=NC(=CC=C1)C#CCC(C)C2=CC=CC=C2
DM0UNM1	IK	QVXDBDKPSMNGHQ-UHFFFAOYSA-N
DM0UNM1	IU	2-methyl-6-(4-phenylpent-1-ynyl)pyridine
DM0UNM1	DE	Discovery agent

DMDVO7Z	ID	DMDVO7Z
DMDVO7Z	DN	2-methyl-6-(5-phenylpent-1-ynyl)pyridine
DMDVO7Z	HS	Investigative
DMDVO7Z	SN	CHEMBL378040; 2-methyl-6-(5-phenylpent-1-ynyl)pyridine; 2-methyl-6-(5-phenylpent-1-yn-1-yl)pyridine; SCHEMBL5703524; BDBM50191123
DMDVO7Z	DT	Small molecular drug
DMDVO7Z	PC	44416004
DMDVO7Z	MW	235.32
DMDVO7Z	FM	C17H17N
DMDVO7Z	IC	InChI=1S/C17H17N/c1-15-9-8-14-17(18-15)13-7-3-6-12-16-10-4-2-5-11-16/h2,4-5,8-11,14H,3,6,12H2,1H3
DMDVO7Z	CS	CC1=NC(=CC=C1)C#CCCCC2=CC=CC=C2
DMDVO7Z	IK	NJJSTWRJIALOHE-UHFFFAOYSA-N
DMDVO7Z	IU	2-methyl-6-(5-phenylpent-1-ynyl)pyridine
DMDVO7Z	DE	Discovery agent

DMVQK4Y	ID	DMVQK4Y
DMVQK4Y	DN	2-methyl-6-(phenylethynyl)pyridine
DMVQK4Y	HS	Investigative
DMVQK4Y	SN	2-Methyl-6-(phenylethynyl)pyridine; MPEP; 96206-92-7; 6-Methyl-2-(phenylethynyl)pyridine; 2-methyl-6-(2-phenylethynyl)pyridine; UNII-7VC0YVI27Y; 7VC0YVI27Y; CHEMBL66654; CHEBI:64159; Pyridine, 2-methyl-6-(phenylethynyl)-; Tocris-1212; AC1MHGB1; Lopac-M-5435; Lopac0_000738; MLS006011229; SCHEMBL103061; 2-Picoline, 6-phenylethynyl-; GTPL1426; DTXSID9043982; MolPort-003-958-770; HMS3651F13; 2-Methyl-6-phenylethynyl-pyridine; ZINC2581406; BCP05962; ZX-AN014840; 2-methyl-6-(phenylethynyl)-pyridine; s2809; HY-14609A; 2151AH
DMVQK4Y	DT	Small molecular drug
DMVQK4Y	PC	3025961
DMVQK4Y	MW	193.24
DMVQK4Y	FM	C14H11N
DMVQK4Y	IC	InChI=1S/C14H11N/c1-12-6-5-9-14(15-12)11-10-13-7-3-2-4-8-13/h2-9H,1H3
DMVQK4Y	CS	CC1=NC(=CC=C1)C#CC2=CC=CC=C2
DMVQK4Y	IK	NEWKHUASLBMWRE-UHFFFAOYSA-N
DMVQK4Y	IU	2-methyl-6-(2-phenylethynyl)pyridine
DMVQK4Y	CA	CAS 96206-92-7
DMVQK4Y	CB	CHEBI:64159
DMVQK4Y	DE	Discovery agent

DMJYSF3	ID	DMJYSF3
DMJYSF3	DN	2-methyl-6-(trifluoromethyl)-9H-carbazole
DMJYSF3	HS	Investigative
DMJYSF3	SN	2-methyl-6-(trifluoromethyl)-9H-carbazole; CHEMBL1170659; SCHEMBL13772410
DMJYSF3	DT	Small molecular drug
DMJYSF3	PC	24741169
DMJYSF3	MW	249.23
DMJYSF3	FM	C14H10F3N
DMJYSF3	IC	InChI=1S/C14H10F3N/c1-8-2-4-10-11-7-9(14(15,16)17)3-5-12(11)18-13(10)6-8/h2-7,18H,1H3
DMJYSF3	CS	CC1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)C(F)(F)F
DMJYSF3	IK	QYXUJSGMFDAAAV-UHFFFAOYSA-N
DMJYSF3	IU	2-methyl-6-(trifluoromethyl)-9H-carbazole
DMJYSF3	DE	Discovery agent

DM8EV4A	ID	DM8EV4A
DM8EV4A	DN	2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime
DM8EV4A	HS	Investigative
DM8EV4A	DT	Small molecular drug
DM8EV4A	PC	91934662
DM8EV4A	MW	194.27
DM8EV4A	FM	C11H18N2O
DM8EV4A	IC	InChI=1S/C11H18N2O/c1-11(10-12-14)6-2-3-7-13-8-4-5-9-13/h11H,4-10H2,1H3
DM8EV4A	CS	CC(CC#CCN1CCCC1)CN=O
DM8EV4A	IK	GMFWCDSZRLSMRO-UHFFFAOYSA-N
DM8EV4A	IU	1-(5-methyl-6-nitrosohex-2-ynyl)pyrrolidine
DM8EV4A	DE	Discovery agent

DM9FZ0B	ID	DM9FZ0B
DM9FZ0B	DN	2-methyl-7-(pyridin-3-yl)quinoline
DM9FZ0B	HS	Investigative
DM9FZ0B	SN	CHEMBL231763; 2-methyl-7-(pyridin-3-yl)quinoline
DM9FZ0B	DT	Small molecular drug
DM9FZ0B	PC	44432659
DM9FZ0B	MW	220.27
DM9FZ0B	FM	C15H12N2
DM9FZ0B	IC	InChI=1S/C15H12N2/c1-11-4-5-12-6-7-13(9-15(12)17-11)14-3-2-8-16-10-14/h2-10H,1H3
DM9FZ0B	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CN=CC=C3
DM9FZ0B	IK	MALXWWORFUKTKQ-UHFFFAOYSA-N
DM9FZ0B	IU	2-methyl-7-pyridin-3-ylquinoline
DM9FZ0B	DE	Discovery agent

DMMFKOH	ID	DMMFKOH
DMMFKOH	DN	2-methyl-7-m-tolyl-1,6-naphthyridine
DMMFKOH	HS	Investigative
DMMFKOH	SN	CHEMBL236431; 2-methyl-7-m-tolyl-1,6-naphthyridine
DMMFKOH	DT	Small molecular drug
DMMFKOH	PC	44434750
DMMFKOH	MW	234.29
DMMFKOH	FM	C16H14N2
DMMFKOH	IC	InChI=1S/C16H14N2/c1-11-4-3-5-13(8-11)15-9-16-14(10-17-15)7-6-12(2)18-16/h3-10H,1-2H3
DMMFKOH	CS	CC1=CC(=CC=C1)C2=NC=C3C=CC(=NC3=C2)C
DMMFKOH	IK	RXRAEDHCPCFPLI-UHFFFAOYSA-N
DMMFKOH	IU	2-methyl-7-(3-methylphenyl)-1,6-naphthyridine
DMMFKOH	DE	Discovery agent

DMZFK4R	ID	DMZFK4R
DMZFK4R	DN	2-methyl-7-m-tolyl-1,8-naphthyridine
DMZFK4R	HS	Investigative
DMZFK4R	SN	CHEMBL235629; 2-methyl-7-m-tolyl-1,8-naphthyridine
DMZFK4R	DT	Small molecular drug
DMZFK4R	PC	44434735
DMZFK4R	MW	234.29
DMZFK4R	FM	C16H14N2
DMZFK4R	IC	InChI=1S/C16H14N2/c1-11-4-3-5-14(10-11)15-9-8-13-7-6-12(2)17-16(13)18-15/h3-10H,1-2H3
DMZFK4R	CS	CC1=CC(=CC=C1)C2=NC3=C(C=CC(=N3)C)C=C2
DMZFK4R	IK	RJHUNTTZZMJQOV-UHFFFAOYSA-N
DMZFK4R	IU	2-methyl-7-(3-methylphenyl)-1,8-naphthyridine
DMZFK4R	DE	Discovery agent

DMC02TI	ID	DMC02TI
DMC02TI	DN	2-methyl-7-m-tolylquinoline
DMC02TI	HS	Investigative
DMC02TI	SN	CHEMBL231765; 2-methyl-7-m-tolylquinoline
DMC02TI	DT	Small molecular drug
DMC02TI	PC	44432662
DMC02TI	MW	233.31
DMC02TI	FM	C17H15N
DMC02TI	IC	InChI=1S/C17H15N/c1-12-4-3-5-15(10-12)16-9-8-14-7-6-13(2)18-17(14)11-16/h3-11H,1-2H3
DMC02TI	CS	CC1=CC(=CC=C1)C2=CC3=C(C=CC(=N3)C)C=C2
DMC02TI	IK	LRWHLTHMQZJGQD-UHFFFAOYSA-N
DMC02TI	IU	2-methyl-7-(3-methylphenyl)quinoline
DMC02TI	DE	Discovery agent

DM8RV5X	ID	DM8RV5X
DM8RV5X	DN	2-methyl-7-phenyl-1,8-naphthyridine
DM8RV5X	HS	Investigative
DM8RV5X	SN	2-methyl-7-phenyl-1,8-naphthyridine; CHEMBL97344; BDBM50090686; 7-Methyl-2-phenyl-1,8-naphthyridine; 2-Methyl-7-phenyl-[1,8]naphthyridine
DM8RV5X	DT	Small molecular drug
DM8RV5X	PC	12431922
DM8RV5X	MW	220.27
DM8RV5X	FM	C15H12N2
DM8RV5X	IC	InChI=1S/C15H12N2/c1-11-7-8-13-9-10-14(17-15(13)16-11)12-5-3-2-4-6-12/h2-10H,1H3
DM8RV5X	CS	CC1=NC2=C(C=C1)C=CC(=N2)C3=CC=CC=C3
DM8RV5X	IK	BGLSJWRWFABGNC-UHFFFAOYSA-N
DM8RV5X	IU	2-methyl-7-phenyl-1,8-naphthyridine
DM8RV5X	DE	Discovery agent

DMT7MVD	ID	DMT7MVD
DMT7MVD	DN	2-methyl-7-phenylquinoline
DMT7MVD	HS	Investigative
DMT7MVD	SN	CHEMBL244418; 2-methyl-7-phenylquinoline; 7-Phenylchinaldin
DMT7MVD	DT	Small molecular drug
DMT7MVD	PC	44427376
DMT7MVD	MW	219.28
DMT7MVD	FM	C16H13N
DMT7MVD	IC	InChI=1S/C16H13N/c1-12-7-8-14-9-10-15(11-16(14)17-12)13-5-3-2-4-6-13/h2-11H,1H3
DMT7MVD	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC=C3
DMT7MVD	IK	FGRQGIBMKYGMEX-UHFFFAOYSA-N
DMT7MVD	IU	2-methyl-7-phenylquinoline
DMT7MVD	DE	Discovery agent

DMY65CX	ID	DMY65CX
DMY65CX	DN	2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline
DMY65CX	HS	Investigative
DMY65CX	SN	AC1MHU5K; 2-methyl-8-phenyl-3,4-dihydro-1H-isoquinoline; CHEMBL13101; SCHEMBL11488388; Isoquinoline, 1,2,3,4-tetrahydro-2-methyl-8-phenyl-
DMY65CX	DT	Small molecular drug
DMY65CX	PC	3057770
DMY65CX	MW	223.31
DMY65CX	FM	C16H17N
DMY65CX	IC	InChI=1S/C16H17N/c1-17-11-10-14-8-5-9-15(16(14)12-17)13-6-3-2-4-7-13/h2-9H,10-12H2,1H3
DMY65CX	CS	CN1CCC2=C(C1)C(=CC=C2)C3=CC=CC=C3
DMY65CX	IK	XBKQADUXVZAYDY-UHFFFAOYSA-N
DMY65CX	IU	2-methyl-8-phenyl-3,4-dihydro-1H-isoquinoline
DMY65CX	DE	Discovery agent

DM06TZN	ID	DM06TZN
DM06TZN	DN	2-methyl-9H-carbazole
DM06TZN	HS	Investigative
DM06TZN	SN	2-METHYLCARBAZOLE; 2-Methyl-9H-carbazole; 9H-Carbazole, 2-methyl-; 3652-91-3; 2-Methyldibenzopyrrole; Carbazole, 2-methyl-; UNII-7MWG08F2MG; 7MWG08F2MG; CHEMBL1173640; PWJYOTPKLOICJK-UHFFFAOYSA-N; 2-methyl carbazole; NSC10153; EINECS 222-894-3; NSC 10153; 2-methyl-9H-carbazol; ACMC-1AHNQ; AC1L2DUH; 2-Methyl-9H-carbazole #; SCHEMBL607346; Carbazole, 2-methyl- (8CI); DTXSID9073963; CTK1C3104; MolPort-006-115-551; ZINC1706058; 9H-Carbazole, 2-methyl- (9CI); FCH838910; NSC-10153; BDBM50322581; AKOS006274371; ACM3652913; KB-25102; OR340083
DM06TZN	DT	Small molecular drug
DM06TZN	PC	19290
DM06TZN	MW	181.23
DM06TZN	FM	C13H11N
DM06TZN	IC	InChI=1S/C13H11N/c1-9-6-7-11-10-4-2-3-5-12(10)14-13(11)8-9/h2-8,14H,1H3
DM06TZN	CS	CC1=CC2=C(C=C1)C3=CC=CC=C3N2
DM06TZN	IK	PWJYOTPKLOICJK-UHFFFAOYSA-N
DM06TZN	IU	2-methyl-9H-carbazole
DM06TZN	CA	CAS 3652-91-3
DM06TZN	DE	Discovery agent

DMEVFJW	ID	DMEVFJW
DMEVFJW	DN	2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
DMEVFJW	HS	Investigative
DMEVFJW	SN	2-methyl-9H-indeno[2,1-d]pyrimidin-9-one; 9H-Indeno[2,1-d]pyrimidin-9-one, 2-methyl-; CHEMBL392622; Aza-heterocyclic Derivative, 2a; BDBM19174
DMEVFJW	DT	Small molecular drug
DMEVFJW	PC	23636012
DMEVFJW	MW	196.2
DMEVFJW	FM	C12H8N2O
DMEVFJW	IC	InChI=1S/C12H8N2O/c1-7-13-6-10-8-4-2-3-5-9(8)12(15)11(10)14-7/h2-6H,1H3
DMEVFJW	CS	CC1=NC=C2C3=CC=CC=C3C(=O)C2=N1
DMEVFJW	IK	QMXCHNWJZQMLGG-UHFFFAOYSA-N
DMEVFJW	IU	2-methylindeno[2,1-d]pyrimidin-9-one
DMEVFJW	DE	Discovery agent

DMKP6BM	ID	DMKP6BM
DMKP6BM	DN	2-Methylamino-succinic acid(NMDA)
DMKP6BM	HS	Investigative
DMKP6BM	SN	N-Methyl-D-aspartic acid; N-methyl-D-aspartic acid; NMDA; 6384-92-5; N-Methyl-D-aspartate; N-Methylaspartate; D-Aspartic acid, N-methyl-; N-Me-D-Asp-OH; (R)-2-(Methylamino)succinic acid; NMDA (N-Methyl-D-aspartic acid); Methyl aspartic acid; n-methyl-d-aspartic acid (nmda); UNII-1903B9Q6PI; N-Methyl aspartic acid; (2R)-2-(methylamino)butanedioic acid; 2-Methylamino-succinic acid; BRN 1724431; CHEMBL291278; CHEBI:31882; HOKKHZGPKSLGJE-GSVOUGTGSA-N; 1903B9Q6PI; N-Methyl-D-aspartic Acid, Hydrate; AK-44365; W-203368; N-Methyl-D-aspartic acid, 98%
DMKP6BM	DT	Small molecular drug
DMKP6BM	PC	22880
DMKP6BM	MW	147.13
DMKP6BM	FM	C5H9NO4
DMKP6BM	IC	InChI=1S/C5H9NO4/c1-6-3(5(9)10)2-4(7)8/h3,6H,2H2,1H3,(H,7,8)(H,9,10)/t3-/m1/s1
DMKP6BM	CS	CN[C@H](CC(=O)O)C(=O)O
DMKP6BM	IK	HOKKHZGPKSLGJE-GSVOUGTGSA-N
DMKP6BM	IU	(2R)-2-(methylamino)butanedioic acid
DMKP6BM	CA	CAS 6384-92-5
DMKP6BM	CB	CHEBI:31882
DMKP6BM	DE	Discovery agent

DMQBF7J	ID	DMQBF7J
DMQBF7J	DN	2-Methyl-beta-carboline-2-ium iodide
DMQBF7J	HS	Investigative
DMQBF7J	SN	2-methylnorharmane iodide; CHEMBL455600; MolPort-001-815-824; AKOS024332881
DMQBF7J	DT	Small molecular drug
DMQBF7J	PC	3036890
DMQBF7J	MW	183.23
DMQBF7J	FM	C12H11N2+
DMQBF7J	IC	InChI=1S/C12H10N2/c1-14-7-6-10-9-4-2-3-5-11(9)13-12(10)8-14/h2-8H,1H3/p+1
DMQBF7J	CS	C[N+]1=CC2=C(C=C1)C3=CC=CC=C3N2
DMQBF7J	IK	UDHBHTHWWOQPBW-UHFFFAOYSA-O
DMQBF7J	IU	2-methyl-9H-pyrido[3,4-b]indol-2-ium
DMQBF7J	CA	CAS 17994-14-8
DMQBF7J	DE	Discovery agent

DMKB2P8	ID	DMKB2P8
DMKB2P8	DN	2-methylbut-3-yn-2-yl 4-methoxybenzoate
DMKB2P8	HS	Investigative
DMKB2P8	SN	2-methylbut-3-yn-2-yl 4-methoxybenzoate; 294619-87-7; 1,1-dimethyl-2-propyn-1-yl 4-methoxybenzoate; ZERO/003209; AC1LE8OG; ARONIS020757; CHEMBL244918; ZINC96414; BDBM23726; KS-00004CEK; MolPort-001-510-482; BBL014263; STK001780; AKOS000487782; MCULE-8443375339; ST036671; 1,1-dimethylprop-2-ynyl 4-methoxybenzoate; BB0275130; 1,1-dimethyl-2-propynyl 4-methoxybenzoate; H2604; EU-0085447; SR-01000525786; AG-205/12908103; SR-01000525786-1; 1,1-dimethylprop-2-yn-1-yl 4-methoxybenzoate, 10; 4-Methoxybenzoic acid 1,1-dimethyl-2-propynyl es
DMKB2P8	DT	Small molecular drug
DMKB2P8	PC	708205
DMKB2P8	MW	218.25
DMKB2P8	FM	C13H14O3
DMKB2P8	IC	InChI=1S/C13H14O3/c1-5-13(2,3)16-12(14)10-6-8-11(15-4)9-7-10/h1,6-9H,2-4H3
DMKB2P8	CS	CC(C)(C#C)OC(=O)C1=CC=C(C=C1)OC
DMKB2P8	IK	WRGOVRZCLGHFFF-UHFFFAOYSA-N
DMKB2P8	IU	2-methylbut-3-yn-2-yl 4-methoxybenzoate
DMKB2P8	DE	Discovery agent

DMD8CQS	ID	DMD8CQS
DMD8CQS	DN	2-methylhistamine
DMD8CQS	HS	Investigative
DMD8CQS	SN	56975-07-6; Tetrahydro-5-(2-hydroxyethyl)-1,3-bis(hydroxymethyl)-1,3,5-triazine-2(1H)-thione; 5-(2-hydroxyethyl)-1,3-bis(hydroxymethyl)-1,3,5-triazinane-2-thione; EINECS 260-494-0; AC1L3OH4; GTPL1268; AC1Q7F21; CTK5A6094; DTXSID70205580; 1,3,5-Triazine-2(1H)-thione,tetrahydro-5-(2-hydroxyethyl)-1,3-bis(hydroxymethyl)-
DMD8CQS	DT	Small molecular drug
DMD8CQS	PC	91613
DMD8CQS	MW	125.17
DMD8CQS	FM	C6H11N3
DMD8CQS	IC	InChI=1S/C6H11N3/c1-5-8-4-6(9-5)2-3-7/h4H,2-3,7H2,1H3,(H,8,9)
DMD8CQS	CS	CC1=NC=C(N1)CCN
DMD8CQS	IK	XDKYTXBAVJELDQ-UHFFFAOYSA-N
DMD8CQS	IU	2-(2-methyl-1H-imidazol-5-yl)ethanamine
DMD8CQS	CA	CAS 34392-54-6
DMD8CQS	CB	CHEBI:74761
DMD8CQS	DE	Discovery agent

DMHW9GL	ID	DMHW9GL
DMHW9GL	DN	2-methylisoquinoline-1,3,4-trione
DMHW9GL	HS	Investigative
DMHW9GL	SN	2-methylisoquinoline-1,3,4(2H)-trione; 21640-33-5; 2-methyl-isoquinoline-1,3,4-trione; 2-methylisoquinoline-1,3,4-trione; 2-methyl-1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; N-methylphthalonimide; AC1LVZDH; AC1Q3XNZ; 1,3,4(2H)-Isoquinolinetrione, 2-methyl-; CHEMBL381480; SCHEMBL13442852; Isoquinoline-1,3,4-trione 2a; CTK4E7387; BDBM10248; DTXSID90364926; MolPort-001-798-932; ZINC2030689; CS-D0370; FCH830488; STK368698; AKOS005444509; MCULE-7985115369; ACM21640335; 2-methyl-1,3,4(2H)-isoquinolinetrione; AK325966
DMHW9GL	DT	Small molecular drug
DMHW9GL	PC	1714901
DMHW9GL	MW	189.17
DMHW9GL	FM	C10H7NO3
DMHW9GL	IC	InChI=1S/C10H7NO3/c1-11-9(13)7-5-3-2-4-6(7)8(12)10(11)14/h2-5H,1H3
DMHW9GL	CS	CN1C(=O)C2=CC=CC=C2C(=O)C1=O
DMHW9GL	IK	LSVJISCDJHIYOW-UHFFFAOYSA-N
DMHW9GL	IU	2-methylisoquinoline-1,3,4-trione
DMHW9GL	CA	CAS 21640-33-5
DMHW9GL	DE	Discovery agent

DMUN3LV	ID	DMUN3LV
DMUN3LV	DN	2-Methylquinoline-8-carboxamide
DMUN3LV	HS	Investigative
DMUN3LV	SN	CHEMBL471966; 2-Methylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 2-methyl-; SCHEMBL422282; BDBM50255329; AKOS022882220
DMUN3LV	DT	Small molecular drug
DMUN3LV	PC	21195867
DMUN3LV	MW	186.21
DMUN3LV	FM	C11H10N2O
DMUN3LV	IC	InChI=1S/C11H10N2O/c1-7-5-6-8-3-2-4-9(11(12)14)10(8)13-7/h2-6H,1H3,(H2,12,14)
DMUN3LV	CS	CC1=NC2=C(C=CC=C2C(=O)N)C=C1
DMUN3LV	IK	FKDAECIKJPVBCN-UHFFFAOYSA-N
DMUN3LV	IU	2-methylquinoline-8-carboxamide
DMUN3LV	DE	Discovery agent

DMM4HXK	ID	DMM4HXK
DMM4HXK	DN	2-methylsulfanylestradiol 3,17-O,O-bis-sulfamate
DMM4HXK	HS	Investigative
DMM4HXK	SN	CHEMBL219273; 2-methylsulfanylestradiol 3,17-O,O-bis-sulfamate
DMM4HXK	DT	Small molecular drug
DMM4HXK	PC	16098588
DMM4HXK	MW	476.6
DMM4HXK	FM	C19H28N2O6S3
DMM4HXK	IC	InChI=1S/C19H28N2O6S3/c1-19-8-7-12-13(15(19)5-6-18(19)27-30(21,24)25)4-3-11-9-16(26-29(20,22)23)17(28-2)10-14(11)12/h9-10,12-13,15,18H,3-8H2,1-2H3,(H2,20,22,23)(H2,21,24,25)/t12-,13+,15-,18-,19-/m0/s1
DMM4HXK	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=CC(=C(C=C34)SC)OS(=O)(=O)N
DMM4HXK	IK	DWVUBFTWKROFPD-SSTWWWIQSA-N
DMM4HXK	IU	[(8R,9S,13S,14S,17S)-13-methyl-2-methylsulfanyl-3-sulfamoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMM4HXK	DE	Discovery agent

DM4IJXW	ID	DM4IJXW
DM4IJXW	DN	2-MOE phosphorothioate gapmers
DM4IJXW	HS	Investigative
DM4IJXW	SN	Oligo445236; Oligo445238
DM4IJXW	CP	Genzyme Corp
DM4IJXW	DT	Antisense drug
DM4IJXW	DE	Myotonic dystrophy

DME9S8M	ID	DME9S8M
DME9S8M	DN	2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M	HS	Investigative
DME9S8M	SN	53-59-8; Cozymase II; Codehydrogenase II; TPN (nucleotide); Codehydrase II; Nadide phosphate; NAD phosphate; EINECS 200-178-1; BRN 3885115; nicotinamide adenine dinucleotide phosphate; CHEBI:44409; beta-NADP; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt; beta-TPN; TPN-ox; nadp nicotinamide-adenine-dinucleotide phosphate; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen p
DME9S8M	DT	Small molecular drug
DME9S8M	PC	46936685
DME9S8M	MW	743.4
DME9S8M	FM	C21H28N7O17P3
DME9S8M	IC	InChI=1S/C21H28N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1-4,7-8,10-11,13-16,20-21,29-31H,5-6H2,(H7-,22,23,24,25,32,33,34,35,36,37,38,39)/t10-,11-,13-,14-,15+,16+,20+,21+/m0/s1
DME9S8M	CS	C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@H]([C@@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@H]3[C@@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)N
DME9S8M	IK	XJLXINKUBYWONI-XCSFTKGKSA-N
DME9S8M	IU	[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
DME9S8M	DE	Discovery agent

DMDYRNF	ID	DMDYRNF
DMDYRNF	DN	2'-Monophosphoadenosine-5'-Diphosphate
DMDYRNF	HS	Investigative
DMDYRNF	SN	2'-MONOPHOSPHOADENOSINE-5'-DIPHOSPHATE; adenosine 2'-(dihydrogen phosphate) 5'-(trihydrogen diphosphate); 2-Phospho-adenosine diphosphate; 1afl; AC1L4WBL; phosphoadenosine diphosphate; AC1Q6S1C; 2'P-ADP; SCHEMBL905455; 5'-Diphosphoadenosine 2'-phosphate; DB02363; Adenosine 2'-phosphoric acid 5'-diphosphoric acid; Adenosine 5'-(trihydrogen diphorphate), 2'-(dihydrogen phosphate); [(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMDYRNF	DT	Small molecular drug
DMDYRNF	PC	165230
DMDYRNF	MW	507.18
DMDYRNF	FM	C10H16N5O13P3
DMDYRNF	IC	InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(27-29(17,18)19)6(16)4(26-10)1-25-31(23,24)28-30(20,21)22/h2-4,6-7,10,16H,1H2,(H,23,24)(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1
DMDYRNF	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)OP(=O)(O)O)N
DMDYRNF	IK	YPTPYQSAVGGMFN-KQYNXXCUSA-N
DMDYRNF	IU	[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMDYRNF	CA	CAS 4457-01-6
DMDYRNF	DE	Discovery agent

DMCVF7R	ID	DMCVF7R
DMCVF7R	DN	2-morpholin-4-yl-6-phenyl-4H-thiopyran-4-one
DMCVF7R	HS	Investigative
DMCVF7R	SN	CHEMBL276746; 2-morpholino-6-phenyl-4H-thiopyran-4-one; 2-morpholin-4-yl-6-phenyl-thiopyran-4-one; 2-morpholin-4-yl-6-phenyl-4H-thiopyran-4-one; SCHEMBL5842568
DMCVF7R	DT	Small molecular drug
DMCVF7R	PC	9965345
DMCVF7R	MW	273.4
DMCVF7R	FM	C15H15NO2S
DMCVF7R	IC	InChI=1S/C15H15NO2S/c17-13-10-14(12-4-2-1-3-5-12)19-15(11-13)16-6-8-18-9-7-16/h1-5,10-11H,6-9H2
DMCVF7R	CS	C1COCCN1C2=CC(=O)C=C(S2)C3=CC=CC=C3
DMCVF7R	IK	ZRGAPZKMQHRLTD-UHFFFAOYSA-N
DMCVF7R	IU	2-morpholin-4-yl-6-phenylthiopyran-4-one
DMCVF7R	DE	Discovery agent

DMTB1KV	ID	DMTB1KV
DMTB1KV	DN	2-Morpholin-4-yl-6-phenyl-chromen-4-one
DMTB1KV	HS	Investigative
DMTB1KV	SN	CHEMBL369146; 2-morpholin-4-yl-6-phenyl-chromen-4-one; SCHEMBL3542251
DMTB1KV	DT	Small molecular drug
DMTB1KV	PC	11358716
DMTB1KV	MW	307.3
DMTB1KV	FM	C19H17NO3
DMTB1KV	IC	InChI=1S/C19H17NO3/c21-17-13-19(20-8-10-22-11-9-20)23-18-7-6-15(12-16(17)18)14-4-2-1-3-5-14/h1-7,12-13H,8-11H2
DMTB1KV	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=CC=C4
DMTB1KV	IK	FGDAUGYDQLYAKT-UHFFFAOYSA-N
DMTB1KV	IU	2-morpholin-4-yl-6-phenylchromen-4-one
DMTB1KV	DE	Discovery agent

DMC1TWI	ID	DMC1TWI
DMC1TWI	DN	2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one
DMC1TWI	HS	Investigative
DMC1TWI	SN	CHEMBL200340; 2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one
DMC1TWI	DT	Small molecular drug
DMC1TWI	PC	11660428
DMC1TWI	MW	357.4
DMC1TWI	FM	C23H19NO3
DMC1TWI	IC	InChI=1S/C23H19NO3/c25-21-15-22(24-10-12-26-13-11-24)27-23-19(6-3-7-20(21)23)18-9-8-16-4-1-2-5-17(16)14-18/h1-9,14-15H,10-13H2
DMC1TWI	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC5=CC=CC=C5C=C4
DMC1TWI	IK	OYLGZUQUTITVHN-UHFFFAOYSA-N
DMC1TWI	IU	2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one
DMC1TWI	DE	Discovery agent

DMVN38H	ID	DMVN38H
DMVN38H	DN	2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one
DMVN38H	HS	Investigative
DMVN38H	SN	CHEMBL197551; 2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one
DMVN38H	DT	Small molecular drug
DMVN38H	PC	11502854
DMVN38H	MW	429.5
DMVN38H	FM	C25H19NO4S
DMVN38H	IC	InChI=1S/C25H19NO4S/c27-19-15-23(26-11-13-28-14-12-26)30-24-16(5-3-7-18(19)24)17-6-4-10-22-25(17)29-20-8-1-2-9-21(20)31-22/h1-10,15H,11-14H2
DMVN38H	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=C5C(=CC=C4)SC6=CC=CC=C6O5
DMVN38H	IK	IAMQVMPIHMBYSY-UHFFFAOYSA-N
DMVN38H	IU	2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one
DMVN38H	DE	Discovery agent

DMNKHOI	ID	DMNKHOI
DMNKHOI	DN	2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one
DMNKHOI	HS	Investigative
DMNKHOI	SN	2-morpholino-8-(2-phenylethynyl)-4H-chromen-4-one
DMNKHOI	PC	10359339
DMNKHOI	MW	331.4
DMNKHOI	FM	C21H17NO3
DMNKHOI	IC	InChI=1S/C21H17NO3/c23-19-15-20(22-11-13-24-14-12-22)25-21-17(7-4-8-18(19)21)10-9-16-5-2-1-3-6-16/h1-8,15H,11-14H2
DMNKHOI	CS	C1COCCN1C2=CC(=O)C3=CC=CC(=C3O2)C#CC4=CC=CC=C4
DMNKHOI	IK	FVCZHPDXMMYSDW-UHFFFAOYSA-N
DMNKHOI	IU	2-morpholin-4-yl-8-(2-phenylethynyl)chromen-4-one
DMNKHOI	DE	Discovery agent

DMNHYQ0	ID	DMNHYQ0
DMNHYQ0	DN	2-morpholin-4-yl-8-styrylchromen-4-one
DMNHYQ0	HS	Investigative
DMNHYQ0	SN	CHEMBL198476; 2-morpholin-4-yl-8-styrylchromen-4-one; SCHEMBL6357331
DMNHYQ0	DT	Small molecular drug
DMNHYQ0	PC	11709748
DMNHYQ0	MW	333.4
DMNHYQ0	FM	C21H19NO3
DMNHYQ0	IC	InChI=1S/C21H19NO3/c23-19-15-20(22-11-13-24-14-12-22)25-21-17(7-4-8-18(19)21)10-9-16-5-2-1-3-6-16/h1-10,15H,11-14H2/b10-9+
DMNHYQ0	CS	C1COCCN1C2=CC(=O)C3=CC=CC(=C3O2)/C=C/C4=CC=CC=C4
DMNHYQ0	IK	OLQGOHPEAUHNBE-MDZDMXLPSA-N
DMNHYQ0	IU	2-morpholin-4-yl-8-[(E)-2-phenylethenyl]chromen-4-one
DMNHYQ0	DE	Discovery agent

DM5JHT6	ID	DM5JHT6
DM5JHT6	DN	2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one
DM5JHT6	HS	Investigative
DM5JHT6	SN	CHEMBL362729; 503468-86-8; 2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one; 2-morpholin-4-yl-8-thiophen-2-yl-chromen-4-one; CTK1G6919; DTXSID30469303; BDBM50156496; AKOS030552940; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-(2-thienyl)-
DM5JHT6	DT	Small molecular drug
DM5JHT6	PC	11602076
DM5JHT6	MW	313.4
DM5JHT6	FM	C17H15NO3S
DM5JHT6	IC	InChI=1S/C17H15NO3S/c19-14-11-16(18-6-8-20-9-7-18)21-17-12(14)3-1-4-13(17)15-5-2-10-22-15/h1-5,10-11H,6-9H2
DM5JHT6	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CS4
DM5JHT6	IK	FEOKXELSWFEHJU-UHFFFAOYSA-N
DM5JHT6	IU	2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one
DM5JHT6	CA	CAS 503468-86-8
DM5JHT6	DE	Discovery agent

DMCY4EP	ID	DMCY4EP
DMCY4EP	DN	2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one
DMCY4EP	HS	Investigative
DMCY4EP	SN	CHEMBL360183; 503468-85-7; 2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one; 2-morpholin-4-yl-8-thiophen-3-yl-chromen-4-one; CTK1G6920; DTXSID30469641; BDBM50156502; AKOS030552941; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-(3-thienyl)-
DMCY4EP	DT	Small molecular drug
DMCY4EP	PC	11623802
DMCY4EP	MW	313.4
DMCY4EP	FM	C17H15NO3S
DMCY4EP	IC	InChI=1S/C17H15NO3S/c19-15-10-16(18-5-7-20-8-6-18)21-17-13(2-1-3-14(15)17)12-4-9-22-11-12/h1-4,9-11H,5-8H2
DMCY4EP	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CSC=C4
DMCY4EP	IK	MHMBRJOWOVNUNC-UHFFFAOYSA-N
DMCY4EP	IU	2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one
DMCY4EP	CA	CAS 503468-85-7
DMCY4EP	DE	Discovery agent

DM3ZWNI	ID	DM3ZWNI
DM3ZWNI	DN	2-Morpholin-4-yl-benzo[h]chromene-4-thione
DM3ZWNI	HS	Investigative
DM3ZWNI	SN	CHEMBL176233; 2-Morpholin-4-yl-benzo[h]chromene-4-thione; SCHEMBL13346492
DM3ZWNI	DT	Small molecular drug
DM3ZWNI	PC	11426483
DM3ZWNI	MW	297.4
DM3ZWNI	FM	C17H15NO2S
DM3ZWNI	IC	InChI=1S/C17H15NO2S/c21-15-11-16(18-7-9-19-10-8-18)20-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2
DM3ZWNI	CS	C1COCCN1C2=CC(=S)C3=C(O2)C4=CC=CC=C4C=C3
DM3ZWNI	IK	VNZKDSHSVFSENH-UHFFFAOYSA-N
DM3ZWNI	IU	2-morpholin-4-ylbenzo[h]chromene-4-thione
DM3ZWNI	DE	Discovery agent

DMDTRZ2	ID	DMDTRZ2
DMDTRZ2	DN	2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide
DMDTRZ2	HS	Investigative
DMDTRZ2	SN	91533-01-6; 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide; CHEMBL180943; Sulfanilamide, N4-(alpha-morpholinoacetyl)-; 2-(morpholin-4-yl)-N-(4-sulfamoylphenyl)acetamide; N4-(alpha-Morpholinoacetyl)sulfanilamide; AE-848/36321029; 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide; AC1L47H0; SCHEMBL15798186; DTXSID70238616; MolPort-000-225-319; BDBM50157946; ZINC19901027; STL294445; AKOS001028531; MCULE-6306887577; ST086382; SR-01000467406; SR-01000467406-1; Z46180370; 4-Morpholineacetamide, N-(4-(aminosulfonyl)phenyl)-
DMDTRZ2	DT	Small molecular drug
DMDTRZ2	PC	180598
DMDTRZ2	MW	299.35
DMDTRZ2	FM	C12H17N3O4S
DMDTRZ2	IC	InChI=1S/C12H17N3O4S/c13-20(17,18)11-3-1-10(2-4-11)14-12(16)9-15-5-7-19-8-6-15/h1-4H,5-9H2,(H,14,16)(H2,13,17,18)
DMDTRZ2	CS	C1COCCN1CC(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMDTRZ2	IK	ZKUIDNFBWWVULC-UHFFFAOYSA-N
DMDTRZ2	IU	2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide
DMDTRZ2	CA	CAS 91533-01-6
DMDTRZ2	DE	Discovery agent

DMCKSX7	ID	DMCKSX7
DMCKSX7	DN	2-Morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one
DMCKSX7	HS	Investigative
DMCKSX7	SN	CHEMBL179043; 2-(morpholin-4-yl)-4h-pyrido[1,2-a]pyrimidin-4-one; 17326-31-7; NSC110390; AC1Q6IJU; AC1L6MD6; 2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one; 2-Morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one; SCHEMBL4544196; CTK4D4568; DTXSID80296606; ZINC1702791; BDBM50159642; AKOS024361168; NSC-110390; MCULE-7092692912; ST50991317
DMCKSX7	DT	Small molecular drug
DMCKSX7	PC	269395
DMCKSX7	MW	231.25
DMCKSX7	FM	C12H13N3O2
DMCKSX7	IC	InChI=1S/C12H13N3O2/c16-12-9-11(14-5-7-17-8-6-14)13-10-3-1-2-4-15(10)12/h1-4,9H,5-8H2
DMCKSX7	CS	C1COCCN1C2=CC(=O)N3C=CC=CC3=N2
DMCKSX7	IK	VDMRPNTZWKDYBB-UHFFFAOYSA-N
DMCKSX7	IU	2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one
DMCKSX7	CA	CAS 17326-31-7
DMCKSX7	DE	Discovery agent

DM79ZOV	ID	DM79ZOV
DM79ZOV	DN	2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one
DM79ZOV	HS	Investigative
DM79ZOV	SN	Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456
DM79ZOV	DT	Small molecular drug
DM79ZOV	PC	10039361
DM79ZOV	MW	281.31
DM79ZOV	FM	C16H15N3O2
DM79ZOV	IC	InChI=1S/C16H15N3O2/c20-15-11-14(18-7-9-21-10-8-18)17-16-13-4-2-1-3-12(13)5-6-19(15)16/h1-6,11H,7-10H2
DM79ZOV	CS	C1COCCN1C2=CC(=O)N3C=CC4=CC=CC=C4C3=N2
DM79ZOV	IK	BVRDQVRQVGRNHG-UHFFFAOYSA-N
DM79ZOV	IU	2-morpholin-4-ylpyrimido[2,1-a]isoquinolin-4-one
DM79ZOV	CA	CAS 168425-64-7
DM79ZOV	DE	Discovery agent

DMFHTEG	ID	DMFHTEG
DMFHTEG	DN	2-morpholino-1,1,2-triphenylethanol
DMFHTEG	HS	Investigative
DMFHTEG	SN	CHEMBL1091863; 2-morpholino-1,1,2-triphenylethanol
DMFHTEG	DT	Small molecular drug
DMFHTEG	PC	46885513
DMFHTEG	MW	359.5
DMFHTEG	FM	C24H25NO2
DMFHTEG	IC	InChI=1S/C24H25NO2/c26-24(21-12-6-2-7-13-21,22-14-8-3-9-15-22)23(20-10-4-1-5-11-20)25-16-18-27-19-17-25/h1-15,23,26H,16-19H2
DMFHTEG	CS	C1COCCN1C(C2=CC=CC=C2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMFHTEG	IK	HOPDHEHFNMVVFR-UHFFFAOYSA-N
DMFHTEG	IU	2-morpholin-4-yl-1,1,2-triphenylethanol
DMFHTEG	DE	Discovery agent

DMH89O5	ID	DMH89O5
DMH89O5	DN	2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol
DMH89O5	HS	Investigative
DMH89O5	SN	CHEMBL1088803; 2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol; SCHEMBL1242083
DMH89O5	DT	Small molecular drug
DMH89O5	PC	11588169
DMH89O5	MW	341.4
DMH89O5	FM	C20H27N3O2
DMH89O5	IC	InChI=1S/C20H27N3O2/c1-2-3-8-19(23-11-13-25-14-12-23)20(24,17-6-4-9-21-15-17)18-7-5-10-22-16-18/h4-7,9-10,15-16,19,24H,2-3,8,11-14H2,1H3
DMH89O5	CS	CCCCC(C(C1=CN=CC=C1)(C2=CN=CC=C2)O)N3CCOCC3
DMH89O5	IK	MHMGSQRAIMZTJJ-UHFFFAOYSA-N
DMH89O5	IU	2-morpholin-4-yl-1,1-dipyridin-3-ylhexan-1-ol
DMH89O5	DE	Discovery agent

DMDMVA1	ID	DMDMVA1
DMDMVA1	DN	2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol
DMDMVA1	HS	Investigative
DMDMVA1	SN	CHEMBL1088804; 2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol; SCHEMBL1242942
DMDMVA1	DT	Small molecular drug
DMDMVA1	PC	11646379
DMDMVA1	MW	369.5
DMDMVA1	FM	C22H31N3O2
DMDMVA1	IC	InChI=1S/C22H31N3O2/c1-2-3-4-5-10-21(25-13-15-27-16-14-25)22(26,19-8-6-11-23-17-19)20-9-7-12-24-18-20/h6-9,11-12,17-18,21,26H,2-5,10,13-16H2,1H3
DMDMVA1	CS	CCCCCCC(C(C1=CN=CC=C1)(C2=CN=CC=C2)O)N3CCOCC3
DMDMVA1	IK	PUFFDHPIZWKLSX-UHFFFAOYSA-N
DMDMVA1	IU	2-morpholin-4-yl-1,1-dipyridin-3-yloctan-1-ol
DMDMVA1	DE	Discovery agent

DM3V5AB	ID	DM3V5AB
DM3V5AB	DN	2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol
DM3V5AB	HS	Investigative
DM3V5AB	SN	CHEMBL1090794; 2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol; SCHEMBL1240366
DM3V5AB	DT	Small molecular drug
DM3V5AB	PC	11710246
DM3V5AB	MW	361.4
DM3V5AB	FM	C22H23N3O2
DM3V5AB	IC	InChI=1S/C22H23N3O2/c26-22(19-8-4-10-23-16-19,20-9-5-11-24-17-20)21(18-6-2-1-3-7-18)25-12-14-27-15-13-25/h1-11,16-17,21,26H,12-15H2
DM3V5AB	CS	C1COCCN1C(C2=CC=CC=C2)C(C3=CN=CC=C3)(C4=CN=CC=C4)O
DM3V5AB	IK	WPLZJOHYEBBPRT-UHFFFAOYSA-N
DM3V5AB	IU	2-morpholin-4-yl-2-phenyl-1,1-dipyridin-3-ylethanol
DM3V5AB	DE	Discovery agent

DM5J6IT	ID	DM5J6IT
DM5J6IT	DN	2-morpholino-4H-benzo[g]chromen-4-one
DM5J6IT	HS	Investigative
DM5J6IT	SN	CHEMBL175883; 503467-97-8; 2-morpholino-4H-benzo[g]chromen-4-one; SCHEMBL3536668; CTK1G6923; DTXSID10465904; BDBM50159668; 2-Morpholin-4-yl-benzo[g]chromen-4-one; 4H-Naphtho[2,3-b]pyran-4-one, 2-(4-morpholinyl)-
DM5J6IT	DT	Small molecular drug
DM5J6IT	PC	11437483
DM5J6IT	MW	281.3
DM5J6IT	FM	C17H15NO3
DM5J6IT	IC	InChI=1S/C17H15NO3/c19-15-11-17(18-5-7-20-8-6-18)21-16-10-13-4-2-1-3-12(13)9-14(15)16/h1-4,9-11H,5-8H2
DM5J6IT	CS	C1COCCN1C2=CC(=O)C3=CC4=CC=CC=C4C=C3O2
DM5J6IT	IK	FKURMCWOGPDJSJ-UHFFFAOYSA-N
DM5J6IT	IU	2-morpholin-4-ylbenzo[g]chromen-4-one
DM5J6IT	CA	CAS 503467-97-8
DM5J6IT	DE	Discovery agent

DMZL6Q1	ID	DMZL6Q1
DMZL6Q1	DN	2-morpholino-6-(naphthalen-1-yl)-4H-chromen-4-one
DMZL6Q1	HS	Investigative
DMZL6Q1	SN	CHEMBL197475
DMZL6Q1	DT	Small molecular drug
DMZL6Q1	PC	11646132
DMZL6Q1	MW	357.4
DMZL6Q1	FM	C23H19NO3
DMZL6Q1	IC	InChI=1S/C23H19NO3/c25-21-15-23(24-10-12-26-13-11-24)27-22-9-8-17(14-20(21)22)19-7-3-5-16-4-1-2-6-18(16)19/h1-9,14-15H,10-13H2
DMZL6Q1	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=CC5=CC=CC=C54
DMZL6Q1	IK	ALYIMYTWUBXFRH-UHFFFAOYSA-N
DMZL6Q1	IU	2-morpholin-4-yl-6-naphthalen-1-ylchromen-4-one
DMZL6Q1	DE	Discovery agent

DMEOI0V	ID	DMEOI0V
DMEOI0V	DN	2-morpholino-6-(naphthalen-1-yl)-4H-pyran-4-one
DMEOI0V	HS	Investigative
DMEOI0V	SN	CHEMBL225608; 2-morpholino-6-(naphthalen-1-yl)-4H-pyran-4-one
DMEOI0V	DT	Small molecular drug
DMEOI0V	PC	16204046
DMEOI0V	MW	307.3
DMEOI0V	FM	C19H17NO3
DMEOI0V	IC	InChI=1S/C19H17NO3/c21-15-12-18(23-19(13-15)20-8-10-22-11-9-20)17-7-3-5-14-4-1-2-6-16(14)17/h1-7,12-13H,8-11H2
DMEOI0V	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC4=CC=CC=C43
DMEOI0V	IK	VSXKSTFHVOSHSV-UHFFFAOYSA-N
DMEOI0V	IU	2-morpholin-4-yl-6-naphthalen-1-ylpyran-4-one
DMEOI0V	DE	Discovery agent

DMO7QCN	ID	DMO7QCN
DMO7QCN	DN	2-morpholino-6-(naphthalen-2-yl)-4H-pyran-4-one
DMO7QCN	HS	Investigative
DMO7QCN	SN	CHEMBL225609; 2-morpholino-6-(naphthalen-2-yl)-4H-pyran-4-one
DMO7QCN	DT	Small molecular drug
DMO7QCN	PC	16204047
DMO7QCN	MW	307.3
DMO7QCN	FM	C19H17NO3
DMO7QCN	IC	InChI=1S/C19H17NO3/c21-17-12-18(23-19(13-17)20-7-9-22-10-8-20)16-6-5-14-3-1-2-4-15(14)11-16/h1-6,11-13H,7-10H2
DMO7QCN	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC4=CC=CC=C4C=C3
DMO7QCN	IK	FNMVAZNGFWLDOQ-UHFFFAOYSA-N
DMO7QCN	IU	2-morpholin-4-yl-6-naphthalen-2-ylpyran-4-one
DMO7QCN	DE	Discovery agent

DMTBRLK	ID	DMTBRLK
DMTBRLK	DN	2-morpholino-6-(quinolin-8-yl)-4H-pyran-4-one
DMTBRLK	HS	Investigative
DMTBRLK	SN	CHEMBL223041; 2-morpholino-6-(quinolin-8-yl)-4H-pyran-4-one
DMTBRLK	DT	Small molecular drug
DMTBRLK	PC	16204049
DMTBRLK	MW	308.3
DMTBRLK	FM	C18H16N2O3
DMTBRLK	IC	InChI=1S/C18H16N2O3/c21-14-11-16(23-17(12-14)20-7-9-22-10-8-20)15-5-1-3-13-4-2-6-19-18(13)15/h1-6,11-12H,7-10H2
DMTBRLK	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC4=C3N=CC=C4
DMTBRLK	IK	GJFZIARIYRYNDJ-UHFFFAOYSA-N
DMTBRLK	IU	2-morpholin-4-yl-6-quinolin-8-ylpyran-4-one
DMTBRLK	DE	Discovery agent

DMATVZB	ID	DMATVZB
DMATVZB	DN	2-morpholino-6-(thianthren-1-yl)-4H-chromen-4-one
DMATVZB	HS	Investigative
DMATVZB	SN	CHEMBL200824
DMATVZB	DT	Small molecular drug
DMATVZB	PC	11583137
DMATVZB	MW	445.6
DMATVZB	FM	C25H19NO3S2
DMATVZB	IC	InChI=1S/C25H19NO3S2/c27-19-15-24(26-10-12-28-13-11-26)29-20-9-8-16(14-18(19)20)17-4-3-7-23-25(17)31-22-6-2-1-5-21(22)30-23/h1-9,14-15H,10-13H2
DMATVZB	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=C5C(=CC=C4)SC6=CC=CC=C6S5
DMATVZB	IK	NXGBJPCXFKHQKN-UHFFFAOYSA-N
DMATVZB	IU	2-morpholin-4-yl-6-thianthren-1-ylchromen-4-one
DMATVZB	DE	Discovery agent

DMTWJMN	ID	DMTWJMN
DMTWJMN	DN	2-morpholino-6-(thiophen-2-yl)-4H-pyran-4-one
DMTWJMN	HS	Investigative
DMTWJMN	SN	CHEMBL374133; 2-morpholino-6-(thiophen-2-yl)-4H-pyran-4-one
DMTWJMN	DT	Small molecular drug
DMTWJMN	PC	16203941
DMTWJMN	MW	263.31
DMTWJMN	FM	C13H13NO3S
DMTWJMN	IC	InChI=1S/C13H13NO3S/c15-10-8-11(12-2-1-7-18-12)17-13(9-10)14-3-5-16-6-4-14/h1-2,7-9H,3-6H2
DMTWJMN	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CS3
DMTWJMN	IK	MEBJAUWWCSKYMY-UHFFFAOYSA-N
DMTWJMN	IU	2-morpholin-4-yl-6-thiophen-2-ylpyran-4-one
DMTWJMN	DE	Discovery agent

DMF3NPW	ID	DMF3NPW
DMF3NPW	DN	2-morpholino-6-(thiophen-3-yl)-4H-pyran-4-one
DMF3NPW	HS	Investigative
DMF3NPW	SN	CHEMBL223381; 2-morpholino-6-(thiophen-3-yl)-4H-pyran-4-one
DMF3NPW	DT	Small molecular drug
DMF3NPW	PC	16203942
DMF3NPW	MW	263.31
DMF3NPW	FM	C13H13NO3S
DMF3NPW	IC	InChI=1S/C13H13NO3S/c15-11-7-12(10-1-6-18-9-10)17-13(8-11)14-2-4-16-5-3-14/h1,6-9H,2-5H2
DMF3NPW	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CSC=C3
DMF3NPW	IK	LICYALMZYZNUAP-UHFFFAOYSA-N
DMF3NPW	IU	2-morpholin-4-yl-6-thiophen-3-ylpyran-4-one
DMF3NPW	DE	Discovery agent

DMMC0ZP	ID	DMMC0ZP
DMMC0ZP	DN	2-morpholino-6-phenyl-4H-pyran-4-one
DMMC0ZP	HS	Investigative
DMMC0ZP	SN	2-morpholino-6-phenyl-4H-pyran-4-one; CHEMBL105613; 2-morpholin-4-yl-6-phenyl-pyran-4-one; SCHEMBL3540014
DMMC0ZP	DT	Small molecular drug
DMMC0ZP	PC	10923175
DMMC0ZP	MW	257.279
DMMC0ZP	FM	C15H15NO3
DMMC0ZP	IC	InChI=1S/C15H15NO3/c17-13-10-14(12-4-2-1-3-5-12)19-15(11-13)16-6-8-18-9-7-16/h1-5,10-11H,6-9H2
DMMC0ZP	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC=C3
DMMC0ZP	IK	QQHMBGBSWORRAG-UHFFFAOYSA-N
DMMC0ZP	IU	2-morpholin-4-yl-6-phenylpyran-4-one
DMMC0ZP	DE	Discovery agent

DM8ZPJI	ID	DM8ZPJI
DM8ZPJI	DN	2-morpholino-6-styryl-4H-pyran-4-one
DM8ZPJI	HS	Investigative
DM8ZPJI	SN	CHEMBL223559; 2-morpholino-6-styryl-4H-pyran-4-one; SCHEMBL13435577
DM8ZPJI	DT	Small molecular drug
DM8ZPJI	PC	16203255
DM8ZPJI	MW	283.32
DM8ZPJI	FM	C17H17NO3
DM8ZPJI	IC	InChI=1S/C17H17NO3/c19-15-12-16(7-6-14-4-2-1-3-5-14)21-17(13-15)18-8-10-20-11-9-18/h1-7,12-13H,8-11H2/b7-6+
DM8ZPJI	CS	C1COCCN1C2=CC(=O)C=C(O2)/C=C/C3=CC=CC=C3
DM8ZPJI	IK	ZJOMZZQTJIYOSC-VOTSOKGWSA-N
DM8ZPJI	IU	2-morpholin-4-yl-6-[(E)-2-phenylethenyl]pyran-4-one
DM8ZPJI	DE	Discovery agent

DM4XKYN	ID	DM4XKYN
DM4XKYN	DN	2-morpholino-7-(2-phenylethynyl)-4H-chromen-4-one
DM4XKYN	HS	Investigative
DM4XKYN	SN	CHEMBL95923
DM4XKYN	DT	Small molecular drug
DM4XKYN	PC	44328640
DM4XKYN	MW	331.4
DM4XKYN	FM	C21H17NO3
DM4XKYN	IC	InChI=1S/C21H17NO3/c23-19-15-21(22-10-12-24-13-11-22)25-20-14-17(8-9-18(19)20)7-6-16-4-2-1-3-5-16/h1-5,8-9,14-15H,10-13H2
DM4XKYN	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)C#CC4=CC=CC=C4
DM4XKYN	IK	INSPUQMNGZSNFZ-UHFFFAOYSA-N
DM4XKYN	IU	2-morpholin-4-yl-7-(2-phenylethynyl)chromen-4-one
DM4XKYN	DE	Discovery agent

DMK7WON	ID	DMK7WON
DMK7WON	DN	2-morpholino-7-phenyl-4H-chromen-4-one
DMK7WON	HS	Investigative
DMK7WON	SN	CHEMBL95309
DMK7WON	DT	Small molecular drug
DMK7WON	PC	23586694
DMK7WON	MW	307.3
DMK7WON	FM	C19H17NO3
DMK7WON	IC	InChI=1S/C19H17NO3/c21-17-13-19(20-8-10-22-11-9-20)23-18-12-15(6-7-16(17)18)14-4-2-1-3-5-14/h1-7,12-13H,8-11H2
DMK7WON	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)C4=CC=CC=C4
DMK7WON	IK	RWIGISKNQAMRJZ-UHFFFAOYSA-N
DMK7WON	IU	2-morpholin-4-yl-7-phenylchromen-4-one
DMK7WON	DE	Discovery agent

DMYP0UI	ID	DMYP0UI
DMYP0UI	DN	2-morpholinobenzo[h]quinolin-4(1H)-one
DMYP0UI	HS	Investigative
DMYP0UI	SN	CHEMBL198675; 2-morpholinobenzo[h]quinolin-4(1H)-one
DMYP0UI	DT	Small molecular drug
DMYP0UI	PC	25817490
DMYP0UI	MW	282.32
DMYP0UI	FM	C16H16N3O2+
DMYP0UI	IC	InChI=1S/C16H15N3O2/c20-15-11-14(18-7-9-21-10-8-18)17-16-13-4-2-1-3-12(13)5-6-19(15)16/h1-6,11H,7-10H2/p+1
DMYP0UI	CS	C1COCCN1C2=CC(=O)N3C=CC4=CC=CC=C4C3=[NH+]2
DMYP0UI	IK	BVRDQVRQVGRNHG-UHFFFAOYSA-O
DMYP0UI	IU	2-morpholin-4-ylpyrimido[2,1-a]isoquinolin-1-ium-4-one
DMYP0UI	DE	Discovery agent

DMIQYWM	ID	DMIQYWM
DMIQYWM	DN	2-morpholino-N-phenethylpyrimidin-4-amine
DMIQYWM	HS	Investigative
DMIQYWM	SN	CHEMBL1085505; 2-morpholino-N-phenethylpyrimidin-4-amine; BDBM50319974
DMIQYWM	DT	Small molecular drug
DMIQYWM	PC	46891060
DMIQYWM	MW	284.36
DMIQYWM	FM	C16H20N4O
DMIQYWM	IC	InChI=1S/C16H20N4O/c1-2-4-14(5-3-1)6-8-17-15-7-9-18-16(19-15)20-10-12-21-13-11-20/h1-5,7,9H,6,8,10-13H2,(H,17,18,19)
DMIQYWM	CS	C1COCCN1C2=NC=CC(=N2)NCCC3=CC=CC=C3
DMIQYWM	IK	QCZVHPUPIBZBLH-UHFFFAOYSA-N
DMIQYWM	IU	2-morpholin-4-yl-N-(2-phenylethyl)pyrimidin-4-amine
DMIQYWM	DE	Discovery agent

DMBWDXH	ID	DMBWDXH
DMBWDXH	DN	2-m-tolyl-1,8-naphthyridine
DMBWDXH	HS	Investigative
DMBWDXH	SN	CHEMBL395902; 2-m-tolyl-1,8-naphthyridine
DMBWDXH	DT	Small molecular drug
DMBWDXH	PC	44434718
DMBWDXH	MW	220.27
DMBWDXH	FM	C15H12N2
DMBWDXH	IC	InChI=1S/C15H12N2/c1-11-4-2-5-13(10-11)14-8-7-12-6-3-9-16-15(12)17-14/h2-10H,1H3
DMBWDXH	CS	CC1=CC(=CC=C1)C2=NC3=C(C=CC=N3)C=C2
DMBWDXH	IK	VOPUZVINSLDWHQ-UHFFFAOYSA-N
DMBWDXH	IU	2-(3-methylphenyl)-1,8-naphthyridine
DMBWDXH	DE	Discovery agent

DM9ZVHJ	ID	DM9ZVHJ
DM9ZVHJ	DN	2-m-Tolyl-1H-[1,8]naphthyridin-4-one
DM9ZVHJ	HS	Investigative
DM9ZVHJ	SN	CHEMBL299979; 2-(3-methylphenyl)-1,8-naphthyridin-4(1h)-one; NSC676185; 2-m-Tolyl-1H-[1,8]naphthyridin-4-one; AC1L8OZI; SCHEMBL7922307; CTK8D2142; ZINC5504118; BDBM50059970; NSC-676185; NCI60_026912
DM9ZVHJ	DT	Small molecular drug
DM9ZVHJ	PC	385181
DM9ZVHJ	MW	236.27
DM9ZVHJ	FM	C15H12N2O
DM9ZVHJ	IC	InChI=1S/C15H12N2O/c1-10-4-2-5-11(8-10)13-9-14(18)12-6-3-7-16-15(12)17-13/h2-9H,1H3,(H,16,17,18)
DM9ZVHJ	CS	CC1=CC(=CC=C1)C2=CC(=O)C3=C(N2)N=CC=C3
DM9ZVHJ	IK	IZFIIAGLKAXALT-UHFFFAOYSA-N
DM9ZVHJ	IU	2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DM9ZVHJ	DE	Discovery agent

DM3AFXM	ID	DM3AFXM
DM3AFXM	DN	2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM3AFXM	HS	Investigative
DM3AFXM	SN	CHEMBL387592; 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one; BDBM50218914; 2-m-Tolyl-2,5-dihydro-pyrazolo[3,4-c]quinolin-4-one
DM3AFXM	DT	Small molecular drug
DM3AFXM	PC	10588437
DM3AFXM	MW	275.3
DM3AFXM	FM	C17H13N3O
DM3AFXM	IC	InChI=1S/C17H13N3O/c1-11-5-4-6-12(9-11)20-10-14-13-7-2-3-8-15(13)18-17(21)16(14)19-20/h2-10H,1H3,(H,18,21)
DM3AFXM	CS	CC1=CC(=CC=C1)N2C=C3C4=CC=CC=C4NC(=O)C3=N2
DM3AFXM	IK	KHYUWCCULSYNJP-UHFFFAOYSA-N
DM3AFXM	IU	2-(3-methylphenyl)-5H-pyrazolo[3,4-c]quinolin-4-one
DM3AFXM	DE	Discovery agent

DMIMRCH	ID	DMIMRCH
DMIMRCH	DN	2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DMIMRCH	HS	Investigative
DMIMRCH	SN	CHEMBL107446; 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine; BDBM50091130; 2-m-Tolyl-2H-pyrazolo[3,4-c]quinolin-4-ylamine
DMIMRCH	DT	Small molecular drug
DMIMRCH	PC	10612371
DMIMRCH	MW	274.32
DMIMRCH	FM	C17H14N4
DMIMRCH	IC	InChI=1S/C17H14N4/c1-11-5-4-6-12(9-11)21-10-14-13-7-2-3-8-15(13)19-17(18)16(14)20-21/h2-10H,1H3,(H2,18,19)
DMIMRCH	CS	CC1=CC(=CC=C1)N2C=C3C4=CC=CC=C4N=C(C3=N2)N
DMIMRCH	IK	NJFGXLMDWIXVEW-UHFFFAOYSA-N
DMIMRCH	IU	2-(3-methylphenyl)pyrazolo[3,4-c]quinolin-4-amine
DMIMRCH	DE	Discovery agent

DM0PT8R	ID	DM0PT8R
DM0PT8R	DN	2-N-(Isopropyl)amino-1-(4-methylthiophenyl)butane
DM0PT8R	HS	Investigative
DM0PT8R	SN	CHEMBL1077899; 2-N-(Isopropyl)amino-1-(4-methylthiophenyl)butane
DM0PT8R	DT	Small molecular drug
DM0PT8R	PC	44613578
DM0PT8R	MW	237.41
DM0PT8R	FM	C14H23NS
DM0PT8R	IC	InChI=1S/C14H23NS/c1-5-13(15-11(2)3)10-12-6-8-14(16-4)9-7-12/h6-9,11,13,15H,5,10H2,1-4H3
DM0PT8R	CS	CCC(CC1=CC=C(C=C1)SC)NC(C)C
DM0PT8R	IK	JPJSEWJNHDIYAS-UHFFFAOYSA-N
DM0PT8R	IU	1-(4-methylsulfanylphenyl)-N-propan-2-ylbutan-2-amine
DM0PT8R	DE	Discovery agent

DMLJ30O	ID	DMLJ30O
DMLJ30O	DN	2-N-(n-Propyl)amino-1-(4-methylthiophenyl)butane
DMLJ30O	HS	Investigative
DMLJ30O	SN	CHEMBL1077898; 2-N-(n-Propyl)amino-1-(4-methylthiophenyl)butane
DMLJ30O	DT	Small molecular drug
DMLJ30O	PC	44613577
DMLJ30O	MW	237.41
DMLJ30O	FM	C14H23NS
DMLJ30O	IC	InChI=1S/C14H23NS/c1-4-10-15-13(5-2)11-12-6-8-14(16-3)9-7-12/h6-9,13,15H,4-5,10-11H2,1-3H3
DMLJ30O	CS	CCCNC(CC)CC1=CC=C(C=C1)SC
DMLJ30O	IK	BVNCGPDTVNALJQ-UHFFFAOYSA-N
DMLJ30O	IU	1-(4-methylsulfanylphenyl)-N-propylbutan-2-amine
DMLJ30O	DE	Discovery agent

DMKSUVH	ID	DMKSUVH
DMKSUVH	DN	2-N,N-Dimethylamino-1-(4-methylthiophenyl)propane
DMKSUVH	HS	Investigative
DMKSUVH	SN	CHEMBL1078835; 2-N,N-Dimethylamino-1-(4-methylthiophenyl)propane; NFRBJBFYUNQIQP-UHFFFAOYSA-N; BDBM50310863; N,N-Dimethyl-1-[4-(methylthio)phenyl]-2-propaneamine
DMKSUVH	DT	Small molecular drug
DMKSUVH	PC	46882974
DMKSUVH	MW	209.35
DMKSUVH	FM	C12H19NS
DMKSUVH	IC	InChI=1S/C12H19NS/c1-10(13(2)3)9-11-5-7-12(14-4)8-6-11/h5-8,10H,9H2,1-4H3
DMKSUVH	CS	CC(CC1=CC=C(C=C1)SC)N(C)C
DMKSUVH	IK	NFRBJBFYUNQIQP-UHFFFAOYSA-N
DMKSUVH	IU	N,N-dimethyl-1-(4-methylsulfanylphenyl)propan-2-amine
DMKSUVH	DE	Discovery agent

DM5S0BY	ID	DM5S0BY
DM5S0BY	DN	2-N-Allylamino-1-(4-methylthiophenyl)propan
DM5S0BY	HS	Investigative
DM5S0BY	SN	CHEMBL1079254; 2-N-Allylamino-1-(4-methylthiophenyl)propan
DM5S0BY	DT	Small molecular drug
DM5S0BY	PC	44613067
DM5S0BY	MW	221.36
DM5S0BY	FM	C13H19NS
DM5S0BY	IC	InChI=1S/C13H19NS/c1-4-9-14-11(2)10-12-5-7-13(15-3)8-6-12/h4-8,11,14H,1,9-10H2,2-3H3
DM5S0BY	CS	CC(CC1=CC=C(C=C1)SC)NCC=C
DM5S0BY	IK	QEAUILQRYNKCJK-UHFFFAOYSA-N
DM5S0BY	IU	1-(4-methylsulfanylphenyl)-N-prop-2-enylpropan-2-amine
DM5S0BY	DE	Discovery agent

DM2FTIC	ID	DM2FTIC
DM2FTIC	DN	2-NAP
DM2FTIC	HS	Investigative
DM2FTIC	SN	N-(2-Naphthylsulfonyl)-L-aspartic acid 2-phenylethylamide sodium salt
DM2FTIC	DT	Small molecular drug
DM2FTIC	PC	9867157
DM2FTIC	MW	426.5
DM2FTIC	FM	C22H22N2O5S
DM2FTIC	IC	InChI=1S/C22H22N2O5S/c25-21(26)15-20(22(27)23-13-12-16-6-2-1-3-7-16)24-30(28,29)19-11-10-17-8-4-5-9-18(17)14-19/h1-11,14,20,24H,12-13,15H2,(H,23,27)(H,25,26)/t20-/m0/s1
DM2FTIC	CS	C1=CC=C(C=C1)CCNC(=O)[C@H](CC(=O)O)NS(=O)(=O)C2=CC3=CC=CC=C3C=C2
DM2FTIC	IK	VMYREBYTVVSDDK-FQEVSTJZSA-N
DM2FTIC	IU	(3S)-3-(naphthalen-2-ylsulfonylamino)-4-oxo-4-(2-phenylethylamino)butanoic acid
DM2FTIC	CA	CAS 141577-40-4
DM2FTIC	DE	Gastrointestinal disease

DMTSF6A	ID	DMTSF6A
DMTSF6A	DN	2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one
DMTSF6A	HS	Investigative
DMTSF6A	SN	CHEMBL423845; NSC676180; AC1L8OZ9; 2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one; SCHEMBL7925077; CTK8D2144; ZINC5647446; BDBM50059969; NSC-676180; NCI60_026907; 2-(1-Naphthyl)-1,8-naphthyridin-4(1H)-one; 2-naphthalen-1-yl-1H-1,8-naphthyridin-4-one
DMTSF6A	DT	Small molecular drug
DMTSF6A	PC	385176
DMTSF6A	MW	272.3
DMTSF6A	FM	C18H12N2O
DMTSF6A	IC	InChI=1S/C18H12N2O/c21-17-11-16(20-18-15(17)9-4-10-19-18)14-8-3-6-12-5-1-2-7-13(12)14/h1-11H,(H,19,20,21)
DMTSF6A	CS	C1=CC=C2C(=C1)C=CC=C2C3=CC(=O)C4=C(N3)N=CC=C4
DMTSF6A	IK	PPEYNRXCXSJVHV-UHFFFAOYSA-N
DMTSF6A	IU	2-naphthalen-1-yl-1H-1,8-naphthyridin-4-one
DMTSF6A	DE	Discovery agent

DMBI6U9	ID	DMBI6U9
DMBI6U9	DN	2-Naphthalen-1-yl-benzooxazol-6-ol
DMBI6U9	HS	Investigative
DMBI6U9	SN	CHEMBL188527; 2-Naphthalen-1-yl-benzooxazol-6-ol; 2-(naphthalen-1-yl)benzo[d]oxazol-6-ol; SCHEMBL6311736; LYJKLNQQSXCGDI-UHFFFAOYSA-N; BDBM50154077; ZINC12353755
DMBI6U9	DT	Small molecular drug
DMBI6U9	PC	10244394
DMBI6U9	MW	261.269
DMBI6U9	FM	C17H11NO2
DMBI6U9	IC	InChI=1S/C17H11NO2/c19-12-8-9-15-16(10-12)20-17(18-15)14-7-3-5-11-4-1-2-6-13(11)14/h1-10,19H
DMBI6U9	CS	C1=CC=C2C(=C1)C=CC=C2C3=NC4=C(O3)C=C(C=C4)O
DMBI6U9	IK	LYJKLNQQSXCGDI-UHFFFAOYSA-N
DMBI6U9	IU	2-naphthalen-1-yl-1,3-benzoxazol-6-ol
DMBI6U9	DE	Discovery agent

DMIDGNB	ID	DMIDGNB
DMIDGNB	DN	2-Naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one
DMIDGNB	HS	Investigative
DMIDGNB	SN	CHEMBL3144719; 2-Naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL273743; SCHEMBL9646265; SXKBSXCUDSHBDF-UHFFFAOYSA-N; BDBM50008985; 2-[(1-Naphthalenyl)methyl]-1H-indazol-3(2H)-one
DMIDGNB	DT	Small molecular drug
DMIDGNB	PC	14898710
DMIDGNB	MW	274.3
DMIDGNB	FM	C18H14N2O
DMIDGNB	IC	InChI=1S/C18H14N2O/c21-18-16-10-3-4-11-17(16)19-20(18)12-14-8-5-7-13-6-1-2-9-15(13)14/h1-11,19H,12H2
DMIDGNB	CS	C1=CC=C2C(=C1)C=CC=C2CN3C(=O)C4=CC=CC=C4N3
DMIDGNB	IK	SXKBSXCUDSHBDF-UHFFFAOYSA-N
DMIDGNB	IU	2-(naphthalen-1-ylmethyl)-1H-indazol-3-one
DMIDGNB	DE	Discovery agent

DM12YH4	ID	DM12YH4
DM12YH4	DN	2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one
DM12YH4	HS	Investigative
DM12YH4	SN	CHEMBL298328; NSC679017; AC1L8RZV; 2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one; SCHEMBL7913593; CTK8D2145; ZINC5541468; BDBM50059980; NSC-679017; NCI60_028216; 2-(2-Naphthyl)-1,8-naphthyridin-4(1H)-one; 2-naphthalen-2-yl-1H-1,8-naphthyridin-4-one
DM12YH4	DT	Small molecular drug
DM12YH4	PC	386569
DM12YH4	MW	272.3
DM12YH4	FM	C18H12N2O
DM12YH4	IC	InChI=1S/C18H12N2O/c21-17-11-16(20-18-15(17)6-3-9-19-18)14-8-7-12-4-1-2-5-13(12)10-14/h1-11H,(H,19,20,21)
DM12YH4	CS	C1=CC=C2C=C(C=CC2=C1)C3=CC(=O)C4=C(N3)N=CC=C4
DM12YH4	IK	SIAZQYUZGIPPRX-UHFFFAOYSA-N
DM12YH4	IU	2-naphthalen-2-yl-1H-1,8-naphthyridin-4-one
DM12YH4	DE	Discovery agent

DM1EJ6W	ID	DM1EJ6W
DM1EJ6W	DN	2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one
DM1EJ6W	HS	Investigative
DM1EJ6W	SN	CHEMBL3144577; CHEMBL8355; 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one; SCHEMBL9645961; BDBM50009006
DM1EJ6W	DT	Small molecular drug
DM1EJ6W	PC	14898720
DM1EJ6W	MW	274.3
DM1EJ6W	FM	C18H14N2O
DM1EJ6W	IC	InChI=1S/C18H14N2O/c21-18-16-7-3-4-8-17(16)19-20(18)12-13-9-10-14-5-1-2-6-15(14)11-13/h1-11,19H,12H2
DM1EJ6W	CS	C1=CC=C2C=C(C=CC2=C1)CN3C(=O)C4=CC=CC=C4N3
DM1EJ6W	IK	UVPPFCAMTBSDRP-UHFFFAOYSA-N
DM1EJ6W	IU	2-(naphthalen-2-ylmethyl)-1H-indazol-3-one
DM1EJ6W	DE	Discovery agent

DMNMEPB	ID	DMNMEPB
DMNMEPB	DN	2-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole
DMNMEPB	HS	Investigative
DMNMEPB	SN	CHEMBL441948; 2-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole; DSSTox_RID_82756; DSSTox_CID_28423; DSSTox_GSID_48449; 2-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-imidazole; CAS-835-31-4; SMR000054538; Lopac-N-5504; AC1LD21I; Lopac0_000828; CBDivE_007782; MLS000104605; SCHEMBL953099; cid_610682; DTXSID3048449; VIXRKFBKWOHVBR-UHFFFAOYSA-N; MolPort-001-896-776; HMS2287I17; ZINC2472262; CCG-2426; Tox21_113058; Tox21_113645; BDBM50057120; MCULE-4581148654; NCGC00015743-03; NCGC00015743-02; NCGC00015743-01; BAS 00364529; AB00076191-01
DMNMEPB	DT	Small molecular drug
DMNMEPB	PC	610682
DMNMEPB	MW	210.27
DMNMEPB	FM	C14H14N2
DMNMEPB	IC	InChI=1S/C14H14N2/c1-2-4-13-9-11(5-6-12(13)3-1)10-14-15-7-8-16-14/h1-6,9H,7-8,10H2,(H,15,16)
DMNMEPB	CS	C1CN=C(N1)CC2=CC3=CC=CC=C3C=C2
DMNMEPB	IK	VIXRKFBKWOHVBR-UHFFFAOYSA-N
DMNMEPB	IU	2-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-imidazole
DMNMEPB	DE	Discovery agent

DMZ4LJ7	ID	DMZ4LJ7
DMZ4LJ7	DN	2-NAPHTHALENESULFONIC ACID
DMZ4LJ7	HS	Investigative
DMZ4LJ7	SN	120-18-3; beta-Naphthylsulfonic acid; beta-Naphthalenesulfonic acid; Naphthalene-2-sulphonic acid; 2-Naphthalene Sulfonic Acid; Kyselina 2-naftalensulfonova; UNII-O9S4K2S25E; 2-Naphthylsulfonic acid; EINECS 204-375-3; Kyselina 2-naftalensulfonova [Czech]; BRN 1955756; AI3-18435; O9S4K2S25E; CHEBI:44229; KVBGVZZKJNLNJU-UHFFFAOYSA-N; MFCD00004089; 2-Naphthalenesulfonic acid, monohydrate; W-109067; 2-Sulfonaphthalene; 2-Naphthalenesulfonic; PubChem19963; AC1L1QYN; AC1Q6WYB
DMZ4LJ7	DT	Small molecular drug
DMZ4LJ7	PC	8420
DMZ4LJ7	MW	208.24
DMZ4LJ7	FM	C10H8O3S
DMZ4LJ7	IC	InChI=1S/C10H8O3S/c11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h1-7H,(H,11,12,13)
DMZ4LJ7	CS	C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)O
DMZ4LJ7	IK	KVBGVZZKJNLNJU-UHFFFAOYSA-N
DMZ4LJ7	IU	naphthalene-2-sulfonic acid
DMZ4LJ7	CA	CAS 120-18-3
DMZ4LJ7	CB	CHEBI:44229
DMZ4LJ7	DE	Discovery agent

DMFXKN1	ID	DMFXKN1
DMFXKN1	DN	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine
DMFXKN1	HS	Investigative
DMFXKN1	SN	(S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE; 2gv6; AC1OA9XW; CHEMBL210771; SCHEMBL12960819; BDBM23902; 3-amidinophenylalanine deriv., 8; 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-(naphthalene-2-sulfonamido)-3-oxopropyl]benzene-1-carboximidamide; 3-{(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}benzenecarboximidamide
DMFXKN1	DT	Small molecular drug
DMFXKN1	PC	6852210
DMFXKN1	MW	549.7
DMFXKN1	FM	C28H35N7O3S
DMFXKN1	IC	InChI=1S/C28H35N7O3S/c29-26(30)23-7-3-4-20(16-23)17-25(27(36)35-14-11-19(12-15-35)10-13-33-28(31)32)34-39(37,38)24-9-8-21-5-1-2-6-22(21)18-24/h1-9,16,18-19,25,34H,10-15,17H2,(H3,29,30)(H4,31,32,33)/t25-/m0/s1
DMFXKN1	CS	C1CN(CCC1CCN=C(N)N)C(=O)[C@H](CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3
DMFXKN1	IK	BKOKSJAQZJNVPN-VWLOTQADSA-N
DMFXKN1	IU	3-[(2S)-3-[4-[2-(diaminomethylideneamino)ethyl]piperidin-1-yl]-2-(naphthalen-2-ylsulfonylamino)-3-oxopropyl]benzenecarboximidamide
DMFXKN1	DE	Discovery agent

DMS0NW3	ID	DMS0NW3
DMS0NW3	DN	2-N-Cyclopropylamino-1-(4-methylthiophenyl)butane
DMS0NW3	HS	Investigative
DMS0NW3	SN	CHEMBL1078818; 2-N-Cyclopropylamino-1-(4-methylthiophenyl)butane
DMS0NW3	DT	Small molecular drug
DMS0NW3	PC	44613579
DMS0NW3	MW	235.39
DMS0NW3	FM	C14H21NS
DMS0NW3	IC	InChI=1S/C14H21NS/c1-3-12(15-13-6-7-13)10-11-4-8-14(16-2)9-5-11/h4-5,8-9,12-13,15H,3,6-7,10H2,1-2H3
DMS0NW3	CS	CCC(CC1=CC=C(C=C1)SC)NC2CC2
DMS0NW3	IK	WWIGSCWWTFIJCJ-UHFFFAOYSA-N
DMS0NW3	IU	N-[1-(4-methylsulfanylphenyl)butan-2-yl]cyclopropanamine
DMS0NW3	DE	Discovery agent

DMCYVS0	ID	DMCYVS0
DMCYVS0	DN	2-N-Ethylamino-1-(4-ethylthiophenyl)butane
DMCYVS0	HS	Investigative
DMCYVS0	SN	CHEMBL1077884; 2-N-Ethylamino-1-(4-ethylthiophenyl)butane
DMCYVS0	DT	Small molecular drug
DMCYVS0	PC	44613456
DMCYVS0	MW	237.41
DMCYVS0	FM	C14H23NS
DMCYVS0	IC	InChI=1S/C14H23NS/c1-4-13(15-5-2)11-12-7-9-14(10-8-12)16-6-3/h7-10,13,15H,4-6,11H2,1-3H3
DMCYVS0	CS	CCC(CC1=CC=C(C=C1)SCC)NCC
DMCYVS0	IK	FXAXBZLCZVSQJT-UHFFFAOYSA-N
DMCYVS0	IU	N-ethyl-1-(4-ethylsulfanylphenyl)butan-2-amine
DMCYVS0	DE	Discovery agent

DM64093	ID	DM64093
DM64093	DN	2-N-Ethylamino-1-(4-ethylthiophenyl)propane
DM64093	HS	Investigative
DM64093	SN	CHEMBL1077873; 2-N-Ethylamino-1-(4-ethylthiophenyl)propane
DM64093	DT	Small molecular drug
DM64093	PC	44613452
DM64093	MW	223.38
DM64093	FM	C13H21NS
DM64093	IC	InChI=1S/C13H21NS/c1-4-14-11(3)10-12-6-8-13(9-7-12)15-5-2/h6-9,11,14H,4-5,10H2,1-3H3
DM64093	CS	CCNC(C)CC1=CC=C(C=C1)SCC
DM64093	IK	UKMQZNZTCNFILP-UHFFFAOYSA-N
DM64093	IU	N-ethyl-1-(4-ethylsulfanylphenyl)propan-2-amine
DM64093	DE	Discovery agent

DMKA3V2	ID	DMKA3V2
DMKA3V2	DN	2-N-Ethylamino-1-(4-methylthiophenyl)butane
DMKA3V2	HS	Investigative
DMKA3V2	SN	CHEMBL1077897; 2-N-Ethylamino-1-(4-methylthiophenyl)butane
DMKA3V2	DT	Small molecular drug
DMKA3V2	PC	44613576
DMKA3V2	MW	223.38
DMKA3V2	FM	C13H21NS
DMKA3V2	IC	InChI=1S/C13H21NS/c1-4-12(14-5-2)10-11-6-8-13(15-3)9-7-11/h6-9,12,14H,4-5,10H2,1-3H3
DMKA3V2	CS	CCC(CC1=CC=C(C=C1)SC)NCC
DMKA3V2	IK	DVPCSQHSLVMBEG-UHFFFAOYSA-N
DMKA3V2	IU	N-ethyl-1-(4-methylsulfanylphenyl)butan-2-amine
DMKA3V2	DE	Discovery agent

DM6O1SY	ID	DM6O1SY
DM6O1SY	DN	2-N-Ethylamino-1-(4-methylthiophenyl)propane
DM6O1SY	HS	Investigative
DM6O1SY	SN	2-N-Ethylamino-1-(4-methylthiophenyl)propane; CHEMBL1078039; 634607-27-5; LAWDOCPCCFOXQO-UHFFFAOYSA-N; BDBM50310856
DM6O1SY	DT	Small molecular drug
DM6O1SY	PC	21978439
DM6O1SY	MW	209.35
DM6O1SY	FM	C12H19NS
DM6O1SY	IC	InChI=1S/C12H19NS/c1-4-13-10(2)9-11-5-7-12(14-3)8-6-11/h5-8,10,13H,4,9H2,1-3H3
DM6O1SY	CS	CCNC(C)CC1=CC=C(C=C1)SC
DM6O1SY	IK	LAWDOCPCCFOXQO-UHFFFAOYSA-N
DM6O1SY	IU	N-ethyl-1-(4-methylsulfanylphenyl)propan-2-amine
DM6O1SY	DE	Discovery agent

DM2MH6J	ID	DM2MH6J
DM2MH6J	DN	2-N-Hydroxyamino-1-(4-ethylthiophenyl)butane
DM2MH6J	HS	Investigative
DM2MH6J	SN	2-N-Hydroxyamino-1-(4-ethylthiophenyl)butane; CHEMBL1077983; 1204749-43-8
DM2MH6J	DT	Small molecular drug
DM2MH6J	PC	44613458
DM2MH6J	MW	225.35
DM2MH6J	FM	C12H19NOS
DM2MH6J	IC	InChI=1S/C12H19NOS/c1-3-11(13-14)9-10-5-7-12(8-6-10)15-4-2/h5-8,11,13-14H,3-4,9H2,1-2H3
DM2MH6J	CS	CCC(CC1=CC=C(C=C1)SCC)NO
DM2MH6J	IK	HZILCAQYLMPMJC-UHFFFAOYSA-N
DM2MH6J	IU	N-[1-(4-ethylsulfanylphenyl)butan-2-yl]hydroxylamine
DM2MH6J	DE	Discovery agent

DMIQGWK	ID	DMIQGWK
DMIQGWK	DN	2-N-Hydroxyamino-1-(4-ethylthiophenyl)propane
DMIQGWK	HS	Investigative
DMIQGWK	SN	2-N-Hydroxyamino-1-(4-ethylthiophenyl)propane; CHEMBL1077874; 1204749-41-6
DMIQGWK	DT	Small molecular drug
DMIQGWK	PC	44613453
DMIQGWK	MW	211.33
DMIQGWK	FM	C11H17NOS
DMIQGWK	IC	InChI=1S/C11H17NOS/c1-3-14-11-6-4-10(5-7-11)8-9(2)12-13/h4-7,9,12-13H,3,8H2,1-2H3
DMIQGWK	CS	CCSC1=CC=C(C=C1)CC(C)NO
DMIQGWK	IK	JDIRZPZVUPWDQO-UHFFFAOYSA-N
DMIQGWK	IU	N-[1-(4-ethylsulfanylphenyl)propan-2-yl]hydroxylamine
DMIQGWK	DE	Discovery agent

DME41NR	ID	DME41NR
DME41NR	DN	2-N-Hydroxyamino-1-(4-methylthiophenyl)butane
DME41NR	HS	Investigative
DME41NR	SN	2-N-Hydroxyamino-1-(4-methylthiophenyl)butane; CHEMBL1078920; 1204749-75-6
DME41NR	DT	Small molecular drug
DME41NR	PC	44613690
DME41NR	MW	211.33
DME41NR	FM	C11H17NOS
DME41NR	IC	InChI=1S/C11H17NOS/c1-3-10(12-13)8-9-4-6-11(14-2)7-5-9/h4-7,10,12-13H,3,8H2,1-2H3
DME41NR	CS	CCC(CC1=CC=C(C=C1)SC)NO
DME41NR	IK	HJFQUPKLSAEIPC-UHFFFAOYSA-N
DME41NR	IU	N-[1-(4-methylsulfanylphenyl)butan-2-yl]hydroxylamine
DME41NR	DE	Discovery agent

DMZDYCW	ID	DMZDYCW
DMZDYCW	DN	2-N-Hydroxyamino-1-(4-methylthiophenyl)propane
DMZDYCW	HS	Investigative
DMZDYCW	SN	2-N-Hydroxyamino-1-(4-methylthiophenyl)propane; CHEMBL1077857; 1204749-10-9; hydroxy-4-methylthioamphetamine
DMZDYCW	DT	Small molecular drug
DMZDYCW	PC	44613192
DMZDYCW	MW	197.3
DMZDYCW	FM	C10H15NOS
DMZDYCW	IC	InChI=1S/C10H15NOS/c1-8(11-12)7-9-3-5-10(13-2)6-4-9/h3-6,8,11-12H,7H2,1-2H3
DMZDYCW	CS	CC(CC1=CC=C(C=C1)SC)NO
DMZDYCW	IK	WSDWYDJPBFHVDU-UHFFFAOYSA-N
DMZDYCW	IU	N-[1-(4-methylsulfanylphenyl)propan-2-yl]hydroxylamine
DMZDYCW	DE	Discovery agent

DM2NX4K	ID	DM2NX4K
DM2NX4K	DN	2'-Nitro-biphenyl-4-carboxylic acid hydroxyamide
DM2NX4K	HS	Investigative
DM2NX4K	SN	CHEMBL177084; BDBM50015162; ZINC28086552; 2''-Nitro-biphenyl-4-carboxylic acid hydroxyamide
DM2NX4K	DT	Small molecular drug
DM2NX4K	PC	44386824
DM2NX4K	MW	258.23
DM2NX4K	FM	C13H10N2O4
DM2NX4K	IC	InChI=1S/C13H10N2O4/c16-13(14-17)10-7-5-9(6-8-10)11-3-1-2-4-12(11)15(18)19/h1-8,17H,(H,14,16)
DM2NX4K	CS	C1=CC=C(C(=C1)C2=CC=C(C=C2)C(=O)NO)[N+](=O)[O-]
DM2NX4K	IK	MDYLSZYFKUGXHL-UHFFFAOYSA-N
DM2NX4K	IU	N-hydroxy-4-(2-nitrophenyl)benzamide
DM2NX4K	DE	Discovery agent

DMRZK9A	ID	DMRZK9A
DMRZK9A	DN	2-nitro-N-(2,4,5-trichlorophenyl)benzamide
DMRZK9A	HS	Investigative
DMRZK9A	SN	2-nitro-N-(2,4,5-trichlorophenyl)benzamide; CHEMBL570080; AC1LEFM1; CBMicro_048760; Oprea1_298416; MolPort-001-513-202; ZINC103157; STL255954; BDBM50297534; AKOS003265549; MCULE-2760222088; ST011169; BIM-0048873.P001
DMRZK9A	DT	Small molecular drug
DMRZK9A	PC	711434
DMRZK9A	MW	345.6
DMRZK9A	FM	C13H7Cl3N2O3
DMRZK9A	IC	InChI=1S/C13H7Cl3N2O3/c14-8-5-10(16)11(6-9(8)15)17-13(19)7-3-1-2-4-12(7)18(20)21/h1-6H,(H,17,19)
DMRZK9A	CS	C1=CC=C(C(=C1)C(=O)NC2=CC(=C(C=C2Cl)Cl)Cl)[N+](=O)[O-]
DMRZK9A	IK	IWLWJYOQIYGDKH-UHFFFAOYSA-N
DMRZK9A	IU	2-nitro-N-(2,4,5-trichlorophenyl)benzamide
DMRZK9A	DE	Discovery agent

DM4Z56O	ID	DM4Z56O
DM4Z56O	DN	2-nitro-N-(quinolin-8-yl)benzenesulfonamide
DM4Z56O	HS	Investigative
DM4Z56O	SN	MLS001123640; SMR000658615; 2-nitro-N-quinolin-8-ylbenzenesulfonamide; 2-Nitro-N-quinolin-8-yl-benzenesulfonamide; AC1LEORR; CBKinase1_000077; CBKinase1_012477; Cambridge id 5175135; Oprea1_237550; CBDivE_007245; cid_739449; CHEMBL270605; SCHEMBL11973295; BDBM60287; MolPort-002-134-446; YCXUFEOBLVZNAP-UHFFFAOYSA-N; ZINC175212; AKOS033118464; MCULE-3457699063; NCGC00161682-02; NCGC00161682-01; NCGC00161682-03; 2-nitro-N-(8-quinolyl)benzenesulfonamide; N-(8-Quinolyl)-2-nitrobenzenesulfonamide
DM4Z56O	DT	Small molecular drug
DM4Z56O	PC	739449
DM4Z56O	MW	329.3
DM4Z56O	FM	C15H11N3O4S
DM4Z56O	IC	InChI=1S/C15H11N3O4S/c19-18(20)13-8-1-2-9-14(13)23(21,22)17-12-7-3-5-11-6-4-10-16-15(11)12/h1-10,17H
DM4Z56O	CS	C1=CC=C(C(=C1)[N+](=O)[O-])S(=O)(=O)NC2=CC=CC3=C2N=CC=C3
DM4Z56O	IK	YCXUFEOBLVZNAP-UHFFFAOYSA-N
DM4Z56O	IU	2-nitro-N-quinolin-8-ylbenzenesulfonamide
DM4Z56O	DE	Discovery agent

DMHCVKJ	ID	DMHCVKJ
DMHCVKJ	DN	2-N-Methoxyamino-1-(4-methylthiophenyl)propane
DMHCVKJ	HS	Investigative
DMHCVKJ	SN	2-N-Methoxyamino-1-(4-methylthiophenyl)propane; CHEMBL1077961; 1204749-12-1
DMHCVKJ	DT	Small molecular drug
DMHCVKJ	PC	44613193
DMHCVKJ	MW	211.33
DMHCVKJ	FM	C11H17NOS
DMHCVKJ	IC	InChI=1S/C11H17NOS/c1-9(12-13-2)8-10-4-6-11(14-3)7-5-10/h4-7,9,12H,8H2,1-3H3
DMHCVKJ	CS	CC(CC1=CC=C(C=C1)SC)NOC
DMHCVKJ	IK	BWEGTFZAQIVRFB-UHFFFAOYSA-N
DMHCVKJ	IU	N-methoxy-1-(4-methylsulfanylphenyl)propan-2-amine
DMHCVKJ	DE	Discovery agent

DM1X5RY	ID	DM1X5RY
DM1X5RY	DN	2-N-Methylamino-1-(4-ethylthiophenyl)propane
DM1X5RY	HS	Investigative
DM1X5RY	SN	2-N-Methylamino-1-(4-ethylthiophenyl)propane; CHEMBL1077872; 1204749-25-6
DM1X5RY	DT	Small molecular drug
DM1X5RY	PC	44613451
DM1X5RY	MW	209.35
DM1X5RY	FM	C12H19NS
DM1X5RY	IC	InChI=1S/C12H19NS/c1-4-14-12-7-5-11(6-8-12)9-10(2)13-3/h5-8,10,13H,4,9H2,1-3H3
DM1X5RY	CS	CCSC1=CC=C(C=C1)CC(C)NC
DM1X5RY	IK	LCGABASJFJNHGF-UHFFFAOYSA-N
DM1X5RY	IU	1-(4-ethylsulfanylphenyl)-N-methylpropan-2-amine
DM1X5RY	DE	Discovery agent

DMCR49K	ID	DMCR49K
DMCR49K	DN	2-N-Methylamino-1-(4-methylthiophenyl)butane
DMCR49K	HS	Investigative
DMCR49K	SN	2-N-Methylamino-1-(4-methylthiophenyl)butane; CHEMBL1078440; 1204749-45-0
DMCR49K	DT	Small molecular drug
DMCR49K	PC	44613575
DMCR49K	MW	209.35
DMCR49K	FM	C12H19NS
DMCR49K	IC	InChI=1S/C12H19NS/c1-4-11(13-2)9-10-5-7-12(14-3)8-6-10/h5-8,11,13H,4,9H2,1-3H3
DMCR49K	CS	CCC(CC1=CC=C(C=C1)SC)NC
DMCR49K	IK	JMLCRWOWZIZAEU-UHFFFAOYSA-N
DMCR49K	IU	N-methyl-1-(4-methylsulfanylphenyl)butan-2-amine
DMCR49K	DE	Discovery agent

DMVLX1T	ID	DMVLX1T
DMVLX1T	DN	2-N-Methylamino-1-(4-methylthiophenyl)propane
DMVLX1T	HS	Investigative
DMVLX1T	SN	CHEMBL1078038; WWHIYWVWPXXBTC-UHFFFAOYSA-N; BDBM50310855
DMVLX1T	DT	Small molecular drug
DMVLX1T	PC	46882957
DMVLX1T	MW	195.33
DMVLX1T	FM	C11H17NS
DMVLX1T	IC	InChI=1S/C11H17NS/c1-9(12-2)8-10-4-6-11(13-3)7-5-10/h4-7,9,12H,8H2,1-3H3
DMVLX1T	CS	CC(CC1=CC=C(C=C1)SC)NC
DMVLX1T	IK	WWHIYWVWPXXBTC-UHFFFAOYSA-N
DMVLX1T	IU	N-methyl-1-(4-methylsulfanylphenyl)propan-2-amine
DMVLX1T	DE	Discovery agent

DMQWR69	ID	DMQWR69
DMQWR69	DN	2-NONYL-4-HYDROXYQUINOLINE N-OXIDE
DMQWR69	HS	Investigative
DMQWR69	SN	QNO; AC1O4QJA
DMQWR69	DT	Small molecular drug
DMQWR69	PC	130804
DMQWR69	MW	287.4
DMQWR69	FM	C18H25NO2
DMQWR69	IC	InChI=1S/C18H25NO2/c1-2-3-4-5-6-7-8-11-15-14-18(20)16-12-9-10-13-17(16)19(15)21/h9-10,12-14,21H,2-8,11H2,1H3
DMQWR69	CS	CCCCCCCCCC1=CC(=O)C2=CC=CC=C2N1O
DMQWR69	IK	JYFNTDPGDPZMCM-UHFFFAOYSA-N
DMQWR69	IU	1-hydroxy-2-nonylquinolin-4-one
DMQWR69	CA	CAS 316-66-5
DMQWR69	DE	Discovery agent

DMOGWIK	ID	DMOGWIK
DMOGWIK	DN	2-nonylamido-5-sulfonamidoindane
DMOGWIK	HS	Investigative
DMOGWIK	SN	CHEMBL208532; 2-nonylamido-5-sulfonamidoindane; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)decanamide; Indanesulfonamide Derivative 12g
DMOGWIK	DT	Small molecular drug
DMOGWIK	PC	11660633
DMOGWIK	MW	366.5
DMOGWIK	FM	C19H30N2O3S
DMOGWIK	IC	InChI=1S/C19H30N2O3S/c1-2-3-4-5-6-7-8-9-19(22)21-17-12-15-10-11-18(25(20,23)24)14-16(15)13-17/h10-11,14,17H,2-9,12-13H2,1H3,(H,21,22)(H2,20,23,24)
DMOGWIK	CS	CCCCCCCCCC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DMOGWIK	IK	CWOKTKYGRFERNA-UHFFFAOYSA-N
DMOGWIK	IU	N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)decanamide
DMOGWIK	DE	Discovery agent

DMRXDS2	ID	DMRXDS2
DMRXDS2	DN	2np8
DMRXDS2	HS	Investigative
DMRXDS2	SN	Aurora Kinase Inhibitor III; 879127-16-9; 2np8; N-{3-[(4-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}cyclopropanecarboxamide; CHEMBL383899; Cyclopropanecarboxylic acid-(3-(4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino)-phenyl)-amide; N-[3-[[4-[3-(trifluoromethyl)anilino]pyrimidin-2-yl]amino]phenyl]cyclopropanecarboxamide; Anilinopyrimidine1; SCHEMBL676556; GTPL5931; CTK8E9807; DTXSID20429557; MolPort-029-945-855; HMS3229O19; HMS3229A22; K00603a; ZINC13831338; MFCD09265250; IN1527; BDBM50200392
DMRXDS2	DT	Small molecular drug
DMRXDS2	PC	9549303
DMRXDS2	MW	413.4
DMRXDS2	FM	C21H18F3N5O
DMRXDS2	IC	InChI=1S/C21H18F3N5O/c22-21(23,24)14-3-1-4-15(11-14)26-18-9-10-25-20(29-18)28-17-6-2-5-16(12-17)27-19(30)13-7-8-13/h1-6,9-13H,7-8H2,(H,27,30)(H2,25,26,28,29)
DMRXDS2	CS	C1CC1C(=O)NC2=CC=CC(=C2)NC3=NC=CC(=N3)NC4=CC=CC(=C4)C(F)(F)F
DMRXDS2	IK	RDTDWGQDFJPTPD-UHFFFAOYSA-N
DMRXDS2	IU	N-[3-[[4-[3-(trifluoromethyl)anilino]pyrimidin-2-yl]amino]phenyl]cyclopropanecarboxamide
DMRXDS2	CA	CAS 879127-16-9
DMRXDS2	DE	Discovery agent

DMLZCOU	ID	DMLZCOU
DMLZCOU	DN	2-N-Propargylamino-1-(4-methylthiophenyl)butane
DMLZCOU	HS	Investigative
DMLZCOU	SN	CHEMBL1077900; 2-N-Propargylamino-1-(4-methylthiophenyl)butane
DMLZCOU	DT	Small molecular drug
DMLZCOU	PC	44613580
DMLZCOU	MW	233.37
DMLZCOU	FM	C14H19NS
DMLZCOU	IC	InChI=1S/C14H19NS/c1-4-10-15-13(5-2)11-12-6-8-14(16-3)9-7-12/h1,6-9,13,15H,5,10-11H2,2-3H3
DMLZCOU	CS	CCC(CC1=CC=C(C=C1)SC)NCC#C
DMLZCOU	IK	LQQBIFPYEKWTOI-UHFFFAOYSA-N
DMLZCOU	IU	1-(4-methylsulfanylphenyl)-N-prop-2-ynylbutan-2-amine
DMLZCOU	DE	Discovery agent

DM9HPG1	ID	DM9HPG1
DM9HPG1	DN	2-N-Propargylamino-1-(4-methylthiophenyl)propane
DM9HPG1	HS	Investigative
DM9HPG1	SN	CHEMBL1079255; 2-N-Propargylamino-1-(4-methylthiophenyl)propane
DM9HPG1	DT	Small molecular drug
DM9HPG1	PC	44613068
DM9HPG1	MW	219.35
DM9HPG1	FM	C13H17NS
DM9HPG1	IC	InChI=1S/C13H17NS/c1-4-9-14-11(2)10-12-5-7-13(15-3)8-6-12/h1,5-8,11,14H,9-10H2,2-3H3
DM9HPG1	CS	CC(CC1=CC=C(C=C1)SC)NCC#C
DM9HPG1	IK	UPHGABWYFBVICE-UHFFFAOYSA-N
DM9HPG1	IU	1-(4-methylsulfanylphenyl)-N-prop-2-ynylpropan-2-amine
DM9HPG1	DE	Discovery agent

DMZK0JV	ID	DMZK0JV
DMZK0JV	DN	2-O-ethyl-PAF C-16
DMZK0JV	HS	Investigative
DMZK0JV	SN	2-O-ethyl-platelet-activating factor C-16
DMZK0JV	DT	Small molecular drug
DMZK0JV	PC	9546625
DMZK0JV	MW	510.7
DMZK0JV	FM	C26H57NO6P+
DMZK0JV	IC	InChI=1S/C26H56NO6P/c1-6-8-9-10-11-12-13-14-15-16-17-18-19-20-22-30-24-26(31-7-2)25-33-34(28,29)32-23-21-27(3,4)5/h26H,6-25H2,1-5H3/p+1
DMZK0JV	CS	CCCCCCCCCCCCCCCCOCC(COP(=O)(O)OCC[N+](C)(C)C)OCC
DMZK0JV	IK	LPHUUVMLQFHHQG-UHFFFAOYSA-O
DMZK0JV	IU	2-[(2-ethoxy-3-hexadecoxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
DMZK0JV	DE	Discovery agent

DM5PXQU	ID	DM5PXQU
DM5PXQU	DN	2-oleoyl glycerol
DM5PXQU	HS	Investigative
DM5PXQU	SN	2-monoolein; 2-oleoyl-glycerol; 2-oleoylglycerol (2OG)
DM5PXQU	DT	Small molecular drug
DM5PXQU	PC	5319879
DM5PXQU	MW	356.5
DM5PXQU	FM	C21H40O4
DM5PXQU	IC	InChI=1S/C21H40O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-20(18-22)19-23/h9-10,20,22-23H,2-8,11-19H2,1H3/b10-9-
DM5PXQU	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OC(CO)CO
DM5PXQU	IK	UPWGQKDVAURUGE-KTKRTIGZSA-N
DM5PXQU	IU	1,3-dihydroxypropan-2-yl (Z)-octadec-9-enoate
DM5PXQU	CA	CAS 3443-84-3
DM5PXQU	CB	CHEBI:73990
DM5PXQU	DE	Discovery agent

DMN9OS1	ID	DMN9OS1
DMN9OS1	DN	2-oleoyl-LPA
DMN9OS1	HS	Investigative
DMN9OS1	SN	2-acyl-1LPA; 2Acyl-LPA
DMN9OS1	DT	Small molecular drug
DMN9OS1	PC	56947016
DMN9OS1	MW	436.5
DMN9OS1	FM	C21H41O7P
DMN9OS1	IC	InChI=1S/C21H41O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)28-20(18-22)19-27-29(24,25)26/h9-10,20,22H,2-8,11-19H2,1H3,(H2,24,25,26)/b10-9-
DMN9OS1	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OC(CO)COP(=O)(O)O
DMN9OS1	IK	ZOOLJLSXNRZLDH-KTKRTIGZSA-N
DMN9OS1	IU	(1-hydroxy-3-phosphonooxypropan-2-yl) (Z)-octadec-9-enoate
DMN9OS1	DE	Discovery agent

DMO6JRW	ID	DMO6JRW
DMO6JRW	DN	2'-O-Methyl G-Clamp Containing Oligonucleotides
DMO6JRW	HS	Investigative
DMO6JRW	DE	Discovery agent

DME7K64	ID	DME7K64
DME7K64	DN	2-O-methyl-PAF C-18
DME7K64	HS	Investigative
DME7K64	SN	2-O-methyl-platelet-activating factor C-18; 2-methyl-C18-PAF; 2-methyloctadecyl PAF
DME7K64	DT	Small molecular drug
DME7K64	PC	132181
DME7K64	MW	565.8
DME7K64	FM	C29H60NO7P
DME7K64	IC	InChI=1S/C29H60NO7P/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(2)24-34-25-29(37-28(3)31)26-36-38(32,33)35-23-22-30(4,5)6/h27,29H,7-26H2,1-6H3
DME7K64	CS	CCCCCCCCCCCCCCCCC(C)COCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)C
DME7K64	IK	CIVAIADZNGBFHP-UHFFFAOYSA-N
DME7K64	IU	[2-acetyloxy-3-(2-methyloctadecoxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
DME7K64	CA	CAS 138852-22-9
DME7K64	DE	Discovery agent

DM2NEX4	ID	DM2NEX4
DM2NEX4	DN	2-Oxa-spiro[4.4]nonan-1-one
DM2NEX4	HS	Investigative
DM2NEX4	SN	2-Oxaspiro[4.4]nonan-1-one; 5732-98-9; 2-oxaspiro[4,4]nonan-1-one; CHEMBL330370; SCHEMBL11055887; CTK1H4141; DTXSID90574422; MolPort-028-950-793; ZINC13734068
DM2NEX4	DT	Small molecular drug
DM2NEX4	PC	15566992
DM2NEX4	MW	140.18
DM2NEX4	FM	C8H12O2
DM2NEX4	IC	InChI=1S/C8H12O2/c9-7-8(5-6-10-7)3-1-2-4-8/h1-6H2
DM2NEX4	CS	C1CCC2(C1)CCOC2=O
DM2NEX4	IK	PBZONIMHAVOWHW-UHFFFAOYSA-N
DM2NEX4	IU	2-oxaspiro[4.4]nonan-1-one
DM2NEX4	CA	CAS 5732-98-9
DM2NEX4	DE	Discovery agent

DMFN769	ID	DMFN769
DMFN769	DN	2-oxo-2H-chromene-3-carboxylic acid
DMFN769	HS	Investigative
DMFN769	SN	Coumarin-3-carboxylic acid; 531-81-7; 2-Oxo-2H-chromene-3-carboxylic acid; 3-Carboxycoumarin; 2-Oxochromene-3-carboxylic acid; 2-Oxobenzopyran-3-carboxylic acid; G 1 (rodenticide); 2H-1-BENZOPYRAN-3-CARBOXYLIC ACID, 2-OXO-; 2-Oxo-2H-1-benzopyran-3-carboxylic acid; UNII-V85UOV8788; G 1 (VAN); G 1 (The rodenticide) (VAN); EINECS 208-518-0; NSC 14797; NSC 53239; BRN 0154276; CHEMBL83294; Malonic acid, salicylidene-, delta-lactone; AI3-36066; ACMLKANOGIVEPB-UHFFFAOYSA-N; V85UOV8788; NSC53239; MFCD00006852; G 1 (The rodenticide); WLN: 
DMFN769	DT	Small molecular drug
DMFN769	PC	10752
DMFN769	MW	190.15
DMFN769	FM	C10H6O4
DMFN769	IC	InChI=1S/C10H6O4/c11-9(12)7-5-6-3-1-2-4-8(6)14-10(7)13/h1-5H,(H,11,12)
DMFN769	CS	C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)O
DMFN769	IK	ACMLKANOGIVEPB-UHFFFAOYSA-N
DMFN769	IU	2-oxochromene-3-carboxylic acid
DMFN769	CA	CAS 531-81-7
DMFN769	DE	Discovery agent

DMZTCOM	ID	DMZTCOM
DMZTCOM	DN	2-oxo-2H-thiochromene-3-carboxylic acid
DMZTCOM	HS	Investigative
DMZTCOM	SN	2-oxo-2H-thiochromene-3-carboxylic acid; CHEMBL571519; 66253-08-5; SCHEMBL7679158
DMZTCOM	DT	Small molecular drug
DMZTCOM	PC	12394434
DMZTCOM	MW	206.22
DMZTCOM	FM	C10H6O3S
DMZTCOM	IC	InChI=1S/C10H6O3S/c11-9(12)7-5-6-3-1-2-4-8(6)14-10(7)13/h1-5H,(H,11,12)
DMZTCOM	CS	C1=CC=C2C(=C1)C=C(C(=O)S2)C(=O)O
DMZTCOM	IK	CIMFYGICTNZOPT-UHFFFAOYSA-N
DMZTCOM	IU	2-oxothiochromene-3-carboxylic acid
DMZTCOM	DE	Discovery agent

DM3UY74	ID	DM3UY74
DM3UY74	DN	2-oxoguaia-1,4(15), 11(13)-trien-12,8beta-olide
DM3UY74	HS	Investigative
DM3UY74	SN	CHEMBL189428
DM3UY74	DT	Small molecular drug
DM3UY74	PC	44398330
DM3UY74	MW	244.28
DM3UY74	FM	C15H16O3
DM3UY74	IC	InChI=1S/C15H16O3/c1-7-4-14-12(9(3)15(17)18-14)5-11-8(2)13(16)6-10(7)11/h6-7,11-12,14H,2-5H2,1H3/t7-,11-,12+,14-/m0/s1
DM3UY74	CS	C[C@H]1C[C@H]2[C@H](C[C@@H]3C1=CC(=O)C3=C)C(=C)C(=O)O2
DM3UY74	IK	RVBPAMCSEVHKLO-MZZAWFPRSA-N
DM3UY74	IU	(3aS,5S,8aR,9aR)-5-methyl-1,8-dimethylidene-3a,4,5,8a,9,9a-hexahydroazuleno[6,5-b]furan-2,7-dione
DM3UY74	DE	Discovery agent

DM23WOV	ID	DM23WOV
DM23WOV	DN	2-oxoguaia-1,4,11(13)-trien-12,8alpha-olide
DM23WOV	HS	Investigative
DM23WOV	SN	CHEMBL191179
DM23WOV	DT	Small molecular drug
DM23WOV	PC	44398347
DM23WOV	MW	244.28
DM23WOV	FM	C15H16O3
DM23WOV	IC	InChI=1S/C15H16O3/c1-7-4-14-12(9(3)15(17)18-14)5-11-8(2)13(16)6-10(7)11/h6-7,11-12,14H,2-5H2,1H3/t7-,11-,12+,14+/m0/s1
DM23WOV	CS	C[C@H]1C[C@@H]2[C@H](C[C@@H]3C1=CC(=O)C3=C)C(=C)C(=O)O2
DM23WOV	IK	RVBPAMCSEVHKLO-LWZBDFBTSA-N
DM23WOV	IU	(3aR,5S,8aR,9aR)-5-methyl-1,8-dimethylidene-3a,4,5,8a,9,9a-hexahydroazuleno[6,5-b]furan-2,7-dione
DM23WOV	DE	Discovery agent

DMDKSZ0	ID	DMDKSZ0
DMDKSZ0	DN	2-oxo-N-m-tolyl-2H-chromene-3-carboxamide
DMDKSZ0	HS	Investigative
DMDKSZ0	SN	1846-99-7; 2-oxo-N-(m-tolyl)-2H-chromene-3-carboxamide; 2-Oxo-2H-chromene-3-carboxylic acid m-tolylamide; N-(3-Methylphenyl)-2-oxo-2H-chromene-3-carboxamide; AC1LCCPQ; BAS 00837918; AC1Q2NKJ; 3-carboxamido coumarin, 8; TimTec1_006709; Oprea1_808053; Oprea1_256730; CBDivE_000076; MLS001209245; CHEMBL445184; SCHEMBL6228552; BDBM29158; 2h-1-benzopyran-3-carboxamide,n-(3-methylphenyl)-2-oxo-; MolPort-000-375-220; XUNAVIWFCXQWCJ-UHFFFAOYSA-N; HMS2825F09; HMS1553A21; ZINC130233; N-(m-Tolyl)-3-coumarincarboxamide; STK408207
DMDKSZ0	DT	Small molecular drug
DMDKSZ0	PC	599289
DMDKSZ0	MW	279.29
DMDKSZ0	FM	C17H13NO3
DMDKSZ0	IC	InChI=1S/C17H13NO3/c1-11-5-4-7-13(9-11)18-16(19)14-10-12-6-2-3-8-15(12)21-17(14)20/h2-10H,1H3,(H,18,19)
DMDKSZ0	CS	CC1=CC(=CC=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMDKSZ0	IK	XUNAVIWFCXQWCJ-UHFFFAOYSA-N
DMDKSZ0	IU	N-(3-methylphenyl)-2-oxochromene-3-carboxamide
DMDKSZ0	DE	Discovery agent

DMH8QWY	ID	DMH8QWY
DMH8QWY	DN	2-oxo-N-phenyl-2H-chromene-3-carboxamide
DMH8QWY	HS	Investigative
DMH8QWY	SN	2-oxo-N-phenyl-2H-chromene-3-carboxamide; NSC375104; 2-oxo-N-phenylchromene-3-carboxamide; 54396-25-7; AC1L7UQ9; Oprea1_247443; Oprea1_472798; CBDivE_011982; JMC521935 Compound 6; SCHEMBL831792; IFLab1_001129; CHEMBL494795; NIOSH/DJ2267500; Coumarin, 3-(anilinocarbonyl)-; BDBM23543; ZINC42178; DTXSID80321427; MolPort-000-375-218; HMS1415D07; (2-oxochromen-3-yl)-N-benzamide; 3-Carboxamide-coumarin deriv., 18; STK337557; AKOS000511884; 2-oxo-N-phenyl-chromene-3-carboxamide; NSC-375104; MCULE-7275389335; IDI1_008996
DMH8QWY	DT	Small molecular drug
DMH8QWY	PC	341782
DMH8QWY	MW	265.26
DMH8QWY	FM	C16H11NO3
DMH8QWY	IC	InChI=1S/C16H11NO3/c18-15(17-12-7-2-1-3-8-12)13-10-11-6-4-5-9-14(11)20-16(13)19/h1-10H,(H,17,18)
DMH8QWY	CS	C1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMH8QWY	IK	IMFBGZCBLOPVCJ-UHFFFAOYSA-N
DMH8QWY	IU	2-oxo-N-phenylchromene-3-carboxamide
DMH8QWY	CA	CAS 54396-25-7
DMH8QWY	DE	Discovery agent

DMWXI6C	ID	DMWXI6C
DMWXI6C	DN	2-oxo-N-p-tolyl-2H-chromene-3-carboxamide
DMWXI6C	HS	Investigative
DMWXI6C	SN	1847-00-3; N-(4-Methylphenyl)-2-oxo-2H-chromene-3-carboxamide; AC1LCCPS; BAS 00837919; Oprea1_724223; Oprea1_384928; 3-carboxamido coumarin, 12; CBDivE_000120; CHEMBL512843; AC1Q2M91; ZINC59647; BDBM29162; 2h-1-benzopyran-3-carboxamide,n-(4-methylphenyl)-2-oxo-; MolPort-000-375-219; RYYPYTSGWXNKDU-UHFFFAOYSA-N; N-(p-Tolyl)coumarin-3-carboxamide; N-(p-Tolyl)-3-coumarincarboxamide; STK709419; AKOS000533534; MCULE-3147355051; ST4011307; KB-284700; EU-0034745; 2-oxo-N-(p-tolyl)-2H-chromene-3-carboxamide
DMWXI6C	DT	Small molecular drug
DMWXI6C	PC	599290
DMWXI6C	MW	279.29
DMWXI6C	FM	C17H13NO3
DMWXI6C	IC	InChI=1S/C17H13NO3/c1-11-6-8-13(9-7-11)18-16(19)14-10-12-4-2-3-5-15(12)21-17(14)20/h2-10H,1H3,(H,18,19)
DMWXI6C	CS	CC1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMWXI6C	IK	RYYPYTSGWXNKDU-UHFFFAOYSA-N
DMWXI6C	IU	N-(4-methylphenyl)-2-oxochromene-3-carboxamide
DMWXI6C	DE	Discovery agent

DMDMK81	ID	DMDMK81
DMDMK81	DN	2-Oxoolean-12-en-28-oic acid
DMDMK81	HS	Investigative
DMDMK81	SN	CHEMBL1081876; 2-Oxoolean-12-en-28-oic acid; 2-Oxooleana-12-ene-28-oic acid
DMDMK81	DT	Small molecular drug
DMDMK81	PC	44254075
DMDMK81	MW	454.7
DMDMK81	FM	C30H46O3
DMDMK81	IC	InChI=1S/C30H46O3/c1-25(2)12-14-30(24(32)33)15-13-28(6)20(21(30)18-25)8-9-23-27(5)17-19(31)16-26(3,4)22(27)10-11-29(23,28)7/h8,21-23H,9-18H2,1-7H3,(H,32,33)/t21-,22-,23+,27-,28+,29+,30-/m0/s1
DMDMK81	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(CC(=O)CC3(C)C)C
DMDMK81	IK	RHPBUWJZKONKCT-CDNBJWEZSA-N
DMDMK81	IU	(4aS,6aR,6aS,6bR,8aS,12aS,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-11-oxo-3,4,5,6,6a,7,8,8a,10,12,13,14b-dodecahydro-1H-picene-4a-carboxylic acid
DMDMK81	DE	Discovery agent

DMZ9NCA	ID	DMZ9NCA
DMZ9NCA	DN	2-pentafluorophenylamido-5-sulfonamidoindane
DMZ9NCA	HS	Investigative
DMZ9NCA	SN	CHEMBL184361; 2-pentafluorophenylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 12c; BDBM11035
DMZ9NCA	DT	Small molecular drug
DMZ9NCA	PC	11718391
DMZ9NCA	MW	406.3
DMZ9NCA	FM	C16H11F5N2O3S
DMZ9NCA	IC	InChI=1S/C16H11F5N2O3S/c17-11-10(12(18)14(20)15(21)13(11)19)16(24)23-8-3-6-1-2-9(27(22,25)26)5-7(6)4-8/h1-2,5,8H,3-4H2,(H,23,24)(H2,22,25,26)
DMZ9NCA	CS	C1C(CC2=C1C=CC(=C2)S(=O)(=O)N)NC(=O)C3=C(C(=C(C(=C3F)F)F)F)F
DMZ9NCA	IK	DTWDCDSAKWSSGY-UHFFFAOYSA-N
DMZ9NCA	IU	2,3,4,5,6-pentafluoro-N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)benzamide
DMZ9NCA	DE	Discovery agent

DM032YM	ID	DM032YM
DM032YM	DN	2-pentenal
DM032YM	HS	Investigative
DM032YM	SN	trans-2-Pentenal; 2-PENTENAL; 1576-87-0; (E)-2-Pentenal; (E)-pent-2-enal; 3-Ethylacrolein; 764-39-6; pent-2-enal; 2-Pentenal, (E)-; 2-(E)-Pentenal; 3-Ethyl-2-propenal; (E)-Pent-2-en-1-al; gamma-Methylcrotonaldehyde; 2-Penten-1-al; trans-2-Penten-1-al; UNII-7A4R3CQA2T; FEMA No. 3218; CCRIS 3514; CCRIS 4564; Pentenal, (E)-; 2-Ethylacrylic aldehyde; (E)-2-penten-1-al; EINECS 212-120-2; EINECS 216-414-1; BRN 1719742; 7A4R3CQA2T; CHEMBL256368; DTCCTIQRPGSLPT-ONEGZZNKSA-N; MFCD00009615; trans-2-Pentenal, 97%; Propylidenacetaldehyd
DM032YM	DT	Small molecular drug
DM032YM	PC	5364752
DM032YM	MW	84.12
DM032YM	FM	C5H8O
DM032YM	IC	InChI=1S/C5H8O/c1-2-3-4-5-6/h3-5H,2H2,1H3/b4-3+
DM032YM	CS	CC/C=C/C=O
DM032YM	IK	DTCCTIQRPGSLPT-ONEGZZNKSA-N
DM032YM	IU	(E)-pent-2-enal
DM032YM	CA	CAS 1576-87-0
DM032YM	CB	CHEBI:61722
DM032YM	DE	Discovery agent

DM0WMBC	ID	DM0WMBC
DM0WMBC	DN	2-Phenethyl-1,2-dihydro-indazol-3-one
DM0WMBC	HS	Investigative
DM0WMBC	SN	CHEMBL3144586; 2-Phenethyl-1,2-dihydro-indazol-3-one; CHEMBL8415; BDBM50009007; ZINC138045731
DM0WMBC	DT	Small molecular drug
DM0WMBC	PC	14898714
DM0WMBC	MW	238.28
DM0WMBC	FM	C15H14N2O
DM0WMBC	IC	InChI=1S/C15H14N2O/c18-15-13-8-4-5-9-14(13)16-17(15)11-10-12-6-2-1-3-7-12/h1-9,16H,10-11H2
DM0WMBC	CS	C1=CC=C(C=C1)CCN2C(=O)C3=CC=CC=C3N2
DM0WMBC	IK	HCKFBGZZOSOLAC-UHFFFAOYSA-N
DM0WMBC	IU	2-(2-phenylethyl)-1H-indazol-3-one
DM0WMBC	DE	Discovery agent

DM4H6PC	ID	DM4H6PC
DM4H6PC	DN	2-Phenethyl-4,5-dihydro-1H-imidazole
DM4H6PC	HS	Investigative
DM4H6PC	SN	beta-Phenylethylimidazoline; 2-Phenethyl-2-imidazoline; 2-IMIDAZOLINE, 2-PHENETHYL-; BRN 0129593; 1H-Imidazole, 4,5-dihydro-2-(2-phenylethyl)-; 26038-62-0; 2-Phenethyl-4,5-dihydro-1H-imidazole; CHEMBL14210; 2-(beta-Phenylaethyl)imidazolin [German]; Phenyzoline; 2-(beta-Phenylaethyl)imidazolin; 2-Phenethyl-1-imidazoline; AC1L1PA8; 5-23-07-00011 (Beilstein Handbook Reference); SCHEMBL3172677; DTXSID30180682; BDBM50138499; AKOS022535828; LS-79674
DM4H6PC	DT	Small molecular drug
DM4H6PC	PC	33273
DM4H6PC	MW	174.24
DM4H6PC	FM	C11H14N2
DM4H6PC	IC	InChI=1S/C11H14N2/c1-2-4-10(5-3-1)6-7-11-12-8-9-13-11/h1-5H,6-9H2,(H,12,13)
DM4H6PC	CS	C1CN=C(N1)CCC2=CC=CC=C2
DM4H6PC	IK	CPMMXSDLEOJRHI-UHFFFAOYSA-N
DM4H6PC	IU	2-(2-phenylethyl)-4,5-dihydro-1H-imidazole
DM4H6PC	CA	CAS 26038-62-0
DM4H6PC	DE	Discovery agent

DMPWG21	ID	DMPWG21
DMPWG21	DN	2-phenethylisoquinoline-1,3,4-trione
DMPWG21	HS	Investigative
DMPWG21	SN	2-phenethylisoquinoline-1,3,4-trione; CHEMBL382860; SCHEMBL13442858; Isoquinoline-1,3,4-trione 2d; BDBM10251; CTK7H5068; AKOS015966189; 2-PHENETHYL-ISOQUINOLINE-1,3,4-TRIONE
DMPWG21	DT	Small molecular drug
DMPWG21	PC	11652039
DMPWG21	MW	279.29
DMPWG21	FM	C17H13NO3
DMPWG21	IC	InChI=1S/C17H13NO3/c19-15-13-8-4-5-9-14(13)16(20)18(17(15)21)11-10-12-6-2-1-3-7-12/h1-9H,10-11H2
DMPWG21	CS	C1=CC=C(C=C1)CCN2C(=O)C3=CC=CC=C3C(=O)C2=O
DMPWG21	IK	QORWHUYLLGKESS-UHFFFAOYSA-N
DMPWG21	IU	2-(2-phenylethyl)isoquinoline-1,3,4-trione
DMPWG21	DE	Discovery agent

DMQX7FW	ID	DMQX7FW
DMQX7FW	DN	2-phenoxy-1-(2-p-tolylthiazolidin-3-yl)ethanone
DMQX7FW	HS	Investigative
DMQX7FW	SN	CHEMBL217530
DMQX7FW	DT	Small molecular drug
DMQX7FW	PC	44418202
DMQX7FW	MW	313.4
DMQX7FW	FM	C18H19NO2S
DMQX7FW	IC	InChI=1S/C18H19NO2S/c1-14-7-9-15(10-8-14)18-19(11-12-22-18)17(20)13-21-16-5-3-2-4-6-16/h2-10,18H,11-13H2,1H3
DMQX7FW	CS	CC1=CC=C(C=C1)C2N(CCS2)C(=O)COC3=CC=CC=C3
DMQX7FW	IK	MHEJSTGXKATLNP-UHFFFAOYSA-N
DMQX7FW	IU	1-[2-(4-methylphenyl)-1,3-thiazolidin-3-yl]-2-phenoxyethanone
DMQX7FW	DE	Discovery agent

DM6JNT5	ID	DM6JNT5
DM6JNT5	DN	2-phenoxy-3-(piperidin-4-yl)pyridine
DM6JNT5	HS	Investigative
DM6JNT5	SN	CHEMBL608148; 2-phenoxy-3-(piperidin-4-yl)pyridine; SCHEMBL4013368
DM6JNT5	DT	Small molecular drug
DM6JNT5	PC	44133490
DM6JNT5	MW	254.33
DM6JNT5	FM	C16H18N2O
DM6JNT5	IC	InChI=1S/C16H18N2O/c1-2-5-14(6-3-1)19-16-15(7-4-10-18-16)13-8-11-17-12-9-13/h1-7,10,13,17H,8-9,11-12H2
DM6JNT5	CS	C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3
DM6JNT5	IK	LKVOLTSPLLAMPJ-UHFFFAOYSA-N
DM6JNT5	IU	2-phenoxy-3-piperidin-4-ylpyridine
DM6JNT5	DE	Discovery agent

DM5E74G	ID	DM5E74G
DM5E74G	DN	2-Phenoxymethyl-4,5-dihydro-1H-imidazole
DM5E74G	HS	Investigative
DM5E74G	SN	2-(phenoxymethyl)-4,5-dihydro-1H-imidazole; CHEMBL14640; 43111-36-0; SCHEMBL546875; 2-(Phenoxymethyl)-2-imidazoline; BDBM50179395; AKOS006278066; 1H-Imidazole, 4,5-dihydro-2-(phenoxymethyl)-
DM5E74G	DT	Small molecular drug
DM5E74G	PC	10442227
DM5E74G	MW	176.21
DM5E74G	FM	C10H12N2O
DM5E74G	IC	InChI=1S/C10H12N2O/c1-2-4-9(5-3-1)13-8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)
DM5E74G	CS	C1CN=C(N1)COC2=CC=CC=C2
DM5E74G	IK	GRMJZZBFHKTYDJ-UHFFFAOYSA-N
DM5E74G	IU	2-(phenoxymethyl)-4,5-dihydro-1H-imidazole
DM5E74G	CA	CAS 43111-36-0
DM5E74G	DE	Discovery agent

DMERNSK	ID	DMERNSK
DMERNSK	DN	2-phenyl-1,1-di(pyridin-3-yl)ethanol
DMERNSK	HS	Investigative
DMERNSK	SN	CHEMBL1088805; 2-phenyl-1,1-di(pyridin-3-yl)ethanol; SCHEMBL4336663
DMERNSK	DT	Small molecular drug
DMERNSK	PC	46885546
DMERNSK	MW	276.3
DMERNSK	FM	C18H16N2O
DMERNSK	IC	InChI=1S/C18H16N2O/c21-18(16-8-4-10-19-13-16,17-9-5-11-20-14-17)12-15-6-2-1-3-7-15/h1-11,13-14,21H,12H2
DMERNSK	CS	C1=CC=C(C=C1)CC(C2=CN=CC=C2)(C3=CN=CC=C3)O
DMERNSK	IK	ISJDJRMNDVLGMU-UHFFFAOYSA-N
DMERNSK	IU	2-phenyl-1,1-dipyridin-3-ylethanol
DMERNSK	DE	Discovery agent

DM28CLZ	ID	DM28CLZ
DM28CLZ	DN	2-Phenyl-1,2-dihydro-indazol-3-one
DM28CLZ	HS	Investigative
DM28CLZ	SN	3-Indazolinone, 2-phenyl-; 2-phenyl-1H-indazol-3-one; 17049-65-9; MLS-0315919.0001; CHEMBL412902; 2-phenylindazolone; NSC34813; 2-Phenyl-1,2-dihydro-indazol-3-one; 2-phenylindazolin-3-one; 3H-Indazol-3-one, 1,2-dihydro-2-phenyl-; AC1L91HU; cid_411519; SCHEMBL2438599; CHEMBL1719803; BDBM46671; DTXSID20328536; CFNJFZDGHGYAMU-UHFFFAOYSA-N; NSC-34813; ZINC84460115; AKOS023543908; 3H-Indazol-3-one,2-dihydro-2-phenyl-; 1,2-Dihydro-2-phenyl-3H-indazol-3-one; 2-Phenyl-1,2-dihydro-3H-indazol-3-one #
DM28CLZ	DT	Small molecular drug
DM28CLZ	PC	411519
DM28CLZ	MW	210.23
DM28CLZ	FM	C13H10N2O
DM28CLZ	IC	InChI=1S/C13H10N2O/c16-13-11-8-4-5-9-12(11)14-15(13)10-6-2-1-3-7-10/h1-9,14H
DM28CLZ	CS	C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N2
DM28CLZ	IK	CFNJFZDGHGYAMU-UHFFFAOYSA-N
DM28CLZ	IU	2-phenyl-1H-indazol-3-one
DM28CLZ	CA	CAS 17049-65-9
DM28CLZ	DE	Discovery agent

DMP8G3C	ID	DMP8G3C
DMP8G3C	DN	2-phenyl-1,2'-spirobi[1H-indene]-5'-ol
DMP8G3C	HS	Investigative
DMP8G3C	SN	CHEMBL439806; SCHEMBL6283895; BDBM50123212; 2-phenyl-1,2''-spirobi[1H-indene]-5''-ol
DMP8G3C	DT	Small molecular drug
DMP8G3C	PC	12133211
DMP8G3C	MW	310.4
DMP8G3C	FM	C23H18O
DMP8G3C	IC	InChI=1S/C23H18O/c24-20-11-10-18-14-23(15-19(18)12-20)21-9-5-4-8-17(21)13-22(23)16-6-2-1-3-7-16/h1-13,24H,14-15H2
DMP8G3C	CS	C1C2=C(CC13C4=CC=CC=C4C=C3C5=CC=CC=C5)C=C(C=C2)O
DMP8G3C	IK	SGBUUCIHANKAQI-UHFFFAOYSA-N
DMP8G3C	IU	2'-phenylspiro[1,3-dihydroindene-2,1'-indene]-5-ol
DMP8G3C	DE	Discovery agent

DM3WOHI	ID	DM3WOHI
DM3WOHI	DN	2-phenyl-1,8-naphthyridine
DM3WOHI	HS	Investigative
DM3WOHI	SN	2-phenyl-1,8-naphthyridine; CHEMBL235396; SKVWGHJCDNDXAG-UHFFFAOYSA-N; SCHEMBL5309600; 1,8-Naphthyridine, 2-phenyl-; ZINC28826013
DM3WOHI	DT	Small molecular drug
DM3WOHI	PC	12333592
DM3WOHI	MW	206.24
DM3WOHI	FM	C14H10N2
DM3WOHI	IC	InChI=1S/C14H10N2/c1-2-5-11(6-3-1)13-9-8-12-7-4-10-15-14(12)16-13/h1-10H
DM3WOHI	CS	C1=CC=C(C=C1)C2=NC3=C(C=CC=N3)C=C2
DM3WOHI	IK	SKVWGHJCDNDXAG-UHFFFAOYSA-N
DM3WOHI	IU	2-phenyl-1,8-naphthyridine
DM3WOHI	DE	Discovery agent

DMDC6XP	ID	DMDC6XP
DMDC6XP	DN	2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DMDC6XP	HS	Investigative
DMDC6XP	SN	CHEMBL276138; 2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine; ZINC13821064; BDBM50011597
DMDC6XP	DT	Small molecular drug
DMDC6XP	PC	14896622
DMDC6XP	MW	260.29
DMDC6XP	FM	C16H12N4
DMDC6XP	IC	InChI=1S/C16H12N4/c17-15-14-13(11-8-4-5-9-12(11)18-15)19-16(20-14)10-6-2-1-3-7-10/h1-9H,(H2,17,18)(H,19,20)
DMDC6XP	CS	C1=CC=C(C=C1)C2=NC3=C(N2)C(=NC4=CC=CC=C43)N
DMDC6XP	IK	IBRIUJBAFMFSDF-UHFFFAOYSA-N
DMDC6XP	IU	2-phenyl-3H-imidazo[4,5-c]quinolin-4-amine
DMDC6XP	DE	Discovery agent

DMZI7O1	ID	DMZI7O1
DMZI7O1	DN	2-phenyl-1H-imidazole-4-carboxylic acid
DMZI7O1	HS	Investigative
DMZI7O1	SN	2-Phenyl-1H-imidazole-4-carboxylic acid; 77498-98-7; 2-phenyl-1H-imidazole-5-carboxylic acid; 1H-Imidazole-5-carboxylic acid, 2-phenyl-; CHEMBL1232889; 1H-Imidazole-4-carboxylic acid, 2-phenyl-; UNII-HGH57KDY8T; HGH57KDY8T; 2-phenylimidazole-4-carboxylic acid; G14; 2-phenyl-3H-imidazole-4-carboxylic Acid; AC1MC8EL; SCHEMBL1080850; CTK4I4538; CTK2I0991; XCAXKZJNJCKTQH-UHFFFAOYSA-N; MolPort-000-146-264; HMS3604D08; ZINC164985; CS-D0591; ALBB-012261; CP-011; BDBM50329857; STK897779; ANW-57703; AKOS007930827; AKOS005173647; NE61009
DMZI7O1	DT	Small molecular drug
DMZI7O1	PC	2738139
DMZI7O1	MW	188.18
DMZI7O1	FM	C10H8N2O2
DMZI7O1	IC	InChI=1S/C10H8N2O2/c13-10(14)8-6-11-9(12-8)7-4-2-1-3-5-7/h1-6H,(H,11,12)(H,13,14)
DMZI7O1	CS	C1=CC=C(C=C1)C2=NC=C(N2)C(=O)O
DMZI7O1	IK	XCAXKZJNJCKTQH-UHFFFAOYSA-N
DMZI7O1	IU	2-phenyl-1H-imidazole-5-carboxylic acid
DMZI7O1	CA	CAS 77498-98-7
DMZI7O1	DE	Discovery agent

DMRNZ4X	ID	DMRNZ4X
DMRNZ4X	DN	2-phenyl-2,3-dihydrobenzo[h]chromen-4-one
DMRNZ4X	HS	Investigative
DMRNZ4X	SN	ALPHA-NAPHTHOFLAVANONE; 2-phenyl-2H-benzo[h]chromen-4(3H)-one; CHEMBL404225; 6051-86-1; 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one; SCHEMBL14027636; BDBM50345186; FT-0758804; 2-Phenyl-2H-naphtho[1,2-b]pyran-4(3H)-one
DMRNZ4X	DT	Small molecular drug
DMRNZ4X	PC	9898204
DMRNZ4X	MW	274.3
DMRNZ4X	FM	C19H14O2
DMRNZ4X	IC	InChI=1S/C19H14O2/c20-17-12-18(14-7-2-1-3-8-14)21-19-15-9-5-4-6-13(15)10-11-16(17)19/h1-11,18H,12H2
DMRNZ4X	CS	C1C(OC2=C(C1=O)C=CC3=CC=CC=C32)C4=CC=CC=C4
DMRNZ4X	IK	QEVIKVQRCYXXSA-UHFFFAOYSA-N
DMRNZ4X	IU	2-phenyl-2,3-dihydrobenzo[h]chromen-4-one
DMRNZ4X	DE	Discovery agent

DMTSBJL	ID	DMTSBJL
DMTSBJL	DN	2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide
DMTSBJL	HS	Investigative
DMTSBJL	SN	CHEMBL1096560; 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide; SCHEMBL2265205
DMTSBJL	DT	Small molecular drug
DMTSBJL	PC	44549505
DMTSBJL	MW	238.24
DMTSBJL	FM	C13H10N4O
DMTSBJL	IC	InChI=1S/C13H10N4O/c14-13(18)10-7-4-8-11-12(10)16-17(15-11)9-5-2-1-3-6-9/h1-8H,(H2,14,18)
DMTSBJL	CS	C1=CC=C(C=C1)N2N=C3C=CC=C(C3=N2)C(=O)N
DMTSBJL	IK	LALFCNWFYNSGHS-UHFFFAOYSA-N
DMTSBJL	IU	2-phenylbenzotriazole-4-carboxamide
DMTSBJL	DE	Discovery agent

DM8HSMU	ID	DM8HSMU
DM8HSMU	DN	2-phenyl-2H-indazole-7-carboxamide
DM8HSMU	HS	Investigative
DM8HSMU	SN	2-phenyl-2H-indazole-7-carboxamide; CHEMBL594298; SCHEMBL1422404; BDBM50306166
DM8HSMU	DT	Small molecular drug
DM8HSMU	PC	44549251
DM8HSMU	MW	237.26
DM8HSMU	FM	C14H11N3O
DM8HSMU	IC	InChI=1S/C14H11N3O/c15-14(18)12-8-4-5-10-9-17(16-13(10)12)11-6-2-1-3-7-11/h1-9H,(H2,15,18)
DM8HSMU	CS	C1=CC=C(C=C1)N2C=C3C=CC=C(C3=N2)C(=O)N
DM8HSMU	IK	MWXFYWRQDSMARJ-UHFFFAOYSA-N
DM8HSMU	IU	2-phenylindazole-7-carboxamide
DM8HSMU	DE	Discovery agent

DMFE2R1	ID	DMFE2R1
DMFE2R1	DN	2-phenyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DMFE2R1	HS	Investigative
DMFE2R1	SN	2-phenyl-2,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one; 109740-09-2; CHEMBL241987; 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one; 2-phenyl-2H,4H,5H-pyrazolo[3,4-c]quinolin-4-one; AC1NLR9L; AC1Q6GQQ; 2-phenyl-5H-pyrazolo[3,4-c]quinolin-4-one; MLS001176701; SCHEMBL728937; cid_4962866; CTK7H0251; DTXSID10407182; ISMLHIIGSRUCOQ-UHFFFAOYSA-N; MolPort-002-469-503; HMS2920J03; HMS1784C01; ZINC3888482; BDBM50218922; AKOS027391050; NE38059; MCULE-7237346858; SMR000595674; EN300-14160; SR-01000074278; SR-01000074278-1; J-002324
DMFE2R1	DT	Small molecular drug
DMFE2R1	PC	4962866
DMFE2R1	MW	261.279
DMFE2R1	FM	C16H11N3O
DMFE2R1	IC	InChI=1S/C16H11N3O/c20-16-15-13(12-8-4-5-9-14(12)17-16)10-19(18-15)11-6-2-1-3-7-11/h1-10H,(H,17,20)
DMFE2R1	CS	C1=CC=C(C=C1)N2C=C3C4=CC=CC=C4NC(=O)C3=N2
DMFE2R1	IK	ISMLHIIGSRUCOQ-UHFFFAOYSA-N
DMFE2R1	IU	2-phenyl-5H-pyrazolo[3,4-c]quinolin-4-one
DMFE2R1	CA	CAS 109740-09-2
DMFE2R1	DE	Discovery agent

DM5WOSM	ID	DM5WOSM
DM5WOSM	DN	2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DM5WOSM	HS	Investigative
DM5WOSM	SN	CHEMBL320805; 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine; BDBM50091117; 2-Phenyl-2H-pyrazolo[3,4-c]quinoline-4-amine
DM5WOSM	DT	Small molecular drug
DM5WOSM	PC	10491577
DM5WOSM	MW	260.29
DM5WOSM	FM	C16H12N4
DM5WOSM	IC	InChI=1S/C16H12N4/c17-16-15-13(12-8-4-5-9-14(12)18-16)10-20(19-15)11-6-2-1-3-7-11/h1-10H,(H2,17,18)
DM5WOSM	CS	C1=CC=C(C=C1)N2C=C3C4=CC=CC=C4N=C(C3=N2)N
DM5WOSM	IK	MVHJGGYPZDDBQV-UHFFFAOYSA-N
DM5WOSM	IU	2-phenylpyrazolo[3,4-c]quinolin-4-amine
DM5WOSM	DE	Discovery agent

DMAHI7G	ID	DMAHI7G
DMAHI7G	DN	2-Phenyl-2H-pyrazolo[4,3-c]quinoline
DMAHI7G	HS	Investigative
DMAHI7G	SN	2-Phenyl-2H-pyrazolo[4,3-c]quinoline; CHEMBL190111; ZINC13648697
DMAHI7G	DT	Small molecular drug
DMAHI7G	PC	11470612
DMAHI7G	MW	245.28
DMAHI7G	FM	C16H11N3
DMAHI7G	IC	InChI=1S/C16H11N3/c1-2-6-13(7-3-1)19-11-12-10-17-15-9-5-4-8-14(15)16(12)18-19/h1-11H
DMAHI7G	CS	C1=CC=C(C=C1)N2C=C3C=NC4=CC=CC=C4C3=N2
DMAHI7G	IK	GUVLEBBZKMQLIY-UHFFFAOYSA-N
DMAHI7G	IU	2-phenylpyrazolo[4,3-c]quinoline
DMAHI7G	DE	Discovery agent

DMQXCIK	ID	DMQXCIK
DMQXCIK	DN	2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
DMQXCIK	HS	Investigative
DMQXCIK	DT	Small molecular drug
DMQXCIK	PC	135911551
DMQXCIK	MW	212.21
DMQXCIK	FM	C11H8N4O
DMQXCIK	IC	InChI=1S/C11H8N4O/c16-11-10-9(12-7-13-11)6-15(14-10)8-4-2-1-3-5-8/h1-7H,(H,12,13,16)
DMQXCIK	CS	C1=CC=C(C=C1)N2C=C3C(=N2)C(=O)NC=N3
DMQXCIK	IK	OQHWVAQCLKFQMO-UHFFFAOYSA-N
DMQXCIK	IU	2-phenyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DMQXCIK	DE	Discovery agent

DMNXI6D	ID	DMNXI6D
DMNXI6D	DN	2-Phenyl-3-(1-phenyl-ethoxy)-piperidine
DMNXI6D	HS	Investigative
DMNXI6D	SN	CHEMBL103657; 2-Phenyl-3-(1-phenyl-ethoxy)-piperidine
DMNXI6D	DT	Small molecular drug
DMNXI6D	PC	44331715
DMNXI6D	MW	281.4
DMNXI6D	FM	C19H23NO
DMNXI6D	IC	InChI=1S/C19H23NO/c1-15(16-9-4-2-5-10-16)21-18-13-8-14-20-19(18)17-11-6-3-7-12-17/h2-7,9-12,15,18-20H,8,13-14H2,1H3/t15-,18+,19+/m1/s1
DMNXI6D	CS	C[C@H](C1=CC=CC=C1)O[C@H]2CCCN[C@H]2C3=CC=CC=C3
DMNXI6D	IK	FFKDZHIKRMLWQT-MNEFBYGVSA-N
DMNXI6D	IU	(2S,3S)-2-phenyl-3-[(1R)-1-phenylethoxy]piperidine
DMNXI6D	DE	Discovery agent

DM5YC2K	ID	DM5YC2K
DM5YC2K	DN	2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole
DM5YC2K	HS	Investigative
DM5YC2K	SN	CHEMBL91205; 2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole; SCHEMBL7645809; BDBM50095028; 2-Phenyl-3-(2-piperidinoethyl)-1H-indole
DM5YC2K	DT	Small molecular drug
DM5YC2K	PC	9817960
DM5YC2K	MW	304.4
DM5YC2K	FM	C21H24N2
DM5YC2K	IC	InChI=1S/C21H24N2/c1-3-9-17(10-4-1)21-19(13-16-23-14-7-2-8-15-23)18-11-5-6-12-20(18)22-21/h1,3-6,9-12,22H,2,7-8,13-16H2
DM5YC2K	CS	C1CCN(CC1)CCC2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DM5YC2K	IK	FKIIRAHSARSGPF-UHFFFAOYSA-N
DM5YC2K	IU	2-phenyl-3-(2-piperidin-1-ylethyl)-1H-indole
DM5YC2K	DE	Discovery agent

DML9DJP	ID	DML9DJP
DML9DJP	DN	2-Phenyl-3H-imidazo[4,5-c]quinoline
DML9DJP	HS	Investigative
DML9DJP	SN	2-Phenyl-3H-imidazo[4,5-c]quinoline; 3H-Imidazo[4,5-c]quinoline,2-phenyl-; CHEMBL95085; SCHEMBL1423662
DML9DJP	DT	Small molecular drug
DML9DJP	PC	10824264
DML9DJP	MW	245.28
DML9DJP	FM	C16H11N3
DML9DJP	IC	InChI=1S/C16H11N3/c1-2-6-11(7-3-1)16-18-14-10-17-13-9-5-4-8-12(13)15(14)19-16/h1-10H,(H,18,19)
DML9DJP	CS	C1=CC=C(C=C1)C2=NC3=C(N2)C=NC4=CC=CC=C43
DML9DJP	IK	ZGICTZVKFFYIEA-UHFFFAOYSA-N
DML9DJP	IU	2-phenyl-3H-imidazo[4,5-c]quinoline
DML9DJP	DE	Discovery agent

DMY6NIT	ID	DMY6NIT
DMY6NIT	DN	2-Phenyl-3-piperidin-3-yl-1H-indole
DMY6NIT	HS	Investigative
DMY6NIT	SN	CHEMBL42557; 2-Phenyl-3-piperidin-3-yl-1H-indole; 2-phenyl-3-(3-piperidinyl)-1H-Indole; SCHEMBL8525019; BDBM50099262; AKOS022450446; 3-(3-Piperidinyl)-2-phenyl-1H-indole; 244086-74-6; 3-(Piperidin-3-yl)-2-phenyl-1H-indole; DA-07759
DMY6NIT	DT	Small molecular drug
DMY6NIT	PC	9795587
DMY6NIT	MW	276.4
DMY6NIT	FM	C19H20N2
DMY6NIT	IC	InChI=1S/C19H20N2/c1-2-7-14(8-3-1)19-18(15-9-6-12-20-13-15)16-10-4-5-11-17(16)21-19/h1-5,7-8,10-11,15,20-21H,6,9,12-13H2
DMY6NIT	CS	C1CC(CNC1)C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DMY6NIT	IK	FYHCOUIJWCQUMZ-UHFFFAOYSA-N
DMY6NIT	IU	2-phenyl-3-piperidin-3-yl-1H-indole
DMY6NIT	DE	Discovery agent

DMEXZQ5	ID	DMEXZQ5
DMEXZQ5	DN	2-Phenyl-3-piperidin-4-yl-1H-indole
DMEXZQ5	HS	Investigative
DMEXZQ5	SN	221109-26-8; 2-PHENYL-3-(PIPERIDIN-4-YL)-1H-INDOLE; 2-Phenyl-3-(4-piperidinyl)-1H-indole; 2-Phenyl-3-piperidin-4-yl-1H-indole; CHEMBL295559; SCHEMBL7962369; CTK4E8621; DTXSID60432328; FWPAVENSJPMGJO-UHFFFAOYSA-N; ZINC2580888; CP-220; ANW-46494; BDBM50095050; AKOS015898489; AJ-42917; 3-(Piperidin-4-yl)-2-phenyl-1H-indole; 1H-Indole,2-phenyl-3-(4-piperidinyl)-; TC-135239; ST2404535; KB-231980; AX8078102; W4568; FT-0707553; AM20030371; P13451
DMEXZQ5	DT	Small molecular drug
DMEXZQ5	PC	9882067
DMEXZQ5	MW	276.4
DMEXZQ5	FM	C19H20N2
DMEXZQ5	IC	InChI=1S/C19H20N2/c1-2-6-15(7-3-1)19-18(14-10-12-20-13-11-14)16-8-4-5-9-17(16)21-19/h1-9,14,20-21H,10-13H2
DMEXZQ5	CS	C1CNCCC1C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DMEXZQ5	IK	FWPAVENSJPMGJO-UHFFFAOYSA-N
DMEXZQ5	IU	2-phenyl-3-piperidin-4-yl-1H-indole
DMEXZQ5	CA	CAS 221109-26-8
DMEXZQ5	DE	Discovery agent

DMKCOS2	ID	DMKCOS2
DMKCOS2	DN	2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one
DMKCOS2	HS	Investigative
DMKCOS2	SN	CHEMBL10072; 2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one; AC1O1A27; BDBM50111271; 3-[(Z)-4-Pyridinylmethylene]flavanone
DMKCOS2	DT	Small molecular drug
DMKCOS2	PC	6116651
DMKCOS2	MW	313.3
DMKCOS2	FM	C21H15NO2
DMKCOS2	IC	InChI=1S/C21H15NO2/c23-20-17-8-4-5-9-19(17)24-21(16-6-2-1-3-7-16)18(20)14-15-10-12-22-13-11-15/h1-14,21H/b18-14+
DMKCOS2	CS	C1=CC=C(C=C1)C2/C(=C/C3=CC=NC=C3)/C(=O)C4=CC=CC=C4O2
DMKCOS2	IK	YQBABXZFWNTIHJ-NBVRZTHBSA-N
DMKCOS2	IU	(3Z)-2-phenyl-3-(pyridin-4-ylmethylidene)chromen-4-one
DMKCOS2	DE	Discovery agent

DMEXYSP	ID	DMEXYSP
DMEXYSP	DN	2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol
DMEXYSP	HS	Investigative
DMEXYSP	SN	CHEMBL187185; 2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol
DMEXYSP	DT	Small molecular drug
DMEXYSP	PC	44394887
DMEXYSP	MW	293.32
DMEXYSP	FM	C17H15N3O2
DMEXYSP	IC	InChI=1S/C17H15N3O2/c21-13-6-7-14-15(20-11-18-10-19-20)9-16(22-17(14)8-13)12-4-2-1-3-5-12/h1-8,10-11,15-16,21H,9H2
DMEXYSP	CS	C1C(C2=C(C=C(C=C2)O)OC1C3=CC=CC=C3)N4C=NC=N4
DMEXYSP	IK	FDEHVWXURCBTAP-UHFFFAOYSA-N
DMEXYSP	IU	2-phenyl-4-(1,2,4-triazol-1-yl)-3,4-dihydro-2H-chromen-7-ol
DMEXYSP	DE	Discovery agent

DM7A3GO	ID	DM7A3GO
DM7A3GO	DN	2-Phenyl-5-(2-methylthiazol-4ylethynyl)pyridine
DM7A3GO	HS	Investigative
DM7A3GO	SN	CHEMBL184995; 2-Phenyl-5-(2-methylthiazol-4ylethynyl)pyridine; SCHEMBL7419236; BDBM50149801
DM7A3GO	DT	Small molecular drug
DM7A3GO	PC	44392990
DM7A3GO	MW	276.4
DM7A3GO	FM	C17H12N2S
DM7A3GO	IC	InChI=1S/C17H12N2S/c1-13-19-16(12-20-13)9-7-14-8-10-17(18-11-14)15-5-3-2-4-6-15/h2-6,8,10-12H,1H3
DM7A3GO	CS	CC1=NC(=CS1)C#CC2=CN=C(C=C2)C3=CC=CC=C3
DM7A3GO	IK	OUYHNXKLIHUODF-UHFFFAOYSA-N
DM7A3GO	IU	2-methyl-4-[2-(6-phenylpyridin-3-yl)ethynyl]-1,3-thiazole
DM7A3GO	DE	Discovery agent

DMUIYZB	ID	DMUIYZB
DMUIYZB	DN	2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline
DMUIYZB	HS	Investigative
DMUIYZB	DT	Small molecular drug
DMUIYZB	PC	10681942
DMUIYZB	DE	Discovery agent

DMMDS2T	ID	DMMDS2T
DMMDS2T	DN	2-phenyl-5H-indeno[1,2-d]pyrimidine
DMMDS2T	HS	Investigative
DMMDS2T	SN	2-phenyl-5H-indeno[1,2-d]pyrimidine; CHEMBL241206; Aza-heterocyclic Derivative, 3b; SCHEMBL18015923; BDBM19179
DMMDS2T	DT	Small molecular drug
DMMDS2T	PC	10728986
DMMDS2T	MW	244.29
DMMDS2T	FM	C17H12N2
DMMDS2T	IC	InChI=1S/C17H12N2/c1-2-6-12(7-3-1)17-18-11-14-10-13-8-4-5-9-15(13)16(14)19-17/h1-9,11H,10H2
DMMDS2T	CS	C1C2=CC=CC=C2C3=NC(=NC=C31)C4=CC=CC=C4
DMMDS2T	IK	GOMPLLCNQNCUNU-UHFFFAOYSA-N
DMMDS2T	IU	2-phenyl-5H-indeno[1,2-d]pyrimidine
DMMDS2T	DE	Discovery agent

DMA1RHE	ID	DMA1RHE
DMA1RHE	DN	2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMA1RHE	HS	Investigative
DMA1RHE	DT	Small molecular drug
DMA1RHE	PC	10659062
DMA1RHE	DE	Discovery agent

DMY9ERA	ID	DMY9ERA
DMY9ERA	DN	2-Phenyl-6-propyl-chromen-4-one
DMY9ERA	HS	Investigative
DMY9ERA	SN	CHEMBL134539
DMY9ERA	DT	Small molecular drug
DMY9ERA	PC	10858340
DMY9ERA	MW	264.3
DMY9ERA	FM	C18H16O2
DMY9ERA	IC	InChI=1S/C18H16O2/c1-2-6-13-9-10-17-15(11-13)16(19)12-18(20-17)14-7-4-3-5-8-14/h3-5,7-12H,2,6H2,1H3
DMY9ERA	CS	CCCC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3
DMY9ERA	IK	PKMXZOUCSSZIGB-UHFFFAOYSA-N
DMY9ERA	IU	2-phenyl-6-propylchromen-4-one
DMY9ERA	DE	Discovery agent

DMMHSYV	ID	DMMHSYV
DMMHSYV	DN	2-phenyl-9H-indeno[2,1-d]pyrimidine
DMMHSYV	HS	Investigative
DMMHSYV	SN	CHEMBL241205
DMMHSYV	DT	Small molecular drug
DMMHSYV	PC	91895927
DMMHSYV	MW	244.29
DMMHSYV	FM	C17H12N2
DMMHSYV	IC	InChI=1S/C17H12N2/c1-2-6-12(7-3-1)17-18-11-15-14-9-5-4-8-13(14)10-16(15)19-17/h1-11H,(H,18,19)
DMMHSYV	CS	C1=CC=C(C=C1)C2=NC=C3C4=CC=CC=C4C=C3N2
DMMHSYV	IK	INQKEQXZMUIZGI-UHFFFAOYSA-N
DMMHSYV	IU	2-phenyl-1H-indeno[2,1-d]pyrimidine
DMMHSYV	DE	Discovery agent

DM60AJ2	ID	DM60AJ2
DM60AJ2	DN	2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE
DM60AJ2	HS	Investigative
DM60AJ2	SN	31609-42-4; 2-Phenylamino-4-Methyl-5-Acetyl Thiazole; 5-acetyl-4-methyl-2-(phenylamino)thiazole; 2-phenylamino-4-methyl-5-acetylthiazole; CHEMBL1235108; 1-(4-Methyl-2-(phenylamino)thiazol-5-yl)ethanone; 5-Acetyl-4-methyl-2-(phenylamino)-1,3-thiazole; 1-(2-anilino-4-methyl-1,3-thiazol-5-yl)ethanone; Ethanone,1-[4-methyl-2-(phenylamino)-5-thiazolyl]-; 1-[4-methyl-2-(phenylamino)-1,3-thiazol-5-yl]ethanone; 1-[4-methyl-2-(phenylamino)-1,3-thiazol-5-yl]ethan-1-one; 5-acetyl-4-methyl-2-phenylamino-thiazole; 2vba; AC1LEGRW
DM60AJ2	DT	Small molecular drug
DM60AJ2	PC	735838
DM60AJ2	MW	232.3
DM60AJ2	FM	C12H12N2OS
DM60AJ2	IC	InChI=1S/C12H12N2OS/c1-8-11(9(2)15)16-12(13-8)14-10-6-4-3-5-7-10/h3-7H,1-2H3,(H,13,14)
DM60AJ2	CS	CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)C
DM60AJ2	IK	UIIUOFPGDKBCEZ-UHFFFAOYSA-N
DM60AJ2	IU	1-(2-anilino-4-methyl-1,3-thiazol-5-yl)ethanone
DM60AJ2	CA	CAS 31609-42-4
DM60AJ2	DE	Discovery agent

DMW0M14	ID	DMW0M14
DMW0M14	DN	2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine
DMW0M14	HS	Investigative
DMW0M14	DT	Small molecular drug
DMW0M14	PC	448110
DMW0M14	DE	Discovery agent

DMUGH6J	ID	DMUGH6J
DMUGH6J	DN	2-Phenyl-cyclopropylamine hydrochloride
DMUGH6J	HS	Investigative
DMUGH6J	DE	Discovery agent

DMW3F5C	ID	DMW3F5C
DMW3F5C	DN	2-phenylethylyl-adenosine derivative
DMW3F5C	HS	Investigative
DMW3F5C	SN	CHEMBL574602; 2-phenylethylyl-adenosine derivative; GTPL5600; BDBM50299701; N6-Methyl-2-phenylethynyl-5''-N-methylcarboxamidoadenosine
DMW3F5C	DT	Small molecular drug
DMW3F5C	PC	44598833
DMW3F5C	MW	408.4
DMW3F5C	FM	C20H20N6O4
DMW3F5C	IC	InChI=1S/C20H20N6O4/c1-21-17-13-18(25-12(24-17)9-8-11-6-4-3-5-7-11)26(10-23-13)20-15(28)14(27)16(30-20)19(29)22-2/h3-7,10,14-16,20,27-28H,1-2H3,(H,22,29)(H,21,24,25)/t14-,15+,16-,20+/m0/s1
DMW3F5C	CS	CNC1=C2C(=NC(=N1)C#CC3=CC=CC=C3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)C(=O)NC)O)O
DMW3F5C	IK	PAFSPMXSTBOTSN-KSVNGYGVSA-N
DMW3F5C	IU	(2S,3S,4R,5R)-3,4-dihydroxy-N-methyl-5-[6-(methylamino)-2-(2-phenylethynyl)purin-9-yl]oxolane-2-carboxamide
DMW3F5C	DE	Discovery agent

DMNYOH5	ID	DMNYOH5
DMNYOH5	DN	2-phenylethynyl-5,6,7,8-tetrahydro-quinolin-5-ol
DMNYOH5	HS	Investigative
DMNYOH5	SN	CHEMBL253157; 2-phenylethynyl-5,6,7,8-tetrahydro-quinolin-5-ol
DMNYOH5	DT	Small molecular drug
DMNYOH5	PC	24777189
DMNYOH5	MW	249.31
DMNYOH5	FM	C17H15NO
DMNYOH5	IC	InChI=1S/C17H15NO/c19-17-8-4-7-16-15(17)12-11-14(18-16)10-9-13-5-2-1-3-6-13/h1-3,5-6,11-12,17,19H,4,7-8H2
DMNYOH5	CS	C1CC(C2=C(C1)N=C(C=C2)C#CC3=CC=CC=C3)O
DMNYOH5	IK	VUDNTKZUIAXLLZ-UHFFFAOYSA-N
DMNYOH5	IU	2-(2-phenylethynyl)-5,6,7,8-tetrahydroquinolin-5-ol
DMNYOH5	DE	Discovery agent

DM4LCRS	ID	DM4LCRS
DM4LCRS	DN	2-phenylethynyl-5,6,7,8-tetrahydro-quinoline
DM4LCRS	HS	Investigative
DM4LCRS	SN	CHEMBL253160; 2-phenylethynyl-5,6,7,8-tetrahydro-quinoline
DM4LCRS	DT	Small molecular drug
DM4LCRS	PC	24777940
DM4LCRS	MW	233.31
DM4LCRS	FM	C17H15N
DM4LCRS	IC	InChI=1S/C17H15N/c1-2-6-14(7-3-1)10-12-16-13-11-15-8-4-5-9-17(15)18-16/h1-3,6-7,11,13H,4-5,8-9H2
DM4LCRS	CS	C1CCC2=C(C1)C=CC(=N2)C#CC3=CC=CC=C3
DM4LCRS	IK	WGJNWKPVRLKAIF-UHFFFAOYSA-N
DM4LCRS	IU	2-(2-phenylethynyl)-5,6,7,8-tetrahydroquinoline
DM4LCRS	DE	Discovery agent

DMFRQJ3	ID	DMFRQJ3
DMFRQJ3	DN	2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one
DMFRQJ3	HS	Investigative
DMFRQJ3	SN	864224-08-8; 2-(PHENYLETHYNYL)-7,8-DIHYDROQUINOLIN-5(6H)-ONE; CHEMBL252956; 2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one; 5(6H)-Quinolinone, 7,8-dihydro-2-(phenylethynyl)-; SCHEMBL4325876; 2-(2-phenylethynyl)-7,8-dihydro-6H-quinolin-5-one; CTK3C7284; DTXSID10464098; XOUDFZJCSDKXLG-UHFFFAOYSA-N; ZINC28967975; BDBM50231741; AKOS025146642; SC-68865; AK164588; AS-41243; 2-(Phenylethynyl)-7,8-dihydroquinolin-5(6H)-one, 98%
DMFRQJ3	DT	Small molecular drug
DMFRQJ3	PC	11379626
DMFRQJ3	MW	247.29
DMFRQJ3	FM	C17H13NO
DMFRQJ3	IC	InChI=1S/C17H13NO/c19-17-8-4-7-16-15(17)12-11-14(18-16)10-9-13-5-2-1-3-6-13/h1-3,5-6,11-12H,4,7-8H2
DMFRQJ3	CS	C1CC2=C(C=CC(=N2)C#CC3=CC=CC=C3)C(=O)C1
DMFRQJ3	IK	XOUDFZJCSDKXLG-UHFFFAOYSA-N
DMFRQJ3	IU	2-(2-phenylethynyl)-7,8-dihydro-6H-quinolin-5-one
DMFRQJ3	CA	CAS 864224-08-8
DMFRQJ3	DE	Discovery agent

DMPIQTE	ID	DMPIQTE
DMPIQTE	DN	2-Phenylheme
DMPIQTE	HS	Investigative
DMPIQTE	DT	Small molecular drug
DMPIQTE	PC	17753777
DMPIQTE	MW	692.6
DMPIQTE	FM	C40H36FeN4O4
DMPIQTE	IC	InChI=1S/C40H38N4O4.Fe/c1-7-26-21(3)30-18-32-23(5)28(14-16-36(45)46)39(43-32)38(25-12-10-9-11-13-25)40-29(15-17-37(47)48)24(6)33(44-40)20-35-27(8-2)22(4)31(42-35)19-34(26)41-30;/h7-13,18-20H,1-2,14-17H2,3-6H3,(H4,41,42,43,44,45,46,47,48);/q;+2/p-2
DMPIQTE	CS	CC1=C(C2=C(C3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C=C)C)C(=C3CCC(=O)O)C)C6=CC=CC=C6)CCC(=O)O.[Fe+2]
DMPIQTE	IK	FQZJPOQXUNESIK-UHFFFAOYSA-L
DMPIQTE	IU	3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethyl-20-phenylporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)
DMPIQTE	DE	Discovery agent

DMFC3B5	ID	DMFC3B5
DMFC3B5	DN	2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide
DMFC3B5	HS	Investigative
DMFC3B5	SN	2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide; AC1LGHTG; CHEMBL225956; MolPort-002-561-993; MolPort-000-823-043; ZINC17043968; STK536010; AKOS002254375; MCULE-9751182652; 84954-79-0; ST50752086; Benzeneacetamide, N-1,3,4-thiadiazol-2-yl-
DMFC3B5	DT	Small molecular drug
DMFC3B5	PC	821620
DMFC3B5	MW	219.27
DMFC3B5	FM	C10H9N3OS
DMFC3B5	IC	InChI=1S/C10H9N3OS/c14-9(12-10-13-11-7-15-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H,12,13,14)
DMFC3B5	CS	C1=CC=C(C=C1)CC(=O)NC2=NN=CS2
DMFC3B5	IK	VRCPUIHHVMQIHP-UHFFFAOYSA-N
DMFC3B5	IU	2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide
DMFC3B5	DE	Discovery agent

DMNOE0V	ID	DMNOE0V
DMNOE0V	DN	2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide
DMNOE0V	HS	Investigative
DMNOE0V	SN	CHEMBL274763; 2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide; AC1ME6SQ; Oprea1_279909; SCHEMBL4477684; MolPort-001-501-804; IEDWYQQEMKCMSQ-UHFFFAOYSA-N; BDBM50074822; STK047893; AKOS022078440; AKOS003267625; MCULE-5320435270; ST45002516; 2-phenyl-N-(1-phenylethyl)-4-quinolinecarboxamide; (2-phenyl(4-quinolyl))-N-(phenylethyl)carboxamide; 2-Phenyl-quinoline-4-carboxylic acid (1-phenyl-ethyl)amide; 2-Phenyl-quinoline-4-carboxylic acid (1-phenyl-ethyl)-amide
DMNOE0V	DT	Small molecular drug
DMNOE0V	PC	2849628
DMNOE0V	MW	352.4
DMNOE0V	FM	C24H20N2O
DMNOE0V	IC	InChI=1S/C24H20N2O/c1-17(18-10-4-2-5-11-18)25-24(27)21-16-23(19-12-6-3-7-13-19)26-22-15-9-8-14-20(21)22/h2-17H,1H3,(H,25,27)
DMNOE0V	CS	CC(C1=CC=CC=C1)NC(=O)C2=CC(=NC3=CC=CC=C32)C4=CC=CC=C4
DMNOE0V	IK	IEDWYQQEMKCMSQ-UHFFFAOYSA-N
DMNOE0V	IU	2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide
DMNOE0V	DE	Discovery agent

DMEFOV6	ID	DMEFOV6
DMEFOV6	DN	2-phenyl-N-(pyridin-4-yl)quinazolin-4-amine
DMEFOV6	HS	Investigative
DMEFOV6	SN	CHEMBL564660; 2-phenyl-N-(pyridin-4-yl)quinazolin-4-amine; AC1O5DWY; SCHEMBL412953; QGWNGFYEPGNYNY-UHFFFAOYSA-N; MolPort-002-121-406; BDBM50293513; ZINC13633702; STL388203; AKOS003232028; AKOS002341780; MCULE-2242877238; 4-(4-pyridylamino)-2-penyl quinazoline; 4-(4-Pyridvlamino)-2-Phenyl Quinazoline; 4-(4-pyridylamino)-2-phenyl quinazoline
DMEFOV6	DT	Small molecular drug
DMEFOV6	PC	6456587
DMEFOV6	MW	298.3
DMEFOV6	FM	C19H14N4
DMEFOV6	IC	InChI=1S/C19H14N4/c1-2-6-14(7-3-1)18-22-17-9-5-4-8-16(17)19(23-18)21-15-10-12-20-13-11-15/h1-13H,(H,20,21,22,23)
DMEFOV6	CS	C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC=NC=C4
DMEFOV6	IK	QGWNGFYEPGNYNY-UHFFFAOYSA-N
DMEFOV6	IU	2-phenyl-N-pyridin-4-ylquinazolin-4-amine
DMEFOV6	DE	Discovery agent

DMP0NW3	ID	DMP0NW3
DMP0NW3	DN	2-phenyl-N-(thiazol-2-yl)acetamide
DMP0NW3	HS	Investigative
DMP0NW3	SN	2-Phenyl-N-(1,3-thiazol-2-yl)acetamide; 2-Phenyl-N-thiazol-2-yl-acetamide; 292051-66-2; Benzeneacetamide, N-2-thiazolyl-; BAS 15431504; ChemDiv2_003476; AC1LBQ73; MLS001211116; CHEMBL227897; SCHEMBL4687548; ZINC29573; HYRZQLIFVQELLP-UHFFFAOYSA-N; MolPort-001-012-138; HMS2829M16; HMS1378N22; STK012295; AKOS000714854; MCULE-4931151694; ST042627; SMR000516648; 2-Phenyl-N-(1,3-thiazol-2-yl)acetamide #; 2-phenyl-N~1~-(1,3-thiazol-2-yl)acetamide; SR-01000415900; SR-01000415900-1; BRD-K98487211-001-07-7; Z28173686
DMP0NW3	DT	Small molecular drug
DMP0NW3	PC	562362
DMP0NW3	MW	218.28
DMP0NW3	FM	C11H10N2OS
DMP0NW3	IC	InChI=1S/C11H10N2OS/c14-10(13-11-12-6-7-15-11)8-9-4-2-1-3-5-9/h1-7H,8H2,(H,12,13,14)
DMP0NW3	CS	C1=CC=C(C=C1)CC(=O)NC2=NC=CS2
DMP0NW3	IK	HYRZQLIFVQELLP-UHFFFAOYSA-N
DMP0NW3	IU	2-phenyl-N-(1,3-thiazol-2-yl)acetamide
DMP0NW3	DE	Discovery agent

DMMJENF	ID	DMMJENF
DMMJENF	DN	2-phenyl-N,N-bis(o-tolylthiomethyl)ethanamine
DMMJENF	HS	Investigative
DMMJENF	SN	CHEMBL398687; AC1MRYJJ; 2-phenyl-N,N-bis(o-tolylthiomethyl)ethanamine; BDBM50232470
DMMJENF	DT	Small molecular drug
DMMJENF	PC	3575822
DMMJENF	MW	393.6
DMMJENF	FM	C24H27NS2
DMMJENF	IC	InChI=1S/C24H27NS2/c1-20-10-6-8-14-23(20)26-18-25(17-16-22-12-4-3-5-13-22)19-27-24-15-9-7-11-21(24)2/h3-15H,16-19H2,1-2H3
DMMJENF	CS	CC1=CC=CC=C1SCN(CCC2=CC=CC=C2)CSC3=CC=CC=C3C
DMMJENF	IK	XPJBCYSDRUCTBK-UHFFFAOYSA-N
DMMJENF	IU	N,N-bis[(2-methylphenyl)sulfanylmethyl]-2-phenylethanamine
DMMJENF	DE	Discovery agent

DM7OHSX	ID	DM7OHSX
DM7OHSX	DN	2-phenylpiperidine hydrochloride
DM7OHSX	HS	Investigative
DM7OHSX	SN	2-Phenylpiperidine; 3466-80-6; 2-phenyl-piperidine; Piperidine, 2-phenyl-; 2-phenyl piperidine; EINECS 222-422-6; PubChem8019; (Piperidin-2-yl)benzene; ACMC-1AG1G; AC1L2U2P; AC1Q1H0F; SCHEMBL938781; SCHEMBL11523711; CTK1C4792; MolPort-000-147-784; WGIAUTGOUJDVEI-UHFFFAOYSA-N; KS-00000N7T; ALBB-006245; SBB022661; STK312087; BBL022420; AKOS000184053; AKOS016344001; FS-1688; MCULE-8351203351; ACN-027346; KB-84880; AM803744; SC-48762; TR-014336; ST2404539; AB0089977; ST45091094; P2005; BB 0254270; A6090; FT-0656912; CS-0028391; K-7884; J-019700
DM7OHSX	DT	Small molecular drug
DM7OHSX	PC	17814274
DM7OHSX	MW	197.7
DM7OHSX	FM	C11H16ClN
DM7OHSX	IC	InChI=1S/C11H15N.ClH/c1-2-6-10(7-3-1)11-8-4-5-9-12-11;/h1-3,6-7,11-12H,4-5,8-9H2;1H
DM7OHSX	CS	C1CCNC(C1)C2=CC=CC=C2.Cl
DM7OHSX	IK	YNQTWZUWWFUKSN-UHFFFAOYSA-N
DM7OHSX	IU	2-phenylpiperidine;hydrochloride
DM7OHSX	CA	CAS 3466-81-7
DM7OHSX	DE	Discovery agent

DMZQCEP	ID	DMZQCEP
DMZQCEP	DN	2-phenylpropoxyadenosine
DMZQCEP	HS	Investigative
DMZQCEP	SN	2-phenylpropoxyadenosine; CHEMBL374151; Adenosine, 2-(3-phenylpropoxy)-; SCHEMBL8110831; 2-(3-Phenylpropyloxy)adenosine; CTK0C0845; 131865-80-0; BDBM50208810
DMZQCEP	DT	Small molecular drug
DMZQCEP	PC	14842885
DMZQCEP	MW	401.4
DMZQCEP	FM	C19H23N5O5
DMZQCEP	IC	InChI=1S/C19H23N5O5/c20-16-13-17(24(10-21-13)18-15(27)14(26)12(9-25)29-18)23-19(22-16)28-8-4-7-11-5-2-1-3-6-11/h1-3,5-6,10,12,14-15,18,25-27H,4,7-9H2,(H2,20,22,23)/t12-,14-,15-,18-/m1/s1
DMZQCEP	CS	C1=CC=C(C=C1)CCCOC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DMZQCEP	IK	UDWLAWJOABGYPL-SCFUHWHPSA-N
DMZQCEP	IU	(2R,3R,4S,5R)-2-[6-amino-2-(3-phenylpropoxy)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMZQCEP	DE	Discovery agent

DM64JE8	ID	DM64JE8
DM64JE8	DN	2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide
DM64JE8	HS	Investigative
DM64JE8	SN	2-phenylpyrazolo[1,5-a]pyridine-7-carboxamide; 1196713-16-2; ZINC64337832; DA-47424
DM64JE8	DT	Small molecular drug
DM64JE8	PC	49799912
DM64JE8	MW	243.3
DM64JE8	FM	C14H17N3O
DM64JE8	IC	InChI=1S/C14H17N3O/c15-14(18)13-8-4-7-11-9-12(16-17(11)13)10-5-2-1-3-6-10/h4,7-10H,1-3,5-6H2,(H2,15,18)
DM64JE8	CS	C1CCC(CC1)C2=NN3C(=C2)C=CC=C3C(=O)N
DM64JE8	IK	YQKBVCBRJDUULG-UHFFFAOYSA-N
DM64JE8	IU	2-cyclohexylpyrazolo[1,5-a]pyridine-7-carboxamide
DM64JE8	DE	Discovery agent

DMAENRQ	ID	DMAENRQ
DMAENRQ	DN	2-phenylquinoline-8-carboxamide
DMAENRQ	HS	Investigative
DMAENRQ	SN	2-phenylquinoline-8-carboxamide; CHEMBL480429; SCHEMBL6442515; ZINC3939668
DMAENRQ	DT	Small molecular drug
DMAENRQ	PC	44156952
DMAENRQ	MW	248.28
DMAENRQ	FM	C16H12N2O
DMAENRQ	IC	InChI=1S/C16H12N2O/c17-16(19)13-8-4-7-12-9-10-14(18-15(12)13)11-5-2-1-3-6-11/h1-10H,(H2,17,19)
DMAENRQ	CS	C1=CC=C(C=C1)C2=NC3=C(C=CC=C3C(=O)N)C=C2
DMAENRQ	IK	BNQJEMTZUOVMLM-UHFFFAOYSA-N
DMAENRQ	IU	2-phenylquinoline-8-carboxamide
DMAENRQ	DE	Discovery agent

DMX6GH5	ID	DMX6GH5
DMX6GH5	DN	2-Phosphoglyceric Acid
DMX6GH5	HS	Investigative
DMX6GH5	SN	2-Phospho-D-Glyceric Acid; D-Glycerate 2-phosphate; 2-phospho-D-glycerate; 2-phosphoglyceric acid; (2R)-3-hydroxy-2-(phosphonooxy)propanoic acid; 3-D-Hydroxy-2-phosphonooxy-propanoic acid; 2-phospho-(R)-glycerate; Glyceric acid-2-phosphate; D(+)2-Phosphoglyceric acid; SCHEMBL2726719; CTK1B7706; CHEBI:17835; GXIURPTVHJPJLF-UWTATZPHSA-N; 1-Carboxy-2-hydroxyethyl phosphate; AC1L9718; ZINC3869232; 3443-57-0; 2PG; 3-D-Hydroxy-2-phosphonooxy-propanoate; DB01709; (2R)-3-hydroxy-2-(phosphonooxy)propanoate
DMX6GH5	DT	Small molecular drug
DMX6GH5	PC	59
DMX6GH5	MW	186.06
DMX6GH5	FM	C3H7O7P
DMX6GH5	IC	InChI=1S/C3H7O7P/c4-1-2(3(5)6)10-11(7,8)9/h2,4H,1H2,(H,5,6)(H2,7,8,9)
DMX6GH5	CS	C(C(C(=O)O)OP(=O)(O)O)O
DMX6GH5	IK	GXIURPTVHJPJLF-UHFFFAOYSA-N
DMX6GH5	IU	3-hydroxy-2-phosphonooxypropanoic acid
DMX6GH5	CA	CAS 2553-59-5
DMX6GH5	CB	CHEBI:24344
DMX6GH5	DE	Discovery agent

DMO14NH	ID	DMO14NH
DMO14NH	DN	2-Phosphoglycolic Acid
DMO14NH	HS	Investigative
DMO14NH	SN	Phosphoglycolic acid; 2-Phosphoglycolic Acid; phosphoglycolate; (Phosphonooxy)acetic acid; 13147-57-4; Glycophosphoric acid; acetic acid, (phosphonooxy)-; UNII-H8593JOP13; 2-phosphoglycolate; Glycolic acid phosphate; CHEBI:17150; H8593JOP13; 2-phosphonatoglycolate; (phosphonooxy)essigs; Glycophosphorate; 1hti; 1lyx; 1egh; 2ypi; 1pdz; 1lzo; EINECS 236-084-2; (Phosphonooxy)acetate; Phosphonooxyacetic acid; (phosphonooxy)-acetate; 1kv5; 1ml1; 1aw1; 2-phosphonooxyacetic acid; Glycolic acid-2-phosphate; (phosphonooxy)-acetic acid; AC1Q6RY7
DMO14NH	DT	Small molecular drug
DMO14NH	PC	529
DMO14NH	MW	156.03
DMO14NH	FM	C2H5O6P
DMO14NH	IC	InChI=1S/C2H5O6P/c3-2(4)1-8-9(5,6)7/h1H2,(H,3,4)(H2,5,6,7)
DMO14NH	CS	C(C(=O)O)OP(=O)(O)O
DMO14NH	IK	ASCFNMCAHFUBCO-UHFFFAOYSA-N
DMO14NH	IU	2-phosphonooxyacetic acid
DMO14NH	CA	CAS 13147-57-4
DMO14NH	CB	CHEBI:17150
DMO14NH	DE	Discovery agent

DMM05AO	ID	DMM05AO
DMM05AO	DN	2-Phosphonooxy-pentanedioic acid
DMM05AO	HS	Investigative
DMM05AO	SN	2-Phosphonooxy-pentanedioic acid; CHEMBL302413; 2-phosphonopentanedioic Acid; SCHEMBL2201753; BDBM50127620
DMM05AO	DT	Small molecular drug
DMM05AO	PC	11020196
DMM05AO	MW	212.09
DMM05AO	FM	C5H9O7P
DMM05AO	IC	InChI=1S/C5H9O7P/c6-4(7)2-1-3(5(8)9)13(10,11)12/h3H,1-2H2,(H,6,7)(H,8,9)(H2,10,11,12)
DMM05AO	CS	C(CC(=O)O)C(C(=O)O)P(=O)(O)O
DMM05AO	IK	HHRBAERKINHBJK-UHFFFAOYSA-N
DMM05AO	IU	2-phosphonopentanedioic acid
DMM05AO	DE	Discovery agent

DM742IJ	ID	DM742IJ
DM742IJ	DN	2-Piperazin-1-yl-benzonitrile
DM742IJ	HS	Investigative
DM742IJ	SN	1-(2-Cyanophenyl)piperazine; 111373-03-6; 2-(piperazin-1-yl)benzonitrile; 2-piperazin-1-ylbenzonitrile; 2-(1-Piperazino)benzonitrile; Benzonitrile, 2-(1-piperazinyl)-; 2-Piperazin-1-yl-benzonitrile; 1-(2-Cyanophenyl)-piperazine; 2-(1-piperazinyl)benzonitrile; CHEMBL275943; 2-piperazinylbenzenecarbonitrile; PubChem9347; 2-Piperazinobenzonitrile; AC1MC4BA; AC1Q4R0F; (2-cyano-phenyl)-piperazine; KSC491G1H; SCHEMBL233169; 1-(2-cyanophenyl) piperazine; ACMC-20999f; 1-(2-cyano phenyl) piperazine; Jsp000853
DM742IJ	DT	Small molecular drug
DM742IJ	PC	2735875
DM742IJ	MW	187.24
DM742IJ	FM	C11H13N3
DM742IJ	IC	InChI=1S/C11H13N3/c12-9-10-3-1-2-4-11(10)14-7-5-13-6-8-14/h1-4,13H,5-8H2
DM742IJ	CS	C1CN(CCN1)C2=CC=CC=C2C#N
DM742IJ	IK	FRICBZWJFIRJOB-UHFFFAOYSA-N
DM742IJ	IU	2-piperazin-1-ylbenzonitrile
DM742IJ	CA	CAS 111373-03-6
DM742IJ	DE	Discovery agent

DMQT9OK	ID	DMQT9OK
DMQT9OK	DN	2-Piperazin-1-yl-phenol
DMQT9OK	HS	Investigative
DMQT9OK	SN	1011-17-2; 2-(piperazin-1-yl)phenol; 1-(2-Hydroxyphenyl)piperazine; 2-(1-piperazinyl)phenol; 2-(1-Piperazino)phenol; 2-piperazin-1-ylphenol; Phenol, 2-(1-piperazinyl)-; o-(1-Piperazinyl)phenol; 2-Piperazin-1-yl-phenol; n-(2-hydroxyphenyl)piperazine; 1-(2-Hydroxyphenyl)-piperazine; CHEMBL266250; 2-piperazinylphenol; EINECS 213-782-5; 2-Piperazinophenol; rarechem ah ck 0117; ACMC-209v6m; 2-(1-piperazinyl) phenol; AC1L2EA8; AC1Q7AO1; 2-(piperazine-1-yl)phenol; Oprea1_446736; labotest-bb lt01596124; SCHEMBL531748; AC1Q788T
DMQT9OK	DT	Small molecular drug
DMQT9OK	PC	70530
DMQT9OK	MW	178.23
DMQT9OK	FM	C10H14N2O
DMQT9OK	IC	InChI=1S/C10H14N2O/c13-10-4-2-1-3-9(10)12-7-5-11-6-8-12/h1-4,11,13H,5-8H2
DMQT9OK	CS	C1CN(CCN1)C2=CC=CC=C2O
DMQT9OK	IK	UORNTHBBLYBAJJ-UHFFFAOYSA-N
DMQT9OK	IU	2-piperazin-1-ylphenol
DMQT9OK	CA	CAS 1011-17-2
DMQT9OK	DE	Discovery agent

DM27GZC	ID	DM27GZC
DM27GZC	DN	2-PMPA
DM27GZC	HS	Investigative
DM27GZC	SN	2-(Phosphonomethyl)pentanedioic acid; 2-(phosphonomethyl)pentanedioic acid; 173039-10-6; PMPA (NAALADase inhibitor); CHEMBL47009; 2-(PHOSPHONOMETHYL)-PENTANEDIOIC ACID; PMPA(NAALADaseinhibitor); 2-PMPA(NAALADaseinhibitor); SCHEMBL383173; BDBM17659; KS-00001CPM; CTK0E4395; DTXSID90436036; MolPort-023-276-085; ISEYJGQFXSTPMQ-UHFFFAOYSA-N; HMS3267D10; 2-Phosphonomethyl-pentanedioic acid; EX-A1248; pentanedioic acid analogue, (RS)-1; ANW-62579; AKOS016004257; API0001123; 2-PMPA, &gt; MP-2042; CS-6202; Pentanedioic acid, 2-(phosphonomethyl)-
DM27GZC	DT	Small molecular drug
DM27GZC	PC	10130754
DM27GZC	MW	226.12
DM27GZC	FM	C6H11O7P
DM27GZC	IC	InChI=1S/C6H11O7P/c7-5(8)2-1-4(6(9)10)3-14(11,12)13/h4H,1-3H2,(H,7,8)(H,9,10)(H2,11,12,13)
DM27GZC	CS	C(CC(=O)O)C(CP(=O)(O)O)C(=O)O
DM27GZC	IK	ISEYJGQFXSTPMQ-UHFFFAOYSA-N
DM27GZC	IU	2-(phosphonomethyl)pentanedioic acid
DM27GZC	CA	CAS 173039-10-6
DM27GZC	DE	Discovery agent

DML5O0H	ID	DML5O0H
DML5O0H	DN	2-Propanol, Isopropanol
DML5O0H	HS	Investigative
DML5O0H	SN	Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand; Isopropyl Alcohol
DML5O0H	DT	Small molecular drug
DML5O0H	PC	3776
DML5O0H	MW	60.1
DML5O0H	FM	C3H8O
DML5O0H	IC	InChI=1S/C3H8O/c1-3(2)4/h3-4H,1-2H3
DML5O0H	CS	CC(C)O
DML5O0H	IK	KFZMGEQAYNKOFK-UHFFFAOYSA-N
DML5O0H	IU	propan-2-ol
DML5O0H	CA	CAS 67-63-0
DML5O0H	CB	CHEBI:17824
DML5O0H	DE	Discovery agent

DMORG3D	ID	DMORG3D
DMORG3D	DN	2-Propionyl-1H-indole-6-carboxamidine
DMORG3D	HS	Investigative
DMORG3D	SN	CHEMBL321960; 2-Propionyl-1H-indole-6-carboxamidine
DMORG3D	DT	Small molecular drug
DMORG3D	PC	44331573
DMORG3D	MW	215.25
DMORG3D	FM	C12H13N3O
DMORG3D	IC	InChI=1S/C12H13N3O/c1-2-11(16)10-5-7-3-4-8(12(13)14)6-9(7)15-10/h3-6,15H,2H2,1H3,(H3,13,14)
DMORG3D	CS	CCC(=O)C1=CC2=C(N1)C=C(C=C2)C(=N)N
DMORG3D	IK	MUIPXQPVWYRDNF-UHFFFAOYSA-N
DMORG3D	IU	2-propanoyl-1H-indole-6-carboximidamide
DMORG3D	DE	Discovery agent

DMP8J7E	ID	DMP8J7E
DMP8J7E	DN	2-Propionyl-cyclohexane-1,3-dione
DMP8J7E	HS	Investigative
DMP8J7E	SN	CHEMBL166694; 104775-30-6; 2-Propionyl-cyclohexane-1,3-dione; 1,3-Cyclohexanedione, 2-(1-oxopropyl)-; SCHEMBL8639644; DTXSID50448337; DVLHCJHTXAHANV-UHFFFAOYSA-N; 2-Propanoyl-1,3-cyclohexanedione; 2-propionylcyclohexane-1,3-dione; BDBM50088802; AKOS006243102
DMP8J7E	DT	Small molecular drug
DMP8J7E	PC	10920903
DMP8J7E	MW	168.19
DMP8J7E	FM	C9H12O3
DMP8J7E	IC	InChI=1S/C9H12O3/c1-2-6(10)9-7(11)4-3-5-8(9)12/h9H,2-5H2,1H3
DMP8J7E	CS	CCC(=O)C1C(=O)CCCC1=O
DMP8J7E	IK	DVLHCJHTXAHANV-UHFFFAOYSA-N
DMP8J7E	IU	2-propanoylcyclohexane-1,3-dione
DMP8J7E	CA	CAS 104775-30-6
DMP8J7E	DE	Discovery agent

DMG0I25	ID	DMG0I25
DMG0I25	DN	2-propylamido-5-sulfonamidoindane
DMG0I25	HS	Investigative
DMG0I25	SN	CHEMBL205743; 2-propylamido-5-sulfonamidoindane; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)butanamide; Indanesulfonamide Derivative 12e
DMG0I25	DT	Small molecular drug
DMG0I25	PC	11536481
DMG0I25	MW	282.36
DMG0I25	FM	C13H18N2O3S
DMG0I25	IC	InChI=1S/C13H18N2O3S/c1-2-3-13(16)15-11-6-9-4-5-12(19(14,17)18)8-10(9)7-11/h4-5,8,11H,2-3,6-7H2,1H3,(H,15,16)(H2,14,17,18)
DMG0I25	CS	CCCC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DMG0I25	IK	ZTRWXFFYFBYLJU-UHFFFAOYSA-N
DMG0I25	IU	N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)butanamide
DMG0I25	DE	Discovery agent

DMBW6GA	ID	DMBW6GA
DMBW6GA	DN	2-Propyl-beta-carboline-2-ium iodide
DMBW6GA	HS	Investigative
DMBW6GA	SN	CHEMBL1088723
DMBW6GA	DT	Small molecular drug
DMBW6GA	PC	44725473
DMBW6GA	MW	211.28
DMBW6GA	FM	C14H15N2+
DMBW6GA	IC	InChI=1S/C14H14N2/c1-2-8-16-9-7-12-11-5-3-4-6-13(11)15-14(12)10-16/h3-7,9-10H,2,8H2,1H3/p+1
DMBW6GA	CS	CCC[N+]1=CC2=C(C=C1)C3=CC=CC=C3N2
DMBW6GA	IK	SFUAYJFEBSOZSQ-UHFFFAOYSA-O
DMBW6GA	IU	2-propyl-9H-pyrido[3,4-b]indol-2-ium
DMBW6GA	DE	Discovery agent

DM1L7PN	ID	DM1L7PN
DM1L7PN	DN	2-Propyl-pentanoic acid 4-sulfamoyl-benzyl ester
DM1L7PN	HS	Investigative
DM1L7PN	SN	CHEMBL107722; 2-Propyl-pentanoic acid 4-sulfamoyl-benzyl ester; BDBM50108587; ZINC13471991; 2-Propylvaleric acid 4-sulfamoylbenzyl ester
DM1L7PN	DT	Small molecular drug
DM1L7PN	PC	10881548
DM1L7PN	MW	313.4
DM1L7PN	FM	C15H23NO4S
DM1L7PN	IC	InChI=1S/C15H23NO4S/c1-3-5-13(6-4-2)15(17)20-11-12-7-9-14(10-8-12)21(16,18)19/h7-10,13H,3-6,11H2,1-2H3,(H2,16,18,19)
DM1L7PN	CS	CCCC(CCC)C(=O)OCC1=CC=C(C=C1)S(=O)(=O)N
DM1L7PN	IK	MSITXBOMUACCFV-UHFFFAOYSA-N
DM1L7PN	IU	(4-sulfamoylphenyl)methyl 2-propylpentanoate
DM1L7PN	DE	Discovery agent

DMVWUME	ID	DMVWUME
DMVWUME	DN	2-Propyl-pentanoic acid 4-sulfamoyl-benzylamide
DMVWUME	HS	Investigative
DMVWUME	SN	CHEMBL432626; 4-(Valproylamide)-Benzyl Sulfonamide; 2-Propyl-pentanoic acid 4-sulfamoyl-benzylamide; ZINC13471978; BDBM50108562
DMVWUME	DT	Small molecular drug
DMVWUME	PC	10946908
DMVWUME	MW	312.4
DMVWUME	FM	C15H24N2O3S
DMVWUME	IC	InChI=1S/C15H24N2O3S/c1-3-5-13(6-4-2)15(18)17-11-12-7-9-14(10-8-12)21(16,19)20/h7-10,13H,3-6,11H2,1-2H3,(H,17,18)(H2,16,19,20)
DMVWUME	CS	CCCC(CCC)C(=O)NCC1=CC=C(C=C1)S(=O)(=O)N
DMVWUME	IK	VQEFALSVKDRQBJ-UHFFFAOYSA-N
DMVWUME	IU	2-propyl-N-[(4-sulfamoylphenyl)methyl]pentanamide
DMVWUME	DE	Discovery agent

DM1NK2M	ID	DM1NK2M
DM1NK2M	DN	2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM1NK2M	HS	Investigative
DM1NK2M	SN	CHEMBL242202; 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one; BDBM50218920; 2-p-Tolyl-2,5-dihydro-pyrazolo[3,4-c]quinolin-4-one
DM1NK2M	DT	Small molecular drug
DM1NK2M	PC	10731097
DM1NK2M	MW	275.3
DM1NK2M	FM	C17H13N3O
DM1NK2M	IC	InChI=1S/C17H13N3O/c1-11-6-8-12(9-7-11)20-10-14-13-4-2-3-5-15(13)18-17(21)16(14)19-20/h2-10H,1H3,(H,18,21)
DM1NK2M	CS	CC1=CC=C(C=C1)N2C=C3C4=CC=CC=C4NC(=O)C3=N2
DM1NK2M	IK	KTONIIHJBREXRC-UHFFFAOYSA-N
DM1NK2M	IU	2-(4-methylphenyl)-5H-pyrazolo[3,4-c]quinolin-4-one
DM1NK2M	DE	Discovery agent

DM9MIC5	ID	DM9MIC5
DM9MIC5	DN	2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DM9MIC5	HS	Investigative
DM9MIC5	SN	CHEMBL106346; 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine; BDBM50091144; 2-p-Tolyl-2H-pyrazolo[3,4-c]quinolin-4-ylamine
DM9MIC5	DT	Small molecular drug
DM9MIC5	PC	10754789
DM9MIC5	MW	274.32
DM9MIC5	FM	C17H14N4
DM9MIC5	IC	InChI=1S/C17H14N4/c1-11-6-8-12(9-7-11)21-10-14-13-4-2-3-5-15(13)19-17(18)16(14)20-21/h2-10H,1H3,(H2,18,19)
DM9MIC5	CS	CC1=CC=C(C=C1)N2C=C3C4=CC=CC=C4N=C(C3=N2)N
DM9MIC5	IK	XVEJYBYRDZTECS-UHFFFAOYSA-N
DM9MIC5	IU	2-(4-methylphenyl)pyrazolo[3,4-c]quinolin-4-amine
DM9MIC5	DE	Discovery agent

DM37S5C	ID	DM37S5C
DM37S5C	DN	2-p-tolyl-4,5-dihydro-1H-imidazole
DM37S5C	HS	Investigative
DM37S5C	DE	Discovery agent

DMFWA9Y	ID	DMFWA9Y
DMFWA9Y	DN	2-p-tolyl-4H-chromen-4-one
DMFWA9Y	HS	Investigative
DMFWA9Y	SN	4'-Methylflavone; 2-(4-methylphenyl)-4H-chromen-4-one; 2-(4-methylphenyl)chromen-4-one; 2-p-Tolyl-chromen-4-one; CHEMBL16861; 2-p-tolyl-4H-chromen-4-one; 4'-Methylflavon; 4hlk; AC1LEMVU; Maybridge3_003060; Oprea1_528340; Oprea1_754899; 2-(p-tolyl)-chromen-4-one; SCHEMBL7593917; ZINC57876; MolPort-000-648-141; OPHKKQQCOYMLPW-UHFFFAOYSA-N; HMS1439L02; BDBM50310190; AKOS000603601; MCULE-3669298263; IDI1_014447; 41255-30-5; ST093690; BAS 01121718; NS-00120; 4H-1-Benzopyran-4-one, 2-(4-methylphenyl)-; AG-690/13115015
DMFWA9Y	DT	Small molecular drug
DMFWA9Y	PC	688829
DMFWA9Y	MW	236.26
DMFWA9Y	FM	C16H12O2
DMFWA9Y	IC	InChI=1S/C16H12O2/c1-11-6-8-12(9-7-11)16-10-14(17)13-4-2-3-5-15(13)18-16/h2-10H,1H3
DMFWA9Y	CS	CC1=CC=C(C=C1)C2=CC(=O)C3=CC=CC=C3O2
DMFWA9Y	IK	OPHKKQQCOYMLPW-UHFFFAOYSA-N
DMFWA9Y	IU	2-(4-methylphenyl)chromen-4-one
DMFWA9Y	DE	Discovery agent

DM2HKCM	ID	DM2HKCM
DM2HKCM	DN	2-p-tolyl-4H-chromene-4-thione
DM2HKCM	HS	Investigative
DM2HKCM	SN	CHEMBL582494; 2-p-tolyl-4H-chromene-4-thione; 4'-methylthioflavone; BDBM50310183
DM2HKCM	DT	Small molecular drug
DM2HKCM	PC	15352647
DM2HKCM	MW	252.3
DM2HKCM	FM	C16H12OS
DM2HKCM	IC	InChI=1S/C16H12OS/c1-11-6-8-12(9-7-11)15-10-16(18)13-4-2-3-5-14(13)17-15/h2-10H,1H3
DM2HKCM	CS	CC1=CC=C(C=C1)C2=CC(=S)C3=CC=CC=C3O2
DM2HKCM	IK	PUUXSOGZGHKVIT-UHFFFAOYSA-N
DM2HKCM	IU	2-(4-methylphenyl)chromene-4-thione
DM2HKCM	DE	Discovery agent

DMJIVL3	ID	DMJIVL3
DMJIVL3	DN	2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMJIVL3	HS	Investigative
DMJIVL3	DT	Small molecular drug
DMJIVL3	PC	135504122
DMJIVL3	MW	275.3
DMJIVL3	FM	C17H13N3O
DMJIVL3	IC	InChI=1S/C17H13N3O/c1-11-6-8-12(9-7-11)15-10-16-13-4-2-3-5-14(13)18-17(21)20(16)19-15/h2-10H,1H3,(H,18,21)
DMJIVL3	CS	CC1=CC=C(C=C1)C2=NN3C(=C2)C4=CC=CC=C4NC3=O
DMJIVL3	IK	MEMISOHEHYPPHH-UHFFFAOYSA-N
DMJIVL3	IU	2-(4-methylphenyl)-6H-pyrazolo[1,5-c]quinazolin-5-one
DMJIVL3	DE	Discovery agent

DMLCDZN	ID	DMLCDZN
DMLCDZN	DN	2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMLCDZN	HS	Investigative
DMLCDZN	DT	Small molecular drug
DMLCDZN	PC	135433795
DMLCDZN	MW	262.27
DMLCDZN	FM	C15H10N4O
DMLCDZN	IC	InChI=1S/C15H10N4O/c20-15-17-11-6-2-1-5-10(11)14-9-13(18-19(14)15)12-7-3-4-8-16-12/h1-9H,(H,17,20)
DMLCDZN	CS	C1=CC=C2C(=C1)C3=CC(=NN3C(=O)N2)C4=CC=CC=N4
DMLCDZN	IK	YUDPHONPFGCUGC-UHFFFAOYSA-N
DMLCDZN	IU	2-pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMLCDZN	DE	Discovery agent

DMAS46B	ID	DMAS46B
DMAS46B	DN	2-Pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one
DMAS46B	HS	Investigative
DMAS46B	SN	CHEMBL3144580; CHEMBL8231; 2-Pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one; BDBM50009010; ZINC107084651; AKOS023543918
DMAS46B	DT	Small molecular drug
DMAS46B	PC	14898722
DMAS46B	MW	225.25
DMAS46B	FM	C13H11N3O
DMAS46B	IC	InChI=1S/C13H11N3O/c17-13-11-6-1-2-7-12(11)15-16(13)9-10-5-3-4-8-14-10/h1-8,15H,9H2
DMAS46B	CS	C1=CC=C2C(=C1)C(=O)N(N2)CC3=CC=CC=N3
DMAS46B	IK	NZOJCPNWISMMAJ-UHFFFAOYSA-N
DMAS46B	IU	2-(pyridin-2-ylmethyl)-1H-indazol-3-one
DMAS46B	DE	Discovery agent

DM7RUNT	ID	DM7RUNT
DM7RUNT	DN	2-Pyridin-3-yl-7-aza-bicyclo[2.2.1]heptane
DM7RUNT	HS	Investigative
DM7RUNT	SN	CHEMBL56817; deschloroepibatidine; SCHEMBL8047370; BDBM50100717; AKOS023808321; 2-(3-Pyridyl)-7-azabicyclo[2.2.1]heptane
DM7RUNT	DT	Small molecular drug
DM7RUNT	PC	10154265
DM7RUNT	MW	174.24
DM7RUNT	FM	C11H14N2
DM7RUNT	IC	InChI=1S/C11H14N2/c1-2-8(7-12-5-1)10-6-9-3-4-11(10)13-9/h1-2,5,7,9-11,13H,3-4,6H2
DM7RUNT	CS	C1CC2C(CC1N2)C3=CN=CC=C3
DM7RUNT	IK	GYACOUGJSVTBRX-UHFFFAOYSA-N
DM7RUNT	IU	2-pyridin-3-yl-7-azabicyclo[2.2.1]heptane
DM7RUNT	DE	Discovery agent

DMT21UX	ID	DMT21UX
DMT21UX	DN	2-Pyridin-3-yl-benzo[h]chromen-4-one
DMT21UX	HS	Investigative
DMT21UX	SN	MLS000757116; CHEMBL177938; 1939-53-3; 2-(pyridin-3-yl)-4H-benzo[h]chromen-4-one; NSC283845; 2-pyridin-3-ylbenzo[h]chromen-4-one; 2-Pyridin-3-yl-benzo[h]chromen-4-one; AC1L88Q3; CTK0E1147; DTXSID00314472; ZINC13143019; BDBM50159611; NSC-283845; SMR000449783; TX-011635; 4H-Naphtho[1,2-b]pyran-4-one, 2-(3-pyridinyl)-
DMT21UX	DT	Small molecular drug
DMT21UX	PC	323484
DMT21UX	MW	273.3
DMT21UX	FM	C18H11NO2
DMT21UX	IC	InChI=1S/C18H11NO2/c20-16-10-17(13-5-3-9-19-11-13)21-18-14-6-2-1-4-12(14)7-8-15(16)18/h1-11H
DMT21UX	CS	C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CN=CC=C4
DMT21UX	IK	RURRJHXFMININK-UHFFFAOYSA-N
DMT21UX	IU	2-pyridin-3-ylbenzo[h]chromen-4-one
DMT21UX	CA	CAS 1939-53-3
DMT21UX	DE	Discovery agent

DMJYI0P	ID	DMJYI0P
DMJYI0P	DN	2-Pyridin-3-ylmethyl-1,2-dihydro-indazol-3-one
DMJYI0P	HS	Investigative
DMJYI0P	SN	2-(3-Pyridylmethyl)indazolinone; ICI-207968; 120273-58-7; CHEMBL3144579; AC1L2UZT; CHEMBL8337; SCHEMBL9596545; DTXSID90152784; BDBM50008992; ZINC100091041; AKOS023543919; 3H-Indazol-3-one,; ICI 207968
DMJYI0P	DT	Small molecular drug
DMJYI0P	PC	129095
DMJYI0P	MW	225.25
DMJYI0P	FM	C13H11N3O
DMJYI0P	IC	InChI=1S/C13H11N3O/c17-13-11-5-1-2-6-12(11)15-16(13)9-10-4-3-7-14-8-10/h1-8,15H,9H2
DMJYI0P	CS	C1=CC=C2C(=C1)C(=O)N(N2)CC3=CN=CC=C3
DMJYI0P	IK	SKZAIZCDZYPCRF-UHFFFAOYSA-N
DMJYI0P	IU	2-(pyridin-3-ylmethyl)-1H-indazol-3-one
DMJYI0P	CA	CAS 120273-58-7
DMJYI0P	DE	Discovery agent

DM5D09Q	ID	DM5D09Q
DM5D09Q	DN	2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline
DM5D09Q	HS	Investigative
DM5D09Q	SN	CHEMBL51594; 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL6441852; CIOBWNSCGKJAQU-UHFFFAOYSA-N; ZINC13489832; BDBM50127824; AKOS027557951
DM5D09Q	DT	Small molecular drug
DM5D09Q	PC	9877750
DM5D09Q	MW	210.27
DM5D09Q	FM	C14H14N2
DM5D09Q	IC	InChI=1S/C14H14N2/c1-2-4-13-11-16(10-7-12(13)3-1)14-5-8-15-9-6-14/h1-6,8-9H,7,10-11H2
DM5D09Q	CS	C1CN(CC2=CC=CC=C21)C3=CC=NC=C3
DM5D09Q	IK	CIOBWNSCGKJAQU-UHFFFAOYSA-N
DM5D09Q	IU	2-pyridin-4-yl-3,4-dihydro-1H-isoquinoline
DM5D09Q	DE	Discovery agent

DMGB1QU	ID	DMGB1QU
DMGB1QU	DN	2-Pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one
DMGB1QU	HS	Investigative
DMGB1QU	SN	CHEMBL3144718; 2-Pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL274331; BDBM50008994; ZINC107084657; AKOS023543920
DMGB1QU	DT	Small molecular drug
DMGB1QU	PC	14898716
DMGB1QU	MW	225.25
DMGB1QU	FM	C13H11N3O
DMGB1QU	IC	InChI=1S/C13H11N3O/c17-13-11-3-1-2-4-12(11)15-16(13)9-10-5-7-14-8-6-10/h1-8,15H,9H2
DMGB1QU	CS	C1=CC=C2C(=C1)C(=O)N(N2)CC3=CC=NC=C3
DMGB1QU	IK	CCCUFFBZCPVPFV-UHFFFAOYSA-N
DMGB1QU	IU	2-(pyridin-4-ylmethyl)-1H-indazol-3-one
DMGB1QU	DE	Discovery agent

DMVAQOZ	ID	DMVAQOZ
DMVAQOZ	DN	2-Pyridinethiol
DMVAQOZ	HS	Investigative
DMVAQOZ	SN	2-Mercaptopyridine; Pyridine-2-thiol; 2-Pyridinethiol; 2637-34-5; 2-Thiopyridine; Pyrid-2-thione; 2(1H)-PYRIDINETHIONE; Pyridinethione; 1H-pyridine-2-thione; 73018-10-7; 2-pyridylthiol; 2-Thiopyridone; 2-Pyridinethione; 2-Mercapto pyridine; 2-Pyridyl mercaptan; 1,2-dihydropyridine-2-thione; Thiopyridone-2 [French]; 2-pyridinylthiol; Alrithiol-2; NSC 41337; UNII-EE982KT952; CHEBI:45223; EINECS 220-131-9; WHMDPDGBKYUEMW-UHFFFAOYSA-N; EE982KT952; 29468-20-0; 2-Mercaptopyridine, 98%; Thiopyridone-2; PYS; Pyridinethiol; mercaptopyridine
DMVAQOZ	DT	Small molecular drug
DMVAQOZ	PC	2723698
DMVAQOZ	MW	111.17
DMVAQOZ	FM	C5H5NS
DMVAQOZ	IC	InChI=1S/C5H5NS/c7-5-3-1-2-4-6-5/h1-4H,(H,6,7)
DMVAQOZ	CS	C1=CC(=S)NC=C1
DMVAQOZ	IK	WHMDPDGBKYUEMW-UHFFFAOYSA-N
DMVAQOZ	IU	1H-pyridine-2-thione
DMVAQOZ	CA	CAS 73018-10-7
DMVAQOZ	CB	CHEBI:45223
DMVAQOZ	DE	Discovery agent

DMN516S	ID	DMN516S
DMN516S	DN	2-pyridylethylamine
DMN516S	HS	Investigative
DMN516S	SN	2-(2-Aminoethyl)pyridine; 2706-56-1; 2-Pyridylethylamine; 2-(pyridin-2-yl)ethanamine; 2-(2-Pyridyl)ethylamine; 2-Pyridineethanamine; 2-pyridin-2-ylethanamine; Demethylbetahistine; alpha-Pyridylethylamine; 2-(pyridin-2-yl)ethan-1-amine; Lilly 04432; Pyridine, 2-(2-aminoethyl)-; UNII-ATW1AH7OJ5; Pyridineethanamine; 2-(2'-Aminoethyl)pyridine; NSC 71989; .alpha.-Pyridylethylamine; EINECS 220-295-1; ATW1AH7OJ5; 2-AMINOETHYLPYRIDINE; 2-(2-Pyridinyl)ethanamine; 2-(2-aminoethyl)-pyridine; 2-(2-aminoethyl) pyridine
DMN516S	DT	Small molecular drug
DMN516S	PC	75919
DMN516S	MW	122.17
DMN516S	FM	C7H10N2
DMN516S	IC	InChI=1S/C7H10N2/c8-5-4-7-3-1-2-6-9-7/h1-3,6H,4-5,8H2
DMN516S	CS	C1=CC=NC(=C1)CCN
DMN516S	IK	XPQIPUZPSLAZDV-UHFFFAOYSA-N
DMN516S	IU	2-pyridin-2-ylethanamine
DMN516S	CA	CAS 2706-56-1
DMN516S	CB	CHEBI:74024
DMN516S	DE	Discovery agent

DMBJXCF	ID	DMBJXCF
DMBJXCF	DN	2pyrrolidin-1-yl-1-phenylpentan-1-one
DMBJXCF	HS	Investigative
DMBJXCF	SN	14530-33-7; alpha-PVP; 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one; alpha-pyrrolidinovalerophenone; Desmethyl pyrovalerone; Alpha-Pyrrolidinopentiophenone; CHEMBL205082; 1-Pentanone, 1-phenyl-2-(1-pyrrolidinyl)-; Flakka; beta-Ketone-prolintane; Prolintanone; Gravel; beta-Keto-prolintane; a-PVP; 2pyrrolidin-1-yl-1-phenylpentan-1-one; 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone; a-Pyrrolidinopentiophenone; O-2387; SCHEMBL4936204; DTXSID70456954; YDIIDRWHPFMLGR-UHFFFAOYSA-N; MFCD24386810; BDBM50182584; alpha-Pyrrolidinopentiophenone, a-PVP
DMBJXCF	DT	Small molecular drug
DMBJXCF	PC	11148955
DMBJXCF	MW	231.33
DMBJXCF	FM	C15H21NO
DMBJXCF	IC	InChI=1S/C15H21NO/c1-2-8-14(16-11-6-7-12-16)15(17)13-9-4-3-5-10-13/h3-5,9-10,14H,2,6-8,11-12H2,1H3
DMBJXCF	CS	CCCC(C(=O)C1=CC=CC=C1)N2CCCC2
DMBJXCF	IK	YDIIDRWHPFMLGR-UHFFFAOYSA-N
DMBJXCF	IU	1-phenyl-2-pyrrolidin-1-ylpentan-1-one
DMBJXCF	CA	CAS 14530-33-7
DMBJXCF	DE	Discovery agent

DMGPI0C	ID	DMGPI0C
DMGPI0C	DN	2-Pyrrolidin-1-yl-benzo[h]chromen-4-one
DMGPI0C	HS	Investigative
DMGPI0C	SN	K 12344; BRN 0412624; 4H-Naphtho(1,2-b)pyran-4-one, 2-(1-pyrrolidinyl)-; CHEMBL179914; 2-(1-Pyrrolidinyl)-4H-naphtho(1,2-b)pyran-4-one; 2-(N-Pirrolidil)-4-oxo-4H-nafto(1,2-b)pirano [Italian]; 61035-04-9; 2-Pyrrolidin-1-yl-benzo[h]chromen-4-one; AC1MIJ0D; 2-(N-Pirrolidil)-4-oxo-4H-nafto(1,2-b)pirano; SCHEMBL3535232; DTXSID00209910; BDBM50159631; 2-pyrrolidin-1-ylbenzo[h]chromen-4-one
DMGPI0C	DT	Small molecular drug
DMGPI0C	PC	3045696
DMGPI0C	MW	265.31
DMGPI0C	FM	C17H15NO2
DMGPI0C	IC	InChI=1S/C17H15NO2/c19-15-11-16(18-9-3-4-10-18)20-17-13-6-2-1-5-12(13)7-8-14(15)17/h1-2,5-8,11H,3-4,9-10H2
DMGPI0C	CS	C1CCN(C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMGPI0C	IK	CYNBNMZZLAYOIM-UHFFFAOYSA-N
DMGPI0C	IU	2-pyrrolidin-1-ylbenzo[h]chromen-4-one
DMGPI0C	CA	CAS 61035-04-9
DMGPI0C	DE	Discovery agent

DMNU1YR	ID	DMNU1YR
DMNU1YR	DN	2S,4R-4-METHYLGLUTAMATE
DMNU1YR	HS	Investigative
DMNU1YR	SN	(2S,4R)-4-Methylglutamic acid; 31137-74-3; (2S,4R)-2-amino-4-methylpentanedioic acid; 2S,4R-4-Methylglutamate; CHEMBL288166; 4-Methylglutamic acid; 4-Methylglutamate; (4r)-4-methyl-l-glutamic acid; threo-gamma-Methylglutamate; 2-Amino-4-methyl-pentanedioic acid; 14561-55-8; 59685-03-9; NSC 41355; Tocris-0903; AC1L3VAT; SYM; Biomol-NT_000218; AC1Q5QI2; SCHEMBL594187; BPBio1_001308; CTK5B0310; KRKRAOXTGDJWNI-DMTCNVIQSA-N; MolPort-003-848-893; ZINC896091; Glutamic acid, 4-methyl- (VAN); (2S,4R)-4-methyl gluta
DMNU1YR	DT	Small molecular drug
DMNU1YR	PC	95883
DMNU1YR	MW	161.16
DMNU1YR	FM	C6H11NO4
DMNU1YR	IC	InChI=1S/C6H11NO4/c1-3(5(8)9)2-4(7)6(10)11/h3-4H,2,7H2,1H3,(H,8,9)(H,10,11)/t3-,4+/m1/s1
DMNU1YR	CS	C[C@H](C[C@@H](C(=O)O)N)C(=O)O
DMNU1YR	IK	KRKRAOXTGDJWNI-DMTCNVIQSA-N
DMNU1YR	IU	(2S,4R)-2-amino-4-methylpentanedioic acid
DMNU1YR	CA	CAS 77842-39-8
DMNU1YR	DE	Discovery agent

DMAO7DS	ID	DMAO7DS
DMAO7DS	DN	2-Sulfamoyl-benzoic acid methyl ester
DMAO7DS	HS	Investigative
DMAO7DS	SN	57683-71-3; Methyl 2-(aminosulfonyl)benzoate; methyl 2-sulfamoylbenzoate; 2-Carbomethoxybenzenesulfonamide; (2-Methoxycarbonyl)benzene sulfonamide; 2-Sulfamoylbenzoic acid methyl ester; Methyl o-sulphamoylbenzoate; Benzoic acid, 2-(aminosulfonyl)-, methyl ester; EINECS 260-903-2; BENZOIC ACID, 2-SULFAMOYL-, METHYL ESTER; BRN 2728611; 2-aminosulfonyl-benzoic acid methyl ester; CHEMBL148680; CHEBI:83512; 2-methoxycarbonylphenylsulfonamide; VSOOBQALJVLTBH-UHFFFAOYSA-N; MFCD00009808; 2-(methoxycarbonyl)benzenesulphonamide
DMAO7DS	DT	Small molecular drug
DMAO7DS	PC	42546
DMAO7DS	MW	215.23
DMAO7DS	FM	C8H9NO4S
DMAO7DS	IC	InChI=1S/C8H9NO4S/c1-13-8(10)6-4-2-3-5-7(6)14(9,11)12/h2-5H,1H3,(H2,9,11,12)
DMAO7DS	CS	COC(=O)C1=CC=CC=C1S(=O)(=O)N
DMAO7DS	IK	VSOOBQALJVLTBH-UHFFFAOYSA-N
DMAO7DS	IU	methyl 2-sulfamoylbenzoate
DMAO7DS	CA	CAS 57683-71-3
DMAO7DS	CB	CHEBI:83512
DMAO7DS	DE	Discovery agent

DMJBO3D	ID	DMJBO3D
DMJBO3D	DN	2-Sulfhydryl-Ethanol
DMJBO3D	HS	Investigative
DMJBO3D	SN	beta-Mercaptoethanol; 2-mercaptoethanol; 60-24-2; Thioglycol; Mercaptoethanol; Beta-Mercaptoethanol; Ethanol, 2-mercapto-; 2-Sulfanylethanol; 2-Thioethanol; Thioethylene glycol; 2-Hydroxyethanethiol; 2-Hydroxyethyl mercaptan; 2-Hydroxy-1-ethanethiol; Thiomonoglycol; Monothioglycol; 2-Mercapto-1-ethanol; 1-Ethanol-2-thiol; Hydroxyethyl mercaptan; Monothioethylene glycol; 2-Mercaptoethyl alcohol; 2-ME; Mercaptoetanol; Ethylene glycol, monothio-; 1-Hydroxy-2-mercaptoethane; 1-Mercapto-2-hydroxyethane; 2-Hydroxyethylmercaptan; Emery 5791; USAF EK-4196
DMJBO3D	DT	Small molecular drug
DMJBO3D	PC	1567
DMJBO3D	MW	78.14
DMJBO3D	FM	C2H6OS
DMJBO3D	IC	InChI=1S/C2H6OS/c3-1-2-4/h3-4H,1-2H2
DMJBO3D	CS	C(CS)O
DMJBO3D	IK	DGVVWUTYPXICAM-UHFFFAOYSA-N
DMJBO3D	IU	2-sulfanylethanol
DMJBO3D	CA	CAS 60-24-2
DMJBO3D	CB	CHEBI:41218
DMJBO3D	DE	Discovery agent

DM26NKG	ID	DM26NKG
DM26NKG	DN	2-tert-butoxy-9H-carbazole
DM26NKG	HS	Investigative
DM26NKG	SN	CHEMBL1170845; 2-tert-butoxy-9H-carbazole; SCHEMBL13064179
DM26NKG	DT	Small molecular drug
DM26NKG	PC	46855214
DM26NKG	MW	239.31
DM26NKG	FM	C16H17NO
DM26NKG	IC	InChI=1S/C16H17NO/c1-16(2,3)18-11-8-9-13-12-6-4-5-7-14(12)17-15(13)10-11/h4-10,17H,1-3H3
DM26NKG	CS	CC(C)(C)OC1=CC2=C(C=C1)C3=CC=CC=C3N2
DM26NKG	IK	VSDPUTYQQKWFAG-UHFFFAOYSA-N
DM26NKG	IU	2-[(2-methylpropan-2-yl)oxy]-9H-carbazole
DM26NKG	DE	Discovery agent

DMJBQD8	ID	DMJBQD8
DMJBQD8	DN	2-tert-butyl-7-(trifluoromethyl)-9H-carbazole
DMJBQD8	HS	Investigative
DMJBQD8	SN	CHEMBL1171079; 2-tert-butyl-7-(trifluoromethyl)-9H-carbazole; ZINC53230612
DMJBQD8	DT	Small molecular drug
DMJBQD8	PC	46855216
DMJBQD8	MW	291.31
DMJBQD8	FM	C17H16F3N
DMJBQD8	IC	InChI=1S/C17H16F3N/c1-16(2,3)10-4-6-12-13-7-5-11(17(18,19)20)9-15(13)21-14(12)8-10/h4-9,21H,1-3H3
DMJBQD8	CS	CC(C)(C)C1=CC2=C(C=C1)C3=C(N2)C=C(C=C3)C(F)(F)F
DMJBQD8	IK	XAQHCEWJSXOCDT-UHFFFAOYSA-N
DMJBQD8	IU	2-tert-butyl-7-(trifluoromethyl)-9H-carbazole
DMJBQD8	DE	Discovery agent

DM6M8Y3	ID	DM6M8Y3
DM6M8Y3	DN	2-tert-butyl-9H-carbazole
DM6M8Y3	HS	Investigative
DM6M8Y3	SN	2-TERT-BUTYL-9H-CARBAZOLE; 69386-36-3; CHEMBL1173703; 2-(tert-Butyl)-9H-carbazole; 2-Tert-butylcarbazole; SCHEMBL10312973; CTK2F2146; DTXSID90499227; MolPort-005-941-197; ZINC22003756; BDBM50322580; AKOS015967050
DM6M8Y3	DT	Small molecular drug
DM6M8Y3	PC	12462654
DM6M8Y3	MW	223.31
DM6M8Y3	FM	C16H17N
DM6M8Y3	IC	InChI=1S/C16H17N/c1-16(2,3)11-8-9-13-12-6-4-5-7-14(12)17-15(13)10-11/h4-10,17H,1-3H3
DM6M8Y3	CS	CC(C)(C)C1=CC2=C(C=C1)C3=CC=CC=C3N2
DM6M8Y3	IK	FUFORZIUGGNDKM-UHFFFAOYSA-N
DM6M8Y3	IU	2-tert-butyl-9H-carbazole
DM6M8Y3	CA	CAS 69386-36-3
DM6M8Y3	DE	Discovery agent

DMNXI1E	ID	DMNXI1E
DMNXI1E	DN	2-tert-butylbenzene-1,4-diol
DMNXI1E	HS	Investigative
DMNXI1E	SN	Tert-Butylhydroquinone; tert-Butylhydroquinone; 1948-33-0; TBHQ; 2-tert-Butylhydroquinone; T-BUTYLHYDROQUINONE; MTBHQ; t-Butyl hydroquinone; 2-tert-Butyl-1,4-benzenediol; 2-t-Butylhydroquinone; Mono-tert-butylhydroquinone; Sustane; Tenox TBHQ; tert-Butyl-1,4-benzenediol; Mono-tertiarybutylhydroquinone; Hydroquinone, tert-butyl-; Banox 20BA; 1,4-Benzenediol, 2-(1,1-dimethylethyl)-; tertiary-Butylhydroquinone; 2-(1,1-Dimethylethyl)-1,4-benzenediol; 2-tert-Butyl(1,4)hydroquinone; 2-(tert-butyl)benzene-1,4-diol
DMNXI1E	DT	Small molecular drug
DMNXI1E	PC	16043
DMNXI1E	MW	166.22
DMNXI1E	FM	C10H14O2
DMNXI1E	IC	InChI=1S/C10H14O2/c1-10(2,3)8-6-7(11)4-5-9(8)12/h4-6,11-12H,1-3H3
DMNXI1E	CS	CC(C)(C)C1=C(C=CC(=C1)O)O
DMNXI1E	IK	BGNXCDMCOKJUMV-UHFFFAOYSA-N
DMNXI1E	IU	2-tert-butylbenzene-1,4-diol
DMNXI1E	CA	CAS 1948-33-0
DMNXI1E	CB	CHEBI:78886
DMNXI1E	DE	Discovery agent

DMFAV5R	ID	DMFAV5R
DMFAV5R	DN	2-tert-Butyldimethylsilyloxylycorine
DMFAV5R	HS	Investigative
DMFAV5R	SN	2-tert-Butyldimethylsilyloxylycorine; CHEMBL558873; SCHEMBL12270994; BDBM50293600
DMFAV5R	DT	Small molecular drug
DMFAV5R	PC	44191462
DMFAV5R	MW	401.6
DMFAV5R	FM	C22H31NO4Si
DMFAV5R	IC	InChI=1S/C22H31NO4Si/c1-22(2,3)28(4,5)27-18-8-13-6-7-23-11-14-9-16-17(26-12-25-16)10-15(14)19(20(13)23)21(18)24/h8-10,18-21,24H,6-7,11-12H2,1-5H3/t18-,19-,20+,21+/m0/s1
DMFAV5R	CS	CC(C)(C)[Si](C)(C)O[C@H]1C=C2CCN3[C@H]2[C@@H]([C@@H]1O)C4=CC5=C(C=C4C3)OCO5
DMFAV5R	IK	RLYPONLPAHPYMG-UWHLTILDSA-N
DMFAV5R	IU	(1S,17S,18S,19S)-17-[tert-butyl(dimethyl)silyl]oxy-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraen-18-ol
DMFAV5R	DE	Discovery agent

DM35JQS	ID	DM35JQS
DM35JQS	DN	2-Thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one
DM35JQS	HS	Investigative
DM35JQS	SN	2-(Thiazol-5-ylmethyl)-1H-indazol-3(2H)-one; 120273-62-3; CHEMBL3144715; 1,2-dihydro-2-(5-thiazolylmethyl)-3H-indazol-3-one; 2-Thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL267524; SCHEMBL16160907; BDBM50008996; ZINC100161259; AKOS022188370; AJ-64420; AJ-64421; AX8285840
DM35JQS	DT	Small molecular drug
DM35JQS	PC	14898745
DM35JQS	MW	231.28
DM35JQS	FM	C11H9N3OS
DM35JQS	IC	InChI=1S/C11H9N3OS/c15-11-9-3-1-2-4-10(9)13-14(11)6-8-5-12-7-16-8/h1-5,7,13H,6H2
DM35JQS	CS	C1=CC=C2C(=C1)C(=O)N(N2)CC3=CN=CS3
DM35JQS	IK	KPXSUQVYEHMEMW-UHFFFAOYSA-N
DM35JQS	IU	2-(1,3-thiazol-5-ylmethyl)-1H-indazol-3-one
DM35JQS	DE	Discovery agent

DMEY9T2	ID	DMEY9T2
DMEY9T2	DN	2-Thioethenamine
DMEY9T2	HS	Investigative
DMEY9T2	SN	AC1NXIBI; (E)-2-aminoethenethiol
DMEY9T2	DT	Small molecular drug
DMEY9T2	PC	5806800
DMEY9T2	MW	75.14
DMEY9T2	FM	C2H5NS
DMEY9T2	IC	InChI=1S/C2H5NS/c3-1-2-4/h1-2,4H,3H2/b2-1+
DMEY9T2	CS	C(=C/S)\\N
DMEY9T2	IK	JLZMZFJVTNYDOT-OWOJBTEDSA-N
DMEY9T2	IU	(E)-2-aminoethenethiol
DMEY9T2	CA	CAS 676992-63-5
DMEY9T2	DE	Discovery agent

DMCEK6N	ID	DMCEK6N
DMCEK6N	DN	2-Thiomethyl-3-Phenylpropanoic Acid
DMCEK6N	HS	Investigative
DMCEK6N	SN	2-Thiomethyl-3-phenylpropanoic acid; 2-THIOMETHYL-3-PHENYLPROPANOIC ACID; CHEMBL90403; (2S)-2-benzyl-3-sulfanylpropanoic acid; S-BMPA; AC1NRAFB; GTPL8676; SCHEMBL1464853; BDBM50281176; DB02953; (S)-2-Mercaptomethyl-3-phenyl-propionic acid; (S)-alpha-(Mercaptomethyl)benzenepropionic acid; (2S)-2-(phenylmethyl)-3-sulfanylpropanoic
DMCEK6N	DT	Small molecular drug
DMCEK6N	PC	5287850
DMCEK6N	MW	196.27
DMCEK6N	FM	C10H12O2S
DMCEK6N	IC	InChI=1S/C10H12O2S/c11-10(12)9(7-13)6-8-4-2-1-3-5-8/h1-5,9,13H,6-7H2,(H,11,12)/t9-/m1/s1
DMCEK6N	CS	C1=CC=C(C=C1)C[C@H](CS)C(=O)O
DMCEK6N	IK	ZUEBVBPVXLQMQR-SECBINFHSA-N
DMCEK6N	IU	(2S)-2-benzyl-3-sulfanylpropanoic acid
DMCEK6N	DE	Discovery agent

DMSKNBA	ID	DMSKNBA
DMSKNBA	DN	2-Thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one
DMSKNBA	HS	Investigative
DMSKNBA	SN	CHEMBL179168; 2-Thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one; SCHEMBL3540143
DMSKNBA	DT	Small molecular drug
DMSKNBA	PC	11289486
DMSKNBA	MW	297.4
DMSKNBA	FM	C16H15N3OS
DMSKNBA	IC	InChI=1S/C16H15N3OS/c20-15-11-14(18-7-9-21-10-8-18)17-16-13-4-2-1-3-12(13)5-6-19(15)16/h1-6,11H,7-10H2
DMSKNBA	CS	C1CSCCN1C2=CC(=O)N3C=CC4=CC=CC=C4C3=N2
DMSKNBA	IK	LGFZVFQIQUWUBJ-UHFFFAOYSA-N
DMSKNBA	IU	2-thiomorpholin-4-ylpyrimido[2,1-a]isoquinolin-4-one
DMSKNBA	DE	Discovery agent

DMFXG2E	ID	DMFXG2E
DMFXG2E	DN	2-thiomorpholino-4H-benzo[h]chromen-4-one
DMFXG2E	HS	Investigative
DMFXG2E	SN	CHEMBL360038; 2-thiomorpholino-4H-benzo[h]chromen-4-one; SCHEMBL3537842; BDBM50159639
DMFXG2E	DT	Small molecular drug
DMFXG2E	PC	11174002
DMFXG2E	MW	297.4
DMFXG2E	FM	C17H15NO2S
DMFXG2E	IC	InChI=1S/C17H15NO2S/c19-15-11-16(18-7-9-21-10-8-18)20-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2
DMFXG2E	CS	C1CSCCN1C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMFXG2E	IK	IIWOVJPSKUAWDA-UHFFFAOYSA-N
DMFXG2E	IU	2-thiomorpholin-4-ylbenzo[h]chromen-4-one
DMFXG2E	DE	Discovery agent

DMPF598	ID	DMPF598
DMPF598	DN	2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline
DMPF598	HS	Investigative
DMPF598	SN	CHEMBL319249; ZINC13756973
DMPF598	DT	Small molecular drug
DMPF598	PC	10705898
DMPF598	MW	251.31
DMPF598	FM	C14H9N3S
DMPF598	IC	InChI=1S/C14H9N3S/c1-2-5-10-9(4-1)13-11(8-15-10)16-14(17-13)12-6-3-7-18-12/h1-8H,(H,16,17)
DMPF598	CS	C1=CC=C2C(=C1)C3=C(C=N2)NC(=N3)C4=CC=CS4
DMPF598	IK	APVZAVOHLAQECW-UHFFFAOYSA-N
DMPF598	IU	2-thiophen-2-yl-3H-imidazo[4,5-c]quinoline
DMPF598	DE	Discovery agent

DM4J8B9	ID	DM4J8B9
DM4J8B9	DN	2-Thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one
DM4J8B9	HS	Investigative
DM4J8B9	SN	CHEMBL3144717; 1,2-dihydro-2-(2-thienylmethyl)-3H-indazol-3-one; 120273-89-4; 2-Thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL269658; BDBM50008989
DM4J8B9	DT	Small molecular drug
DM4J8B9	PC	14898713
DM4J8B9	MW	230.29
DM4J8B9	FM	C12H10N2OS
DM4J8B9	IC	InChI=1S/C12H10N2OS/c15-12-10-5-1-2-6-11(10)13-14(12)8-9-4-3-7-16-9/h1-7,13H,8H2
DM4J8B9	CS	C1=CC=C2C(=C1)C(=O)N(N2)CC3=CC=CS3
DM4J8B9	IK	JGPURYLHMLRGGI-UHFFFAOYSA-N
DM4J8B9	IU	2-(thiophen-2-ylmethyl)-1H-indazol-3-one
DM4J8B9	DE	Discovery agent

DMIEGF4	ID	DMIEGF4
DMIEGF4	DN	2-THIOSALVINORIN B
DMIEGF4	HS	Investigative
DMIEGF4	SN	2-thiosalvinorin B; CHEMBL231536; SCHEMBL13415898
DMIEGF4	DT	Small molecular drug
DMIEGF4	PC	17747979
DMIEGF4	MW	406.5
DMIEGF4	FM	C21H26O6S
DMIEGF4	IC	InChI=1S/C21H26O6S/c1-20-6-4-12-19(24)27-14(11-5-7-26-10-11)9-21(12,2)17(20)16(22)15(28)8-13(20)18(23)25-3/h5,7,10,12-15,17,28H,4,6,8-9H2,1-3H3/t12-,13-,14-,15-,17-,20-,21-/m0/s1
DMIEGF4	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)S)C)C4=COC=C4
DMIEGF4	IK	NGNBKFTYZQINBO-CEFSSPBYSA-N
DMIEGF4	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-sulfanyl-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMIEGF4	DE	Discovery agent

DM84R6C	ID	DM84R6C
DM84R6C	DN	2-thio-UDP
DM84R6C	HS	Investigative
DM84R6C	SN	CHEMBL216011; 2-thio-UDP; thiouridine 5'-diphosphate; GTPL6202; SCHEMBL9397187; BDBM50194160; [(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate; (2R,3R,4S,5R)-1-(3,4-dihydroxy-5-(diphosphoryloxymethyl)-tetrahydrofuran-2-yl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one ammonium salt
DM84R6C	DT	Small molecular drug
DM84R6C	PC	16082712
DM84R6C	MW	420.23
DM84R6C	FM	C9H14N2O11P2S
DM84R6C	IC	InChI=1S/C9H14N2O11P2S/c12-5-1-2-11(9(25)10-5)8-7(14)6(13)4(21-8)3-20-24(18,19)22-23(15,16)17/h1-2,4,6-8,13-14H,3H2,(H,18,19)(H,10,12,25)(H2,15,16,17)/t4-,6-,7-,8-/m1/s1
DM84R6C	CS	C1=CN(C(=S)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)O)O
DM84R6C	IK	BMJOHSBBMARQHC-XVFCMESISA-N
DM84R6C	IU	[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate
DM84R6C	DE	Discovery agent

DMJZ5V0	ID	DMJZ5V0
DMJZ5V0	DN	2-thioUTP
DMJZ5V0	HS	Investigative
DMJZ5V0	SN	2-thio-UTP
DMJZ5V0	DT	Small molecular drug
DMJZ5V0	PC	10174453
DMJZ5V0	MW	500.21
DMJZ5V0	FM	C9H15N2O14P3S
DMJZ5V0	IC	InChI=1S/C9H15N2O14P3S/c12-5-1-2-11(9(29)10-5)8-7(14)6(13)4(23-8)3-22-27(18,19)25-28(20,21)24-26(15,16)17/h1-2,4,6-8,13-14H,3H2,(H,18,19)(H,20,21)(H,10,12,29)(H2,15,16,17)/t4-,6-,7-,8-/m1/s1
DMJZ5V0	CS	C1=CN(C(=S)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMJZ5V0	IK	KHYOUGAATNYCAZ-XVFCMESISA-N
DMJZ5V0	IU	[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMJZ5V0	DE	Discovery agent

DM1HABS	ID	DM1HABS
DM1HABS	DN	2-tolyl-6-phenyl-9H-purine
DM1HABS	HS	Investigative
DM1HABS	SN	CHEMBL205194; 2-tolyl-6-phenyl-9H-purine
DM1HABS	DT	Small molecular drug
DM1HABS	PC	11652153
DM1HABS	MW	286.3
DM1HABS	FM	C18H14N4
DM1HABS	IC	InChI=1S/C18H14N4/c1-12-7-9-14(10-8-12)17-21-15(13-5-3-2-4-6-13)16-18(22-17)20-11-19-16/h2-11H,1H3,(H,19,20,21,22)
DM1HABS	CS	CC1=CC=C(C=C1)C2=NC(=C3C(=N2)N=CN3)C4=CC=CC=C4
DM1HABS	IK	OPFZHJCGZXEIRY-UHFFFAOYSA-N
DM1HABS	IU	2-(4-methylphenyl)-6-phenyl-7H-purine
DM1HABS	DE	Discovery agent

DMOFDVE	ID	DMOFDVE
DMOFDVE	DN	2-tosylanthracene-1,4-diol
DMOFDVE	HS	Investigative
DMOFDVE	SN	CHEMBL451059; 2-tosylanthracene-1,4-diol
DMOFDVE	DT	Small molecular drug
DMOFDVE	PC	44562748
DMOFDVE	MW	364.4
DMOFDVE	FM	C21H16O4S
DMOFDVE	IC	InChI=1S/C21H16O4S/c1-13-6-8-16(9-7-13)26(24,25)20-12-19(22)17-10-14-4-2-3-5-15(14)11-18(17)21(20)23/h2-12,22-23H,1H3
DMOFDVE	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=C(C3=CC4=CC=CC=C4C=C3C(=C2)O)O
DMOFDVE	IK	DKOISANXNBXJMG-UHFFFAOYSA-N
DMOFDVE	IU	2-(4-methylphenyl)sulfonylanthracene-1,4-diol
DMOFDVE	DE	Discovery agent

DM8LS6H	ID	DM8LS6H
DM8LS6H	DN	2-tosylbenzene-1,4-diol
DM8LS6H	HS	Investigative
DM8LS6H	SN	2-tosylbenzene-1,4-diol; 2-Tosylhydroquinone; 30958-16-8; CHEMBL462375; 2-(4-Methylbenzenesulfonyl)benzene-1,4-diol; 2-[(4-methylphenyl)sulfonyl]benzene-1,4-diol; AC1LDN5E; CBMicro_029952; Cambridge id 5869439; Oprea1_104843; Oprea1_717162; SCHEMBL10489221; ZINC36613; MolPort-015-161-937; JDVLOEPBUIGUKP-UHFFFAOYSA-N; MolPort-000-279-703; BDBM50245925; STK739706; AKOS000727738; MCULE-7472387969; BAS 00095777; ST001815; BIM-0030021.P001; 2-(Toluene-4-sulfonyl)-benzene-1,4-diol; 2-(4-methylphenyl)sulfonylbenzene-1,4-diol
DM8LS6H	DT	Small molecular drug
DM8LS6H	PC	621969
DM8LS6H	MW	264.3
DM8LS6H	FM	C13H12O4S
DM8LS6H	IC	InChI=1S/C13H12O4S/c1-9-2-5-11(6-3-9)18(16,17)13-8-10(14)4-7-12(13)15/h2-8,14-15H,1H3
DM8LS6H	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=C(C=CC(=C2)O)O
DM8LS6H	IK	JDVLOEPBUIGUKP-UHFFFAOYSA-N
DM8LS6H	IU	2-(4-methylphenyl)sulfonylbenzene-1,4-diol
DM8LS6H	CA	CAS 30958-16-8
DM8LS6H	DE	Discovery agent

DM2OUG0	ID	DM2OUG0
DM2OUG0	DN	2-tosylnaphthalene
DM2OUG0	HS	Investigative
DM2OUG0	SN	2-tosylnaphthalene; 2-Naphthyl-p-tolyl sulfone; CHEMBL462553; AC1LAR2N; SCHEMBL9587829; UOUHDIZYOCFQKG-UHFFFAOYSA-N; 4-methylphenyl 2-naphthyl sulfone; ZINC32149231; BDBM50245927; 2-(4-methylphenyl)sulfonylnaphthalene; 2-[(4-Methylphenyl)sulfonyl]naphthalene; 2-[(4-Methylphenyl)sulfonyl]naphthalene #
DM2OUG0	DT	Small molecular drug
DM2OUG0	PC	518736
DM2OUG0	MW	282.4
DM2OUG0	FM	C17H14O2S
DM2OUG0	IC	InChI=1S/C17H14O2S/c1-13-6-9-16(10-7-13)20(18,19)17-11-8-14-4-2-3-5-15(14)12-17/h2-12H,1H3
DM2OUG0	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=CC3=CC=CC=C3C=C2
DM2OUG0	IK	UOUHDIZYOCFQKG-UHFFFAOYSA-N
DM2OUG0	IU	2-(4-methylphenyl)sulfonylnaphthalene
DM2OUG0	DE	Discovery agent

DM5FHO4	ID	DM5FHO4
DM5FHO4	DN	2-Tosylnaphthalene-1,4-diol
DM5FHO4	HS	Investigative
DM5FHO4	SN	CHEMBL509952; 2-Tosylnaphthalene-1,4-diol; 4-Tolyl-2-[1,4-dihydroxynaphthyl]sulfone; AC1LC4IM; CYYDOKQRZQTSOL-UHFFFAOYSA-N; BDBM50245828; 2-(4-methylphenyl)sulfonylnaphthalene-1,4-diol; 2-[(4-Methylphenyl)sulfonyl]-1,4-naphthalenediol #
DM5FHO4	DT	Small molecular drug
DM5FHO4	PC	594215
DM5FHO4	MW	314.4
DM5FHO4	FM	C17H14O4S
DM5FHO4	IC	InChI=1S/C17H14O4S/c1-11-6-8-12(9-7-11)22(20,21)16-10-15(18)13-4-2-3-5-14(13)17(16)19/h2-10,18-19H,1H3
DM5FHO4	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=C(C3=CC=CC=C3C(=C2)O)O
DM5FHO4	IK	CYYDOKQRZQTSOL-UHFFFAOYSA-N
DM5FHO4	IU	2-(4-methylphenyl)sulfonylnaphthalene-1,4-diol
DM5FHO4	DE	Discovery agent

DMK9OYM	ID	DMK9OYM
DMK9OYM	DN	2-tosylnaphthalene-1,4-dione
DMK9OYM	HS	Investigative
DMK9OYM	SN	2-[4-Toluenesulfonyl]-1,4-naphthoquinone; CHEMBL454282; 2-(4-methylphenyl)sulfonylnaphthalene-1,4-dione; 40852-77-5; 2-tosylnaphthalene-1,4-dione; NSC124929; AC1L5KCI; AC1Q6TN2; CTK4I3907; DTXSID00298642; UCFUGRHGHVYUOA-UHFFFAOYSA-N; ZINC1714192; BDBM50245928; NSC-124929; 2-(p-Tolylsulfonyl)-1,4-naphthoquinone; 2-[(4-Methylphenyl)sulfonyl]naphthoquinone #
DMK9OYM	DT	Small molecular drug
DMK9OYM	PC	276683
DMK9OYM	MW	312.3
DMK9OYM	FM	C17H12O4S
DMK9OYM	IC	InChI=1S/C17H12O4S/c1-11-6-8-12(9-7-11)22(20,21)16-10-15(18)13-4-2-3-5-14(13)17(16)19/h2-10H,1H3
DMK9OYM	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=CC(=O)C3=CC=CC=C3C2=O
DMK9OYM	IK	UCFUGRHGHVYUOA-UHFFFAOYSA-N
DMK9OYM	IU	2-(4-methylphenyl)sulfonylnaphthalene-1,4-dione
DMK9OYM	CA	CAS 40852-77-5
DMK9OYM	DE	Discovery agent

DMVJORE	ID	DMVJORE
DMVJORE	DN	2-trityl-4,5-dihydrooxazole
DMVJORE	HS	Investigative
DMVJORE	SN	CHEMBL271167
DMVJORE	DT	Small molecular drug
DMVJORE	PC	24799664
DMVJORE	MW	313.4
DMVJORE	FM	C22H19NO
DMVJORE	IC	InChI=1S/C22H19NO/c1-4-10-18(11-5-1)22(21-23-16-17-24-21,19-12-6-2-7-13-19)20-14-8-3-9-15-20/h1-15H,16-17H2
DMVJORE	CS	C1COC(=N1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMVJORE	IK	PHFOYYZFWZIUBU-UHFFFAOYSA-N
DMVJORE	IU	2-trityl-4,5-dihydro-1,3-oxazole
DMVJORE	DE	Discovery agent

DM8XSE3	ID	DM8XSE3
DM8XSE3	DN	2-valproylamido-5-sulfonamidoindane
DM8XSE3	HS	Investigative
DM8XSE3	SN	CHEMBL381730; 2-valproylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 12a; BDBM11031
DM8XSE3	DT	Small molecular drug
DM8XSE3	PC	11537386
DM8XSE3	MW	338.5
DM8XSE3	FM	C17H26N2O3S
DM8XSE3	IC	InChI=1S/C17H26N2O3S/c1-3-5-12(6-4-2)17(20)19-15-9-13-7-8-16(23(18,21)22)11-14(13)10-15/h7-8,11-12,15H,3-6,9-10H2,1-2H3,(H,19,20)(H2,18,21,22)
DM8XSE3	CS	CCCC(CCC)C(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DM8XSE3	IK	XBYJCVDSFWJBSM-UHFFFAOYSA-N
DM8XSE3	IU	2-propyl-N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)pentanamide
DM8XSE3	DE	Discovery agent

DMOAY8R	ID	DMOAY8R
DMOAY8R	DN	3 9-DIHYDRO-N-DESMETHYL-N-ISOPROPYLERYTHROMYCIN A
DMOAY8R	HS	Investigative
DMOAY8R	SN	CHEMBL584549; 3 9-dihydro-N-desmethyl-N-isopropylerythromycin A; SCHEMBL13681692
DMOAY8R	DT	Small molecular drug
DMOAY8R	PC	44542667
DMOAY8R	MW	764
DMOAY8R	FM	C39H73NO13
DMOAY8R	IC	InChI=1S/C39H73NO13/c1-15-27-39(12,47)32(43)22(6)29(41)20(4)17-37(10,46)34(53-36-30(42)26(16-21(5)49-36)40(13)19(2)3)23(7)31(24(8)35(45)51-27)52-28-18-38(11,48-14)33(44)25(9)50-28/h19-34,36,41-44,46-47H,15-18H2,1-14H3/t20-,21-,22+,23+,24-,25+,26+,27-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39-/m1/s1
DMOAY8R	CS	CC[C@@H]1[C@@]([C@@H]([C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C(C)C)O)(C)O)C)O)C)O)(C)O
DMOAY8R	IK	RXJCJWPPKSQMAS-IRNFSOKPSA-N
DMOAY8R	IU	(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-6-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
DMOAY8R	DE	Discovery agent

DM1L5IJ	ID	DM1L5IJ
DM1L5IJ	DN	3 beta-O-acetyloleanolic acid
DM1L5IJ	HS	Investigative
DM1L5IJ	SN	3 beta-O-acetyloleanolic acid; CHEMBL503071
DM1L5IJ	DT	Small molecular drug
DM1L5IJ	PC	44583799
DM1L5IJ	MW	498.7
DM1L5IJ	FM	C32H50O4
DM1L5IJ	IC	InChI=1S/C32H50O4/c1-27(2)15-17-32(26(34)35)18-16-30(6)20(22(32)19-27)9-10-24-29(5)13-11-21(25(33)36-8)28(3,4)23(29)12-14-31(24,30)7/h9,21-24H,10-19H2,1-8H3,(H,34,35)/t21-,22+,23+,24-,29+,30-,31-,32+/m1/s1
DM1L5IJ	CS	C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C)C(=O)OC
DM1L5IJ	IK	HDWYAPCZHCDUNP-JVZQWSIASA-N
DM1L5IJ	IU	(4aS,6aR,6aS,6bR,8aS,10S,12aS,14bS)-10-methoxycarbonyl-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DM1L5IJ	DE	Discovery agent

DM491YV	ID	DM491YV
DM491YV	DN	3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one
DM491YV	HS	Investigative
DM491YV	SN	CHEMBL350922; 3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one; BDBM50097364; 3-Imidazol-1-ylmethyl-xanthen-9-one
DM491YV	DT	Small molecular drug
DM491YV	PC	10588478
DM491YV	MW	276.29
DM491YV	FM	C17H12N2O2
DM491YV	IC	InChI=1S/C17H12N2O2/c20-17-13-3-1-2-4-15(13)21-16-9-12(5-6-14(16)17)10-19-8-7-18-11-19/h1-9,11H,10H2
DM491YV	CS	C1=CC=C2C(=C1)C(=O)C3=C(O2)C=C(C=C3)CN4C=CN=C4
DM491YV	IK	GFCUIFVKCOEHQN-UHFFFAOYSA-N
DM491YV	IU	3-(imidazol-1-ylmethyl)xanthen-9-one
DM491YV	DE	Discovery agent

DMZ9L6Q	ID	DMZ9L6Q
DMZ9L6Q	DN	3-((1H-imidazol-1-yl)methyl)aniline
DMZ9L6Q	HS	Investigative
DMZ9L6Q	SN	3-(1H-imidazol-1-ylmethyl)aniline; 120107-85-9; 3-((1H-imidazol-1-yl)methyl)aniline; 3-(1-Imidazolylmethyl)aniline; 3-(imidazol-1-ylmethyl)aniline; Benzenamine, 3-(1H-imidazol-1-ylmethyl)-; 3-Imidazol-1-ylmethyl-phenylamine; Benzenamine,3-(1H-imidazol-1-ylmethyl)-; CHEMBL597369; 3-(imidazolylmethyl)phenylamine; 3-[(1H-Imidazol-1-yl)methyl]aniline; ACMC-20e0av; AC1Q51NE; 1-(3-aminobenzyl)imidazole; SCHEMBL860653; 3-(Imidazo-1-ylmethyl)aniline; AC1O5C89; CTK4B1687; DTXSID20424305; MolPort-000-143-257
DMZ9L6Q	DT	Small molecular drug
DMZ9L6Q	PC	6481821
DMZ9L6Q	MW	173.21
DMZ9L6Q	FM	C10H11N3
DMZ9L6Q	IC	InChI=1S/C10H11N3/c11-10-3-1-2-9(6-10)7-13-5-4-12-8-13/h1-6,8H,7,11H2
DMZ9L6Q	CS	C1=CC(=CC(=C1)N)CN2C=CN=C2
DMZ9L6Q	IK	HOZXQBSHRUITCX-UHFFFAOYSA-N
DMZ9L6Q	IU	3-(imidazol-1-ylmethyl)aniline
DMZ9L6Q	CA	CAS 120107-85-9
DMZ9L6Q	DE	Discovery agent

DMJ6O43	ID	DMJ6O43
DMJ6O43	DN	3-((1H-imidazol-4-yl)methyl)pyridine
DMJ6O43	HS	Investigative
DMJ6O43	SN	CHEMBL78838; 3-((1H-imidazol-4-yl)methyl)pyridine; BDBM50326297
DMJ6O43	DT	Small molecular drug
DMJ6O43	PC	9812843
DMJ6O43	MW	159.19
DMJ6O43	FM	C9H9N3
DMJ6O43	IC	InChI=1S/C9H9N3/c1-2-8(5-10-3-1)4-9-6-11-7-12-9/h1-3,5-7H,4H2,(H,11,12)
DMJ6O43	CS	C1=CC(=CN=C1)CC2=CN=CN2
DMJ6O43	IK	IQMRECYOUIKYGG-UHFFFAOYSA-N
DMJ6O43	IU	3-(1H-imidazol-5-ylmethyl)pyridine
DMJ6O43	DE	Discovery agent

DMSGX7V	ID	DMSGX7V
DMSGX7V	DN	3-((2-Pyrrolidine-1-yl)-ethyl)uracil
DMSGX7V	HS	Investigative
DMSGX7V	SN	CHEMBL1275720; 3-((2-pyrrolidin-1-yl)ethyl)uracil; 1254329-95-7; 3-((2-Pyrrolidine-1-yl)-ethyl)uracil
DMSGX7V	DT	Small molecular drug
DMSGX7V	PC	49845542
DMSGX7V	MW	209.24
DMSGX7V	FM	C10H15N3O2
DMSGX7V	IC	InChI=1S/C10H15N3O2/c14-9-3-4-11-10(15)13(9)8-7-12-5-1-2-6-12/h3-4H,1-2,5-8H2,(H,11,15)
DMSGX7V	CS	C1CCN(C1)CCN2C(=O)C=CNC2=O
DMSGX7V	IK	XKWFMZHWDROEIH-UHFFFAOYSA-N
DMSGX7V	IU	3-(2-pyrrolidin-1-ylethyl)-1H-pyrimidine-2,4-dione
DMSGX7V	DE	Discovery agent

DMJZK40	ID	DMJZK40
DMJZK40	DN	3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DMJZK40	HS	Investigative
DMJZK40	DT	Small molecular drug
DMJZK40	PC	9964499
DMJZK40	DE	Discovery agent

DME3079	ID	DME3079
DME3079	DN	3-((3-bromothiophen-2-yl)methylene)indolin-2-one
DME3079	HS	Investigative
DME3079	SN	CHEMBL230414; 3-((3-bromothiophen-2-yl)methylene)indolin-2-one
DME3079	DT	Small molecular drug
DME3079	PC	22394620
DME3079	MW	306.18
DME3079	FM	C13H8BrNOS
DME3079	IC	InChI=1S/C13H8BrNOS/c14-10-5-6-17-12(10)7-9-8-3-1-2-4-11(8)15-13(9)16/h1-7H,(H,15,16)/b9-7+
DME3079	CS	C1=CC=C2C(=C1)/C(=C\\C3=C(C=CS3)Br)/C(=O)N2
DME3079	IK	ZGCKMTQNGWQKEN-VQHVLOKHSA-N
DME3079	IU	(3E)-3-[(3-bromothiophen-2-yl)methylidene]-1H-indol-2-one
DME3079	DE	Discovery agent

DM37X04	ID	DM37X04
DM37X04	DN	3-((4-aminophenyl)diazenyl)benzenesulfonamide
DM37X04	HS	Investigative
DM37X04	SN	3-(4'-Aminophenyl)diazenylbenzenesulfonamide
DM37X04	DT	Small molecular drug
DM37X04	PC	44246267
DM37X04	MW	276.32
DM37X04	FM	C12H12N4O2S
DM37X04	IC	InChI=1S/C12H12N4O2S/c13-9-4-6-10(7-5-9)15-16-11-2-1-3-12(8-11)19(14,17)18/h1-8H,13H2,(H2,14,17,18)
DM37X04	CS	C1=CC(=CC(=C1)S(=O)(=O)N)N=NC2=CC=C(C=C2)N
DM37X04	IK	VAOWCMBATGAWIO-UHFFFAOYSA-N
DM37X04	IU	3-[(4-aminophenyl)diazenyl]benzenesulfonamide
DM37X04	DE	Discovery agent

DMAPZQW	ID	DMAPZQW
DMAPZQW	DN	3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DMAPZQW	HS	Investigative
DMAPZQW	DT	Small molecular drug
DMAPZQW	PC	135932620
DMAPZQW	MW	277.3
DMAPZQW	FM	C12H11N3O3S
DMAPZQW	IC	InChI=1S/C12H11N3O3S/c13-19(17,18)12-3-1-2-10(8-12)15-14-9-4-6-11(16)7-5-9/h1-8,16H,(H2,13,17,18)
DMAPZQW	CS	C1=CC(=CC(=C1)S(=O)(=O)N)N=NC2=CC=C(C=C2)O
DMAPZQW	IK	HJVKSSWMWPZDOV-UHFFFAOYSA-N
DMAPZQW	IU	3-[(4-hydroxyphenyl)diazenyl]benzenesulfonamide
DMAPZQW	DE	Discovery agent

DMAO64J	ID	DMAO64J
DMAO64J	DN	3-((E)-Styryl)-quinoline
DMAO64J	HS	Investigative
DMAO64J	SN	CHEMBL65858; 3-((E)-Styryl)-quinoline; (e)-3-styrylquinoline; 3-[(E)-Styryl]quinoline; SCHEMBL3164863; ZINC3832235; BDBM50039053
DMAO64J	DT	Small molecular drug
DMAO64J	PC	10243001
DMAO64J	MW	231.29
DMAO64J	FM	C17H13N
DMAO64J	IC	InChI=1S/C17H13N/c1-2-6-14(7-3-1)10-11-15-12-16-8-4-5-9-17(16)18-13-15/h1-13H/b11-10+
DMAO64J	CS	C1=CC=C(C=C1)/C=C/C2=CC3=CC=CC=C3N=C2
DMAO64J	IK	OHHPAEZEBAYVPW-ZHACJKMWSA-N
DMAO64J	IU	3-[(E)-2-phenylethenyl]quinoline
DMAO64J	DE	Discovery agent

DMZU74I	ID	DMZU74I
DMZU74I	DN	3-((S)-Azetidin-2-yloxy)-5-iodo-pyridine
DMZU74I	HS	Investigative
DMZU74I	SN	CHEMBL55138; 3-((S)-Azetidin-2-yloxy)-5-iodo-pyridine
DMZU74I	DT	Small molecular drug
DMZU74I	PC	44297909
DMZU74I	MW	276.07
DMZU74I	FM	C8H9IN2O
DMZU74I	IC	InChI=1S/C8H9IN2O/c9-6-3-7(5-10-4-6)12-8-1-2-11-8/h3-5,8,11H,1-2H2/t8-/m0/s1
DMZU74I	CS	C1CN[C@H]1OC2=CC(=CN=C2)I
DMZU74I	IK	KSOZTGQWGPTPSV-QMMMGPOBSA-N
DMZU74I	IU	3-[(2S)-azetidin-2-yl]oxy-5-iodopyridine
DMZU74I	DE	Discovery agent

DM57ZMJ	ID	DM57ZMJ
DM57ZMJ	DN	3-(1,1-Dimethyl-2-phenyl-ethyl)-pyridine
DM57ZMJ	HS	Investigative
DM57ZMJ	SN	CHEMBL440299; 87372-78-9; 3-(1,1-Dimethyl-2-phenyl-ethyl)-pyridine; CTK3C4529; DTXSID20658229; ZINC29556563; BDBM50028169; 3-(2-Methyl-1-phenylpropan-2-yl)pyridine; Pyridine, 3-(1,1-dimethyl-2-phenylethyl)-
DM57ZMJ	DT	Small molecular drug
DM57ZMJ	PC	44299138
DM57ZMJ	MW	211.3
DM57ZMJ	FM	C15H17N
DM57ZMJ	IC	InChI=1S/C15H17N/c1-15(2,14-9-6-10-16-12-14)11-13-7-4-3-5-8-13/h3-10,12H,11H2,1-2H3
DM57ZMJ	CS	CC(C)(CC1=CC=CC=C1)C2=CN=CC=C2
DM57ZMJ	IK	MSUUKPGKCBHOAJ-UHFFFAOYSA-N
DM57ZMJ	IU	3-(2-methyl-1-phenylpropan-2-yl)pyridine
DM57ZMJ	CA	CAS 87372-78-9
DM57ZMJ	DE	Discovery agent

DMTDB62	ID	DMTDB62
DMTDB62	DN	3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole
DMTDB62	HS	Investigative
DMTDB62	SN	3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole; 65347-55-9; 38620-69-8; MLS000093715; SMR000029333; CHEMBL27811; 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole; 3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole; 3-(4-1,2,5,6-tetrahydropyridyl)indole; THPindole; ChemDiv2_002931; AC1Q1GX4; SCHEMBL653742; AC1MC402; CTK5C2597; cid_2761023; BDBM31023; DTXSID20375484; CIRSPTXGPFAXRE-UHFFFAOYSA-N; MolPort-000-159-541; HMS1377F05; ZINC154399; STK801496; 2202AE; SBB092334; BBL010213; MFCD03695471; AKOS000505683; FS-1743; NE12559; CCG-139909
DMTDB62	DT	Small molecular drug
DMTDB62	PC	2761023
DMTDB62	MW	198.26
DMTDB62	FM	C13H14N2
DMTDB62	IC	InChI=1S/C13H14N2/c1-2-4-13-11(3-1)12(9-15-13)10-5-7-14-8-6-10/h1-5,9,14-15H,6-8H2
DMTDB62	CS	C1CNCC=C1C2=CNC3=CC=CC=C32
DMTDB62	IK	CIRSPTXGPFAXRE-UHFFFAOYSA-N
DMTDB62	IU	3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
DMTDB62	CA	CAS 65347-55-9
DMTDB62	DE	Discovery agent

DM5UL3F	ID	DM5UL3F
DM5UL3F	DN	3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine
DM5UL3F	HS	Investigative
DM5UL3F	SN	3'-(1,2,3-Triazol)dT; 3'-Deoxy-3'-(1,2,3-triazol-1-yl)thymidine; 122370-58-5; CHEMBL1092729; Thymidine,3'-deoxy-3'-(1H-1,2,3-triazol-1-yl)- (9CI); AC1L9Q42; SCHEMBL9965127; CTK4B3087; DTXSID60153586; BDBM50314847; 3'-(1H-1,2,3-Triazol-1-yl)-3'-deoxythymidine; 3''-(1,2,3-Triazol-1-yl)-3''-deoxy-beta-D-thymidine; 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
DM5UL3F	DT	Small molecular drug
DM5UL3F	PC	452142
DM5UL3F	MW	293.28
DM5UL3F	FM	C12H15N5O4
DM5UL3F	IC	InChI=1S/C12H15N5O4/c1-7-5-16(12(20)14-11(7)19)10-4-8(9(6-18)21-10)17-3-2-13-15-17/h2-3,5,8-10,18H,4,6H2,1H3,(H,14,19,20)/t8-,9+,10+/m0/s1
DM5UL3F	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N3C=CN=N3
DM5UL3F	IK	CPWUCLYZTKEZPT-IVZWLZJFSA-N
DM5UL3F	IU	1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM5UL3F	CA	CAS 122370-58-5
DM5UL3F	DE	Discovery agent

DMXZBQL	ID	DMXZBQL
DMXZBQL	DN	3-(1,2-dihydroacenaphthylen-3-yl)pyridine
DMXZBQL	HS	Investigative
DMXZBQL	SN	acenaphthene derivative A; 3-(1,2-dihydroacenaphthylen-3-yl)pyridine; CHEMBL372747; SCHEMBL4225082
DMXZBQL	DT	Small molecular drug
DMXZBQL	PC	11586681
DMXZBQL	MW	231.29
DMXZBQL	FM	C17H13N
DMXZBQL	IC	InChI=1S/C17H13N/c1-3-12-6-8-15(14-5-2-10-18-11-14)16-9-7-13(4-1)17(12)16/h1-6,8,10-11H,7,9H2
DMXZBQL	CS	C1CC2=C(C=CC3=C2C1=CC=C3)C4=CN=CC=C4
DMXZBQL	IK	CKORXOPHZBFEPV-UHFFFAOYSA-N
DMXZBQL	IU	3-(1,2-dihydroacenaphthylen-3-yl)pyridine
DMXZBQL	DE	Discovery agent

DMHB4PA	ID	DMHB4PA
DMHB4PA	DN	3-(1,2-dihydroacenaphthylen-5-yl)pyridine
DMHB4PA	HS	Investigative
DMHB4PA	SN	acenaphthene derivative B; 3-(1,2-dihydroacenaphthylen-5-yl)pyridine; CHEMBL199683
DMHB4PA	DT	Small molecular drug
DMHB4PA	PC	23644953
DMHB4PA	MW	231.29
DMHB4PA	FM	C17H13N
DMHB4PA	IC	InChI=1S/C17H13N/c1-3-12-6-7-13-8-9-15(16(5-1)17(12)13)14-4-2-10-18-11-14/h1-5,8-11H,6-7H2
DMHB4PA	CS	C1CC2=CC=C(C3=CC=CC1=C23)C4=CN=CC=C4
DMHB4PA	IK	BWVFIMXEVGYZOM-UHFFFAOYSA-N
DMHB4PA	IU	3-(1,2-dihydroacenaphthylen-5-yl)pyridine
DMHB4PA	DE	Discovery agent

DMQC168	ID	DMQC168
DMQC168	DN	3-(1,3 dodecadiynyl)-6-oxiranebutanoic acid
DMQC168	HS	Investigative
DMQC168	SN	4-[3-(Dodeca-1,3-diyn-1-yl)oxiran-2-yl]butanoic acid; CHEMBL483819; FA(18:4)(Ep,cyclo); GTPL2958; LMFA01070030; BDBM50292404; 5,6-Epoxyoctadeca-7,9-diynoic acid; 5,6-epoxy-7,9-octadecadiynoic acid; compound 9a [Patil et al, 1989]; 4-[3-(dodeca-1,3-diyn-1-yl)oxiran-2-yl]butanoic; compound 9a (Patil et al., 1989)
DMQC168	DT	Small molecular drug
DMQC168	PC	14309407
DMQC168	MW	290.4
DMQC168	FM	C18H26O3
DMQC168	IC	InChI=1S/C18H26O3/c1-2-3-4-5-6-7-8-9-10-11-13-16-17(21-16)14-12-15-18(19)20/h16-17H,2-8,12,14-15H2,1H3,(H,19,20)
DMQC168	CS	CCCCCCCCC#CC#CC1C(O1)CCCC(=O)O
DMQC168	IK	XLDNBXDVNANPCY-UHFFFAOYSA-N
DMQC168	IU	4-(3-dodeca-1,3-diynyloxiran-2-yl)butanoic acid
DMQC168	DE	Discovery agent

DM24BG6	ID	DM24BG6
DM24BG6	DN	3-(1,5-naphthyridin-3-yl)benzonitrile
DM24BG6	HS	Investigative
DM24BG6	SN	CHEMBL394718; 3-(1,5-naphthyridin-3-yl)benzonitrile
DM24BG6	DT	Small molecular drug
DM24BG6	PC	44434729
DM24BG6	MW	231.25
DM24BG6	FM	C15H9N3
DM24BG6	IC	InChI=1S/C15H9N3/c16-9-11-3-1-4-12(7-11)13-8-15-14(18-10-13)5-2-6-17-15/h1-8,10H
DM24BG6	CS	C1=CC(=CC(=C1)C2=CC3=C(C=CC=N3)N=C2)C#N
DM24BG6	IK	GOWMBIHHRVFADP-UHFFFAOYSA-N
DM24BG6	IU	3-(1,5-naphthyridin-3-yl)benzonitrile
DM24BG6	DE	Discovery agent

DMSP4N5	ID	DMSP4N5
DMSP4N5	DN	3-(1,8-naphthyridin-2-yl)benzonitrile
DMSP4N5	HS	Investigative
DMSP4N5	SN	CHEMBL235397; 3-(1,8-naphthyridin-2-yl)benzonitrile
DMSP4N5	DT	Small molecular drug
DMSP4N5	PC	44434717
DMSP4N5	MW	231.25
DMSP4N5	FM	C15H9N3
DMSP4N5	IC	InChI=1S/C15H9N3/c16-10-11-3-1-4-13(9-11)14-7-6-12-5-2-8-17-15(12)18-14/h1-9H
DMSP4N5	CS	C1=CC(=CC(=C1)C2=NC3=C(C=CC=N3)C=C2)C#N
DMSP4N5	IK	ANJYTIPEHJCPPM-UHFFFAOYSA-N
DMSP4N5	IU	3-(1,8-naphthyridin-2-yl)benzonitrile
DMSP4N5	DE	Discovery agent

DMSZLNE	ID	DMSZLNE
DMSZLNE	DN	3'-(1-Benzothien-2-yl)biphenyl-3-ol
DMSZLNE	HS	Investigative
DMSZLNE	SN	CHEMBL1097016; BDBM50318420
DMSZLNE	DT	Small molecular drug
DMSZLNE	PC	46887555
DMSZLNE	MW	302.4
DMSZLNE	FM	C20H14OS
DMSZLNE	IC	InChI=1S/C20H14OS/c21-18-9-4-7-15(12-18)14-6-3-8-16(11-14)20-13-17-5-1-2-10-19(17)22-20/h1-13,21H
DMSZLNE	CS	C1=CC=C2C(=C1)C=C(S2)C3=CC=CC(=C3)C4=CC(=CC=C4)O
DMSZLNE	IK	BQKUVAJYBNSSNI-UHFFFAOYSA-N
DMSZLNE	IU	3-[3-(1-benzothiophen-2-yl)phenyl]phenol
DMSZLNE	DE	Discovery agent

DMGYDEK	ID	DMGYDEK
DMGYDEK	DN	3-(1-Benzyl-1H-imidazol-5-yl)-1-propanol
DMGYDEK	HS	Investigative
DMGYDEK	SN	CHEMBL610794; 3-(1-Benzyl-1H-imidazol-5-yl)-1-propanol
DMGYDEK	DT	Small molecular drug
DMGYDEK	PC	45103805
DMGYDEK	MW	216.28
DMGYDEK	FM	C13H16N2O
DMGYDEK	IC	InChI=1S/C13H16N2O/c16-8-4-7-13-9-14-11-15(13)10-12-5-2-1-3-6-12/h1-3,5-6,9,11,16H,4,7-8,10H2
DMGYDEK	CS	C1=CC=C(C=C1)CN2C=NC=C2CCCO
DMGYDEK	IK	TZVJUMCHCPZGTM-UHFFFAOYSA-N
DMGYDEK	IU	3-(3-benzylimidazol-4-yl)propan-1-ol
DMGYDEK	CA	CAS 1000540-66-8
DMGYDEK	DE	Discovery agent

DMGDN93	ID	DMGDN93
DMGDN93	DN	3-(1-Benzyl-piperidin-3-yl)-2-phenyl-1H-indole
DMGDN93	HS	Investigative
DMGDN93	SN	CHEMBL46523; 3-(1-Benzyl-piperidin-3-yl)-2-phenyl-1H-indole; SCHEMBL8524973; BDBM50099274
DMGDN93	DT	Small molecular drug
DMGDN93	PC	9842124
DMGDN93	MW	366.5
DMGDN93	FM	C26H26N2
DMGDN93	IC	InChI=1S/C26H26N2/c1-3-10-20(11-4-1)18-28-17-9-14-22(19-28)25-23-15-7-8-16-24(23)27-26(25)21-12-5-2-6-13-21/h1-8,10-13,15-16,22,27H,9,14,17-19H2
DMGDN93	CS	C1CC(CN(C1)CC2=CC=CC=C2)C3=C(NC4=CC=CC=C43)C5=CC=CC=C5
DMGDN93	IK	RXGPCIHYSMKIRI-UHFFFAOYSA-N
DMGDN93	IU	3-(1-benzylpiperidin-3-yl)-2-phenyl-1H-indole
DMGDN93	DE	Discovery agent

DMWP0VK	ID	DMWP0VK
DMWP0VK	DN	3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole
DMWP0VK	HS	Investigative
DMWP0VK	SN	CHEMBL327169; 3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole; SCHEMBL7955758; BDBM50095051; L018754
DMWP0VK	DT	Small molecular drug
DMWP0VK	PC	18354719
DMWP0VK	MW	366.5
DMWP0VK	FM	C26H26N2
DMWP0VK	IC	InChI=1S/C26H26N2/c1-3-9-20(10-4-1)19-28-17-15-21(16-18-28)25-23-13-7-8-14-24(23)27-26(25)22-11-5-2-6-12-22/h1-14,21,27H,15-19H2
DMWP0VK	CS	C1CN(CCC1C2=C(NC3=CC=CC=C32)C4=CC=CC=C4)CC5=CC=CC=C5
DMWP0VK	IK	DGLKVJXUWHYMSL-UHFFFAOYSA-N
DMWP0VK	IU	3-(1-benzylpiperidin-4-yl)-2-phenyl-1H-indole
DMWP0VK	DE	Discovery agent

DM2YKHI	ID	DM2YKHI
DM2YKHI	DN	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole
DM2YKHI	HS	Investigative
DM2YKHI	SN	CHEMBL210770; 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole; SCHEMBL14280723; NRIVFQIOYWIUPX-UHFFFAOYSA-N; BDBM50185792
DM2YKHI	DT	Small molecular drug
DM2YKHI	PC	44413409
DM2YKHI	MW	324.8
DM2YKHI	FM	C20H21ClN2
DM2YKHI	IC	InChI=1S/C20H21ClN2/c21-17-6-7-20-18(12-17)19(13-22-20)16-8-10-23(11-9-16)14-15-4-2-1-3-5-15/h1-7,12-13,16,22H,8-11,14H2
DM2YKHI	CS	C1CN(CCC1C2=CNC3=C2C=C(C=C3)Cl)CC4=CC=CC=C4
DM2YKHI	IK	NRIVFQIOYWIUPX-UHFFFAOYSA-N
DM2YKHI	IU	3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole
DM2YKHI	DE	Discovery agent

DMG3A4Z	ID	DMG3A4Z
DMG3A4Z	DN	3-(1-benzylpiperidin-4-yloxy)benzamide
DMG3A4Z	HS	Investigative
DMG3A4Z	SN	3-((1-Benzylpiperidin-4-yl)oxy)benzamide; 1254475-25-6; CHEMBL1257457; 3-[(1-Benzylpiperidin-4-yl)oxy]benzamide; 3-(1-benzylpiperidin-4-yloxy)benzamide; DTXSID90680658; ZINC64548741; BDBM50327259; AKOS022176132; AJ-114866
DMG3A4Z	DT	Small molecular drug
DMG3A4Z	PC	52946209
DMG3A4Z	MW	310.4
DMG3A4Z	FM	C19H22N2O2
DMG3A4Z	IC	InChI=1S/C19H22N2O2/c20-19(22)16-7-4-8-18(13-16)23-17-9-11-21(12-10-17)14-15-5-2-1-3-6-15/h1-8,13,17H,9-12,14H2,(H2,20,22)
DMG3A4Z	CS	C1CN(CCC1OC2=CC=CC(=C2)C(=O)N)CC3=CC=CC=C3
DMG3A4Z	IK	IDSIUINGWBNUFD-UHFFFAOYSA-N
DMG3A4Z	IU	3-(1-benzylpiperidin-4-yl)oxybenzamide
DMG3A4Z	CA	CAS 1254475-25-6
DMG3A4Z	DE	Discovery agent

DMOMSTN	ID	DMOMSTN
DMOMSTN	DN	3-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenylethyl)pyrrolidine (APP)
DMOMSTN	HS	Investigative
DMOMSTN	DE	Discovery agent

DMHPYWM	ID	DMHPYWM
DMHPYWM	DN	3-(1-carboxy-4-mercaptobutoxy)benzoic acid
DMHPYWM	HS	Investigative
DMHPYWM	SN	Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)-; Thiol-Based Inhibitor, 26a; CHEMBL207350; SCHEMBL5053092; BDBM17775; KUHQPVJMGPHXPD-UHFFFAOYSA-N; 378242-30-9; 3-(1-carboxy-4-sulfanylbutoxy)benzoic acid; 3-(l-carboxy-4-mercaptobutoxy)-benzoic acid; 3-(1-Carboxy-4-mercaptobutoxy)-benzoic Acid
DMHPYWM	DT	Small molecular drug
DMHPYWM	PC	9900104
DMHPYWM	MW	270.3
DMHPYWM	FM	C12H14O5S
DMHPYWM	IC	InChI=1S/C12H14O5S/c13-11(14)8-3-1-4-9(7-8)17-10(12(15)16)5-2-6-18/h1,3-4,7,10,18H,2,5-6H2,(H,13,14)(H,15,16)
DMHPYWM	CS	C1=CC(=CC(=C1)OC(CCCS)C(=O)O)C(=O)O
DMHPYWM	IK	KUHQPVJMGPHXPD-UHFFFAOYSA-N
DMHPYWM	IU	3-(1-carboxy-4-sulfanylbutoxy)benzoic acid
DMHPYWM	DE	Discovery agent

DMLH7YI	ID	DMLH7YI
DMLH7YI	DN	3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine
DMLH7YI	HS	Investigative
DMLH7YI	SN	SCHEMBL4517614; BDBM8913; CHEMBL371430; Pyridine-substituted naphthalene 14; ZINC13674470; 3-(1-chloro-7-methoxy-2-naphthyl)pyridine; 3-(1-chloro-7-methoxynaphthalen-2-yl)pyridine
DMLH7YI	DT	Small molecular drug
DMLH7YI	PC	11680597
DMLH7YI	MW	269.72
DMLH7YI	FM	C16H12ClNO
DMLH7YI	IC	InChI=1S/C16H12ClNO/c1-19-13-6-4-11-5-7-14(16(17)15(11)9-13)12-3-2-8-18-10-12/h2-10H,1H3
DMLH7YI	CS	COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CN=CC=C3
DMLH7YI	IK	KRLGQBXIHBDUPS-UHFFFAOYSA-N
DMLH7YI	IU	3-(1-chloro-7-methoxynaphthalen-2-yl)pyridine
DMLH7YI	DE	Discovery agent

DMR7M82	ID	DMR7M82
DMR7M82	DN	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMR7M82	HS	Investigative
DMR7M82	SN	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 7; AC1O70HD; 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine; CHEMBL205503; BDBM8893; SCHEMBL4505824; CTK6D0393; ZINC13684518; AKOS015965702
DMR7M82	DT	Small molecular drug
DMR7M82	PC	6540051
DMR7M82	MW	235.32
DMR7M82	FM	C17H17N
DMR7M82	IC	InChI=1S/C17H17N/c1-2-15-16-8-4-3-6-13(16)9-10-17(15)14-7-5-11-18-12-14/h3-8,11-12H,2,9-10H2,1H3
DMR7M82	CS	CCC1=C(CCC2=CC=CC=C21)C3=CN=CC=C3
DMR7M82	IK	ZKPVULIWDZEZIT-UHFFFAOYSA-N
DMR7M82	IU	3-(1-ethyl-3,4-dihydronaphthalen-2-yl)pyridine
DMR7M82	DE	Discovery agent

DMERZHK	ID	DMERZHK
DMERZHK	DN	3-(1H-Imidazol-4-yl)benzenethiol
DMERZHK	HS	Investigative
DMERZHK	SN	3-(1H-Imidazol-4-yl)benzenethiol; 1048983-24-9; CHEMBL446387; SCHEMBL1501883; BDBM24665; 3-(1H-imidazol-4-yl)benzene-1-thiol; 3-(1H-imidazol-4-yl)benzenethiol, 17
DMERZHK	DT	Small molecular drug
DMERZHK	PC	24971327
DMERZHK	MW	176.24
DMERZHK	FM	C9H8N2S
DMERZHK	IC	InChI=1S/C9H8N2S/c12-8-3-1-2-7(4-8)9-5-10-6-11-9/h1-6,12H,(H,10,11)
DMERZHK	CS	C1=CC(=CC(=C1)S)C2=CN=CN2
DMERZHK	IK	GZDISEVTMUIDGB-UHFFFAOYSA-N
DMERZHK	IU	3-(1H-imidazol-5-yl)benzenethiol
DMERZHK	DE	Discovery agent

DM9ZDIK	ID	DM9ZDIK
DM9ZDIK	DN	3-(1H-inden-2-yl)pyridine
DM9ZDIK	HS	Investigative
DM9ZDIK	SN	3-(1H-inden-2-yl)pyridine; indene 1; SCHEMBL4504698; CHEMBL205782; BDBM8888; AC1O70H3
DM9ZDIK	DT	Small molecular drug
DM9ZDIK	PC	6540046
DM9ZDIK	MW	193.24
DM9ZDIK	FM	C14H11N
DM9ZDIK	IC	InChI=1S/C14H11N/c1-2-5-12-9-14(8-11(12)4-1)13-6-3-7-15-10-13/h1-8,10H,9H2
DM9ZDIK	CS	C1C2=CC=CC=C2C=C1C3=CN=CC=C3
DM9ZDIK	IK	NNEAKBWZBQOQDH-UHFFFAOYSA-N
DM9ZDIK	IU	3-(1H-inden-2-yl)pyridine
DM9ZDIK	DE	Discovery agent

DMLV80B	ID	DMLV80B
DMLV80B	DN	3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine
DMLV80B	HS	Investigative
DMLV80B	SN	CHEMBL453838; SCHEMBL2074980; 3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine; VDFAJYFMKVKZLC-UHFFFAOYSA-N; BDBM50245797
DMLV80B	DT	Small molecular drug
DMLV80B	PC	44593439
DMLV80B	MW	264.4
DMLV80B	FM	C18H20N2
DMLV80B	IC	InChI=1S/C18H20N2/c1-19-13-11-18(15-7-3-2-4-8-15)20-14-12-16-9-5-6-10-17(16)20/h2-10,12,14,18-19H,11,13H2,1H3
DMLV80B	CS	CNCCC(C1=CC=CC=C1)N2C=CC3=CC=CC=C32
DMLV80B	IK	VDFAJYFMKVKZLC-UHFFFAOYSA-N
DMLV80B	IU	3-indol-1-yl-N-methyl-3-phenylpropan-1-amine
DMLV80B	DE	Discovery agent

DMS3JCN	ID	DMS3JCN
DMS3JCN	DN	3-(1H-Indol-2-yl)-1H-quinolin-2-one
DMS3JCN	HS	Investigative
DMS3JCN	SN	3-(1H-indol-2-yl)quinolin-2(1H)-one
DMS3JCN	DT	Small molecular drug
DMS3JCN	PC	5329371
DMS3JCN	MW	260.29
DMS3JCN	FM	C17H12N2O
DMS3JCN	IC	InChI=1S/C17H12N2O/c20-17-13(9-11-5-1-4-8-15(11)19-17)16-10-12-6-2-3-7-14(12)18-16/h1-10,18H,(H,19,20)
DMS3JCN	CS	C1=CC=C2C(=C1)C=C(C(=O)N2)C3=CC4=CC=CC=C4N3
DMS3JCN	IK	OSFGHYZLBDAJTP-UHFFFAOYSA-N
DMS3JCN	IU	3-(1H-indol-2-yl)-1H-quinolin-2-one
DMS3JCN	DE	Discovery agent

DMP0RYB	ID	DMP0RYB
DMP0RYB	DN	3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione
DMP0RYB	HS	Investigative
DMP0RYB	SN	CHEMBL183310; 3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione; SCHEMBL7840920; 1H-Pyrrole-2,5-dione,3-(1H-indol-3-yl)-4-(phenylamino)-; BDBM50153450; 257878-66-3
DMP0RYB	DT	Small molecular drug
DMP0RYB	PC	17814743
DMP0RYB	MW	303.3
DMP0RYB	FM	C18H13N3O2
DMP0RYB	IC	InChI=1S/C18H13N3O2/c22-17-15(13-10-19-14-9-5-4-8-12(13)14)16(18(23)21-17)20-11-6-2-1-3-7-11/h1-10,19H,(H2,20,21,22,23)
DMP0RYB	CS	C1=CC=C(C=C1)NC2=C(C(=O)NC2=O)C3=CNC4=CC=CC=C43
DMP0RYB	IK	WEKZVKNLORTLQV-UHFFFAOYSA-N
DMP0RYB	IU	3-anilino-4-(1H-indol-3-yl)pyrrole-2,5-dione
DMP0RYB	DE	Discovery agent

DMSGCKU	ID	DMSGCKU
DMSGCKU	DN	3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline
DMSGCKU	HS	Investigative
DMSGCKU	SN	CHEMBL302545; 3-(1H-indol-3-yl)-6,7-dimethoxy-quinoline; SCHEMBL8172242
DMSGCKU	DT	Small molecular drug
DMSGCKU	PC	9972296
DMSGCKU	MW	304.3
DMSGCKU	FM	C19H16N2O2
DMSGCKU	IC	InChI=1S/C19H16N2O2/c1-22-18-8-12-7-13(10-20-17(12)9-19(18)23-2)15-11-21-16-6-4-3-5-14(15)16/h3-11,21H,1-2H3
DMSGCKU	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CNC4=CC=CC=C43
DMSGCKU	IK	CTHPHODXZDFNPE-UHFFFAOYSA-N
DMSGCKU	IU	3-(1H-indol-3-yl)-6,7-dimethoxyquinoline
DMSGCKU	DE	Discovery agent

DM6Y2XK	ID	DM6Y2XK
DM6Y2XK	DN	3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine
DM6Y2XK	HS	Investigative
DM6Y2XK	SN	NSC88622; 3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine; NSC-88622; 13117-35-6; CHEMBL360575; AC1Q3WPU; NCIStruc2_000554; NCIStruc1_000767; AC1L1D58; SCHEMBL3957606; N,N-DIMETHYLHOMOTRYPTAMINE; DTXSID00275574; ZINC393884; NCI88622; NCGC00013925; BDBM50162709; CCG-38332; AKOS024323101; MCULE-7123094039; NCGC00097034-01; NCGC00013925-02; NCI60_041964; [3-(1H-indol-3-yl)propyl]dimethylamine; [3-(1H-Indol-3-yl)-propyl]-dimethyl-amine
DM6Y2XK	DT	Small molecular drug
DM6Y2XK	PC	52549
DM6Y2XK	MW	202.3
DM6Y2XK	FM	C13H18N2
DM6Y2XK	IC	InChI=1S/C13H18N2/c1-15(2)9-5-6-11-10-14-13-8-4-3-7-12(11)13/h3-4,7-8,10,14H,5-6,9H2,1-2H3
DM6Y2XK	CS	CN(C)CCCC1=CNC2=CC=CC=C21
DM6Y2XK	IK	QHNWPRMHGXRBAO-UHFFFAOYSA-N
DM6Y2XK	IU	3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine
DM6Y2XK	CA	CAS 13117-35-6
DM6Y2XK	DE	Discovery agent

DMEV6Q2	ID	DMEV6Q2
DMEV6Q2	DN	3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine
DMEV6Q2	HS	Investigative
DMEV6Q2	SN	CHEMBL487763; 3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine; SCHEMBL2074218; HYXMIUGYZHSSJS-UHFFFAOYSA-N; BDBM50275378
DMEV6Q2	DT	Small molecular drug
DMEV6Q2	PC	44589528
DMEV6Q2	MW	264.4
DMEV6Q2	FM	C18H20N2
DMEV6Q2	IC	InChI=1S/C18H20N2/c1-19-12-11-15(14-7-3-2-4-8-14)17-13-20-18-10-6-5-9-16(17)18/h2-10,13,15,19-20H,11-12H2,1H3
DMEV6Q2	CS	CNCCC(C1=CC=CC=C1)C2=CNC3=CC=CC=C32
DMEV6Q2	IK	HYXMIUGYZHSSJS-UHFFFAOYSA-N
DMEV6Q2	IU	3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine
DMEV6Q2	DE	Discovery agent

DMW7XN5	ID	DMW7XN5
DMW7XN5	DN	3-(1H-Indol-3-yl)-quinoline
DMW7XN5	HS	Investigative
DMW7XN5	SN	3-(1H-indol-3-yl)quinoline; CHEMBL309116; 3-(1H-Indol-3-yl)-quinoline; 3-(3-Quinolyl)-1H-indole; SCHEMBL8171583; ZINC13737696; BDBM50039096
DMW7XN5	DT	Small molecular drug
DMW7XN5	PC	10243546
DMW7XN5	MW	244.29
DMW7XN5	FM	C17H12N2
DMW7XN5	IC	InChI=1S/C17H12N2/c1-3-7-16-12(5-1)9-13(10-18-16)15-11-19-17-8-4-2-6-14(15)17/h1-11,19H
DMW7XN5	CS	C1=CC=C2C(=C1)C=C(C=N2)C3=CNC4=CC=CC=C43
DMW7XN5	IK	BJQHKICYZOBROI-UHFFFAOYSA-N
DMW7XN5	IU	3-(1H-indol-3-yl)quinoline
DMW7XN5	DE	Discovery agent

DMKFGDI	ID	DMKFGDI
DMKFGDI	DN	3-(1H-pyrazol-3-yl)benzoic acid
DMKFGDI	HS	Investigative
DMKFGDI	SN	3-(1H-pyrazol-5-yl)benzoic acid; 850375-11-0; 3-(1H-pyrazol-3-yl)benzoic acid; 3-(2H-pyrazol-3-yl)benzoic Acid; Benzoic acid, 3-(1H-pyrazol-3-yl)-; CHEMBL497801; 5-(3-Carboxyphenyl)-1H-pyrazole; PubChem22748; AC1MDTM0; buttpark 44\01-87; 3-pyrazol-5-ylbenzoic acid; 3-pyrazol-3-ylbenzoic acid; SCHEMBL939810; CTK5F3854; CTK7I8615; DTXSID80383762; MolPort-000-142-934; RXZRBZWATRFHCS-UHFFFAOYSA-N; MolPort-009-196-824; 3-(2h-pyrazol-3-yl)-benzoicacid; KS-00002A0D; ZX-AT019147; ZINC4200665; 3-(1H-Pyrazole-3-yl)benzoic acid
DMKFGDI	DT	Small molecular drug
DMKFGDI	PC	2795542
DMKFGDI	MW	188.18
DMKFGDI	FM	C10H8N2O2
DMKFGDI	IC	InChI=1S/C10H8N2O2/c13-10(14)8-3-1-2-7(6-8)9-4-5-11-12-9/h1-6H,(H,11,12)(H,13,14)
DMKFGDI	CS	C1=CC(=CC(=C1)C(=O)O)C2=CC=NN2
DMKFGDI	IK	RXZRBZWATRFHCS-UHFFFAOYSA-N
DMKFGDI	IU	3-(1H-pyrazol-5-yl)benzoic acid
DMKFGDI	CA	CAS 850375-11-0
DMKFGDI	DE	Discovery agent

DMCKJ27	ID	DMCKJ27
DMCKJ27	DN	3-(1H-Pyrrol-3-yl)-propionamide
DMCKJ27	HS	Investigative
DMCKJ27	SN	1H-Pyrrole-3-propanamide; CHEMBL277776; 152509-75-6; 3-(1H-Pyrrol-3-yl)-propionamide; ACMC-20n6gu; CTK0I3006; DTXSID90435928; BDBM50287316
DMCKJ27	DT	Small molecular drug
DMCKJ27	PC	10129992
DMCKJ27	MW	138.17
DMCKJ27	FM	C7H10N2O
DMCKJ27	IC	InChI=1S/C7H10N2O/c8-7(10)2-1-6-3-4-9-5-6/h3-5,9H,1-2H2,(H2,8,10)
DMCKJ27	CS	C1=CNC=C1CCC(=O)N
DMCKJ27	IK	TWGRVIPCCGRSNM-UHFFFAOYSA-N
DMCKJ27	IU	3-(1H-pyrrol-3-yl)propanamide
DMCKJ27	CA	CAS 152509-75-6
DMCKJ27	DE	Discovery agent

DMU5HMC	ID	DMU5HMC
DMU5HMC	DN	3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMU5HMC	HS	Investigative
DMU5HMC	SN	3614-50-4; 3-(1-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 6; 2-yl)-pyridine; 3-(1-Methyl-3,4-dihydro-naphthalen-; AC1O70HB; 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine; SCHEMBL4514804; CHEMBL206283; BDBM8892; CTK4H5985; DTXSID90424897; ZINC13684515; AKOS015965701; ACM3614504; AC-20696; KB-232450
DMU5HMC	DT	Small molecular drug
DMU5HMC	PC	6540050
DMU5HMC	MW	221.3
DMU5HMC	FM	C16H15N
DMU5HMC	IC	InChI=1S/C16H15N/c1-12-15-7-3-2-5-13(15)8-9-16(12)14-6-4-10-17-11-14/h2-7,10-11H,8-9H2,1H3
DMU5HMC	CS	CC1=C(CCC2=CC=CC=C12)C3=CN=CC=C3
DMU5HMC	IK	WBEMJRFRGOAAJI-UHFFFAOYSA-N
DMU5HMC	IU	3-(1-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DMU5HMC	CA	CAS 3614-50-4
DMU5HMC	DE	Discovery agent

DMK8LHB	ID	DMK8LHB
DMK8LHB	DN	3-(1-Methyl-piperidin-2-yl)-2-phenyl-1H-indole
DMK8LHB	HS	Investigative
DMK8LHB	SN	CHEMBL43697; 3-(1-Methyl-piperidin-2-yl)-2-phenyl-1H-indole; BDBM50099263
DMK8LHB	DT	Small molecular drug
DMK8LHB	PC	10493741
DMK8LHB	MW	290.4
DMK8LHB	FM	C20H22N2
DMK8LHB	IC	InChI=1S/C20H22N2/c1-22-14-8-7-13-18(22)19-16-11-5-6-12-17(16)21-20(19)15-9-3-2-4-10-15/h2-6,9-12,18,21H,7-8,13-14H2,1H3
DMK8LHB	CS	CN1CCCCC1C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DMK8LHB	IK	YKKPUIDGSXNPRO-UHFFFAOYSA-N
DMK8LHB	IU	3-(1-methylpiperidin-2-yl)-2-phenyl-1H-indole
DMK8LHB	DE	Discovery agent

DM4UD8C	ID	DM4UD8C
DM4UD8C	DN	3-(1-Methyl-piperidin-3-yl)-2-phenyl-1H-indole
DM4UD8C	HS	Investigative
DM4UD8C	SN	CHEMBL43819; 3-(1-Methyl-piperidin-3-yl)-2-phenyl-1H-indole; SCHEMBL8525408; BDBM50099264; 3-(1-methylpiperidin-3-yl)-2-phenyl-1H-indole
DM4UD8C	DT	Small molecular drug
DM4UD8C	PC	9838960
DM4UD8C	MW	290.4
DM4UD8C	FM	C20H22N2
DM4UD8C	IC	InChI=1S/C20H22N2/c1-22-13-7-10-16(14-22)19-17-11-5-6-12-18(17)21-20(19)15-8-3-2-4-9-15/h2-6,8-9,11-12,16,21H,7,10,13-14H2,1H3
DM4UD8C	CS	CN1CCCC(C1)C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DM4UD8C	IK	JRFXDRYERZNJFJ-UHFFFAOYSA-N
DM4UD8C	IU	3-(1-methylpiperidin-3-yl)-2-phenyl-1H-indole
DM4UD8C	DE	Discovery agent

DM6R5HU	ID	DM6R5HU
DM6R5HU	DN	3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole
DM6R5HU	HS	Investigative
DM6R5HU	SN	CHEMBL91667; 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole; SCHEMBL7959758; UBCVYEFSXHCFPK-UHFFFAOYSA-N; BDBM50095055; 3-(1-methylpiperidin-4-yl)-2-phenyl-1H-indole; L018753
DM6R5HU	DT	Small molecular drug
DM6R5HU	PC	9838958
DM6R5HU	MW	290.4
DM6R5HU	FM	C20H22N2
DM6R5HU	IC	InChI=1S/C20H22N2/c1-22-13-11-15(12-14-22)19-17-9-5-6-10-18(17)21-20(19)16-7-3-2-4-8-16/h2-10,15,21H,11-14H2,1H3
DM6R5HU	CS	CN1CCC(CC1)C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DM6R5HU	IK	UBCVYEFSXHCFPK-UHFFFAOYSA-N
DM6R5HU	IU	3-(1-methylpiperidin-4-yl)-2-phenyl-1H-indole
DM6R5HU	DE	Discovery agent

DMXMBEF	ID	DMXMBEF
DMXMBEF	DN	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
DMXMBEF	HS	Investigative
DMXMBEF	SN	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE; 3-(naphthalen-1-ylmethoxy)pyridin-2-amine; 2-amino-3-(1-naphthylmethyloxy)pyridine; LI4; 1wbw; CHEMBL195393; AC1NS185; SCHEMBL6080116; BDBM13340; AKOS009255557; DB08093; Pyridine derived fragment based inhibitor 5
DMXMBEF	DT	Small molecular drug
DMXMBEF	PC	5326871
DMXMBEF	MW	250.29
DMXMBEF	FM	C16H14N2O
DMXMBEF	IC	InChI=1S/C16H14N2O/c17-16-15(9-4-10-18-16)19-11-13-7-3-6-12-5-1-2-8-14(12)13/h1-10H,11H2,(H2,17,18)
DMXMBEF	CS	C1=CC=C2C(=C1)C=CC=C2COC3=C(N=CC=C3)N
DMXMBEF	IK	SZANYTFSQVBOBA-UHFFFAOYSA-N
DMXMBEF	IU	3-(naphthalen-1-ylmethoxy)pyridin-2-amine
DMXMBEF	DE	Discovery agent

DMOQ4ER	ID	DMOQ4ER
DMOQ4ER	DN	3-(1-Phenethyl-piperidin-3-yl)-2-phenyl-1H-indole
DMOQ4ER	HS	Investigative
DMOQ4ER	SN	CHEMBL44310; 3-(1-Phenethyl-piperidin-3-yl)-2-phenyl-1H-indole; SCHEMBL8525084; BDBM50099267
DMOQ4ER	DT	Small molecular drug
DMOQ4ER	PC	9821248
DMOQ4ER	MW	380.5
DMOQ4ER	FM	C27H28N2
DMOQ4ER	IC	InChI=1S/C27H28N2/c1-3-10-21(11-4-1)17-19-29-18-9-14-23(20-29)26-24-15-7-8-16-25(24)28-27(26)22-12-5-2-6-13-22/h1-8,10-13,15-16,23,28H,9,14,17-20H2
DMOQ4ER	CS	C1CC(CN(C1)CCC2=CC=CC=C2)C3=C(NC4=CC=CC=C43)C5=CC=CC=C5
DMOQ4ER	IK	HQXCPXHVSRWLFR-UHFFFAOYSA-N
DMOQ4ER	IU	2-phenyl-3-[1-(2-phenylethyl)piperidin-3-yl]-1H-indole
DMOQ4ER	DE	Discovery agent

DM8TH2N	ID	DM8TH2N
DM8TH2N	DN	3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole
DM8TH2N	HS	Investigative
DM8TH2N	SN	CHEMBL40584; 3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole; SCHEMBL7948313; BDBM50095049; L018755; 3-(1-phenethylpiperidin-4-yl)-2-phenyl-1H-indole
DM8TH2N	DT	Small molecular drug
DM8TH2N	PC	10091189
DM8TH2N	MW	380.5
DM8TH2N	FM	C27H28N2
DM8TH2N	IC	InChI=1S/C27H28N2/c1-3-9-21(10-4-1)15-18-29-19-16-22(17-20-29)26-24-13-7-8-14-25(24)28-27(26)23-11-5-2-6-12-23/h1-14,22,28H,15-20H2
DM8TH2N	CS	C1CN(CCC1C2=C(NC3=CC=CC=C32)C4=CC=CC=C4)CCC5=CC=CC=C5
DM8TH2N	IK	MONKRYYJEIHBRU-UHFFFAOYSA-N
DM8TH2N	IU	2-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]-1H-indole
DM8TH2N	DE	Discovery agent

DM4QRV9	ID	DM4QRV9
DM4QRV9	DN	3-(1-Propyl-pyrrolidin-3-yl)-phenol
DM4QRV9	HS	Investigative
DM4QRV9	SN	CHEMBL81675; 3-(1-Propyl-pyrrolidin-3-yl)-phenol; SCHEMBL7316143
DM4QRV9	DT	Small molecular drug
DM4QRV9	PC	11074524
DM4QRV9	MW	205.3
DM4QRV9	FM	C13H19NO
DM4QRV9	IC	InChI=1S/C13H19NO/c1-2-7-14-8-6-12(10-14)11-4-3-5-13(15)9-11/h3-5,9,12,15H,2,6-8,10H2,1H3
DM4QRV9	CS	CCCN1CCC(C1)C2=CC(=CC=C2)O
DM4QRV9	IK	WPYVGSUSOOZONM-UHFFFAOYSA-N
DM4QRV9	IU	3-(1-propylpyrrolidin-3-yl)phenol
DM4QRV9	DE	Discovery agent

DMTD7VE	ID	DMTD7VE
DMTD7VE	DN	3-(1-Pyridin-2-yl-1H-pyrazol-3-yl)-benzonitrile
DMTD7VE	HS	Investigative
DMTD7VE	SN	CHEMBL182771; 3-(1-Pyridin-2-yl-1H-pyrazol-3-yl)-benzonitrile; SCHEMBL3922673; LQROCYQCXGUXNA-UHFFFAOYSA-N; ZINC13582316; BDBM50151902
DMTD7VE	DT	Small molecular drug
DMTD7VE	PC	10236192
DMTD7VE	MW	246.27
DMTD7VE	FM	C15H10N4
DMTD7VE	IC	InChI=1S/C15H10N4/c16-11-12-4-3-5-13(10-12)14-7-9-19(18-14)15-6-1-2-8-17-15/h1-10H
DMTD7VE	CS	C1=CC=NC(=C1)N2C=CC(=N2)C3=CC=CC(=C3)C#N
DMTD7VE	IK	LQROCYQCXGUXNA-UHFFFAOYSA-N
DMTD7VE	IU	3-(1-pyridin-2-ylpyrazol-3-yl)benzonitrile
DMTD7VE	DE	Discovery agent

DMWI37C	ID	DMWI37C
DMWI37C	DN	3-(1-Pyridin-2-yl-1H-pyrazol-4-yl)-benzonitrile
DMWI37C	HS	Investigative
DMWI37C	SN	CHEMBL182973; 3-(1-Pyridin-2-yl-1H-pyrazol-4-yl)-benzonitrile; SCHEMBL3923401; WCEMBGUJGXXYCF-UHFFFAOYSA-N; BDBM50151912; ZINC13582322
DMWI37C	DT	Small molecular drug
DMWI37C	PC	10308060
DMWI37C	MW	246.27
DMWI37C	FM	C15H10N4
DMWI37C	IC	InChI=1S/C15H10N4/c16-9-12-4-3-5-13(8-12)14-10-18-19(11-14)15-6-1-2-7-17-15/h1-8,10-11H
DMWI37C	CS	C1=CC=NC(=C1)N2C=C(C=N2)C3=CC=CC(=C3)C#N
DMWI37C	IK	WCEMBGUJGXXYCF-UHFFFAOYSA-N
DMWI37C	IU	3-(1-pyridin-2-ylpyrazol-4-yl)benzonitrile
DMWI37C	DE	Discovery agent

DMJ9LRE	ID	DMJ9LRE
DMJ9LRE	DN	3-(1-Pyridin-2-yl-1H-pyrrol-3-yl)-benzonitrile
DMJ9LRE	HS	Investigative
DMJ9LRE	SN	CHEMBL361120; 3-(1-Pyridin-2-yl-1H-pyrrol-3-yl)-benzonitrile; SCHEMBL5104615; GXXRNNGNWUNPKZ-UHFFFAOYSA-N; BDBM50151899; ZINC13582310
DMJ9LRE	DT	Small molecular drug
DMJ9LRE	PC	10131083
DMJ9LRE	MW	245.28
DMJ9LRE	FM	C16H11N3
DMJ9LRE	IC	InChI=1S/C16H11N3/c17-11-13-4-3-5-14(10-13)15-7-9-19(12-15)16-6-1-2-8-18-16/h1-10,12H
DMJ9LRE	CS	C1=CC=NC(=C1)N2C=CC(=C2)C3=CC=CC(=C3)C#N
DMJ9LRE	IK	GXXRNNGNWUNPKZ-UHFFFAOYSA-N
DMJ9LRE	IU	3-(1-pyridin-2-ylpyrrol-3-yl)benzonitrile
DMJ9LRE	CA	CAS 566931-83-7
DMJ9LRE	DE	Discovery agent

DM8P26J	ID	DM8P26J
DM8P26J	DN	3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid
DM8P26J	HS	Investigative
DM8P26J	DT	Small molecular drug
DM8P26J	PC	52947851
DM8P26J	MW	528.6
DM8P26J	FM	C36H32O4
DM8P26J	IC	InChI=1S/2C18H16O2/c2*19-18(20)14-13-17-11-5-4-10-16(17)12-6-9-15-7-2-1-3-8-15/h1-8,10-14H,9H2,(H,19,20);1-11,13-14H,12H2,(H,19,20)/b12-6+,14-13+;9-6+,14-13+
DM8P26J	CS	C1=CC=C(C=C1)C/C=C/C2=CC=CC=C2/C=C/C(=O)O.C1=CC=C(C=C1)/C=C/CC2=CC=CC=C2/C=C/C(=O)O
DM8P26J	IK	QRLAGHDTOFFHIC-UMYPGWKJSA-N
DM8P26J	IU	(E)-3-[2-[(E)-3-phenylprop-1-enyl]phenyl]prop-2-enoic acid;(E)-3-[2-[(E)-3-phenylprop-2-enyl]phenyl]prop-2-enoic acid
DM8P26J	DE	Discovery agent

DM61CHU	ID	DM61CHU
DM61CHU	DN	3-(2-(4-methoxycinnamyl)phenyl)acrylic acid
DM61CHU	HS	Investigative
DM61CHU	SN	CHEMBL219590; 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid
DM61CHU	DT	Small molecular drug
DM61CHU	PC	44419388
DM61CHU	MW	294.3
DM61CHU	FM	C19H18O3
DM61CHU	IC	InChI=1S/C19H18O3/c1-22-18-12-9-15(10-13-18)5-4-8-16-6-2-3-7-17(16)11-14-19(20)21/h2-7,9-14H,8H2,1H3,(H,20,21)/b5-4+,14-11+
DM61CHU	CS	COC1=CC=C(C=C1)/C=C/CC2=CC=CC=C2/C=C/C(=O)O
DM61CHU	IK	UIMOCAMZLBHNCQ-CTLAPNPFSA-N
DM61CHU	IU	(E)-3-[2-[(E)-3-(4-methoxyphenyl)prop-2-enyl]phenyl]prop-2-enoic acid
DM61CHU	DE	Discovery agent

DM9O5CH	ID	DM9O5CH
DM9O5CH	DN	3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid
DM9O5CH	HS	Investigative
DM9O5CH	SN	CHEMBL423815; 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid; SCHEMBL7922112; SCHEMBL7922115; BDBM50097792; 2-(2-Naphthylmethyl)benzeneacrylic acid; (E)-3-(2-Naphthalen-2-ylmethyl-phenyl)-acrylic acid
DM9O5CH	DT	Small molecular drug
DM9O5CH	PC	9817405
DM9O5CH	MW	288.3
DM9O5CH	FM	C20H16O2
DM9O5CH	IC	InChI=1S/C20H16O2/c21-20(22)12-11-17-6-2-4-8-19(17)14-15-9-10-16-5-1-3-7-18(16)13-15/h1-13H,14H2,(H,21,22)/b12-11+
DM9O5CH	CS	C1=CC=C2C=C(C=CC2=C1)CC3=CC=CC=C3/C=C/C(=O)O
DM9O5CH	IK	MOLQZQYMXCCLHS-VAWYXSNFSA-N
DM9O5CH	IU	(E)-3-[2-(naphthalen-2-ylmethyl)phenyl]prop-2-enoic acid
DM9O5CH	DE	Discovery agent

DMSCIP2	ID	DMSCIP2
DMSCIP2	DN	3-(2,2-Dimethyl-propoxy)-9H-beta-carboline
DMSCIP2	HS	Investigative
DMSCIP2	SN	3-(Neopentyloxy)-9H-pyrido[3,4-b]indole; CHEMBL128348
DMSCIP2	DT	Small molecular drug
DMSCIP2	PC	10402001
DMSCIP2	MW	254.33
DMSCIP2	FM	C16H18N2O
DMSCIP2	IC	InChI=1S/C16H18N2O/c1-16(2,3)10-19-15-8-12-11-6-4-5-7-13(11)18-14(12)9-17-15/h4-9,18H,10H2,1-3H3
DMSCIP2	CS	CC(C)(C)COC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMSCIP2	IK	YABCOKXBPACNCE-UHFFFAOYSA-N
DMSCIP2	IU	3-(2,2-dimethylpropoxy)-9H-pyrido[3,4-b]indole
DMSCIP2	DE	Discovery agent

DMCPOQ9	ID	DMCPOQ9
DMCPOQ9	DN	3-(2,2-Diphenyl-vinyl)-pyridine
DMCPOQ9	HS	Investigative
DMCPOQ9	SN	3-(2,2-diphenylethenyl)pyridine; 3-Pyridylmethylene 33; BDBM8638; CHEMBL370317; 3-(2,2-Diphenylvinyl)Pyridine
DMCPOQ9	DT	Small molecular drug
DMCPOQ9	PC	6539811
DMCPOQ9	MW	257.3
DMCPOQ9	FM	C19H15N
DMCPOQ9	IC	InChI=1S/C19H15N/c1-3-9-17(10-4-1)19(18-11-5-2-6-12-18)14-16-8-7-13-20-15-16/h1-15H
DMCPOQ9	CS	C1=CC=C(C=C1)C(=CC2=CN=CC=C2)C3=CC=CC=C3
DMCPOQ9	IK	GOQNCJGTIMHWGO-UHFFFAOYSA-N
DMCPOQ9	IU	3-(2,2-diphenylethenyl)pyridine
DMCPOQ9	DE	Discovery agent

DMTS4YD	ID	DMTS4YD
DMTS4YD	DN	3-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine
DMTS4YD	HS	Investigative
DMTS4YD	SN	CHEMBL462092; 1092522-84-3; 3-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)pyridine; 3-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine; 3-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-pyridine; ZINC40873967; BDBM50273702
DMTS4YD	DT	Small molecular drug
DMTS4YD	PC	25180306
DMTS4YD	MW	213.23
DMTS4YD	FM	C13H11NO2
DMTS4YD	IC	InChI=1S/C13H11NO2/c1-2-11(9-14-5-1)10-3-4-12-13(8-10)16-7-6-15-12/h1-5,8-9H,6-7H2
DMTS4YD	CS	C1COC2=C(O1)C=CC(=C2)C3=CN=CC=C3
DMTS4YD	IK	WBKBSDQNOSGKCC-UHFFFAOYSA-N
DMTS4YD	IU	3-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridine
DMTS4YD	DE	Discovery agent

DM0ZRDV	ID	DM0ZRDV
DM0ZRDV	DN	3-(2,3-Dimethyl-phenyl)-1-propyl-piperidine
DM0ZRDV	HS	Investigative
DM0ZRDV	SN	CHEMBL341825; 3-(2,3-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068421
DM0ZRDV	DT	Small molecular drug
DM0ZRDV	PC	10609576
DM0ZRDV	MW	231.38
DM0ZRDV	FM	C16H25N
DM0ZRDV	IC	InChI=1S/C16H25N/c1-4-10-17-11-6-8-15(12-17)16-9-5-7-13(2)14(16)3/h5,7,9,15H,4,6,8,10-12H2,1-3H3
DM0ZRDV	CS	CCCN1CCCC(C1)C2=CC=CC(=C2C)C
DM0ZRDV	IK	AORDKZRSVBDZJZ-UHFFFAOYSA-N
DM0ZRDV	IU	3-(2,3-dimethylphenyl)-1-propylpiperidine
DM0ZRDV	DE	Discovery agent

DMEFKJD	ID	DMEFKJD
DMEFKJD	DN	3-(2,3-Dimethyl-phenyl)-piperidine
DMEFKJD	HS	Investigative
DMEFKJD	SN	3-(2,3-dimethylphenyl)piperidine; CHEMBL144019; 219703-97-6; 3-(2,3-Dimethyl-phenyl)-piperidine; 3-(dimethylphenyl) piperidine; SCHEMBL9310414; BDBM50068426; AKOS006308927
DMEFKJD	DT	Small molecular drug
DMEFKJD	PC	10679213
DMEFKJD	MW	189.3
DMEFKJD	FM	C13H19N
DMEFKJD	IC	InChI=1S/C13H19N/c1-10-5-3-7-13(11(10)2)12-6-4-8-14-9-12/h3,5,7,12,14H,4,6,8-9H2,1-2H3
DMEFKJD	CS	CC1=C(C(=CC=C1)C2CCCNC2)C
DMEFKJD	IK	TXQGNZXKUWJMKW-UHFFFAOYSA-N
DMEFKJD	IU	3-(2,3-dimethylphenyl)piperidine
DMEFKJD	DE	Discovery agent

DMXQROU	ID	DMXQROU
DMXQROU	DN	3-(2,4-dihydroxyphenyl)propionic acid
DMXQROU	HS	Investigative
DMXQROU	SN	5631-68-5; 3-(2,4-dihydroxyphenyl)propanoic acid; 3-(2,4-Dihydroxyphenyl)propionic acid; Hydroumbellic acid; Benzenepropanoic acid, 2,4-dihydroxy-; CHEMBL228155; 2,4-Dihydroxybenzenepropanoic acid; AI3-13072; AC1L3WC8; AC1Q5VW7; NCIOpen2_000618; SCHEMBL490491; ACMC-1B046; 2,4-Dihydroxyhydrocinnamic acid; CTK5A4966; DTXSID50204854; MolPort-000-877-529; HMCMTJPPXSGYJY-UHFFFAOYSA-N; ZINC388556; NSC71551; KS-00000N9R; NSC-71551; BDBM50211056; STL034241; SBB068271; BBL028276; Benzenepropanoic acid,2,4-dihydroxy-
DMXQROU	DT	Small molecular drug
DMXQROU	PC	96384
DMXQROU	MW	182.17
DMXQROU	FM	C9H10O4
DMXQROU	IC	InChI=1S/C9H10O4/c10-7-3-1-6(8(11)5-7)2-4-9(12)13/h1,3,5,10-11H,2,4H2,(H,12,13)
DMXQROU	CS	C1=CC(=C(C=C1O)O)CCC(=O)O
DMXQROU	IK	HMCMTJPPXSGYJY-UHFFFAOYSA-N
DMXQROU	IU	3-(2,4-dihydroxyphenyl)propanoic acid
DMXQROU	CA	CAS 5631-68-5
DMXQROU	DE	Discovery agent

DMB71FZ	ID	DMB71FZ
DMB71FZ	DN	3-(2,4-Dimethyl-phenyl)-1-propyl-piperidine
DMB71FZ	HS	Investigative
DMB71FZ	SN	CHEMBL144302; 3-(2,4-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068425
DMB71FZ	DT	Small molecular drug
DMB71FZ	PC	10633305
DMB71FZ	MW	231.38
DMB71FZ	FM	C16H25N
DMB71FZ	IC	InChI=1S/C16H25N/c1-4-9-17-10-5-6-15(12-17)16-8-7-13(2)11-14(16)3/h7-8,11,15H,4-6,9-10,12H2,1-3H3
DMB71FZ	CS	CCCN1CCCC(C1)C2=C(C=C(C=C2)C)C
DMB71FZ	IK	XMWBOCKXCDCQOT-UHFFFAOYSA-N
DMB71FZ	IU	3-(2,4-dimethylphenyl)-1-propylpiperidine
DMB71FZ	CA	CAS 219704-01-5
DMB71FZ	DE	Discovery agent

DMUDW1J	ID	DMUDW1J
DMUDW1J	DN	3-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid
DMUDW1J	HS	Investigative
DMUDW1J	SN	3-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid; 26180-28-9; 3-(2,5-dimethylpyrrol-1-yl)benzoic acid; 3-(2,5-Dimethyl-pyrrol-1-yl)-benzoic acid; MLS000053036; Benzoic acid, m-(2,5-dimethylpyrrol-1-yl)-; SMR000068999; m-(2,5-Dimethylpyrrol-1-yl)benzoic acid; Benzoic acid,3-(2,5-dimethyl-1H-pyrrol-1-yl)-; 3-(2,5-dimethylpyrrolyl)benzoic acid; SR-01000430237; 3-(2,5-dimethylpyrrol-1-yl) benzoic acd; benzoic acid, 3-(2,5-dimethyl-1h-pyrrol-1-yl)-; BAS 00687694; AC1L4UOW; Probes2_000222; Probes2_000239; Probes1_000276
DMUDW1J	DT	Small molecular drug
DMUDW1J	PC	213329
DMUDW1J	MW	215.25
DMUDW1J	FM	C13H13NO2
DMUDW1J	IC	InChI=1S/C13H13NO2/c1-9-6-7-10(2)14(9)12-5-3-4-11(8-12)13(15)16/h3-8H,1-2H3,(H,15,16)
DMUDW1J	CS	CC1=CC=C(N1C2=CC=CC(=C2)C(=O)O)C
DMUDW1J	IK	NJPUZFUOUGTNOV-UHFFFAOYSA-N
DMUDW1J	IU	3-(2,5-dimethylpyrrol-1-yl)benzoic acid
DMUDW1J	CA	CAS 26180-28-9
DMUDW1J	DE	Discovery agent

DM974E5	ID	DM974E5
DM974E5	DN	3-(2,5-Dimethyl-phenyl)-1-propyl-piperidine
DM974E5	HS	Investigative
DM974E5	SN	CHEMBL280491; 3-(2,5-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068420
DM974E5	DT	Small molecular drug
DM974E5	PC	10847137
DM974E5	MW	231.38
DM974E5	FM	C16H25N
DM974E5	IC	InChI=1S/C16H25N/c1-4-9-17-10-5-6-15(12-17)16-11-13(2)7-8-14(16)3/h7-8,11,15H,4-6,9-10,12H2,1-3H3
DM974E5	CS	CCCN1CCCC(C1)C2=C(C=CC(=C2)C)C
DM974E5	IK	SSDVDUAQCIGPNR-UHFFFAOYSA-N
DM974E5	IU	3-(2,5-dimethylphenyl)-1-propylpiperidine
DM974E5	DE	Discovery agent

DM6JTNW	ID	DM6JTNW
DM6JTNW	DN	3-(2,5-Dioxo-pyrrolidin-1-yl)-benzoic acid
DM6JTNW	HS	Investigative
DM6JTNW	SN	3-(2,5-dioxopyrrolidin-1-yl)benzoic acid; 60693-31-4; 3-(2,5-Dioxo-pyrrolidin-1-yl)-benzoic acid; 3-(2,5-dioxo-1-pyrrolidinyl)benzoic acid; 3-(2,5-dioxoazolidinyl)benzoic acid; AC1LETYJ; BAS 16153444; Enamine_005131; 3-succinimidobenzoic acid; 3-Succinimidylbenzoic acid; Cambridge id 5631823; AC1Q5U3M; AC1Q73IP; Oprea1_343380; Oprea1_386853; MLS000061625; SCHEMBL20053775; ZINC63844; CTK5B2080; DTXSID80351143; MolPort-000-385-168; HMS1408J05; ANW-46498; STK155926; SBB011404; AKOS000112869; MCULE-3726251625; IDI1_007718; SMR000069955
DM6JTNW	DT	Small molecular drug
DM6JTNW	PC	692331
DM6JTNW	MW	219.19
DM6JTNW	FM	C11H9NO4
DM6JTNW	IC	InChI=1S/C11H9NO4/c13-9-4-5-10(14)12(9)8-3-1-2-7(6-8)11(15)16/h1-3,6H,4-5H2,(H,15,16)
DM6JTNW	CS	C1CC(=O)N(C1=O)C2=CC=CC(=C2)C(=O)O
DM6JTNW	IK	BEQRYKGDEGNALQ-UHFFFAOYSA-N
DM6JTNW	IU	3-(2,5-dioxopyrrolidin-1-yl)benzoic acid
DM6JTNW	CA	CAS 60693-31-4
DM6JTNW	DE	Discovery agent

DMPSAQW	ID	DMPSAQW
DMPSAQW	DN	3-(2,6-Dimethyl-phenyl)-1-propyl-piperidine
DMPSAQW	HS	Investigative
DMPSAQW	SN	CHEMBL144501; 3-(2,6-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068424
DMPSAQW	DT	Small molecular drug
DMPSAQW	PC	10561522
DMPSAQW	MW	231.38
DMPSAQW	FM	C16H25N
DMPSAQW	IC	InChI=1S/C16H25N/c1-4-10-17-11-6-9-15(12-17)16-13(2)7-5-8-14(16)3/h5,7-8,15H,4,6,9-12H2,1-3H3
DMPSAQW	CS	CCCN1CCCC(C1)C2=C(C=CC=C2C)C
DMPSAQW	IK	HBTLGWNZDLWXQJ-UHFFFAOYSA-N
DMPSAQW	IU	3-(2,6-dimethylphenyl)-1-propylpiperidine
DMPSAQW	DE	Discovery agent

DMDYW4J	ID	DMDYW4J
DMDYW4J	DN	3-(2,6-diphenylpyridin-4-yl)phenol
DMDYW4J	HS	Investigative
DMDYW4J	SN	CHEMBL1096032
DMDYW4J	DT	Small molecular drug
DMDYW4J	PC	46887217
DMDYW4J	MW	323.4
DMDYW4J	FM	C23H17NO
DMDYW4J	IC	InChI=1S/C23H17NO/c25-21-13-7-12-19(14-21)20-15-22(17-8-3-1-4-9-17)24-23(16-20)18-10-5-2-6-11-18/h1-16,25H
DMDYW4J	CS	C1=CC=C(C=C1)C2=CC(=CC(=N2)C3=CC=CC=C3)C4=CC(=CC=C4)O
DMDYW4J	IK	JTTGRNWIRRFPKZ-UHFFFAOYSA-N
DMDYW4J	IU	3-(2,6-diphenylpyridin-4-yl)phenol
DMDYW4J	DE	Discovery agent

DMS98WA	ID	DMS98WA
DMS98WA	DN	3-(2-adamantyl) pyrrolidine
DMS98WA	HS	Investigative
DMS98WA	SN	3-(2-adamantyl)pyrrolidine; AC1MHVT3; CHEMBL67992; SCHEMBL587443; AKOS023848508; Pyrrolidine, 3-tricyclo[3.3.1.13,7]dec-2-yl-
DMS98WA	DT	Small molecular drug
DMS98WA	PC	3012268
DMS98WA	MW	205.34
DMS98WA	FM	C14H23N
DMS98WA	IC	InChI=1S/C14H23N/c1-2-15-8-11(1)14-12-4-9-3-10(6-12)7-13(14)5-9/h9-15H,1-8H2
DMS98WA	CS	C1CNCC1C2C3CC4CC(C3)CC2C4
DMS98WA	IK	IULGEPJXNLPTSZ-UHFFFAOYSA-N
DMS98WA	IU	3-(2-adamantyl)pyrrolidine
DMS98WA	DE	Discovery agent

DMQXPM3	ID	DMQXPM3
DMQXPM3	DN	3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid
DMQXPM3	HS	Investigative
DMQXPM3	SN	3-(2-AMINOETHYL)-4-(AMINOMETHYL)HEPTANEDIOIC ACID; (3R,4S)-3-(2-aminoethyl)-4-(aminomethyl)heptanedioic acid; AC1NRCOO
DMQXPM3	DT	Small molecular drug
DMQXPM3	PC	5289108
DMQXPM3	MW	232.28
DMQXPM3	FM	C10H20N2O4
DMQXPM3	IC	InChI=1S/C10H20N2O4/c11-4-3-7(5-10(15)16)8(6-12)1-2-9(13)14/h7-8H,1-6,11-12H2,(H,13,14)(H,15,16)/t7-,8-/m1/s1
DMQXPM3	CS	C(CC(=O)O)[C@H](CN)[C@H](CCN)CC(=O)O
DMQXPM3	IK	QMRGRIXXWLVLTR-HTQZYQBOSA-N
DMQXPM3	IU	(3R,4S)-3-(2-aminoethyl)-4-(aminomethyl)heptanedioic acid
DMQXPM3	DE	Discovery agent

DM95R6O	ID	DM95R6O
DM95R6O	DN	3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane
DM95R6O	HS	Investigative
DM95R6O	SN	CHEMBL89735; 3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane; SCHEMBL8551346; BDBM50104651
DM95R6O	DT	Small molecular drug
DM95R6O	PC	44323014
DM95R6O	MW	157.21
DM95R6O	FM	C7H15N3O
DM95R6O	IC	InChI=1S/C7H15N3O/c8-3-1-6-5-11-4-2-7(9)10-6/h6H,1-5,8H2,(H2,9,10)
DM95R6O	CS	C1COCC(N=C1N)CCN
DM95R6O	IK	ZPHRNAHMHZVACD-UHFFFAOYSA-N
DM95R6O	IU	3-(2-aminoethyl)-2,3,6,7-tetrahydro-1,4-oxazepin-5-amine
DM95R6O	DE	Discovery agent

DMQPNUM	ID	DMQPNUM
DMQPNUM	DN	3-(2-Amino-propyl)-1H-indol-5-ol
DMQPNUM	HS	Investigative
DMQPNUM	SN	5-hydroxy-alpha-methyltryptamine
DMQPNUM	DE	Discovery agent

DMZCTGF	ID	DMZCTGF
DMZCTGF	DN	3-(2-Benzylamino-ethoxy)-phenol
DMZCTGF	HS	Investigative
DMZCTGF	SN	CHEMBL64508; 3-[2-(benzylamino)ethoxy]phenol; 3-(2-Benzylamino-ethoxy)-phenol
DMZCTGF	DT	Small molecular drug
DMZCTGF	PC	11776546
DMZCTGF	MW	243.3
DMZCTGF	FM	C15H17NO2
DMZCTGF	IC	InChI=1S/C15H17NO2/c17-14-7-4-8-15(11-14)18-10-9-16-12-13-5-2-1-3-6-13/h1-8,11,16-17H,9-10,12H2
DMZCTGF	CS	C1=CC=C(C=C1)CNCCOC2=CC=CC(=C2)O
DMZCTGF	IK	VBTFJGYCISLKEQ-UHFFFAOYSA-N
DMZCTGF	IU	3-[2-(benzylamino)ethoxy]phenol
DMZCTGF	CA	CAS 129689-29-8
DMZCTGF	DE	Discovery agent

DMH6I4E	ID	DMH6I4E
DMH6I4E	DN	3-(2-Bromophenyl)-2-thioxo-(1H )-quinazolin-4-one
DMH6I4E	HS	Investigative
DMH6I4E	SN	CHEMBL496735; SCHEMBL18239972
DMH6I4E	DT	Small molecular drug
DMH6I4E	PC	11427575
DMH6I4E	MW	333.2
DMH6I4E	FM	C14H9BrN2OS
DMH6I4E	IC	InChI=1S/C14H9BrN2OS/c15-10-6-2-4-8-12(10)17-13(18)9-5-1-3-7-11(9)16-14(17)19/h1-8H,(H,16,19)
DMH6I4E	CS	C1=CC=C2C(=C1)C(=O)N(C(=S)N2)C3=CC=CC=C3Br
DMH6I4E	IK	FHKTYFZUNGXFGS-UHFFFAOYSA-N
DMH6I4E	IU	3-(2-bromophenyl)-2-sulfanylidene-1H-quinazolin-4-one
DMH6I4E	DE	Discovery agent

DMDM0R6	ID	DMDM0R6
DMDM0R6	DN	3-(2-Bromophenyl)-6-methylcoumarin
DMDM0R6	HS	Investigative
DMDM0R6	SN	CHEMBL1221929; 3-(2-Bromophenyl)-6-methylcoumarin
DMDM0R6	DT	Small molecular drug
DMDM0R6	PC	49864488
DMDM0R6	MW	315.16
DMDM0R6	FM	C16H11BrO2
DMDM0R6	IC	InChI=1S/C16H11BrO2/c1-10-6-7-15-11(8-10)9-13(16(18)19-15)12-4-2-3-5-14(12)17/h2-9H,1H3
DMDM0R6	CS	CC1=CC2=C(C=C1)OC(=O)C(=C2)C3=CC=CC=C3Br
DMDM0R6	IK	AEOXYENOHINSQF-UHFFFAOYSA-N
DMDM0R6	IU	3-(2-bromophenyl)-6-methylchromen-2-one
DMDM0R6	DE	Discovery agent

DMNOKR3	ID	DMNOKR3
DMNOKR3	DN	3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
DMNOKR3	HS	Investigative
DMNOKR3	SN	Thiol-Based Inhibitor, 16; CHEMBL377648; CTK8A8852; BDBM17771; AKOS015965622; 3-[2-carbamoyl-2-(3-sulfanylpropyl)ethyl]benzoic acid; 3-(2-CARBAMOYL-5-MERCAPTO-PENTYL)-BENZOIC ACID
DMNOKR3	DT	Small molecular drug
DMNOKR3	PC	11694647
DMNOKR3	MW	267.35
DMNOKR3	FM	C13H17NO3S
DMNOKR3	IC	InChI=1S/C13H17NO3S/c14-12(15)10(5-2-6-18)7-9-3-1-4-11(8-9)13(16)17/h1,3-4,8,10,18H,2,5-7H2,(H2,14,15)(H,16,17)
DMNOKR3	CS	C1=CC(=CC(=C1)C(=O)O)CC(CCCS)C(=O)N
DMNOKR3	IK	KSGSHIYQUPDDPN-UHFFFAOYSA-N
DMNOKR3	IU	3-(2-carbamoyl-5-sulfanylpentyl)benzoic acid
DMNOKR3	DE	Discovery agent

DM67B8S	ID	DM67B8S
DM67B8S	DN	3-(2-carboxy-3-mercaptopropyl)benzoic acid
DM67B8S	HS	Investigative
DM67B8S	SN	Thiol-Based Inhibitor, 7a; CHEMBL206699; CTK8A8777; BDBM17764; AKOS015965664; 3-[2-carboxy-2-(sulfanylmethyl)ethyl]benzoic acid; 3-(2-CARBOXY-3-MERCAPTO-PROPYL)-BENZOIC ACID
DM67B8S	DT	Small molecular drug
DM67B8S	PC	11557761
DM67B8S	MW	240.28
DM67B8S	FM	C11H12O4S
DM67B8S	IC	InChI=1S/C11H12O4S/c12-10(13)8-3-1-2-7(4-8)5-9(6-16)11(14)15/h1-4,9,16H,5-6H2,(H,12,13)(H,14,15)
DM67B8S	CS	C1=CC(=CC(=C1)C(=O)O)CC(CS)C(=O)O
DM67B8S	IK	LQVBVNPZOILYPX-UHFFFAOYSA-N
DM67B8S	IU	3-(2-carboxy-3-sulfanylpropyl)benzoic acid
DM67B8S	DE	Discovery agent

DMG5R0N	ID	DMG5R0N
DMG5R0N	DN	3-(2-carboxy-3-phosphonopropyl)benzoic acid
DMG5R0N	HS	Investigative
DMG5R0N	SN	phosphonate, 28; CHEMBL207343; BDBM17777; 3-[2-carboxy-2-(phosphonomethyl)ethyl]benzoic acid
DMG5R0N	DT	Small molecular drug
DMG5R0N	PC	11492994
DMG5R0N	MW	288.19
DMG5R0N	FM	C11H13O7P
DMG5R0N	IC	InChI=1S/C11H13O7P/c12-10(13)8-3-1-2-7(4-8)5-9(11(14)15)6-19(16,17)18/h1-4,9H,5-6H2,(H,12,13)(H,14,15)(H2,16,17,18)
DMG5R0N	CS	C1=CC(=CC(=C1)C(=O)O)CC(CP(=O)(O)O)C(=O)O
DMG5R0N	IK	JQOYXWMDISLLFO-UHFFFAOYSA-N
DMG5R0N	IU	3-(2-carboxy-3-phosphonopropyl)benzoic acid
DMG5R0N	DE	Discovery agent

DM6HPYN	ID	DM6HPYN
DM6HPYN	DN	3-(2-carboxy-4-mercaptobutyl)benzoic acid
DM6HPYN	HS	Investigative
DM6HPYN	SN	Thiol-Based Inhibitor, 7b; CHEMBL206078; BDBM17765; Benzenepropanoic acid, 3-carboxy-alpha-(2-mercaptoethyl)-; 378241-99-7; 3-[2-carboxy-2-(2-sulfanylethyl)ethyl]benzoic acid
DM6HPYN	DT	Small molecular drug
DM6HPYN	PC	11615808
DM6HPYN	MW	254.3
DM6HPYN	FM	C12H14O4S
DM6HPYN	IC	InChI=1S/C12H14O4S/c13-11(14)9-3-1-2-8(6-9)7-10(4-5-17)12(15)16/h1-3,6,10,17H,4-5,7H2,(H,13,14)(H,15,16)
DM6HPYN	CS	C1=CC(=CC(=C1)C(=O)O)CC(CCS)C(=O)O
DM6HPYN	IK	NTMSKDFHMVZFMA-UHFFFAOYSA-N
DM6HPYN	IU	3-(2-carboxy-4-sulfanylbutyl)benzoic acid
DM6HPYN	DE	Discovery agent

DM6H52B	ID	DM6H52B
DM6H52B	DN	3-(2-carboxy-5-mercaptopentyl)benzoic acid
DM6H52B	HS	Investigative
DM6H52B	SN	3-(2-carboxy-5-mercaptopentyl)benzoic acid; Thiol-Based Inhibitor, 6c; SCHEMBL2058464; CHEMBL382398; CTK8A8854; BDBM17762; JKPYNGWTXQIZFC-UHFFFAOYSA-N; AKOS015966199; 3-[2-carboxy-2-(3-sulfanylpropyl)ethyl]benzoic acid; 3-(2-CARBOXY-5-MERCAPTO-PENTYL)-BENZOIC ACID
DM6H52B	DT	Small molecular drug
DM6H52B	PC	9878510
DM6H52B	MW	268.33
DM6H52B	FM	C13H16O4S
DM6H52B	IC	InChI=1S/C13H16O4S/c14-12(15)10-4-1-3-9(7-10)8-11(13(16)17)5-2-6-18/h1,3-4,7,11,18H,2,5-6,8H2,(H,14,15)(H,16,17)
DM6H52B	CS	C1=CC(=CC(=C1)C(=O)O)CC(CCCS)C(=O)O
DM6H52B	IK	JKPYNGWTXQIZFC-UHFFFAOYSA-N
DM6H52B	IU	3-(2-carboxy-5-sulfanylpentyl)benzoic acid
DM6H52B	DE	Discovery agent

DM870W1	ID	DM870W1
DM870W1	DN	3-(2-carboxy-6-mercaptohexyl)benzoic acid
DM870W1	HS	Investigative
DM870W1	SN	Thiol-Based Inhibitor, 7c; CHEMBL204412; BDBM17766; 3-[2-carboxy-2-(4-sulfanylbutyl)ethyl]benzoic acid
DM870W1	DT	Small molecular drug
DM870W1	PC	11666341
DM870W1	MW	282.36
DM870W1	FM	C14H18O4S
DM870W1	IC	InChI=1S/C14H18O4S/c15-13(16)11(5-1-2-7-19)8-10-4-3-6-12(9-10)14(17)18/h3-4,6,9,11,19H,1-2,5,7-8H2,(H,15,16)(H,17,18)
DM870W1	CS	C1=CC(=CC(=C1)C(=O)O)CC(CCCCS)C(=O)O
DM870W1	IK	NHGYNJPSUMLAJY-UHFFFAOYSA-N
DM870W1	IU	3-(2-carboxy-6-sulfanylhexyl)benzoic acid
DM870W1	DE	Discovery agent

DMDS4Q0	ID	DMDS4Q0
DMDS4Q0	DN	3-(2-Chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine
DMDS4Q0	HS	Investigative
DMDS4Q0	SN	CHEMBL55746; 87372-77-8; 3-(1-Chloro-2-methyl-1-phenylpropan-2-yl)pyridine; 3-(2-Chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine; CTK3C4530; DTXSID30658230; BDBM50028163; Pyridine, 3-(2-chloro-1,1-dimethyl-2-phenylethyl)-
DMDS4Q0	DT	Small molecular drug
DMDS4Q0	PC	44299142
DMDS4Q0	MW	245.74
DMDS4Q0	FM	C15H16ClN
DMDS4Q0	IC	InChI=1S/C15H16ClN/c1-15(2,13-9-6-10-17-11-13)14(16)12-7-4-3-5-8-12/h3-11,14H,1-2H3
DMDS4Q0	CS	CC(C)(C1=CN=CC=C1)C(C2=CC=CC=C2)Cl
DMDS4Q0	IK	DEEQECRKPXLAOA-UHFFFAOYSA-N
DMDS4Q0	IU	3-(1-chloro-2-methyl-1-phenylpropan-2-yl)pyridine
DMDS4Q0	CA	CAS 87372-77-8
DMDS4Q0	DE	Discovery agent

DM4XWME	ID	DM4XWME
DM4XWME	DN	3-(2-cinnamylphenyl)acrylic acid
DM4XWME	HS	Investigative
DM4XWME	SN	3-(2-cinnamylphenyl)acrylic acid; CHEMBL376282; SCHEMBL585953
DM4XWME	DT	Small molecular drug
DM4XWME	PC	9813912
DM4XWME	MW	264.3
DM4XWME	FM	C18H16O2
DM4XWME	IC	InChI=1S/C18H16O2/c19-18(20)14-13-17-11-5-4-10-16(17)12-6-9-15-7-2-1-3-8-15/h1-11,13-14H,12H2,(H,19,20)/b9-6+,14-13+
DM4XWME	CS	C1=CC=C(C=C1)/C=C/CC2=CC=CC=C2/C=C/C(=O)O
DM4XWME	IK	LDBYEQVSQBZSEH-BDXQXIFWSA-N
DM4XWME	IU	(E)-3-[2-[(E)-3-phenylprop-2-enyl]phenyl]prop-2-enoic acid
DM4XWME	DE	Discovery agent

DMVUK96	ID	DMVUK96
DMVUK96	DN	3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline
DMVUK96	HS	Investigative
DMVUK96	SN	CHEMBL66786; 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline; SCHEMBL8166505; HLKSYKUFDFBKPC-UHFFFAOYSA-N; ZINC3834045; BDBM50039049
DMVUK96	DT	Small molecular drug
DMVUK96	PC	10040402
DMVUK96	MW	299.4
DMVUK96	FM	C19H25NO2
DMVUK96	IC	InChI=1S/C19H25NO2/c1-21-18-11-16-10-15(9-8-14-6-4-3-5-7-14)13-20-17(16)12-19(18)22-2/h10-14H,3-9H2,1-2H3
DMVUK96	CS	COC1=CC2=CC(=CN=C2C=C1OC)CCC3CCCCC3
DMVUK96	IK	HLKSYKUFDFBKPC-UHFFFAOYSA-N
DMVUK96	IU	3-(2-cyclohexylethyl)-6,7-dimethoxyquinoline
DMVUK96	DE	Discovery agent

DM08GRF	ID	DM08GRF
DM08GRF	DN	3-(2-Diethylamino-acetamino)-rutaecarpine
DM08GRF	HS	Investigative
DM08GRF	SN	CHEMBL1095603; 3-(2-Diethylamino-acetamino)-rutaecarpine
DM08GRF	DT	Small molecular drug
DM08GRF	PC	44623996
DM08GRF	MW	415.5
DM08GRF	FM	C24H25N5O2
DM08GRF	IC	InChI=1S/C24H25N5O2/c1-3-28(4-2)14-21(30)25-15-9-10-20-18(13-15)24(31)29-12-11-17-16-7-5-6-8-19(16)26-22(17)23(29)27-20/h5-10,13,26H,3-4,11-12,14H2,1-2H3,(H,25,30)
DM08GRF	CS	CCN(CC)CC(=O)NC1=CC2=C(C=C1)N=C3C4=C(CCN3C2=O)C5=CC=CC=C5N4
DM08GRF	IK	IIFLCYXLKCVJJT-UHFFFAOYSA-N
DM08GRF	IU	2-(diethylamino)-N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)acetamide
DM08GRF	DE	Discovery agent

DM1FOIZ	ID	DM1FOIZ
DM1FOIZ	DN	3-(2-Diethylamino-propionamino)-rutaecarpine
DM1FOIZ	HS	Investigative
DM1FOIZ	SN	CHEMBL1098295; 3-(2-Diethylamino-propionamino)-rutaecarpine
DM1FOIZ	DT	Small molecular drug
DM1FOIZ	PC	44624062
DM1FOIZ	MW	429.5
DM1FOIZ	FM	C25H27N5O2
DM1FOIZ	IC	InChI=1S/C25H27N5O2/c1-3-29(4-2)13-12-22(31)26-16-9-10-21-19(15-16)25(32)30-14-11-18-17-7-5-6-8-20(17)27-23(18)24(30)28-21/h5-10,15,27H,3-4,11-14H2,1-2H3,(H,26,31)
DM1FOIZ	CS	CCN(CC)CCC(=O)NC1=CC2=C(C=C1)N=C3C4=C(CCN3C2=O)C5=CC=CC=C5N4
DM1FOIZ	IK	XTKDYIOBJOQMHV-UHFFFAOYSA-N
DM1FOIZ	IU	3-(diethylamino)-N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)propanamide
DM1FOIZ	DE	Discovery agent

DM32MIE	ID	DM32MIE
DM32MIE	DN	3-(2-Dimethylamino-ethyl)-1H-indol-6-ol
DM32MIE	HS	Investigative
DM32MIE	SN	BRN 0160817; 6-Hydroxy-N,N-dimethyltryptamine; 1476-33-1; INDOL-6-OL, 3-(2-(DIMETHYLAMINO)ETHYL)-; CHEMBL382750; 3-(2-dimethylaminoethyl)-1H-indol-6-ol; 1H-Indol-6-ol, 3-[2-(dimethylamino)ethyl]-; 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol; 5-22-12-00067 (Beilstein Handbook Reference); 6-hydroxy-N-dimethyltryptamine; AC1L257Q; DTXSID70163752; BDBM50171259; AKOS023092717; LS-83678
DM32MIE	DT	Small molecular drug
DM32MIE	PC	15124
DM32MIE	MW	204.27
DM32MIE	FM	C12H16N2O
DM32MIE	IC	InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-7-10(15)3-4-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3
DM32MIE	CS	CN(C)CCC1=CNC2=C1C=CC(=C2)O
DM32MIE	IK	WUQMRWPLIMXBDX-UHFFFAOYSA-N
DM32MIE	IU	3-[2-(dimethylamino)ethyl]-1H-indol-6-ol
DM32MIE	CA	CAS 1476-33-1
DM32MIE	DE	Discovery agent

DMKYZGD	ID	DMKYZGD
DMKYZGD	DN	3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol
DMKYZGD	HS	Investigative
DMKYZGD	SN	1-METHYLPSILOCIN; 1465-16-3; 3-[2-(DIMETHYLAMINO)ETHYL]-1-METHYLINDOL-4-OL; CHEMBL197664; 3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol; SCHEMBL12558828; CTK4C4996; DTXSID40658761; MolPort-023-276-636; ZINC13985099; BDBM50171261; AKOS024457385; API0007835; B7244; J-008232
DMKYZGD	DT	Small molecular drug
DMKYZGD	PC	44404883
DMKYZGD	MW	218.29
DMKYZGD	FM	C13H18N2O
DMKYZGD	IC	InChI=1S/C13H18N2O/c1-14(2)8-7-10-9-15(3)11-5-4-6-12(16)13(10)11/h4-6,9,16H,7-8H2,1-3H3
DMKYZGD	CS	CN1C=C(C2=C1C=CC=C2O)CCN(C)C
DMKYZGD	IK	MZZRFEIDRWKTKJ-UHFFFAOYSA-N
DMKYZGD	IU	3-[2-(dimethylamino)ethyl]-1-methylindol-4-ol
DMKYZGD	CA	CAS 1465-16-3
DMKYZGD	DE	Discovery agent

DM9BTLC	ID	DM9BTLC
DM9BTLC	DN	3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol
DM9BTLC	HS	Investigative
DM9BTLC	SN	CHEMBL370859; 3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol
DM9BTLC	DT	Small molecular drug
DM9BTLC	PC	44404892
DM9BTLC	MW	218.29
DM9BTLC	FM	C13H18N2O
DM9BTLC	IC	InChI=1S/C13H18N2O/c1-9-10(7-8-15(2)3)13-11(14-9)5-4-6-12(13)16/h4-6,14,16H,7-8H2,1-3H3
DM9BTLC	CS	CC1=C(C2=C(N1)C=CC=C2O)CCN(C)C
DM9BTLC	IK	HXNGZUVNHQYMKL-UHFFFAOYSA-N
DM9BTLC	IU	3-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-4-ol
DM9BTLC	DE	Discovery agent

DMMJP9D	ID	DMMJP9D
DMMJP9D	DN	3-(2-Dimethylamino-propyl)-1H-indol-4-ol
DMMJP9D	HS	Investigative
DMMJP9D	SN	CHEMBL194202; 3-(2-Dimethylamino-propyl)-1H-indol-4-ol
DMMJP9D	DT	Small molecular drug
DMMJP9D	PC	44404906
DMMJP9D	MW	218.29
DMMJP9D	FM	C13H18N2O
DMMJP9D	IC	InChI=1S/C13H18N2O/c1-9(15(2)3)7-10-8-14-11-5-4-6-12(16)13(10)11/h4-6,8-9,14,16H,7H2,1-3H3
DMMJP9D	CS	CC(CC1=CNC2=C1C(=CC=C2)O)N(C)C
DMMJP9D	IK	GRWDWEFPYLWISL-UHFFFAOYSA-N
DMMJP9D	IU	3-[2-(dimethylamino)propyl]-1H-indol-4-ol
DMMJP9D	DE	Discovery agent

DMD24EW	ID	DMD24EW
DMD24EW	DN	3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol
DMD24EW	HS	Investigative
DMD24EW	DT	Small molecular drug
DMD24EW	PC	135474202
DMD24EW	MW	227.21
DMD24EW	FM	C13H9NO3
DMD24EW	IC	InChI=1S/C13H9NO3/c15-8-5-6-10-12(7-8)17-14-13(10)9-3-1-2-4-11(9)16/h1-7,15-16H
DMD24EW	CS	C1=CC=C(C(=C1)C2=NOC3=C2C=CC(=C3)O)O
DMD24EW	IK	PKKSNVBSDIEUEZ-UHFFFAOYSA-N
DMD24EW	IU	3-(2-hydroxyphenyl)-1,2-benzoxazol-6-ol
DMD24EW	DE	Discovery agent

DM1DQGJ	ID	DM1DQGJ
DM1DQGJ	DN	3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol
DM1DQGJ	HS	Investigative
DM1DQGJ	SN	CHEMBL285250; 27107-68-2; 3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol; CTK0I5787; DTXSID80494706; BDBM50000570; AKOS022657931; 3-(2-Methyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol; Phenol, 3-(2-methyl-2-azabicyclo[3.3.1]non-5-yl)-; 2-Methyl-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonane
DM1DQGJ	DT	Small molecular drug
DM1DQGJ	PC	12368881
DM1DQGJ	MW	231.33
DM1DQGJ	FM	C15H21NO
DM1DQGJ	IC	InChI=1S/C15H21NO/c1-16-9-8-15(7-3-5-13(16)11-15)12-4-2-6-14(17)10-12/h2,4,6,10,13,17H,3,5,7-9,11H2,1H3
DM1DQGJ	CS	CN1CCC2(CCCC1C2)C3=CC(=CC=C3)O
DM1DQGJ	IK	ZQJGRSYDDMBMPJ-UHFFFAOYSA-N
DM1DQGJ	IU	3-(2-methyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol
DM1DQGJ	CA	CAS 27107-68-2
DM1DQGJ	DE	Discovery agent

DMY782R	ID	DMY782R
DMY782R	DN	3-(2-methylbenzo[d]thiazol-5-yl)benzonitrile
DMY782R	HS	Investigative
DMY782R	SN	CHEMBL244585; 3-(2-methylbenzo[d]thiazol-5-yl)benzonitrile
DMY782R	DT	Small molecular drug
DMY782R	PC	44427389
DMY782R	MW	250.32
DMY782R	FM	C15H10N2S
DMY782R	IC	InChI=1S/C15H10N2S/c1-10-17-14-8-13(5-6-15(14)18-10)12-4-2-3-11(7-12)9-16/h2-8H,1H3
DMY782R	CS	CC1=NC2=C(S1)C=CC(=C2)C3=CC=CC(=C3)C#N
DMY782R	IK	QCTQEXSACACMOJ-UHFFFAOYSA-N
DMY782R	IU	3-(2-methyl-1,3-benzothiazol-5-yl)benzonitrile
DMY782R	DE	Discovery agent

DMUPB9H	ID	DMUPB9H
DMUPB9H	DN	3-(2-methylquinolin-7-yl)benzonitrile
DMUPB9H	HS	Investigative
DMUPB9H	SN	CHEMBL244796; 3-(2-methylquinolin-7-yl)benzonitrile; SCHEMBL4296051
DMUPB9H	DT	Small molecular drug
DMUPB9H	PC	16747725
DMUPB9H	MW	244.29
DMUPB9H	FM	C17H12N2
DMUPB9H	IC	InChI=1S/C17H12N2/c1-12-5-6-14-7-8-16(10-17(14)19-12)15-4-2-3-13(9-15)11-18/h2-10H,1H3
DMUPB9H	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC(=C3)C#N
DMUPB9H	IK	RPEUOKKTGONULE-UHFFFAOYSA-N
DMUPB9H	IU	3-(2-methylquinolin-7-yl)benzonitrile
DMUPB9H	DE	Discovery agent

DM41HMZ	ID	DM41HMZ
DM41HMZ	DN	3-(2-methylquinolin-7-yl)phenol
DM41HMZ	HS	Investigative
DM41HMZ	SN	CHEMBL231988; 3-(2-methylquinolin-7-yl)phenol
DM41HMZ	DT	Small molecular drug
DM41HMZ	PC	44432667
DM41HMZ	MW	235.28
DM41HMZ	FM	C16H13NO
DM41HMZ	IC	InChI=1S/C16H13NO/c1-11-5-6-12-7-8-14(10-16(12)17-11)13-3-2-4-15(18)9-13/h2-10,18H,1H3
DM41HMZ	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)O
DM41HMZ	IK	ONBWGZNKVDEPCB-UHFFFAOYSA-N
DM41HMZ	IU	3-(2-methylquinolin-7-yl)phenol
DM41HMZ	DE	Discovery agent

DM27HSO	ID	DM27HSO
DM27HSO	DN	3-(2-naphthyl)phenol
DM27HSO	HS	Investigative
DM27HSO	SN	3-(2-naphthyl)phenol; 2-(3-Hydroxyphenyl)naphthalene; 3-(NAPHTHALEN-2-YL)PHENOL; 33104-32-4; CHEMBL258687; 3-Naphthalene-2-ylphenol; 3-naphthalen-2-yl-phenol; SCHEMBL3015094; DTXSID90487649; FQDQJXSIUCYJDC-UHFFFAOYSA-N; BDBM50373033
DM27HSO	DT	Small molecular drug
DM27HSO	PC	12316406
DM27HSO	MW	220.26
DM27HSO	FM	C16H12O
DM27HSO	IC	InChI=1S/C16H12O/c17-16-7-3-6-14(11-16)15-9-8-12-4-1-2-5-13(12)10-15/h1-11,17H
DM27HSO	CS	C1=CC=C2C=C(C=CC2=C1)C3=CC(=CC=C3)O
DM27HSO	IK	FQDQJXSIUCYJDC-UHFFFAOYSA-N
DM27HSO	IU	3-naphthalen-2-ylphenol
DM27HSO	CA	CAS 33104-32-4
DM27HSO	DE	Discovery agent

DMYXQ7L	ID	DMYXQ7L
DMYXQ7L	DN	3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine
DMYXQ7L	HS	Investigative
DMYXQ7L	SN	CHEMBL314727; 3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine; SCHEMBL8550044; BDBM50104648
DMYXQ7L	DT	Small molecular drug
DMYXQ7L	PC	44322572
DMYXQ7L	MW	187.2
DMYXQ7L	FM	C7H13N3O3
DMYXQ7L	IC	InChI=1S/C7H13N3O3/c8-7-2-4-13-5-6(9-7)1-3-10(11)12/h6H,1-5H2,(H2,8,9)
DMYXQ7L	CS	C1COCC(N=C1N)CC[N+](=O)[O-]
DMYXQ7L	IK	BWBBVEBIAZILKQ-UHFFFAOYSA-N
DMYXQ7L	IU	3-(2-nitroethyl)-2,3,6,7-tetrahydro-1,4-oxazepin-5-amine
DMYXQ7L	DE	Discovery agent

DM3BQO0	ID	DM3BQO0
DM3BQO0	DN	3-(2-N-Piperidyl-acetamino)-rutaecarpine
DM3BQO0	HS	Investigative
DM3BQO0	SN	CHEMBL1097952; 3-(2-N-Piperidyl-acetamino)-rutaecarpine
DM3BQO0	DT	Small molecular drug
DM3BQO0	PC	44624061
DM3BQO0	MW	427.5
DM3BQO0	FM	C25H25N5O2
DM3BQO0	IC	InChI=1S/C25H25N5O2/c31-22(15-29-11-4-1-5-12-29)26-16-8-9-21-19(14-16)25(32)30-13-10-18-17-6-2-3-7-20(17)27-23(18)24(30)28-21/h2-3,6-9,14,27H,1,4-5,10-13,15H2,(H,26,31)
DM3BQO0	CS	C1CCN(CC1)CC(=O)NC2=CC3=C(C=C2)N=C4C5=C(CCN4C3=O)C6=CC=CC=C6N5
DM3BQO0	IK	QCNQXHWYZYJQDL-UHFFFAOYSA-N
DM3BQO0	IU	N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)-2-piperidin-1-ylacetamide
DM3BQO0	DE	Discovery agent

DMFEHDY	ID	DMFEHDY
DMFEHDY	DN	3-(2-N-Piperidyl-propionamino)-rutaecarpine
DMFEHDY	HS	Investigative
DMFEHDY	SN	CHEMBL1096951; 3-(2-N-Piperidyl-propionamino)-rutaecarpine
DMFEHDY	DT	Small molecular drug
DMFEHDY	PC	44624064
DMFEHDY	MW	441.5
DMFEHDY	FM	C26H27N5O2
DMFEHDY	IC	InChI=1S/C26H27N5O2/c32-23(11-14-30-12-4-1-5-13-30)27-17-8-9-22-20(16-17)26(33)31-15-10-19-18-6-2-3-7-21(18)28-24(19)25(31)29-22/h2-3,6-9,16,28H,1,4-5,10-15H2,(H,27,32)
DMFEHDY	CS	C1CCN(CC1)CCC(=O)NC2=CC3=C(C=C2)N=C4C5=C(CCN4C3=O)C6=CC=CC=C6N5
DMFEHDY	IK	SJTYFVUMCWQRRK-UHFFFAOYSA-N
DMFEHDY	IU	N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)-3-piperidin-1-ylpropanamide
DMFEHDY	DE	Discovery agent

DMQ0A8W	ID	DMQ0A8W
DMQ0A8W	DN	3-(2-N-Pyrrolyl-acetamino)-rutaecarpine
DMQ0A8W	HS	Investigative
DMQ0A8W	SN	CHEMBL1097951; 3-(2-N-Pyrrolyl-acetamino)-rutaecarpine
DMQ0A8W	DT	Small molecular drug
DMQ0A8W	PC	44624060
DMQ0A8W	MW	413.5
DMQ0A8W	FM	C24H23N5O2
DMQ0A8W	IC	InChI=1S/C24H23N5O2/c30-21(14-28-10-3-4-11-28)25-15-7-8-20-18(13-15)24(31)29-12-9-17-16-5-1-2-6-19(16)26-22(17)23(29)27-20/h1-2,5-8,13,26H,3-4,9-12,14H2,(H,25,30)
DMQ0A8W	CS	C1CCN(C1)CC(=O)NC2=CC3=C(C=C2)N=C4C5=C(CCN4C3=O)C6=CC=CC=C6N5
DMQ0A8W	IK	WZTWUTJMQXWCQN-UHFFFAOYSA-N
DMQ0A8W	IU	N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)-2-pyrrolidin-1-ylacetamide
DMQ0A8W	DE	Discovery agent

DM9MRTW	ID	DM9MRTW
DM9MRTW	DN	3-(2-N-Pyrrolyl-propionamino)-rutaecarpine
DM9MRTW	HS	Investigative
DM9MRTW	SN	CHEMBL1094633; 3-(2-N-Pyrrolyl-propionamino)-rutaecarpine
DM9MRTW	DT	Small molecular drug
DM9MRTW	PC	44624063
DM9MRTW	MW	427.5
DM9MRTW	FM	C25H25N5O2
DM9MRTW	IC	InChI=1S/C25H25N5O2/c31-22(10-13-29-11-3-4-12-29)26-16-7-8-21-19(15-16)25(32)30-14-9-18-17-5-1-2-6-20(17)27-23(18)24(30)28-21/h1-2,5-8,15,27H,3-4,9-14H2,(H,26,31)
DM9MRTW	CS	C1CCN(C1)CCC(=O)NC2=CC3=C(C=C2)N=C4C5=C(CCN4C3=O)C6=CC=CC=C6N5
DM9MRTW	IK	QEZVUWPDYKSHCV-UHFFFAOYSA-N
DM9MRTW	IU	N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)-3-pyrrolidin-1-ylpropanamide
DM9MRTW	DE	Discovery agent

DM0YEGM	ID	DM0YEGM
DM0YEGM	DN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzamide
DM0YEGM	HS	Investigative
DM0YEGM	SN	CHEMBL379536; 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzamide
DM0YEGM	DT	Small molecular drug
DM0YEGM	PC	44414732
DM0YEGM	MW	309.4
DM0YEGM	FM	C19H23N3O
DM0YEGM	IC	InChI=1S/C19H23N3O/c20-19(23)17-8-4-5-15(13-17)14-18(16-6-2-1-3-7-16)22-11-9-21-10-12-22/h1-8,13,18,21H,9-12,14H2,(H2,20,23)
DM0YEGM	CS	C1CN(CCN1)C(CC2=CC(=CC=C2)C(=O)N)C3=CC=CC=C3
DM0YEGM	IK	AGCDRDCNYZHHKS-UHFFFAOYSA-N
DM0YEGM	IU	3-(2-phenyl-2-piperazin-1-ylethyl)benzamide
DM0YEGM	DE	Discovery agent

DM6YJOU	ID	DM6YJOU
DM6YJOU	DN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DM6YJOU	HS	Investigative
DM6YJOU	SN	CHEMBL386223; 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DM6YJOU	DT	Small molecular drug
DM6YJOU	PC	44414721
DM6YJOU	MW	291.4
DM6YJOU	FM	C19H21N3
DM6YJOU	IC	InChI=1S/C19H21N3/c20-15-17-6-4-5-16(13-17)14-19(18-7-2-1-3-8-18)22-11-9-21-10-12-22/h1-8,13,19,21H,9-12,14H2
DM6YJOU	CS	C1CN(CCN1)C(CC2=CC(=CC=C2)C#N)C3=CC=CC=C3
DM6YJOU	IK	JQQRBSOAFDAWGZ-UHFFFAOYSA-N
DM6YJOU	IU	3-(2-phenyl-2-piperazin-1-ylethyl)benzonitrile
DM6YJOU	DE	Discovery agent

DM6QZTB	ID	DM6QZTB
DM6QZTB	DN	3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM6QZTB	HS	Investigative
DM6QZTB	SN	CHEMBL210026; 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol; 61311-64-6; 3-[2-Phenyl-2-(piperazin-1-yl)ethyl]phenol; SCHEMBL8531930; CTK2E2737; DTXSID30552209; VPNYIGJUQBPBMU-UHFFFAOYSA-N; BDBM50188056; Phenol, 3-[2-phenyl-2-(1-piperazinyl)ethyl]-; 1-[1-Phenyl-2-(3-hydroxyphenyl)ethyl]piperazine
DM6QZTB	DT	Small molecular drug
DM6QZTB	PC	13904714
DM6QZTB	MW	282.4
DM6QZTB	FM	C18H22N2O
DM6QZTB	IC	InChI=1S/C18H22N2O/c21-17-8-4-5-15(13-17)14-18(16-6-2-1-3-7-16)20-11-9-19-10-12-20/h1-8,13,18-19,21H,9-12,14H2
DM6QZTB	CS	C1CN(CCN1)C(CC2=CC(=CC=C2)O)C3=CC=CC=C3
DM6QZTB	IK	VPNYIGJUQBPBMU-UHFFFAOYSA-N
DM6QZTB	IU	3-(2-phenyl-2-piperazin-1-ylethyl)phenol
DM6QZTB	CA	CAS 61311-64-6
DM6QZTB	DE	Discovery agent

DM63T9D	ID	DM63T9D
DM63T9D	DN	3-(2-phenyl-6-(thiophen-2-yl)pyridin-4-yl)-phenol
DM63T9D	HS	Investigative
DM63T9D	SN	CHEMBL1096659
DM63T9D	DT	Small molecular drug
DM63T9D	PC	46887242
DM63T9D	MW	329.4
DM63T9D	FM	C21H15NOS
DM63T9D	IC	InChI=1S/C21H15NOS/c23-18-9-4-8-16(12-18)17-13-19(15-6-2-1-3-7-15)22-20(14-17)21-10-5-11-24-21/h1-14,23H
DM63T9D	CS	C1=CC=C(C=C1)C2=NC(=CC(=C2)C3=CC(=CC=C3)O)C4=CC=CS4
DM63T9D	IK	VNKCREXUIZRWPF-UHFFFAOYSA-N
DM63T9D	IU	3-(2-phenyl-6-thiophen-2-ylpyridin-4-yl)phenol
DM63T9D	DE	Discovery agent

DMF369N	ID	DMF369N
DMF369N	DN	3-(2-phenyl-6-(thiophen-3-yl)pyridin-4-yl)-phenol
DMF369N	HS	Investigative
DMF369N	SN	CHEMBL1094745
DMF369N	DT	Small molecular drug
DMF369N	PC	46887243
DMF369N	MW	329.4
DMF369N	FM	C21H15NOS
DMF369N	IC	InChI=1S/C21H15NOS/c23-19-8-4-7-16(11-19)18-12-20(15-5-2-1-3-6-15)22-21(13-18)17-9-10-24-14-17/h1-14,23H
DMF369N	CS	C1=CC=C(C=C1)C2=NC(=CC(=C2)C3=CC(=CC=C3)O)C4=CSC=C4
DMF369N	IK	GWFRFJZJQITLHW-UHFFFAOYSA-N
DMF369N	IU	3-(2-phenyl-6-thiophen-3-ylpyridin-4-yl)phenol
DMF369N	DE	Discovery agent

DMQC9WV	ID	DMQC9WV
DMQC9WV	DN	3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one
DMQC9WV	HS	Investigative
DMQC9WV	SN	SCHEMBL5463666; CHEMBL240264; BDBM20859; quinolin-2(1H)-one derivative, 17a
DMQC9WV	DT	Small molecular drug
DMQC9WV	PC	22638512
DMQC9WV	MW	304.4
DMQC9WV	FM	C18H12N2OS
DMQC9WV	IC	InChI=1S/C18H12N2OS/c21-17-14(10-13-8-4-5-9-15(13)19-17)16-11-22-18(20-16)12-6-2-1-3-7-12/h1-11H,(H,19,21)
DMQC9WV	CS	C1=CC=C(C=C1)C2=NC(=CS2)C3=CC4=CC=CC=C4NC3=O
DMQC9WV	IK	OANBFUCSFFQVAU-UHFFFAOYSA-N
DMQC9WV	IU	3-(2-phenyl-1,3-thiazol-4-yl)-1H-quinolin-2-one
DMQC9WV	DE	Discovery agent

DM2IYAP	ID	DM2IYAP
DM2IYAP	DN	3-(2-propyn-1-yl)thymidine
DM2IYAP	HS	Investigative
DM2IYAP	SN	3-(2-propyn-1-yl)thymidine; 3-Propargylthymidine; SCHEMBL1619074; CHEMBL524872
DM2IYAP	DT	Small molecular drug
DM2IYAP	PC	11323459
DM2IYAP	MW	280.28
DM2IYAP	FM	C13H16N2O5
DM2IYAP	IC	InChI=1S/C13H16N2O5/c1-3-4-14-12(18)8(2)6-15(13(14)19)11-5-9(17)10(7-16)20-11/h1,6,9-11,16-17H,4-5,7H2,2H3/t9-,10+,11+/m0/s1
DM2IYAP	CS	CC1=CN(C(=O)N(C1=O)CC#C)[C@H]2C[C@@H]([C@H](O2)CO)O
DM2IYAP	IK	LZHTUGCZNRVCGE-HBNTYKKESA-N
DM2IYAP	IU	1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-3-prop-2-ynylpyrimidine-2,4-dione
DM2IYAP	DE	Discovery agent

DMPWEL8	ID	DMPWEL8
DMPWEL8	DN	3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)-benzonitrile
DMPWEL8	HS	Investigative
DMPWEL8	SN	CHEMBL366288; 3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)-benzonitrile; SCHEMBL4703496; ZINC13582347
DMPWEL8	DT	Small molecular drug
DMPWEL8	PC	9813637
DMPWEL8	MW	248.24
DMPWEL8	FM	C13H8N6
DMPWEL8	IC	InChI=1S/C13H8N6/c14-9-10-4-3-5-11(8-10)13-16-18-19(17-13)12-6-1-2-7-15-12/h1-8H
DMPWEL8	CS	C1=CC=NC(=C1)N2N=C(N=N2)C3=CC=CC(=C3)C#N
DMPWEL8	IK	GHRSDAGWCBAULR-UHFFFAOYSA-N
DMPWEL8	IU	3-(2-pyridin-2-yltetrazol-5-yl)benzonitrile
DMPWEL8	DE	Discovery agent

DM7VJPX	ID	DM7VJPX
DM7VJPX	DN	3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol
DM7VJPX	HS	Investigative
DM7VJPX	SN	CHEMBL364061; 3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol; BDBM50171265; AKOS022506696
DM7VJPX	DT	Small molecular drug
DM7VJPX	PC	21854226
DM7VJPX	MW	230.31
DM7VJPX	FM	C14H18N2O
DM7VJPX	IC	InChI=1S/C14H18N2O/c17-13-5-3-4-12-14(13)11(10-15-12)6-9-16-7-1-2-8-16/h3-5,10,15,17H,1-2,6-9H2
DM7VJPX	CS	C1CCN(C1)CCC2=CNC3=C2C(=CC=C3)O
DM7VJPX	IK	XASLPZWIPBCAPF-UHFFFAOYSA-N
DM7VJPX	IU	3-(2-pyrrolidin-1-ylethyl)-1H-indol-4-ol
DM7VJPX	CA	CAS 63097-26-7
DM7VJPX	DE	Discovery agent

DMKAEUD	ID	DMKAEUD
DMKAEUD	DN	3-(3-(3-chlorobenzyloxy)-5-methylphenyl)pyridine
DMKAEUD	HS	Investigative
DMKAEUD	SN	CHEMBL208506; 3-(3-(3-chlorobenzyloxy)-5-methylphenyl)pyridine
DMKAEUD	DT	Small molecular drug
DMKAEUD	PC	44409820
DMKAEUD	MW	309.8
DMKAEUD	FM	C19H16ClNO
DMKAEUD	IC	InChI=1S/C19H16ClNO/c1-14-8-17(16-5-3-7-21-12-16)11-19(9-14)22-13-15-4-2-6-18(20)10-15/h2-12H,13H2,1H3
DMKAEUD	CS	CC1=CC(=CC(=C1)OCC2=CC(=CC=C2)Cl)C3=CN=CC=C3
DMKAEUD	IK	XCVOOHGTUQHYAX-UHFFFAOYSA-N
DMKAEUD	IU	3-[3-[(3-chlorophenyl)methoxy]-5-methylphenyl]pyridine
DMKAEUD	DE	Discovery agent

DMY4VX2	ID	DMY4VX2
DMY4VX2	DN	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid
DMY4VX2	HS	Investigative
DMY4VX2	SN	CHEMBL218226
DMY4VX2	DT	Small molecular drug
DMY4VX2	PC	44418282
DMY4VX2	MW	412.4
DMY4VX2	FM	C20H20N4O6
DMY4VX2	IC	InChI=1S/C20H20N4O6/c25-18(26)4-6-22-19(27)13-7-14(10-17(9-13)24(29)30)20(28)23-16-2-1-12-3-5-21-11-15(12)8-16/h1-2,7-10,21H,3-6,11H2,(H,22,27)(H,23,28)(H,25,26)
DMY4VX2	CS	C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC(=CC(=C3)C(=O)NCCC(=O)O)[N+](=O)[O-]
DMY4VX2	IK	VGPKJRDGGNBIGH-UHFFFAOYSA-N
DMY4VX2	IU	3-[[3-nitro-5-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzoyl]amino]propanoic acid
DMY4VX2	DE	Discovery agent

DM2K51S	ID	DM2K51S
DM2K51S	DN	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid
DM2K51S	HS	Investigative
DM2K51S	SN	CHEMBL220128; 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid
DM2K51S	DT	Small molecular drug
DM2K51S	PC	44418281
DM2K51S	MW	443.5
DM2K51S	FM	C26H25N3O4
DM2K51S	IC	InChI=1S/C26H25N3O4/c30-24(31)15-23(18-5-2-1-3-6-18)29-26(33)20-8-4-7-19(13-20)25(32)28-22-10-9-17-11-12-27-16-21(17)14-22/h1-10,13-14,23,27H,11-12,15-16H2,(H,28,32)(H,29,33)(H,30,31)
DM2K51S	CS	C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC(=CC=C3)C(=O)NC(CC(=O)O)C4=CC=CC=C4
DM2K51S	IK	OCNALRIBAIFGLP-UHFFFAOYSA-N
DM2K51S	IU	3-phenyl-3-[[3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzoyl]amino]propanoic acid
DM2K51S	DE	Discovery agent

DM31JAZ	ID	DM31JAZ
DM31JAZ	DN	3-(3-(carbamoyl)benzamido)propanoic acid
DM31JAZ	HS	Investigative
DM31JAZ	SN	CHEMBL219603; 3-(3-(carbamoyl)benzamido)propanoic acid
DM31JAZ	DT	Small molecular drug
DM31JAZ	PC	44418280
DM31JAZ	MW	367.4
DM31JAZ	FM	C20H21N3O4
DM31JAZ	IC	InChI=1S/C20H21N3O4/c24-18(25)7-9-22-19(26)14-2-1-3-15(10-14)20(27)23-17-5-4-13-6-8-21-12-16(13)11-17/h1-5,10-11,21H,6-9,12H2,(H,22,26)(H,23,27)(H,24,25)
DM31JAZ	CS	C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC=CC(=C3)C(=O)NCCC(=O)O
DM31JAZ	IK	MPYXISYAFIYYRD-UHFFFAOYSA-N
DM31JAZ	IU	3-[[3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzoyl]amino]propanoic acid
DM31JAZ	DE	Discovery agent

DMSHORK	ID	DMSHORK
DMSHORK	DN	3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile
DMSHORK	HS	Investigative
DMSHORK	SN	CHEMBL117187; 3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile; SCHEMBL3518135; BDBM50121164; 3,3-Dimethyl-5-(3-cyanophenyl)indoline-2-one
DMSHORK	DT	Small molecular drug
DMSHORK	PC	9903358
DMSHORK	MW	262.3
DMSHORK	FM	C17H14N2O
DMSHORK	IC	InChI=1S/C17H14N2O/c1-17(2)14-9-13(6-7-15(14)19-16(17)20)12-5-3-4-11(8-12)10-18/h3-9H,1-2H3,(H,19,20)
DMSHORK	CS	CC1(C2=C(C=CC(=C2)C3=CC=CC(=C3)C#N)NC1=O)C
DMSHORK	IK	WZZPSUKZMZKXTQ-UHFFFAOYSA-N
DMSHORK	IU	3-(3,3-dimethyl-2-oxo-1H-indol-5-yl)benzonitrile
DMSHORK	DE	Discovery agent

DMT3AW8	ID	DMT3AW8
DMT3AW8	DN	3-(3,4-dichlorophenyl)-2-nortropene
DMT3AW8	HS	Investigative
DMT3AW8	SN	CHEMBL578130; 3-(3,4-dichlorophenyl)-2-nortropene; SCHEMBL5194296; WNTMTTVEDFGEMS-UHFFFAOYSA-N; BDBM50303309
DMT3AW8	DT	Small molecular drug
DMT3AW8	PC	10220657
DMT3AW8	MW	254.15
DMT3AW8	FM	C13H13Cl2N
DMT3AW8	IC	InChI=1S/C13H13Cl2N/c14-12-4-1-8(7-13(12)15)9-5-10-2-3-11(6-9)16-10/h1,4-5,7,10-11,16H,2-3,6H2
DMT3AW8	CS	C1CC2C=C(CC1N2)C3=CC(=C(C=C3)Cl)Cl
DMT3AW8	IK	WNTMTTVEDFGEMS-UHFFFAOYSA-N
DMT3AW8	IU	3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene
DMT3AW8	DE	Discovery agent

DMEJH13	ID	DMEJH13
DMEJH13	DN	3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline
DMEJH13	HS	Investigative
DMEJH13	SN	CHEMBL67702; 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline; SCHEMBL8502992; BDBM50039074
DMEJH13	DT	Small molecular drug
DMEJH13	PC	10065445
DMEJH13	MW	334.2
DMEJH13	FM	C17H13Cl2NO2
DMEJH13	IC	InChI=1S/C17H13Cl2NO2/c1-21-16-7-11-5-12(9-20-15(11)8-17(16)22-2)10-3-4-13(18)14(19)6-10/h3-9H,1-2H3
DMEJH13	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC(=C(C=C3)Cl)Cl
DMEJH13	IK	PSUROKVLDMNXCQ-UHFFFAOYSA-N
DMEJH13	IU	3-(3,4-dichlorophenyl)-6,7-dimethoxyquinoline
DMEJH13	DE	Discovery agent

DMX3AMB	ID	DMX3AMB
DMX3AMB	DN	3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline
DMX3AMB	HS	Investigative
DMX3AMB	SN	CHEMBL67424; 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline; ZINC3834040
DMX3AMB	DT	Small molecular drug
DMX3AMB	PC	10402592
DMX3AMB	MW	301.29
DMX3AMB	FM	C17H13F2NO2
DMX3AMB	IC	InChI=1S/C17H13F2NO2/c1-21-16-7-11-5-12(9-20-15(11)8-17(16)22-2)10-3-4-13(18)14(19)6-10/h3-9H,1-2H3
DMX3AMB	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC(=C(C=C3)F)F
DMX3AMB	IK	RETQZWLIOAJIRM-UHFFFAOYSA-N
DMX3AMB	IU	3-(3,4-difluorophenyl)-6,7-dimethoxyquinoline
DMX3AMB	DE	Discovery agent

DM0VL17	ID	DM0VL17
DM0VL17	DN	3-(3,4-dihydronaphthalen-2-yl)pyridine
DM0VL17	HS	Investigative
DM0VL17	SN	3-(3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 2; AC1O70H5; BDBM8889; SCHEMBL4508891; CHEMBL205881
DM0VL17	DT	Small molecular drug
DM0VL17	PC	6540047
DM0VL17	MW	207.27
DM0VL17	FM	C15H13N
DM0VL17	IC	InChI=1S/C15H13N/c1-2-5-13-10-14(8-7-12(13)4-1)15-6-3-9-16-11-15/h1-6,9-11H,7-8H2
DM0VL17	CS	C1CC(=CC2=CC=CC=C21)C3=CN=CC=C3
DM0VL17	IK	AXLDMZNUHQOZFK-UHFFFAOYSA-N
DM0VL17	IU	3-(3,4-dihydronaphthalen-2-yl)pyridine
DM0VL17	DE	Discovery agent

DMDU10A	ID	DMDU10A
DMDU10A	DN	3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline
DMDU10A	HS	Investigative
DMDU10A	SN	CHEMBL66100; 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline; BDBM50039089
DMDU10A	DT	Small molecular drug
DMDU10A	PC	10336427
DMDU10A	MW	325.4
DMDU10A	FM	C19H19NO4
DMDU10A	IC	InChI=1S/C19H19NO4/c1-21-16-6-5-12(8-17(16)22-2)14-7-13-9-18(23-3)19(24-4)10-15(13)20-11-14/h5-11H,1-4H3
DMDU10A	CS	COC1=C(C=C(C=C1)C2=CN=C3C=C(C(=CC3=C2)OC)OC)OC
DMDU10A	IK	BWIYMDQJIKNCMK-UHFFFAOYSA-N
DMDU10A	IU	3-(3,4-dimethoxyphenyl)-6,7-dimethoxyquinoline
DMDU10A	DE	Discovery agent

DM9BYVL	ID	DM9BYVL
DM9BYVL	DN	3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one
DM9BYVL	HS	Investigative
DM9BYVL	SN	CHEMBL576116; BDBM35551; 4-hydroxy-2H-chromen-2-one core, 28
DM9BYVL	DT	Small molecular drug
DM9BYVL	PC	54736444
DM9BYVL	MW	280.3
DM9BYVL	FM	C18H16O3
DM9BYVL	IC	InChI=1S/C18H16O3/c1-11-7-8-13(9-12(11)2)10-15-17(19)14-5-3-4-6-16(14)21-18(15)20/h3-9,19H,10H2,1-2H3
DM9BYVL	CS	CC1=C(C=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O)C
DM9BYVL	IK	YGMVKOKEKHJHOV-UHFFFAOYSA-N
DM9BYVL	IU	3-[(3,4-dimethylphenyl)methyl]-4-hydroxychromen-2-one
DM9BYVL	DE	Discovery agent

DMULX9O	ID	DMULX9O
DMULX9O	DN	3-(3,4-dimethylphenyl)-1,5-naphthyridine
DMULX9O	HS	Investigative
DMULX9O	SN	CHEMBL236264; 3-(3,4-dimethylphenyl)-1,5-naphthyridine
DMULX9O	DT	Small molecular drug
DMULX9O	PC	44434731
DMULX9O	MW	234.29
DMULX9O	FM	C16H14N2
DMULX9O	IC	InChI=1S/C16H14N2/c1-11-5-6-13(8-12(11)2)14-9-16-15(18-10-14)4-3-7-17-16/h3-10H,1-2H3
DMULX9O	CS	CC1=C(C=C(C=C1)C2=CC3=C(C=CC=N3)N=C2)C
DMULX9O	IK	MGYKFCHFCGICOX-UHFFFAOYSA-N
DMULX9O	IU	3-(3,4-dimethylphenyl)-1,5-naphthyridine
DMULX9O	DE	Discovery agent

DM8W9EO	ID	DM8W9EO
DM8W9EO	DN	3-(3,4-Dimethyl-phenyl)-1-propyl-piperidine
DM8W9EO	HS	Investigative
DM8W9EO	SN	CHEMBL72630; 3-(3,4-Dimethyl-phenyl)-1-propyl-piperidine; CTK8F4622; DTXSID60441778; BDBM50068422; 1-Propyl-3-(3,4-dimethylphenyl)piperidine
DM8W9EO	DT	Small molecular drug
DM8W9EO	PC	10561521
DM8W9EO	MW	231.38
DM8W9EO	FM	C16H25N
DM8W9EO	IC	InChI=1S/C16H25N/c1-4-9-17-10-5-6-16(12-17)15-8-7-13(2)14(3)11-15/h7-8,11,16H,4-6,9-10,12H2,1-3H3
DM8W9EO	CS	CCCN1CCCC(C1)C2=CC(=C(C=C2)C)C
DM8W9EO	IK	WKCUEEXFTZSNLI-UHFFFAOYSA-N
DM8W9EO	IU	3-(3,4-dimethylphenyl)-1-propylpiperidine
DM8W9EO	DE	Discovery agent

DMOW0L9	ID	DMOW0L9
DMOW0L9	DN	3-(3,4-Dimethyl-phenyl)-piperidine
DMOW0L9	HS	Investigative
DMOW0L9	SN	3-(3,4-dimethylphenyl)piperidine; CHEMBL356746; 219703-95-4; 3-(3,4-Dimethyl-phenyl)-piperidine; BDBM50068423; AKOS013783555
DMOW0L9	DT	Small molecular drug
DMOW0L9	PC	10103976
DMOW0L9	MW	189.3
DMOW0L9	FM	C13H19N
DMOW0L9	IC	InChI=1S/C13H19N/c1-10-5-6-12(8-11(10)2)13-4-3-7-14-9-13/h5-6,8,13-14H,3-4,7,9H2,1-2H3
DMOW0L9	CS	CC1=C(C=C(C=C1)C2CCCNC2)C
DMOW0L9	IK	NDGKSXYKTXZIQO-UHFFFAOYSA-N
DMOW0L9	IU	3-(3,4-dimethylphenyl)piperidine
DMOW0L9	DE	Discovery agent

DMDFHCU	ID	DMDFHCU
DMDFHCU	DN	3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid
DMDFHCU	HS	Investigative
DMDFHCU	SN	SCHEMBL4895878; CHEMBL195556; BDBM18906; ZINC13643210; 3,5-Dibromo-4-alkoxyphenylalkanoic Acid, 9i; 3-[3,5-dibromo-4-(hexyloxy)phenyl]propanoic acid
DMDFHCU	DT	Small molecular drug
DMDFHCU	PC	11350323
DMDFHCU	MW	408.12
DMDFHCU	FM	C15H20Br2O3
DMDFHCU	IC	InChI=1S/C15H20Br2O3/c1-2-3-4-5-8-20-15-12(16)9-11(10-13(15)17)6-7-14(18)19/h9-10H,2-8H2,1H3,(H,18,19)
DMDFHCU	CS	CCCCCCOC1=C(C=C(C=C1Br)CCC(=O)O)Br
DMDFHCU	IK	FVDRTJXVCUAOCA-UHFFFAOYSA-N
DMDFHCU	IU	3-(3,5-dibromo-4-hexoxyphenyl)propanoic acid
DMDFHCU	DE	Discovery agent

DMSI3V4	ID	DMSI3V4
DMSI3V4	DN	3-(3,5-Dimethyl-phenyl)-1-propyl-piperidine
DMSI3V4	HS	Investigative
DMSI3V4	SN	CHEMBL144114; 3-(3,5-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068419
DMSI3V4	DT	Small molecular drug
DMSI3V4	PC	10775901
DMSI3V4	MW	231.38
DMSI3V4	FM	C16H25N
DMSI3V4	IC	InChI=1S/C16H25N/c1-4-7-17-8-5-6-15(12-17)16-10-13(2)9-14(3)11-16/h9-11,15H,4-8,12H2,1-3H3
DMSI3V4	CS	CCCN1CCCC(C1)C2=CC(=CC(=C2)C)C
DMSI3V4	IK	AMPXVBOIQBSQML-UHFFFAOYSA-N
DMSI3V4	IU	3-(3,5-dimethylphenyl)-1-propylpiperidine
DMSI3V4	CA	CAS 219704-08-2
DMSI3V4	DE	Discovery agent

DMUWKMN	ID	DMUWKMN
DMUWKMN	DN	3-(3,5-Dimethyl-phenyl)-piperidine
DMUWKMN	HS	Investigative
DMUWKMN	SN	3-(3,5-dimethylphenyl)piperidine; CHEMBL342345; 219704-07-1; 3-(3,5-Dimethyl-phenyl)-piperidine; BDBM50068427; AKOS006308924
DMUWKMN	DT	Small molecular drug
DMUWKMN	PC	10035413
DMUWKMN	MW	189.3
DMUWKMN	FM	C13H19N
DMUWKMN	IC	InChI=1S/C13H19N/c1-10-6-11(2)8-13(7-10)12-4-3-5-14-9-12/h6-8,12,14H,3-5,9H2,1-2H3
DMUWKMN	CS	CC1=CC(=CC(=C1)C2CCCNC2)C
DMUWKMN	IK	KCTMOZHTZAFYSJ-UHFFFAOYSA-N
DMUWKMN	IU	3-(3,5-dimethylphenyl)piperidine
DMUWKMN	DE	Discovery agent

DMT0M94	ID	DMT0M94
DMT0M94	DN	3-(3-Adamantan-1-yl-ureido)-benzoic acid
DMT0M94	HS	Investigative
DMT0M94	SN	CHEMBL478320; 3-(3-Adamantan-1-yl-ureido)-benzoic acid; SCHEMBL12932180; BDBM50267173; AKOS029868879; 3-(1-adamantylcarbamoylamino)benzoic acid
DMT0M94	DT	Small molecular drug
DMT0M94	PC	44582455
DMT0M94	MW	314.4
DMT0M94	FM	C18H22N2O3
DMT0M94	IC	InChI=1S/C18H22N2O3/c21-16(22)14-2-1-3-15(7-14)19-17(23)20-18-8-11-4-12(9-18)6-13(5-11)10-18/h1-3,7,11-13H,4-6,8-10H2,(H,21,22)(H2,19,20,23)
DMT0M94	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=CC(=C4)C(=O)O
DMT0M94	IK	IPTYXUOUPSNRTP-UHFFFAOYSA-N
DMT0M94	IU	3-(1-adamantylcarbamoylamino)benzoic acid
DMT0M94	DE	Discovery agent

DMLYVPH	ID	DMLYVPH
DMLYVPH	DN	3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol
DMLYVPH	HS	Investigative
DMLYVPH	SN	CHEMBL218003; 3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol; Phenol,3-(3-amino-1,2,4-benzotriazin-7-yl)-; SCHEMBL3737100; BDBM50193876
DMLYVPH	DT	Small molecular drug
DMLYVPH	PC	18455703
DMLYVPH	MW	238.24
DMLYVPH	FM	C13H10N4O
DMLYVPH	IC	InChI=1S/C13H10N4O/c14-13-15-11-5-4-9(7-12(11)16-17-13)8-2-1-3-10(18)6-8/h1-7,18H,(H2,14,15,17)
DMLYVPH	CS	C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)N=C(N=N3)N
DMLYVPH	IK	WCBDDBSMIBIXTG-UHFFFAOYSA-N
DMLYVPH	IU	3-(3-amino-1,2,4-benzotriazin-7-yl)phenol
DMLYVPH	DE	Discovery agent

DMB6SP8	ID	DMB6SP8
DMB6SP8	DN	3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile
DMB6SP8	HS	Investigative
DMB6SP8	SN	CHEMBL1276297; 3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile; SCHEMBL6087331
DMB6SP8	DT	Small molecular drug
DMB6SP8	PC	22139473
DMB6SP8	MW	225.29
DMB6SP8	FM	C14H15N3
DMB6SP8	IC	InChI=1S/C14H15N3/c15-7-9-1-4-14-12(5-9)13(8-17-14)10-2-3-11(16)6-10/h1,4-5,8,10-11,17H,2-3,6,16H2
DMB6SP8	CS	C1CC(CC1C2=CNC3=C2C=C(C=C3)C#N)N
DMB6SP8	IK	MBZJCLUPDBZVMZ-UHFFFAOYSA-N
DMB6SP8	IU	3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile
DMB6SP8	DE	Discovery agent

DMXKL75	ID	DMXKL75
DMXKL75	DN	3-(3-Benzoyl-1H-pyrrol-1-yl)propanoic acid
DMXKL75	HS	Investigative
DMXKL75	SN	CHEMBL602309; 3-(3-Benzoyl-1H-pyrrol-1-yl)propanoic acid
DMXKL75	DT	Small molecular drug
DMXKL75	PC	46229306
DMXKL75	MW	243.26
DMXKL75	FM	C14H13NO3
DMXKL75	IC	InChI=1S/C14H13NO3/c16-13(17)7-9-15-8-6-12(10-15)14(18)11-4-2-1-3-5-11/h1-6,8,10H,7,9H2,(H,16,17)
DMXKL75	CS	C1=CC=C(C=C1)C(=O)C2=CN(C=C2)CCC(=O)O
DMXKL75	IK	SZVSICYEXHCWBP-UHFFFAOYSA-N
DMXKL75	IU	3-(3-benzoylpyrrol-1-yl)propanoic acid
DMXKL75	DE	Discovery agent

DM1325C	ID	DM1325C
DM1325C	DN	3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine
DM1325C	HS	Investigative
DM1325C	SN	CHEMBL523196; 3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine
DM1325C	DT	Small molecular drug
DM1325C	PC	25129117
DM1325C	MW	325.4
DM1325C	FM	C23H19NO
DM1325C	IC	InChI=1S/C23H19NO/c1-25-22-10-9-18-15-23(19-8-5-11-24-16-19)21(13-20(18)14-22)12-17-6-3-2-4-7-17/h2-11,13-16H,12H2,1H3
DM1325C	CS	COC1=CC2=CC(=C(C=C2C=C1)C3=CN=CC=C3)CC4=CC=CC=C4
DM1325C	IK	OXCXOWFIXPOTGG-UHFFFAOYSA-N
DM1325C	IU	3-(3-benzyl-6-methoxynaphthalen-2-yl)pyridine
DM1325C	DE	Discovery agent

DMYN6Z9	ID	DMYN6Z9
DMYN6Z9	DN	3-(3-benzylamino)-piperidin-2-one
DMYN6Z9	HS	Investigative
DMYN6Z9	SN	CHEMBL223197
DMYN6Z9	DT	Small molecular drug
DMYN6Z9	PC	16203227
DMYN6Z9	MW	218.29
DMYN6Z9	FM	C13H18N2O
DMYN6Z9	IC	InChI=1S/C13H18N2O/c14-9-11-4-1-3-10(7-11)8-12-5-2-6-15-13(12)16/h1,3-4,7,12H,2,5-6,8-9,14H2,(H,15,16)
DMYN6Z9	CS	C1CC(C(=O)NC1)CC2=CC(=CC=C2)CN
DMYN6Z9	IK	WOUBCSVRQLAOBC-UHFFFAOYSA-N
DMYN6Z9	IU	3-[[3-(aminomethyl)phenyl]methyl]piperidin-2-one
DMYN6Z9	DE	Discovery agent

DM9S36A	ID	DM9S36A
DM9S36A	DN	3-(3-Benzylnaphthalen-2-yl)pyridine
DM9S36A	HS	Investigative
DM9S36A	SN	CHEMBL493485; 3-(3-Benzylnaphthalen-2-yl)pyridine
DM9S36A	DT	Small molecular drug
DM9S36A	PC	25130517
DM9S36A	MW	295.4
DM9S36A	FM	C22H17N
DM9S36A	IC	InChI=1S/C22H17N/c1-2-7-17(8-3-1)13-21-14-18-9-4-5-10-19(18)15-22(21)20-11-6-12-23-16-20/h1-12,14-16H,13H2
DM9S36A	CS	C1=CC=C(C=C1)CC2=CC3=CC=CC=C3C=C2C4=CN=CC=C4
DM9S36A	IK	RPMMFOVAHREENB-UHFFFAOYSA-N
DM9S36A	IU	3-(3-benzylnaphthalen-2-yl)pyridine
DM9S36A	DE	Discovery agent

DMFPTXO	ID	DMFPTXO
DMFPTXO	DN	3-(3-bromophenylethynyl)-5-methyl[1,2,4]triazine
DMFPTXO	HS	Investigative
DMFPTXO	SN	CHEMBL390803; 3-(3-bromophenylethynyl)-5-methyl[1,2,4]triazine; SCHEMBL4289011; 1,2,4-Triazine, 3-[2-(3-bromophenyl)ethynyl]-5-methyl-; BDBM50215451
DMFPTXO	DT	Small molecular drug
DMFPTXO	PC	16735841
DMFPTXO	MW	274.12
DMFPTXO	FM	C12H8BrN3
DMFPTXO	IC	InChI=1S/C12H8BrN3/c1-9-8-14-16-12(15-9)6-5-10-3-2-4-11(13)7-10/h2-4,7-8H,1H3
DMFPTXO	CS	CC1=CN=NC(=N1)C#CC2=CC(=CC=C2)Br
DMFPTXO	IK	ZFPUZPDBHDTJCE-UHFFFAOYSA-N
DMFPTXO	IU	3-[2-(3-bromophenyl)ethynyl]-5-methyl-1,2,4-triazine
DMFPTXO	DE	Discovery agent

DMSJGQE	ID	DMSJGQE
DMSJGQE	DN	3-(3-Carboxy-propionylamino)-benzoic acid
DMSJGQE	HS	Investigative
DMSJGQE	SN	CHEMBL296834; 3-(3-carboxypropanamido)benzoic acid; 3-[(3-carboxypropanoyl)amino]benzoic acid; 259222-20-3; IFLab1_001254; 3-(3-carboxypropanoylamino)benzoic acid; 3-(3-Carboxy-propionylamino)-benzoic acid; AC1LFPO3; Oprea1_683242; Oprea1_208346; CTK0J3689; DTXSID30353899; MolPort-000-385-127; HMS1415I22; ZINC216961; STK032065; BDBM50127981; AKOS000112854; MCULE-6483245282; IDI1_009121; ST50036495; 3-(4-Oxo-4-hydroxybutyrylamino)benzoic acid; 3-[(4-hydroxy-4-oxobutanoyl)amino]benzoic acid; SR-01000005669; Benzoic acid, 3-[(3-carbo
DMSJGQE	DT	Small molecular drug
DMSJGQE	PC	757562
DMSJGQE	MW	237.21
DMSJGQE	FM	C11H11NO5
DMSJGQE	IC	InChI=1S/C11H11NO5/c13-9(4-5-10(14)15)12-8-3-1-2-7(6-8)11(16)17/h1-3,6H,4-5H2,(H,12,13)(H,14,15)(H,16,17)
DMSJGQE	CS	C1=CC(=CC(=C1)NC(=O)CCC(=O)O)C(=O)O
DMSJGQE	IK	IKRKGFIXYILHIJ-UHFFFAOYSA-N
DMSJGQE	IU	3-(3-carboxypropanoylamino)benzoic acid
DMSJGQE	CA	CAS 259222-20-3
DMSJGQE	DE	Discovery agent

DMI2RH1	ID	DMI2RH1
DMI2RH1	DN	3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one
DMI2RH1	HS	Investigative
DMI2RH1	DT	Small molecular drug
DMI2RH1	PC	135407706
DMI2RH1	MW	246.65
DMI2RH1	FM	C11H7ClN4O
DMI2RH1	IC	InChI=1S/C11H7ClN4O/c12-9-5-8(15-16-9)10-11(17)14-7-4-2-1-3-6(7)13-10/h1-5H,(H,14,17)(H,15,16)
DMI2RH1	CS	C1=CC=C2C(=C1)NC(=O)C(=N2)C3=NNC(=C3)Cl
DMI2RH1	IK	HKRYFPDYIBYUGZ-UHFFFAOYSA-N
DMI2RH1	IU	3-(5-chloro-1H-pyrazol-3-yl)-1H-quinoxalin-2-one
DMI2RH1	DE	Discovery agent

DMD4O6V	ID	DMD4O6V
DMD4O6V	DN	3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one
DMD4O6V	HS	Investigative
DMD4O6V	SN	CHEMBL7827; SCHEMBL3355884; 62845-10-7; 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-
DMD4O6V	DT	Small molecular drug
DMD4O6V	PC	10850934
DMD4O6V	MW	288.68
DMD4O6V	FM	C15H9ClO4
DMD4O6V	IC	InChI=1S/C15H9ClO4/c16-9-3-1-2-8(4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,17-18H
DMD4O6V	CS	C1=CC(=CC(=C1)Cl)C2=COC3=CC(=CC(=C3C2=O)O)O
DMD4O6V	IK	NKDPIBPNSMKOPN-UHFFFAOYSA-N
DMD4O6V	IU	3-(3-chlorophenyl)-5,7-dihydroxychromen-4-one
DMD4O6V	CA	CAS 62845-10-7
DMD4O6V	DE	Discovery agent

DMGJS9N	ID	DMGJS9N
DMGJS9N	DN	3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea
DMGJS9N	HS	Investigative
DMGJS9N	SN	CHEMBL205328; 3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea
DMGJS9N	DT	Small molecular drug
DMGJS9N	PC	44410465
DMGJS9N	MW	290.32
DMGJS9N	FM	C17H14N4O
DMGJS9N	IC	InChI=1S/C17H14N4O/c1-21(14-5-3-2-4-6-14)17(22)20-13-7-8-15-12(10-18)11-19-16(15)9-13/h2-9,11,19H,1H3,(H,20,22)
DMGJS9N	CS	CN(C1=CC=CC=C1)C(=O)NC2=CC3=C(C=C2)C(=CN3)C#N
DMGJS9N	IK	QBNNBKXETLRTHU-UHFFFAOYSA-N
DMGJS9N	IU	3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea
DMGJS9N	DE	Discovery agent

DM0O2ZB	ID	DM0O2ZB
DM0O2ZB	DN	3-(3-Dimethylamino-propyl)-1H-indol-4-ol
DM0O2ZB	HS	Investigative
DM0O2ZB	SN	CHEMBL198617; 3-(3-Dimethylamino-propyl)-1H-indol-4-ol
DM0O2ZB	DT	Small molecular drug
DM0O2ZB	PC	44404905
DM0O2ZB	MW	218.29
DM0O2ZB	FM	C13H18N2O
DM0O2ZB	IC	InChI=1S/C13H18N2O/c1-15(2)8-4-5-10-9-14-11-6-3-7-12(16)13(10)11/h3,6-7,9,14,16H,4-5,8H2,1-2H3
DM0O2ZB	CS	CN(C)CCCC1=CNC2=C1C(=CC=C2)O
DM0O2ZB	IK	IBSZSSDQXMYZOZ-UHFFFAOYSA-N
DM0O2ZB	IU	3-[3-(dimethylamino)propyl]-1H-indol-4-ol
DM0O2ZB	DE	Discovery agent

DM0ZHJQ	ID	DM0ZHJQ
DM0ZHJQ	DN	3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline
DM0ZHJQ	HS	Investigative
DM0ZHJQ	SN	CHEMBL302491; 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline; SCHEMBL8502238; ZINC3834024; BDBM50039084
DM0ZHJQ	DT	Small molecular drug
DM0ZHJQ	PC	9971060
DM0ZHJQ	MW	283.3
DM0ZHJQ	FM	C17H14FNO2
DM0ZHJQ	IC	InChI=1S/C17H14FNO2/c1-20-16-8-12-6-13(11-4-3-5-14(18)7-11)10-19-15(12)9-17(16)21-2/h3-10H,1-2H3
DM0ZHJQ	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC(=CC=C3)F
DM0ZHJQ	IK	UECRIUGPTSAZMC-UHFFFAOYSA-N
DM0ZHJQ	IU	3-(3-fluorophenyl)-6,7-dimethoxyquinoline
DM0ZHJQ	DE	Discovery agent

DM7FQVC	ID	DM7FQVC
DM7FQVC	DN	3-(3'-furyl)-aniline
DM7FQVC	HS	Investigative
DM7FQVC	SN	936249-46-6; 3-(3-furanyl)-Benzenamine; 3-(furan-3-yl)aniline; Benzenamine, 3-(3-furanyl)-; SCHEMBL1019148; CHEMBL222787; LQDARHFLRKPAMM-UHFFFAOYSA-N
DM7FQVC	DT	Small molecular drug
DM7FQVC	PC	16203332
DM7FQVC	MW	159.18
DM7FQVC	FM	C10H9NO
DM7FQVC	IC	InChI=1S/C10H9NO/c11-10-3-1-2-8(6-10)9-4-5-12-7-9/h1-7H,11H2
DM7FQVC	CS	C1=CC(=CC(=C1)N)C2=COC=C2
DM7FQVC	IK	LQDARHFLRKPAMM-UHFFFAOYSA-N
DM7FQVC	IU	3-(furan-3-yl)aniline
DM7FQVC	CA	CAS 936249-46-6
DM7FQVC	DE	Discovery agent

DMP0DQE	ID	DMP0DQE
DMP0DQE	DN	3-(3-hydroxyphenyl)quinolin-7-ol
DMP0DQE	HS	Investigative
DMP0DQE	DT	Small molecular drug
DMP0DQE	PC	135783365
DMP0DQE	MW	237.25
DMP0DQE	FM	C15H11NO2
DMP0DQE	IC	InChI=1S/C15H11NO2/c17-13-3-1-2-10(7-13)12-6-11-4-5-14(18)8-15(11)16-9-12/h1-9,17-18H
DMP0DQE	CS	C1=CC(=CC(=C1)O)C2=CN=C3C=C(C=CC3=C2)O
DMP0DQE	IK	DQXYHOHBSRRAIV-UHFFFAOYSA-N
DMP0DQE	IU	3-(3-hydroxyphenyl)quinolin-7-ol
DMP0DQE	DE	Discovery agent

DMRDS1U	ID	DMRDS1U
DMRDS1U	DN	3-(3-Methanesulfonyl-phenyl)-1-propyl-pyrrolidine
DMRDS1U	HS	Investigative
DMRDS1U	SN	CHEMBL310745; 3-(3-Methanesulfonyl-phenyl)-1-propyl-pyrrolidine
DMRDS1U	DT	Small molecular drug
DMRDS1U	PC	44461148
DMRDS1U	MW	267.39
DMRDS1U	FM	C14H21NO2S
DMRDS1U	IC	InChI=1S/C14H21NO2S/c1-3-8-15-9-7-13(11-15)12-5-4-6-14(10-12)18(2,16)17/h4-6,10,13H,3,7-9,11H2,1-2H3
DMRDS1U	CS	CCCN1CCC(C1)C2=CC(=CC=C2)S(=O)(=O)C
DMRDS1U	IK	RJYDYJIGFDPBRL-UHFFFAOYSA-N
DMRDS1U	IU	3-(3-methylsulfonylphenyl)-1-propylpyrrolidine
DMRDS1U	DE	Discovery agent

DMU53NZ	ID	DMU53NZ
DMU53NZ	DN	3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
DMU53NZ	HS	Investigative
DMU53NZ	SN	CHEMBL1231606; 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine; 3c4f; SCHEMBL857805; BDBM50065455; DB07525; 3-(3-Methoxybenzyl)-7-aza-1H-indole; 3-[(3-methoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridine
DMU53NZ	DT	Small molecular drug
DMU53NZ	PC	24180722
DMU53NZ	MW	238.28
DMU53NZ	FM	C15H14N2O
DMU53NZ	IC	InChI=1S/C15H14N2O/c1-18-13-5-2-4-11(9-13)8-12-10-17-15-14(12)6-3-7-16-15/h2-7,9-10H,8H2,1H3,(H,16,17)
DMU53NZ	CS	COC1=CC=CC(=C1)CC2=CNC3=C2C=CC=N3
DMU53NZ	IK	GHQCCHWTDLTMJT-UHFFFAOYSA-N
DMU53NZ	IU	3-[(3-methoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridine
DMU53NZ	DE	Discovery agent

DMZQ2CJ	ID	DMZQ2CJ
DMZQ2CJ	DN	3-(3-methoxyphenyl)-6-methyl-2H-chromen-2-one
DMZQ2CJ	HS	Investigative
DMZQ2CJ	SN	CHEMBL570731; 3-(3-methoxyphenyl)-6-methyl-2H-chromen-2-one; 2H-1-Benzopyran-2-one,3-(3-methoxyphenyl)-6-methyl-; SCHEMBL17857194; BDBM50300895
DMZQ2CJ	DT	Small molecular drug
DMZQ2CJ	PC	44622873
DMZQ2CJ	MW	266.29
DMZQ2CJ	FM	C17H14O3
DMZQ2CJ	IC	InChI=1S/C17H14O3/c1-11-6-7-16-13(8-11)10-15(17(18)20-16)12-4-3-5-14(9-12)19-2/h3-10H,1-2H3
DMZQ2CJ	CS	CC1=CC2=C(C=C1)OC(=O)C(=C2)C3=CC(=CC=C3)OC
DMZQ2CJ	IK	FXKIDMXANLWDBM-UHFFFAOYSA-N
DMZQ2CJ	IU	3-(3-methoxyphenyl)-6-methylchromen-2-one
DMZQ2CJ	DE	Discovery agent

DM2YLBD	ID	DM2YLBD
DM2YLBD	DN	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DM2YLBD	HS	Investigative
DM2YLBD	SN	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 8; AC1O70HF; SCHEMBL4505804; BDBM8894
DM2YLBD	DT	Small molecular drug
DM2YLBD	PC	6540052
DM2YLBD	MW	221.3
DM2YLBD	FM	C16H15N
DM2YLBD	IC	InChI=1S/C16H15N/c1-12-9-13-5-2-3-6-14(13)10-16(12)15-7-4-8-17-11-15/h2-8,10-12H,9H2,1H3
DM2YLBD	CS	CC1CC2=CC=CC=C2C=C1C3=CN=CC=C3
DM2YLBD	IK	ARDWAGDGUKXSPH-UHFFFAOYSA-N
DM2YLBD	IU	3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DM2YLBD	DE	Discovery agent

DMTNCXP	ID	DMTNCXP
DMTNCXP	DN	3-(3-Methyl-butoxy)-9H-beta-carboline
DMTNCXP	HS	Investigative
DMTNCXP	SN	CHEMBL87641; 3-(isopentyloxy)-9H-pyrido[3,4-b]indole; SCHEMBL10644963; BDBM50001483
DMTNCXP	DT	Small molecular drug
DMTNCXP	PC	11779007
DMTNCXP	MW	254.33
DMTNCXP	FM	C16H18N2O
DMTNCXP	IC	InChI=1S/C16H18N2O/c1-11(2)7-8-19-16-9-13-12-5-3-4-6-14(12)18-15(13)10-17-16/h3-6,9-11,18H,7-8H2,1-2H3
DMTNCXP	CS	CC(C)CCOC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMTNCXP	IK	LGSILYYIMNHYCP-UHFFFAOYSA-N
DMTNCXP	IU	3-(3-methylbutoxy)-9H-pyrido[3,4-b]indole
DMTNCXP	DE	Discovery agent

DMXAD0R	ID	DMXAD0R
DMXAD0R	DN	3-(3-methylphenylethynyl)-5-methyl[1,2,4]triazine
DMXAD0R	HS	Investigative
DMXAD0R	SN	CHEMBL227200; 3-(3-methylphenylethynyl)-5-methyl[1,2,4]triazine; SCHEMBL4298939; ZINC28701667; BDBM50215452
DMXAD0R	DT	Small molecular drug
DMXAD0R	PC	16735840
DMXAD0R	MW	209.25
DMXAD0R	FM	C13H11N3
DMXAD0R	IC	InChI=1S/C13H11N3/c1-10-4-3-5-12(8-10)6-7-13-15-11(2)9-14-16-13/h3-5,8-9H,1-2H3
DMXAD0R	CS	CC1=CC(=CC=C1)C#CC2=NC(=CN=N2)C
DMXAD0R	IK	SGAMWPHZFACGBU-UHFFFAOYSA-N
DMXAD0R	IU	5-methyl-3-[2-(3-methylphenyl)ethynyl]-1,2,4-triazine
DMXAD0R	DE	Discovery agent

DMHU9V5	ID	DMHU9V5
DMHU9V5	DN	3-(3-methylthiophen-2-yl)pyridine
DMHU9V5	HS	Investigative
DMHU9V5	SN	3-(3-methylthiophen-2-yl)pyridine; CHEMBL179669; Pyridine, 3-(3-methyl-2-thienyl)-; 837376-35-9; SCHEMBL3606167; BDBM12351; CTK3D1375; DTXSID20635313; nicotine 3-heteroaromatic analogue 4; US8609708, 4
DMHU9V5	DT	Small molecular drug
DMHU9V5	PC	23646069
DMHU9V5	MW	175.25
DMHU9V5	FM	C10H9NS
DMHU9V5	IC	InChI=1S/C10H9NS/c1-8-4-6-12-10(8)9-3-2-5-11-7-9/h2-7H,1H3
DMHU9V5	CS	CC1=C(SC=C1)C2=CN=CC=C2
DMHU9V5	IK	JIOQSJVEVFADJG-UHFFFAOYSA-N
DMHU9V5	IU	3-(3-methylthiophen-2-yl)pyridine
DMHU9V5	CA	CAS 837376-35-9
DMHU9V5	DE	Discovery agent

DM314ZE	ID	DM314ZE
DM314ZE	DN	3-(3-Phenyl-ureido)-benzenesulfonamide
DM314ZE	HS	Investigative
DM314ZE	SN	CHEMBL370526; 3-(3-Phenyl-ureido)-benzenesulfonamide; AC1MDJRG; MLS000850240; SCHEMBL1395590; MolPort-002-901-146; HMS2801K06; ZINC4325112; 3-(3-Phenylureido)benzenesulfonamide; BDBM50174039; 1-phenyl-3-(3-sulfamoylphenyl)urea; AKOS008966131; MCULE-8491785004; SMR000456258
DM314ZE	DT	Small molecular drug
DM314ZE	PC	2812287
DM314ZE	MW	291.33
DM314ZE	FM	C13H13N3O3S
DM314ZE	IC	InChI=1S/C13H13N3O3S/c14-20(18,19)12-8-4-7-11(9-12)16-13(17)15-10-5-2-1-3-6-10/h1-9H,(H2,14,18,19)(H2,15,16,17)
DM314ZE	CS	C1=CC=C(C=C1)NC(=O)NC2=CC(=CC=C2)S(=O)(=O)N
DM314ZE	IK	BXGWKSJDQKSXDR-UHFFFAOYSA-N
DM314ZE	IU	1-phenyl-3-(3-sulfamoylphenyl)urea
DM314ZE	DE	Discovery agent

DMU52WA	ID	DMU52WA
DMU52WA	DN	3-(3-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile
DMU52WA	HS	Investigative
DMU52WA	SN	CHEMBL182558; 3-(3-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile; SCHEMBL3922587; FUXJRPCONXOULZ-UHFFFAOYSA-N; BDBM50151895; ZINC13582319
DMU52WA	DT	Small molecular drug
DMU52WA	PC	10192768
DMU52WA	MW	246.27
DMU52WA	FM	C15H10N4
DMU52WA	IC	InChI=1S/C15H10N4/c16-11-12-4-3-5-13(10-12)19-9-7-15(18-19)14-6-1-2-8-17-14/h1-10H
DMU52WA	CS	C1=CC=NC(=C1)C2=NN(C=C2)C3=CC=CC(=C3)C#N
DMU52WA	IK	FUXJRPCONXOULZ-UHFFFAOYSA-N
DMU52WA	IU	3-(3-pyridin-2-ylpyrazol-1-yl)benzonitrile
DMU52WA	DE	Discovery agent

DMZLT24	ID	DMZLT24
DMZLT24	DN	3-(3-Pyridin-2-yl-pyrrol-1-yl)-benzonitrile
DMZLT24	HS	Investigative
DMZLT24	SN	CHEMBL361325; 3-(3-Pyridin-2-yl-pyrrol-1-yl)-benzonitrile; SCHEMBL5100840; VWIHRRSEESXDSS-UHFFFAOYSA-N; ZINC13582313; BDBM50151897
DMZLT24	DT	Small molecular drug
DMZLT24	PC	10332109
DMZLT24	MW	245.28
DMZLT24	FM	C16H11N3
DMZLT24	IC	InChI=1S/C16H11N3/c17-11-13-4-3-5-15(10-13)19-9-7-14(12-19)16-6-1-2-8-18-16/h1-10,12H
DMZLT24	CS	C1=CC=NC(=C1)C2=CN(C=C2)C3=CC=CC(=C3)C#N
DMZLT24	IK	VWIHRRSEESXDSS-UHFFFAOYSA-N
DMZLT24	IU	3-(3-pyridin-2-ylpyrrol-1-yl)benzonitrile
DMZLT24	DE	Discovery agent

DMQDPHT	ID	DMQDPHT
DMQDPHT	DN	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid
DMQDPHT	HS	Investigative
DMQDPHT	SN	CHEMBL202875; 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid
DMQDPHT	DT	Small molecular drug
DMQDPHT	PC	11609208
DMQDPHT	MW	306.4
DMQDPHT	FM	C20H18O3
DMQDPHT	IC	InChI=1S/C20H18O3/c1-2-17(14-19(21)22)20(23)18-12-10-16(11-13-18)9-8-15-6-4-3-5-7-15/h3-7,10-13,17H,2,14H2,1H3,(H,21,22)
DMQDPHT	CS	CCC(CC(=O)O)C(=O)C1=CC=C(C=C1)C#CC2=CC=CC=C2
DMQDPHT	IK	OQWWYXZJKRAMIK-UHFFFAOYSA-N
DMQDPHT	IU	3-[4-(2-phenylethynyl)benzoyl]pentanoic acid
DMQDPHT	DE	Discovery agent

DM1GVE8	ID	DM1GVE8
DM1GVE8	DN	3-(4-(4-hydroxyphenyl)phthalazin-1-ylamino)phenol
DM1GVE8	HS	Investigative
DM1GVE8	DT	Small molecular drug
DM1GVE8	PC	5521244
DM1GVE8	DE	Discovery agent

DM8EH07	ID	DM8EH07
DM8EH07	DN	3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol
DM8EH07	HS	Investigative
DM8EH07	SN	CHEMBL552961; 3-{[4-(4-hydroxyphenyl)-1,3-thiazol-2-yl]amino}phenol; 3-[[4-(4-hydroxyphenyl)-1,3-thiazol-2-yl]amino]phenol; AC1MOQ7Z; 3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol; BDBM50293580; STK163120; AKOS005408679; MCULE-5910300038; NCGC00285022-01
DM8EH07	DT	Small molecular drug
DM8EH07	PC	3324368
DM8EH07	MW	284.3
DM8EH07	FM	C15H12N2O2S
DM8EH07	IC	InChI=1S/C15H12N2O2S/c18-12-6-4-10(5-7-12)14-9-20-15(17-14)16-11-2-1-3-13(19)8-11/h1-9,18-19H,(H,16,17)
DM8EH07	CS	C1=CC(=CC(=C1)O)NC2=NC(=CS2)C3=CC=C(C=C3)O
DM8EH07	IK	SAFZMMTWTRFRQE-UHFFFAOYSA-N
DM8EH07	IU	3-[[4-(4-hydroxyphenyl)-1,3-thiazol-2-yl]amino]phenol
DM8EH07	DE	Discovery agent

DM36VA0	ID	DM36VA0
DM36VA0	DN	3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid
DM36VA0	HS	Investigative
DM36VA0	SN	benzyl derivative, 8; CHEMBL402713; BDBM18888; 3-[4-(benzyloxy)-3,5-dibromophenyl]propanoic acid
DM36VA0	DT	Small molecular drug
DM36VA0	PC	23648092
DM36VA0	MW	414.09
DM36VA0	FM	C16H14Br2O3
DM36VA0	IC	InChI=1S/C16H14Br2O3/c17-13-8-12(6-7-15(19)20)9-14(18)16(13)21-10-11-4-2-1-3-5-11/h1-5,8-9H,6-7,10H2,(H,19,20)
DM36VA0	CS	C1=CC=C(C=C1)COC2=C(C=C(C=C2Br)CCC(=O)O)Br
DM36VA0	IK	ZCVQDNGOBFARHQ-UHFFFAOYSA-N
DM36VA0	IU	3-(3,5-dibromo-4-phenylmethoxyphenyl)propanoic acid
DM36VA0	DE	Discovery agent

DMX6ZHQ	ID	DMX6ZHQ
DMX6ZHQ	DN	3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide
DMX6ZHQ	HS	Investigative
DMX6ZHQ	SN	2,4-dianilino pyrimidine, 8; CHEMBL400798; BDBM26151
DMX6ZHQ	DT	Small molecular drug
DMX6ZHQ	PC	25138018
DMX6ZHQ	MW	319.4
DMX6ZHQ	FM	C18H17N5O
DMX6ZHQ	IC	InChI=1S/C18H17N5O/c1-12-5-2-3-8-15(12)22-16-9-10-20-18(23-16)21-14-7-4-6-13(11-14)17(19)24/h2-11H,1H3,(H2,19,24)(H2,20,21,22,23)
DMX6ZHQ	CS	CC1=CC=CC=C1NC2=NC(=NC=C2)NC3=CC=CC(=C3)C(=O)N
DMX6ZHQ	IK	ZUJLZMHZCZZHLN-UHFFFAOYSA-N
DMX6ZHQ	IU	3-[[4-(2-methylanilino)pyrimidin-2-yl]amino]benzamide
DMX6ZHQ	DE	Discovery agent

DMGXPJV	ID	DMGXPJV
DMGXPJV	DN	3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol
DMGXPJV	HS	Investigative
DMGXPJV	SN	3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol; 296792-52-4; CHEMBL443007; 3-[4,5-bis(4-phenylphenyl)-1H-imidazol-2-yl]phenol; AC1M4HYZ; AC1Q790A; CTK8A0066; MolPort-001-732-645; ZINC6028400; BDBM50113297; STK758717; AKOS001063669; NE26785; MCULE-4347250395; UPCMLD0ENAT5224754:001; ST4040901; KB-335272; EN300-07381; 3-[4,5-bis(4-phenylphenyl)imidazol-2-yl]phenol; SR-01000521283; J-510645; SR-01000521283-1; Z56935326; 3-[4,5-di(biphenyl-4-yl)-1H-imidazol-2-yl]phenol; 3-(4,5-bis-biphenyl-4-yl-1h-imidazol-2-yl)phenol
DMGXPJV	DT	Small molecular drug
DMGXPJV	PC	2259222
DMGXPJV	MW	464.6
DMGXPJV	FM	C33H24N2O
DMGXPJV	IC	InChI=1S/C33H24N2O/c36-30-13-7-12-29(22-30)33-34-31(27-18-14-25(15-19-27)23-8-3-1-4-9-23)32(35-33)28-20-16-26(17-21-28)24-10-5-2-6-11-24/h1-22,36H,(H,34,35)
DMGXPJV	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C3=C(N=C(N3)C4=CC(=CC=C4)O)C5=CC=C(C=C5)C6=CC=CC=C6
DMGXPJV	IK	JTVSGRFYVCXWNC-UHFFFAOYSA-N
DMGXPJV	IU	3-[4,5-bis(4-phenylphenyl)-1H-imidazol-2-yl]phenol
DMGXPJV	DE	Discovery agent

DMONSM1	ID	DMONSM1
DMONSM1	DN	3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate
DMONSM1	HS	Investigative
DMONSM1	SN	CHEMBL576381; 3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate; SCHEMBL4751773
DMONSM1	DT	Small molecular drug
DMONSM1	PC	44243876
DMONSM1	MW	248.28
DMONSM1	FM	C13H16N2O3
DMONSM1	IC	InChI=1S/C13H16N2O3/c1-2-6-15-13(16)18-11-5-3-4-10(9-11)12-14-7-8-17-12/h3-5,9H,2,6-8H2,1H3,(H,15,16)
DMONSM1	CS	CCCNC(=O)OC1=CC=CC(=C1)C2=NCCO2
DMONSM1	IK	JLCYRBIRENXOKD-UHFFFAOYSA-N
DMONSM1	IU	[3-(4,5-dihydro-1,3-oxazol-2-yl)phenyl] N-propylcarbamate
DMONSM1	DE	Discovery agent

DMS1LDH	ID	DMS1LDH
DMS1LDH	DN	3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione
DMS1LDH	HS	Investigative
DMS1LDH	SN	CHEMBL357775; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-1-methyl-; 59512-13-9; 3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione; CTK1E7233; DTXSID50490593; BDBM50025151; AKOS022647888
DMS1LDH	DT	Small molecular drug
DMS1LDH	PC	12331302
DMS1LDH	MW	204.22
DMS1LDH	FM	C11H12N2O2
DMS1LDH	IC	InChI=1S/C11H12N2O2/c1-13-10(14)6-9(11(13)15)7-2-4-8(12)5-3-7/h2-5,9H,6,12H2,1H3
DMS1LDH	CS	CN1C(=O)CC(C1=O)C2=CC=C(C=C2)N
DMS1LDH	IK	QMQMEAAIWVAXHW-UHFFFAOYSA-N
DMS1LDH	IU	3-(4-aminophenyl)-1-methylpyrrolidine-2,5-dione
DMS1LDH	CA	CAS 59512-13-9
DMS1LDH	DE	Discovery agent

DMD5YKO	ID	DMD5YKO
DMD5YKO	DN	3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione
DMD5YKO	HS	Investigative
DMD5YKO	SN	CHEMBL29863; 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione
DMD5YKO	DT	Small molecular drug
DMD5YKO	PC	13660218
DMD5YKO	MW	260.329
DMD5YKO	FM	C15H20N2O2
DMD5YKO	IC	InChI=1S/C15H20N2O2/c1-2-3-9-15(10-8-13(18)17-14(15)19)11-4-6-12(16)7-5-11/h4-7H,2-3,8-10,16H2,1H3,(H,17,18,19)
DMD5YKO	CS	CCCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMD5YKO	IK	HECRHMWBGLSDHM-UHFFFAOYSA-N
DMD5YKO	IU	3-(4-aminophenyl)-3-butylpiperidine-2,6-dione
DMD5YKO	DE	Discovery agent

DM3I15D	ID	DM3I15D
DM3I15D	DN	3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione
DM3I15D	HS	Investigative
DM3I15D	SN	CHEMBL151212; 91567-07-6; 3-(4-aminophenyl)-3-ethylpyrrolidine-2,5-dione; 3-Apepd; AC1Q6LV5; AC1L3YU4; 3-(4-aminophenyl)-3-ethyl-2,5-Pyrrolidinedione; 3-(4'-Aminophenyl)-3-ethylpyrollidine-2,5-dione; 3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione; SCHEMBL9634038; BDBM50025152; DA-01219; FT-0716174; 3-Ethyl-3-(4-aminophenyl)pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-3-ethyl-
DM3I15D	DT	Small molecular drug
DM3I15D	PC	124662
DM3I15D	MW	218.25
DM3I15D	FM	C12H14N2O2
DM3I15D	IC	InChI=1S/C12H14N2O2/c1-2-12(7-10(15)14-11(12)16)8-3-5-9(13)6-4-8/h3-6H,2,7,13H2,1H3,(H,14,15,16)
DM3I15D	CS	CCC1(CC(=O)NC1=O)C2=CC=C(C=C2)N
DM3I15D	IK	QPJZAHJMZUCFMF-UHFFFAOYSA-N
DM3I15D	IU	3-(4-aminophenyl)-3-ethylpyrrolidine-2,5-dione
DM3I15D	CA	CAS 91567-07-6
DM3I15D	DE	Discovery agent

DMZ86CS	ID	DMZ86CS
DMZ86CS	DN	3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione
DMZ86CS	HS	Investigative
DMZ86CS	SN	CHEMBL29338; 3-(4-aminophenyl)-3-heptylpiperidine-2,6-dione; NSC622730; AC1L7GXY; 3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione; AC1Q6G81; CTK6D7912; 2,3-(4-aminophenyl)-3-heptyl-; BDBM50025057; NSC-622730; NCI60_006748; 2,6-piperidinedione, 3-(4-aminophenyl)-3-heptyl-
DMZ86CS	DT	Small molecular drug
DMZ86CS	PC	360578
DMZ86CS	MW	302.4
DMZ86CS	FM	C18H26N2O2
DMZ86CS	IC	InChI=1S/C18H26N2O2/c1-2-3-4-5-6-12-18(13-11-16(21)20-17(18)22)14-7-9-15(19)10-8-14/h7-10H,2-6,11-13,19H2,1H3,(H,20,21,22)
DMZ86CS	CS	CCCCCCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMZ86CS	IK	OSRMOQHQZPPFAZ-UHFFFAOYSA-N
DMZ86CS	IU	3-(4-aminophenyl)-3-heptylpiperidine-2,6-dione
DMZ86CS	DE	Discovery agent

DMW62U8	ID	DMW62U8
DMW62U8	DN	3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione
DMW62U8	HS	Investigative
DMW62U8	SN	CHEMBL29339; 3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione
DMW62U8	DT	Small molecular drug
DMW62U8	PC	13660225
DMW62U8	MW	288.4
DMW62U8	FM	C17H24N2O2
DMW62U8	IC	InChI=1S/C17H24N2O2/c1-2-3-4-5-11-17(12-10-15(20)19-16(17)21)13-6-8-14(18)9-7-13/h6-9H,2-5,10-12,18H2,1H3,(H,19,20,21)
DMW62U8	CS	CCCCCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMW62U8	IK	VWJXCBZWAWHJLE-UHFFFAOYSA-N
DMW62U8	IU	3-(4-aminophenyl)-3-hexylpiperidine-2,6-dione
DMW62U8	DE	Discovery agent

DMITHX5	ID	DMITHX5
DMITHX5	DN	3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione
DMITHX5	HS	Investigative
DMITHX5	SN	CHEMBL149238; 3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-3-methyl-; SCHEMBL19074638; BDBM50025155
DMITHX5	DT	Small molecular drug
DMITHX5	PC	13596072
DMITHX5	MW	204.22
DMITHX5	FM	C11H12N2O2
DMITHX5	IC	InChI=1S/C11H12N2O2/c1-11(6-9(14)13-10(11)15)7-2-4-8(12)5-3-7/h2-5H,6,12H2,1H3,(H,13,14,15)
DMITHX5	CS	CC1(CC(=O)NC1=O)C2=CC=C(C=C2)N
DMITHX5	IK	MAUIJSRGENXQBY-UHFFFAOYSA-N
DMITHX5	IU	3-(4-aminophenyl)-3-methylpyrrolidine-2,5-dione
DMITHX5	DE	Discovery agent

DM20DXS	ID	DM20DXS
DM20DXS	DN	3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione
DM20DXS	HS	Investigative
DM20DXS	SN	CHEMBL25735; 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione
DM20DXS	DT	Small molecular drug
DM20DXS	PC	13660221
DM20DXS	MW	274.36
DM20DXS	FM	C16H22N2O2
DM20DXS	IC	InChI=1S/C16H22N2O2/c1-2-3-4-10-16(11-9-14(19)18-15(16)20)12-5-7-13(17)8-6-12/h5-8H,2-4,9-11,17H2,1H3,(H,18,19,20)
DM20DXS	CS	CCCCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DM20DXS	IK	VFLOMQQDKBQIOE-UHFFFAOYSA-N
DM20DXS	IU	3-(4-aminophenyl)-3-pentylpiperidine-2,6-dione
DM20DXS	DE	Discovery agent

DM39XMT	ID	DM39XMT
DM39XMT	DN	3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione
DM39XMT	HS	Investigative
DM39XMT	SN	CHEMBL29864; 3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione; BDBM50025059
DM39XMT	DT	Small molecular drug
DM39XMT	PC	13660216
DM39XMT	MW	246.3
DM39XMT	FM	C14H18N2O2
DM39XMT	IC	InChI=1S/C14H18N2O2/c1-2-8-14(9-7-12(17)16-13(14)18)10-3-5-11(15)6-4-10/h3-6H,2,7-9,15H2,1H3,(H,16,17,18)
DM39XMT	CS	CCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DM39XMT	IK	CKRTXCPPNWSZFC-UHFFFAOYSA-N
DM39XMT	IU	3-(4-aminophenyl)-3-propylpiperidine-2,6-dione
DM39XMT	DE	Discovery agent

DMVN0O5	ID	DMVN0O5
DMVN0O5	DN	3-(4-Amino-phenyl)-pyrrolidine-2,5-dione
DMVN0O5	HS	Investigative
DMVN0O5	SN	32856-49-8; 3-(4-Amino-phenyl)-pyrrolidine-2,5-dione; 3-(4-aminophenyl)pyrrolidine-2,5-dione; 3-(4-Aminophenyl)-2,5-pyrrolidinedione; CHEMBL148903; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-; WSP-3; 3-(4'-aminophenyl)pyrrolidine-2,5-dione; AC1Q6LVA; 2-(p-aminophenyl) succinimide; SCHEMBL3274268; AC1L4Q15; CTK4G9448; BDBM50025154; FCH920777; AKOS006343465; AB07636; CC-12440; KB-26942; AS-35730; 2,5-Pyrrolidinedione,3-(4-aminophenyl)-; AX8033232; AB0073720; FT-0691904; X-3375; C-33345; 3-(4-amino-phenyl)-pyrrolidine-2,5-dione, AldrichCP
DMVN0O5	DT	Small molecular drug
DMVN0O5	PC	161760
DMVN0O5	MW	190.2
DMVN0O5	FM	C10H10N2O2
DMVN0O5	IC	InChI=1S/C10H10N2O2/c11-7-3-1-6(2-4-7)8-5-9(13)12-10(8)14/h1-4,8H,5,11H2,(H,12,13,14)
DMVN0O5	CS	C1C(C(=O)NC1=O)C2=CC=C(C=C2)N
DMVN0O5	IK	AFLGSUFOCCZEEZ-UHFFFAOYSA-N
DMVN0O5	IU	3-(4-aminophenyl)pyrrolidine-2,5-dione
DMVN0O5	CA	CAS 32856-49-8
DMVN0O5	DE	Discovery agent

DM6XTBI	ID	DM6XTBI
DM6XTBI	DN	3-(4-aminophenyl)quinoxaline-5-carboxamide
DM6XTBI	HS	Investigative
DM6XTBI	SN	CHEMBL443077; quinoxaline analogue, 3f; 3-(4-aminophenyl)quinoxaline-5-carboxamide; SCHEMBL7112515
DM6XTBI	DT	Small molecular drug
DM6XTBI	PC	25218519
DM6XTBI	MW	264.28
DM6XTBI	FM	C15H12N4O
DM6XTBI	IC	InChI=1S/C15H12N4O/c16-10-6-4-9(5-7-10)13-8-18-12-3-1-2-11(15(17)20)14(12)19-13/h1-8H,16H2,(H2,17,20)
DM6XTBI	CS	C1=CC(=C2C(=C1)N=CC(=N2)C3=CC=C(C=C3)N)C(=O)N
DM6XTBI	IK	JCXJUCVUESBKLT-UHFFFAOYSA-N
DM6XTBI	IU	3-(4-aminophenyl)quinoxaline-5-carboxamide
DM6XTBI	DE	Discovery agent

DM30GV2	ID	DM30GV2
DM30GV2	DN	3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine
DM30GV2	HS	Investigative
DM30GV2	SN	3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine; CHEMBL231153; 832694-16-3; Kinome_611; SCHEMBL3531281; CTK3D3472; DTXSID50593932; RSUCBZJSTXEGSF-UHFFFAOYSA-N; BDBM50201316; Thieno[3,2-c]pyridin-4-amine, 3-(4-aminophenyl)-
DM30GV2	DT	Small molecular drug
DM30GV2	PC	18450753
DM30GV2	MW	241.31
DM30GV2	FM	C13H11N3S
DM30GV2	IC	InChI=1S/C13H11N3S/c14-9-3-1-8(2-4-9)10-7-17-11-5-6-16-13(15)12(10)11/h1-7H,14H2,(H2,15,16)
DM30GV2	CS	C1=CC(=CC=C1C2=CSC3=C2C(=NC=C3)N)N
DM30GV2	IK	RSUCBZJSTXEGSF-UHFFFAOYSA-N
DM30GV2	IU	3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine
DM30GV2	CA	CAS 832694-16-3
DM30GV2	DE	Discovery agent

DMAT7VN	ID	DMAT7VN
DMAT7VN	DN	3-(4-Benzoylpiperazine-1-carbonyl)coumarin
DMAT7VN	HS	Investigative
DMAT7VN	SN	CHEMBL453852; 3-(4-Benzoyl-piperazine-1-carbonyl)-chromen-2-one; 3-(4-Benzoylpiperazine-1-carbonyl)coumarin; Oprea1_255077; Oprea1_655896; MLS001221424; MolPort-000-517-247; ZINC887160; HMS2917O18; HMS1690L15; BDBM50244614; AKOS000599038; MCULE-2543571988; SMR000611504; BAS 02911887; ST50014713; 3-{[4-(phenylcarbonyl)piperazinyl]carbonyl}chromen-2-one
DMAT7VN	DT	Small molecular drug
DMAT7VN	PC	1143426
DMAT7VN	MW	362.4
DMAT7VN	FM	C21H18N2O4
DMAT7VN	IC	InChI=1S/C21H18N2O4/c24-19(15-6-2-1-3-7-15)22-10-12-23(13-11-22)20(25)17-14-16-8-4-5-9-18(16)27-21(17)26/h1-9,14H,10-13H2
DMAT7VN	CS	C1CN(CCN1C(=O)C2=CC=CC=C2)C(=O)C3=CC4=CC=CC=C4OC3=O
DMAT7VN	IK	YBJQFYCTDMHHMH-UHFFFAOYSA-N
DMAT7VN	IU	3-(4-benzoylpiperazine-1-carbonyl)chromen-2-one
DMAT7VN	DE	Discovery agent

DMWPB0G	ID	DMWPB0G
DMWPB0G	DN	3-(4-Benzyl-piperazin-1-yl)-phenol
DMWPB0G	HS	Investigative
DMWPB0G	SN	CHEMBL88365; 3-(4-Benzyl-piperazin-1-yl)-phenol; SCHEMBL13902706; ZINC26638652; BDBM50069907
DMWPB0G	DT	Small molecular drug
DMWPB0G	PC	10015867
DMWPB0G	MW	268.35
DMWPB0G	FM	C17H20N2O
DMWPB0G	IC	InChI=1S/C17H20N2O/c20-17-8-4-7-16(13-17)19-11-9-18(10-12-19)14-15-5-2-1-3-6-15/h1-8,13,20H,9-12,14H2
DMWPB0G	CS	C1CN(CCN1CC2=CC=CC=C2)C3=CC(=CC=C3)O
DMWPB0G	IK	BISVFNHMXVNVMG-UHFFFAOYSA-N
DMWPB0G	IU	3-(4-benzylpiperazin-1-yl)phenol
DMWPB0G	DE	Discovery agent

DMFVCOP	ID	DMFVCOP
DMFVCOP	DN	3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMFVCOP	HS	Investigative
DMFVCOP	SN	CHEMBL178519; 3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMFVCOP	DT	Small molecular drug
DMFVCOP	PC	11773145
DMFVCOP	MW	335.4
DMFVCOP	FM	C22H25NO2
DMFVCOP	IC	InChI=1S/C22H25NO2/c24-22-19(16-25-21-9-5-4-8-20(21)22)15-23-12-10-18(11-13-23)14-17-6-2-1-3-7-17/h1-9,18-19H,10-16H2
DMFVCOP	CS	C1CN(CCC1CC2=CC=CC=C2)CC3COC4=CC=CC=C4C3=O
DMFVCOP	IK	ODWZSCLUZWGCOH-UHFFFAOYSA-N
DMFVCOP	IU	3-[(4-benzylpiperidin-1-yl)methyl]-2,3-dihydrochromen-4-one
DMFVCOP	DE	Discovery agent

DM7LMD6	ID	DM7LMD6
DM7LMD6	DN	3-(4-Benzyl-piperidin-1-ylmethyl)-chromen-4-one
DM7LMD6	HS	Investigative
DM7LMD6	SN	CHEMBL426958; AC1MDK2H; Oprea1_222683; 3-(4-Benzyl-piperidin-1-ylmethyl)-chromen-4-one; MolPort-045-902-159; BDBM50159007
DM7LMD6	DT	Small molecular drug
DM7LMD6	PC	2838196
DM7LMD6	MW	333.4
DM7LMD6	FM	C22H23NO2
DM7LMD6	IC	InChI=1S/C22H23NO2/c24-22-19(16-25-21-9-5-4-8-20(21)22)15-23-12-10-18(11-13-23)14-17-6-2-1-3-7-17/h1-9,16,18H,10-15H2
DM7LMD6	CS	C1CN(CCC1CC2=CC=CC=C2)CC3=COC4=CC=CC=C4C3=O
DM7LMD6	IK	WZWRAAKVOATXPL-UHFFFAOYSA-N
DM7LMD6	IU	3-[(4-benzylpiperidin-1-yl)methyl]chromen-4-one
DM7LMD6	DE	Discovery agent

DMAKMIJ	ID	DMAKMIJ
DMAKMIJ	DN	3-(4-bromobenzyl)-1,1-dimethylselenourea
DMAKMIJ	HS	Investigative
DMAKMIJ	SN	CHEMBL398715; 3-(4-bromobenzyl)-1,1-dimethylselenourea
DMAKMIJ	DT	Small molecular drug
DMAKMIJ	PC	44442159
DMAKMIJ	MW	319.09
DMAKMIJ	FM	C10H12BrN2Se
DMAKMIJ	IC	InChI=1S/C10H12BrN2Se/c1-13(2)10(14)12-7-8-3-5-9(11)6-4-8/h3-6H,7H2,1-2H3
DMAKMIJ	CS	CN(C)C(=NCC1=CC=C(C=C1)Br)[Se]
DMAKMIJ	IK	FFMCEZVYXHAZHZ-UHFFFAOYSA-N
DMAKMIJ	DE	Discovery agent

DMXMZRE	ID	DMXMZRE
DMXMZRE	DN	3-(4-bromophenyl)-1,1-dimethylthiourea
DMXMZRE	HS	Investigative
DMXMZRE	SN	3-(4-bromophenyl)-1,1-dimethylthiourea; CHEMBL249923; 75105-07-6; 3-(p-Bromophenyl)-1,1-dimethylthiourea; AC1NT9ZG; CTK2G1172; DTXSID30418775; YZPBPTSRPUXFGV-UHFFFAOYSA-N; STL265123; BDBM50223160; AKOS023092916; AKOS009470673; MCULE-1938000461; 1-(4-Bromophenyl)-3,3-dimethylthiourea; N'-(4-Bromophenyl)-N,N-dimethylthiourea #; Thiourea, N'-(4-bromophenyl)-N,N-dimethyl-
DMXMZRE	DT	Small molecular drug
DMXMZRE	PC	5376123
DMXMZRE	MW	259.17
DMXMZRE	FM	C9H11BrN2S
DMXMZRE	IC	InChI=1S/C9H11BrN2S/c1-12(2)9(13)11-8-5-3-7(10)4-6-8/h3-6H,1-2H3,(H,11,13)
DMXMZRE	CS	CN(C)C(=S)NC1=CC=C(C=C1)Br
DMXMZRE	IK	YZPBPTSRPUXFGV-UHFFFAOYSA-N
DMXMZRE	IU	3-(4-bromophenyl)-1,1-dimethylthiourea
DMXMZRE	CA	CAS 75105-07-6
DMXMZRE	DE	Discovery agent

DM8W3GC	ID	DM8W3GC
DM8W3GC	DN	3-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acrylamide
DM8W3GC	HS	Investigative
DM8W3GC	SN	CHEMBL446362; 3-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acrylamide; BDBM50015130; (E)-3-[4-Butoxyphenyl]-N-methyl-2-propenehydroxamic acid
DM8W3GC	DT	Small molecular drug
DM8W3GC	PC	44387153
DM8W3GC	MW	249.3
DM8W3GC	FM	C14H19NO3
DM8W3GC	IC	InChI=1S/C14H19NO3/c1-3-4-11-18-13-8-5-12(6-9-13)7-10-14(16)15(2)17/h5-10,17H,3-4,11H2,1-2H3/b10-7+
DM8W3GC	CS	CCCCOC1=CC=C(C=C1)/C=C/C(=O)N(C)O
DM8W3GC	IK	HAQOPUCXUDNSDH-JXMROGBWSA-N
DM8W3GC	IU	(E)-3-(4-butoxyphenyl)-N-hydroxy-N-methylprop-2-enamide
DM8W3GC	DE	Discovery agent

DMQ2D09	ID	DMQ2D09
DMQ2D09	DN	3-(4-chloro-2-cyclohexylphenoxy)propanoic acid
DMQ2D09	HS	Investigative
DMQ2D09	SN	CHEMBL247544; 3-(4-chloro-2-cyclohexylphenoxy)propanoic acid; CTK7J4510; BDBM50213910
DMQ2D09	DT	Small molecular drug
DMQ2D09	PC	16775011
DMQ2D09	MW	282.76
DMQ2D09	FM	C15H19ClO3
DMQ2D09	IC	InChI=1S/C15H19ClO3/c16-12-6-7-14(19-9-8-15(17)18)13(10-12)11-4-2-1-3-5-11/h6-7,10-11H,1-5,8-9H2,(H,17,18)
DMQ2D09	CS	C1CCC(CC1)C2=C(C=CC(=C2)Cl)OCCC(=O)O
DMQ2D09	IK	ZHWIAECJQUFYPY-UHFFFAOYSA-N
DMQ2D09	IU	3-(4-chloro-2-cyclohexylphenoxy)propanoic acid
DMQ2D09	DE	Discovery agent

DM71EUO	ID	DM71EUO
DM71EUO	DN	3-(4-Chlorophenyl)-2-nortropene
DM71EUO	HS	Investigative
DM71EUO	SN	CHEMBL576508; 189746-53-0; 3-(4-Chlorophenyl)-2-nortropene; SCHEMBL6214667; CTK0A2712; DTXSID10431947; QBSBBGLHCMPGNO-UHFFFAOYSA-N; BDBM50303307; 8-Azabicyclo[3.2.1]oct-2-ene, 3-(4-chlorophenyl)-; racemic 3-(4-Chloro-phenyl)-8-aza-bicyclo[3.2.1]oct-2-ene
DM71EUO	DT	Small molecular drug
DM71EUO	PC	9859279
DM71EUO	MW	219.71
DM71EUO	FM	C13H14ClN
DM71EUO	IC	InChI=1S/C13H14ClN/c14-11-3-1-9(2-4-11)10-7-12-5-6-13(8-10)15-12/h1-4,7,12-13,15H,5-6,8H2
DM71EUO	CS	C1CC2C=C(CC1N2)C3=CC=C(C=C3)Cl
DM71EUO	IK	QBSBBGLHCMPGNO-UHFFFAOYSA-N
DM71EUO	IU	3-(4-chlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene
DM71EUO	CA	CAS 189746-53-0
DM71EUO	DE	Discovery agent

DM23JIY	ID	DM23JIY
DM23JIY	DN	3-(4-cyanophenyl)quinoxaline-5-carboxamide
DM23JIY	HS	Investigative
DM23JIY	SN	CHEMBL481603; quinoxaline analogue, 3c; 3-(4-cyanophenyl)quinoxaline-5-carboxamide; SCHEMBL7108289
DM23JIY	DT	Small molecular drug
DM23JIY	PC	25218518
DM23JIY	MW	274.28
DM23JIY	FM	C16H10N4O
DM23JIY	IC	InChI=1S/C16H10N4O/c17-8-10-4-6-11(7-5-10)14-9-19-13-3-1-2-12(16(18)21)15(13)20-14/h1-7,9H,(H2,18,21)
DM23JIY	CS	C1=CC(=C2C(=C1)N=CC(=N2)C3=CC=C(C=C3)C#N)C(=O)N
DM23JIY	IK	WCZAODKSIJSHQD-UHFFFAOYSA-N
DM23JIY	IU	3-(4-cyanophenyl)quinoxaline-5-carboxamide
DM23JIY	DE	Discovery agent

DMGQE8D	ID	DMGQE8D
DMGQE8D	DN	3-(4-cyclohexylthiosemicarbazono)methyl-phenol
DMGQE8D	HS	Investigative
DMGQE8D	SN	CHEMBL387708; 3-(4-cyclohexylthiosemicarbazono)methyl-phenol; BDBM50216118; (Z)-3-Hydroxybenzaldehyde 4-cyclohexyl thiosemicarbazone
DMGQE8D	DT	Small molecular drug
DMGQE8D	PC	9729029
DMGQE8D	MW	277.39
DMGQE8D	FM	C14H19N3OS
DMGQE8D	IC	InChI=1S/C14H19N3OS/c18-13-8-4-5-11(9-13)10-15-17-14(19)16-12-6-2-1-3-7-12/h4-5,8-10,12,18H,1-3,6-7H2,(H2,16,17,19)/b15-10+
DMGQE8D	CS	C1CCC(CC1)NC(=S)N/N=C/C2=CC(=CC=C2)O
DMGQE8D	IK	GVMJJZTZCKCYTK-XNTDXEJSSA-N
DMGQE8D	IU	1-cyclohexyl-3-[(E)-(3-hydroxyphenyl)methylideneamino]thiourea
DMGQE8D	DE	Discovery agent

DM6XC0M	ID	DM6XC0M
DM6XC0M	DN	3-(4-dimethylamino-benzylidenyl)-2-indolinone
DM6XC0M	HS	Investigative
DM6XC0M	SN	dmbi; 3-(4-Dimethylaminobenzylidenyl)-2-indolinone; CHEMBL296455; (Z)-3-[4-(Dimethylamino)benzylidenyl]indolin-2-one; 3-[4-(dimethylamino)benzylidene]-1,3-dihydro-2H-indol-2-one; SU-4312; Tocris-1459; trans-SU 4312; AC1NS4CN; Lopac-S-8567; AC1Q6J0Q; SCHEMBL644678; GTPL5958; SCHEMBL13394695; ZINC21786; MolPort-019-728-327; MolPort-002-894-447; 3-[[(4-Dimethyl-amino)phenyl]methylene]-1,3-dihydro-2H-indol-2-one, E/Z mixture; HMS3229C19; HSCI1_000057; MFCD00118147; BDBM50111603; AKOS001034409; CCG-206747; NCGC00025170-01
DM6XC0M	DT	Small molecular drug
DM6XC0M	PC	3135
DM6XC0M	MW	264.32
DM6XC0M	FM	C17H16N2O
DM6XC0M	IC	InChI=1S/C17H16N2O/c1-19(2)13-9-7-12(8-10-13)11-15-14-5-3-4-6-16(14)18-17(15)20/h3-11H,1-2H3,(H,18,20)
DM6XC0M	CS	CN(C)C1=CC=C(C=C1)C=C2C3=CC=CC=C3NC2=O
DM6XC0M	IK	UAKWLVYMKBWHMX-UHFFFAOYSA-N
DM6XC0M	IU	3-[[4-(dimethylamino)phenyl]methylidene]-1H-indol-2-one
DM6XC0M	CA	CAS 5812-07-7
DM6XC0M	CB	CHEBI:92369
DM6XC0M	DE	Discovery agent

DMM7BQP	ID	DMM7BQP
DMM7BQP	DN	3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine
DMM7BQP	HS	Investigative
DMM7BQP	SN	3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 10; AC1O70HJ; BDBM8896; CHEMBL205250
DMM7BQP	DT	Small molecular drug
DMM7BQP	PC	6540054
DMM7BQP	MW	235.32
DMM7BQP	FM	C17H17N
DMM7BQP	IC	InChI=1S/C17H17N/c1-2-13-10-16(15-7-5-9-18-12-15)11-14-6-3-4-8-17(13)14/h3-9,11-13H,2,10H2,1H3
DMM7BQP	CS	CCC1CC(=CC2=CC=CC=C12)C3=CN=CC=C3
DMM7BQP	IK	FTBOKBNMIAPUAJ-UHFFFAOYSA-N
DMM7BQP	IU	3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine
DMM7BQP	DE	Discovery agent

DM8CK9M	ID	DM8CK9M
DM8CK9M	DN	3-(4-Fluorophenyl)-2-nortropene
DM8CK9M	HS	Investigative
DM8CK9M	SN	CHEMBL570638; 3-(4-Fluorophenyl)-2-nortropene; 3-(4-fluorophenyl)-8-azabicyclo[3.2.1]oct-3-ene; SCHEMBL6993886; LKSXLNMBLGXHQS-UHFFFAOYSA-N; BDBM50303306; 163630-91-9
DM8CK9M	DT	Small molecular drug
DM8CK9M	PC	9815620
DM8CK9M	MW	203.25
DM8CK9M	FM	C13H14FN
DM8CK9M	IC	InChI=1S/C13H14FN/c14-11-3-1-9(2-4-11)10-7-12-5-6-13(8-10)15-12/h1-4,7,12-13,15H,5-6,8H2
DM8CK9M	CS	C1CC2C=C(CC1N2)C3=CC=C(C=C3)F
DM8CK9M	IK	LKSXLNMBLGXHQS-UHFFFAOYSA-N
DM8CK9M	IU	3-(4-fluorophenyl)-8-azabicyclo[3.2.1]oct-2-ene
DM8CK9M	DE	Discovery agent

DM0POH2	ID	DM0POH2
DM0POH2	DN	3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline
DM0POH2	HS	Investigative
DM0POH2	SN	CHEMBL68401; 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline; ZINC3834028
DM0POH2	DT	Small molecular drug
DM0POH2	PC	10039460
DM0POH2	MW	283.3
DM0POH2	FM	C17H14FNO2
DM0POH2	IC	InChI=1S/C17H14FNO2/c1-20-16-8-12-7-13(11-3-5-14(18)6-4-11)10-19-15(12)9-17(16)21-2/h3-10H,1-2H3
DM0POH2	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=C(C=C3)F
DM0POH2	IK	UKJTWBAIJVXDSM-UHFFFAOYSA-N
DM0POH2	IU	3-(4-fluorophenyl)-6,7-dimethoxyquinoline
DM0POH2	DE	Discovery agent

DMDYS7Q	ID	DMDYS7Q
DMDYS7Q	DN	3-(4-hexylthiosemicarbazono)methyl-benzoic acid
DMDYS7Q	HS	Investigative
DMDYS7Q	SN	CHEMBL228317; 3-(4-hexylthiosemicarbazono)methyl-benzoic acid
DMDYS7Q	DT	Small molecular drug
DMDYS7Q	PC	16748617
DMDYS7Q	MW	307.4
DMDYS7Q	FM	C15H21N3O2S
DMDYS7Q	IC	InChI=1S/C15H21N3O2S/c1-2-3-4-5-9-16-15(21)18-17-11-12-7-6-8-13(10-12)14(19)20/h6-8,10-11H,2-5,9H2,1H3,(H,19,20)(H2,16,18,21)/b17-11+
DMDYS7Q	CS	CCCCCCNC(=S)N/N=C/C1=CC(=CC=C1)C(=O)O
DMDYS7Q	IK	WAIVPXALQIYLJU-GZTJUZNOSA-N
DMDYS7Q	IU	3-[(E)-(hexylcarbamothioylhydrazinylidene)methyl]benzoic acid
DMDYS7Q	DE	Discovery agent

DMPS1GW	ID	DMPS1GW
DMPS1GW	DN	3-(4H-Imidazol-4-yl)benzenethiol
DMPS1GW	HS	Investigative
DMPS1GW	PC	25194941
DMPS1GW	MW	176.24
DMPS1GW	FM	C9H8N2S
DMPS1GW	IC	InChI=1S/C9H8N2S/c12-8-3-1-2-7(4-8)9-5-10-6-11-9/h1-6,9,12H
DMPS1GW	CS	C1=CC(=CC(=C1)S)C2C=NC=N2
DMPS1GW	IK	GGVYLSRKJAVBST-UHFFFAOYSA-N
DMPS1GW	IU	3-(4H-imidazol-4-yl)benzenethiol
DMPS1GW	DE	Discovery agent

DME5238	ID	DME5238
DME5238	DN	3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile
DME5238	HS	Investigative
DME5238	SN	CHEMBL303801
DME5238	DT	Small molecular drug
DME5238	PC	14537255
DME5238	MW	297.3
DME5238	FM	C21H15NO
DME5238	IC	InChI=1S/C21H15NO/c22-15-20(16-7-3-1-4-8-16)21(17-9-5-2-6-10-17)18-11-13-19(23)14-12-18/h1-14,23H/b21-20-
DME5238	CS	C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\C3=CC=C(C=C3)O)/C#N
DME5238	IK	ASWQVWZGOMLNRM-MRCUWXFGSA-N
DME5238	IU	(E)-3-(4-hydroxyphenyl)-2,3-diphenylprop-2-enenitrile
DME5238	DE	Discovery agent

DMN01PI	ID	DMN01PI
DMN01PI	DN	3-(4-Hydroxy-phenyl)-4H-chromen-7-ol
DMN01PI	HS	Investigative
DMN01PI	SN	CHEMBL195560; 4h-1-benzopyran-7-ol,3-(4-hydroxyphenyl)-; 232261-61-9; isophenoxodiol; 3-(4-Hydroxy-phenyl)-4H-chromen-7-ol; SCHEMBL3755117; BDBM50166895; ZINC13643803; KB-290777; US8552057, 4
DMN01PI	DT	Small molecular drug
DMN01PI	PC	11356877
DMN01PI	MW	240.25
DMN01PI	FM	C15H12O3
DMN01PI	IC	InChI=1S/C15H12O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8-9,16-17H,7H2
DMN01PI	CS	C1C2=C(C=C(C=C2)O)OC=C1C3=CC=C(C=C3)O
DMN01PI	IK	QCNUDDPWPNUALZ-UHFFFAOYSA-N
DMN01PI	IU	3-(4-hydroxyphenyl)-4H-chromen-7-ol
DMN01PI	DE	Discovery agent

DM3XOVL	ID	DM3XOVL
DM3XOVL	DN	3-(4-hydroxyphenyl)-6-methyl-2H-chromen-2-one
DM3XOVL	HS	Investigative
DM3XOVL	SN	CHEMBL577099; 3-(4-hydroxyphenyl)-6-methyl-2H-chromen-2-one; ZINC45291389
DM3XOVL	DT	Small molecular drug
DM3XOVL	PC	45485414
DM3XOVL	MW	252.26
DM3XOVL	FM	C16H12O3
DM3XOVL	IC	InChI=1S/C16H12O3/c1-10-2-7-15-12(8-10)9-14(16(18)19-15)11-3-5-13(17)6-4-11/h2-9,17H,1H3
DM3XOVL	CS	CC1=CC2=C(C=C1)OC(=O)C(=C2)C3=CC=C(C=C3)O
DM3XOVL	IK	JSHUCMRTLUIFTM-UHFFFAOYSA-N
DM3XOVL	IU	3-(4-hydroxyphenyl)-6-methylchromen-2-one
DM3XOVL	DE	Discovery agent

DMS5N6Y	ID	DMS5N6Y
DMS5N6Y	DN	3-(4-Hydroxyphenyl)-7-isobutoxychromen-4-one
DMS5N6Y	HS	Investigative
DMS5N6Y	SN	SCHEMBL1701136
DMS5N6Y	DT	Small molecular drug
DMS5N6Y	PC	46914766
DMS5N6Y	MW	310.3
DMS5N6Y	FM	C19H18O4
DMS5N6Y	IC	InChI=1S/C19H18O4/c1-12(2)10-22-15-7-8-16-18(9-15)23-11-17(19(16)21)13-3-5-14(20)6-4-13/h3-9,11-12,20H,10H2,1-2H3
DMS5N6Y	CS	CC(C)COC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O
DMS5N6Y	IK	WYYSKWHYOXHLTB-UHFFFAOYSA-N
DMS5N6Y	IU	3-(4-hydroxyphenyl)-7-(2-methylpropoxy)chromen-4-one
DMS5N6Y	DE	Discovery agent

DMH75AO	ID	DMH75AO
DMH75AO	DN	3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one
DMH75AO	HS	Investigative
DMH75AO	SN	CHEMBL115109; 97846-18-9; 4H-1-Benzopyran-4-one, 3-(4-hydroxyphenyl)-7-(1-methylethoxy)-; ACMC-20m1ro; 3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one; SCHEMBL1701110; CTK3G8070; DTXSID70440494; 7-Isopropoxy-4'-hydroxyisoflavone; BDBM50104874; ZINC13864225; AKOS030553087; 3-(4-Hydroxy-phenyl)-7-isopropoxy-chromen-4-one
DMH75AO	DT	Small molecular drug
DMH75AO	PC	10469827
DMH75AO	MW	296.3
DMH75AO	FM	C18H16O4
DMH75AO	IC	InChI=1S/C18H16O4/c1-11(2)22-14-7-8-15-17(9-14)21-10-16(18(15)20)12-3-5-13(19)6-4-12/h3-11,19H,1-2H3
DMH75AO	CS	CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O
DMH75AO	IK	DEQMUPGWSXUDKV-UHFFFAOYSA-N
DMH75AO	IU	3-(4-hydroxyphenyl)-7-propan-2-yloxychromen-4-one
DMH75AO	CA	CAS 97846-18-9
DMH75AO	DE	Discovery agent

DMXZ9T6	ID	DMXZ9T6
DMXZ9T6	DN	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol
DMXZ9T6	HS	Investigative
DMXZ9T6	DT	Small molecular drug
DMXZ9T6	PC	135474625
DMXZ9T6	MW	227.21
DMXZ9T6	FM	C13H9NO3
DMXZ9T6	IC	InChI=1S/C13H9NO3/c15-9-3-1-8(2-4-9)13-11-7-10(16)5-6-12(11)17-14-13/h1-7,15-16H
DMXZ9T6	CS	C1=CC(=CC=C1C2=NOC3=C2C=C(C=C3)O)O
DMXZ9T6	IK	SSWFRICEKZJJHY-UHFFFAOYSA-N
DMXZ9T6	IU	3-(4-hydroxyphenyl)-1,2-benzoxazol-5-ol
DMXZ9T6	DE	Discovery agent

DMYLDFG	ID	DMYLDFG
DMYLDFG	DN	3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol
DMYLDFG	HS	Investigative
DMYLDFG	DT	Small molecular drug
DMYLDFG	PC	135526958
DMYLDFG	MW	227.21
DMYLDFG	FM	C13H9NO3
DMYLDFG	IC	InChI=1S/C13H9NO3/c15-9-3-1-8(2-4-9)13-11-6-5-10(16)7-12(11)17-14-13/h1-7,15-16H
DMYLDFG	CS	C1=CC(=CC=C1C2=NOC3=C2C=CC(=C3)O)O
DMYLDFG	IK	DPKXDXRRZZTHNM-UHFFFAOYSA-N
DMYLDFG	IU	3-(4-hydroxyphenyl)-1,2-benzoxazol-6-ol
DMYLDFG	DE	Discovery agent

DM18MOH	ID	DM18MOH
DM18MOH	DN	3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide
DM18MOH	HS	Investigative
DM18MOH	SN	4-((4-aminophenyl)diazenyl)benzenesulfonamide
DM18MOH	DT	Small molecular drug
DM18MOH	PC	405487
DM18MOH	MW	276.32
DM18MOH	FM	C12H12N4O2S
DM18MOH	IC	InChI=1S/C12H12N4O2S/c13-9-1-3-10(4-2-9)15-16-11-5-7-12(8-6-11)19(14,17)18/h1-8H,13H2,(H2,14,17,18)
DM18MOH	CS	C1=CC(=CC=C1N)N=NC2=CC=C(C=C2)S(=O)(=O)N
DM18MOH	IK	JSHXITVMUADQEA-UHFFFAOYSA-N
DM18MOH	IU	4-[(4-aminophenyl)diazenyl]benzenesulfonamide
DM18MOH	CA	CAS 59553-77-4
DM18MOH	DE	Discovery agent

DMSR2O3	ID	DMSR2O3
DMSR2O3	DN	3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone
DMSR2O3	HS	Investigative
DMSR2O3	SN	CHEMBL193856; BDBM22344; ZINC13683316; 1,3-Diarylprop-2-yn-1-one, 13a
DMSR2O3	DT	Small molecular drug
DMSR2O3	PC	11231439
DMSR2O3	MW	284.3
DMSR2O3	FM	C16H12O3S
DMSR2O3	IC	InChI=1S/C16H12O3S/c1-20(18,19)15-10-7-13(8-11-15)9-12-16(17)14-5-3-2-4-6-14/h2-8,10-11H,1H3
DMSR2O3	CS	CS(=O)(=O)C1=CC=C(C=C1)C#CC(=O)C2=CC=CC=C2
DMSR2O3	IK	OIHHELVXIPDXIK-UHFFFAOYSA-N
DMSR2O3	IU	3-(4-methylsulfonylphenyl)-1-phenylprop-2-yn-1-one
DMSR2O3	DE	Discovery agent

DM206M1	ID	DM206M1
DM206M1	DN	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol
DM206M1	HS	Investigative
DM206M1	SN	CHEMBL295066; 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol; SCHEMBL7208466
DM206M1	DT	Small molecular drug
DM206M1	PC	19366816
DM206M1	MW	286.4
DM206M1	FM	C13H18O3S2
DM206M1	IC	InChI=1S/C13H18O3S2/c1-16-10-5-7-12(8-6-10)18(14,15)13-4-2-3-11(17)9-13/h5-8,11,13,17H,2-4,9H2,1H3
DM206M1	CS	COC1=CC=C(C=C1)S(=O)(=O)C2CCCC(C2)S
DM206M1	IK	CTONTIQKTODDRQ-UHFFFAOYSA-N
DM206M1	IU	3-(4-methoxyphenyl)sulfonylcyclohexane-1-thiol
DM206M1	DE	Discovery agent

DMK79U1	ID	DMK79U1
DMK79U1	DN	3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol
DMK79U1	HS	Investigative
DMK79U1	SN	CHEMBL51013; 3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol
DMK79U1	DT	Small molecular drug
DMK79U1	PC	44294636
DMK79U1	MW	272.4
DMK79U1	FM	C12H16O3S2
DMK79U1	IC	InChI=1S/C12H16O3S2/c1-15-9-2-5-11(6-3-9)17(13,14)12-7-4-10(16)8-12/h2-3,5-6,10,12,16H,4,7-8H2,1H3
DMK79U1	CS	COC1=CC=C(C=C1)S(=O)(=O)C2CCC(C2)S
DMK79U1	IK	JDPMCWHMTGTQGU-UHFFFAOYSA-N
DMK79U1	IU	3-(4-methoxyphenyl)sulfonylcyclopentane-1-thiol
DMK79U1	DE	Discovery agent

DMRLAX8	ID	DMRLAX8
DMRLAX8	DN	3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol
DMRLAX8	HS	Investigative
DMRLAX8	SN	CHEMBL175113; 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol; SCHEMBL7212134
DMRLAX8	DT	Small molecular drug
DMRLAX8	PC	19366844
DMRLAX8	MW	288.4
DMRLAX8	FM	C13H20O3S2
DMRLAX8	IC	InChI=1S/C13H20O3S2/c1-3-4-12(9-10-17)18(14,15)13-7-5-11(16-2)6-8-13/h5-8,12,17H,3-4,9-10H2,1-2H3
DMRLAX8	CS	CCCC(CCS)S(=O)(=O)C1=CC=C(C=C1)OC
DMRLAX8	IK	SHMJSERYBLZGBT-UHFFFAOYSA-N
DMRLAX8	IU	3-(4-methoxyphenyl)sulfonylhexane-1-thiol
DMRLAX8	DE	Discovery agent

DM854IG	ID	DM854IG
DM854IG	DN	3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol
DM854IG	HS	Investigative
DM854IG	SN	CHEMBL368972; 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol; SCHEMBL7207764
DM854IG	DT	Small molecular drug
DM854IG	PC	19366856
DM854IG	MW	274.4
DM854IG	FM	C12H18O3S2
DM854IG	IC	InChI=1S/C12H18O3S2/c1-3-11(8-9-16)17(13,14)12-6-4-10(15-2)5-7-12/h4-7,11,16H,3,8-9H2,1-2H3
DM854IG	CS	CCC(CCS)S(=O)(=O)C1=CC=C(C=C1)OC
DM854IG	IK	PKYBEORBMGUOOP-UHFFFAOYSA-N
DM854IG	IU	3-(4-methoxyphenyl)sulfonylpentane-1-thiol
DM854IG	DE	Discovery agent

DM7B1VT	ID	DM7B1VT
DM7B1VT	DN	3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol
DM7B1VT	HS	Investigative
DM7B1VT	SN	CHEMBL51638; 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol; SCHEMBL7076532; JIFLEYNNNKKNOQ-UHFFFAOYSA-N; BDBM50076592; 3-(4-Methoxyphenylsulfonyl)propane-1-thiol
DM7B1VT	DT	Small molecular drug
DM7B1VT	PC	18411961
DM7B1VT	MW	246.4
DM7B1VT	FM	C10H14O3S2
DM7B1VT	IC	InChI=1S/C10H14O3S2/c1-13-9-3-5-10(6-4-9)15(11,12)8-2-7-14/h3-6,14H,2,7-8H2,1H3
DM7B1VT	CS	COC1=CC=C(C=C1)S(=O)(=O)CCCS
DM7B1VT	IK	JIFLEYNNNKKNOQ-UHFFFAOYSA-N
DM7B1VT	IU	3-(4-methoxyphenyl)sulfonylpropane-1-thiol
DM7B1VT	DE	Discovery agent

DMFRZGS	ID	DMFRZGS
DMFRZGS	DN	3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one
DMFRZGS	HS	Investigative
DMFRZGS	SN	CHEMBL386837; 921611-05-4; 3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one; CTK3H0752; DTXSID80658821; BDBM50198253; AKOS030552092; 4-Thiazolidinone, 3-[(4-methoxyphenyl)methoxy]-2-phenyl-
DMFRZGS	DT	Small molecular drug
DMFRZGS	PC	44418200
DMFRZGS	MW	315.4
DMFRZGS	FM	C17H17NO3S
DMFRZGS	IC	InChI=1S/C17H17NO3S/c1-20-15-9-7-13(8-10-15)11-21-18-16(19)12-22-17(18)14-5-3-2-4-6-14/h2-10,17H,11-12H2,1H3
DMFRZGS	CS	COC1=CC=C(C=C1)CON2C(SCC2=O)C3=CC=CC=C3
DMFRZGS	IK	IUBPXBYZGYCTMU-UHFFFAOYSA-N
DMFRZGS	IU	3-[(4-methoxyphenyl)methoxy]-2-phenyl-1,3-thiazolidin-4-one
DMFRZGS	CA	CAS 921611-05-4
DMFRZGS	DE	Discovery agent

DMGC7RY	ID	DMGC7RY
DMGC7RY	DN	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY	HS	Investigative
DMGC7RY	SN	CHEMBL372076; SCHEMBL3822337
DMGC7RY	DT	Small molecular drug
DMGC7RY	PC	11572699
DMGC7RY	MW	279.29
DMGC7RY	FM	C17H13NO3
DMGC7RY	IC	InChI=1S/C17H13NO3/c1-21-13-9-7-12(8-10-13)15-14(16(19)18-17(15)20)11-5-3-2-4-6-11/h2-10H,1H3,(H,18,19,20)
DMGC7RY	CS	COC1=CC=C(C=C1)C2=C(C(=O)NC2=O)C3=CC=CC=C3
DMGC7RY	IK	PXJXUZZVGCBPLM-UHFFFAOYSA-N
DMGC7RY	IU	3-(4-methoxyphenyl)-4-phenylpyrrole-2,5-dione
DMGC7RY	DE	Discovery agent

DMXKJOC	ID	DMXKJOC
DMXKJOC	DN	3-(4-methoxyphenyl)-6-methyl-2H-chromen-2-one
DMXKJOC	HS	Investigative
DMXKJOC	SN	CHEMBL572233; 3-(4-methoxyphenyl)-6-methyl-2H-chromen-2-one; SCHEMBL17857190; BDBM50300894; 3-(4-methoxyphenyl)-6-methylcoumarin; 113769-77-0; 3-(4-Methoxyphenyl)-6-methyl-3-chromene-2-one
DMXKJOC	DT	Small molecular drug
DMXKJOC	PC	14054762
DMXKJOC	MW	266.29
DMXKJOC	FM	C17H14O3
DMXKJOC	IC	InChI=1S/C17H14O3/c1-11-3-8-16-13(9-11)10-15(17(18)20-16)12-4-6-14(19-2)7-5-12/h3-10H,1-2H3
DMXKJOC	CS	CC1=CC2=C(C=C1)OC(=O)C(=C2)C3=CC=C(C=C3)OC
DMXKJOC	IK	IXPFLPLQVXPBGF-UHFFFAOYSA-N
DMXKJOC	IU	3-(4-methoxyphenyl)-6-methylchromen-2-one
DMXKJOC	DE	Discovery agent

DM7WPQC	ID	DM7WPQC
DM7WPQC	DN	3-(4-methoxyphenyl)quinoxaline-5-carboxamide
DM7WPQC	HS	Investigative
DM7WPQC	SN	CHEMBL519443; 3-(4-methoxyphenyl)quinoxaline-5-carboxamide; quinoxaline analogue, 3e; SCHEMBL7045177
DM7WPQC	DT	Small molecular drug
DM7WPQC	PC	9965481
DM7WPQC	MW	279.29
DM7WPQC	FM	C16H13N3O2
DM7WPQC	IC	InChI=1S/C16H13N3O2/c1-21-11-7-5-10(6-8-11)14-9-18-13-4-2-3-12(16(17)20)15(13)19-14/h2-9H,1H3,(H2,17,20)
DM7WPQC	CS	COC1=CC=C(C=C1)C2=NC3=C(C=CC=C3N=C2)C(=O)N
DM7WPQC	IK	XLKSSLKAULIQEE-UHFFFAOYSA-N
DM7WPQC	IU	3-(4-methoxyphenyl)quinoxaline-5-carboxamide
DM7WPQC	DE	Discovery agent

DMDR20P	ID	DMDR20P
DMDR20P	DN	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DMDR20P	HS	Investigative
DMDR20P	SN	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 9; AC1O70HH; SCHEMBL4507080; CHEMBL206070
DMDR20P	DT	Small molecular drug
DMDR20P	PC	6540053
DMDR20P	MW	221.3
DMDR20P	FM	C16H15N
DMDR20P	IC	InChI=1S/C16H15N/c1-12-9-15(14-6-4-8-17-11-14)10-13-5-2-3-7-16(12)13/h2-8,10-12H,9H2,1H3
DMDR20P	CS	CC1CC(=CC2=CC=CC=C12)C3=CN=CC=C3
DMDR20P	IK	HIOBIABFPPEMPT-UHFFFAOYSA-N
DMDR20P	IU	3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DMDR20P	DE	Discovery agent

DM0HYDZ	ID	DM0HYDZ
DM0HYDZ	DN	3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole
DM0HYDZ	HS	Investigative
DM0HYDZ	SN	21000-95-3; BRN 0191400; CHEMBL57478; 3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole; INDOLE, 3-((4-METHYLPIPERIDINO)METHYL)-; 3-((4-Methylpiperidino)methyl)indole; 3-[(4-methylpiperidin-1-yl)methyl]-1H-indole; AC1L1JK7; AC1Q2R9P; Oprea1_731728; Oprea1_382776; AURORA 16336; SCHEMBL13504100; CTK8H5660; DTXSID30175210; MolPort-001-815-823; ZINC142608; BDBM50050469; STK617550; 3-[(4-methylpiperidyl)methyl]indole; AKOS002266584; MCULE-4620579742; ACM21000953; 3-(4-Methylpiperidinomethyl)-1H-indole; LS-83280; BAS 02946824; ST50190326
DM0HYDZ	DT	Small molecular drug
DM0HYDZ	PC	30438
DM0HYDZ	MW	228.33
DM0HYDZ	FM	C15H20N2
DM0HYDZ	IC	InChI=1S/C15H20N2/c1-12-6-8-17(9-7-12)11-13-10-16-15-5-3-2-4-14(13)15/h2-5,10,12,16H,6-9,11H2,1H3
DM0HYDZ	CS	CC1CCN(CC1)CC2=CNC3=CC=CC=C32
DM0HYDZ	IK	DGCGMYNLCDVYMB-UHFFFAOYSA-N
DM0HYDZ	IU	3-[(4-methylpiperidin-1-yl)methyl]-1H-indole
DM0HYDZ	CA	CAS 21000-95-3
DM0HYDZ	DE	Discovery agent

DM54MDH	ID	DM54MDH
DM54MDH	DN	3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol
DM54MDH	HS	Investigative
DM54MDH	SN	CHEMBL541643
DM54MDH	DT	Small molecular drug
DM54MDH	PC	9901372
DM54MDH	MW	313.4
DM54MDH	FM	C16H15N3O2S
DM54MDH	IC	InChI=1S/C16H15N3O2S/c20-12-3-1-2-11(10-12)15-17-13-4-9-22-14(13)16(18-15)19-5-7-21-8-6-19/h1-4,9-10,20H,5-8H2
DM54MDH	CS	C1COCCN1C2=NC(=NC3=C2SC=C3)C4=CC(=CC=C4)O
DM54MDH	IK	XXLAEKOWCYJOKK-UHFFFAOYSA-N
DM54MDH	IU	3-(4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol
DM54MDH	CA	CAS 371943-05-4
DM54MDH	DE	Discovery agent

DMIBAM2	ID	DMIBAM2
DMIBAM2	DN	3-(4-o-Tolylpiperazine-1-carbonyl)coumarin
DMIBAM2	HS	Investigative
DMIBAM2	SN	CHEMBL509131; AC1PLLS0; 3-(4-o-Tolylpiperazine-1-carbonyl)coumarin; BDBM50244558; AKOS002932058
DMIBAM2	DT	Small molecular drug
DMIBAM2	PC	9153545
DMIBAM2	MW	348.4
DMIBAM2	FM	C21H20N2O3
DMIBAM2	IC	InChI=1S/C21H20N2O3/c1-15-6-2-4-8-18(15)22-10-12-23(13-11-22)20(24)17-14-16-7-3-5-9-19(16)26-21(17)25/h2-9,14H,10-13H2,1H3
DMIBAM2	CS	CC1=CC=CC=C1N2CCN(CC2)C(=O)C3=CC4=CC=CC=C4OC3=O
DMIBAM2	IK	IVCTUFTWYWRJLW-UHFFFAOYSA-N
DMIBAM2	IU	3-[4-(2-methylphenyl)piperazine-1-carbonyl]chromen-2-one
DMIBAM2	DE	Discovery agent

DMBKDZ3	ID	DMBKDZ3
DMBKDZ3	DN	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol
DMBKDZ3	HS	Investigative
DMBKDZ3	SN	CHEMBL48474; 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol
DMBKDZ3	DT	Small molecular drug
DMBKDZ3	PC	44294677
DMBKDZ3	MW	348.5
DMBKDZ3	FM	C18H20O3S2
DMBKDZ3	IC	InChI=1S/C18H20O3S2/c19-23(20,18-8-4-7-16(22)13-18)17-11-9-15(10-12-17)21-14-5-2-1-3-6-14/h1-3,5-6,9-12,16,18,22H,4,7-8,13H2
DMBKDZ3	CS	C1CC(CC(C1)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=CC=C3)S
DMBKDZ3	IK	XOVSRAFNJNQNRK-UHFFFAOYSA-N
DMBKDZ3	IU	3-(4-phenoxyphenyl)sulfonylcyclohexane-1-thiol
DMBKDZ3	DE	Discovery agent

DM2HBGL	ID	DM2HBGL
DM2HBGL	DN	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol
DM2HBGL	HS	Investigative
DM2HBGL	SN	CHEMBL301565; 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol; SCHEMBL7208687; BDBM50076589
DM2HBGL	DT	Small molecular drug
DM2HBGL	PC	10267279
DM2HBGL	MW	308.4
DM2HBGL	FM	C15H16O3S2
DM2HBGL	IC	InChI=1S/C15H16O3S2/c16-20(17,12-4-11-19)15-9-7-14(8-10-15)18-13-5-2-1-3-6-13/h1-3,5-10,19H,4,11-12H2
DM2HBGL	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)S(=O)(=O)CCCS
DM2HBGL	IK	CTVWOVYWOFCAMW-UHFFFAOYSA-N
DM2HBGL	IU	3-(4-phenoxyphenyl)sulfonylpropane-1-thiol
DM2HBGL	DE	Discovery agent

DMO6LID	ID	DMO6LID
DMO6LID	DN	3-(4-Phenoxy-phenyl)-1H-pyrazole
DMO6LID	HS	Investigative
DMO6LID	SN	5-(4-phenoxyphenyl)-1H-pyrazole; CHEMBL41864; 111273-31-5; 1H-Pyrazole, 3-(4-phenoxyphenyl)-; 3-(4-Phenoxy-phenyl)-1H-pyrazole; ACMC-20me6r; AC1MD5RK; Maybridge3_001296; Oprea1_637414; MLS000851363; SCHEMBL3364770; CTK0G1854; DTXSID00384478; MolPort-001-792-591; SGQSMRQYEPPNIA-UHFFFAOYSA-N; 3-(4-phenoxyphenyl)-1H-pyrazole; HMS2799J18; HMS1434K20; BDBM50141064; ZINC13559817; AKOS023552923; MCULE-9803599814; IDI1_012683
DMO6LID	DT	Small molecular drug
DMO6LID	PC	2806138
DMO6LID	MW	236.27
DMO6LID	FM	C15H12N2O
DMO6LID	IC	InChI=1S/C15H12N2O/c1-2-4-13(5-3-1)18-14-8-6-12(7-9-14)15-10-11-16-17-15/h1-11H,(H,16,17)
DMO6LID	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=CC=NN3
DMO6LID	IK	SGQSMRQYEPPNIA-UHFFFAOYSA-N
DMO6LID	IU	5-(4-phenoxyphenyl)-1H-pyrazole
DMO6LID	CA	CAS 111273-31-5
DMO6LID	DE	Discovery agent

DMSZ1VC	ID	DMSZ1VC
DMSZ1VC	DN	3-(4-phenyl-2,4'-bipyridin-6-yl)phenol
DMSZ1VC	HS	Investigative
DMSZ1VC	SN	CHEMBL1095650
DMSZ1VC	DT	Small molecular drug
DMSZ1VC	PC	46861757
DMSZ1VC	MW	324.4
DMSZ1VC	FM	C22H16N2O
DMSZ1VC	IC	InChI=1S/C22H16N2O/c25-20-8-4-7-18(13-20)22-15-19(16-5-2-1-3-6-16)14-21(24-22)17-9-11-23-12-10-17/h1-15,25H
DMSZ1VC	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC(=CC=C3)O)C4=CC=NC=C4
DMSZ1VC	IK	CBYVMWRLWYKHTF-UHFFFAOYSA-N
DMSZ1VC	IU	3-(4-phenyl-6-pyridin-4-ylpyridin-2-yl)phenol
DMSZ1VC	DE	Discovery agent

DM0OF64	ID	DM0OF64
DM0OF64	DN	3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol
DM0OF64	HS	Investigative
DM0OF64	SN	CHEMBL1094819
DM0OF64	DT	Small molecular drug
DM0OF64	PC	46887131
DM0OF64	MW	329.4
DM0OF64	FM	C21H15NOS
DM0OF64	IC	InChI=1S/C21H15NOS/c23-18-9-4-8-16(12-18)19-13-17(15-6-2-1-3-7-15)14-20(22-19)21-10-5-11-24-21/h1-14,23H
DM0OF64	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC=CS3)C4=CC(=CC=C4)O
DM0OF64	IK	ARUHBJGNLAPWGO-UHFFFAOYSA-N
DM0OF64	IU	3-(4-phenyl-6-thiophen-2-ylpyridin-2-yl)phenol
DM0OF64	DE	Discovery agent

DMTR8SZ	ID	DMTR8SZ
DMTR8SZ	DN	3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol
DMTR8SZ	HS	Investigative
DMTR8SZ	SN	CHEMBL1095140
DMTR8SZ	DT	Small molecular drug
DMTR8SZ	PC	46887132
DMTR8SZ	MW	329.4
DMTR8SZ	FM	C21H15NOS
DMTR8SZ	IC	InChI=1S/C21H15NOS/c23-19-8-4-7-16(11-19)20-12-18(15-5-2-1-3-6-15)13-21(22-20)17-9-10-24-14-17/h1-14,23H
DMTR8SZ	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CSC=C3)C4=CC(=CC=C4)O
DMTR8SZ	IK	GZCPVCLLSOKGCF-UHFFFAOYSA-N
DMTR8SZ	IU	3-(4-phenyl-6-thiophen-3-ylpyridin-2-yl)phenol
DMTR8SZ	DE	Discovery agent

DMXL0J5	ID	DMXL0J5
DMXL0J5	DN	3-(4-Phenylethynylbenzoyl)nonanoic acid
DMXL0J5	HS	Investigative
DMXL0J5	SN	3-(4-Phenylethynylbenzoyl)nonanoic acid; CHEMBL201298
DMXL0J5	DT	Small molecular drug
DMXL0J5	PC	11581319
DMXL0J5	MW	362.5
DMXL0J5	FM	C24H26O3
DMXL0J5	IC	InChI=1S/C24H26O3/c1-2-3-4-8-11-22(18-23(25)26)24(27)21-16-14-20(15-17-21)13-12-19-9-6-5-7-10-19/h5-7,9-10,14-17,22H,2-4,8,11,18H2,1H3,(H,25,26)
DMXL0J5	CS	CCCCCCC(CC(=O)O)C(=O)C1=CC=C(C=C1)C#CC2=CC=CC=C2
DMXL0J5	IK	RPSYWEPJQQLLJN-UHFFFAOYSA-N
DMXL0J5	IU	3-[4-(2-phenylethynyl)benzoyl]nonanoic acid
DMXL0J5	DE	Discovery agent

DMH27E0	ID	DMH27E0
DMH27E0	DN	3-(4-Phenylpiperazin-1-carbonyl)coumarin
DMH27E0	HS	Investigative
DMH27E0	SN	CHEMBL486460; 3-(4-phenylpiperazine-1-carbonyl)-2H-chromen-2-one; 420099-59-8; 3-(4-Phenylpiperazin-1-carbonyl)coumarin; AC1LEC4F; CBMicro_029395; Oprea1_062891; ZINC99797; PEIQALYIIRRQAZ-UHFFFAOYSA-N; MolPort-000-467-605; STK414837; BDBM50244417; AKOS001407600; MCULE-7805538534; NCGC00306822-01; BIM-0029313.P001; ST4080681; AB00094693-01; 3-[(4-phenylpiperazinyl)carbonyl]chromen-2-one; AB00094693-02; 3-(4-phenylpiperazine-1-carbonyl)chromen-2-one; SR-01000218055; Chromen-2-one, 3-(4-phenylpiperazine-1-carbonyl)-
DMH27E0	DT	Small molecular drug
DMH27E0	PC	709819
DMH27E0	MW	334.4
DMH27E0	FM	C20H18N2O3
DMH27E0	IC	InChI=1S/C20H18N2O3/c23-19(17-14-15-6-4-5-9-18(15)25-20(17)24)22-12-10-21(11-13-22)16-7-2-1-3-8-16/h1-9,14H,10-13H2
DMH27E0	CS	C1CN(CCN1C2=CC=CC=C2)C(=O)C3=CC4=CC=CC=C4OC3=O
DMH27E0	IK	PEIQALYIIRRQAZ-UHFFFAOYSA-N
DMH27E0	IU	3-(4-phenylpiperazine-1-carbonyl)chromen-2-one
DMH27E0	DE	Discovery agent

DM17SNR	ID	DM17SNR
DM17SNR	DN	3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole
DM17SNR	HS	Investigative
DM17SNR	SN	3-[(4-phenylpiperazino)methyl]-1h-indole; CHEMBL59324; 4281-72-5; 3-[(4-phenylpiperazin-1-yl)methyl]-1H-indole; NSC33115; AC1Q1ILD; 3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole; AC1L5R6D; Oprea1_259378; CBDivE_012786; CTK4I6632; MolPort-002-141-505; NSC-33115; CCG-45935; ZINC53151307; BDBM50050464; AKOS030540271; MCULE-7772581256; KB-286915
DM17SNR	DT	Small molecular drug
DM17SNR	PC	233952
DM17SNR	MW	291.4
DM17SNR	FM	C19H21N3
DM17SNR	IC	InChI=1S/C19H21N3/c1-2-6-17(7-3-1)22-12-10-21(11-13-22)15-16-14-20-19-9-5-4-8-18(16)19/h1-9,14,20H,10-13,15H2
DM17SNR	CS	C1CN(CCN1CC2=CNC3=CC=CC=C32)C4=CC=CC=C4
DM17SNR	IK	FDOZNCJWYJMHAG-UHFFFAOYSA-N
DM17SNR	IU	3-[(4-phenylpiperazin-1-yl)methyl]-1H-indole
DM17SNR	CA	CAS 4281-72-5
DM17SNR	DE	Discovery agent

DMM0WGI	ID	DMM0WGI
DMM0WGI	DN	3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole
DMM0WGI	HS	Investigative
DMM0WGI	SN	CHEMBL59103; 3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole; BDBM50050468; ZINC13755886
DMM0WGI	DT	Small molecular drug
DMM0WGI	PC	10851078
DMM0WGI	MW	290.4
DMM0WGI	FM	C20H22N2
DMM0WGI	IC	InChI=1S/C20H22N2/c1-2-6-16(7-3-1)17-10-12-22(13-11-17)15-18-14-21-20-9-5-4-8-19(18)20/h1-9,14,17,21H,10-13,15H2
DMM0WGI	CS	C1CN(CCC1C2=CC=CC=C2)CC3=CNC4=CC=CC=C43
DMM0WGI	IK	XNXQFTTXHFQTRX-UHFFFAOYSA-N
DMM0WGI	IU	3-[(4-phenylpiperidin-1-yl)methyl]-1H-indole
DMM0WGI	DE	Discovery agent

DMDYVA7	ID	DMDYVA7
DMDYVA7	DN	3-(4-Pyridin-2-yl-imidazol-1-yl)-benzonitrile
DMDYVA7	HS	Investigative
DMDYVA7	SN	CHEMBL363883; 3-(4-Pyridin-2-yl-imidazol-1-yl)-benzonitrile; SCHEMBL5224021; WFXSTBNPVNZJHP-UHFFFAOYSA-N; BDBM50151900; ZINC13582329
DMDYVA7	DT	Small molecular drug
DMDYVA7	PC	11242036
DMDYVA7	MW	246.27
DMDYVA7	FM	C15H10N4
DMDYVA7	IC	InChI=1S/C15H10N4/c16-9-12-4-3-5-13(8-12)19-10-15(18-11-19)14-6-1-2-7-17-14/h1-8,10-11H
DMDYVA7	CS	C1=CC=NC(=C1)C2=CN(C=N2)C3=CC=CC(=C3)C#N
DMDYVA7	IK	WFXSTBNPVNZJHP-UHFFFAOYSA-N
DMDYVA7	IU	3-(4-pyridin-2-ylimidazol-1-yl)benzonitrile
DMDYVA7	DE	Discovery agent

DMTD16H	ID	DMTD16H
DMTD16H	DN	3-(4-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile
DMTD16H	HS	Investigative
DMTD16H	SN	CHEMBL189389; 546141-91-7; 3-(4-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile; SCHEMBL3922456; CTK1F8523; DTXSID40432285; ZINC13582324; BDBM50151901; Benzonitrile, 3-[4-(2-pyridinyl)-1H-pyrazol-1-yl]-
DMTD16H	DT	Small molecular drug
DMTD16H	PC	9881352
DMTD16H	MW	246.27
DMTD16H	FM	C15H10N4
DMTD16H	IC	InChI=1S/C15H10N4/c16-9-12-4-3-5-14(8-12)19-11-13(10-18-19)15-6-1-2-7-17-15/h1-8,10-11H
DMTD16H	CS	C1=CC=NC(=C1)C2=CN(N=C2)C3=CC=CC(=C3)C#N
DMTD16H	IK	SLFBHONCPFNHGU-UHFFFAOYSA-N
DMTD16H	IU	3-(4-pyridin-2-ylpyrazol-1-yl)benzonitrile
DMTD16H	CA	CAS 546141-91-7
DMTD16H	DE	Discovery agent

DMBDW8P	ID	DMBDW8P
DMBDW8P	DN	3-(4-sulfamoylphenyl)propanoic acid
DMBDW8P	HS	Investigative
DMBDW8P	SN	3-(4-Sulfamoylphenyl)propanoic acid; 90610-69-8; 3-(4-Sulfamoyl-phenyl)-propionic acid; 3-[4-(Aminosulfonyl)phenyl]propanoic Acid; CHEMBL451332; 4-(2-carboxyethyl)-benzenesulfonamide; M28; BAS 12384209; AC1MKR5Y; AC1Q55BB; 4-carboxyethylbenzenesulfonamide; SCHEMBL4964212; CTK7J3040; BDBM29277; MolPort-001-769-253; JUEONDBIBADVGD-UHFFFAOYSA-N; HMS3604J11; ZINC4362893; 4-(Aminosulphonyl)hydrocinnamic acid; STK802680; ANW-44559; SBB011591; BBL002635; 4-(2-Carboxyethyl)benzenesulphonamide; P-CARBOXYETHYLBENZENESULFONAMIDE; 3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID
DMBDW8P	DT	Small molecular drug
DMBDW8P	PC	3161908
DMBDW8P	MW	229.26
DMBDW8P	FM	C9H11NO4S
DMBDW8P	IC	InChI=1S/C9H11NO4S/c10-15(13,14)8-4-1-7(2-5-8)3-6-9(11)12/h1-2,4-5H,3,6H2,(H,11,12)(H2,10,13,14)
DMBDW8P	CS	C1=CC(=CC=C1CCC(=O)O)S(=O)(=O)N
DMBDW8P	IK	JUEONDBIBADVGD-UHFFFAOYSA-N
DMBDW8P	IU	3-(4-sulfamoylphenyl)propanoic acid
DMBDW8P	DE	Discovery agent

DMZB804	ID	DMZB804
DMZB804	DN	3-(4-Trifluoromethylphenyl)-2-nortropene
DMZB804	HS	Investigative
DMZB804	SN	CHEMBL570871; (+/-)-3-(4-trifluoromethylphenyl)-8-azabicyclo(3.2.1]oct-2-ene; (+/-)-3-(4-trifluoromethylphenyl)-8-azabicyclo[3.2.1]oct-2-ene; 3-(4-Trifluoromethylphenyl)-2-nortropene; SCHEMBL6577750; TVAPTTJJXRUWFI-UHFFFAOYSA-N
DMZB804	DT	Small molecular drug
DMZB804	PC	9816454
DMZB804	MW	253.26
DMZB804	FM	C14H14F3N
DMZB804	IC	InChI=1S/C14H14F3N/c15-14(16,17)11-3-1-9(2-4-11)10-7-12-5-6-13(8-10)18-12/h1-4,7,12-13,18H,5-6,8H2
DMZB804	CS	C1CC2C=C(CC1N2)C3=CC=C(C=C3)C(F)(F)F
DMZB804	IK	TVAPTTJJXRUWFI-UHFFFAOYSA-N
DMZB804	IU	3-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]oct-2-ene
DMZB804	DE	Discovery agent

DM6S28U	ID	DM6S28U
DM6S28U	DN	3-(5-((methylthio)methyl)furan-2-yl)pyridine
DM6S28U	HS	Investigative
DM6S28U	SN	3-(5-((methylthio)methyl)furan-2-yl)pyridine; 859239-20-6; Pyridine, 3-[5-[(methylthio)methyl]-2-furanyl]-; SCHEMBL3611062; CHEMBL214990; CTK2I3857; BDBM12361; DTXSID60475412; QSLAHFFHHYZNQL-UHFFFAOYSA-N; nicotine 3-heteroaromatic analogue 15
DM6S28U	DT	Small molecular drug
DM6S28U	PC	11993873
DM6S28U	MW	205.28
DM6S28U	FM	C11H11NOS
DM6S28U	IC	InChI=1S/C11H11NOS/c1-14-8-10-4-5-11(13-10)9-3-2-6-12-7-9/h2-7H,8H2,1H3
DM6S28U	CS	CSCC1=CC=C(O1)C2=CN=CC=C2
DM6S28U	IK	QSLAHFFHHYZNQL-UHFFFAOYSA-N
DM6S28U	IU	3-[5-(methylsulfanylmethyl)furan-2-yl]pyridine
DM6S28U	CA	CAS 859239-20-6
DM6S28U	DE	Discovery agent

DMTVYLM	ID	DMTVYLM
DMTVYLM	DN	3-(5,6,7,8-Tetrahydronaphthalen-2-yl)pyridine
DMTVYLM	HS	Investigative
DMTVYLM	SN	CHEMBL461457; 3-(5,6,7,8-Tetrahydronaphthalen-2-yl)pyridine; SCHEMBL8081400; ZINC40863212
DMTVYLM	DT	Small molecular drug
DMTVYLM	PC	25180303
DMTVYLM	MW	209.29
DMTVYLM	FM	C15H15N
DMTVYLM	IC	InChI=1S/C15H15N/c1-2-5-13-10-14(8-7-12(13)4-1)15-6-3-9-16-11-15/h3,6-11H,1-2,4-5H2
DMTVYLM	CS	C1CCC2=C(C1)C=CC(=C2)C3=CN=CC=C3
DMTVYLM	IK	WGNJGUOGXBTDMP-UHFFFAOYSA-N
DMTVYLM	IU	3-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridine
DMTVYLM	CA	CAS 1092522-77-4
DMTVYLM	DE	Discovery agent

DMOUNPH	ID	DMOUNPH
DMOUNPH	DN	3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine
DMOUNPH	HS	Investigative
DMOUNPH	SN	Pyridine, 3-[5-(1,3-dithiolan-2-yl)-2-furanyl]-; 859239-21-7; 3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine; 3-[5-(1,3-dithiolan-2-yl)furan-2-yl]pyridine; CHEMBL215174; SCHEMBL3608709; CTK2I3856; BDBM12362; DTXSID40475410; nicotine 3-heteroaromatic analogue 17
DMOUNPH	DT	Small molecular drug
DMOUNPH	PC	11993867
DMOUNPH	MW	249.4
DMOUNPH	FM	C12H11NOS2
DMOUNPH	IC	InChI=1S/C12H11NOS2/c1-2-9(8-13-5-1)10-3-4-11(14-10)12-15-6-7-16-12/h1-5,8,12H,6-7H2
DMOUNPH	CS	C1CSC(S1)C2=CC=C(O2)C3=CN=CC=C3
DMOUNPH	IK	UITMTMQMFFBLFB-UHFFFAOYSA-N
DMOUNPH	IU	3-[5-(1,3-dithiolan-2-yl)furan-2-yl]pyridine
DMOUNPH	CA	CAS 859239-21-7
DMOUNPH	DE	Discovery agent

DMUIXNS	ID	DMUIXNS
DMUIXNS	DN	3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine
DMUIXNS	HS	Investigative
DMUIXNS	SN	SCHEMBL4508450; CHEMBL196328; BDBM8911; Pyridine-substituted naphthalene 10; ZINC13674462; 3-(5-bromo-6-methoxy-2-naphthyl)pyridine
DMUIXNS	DT	Small molecular drug
DMUIXNS	PC	11616637
DMUIXNS	MW	314.18
DMUIXNS	FM	C16H12BrNO
DMUIXNS	IC	InChI=1S/C16H12BrNO/c1-19-15-7-5-12-9-11(4-6-14(12)16(15)17)13-3-2-8-18-10-13/h2-10H,1H3
DMUIXNS	CS	COC1=C(C2=C(C=C1)C=C(C=C2)C3=CN=CC=C3)Br
DMUIXNS	IK	ZVOWEWSHEFYCIY-UHFFFAOYSA-N
DMUIXNS	IU	3-(5-bromo-6-methoxynaphthalen-2-yl)pyridine
DMUIXNS	DE	Discovery agent

DMM4HF8	ID	DMM4HF8
DMM4HF8	DN	3'-(5-Chloro-2-thienyl)biphenyl-3-ol
DMM4HF8	HS	Investigative
DMM4HF8	SN	CHEMBL1097014; BDBM50318419
DMM4HF8	DT	Small molecular drug
DMM4HF8	PC	46844318
DMM4HF8	MW	286.8
DMM4HF8	FM	C16H11ClOS
DMM4HF8	IC	InChI=1S/C16H11ClOS/c17-16-8-7-15(19-16)13-5-1-3-11(9-13)12-4-2-6-14(18)10-12/h1-10,18H
DMM4HF8	CS	C1=CC(=CC(=C1)C2=CC=C(S2)Cl)C3=CC(=CC=C3)O
DMM4HF8	IK	IBTNRYGKAUWUJS-UHFFFAOYSA-N
DMM4HF8	IU	3-[3-(5-chlorothiophen-2-yl)phenyl]phenol
DMM4HF8	DE	Discovery agent

DM67DVU	ID	DM67DVU
DM67DVU	DN	3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine
DM67DVU	HS	Investigative
DM67DVU	SN	CHEMBL197576; BDBM8910; SCHEMBL4509209; Pyridine-substituted naphthalene 9; ZINC13674461; 3-(5-chloro-6-methoxy-2-naphthyl)pyridine
DM67DVU	DT	Small molecular drug
DM67DVU	PC	11529133
DM67DVU	MW	269.72
DM67DVU	FM	C16H12ClNO
DM67DVU	IC	InChI=1S/C16H12ClNO/c1-19-15-7-5-12-9-11(4-6-14(12)16(15)17)13-3-2-8-18-10-13/h2-10H,1H3
DM67DVU	CS	COC1=C(C2=C(C=C1)C=C(C=C2)C3=CN=CC=C3)Cl
DM67DVU	IK	BMTHOHYTXCPKJC-UHFFFAOYSA-N
DM67DVU	IU	3-(5-chloro-6-methoxynaphthalen-2-yl)pyridine
DM67DVU	DE	Discovery agent

DMPRBLH	ID	DMPRBLH
DMPRBLH	DN	3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DMPRBLH	HS	Investigative
DMPRBLH	DT	Small molecular drug
DMPRBLH	PC	135522274
DMPRBLH	MW	243.21
DMPRBLH	FM	C13H9NO4
DMPRBLH	IC	InChI=1S/C13H9NO4/c15-7-4-5-11-9(6-7)14-13(18-11)8-2-1-3-10(16)12(8)17/h1-6,15-17H
DMPRBLH	CS	C1=CC(=C(C(=C1)O)O)C2=NC3=C(O2)C=CC(=C3)O
DMPRBLH	IK	XVMUZRUUMXAORF-UHFFFAOYSA-N
DMPRBLH	IU	3-(5-hydroxy-1,3-benzoxazol-2-yl)benzene-1,2-diol
DMPRBLH	DE	Discovery agent

DMTJXOU	ID	DMTJXOU
DMTJXOU	DN	3-(5-methoxy-1H-inden-2-yl)pyridine
DMTJXOU	HS	Investigative
DMTJXOU	SN	3-(5-methoxy-1H-inden-2-yl)pyridine; indene 3; AC1O70H7; CHEMBL206300; BDBM8890
DMTJXOU	DT	Small molecular drug
DMTJXOU	PC	6540048
DMTJXOU	MW	223.27
DMTJXOU	FM	C15H13NO
DMTJXOU	IC	InChI=1S/C15H13NO/c1-17-15-5-4-11-7-13(8-14(11)9-15)12-3-2-6-16-10-12/h2-6,8-10H,7H2,1H3
DMTJXOU	CS	COC1=CC2=C(CC(=C2)C3=CN=CC=C3)C=C1
DMTJXOU	IK	KPJYOCDWGFDTFR-UHFFFAOYSA-N
DMTJXOU	IU	3-(5-methoxy-1H-inden-2-yl)pyridine
DMTJXOU	DE	Discovery agent

DMXLVG6	ID	DMXLVG6
DMXLVG6	DN	3-(5-methoxy-1H-indol-3-yl)propanoic acid
DMXLVG6	HS	Investigative
DMXLVG6	SN	3-(5-methoxy-1H-indol-3-yl)propanoic acid; 39547-16-5; 3-(5-Methoxy-1H-indol-3-yl)-propionic acid; 1H-Indole-3-propanoic acid, 5-methoxy-; 3-(5-methoxyindol-3-yl)propanoic acid; CBMicro_030931; ChemDiv2_000435; AC1L48GT; Oprea1_046476; SCHEMBL3024961; CTK1C3093; 5-methoxyindole-3-propionic acid; ZLSZCJIWILJKMR-UHFFFAOYSA-N; MolPort-002-085-835; ZINC195148; HMS3604K06; HMS1370D17; 2429AE; STK984200; SBB028111; AKOS000300418; MCULE-1797370196; DB07723; CCG-108176; DS-3311; AK403360; SC-43672; BIM-0030775.P001; TR-055403; AX8188175
DMXLVG6	DT	Small molecular drug
DMXLVG6	PC	181137
DMXLVG6	MW	219.24
DMXLVG6	FM	C12H13NO3
DMXLVG6	IC	InChI=1S/C12H13NO3/c1-16-9-3-4-11-10(6-9)8(7-13-11)2-5-12(14)15/h3-4,6-7,13H,2,5H2,1H3,(H,14,15)
DMXLVG6	CS	COC1=CC2=C(C=C1)NC=C2CCC(=O)O
DMXLVG6	IK	ZLSZCJIWILJKMR-UHFFFAOYSA-N
DMXLVG6	IU	3-(5-methoxy-1H-indol-3-yl)propanoic acid
DMXLVG6	CA	CAS 39547-16-5
DMXLVG6	DE	Discovery agent

DM5NIE7	ID	DM5NIE7
DM5NIE7	DN	3-(5-phenyl-2-thienyl)phenol
DM5NIE7	HS	Investigative
DM5NIE7	SN	SCHEMBL1180118; CHEMBL457438; BDBM25847; 3-(5-phenylthiophen-2-yl)phenol; ZINC40847377; hydroxyphenyl substituted thiophene, 19
DM5NIE7	DT	Small molecular drug
DM5NIE7	PC	25093384
DM5NIE7	MW	252.3
DM5NIE7	FM	C16H12OS
DM5NIE7	IC	InChI=1S/C16H12OS/c17-14-8-4-7-13(11-14)16-10-9-15(18-16)12-5-2-1-3-6-12/h1-11,17H
DM5NIE7	CS	C1=CC=C(C=C1)C2=CC=C(S2)C3=CC(=CC=C3)O
DM5NIE7	IK	DVGFXRZFDOGHJL-UHFFFAOYSA-N
DM5NIE7	IU	3-(5-phenylthiophen-2-yl)phenol
DM5NIE7	DE	Discovery agent

DMPBLM2	ID	DMPBLM2
DMPBLM2	DN	3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMPBLM2	HS	Investigative
DMPBLM2	SN	3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile; GW627834A; 2-Anilino-5-aryloxazole 10; AC1NS7R5; BDBM5849; CHEMBL192413; NCGC00241897-01; AB01092081-01; N-(3-Cyanophenyl)-5-phenyl-1,3-oxazol-2-amine Hydrochloride
DMPBLM2	DT	Small molecular drug
DMPBLM2	PC	5329845
DMPBLM2	MW	261.279
DMPBLM2	FM	C16H11N3O
DMPBLM2	IC	InChI=1S/C16H11N3O/c17-10-12-5-4-8-14(9-12)19-16-18-11-15(20-16)13-6-2-1-3-7-13/h1-9,11H,(H,18,19)
DMPBLM2	CS	C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=CC(=C3)C#N
DMPBLM2	IK	VZMXZHOJAGFSNF-UHFFFAOYSA-N
DMPBLM2	IU	3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile
DMPBLM2	DE	Discovery agent

DMM1CKZ	ID	DMM1CKZ
DMM1CKZ	DN	3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile
DMM1CKZ	HS	Investigative
DMM1CKZ	SN	507268-13-5; CHEMBL365499; 3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile; 3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]Benzonitrile; 3-(5-(pyridin-2-yl)-2h-tetrazol-2-yl)benzonitrile; 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile; SCHEMBL660355; CTK1G6179; DTXSID70436690; OGIBYDWBTRKAOL-UHFFFAOYSA-N; ZINC3962980; BDBM50151907; AKOS015995227; RP28801; DA-05371; DB-050669; KB-233258; FT-0760671; J-510771; 3-[5-(2-Pyridinyl)-2H-tetrazole-2-yl]benzonitrile; Benzonitrile, 3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
DMM1CKZ	DT	Small molecular drug
DMM1CKZ	PC	10198811
DMM1CKZ	MW	248.24
DMM1CKZ	FM	C13H8N6
DMM1CKZ	IC	InChI=1S/C13H8N6/c14-9-10-4-3-5-11(8-10)19-17-13(16-18-19)12-6-1-2-7-15-12/h1-8H
DMM1CKZ	CS	C1=CC=NC(=C1)C2=NN(N=N2)C3=CC=CC(=C3)C#N
DMM1CKZ	IK	OGIBYDWBTRKAOL-UHFFFAOYSA-N
DMM1CKZ	IU	3-(5-pyridin-2-yltetrazol-2-yl)benzonitrile
DMM1CKZ	CA	CAS 507268-13-5
DMM1CKZ	DE	Discovery agent

DM9LVR5	ID	DM9LVR5
DM9LVR5	DN	3-(5-Thiophen-3-yl-pyridin-3-yl)-1H-indole
DM9LVR5	HS	Investigative
DM9LVR5	SN	3-(5-Thien-3-ylpyridin-3-yl)-1Hindole 3a; AC1NS6N5; SCHEMBL7506919; BDBM5318; CHEMBL327518; 3-[5-(3-Thienyl)-3-pyridinyl]-1H-indole; 3-(5-thiophen-3-ylpyridin-3-yl)-1H-indole
DM9LVR5	DT	Small molecular drug
DM9LVR5	PC	5329361
DM9LVR5	MW	276.4
DM9LVR5	FM	C17H12N2S
DM9LVR5	IC	InChI=1S/C17H12N2S/c1-2-4-17-15(3-1)16(10-19-17)14-7-13(8-18-9-14)12-5-6-20-11-12/h1-11,19H
DM9LVR5	CS	C1=CC=C2C(=C1)C(=CN2)C3=CN=CC(=C3)C4=CSC=C4
DM9LVR5	IK	GDLQJKCZVIUEDN-UHFFFAOYSA-N
DM9LVR5	IU	3-(5-thiophen-3-ylpyridin-3-yl)-1H-indole
DM9LVR5	DE	Discovery agent

DMADQCW	ID	DMADQCW
DMADQCW	DN	3-(6-(furan-2-yl)-4-phenylpyridin-2-yl)-phenol
DMADQCW	HS	Investigative
DMADQCW	SN	CHEMBL1095141
DMADQCW	DT	Small molecular drug
DMADQCW	PC	46887133
DMADQCW	MW	313.3
DMADQCW	FM	C21H15NO2
DMADQCW	IC	InChI=1S/C21H15NO2/c23-18-9-4-8-16(12-18)19-13-17(15-6-2-1-3-7-15)14-20(22-19)21-10-5-11-24-21/h1-14,23H
DMADQCW	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC=CO3)C4=CC(=CC=C4)O
DMADQCW	IK	CYYONTBOQHHDLF-UHFFFAOYSA-N
DMADQCW	IU	3-[6-(furan-2-yl)-4-phenylpyridin-2-yl]phenol
DMADQCW	DE	Discovery agent

DM8WL21	ID	DM8WL21
DM8WL21	DN	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile
DM8WL21	HS	Investigative
DM8WL21	SN	CHEMBL1210236; 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile; BDBM50322829
DM8WL21	DT	Small molecular drug
DM8WL21	PC	46894038
DM8WL21	MW	312.3
DM8WL21	FM	C18H12N6
DM8WL21	IC	InChI=1S/C18H12N6/c19-10-12-5-4-6-13(9-12)16-23-15-17(20-11-21-18(15)24-16)22-14-7-2-1-3-8-14/h1-9,11H,(H2,20,21,22,23,24)
DM8WL21	CS	C1=CC=C(C=C1)NC2=NC=NC3=C2NC(=N3)C4=CC=CC(=C4)C#N
DM8WL21	IK	JMBXPIFLNLGLKP-UHFFFAOYSA-N
DM8WL21	IU	3-(6-anilino-7H-purin-8-yl)benzonitrile
DM8WL21	DE	Discovery agent

DM4DFUS	ID	DM4DFUS
DM4DFUS	DN	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol
DM4DFUS	HS	Investigative
DM4DFUS	SN	CHEMBL101389; 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol; SCHEMBL6431286; CGIFTRWAYIWEGG-UHFFFAOYSA-N; BDBM50290850
DM4DFUS	DT	Small molecular drug
DM4DFUS	PC	22646527
DM4DFUS	MW	297.3
DM4DFUS	FM	C17H15NO4
DM4DFUS	IC	InChI=1S/C17H15NO4/c1-20-16-9-13-14(10-17(16)21-2)18-7-6-15(13)22-12-5-3-4-11(19)8-12/h3-10,19H,1-2H3
DM4DFUS	CS	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=CC(=C3)O
DM4DFUS	IK	CGIFTRWAYIWEGG-UHFFFAOYSA-N
DM4DFUS	IU	3-(6,7-dimethoxyquinolin-4-yl)oxyphenol
DM4DFUS	DE	Discovery agent

DMAWXV6	ID	DMAWXV6
DMAWXV6	DN	3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine
DMAWXV6	HS	Investigative
DMAWXV6	SN	CHEMBL321572; 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine; SCHEMBL7478985; ZINC13859457; BDBM50290846
DMAWXV6	DT	Small molecular drug
DMAWXV6	PC	22132655
DMAWXV6	MW	296.32
DMAWXV6	FM	C17H16N2O3
DMAWXV6	IC	InChI=1S/C17H16N2O3/c1-20-16-9-13-14(10-17(16)21-2)19-7-6-15(13)22-12-5-3-4-11(18)8-12/h3-10H,18H2,1-2H3
DMAWXV6	CS	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=CC(=C3)N
DMAWXV6	IK	KOTHQRYMXOUUHZ-UHFFFAOYSA-N
DMAWXV6	IU	3-(6,7-dimethoxyquinolin-4-yl)oxyaniline
DMAWXV6	DE	Discovery agent

DMISL9R	ID	DMISL9R
DMISL9R	DN	3-(6-Amino-purin-9-yl)-4-butoxy-butan-2-ol
DMISL9R	HS	Investigative
DMISL9R	SN	CHEMBL606665; ZINC13835548
DMISL9R	DT	Small molecular drug
DMISL9R	PC	44361699
DMISL9R	MW	279.34
DMISL9R	FM	C13H21N5O2
DMISL9R	IC	InChI=1S/C13H21N5O2/c1-3-4-5-20-6-10(9(2)19)18-8-17-11-12(14)15-7-16-13(11)18/h7-10,19H,3-6H2,1-2H3,(H2,14,15,16)/t9-,10?/m0/s1
DMISL9R	CS	CCCCOCC([C@H](C)O)N1C=NC2=C(N=CN=C21)N
DMISL9R	IK	JLZPQJZPCMKWRD-RGURZIINSA-N
DMISL9R	IU	(2S)-3-(6-aminopurin-9-yl)-4-butoxybutan-2-ol
DMISL9R	DE	Discovery agent

DMMTU78	ID	DMMTU78
DMMTU78	DN	3-(6-Amino-purin-9-yl)-4-phenethyloxy-butan-2-ol
DMMTU78	HS	Investigative
DMMTU78	SN	CHEMBL606664
DMMTU78	DT	Small molecular drug
DMMTU78	PC	44361680
DMMTU78	MW	327.4
DMMTU78	FM	C17H21N5O2
DMMTU78	IC	InChI=1S/C17H21N5O2/c1-12(23)14(9-24-8-7-13-5-3-2-4-6-13)22-11-21-15-16(18)19-10-20-17(15)22/h2-6,10-12,14,23H,7-9H2,1H3,(H2,18,19,20)/t12-,14?/m0/s1
DMMTU78	CS	C[C@@H](C(COCCC1=CC=CC=C1)N2C=NC3=C(N=CN=C32)N)O
DMMTU78	IK	AGLLOYCRAOLWDZ-NBFOIZRFSA-N
DMMTU78	IU	(2S)-3-(6-aminopurin-9-yl)-4-(2-phenylethoxy)butan-2-ol
DMMTU78	DE	Discovery agent

DMU08A4	ID	DMU08A4
DMU08A4	DN	3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol
DMU08A4	HS	Investigative
DMU08A4	SN	CHEMBL43261; 3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol; SCHEMBL7454006; BDBM50070640; ZINC13835542; (2S,3R)-3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol
DMU08A4	DT	Small molecular drug
DMU08A4	PC	10709134
DMU08A4	MW	297.35
DMU08A4	FM	C16H19N5O
DMU08A4	IC	InChI=1S/C16H19N5O/c1-10-3-5-12(6-4-10)7-13(11(2)22)21-9-20-14-15(17)18-8-19-16(14)21/h3-6,8-9,11,13,22H,7H2,1-2H3,(H2,17,18,19)/t11-,13+/m0/s1
DMU08A4	CS	CC1=CC=C(C=C1)C[C@H]([C@H](C)O)N2C=NC3=C(N=CN=C32)N
DMU08A4	IK	BHZLBHHOPOAOSL-WCQYABFASA-N
DMU08A4	IU	(2S,3R)-3-(6-aminopurin-9-yl)-4-(4-methylphenyl)butan-2-ol
DMU08A4	DE	Discovery agent

DMHXI21	ID	DMHXI21
DMHXI21	DN	3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol
DMHXI21	HS	Investigative
DMHXI21	SN	CHEMBL418074; 3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol; SCHEMBL7455950; ZINC13835543; BDBM50070643; (2S,3R)-3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol
DMHXI21	DT	Small molecular drug
DMHXI21	PC	10567019
DMHXI21	MW	311.4
DMHXI21	FM	C17H21N5O
DMHXI21	IC	InChI=1S/C17H21N5O/c1-11-4-3-5-13(8-11)6-7-14(12(2)23)22-10-21-15-16(18)19-9-20-17(15)22/h3-5,8-10,12,14,23H,6-7H2,1-2H3,(H2,18,19,20)/t12-,14+/m0/s1
DMHXI21	CS	CC1=CC(=CC=C1)CC[C@H]([C@H](C)O)N2C=NC3=C(N=CN=C32)N
DMHXI21	IK	VVISVMDMFZVYMH-GXTWGEPZSA-N
DMHXI21	IU	(2S,3R)-3-(6-aminopurin-9-yl)-5-(3-methylphenyl)pentan-2-ol
DMHXI21	DE	Discovery agent

DMYIZBK	ID	DMYIZBK
DMYIZBK	DN	3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol
DMYIZBK	HS	Investigative
DMYIZBK	SN	CHEMBL42063; 3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol; SCHEMBL7458391; BDBM50070641; (2S,3R)-3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol
DMYIZBK	DT	Small molecular drug
DMYIZBK	PC	9862110
DMYIZBK	MW	325.4
DMYIZBK	FM	C18H23N5O
DMYIZBK	IC	InChI=1S/C18H23N5O/c1-12-6-3-4-7-14(12)8-5-9-15(13(2)24)23-11-22-16-17(19)20-10-21-18(16)23/h3-4,6-7,10-11,13,15,24H,5,8-9H2,1-2H3,(H2,19,20,21)/t13-,15+/m0/s1
DMYIZBK	CS	CC1=CC=CC=C1CCC[C@H]([C@H](C)O)N2C=NC3=C(N=CN=C32)N
DMYIZBK	IK	GLTLCSYYROAISP-DZGCQCFKSA-N
DMYIZBK	IU	(2S,3R)-3-(6-aminopurin-9-yl)-6-(2-methylphenyl)hexan-2-ol
DMYIZBK	DE	Discovery agent

DMZT8QX	ID	DMZT8QX
DMZT8QX	DN	3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol
DMZT8QX	HS	Investigative
DMZT8QX	SN	CHEMBL295417; 3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol; SCHEMBL7459663; ZINC13835544; BDBM50070642; (2S,3R)-3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol
DMZT8QX	DT	Small molecular drug
DMZT8QX	PC	10543066
DMZT8QX	MW	311.4
DMZT8QX	FM	C17H21N5O
DMZT8QX	IC	InChI=1S/C17H21N5O/c1-12(23)14(9-5-8-13-6-3-2-4-7-13)22-11-21-15-16(18)19-10-20-17(15)22/h2-4,6-7,10-12,14,23H,5,8-9H2,1H3,(H2,18,19,20)/t12-,14+/m0/s1
DMZT8QX	CS	C[C@@H]([C@@H](CCCC1=CC=CC=C1)N2C=NC3=C(N=CN=C32)N)O
DMZT8QX	IK	KTRFRUCNFHFSAF-GXTWGEPZSA-N
DMZT8QX	IU	(2S,3R)-3-(6-aminopurin-9-yl)-6-phenylhexan-2-ol
DMZT8QX	DE	Discovery agent

DMUYELJ	ID	DMUYELJ
DMUYELJ	DN	3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol
DMUYELJ	HS	Investigative
DMUYELJ	SN	CHEMBL295003; 3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol; SCHEMBL7458479; BDBM50070646; ZINC13835546; (2S,3R)-3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol
DMUYELJ	DT	Small molecular drug
DMUYELJ	PC	10404061
DMUYELJ	MW	325.4
DMUYELJ	FM	C18H23N5O
DMUYELJ	IC	InChI=1S/C18H23N5O/c1-13(24)15(10-6-5-9-14-7-3-2-4-8-14)23-12-22-16-17(19)20-11-21-18(16)23/h2-4,7-8,11-13,15,24H,5-6,9-10H2,1H3,(H2,19,20,21)/t13-,15+/m0/s1
DMUYELJ	CS	C[C@@H]([C@@H](CCCCC1=CC=CC=C1)N2C=NC3=C(N=CN=C32)N)O
DMUYELJ	IK	HWARBJPXURXCIU-DZGCQCFKSA-N
DMUYELJ	IU	(2S,3R)-3-(6-aminopurin-9-yl)-7-phenylheptan-2-ol
DMUYELJ	DE	Discovery agent

DMAIS1D	ID	DMAIS1D
DMAIS1D	DN	3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol
DMAIS1D	HS	Investigative
DMAIS1D	SN	CHEMBL43742; 3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol; SCHEMBL7458088; ZINC13835547; BDBM50070645; (2S,3R)-3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol
DMAIS1D	DT	Small molecular drug
DMAIS1D	PC	10593196
DMAIS1D	MW	339.4
DMAIS1D	FM	C19H25N5O
DMAIS1D	IC	InChI=1S/C19H25N5O/c1-14(25)16(11-7-3-6-10-15-8-4-2-5-9-15)24-13-23-17-18(20)21-12-22-19(17)24/h2,4-5,8-9,12-14,16,25H,3,6-7,10-11H2,1H3,(H2,20,21,22)/t14-,16+/m0/s1
DMAIS1D	CS	C[C@@H]([C@@H](CCCCCC1=CC=CC=C1)N2C=NC3=C(N=CN=C32)N)O
DMAIS1D	IK	JVHQYTUGDFGNES-GOEBONIOSA-N
DMAIS1D	IU	(2S,3R)-3-(6-aminopurin-9-yl)-8-phenyloctan-2-ol
DMAIS1D	DE	Discovery agent

DM6FHWZ	ID	DM6FHWZ
DM6FHWZ	DN	3-(6-Amino-purin-9-yl)-non-5-en-2-ol
DM6FHWZ	HS	Investigative
DM6FHWZ	SN	CHEMBL81390; 3-(6-Amino-purin-9-yl)-non-5-en-2-ol; BDBM50288072; (Z)-(2S,3R)-3-(6-Amino-purin-9-yl)-non-5-en-2-ol
DM6FHWZ	DT	Small molecular drug
DM6FHWZ	PC	10516542
DM6FHWZ	MW	275.35
DM6FHWZ	FM	C14H21N5O
DM6FHWZ	IC	InChI=1S/C14H21N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h5-6,8-11,20H,3-4,7H2,1-2H3,(H2,15,16,17)/b6-5+/t10-,11+/m0/s1
DM6FHWZ	CS	CCC/C=C/C[C@H]([C@H](C)O)N1C=NC2=C(N=CN=C21)N
DM6FHWZ	IK	QZMKAUPEGUOLDB-PFDYWKIBSA-N
DM6FHWZ	IU	(E,2S,3R)-3-(6-aminopurin-9-yl)non-5-en-2-ol
DM6FHWZ	DE	Discovery agent

DM0YOZJ	ID	DM0YOZJ
DM0YOZJ	DN	3-(6-Amino-purin-9-yl)-non-5-yn-2-ol
DM0YOZJ	HS	Investigative
DM0YOZJ	SN	CHEMBL311182; 3-(6-Amino-purin-9-yl)-non-5-yn-2-ol; BDBM50288071; (2S,3R)-3-(6-Amino-purin-9-yl)-non-5-yn-2-ol
DM0YOZJ	DT	Small molecular drug
DM0YOZJ	PC	10754736
DM0YOZJ	MW	273.33
DM0YOZJ	FM	C14H19N5O
DM0YOZJ	IC	InChI=1S/C14H19N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-4,7H2,1-2H3,(H2,15,16,17)/t10-,11+/m0/s1
DM0YOZJ	CS	CCCC#CC[C@H]([C@H](C)O)N1C=NC2=C(N=CN=C21)N
DM0YOZJ	IK	GXOXTRCBYSFJKS-WDEREUQCSA-N
DM0YOZJ	IU	(2S,3R)-3-(6-aminopurin-9-yl)non-5-yn-2-ol
DM0YOZJ	DE	Discovery agent

DM63BI9	ID	DM63BI9
DM63BI9	DN	3-(6-Bromo-naphthalen-2-yl)-pyridine
DM63BI9	HS	Investigative
DM63BI9	SN	3-(6-bromonaphthalen-2-yl)pyridine; BDBM8907; SCHEMBL4499954; CHEMBL193534; 3-(6-bromo-2-naphthyl)pyridine; Pyridine-substituted naphthalene 4
DM63BI9	DT	Small molecular drug
DM63BI9	PC	11558270
DM63BI9	MW	284.15
DM63BI9	FM	C15H10BrN
DM63BI9	IC	InChI=1S/C15H10BrN/c16-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-17-10-14/h1-10H
DM63BI9	CS	C1=CC(=CN=C1)C2=CC3=C(C=C2)C=C(C=C3)Br
DM63BI9	IK	MAIJPIYXFRLIEK-UHFFFAOYSA-N
DM63BI9	IU	3-(6-bromonaphthalen-2-yl)pyridine
DM63BI9	DE	Discovery agent

DMUQ0WI	ID	DMUQ0WI
DMUQ0WI	DN	3-(6-Ethoxy-naphthalen-2-yl)-pyridine
DMUQ0WI	HS	Investigative
DMUQ0WI	SN	3-(6-ethoxynaphthalen-2-yl)pyridine; SCHEMBL4511117; BDBM8908; CHEMBL193343; 3-(6-ethoxy-2-naphthyl)pyridine; Pyridine-substituted naphthalene 5
DMUQ0WI	DT	Small molecular drug
DMUQ0WI	PC	11557864
DMUQ0WI	MW	249.31
DMUQ0WI	FM	C17H15NO
DMUQ0WI	IC	InChI=1S/C17H15NO/c1-2-19-17-8-7-13-10-14(5-6-15(13)11-17)16-4-3-9-18-12-16/h3-12H,2H2,1H3
DMUQ0WI	CS	CCOC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC=C3
DMUQ0WI	IK	CQLHDOYGDGBDQA-UHFFFAOYSA-N
DMUQ0WI	IU	3-(6-ethoxynaphthalen-2-yl)pyridine
DMUQ0WI	DE	Discovery agent

DMHJ0SV	ID	DMHJ0SV
DMHJ0SV	DN	3-(6-fluoroquinazolin-4-ylamino)benzonitrile
DMHJ0SV	HS	Investigative
DMHJ0SV	SN	CHEMBL1080128; 3-(6-fluoroquinazolin-4-ylamino)benzonitrile; BDBM50311855
DMHJ0SV	DT	Small molecular drug
DMHJ0SV	PC	46879811
DMHJ0SV	MW	264.26
DMHJ0SV	FM	C15H9FN4
DMHJ0SV	IC	InChI=1S/C15H9FN4/c16-11-4-5-14-13(7-11)15(19-9-18-14)20-12-3-1-2-10(6-12)8-17/h1-7,9H,(H,18,19,20)
DMHJ0SV	CS	C1=CC(=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)F)C#N
DMHJ0SV	IK	NWRSWZMZACUZPY-UHFFFAOYSA-N
DMHJ0SV	IU	3-[(6-fluoroquinazolin-4-yl)amino]benzonitrile
DMHJ0SV	DE	Discovery agent

DMTIKF7	ID	DMTIKF7
DMTIKF7	DN	3-(6-hydroxy-2-naphthyl)benzoic acid
DMTIKF7	HS	Investigative
DMTIKF7	SN	SCHEMBL3020903
DMTIKF7	DT	Small molecular drug
DMTIKF7	PC	24827299
DMTIKF7	MW	264.27
DMTIKF7	FM	C17H12O3
DMTIKF7	IC	InChI=1S/C17H12O3/c18-16-7-6-13-8-12(4-5-14(13)10-16)11-2-1-3-15(9-11)17(19)20/h1-10,18H,(H,19,20)
DMTIKF7	CS	C1=CC(=CC(=C1)C(=O)O)C2=CC3=C(C=C2)C=C(C=C3)O
DMTIKF7	IK	QKQDCOMEKVAYFS-UHFFFAOYSA-N
DMTIKF7	IU	3-(6-hydroxynaphthalen-2-yl)benzoic acid
DMTIKF7	DE	Discovery agent

DM5H9QT	ID	DM5H9QT
DM5H9QT	DN	3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DM5H9QT	HS	Investigative
DM5H9QT	DT	Small molecular drug
DM5H9QT	PC	135430305
DM5H9QT	MW	243.21
DM5H9QT	FM	C13H9NO4
DM5H9QT	IC	InChI=1S/C13H9NO4/c15-7-4-5-9-11(6-7)18-13(14-9)8-2-1-3-10(16)12(8)17/h1-6,15-17H
DM5H9QT	CS	C1=CC(=C(C(=C1)O)O)C2=NC3=C(O2)C=C(C=C3)O
DM5H9QT	IK	MRXLNZKXLFWEGB-UHFFFAOYSA-N
DM5H9QT	IU	3-(6-hydroxy-1,3-benzoxazol-2-yl)benzene-1,2-diol
DM5H9QT	DE	Discovery agent

DMAJHXO	ID	DMAJHXO
DMAJHXO	DN	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DMAJHXO	HS	Investigative
DMAJHXO	SN	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine; CHEMBL206351; Dihydronaphthalene 4; AC1O70H9; SCHEMBL4504105; BDBM8891
DMAJHXO	DT	Small molecular drug
DMAJHXO	PC	6540049
DMAJHXO	MW	237.3
DMAJHXO	FM	C16H15NO
DMAJHXO	IC	InChI=1S/C16H15NO/c1-18-16-7-6-12-9-13(4-5-14(12)10-16)15-3-2-8-17-11-15/h2-3,6-11H,4-5H2,1H3
DMAJHXO	CS	COC1=CC2=C(C=C1)C=C(CC2)C3=CN=CC=C3
DMAJHXO	IK	WUTGTMFGCHNUET-UHFFFAOYSA-N
DMAJHXO	IU	3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DMAJHXO	DE	Discovery agent

DMISLV4	ID	DMISLV4
DMISLV4	DN	3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine
DMISLV4	HS	Investigative
DMISLV4	SN	CHEMBL499871; 3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine; BDBM50272194
DMISLV4	DT	Small molecular drug
DMISLV4	PC	44586852
DMISLV4	MW	249.31
DMISLV4	FM	C17H15NO
DMISLV4	IC	InChI=1S/C17H15NO/c1-12-8-15-9-16(19-2)6-5-13(15)10-17(12)14-4-3-7-18-11-14/h3-11H,1-2H3
DMISLV4	CS	CC1=CC2=C(C=CC(=C2)OC)C=C1C3=CN=CC=C3
DMISLV4	IK	YGFDDQOJFLQBKT-UHFFFAOYSA-N
DMISLV4	IU	3-(6-methoxy-3-methylnaphthalen-2-yl)pyridine
DMISLV4	DE	Discovery agent

DM0GXFB	ID	DM0GXFB
DM0GXFB	DN	3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine
DM0GXFB	HS	Investigative
DM0GXFB	SN	CHEMBL500664; 3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine; ZINC40976977
DM0GXFB	DT	Small molecular drug
DM0GXFB	PC	25034430
DM0GXFB	MW	249.31
DM0GXFB	FM	C17H15NO
DM0GXFB	IC	InChI=1S/C17H15NO/c1-12-7-8-18-11-17(12)15-4-3-14-10-16(19-2)6-5-13(14)9-15/h3-11H,1-2H3
DM0GXFB	CS	CC1=C(C=NC=C1)C2=CC3=C(C=C2)C=C(C=C3)OC
DM0GXFB	IK	DBZOUPBQQHJUKL-UHFFFAOYSA-N
DM0GXFB	IU	3-(6-methoxynaphthalen-2-yl)-4-methylpyridine
DM0GXFB	DE	Discovery agent

DM704R5	ID	DM704R5
DM704R5	DN	3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine
DM704R5	HS	Investigative
DM704R5	SN	CHEMBL500393; 3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine
DM704R5	DT	Small molecular drug
DM704R5	PC	25034426
DM704R5	MW	311.4
DM704R5	FM	C22H17NO
DM704R5	IC	InChI=1S/C22H17NO/c1-24-22-10-9-17-11-18(7-8-19(17)13-22)21-12-20(14-23-15-21)16-5-3-2-4-6-16/h2-15H,1H3
DM704R5	CS	COC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC(=C3)C4=CC=CC=C4
DM704R5	IK	SQTORKYTOSOTPB-UHFFFAOYSA-N
DM704R5	IU	3-(6-methoxynaphthalen-2-yl)-5-phenylpyridine
DM704R5	DE	Discovery agent

DMN75RD	ID	DMN75RD
DMN75RD	DN	3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine
DMN75RD	HS	Investigative
DMN75RD	SN	CHEMBL453169; 3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine; ZINC40835651; BDBM50272248
DMN75RD	DT	Small molecular drug
DMN75RD	PC	25034431
DMN75RD	MW	250.29
DMN75RD	FM	C16H14N2O
DMN75RD	IC	InChI=1S/C16H14N2O/c1-19-14-5-4-11-8-13(3-2-12(11)9-14)15-10-18-7-6-16(15)17/h2-10H,1H3,(H2,17,18)
DMN75RD	CS	COC1=CC2=C(C=C1)C=C(C=C2)C3=C(C=CN=C3)N
DMN75RD	IK	WAIWXNYKRBBVSH-UHFFFAOYSA-N
DMN75RD	IU	3-(6-methoxynaphthalen-2-yl)pyridin-4-amine
DMN75RD	DE	Discovery agent

DMYRJAB	ID	DMYRJAB
DMYRJAB	DN	3-(6-methoxynaphthalen-2-yl)pyridine
DMYRJAB	HS	Investigative
DMYRJAB	SN	CHEMBL362968; 3-(6-methoxynaphthalen-2-yl)pyridine; BDBM8905; SCHEMBL4500403; Pyridine-substituted naphthalene 2; 3-(6-methoxy-2-naphthyl)pyridine
DMYRJAB	DT	Small molecular drug
DMYRJAB	PC	11506923
DMYRJAB	MW	235.28
DMYRJAB	FM	C16H13NO
DMYRJAB	IC	InChI=1S/C16H13NO/c1-18-16-7-6-12-9-13(4-5-14(12)10-16)15-3-2-8-17-11-15/h2-11H,1H3
DMYRJAB	CS	COC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC=C3
DMYRJAB	IK	DCVWYSMRLGKIJB-UHFFFAOYSA-N
DMYRJAB	IU	3-(6-methoxynaphthalen-2-yl)pyridine
DMYRJAB	DE	Discovery agent

DMS9DPO	ID	DMS9DPO
DMS9DPO	DN	3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzaldehyde
DMS9DPO	HS	Investigative
DMS9DPO	SN	CHEMBL223437; 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzaldehyde; SCHEMBL3535188
DMS9DPO	DT	Small molecular drug
DMS9DPO	PC	16203472
DMS9DPO	MW	285.29
DMS9DPO	FM	C16H15NO4
DMS9DPO	IC	InChI=1S/C16H15NO4/c18-11-12-2-1-3-13(8-12)15-9-14(19)10-16(21-15)17-4-6-20-7-5-17/h1-3,8-11H,4-7H2
DMS9DPO	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC(=C3)C=O
DMS9DPO	IK	JXTKUJIDCHLXDV-UHFFFAOYSA-N
DMS9DPO	IU	3-(6-morpholin-4-yl-4-oxopyran-2-yl)benzaldehyde
DMS9DPO	DE	Discovery agent

DM2VNLK	ID	DM2VNLK
DM2VNLK	DN	3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzoic acid
DM2VNLK	HS	Investigative
DM2VNLK	SN	CHEMBL222180; 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzoic acid; SCHEMBL13435565
DM2VNLK	DT	Small molecular drug
DM2VNLK	PC	16203474
DM2VNLK	MW	301.29
DM2VNLK	FM	C16H15NO5
DM2VNLK	IC	InChI=1S/C16H15NO5/c18-13-9-14(11-2-1-3-12(8-11)16(19)20)22-15(10-13)17-4-6-21-7-5-17/h1-3,8-10H,4-7H2,(H,19,20)
DM2VNLK	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC(=CC=C3)C(=O)O
DM2VNLK	IK	DIBMCWVULMJJDM-UHFFFAOYSA-N
DM2VNLK	IU	3-(6-morpholin-4-yl-4-oxopyran-2-yl)benzoic acid
DM2VNLK	DE	Discovery agent

DM2J63V	ID	DM2J63V
DM2J63V	DN	3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM2J63V	HS	Investigative
DM2J63V	SN	CHEMBL223034; 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM2J63V	DT	Small molecular drug
DM2J63V	PC	16203599
DM2J63V	MW	282.29
DM2J63V	FM	C16H14N2O3
DM2J63V	IC	InChI=1S/C16H14N2O3/c17-11-12-2-1-3-13(8-12)15-9-14(19)10-16(21-15)18-4-6-20-7-5-18/h1-3,8-10H,4-7H2
DM2J63V	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC(=C3)C#N
DM2J63V	IK	IBXUISQIAHYEGD-UHFFFAOYSA-N
DM2J63V	IU	3-(6-morpholin-4-yl-4-oxopyran-2-yl)benzonitrile
DM2J63V	DE	Discovery agent

DMS2OY9	ID	DMS2OY9
DMS2OY9	DN	3-(6-morpholino-9H-purin-2-yl)phenol
DMS2OY9	HS	Investigative
DMS2OY9	SN	3-(6-morpholino-9H-purin-2-yl)phenol; CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N
DMS2OY9	DT	Small molecular drug
DMS2OY9	PC	16049458
DMS2OY9	MW	297.31
DMS2OY9	FM	C15H15N5O2
DMS2OY9	IC	InChI=1S/C15H15N5O2/c21-11-3-1-2-10(8-11)13-18-14-12(16-9-17-14)15(19-13)20-4-6-22-7-5-20/h1-3,8-9,21H,4-7H2,(H,16,17,18,19)
DMS2OY9	CS	C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC(=CC=C4)O
DMS2OY9	IK	FUDQNOGEMXSUSQ-UHFFFAOYSA-N
DMS2OY9	IU	3-(6-morpholin-4-yl-7H-purin-2-yl)phenol
DMS2OY9	DE	Discovery agent

DM8ZUBY	ID	DM8ZUBY
DM8ZUBY	DN	3-(6-phenyl-2,4'-bipyridin-4-yl)phenol
DM8ZUBY	HS	Investigative
DM8ZUBY	SN	CHEMBL1094095
DM8ZUBY	DT	Small molecular drug
DM8ZUBY	PC	46887284
DM8ZUBY	MW	324.4
DM8ZUBY	FM	C22H16N2O
DM8ZUBY	IC	InChI=1S/C22H16N2O/c25-20-8-4-7-18(13-20)19-14-21(16-5-2-1-3-6-16)24-22(15-19)17-9-11-23-12-10-17/h1-15,25H
DM8ZUBY	CS	C1=CC=C(C=C1)C2=NC(=CC(=C2)C3=CC(=CC=C3)O)C4=CC=NC=C4
DM8ZUBY	IK	DFVGOMXQSFFZEA-UHFFFAOYSA-N
DM8ZUBY	IU	3-(2-phenyl-6-pyridin-4-ylpyridin-4-yl)phenol
DM8ZUBY	DE	Discovery agent

DMZ53N4	ID	DMZ53N4
DMZ53N4	DN	3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile
DMZ53N4	HS	Investigative
DMZ53N4	SN	CHEMBL235837; 3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile
DMZ53N4	DT	Small molecular drug
DMZ53N4	PC	44434734
DMZ53N4	MW	245.28
DMZ53N4	FM	C16H11N3
DMZ53N4	IC	InChI=1S/C16H11N3/c1-11-5-6-13-7-8-15(19-16(13)18-11)14-4-2-3-12(9-14)10-17/h2-9H,1H3
DMZ53N4	CS	CC1=NC2=C(C=C1)C=CC(=N2)C3=CC=CC(=C3)C#N
DMZ53N4	IK	LAVFGKYBDJIZSF-UHFFFAOYSA-N
DMZ53N4	IU	3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile
DMZ53N4	DE	Discovery agent

DMDIQ7H	ID	DMDIQ7H
DMDIQ7H	DN	3-(9-Acridinylamino)-5-(hydroxymethyl)aniline (AHMA)
DMDIQ7H	HS	Investigative
DMDIQ7H	SN	CHEMBL321473; NSC666097; 3-(9-acridinylamino)-5-(hydroxymethyl)aniline; 154310-42-6; [3-(acridin-9-ylamino)-5-aminophenyl]methanol; AC1Q7C6S; AC1L8FG4; SCHEMBL1865418; CTK0E7866; DTXSID30327555; GZHHMAFXYHPHBO-UHFFFAOYSA-N; ZINC3799478; AKOS030584742; NCI60_022917; 3-(9-acridinylamino)-5-hydroxymethylaniline; 3-(acridin-9-yl)amino-5-hydroxymethylaniline; Benzenemethanol, 3-(9-acridinylamino)-5-amino-; [3-(acridin-9-ylamino)-5-amino-phenyl]methanol
DMDIQ7H	DT	Small molecular drug
DMDIQ7H	PC	380482
DMDIQ7H	MW	315.4
DMDIQ7H	FM	C20H17N3O
DMDIQ7H	IC	InChI=1S/C20H17N3O/c21-14-9-13(12-24)10-15(11-14)22-20-16-5-1-3-7-18(16)23-19-8-4-2-6-17(19)20/h1-11,24H,12,21H2,(H,22,23)
DMDIQ7H	CS	C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC(=CC(=C4)N)CO
DMDIQ7H	IK	GZHHMAFXYHPHBO-UHFFFAOYSA-N
DMDIQ7H	IU	[3-(acridin-9-ylamino)-5-aminophenyl]methanol
DMDIQ7H	CA	CAS 154310-42-6
DMDIQ7H	DE	Discovery agent

DM5497S	ID	DM5497S
DM5497S	DN	3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM5497S	HS	Investigative
DM5497S	SN	CHEMBL382876; 3-aminomethyl-4-furan-2-yl-butyric acid; 311803-95-9; 3-(aminomethyl)-4-(furan-2-yl)butanoic acid; SCHEMBL6375245; BDBM50171795
DM5497S	DT	Small molecular drug
DM5497S	PC	10130245
DM5497S	MW	183.2
DM5497S	FM	C9H13NO3
DM5497S	IC	InChI=1S/C9H13NO3/c10-6-7(5-9(11)12)4-8-2-1-3-13-8/h1-3,7H,4-6,10H2,(H,11,12)
DM5497S	CS	C1=COC(=C1)CC(CC(=O)O)CN
DM5497S	IK	JASKMEUWYOXVFB-UHFFFAOYSA-N
DM5497S	IU	3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM5497S	DE	Discovery agent

DMG3FPJ	ID	DMG3FPJ
DMG3FPJ	DN	3-(aminomethyl)-4-(furan-3-yl)butanoic acid
DMG3FPJ	HS	Investigative
DMG3FPJ	SN	CHEMBL381742; 3-aminomethyl-4-(furan-3-yl)butyric acid; 311804-13-4; 3-(aminomethyl)-4-(furan-3-yl)butanoic acid; SCHEMBL6376423
DMG3FPJ	DT	Small molecular drug
DMG3FPJ	PC	9794064
DMG3FPJ	MW	183.2
DMG3FPJ	FM	C9H13NO3
DMG3FPJ	IC	InChI=1S/C9H13NO3/c10-5-8(4-9(11)12)3-7-1-2-13-6-7/h1-2,6,8H,3-5,10H2,(H,11,12)
DMG3FPJ	CS	C1=COC=C1CC(CC(=O)O)CN
DMG3FPJ	IK	CZUZSIQSURACNQ-UHFFFAOYSA-N
DMG3FPJ	IU	3-(aminomethyl)-4-(furan-3-yl)butanoic acid
DMG3FPJ	DE	Discovery agent

DMT72FB	ID	DMT72FB
DMT72FB	DN	3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid
DMT72FB	HS	Investigative
DMT72FB	SN	CHEMBL208302; 3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid; SCHEMBL6377686; BDBM50171789
DMT72FB	DT	Small molecular drug
DMT72FB	PC	10198102
DMT72FB	MW	199.27
DMT72FB	FM	C9H13NO2S
DMT72FB	IC	InChI=1S/C9H13NO2S/c10-6-7(5-9(11)12)4-8-2-1-3-13-8/h1-3,7H,4-6,10H2,(H,11,12)
DMT72FB	CS	C1=CSC(=C1)CC(CC(=O)O)CN
DMT72FB	IK	BSTBHLRENZEVEM-UHFFFAOYSA-N
DMT72FB	IU	3-(aminomethyl)-4-thiophen-2-ylbutanoic acid
DMT72FB	DE	Discovery agent

DMWO1Z7	ID	DMWO1Z7
DMWO1Z7	DN	3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid
DMWO1Z7	HS	Investigative
DMWO1Z7	SN	CHEMBL382417; 3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid; SCHEMBL6376202
DMWO1Z7	DT	Small molecular drug
DMWO1Z7	PC	10198101
DMWO1Z7	MW	199.27
DMWO1Z7	FM	C9H13NO2S
DMWO1Z7	IC	InChI=1S/C9H13NO2S/c10-5-8(4-9(11)12)3-7-1-2-13-6-7/h1-2,6,8H,3-5,10H2,(H,11,12)
DMWO1Z7	CS	C1=CSC=C1CC(CC(=O)O)CN
DMWO1Z7	IK	DZFWQAKTRWBNFX-UHFFFAOYSA-N
DMWO1Z7	IU	3-(aminomethyl)-4-thiophen-3-ylbutanoic acid
DMWO1Z7	DE	Discovery agent

DMPFH15	ID	DMPFH15
DMPFH15	DN	3-(Aminooxy)propan-1-amine hydrochloride
DMPFH15	HS	Investigative
DMPFH15	SN	CHEMBL1209776
DMPFH15	DT	Small molecular drug
DMPFH15	PC	49862725
DMPFH15	MW	126.58
DMPFH15	FM	C3H11ClN2O
DMPFH15	IC	InChI=1S/C3H10N2O.ClH/c4-2-1-3-6-5;/h1-5H2;1H
DMPFH15	CS	C(CN)CON.Cl
DMPFH15	IK	KJXCRFUWQRHVMV-UHFFFAOYSA-N
DMPFH15	IU	O-(3-aminopropyl)hydroxylamine;hydrochloride
DMPFH15	DE	Discovery agent

DM58GRA	ID	DM58GRA
DM58GRA	DN	3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine
DM58GRA	HS	Investigative
DM58GRA	SN	CHEMBL486537; 3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine; SCHEMBL984632; VVROCSNBKQTQEO-UHFFFAOYSA-N; BDBM50275440
DM58GRA	DT	Small molecular drug
DM58GRA	PC	44231007
DM58GRA	MW	293.4
DM58GRA	FM	C19H19NS
DM58GRA	IC	InChI=1S/C19H19NS/c1-2-4-15(5-3-1)13-19(9-10-20-14-19)17-6-7-18-16(12-17)8-11-21-18/h1-8,11-12,20H,9-10,13-14H2
DM58GRA	CS	C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)SC=C4
DM58GRA	IK	VVROCSNBKQTQEO-UHFFFAOYSA-N
DM58GRA	IU	3-(1-benzothiophen-5-yl)-3-benzylpyrrolidine
DM58GRA	DE	Discovery agent

DMPFH8U	ID	DMPFH8U
DMPFH8U	DN	3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate
DMPFH8U	HS	Investigative
DMPFH8U	SN	CHEMBL573871; 3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate
DMPFH8U	DT	Small molecular drug
DMPFH8U	PC	44244229
DMPFH8U	MW	296.32
DMPFH8U	FM	C17H16N2O3
DMPFH8U	IC	InChI=1S/C17H16N2O3/c1-2-10-18-17(20)21-13-7-5-6-12(11-13)16-19-14-8-3-4-9-15(14)22-16/h3-9,11H,2,10H2,1H3,(H,18,20)
DMPFH8U	CS	CCCNC(=O)OC1=CC=CC(=C1)C2=NC3=CC=CC=C3O2
DMPFH8U	IK	VWTFAQPOTOAJGW-UHFFFAOYSA-N
DMPFH8U	IU	[3-(1,3-benzoxazol-2-yl)phenyl] N-propylcarbamate
DMPFH8U	DE	Discovery agent

DMD4WHN	ID	DMD4WHN
DMD4WHN	DN	3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one
DMD4WHN	HS	Investigative
DMD4WHN	SN	CHEMBL217096; 921611-01-0; 3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one; CTK3H0755; DTXSID50658813; BDBM50198243; AKOS030551987; 4-Thiazolidinone, 2-(4-chlorophenyl)-3-(phenylmethoxy)-
DMD4WHN	DT	Small molecular drug
DMD4WHN	PC	44418147
DMD4WHN	MW	319.8
DMD4WHN	FM	C16H14ClNO2S
DMD4WHN	IC	InChI=1S/C16H14ClNO2S/c17-14-8-6-13(7-9-14)16-18(15(19)11-21-16)20-10-12-4-2-1-3-5-12/h1-9,16H,10-11H2
DMD4WHN	CS	C1C(=O)N(C(S1)C2=CC=C(C=C2)Cl)OCC3=CC=CC=C3
DMD4WHN	IK	HYDHJKJHWORBLX-UHFFFAOYSA-N
DMD4WHN	IU	2-(4-chlorophenyl)-3-phenylmethoxy-1,3-thiazolidin-4-one
DMD4WHN	CA	CAS 921611-01-0
DMD4WHN	DE	Discovery agent

DMDNEKR	ID	DMDNEKR
DMDNEKR	DN	3-(benzyloxy)-9H-pyrido[3,4-b]indole
DMDNEKR	HS	Investigative
DMDNEKR	SN	CHEMBL87331; 3-Benzyloxy-9H-beta-carboline; SCHEMBL10641576; BDBM50001481; ZINC13728535
DMDNEKR	DT	Small molecular drug
DMDNEKR	PC	10335601
DMDNEKR	MW	274.3
DMDNEKR	FM	C18H14N2O
DMDNEKR	IC	InChI=1S/C18H14N2O/c1-2-6-13(7-3-1)12-21-18-10-15-14-8-4-5-9-16(14)20-17(15)11-19-18/h1-11,20H,12H2
DMDNEKR	CS	C1=CC=C(C=C1)COC2=NC=C3C(=C2)C4=CC=CC=C4N3
DMDNEKR	IK	ZROLETFFKMIVMZ-UHFFFAOYSA-N
DMDNEKR	IU	3-phenylmethoxy-9H-pyrido[3,4-b]indole
DMDNEKR	DE	Discovery agent

DM35VEI	ID	DM35VEI
DM35VEI	DN	3-(Benzyloxy)Pyridin-2-Amine
DM35VEI	HS	Investigative
DM35VEI	SN	2-Amino-3-benzyloxypyridine; 24016-03-3; 3-(BENZYLOXY)PYRIDIN-2-AMINE; 3-Benzyloxy-2-pyridylamine; 2-Pyridinamine, 3-(phenylmethoxy)-; 3-benzyloxypyridin-2-amine; 3-Benzyloxy-2-aminopyridine; 2-amino-3-benzyloxy pyridine; 3-phenylmethoxypyridin-2-amine; 2-Amino-3-(benzyloxy)pyridine; 3-(phenylmethoxy)-2-pyridinamine; MFCD00006316; 3IP; 3-(phenylmethoxy)-2-pyridylamine; 2-Amino-3-benzyloxypyridine, 98.5%; 3-(benzyloxy)pyridin-2-amin; 3fty; EINECS 245-983-9; PubChem2575; 1w7h; ACMC-1COKO; AC1L3JRI; Maybridge1_001801; AC1Q52WQ
DM35VEI	DT	Small molecular drug
DM35VEI	PC	90334
DM35VEI	MW	200.24
DM35VEI	FM	C12H12N2O
DM35VEI	IC	InChI=1S/C12H12N2O/c13-12-11(7-4-8-14-12)15-9-10-5-2-1-3-6-10/h1-8H,9H2,(H2,13,14)
DM35VEI	CS	C1=CC=C(C=C1)COC2=C(N=CC=C2)N
DM35VEI	IK	NMCBWICNRJLKKM-UHFFFAOYSA-N
DM35VEI	IU	3-phenylmethoxypyridin-2-amine
DM35VEI	CA	CAS 24016-03-3
DM35VEI	DE	Discovery agent

DM4GWJO	ID	DM4GWJO
DM4GWJO	DN	3-(biphenyl-4-yl)-1-(oxazol-2-yl)propan-1-one
DM4GWJO	HS	Investigative
DM4GWJO	SN	CHEMBL261172
DM4GWJO	DT	Small molecular drug
DM4GWJO	PC	24801394
DM4GWJO	MW	277.3
DM4GWJO	FM	C18H15NO2
DM4GWJO	IC	InChI=1S/C18H15NO2/c20-17(18-19-12-13-21-18)11-8-14-6-9-16(10-7-14)15-4-2-1-3-5-15/h1-7,9-10,12-13H,8,11H2
DM4GWJO	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCC(=O)C3=NC=CO3
DM4GWJO	IK	RKXYRLSZCAAEPX-UHFFFAOYSA-N
DM4GWJO	IU	1-(1,3-oxazol-2-yl)-3-(4-phenylphenyl)propan-1-one
DM4GWJO	DE	Discovery agent

DM8PM0E	ID	DM8PM0E
DM8PM0E	DN	3-(butylsulfinyl)-1,1,1-trifluoropropan-2-one
DM8PM0E	HS	Investigative
DM8PM0E	SN	CHEMBL403288
DM8PM0E	DT	Small molecular drug
DM8PM0E	PC	44455868
DM8PM0E	MW	216.22
DM8PM0E	FM	C7H11F3O2S
DM8PM0E	IC	InChI=1S/C7H11F3O2S/c1-2-3-4-13(12)5-6(11)7(8,9)10/h2-5H2,1H3
DM8PM0E	CS	CCCCS(=O)CC(=O)C(F)(F)F
DM8PM0E	IK	MFTBLUCHUFLEGX-UHFFFAOYSA-N
DM8PM0E	IU	3-butylsulfinyl-1,1,1-trifluoropropan-2-one
DM8PM0E	DE	Discovery agent

DM8T2OX	ID	DM8T2OX
DM8T2OX	DN	3-(butylthio)-1,1,1-trifluoropropan-2-one
DM8T2OX	HS	Investigative
DM8T2OX	SN	3-Butylsulfanyl-1,1,1-trifluoropropan-2-one; 34509-08-5; CHEMBL402615; 3-(butylthio)-1,1,1-trifluoropropan-2-one; AC1L4AHE; 3-butylsulfanyl-1,1,1-trifluoro-propan-2-one; CTK1C3366; DTXSID90188068; BDBM50371973
DM8T2OX	DT	Small molecular drug
DM8T2OX	PC	182197
DM8T2OX	MW	200.22
DM8T2OX	FM	C7H11F3OS
DM8T2OX	IC	InChI=1S/C7H11F3OS/c1-2-3-4-12-5-6(11)7(8,9)10/h2-5H2,1H3
DM8T2OX	CS	CCCCSCC(=O)C(F)(F)F
DM8T2OX	IK	PEBSSHOGFAFMQB-UHFFFAOYSA-N
DM8T2OX	IU	3-butylsulfanyl-1,1,1-trifluoropropan-2-one
DM8T2OX	CA	CAS 34509-08-5
DM8T2OX	DE	Discovery agent

DMWJ6UD	ID	DMWJ6UD
DMWJ6UD	DN	3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one
DMWJ6UD	HS	Investigative
DMWJ6UD	SN	CHEMBL269931
DMWJ6UD	DT	Small molecular drug
DMWJ6UD	PC	44455842
DMWJ6UD	MW	300.38
DMWJ6UD	FM	C13H23F3O2S
DMWJ6UD	IC	InChI=1S/C13H23F3O2S/c1-2-3-4-5-6-7-8-9-10-19(18)11-12(17)13(14,15)16/h2-11H2,1H3
DMWJ6UD	CS	CCCCCCCCCCS(=O)CC(=O)C(F)(F)F
DMWJ6UD	IK	PWWCYKIIRMNUAY-UHFFFAOYSA-N
DMWJ6UD	IU	3-decylsulfinyl-1,1,1-trifluoropropan-2-one
DMWJ6UD	DE	Discovery agent

DMF27YT	ID	DMF27YT
DMF27YT	DN	3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one
DMF27YT	HS	Investigative
DMF27YT	SN	CHEMBL272075
DMF27YT	DT	Small molecular drug
DMF27YT	PC	44455838
DMF27YT	MW	316.38
DMF27YT	FM	C13H23F3O3S
DMF27YT	IC	InChI=1S/C13H23F3O3S/c1-2-3-4-5-6-7-8-9-10-20(18,19)11-12(17)13(14,15)16/h2-11H2,1H3
DMF27YT	CS	CCCCCCCCCCS(=O)(=O)CC(=O)C(F)(F)F
DMF27YT	IK	QTDVUUSBCIIYIV-UHFFFAOYSA-N
DMF27YT	IU	3-decylsulfonyl-1,1,1-trifluoropropan-2-one
DMF27YT	DE	Discovery agent

DM1Y6L8	ID	DM1Y6L8
DM1Y6L8	DN	3-(decylthio)-1,1,1-trifluoropropan-2-one
DM1Y6L8	HS	Investigative
DM1Y6L8	SN	3-decylsulfanyl-1,1,1-trifluoropropan-2-one; CHEMBL270374; 92682-26-3; AC1L4GC5; decyl-thio-trifluoropropanone; CTK5H1583; DTXSID50239101; BDBM50371969; 2-propanone, 3-(decylthio)-1,1,1-trifluoro-
DM1Y6L8	DT	Small molecular drug
DM1Y6L8	PC	185195
DM1Y6L8	MW	284.38
DM1Y6L8	FM	C13H23F3OS
DM1Y6L8	IC	InChI=1S/C13H23F3OS/c1-2-3-4-5-6-7-8-9-10-18-11-12(17)13(14,15)16/h2-11H2,1H3
DM1Y6L8	CS	CCCCCCCCCCSCC(=O)C(F)(F)F
DM1Y6L8	IK	PGAJDYUDVRIKCP-UHFFFAOYSA-N
DM1Y6L8	IU	3-decylsulfanyl-1,1,1-trifluoropropan-2-one
DM1Y6L8	CA	CAS 92682-26-3
DM1Y6L8	DE	Discovery agent

DM2JBQI	ID	DM2JBQI
DM2JBQI	DN	3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one
DM2JBQI	HS	Investigative
DM2JBQI	SN	beta-Aminophenylketone, 3g; 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one; CHEMBL396086; SCHEMBL15862326; BDBM18820
DM2JBQI	DT	Small molecular drug
DM2JBQI	PC	23635364
DM2JBQI	MW	345.6
DM2JBQI	FM	C23H39NO
DM2JBQI	IC	InChI=1S/C23H39NO/c1-4-7-10-11-12-21-13-15-22(16-14-21)23(25)17-20-24(18-8-5-2)19-9-6-3/h13-16H,4-12,17-20H2,1-3H3
DM2JBQI	CS	CCCCCCC1=CC=C(C=C1)C(=O)CCN(CCCC)CCCC
DM2JBQI	IK	UMFRWWULZNWTFF-UHFFFAOYSA-N
DM2JBQI	IU	3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one
DM2JBQI	DE	Discovery agent

DMG5VMH	ID	DMG5VMH
DMG5VMH	DN	3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one
DMG5VMH	HS	Investigative
DMG5VMH	SN	CHEMBL561850; 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one
DMG5VMH	DT	Small molecular drug
DMG5VMH	PC	21653696
DMG5VMH	MW	275.4
DMG5VMH	FM	C18H29NO
DMG5VMH	IC	InChI=1S/C18H29NO/c1-4-5-6-7-8-9-16-10-12-17(13-11-16)18(20)14-15-19(2)3/h10-13H,4-9,14-15H2,1-3H3
DMG5VMH	CS	CCCCCCCC1=CC=C(C=C1)C(=O)CCN(C)C
DMG5VMH	IK	ANCSLKGKDIAGLN-UHFFFAOYSA-N
DMG5VMH	IU	3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one
DMG5VMH	DE	Discovery agent

DMJYCHG	ID	DMJYCHG
DMJYCHG	DN	3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one
DMJYCHG	HS	Investigative
DMJYCHG	SN	3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one; BAS 00130047; AC1MJHY9; beta-Aminophenylketone, 3h; CHEMBL236033; BDBM18821; ZINC3065713; NCGC00168202-01; 4'-Hexyl-beta-(dimethylamino)propiophenone
DMJYCHG	DT	Small molecular drug
DMJYCHG	PC	3092218
DMJYCHG	MW	261.399
DMJYCHG	FM	C17H27NO
DMJYCHG	IC	InChI=1S/C17H27NO/c1-4-5-6-7-8-15-9-11-16(12-10-15)17(19)13-14-18(2)3/h9-12H,4-8,13-14H2,1-3H3
DMJYCHG	CS	CCCCCCC1=CC=C(C=C1)C(=O)CCN(C)C
DMJYCHG	IK	KDBREDBLOZXWHK-UHFFFAOYSA-N
DMJYCHG	IU	3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one
DMJYCHG	DE	Discovery agent

DMM05G2	ID	DMM05G2
DMM05G2	DN	3-(dimethylamino)phenyl phenylcarbamate
DMM05G2	HS	Investigative
DMM05G2	SN	3-(dimethylamino)phenyl phenylcarbamate; CHEMBL1171854; AC1L2FAU; AC1Q61FO; YNGSTYODGGYXSA-UHFFFAOYSA-N; BDBM50321912; AKOS029953756; [3-(dimethylamino)phenyl] N-phenylcarbamate; phenol, 3-(dimethylamino)-, phenylcarbamate (ester)
DMM05G2	DT	Small molecular drug
DMM05G2	PC	46080
DMM05G2	MW	256.3
DMM05G2	FM	C15H16N2O2
DMM05G2	IC	InChI=1S/C15H16N2O2/c1-17(2)13-9-6-10-14(11-13)19-15(18)16-12-7-4-3-5-8-12/h3-11H,1-2H3,(H,16,18)
DMM05G2	CS	CN(C)C1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2
DMM05G2	IK	YNGSTYODGGYXSA-UHFFFAOYSA-N
DMM05G2	IU	[3-(dimethylamino)phenyl] N-phenylcarbamate
DMM05G2	DE	Discovery agent

DM7AG6Y	ID	DM7AG6Y
DM7AG6Y	DN	3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one
DM7AG6Y	HS	Investigative
DM7AG6Y	SN	CHEMBL273138
DM7AG6Y	DT	Small molecular drug
DM7AG6Y	PC	44455839
DM7AG6Y	MW	328.4
DM7AG6Y	FM	C15H27F3O2S
DM7AG6Y	IC	InChI=1S/C15H27F3O2S/c1-2-3-4-5-6-7-8-9-10-11-12-21(20)13-14(19)15(16,17)18/h2-13H2,1H3
DM7AG6Y	CS	CCCCCCCCCCCCS(=O)CC(=O)C(F)(F)F
DM7AG6Y	IK	HIQQJIUOQKSANW-UHFFFAOYSA-N
DM7AG6Y	IU	3-dodecylsulfinyl-1,1,1-trifluoropropan-2-one
DM7AG6Y	DE	Discovery agent

DMPRCS0	ID	DMPRCS0
DMPRCS0	DN	3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one
DMPRCS0	HS	Investigative
DMPRCS0	SN	CHEMBL257071
DMPRCS0	DT	Small molecular drug
DMPRCS0	PC	44455814
DMPRCS0	MW	344.4
DMPRCS0	FM	C15H27F3O3S
DMPRCS0	IC	InChI=1S/C15H27F3O3S/c1-2-3-4-5-6-7-8-9-10-11-12-22(20,21)13-14(19)15(16,17)18/h2-13H2,1H3
DMPRCS0	CS	CCCCCCCCCCCCS(=O)(=O)CC(=O)C(F)(F)F
DMPRCS0	IK	JUVLUOYDHJEJIQ-UHFFFAOYSA-N
DMPRCS0	IU	3-dodecylsulfonyl-1,1,1-trifluoropropan-2-one
DMPRCS0	DE	Discovery agent

DM71EMN	ID	DM71EMN
DM71EMN	DN	3-(ethoxycarbonyl)phenylboronic acid
DM71EMN	HS	Investigative
DM71EMN	SN	3-Ethoxycarbonylphenylboronic acid; 4334-87-6; 3-(Ethoxycarbonyl)phenylboronic acid; (3-ethoxycarbonylphenyl)boronic Acid; 3-carbethoxyphenylboronic acid; (3-(ethoxycarbonyl)phenyl)boronic acid; m-ethoxycarbonylphenylboronic acid; 3-Ethoxycarbonylbenzeneboronic acid; Ethyl 3-(Dihydroxyboranyl)Benzoate; MFCD02179444; [3-(ethoxycarbonyl)phenyl]boronic acid; 3-(ethoxycarbonyl)benzeneboronic acid; 3-(ethoxycarbonyl)phenyl boronic acid; Akos Brn-0097; BENZOIC ACID, 3-BORONO-, 1-ETHYL ESTER; PubChem6092; Phenylboronic Acid, 2
DM71EMN	DT	Small molecular drug
DM71EMN	PC	3249312
DM71EMN	MW	193.99
DM71EMN	FM	C9H11BO4
DM71EMN	IC	InChI=1S/C9H11BO4/c1-2-14-9(11)7-4-3-5-8(6-7)10(12)13/h3-6,12-13H,2H2,1H3
DM71EMN	CS	B(C1=CC(=CC=C1)C(=O)OCC)(O)O
DM71EMN	IK	REHVCPNQQBDOJJ-UHFFFAOYSA-N
DM71EMN	IU	(3-ethoxycarbonylphenyl)boronic acid
DM71EMN	CA	CAS 4334-87-6
DM71EMN	DE	Discovery agent

DMM2AR3	ID	DMM2AR3
DMM2AR3	DN	3-(furan-3-yl)-1H-indole
DMM2AR3	HS	Investigative
DMM2AR3	SN	CHEMBL381132; 155440-58-7; 3-(3-furyl)indole; 3-(furan-3-yl)-1H-indole; 3-(3-Furanyl)-1H-indole; BDBM50182886
DMM2AR3	DT	Small molecular drug
DMM2AR3	PC	10607518
DMM2AR3	MW	183.21
DMM2AR3	FM	C12H9NO
DMM2AR3	IC	InChI=1S/C12H9NO/c1-2-4-12-10(3-1)11(7-13-12)9-5-6-14-8-9/h1-8,13H
DMM2AR3	CS	C1=CC=C2C(=C1)C(=CN2)C3=COC=C3
DMM2AR3	IK	AFKNGDFJVAPDNN-UHFFFAOYSA-N
DMM2AR3	IU	3-(furan-3-yl)-1H-indole
DMM2AR3	DE	Discovery agent

DM6L4J8	ID	DM6L4J8
DM6L4J8	DN	3-(furan-3-yl)-1-methyl-1H-indole
DM6L4J8	HS	Investigative
DM6L4J8	SN	CHEMBL207375; 3-(furan-3-yl)-1-methyl-1H-indole; 1H-Indole, 3-(3-furanyl)-1-methyl-; BDBM50182882
DM6L4J8	DT	Small molecular drug
DM6L4J8	PC	44410800
DM6L4J8	MW	197.23
DM6L4J8	FM	C13H11NO
DM6L4J8	IC	InChI=1S/C13H11NO/c1-14-8-12(10-6-7-15-9-10)11-4-2-3-5-13(11)14/h2-9H,1H3
DM6L4J8	CS	CN1C=C(C2=CC=CC=C21)C3=COC=C3
DM6L4J8	IK	UFMJKAKKDCGNEF-UHFFFAOYSA-N
DM6L4J8	IU	3-(furan-3-yl)-1-methylindole
DM6L4J8	DE	Discovery agent

DMQZU9G	ID	DMQZU9G
DMQZU9G	DN	3-(heptyloxy)benzoic acid
DMQZU9G	HS	Investigative
DMQZU9G	SN	3-(Heptyloxy)benzoic Acid; 3-(heptyloxy)benzoate; 3-heptyloxybenzoate; 3-heptyloxybenzoic acid; 3-n-Heptyloxybenzoic acid; SCHEMBL7047692; CHEMBL1161949; FOFZVIUYGPBWLV-UHFFFAOYSA-N; ZINC14980578; AKOS005288423; AS01084; DB07355
DMQZU9G	DT	Small molecular drug
DMQZU9G	PC	14368760
DMQZU9G	MW	236.31
DMQZU9G	FM	C14H20O3
DMQZU9G	IC	InChI=1S/C14H20O3/c1-2-3-4-5-6-10-17-13-9-7-8-12(11-13)14(15)16/h7-9,11H,2-6,10H2,1H3,(H,15,16)
DMQZU9G	CS	CCCCCCCOC1=CC=CC(=C1)C(=O)O
DMQZU9G	IK	FOFZVIUYGPBWLV-UHFFFAOYSA-N
DMQZU9G	IU	3-heptoxybenzoic acid
DMQZU9G	DE	Discovery agent

DMKHNTY	ID	DMKHNTY
DMKHNTY	DN	3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY	HS	Investigative
DMKHNTY	SN	CHEMBL1269094; 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY	DT	Small molecular drug
DMKHNTY	PC	52945666
DMKHNTY	MW	264.32
DMKHNTY	FM	C17H16N2O
DMKHNTY	IC	InChI=1S/C17H16N2O/c1-2-3-4-7-10-20-17-11-14-13-8-5-6-9-15(13)19-16(14)12-18-17/h3-12,19H,2H2,1H3/b4-3+,10-7+
DMKHNTY	CS	CC/C=C/C=C/OC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMKHNTY	IK	PUUXLLSHSWLAML-YZQQHVNFSA-N
DMKHNTY	IU	3-[(1E,3E)-hexa-1,3-dienoxy]-9H-pyrido[3,4-b]indole
DMKHNTY	DE	Discovery agent

DMM52LC	ID	DMM52LC
DMM52LC	DN	3-(imidazolylmethyl)-4'-methoxyflavone
DMM52LC	HS	Investigative
DMM52LC	SN	CHEMBL212473; BDBM50191600; 3-(imidazolylmethyl)-4''-methoxyflavone
DMM52LC	DT	Small molecular drug
DMM52LC	PC	11847320
DMM52LC	MW	332.4
DMM52LC	FM	C20H16N2O3
DMM52LC	IC	InChI=1S/C20H16N2O3/c1-24-15-8-6-14(7-9-15)20-17(12-22-11-10-21-13-22)19(23)16-4-2-3-5-18(16)25-20/h2-11,13H,12H2,1H3
DMM52LC	CS	COC1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C3O2)CN4C=CN=C4
DMM52LC	IK	GMZSVBKZQWIFKJ-UHFFFAOYSA-N
DMM52LC	IU	3-(imidazol-1-ylmethyl)-2-(4-methoxyphenyl)chromen-4-one
DMM52LC	DE	Discovery agent

DMX2LT5	ID	DMX2LT5
DMX2LT5	DN	3-(imidazolylmethyl)-4'-nitroflavone
DMX2LT5	HS	Investigative
DMX2LT5	SN	CHEMBL213588; BDBM50191598; 3-(imidazolylmethyl)-4''-nitroflavone
DMX2LT5	DT	Small molecular drug
DMX2LT5	PC	11847317
DMX2LT5	MW	347.3
DMX2LT5	FM	C19H13N3O4
DMX2LT5	IC	InChI=1S/C19H13N3O4/c23-18-15-3-1-2-4-17(15)26-19(16(18)11-21-10-9-20-12-21)13-5-7-14(8-6-13)22(24)25/h1-10,12H,11H2
DMX2LT5	CS	C1=CC=C2C(=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])CN4C=CN=C4
DMX2LT5	IK	QRPSGPSYOIPDIF-UHFFFAOYSA-N
DMX2LT5	IU	3-(imidazol-1-ylmethyl)-2-(4-nitrophenyl)chromen-4-one
DMX2LT5	DE	Discovery agent

DML63MX	ID	DML63MX
DML63MX	DN	3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone
DML63MX	HS	Investigative
DML63MX	SN	CHEMBL212168; BDBM50191603; 3-(imidazolylmethyl)-7-methoxy-4''-nitroflavone
DML63MX	DT	Small molecular drug
DML63MX	PC	11847169
DML63MX	MW	377.3
DML63MX	FM	C20H15N3O5
DML63MX	IC	InChI=1S/C20H15N3O5/c1-27-15-6-7-16-18(10-15)28-20(13-2-4-14(5-3-13)23(25)26)17(19(16)24)11-22-9-8-21-12-22/h2-10,12H,11H2,1H3
DML63MX	CS	COC1=CC2=C(C=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])CN4C=CN=C4
DML63MX	IK	DTEZOESXMOWJRN-UHFFFAOYSA-N
DML63MX	IU	3-(imidazol-1-ylmethyl)-7-methoxy-2-(4-nitrophenyl)chromen-4-one
DML63MX	DE	Discovery agent

DMLI7F4	ID	DMLI7F4
DMLI7F4	DN	3-(imidazolylmethyl)flavone
DMLI7F4	HS	Investigative
DMLI7F4	SN	3-(imidazolylmethyl)flavone; CHEMBL213587; BDBM50191599
DMLI7F4	DT	Small molecular drug
DMLI7F4	PC	11847316
DMLI7F4	MW	302.3
DMLI7F4	FM	C19H14N2O2
DMLI7F4	IC	InChI=1S/C19H14N2O2/c22-18-15-8-4-5-9-17(15)23-19(14-6-2-1-3-7-14)16(18)12-21-11-10-20-13-21/h1-11,13H,12H2
DMLI7F4	CS	C1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C3O2)CN4C=CN=C4
DMLI7F4	IK	CAKKGEJFZFTSEV-UHFFFAOYSA-N
DMLI7F4	IU	3-(imidazol-1-ylmethyl)-2-phenylchromen-4-one
DMLI7F4	DE	Discovery agent

DM3EV9N	ID	DM3EV9N
DM3EV9N	DN	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N	HS	Investigative
DM3EV9N	SN	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide
DM3EV9N	DT	Small molecular drug
DM3EV9N	PC	15422868
DM3EV9N	MW	288.3
DM3EV9N	FM	C18H12N2O2
DM3EV9N	IC	InChI=1S/C18H12N2O2/c21-17-15(11-6-2-1-3-7-11)16(18(22)20-17)13-10-19-14-9-5-4-8-12(13)14/h1-10,19H,(H,20,21,22)
DM3EV9N	CS	C1=CC=C(C=C1)C2=C(C(=O)NC2=O)C3=CNC4=CC=CC=C43
DM3EV9N	IK	HVQJGNALTWNDMX-UHFFFAOYSA-N
DM3EV9N	IU	3-(1H-indol-3-yl)-4-phenylpyrrole-2,5-dione
DM3EV9N	DE	Discovery agent

DMJDG9C	ID	DMJDG9C
DMJDG9C	DN	3-(N-alkylamino) propylphosphonic acid derivative
DMJDG9C	HS	Investigative
DMJDG9C	SN	CHEMBL1161691
DMJDG9C	DT	Small molecular drug
DMJDG9C	PC	46905530
DMJDG9C	MW	388.5
DMJDG9C	FM	C19H35NO5P+
DMJDG9C	IC	InChI=1S/C19H35NO5P/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-25-26(22,23)24/h9-12,21-24H,2-8,13-16,20H2,1H3/q+1
DMJDG9C	CS	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO[P+](O)(O)O)N
DMJDG9C	IK	CGCGFGUOJDITDE-UHFFFAOYSA-N
DMJDG9C	IU	[2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butoxy]-trihydroxyphosphanium
DMJDG9C	DE	Discovery agent

DMJRBT1	ID	DMJRBT1
DMJRBT1	DN	3-(naphthalen-2-yl)pyridine
DMJRBT1	HS	Investigative
DMJRBT1	SN	3-(2-naphthyl)pyridine; CHEMBL365735; 3-(naphthalen-2-yl)pyridine; 2-(3-pyridyl)-naphthalene; SCHEMBL4510935; BDBM8904; Pyridine-substituted naphthalene 1
DMJRBT1	DT	Small molecular drug
DMJRBT1	PC	11845485
DMJRBT1	MW	205.25
DMJRBT1	FM	C15H11N
DMJRBT1	IC	InChI=1S/C15H11N/c1-2-5-13-10-14(8-7-12(13)4-1)15-6-3-9-16-11-15/h1-11H
DMJRBT1	CS	C1=CC=C2C=C(C=CC2=C1)C3=CN=CC=C3
DMJRBT1	IK	JVWGLICJXUMGHN-UHFFFAOYSA-N
DMJRBT1	IU	3-naphthalen-2-ylpyridine
DMJRBT1	DE	Discovery agent

DM6OCU5	ID	DM6OCU5
DM6OCU5	DN	3-(N-propylpiperidin-4-yl)phenol
DM6OCU5	HS	Investigative
DM6OCU5	SN	CHEMBL592618; 3-(N-propylpiperidin-4-yl)phenol; SCHEMBL3454031; HPUYFCNUROWQBG-UHFFFAOYSA-N; BDBM50308024
DM6OCU5	DT	Small molecular drug
DM6OCU5	PC	12988959
DM6OCU5	MW	219.32
DM6OCU5	FM	C14H21NO
DM6OCU5	IC	InChI=1S/C14H21NO/c1-2-8-15-9-6-12(7-10-15)13-4-3-5-14(16)11-13/h3-5,11-12,16H,2,6-10H2,1H3
DM6OCU5	CS	CCCN1CCC(CC1)C2=CC(=CC=C2)O
DM6OCU5	IK	HPUYFCNUROWQBG-UHFFFAOYSA-N
DM6OCU5	IU	3-(1-propylpiperidin-4-yl)phenol
DM6OCU5	CA	CAS 346688-61-7
DM6OCU5	DE	Discovery agent

DMJRNI7	ID	DMJRNI7
DMJRNI7	DN	3-(Octahydro-indolizin-8-yl)-phenol
DMJRNI7	HS	Investigative
DMJRNI7	SN	CHEMBL268240; 3-(Octahydro-indolizin-8-yl)-phenol; SCHEMBL9406084; BDBM50010616; AKOS022652621; (-)-3-(Octahydro-indolizin-8-yl)-phenol; (+)-3-(Octahydro-indolizin-8-yl)-phenol; isomer-13-(Octahydro-indolizin-8-yl)-phenol
DMJRNI7	DT	Small molecular drug
DMJRNI7	PC	13720757
DMJRNI7	MW	217.31
DMJRNI7	FM	C14H19NO
DMJRNI7	IC	InChI=1S/C14H19NO/c16-12-5-1-4-11(10-12)13-6-2-8-15-9-3-7-14(13)15/h1,4-5,10,13-14,16H,2-3,6-9H2/t13-,14?/m1/s1
DMJRNI7	CS	C1C[C@@H](C2CCCN2C1)C3=CC(=CC=C3)O
DMJRNI7	IK	WOXUXMJHVREOKX-KWCCSABGSA-N
DMJRNI7	IU	3-[(8R)-1,2,3,5,6,7,8,8a-octahydroindolizin-8-yl]phenol
DMJRNI7	DE	Discovery agent

DMU1SGX	ID	DMU1SGX
DMU1SGX	DN	3-(Octahydro-quinolizin-1-yl)-phenol
DMU1SGX	HS	Investigative
DMU1SGX	SN	CHEMBL7381; 3-(Octahydro-quinolizin-1-yl)-phenol; SCHEMBL7351093; BDBM50010614; AKOS022657925; 3-[(Octahydro-4H-quinolizin)-1-yl]phenol; isomer-23-(Octahydro-quinolizin-1-yl)-phenol
DMU1SGX	DT	Small molecular drug
DMU1SGX	PC	13720739
DMU1SGX	MW	231.33
DMU1SGX	FM	C15H21NO
DMU1SGX	IC	InChI=1S/C15H21NO/c17-13-6-3-5-12(11-13)14-7-4-10-16-9-2-1-8-15(14)16/h3,5-6,11,14-15,17H,1-2,4,7-10H2
DMU1SGX	CS	C1CCN2CCCC(C2C1)C3=CC(=CC=C3)O
DMU1SGX	IK	RUTLNJGVITWMQE-UHFFFAOYSA-N
DMU1SGX	IU	3-(2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl)phenol
DMU1SGX	DE	Discovery agent

DM01BKR	ID	DM01BKR
DM01BKR	DN	3-(Octahydro-quinolizin-3-yl)-phenol
DM01BKR	HS	Investigative
DM01BKR	SN	CHEMBL8120
DM01BKR	DT	Small molecular drug
DM01BKR	PC	13720748
DM01BKR	MW	231.33
DM01BKR	FM	C15H21NO
DM01BKR	IC	InChI=1S/C15H21NO/c17-15-6-3-4-12(10-15)13-7-8-14-5-1-2-9-16(14)11-13/h3-4,6,10,13-14,17H,1-2,5,7-9,11H2
DM01BKR	CS	C1CCN2CC(CCC2C1)C3=CC(=CC=C3)O
DM01BKR	IK	GBPVZNJTTUIKKY-UHFFFAOYSA-N
DM01BKR	IU	3-(2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-3-yl)phenol
DM01BKR	DE	Discovery agent

DMMRV1N	ID	DMMRV1N
DMMRV1N	DN	3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
DMMRV1N	HS	Investigative
DMMRV1N	SN	3-(oxalyl-amino)-naphthalene-2-carboxylic acid; CHEMBL383570; 3-[(carboxycarbonyl)amino]naphthalene-2-carboxylic acid; AC1L1BVL; SCHEMBL4311266; CTK7I3794; 1c84; ZINC2007904; BDBM50416040; DB01734; N-(3-Carboxy-2-naphthyl)oxamidic acid; 3-(oxaloamino)naphthalene-2-carboxylic acid; 3-(carboxyformamido)naphthalene-2-carboxylic acid
DMMRV1N	DT	Small molecular drug
DMMRV1N	PC	1628
DMMRV1N	MW	259.209
DMMRV1N	FM	C13H9NO5
DMMRV1N	IC	InChI=1S/C13H9NO5/c15-11(13(18)19)14-10-6-8-4-2-1-3-7(8)5-9(10)12(16)17/h1-6H,(H,14,15)(H,16,17)(H,18,19)
DMMRV1N	CS	C1=CC=C2C=C(C(=CC2=C1)C(=O)O)NC(=O)C(=O)O
DMMRV1N	IK	DQBLKSRRWDWNKQ-UHFFFAOYSA-N
DMMRV1N	IU	3-(oxaloamino)naphthalene-2-carboxylic acid
DMMRV1N	DE	Discovery agent

DM2UPQG	ID	DM2UPQG
DM2UPQG	DN	3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
DM2UPQG	HS	Investigative
DM2UPQG	SN	3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one; CHEMBL239282; Aza-heterocyclic Derivative, 1e
DM2UPQG	DT	Small molecular drug
DM2UPQG	PC	23635754
DM2UPQG	MW	288.3
DM2UPQG	FM	C18H12N2O2
DM2UPQG	IC	InChI=1S/C18H12N2O2/c21-18-15-9-5-4-8-14(15)17-16(18)10-12(19-20-17)11-22-13-6-2-1-3-7-13/h1-10H,11H2
DM2UPQG	CS	C1=CC=C(C=C1)OCC2=CC3=C(C4=CC=CC=C4C3=O)N=N2
DM2UPQG	IK	FYSBXMGLLLBKBR-UHFFFAOYSA-N
DM2UPQG	IU	3-(phenoxymethyl)indeno[1,2-c]pyridazin-5-one
DM2UPQG	DE	Discovery agent

DMSRHLC	ID	DMSRHLC
DMSRHLC	DN	3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole
DMSRHLC	HS	Investigative
DMSRHLC	SN	CHEMBL1076583; 651335-52-3; 3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole; SCHEMBL4077273; CTK1J9031; DTXSID60434701; BDBM50313130; 1H-Indole, 3-(phenylsulfonyl)-1-(3-piperidinyl)-
DMSRHLC	DT	Small molecular drug
DMSRHLC	PC	10042892
DMSRHLC	MW	340.4
DMSRHLC	FM	C19H20N2O2S
DMSRHLC	IC	InChI=1S/C19H20N2O2S/c22-24(23,16-8-2-1-3-9-16)19-14-21(15-7-6-12-20-13-15)18-11-5-4-10-17(18)19/h1-5,8-11,14-15,20H,6-7,12-13H2
DMSRHLC	CS	C1CC(CNC1)N2C=C(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DMSRHLC	IK	QAYPUMLPFJDPQW-UHFFFAOYSA-N
DMSRHLC	IU	3-(benzenesulfonyl)-1-piperidin-3-ylindole
DMSRHLC	CA	CAS 651335-52-3
DMSRHLC	DE	Discovery agent

DM9QB0X	ID	DM9QB0X
DM9QB0X	DN	3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole
DM9QB0X	HS	Investigative
DM9QB0X	SN	CHEMBL1080574; 651335-50-1; 3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole; SCHEMBL4077678; CTK1J9032; DTXSID00437312; BDBM50313128; 1H-Indole, 3-(phenylsulfonyl)-1-(4-piperidinyl)-
DM9QB0X	DT	Small molecular drug
DM9QB0X	PC	10246639
DM9QB0X	MW	340.4
DM9QB0X	FM	C19H20N2O2S
DM9QB0X	IC	InChI=1S/C19H20N2O2S/c22-24(23,16-6-2-1-3-7-16)19-14-21(15-10-12-20-13-11-15)18-9-5-4-8-17(18)19/h1-9,14-15,20H,10-13H2
DM9QB0X	CS	C1CNCCC1N2C=C(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DM9QB0X	IK	VDJWPWVFSZYDTQ-UHFFFAOYSA-N
DM9QB0X	IU	3-(benzenesulfonyl)-1-piperidin-4-ylindole
DM9QB0X	CA	CAS 651335-50-1
DM9QB0X	DE	Discovery agent

DMVKO5N	ID	DMVKO5N
DMVKO5N	DN	3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole
DMVKO5N	HS	Investigative
DMVKO5N	SN	CHEMBL1076665; 651335-54-5; 3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole; SCHEMBL4067463; CTK1J9030; DTXSID20431690; BDBM50313139; 1H-Indole, 3-(phenylsulfonyl)-1-(3-pyrrolidinyl)-
DMVKO5N	DT	Small molecular drug
DMVKO5N	PC	9840311
DMVKO5N	MW	326.4
DMVKO5N	FM	C18H18N2O2S
DMVKO5N	IC	InChI=1S/C18H18N2O2S/c21-23(22,15-6-2-1-3-7-15)18-13-20(14-10-11-19-12-14)17-9-5-4-8-16(17)18/h1-9,13-14,19H,10-12H2
DMVKO5N	CS	C1CNCC1N2C=C(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DMVKO5N	IK	RLICEYAZXFQQMC-UHFFFAOYSA-N
DMVKO5N	IU	3-(benzenesulfonyl)-1-pyrrolidin-3-ylindole
DMVKO5N	CA	CAS 651335-54-5
DMVKO5N	DE	Discovery agent

DMN1DWF	ID	DMN1DWF
DMN1DWF	DN	3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine
DMN1DWF	HS	Investigative
DMN1DWF	SN	3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine; CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-
DMN1DWF	DT	Small molecular drug
DMN1DWF	PC	22028181
DMN1DWF	MW	258.3
DMN1DWF	FM	C13H10N2O2S
DMN1DWF	IC	InChI=1S/C13H10N2O2S/c16-18(17,10-5-2-1-3-6-10)12-9-15-13-11(12)7-4-8-14-13/h1-9H,(H,14,15)
DMN1DWF	CS	C1=CC=C(C=C1)S(=O)(=O)C2=CNC3=C2C=CC=N3
DMN1DWF	IK	XIVJYIWQYBHEBJ-UHFFFAOYSA-N
DMN1DWF	IU	3-(benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine
DMN1DWF	CA	CAS 633303-90-9
DMN1DWF	DE	Discovery agent

DM2ETXB	ID	DM2ETXB
DM2ETXB	DN	3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine
DM2ETXB	HS	Investigative
DM2ETXB	SN	CHEMBL596714; 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine
DM2ETXB	DT	Small molecular drug
DM2ETXB	PC	46230706
DM2ETXB	MW	268.35
DM2ETXB	FM	C17H20N2O
DM2ETXB	IC	InChI=1S/C17H20N2O/c1-13-5-2-3-7-16(13)20-17-15(6-4-10-19-17)14-8-11-18-12-9-14/h2-7,10,14,18H,8-9,11-12H2,1H3
DM2ETXB	CS	CC1=CC=CC=C1OC2=C(C=CC=N2)C3CCNCC3
DM2ETXB	IK	BLKKGRNFYMEBJN-UHFFFAOYSA-N
DM2ETXB	IU	2-(2-methylphenoxy)-3-piperidin-4-ylpyridine
DM2ETXB	DE	Discovery agent

DMMOE40	ID	DMMOE40
DMMOE40	DN	3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol
DMMOE40	HS	Investigative
DMMOE40	SN	3-(prop-2-ene-1-sulfinyl)-propene-1-thiol; AJ3; DB02895; (1E)-3-[(R)-prop-2-ene-1-sulfinyl]prop-1-ene-1-thiol
DMMOE40	DT	Small molecular drug
DMMOE40	PC	9543424
DMMOE40	MW	162.3
DMMOE40	FM	C6H10OS2
DMMOE40	IC	InChI=1S/C6H10OS2/c1-2-5-9(7)6-3-4-8/h2-4,8H,1,5-6H2/b4-3+/t9-/m1/s1
DMMOE40	CS	C=CC[S@@](=O)C/C=C/S
DMMOE40	IK	HSVQDVSVQIMRSS-CDAZIORVSA-N
DMMOE40	IU	(E)-3-[(R)-prop-2-enylsulfinyl]prop-1-ene-1-thiol
DMMOE40	DE	Discovery agent

DM3EDQ1	ID	DM3EDQ1
DM3EDQ1	DN	3-(pyridin-3-yl)prop-2-yn-1-amine
DM3EDQ1	HS	Investigative
DM3EDQ1	SN	3-(pyridin-3-yl)prop-2-yn-1-amine; 777856-62-9; 2-PROPYN-1-AMINE, 3-(3-PYRIDINYL)-; CHEMBL360541; SCHEMBL3603698; CTK2G6074; BDBM12348; DTXSID90460412; MolPort-014-472-743; BGKUWZFWNZFRMO-UHFFFAOYSA-N; ZINC13607158; nicotine 3-heteroaromatic analogue 3a; AKOS010148504; MCULE-3042424640; NE58716; US8609708, 3; Z1333761438
DM3EDQ1	DT	Small molecular drug
DM3EDQ1	PC	11263510
DM3EDQ1	MW	132.16
DM3EDQ1	FM	C8H8N2
DM3EDQ1	IC	InChI=1S/C8H8N2/c9-5-1-3-8-4-2-6-10-7-8/h2,4,6-7H,5,9H2
DM3EDQ1	CS	C1=CC(=CN=C1)C#CCN
DM3EDQ1	IK	BGKUWZFWNZFRMO-UHFFFAOYSA-N
DM3EDQ1	IU	3-pyridin-3-ylprop-2-yn-1-amine
DM3EDQ1	CA	CAS 777856-62-9
DM3EDQ1	DE	Discovery agent

DMZARSD	ID	DMZARSD
DMZARSD	DN	3-(pyridin-4-yl)-1H-indol-6-amine
DMZARSD	HS	Investigative
DMZARSD	SN	3-(pyridin-4-yl)-1H-indol-6-amine; CHEMBL207612; 887615-80-7; CTK3A6374; DTXSID00658787; BDBM50182874; AKOS030619478; 1H-Indol-6-amine, 3-(4-pyridinyl)-
DMZARSD	DT	Small molecular drug
DMZARSD	PC	44410928
DMZARSD	MW	209.25
DMZARSD	FM	C13H11N3
DMZARSD	IC	InChI=1S/C13H11N3/c14-10-1-2-11-12(8-16-13(11)7-10)9-3-5-15-6-4-9/h1-8,16H,14H2
DMZARSD	CS	C1=CC2=C(C=C1N)NC=C2C3=CC=NC=C3
DMZARSD	IK	NUDVKMUJCFEKEL-UHFFFAOYSA-N
DMZARSD	IU	3-pyridin-4-yl-1H-indol-6-amine
DMZARSD	CA	CAS 887615-80-7
DMZARSD	DE	Discovery agent

DMRFPNE	ID	DMRFPNE
DMRFPNE	DN	3-(pyridin-4-yl)-1H-indol-7-amine
DMRFPNE	HS	Investigative
DMRFPNE	SN	CHEMBL207262; 3-(pyridin-4-yl)-1H-indol-7-amine; SCHEMBL3500355
DMRFPNE	DT	Small molecular drug
DMRFPNE	PC	44410707
DMRFPNE	MW	209.25
DMRFPNE	FM	C13H11N3
DMRFPNE	IC	InChI=1S/C13H11N3/c14-12-3-1-2-10-11(8-16-13(10)12)9-4-6-15-7-5-9/h1-8,16H,14H2
DMRFPNE	CS	C1=CC2=C(C(=C1)N)NC=C2C3=CC=NC=C3
DMRFPNE	IK	NVYSWJKBWRBXSR-UHFFFAOYSA-N
DMRFPNE	IU	3-pyridin-4-yl-1H-indol-7-amine
DMRFPNE	DE	Discovery agent

DMNA6LF	ID	DMNA6LF
DMNA6LF	DN	3-(tetradecylamino)propylphosphonic acid
DMNA6LF	HS	Investigative
DMNA6LF	SN	3-(tetradecylamino)propylphosphonic acid; CHEMBL334213; 725724-60-7; CTK2H2323; DTXSID50658353; BDBM50148403; (3-Tetradecylamino-propyl)-phosphonic acid; [3-(Tetradecylamino)propyl]phosphonic acid; Phosphonic acid, [3-(tetradecylamino)propyl]-
DMNA6LF	DT	Small molecular drug
DMNA6LF	PC	44344193
DMNA6LF	MW	335.5
DMNA6LF	FM	C17H38NO3P
DMNA6LF	IC	InChI=1S/C17H38NO3P/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-16-14-17-22(19,20)21/h18H,2-17H2,1H3,(H2,19,20,21)
DMNA6LF	CS	CCCCCCCCCCCCCCNCCCP(=O)(O)O
DMNA6LF	IK	ROTPOJPBVJTWLI-UHFFFAOYSA-N
DMNA6LF	IU	3-(tetradecylamino)propylphosphonic acid
DMNA6LF	CA	CAS 725724-60-7
DMNA6LF	DE	Discovery agent

DMMI0UC	ID	DMMI0UC
DMMI0UC	DN	3-(thiophen-3-yl)-1H-indol-6-amine
DMMI0UC	HS	Investigative
DMMI0UC	SN	CHEMBL206475; 3-(thiophen-3-yl)-1H-indol-6-amine; SCHEMBL20561548
DMMI0UC	DT	Small molecular drug
DMMI0UC	PC	44410875
DMMI0UC	MW	214.29
DMMI0UC	FM	C12H10N2S
DMMI0UC	IC	InChI=1S/C12H10N2S/c13-9-1-2-10-11(6-14-12(10)5-9)8-3-4-15-7-8/h1-7,14H,13H2
DMMI0UC	CS	C1=CC2=C(C=C1N)NC=C2C3=CSC=C3
DMMI0UC	IK	QEKXSCXVUJXAFF-UHFFFAOYSA-N
DMMI0UC	IU	3-thiophen-3-yl-1H-indol-6-amine
DMMI0UC	DE	Discovery agent

DMWX4L5	ID	DMWX4L5
DMWX4L5	DN	3-(trifluoromethyl)-9H-carbazole
DMWX4L5	HS	Investigative
DMWX4L5	SN	3-(trifluoromethyl)-9H-carbazole; 2467-83-6; CHEMBL1170444; 3-trifluoromethyl-9H-carbazole; SCHEMBL4130017; JGFJDDMRCMCZMU-UHFFFAOYSA-N; CS-B1171; 9H-Carbazole, 3-(trifluoromethyl)-; BDBM50322575; ZINC53243063
DMWX4L5	DT	Small molecular drug
DMWX4L5	PC	42611896
DMWX4L5	MW	235.2
DMWX4L5	FM	C13H8F3N
DMWX4L5	IC	InChI=1S/C13H8F3N/c14-13(15,16)8-5-6-12-10(7-8)9-3-1-2-4-11(9)17-12/h1-7,17H
DMWX4L5	CS	C1=CC=C2C(=C1)C3=C(N2)C=CC(=C3)C(F)(F)F
DMWX4L5	IK	JGFJDDMRCMCZMU-UHFFFAOYSA-N
DMWX4L5	IU	3-(trifluoromethyl)-9H-carbazole
DMWX4L5	DE	Discovery agent

DM2YVA1	ID	DM2YVA1
DM2YVA1	DN	3-(trifluoromethyl)benzaldehyde thiosemicarbazone
DM2YVA1	HS	Investigative
DM2YVA1	SN	CHEMBL90688; 3-(trifluoromethyl)benzaldehyde thiosemicarbazone; (2E)-2-[3-(trifluoromethyl)benzylidene]hydrazinecarbothioamide; 264148-89-2; MolPort-002-925-405; HMS1669J15; STK179777; BDBM50114639; AKOS005411111; CCG-254652; MS-7103
DM2YVA1	DT	Small molecular drug
DM2YVA1	PC	9580972
DM2YVA1	MW	247.24
DM2YVA1	FM	C9H8F3N3S
DM2YVA1	IC	InChI=1S/C9H8F3N3S/c10-9(11,12)7-3-1-2-6(4-7)5-14-15-8(13)16/h1-5H,(H3,13,15,16)/b14-5+
DM2YVA1	CS	C1=CC(=CC(=C1)C(F)(F)F)/C=N/NC(=S)N
DM2YVA1	IK	GDIMOASDCOFPTD-LHHJGKSTSA-N
DM2YVA1	IU	[(E)-[3-(trifluoromethyl)phenyl]methylideneamino]thiourea
DM2YVA1	DE	Discovery agent

DMH7K0N	ID	DMH7K0N
DMH7K0N	DN	3-(trifluoromethyl)phenyl 4-butoxybenzylcarbamate
DMH7K0N	HS	Investigative
DMH7K0N	SN	CHEMBL597272; 3-(trifluoromethyl)phenyl 4-butoxybenzylcarbamate
DMH7K0N	DT	Small molecular drug
DMH7K0N	PC	46230998
DMH7K0N	MW	367.4
DMH7K0N	FM	C19H20F3NO3
DMH7K0N	IC	InChI=1S/C19H20F3NO3/c1-2-3-11-25-16-9-7-14(8-10-16)13-23-18(24)26-17-6-4-5-15(12-17)19(20,21)22/h4-10,12H,2-3,11,13H2,1H3,(H,23,24)
DMH7K0N	CS	CCCCOC1=CC=C(C=C1)CNC(=O)OC2=CC=CC(=C2)C(F)(F)F
DMH7K0N	IK	ULJSSIFMAROIAL-UHFFFAOYSA-N
DMH7K0N	IU	[3-(trifluoromethyl)phenyl] N-[(4-butoxyphenyl)methyl]carbamate
DMH7K0N	DE	Discovery agent

DM4B5JY	ID	DM4B5JY
DM4B5JY	DN	3-(trifluoromethyl)phenylboronic acid
DM4B5JY	HS	Investigative
DM4B5JY	SN	1423-26-3; 3-(Trifluoromethyl)phenylboronic acid; 3-Trifluoromethylphenylboronic acid; (3-(Trifluoromethyl)phenyl)boronic acid; [3-(trifluoromethyl)phenyl]boronic Acid; 3-(Trifluoromethyl)benzeneboronic acid; 3-(Trifluoromethyl)phenylbornic acid; m-(trifluoromethyl)phenylboronic acid; CHEMBL336239; 3-trifluoromethylphenyl boronic acid; MFCD00151854; [3-(Trifluoromethyl)Phenyl]Boranediol; 3-(trifluoromethyl)benzene boronic acid; Boronic acid, [3-(trifluoromethyl)phenyl]-; Boronic acid, B-[3-(trifluoromethyl)phenyl]-
DM4B5JY	DT	Small molecular drug
DM4B5JY	PC	2734388
DM4B5JY	MW	189.93
DM4B5JY	FM	C7H6BF3O2
DM4B5JY	IC	InChI=1S/C7H6BF3O2/c9-7(10,11)5-2-1-3-6(4-5)8(12)13/h1-4,12-13H
DM4B5JY	CS	B(C1=CC(=CC=C1)C(F)(F)F)(O)O
DM4B5JY	IK	WOAORAPRPVIATR-UHFFFAOYSA-N
DM4B5JY	IU	[3-(trifluoromethyl)phenyl]boronic acid
DM4B5JY	CA	CAS 1423-26-3
DM4B5JY	DE	Discovery agent

DMR9WF7	ID	DMR9WF7
DMR9WF7	DN	3,14-DIDEHYDROGINKGOLIDE A
DMR9WF7	HS	Investigative
DMR9WF7	SN	3,14-didehydroginkgolide A; CHEMBL373969
DMR9WF7	DT	Small molecular drug
DMR9WF7	PC	44420886
DMR9WF7	MW	390.4
DMR9WF7	FM	C20H22O8
DMR9WF7	IC	InChI=1S/C20H22O8/c1-7-11-9(25-13(7)22)6-18-8-5-10(17(2,3)4)19(18)12(21)15(24)26-16(19)28-20(11,18)27-14(8)23/h8-10,12,16,21H,5-6H2,1-4H3/t8-,9-,10-,12-,16-,18-,19-,20+/m0/s1
DMR9WF7	CS	CC1=C2[C@H](C[C@@]34[C@]25O[C@H]6[C@]3([C@@H](C[C@H]4C(=O)O5)C(C)(C)C)[C@H](C(=O)O6)O)OC1=O
DMR9WF7	IK	KQXWWKYPPREDFP-VETRYGRWSA-N
DMR9WF7	IU	(1R,3R,6R,7S,8S,10R,11S,13S)-8-tert-butyl-6-hydroxy-16-methyl-2,4,14,18-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadec-16-ene-5,15,19-trione
DMR9WF7	DE	Discovery agent

DMD0Z3U	ID	DMD0Z3U
DMD0Z3U	DN	3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile
DMD0Z3U	HS	Investigative
DMD0Z3U	SN	CHEMBL396656; BDBM50220379; 582293-27-4; 3,2''-bis-trifluoromethyl-biphenyl-4-carbonitrile
DMD0Z3U	DT	Small molecular drug
DMD0Z3U	PC	44434099
DMD0Z3U	MW	315.21
DMD0Z3U	FM	C15H7F6N
DMD0Z3U	IC	InChI=1S/C15H7F6N/c16-14(17,18)12-4-2-1-3-11(12)9-5-6-10(8-22)13(7-9)15(19,20)21/h1-7H
DMD0Z3U	CS	C1=CC=C(C(=C1)C2=CC(=C(C=C2)C#N)C(F)(F)F)C(F)(F)F
DMD0Z3U	IK	LVFYAAITUNIVMI-UHFFFAOYSA-N
DMD0Z3U	IU	2-(trifluoromethyl)-4-[2-(trifluoromethyl)phenyl]benzonitrile
DMD0Z3U	DE	Discovery agent

DM9GO8Y	ID	DM9GO8Y
DM9GO8Y	DN	3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol
DM9GO8Y	HS	Investigative
DM9GO8Y	SN	3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol; MLS002706401; 71123-38-1; 3-[6-(3-hydroxyphenyl)-1,2,4,5-tetrazin-3-yl]phenol; NSC111295; AC1Q4XDI; AC1L6N8F; SCHEMBL1180643; cid_269792; CHEMBL457636; CTK5D3544; BDBM25867; DTXSID10296755; YDADTNARCJIMQM-UHFFFAOYSA-N; ZINC1703222; AKOS030537993; NSC-111295; hydroxyphenyl substituted tetrazine, 39
DM9GO8Y	DT	Small molecular drug
DM9GO8Y	PC	269792
DM9GO8Y	MW	266.25
DM9GO8Y	FM	C14H10N4O2
DM9GO8Y	IC	InChI=1S/C14H10N4O2/c19-11-5-1-3-9(7-11)13-15-17-14(18-16-13)10-4-2-6-12(20)8-10/h1-8,19-20H
DM9GO8Y	CS	C1=CC(=CC(=C1)O)C2=NN=C(N=N2)C3=CC(=CC=C3)O
DM9GO8Y	IK	YDADTNARCJIMQM-UHFFFAOYSA-N
DM9GO8Y	IU	3-[6-(3-hydroxyphenyl)-1,2,4,5-tetrazin-3-yl]phenol
DM9GO8Y	CA	CAS 71123-38-1
DM9GO8Y	DE	Discovery agent

DM4O2VC	ID	DM4O2VC
DM4O2VC	DN	3,3'-(1,2,4-Thiadiazol-2,5-diyl)diphenol
DM4O2VC	HS	Investigative
DM4O2VC	SN	3,3'-(1,3,4-Thiadiazole-2,5-diyl)diphenol; 155877-54-6; CHEMBL450189; SCHEMBL1180710; BDBM25837; CTK0E7552; DTXSID00618942; KZZBPNSRBQBVII-UHFFFAOYSA-N; hydroxyphenyl substituted thiadiazole, 9; 2,5-Bis(3-hydroxyphenyl)-1,3,4-thiadiazole; Phenol, 3,3'-(1,3,4-thiadiazole-2,5-diyl)bis-
DM4O2VC	DT	Small molecular drug
DM4O2VC	PC	21861202
DM4O2VC	MW	270.31
DM4O2VC	FM	C14H10N2O2S
DM4O2VC	IC	InChI=1S/C14H10N2O2S/c17-11-5-1-3-9(7-11)13-15-16-14(19-13)10-4-2-6-12(18)8-10/h1-8,17-18H
DM4O2VC	CS	C1=CC(=CC(=C1)O)C2=NN=C(S2)C3=CC(=CC=C3)O
DM4O2VC	IK	KZZBPNSRBQBVII-UHFFFAOYSA-N
DM4O2VC	IU	3-[5-(3-hydroxyphenyl)-1,3,4-thiadiazol-2-yl]phenol
DM4O2VC	CA	CAS 155877-54-6
DM4O2VC	DE	Discovery agent

DMC34UW	ID	DMC34UW
DMC34UW	DN	3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol
DMC34UW	HS	Investigative
DMC34UW	SN	CHEMBL503399; SCHEMBL12871356; BDBM25839; hydroxyphenyl substituted thiadiazole, 11
DMC34UW	DT	Small molecular drug
DMC34UW	PC	25093379
DMC34UW	MW	270.31
DMC34UW	FM	C14H10N2O2S
DMC34UW	IC	InChI=1S/C14H10N2O2S/c17-11-5-1-3-9(7-11)13-15-14(19-16-13)10-4-2-6-12(18)8-10/h1-8,17-18H
DMC34UW	CS	C1=CC(=CC(=C1)O)C2=NSC(=N2)C3=CC(=CC=C3)O
DMC34UW	IK	OYXDKVOVGLCIIZ-UHFFFAOYSA-N
DMC34UW	IU	3-[5-(3-hydroxyphenyl)-1,2,4-thiadiazol-3-yl]phenol
DMC34UW	DE	Discovery agent

DM9AJNW	ID	DM9AJNW
DM9AJNW	DN	3,3'-(1,3-Thiazol-2,4-diyl)diphenol
DM9AJNW	HS	Investigative
DM9AJNW	SN	CHEMBL512196; SCHEMBL1180078; BDBM25836; WSUUHCNQLBCNOV-UHFFFAOYSA-N; hydroxyphenyl substituted thiazole, 8; 3,3'-(1,3-Thiazole-2,4-diyl)diphenol
DM9AJNW	DT	Small molecular drug
DM9AJNW	PC	25093377
DM9AJNW	MW	269.3
DM9AJNW	FM	C15H11NO2S
DM9AJNW	IC	InChI=1S/C15H11NO2S/c17-12-5-1-3-10(7-12)14-9-19-15(16-14)11-4-2-6-13(18)8-11/h1-9,17-18H
DM9AJNW	CS	C1=CC(=CC(=C1)O)C2=CSC(=N2)C3=CC(=CC=C3)O
DM9AJNW	IK	WSUUHCNQLBCNOV-UHFFFAOYSA-N
DM9AJNW	IU	3-[2-(3-hydroxyphenyl)-1,3-thiazol-4-yl]phenol
DM9AJNW	DE	Discovery agent

DMQY50A	ID	DMQY50A
DMQY50A	DN	3,3-(1,3-Thiazole-2,5-diyl)diphenol
DMQY50A	HS	Investigative
DMQY50A	SN	CHEMBL456379; SCHEMBL1181184; BDBM25832; hydroxyphenyl substituted thiazole, 4
DMQY50A	DT	Small molecular drug
DMQY50A	PC	25093374
DMQY50A	MW	269.3
DMQY50A	FM	C15H11NO2S
DMQY50A	IC	InChI=1S/C15H11NO2S/c17-12-5-1-3-10(7-12)14-9-16-15(19-14)11-4-2-6-13(18)8-11/h1-9,17-18H
DMQY50A	CS	C1=CC(=CC(=C1)O)C2=CN=C(S2)C3=CC(=CC=C3)O
DMQY50A	IK	OYFRXCWZMBHNHW-UHFFFAOYSA-N
DMQY50A	IU	3-[2-(3-hydroxyphenyl)-1,3-thiazol-5-yl]phenol
DMQY50A	DE	Discovery agent

DM40SNY	ID	DM40SNY
DM40SNY	DN	3,3'-(3-Methylthiene-2,5-diyl]diphenol
DM40SNY	HS	Investigative
DM40SNY	SN	CHEMBL572171; BDBM50299646
DM40SNY	DT	Small molecular drug
DM40SNY	PC	44543261
DM40SNY	MW	282.4
DM40SNY	FM	C17H14O2S
DM40SNY	IC	InChI=1S/C17H14O2S/c1-11-8-16(12-4-2-6-14(18)9-12)20-17(11)13-5-3-7-15(19)10-13/h2-10,18-19H,1H3
DM40SNY	CS	CC1=C(SC(=C1)C2=CC(=CC=C2)O)C3=CC(=CC=C3)O
DM40SNY	IK	LRHCSXOEZSEMIF-UHFFFAOYSA-N
DM40SNY	IU	3-[5-(3-hydroxyphenyl)-4-methylthiophen-2-yl]phenol
DM40SNY	DE	Discovery agent

DMUK1VX	ID	DMUK1VX
DMUK1VX	DN	3,3'-(3-Phenylthiene-2,5-diyl)diphenol
DMUK1VX	HS	Investigative
DMUK1VX	SN	CHEMBL569885; BDBM50299649
DMUK1VX	DT	Small molecular drug
DMUK1VX	PC	44542047
DMUK1VX	MW	344.4
DMUK1VX	FM	C22H16O2S
DMUK1VX	IC	InChI=1S/C22H16O2S/c23-18-10-4-8-16(12-18)21-14-20(15-6-2-1-3-7-15)22(25-21)17-9-5-11-19(24)13-17/h1-14,23-24H
DMUK1VX	CS	C1=CC=C(C=C1)C2=C(SC(=C2)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMUK1VX	IK	ZQUCGOXYEIRCOX-UHFFFAOYSA-N
DMUK1VX	IU	3-[5-(3-hydroxyphenyl)-4-phenylthiophen-2-yl]phenol
DMUK1VX	DE	Discovery agent

DMJVKMO	ID	DMJVKMO
DMJVKMO	DN	3,3'-(4-phenylpyridine-2,6-diyl)diphenol
DMJVKMO	HS	Investigative
DMJVKMO	SN	CHEMBL1095114
DMJVKMO	DT	Small molecular drug
DMJVKMO	PC	46887181
DMJVKMO	MW	339.4
DMJVKMO	FM	C23H17NO2
DMJVKMO	IC	InChI=1S/C23H17NO2/c25-20-10-4-8-17(12-20)22-14-19(16-6-2-1-3-7-16)15-23(24-22)18-9-5-11-21(26)13-18/h1-15,25-26H
DMJVKMO	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMJVKMO	IK	DLUFNTXHXJNUFJ-UHFFFAOYSA-N
DMJVKMO	IU	3-[6-(3-hydroxyphenyl)-4-phenylpyridin-2-yl]phenol
DMJVKMO	DE	Discovery agent

DMH7A32	ID	DMH7A32
DMH7A32	DN	3,3',3''-Thiene-2,3,5-triyltriphenol
DMH7A32	HS	Investigative
DMH7A32	SN	CHEMBL576682; BDBM50299657
DMH7A32	DT	Small molecular drug
DMH7A32	PC	44542800
DMH7A32	MW	360.4
DMH7A32	FM	C22H16O3S
DMH7A32	IC	InChI=1S/C22H16O3S/c23-17-7-1-4-14(10-17)20-13-21(15-5-2-8-18(24)11-15)26-22(20)16-6-3-9-19(25)12-16/h1-13,23-25H
DMH7A32	CS	C1=CC(=CC(=C1)O)C2=CC(=C(S2)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMH7A32	IK	ZBWIOPSLXQDYEV-UHFFFAOYSA-N
DMH7A32	IU	3-[4,5-bis(3-hydroxyphenyl)thiophen-2-yl]phenol
DMH7A32	DE	Discovery agent

DMBFY4H	ID	DMBFY4H
DMBFY4H	DN	3,3,3-tris(4-chlorophenyl)propanoic acid
DMBFY4H	HS	Investigative
DMBFY4H	SN	3,3,3-Tris(4-chlorophenyl)propionic acid; 2168-06-1; 3,3,3-Tris(4-chlorophenyl)propanoic acid; 3,3,3-Tris(p-chlorophenyl)propionic acid; CHEMBL201593; AK-23664; 3,3,3-tris-(4-Chlorophenyl)propionic acid; 3,3,3-TRIS(4-CHLOROPHENYL)PROPIONIS ACID; W-107531; rarechem al bo 1263; AC1Q3NC9; ACMC-1CB39; SCHEMBL503944; C21H15Cl3O2; AC1L2O20; LHIVWYJOCNGZRI-UHFFFAOYSA-; CTK4E7478; DTXSID30176065; LHIVWYJOCNGZRI-UHFFFAOYSA-N; MolPort-003-928-967; 3,3,3-tris-(4-chlorophenyl)-pr; ZINC4529217; KS-00000NC6; EINECS 218-509-3; CT-098
DMBFY4H	DT	Small molecular drug
DMBFY4H	PC	75107
DMBFY4H	MW	405.7
DMBFY4H	FM	C21H15Cl3O2
DMBFY4H	IC	InChI=1S/C21H15Cl3O2/c22-17-7-1-14(2-8-17)21(13-20(25)26,15-3-9-18(23)10-4-15)16-5-11-19(24)12-6-16/h1-12H,13H2,(H,25,26)
DMBFY4H	CS	C1=CC(=CC=C1C(CC(=O)O)(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)Cl
DMBFY4H	IK	LHIVWYJOCNGZRI-UHFFFAOYSA-N
DMBFY4H	IU	3,3,3-tris(4-chlorophenyl)propanoic acid
DMBFY4H	CA	CAS 2168-06-1
DMBFY4H	DE	Discovery agent

DMO51QG	ID	DMO51QG
DMO51QG	DN	3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile
DMO51QG	HS	Investigative
DMO51QG	SN	3,3-bis(4-hydroxyphenyl)-2-phenylprop-2-enenitrile; CHEMBL65053
DMO51QG	DT	Small molecular drug
DMO51QG	PC	14537247
DMO51QG	MW	313.3
DMO51QG	FM	C21H15NO2
DMO51QG	IC	InChI=1S/C21H15NO2/c22-14-20(15-4-2-1-3-5-15)21(16-6-10-18(23)11-7-16)17-8-12-19(24)13-9-17/h1-13,23-24H
DMO51QG	CS	C1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)C#N
DMO51QG	IK	PMKMHLVHNOXPOY-UHFFFAOYSA-N
DMO51QG	IU	3,3-bis(4-hydroxyphenyl)-2-phenylprop-2-enenitrile
DMO51QG	DE	Discovery agent

DMZPYN2	ID	DMZPYN2
DMZPYN2	DN	3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile
DMZPYN2	HS	Investigative
DMZPYN2	SN	CHEMBL304867
DMZPYN2	DT	Small molecular drug
DMZPYN2	PC	14537244
DMZPYN2	MW	341.4
DMZPYN2	FM	C23H19NO2
DMZPYN2	IC	InChI=1S/C23H19NO2/c1-25-20-12-8-18(9-13-20)23(19-10-14-21(26-2)15-11-19)22(16-24)17-6-4-3-5-7-17/h3-15H,1-2H3
DMZPYN2	CS	COC1=CC=C(C=C1)C(=C(C#N)C2=CC=CC=C2)C3=CC=C(C=C3)OC
DMZPYN2	IK	RQZZPWWADAMYCL-UHFFFAOYSA-N
DMZPYN2	IU	3,3-bis(4-methoxyphenyl)-2-phenylprop-2-enenitrile
DMZPYN2	DE	Discovery agent

DMK9BN0	ID	DMK9BN0
DMK9BN0	DN	3,3-di(pent-4-enyl)azetidin-2-one
DMK9BN0	HS	Investigative
DMK9BN0	SN	CHEMBL487447; 3,3-di(pent-4-enyl)azetidin-2-one
DMK9BN0	DT	Small molecular drug
DMK9BN0	PC	44560664
DMK9BN0	MW	207.31
DMK9BN0	FM	C13H21NO
DMK9BN0	IC	InChI=1S/C13H21NO/c1-3-5-7-9-13(10-8-6-4-2)11-14-12(13)15/h3-4H,1-2,5-11H2,(H,14,15)
DMK9BN0	CS	C=CCCCC1(CNC1=O)CCCC=C
DMK9BN0	IK	RZYCKKZEBQDDLK-UHFFFAOYSA-N
DMK9BN0	IU	3,3-bis(pent-4-enyl)azetidin-2-one
DMK9BN0	DE	Discovery agent

DMWFD5C	ID	DMWFD5C
DMWFD5C	DN	3,3-Diethyl-1-(pyridin-3-yl)azetidine-2,4-dione
DMWFD5C	HS	Investigative
DMWFD5C	SN	3,3-Diethyl-1-(pyridin-3-yl)azetidine-2,4-dione; CHEMBL566906; BDBM50303356
DMWFD5C	DT	Small molecular drug
DMWFD5C	PC	44626811
DMWFD5C	MW	218.25
DMWFD5C	FM	C12H14N2O2
DMWFD5C	IC	InChI=1S/C12H14N2O2/c1-3-12(4-2)10(15)14(11(12)16)9-6-5-7-13-8-9/h5-8H,3-4H2,1-2H3
DMWFD5C	CS	CCC1(C(=O)N(C1=O)C2=CN=CC=C2)CC
DMWFD5C	IK	OHEZXQVPDSACCJ-UHFFFAOYSA-N
DMWFD5C	IU	3,3-diethyl-1-pyridin-3-ylazetidine-2,4-dione
DMWFD5C	DE	Discovery agent

DMY8S94	ID	DMY8S94
DMY8S94	DN	3,3-Diethyl-1-o-tolylazetidine-2,4-dione
DMY8S94	HS	Investigative
DMY8S94	SN	CHEMBL566918; 3,3-Diethyl-1-o-tolylazetidine-2,4-dione
DMY8S94	DT	Small molecular drug
DMY8S94	PC	44626810
DMY8S94	MW	231.29
DMY8S94	FM	C14H17NO2
DMY8S94	IC	InChI=1S/C14H17NO2/c1-4-14(5-2)12(16)15(13(14)17)11-9-7-6-8-10(11)3/h6-9H,4-5H2,1-3H3
DMY8S94	CS	CCC1(C(=O)N(C1=O)C2=CC=CC=C2C)CC
DMY8S94	IK	QNAKQLGCEYBHNC-UHFFFAOYSA-N
DMY8S94	IU	3,3-diethyl-1-(2-methylphenyl)azetidine-2,4-dione
DMY8S94	DE	Discovery agent

DMCFJIP	ID	DMCFJIP
DMCFJIP	DN	3,3-diethyl-1-phenylazetidine-2,4-dione
DMCFJIP	HS	Investigative
DMCFJIP	SN	3,3-diethyl-1-phenylazetidine-2,4-dione; CHEMBL272413; 2,4-Azetidinedione, 3,3-diethyl-1-phenyl-; 15745-94-5; 3,3-Diethyl-1-phenylazetidin-2,4-dione; AC1L3FYP; DTXSID30166264; KDXSTYUPRNLDGW-UHFFFAOYSA-N; BDBM50235613; 1-Phenyl-3,3-diethylazetidine-2,4-dione
DMCFJIP	DT	Small molecular drug
DMCFJIP	PC	139973
DMCFJIP	MW	217.26
DMCFJIP	FM	C13H15NO2
DMCFJIP	IC	InChI=1S/C13H15NO2/c1-3-13(4-2)11(15)14(12(13)16)10-8-6-5-7-9-10/h5-9H,3-4H2,1-2H3
DMCFJIP	CS	CCC1(C(=O)N(C1=O)C2=CC=CC=C2)CC
DMCFJIP	IK	KDXSTYUPRNLDGW-UHFFFAOYSA-N
DMCFJIP	IU	3,3-diethyl-1-phenylazetidine-2,4-dione
DMCFJIP	CA	CAS 15745-94-5
DMCFJIP	DE	Discovery agent

DMFJ9N0	ID	DMFJ9N0
DMFJ9N0	DN	3,3-Diethyl-dihydro-furan-2-one
DMFJ9N0	HS	Investigative
DMFJ9N0	SN	2(3H)-Furanone, 3,3-diethyldihydro-; 50994-87-1; SCHEMBL576533; CHEMBL286415; dihydro-3,3-diethyl-2(3h)-furanone
DMFJ9N0	DT	Small molecular drug
DMFJ9N0	PC	14872649
DMFJ9N0	MW	142.2
DMFJ9N0	FM	C8H14O2
DMFJ9N0	IC	InChI=1S/C8H14O2/c1-3-8(4-2)5-6-10-7(8)9/h3-6H2,1-2H3
DMFJ9N0	CS	CCC1(CCOC1=O)CC
DMFJ9N0	IK	OKKTUDVXPHANCU-UHFFFAOYSA-N
DMFJ9N0	IU	3,3-diethyloxolan-2-one
DMFJ9N0	DE	Discovery agent

DMGMJWL	ID	DMGMJWL
DMGMJWL	DN	3,3'-difluorobenzaldazine
DMGMJWL	HS	Investigative
DMGMJWL	SN	3,3'-Difluorobenzaldazine; DFB; 15332-10-2; CHEMBL371811; 1,2-Bis(3-Fluorobenzylidene)Hydrazine; AC1O7H0M; SCHEMBL12017614; SCHEMBL12497017; bis(3-fluorobenzylidene)hydrazine; CHEBI:92414; MolPort-003-940-930; HMS3262J07; Tox21_500843; DFB, &gt; MFCD03653615; BDBM50156074; ZINC13719901; AKOS024456711; VZ25360; CCG-222147; NCGC00261528-01; NCGC00025238-05; NCGC00025238-02; NCGC00025238-03; NCGC00025238-04; KB-76455; SR-01000597595; C-14798; J-009001; SR-01000597595-1; 3,3 inverted exclamation marka-Difluorobenzaldazine
DMGMJWL	DT	Small molecular drug
DMGMJWL	PC	6604893
DMGMJWL	MW	244.24
DMGMJWL	FM	C14H10F2N2
DMGMJWL	IC	InChI=1S/C14H10F2N2/c15-13-5-1-3-11(7-13)9-17-18-10-12-4-2-6-14(16)8-12/h1-10H/b17-9+,18-10+
DMGMJWL	CS	C1=CC(=CC(=C1)F)/C=N/N=C/C2=CC(=CC=C2)F
DMGMJWL	IK	YYMCVDNIIFNDJK-BEQMOXJMSA-N
DMGMJWL	IU	(E)-1-(3-fluorophenyl)-N-[(E)-(3-fluorophenyl)methylideneamino]methanimine
DMGMJWL	CB	CHEBI:92414
DMGMJWL	DE	Discovery agent

DMIFUDG	ID	DMIFUDG
DMIFUDG	DN	3,3-Diisopropyl-dihydro-furan-2-one
DMIFUDG	HS	Investigative
DMIFUDG	SN	CHEMBL34879; 2(3H)-Furanone, dihydro-3,3-bis(1-methylethyl)-; SCHEMBL10358026; 132462-12-5
DMIFUDG	DT	Small molecular drug
DMIFUDG	PC	10352121
DMIFUDG	MW	170.25
DMIFUDG	FM	C10H18O2
DMIFUDG	IC	InChI=1S/C10H18O2/c1-7(2)10(8(3)4)5-6-12-9(10)11/h7-8H,5-6H2,1-4H3
DMIFUDG	CS	CC(C)C1(CCOC1=O)C(C)C
DMIFUDG	IK	HBNIKFYZKDWFNE-UHFFFAOYSA-N
DMIFUDG	IU	3,3-di(propan-2-yl)oxolan-2-one
DMIFUDG	DE	Discovery agent

DMUS0A4	ID	DMUS0A4
DMUS0A4	DN	3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one
DMUS0A4	HS	Investigative
DMUS0A4	SN	CHEMBL566982; SCHEMBL4421269; 3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one; IQXQUXAACBOTRO-UHFFFAOYSA-N; ZINC45245855; BDBM50299884
DMUS0A4	DT	Small molecular drug
DMUS0A4	PC	45483822
DMUS0A4	MW	250.3
DMUS0A4	FM	C18H18O
DMUS0A4	IC	InChI=1S/C18H18O/c1-12-5-4-6-13(9-12)14-7-8-15-16(10-14)18(2,3)11-17(15)19/h4-10H,11H2,1-3H3
DMUS0A4	CS	CC1=CC(=CC=C1)C2=CC3=C(C=C2)C(=O)CC3(C)C
DMUS0A4	IK	IQXQUXAACBOTRO-UHFFFAOYSA-N
DMUS0A4	IU	3,3-dimethyl-5-(3-methylphenyl)-2H-inden-1-one
DMUS0A4	DE	Discovery agent

DM09LY4	ID	DM09LY4
DM09LY4	DN	3,3-Dimethyl-dihydro-furan-2-one
DM09LY4	HS	Investigative
DM09LY4	SN	3709-08-8; alpha,alpha-Dimethyl-gamma-butyrolactone; 3,3-dimethyldihydrofuran-2(3h)-one; 3,3-dimethyloxolan-2-one; 2(3H)-Furanone, dihydro-3,3-dimethyl-; Dihydro-3,3-dimethyl-2(3H)-furanone; 2,2-Dimethyl-4-butyrolactone; UPVAIJPDWVTFKT-UHFFFAOYSA-N; Butyric acid, 2,2-dimethyl-4-hydroxy-, g-lactone; Dimethylbutanolid; alpha-DMgBL; NSC1094; AC1L3STF; AC1Q6HQD; 2,2-dimethylbutyrolactone; Furanone, dihydrodimethyl-; a,a-Dimethyl- -butyrolactone; SCHEMBL149596; CHEMBL33962; CTK2A6366; DTXSID30190584; MolPort-009-198-442
DM09LY4	DT	Small molecular drug
DM09LY4	PC	94746
DM09LY4	MW	114.14
DM09LY4	FM	C6H10O2
DM09LY4	IC	InChI=1S/C6H10O2/c1-6(2)3-4-8-5(6)7/h3-4H2,1-2H3
DM09LY4	CS	CC1(CCOC1=O)C
DM09LY4	IK	UPVAIJPDWVTFKT-UHFFFAOYSA-N
DM09LY4	IU	3,3-dimethyloxolan-2-one
DM09LY4	CA	CAS 3709-08-8
DM09LY4	DE	Discovery agent

DMNOUSV	ID	DMNOUSV
DMNOUSV	DN	3,3-diphenylpropan-1-amine
DMNOUSV	HS	Investigative
DMNOUSV	SN	3,3-Diphenylpropylamine; 5586-73-2; 3,3-diphenylpropan-1-amine; UNII-C31E561S64; KISZTEOELCMZPY-UHFFFAOYSA-N; Benzenepropanamine, .gamma.-phenyl-; MFCD00008202; C31E561S64; 3-3-Diphenylpropylamine; 3,3-diphenylpropylamine e; 3,3-diphenylpropan-1-amin; EINECS 226-984-3; NSC137832; NSC 137832; ACMC-209lpx; 3.3-diphenylpropylamine; 3,3 Diphenylpropylamine; 3,3-diphenyl-propylamine; 3,3-diphenyl propylamine; EC 226-984-3; (3,3-diphenylpropyl)amine; AC1Q1HZ2; AC1L2XY3; TimTec1_004202; 3,3-Diphenyl-1-propanamine; Propylamine, 3,3-dipheny
DMNOUSV	DT	Small molecular drug
DMNOUSV	PC	79698
DMNOUSV	MW	211.3
DMNOUSV	FM	C15H17N
DMNOUSV	IC	InChI=1S/C15H17N/c16-12-11-15(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10,15H,11-12,16H2
DMNOUSV	CS	C1=CC=C(C=C1)C(CCN)C2=CC=CC=C2
DMNOUSV	IK	KISZTEOELCMZPY-UHFFFAOYSA-N
DMNOUSV	IU	3,3-diphenylpropan-1-amine
DMNOUSV	CA	CAS 5586-73-2
DMNOUSV	DE	Discovery agent

DMZTIPJ	ID	DMZTIPJ
DMZTIPJ	DN	3,3'-pyrazine-2,5-diyldiphenol
DMZTIPJ	HS	Investigative
DMZTIPJ	SN	SCHEMBL1180306; CHEMBL450256; BDBM25866; ZINC40835319; hydroxyphenyl substituted pyrazine, 38
DMZTIPJ	DT	Small molecular drug
DMZTIPJ	PC	25093399
DMZTIPJ	MW	264.28
DMZTIPJ	FM	C16H12N2O2
DMZTIPJ	IC	InChI=1S/C16H12N2O2/c19-13-5-1-3-11(7-13)15-9-18-16(10-17-15)12-4-2-6-14(20)8-12/h1-10,19-20H
DMZTIPJ	CS	C1=CC(=CC(=C1)O)C2=CN=C(C=N2)C3=CC(=CC=C3)O
DMZTIPJ	IK	NBGGRQZLXLTPFA-UHFFFAOYSA-N
DMZTIPJ	IU	3-[5-(3-hydroxyphenyl)pyrazin-2-yl]phenol
DMZTIPJ	DE	Discovery agent

DMZILNC	ID	DMZILNC
DMZILNC	DN	3,3'-Pyridine-2,5-diyldiphenol
DMZILNC	HS	Investigative
DMZILNC	SN	SCHEMBL1181050; CHEMBL460182; BDBM25865; 3,3'-(2,5-Pyridinediyl)bisphenol; ZINC40865361; hydroxyphenyl substituted pyridine, 37
DMZILNC	DT	Small molecular drug
DMZILNC	PC	25093398
DMZILNC	MW	263.29
DMZILNC	FM	C17H13NO2
DMZILNC	IC	InChI=1S/C17H13NO2/c19-15-5-1-3-12(9-15)14-7-8-17(18-11-14)13-4-2-6-16(20)10-13/h1-11,19-20H
DMZILNC	CS	C1=CC(=CC(=C1)O)C2=CN=C(C=C2)C3=CC(=CC=C3)O
DMZILNC	IK	GWBPLTAHNKSFLG-UHFFFAOYSA-N
DMZILNC	IU	3-[6-(3-hydroxyphenyl)pyridin-3-yl]phenol
DMZILNC	DE	Discovery agent

DMW7XFQ	ID	DMW7XFQ
DMW7XFQ	DN	3,3'-Thiene-2,4-diyldiphenol
DMW7XFQ	HS	Investigative
DMW7XFQ	SN	3,3'-Thiene-2,4-diyldiphenol; SCHEMBL1180152; CHEMBL461027; BDBM25856; FIVXNZZSAFLVFQ-UHFFFAOYSA-N; ZINC40391436; hydroxyphenyl substituted thiophene, 28
DMW7XFQ	DT	Small molecular drug
DMW7XFQ	PC	25093392
DMW7XFQ	MW	268.3
DMW7XFQ	FM	C16H12O2S
DMW7XFQ	IC	InChI=1S/C16H12O2S/c17-14-5-1-3-11(7-14)13-9-16(19-10-13)12-4-2-6-15(18)8-12/h1-10,17-18H
DMW7XFQ	CS	C1=CC(=CC(=C1)O)C2=CC(=CS2)C3=CC(=CC=C3)O
DMW7XFQ	IK	FIVXNZZSAFLVFQ-UHFFFAOYSA-N
DMW7XFQ	IU	3-[4-(3-hydroxyphenyl)thiophen-2-yl]phenol
DMW7XFQ	DE	Discovery agent

DMWH0ER	ID	DMWH0ER
DMWH0ER	DN	3,3'-thiene-2,5-diyldiphenol
DMWH0ER	HS	Investigative
DMWH0ER	SN	3,3'-Thiene-2,5-diyldiphenol; SCHEMBL1181010; CHEMBL511530; BDBM25851; SVBBCXVMACPXGW-UHFFFAOYSA-N; ZINC40393198; hydroxyphenyl substituted thiophene, 23
DMWH0ER	DT	Small molecular drug
DMWH0ER	PC	25093387
DMWH0ER	MW	268.3
DMWH0ER	FM	C16H12O2S
DMWH0ER	IC	InChI=1S/C16H12O2S/c17-13-5-1-3-11(9-13)15-7-8-16(19-15)12-4-2-6-14(18)10-12/h1-10,17-18H
DMWH0ER	CS	C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=CC=C3)O
DMWH0ER	IK	SVBBCXVMACPXGW-UHFFFAOYSA-N
DMWH0ER	IU	3-[5-(3-hydroxyphenyl)thiophen-2-yl]phenol
DMWH0ER	DE	Discovery agent

DMQDKYI	ID	DMQDKYI
DMQDKYI	DN	3,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine
DMQDKYI	HS	Investigative
DMQDKYI	SN	CHEMBL1077387; 36770-51-1; 1H-3-(3-pyridyl)-5-(4-pyridyl)-1,2,4-triazole; AC1LJ7ET; SCHEMBL11592234; MolPort-002-889-160; BDBM50311281; STL442012; CCG-42398; ZINC18164784; AKOS002669464; AKOS005228430; AKOS002732698; MCULE-6941572691; FT-0749446; 3,4''-(1H-1,2,4-triazole-3,5-diyl)dipyridine; SR-01000632401-1; 3-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine; 3-(3-Pyridyl)-5-(4-pyridyl)-1H-1,2,4-triazole
DMQDKYI	DT	Small molecular drug
DMQDKYI	PC	918281
DMQDKYI	MW	223.23
DMQDKYI	FM	C12H9N5
DMQDKYI	IC	InChI=1S/C12H9N5/c1-2-10(8-14-5-1)12-15-11(16-17-12)9-3-6-13-7-4-9/h1-8H,(H,15,16,17)
DMQDKYI	CS	C1=CC(=CN=C1)C2=NNC(=N2)C3=CC=NC=C3
DMQDKYI	IK	WIHUWTSKKGOEGI-UHFFFAOYSA-N
DMQDKYI	IU	3-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine
DMQDKYI	CA	CAS 36770-51-1
DMQDKYI	DE	Discovery agent

DMFM60H	ID	DMFM60H
DMFM60H	DN	3,4'-(Ethane-1,2-diyl)dibenzenamine
DMFM60H	HS	Investigative
DMFM60H	SN	CHEMBL1172396; 3,4'-Ethylenedianiline; BDBM50322062
DMFM60H	DT	Small molecular drug
DMFM60H	PC	13580711
DMFM60H	MW	212.29
DMFM60H	FM	C14H16N2
DMFM60H	IC	InChI=1S/C14H16N2/c15-13-8-6-11(7-9-13)4-5-12-2-1-3-14(16)10-12/h1-3,6-10H,4-5,15-16H2
DMFM60H	CS	C1=CC(=CC(=C1)N)CCC2=CC=C(C=C2)N
DMFM60H	IK	INOLZHNXGZQKJJ-UHFFFAOYSA-N
DMFM60H	IU	3-[2-(4-aminophenyl)ethyl]aniline
DMFM60H	DE	Discovery agent

DMEN9T4	ID	DMEN9T4
DMEN9T4	DN	3,4'-(thiophene-2,4-diyl)diphenol
DMEN9T4	HS	Investigative
DMEN9T4	SN	SCHEMBL1180505; CHEMBL505523; BDBM25855; VPHQUMICJYAMAM-UHFFFAOYSA-N; ZINC40835480; 3,4'-(2,4-Thiophenediyl)bisphenol; hydroxyphenyl substituted thiophene, 27; 3-[4-(4-Hydroxyphenyl)-2-thienyl]phenol
DMEN9T4	DT	Small molecular drug
DMEN9T4	PC	25093391
DMEN9T4	MW	268.3
DMEN9T4	FM	C16H12O2S
DMEN9T4	IC	InChI=1S/C16H12O2S/c17-14-6-4-11(5-7-14)13-9-16(19-10-13)12-2-1-3-15(18)8-12/h1-10,17-18H
DMEN9T4	CS	C1=CC(=CC(=C1)O)C2=CC(=CS2)C3=CC=C(C=C3)O
DMEN9T4	IK	VPHQUMICJYAMAM-UHFFFAOYSA-N
DMEN9T4	IU	3-[4-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMEN9T4	DE	Discovery agent

DMSN814	ID	DMSN814
DMSN814	DN	3,4,4',5-tetramethoxy-(Z)-stilbene
DMSN814	HS	Investigative
DMSN814	SN	CHEMBL47426; 134029-49-5; 1-Mtpe; NSC638499; Deoxycombretastatin A4; AC1NTUK5; ZINC5900; SCHEMBL3834841; (Z)-1,2,3-Trimethoxy-5-(2-(4-methoxyphenyl)ethenyl)benzene; cis-3,4,5,4'-tetramethoxystilbene; BDBM50006677; 10Z-3,4,4',5-tetramethoxystilbene; AKOS027382909; NSC-638499; 10Z-3,4,4'',5-tetramethoxystilbene; 3,4,4'',5-tetramethoxy-(Z)-stilbene; (Z) 3,4',5-TETRAMETHOXYSTILBENE; 5-(4-methoxystyryl)-1,2,3-trimethoxybenzene; (Z)-1,2,3-Trimethoxy-5-(4-methoxystyryl)benzene
DMSN814	DT	Small molecular drug
DMSN814	PC	5388779
DMSN814	MW	300.3
DMSN814	FM	C18H20O4
DMSN814	IC	InChI=1S/C18H20O4/c1-19-15-9-7-13(8-10-15)5-6-14-11-16(20-2)18(22-4)17(12-14)21-3/h5-12H,1-4H3/b6-5-
DMSN814	CS	COC1=CC=C(C=C1)/C=C\\C2=CC(=C(C(=C2)OC)OC)OC
DMSN814	IK	GGFQQRXTLIJXNY-WAYWQWQTSA-N
DMSN814	IU	1,2,3-trimethoxy-5-[(Z)-2-(4-methoxyphenyl)ethenyl]benzene
DMSN814	CA	CAS 134029-49-5
DMSN814	DE	Discovery agent

DMSV6K5	ID	DMSV6K5
DMSV6K5	DN	3,4,5,6-Tetrachloro-[1,2]benzoquinone
DMSV6K5	HS	Investigative
DMSV6K5	SN	o-Chloranil; 2435-53-2; Tetrachloro-O-benzoquinone; 3,4,5,6-tetrachlorocyclohexa-3,5-diene-1,2-dione; 3,4,5,6-Tetrachloro-1,2-benzoquinone; Tetrachloro-o-quinone; 2-Chloranil; Tetrachloro-1,2-benzoquinone; o-Chloroanil; Isochloranil; 3,5-Cyclohexadiene-1,2-dione, 3,4,5,6-tetrachloro-; ortho-Chloranil; UNII-QN2NZL16NG; 3,4,5,6-Tetrachloro-o-benzoquinone; QN2NZL16NG; NSC 403503; o-Benzoquinone, 3,4,5,6-tetrachloro-; 3,4,5,6-Tetrachloro-3,5-cyclohexadiene-1,2-dione; MLS003171542; VRGCYEIGVVTZCC-UHFFFAOYSA-N
DMSV6K5	DT	Small molecular drug
DMSV6K5	PC	73252
DMSV6K5	MW	245.9
DMSV6K5	FM	C6Cl4O2
DMSV6K5	IC	InChI=1S/C6Cl4O2/c7-1-2(8)4(10)6(12)5(11)3(1)9
DMSV6K5	CS	C1(=C(C(=O)C(=O)C(=C1Cl)Cl)Cl)Cl
DMSV6K5	IK	VRGCYEIGVVTZCC-UHFFFAOYSA-N
DMSV6K5	IU	3,4,5,6-tetrachlorocyclohexa-3,5-diene-1,2-dione
DMSV6K5	CA	CAS 2435-53-2
DMSV6K5	DE	Discovery agent

DMKOE9I	ID	DMKOE9I
DMKOE9I	DN	3,4,5,6-Tetrahydrobenzo[c]quinolizin-3-(4aH)-one
DMKOE9I	HS	Investigative
DMKOE9I	SN	CHEMBL99448; 3,4,5,6-Tetrahydrobenzo[c]quinolizin-3-(4aH)-one; SCHEMBL6940070; LNTWPSKEEYNUKK-UHFFFAOYSA-N; BDBM50072192; 4,4a,5,6-Tetrahydro-pyrido[1,2-a]quinolin-3-one; 4,4a,5,6-Tetrahydro-3H-benzo[c]quinolizine-3-one
DMKOE9I	DT	Small molecular drug
DMKOE9I	PC	10442752
DMKOE9I	MW	199.25
DMKOE9I	FM	C13H13NO
DMKOE9I	IC	InChI=1S/C13H13NO/c15-12-7-8-14-11(9-12)6-5-10-3-1-2-4-13(10)14/h1-4,7-8,11H,5-6,9H2
DMKOE9I	CS	C1CC2=CC=CC=C2N3C1CC(=O)C=C3
DMKOE9I	IK	LNTWPSKEEYNUKK-UHFFFAOYSA-N
DMKOE9I	IU	4,4a,5,6-tetrahydrobenzo[f]quinolizin-3-one
DMKOE9I	DE	Discovery agent

DMS42CA	ID	DMS42CA
DMS42CA	DN	3,4,5-tribromo-2-(2', 4'-dibromo-phenoxy)phenol
DMS42CA	HS	Investigative
DMS42CA	SN	CHEMBL464577; CHEBI:68326; 3,4,5-tribromo-2-(2,4-dibromophenoxy)phenol; 35162-01-7; Dysidea substance A; 6-hydroxy-2,2',3,4,4'-pentabromodiphenyl ether; SCHEMBL5527228; CTK1B7172; DTXSID60474586; BDBM50292443; ACM35162017; 3,4,5-tribromo-2-(2',4'-dibromophenoxy)phenol; Phenol, 3,4,5-tribromo-2-(2,4-dibromophenoxy)-; 3,4,5-tribromo-2-(2'', 4''-dibromo-phenoxy)phenol
DMS42CA	DT	Small molecular drug
DMS42CA	PC	11952901
DMS42CA	MW	580.7
DMS42CA	FM	C12H5Br5O2
DMS42CA	IC	InChI=1S/C12H5Br5O2/c13-5-1-2-9(6(14)3-5)19-12-8(18)4-7(15)10(16)11(12)17/h1-4,18H
DMS42CA	CS	C1=CC(=C(C=C1Br)Br)OC2=C(C(=C(C=C2O)Br)Br)Br
DMS42CA	IK	LNZHBUPVHNJGJG-UHFFFAOYSA-N
DMS42CA	IU	3,4,5-tribromo-2-(2,4-dibromophenoxy)phenol
DMS42CA	CA	CAS 35162-01-7
DMS42CA	CB	CHEBI:68326
DMS42CA	DE	Discovery agent

DMYHC3S	ID	DMYHC3S
DMYHC3S	DN	3,4',5-trimethoxy-(Z)-stilbene
DMYHC3S	HS	Investigative
DMYHC3S	SN	(Z)-3,5,4'-TRIMETHOXYSTILBENE; cis-trismethoxy Resveratrol; 94608-23-8; CHEMBL311636; (Z)-3,4',5-trimethoxystilbene; cis-Trismethoxyresveratrol; cis-Stilbene Derivative, 5a; SCHEMBL1006207; ZINC9252; 8Z-3,4',5-trimethoxystilbene; BDBM23940; MolPort-009-018-268; GDHNBPHYVRHYCC-PLNGDYQASA-N; (Z)-3,5,40-Trimethoxystilbene; HMS3648G16; 1101AH; AKOS025401671; AC-24237; DB-079973; 608T238; SR-01000946368; SR-01000946368-1; I14-7426; 1,3-dimethoxy-5-[(Z)-2-(4-methoxyphenyl)ethenyl]benzene
DMYHC3S	DT	Small molecular drug
DMYHC3S	PC	9878556
DMYHC3S	MW	270.32
DMYHC3S	FM	C17H18O3
DMYHC3S	IC	InChI=1S/C17H18O3/c1-18-15-8-6-13(7-9-15)4-5-14-10-16(19-2)12-17(11-14)20-3/h4-12H,1-3H3/b5-4-
DMYHC3S	CS	COC1=CC=C(C=C1)/C=C\\C2=CC(=CC(=C2)OC)OC
DMYHC3S	IK	GDHNBPHYVRHYCC-PLNGDYQASA-N
DMYHC3S	IU	1,3-dimethoxy-5-[(Z)-2-(4-methoxyphenyl)ethenyl]benzene
DMYHC3S	CA	CAS 94608-23-8
DMYHC3S	DE	Discovery agent

DMCA7XU	ID	DMCA7XU
DMCA7XU	DN	3,4,5-Trimethoxy-3'-amino-trans-stilbene
DMCA7XU	HS	Investigative
DMCA7XU	SN	CHEMBL1173065; SCHEMBL17236642; BDBM50322052
DMCA7XU	DT	Small molecular drug
DMCA7XU	PC	49799650
DMCA7XU	MW	285.34
DMCA7XU	FM	C17H19NO3
DMCA7XU	IC	InChI=1S/C17H19NO3/c1-19-15-10-13(11-16(20-2)17(15)21-3)8-7-12-5-4-6-14(18)9-12/h4-11H,18H2,1-3H3/b8-7+
DMCA7XU	CS	COC1=CC(=CC(=C1OC)OC)/C=C/C2=CC(=CC=C2)N
DMCA7XU	IK	KHIQMXWOBUJQMV-BQYQJAHWSA-N
DMCA7XU	IU	3-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline
DMCA7XU	DE	Discovery agent

DMDBOJ5	ID	DMDBOJ5
DMDBOJ5	DN	3,4,5-Trimethoxy-4'-amino-trans-stilbene
DMDBOJ5	HS	Investigative
DMDBOJ5	SN	CHEMBL87477; SCHEMBL4263050; MWXBWYJFAGYFKS-SNAWJCMRSA-N; ZINC26575008; BDBM50322046; (E)-4'-Amino-3,4,5-trimethoxystilbene; 3,4,5-Trimethoxy-4''-amino-trans-stilbene; 4-[2-(3,4,5-Trimethoxy-phenyl)-vinyl]-phenylamine
DMDBOJ5	DT	Small molecular drug
DMDBOJ5	PC	15696376
DMDBOJ5	MW	285.34
DMDBOJ5	FM	C17H19NO3
DMDBOJ5	IC	InChI=1S/C17H19NO3/c1-19-15-10-13(11-16(20-2)17(15)21-3)5-4-12-6-8-14(18)9-7-12/h4-11H,18H2,1-3H3/b5-4+
DMDBOJ5	CS	COC1=CC(=CC(=C1OC)OC)/C=C/C2=CC=C(C=C2)N
DMDBOJ5	IK	MWXBWYJFAGYFKS-SNAWJCMRSA-N
DMDBOJ5	IU	4-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline
DMDBOJ5	DE	Discovery agent

DMU5NRA	ID	DMU5NRA
DMU5NRA	DN	3,4,5-trimethoxy-N-(thiazol-2-yl)benzamide
DMU5NRA	HS	Investigative
DMU5NRA	SN	3,4,5-Trimethoxy-N-(1,3-thiazol-2-yl)benzamide; 50591-71-4; AC1LCU6P; Cambridge id 5149479; Oprea1_821264; MLS000027375; CHEMBL225354; ZINC45264; XSAYHNGEJLPKEX-UHFFFAOYSA-N; MolPort-000-653-421; HMS2331F23; STK731712; AKOS001625155; MCULE-9743171840; NCGC00018998-01; NCGC00018998-02; ST067007; SMR000034190; Benzamide, 3,4,5-trimethoxy-N-2-thiazolyl-; Thiazole, 2-(3,4,5-trimethoxybenzoylamino)-; 3,4,5-trimethoxy-N-1,3-thiazol-2-ylbenzamide; SR-01000000944; SR-01000000944-2; Z28173733
DMU5NRA	DT	Small molecular drug
DMU5NRA	PC	606801
DMU5NRA	MW	294.33
DMU5NRA	FM	C13H14N2O4S
DMU5NRA	IC	InChI=1S/C13H14N2O4S/c1-17-9-6-8(7-10(18-2)11(9)19-3)12(16)15-13-14-4-5-20-13/h4-7H,1-3H3,(H,14,15,16)
DMU5NRA	CS	COC1=CC(=CC(=C1OC)OC)C(=O)NC2=NC=CS2
DMU5NRA	IK	XSAYHNGEJLPKEX-UHFFFAOYSA-N
DMU5NRA	IU	3,4,5-trimethoxy-N-(1,3-thiazol-2-yl)benzamide
DMU5NRA	DE	Discovery agent

DMO34LJ	ID	DMO34LJ
DMO34LJ	DN	3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol
DMO34LJ	HS	Investigative
DMO34LJ	SN	CHEMBL186098; 6-hydroxy-2,2',3,4',5-pentabromodiphenyl ether; 3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol; ZINC95606620; BDBM50150782; 497069-29-1; 2-(2,4-Dibromophenoxy)-3,4,6-tribromophenol
DMO34LJ	DT	Small molecular drug
DMO34LJ	PC	11093078
DMO34LJ	MW	580.7
DMO34LJ	FM	C12H5Br5O2
DMO34LJ	IC	InChI=1S/C12H5Br5O2/c13-5-1-2-9(6(14)3-5)19-12-10(17)7(15)4-8(16)11(12)18/h1-4,18H
DMO34LJ	CS	C1=CC(=C(C=C1Br)Br)OC2=C(C(=CC(=C2Br)Br)Br)O
DMO34LJ	IK	FAGFPLJEMPQMRV-UHFFFAOYSA-N
DMO34LJ	IU	3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
DMO34LJ	DE	Discovery agent

DM3MAEQ	ID	DM3MAEQ
DM3MAEQ	DN	3,4,6-Trihydroxy-2-(4-hydroxy-phenyl)-inden-1-one
DM3MAEQ	HS	Investigative
DM3MAEQ	DT	Small molecular drug
DM3MAEQ	PC	10308184
DM3MAEQ	MW	270.24
DM3MAEQ	FM	C15H10O5
DM3MAEQ	IC	InChI=1S/C15H10O5/c16-8-3-1-7(2-4-8)12-14(19)10-5-9(17)6-11(18)13(10)15(12)20/h1-6,12,16-18H
DM3MAEQ	CS	C1=CC(=CC=C1C2C(=O)C3=C(C2=O)C(=CC(=C3)O)O)O
DM3MAEQ	IK	GXKXWCKNQMYETG-UHFFFAOYSA-N
DM3MAEQ	IU	4,6-dihydroxy-2-(4-hydroxyphenyl)indene-1,3-dione
DM3MAEQ	DE	Discovery agent

DMN4Z27	ID	DMN4Z27
DMN4Z27	DN	3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin
DMN4Z27	HS	Investigative
DMN4Z27	SN	CHEMBL487235; 3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin
DMN4Z27	DT	Small molecular drug
DMN4Z27	PC	25139469
DMN4Z27	MW	345.2
DMN4Z27	FM	C17H13BrO3
DMN4Z27	IC	InChI=1S/C17H13BrO3/c1-10(18)9-20-15-8-7-13-12-5-3-4-6-14(12)17(19)21-16(13)11(15)2/h3-8H,1,9H2,2H3
DMN4Z27	CS	CC1=C(C=CC2=C1OC(=O)C3=CC=CC=C23)OCC(=C)Br
DMN4Z27	IK	GGTNLZBSSNHXRY-UHFFFAOYSA-N
DMN4Z27	IU	3-(2-bromoprop-2-enoxy)-4-methylbenzo[c]chromen-6-one
DMN4Z27	DE	Discovery agent

DM1MC06	ID	DM1MC06
DM1MC06	DN	3,4-Benzo-7-acetonyloxy-8-methoxycoumarin
DM1MC06	HS	Investigative
DM1MC06	SN	CHEMBL520061; 3,4-Benzo-7-acetonyloxy-8-methoxycoumarin
DM1MC06	DT	Small molecular drug
DM1MC06	PC	25139473
DM1MC06	MW	298.29
DM1MC06	FM	C17H14O5
DM1MC06	IC	InChI=1S/C17H14O5/c1-10(18)9-21-14-8-7-12-11-5-3-4-6-13(11)17(19)22-15(12)16(14)20-2/h3-8H,9H2,1-2H3
DM1MC06	CS	CC(=O)COC1=C(C2=C(C=C1)C3=CC=CC=C3C(=O)O2)OC
DM1MC06	IK	KXJLOTAAVRETIT-UHFFFAOYSA-N
DM1MC06	IU	4-methoxy-3-(2-oxopropoxy)benzo[c]chromen-6-one
DM1MC06	DE	Discovery agent

DMKC6L8	ID	DMKC6L8
DMKC6L8	DN	3,4-Benzo-7-acetonyloxy-8-methylcoumarin
DMKC6L8	HS	Investigative
DMKC6L8	SN	4-Methyl-3-(2-oxopropoxy)-6H-benzo[c]chromen-6-one; 307551-49-1; CHEMBL488072; CHEMBRDG-BB 6146055; CBMicro_001512; AC1LDVAV; 3,4-Benzo-7-acetonyloxy-8-methylcoumarin; ZINC83619; MolPort-000-689-004; ZX-CM016545; SMSF0015505; STL457381; BDBM50246269; AKOS002377781; MCULE-6636508935; CB03255; ACM307551491; AJ-10649; BIM-0001590.P001; W-9060; 4-methyl-3-(2-oxopropoxy)benzo[c]chromen-6-one; SR-01000229085
DMKC6L8	DT	Small molecular drug
DMKC6L8	PC	701990
DMKC6L8	MW	282.29
DMKC6L8	FM	C17H14O4
DMKC6L8	IC	InChI=1S/C17H14O4/c1-10(18)9-20-15-8-7-13-12-5-3-4-6-14(12)17(19)21-16(13)11(15)2/h3-8H,9H2,1-2H3
DMKC6L8	CS	CC1=C(C=CC2=C1OC(=O)C3=CC=CC=C23)OCC(=O)C
DMKC6L8	IK	VNVLPLZRLNYOQH-UHFFFAOYSA-N
DMKC6L8	IU	4-methyl-3-(2-oxopropoxy)benzo[c]chromen-6-one
DMKC6L8	DE	Discovery agent

DM91W2K	ID	DM91W2K
DM91W2K	DN	3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one
DM91W2K	HS	Investigative
DM91W2K	SN	CHEMBL1098382; 3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one
DM91W2K	DT	Small molecular drug
DM91W2K	PC	11760063
DM91W2K	MW	356.4
DM91W2K	FM	C20H20O6
DM91W2K	IC	InChI=1S/C20H20O6/c1-22-15-7-5-12(9-17(15)24-3)14-11-26-20(21)19(14)13-6-8-16(23-2)18(10-13)25-4/h5-10H,11H2,1-4H3
DM91W2K	CS	COC1=C(C=C(C=C1)C2=C(C(=O)OC2)C3=CC(=C(C=C3)OC)OC)OC
DM91W2K	IK	FGMQIGBHXSBGMS-UHFFFAOYSA-N
DM91W2K	IU	3,4-bis(3,4-dimethoxyphenyl)-2H-furan-5-one
DM91W2K	DE	Discovery agent

DMEQ1HC	ID	DMEQ1HC
DMEQ1HC	DN	3,4-bis(indol-3-yl)maleimide derivative
DMEQ1HC	HS	Investigative
DMEQ1HC	SN	CHEMBL7364
DMEQ1HC	DT	Small molecular drug
DMEQ1HC	PC	10033891
DMEQ1HC	MW	971.2
DMEQ1HC	FM	C49H66N10O9S
DMEQ1HC	IC	InChI=1S/C49H66N10O9S/c1-31(60)54-39(49(66)59-21-11-18-41(59)46(63)56-38(16-8-10-20-51)45(62)55-37(44(61)52-2)15-7-9-19-50)30-69-27-26-68-25-24-67-23-22-58-29-35(33-13-4-6-17-40(33)58)43-42(47(64)57-48(43)65)34-28-53-36-14-5-3-12-32(34)36/h3-6,12-14,17,28-29,37-39,41,53H,7-11,15-16,18-27,30,50-51H2,1-2H3,(H,52,61)(H,54,60)(H,55,62)(H,56,63)(H,57,64,65)/t37-,38-,39-,41-/m0/s1
DMEQ1HC	CS	CC(=O)N[C@@H](CSCCOCCOCCN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NC
DMEQ1HC	IK	HOAREJUGBLUUJD-MJSJRNKMSA-N
DMEQ1HC	IU	(2S)-1-[(2R)-2-acetamido-3-[2-[2-[2-[3-[4-(1H-indol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]ethoxy]ethoxy]ethylsulfanyl]propanoyl]-N-[(2S)-6-amino-1-[[(2S)-6-amino-1-(methylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
DMEQ1HC	DE	Discovery agent

DMDO175	ID	DMDO175
DMDO175	DN	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175	HS	Investigative
DMDO175	SN	1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388
DMDO175	DT	Small molecular drug
DMDO175	PC	10946795
DMDO175	MW	309.3
DMDO175	FM	C18H15NO4
DMDO175	IC	InChI=1S/C18H15NO4/c1-22-13-7-3-11(4-8-13)15-16(18(21)19-17(15)20)12-5-9-14(23-2)10-6-12/h3-10H,1-2H3,(H,19,20,21)
DMDO175	CS	COC1=CC=C(C=C1)C2=C(C(=O)NC2=O)C3=CC=C(C=C3)OC
DMDO175	IK	WRDXDCMVUJADCC-UHFFFAOYSA-N
DMDO175	IU	3,4-bis(4-methoxyphenyl)pyrrole-2,5-dione
DMDO175	CA	CAS 108774-82-9
DMDO175	DE	Discovery agent

DM8R03D	ID	DM8R03D
DM8R03D	DN	3,4-diarylpyrazoline derivative
DM8R03D	HS	Investigative
DM8R03D	DE	Discovery agent

DMBUT8A	ID	DMBUT8A
DMBUT8A	DN	3,4-dibenzyloxy-2'-hydroxychalcone
DMBUT8A	HS	Investigative
DMBUT8A	SN	CHEMBL492554; SCHEMBL17509393; SCHEMBL17509394; LHMDXKJKKAITQJ-BMRADRMJSA-N; BDBM50257724; 3,4-dibenzyloxy-2''-hydroxychalcone
DMBUT8A	DT	Small molecular drug
DMBUT8A	PC	25256831
DMBUT8A	MW	436.5
DMBUT8A	FM	C29H24O4
DMBUT8A	IC	InChI=1S/C29H24O4/c30-26-14-8-7-13-25(26)27(31)17-15-22-16-18-28(32-20-23-9-3-1-4-10-23)29(19-22)33-21-24-11-5-2-6-12-24/h1-19,30H,20-21H2/b17-15+
DMBUT8A	CS	C1=CC=C(C=C1)COC2=C(C=C(C=C2)/C=C/C(=O)C3=CC=CC=C3O)OCC4=CC=CC=C4
DMBUT8A	IK	LHMDXKJKKAITQJ-BMRADRMJSA-N
DMBUT8A	IU	(E)-3-[3,4-bis(phenylmethoxy)phenyl]-1-(2-hydroxyphenyl)prop-2-en-1-one
DMBUT8A	DE	Discovery agent

DMXQVRD	ID	DMXQVRD
DMXQVRD	DN	3,4-Dibromo-2-(5-bromo-2-hydroxy-phenoxy)-phenol
DMXQVRD	HS	Investigative
DMXQVRD	SN	CHEMBL187472; 3,4-Dibromo-2-(5-bromo-2-hydroxy-phenoxy)-phenol; Phenol, 3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)-; BDBM50150781; 741285-19-8; 5,5',6-Tribromo-2,2'-dihydroxydiphenyl ether
DMXQVRD	DT	Small molecular drug
DMXQVRD	PC	44396194
DMXQVRD	MW	438.89
DMXQVRD	FM	C12H7Br3O3
DMXQVRD	IC	InChI=1S/C12H7Br3O3/c13-6-1-3-8(16)10(5-6)18-12-9(17)4-2-7(14)11(12)15/h1-5,16-17H
DMXQVRD	CS	C1=CC(=C(C=C1Br)OC2=C(C=CC(=C2Br)Br)O)O
DMXQVRD	IK	MQTQEJZMDKSDNZ-UHFFFAOYSA-N
DMXQVRD	IU	3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)phenol
DMXQVRD	DE	Discovery agent

DMS1QIJ	ID	DMS1QIJ
DMS1QIJ	DN	3',4'-dichloroacetophenonethiosemicarbazone
DMS1QIJ	HS	Investigative
DMS1QIJ	SN	CHEMBL90512; 3',4'-dichloroacetophenonethiosemicarbazone; HMS544L20; MolPort-000-519-093; 18087-41-7; BDBM50114653; AKOS002268894; CCG-244059; ST50170879; [(E)-1-(3,4-dichlorophenyl)ethylideneamino]thiourea; 1-(3,4-DICHLOROPHENYL)ETHANONE THIOSEMICARBAZONE; (1E)-1-(3,4-dichlorophenyl)ethan-1-one thiosemicarbazone
DMS1QIJ	DT	Small molecular drug
DMS1QIJ	PC	9583002
DMS1QIJ	MW	262.16
DMS1QIJ	FM	C9H9Cl2N3S
DMS1QIJ	IC	InChI=1S/C9H9Cl2N3S/c1-5(13-14-9(12)15)6-2-3-7(10)8(11)4-6/h2-4H,1H3,(H3,12,14,15)/b13-5+
DMS1QIJ	CS	C/C(=N\\NC(=S)N)/C1=CC(=C(C=C1)Cl)Cl
DMS1QIJ	IK	WLYQLQVFJXFMJD-WLRTZDKTSA-N
DMS1QIJ	IU	[(E)-1-(3,4-dichlorophenyl)ethylideneamino]thiourea
DMS1QIJ	DE	Discovery agent

DMUSPIC	ID	DMUSPIC
DMUSPIC	DN	3,4-dichlorobenzaldehyde thiosemicarbazone
DMUSPIC	HS	Investigative
DMUSPIC	SN	3,4-Dichlorobenzaldehyde thiosemicarbazone; CHEMBL415311; 6292-74-6; 2-(3,4-dichlorobenzylidene)hydrazine-1-carbothioamide; NSC9937; AC1OR2L6; HMS556D17; DTXSID30428879; OMVGKAWQTXZISA-UUILKARUSA-N; MolPort-002-909-527; NSC-9937; BDBM50114648; ZINC20164022; AKOS008939634; CCG-247690; KB-279883
DMUSPIC	DT	Small molecular drug
DMUSPIC	PC	7695053
DMUSPIC	MW	248.13
DMUSPIC	FM	C8H7Cl2N3S
DMUSPIC	IC	InChI=1S/C8H7Cl2N3S/c9-6-2-1-5(3-7(6)10)4-12-13-8(11)14/h1-4H,(H3,11,13,14)/b12-4+
DMUSPIC	CS	C1=CC(=C(C=C1/C=N/NC(=S)N)Cl)Cl
DMUSPIC	IK	OMVGKAWQTXZISA-UUILKARUSA-N
DMUSPIC	IU	[(E)-(3,4-dichlorophenyl)methylideneamino]thiourea
DMUSPIC	CA	CAS 6292-74-6
DMUSPIC	DE	Discovery agent

DMN61Q5	ID	DMN61Q5
DMN61Q5	DN	3,4-Dichlorobenzenemethanethiol
DMN61Q5	HS	Investigative
DMN61Q5	SN	3,4-Dichlorobenzyl mercaptan; 36480-40-7; 3,4-Dichlorobenzenemethanethiol; (3,4-Dichlorophenyl)methanethiol; 3,4-Dichlorotoluene-alpha-thiol; CHEMBL1224626; CEGBRSQPRQXALB-UHFFFAOYSA-N; Benzenemethanethiol, 3,4-dichloro-; EINECS 253-054-4; AC1L3NZT; ACMC-1AEX5; AC1Q3O9X; 3,4-dichlorobenzylmercaptan; SCHEMBL232137; CTK3J7596; 3,4-Dichloro-alpha-toluenethiol; DTXSID50189990; MolPort-002-498-119; ZINC4802670; (3,4-Dichlorophenyl)methanethiol #; (3,4-Dichloro-phenyl)-methanethiol; BDBM50325571; MFCD00039651; GEO-00980
DMN61Q5	DT	Small molecular drug
DMN61Q5	PC	118986
DMN61Q5	MW	193.09
DMN61Q5	FM	C7H6Cl2S
DMN61Q5	IC	InChI=1S/C7H6Cl2S/c8-6-2-1-5(4-10)3-7(6)9/h1-3,10H,4H2
DMN61Q5	CS	C1=CC(=C(C=C1CS)Cl)Cl
DMN61Q5	IK	CEGBRSQPRQXALB-UHFFFAOYSA-N
DMN61Q5	IU	(3,4-dichlorophenyl)methanethiol
DMN61Q5	CA	CAS 36480-40-7
DMN61Q5	DE	Discovery agent

DMOZCDK	ID	DMOZCDK
DMOZCDK	DN	3,4-dichloroisocoumarin
DMOZCDK	HS	Investigative
DMOZCDK	SN	3,4-dichloroisocoumarin; 51050-59-0; 3,4-Dcl; 3,4-Dichloro-1H-isochromen-1-one; 1H-2-Benzopyran-1-one,3,4-dichloro-; 3,4-DCI; 3,4 dichloroisocoumarin; 3,4-Dichloro-1H-2-benzopyran-1-one; 1H-2-Benzopyran-1-one, 3,4-dichloro-; CHEMBL24983; 3,4-dichloroisochromen-1-one; 3,4-Dichloro-2-benzopyran-1-one; C9H4Cl2O2; Lopac-D-7910; cid_1609; AC1Q3H9V; AC1L1BU9; Lopac0_000442; KBioGR_000269; KBioSS_000269; BSPBio_001549; MLS002153325; SCHEMBL106901; 3,4-Dichloro-isochromen-1-one; KBio3_000538; KBio2_002837; CTK4J3543; KBio2_005405
DMOZCDK	DT	Small molecular drug
DMOZCDK	PC	1609
DMOZCDK	MW	215.03
DMOZCDK	FM	C9H4Cl2O2
DMOZCDK	IC	InChI=1S/C9H4Cl2O2/c10-7-5-3-1-2-4-6(5)9(12)13-8(7)11/h1-4H
DMOZCDK	CS	C1=CC=C2C(=C1)C(=C(OC2=O)Cl)Cl
DMOZCDK	IK	SUGXUUGGLDCZKB-UHFFFAOYSA-N
DMOZCDK	IU	3,4-dichloroisochromen-1-one
DMOZCDK	CA	CAS 51050-59-0
DMOZCDK	CB	CHEBI:109540
DMOZCDK	DE	Discovery agent

DMMZURL	ID	DMMZURL
DMMZURL	DN	3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMMZURL	HS	Investigative
DMMZURL	SN	CHEMBL1254552; 3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMMZURL	DT	Small molecular drug
DMMZURL	PC	46947643
DMMZURL	MW	319.2
DMMZURL	FM	C16H12Cl2N2O
DMMZURL	IC	InChI=1S/C16H12Cl2N2O/c1-9-6-11-7-12(3-5-15(11)19-9)20-16(21)10-2-4-13(17)14(18)8-10/h2-8,19H,1H3,(H,20,21)
DMMZURL	CS	CC1=CC2=C(N1)C=CC(=C2)NC(=O)C3=CC(=C(C=C3)Cl)Cl
DMMZURL	IK	ICMYUZJRKLEKDA-UHFFFAOYSA-N
DMMZURL	IU	3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMMZURL	DE	Discovery agent

DMWOMVF	ID	DMWOMVF
DMWOMVF	DN	3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide
DMWOMVF	HS	Investigative
DMWOMVF	SN	CHEMBL8893; 3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide; BDBM50005468
DMWOMVF	DT	Small molecular drug
DMWOMVF	PC	44265913
DMWOMVF	MW	382.3
DMWOMVF	FM	C22H17Cl2NO
DMWOMVF	IC	InChI=1S/C22H17Cl2NO/c23-20-12-11-18(15-21(20)24)22(26)25-14-13-19(16-7-3-1-4-8-16)17-9-5-2-6-10-17/h1-13,15H,14H2,(H,25,26)
DMWOMVF	CS	C1=CC=C(C=C1)C(=CCNC(=O)C2=CC(=C(C=C2)Cl)Cl)C3=CC=CC=C3
DMWOMVF	IK	OYXWUVAZLKNOAB-UHFFFAOYSA-N
DMWOMVF	IU	3,4-dichloro-N-(3,3-diphenylprop-2-enyl)benzamide
DMWOMVF	DE	Discovery agent

DM4RNOE	ID	DM4RNOE
DM4RNOE	DN	3,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DM4RNOE	HS	Investigative
DM4RNOE	SN	CHEMBL293437; 3,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide; 3,4-dichloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; AC1LF45X; Oprea1_772660; Oprea1_724335; ZINC73690; CCG-993; MolPort-001-949-151; BDBM50101784; STK017434; AKOS000519164; MCULE-6935310530; BAS 00860111; ST50005447; N-(4-Phenyl-2-thiazolyl)-3,4-dichlorobenzamide; Z27772110; (3,4-dichlorophenyl)-N-(4-phenyl(1,3-thiazol-2-yl))carboxamide
DM4RNOE	DT	Small molecular drug
DM4RNOE	PC	697363
DM4RNOE	MW	349.2
DM4RNOE	FM	C16H10Cl2N2OS
DM4RNOE	IC	InChI=1S/C16H10Cl2N2OS/c17-12-7-6-11(8-13(12)18)15(21)20-16-19-14(9-22-16)10-4-2-1-3-5-10/h1-9H,(H,19,20,21)
DM4RNOE	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC(=C(C=C3)Cl)Cl
DM4RNOE	IK	AYVXSTQWLPUGKB-UHFFFAOYSA-N
DM4RNOE	IU	3,4-dichloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DM4RNOE	DE	Discovery agent

DMFV3Y9	ID	DMFV3Y9
DMFV3Y9	DN	3,4-difluorobenzaldehyde O-benzoyloxime
DMFV3Y9	HS	Investigative
DMFV3Y9	SN	3,4-difluorobenzaldehyde O-benzoyloxime; CHEMBL178450; SCHEMBL3226311; SCHEMBL3226318
DMFV3Y9	DT	Small molecular drug
DMFV3Y9	PC	11470979
DMFV3Y9	MW	261.22
DMFV3Y9	FM	C14H9F2NO2
DMFV3Y9	IC	InChI=1S/C14H9F2NO2/c15-12-7-6-10(8-13(12)16)9-17-19-14(18)11-4-2-1-3-5-11/h1-9H/b17-9+
DMFV3Y9	CS	C1=CC=C(C=C1)C(=O)O/N=C/C2=CC(=C(C=C2)F)F
DMFV3Y9	IK	HOHACQRGFZUDCD-RQZCQDPDSA-N
DMFV3Y9	IU	[(E)-(3,4-difluorophenyl)methylideneamino] benzoate
DMFV3Y9	DE	Discovery agent

DM0I6UT	ID	DM0I6UT
DM0I6UT	DN	3,4-Dihydro-1H-quinolin-(2E)-ylideneamine
DM0I6UT	HS	Investigative
DM0I6UT	SN	CHEMBL6656; 2-amino-3,4-dihydroquinoline; 1,2,3,4-tetrahydroquinolin-2-imine; AC1N2ULT; 3,4-Dihydro-1H-quinolin-(2E)-ylideneamine; 3,4-dihydroquinolin-2-amine; SCHEMBL2075410; RREBANHDFAXBEZ-UHFFFAOYSA-N; MolPort-005-905-447; HMS1726J17; 3,4-Dihydroquinolin-2(1H)-imine; ZINC13014981; BDBM50062129; AKOS006221851; AKOS008024789; MCULE-1322063466; 3,4-Dihydro-1H-quinolin-(2Z)-ylideneamine
DM0I6UT	DT	Small molecular drug
DM0I6UT	PC	4102304
DM0I6UT	MW	146.19
DM0I6UT	FM	C9H10N2
DM0I6UT	IC	InChI=1S/C9H10N2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-4H,5-6H2,(H2,10,11)
DM0I6UT	CS	C1CC(=NC2=CC=CC=C21)N
DM0I6UT	IK	RREBANHDFAXBEZ-UHFFFAOYSA-N
DM0I6UT	IU	3,4-dihydroquinolin-2-amine
DM0I6UT	DE	Discovery agent

DMUOXHP	ID	DMUOXHP
DMUOXHP	DN	3,4-dihydroquinazolin-2-amine hydrobromide
DMUOXHP	HS	Investigative
DMUOXHP	SN	CHEMBL557381; SCHEMBL2386507; RXCXYMVUYRKQAO-UHFFFAOYSA-N; 1,4-dihydro-quinazolin-2-ylamine monohydrobromide
DMUOXHP	DT	Small molecular drug
DMUOXHP	PC	45263885
DMUOXHP	MW	228.09
DMUOXHP	FM	C8H10BrN3
DMUOXHP	IC	InChI=1S/C8H9N3.BrH/c9-8-10-5-6-3-1-2-4-7(6)11-8;/h1-4H,5H2,(H3,9,10,11);1H
DMUOXHP	CS	C1C2=CC=CC=C2NC(=N1)N.Br
DMUOXHP	IK	RXCXYMVUYRKQAO-UHFFFAOYSA-N
DMUOXHP	IU	1,4-dihydroquinazolin-2-amine;hydrobromide
DMUOXHP	DE	Discovery agent

DMG4NR3	ID	DMG4NR3
DMG4NR3	DN	3,4-Dihydroxy-10H-anthracen-9-one
DMG4NR3	HS	Investigative
DMG4NR3	SN	CHEMBL121693; 3,4-Dihydroxy-10H-anthracen-9-one; 1,2-dihydroxy-10-anthrone; SCHEMBL5034789; KBOKOYAHHLPGSJ-UHFFFAOYSA-N; BDBM50060872; ZINC13606495; 3,4-Dihydroxyanthracen-9(10H)-one
DMG4NR3	DT	Small molecular drug
DMG4NR3	PC	12976294
DMG4NR3	MW	226.23
DMG4NR3	FM	C14H10O3
DMG4NR3	IC	InChI=1S/C14H10O3/c15-12-6-5-10-11(14(12)17)7-8-3-1-2-4-9(8)13(10)16/h1-6,15,17H,7H2
DMG4NR3	CS	C1C2=CC=CC=C2C(=O)C3=C1C(=C(C=C3)O)O
DMG4NR3	IK	KBOKOYAHHLPGSJ-UHFFFAOYSA-N
DMG4NR3	IU	3,4-dihydroxy-10H-anthracen-9-one
DMG4NR3	DE	Discovery agent

DMZJ4VL	ID	DMZJ4VL
DMZJ4VL	DN	3,4-dihydroxybenzaldehyde-O-ethyloxime
DMZJ4VL	HS	Investigative
DMZJ4VL	DT	Small molecular drug
DMZJ4VL	PC	136180746
DMZJ4VL	MW	181.19
DMZJ4VL	FM	C9H11NO3
DMZJ4VL	IC	InChI=1S/C9H11NO3/c1-2-13-10-6-7-3-4-8(11)9(12)5-7/h3-6,11-12H,2H2,1H3/b10-6-
DMZJ4VL	CS	CCO/N=C\\C1=CC(=C(C=C1)O)O
DMZJ4VL	IK	XMXAPNDTHZRELH-POHAHGRESA-N
DMZJ4VL	IU	4-[(Z)-ethoxyiminomethyl]benzene-1,2-diol
DMZJ4VL	DE	Discovery agent

DM7N3MX	ID	DM7N3MX
DM7N3MX	DN	3,4-dihydroxyphenylacetaldehyde
DM7N3MX	HS	Investigative
DM7N3MX	SN	DOPAL
DM7N3MX	DT	Small molecular drug
DM7N3MX	PC	119219
DM7N3MX	MW	152.15
DM7N3MX	FM	C8H8O3
DM7N3MX	IC	InChI=1S/C8H8O3/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,4-5,10-11H,3H2
DM7N3MX	CS	C1=CC(=C(C=C1CC=O)O)O
DM7N3MX	IK	IADQVXRMSNIUEL-UHFFFAOYSA-N
DM7N3MX	IU	2-(3,4-dihydroxyphenyl)acetaldehyde
DM7N3MX	CA	CAS 5707-55-1
DM7N3MX	CB	CHEBI:27978
DM7N3MX	DE	Discovery agent

DMTQX92	ID	DMTQX92
DMTQX92	DN	3,4-dihydroxyxanthone
DMTQX92	HS	Investigative
DMTQX92	SN	3,4-Dihydroxyxanthone; 3,4-Dihydroxy-xanthone; 3,4-dihydroxyxanthen-9-one; CHEMBL446323; 39731-48-1; AC1NX8OR; SCHEMBL133422; 3,4-dihydroxy-xanthen-9-one; CTK4I1796; DTXSID20192815; YFVCSEXMOBEPQB-UHFFFAOYSA-N; 3,4-dihydroxy-9H-xanthen-9-one; 9H-Xanthen-9-one,3,4-dihydroxy-; ZINC15119047; BDBM50269645; 9H-Xanthen-9-one, 3,4-dihydroxy-
DMTQX92	DT	Small molecular drug
DMTQX92	PC	5748382
DMTQX92	MW	228.2
DMTQX92	FM	C13H8O4
DMTQX92	IC	InChI=1S/C13H8O4/c14-9-6-5-8-11(15)7-3-1-2-4-10(7)17-13(8)12(9)16/h1-6,14,16H
DMTQX92	CS	C1=CC=C2C(=C1)C(=O)C3=C(O2)C(=C(C=C3)O)O
DMTQX92	IK	YFVCSEXMOBEPQB-UHFFFAOYSA-N
DMTQX92	IU	3,4-dihydroxyxanthen-9-one
DMTQX92	CA	CAS 39731-48-1
DMTQX92	DE	Discovery agent

DMVDZCE	ID	DMVDZCE
DMVDZCE	DN	3,4-Dimethoxy-4'-amino-trans-stilbene
DMVDZCE	HS	Investigative
DMVDZCE	SN	CHEMBL1172937; BDBM50322051
DMVDZCE	DT	Small molecular drug
DMVDZCE	PC	49799648
DMVDZCE	MW	255.31
DMVDZCE	FM	C16H17NO2
DMVDZCE	IC	InChI=1S/C16H17NO2/c1-18-15-10-7-13(11-16(15)19-2)4-3-12-5-8-14(17)9-6-12/h3-11H,17H2,1-2H3/b4-3+
DMVDZCE	CS	COC1=C(C=C(C=C1)/C=C/C2=CC=C(C=C2)N)OC
DMVDZCE	IK	JZZHXIPQAWDZPC-ONEGZZNKSA-N
DMVDZCE	IU	4-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]aniline
DMVDZCE	DE	Discovery agent

DMMO6QI	ID	DMMO6QI
DMMO6QI	DN	3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMMO6QI	HS	Investigative
DMMO6QI	SN	CHEMBL185161; 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine; 3,4-dimethylpyrrolidin-2-on imine; BDBM50150928
DMMO6QI	DT	Small molecular drug
DMMO6QI	PC	19049163
DMMO6QI	MW	112.17
DMMO6QI	FM	C6H12N2
DMMO6QI	IC	InChI=1S/C6H12N2/c1-4-3-8-6(7)5(4)2/h4-5H,3H2,1-2H3,(H2,7,8)
DMMO6QI	CS	CC1CN=C(C1C)N
DMMO6QI	IK	YVPMIGCVKYQACC-UHFFFAOYSA-N
DMMO6QI	IU	3,4-dimethyl-3,4-dihydro-2H-pyrrol-5-amine
DMMO6QI	DE	Discovery agent

DMPK6YT	ID	DMPK6YT
DMPK6YT	DN	3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT	HS	Investigative
DMPK6YT	SN	2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; 3,4-diphenyl-1H-pyrrole-2,5-dione; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556
DMPK6YT	DT	Small molecular drug
DMPK6YT	PC	2752461
DMPK6YT	MW	249.26
DMPK6YT	FM	C16H11NO2
DMPK6YT	IC	InChI=1S/C16H11NO2/c18-15-13(11-7-3-1-4-8-11)14(16(19)17-15)12-9-5-2-6-10-12/h1-10H,(H,17,18,19)
DMPK6YT	CS	C1=CC=C(C=C1)C2=C(C(=O)NC2=O)C3=CC=CC=C3
DMPK6YT	IK	WADCPEMKIBAJHH-UHFFFAOYSA-N
DMPK6YT	IU	3,4-diphenylpyrrole-2,5-dione
DMPK6YT	CA	CAS 31295-36-0
DMPK6YT	DE	Discovery agent

DM8BJPU	ID	DM8BJPU
DM8BJPU	DN	3,4-epoxydehydroleucodin
DM8BJPU	HS	Investigative
DM8BJPU	SN	3,4-epoxydehydroleucodin; Eminensin A
DM8BJPU	DT	Small molecular drug
DM8BJPU	PC	10422717
DM8BJPU	MW	260.279
DM8BJPU	FM	C15H16O4
DM8BJPU	IC	InChI=1S/C15H16O4/c1-6-4-5-8-7(2)14(17)18-12(8)10-9(6)11(16)13-15(10,3)19-13/h8,10,12-13H,2,4-5H2,1,3H3/t8-,10-,12-,13+,15-/m0/s1
DM8BJPU	CS	CC1=C2[C@@H]([C@@H]3[C@@H](CC1)C(=C)C(=O)O3)[C@]4([C@@H](C2=O)O4)C
DM8BJPU	IK	IQFFYNSHANWLIR-FJKOOJNLSA-N
DM8BJPU	IU	(1S,2S,6S,12S,14S)-9,14-dimethyl-5-methylidene-3,13-dioxatetracyclo[8.4.0.02,6.012,14]tetradec-9-ene-4,11-dione
DM8BJPU	DE	Discovery agent

DMLIG3X	ID	DMLIG3X
DMLIG3X	DN	3,5 DIBROMOTYROSINE
DMLIG3X	HS	Investigative
DMLIG3X	SN	3,5-DIBROMOTYROSINE; 2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid; 537-24-6; 3,5-Dibromo-tyrosine; NSC210786; 3,5-Dibromo-DL-tyrosine; Bromotiren; CHEMBL1253341; CHEBI:80912; L-Tyrosine,5-dibromo-; Tyrosine,5-dibromo-, L-; Dibromotirina; Biotiren; NSC-210786; EINECS 208-661-9; Tyrosine,5-dibromo-; .beta.-(3,5-Dibromo-4-hydroxyphenyl)alanine; ACMC-209hco; AC1L1W1Q; SCHEMBL145218; CTK7I4423; MolPort-002-887-590; NSC97935; ZX-AN012875; NSC39452; ALBB-014135; NSC-97935; NSC-39452; BDBM50326563; AKOS005109959; MS-3024
DMLIG3X	DT	Small molecular drug
DMLIG3X	PC	67532
DMLIG3X	MW	338.98
DMLIG3X	FM	C9H9Br2NO3
DMLIG3X	IC	InChI=1S/C9H9Br2NO3/c10-5-1-4(2-6(11)8(5)13)3-7(12)9(14)15/h1-2,7,13H,3,12H2,(H,14,15)/t7-/m0/s1
DMLIG3X	CS	C1=C(C=C(C(=C1Br)O)Br)C[C@@H](C(=O)O)N
DMLIG3X	IK	COESHZUDRKCEPA-ZETCQYMHSA-N
DMLIG3X	IU	(2S)-2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid
DMLIG3X	CA	CAS 300-38-9
DMLIG3X	CB	CHEBI:28335
DMLIG3X	DE	Discovery agent

DMAU80W	ID	DMAU80W
DMAU80W	DN	3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium
DMAU80W	HS	Investigative
DMAU80W	SN	1,3,5,6,8-Pentamethyl-1,10-phenanthrolinium; 1,3,5,6,8-pentamethyl-1,10-phenanthrolin-1-ium; 55247-91-1; AC1Q4YDA; 3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium; AC1L519F; CTK5A3287; 23624-78-4 (iodide); DB02310; 3,4,6,8-Tetramethyl-N-methyl phenanthrolinium
DMAU80W	DT	Small molecular drug
DMAU80W	PC	168131
DMAU80W	MW	251.35
DMAU80W	FM	C17H19N2+
DMAU80W	IC	InChI=1S/C17H19N2/c1-10-6-14-12(3)13(4)15-7-11(2)9-19(5)17(15)16(14)18-8-10/h6-9H,1-5H3/q+1
DMAU80W	CS	CC1=CC2=C(C3=C(C=C(C=[N+]3C)C)C(=C2C)C)N=C1
DMAU80W	IK	FQTUZNACZKILMC-UHFFFAOYSA-N
DMAU80W	IU	1,3,5,6,8-pentamethyl-1,10-phenanthrolin-1-ium
DMAU80W	CA	CAS 55247-91-1
DMAU80W	DE	Discovery agent

DMV859W	ID	DMV859W
DMV859W	DN	3,5-bis(2-methylpyridin-4-yl)-1H-1,2,4-triazole
DMV859W	HS	Investigative
DMV859W	SN	CHEMBL1079001; 3,5-bis(2-methylpyridin-4-yl)-1H-1,2,4-triazole; SCHEMBL11589338
DMV859W	DT	Small molecular drug
DMV859W	PC	20309751
DMV859W	MW	251.29
DMV859W	FM	C14H13N5
DMV859W	IC	InChI=1S/C14H13N5/c1-9-7-11(3-5-15-9)13-17-14(19-18-13)12-4-6-16-10(2)8-12/h3-8H,1-2H3,(H,17,18,19)
DMV859W	CS	CC1=NC=CC(=C1)C2=NC(=NN2)C3=CC(=NC=C3)C
DMV859W	IK	VTUBKJFCLVZEFR-UHFFFAOYSA-N
DMV859W	IU	2-methyl-4-[3-(2-methylpyridin-4-yl)-1H-1,2,4-triazol-5-yl]pyridine
DMV859W	DE	Discovery agent

DMFEQ6S	ID	DMFEQ6S
DMFEQ6S	DN	3,5-DHPG
DMFEQ6S	HS	Investigative
DMFEQ6S	SN	3,5-dihydroxyphenylglycine
DMFEQ6S	DT	Small molecular drug
DMFEQ6S	PC	108001
DMFEQ6S	MW	183.16
DMFEQ6S	FM	C8H9NO4
DMFEQ6S	IC	InChI=1S/C8H9NO4/c9-7(8(12)13)4-1-5(10)3-6(11)2-4/h1-3,7,10-11H,9H2,(H,12,13)
DMFEQ6S	CS	C1=C(C=C(C=C1O)O)C(C(=O)O)N
DMFEQ6S	IK	HOOWCUZPEFNHDT-UHFFFAOYSA-N
DMFEQ6S	IU	2-amino-2-(3,5-dihydroxyphenyl)acetic acid
DMFEQ6S	CA	CAS 146255-66-5
DMFEQ6S	CB	CHEBI:93822
DMFEQ6S	DE	Discovery agent

DM6CBTE	ID	DM6CBTE
DM6CBTE	DN	3,5-di(pyridin-4-yl)-1H-1,2,4-triazole
DM6CBTE	HS	Investigative
DM6CBTE	SN	4329-78-6; CHEMBL1078978; 4,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine; 3,5-DI(4-pyridyl)-1,2,4-triazole; 3,5-bis(pyridin-4-yl)-1,2,4-triazole; AC1M7KCV; 3,5-di(pyridin-4-yl)-1H-1,2,4-triazole; MLS000999673; 4-(3-pyridin-4-yl-1H-1,2,4-triazol-5-yl)pyridine; SCHEMBL10000033; CTK1D2724; QUKGHTHKDNHSOX-UHFFFAOYSA-; DTXSID00368692; QUKGHTHKDNHSOX-UHFFFAOYSA-N; MolPort-000-263-064; ZINC8048404; BDBM50311280; STK246494; AKOS002269457; AKOS001080808; MCULE-5677308017; 3,5-bis(4-pyridyl)-1,2,4-triazole; SMR000498789; ST092086
DM6CBTE	DT	Small molecular drug
DM6CBTE	PC	2443499
DM6CBTE	MW	223.23
DM6CBTE	FM	C12H9N5
DM6CBTE	IC	InChI=1S/C12H9N5/c1-5-13-6-2-9(1)11-15-12(17-16-11)10-3-7-14-8-4-10/h1-8H,(H,15,16,17)
DM6CBTE	CS	C1=CN=CC=C1C2=NC(=NN2)C3=CC=NC=C3
DM6CBTE	IK	QUKGHTHKDNHSOX-UHFFFAOYSA-N
DM6CBTE	IU	4-(3-pyridin-4-yl-1H-1,2,4-triazol-5-yl)pyridine
DM6CBTE	CA	CAS 4329-78-6
DM6CBTE	DE	Discovery agent

DMEXPIJ	ID	DMEXPIJ
DMEXPIJ	DN	3,5-Diacetoxy-4'-amino-trans-stilbene
DMEXPIJ	HS	Investigative
DMEXPIJ	SN	CHEMBL1172400; BDBM50322065
DMEXPIJ	DT	Small molecular drug
DMEXPIJ	PC	49798801
DMEXPIJ	MW	311.3
DMEXPIJ	FM	C18H17NO4
DMEXPIJ	IC	InChI=1S/C18H17NO4/c1-12(20)22-17-9-15(10-18(11-17)23-13(2)21)4-3-14-5-7-16(19)8-6-14/h3-11H,19H2,1-2H3/b4-3+
DMEXPIJ	CS	CC(=O)OC1=CC(=CC(=C1)/C=C/C2=CC=C(C=C2)N)OC(=O)C
DMEXPIJ	IK	QERWBDJMMUMFOT-ONEGZZNKSA-N
DMEXPIJ	IU	[3-acetyloxy-5-[(E)-2-(4-aminophenyl)ethenyl]phenyl] acetate
DMEXPIJ	DE	Discovery agent

DMK9JCA	ID	DMK9JCA
DMK9JCA	DN	3,5-Diamino-4'-amino-trans-stilbene
DMK9JCA	HS	Investigative
DMK9JCA	SN	CHEMBL1171091; BDBM50322064
DMK9JCA	DT	Small molecular drug
DMK9JCA	PC	49798900
DMK9JCA	MW	225.29
DMK9JCA	FM	C14H15N3
DMK9JCA	IC	InChI=1S/C14H15N3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9H,15-17H2/b2-1+
DMK9JCA	CS	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)N)N)N
DMK9JCA	IK	QRFAISVLMWANDO-OWOJBTEDSA-N
DMK9JCA	IU	5-[(E)-2-(4-aminophenyl)ethenyl]benzene-1,3-diamine
DMK9JCA	DE	Discovery agent

DMCEY6O	ID	DMCEY6O
DMCEY6O	DN	3,5-dibromo-2-(2,4-dibromophenoxy)phenol
DMCEY6O	HS	Investigative
DMCEY6O	SN	3,5-Dibromo-2-(2,4-dibromophenoxy)phenol; CHEMBL258224; 79755-43-4; BPE-5; AC1MJ5LD; AC1Q78K6; 6-OH-BDE47; DTXSID60229856; ZINC14676777; SR-1-1; BDBM50232491; 6-Hydroxy-2,2,4,4-tetrabromodiphenyl ether; 6-hydroxy-2,2',4,4'-tetrabromodiphenylether; 3,5-dibromo-2-(2'',4''-dibromophenoxy)phenol; Phenol, 3,5-dibromo-2-(2,4-dibromophenoxy)-
DMCEY6O	DT	Small molecular drug
DMCEY6O	PC	3086109
DMCEY6O	MW	501.79
DMCEY6O	FM	C12H6Br4O2
DMCEY6O	IC	InChI=1S/C12H6Br4O2/c13-6-1-2-11(8(15)3-6)18-12-9(16)4-7(14)5-10(12)17/h1-5,17H
DMCEY6O	CS	C1=CC(=C(C=C1Br)Br)OC2=C(C=C(C=C2Br)Br)O
DMCEY6O	IK	SNCQITRZEBFIRW-UHFFFAOYSA-N
DMCEY6O	IU	3,5-dibromo-2-(2,4-dibromophenoxy)phenol
DMCEY6O	CA	CAS 79755-43-4
DMCEY6O	DE	Discovery agent

DMPVI9W	ID	DMPVI9W
DMPVI9W	DN	3,5-dichlorobenzaldehyde thiosemicarbazone
DMPVI9W	HS	Investigative
DMPVI9W	SN	3,5-Dichlorobenzaldehyde thiosemicarbazone; CHEMBL421363; NSC109597; AC1NSHS0; ZINC33848878; BDBM50114607; AKOS014545904; NSC-109597
DMPVI9W	DT	Small molecular drug
DMPVI9W	PC	5363470
DMPVI9W	MW	248.13
DMPVI9W	FM	C8H7Cl2N3S
DMPVI9W	IC	InChI=1S/C8H7Cl2N3S/c9-6-1-5(2-7(10)3-6)4-12-13-8(11)14/h1-4H,(H3,11,13,14)/b12-4+
DMPVI9W	CS	C1=C(C=C(C=C1Cl)Cl)/C=N/NC(=S)N
DMPVI9W	IK	OTKIBPHYGDDNDE-UUILKARUSA-N
DMPVI9W	IU	[(E)-(3,5-dichlorophenyl)methylideneamino]thiourea
DMPVI9W	DE	Discovery agent

DMQ45WH	ID	DMQ45WH
DMQ45WH	DN	3,5-dichlorosalicylic acid
DMQ45WH	HS	Investigative
DMQ45WH	SN	3,5-DICHLOROSALICYLIC ACID; 3,5-Dichloro-2-hydroxybenzoic acid; 320-72-9; Benzoic acid, 3,5-dichloro-2-hydroxy-; Salicylic acid, 3,5-dichloro-; USAF DO-68; 2-Hydroxy-3,5-dichlorobenzoic acid; 3,5-Dichlorosalicylicacid; UNII-O6PXR32G3V; 3,5-Dichlorosalicyclic acid; HSDB 5562; EINECS 206-281-8; NSC 30109; 3,5-dichloro-2-hydroxy-benzoic acid; BRN 2210803; O6PXR32G3V; AI3-22601; CHEMBL449129; CNJGWCQEGROXEE-UHFFFAOYSA-N; C2U; ACMC-1CUK7; Salicylic acid,5-dichloro-; AC1Q3M9M; WLN: QVR BQ CG EG; DSSTox_RID_80582; DSSTox_CID_24914
DMQ45WH	DT	Small molecular drug
DMQ45WH	PC	9445
DMQ45WH	MW	207.01
DMQ45WH	FM	C7H4Cl2O3
DMQ45WH	IC	InChI=1S/C7H4Cl2O3/c8-3-1-4(7(11)12)6(10)5(9)2-3/h1-2,10H,(H,11,12)
DMQ45WH	CS	C1=C(C=C(C(=C1C(=O)O)O)Cl)Cl
DMQ45WH	IK	CNJGWCQEGROXEE-UHFFFAOYSA-N
DMQ45WH	IU	3,5-dichloro-2-hydroxybenzoic acid
DMQ45WH	CA	CAS 320-72-9
DMQ45WH	CB	CHEBI:165214
DMQ45WH	DE	Discovery agent

DMET46F	ID	DMET46F
DMET46F	DN	3,5-Difluorobenzenesulfonamide
DMET46F	HS	Investigative
DMET46F	SN	3,5-DIFLUOROBENZENESULFONAMIDE; 140480-89-3; 3,5-Difluorobenzenesulphonamide; Benzenesulfonamide, 3,5-difluoro-; 3,5-difluorobenzene-1-sulfonamide; Buttpark 27\07-04; FBU; PubChem11783; ACMC-20ai3d; AC1L9JFC; KSC493S5P; SCHEMBL602631; CHEBI:42566; CTK3J3957; DTXSID20332219; MKQPOVUFDWKPNO-UHFFFAOYSA-N; MolPort-000-150-739; ZINC2576766; JRD-1790; MFCD02091379; BBL100443; 6828AA; STL554237; ANW-74375; SBB091558; 3,5-Difluorobenzenesulfonamide, 97%; AKOS000148222; DB02087; VZ25762; TRA0083487; PS-8315; MCULE-4003409613; RTR-005258; CJ-10108
DMET46F	DT	Small molecular drug
DMET46F	PC	446275
DMET46F	MW	193.17
DMET46F	FM	C6H5F2NO2S
DMET46F	IC	InChI=1S/C6H5F2NO2S/c7-4-1-5(8)3-6(2-4)12(9,10)11/h1-3H,(H2,9,10,11)
DMET46F	CS	C1=C(C=C(C=C1F)S(=O)(=O)N)F
DMET46F	IK	MKQPOVUFDWKPNO-UHFFFAOYSA-N
DMET46F	IU	3,5-difluorobenzenesulfonamide
DMET46F	CA	CAS 140480-89-3
DMET46F	CB	CHEBI:42566
DMET46F	DE	Discovery agent

DM4VT0Q	ID	DM4VT0Q
DM4VT0Q	DN	3,5-difluorophenol
DM4VT0Q	HS	Investigative
DM4VT0Q	SN	3,5-Difluorophenol; 2713-34-0; Phenol, 3,5-difluoro-; 3,5-difluoro phenol; 3,5-difluoro-phenol; Phenol,3,5-difluoro-; HJSSBIMVTMYKPD-UHFFFAOYSA-N; MFCD00002255; 3,5difluorophenol; 3,5-difluorphenol; 3.5-difluorophenol; PubChem1496; phenol derivative, 6; ACMC-209gvc; AC1Q4NDO; AC1L2PTJ; 3,5-Difluorophenol, 99%; KSC203O5T; SCHEMBL156265; AC1Q78L9; CHEMBL259068; CTK1A3759; BDBM26192; HJSSBIMVTMYKPD-UHFFFAOYSA-; DTXSID10181596; ABLOCK AB-12-1639; MolPort-000-154-449; ZINC406989; ACT11666; JRD-0083; CS-D1731; SBB085756; ANW-26134
DM4VT0Q	DT	Small molecular drug
DM4VT0Q	PC	75928
DM4VT0Q	MW	130.09
DM4VT0Q	FM	C6H4F2O
DM4VT0Q	IC	InChI=1S/C6H4F2O/c7-4-1-5(8)3-6(9)2-4/h1-3,9H
DM4VT0Q	CS	C1=C(C=C(C=C1F)F)O
DM4VT0Q	IK	HJSSBIMVTMYKPD-UHFFFAOYSA-N
DM4VT0Q	IU	3,5-difluorophenol
DM4VT0Q	CA	CAS 2713-34-0
DM4VT0Q	DE	Discovery agent

DM04N7I	ID	DM04N7I
DM04N7I	DN	3,5-dihydroxybenzoic acid
DM04N7I	HS	Investigative
DM04N7I	SN	NSC 22948; alpha-resorcylic acid; 5-carboxyresorcinol
DM04N7I	DT	Small molecular drug
DM04N7I	PC	7424
DM04N7I	MW	154.12
DM04N7I	FM	C7H6O4
DM04N7I	IC	InChI=1S/C7H6O4/c8-5-1-4(7(10)11)2-6(9)3-5/h1-3,8-9H,(H,10,11)
DM04N7I	CS	C1=C(C=C(C=C1O)O)C(=O)O
DM04N7I	IK	UYEMGAFJOZZIFP-UHFFFAOYSA-N
DM04N7I	IU	3,5-dihydroxybenzoic acid
DM04N7I	CA	CAS 99-10-5
DM04N7I	CB	CHEBI:39912
DM04N7I	DE	Discovery agent

DMQ9TNB	ID	DMQ9TNB
DMQ9TNB	DN	3,5-Dihydroxyl-4'-amino-trans-stilbene
DMQ9TNB	HS	Investigative
DMQ9TNB	SN	CHEMBL1172402; Stilbene derivative, 3; SCHEMBL2516281; CHEBI:125141; (E)-4'-Aminostilbene-3,5-diol; BDBM50322066; 3,5-Dihydroxyl-4''-amino-trans-stilbene
DMQ9TNB	DT	Small molecular drug
DMQ9TNB	PC	46191176
DMQ9TNB	MW	227.26
DMQ9TNB	FM	C14H13NO2
DMQ9TNB	IC	InChI=1S/C14H13NO2/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,16-17H,15H2/b2-1+
DMQ9TNB	CS	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)N
DMQ9TNB	IK	MDUTXYLPODCITG-OWOJBTEDSA-N
DMQ9TNB	IU	5-[(E)-2-(4-aminophenyl)ethenyl]benzene-1,3-diol
DMQ9TNB	CB	CHEBI:125141
DMQ9TNB	DE	Discovery agent

DMRY2ZC	ID	DMRY2ZC
DMRY2ZC	DN	3'',5''-dimethoxy-[1,1':2',1'']-terphenyl-4-ol
DMRY2ZC	HS	Investigative
DMRY2ZC	SN	CHEMBL207240; ZINC35929342; BDBM50186755
DMRY2ZC	DT	Small molecular drug
DMRY2ZC	PC	11609210
DMRY2ZC	MW	306.4
DMRY2ZC	FM	C20H18O3
DMRY2ZC	IC	InChI=1S/C20H18O3/c1-22-17-11-15(12-18(13-17)23-2)20-6-4-3-5-19(20)14-7-9-16(21)10-8-14/h3-13,21H,1-2H3
DMRY2ZC	CS	COC1=CC(=CC(=C1)C2=CC=CC=C2C3=CC=C(C=C3)O)OC
DMRY2ZC	IK	WBVVLROKTBXXTP-UHFFFAOYSA-N
DMRY2ZC	IU	4-[2-(3,5-dimethoxyphenyl)phenyl]phenol
DMRY2ZC	DE	Discovery agent

DMXCZAK	ID	DMXCZAK
DMXCZAK	DN	3'',5''-dimethoxy-[1,1':3',1'']-terphenyl-4-ol
DMXCZAK	HS	Investigative
DMXCZAK	SN	CHEMBL381164; BDBM50186750; ZINC40763401
DMXCZAK	DT	Small molecular drug
DMXCZAK	PC	11493254
DMXCZAK	MW	306.4
DMXCZAK	FM	C20H18O3
DMXCZAK	IC	InChI=1S/C20H18O3/c1-22-19-11-17(12-20(13-19)23-2)16-5-3-4-15(10-16)14-6-8-18(21)9-7-14/h3-13,21H,1-2H3
DMXCZAK	CS	COC1=CC(=CC(=C1)C2=CC=CC(=C2)C3=CC=C(C=C3)O)OC
DMXCZAK	IK	MWVCWBDXUJZBEC-UHFFFAOYSA-N
DMXCZAK	IU	4-[3-(3,5-dimethoxyphenyl)phenyl]phenol
DMXCZAK	DE	Discovery agent

DMC3917	ID	DMC3917
DMC3917	DN	3,5-Dimethoxy-4'-amino-trans-stilbene
DMC3917	HS	Investigative
DMC3917	SN	CHEMBL324290; SCHEMBL3359253; BDBM50131692; ZINC27107058; AKOS030581623; trans-3,5-dimethoxyl-4''-aminostilbene; 3,5-Dimethoxy-4''-amino-trans-stilbene; (e)-1-(4'-aminostyryl)-3,5-dimethoxybenzene; 4-[2-(3,5-Dimethoxyphenyl)ethenyl]benzeneamine
DMC3917	DT	Small molecular drug
DMC3917	PC	18785180
DMC3917	MW	255.31
DMC3917	FM	C16H17NO2
DMC3917	IC	InChI=1S/C16H17NO2/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11H,17H2,1-2H3/b4-3+
DMC3917	CS	COC1=CC(=CC(=C1)/C=C/C2=CC=C(C=C2)N)OC
DMC3917	IK	LGVZJSLFOMGJOS-ONEGZZNKSA-N
DMC3917	IU	4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]aniline
DMC3917	DE	Discovery agent

DM3E98I	ID	DM3E98I
DM3E98I	DN	3,5-dimethyl PPP
DM3E98I	HS	Investigative
DM3E98I	SN	3,5-DMPPP
DM3E98I	DT	Small molecular drug
DM3E98I	PC	11722867
DM3E98I	MW	309.4
DM3E98I	FM	C17H27NO4
DM3E98I	IC	InChI=1S/C17H27NO4/c1-8-9-21-16(20)14-10(2)13(11(3)18-14)15(19)22-12(4)17(5,6)7/h12,18H,8-9H2,1-7H3
DM3E98I	CS	CCCOC(=O)C1=C(C(=C(N1)C)C(=O)OC(C)C(C)(C)C)C
DM3E98I	IK	DOYZAIRDDZPMQZ-UHFFFAOYSA-N
DM3E98I	IU	4-O-(3,3-dimethylbutan-2-yl) 2-O-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate
DM3E98I	DE	Discovery agent

DMAQ6OM	ID	DMAQ6OM
DMAQ6OM	DN	3,5-dimethyl-2-(phenylsulfonamido)benzoic acid
DMAQ6OM	HS	Investigative
DMAQ6OM	SN	sulfonamide compound, 5; CHEMBL209317; SCHEMBL10116990; BDBM17599; AKOS012072515; 2-benzenesulfonamido-3,5-dimethylbenzoic acid
DMAQ6OM	DT	Small molecular drug
DMAQ6OM	PC	23647758
DMAQ6OM	MW	305.4
DMAQ6OM	FM	C15H15NO4S
DMAQ6OM	IC	InChI=1S/C15H15NO4S/c1-10-8-11(2)14(13(9-10)15(17)18)16-21(19,20)12-6-4-3-5-7-12/h3-9,16H,1-2H3,(H,17,18)
DMAQ6OM	CS	CC1=CC(=C(C(=C1)C(=O)O)NS(=O)(=O)C2=CC=CC=C2)C
DMAQ6OM	IK	ORCGTMODRHXXRZ-UHFFFAOYSA-N
DMAQ6OM	IU	2-(benzenesulfonamido)-3,5-dimethylbenzoic acid
DMAQ6OM	DE	Discovery agent

DMBGSHD	ID	DMBGSHD
DMBGSHD	DN	3,5-Dinitrocatechol
DMBGSHD	HS	Investigative
DMBGSHD	SN	3,5-dinitrocatechol; 3,5-dinitrobenzene-1,2-diol; 7659-29-2; 3,5-Dinitro-1,2-benzenediol; OR-486; 3,5-Dinitropyrocatechol; OR486; UNII-VK0VA22GY2; Pyrocatechol, 3,5-dinitro-; 1,2-Benzenediol, 3,5-dinitro-; BRN 2217246; VK0VA22GY2; 3,5-DINITROCATECHOL (OR-486); CHEMBL168276; 3,5-DINITRO-BENZENE-1,2-DIOL; DNC; SR-01000075610; OR 486; Ro 12812; Ro 01-2812; Tocris-0483; Spectrum_000187; Lopac-D-131; AC1MZC4M; Spectrum4_000747; Spectrum2_001109; Spectrum5_001163; Entacapone EP Impurity E; 3,5-Dinitrocatechol, solid; Lopac0_000477
DMBGSHD	DT	Small molecular drug
DMBGSHD	PC	3870203
DMBGSHD	MW	200.11
DMBGSHD	FM	C6H4N2O6
DMBGSHD	IC	InChI=1S/C6H4N2O6/c9-5-2-3(7(11)12)1-4(6(5)10)8(13)14/h1-2,9-10H
DMBGSHD	CS	C1=C(C=C(C(=C1[N+](=O)[O-])O)O)[N+](=O)[O-]
DMBGSHD	IK	VDCDWNDTNSWDFJ-UHFFFAOYSA-N
DMBGSHD	IU	3,5-dinitrobenzene-1,2-diol
DMBGSHD	CA	CAS 7659-29-2
DMBGSHD	DE	Discovery agent

DMWOB7Q	ID	DMWOB7Q
DMWOB7Q	DN	3,5-Di-tert-butyl-[1,2]benzoquinone
DMWOB7Q	HS	Investigative
DMWOB7Q	SN	3383-21-9; 3,5-Di-tert-butyl-o-benzoquinone; 3,5-Di-tert-butyl-1,2-benzoquinone; 3,5-di(tert-butyl)benzo-1,2-quinone; 3,5-Cyclohexadiene-1,2-dione, 3,5-bis(1,1-dimethylethyl)-; 3,5-di-tert-butylcyclohexa-3,5-diene-1,2-dione; o-Benzoquinone, 3,5-di-tert-butyl-; 3,5-di-tert-butylbenzo-1,2-quinone; NOUZOVBGCDDMSX-UHFFFAOYSA-N; 3,5-di-t-butyl-1,2-benzoquinone; 3,5-Ditert-butylbenzo-1,2-quinone; MFCD00001647; 3,5-bis(tert-butyl)cyclohexa-3,5-diene-1,2-dione; Benzil-related compound, 54; EINECS 222-189-0; NSC 149061; AC1Q6BRK
DMWOB7Q	DT	Small molecular drug
DMWOB7Q	PC	76915
DMWOB7Q	MW	220.31
DMWOB7Q	FM	C14H20O2
DMWOB7Q	IC	InChI=1S/C14H20O2/c1-13(2,3)9-7-10(14(4,5)6)12(16)11(15)8-9/h7-8H,1-6H3
DMWOB7Q	CS	CC(C)(C)C1=CC(=O)C(=O)C(=C1)C(C)(C)C
DMWOB7Q	IK	NOUZOVBGCDDMSX-UHFFFAOYSA-N
DMWOB7Q	IU	3,5-ditert-butylcyclohexa-3,5-diene-1,2-dione
DMWOB7Q	CA	CAS 3383-21-9
DMWOB7Q	DE	Discovery agent

DMM632N	ID	DMM632N
DMM632N	DN	3,6,8-Tribromo-dibenzo[1,4]dioxin-1-ol
DMM632N	HS	Investigative
DMM632N	SN	Spongiadioxin C; CHEMBL185753; 3,6,8-Tribromo-dibenzo[1,4]dioxin-1-ol; 3,6,8-tribromooxanthren-1-ol; dibenzo[b,e][1,4]dioxin-1-ol, 3,6,8-tribromo-; 3,6,8-tribromodibenzo[b,e][1,4]dioxin-1-ol; AC1LCT04; BDBM50150791; 3,6,8-tribromodibenzo-p-dioxin-1-ol; 460092-06-2
DMM632N	DT	Small molecular drug
DMM632N	PC	636835
DMM632N	MW	436.88
DMM632N	FM	C12H5Br3O3
DMM632N	IC	InChI=1S/C12H5Br3O3/c13-5-1-7(15)11-9(3-5)18-12-8(16)2-6(14)4-10(12)17-11/h1-4,16H
DMM632N	CS	C1=C(C=C2C(=C1O)OC3=C(O2)C(=CC(=C3)Br)Br)Br
DMM632N	IK	XZPITRJUKODSMI-UHFFFAOYSA-N
DMM632N	IU	3,6,8-tribromodibenzo-p-dioxin-1-ol
DMM632N	DE	Discovery agent

DMY26JI	ID	DMY26JI
DMY26JI	DN	3,6,9,12,15,18-HEXAOXAICOSANE
DMY26JI	HS	Investigative
DMY26JI	SN	3,6,9,12,15,18-Hexaoxaicosane; 3,6,9,12,15,18-Hexaoxaeicosane; 23601-39-0; 1-ethoxy-2-[2-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]ethoxy]ethane; EINECS 245-774-2; AC1L3JHX; SCHEMBL987828; DTXSID1041473; CHEBI:39576; CTK1A3907; DB06867
DMY26JI	DT	Small molecular drug
DMY26JI	PC	90206
DMY26JI	MW	294.38
DMY26JI	FM	C14H30O6
DMY26JI	IC	InChI=1S/C14H30O6/c1-3-15-5-7-17-9-11-19-13-14-20-12-10-18-8-6-16-4-2/h3-14H2,1-2H3
DMY26JI	CS	CCOCCOCCOCCOCCOCCOCC
DMY26JI	IK	IXFAFGFZFQHRLB-UHFFFAOYSA-N
DMY26JI	IU	1-ethoxy-2-[2-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]ethoxy]ethane
DMY26JI	CA	CAS 23601-39-0
DMY26JI	CB	CHEBI:39576
DMY26JI	DE	Discovery agent

DMY8IOP	ID	DMY8IOP
DMY8IOP	DN	3,6,9,12,15-Pentaoxaheptadecane
DMY8IOP	HS	Investigative
DMY8IOP	SN	3,6,9,12,15-Pentaoxaheptadecane; Diethoxytetraethylene glycol; Tetraethylene glycol diethyl ether; 4353-28-0; Glycol, diethoxytetraethylene; Ether, bis(2-(2-ethoxyethoxy)ethyl); Diethylether tetraethylenglykolu; EINECS 224-423-7; Diethylether tetraethylenglykolu [Czech]; BRN 1767873; bis(2-(2-ethoxyethoxy)ethyl) ether; P3G; 1-ethoxy-2-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]ethane; AC1Q58NT; AC1L2UE6; SCHEMBL216926; tetraethyleneglycol diethyl ether; DTXSID0052099; CTK3I9254; CHEBI:44751; HYDWALOBQJFOMS-UHFFFAOYSA-N; ZINC5650744
DMY8IOP	DT	Small molecular drug
DMY8IOP	PC	78057
DMY8IOP	MW	250.33
DMY8IOP	FM	C12H26O5
DMY8IOP	IC	InChI=1S/C12H26O5/c1-3-13-5-7-15-9-11-17-12-10-16-8-6-14-4-2/h3-12H2,1-2H3
DMY8IOP	CS	CCOCCOCCOCCOCCOCC
DMY8IOP	IK	HYDWALOBQJFOMS-UHFFFAOYSA-N
DMY8IOP	IU	1-ethoxy-2-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]ethane
DMY8IOP	CA	CAS 4353-28-0
DMY8IOP	CB	CHEBI:44751
DMY8IOP	DE	Discovery agent

DMMVL5P	ID	DMMVL5P
DMMVL5P	DN	3,6,9,12,15-PENTAOXATRICOSAN-1-OL
DMMVL5P	HS	Investigative
DMMVL5P	SN	3,6,9,12,15-Pentaoxatricosan-1-ol; n-Octylpentaoxyethylene; 19327-40-3; PENTAETHYLENE GLYCOL MONOOCTYL ETHER; Pentaoxyethylene monooctyl ether; polyoxyethylene 5 octyl ether; C;Pentaethyleneglycolmonooctylether; 2-[2-[2-[2-(2-octoxyethoxy)ethoxy]ethoxy]ethoxy]ethanol; Octylpentaglycol; N8E; C18H38O6; AC1L4MMQ; SCHEMBL61744; C8E5; Octyl pentaethylene glycol ether; DTXSID6075192; CTK0H9802; Pentaethylene glycol, octyl ether; MJELOWOAIAAUJT-UHFFFAOYSA-N; AC1Q5919; ZINC16051619; 7571AH; MFCD00043032; AKOS027320404; DB08249; LS-102023
DMMVL5P	DT	Small molecular drug
DMMVL5P	PC	159866
DMMVL5P	MW	350.5
DMMVL5P	FM	C18H38O6
DMMVL5P	IC	InChI=1S/C18H38O6/c1-2-3-4-5-6-7-9-20-11-13-22-15-17-24-18-16-23-14-12-21-10-8-19/h19H,2-18H2,1H3
DMMVL5P	CS	CCCCCCCCOCCOCCOCCOCCOCCO
DMMVL5P	IK	MJELOWOAIAAUJT-UHFFFAOYSA-N
DMMVL5P	IU	2-[2-[2-[2-(2-octoxyethoxy)ethoxy]ethoxy]ethoxy]ethanol
DMMVL5P	CA	CAS 19327-40-3
DMMVL5P	DE	Discovery agent

DMWTP7Y	ID	DMWTP7Y
DMWTP7Y	DN	3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone
DMWTP7Y	HS	Investigative
DMWTP7Y	SN	CHEMBL373668; 3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone
DMWTP7Y	DT	Small molecular drug
DMWTP7Y	PC	44405182
DMWTP7Y	MW	953.2
DMWTP7Y	FM	C55H68N8O7
DMWTP7Y	IC	InChI=1S/C55H68N8O7/c1-32-22-41(64)23-33(2)43(32)28-45(56)54(69)62-30-39-16-8-6-14-37(39)26-49(62)52(67)58-20-12-10-18-47-36(5)60-48(51(66)61-47)19-11-13-21-59-53(68)50-27-38-15-7-9-17-40(38)31-63(50)55(70)46(57)29-44-34(3)24-42(65)25-35(44)4/h6-9,14-17,22-25,45-46,49-50,64-65H,10-13,18-21,26-31,56-57H2,1-5H3,(H,58,67)(H,59,68)(H,61,66)/t45-,46-,49?,50?/m0/s1
DMWTP7Y	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCC4=C(N=C(C(=O)N4)CCCCNC(=O)C5CC6=CC=CC=C6CN5C(=O)[C@H](CC7=C(C=C(C=C7C)O)C)N)C)N)C)O
DMWTP7Y	IK	HHTSJHJHPFGARW-RFLUKDKXSA-N
DMWTP7Y	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[4-[5-[4-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]butyl]-3-methyl-6-oxo-1H-pyrazin-2-yl]butyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMWTP7Y	DE	Discovery agent

DM2Y4A6	ID	DM2Y4A6
DM2Y4A6	DN	3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone
DM2Y4A6	HS	Investigative
DM2Y4A6	SN	CHEMBL198800; 3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone
DM2Y4A6	DT	Small molecular drug
DM2Y4A6	PC	44405192
DM2Y4A6	MW	897.1
DM2Y4A6	FM	C51H60N8O7
DM2Y4A6	IC	InChI=1S/C51H60N8O7/c1-28-18-37(60)19-29(2)39(28)24-41(52)50(65)58-26-35-12-8-6-10-33(35)22-45(58)48(63)54-16-14-43-32(5)56-44(47(62)57-43)15-17-55-49(64)46-23-34-11-7-9-13-36(34)27-59(46)51(66)42(53)25-40-30(3)20-38(61)21-31(40)4/h6-13,18-21,41-42,45-46,60-61H,14-17,22-27,52-53H2,1-5H3,(H,54,63)(H,55,64)(H,57,62)/t41-,42-,45?,46?/m0/s1
DM2Y4A6	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCC4=C(N=C(C(=O)N4)CCNC(=O)C5CC6=CC=CC=C6CN5C(=O)[C@H](CC7=C(C=C(C=C7C)O)C)N)C)N)C)O
DM2Y4A6	IK	OOTASVYBVWGNJP-KJLUANBESA-N
DM2Y4A6	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-[5-[2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]ethyl]-3-methyl-6-oxo-1H-pyrazin-2-yl]ethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM2Y4A6	DE	Discovery agent

DMJR983	ID	DMJR983
DMJR983	DN	3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone
DMJR983	HS	Investigative
DMJR983	SN	CHEMBL200890; 3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone
DMJR983	DT	Small molecular drug
DMJR983	PC	44405233
DMJR983	MW	869
DMJR983	FM	C49H56N8O7
DMJR983	IC	InChI=1S/C49H56N8O7/c1-26-14-35(58)15-27(2)37(26)20-39(50)48(63)56-24-33-12-8-6-10-31(33)18-43(56)46(61)52-22-41-30(5)54-42(45(60)55-41)23-53-47(62)44-19-32-11-7-9-13-34(32)25-57(44)49(64)40(51)21-38-28(3)16-36(59)17-29(38)4/h6-17,39-40,43-44,58-59H,18-25,50-51H2,1-5H3,(H,52,61)(H,53,62)(H,55,60)/t39-,40-,43?,44?/m0/s1
DMJR983	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCC4=C(N=C(C(=O)N4)CNC(=O)C5CC6=CC=CC=C6CN5C(=O)[C@H](CC7=C(C=C(C=C7C)O)C)N)C)N)C)O
DMJR983	IK	BOYVBTQTUISOKQ-XQIDWOBFSA-N
DMJR983	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[[5-[[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]methyl]-3-methyl-6-oxo-1H-pyrazin-2-yl]methyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMJR983	DE	Discovery agent

DMEQBS3	ID	DMEQBS3
DMEQBS3	DN	3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone
DMEQBS3	HS	Investigative
DMEQBS3	SN	CHEMBL381874; 3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone
DMEQBS3	DT	Small molecular drug
DMEQBS3	PC	44405208
DMEQBS3	MW	925.1
DMEQBS3	FM	C53H64N8O7
DMEQBS3	IC	InChI=1S/C53H64N8O7/c1-30-20-39(62)21-31(2)41(30)26-43(54)52(67)60-28-37-14-8-6-12-35(37)24-47(60)50(65)56-18-10-16-45-34(5)58-46(49(64)59-45)17-11-19-57-51(66)48-25-36-13-7-9-15-38(36)29-61(48)53(68)44(55)27-42-32(3)22-40(63)23-33(42)4/h6-9,12-15,20-23,43-44,47-48,62-63H,10-11,16-19,24-29,54-55H2,1-5H3,(H,56,65)(H,57,66)(H,59,64)/t43-,44-,47?,48?/m0/s1
DMEQBS3	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCC4=C(N=C(C(=O)N4)CCCNC(=O)C5CC6=CC=CC=C6CN5C(=O)[C@H](CC7=C(C=C(C=C7C)O)C)N)C)N)C)O
DMEQBS3	IK	NATWHSVYZBCLOS-OYVXWBFTSA-N
DMEQBS3	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[3-[5-[3-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]propyl]-3-methyl-6-oxo-1H-pyrazin-2-yl]propyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMEQBS3	DE	Discovery agent

DMUH4OV	ID	DMUH4OV
DMUH4OV	DN	3,6-Dihydroxy-2-(4-hydroxy-phenyl)-inden-1-one
DMUH4OV	HS	Investigative
DMUH4OV	DT	Small molecular drug
DMUH4OV	PC	10308089
DMUH4OV	MW	254.24
DMUH4OV	FM	C15H10O4
DMUH4OV	IC	InChI=1S/C15H10O4/c16-9-3-1-8(2-4-9)13-14(18)11-6-5-10(17)7-12(11)15(13)19/h1-7,13,16-17H
DMUH4OV	CS	C1=CC(=CC=C1C2C(=O)C3=C(C2=O)C=C(C=C3)O)O
DMUH4OV	IK	QKHHOGHOHPKHGS-UHFFFAOYSA-N
DMUH4OV	IU	5-hydroxy-2-(4-hydroxyphenyl)indene-1,3-dione
DMUH4OV	DE	Discovery agent

DM7AORH	ID	DM7AORH
DM7AORH	DN	3,6-Dihydroxy-Xanthene-9-Propionic Acid
DM7AORH	HS	Investigative
DM7AORH	SN	3,6-DIHYDROXY-XANTHENE-9-PROPIONIC ACID; HXP; 3-(3,6-dihydroxy-9H-xanthen-9-yl)propanoic acid; AC1L9MSN; SCHEMBL4315610
DM7AORH	DT	Small molecular drug
DM7AORH	PC	449159
DM7AORH	MW	286.28
DM7AORH	FM	C16H14O5
DM7AORH	IC	InChI=1S/C16H14O5/c17-9-1-3-12-11(5-6-16(19)20)13-4-2-10(18)8-15(13)21-14(12)7-9/h1-4,7-8,11,17-18H,5-6H2,(H,19,20)
DM7AORH	CS	C1=CC2=C(C=C1O)OC3=C(C2CCC(=O)O)C=CC(=C3)O
DM7AORH	IK	PFQGLFBMMPZYEU-UHFFFAOYSA-N
DM7AORH	IU	3-(3,6-dihydroxy-9H-xanthen-9-yl)propanoic acid
DM7AORH	DE	Discovery agent

DMEOBNJ	ID	DMEOBNJ
DMEOBNJ	DN	3,6-Diphenyl-1-oxa-7-aza-spiro[4.5]decane
DMEOBNJ	HS	Investigative
DMEOBNJ	DT	Small molecular drug
DMEOBNJ	PC	44324916
DMEOBNJ	MW	293.4
DMEOBNJ	FM	C20H23NO
DMEOBNJ	IC	InChI=1S/C20H23NO/c1-3-8-16(9-4-1)18-14-20(22-15-18)12-7-13-21-19(20)17-10-5-2-6-11-17/h1-6,8-11,18-19,21H,7,12-15H2/t18-,19?,20?/m1/s1
DMEOBNJ	CS	C1CC2(C[C@H](CO2)C3=CC=CC=C3)C(NC1)C4=CC=CC=C4
DMEOBNJ	IK	WJRYRJACQITXQC-XEVCZEQESA-N
DMEOBNJ	IU	(3S)-3,10-diphenyl-1-oxa-9-azaspiro[4.5]decane
DMEOBNJ	DE	Discovery agent

DMNV0EZ	ID	DMNV0EZ
DMNV0EZ	DN	3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine
DMNV0EZ	HS	Investigative
DMNV0EZ	SN	pyrazolo[1,5-a]pyrimidine 1a; AC1NS6UW; CHEMBL92279; BDBM5417; 3,6-dipyridin-4-ylpyrazolo[1,5-a]pyrimidine; 3,6-Bis(4-pyridyl)pyrazolo[1,5-a]pyrimidine
DMNV0EZ	DT	Small molecular drug
DMNV0EZ	PC	5329454
DMNV0EZ	MW	273.29
DMNV0EZ	FM	C16H11N5
DMNV0EZ	IC	InChI=1S/C16H11N5/c1-5-17-6-2-12(1)14-9-19-16-15(10-20-21(16)11-14)13-3-7-18-8-4-13/h1-11H
DMNV0EZ	CS	C1=CN=CC=C1C2=CN3C(=C(C=N3)C4=CC=NC=C4)N=C2
DMNV0EZ	IK	ZLISHOMLHVNDJG-UHFFFAOYSA-N
DMNV0EZ	IU	3,6-dipyridin-4-ylpyrazolo[1,5-a]pyrimidine
DMNV0EZ	DE	Discovery agent

DMES906	ID	DMES906
DMES906	DN	3,7,3',4'-TETRAHYDROXYFLAVONE
DMES906	HS	Investigative
DMES906	SN	Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; 3,7,3',4'-Tetrahydroxyflavone; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1; FISETIN
DMES906	DT	Small molecular drug
DMES906	PC	5281614
DMES906	MW	286.24
DMES906	FM	C15H10O6
DMES906	IC	InChI=1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H
DMES906	CS	C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O)O)O
DMES906	IK	XHEFDIBZLJXQHF-UHFFFAOYSA-N
DMES906	IU	2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one
DMES906	CA	CAS 528-48-3
DMES906	CB	CHEBI:42567
DMES906	DE	Discovery agent

DMQADXL	ID	DMQADXL
DMQADXL	DN	3,7-Bis(2-hydroxyethyl)icaritin
DMQADXL	HS	Investigative
DMQADXL	SN	3,7-Bis(2-hydroxyethyl)icaritin; UNII-5U58D99D1L; CHEMBL498486; 5U58D99D1L; SCHEMBL18533069; BDBM50272529; 3,7-Bis(2-hydroxyethoxy)-5-hydroxy-4'-methoxy-8-(3-methyl-2-butenyl)flavone; 1067198-74-6; 4H-1-Benzopyran-4-one, 5-hydroxy-3,7-bis(2-hydroxyethoxy)-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-
DMQADXL	DT	Small molecular drug
DMQADXL	PC	25058047
DMQADXL	MW	456.5
DMQADXL	FM	C25H28O8
DMQADXL	IC	InChI=1S/C25H28O8/c1-15(2)4-9-18-20(31-12-10-26)14-19(28)21-22(29)25(32-13-11-27)23(33-24(18)21)16-5-7-17(30-3)8-6-16/h4-8,14,26-28H,9-13H2,1-3H3
DMQADXL	CS	CC(=CCC1=C(C=C(C2=C1OC(=C(C2=O)OCCO)C3=CC=C(C=C3)OC)O)OCCO)C
DMQADXL	IK	WTJGVHRGWYENBZ-UHFFFAOYSA-N
DMQADXL	IU	5-hydroxy-3,7-bis(2-hydroxyethoxy)-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
DMQADXL	CA	CAS 1067198-74-6
DMQADXL	DE	Discovery agent

DMBIRC6	ID	DMBIRC6
DMBIRC6	DN	3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM
DMBIRC6	HS	Investigative
DMBIRC6	SN	Methylene Blue cation; 3,7-bis(dimethylamino)phenothiazin-5-ium; UNII-ZMZ79891ZH; N-[7-(dimethylamino)-3H-phenothiazin-3-ylidene]-N-methylmethanaminium; ZMZ79891ZH; CHEBI:43830; azul de metileno; Methylthionine HCl; Methylthionine chloride; CHEMBL405110; NSC3089; NSC617593; NSC215213; NCGC00167496-03; NCGC00167496-01; C.I. 52015; Methylthioninium; Methylene Blue parent; AI3-52463; cid_6099; AC1Q4UZ6; AC1L1HI1; SCHEMBL109755; CHEMBL191083; DTXSID3047009; NOCAS_47009; RBTBFTRPCNLSDE-UHFFFAOYSA-N; MolPort-003-700-760
DMBIRC6	DT	Small molecular drug
DMBIRC6	PC	4139
DMBIRC6	MW	284.4
DMBIRC6	FM	C16H18N3S+
DMBIRC6	IC	InChI=1S/C16H18N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10H,1-4H3/q+1
DMBIRC6	CS	CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2
DMBIRC6	IK	RBTBFTRPCNLSDE-UHFFFAOYSA-N
DMBIRC6	IU	[7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium
DMBIRC6	CA	CAS 7060-82-4
DMBIRC6	CB	CHEBI:43830
DMBIRC6	DE	Discovery agent

DMH04P7	ID	DMH04P7
DMH04P7	DN	3,7-dihydroxy-flavone
DMH04P7	HS	Investigative
DMH04P7	SN	3,7-dihydroxyflavone; 7-Hydroxyflavonol; 492-00-2; 3,7-dihydroxy-2-phenyl-4H-chromen-4-one; 5-Deoxygalangin; 4H-1-Benzopyran-4-one, 3,7-dihydroxy-2-phenyl-; UNII-O948D0K9BQ; O948D0K9BQ; CHEMBL210276; 3,7-dihydroxy-2-phenylchromen-4-one; 3,7-dihydroxy-flavone; 7,3'-dihydroxyflavonol; SR-01000314616; Resogalangin; SPBio_001803; Spectrum_001462; SpecPlus_000778; AC1NU2BD; Spectrum4_001767; Spectrum3_001623; Spectrum2_001652; Spectrum5_000353; 3,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; Oprea1_793720; KBioSS_001942; KBioGR_002253
DMH04P7	DT	Small molecular drug
DMH04P7	PC	5393152
DMH04P7	MW	254.24
DMH04P7	FM	C15H10O4
DMH04P7	IC	InChI=1S/C15H10O4/c16-10-6-7-11-12(8-10)19-15(14(18)13(11)17)9-4-2-1-3-5-9/h1-8,16,18H
DMH04P7	CS	C1=CC=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O
DMH04P7	IK	UWQJWDYDYIJWKY-UHFFFAOYSA-N
DMH04P7	IU	3,7-dihydroxy-2-phenylchromen-4-one
DMH04P7	CA	CAS 492-00-2
DMH04P7	CB	CHEBI:109535
DMH04P7	DE	Discovery agent

DMJ0654	ID	DMJ0654
DMJ0654	DN	3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID
DMJ0654	HS	Investigative
DMJ0654	SN	3,7-DIHYDROXY-2-NAPHTHOIC ACID; 83511-07-3; 2,6-Dihydroxy-3-Naphthoic acid; 3,7-Dihydroxy-2-naphthalenecarboxylic Acid; CHEMBL1231350; 2,6-DIOXYNAPHTHALENE-3-CARBOXYLIC ACID; PubChem9419; ACMC-209psi; AC1LEHT6; AC1Q5UP9; AC1Q72HK; SCHEMBL124773; 3,7-dihydroxy-2-naphtoic acid; KS-00000GHV; CTK3E8003; DTXSID30352988; QMWOUSYSNFCKAZ-UHFFFAOYSA-N; MolPort-001-790-958; ZINC156898; STL426758; BDBM50379183; BBL034659; ANW-37696; SBB037881; AKOS015856275; VZ22995; MCULE-9133006477; CD-1291
DMJ0654	DT	Small molecular drug
DMJ0654	PC	736299
DMJ0654	MW	204.18
DMJ0654	FM	C11H8O4
DMJ0654	IC	InChI=1S/C11H8O4/c12-8-2-1-6-5-10(13)9(11(14)15)4-7(6)3-8/h1-5,12-13H,(H,14,15)
DMJ0654	CS	C1=CC(=CC2=CC(=C(C=C21)O)C(=O)O)O
DMJ0654	IK	QMWOUSYSNFCKAZ-UHFFFAOYSA-N
DMJ0654	IU	3,7-dihydroxynaphthalene-2-carboxylic acid
DMJ0654	CA	CAS 83511-07-3
DMJ0654	DE	Discovery agent

DM23CEI	ID	DM23CEI
DM23CEI	DN	3,8-dibromoboldine
DM23CEI	HS	Investigative
DM23CEI	SN	3,8-dibromoboldine; CHEMBL388564
DM23CEI	DT	Small molecular drug
DM23CEI	PC	10480509
DM23CEI	MW	485.2
DM23CEI	FM	C19H19Br2NO4
DM23CEI	IC	InChI=1S/C19H19Br2NO4/c1-22-5-4-8-13-11(22)6-10-9(7-12(25-2)17(23)16(10)21)14(13)19(26-3)18(24)15(8)20/h7,11,23-24H,4-6H2,1-3H3/t11-/m0/s1
DM23CEI	CS	CN1CCC2=C3[C@@H]1CC4=C(C(=C(C=C4C3=C(C(=C2Br)O)OC)OC)O)Br
DM23CEI	IK	FTUCKVYWXINSAK-NSHDSACASA-N
DM23CEI	IU	(6aS)-3,8-dibromo-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DM23CEI	DE	Discovery agent

DMIFJRS	ID	DMIFJRS
DMIFJRS	DN	3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one
DMIFJRS	HS	Investigative
DMIFJRS	SN	CHEMBL206600; 3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one; SCHEMBL6828078
DMIFJRS	DT	Small molecular drug
DMIFJRS	PC	10331951
DMIFJRS	MW	242.23
DMIFJRS	FM	C14H10O4
DMIFJRS	IC	InChI=1S/C14H10O4/c1-7-12(16)5-4-10-9-3-2-8(15)6-11(9)14(17)18-13(7)10/h2-6,15-16H,1H3
DMIFJRS	CS	CC1=C(C=CC2=C1OC(=O)C3=C2C=CC(=C3)O)O
DMIFJRS	IK	JVSYWKIVBHXUKB-UHFFFAOYSA-N
DMIFJRS	IU	3,8-dihydroxy-4-methylbenzo[c]chromen-6-one
DMIFJRS	DE	Discovery agent

DMW0B4H	ID	DMW0B4H
DMW0B4H	DN	3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one
DMW0B4H	HS	Investigative
DMW0B4H	SN	CHEMBL206226; 3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one
DMW0B4H	DT	Small molecular drug
DMW0B4H	PC	44408971
DMW0B4H	MW	242.23
DMW0B4H	FM	C14H10O4
DMW0B4H	IC	InChI=1S/C14H10O4/c1-7-11(16)5-4-10-9-3-2-8(15)6-12(9)18-14(17)13(7)10/h2-6,15-16H,1H3
DMW0B4H	CS	CC1=C(C=CC2=C1C(=O)OC3=C2C=CC(=C3)O)O
DMW0B4H	IK	UQGMRVBIHYSKJN-UHFFFAOYSA-N
DMW0B4H	IU	3,8-dihydroxy-7-methylbenzo[c]chromen-6-one
DMW0B4H	DE	Discovery agent

DMXZ8RJ	ID	DMXZ8RJ
DMXZ8RJ	DN	3,9-dihydroxy-2,10-diprenylpterocap-6a-ene
DMXZ8RJ	HS	Investigative
DMXZ8RJ	SN	Erycristagallin; CHEMBL462699; 3,9-Dihydroxy-2,10-diprenylpterocarpene; Erycrystagallin; 3,9-dihydroxy-2,10-diprenylpterocap-6a-ene; SCHEMBL571693; BDBM50292388; LMPK12070146
DMXZ8RJ	DT	Small molecular drug
DMXZ8RJ	PC	10362969
DMXZ8RJ	MW	390.5
DMXZ8RJ	FM	C25H26O4
DMXZ8RJ	IC	InChI=1S/C25H26O4/c1-14(2)5-7-16-11-19-23(12-22(16)27)28-13-20-17-9-10-21(26)18(8-6-15(3)4)24(17)29-25(19)20/h5-6,9-12,26-27H,7-8,13H2,1-4H3
DMXZ8RJ	CS	CC(=CCC1=CC2=C(C=C1O)OCC3=C2OC4=C3C=CC(=C4CC=C(C)C)O)C
DMXZ8RJ	IK	VNTSSLCFFUCTNP-UHFFFAOYSA-N
DMXZ8RJ	IU	2,10-bis(3-methylbut-2-enyl)-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMXZ8RJ	CA	CAS 92533-56-7
DMXZ8RJ	DE	Discovery agent

DMK53AT	ID	DMK53AT
DMK53AT	DN	3,9-Dihydroxy-4-prenyl-[6aR,11aR]pterocarpan
DMK53AT	HS	Investigative
DMK53AT	SN	CHEMBL1087027; BDBM50311578
DMK53AT	DT	Small molecular drug
DMK53AT	PC	46880035
DMK53AT	MW	324.4
DMK53AT	FM	C20H20O4
DMK53AT	IC	InChI=1S/C20H20O4/c1-11(2)3-5-14-17(22)8-7-15-19(14)23-10-16-13-6-4-12(21)9-18(13)24-20(15)16/h3-4,6-9,16,20-22H,5,10H2,1-2H3/t16-,20-/m0/s1
DMK53AT	CS	CC(=CCC1=C(C=CC2=C1OC[C@@H]3[C@H]2OC4=C3C=CC(=C4)O)O)C
DMK53AT	IK	QKYUTKLCEVEMIE-JXFKEZNVSA-N
DMK53AT	IU	(6aR,11aR)-4-(3-methylbut-2-enyl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMK53AT	DE	Discovery agent

DMLSET4	ID	DMLSET4
DMLSET4	DN	3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
DMLSET4	HS	Investigative
DMLSET4	SN	Thiol-Based Inhibitor, 26b; CHEMBL207288; SCHEMBL9965357; Benzoic acid, 3-[(1-carboxy-4-mercaptobutyl)thio]-; BDBM17776; 378242-58-1; 3-[(1-carboxy-4-sulfanylbutyl)sulfanyl]benzoic acid
DMLSET4	DT	Small molecular drug
DMLSET4	PC	11666386
DMLSET4	MW	286.4
DMLSET4	FM	C12H14O4S2
DMLSET4	IC	InChI=1S/C12H14O4S2/c13-11(14)8-3-1-4-9(7-8)18-10(12(15)16)5-2-6-17/h1,3-4,7,10,17H,2,5-6H2,(H,13,14)(H,15,16)
DMLSET4	CS	C1=CC(=CC(=C1)SC(CCCS)C(=O)O)C(=O)O
DMLSET4	IK	QIPLUMAHVZVCQB-UHFFFAOYSA-N
DMLSET4	IU	3-(1-carboxy-4-sulfanylbutyl)sulfanylbenzoic acid
DMLSET4	DE	Discovery agent

DM2KXFS	ID	DM2KXFS
DM2KXFS	DN	3-[(1s)-1-(Dimethylamino)Ethyl]Phenol
DM2KXFS	HS	Investigative
DM2KXFS	SN	139306-10-8; (S)-3-(1-(dimethylamino)ethyl)phenol; 3-[(1S)-1-(DIMETHYLAMINO)ETHYL]PHENOL; 3-[(1S)-1-(Dimethylaminoethyl)]phenol; (s)-3-[1-(dimethylamino)ethyl]phenol; 3-((S)-1-Dimethylamino-ethyl)-phenol; UNII-1608PLR9ZO; (S)-3-1(-Dimethylamino)ethylphenol; NAP-226-90; (S)-3-1(- Dimethylamino)ethylphenol; NAP 226-90; 1608PLR9ZO; (S)-3-(1-DIMETHYLAMINOETHYL)PHENOL; Phenol, 3-[(1S)-1-(dimethylamino)ethyl]-; AK-51758; 3-((1S)-1-(Dimethylamino)ethyl)phenol; Phenol, 3-((1S)-1-(dimethylamino)ethyl)-; SAF; A1-00312; W-205531
DM2KXFS	DT	Small molecular drug
DM2KXFS	PC	445892
DM2KXFS	MW	165.23
DM2KXFS	FM	C10H15NO
DM2KXFS	IC	InChI=1S/C10H15NO/c1-8(11(2)3)9-5-4-6-10(12)7-9/h4-8,12H,1-3H3/t8-/m0/s1
DM2KXFS	CS	C[C@@H](C1=CC(=CC=C1)O)N(C)C
DM2KXFS	IK	GQZXRLWUYONVCP-QMMMGPOBSA-N
DM2KXFS	IU	3-[(1S)-1-(dimethylamino)ethyl]phenol
DM2KXFS	CA	CAS 139306-10-8
DM2KXFS	DE	Discovery agent

DMBAHRJ	ID	DMBAHRJ
DMBAHRJ	DN	3-[(2,5-dimethyl-4-thiazolyl)ethynyl]pyridine
DMBAHRJ	HS	Investigative
DMBAHRJ	SN	CHEMBL201857; 3-[(2,5-dimethyl-4-thiazolyl)ethynyl]pyridine; SCHEMBL4149620
DMBAHRJ	DT	Small molecular drug
DMBAHRJ	PC	11615445
DMBAHRJ	MW	214.29
DMBAHRJ	FM	C12H10N2S
DMBAHRJ	IC	InChI=1S/C12H10N2S/c1-9-12(14-10(2)15-9)6-5-11-4-3-7-13-8-11/h3-4,7-8H,1-2H3
DMBAHRJ	CS	CC1=C(N=C(S1)C)C#CC2=CN=CC=C2
DMBAHRJ	IK	JDFSJBMBMZRXML-UHFFFAOYSA-N
DMBAHRJ	IU	2,5-dimethyl-4-(2-pyridin-3-ylethynyl)-1,3-thiazole
DMBAHRJ	DE	Discovery agent

DMZ78WB	ID	DMZ78WB
DMZ78WB	DN	3-[(2-methyl-4-thiazolyl)ethynyl]-5-vinylpyridine
DMZ78WB	HS	Investigative
DMZ78WB	SN	CHEMBL202307; 3-[(2-methyl-4-thiazolyl)ethynyl]-5-vinylpyridine; SCHEMBL4160862; BDBM50181753; ZINC13680962; US8609852, 78
DMZ78WB	DT	Small molecular drug
DMZ78WB	PC	11608287
DMZ78WB	MW	226.3
DMZ78WB	FM	C13H10N2S
DMZ78WB	IC	InChI=1S/C13H10N2S/c1-3-11-6-12(8-14-7-11)4-5-13-9-16-10(2)15-13/h3,6-9H,1H2,2H3
DMZ78WB	CS	CC1=NC(=CS1)C#CC2=CN=CC(=C2)C=C
DMZ78WB	IK	BZJCMXLEGBDDGI-UHFFFAOYSA-N
DMZ78WB	IU	4-[2-(5-ethenylpyridin-3-yl)ethynyl]-2-methyl-1,3-thiazole
DMZ78WB	DE	Discovery agent

DMMLDOZ	ID	DMMLDOZ
DMMLDOZ	DN	3-[(2-methyl-4-thiazolyl)ethynyl]benzamide
DMMLDOZ	HS	Investigative
DMMLDOZ	SN	CHEMBL414673; 3-[(2-methyl-4-thiazolyl)ethynyl]benzamide; Benzamide, 3-[2-(2-methyl-4-thiazolyl)ethynyl]-; SCHEMBL4157102; BDBM50181774
DMMLDOZ	DT	Small molecular drug
DMMLDOZ	PC	11586785
DMMLDOZ	MW	242.3
DMMLDOZ	FM	C13H10N2OS
DMMLDOZ	IC	InChI=1S/C13H10N2OS/c1-9-15-12(8-17-9)6-5-10-3-2-4-11(7-10)13(14)16/h2-4,7-8H,1H3,(H2,14,16)
DMMLDOZ	CS	CC1=NC(=CS1)C#CC2=CC(=CC=C2)C(=O)N
DMMLDOZ	IK	WCIRCOOMYHNZHE-UHFFFAOYSA-N
DMMLDOZ	IU	3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]benzamide
DMMLDOZ	DE	Discovery agent

DMQUDR1	ID	DMQUDR1
DMQUDR1	DN	3-[(2-methyl-4-thiazolyl)ethynyl]benzonitrile
DMQUDR1	HS	Investigative
DMQUDR1	SN	3-[(2-Methyl-4-thiazolyl)ethynyl]benzonitrile; CHEMBL201943; MTEB; SCHEMBL4153877; Benzonitrile, 3-[2-(2-methyl-4-thiazolyl)ethynyl]-; GTPL1428; 3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile; BDBM50181745
DMQUDR1	DT	Small molecular drug
DMQUDR1	PC	11535913
DMQUDR1	MW	224.28
DMQUDR1	FM	C13H8N2S
DMQUDR1	IC	InChI=1S/C13H8N2S/c1-10-15-13(9-16-10)6-5-11-3-2-4-12(7-11)8-14/h2-4,7,9H,1H3
DMQUDR1	CS	CC1=NC(=CS1)C#CC2=CC(=CC=C2)C#N
DMQUDR1	IK	GRUPMMBRLDBTDD-UHFFFAOYSA-N
DMQUDR1	IU	3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile
DMQUDR1	DE	Discovery agent

DMF0QM2	ID	DMF0QM2
DMF0QM2	DN	3-[(2-methyl-4-thiazolyl)ethynyl]phenol
DMF0QM2	HS	Investigative
DMF0QM2	SN	CHEMBL201974; 3-[(2-methyl-4-thiazolyl)ethynyl]phenol; SCHEMBL4152997; BDBM50181784
DMF0QM2	DT	Small molecular drug
DMF0QM2	PC	11708325
DMF0QM2	MW	215.27
DMF0QM2	FM	C12H9NOS
DMF0QM2	IC	InChI=1S/C12H9NOS/c1-9-13-11(8-15-9)6-5-10-3-2-4-12(14)7-10/h2-4,7-8,14H,1H3
DMF0QM2	CS	CC1=NC(=CS1)C#CC2=CC(=CC=C2)O
DMF0QM2	IK	HMWLZOIKORRPSN-UHFFFAOYSA-N
DMF0QM2	IU	3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]phenol
DMF0QM2	DE	Discovery agent

DMHISM2	ID	DMHISM2
DMHISM2	DN	3-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine
DMHISM2	HS	Investigative
DMHISM2	SN	CHEMBL1215663; BDBM50324610
DMHISM2	DT	Small molecular drug
DMHISM2	PC	49864180
DMHISM2	MW	277.3
DMHISM2	FM	C18H15NO2
DMHISM2	IC	InChI=1S/C18H15NO2/c20-17-9-7-14(8-10-17)13-3-5-15(6-4-13)18(21)16-2-1-11-19-12-16/h1-12,18,20-21H
DMHISM2	CS	C1=CC(=CN=C1)C(C2=CC=C(C=C2)C3=CC=C(C=C3)O)O
DMHISM2	IK	ZSARFSCMOGDZTE-UHFFFAOYSA-N
DMHISM2	IU	4-[4-[hydroxy(pyridin-3-yl)methyl]phenyl]phenol
DMHISM2	DE	Discovery agent

DM9OI2R	ID	DM9OI2R
DM9OI2R	DN	3-[(5-ethyl-2-methyl-4-thiazolyl)ethynyl]pyridine
DM9OI2R	HS	Investigative
DM9OI2R	SN	CHEMBL202277; 3-[(5-ethyl-2-methyl-4-thiazolyl)ethynyl]pyridine; SCHEMBL4151649
DM9OI2R	DT	Small molecular drug
DM9OI2R	PC	11572145
DM9OI2R	MW	228.31
DM9OI2R	FM	C13H12N2S
DM9OI2R	IC	InChI=1S/C13H12N2S/c1-3-13-12(15-10(2)16-13)7-6-11-5-4-8-14-9-11/h4-5,8-9H,3H2,1-2H3
DM9OI2R	CS	CCC1=C(N=C(S1)C)C#CC2=CN=CC=C2
DM9OI2R	IK	SJJSHLRFCBWELS-UHFFFAOYSA-N
DM9OI2R	IU	5-ethyl-2-methyl-4-(2-pyridin-3-ylethynyl)-1,3-thiazole
DM9OI2R	DE	Discovery agent

DMH5329	ID	DMH5329
DMH5329	DN	3-[(6-Methylpyridin-2-yl)ethynyl]benzonitrile
DMH5329	HS	Investigative
DMH5329	SN	CHEMBL181483; 3-[(6-Methylpyridin-2-yl)ethynyl]benzonitrile; SCHEMBL4711543; FKODYULBKPINFM-UHFFFAOYSA-N; BDBM50160632; ZINC28362342; 3-(6-Methyl-pyridin-2-ylethynyl)-benzonitrile
DMH5329	DT	Small molecular drug
DMH5329	PC	11378977
DMH5329	MW	218.25
DMH5329	FM	C15H10N2
DMH5329	IC	InChI=1S/C15H10N2/c1-12-4-2-7-15(17-12)9-8-13-5-3-6-14(10-13)11-16/h2-7,10H,1H3
DMH5329	CS	CC1=NC(=CC=C1)C#CC2=CC(=CC=C2)C#N
DMH5329	IK	FKODYULBKPINFM-UHFFFAOYSA-N
DMH5329	IU	3-[2-(6-methylpyridin-2-yl)ethynyl]benzonitrile
DMH5329	DE	Discovery agent

DMNPKZ6	ID	DMNPKZ6
DMNPKZ6	DN	3-[(Z)-2-phenylvinyl]pyridine
DMNPKZ6	HS	Investigative
DMNPKZ6	SN	pyridine,3-(2-phenylethenyl)-,(z)-; 3-[(Z)-2-phenylethenyl]pyridine; 5097-90-5; Styrylpyridine 16; 3-[(Z)-2-phenylvinyl]pyridine; cis-3-styrylpyridine; 3-[(Z)-Styryl]pyridine; AC1O70HN; BDBM8900; CHEMBL206125; ZINC13684559; AKOS024262946
DMNPKZ6	DT	Small molecular drug
DMNPKZ6	PC	6540056
DMNPKZ6	MW	181.23
DMNPKZ6	FM	C13H11N
DMNPKZ6	IC	InChI=1S/C13H11N/c1-2-5-12(6-3-1)8-9-13-7-4-10-14-11-13/h1-11H/b9-8-
DMNPKZ6	CS	C1=CC=C(C=C1)/C=C\\C2=CN=CC=C2
DMNPKZ6	IK	RMSGACVDMOLUPL-HJWRWDBZSA-N
DMNPKZ6	IU	3-[(Z)-2-phenylethenyl]pyridine
DMNPKZ6	DE	Discovery agent

DM7URMW	ID	DM7URMW
DM7URMW	DN	3-[1-(4-Bromobenzyl)-1H-imidazol-5-yl]-1-propanol
DM7URMW	HS	Investigative
DM7URMW	SN	CHEMBL598810; SCHEMBL3823053; 3-[1-(4-Bromobenzyl)-1H-imidazol-5-yl]-1-propanol; HNOJMJNDVRPLSW-UHFFFAOYSA-N; BDBM50307229; 1-p-Bromobenzyl-5-(3-hydroxypropyl)-1H-imidazole
DM7URMW	DT	Small molecular drug
DM7URMW	PC	22466877
DM7URMW	MW	295.17
DM7URMW	FM	C13H15BrN2O
DM7URMW	IC	InChI=1S/C13H15BrN2O/c14-12-5-3-11(4-6-12)9-16-10-15-8-13(16)2-1-7-17/h3-6,8,10,17H,1-2,7,9H2
DM7URMW	CS	C1=CC(=CC=C1CN2C=NC=C2CCCO)Br
DM7URMW	IK	HNOJMJNDVRPLSW-UHFFFAOYSA-N
DM7URMW	IU	3-[3-[(4-bromophenyl)methyl]imidazol-4-yl]propan-1-ol
DM7URMW	DE	Discovery agent

DM63IKF	ID	DM63IKF
DM63IKF	DN	3-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]-1-propanol
DM63IKF	HS	Investigative
DM63IKF	SN	CHEMBL598399; SCHEMBL3822518; 3-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]-1-propanol; ACOYOVQVLSTOMH-UHFFFAOYSA-N; ZINC34123980; BDBM50307226; AKOS027324260; 1-p-Cyanophenylmethyl-5-(3-hydroxypropyl)-1H-imidazole; 1-(p-cyanophenylmethyl)-5-(3-hydroxypropyl)-1H-imidazole; 1-(p-Cyanophenylmethyl)-5-(3-hydroxypropyl) -1H-imidazole
DM63IKF	DT	Small molecular drug
DM63IKF	PC	13688208
DM63IKF	MW	241.29
DM63IKF	FM	C14H15N3O
DM63IKF	IC	InChI=1S/C14H15N3O/c15-8-12-3-5-13(6-4-12)10-17-11-16-9-14(17)2-1-7-18/h3-6,9,11,18H,1-2,7,10H2
DM63IKF	CS	C1=CC(=CC=C1CN2C=NC=C2CCCO)C#N
DM63IKF	IK	ACOYOVQVLSTOMH-UHFFFAOYSA-N
DM63IKF	IU	4-[[5-(3-hydroxypropyl)imidazol-1-yl]methyl]benzonitrile
DM63IKF	DE	Discovery agent

DMIHWAJ	ID	DMIHWAJ
DMIHWAJ	DN	3-[1'-{4'-(Benzyloxy)-phenyl}]-quinuclidine-2-ene
DMIHWAJ	HS	Investigative
DMIHWAJ	SN	CHEMBL453439; 3-[1'-{4'-(Benzyloxy)-phenyl}]-quinuclidine-2-ene; BDBM50270321; 3-[1''-{4''-(Benzyloxy)-phenyl}]-quinuclidine-2-ene
DMIHWAJ	DT	Small molecular drug
DMIHWAJ	PC	23653492
DMIHWAJ	MW	291.4
DMIHWAJ	FM	C20H21NO
DMIHWAJ	IC	InChI=1S/C20H21NO/c1-2-4-16(5-3-1)15-22-19-8-6-17(7-9-19)20-14-21-12-10-18(20)11-13-21/h1-9,14,18H,10-13,15H2
DMIHWAJ	CS	C1CN2CCC1C(=C2)C3=CC=C(C=C3)OCC4=CC=CC=C4
DMIHWAJ	IK	OKNMXSHKBLYYKN-UHFFFAOYSA-N
DMIHWAJ	IU	3-(4-phenylmethoxyphenyl)-1-azabicyclo[2.2.2]oct-2-ene
DMIHWAJ	DE	Discovery agent

DMBHUP3	ID	DMBHUP3
DMBHUP3	DN	3-[10-(benzylmethylamino)decyloxy]xanthen-9-one
DMBHUP3	HS	Investigative
DMBHUP3	SN	CHEMBL390598; 3-[10-(benzylmethylamino)decyloxy]xanthen-9-one
DMBHUP3	DT	Small molecular drug
DMBHUP3	PC	44421959
DMBHUP3	MW	471.6
DMBHUP3	FM	C31H37NO3
DMBHUP3	IC	InChI=1S/C31H37NO3/c1-32(24-25-15-9-8-10-16-25)21-13-6-4-2-3-5-7-14-22-34-26-19-20-28-30(23-26)35-29-18-12-11-17-27(29)31(28)33/h8-12,15-20,23H,2-7,13-14,21-22,24H2,1H3
DMBHUP3	CS	CN(CCCCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMBHUP3	IK	YOTLTNQICYMZSI-UHFFFAOYSA-N
DMBHUP3	IU	3-[10-[benzyl(methyl)amino]decoxy]xanthen-9-one
DMBHUP3	DE	Discovery agent

DM287UO	ID	DM287UO
DM287UO	DN	3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one
DM287UO	HS	Investigative
DM287UO	SN	CHEMBL224347; 3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one
DM287UO	DT	Small molecular drug
DM287UO	PC	44421960
DM287UO	MW	485.7
DM287UO	FM	C32H39NO3
DM287UO	IC	InChI=1S/C32H39NO3/c1-33(25-26-16-10-9-11-17-26)22-14-7-5-3-2-4-6-8-15-23-35-27-20-21-29-31(24-27)36-30-19-13-12-18-28(30)32(29)34/h9-13,16-21,24H,2-8,14-15,22-23,25H2,1H3
DM287UO	CS	CN(CCCCCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DM287UO	IK	GQHNOERJFAPKTD-UHFFFAOYSA-N
DM287UO	IU	3-[11-[benzyl(methyl)amino]undecoxy]xanthen-9-one
DM287UO	DE	Discovery agent

DM9KVHQ	ID	DM9KVHQ
DM9KVHQ	DN	3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one
DM9KVHQ	HS	Investigative
DM9KVHQ	SN	CHEMBL224555; 3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one
DM9KVHQ	DT	Small molecular drug
DM9KVHQ	PC	16066832
DM9KVHQ	MW	499.7
DM9KVHQ	FM	C33H41NO3
DM9KVHQ	IC	InChI=1S/C33H41NO3/c1-34(26-27-17-11-10-12-18-27)23-15-8-6-4-2-3-5-7-9-16-24-36-28-21-22-30-32(25-28)37-31-20-14-13-19-29(31)33(30)35/h10-14,17-22,25H,2-9,15-16,23-24,26H2,1H3
DM9KVHQ	CS	CN(CCCCCCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DM9KVHQ	IK	JLVUWPGHBWDHKA-UHFFFAOYSA-N
DM9KVHQ	IU	3-[12-[benzyl(methyl)amino]dodecoxy]xanthen-9-one
DM9KVHQ	DE	Discovery agent

DMPTI1Z	ID	DMPTI1Z
DMPTI1Z	DN	3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol
DMPTI1Z	HS	Investigative
DMPTI1Z	SN	Metahexes trol; 3,3'-Hexestrol; Metahexestrol; 3,3'-Hes; 68266-24-0; meso-3,4-Bis(3'-hydroxyphenyl)hexane; BRN 3971661; NSC-297,170; meso-3,3'-(1,2-Diethylethylene)diphenol; NSC-297170; (R*,S*)-3,3'-(1,2-Diethyl-1,2-ethanediyl)bisphenol; Phenol, 3,3'-(1,2-diethyl-1,2-ethanediyl)bis-, (R*,S*)-; Phenol, 3,3'-((1R,2S)-1,2-diethyl-1,2-ethanediyl)bis-, rel-; UNII-DSF584X94B; DSF584X94B; NSC 297170; 3-[4-(3-hydroxyphenyl)hexan-3-yl]phenol; AC1L2OPY; 1,2-Diethyl-1,2-bis(3'-hydroxyphenyl)ethane; AC1Q79WV; CHEMBL18268; SCHEMBL5014485
DMPTI1Z	DT	Small molecular drug
DMPTI1Z	PC	100424
DMPTI1Z	MW	270.4
DMPTI1Z	FM	C18H22O2
DMPTI1Z	IC	InChI=1S/C18H22O2/c1-3-17(13-7-5-9-15(19)11-13)18(4-2)14-8-6-10-16(20)12-14/h5-12,17-20H,3-4H2,1-2H3
DMPTI1Z	CS	CCC(C1=CC(=CC=C1)O)C(CC)C2=CC(=CC=C2)O
DMPTI1Z	IK	KUJAWCSIKNKXLL-UHFFFAOYSA-N
DMPTI1Z	IU	3-[4-(3-hydroxyphenyl)hexan-3-yl]phenol
DMPTI1Z	CA	CAS 68266-24-0
DMPTI1Z	DE	Discovery agent

DME1UNY	ID	DME1UNY
DME1UNY	DN	3-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1H-indazole
DME1UNY	HS	Investigative
DME1UNY	SN	CHEMBL92958; SCHEMBL6989630; 3-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1H-indazole; BDBM50039720
DME1UNY	DT	Small molecular drug
DME1UNY	PC	9996081
DME1UNY	MW	319.4
DME1UNY	FM	C21H25N3
DME1UNY	IC	InChI=1S/C21H25N3/c1-2-6-18(7-3-1)16-24-14-12-17(13-15-24)10-11-21-19-8-4-5-9-20(19)22-23-21/h1-9,17H,10-16H2,(H,22,23)
DME1UNY	CS	C1CN(CCC1CCC2=C3C=CC=CC3=NN2)CC4=CC=CC=C4
DME1UNY	IK	NPZKLBFCTYVTBS-UHFFFAOYSA-N
DME1UNY	IU	3-[2-(1-benzylpiperidin-4-yl)ethyl]-2H-indazole
DME1UNY	DE	Discovery agent

DMXE1LC	ID	DMXE1LC
DMXE1LC	DN	3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan
DMXE1LC	HS	Investigative
DMXE1LC	SN	CHEMBL43396; 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan; SCHEMBL7047273; SCHEMBL7047277; 3-[(E)-3,5-Dimethoxystyryl]furan; ZINC13471767; BDBM50108047; AKOS015967552
DMXE1LC	DT	Small molecular drug
DMXE1LC	PC	10105252
DMXE1LC	MW	230.26
DMXE1LC	FM	C14H14O3
DMXE1LC	IC	InChI=1S/C14H14O3/c1-15-13-7-12(8-14(9-13)16-2)4-3-11-5-6-17-10-11/h3-10H,1-2H3/b4-3+
DMXE1LC	CS	COC1=CC(=CC(=C1)/C=C/C2=COC=C2)OC
DMXE1LC	IK	UUOXVOMLPNADJK-ONEGZZNKSA-N
DMXE1LC	IU	3-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]furan
DMXE1LC	DE	Discovery agent

DM5EJLD	ID	DM5EJLD
DM5EJLD	DN	3-[2-(5-Chloro-2-thienyl)pyridin-4-yl]phenol
DM5EJLD	HS	Investigative
DM5EJLD	SN	CHEMBL1096026; 3-[2-(5-Chloro-2-thienyl)pyridin-4-yl]phenol
DM5EJLD	DT	Small molecular drug
DM5EJLD	PC	46887579
DM5EJLD	MW	287.8
DM5EJLD	FM	C15H10ClNOS
DM5EJLD	IC	InChI=1S/C15H10ClNOS/c16-15-5-4-14(19-15)13-9-11(6-7-17-13)10-2-1-3-12(18)8-10/h1-9,18H
DM5EJLD	CS	C1=CC(=CC(=C1)O)C2=CC(=NC=C2)C3=CC=C(S3)Cl
DM5EJLD	IK	IJRUJPYMZCIXQJ-UHFFFAOYSA-N
DM5EJLD	IU	3-[2-(5-chlorothiophen-2-yl)pyridin-4-yl]phenol
DM5EJLD	DE	Discovery agent

DMJB1KL	ID	DMJB1KL
DMJB1KL	DN	3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine
DMJB1KL	HS	Investigative
DMJB1KL	SN	CHEMBL345732; BDBM50135703; 3-[2-(Trimethylaminio)ethoxy]pyridine; Trimethyl-[2-(pyridin-3-yloxy)-ethyl]-ammonium
DMJB1KL	DT	Small molecular drug
DMJB1KL	PC	9794401
DMJB1KL	MW	181.25
DMJB1KL	FM	C10H17N2O+
DMJB1KL	IC	InChI=1S/C10H17N2O/c1-12(2,3)7-8-13-10-5-4-6-11-9-10/h4-6,9H,7-8H2,1-3H3/q+1
DMJB1KL	CS	C[N+](C)(C)CCOC1=CN=CC=C1
DMJB1KL	IK	WBRKKKJHXQZXEM-UHFFFAOYSA-N
DMJB1KL	IU	trimethyl(2-pyridin-3-yloxyethyl)azanium
DMJB1KL	DE	Discovery agent

DMLX9SI	ID	DMLX9SI
DMLX9SI	DN	3-[3-(2-Hydroxy-ethoxy)-phenyl]-1H-quinolin-2-one
DMLX9SI	HS	Investigative
DMLX9SI	SN	CHEMBL97218; AC1OCFMJ; 3-[3-(2-hydroxyethoxy)phenyl]-1H-quinolin-2-one; 3-[3-(2-Hydroxy-ethoxy)-phenyl]-1H-quinolin-2-one; ZINC13584303; BDBM50105767
DMLX9SI	DT	Small molecular drug
DMLX9SI	PC	6918599
DMLX9SI	MW	281.3
DMLX9SI	FM	C17H15NO3
DMLX9SI	IC	InChI=1S/C17H15NO3/c19-8-9-21-14-6-3-5-12(10-14)15-11-13-4-1-2-7-16(13)18-17(15)20/h1-7,10-11,19H,8-9H2,(H,18,20)
DMLX9SI	CS	C1=CC=C2C(=C1)C=C(C(=O)N2)C3=CC(=CC=C3)OCCO
DMLX9SI	IK	CAPTUZLISRNFKN-UHFFFAOYSA-N
DMLX9SI	IU	3-[3-(2-hydroxyethoxy)phenyl]-1H-quinolin-2-one
DMLX9SI	DE	Discovery agent

DM60YGF	ID	DM60YGF
DM60YGF	DN	3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide
DM60YGF	HS	Investigative
DM60YGF	SN	CHEMBL201394; 3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide; BDBM50181479; 3-[(3-benzyloxy-2-pyridyl)carbamoylamino]benzamide; Benzamide, 3-[[[[3-(phenylmethoxy)-2-pyridinyl]amino]carbonyl]amino]-
DM60YGF	DT	Small molecular drug
DM60YGF	PC	11639129
DM60YGF	MW	362.4
DM60YGF	FM	C20H18N4O3
DM60YGF	IC	InChI=1S/C20H18N4O3/c21-18(25)15-8-4-9-16(12-15)23-20(26)24-19-17(10-5-11-22-19)27-13-14-6-2-1-3-7-14/h1-12H,13H2,(H2,21,25)(H2,22,23,24,26)
DM60YGF	CS	C1=CC=C(C=C1)COC2=C(N=CC=C2)NC(=O)NC3=CC=CC(=C3)C(=O)N
DM60YGF	IK	RLBJUMUHKDTSCO-UHFFFAOYSA-N
DM60YGF	IU	3-[(3-phenylmethoxypyridin-2-yl)carbamoylamino]benzamide
DM60YGF	DE	Discovery agent

DMNC6W9	ID	DMNC6W9
DMNC6W9	DN	3-[3-(4-hydroxyphenyl)isoxazol-5-yl]phenol
DMNC6W9	HS	Investigative
DMNC6W9	DT	Small molecular drug
DMNC6W9	PC	135855877
DMNC6W9	MW	253.25
DMNC6W9	FM	C15H11NO3
DMNC6W9	IC	InChI=1S/C15H11NO3/c17-12-6-4-10(5-7-12)14-9-15(19-16-14)11-2-1-3-13(18)8-11/h1-9,17-18H
DMNC6W9	CS	C1=CC(=CC(=C1)O)C2=CC(=NO2)C3=CC=C(C=C3)O
DMNC6W9	IK	ZYSCCHLCNRGGTO-UHFFFAOYSA-N
DMNC6W9	IU	3-[3-(4-hydroxyphenyl)-1,2-oxazol-5-yl]phenol
DMNC6W9	DE	Discovery agent

DMTLJMF	ID	DMTLJMF
DMTLJMF	DN	3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DMTLJMF	HS	Investigative
DMTLJMF	SN	CHEMBL262968; 3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine; SCHEMBL14130000; BDBM50138237
DMTLJMF	DT	Small molecular drug
DMTLJMF	PC	44341278
DMTLJMF	MW	279.34
DMTLJMF	FM	C17H17N3O
DMTLJMF	IC	InChI=1S/C17H17N3O/c1-3-15(13-18-9-1)4-2-12-21-17-7-5-16(6-8-17)20-11-10-19-14-20/h1,3,5-11,13-14H,2,4,12H2
DMTLJMF	CS	C1=CC(=CN=C1)CCCOC2=CC=C(C=C2)N3C=CN=C3
DMTLJMF	IK	GCRYIIOKZWQWIH-UHFFFAOYSA-N
DMTLJMF	IU	3-[3-(4-imidazol-1-ylphenoxy)propyl]pyridine
DMTLJMF	CA	CAS 742691-87-8
DMTLJMF	DE	Discovery agent

DM8NRJQ	ID	DM8NRJQ
DM8NRJQ	DN	3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine
DM8NRJQ	HS	Investigative
DM8NRJQ	SN	CHEMBL493082; 3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine
DM8NRJQ	DT	Small molecular drug
DM8NRJQ	PC	25130848
DM8NRJQ	MW	325.4
DM8NRJQ	FM	C23H19NO
DM8NRJQ	IC	InChI=1S/C23H19NO/c1-25-22-10-8-17(9-11-22)13-21-14-18-5-2-3-6-19(18)15-23(21)20-7-4-12-24-16-20/h2-12,14-16H,13H2,1H3
DM8NRJQ	CS	COC1=CC=C(C=C1)CC2=CC3=CC=CC=C3C=C2C4=CN=CC=C4
DM8NRJQ	IK	GOGQHVZGANJJDF-UHFFFAOYSA-N
DM8NRJQ	IU	3-[3-[(4-methoxyphenyl)methyl]naphthalen-2-yl]pyridine
DM8NRJQ	DE	Discovery agent

DMPVXTB	ID	DMPVXTB
DMPVXTB	DN	3-[3-(benzylmethylamino)propoxy]xanthen-9-one
DMPVXTB	HS	Investigative
DMPVXTB	SN	CHEMBL225610; 3-[3-(benzylmethylamino)propoxy]xanthen-9-one
DMPVXTB	DT	Small molecular drug
DMPVXTB	PC	44421937
DMPVXTB	MW	373.4
DMPVXTB	FM	C24H23NO3
DMPVXTB	IC	InChI=1S/C24H23NO3/c1-25(17-18-8-3-2-4-9-18)14-7-15-27-19-12-13-21-23(16-19)28-22-11-6-5-10-20(22)24(21)26/h2-6,8-13,16H,7,14-15,17H2,1H3
DMPVXTB	CS	CN(CCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMPVXTB	IK	OTLLABLRJBVBHD-UHFFFAOYSA-N
DMPVXTB	IU	3-[3-[benzyl(methyl)amino]propoxy]xanthen-9-one
DMPVXTB	DE	Discovery agent

DMDS8UJ	ID	DMDS8UJ
DMDS8UJ	DN	3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMDS8UJ	HS	Investigative
DMDS8UJ	SN	(3-Pyridylmethylene)indane 36a; CHEMBL195688; AC1O707D; BDBM8646; SCHEMBL13877113; 3-[(E)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMDS8UJ	DT	Small molecular drug
DMDS8UJ	PC	6539817
DMDS8UJ	MW	221.3
DMDS8UJ	FM	C16H15N
DMDS8UJ	IC	InChI=1S/C16H15N/c1-12-9-14(10-13-5-4-8-17-11-13)16-7-3-2-6-15(12)16/h2-8,10-12H,9H2,1H3/b14-10+
DMDS8UJ	CS	CC1C/C(=C\\C2=CN=CC=C2)/C3=CC=CC=C13
DMDS8UJ	IK	KMRIBBKLCIMDTB-GXDHUFHOSA-N
DMDS8UJ	IU	3-[(E)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMDS8UJ	DE	Discovery agent

DMTF520	ID	DMTF520
DMTF520	DN	3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DMTF520	HS	Investigative
DMTF520	SN	CHEMBL373074; AC1O707F; BDBM8647; (3-Pyridylmethylene)indane 36b; 3-[(Z)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMTF520	DT	Small molecular drug
DMTF520	PC	6539818
DMTF520	MW	221.3
DMTF520	FM	C16H15N
DMTF520	IC	InChI=1S/C16H15N/c1-12-9-14(10-13-5-4-8-17-11-13)16-7-3-2-6-15(12)16/h2-8,10-12H,9H2,1H3/b14-10-
DMTF520	CS	CC1C/C(=C/C2=CN=CC=C2)/C3=CC=CC=C13
DMTF520	IK	KMRIBBKLCIMDTB-UVTDQMKNSA-N
DMTF520	IU	3-[(Z)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMTF520	DE	Discovery agent

DMYEWA4	ID	DMYEWA4
DMYEWA4	DN	3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine
DMYEWA4	HS	Investigative
DMYEWA4	SN	(3-Pyridylmethylene)indane 37a; BDBM8648; AC1O707H; CHEMBL193555; 3-[(E)-(3-phenyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMYEWA4	DT	Small molecular drug
DMYEWA4	PC	6539819
DMYEWA4	MW	283.4
DMYEWA4	FM	C21H17N
DMYEWA4	IC	InChI=1S/C21H17N/c1-2-8-17(9-3-1)21-14-18(13-16-7-6-12-22-15-16)19-10-4-5-11-20(19)21/h1-13,15,21H,14H2/b18-13+
DMYEWA4	CS	C\\1C(C2=CC=CC=C2/C1=C/C3=CN=CC=C3)C4=CC=CC=C4
DMYEWA4	IK	ADQBWRCDKUIPFI-QGOAFFKASA-N
DMYEWA4	IU	3-[(E)-(3-phenyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMYEWA4	DE	Discovery agent

DME86OK	ID	DME86OK
DME86OK	DN	3-[4-(4-Fluoro-phenoxy)-phenyl]-1H-pyrazole
DME86OK	HS	Investigative
DME86OK	SN	CHEMBL38031; 3-[4-(4-Fluorophenoxy)phenyl]-1H-pyrazole; 3-(4-(4-Fluorophenoxy)phenyl)-1H-pyrazole; 3-[4-(4-Fluoro-phenoxy)-phenyl]-1H-pyrazole; SCHEMBL1385301; CTK7C0984; CGMPMLHCCFCLQL-UHFFFAOYSA-N; BDBM50141066; ZINC13559818
DME86OK	DT	Small molecular drug
DME86OK	PC	9816478
DME86OK	MW	254.26
DME86OK	FM	C15H11FN2O
DME86OK	IC	InChI=1S/C15H11FN2O/c16-12-3-7-14(8-4-12)19-13-5-1-11(2-6-13)15-9-10-17-18-15/h1-10H,(H,17,18)
DME86OK	CS	C1=CC(=CC=C1C2=CC=NN2)OC3=CC=C(C=C3)F
DME86OK	IK	CGMPMLHCCFCLQL-UHFFFAOYSA-N
DME86OK	IU	5-[4-(4-fluorophenoxy)phenyl]-1H-pyrazole
DME86OK	DE	Discovery agent

DMIM5WE	ID	DMIM5WE
DMIM5WE	DN	3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DMIM5WE	HS	Investigative
DMIM5WE	SN	CHEMBL529446; 3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol; SCHEMBL1180107; BDBM50271078
DMIM5WE	DT	Small molecular drug
DMIM5WE	PC	25192184
DMIM5WE	MW	253.25
DMIM5WE	FM	C15H11NO3
DMIM5WE	IC	InChI=1S/C15H11NO3/c17-12-6-4-10(5-7-12)14-9-19-15(16-14)11-2-1-3-13(18)8-11/h1-9,17-18H
DMIM5WE	CS	C1=CC(=CC(=C1)O)C2=NC(=CO2)C3=CC=C(C=C3)O
DMIM5WE	IK	NOWYSMIMXQPTPC-UHFFFAOYSA-N
DMIM5WE	IU	3-[4-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DMIM5WE	DE	Discovery agent

DM75F1Q	ID	DM75F1Q
DM75F1Q	DN	3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid
DM75F1Q	HS	Investigative
DM75F1Q	SN	CHEMBL201425; 3-[4-(4-phenoxybenzoyl)phenyl]propanoic Acid
DM75F1Q	DT	Small molecular drug
DM75F1Q	PC	11515759
DM75F1Q	MW	346.4
DM75F1Q	FM	C22H18O4
DM75F1Q	IC	InChI=1S/C22H18O4/c23-21(24)15-8-16-6-9-17(10-7-16)22(25)18-11-13-20(14-12-18)26-19-4-2-1-3-5-19/h1-7,9-14H,8,15H2,(H,23,24)
DM75F1Q	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)CCC(=O)O
DM75F1Q	IK	FYPQECPTVJQSOG-UHFFFAOYSA-N
DM75F1Q	IU	3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid
DM75F1Q	DE	Discovery agent

DMZCO83	ID	DMZCO83
DMZCO83	DN	3-[4-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMZCO83	HS	Investigative
DMZCO83	SN	CHEMBL1096375; 3-[4-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMZCO83	DT	Small molecular drug
DMZCO83	PC	46887581
DMZCO83	MW	287.8
DMZCO83	FM	C15H10ClNOS
DMZCO83	IC	InChI=1S/C15H10ClNOS/c16-15-5-4-14(19-15)11-6-7-17-13(9-11)10-2-1-3-12(18)8-10/h1-9,18H
DMZCO83	CS	C1=CC(=CC(=C1)O)C2=NC=CC(=C2)C3=CC=C(S3)Cl
DMZCO83	IK	MOVQEDAJQOEYIC-UHFFFAOYSA-N
DMZCO83	IU	3-[4-(5-chlorothiophen-2-yl)pyridin-2-yl]phenol
DMZCO83	DE	Discovery agent

DMZPULH	ID	DMZPULH
DMZPULH	DN	3-[4-(benzylmethylamino)butoxy]xanthen-9-one
DMZPULH	HS	Investigative
DMZPULH	SN	CHEMBL225611; 3-[4-(benzylmethylamino)butoxy]xanthen-9-one
DMZPULH	DT	Small molecular drug
DMZPULH	PC	44421938
DMZPULH	MW	387.5
DMZPULH	FM	C25H25NO3
DMZPULH	IC	InChI=1S/C25H25NO3/c1-26(18-19-9-3-2-4-10-19)15-7-8-16-28-20-13-14-22-24(17-20)29-23-12-6-5-11-21(23)25(22)27/h2-6,9-14,17H,7-8,15-16,18H2,1H3
DMZPULH	CS	CN(CCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMZPULH	IK	VUBALVZUDJIWHQ-UHFFFAOYSA-N
DMZPULH	IU	3-[4-[benzyl(methyl)amino]butoxy]xanthen-9-one
DMZPULH	DE	Discovery agent

DM0XD6T	ID	DM0XD6T
DM0XD6T	DN	3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DM0XD6T	HS	Investigative
DM0XD6T	SN	AC1O705J; SCHEMBL4231098; SCHEMBL4231088; CHEMBL176287; BDBM8608; (3-Pyridylmethylene)indane 25a; 3-[(E)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM0XD6T	DT	Small molecular drug
DM0XD6T	PC	6539784
DM0XD6T	MW	241.71
DM0XD6T	FM	C15H12ClN
DM0XD6T	IC	InChI=1S/C15H12ClN/c16-15-5-1-4-13-12(6-7-14(13)15)9-11-3-2-8-17-10-11/h1-5,8-10H,6-7H2/b12-9+
DM0XD6T	CS	C\\1CC2=C(/C1=C/C3=CN=CC=C3)C=CC=C2Cl
DM0XD6T	IK	OAISOHCDZRMGCP-FMIVXFBMSA-N
DM0XD6T	IU	3-[(E)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM0XD6T	DE	Discovery agent

DMMDIB9	ID	DMMDIB9
DMMDIB9	DN	3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DMMDIB9	HS	Investigative
DMMDIB9	SN	(3-Pyridylmethylene)indane 25b; CHEMBL369623; SCHEMBL4231092; BDBM8609; AC1O705L; 3-[(Z)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMMDIB9	DT	Small molecular drug
DMMDIB9	PC	6539785
DMMDIB9	MW	241.71
DMMDIB9	FM	C15H12ClN
DMMDIB9	IC	InChI=1S/C15H12ClN/c16-15-5-1-4-13-12(6-7-14(13)15)9-11-3-2-8-17-10-11/h1-5,8-10H,6-7H2/b12-9-
DMMDIB9	CS	C\\1CC2=C(/C1=C\\C3=CN=CC=C3)C=CC=C2Cl
DMMDIB9	IK	OAISOHCDZRMGCP-XFXZXTDPSA-N
DMMDIB9	IU	3-[(Z)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMMDIB9	DE	Discovery agent

DMZS20Y	ID	DMZS20Y
DMZS20Y	DN	3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMZS20Y	HS	Investigative
DMZS20Y	SN	(3-Pyridylmethylene)indane 24a; SCHEMBL4221248; SCHEMBL4221241; AC1O705H; CHEMBL366490; BDBM8607; 3-[(E)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMZS20Y	DT	Small molecular drug
DMZS20Y	PC	6539783
DMZS20Y	MW	225.26
DMZS20Y	FM	C15H12FN
DMZS20Y	IC	InChI=1S/C15H12FN/c16-15-5-1-4-13-12(6-7-14(13)15)9-11-3-2-8-17-10-11/h1-5,8-10H,6-7H2/b12-9+
DMZS20Y	CS	C\\1CC2=C(/C1=C/C3=CN=CC=C3)C=CC=C2F
DMZS20Y	IK	JKDSUQNXZNYUED-FMIVXFBMSA-N
DMZS20Y	IU	3-[(E)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMZS20Y	DE	Discovery agent

DMPS340	ID	DMPS340
DMPS340	DN	3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMPS340	HS	Investigative
DMPS340	SN	CHEMBL176076; AC1O705X; BDBM8617; SCHEMBL4221244; (3-Pyridylmethylene)indane 24b; 3-[(Z)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMPS340	DT	Small molecular drug
DMPS340	PC	6539791
DMPS340	MW	225.26
DMPS340	FM	C15H12FN
DMPS340	IC	InChI=1S/C15H12FN/c16-15-5-1-4-13-12(6-7-14(13)15)9-11-3-2-8-17-10-11/h1-5,8-10H,6-7H2/b12-9-
DMPS340	CS	C\\1CC2=C(/C1=C\\C3=CN=CC=C3)C=CC=C2F
DMPS340	IK	JKDSUQNXZNYUED-XFXZXTDPSA-N
DMPS340	IU	3-[(Z)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMPS340	DE	Discovery agent

DMJN93U	ID	DMJN93U
DMJN93U	DN	3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMJN93U	HS	Investigative
DMJN93U	SN	SCHEMBL4224799; BDBM8599; CHEMBL368305; SCHEMBL4224793; (3-Pyridylmethylene)indane 23a; AC1O7051; 3-[(E)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMJN93U	DT	Small molecular drug
DMJN93U	PC	6539775
DMJN93U	MW	221.3
DMJN93U	FM	C16H15N
DMJN93U	IC	InChI=1S/C16H15N/c1-12-4-2-6-16-14(7-8-15(12)16)10-13-5-3-9-17-11-13/h2-6,9-11H,7-8H2,1H3/b14-10+
DMJN93U	CS	CC1=C2CC/C(=C\\C3=CN=CC=C3)/C2=CC=C1
DMJN93U	IK	ORCOWTSQEFCEFC-GXDHUFHOSA-N
DMJN93U	IU	3-[(E)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMJN93U	DE	Discovery agent

DMNILXG	ID	DMNILXG
DMNILXG	DN	3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DMNILXG	HS	Investigative
DMNILXG	SN	(3-Pyridylmethylene)indane 23b; AC1O705F; SCHEMBL4224796; BDBM8606; CHEMBL176009; 3-[(Z)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMNILXG	DT	Small molecular drug
DMNILXG	PC	6539782
DMNILXG	MW	221.3
DMNILXG	FM	C16H15N
DMNILXG	IC	InChI=1S/C16H15N/c1-12-4-2-6-16-14(7-8-15(12)16)10-13-5-3-9-17-11-13/h2-6,9-11H,7-8H2,1H3/b14-10-
DMNILXG	CS	CC1=C2CC/C(=C/C3=CN=CC=C3)/C2=CC=C1
DMNILXG	IK	ORCOWTSQEFCEFC-UVTDQMKNSA-N
DMNILXG	IU	3-[(Z)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMNILXG	DE	Discovery agent

DMYZIG3	ID	DMYZIG3
DMYZIG3	DN	3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol
DMYZIG3	HS	Investigative
DMYZIG3	SN	CHEMBL566521; 3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol
DMYZIG3	DT	Small molecular drug
DMYZIG3	PC	44542795
DMYZIG3	MW	288.3
DMYZIG3	FM	C16H10F2OS
DMYZIG3	IC	InChI=1S/C16H10F2OS/c17-13-5-4-11(9-14(13)18)16-7-6-15(20-16)10-2-1-3-12(19)8-10/h1-9,19H
DMYZIG3	CS	C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=C(C=C3)F)F
DMYZIG3	IK	PKUPEZBIFLWEBN-UHFFFAOYSA-N
DMYZIG3	IU	3-[5-(3,4-difluorophenyl)thiophen-2-yl]phenol
DMYZIG3	DE	Discovery agent

DMD5QOW	ID	DMD5QOW
DMD5QOW	DN	3-[5-(3-Fluorophenyl)-2-thienyl]phenol
DMD5QOW	HS	Investigative
DMD5QOW	SN	CHEMBL576318; 3-[5-(3-Fluorophenyl)-2-thienyl]phenol; SCHEMBL1179817
DMD5QOW	DT	Small molecular drug
DMD5QOW	PC	25192480
DMD5QOW	MW	270.3
DMD5QOW	FM	C16H11FOS
DMD5QOW	IC	InChI=1S/C16H11FOS/c17-13-5-1-3-11(9-13)15-7-8-16(19-15)12-4-2-6-14(18)10-12/h1-10,18H
DMD5QOW	CS	C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=CC=C3)F
DMD5QOW	IK	BZEWIGQYBSBQAI-UHFFFAOYSA-N
DMD5QOW	IU	3-[5-(3-fluorophenyl)thiophen-2-yl]phenol
DMD5QOW	DE	Discovery agent

DM1QKNU	ID	DM1QKNU
DM1QKNU	DN	3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid
DM1QKNU	HS	Investigative
DM1QKNU	SN	3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid; 53N; DB07139; 3-[5-(3-nitrophenyl)thiophen-2-yl] propanoic acid
DM1QKNU	DT	Small molecular drug
DM1QKNU	PC	25210476
DM1QKNU	MW	277.3
DM1QKNU	FM	C13H11NO4S
DM1QKNU	IC	InChI=1S/C13H11NO4S/c15-13(16)7-5-11-4-6-12(19-11)9-2-1-3-10(8-9)14(17)18/h1-4,6,8H,5,7H2,(H,15,16)
DM1QKNU	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC=C(S2)CCC(=O)O
DM1QKNU	IK	IHKCOKRMJRDWAL-UHFFFAOYSA-N
DM1QKNU	IU	3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid
DM1QKNU	DE	Discovery agent

DMYZ2U0	ID	DMYZ2U0
DMYZ2U0	DN	3-[5-(4-Fluorophenyl)-2-thienyl]phenol
DMYZ2U0	HS	Investigative
DMYZ2U0	SN	CHEMBL570368; 3-[5-(4-Fluorophenyl)-2-thienyl]phenol; SCHEMBL1180762
DMYZ2U0	DT	Small molecular drug
DMYZ2U0	PC	25192620
DMYZ2U0	MW	270.3
DMYZ2U0	FM	C16H11FOS
DMYZ2U0	IC	InChI=1S/C16H11FOS/c17-13-6-4-11(5-7-13)15-8-9-16(19-15)12-2-1-3-14(18)10-12/h1-10,18H
DMYZ2U0	CS	C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC=C(C=C3)F
DMYZ2U0	IK	LBERAJGCBDGPHK-UHFFFAOYSA-N
DMYZ2U0	IU	3-[5-(4-fluorophenyl)thiophen-2-yl]phenol
DMYZ2U0	DE	Discovery agent

DM4TFMA	ID	DM4TFMA
DM4TFMA	DN	3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DM4TFMA	HS	Investigative
DM4TFMA	SN	CHEMBL488752; 3-[5-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol; SCHEMBL1180391
DM4TFMA	DT	Small molecular drug
DM4TFMA	PC	24857878
DM4TFMA	MW	253.25
DM4TFMA	FM	C15H11NO3
DM4TFMA	IC	InChI=1S/C15H11NO3/c17-12-6-4-10(5-7-12)14-9-16-15(19-14)11-2-1-3-13(18)8-11/h1-9,17-18H
DM4TFMA	CS	C1=CC(=CC(=C1)O)C2=NC=C(O2)C3=CC=C(C=C3)O
DM4TFMA	IK	QWBAQAYKEITCRE-UHFFFAOYSA-N
DM4TFMA	IU	3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DM4TFMA	DE	Discovery agent

DM2IXO0	ID	DM2IXO0
DM2IXO0	DN	3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol
DM2IXO0	HS	Investigative
DM2IXO0	SN	SCHEMBL1180532; CHEMBL458727; BDBM25831; WBUPCNHALRFMCB-UHFFFAOYSA-N; hydroxyphenyl substituted thiazole, 3; 3-[5-(4-Hydroxyphenyl)-1,3-thiazole-2-yl]phenol
DM2IXO0	DT	Small molecular drug
DM2IXO0	PC	25093373
DM2IXO0	MW	269.3
DM2IXO0	FM	C15H11NO2S
DM2IXO0	IC	InChI=1S/C15H11NO2S/c17-12-6-4-10(5-7-12)14-9-16-15(19-14)11-2-1-3-13(18)8-11/h1-9,17-18H
DM2IXO0	CS	C1=CC(=CC(=C1)O)C2=NC=C(S2)C3=CC=C(C=C3)O
DM2IXO0	IK	WBUPCNHALRFMCB-UHFFFAOYSA-N
DM2IXO0	IU	3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol
DM2IXO0	DE	Discovery agent

DMAMOJE	ID	DMAMOJE
DMAMOJE	DN	3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol
DMAMOJE	HS	Investigative
DMAMOJE	SN	CHEMBL583519; 3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol; SCHEMBL1180575
DMAMOJE	DT	Small molecular drug
DMAMOJE	PC	25192619
DMAMOJE	MW	282.4
DMAMOJE	FM	C17H14O2S
DMAMOJE	IC	InChI=1S/C17H14O2S/c1-11-8-13(10-15(19)9-11)17-7-6-16(20-17)12-2-4-14(18)5-3-12/h2-10,18-19H,1H3
DMAMOJE	CS	CC1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC=C(C=C3)O
DMAMOJE	IK	NWLAWEHHCISQCM-UHFFFAOYSA-N
DMAMOJE	IU	3-[5-(4-hydroxyphenyl)thiophen-2-yl]-5-methylphenol
DMAMOJE	DE	Discovery agent

DMSFW9T	ID	DMSFW9T
DMSFW9T	DN	3-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMSFW9T	HS	Investigative
DMSFW9T	SN	3-[5-(4-Hydroxyphenyl)-2-thienyl]phenol; SCHEMBL1180468; CHEMBL457323; BDBM25850; PKHBRBMFZXTMIS-UHFFFAOYSA-N; ZINC40847645; 4,3'-(2,5-Thiophenediyl)bisphenol; hydroxyphenyl substituted thiophene, 22
DMSFW9T	DT	Small molecular drug
DMSFW9T	PC	25093386
DMSFW9T	MW	268.3
DMSFW9T	FM	C16H12O2S
DMSFW9T	IC	InChI=1S/C16H12O2S/c17-13-6-4-11(5-7-13)15-8-9-16(19-15)12-2-1-3-14(18)10-12/h1-10,17-18H
DMSFW9T	CS	C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC=C(C=C3)O
DMSFW9T	IK	PKHBRBMFZXTMIS-UHFFFAOYSA-N
DMSFW9T	IU	3-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMSFW9T	DE	Discovery agent

DM40GJ8	ID	DM40GJ8
DM40GJ8	DN	3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol
DM40GJ8	HS	Investigative
DM40GJ8	SN	CHEMBL462513; SCHEMBL1180467; BDBM25853; ZINC40393334; 4,3'-(2,4-Thiophenediyl)bisphenol; hydroxyphenyl substituted thiophene, 25
DM40GJ8	DT	Small molecular drug
DM40GJ8	PC	25093389
DM40GJ8	MW	268.3
DM40GJ8	FM	C16H12O2S
DM40GJ8	IC	InChI=1S/C16H12O2S/c17-14-6-4-11(5-7-14)16-9-13(10-19-16)12-2-1-3-15(18)8-12/h1-10,17-18H
DM40GJ8	CS	C1=CC(=CC(=C1)O)C2=CSC(=C2)C3=CC=C(C=C3)O
DM40GJ8	IK	JECPEAXUEYTRPA-UHFFFAOYSA-N
DM40GJ8	IU	3-[5-(4-hydroxyphenyl)thiophen-3-yl]phenol
DM40GJ8	DE	Discovery agent

DMQZ0A7	ID	DMQZ0A7
DMQZ0A7	DN	3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one
DMQZ0A7	HS	Investigative
DMQZ0A7	SN	CHEMBL427249; 3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one
DMQZ0A7	DT	Small molecular drug
DMQZ0A7	PC	44421943
DMQZ0A7	MW	401.5
DMQZ0A7	FM	C26H27NO3
DMQZ0A7	IC	InChI=1S/C26H27NO3/c1-27(19-20-10-4-2-5-11-20)16-8-3-9-17-29-21-14-15-23-25(18-21)30-24-13-7-6-12-22(24)26(23)28/h2,4-7,10-15,18H,3,8-9,16-17,19H2,1H3
DMQZ0A7	CS	CN(CCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMQZ0A7	IK	NDUSIOVFIPORBY-UHFFFAOYSA-N
DMQZ0A7	IU	3-[5-[benzyl(methyl)amino]pentoxy]xanthen-9-one
DMQZ0A7	DE	Discovery agent

DMUEVAQ	ID	DMUEVAQ
DMUEVAQ	DN	3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine
DMUEVAQ	HS	Investigative
DMUEVAQ	SN	(3-Pyridylmethylene)indane 9a; SCHEMBL4231367; BDBM8590; SCHEMBL4231363; AC1O704L; CHEMBL194440; 3-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMUEVAQ	DT	Small molecular drug
DMUEVAQ	PC	6539767
DMUEVAQ	MW	286.17
DMUEVAQ	FM	C15H12BrN
DMUEVAQ	IC	InChI=1S/C15H12BrN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8+
DMUEVAQ	CS	C1C/C(=C\\C2=CN=CC=C2)/C3=C1C=C(C=C3)Br
DMUEVAQ	IK	QWAFSKBCSGIDRF-XYOKQWHBSA-N
DMUEVAQ	IU	3-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMUEVAQ	DE	Discovery agent

DMCXSIH	ID	DMCXSIH
DMCXSIH	DN	3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine
DMCXSIH	HS	Investigative
DMCXSIH	SN	(3-Pyridylmethylene)indane 9b; BDBM8591; AC1O704N; CHEMBL176118; SCHEMBL4231365; 3-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMCXSIH	DT	Small molecular drug
DMCXSIH	PC	6539768
DMCXSIH	MW	286.17
DMCXSIH	FM	C15H12BrN
DMCXSIH	IC	InChI=1S/C15H12BrN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8-
DMCXSIH	CS	C1C/C(=C/C2=CN=CC=C2)/C3=C1C=C(C=C3)Br
DMCXSIH	IK	QWAFSKBCSGIDRF-WQLSENKSSA-N
DMCXSIH	IU	3-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMCXSIH	DE	Discovery agent

DM8TWLO	ID	DM8TWLO
DM8TWLO	DN	3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DM8TWLO	HS	Investigative
DM8TWLO	SN	(3-Pyridylmethylene)indane 7a; CHEMBL383807; SCHEMBL4220789; AC1O704H; SCHEMBL4220782; BDBM8588; ZINC13610774; 3-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM8TWLO	DT	Small molecular drug
DM8TWLO	PC	6539765
DM8TWLO	MW	241.71
DM8TWLO	FM	C15H12ClN
DM8TWLO	IC	InChI=1S/C15H12ClN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8+
DM8TWLO	CS	C1C/C(=C\\C2=CN=CC=C2)/C3=C1C=C(C=C3)Cl
DM8TWLO	IK	GQENGHZHJWXFLG-XYOKQWHBSA-N
DM8TWLO	IU	3-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM8TWLO	DE	Discovery agent

DMN60YG	ID	DMN60YG
DMN60YG	DN	3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DMN60YG	HS	Investigative
DMN60YG	SN	(3-Pyridylmethylene)indane 7b; AC1O704J; CHEMBL193652; BDBM8589; SCHEMBL4220785; ZINC13610777; 3-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMN60YG	DT	Small molecular drug
DMN60YG	PC	6539766
DMN60YG	MW	241.71
DMN60YG	FM	C15H12ClN
DMN60YG	IC	InChI=1S/C15H12ClN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8-
DMN60YG	CS	C1C/C(=C/C2=CN=CC=C2)/C3=C1C=C(C=C3)Cl
DMN60YG	IK	GQENGHZHJWXFLG-WQLSENKSSA-N
DMN60YG	IU	3-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMN60YG	DE	Discovery agent

DMLJQZS	ID	DMLJQZS
DMLJQZS	DN	3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine
DMLJQZS	HS	Investigative
DMLJQZS	SN	(3-Pyridylmethylene)indane 19a; SCHEMBL4226312; CHEMBL425323; SCHEMBL4226322; BDBM8597; AC1O704X; 3-[(E)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMLJQZS	DT	Small molecular drug
DMLJQZS	PC	6539773
DMLJQZS	MW	251.32
DMLJQZS	FM	C17H17NO
DMLJQZS	IC	InChI=1S/C17H17NO/c1-2-19-16-7-8-17-14(5-6-15(17)11-16)10-13-4-3-9-18-12-13/h3-4,7-12H,2,5-6H2,1H3/b14-10+
DMLJQZS	CS	CCOC1=CC2=C(C=C1)/C(=C/C3=CN=CC=C3)/CC2
DMLJQZS	IK	PXXLKRIIKURDBT-GXDHUFHOSA-N
DMLJQZS	IU	3-[(E)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMLJQZS	DE	Discovery agent

DMMTUON	ID	DMMTUON
DMMTUON	DN	3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMMTUON	HS	Investigative
DMMTUON	SN	CHEMBL176886; SCHEMBL4226316; BDBM8598; AC1O704Z; (3-Pyridylmethylene)indane 19b; 3-[(Z)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMMTUON	DT	Small molecular drug
DMMTUON	PC	6539774
DMMTUON	MW	251.32
DMMTUON	FM	C17H17NO
DMMTUON	IC	InChI=1S/C17H17NO/c1-2-19-16-7-8-17-14(5-6-15(17)11-16)10-13-4-3-9-18-12-13/h3-4,7-12H,2,5-6H2,1H3/b14-10-
DMMTUON	CS	CCOC1=CC2=C(C=C1)/C(=C\\C3=CN=CC=C3)/CC2
DMMTUON	IK	PXXLKRIIKURDBT-UVTDQMKNSA-N
DMMTUON	IU	3-[(Z)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMMTUON	DE	Discovery agent

DMWSFIR	ID	DMWSFIR
DMWSFIR	DN	3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMWSFIR	HS	Investigative
DMWSFIR	SN	(3-Pyridylmethylene)indane 5a; SCHEMBL4220971; AC1O704D; CHEMBL193997; BDBM8586; SCHEMBL4220959; ZINC13610768; 3-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMWSFIR	DT	Small molecular drug
DMWSFIR	PC	6539763
DMWSFIR	MW	225.26
DMWSFIR	FM	C15H12FN
DMWSFIR	IC	InChI=1S/C15H12FN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8+
DMWSFIR	CS	C1C/C(=C\\C2=CN=CC=C2)/C3=C1C=C(C=C3)F
DMWSFIR	IK	WLUDJBASYYHRDC-XYOKQWHBSA-N
DMWSFIR	IU	3-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMWSFIR	DE	Discovery agent

DMN42I5	ID	DMN42I5
DMN42I5	DN	3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMN42I5	HS	Investigative
DMN42I5	SN	(3-Pyridylmethylene)indane 5b; BDBM8587; CHEMBL383806; AC1O704F; SCHEMBL4220962; ZINC13610771; 3-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMN42I5	DT	Small molecular drug
DMN42I5	PC	6539764
DMN42I5	MW	225.26
DMN42I5	FM	C15H12FN
DMN42I5	IC	InChI=1S/C15H12FN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8-
DMN42I5	CS	C1C/C(=C/C2=CN=CC=C2)/C3=C1C=C(C=C3)F
DMN42I5	IK	WLUDJBASYYHRDC-WQLSENKSSA-N
DMN42I5	IU	3-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMN42I5	DE	Discovery agent

DM9AW5U	ID	DM9AW5U
DM9AW5U	DN	3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM9AW5U	HS	Investigative
DM9AW5U	SN	CHEMBL176609; AC1O704P; SCHEMBL4226031; SCHEMBL4226036; BDBM8593; (3-Pyridylmethylene)indane 11a; 3-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM9AW5U	DT	Small molecular drug
DM9AW5U	PC	6539769
DM9AW5U	MW	237.3
DM9AW5U	FM	C16H15NO
DM9AW5U	IC	InChI=1S/C16H15NO/c1-18-15-6-7-16-13(4-5-14(16)10-15)9-12-3-2-8-17-11-12/h2-3,6-11H,4-5H2,1H3/b13-9+
DM9AW5U	CS	COC1=CC2=C(C=C1)/C(=C/C3=CN=CC=C3)/CC2
DM9AW5U	IK	HVRLSDXXVKSVBR-UKTHLTGXSA-N
DM9AW5U	IU	3-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM9AW5U	DE	Discovery agent

DMB3XYE	ID	DMB3XYE
DMB3XYE	DN	3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMB3XYE	HS	Investigative
DMB3XYE	SN	(3-Pyridylmethylene)indane 11b; AC1O704R; SCHEMBL4226034; CHEMBL176101; BDBM8594; 3-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMB3XYE	DT	Small molecular drug
DMB3XYE	PC	6539770
DMB3XYE	MW	237.3
DMB3XYE	FM	C16H15NO
DMB3XYE	IC	InChI=1S/C16H15NO/c1-18-15-6-7-16-13(4-5-14(16)10-15)9-12-3-2-8-17-11-12/h2-3,6-11H,4-5H2,1H3/b13-9-
DMB3XYE	CS	COC1=CC2=C(C=C1)/C(=C\\C3=CN=CC=C3)/CC2
DMB3XYE	IK	HVRLSDXXVKSVBR-LCYFTJDESA-N
DMB3XYE	IU	3-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMB3XYE	DE	Discovery agent

DMLTZ5F	ID	DMLTZ5F
DMLTZ5F	DN	3-[6-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMLTZ5F	HS	Investigative
DMLTZ5F	SN	CHEMBL1096027; 3-[6-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMLTZ5F	DT	Small molecular drug
DMLTZ5F	PC	46887580
DMLTZ5F	MW	287.8
DMLTZ5F	FM	C15H10ClNOS
DMLTZ5F	IC	InChI=1S/C15H10ClNOS/c16-15-8-7-14(19-15)13-6-2-5-12(17-13)10-3-1-4-11(18)9-10/h1-9,18H
DMLTZ5F	CS	C1=CC(=CC(=C1)O)C2=NC(=CC=C2)C3=CC=C(S3)Cl
DMLTZ5F	IK	IYXPXDBFKHBESO-UHFFFAOYSA-N
DMLTZ5F	IU	3-[6-(5-chlorothiophen-2-yl)pyridin-2-yl]phenol
DMLTZ5F	DE	Discovery agent

DM89RN3	ID	DM89RN3
DM89RN3	DN	3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one
DM89RN3	HS	Investigative
DM89RN3	SN	CHEMBL390737; 3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one
DM89RN3	DT	Small molecular drug
DM89RN3	PC	44421948
DM89RN3	MW	415.5
DM89RN3	FM	C27H29NO3
DM89RN3	IC	InChI=1S/C27H29NO3/c1-28(20-21-11-5-4-6-12-21)17-9-2-3-10-18-30-22-15-16-24-26(19-22)31-25-14-8-7-13-23(25)27(24)29/h4-8,11-16,19H,2-3,9-10,17-18,20H2,1H3
DM89RN3	CS	CN(CCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DM89RN3	IK	NKJXMWCNCBVIAA-UHFFFAOYSA-N
DM89RN3	IU	3-[6-[benzyl(methyl)amino]hexoxy]xanthen-9-one
DM89RN3	DE	Discovery agent

DMHT6FX	ID	DMHT6FX
DMHT6FX	DN	3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DMHT6FX	HS	Investigative
DMHT6FX	SN	(3-Pyridylmethylene)indane 15a; CHEMBL366772; BDBM8601; AC1O7055; 3-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMHT6FX	DT	Small molecular drug
DMHT6FX	PC	6539777
DMHT6FX	MW	237.3
DMHT6FX	FM	C16H15NO
DMHT6FX	IC	InChI=1S/C16H15NO/c1-18-15-7-6-13-4-5-14(16(13)10-15)9-12-3-2-8-17-11-12/h2-3,6-11H,4-5H2,1H3/b14-9+
DMHT6FX	CS	COC1=CC\\2=C(CC/C2=C\\C3=CN=CC=C3)C=C1
DMHT6FX	IK	NDEGTMIIOPDVPA-NTEUORMPSA-N
DMHT6FX	IU	3-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMHT6FX	DE	Discovery agent

DMG76LS	ID	DMG76LS
DMG76LS	DN	3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMG76LS	HS	Investigative
DMG76LS	SN	CHEMBL175550; BDBM8604; AC1O705B; (3-Pyridylmethylene)indane 21a; 3-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMG76LS	DT	Small molecular drug
DMG76LS	PC	6539780
DMG76LS	MW	221.3
DMG76LS	FM	C16H15N
DMG76LS	IC	InChI=1S/C16H15N/c1-12-4-5-14-6-7-15(16(14)9-12)10-13-3-2-8-17-11-13/h2-5,8-11H,6-7H2,1H3/b15-10+
DMG76LS	CS	CC1=CC\\2=C(CC/C2=C\\C3=CN=CC=C3)C=C1
DMG76LS	IK	INXZXCKRUCKCJE-XNTDXEJSSA-N
DMG76LS	IU	3-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMG76LS	DE	Discovery agent

DMKOB2T	ID	DMKOB2T
DMKOB2T	DN	3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DMKOB2T	HS	Investigative
DMKOB2T	SN	(3-Pyridylmethylene)indane 21b; CHEMBL366570; BDBM8605; AC1O705D; 3-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMKOB2T	DT	Small molecular drug
DMKOB2T	PC	6539781
DMKOB2T	MW	221.3
DMKOB2T	FM	C16H15N
DMKOB2T	IC	InChI=1S/C16H15N/c1-12-4-5-14-6-7-15(16(14)9-12)10-13-3-2-8-17-11-13/h2-5,8-11H,6-7H2,1H3/b15-10-
DMKOB2T	CS	CC1=CC\\2=C(CC/C2=C/C3=CN=CC=C3)C=C1
DMKOB2T	IK	INXZXCKRUCKCJE-GDNBJRDFSA-N
DMKOB2T	IU	3-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMKOB2T	DE	Discovery agent

DMMD3G6	ID	DMMD3G6
DMMD3G6	DN	3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one
DMMD3G6	HS	Investigative
DMMD3G6	SN	CHEMBL224433; 3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one
DMMD3G6	DT	Small molecular drug
DMMD3G6	PC	44421953
DMMD3G6	MW	429.5
DMMD3G6	FM	C28H31NO3
DMMD3G6	IC	InChI=1S/C28H31NO3/c1-29(21-22-12-6-5-7-13-22)18-10-3-2-4-11-19-31-23-16-17-25-27(20-23)32-26-15-9-8-14-24(26)28(25)30/h5-9,12-17,20H,2-4,10-11,18-19,21H2,1H3
DMMD3G6	CS	CN(CCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMMD3G6	IK	JUEPMIFCYDBLJZ-UHFFFAOYSA-N
DMMD3G6	IU	3-[7-[benzyl(methyl)amino]heptoxy]xanthen-9-one
DMMD3G6	DE	Discovery agent

DM7IHUK	ID	DM7IHUK
DM7IHUK	DN	3-[7'-(Methoxy)-napht-2'-yl]-quinuclidine-2-ene
DM7IHUK	HS	Investigative
DM7IHUK	SN	CHEMBL478981; SCHEMBL2422138; KZWBNNXTWZPPPP-UHFFFAOYSA-N; BDBM50270302; 3-[7''-(Methoxy)-napht-2''-yl]-quinuclidine-2-ene; 3-(6-methoxy-2-naphthyl)-1-azabicyclo[2.2.2]oct-2-ene
DM7IHUK	DT	Small molecular drug
DM7IHUK	PC	11550718
DM7IHUK	MW	265.3
DM7IHUK	FM	C18H19NO
DM7IHUK	IC	InChI=1S/C18H19NO/c1-20-17-5-4-14-10-16(3-2-15(14)11-17)18-12-19-8-6-13(18)7-9-19/h2-5,10-13H,6-9H2,1H3
DM7IHUK	CS	COC1=CC2=C(C=C1)C=C(C=C2)C3=CN4CCC3CC4
DM7IHUK	IK	KZWBNNXTWZPPPP-UHFFFAOYSA-N
DM7IHUK	IU	3-(6-methoxynaphthalen-2-yl)-1-azabicyclo[2.2.2]oct-2-ene
DM7IHUK	CA	CAS 894079-46-0
DM7IHUK	DE	Discovery agent

DMVWIQ2	ID	DMVWIQ2
DMVWIQ2	DN	3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DMVWIQ2	HS	Investigative
DMVWIQ2	SN	(3-Pyridylmethylene)indane 26a; SCHEMBL4221327; SCHEMBL4221321; CHEMBL175791; BDBM8600; AC1O7053; 3-[(E)-(7-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMVWIQ2	DT	Small molecular drug
DMVWIQ2	PC	6539776
DMVWIQ2	MW	237.3
DMVWIQ2	FM	C16H15NO
DMVWIQ2	IC	InChI=1S/C16H15NO/c1-18-15-6-2-5-13-7-8-14(16(13)15)10-12-4-3-9-17-11-12/h2-6,9-11H,7-8H2,1H3/b14-10+
DMVWIQ2	CS	COC1=CC=CC2=C1/C(=C/C3=CN=CC=C3)/CC2
DMVWIQ2	IK	VTCRFWNOJMKNRS-GXDHUFHOSA-N
DMVWIQ2	IU	3-[(E)-(7-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMVWIQ2	DE	Discovery agent

DM31WYF	ID	DM31WYF
DM31WYF	DN	3-[8-(benzylmethylamino)octyloxy]xanthen-9-one
DM31WYF	HS	Investigative
DM31WYF	SN	CHEMBL224469; 3-[8-(benzylmethylamino)octyloxy]xanthen-9-one
DM31WYF	DT	Small molecular drug
DM31WYF	PC	44421954
DM31WYF	MW	443.6
DM31WYF	FM	C29H33NO3
DM31WYF	IC	InChI=1S/C29H33NO3/c1-30(22-23-13-7-6-8-14-23)19-11-4-2-3-5-12-20-32-24-17-18-26-28(21-24)33-27-16-10-9-15-25(27)29(26)31/h6-10,13-18,21H,2-5,11-12,19-20,22H2,1H3
DM31WYF	CS	CN(CCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DM31WYF	IK	QDZBIUGFNUHGNM-UHFFFAOYSA-N
DM31WYF	IU	3-[8-[benzyl(methyl)amino]octoxy]xanthen-9-one
DM31WYF	DE	Discovery agent

DMZSBU5	ID	DMZSBU5
DMZSBU5	DN	3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one
DMZSBU5	HS	Investigative
DMZSBU5	SN	CHEMBL427090; 3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one
DMZSBU5	DT	Small molecular drug
DMZSBU5	PC	44421955
DMZSBU5	MW	457.6
DMZSBU5	FM	C30H35NO3
DMZSBU5	IC	InChI=1S/C30H35NO3/c1-31(23-24-14-8-7-9-15-24)20-12-5-3-2-4-6-13-21-33-25-18-19-27-29(22-25)34-28-17-11-10-16-26(28)30(27)32/h7-11,14-19,22H,2-6,12-13,20-21,23H2,1H3
DMZSBU5	CS	CN(CCCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMZSBU5	IK	QDYNPKJXQNLYFL-UHFFFAOYSA-N
DMZSBU5	IU	3-[9-[benzyl(methyl)amino]nonoxy]xanthen-9-one
DMZSBU5	DE	Discovery agent

DMLZ5F1	ID	DMLZ5F1
DMLZ5F1	DN	3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DMLZ5F1	HS	Investigative
DMLZ5F1	SN	CHEMBL217425; 3-((2-phenethylphenoxy)methyl)pyridine; 3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DMLZ5F1	DT	Small molecular drug
DMLZ5F1	PC	11973810
DMLZ5F1	MW	289.4
DMLZ5F1	FM	C20H19NO
DMLZ5F1	IC	InChI=1S/C20H19NO/c1-2-7-17(8-3-1)12-13-19-10-4-5-11-20(19)22-16-18-9-6-14-21-15-18/h1-11,14-15H,12-13,16H2
DMLZ5F1	CS	C1=CC=C(C=C1)CCC2=CC=CC=C2OCC3=CN=CC=C3
DMLZ5F1	IK	WUVSQVHZKKJEHX-UHFFFAOYSA-N
DMLZ5F1	IU	3-[[2-(2-phenylethyl)phenoxy]methyl]pyridine
DMLZ5F1	DE	Discovery agent

DMUH9PF	ID	DMUH9PF
DMUH9PF	DN	3-{3-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMUH9PF	HS	Investigative
DMUH9PF	SN	CHEMBL65204; 3-{3-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMUH9PF	DT	Small molecular drug
DMUH9PF	PC	44306774
DMUH9PF	MW	372.4
DMUH9PF	FM	C13H12N2O7S2
DMUH9PF	IC	InChI=1S/C13H12N2O7S2/c14-23(17,18)21-11-5-1-3-9(7-11)13(16)10-4-2-6-12(8-10)22-24(15,19)20/h1-8H,(H2,14,17,18)(H2,15,19,20)
DMUH9PF	CS	C1=CC(=CC(=C1)OS(=O)(=O)N)C(=O)C2=CC(=CC=C2)OS(=O)(=O)N
DMUH9PF	IK	YKEGOWCJKMPGLE-UHFFFAOYSA-N
DMUH9PF	IU	[3-(3-sulfamoyloxybenzoyl)phenyl] sulfamate
DMUH9PF	DE	Discovery agent

DMGS2X7	ID	DMGS2X7
DMGS2X7	DN	3-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMGS2X7	HS	Investigative
DMGS2X7	SN	CHEMBL65211; 3-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMGS2X7	DT	Small molecular drug
DMGS2X7	PC	44306753
DMGS2X7	MW	372.4
DMGS2X7	FM	C13H12N2O7S2
DMGS2X7	IC	InChI=1S/C13H12N2O7S2/c14-23(17,18)21-11-6-4-9(5-7-11)13(16)10-2-1-3-12(8-10)22-24(15,19)20/h1-8H,(H2,14,17,18)(H2,15,19,20)
DMGS2X7	CS	C1=CC(=CC(=C1)OS(=O)(=O)N)C(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMGS2X7	IK	NEMACRXQAFHGPF-UHFFFAOYSA-N
DMGS2X7	IU	[3-(4-sulfamoyloxybenzoyl)phenyl] sulfamate
DMGS2X7	DE	Discovery agent

DMT80IF	ID	DMT80IF
DMT80IF	DN	3570-0208
DMT80IF	HS	Investigative
DMT80IF	SN	[6-ethyl-2-methyl-3-(1-methylbenzimidazol-2-yl)-4-oxochromen-7-yl] acetate; UNM000003536701; AC1MJIQD; BAS 00135206; Oprea1_681432; Oprea1_151337; MLS001242385; GTPL5828; CHEMBL1329101; cid_3092570; CHEBI:92290; BDBM40404; ML048; HMS2231A24; HMS3372G14; ZINC4247033; STK922580; AKOS000525202; MCULE-3542011334; SMR000686159; ST50330694; EU-0040874; SR-01000456743; SR-01000456743-1; 3570-0208 [PMID:19807662]; 2-methyl-3-(1-methyl-2-benzimidazolyl)-6-ethyl-7-acetoxychromone
DMT80IF	DT	Small molecular drug
DMT80IF	PC	3092570
DMT80IF	MW	376.4
DMT80IF	FM	C22H20N2O4
DMT80IF	IC	InChI=1S/C22H20N2O4/c1-5-14-10-15-19(11-18(14)28-13(3)25)27-12(2)20(21(15)26)22-23-16-8-6-7-9-17(16)24(22)4/h6-11H,5H2,1-4H3
DMT80IF	CS	CCC1=CC2=C(C=C1OC(=O)C)OC(=C(C2=O)C3=NC4=CC=CC=C4N3C)C
DMT80IF	IK	HTTVYKXJCQENKW-UHFFFAOYSA-N
DMT80IF	IU	[6-ethyl-2-methyl-3-(1-methylbenzimidazol-2-yl)-4-oxochromen-7-yl] acetate
DMT80IF	CB	CHEBI:92290
DMT80IF	DE	Discovery agent

DMGO2D7	ID	DMGO2D7
DMGO2D7	DN	3-acetyl-11-keto-beta-boswellic acid
DMGO2D7	HS	Investigative
DMGO2D7	SN	AKBA; 67416-61-9; 3-O-Acetyl-11-keto-beta-Boswellic Acid; AKbetaBA; UNII-BS16QT99Q1; Acetyl-11-keto-beta-boswellic acid; CHEMBL237111; BS16QT99Q1; Acetyl-11-keto--boswellic acid; AKBA cpd; Acetyl-11-keto-b-boswellic acid; acetyl-11-ketoboswellic acid; Acetyl-11-keto-beta-Boswellic Acid, Boswellia serrata; 3-Acetyl-11-keto-; 3alpha-acetoxy-11-keto-beta-boswellic acid; Curator_000001; MolPort-020-005-785; HMMGKOVEOFBCAU-BCDBGHSCSA-N
DMGO2D7	DT	Small molecular drug
DMGO2D7	PC	11168203
DMGO2D7	MW	512.7
DMGO2D7	FM	C32H48O5
DMGO2D7	IC	InChI=1S/C32H48O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)/t18-,19+,23-,24-,25+,26-,28-,29+,30-,31-,32-/m1/s1
DMGO2D7	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@H]([C@]5(C)C(=O)O)OC(=O)C)C)C)[C@@H]2[C@H]1C)C)C
DMGO2D7	IK	HMMGKOVEOFBCAU-BCDBGHSCSA-N
DMGO2D7	IU	(3R,4R,4aR,6aR,6bS,8aR,11R,12S,12aR,14aR,14bS)-3-acetyloxy-4,6a,6b,8a,11,12,14b-heptamethyl-14-oxo-1,2,3,4a,5,6,7,8,9,10,11,12,12a,14a-tetradecahydropicene-4-carboxylic acid
DMGO2D7	CA	CAS 67416-61-9
DMGO2D7	CB	CHEBI:166842
DMGO2D7	DE	Discovery agent

DMHRZ2V	ID	DMHRZ2V
DMHRZ2V	DN	3-acetyl-11-keto-ursolic acid
DMHRZ2V	HS	Investigative
DMHRZ2V	SN	11-OXOURSOLIC ACID ACETATE; CHEMBL601891; 3-acetyl-11-keto-ursolic acid; NSC33403; AC1L5RI4; 3-O-acetyl-11-oxoursolic acid; MolPort-044-649-591; NSC-33403; BDBM50307109; AKOS016036264; 35959-01-4; (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bS)-10-acetyloxy-1,2,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,5,6,6a,7,8,8a,10,11,12,14b-tetradecahydropicene-4a-carboxylic acid
DMHRZ2V	DT	Small molecular drug
DMHRZ2V	PC	234102
DMHRZ2V	MW	512.7
DMHRZ2V	FM	C32H48O5
DMHRZ2V	IC	InChI=1S/C32H48O5/c1-18-9-14-32(27(35)36)16-15-30(7)21(25(32)19(18)2)17-22(34)26-29(6)12-11-24(37-20(3)33)28(4,5)23(29)10-13-31(26,30)8/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)/t18-,19+,23+,24+,25+,26-,29+,30-,31-,32+/m1/s1
DMHRZ2V	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OC(=O)C)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMHRZ2V	IK	XDHCWTUZCOFKRH-CIKBGXLUSA-N
DMHRZ2V	IU	(1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bS)-10-acetyloxy-1,2,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,5,6,6a,7,8,8a,10,11,12,14b-tetradecahydropicene-4a-carboxylic acid
DMHRZ2V	CA	CAS 35959-01-4
DMHRZ2V	DE	Discovery agent

DM01WBD	ID	DM01WBD
DM01WBD	DN	3-acetyl-7-hydroxy-2H-chromen-2-one
DM01WBD	HS	Investigative
DM01WBD	SN	3-acetyl-7-hydroxy-2H-chromen-2-one; 10441-27-7; 3-Acetyl-7-hydroxy-chromen-2-one; 3-Acetyl-umbelliferone; 3-acetylumbelliferone; CHEMBL153064; 2H-1-Benzopyran-2-one, 3-acetyl-7-hydroxy-; BRQZHMHHZLRXOO-UHFFFAOYSA-N; 3-acetyl-7-hydroxy-2-oxochromene; 3-acetyl-7-hydroxychromen-2-one; 3-Acetyl-7-Hydroxy-1H-Chromen-2-One; 3-acethyl-umbelliferone; AC1NU0NR; 3-Acetyl-7-hydroxycoumarin; CBDivE_005922; MLS000777662; SCHEMBL592707; ZINC47516; cid_5392139; ASIS-0097; CTK4A3026; DTXSID20419817; MolPort-000-820-976; BB_NC-01216; STK365153
DM01WBD	DT	Small molecular drug
DM01WBD	PC	5392139
DM01WBD	MW	204.18
DM01WBD	FM	C11H8O4
DM01WBD	IC	InChI=1S/C11H8O4/c1-6(12)9-4-7-2-3-8(13)5-10(7)15-11(9)14/h2-5,13H,1H3
DM01WBD	CS	CC(=O)C1=CC2=C(C=C(C=C2)O)OC1=O
DM01WBD	IK	BRQZHMHHZLRXOO-UHFFFAOYSA-N
DM01WBD	IU	3-acetyl-7-hydroxychromen-2-one
DM01WBD	CA	CAS 10441-27-7
DM01WBD	DE	Discovery agent

DMCNX34	ID	DMCNX34
DMCNX34	DN	3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane
DMCNX34	HS	Investigative
DMCNX34	SN	CHEMBL593963; BDBM50304334
DMCNX34	DT	Small molecular drug
DMCNX34	PC	46226590
DMCNX34	MW	298.4
DMCNX34	FM	C18H22N2O2
DMCNX34	IC	InChI=1S/C18H22N2O2/c1-19-13-7-8-14(19)11-15(10-13)22-18(21)17-9-12-5-3-4-6-16(12)20(17)2/h3-6,9,13-15H,7-8,10-11H2,1-2H3/t13-,14-/m1/s1
DMCNX34	CS	CN1[C@@H]2CC[C@@H]1CC(C2)OC(=O)C3=CC4=CC=CC=C4N3C
DMCNX34	IK	WGAYVVNWRFPKMG-ZIAGYGMSSA-N
DMCNX34	IU	[(1R,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1-methylindole-2-carboxylate
DMCNX34	DE	Discovery agent

DM3BRYJ	ID	DM3BRYJ
DM3BRYJ	DN	3alpha-(2'-Indolecarbonyloxy)-nortropane
DM3BRYJ	HS	Investigative
DM3BRYJ	SN	CHEMBL596256; BDBM50304333
DM3BRYJ	DT	Small molecular drug
DM3BRYJ	PC	46226582
DM3BRYJ	MW	270.33
DM3BRYJ	FM	C16H18N2O2
DM3BRYJ	IC	InChI=1S/C16H18N2O2/c19-16(15-7-10-3-1-2-4-14(10)18-15)20-13-8-11-5-6-12(9-13)17-11/h1-4,7,11-13,17-18H,5-6,8-9H2/t11-,12-/m1/s1
DM3BRYJ	CS	C1C[C@@H]2CC(C[C@@H]1N2)OC(=O)C3=CC4=CC=CC=C4N3
DM3BRYJ	IK	JTIOAVUBNSKIPD-VXGBXAGGSA-N
DM3BRYJ	IU	[(1R,5R)-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-2-carboxylate
DM3BRYJ	DE	Discovery agent

DMBUZWQ	ID	DMBUZWQ
DMBUZWQ	DN	3alpha-(bis-chloro-phenylmethoxy)tropane
DMBUZWQ	HS	Investigative
DMBUZWQ	SN	CHEMBL119664; CHEMBL541825; SCHEMBL1152029; BDBM50039177; 3-[Bis(4-chlorophenyl)methoxy]tropane; 3-[Bis-(4-chloro-phenyl)-methoxy]-8-methyl-8-aza-bicyclo[3.2.1]octane
DMBUZWQ	DT	Small molecular drug
DMBUZWQ	PC	10068100
DMBUZWQ	MW	376.3
DMBUZWQ	FM	C21H23Cl2NO
DMBUZWQ	IC	InChI=1S/C21H23Cl2NO/c1-24-18-10-11-19(24)13-20(12-18)25-21(14-2-6-16(22)7-3-14)15-4-8-17(23)9-5-15/h2-9,18-21H,10-13H2,1H3
DMBUZWQ	CS	CN1C2CCC1CC(C2)OC(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl
DMBUZWQ	IK	DAAKBMHWKLVSKY-UHFFFAOYSA-N
DMBUZWQ	IU	3-[bis(4-chlorophenyl)methoxy]-8-methyl-8-azabicyclo[3.2.1]octane
DMBUZWQ	DE	Discovery agent

DM3ZR7A	ID	DM3ZR7A
DM3ZR7A	DN	3alpha,24-dihydroxyolean-12-en-27-oic acid
DM3ZR7A	HS	Investigative
DM3ZR7A	SN	CHEMBL207657; 3alpha,24-dihydroxyolean-12-en-27-oic acid
DM3ZR7A	DT	Small molecular drug
DM3ZR7A	PC	44411959
DM3ZR7A	MW	472.7
DM3ZR7A	FM	C30H48O4
DM3ZR7A	IC	InChI=1S/C30H48O4/c1-25(2)13-14-26(3)15-16-30(24(33)34)19(20(26)17-25)7-8-22-27(4)11-10-23(32)28(5,18-31)21(27)9-12-29(22,30)6/h7,20-23,31-32H,8-18H2,1-6H3,(H,33,34)/t20-,21?,22+,23+,26+,27-,28+,29+,30+/m0/s1
DM3ZR7A	CS	C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CC[C@H]([C@]5(C)CO)O)C)C)[C@@H]1CC(CC2)(C)C)C(=O)O
DM3ZR7A	IK	HQGWITLOHQUPBL-NFHCHMPHSA-N
DM3ZR7A	IU	(4aR,6aR,6aR,6bR,9S,10R,12aR,14bR)-10-hydroxy-9-(hydroxymethyl)-2,2,4a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylic acid
DM3ZR7A	DE	Discovery agent

DMV6OPB	ID	DMV6OPB
DMV6OPB	DN	3alpha-Hydroxyurs-12-en-28-oic Acid
DMV6OPB	HS	Investigative
DMV6OPB	SN	989-30-0; CHEMBL491715; AC1OG92I; SCHEMBL19714770; MolPort-039-338-864; ZINC12890906; BDBM50346612; 9.89E+302; (1S,2R,4aS,6aR,6aS,6bR,8aR,10R,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMV6OPB	DT	Small molecular drug
DMV6OPB	PC	7163177
DMV6OPB	MW	456.7
DMV6OPB	FM	C30H48O3
DMV6OPB	IC	InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23-,24+,27+,28-,29-,30+/m1/s1
DMV6OPB	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMV6OPB	IK	WCGUUGGRBIKTOS-XHINXETDSA-N
DMV6OPB	IU	(1S,2R,4aS,6aR,6aS,6bR,8aR,10R,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMV6OPB	DE	Discovery agent

DM4M6LR	ID	DM4M6LR
DM4M6LR	DN	3alpha-O-trans-p-coumaroyl-7-labden-15-oic acid
DM4M6LR	HS	Investigative
DM4M6LR	SN	CHEMBL494656; 3alpha-O-trans-p-coumaroyl-7-labden-15-oic acid
DM4M6LR	DT	Small molecular drug
DM4M6LR	PC	44566339
DM4M6LR	MW	454.6
DM4M6LR	FM	C28H38O5
DM4M6LR	IC	InChI=1S/C28H38O5/c1-18(17-26(30)31)5-12-22-19(2)6-14-24-23(22)13-15-25(28(24,3)4)33-27(32)16-9-20-7-10-21(29)11-8-20/h6-11,16,18,22-25,29H,5,12-15,17H2,1-4H3,(H,30,31)/b16-9+/t18-,22-,23+,24+,25-/m0/s1
DM4M6LR	CS	CC1=CC[C@@H]2[C@@H]([C@H]1CC[C@H](C)CC(=O)O)CC[C@@H](C2(C)C)OC(=O)/C=C/C3=CC=C(C=C3)O
DM4M6LR	IK	ZSKLTPLHCIUPKA-LOWUFNJHSA-N
DM4M6LR	IU	(3S)-5-[(1R,4aR,6S,8aR)-6-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy-2,5,5-trimethyl-4,4a,6,7,8,8a-hexahydro-1H-naphthalen-1-yl]-3-methylpentanoic acid
DM4M6LR	DE	Discovery agent

DMO5IJA	ID	DMO5IJA
DMO5IJA	DN	3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane
DMO5IJA	HS	Investigative
DMO5IJA	SN	3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane; CHEMBL566837
DMO5IJA	DT	Small molecular drug
DMO5IJA	PC	45488086
DMO5IJA	MW	293.4
DMO5IJA	FM	C20H23NO
DMO5IJA	IC	InChI=1S/C20H23NO/c1-3-7-16(8-4-1)15-22-20(17-9-5-2-6-10-17)13-18-11-12-19(14-20)21-18/h1-10,18-19,21H,11-15H2
DMO5IJA	CS	C1CC2CC(CC1N2)(C3=CC=CC=C3)OCC4=CC=CC=C4
DMO5IJA	IK	DFUGHSKLQQMYID-UHFFFAOYSA-N
DMO5IJA	IU	3-phenyl-3-phenylmethoxy-8-azabicyclo[3.2.1]octane
DMO5IJA	DE	Discovery agent

DMKGIQ1	ID	DMKGIQ1
DMKGIQ1	DN	3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one
DMKGIQ1	HS	Investigative
DMKGIQ1	SN	CHEMBL156974; 5-Methoxykynuramine
DMKGIQ1	DT	Small molecular drug
DMKGIQ1	PC	44372211
DMKGIQ1	MW	194.23
DMKGIQ1	FM	C10H14N2O2
DMKGIQ1	IC	InChI=1S/C10H14N2O2/c1-14-7-2-3-9(12)8(6-7)10(13)4-5-11/h2-3,6H,4-5,11-12H2,1H3
DMKGIQ1	CS	COC1=CC(=C(C=C1)N)C(=O)CCN
DMKGIQ1	IK	DFZXDYZPSYJYBU-UHFFFAOYSA-N
DMKGIQ1	IU	3-amino-1-(2-amino-5-methoxyphenyl)propan-1-one
DMKGIQ1	DE	Discovery agent

DMF3DBE	ID	DMF3DBE
DMF3DBE	DN	3-amino-2-(benzylideneamino)-5-mercaptophenol
DMF3DBE	HS	Investigative
DMF3DBE	SN	CHEMBL468589; 3-amino-2-(benzylideneamino)-5-mercaptophenol
DMF3DBE	DT	Small molecular drug
DMF3DBE	PC	44577786
DMF3DBE	MW	244.31
DMF3DBE	FM	C13H12N2OS
DMF3DBE	IC	InChI=1S/C13H12N2OS/c14-11-6-10(17)7-12(16)13(11)15-8-9-4-2-1-3-5-9/h1-8,16-17H,14H2
DMF3DBE	CS	C1=CC=C(C=C1)C=NC2=C(C=C(C=C2O)S)N
DMF3DBE	IK	ZHJMODAVTYPZRG-UHFFFAOYSA-N
DMF3DBE	IU	3-amino-2-(benzylideneamino)-5-sulfanylphenol
DMF3DBE	DE	Discovery agent

DMV4XGT	ID	DMV4XGT
DMV4XGT	DN	3-Amino-3-(methoxycarbonyl)-1,5-pentandioic acid
DMV4XGT	HS	Investigative
DMV4XGT	SN	CHEMBL541497
DMV4XGT	DT	Small molecular drug
DMV4XGT	PC	49797638
DMV4XGT	MW	241.62
DMV4XGT	FM	C7H12ClNO6
DMV4XGT	IC	InChI=1S/C7H11NO6.ClH/c1-14-6(13)7(8,2-4(9)10)3-5(11)12;/h2-3,8H2,1H3,(H,9,10)(H,11,12);1H
DMV4XGT	CS	COC(=O)C(CC(=O)O)(CC(=O)O)N.Cl
DMV4XGT	IK	SQNZWVALOOOEKW-UHFFFAOYSA-N
DMV4XGT	IU	3-amino-3-methoxycarbonylpentanedioic acid;hydrochloride
DMV4XGT	DE	Discovery agent

DM60K7H	ID	DM60K7H
DM60K7H	DN	3-amino-3-demethoxythiocolchicine
DM60K7H	HS	Investigative
DM60K7H	SN	SCHEMBL8239297
DM60K7H	DT	Small molecular drug
DM60K7H	PC	16081784
DM60K7H	MW	400.5
DM60K7H	FM	C21H24N2O4S
DM60K7H	IC	InChI=1S/C21H24N2O4S/c1-11(24)23-16-7-5-12-9-15(22)20(26-2)21(27-3)19(12)13-6-8-18(28-4)17(25)10-14(13)16/h6,8-10,16H,5,7,22H2,1-4H3,(H,23,24)/t16-/m0/s1
DM60K7H	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)N
DM60K7H	IK	HGWINWYVDWEKKX-INIZCTEOSA-N
DM60K7H	IU	N-[(7S)-3-amino-1,2-dimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DM60K7H	DE	Discovery agent

DMJ7Y3H	ID	DMJ7Y3H
DMJ7Y3H	DN	3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMJ7Y3H	HS	Investigative
DMJ7Y3H	SN	CHEMBL237897; BDBM50213160
DMJ7Y3H	DT	Small molecular drug
DMJ7Y3H	PC	44431966
DMJ7Y3H	MW	311.5
DMJ7Y3H	FM	C21H29NO
DMJ7Y3H	IC	InChI=1S/C21H29NO/c1-4-5-6-7-13-21(2,3)17-11-12-19(20(23)15-17)16-9-8-10-18(22)14-16/h8-12,14-15,23H,4-7,13,22H2,1-3H3
DMJ7Y3H	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC(=CC=C2)N)O
DMJ7Y3H	IK	GWRWPRMABCQODZ-UHFFFAOYSA-N
DMJ7Y3H	IU	2-(3-aminophenyl)-5-(2-methyloctan-2-yl)phenol
DMJ7Y3H	DE	Discovery agent

DMIS3LN	ID	DMIS3LN
DMIS3LN	DN	3-Amino-4'-amino-trans-stilbene
DMIS3LN	HS	Investigative
DMIS3LN	SN	3,4'-Diaminostilbene; CCRIS 6786; CHEMBL1171628; BRN 3129972; 3-(2-(4-Aminophenyl)ethenyl)benzenamine; Benzenamine, 3-(2-(4-aminophenyl)ethenyl)-; 79305-82-1; 3-[2-(4-aminophenyl)ethenyl]aniline; AC1NYYMC; Stilbene-3,4'-diamine; AC1Q51YO; (E)-Stilbene-3,4'-diamine; SCHEMBL2774636; SCHEMBL2774639; 3-Amino-4''-amino-trans-stilbene; ZINC5161777; BDBM50322063; AKOS030582755; LS-28069; 3-[(E)-2-(4-aminophenyl)ethenyl]aniline; 3-13-00-00512 (Beilstein Handbook Reference)
DMIS3LN	DT	Small molecular drug
DMIS3LN	PC	5844100
DMIS3LN	MW	210.27
DMIS3LN	FM	C14H14N2
DMIS3LN	IC	InChI=1S/C14H14N2/c15-13-8-6-11(7-9-13)4-5-12-2-1-3-14(16)10-12/h1-10H,15-16H2/b5-4+
DMIS3LN	CS	C1=CC(=CC(=C1)N)/C=C/C2=CC=C(C=C2)N
DMIS3LN	IK	IXGDBTKLQUHIAX-SNAWJCMRSA-N
DMIS3LN	IU	3-[(E)-2-(4-aminophenyl)ethenyl]aniline
DMIS3LN	CA	CAS 79305-82-1
DMIS3LN	DE	Discovery agent

DM5Z0O6	ID	DM5Z0O6
DM5Z0O6	DN	3-Amino-4-Oxybenzyl-2-Butanone
DM5Z0O6	HS	Investigative
DM5Z0O6	SN	3-AMINO-4-OXYBENZYL-2-BUTANONE; AC1NRD4M; SCHEMBL15172323; CHEMBL1235900; DB02148
DM5Z0O6	DT	Small molecular drug
DM5Z0O6	PC	5289348
DM5Z0O6	MW	193.24
DM5Z0O6	FM	C11H15NO2
DM5Z0O6	IC	InChI=1S/C11H15NO2/c1-9(13)11(12)8-14-7-10-5-3-2-4-6-10/h2-6,11H,7-8,12H2,1H3/t11-/m0/s1
DM5Z0O6	CS	CC(=O)[C@H](COCC1=CC=CC=C1)N
DM5Z0O6	IK	ISLRAQPEXPIKDJ-NSHDSACASA-N
DM5Z0O6	IU	(3S)-3-amino-4-phenylmethoxybutan-2-one
DM5Z0O6	DE	Discovery agent

DM2U9RY	ID	DM2U9RY
DM2U9RY	DN	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide
DM2U9RY	HS	Investigative
DM2U9RY	SN	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide; 175137-05-0; CHEMBL444884; 515142-45-7; 2-Thiophenecarboxamide,3-amino-5-(4-chlorophenyl)-; AC1MBTGN; 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxamide; SCHEMBL4097325; CTK4D5319; DTXSID90373351; MQYJPACEBWKWEH-UHFFFAOYSA-N; MolPort-000-150-990; ZX-AT016871; ZINC2556119; SBB101177; BDBM50186632; 5704AD; AKOS022181810; AJ-39853; ACM175137050; RT-019539; FT-0704094; 3-Amino-5-(4-chloro-phenyl)-thiophene-2-carboxylic acid amide
DM2U9RY	DT	Small molecular drug
DM2U9RY	PC	2756390
DM2U9RY	MW	252.72
DM2U9RY	FM	C11H9ClN2OS
DM2U9RY	IC	InChI=1S/C11H9ClN2OS/c12-7-3-1-6(2-4-7)9-5-8(13)10(16-9)11(14)15/h1-5H,13H2,(H2,14,15)
DM2U9RY	CS	C1=CC(=CC=C1C2=CC(=C(S2)C(=O)N)N)Cl
DM2U9RY	IK	MQYJPACEBWKWEH-UHFFFAOYSA-N
DM2U9RY	IU	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide
DM2U9RY	CA	CAS 175137-05-0
DM2U9RY	DE	Discovery agent

DMONHFR	ID	DMONHFR
DMONHFR	DN	3-amino-5-(4-octylphenyl)pentanoic acid
DMONHFR	HS	Investigative
DMONHFR	SN	CHEMBL326346; 3-amino-5-(4-octylphenyl)pentanoic Acid; SCHEMBL5464250; BDBM50147707; 3-Amino-5-(4-octyl-phenyl)-pentanoic acid
DMONHFR	DT	Small molecular drug
DMONHFR	PC	10149595
DMONHFR	MW	305.5
DMONHFR	FM	C19H31NO2
DMONHFR	IC	InChI=1S/C19H31NO2/c1-2-3-4-5-6-7-8-16-9-11-17(12-10-16)13-14-18(20)15-19(21)22/h9-12,18H,2-8,13-15,20H2,1H3,(H,21,22)
DMONHFR	CS	CCCCCCCCC1=CC=C(C=C1)CCC(CC(=O)O)N
DMONHFR	IK	UDEAYIGFOWYIGY-UHFFFAOYSA-N
DMONHFR	IU	3-amino-5-(4-octylphenyl)pentanoic acid
DMONHFR	DE	Discovery agent

DM6Y2KW	ID	DM6Y2KW
DM6Y2KW	DN	3-amino-5-(furan-2-yl)biphenyl-2,4-dicarbonitrile
DM6Y2KW	HS	Investigative
DM6Y2KW	SN	3-amino-5-(furan-2-yl)biphenyl-2,4-dicarbonitrile; CHEMBL577938; SMR000054390; AC1LCDQ5; Cambridge id 5105969; MLS000104455; cid_625239; ZINC28097; SLQVQKSDEBBOSA-UHFFFAOYSA-N; MolPort-000-475-780; HMS1700M17; BDBM50303384; STK831931; AKOS000663950; MCULE-3002689151; BAS 13070166; ST001263; AB00073722-01; 3-Amino-5-furan-2-yl-biphenyl-2,4-dicarbonitrile; 2-amino-6-(2-furyl)-4-phenylbenzene-1,3-dicarbonitrile; 1,1'-Biphenyl-2,4-dicarbonitrile, 3-amino-5-(2-furyl)-; 3-Amino-5-(2-furyl)[1,1'-biphenyl]-2,4-dicarbonitrile #
DM6Y2KW	DT	Small molecular drug
DM6Y2KW	PC	625239
DM6Y2KW	MW	285.3
DM6Y2KW	FM	C18H11N3O
DM6Y2KW	IC	InChI=1S/C18H11N3O/c19-10-15-13(12-5-2-1-3-6-12)9-14(16(11-20)18(15)21)17-7-4-8-22-17/h1-9H,21H2
DM6Y2KW	CS	C1=CC=C(C=C1)C2=CC(=C(C(=C2C#N)N)C#N)C3=CC=CO3
DM6Y2KW	IK	SLQVQKSDEBBOSA-UHFFFAOYSA-N
DM6Y2KW	IU	2-amino-4-(furan-2-yl)-6-phenylbenzene-1,3-dicarbonitrile
DM6Y2KW	DE	Discovery agent

DMP2K1A	ID	DMP2K1A
DMP2K1A	DN	3-Amino-5,6-dihydro-2H-benzo[f]quinazolin-1-one
DMP2K1A	HS	Investigative
DMP2K1A	DT	Small molecular drug
DMP2K1A	PC	135838221
DMP2K1A	MW	213.23
DMP2K1A	FM	C12H11N3O
DMP2K1A	IC	InChI=1S/C12H11N3O/c13-12-14-9-6-5-7-3-1-2-4-8(7)10(9)11(16)15-12/h1-4H,5-6H2,(H3,13,14,15,16)
DMP2K1A	CS	C1CC2=C(C3=CC=CC=C31)C(=O)NC(=N2)N
DMP2K1A	IK	VXKOVZZJDGUSEF-UHFFFAOYSA-N
DMP2K1A	IU	3-amino-5,6-dihydro-2H-benzo[f]quinazolin-1-one
DMP2K1A	CA	CAS 33987-08-5
DMP2K1A	DE	Discovery agent

DMHDFZE	ID	DMHDFZE
DMHDFZE	DN	3-Amino-5-Phenylpentane
DMHDFZE	HS	Investigative
DMHDFZE	SN	SCHEMBL7412184
DMHDFZE	DT	Small molecular drug
DMHDFZE	PC	46936513
DMHDFZE	MW	303.4
DMHDFZE	FM	C17H21NO2S
DMHDFZE	IC	InChI=1S/C17H21NO2S/c18-16(12-11-15-7-3-1-4-8-15)13-14-21(19,20)17-9-5-2-6-10-17/h1-10,16H,11-14,18H2/t16-/m0/s1
DMHDFZE	CS	C1=CC=C(C=C1)CC[C@@H](CCS(=O)(=O)C2=CC=CC=C2)N
DMHDFZE	IK	WQRZZKAHRWPIFX-INIZCTEOSA-N
DMHDFZE	IU	(3S)-1-(benzenesulfonyl)-5-phenylpentan-3-amine
DMHDFZE	DE	Discovery agent

DM0GJZM	ID	DM0GJZM
DM0GJZM	DN	3-aminoacetamido-4'-methylfuro[3,2-g]coumarin
DM0GJZM	HS	Investigative
DM0GJZM	SN	CHEMBL202017; BDBM50181852
DM0GJZM	DT	Small molecular drug
DM0GJZM	PC	11492774
DM0GJZM	MW	272.26
DM0GJZM	FM	C14H12N2O4
DM0GJZM	IC	InChI=1S/C14H12N2O4/c1-7-6-19-12-4-11-8(2-9(7)12)3-10(14(18)20-11)16-13(17)5-15/h2-4,6H,5,15H2,1H3,(H,16,17)
DM0GJZM	CS	CC1=COC2=C1C=C3C=C(C(=O)OC3=C2)NC(=O)CN
DM0GJZM	IK	MNKUYMIFZBIEPU-UHFFFAOYSA-N
DM0GJZM	IU	2-amino-N-(3-methyl-7-oxofuro[3,2-g]chromen-6-yl)acetamide
DM0GJZM	DE	Discovery agent

DM5073T	ID	DM5073T
DM5073T	DN	3-AMINO-AZACYCLOTRIDECAN-2-ONE
DM5073T	HS	Investigative
DM5073T	SN	3-AMINO-AZACYCLOTRIDECAN-2-ONE; RIN; AC1L9JYK; (3S)-3-aminoazacyclotridecan-2-one; (3S)-3-amino-azacyclotridecan-2-one; DB08476
DM5073T	DT	Small molecular drug
DM5073T	PC	446676
DM5073T	MW	212.33
DM5073T	FM	C12H24N2O
DM5073T	IC	InChI=1S/C12H24N2O/c13-11-9-7-5-3-1-2-4-6-8-10-14-12(11)15/h11H,1-10,13H2,(H,14,15)/t11-/m0/s1
DM5073T	CS	C1CCCCCNC(=O)[C@H](CCCC1)N
DM5073T	IK	CQZLEYBEPASILI-NSHDSACASA-N
DM5073T	IU	(3S)-3-amino-azacyclotridecan-2-one
DM5073T	DE	Discovery agent

DM7P3IZ	ID	DM7P3IZ
DM7P3IZ	DN	3-aminobenzamide
DM7P3IZ	HS	Investigative
DM7P3IZ	SN	3-Aminobenzamide; 3544-24-9; m-Aminobenzamide; Benzamide, 3-amino-; 3-Amino-benzamide; Benzamide, m-amino-; meta-aminobenzamide; 3-ABA; 3-Aminobenzimide; 3-amino benzamide; aniline-3-carboxamide; 3-aminobenzoic acid amide; UNII-8J365YF1YH; CCRIS 3925; EINECS 222-586-9; NSC 36962; BRN 2802373; PARP Inhibitor I, 3-ABA; 3-H2NC6H4CONH2; CHEMBL81977; 3-AB; 8J365YF1YH; CHEBI:64042; GSCPDZHWVNUUFI-UHFFFAOYSA-N; MFCD00007989; 3-Aminobenzamide, 98%; SR-01000075657; HSDB 7581; 3-azanylbenzamide; m-amino benzamide; 4pml; 3-Aminobenzaminde
DM7P3IZ	DT	Small molecular drug
DM7P3IZ	PC	1645
DM7P3IZ	MW	136.15
DM7P3IZ	FM	C7H8N2O
DM7P3IZ	IC	InChI=1S/C7H8N2O/c8-6-3-1-2-5(4-6)7(9)10/h1-4H,8H2,(H2,9,10)
DM7P3IZ	CS	C1=CC(=CC(=C1)N)C(=O)N
DM7P3IZ	IK	GSCPDZHWVNUUFI-UHFFFAOYSA-N
DM7P3IZ	IU	3-aminobenzamide
DM7P3IZ	CA	CAS 3544-24-9
DM7P3IZ	CB	CHEBI:64042
DM7P3IZ	DE	Discovery agent

DME0TNA	ID	DME0TNA
DME0TNA	DN	3-Amino-benzenesulfonamide
DME0TNA	HS	Investigative
DME0TNA	SN	3-AMINOBENZENESULFONAMIDE; 98-18-0; Metanilamide; m-Aminobenzenesulfonamide; Benzenesulfonamide, 3-amino-; m-Sulfamoylaniline; 3-Aminobenzene-1-Sulfonamide; Benzenesulfonamide, m-amino-; m-Aminobenzenesulphonamide; Metaniilamide; 3-Aminosulfonylaniline; 3-Amino-benzenesulfonamide; NSC 7542; EINECS 202-646-0; BRN 0511851; CHEMBL6852; JPVKCHIPRSQDKL-UHFFFAOYSA-N; MFCD00035781; 3-Sulfanilamide; m-sulfamylaniline; NSC7542; 3-sulfamoyl-aniline; 3-sulfamoyl-phenylamine; 3-aminobenzensulfonamide; AC1Q6UKN; AC1L1OMG
DME0TNA	DT	Small molecular drug
DME0TNA	PC	7377
DME0TNA	MW	172.21
DME0TNA	FM	C6H8N2O2S
DME0TNA	IC	InChI=1S/C6H8N2O2S/c7-5-2-1-3-6(4-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
DME0TNA	CS	C1=CC(=CC(=C1)S(=O)(=O)N)N
DME0TNA	IK	JPVKCHIPRSQDKL-UHFFFAOYSA-N
DME0TNA	IU	3-aminobenzenesulfonamide
DME0TNA	CA	CAS 98-18-0
DME0TNA	DE	Discovery agent

DMWOTD3	ID	DMWOTD3
DMWOTD3	DN	3-amino-benzo[b]thiophene-2-carboxylic acid amide
DMWOTD3	HS	Investigative
DMWOTD3	SN	3-amino-1-benzothiophene-2-carboxamide; 37839-59-1; 3-Aminobenzo[b]thiophene-2-carboxamide; CHEMBL211002; Benzo[b]thiophene-2-carboxamide, 3-amino-; 3-aminobenzo[b]thiophene-2-carboxylic acid amide; AC1LGIJV; 3-amino-benzo[b]thiophene-2-carboxylic acid amide; SCHEMBL6609258; CTK1B5350; DTXSID80356350; MolPort-002-798-643; ZINC339150; STL134701; BDBM50186634; AKOS001782516; CCG-127335; MCULE-9206749194; NE38914; EN300-88534
DMWOTD3	DT	Small molecular drug
DMWOTD3	PC	821974
DMWOTD3	MW	192.24
DMWOTD3	FM	C9H8N2OS
DMWOTD3	IC	InChI=1S/C9H8N2OS/c10-7-5-3-1-2-4-6(5)13-8(7)9(11)12/h1-4H,10H2,(H2,11,12)
DMWOTD3	CS	C1=CC=C2C(=C1)C(=C(S2)C(=O)N)N
DMWOTD3	IK	LTNWICBPQWPXDK-UHFFFAOYSA-N
DMWOTD3	IU	3-amino-1-benzothiophene-2-carboxamide
DMWOTD3	CA	CAS 37839-59-1
DMWOTD3	DE	Discovery agent

DML2UCP	ID	DML2UCP
DML2UCP	DN	3-aminobenzo[c][1,5]naphthyridin-6(5H)-one
DML2UCP	HS	Investigative
DML2UCP	SN	CHEMBL106154; 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one; Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-amino-; SCHEMBL12750402; BDBM50130580; 433726-73-9
DML2UCP	DT	Small molecular drug
DML2UCP	PC	16221809
DML2UCP	MW	211.22
DML2UCP	FM	C12H9N3O
DML2UCP	IC	InChI=1S/C12H9N3O/c13-7-5-10-11(14-6-7)8-3-1-2-4-9(8)12(16)15-10/h1-6H,13H2,(H,15,16)
DML2UCP	CS	C1=CC=C2C(=C1)C3=C(C=C(C=N3)N)NC2=O
DML2UCP	IK	PSWYPUADRXNJGE-UHFFFAOYSA-N
DML2UCP	IU	3-amino-5H-benzo[c][1,5]naphthyridin-6-one
DML2UCP	DE	Discovery agent

DMTYXH1	ID	DMTYXH1
DMTYXH1	DN	3-Aminomethyl-5-methyl-hexanoic acid
DMTYXH1	HS	Investigative
DMTYXH1	SN	3-(aminomethyl)-5-methylhexanoic acid; 128013-69-4; 130912-52-6; rac-Pregabalin; 3-(Aminomethyl)-5-methylhexanoicacid; 3-(aminomethyl)-5-methyl-hexanoic acid; Hexanoic acid,3-(aminomethyl)-5-methyl-; Hexanoic acid, 3-(aminomethyl)-5-methyl-; AYXYPKUFHZROOJ-UHFFFAOYSA-N; NCGC00095186-01; AC1NFWUF; PubChem15652; ACMC-20p1cu; ACMC-1CF05; SCHEMBL15497; CHEMBL88034; PHARMA-0589; KS-00000AKV; CTK4B5836; BCP17115; BCP05685; BBL100350; CA-452; FC0023; ANW-51583; STK894330
DMTYXH1	DT	Small molecular drug
DMTYXH1	PC	4715169
DMTYXH1	MW	159.23
DMTYXH1	FM	C8H17NO2
DMTYXH1	IC	InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)
DMTYXH1	CS	CC(C)CC(CC(=O)O)CN
DMTYXH1	IK	AYXYPKUFHZROOJ-UHFFFAOYSA-N
DMTYXH1	IU	3-(aminomethyl)-5-methylhexanoic acid
DMTYXH1	DE	Discovery agent

DM5SQVC	ID	DM5SQVC
DM5SQVC	DN	3-ammoniopropane-1-sulfinate
DM5SQVC	HS	Investigative
DM5SQVC	SN	Homohypotaurine; 3-aminopropane-1-sulfinic acid; 25346-09-2; CHEMBL32102; 1-Propanesulfinic acid,3-amino-; 3-ammoniopropane-1-sulfinate; AC1L4VIZ; AC1Q6YOU; 3-aminopropylsulfinic acid; 3-Aminopropansulfinic acid; 3-amino-propane sulfinic acid; SCHEMBL341598; CTK4F5523; DTXSID30179995; NPGXQDBNBFXJKB-UHFFFAOYSA-N; MolPort-028-749-783; ZINC5410694; BDBM50087276; AKOS006338176; NE49789; 3-Amino-propane-1-sulfinic acid (Homohypotaurine)
DM5SQVC	DT	Small molecular drug
DM5SQVC	PC	193060
DM5SQVC	MW	123.18
DM5SQVC	FM	C3H9NO2S
DM5SQVC	IC	InChI=1S/C3H9NO2S/c4-2-1-3-7(5)6/h1-4H2,(H,5,6)
DM5SQVC	CS	C(CN)CS(=O)O
DM5SQVC	IK	NPGXQDBNBFXJKB-UHFFFAOYSA-N
DM5SQVC	IU	3-aminopropane-1-sulfinic acid
DM5SQVC	CA	CAS 25346-09-2
DM5SQVC	DE	Discovery agent

DM3VYNJ	ID	DM3VYNJ
DM3VYNJ	DN	3-anilino-5-benzylthio-1,2,4-triazole
DM3VYNJ	HS	Investigative
DM3VYNJ	SN	3-anilino-5-benzylthio-1,2,4-triazole; CHEMBL243303; SCHEMBL5376882; 1,2,4-Triazole Compound, 6; BDBM17352; QBUZLNWDECJZMT-UHFFFAOYSA-N
DM3VYNJ	DT	Small molecular drug
DM3VYNJ	PC	9838682
DM3VYNJ	MW	282.4
DM3VYNJ	FM	C15H14N4S
DM3VYNJ	IC	InChI=1S/C15H14N4S/c1-3-7-12(8-4-1)11-20-15-17-14(18-19-15)16-13-9-5-2-6-10-13/h1-10H,11H2,(H2,16,17,18,19)
DM3VYNJ	CS	C1=CC=C(C=C1)CSC2=NNC(=N2)NC3=CC=CC=C3
DM3VYNJ	IK	QBUZLNWDECJZMT-UHFFFAOYSA-N
DM3VYNJ	IU	3-benzylsulfanyl-N-phenyl-1H-1,2,4-triazol-5-amine
DM3VYNJ	DE	Discovery agent

DM6KNMB	ID	DM6KNMB
DM6KNMB	DN	3-azageranylgeranyl diphosphate
DM6KNMB	HS	Investigative
DM6KNMB	SN	3-Azageranylgeranyl diphosphate; CHEMBL71360; 2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE; MGM; 150942-60-2; AC1L9KO8; GTPL3199; DTXSID70332249; BDBM50113289; 3-aza-geranylgeranyl diphosphoric acid; DB08180; 3-aza-geranylgeranyl pyrophosphoric acid; Diphosphoric acid, mono[2-[methyl[(3E,7E)-4,8,12-trimethyl-3,7,11-tridecatrienyl]amino]ethyl] ester (9CI); 2-[methyl-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-amino]-ethyl trihydrogendiphosphate(3-aza-GGPP)
DM6KNMB	DT	Small molecular drug
DM6KNMB	PC	447278
DM6KNMB	MW	453.4
DM6KNMB	FM	C19H37NO7P2
DM6KNMB	IC	InChI=1S/C19H37NO7P2/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-26-29(24,25)27-28(21,22)23/h9,11,13H,6-8,10,12,14-16H2,1-5H3,(H,24,25)(H2,21,22,23)/b18-11+,19-13+
DM6KNMB	CS	CC(=CCC/C(=C/CC/C(=C/CCN(C)CCOP(=O)(O)OP(=O)(O)O)/C)/C)C
DM6KNMB	IK	OEMBPHBKZPOPBN-NWLVNBMCSA-N
DM6KNMB	IU	2-[methyl-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]amino]ethyl phosphono hydrogen phosphate
DM6KNMB	CA	CAS 150942-60-2
DM6KNMB	DE	Discovery agent

DMU08MN	ID	DMU08MN
DMU08MN	DN	3'-Azido-3'-Deoxythymidine-5'-Monophosphate
DMU08MN	HS	Investigative
DMU08MN	SN	AZTMP; Zidovudine 5'-monophosphate; UNII-97YMU05VPJ; ZDVMP; AZT-MP; 3'-azido-3'-deoxythymidine-5'-monophosphate; 97YMU05VPJ; Zidovudine monophosphate; 3'-Azido-3'-deoxythymidine 5'-phosphate; 29706-85-2; 5'-Thymidylic acid, 3'-azido-3'-deoxy-; Zdv 5'-monophosphate; AzddTMP; 3'-azido-3'-deoxythymidine monophosphate; AZT-monophosphate; 3'-Azido-2',3'-deoxythymidine 5'-monophosphate; NSC742230; 3'-Azido-3'-deoxythymidine 5'phosphate; AC1Q6RVL; [(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methyl d
DMU08MN	DT	Small molecular drug
DMU08MN	PC	65374
DMU08MN	MW	347.22
DMU08MN	FM	C10H14N5O7P
DMU08MN	IC	InChI=1S/C10H14N5O7P/c1-5-3-15(10(17)12-9(5)16)8-2-6(13-14-11)7(22-8)4-21-23(18,19)20/h3,6-8H,2,4H2,1H3,(H,12,16,17)(H2,18,19,20)/t6-,7+,8+/m0/s1
DMU08MN	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O)N=[N+]=[N-]
DMU08MN	IK	OIFWQOKDSPDILA-XLPZGREQSA-N
DMU08MN	IU	[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMU08MN	CA	CAS 29706-85-2
DMU08MN	DE	Discovery agent

DMQXD0N	ID	DMQXD0N
DMQXD0N	DN	3-Benzenesulfinyl-heptanoic acid hydroxyamide
DMQXD0N	HS	Investigative
DMQXD0N	SN	CHEMBL75433; 3-Benzenesulfinyl-heptanoic acid hydroxyamide; BDBM50089197
DMQXD0N	DT	Small molecular drug
DMQXD0N	PC	9816867
DMQXD0N	MW	269.36
DMQXD0N	FM	C13H19NO3S
DMQXD0N	IC	InChI=1S/C13H19NO3S/c1-2-3-7-12(10-13(15)14-16)18(17)11-8-5-4-6-9-11/h4-6,8-9,12,16H,2-3,7,10H2,1H3,(H,14,15)
DMQXD0N	CS	CCCCC(CC(=O)NO)S(=O)C1=CC=CC=C1
DMQXD0N	IK	SQIUCETXNXHTSW-UHFFFAOYSA-N
DMQXD0N	IU	3-(benzenesulfinyl)-N-hydroxyheptanamide
DMQXD0N	DE	Discovery agent

DM7XDCF	ID	DM7XDCF
DM7XDCF	DN	3-Benzenesulfonyl-heptanoic acid hydroxyamide
DM7XDCF	HS	Investigative
DM7XDCF	SN	CHEMBL263501; 3-Benzenesulfonyl-heptanoic acid hydroxyamide; BDBM50089196
DM7XDCF	DT	Small molecular drug
DM7XDCF	PC	9838786
DM7XDCF	MW	285.36
DM7XDCF	FM	C13H19NO4S
DM7XDCF	IC	InChI=1S/C13H19NO4S/c1-2-3-7-12(10-13(15)14-16)19(17,18)11-8-5-4-6-9-11/h4-6,8-9,12,16H,2-3,7,10H2,1H3,(H,14,15)
DM7XDCF	CS	CCCCC(CC(=O)NO)S(=O)(=O)C1=CC=CC=C1
DM7XDCF	IK	TUUMURVUDGZZQZ-UHFFFAOYSA-N
DM7XDCF	IU	3-(benzenesulfonyl)-N-hydroxyheptanamide
DM7XDCF	DE	Discovery agent

DMQXJA1	ID	DMQXJA1
DMQXJA1	DN	3-Benzimidazol-2-ylhydroquinolin-2-one
DMQXJA1	HS	Investigative
DMQXJA1	DT	Small molecular drug
DMQXJA1	PC	5329370
DMQXJA1	DE	Discovery agent

DMWLIK1	ID	DMWLIK1
DMWLIK1	DN	3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile
DMWLIK1	HS	Investigative
DMWLIK1	DE	Glioma; Melanoma

DMHXRQL	ID	DMHXRQL
DMHXRQL	DN	3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one
DMHXRQL	HS	Investigative
DMHXRQL	SN	CHEMBL237166; 3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one; BDBM50224060
DMHXRQL	DT	Small molecular drug
DMHXRQL	PC	44436068
DMHXRQL	MW	319.4
DMHXRQL	FM	C21H21NO2
DMHXRQL	IC	InChI=1S/C21H21NO2/c1-2-3-9-14-22-15-18(20(23)16-10-5-4-6-11-16)21(24)17-12-7-8-13-19(17)22/h4-8,10-13,15H,2-3,9,14H2,1H3
DMHXRQL	CS	CCCCCN1C=C(C(=O)C2=CC=CC=C21)C(=O)C3=CC=CC=C3
DMHXRQL	IK	IEVKXDBTVSPAJD-UHFFFAOYSA-N
DMHXRQL	IU	3-benzoyl-1-pentylquinolin-4-one
DMHXRQL	DE	Discovery agent

DMAH4DG	ID	DMAH4DG
DMAH4DG	DN	3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one
DMAH4DG	HS	Investigative
DMAH4DG	DT	Small molecular drug
DMAH4DG	PC	54696209
DMAH4DG	DE	Discovery agent

DM25K86	ID	DM25K86
DM25K86	DN	3-Benzoyl-N-hydroxy-benzamide
DM25K86	HS	Investigative
DM25K86	SN	CHEMBL175908; 3-Benzoyl-N-hydroxy-benzamide; 3-Benzoylbenzohydroximic acid; SCHEMBL14880296; ZINC28108876
DM25K86	DT	Small molecular drug
DM25K86	PC	44386957
DM25K86	MW	241.24
DM25K86	FM	C14H11NO3
DM25K86	IC	InChI=1S/C14H11NO3/c16-13(10-5-2-1-3-6-10)11-7-4-8-12(9-11)14(17)15-18/h1-9,18H,(H,15,17)
DM25K86	CS	C1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)C(=O)NO
DM25K86	IK	LAZDNRBVPKMJSY-UHFFFAOYSA-N
DM25K86	IU	3-benzoyl-N-hydroxybenzamide
DM25K86	DE	Discovery agent

DMNG0TY	ID	DMNG0TY
DMNG0TY	DN	3-benzyl-1-cyclohexylpyrrolidin-2-one
DMNG0TY	HS	Investigative
DMNG0TY	SN	CHEMBL218285; 3-benzyl-1-cyclohexylpyrrolidin-2-one; 3-benzyl-1-cyclohexyl-pyrrolidin-2-one; SCHEMBL2986964; DGGDICYTCJZLPW-UHFFFAOYSA-N
DMNG0TY	DT	Small molecular drug
DMNG0TY	PC	11673314
DMNG0TY	MW	257.37
DMNG0TY	FM	C17H23NO
DMNG0TY	IC	InChI=1S/C17H23NO/c19-17-15(13-14-7-3-1-4-8-14)11-12-18(17)16-9-5-2-6-10-16/h1,3-4,7-8,15-16H,2,5-6,9-13H2
DMNG0TY	CS	C1CCC(CC1)N2CCC(C2=O)CC3=CC=CC=C3
DMNG0TY	IK	DGGDICYTCJZLPW-UHFFFAOYSA-N
DMNG0TY	IU	3-benzyl-1-cyclohexylpyrrolidin-2-one
DMNG0TY	DE	Discovery agent

DMQ13Z8	ID	DMQ13Z8
DMQ13Z8	DN	3-Benzyl-2-ethylthio-6-nitro-quinazolin-4(3H)-one
DMQ13Z8	HS	Investigative
DMQ13Z8	SN	CHEMBL1092690; 3-Benzyl-2-ethylthio-6-nitro-quinazolin-4(3H)-one
DMQ13Z8	DT	Small molecular drug
DMQ13Z8	PC	46886465
DMQ13Z8	MW	341.4
DMQ13Z8	FM	C17H15N3O3S
DMQ13Z8	IC	InChI=1S/C17H15N3O3S/c1-2-24-17-18-15-9-8-13(20(22)23)10-14(15)16(21)19(17)11-12-6-4-3-5-7-12/h3-10H,2,11H2,1H3
DMQ13Z8	CS	CCSC1=NC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)N1CC3=CC=CC=C3
DMQ13Z8	IK	XLPYZVKSRJZTGS-UHFFFAOYSA-N
DMQ13Z8	IU	3-benzyl-2-ethylsulfanyl-6-nitroquinazolin-4-one
DMQ13Z8	DE	Discovery agent

DM4GWAH	ID	DM4GWAH
DM4GWAH	DN	3-benzyl-2-mercapto-6-nitroquinazolin-4(3H)-one
DM4GWAH	HS	Investigative
DM4GWAH	SN	CHEMBL1093884; 3-benzyl-2-mercapto-6-nitroquinazolin-4(3H)-one; BDBM50316110
DM4GWAH	DT	Small molecular drug
DM4GWAH	PC	46886435
DM4GWAH	MW	313.3
DM4GWAH	FM	C15H11N3O3S
DM4GWAH	IC	InChI=1S/C15H11N3O3S/c19-14-12-8-11(18(20)21)6-7-13(12)16-15(22)17(14)9-10-4-2-1-3-5-10/h1-8H,9H2,(H,16,22)
DM4GWAH	CS	C1=CC=C(C=C1)CN2C(=O)C3=C(C=CC(=C3)[N+](=O)[O-])NC2=S
DM4GWAH	IK	CAFCJNRLHXPRGN-UHFFFAOYSA-N
DM4GWAH	IU	3-benzyl-6-nitro-2-sulfanylidene-1H-quinazolin-4-one
DM4GWAH	DE	Discovery agent

DMDAO28	ID	DMDAO28
DMDAO28	DN	3-Benzyl-3-ethyl-1-phenylazetidine-2,4-dione
DMDAO28	HS	Investigative
DMDAO28	SN	CHEMBL578583; 3-Benzyl-3-ethyl-1-phenylazetidine-2,4-dione
DMDAO28	DT	Small molecular drug
DMDAO28	PC	44626901
DMDAO28	MW	279.3
DMDAO28	FM	C18H17NO2
DMDAO28	IC	InChI=1S/C18H17NO2/c1-2-18(13-14-9-5-3-6-10-14)16(20)19(17(18)21)15-11-7-4-8-12-15/h3-12H,2,13H2,1H3
DMDAO28	CS	CCC1(C(=O)N(C1=O)C2=CC=CC=C2)CC3=CC=CC=C3
DMDAO28	IK	FWZVCEYFFJOHOK-UHFFFAOYSA-N
DMDAO28	IU	3-benzyl-3-ethyl-1-phenylazetidine-2,4-dione
DMDAO28	DE	Discovery agent

DMHINWF	ID	DMHINWF
DMHINWF	DN	3-Benzyl-3-methyl-1-phenylazetidine-2,4-dione
DMHINWF	HS	Investigative
DMHINWF	SN	CHEMBL567138; 3-Benzyl-3-methyl-1-phenylazetidine-2,4-dione
DMHINWF	DT	Small molecular drug
DMHINWF	PC	44626902
DMHINWF	MW	265.31
DMHINWF	FM	C17H15NO2
DMHINWF	IC	InChI=1S/C17H15NO2/c1-17(12-13-8-4-2-5-9-13)15(19)18(16(17)20)14-10-6-3-7-11-14/h2-11H,12H2,1H3
DMHINWF	CS	CC1(C(=O)N(C1=O)C2=CC=CC=C2)CC3=CC=CC=C3
DMHINWF	IK	ZFHCQEMYYXRUAS-UHFFFAOYSA-N
DMHINWF	IU	3-benzyl-3-methyl-1-phenylazetidine-2,4-dione
DMHINWF	DE	Discovery agent

DMA5EHC	ID	DMA5EHC
DMA5EHC	DN	3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one
DMA5EHC	HS	Investigative
DMA5EHC	SN	CHEMBL576081
DMA5EHC	DT	Small molecular drug
DMA5EHC	PC	54736438
DMA5EHC	MW	306.4
DMA5EHC	FM	C20H18O3
DMA5EHC	IC	InChI=1S/C20H18O3/c21-18-16-11-10-14-8-4-5-9-15(14)19(16)23-20(22)17(18)12-13-6-2-1-3-7-13/h1-3,6-7,10-11,21H,4-5,8-9,12H2
DMA5EHC	CS	C1CCC2=C(C1)C=CC3=C2OC(=O)C(=C3O)CC4=CC=CC=C4
DMA5EHC	IK	AGXYLUCTDKGDGR-UHFFFAOYSA-N
DMA5EHC	IU	3-benzyl-4-hydroxy-7,8,9,10-tetrahydrobenzo[h]chromen-2-one
DMA5EHC	DE	Discovery agent

DM3BFX0	ID	DM3BFX0
DM3BFX0	DN	3-Benzyl-4-hydroxy-2H-chromen-2-one
DM3BFX0	HS	Investigative
DM3BFX0	SN	4-Hydroxy-3-benzylcoumarin; 15074-18-7; 3-Benzyl-4-hydroxy-2H-chromen-2-one; 3-Benzyl-4-hydroxy-chromen-2-one; 3-benzyl-4-hydroxycoumarin; 3-benzyl-4-hydroxy-2h-1-benzopyran-2-one; 3Bz-4OHBzpyran2one; 4-hydroxy-coumarin 8; CBMicro_020160; AC1L9T1B; 3-Benzyl-4-hydroxy-cumarin; Oprea1_155335; 3-benzyl-4-hydroxy-coumarin; Oprea1_579559; 3-benzyl-4 -hydroxycoumarin; SCHEMBL1648186; CHEMBL574145; BDBM2566; JMC527142 Compound 27; 3-benzyl-2-hydroxychromen-4-one; DTXSID60715769; 4-hydroxy-3-benzylchromen-2-one; MolPort-001-017-230
DM3BFX0	DT	Small molecular drug
DM3BFX0	PC	54686112
DM3BFX0	MW	252.26
DM3BFX0	FM	C16H12O3
DM3BFX0	IC	InChI=1S/C16H12O3/c17-15-12-8-4-5-9-14(12)19-16(18)13(15)10-11-6-2-1-3-7-11/h1-9,17H,10H2
DM3BFX0	CS	C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O
DM3BFX0	IK	AEIVRFFWQSJCAR-UHFFFAOYSA-N
DM3BFX0	IU	3-benzyl-4-hydroxychromen-2-one
DM3BFX0	CA	CAS 15074-18-7
DM3BFX0	DE	Discovery agent

DML0ME9	ID	DML0ME9
DML0ME9	DN	3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one
DML0ME9	HS	Investigative
DML0ME9	SN	CHEMBL573693; BDBM35542; 4-hydroxy-2H-chromen-2-one core, 18
DML0ME9	DT	Small molecular drug
DML0ME9	PC	54736428
DML0ME9	MW	280.3
DML0ME9	FM	C18H16O3
DML0ME9	IC	InChI=1S/C18H16O3/c1-11-8-14-16(9-12(11)2)21-18(20)15(17(14)19)10-13-6-4-3-5-7-13/h3-9,19H,10H2,1-2H3
DML0ME9	CS	CC1=CC2=C(C=C1C)OC(=O)C(=C2O)CC3=CC=CC=C3
DML0ME9	IK	XYLBSWJPINWPSC-UHFFFAOYSA-N
DML0ME9	IU	3-benzyl-4-hydroxy-6,7-dimethylchromen-2-one
DML0ME9	DE	Discovery agent

DMZ85NC	ID	DMZ85NC
DMZ85NC	DN	3-benzyl-5-fluorobenzo[d]oxazol-2(3H)-one
DMZ85NC	HS	Investigative
DMZ85NC	SN	CHEMBL1256370; 3-benzyl-5-fluorobenzo[d]oxazol-2(3H)-one; SCHEMBL18805702
DMZ85NC	DT	Small molecular drug
DMZ85NC	PC	52942744
DMZ85NC	MW	243.23
DMZ85NC	FM	C14H10FNO2
DMZ85NC	IC	InChI=1S/C14H10FNO2/c15-11-6-7-13-12(8-11)16(14(17)18-13)9-10-4-2-1-3-5-10/h1-8H,9H2
DMZ85NC	CS	C1=CC=C(C=C1)CN2C3=C(C=CC(=C3)F)OC2=O
DMZ85NC	IK	YYEOCYSVLLWJQE-UHFFFAOYSA-N
DMZ85NC	IU	3-benzyl-5-fluoro-1,3-benzoxazol-2-one
DMZ85NC	DE	Discovery agent

DMKZDYP	ID	DMKZDYP
DMKZDYP	DN	3-Benzyl-5-isopropyl-8-methylchromen-2-one
DMKZDYP	HS	Investigative
DMKZDYP	SN	CHEMBL470224; 3-Benzyl-5-isopropyl-8-methylchromen-2-one
DMKZDYP	DT	Small molecular drug
DMKZDYP	PC	16066912
DMKZDYP	MW	292.4
DMKZDYP	FM	C20H20O2
DMKZDYP	IC	InChI=1S/C20H20O2/c1-13(2)17-10-9-14(3)19-18(17)12-16(20(21)22-19)11-15-7-5-4-6-8-15/h4-10,12-13H,11H2,1-3H3
DMKZDYP	CS	CC1=C2C(=C(C=C1)C(C)C)C=C(C(=O)O2)CC3=CC=CC=C3
DMKZDYP	IK	PFSLDHWSUPFZPK-UHFFFAOYSA-N
DMKZDYP	IU	3-benzyl-8-methyl-5-propan-2-ylchromen-2-one
DMKZDYP	DE	Discovery agent

DMF04YH	ID	DMF04YH
DMF04YH	DN	3-Benzyl-5-methoxy-7-methylchromen-2-one
DMF04YH	HS	Investigative
DMF04YH	SN	CHEMBL470199; 3-Benzyl-5-methoxy-7-methylchromen-2-one
DMF04YH	DT	Small molecular drug
DMF04YH	PC	16067266
DMF04YH	MW	280.3
DMF04YH	FM	C18H16O3
DMF04YH	IC	InChI=1S/C18H16O3/c1-12-8-16(20-2)15-11-14(18(19)21-17(15)9-12)10-13-6-4-3-5-7-13/h3-9,11H,10H2,1-2H3
DMF04YH	CS	CC1=CC2=C(C=C(C(=O)O2)CC3=CC=CC=C3)C(=C1)OC
DMF04YH	IK	AOPKGUPAQXHRKK-UHFFFAOYSA-N
DMF04YH	IU	3-benzyl-5-methoxy-7-methylchromen-2-one
DMF04YH	DE	Discovery agent

DMSIAMN	ID	DMSIAMN
DMSIAMN	DN	3-Benzyl-5-methoxychromen-2-one
DMSIAMN	HS	Investigative
DMSIAMN	SN	CHEMBL471247; 3-Benzyl-5-methoxychromen-2-one
DMSIAMN	DT	Small molecular drug
DMSIAMN	PC	16067269
DMSIAMN	MW	266.29
DMSIAMN	FM	C17H14O3
DMSIAMN	IC	InChI=1S/C17H14O3/c1-19-15-8-5-9-16-14(15)11-13(17(18)20-16)10-12-6-3-2-4-7-12/h2-9,11H,10H2,1H3
DMSIAMN	CS	COC1=CC=CC2=C1C=C(C(=O)O2)CC3=CC=CC=C3
DMSIAMN	IK	XJSXZFXFKVCTQS-UHFFFAOYSA-N
DMSIAMN	IU	3-benzyl-5-methoxychromen-2-one
DMSIAMN	DE	Discovery agent

DMHYQ3Z	ID	DMHYQ3Z
DMHYQ3Z	DN	3-benzyl-5-methylbenzo[d]oxazol-2(3H)-one
DMHYQ3Z	HS	Investigative
DMHYQ3Z	SN	3-Benzyl-5-methyl-3H-benzooxazol-2-one; CHEMBL523238; 3-benzyl-5-methylbenzo[d]oxazol-2(3H)-one; F1633-0044; 107235-17-6; AC1LLOHB; BAS 07089306; MLS001205717; SCHEMBL10874258; MolPort-000-473-697; ZINC806272; HMS2816L07; BDBM50265523; ZINC 00806272; AKOS000649124; MCULE-9514588723; CCG-142613; SMR000523953; 3-benzyl-5-methyl-1,3-benzoxazol-2-one; 5-methyl-3-benzyl-3-hydrobenzoxazol-2-one
DMHYQ3Z	DT	Small molecular drug
DMHYQ3Z	PC	1087842
DMHYQ3Z	MW	239.27
DMHYQ3Z	FM	C15H13NO2
DMHYQ3Z	IC	InChI=1S/C15H13NO2/c1-11-7-8-14-13(9-11)16(15(17)18-14)10-12-5-3-2-4-6-12/h2-9H,10H2,1H3
DMHYQ3Z	CS	CC1=CC2=C(C=C1)OC(=O)N2CC3=CC=CC=C3
DMHYQ3Z	IK	OHZOKKGTLRVETE-UHFFFAOYSA-N
DMHYQ3Z	IU	3-benzyl-5-methyl-1,3-benzoxazol-2-one
DMHYQ3Z	DE	Discovery agent

DMGPKIY	ID	DMGPKIY
DMGPKIY	DN	3-benzyl-6-methylbenzo[d]oxazol-2(3H)-one
DMGPKIY	HS	Investigative
DMGPKIY	SN	CHEMBL1256155; 3-benzyl-6-methylbenzo[d]oxazol-2(3H)-one; SCHEMBL243468; HYWGUCHKPHXSGZ-UHFFFAOYSA-N; BDBM50327347
DMGPKIY	DT	Small molecular drug
DMGPKIY	PC	52950186
DMGPKIY	MW	239.27
DMGPKIY	FM	C15H13NO2
DMGPKIY	IC	InChI=1S/C15H13NO2/c1-11-7-8-13-14(9-11)18-15(17)16(13)10-12-5-3-2-4-6-12/h2-9H,10H2,1H3
DMGPKIY	CS	CC1=CC2=C(C=C1)N(C(=O)O2)CC3=CC=CC=C3
DMGPKIY	IK	HYWGUCHKPHXSGZ-UHFFFAOYSA-N
DMGPKIY	IU	3-benzyl-6-methyl-1,3-benzoxazol-2-one
DMGPKIY	DE	Discovery agent

DMHQ467	ID	DMHQ467
DMHQ467	DN	3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol
DMHQ467	HS	Investigative
DMHQ467	SN	CHEMBL198760; 3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol; BDBM50171758; 3-benzyl-7-methyl-1H-1,8-naphthyridin-4-one
DMHQ467	DT	Small molecular drug
DMHQ467	PC	15557795
DMHQ467	MW	250.29
DMHQ467	FM	C16H14N2O
DMHQ467	IC	InChI=1S/C16H14N2O/c1-11-7-8-14-15(19)13(10-17-16(14)18-11)9-12-5-3-2-4-6-12/h2-8,10H,9H2,1H3,(H,17,18,19)
DMHQ467	CS	CC1=NC2=C(C=C1)C(=O)C(=CN2)CC3=CC=CC=C3
DMHQ467	IK	QRUPNIJLOWMQBO-UHFFFAOYSA-N
DMHQ467	IU	3-benzyl-7-methyl-1H-1,8-naphthyridin-4-one
DMHQ467	DE	Discovery agent

DM12RH3	ID	DM12RH3
DM12RH3	DN	3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol
DM12RH3	HS	Investigative
DM12RH3	SN	CHEMBL427178; 3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol
DM12RH3	DT	Small molecular drug
DM12RH3	PC	44403594
DM12RH3	MW	266.4
DM12RH3	FM	C16H14N2S
DM12RH3	IC	InChI=1S/C16H14N2S/c1-11-7-8-14-15(19)13(10-17-16(14)18-11)9-12-5-3-2-4-6-12/h2-8,10H,9H2,1H3,(H,17,18,19)
DM12RH3	CS	CC1=NC2=C(C=C1)C(=S)C(=CN2)CC3=CC=CC=C3
DM12RH3	IK	JNNOALSYCGYTDY-UHFFFAOYSA-N
DM12RH3	IU	3-benzyl-7-methyl-1H-1,8-naphthyridine-4-thione
DM12RH3	DE	Discovery agent

DMB4WP5	ID	DMB4WP5
DMB4WP5	DN	3-Benzylamino-5-ethyl-6-methyl-1H-pyridin-2-one
DMB4WP5	HS	Investigative
DMB4WP5	SN	CHEMBL86064; 3-(benzylamino)-5-ethyl-6-methyl-1H-pyridin-2-one; AC1L9RKU; 2-pyridinone deriv. 28; BDBM1298; ZINC5887250; 3-Aminopyridin-2(1H)-one analogue 18; 3-(Benzylamino)-5-ethyl-6-methyl-2(1H)-pyridinone; 3-(Benzylamino)-5-ethyl-6-methylpyridin-2(1H)-one
DMB4WP5	DT	Small molecular drug
DMB4WP5	PC	454349
DMB4WP5	MW	242.32
DMB4WP5	FM	C15H18N2O
DMB4WP5	IC	InChI=1S/C15H18N2O/c1-3-13-9-14(15(18)17-11(13)2)16-10-12-7-5-4-6-8-12/h4-9,16H,3,10H2,1-2H3,(H,17,18)
DMB4WP5	CS	CCC1=C(NC(=O)C(=C1)NCC2=CC=CC=C2)C
DMB4WP5	IK	HEQCOEDABQUKBA-UHFFFAOYSA-N
DMB4WP5	IU	3-(benzylamino)-5-ethyl-6-methyl-1H-pyridin-2-one
DMB4WP5	DE	Discovery agent

DMZIOJS	ID	DMZIOJS
DMZIOJS	DN	3-benzyl-N-(2-morpholinoethyl)quinoxalin-2-amine
DMZIOJS	HS	Investigative
DMZIOJS	SN	CHEMBL206465; 3-benzyl-N-(2-morpholinoethyl)quinoxalin-2-amine
DMZIOJS	DT	Small molecular drug
DMZIOJS	PC	11624425
DMZIOJS	MW	348.4
DMZIOJS	FM	C21H24N4O
DMZIOJS	IC	InChI=1S/C21H24N4O/c1-2-6-17(7-3-1)16-20-21(22-10-11-25-12-14-26-15-13-25)24-19-9-5-4-8-18(19)23-20/h1-9H,10-16H2,(H,22,24)
DMZIOJS	CS	C1COCCN1CCNC2=NC3=CC=CC=C3N=C2CC4=CC=CC=C4
DMZIOJS	IK	JEKWAIMSNCODJF-UHFFFAOYSA-N
DMZIOJS	IU	3-benzyl-N-(2-morpholin-4-ylethyl)quinoxalin-2-amine
DMZIOJS	DE	Discovery agent

DM94K83	ID	DM94K83
DM94K83	DN	3-Benzyloxy-2-phenyl-piperidine
DM94K83	HS	Investigative
DM94K83	SN	CHEMBL100178; 3-Benzyloxy-2-phenyl-piperidine; SCHEMBL9023808
DM94K83	DT	Small molecular drug
DM94K83	PC	44331794
DM94K83	MW	267.4
DM94K83	FM	C18H21NO
DM94K83	IC	InChI=1S/C18H21NO/c1-3-8-15(9-4-1)14-20-17-12-7-13-19-18(17)16-10-5-2-6-11-16/h1-6,8-11,17-19H,7,12-14H2/t17-,18-/m0/s1
DM94K83	CS	C1C[C@@H]([C@@H](NC1)C2=CC=CC=C2)OCC3=CC=CC=C3
DM94K83	IK	VPMJRXBIGDTSRT-ROUUACIJSA-N
DM94K83	IU	(2S,3S)-2-phenyl-3-phenylmethoxypiperidine
DM94K83	DE	Discovery agent

DMKD874	ID	DMKD874
DMKD874	DN	3-benzyloxy-4-methoxy-2'-hydroxychalcone
DMKD874	HS	Investigative
DMKD874	SN	CHEMBL437006
DMKD874	DT	Small molecular drug
DMKD874	PC	12681944
DMKD874	MW	360.4
DMKD874	FM	C23H20O4
DMKD874	IC	InChI=1S/C23H20O4/c1-26-22-14-12-17(11-13-21(25)19-9-5-6-10-20(19)24)15-23(22)27-16-18-7-3-2-4-8-18/h2-15,24H,16H2,1H3/b13-11+
DMKD874	CS	COC1=C(C=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O)OCC3=CC=CC=C3
DMKD874	IK	QYADGBNDKLLFIV-ACCUITESSA-N
DMKD874	IU	(E)-1-(2-hydroxyphenyl)-3-(4-methoxy-3-phenylmethoxyphenyl)prop-2-en-1-one
DMKD874	DE	Discovery agent

DMPG315	ID	DMPG315
DMPG315	DN	3-Benzyloxy-6,7-dimethoxy-quinoline
DMPG315	HS	Investigative
DMPG315	SN	CHEMBL66932; 3-Benzyloxy-6,7-dimethoxy-quinoline; SCHEMBL8172572; ZJIOVLLLFWQBKA-UHFFFAOYSA-N; 3-benzyloxy-6,7-dimethoxyquinoline; ZINC3834031
DMPG315	DT	Small molecular drug
DMPG315	PC	10085863
DMPG315	MW	295.3
DMPG315	FM	C18H17NO3
DMPG315	IC	InChI=1S/C18H17NO3/c1-20-17-9-14-8-15(11-19-16(14)10-18(17)21-2)22-12-13-6-4-3-5-7-13/h3-11H,12H2,1-2H3
DMPG315	CS	COC1=CC2=CC(=CN=C2C=C1OC)OCC3=CC=CC=C3
DMPG315	IK	ZJIOVLLLFWQBKA-UHFFFAOYSA-N
DMPG315	IU	6,7-dimethoxy-3-phenylmethoxyquinoline
DMPG315	DE	Discovery agent

DMLEXWC	ID	DMLEXWC
DMLEXWC	DN	3beta,6beta-dihydroxyolean-12-en-27-oic acid
DMLEXWC	HS	Investigative
DMLEXWC	SN	CHEMBL377760; 3beta,6beta-dihydroxyolean-12-en-27-oic acid
DMLEXWC	DT	Small molecular drug
DMLEXWC	PC	44411962
DMLEXWC	MW	472.7
DMLEXWC	FM	C30H48O4
DMLEXWC	IC	InChI=1S/C30H48O4/c1-25(2)12-13-27(5)14-15-30(24(33)34)18(19(27)16-25)8-9-21-28(6)11-10-22(32)26(3,4)23(28)20(31)17-29(21,30)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20+,21+,22-,23?,27+,28+,29+,30+/m0/s1
DMLEXWC	CS	C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(C[C@H](C5[C@@]4(CC[C@@H](C5(C)C)O)C)O)C)[C@@H]1CC(CC2)(C)C)C(=O)O
DMLEXWC	IK	LUJTWDWEYNWTBP-ULYQHCOQSA-N
DMLEXWC	IU	(4aR,6aR,6aR,6bR,8R,10S,12aR,14bR)-8,10-dihydroxy-2,2,4a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylic acid
DMLEXWC	DE	Discovery agent

DMOZAHB	ID	DMOZAHB
DMOZAHB	DN	3beta-acetoxyolean-12-en-27-oic acid
DMOZAHB	HS	Investigative
DMOZAHB	SN	CHEMBL208639; 3beta-acetoxyolean-12-en-27-oic acid
DMOZAHB	DT	Small molecular drug
DMOZAHB	PC	44411975
DMOZAHB	MW	498.7
DMOZAHB	FM	C32H50O4
DMOZAHB	IC	InChI=1S/C32H50O4/c1-20(33)36-25-12-13-30(7)23(28(25,4)5)11-14-31(8)24(30)10-9-21-22-19-27(2,3)15-16-29(22,6)17-18-32(21,31)26(34)35/h9,22-25H,10-19H2,1-8H3,(H,34,35)/t22-,23?,24+,25-,29+,30-,31+,32+/m0/s1
DMOZAHB	CS	CC(=O)O[C@H]1CC[C@@]2([C@H]3CC=C4[C@@H]5CC(CC[C@@]5(CC[C@]4([C@@]3(CCC2C1(C)C)C)C(=O)O)C)(C)C)C
DMOZAHB	IK	IQYUEJTVDLHZDJ-PVLVPSCMSA-N
DMOZAHB	IU	(4aR,6aR,6aR,6bR,10S,12aR,14bR)-10-acetyloxy-2,2,4a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylic acid
DMOZAHB	DE	Discovery agent

DMF6VGK	ID	DMF6VGK
DMF6VGK	DN	3beta-hydroxyolean-12-en-27-oic acid
DMF6VGK	HS	Investigative
DMF6VGK	SN	CHEMBL210970; 3beta-hydroxyolean-12-en-27-oic acid
DMF6VGK	DT	Small molecular drug
DMF6VGK	PC	44411858
DMF6VGK	MW	456.7
DMF6VGK	FM	C30H48O3
DMF6VGK	IC	InChI=1S/C30H48O3/c1-25(2)14-15-27(5)16-17-30(24(32)33)19(20(27)18-25)8-9-22-28(6)12-11-23(31)26(3,4)21(28)10-13-29(22,30)7/h8,20-23,31H,9-18H2,1-7H3,(H,32,33)/t20-,21?,22+,23-,27+,28-,29+,30+/m0/s1
DMF6VGK	CS	C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]1CC(CC2)(C)C)C(=O)O
DMF6VGK	IK	QGOSJBZFTWGWDU-ROOBTRRZSA-N
DMF6VGK	IU	(4aR,6aR,6aR,6bR,10S,12aR,14bR)-10-hydroxy-2,2,4a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylic acid
DMF6VGK	DE	Discovery agent

DML8NY0	ID	DML8NY0
DML8NY0	DN	3beta-hydroxyrus-12,19(29)-dien-28-oic acid
DML8NY0	HS	Investigative
DML8NY0	SN	CHEMBL517522; 3beta-hydroxyrus-12,19(29)-dien-28-oic acid; BDBM50259781; 3beta-Hydroxyurs-12,19(29)-diene-28-oic acid
DML8NY0	DT	Small molecular drug
DML8NY0	PC	21670092
DML8NY0	MW	454.7
DML8NY0	FM	C30H46O3
DML8NY0	IC	InChI=1S/C30H46O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18,21-24,31H,2,9-17H2,1,3-7H3,(H,32,33)/t18-,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1
DML8NY0	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2C1=C)C)C(=O)O
DML8NY0	IK	VPMTUSRUIJFRMW-XCYSCKFXSA-N
DML8NY0	IU	(2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,6a,6b,9,9,12a-hexamethyl-1-methylidene-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DML8NY0	DE	Discovery agent

DMKL59W	ID	DMKL59W
DMKL59W	DN	3beta-hydroxyrus-18,20(30)-dien-28-oic acid
DMKL59W	HS	Investigative
DMKL59W	SN	CHEMBL479472; 3beta-hydroxyrus-18,20(30)-dien-28-oic acid; BDBM50259782; 3beta-Hydroxyurs-18,20(30)-diene-28-oic acid
DMKL59W	DT	Small molecular drug
DMKL59W	PC	10718553
DMKL59W	MW	454.7
DMKL59W	FM	C30H46O3
DMKL59W	IC	InChI=1S/C30H46O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h20-23,31H,1,8-17H2,2-7H3,(H,32,33)/t20-,21+,22-,23+,27+,28-,29-,30+/m1/s1
DMKL59W	CS	CC1=C2[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC[C@]2(CCC1=C)C(=O)O)C)C)(C)C)O)C
DMKL59W	IK	DZVARQVBYAEZFI-JZQYXDLISA-N
DMKL59W	IU	(4aS,6aR,6aR,6bR,8aR,10S,12aR,14aS)-10-hydroxy-1,6a,6b,9,9,12a-hexamethyl-2-methylidene-3,4,5,6,6a,7,8,8a,10,11,12,13,14,14a-tetradecahydropicene-4a-carboxylic acid
DMKL59W	DE	Discovery agent

DM6NFO0	ID	DM6NFO0
DM6NFO0	DN	3beta-hydroxyurs-12-en-27-oic acid
DM6NFO0	HS	Investigative
DM6NFO0	SN	CHEMBL380467; 3beta-hydroxyurs-12-en-27-oic acid
DM6NFO0	DT	Small molecular drug
DM6NFO0	PC	179431
DM6NFO0	MW	456.7
DM6NFO0	FM	C30H48O3
DM6NFO0	IC	InChI=1S/C30H48O3/c1-18-10-13-27(5)16-17-30(25(32)33)20(24(27)19(18)2)8-9-22-28(6)14-12-23(31)26(3,4)21(28)11-15-29(22,30)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21?,22-,23+,24-,27-,28+,29-,30-/m1/s1
DM6NFO0	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@H]2[C@H]1C)C(=O)O)C
DM6NFO0	IK	RXVRYAUOTRSYDU-RKQWDYETSA-N
DM6NFO0	IU	(1S,2R,4aR,6aR,6aR,6bR,10S,12aR,14bS)-10-hydroxy-1,2,4a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-6a-carboxylic acid
DM6NFO0	CA	CAS 24778-49-2
DM6NFO0	DE	Discovery agent

DMZ8WMA	ID	DMZ8WMA
DMZ8WMA	DN	3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol
DMZ8WMA	HS	Investigative
DMZ8WMA	SN	1,2-benzenediol,3-bicyclo[2.2.1]hept-2-yl-; 462606-73-1; AC1MXF8P; 3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol; Oprea1_604715; GTPL2569; CTK8I7953; AKOS027407656; KB-148826; 3-(3-bicyclo[2.2.1]heptanyl)benzene-1,2-diol
DMZ8WMA	DT	Small molecular drug
DMZ8WMA	PC	3764681
DMZ8WMA	MW	204.26
DMZ8WMA	FM	C13H16O2
DMZ8WMA	IC	InChI=1S/C13H16O2/c14-12-3-1-2-10(13(12)15)11-7-8-4-5-9(11)6-8/h1-3,8-9,11,14-15H,4-7H2
DMZ8WMA	CS	C1CC2CC1CC2C3=C(C(=CC=C3)O)O
DMZ8WMA	IK	DWWJNUSFHLSDSW-UHFFFAOYSA-N
DMZ8WMA	IU	3-(2-bicyclo[2.2.1]heptanyl)benzene-1,2-diol
DMZ8WMA	DE	Discovery agent

DMHSAOQ	ID	DMHSAOQ
DMHSAOQ	DN	3-Biphenyl-3-yl-N-hydroxy-N-methyl-acrylamide
DMHSAOQ	HS	Investigative
DMHSAOQ	SN	CHEMBL177549; 3-Biphenyl-3-yl-N-hydroxy-N-methyl-acrylamide; SCHEMBL10876301; BDBM50015161; (E)-3-[3-Phenylphenyl]-N-methyl-2-propenehydroxamic acid
DMHSAOQ	DT	Small molecular drug
DMHSAOQ	PC	13746841
DMHSAOQ	MW	253.29
DMHSAOQ	FM	C16H15NO2
DMHSAOQ	IC	InChI=1S/C16H15NO2/c1-17(19)16(18)11-10-13-6-5-9-15(12-13)14-7-3-2-4-8-14/h2-12,19H,1H3/b11-10+
DMHSAOQ	CS	CN(C(=O)/C=C/C1=CC(=CC=C1)C2=CC=CC=C2)O
DMHSAOQ	IK	CXMSWAWAJRLYBE-ZHACJKMWSA-N
DMHSAOQ	IU	(E)-N-hydroxy-N-methyl-3-(3-phenylphenyl)prop-2-enamide
DMHSAOQ	DE	Discovery agent

DMMC2Q9	ID	DMMC2Q9
DMMC2Q9	DN	3-biphenyl-4-ylethynyl-5-methyl-[1,2,4]triazine
DMMC2Q9	HS	Investigative
DMMC2Q9	SN	CHEMBL226831; 3-biphenyl-4-ylethynyl-5-methyl-[1,2,4]triazine
DMMC2Q9	DT	Small molecular drug
DMMC2Q9	PC	16735659
DMMC2Q9	MW	271.3
DMMC2Q9	FM	C18H13N3
DMMC2Q9	IC	InChI=1S/C18H13N3/c1-14-13-19-21-18(20-14)12-9-15-7-10-17(11-8-15)16-5-3-2-4-6-16/h2-8,10-11,13H,1H3
DMMC2Q9	CS	CC1=CN=NC(=N1)C#CC2=CC=C(C=C2)C3=CC=CC=C3
DMMC2Q9	IK	OXVAGVMMJCNKRK-UHFFFAOYSA-N
DMMC2Q9	IU	5-methyl-3-[2-(4-phenylphenyl)ethynyl]-1,2,4-triazine
DMMC2Q9	DE	Discovery agent

DMKBRIM	ID	DMKBRIM
DMKBRIM	DN	3-Biphenyl-4-yl-N-hydroxy-N-methyl-acrylamide
DMKBRIM	HS	Investigative
DMKBRIM	SN	CHEMBL178053; 3-Biphenyl-4-yl-N-hydroxy-N-methyl-acrylamide; ZINC28103871; BDBM50015167; (E)-3-[4-Phenylphenyl]-N-methyl-2-propenehydroxamic acid
DMKBRIM	DT	Small molecular drug
DMKBRIM	PC	13746840
DMKBRIM	MW	253.29
DMKBRIM	FM	C16H15NO2
DMKBRIM	IC	InChI=1S/C16H15NO2/c1-17(19)16(18)12-9-13-7-10-15(11-8-13)14-5-3-2-4-6-14/h2-12,19H,1H3/b12-9+
DMKBRIM	CS	CN(C(=O)/C=C/C1=CC=C(C=C1)C2=CC=CC=C2)O
DMKBRIM	IK	TUEHLNCQVBWQNV-FMIVXFBMSA-N
DMKBRIM	IU	(E)-N-hydroxy-N-methyl-3-(4-phenylphenyl)prop-2-enamide
DMKBRIM	DE	Discovery agent

DMRCJW0	ID	DMRCJW0
DMRCJW0	DN	3-boronobenzoic acid
DMRCJW0	HS	Investigative
DMRCJW0	SN	3-Carboxyphenylboronic acid; 25487-66-5; 3-Boronobenzoic acid; 3-(dihydroxyboranyl)benzoic acid; 3-Carboxybenzeneboronic Acid; m-Carboxyphenylboronic acid; Benzoic acid, 3-borono-; 3-(dihydroxyborane)benzoic acid; 3-Carboxyphenylboronicacid; 3-(DIHYDROXYBORYL)BENZOIC ACID; 3-phenyl ester boronic acid; 3-carboxy-phenyl-boronic acid; (3-carboxyphenyl)boronic acid; CHEMBL421765; MFCD00036833; 3-Carboxyphenylboronic acid, 97%; zlchem 425; PubChem1773; 3-borono-benzoic acid; ACMC-1CMDG; 3-carboxyphenyboronic acid; AC1MC01N
DMRCJW0	DT	Small molecular drug
DMRCJW0	PC	2733957
DMRCJW0	MW	165.94
DMRCJW0	FM	C7H7BO4
DMRCJW0	IC	InChI=1S/C7H7BO4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4,11-12H,(H,9,10)
DMRCJW0	CS	B(C1=CC(=CC=C1)C(=O)O)(O)O
DMRCJW0	IK	DBVFWZMQJQMJCB-UHFFFAOYSA-N
DMRCJW0	IU	3-boronobenzoic acid
DMRCJW0	CA	CAS 25487-66-5
DMRCJW0	DE	Discovery agent

DM03ROH	ID	DM03ROH
DM03ROH	DN	3-bromo-1-(4-hexylphenyl)propan-1-one
DM03ROH	HS	Investigative
DM03ROH	SN	beta-bromo ketone, 8e; 3-bromo-1-(4-hexylphenyl)propan-1-one; CHEMBL395602; BDBM18857; ZINC14969063
DM03ROH	DT	Small molecular drug
DM03ROH	PC	23635858
DM03ROH	MW	297.23
DM03ROH	FM	C15H21BrO
DM03ROH	IC	InChI=1S/C15H21BrO/c1-2-3-4-5-6-13-7-9-14(10-8-13)15(17)11-12-16/h7-10H,2-6,11-12H2,1H3
DM03ROH	CS	CCCCCCC1=CC=C(C=C1)C(=O)CCBr
DM03ROH	IK	IKJXBCMGQCDIDG-UHFFFAOYSA-N
DM03ROH	IU	3-bromo-1-(4-hexylphenyl)propan-1-one
DM03ROH	DE	Discovery agent

DMZGWL2	ID	DMZGWL2
DMZGWL2	DN	3-Bromo-1H-indazole-7-carbonitrile
DMZGWL2	HS	Investigative
DMZGWL2	SN	3-Bromo-1H-indazole-7-carbonitrile; 945762-00-5; CHEMBL451541; 1H-Indazole-7-carbonitrile,3-bromo-; AK-27881; CTK8B8302; KS-00000HFF; DTXSID00659577; MolPort-009-197-290; 3-bromo-2H-indazole-7-carbonitrile; ZINC40448363; BDBM50270530; ANW-59984; AKOS015898261; FCH1406736; VI20021; RP05214; SC-35603; QC-11297; KB-70485; DS-11111; CJ-20125; TC-148729; ST2417498; AX8158454; AB0037522; AJ-102668; AJ-102669; FT-0646755; Y4808; 4CH-016057; A15929; J-511797
DMZGWL2	DT	Small molecular drug
DMZGWL2	PC	44585510
DMZGWL2	MW	222.04
DMZGWL2	FM	C8H4BrN3
DMZGWL2	IC	InChI=1S/C8H4BrN3/c9-8-6-3-1-2-5(4-10)7(6)11-12-8/h1-3H,(H,11,12)
DMZGWL2	CS	C1=CC2=C(NN=C2C(=C1)C#N)Br
DMZGWL2	IK	MRGZUAUMTMLMTE-UHFFFAOYSA-N
DMZGWL2	IU	3-bromo-2H-indazole-7-carbonitrile
DMZGWL2	CA	CAS 945762-00-5
DMZGWL2	DE	Discovery agent

DM1BALV	ID	DM1BALV
DM1BALV	DN	3-Bromo-2'-hydroxy-4-methoxychalcone
DM1BALV	HS	Investigative
DM1BALV	SN	AC1ORO2M; CHEMBL492941; MolPort-000-648-211; ZINC5549056; STL192121; AKOS025268524; (E)-3-(3-bromo-4-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
DM1BALV	DT	Small molecular drug
DM1BALV	PC	7729032
DM1BALV	MW	333.18
DM1BALV	FM	C16H13BrO3
DM1BALV	IC	InChI=1S/C16H13BrO3/c1-20-16-9-7-11(10-13(16)17)6-8-15(19)12-4-2-3-5-14(12)18/h2-10,18H,1H3/b8-6+
DM1BALV	CS	COC1=C(C=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O)Br
DM1BALV	IK	KXSKRIQLDQIBNJ-SOFGYWHQSA-N
DM1BALV	IU	(E)-3-(3-bromo-4-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
DM1BALV	DE	Discovery agent

DMPZ4M8	ID	DMPZ4M8
DMPZ4M8	DN	3-bromo-4,4',5-trimethoxy-(Z)-stilbene
DMPZ4M8	HS	Investigative
DMPZ4M8	SN	SCHEMBL4219422; CHEMBL424885
DMPZ4M8	DT	Small molecular drug
DMPZ4M8	PC	16090832
DMPZ4M8	MW	349.2
DMPZ4M8	FM	C17H17BrO3
DMPZ4M8	IC	InChI=1S/C17H17BrO3/c1-19-14-8-6-12(7-9-14)4-5-13-10-15(18)17(21-3)16(11-13)20-2/h4-11H,1-3H3/b5-4-
DMPZ4M8	CS	COC1=CC=C(C=C1)/C=C\\C2=CC(=C(C(=C2)Br)OC)OC
DMPZ4M8	IK	HORVHXITWDPZBG-PLNGDYQASA-N
DMPZ4M8	IU	1-bromo-2,3-dimethoxy-5-[(Z)-2-(4-methoxyphenyl)ethenyl]benzene
DMPZ4M8	DE	Discovery agent

DMPQOS2	ID	DMPQOS2
DMPQOS2	DN	3-bromo-5-(2-methylquinolin-7-yl)benzonitrile
DMPQOS2	HS	Investigative
DMPQOS2	SN	CHEMBL396177; 3-bromo-5-(2-methylquinolin-7-yl)benzonitrile
DMPQOS2	DT	Small molecular drug
DMPQOS2	PC	44432681
DMPQOS2	MW	323.2
DMPQOS2	FM	C17H11BrN2
DMPQOS2	IC	InChI=1S/C17H11BrN2/c1-11-2-3-13-4-5-14(9-17(13)20-11)15-6-12(10-19)7-16(18)8-15/h2-9H,1H3
DMPQOS2	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)Br
DMPQOS2	IK	UCLWCGCRIQDNMD-UHFFFAOYSA-N
DMPQOS2	IU	3-bromo-5-(2-methylquinolin-7-yl)benzonitrile
DMPQOS2	DE	Discovery agent

DMOXY78	ID	DMOXY78
DMOXY78	DN	3-bromo-5-[(2-methyl-4-thiazolyl)ethynyl]pyridine
DMOXY78	HS	Investigative
DMOXY78	SN	3-bromo-5-[(2-methyl-4-thiazolyl)ethynyl]pyridine; CHEMBL202116; 329204-97-9; SCHEMBL4144716; SLLMZMSYBFFSLX-UHFFFAOYSA-N; BDBM50181777; 2-Methyl-4-(5-bromo-3-pyridylethynyl)thiazole
DMOXY78	DT	Small molecular drug
DMOXY78	PC	11701860
DMOXY78	MW	279.16
DMOXY78	FM	C11H7BrN2S
DMOXY78	IC	InChI=1S/C11H7BrN2S/c1-8-14-11(7-15-8)3-2-9-4-10(12)6-13-5-9/h4-7H,1H3
DMOXY78	CS	CC1=NC(=CS1)C#CC2=CC(=CN=C2)Br
DMOXY78	IK	SLLMZMSYBFFSLX-UHFFFAOYSA-N
DMOXY78	IU	4-[2-(5-bromopyridin-3-yl)ethynyl]-2-methyl-1,3-thiazole
DMOXY78	DE	Discovery agent

DMZTDCL	ID	DMZTDCL
DMZTDCL	DN	3-Bromo-5-phenylsalicylc acid
DMZTDCL	HS	Investigative
DMZTDCL	SN	4906-68-7; CHEMBL387536; 3-bromo-5-phenylsalicylic acid; 3-bromo-5-phenylsalicyclic acid; 5-bromo-4-hydroxybiphenyl-3-carboxylic acid; 5-Bromo-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3-bromo-2-hydroxy-5-phenylbenzoic acid; 3-Bromo-5-phenylsalicylc acid; NSC109116; [1,1'-biphenyl]-3-carboxylic acid, 5-bromo-4-hydroxy-; AC1L6KWF; AC1Q25S5; SCHEMBL18319714; KS-00002WWQ; CTK1D8664; 3-bromo-5-phenyl-Salicylic Acid; DTXSID70296397; MolPort-018-496-593; XVZSXNULHSIRCQ-UHFFFAOYSA-N; ZINC1701218; BDBM50219490; AKOS005151372
DMZTDCL	DT	Small molecular drug
DMZTDCL	PC	268734
DMZTDCL	MW	293.11
DMZTDCL	FM	C13H9BrO3
DMZTDCL	IC	InChI=1S/C13H9BrO3/c14-11-7-9(8-4-2-1-3-5-8)6-10(12(11)15)13(16)17/h1-7,15H,(H,16,17)
DMZTDCL	CS	C1=CC=C(C=C1)C2=CC(=C(C(=C2)Br)O)C(=O)O
DMZTDCL	IK	XVZSXNULHSIRCQ-UHFFFAOYSA-N
DMZTDCL	IU	3-bromo-2-hydroxy-5-phenylbenzoic acid
DMZTDCL	CA	CAS 4906-68-7
DMZTDCL	DE	Discovery agent

DMXZB5C	ID	DMXZB5C
DMXZB5C	DN	3-Bromo-6-nitro-2-piperazin-1-yl-quinoline
DMXZB5C	HS	Investigative
DMXZB5C	SN	CHEMBL290523; 3-bromo-6-nitro-2-piperazin-1-yl-quinoline; SCHEMBL6365221; MPHPQAKQQDLIGK-UHFFFAOYSA-N; BDBM50090214; 2-Piperazino-3-bromo-6-nitroquinoline
DMXZB5C	DT	Small molecular drug
DMXZB5C	PC	10246440
DMXZB5C	MW	337.17
DMXZB5C	FM	C13H13BrN4O2
DMXZB5C	IC	InChI=1S/C13H13BrN4O2/c14-11-8-9-7-10(18(19)20)1-2-12(9)16-13(11)17-5-3-15-4-6-17/h1-2,7-8,15H,3-6H2
DMXZB5C	CS	C1CN(CCN1)C2=C(C=C3C=C(C=CC3=N2)[N+](=O)[O-])Br
DMXZB5C	IK	MPHPQAKQQDLIGK-UHFFFAOYSA-N
DMXZB5C	IU	3-bromo-6-nitro-2-piperazin-1-ylquinoline
DMXZB5C	DE	Discovery agent

DMM7DHB	ID	DMM7DHB
DMM7DHB	DN	3-bromo-7-nitro-1H-indazole
DMM7DHB	HS	Investigative
DMM7DHB	SN	3-Bromo-7-nitroindazole; 3-Bromo-7-nitro-1H-indazole; 3-bromo-7-nitroindazole; 74209-34-0; 1H-Indazole,3-bromo-7-nitro-; 3-bromo-7-nitro-2H-indazole; CHEMBL479014; NFSTZPMYAZRZPC-UHFFFAOYSA-N; MFCD00159910; AK-27879; SR-01000075708; 3-bromo-7NI; Tocris-0735; 3-Br-7-Nitroindazole; AC1L1BXC; Lopac-B-2050; 3-Br-7NI; Lopac0_000161; BSPBio_002434; BSPBio_001502; KBioGR_000222; KBioSS_000222; SPECTRUM1505105; SCHEMBL499422; SCHEMBL499421; GTPL5113; KBio3_000444; KBio3_000443; KBio2_002790; CTK5D9545; BCBcMAP01_000129; KBio2_005358; KBio2_000222; DTXSID90274319; OR6862T; 3-Bromo-7-Nitroindazole
DMM7DHB	DT	Small molecular drug
DMM7DHB	PC	1649
DMM7DHB	MW	242.03
DMM7DHB	FM	C7H4BrN3O2
DMM7DHB	IC	InChI=1S/C7H4BrN3O2/c8-7-4-2-1-3-5(11(12)13)6(4)9-10-7/h1-3H,(H,9,10)
DMM7DHB	CS	C1=CC2=C(NN=C2C(=C1)[N+](=O)[O-])Br
DMM7DHB	IK	NFSTZPMYAZRZPC-UHFFFAOYSA-N
DMM7DHB	IU	3-bromo-7-nitro-2H-indazole
DMM7DHB	CA	CAS 74209-34-0
DMM7DHB	DE	Discovery agent

DMPF7O2	ID	DMPF7O2
DMPF7O2	DN	3-bromoboldine
DMPF7O2	HS	Investigative
DMPF7O2	SN	3-bromoboldine; CHEMBL225853; BDBM50202340
DMPF7O2	DT	Small molecular drug
DMPF7O2	PC	10409038
DMPF7O2	MW	406.3
DMPF7O2	FM	C19H20BrNO4
DMPF7O2	IC	InChI=1S/C19H20BrNO4/c1-21-5-4-10-15-12(21)6-9-7-13(22)14(24-2)8-11(9)16(15)19(25-3)18(23)17(10)20/h7-8,12,22-23H,4-6H2,1-3H3/t12-/m0/s1
DMPF7O2	CS	CN1CCC2=C3[C@@H]1CC4=CC(=C(C=C4C3=C(C(=C2Br)O)OC)OC)O
DMPF7O2	IK	ORZPHDSNVICTTE-LBPRGKRZSA-N
DMPF7O2	IU	(6aS)-3-bromo-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DMPF7O2	DE	Discovery agent

DM62Y1S	ID	DM62Y1S
DM62Y1S	DN	3-bromo-N-(6-methylpyridin-2-yl)benzamide
DM62Y1S	HS	Investigative
DM62Y1S	SN	3-bromo-N-(6-methylpyridin-2-yl)benzamide; CHEMBL377195; 188747-28-6; AC1LCNCE; TimTec1_002275; Oprea1_606042; CTK0A3803; DTXSID30345279; MolPort-002-316-872; BOCBDQIZNZCOPX-UHFFFAOYSA-N; HMS1540H09; ZINC138486; STK182187; BDBM50186324; AKOS000204447; MCULE-1961959863; ST031112; 3-bromo-N~1~-(6-methyl-2-pyridyl)benzamide; 3-Bromo-N-(6-methyl-pyridin-2-yl)-benzamide; 3-Bromo-N-(6-methyl-2-pyridinyl)benzamide #; Benzamide, 3-bromo-N-(6-methyl-2-pyridinyl)-; Z57716131; (3-bromophenyl)-N-(6-methyl(2-pyridyl))carboxamide
DM62Y1S	DT	Small molecular drug
DM62Y1S	PC	603306
DM62Y1S	MW	291.14
DM62Y1S	FM	C13H11BrN2O
DM62Y1S	IC	InChI=1S/C13H11BrN2O/c1-9-4-2-7-12(15-9)16-13(17)10-5-3-6-11(14)8-10/h2-8H,1H3,(H,15,16,17)
DM62Y1S	CS	CC1=NC(=CC=C1)NC(=O)C2=CC(=CC=C2)Br
DM62Y1S	IK	BOCBDQIZNZCOPX-UHFFFAOYSA-N
DM62Y1S	IU	3-bromo-N-(6-methylpyridin-2-yl)benzamide
DM62Y1S	CA	CAS 188747-28-6
DM62Y1S	DE	Discovery agent

DMXZW3R	ID	DMXZW3R
DMXZW3R	DN	3-bromophenyl-difluoromethanesulfonamide
DMXZW3R	HS	Investigative
DMXZW3R	SN	3-bromophenyl-difluoromethanesulfonamide; CHEMBL200673; BDBM50175006
DMXZW3R	DT	Small molecular drug
DMXZW3R	PC	11687831
DMXZW3R	MW	286.1
DMXZW3R	FM	C7H6BrF2NO2S
DMXZW3R	IC	InChI=1S/C7H6BrF2NO2S/c8-6-3-1-2-5(4-6)7(9,10)14(11,12)13/h1-4H,(H2,11,12,13)
DMXZW3R	CS	C1=CC(=CC(=C1)Br)C(F)(F)S(=O)(=O)N
DMXZW3R	IK	RXNVOIIGCVXUGN-UHFFFAOYSA-N
DMXZW3R	IU	(3-bromophenyl)-difluoromethanesulfonamide
DMXZW3R	DE	Discovery agent

DMK7D8N	ID	DMK7D8N
DMK7D8N	DN	3'-bromopropiophenonethiosemicarbazone
DMK7D8N	HS	Investigative
DMK7D8N	SN	CHEMBL313679; (1E)-1-(3-bromophenyl)propan-1-one thiosemicarbazone; 3'-bromopropiophenonethiosemicarbazone; SCHEMBL6338417; BDBM50114613; 3'-Bromopropiophenone Thiosemicarbazone
DMK7D8N	DT	Small molecular drug
DMK7D8N	PC	10356636
DMK7D8N	MW	286.19
DMK7D8N	FM	C10H12BrN3S
DMK7D8N	IC	InChI=1S/C10H12BrN3S/c1-2-9(13-14-10(12)15)7-4-3-5-8(11)6-7/h3-6H,2H2,1H3,(H3,12,14,15)/b13-9+
DMK7D8N	CS	CC/C(=N\\NC(=S)N)/C1=CC(=CC=C1)Br
DMK7D8N	IK	WBIKZQWGHHXZTG-UKTHLTGXSA-N
DMK7D8N	IU	[(E)-1-(3-bromophenyl)propylideneamino]thiourea
DMK7D8N	DE	Discovery agent

DMYL3ST	ID	DMYL3ST
DMYL3ST	DN	3-bromopyruvate
DMYL3ST	HS	Investigative
DMYL3ST	SN	bromopyruvate; 3-bromo-2-oxopropanoate; AC1ODWIN; 3-bromo-2-oxo-propionate; GTPL4517; CHEBI:131592; PRRZDZJYSJLDBS-UHFFFAOYSA-M
DMYL3ST	DT	Small molecular drug
DMYL3ST	PC	6994776
DMYL3ST	MW	165.95
DMYL3ST	FM	C3H2BrO3-
DMYL3ST	IC	InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)/p-1
DMYL3ST	CS	C(C(=O)C(=O)[O-])Br
DMYL3ST	IK	PRRZDZJYSJLDBS-UHFFFAOYSA-M
DMYL3ST	IU	3-bromo-2-oxopropanoate
DMYL3ST	CA	CAS 68-38-2
DMYL3ST	CB	CHEBI:131592
DMYL3ST	DE	Discovery agent

DMQ8H74	ID	DMQ8H74
DMQ8H74	DN	3-Butoxy-9H-beta-carboline
DMQ8H74	HS	Investigative
DMQ8H74	SN	CHEMBL66902; 3-butoxy-9H-pyrido[3,4-b]indole; AC1NFSYC; 3-Butoxy-beta-carboline; CHEMBL458012; SCHEMBL10644773; ZINC6869004
DMQ8H74	DT	Small molecular drug
DMQ8H74	PC	4713436
DMQ8H74	MW	240.3
DMQ8H74	FM	C15H16N2O
DMQ8H74	IC	InChI=1S/C15H16N2O/c1-2-3-8-18-15-9-12-11-6-4-5-7-13(11)17-14(12)10-16-15/h4-7,9-10,17H,2-3,8H2,1H3
DMQ8H74	CS	CCCCOC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMQ8H74	IK	UARMCWOWRLFTFP-UHFFFAOYSA-N
DMQ8H74	IU	3-butoxy-9H-pyrido[3,4-b]indole
DMQ8H74	DE	Discovery agent

DMRF2Q8	ID	DMRF2Q8
DMRF2Q8	DN	3-butoxycarbonyl-4-quinolone
DMRF2Q8	HS	Investigative
DMRF2Q8	SN	CHEMBL205456; AKOS017354707; 4-Hydroxyquinoline-3-carboxylic acid butyl ester
DMRF2Q8	DT	Small molecular drug
DMRF2Q8	PC	11630136
DMRF2Q8	MW	245.27
DMRF2Q8	FM	C14H15NO3
DMRF2Q8	IC	InChI=1S/C14H15NO3/c1-2-3-8-18-14(17)11-9-15-12-7-5-4-6-10(12)13(11)16/h4-7,9H,2-3,8H2,1H3,(H,15,16)
DMRF2Q8	CS	CCCCOC(=O)C1=CNC2=CC=CC=C2C1=O
DMRF2Q8	IK	LKWHYYPRQAIKDW-UHFFFAOYSA-N
DMRF2Q8	IU	butyl 4-oxo-1H-quinoline-3-carboxylate
DMRF2Q8	DE	Discovery agent

DMD6PMZ	ID	DMD6PMZ
DMD6PMZ	DN	3-butoxycarbonyl-6-ethyl-4-quinolone
DMD6PMZ	HS	Investigative
DMD6PMZ	SN	CHEMBL206591
DMD6PMZ	DT	Small molecular drug
DMD6PMZ	PC	11587151
DMD6PMZ	MW	273.33
DMD6PMZ	FM	C16H19NO3
DMD6PMZ	IC	InChI=1S/C16H19NO3/c1-3-5-8-20-16(19)13-10-17-14-7-6-11(4-2)9-12(14)15(13)18/h6-7,9-10H,3-5,8H2,1-2H3,(H,17,18)
DMD6PMZ	CS	CCCCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DMD6PMZ	IK	CJTBJWFADVNZQZ-UHFFFAOYSA-N
DMD6PMZ	IU	butyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMD6PMZ	DE	Discovery agent

DMRI503	ID	DMRI503
DMRI503	DN	3-Butyl-[1,4]oxazepan-(5Z)-ylideneamine
DMRI503	HS	Investigative
DMRI503	SN	CHEMBL89282; 3-Butyl-[1,4]oxazepan-(5Z)-ylideneamine; SCHEMBL8550109; BDBM50104656
DMRI503	DT	Small molecular drug
DMRI503	PC	44322997
DMRI503	MW	170.25
DMRI503	FM	C9H18N2O
DMRI503	IC	InChI=1S/C9H18N2O/c1-2-3-4-8-7-12-6-5-9(10)11-8/h8H,2-7H2,1H3,(H2,10,11)
DMRI503	CS	CCCCC1COCCC(=N1)N
DMRI503	IK	YXURWRQCUHZROM-UHFFFAOYSA-N
DMRI503	IU	3-butyl-2,3,6,7-tetrahydro-1,4-oxazepin-5-amine
DMRI503	DE	Discovery agent

DM6A80U	ID	DM6A80U
DM6A80U	DN	3-Butyl-[1,4]thiazepan-(5E)-ylideneamine
DM6A80U	HS	Investigative
DM6A80U	SN	CHEMBL186091; 3-Butyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7679025
DM6A80U	DT	Small molecular drug
DM6A80U	PC	22617750
DM6A80U	MW	186.32
DM6A80U	FM	C9H18N2S
DM6A80U	IC	InChI=1S/C9H18N2S/c1-2-3-4-8-7-12-6-5-9(10)11-8/h8H,2-7H2,1H3,(H2,10,11)
DM6A80U	CS	CCCCC1CSCCC(=N1)N
DM6A80U	IK	FGUKFZPUKNZRSR-UHFFFAOYSA-N
DM6A80U	IU	3-butyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DM6A80U	DE	Discovery agent

DMXF8M0	ID	DMXF8M0
DMXF8M0	DN	3-butyl-1-(naphthalen-1-yl)piperidin-4-amine
DMXF8M0	HS	Investigative
DMXF8M0	SN	CHEMBL234615; 3-butyl-1-(naphthalen-1-yl)piperidin-4-amine
DMXF8M0	DT	Small molecular drug
DMXF8M0	PC	44431763
DMXF8M0	MW	282.4
DMXF8M0	FM	C19H26N2
DMXF8M0	IC	InChI=1S/C19H26N2/c1-2-3-7-16-14-21(13-12-18(16)20)19-11-6-9-15-8-4-5-10-17(15)19/h4-6,8-11,16,18H,2-3,7,12-14,20H2,1H3
DMXF8M0	CS	CCCCC1CN(CCC1N)C2=CC=CC3=CC=CC=C32
DMXF8M0	IK	CPKGFALQFTVZTA-UHFFFAOYSA-N
DMXF8M0	IU	3-butyl-1-naphthalen-1-ylpiperidin-4-amine
DMXF8M0	DE	Discovery agent

DMDOPVM	ID	DMDOPVM
DMDOPVM	DN	3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol
DMDOPVM	HS	Investigative
DMDOPVM	SN	CHEMBL132112; 3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol; ZINC13728506; BDBM50003343
DMDOPVM	DT	Small molecular drug
DMDOPVM	PC	10376148
DMDOPVM	MW	219.32
DMDOPVM	FM	C14H21NO
DMDOPVM	IC	InChI=1S/C14H21NO/c1-2-3-9-15-10-7-12-5-4-6-14(16)13(12)8-11-15/h4-6,16H,2-3,7-11H2,1H3
DMDOPVM	CS	CCCCN1CCC2=C(CC1)C(=CC=C2)O
DMDOPVM	IK	LLOMAHVTVGHSNN-UHFFFAOYSA-N
DMDOPVM	IU	3-butyl-1,2,4,5-tetrahydro-3-benzazepin-6-ol
DMDOPVM	DE	Discovery agent

DMOGZUK	ID	DMOGZUK
DMOGZUK	DN	3-butyl-3-ethyl-1-phenylazetidine-2,4-dione
DMOGZUK	HS	Investigative
DMOGZUK	SN	CHEMBL566476; 3-butyl-3-ethyl-1-phenylazetidine-2,4-dione; SCHEMBL10952562; BDBM50303373
DMOGZUK	DT	Small molecular drug
DMOGZUK	PC	20283207
DMOGZUK	MW	245.32
DMOGZUK	FM	C15H19NO2
DMOGZUK	IC	InChI=1S/C15H19NO2/c1-3-5-11-15(4-2)13(17)16(14(15)18)12-9-7-6-8-10-12/h6-10H,3-5,11H2,1-2H3
DMOGZUK	CS	CCCCC1(C(=O)N(C1=O)C2=CC=CC=C2)CC
DMOGZUK	IK	OMJBWYRKWVXDDX-UHFFFAOYSA-N
DMOGZUK	IU	3-butyl-3-ethyl-1-phenylazetidine-2,4-dione
DMOGZUK	DE	Discovery agent

DM95XWR	ID	DM95XWR
DM95XWR	DN	3-butylaminocarbonyl-6-ethyl-4-quinolone
DM95XWR	HS	Investigative
DM95XWR	SN	CHEMBL205536
DM95XWR	DT	Small molecular drug
DM95XWR	PC	11673471
DM95XWR	MW	272.34
DM95XWR	FM	C16H20N2O2
DM95XWR	IC	InChI=1S/C16H20N2O2/c1-3-5-8-17-16(20)13-10-18-14-7-6-11(4-2)9-12(14)15(13)19/h6-7,9-10H,3-5,8H2,1-2H3,(H,17,20)(H,18,19)
DM95XWR	CS	CCCCNC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DM95XWR	IK	QHHMSXBSEWIFOB-UHFFFAOYSA-N
DM95XWR	IU	N-butyl-6-ethyl-4-oxo-1H-quinoline-3-carboxamide
DM95XWR	DE	Discovery agent

DMP6TLY	ID	DMP6TLY
DMP6TLY	DN	3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid
DMP6TLY	HS	Investigative
DMP6TLY	SN	CHEMBL42415; 3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid; BDBM50280277; 6-Chloro-3-carbamoyl-1H-indole-2-carboxylic acid
DMP6TLY	DT	Small molecular drug
DMP6TLY	PC	44289108
DMP6TLY	MW	238.63
DMP6TLY	FM	C10H7ClN2O3
DMP6TLY	IC	InChI=1S/C10H7ClN2O3/c11-4-1-2-5-6(3-4)13-8(10(15)16)7(5)9(12)14/h1-3,13H,(H2,12,14)(H,15,16)
DMP6TLY	CS	C1=CC2=C(C=C1Cl)NC(=C2C(=O)N)C(=O)O
DMP6TLY	IK	UVIJBMMICWJDAD-UHFFFAOYSA-N
DMP6TLY	IU	3-carbamoyl-6-chloro-1H-indole-2-carboxylic acid
DMP6TLY	DE	Discovery agent

DM530OW	ID	DM530OW
DM530OW	DN	3'-carbamoylbiphenyl-3-yl 6-phenylhexylcarbamate
DM530OW	HS	Investigative
DM530OW	SN	CHEMBL451909; 887264-44-0; C26H28N2O3; JP83; MolPort-009-019-196; HMS3650I04; BDBM50275301; 1384AH; ZINC27646193; AKOS027282688; 3'-Carbamoyl-biphenyl-3-yl-hexylphenylcarbamate; SR-01000946289; 3''-carbamoylbiphenyl-3-yl 6-phenylhexylcarbamate
DM530OW	DT	Small molecular drug
DM530OW	PC	35027739
DM530OW	MW	416.5
DM530OW	FM	C26H28N2O3
DM530OW	IC	InChI=1S/C26H28N2O3/c27-25(29)23-15-8-13-21(18-23)22-14-9-16-24(19-22)31-26(30)28-17-7-2-1-4-10-20-11-5-3-6-12-20/h3,5-6,8-9,11-16,18-19H,1-2,4,7,10,17H2,(H2,27,29)(H,28,30)
DM530OW	CS	C1=CC=C(C=C1)CCCCCCNC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N
DM530OW	IK	JMLPLSJWSHVJLP-UHFFFAOYSA-N
DM530OW	IU	[3-(3-carbamoylphenyl)phenyl] N-(6-phenylhexyl)carbamate
DM530OW	DE	Discovery agent

DMHUBT5	ID	DMHUBT5
DMHUBT5	DN	3-Carbazol-9-yl-propionic acid
DMHUBT5	HS	Investigative
DMHUBT5	SN	6622-54-4; 3-(9H-carbazol-9-yl)propanoic acid; 3-carbazol-9-ylpropanoic acid; CHEMBL184817; Carbazole-9-propionic acid; NSC400; Carbazol-N-propionsaure; AC1Q75LO; AC1Q5WE7; TimTec1_004366; Oprea1_037143; Oprea1_183633; SCHEMBL150033; 9H-Carbazole-9-propionic acid; AC1L56H9; DTXSID30277021; 3-(carbazol-9-yl)propanoic acid; NSC-400; MolPort-000-474-043; 3-(Carbazol-9-yl)propionic acid; HMS1546G10; NSC54636; ZINC1841595; STK387004; BDBM50152856; 7615AE; BBL007862; SBB010078
DMHUBT5	DT	Small molecular drug
DMHUBT5	PC	219301
DMHUBT5	MW	239.27
DMHUBT5	FM	C15H13NO2
DMHUBT5	IC	InChI=1S/C15H13NO2/c17-15(18)9-10-16-13-7-3-1-5-11(13)12-6-2-4-8-14(12)16/h1-8H,9-10H2,(H,17,18)
DMHUBT5	CS	C1=CC=C2C(=C1)C3=CC=CC=C3N2CCC(=O)O
DMHUBT5	IK	ZAJJJOMMWPVJMH-UHFFFAOYSA-N
DMHUBT5	IU	3-carbazol-9-ylpropanoic acid
DMHUBT5	CA	CAS 6622-54-4
DMHUBT5	DE	Discovery agent

DMRUX93	ID	DMRUX93
DMRUX93	DN	3-carboxy-6-ethyl-4-quinolone
DMRUX93	HS	Investigative
DMRUX93	SN	6-ethyl-4-hydroxyquinoline-3-carboxylic acid; 6-Ethyl-4-hydroxy-quinoline-3-carboxylic acid; 103802-41-1; 35128-00-8; 111185-85-4; BAS 02168017; CBMicro_031482; AC1LF0Z6; Cambridge id 6145909; Oprea1_555463; Oprea1_768752; SCHEMBL396402; CHEMBL206122; 3-Quinolinecarboxylic acid, 6-ethyl-1,4-dihydro-4-oxo-; SCHEMBL10032038; CTK6D1895; CTK8F7130; DTXSID70352225; MolPort-000-653-081; MolPort-015-116-184; ZINC3677328; STL229952; 1251AE; SBB015438; AKOS000273237; AKOS009582526; CCG-108136; AB11572; MCULE-1628369792; OR309458
DMRUX93	DT	Small molecular drug
DMRUX93	PC	721200
DMRUX93	MW	217.22
DMRUX93	FM	C12H11NO3
DMRUX93	IC	InChI=1S/C12H11NO3/c1-2-7-3-4-10-8(5-7)11(14)9(6-13-10)12(15)16/h3-6H,2H2,1H3,(H,13,14)(H,15,16)
DMRUX93	CS	CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)O
DMRUX93	IK	RESVKOSPFKHQBK-UHFFFAOYSA-N
DMRUX93	IU	6-ethyl-4-oxo-1H-quinoline-3-carboxylic acid
DMRUX93	CA	CAS 103802-41-1
DMRUX93	DE	Discovery agent

DM9OGNE	ID	DM9OGNE
DM9OGNE	DN	3-chloro-1-(4-hydroxyphenyl)propan-1-one
DM9OGNE	HS	Investigative
DM9OGNE	SN	3-chloro-1-(4-hydroxyphenyl)propan-1-one; 7182-38-9; 3-Chloro-4'-hydroxypropiophenone; CHEMBL500579; NSC46501; AC1Q5ECM; SCHEMBL2392675; AC1L650T; CTK5D5119; DTXSID20286561; QRXBKSZGQHXBDO-UHFFFAOYSA-N; MolPort-022-892-113; ZINC1678195; BDBM50255245; NSC-46501; AKOS022516648; KS-000009D4; SY028371; CS-11693; 1-Propanone,3-chloro-1-(4-hydroxyphenyl)-; MFCD18393259 (97%); 3-Chloro-4 inverted exclamation mark -hydroxypropiophenone
DM9OGNE	DT	Small molecular drug
DM9OGNE	PC	240358
DM9OGNE	MW	184.62
DM9OGNE	FM	C9H9ClO2
DM9OGNE	IC	InChI=1S/C9H9ClO2/c10-6-5-9(12)7-1-3-8(11)4-2-7/h1-4,11H,5-6H2
DM9OGNE	CS	C1=CC(=CC=C1C(=O)CCCl)O
DM9OGNE	IK	QRXBKSZGQHXBDO-UHFFFAOYSA-N
DM9OGNE	IU	3-chloro-1-(4-hydroxyphenyl)propan-1-one
DM9OGNE	CA	CAS 7182-38-9
DM9OGNE	DE	Discovery agent

DM3R8OM	ID	DM3R8OM
DM3R8OM	DN	3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
DM3R8OM	HS	Investigative
DM3R8OM	SN	3-chloro-2-(4-hydroxyphenyl)-2H-indazol-5-ol; 848142-62-1; 3-chloro-2-(4-hydroxyphenyl)indazol-5-ol; CHEMBL180071; CTK2I5101; DTXSID40463812; Indazole-Cl, &gt; ZINC13609473; AKOS030536245; DB07708; 2-(p-Hydroxyphenyl)-3-chloro-2H-indazole-5-ol; 2H-Indazol-5-ol, 3-chloro-2-(4-hydroxyphenyl)-
DM3R8OM	DT	Small molecular drug
DM3R8OM	PC	11368987
DM3R8OM	MW	260.67
DM3R8OM	FM	C13H9ClN2O2
DM3R8OM	IC	InChI=1S/C13H9ClN2O2/c14-13-11-7-10(18)5-6-12(11)15-16(13)8-1-3-9(17)4-2-8/h1-7,17-18H
DM3R8OM	CS	C1=CC(=CC=C1N2C(=C3C=C(C=CC3=N2)O)Cl)O
DM3R8OM	IK	ZNHQDSBJVFFIAK-UHFFFAOYSA-N
DM3R8OM	IU	3-chloro-2-(4-hydroxyphenyl)indazol-5-ol
DM3R8OM	CA	CAS 848142-62-1
DM3R8OM	DE	Discovery agent

DMZ5JFG	ID	DMZ5JFG
DMZ5JFG	DN	3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide
DMZ5JFG	HS	Investigative
DMZ5JFG	SN	CHEMBL198887; 3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide
DMZ5JFG	DT	Small molecular drug
DMZ5JFG	PC	44405331
DMZ5JFG	MW	298.12
DMZ5JFG	FM	C13H9Cl2NO3
DMZ5JFG	IC	InChI=1S/C13H9Cl2NO3/c14-8-2-4-12(10(17)6-8)19-11-3-1-7(13(16)18)5-9(11)15/h1-6,17H,(H2,16,18)
DMZ5JFG	CS	C1=CC(=C(C=C1C(=O)N)Cl)OC2=C(C=C(C=C2)Cl)O
DMZ5JFG	IK	XMCNGTFAEHHMRY-UHFFFAOYSA-N
DMZ5JFG	IU	3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide
DMZ5JFG	DE	Discovery agent

DMER4U1	ID	DMER4U1
DMER4U1	DN	3-chloro-4-(4-hydroxyphenyl)salicylaldoxime
DMER4U1	HS	Investigative
DMER4U1	DT	Small molecular drug
DMER4U1	PC	91066436
DMER4U1	MW	263.67
DMER4U1	FM	C13H10ClNO3
DMER4U1	IC	InChI=1S/C13H10ClNO3/c14-12-11(8-1-4-10(16)5-2-8)6-3-9(7-15-18)13(12)17/h1-6,16-17H,7H2
DMER4U1	CS	C1=CC(=CC=C1C2=C(C(=C(C=C2)CN=O)O)Cl)O
DMER4U1	IK	CIYDFCOZUPKHFA-UHFFFAOYSA-N
DMER4U1	IU	2-chloro-3-(4-hydroxyphenyl)-6-(nitrosomethyl)phenol
DMER4U1	DE	Discovery agent

DMNQF03	ID	DMNQF03
DMNQF03	DN	3-chloro-4-(o-tolyloxy)benzonitrile
DMNQF03	HS	Investigative
DMNQF03	SN	CHEMBL490955; 3-chloro-4-(o-tolyloxy)benzonitrile; SCHEMBL4168825; BDBM50248505
DMNQF03	DT	Small molecular drug
DMNQF03	PC	11673174
DMNQF03	MW	243.69
DMNQF03	FM	C14H10ClNO
DMNQF03	IC	InChI=1S/C14H10ClNO/c1-10-4-2-3-5-13(10)17-14-7-6-11(9-16)8-12(14)15/h2-8H,1H3
DMNQF03	CS	CC1=CC=CC=C1OC2=C(C=C(C=C2)C#N)Cl
DMNQF03	IK	LMZHFUQMQDTSFO-UHFFFAOYSA-N
DMNQF03	IU	3-chloro-4-(2-methylphenoxy)benzonitrile
DMNQF03	DE	Discovery agent

DM6Z3I8	ID	DM6Z3I8
DM6Z3I8	DN	3-chloro-4-(o-tolylthio)benzonitrile
DM6Z3I8	HS	Investigative
DM6Z3I8	SN	CHEMBL490956; 3-chloro-4-(o-tolylthio)benzonitrile; BDBM50248506
DM6Z3I8	DT	Small molecular drug
DM6Z3I8	PC	44565102
DM6Z3I8	MW	259.8
DM6Z3I8	FM	C14H10ClNS
DM6Z3I8	IC	InChI=1S/C14H10ClNS/c1-10-4-2-3-5-13(10)17-14-7-6-11(9-16)8-12(14)15/h2-8H,1H3
DM6Z3I8	CS	CC1=CC=CC=C1SC2=C(C=C(C=C2)C#N)Cl
DM6Z3I8	IK	XNDBEERQWNGTKH-UHFFFAOYSA-N
DM6Z3I8	IU	3-chloro-4-(2-methylphenyl)sulfanylbenzonitrile
DM6Z3I8	DE	Discovery agent

DMSB5IQ	ID	DMSB5IQ
DMSB5IQ	DN	3-Chloro-4-hydrazino-benzenesulfonamide
DMSB5IQ	HS	Investigative
DMSB5IQ	SN	3-chloro-4-hydrazino-benzenesulphonamide; 776281-37-9; hydrazide deriv. 16; SCHEMBL3952309; CHEMBL176203; CTK2G6221; BDBM12161; DTXSID30461261; MIIRMBFCBFPOKU-UHFFFAOYSA-N; 4-Hydrazino-3-chlorobenzenesulfonamide; AKOS030585345; Benzenesulfonamide, 3-chloro-4-hydrazino-
DMSB5IQ	DT	Small molecular drug
DMSB5IQ	PC	11287480
DMSB5IQ	MW	221.67
DMSB5IQ	FM	C6H8ClN3O2S
DMSB5IQ	IC	InChI=1S/C6H8ClN3O2S/c7-5-3-4(13(9,11)12)1-2-6(5)10-8/h1-3,10H,8H2,(H2,9,11,12)
DMSB5IQ	CS	C1=CC(=C(C=C1S(=O)(=O)N)Cl)NN
DMSB5IQ	IK	MIIRMBFCBFPOKU-UHFFFAOYSA-N
DMSB5IQ	IU	3-chloro-4-hydrazinylbenzenesulfonamide
DMSB5IQ	CA	CAS 776281-37-9
DMSB5IQ	DE	Discovery agent

DMBMH96	ID	DMBMH96
DMBMH96	DN	3-chloro-5-(2-methylquinolin-7-yl)benzonitrile
DMBMH96	HS	Investigative
DMBMH96	SN	CHEMBL396135; 3-chloro-5-(2-methylquinolin-7-yl)benzonitrile; SCHEMBL4297824
DMBMH96	DT	Small molecular drug
DMBMH96	PC	44432675
DMBMH96	MW	278.7
DMBMH96	FM	C17H11ClN2
DMBMH96	IC	InChI=1S/C17H11ClN2/c1-11-2-3-13-4-5-14(9-17(13)20-11)15-6-12(10-19)7-16(18)8-15/h2-9H,1H3
DMBMH96	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)Cl
DMBMH96	IK	NJKOTXYVFGIDOL-UHFFFAOYSA-N
DMBMH96	IU	3-chloro-5-(2-methylquinolin-7-yl)benzonitrile
DMBMH96	DE	Discovery agent

DMCD901	ID	DMCD901
DMCD901	DN	3-Chloro-9H-beta-carboline
DMCD901	HS	Investigative
DMCD901	SN	3-chloro-9H-pyrido[3,4-b]indole; CHEMBL298561; 91985-80-7; 3-Chloro-9H-beta-carboline; 3-chloro-b-carboline; 3-Chloro-beta-carboline; AC1O2G3D; CHEMBL496742; SCHEMBL10642293; BDBM50013805; 9H-Pyrido[3,4-b]indole, 3-chloro-
DMCD901	DT	Small molecular drug
DMCD901	PC	6198020
DMCD901	MW	202.64
DMCD901	FM	C11H7ClN2
DMCD901	IC	InChI=1S/C11H7ClN2/c12-11-5-8-7-3-1-2-4-9(7)14-10(8)6-13-11/h1-6,14H
DMCD901	CS	C1=CC=C2C(=C1)C3=CC(=NC=C3N2)Cl
DMCD901	IK	JDYLMOJCIKYTGV-UHFFFAOYSA-N
DMCD901	IU	3-chloro-9H-pyrido[3,4-b]indole
DMCD901	DE	Discovery agent

DM5J1TX	ID	DM5J1TX
DM5J1TX	DN	3-Chloroboldine
DM5J1TX	HS	Investigative
DM5J1TX	SN	3-Chloroboldine; CHEMBL524439
DM5J1TX	DT	Small molecular drug
DM5J1TX	PC	10406315
DM5J1TX	MW	361.8
DM5J1TX	FM	C19H20ClNO4
DM5J1TX	IC	InChI=1S/C19H20ClNO4/c1-21-5-4-10-15-12(21)6-9-7-13(22)14(24-2)8-11(9)16(15)19(25-3)18(23)17(10)20/h7-8,12,22-23H,4-6H2,1-3H3/t12-/m0/s1
DM5J1TX	CS	CN1CCC2=C3[C@@H]1CC4=CC(=C(C=C4C3=C(C(=C2Cl)O)OC)OC)O
DM5J1TX	IK	HRPJZDTZANKXQI-LBPRGKRZSA-N
DM5J1TX	IU	(6aS)-3-chloro-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DM5J1TX	DE	Discovery agent

DMIEZGD	ID	DMIEZGD
DMIEZGD	DN	3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMIEZGD	HS	Investigative
DMIEZGD	SN	CHEMBL1253604; 3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide; BDBM50326843
DMIEZGD	DT	Small molecular drug
DMIEZGD	PC	24219273
DMIEZGD	MW	284.74
DMIEZGD	FM	C16H13ClN2O
DMIEZGD	IC	InChI=1S/C16H13ClN2O/c1-10-7-12-9-14(5-6-15(12)18-10)19-16(20)11-3-2-4-13(17)8-11/h2-9,18H,1H3,(H,19,20)
DMIEZGD	CS	CC1=CC2=C(N1)C=CC(=C2)NC(=O)C3=CC(=CC=C3)Cl
DMIEZGD	IK	SSPHXZNBIVJTMG-UHFFFAOYSA-N
DMIEZGD	IU	3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMIEZGD	DE	Discovery agent

DMV8TNO	ID	DMV8TNO
DMV8TNO	DN	3-chloro-N-(3-isobutyramidophenyl)benzamide
DMV8TNO	HS	Investigative
DMV8TNO	SN	CHEMBL1081896; 3-chloro-N-[3-(isobutyrylamino)phenyl]benzamide; 3-chloro-N-(3-isobutyramidophenyl)benzamide; AC1LR77A; Oprea1_474979; 3-chloro-N-[3-(2-methylpropanoylamino)phenyl]benzamide; MolPort-003-001-488; ZINC1207329; BDBM50312135; STK319961; AKOS000471367; MCULE-7229085520; AP-970/13572856
DMV8TNO	DT	Small molecular drug
DMV8TNO	PC	1363600
DMV8TNO	MW	316.8
DMV8TNO	FM	C17H17ClN2O2
DMV8TNO	IC	InChI=1S/C17H17ClN2O2/c1-11(2)16(21)19-14-7-4-8-15(10-14)20-17(22)12-5-3-6-13(18)9-12/h3-11H,1-2H3,(H,19,21)(H,20,22)
DMV8TNO	CS	CC(C)C(=O)NC1=CC=CC(=C1)NC(=O)C2=CC(=CC=C2)Cl
DMV8TNO	IK	ZXAGKBUSUTVPML-UHFFFAOYSA-N
DMV8TNO	IU	3-chloro-N-[3-(2-methylpropanoylamino)phenyl]benzamide
DMV8TNO	DE	Discovery agent

DMBVCLY	ID	DMBVCLY
DMBVCLY	DN	3-chloro-N-(4-(phenyldiazenyl)phenyl)benzamide
DMBVCLY	HS	Investigative
DMBVCLY	SN	CHEMBL566920; 3-chloro-N-(4-(phenyldiazenyl)phenyl)benzamide; 3-chloro-N-[4-(phenyldiazenyl)phenyl]benzamide; AC1MEGAF; MLS000571688; CHEMBL1585037; MolPort-002-176-797; HMS2431J18; ZINC18006916; BDBM50303375; AKOS002249913; MCULE-8045658796; SMR000193697; 3-chloro-N-(4-phenyldiazenylphenyl)benzamide; ST50752429
DMBVCLY	DT	Small molecular drug
DMBVCLY	PC	2877914
DMBVCLY	MW	335.8
DMBVCLY	FM	C19H14ClN3O
DMBVCLY	IC	InChI=1S/C19H14ClN3O/c20-15-6-4-5-14(13-15)19(24)21-16-9-11-18(12-10-16)23-22-17-7-2-1-3-8-17/h1-13H,(H,21,24)
DMBVCLY	CS	C1=CC=C(C=C1)N=NC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)Cl
DMBVCLY	IK	BVHXJXQDOFAUQY-UHFFFAOYSA-N
DMBVCLY	IU	3-chloro-N-(4-phenyldiazenylphenyl)benzamide
DMBVCLY	DE	Discovery agent

DM4EL6M	ID	DM4EL6M
DM4EL6M	DN	3-chloro-N-(4-methylthiazol-2-yl)benzamide
DM4EL6M	HS	Investigative
DM4EL6M	SN	3-chloro-N-(4-methyl-1,3-thiazol-2-yl)benzamide; CHEMBL212529; 3-chloro-N-(4-methylthiazol-2-yl)benzamide; AC1LI75J; MolPort-003-812-188; ZINC477397; BDBM50186320; AKOS003848769; MCULE-7000942763
DM4EL6M	DT	Small molecular drug
DM4EL6M	PC	899301
DM4EL6M	MW	252.72
DM4EL6M	FM	C11H9ClN2OS
DM4EL6M	IC	InChI=1S/C11H9ClN2OS/c1-7-6-16-11(13-7)14-10(15)8-3-2-4-9(12)5-8/h2-6H,1H3,(H,13,14,15)
DM4EL6M	CS	CC1=CSC(=N1)NC(=O)C2=CC(=CC=C2)Cl
DM4EL6M	IK	MXGUAAMFCPDOEZ-UHFFFAOYSA-N
DM4EL6M	IU	3-chloro-N-(4-methyl-1,3-thiazol-2-yl)benzamide
DM4EL6M	DE	Discovery agent

DMAWC7S	ID	DMAWC7S
DMAWC7S	DN	3-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMAWC7S	HS	Investigative
DMAWC7S	SN	3-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide; CHEMBL61222; AC1LFIX3; Oprea1_263322; Oprea1_095427; SCHEMBL2754070; 2-[(3-chlorophenyl)carboxamido]-4-phenyl-1,3-thiazole; OHXHEHNTSIBWMV-UHFFFAOYSA-N; MolPort-001-997-617; ZINC208080; BDBM50101789; AKOS000651093; MCULE-4878334658; BAS 04456777; 50591-72-5; N-(4-Phenyl-2-thiazolyl)-3-chlorobenzamide
DMAWC7S	DT	Small molecular drug
DMAWC7S	PC	754492
DMAWC7S	MW	314.8
DMAWC7S	FM	C16H11ClN2OS
DMAWC7S	IC	InChI=1S/C16H11ClN2OS/c17-13-8-4-7-12(9-13)15(20)19-16-18-14(10-21-16)11-5-2-1-3-6-11/h1-10H,(H,18,19,20)
DMAWC7S	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC(=CC=C3)Cl
DMAWC7S	IK	OHXHEHNTSIBWMV-UHFFFAOYSA-N
DMAWC7S	IU	3-chloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMAWC7S	DE	Discovery agent

DMLC2I6	ID	DMLC2I6
DMLC2I6	DN	3-chloro-N-(6-chloropyridin-2-yl)benzamide
DMLC2I6	HS	Investigative
DMLC2I6	SN	CHEMBL208976; 3-chloro-N-(6-chloropyridin-2-yl)benzamide; BDBM50186322
DMLC2I6	DT	Small molecular drug
DMLC2I6	PC	44412923
DMLC2I6	MW	267.11
DMLC2I6	FM	C12H8Cl2N2O
DMLC2I6	IC	InChI=1S/C12H8Cl2N2O/c13-9-4-1-3-8(7-9)12(17)16-11-6-2-5-10(14)15-11/h1-7H,(H,15,16,17)
DMLC2I6	CS	C1=CC(=CC(=C1)Cl)C(=O)NC2=NC(=CC=C2)Cl
DMLC2I6	IK	FCJWDXAXERKUEZ-UHFFFAOYSA-N
DMLC2I6	IU	3-chloro-N-(6-chloropyridin-2-yl)benzamide
DMLC2I6	DE	Discovery agent

DMLJGF1	ID	DMLJGF1
DMLJGF1	DN	3-chloro-N-(6-methylpyridin-2-yl)benzamide
DMLJGF1	HS	Investigative
DMLJGF1	SN	3-chloro-N-(6-methylpyridin-2-yl)benzamide; CHEMBL377829; AC1LHBCW; Oprea1_422679; ZINC361715; BDBM50186323; STK028098; AKOS003227907; MCULE-3037986633; ST51016900
DMLJGF1	DT	Small molecular drug
DMLJGF1	PC	835261
DMLJGF1	MW	246.69
DMLJGF1	FM	C13H11ClN2O
DMLJGF1	IC	InChI=1S/C13H11ClN2O/c1-9-4-2-7-12(15-9)16-13(17)10-5-3-6-11(14)8-10/h2-8H,1H3,(H,15,16,17)
DMLJGF1	CS	CC1=NC(=CC=C1)NC(=O)C2=CC(=CC=C2)Cl
DMLJGF1	IK	HNLLGNJHYQMYEI-UHFFFAOYSA-N
DMLJGF1	IU	3-chloro-N-(6-methylpyridin-2-yl)benzamide
DMLJGF1	DE	Discovery agent

DMQCVKO	ID	DMQCVKO
DMQCVKO	DN	3-chlorophenyl 10H-phenothiazine-10-carboxylate
DMQCVKO	HS	Investigative
DMQCVKO	SN	CHEMBL481529; 3-chlorophenyl 10H-phenothiazine-10-carboxylate
DMQCVKO	DT	Small molecular drug
DMQCVKO	PC	24905653
DMQCVKO	MW	353.8
DMQCVKO	FM	C19H12ClNO2S
DMQCVKO	IC	InChI=1S/C19H12ClNO2S/c20-13-6-5-7-14(12-13)23-19(22)21-15-8-1-3-10-17(15)24-18-11-4-2-9-16(18)21/h1-12H
DMQCVKO	CS	C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)OC4=CC(=CC=C4)Cl
DMQCVKO	IK	IXZXEECBRFSNPQ-UHFFFAOYSA-N
DMQCVKO	IU	(3-chlorophenyl) phenothiazine-10-carboxylate
DMQCVKO	DE	Discovery agent

DMZ0F7E	ID	DMZ0F7E
DMZ0F7E	DN	3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate
DMZ0F7E	HS	Investigative
DMZ0F7E	SN	CHEMBL199203; SCHEMBL7682509; 2-Oxo-2H-1-benzopyran-3-carboxylic acid 3-chlorophenyl ester
DMZ0F7E	DT	Small molecular drug
DMZ0F7E	PC	11616411
DMZ0F7E	MW	300.69
DMZ0F7E	FM	C16H9ClO4
DMZ0F7E	IC	InChI=1S/C16H9ClO4/c17-11-5-3-6-12(9-11)20-15(18)13-8-10-4-1-2-7-14(10)21-16(13)19/h1-9H
DMZ0F7E	CS	C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)OC3=CC(=CC=C3)Cl
DMZ0F7E	IK	HDIMJBWUBWTFNJ-UHFFFAOYSA-N
DMZ0F7E	IU	(3-chlorophenyl) 2-oxochromene-3-carboxylate
DMZ0F7E	DE	Discovery agent

DMJ2SZ1	ID	DMJ2SZ1
DMJ2SZ1	DN	3-chlorophenyl 4-butoxybenzylcarbamate
DMJ2SZ1	HS	Investigative
DMJ2SZ1	SN	3-chlorophenyl 4-butoxybenzylcarbamate; CHEMBL596874; SCHEMBL5222756
DMJ2SZ1	DT	Small molecular drug
DMJ2SZ1	PC	20872705
DMJ2SZ1	MW	333.8
DMJ2SZ1	FM	C18H20ClNO3
DMJ2SZ1	IC	InChI=1S/C18H20ClNO3/c1-2-3-11-22-16-9-7-14(8-10-16)13-20-18(21)23-17-6-4-5-15(19)12-17/h4-10,12H,2-3,11,13H2,1H3,(H,20,21)
DMJ2SZ1	CS	CCCCOC1=CC=C(C=C1)CNC(=O)OC2=CC(=CC=C2)Cl
DMJ2SZ1	IK	RFAALCRYXIMHGO-UHFFFAOYSA-N
DMJ2SZ1	IU	(3-chlorophenyl) N-[(4-butoxyphenyl)methyl]carbamate
DMJ2SZ1	DE	Discovery agent

DMJ4SDM	ID	DMJ4SDM
DMJ4SDM	DN	3-chlorotyrosine
DMJ4SDM	HS	Investigative
DMJ4SDM	SN	Monochlorotyrosine; Tyrosine, 3-chloro-; 3-Chloro-DL-tyrosine; C9H10ClNO3; 2-amino-3-(3-chloro-4-hydroxyphenyl)propanoic acid; 7298-90-0; AC1L3OFH; AC1Q3M6L; SCHEMBL157442; L-(8CI)-3-chloro-Tyrosine; GTPL5114; CTK7I4440; ACWBBAGYTKWBCD-UHFFFAOYSA-N; AKOS009158821; VZ26714; MCULE-5698335509; KB-31251; LS-177012; A838069; 2-azanyl-3-(3-chloranyl-4-oxidanyl-phenyl)propanoic acid
DMJ4SDM	DT	Small molecular drug
DMJ4SDM	PC	110992
DMJ4SDM	MW	215.63
DMJ4SDM	FM	C9H10ClNO3
DMJ4SDM	IC	InChI=1S/C9H10ClNO3/c10-6-3-5(1-2-8(6)12)4-7(11)9(13)14/h1-3,7,12H,4,11H2,(H,13,14)/t7-/m0/s1
DMJ4SDM	CS	C1=CC(=C(C=C1C[C@@H](C(=O)O)N)Cl)O
DMJ4SDM	IK	ACWBBAGYTKWBCD-ZETCQYMHSA-N
DMJ4SDM	IU	(2S)-2-amino-3-(3-chloro-4-hydroxyphenyl)propanoic acid
DMJ4SDM	CA	CAS 7423-93-0
DMJ4SDM	CB	CHEBI:53678
DMJ4SDM	DE	Discovery agent

DM78FWG	ID	DM78FWG
DM78FWG	DN	3-cis-p-coumaroyl maslinic acid
DM78FWG	HS	Investigative
DM78FWG	SN	CHEMBL463995; 3-cis-p-coumaroyl maslinic acid
DM78FWG	DT	Small molecular drug
DM78FWG	PC	16664518
DM78FWG	MW	602.8
DM78FWG	FM	C39H54O5
DM78FWG	IC	InChI=1S/C39H54O5/c1-34(2)19-21-39(33(42)43)22-20-37(6)26(27(39)23-34)14-15-30-36(5)24-28(40)32(35(3,4)29(36)17-18-38(30,37)7)44-31(41)16-13-25-11-9-8-10-12-25/h8-14,16,27-30,32,40H,15,17-24H2,1-7H3,(H,42,43)/b16-13-/t27-,28+,29-,30+,32-,36-,37+,38+,39-/m0/s1
DM78FWG	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@@H](C3(C)C)OC(=O)/C=C\\C6=CC=CC=C6)O)C
DM78FWG	IK	QYNZDAXHBDWWFS-GZOAODGCSA-N
DM78FWG	IU	(4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-[(Z)-3-phenylprop-2-enoyl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DM78FWG	DE	Discovery agent

DMF1PIW	ID	DMF1PIW
DMF1PIW	DN	3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide
DMF1PIW	HS	Investigative
DMF1PIW	SN	CHEMBL1209394; 3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide
DMF1PIW	DT	Small molecular drug
DMF1PIW	PC	49862433
DMF1PIW	MW	258.22
DMF1PIW	FM	C14H8F2N2O
DMF1PIW	IC	InChI=1S/C14H8F2N2O/c15-11-2-1-3-13(7-11)18-14(19)10-4-9(8-17)5-12(16)6-10/h1-7H,(H,18,19)
DMF1PIW	CS	C1=CC(=CC(=C1)F)NC(=O)C2=CC(=CC(=C2)C#N)F
DMF1PIW	IK	PXKKWNKVXLXAEB-UHFFFAOYSA-N
DMF1PIW	IU	3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide
DMF1PIW	DE	Discovery agent

DMBA4XN	ID	DMBA4XN
DMBA4XN	DN	3-cyano-5-fluoro-N-(pyridin-2-yl)benzamide
DMBA4XN	HS	Investigative
DMBA4XN	SN	CHEMBL1209204; 3-cyano-5-fluoro-N-(pyridin-2-yl)benzamide
DMBA4XN	DT	Small molecular drug
DMBA4XN	PC	49862277
DMBA4XN	MW	241.22
DMBA4XN	FM	C13H8FN3O
DMBA4XN	IC	InChI=1S/C13H8FN3O/c14-11-6-9(8-15)5-10(7-11)13(18)17-12-3-1-2-4-16-12/h1-7H,(H,16,17,18)
DMBA4XN	CS	C1=CC=NC(=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMBA4XN	IK	QSQNDNOCUDDTAZ-UHFFFAOYSA-N
DMBA4XN	IU	3-cyano-5-fluoro-N-pyridin-2-ylbenzamide
DMBA4XN	DE	Discovery agent

DMF097H	ID	DMF097H
DMF097H	DN	3-cyano-5-fluoro-N-m-tolylbenzamide
DMF097H	HS	Investigative
DMF097H	SN	CHEMBL1209203; 3-cyano-5-fluoro-N-m-tolylbenzamide
DMF097H	DT	Small molecular drug
DMF097H	PC	49862276
DMF097H	MW	254.26
DMF097H	FM	C15H11FN2O
DMF097H	IC	InChI=1S/C15H11FN2O/c1-10-3-2-4-14(5-10)18-15(19)12-6-11(9-17)7-13(16)8-12/h2-8H,1H3,(H,18,19)
DMF097H	CS	CC1=CC(=CC=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMF097H	IK	JHLDQKUSWAUHCQ-UHFFFAOYSA-N
DMF097H	IU	3-cyano-5-fluoro-N-(3-methylphenyl)benzamide
DMF097H	DE	Discovery agent

DMIZ8RC	ID	DMIZ8RC
DMIZ8RC	DN	3-cyano-5-fluoro-N-phenylbenzamide
DMIZ8RC	HS	Investigative
DMIZ8RC	SN	CHEMBL1209392; 3-cyano-5-fluoro-N-phenylbenzamide
DMIZ8RC	DT	Small molecular drug
DMIZ8RC	PC	49862431
DMIZ8RC	MW	240.23
DMIZ8RC	FM	C14H9FN2O
DMIZ8RC	IC	InChI=1S/C14H9FN2O/c15-12-7-10(9-16)6-11(8-12)14(18)17-13-4-2-1-3-5-13/h1-8H,(H,17,18)
DMIZ8RC	CS	C1=CC=C(C=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMIZ8RC	IK	MCCCAUONCIKYRV-UHFFFAOYSA-N
DMIZ8RC	IU	3-cyano-5-fluoro-N-phenylbenzamide
DMIZ8RC	DE	Discovery agent

DMH7FC9	ID	DMH7FC9
DMH7FC9	DN	3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMH7FC9	HS	Investigative
DMH7FC9	SN	3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; CDPPB; 781652-57-1; mGluR5 Ligand, CDPPB; CHEMBL190270; GTPL1422; SCHEMBL1823352; CTK5E5464; DTXSID80459996; MolPort-009-199-287; ZINC3986698; BDBM50156071; IN1239; AKOS024457497; RTC-070344; NCGC00370800-01; KB-75992; EN002594; TC-070344; DB-075421; FT-0763465; B7324; A9858; 3-cyano-N-[2,5-di(phenyl)pyrazol-3-yl]benzamide; 3-Cyano-N-1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMH7FC9	DT	Small molecular drug
DMH7FC9	PC	11245456
DMH7FC9	MW	364.4
DMH7FC9	FM	C23H16N4O
DMH7FC9	IC	InChI=1S/C23H16N4O/c24-16-17-8-7-11-19(14-17)23(28)25-22-15-21(18-9-3-1-4-10-18)26-27(22)20-12-5-2-6-13-20/h1-15H,(H,25,28)
DMH7FC9	CS	C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC=CC(=C3)C#N)C4=CC=CC=C4
DMH7FC9	IK	BKUIZWILNWHFHD-UHFFFAOYSA-N
DMH7FC9	IU	3-cyano-N-(2,5-diphenylpyrazol-3-yl)benzamide
DMH7FC9	CA	CAS 781652-57-1
DMH7FC9	DE	Discovery agent

DM3EIWC	ID	DM3EIWC
DM3EIWC	DN	3-cyano-N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DM3EIWC	HS	Investigative
DM3EIWC	SN	CHEMBL210488; 3-cyano-N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DM3EIWC	DT	Small molecular drug
DM3EIWC	PC	11494297
DM3EIWC	MW	364.4
DM3EIWC	FM	C23H16N4O
DM3EIWC	IC	InChI=1S/C23H16N4O/c24-15-17-8-7-11-19(14-17)23(28)26-22-21(18-9-3-1-4-10-18)16-25-27(22)20-12-5-2-6-13-20/h1-14,16H,(H,26,28)
DM3EIWC	CS	C1=CC=C(C=C1)C2=C(N(N=C2)C3=CC=CC=C3)NC(=O)C4=CC=CC(=C4)C#N
DM3EIWC	IK	ZNMCOYKAPQGPBZ-UHFFFAOYSA-N
DM3EIWC	IU	3-cyano-N-(2,4-diphenylpyrazol-3-yl)benzamide
DM3EIWC	DE	Discovery agent

DMRD8VM	ID	DMRD8VM
DMRD8VM	DN	3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide
DMRD8VM	HS	Investigative
DMRD8VM	SN	CHEMBL1209548; 3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide
DMRD8VM	DT	Small molecular drug
DMRD8VM	PC	49862542
DMRD8VM	MW	265.24
DMRD8VM	FM	C15H8FN3O
DMRD8VM	IC	InChI=1S/C15H8FN3O/c16-13-5-11(9-18)4-12(7-13)15(20)19-14-3-1-2-10(6-14)8-17/h1-7H,(H,19,20)
DMRD8VM	CS	C1=CC(=CC(=C1)NC(=O)C2=CC(=CC(=C2)C#N)F)C#N
DMRD8VM	IK	YKPYRZLWZZAYPC-UHFFFAOYSA-N
DMRD8VM	IU	3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide
DMRD8VM	DE	Discovery agent

DMFUT57	ID	DMFUT57
DMFUT57	DN	3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide
DMFUT57	HS	Investigative
DMFUT57	SN	CHEMBL1209550; 3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide
DMFUT57	DT	Small molecular drug
DMFUT57	PC	49862544
DMFUT57	MW	268.28
DMFUT57	FM	C16H13FN2O
DMFUT57	IC	InChI=1S/C16H13FN2O/c1-2-11-4-3-5-15(8-11)19-16(20)13-6-12(10-18)7-14(17)9-13/h3-9H,2H2,1H3,(H,19,20)
DMFUT57	CS	CCC1=CC(=CC=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMFUT57	IK	FGYATISUHIGFJB-UHFFFAOYSA-N
DMFUT57	IU	3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide
DMFUT57	DE	Discovery agent

DM9FEMV	ID	DM9FEMV
DM9FEMV	DN	3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide
DM9FEMV	HS	Investigative
DM9FEMV	SN	CHEMBL1209549; 3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide
DM9FEMV	DT	Small molecular drug
DM9FEMV	PC	49862543
DM9FEMV	MW	264.25
DM9FEMV	FM	C16H9FN2O
DM9FEMV	IC	InChI=1S/C16H9FN2O/c1-2-11-4-3-5-15(8-11)19-16(20)13-6-12(10-18)7-14(17)9-13/h1,3-9H,(H,19,20)
DM9FEMV	CS	C#CC1=CC(=CC=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DM9FEMV	IK	WPLAMCXDNWYUEU-UHFFFAOYSA-N
DM9FEMV	IU	3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide
DM9FEMV	DE	Discovery agent

DMUB9XW	ID	DMUB9XW
DMUB9XW	DN	3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide
DMUB9XW	HS	Investigative
DMUB9XW	SN	CHEMBL1209330; 3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide
DMUB9XW	DT	Small molecular drug
DMUB9XW	PC	49862385
DMUB9XW	MW	269.27
DMUB9XW	FM	C15H12FN3O
DMUB9XW	IC	InChI=1S/C15H12FN3O/c1-2-13-4-3-5-14(18-13)19-15(20)11-6-10(9-17)7-12(16)8-11/h3-8H,2H2,1H3,(H,18,19,20)
DMUB9XW	CS	CCC1=NC(=CC=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMUB9XW	IK	LBPUNEZWEHBQQO-UHFFFAOYSA-N
DMUB9XW	IU	3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide
DMUB9XW	DE	Discovery agent

DMTDEYL	ID	DMTDEYL
DMTDEYL	DN	3-cyano-N-(6-methylpyridin-2-yl)benzamide
DMTDEYL	HS	Investigative
DMTDEYL	SN	3-cyano-N-(6-methylpyridin-2-yl)benzamide; CHEMBL208927; 900801-18-5; benzamide,3-cyano-n-(6-methyl-2-pyridinyl)-; MolPort-004-359-738; ZINC12545036; BDBM50186330; AKOS000205559; MCULE-1984522308; SC-60782; KB-270891
DMTDEYL	DT	Small molecular drug
DMTDEYL	PC	16007001
DMTDEYL	MW	237.26
DMTDEYL	FM	C14H11N3O
DMTDEYL	IC	InChI=1S/C14H11N3O/c1-10-4-2-7-13(16-10)17-14(18)12-6-3-5-11(8-12)9-15/h2-8H,1H3,(H,16,17,18)
DMTDEYL	CS	CC1=NC(=CC=C1)NC(=O)C2=CC=CC(=C2)C#N
DMTDEYL	IK	HRIDAJBBAATPGT-UHFFFAOYSA-N
DMTDEYL	IU	3-cyano-N-(6-methylpyridin-2-yl)benzamide
DMTDEYL	DE	Discovery agent

DMPWR90	ID	DMPWR90
DMPWR90	DN	3-cyanophenylboronic acid
DMPWR90	HS	Investigative
DMPWR90	SN	3-Cyanophenylboronic acid; 150255-96-2; (3-cyanophenyl)boronic Acid; 3-Cyanobenzeneboronic Acid; 3-Boronobenzonitrile; 3-(dihydroxyboranyl)benzonitrile; 3-cyanophenyl boronic acid; 3-cyanobenzene boronic acid; 3-cyano-phenyl-boronic acid; Boronic acid, B-(3-cyanophenyl)-; MFCD01318967; BORONIC ACID, (3-CYANOPHENYL)-; PubChem1804; Phenylboronic Acid, 4; m-cyanophenyl boronic acid; 3-cyano-phenylboronic acid; 3-cyano phenylboronic acid; 3-cyanophenyl-boronic acid; 3-Cyanophenylboronic  acid; 3-Cyanophenylboronic acid,
DMPWR90	DT	Small molecular drug
DMPWR90	PC	2734325
DMPWR90	MW	146.94
DMPWR90	FM	C7H6BNO2
DMPWR90	IC	InChI=1S/C7H6BNO2/c9-5-6-2-1-3-7(4-6)8(10)11/h1-4,10-11H
DMPWR90	CS	B(C1=CC(=CC=C1)C#N)(O)O
DMPWR90	IK	XDBHWPLGGBLUHH-UHFFFAOYSA-N
DMPWR90	IU	(3-cyanophenyl)boronic acid
DMPWR90	CA	CAS 150255-96-2
DMPWR90	DE	Discovery agent

DMJSOTE	ID	DMJSOTE
DMJSOTE	DN	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide
DMJSOTE	HS	Investigative
DMJSOTE	SN	CHEMBL77258; 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide
DMJSOTE	DT	Small molecular drug
DMJSOTE	PC	10565532
DMJSOTE	MW	291.41
DMJSOTE	FM	C13H25NO4S
DMJSOTE	IC	InChI=1S/C13H25NO4S/c1-2-3-7-12(10-13(15)14-16)19(17,18)11-8-5-4-6-9-11/h11-12,16H,2-10H2,1H3,(H,14,15)
DMJSOTE	CS	CCCCC(CC(=O)NO)S(=O)(=O)C1CCCCC1
DMJSOTE	IK	LUHJAOVICRNTRC-UHFFFAOYSA-N
DMJSOTE	IU	3-cyclohexylsulfonyl-N-hydroxyheptanamide
DMJSOTE	DE	Discovery agent

DMWMFZ3	ID	DMWMFZ3
DMWMFZ3	DN	3-Cyclohexyl-1-propyl-piperidine hydrochloride
DMWMFZ3	HS	Investigative
DMWMFZ3	DE	Discovery agent

DMCQ6J8	ID	DMCQ6J8
DMCQ6J8	DN	3-Cyclohexylethynyl-6,7-dimethoxy-quinoline
DMCQ6J8	HS	Investigative
DMCQ6J8	SN	CHEMBL63575; 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline; SCHEMBL8172563; MBQNQJQVMOFJOD-UHFFFAOYSA-N; ZINC8552727; BDBM50039040
DMCQ6J8	DT	Small molecular drug
DMCQ6J8	PC	10402251
DMCQ6J8	MW	295.4
DMCQ6J8	FM	C19H21NO2
DMCQ6J8	IC	InChI=1S/C19H21NO2/c1-21-18-11-16-10-15(9-8-14-6-4-3-5-7-14)13-20-17(16)12-19(18)22-2/h10-14H,3-7H2,1-2H3
DMCQ6J8	CS	COC1=CC2=CC(=CN=C2C=C1OC)C#CC3CCCCC3
DMCQ6J8	IK	MBQNQJQVMOFJOD-UHFFFAOYSA-N
DMCQ6J8	IU	3-(2-cyclohexylethynyl)-6,7-dimethoxyquinoline
DMCQ6J8	DE	Discovery agent

DM1FSZM	ID	DM1FSZM
DM1FSZM	DN	3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline
DM1FSZM	HS	Investigative
DM1FSZM	SN	CHEMBL66618; 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline; ZINC8079; SCHEMBL4364039; BDBM50039090
DM1FSZM	DT	Small molecular drug
DM1FSZM	PC	10083699
DM1FSZM	MW	255.31
DM1FSZM	FM	C16H17NO2
DM1FSZM	IC	InChI=1S/C16H17NO2/c1-18-15-8-12-7-13(11-5-3-4-6-11)10-17-14(12)9-16(15)19-2/h5,7-10H,3-4,6H2,1-2H3
DM1FSZM	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CCCC3
DM1FSZM	IK	DVMMSUYWABLYCR-UHFFFAOYSA-N
DM1FSZM	IU	3-(cyclopenten-1-yl)-6,7-dimethoxyquinoline
DM1FSZM	DE	Discovery agent

DMEL8S5	ID	DMEL8S5
DMEL8S5	DN	3-cyclopentoxycarbonyl-6-ethyl-4-quinolone
DMEL8S5	HS	Investigative
DMEL8S5	SN	CHEMBL202724
DMEL8S5	DT	Small molecular drug
DMEL8S5	PC	11565450
DMEL8S5	MW	285.34
DMEL8S5	FM	C17H19NO3
DMEL8S5	IC	InChI=1S/C17H19NO3/c1-2-11-7-8-15-13(9-11)16(19)14(10-18-15)17(20)21-12-5-3-4-6-12/h7-10,12H,2-6H2,1H3,(H,18,19)
DMEL8S5	CS	CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OC3CCCC3
DMEL8S5	IK	XLRFFZMGTKMUJJ-UHFFFAOYSA-N
DMEL8S5	IU	cyclopentyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMEL8S5	DE	Discovery agent

DMS7B6T	ID	DMS7B6T
DMS7B6T	DN	3-Cyclopentyl-6,7-dimethoxy-quinoline
DMS7B6T	HS	Investigative
DMS7B6T	SN	CHEMBL66785; 3-cyclopentyl-6,7-dimethoxy-quinoline; SCHEMBL8801444; ZINC3834044
DMS7B6T	DT	Small molecular drug
DMS7B6T	PC	10422592
DMS7B6T	MW	257.329
DMS7B6T	FM	C16H19NO2
DMS7B6T	IC	InChI=1S/C16H19NO2/c1-18-15-8-12-7-13(11-5-3-4-6-11)10-17-14(12)9-16(15)19-2/h7-11H,3-6H2,1-2H3
DMS7B6T	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3CCCC3
DMS7B6T	IK	BYQWDMZNUPGMNG-UHFFFAOYSA-N
DMS7B6T	IU	3-cyclopentyl-6,7-dimethoxyquinoline
DMS7B6T	DE	Discovery agent

DMLQJ64	ID	DMLQJ64
DMLQJ64	DN	3-Decanoyl-4-hydroxy-6-nonyl-pyran-2-one
DMLQJ64	HS	Investigative
DMLQJ64	SN	CHEMBL7958; 3-Decanoyl-4-hydroxy-6-nonyl-pyran-2-one; SCHEMBL10337595
DMLQJ64	DT	Small molecular drug
DMLQJ64	PC	54736658
DMLQJ64	MW	392.6
DMLQJ64	FM	C24H40O4
DMLQJ64	IC	InChI=1S/C24H40O4/c1-3-5-7-9-11-13-15-17-20-19-22(26)23(24(27)28-20)21(25)18-16-14-12-10-8-6-4-2/h19,26H,3-18H2,1-2H3
DMLQJ64	CS	CCCCCCCCCC1=CC(=C(C(=O)O1)C(=O)CCCCCCCCC)O
DMLQJ64	IK	FFXYZCMDXPBYIG-UHFFFAOYSA-N
DMLQJ64	IU	3-decanoyl-4-hydroxy-6-nonylpyran-2-one
DMLQJ64	DE	Discovery agent

DMID7TC	ID	DMID7TC
DMID7TC	DN	3-demethoxy-3D-glucopyranosylaminothiocolchicine
DMID7TC	HS	Investigative
DMID7TC	SN	CHEMBL438794
DMID7TC	DT	Small molecular drug
DMID7TC	PC	16043015
DMID7TC	MW	562.6
DMID7TC	FM	C27H34N2O9S
DMID7TC	IC	InChI=1S/C27H34N2O9S/c1-12(31)28-16-7-5-13-9-17(29-27-24(35)23(34)22(33)19(11-30)38-27)25(36-2)26(37-3)21(13)14-6-8-20(39-4)18(32)10-15(14)16/h6,8-10,16,19,22-24,27,29-30,33-35H,5,7,11H2,1-4H3,(H,28,31)/t16-,19+,22+,23-,24+,27?/m0/s1
DMID7TC	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)NC4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DMID7TC	IK	FPOIHQLRIKBTGP-DCWZWRKFSA-N
DMID7TC	IU	N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMID7TC	DE	Discovery agent

DME8VPC	ID	DME8VPC
DME8VPC	DN	3-demethoxy-3-D-lyxopyranosylaminothiocolchicine
DME8VPC	HS	Investigative
DME8VPC	SN	CHEMBL215655
DME8VPC	DT	Small molecular drug
DME8VPC	PC	16043019
DME8VPC	MW	532.6
DME8VPC	FM	C26H32N2O8S
DME8VPC	IC	InChI=1S/C26H32N2O8S/c1-12(29)27-16-7-5-13-9-17(28-26-23(33)22(32)19(31)11-36-26)24(34-2)25(35-3)21(13)14-6-8-20(37-4)18(30)10-15(14)16/h6,8-10,16,19,22-23,26,28,31-33H,5,7,11H2,1-4H3,(H,27,29)/t16-,19+,22-,23-,26?/m0/s1
DME8VPC	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)NC4[C@H]([C@H]([C@@H](CO4)O)O)O
DME8VPC	IK	MCKYAFJMJJFRCX-NFKHFCJPSA-N
DME8VPC	IU	N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(3S,4S,5R)-3,4,5-trihydroxyoxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DME8VPC	DE	Discovery agent

DMALMGH	ID	DMALMGH
DMALMGH	DN	3-demethoxy-3-D-mannopyranosylaminothiocolchicine
DMALMGH	HS	Investigative
DMALMGH	SN	CHEMBL214305
DMALMGH	DT	Small molecular drug
DMALMGH	PC	16081752
DMALMGH	MW	562.6
DMALMGH	FM	C27H34N2O9S
DMALMGH	IC	InChI=1S/C27H34N2O9S/c1-12(31)28-16-7-5-13-9-17(29-27-24(35)23(34)22(33)19(11-30)38-27)25(36-2)26(37-3)21(13)14-6-8-20(39-4)18(32)10-15(14)16/h6,8-10,16,19,22-24,27,29-30,33-35H,5,7,11H2,1-4H3,(H,28,31)/t16-,19+,22+,23-,24-,27+/m0/s1
DMALMGH	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)N[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DMALMGH	IK	FPOIHQLRIKBTGP-LMOMQKJLSA-N
DMALMGH	IU	N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMALMGH	DE	Discovery agent

DMXFVD1	ID	DMXFVD1
DMXFVD1	DN	3-demethoxy-3-D-xylopyranosylaminothiocolchicine
DMXFVD1	HS	Investigative
DMXFVD1	SN	CHEMBL213312
DMXFVD1	DT	Small molecular drug
DMXFVD1	PC	12001016
DMXFVD1	MW	532.6
DMXFVD1	FM	C26H32N2O8S
DMXFVD1	IC	InChI=1S/C26H32N2O8S/c1-12(29)27-16-7-5-13-9-17(28-26-23(33)22(32)19(31)11-36-26)24(34-2)25(35-3)21(13)14-6-8-20(37-4)18(30)10-15(14)16/h6,8-10,16,19,22-23,26,28,31-33H,5,7,11H2,1-4H3,(H,27,29)/t16-,19+,22-,23+,26?/m0/s1
DMXFVD1	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)NC4[C@@H]([C@H]([C@@H](CO4)O)O)O
DMXFVD1	IK	MCKYAFJMJJFRCX-PXSUQPJVSA-N
DMXFVD1	IU	N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMXFVD1	DE	Discovery agent

DM4ERYF	ID	DM4ERYF
DM4ERYF	DN	3-demethoxy-3-L-fucopyranosylaminothiocolchicine
DM4ERYF	HS	Investigative
DM4ERYF	SN	CHEMBL214151
DM4ERYF	DT	Small molecular drug
DM4ERYF	PC	16082784
DM4ERYF	MW	546.6
DM4ERYF	FM	C27H34N2O8S
DM4ERYF	IC	InChI=1S/C27H34N2O8S/c1-12-22(32)23(33)24(34)27(37-12)29-18-10-14-6-8-17(28-13(2)30)16-11-19(31)20(38-5)9-7-15(16)21(14)26(36-4)25(18)35-3/h7,9-12,17,22-24,27,29,32-34H,6,8H2,1-5H3,(H,28,30)/t12-,17-,22+,23+,24-,27+/m0/s1
DM4ERYF	CS	C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)NC2=C(C(=C3C(=C2)CC[C@@H](C4=CC(=O)C(=CC=C43)SC)NC(=O)C)OC)OC)O)O)O
DM4ERYF	IK	ZYVFSIDQHJSZKV-MPHDHXMWSA-N
DM4ERYF	IU	N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DM4ERYF	DE	Discovery agent

DMFQUGE	ID	DMFQUGE
DMFQUGE	DN	3-Deoxyguanosine
DMFQUGE	HS	Investigative
DMFQUGE	DT	Small molecular drug
DMFQUGE	PC	135440068
DMFQUGE	MW	267.24
DMFQUGE	FM	C10H13N5O4
DMFQUGE	IC	InChI=1S/C10H13N5O4/c11-10-13-7-6(8(18)14-10)12-3-15(7)9-5(17)1-4(2-16)19-9/h3-5,9,16-17H,1-2H2,(H3,11,13,14,18)/t4-,5+,9+/m0/s1
DMFQUGE	CS	C1[C@H](O[C@H]([C@@H]1O)N2C=NC3=C2N=C(NC3=O)N)CO
DMFQUGE	IK	OROIAVZITJBGSM-OBXARNEKSA-N
DMFQUGE	IU	2-amino-9-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DMFQUGE	CA	CAS 3608-58-0
DMFQUGE	DE	Discovery agent

DMBNA0V	ID	DMBNA0V
DMBNA0V	DN	3-desoxy-3-carboxamidonaltrexone
DMBNA0V	HS	Investigative
DMBNA0V	SN	CHEMBL56695; 3-desoxy-3-carboxamidonaltrexone; SCHEMBL2785528; QAICPHMNUHNDMC-WUHBCXKYSA-N; BDBM50128411; 6-Oxo-17-(cyclopropylmethyl)-14-hydroxy-4,5alpha-epoxymorphinan-3-carboxamide; (5a)-17-(cyclopropylmethyl)-14-hydroxy-6-oxo-4,5-epoxymorphinan-3-carboxamide
DMBNA0V	DT	Small molecular drug
DMBNA0V	PC	10021946
DMBNA0V	MW	368.4
DMBNA0V	FM	C21H24N2O4
DMBNA0V	IC	InChI=1S/C21H24N2O4/c22-19(25)13-4-3-12-9-15-21(26)6-5-14(24)18-20(21,16(12)17(13)27-18)7-8-23(15)10-11-1-2-11/h3-4,11,15,18,26H,1-2,5-10H2,(H2,22,25)/t15-,18+,20+,21-/m1/s1
DMBNA0V	CS	C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)C(=O)N)O5)O
DMBNA0V	IK	QAICPHMNUHNDMC-WUHBCXKYSA-N
DMBNA0V	IU	(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-9-carboxamide
DMBNA0V	DE	Discovery agent

DMSJUOH	ID	DMSJUOH
DMSJUOH	DN	3-Dimethylaminomethyl-1H-indol-4-ol
DMSJUOH	HS	Investigative
DMSJUOH	SN	CHEMBL194588; 3-Dimethylaminomethyl-1H-indol-4-ol; BDBM50171272
DMSJUOH	DT	Small molecular drug
DMSJUOH	PC	44404899
DMSJUOH	MW	190.24
DMSJUOH	FM	C11H14N2O
DMSJUOH	IC	InChI=1S/C11H14N2O/c1-13(2)7-8-6-12-9-4-3-5-10(14)11(8)9/h3-6,12,14H,7H2,1-2H3
DMSJUOH	CS	CN(C)CC1=CNC2=C1C(=CC=C2)O
DMSJUOH	IK	YJJMKVPZBCHYHD-UHFFFAOYSA-N
DMSJUOH	IU	3-[(dimethylamino)methyl]-1H-indol-4-ol
DMSJUOH	DE	Discovery agent

DMDOIJM	ID	DMDOIJM
DMDOIJM	DN	3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol
DMDOIJM	HS	Investigative
DMDOIJM	SN	CHEMBL370221; 3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol
DMDOIJM	DT	Small molecular drug
DMDOIJM	PC	44404904
DMDOIJM	MW	204.27
DMDOIJM	FM	C12H16N2O
DMDOIJM	IC	InChI=1S/C12H16N2O/c1-13(2)7-9-8-14(3)10-5-4-6-11(15)12(9)10/h4-6,8,15H,7H2,1-3H3
DMDOIJM	CS	CN1C=C(C2=C1C=CC=C2O)CN(C)C
DMDOIJM	IK	QOWUCENJFGRMQC-UHFFFAOYSA-N
DMDOIJM	IU	3-[(dimethylamino)methyl]-1-methylindol-4-ol
DMDOIJM	DE	Discovery agent

DMVHQB8	ID	DMVHQB8
DMVHQB8	DN	3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE
DMVHQB8	HS	Investigative
DMVHQB8	SN	CHEMBL303950; MR2; 3,3-Bis-(4-hydroxy-phenyl)-6-nitro-3H-benzo[de]isochromen-1-one; 1tsm; AC1L9MC8; bis(4-hydroxyphenyl)-nitro-[ ]one; BDBM50077849; DB08204; 3,3-bis(4-hydroxyphenyl)-6-nitro-1H,3H-benzo[de]isochromen-1-one; 3,3-Bis(4-hydroxyphenyl)-6-nitro-1H,3H-naphtho[1,8-cd]pyran-1-one
DMVHQB8	DT	Small molecular drug
DMVHQB8	PC	448781
DMVHQB8	MW	413.4
DMVHQB8	FM	C24H15NO6
DMVHQB8	IC	InChI=1S/C24H15NO6/c26-16-8-4-14(5-9-16)24(15-6-10-17(27)11-7-15)20-12-13-21(25(29)30)18-2-1-3-19(22(18)20)23(28)31-24/h1-13,26-27H
DMVHQB8	CS	C1=CC2=C(C=CC3=C2C(=C1)C(=O)OC3(C4=CC=C(C=C4)O)C5=CC=C(C=C5)O)[N+](=O)[O-]
DMVHQB8	IK	FLWABCQDXUKNQY-UHFFFAOYSA-N
DMVHQB8	IU	4,4-bis(4-hydroxyphenyl)-8-nitro-3-oxatricyclo[7.3.1.05,13]trideca-1(12),5(13),6,8,10-pentaen-2-one
DMVHQB8	DE	Discovery agent

DMO5EBI	ID	DMO5EBI
DMO5EBI	DN	3-dodecyl-1,1-dimethylthiourea
DMO5EBI	HS	Investigative
DMO5EBI	SN	CHEMBL251521; 3-dodecyl-1,1-dimethylthiourea
DMO5EBI	DT	Small molecular drug
DMO5EBI	PC	44442157
DMO5EBI	MW	272.5
DMO5EBI	FM	C15H32N2S
DMO5EBI	IC	InChI=1S/C15H32N2S/c1-4-5-6-7-8-9-10-11-12-13-14-16-15(18)17(2)3/h4-14H2,1-3H3,(H,16,18)
DMO5EBI	CS	CCCCCCCCCCCCNC(=S)N(C)C
DMO5EBI	IK	ZZKLRJUYYVBOIF-UHFFFAOYSA-N
DMO5EBI	IU	3-dodecyl-1,1-dimethylthiourea
DMO5EBI	DE	Discovery agent

DMQ8VIU	ID	DMQ8VIU
DMQ8VIU	DN	3-epicorosolic acid methyl ester
DMQ8VIU	HS	Investigative
DMQ8VIU	SN	3-epicorosolic acid methyl ester; CHEMBL604538; BDBM50307106; 2alpha,3alpha-Dihydroxyurs-12-en-28-oic acid methyl ester
DMQ8VIU	DT	Small molecular drug
DMQ8VIU	PC	21672621
DMQ8VIU	MW	486.7
DMQ8VIU	FM	C31H50O4
DMQ8VIU	IC	InChI=1S/C31H50O4/c1-18-11-14-31(26(34)35-8)16-15-29(6)20(24(31)19(18)2)9-10-23-28(5)17-21(32)25(33)27(3,4)22(28)12-13-30(23,29)7/h9,18-19,21-25,32-33H,10-17H2,1-8H3/t18-,19+,21-,22+,23-,24+,25-,28+,29-,30-,31+/m1/s1
DMQ8VIU	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@H](C5(C)C)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)OC
DMQ8VIU	IK	BRZWXKGDPAZBLF-ZLSCOBDWSA-N
DMQ8VIU	IU	methyl (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,11R,12aR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylate
DMQ8VIU	CA	CAS 52213-28-2
DMQ8VIU	DE	Discovery agent

DM1UOWB	ID	DM1UOWB
DM1UOWB	DN	3-epi-masilinic acid
DM1UOWB	HS	Investigative
DM1UOWB	SN	3-epimaslinic acid; epi-Maslinic acid; 3-epi-masilinic acid; 3-epi-maslinic acid; CHEMBL383749; CHEBI:66683; 26563-68-8; (2alpha,3alpha)-2,3-dihydroxyolean-12-en-28-oic acid; 2alpha,3alpha-Dihydroxyolean-12-en-28-oic acid; Epimaslinic acid; SCHEMBL5797455; MolPort-039-338-353; BDBM50175873; ZINC12868514; LMPR0106150030
DM1UOWB	DT	Small molecular drug
DM1UOWB	PC	25564831
DM1UOWB	MW	472.7
DM1UOWB	FM	C30H48O4
DM1UOWB	IC	InChI=1S/C30H48O4/c1-25(2)12-14-30(24(33)34)15-13-28(6)18(19(30)16-25)8-9-22-27(5)17-20(31)23(32)26(3,4)21(27)10-11-29(22,28)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20+,21-,22+,23+,27-,28+,29+,30-/m0/s1
DM1UOWB	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@H](C3(C)C)O)O)C
DM1UOWB	IK	MDZKJHQSJHYOHJ-HFYZCPLSSA-N
DM1UOWB	IU	(4aS,6aR,6aS,6bR,8aR,10S,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DM1UOWB	CA	CAS 26563-68-8
DM1UOWB	CB	CHEBI:66683
DM1UOWB	DE	Discovery agent

DMTKQNU	ID	DMTKQNU
DMTKQNU	DN	3-Ethenylquinoline-8-carboxamide
DMTKQNU	HS	Investigative
DMTKQNU	SN	CHEMBL481793; 3-Ethenylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethenyl-; BDBM50255270
DMTKQNU	DT	Small molecular drug
DMTKQNU	PC	25208747
DMTKQNU	MW	198.22
DMTKQNU	FM	C12H10N2O
DMTKQNU	IC	InChI=1S/C12H10N2O/c1-2-8-6-9-4-3-5-10(12(13)15)11(9)14-7-8/h2-7H,1H2,(H2,13,15)
DMTKQNU	CS	C=CC1=CN=C2C(=C1)C=CC=C2C(=O)N
DMTKQNU	IK	CODIVOZOEAWHDX-UHFFFAOYSA-N
DMTKQNU	IU	3-ethenylquinoline-8-carboxamide
DMTKQNU	DE	Discovery agent

DMSK6EM	ID	DMSK6EM
DMSK6EM	DN	3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMSK6EM	HS	Investigative
DMSK6EM	SN	CHEMBL233358; 3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMSK6EM	DT	Small molecular drug
DMSK6EM	PC	44432682
DMSK6EM	MW	288.3
DMSK6EM	FM	C19H16N2O
DMSK6EM	IC	InChI=1S/C19H16N2O/c1-3-22-18-9-14(12-20)8-17(10-18)16-7-6-15-5-4-13(2)21-19(15)11-16/h4-11H,3H2,1-2H3
DMSK6EM	CS	CCOC1=CC(=CC(=C1)C2=CC3=C(C=CC(=N3)C)C=C2)C#N
DMSK6EM	IK	QGNKITVJGNCQSU-UHFFFAOYSA-N
DMSK6EM	IU	3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMSK6EM	DE	Discovery agent

DMWZDA1	ID	DMWZDA1
DMWZDA1	DN	3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMWZDA1	HS	Investigative
DMWZDA1	SN	CHEMBL445259; 3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMWZDA1	DT	Small molecular drug
DMWZDA1	PC	25034346
DMWZDA1	MW	279.3
DMWZDA1	FM	C18H17NO2
DMWZDA1	IC	InChI=1S/C18H17NO2/c1-3-21-18-10-16(11-19-12-18)14-4-5-15-9-17(20-2)7-6-13(15)8-14/h4-12H,3H2,1-2H3
DMWZDA1	CS	CCOC1=CN=CC(=C1)C2=CC3=C(C=C2)C=C(C=C3)OC
DMWZDA1	IK	YYDLHEYJRYMTMO-UHFFFAOYSA-N
DMWZDA1	IU	3-ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMWZDA1	DE	Discovery agent

DM6K7BI	ID	DM6K7BI
DM6K7BI	DN	3-Ethoxy-9H-beta-carboline
DM6K7BI	HS	Investigative
DM6K7BI	SN	3-Ethoxy-beta-carboline; 3-ethoxy-9H-pyrido[3,4-b]indole; CHEMBL498936; CHEMBL299250; 3-ethoxy-9h-; AC1Q4YMX; AC1L3YI4; SCHEMBL9531510; FNNPSIGQQWCKKB-UHFFFAOYSA-N; ZINC5139892; BDBM50001475; PDSP2_001734; BDBM50244034; PDSP1_001751; 3-Ethoxy-9H-beta-carboline(3-EBC); 9H-Pyrido(3,4-b)indole, 3-ethoxy-
DM6K7BI	DT	Small molecular drug
DM6K7BI	PC	124477
DM6K7BI	MW	212.25
DM6K7BI	FM	C13H12N2O
DM6K7BI	IC	InChI=1S/C13H12N2O/c1-2-16-13-7-10-9-5-3-4-6-11(9)15-12(10)8-14-13/h3-8,15H,2H2,1H3
DM6K7BI	CS	CCOC1=NC=C2C(=C1)C3=CC=CC=C3N2
DM6K7BI	IK	FNNPSIGQQWCKKB-UHFFFAOYSA-N
DM6K7BI	IU	3-ethoxy-9H-pyrido[3,4-b]indole
DM6K7BI	CA	CAS 91985-81-8
DM6K7BI	DE	Discovery agent

DMY4VOI	ID	DMY4VOI
DMY4VOI	DN	3-ethoxycarbonyl-4-quinolone
DMY4VOI	HS	Investigative
DMY4VOI	SN	ethyl 4-hydroxyquinoline-3-carboxylate; 26892-90-0; 52980-28-6; 4-Hydroxyquinoline-3-carboxylic acid ethyl ester; Ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate; Ethyl 4-oxo-1,4-dihydro-3-quinolinecarboxylate; ethyl 1,4-dihydro-4-oxoquinoline-3-carboxylate; 3-Quinolinecarboxylic acid, 1,4-dihydro-4-oxo-, ethyl ester; ethyl 4-oxohydroquinoline-3-carboxylate; ethyl 4-oxo-1H-quinoline-3-carboxylate; 4-HYDROXY-QUINOLINE-3-CARBOXYLIC ACID METHYL ESTER; 4-Oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester
DMY4VOI	DT	Small molecular drug
DMY4VOI	PC	220876
DMY4VOI	MW	217.22
DMY4VOI	FM	C12H11NO3
DMY4VOI	IC	InChI=1S/C12H11NO3/c1-2-16-12(15)9-7-13-10-6-4-3-5-8(10)11(9)14/h3-7H,2H2,1H3,(H,13,14)
DMY4VOI	CS	CCOC(=O)C1=CNC2=CC=CC=C2C1=O
DMY4VOI	IK	YBEOYBKKSWUSBR-UHFFFAOYSA-N
DMY4VOI	IU	ethyl 4-oxo-1H-quinoline-3-carboxylate
DMY4VOI	CA	CAS 52980-28-6
DMY4VOI	DE	Discovery agent

DMMDOI4	ID	DMMDOI4
DMMDOI4	DN	3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone
DMMDOI4	HS	Investigative
DMMDOI4	SN	CHEMBL205159
DMMDOI4	DT	Small molecular drug
DMMDOI4	PC	11521754
DMMDOI4	MW	259.3
DMMDOI4	FM	C15H17NO3
DMMDOI4	IC	InChI=1S/C15H17NO3/c1-4-10-6-7-12-11(8-10)14(17)13(9(3)16-12)15(18)19-5-2/h6-8H,4-5H2,1-3H3,(H,16,17)
DMMDOI4	CS	CCC1=CC2=C(C=C1)NC(=C(C2=O)C(=O)OCC)C
DMMDOI4	IK	RYTCQLITPWABMH-UHFFFAOYSA-N
DMMDOI4	IU	ethyl 6-ethyl-2-methyl-4-oxo-1H-quinoline-3-carboxylate
DMMDOI4	DE	Discovery agent

DM1E5QZ	ID	DM1E5QZ
DM1E5QZ	DN	3-ethoxycarbonyl-6-propyl-4-quinolone
DM1E5QZ	HS	Investigative
DM1E5QZ	SN	CHEMBL381491
DM1E5QZ	DT	Small molecular drug
DM1E5QZ	PC	11572455
DM1E5QZ	MW	259.3
DM1E5QZ	FM	C15H17NO3
DM1E5QZ	IC	InChI=1S/C15H17NO3/c1-3-5-10-6-7-13-11(8-10)14(17)12(9-16-13)15(18)19-4-2/h6-9H,3-5H2,1-2H3,(H,16,17)
DM1E5QZ	CS	CCCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCC
DM1E5QZ	IK	GLVXKESFOXDNRX-UHFFFAOYSA-N
DM1E5QZ	IU	ethyl 4-oxo-6-propyl-1H-quinoline-3-carboxylate
DM1E5QZ	DE	Discovery agent

DM4YL5Q	ID	DM4YL5Q
DM4YL5Q	DN	3-ethoxycarbonylpyroglutamate
DM4YL5Q	HS	Investigative
DM4YL5Q	SN	3-ethoxycarbonylpyroglutamate
DM4YL5Q	DT	Small molecular drug
DM4YL5Q	PC	45272996
DM4YL5Q	MW	229.23
DM4YL5Q	FM	C10H15NO5
DM4YL5Q	IC	InChI=1S/C10H15NO5/c1-3-15-9(13)6-5-7(12)11-8(6)10(14)16-4-2/h6,8H,3-5H2,1-2H3,(H,11,12)
DM4YL5Q	CS	CCOC(=O)C1CC(=O)NC1C(=O)OCC
DM4YL5Q	IK	OUZUMLMSKXXOLI-UHFFFAOYSA-N
DM4YL5Q	IU	diethyl 5-oxopyrrolidine-2,3-dicarboxylate
DM4YL5Q	DE	Discovery agent

DMX2JKQ	ID	DMX2JKQ
DMX2JKQ	DN	3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine
DMX2JKQ	HS	Investigative
DMX2JKQ	SN	CHEMBL185833; 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine
DMX2JKQ	DT	Small molecular drug
DMX2JKQ	PC	18721724
DMX2JKQ	MW	158.27
DMX2JKQ	FM	C7H14N2S
DMX2JKQ	IC	InChI=1S/C7H14N2S/c1-2-6-5-10-4-3-7(8)9-6/h6H,2-5H2,1H3,(H2,8,9)
DMX2JKQ	CS	CCC1CSCCC(=N1)N
DMX2JKQ	IK	BJFMNSRYUNDINA-UHFFFAOYSA-N
DMX2JKQ	IU	3-ethyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMX2JKQ	DE	Discovery agent

DMEWAVM	ID	DMEWAVM
DMEWAVM	DN	3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
DMEWAVM	HS	Investigative
DMEWAVM	SN	3-ethyl-2-(4-hydroxyphenyl)-2H-indazol-5-ol; CHEMBL180517
DMEWAVM	DT	Small molecular drug
DMEWAVM	PC	11149479
DMEWAVM	MW	254.28
DMEWAVM	FM	C15H14N2O2
DMEWAVM	IC	InChI=1S/C15H14N2O2/c1-2-15-13-9-12(19)7-8-14(13)16-17(15)10-3-5-11(18)6-4-10/h3-9,18-19H,2H2,1H3
DMEWAVM	CS	CCC1=C2C=C(C=CC2=NN1C3=CC=C(C=C3)O)O
DMEWAVM	IK	XBMVVMYGKMGLJX-UHFFFAOYSA-N
DMEWAVM	IU	3-ethyl-2-(4-hydroxyphenyl)indazol-5-ol
DMEWAVM	DE	Discovery agent

DMN8C93	ID	DMN8C93
DMN8C93	DN	3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol
DMN8C93	HS	Investigative
DMN8C93	SN	CHEMBL129249; 3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol; 1H-3-Benzazepin-6-ol, 3-ethyl-2,3,4,5-tetrahydro-; BDBM50003341; 143620-42-2
DMN8C93	DT	Small molecular drug
DMN8C93	PC	10261961
DMN8C93	MW	191.27
DMN8C93	FM	C12H17NO
DMN8C93	IC	InChI=1S/C12H17NO/c1-2-13-8-6-10-4-3-5-12(14)11(10)7-9-13/h3-5,14H,2,6-9H2,1H3
DMN8C93	CS	CCN1CCC2=C(CC1)C(=CC=C2)O
DMN8C93	IK	HTCXSPINZBVTNI-UHFFFAOYSA-N
DMN8C93	IU	3-ethyl-1,2,4,5-tetrahydro-3-benzazepin-6-ol
DMN8C93	DE	Discovery agent

DMB8Q7T	ID	DMB8Q7T
DMB8Q7T	DN	3-Ethyl-3-isobutyl-1-phenylazetidine-2,4-dione
DMB8Q7T	HS	Investigative
DMB8Q7T	SN	CHEMBL566475; 3-Ethyl-3-isobutyl-1-phenylazetidine-2,4-dione
DMB8Q7T	DT	Small molecular drug
DMB8Q7T	PC	44626814
DMB8Q7T	MW	245.32
DMB8Q7T	FM	C15H19NO2
DMB8Q7T	IC	InChI=1S/C15H19NO2/c1-4-15(10-11(2)3)13(17)16(14(15)18)12-8-6-5-7-9-12/h5-9,11H,4,10H2,1-3H3
DMB8Q7T	CS	CCC1(C(=O)N(C1=O)C2=CC=CC=C2)CC(C)C
DMB8Q7T	IK	IDCYZOAEGDFOSJ-UHFFFAOYSA-N
DMB8Q7T	IU	3-ethyl-3-(2-methylpropyl)-1-phenylazetidine-2,4-dione
DMB8Q7T	DE	Discovery agent

DMZK13I	ID	DMZK13I
DMZK13I	DN	3-Ethyl-3-isopropyl-dihydro-furan-2-one
DMZK13I	HS	Investigative
DMZK13I	SN	CHEMBL95665
DMZK13I	DT	Small molecular drug
DMZK13I	PC	10261321
DMZK13I	MW	156.22
DMZK13I	FM	C9H16O2
DMZK13I	IC	InChI=1S/C9H16O2/c1-4-9(7(2)3)5-6-11-8(9)10/h7H,4-6H2,1-3H3
DMZK13I	CS	CCC1(CCOC1=O)C(C)C
DMZK13I	IK	RQXMJDAZNMCZLO-UHFFFAOYSA-N
DMZK13I	IU	3-ethyl-3-propan-2-yloxolan-2-one
DMZK13I	DE	Discovery agent

DM1VTFU	ID	DM1VTFU
DM1VTFU	DN	3-Ethyl-3-methyl-dihydro-furan-2-one
DM1VTFU	HS	Investigative
DM1VTFU	SN	alpha-Emgbl; 2-Ethyl-2-methyl-4-butyrolactone; 3-ethyl-3-methyldihydrofuran-2(3h)-one; 31004-76-9; AC1Q6HQE; CHEBI:35057; 2(3H)-Furanone, 3-ethyldihydro-3-methyl-; alpha-Ethyl-alpha-methyl-gamma-butyrolactone; SureCN132980; C13714; AC1L53DL; SCHEMBL132980; CHEMBL285171; 3-ethyl-3-methyloxolan-2-one; CTK4G6275; 3-ethyl-3-methyl-tetrahydrofuran-2-one
DM1VTFU	DT	Small molecular drug
DM1VTFU	PC	169232
DM1VTFU	MW	128.169
DM1VTFU	FM	C7H12O2
DM1VTFU	IC	InChI=1S/C7H12O2/c1-3-7(2)4-5-9-6(7)8/h3-5H2,1-2H3
DM1VTFU	CS	CCC1(CCOC1=O)C
DM1VTFU	IK	DRTXQTMTWPIHLI-UHFFFAOYSA-N
DM1VTFU	IU	3-ethyl-3-methyloxolan-2-one
DM1VTFU	CA	CAS 31004-76-9
DM1VTFU	CB	CHEBI:35057
DM1VTFU	DE	Discovery agent

DMGPRBE	ID	DMGPRBE
DMGPRBE	DN	3-Ethylquinoline-8-carboxamide
DMGPRBE	HS	Investigative
DMGPRBE	SN	CHEMBL453989; 3-Ethylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethyl-; BDBM50255269
DMGPRBE	DT	Small molecular drug
DMGPRBE	PC	25208904
DMGPRBE	MW	200.24
DMGPRBE	FM	C12H12N2O
DMGPRBE	IC	InChI=1S/C12H12N2O/c1-2-8-6-9-4-3-5-10(12(13)15)11(9)14-7-8/h3-7H,2H2,1H3,(H2,13,15)
DMGPRBE	CS	CCC1=CN=C2C(=C1)C=CC=C2C(=O)N
DMGPRBE	IK	ACADFMJVXMCIFY-UHFFFAOYSA-N
DMGPRBE	IU	3-ethylquinoline-8-carboxamide
DMGPRBE	DE	Discovery agent

DMS4JGT	ID	DMS4JGT
DMS4JGT	DN	3-Ethynylquinoline-8-carboxamide
DMS4JGT	HS	Investigative
DMS4JGT	SN	CHEMBL501330; 3-Ethynylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethynyl-; BDBM50255268
DMS4JGT	DT	Small molecular drug
DMS4JGT	PC	25208746
DMS4JGT	MW	196.2
DMS4JGT	FM	C12H8N2O
DMS4JGT	IC	InChI=1S/C12H8N2O/c1-2-8-6-9-4-3-5-10(12(13)15)11(9)14-7-8/h1,3-7H,(H2,13,15)
DMS4JGT	CS	C#CC1=CN=C2C(=C1)C=CC=C2C(=O)N
DMS4JGT	IK	FVYCGVPNXRWDOH-UHFFFAOYSA-N
DMS4JGT	IU	3-ethynylquinoline-8-carboxamide
DMS4JGT	DE	Discovery agent

DMR29IQ	ID	DMR29IQ
DMR29IQ	DN	3-Fluoren-9-ylidenemethyl-pyridine
DMR29IQ	HS	Investigative
DMR29IQ	SN	3-(9h-fluoren-9-ylidenemethyl)pyridine; 3-(fluoren-9-ylidenemethyl)pyridine; 3239-00-7; NSC83320; AC1Q4YVX; AC1L5UM9; NCIOpen2_004633; CHEMBL194928; BDBM8637; SCHEMBL8276088; CTK1C4120; (3-Pyridylmethylene)fluorene 32; DTXSID10292510; NSC-83320; ZINC13283158; AKOS030540073; 3-(9H-Fluorene-9-ylidenemethyl)pyridine
DMR29IQ	DT	Small molecular drug
DMR29IQ	PC	139138079
DMR29IQ	MW	510.6
DMR29IQ	FM	C38H26N2
DMR29IQ	IC	InChI=1S/2C19H13N/c2*1-3-9-17-15(7-1)16-8-2-4-10-18(16)19(17)12-14-6-5-11-20-13-14/h2*1-13H
DMR29IQ	CS	C1=CC=C2C(=C1)C3=CC=CC=C3C2=CC4=CN=CC=C4.C1=CC=C2C(=C1)C3=CC=CC=C3C2=CC4=CN=CC=C4
DMR29IQ	IK	QQJHSQKNTSNWIQ-UHFFFAOYSA-N
DMR29IQ	IU	3-(fluoren-9-ylidenemethyl)pyridine
DMR29IQ	DE	Discovery agent

DMTY92S	ID	DMTY92S
DMTY92S	DN	3-Fluoro-2-(Phosphonooxy)Propanoic Acid
DMTY92S	HS	Investigative
DMTY92S	SN	3-FLUORO-2-(PHOSPHONOOXY)PROPANOIC ACID; AC1NRB38; DB03113; (2R)-3-fluoro-2-phosphonooxypropanoic acid; (2R)-3-fluoro-2-(phosphonooxy)propanoic acid
DMTY92S	DT	Small molecular drug
DMTY92S	PC	5288237
DMTY92S	MW	188.05
DMTY92S	FM	C3H6FO6P
DMTY92S	IC	InChI=1S/C3H6FO6P/c4-1-2(3(5)6)10-11(7,8)9/h2H,1H2,(H,5,6)(H2,7,8,9)/t2-/m0/s1
DMTY92S	CS	C([C@@H](C(=O)O)OP(=O)(O)O)F
DMTY92S	IK	BNOCDEBUFVJMQI-REOHCLBHSA-N
DMTY92S	IU	(2R)-3-fluoro-2-phosphonooxypropanoic acid
DMTY92S	DE	Discovery agent

DM4PLSU	ID	DM4PLSU
DM4PLSU	DN	3-fluoro-4'-(1-(pyridin-4-yl)propyl)biphenyl-4-ol
DM4PLSU	HS	Investigative
DM4PLSU	SN	CHEMBL1173261; SCHEMBL18770414; BDBM50322797
DM4PLSU	DT	Small molecular drug
DM4PLSU	PC	46854606
DM4PLSU	MW	307.4
DM4PLSU	FM	C20H18FNO
DM4PLSU	IC	InChI=1S/C20H18FNO/c1-2-18(16-9-11-22-12-10-16)15-5-3-14(4-6-15)17-7-8-20(23)19(21)13-17/h3-13,18,23H,2H2,1H3
DM4PLSU	CS	CCC(C1=CC=C(C=C1)C2=CC(=C(C=C2)O)F)C3=CC=NC=C3
DM4PLSU	IK	MSZSUMNJIMRHDP-UHFFFAOYSA-N
DM4PLSU	IU	2-fluoro-4-[4-(1-pyridin-4-ylpropyl)phenyl]phenol
DM4PLSU	DE	Discovery agent

DMJ3WNP	ID	DMJ3WNP
DMJ3WNP	DN	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol
DMJ3WNP	HS	Investigative
DMJ3WNP	SN	CHEMBL1173260; SCHEMBL18770351; BDBM50322791
DMJ3WNP	DT	Small molecular drug
DMJ3WNP	PC	46901611
DMJ3WNP	MW	279.3
DMJ3WNP	FM	C18H14FNO
DMJ3WNP	IC	InChI=1S/C18H14FNO/c19-17-12-16(5-6-18(17)21)15-3-1-13(2-4-15)11-14-7-9-20-10-8-14/h1-10,12,21H,11H2
DMJ3WNP	CS	C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)F
DMJ3WNP	IK	SFFLHOMUFWFHRI-UHFFFAOYSA-N
DMJ3WNP	IU	2-fluoro-4-[4-(pyridin-4-ylmethyl)phenyl]phenol
DMJ3WNP	DE	Discovery agent

DMLG69R	ID	DMLG69R
DMLG69R	DN	3-Fluoro-4-hydrazino-benzenesulfonamide
DMLG69R	HS	Investigative
DMLG69R	SN	3-Fluoro-4-hydrazino-benzenesulfonamide; 606126-17-4; 3-fluoro-4-hydrazinobenzenesulfonamide; hydrazide deriv. 15; SCHEMBL1244816; CHEMBL176180; CTK2E9801; BDBM12160; DTXSID90448811; IDSRHQBHQWPDNY-UHFFFAOYSA-N; AKOS013645919; 4-Hydrazino-3-fluorobenzenesulfonamide; Benzenesulfonamide, 3-fluoro-4-hydrazino-; TC-063144; 3-fluoro-4-hydrazinylbenzene-1-sulfonamide; 144147-EP2287165A2; 144147-EP2292620A2
DMLG69R	DT	Small molecular drug
DMLG69R	PC	10932611
DMLG69R	MW	205.21
DMLG69R	FM	C6H8FN3O2S
DMLG69R	IC	InChI=1S/C6H8FN3O2S/c7-5-3-4(13(9,11)12)1-2-6(5)10-8/h1-3,10H,8H2,(H2,9,11,12)
DMLG69R	CS	C1=CC(=C(C=C1S(=O)(=O)N)F)NN
DMLG69R	IK	IDSRHQBHQWPDNY-UHFFFAOYSA-N
DMLG69R	IU	3-fluoro-4-hydrazinylbenzenesulfonamide
DMLG69R	CA	CAS 606126-17-4
DMLG69R	DE	Discovery agent

DMH9VLF	ID	DMH9VLF
DMH9VLF	DN	3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile
DMH9VLF	HS	Investigative
DMH9VLF	SN	CHEMBL238390; 3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile
DMH9VLF	DT	Small molecular drug
DMH9VLF	PC	44434724
DMH9VLF	MW	249.24
DMH9VLF	FM	C15H8FN3
DMH9VLF	IC	InChI=1S/C15H8FN3/c16-13-5-10(8-17)4-12(6-13)15-7-14-11(9-19-15)2-1-3-18-14/h1-7,9H
DMH9VLF	CS	C1=CC2=CN=C(C=C2N=C1)C3=CC(=CC(=C3)C#N)F
DMH9VLF	IK	PSQNPPVCWZBHDY-UHFFFAOYSA-N
DMH9VLF	IU	3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile
DMH9VLF	DE	Discovery agent

DM2V45Z	ID	DM2V45Z
DM2V45Z	DN	3-fluoro-5-(2-methylquinolin-7-yl)benzonitrile
DM2V45Z	HS	Investigative
DM2V45Z	SN	3-Fluoro-5-(2-methylquinolin-7-yl)benzonitrile; CHEMBL232188; GTPL6444; SCHEMBL4303163; BDBM50216746; compound 23 [PMID:; compound 23
DM2V45Z	DT	Small molecular drug
DM2V45Z	PC	23661671
DM2V45Z	MW	262.28
DM2V45Z	FM	C17H11FN2
DM2V45Z	IC	InChI=1S/C17H11FN2/c1-11-2-3-13-4-5-14(9-17(13)20-11)15-6-12(10-19)7-16(18)8-15/h2-9H,1H3
DM2V45Z	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)F
DM2V45Z	IK	SDOLISUYGVMVBK-UHFFFAOYSA-N
DM2V45Z	IU	3-fluoro-5-(2-methylquinolin-7-yl)benzonitrile
DM2V45Z	DE	Discovery agent

DMDPY9N	ID	DMDPY9N
DMDPY9N	DN	3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMDPY9N	HS	Investigative
DMDPY9N	SN	CHEMBL583520; 3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMDPY9N	DT	Small molecular drug
DMDPY9N	PC	44542048
DMDPY9N	MW	286.3
DMDPY9N	FM	C16H11FO2S
DMDPY9N	IC	InChI=1S/C16H11FO2S/c17-12-7-11(8-14(19)9-12)16-6-5-15(20-16)10-1-3-13(18)4-2-10/h1-9,18-19H
DMDPY9N	CS	C1=CC(=CC=C1C2=CC=C(S2)C3=CC(=CC(=C3)F)O)O
DMDPY9N	IK	OWTLTMXTNPNZPH-UHFFFAOYSA-N
DMDPY9N	IU	3-fluoro-5-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMDPY9N	DE	Discovery agent

DMDPUC7	ID	DMDPUC7
DMDPUC7	DN	3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline
DMDPUC7	HS	Investigative
DMDPUC7	SN	CHEMBL121531; 3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline; Isoquinoline, 3-(fluoromethyl)-1,2,3,4-tetrahydro-; SCHEMBL6847135; BDBM50080517; AKOS024125792
DMDPUC7	DT	Small molecular drug
DMDPUC7	PC	10654599
DMDPUC7	MW	165.21
DMDPUC7	FM	C10H12FN
DMDPUC7	IC	InChI=1S/C10H12FN/c11-6-10-5-8-3-1-2-4-9(8)7-12-10/h1-4,10,12H,5-7H2
DMDPUC7	CS	C1C(NCC2=CC=CC=C21)CF
DMDPUC7	IK	SLBKHMRNZGCZIO-UHFFFAOYSA-N
DMDPUC7	IU	3-(fluoromethyl)-1,2,3,4-tetrahydroisoquinoline
DMDPUC7	DE	Discovery agent

DMECBLA	ID	DMECBLA
DMECBLA	DN	3-fluorovinylglycine
DMECBLA	HS	Investigative
DMECBLA	SN	Fluorovinylglycine; 3-Fluorovinylglycine; FVGly; ACMC-20melc; 3-Butenoic acid, 2-amino-3-fluoro-, (S)-; AC1MIW53; 2-amino-3-fluorobut-3-enoic acid; 2-Amino-3-fluoro-3-butenoic acid; 111687-18-4; AKOS006361808; 3-Butenoic acid, 2-amino-3-fluoro-, (+-)-
DMECBLA	DT	Small molecular drug
DMECBLA	PC	3081008
DMECBLA	MW	119.09
DMECBLA	FM	C4H6FNO2
DMECBLA	IC	InChI=1S/C4H6FNO2/c1-2(5)3(6)4(7)8/h3H,1,6H2,(H,7,8)
DMECBLA	CS	C=C(C(C(=O)O)N)F
DMECBLA	IK	HMOXWHQSNHKKFM-UHFFFAOYSA-N
DMECBLA	IU	2-amino-3-fluorobut-3-enoic acid
DMECBLA	CA	CAS 111581-52-3
DMECBLA	DE	Discovery agent

DM8RY7G	ID	DM8RY7G
DM8RY7G	DN	3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide
DM8RY7G	HS	Investigative
DM8RY7G	SN	CHEMBL567637; 135733-34-5; 1,2,5-Oxadiazole-3-carboxaldehyde, 4-phenyl-, 2-oxide; 3-formyl-4-phenyl-1,2,5-oxadiazole n2-oxide; ACMC-20mvvi; 3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide; CTK0F4054; DTXSID00438521; 3-Formyl-4-phenylfurazan 2-oxide; BDBM50300756
DM8RY7G	DT	Small molecular drug
DM8RY7G	PC	10352496
DM8RY7G	MW	190.16
DM8RY7G	FM	C9H6N2O3
DM8RY7G	IC	InChI=1S/C9H6N2O3/c12-6-8-9(10-14-11(8)13)7-4-2-1-3-5-7/h1-6H
DM8RY7G	CS	C1=CC=C(C=C1)C2=NO[N+](=C2C=O)[O-]
DM8RY7G	IK	MNNADPGXJASGIU-UHFFFAOYSA-N
DM8RY7G	IU	2-oxido-4-phenyl-1,2,5-oxadiazol-2-ium-3-carbaldehyde
DM8RY7G	CA	CAS 135733-34-5
DM8RY7G	DE	Discovery agent

DMBFCTZ	ID	DMBFCTZ
DMBFCTZ	DN	3h-Indole-5,6-Diol
DMBFCTZ	HS	Investigative
DMBFCTZ	SN	5,6-Dihydroxyindole; 3131-52-0; 1H-Indole-5,6-diol; Dopamine lutine; 3H-INDOLE-5,6-DIOL; dhi; UNII-Z3OC8499KG; 5,6-DihydroxyindoleI; C8H7NO2; CHEMBL92636; Z3OC8499KG; CHEBI:27404; AK-25753; D-3560; 3ID; 5,6-Dihydroxy-1H-indole; indole-5,6-diol; 5,6-dihydroxy indole; AC1L3FSK; EC 412-130-9; SCHEMBL48994; AC1Q7A19; CTK1C3371; DTXSID20185242; SGNZYJXNUURYCH-UHFFFAOYSA-N; MolPort-001-782-232; ZINC895800; BCP02562; ACT06797; EBD26988; ZX-AT011826; KS-00000J9K; CD-595; BDBM50028548; BBL102959; ANW-44822; STL556768; MFCD00798933; FCH834612
DMBFCTZ	DT	Small molecular drug
DMBFCTZ	PC	114683
DMBFCTZ	MW	149.15
DMBFCTZ	FM	C8H7NO2
DMBFCTZ	IC	InChI=1S/C8H7NO2/c10-7-3-5-1-2-9-6(5)4-8(7)11/h1-4,9-11H
DMBFCTZ	CS	C1=CNC2=CC(=C(C=C21)O)O
DMBFCTZ	IK	SGNZYJXNUURYCH-UHFFFAOYSA-N
DMBFCTZ	IU	1H-indole-5,6-diol
DMBFCTZ	CA	CAS 3131-52-0
DMBFCTZ	CB	CHEBI:27404
DMBFCTZ	DE	Discovery agent

DMLB2W5	ID	DMLB2W5
DMLB2W5	DN	3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol
DMLB2W5	HS	Investigative
DMLB2W5	DT	Small molecular drug
DMLB2W5	PC	135403816
DMLB2W5	MW	136.11
DMLB2W5	FM	C5H4N4O
DMLB2W5	IC	InChI=1S/C5H4N4O/c10-5-4-3(1-8-9-4)6-2-7-5/h2H,1H2,(H,6,7,10)
DMLB2W5	CS	C1C2=C(C(=O)NC=N2)N=N1
DMLB2W5	IK	OGCXIHWGXUQTCQ-UHFFFAOYSA-N
DMLB2W5	IU	3,6-dihydropyrazolo[4,3-d]pyrimidin-7-one
DMLB2W5	CA	CAS 161746-78-7
DMLB2W5	CB	CHEBI:44995
DMLB2W5	DE	Discovery agent

DMC70P1	ID	DMC70P1
DMC70P1	DN	3-hydroxy capric acid
DMC70P1	HS	Investigative
DMC70P1	SN	3-OH-C10; 3-hydroxy-decanoic acid
DMC70P1	DT	Small molecular drug
DMC70P1	PC	26612
DMC70P1	MW	188.26
DMC70P1	FM	C10H20O3
DMC70P1	IC	InChI=1S/C10H20O3/c1-2-3-4-5-6-7-9(11)8-10(12)13/h9,11H,2-8H2,1H3,(H,12,13)
DMC70P1	CS	CCCCCCCC(CC(=O)O)O
DMC70P1	IK	FYSSBMZUBSBFJL-UHFFFAOYSA-N
DMC70P1	IU	3-hydroxydecanoic acid
DMC70P1	CA	CAS 14292-26-3
DMC70P1	CB	CHEBI:132983
DMC70P1	DE	Discovery agent

DMZSOPU	ID	DMZSOPU
DMZSOPU	DN	3-Hydroxy-1H-benzo[b]azepine-2,5-dione
DMZSOPU	HS	Investigative
DMZSOPU	SN	3-hydroxy-1H-1-benzazepine-2,5-dione; CHEMBL91742; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-; 52280-64-5; 3-Hydroxy-1H-benzo[b]azepine-2,5-dione; SCHEMBL2639080; CTK1E4553; DTXSID10618296; BDBM50054638; 5-hydroxy-1H-1-benzazepine-2,3-dione
DMZSOPU	DT	Small molecular drug
DMZSOPU	PC	21812299
DMZSOPU	MW	189.17
DMZSOPU	FM	C10H7NO3
DMZSOPU	IC	InChI=1S/C10H7NO3/c12-8-5-9(13)10(14)11-7-4-2-1-3-6(7)8/h1-5,12H,(H,11,13,14)
DMZSOPU	CS	C1=CC=C2C(=C1)C(=CC(=O)C(=O)N2)O
DMZSOPU	IK	LRWDJVXXZACNEV-UHFFFAOYSA-N
DMZSOPU	IU	5-hydroxy-1H-1-benzazepine-2,3-dione
DMZSOPU	CA	CAS 52280-64-5
DMZSOPU	DE	Discovery agent

DM4758S	ID	DM4758S
DM4758S	DN	3hydroxy-1-methyl-1-phenylurea
DM4758S	HS	Investigative
DM4758S	SN	CHEMBL262340; N'-hydroxy-N-methyl-N-phenylurea; 13262-41-4; 1-Methyl-1-phenyl-3-hydroxyurea; BDBM50377110
DM4758S	DT	Small molecular drug
DM4758S	PC	11672724
DM4758S	MW	166.18
DM4758S	FM	C8H10N2O2
DM4758S	IC	InChI=1S/C8H10N2O2/c1-10(8(11)9-12)7-5-3-2-4-6-7/h2-6,12H,1H3,(H,9,11)
DM4758S	CS	CN(C1=CC=CC=C1)C(=O)NO
DM4758S	IK	UDJKPENTLREIMW-UHFFFAOYSA-N
DM4758S	IU	3-hydroxy-1-methyl-1-phenylurea
DM4758S	DE	Discovery agent

DMI785L	ID	DMI785L
DMI785L	DN	3-hydroxy-2-methoxybenzaldehyde
DMI785L	HS	Investigative
DMI785L	SN	3-hydroxy-2-methoxybenzaldehyde; 66495-88-3; CHEMBL507918; 3-hydroxy-2-methoxy-benzaldehyde; hydroxy-methoxy-benzaldehyde; SCHEMBL470709; 2-methoxy-3-hydroxybenzaldehyde; CTK1J4694; DTXSID70473025; GRIWJVSWLJHHEM-UHFFFAOYSA-N; MolPort-002-462-004; Benzaldehyde,3-hydroxy-2-methoxy-; KS-00000B2L; Benzaldehyde, 3-hydroxy-2-methoxy-; ZINC12505037; BDBM50266963; 5891AJ; AKOS000119267; MB03871; SY025931; CS-11591; KB-236283; MFCD06656119 (95%)
DMI785L	DT	Small molecular drug
DMI785L	PC	11804953
DMI785L	MW	152.15
DMI785L	FM	C8H8O3
DMI785L	IC	InChI=1S/C8H8O3/c1-11-8-6(5-9)3-2-4-7(8)10/h2-5,10H,1H3
DMI785L	CS	COC1=C(C=CC=C1O)C=O
DMI785L	IK	GRIWJVSWLJHHEM-UHFFFAOYSA-N
DMI785L	IU	3-hydroxy-2-methoxybenzaldehyde
DMI785L	CA	CAS 66495-88-3
DMI785L	DE	Discovery agent

DMIVDFW	ID	DMIVDFW
DMIVDFW	DN	3-hydroxy-2-phenylquinoline-4-carboxylic acid
DMIVDFW	HS	Investigative
DMIVDFW	SN	Oxycinchophen; 485-89-2; Oxinofen; Chinoxone; Fenidrone; 3-hydroxy-2-phenylquinoline-4-carboxylic acid; Hydroxycinchophene; Sintofene; Magnofenyl; Reumartril; Magnophenyl; 3-Hydroxy-2-phenylcinchoninic acid; 3-Hydroxycinchophen; oxicinchophen; Oxicinchophenum; Oxycinchophen [INN:BAN]; Oxicincofeno [INN-Spanish]; UNII-UK6392GD5W; Oxycinchophene [INN-French]; Oxycinchophenum [INN-Latin]; 3-Hydroxy-2-phenyl-4-quinolinecarboxylic acid; 3-Hydroxy-2-phenyl-chinchoninsaeure; EINECS 207-624-4; NSC 41784; BRN 0224526; CHEMBL219376
DMIVDFW	DT	Small molecular drug
DMIVDFW	PC	10239
DMIVDFW	MW	265.26
DMIVDFW	FM	C16H11NO3
DMIVDFW	IC	InChI=1S/C16H11NO3/c18-15-13(16(19)20)11-8-4-5-9-12(11)17-14(15)10-6-2-1-3-7-10/h1-9,18H,(H,19,20)
DMIVDFW	CS	C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2O)C(=O)O
DMIVDFW	IK	XAPRFLSJBSXESP-UHFFFAOYSA-N
DMIVDFW	IU	3-hydroxy-2-phenylquinoline-4-carboxylic acid
DMIVDFW	CA	CAS 485-89-2
DMIVDFW	CB	CHEBI:135094
DMIVDFW	DE	Discovery agent

DMEK9DH	ID	DMEK9DH
DMEK9DH	DN	3-hydroxy-2-propionylcyclohex-2-enone
DMEK9DH	HS	Investigative
DMEK9DH	SN	CHEMBL308796; 62847-90-9; AC1LBQYE; 2-(1-hydroxypropylidene)cyclohexane-1,3-dione; CTK2B1414; DTXSID40343105; ROVGIVWUAMEQQN-UHFFFAOYSA-N; ZINC4786244; 2-Cyclohexen-3-ol-1-one, 2-propioyl-; 2-Propionyl-3-hydroxy-2-cyclohexene-1-one; 3-Hydroxy-2-propionyl-2-cyclohexen-1-one #; 2-Cyclohexen-1-one, 3-hydroxy-2-(1-oxopropyl)-
DMEK9DH	DT	Small molecular drug
DMEK9DH	PC	587484
DMEK9DH	MW	168.19
DMEK9DH	FM	C9H12O3
DMEK9DH	IC	InChI=1S/C9H12O3/c1-2-6(10)9-7(11)4-3-5-8(9)12/h10H,2-5H2,1H3
DMEK9DH	CS	CCC(=C1C(=O)CCCC1=O)O
DMEK9DH	IK	KIXYWPAKWURPPK-UHFFFAOYSA-N
DMEK9DH	IU	2-(1-hydroxypropylidene)cyclohexane-1,3-dione
DMEK9DH	CA	CAS 62847-90-9
DMEK9DH	DE	Discovery agent

DM3YO72	ID	DM3YO72
DM3YO72	DN	3-hydroxy-3-methyl-6-phosphohexanoic acid
DM3YO72	HS	Investigative
DM3YO72	SN	3-hydroxy-3-methyl-6-phosphonohexanoic acid; 63370-13-8; GTPL3202; SCHEMBL11310701; CTK2A9401; DTXSID80634286; Hexanoic acid, 3-hydroxy-3-methyl-6-phosphono-
DM3YO72	DT	Small molecular drug
DM3YO72	PC	23452327
DM3YO72	MW	226.16
DM3YO72	FM	C7H15O6P
DM3YO72	IC	InChI=1S/C7H15O6P/c1-7(10,5-6(8)9)3-2-4-14(11,12)13/h10H,2-5H2,1H3,(H,8,9)(H2,11,12,13)
DM3YO72	CS	CC(CCCP(=O)(O)O)(CC(=O)O)O
DM3YO72	IK	XRCIRZGXKWCWNQ-UHFFFAOYSA-N
DM3YO72	IU	3-hydroxy-3-methyl-6-phosphonohexanoic acid
DM3YO72	CA	CAS 63370-13-8
DM3YO72	DE	Discovery agent

DMJD0UV	ID	DMJD0UV
DMJD0UV	DN	3-Hydroxy-3-Methyl-Glutaric Acid
DMJD0UV	HS	Investigative
DMJD0UV	SN	Meglutol; MEGLUTOL; 3-Hydroxy-3-methylglutaric acid; 503-49-1; Dicrotalic acid; 3-Hydroxy-3-methylpentanedioic acid; Lipoglutaren; Medroglutaric acid; 3-hydroxy-3-methyl-glutaric acid; HMGA; beta-Hydroxy-beta-methylglutaric acid; Meglutolum; Meglutol [USAN:INN]; Meglutolum [INN-Latin]; Pentanedioic acid, 3-hydroxy-3-methyl-; CB-337; CB 337; UNII-CLA99KCD53; 3-Hydroxy-3-methylglutarate; Glutaric acid, 3-hydroxy-3-methyl-; EINECS 207-971-1; NSC 361411; 3-Hydroxymethylglutaric acid; BRN 1769194; CLA99KCD53; CHEMBL50444; CHEBI:16831
DMJD0UV	DT	Small molecular drug
DMJD0UV	PC	1662
DMJD0UV	MW	162.14
DMJD0UV	FM	C6H10O5
DMJD0UV	IC	InChI=1S/C6H10O5/c1-6(11,2-4(7)8)3-5(9)10/h11H,2-3H2,1H3,(H,7,8)(H,9,10)
DMJD0UV	CS	CC(CC(=O)O)(CC(=O)O)O
DMJD0UV	IK	NPOAOTPXWNWTSH-UHFFFAOYSA-N
DMJD0UV	IU	3-hydroxy-3-methylpentanedioic acid
DMJD0UV	CA	CAS 503-49-1
DMJD0UV	CB	CHEBI:16831
DMJD0UV	DE	Discovery agent

DMEJQTA	ID	DMEJQTA
DMEJQTA	DN	3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one
DMEJQTA	HS	Investigative
DMEJQTA	SN	CHEMBL205988; 3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one; SCHEMBL6828383
DMEJQTA	DT	Small molecular drug
DMEJQTA	PC	10082995
DMEJQTA	MW	240.25
DMEJQTA	FM	C15H12O3
DMEJQTA	IC	InChI=1S/C15H12O3/c1-8-4-3-5-11-13(8)10-6-7-12(16)9(2)14(10)18-15(11)17/h3-7,16H,1-2H3
DMEJQTA	CS	CC1=C2C3=C(C(=C(C=C3)O)C)OC(=O)C2=CC=C1
DMEJQTA	IK	PSZUCXJKMVSZSN-UHFFFAOYSA-N
DMEJQTA	IU	3-hydroxy-4,10-dimethylbenzo[c]chromen-6-one
DMEJQTA	DE	Discovery agent

DMUME74	ID	DMUME74
DMUME74	DN	3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one
DMUME74	HS	Investigative
DMUME74	SN	CHEMBL204959; 3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one; BDBM50180476
DMUME74	DT	Small molecular drug
DMUME74	PC	10399376
DMUME74	MW	240.25
DMUME74	FM	C15H12O3
DMUME74	IC	InChI=1S/C15H12O3/c1-8-4-3-5-10-11-6-7-12(16)9(2)14(11)18-15(17)13(8)10/h3-7,16H,1-2H3
DMUME74	CS	CC1=C2C(=CC=C1)C3=C(C(=C(C=C3)O)C)OC2=O
DMUME74	IK	BSCZPVUHFUQDQP-UHFFFAOYSA-N
DMUME74	IU	3-hydroxy-4,7-dimethylbenzo[c]chromen-6-one
DMUME74	DE	Discovery agent

DMDBJCY	ID	DMDBJCY
DMDBJCY	DN	3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one
DMDBJCY	HS	Investigative
DMDBJCY	SN	3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one; 3-hydroxy-4-methylbenzo[c]chromen-6-one; CHEMBL203519; 76244-77-4; CBMicro_031406; AC1NT8BO; AC1Q2GPY; Oprea1_200366; SCHEMBL6825266; MolPort-000-688-996; ALBB-015456; ZINC5921519; BDBM50180504; STL466134; AKOS002377900; MCULE-5900160059; NS-02841; BIM-0031475.P001; R5445; 4-Methyl-3-hydroxy-6H-dibenzo[b,d]pyran-6-one; SR-01000229483; SR-01000229483-1; 6H-Dibenzo[b,d]pyran-6-one, 3-hydroxy-4-methyl-
DMDBJCY	DT	Small molecular drug
DMDBJCY	PC	5348729
DMDBJCY	MW	226.23
DMDBJCY	FM	C14H10O3
DMDBJCY	IC	InChI=1S/C14H10O3/c1-8-12(15)7-6-10-9-4-2-3-5-11(9)14(16)17-13(8)10/h2-7,15H,1H3
DMDBJCY	CS	CC1=C(C=CC2=C1OC(=O)C3=CC=CC=C23)O
DMDBJCY	IK	LAVHXGNOROFSCU-UHFFFAOYSA-N
DMDBJCY	IU	3-hydroxy-4-methylbenzo[c]chromen-6-one
DMDBJCY	DE	Discovery agent

DM5QZDL	ID	DM5QZDL
DM5QZDL	DN	3-Hydroxy-4-phenyl-5H-furan-2-one
DM5QZDL	HS	Investigative
DM5QZDL	SN	CHEMBL295478; 6362-76-1; 3-Hydroxy-4-phenylfuran-2(5H)-one; CTK2A8725; DTXSID60446001; 3-hydroxy-4-phenyl-2(5h)-furanone; 2(5H)-Furanone, 3-hydroxy-4-phenyl-
DM5QZDL	DT	Small molecular drug
DM5QZDL	PC	10103675
DM5QZDL	MW	176.17
DM5QZDL	FM	C10H8O3
DM5QZDL	IC	InChI=1S/C10H8O3/c11-9-8(6-13-10(9)12)7-4-2-1-3-5-7/h1-5,8H,6H2
DM5QZDL	CS	C1C(C(=O)C(=O)O1)C2=CC=CC=C2
DM5QZDL	IK	WYGILTLZANOLBZ-UHFFFAOYSA-N
DM5QZDL	IU	4-phenyloxolane-2,3-dione
DM5QZDL	DE	Discovery agent

DMZS4P7	ID	DMZS4P7
DMZS4P7	DN	3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile
DMZS4P7	HS	Investigative
DMZS4P7	SN	CHEMBL233618; 3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile
DMZS4P7	DT	Small molecular drug
DMZS4P7	PC	44432687
DMZS4P7	MW	260.29
DMZS4P7	FM	C17H12N2O
DMZS4P7	IC	InChI=1S/C17H12N2O/c1-11-2-3-13-4-5-14(9-17(13)19-11)15-6-12(10-18)7-16(20)8-15/h2-9,20H,1H3
DMZS4P7	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)O
DMZS4P7	IK	DYISJDYQAJMMQY-UHFFFAOYSA-N
DMZS4P7	IU	3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile
DMZS4P7	DE	Discovery agent

DMYR350	ID	DMYR350
DMYR350	DN	3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione
DMYR350	HS	Investigative
DMYR350	SN	3-Hydroxy-6-methyl-1H-1-benzazepine-2,5-dione; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-6-methyl-; SCHEMBL8580170; CHEMBL143225; LPRUKTXSSXGABW-UHFFFAOYSA-N
DMYR350	DT	Small molecular drug
DMYR350	PC	10655753
DMYR350	MW	203.19
DMYR350	FM	C11H9NO3
DMYR350	IC	InChI=1S/C11H9NO3/c1-6-3-2-4-7-10(6)8(13)5-9(14)11(15)12-7/h2-5,13H,1H3,(H,12,14,15)
DMYR350	CS	CC1=C2C(=CC=C1)NC(=O)C(=O)C=C2O
DMYR350	IK	SFRUZUUPMLUZHX-UHFFFAOYSA-N
DMYR350	IU	5-hydroxy-6-methyl-1H-1-benzazepine-2,3-dione
DMYR350	DE	Discovery agent

DM3SOFX	ID	DM3SOFX
DM3SOFX	DN	3-Hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile
DM3SOFX	HS	Investigative
DM3SOFX	SN	3-Hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile; CHEMBL508693; SCHEMBL3015500; PBXARVUJEROSCH-UHFFFAOYSA-N
DM3SOFX	DT	Small molecular drug
DM3SOFX	PC	24950552
DM3SOFX	MW	261.269
DM3SOFX	FM	C17H11NO2
DM3SOFX	IC	InChI=1S/C17H11NO2/c18-10-14-8-16(20)7-13-5-4-12(9-17(13)14)11-2-1-3-15(19)6-11/h1-9,19-20H
DM3SOFX	CS	C1=CC(=CC(=C1)O)C2=CC3=C(C=C(C=C3C=C2)O)C#N
DM3SOFX	IK	PBXARVUJEROSCH-UHFFFAOYSA-N
DM3SOFX	IU	3-hydroxy-7-(3-hydroxyphenyl)naphthalene-1-carbonitrile
DM3SOFX	DE	Discovery agent

DMTEJOY	ID	DMTEJOY
DMTEJOY	DN	3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione
DMTEJOY	HS	Investigative
DMTEJOY	SN	SCHEMBL9389021
DMTEJOY	DT	Small molecular drug
DMTEJOY	PC	10633414
DMTEJOY	MW	234.16
DMTEJOY	FM	C10H6N2O5
DMTEJOY	IC	InChI=1S/C10H6N2O5/c13-8-4-9(14)10(15)11-7-2-1-5(12(16)17)3-6(7)8/h1-4,13H,(H,11,14,15)
DMTEJOY	CS	C1=CC2=C(C=C1[N+](=O)[O-])C(=CC(=O)C(=O)N2)O
DMTEJOY	IK	QIUGYFFOPLNZSP-UHFFFAOYSA-N
DMTEJOY	IU	5-hydroxy-7-nitro-1H-1-benzazepine-2,3-dione
DMTEJOY	DE	Discovery agent

DM3H56L	ID	DM3H56L
DM3H56L	DN	3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one
DM3H56L	HS	Investigative
DM3H56L	SN	CHEMBL380720; 3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one
DM3H56L	DT	Small molecular drug
DM3H56L	PC	44408769
DM3H56L	MW	240.25
DM3H56L	FM	C15H12O3
DM3H56L	IC	InChI=1S/C15H12O3/c1-8-5-9(2)14-11-4-3-10(16)7-13(11)18-15(17)12(14)6-8/h3-7,16H,1-2H3
DM3H56L	CS	CC1=CC(=C2C3=C(C=C(C=C3)O)OC(=O)C2=C1)C
DM3H56L	IK	LTZNXKCOWADUFT-UHFFFAOYSA-N
DM3H56L	IU	3-hydroxy-8,10-dimethylbenzo[c]chromen-6-one
DM3H56L	DE	Discovery agent

DM7HKIF	ID	DM7HKIF
DM7HKIF	DN	3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione
DM7HKIF	HS	Investigative
DM7HKIF	SN	144040-48-2; 2,5-Dihydro-2,5-dioxo-3-hydroxy-8-methyl-1H-benzazepine; 8-Me-Ddhb; AC1L2QYL; 5-hydroxy-8-methyl-1H-1-benzazepine-2,3-dione; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-8-methyl-; CHEMBL143519; SCHEMBL9387738; CTK4C3913; 8-Methyl-3-hydroxy-1H-1-benzazepine-2,5-dione; 1H-1-Benzaepine-2,5-dione, 3-hydroxy-8-methyl-
DM7HKIF	DT	Small molecular drug
DM7HKIF	PC	126810
DM7HKIF	MW	203.19
DM7HKIF	FM	C11H9NO3
DM7HKIF	IC	InChI=1S/C11H9NO3/c1-6-2-3-7-8(4-6)12-11(15)10(14)5-9(7)13/h2-5,13H,1H3,(H,12,14,15)
DM7HKIF	CS	CC1=CC2=C(C=C1)C(=CC(=O)C(=O)N2)O
DM7HKIF	IK	HJKATLKAMYKFOH-UHFFFAOYSA-N
DM7HKIF	IU	5-hydroxy-8-methyl-1H-1-benzazepine-2,3-dione
DM7HKIF	CA	CAS 144040-48-2
DM7HKIF	DE	Discovery agent

DMNV1P3	ID	DMNV1P3
DMNV1P3	DN	3-Hydroxy-benzamide
DMNV1P3	HS	Investigative
DMNV1P3	SN	3-hydroxybenzamide; 618-49-5; benzamide, 3-hydroxy-; 3-Hydroxy-benzamide; CHEMBL419424; 3-Hydroxy benzamide; NSC379289; 3-hydroxybenzenecarboxamide; AC1Q4ZB3; AC1L7W2U; ACMC-1B71B; Oprea1_435073; SCHEMBL161861; 3-Hydroxybenzamide, AldrichCPR; CTK2F7291; DTXSID90321635; NGMMGKYJUWYIIG-UHFFFAOYSA-N; MolPort-001-791-593; ZINC1590754; KM0548; BDBM50068769; 9282AB; ANW-33964; 3-HYDROXY-BENZOIC ACID,AMIDE; SBB079277; AKOS000207073; VZ26952; NSC-379289; MB00281; MCULE-9599926365; NCGC00323509-01; KB-32185; CJ-25437; AJ-27681; CJ-05592; SC-47787
DMNV1P3	DT	Small molecular drug
DMNV1P3	PC	342403
DMNV1P3	MW	137.14
DMNV1P3	FM	C7H7NO2
DMNV1P3	IC	InChI=1S/C7H7NO2/c8-7(10)5-2-1-3-6(9)4-5/h1-4,9H,(H2,8,10)
DMNV1P3	CS	C1=CC(=CC(=C1)O)C(=O)N
DMNV1P3	IK	NGMMGKYJUWYIIG-UHFFFAOYSA-N
DMNV1P3	IU	3-hydroxybenzamide
DMNV1P3	CA	CAS 618-49-5
DMNV1P3	DE	Discovery agent

DMNUM4K	ID	DMNUM4K
DMNUM4K	DN	3-hydroxybenzylhydrazine
DMNUM4K	HS	Investigative
DMNUM4K	SN	3-hydroxybenzylhydrazine; 3-(hydrazinylmethyl)phenol; 637-33-2; 3-(Hydrazinomethyl)phenol; Nsd 1015; m-Hydroxybenzyl hydrazine; UNII-A27K5Q85R2; 3-Hydrazinomethyl-phenol; BRN 1841459; HYDRAZINE, 1-(3-HYDROXYBENZYL)-; CHEMBL352205; NSD-1015; A27K5Q85R2; 3-hydroxy-benzylhydrazine; C7H10N2O; m-hydroxybenzylhydrazine; Phenol,3-(hydrazinylmethyl)-; Spectrum_000313; SpecPlus_000785; AC1L1BYI; Spectrum4_001209; Spectrum5_001883; Spectrum3_000726; Lopac-H-9382; Lopac0_000597; BSPBio_002252; KBioGR_001618; 3-(Hydrazinomethyl)phenol #
DMNUM4K	DT	Small molecular drug
DMNUM4K	PC	1663
DMNUM4K	MW	138.17
DMNUM4K	FM	C7H10N2O
DMNUM4K	IC	InChI=1S/C7H10N2O/c8-9-5-6-2-1-3-7(10)4-6/h1-4,9-10H,5,8H2
DMNUM4K	CS	C1=CC(=CC(=C1)O)CNN
DMNUM4K	IK	OFKWWALNMPEOSZ-UHFFFAOYSA-N
DMNUM4K	IU	3-(hydrazinylmethyl)phenol
DMNUM4K	CA	CAS 637-33-2
DMNUM4K	CB	CHEBI:104133
DMNUM4K	DE	Discovery agent

DM5T6AM	ID	DM5T6AM
DM5T6AM	DN	3-hydroxydesaminokynurenine
DM5T6AM	HS	Investigative
DM5T6AM	DT	Small molecular drug
DM5T6AM	PC	56603743
DM5T6AM	MW	223.22
DM5T6AM	FM	C11H13NO4
DM5T6AM	IC	InChI=1S/C11H13NO4/c1-11(12,10(15)16)6-9(14)7-3-2-4-8(13)5-7/h2-5,13H,6,12H2,1H3,(H,15,16)
DM5T6AM	CS	CC(CC(=O)C1=CC(=CC=C1)O)(C(=O)O)N
DM5T6AM	IK	DVMCGTUZEKNSGK-UHFFFAOYSA-N
DM5T6AM	IU	2-amino-4-(3-hydroxyphenyl)-2-methyl-4-oxobutanoic acid
DM5T6AM	DE	Discovery agent

DM2LBFW	ID	DM2LBFW
DM2LBFW	DN	3-Hydroxyhippuric acid
DM2LBFW	HS	Investigative
DM2LBFW	SN	3-hydroxyhippuric acid; m-Hydroxyhippuric acid; 1637-75-8; (3-Hydroxybenzoylamino)acetic acid; 2-[(3-hydroxyphenyl)formamido]acetic acid; Glycine, N-(3-hydroxybenzoyl)-; UNII-17HCX0HNRT; N-m-Hydroxylbenzoylglycine; 3-Hydroxybenzoylglycine; 17HCX0HNRT; CHEMBL447627; Glycine,N-(3-hydroxybenzoyl)-; (3-hydroxybenzamido)acetic acid; CHEBI:70824; m-Hydroxyhippurate; 3-Hydroxyhippurate; AC1L9OTS; (3-hydroxybenzoyl)glycine; AC1Q75XZ; N-(3-hydroxybenzoyl)glycine; SCHEMBL600772; CTK4D1647; DTXSID30167650; MolPort-004-292-678
DM2LBFW	DT	Small molecular drug
DM2LBFW	PC	450268
DM2LBFW	MW	195.17
DM2LBFW	FM	C9H9NO4
DM2LBFW	IC	InChI=1S/C9H9NO4/c11-7-3-1-2-6(4-7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13)
DM2LBFW	CS	C1=CC(=CC(=C1)O)C(=O)NCC(=O)O
DM2LBFW	IK	XDOFWFNMYJRHEW-UHFFFAOYSA-N
DM2LBFW	IU	2-[(3-hydroxybenzoyl)amino]acetic acid
DM2LBFW	CA	CAS 1637-75-8
DM2LBFW	CB	CHEBI:70824
DM2LBFW	DE	Discovery agent

DMKLZXV	ID	DMKLZXV
DMKLZXV	DN	3-Hydroxyisoxazole-4-Carboxylic Acid
DMKLZXV	HS	Investigative
DMKLZXV	SN	3-HYDROXYISOXAZOLE-4-CARBOXYLIC ACID; 178316-78-4; GAG; AC1L9M6X; 3-isoxazolol carboxylic acid; SCHEMBL353410; CHEMBL1232960; CTK0H1143; BDBM23242; DTXSID30332285; 1,2(1,5)-Isoxazole, IOA1; AKOS022719234; AKOS006383552; 3-oxo-1,2-oxazole-4-carboxylic acid; DB02111; 3-hydroxy-1,2-oxazole-4-carboxylic acid; 3-oxo-2,3-dihydroisoxazole-4-carboxylic acid; 2429-EP2311823A1; 2429-EP2308960A1; 4-Isoxazolecarboxylicacid, 2,3-dihydro-3-oxo-
DMKLZXV	DT	Small molecular drug
DMKLZXV	PC	448651
DMKLZXV	MW	129.07
DMKLZXV	FM	C4H3NO4
DMKLZXV	IC	InChI=1S/C4H3NO4/c6-3-2(4(7)8)1-9-5-3/h1H,(H,5,6)(H,7,8)
DMKLZXV	CS	C1=C(C(=O)NO1)C(=O)O
DMKLZXV	IK	JLPHBZYAQYOJND-UHFFFAOYSA-N
DMKLZXV	IU	3-oxo-1,2-oxazole-4-carboxylic acid
DMKLZXV	CA	CAS 178316-78-4
DMKLZXV	DE	Discovery agent

DMNMB6V	ID	DMNMB6V
DMNMB6V	DN	3-hydroxylauric acid
DMNMB6V	HS	Investigative
DMNMB6V	SN	3-hydroxy lauric acid
DMNMB6V	DT	Small molecular drug
DMNMB6V	PC	94216
DMNMB6V	MW	216.32
DMNMB6V	FM	C12H24O3
DMNMB6V	IC	InChI=1S/C12H24O3/c1-2-3-4-5-6-7-8-9-11(13)10-12(14)15/h11,13H,2-10H2,1H3,(H,14,15)
DMNMB6V	CS	CCCCCCCCCC(CC(=O)O)O
DMNMB6V	IK	MUCMKTPAZLSKTL-UHFFFAOYSA-N
DMNMB6V	IU	3-hydroxydodecanoic acid
DMNMB6V	CA	CAS 1883-13-2
DMNMB6V	CB	CHEBI:36206
DMNMB6V	DE	Discovery agent

DMFJLWO	ID	DMFJLWO
DMFJLWO	DN	3-Hydroxy-Myristic Acid
DMFJLWO	HS	Investigative
DMFJLWO	SN	3-hydroxymyristate; 3-hydroxytetradecanoate; beta-hydroxymyristate; 3-hydroxy myristic acid; 3-hydroxytetradecanoate(1-)
DMFJLWO	DT	Small molecular drug
DMFJLWO	PC	5288266
DMFJLWO	MW	244.37
DMFJLWO	FM	C14H28O3
DMFJLWO	IC	InChI=1S/C14H28O3/c1-2-3-4-5-6-7-8-9-10-11-13(15)12-14(16)17/h13,15H,2-12H2,1H3,(H,16,17)/t13-/m1/s1
DMFJLWO	CS	CCCCCCCCCCC[C@H](CC(=O)O)O
DMFJLWO	IK	ATRNZOYKSNPPBF-CYBMUJFWSA-N
DMFJLWO	IU	(3R)-3-hydroxytetradecanoic acid
DMFJLWO	CA	CAS 28715-21-1
DMFJLWO	CB	CHEBI:42539
DMFJLWO	DE	Discovery agent

DMXO98C	ID	DMXO98C
DMXO98C	DN	3-hydroxy-N,N,N-trimethylbenzenaminium iodide
DMXO98C	HS	Investigative
DMXO98C	SN	TMPH; 3-(Trimethylammonio)phenol iodide; m-(Dimethylamino)phenol methiodide; 3-Hydroxy-N,N,N-trimethylbenzenaminium iodide; 3-Oxyphenyl trimethylammonium iodide; (m-Hydroxyphenyl)trimethylammonium iodide; CHEMBL37773; AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, IODIDE; 2498-27-3; 3483-84-9 (Parent); 3-Hydroxyphenyltrimethylammonium Iodide; AC1L29MQ; Benzenaminium, 3-hydroxy-N,N,N-trimethyl-, iodide; KNPHMCQIKGHPRU-UHFFFAOYSA-N; m-hydroxyphenyltrimethylammonium iodide; LS-18453; (3-hydroxyphenyl)-trimethylazanium iodide
DMXO98C	DT	Small molecular drug
DMXO98C	PC	17250
DMXO98C	MW	279.12
DMXO98C	FM	C9H14INO
DMXO98C	IC	InChI=1S/C9H13NO.HI/c1-10(2,3)8-5-4-6-9(11)7-8;/h4-7H,1-3H3;1H
DMXO98C	CS	C[N+](C)(C)C1=CC(=CC=C1)O.[I-]
DMXO98C	IK	KNPHMCQIKGHPRU-UHFFFAOYSA-N
DMXO98C	IU	(3-hydroxyphenyl)-trimethylazanium;iodide
DMXO98C	CA	CAS 2498-27-3
DMXO98C	DE	Discovery agent

DMS658R	ID	DMS658R
DMS658R	DN	3-hydroxyoctanoic acid
DMS658R	HS	Investigative
DMS658R	SN	3-hydroxyoctanoate; 3-OH-octanoic acid
DMS658R	DT	Small molecular drug
DMS658R	PC	26613
DMS658R	MW	160.21
DMS658R	FM	C8H16O3
DMS658R	IC	InChI=1S/C8H16O3/c1-2-3-4-5-7(9)6-8(10)11/h7,9H,2-6H2,1H3,(H,10,11)
DMS658R	CS	CCCCCC(CC(=O)O)O
DMS658R	IK	NDPLAKGOSZHTPH-UHFFFAOYSA-N
DMS658R	IU	3-hydroxyoctanoic acid
DMS658R	CA	CAS 14292-27-4
DMS658R	CB	CHEBI:37098
DMS658R	DE	Discovery agent

DMMAK83	ID	DMMAK83
DMMAK83	DN	3-hydroxyphenethyl 3,4,5-trihydroxybenzoate
DMMAK83	HS	Investigative
DMMAK83	SN	CHEMBL246622; 3-hydroxyphenethyl 3,4,5-trihydroxybenzoate; Gallic acid 3-hydroxyphenethyl ester
DMMAK83	DT	Small molecular drug
DMMAK83	PC	24180539
DMMAK83	MW	290.27
DMMAK83	FM	C15H14O6
DMMAK83	IC	InChI=1S/C15H14O6/c16-11-3-1-2-9(6-11)4-5-21-15(20)10-7-12(17)14(19)13(18)8-10/h1-3,6-8,16-19H,4-5H2
DMMAK83	CS	C1=CC(=CC(=C1)O)CCOC(=O)C2=CC(=C(C(=C2)O)O)O
DMMAK83	IK	VXELBUJPXRMMLF-UHFFFAOYSA-N
DMMAK83	IU	2-(3-hydroxyphenyl)ethyl 3,4,5-trihydroxybenzoate
DMMAK83	DE	Discovery agent

DM5OR96	ID	DM5OR96
DM5OR96	DN	3-Hydroxy-piperidine-4-carboxylic acid
DM5OR96	HS	Investigative
DM5OR96	SN	CHEMBL16132; BDBM50223877
DM5OR96	DT	Small molecular drug
DM5OR96	PC	44270790
DM5OR96	MW	145.16
DM5OR96	FM	C6H11NO3
DM5OR96	IC	InChI=1S/C6H11NO3/c8-5-3-7-2-1-4(5)6(9)10/h4-5,7-8H,1-3H2,(H,9,10)/t4-,5+/m1/s1
DM5OR96	CS	C1CNC[C@@H]([C@@H]1C(=O)O)O
DM5OR96	IK	ASDFUVTYTVOHPL-UHNVWZDZSA-N
DM5OR96	IU	(3R,4R)-3-hydroxypiperidine-4-carboxylic acid
DM5OR96	DE	Discovery agent

DM67QDT	ID	DM67QDT
DM67QDT	DN	3-Hydroxypyruvic Acid
DM67QDT	HS	Investigative
DM67QDT	SN	3-Hydroxypyruvic acid; hydroxypyruvic acid; 3-Hydroxy-2-oxopropanoic acid; hydroxypyruvate; 1113-60-6; beta-Hydroxypyruvate; UNII-934B2KHY0S; 3-hydroxypyruvate; 934B2KHY0S; OH-pyruvate; OH-pyr; 3PY; 4mfe; beta-Hydoxypyruvic acid; beta-Hydroxypyruvic acid; AC1L1AFB; SCHEMBL60708; CTK8A1122; CHEBI:30841; DTXSID40149588; MolPort-006-168-729; ZINC1532558; AKOS006378194; DB02951; HY-113013; CS-0059352; C00168; J-002568; beta-Hydroxypyruvic acid, &gt;=95.0% (dry substance, T)
DM67QDT	DT	Small molecular drug
DM67QDT	PC	964
DM67QDT	MW	104.06
DM67QDT	FM	C3H4O4
DM67QDT	IC	InChI=1S/C3H4O4/c4-1-2(5)3(6)7/h4H,1H2,(H,6,7)
DM67QDT	CS	C(C(=O)C(=O)O)O
DM67QDT	IK	HHDDCCUIIUWNGJ-UHFFFAOYSA-N
DM67QDT	IU	3-hydroxy-2-oxopropanoic acid
DM67QDT	CA	CAS 1113-60-6
DM67QDT	CB	CHEBI:30841
DM67QDT	DE	Discovery agent

DMCXZ9L	ID	DMCXZ9L
DMCXZ9L	DN	3-hydroxyquinazoline-2,4(1H,3H)-dione
DMCXZ9L	HS	Investigative
DMCXZ9L	SN	3-hydroxyquinazoline-2,4(1H,3H)-dione; 3-hydroxy-quinazoline-2,4-dione; CHEMBL183852; 5329-43-1; NSC2552; AC1Q6JF3; AC1L58DP; N-hydroxy quinazolinedione, 4; SCHEMBL1520708; 3-hydroxyquinazoline-2,4-dione; CTK4J7468; BDBM33412; DTXSID00277492; ZINC1640999; NSC-2552; 3-hydroxy-1H-quinazoline-2,4-dione; 3-HYDROXY-2,3H)-QUINAZOLINEDIONE
DMCXZ9L	DT	Small molecular drug
DMCXZ9L	PC	220188
DMCXZ9L	MW	178.14
DMCXZ9L	FM	C8H6N2O3
DMCXZ9L	IC	InChI=1S/C8H6N2O3/c11-7-5-3-1-2-4-6(5)9-8(12)10(7)13/h1-4,13H,(H,9,12)
DMCXZ9L	CS	C1=CC=C2C(=C1)C(=O)N(C(=O)N2)O
DMCXZ9L	IK	TZZSQUATPYDROZ-UHFFFAOYSA-N
DMCXZ9L	IU	3-hydroxy-1H-quinazoline-2,4-dione
DMCXZ9L	CA	CAS 5329-43-1
DMCXZ9L	DE	Discovery agent

DMBZ60O	ID	DMBZ60O
DMBZ60O	DN	3-Imidazol-1-ylmethyl-1H-indole
DMBZ60O	HS	Investigative
DMBZ60O	SN	CHEMBL116794; 3-Imidazol-1-ylmethyl-1H-indole; 1H-Indole, 3-(1H-imidazol-1-ylmethyl)-; 19714-15-9; MLS000105265; AC1LGCIB; Cambridge id 5261471; CBDivE_013805; SCHEMBL9214699; 3-(imidazol-1-ylmethyl)indole; CTK0E0809; DTXSID40355147; FRADTKAUXQUOIJ-UHFFFAOYSA-N; MolPort-001-788-875; HMS2390H20; ZINC293947; 3-(imidazol-1-ylmethyl)-1H-indole; BDBM50022120; AKOS030489795; MCULE-1147695503; 3-(1H-imidazol-1-ylmethyl)-1H-Indole; BAS 01027138; 1-(1H-Indole-3-ylmethyl)-1H-imidazole
DMBZ60O	DT	Small molecular drug
DMBZ60O	PC	792486
DMBZ60O	MW	197.24
DMBZ60O	FM	C12H11N3
DMBZ60O	IC	InChI=1S/C12H11N3/c1-2-4-12-11(3-1)10(7-14-12)8-15-6-5-13-9-15/h1-7,9,14H,8H2
DMBZ60O	CS	C1=CC=C2C(=C1)C(=CN2)CN3C=CN=C3
DMBZ60O	IK	FRADTKAUXQUOIJ-UHFFFAOYSA-N
DMBZ60O	IU	3-(imidazol-1-ylmethyl)-1H-indole
DMBZ60O	CA	CAS 19714-15-9
DMBZ60O	DE	Discovery agent

DMAQOL0	ID	DMAQOL0
DMAQOL0	DN	3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole
DMAQOL0	HS	Investigative
DMAQOL0	SN	72818-36-1; UK 34787; UK-34787; CHEMBL284356; 3-(1h-imidazol-1-ylmethyl)-2-(propan-2-yl)-1h-indole; 3-(imidazol-1-ylmethyl)-2-propan-2-yl-1H-indole; 3-Isopropyl-3-(1-imidazolylmethyl)indole; AC1L4YBG; 3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole; AC1Q4X5Y; SCHEMBL11346119; CTK5D6874; DTXSID00223136; NZXGMVRYQLENHC-UHFFFAOYSA-N; BDBM50022121; NSC342229; AKOS030539398; NSC-342229; 3-(imidazol-1-ylmethyl)-2-isopropylindole; 3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole(UK-34787); 1H-Indole, 3-(1H-imidazol-1-ylmethyl)-2-(1-methylethy
DMAQOL0	DT	Small molecular drug
DMAQOL0	PC	194468
DMAQOL0	MW	239.32
DMAQOL0	FM	C15H17N3
DMAQOL0	IC	InChI=1S/C15H17N3/c1-11(2)15-13(9-18-8-7-16-10-18)12-5-3-4-6-14(12)17-15/h3-8,10-11,17H,9H2,1-2H3
DMAQOL0	CS	CC(C)C1=C(C2=CC=CC=C2N1)CN3C=CN=C3
DMAQOL0	IK	NZXGMVRYQLENHC-UHFFFAOYSA-N
DMAQOL0	IU	3-(imidazol-1-ylmethyl)-2-propan-2-yl-1H-indole
DMAQOL0	CA	CAS 72818-36-1
DMAQOL0	DE	Discovery agent

DMVF6OQ	ID	DMVF6OQ
DMVF6OQ	DN	3-Imidazol-1-yl-quinoline
DMVF6OQ	HS	Investigative
DMVF6OQ	SN	3-Imidazol-1-yl-quinoline; MLS003269485; SCHEMBL4514468; CHEMBL193556; BDBM8919; 3-(1h-imidazol-1-yl)quinoline; 3-(1H-Imidazole-1-yl)quinoline; Imidazole-substituted quinoline 26; ZINC13674486; Quinoline, 3-(1H-imidazol-1-yl)-; 63822-85-5
DMVF6OQ	DT	Small molecular drug
DMVF6OQ	PC	12354256
DMVF6OQ	MW	195.22
DMVF6OQ	FM	C12H9N3
DMVF6OQ	IC	InChI=1S/C12H9N3/c1-2-4-12-10(3-1)7-11(8-14-12)15-6-5-13-9-15/h1-9H
DMVF6OQ	CS	C1=CC=C2C(=C1)C=C(C=N2)N3C=CN=C3
DMVF6OQ	IK	SRUVTPIFNUPTIR-UHFFFAOYSA-N
DMVF6OQ	IU	3-imidazol-1-ylquinoline
DMVF6OQ	DE	Discovery agent

DMYH6A2	ID	DMYH6A2
DMYH6A2	DN	3-Indan-(1E)-ylidenemethyl-pyridine
DMYH6A2	HS	Investigative
DMYH6A2	SN	(3-Pyridylmethylene)indane 1a; SCHEMBL4221377; SCHEMBL4221371; CHEMBL364080; BDBM8581; AC1O7046; 3-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 3-[(1E)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 3-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Hydrochloride
DMYH6A2	DT	Small molecular drug
DMYH6A2	PC	6539759
DMYH6A2	MW	207.27
DMYH6A2	FM	C15H13N
DMYH6A2	IC	InChI=1S/C15H13N/c1-2-6-15-13(5-1)7-8-14(15)10-12-4-3-9-16-11-12/h1-6,9-11H,7-8H2/b14-10+
DMYH6A2	CS	C1C/C(=C\\C2=CN=CC=C2)/C3=CC=CC=C31
DMYH6A2	IK	WDSJJUYCBHIJRT-GXDHUFHOSA-N
DMYH6A2	IU	3-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine
DMYH6A2	DE	Discovery agent

DMTQERW	ID	DMTQERW
DMTQERW	DN	3-Indan-(1Z)-ylidenemethyl-pyridine
DMTQERW	HS	Investigative
DMTQERW	SN	(3-Pyridylmethylene)indane 1b; BDBM8583; SCHEMBL4221374; CHEMBL363621; AC1O7048; 3-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 3-[(1Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 3-[(Z)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Hydrochloride
DMTQERW	DT	Small molecular drug
DMTQERW	PC	6539760
DMTQERW	MW	207.27
DMTQERW	FM	C15H13N
DMTQERW	IC	InChI=1S/C15H13N/c1-2-6-15-13(5-1)7-8-14(15)10-12-4-3-9-16-11-12/h1-6,9-11H,7-8H2/b14-10-
DMTQERW	CS	C1C/C(=C/C2=CN=CC=C2)/C3=CC=CC=C31
DMTQERW	IK	WDSJJUYCBHIJRT-UVTDQMKNSA-N
DMTQERW	IU	3-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine
DMTQERW	DE	Discovery agent

DM890WJ	ID	DM890WJ
DM890WJ	DN	3-Iodoboldine
DM890WJ	HS	Investigative
DM890WJ	SN	3-Iodoboldine; CHEMBL256075; BDBM50202337
DM890WJ	DT	Small molecular drug
DM890WJ	PC	10004036
DM890WJ	MW	453.3
DM890WJ	FM	C19H20INO4
DM890WJ	IC	InChI=1S/C19H20INO4/c1-21-5-4-10-15-12(21)6-9-7-13(22)14(24-2)8-11(9)16(15)19(25-3)18(23)17(10)20/h7-8,12,22-23H,4-6H2,1-3H3/t12-/m0/s1
DM890WJ	CS	CN1CCC2=C3[C@@H]1CC4=CC(=C(C=C4C3=C(C(=C2I)O)OC)OC)O
DM890WJ	IK	YCBIBKGMUXWRRT-LBPRGKRZSA-N
DM890WJ	IU	(6aS)-3-iodo-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DM890WJ	DE	Discovery agent

DMDSJ0O	ID	DMDSJ0O
DMDSJ0O	DN	3-iodo-N-(6-methylpyridin-2-yl)benzamide
DMDSJ0O	HS	Investigative
DMDSJ0O	SN	3-iodo-N-(6-methylpyridin-2-yl)benzamide; CHEMBL210550; AC1MPEXW; Oprea1_504239; BDBM50186325
DMDSJ0O	DT	Small molecular drug
DMDSJ0O	PC	3410100
DMDSJ0O	MW	338.14
DMDSJ0O	FM	C13H11IN2O
DMDSJ0O	IC	InChI=1S/C13H11IN2O/c1-9-4-2-7-12(15-9)16-13(17)10-5-3-6-11(14)8-10/h2-8H,1H3,(H,15,16,17)
DMDSJ0O	CS	CC1=NC(=CC=C1)NC(=O)C2=CC(=CC=C2)I
DMDSJ0O	IK	YFGDUEHHLUXXKH-UHFFFAOYSA-N
DMDSJ0O	IU	3-iodo-N-(6-methylpyridin-2-yl)benzamide
DMDSJ0O	DE	Discovery agent

DM3L0F8	ID	DM3L0F8
DM3L0F8	DN	3-iodothyronamine
DM3L0F8	HS	Investigative
DM3L0F8	SN	CHEMBL201002; 3'-iodothyronamine; 3''-iodothyronamine; GTPL2145; SCHEMBL13886595; BDBM50181801; 4-[4-(2-aminoethyl)phenoxy]-2-iodophenol
DM3L0F8	DT	Small molecular drug
DM3L0F8	PC	9950514
DM3L0F8	MW	355.17
DM3L0F8	FM	C14H14INO2
DM3L0F8	IC	InChI=1S/C14H14INO2/c15-13-9-10(7-8-16)1-6-14(13)18-12-4-2-11(17)3-5-12/h1-6,9,17H,7-8,16H2
DM3L0F8	CS	C1=CC(=CC=C1O)OC2=C(C=C(C=C2)CCN)I
DM3L0F8	IK	XIINYOJWNGOUPF-UHFFFAOYSA-N
DM3L0F8	IU	4-[4-(2-aminoethyl)-2-iodophenoxy]phenol
DM3L0F8	CA	CAS 712349-95-6
DM3L0F8	CB	CHEBI:89700
DM3L0F8	DE	Discovery agent

DMNZMH6	ID	DMNZMH6
DMNZMH6	DN	3-iodotyrosine
DMNZMH6	HS	Investigative
DMNZMH6	SN	2-amino-3-(4-hydroxy-3-iodophenyl)propanoic acid; 3078-39-5; 3-Iodo-DL-tyrosine; C9H10INO3; 3-iodo-l-tyr; AC1Q4PGG; ACMC-209og3; SCHEMBL159411; AC1L1M60; GTPL5117; CTK7I4445; UQTZMGFTRHFAAM-UHFFFAOYSA-N; MolPort-006-167-934; NSC210787; AKOS022187633; S(-)-3-Iodo-4-hydroxy- phenylamine; TRA0009499; MCULE-7084802066; AN-8912; NSC-210787; FCH1320103; SC-11023; KB-32311; AX8285033; Z5788; 2-Amino-3-(3-iodo-4-hydroxyphenyl)propionic acid; 2-Amino-3-(4-hydroxy-3-iodophenyl)propionic acid; 2-amino-3-(4-hydroxy-3-iodo-phenyl)propanoic acid
DMNZMH6	DT	Small molecular drug
DMNZMH6	PC	439744
DMNZMH6	MW	307.08
DMNZMH6	FM	C9H10INO3
DMNZMH6	IC	InChI=1S/C9H10INO3/c10-6-3-5(1-2-8(6)12)4-7(11)9(13)14/h1-3,7,12H,4,11H2,(H,13,14)/t7-/m0/s1
DMNZMH6	CS	C1=CC(=C(C=C1C[C@@H](C(=O)O)N)I)O
DMNZMH6	IK	UQTZMGFTRHFAAM-ZETCQYMHSA-N
DMNZMH6	IU	(2S)-2-amino-3-(4-hydroxy-3-iodophenyl)propanoic acid
DMNZMH6	CA	CAS 70-78-0
DMNZMH6	CB	CHEBI:27847
DMNZMH6	DE	Discovery agent

DMJSLVT	ID	DMJSLVT
DMJSLVT	DN	3-Iodyl-benzoic acid
DMJSLVT	HS	Investigative
DMJSLVT	SN	3-Iodyl-benzoic acid; 3-iodylbenzoic Acid; CHEMBL332161; 64297-65-0; m-iodoxybenzoic acid; AC1MTEHD; Benzoic acid, 3-iodyl-; SCHEMBL752292; CTK2A6346; DTXSID40393544
DMJSLVT	DT	Small molecular drug
DMJSLVT	PC	3549290
DMJSLVT	MW	280.02
DMJSLVT	FM	C7H5IO4
DMJSLVT	IC	InChI=1S/C7H5IO4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4H,(H,9,10)
DMJSLVT	CS	C1=CC(=CC(=C1)I(=O)=O)C(=O)O
DMJSLVT	IK	PXGYMLKSIXWMJW-UHFFFAOYSA-N
DMJSLVT	IU	3-iodylbenzoic acid
DMJSLVT	CA	CAS 64297-65-0
DMJSLVT	DE	Discovery agent

DMWP0LZ	ID	DMWP0LZ
DMWP0LZ	DN	3-isobutoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMWP0LZ	HS	Investigative
DMWP0LZ	SN	CHEMBL413487; 3-isobutoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMWP0LZ	DT	Small molecular drug
DMWP0LZ	PC	44432689
DMWP0LZ	MW	316.4
DMWP0LZ	FM	C21H20N2O
DMWP0LZ	IC	InChI=1S/C21H20N2O/c1-14(2)13-24-20-9-16(12-22)8-19(10-20)18-7-6-17-5-4-15(3)23-21(17)11-18/h4-11,14H,13H2,1-3H3
DMWP0LZ	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)OCC(C)C
DMWP0LZ	IK	HPDNDHJWHRZLDU-UHFFFAOYSA-N
DMWP0LZ	IU	3-(2-methylpropoxy)-5-(2-methylquinolin-7-yl)benzonitrile
DMWP0LZ	DE	Discovery agent

DM6X5TZ	ID	DM6X5TZ
DM6X5TZ	DN	3-Isobutoxy-9H-beta-carboline
DM6X5TZ	HS	Investigative
DM6X5TZ	SN	CHEMBL87334; CHEMBL1269093; ZINC13728526; BDBM50001470; 3-isobutoxy-9H-pyrido[3,4-b]indole
DM6X5TZ	DT	Small molecular drug
DM6X5TZ	PC	10333698
DM6X5TZ	MW	240.3
DM6X5TZ	FM	C15H16N2O
DM6X5TZ	IC	InChI=1S/C15H16N2O/c1-10(2)9-18-15-7-12-11-5-3-4-6-13(11)17-14(12)8-16-15/h3-8,10,17H,9H2,1-2H3
DM6X5TZ	CS	CC(C)COC1=NC=C2C(=C1)C3=CC=CC=C3N2
DM6X5TZ	IK	KWHWSXISOMCUPZ-UHFFFAOYSA-N
DM6X5TZ	IU	3-(2-methylpropoxy)-9H-pyrido[3,4-b]indole
DM6X5TZ	DE	Discovery agent

DMQXP7C	ID	DMQXP7C
DMQXP7C	DN	3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine
DMQXP7C	HS	Investigative
DMQXP7C	SN	CHEMBL185919; 3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine
DMQXP7C	DT	Small molecular drug
DMQXP7C	PC	18721725
DMQXP7C	MW	186.32
DMQXP7C	FM	C9H18N2S
DMQXP7C	IC	InChI=1S/C9H18N2S/c1-7(2)5-8-6-12-4-3-9(10)11-8/h7-8H,3-6H2,1-2H3,(H2,10,11)
DMQXP7C	CS	CC(C)CC1CSCCC(=N1)N
DMQXP7C	IK	KMFANDQFKVBAJW-UHFFFAOYSA-N
DMQXP7C	IU	3-(2-methylpropyl)-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMQXP7C	DE	Discovery agent

DM9GM1H	ID	DM9GM1H
DM9GM1H	DN	3-isobutyl-8-pyrrolidinoxanthine
DM9GM1H	HS	Investigative
DM9GM1H	SN	3-isobutyl-8-pyrrolidinoxanthine; IPDX; GTPL447; SCHEMBL2954176; KHQOTPZSYMSVHB-UHFFFAOYSA-N
DM9GM1H	DT	Small molecular drug
DM9GM1H	PC	10221256
DM9GM1H	MW	277.32
DM9GM1H	FM	C13H19N5O2
DM9GM1H	IC	InChI=1S/C13H19N5O2/c1-8(2)7-18-10-9(11(19)16-13(18)20)14-12(15-10)17-5-3-4-6-17/h8H,3-7H2,1-2H3,(H,14,15)(H,16,19,20)
DM9GM1H	CS	CC(C)CN1C2=C(C(=O)NC1=O)NC(=N2)N3CCCC3
DM9GM1H	IK	KHQOTPZSYMSVHB-UHFFFAOYSA-N
DM9GM1H	IU	3-(2-methylpropyl)-8-pyrrolidin-1-yl-7H-purine-2,6-dione
DM9GM1H	DE	Discovery agent

DM7PHO4	ID	DM7PHO4
DM7PHO4	DN	3-Isopropoxy-9H-beta-carboline
DM7PHO4	HS	Investigative
DM7PHO4	SN	CHEMBL67421; 3-Isopropoxy-9H-beta-carboline; AC1NFSY9; 3-Isopropyloxy-beta-carboline; CHEMBL458006; SCHEMBL10642443; ZINC6858948; BDBM50001471
DM7PHO4	DT	Small molecular drug
DM7PHO4	PC	4713435
DM7PHO4	MW	226.27
DM7PHO4	FM	C14H14N2O
DM7PHO4	IC	InChI=1S/C14H14N2O/c1-9(2)17-14-7-11-10-5-3-4-6-12(10)16-13(11)8-15-14/h3-9,16H,1-2H3
DM7PHO4	CS	CC(C)OC1=NC=C2C(=C1)C3=CC=CC=C3N2
DM7PHO4	IK	AKHQVIZELNFWSQ-UHFFFAOYSA-N
DM7PHO4	IU	3-propan-2-yloxy-9H-pyrido[3,4-b]indole
DM7PHO4	DE	Discovery agent

DMYKVRF	ID	DMYKVRF
DMYKVRF	DN	3-Isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione
DMYKVRF	HS	Investigative
DMYKVRF	SN	3-isopropyl-1-methylxanthine; CHEMBL26119; 102284-72-0; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-(1-methylethyl)-; ACMC-20m5ap; 1-Methyl-3-isopropylxanthine; 3-Isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione; 3-isopropyl-1-methyl xanthine; CTK0D9143; DTXSID50436895; BDBM50025581
DMYKVRF	DT	Small molecular drug
DMYKVRF	PC	10219934
DMYKVRF	MW	208.22
DMYKVRF	FM	C9H12N4O2
DMYKVRF	IC	InChI=1S/C9H12N4O2/c1-5(2)13-7-6(10-4-11-7)8(14)12(3)9(13)15/h4-5H,1-3H3,(H,10,11)
DMYKVRF	CS	CC(C)N1C2=C(C(=O)N(C1=O)C)NC=N2
DMYKVRF	IK	ZBQTVZYXBOKEMJ-UHFFFAOYSA-N
DMYKVRF	IU	1-methyl-3-propan-2-yl-7H-purine-2,6-dione
DMYKVRF	CA	CAS 102284-72-0
DMYKVRF	DE	Discovery agent

DMSLPGZ	ID	DMSLPGZ
DMSLPGZ	DN	3-Isopropyl-3-methyl-dihydro-furan-2-one
DMSLPGZ	HS	Investigative
DMSLPGZ	SN	132462-11-4; alpha-Imgbl; 2(3H)-Furanone, dihydro-3-methyl-3-(1-methylethyl)-; 3-methyl-3-propan-2-yloxolan-2-one; alpha-Isopropyl-alpha-methyl-gamma-butyrolactone; AC1L2ZBI; CHEMBL35007; SCHEMBL10171772
DMSLPGZ	DT	Small molecular drug
DMSLPGZ	PC	131516
DMSLPGZ	MW	142.2
DMSLPGZ	FM	C8H14O2
DMSLPGZ	IC	InChI=1S/C8H14O2/c1-6(2)8(3)4-5-10-7(8)9/h6H,4-5H2,1-3H3
DMSLPGZ	CS	CC(C)C1(CCOC1=O)C
DMSLPGZ	IK	NUQBWYMPMSPNQT-UHFFFAOYSA-N
DMSLPGZ	IU	3-methyl-3-propan-2-yloxolan-2-one
DMSLPGZ	CA	CAS 132462-11-4
DMSLPGZ	DE	Discovery agent

DMHAJ6W	ID	DMHAJ6W
DMHAJ6W	DN	3-isopropyl-4-(phenylamino)naphthalene-1,2-dione
DMHAJ6W	HS	Investigative
DMHAJ6W	SN	CHEMBL204939; 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione
DMHAJ6W	DT	Small molecular drug
DMHAJ6W	PC	44409841
DMHAJ6W	MW	291.3
DMHAJ6W	FM	C19H17NO2
DMHAJ6W	IC	InChI=1S/C19H17NO2/c1-12(2)16-17(20-13-8-4-3-5-9-13)14-10-6-7-11-15(14)18(21)19(16)22/h3-12,20H,1-2H3
DMHAJ6W	CS	CC(C)C1=C(C2=CC=CC=C2C(=O)C1=O)NC3=CC=CC=C3
DMHAJ6W	IK	HHIYZEJIOLXXOB-UHFFFAOYSA-N
DMHAJ6W	IU	4-anilino-3-propan-2-ylnaphthalene-1,2-dione
DMHAJ6W	DE	Discovery agent

DMJZEMB	ID	DMJZEMB
DMJZEMB	DN	3-isopropyl-4-(phenylthio)naphthalene-1,2-dione
DMJZEMB	HS	Investigative
DMJZEMB	SN	CHEMBL205381; 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione
DMJZEMB	DT	Small molecular drug
DMJZEMB	PC	44409669
DMJZEMB	MW	308.4
DMJZEMB	FM	C19H16O2S
DMJZEMB	IC	InChI=1S/C19H16O2S/c1-12(2)16-18(21)17(20)14-10-6-7-11-15(14)19(16)22-13-8-4-3-5-9-13/h3-12H,1-2H3
DMJZEMB	CS	CC(C)C1=C(C2=CC=CC=C2C(=O)C1=O)SC3=CC=CC=C3
DMJZEMB	IK	VHVWQYNOEGPBOE-UHFFFAOYSA-N
DMJZEMB	IU	4-phenylsulfanyl-3-propan-2-ylnaphthalene-1,2-dione
DMJZEMB	DE	Discovery agent

DMYZCWX	ID	DMYZCWX
DMYZCWX	DN	3-isopropyl-4-phenylnaphthalene-1,2-dione
DMYZCWX	HS	Investigative
DMYZCWX	SN	CHEMBL207833; 3-isopropyl-4-phenylnaphthalene-1,2-dione
DMYZCWX	DT	Small molecular drug
DMYZCWX	PC	44409685
DMYZCWX	MW	276.3
DMYZCWX	FM	C19H16O2
DMYZCWX	IC	InChI=1S/C19H16O2/c1-12(2)16-17(13-8-4-3-5-9-13)14-10-6-7-11-15(14)18(20)19(16)21/h3-12H,1-2H3
DMYZCWX	CS	CC(C)C1=C(C2=CC=CC=C2C(=O)C1=O)C3=CC=CC=C3
DMYZCWX	IK	ZMFOKOSZYNMITK-UHFFFAOYSA-N
DMYZCWX	IU	4-phenyl-3-propan-2-ylnaphthalene-1,2-dione
DMYZCWX	DE	Discovery agent

DM46ID2	ID	DM46ID2
DM46ID2	DN	3-isopropylnaphthalene-1,2-dione
DM46ID2	HS	Investigative
DM46ID2	SN	CHEMBL44166; 3-Isopropyl-[1,2]naphthoquinone; 3-isopropylnaphthalene-1,2-dione; 3-Isopropyl-1,2-naphthoquinone; BDBM50009207; ZINC13821901
DM46ID2	DT	Small molecular drug
DM46ID2	PC	14828129
DM46ID2	MW	200.23
DM46ID2	FM	C13H12O2
DM46ID2	IC	InChI=1S/C13H12O2/c1-8(2)11-7-9-5-3-4-6-10(9)12(14)13(11)15/h3-8H,1-2H3
DM46ID2	CS	CC(C)C1=CC2=CC=CC=C2C(=O)C1=O
DM46ID2	IK	KGCDZSGUSQQVKL-UHFFFAOYSA-N
DM46ID2	IU	3-propan-2-ylnaphthalene-1,2-dione
DM46ID2	DE	Discovery agent

DMZPGBT	ID	DMZPGBT
DMZPGBT	DN	3-isopr-sal-cyclosal-d4TMP
DMZPGBT	HS	Investigative
DMZPGBT	SN	CHEMBL375636; 3-isopr-sal-cyclosal-d4TMP; (Sp)-3-isopr-sal-cyclosal-d4TMP; (Rp)-3-isopr-sal-cyclosal-d4TMP; BDBM50206632; 2,4(1H,3H)-Pyrimidinedione, 1-[(2R,5S)-5-[[[8-(2,2-dimethyl-4H-1,3-benzodioxin-8-yl)-2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl]oxy]methyl]-2,5-dihydro-2-furanyl]-5-methyl-
DMZPGBT	DT	Small molecular drug
DMZPGBT	PC	16728608
DMZPGBT	MW	554.5
DMZPGBT	FM	C27H27N2O9P
DMZPGBT	IC	InChI=1S/C27H27N2O9P/c1-16-12-29(26(31)28-25(16)30)22-11-10-19(36-22)15-35-39(32)34-14-18-7-5-9-21(24(18)38-39)20-8-4-6-17-13-33-27(2,3)37-23(17)20/h4-12,19,22H,13-15H2,1-3H3,(H,28,30,31)/t19-,22+,39?/m0/s1
DMZPGBT	CS	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=C(O3)C(=CC=C4)C5=CC=CC6=C5OC(OC6)(C)C
DMZPGBT	IK	CCBOYGOTQIYLJA-CATCILLUSA-N
DMZPGBT	IU	1-[(2R,5S)-5-[[8-(2,2-dimethyl-4H-1,3-benzodioxin-8-yl)-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl]oxymethyl]-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
DMZPGBT	DE	Discovery agent

DM9LEWH	ID	DM9LEWH
DM9LEWH	DN	3-Isothiocyanato-9H-beta-carboline
DM9LEWH	HS	Investigative
DM9LEWH	SN	CHEMBL53651; 3-Isothiocyanato-9H-beta-carboline; 9H-Pyrido[3,4-b]indole, 3-isothiocyanato-; CHEMBL2262044; beta-Carbolin-3-yl isothiocyanate; BDBM50013788
DM9LEWH	DT	Small molecular drug
DM9LEWH	PC	14146437
DM9LEWH	MW	225.27
DM9LEWH	FM	C12H7N3S
DM9LEWH	IC	InChI=1S/C12H7N3S/c16-7-14-12-5-9-8-3-1-2-4-10(8)15-11(9)6-13-12/h1-6,15H
DM9LEWH	CS	C1=CC=C2C(=C1)C3=CC(=NC=C3N2)N=C=S
DM9LEWH	IK	NEOUOHDNZDRDNJ-UHFFFAOYSA-N
DM9LEWH	IU	3-isothiocyanato-9H-pyrido[3,4-b]indole
DM9LEWH	DE	Discovery agent

DM5LUED	ID	DM5LUED
DM5LUED	DN	3-keto-lithocholic acid
DM5LUED	HS	Investigative
DM5LUED	SN	dehydrolithocholic acid; 3-keto-LCA
DM5LUED	DT	Small molecular drug
DM5LUED	PC	5283906
DM5LUED	MW	374.6
DM5LUED	FM	C24H38O3
DM5LUED	IC	InChI=1S/C24H38O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-16,18-21H,4-14H2,1-3H3,(H,26,27)/t15-,16-,18+,19-,20+,21+,23+,24-/m1/s1
DM5LUED	CS	C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CCC(=O)C4)C)C
DM5LUED	IK	KIQFUORWRVZTHT-OPTMKGCMSA-N
DM5LUED	IU	(4R)-4-[(5R,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
DM5LUED	CA	CAS 1553-56-6
DM5LUED	CB	CHEBI:17639
DM5LUED	DE	Discovery agent

DMRMF13	ID	DMRMF13
DMRMF13	DN	3-MATIDA
DMRMF13	HS	Investigative
DMRMF13	SN	alpha-amino-5-carboxy-3-methyl-2-thiopheneacetic acid
DMRMF13	DT	Small molecular drug
DMRMF13	PC	10398360
DMRMF13	MW	215.23
DMRMF13	FM	C8H9NO4S
DMRMF13	IC	InChI=1S/C8H9NO4S/c1-3-2-4(7(10)11)14-6(3)5(9)8(12)13/h2,5H,9H2,1H3,(H,10,11)(H,12,13)
DMRMF13	CS	CC1=C(SC(=C1)C(=O)O)C(C(=O)O)N
DMRMF13	IK	KOMWRBFEDDEWEP-UHFFFAOYSA-N
DMRMF13	IU	5-[amino(carboxy)methyl]-4-methylthiophene-2-carboxylic acid
DMRMF13	CA	CAS 518357-51-2
DMRMF13	CB	CHEBI:93911
DMRMF13	DE	Discovery agent

DMPJBNC	ID	DMPJBNC
DMPJBNC	DN	3-mercapto-2-(piperidin-3-yl)propanoic acid
DMPJBNC	HS	Investigative
DMPJBNC	SN	CHEMBL245591; 3-mercapto-2-(piperidin-3-yl)propanoic acid; SCHEMBL2354438
DMPJBNC	DT	Small molecular drug
DMPJBNC	PC	10214441
DMPJBNC	MW	189.28
DMPJBNC	FM	C8H15NO2S
DMPJBNC	IC	InChI=1S/C8H15NO2S/c10-8(11)7(5-12)6-2-1-3-9-4-6/h6-7,9,12H,1-5H2,(H,10,11)
DMPJBNC	CS	C1CC(CNC1)C(CS)C(=O)O
DMPJBNC	IK	ZEKJYPSRDZCIDP-UHFFFAOYSA-N
DMPJBNC	IU	2-piperidin-3-yl-3-sulfanylpropanoic acid
DMPJBNC	DE	Discovery agent

DMYQG7A	ID	DMYQG7A
DMYQG7A	DN	3-mercapto-2-(piperidin-4-yl)propanoic acid
DMYQG7A	HS	Investigative
DMYQG7A	SN	CHEMBL246978; 3-mercapto-2-(piperidin-4-yl)propanoic acid; SCHEMBL2353967
DMYQG7A	DT	Small molecular drug
DMYQG7A	PC	10192614
DMYQG7A	MW	189.28
DMYQG7A	FM	C8H15NO2S
DMYQG7A	IC	InChI=1S/C8H15NO2S/c10-8(11)7(5-12)6-1-3-9-4-2-6/h6-7,9,12H,1-5H2,(H,10,11)
DMYQG7A	CS	C1CNCCC1C(CS)C(=O)O
DMYQG7A	IK	AYOUKDACKXEDFA-UHFFFAOYSA-N
DMYQG7A	IU	2-piperidin-4-yl-3-sulfanylpropanoic acid
DMYQG7A	DE	Discovery agent

DMQ09J8	ID	DMQ09J8
DMQ09J8	DN	3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide
DMQ09J8	HS	Investigative
DMQ09J8	SN	reduced thio H2a; CHEMBL214201; SCHEMBL5805803; BDBM11041; reduced monomeric thio of compound 2a; AKOS023511640
DMQ09J8	DT	Small molecular drug
DMQ09J8	PC	23645365
DMQ09J8	MW	260.3
DMQ09J8	FM	C9H12N2O3S2
DMQ09J8	IC	InChI=1S/C9H12N2O3S2/c10-16(13,14)8-3-1-7(2-4-8)11-9(12)5-6-15/h1-4,15H,5-6H2,(H,11,12)(H2,10,13,14)
DMQ09J8	CS	C1=CC(=CC=C1NC(=O)CCS)S(=O)(=O)N
DMQ09J8	IK	QGPJKQACZFKJBW-UHFFFAOYSA-N
DMQ09J8	IU	N-(4-sulfamoylphenyl)-3-sulfanylpropanamide
DMQ09J8	DE	Discovery agent

DMX3ANZ	ID	DMX3ANZ
DMX3ANZ	DN	3-Mercuri-4-Aminobenzenesulfonamide
DMX3ANZ	HS	Investigative
DMX3ANZ	SN	3-Mercuri-4-Aminobenzenesulfonamide; (2-amino-5-sulfamoylphenyl)mercury; AC1L4WFQ; SCHEMBL678556; CTK7D7985; CHEBI:49484; [2-amino-5-(sulfamoyl)phenyl]mercury; DB04203
DMX3ANZ	DT	Small molecular drug
DMX3ANZ	PC	193512
DMX3ANZ	MW	371.79
DMX3ANZ	FM	C6H7HgN2O2S
DMX3ANZ	IC	InChI=1S/C6H7N2O2S.Hg/c7-5-1-3-6(4-2-5)11(8,9)10;/h1,3-4H,7H2,(H2,8,9,10);
DMX3ANZ	CS	C1=CC(=C(C=C1S(=O)(=O)N)[Hg])N
DMX3ANZ	IK	KGGLGSZFQPTPPT-UHFFFAOYSA-N
DMX3ANZ	IU	(2-amino-5-sulfamoylphenyl)mercury
DMX3ANZ	CB	CHEBI:49484
DMX3ANZ	DE	Discovery agent

DMAWEQH	ID	DMAWEQH
DMAWEQH	DN	3-MeSO2-DDE
DMAWEQH	HS	Investigative
DMAWEQH	SN	1-Chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene; Meso2-dde; 62938-14-1; 3-Methylsulfonyl-dde; 3-Meso(2)-dde; AC1Q3QDJ; AC1L3O8E; CTK2F6395; DTXSID20212143; 5-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)vinyl]phenyl methyl sulfone; 2-(2-methylsulphonyl-4-chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethene; Benzene, 4-chloro-1-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-2-(methylsulfonyl)-
DMAWEQH	DT	Small molecular drug
DMAWEQH	PC	119115
DMAWEQH	MW	396.1
DMAWEQH	FM	C15H10Cl4O2S
DMAWEQH	IC	InChI=1S/C15H10Cl4O2S/c1-22(20,21)13-8-11(17)6-7-12(13)14(15(18)19)9-2-4-10(16)5-3-9/h2-8H,1H3
DMAWEQH	CS	CS(=O)(=O)C1=C(C=CC(=C1)Cl)C(=C(Cl)Cl)C2=CC=C(C=C2)Cl
DMAWEQH	IK	YQCQEXWXRQQMAR-UHFFFAOYSA-N
DMAWEQH	IU	4-chloro-1-[2,2-dichloro-1-(4-chlorophenyl)ethenyl]-2-methylsulfonylbenzene
DMAWEQH	CA	CAS 62938-14-1
DMAWEQH	DE	Discovery agent

DM2QD45	ID	DM2QD45
DM2QD45	DN	3-methoxy-4-(m-tolyloxy)benzonitrile
DM2QD45	HS	Investigative
DM2QD45	SN	CHEMBL447604; 3-methoxy-4-(m-tolyloxy)benzonitrile
DM2QD45	DT	Small molecular drug
DM2QD45	PC	44565151
DM2QD45	MW	239.27
DM2QD45	FM	C15H13NO2
DM2QD45	IC	InChI=1S/C15H13NO2/c1-11-4-3-5-13(8-11)18-14-7-6-12(10-16)9-15(14)17-2/h3-9H,1-2H3
DM2QD45	CS	CC1=CC(=CC=C1)OC2=C(C=C(C=C2)C#N)OC
DM2QD45	IK	XMFGJPOABFQKTB-UHFFFAOYSA-N
DM2QD45	IU	3-methoxy-4-(3-methylphenoxy)benzonitrile
DM2QD45	DE	Discovery agent

DMEGF58	ID	DMEGF58
DMEGF58	DN	3-methoxy-4-(o-tolyloxy)benzonitrile
DMEGF58	HS	Investigative
DMEGF58	SN	CHEMBL449867; 3-methoxy-4-(o-tolyloxy)benzonitrile; SCHEMBL4183144
DMEGF58	DT	Small molecular drug
DMEGF58	PC	11557752
DMEGF58	MW	239.27
DMEGF58	FM	C15H13NO2
DMEGF58	IC	InChI=1S/C15H13NO2/c1-11-5-3-4-6-13(11)18-14-8-7-12(10-16)9-15(14)17-2/h3-9H,1-2H3
DMEGF58	CS	CC1=CC=CC=C1OC2=C(C=C(C=C2)C#N)OC
DMEGF58	IK	VDMHQBDHJWOOTF-UHFFFAOYSA-N
DMEGF58	IU	3-methoxy-4-(2-methylphenoxy)benzonitrile
DMEGF58	DE	Discovery agent

DMKUM4L	ID	DMKUM4L
DMKUM4L	DN	3-methoxy-4-(oxazol-5-yl)aniline
DMKUM4L	HS	Investigative
DMKUM4L	SN	3-methoxy-4-(oxazol-5-yl)aniline; 198821-79-3; 3-METHOXY-4-(1,3-OXAZOL-5-YL)ANILINE; Benzenamine, 3-methoxy-4-(5-oxazolyl)-; 3-methoxy-4-(5-oxazolyl)aniline; CHEMBL45870; 5-(4-amino-2-methoxyphenyl)oxazole; AK116113; A1-00139; SCHEMBL1353846; CTK4E2632; KS-00000NNJ; DTXSID80572997; MolPort-006-666-066; KYCMMXMEXWSPCV-UHFFFAOYSA-N; ZINC2518269; FCH848314; 3-methoxy-4-(oxazol-5-yl) aniline; BDBM50127715; 3-Methoxy-4-oxazol-5-yl-phenylamine; AKOS006278384; CS-W005501; MP-1879; DS-2798; 3-methoxy-4-(oxazol-5-yl)benzenamine; AJ-37081
DMKUM4L	DT	Small molecular drug
DMKUM4L	PC	15462732
DMKUM4L	MW	190.2
DMKUM4L	FM	C10H10N2O2
DMKUM4L	IC	InChI=1S/C10H10N2O2/c1-13-9-4-7(11)2-3-8(9)10-5-12-6-14-10/h2-6H,11H2,1H3
DMKUM4L	CS	COC1=C(C=CC(=C1)N)C2=CN=CO2
DMKUM4L	IK	KYCMMXMEXWSPCV-UHFFFAOYSA-N
DMKUM4L	IU	3-methoxy-4-(1,3-oxazol-5-yl)aniline
DMKUM4L	CA	CAS 198821-79-3
DMKUM4L	DE	Discovery agent

DM37QE8	ID	DM37QE8
DM37QE8	DN	3-methoxy-4-(p-tolyloxy)benzonitrile
DM37QE8	HS	Investigative
DM37QE8	SN	CHEMBL464929; 3-methoxy-4-(p-tolyloxy)benzonitrile
DM37QE8	DT	Small molecular drug
DM37QE8	PC	44565152
DM37QE8	MW	239.27
DM37QE8	FM	C15H13NO2
DM37QE8	IC	InChI=1S/C15H13NO2/c1-11-3-6-13(7-4-11)18-14-8-5-12(10-16)9-15(14)17-2/h3-9H,1-2H3
DM37QE8	CS	CC1=CC=C(C=C1)OC2=C(C=C(C=C2)C#N)OC
DM37QE8	IK	YKRUICLEGSVULK-UHFFFAOYSA-N
DM37QE8	IU	3-methoxy-4-(4-methylphenoxy)benzonitrile
DM37QE8	DE	Discovery agent

DMG1T6H	ID	DMG1T6H
DMG1T6H	DN	3'-Methoxy-4'Hydroxyclomiphene
DMG1T6H	HS	Investigative
DMG1T6H	SN	CHEMBL955; 3-Methoxy-4-hydroxyclomiphene; 3'-METHOXY-4'HYDROXYCLOMIPHENE; AC1MIWC3; SCHEMBL20193223; 3''-Methoxy-4''Hydroxyclomiphene; BDBM50020285; 4-{2-Chloro-1-[4-(2-diethylamino-ethoxy)-phenyl]-2-phenyl-vinyl}-2-methoxy-phenol; Phenol, 4-(2-chloro-1-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenylethenyl)-2-methoxy-; 4-[(Z)-2-chloro-1-[4-(2-diethylaminoethyloxy)phenyl]-2-phenylethenyl]-2-methoxyphenol; 4-(2-Chloro-1-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenylethenyl)-2-methoxyphenol
DMG1T6H	DT	Small molecular drug
DMG1T6H	PC	3081117
DMG1T6H	MW	452
DMG1T6H	FM	C27H30ClNO3
DMG1T6H	IC	InChI=1S/C27H30ClNO3/c1-4-29(5-2)17-18-32-23-14-11-20(12-15-23)26(27(28)21-9-7-6-8-10-21)22-13-16-24(30)25(19-22)31-3/h6-16,19,30H,4-5,17-18H2,1-3H3/b27-26-
DMG1T6H	CS	CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\\C2=CC=CC=C2)/Cl)/C3=CC(=C(C=C3)O)OC
DMG1T6H	IK	QRVWKOHAAHLWBP-RQZHXJHFSA-N
DMG1T6H	IU	4-[(Z)-2-chloro-1-[4-[2-(diethylamino)ethoxy]phenyl]-2-phenylethenyl]-2-methoxyphenol
DMG1T6H	CA	CAS 117095-59-7
DMG1T6H	DE	Discovery agent

DMAL1CP	ID	DMAL1CP
DMAL1CP	DN	3-methoxy-4-hydroxylonchocarpin
DMAL1CP	HS	Investigative
DMAL1CP	SN	Pongachalcone II; 3-methoxy-4-hydroxylonchocarpin; CHEMBL463206; Polyarvin; LMPK12120083
DMAL1CP	DT	Small molecular drug
DMAL1CP	PC	10712965
DMAL1CP	MW	352.4
DMAL1CP	FM	C21H20O5
DMAL1CP	IC	InChI=1S/C21H20O5/c1-21(2)11-10-15-18(26-21)9-6-14(20(15)24)16(22)7-4-13-5-8-17(23)19(12-13)25-3/h4-12,23-24H,1-3H3/b7-4+
DMAL1CP	CS	CC1(C=CC2=C(O1)C=CC(=C2O)C(=O)/C=C/C3=CC(=C(C=C3)O)OC)C
DMAL1CP	IK	WNUBZQVPFKTBOZ-QPJJXVBHSA-N
DMAL1CP	IU	(E)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
DMAL1CP	DE	Discovery agent

DMHYRES	ID	DMHYRES
DMHYRES	DN	3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile
DMHYRES	HS	Investigative
DMHYRES	SN	CHEMBL397617; 3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile
DMHYRES	DT	Small molecular drug
DMHYRES	PC	44434733
DMHYRES	MW	261.279
DMHYRES	FM	C16H11N3O
DMHYRES	IC	InChI=1S/C16H11N3O/c1-20-14-6-11(9-17)5-12(7-14)13-8-16-15(19-10-13)3-2-4-18-16/h2-8,10H,1H3
DMHYRES	CS	COC1=CC(=CC(=C1)C2=CC3=C(C=CC=N3)N=C2)C#N
DMHYRES	IK	KPRNNBVYUUWBLA-UHFFFAOYSA-N
DMHYRES	IU	3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile
DMHYRES	DE	Discovery agent

DMKHJ8G	ID	DMKHJ8G
DMKHJ8G	DN	3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile
DMKHJ8G	HS	Investigative
DMKHJ8G	SN	CHEMBL395122; 3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile
DMKHJ8G	DT	Small molecular drug
DMKHJ8G	PC	44434727
DMKHJ8G	MW	261.279
DMKHJ8G	FM	C16H11N3O
DMKHJ8G	IC	InChI=1S/C16H11N3O/c1-20-14-6-11(9-17)5-13(7-14)16-8-15-12(10-19-16)3-2-4-18-15/h2-8,10H,1H3
DMKHJ8G	CS	COC1=CC(=CC(=C1)C2=NC=C3C=CC=NC3=C2)C#N
DMKHJ8G	IK	YBYSMAYSUKEUHM-UHFFFAOYSA-N
DMKHJ8G	IU	3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile
DMKHJ8G	DE	Discovery agent

DMRMZLV	ID	DMRMZLV
DMRMZLV	DN	3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMRMZLV	HS	Investigative
DMRMZLV	SN	CHEMBL233417; 3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile; SCHEMBL4296310
DMRMZLV	DT	Small molecular drug
DMRMZLV	PC	44432680
DMRMZLV	MW	274.3
DMRMZLV	FM	C18H14N2O
DMRMZLV	IC	InChI=1S/C18H14N2O/c1-12-3-4-14-5-6-15(10-18(14)20-12)16-7-13(11-19)8-17(9-16)21-2/h3-10H,1-2H3
DMRMZLV	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)OC
DMRMZLV	IK	UYKOUDWFOWHINO-UHFFFAOYSA-N
DMRMZLV	IU	3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMRMZLV	DE	Discovery agent

DMF2IW8	ID	DMF2IW8
DMF2IW8	DN	3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMF2IW8	HS	Investigative
DMF2IW8	SN	CHEMBL447591; 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine; SCHEMBL3004402; SEXSHORPOJSDHK-UHFFFAOYSA-N; BDBM50272250; ZINC40979781
DMF2IW8	DT	Small molecular drug
DMF2IW8	PC	24827305
DMF2IW8	MW	265.31
DMF2IW8	FM	C17H15NO2
DMF2IW8	IC	InChI=1S/C17H15NO2/c1-19-16-6-5-12-7-13(3-4-14(12)8-16)15-9-17(20-2)11-18-10-15/h3-11H,1-2H3
DMF2IW8	CS	COC1=CC2=C(C=C1)C=C(C=C2)C3=CC(=CN=C3)OC
DMF2IW8	IK	SEXSHORPOJSDHK-UHFFFAOYSA-N
DMF2IW8	IU	3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMF2IW8	DE	Discovery agent

DMO2N56	ID	DMO2N56
DMO2N56	DN	3-methoxy-9-aminomethyl-9,10-dihydroanthracene
DMO2N56	HS	Investigative
DMO2N56	SN	3-METHOXY-9-AMINOMETHYL-9,10-DIHYDROANTHRACENE; CHEMBL83081; 1075741-20-6; DTXSID10648836; BDBM50131086; 3-Methoxy-9,10-dihydroanthracene-9-methanamine; 1-(3-Methoxy-9,10-dihydroanthracen-9-yl)methanamine
DMO2N56	DT	Small molecular drug
DMO2N56	PC	25138699
DMO2N56	MW	239.31
DMO2N56	FM	C16H17NO
DMO2N56	IC	InChI=1S/C16H17NO/c1-18-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)16(15)10-17/h2-7,9,16H,8,10,17H2,1H3
DMO2N56	CS	COC1=CC2=C(C=C1)C(C3=CC=CC=C3C2)CN
DMO2N56	IK	DTEPCKRLYVEVEM-UHFFFAOYSA-N
DMO2N56	IU	(3-methoxy-9,10-dihydroanthracen-9-yl)methanamine
DMO2N56	CA	CAS 1075741-20-6
DMO2N56	DE	Discovery agent

DMTBX0D	ID	DMTBX0D
DMTBX0D	DN	3-Methoxy-9H-beta-carboline
DMTBX0D	HS	Investigative
DMTBX0D	SN	3-methoxy-9H-pyrido[3,4-b]indole; NSC627681; 91985-82-9; 9H-Pyrido[3,4-b]indole, 3-methoxy-; AC1Q4YMW; 3-Methoxy-beta-carboline; AC1L7M1C; 3-Methoxy-9H-; CHEMBL54228; CHEMBL496741; 3-Methoxy-9H-.beta.-carboline; SCHEMBL10646617; NSC-627681; 9H-.Beta.-Carbolin-3-yl methyl ether
DMTBX0D	DT	Small molecular drug
DMTBX0D	PC	363113
DMTBX0D	MW	198.22
DMTBX0D	FM	C12H10N2O
DMTBX0D	IC	InChI=1S/C12H10N2O/c1-15-12-6-9-8-4-2-3-5-10(8)14-11(9)7-13-12/h2-7,14H,1H3
DMTBX0D	CS	COC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMTBX0D	IK	UFGGNIMGPVLCJZ-UHFFFAOYSA-N
DMTBX0D	IU	3-methoxy-9H-pyrido[3,4-b]indole
DMTBX0D	DE	Discovery agent

DM245AB	ID	DM245AB
DM245AB	DN	3-Methoxybenzamide
DM245AB	HS	Investigative
DM245AB	SN	3-Methoxybenzamide; 5813-86-5; m-Methoxybenzamide; m-Anisamide; 3-Methoxy-benzamide; Benzamide, 3-methoxy-; UNII-M8502TLK98; EINECS 227-379-7; NSC 28589; NSC 209527; BRN 2206857; CHEMBL123978; VKPLPDIMEREJJF-UHFFFAOYSA-N; M8502TLK98; 3MB; 3pax; 5-methoxybenzamide; 3-methoxy-benzamid; ACMC-1ASRE; AC1Q5DMC; M-METHOXY BENZAMIDE; bmse000775; 3-Methoxybenzamide, 97%; Oprea1_695428; MLS001066418; 4-10-00-00326 (Beilstein Handbook Reference); cid_98487; SCHEMBL283787; AC1L407F; KS-00000VVU; CTK1H2082; VKPLPDIMEREJJF-UHFFFAOYSA-; DTXSID00206848
DM245AB	DT	Small molecular drug
DM245AB	PC	98487
DM245AB	MW	151.16
DM245AB	FM	C8H9NO2
DM245AB	IC	InChI=1S/C8H9NO2/c1-11-7-4-2-3-6(5-7)8(9)10/h2-5H,1H3,(H2,9,10)
DM245AB	CS	COC1=CC=CC(=C1)C(=O)N
DM245AB	IK	VKPLPDIMEREJJF-UHFFFAOYSA-N
DM245AB	IU	3-methoxybenzamide
DM245AB	CA	CAS 5813-86-5
DM245AB	DE	Discovery agent

DMQMT1A	ID	DMQMT1A
DMQMT1A	DN	3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium
DMQMT1A	HS	Investigative
DMQMT1A	SN	CHEMBL97741
DMQMT1A	DT	Small molecular drug
DMQMT1A	PC	15630152
DMQMT1A	MW	241.26
DMQMT1A	FM	C14H13N2O2+
DMQMT1A	IC	InChI=1S/C14H12N2O2/c1-16-8-12-10(7-13(16)14(17)18-2)9-5-3-4-6-11(9)15-12/h3-8H,1-2H3/p+1
DMQMT1A	CS	C[N+]1=C(C=C2C3=CC=CC=C3NC2=C1)C(=O)OC
DMQMT1A	IK	UUMQQVGTICTWCW-UHFFFAOYSA-O
DMQMT1A	IU	methyl 2-methyl-9H-pyrido[3,4-b]indol-2-ium-3-carboxylate
DMQMT1A	DE	Discovery agent

DMHVIK3	ID	DMHVIK3
DMHVIK3	DN	3-methoxydesaminokynurenine
DMHVIK3	HS	Investigative
DMHVIK3	DT	Small molecular drug
DMHVIK3	PC	56603744
DMHVIK3	MW	237.25
DMHVIK3	FM	C12H15NO4
DMHVIK3	IC	InChI=1S/C12H15NO4/c1-12(13,11(15)16)7-10(14)8-4-3-5-9(6-8)17-2/h3-6H,7,13H2,1-2H3,(H,15,16)
DMHVIK3	CS	CC(CC(=O)C1=CC(=CC=C1)OC)(C(=O)O)N
DMHVIK3	IK	WRBHWPHQKJOLHX-UHFFFAOYSA-N
DMHVIK3	IU	2-amino-4-(3-methoxyphenyl)-2-methyl-4-oxobutanoic acid
DMHVIK3	DE	Discovery agent

DMWNO4D	ID	DMWNO4D
DMWNO4D	DN	3-Methoxyl-4'-amino-trans-stilbene
DMWNO4D	HS	Investigative
DMWNO4D	SN	4-Amino-3'-methoxystilbene; CCRIS 6787; CHEMBL1173573; 4-(2-(3-Methoxyphenyl)ethenyl)benzenamine; Benzenamine, 4-(2-(3-methoxyphenyl)ethenyl)-; 154028-32-7; AC1O5THI; 3'-Methoxystilben-4-amine; SCHEMBL3365675; SCHEMBL3365670; KQIPLUOUWQXDOT-AATRIKPKSA-N; BDBM50322058; 3-Methoxyl-4''-amino-trans-stilbene; AKOS030582815; LS-28359; 4-[(E)-2-(3-methoxyphenyl)ethenyl]aniline
DMWNO4D	DT	Small molecular drug
DMWNO4D	PC	6440384
DMWNO4D	MW	225.28
DMWNO4D	FM	C15H15NO
DMWNO4D	IC	InChI=1S/C15H15NO/c1-17-15-4-2-3-13(11-15)6-5-12-7-9-14(16)10-8-12/h2-11H,16H2,1H3/b6-5+
DMWNO4D	CS	COC1=CC=CC(=C1)/C=C/C2=CC=C(C=C2)N
DMWNO4D	IK	KQIPLUOUWQXDOT-AATRIKPKSA-N
DMWNO4D	IU	4-[(E)-2-(3-methoxyphenyl)ethenyl]aniline
DMWNO4D	CA	CAS 154028-32-7
DMWNO4D	DE	Discovery agent

DMH1RX6	ID	DMH1RX6
DMH1RX6	DN	3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline
DMH1RX6	HS	Investigative
DMH1RX6	SN	CHEMBL294562; Isoquinoline, 1,2,3,4-tetrahydro-3-(methoxymethyl)-; 245125-98-8; 3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline; 3-(methoxymethyl)-1,2,3,4-tetrahydroisoquinoline; SCHEMBL7585285
DMH1RX6	DT	Small molecular drug
DMH1RX6	PC	10797392
DMH1RX6	MW	177.24
DMH1RX6	FM	C11H15NO
DMH1RX6	IC	InChI=1S/C11H15NO/c1-13-8-11-6-9-4-2-3-5-10(9)7-12-11/h2-5,11-12H,6-8H2,1H3
DMH1RX6	CS	COCC1CC2=CC=CC=C2CN1
DMH1RX6	IK	IDSUOIGUQHWCCU-UHFFFAOYSA-N
DMH1RX6	IU	3-(methoxymethyl)-1,2,3,4-tetrahydroisoquinoline
DMH1RX6	DE	Discovery agent

DMFEL39	ID	DMFEL39
DMFEL39	DN	3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide
DMFEL39	HS	Investigative
DMFEL39	SN	3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide; ASN 03033124; AC1N2XQD; Oprea1_831715; CHEMBL388817; MolPort-000-015-090; HMS1702F08; ZINC4167694; STK237517; AKOS000648965; MCULE-6144605851; ST064843; 3-Methoxy-N-[1,3,4]thiadiazol-2-yl-benzamide; 3-methoxy-N~1~-(1,3,4-thiadiazol-2-yl)benzamide
DMFEL39	DT	Small molecular drug
DMFEL39	PC	4055929
DMFEL39	MW	235.26
DMFEL39	FM	C10H9N3O2S
DMFEL39	IC	InChI=1S/C10H9N3O2S/c1-15-8-4-2-3-7(5-8)9(14)12-10-13-11-6-16-10/h2-6H,1H3,(H,12,13,14)
DMFEL39	CS	COC1=CC=CC(=C1)C(=O)NC2=NN=CS2
DMFEL39	IK	UMVWXZHHIZNLAO-UHFFFAOYSA-N
DMFEL39	IU	3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide
DMFEL39	DE	Discovery agent

DM4WJX3	ID	DM4WJX3
DM4WJX3	DN	3-methoxy-N-(4-methylthiazol-2-yl)benzamide
DM4WJX3	HS	Investigative
DM4WJX3	SN	CHEMBL211740; 477516-34-0; 3-methoxy-N-(4-methyl-1,3-thiazol-2-yl)benzamide; SMR000155061; AC1MAGB1; 3-methoxy-N-(4-methylthiazol-2-yl)benzamide; Oprea1_281072; Oprea1_273858; MLS000569675; CTK4J0236; cid_2679292; DTXSID80369021; MolPort-000-631-036; CHEBI:114888; HMS2341M09; ZINC3562014; BDBM50186332; AKOS001313290; MCULE-7375167923; KB-288021; BENZAMIDE, 3-METHOXY-N-(4-METHYL-2-THIAZOLYL)-
DM4WJX3	DT	Small molecular drug
DM4WJX3	PC	2679292
DM4WJX3	MW	248.3
DM4WJX3	FM	C12H12N2O2S
DM4WJX3	IC	InChI=1S/C12H12N2O2S/c1-8-7-17-12(13-8)14-11(15)9-4-3-5-10(6-9)16-2/h3-7H,1-2H3,(H,13,14,15)
DM4WJX3	CS	CC1=CSC(=N1)NC(=O)C2=CC(=CC=C2)OC
DM4WJX3	IK	PAGPVSQZNPBQLP-UHFFFAOYSA-N
DM4WJX3	IU	3-methoxy-N-(4-methyl-1,3-thiazol-2-yl)benzamide
DM4WJX3	CA	CAS 477516-34-0
DM4WJX3	CB	CHEBI:114888
DM4WJX3	DE	Discovery agent

DMSFJNE	ID	DMSFJNE
DMSFJNE	DN	3-methoxy-N-(6-methylpyridin-2-yl)benzamide
DMSFJNE	HS	Investigative
DMSFJNE	SN	3-methoxy-N-(6-methylpyridin-2-yl)benzamide; CHEMBL211801; AC1LBN1X; TimTec1_005849; Oprea1_873046; Oprea1_343584; ZINC92708; RGDXTZSZZQXINX-UHFFFAOYSA-N; MolPort-002-713-956; HMS1550J19; BDBM50186321; STK696160; AKOS003855494; MCULE-9890451107; NCGC00173451-01; ST090431; EU-0053201; 3-Methoxy-N-(6-methyl-2-pyridinyl)benzamide #; 3-Methoxy-N-(6-methyl-pyridin-2-yl)-benzamide; (3-methoxyphenyl)-N-(6-methyl(2-pyridyl))carboxamide
DMSFJNE	DT	Small molecular drug
DMSFJNE	PC	585532
DMSFJNE	MW	242.27
DMSFJNE	FM	C14H14N2O2
DMSFJNE	IC	InChI=1S/C14H14N2O2/c1-10-5-3-8-13(15-10)16-14(17)11-6-4-7-12(9-11)18-2/h3-9H,1-2H3,(H,15,16,17)
DMSFJNE	CS	CC1=NC(=CC=C1)NC(=O)C2=CC(=CC=C2)OC
DMSFJNE	IK	RGDXTZSZZQXINX-UHFFFAOYSA-N
DMSFJNE	IU	3-methoxy-N-(6-methylpyridin-2-yl)benzamide
DMSFJNE	DE	Discovery agent

DMZ9MQ5	ID	DMZ9MQ5
DMZ9MQ5	DN	3-methoxy-N',2-diphenylquinoline-4-carbohydrazide
DMZ9MQ5	HS	Investigative
DMZ9MQ5	SN	CHEMBL218717; SCHEMBL3963611; WQHSKTAHWLQAGK-UHFFFAOYSA-N; BDBM50194593; 3-methyloxy-N',2-diphenyl-4-quinolinecarbohydrazide
DMZ9MQ5	DT	Small molecular drug
DMZ9MQ5	PC	44419758
DMZ9MQ5	MW	369.4
DMZ9MQ5	FM	C23H19N3O2
DMZ9MQ5	IC	InChI=1S/C23H19N3O2/c1-28-22-20(23(27)26-25-17-12-6-3-7-13-17)18-14-8-9-15-19(18)24-21(22)16-10-4-2-5-11-16/h2-15,25H,1H3,(H,26,27)
DMZ9MQ5	CS	COC1=C(C2=CC=CC=C2N=C1C3=CC=CC=C3)C(=O)NNC4=CC=CC=C4
DMZ9MQ5	IK	WQHSKTAHWLQAGK-UHFFFAOYSA-N
DMZ9MQ5	IU	3-methoxy-N',2-diphenylquinoline-4-carbohydrazide
DMZ9MQ5	DE	Discovery agent

DMKHVGJ	ID	DMKHVGJ
DMKHVGJ	DN	3-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMKHVGJ	HS	Investigative
DMKHVGJ	SN	CHEMBL481871; 3-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMKHVGJ	DT	Small molecular drug
DMKHVGJ	PC	24905596
DMKHVGJ	MW	349.4
DMKHVGJ	FM	C20H15NO3S
DMKHVGJ	IC	InChI=1S/C20H15NO3S/c1-23-14-7-6-8-15(13-14)24-20(22)21-16-9-2-4-11-18(16)25-19-12-5-3-10-17(19)21/h2-13H,1H3
DMKHVGJ	CS	COC1=CC(=CC=C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMKHVGJ	IK	UVKJOYFYOPXYID-UHFFFAOYSA-N
DMKHVGJ	IU	(3-methoxyphenyl) phenothiazine-10-carboxylate
DMKHVGJ	DE	Discovery agent

DMHJTLW	ID	DMHJTLW
DMHJTLW	DN	3-methoxyphenylboronic acid
DMHJTLW	HS	Investigative
DMHJTLW	SN	3-Methoxyphenylboronic acid; 10365-98-7; (3-methoxyphenyl)boronic acid; 3-Methoxybenzeneboronic acid; 3-methoxyphenyl boronic acid; (3-Methoxyphenyl)Boranediol; 3-Boronoanisole; 3-methoxypenylboronic acid; m-methoxyphenylboronic acid; boronic acid, (3-methoxyphenyl)-; 3-methoxy phenylboronic acid; 3-Methoxyphenylboronic acid, 97%; 3-methoxyphenylboronicacid; 3-boronanisole; Phenylboronic Acid, 6; AC1MC0ZC; ACMC-1BR3R; 3-methoxyphenylbornoic acid; m-methoxy phenylboronic acid; 3-methoxylphenylboronic acid; SCHEMBL5140
DMHJTLW	DT	Small molecular drug
DMHJTLW	PC	2734370
DMHJTLW	MW	151.96
DMHJTLW	FM	C7H9BO3
DMHJTLW	IC	InChI=1S/C7H9BO3/c1-11-7-4-2-3-6(5-7)8(9)10/h2-5,9-10H,1H3
DMHJTLW	CS	B(C1=CC(=CC=C1)OC)(O)O
DMHJTLW	IK	NLLGFYPSWCMUIV-UHFFFAOYSA-N
DMHJTLW	IU	(3-methoxyphenyl)boronic acid
DMHJTLW	CA	CAS 10365-98-7
DMHJTLW	DE	Discovery agent

DMCOH46	ID	DMCOH46
DMCOH46	DN	3-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMCOH46	HS	Investigative
DMCOH46	SN	CHEMBL364999; 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine; BDBM50155779
DMCOH46	DT	Small molecular drug
DMCOH46	PC	18721726
DMCOH46	MW	144.24
DMCOH46	FM	C6H12N2S
DMCOH46	IC	InChI=1S/C6H12N2S/c1-5-4-9-3-2-6(7)8-5/h5H,2-4H2,1H3,(H2,7,8)
DMCOH46	CS	CC1CSCCC(=N1)N
DMCOH46	IK	XAKJYXSNTIZTRW-UHFFFAOYSA-N
DMCOH46	IU	3-methyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMCOH46	DE	Discovery agent

DMIWQ7G	ID	DMIWQ7G
DMIWQ7G	DN	3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMIWQ7G	HS	Investigative
DMIWQ7G	SN	3-Methyl-1,2,3,4-tetrahydroisoquinoline; 29726-60-1; 1,2,3,4-Tetrahydro-3-methylisoquinoline; Isoquinoline, 1,2,3,4-tetrahydro-3-methyl-; 3-Methyl-1,2,3,4-tetrahydro-isoquinoline; CHEMBL60434; UEKQPSAKUNXFHL-UHFFFAOYSA-N; BAS 03334621; AC1Q1HKS; AC1LC3M2; SCHEMBL1011182; SCHEMBL15334650; KS-00000JVD; MolPort-001-990-837; HMS1698C16; BDBM50023304; ANW-75096; AKOS016843414; AKOS000650337; AB30586; NE31770; MCULE-3517571472; NCGC00184271-01; DA-07231; KB-70931; BS-13528; TC-163841; ST24042290; FT-0729461; EN300-86328
DMIWQ7G	DT	Small molecular drug
DMIWQ7G	PC	568974
DMIWQ7G	MW	147.22
DMIWQ7G	FM	C10H13N
DMIWQ7G	IC	InChI=1S/C10H13N/c1-8-6-9-4-2-3-5-10(9)7-11-8/h2-5,8,11H,6-7H2,1H3
DMIWQ7G	CS	CC1CC2=CC=CC=C2CN1
DMIWQ7G	IK	UEKQPSAKUNXFHL-UHFFFAOYSA-N
DMIWQ7G	IU	3-methyl-1,2,3,4-tetrahydroisoquinoline
DMIWQ7G	DE	Discovery agent

DMKOX0N	ID	DMKOX0N
DMKOX0N	DN	3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide
DMKOX0N	HS	Investigative
DMKOX0N	SN	CHEMBL198022; 3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide; SCHEMBL15514276
DMKOX0N	DT	Small molecular drug
DMKOX0N	PC	44405988
DMKOX0N	MW	181.22
DMKOX0N	FM	C7H7N3OS
DMKOX0N	IC	InChI=1S/C7H7N3OS/c1-3-4-2-5(6(8)11)12-7(4)10-9-3/h2H,1H3,(H2,8,11)(H,9,10)
DMKOX0N	CS	CC1=C2C=C(SC2=NN1)C(=O)N
DMKOX0N	IK	MELHJKUYOBXOER-UHFFFAOYSA-N
DMKOX0N	IU	3-methyl-2H-thieno[2,3-c]pyrazole-5-carboxamide
DMKOX0N	DE	Discovery agent

DMKYPUW	ID	DMKYPUW
DMKYPUW	DN	3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione
DMKYPUW	HS	Investigative
DMKYPUW	SN	CHEMBL67228; 3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione
DMKYPUW	DT	Small molecular drug
DMKYPUW	PC	10869347
DMKYPUW	MW	270.29
DMKYPUW	FM	C14H14N4O2
DMKYPUW	IC	InChI=1S/C14H14N4O2/c1-17-12-11(15-9-16-12)13(19)18(14(17)20)8-7-10-5-3-2-4-6-10/h2-6,9H,7-8H2,1H3,(H,15,16)
DMKYPUW	CS	CN1C2=C(C(=O)N(C1=O)CCC3=CC=CC=C3)NC=N2
DMKYPUW	IK	FVUNKKIGHICYFX-UHFFFAOYSA-N
DMKYPUW	IU	3-methyl-1-(2-phenylethyl)-7H-purine-2,6-dione
DMKYPUW	DE	Discovery agent

DMTM6B0	ID	DMTM6B0
DMTM6B0	DN	3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one
DMTM6B0	HS	Investigative
DMTM6B0	SN	CHEMBL412610; AC1MDPHC; BDBM50026583; 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-one
DMTM6B0	DT	Small molecular drug
DMTM6B0	PC	2793709
DMTM6B0	MW	276.29
DMTM6B0	FM	C17H12N2O2
DMTM6B0	IC	InChI=1S/C17H12N2O2/c1-11-15-16(19(18-11)12-7-3-2-4-8-12)13-9-5-6-10-14(13)21-17(15)20/h2-10H,1H3
DMTM6B0	CS	CC1=NN(C2=C1C(=O)OC3=CC=CC=C32)C4=CC=CC=C4
DMTM6B0	IK	XQVHTRBZHCYIDD-UHFFFAOYSA-N
DMTM6B0	IU	3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-one
DMTM6B0	DE	Discovery agent

DMHVNQM	ID	DMHVNQM
DMHVNQM	DN	3-methyl-2(1H)-thioxo-4(3H)-quinazolinone
DMHVNQM	HS	Investigative
DMHVNQM	SN	1705-09-5; 2-mercapto-3-methylquinazolin-4(3H)-one; 2-Mercapto-3-methyl-3H-quinazolin-4-one; CHEMBL460734; 3-methyl-2-sulfanylidene-1H-quinazolin-4-one; 2-mercapto-3-methyl-3,4-dihydroquinazolin-4-one; 3-methyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one; 3-Methyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one; 4(1H)-Quinazolinone, 2,3-dihydro-3-methyl-2-thioxo-; 3-methyl-2-thioxo-1H-quinazolin-4-one; 3-methyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone; 3-methyl-2-sulfanylquinazolin-4(3H)-one
DMHVNQM	DT	Small molecular drug
DMHVNQM	PC	747056
DMHVNQM	MW	192.24
DMHVNQM	FM	C9H8N2OS
DMHVNQM	IC	InChI=1S/C9H8N2OS/c1-11-8(12)6-4-2-3-5-7(6)10-9(11)13/h2-5H,1H3,(H,10,13)
DMHVNQM	CS	CN1C(=O)C2=CC=CC=C2NC1=S
DMHVNQM	IK	NVINMHFLRZHVKS-UHFFFAOYSA-N
DMHVNQM	IU	3-methyl-2-sulfanylidene-1H-quinazolin-4-one
DMHVNQM	CA	CAS 1705-09-5
DMHVNQM	DE	Discovery agent

DMFC0H5	ID	DMFC0H5
DMFC0H5	DN	3-Methyl-2H-benzo[f]quinazolin-1-one
DMFC0H5	HS	Investigative
DMFC0H5	DT	Small molecular drug
DMFC0H5	PC	135838247
DMFC0H5	MW	210.23
DMFC0H5	FM	C13H10N2O
DMFC0H5	IC	InChI=1S/C13H10N2O/c1-8-14-11-7-6-9-4-2-3-5-10(9)12(11)13(16)15-8/h2-7H,1H3,(H,14,15,16)
DMFC0H5	CS	CC1=NC2=C(C3=CC=CC=C3C=C2)C(=O)N1
DMFC0H5	IK	HVULCQPSGYYROI-UHFFFAOYSA-N
DMFC0H5	IU	3-methyl-2H-benzo[f]quinazolin-1-one
DMFC0H5	DE	Discovery agent

DMKWAV6	ID	DMKWAV6
DMKWAV6	DN	3-methyl-2-morpholino-1,1-diphenylbutan-1-ol
DMKWAV6	HS	Investigative
DMKWAV6	SN	CHEMBL1090793; 3-methyl-2-morpholino-1,1-diphenylbutan-1-ol
DMKWAV6	DT	Small molecular drug
DMKWAV6	PC	46885515
DMKWAV6	MW	325.4
DMKWAV6	FM	C21H27NO2
DMKWAV6	IC	InChI=1S/C21H27NO2/c1-17(2)20(22-13-15-24-16-14-22)21(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3-12,17,20,23H,13-16H2,1-2H3
DMKWAV6	CS	CC(C)C(C(C1=CC=CC=C1)(C2=CC=CC=C2)O)N3CCOCC3
DMKWAV6	IK	DKXSPARARMBTSS-UHFFFAOYSA-N
DMKWAV6	IU	3-methyl-2-morpholin-4-yl-1,1-diphenylbutan-1-ol
DMKWAV6	DE	Discovery agent

DM870UV	ID	DM870UV
DM870UV	DN	3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one
DM870UV	HS	Investigative
DM870UV	SN	86100-07-4; CHEMBL102071; CTK2I3740; DTXSID80574491; AKOS030534429; 3-Methyl-2-phenyl[1]benzopyrano[4,3-c]pyrazol-4(2H)-one; [1]Benzopyrano[4,3-c]pyrazol-4(2H)-one, 3-methyl-2-phenyl-
DM870UV	DT	Small molecular drug
DM870UV	PC	15569045
DM870UV	MW	276.29
DM870UV	FM	C17H12N2O2
DM870UV	IC	InChI=1S/C17H12N2O2/c1-11-15-16(18-19(11)12-7-3-2-4-8-12)13-9-5-6-10-14(13)21-17(15)20/h2-10H,1H3
DM870UV	CS	CC1=C2C(=NN1C3=CC=CC=C3)C4=CC=CC=C4OC2=O
DM870UV	IK	VJSRCIFAUSKZHJ-UHFFFAOYSA-N
DM870UV	IU	3-methyl-2-phenylchromeno[4,3-c]pyrazol-4-one
DM870UV	CA	CAS 86100-07-4
DM870UV	DE	Discovery agent

DM0WVTF	ID	DM0WVTF
DM0WVTF	DN	3-Methyl-4-phenylbut-3-en-2-one oxime
DM0WVTF	HS	Investigative
DM0WVTF	SN	5460-65-1; AC1L5FRS; Maybridge4_003045; CTK1H3786; MCULE-8988176310; 4-Phenyl-3-methyl-3-buten-2-on-oxim; N-(3-methyl-4-phenylbut-3-en-2-ylidene)hydroxylamine
DM0WVTF	DT	Small molecular drug
DM0WVTF	PC	91934004
DM0WVTF	MW	175.23
DM0WVTF	FM	C11H13NO
DM0WVTF	IC	InChI=1S/C11H13NO/c1-9(10(2)12-13)8-11-6-4-3-5-7-11/h3-8,10H,1-2H3/b9-8+
DM0WVTF	CS	CC(/C(=C/C1=CC=CC=C1)/C)N=O
DM0WVTF	IK	LZZIRBNCATZAGX-CMDGGOBGSA-N
DM0WVTF	IU	[(E)-2-methyl-3-nitrosobut-1-enyl]benzene
DM0WVTF	DE	Discovery agent

DMM3RNV	ID	DMM3RNV
DMM3RNV	DN	3-methyl-5-(2-methylquinolin-7-yl)benzonitrile
DMM3RNV	HS	Investigative
DMM3RNV	SN	CHEMBL232189; 3-methyl-5-(2-methylquinolin-7-yl)benzonitrile; SCHEMBL4291326
DMM3RNV	DT	Small molecular drug
DMM3RNV	PC	44432676
DMM3RNV	MW	258.3
DMM3RNV	FM	C18H14N2
DMM3RNV	IC	InChI=1S/C18H14N2/c1-12-7-14(11-19)9-17(8-12)16-6-5-15-4-3-13(2)20-18(15)10-16/h3-10H,1-2H3
DMM3RNV	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)C
DMM3RNV	IK	FSRORMXGJWDWBA-UHFFFAOYSA-N
DMM3RNV	IU	3-methyl-5-(2-methylquinolin-7-yl)benzonitrile
DMM3RNV	DE	Discovery agent

DM3BL45	ID	DM3BL45
DM3BL45	DN	3-methyl-6-(trifluoromethyl)-9H-carbazole
DM3BL45	HS	Investigative
DM3BL45	SN	CHEMBL1172905; 3-methyl-6-(trifluoromethyl)-9H-carbazole; SCHEMBL10253400
DM3BL45	DT	Small molecular drug
DM3BL45	PC	46855064
DM3BL45	MW	249.23
DM3BL45	FM	C14H10F3N
DM3BL45	IC	InChI=1S/C14H10F3N/c1-8-2-4-12-10(6-8)11-7-9(14(15,16)17)3-5-13(11)18-12/h2-7,18H,1H3
DM3BL45	CS	CC1=CC2=C(C=C1)NC3=C2C=C(C=C3)C(F)(F)F
DM3BL45	IK	KIKCAVCUKRAGJM-UHFFFAOYSA-N
DM3BL45	IU	3-methyl-6-(trifluoromethyl)-9H-carbazole
DM3BL45	DE	Discovery agent

DMZY6VX	ID	DMZY6VX
DMZY6VX	DN	3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline
DMZY6VX	HS	Investigative
DMZY6VX	SN	CHEMBL59719; 3-methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline; 3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL7512740; Isoquinoline, 1,2,3,4-tetrahydro-3-methyl-7-nitro-; OTVSEAHLIUCIKT-UHFFFAOYSA-N; BDBM50077543
DMZY6VX	DT	Small molecular drug
DMZY6VX	PC	15407445
DMZY6VX	MW	192.21
DMZY6VX	FM	C10H12N2O2
DMZY6VX	IC	InChI=1S/C10H12N2O2/c1-7-4-8-2-3-10(12(13)14)5-9(8)6-11-7/h2-3,5,7,11H,4,6H2,1H3
DMZY6VX	CS	CC1CC2=C(CN1)C=C(C=C2)[N+](=O)[O-]
DMZY6VX	IK	OTVSEAHLIUCIKT-UHFFFAOYSA-N
DMZY6VX	IU	3-methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline
DMZY6VX	DE	Discovery agent

DME81U3	ID	DME81U3
DME81U3	DN	3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one
DME81U3	HS	Investigative
DME81U3	SN	CHEMBL353023; 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one
DME81U3	DT	Small molecular drug
DME81U3	PC	15685977
DME81U3	MW	193.28
DME81U3	FM	C12H19NO
DME81U3	IC	InChI=1S/C12H19NO/c1-11(12(2)14)7-3-4-8-13-9-5-6-10-13/h11H,5-10H2,1-2H3
DME81U3	CS	CC(CC#CCN1CCCC1)C(=O)C
DME81U3	IK	FFWLTEFDRQBMQC-UHFFFAOYSA-N
DME81U3	IU	3-methyl-7-pyrrolidin-1-ylhept-5-yn-2-one
DME81U3	DE	Discovery agent

DMEJKZN	ID	DMEJKZN
DMEJKZN	DN	3-Methyl-9H-beta-carboline
DMEJKZN	HS	Investigative
DMEJKZN	SN	3-methyl-beta-carboline; 3-Methyl-9h-pyrido[3,4-b]indole; CHEMBL344859; 18203-06-0; 3-Methyl-9H-beta-carboline; 3-methyl-b-carboline; SCHEMBL3333771; XOHBPUCYRSORIZ-UHFFFAOYSA-N; BDBM50035527
DMEJKZN	DT	Small molecular drug
DMEJKZN	PC	13315103
DMEJKZN	MW	182.22
DMEJKZN	FM	C12H10N2
DMEJKZN	IC	InChI=1S/C12H10N2/c1-8-6-10-9-4-2-3-5-11(9)14-12(10)7-13-8/h2-7,14H,1H3
DMEJKZN	CS	CC1=CC2=C(C=N1)NC3=CC=CC=C32
DMEJKZN	IK	XOHBPUCYRSORIZ-UHFFFAOYSA-N
DMEJKZN	IU	3-methyl-9H-pyrido[3,4-b]indole
DMEJKZN	DE	Discovery agent

DMX71N9	ID	DMX71N9
DMX71N9	DN	3-Methylfentanyl
DMX71N9	HS	Investigative
DMX71N9	SN	Mefentanyl; 3-METHYLFENTANYL; 3-MF; 42045-86-3; N-(3-Methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide; F 7209; DEA No. 9813; Propanamide, N-(3-methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-; CHEBI:61092; N-(3-Methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide; N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide; 3-methyl-fentanyl; C23H30N2O; 3-Methylfentanil; AC1L1WAM; Epitope ID:153511; AC1Q5I8R; SCHEMBL2337401; HSDB 8379; CTK1D6517; MLQRZXNZHAOCHQ-UHFFFAOYSA-N; DB01571; LS-119344; R-26800
DMX71N9	DT	Small molecular drug
DMX71N9	PC	61996
DMX71N9	MW	350.5
DMX71N9	FM	C23H30N2O
DMX71N9	IC	InChI=1S/C23H30N2O/c1-3-23(26)25(21-12-8-5-9-13-21)22-15-17-24(18-19(22)2)16-14-20-10-6-4-7-11-20/h4-13,19,22H,3,14-18H2,1-2H3
DMX71N9	CS	CCC(=O)N(C1CCN(CC1C)CCC2=CC=CC=C2)C3=CC=CC=C3
DMX71N9	IK	MLQRZXNZHAOCHQ-UHFFFAOYSA-N
DMX71N9	IU	N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide
DMX71N9	CA	CAS 42045-86-3
DMX71N9	CB	CHEBI:61092
DMX71N9	DE	Discovery agent

DMRNMKG	ID	DMRNMKG
DMRNMKG	DN	3-methyl-N-(6-methylpyridin-2-yl)benzamide
DMRNMKG	HS	Investigative
DMRNMKG	SN	3-methyl-N-(6-methylpyridin-2-yl)benzamide; CHEMBL212724; AC1LJ0IB; Oprea1_323038; Oprea1_123319; SCHEMBL8557860; MolPort-003-351-883; ZINC579315; BDBM50186319; AKOS001316653; MCULE-8428043810; 346720-66-9; ST51016902; N-(6-methyl(2-pyridyl))(3-methylphenyl)carboxamide
DMRNMKG	DT	Small molecular drug
DMRNMKG	PC	966005
DMRNMKG	MW	226.27
DMRNMKG	FM	C14H14N2O
DMRNMKG	IC	InChI=1S/C14H14N2O/c1-10-5-3-7-12(9-10)14(17)16-13-8-4-6-11(2)15-13/h3-9H,1-2H3,(H,15,16,17)
DMRNMKG	CS	CC1=CC(=CC=C1)C(=O)NC2=CC=CC(=N2)C
DMRNMKG	IK	AKCGNQRHTCXVRF-UHFFFAOYSA-N
DMRNMKG	IU	3-methyl-N-(6-methylpyridin-2-yl)benzamide
DMRNMKG	DE	Discovery agent

DMQOI5X	ID	DMQOI5X
DMQOI5X	DN	3-Methylphenylalanine
DMQOI5X	HS	Investigative
DMQOI5X	SN	5472-70-8; 2-Amino-3-(m-tolyl)propanoic acid; 2-amino-3-m-tolyl-propionic acid; 3-Methy-DL-Phenylalanine; DL-3-ME-PHE-OH; 2-amino-3-(3-methylphenyl)propanoic acid; 3-METHYLPHENYLALANINE; 3-Methylphe; NSC14793; AC1L5E1A; SCHEMBL42906; AC1Q5S51; ss-m-Tolyl-a-amino-propionsaure; CTK8E3667; KS-00000JHC; 3-METHYL-DL-PHENYLALANINE; MolPort-003-990-079; 2-amino-3-(m-tolyl)propionic acid; 2283-42-3; NSC29447; NSC-29447; NSC-14793; AKOS016843161; AKOS000174493; MCULE-1997175050; AM83420; AB21660; 2-AMINO-3-M-TOLYLPROPANOIC ACID
DMQOI5X	DT	Small molecular drug
DMQOI5X	PC	2761494
DMQOI5X	MW	179.22
DMQOI5X	FM	C10H13NO2
DMQOI5X	IC	InChI=1S/C10H13NO2/c1-7-3-2-4-8(5-7)6-9(11)10(12)13/h2-5,9H,6,11H2,1H3,(H,12,13)/t9-/m0/s1
DMQOI5X	CS	CC1=CC(=CC=C1)C[C@@H](C(=O)O)N
DMQOI5X	IK	JZRBSTONIYRNRI-VIFPVBQESA-N
DMQOI5X	IU	(2S)-2-amino-3-(3-methylphenyl)propanoic acid
DMQOI5X	CA	CAS 114926-37-3
DMQOI5X	DE	Discovery agent

DMF3JHM	ID	DMF3JHM
DMF3JHM	DN	3-Methylpyridine
DMF3JHM	HS	Investigative
DMF3JHM	SN	3-METHYLPYRIDINE; 3-Picoline; 108-99-6; beta-Picoline; Pyridine, 3-methyl-; m-Picoline; m-Methylpyridine; B-Picoline; beta-Methylpyridine; 3-Methyl pyridine; .beta.-Methylpyridine; NSC 18251; .beta.-Picoline; meta-Methylpyridine; UNII-B083J4KF7F; 3-Mepy; CCRIS 1722; HSDB 4254; EINECS 203-636-9; AI3-24110; B083J4KF7F; 3-Methylpyridin; CHEBI:39922; ITQTTZVARXURQS-UHFFFAOYSA-N; 3-Picoline, 99%; DSSTox_CID_1897; DSSTox_RID_76391; DSSTox_GSID_21897; CAS-108-99-6; bpicolin; 3-methypyridine; 5-methylpyridine; 3-methyl-pyridin; 3-methyl pyridin
DMF3JHM	DT	Small molecular drug
DMF3JHM	PC	7970
DMF3JHM	MW	93.13
DMF3JHM	FM	C6H7N
DMF3JHM	IC	InChI=1S/C6H7N/c1-6-3-2-4-7-5-6/h2-5H,1H3
DMF3JHM	CS	CC1=CN=CC=C1
DMF3JHM	IK	ITQTTZVARXURQS-UHFFFAOYSA-N
DMF3JHM	IU	3-methylpyridine
DMF3JHM	CB	CHEBI:39922
DMF3JHM	DE	Discovery agent

DMHVUF8	ID	DMHVUF8
DMHVUF8	DN	3-Methyl-pyrrolidin-(2Z)-ylideneamine
DMHVUF8	HS	Investigative
DMHVUF8	SN	CHEMBL359703; CHEMBL545291; 3-Methylpyrrolidine-2-imine; BDBM50066781; AKOS006353988; 3-Methyl-pyrrolidin-(2E)-ylideneamine
DMHVUF8	DT	Small molecular drug
DMHVUF8	PC	9942127
DMHVUF8	MW	98.15
DMHVUF8	FM	C5H10N2
DMHVUF8	IC	InChI=1S/C5H10N2/c1-4-2-3-7-5(4)6/h4H,2-3H2,1H3,(H2,6,7)
DMHVUF8	CS	CC1CCN=C1N
DMHVUF8	IK	IIZNRRGQKIIKRY-UHFFFAOYSA-N
DMHVUF8	IU	4-methyl-3,4-dihydro-2H-pyrrol-5-amine
DMHVUF8	DE	Discovery agent

DMQZULR	ID	DMQZULR
DMQZULR	DN	3-Methylquinoline-8-carboxamide
DMQZULR	HS	Investigative
DMQZULR	SN	CHEMBL504998; 3-Methylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-methyl-; BDBM50255267
DMQZULR	DT	Small molecular drug
DMQZULR	PC	25208598
DMQZULR	MW	186.21
DMQZULR	FM	C11H10N2O
DMQZULR	IC	InChI=1S/C11H10N2O/c1-7-5-8-3-2-4-9(11(12)14)10(8)13-6-7/h2-6H,1H3,(H2,12,14)
DMQZULR	CS	CC1=CC2=C(C(=CC=C2)C(=O)N)N=C1
DMQZULR	IK	BRQFPNHEOMCVCI-UHFFFAOYSA-N
DMQZULR	IU	3-methylquinoline-8-carboxamide
DMQZULR	DE	Discovery agent

DMC153X	ID	DMC153X
DMC153X	DN	3-Methylthiofentanyl
DMC153X	HS	Investigative
DMC153X	SN	3-Methylthiofentanyl; 3-Methyl-thiofentanyl; UNII-C9C204973M; 86052-04-2; CHEBI:53763; N-(3-Methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide; C9C204973M; Propanamide, N-(3-methyl-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenyl-; N-{3-methyl-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; DEA No. 9833; 3-Methylthiofentanil; Epitope ID:153515; AC1Q5I8I; AC1L1WU2; SCHEMBL1742151; CHEMBL2365680; DB01439; FT-0672232
DMC153X	DT	Small molecular drug
DMC153X	PC	62296
DMC153X	MW	356.5
DMC153X	FM	C21H28N2OS
DMC153X	IC	InChI=1S/C21H28N2OS/c1-3-21(24)23(18-8-5-4-6-9-18)20-12-14-22(16-17(20)2)13-11-19-10-7-15-25-19/h4-10,15,17,20H,3,11-14,16H2,1-2H3
DMC153X	CS	CCC(=O)N(C1CCN(CC1C)CCC2=CC=CS2)C3=CC=CC=C3
DMC153X	IK	SRARDYUHGVMEQI-UHFFFAOYSA-N
DMC153X	IU	N-[3-methyl-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
DMC153X	CA	CAS 86052-04-2
DMC153X	CB	CHEBI:53763
DMC153X	DE	Discovery agent

DM0YS25	ID	DM0YS25
DM0YS25	DN	3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one
DM0YS25	HS	Investigative
DM0YS25	SN	CHEMBL194535; 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one
DM0YS25	DT	Small molecular drug
DM0YS25	PC	44403357
DM0YS25	MW	294.3
DM0YS25	FM	C18H18N2O2
DM0YS25	IC	InChI=1S/C18H18N2O2/c21-18-16-4-2-1-3-14(16)15-6-5-13(11-17(15)19-18)12-20-7-9-22-10-8-20/h1-6,11H,7-10,12H2,(H,19,21)
DM0YS25	CS	C1COCCN1CC2=CC3=C(C=C2)C4=CC=CC=C4C(=O)N3
DM0YS25	IK	YRZWAGRTCFCAAG-UHFFFAOYSA-N
DM0YS25	IU	3-(morpholin-4-ylmethyl)-5H-phenanthridin-6-one
DM0YS25	DE	Discovery agent

DMGWH0E	ID	DMGWH0E
DMGWH0E	DN	3-morpholino-1H-benzo[f]chromen-1-one
DMGWH0E	HS	Investigative
DMGWH0E	SN	CHEMBL367537; 3-morpholino-1H-benzo[f]chromen-1-one; SCHEMBL13346489; BDBM50159678; 3-Morpholin-4-yl-benzo[f]chromen-1-one
DMGWH0E	DT	Small molecular drug
DMGWH0E	PC	11437484
DMGWH0E	MW	281.3
DMGWH0E	FM	C17H15NO3
DMGWH0E	IC	InChI=1S/C17H15NO3/c19-14-11-16(18-7-9-20-10-8-18)21-15-6-5-12-3-1-2-4-13(12)17(14)15/h1-6,11H,7-10H2
DMGWH0E	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=CC4=CC=CC=C43
DMGWH0E	IK	UEWQIWVPOFKCFX-UHFFFAOYSA-N
DMGWH0E	IU	3-morpholin-4-ylbenzo[f]chromen-1-one
DMGWH0E	DE	Discovery agent

DMCDLG4	ID	DMCDLG4
DMCDLG4	DN	3-MPPTS
DMCDLG4	HS	Investigative
DMCDLG4	SN	2,2,2-Trifluoro-N-[3-(2-methoxyphenoxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide; 3-MPPTS; SCHEMBL6732943; GTPL1401; GJWZEUKWBMFOAA-UHFFFAOYSA-N; 2,2,2-trifluoro-N-[3-(2-methoxyphenoxy)phenyl]-N-(pyridin-3-ylmethyl)ethanesulfonamide
DMCDLG4	DT	Small molecular drug
DMCDLG4	PC	10275802
DMCDLG4	MW	452.4
DMCDLG4	FM	C21H19F3N2O4S
DMCDLG4	IC	InChI=1S/C21H19F3N2O4S/c1-29-19-9-2-3-10-20(19)30-18-8-4-7-17(12-18)26(14-16-6-5-11-25-13-16)31(27,28)15-21(22,23)24/h2-13H,14-15H2,1H3
DMCDLG4	CS	COC1=CC=CC=C1OC2=CC=CC(=C2)N(CC3=CN=CC=C3)S(=O)(=O)CC(F)(F)F
DMCDLG4	IK	GJWZEUKWBMFOAA-UHFFFAOYSA-N
DMCDLG4	IU	2,2,2-trifluoro-N-[3-(2-methoxyphenoxy)phenyl]-N-(pyridin-3-ylmethyl)ethanesulfonamide
DMCDLG4	DE	Discovery agent

DMMFA4N	ID	DMMFA4N
DMMFA4N	DN	3-m-tolyl-1,5-naphthyridine
DMMFA4N	HS	Investigative
DMMFA4N	SN	CHEMBL236263; 3-m-tolyl-1,5-naphthyridine
DMMFA4N	DT	Small molecular drug
DMMFA4N	PC	44434730
DMMFA4N	MW	220.27
DMMFA4N	FM	C15H12N2
DMMFA4N	IC	InChI=1S/C15H12N2/c1-11-4-2-5-12(8-11)13-9-15-14(17-10-13)6-3-7-16-15/h2-10H,1H3
DMMFA4N	CS	CC1=CC(=CC=C1)C2=CC3=C(C=CC=N3)N=C2
DMMFA4N	IK	OICHXALTVOUDOG-UHFFFAOYSA-N
DMMFA4N	IU	3-(3-methylphenyl)-1,5-naphthyridine
DMMFA4N	DE	Discovery agent

DMNZI9R	ID	DMNZI9R
DMNZI9R	DN	3-Naphthalen-1-yl-1-propyl-pyrrolidine
DMNZI9R	HS	Investigative
DMNZI9R	SN	CHEMBL82485; 3-Naphthalen-1-yl-1-propyl-pyrrolidine
DMNZI9R	DT	Small molecular drug
DMNZI9R	PC	44460743
DMNZI9R	MW	239.35
DMNZI9R	FM	C17H21N
DMNZI9R	IC	InChI=1S/C17H21N/c1-2-11-18-12-10-15(13-18)17-9-5-7-14-6-3-4-8-16(14)17/h3-9,15H,2,10-13H2,1H3
DMNZI9R	CS	CCCN1CCC(C1)C2=CC=CC3=CC=CC=C32
DMNZI9R	IK	JPGGRFYDEHKZFB-UHFFFAOYSA-N
DMNZI9R	IU	3-naphthalen-1-yl-1-propylpyrrolidine
DMNZI9R	DE	Discovery agent

DMCW7F5	ID	DMCW7F5
DMCW7F5	DN	3-Naphthalen-1-yl-pyrrolidine
DMCW7F5	HS	Investigative
DMCW7F5	SN	3-(1-NAPHTHYL)PYRROLIDINE; 178483-14-2; 3-(naphthalen-1-yl)pyrrolidine; CHEMBL311972; 3-Naphthalen-1-yl-pyrrolidine; SCHEMBL8878356; CTK5J7733; BDBM50290933; 5967AD; AKOS011343953
DMCW7F5	DT	Small molecular drug
DMCW7F5	PC	10584082
DMCW7F5	MW	197.27
DMCW7F5	FM	C14H15N
DMCW7F5	IC	InChI=1S/C14H15N/c1-2-6-13-11(4-1)5-3-7-14(13)12-8-9-15-10-12/h1-7,12,15H,8-10H2
DMCW7F5	CS	C1CNCC1C2=CC=CC3=CC=CC=C32
DMCW7F5	IK	KTMCVZGLGDBGJZ-UHFFFAOYSA-N
DMCW7F5	IU	3-naphthalen-1-ylpyrrolidine
DMCW7F5	DE	Discovery agent

DMZRNOT	ID	DMZRNOT
DMZRNOT	DN	3-Nitro-4'-nitro-trans-stilbene
DMZRNOT	HS	Investigative
DMZRNOT	SN	(E)-3,4'-Dinitrostilbene; 3,4'-Dinitrostilbene; CHEMBL1173131; (E)-1-Nitro-3-(2-(4-nitrophenyl)ethenyl)benzene; 51042-51-4; Benzene, 1-nitro-3-(2-(4-nitrophenyl)ethenyl)-, (E)-; Stilbene, 3,4'-dinitro-; CCRIS 8545; AC1NTBW4; Benzene, 1-nitro-3-(2-(4-nitrophenyl)ethenyl)-; WMOGPQFWQAXCTI-SNAWJCMRSA-N; 3-Nitro-4''-nitro-trans-stilbene; ZINC6092536; BDBM50322057; 27892-99-5; LS-30911; 1-Nitro-3-[2-[4-nitrophenyl]ethenyl]benzene; 1-Nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene; 1-Nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene #
DMZRNOT	DT	Small molecular drug
DMZRNOT	PC	5377857
DMZRNOT	MW	270.24
DMZRNOT	FM	C14H10N2O4
DMZRNOT	IC	InChI=1S/C14H10N2O4/c17-15(18)13-8-6-11(7-9-13)4-5-12-2-1-3-14(10-12)16(19)20/h1-10H/b5-4+
DMZRNOT	CS	C1=CC(=CC(=C1)[N+](=O)[O-])/C=C/C2=CC=C(C=C2)[N+](=O)[O-]
DMZRNOT	IK	WMOGPQFWQAXCTI-SNAWJCMRSA-N
DMZRNOT	IU	1-nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene
DMZRNOT	CA	CAS 27892-99-5
DMZRNOT	DE	Discovery agent

DM08V9W	ID	DM08V9W
DM08V9W	DN	3-Nitro-9H-beta-carboline
DM08V9W	HS	Investigative
DM08V9W	SN	9H-Pyrido[3,4-b]indole, 3-nitro-; AC1NFSZR; 3-Nitro-beta-carboline; CHEMBL53229; CHEMBL487006; 3-nitro-9H-pyrido[3,4-b]indole
DM08V9W	DT	Small molecular drug
DM08V9W	PC	4713455
DM08V9W	MW	213.19
DM08V9W	FM	C11H7N3O2
DM08V9W	IC	InChI=1S/C11H7N3O2/c15-14(16)11-5-8-7-3-1-2-4-9(7)13-10(8)6-12-11/h1-6,13H
DM08V9W	CS	C1=CC=C2C(=C1)C3=CC(=NC=C3N2)[N+](=O)[O-]
DM08V9W	IK	XQNOYQREYCKAIN-UHFFFAOYSA-N
DM08V9W	IU	3-nitro-9H-pyrido[3,4-b]indole
DM08V9W	DE	Discovery agent

DMAY4OZ	ID	DMAY4OZ
DMAY4OZ	DN	3-Nitro-benzenesulfonamide
DMAY4OZ	HS	Investigative
DMAY4OZ	SN	3-Nitrobenzenesulfonamide; 121-52-8; Benzenesulfonamide, 3-nitro-; m-Nitrobenzenesulfonamide; 3-Nitrobenzolesulfamide; m-Nitrobenzenesulphonamide; 3-nitrobenzenesulphonamide; 3-Nitro-benzenesulfonamide; Benzenesulfonamide, m-nitro-; 3-nitrobenzene-1-sulfonamide; CHEMBL367035; TXTQURPQLVHJRE-UHFFFAOYSA-N; EINECS 204-477-8; NSC 407487; m-nitrobenzolsulfonamid; 3-nitrophenylsulfonamide; AI3-50018; AC1Q1GYY; 3-nitro-benzenesulfonamid; m-Nitrobenzene sulfonamide; 3-nitrophenyl sulphonamide; 3-nitrobenzene sulfonamide; AC1L26XH
DMAY4OZ	DT	Small molecular drug
DMAY4OZ	PC	67138
DMAY4OZ	MW	202.19
DMAY4OZ	FM	C6H6N2O4S
DMAY4OZ	IC	InChI=1S/C6H6N2O4S/c7-13(11,12)6-3-1-2-5(4-6)8(9)10/h1-4H,(H2,7,11,12)
DMAY4OZ	CS	C1=CC(=CC(=C1)S(=O)(=O)N)[N+](=O)[O-]
DMAY4OZ	IK	TXTQURPQLVHJRE-UHFFFAOYSA-N
DMAY4OZ	IU	3-nitrobenzenesulfonamide
DMAY4OZ	CA	CAS 121-52-8
DMAY4OZ	DE	Discovery agent

DMIZJ9G	ID	DMIZJ9G
DMIZJ9G	DN	3-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMIZJ9G	HS	Investigative
DMIZJ9G	SN	CHEMBL381264; 3-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMIZJ9G	DT	Small molecular drug
DMIZJ9G	PC	11625160
DMIZJ9G	MW	384.4
DMIZJ9G	FM	C22H16N4O3
DMIZJ9G	IC	InChI=1S/C22H16N4O3/c27-22(17-10-7-13-19(14-17)26(28)29)23-21-15-20(16-8-3-1-4-9-16)24-25(21)18-11-5-2-6-12-18/h1-15H,(H,23,27)
DMIZJ9G	CS	C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-])C4=CC=CC=C4
DMIZJ9G	IK	NTGZFLVYBRAVEA-UHFFFAOYSA-N
DMIZJ9G	IU	N-(2,5-diphenylpyrazol-3-yl)-3-nitrobenzamide
DMIZJ9G	DE	Discovery agent

DMPMX8R	ID	DMPMX8R
DMPMX8R	DN	3-Nitrophenylboronic Acid
DMPMX8R	HS	Investigative
DMPMX8R	SN	3-nitrophenylboronic acid; 13331-27-6; (3-nitrophenyl)boronic acid; 3-Nitrobenzeneboronic acid; m-Nitrophenylboronic acid; Boronic acid, (3-nitrophenyl)-; Benzeneboronic acid, m-nitro-; m-Nitrobenzeneboronic acid; 3-Nitrophenyl boronic acid; Boronic acid, B-(3-nitrophenyl)-; m-nitophenyl boronic acid; NSC 59739; BRN 2938638; 3-nitro-phenyl boronic acid; CHEMBL20945; AI3-60393; MFCD00007193; WLN: WNR CBQQ; 3-Nitrophenylboronic acid, 97%; zlchem 233; PubChem6366; AC1L1BZL; (3-nitrophenyl)boranediol; 3-nitropenyl boronic acid
DMPMX8R	DT	Small molecular drug
DMPMX8R	PC	1677
DMPMX8R	MW	166.93
DMPMX8R	FM	C6H6BNO4
DMPMX8R	IC	InChI=1S/C6H6BNO4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4,9-10H
DMPMX8R	CS	B(C1=CC(=CC=C1)[N+](=O)[O-])(O)O
DMPMX8R	IK	ZNRGSYUVFVNSAW-UHFFFAOYSA-N
DMPMX8R	IU	(3-nitrophenyl)boronic acid
DMPMX8R	CA	CAS 13331-27-6
DMPMX8R	DE	Discovery agent

DMH798G	ID	DMH798G
DMH798G	DN	3-nitropropionate
DMH798G	HS	Investigative
DMH798G	SN	3-Nitropropanoate; 3-nitro-1-propionate; CHEMBL451226; 3-nitropropanoate anion; 3-nitropropionate anion; 3-nitropropanoate(1-); 3-nitropropionate(1-); AC1ODZ5Z; SCHEMBL3292643; CHEBI:59899; BDBM50274515
DMH798G	DT	Small molecular drug
DMH798G	PC	1678
DMH798G	MW	119.08
DMH798G	FM	C3H5NO4
DMH798G	IC	InChI=1S/C3H5NO4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)
DMH798G	CS	C(C[N+](=O)[O-])C(=O)O
DMH798G	IK	WBLZUCOIBUDNBV-UHFFFAOYSA-N
DMH798G	IU	3-nitropropanoic acid
DMH798G	CA	CAS 504-88-1
DMH798G	CB	CHEBI:16348
DMH798G	DE	Discovery agent

DMFHYAE	ID	DMFHYAE
DMFHYAE	DN	3-noradamantyl-1,3-dipropylxanthine
DMFHYAE	HS	Investigative
DMFHYAE	DT	Small molecular drug
DMFHYAE	PC	129846038
DMFHYAE	MW	356.5
DMFHYAE	FM	C20H28N4O2
DMFHYAE	IC	InChI=1S/C20H28N4O2/c1-3-5-22-18-17(19(25)23(6-4-2)20(22)26)24(11-21-18)16-14-8-12-7-13(10-14)15(16)9-12/h11-16H,3-10H2,1-2H3
DMFHYAE	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)N(C=N2)C3C4CC5CC(C4)C3C5
DMFHYAE	IK	CTRHINADNBPODV-UHFFFAOYSA-N
DMFHYAE	IU	1,3-dipropyl-7-(2-tricyclo[3.3.1.03,7]nonanyl)purine-2,6-dione
DMFHYAE	DE	Discovery agent

DMVIZ1S	ID	DMVIZ1S
DMVIZ1S	DN	3-O-METHYLQUERCETIN
DMVIZ1S	HS	Investigative
DMVIZ1S	SN	1486-70-0; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxy-4H-chromen-4-one; Quercetin 3-O-methyl ether; 3-Methylquercetol; NSC 154016; Quercetin-3-O-methyl ether; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-3-methoxy-4H-1-benzopyran-4-one; UNII-7J92C373RH; CHEMBL163316; CHEBI:16860; 7J92C373RH; NSC-154016; 3-Methoxy-5,7,3',4'-tetrahydroxyflavone; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxy-
DMVIZ1S	DT	Small molecular drug
DMVIZ1S	PC	5280681
DMVIZ1S	MW	316.26
DMVIZ1S	FM	C16H12O7
DMVIZ1S	IC	InChI=1S/C16H12O7/c1-22-16-14(21)13-11(20)5-8(17)6-12(13)23-15(16)7-2-3-9(18)10(19)4-7/h2-6,17-20H,1H3
DMVIZ1S	CS	COC1=C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C=C3)O)O
DMVIZ1S	IK	WEPBGSIAWZTEJR-UHFFFAOYSA-N
DMVIZ1S	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxychromen-4-one
DMVIZ1S	CA	CAS 1486-70-0
DMVIZ1S	CB	CHEBI:16860
DMVIZ1S	DE	Discovery agent

DMVIRLX	ID	DMVIRLX
DMVIRLX	DN	3-Oximo-olean-12-en-29-oic acid
DMVIRLX	HS	Investigative
DMVIRLX	SN	3-(Hydroxyimino)oleana-12-ene-29-oic acid
DMVIRLX	DT	Small molecular drug
DMVIRLX	PC	91935881
DMVIRLX	MW	469.7
DMVIRLX	FM	C30H47NO3
DMVIRLX	IC	InChI=1S/C30H47NO3/c1-25(2)21-10-13-30(7)22(28(21,5)12-11-23(25)31-34)9-8-19-20-18-27(4,24(32)33)15-14-26(20,3)16-17-29(19,30)6/h8,20-23H,9-18H2,1-7H3,(H,32,33)/t20-,21-,22+,23?,26+,27+,28-,29+,30+/m0/s1
DMVIRLX	CS	C[C@]12CC[C@@](C[C@H]1C3=CC[C@@H]4[C@]5(CCC(C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)N=O)C)(C)C(=O)O
DMVIRLX	IK	WINMXRJYKUPMJI-DEXHSINNSA-N
DMVIRLX	IU	(2R,4aS,6aR,6aS,6bR,8aR,12aR,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10-nitroso-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-2-carboxylic acid
DMVIRLX	DE	Discovery agent

DM47ZWK	ID	DM47ZWK
DM47ZWK	DN	3'-Oxo-Adenosine
DM47ZWK	HS	Investigative
DM47ZWK	SN	3'-OXO-ADENOSINE; ADY; AC1L9K4U; DB03273; 9-beta-D-erythro-pentofuranosyl-3-ulose-9H-purin-6-amine
DM47ZWK	DT	Small molecular drug
DM47ZWK	PC	446824
DM47ZWK	MW	265.23
DM47ZWK	FM	C10H11N5O4
DM47ZWK	IC	InChI=1S/C10H11N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,7,10,16,18H,1H2,(H2,11,12,13)/t4-,7-,10-/m1/s1
DM47ZWK	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H](C(=O)[C@H](O3)CO)O)N
DM47ZWK	IK	MIAZJCOESMXYNJ-XMRAEQSQSA-N
DM47ZWK	IU	(2R,4S,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-one
DM47ZWK	DE	Discovery agent

DM6JYWQ	ID	DM6JYWQ
DM6JYWQ	DN	3-oxoolean-12-en-27-oic acid
DM6JYWQ	HS	Investigative
DM6JYWQ	DT	Small molecular drug
DM6JYWQ	PC	44411850
DM6JYWQ	MW	454.7
DM6JYWQ	FM	C30H46O3
DM6JYWQ	IC	InChI=1S/C30H46O3/c1-25(2)14-15-27(5)16-17-30(24(32)33)19(20(27)18-25)8-9-22-28(6)12-11-23(31)26(3,4)21(28)10-13-29(22,30)7/h8,20-22H,9-18H2,1-7H3,(H,32,33)/t20-,21?,22+,27+,28-,29+,30+/m0/s1
DM6JYWQ	CS	C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CCC(=O)C5(C)C)C)C)[C@@H]1CC(CC2)(C)C)C(=O)O
DM6JYWQ	IK	DQHMTWAVBRLUSK-YHNOYPSGSA-N
DM6JYWQ	IU	(4aR,6aR,6aR,6bR,12aR,14bR)-2,2,4a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-6a-carboxylic acid
DM6JYWQ	DE	Discovery agent

DMOLZ65	ID	DMOLZ65
DMOLZ65	DN	3-phenacyl-UDP
DMOLZ65	HS	Investigative
DMOLZ65	SN	phenacyl-UDP
DMOLZ65	DT	Small molecular drug
DMOLZ65	PC	11994011
DMOLZ65	MW	522.299
DMOLZ65	FM	C17H20N2O13P2
DMOLZ65	IC	InChI=1S/C17H20N2O13P2/c20-11(10-4-2-1-3-5-10)8-19-13(21)6-7-18(17(19)24)16-15(23)14(22)12(31-16)9-30-34(28,29)32-33(25,26)27/h1-7,12,14-16,22-23H,8-9H2,(H,28,29)(H2,25,26,27)/t12-,14-,15-,16-/m1/s1
DMOLZ65	CS	C1=CC=C(C=C1)C(=O)CN2C(=O)C=CN(C2=O)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O
DMOLZ65	IK	SEUHNFHNNANEAJ-DTZQCDIJSA-N
DMOLZ65	IU	[(2R,3S,4R,5R)-5-(2,4-dioxo-3-phenacylpyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMOLZ65	DE	Discovery agent

DM7RWQT	ID	DM7RWQT
DM7RWQT	DN	3-Phenanthren-9-yl-pyridine
DM7RWQT	HS	Investigative
DM7RWQT	SN	3-(9-phenanthryl)pyridine; 3-(phenanthren-9-yl)pyridine; SCHEMBL4508899; BDBM8915; CHEMBL194277; Pyridine-substituted phenanthryl 22
DM7RWQT	DT	Small molecular drug
DM7RWQT	PC	11687499
DM7RWQT	MW	255.3
DM7RWQT	FM	C19H13N
DM7RWQT	IC	InChI=1S/C19H13N/c1-2-8-16-14(6-1)12-19(15-7-5-11-20-13-15)18-10-4-3-9-17(16)18/h1-13H
DM7RWQT	CS	C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)C4=CN=CC=C4
DM7RWQT	IK	PNVGXPZDAYDCKZ-UHFFFAOYSA-N
DM7RWQT	IU	3-phenanthren-9-ylpyridine
DM7RWQT	DE	Discovery agent

DMVSQFI	ID	DMVSQFI
DMVSQFI	DN	3-Phenethyl-2-phenyl-3H-quinazolin-4-one
DMVSQFI	HS	Investigative
DMVSQFI	SN	3-Phenethyl-2-phenyl-3H-quinazolin-4-one; CHEMBL180391; AC1LJAK1; Oprea1_440152; SCHEMBL5777984; MolPort-002-576-141; KANHEDFPOIQKTH-UHFFFAOYSA-N; ZINC546443; BDBM50162540; STL361550; 3-phenethyl-2-phenylquinazolin-4-one; AKOS003179499; MCULE-6975064033; 3-Phenethyl-2-phenylquinazoline-4(3H)-one; 2-phenyl-3-(2-phenylethyl)quinazolin-4(3H)-one
DMVSQFI	DT	Small molecular drug
DMVSQFI	PC	947434
DMVSQFI	MW	326.4
DMVSQFI	FM	C22H18N2O
DMVSQFI	IC	InChI=1S/C22H18N2O/c25-22-19-13-7-8-14-20(19)23-21(18-11-5-2-6-12-18)24(22)16-15-17-9-3-1-4-10-17/h1-14H,15-16H2
DMVSQFI	CS	C1=CC=C(C=C1)CCN2C(=NC3=CC=CC=C3C2=O)C4=CC=CC=C4
DMVSQFI	IK	KANHEDFPOIQKTH-UHFFFAOYSA-N
DMVSQFI	IU	2-phenyl-3-(2-phenylethyl)quinazolin-4-one
DMVSQFI	DE	Discovery agent

DMGPOZE	ID	DMGPOZE
DMGPOZE	DN	3-Phenyl-1-(2-methylthiazol-4-ylethynyl)benzene
DMGPOZE	HS	Investigative
DMGPOZE	SN	CHEMBL365403; 3-Phenyl-1-(2-methylthiazol-4-ylethynyl)benzene; BDBM50149798
DMGPOZE	DT	Small molecular drug
DMGPOZE	PC	44392958
DMGPOZE	MW	275.4
DMGPOZE	FM	C18H13NS
DMGPOZE	IC	InChI=1S/C18H13NS/c1-14-19-18(13-20-14)11-10-15-6-5-9-17(12-15)16-7-3-2-4-8-16/h2-9,12-13H,1H3
DMGPOZE	CS	CC1=NC(=CS1)C#CC2=CC(=CC=C2)C3=CC=CC=C3
DMGPOZE	IK	JWWDWRFQBGXCEK-UHFFFAOYSA-N
DMGPOZE	IU	2-methyl-4-[2-(3-phenylphenyl)ethynyl]-1,3-thiazole
DMGPOZE	DE	Discovery agent

DMU9WGT	ID	DMU9WGT
DMU9WGT	DN	3-Phenyl-1,2-Propandiol
DMU9WGT	HS	Investigative
DMU9WGT	SN	3-phenylpropane-1,2-diol; 17131-14-5; 3-phenyl-1,2-propanediol; AC1L59FY; AC1Q77AE; SCHEMBL25158; 1,2-Propanediol,3-phenyl-; CTK4D3895; NSC4322; DTXSID80277814; NSC-4322; AKOS017514819; DA-09349
DMU9WGT	DT	Small molecular drug
DMU9WGT	PC	446127
DMU9WGT	MW	152.19
DMU9WGT	FM	C9H12O2
DMU9WGT	IC	InChI=1S/C9H12O2/c10-7-9(11)6-8-4-2-1-3-5-8/h1-5,9-11H,6-7H2/t9-/m0/s1
DMU9WGT	CS	C1=CC=C(C=C1)C[C@@H](CO)O
DMU9WGT	IK	JHWQMXKQJVAWKI-VIFPVBQESA-N
DMU9WGT	IU	(2S)-3-phenylpropane-1,2-diol
DMU9WGT	CA	CAS 61475-32-9
DMU9WGT	DE	Discovery agent

DMD0OZ8	ID	DMD0OZ8
DMD0OZ8	DN	3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole
DMD0OZ8	HS	Investigative
DMD0OZ8	SN	3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole; CHEMBL215971; SCHEMBL6968182; NZNCUNCNFCUBOK-UHFFFAOYSA-N; BDBM50188284; ZINC36338882
DMD0OZ8	DT	Small molecular drug
DMD0OZ8	PC	12043829
DMD0OZ8	MW	232.28
DMD0OZ8	FM	C16H12N2
DMD0OZ8	IC	InChI=1S/C16H12N2/c1-2-6-11(7-3-1)15-14-10-12-8-4-5-9-13(12)16(14)18-17-15/h1-9H,10H2,(H,17,18)
DMD0OZ8	CS	C1C2=CC=CC=C2C3=C1C(=NN3)C4=CC=CC=C4
DMD0OZ8	IK	NZNCUNCNFCUBOK-UHFFFAOYSA-N
DMD0OZ8	IU	3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole
DMD0OZ8	DE	Discovery agent

DM568CK	ID	DM568CK
DM568CK	DN	3-Phenyl-1-propyl-piperidine hydrochloride
DM568CK	HS	Investigative
DM568CK	DE	Discovery agent

DMJ0SVB	ID	DMJ0SVB
DMJ0SVB	DN	3-Phenyl-1-propyl-pyrrolidine
DMJ0SVB	HS	Investigative
DMJ0SVB	SN	CHEMBL82541; 3-Phenyl-1-propyl-pyrrolidine; SCHEMBL1546830
DMJ0SVB	DT	Small molecular drug
DMJ0SVB	PC	12101308
DMJ0SVB	MW	189.3
DMJ0SVB	FM	C13H19N
DMJ0SVB	IC	InChI=1S/C13H19N/c1-2-9-14-10-8-13(11-14)12-6-4-3-5-7-12/h3-7,13H,2,8-11H2,1H3
DMJ0SVB	CS	CCCN1CCC(C1)C2=CC=CC=C2
DMJ0SVB	IK	SUMWVMTWESCBLU-UHFFFAOYSA-N
DMJ0SVB	IU	3-phenyl-1-propylpyrrolidine
DMJ0SVB	DE	Discovery agent

DMEG3YX	ID	DMEG3YX
DMEG3YX	DN	3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione
DMEG3YX	HS	Investigative
DMEG3YX	SN	3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione; CHEMBL479747; MolPort-002-665-959; ZINC6670445; STK789842; BDBM50251664; AKOS003747776; MCULE-9417936038
DMEG3YX	DT	Small molecular drug
DMEG3YX	PC	17067759
DMEG3YX	MW	280.32
DMEG3YX	FM	C17H16N2O2
DMEG3YX	IC	InChI=1S/C17H16N2O2/c1-2-12-18-15-11-7-6-10-14(15)16(20)19(17(18)21)13-8-4-3-5-9-13/h3-11H,2,12H2,1H3
DMEG3YX	CS	CCCN1C2=CC=CC=C2C(=O)N(C1=O)C3=CC=CC=C3
DMEG3YX	IK	HDWMSIFMWUKWBC-UHFFFAOYSA-N
DMEG3YX	IU	3-phenyl-1-propylquinazoline-2,4-dione
DMEG3YX	DE	Discovery agent

DMAJMU6	ID	DMAJMU6
DMAJMU6	DN	3-Phenyl-2-nortropene
DMAJMU6	HS	Investigative
DMAJMU6	SN	CHEMBL576092; 3-Phenyl-2-nortropene; SCHEMBL2881954; BDBM50303305; 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene
DMAJMU6	DT	Small molecular drug
DMAJMU6	PC	10154356
DMAJMU6	MW	185.26
DMAJMU6	FM	C13H15N
DMAJMU6	IC	InChI=1S/C13H15N/c1-2-4-10(5-3-1)11-8-12-6-7-13(9-11)14-12/h1-5,8,12-14H,6-7,9H2
DMAJMU6	CS	C1CC2C=C(CC1N2)C3=CC=CC=C3
DMAJMU6	IK	VHBRUQHAUJNUAM-UHFFFAOYSA-N
DMAJMU6	IU	3-phenyl-8-azabicyclo[3.2.1]oct-2-ene
DMAJMU6	CA	CAS 36769-07-0
DMAJMU6	DE	Discovery agent

DM6T5K4	ID	DM6T5K4
DM6T5K4	DN	3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione
DM6T5K4	HS	Investigative
DM6T5K4	SN	SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01
DM6T5K4	DT	Small molecular drug
DM6T5K4	PC	6539451
DM6T5K4	MW	264.28
DM6T5K4	FM	C16H12N2O2
DM6T5K4	IC	InChI=1S/C16H12N2O2/c19-15-13(11-7-3-1-4-8-11)14(16(20)18-15)17-12-9-5-2-6-10-12/h1-10H,(H2,17,18,19,20)
DM6T5K4	CS	C1=CC=C(C=C1)C2=C(C(=O)NC2=O)NC3=CC=CC=C3
DM6T5K4	IK	ACQZMAJVOPRMQJ-UHFFFAOYSA-N
DM6T5K4	IU	3-anilino-4-phenylpyrrole-2,5-dione
DM6T5K4	DE	Discovery agent

DM2C9X8	ID	DM2C9X8
DM2C9X8	DN	3-phenyl-4-hydroxyquinolin-2(1H)-one
DM2C9X8	HS	Investigative
DM2C9X8	SN	14933-29-0; 3-Phenyl-2,4-quinolinediol; 3-phenyl-4-hydroxyquinolin-2(1H)-one; 2,4-Dihydroxy-3-phenylquinoline; NSC16582; UNII-98SFL4LU2U; 98SFL4LU2U; 3-phenylquinoline-2,4-diol; CHEMBL324519; 4-hydroxy-3-phenylquinolin-2(1H)-one; 4-Hydroxy-3-phenyl-1H-quinolin-2-one; 2,4-quinolinediol, 3-phenyl-; NSC 16582; Maybridge1_005460; AC1L5EN7; Oprea1_589873; MLS000850648; DivK1c_001748; SCHEMBL625364; AC1Q6B83; HMS557A04; CTK4C6143; DTXSID90164221; MolPort-002-043-580; MolPort-000-808-473; HMS2269O16; NSC-16582; BDBM50001260; STK587488
DM2C9X8	DT	Small molecular drug
DM2C9X8	PC	54677756
DM2C9X8	MW	237.25
DM2C9X8	FM	C15H11NO2
DM2C9X8	IC	InChI=1S/C15H11NO2/c17-14-11-8-4-5-9-12(11)16-15(18)13(14)10-6-2-1-3-7-10/h1-9H,(H2,16,17,18)
DM2C9X8	CS	C1=CC=C(C=C1)C2=C(C3=CC=CC=C3NC2=O)O
DM2C9X8	IK	WNISVGSZMGXKHE-UHFFFAOYSA-N
DM2C9X8	IU	4-hydroxy-3-phenyl-1H-quinolin-2-one
DM2C9X8	CA	CAS 14933-29-0
DM2C9X8	DE	Discovery agent

DM43CIK	ID	DM43CIK
DM43CIK	DN	3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide
DM43CIK	HS	Investigative
DM43CIK	SN	CHEMBL512633; 3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide
DM43CIK	DT	Small molecular drug
DM43CIK	PC	44574267
DM43CIK	MW	315.3
DM43CIK	FM	C15H13N3O3S
DM43CIK	IC	InChI=1S/C15H13N3O3S/c16-15(19)14-13(9-4-2-1-3-5-9)11-8-10(22(17,20)21)6-7-12(11)18-14/h1-8,18H,(H2,16,19)(H2,17,20,21)
DM43CIK	CS	C1=CC=C(C=C1)C2=C(NC3=C2C=C(C=C3)S(=O)(=O)N)C(=O)N
DM43CIK	IK	QMGMALTZHHCWGS-UHFFFAOYSA-N
DM43CIK	IU	3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide
DM43CIK	DE	Discovery agent

DM830FW	ID	DM830FW
DM830FW	DN	3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
DM830FW	HS	Investigative
DM830FW	SN	CHEMBL399620; Aza-heterocyclic Derivative, 4a; BDBM19181; AC1O4770; 3-phenylindeno[1,2-e][1,2,4]triazin-9-one
DM830FW	DT	Small molecular drug
DM830FW	PC	6401016
DM830FW	MW	259.26
DM830FW	FM	C16H9N3O
DM830FW	IC	InChI=1S/C16H9N3O/c20-15-12-9-5-4-8-11(12)13-14(15)18-19-16(17-13)10-6-2-1-3-7-10/h1-9H
DM830FW	CS	C1=CC=C(C=C1)C2=NC3=C(C(=O)C4=CC=CC=C43)N=N2
DM830FW	IK	OERHOWFXDDHRBP-UHFFFAOYSA-N
DM830FW	IU	3-phenylindeno[1,2-e][1,2,4]triazin-9-one
DM830FW	DE	Discovery agent

DMQZJYS	ID	DMQZJYS
DMQZJYS	DN	3-phenyl-CPP
DMQZJYS	HS	Investigative
DMQZJYS	SN	3-phenyl-CPP; GTPL4104; SCHEMBL20553475; 2-(4-chlorophenoxy)-3-phenylpropanoic acid; 2-(p-chlorophenoxy)-3-phenylpropionic acid
DMQZJYS	DT	Small molecular drug
DMQZJYS	PC	10356116
DMQZJYS	MW	276.71
DMQZJYS	FM	C15H13ClO3
DMQZJYS	IC	InChI=1S/C15H13ClO3/c16-12-6-8-13(9-7-12)19-14(15(17)18)10-11-4-2-1-3-5-11/h1-9,14H,10H2,(H,17,18)
DMQZJYS	CS	C1=CC=C(C=C1)CC(C(=O)O)OC2=CC=C(C=C2)Cl
DMQZJYS	IK	CPBLTMSKPQDJPW-UHFFFAOYSA-N
DMQZJYS	IU	2-(4-chlorophenoxy)-3-phenylpropanoic acid
DMQZJYS	DE	Discovery agent

DMJOD1T	ID	DMJOD1T
DMJOD1T	DN	3-Phenylcyclopentanecarboxylic acid
DMJOD1T	HS	Investigative
DMJOD1T	SN	3-Phenylcyclopentanecarboxylic acid; 91495-75-9; 3-phenylcyclopentane-1-carboxylic acid; CHEMBL554283; 3-phenyl-cyclopentanecarboxylic acid; SCHEMBL1073107; CTK3I5725; DTXSID80605012; MolPort-020-002-441; BDBM50293437; CP-858; Cyclopentanecarboxylicacid, 3-phenyl-; 3-phenyl-1-cyclopentanecarboxylic acid; AKOS022536861; A843950
DMJOD1T	DT	Small molecular drug
DMJOD1T	PC	20313173
DMJOD1T	MW	190.24
DMJOD1T	FM	C12H14O2
DMJOD1T	IC	InChI=1S/C12H14O2/c13-12(14)11-7-6-10(8-11)9-4-2-1-3-5-9/h1-5,10-11H,6-8H2,(H,13,14)
DMJOD1T	CS	C1CC(CC1C2=CC=CC=C2)C(=O)O
DMJOD1T	IK	IWOLSKRVZNXDNU-UHFFFAOYSA-N
DMJOD1T	IU	3-phenylcyclopentane-1-carboxylic acid
DMJOD1T	CA	CAS 91495-75-9
DMJOD1T	DE	Discovery agent

DM3LM6B	ID	DM3LM6B
DM3LM6B	DN	3-phenyl-cyclosal-d4TMP
DM3LM6B	HS	Investigative
DM3LM6B	SN	CHEMBL221156; 3-phenyl-cyclosal-d4TMP; AC1LAXDT; BDBM50206640; 5-methyl-1-[(2R,5S)-5-[(2-oxo-8-phenyl-4H-1,3,2; 5-Methyl-1-[(2R,5S)-5-(2-oxo-8-phenyl-4H-2.lambda. 5-benzo[1,3,2]dioxaphosphinin-2-yloxymethyl)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione; 5-Methyl-1-[(2R,5S)-5-(2-oxo-8-phenyl-4H-2lambda*5*-benzo[1,3,2]dioxaphosphinin-2-yloxymethyl)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione
DM3LM6B	DT	Small molecular drug
DM3LM6B	PC	497286
DM3LM6B	MW	468.4
DM3LM6B	FM	C23H21N2O7P
DM3LM6B	IC	InChI=1S/C23H21N2O7P/c1-15-12-25(23(27)24-22(15)26)20-11-10-18(31-20)14-30-33(28)29-13-17-8-5-9-19(21(17)32-33)16-6-3-2-4-7-16/h2-12,18,20H,13-14H2,1H3,(H,24,26,27)/t18-,20+,33?/m0/s1
DM3LM6B	CS	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=C(O3)C(=CC=C4)C5=CC=CC=C5
DM3LM6B	IK	OQMPUIYQXGGVDT-GQODUDPDSA-N
DM3LM6B	IU	5-methyl-1-[(2R,5S)-5-[(2-oxo-8-phenyl-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl)oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione
DM3LM6B	DE	Discovery agent

DMIJN9E	ID	DMIJN9E
DMIJN9E	DN	3-phenylprop-1-enylboronic acid
DMIJN9E	HS	Investigative
DMIJN9E	SN	129423-29-6; trans-3-phenylpropen-1-yl-boronic acid; trans-3-Phenyl-1-propen-1-ylboronic acid; (3-Phenylprop-1-en-1-yl)boronic acid; CHEMBL539140; Boronic acid, (3-phenyl-1-propenyl)-, (E)-; 3-phenylprop-1-enylboronic acid; SCHEMBL2207331; 3-Phenyl-1-propenylboronic acid; GMGWFDHLFMBIDS-XBXARRHUSA-N; 214907-30-9; BDBM50294581; (e)-3-phenylprop-1-enylboronic acid; Trans-3-phenylpropen-1-ylboronic acid; (E)-3-Phenyl-1-propenylboronic acid; ZINC169877170; AKOS015840563; (E)-3-phenylpropen-1-yl-boronic acid; RTR-004066
DMIJN9E	DT	Small molecular drug
DMIJN9E	PC	11041016
DMIJN9E	MW	162
DMIJN9E	FM	C9H11BO2
DMIJN9E	IC	InChI=1S/C9H11BO2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-6,8,11-12H,7H2/b8-4+
DMIJN9E	CS	B(/C=C/CC1=CC=CC=C1)(O)O
DMIJN9E	IK	GMGWFDHLFMBIDS-XBXARRHUSA-N
DMIJN9E	IU	[(E)-3-phenylprop-1-enyl]boronic acid
DMIJN9E	DE	Discovery agent

DMBTDZL	ID	DMBTDZL
DMBTDZL	DN	3-Phenyl-pyrrolidine
DMBTDZL	HS	Investigative
DMBTDZL	SN	3-Phenylpyrrolidine; 936-44-7; 3-Phenyl-pyrrolidine; Pyrrolidine, 3-phenyl-; (Pyrrolidin-3-yl)benzene; CHEMBL75207; PRRFFTYUBPGHLE-UHFFFAOYSA-N; F2189-0088; 3-phenyl-pyrolidine; 3-phenyl-pyrollidine; 4-phenyl-pyrrolidine; PubChem22374; BAS 03334576; AC1MK0OA; SCHEMBL4122; AC1Q1H4Y; (+/-)-3-phenyl-pyrrolidine; 3-phenylpyrrolidine, AldrichCPR; KS-00001OYR; CTK3I6515; DTXSID60389848; MolPort-000-006-168; HMS1704P05; 3AAX-0-0; BBL008865; ANW-54854; SBB010168; KM3208; BDBM50144660; STK006609; AKOS000674061; AKOS016051772; MCULE-5600189216
DMBTDZL	DT	Small molecular drug
DMBTDZL	PC	3146743
DMBTDZL	MW	147.22
DMBTDZL	FM	C10H13N
DMBTDZL	IC	InChI=1S/C10H13N/c1-2-4-9(5-3-1)10-6-7-11-8-10/h1-5,10-11H,6-8H2
DMBTDZL	CS	C1CNCC1C2=CC=CC=C2
DMBTDZL	IK	PRRFFTYUBPGHLE-UHFFFAOYSA-N
DMBTDZL	IU	3-phenylpyrrolidine
DMBTDZL	CA	CAS 936-44-7
DMBTDZL	DE	Discovery agent

DM12SKU	ID	DM12SKU
DM12SKU	DN	3-Phenylquinoline-8-carboxamide
DM12SKU	HS	Investigative
DM12SKU	SN	CHEMBL450259; 3-Phenylquinoline-8-carboxamide; BDBM50255264
DM12SKU	DT	Small molecular drug
DM12SKU	PC	25208596
DM12SKU	MW	248.28
DM12SKU	FM	C16H12N2O
DM12SKU	IC	InChI=1S/C16H12N2O/c17-16(19)14-8-4-7-12-9-13(10-18-15(12)14)11-5-2-1-3-6-11/h1-10H,(H2,17,19)
DM12SKU	CS	C1=CC=C(C=C1)C2=CN=C3C(=C2)C=CC=C3C(=O)N
DM12SKU	IK	DFGJDJRADWQKAW-UHFFFAOYSA-N
DM12SKU	IU	3-phenylquinoline-8-carboxamide
DM12SKU	DE	Discovery agent

DMRNHXE	ID	DMRNHXE
DMRNHXE	DN	3-Phenylsulfanylmethyl-quinoxaline-5,7-diamine
DMRNHXE	HS	Investigative
DMRNHXE	SN	CHEMBL141548; 3-Phenylsulfanylmethyl-quinoxaline-5,7-diamine
DMRNHXE	DT	Small molecular drug
DMRNHXE	PC	44362450
DMRNHXE	MW	282.4
DMRNHXE	FM	C15H14N4S
DMRNHXE	IC	InChI=1S/C15H14N4S/c16-10-6-13(17)15-14(7-10)18-8-11(19-15)9-20-12-4-2-1-3-5-12/h1-8H,9,16-17H2
DMRNHXE	CS	C1=CC=C(C=C1)SCC2=NC3=C(C=C(C=C3N=C2)N)N
DMRNHXE	IK	PBRHNJQCRCVADQ-UHFFFAOYSA-N
DMRNHXE	IU	3-(phenylsulfanylmethyl)quinoxaline-5,7-diamine
DMRNHXE	DE	Discovery agent

DMIK9VO	ID	DMIK9VO
DMIK9VO	DN	3-Phosphoglyceric Acid
DMIK9VO	HS	Investigative
DMIK9VO	SN	3-phospho-D-glycerate; 3-phosphoglycerate; 3-phosphoglyceric acid; D-Glycerate 3-phosphate; 3-phospho-(R)-glycerate; CHEBI:17794; 3-phospho-D-glyceric acid; (2R)-2-hydroxy-3-(phosphonooxy)propanoic acid; 2-D-Hydroxy-3-phosphonooxy-propanoic acid; 3443-58-1; 3PG; (2R)-2-hydroxy-3-(phosphonatooxy)propanoate; 1iih; 820-11-1; bmse000007; SCHEMBL2497743; AC1L96U5; CHEMBL1160563; CTK1B7705; OSJPPGNTCRNQQC-UWTATZPHSA-N; ZINC3869934; BDBM50216218; DB04510; (2R)-2-hydroxy-3-phosphonooxypropanoic acid; C00197; Propanoic acid, 2-hydroxy-3-(ph
DMIK9VO	DT	Small molecular drug
DMIK9VO	PC	439183
DMIK9VO	MW	186.06
DMIK9VO	FM	C3H7O7P
DMIK9VO	IC	InChI=1S/C3H7O7P/c4-2(3(5)6)1-10-11(7,8)9/h2,4H,1H2,(H,5,6)(H2,7,8,9)/t2-/m1/s1
DMIK9VO	CS	C([C@H](C(=O)O)O)OP(=O)(O)O
DMIK9VO	IK	OSJPPGNTCRNQQC-UWTATZPHSA-N
DMIK9VO	IU	(2R)-2-hydroxy-3-phosphonooxypropanoic acid
DMIK9VO	CA	CAS 820-11-1
DMIK9VO	CB	CHEBI:17794
DMIK9VO	DE	Discovery agent

DM9BDV2	ID	DM9BDV2
DM9BDV2	DN	3-Phosphoglycerol
DM9BDV2	HS	Investigative
DM9BDV2	SN	L-Glycerol 1-phosphate; sn-glycerol-1-phosphate; sn-Glycerol 1-phosphate; UNII-196623779E; 5746-57-6; D-(glycerol 3-phosphate); L-(glycerol 1-phosphate); 3-phosphoglycerol; (2S)-2,3-dihydroxypropyl dihydrogen phosphate; sn-glycerol 1-(dihydrogen phosphate); sn-Gro-1-P; 196623779E; L-alpha-glycerophosphate; 1GP; L-alpha-Glycerol phosphate; Glyceryl 1-phosphate, (S)-; L-alpha-Glycerophosphoric acid; 6tim; g3p; Glycerophosphoric acid L-alpha-form [MI]; SCHEMBL7341
DM9BDV2	DT	Small molecular drug
DM9BDV2	PC	439276
DM9BDV2	MW	172.07
DM9BDV2	FM	C3H9O6P
DM9BDV2	IC	InChI=1S/C3H9O6P/c4-1-3(5)2-9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)/t3-/m0/s1
DM9BDV2	CS	C([C@@H](COP(=O)(O)O)O)O
DM9BDV2	IK	AWUCVROLDVIAJX-VKHMYHEASA-N
DM9BDV2	IU	[(2S)-2,3-dihydroxypropyl] dihydrogen phosphate
DM9BDV2	CA	CAS 5746-57-6
DM9BDV2	CB	CHEBI:16221
DM9BDV2	DE	Discovery agent

DMPF5OX	ID	DMPF5OX
DMPF5OX	DN	3PO
DMPF5OX	HS	Investigative
DMPF5OX	SN	18550-98-6; 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3PO; 13309-08-5; CHEMBL3105848; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one; (E)-3-(Pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; SCHEMBL196639; 3-PO; (E)-3PO;3PO; CHEBI:144367; BCP34641; ZINC3997313; BDBM50445948; s7639; 3PO, >=98% (HPLC); AKOS025142053; CCG-266648; CS-5491; SB17190; NCGC00386709-03; AS-55969; HY-19824; AB00079158-01; SR-01000203323; SR-01000203323-1; 2-Propen-1-one, 3-(3-pyridinyl)-1-(4-pyridinyl)-; 3-(pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (2E)-3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one (3PO); (2E)-3-(PYRIDIN-3-YL)-1-(PYRIDIN-4-YL)PROP-2-EN-1-ONE
DMPF5OX	DT	Small molecular drug
DMPF5OX	PC	5720233
DMPF5OX	MW	210.23
DMPF5OX	FM	C13H10N2O
DMPF5OX	IC	InChI=1S/C13H10N2O/c16-13(12-5-8-14-9-6-12)4-3-11-2-1-7-15-10-11/h1-10H/b4-3+
DMPF5OX	CS	C1=CC(=CN=C1)/C=C/C(=O)C2=CC=NC=C2
DMPF5OX	IK	UOWGYMNWMDNSTL-ONEGZZNKSA-N
DMPF5OX	IU	(E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one
DMPF5OX	CB	CHEBI:144367
DMPF5OX	DE	Pulmonary fibrosis

DM23I8E	ID	DM23I8E
DM23I8E	DN	3-Prop-1-ynylquinoline-8-carboxamide
DM23I8E	HS	Investigative
DM23I8E	SN	CHEMBL504903; 3-Prop-1-ynylquinoline-8-carboxamide; ZINC40829471
DM23I8E	DT	Small molecular drug
DM23I8E	PC	25208905
DM23I8E	MW	210.23
DM23I8E	FM	C13H10N2O
DM23I8E	IC	InChI=1S/C13H10N2O/c1-2-4-9-7-10-5-3-6-11(13(14)16)12(10)15-8-9/h3,5-8H,1H3,(H2,14,16)
DM23I8E	CS	CC#CC1=CN=C2C(=C1)C=CC=C2C(=O)N
DM23I8E	IK	IUUKYHUSWYCGAA-UHFFFAOYSA-N
DM23I8E	IU	3-prop-1-ynylquinoline-8-carboxamide
DM23I8E	DE	Discovery agent

DMDEV64	ID	DMDEV64
DMDEV64	DN	3-Propoxy-9H-beta-carboline
DMDEV64	HS	Investigative
DMDEV64	SN	3-Propoxy-9H-pyrido[3,4-b]indole; 3-propoxy-9H-pyrido[3,4-b]indole; 3-propyloxy-beta-carboline; CHEMBL52750; CHEMBL499814; AC1NFSYF; 3-propoxy-beta-carboline; SCHEMBL2347434; LPAODQAWVMEXKR-UHFFFAOYSA-N; ZINC6869122; BDBM50001473; PDSP1_001752; BDBM50244037; PDSP2_001735
DMDEV64	DT	Small molecular drug
DMDEV64	PC	4713437
DMDEV64	MW	226.27
DMDEV64	FM	C14H14N2O
DMDEV64	IC	InChI=1S/C14H14N2O/c1-2-7-17-14-8-11-10-5-3-4-6-12(10)16-13(11)9-15-14/h3-6,8-9,16H,2,7H2,1H3
DMDEV64	CS	CCCOC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMDEV64	IK	LPAODQAWVMEXKR-UHFFFAOYSA-N
DMDEV64	IU	3-propoxy-9H-pyrido[3,4-b]indole
DMDEV64	DE	Discovery agent

DMYACO7	ID	DMYACO7
DMYACO7	DN	3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DMYACO7	HS	Investigative
DMYACO7	SN	CHEMBL186969; 3-Propyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7675949
DMYACO7	DT	Small molecular drug
DMYACO7	PC	15463449
DMYACO7	MW	172.29
DMYACO7	FM	C8H16N2S
DMYACO7	IC	InChI=1S/C8H16N2S/c1-2-3-7-6-11-5-4-8(9)10-7/h7H,2-6H2,1H3,(H2,9,10)
DMYACO7	CS	CCCC1CSCCC(=N1)N
DMYACO7	IK	SWOQAUBWIBZBLQ-UHFFFAOYSA-N
DMYACO7	IU	3-propyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMYACO7	DE	Discovery agent

DM0872E	ID	DM0872E
DM0872E	DN	3-p-Tolyl-8-aza-bicyclo[3.2.1]octane
DM0872E	HS	Investigative
DM0872E	SN	CHEMBL80262; 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane; SCHEMBL15961866; 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester
DM0872E	DT	Small molecular drug
DM0872E	PC	10106631
DM0872E	MW	259.339
DM0872E	FM	C16H21NO2
DM0872E	IC	InChI=1S/C16H21NO2/c1-10-3-5-11(6-4-10)13-9-12-7-8-14(17-12)15(13)16(18)19-2/h3-6,12-15,17H,7-9H2,1-2H3
DM0872E	CS	CC1=CC=C(C=C1)C2CC3CCC(C2C(=O)OC)N3
DM0872E	IK	YUMUSCBAOZYAIX-UHFFFAOYSA-N
DM0872E	IU	methyl 3-(4-methylphenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
DM0872E	DE	Discovery agent

DM60Q1B	ID	DM60Q1B
DM60Q1B	DN	3-Pyridin-3-yl-quinoline-6,7-diol
DM60Q1B	HS	Investigative
DM60Q1B	DT	Small molecular drug
DM60Q1B	PC	135453851
DM60Q1B	MW	238.24
DM60Q1B	FM	C14H10N2O2
DM60Q1B	IC	InChI=1S/C14H10N2O2/c17-13-5-10-4-11(9-2-1-3-15-7-9)8-16-12(10)6-14(13)18/h1-8,17-18H
DM60Q1B	CS	C1=CC(=CN=C1)C2=CN=C3C=C(C(=CC3=C2)O)O
DM60Q1B	IK	QQQXEUOUDIWAIJ-UHFFFAOYSA-N
DM60Q1B	IU	3-pyridin-3-ylquinoline-6,7-diol
DM60Q1B	DE	Discovery agent

DM0SEL5	ID	DM0SEL5
DM0SEL5	DN	3-Pyridin-4-yl-quinolin-7-ol
DM0SEL5	HS	Investigative
DM0SEL5	DT	Small molecular drug
DM0SEL5	PC	135449022
DM0SEL5	MW	222.24
DM0SEL5	FM	C14H10N2O
DM0SEL5	IC	InChI=1S/C14H10N2O/c17-13-2-1-11-7-12(9-16-14(11)8-13)10-3-5-15-6-4-10/h1-9,17H
DM0SEL5	CS	C1=CC(=CC2=NC=C(C=C21)C3=CC=NC=C3)O
DM0SEL5	IK	NYQMESYHKIIFEI-UHFFFAOYSA-N
DM0SEL5	IU	3-pyridin-4-ylquinolin-7-ol
DM0SEL5	CA	CAS 156909-26-1
DM0SEL5	DE	Discovery agent

DM6U074	ID	DM6U074
DM6U074	DN	3-Pyridin-4-yl-quinoline
DM6U074	HS	Investigative
DM6U074	SN	3-(4-Pyridinyl)quinoline; CHEMBL89550; 3-Pyridin-4-yl-quinoline; 3-(pyridin-4-yl)quinoline; SCHEMBL2346887; QYCONSXONLLGHQ-UHFFFAOYSA-N; BDBM50039658
DM6U074	DT	Small molecular drug
DM6U074	PC	10081720
DM6U074	MW	206.24
DM6U074	FM	C14H10N2
DM6U074	IC	InChI=1S/C14H10N2/c1-2-4-14-12(3-1)9-13(10-16-14)11-5-7-15-8-6-11/h1-10H
DM6U074	CS	C1=CC=C2C(=C1)C=C(C=N2)C3=CC=NC=C3
DM6U074	IK	QYCONSXONLLGHQ-UHFFFAOYSA-N
DM6U074	IU	3-pyridin-4-ylquinoline
DM6U074	DE	Discovery agent

DMPCT0A	ID	DMPCT0A
DMPCT0A	DN	3-Pyridin-4-yl-quinoline-5,7-diol
DMPCT0A	HS	Investigative
DMPCT0A	DT	Small molecular drug
DMPCT0A	PC	135474209
DMPCT0A	MW	238.24
DMPCT0A	FM	C14H10N2O2
DMPCT0A	IC	InChI=1S/C14H10N2O2/c17-11-6-13-12(14(18)7-11)5-10(8-16-13)9-1-3-15-4-2-9/h1-8,17-18H
DMPCT0A	CS	C1=CN=CC=C1C2=CC3=C(C=C(C=C3O)O)N=C2
DMPCT0A	IK	QYWQBBCHWNMFSG-UHFFFAOYSA-N
DMPCT0A	IU	3-pyridin-4-ylquinoline-5,7-diol
DMPCT0A	DE	Discovery agent

DME1TUK	ID	DME1TUK
DME1TUK	DN	3-Pyridin-4-yl-quinoline-6,7-diol
DME1TUK	HS	Investigative
DME1TUK	DT	Small molecular drug
DME1TUK	PC	135469328
DME1TUK	MW	238.24
DME1TUK	FM	C14H10N2O2
DME1TUK	IC	InChI=1S/C14H10N2O2/c17-13-6-10-5-11(9-1-3-15-4-2-9)8-16-12(10)7-14(13)18/h1-8,17-18H
DME1TUK	CS	C1=CN=CC=C1C2=CN=C3C=C(C(=CC3=C2)O)O
DME1TUK	IK	PWPSIWFFYVGDHO-UHFFFAOYSA-N
DME1TUK	IU	3-pyridin-4-ylquinoline-6,7-diol
DME1TUK	DE	Discovery agent

DMAGXMJ	ID	DMAGXMJ
DMAGXMJ	DN	3-pyridine-acetic acid
DMAGXMJ	HS	Investigative
DMAGXMJ	SN	lessterol; lioxone; minedil; 3-pyridineacetic acid; piridil; toneon; Piristerol
DMAGXMJ	DT	Small molecular drug
DMAGXMJ	PC	108
DMAGXMJ	MW	137.14
DMAGXMJ	FM	C7H7NO2
DMAGXMJ	IC	InChI=1S/C7H7NO2/c9-7(10)4-6-2-1-3-8-5-6/h1-3,5H,4H2,(H,9,10)
DMAGXMJ	CS	C1=CC(=CN=C1)CC(=O)O
DMAGXMJ	IK	WGNUNYPERJMVRM-UHFFFAOYSA-N
DMAGXMJ	IU	2-pyridin-3-ylacetic acid
DMAGXMJ	CA	CAS 501-81-5
DMAGXMJ	CB	CHEBI:86390
DMAGXMJ	DE	Discovery agent

DM2KEW6	ID	DM2KEW6
DM2KEW6	DN	3R14S-OCHRATOXIN A
DM2KEW6	HS	Investigative
DM2KEW6	SN	Ochratoxin A; OCHRATOXIN A; Antibiotic 9663; 303-47-9; Phenylalanine - ochratoxin A; NCI-C56586; C20H18ClNO6; CHEBI:7719; RWQKHEORZBHNRI-BMIGLBTASA-N; Ochratoxin A, aspergillus ochraceus; Ochratoxin A-BSA conjugate from Aspergillus ochraceus; N-(((3R)-5-Chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl)-3-phenyl-L-alanine; (-)-N-((5-Chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl)-3-phenylalanine; NSC 201422; UNII-1779SX6LUY; OTA; ochratoxin A
DM2KEW6	DT	Small molecular drug
DM2KEW6	PC	442530
DM2KEW6	MW	403.8
DM2KEW6	FM	C20H18ClNO6
DM2KEW6	IC	InChI=1S/C20H18ClNO6/c1-10-7-12-14(21)9-13(17(23)16(12)20(27)28-10)18(24)22-15(19(25)26)8-11-5-3-2-4-6-11/h2-6,9-10,15,23H,7-8H2,1H3,(H,22,24)(H,25,26)/t10-,15+/m1/s1
DM2KEW6	CS	C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)Cl
DM2KEW6	IK	RWQKHEORZBHNRI-BMIGLBTASA-N
DM2KEW6	IU	(2S)-2-[[(3R)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydroisochromene-7-carbonyl]amino]-3-phenylpropanoic acid
DM2KEW6	CA	CAS 303-47-9
DM2KEW6	CB	CHEBI:7719
DM2KEW6	DE	Discovery agent

DMV1HMX	ID	DMV1HMX
DMV1HMX	DN	3r-Hydroxydecanoyl-Coa
DMV1HMX	HS	Investigative
DMV1HMX	SN	3R-HYDROXYDECANOYL-COA; 3R-HYDROXYDECANOYL-COENZYME A; (R)-3-hydroxydecanoyl-CoA; AC1L9LCA; CHEBI:74405; (R)-3-hydroxydecanoyl-coenzyme A; DB03192; S-{(9R,13S,15R)-17-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-9,13,15-trihydroxy-10,10-dimethyl-13,15-dioxido-4,8-dioxo-12,14,16-trioxa-3,7-diaza-13,15-diphosphaheptadec-1-yl} (3R)-3-hydroxydecanethioate (non-preferred name)
DMV1HMX	DT	Small molecular drug
DMV1HMX	PC	447877
DMV1HMX	MW	937.8
DMV1HMX	FM	C31H54N7O18P3S
DMV1HMX	IC	InChI=1S/C31H54N7O18P3S/c1-4-5-6-7-8-9-19(39)14-22(41)60-13-12-33-21(40)10-11-34-29(44)26(43)31(2,3)16-53-59(50,51)56-58(48,49)52-15-20-25(55-57(45,46)47)24(42)30(54-20)38-18-37-23-27(32)35-17-36-28(23)38/h17-20,24-26,30,39,42-43H,4-16H2,1-3H3,(H,33,40)(H,34,44)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t19-,20-,24-,25-,26+,30-/m1/s1
DMV1HMX	CS	CCCCCCC[C@H](CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O
DMV1HMX	IK	HIVSMYZAMUNFKZ-PDQACDDGSA-N
DMV1HMX	IU	S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (3R)-3-hydroxydecanethioate
DMV1HMX	CB	CHEBI:74405
DMV1HMX	DE	Discovery agent

DMVGDSM	ID	DMVGDSM
DMVGDSM	DN	3S,4R-293B
DMVGDSM	HS	Investigative
DMVGDSM	DT	Small molecular drug
DMVGDSM	PC	6604863
DMVGDSM	MW	324.4
DMVGDSM	FM	C15H20N2O4S
DMVGDSM	IC	InChI=1S/C15H20N2O4S/c1-5-22(19,20)17(4)13-11-8-10(9-16)6-7-12(11)21-15(2,3)14(13)18/h6-8,13-14,18H,5H2,1-4H3/t13-,14+/m1/s1
DMVGDSM	CS	CCS(=O)(=O)N(C)[C@H]1[C@@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O
DMVGDSM	IK	HVSJHHXUORMCGK-KGLIPLIRSA-N
DMVGDSM	IU	N-[(3S,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-N-methylethanesulfonamide
DMVGDSM	CA	CAS 163163-25-5
DMVGDSM	DE	Discovery agent

DMCD4GR	ID	DMCD4GR
DMCD4GR	DN	3-sal-cyclosal-d4TMP
DMCD4GR	HS	Investigative
DMCD4GR	SN	CHEMBL373537; 3-sal-cyclosal-d4TMP; (Sp)-3-sal-cyclosal-d4TMP; (Rp)-3-sal-cyclosal-d4TMP
DMCD4GR	DT	Small molecular drug
DMCD4GR	PC	44420671
DMCD4GR	MW	514.4
DMCD4GR	FM	C24H23N2O9P
DMCD4GR	IC	InChI=1S/C24H23N2O9P/c1-14-10-26(24(30)25-23(14)29)20-9-8-17(34-20)13-33-36(31)32-12-16-5-3-7-19(22(16)35-36)18-6-2-4-15(11-27)21(18)28/h2-10,17,20,27-28H,11-13H2,1H3,(H,25,29,30)/t17-,20+,36?/m0/s1
DMCD4GR	CS	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=C(O3)C(=CC=C4)C5=CC=CC(=C5O)CO
DMCD4GR	IK	ONCMROQDJNEQJX-AVINKISOSA-N
DMCD4GR	IU	1-[(2R,5S)-5-[[8-[2-hydroxy-3-(hydroxymethyl)phenyl]-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl]oxymethyl]-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
DMCD4GR	DE	Discovery agent

DMNP8DQ	ID	DMNP8DQ
DMNP8DQ	DN	3-sec-Butoxy-9H-beta-carboline
DMNP8DQ	HS	Investigative
DMNP8DQ	SN	CHEMBL86231; 3-sec-Butoxy-9H-beta-carboline; BDBM50001480
DMNP8DQ	DT	Small molecular drug
DMNP8DQ	PC	11778239
DMNP8DQ	MW	240.3
DMNP8DQ	FM	C15H16N2O
DMNP8DQ	IC	InChI=1S/C15H16N2O/c1-3-10(2)18-15-8-12-11-6-4-5-7-13(11)17-14(12)9-16-15/h4-10,17H,3H2,1-2H3
DMNP8DQ	CS	CCC(C)OC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMNP8DQ	IK	JKWXAXMOLXCXJS-UHFFFAOYSA-N
DMNP8DQ	IU	3-butan-2-yloxy-9H-pyrido[3,4-b]indole
DMNP8DQ	DE	Discovery agent

DMILTRN	ID	DMILTRN
DMILTRN	DN	3-Sulfinoalanine
DMILTRN	HS	Investigative
DMILTRN	SN	2-amino-3-sulfinopropanoic acid; 2381-08-0; Alanine 3-sulfinic acid; Cysteine hydrogen sulfite ester; L-Cysteinesulfinic acid monohydrate; Alanine, 3-sulfino-; UNII-56X032NVQL; 56X032NVQL; Cysteinesulfinic acid, L-; AC1Q5S9C; MLS000859909; SCHEMBL443654; AC1L18I0; GTPL4695; CHEMBL1702607; 2-Amino-3-sulfinopropionic acid; BDBM86194; NSC_109; CAS_109; ADVPTQAUNPRNPO-UHFFFAOYSA-N; HMS3369H02; HMS3266C09; HMS2235M21; EINECS 214-228-5; AKOS022145786; SMR000326770; ST45022126; 207121-48-0
DMILTRN	DT	Small molecular drug
DMILTRN	PC	1549098
DMILTRN	MW	153.16
DMILTRN	FM	C3H7NO4S
DMILTRN	IC	InChI=1S/C3H7NO4S/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)(H,7,8)/t2-/m0/s1
DMILTRN	CS	C([C@@H](C(=O)O)N)S(=O)O
DMILTRN	IK	ADVPTQAUNPRNPO-REOHCLBHSA-N
DMILTRN	IU	(2R)-2-amino-3-sulfinopropanoic acid
DMILTRN	CA	CAS 1115-65-7
DMILTRN	CB	CHEBI:16345

DMKSUV9	ID	DMKSUV9
DMKSUV9	DN	3-tapap
DMKSUV9	HS	Investigative
DMKSUV9	SN	3-Tapap; TAPAP; AC1Q5K4B; AC1L2Q7B; Nalpha-Tosyl-(3-amidinophenyl)alanine piperidide; N(alpha)-(4-Toluenesulfonyl)-3-amidinophenylalanylpiperidine; CHEMBL384295; 80457-09-6; 3-[2-{[(4-methylphenyl)sulfonyl]amino}-3-oxo-3-(piperidin-1-yl)propyl]benzenecarboximidamide; 1-(3-(3-(Aminoiminomethyl)phenyl)-2-(((4-methylphenyl)sulfonyl)amino)-1-oxopropyl)piperidine; Piperidine, 1-(3-(3-(aminoiminomethyl)phenyl)-2-(((4-methylphenyl)sulfonyl)amino)-1-oxopropyl)-; 73438-63-8; N(alpha)-Tosyl-(3-amidinophenyl)alanine piperidide
DMKSUV9	DT	Small molecular drug
DMKSUV9	PC	126363
DMKSUV9	MW	428.5
DMKSUV9	FM	C22H28N4O3S
DMKSUV9	IC	InChI=1S/C22H28N4O3S/c1-16-8-10-19(11-9-16)30(28,29)25-20(22(27)26-12-3-2-4-13-26)15-17-6-5-7-18(14-17)21(23)24/h5-11,14,20,25H,2-4,12-13,15H2,1H3,(H3,23,24)
DMKSUV9	CS	CC1=CC=C(C=C1)S(=O)(=O)NC(CC2=CC(=CC=C2)C(=N)N)C(=O)N3CCCCC3
DMKSUV9	IK	RNNMXTSTLVYYQG-UHFFFAOYSA-N
DMKSUV9	IU	3-[2-[(4-methylphenyl)sulfonylamino]-3-oxo-3-piperidin-1-ylpropyl]benzenecarboximidamide
DMKSUV9	CA	CAS 73438-63-8
DMKSUV9	DE	Discovery agent

DMGDT8V	ID	DMGDT8V
DMGDT8V	DN	3-tert-Butyl-3-ethyl-dihydro-furan-2-one
DMGDT8V	HS	Investigative
DMGDT8V	SN	CHEMBL97749; 2(3H)-Furanone, 3-(1,1-dimethylethyl)-3-ethyldihydro-; 153579-88-5
DMGDT8V	DT	Small molecular drug
DMGDT8V	PC	10261531
DMGDT8V	MW	170.25
DMGDT8V	FM	C10H18O2
DMGDT8V	IC	InChI=1S/C10H18O2/c1-5-10(9(2,3)4)6-7-12-8(10)11/h5-7H2,1-4H3
DMGDT8V	CS	CCC1(CCOC1=O)C(C)(C)C
DMGDT8V	IK	LHTNJLBXDQITGL-UHFFFAOYSA-N
DMGDT8V	IU	3-tert-butyl-3-ethyloxolan-2-one
DMGDT8V	DE	Discovery agent

DMY57CV	ID	DMY57CV
DMY57CV	DN	3-tert-butyl-9H-carbazole
DMY57CV	HS	Investigative
DMY57CV	SN	3-(tert-Butyl)-9H-carbazole; 3-tert-butyl-9H-carbazole; 22401-74-7; CHEMBL1170621; SCHEMBL10090582; CTK0J6436; DTXSID30477842; MolPort-044-724-355; KS-000017WT; BDBM50322591; AKOS030561970; 9H-Carbazole, 3-(1,1-dimethylethyl)-
DMY57CV	DT	Small molecular drug
DMY57CV	PC	12117342
DMY57CV	MW	223.31
DMY57CV	FM	C16H17N
DMY57CV	IC	InChI=1S/C16H17N/c1-16(2,3)11-8-9-15-13(10-11)12-6-4-5-7-14(12)17-15/h4-10,17H,1-3H3
DMY57CV	CS	CC(C)(C)C1=CC2=C(C=C1)NC3=CC=CC=C32
DMY57CV	IK	TYXSZNGDCCGIBO-UHFFFAOYSA-N
DMY57CV	IU	3-tert-butyl-9H-carbazole
DMY57CV	CA	CAS 22401-74-7
DMY57CV	DE	Discovery agent

DMIH6JU	ID	DMIH6JU
DMIH6JU	DN	3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane
DMIH6JU	HS	Investigative
DMIH6JU	SN	CHEMBL23563; SCHEMBL8430767; AMJXIOSRIOJUEM-UHFFFAOYSA-N; BDBM50229667
DMIH6JU	DT	Small molecular drug
DMIH6JU	PC	15663667
DMIH6JU	MW	179.22
DMIH6JU	FM	C8H13N5
DMIH6JU	IC	InChI=1S/C8H13N5/c1-3-12-4-2-7(1)8(5-12)13-10-6-9-11-13/h6-8H,1-5H2
DMIH6JU	CS	C1CN2CCC1C(C2)N3N=CN=N3
DMIH6JU	IK	AMJXIOSRIOJUEM-UHFFFAOYSA-N
DMIH6JU	IU	3-(tetrazol-2-yl)-1-azabicyclo[2.2.2]octane
DMIH6JU	DE	Discovery agent

DM2K59V	ID	DM2K59V
DM2K59V	DN	3'thiacytidine
DM2K59V	HS	Investigative
DM2K59V	DT	Small molecular drug
DM2K59V	PC	9825995
DM2K59V	MW	470.6
DM2K59V	FM	C29H34N4O2
DM2K59V	IC	InChI=1S/C19H20N2O2.C10H14N2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16;1-11-7-3-2-5-10-6-4-8-12-9-10/h3,6-9,11-13H,4-5,10H2,1-2H3;2,4-6,8-9,11H,3,7H2,1H3/b15-11+;5-2+
DM2K59V	CS	CNCC/C=C/C1=CN=CC=C1.COC1=CC(=C(C=C1)/C=C/2\\CCCN=C2C3=CN=CC=C3)OC
DM2K59V	IK	MILFUDCXGDJQOI-ZSPSLKEUSA-N
DM2K59V	IU	3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine;(E)-N-methyl-4-pyridin-3-ylbut-3-en-1-amine
DM2K59V	DE	Discovery agent

DM9MFZ1	ID	DM9MFZ1
DM9MFZ1	DN	3-Thiophen-3-yl-quinoline
DM9MFZ1	HS	Investigative
DM9MFZ1	SN	3-(3-Thienyl)quinoline; 56421-85-3; 3-(Thiophen-3-yl)quinoline; CHEMBL304310; 3-thiophen-3-ylquinoline; 3-Thiophen-3-yl-quinoline; 3-(3-thiophenyl)quinoline; SCHEMBL19180724; ZINC2392505; BDBM50039081; AKOS004118779; BB 0223675
DM9MFZ1	DT	Small molecular drug
DM9MFZ1	PC	10242258
DM9MFZ1	MW	211.28
DM9MFZ1	FM	C13H9NS
DM9MFZ1	IC	InChI=1S/C13H9NS/c1-2-4-13-10(3-1)7-12(8-14-13)11-5-6-15-9-11/h1-9H
DM9MFZ1	CS	C1=CC=C2C(=C1)C=C(C=N2)C3=CSC=C3
DM9MFZ1	IK	ZWOOWBWBVMAYGL-UHFFFAOYSA-N
DM9MFZ1	IU	3-thiophen-3-ylquinoline
DM9MFZ1	DE	Discovery agent

DM5SM8X	ID	DM5SM8X
DM5SM8X	DN	3'-THIO-THYMIDINE-5'-PHOSPHATE
DM5SM8X	HS	Investigative
DM5SM8X	SN	3'-THIO-THYMIDINE-5'-PHOSPHATE; DB08651; 3'-thiothymidine 5'-(dihydrogen phosphate); 3'-Mercapto-3'-deoxythymidine 5'-phosphoric acid; [(2R,3S,5R)-5-(5-methyl-2,4-dioxo-3H-pyrimidin-1-yl)-3-sulfanyloxolan-2-yl]methoxyphosphonic acid
DM5SM8X	DT	Small molecular drug
DM5SM8X	PC	46937170
DM5SM8X	MW	338.28
DM5SM8X	FM	C10H15N2O7PS
DM5SM8X	IC	InChI=1S/C10H15N2O7PS/c1-5-3-12(10(14)11-9(5)13)8-2-7(21)6(19-8)4-18-20(15,16)17/h3,6-8,21H,2,4H2,1H3,(H,11,13,14)(H2,15,16,17)/t6-,7+,8-/m1/s1
DM5SM8X	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O)S
DM5SM8X	IK	BORVFKJZAOEGOO-GJMOJQLCSA-N
DM5SM8X	IU	[(2R,3S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-3-sulfanyloxolan-2-yl]methyl dihydrogen phosphate
DM5SM8X	DE	Discovery agent

DMOQWDS	ID	DMOQWDS
DMOQWDS	DN	3-trans-p-coumaroyl maslinic acid
DMOQWDS	HS	Investigative
DMOQWDS	SN	CHEMBL453751; 3-trans-p-coumaroyl maslinic acid
DMOQWDS	DT	Small molecular drug
DMOQWDS	PC	16664517
DMOQWDS	MW	602.8
DMOQWDS	FM	C39H54O5
DMOQWDS	IC	InChI=1S/C39H54O5/c1-34(2)19-21-39(33(42)43)22-20-37(6)26(27(39)23-34)14-15-30-36(5)24-28(40)32(35(3,4)29(36)17-18-38(30,37)7)44-31(41)16-13-25-11-9-8-10-12-25/h8-14,16,27-30,32,40H,15,17-24H2,1-7H3,(H,42,43)/b16-13+/t27-,28+,29-,30+,32-,36-,37+,38+,39-/m0/s1
DMOQWDS	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@@H](C3(C)C)OC(=O)/C=C/C6=CC=CC=C6)O)C
DMOQWDS	IK	QYNZDAXHBDWWFS-BECYFJCGSA-N
DMOQWDS	IU	(4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-[(E)-3-phenylprop-2-enoyl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMOQWDS	DE	Discovery agent

DMI15VQ	ID	DMI15VQ
DMI15VQ	DN	4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate
DMI15VQ	HS	Investigative
DMI15VQ	SN	CHEMBL224828; 4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate; BDBM50158415; 4-(1-Imidazolyl)retinoic acid methyl ester
DMI15VQ	DT	Small molecular drug
DMI15VQ	PC	10786043
DMI15VQ	MW	380.5
DMI15VQ	FM	C24H32N2O2
DMI15VQ	IC	InChI=1S/C24H32N2O2/c1-18(8-7-9-19(2)16-23(27)28-6)10-11-21-20(3)22(12-13-24(21,4)5)26-15-14-25-17-26/h7-11,14-17,22H,12-13H2,1-6H3/b9-7+,11-10+,18-8+,19-16+
DMI15VQ	CS	CC1=C(C(CCC1N2C=CN=C2)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)OC)/C)/C
DMI15VQ	IK	LEOKNFOQHCUMCU-PFLBVIONSA-N
DMI15VQ	IU	methyl (2E,4E,6E,8E)-9-(3-imidazol-1-yl-2,6,6-trimethylcyclohexen-1-yl)-3,7-dimethylnona-2,4,6,8-tetraenoate
DMI15VQ	DE	Discovery agent

DMKYB4D	ID	DMKYB4D
DMKYB4D	DN	4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid
DMKYB4D	HS	Investigative
DMKYB4D	SN	CHEMBL57765; 4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid; SCHEMBL1234027; 4-(1-Imidazolyl)retinoic acid; BDBM50091698; (2E,4E,6E,8E)-9-(3-Imidazol-1-yl-2,6,6-trimethyl-cyclohex-1-enyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid
DMKYB4D	DT	Small molecular drug
DMKYB4D	PC	9951075
DMKYB4D	MW	366.5
DMKYB4D	FM	C23H30N2O2
DMKYB4D	IC	InChI=1S/C23H30N2O2/c1-17(7-6-8-18(2)15-22(26)27)9-10-20-19(3)21(11-12-23(20,4)5)25-14-13-24-16-25/h6-10,13-16,21H,11-12H2,1-5H3,(H,26,27)/b8-6+,10-9+,17-7+,18-15+
DMKYB4D	CS	CC1=C(C(CCC1N2C=CN=C2)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
DMKYB4D	IK	MRFBVQCSZMKBFY-UBFIAYEVSA-N
DMKYB4D	IU	(2E,4E,6E,8E)-9-(3-imidazol-1-yl-2,6,6-trimethylcyclohexen-1-yl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DMKYB4D	DE	Discovery agent

DMDHV0N	ID	DMDHV0N
DMDHV0N	DN	4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one
DMDHV0N	HS	Investigative
DMDHV0N	SN	CHEMBL427247; 2H-1-Benzopyran-2-one, 4-(1H-imidazol-1-ylmethyl)-; 828265-54-9; Coumarin deriv. 19; BDBM9470; CTK3D6009; DTXSID40460922; ZINC13586713
DMDHV0N	DT	Small molecular drug
DMDHV0N	PC	11276192
DMDHV0N	MW	226.23
DMDHV0N	FM	C13H10N2O2
DMDHV0N	IC	InChI=1S/C13H10N2O2/c16-13-7-10(8-15-6-5-14-9-15)11-3-1-2-4-12(11)17-13/h1-7,9H,8H2
DMDHV0N	CS	C1=CC=C2C(=C1)C(=CC(=O)O2)CN3C=CN=C3
DMDHV0N	IK	SOWQJCOJWDYZNR-UHFFFAOYSA-N
DMDHV0N	IU	4-(imidazol-1-ylmethyl)chromen-2-one
DMDHV0N	CA	CAS 828265-54-9
DMDHV0N	DE	Discovery agent

DMFUBRC	ID	DMFUBRC
DMFUBRC	DN	4-((1H-imidazol-1-yl)methyl)benzonitrile
DMFUBRC	HS	Investigative
DMFUBRC	SN	1-(4-Cyanobenzyl)-1H-imidazole; 4-Imidazol-1-ylmethyl-benzonitrile
DMFUBRC	PC	1236449
DMFUBRC	MW	183.21
DMFUBRC	FM	C11H9N3
DMFUBRC	IC	InChI=1S/C11H9N3/c12-7-10-1-3-11(4-2-10)8-14-6-5-13-9-14/h1-6,9H,8H2
DMFUBRC	CS	C1=CC(=CC=C1CN2C=CN=C2)C#N
DMFUBRC	IK	LUSFCTSUDCCYLQ-UHFFFAOYSA-N
DMFUBRC	IU	4-(imidazol-1-ylmethyl)benzonitrile
DMFUBRC	CA	CAS 112809-54-8
DMFUBRC	DE	Discovery agent

DMYDGH4	ID	DMYDGH4
DMYDGH4	DN	4-((1H-imidazol-1-yl)methyl)phenol
DMYDGH4	HS	Investigative
DMYDGH4	SN	4-(1h-imidazol-1-ylmethyl)phenol; 1-(4-Hydroxybenzyl)imidazole; 41833-17-4; 4-((1H-imidazol-1-yl)methyl)phenol; Phenol, 4-(1H-imidazol-1-ylmethyl)-; CHEMBL166845; ZEFROCQEWXHIEP-UHFFFAOYSA-N; 4-(imidazolylmethyl)phenol; 4-Hobi; n-p-hydroxybenzylimidazole; AC1L4X2E; AC1Q7A8C; 4-Imidazol-1-ylmethyl-phenol; 4-(1h-imidazolylmethyl)phenol; 4-(imidazol-1-ylmethyl)phenol; SCHEMBL6323414; 4-[(1-imidazolyl)methyl]phenol; CTK4I5281; DTXSID30194643; MolPort-006-827-429; 1-(4-Hydroxybenzyl)-1H-imidazole; ZINC13549136; SBB051635
DMYDGH4	DT	Small molecular drug
DMYDGH4	PC	193822
DMYDGH4	MW	174.2
DMYDGH4	FM	C10H10N2O
DMYDGH4	IC	InChI=1S/C10H10N2O/c13-10-3-1-9(2-4-10)7-12-6-5-11-8-12/h1-6,8,13H,7H2
DMYDGH4	CS	C1=CC(=CC=C1CN2C=CN=C2)O
DMYDGH4	IK	ZEFROCQEWXHIEP-UHFFFAOYSA-N
DMYDGH4	IU	4-(imidazol-1-ylmethyl)phenol
DMYDGH4	CA	CAS 41833-17-4
DMYDGH4	DE	Discovery agent

DMX2QD5	ID	DMX2QD5
DMX2QD5	DN	4-((1H-imidazol-4-yl)methyl)-1-heptylpiperidine
DMX2QD5	HS	Investigative
DMX2QD5	SN	CHEMBL424847; 4-((1H-imidazol-4-yl)methyl)-1-heptylpiperidine
DMX2QD5	DT	Small molecular drug
DMX2QD5	PC	44406484
DMX2QD5	MW	263.42
DMX2QD5	FM	C16H29N3
DMX2QD5	IC	InChI=1S/C16H29N3/c1-2-3-4-5-6-9-19-10-7-15(8-11-19)12-16-13-17-14-18-16/h13-15H,2-12H2,1H3,(H,17,18)
DMX2QD5	CS	CCCCCCCN1CCC(CC1)CC2=CN=CN2
DMX2QD5	IK	PKTDABXMBJERIM-UHFFFAOYSA-N
DMX2QD5	IU	1-heptyl-4-(1H-imidazol-5-ylmethyl)piperidine
DMX2QD5	DE	Discovery agent

DMRYWSN	ID	DMRYWSN
DMRYWSN	DN	4-((1H-Imidazol-4-yl)methyl)-1-phenylpiperidine
DMRYWSN	HS	Investigative
DMRYWSN	SN	CHEMBL1171443; 4-((1H-Imidazol-4-yl)methyl)-1-phenylpiperidine
DMRYWSN	DT	Small molecular drug
DMRYWSN	PC	49799252
DMRYWSN	MW	241.33
DMRYWSN	FM	C15H19N3
DMRYWSN	IC	InChI=1S/C15H19N3/c1-2-4-15(5-3-1)18-8-6-13(7-9-18)10-14-11-16-12-17-14/h1-5,11-13H,6-10H2,(H,16,17)
DMRYWSN	CS	C1CN(CCC1CC2=CN=CN2)C3=CC=CC=C3
DMRYWSN	IK	DKJLGZJEDGFKIC-UHFFFAOYSA-N
DMRYWSN	IU	4-(1H-imidazol-5-ylmethyl)-1-phenylpiperidine
DMRYWSN	DE	Discovery agent

DMLV59R	ID	DMLV59R
DMLV59R	DN	4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol
DMLV59R	HS	Investigative
DMLV59R	SN	CHEMBL1240676; 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol; BDBM50326004
DMLV59R	DT	Small molecular drug
DMLV59R	PC	43743432
DMLV59R	MW	255.27
DMLV59R	FM	C14H13N3O2
DMLV59R	IC	InChI=1S/C14H13N3O2/c18-13-4-1-9(5-14(13)19)7-15-11-3-2-10-8-16-17-12(10)6-11/h1-6,8,15,18-19H,7H2,(H,16,17)
DMLV59R	CS	C1=CC(=C(C=C1CNC2=CC3=C(C=C2)C=NN3)O)O
DMLV59R	IK	FOCLURCEJLBSGE-UHFFFAOYSA-N
DMLV59R	IU	4-[(1H-indazol-6-ylamino)methyl]benzene-1,2-diol
DMLV59R	DE	Discovery agent

DMRWZ6T	ID	DMRWZ6T
DMRWZ6T	DN	4-((1H-indol-1-yl)methyl)benzenamine
DMRWZ6T	HS	Investigative
DMRWZ6T	SN	CHEMBL247281; 4-((1H-indol-1-yl)methyl)benzenamine; SCHEMBL14338710; BDBM50203132
DMRWZ6T	DT	Small molecular drug
DMRWZ6T	PC	19779451
DMRWZ6T	MW	222.28
DMRWZ6T	FM	C15H14N2
DMRWZ6T	IC	InChI=1S/C15H14N2/c16-14-7-5-12(6-8-14)11-17-10-9-13-3-1-2-4-15(13)17/h1-10H,11,16H2
DMRWZ6T	CS	C1=CC=C2C(=C1)C=CN2CC3=CC=C(C=C3)N
DMRWZ6T	IK	CRNJIXJRSKNGTP-UHFFFAOYSA-N
DMRWZ6T	IU	4-(indol-1-ylmethyl)aniline
DMRWZ6T	DE	Discovery agent

DMCRWTH	ID	DMCRWTH
DMCRWTH	DN	4'-((2-butylbenzofuran-3-yl)methyl)biphenyl-4-ol
DMCRWTH	HS	Investigative
DMCRWTH	SN	CHEMBL24141; BDBM50086945; 4''-((2-butylbenzofuran-3-yl)methyl)biphenyl-4-ol; 4''-(2-Butyl-benzofuran-3-ylmethyl)-biphenyl-4-ol
DMCRWTH	DT	Small molecular drug
DMCRWTH	PC	9841650
DMCRWTH	MW	356.5
DMCRWTH	FM	C25H24O2
DMCRWTH	IC	InChI=1S/C25H24O2/c1-2-3-7-25-23(22-6-4-5-8-24(22)27-25)17-18-9-11-19(12-10-18)20-13-15-21(26)16-14-20/h4-6,8-16,26H,2-3,7,17H2,1H3
DMCRWTH	CS	CCCCC1=C(C2=CC=CC=C2O1)CC3=CC=C(C=C3)C4=CC=C(C=C4)O
DMCRWTH	IK	AESGURZHBVMCOS-UHFFFAOYSA-N
DMCRWTH	IU	4-[4-[(2-butyl-1-benzofuran-3-yl)methyl]phenyl]phenol
DMCRWTH	DE	Discovery agent

DMJN2OW	ID	DMJN2OW
DMJN2OW	DN	4-((2R,3S)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole
DMJN2OW	HS	Investigative
DMJN2OW	SN	CHEMBL18735; Immepyr; 4-((2R,3S)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole; 1H-Imidazole, 4-[(2R,3S)-2-methyl-3-pyrrolidinyl]-; BDBM50034708
DMJN2OW	DT	Small molecular drug
DMJN2OW	PC	9815231
DMJN2OW	MW	151.21
DMJN2OW	FM	C8H13N3
DMJN2OW	IC	InChI=1S/C8H13N3/c1-6-7(2-3-10-6)8-4-9-5-11-8/h4-7,10H,2-3H2,1H3,(H,9,11)/t6-,7+/m1/s1
DMJN2OW	CS	C[C@@H]1[C@H](CCN1)C2=CN=CN2
DMJN2OW	IK	FLOJCNYYPGNYBP-RQJHMYQMSA-N
DMJN2OW	IU	5-[(2R,3S)-2-methylpyrrolidin-3-yl]-1H-imidazole
DMJN2OW	DE	Discovery agent

DM8WCJK	ID	DM8WCJK
DM8WCJK	DN	4-((2S,3R)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole
DM8WCJK	HS	Investigative
DM8WCJK	SN	CHEMBL18980; 4-((2S,3R)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole; BDBM50034707; 151093-64-0; 1H-Imidazole, 4-[(2S,3R)-2-methyl-3-pyrrolidinyl]-
DM8WCJK	DT	Small molecular drug
DM8WCJK	PC	10329450
DM8WCJK	MW	151.21
DM8WCJK	FM	C8H13N3
DM8WCJK	IC	InChI=1S/C8H13N3/c1-6-7(2-3-10-6)8-4-9-5-11-8/h4-7,10H,2-3H2,1H3,(H,9,11)/t6-,7+/m0/s1
DM8WCJK	CS	C[C@H]1[C@@H](CCN1)C2=CN=CN2
DM8WCJK	IK	FLOJCNYYPGNYBP-NKWVEPMBSA-N
DM8WCJK	IU	5-[(2S,3R)-2-methylpyrrolidin-3-yl]-1H-imidazole
DM8WCJK	DE	Discovery agent

DMHN5OL	ID	DMHN5OL
DMHN5OL	DN	4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine
DMHN5OL	HS	Investigative
DMHN5OL	SN	CHEMBL1214660; SCHEMBL18770342; BDBM50324617; ZINC58563870
DMHN5OL	DT	Small molecular drug
DMHN5OL	PC	46901616
DMHN5OL	MW	281.3
DMHN5OL	FM	C18H13F2N
DMHN5OL	IC	InChI=1S/C18H13F2N/c19-17-6-5-16(12-18(17)20)15-3-1-13(2-4-15)11-14-7-9-21-10-8-14/h1-10,12H,11H2
DMHN5OL	CS	C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)F)F
DMHN5OL	IK	KREPMUWCVWQPGH-UHFFFAOYSA-N
DMHN5OL	IU	4-[[4-(3,4-difluorophenyl)phenyl]methyl]pyridine
DMHN5OL	DE	Discovery agent

DM5EP3V	ID	DM5EP3V
DM5EP3V	DN	4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DM5EP3V	HS	Investigative
DM5EP3V	SN	4-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide
DM5EP3V	DT	Small molecular drug
DM5EP3V	PC	404195
DM5EP3V	MW	277.3
DM5EP3V	FM	C12H11N3O3S
DM5EP3V	IC	InChI=1S/C12H11N3O3S/c13-19(17,18)12-7-3-10(4-8-12)15-14-9-1-5-11(16)6-2-9/h1-8,16H,(H2,13,17,18)
DM5EP3V	CS	C1=CC(=CC=C1N=NC2=CC=C(C=C2)S(=O)(=O)N)O
DM5EP3V	IK	IPPFWRRJWLCWGK-UHFFFAOYSA-N
DM5EP3V	IU	4-[(4-hydroxyphenyl)diazenyl]benzenesulfonamide
DM5EP3V	CA	CAS 2497-37-2
DM5EP3V	DE	Discovery agent

DMNAT1D	ID	DMNAT1D
DMNAT1D	DN	4-((4-methoxyphenyl)diazenyl)benzenesulfonamide
DMNAT1D	HS	Investigative
DMNAT1D	SN	CHEMBL213267; 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide; 4-[(4-methoxyphenyl)diazenyl]benzenesulfonamide; NSC722840; AC1L8P6K; CTK7A1570; MolPort-002-934-354; ZINC6484196; STK037234; BDBM50190339; AKOS005382697; NSC-722840; MCULE-3486440340; 4-(4-Methoxy-phenylazo)-benzenesulfonamide; 4-[(E)-(4-methoxyphenyl)diazenyl]benzenesulfonamide; benzenesulfonamide, 4-[(e)-2-(4-methoxyphenyl)diazenyl]-
DMNAT1D	DT	Small molecular drug
DMNAT1D	PC	405489
DMNAT1D	MW	291.33
DMNAT1D	FM	C13H13N3O3S
DMNAT1D	IC	InChI=1S/C13H13N3O3S/c1-19-12-6-2-10(3-7-12)15-16-11-4-8-13(9-5-11)20(14,17)18/h2-9H,1H3,(H2,14,17,18)
DMNAT1D	CS	COC1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)N
DMNAT1D	IK	IPDZIIYOQAEWIC-UHFFFAOYSA-N
DMNAT1D	IU	4-[(4-methoxyphenyl)diazenyl]benzenesulfonamide
DMNAT1D	DE	Discovery agent

DM6R43J	ID	DM6R43J
DM6R43J	DN	4-((benzylideneamino)methyl)benzenesulfonamide
DM6R43J	HS	Investigative
DM6R43J	SN	CHEMBL582858; 4-((benzylideneamino)methyl)benzenesulfonamide; 4-[(benzylideneamino)methyl]benzenesulfonamide
DM6R43J	DT	Small molecular drug
DM6R43J	PC	45483206
DM6R43J	MW	274.34
DM6R43J	FM	C14H14N2O2S
DM6R43J	IC	InChI=1S/C14H14N2O2S/c15-19(17,18)14-8-6-13(7-9-14)11-16-10-12-4-2-1-3-5-12/h1-10H,11H2,(H2,15,17,18)
DM6R43J	CS	C1=CC=C(C=C1)C=NCC2=CC=C(C=C2)S(=O)(=O)N
DM6R43J	IK	IUUNKBLBYPIGMX-UHFFFAOYSA-N
DM6R43J	IU	4-[(benzylideneamino)methyl]benzenesulfonamide
DM6R43J	DE	Discovery agent

DMDOJ4E	ID	DMDOJ4E
DMDOJ4E	DN	4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DMDOJ4E	HS	Investigative
DMDOJ4E	SN	CHEMBL102669; ZINC13757203
DMDOJ4E	DT	Small molecular drug
DMDOJ4E	PC	10704862
DMDOJ4E	MW	234.29
DMDOJ4E	FM	C16H14N2
DMDOJ4E	IC	InChI=1S/C16H14N2/c1-2-13(16-10-17-11-18-16)15-9-5-7-12-6-3-4-8-14(12)15/h2-11H,1H3,(H,17,18)/b13-2+
DMDOJ4E	CS	C/C=C(\\C1=CC=CC2=CC=CC=C21)/C3=CN=CN3
DMDOJ4E	IK	VDVBKYMIYSQNPM-XNJYKOPJSA-N
DMDOJ4E	IU	5-[(E)-1-naphthalen-1-ylprop-1-enyl]-1H-imidazole
DMDOJ4E	DE	Discovery agent

DM52Y3Q	ID	DM52Y3Q
DM52Y3Q	DN	4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol
DM52Y3Q	HS	Investigative
DM52Y3Q	SN	CHEMBL1240677; 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol; BDBM50326006
DM52Y3Q	DT	Small molecular drug
DM52Y3Q	PC	43680262
DM52Y3Q	MW	265.31
DM52Y3Q	FM	C17H15NO2
DM52Y3Q	IC	InChI=1S/C17H15NO2/c19-16-8-5-12(9-17(16)20)11-18-15-7-6-13-3-1-2-4-14(13)10-15/h1-10,18-20H,11H2
DM52Y3Q	CS	C1=CC=C2C=C(C=CC2=C1)NCC3=CC(=C(C=C3)O)O
DM52Y3Q	IK	QYMHAOZLKJHVDJ-UHFFFAOYSA-N
DM52Y3Q	IU	4-[(naphthalen-2-ylamino)methyl]benzene-1,2-diol
DM52Y3Q	DE	Discovery agent

DMIQHYZ	ID	DMIQHYZ
DMIQHYZ	DN	4-((naphthalen-2-yloxy)methyl)piperidine
DMIQHYZ	HS	Investigative
DMIQHYZ	SN	4-[(2-Naphthyloxy)methyl]piperidine; CHEMBL453996; 4-((naphthalen-2-yloxy)methyl)piperidine; 946680-75-7; 4-[(naphthalen-2-yloxy)methyl]piperidine; CTK7D1529; ZINC14631494; BDBM50278526; AKOS000172158
DMIQHYZ	DT	Small molecular drug
DMIQHYZ	PC	24691160
DMIQHYZ	MW	241.33
DMIQHYZ	FM	C16H19NO
DMIQHYZ	IC	InChI=1S/C16H19NO/c1-2-4-15-11-16(6-5-14(15)3-1)18-12-13-7-9-17-10-8-13/h1-6,11,13,17H,7-10,12H2
DMIQHYZ	CS	C1CNCCC1COC2=CC3=CC=CC=C3C=C2
DMIQHYZ	IK	MUOXAGUZMVATIC-UHFFFAOYSA-N
DMIQHYZ	IU	4-(naphthalen-2-yloxymethyl)piperidine
DMIQHYZ	DE	Discovery agent

DM7X2AY	ID	DM7X2AY
DM7X2AY	DN	4-((pyridin-4-ylthio)methyl)benzene-1,2-diol
DM7X2AY	HS	Investigative
DM7X2AY	SN	CHEMBL199691; 4-((pyridin-4-ylthio)methyl)benzene-1,2-diol
DM7X2AY	DT	Small molecular drug
DM7X2AY	PC	44406762
DM7X2AY	MW	233.29
DM7X2AY	FM	C12H11NO2S
DM7X2AY	IC	InChI=1S/C12H11NO2S/c14-11-2-1-9(7-12(11)15)8-16-10-3-5-13-6-4-10/h1-7,14-15H,8H2
DM7X2AY	CS	C1=CC(=C(C=C1CSC2=CC=NC=C2)O)O
DM7X2AY	IK	JVOZIFHFAIJCMB-UHFFFAOYSA-N
DM7X2AY	IU	4-(pyridin-4-ylsulfanylmethyl)benzene-1,2-diol
DM7X2AY	DE	Discovery agent

DM1UK3G	ID	DM1UK3G
DM1UK3G	DN	4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DM1UK3G	HS	Investigative
DM1UK3G	SN	CHEMBL322844; SCHEMBL7919847; ZINC13757204
DM1UK3G	DT	Small molecular drug
DM1UK3G	PC	9991628
DM1UK3G	MW	234.29
DM1UK3G	FM	C16H14N2
DM1UK3G	IC	InChI=1S/C16H14N2/c1-2-13(16-10-17-11-18-16)15-9-5-7-12-6-3-4-8-14(12)15/h2-11H,1H3,(H,17,18)/b13-2-
DM1UK3G	CS	C/C=C(/C1=CC=CC2=CC=CC=C21)\\C3=CN=CN3
DM1UK3G	IK	VDVBKYMIYSQNPM-SILLCRNTSA-N
DM1UK3G	IU	5-[(Z)-1-naphthalen-1-ylprop-1-enyl]-1H-imidazole
DM1UK3G	DE	Discovery agent

DMEW1CP	ID	DMEW1CP
DMEW1CP	DN	4'-(1-(pyridin-4-yl)propyl)biphenyl-3-ol
DMEW1CP	HS	Investigative
DMEW1CP	SN	CHEMBL1172883; SCHEMBL18770306; BDBM50322795
DMEW1CP	DT	Small molecular drug
DMEW1CP	PC	46854448
DMEW1CP	MW	289.4
DMEW1CP	FM	C20H19NO
DMEW1CP	IC	InChI=1S/C20H19NO/c1-2-20(17-10-12-21-13-11-17)16-8-6-15(7-9-16)18-4-3-5-19(22)14-18/h3-14,20,22H,2H2,1H3
DMEW1CP	CS	CCC(C1=CC=C(C=C1)C2=CC(=CC=C2)O)C3=CC=NC=C3
DMEW1CP	IK	CANWOPWELBFZMH-UHFFFAOYSA-N
DMEW1CP	IU	3-[4-(1-pyridin-4-ylpropyl)phenyl]phenol
DMEW1CP	DE	Discovery agent

DMV4QRF	ID	DMV4QRF
DMV4QRF	DN	4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol
DMV4QRF	HS	Investigative
DMV4QRF	SN	CHEMBL234678; BDBM50213141
DMV4QRF	DT	Small molecular drug
DMV4QRF	PC	11290338
DMV4QRF	MW	326.5
DMV4QRF	FM	C22H30O2
DMV4QRF	IC	InChI=1S/C22H30O2/c1-5-6-7-10-15-22(2,3)17-13-14-18(20(23)16-17)19-11-8-9-12-21(19)24-4/h8-9,11-14,16,23H,5-7,10,15H2,1-4H3
DMV4QRF	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC=CC=C2OC)O
DMV4QRF	IK	WXRCAYBWSXUGLS-UHFFFAOYSA-N
DMV4QRF	IU	2-(2-methoxyphenyl)-5-(2-methyloctan-2-yl)phenol
DMV4QRF	DE	Discovery agent

DMUMD8L	ID	DMUMD8L
DMUMD8L	DN	4'-(1,1-dimethyl-heptyl)-3,5-dimethyl-biphenyl
DMUMD8L	HS	Investigative
DMUMD8L	SN	CHEMBL61038; BDBM50213142
DMUMD8L	DT	Small molecular drug
DMUMD8L	PC	44300692
DMUMD8L	MW	308.5
DMUMD8L	FM	C23H32
DMUMD8L	IC	InChI=1S/C23H32/c1-6-7-8-9-14-23(4,5)22-12-10-20(11-13-22)21-16-18(2)15-19(3)17-21/h10-13,15-17H,6-9,14H2,1-5H3
DMUMD8L	CS	CCCCCCC(C)(C)C1=CC=C(C=C1)C2=CC(=CC(=C2)C)C
DMUMD8L	IK	KOXFWOOFJAOOQK-UHFFFAOYSA-N
DMUMD8L	IU	1,3-dimethyl-5-[4-(2-methyloctan-2-yl)phenyl]benzene
DMUMD8L	DE	Discovery agent

DM5BN41	ID	DM5BN41
DM5BN41	DN	4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol
DM5BN41	HS	Investigative
DM5BN41	SN	CHEMBL234845; BDBM50213171
DM5BN41	DT	Small molecular drug
DM5BN41	PC	44431961
DM5BN41	MW	326.5
DM5BN41	FM	C22H30O2
DM5BN41	IC	InChI=1S/C22H30O2/c1-5-6-7-8-14-22(2,3)18-12-13-20(21(23)16-18)17-10-9-11-19(15-17)24-4/h9-13,15-16,23H,5-8,14H2,1-4H3
DM5BN41	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC(=CC=C2)OC)O
DM5BN41	IK	XKFBIUKAHKJONV-UHFFFAOYSA-N
DM5BN41	IU	2-(3-methoxyphenyl)-5-(2-methyloctan-2-yl)phenol
DM5BN41	DE	Discovery agent

DMG4HO3	ID	DMG4HO3
DMG4HO3	DN	4-(1,2,3-thiadiazol-4-yl)phenyl butylcarbamate
DMG4HO3	HS	Investigative
DMG4HO3	SN	CHEMBL551567; AC1MCABO; 4-(1,2,3-thiadiazol-4-yl)phenyl butylcarbamate; MolPort-002-920-365; HMS1668O20; ZINC3119736; BDBM50295657; MCULE-2085974247; CCG-245837; [4-(thiadiazol-4-yl)phenyl] N-butylcarbamate
DMG4HO3	DT	Small molecular drug
DMG4HO3	PC	2739381
DMG4HO3	MW	277.34
DMG4HO3	FM	C13H15N3O2S
DMG4HO3	IC	InChI=1S/C13H15N3O2S/c1-2-3-8-14-13(17)18-11-6-4-10(5-7-11)12-9-19-16-15-12/h4-7,9H,2-3,8H2,1H3,(H,14,17)
DMG4HO3	CS	CCCCNC(=O)OC1=CC=C(C=C1)C2=CSN=N2
DMG4HO3	IK	XVFSPFDRDOHQIV-UHFFFAOYSA-N
DMG4HO3	IU	[4-(thiadiazol-4-yl)phenyl] N-butylcarbamate
DMG4HO3	DE	Discovery agent

DMSFGRI	ID	DMSFGRI
DMSFGRI	DN	4-(1,2,3-thiadiazol-4-yl)phenyl hexylcarbamate
DMSFGRI	HS	Investigative
DMSFGRI	SN	CHEMBL550587; 4-(1,2,3-thiadiazol-4-yl)phenyl hexylcarbamate
DMSFGRI	DT	Small molecular drug
DMSFGRI	PC	42645847
DMSFGRI	MW	305.4
DMSFGRI	FM	C15H19N3O2S
DMSFGRI	IC	InChI=1S/C15H19N3O2S/c1-2-3-4-5-10-16-15(19)20-13-8-6-12(7-9-13)14-11-21-18-17-14/h6-9,11H,2-5,10H2,1H3,(H,16,19)
DMSFGRI	CS	CCCCCCNC(=O)OC1=CC=C(C=C1)C2=CSN=N2
DMSFGRI	IK	KWDYSOZHSAWBCY-UHFFFAOYSA-N
DMSFGRI	IU	[4-(thiadiazol-4-yl)phenyl] N-hexylcarbamate
DMSFGRI	DE	Discovery agent

DMJDW50	ID	DMJDW50
DMJDW50	DN	4-(1,2-Diphenyl-but-1-enyl)-phenol
DMJDW50	HS	Investigative
DMJDW50	SN	CHEMBL50995; 4-(1,2-Diphenyl-1-butenyl)phenol; Monophenoltamoxifen; 4-(1,2-Diphenyl-but-1-enyl)-phenol; 4-[(Z)-1,2-diphenylbut-1-enyl]phenol; AC1O4GB8; SCHEMBL5354173; BDBM50121319; ZINC29469549; 69967-80-2; LS-104581
DMJDW50	DT	Small molecular drug
DMJDW50	PC	6366969
DMJDW50	MW	300.4
DMJDW50	FM	C22H20O
DMJDW50	IC	InChI=1S/C22H20O/c1-2-21(17-9-5-3-6-10-17)22(18-11-7-4-8-12-18)19-13-15-20(23)16-14-19/h3-16,23H,2H2,1H3/b22-21-
DMJDW50	CS	CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)O)/C3=CC=CC=C3
DMJDW50	IK	YJVFSITVRZYTHO-DQRAZIAOSA-N
DMJDW50	IU	4-[(Z)-1,2-diphenylbut-1-enyl]phenol
DMJDW50	DE	Discovery agent

DM1SP36	ID	DM1SP36
DM1SP36	DN	4-(10H-Anthracen-9-ylidene)-1-methyl-piperidine
DM1SP36	HS	Investigative
DM1SP36	SN	CHEMBL348459; 4-(10H-anthracen-9-ylidene)-1-methyl-piperidine; SCHEMBL13921290; BDBM50097218
DM1SP36	DT	Small molecular drug
DM1SP36	PC	10468648
DM1SP36	MW	275.4
DM1SP36	FM	C20H21N
DM1SP36	IC	InChI=1S/C20H21N/c1-21-12-10-15(11-13-21)20-18-8-4-2-6-16(18)14-17-7-3-5-9-19(17)20/h2-9H,10-14H2,1H3
DM1SP36	CS	CN1CCC(=C2C3=CC=CC=C3CC4=CC=CC=C42)CC1
DM1SP36	IK	ZOARGTMABFXNDY-UHFFFAOYSA-N
DM1SP36	IU	4-(10H-anthracen-9-ylidene)-1-methylpiperidine
DM1SP36	DE	Discovery agent

DMNV9H5	ID	DMNV9H5
DMNV9H5	DN	4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol
DMNV9H5	HS	Investigative
DMNV9H5	DT	Small molecular drug
DMNV9H5	PC	135503667
DMNV9H5	MW	334.8
DMNV9H5	FM	C20H15ClN2O
DMNV9H5	IC	InChI=1S/C20H15ClN2O/c21-18-8-4-7-17-19(15-9-11-16(24)12-10-15)22-23(20(17)18)13-14-5-2-1-3-6-14/h1-12,24H,13H2
DMNV9H5	CS	C1=CC=C(C=C1)CN2C3=C(C=CC=C3Cl)C(=N2)C4=CC=C(C=C4)O
DMNV9H5	IK	DPRKSCQCEZRMAF-UHFFFAOYSA-N
DMNV9H5	IU	4-(1-benzyl-7-chloroindazol-3-yl)phenol
DMNV9H5	CA	CAS 680613-14-3
DMNV9H5	DE	Discovery agent

DMS1OYA	ID	DMS1OYA
DMS1OYA	DN	4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol
DMS1OYA	HS	Investigative
DMS1OYA	DT	Small molecular drug
DMS1OYA	PC	135458016
DMS1OYA	MW	300.8
DMS1OYA	FM	C17H17ClN2O
DMS1OYA	IC	InChI=1S/C17H17ClN2O/c1-2-3-11-20-17-14(5-4-6-15(17)18)16(19-20)12-7-9-13(21)10-8-12/h4-10,21H,2-3,11H2,1H3
DMS1OYA	CS	CCCCN1C2=C(C=CC=C2Cl)C(=N1)C3=CC=C(C=C3)O
DMS1OYA	IK	NPAAZPFDWTWFDL-UHFFFAOYSA-N
DMS1OYA	IU	4-(1-butyl-7-chloroindazol-3-yl)phenol
DMS1OYA	CA	CAS 680613-52-9
DMS1OYA	DE	Discovery agent

DM3NEYB	ID	DM3NEYB
DM3NEYB	DN	4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol
DM3NEYB	HS	Investigative
DM3NEYB	DT	Small molecular drug
DM3NEYB	PC	135524867
DM3NEYB	MW	296.3
DM3NEYB	FM	C18H17FN2O
DM3NEYB	IC	InChI=1S/C18H17FN2O/c19-16-7-3-6-15-17(12-8-10-14(22)11-9-12)20-21(18(15)16)13-4-1-2-5-13/h3,6-11,13,22H,1-2,4-5H2
DM3NEYB	CS	C1CCC(C1)N2C3=C(C=CC=C3F)C(=N2)C4=CC=C(C=C4)O
DM3NEYB	IK	IYPUUNMLLKLEOH-UHFFFAOYSA-N
DM3NEYB	IU	4-(1-cyclopentyl-7-fluoroindazol-3-yl)phenol
DM3NEYB	CA	CAS 680611-78-3
DM3NEYB	DE	Discovery agent

DMFWVJI	ID	DMFWVJI
DMFWVJI	DN	4-(1H-1,2,3-triazol-5-yl)pyridine
DMFWVJI	HS	Investigative
DMFWVJI	SN	(4-pyridyl)triazole; 4-(1H-1,2,3-triazol-5-yl)pyridine; SCHEMBL4806159; CHEMBL364898; ZINC27317; BDBM17472; 1,2,3-triazole analogue, 28; AKOS027406024
DMFWVJI	DT	Small molecular drug
DMFWVJI	PC	9942176
DMFWVJI	MW	146.15
DMFWVJI	FM	C7H6N4
DMFWVJI	IC	InChI=1S/C7H6N4/c1-3-8-4-2-6(1)7-5-9-11-10-7/h1-5H,(H,9,10,11)
DMFWVJI	CS	C1=CN=CC=C1C2=NNN=C2
DMFWVJI	IK	KEFBRERBEDJOQZ-UHFFFAOYSA-N
DMFWVJI	IU	4-(2H-triazol-4-yl)pyridine
DMFWVJI	DE	Discovery agent

DM5JDYO	ID	DM5JDYO
DM5JDYO	DN	4-(1H-IMIDAZOL-1-YL)PHENOL
DM5JDYO	HS	Investigative
DM5JDYO	SN	4-(Imidazol-1-yl)phenol; 10041-02-8; 4-(1h-imidazol-1-yl)phenol; 4-Imidazol-1-yl-phenol; 4-(1-Imidazolyl)Phenol; Phenol, 4-(1H-imidazol-1-yl)-; 1-(p-Hydroxyphenyl)imidazole; 1-(4-Hydroxyphenyl)imidazole; p-(1-imidazolyl)phenol; CYKCUAPYWQDIKR-UHFFFAOYSA-N; 4-imidazolylphenol; (1H&amp; imidazol&amp; 1&amp; yl)phenol (Compound 1); EINECS 233-121-4; 4-imidazol-1-ylphenol; 4m5r; p-(Imidazol-1-yl)phenol; ACMC-209vy5; AC1Q78RW; AC1Q4YG7; 4-(1H-imidazol-yl)phenol; 4(1H-imidazol-1-yl)phenol
DM5JDYO	DT	Small molecular drug
DM5JDYO	PC	82315
DM5JDYO	MW	160.17
DM5JDYO	FM	C9H8N2O
DM5JDYO	IC	InChI=1S/C9H8N2O/c12-9-3-1-8(2-4-9)11-6-5-10-7-11/h1-7,12H
DM5JDYO	CS	C1=CC(=CC=C1N2C=CN=C2)O
DM5JDYO	IK	CYKCUAPYWQDIKR-UHFFFAOYSA-N
DM5JDYO	IU	4-imidazol-1-ylphenol
DM5JDYO	CA	CAS 10041-02-8
DM5JDYO	DE	Discovery agent

DMMJI4R	ID	DMMJI4R
DMMJI4R	DN	4-(1H-Inden-1-ylmethyl)-phenylamine
DMMJI4R	HS	Investigative
DMMJI4R	SN	CHEMBL193637; 4-(1H-Inden-1-ylmethyl)-phenylamine
DMMJI4R	DT	Small molecular drug
DMMJI4R	PC	44401550
DMMJI4R	MW	221.3
DMMJI4R	FM	C16H15N
DMMJI4R	IC	InChI=1S/C16H15N/c17-15-9-5-12(6-10-15)11-14-8-7-13-3-1-2-4-16(13)14/h1-10,14H,11,17H2
DMMJI4R	CS	C1=CC=C2C(C=CC2=C1)CC3=CC=C(C=C3)N
DMMJI4R	IK	CTQZYHBDQGUTCI-UHFFFAOYSA-N
DMMJI4R	IU	4-(1H-inden-1-ylmethyl)aniline
DMMJI4R	DE	Discovery agent

DMY5QBF	ID	DMY5QBF
DMY5QBF	DN	4-(1H-indol-1-ylsulfonyl)benzenamine
DMY5QBF	HS	Investigative
DMY5QBF	SN	CHEMBL372109; BDBM34151; N-arenesulfonylindole antagonist, 10
DMY5QBF	DT	Small molecular drug
DMY5QBF	PC	44263491
DMY5QBF	MW	272.32
DMY5QBF	FM	C14H12N2O2S
DMY5QBF	IC	InChI=1S/C14H12N2O2S/c15-12-5-7-13(8-6-12)19(17,18)16-10-9-11-3-1-2-4-14(11)16/h1-10H,15H2
DMY5QBF	CS	C1=CC=C2C(=C1)C=CN2S(=O)(=O)C3=CC=C(C=C3)N
DMY5QBF	IK	FLNRELDLHZADER-UHFFFAOYSA-N
DMY5QBF	IU	4-indol-1-ylsulfonylaniline
DMY5QBF	DE	Discovery agent

DM9FKSM	ID	DM9FKSM
DM9FKSM	DN	4-(1H-indol-3-yl)-1-morpholinobutan-1-one
DM9FKSM	HS	Investigative
DM9FKSM	SN	CHEMBL395709; 4-(1H-indol-3-yl)-1-(morpholin-4-yl)butan-1-one; AC1LDAKL; 4-(1H-indol-3-yl)-1-morpholinobutan-1-one; Oprea1_287687; MLS000073378; SCHEMBL14882056; MolPort-001-888-170; ZINC280650; HMS2314G24; BDBM50207035; STK110153; AKOS000614077; MCULE-8725603794; SMR000013452; 313532-54-6; ST50900693; 4-indol-3-yl-1-morpholin-4-ylbutan-1-one; 4-(1H-indol-3-yl)-1-morpholin-4-ylbutan-1-one; SR-01000362492; 4-(1H-Indol-3-yl)-1-morpholin-4-yl-butan-1-one; SR-01000362492-1
DM9FKSM	DT	Small molecular drug
DM9FKSM	PC	645040
DM9FKSM	MW	272.34
DM9FKSM	FM	C16H20N2O2
DM9FKSM	IC	InChI=1S/C16H20N2O2/c19-16(18-8-10-20-11-9-18)7-3-4-13-12-17-15-6-2-1-5-14(13)15/h1-2,5-6,12,17H,3-4,7-11H2
DM9FKSM	CS	C1COCCN1C(=O)CCCC2=CNC3=CC=CC=C32
DM9FKSM	IK	YFXYLXOHDNYDNC-UHFFFAOYSA-N
DM9FKSM	IU	4-(1H-indol-3-yl)-1-morpholin-4-ylbutan-1-one
DM9FKSM	DE	Discovery agent

DM7Y1ZD	ID	DM7Y1ZD
DM7Y1ZD	DN	4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine
DM7Y1ZD	HS	Investigative
DM7Y1ZD	SN	CHEMBL231809; 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine
DM7Y1ZD	DT	Small molecular drug
DM7Y1ZD	PC	44430859
DM7Y1ZD	MW	240.34
DM7Y1ZD	FM	C16H20N2
DM7Y1ZD	IC	InChI=1S/C16H20N2/c1-18(2)13-9-7-12(8-10-13)15-11-17-16-6-4-3-5-14(15)16/h3-7,11,13,17H,8-10H2,1-2H3
DM7Y1ZD	CS	CN(C)C1CCC(=CC1)C2=CNC3=CC=CC=C32
DM7Y1ZD	IK	OLBSGDZXLHSPOR-UHFFFAOYSA-N
DM7Y1ZD	IU	4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-en-1-amine
DM7Y1ZD	DE	Discovery agent

DMK5CJO	ID	DMK5CJO
DMK5CJO	DN	4-(1H-Indol-3-ylmethyl)-phenylamine
DMK5CJO	HS	Investigative
DMK5CJO	SN	Benzenamine, 4-(1H-indol-3-ylmethyl)-; CHEMBL364248; 134627-70-6; 4-(1H-indol-3-ylmethyl)aniline; ACMC-20mvfl; 4-(1H-Indol-3-ylmethyl)-phenylamine; AC1N7FQI; SCHEMBL4224120; CTK0F4358; DTXSID30401708; 4-[(1H-Indol-3-yl)methyl]aniline; BDBM50164747
DMK5CJO	DT	Small molecular drug
DMK5CJO	PC	4301799
DMK5CJO	MW	222.28
DMK5CJO	FM	C15H14N2
DMK5CJO	IC	InChI=1S/C15H14N2/c16-13-7-5-11(6-8-13)9-12-10-17-15-4-2-1-3-14(12)15/h1-8,10,17H,9,16H2
DMK5CJO	CS	C1=CC=C2C(=C1)C(=CN2)CC3=CC=C(C=C3)N
DMK5CJO	IK	KDXYOBVEKNURNB-UHFFFAOYSA-N
DMK5CJO	IU	4-(1H-indol-3-ylmethyl)aniline
DMK5CJO	CA	CAS 134627-70-6
DMK5CJO	DE	Discovery agent

DMQVOSU	ID	DMQVOSU
DMQVOSU	DN	4-(1H-indol-4-yloxy)-1-(isopropylamino)butan-2-ol
DMQVOSU	HS	Investigative
DMQVOSU	SN	CHEMBL412022; 4-(1H-indol-4-yloxy)-1-(isopropylamino)butan-2-ol
DMQVOSU	DT	Small molecular drug
DMQVOSU	PC	44433256
DMQVOSU	MW	262.35
DMQVOSU	FM	C15H22N2O2
DMQVOSU	IC	InChI=1S/C15H22N2O2/c1-11(2)17-10-12(18)7-9-19-15-5-3-4-14-13(15)6-8-16-14/h3-6,8,11-12,16-18H,7,9-10H2,1-2H3
DMQVOSU	CS	CC(C)NCC(CCOC1=CC=CC2=C1C=CN2)O
DMQVOSU	IK	DJWOTJGQRBWXIN-UHFFFAOYSA-N
DMQVOSU	IU	4-(1H-indol-4-yloxy)-1-(propan-2-ylamino)butan-2-ol
DMQVOSU	DE	Discovery agent

DMAU0SF	ID	DMAU0SF
DMAU0SF	DN	4-(1H-indol-5-ylamino)-5-styrylnicotinonitrile
DMAU0SF	HS	Investigative
DMAU0SF	SN	CHEMBL579201; 4-(1H-indol-5-ylamino)-5-styrylnicotinonitrile; SCHEMBL2935239
DMAU0SF	DT	Small molecular drug
DMAU0SF	PC	45485012
DMAU0SF	MW	336.4
DMAU0SF	FM	C22H16N4
DMAU0SF	IC	InChI=1S/C22H16N4/c23-13-19-15-24-14-18(7-6-16-4-2-1-3-5-16)22(19)26-20-8-9-21-17(12-20)10-11-25-21/h1-12,14-15,25H,(H,24,26)/b7-6+
DMAU0SF	CS	C1=CC=C(C=C1)/C=C/C2=CN=CC(=C2NC3=CC4=C(C=C3)NC=C4)C#N
DMAU0SF	IK	GLBDOEWDGNREFF-VOTSOKGWSA-N
DMAU0SF	IU	4-(1H-indol-5-ylamino)-5-[(E)-2-phenylethenyl]pyridine-3-carbonitrile
DMAU0SF	DE	Discovery agent

DMH360U	ID	DMH360U
DMH360U	DN	4-(1H-indol-5-yloxy)-5-styrylnicotinonitrile
DMH360U	HS	Investigative
DMH360U	SN	CHEMBL568973; 4-(1H-indol-5-yloxy)-5-styrylnicotinonitrile; SCHEMBL2935007
DMH360U	DT	Small molecular drug
DMH360U	PC	45484993
DMH360U	MW	337.4
DMH360U	FM	C22H15N3O
DMH360U	IC	InChI=1S/C22H15N3O/c23-13-19-15-24-14-18(7-6-16-4-2-1-3-5-16)22(19)26-20-8-9-21-17(12-20)10-11-25-21/h1-12,14-15,25H/b7-6+
DMH360U	CS	C1=CC=C(C=C1)/C=C/C2=CN=CC(=C2OC3=CC4=C(C=C3)NC=C4)C#N
DMH360U	IK	IMMBFBPNPIRCBR-VOTSOKGWSA-N
DMH360U	IU	4-(1H-indol-5-yloxy)-5-[(E)-2-phenylethenyl]pyridine-3-carbonitrile
DMH360U	DE	Discovery agent

DMB07TU	ID	DMB07TU
DMB07TU	DN	4-(1H-indol-6-ylamino)-5-styrylnicotinonitrile
DMB07TU	HS	Investigative
DMB07TU	SN	CHEMBL578348; 4-(1H-indol-6-ylamino)-5-styrylnicotinonitrile; SCHEMBL2935272
DMB07TU	DT	Small molecular drug
DMB07TU	PC	45485036
DMB07TU	MW	336.4
DMB07TU	FM	C22H16N4
DMB07TU	IC	InChI=1S/C22H16N4/c23-13-19-15-24-14-18(7-6-16-4-2-1-3-5-16)22(19)26-20-9-8-17-10-11-25-21(17)12-20/h1-12,14-15,25H,(H,24,26)/b7-6+
DMB07TU	CS	C1=CC=C(C=C1)/C=C/C2=CN=CC(=C2NC3=CC4=C(C=C3)C=CN4)C#N
DMB07TU	IK	DDIZHXIEUONSME-VOTSOKGWSA-N
DMB07TU	IU	4-(1H-indol-6-ylamino)-5-[(E)-2-phenylethenyl]pyridine-3-carbonitrile
DMB07TU	DE	Discovery agent

DM9MPHF	ID	DM9MPHF
DM9MPHF	DN	4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
DM9MPHF	HS	Investigative
DM9MPHF	SN	CHEMBL1089985; 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine; SCHEMBL2239177; 1H-Pyrrolo[2,3-b]pyridine, 4-(1H-pyrazol-4-yl)-; BDBM50315770
DM9MPHF	DT	Small molecular drug
DM9MPHF	PC	46885627
DM9MPHF	MW	184.2
DM9MPHF	FM	C10H8N4
DM9MPHF	IC	InChI=1S/C10H8N4/c1-3-11-10-9(2-4-12-10)8(1)7-5-13-14-6-7/h1-6H,(H,11,12)(H,13,14)
DM9MPHF	CS	C1=CNC2=NC=CC(=C21)C3=CNN=C3
DM9MPHF	IK	FATFDRYYCYZBQB-UHFFFAOYSA-N
DM9MPHF	IU	4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
DM9MPHF	DE	Discovery agent

DM08963	ID	DM08963
DM08963	DN	4-(1-Imidazol-1-yl-vinyl)-benzonitrile
DM08963	HS	Investigative
DM08963	SN	CHEMBL31760; Benzonitrile, 4-[1-(1H-imidazol-1-yl)ethenyl]-; 112809-36-6; 4-(1-Imidazol-1-yl-vinyl)-benzonitrile; SCHEMBL1507802; BDBM50047259; 4-(1-(1H-imidazol-1-yl)vinyl)benzonitrile
DM08963	DT	Small molecular drug
DM08963	PC	11819989
DM08963	MW	195.22
DM08963	FM	C12H9N3
DM08963	IC	InChI=1S/C12H9N3/c1-10(15-7-6-14-9-15)12-4-2-11(8-13)3-5-12/h2-7,9H,1H2
DM08963	CS	C=C(C1=CC=C(C=C1)C#N)N2C=CN=C2
DM08963	IK	FUFISTOVGRWOOB-UHFFFAOYSA-N
DM08963	IU	4-(1-imidazol-1-ylethenyl)benzonitrile
DM08963	DE	Discovery agent

DMFYBLH	ID	DMFYBLH
DMFYBLH	DN	4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole
DMFYBLH	HS	Investigative
DMFYBLH	SN	CHEMBL306751; 1H-Imidazole, 4-[1-(1-naphthalenyl)ethyl]-; 137967-87-4; ACMC-20mx1j; 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole; AC1L30EQ; SCHEMBL1551477; CTK0F3329; DTXSID60276325; BDBM50036910; 4-[1-(1-Naphthyl)ethyl]-1H-imidazole; 5-(1-naphthalen-1-ylethyl)-1H-imidazole; 4-(1-(naphthalene-1-yl) ethyl)-1h-imidazole
DMFYBLH	DT	Small molecular drug
DMFYBLH	PC	132111
DMFYBLH	MW	222.28
DMFYBLH	FM	C15H14N2
DMFYBLH	IC	InChI=1S/C15H14N2/c1-11(15-9-16-10-17-15)13-8-4-6-12-5-2-3-7-14(12)13/h2-11H,1H3,(H,16,17)
DMFYBLH	CS	CC(C1=CC=CC2=CC=CC=C21)C3=CN=CN3
DMFYBLH	IK	DZSQSLQSMKNVBV-UHFFFAOYSA-N
DMFYBLH	IU	5-(1-naphthalen-1-ylethyl)-1H-imidazole
DMFYBLH	CA	CAS 137967-87-4
DMFYBLH	DE	Discovery agent

DM64THP	ID	DM64THP
DM64THP	DN	4-(1-Naphthalen-1-yl-propyl)-1H-imidazole
DM64THP	HS	Investigative
DM64THP	SN	SCHEMBL2104730; CHEMBL102076
DM64THP	DT	Small molecular drug
DM64THP	PC	10657471
DM64THP	MW	236.31
DM64THP	FM	C16H16N2
DM64THP	IC	InChI=1S/C16H16N2/c1-2-13(16-10-17-11-18-16)15-9-5-7-12-6-3-4-8-14(12)15/h3-11,13H,2H2,1H3,(H,17,18)
DM64THP	CS	CCC(C1=CC=CC2=CC=CC=C21)C3=CN=CN3
DM64THP	IK	LDZDVSZUAUUBGV-UHFFFAOYSA-N
DM64THP	IU	5-(1-naphthalen-1-ylpropyl)-1H-imidazole
DM64THP	DE	Discovery agent

DM49PR1	ID	DM49PR1
DM49PR1	DN	4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole
DM49PR1	HS	Investigative
DM49PR1	SN	4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole; CHEMBL105487; SCHEMBL3751615; RADFITYEEZIPNJ-UHFFFAOYSA-N; ZINC13757201
DM49PR1	DT	Small molecular drug
DM49PR1	PC	10632725
DM49PR1	MW	220.27
DM49PR1	FM	C15H12N2
DM49PR1	IC	InChI=1S/C15H12N2/c1-11(15-9-16-10-17-15)13-8-4-6-12-5-2-3-7-14(12)13/h2-10H,1H2,(H,16,17)
DM49PR1	CS	C=C(C1=CC=CC2=CC=CC=C21)C3=CN=CN3
DM49PR1	IK	RADFITYEEZIPNJ-UHFFFAOYSA-N
DM49PR1	IU	5-(1-naphthalen-1-ylethenyl)-1H-imidazole
DM49PR1	DE	Discovery agent

DMJ9CNA	ID	DMJ9CNA
DMJ9CNA	DN	4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine
DMJ9CNA	HS	Investigative
DMJ9CNA	SN	CHEMBL573766; 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine
DMJ9CNA	DT	Small molecular drug
DMJ9CNA	PC	45483528
DMJ9CNA	MW	285.4
DMJ9CNA	FM	C18H20FNO
DMJ9CNA	IC	InChI=1S/C18H20FNO/c19-16-5-3-6-17(12-16)21-13-15-4-1-2-7-18(15)14-8-10-20-11-9-14/h1-7,12,14,20H,8-11,13H2
DMJ9CNA	CS	C1CNCCC1C2=CC=CC=C2COC3=CC(=CC=C3)F
DMJ9CNA	IK	LGSKMJOUAMVJKK-UHFFFAOYSA-N
DMJ9CNA	IU	4-[2-[(3-fluorophenoxy)methyl]phenyl]piperidine
DMJ9CNA	DE	Discovery agent

DM0MWVU	ID	DM0MWVU
DM0MWVU	DN	4-(2-((dimethylamino)methyl)phenoxy)benzonitrile
DM0MWVU	HS	Investigative
DM0MWVU	SN	CHEMBL481941; 4-(2-((dimethylamino)methyl)phenoxy)benzonitrile
DM0MWVU	DT	Small molecular drug
DM0MWVU	PC	44568213
DM0MWVU	MW	252.31
DM0MWVU	FM	C16H16N2O
DM0MWVU	IC	InChI=1S/C16H16N2O/c1-18(2)12-14-5-3-4-6-16(14)19-15-9-7-13(11-17)8-10-15/h3-10H,12H2,1-2H3
DM0MWVU	CS	CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)C#N
DM0MWVU	IK	RQDOQYXVLGVVBA-UHFFFAOYSA-N
DM0MWVU	IU	4-[2-[(dimethylamino)methyl]phenoxy]benzonitrile
DM0MWVU	DE	Discovery agent

DM1043B	ID	DM1043B
DM1043B	DN	4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one
DM1043B	HS	Investigative
DM1043B	SN	CHEMBL225178; 2H-1-Benzopyran-2-one, 4-[2-(1H-imidazol-1-yl)ethoxy]-; 828265-57-2; Coumarin deriv. 22; BDBM9473; CTK3D6006; DTXSID60462004
DM1043B	DT	Small molecular drug
DM1043B	PC	11311402
DM1043B	MW	256.26
DM1043B	FM	C14H12N2O3
DM1043B	IC	InChI=1S/C14H12N2O3/c17-14-9-13(11-3-1-2-4-12(11)19-14)18-8-7-16-6-5-15-10-16/h1-6,9-10H,7-8H2
DM1043B	CS	C1=CC=C2C(=C1)C(=CC(=O)O2)OCCN3C=CN=C3
DM1043B	IK	MXJNKMWQNZHBOE-UHFFFAOYSA-N
DM1043B	IU	4-(2-imidazol-1-ylethoxy)chromen-2-one
DM1043B	CA	CAS 828265-57-2
DM1043B	DE	Discovery agent

DMTJGBL	ID	DMTJGBL
DMTJGBL	DN	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine
DMTJGBL	HS	Investigative
DMTJGBL	SN	CHEMBL611630; 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine
DMTJGBL	DT	Small molecular drug
DMTJGBL	PC	46225260
DMTJGBL	MW	320.3
DMTJGBL	FM	C17H16N6O
DMTJGBL	IC	InChI=1S/C17H16N6O/c1-2-12(9-13-11(1)3-4-18-13)15-21-16-14(19-10-20-16)17(22-15)23-5-7-24-8-6-23/h1-4,9-10,18H,5-8H2,(H,19,20,21,22)
DMTJGBL	CS	C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC5=C(C=C4)C=CN5
DMTJGBL	IK	LYJKHCYTQHFQLX-UHFFFAOYSA-N
DMTJGBL	IU	4-[2-(1H-indol-6-yl)-7H-purin-6-yl]morpholine
DMTJGBL	DE	Discovery agent

DM9UA0N	ID	DM9UA0N
DM9UA0N	DN	4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine
DM9UA0N	HS	Investigative
DM9UA0N	SN	CHEMBL583332; 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine
DM9UA0N	DT	Small molecular drug
DM9UA0N	PC	45483409
DM9UA0N	MW	285.4
DM9UA0N	FM	C18H20FNO
DM9UA0N	IC	InChI=1S/C18H20FNO/c1-13-6-7-16(19)18(12-13)21-17-5-3-2-4-15(17)14-8-10-20-11-9-14/h2-7,12,14,20H,8-11H2,1H3
DM9UA0N	CS	CC1=CC(=C(C=C1)F)OC2=CC=CC=C2C3CCNCC3
DM9UA0N	IK	QPPDVPUFQFPJKK-UHFFFAOYSA-N
DM9UA0N	IU	4-[2-(2-fluoro-5-methylphenoxy)phenyl]piperidine
DM9UA0N	DE	Discovery agent

DMCR3VM	ID	DMCR3VM
DMCR3VM	DN	4-(2-(2-fluorobenzyloxy)phenyl)piperidine
DMCR3VM	HS	Investigative
DMCR3VM	SN	CHEMBL573897; 4-(2-(2-fluorobenzyloxy)phenyl)piperidine
DMCR3VM	DT	Small molecular drug
DMCR3VM	PC	45483400
DMCR3VM	MW	285.4
DMCR3VM	FM	C18H20FNO
DMCR3VM	IC	InChI=1S/C18H20FNO/c19-17-7-3-1-5-15(17)13-21-18-8-4-2-6-16(18)14-9-11-20-12-10-14/h1-8,14,20H,9-13H2
DMCR3VM	CS	C1CNCCC1C2=CC=CC=C2OCC3=CC=CC=C3F
DMCR3VM	IK	CDVPUDLPRZVZHB-UHFFFAOYSA-N
DMCR3VM	IU	4-[2-[(2-fluorophenyl)methoxy]phenyl]piperidine
DMCR3VM	DE	Discovery agent

DMKZ6JW	ID	DMKZ6JW
DMKZ6JW	DN	4-(2-(3,4-Dimethylphenylamino)ethyl)-1H-imidazole
DMKZ6JW	HS	Investigative
DMKZ6JW	SN	CHEMBL1097658; 4-(2-(3,4-Dimethylphenylamino)ethyl)-1H-imidazole
DMKZ6JW	DT	Small molecular drug
DMKZ6JW	PC	46222044
DMKZ6JW	MW	215.29
DMKZ6JW	FM	C13H17N3
DMKZ6JW	IC	InChI=1S/C13H17N3/c1-10-3-4-12(7-11(10)2)15-6-5-13-8-14-9-16-13/h3-4,7-9,15H,5-6H2,1-2H3,(H,14,16)
DMKZ6JW	CS	CC1=C(C=C(C=C1)NCCC2=CN=CN2)C
DMKZ6JW	IK	GHCPLWBMALOXTM-UHFFFAOYSA-N
DMKZ6JW	IU	N-[2-(1H-imidazol-5-yl)ethyl]-3,4-dimethylaniline
DMKZ6JW	DE	Discovery agent

DM0IT5E	ID	DM0IT5E
DM0IT5E	DN	4-(2-(3-chlorophenoxy)phenyl)piperidine
DM0IT5E	HS	Investigative
DM0IT5E	SN	CHEMBL575290; 4-(2-(3-chlorophenoxy)phenyl)piperidine
DM0IT5E	DT	Small molecular drug
DM0IT5E	PC	45483512
DM0IT5E	MW	287.8
DM0IT5E	FM	C17H18ClNO
DM0IT5E	IC	InChI=1S/C17H18ClNO/c18-14-4-3-5-15(12-14)20-17-7-2-1-6-16(17)13-8-10-19-11-9-13/h1-7,12-13,19H,8-11H2
DM0IT5E	CS	C1CNCCC1C2=CC=CC=C2OC3=CC(=CC=C3)Cl
DM0IT5E	IK	QHHWSRAVBLCPAI-UHFFFAOYSA-N
DM0IT5E	IU	4-[2-(3-chlorophenoxy)phenyl]piperidine
DM0IT5E	DE	Discovery agent

DMEPB9L	ID	DMEPB9L
DMEPB9L	DN	4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine
DMEPB9L	HS	Investigative
DMEPB9L	SN	CHEMBL573898; 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine
DMEPB9L	DT	Small molecular drug
DMEPB9L	PC	45483408
DMEPB9L	MW	285.4
DMEPB9L	FM	C18H20FNO
DMEPB9L	IC	InChI=1S/C18H20FNO/c1-13-5-6-17(14-7-9-20-10-8-14)18(11-13)21-16-4-2-3-15(19)12-16/h2-6,11-12,14,20H,7-10H2,1H3
DMEPB9L	CS	CC1=CC(=C(C=C1)C2CCNCC2)OC3=CC(=CC=C3)F
DMEPB9L	IK	BBYFZRZFESDGLZ-UHFFFAOYSA-N
DMEPB9L	IU	4-[2-(3-fluorophenoxy)-4-methylphenyl]piperidine
DMEPB9L	DE	Discovery agent

DMZMEOG	ID	DMZMEOG
DMZMEOG	DN	4-(2-(3-fluorophenoxy)phenyl)piperidine
DMZMEOG	HS	Investigative
DMZMEOG	SN	CHEMBL583752; 4-(2-(3-fluorophenoxy)phenyl)piperidine
DMZMEOG	DT	Small molecular drug
DMZMEOG	PC	45375937
DMZMEOG	MW	271.33
DMZMEOG	FM	C17H18FNO
DMZMEOG	IC	InChI=1S/C17H18FNO/c18-14-4-3-5-15(12-14)20-17-7-2-1-6-16(17)13-8-10-19-11-9-13/h1-7,12-13,19H,8-11H2
DMZMEOG	CS	C1CNCCC1C2=CC=CC=C2OC3=CC(=CC=C3)F
DMZMEOG	IK	WLJMFBUPVRQPDQ-UHFFFAOYSA-N
DMZMEOG	IU	4-[2-(3-fluorophenoxy)phenyl]piperidine
DMZMEOG	DE	Discovery agent

DMRDWUT	ID	DMRDWUT
DMRDWUT	DN	4-(2-(3-fluorophenyl)ethynyl)-2-methylthiazole
DMRDWUT	HS	Investigative
DMRDWUT	SN	CHEMBL202323; 4-(2-(3-fluorophenyl)ethynyl)-2-methylthiazole; SCHEMBL4145662
DMRDWUT	DT	Small molecular drug
DMRDWUT	PC	11557579
DMRDWUT	MW	217.26
DMRDWUT	FM	C12H8FNS
DMRDWUT	IC	InChI=1S/C12H8FNS/c1-9-14-12(8-15-9)6-5-10-3-2-4-11(13)7-10/h2-4,7-8H,1H3
DMRDWUT	CS	CC1=NC(=CS1)C#CC2=CC(=CC=C2)F
DMRDWUT	IK	SCVDCVQUJSBAAM-UHFFFAOYSA-N
DMRDWUT	IU	4-[2-(3-fluorophenyl)ethynyl]-2-methyl-1,3-thiazole
DMRDWUT	DE	Discovery agent

DMP1LY4	ID	DMP1LY4
DMP1LY4	DN	4-(2-(3-tert-Butylphenylamino)ethyl)-1H-imidazole
DMP1LY4	HS	Investigative
DMP1LY4	SN	CHEMBL1096517; 4-(2-(3-tert-Butylphenylamino)ethyl)-1H-imidazole
DMP1LY4	DT	Small molecular drug
DMP1LY4	PC	46222046
DMP1LY4	MW	243.35
DMP1LY4	FM	C15H21N3
DMP1LY4	IC	InChI=1S/C15H21N3/c1-15(2,3)12-5-4-6-13(9-12)17-8-7-14-10-16-11-18-14/h4-6,9-11,17H,7-8H2,1-3H3,(H,16,18)
DMP1LY4	CS	CC(C)(C)C1=CC(=CC=C1)NCCC2=CN=CN2
DMP1LY4	IK	LRIVTYQQFCXAFC-UHFFFAOYSA-N
DMP1LY4	IU	3-tert-butyl-N-[2-(1H-imidazol-5-yl)ethyl]aniline
DMP1LY4	DE	Discovery agent

DMN97TC	ID	DMN97TC
DMN97TC	DN	4-(2-(4-chlorobenzyloxy)-5-bromobenzyl)morpholine
DMN97TC	HS	Investigative
DMN97TC	SN	CHEMBL391379; Morpholine, 4-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]-; 851546-84-4; 4-(2-(4-chlorobenzyloxy)-5-bromobenzyl)morpholine; SCHEMBL5699765; CTK3C9230; DTXSID80458181; 4-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]morpholine
DMN97TC	DT	Small molecular drug
DMN97TC	PC	11188669
DMN97TC	MW	396.7
DMN97TC	FM	C18H19BrClNO2
DMN97TC	IC	InChI=1S/C18H19BrClNO2/c19-16-3-6-18(23-13-14-1-4-17(20)5-2-14)15(11-16)12-21-7-9-22-10-8-21/h1-6,11H,7-10,12-13H2
DMN97TC	CS	C1COCCN1CC2=C(C=CC(=C2)Br)OCC3=CC=C(C=C3)Cl
DMN97TC	IK	JUKUHNUKMFGLIK-UHFFFAOYSA-N
DMN97TC	IU	4-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]morpholine
DMN97TC	CA	CAS 851546-84-4
DMN97TC	DE	Discovery agent

DMM8CU2	ID	DMM8CU2
DMM8CU2	DN	4-(2-(4-Cyclohexylphenylamino)ethyl)-1H-imidazole
DMM8CU2	HS	Investigative
DMM8CU2	SN	CHEMBL1098229; 4-(2-(4-Cyclohexylphenylamino)ethyl)-1H-imidazole
DMM8CU2	DT	Small molecular drug
DMM8CU2	PC	46222047
DMM8CU2	MW	269.4
DMM8CU2	FM	C17H23N3
DMM8CU2	IC	InChI=1S/C17H23N3/c1-2-4-14(5-3-1)15-6-8-16(9-7-15)19-11-10-17-12-18-13-20-17/h6-9,12-14,19H,1-5,10-11H2,(H,18,20)
DMM8CU2	CS	C1CCC(CC1)C2=CC=C(C=C2)NCCC3=CN=CN3
DMM8CU2	IK	GEYDSVZUDGXVCV-UHFFFAOYSA-N
DMM8CU2	IU	4-cyclohexyl-N-[2-(1H-imidazol-5-yl)ethyl]aniline
DMM8CU2	DE	Discovery agent

DM29QLG	ID	DM29QLG
DM29QLG	DN	4-(2-(4-fluorobenzyloxy)phenyl)piperidine
DM29QLG	HS	Investigative
DM29QLG	SN	CHEMBL573531; 4-(2-(4-fluorobenzyloxy)phenyl)piperidine
DM29QLG	DT	Small molecular drug
DM29QLG	PC	45483407
DM29QLG	MW	285.4
DM29QLG	FM	C18H20FNO
DM29QLG	IC	InChI=1S/C18H20FNO/c19-16-7-5-14(6-8-16)13-21-18-4-2-1-3-17(18)15-9-11-20-12-10-15/h1-8,15,20H,9-13H2
DM29QLG	CS	C1CNCCC1C2=CC=CC=C2OCC3=CC=C(C=C3)F
DM29QLG	IK	QJRQNVRAJVCSDH-UHFFFAOYSA-N
DM29QLG	IU	4-[2-[(4-fluorophenyl)methoxy]phenyl]piperidine
DM29QLG	DE	Discovery agent

DMJNB8C	ID	DMJNB8C
DMJNB8C	DN	4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine
DMJNB8C	HS	Investigative
DMJNB8C	SN	CHEMBL574347; 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine
DMJNB8C	DT	Small molecular drug
DMJNB8C	PC	45483520
DMJNB8C	MW	285.4
DMJNB8C	FM	C18H20FNO
DMJNB8C	IC	InChI=1S/C18H20FNO/c1-13-2-7-17(14-8-10-20-11-9-14)18(12-13)21-16-5-3-15(19)4-6-16/h2-7,12,14,20H,8-11H2,1H3
DMJNB8C	CS	CC1=CC(=C(C=C1)C2CCNCC2)OC3=CC=C(C=C3)F
DMJNB8C	IK	MUPPOMFFBLBAKT-UHFFFAOYSA-N
DMJNB8C	IU	4-[2-(4-fluorophenoxy)-4-methylphenyl]piperidine
DMJNB8C	DE	Discovery agent

DMFQT9O	ID	DMFQT9O
DMFQT9O	DN	4-(2-(4-fluorophenoxy)phenyl)piperidine
DMFQT9O	HS	Investigative
DMFQT9O	SN	CHEMBL584173; 4-(2-(4-fluorophenoxy)phenyl)piperidine; SCHEMBL3040991; BDBM50299806
DMFQT9O	DT	Small molecular drug
DMFQT9O	PC	22599992
DMFQT9O	MW	271.33
DMFQT9O	FM	C17H18FNO
DMFQT9O	IC	InChI=1S/C17H18FNO/c18-14-5-7-15(8-6-14)20-17-4-2-1-3-16(17)13-9-11-19-12-10-13/h1-8,13,19H,9-12H2
DMFQT9O	CS	C1CNCCC1C2=CC=CC=C2OC3=CC=C(C=C3)F
DMFQT9O	IK	BXXRQIARNFYYBC-UHFFFAOYSA-N
DMFQT9O	IU	4-[2-(4-fluorophenoxy)phenyl]piperidine
DMFQT9O	DE	Discovery agent

DMOX40J	ID	DMOX40J
DMOX40J	DN	4-(2-(4-fluorophenyl)ethynyl)-2-methylthiazole
DMOX40J	HS	Investigative
DMOX40J	SN	CHEMBL202125; 4-(2-(4-fluorophenyl)ethynyl)-2-methylthiazole; SCHEMBL4146642
DMOX40J	DT	Small molecular drug
DMOX40J	PC	11550292
DMOX40J	MW	217.26
DMOX40J	FM	C12H8FNS
DMOX40J	IC	InChI=1S/C12H8FNS/c1-9-14-12(8-15-9)7-4-10-2-5-11(13)6-3-10/h2-3,5-6,8H,1H3
DMOX40J	CS	CC1=NC(=CS1)C#CC2=CC=C(C=C2)F
DMOX40J	IK	UUKQDEMVLZEXPO-UHFFFAOYSA-N
DMOX40J	IU	4-[2-(4-fluorophenyl)ethynyl]-2-methyl-1,3-thiazole
DMOX40J	DE	Discovery agent

DMFCS8G	ID	DMFCS8G
DMFCS8G	DN	4-(2-(4-Methoxyphenylamino)ethyl)-1H-imidazole
DMFCS8G	HS	Investigative
DMFCS8G	SN	CHEMBL1098527; 4-(2-(4-Methoxyphenylamino)ethyl)-1H-imidazole
DMFCS8G	DT	Small molecular drug
DMFCS8G	PC	46888007
DMFCS8G	MW	234.32
DMFCS8G	FM	C12H14N2OS
DMFCS8G	IC	InChI=1S/C12H14N2OS/c1-15-11-2-4-12(5-3-11)16-7-6-10-8-13-9-14-10/h2-5,8-9H,6-7H2,1H3,(H,13,14)
DMFCS8G	CS	COC1=CC=C(C=C1)SCCC2=CN=CN2
DMFCS8G	IK	MFQHSSADNRVZAE-UHFFFAOYSA-N
DMFCS8G	IU	5-[2-(4-methoxyphenyl)sulfanylethyl]-1H-imidazole
DMFCS8G	DE	Discovery agent

DMYM72T	ID	DMYM72T
DMYM72T	DN	4-(2-(4-Methylphenylamino)ethyl)-1H-imidazole
DMYM72T	HS	Investigative
DMYM72T	SN	4-(2-(4-Methylphenylamino)ethyl)-1H-imidazole; CHEMBL1096515; BDBM50317870
DMYM72T	DT	Small molecular drug
DMYM72T	PC	46222043
DMYM72T	MW	201.27
DMYM72T	FM	C12H15N3
DMYM72T	IC	InChI=1S/C12H15N3/c1-10-2-4-11(5-3-10)14-7-6-12-8-13-9-15-12/h2-5,8-9,14H,6-7H2,1H3,(H,13,15)
DMYM72T	CS	CC1=CC=C(C=C1)NCCC2=CN=CN2
DMYM72T	IK	OOTAMYWJHGNDAH-UHFFFAOYSA-N
DMYM72T	IU	N-[2-(1H-imidazol-5-yl)ethyl]-4-methylaniline
DMYM72T	DE	Discovery agent

DMK8ROX	ID	DMK8ROX
DMK8ROX	DN	4-(2-(4-tert-Butylphenylamino)ethyl)-1H-imidazole
DMK8ROX	HS	Investigative
DMK8ROX	SN	CHEMBL1096516; 4-(2-(4-tert-Butylphenylamino)ethyl)-1H-imidazole
DMK8ROX	DT	Small molecular drug
DMK8ROX	PC	46222045
DMK8ROX	MW	243.35
DMK8ROX	FM	C15H21N3
DMK8ROX	IC	InChI=1S/C15H21N3/c1-15(2,3)12-4-6-13(7-5-12)17-9-8-14-10-16-11-18-14/h4-7,10-11,17H,8-9H2,1-3H3,(H,16,18)
DMK8ROX	CS	CC(C)(C)C1=CC=C(C=C1)NCCC2=CN=CN2
DMK8ROX	IK	CAUIWLDBMLQRJD-UHFFFAOYSA-N
DMK8ROX	IU	4-tert-butyl-N-[2-(1H-imidazol-5-yl)ethyl]aniline
DMK8ROX	DE	Discovery agent

DMUYPMO	ID	DMUYPMO
DMUYPMO	DN	4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol
DMUYPMO	HS	Investigative
DMUYPMO	SN	CHEMBL234581; 4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol
DMUYPMO	DT	Small molecular drug
DMUYPMO	PC	44430036
DMUYPMO	MW	296.4
DMUYPMO	FM	C19H24N2O
DMUYPMO	IC	InChI=1S/C19H24N2O/c20-14-17-8-4-5-9-18(17)19(22)10-12-21(13-11-19)15-16-6-2-1-3-7-16/h1-9,22H,10-15,20H2
DMUYPMO	CS	C1CN(CCC1(C2=CC=CC=C2CN)O)CC3=CC=CC=C3
DMUYPMO	IK	RPBRGKBDJGSAFB-UHFFFAOYSA-N
DMUYPMO	IU	4-[2-(aminomethyl)phenyl]-1-benzylpiperidin-4-ol
DMUYPMO	DE	Discovery agent

DMM2NHZ	ID	DMM2NHZ
DMM2NHZ	DN	4-(2-(benzyloxy)-3-fluorophenyl)piperidine
DMM2NHZ	HS	Investigative
DMM2NHZ	SN	CHEMBL583750; 4-(2-(benzyloxy)-3-fluorophenyl)piperidine
DMM2NHZ	DT	Small molecular drug
DMM2NHZ	PC	45483405
DMM2NHZ	MW	285.4
DMM2NHZ	FM	C18H20FNO
DMM2NHZ	IC	InChI=1S/C18H20FNO/c19-17-8-4-7-16(15-9-11-20-12-10-15)18(17)21-13-14-5-2-1-3-6-14/h1-8,15,20H,9-13H2
DMM2NHZ	CS	C1CNCCC1C2=C(C(=CC=C2)F)OCC3=CC=CC=C3
DMM2NHZ	IK	ONPYWJJNTLFDAR-UHFFFAOYSA-N
DMM2NHZ	IU	4-(3-fluoro-2-phenylmethoxyphenyl)piperidine
DMM2NHZ	DE	Discovery agent

DMF3S50	ID	DMF3S50
DMF3S50	DN	4-(2-(benzyloxy)-6-fluorophenyl)piperidine
DMF3S50	HS	Investigative
DMF3S50	SN	CHEMBL575930; 4-(2-(benzyloxy)-6-fluorophenyl)piperidine
DMF3S50	DT	Small molecular drug
DMF3S50	PC	45483406
DMF3S50	MW	285.4
DMF3S50	FM	C18H20FNO
DMF3S50	IC	InChI=1S/C18H20FNO/c19-16-7-4-8-17(18(16)15-9-11-20-12-10-15)21-13-14-5-2-1-3-6-14/h1-8,15,20H,9-13H2
DMF3S50	CS	C1CNCCC1C2=C(C=CC=C2F)OCC3=CC=CC=C3
DMF3S50	IK	WEBWNOZIRPUGTR-UHFFFAOYSA-N
DMF3S50	IU	4-(2-fluoro-6-phenylmethoxyphenyl)piperidine
DMF3S50	DE	Discovery agent

DMOC7PY	ID	DMOC7PY
DMOC7PY	DN	4-(2-(benzyloxy)phenyl)piperidine
DMOC7PY	HS	Investigative
DMOC7PY	SN	4-(2-(benzyloxy)phenyl)piperidine; CHEMBL573769
DMOC7PY	DT	Small molecular drug
DMOC7PY	PC	45483529
DMOC7PY	MW	267.4
DMOC7PY	FM	C18H21NO
DMOC7PY	IC	InChI=1S/C18H21NO/c1-2-6-15(7-3-1)14-20-18-9-5-4-8-17(18)16-10-12-19-13-11-16/h1-9,16,19H,10-14H2
DMOC7PY	CS	C1CNCCC1C2=CC=CC=C2OCC3=CC=CC=C3
DMOC7PY	IK	XJJHPGZYVOFINN-UHFFFAOYSA-N
DMOC7PY	IU	4-(2-phenylmethoxyphenyl)piperidine
DMOC7PY	DE	Discovery agent

DM1MP96	ID	DM1MP96
DM1MP96	DN	4-(2-(Cyclohexylamino)ethyl)-1H-imidazole
DM1MP96	HS	Investigative
DM1MP96	SN	CHEMBL1096513; 4-(2-(Cyclohexylamino)ethyl)-1H-imidazole; BDBM50317872
DM1MP96	DT	Small molecular drug
DM1MP96	PC	12647300
DM1MP96	MW	193.29
DM1MP96	FM	C11H19N3
DM1MP96	IC	InChI=1S/C11H19N3/c1-2-4-10(5-3-1)13-7-6-11-8-12-9-14-11/h8-10,13H,1-7H2,(H,12,14)
DM1MP96	CS	C1CCC(CC1)NCCC2=CN=CN2
DM1MP96	IK	OKJFYIHINPOKMF-UHFFFAOYSA-N
DM1MP96	IU	N-[2-(1H-imidazol-5-yl)ethyl]cyclohexanamine
DM1MP96	DE	Discovery agent

DMRQ8T9	ID	DMRQ8T9
DMRQ8T9	DN	4-(2-(diethylamino)ethylamino)-1-naphthol
DMRQ8T9	HS	Investigative
DMRQ8T9	SN	CHEMBL576113; Kinome_2771; 4-(2-(diethylamino)ethylamino)-1-naphthol; SCHEMBL12649369
DMRQ8T9	DT	Small molecular drug
DMRQ8T9	PC	44466196
DMRQ8T9	MW	258.36
DMRQ8T9	FM	C16H22N2O
DMRQ8T9	IC	InChI=1S/C16H22N2O/c1-3-18(4-2)12-11-17-15-9-10-16(19)14-8-6-5-7-13(14)15/h5-10,17,19H,3-4,11-12H2,1-2H3
DMRQ8T9	CS	CCN(CC)CCNC1=CC=C(C2=CC=CC=C21)O
DMRQ8T9	IK	LVUBFHBEMVTCJQ-UHFFFAOYSA-N
DMRQ8T9	IU	4-[2-(diethylamino)ethylamino]naphthalen-1-ol
DMRQ8T9	DE	Discovery agent

DM0OFRQ	ID	DM0OFRQ
DM0OFRQ	DN	4-(2-(phenoxymethyl)phenyl)piperidine
DM0OFRQ	HS	Investigative
DM0OFRQ	SN	4-(2-(phenoxymethyl)phenyl)piperidine; CHEMBL574348; SCHEMBL12965384
DM0OFRQ	DT	Small molecular drug
DM0OFRQ	PC	45483527
DM0OFRQ	MW	267.4
DM0OFRQ	FM	C18H21NO
DM0OFRQ	IC	InChI=1S/C18H21NO/c1-2-7-17(8-3-1)20-14-16-6-4-5-9-18(16)15-10-12-19-13-11-15/h1-9,15,19H,10-14H2
DM0OFRQ	CS	C1CNCCC1C2=CC=CC=C2COC3=CC=CC=C3
DM0OFRQ	IK	SYLMRMITUMFBTA-UHFFFAOYSA-N
DM0OFRQ	IU	4-[2-(phenoxymethyl)phenyl]piperidine
DM0OFRQ	DE	Discovery agent

DMX1HKU	ID	DMX1HKU
DMX1HKU	DN	4-(2-(Phenylamino)ethyl)-1H-imidazole
DMX1HKU	HS	Investigative
DMX1HKU	SN	4-(2-(Phenylamino)ethyl)-1H-imidazole; CHEMBL1096514; 51720-84-4; phenylhistamine; BDBM50317871; ZINC49088978
DMX1HKU	DT	Small molecular drug
DMX1HKU	PC	46222042
DMX1HKU	MW	187.24
DMX1HKU	FM	C11H13N3
DMX1HKU	IC	InChI=1S/C11H13N3/c1-2-4-10(5-3-1)13-7-6-11-8-12-9-14-11/h1-5,8-9,13H,6-7H2,(H,12,14)
DMX1HKU	CS	C1=CC=C(C=C1)NCCC2=CN=CN2
DMX1HKU	IK	JNHQUQHJWWFGKK-UHFFFAOYSA-N
DMX1HKU	IU	N-[2-(1H-imidazol-5-yl)ethyl]aniline
DMX1HKU	DE	Discovery agent

DMHWD2C	ID	DMHWD2C
DMHWD2C	DN	4-(2-(pyrrolidin-1-yl)ethyl)pyridine
DMHWD2C	HS	Investigative
DMHWD2C	SN	67580-65-8; 4-[2-(pyrrolidin-1-yl)ethyl]pyridine; 4-(2-Tetrahydro-1H-pyrrol-1-ylethyl)pyridine; 4-(2-pyrrolidin-1-ylethyl)pyridine; MLS000737070; CHEMBL405070; 4-(2-(pyrrolidin-1-yl)ethyl)pyridine; 4-(2-pyrrolidin-1-yl-ethyl)-pyridine; NSC42776; AC1Q4WU8; AC1Q28PY; AC1L60Z5; SCHEMBL3993201; 4-(2-pyrrolidinylethyl)pyridine; CTK2F7988; DTXSID30285782; MolPort-000-145-638; ZINC163336; HMS2752A23; SBB089201; BDBM50372345; STL324986; NSC-42776; AKOS006227946; VP14627; MCULE-2911571696; 4-(2-PYRROLIDINOETHYL)PYRIDINE; SMR000038089
DMHWD2C	DT	Small molecular drug
DMHWD2C	PC	238432
DMHWD2C	MW	176.26
DMHWD2C	FM	C11H16N2
DMHWD2C	IC	InChI=1S/C11H16N2/c1-2-9-13(8-1)10-5-11-3-6-12-7-4-11/h3-4,6-7H,1-2,5,8-10H2
DMHWD2C	CS	C1CCN(C1)CCC2=CC=NC=C2
DMHWD2C	IK	GNJYGFKCUMGKOY-UHFFFAOYSA-N
DMHWD2C	IU	4-(2-pyrrolidin-1-ylethyl)pyridine
DMHWD2C	CA	CAS 67580-65-8
DMHWD2C	DE	Discovery agent

DMWN1CM	ID	DMWN1CM
DMWN1CM	DN	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine
DMWN1CM	HS	Investigative
DMWN1CM	SN	CHEMBL604876; 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine; SCHEMBL4439490
DMWN1CM	DT	Small molecular drug
DMWN1CM	PC	25074311
DMWN1CM	MW	287.34
DMWN1CM	FM	C13H13N5OS
DMWN1CM	IC	InChI=1S/C13H13N5OS/c1-2-9(20-7-1)11-16-12-10(14-8-15-12)13(17-11)18-3-5-19-6-4-18/h1-2,7-8H,3-6H2,(H,14,15,16,17)
DMWN1CM	CS	C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC=CS4
DMWN1CM	IK	WKJDCMFOOMWIQG-UHFFFAOYSA-N
DMWN1CM	IU	4-(2-thiophen-2-yl-7H-purin-6-yl)morpholine
DMWN1CM	DE	Discovery agent

DMAO6X9	ID	DMAO6X9
DMAO6X9	DN	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine
DMAO6X9	HS	Investigative
DMAO6X9	SN	CHEMBL608095; 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine; SCHEMBL4438208
DMAO6X9	DT	Small molecular drug
DMAO6X9	PC	25074312
DMAO6X9	MW	287.34
DMAO6X9	FM	C13H13N5OS
DMAO6X9	IC	InChI=1S/C13H13N5OS/c1-6-20-7-9(1)11-16-12-10(14-8-15-12)13(17-11)18-2-4-19-5-3-18/h1,6-8H,2-5H2,(H,14,15,16,17)
DMAO6X9	CS	C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CSC=C4
DMAO6X9	IK	SQTGJTBXJLFTBF-UHFFFAOYSA-N
DMAO6X9	IU	4-(2-thiophen-3-yl-7H-purin-6-yl)morpholine
DMAO6X9	DE	Discovery agent

DMIL45X	ID	DMIL45X
DMIL45X	DN	4-(2'-(trifluoromethoxy)biphenyl-3-yl)oxazole
DMIL45X	HS	Investigative
DMIL45X	SN	CHEMBL1224520; BDBM50325802
DMIL45X	DT	Small molecular drug
DMIL45X	PC	11324184
DMIL45X	MW	305.25
DMIL45X	FM	C16H10F3NO2
DMIL45X	IC	InChI=1S/C16H10F3NO2/c17-16(18,19)22-15-7-2-1-6-13(15)11-4-3-5-12(8-11)14-9-21-10-20-14/h1-10H
DMIL45X	CS	C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=COC=N3)OC(F)(F)F
DMIL45X	IK	QUFLMZRMQIORDK-UHFFFAOYSA-N
DMIL45X	IU	4-[3-[2-(trifluoromethoxy)phenyl]phenyl]-1,3-oxazole
DMIL45X	DE	Discovery agent

DM3R2D1	ID	DM3R2D1
DM3R2D1	DN	4-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole
DM3R2D1	HS	Investigative
DM3R2D1	SN	CHEMBL1224656; BDBM50325809
DM3R2D1	DT	Small molecular drug
DM3R2D1	PC	11427214
DM3R2D1	MW	321.3
DM3R2D1	FM	C16H10F3NOS
DM3R2D1	IC	InChI=1S/C16H10F3NOS/c17-16(18,19)21-15-7-2-1-6-13(15)11-4-3-5-12(8-11)14-9-22-10-20-14/h1-10H
DM3R2D1	CS	C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=CSC=N3)OC(F)(F)F
DM3R2D1	IK	AJYWSJBYBSJCBJ-UHFFFAOYSA-N
DM3R2D1	IU	4-[3-[2-(trifluoromethoxy)phenyl]phenyl]-1,3-thiazole
DM3R2D1	DE	Discovery agent

DMXC5S0	ID	DMXC5S0
DMXC5S0	DN	4-(2'-(trifluoromethyl)biphenyl-3-yl)oxazole
DMXC5S0	HS	Investigative
DMXC5S0	SN	CHEMBL1224519; BDBM50325801
DMXC5S0	DT	Small molecular drug
DMXC5S0	PC	11460438
DMXC5S0	MW	289.25
DMXC5S0	FM	C16H10F3NO
DMXC5S0	IC	InChI=1S/C16H10F3NO/c17-16(18,19)14-7-2-1-6-13(14)11-4-3-5-12(8-11)15-9-21-10-20-15/h1-10H
DMXC5S0	CS	C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=COC=N3)C(F)(F)F
DMXC5S0	IK	SRZDIBWHWBVAAW-UHFFFAOYSA-N
DMXC5S0	IU	4-[3-[2-(trifluoromethyl)phenyl]phenyl]-1,3-oxazole
DMXC5S0	DE	Discovery agent

DMRZY0B	ID	DMRZY0B
DMRZY0B	DN	4-(2,2'-bithiophen-5-ylmethyleneamino)phenol
DMRZY0B	HS	Investigative
DMRZY0B	SN	MLS000106248; SMR000103217; CHEMBL504791; 4-[(5-thiophen-2-ylthiophen-2-yl)methylideneamino]phenol; AC1LGKRK; cid_796420; BDBM29642; HMS2448D05; MCULE-1982148585; SR-01000609337; SR-01000609337-2; 4-[[5-(2-thienyl)-2-thienyl]methyleneamino]phenol
DMRZY0B	DT	Small molecular drug
DMRZY0B	PC	796420
DMRZY0B	MW	285.4
DMRZY0B	FM	C15H11NOS2
DMRZY0B	IC	InChI=1S/C15H11NOS2/c17-12-5-3-11(4-6-12)16-10-13-7-8-15(19-13)14-2-1-9-18-14/h1-10,17H
DMRZY0B	CS	C1=CSC(=C1)C2=CC=C(S2)C=NC3=CC=C(C=C3)O
DMRZY0B	IK	UMPJRGAFFRSXRX-UHFFFAOYSA-N
DMRZY0B	IU	4-[(5-thiophen-2-ylthiophen-2-yl)methylideneamino]phenol
DMRZY0B	DE	Discovery agent

DMI638K	ID	DMI638K
DMI638K	DN	4-(2,2-Diphenyl-vinyl)-pyridine
DMI638K	HS	Investigative
DMI638K	SN	4-(2,2-diphenylethenyl)pyridine; 4-Pyridylmethylene 35; AC1NEND1; CHEMBL381194; BDBM8645; SCHEMBL16946606
DMI638K	DT	Small molecular drug
DMI638K	PC	4594970
DMI638K	MW	257.3
DMI638K	FM	C19H15N
DMI638K	IC	InChI=1S/C19H15N/c1-3-7-17(8-4-1)19(18-9-5-2-6-10-18)15-16-11-13-20-14-12-16/h1-15H
DMI638K	CS	C1=CC=C(C=C1)C(=CC2=CC=NC=C2)C3=CC=CC=C3
DMI638K	IK	QSVVYMBWQOGDNI-UHFFFAOYSA-N
DMI638K	IU	4-(2,2-diphenylethenyl)pyridine
DMI638K	CA	CAS 15814-97-8
DMI638K	DE	Discovery agent

DMGOHSF	ID	DMGOHSF
DMGOHSF	DN	4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid
DMGOHSF	HS	Investigative
DMGOHSF	SN	CHEMBL413572; 4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid
DMGOHSF	DT	Small molecular drug
DMGOHSF	PC	44408224
DMGOHSF	MW	294.2
DMGOHSF	FM	C11H13Cl2NO2S
DMGOHSF	IC	InChI=1S/C11H13Cl2NO2S/c12-8-3-1-2-7(10(8)13)6-17-5-4-9(14)11(15)16/h1-3,9H,4-6,14H2,(H,15,16)
DMGOHSF	CS	C1=CC(=C(C(=C1)Cl)Cl)CSCCC(C(=O)O)N
DMGOHSF	IK	IHFPLLZGLBOAJJ-UHFFFAOYSA-N
DMGOHSF	IU	2-amino-4-[(2,3-dichlorophenyl)methylsulfanyl]butanoic acid
DMGOHSF	DE	Discovery agent

DMVIQ7F	ID	DMVIQ7F
DMVIQ7F	DN	4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole
DMVIQ7F	HS	Investigative
DMVIQ7F	SN	CHEMBL105328; 178556-61-1; CTK0A6889; DTXSID50441101; 4-[(2,3-Dihydro-1H-phenalen)-1-yl]-1H-imidazole; 1H-Imidazole, 4-(2,3-dihydro-1H-phenalen-1-yl)-
DMVIQ7F	DT	Small molecular drug
DMVIQ7F	PC	10513867
DMVIQ7F	MW	234.29
DMVIQ7F	FM	C16H14N2
DMVIQ7F	IC	InChI=1S/C16H14N2/c1-3-11-5-2-6-14-13(15-9-17-10-18-15)8-7-12(4-1)16(11)14/h1-6,9-10,13H,7-8H2,(H,17,18)
DMVIQ7F	CS	C1CC2=CC=CC3=C2C(=CC=C3)C1C4=CN=CN4
DMVIQ7F	IK	KFGFWNKBPWPCKX-UHFFFAOYSA-N
DMVIQ7F	IU	5-(2,3-dihydro-1H-phenalen-1-yl)-1H-imidazole
DMVIQ7F	CA	CAS 178556-61-1
DMVIQ7F	DE	Discovery agent

DM6PMFJ	ID	DM6PMFJ
DM6PMFJ	DN	4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM6PMFJ	HS	Investigative
DM6PMFJ	SN	CHEMBL98155; 4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM6PMFJ	DT	Small molecular drug
DM6PMFJ	PC	44331261
DM6PMFJ	MW	341.4
DM6PMFJ	FM	C19H19NO5
DM6PMFJ	IC	InChI=1S/C19H19NO5/c1-21-15-6-5-7-16(19(15)24-4)25-14-8-9-20-13-11-18(23-3)17(22-2)10-12(13)14/h5-11H,1-4H3
DM6PMFJ	CS	COC1=C(C(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC)OC
DM6PMFJ	IK	NQWDTJUCVNPURX-UHFFFAOYSA-N
DM6PMFJ	IU	4-(2,3-dimethoxyphenoxy)-6,7-dimethoxyquinoline
DM6PMFJ	DE	Discovery agent

DMPKE6G	ID	DMPKE6G
DMPKE6G	DN	4-(2,4-dichloro-phenoxy)-2'-methyl-biphenyl-3-ol
DMPKE6G	HS	Investigative
DMPKE6G	SN	4-(2,4-Dichlorophenoxy)-2'-Methylbiphenyl-3-Ol; Triclosan derivative, 15; CHEMBL261708; BDBM25414; 2-(2,4-dichlorophenoxy)-5-(2-methylphenyl)phenol
DMPKE6G	DT	Small molecular drug
DMPKE6G	PC	15942656
DMPKE6G	MW	345.2
DMPKE6G	FM	C19H14Cl2O2
DMPKE6G	IC	InChI=1S/C19H14Cl2O2/c1-12-4-2-3-5-15(12)13-6-8-19(17(22)10-13)23-18-9-7-14(20)11-16(18)21/h2-11,22H,1H3
DMPKE6G	CS	CC1=CC=CC=C1C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DMPKE6G	IK	VDWAWADVXJMBAA-UHFFFAOYSA-N
DMPKE6G	IU	2-(2,4-dichlorophenoxy)-5-(2-methylphenyl)phenol
DMPKE6G	DE	Discovery agent

DMS7POY	ID	DMS7POY
DMS7POY	DN	4-(2,4-dichlorophenoxy)-3-hydroxybenzonitrile
DMS7POY	HS	Investigative
DMS7POY	SN	Triclosan derivative, 4; SCHEMBL3365482; CHEMBL260168; BDBM25403; QYLRCMQANMWAOJ-UHFFFAOYSA-N; ZINC29059641; 4-(2,4-dichlorophenoxy)-3-hydroxy-benzonitrile; hydroxybenzonitrile (19)
DMS7POY	DT	Small molecular drug
DMS7POY	PC	25023955
DMS7POY	MW	280.1
DMS7POY	FM	C13H7Cl2NO2
DMS7POY	IC	InChI=1S/C13H7Cl2NO2/c14-9-2-4-12(10(15)6-9)18-13-3-1-8(7-16)5-11(13)17/h1-6,17H
DMS7POY	CS	C1=CC(=C(C=C1C#N)O)OC2=C(C=C(C=C2)Cl)Cl
DMS7POY	IK	QYLRCMQANMWAOJ-UHFFFAOYSA-N
DMS7POY	IU	4-(2,4-dichlorophenoxy)-3-hydroxybenzonitrile
DMS7POY	DE	Discovery agent

DMY6GWF	ID	DMY6GWF
DMY6GWF	DN	4-(2,4-dichlorophenoxy)-3'-methylbiphenyl-3-ol
DMY6GWF	HS	Investigative
DMY6GWF	SN	Triclosan derivative, 17; CHEMBL260978; BDBM25416; 2-(2,4-dichlorophenoxy)-5-(m-tolyl)phenol
DMY6GWF	DT	Small molecular drug
DMY6GWF	PC	25023966
DMY6GWF	MW	345.2
DMY6GWF	FM	C19H14Cl2O2
DMY6GWF	IC	InChI=1S/C19H14Cl2O2/c1-12-3-2-4-13(9-12)14-5-7-19(17(22)10-14)23-18-8-6-15(20)11-16(18)21/h2-11,22H,1H3
DMY6GWF	CS	CC1=CC(=CC=C1)C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DMY6GWF	IK	GFJKNHKOZLFIJW-UHFFFAOYSA-N
DMY6GWF	IU	2-(2,4-dichlorophenoxy)-5-(3-methylphenyl)phenol
DMY6GWF	DE	Discovery agent

DMAK789	ID	DMAK789
DMAK789	DN	4-(2,4-dichloro-phenoxy)-4'-fluoro-biphenyl-3-ol
DMAK789	HS	Investigative
DMAK789	SN	2-(2,4-dichlorophenoxy)-5-(4-fluorophenyl)phenol; Triclosan derivative, 19; CHEMBL260979
DMAK789	DT	Small molecular drug
DMAK789	PC	25023968
DMAK789	MW	349.2
DMAK789	FM	C18H11Cl2FO2
DMAK789	IC	InChI=1S/C18H11Cl2FO2/c19-13-4-8-17(15(20)10-13)23-18-7-3-12(9-16(18)22)11-1-5-14(21)6-2-11/h1-10,22H
DMAK789	CS	C1=CC(=CC=C1C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O)F
DMAK789	IK	LFNMTUYVBXAAKI-UHFFFAOYSA-N
DMAK789	IU	2-(2,4-dichlorophenoxy)-5-(4-fluorophenyl)phenol
DMAK789	DE	Discovery agent

DMRPVO3	ID	DMRPVO3
DMRPVO3	DN	4-(2,4-dichlorophenoxy)-4'-methylbiphenyl-3-ol
DMRPVO3	HS	Investigative
DMRPVO3	SN	Triclosan derivative, 18; CHEMBL408744; BDBM25417; 2-(2,4-dichlorophenoxy)-5-(p-tolyl)phenol
DMRPVO3	DT	Small molecular drug
DMRPVO3	PC	25023967
DMRPVO3	MW	345.2
DMRPVO3	FM	C19H14Cl2O2
DMRPVO3	IC	InChI=1S/C19H14Cl2O2/c1-12-2-4-13(5-3-12)14-6-8-19(17(22)10-14)23-18-9-7-15(20)11-16(18)21/h2-11,22H,1H3
DMRPVO3	CS	CC1=CC=C(C=C1)C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DMRPVO3	IK	MJKDRJABBJYCNP-UHFFFAOYSA-N
DMRPVO3	IU	2-(2,4-dichlorophenoxy)-5-(4-methylphenyl)phenol
DMRPVO3	DE	Discovery agent

DMB96SY	ID	DMB96SY
DMB96SY	DN	4-(2,4-dichloro-phenoxy)-biphenyl-3-ol
DMB96SY	HS	Investigative
DMB96SY	SN	Triclosan derivative, 3; CHEMBL258772; BDBM25402; 2-(2,4-dichlorophenoxy)-5-phenylphenol
DMB96SY	DT	Small molecular drug
DMB96SY	PC	25023954
DMB96SY	MW	331.2
DMB96SY	FM	C18H12Cl2O2
DMB96SY	IC	InChI=1S/C18H12Cl2O2/c19-14-7-9-17(15(20)11-14)22-18-8-6-13(10-16(18)21)12-4-2-1-3-5-12/h1-11,21H
DMB96SY	CS	C1=CC=C(C=C1)C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DMB96SY	IK	NOKHJANPMHROFU-UHFFFAOYSA-N
DMB96SY	IU	2-(2,4-dichlorophenoxy)-5-phenylphenol
DMB96SY	DE	Discovery agent

DMCGOPQ	ID	DMCGOPQ
DMCGOPQ	DN	4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine
DMCGOPQ	HS	Investigative
DMCGOPQ	SN	CHEMBL396300
DMCGOPQ	DT	Small molecular drug
DMCGOPQ	PC	44440632
DMCGOPQ	MW	307.2
DMCGOPQ	FM	C16H16Cl2N2
DMCGOPQ	IC	InChI=1S/C16H16Cl2N2/c17-11-6-7-13(15(18)8-11)14-9-20(10-16(14)19)12-4-2-1-3-5-12/h1-8,14,16H,9-10,19H2
DMCGOPQ	CS	C1C(C(CN1C2=CC=CC=C2)N)C3=C(C=C(C=C3)Cl)Cl
DMCGOPQ	IK	KQIXDQQTPCBRIX-UHFFFAOYSA-N
DMCGOPQ	IU	4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine
DMCGOPQ	DE	Discovery agent

DMRMAOI	ID	DMRMAOI
DMRMAOI	DN	4-(2,4-dichlorophenyl)-1-tosylpyrrolidin-3-amine
DMRMAOI	HS	Investigative
DMRMAOI	SN	CHEMBL245552
DMRMAOI	DT	Small molecular drug
DMRMAOI	PC	44440628
DMRMAOI	MW	385.3
DMRMAOI	FM	C17H18Cl2N2O2S
DMRMAOI	IC	InChI=1S/C17H18Cl2N2O2S/c1-11-2-5-13(6-3-11)24(22,23)21-9-15(17(20)10-21)14-7-4-12(18)8-16(14)19/h2-8,15,17H,9-10,20H2,1H3
DMRMAOI	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CC(C(C2)N)C3=C(C=C(C=C3)Cl)Cl
DMRMAOI	IK	XFWVFJXNYYSICX-UHFFFAOYSA-N
DMRMAOI	IU	4-(2,4-dichlorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-3-amine
DMRMAOI	DE	Discovery agent

DMBLAI1	ID	DMBLAI1
DMBLAI1	DN	4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile
DMBLAI1	HS	Investigative
DMBLAI1	SN	CHEMBL1084705; 4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile
DMBLAI1	DT	Small molecular drug
DMBLAI1	PC	46889764
DMBLAI1	MW	240.3
DMBLAI1	FM	C15H16N2O
DMBLAI1	IC	InChI=1S/C15H16N2O/c1-3-12-10-17-14(4-2)15(12)18-13-7-5-11(9-16)6-8-13/h5-8,10,17H,3-4H2,1-2H3
DMBLAI1	CS	CCC1=CNC(=C1OC2=CC=C(C=C2)C#N)CC
DMBLAI1	IK	XXYHXMUPGLKKGE-UHFFFAOYSA-N
DMBLAI1	IU	4-[(2,4-diethyl-1H-pyrrol-3-yl)oxy]benzonitrile
DMBLAI1	DE	Discovery agent

DME8BLW	ID	DME8BLW
DME8BLW	DN	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
DME8BLW	HS	Investigative
DME8BLW	SN	364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780
DME8BLW	DT	Small molecular drug
DME8BLW	PC	447956
DME8BLW	MW	206.27
DME8BLW	FM	C9H10N4S
DME8BLW	IC	InChI=1S/C9H10N4S/c1-5-8(14-6(2)12-5)7-3-4-11-9(10)13-7/h3-4H,1-2H3,(H2,10,11,13)
DME8BLW	CS	CC1=C(SC(=N1)C)C2=NC(=NC=C2)N
DME8BLW	IK	CTFDMGIBHFQWKB-UHFFFAOYSA-N
DME8BLW	IU	4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine
DME8BLW	CA	CAS 364334-94-1
DME8BLW	DE	Discovery agent

DM3D8OK	ID	DM3D8OK
DM3D8OK	DN	4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL
DM3D8OK	HS	Investigative
DM3D8OK	SN	AC1NBQIC
DM3D8OK	DT	Small molecular drug
DM3D8OK	PC	46937065
DM3D8OK	MW	210.27
DM3D8OK	FM	C11H18N2O2
DM3D8OK	IC	InChI=1S/C11H18N2O2/c12-9(3-6-11(13)15)7-8-1-4-10(14)5-2-8/h1-2,4-5,9,11,14-15H,3,6-7,12-13H2/t9-,11+/m1/s1
DM3D8OK	CS	C1=CC(=CC=C1C[C@@H](CC[C@@H](N)O)N)O
DM3D8OK	IK	VTBBVHAOBBELOH-KOLCDFICSA-N
DM3D8OK	IU	4-[(2R,5S)-2,5-diamino-5-hydroxypentyl]phenol
DM3D8OK	DE	Discovery agent

DMKVH90	ID	DMKVH90
DMKVH90	DN	4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid
DMKVH90	HS	Investigative
DMKVH90	SN	CHEMBL205126; 4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid; BDBM50179736
DMKVH90	DT	Small molecular drug
DMKVH90	PC	44408335
DMKVH90	MW	294.2
DMKVH90	FM	C11H13Cl2NO2S
DMKVH90	IC	InChI=1S/C11H13Cl2NO2S/c12-8-1-2-9(13)7(5-8)6-17-4-3-10(14)11(15)16/h1-2,5,10H,3-4,6,14H2,(H,15,16)
DMKVH90	CS	C1=CC(=C(C=C1Cl)CSCCC(C(=O)O)N)Cl
DMKVH90	IK	TYFOZYAERVGDAT-UHFFFAOYSA-N
DMKVH90	IU	2-amino-4-[(2,5-dichlorophenyl)methylsulfanyl]butanoic acid
DMKVH90	DE	Discovery agent

DMVYALJ	ID	DMVYALJ
DMVYALJ	DN	4-(2,5-Diphenyl-furan-3-yl)-morpholine
DMVYALJ	HS	Investigative
DMVYALJ	SN	CHEMBL323451; 4-(2,5-Diphenyl-furan-3-yl)-morpholine; 2,5-Diphenyl-3-morpholinofuran
DMVYALJ	DT	Small molecular drug
DMVYALJ	PC	10990391
DMVYALJ	MW	305.4
DMVYALJ	FM	C20H19NO2
DMVYALJ	IC	InChI=1S/C20H19NO2/c1-3-7-16(8-4-1)19-15-18(21-11-13-22-14-12-21)20(23-19)17-9-5-2-6-10-17/h1-10,15H,11-14H2
DMVYALJ	CS	C1COCCN1C2=C(OC(=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMVYALJ	IK	UIZBMSXOYPJXSV-UHFFFAOYSA-N
DMVYALJ	IU	4-(2,5-diphenylfuran-3-yl)morpholine
DMVYALJ	DE	Discovery agent

DMH3TBQ	ID	DMH3TBQ
DMH3TBQ	DN	4-(2,6-diamino-9H-purin-8-yl)-2,6-dimethoxyphenol
DMH3TBQ	HS	Investigative
DMH3TBQ	DT	Small molecular drug
DMH3TBQ	PC	457716
DMH3TBQ	MW	302.29
DMH3TBQ	FM	C13H14N6O3
DMH3TBQ	IC	InChI=1S/C13H14N6O3/c1-21-6-3-5(4-7(22-2)9(6)20)11-16-8-10(14)17-13(15)19-12(8)18-11/h3-4,20H,1-2H3,(H5,14,15,16,17,18,19)
DMH3TBQ	CS	COC1=CC(=CC(=C1O)OC)C2=NC3=NC(=NC(=C3N2)N)N
DMH3TBQ	IK	TWOVCAQBEASXFN-UHFFFAOYSA-N
DMH3TBQ	IU	4-(2,6-diamino-7H-purin-8-yl)-2,6-dimethoxyphenol
DMH3TBQ	DE	Discovery agent

DMPLG9Q	ID	DMPLG9Q
DMPLG9Q	DN	4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile
DMPLG9Q	HS	Investigative
DMPLG9Q	SN	CHEMBL448454; 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile
DMPLG9Q	DT	Small molecular drug
DMPLG9Q	PC	44157041
DMPLG9Q	MW	269.4
DMPLG9Q	FM	C16H15NOS
DMPLG9Q	IC	InChI=1S/C16H15NOS/c1-11-5-4-6-12(2)16(11)19-14-8-7-13(10-17)15(9-14)18-3/h4-9H,1-3H3
DMPLG9Q	CS	CC1=C(C(=CC=C1)C)SC2=CC(=C(C=C2)C#N)OC
DMPLG9Q	IK	AAYYOXKEPZBTIZ-UHFFFAOYSA-N
DMPLG9Q	IU	4-(2,6-dimethylphenyl)sulfanyl-2-methoxybenzonitrile
DMPLG9Q	DE	Discovery agent

DMH5CAQ	ID	DMH5CAQ
DMH5CAQ	DN	4-(2-amino-1,3-thiazol-4-yl)phenol
DMH5CAQ	HS	Investigative
DMH5CAQ	SN	4-(2-Amino-1,3-thiazol-4-yl)phenol; 57634-55-6; 4-(2-amino-4-thiazolyl)phenol; 4-(2-Amino-thiazol-4-yl)-phenol; 4-(2-aminothiazol-4-yl)phenol; CHEMBL483790; QGSJYYIRAFRPIT-UHFFFAOYSA-N; Phenol, 4-(2-amino-4-thiazolyl)-; 2-amino-4-(4-hydroxyphenyl)-thiazole; NSC405294; 3fu3; Oprea1_415030; SCHEMBL5321407; p-(2-Amino-4-thiazolyl)phenol; CTK5A7198; DTXSID30323956; MolPort-000-141-769; HMS3604B06; Phenol,4-(2-amino-4-thiazolyl)-; AC1L8637; KS-00000A4L; ZINC16951624; STK723345; SBB018017; BDBM50293592; KM0129; 5926AE; 4-(2-Aminothiazol-4-yl)phenol
DMH5CAQ	DT	Small molecular drug
DMH5CAQ	PC	346926
DMH5CAQ	MW	192.24
DMH5CAQ	FM	C9H8N2OS
DMH5CAQ	IC	InChI=1S/C9H8N2OS/c10-9-11-8(5-13-9)6-1-3-7(12)4-2-6/h1-5,12H,(H2,10,11)
DMH5CAQ	CS	C1=CC(=CC=C1C2=CSC(=N2)N)O
DMH5CAQ	IK	QGSJYYIRAFRPIT-UHFFFAOYSA-N
DMH5CAQ	IU	4-(2-amino-1,3-thiazol-4-yl)phenol
DMH5CAQ	CA	CAS 57634-55-6
DMH5CAQ	DE	Discovery agent

DMWHDRI	ID	DMWHDRI
DMWHDRI	DN	4-(2-Aminoethyl) benzenesulfonyl fluoride
DMWHDRI	HS	Investigative
DMWHDRI	SN	4-(2-Aminoethyl)benzenesulfonyl fluoride; 4-(2-Aminoethyl)benzenesulfonylfluoride; 4-(2-aminoethyl)-benzenesulfonyl fluoride; 4-(2-aminoethyl)benzene-1-sulfonyl fluoride; 4-beta-Aminoethylbenzolsulfofluoride; AC1L1C1L; AC1Q4OX1; AEBSF; AEBSF.HCl; AES; Benzenesulfonyl fluoride, 4-(2-aminoethyl)-; C8H10FNO2S; CHEMBL1256178; Lopac-A-8456; Lopac0_000132; MGSKVZWGBWPBTF-UHFFFAOYSA-N; Pefabloc; SR-01000075690
DMWHDRI	DT	Small molecular drug
DMWHDRI	PC	1701
DMWHDRI	MW	203.231
DMWHDRI	FM	C8H10FNO2S
DMWHDRI	IC	InChI=1S/C8H10FNO2S/c9-13(11,12)8-3-1-7(2-4-8)5-6-10/h1-4H,5-6,10H2
DMWHDRI	CS	C1=CC(=CC=C1CCN)S(=O)(=O)F
DMWHDRI	IK	MGSKVZWGBWPBTF-UHFFFAOYSA-N
DMWHDRI	IU	4-(2-aminoethyl)benzenesulfonyl fluoride
DMWHDRI	CA	CAS 34284-75-8

DMCS538	ID	DMCS538
DMCS538	DN	4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol
DMCS538	HS	Investigative
DMCS538	SN	CHEMBL211176; AKOS006351843; 4-(2-Aminoethyl)-1,2,5-oxadiazole-3-ol
DMCS538	DT	Small molecular drug
DMCS538	PC	11607975
DMCS538	MW	129.12
DMCS538	FM	C4H7N3O2
DMCS538	IC	InChI=1S/C4H7N3O2/c5-2-1-3-4(8)7-9-6-3/h1-2,5H2,(H,7,8)
DMCS538	CS	C(CN)C1=NONC1=O
DMCS538	IK	LGTWAFYEFVSZIU-UHFFFAOYSA-N
DMCS538	IU	4-(2-aminoethyl)-1,2,5-oxadiazol-3-one
DMCS538	DE	Discovery agent

DMZSN1Y	ID	DMZSN1Y
DMZSN1Y	DN	4-(2-aminoethyl)-2-cyclohexylphenol
DMZSN1Y	HS	Investigative
DMZSN1Y	SN	4-(2-aminoethyl)-2-cyclohexylphenol; CHEMBL404150; BDBM50372980
DMZSN1Y	DT	Small molecular drug
DMZSN1Y	PC	24748051
DMZSN1Y	MW	219.32
DMZSN1Y	FM	C14H21NO
DMZSN1Y	IC	InChI=1S/C14H21NO/c15-9-8-11-6-7-14(16)13(10-11)12-4-2-1-3-5-12/h6-7,10,12,16H,1-5,8-9,15H2
DMZSN1Y	CS	C1CCC(CC1)C2=C(C=CC(=C2)CCN)O
DMZSN1Y	IK	DOCCSEDGBYCYLS-UHFFFAOYSA-N
DMZSN1Y	IU	4-(2-aminoethyl)-2-cyclohexylphenol
DMZSN1Y	DE	Discovery agent

DMF8D5S	ID	DMF8D5S
DMF8D5S	DN	4-(2-aminoethyl)-2-ethylphenol
DMF8D5S	HS	Investigative
DMF8D5S	SN	4-(2-aminoethyl)-2-ethylphenol; CHEMBL255750; 4-methyl-a-methyl-tyramine; BDBM50372983; DB07346
DMF8D5S	DT	Small molecular drug
DMF8D5S	PC	24748050
DMF8D5S	MW	165.23
DMF8D5S	FM	C10H15NO
DMF8D5S	IC	InChI=1S/C10H15NO/c1-2-9-7-8(5-6-11)3-4-10(9)12/h3-4,7,12H,2,5-6,11H2,1H3
DMF8D5S	CS	CCC1=C(C=CC(=C1)CCN)O
DMF8D5S	IK	LDAFQVRTSOETPE-UHFFFAOYSA-N
DMF8D5S	IU	4-(2-aminoethyl)-2-ethylphenol
DMF8D5S	DE	Discovery agent

DMEK6WX	ID	DMEK6WX
DMEK6WX	DN	4-(2-AMINOETHYL)BENZENESULFONAMIDE
DMEK6WX	HS	Investigative
DMEK6WX	SN	4-(2-Aminoethyl)benzenesulfonamide; 35303-76-5; 4-(2-aminoethyl)benzene-1-sulfonamide; 4-(2-Aminoethyl)benzene sulfonamide; 4-(2-Amino-ethyl)-benzenesulfonamide; Benzenesulfonamide, 4-(2-aminoethyl)-; 4-(2-Aminoethyl)benzenesulphonamide; CHEMBL7087; 4-aminoethylbenzenesulfonamide; 2-(4-sulfamoylphenyl)ethylamine; 4-(2-Aminoethyl)benzesulfonamide; FXNSVEQMUYPYJS-UHFFFAOYSA-N; 4-(2-Aminoethyl) Benzenesulfonamide; MFCD00010301; 4-(2-aminoethyl)-benzenesulfonamide hydrochloride; EINECS 252-501-0
DMEK6WX	DT	Small molecular drug
DMEK6WX	PC	169682
DMEK6WX	MW	200.26
DMEK6WX	FM	C8H12N2O2S
DMEK6WX	IC	InChI=1S/C8H12N2O2S/c9-6-5-7-1-3-8(4-2-7)13(10,11)12/h1-4H,5-6,9H2,(H2,10,11,12)
DMEK6WX	CS	C1=CC(=CC=C1CCN)S(=O)(=O)N
DMEK6WX	IK	FXNSVEQMUYPYJS-UHFFFAOYSA-N
DMEK6WX	IU	4-(2-aminoethyl)benzenesulfonamide
DMEK6WX	CA	CAS 35303-76-5
DMEK6WX	DE	Discovery agent

DMWG706	ID	DMWG706
DMWG706	DN	4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide
DMWG706	HS	Investigative
DMWG706	SN	NSC135784; 2153-13-1; 4-[(2-aminopyrimidin-4-yl)amino]benzenesulfonamide; UNII-1DW8U29X8S; CHEMBL6633; 1DW8U29X8S; 4-((2-amino-4-pyrimidinyl)amino)benzenesulfonamide; NSC-135784; NSC683526; AC1L1KSM; NCIStruc2_000899; NCIStruc1_000852; Oprea1_770349; SCHEMBL3791868; ZINC56465; CTK4E7061; BDBM10873; NCI135784; NCGC00014345; CCG-38281; AKOS030546962; aromatic/heteroaromatic sulfonamide 18; MCULE-1716829198; NCGC00097454-01; NCGC00014345-02; NCI60_000801; EN300-24853; 4-(2-Amino-4-pyrimidinylamino)benzenesulfonamide
DMWG706	DT	Small molecular drug
DMWG706	PC	31036
DMWG706	MW	265.29
DMWG706	FM	C10H11N5O2S
DMWG706	IC	InChI=1S/C10H11N5O2S/c11-10-13-6-5-9(15-10)14-7-1-3-8(4-2-7)18(12,16)17/h1-6H,(H2,12,16,17)(H3,11,13,14,15)
DMWG706	CS	C1=CC(=CC=C1NC2=NC(=NC=C2)N)S(=O)(=O)N
DMWG706	IK	QOAXQANKSMHFKJ-UHFFFAOYSA-N
DMWG706	IU	4-[(2-aminopyrimidin-4-yl)amino]benzenesulfonamide
DMWG706	CA	CAS 2153-13-1
DMWG706	DE	Discovery agent

DMAZ0LV	ID	DMAZ0LV
DMAZ0LV	DN	4-(2-benzenesulfonylphenyl)piperazine
DMAZ0LV	HS	Investigative
DMAZ0LV	SN	4-(2-benzenesulfonylphenyl)piperazine; CHEMBL209893; SCHEMBL3796417
DMAZ0LV	DT	Small molecular drug
DMAZ0LV	PC	11849201
DMAZ0LV	MW	302.4
DMAZ0LV	FM	C16H18N2O2S
DMAZ0LV	IC	InChI=1S/C16H18N2O2S/c19-21(20,14-6-2-1-3-7-14)16-9-5-4-8-15(16)18-12-10-17-11-13-18/h1-9,17H,10-13H2
DMAZ0LV	CS	C1CN(CCN1)C2=CC=CC=C2S(=O)(=O)C3=CC=CC=C3
DMAZ0LV	IK	QHMSQHVDMJCBCI-UHFFFAOYSA-N
DMAZ0LV	IU	1-[2-(benzenesulfonyl)phenyl]piperazine
DMAZ0LV	DE	Discovery agent

DMYVD2E	ID	DMYVD2E
DMYVD2E	DN	4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one
DMYVD2E	HS	Investigative
DMYVD2E	SN	CHEMBL59752; 4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one; SCHEMBL7478147; CVWQKEFTSSJDLS-UHFFFAOYSA-N; ZINC1903144; BDBM50077578; 4-[2-(Benzylamino)ethoxy]indoline-2-one
DMYVD2E	DT	Small molecular drug
DMYVD2E	PC	9903877
DMYVD2E	MW	282.34
DMYVD2E	FM	C17H18N2O2
DMYVD2E	IC	InChI=1S/C17H18N2O2/c20-17-11-14-15(19-17)7-4-8-16(14)21-10-9-18-12-13-5-2-1-3-6-13/h1-8,18H,9-12H2,(H,19,20)
DMYVD2E	CS	C1C2=C(C=CC=C2OCCNCC3=CC=CC=C3)NC1=O
DMYVD2E	IK	CVWQKEFTSSJDLS-UHFFFAOYSA-N
DMYVD2E	IU	4-[2-(benzylamino)ethoxy]-1,3-dihydroindol-2-one
DMYVD2E	DE	Discovery agent

DMZ9TSR	ID	DMZ9TSR
DMZ9TSR	DN	4-(2-bromobenzylthio)-2-aminobutanoic acid
DMZ9TSR	HS	Investigative
DMZ9TSR	SN	CHEMBL204646; 4-(2-bromobenzylthio)-2-aminobutanoic acid; BDBM50179711
DMZ9TSR	DT	Small molecular drug
DMZ9TSR	PC	44408327
DMZ9TSR	MW	304.21
DMZ9TSR	FM	C11H14BrNO2S
DMZ9TSR	IC	InChI=1S/C11H14BrNO2S/c12-9-4-2-1-3-8(9)7-16-6-5-10(13)11(14)15/h1-4,10H,5-7,13H2,(H,14,15)
DMZ9TSR	CS	C1=CC=C(C(=C1)CSCCC(C(=O)O)N)Br
DMZ9TSR	IK	MWUVRUMWNBKYCW-UHFFFAOYSA-N
DMZ9TSR	IU	2-amino-4-[(2-bromophenyl)methylsulfanyl]butanoic acid
DMZ9TSR	DE	Discovery agent

DM2MSEF	ID	DM2MSEF
DM2MSEF	DN	4'-(2-butylbenzofuran-3-yl)biphenyl-4-ol
DM2MSEF	HS	Investigative
DM2MSEF	SN	CHEMBL286007; SCHEMBL7499937; JIBMWJCMDPEYQP-UHFFFAOYSA-N; BDBM50086976; 4''-(2-butylbenzofuran-3-yl)biphenyl-4-ol; 4'-(2-Butyl-benzofuran-3-yl)-biphenyl-4-ol; 4''-(2-Butyl-benzofuran-3-yl)-biphenyl-4-ol
DM2MSEF	DT	Small molecular drug
DM2MSEF	PC	10854796
DM2MSEF	MW	342.4
DM2MSEF	FM	C24H22O2
DM2MSEF	IC	InChI=1S/C24H22O2/c1-2-3-7-23-24(21-6-4-5-8-22(21)26-23)19-11-9-17(10-12-19)18-13-15-20(25)16-14-18/h4-6,8-16,25H,2-3,7H2,1H3
DM2MSEF	CS	CCCCC1=C(C2=CC=CC=C2O1)C3=CC=C(C=C3)C4=CC=C(C=C4)O
DM2MSEF	IK	JIBMWJCMDPEYQP-UHFFFAOYSA-N
DM2MSEF	IU	4-[4-(2-butyl-1-benzofuran-3-yl)phenyl]phenol
DM2MSEF	DE	Discovery agent

DM8HLEP	ID	DM8HLEP
DM8HLEP	DN	4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol
DM8HLEP	HS	Investigative
DM8HLEP	SN	CHEMBL71254; 4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol; SCHEMBL9129370
DM8HLEP	DT	Small molecular drug
DM8HLEP	PC	15288898
DM8HLEP	MW	280.4
DM8HLEP	FM	C18H20N2O
DM8HLEP	IC	InChI=1S/C18H20N2O/c1-2-3-8-18-19-16-6-4-5-7-17(16)20(18)13-14-9-11-15(21)12-10-14/h4-7,9-12,21H,2-3,8,13H2,1H3
DM8HLEP	CS	CCCCC1=NC2=CC=CC=C2N1CC3=CC=C(C=C3)O
DM8HLEP	IK	SSRIUMAFZMGUFE-UHFFFAOYSA-N
DM8HLEP	IU	4-[(2-butylbenzimidazol-1-yl)methyl]phenol
DM8HLEP	DE	Discovery agent

DM5L4WP	ID	DM5L4WP
DM5L4WP	DN	4-(2-carboxy-5-mercaptopentyl)benzoic acid
DM5L4WP	HS	Investigative
DM5L4WP	SN	Thiol-Based Inhibitor, 6d; SCHEMBL5051284; CHEMBL205399; BDBM17763; CTK8A8853; AKOS015966200; 4-[2-carboxy-2-(3-sulfanylpropyl)ethyl]benzoic acid; 4-(2-CARBOXY-5-MERCAPTO-PENTYL)-BENZOIC ACID
DM5L4WP	DT	Small molecular drug
DM5L4WP	PC	9878511
DM5L4WP	MW	268.33
DM5L4WP	FM	C13H16O4S
DM5L4WP	IC	InChI=1S/C13H16O4S/c14-12(15)10-5-3-9(4-6-10)8-11(13(16)17)2-1-7-18/h3-6,11,18H,1-2,7-8H2,(H,14,15)(H,16,17)
DM5L4WP	CS	C1=CC(=CC=C1CC(CCCS)C(=O)O)C(=O)O
DM5L4WP	IK	WDVWCNCIBNEXCG-UHFFFAOYSA-N
DM5L4WP	IU	4-(2-carboxy-5-sulfanylpentyl)benzoic acid
DM5L4WP	DE	Discovery agent

DM82D9N	ID	DM82D9N
DM82D9N	DN	4-(2-cyanobenzylthio)-2-aminobutanoic acid
DM82D9N	HS	Investigative
DM82D9N	SN	CHEMBL204479; 4-(2-cyanobenzylthio)-2-aminobutanoic acid; BDBM50179704
DM82D9N	DT	Small molecular drug
DM82D9N	PC	44408228
DM82D9N	MW	250.32
DM82D9N	FM	C12H14N2O2S
DM82D9N	IC	InChI=1S/C12H14N2O2S/c13-7-9-3-1-2-4-10(9)8-17-6-5-11(14)12(15)16/h1-4,11H,5-6,8,14H2,(H,15,16)
DM82D9N	CS	C1=CC=C(C(=C1)CSCCC(C(=O)O)N)C#N
DM82D9N	IK	JVNHJGWGKVBEAG-UHFFFAOYSA-N
DM82D9N	IU	2-amino-4-[(2-cyanophenyl)methylsulfanyl]butanoic acid
DM82D9N	DE	Discovery agent

DMFJW2E	ID	DMFJW2E
DMFJW2E	DN	4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine
DMFJW2E	HS	Investigative
DMFJW2E	SN	CHEMBL198334; 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine; BDBM50173628
DMFJW2E	DT	Small molecular drug
DMFJW2E	PC	11277481
DMFJW2E	MW	280.4
DMFJW2E	FM	C17H16N2S
DMFJW2E	IC	InChI=1S/C17H16N2S/c1-3-15-19-16(14-6-4-5-12(2)11-14)17(20-15)13-7-9-18-10-8-13/h4-11H,3H2,1-2H3
DMFJW2E	CS	CCC1=NC(=C(S1)C2=CC=NC=C2)C3=CC=CC(=C3)C
DMFJW2E	IK	QUKIIQWKXMTFAE-UHFFFAOYSA-N
DMFJW2E	IU	2-ethyl-4-(3-methylphenyl)-5-pyridin-4-yl-1,3-thiazole
DMFJW2E	DE	Discovery agent

DMQUAP2	ID	DMQUAP2
DMQUAP2	DN	4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine
DMQUAP2	HS	Investigative
DMQUAP2	SN	CHEMBL598346; 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine
DMQUAP2	DT	Small molecular drug
DMQUAP2	PC	46230654
DMQUAP2	MW	289.32
DMQUAP2	FM	C17H17F2NO
DMQUAP2	IC	InChI=1S/C17H17F2NO/c18-13-4-1-2-6-15(13)21-16-7-3-5-14(19)17(16)12-8-10-20-11-9-12/h1-7,12,20H,8-11H2
DMQUAP2	CS	C1CNCCC1C2=C(C=CC=C2F)OC3=CC=CC=C3F
DMQUAP2	IK	ZSIHFDAUAFSTIM-UHFFFAOYSA-N
DMQUAP2	IU	4-[2-fluoro-6-(2-fluorophenoxy)phenyl]piperidine
DMQUAP2	DE	Discovery agent

DMUBHRF	ID	DMUBHRF
DMUBHRF	DN	4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine
DMUBHRF	HS	Investigative
DMUBHRF	SN	CHEMBL574004; 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine
DMUBHRF	DT	Small molecular drug
DMUBHRF	PC	45375938
DMUBHRF	MW	289.32
DMUBHRF	FM	C17H17F2NO
DMUBHRF	IC	InChI=1S/C17H17F2NO/c18-13-3-1-4-14(11-13)21-16-6-2-5-15(19)17(16)12-7-9-20-10-8-12/h1-6,11-12,20H,7-10H2
DMUBHRF	CS	C1CNCCC1C2=C(C=CC=C2F)OC3=CC(=CC=C3)F
DMUBHRF	IK	IMXJQWVQVSZOKO-UHFFFAOYSA-N
DMUBHRF	IU	4-[2-fluoro-6-(3-fluorophenoxy)phenyl]piperidine
DMUBHRF	DE	Discovery agent

DMJ2GW0	ID	DMJ2GW0
DMJ2GW0	DN	4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine
DMJ2GW0	HS	Investigative
DMJ2GW0	SN	CHEMBL574231; 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine
DMJ2GW0	DT	Small molecular drug
DMJ2GW0	PC	45483536
DMJ2GW0	MW	289.32
DMJ2GW0	FM	C17H17F2NO
DMJ2GW0	IC	InChI=1S/C17H17F2NO/c18-13-4-6-14(7-5-13)21-16-3-1-2-15(19)17(16)12-8-10-20-11-9-12/h1-7,12,20H,8-11H2
DMJ2GW0	CS	C1CNCCC1C2=C(C=CC=C2F)OC3=CC=C(C=C3)F
DMJ2GW0	IK	WPYMMOOTBZOFOZ-UHFFFAOYSA-N
DMJ2GW0	IU	4-[2-fluoro-6-(4-fluorophenoxy)phenyl]piperidine
DMJ2GW0	DE	Discovery agent

DMXIGWC	ID	DMXIGWC
DMXIGWC	DN	4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC	HS	Investigative
DMXIGWC	SN	CHEMBL574428; 4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC	DT	Small molecular drug
DMXIGWC	PC	45483451
DMXIGWC	MW	271.33
DMXIGWC	FM	C17H18FNO
DMXIGWC	IC	InChI=1S/C17H18FNO/c18-15-7-4-8-16(20-14-5-2-1-3-6-14)17(15)13-9-11-19-12-10-13/h1-8,13,19H,9-12H2
DMXIGWC	CS	C1CNCCC1C2=C(C=CC=C2F)OC3=CC=CC=C3
DMXIGWC	IK	PTVWULKTBHSTNS-UHFFFAOYSA-N
DMXIGWC	IU	4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC	DE	Discovery agent

DMCWZF6	ID	DMCWZF6
DMCWZF6	DN	4-(2-fluorophenylethynyl)-2-methylthiazole
DMCWZF6	HS	Investigative
DMCWZF6	SN	CHEMBL370453; 4-(2-fluorophenylethynyl)-2-methylthiazole; SCHEMBL4137694
DMCWZF6	DT	Small molecular drug
DMCWZF6	PC	11572058
DMCWZF6	MW	217.26
DMCWZF6	FM	C12H8FNS
DMCWZF6	IC	InChI=1S/C12H8FNS/c1-9-14-11(8-15-9)7-6-10-4-2-3-5-12(10)13/h2-5,8H,1H3
DMCWZF6	CS	CC1=NC(=CS1)C#CC2=CC=CC=C2F
DMCWZF6	IK	IDJAGQSTASLJRW-UHFFFAOYSA-N
DMCWZF6	IU	4-[2-(2-fluorophenyl)ethynyl]-2-methyl-1,3-thiazole
DMCWZF6	DE	Discovery agent

DM17QG8	ID	DM17QG8
DM17QG8	DN	4-(2-Hydroxyethoxy)-1-naphthol
DM17QG8	HS	Investigative
DM17QG8	SN	4-(2-Hydroxyethoxy)-1-naphthol; CHEMBL570066; 83115-56-4; SCHEMBL12599103
DM17QG8	DT	Small molecular drug
DM17QG8	PC	45487214
DM17QG8	MW	204.22
DM17QG8	FM	C12H12O3
DM17QG8	IC	InChI=1S/C12H12O3/c13-7-8-15-12-6-5-11(14)9-3-1-2-4-10(9)12/h1-6,13-14H,7-8H2
DM17QG8	CS	C1=CC=C2C(=C1)C(=CC=C2OCCO)O
DM17QG8	IK	PABAILNRYWRUQG-UHFFFAOYSA-N
DM17QG8	IU	4-(2-hydroxyethoxy)naphthalen-1-ol
DM17QG8	DE	Discovery agent

DM1C5U6	ID	DM1C5U6
DM1C5U6	DN	4-(2-Hydroxy-ethyl)-benzenesulfonamide
DM1C5U6	HS	Investigative
DM1C5U6	SN	4-(2-hydroxyethyl)benzenesulfonamide
DM1C5U6	DE	Discovery agent

DMB6SNE	ID	DMB6SNE
DMB6SNE	DN	4-(2-Imidazol-1-yl-ethoxy)-benzamide
DMB6SNE	HS	Investigative
DMB6SNE	SN	CHEMBL30395; 4-(2-Imidazol-1-yl-ethoxy)-benzamide; SCHEMBL3005716; DVALIYTWWUIPGC-UHFFFAOYSA-N; BDBM50025995; 75912-57-1; 1-[2-(4-carbamoylphenoxy)ethyl]imidazole; 4-(2-(1H-imidazol-1-yl)ethoxy)benzamide; 1-[2-(4-carbamoyl phenoxy)ethyl]imidazole
DMB6SNE	DT	Small molecular drug
DMB6SNE	PC	13569177
DMB6SNE	MW	231.25
DMB6SNE	FM	C12H13N3O2
DMB6SNE	IC	InChI=1S/C12H13N3O2/c13-12(16)10-1-3-11(4-2-10)17-8-7-15-6-5-14-9-15/h1-6,9H,7-8H2,(H2,13,16)
DMB6SNE	CS	C1=CC(=CC=C1C(=O)N)OCCN2C=CN=C2
DMB6SNE	IK	DVALIYTWWUIPGC-UHFFFAOYSA-N
DMB6SNE	IU	4-(2-imidazol-1-ylethoxy)benzamide
DMB6SNE	DE	Discovery agent

DMNSKXR	ID	DMNSKXR
DMNSKXR	DN	4-(2-methoxybenzylthio)-2-aminobutanoic acid
DMNSKXR	HS	Investigative
DMNSKXR	SN	CHEMBL204961; 4-(2-methoxybenzylthio)-2-aminobutanoic acid; BDBM50179708
DMNSKXR	DT	Small molecular drug
DMNSKXR	PC	44408324
DMNSKXR	MW	255.34
DMNSKXR	FM	C12H17NO3S
DMNSKXR	IC	InChI=1S/C12H17NO3S/c1-16-11-5-3-2-4-9(11)8-17-7-6-10(13)12(14)15/h2-5,10H,6-8,13H2,1H3,(H,14,15)
DMNSKXR	CS	COC1=CC=CC=C1CSCCC(C(=O)O)N
DMNSKXR	IK	OCNLPBAJIIKAGX-UHFFFAOYSA-N
DMNSKXR	IU	2-amino-4-[(2-methoxyphenyl)methylsulfanyl]butanoic acid
DMNSKXR	DE	Discovery agent

DM9WQOJ	ID	DM9WQOJ
DM9WQOJ	DN	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
DM9WQOJ	HS	Investigative
DM9WQOJ	SN	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidin-2-ylamine; 75435-54-0; 2wi1; AC1MWPG2; pyrimidin-2-amine, 11; CHEMBL538937; SCHEMBL10752783; BDBM33223; CCG-774; VCJHOFUOIQHNBC-UHFFFAOYSA-N; AKOS017529730; DB08786; 2-amino-4-(2-methoxyethoxy)-6-methylpyrimidine; 4-Methyl-6-(2-methoxyethoxy)pyrimidine-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidine-2-ylamine
DM9WQOJ	DT	Small molecular drug
DM9WQOJ	PC	3777900
DM9WQOJ	MW	183.21
DM9WQOJ	FM	C8H13N3O2
DM9WQOJ	IC	InChI=1S/C8H13N3O2/c1-6-5-7(11-8(9)10-6)13-4-3-12-2/h5H,3-4H2,1-2H3,(H2,9,10,11)
DM9WQOJ	CS	CC1=CC(=NC(=N1)N)OCCOC
DM9WQOJ	IK	VCJHOFUOIQHNBC-UHFFFAOYSA-N
DM9WQOJ	IU	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
DM9WQOJ	DE	Discovery agent

DMFVYHI	ID	DMFVYHI
DMFVYHI	DN	4-(2-methoxyphenylethynyl)-2-methylthiazole
DMFVYHI	HS	Investigative
DMFVYHI	SN	CHEMBL202002; 4-(2-methoxyphenylethynyl)-2-methylthiazole; Thiazole, 4-[2-(2-methoxyphenyl)ethynyl]-2-methyl-; SCHEMBL4291588; BDBM50181749; 878018-34-9
DMFVYHI	DT	Small molecular drug
DMFVYHI	PC	11665793
DMFVYHI	MW	229.3
DMFVYHI	FM	C13H11NOS
DMFVYHI	IC	InChI=1S/C13H11NOS/c1-10-14-12(9-16-10)8-7-11-5-3-4-6-13(11)15-2/h3-6,9H,1-2H3
DMFVYHI	CS	CC1=NC(=CS1)C#CC2=CC=CC=C2OC
DMFVYHI	IK	WOLUACOHPFWBIX-UHFFFAOYSA-N
DMFVYHI	IU	4-[2-(2-methoxyphenyl)ethynyl]-2-methyl-1,3-thiazole
DMFVYHI	DE	Discovery agent

DM6DSNI	ID	DM6DSNI
DM6DSNI	DN	4'-(2-methyl-1-(pyridin-4-yl)propyl)biphenyl-3-ol
DM6DSNI	HS	Investigative
DM6DSNI	SN	CHEMBL1172559; SCHEMBL18770344; BDBM50322796
DM6DSNI	DT	Small molecular drug
DM6DSNI	PC	46854449
DM6DSNI	MW	303.4
DM6DSNI	FM	C21H21NO
DM6DSNI	IC	InChI=1S/C21H21NO/c1-15(2)21(18-10-12-22-13-11-18)17-8-6-16(7-9-17)19-4-3-5-20(23)14-19/h3-15,21,23H,1-2H3
DM6DSNI	CS	CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)O)C3=CC=NC=C3
DM6DSNI	IK	YNPHCSJZYQIGGU-UHFFFAOYSA-N
DM6DSNI	IU	3-[4-(2-methyl-1-pyridin-4-ylpropyl)phenyl]phenol
DM6DSNI	DE	Discovery agent

DME6DHX	ID	DME6DHX
DME6DHX	DN	4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide
DME6DHX	HS	Investigative
DME6DHX	SN	CHEMBL1165071; 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide
DME6DHX	DT	Small molecular drug
DME6DHX	PC	46703923
DME6DHX	MW	315.3
DME6DHX	FM	C15H13N3O3S
DME6DHX	IC	InChI=1S/C15H13N3O3S/c1-10-5-6-11-3-2-4-13(15(11)18-10)21-12-7-8-17-9-14(12)22(16,19)20/h2-9H,1H3,(H2,16,19,20)
DME6DHX	CS	CC1=NC2=C(C=CC=C2OC3=C(C=NC=C3)S(=O)(=O)N)C=C1
DME6DHX	IK	LNNGPAKWWNABIA-UHFFFAOYSA-N
DME6DHX	IU	4-(2-methylquinolin-8-yl)oxypyridine-3-sulfonamide
DME6DHX	DE	Discovery agent

DMEAV9Q	ID	DMEAV9Q
DMEAV9Q	DN	4-(2-Methyl-thiazol-4-ylethynyl)-pyridine
DMEAV9Q	HS	Investigative
DMEAV9Q	SN	CHEMBL303090; 4-(2-Methyl-thiazol-4-ylethynyl)-pyridine
DMEAV9Q	DT	Small molecular drug
DMEAV9Q	PC	11095641
DMEAV9Q	MW	200.26
DMEAV9Q	FM	C11H8N2S
DMEAV9Q	IC	InChI=1S/C11H8N2S/c1-9-13-11(8-14-9)3-2-10-4-6-12-7-5-10/h4-8H,1H3
DMEAV9Q	CS	CC1=NC(=CS1)C#CC2=CC=NC=C2
DMEAV9Q	IK	WWKCHJLBBNNNCI-UHFFFAOYSA-N
DMEAV9Q	IU	2-methyl-4-(2-pyridin-4-ylethynyl)-1,3-thiazole
DMEAV9Q	DE	Discovery agent

DMC1KEG	ID	DMC1KEG
DMC1KEG	DN	4-(2-nitrobenzylthio)-2-aminobutanoic acid
DMC1KEG	HS	Investigative
DMC1KEG	SN	CHEMBL380506; 4-(2-nitrobenzylthio)-2-aminobutanoic acid; BDBM50179699
DMC1KEG	DT	Small molecular drug
DMC1KEG	PC	44408226
DMC1KEG	MW	270.31
DMC1KEG	FM	C11H14N2O4S
DMC1KEG	IC	InChI=1S/C11H14N2O4S/c12-9(11(14)15)5-6-18-7-8-3-1-2-4-10(8)13(16)17/h1-4,9H,5-7,12H2,(H,14,15)
DMC1KEG	CS	C1=CC=C(C(=C1)CSCCC(C(=O)O)N)[N+](=O)[O-]
DMC1KEG	IK	QZOGSZKBBMQKMN-UHFFFAOYSA-N
DMC1KEG	IU	2-amino-4-[(2-nitrophenyl)methylsulfanyl]butanoic acid
DMC1KEG	DE	Discovery agent

DMCHTI0	ID	DMCHTI0
DMCHTI0	DN	4-(2-nitroprop-1-enyl)benzene-1,2-diol
DMCHTI0	HS	Investigative
DMCHTI0	SN	4-(2-nitroprop-1-enyl)benzene-1,2-diol; 13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192
DMCHTI0	DT	Small molecular drug
DMCHTI0	PC	3260632
DMCHTI0	MW	195.17
DMCHTI0	FM	C9H9NO4
DMCHTI0	IC	InChI=1S/C9H9NO4/c1-6(10(13)14)4-7-2-3-8(11)9(12)5-7/h2-5,11-12H,1H3
DMCHTI0	CS	CC(=CC1=CC(=C(C=C1)O)O)[N+](=O)[O-]
DMCHTI0	IK	CBBBJLQAIWVLBM-UHFFFAOYSA-N
DMCHTI0	IU	4-(2-nitroprop-1-enyl)benzene-1,2-diol
DMCHTI0	CA	CAS 13662-96-9
DMCHTI0	DE	Discovery agent

DM62ZRE	ID	DM62ZRE
DM62ZRE	DN	4-(2-nitrovinyl)benzene-1,2-diol
DM62ZRE	HS	Investigative
DM62ZRE	SN	SL-1; CHEMBL78224; 108074-44-8; 4-(2-nitrovinyl)benzene-1,2-diol; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-
DM62ZRE	DT	Small molecular drug
DM62ZRE	PC	6439158
DM62ZRE	MW	181.15
DM62ZRE	FM	C8H7NO4
DM62ZRE	IC	InChI=1S/C8H7NO4/c10-7-2-1-6(5-8(7)11)3-4-9(12)13/h1-5,10-11H/b4-3+
DM62ZRE	CS	C1=CC(=C(C=C1/C=C/[N+](=O)[O-])O)O
DM62ZRE	IK	LLJASJHXECDHOM-ONEGZZNKSA-N
DM62ZRE	IU	4-[(E)-2-nitroethenyl]benzene-1,2-diol
DM62ZRE	CA	CAS 108074-44-8
DM62ZRE	DE	Discovery agent

DMPTVR2	ID	DMPTVR2
DMPTVR2	DN	4-(2-nitrovinyl)phenol
DMPTVR2	HS	Investigative
DMPTVR2	SN	4-(2-nitrovinyl)phenol; 3179-08-6; 4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-
DMPTVR2	DT	Small molecular drug
DMPTVR2	PC	638437
DMPTVR2	MW	165.15
DMPTVR2	FM	C8H7NO3
DMPTVR2	IC	InChI=1S/C8H7NO3/c10-8-3-1-7(2-4-8)5-6-9(11)12/h1-6,10H/b6-5+
DMPTVR2	CS	C1=CC(=CC=C1/C=C/[N+](=O)[O-])O
DMPTVR2	IK	CTJKRKMPTRJAIT-AATRIKPKSA-N
DMPTVR2	IU	4-[(E)-2-nitroethenyl]phenol
DMPTVR2	CA	CAS 22568-49-6
DMPTVR2	DE	Discovery agent

DMWIALU	ID	DMWIALU
DMWIALU	DN	4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid
DMWIALU	HS	Investigative
DMWIALU	SN	4-[(2-Oxo-2H-chromene-3-carbonyl)-amino]-benzoic acid; 4-[(2-oxochromen-3-yl)carbonylamino]benzoic acid; 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoic acid; BAS 00518567; AC1MJCO7; 3-carboxamido coumarin, 19; Oprea1_826423; Oprea1_127959; CHEMBL513209; SCHEMBL4389144; BDBM29169; MolPort-000-375-260; ZINC3076649; STL353172; SBB041117; BBL026015; AKOS000269615; MCULE-2534949799; ST50102584; 4-[(2-oxochromene-3-carbonyl)amino]benzoic acid
DMWIALU	DT	Small molecular drug
DMWIALU	PC	3110315
DMWIALU	MW	309.27
DMWIALU	FM	C17H11NO5
DMWIALU	IC	InChI=1S/C17H11NO5/c19-15(18-12-7-5-10(6-8-12)16(20)21)13-9-11-3-1-2-4-14(11)23-17(13)22/h1-9H,(H,18,19)(H,20,21)
DMWIALU	CS	C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)NC3=CC=C(C=C3)C(=O)O
DMWIALU	IK	IMGLCZZPWOJMLB-UHFFFAOYSA-N
DMWIALU	IU	4-[(2-oxochromene-3-carbonyl)amino]benzoic acid
DMWIALU	DE	Discovery agent

DMFPNQ9	ID	DMFPNQ9
DMFPNQ9	DN	4-(2-Oxo-2-phenyl-acetyl)-benzoic acid
DMFPNQ9	HS	Investigative
DMFPNQ9	SN	4-(2-oxo-2-phenylacetyl)benzoic acid; 72857-25-1; 4-(2-Oxo-2-phenyl-acetyl)-benzoic acid; MLS000775407; SMR000368487; Opera_ID_465; Benzil-based compound, 14; AC1M5V1J; CHEMBL370059; SCHEMBL2156860; 4-(oxophenylacetyl)benzoic acid; BDBM22736; CTK5D6959; DTXSID10368385; MolPort-000-510-282; HMS2753L08; 4-[oxo(phenyl)acetyl]benzoic acid; ZINC3269660; ZX-AL000632; STK246909; SBB039312; AKOS000267727; MCULE-7710064147; Benzoic acid,4-(2-oxo-2-phenylacetyl)-; KB-237683; ST50160330
DMFPNQ9	DT	Small molecular drug
DMFPNQ9	PC	2385968
DMFPNQ9	MW	254.24
DMFPNQ9	FM	C15H10O4
DMFPNQ9	IC	InChI=1S/C15H10O4/c16-13(10-4-2-1-3-5-10)14(17)11-6-8-12(9-7-11)15(18)19/h1-9H,(H,18,19)
DMFPNQ9	CS	C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)C(=O)O
DMFPNQ9	IK	MWJHDSAAGSURCA-UHFFFAOYSA-N
DMFPNQ9	IU	4-(2-oxo-2-phenylacetyl)benzoic acid
DMFPNQ9	CA	CAS 72857-25-1
DMFPNQ9	DE	Discovery agent

DMBMJC5	ID	DMBMJC5
DMBMJC5	DN	4-(2-oxohexadecanamido)butanoic acid
DMBMJC5	HS	Investigative
DMBMJC5	SN	4-(2-oxohexadecanamido)butanoic acid; CHEMBL95190; SCHEMBL1877382; ZINC36310606; BDBM50149408; 4-(2-Oxo-hexadecanoylamino)-butyric acid; 4-[(1,2-Dioxohexadecyl)amino]butanoic acid
DMBMJC5	DT	Small molecular drug
DMBMJC5	PC	9906670
DMBMJC5	MW	355.5
DMBMJC5	FM	C20H37NO4
DMBMJC5	IC	InChI=1S/C20H37NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18(22)20(25)21-17-14-16-19(23)24/h2-17H2,1H3,(H,21,25)(H,23,24)
DMBMJC5	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCCCC(=O)O
DMBMJC5	IK	GCTDVJHSYNCJRN-UHFFFAOYSA-N
DMBMJC5	IU	4-(2-oxohexadecanoylamino)butanoic acid
DMBMJC5	DE	Discovery agent

DMB5IFA	ID	DMB5IFA
DMB5IFA	DN	4-(2-phenoxyphenyl)piperidine
DMB5IFA	HS	Investigative
DMB5IFA	SN	4-(2-phenoxyphenyl)piperidine; CHEMBL575077; SCHEMBL4699769
DMB5IFA	DT	Small molecular drug
DMB5IFA	PC	23113096
DMB5IFA	MW	253.34
DMB5IFA	FM	C17H19NO
DMB5IFA	IC	InChI=1S/C17H19NO/c1-2-6-15(7-3-1)19-17-9-5-4-8-16(17)14-10-12-18-13-11-14/h1-9,14,18H,10-13H2
DMB5IFA	CS	C1CNCCC1C2=CC=CC=C2OC3=CC=CC=C3
DMB5IFA	IK	YWIYMDPWBAXEKQ-UHFFFAOYSA-N
DMB5IFA	IU	4-(2-phenoxyphenyl)piperidine
DMB5IFA	DE	Discovery agent

DMFQZOI	ID	DMFQZOI
DMFQZOI	DN	4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol
DMFQZOI	HS	Investigative
DMFQZOI	SN	CHEMBL200483; 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol; SCHEMBL6440186
DMFQZOI	DT	Small molecular drug
DMFQZOI	PC	44405888
DMFQZOI	MW	286.3
DMFQZOI	FM	C19H14N2O
DMFQZOI	IC	InChI=1S/C19H14N2O/c22-16-12-10-15(11-13-16)21-18-9-5-4-8-17(18)20-19(21)14-6-2-1-3-7-14/h1-13,22H
DMFQZOI	CS	C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2C4=CC=C(C=C4)O
DMFQZOI	IK	MXMPRHRVFXJSFN-UHFFFAOYSA-N
DMFQZOI	IU	4-(2-phenylbenzimidazol-1-yl)phenol
DMFQZOI	DE	Discovery agent

DMCPSE9	ID	DMCPSE9
DMCPSE9	DN	4-(2-phenyl-1H-indol-3-yl)phenol
DMCPSE9	HS	Investigative
DMCPSE9	SN	CHEMBL371012; 4-(2-phenyl-1H-indol-3-yl)phenol; SCHEMBL7041571; OITCYCYIUVYFKQ-UHFFFAOYSA-N; BDBM50175419; 4-(2-Phenyl-1H-indol-3-yl)-phenol
DMCPSE9	DT	Small molecular drug
DMCPSE9	PC	13896065
DMCPSE9	MW	285.3
DMCPSE9	FM	C20H15NO
DMCPSE9	IC	InChI=1S/C20H15NO/c22-16-12-10-14(11-13-16)19-17-8-4-5-9-18(17)21-20(19)15-6-2-1-3-7-15/h1-13,21-22H
DMCPSE9	CS	C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C4=CC=C(C=C4)O
DMCPSE9	IK	OITCYCYIUVYFKQ-UHFFFAOYSA-N
DMCPSE9	IU	4-(2-phenyl-1H-indol-3-yl)phenol
DMCPSE9	DE	Discovery agent

DMZ62L3	ID	DMZ62L3
DMZ62L3	DN	4-(2-Phenylacetamido)-3-bromobenzenesulfonamide
DMZ62L3	HS	Investigative
DMZ62L3	SN	sulfonamide deriv., 7f; CHEMBL574021; BDBM35738
DMZ62L3	DT	Small molecular drug
DMZ62L3	PC	44520902
DMZ62L3	MW	369.24
DMZ62L3	FM	C14H13BrN2O3S
DMZ62L3	IC	InChI=1S/C14H13BrN2O3S/c15-12-9-11(21(16,19)20)6-7-13(12)17-14(18)8-10-4-2-1-3-5-10/h1-7,9H,8H2,(H,17,18)(H2,16,19,20)
DMZ62L3	CS	C1=CC=C(C=C1)CC(=O)NC2=C(C=C(C=C2)S(=O)(=O)N)Br
DMZ62L3	IK	LBFJKAVSXZGFAX-UHFFFAOYSA-N
DMZ62L3	IU	N-(2-bromo-4-sulfamoylphenyl)-2-phenylacetamide
DMZ62L3	DE	Discovery agent

DM9GOTA	ID	DM9GOTA
DM9GOTA	DN	4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide
DM9GOTA	HS	Investigative
DM9GOTA	SN	BRN 2157920; N-(4-(Aminosulfonyl)-2-chlorophenyl)benzeneacetamide; 3-Chloro-4-phenacetamido-benzenesulfonamide; Benzeneacetamide, N-(4-(aminosulfonyl)-2-chlorophenyl)-; 68252-75-5; AC1MHICQ; sulfonamide deriv., 7e; SCHEMBL8222515; CHEMBL583971; CTK5C7613; BDBM35737; DTXSID70218418; LS-28479; 3-Chloro-4-(phenylacetylamino)benzenesulfonamide
DM9GOTA	DT	Small molecular drug
DM9GOTA	PC	3051968
DM9GOTA	MW	324.8
DM9GOTA	FM	C14H13ClN2O3S
DM9GOTA	IC	InChI=1S/C14H13ClN2O3S/c15-12-9-11(21(16,19)20)6-7-13(12)17-14(18)8-10-4-2-1-3-5-10/h1-7,9H,8H2,(H,17,18)(H2,16,19,20)
DM9GOTA	CS	C1=CC=C(C=C1)CC(=O)NC2=C(C=C(C=C2)S(=O)(=O)N)Cl
DM9GOTA	IK	PCTUCNXXOLZRTM-UHFFFAOYSA-N
DM9GOTA	IU	N-(2-chloro-4-sulfamoylphenyl)-2-phenylacetamide
DM9GOTA	CA	CAS 68252-75-5
DM9GOTA	DE	Discovery agent

DMCOD4N	ID	DMCOD4N
DMCOD4N	DN	4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide
DMCOD4N	HS	Investigative
DMCOD4N	SN	sulfonamide deriv., 7d; CHEMBL575660; BDBM35736
DMCOD4N	DT	Small molecular drug
DMCOD4N	PC	44520901
DMCOD4N	MW	308.33
DMCOD4N	FM	C14H13FN2O3S
DMCOD4N	IC	InChI=1S/C14H13FN2O3S/c15-12-9-11(21(16,19)20)6-7-13(12)17-14(18)8-10-4-2-1-3-5-10/h1-7,9H,8H2,(H,17,18)(H2,16,19,20)
DMCOD4N	CS	C1=CC=C(C=C1)CC(=O)NC2=C(C=C(C=C2)S(=O)(=O)N)F
DMCOD4N	IK	NPXJDOTWYYSLEJ-UHFFFAOYSA-N
DMCOD4N	IU	N-(2-fluoro-4-sulfamoylphenyl)-2-phenylacetamide
DMCOD4N	DE	Discovery agent

DMFYR6H	ID	DMFYR6H
DMFYR6H	DN	4-(2-Phenylacetamido)benzenesulfonamide
DMFYR6H	HS	Investigative
DMFYR6H	SN	2-phenyl-N-(4-sulfamoylphenyl)acetamide; N-[4-(aminosulfonyl)phenyl]-2-phenylacetamide; 331274-56-7; 3oys; 4-(2-Phenylacetamido)benzenesulfonamide; sulfonamide deriv., 7a; AC1LE45L; Oprea1_842052; CHEMBL574782; ARONIS000876; SCHEMBL13276539; KS-00003UGZ; BDBM35733; MolPort-001-503-086; ZINC142256; STK097687; AKOS000490206; MCULE-4432635286; ST039768; AN-329/10027012; F3145-0673
DMFYR6H	DT	Small molecular drug
DMFYR6H	PC	729977
DMFYR6H	MW	290.34
DMFYR6H	FM	C14H14N2O3S
DMFYR6H	IC	InChI=1S/C14H14N2O3S/c15-20(18,19)13-8-6-12(7-9-13)16-14(17)10-11-4-2-1-3-5-11/h1-9H,10H2,(H,16,17)(H2,15,18,19)
DMFYR6H	CS	C1=CC=C(C=C1)CC(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMFYR6H	IK	JWDLYKTZCRIGNW-UHFFFAOYSA-N
DMFYR6H	IU	2-phenyl-N-(4-sulfamoylphenyl)acetamide
DMFYR6H	DE	Discovery agent

DM1JL03	ID	DM1JL03
DM1JL03	DN	4-(2-Phenylacetamidoethyl)benzenesulfonamide
DM1JL03	HS	Investigative
DM1JL03	SN	AC1MPEEB; sulfonamide deriv., 7c; 4-(2-Phenylacetamidoethyl)benzenesulfonamide; Oprea1_837732; CHEMBL573859; BDBM35735; AKOS027674184
DM1JL03	DT	Small molecular drug
DM1JL03	PC	3433937
DM1JL03	MW	318.4
DM1JL03	FM	C16H18N2O3S
DM1JL03	IC	InChI=1S/C16H18N2O3S/c17-22(20,21)15-8-6-13(7-9-15)10-11-18-16(19)12-14-4-2-1-3-5-14/h1-9H,10-12H2,(H,18,19)(H2,17,20,21)
DM1JL03	CS	C1=CC=C(C=C1)CC(=O)NCCC2=CC=C(C=C2)S(=O)(=O)N
DM1JL03	IK	DIZLDASYQVXHTB-UHFFFAOYSA-N
DM1JL03	IU	2-phenyl-N-[2-(4-sulfamoylphenyl)ethyl]acetamide
DM1JL03	DE	Discovery agent

DMDYHXE	ID	DMDYHXE
DMDYHXE	DN	4-(2-Phenylacetamidomethyl)benzenesulfonamide
DMDYHXE	HS	Investigative
DMDYHXE	SN	2-phenyl-N-(4-sulfamoylbenzyl)acetamide; 41352-39-0; 4itp; sulfonamide deriv., 7b; 4-(2-Phenylacetamidomethyl)benzenesulfonamide; AC1N3X6Y; 2-phenyl-N-[(4-sulfamoylphenyl)methyl]acetamide; Oprea1_692071; ARONIS26431; CHEMBL574783; BDBM35734; MolPort-010-990-071; ZINC6864120; STL261373; AKOS003796845; MCULE-9432670742; 4-phenylacetamidomethyl-benzenesulfonamide; BB0294421; 4-(Phenylacetylaminomethyl)benzenesulfonamide; KS-00004825; N-[4-(aminosulfonyl)benzyl]-2-phenylacetamide; Benzeneacetamide, N-[[4-(aminosulfonyl)phenyl]methy
DMDYHXE	DT	Small molecular drug
DMDYHXE	PC	4119643
DMDYHXE	MW	304.4
DMDYHXE	FM	C15H16N2O3S
DMDYHXE	IC	InChI=1S/C15H16N2O3S/c16-21(19,20)14-8-6-13(7-9-14)11-17-15(18)10-12-4-2-1-3-5-12/h1-9H,10-11H2,(H,17,18)(H2,16,19,20)
DMDYHXE	CS	C1=CC=C(C=C1)CC(=O)NCC2=CC=C(C=C2)S(=O)(=O)N
DMDYHXE	IK	FTDLZZRRCJRQAA-UHFFFAOYSA-N
DMDYHXE	IU	2-phenyl-N-[(4-sulfamoylphenyl)methyl]acetamide
DMDYHXE	DE	Discovery agent

DMT9RAC	ID	DMT9RAC
DMT9RAC	DN	4-(2-Propynylthio)pyridine-3-sulfonamide
DMT9RAC	HS	Investigative
DMT9RAC	SN	CHEMBL1164486; 4-(2-Propynylthio)pyridine-3-sulfonamide
DMT9RAC	DT	Small molecular drug
DMT9RAC	PC	46907399
DMT9RAC	MW	228.3
DMT9RAC	FM	C8H8N2O2S2
DMT9RAC	IC	InChI=1S/C8H8N2O2S2/c1-2-5-13-7-3-4-10-6-8(7)14(9,11)12/h1,3-4,6H,5H2,(H2,9,11,12)
DMT9RAC	CS	C#CCSC1=C(C=NC=C1)S(=O)(=O)N
DMT9RAC	IK	DGLKDMDQEUWHSZ-UHFFFAOYSA-N
DMT9RAC	IU	4-prop-2-ynylsulfanylpyridine-3-sulfonamide
DMT9RAC	DE	Discovery agent

DM9LKMP	ID	DM9LKMP
DM9LKMP	DN	4-(2-Pyridin-2-ylacetamido)benzenesulfonamide
DM9LKMP	HS	Investigative
DM9LKMP	SN	sulfonamide deriv., 7g; CHEMBL582965; BDBM35739
DM9LKMP	DT	Small molecular drug
DM9LKMP	PC	44520903
DM9LKMP	MW	291.33
DM9LKMP	FM	C13H13N3O3S
DM9LKMP	IC	InChI=1S/C13H13N3O3S/c14-20(18,19)12-6-4-10(5-7-12)16-13(17)9-11-3-1-2-8-15-11/h1-8H,9H2,(H,16,17)(H2,14,18,19)
DM9LKMP	CS	C1=CC=NC(=C1)CC(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DM9LKMP	IK	AVVKIKWNABJSCP-UHFFFAOYSA-N
DM9LKMP	IU	2-pyridin-2-yl-N-(4-sulfamoylphenyl)acetamide
DM9LKMP	DE	Discovery agent

DMD6AYQ	ID	DMD6AYQ
DMD6AYQ	DN	4-(2-Pyridin-4-ylacetamido)benzenesulfonamide
DMD6AYQ	HS	Investigative
DMD6AYQ	SN	sulfonamide deriv., 7h; CHEMBL574245
DMD6AYQ	DT	Small molecular drug
DMD6AYQ	PC	44520904
DMD6AYQ	MW	291.33
DMD6AYQ	FM	C13H13N3O3S
DMD6AYQ	IC	InChI=1S/C13H13N3O3S/c14-20(18,19)12-3-1-11(2-4-12)16-13(17)9-10-5-7-15-8-6-10/h1-8H,9H2,(H,16,17)(H2,14,18,19)
DMD6AYQ	CS	C1=CC(=CC=C1NC(=O)CC2=CC=NC=C2)S(=O)(=O)N
DMD6AYQ	IK	CXBVXOMVANONBT-UHFFFAOYSA-N
DMD6AYQ	IU	2-pyridin-4-yl-N-(4-sulfamoylphenyl)acetamide
DMD6AYQ	DE	Discovery agent

DMOSDAN	ID	DMOSDAN
DMOSDAN	DN	4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile
DMOSDAN	HS	Investigative
DMOSDAN	SN	CHEMBL202518; 4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile; SCHEMBL4932714
DMOSDAN	DT	Small molecular drug
DMOSDAN	PC	11550626
DMOSDAN	MW	256.339
DMOSDAN	FM	C16H20N2O
DMOSDAN	IC	InChI=1S/C16H20N2O/c1-2-5-15(18-10-3-4-11-18)16(19)14-8-6-13(12-17)7-9-14/h6-9,15H,2-5,10-11H2,1H3
DMOSDAN	CS	CCCC(C(=O)C1=CC=C(C=C1)C#N)N2CCCC2
DMOSDAN	IK	AQQRGNNYEPRIIF-UHFFFAOYSA-N
DMOSDAN	IU	4-(2-pyrrolidin-1-ylpentanoyl)benzonitrile
DMOSDAN	DE	Discovery agent

DMX681M	ID	DMX681M
DMX681M	DN	4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
DMX681M	HS	Investigative
DMX681M	SN	4-(2-THIENYL)-1-(4-METHYLBENZYL)-1H-IMIDAZOLE; Disubstituted imidazole 1; AC1L9J9C; CHEMBL66526; SCHEMBL4319860; BDBM8738; DB03030; 1-(4-methylbenzyl)-4-(2-thienyl)-1h-imidazole; 1-(4-methylbenzyl)-4-thiophen-2-yl-1H-imidazole; 1-[(4-methylphenyl)methyl]-4-thiophen-2-ylimidazole; 1-[(4-methylphenyl)methyl]-4-(thiophen-2-yl)imidazole
DMX681M	DT	Small molecular drug
DMX681M	PC	446185
DMX681M	MW	254.4
DMX681M	FM	C15H14N2S
DMX681M	IC	InChI=1S/C15H14N2S/c1-12-4-6-13(7-5-12)9-17-10-14(16-11-17)15-3-2-8-18-15/h2-8,10-11H,9H2,1H3
DMX681M	CS	CC1=CC=C(C=C1)CN2C=C(N=C2)C3=CC=CS3
DMX681M	IK	UMOFOLLUKPBVQG-UHFFFAOYSA-N
DMX681M	IU	1-[(4-methylphenyl)methyl]-4-thiophen-2-ylimidazole
DMX681M	DE	Discovery agent

DM4YWQN	ID	DM4YWQN
DM4YWQN	DN	4-(2-thienyl)benzene-1,2-diamine
DM4YWQN	HS	Investigative
DM4YWQN	SN	4-(thiophen-2-yl)benzene-1,2-diamine; 471239-63-1; 4-(2-thienyl)-1,2-Benzenediamine; CHEMBL495702; SCHEMBL2873589; XWTMGMKBRLLEFX-UHFFFAOYSA-N; MolPort-042-605-637; ZINC40977399; AKOS033921192; DA-05644; FT-0738633
DM4YWQN	DT	Small molecular drug
DM4YWQN	PC	13007805
DM4YWQN	MW	190.27
DM4YWQN	FM	C10H10N2S
DM4YWQN	IC	InChI=1S/C10H10N2S/c11-8-4-3-7(6-9(8)12)10-2-1-5-13-10/h1-6H,11-12H2
DM4YWQN	CS	C1=CSC(=C1)C2=CC(=C(C=C2)N)N
DM4YWQN	IK	XWTMGMKBRLLEFX-UHFFFAOYSA-N
DM4YWQN	IU	4-thiophen-2-ylbenzene-1,2-diamine
DM4YWQN	DE	Discovery agent

DMR3T2D	ID	DMR3T2D
DMR3T2D	DN	4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol
DMR3T2D	HS	Investigative
DMR3T2D	SN	Phenol, 4,4'-indole-2,3-diyldi-; BRN 1541731; 4,4'-Indole-2,3-diyldiphenol; CHEMBL200232; 5890-93-7; 4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol; SCHEMBL7037980; AC1L46D4; DTXSID90207642; ZINC3638330; BDBM50175412; LS-104733; 4,4'-[1H-Indole-2,3-diyl]bis(phenol)
DMR3T2D	DT	Small molecular drug
DMR3T2D	PC	201385
DMR3T2D	MW	301.3
DMR3T2D	FM	C20H15NO2
DMR3T2D	IC	InChI=1S/C20H15NO2/c22-15-9-5-13(6-10-15)19-17-3-1-2-4-18(17)21-20(19)14-7-11-16(23)12-8-14/h1-12,21-23H
DMR3T2D	CS	C1=CC=C2C(=C1)C(=C(N2)C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
DMR3T2D	IK	MGOARPQWMKCCSF-UHFFFAOYSA-N
DMR3T2D	IU	4-[2-(4-hydroxyphenyl)-1H-indol-3-yl]phenol
DMR3T2D	CA	CAS 5890-93-7
DMR3T2D	DE	Discovery agent

DMX5V9T	ID	DMX5V9T
DMX5V9T	DN	4-(3-(Dimethylamino)propanoyl)-N-hexylbenzamide
DMX5V9T	HS	Investigative
DMX5V9T	SN	CHEMBL561648; 4-(3-(Dimethylamino)propanoyl)-N-hexylbenzamide
DMX5V9T	DT	Small molecular drug
DMX5V9T	PC	44186304
DMX5V9T	MW	304.4
DMX5V9T	FM	C18H28N2O2
DMX5V9T	IC	InChI=1S/C18H28N2O2/c1-4-5-6-7-13-19-18(22)16-10-8-15(9-11-16)17(21)12-14-20(2)3/h8-11H,4-7,12-14H2,1-3H3,(H,19,22)
DMX5V9T	CS	CCCCCCNC(=O)C1=CC=C(C=C1)C(=O)CCN(C)C
DMX5V9T	IK	BARBHIHQBFLEIN-UHFFFAOYSA-N
DMX5V9T	IU	4-[3-(dimethylamino)propanoyl]-N-hexylbenzamide
DMX5V9T	DE	Discovery agent

DMNUWK2	ID	DMNUWK2
DMNUWK2	DN	4-(3,4,5-Trimethoxyphenethyl)aniline
DMNUWK2	HS	Investigative
DMNUWK2	SN	CHEMBL86928; 4-(3,4,5-Trimethoxyphenethyl)aniline; 110997-90-5; Benzenamine, 4-[2-(3,4,5-trimethoxyphenyl)ethyl]-; 4-[2-(3,4,5-Trimethoxy-phenyl)-ethyl]-phenylamine; 4-[2-(3,4,5-Trimethoxyphenyl)Ethyl]Aniline; NSC631359; ACMC-20mdvn; AC1L7PCU; AC1Q56FF; SCHEMBL6483085; CTK0G1952; DTXSID30327095; BPIQFCQFIYIISU-UHFFFAOYSA-N; ZINC1622338; BDBM50322061; 4'-Amino-3,4,5-trimethoxybibenzyl; AKOS030581735; NSC-631359; NCI60_010236; 4-[2-(3,5-Trimethoxyphenyl)Ethyl]Aniline; 4-[2-(3,4,5-trimethoxy-phenyl)ethyl]-phenylamine
DMNUWK2	DT	Small molecular drug
DMNUWK2	PC	364705
DMNUWK2	MW	287.35
DMNUWK2	FM	C17H21NO3
DMNUWK2	IC	InChI=1S/C17H21NO3/c1-19-15-10-13(11-16(20-2)17(15)21-3)5-4-12-6-8-14(18)9-7-12/h6-11H,4-5,18H2,1-3H3
DMNUWK2	CS	COC1=CC(=CC(=C1OC)OC)CCC2=CC=C(C=C2)N
DMNUWK2	IK	BPIQFCQFIYIISU-UHFFFAOYSA-N
DMNUWK2	IU	4-[2-(3,4,5-trimethoxyphenyl)ethyl]aniline
DMNUWK2	CA	CAS 110997-90-5
DMNUWK2	DE	Discovery agent

DMBEA23	ID	DMBEA23
DMBEA23	DN	4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid
DMBEA23	HS	Investigative
DMBEA23	SN	CHEMBL382682; 4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid; BDBM50179735
DMBEA23	DT	Small molecular drug
DMBEA23	PC	44408336
DMBEA23	MW	294.2
DMBEA23	FM	C11H13Cl2NO2S
DMBEA23	IC	InChI=1S/C11H13Cl2NO2S/c12-8-2-1-7(5-9(8)13)6-17-4-3-10(14)11(15)16/h1-2,5,10H,3-4,6,14H2,(H,15,16)
DMBEA23	CS	C1=CC(=C(C=C1CSCCC(C(=O)O)N)Cl)Cl
DMBEA23	IK	FCRWKMQNOHHYCO-UHFFFAOYSA-N
DMBEA23	IU	2-amino-4-[(3,4-dichlorophenyl)methylsulfanyl]butanoic acid
DMBEA23	DE	Discovery agent

DMIZXYM	ID	DMIZXYM
DMIZXYM	DN	4-(3,4-Diethoxy-benzylamino)-benzamidine
DMIZXYM	HS	Investigative
DMIZXYM	SN	benzylamine 5; CHEMBL181265; BDBM13579
DMIZXYM	DT	Small molecular drug
DMIZXYM	PC	23646461
DMIZXYM	MW	313.4
DMIZXYM	FM	C18H23N3O2
DMIZXYM	IC	InChI=1S/C18H23N3O2/c1-3-22-16-10-5-13(11-17(16)23-4-2)12-21-15-8-6-14(7-9-15)18(19)20/h5-11,21H,3-4,12H2,1-2H3,(H3,19,20)
DMIZXYM	CS	CCOC1=C(C=C(C=C1)CNC2=CC=C(C=C2)C(=N)N)OCC
DMIZXYM	IK	KWXVDUACPKJCCN-UHFFFAOYSA-N
DMIZXYM	IU	4-[(3,4-diethoxyphenyl)methylamino]benzenecarboximidamide
DMIZXYM	DE	Discovery agent

DMCOJIL	ID	DMCOJIL
DMCOJIL	DN	4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline
DMCOJIL	HS	Investigative
DMCOJIL	SN	CHEMBL50166; 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline; SCHEMBL6159581; ZINC26870; BDBM50127827
DMCOJIL	DT	Small molecular drug
DMCOJIL	PC	18326767
DMCOJIL	MW	260.3
DMCOJIL	FM	C18H16N2
DMCOJIL	IC	InChI=1S/C18H16N2/c1-2-6-15-13-20(12-10-14(15)5-1)18-9-11-19-17-8-4-3-7-16(17)18/h1-9,11H,10,12-13H2
DMCOJIL	CS	C1CN(CC2=CC=CC=C21)C3=CC=NC4=CC=CC=C43
DMCOJIL	IK	HRDFYQVITWAQGZ-UHFFFAOYSA-N
DMCOJIL	IU	4-(3,4-dihydro-1H-isoquinolin-2-yl)quinoline
DMCOJIL	DE	Discovery agent

DMBI7MS	ID	DMBI7MS
DMBI7MS	DN	4-(3,4-Dimethoxyphenethyl)aniline
DMBI7MS	HS	Investigative
DMBI7MS	SN	4-(3,4-Dimethoxyphenethyl)aniline; CHEMBL1171680; SCHEMBL6481605; MEJNYOQOZUXCOG-UHFFFAOYSA-N; ZINC34258590; BDBM50322060; 4-[2-[3,4-dimethoxyphenyl)ethyl]aniline; 4[2-(3,4-dimethoxyphenyl)ethyl]benzenamine; 4-[2-(3,4-dimethoxyphenyl)ethyl]benzenamine; 4-[2-(3,4-dimethoxyphenyl)ethyl]phenylamine; 4-[2-(3,4-Dimethoxy-phenyl)ethyl]-phenylamine; 4-[2-(3,4-dimethoxy-phenyl)-ethyl]phenylamine
DMBI7MS	DT	Small molecular drug
DMBI7MS	PC	14256024
DMBI7MS	MW	257.329
DMBI7MS	FM	C16H19NO2
DMBI7MS	IC	InChI=1S/C16H19NO2/c1-18-15-10-7-13(11-16(15)19-2)4-3-12-5-8-14(17)9-6-12/h5-11H,3-4,17H2,1-2H3
DMBI7MS	CS	COC1=C(C=C(C=C1)CCC2=CC=C(C=C2)N)OC
DMBI7MS	IK	MEJNYOQOZUXCOG-UHFFFAOYSA-N
DMBI7MS	IU	4-[2-(3,4-dimethoxyphenyl)ethyl]aniline
DMBI7MS	DE	Discovery agent

DMW1H6C	ID	DMW1H6C
DMW1H6C	DN	4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DMW1H6C	HS	Investigative
DMW1H6C	SN	CHEMBL327300; Ki-6783; 6,7-Dimethoxy-4-(3,4-dimethoxyphenoxy)quinoline; SCHEMBL925876; 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline; ZQSHUGGLESWJFP-UHFFFAOYSA-N
DMW1H6C	DT	Small molecular drug
DMW1H6C	PC	9927943
DMW1H6C	MW	341.4
DMW1H6C	FM	C19H19NO5
DMW1H6C	IC	InChI=1S/C19H19NO5/c1-21-16-6-5-12(9-17(16)22-2)25-15-7-8-20-14-11-19(24-4)18(23-3)10-13(14)15/h5-11H,1-4H3
DMW1H6C	CS	COC1=C(C=C(C=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC)OC
DMW1H6C	IK	ZQSHUGGLESWJFP-UHFFFAOYSA-N
DMW1H6C	IU	4-(3,4-dimethoxyphenoxy)-6,7-dimethoxyquinoline
DMW1H6C	DE	Discovery agent

DM5ZTXO	ID	DM5ZTXO
DM5ZTXO	DN	4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid
DM5ZTXO	HS	Investigative
DM5ZTXO	SN	CHEMBL204870; 4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid; BDBM50179737
DM5ZTXO	DT	Small molecular drug
DM5ZTXO	PC	44408222
DM5ZTXO	MW	253.36
DM5ZTXO	FM	C13H19NO2S
DM5ZTXO	IC	InChI=1S/C13H19NO2S/c1-9-3-4-11(7-10(9)2)8-17-6-5-12(14)13(15)16/h3-4,7,12H,5-6,8,14H2,1-2H3,(H,15,16)
DM5ZTXO	CS	CC1=C(C=C(C=C1)CSCCC(C(=O)O)N)C
DM5ZTXO	IK	HMCZVDYIAXLHNI-UHFFFAOYSA-N
DM5ZTXO	IU	2-amino-4-[(3,4-dimethylphenyl)methylsulfanyl]butanoic acid
DM5ZTXO	DE	Discovery agent

DMM3F9K	ID	DMM3F9K
DMM3F9K	DN	4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid
DMM3F9K	HS	Investigative
DMM3F9K	SN	CHEMBL204818; 4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid
DMM3F9K	DT	Small molecular drug
DMM3F9K	PC	44408337
DMM3F9K	MW	294.2
DMM3F9K	FM	C11H13Cl2NO2S
DMM3F9K	IC	InChI=1S/C11H13Cl2NO2S/c12-8-3-7(4-9(13)5-8)6-17-2-1-10(14)11(15)16/h3-5,10H,1-2,6,14H2,(H,15,16)
DMM3F9K	CS	C1=C(C=C(C=C1Cl)Cl)CSCCC(C(=O)O)N
DMM3F9K	IK	CLPWTUZDSOPCKQ-UHFFFAOYSA-N
DMM3F9K	IU	2-amino-4-[(3,5-dichlorophenyl)methylsulfanyl]butanoic acid
DMM3F9K	DE	Discovery agent

DM48Z5Y	ID	DM48Z5Y
DM48Z5Y	DN	4-(3,5-difluorophenylethynyl)-2-methylthiazole
DM48Z5Y	HS	Investigative
DM48Z5Y	SN	CHEMBL202436; 4-(3,5-difluorophenylethynyl)-2-methylthiazole; SCHEMBL4161912
DM48Z5Y	DT	Small molecular drug
DM48Z5Y	PC	11543200
DM48Z5Y	MW	235.25
DM48Z5Y	FM	C12H7F2NS
DM48Z5Y	IC	InChI=1S/C12H7F2NS/c1-8-15-12(7-16-8)3-2-9-4-10(13)6-11(14)5-9/h4-7H,1H3
DM48Z5Y	CS	CC1=NC(=CS1)C#CC2=CC(=CC(=C2)F)F
DM48Z5Y	IK	RIXDIVBFRYYMRM-UHFFFAOYSA-N
DM48Z5Y	IU	4-[2-(3,5-difluorophenyl)ethynyl]-2-methyl-1,3-thiazole
DM48Z5Y	DE	Discovery agent

DM4FC9O	ID	DM4FC9O
DM4FC9O	DN	4-(3,5-Dimethoxyphenethyl)benzenamine
DM4FC9O	HS	Investigative
DM4FC9O	SN	4-(3,5-Dimethoxyphenethyl)benzenamine; CHEMBL1171818; SCHEMBL10384348
DM4FC9O	DT	Small molecular drug
DM4FC9O	PC	14256034
DM4FC9O	MW	257.329
DM4FC9O	FM	C16H19NO2
DM4FC9O	IC	InChI=1S/C16H19NO2/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h5-11H,3-4,17H2,1-2H3
DM4FC9O	CS	COC1=CC(=CC(=C1)CCC2=CC=C(C=C2)N)OC
DM4FC9O	IK	LIBKKCPPEBZEHD-UHFFFAOYSA-N
DM4FC9O	IU	4-[2-(3,5-dimethoxyphenyl)ethyl]aniline
DM4FC9O	DE	Discovery agent

DM5279R	ID	DM5279R
DM5279R	DN	4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM5279R	HS	Investigative
DM5279R	SN	CHEMBL101733; 4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM5279R	DT	Small molecular drug
DM5279R	PC	44330968
DM5279R	MW	341.4
DM5279R	FM	C19H19NO5
DM5279R	IC	InChI=1S/C19H19NO5/c1-21-12-7-13(22-2)9-14(8-12)25-17-5-6-20-16-11-19(24-4)18(23-3)10-15(16)17/h5-11H,1-4H3
DM5279R	CS	COC1=CC(=CC(=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC)OC
DM5279R	IK	RNXKKASQCMYWCJ-UHFFFAOYSA-N
DM5279R	IU	4-(3,5-dimethoxyphenoxy)-6,7-dimethoxyquinoline
DM5279R	DE	Discovery agent

DM9MIQB	ID	DM9MIQB
DM9MIQB	DN	4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid
DM9MIQB	HS	Investigative
DM9MIQB	SN	CHEMBL380950; 4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid; BDBM50179702
DM9MIQB	DT	Small molecular drug
DM9MIQB	PC	44408223
DM9MIQB	MW	253.36
DM9MIQB	FM	C13H19NO2S
DM9MIQB	IC	InChI=1S/C13H19NO2S/c1-9-5-10(2)7-11(6-9)8-17-4-3-12(14)13(15)16/h5-7,12H,3-4,8,14H2,1-2H3,(H,15,16)
DM9MIQB	CS	CC1=CC(=CC(=C1)CSCCC(C(=O)O)N)C
DM9MIQB	IK	XBQZUMGAFICQFC-UHFFFAOYSA-N
DM9MIQB	IU	2-amino-4-[(3,5-dimethylphenyl)methylsulfanyl]butanoic acid
DM9MIQB	DE	Discovery agent

DMKUAEY	ID	DMKUAEY
DMKUAEY	DN	4-(3-Adamantan-1-yl-ureido)-benzoic acid
DMKUAEY	HS	Investigative
DMKUAEY	SN	CHEMBL478321; 4-(3-Adamantan-1-yl-ureido)-benzoic acid; SCHEMBL12932181; BDBM50267174
DMKUAEY	DT	Small molecular drug
DMKUAEY	PC	44582456
DMKUAEY	MW	314.4
DMKUAEY	FM	C18H22N2O3
DMKUAEY	IC	InChI=1S/C18H22N2O3/c21-16(22)14-1-3-15(4-2-14)19-17(23)20-18-8-11-5-12(9-18)7-13(6-11)10-18/h1-4,11-13H,5-10H2,(H,21,22)(H2,19,20,23)
DMKUAEY	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=C(C=C4)C(=O)O
DMKUAEY	IK	KBCDTFQYSZRNRK-UHFFFAOYSA-N
DMKUAEY	IU	4-(1-adamantylcarbamoylamino)benzoic acid
DMKUAEY	DE	Discovery agent

DMLVZ6O	ID	DMLVZ6O
DMLVZ6O	DN	4-(3-benzenesulfonamidophenyl)piperazine
DMLVZ6O	HS	Investigative
DMLVZ6O	SN	4-(3-benzenesulfonamidophenyl)piperazine; CHEMBL213586; BDBM50193466
DMLVZ6O	DT	Small molecular drug
DMLVZ6O	PC	11849196
DMLVZ6O	MW	317.4
DMLVZ6O	FM	C16H19N3O2S
DMLVZ6O	IC	InChI=1S/C16H19N3O2S/c20-22(21,16-7-2-1-3-8-16)18-14-5-4-6-15(13-14)19-11-9-17-10-12-19/h1-8,13,17-18H,9-12H2
DMLVZ6O	CS	C1CN(CCN1)C2=CC=CC(=C2)NS(=O)(=O)C3=CC=CC=C3
DMLVZ6O	IK	KUAATZXIILUWMF-UHFFFAOYSA-N
DMLVZ6O	IU	N-(3-piperazin-1-ylphenyl)benzenesulfonamide
DMLVZ6O	DE	Discovery agent

DMG4X13	ID	DMG4X13
DMG4X13	DN	4-(3-benzenesulfonylphenyl)piperazine
DMG4X13	HS	Investigative
DMG4X13	SN	4-(3-benzenesulfonylphenyl)piperazine; CHEMBL212995; SCHEMBL3826873; KDBOZUADFFNYSM-UHFFFAOYSA-N; BDBM50193464
DMG4X13	DT	Small molecular drug
DMG4X13	PC	9948345
DMG4X13	MW	302.4
DMG4X13	FM	C16H18N2O2S
DMG4X13	IC	InChI=1S/C16H18N2O2S/c19-21(20,15-6-2-1-3-7-15)16-8-4-5-14(13-16)18-11-9-17-10-12-18/h1-8,13,17H,9-12H2
DMG4X13	CS	C1CN(CCN1)C2=CC(=CC=C2)S(=O)(=O)C3=CC=CC=C3
DMG4X13	IK	KDBOZUADFFNYSM-UHFFFAOYSA-N
DMG4X13	IU	1-[3-(benzenesulfonyl)phenyl]piperazine
DMG4X13	DE	Discovery agent

DMT0EK8	ID	DMT0EK8
DMT0EK8	DN	4-(3-Benzoyl-1H-pyrrol-1-yl)butanoic acid
DMT0EK8	HS	Investigative
DMT0EK8	SN	CHEMBL590016; 4-(3-Benzoyl-1H-pyrrol-1-yl)butanoic acid
DMT0EK8	DT	Small molecular drug
DMT0EK8	PC	46229307
DMT0EK8	MW	257.279
DMT0EK8	FM	C15H15NO3
DMT0EK8	IC	InChI=1S/C15H15NO3/c17-14(18)7-4-9-16-10-8-13(11-16)15(19)12-5-2-1-3-6-12/h1-3,5-6,8,10-11H,4,7,9H2,(H,17,18)
DMT0EK8	CS	C1=CC=C(C=C1)C(=O)C2=CN(C=C2)CCCC(=O)O
DMT0EK8	IK	DMGGHIOFOITOLX-UHFFFAOYSA-N
DMT0EK8	IU	4-(3-benzoylpyrrol-1-yl)butanoic acid
DMT0EK8	DE	Discovery agent

DML3VB7	ID	DML3VB7
DML3VB7	DN	4-(3-bromobenzylthio)-2-aminobutanoic acid
DML3VB7	HS	Investigative
DML3VB7	SN	CHEMBL380929; 4-(3-bromobenzylthio)-2-aminobutanoic acid; BDBM50179727
DML3VB7	DT	Small molecular drug
DML3VB7	PC	44408328
DML3VB7	MW	304.21
DML3VB7	FM	C11H14BrNO2S
DML3VB7	IC	InChI=1S/C11H14BrNO2S/c12-9-3-1-2-8(6-9)7-16-5-4-10(13)11(14)15/h1-3,6,10H,4-5,7,13H2,(H,14,15)
DML3VB7	CS	C1=CC(=CC(=C1)Br)CSCCC(C(=O)O)N
DML3VB7	IK	NFPJCMSYLUNWCI-UHFFFAOYSA-N
DML3VB7	IU	2-amino-4-[(3-bromophenyl)methylsulfanyl]butanoic acid
DML3VB7	DE	Discovery agent

DMNBLQ8	ID	DMNBLQ8
DMNBLQ8	DN	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline
DMNBLQ8	HS	Investigative
DMNBLQ8	SN	CHEMBL98798; 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline
DMNBLQ8	DT	Small molecular drug
DMNBLQ8	PC	44331231
DMNBLQ8	MW	361.19
DMNBLQ8	FM	C16H13BrN2O3
DMNBLQ8	IC	InChI=1S/C16H13BrN2O3/c1-20-14-7-12-13(8-15(14)21-2)18-9-19-16(12)22-11-5-3-4-10(17)6-11/h3-9H,1-2H3
DMNBLQ8	CS	COC1=C(C=C2C(=C1)C(=NC=N2)OC3=CC(=CC=C3)Br)OC
DMNBLQ8	IK	BRHOGFZRGDIAMT-UHFFFAOYSA-N
DMNBLQ8	IU	4-(3-bromophenoxy)-6,7-dimethoxyquinazoline
DMNBLQ8	DE	Discovery agent

DMK6JV7	ID	DMK6JV7
DMK6JV7	DN	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline
DMK6JV7	HS	Investigative
DMK6JV7	SN	CHEMBL101581; 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline
DMK6JV7	DT	Small molecular drug
DMK6JV7	PC	44331083
DMK6JV7	MW	360.2
DMK6JV7	FM	C17H14BrNO3
DMK6JV7	IC	InChI=1S/C17H14BrNO3/c1-20-16-9-13-14(10-17(16)21-2)19-7-6-15(13)22-12-5-3-4-11(18)8-12/h3-10H,1-2H3
DMK6JV7	CS	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC(=CC=C3)Br
DMK6JV7	IK	OVJMXMWWASQPSL-UHFFFAOYSA-N
DMK6JV7	IU	4-(3-bromophenoxy)-6,7-dimethoxyquinoline
DMK6JV7	DE	Discovery agent

DM3LGOT	ID	DM3LGOT
DM3LGOT	DN	4-(3-bromophenoxy)-6-chloroquinazoline
DM3LGOT	HS	Investigative
DM3LGOT	SN	CHEMBL1082103; 4-(3-bromophenoxy)-6-chloroquinazoline
DM3LGOT	DT	Small molecular drug
DM3LGOT	PC	46879772
DM3LGOT	MW	335.58
DM3LGOT	FM	C14H8BrClN2O
DM3LGOT	IC	InChI=1S/C14H8BrClN2O/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H
DM3LGOT	CS	C1=CC(=CC(=C1)Br)OC2=NC=NC3=C2C=C(C=C3)Cl
DM3LGOT	IK	WAILHPROBXVCQL-UHFFFAOYSA-N
DM3LGOT	IU	4-(3-bromophenoxy)-6-chloroquinazoline
DM3LGOT	DE	Discovery agent

DM1Q5KV	ID	DM1Q5KV
DM1Q5KV	DN	4-(3-Bromo-phenylamino)-quinazoline-6,7-diol
DM1Q5KV	HS	Investigative
DM1Q5KV	DT	Small molecular drug
DM1Q5KV	PC	5328050
DM1Q5KV	DE	Discovery agent

DMQBHF2	ID	DMQBHF2
DMQBHF2	DN	4-(3-bromophenylthio)-2-(pyridin-2-yl)pyrimidine
DMQBHF2	HS	Investigative
DMQBHF2	SN	CHEMBL208163; 4-(3-bromophenylthio)-2-(pyridin-2-yl)pyrimidine; SCHEMBL6504580; 4-(3-bromo-phenylsulfanyl)-2-pyridin-2-yl-pyrimidine; BDBM50182817
DMQBHF2	DT	Small molecular drug
DMQBHF2	PC	11473392
DMQBHF2	MW	344.2
DMQBHF2	FM	C15H10BrN3S
DMQBHF2	IC	InChI=1S/C15H10BrN3S/c16-11-4-3-5-12(10-11)20-14-7-9-18-15(19-14)13-6-1-2-8-17-13/h1-10H
DMQBHF2	CS	C1=CC=NC(=C1)C2=NC=CC(=N2)SC3=CC(=CC=C3)Br
DMQBHF2	IK	GOUWEKQNTSGAGA-UHFFFAOYSA-N
DMQBHF2	IU	4-(3-bromophenyl)sulfanyl-2-pyridin-2-ylpyrimidine
DMQBHF2	DE	Discovery agent

DML5NF6	ID	DML5NF6
DML5NF6	DN	4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol
DML5NF6	HS	Investigative
DML5NF6	SN	4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol; 945376-95-4; CHEMBL1269227; AK-87708; SCHEMBL2813127; CTK8B8546; DTXSID20680661; MolPort-023-331-308; XBHIAJWNXVJSAA-UHFFFAOYSA-N; KS-00000P8Z; ZINC64512573; ANW-60649; 6223AC; AKOS016003310; ACN-048482; QC-10378; DS-18362; ST2405344; KB-237849; AX8219172; AB0098071; DB-079951; TC-149394; AJ-114863; 4CH-017501
DML5NF6	DT	Small molecular drug
DML5NF6	PC	52947893
DML5NF6	MW	290.11
DML5NF6	FM	C12H8BrN3O
DML5NF6	IC	InChI=1S/C12H8BrN3O/c13-11-6-15-16-7-9(5-14-12(11)16)8-1-3-10(17)4-2-8/h1-7,17H
DML5NF6	CS	C1=CC(=CC=C1C2=CN3C(=C(C=N3)Br)N=C2)O
DML5NF6	IK	XBHIAJWNXVJSAA-UHFFFAOYSA-N
DML5NF6	IU	4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol
DML5NF6	CA	CAS 945376-95-4
DML5NF6	DE	Discovery agent

DMQVXMZ	ID	DMQVXMZ
DMQVXMZ	DN	4-(3-chlorobenzylthio)-2-aminobutanoic acid
DMQVXMZ	HS	Investigative
DMQVXMZ	SN	CHEMBL203616; 4-(3-chlorobenzylthio)-2-aminobutanoic acid; BDBM50179722
DMQVXMZ	DT	Small molecular drug
DMQVXMZ	PC	44408320
DMQVXMZ	MW	259.75
DMQVXMZ	FM	C11H14ClNO2S
DMQVXMZ	IC	InChI=1S/C11H14ClNO2S/c12-9-3-1-2-8(6-9)7-16-5-4-10(13)11(14)15/h1-3,6,10H,4-5,7,13H2,(H,14,15)
DMQVXMZ	CS	C1=CC(=CC(=C1)Cl)CSCCC(C(=O)O)N
DMQVXMZ	IK	CHLGWHKXVGUGBH-UHFFFAOYSA-N
DMQVXMZ	IU	2-amino-4-[(3-chlorophenyl)methylsulfanyl]butanoic acid
DMQVXMZ	DE	Discovery agent

DMDS2LZ	ID	DMDS2LZ
DMDS2LZ	DN	4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline
DMDS2LZ	HS	Investigative
DMDS2LZ	SN	CHEMBL135853; 4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline; SCHEMBL6182199; XDUSWBSGDKRQAF-UHFFFAOYSA-N; BDBM50291080
DMDS2LZ	DT	Small molecular drug
DMDS2LZ	PC	9948853
DMDS2LZ	MW	316.74
DMDS2LZ	FM	C16H13ClN2O3
DMDS2LZ	IC	InChI=1S/C16H13ClN2O3/c1-20-14-7-12-13(8-15(14)21-2)18-9-19-16(12)22-11-5-3-4-10(17)6-11/h3-9H,1-2H3
DMDS2LZ	CS	COC1=C(C=C2C(=C1)C(=NC=N2)OC3=CC(=CC=C3)Cl)OC
DMDS2LZ	IK	XDUSWBSGDKRQAF-UHFFFAOYSA-N
DMDS2LZ	IU	4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline
DMDS2LZ	DE	Discovery agent

DMDTFKL	ID	DMDTFKL
DMDTFKL	DN	4-(3-chlorophenylethynyl)-2-methylthiazole
DMDTFKL	HS	Investigative
DMDTFKL	SN	CHEMBL202124; 4-(3-chlorophenylethynyl)-2-methylthiazole; SCHEMBL4153004
DMDTFKL	DT	Small molecular drug
DMDTFKL	PC	11701423
DMDTFKL	MW	233.72
DMDTFKL	FM	C12H8ClNS
DMDTFKL	IC	InChI=1S/C12H8ClNS/c1-9-14-12(8-15-9)6-5-10-3-2-4-11(13)7-10/h2-4,7-8H,1H3
DMDTFKL	CS	CC1=NC(=CS1)C#CC2=CC(=CC=C2)Cl
DMDTFKL	IK	ORFSHDWOPQJKQL-UHFFFAOYSA-N
DMDTFKL	IU	4-[2-(3-chlorophenyl)ethynyl]-2-methyl-1,3-thiazole
DMDTFKL	DE	Discovery agent

DMJH2OE	ID	DMJH2OE
DMJH2OE	DN	4-(3-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine
DMJH2OE	HS	Investigative
DMJH2OE	SN	4-(3-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine; CHEMBL208781; SCHEMBL6507354; BDBM50182809
DMJH2OE	DT	Small molecular drug
DMJH2OE	PC	11460771
DMJH2OE	MW	299.8
DMJH2OE	FM	C15H10ClN3S
DMJH2OE	IC	InChI=1S/C15H10ClN3S/c16-11-4-3-5-12(10-11)20-14-7-9-18-15(19-14)13-6-1-2-8-17-13/h1-10H
DMJH2OE	CS	C1=CC=NC(=C1)C2=NC=CC(=N2)SC3=CC(=CC=C3)Cl
DMJH2OE	IK	UISOVRMNRPVABO-UHFFFAOYSA-N
DMJH2OE	IU	4-(3-chlorophenyl)sulfanyl-2-pyridin-2-ylpyrimidine
DMJH2OE	DE	Discovery agent

DMSUB8D	ID	DMSUB8D
DMSUB8D	DN	4-(3-cyanobenzylthio)-2-aminobutanoic acid
DMSUB8D	HS	Investigative
DMSUB8D	SN	CHEMBL380507; 4-(3-cyanobenzylthio)-2-aminobutanoic acid; BDBM50179730
DMSUB8D	DT	Small molecular drug
DMSUB8D	PC	44408229
DMSUB8D	MW	250.32
DMSUB8D	FM	C12H14N2O2S
DMSUB8D	IC	InChI=1S/C12H14N2O2S/c13-7-9-2-1-3-10(6-9)8-17-5-4-11(14)12(15)16/h1-3,6,11H,4-5,8,14H2,(H,15,16)
DMSUB8D	CS	C1=CC(=CC(=C1)C#N)CSCCC(C(=O)O)N
DMSUB8D	IK	HDBDOMDCBCMSJT-UHFFFAOYSA-N
DMSUB8D	IU	2-amino-4-[(3-cyanophenyl)methylsulfanyl]butanoic acid
DMSUB8D	DE	Discovery agent

DMXFLMK	ID	DMXFLMK
DMXFLMK	DN	4-(3-cyclohexylureido)butanoic acid
DMXFLMK	HS	Investigative
DMXFLMK	SN	4-{[(Cyclohexylamino)carbonyl]amino}butanoic acid; 4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID; 4-[(cyclohexylcarbamoyl)amino]butanoic acid; 511552-46-8; 4-(3-Cyclohexyl-ureido)-butyric acid; CHEMBL219695; 4-([(Cyclohexylamino)carbonyl]amino)butanoic acid; 4-(3-CYCLOHEXYLURIEDO)-BUTYRIC ACID; NC4; 1zd3; AC1O4WJY; AC1Q75I7; SCHEMBL1065092; WSVFRGGLURJIMG-UHFFFAOYSA-N; MolPort-004-290-136; HMS3604L06; ZINC8754389; BDBM50192936; AKOS000125413; 4-(3-cyclohexylur-eido)-butyric acid; NE13821; MCULE-1918218076; DB08257
DMXFLMK	DT	Small molecular drug
DMXFLMK	PC	6420119
DMXFLMK	MW	228.29
DMXFLMK	FM	C11H20N2O3
DMXFLMK	IC	InChI=1S/C11H20N2O3/c14-10(15)7-4-8-12-11(16)13-9-5-2-1-3-6-9/h9H,1-8H2,(H,14,15)(H2,12,13,16)
DMXFLMK	CS	C1CCC(CC1)NC(=O)NCCCC(=O)O
DMXFLMK	IK	WSVFRGGLURJIMG-UHFFFAOYSA-N
DMXFLMK	IU	4-(cyclohexylcarbamoylamino)butanoic acid
DMXFLMK	DE	Discovery agent

DMOQE5W	ID	DMOQE5W
DMOQE5W	DN	4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline
DMOQE5W	HS	Investigative
DMOQE5W	SN	CHEMBL98169; 4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline
DMOQE5W	DT	Small molecular drug
DMOQE5W	PC	44331209
DMOQE5W	MW	325.4
DMOQE5W	FM	C19H19NO4
DMOQE5W	IC	InChI=1S/C19H19NO4/c1-4-23-13-6-5-7-14(10-13)24-17-8-9-20-16-12-19(22-3)18(21-2)11-15(16)17/h5-12H,4H2,1-3H3
DMOQE5W	CS	CCOC1=CC(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMOQE5W	IK	PKUBIFVLLLNKCO-UHFFFAOYSA-N
DMOQE5W	IU	4-(3-ethoxyphenoxy)-6,7-dimethoxyquinoline
DMOQE5W	DE	Discovery agent

DMFM9SH	ID	DMFM9SH
DMFM9SH	DN	4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline
DMFM9SH	HS	Investigative
DMFM9SH	SN	CHEMBL100765; 4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline
DMFM9SH	DT	Small molecular drug
DMFM9SH	PC	44331127
DMFM9SH	MW	309.4
DMFM9SH	FM	C19H19NO3
DMFM9SH	IC	InChI=1S/C19H19NO3/c1-4-13-6-5-7-14(10-13)23-17-8-9-20-16-12-19(22-3)18(21-2)11-15(16)17/h5-12H,4H2,1-3H3
DMFM9SH	CS	CCC1=CC(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMFM9SH	IK	BXXFKNUQXUJVKP-UHFFFAOYSA-N
DMFM9SH	IU	4-(3-ethylphenoxy)-6,7-dimethoxyquinoline
DMFM9SH	DE	Discovery agent

DM1C3NZ	ID	DM1C3NZ
DM1C3NZ	DN	4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ	HS	Investigative
DM1C3NZ	SN	CHEMBL583751; 4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ	DT	Small molecular drug
DM1C3NZ	PC	45483459
DM1C3NZ	MW	271.33
DM1C3NZ	FM	C17H18FNO
DM1C3NZ	IC	InChI=1S/C17H18FNO/c18-16-8-4-7-15(13-9-11-19-12-10-13)17(16)20-14-5-2-1-3-6-14/h1-8,13,19H,9-12H2
DM1C3NZ	CS	C1CNCCC1C2=C(C(=CC=C2)F)OC3=CC=CC=C3
DM1C3NZ	IK	WWIFVPBPYYVHTD-UHFFFAOYSA-N
DM1C3NZ	IU	4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ	DE	Discovery agent

DMXLC94	ID	DMXLC94
DMXLC94	DN	4-(3-fluorobenzylthio)-2-aminobutanoic acid
DMXLC94	HS	Investigative
DMXLC94	SN	CHEMBL204611; 4-(3-fluorobenzylthio)-2-aminobutanoic acid; BDBM50179707
DMXLC94	DT	Small molecular drug
DMXLC94	PC	44408322
DMXLC94	MW	243.3
DMXLC94	FM	C11H14FNO2S
DMXLC94	IC	InChI=1S/C11H14FNO2S/c12-9-3-1-2-8(6-9)7-16-5-4-10(13)11(14)15/h1-3,6,10H,4-5,7,13H2,(H,14,15)
DMXLC94	CS	C1=CC(=CC(=C1)F)CSCCC(C(=O)O)N
DMXLC94	IK	BWUFBZIPJLPDQV-UHFFFAOYSA-N
DMXLC94	IU	2-amino-4-[(3-fluorophenyl)methylsulfanyl]butanoic acid
DMXLC94	DE	Discovery agent

DMER3D9	ID	DMER3D9
DMER3D9	DN	4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline
DMER3D9	HS	Investigative
DMER3D9	SN	CHEMBL102191; 4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline; SCHEMBL7490337; LQOBRLFNSGKIFO-UHFFFAOYSA-N; BDBM50290841
DMER3D9	DT	Small molecular drug
DMER3D9	PC	22132626
DMER3D9	MW	299.3
DMER3D9	FM	C17H14FNO3
DMER3D9	IC	InChI=1S/C17H14FNO3/c1-20-16-9-13-14(10-17(16)21-2)19-7-6-15(13)22-12-5-3-4-11(18)8-12/h3-10H,1-2H3
DMER3D9	CS	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC(=CC=C3)F
DMER3D9	IK	LQOBRLFNSGKIFO-UHFFFAOYSA-N
DMER3D9	IU	4-(3-fluorophenoxy)-6,7-dimethoxyquinoline
DMER3D9	DE	Discovery agent

DM6RV9L	ID	DM6RV9L
DM6RV9L	DN	4-(3-fluorophenylethynyl)-2-thiazolylamine
DM6RV9L	HS	Investigative
DM6RV9L	SN	4-(3-fluorophenylethynyl)-2-thiazolylamine; CHEMBL370559; 878018-65-6; SCHEMBL4140841
DM6RV9L	DT	Small molecular drug
DM6RV9L	PC	11629906
DM6RV9L	MW	218.25
DM6RV9L	FM	C11H7FN2S
DM6RV9L	IC	InChI=1S/C11H7FN2S/c12-9-3-1-2-8(6-9)4-5-10-7-15-11(13)14-10/h1-3,6-7H,(H2,13,14)
DM6RV9L	CS	C1=CC(=CC(=C1)F)C#CC2=CSC(=N2)N
DM6RV9L	IK	XTUCFPVDIBJRML-UHFFFAOYSA-N
DM6RV9L	IU	4-[2-(3-fluorophenyl)ethynyl]-1,3-thiazol-2-amine
DM6RV9L	DE	Discovery agent

DMZ1TNM	ID	DMZ1TNM
DMZ1TNM	DN	4-(3'-furyl)-aniline
DMZ1TNM	HS	Investigative
DMZ1TNM	SN	Benzenamine, 4-(3-furanyl)-; 4-(furan-3-yl)aniline; 4-furan-3-yl-phenylamine; CHEMBL374967; SCHEMBL1016530; NSKKXDBWURWAOW-UHFFFAOYSA-N; AKOS013265082
DMZ1TNM	DT	Small molecular drug
DMZ1TNM	PC	44420988
DMZ1TNM	MW	159.18
DMZ1TNM	FM	C10H9NO
DMZ1TNM	IC	InChI=1S/C10H9NO/c11-10-3-1-8(2-4-10)9-5-6-12-7-9/h1-7H,11H2
DMZ1TNM	CS	C1=CC(=CC=C1C2=COC=C2)N
DMZ1TNM	IK	NSKKXDBWURWAOW-UHFFFAOYSA-N
DMZ1TNM	IU	4-(furan-3-yl)aniline
DMZ1TNM	CA	CAS 936249-47-7
DMZ1TNM	DE	Discovery agent

DMC5GAW	ID	DMC5GAW
DMC5GAW	DN	4-(3-hexylureido)-N-phenylbenzenesulfonamide
DMC5GAW	HS	Investigative
DMC5GAW	SN	CHEMBL1077716; 4-(3-hexylureido)-N-phenylbenzenesulfonamide
DMC5GAW	DT	Small molecular drug
DMC5GAW	PC	46882764
DMC5GAW	MW	375.5
DMC5GAW	FM	C19H25N3O3S
DMC5GAW	IC	InChI=1S/C19H25N3O3S/c1-2-3-4-8-15-20-19(23)21-16-11-13-18(14-12-16)26(24,25)22-17-9-6-5-7-10-17/h5-7,9-14,22H,2-4,8,15H2,1H3,(H2,20,21,23)
DMC5GAW	CS	CCCCCCNC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2
DMC5GAW	IK	ADKICSRVDIFTQJ-UHFFFAOYSA-N
DMC5GAW	IU	1-hexyl-3-[4-(phenylsulfamoyl)phenyl]urea
DMC5GAW	DE	Discovery agent

DM3QJVT	ID	DM3QJVT
DM3QJVT	DN	4-(3H-Inden-1-ylmethyl)-phenylamine
DM3QJVT	HS	Investigative
DM3QJVT	SN	CHEMBL371048; 4-(3H-Inden-1-ylmethyl)-phenylamine
DM3QJVT	DT	Small molecular drug
DM3QJVT	PC	44401549
DM3QJVT	MW	221.3
DM3QJVT	FM	C16H15N
DM3QJVT	IC	InChI=1S/C16H15N/c17-15-9-5-12(6-10-15)11-14-8-7-13-3-1-2-4-16(13)14/h1-6,8-10H,7,11,17H2
DM3QJVT	CS	C1C=C(C2=CC=CC=C21)CC3=CC=C(C=C3)N
DM3QJVT	IK	IJBWRSORBVHQFX-UHFFFAOYSA-N
DM3QJVT	IU	4-(3H-inden-1-ylmethyl)aniline
DM3QJVT	DE	Discovery agent

DMM8AY5	ID	DMM8AY5
DMM8AY5	DN	4-(3H-indol-4-ylamino)-5-styrylnicotinonitrile
DMM8AY5	HS	Investigative
DMM8AY5	DT	Small molecular drug
DMM8AY5	PC	68447853
DMM8AY5	MW	336.4
DMM8AY5	FM	C22H16N4
DMM8AY5	IC	InChI=1S/C22H16N4/c23-13-18-15-24-14-17(10-9-16-5-2-1-3-6-16)22(18)26-21-8-4-7-20-19(21)11-12-25-20/h1-12,14-15,25H,(H,24,26)/b10-9+
DMM8AY5	CS	C1=CC=C(C=C1)/C=C/C2=CN=CC(=C2NC3=CC=CC4=C3C=CN4)C#N
DMM8AY5	IK	HETWGNHMXYNQPB-MDZDMXLPSA-N
DMM8AY5	IU	4-(1H-indol-4-ylamino)-5-[(E)-2-phenylethenyl]pyridine-3-carbonitrile
DMM8AY5	DE	Discovery agent

DMY2OVL	ID	DMY2OVL
DMY2OVL	DN	4-(3-hydroxy-benzylideneamino)-benzenesulfonamide
DMY2OVL	HS	Investigative
DMY2OVL	SN	CHEMBL270243; 66667-57-0; NSC722923; AC1L8PAB; CBDivE_016053; 4-[(3-hydroxyphenyl)methylideneamino]benzenesulfonamide; CTK1H9643; CTK7J9950; DTXSID20328076; BDBM50371761; AKOS030585458; MCULE-4187647437; NSC-722923; SR-01000199564; SR-01000199564-1; 4-[(3-Hydroxy-benzylidene)-amino]-benzenesulfonamide; Benzenesulfonamide, 4-[[(3-hydroxyphenyl)methylene]amino]-
DMY2OVL	DT	Small molecular drug
DMY2OVL	PC	405560
DMY2OVL	MW	276.31
DMY2OVL	FM	C13H12N2O3S
DMY2OVL	IC	InChI=1S/C13H12N2O3S/c14-19(17,18)13-6-4-11(5-7-13)15-9-10-2-1-3-12(16)8-10/h1-9,16H,(H2,14,17,18)
DMY2OVL	CS	C1=CC(=CC(=C1)O)C=NC2=CC=C(C=C2)S(=O)(=O)N
DMY2OVL	IK	FNUVWCBUDJAFOI-UHFFFAOYSA-N
DMY2OVL	IU	4-[(3-hydroxyphenyl)methylideneamino]benzenesulfonamide
DMY2OVL	CA	CAS 66667-57-0
DMY2OVL	DE	Discovery agent

DMUQWJZ	ID	DMUQWJZ
DMUQWJZ	DN	4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol
DMUQWJZ	HS	Investigative
DMUQWJZ	SN	CHEMBL7278; 100112-61-6; 1,2-benzenediol,4-(3-hydroxy-3-piperidinyl)-; 4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(3-hydroxy-3-piperidinyl)-; CTK8G4032; BDBM50000496; AKOS022649735; 3-(3,4-Dihydroxyphenyl)piperidin-3-ol
DMUQWJZ	DT	Small molecular drug
DMUQWJZ	PC	11820398
DMUQWJZ	MW	209.24
DMUQWJZ	FM	C11H15NO3
DMUQWJZ	IC	InChI=1S/C11H15NO3/c13-9-3-2-8(6-10(9)14)11(15)4-1-5-12-7-11/h2-3,6,12-15H,1,4-5,7H2
DMUQWJZ	CS	C1CC(CNC1)(C2=CC(=C(C=C2)O)O)O
DMUQWJZ	IK	REBGJGKBMBFBHE-UHFFFAOYSA-N
DMUQWJZ	IU	4-(3-hydroxypiperidin-3-yl)benzene-1,2-diol
DMUQWJZ	DE	Discovery agent

DMO8SQA	ID	DMO8SQA
DMO8SQA	DN	4-(3-methoxy-benzylideneamino)-benzenesulfonamide
DMO8SQA	HS	Investigative
DMO8SQA	SN	CHEMBL271930; NSC720589; AC1L8N6O; CTK7A8689; BDBM50371745; NSC-720589; 4-[(3-Methoxy-benzylidene)-amino]-benzenesulfonamide; 4-[(3-methoxyphenyl)methylideneamino]benzenesulfonamide
DMO8SQA	DT	Small molecular drug
DMO8SQA	PC	404378
DMO8SQA	MW	290.34
DMO8SQA	FM	C14H14N2O3S
DMO8SQA	IC	InChI=1S/C14H14N2O3S/c1-19-13-4-2-3-11(9-13)10-16-12-5-7-14(8-6-12)20(15,17)18/h2-10H,1H3,(H2,15,17,18)
DMO8SQA	CS	COC1=CC=CC(=C1)C=NC2=CC=C(C=C2)S(=O)(=O)N
DMO8SQA	IK	PMXSUWQVMRZMRV-UHFFFAOYSA-N
DMO8SQA	IU	4-[(3-methoxyphenyl)methylideneamino]benzenesulfonamide
DMO8SQA	DE	Discovery agent

DMTPL0C	ID	DMTPL0C
DMTPL0C	DN	4-(3-methoxybenzylthio)-2-aminobutanoic acid
DMTPL0C	HS	Investigative
DMTPL0C	SN	CHEMBL204963; 4-(3-methoxybenzylthio)-2-aminobutanoic acid; BDBM50179714
DMTPL0C	DT	Small molecular drug
DMTPL0C	PC	44408325
DMTPL0C	MW	255.34
DMTPL0C	FM	C12H17NO3S
DMTPL0C	IC	InChI=1S/C12H17NO3S/c1-16-10-4-2-3-9(7-10)8-17-6-5-11(13)12(14)15/h2-4,7,11H,5-6,8,13H2,1H3,(H,14,15)
DMTPL0C	CS	COC1=CC=CC(=C1)CSCCC(C(=O)O)N
DMTPL0C	IK	WAUOPBRKRQFQTA-UHFFFAOYSA-N
DMTPL0C	IU	2-amino-4-[(3-methoxyphenyl)methylsulfanyl]butanoic acid
DMTPL0C	DE	Discovery agent

DMSUFJZ	ID	DMSUFJZ
DMSUFJZ	DN	4-(3-Methoxy-phenyl)-isoxazolidine-3,5-dione
DMSUFJZ	HS	Investigative
DMSUFJZ	SN	3,5-Isoxazolidinedione, 4-(3-methoxyphenyl)-; CHEMBL165286
DMSUFJZ	DT	Small molecular drug
DMSUFJZ	PC	12762411
DMSUFJZ	MW	207.18
DMSUFJZ	FM	C10H9NO4
DMSUFJZ	IC	InChI=1S/C10H9NO4/c1-14-7-4-2-3-6(5-7)8-9(12)11-15-10(8)13/h2-5,8H,1H3,(H,11,12)
DMSUFJZ	CS	COC1=CC=CC(=C1)C2C(=O)NOC2=O
DMSUFJZ	IK	GTLJNZXLCZDZRN-UHFFFAOYSA-N
DMSUFJZ	IU	4-(3-methoxyphenyl)-1,2-oxazolidine-3,5-dione
DMSUFJZ	DE	Discovery agent

DMGCPKU	ID	DMGCPKU
DMGCPKU	DN	4-(3-methoxyphenylethynyl)-2-methylthiazole
DMGCPKU	HS	Investigative
DMGCPKU	SN	CHEMBL440220; 4-(3-methoxyphenylethynyl)-2-methylthiazole; Thiazole, 4-[2-(3-methoxyphenyl)ethynyl]-2-methyl-; SCHEMBL4150915; BDBM50181739
DMGCPKU	DT	Small molecular drug
DMGCPKU	PC	11564861
DMGCPKU	MW	229.3
DMGCPKU	FM	C13H11NOS
DMGCPKU	IC	InChI=1S/C13H11NOS/c1-10-14-12(9-16-10)7-6-11-4-3-5-13(8-11)15-2/h3-5,8-9H,1-2H3
DMGCPKU	CS	CC1=NC(=CS1)C#CC2=CC(=CC=C2)OC
DMGCPKU	IK	OFMNNPTVFPHRMM-UHFFFAOYSA-N
DMGCPKU	IU	4-[2-(3-methoxyphenyl)ethynyl]-2-methyl-1,3-thiazole
DMGCPKU	DE	Discovery agent

DM67A4U	ID	DM67A4U
DM67A4U	DN	4-(3-Methyl-indole-1-sulfonyl)-phenylamine
DM67A4U	HS	Investigative
DM67A4U	SN	CHEMBL328816; SCHEMBL14642142; BDBM34150; n1-(4-aminobenzenesulfonyl)skatole; N-arenesulfonylindole antagonist, 9; 4-(3-methyl-1H-indole-1-sulfonyl)aniline, 8
DM67A4U	DT	Small molecular drug
DM67A4U	PC	10356663
DM67A4U	MW	286.4
DM67A4U	FM	C15H14N2O2S
DM67A4U	IC	InChI=1S/C15H14N2O2S/c1-11-10-17(15-5-3-2-4-14(11)15)20(18,19)13-8-6-12(16)7-9-13/h2-10H,16H2,1H3
DM67A4U	CS	CC1=CN(C2=CC=CC=C12)S(=O)(=O)C3=CC=C(C=C3)N
DM67A4U	IK	ZNRJXSHXWJKTGJ-UHFFFAOYSA-N
DM67A4U	IU	4-(3-methylindol-1-yl)sulfonylaniline
DM67A4U	DE	Discovery agent

DM5I6O2	ID	DM5I6O2
DM5I6O2	DN	4-(3-methylpyridin-2-yl)-N-p-tolylbenzamide
DM5I6O2	HS	Investigative
DM5I6O2	SN	CHEMBL215015; 4-(3-methylpyridin-2-yl)-N-p-tolylbenzamide
DM5I6O2	DT	Small molecular drug
DM5I6O2	PC	44416783
DM5I6O2	MW	302.4
DM5I6O2	FM	C20H18N2O
DM5I6O2	IC	InChI=1S/C20H18N2O/c1-14-5-11-18(12-6-14)22-20(23)17-9-7-16(8-10-17)19-15(2)4-3-13-21-19/h3-13H,1-2H3,(H,22,23)
DM5I6O2	CS	CC1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)C3=C(C=CC=N3)C
DM5I6O2	IK	ACHPKRXTLZWRLG-UHFFFAOYSA-N
DM5I6O2	IU	N-(4-methylphenyl)-4-(3-methylpyridin-2-yl)benzamide
DM5I6O2	DE	Discovery agent

DMD94OB	ID	DMD94OB
DMD94OB	DN	4-(3-nitro-benzylideneamino)-benzenesulfonamide
DMD94OB	HS	Investigative
DMD94OB	SN	CHEMBL404921; BDBM50371766; AKOS003620777
DMD94OB	DT	Small molecular drug
DMD94OB	PC	21177358
DMD94OB	MW	305.31
DMD94OB	FM	C13H11N3O4S
DMD94OB	IC	InChI=1S/C13H11N3O4S/c14-21(19,20)13-6-4-11(5-7-13)15-9-10-2-1-3-12(8-10)16(17)18/h1-9H,(H2,14,19,20)
DMD94OB	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C=NC2=CC=C(C=C2)S(=O)(=O)N
DMD94OB	IK	QDRKXDMYDRNCDI-UHFFFAOYSA-N
DMD94OB	IU	4-[(3-nitrophenyl)methylideneamino]benzenesulfonamide
DMD94OB	DE	Discovery agent

DM4WI0Y	ID	DM4WI0Y
DM4WI0Y	DN	4-(3-nitrobenzylthio)-2-aminobutanoic acid
DM4WI0Y	HS	Investigative
DM4WI0Y	SN	CHEMBL204478; 4-(3-nitrobenzylthio)-2-aminobutanoic acid; BDBM50179690
DM4WI0Y	DT	Small molecular drug
DM4WI0Y	PC	44408227
DM4WI0Y	MW	270.31
DM4WI0Y	FM	C11H14N2O4S
DM4WI0Y	IC	InChI=1S/C11H14N2O4S/c12-10(11(14)15)4-5-18-7-8-2-1-3-9(6-8)13(16)17/h1-3,6,10H,4-5,7,12H2,(H,14,15)
DM4WI0Y	CS	C1=CC(=CC(=C1)[N+](=O)[O-])CSCCC(C(=O)O)N
DM4WI0Y	IK	OLFRZJABCSLPAK-UHFFFAOYSA-N
DM4WI0Y	IU	2-amino-4-[(3-nitrophenyl)methylsulfanyl]butanoic acid
DM4WI0Y	DE	Discovery agent

DMEYV1B	ID	DMEYV1B
DMEYV1B	DN	4-(3-Pent-1-ynyl-benzyl)-1H-imidazole
DMEYV1B	HS	Investigative
DMEYV1B	SN	CHEMBL451399; BDBM22540; 4-Benzyl-1H-imidazole derivative, 21
DMEYV1B	DT	Small molecular drug
DMEYV1B	PC	24825518
DMEYV1B	MW	224.3
DMEYV1B	FM	C15H16N2
DMEYV1B	IC	InChI=1S/C15H16N2/c1-2-3-4-6-13-7-5-8-14(9-13)10-15-11-16-12-17-15/h5,7-9,11-12H,2-3,10H2,1H3,(H,16,17)
DMEYV1B	CS	CCCC#CC1=CC=CC(=C1)CC2=CN=CN2
DMEYV1B	IK	JAPGJDHRYBFKBD-UHFFFAOYSA-N
DMEYV1B	IU	5-[(3-pent-1-ynylphenyl)methyl]-1H-imidazole
DMEYV1B	DE	Discovery agent

DMSXG23	ID	DMSXG23
DMSXG23	DN	4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole
DMSXG23	HS	Investigative
DMSXG23	SN	CHEMBL428206; 4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969160; CTK8F9477; BDBM50200766
DMSXG23	DT	Small molecular drug
DMSXG23	PC	16216595
DMSXG23	MW	262.27
DMSXG23	FM	C15H10N4O
DMSXG23	IC	InChI=1S/C15H10N4O/c16-10-14-15(18-19-17-14)11-6-8-13(9-7-11)20-12-4-2-1-3-5-12/h1-9H,(H,17,18,19)
DMSXG23	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=NNN=C3C#N
DMSXG23	IK	LHOBXXROLCTUBM-UHFFFAOYSA-N
DMSXG23	IU	5-(4-phenoxyphenyl)-2H-triazole-4-carbonitrile
DMSXG23	DE	Discovery agent

DM5F13I	ID	DM5F13I
DM5F13I	DN	4-(3-Phenoxy-propyl)-1H-imidazole
DM5F13I	HS	Investigative
DM5F13I	SN	CHEMBL112951; CHEMBL128923; 4-(3-Phenoxypropyl)-1H-imidazole; BDBM50092833; 4-(3-Phenoxy-propyl)-1H-imidazole with (0.95M)oxalic acid
DM5F13I	DT	Small molecular drug
DM5F13I	PC	10774476
DM5F13I	MW	202.25
DM5F13I	FM	C12H14N2O
DM5F13I	IC	InChI=1S/C12H14N2O/c1-2-6-12(7-3-1)15-8-4-5-11-9-13-10-14-11/h1-3,6-7,9-10H,4-5,8H2,(H,13,14)
DM5F13I	CS	C1=CC=C(C=C1)OCCCC2=CN=CN2
DM5F13I	IK	DOOCQHQHBHNOGX-UHFFFAOYSA-N
DM5F13I	IU	5-(3-phenoxypropyl)-1H-imidazole
DM5F13I	DE	Discovery agent

DMEJF6V	ID	DMEJF6V
DMEJF6V	DN	4-(3-phenyl-1H-indol-2-yl)phenol
DMEJF6V	HS	Investigative
DMEJF6V	SN	CHEMBL199766; 4-(3-phenyl-1H-indol-2-yl)phenol; SCHEMBL7040440; BDBM50175418
DMEJF6V	DT	Small molecular drug
DMEJF6V	PC	44405867
DMEJF6V	MW	285.3
DMEJF6V	FM	C20H15NO
DMEJF6V	IC	InChI=1S/C20H15NO/c22-16-12-10-15(11-13-16)20-19(14-6-2-1-3-7-14)17-8-4-5-9-18(17)21-20/h1-13,21-22H
DMEJF6V	CS	C1=CC=C(C=C1)C2=C(NC3=CC=CC=C32)C4=CC=C(C=C4)O
DMEJF6V	IK	HRWBDGGFCFVAHP-UHFFFAOYSA-N
DMEJF6V	IU	4-(3-phenyl-1H-indol-2-yl)phenol
DMEJF6V	DE	Discovery agent

DMS4JVT	ID	DMS4JVT
DMS4JVT	DN	4-(3-Phenylethynyl-benzyl)-1H-imidazole
DMS4JVT	HS	Investigative
DMS4JVT	SN	CHEMBL449840; BDBM22538; 4-Benzyl-1H-imidazole derivative, 19
DMS4JVT	DT	Small molecular drug
DMS4JVT	PC	24825516
DMS4JVT	MW	258.3
DMS4JVT	FM	C18H14N2
DMS4JVT	IC	InChI=1S/C18H14N2/c1-2-5-15(6-3-1)9-10-16-7-4-8-17(11-16)12-18-13-19-14-20-18/h1-8,11,13-14H,12H2,(H,19,20)
DMS4JVT	CS	C1=CC=C(C=C1)C#CC2=CC=CC(=C2)CC3=CN=CN3
DMS4JVT	IK	VIPAIZRIFZFESY-UHFFFAOYSA-N
DMS4JVT	IU	5-[[3-(2-phenylethynyl)phenyl]methyl]-1H-imidazole
DMS4JVT	DE	Discovery agent

DMRXKMP	ID	DMRXKMP
DMRXKMP	DN	4-(3-pyridylethynyl)-2-thiazolylamine
DMRXKMP	HS	Investigative
DMRXKMP	SN	4-(3-pyridylethynyl)-2-thiazolylamine; CHEMBL381031; 329205-54-1; SCHEMBL4158461
DMRXKMP	DT	Small molecular drug
DMRXKMP	PC	11564671
DMRXKMP	MW	201.25
DMRXKMP	FM	C10H7N3S
DMRXKMP	IC	InChI=1S/C10H7N3S/c11-10-13-9(7-14-10)4-3-8-2-1-5-12-6-8/h1-2,5-7H,(H2,11,13)
DMRXKMP	CS	C1=CC(=CN=C1)C#CC2=CSC(=N2)N
DMRXKMP	IK	BQUGCIBMYSKXRH-UHFFFAOYSA-N
DMRXKMP	IU	4-(2-pyridin-3-ylethynyl)-1,3-thiazol-2-amine
DMRXKMP	DE	Discovery agent

DML4NJU	ID	DML4NJU
DML4NJU	DN	4-(3-thienyl)benzene-1,2-diamine)
DML4NJU	HS	Investigative
DML4NJU	SN	SCHEMBL3568658
DML4NJU	DT	Small molecular drug
DML4NJU	PC	13007806
DML4NJU	MW	190.27
DML4NJU	FM	C10H10N2S
DML4NJU	IC	InChI=1S/C10H10N2S/c11-9-2-1-7(5-10(9)12)8-3-4-13-6-8/h1-6H,11-12H2
DML4NJU	CS	C1=CC(=C(C=C1C2=CSC=C2)N)N
DML4NJU	IK	OZEWMDJTNVDPJN-UHFFFAOYSA-N
DML4NJU	IU	4-thiophen-3-ylbenzene-1,2-diamine
DML4NJU	DE	Discovery agent

DM0QRJ3	ID	DM0QRJ3
DM0QRJ3	DN	4-(4-((phenethylamino)methyl)phenoxy)benzamide
DM0QRJ3	HS	Investigative
DM0QRJ3	SN	CHEMBL238317; 4-(4-((phenethylamino)methyl)phenoxy)benzamide; SCHEMBL3692341; FARQYUHOSNLRKV-UHFFFAOYSA-N; BDBM50219921
DM0QRJ3	DT	Small molecular drug
DM0QRJ3	PC	44434950
DM0QRJ3	MW	346.4
DM0QRJ3	FM	C22H22N2O2
DM0QRJ3	IC	InChI=1S/C22H22N2O2/c23-22(25)19-8-12-21(13-9-19)26-20-10-6-18(7-11-20)16-24-15-14-17-4-2-1-3-5-17/h1-13,24H,14-16H2,(H2,23,25)
DM0QRJ3	CS	C1=CC=C(C=C1)CCNCC2=CC=C(C=C2)OC3=CC=C(C=C3)C(=O)N
DM0QRJ3	IK	FARQYUHOSNLRKV-UHFFFAOYSA-N
DM0QRJ3	IU	4-[4-[(2-phenylethylamino)methyl]phenoxy]benzamide
DM0QRJ3	DE	Discovery agent

DMWBVMH	ID	DMWBVMH
DMWBVMH	DN	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid
DMWBVMH	HS	Investigative
DMWBVMH	SN	CHEMBL76958; 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid
DMWBVMH	DT	Small molecular drug
DMWBVMH	PC	14862522
DMWBVMH	MW	349.3
DMWBVMH	FM	C15H11NO7S
DMWBVMH	IC	InChI=1S/C15H11NO7S/c17-15(18)12-3-7-14(8-4-12)24(21,22)23-13-5-1-11(2-6-13)9-10-16(19)20/h1-10H,(H,17,18)/b10-9+
DMWBVMH	CS	C1=CC(=CC=C1/C=C/[N+](=O)[O-])OS(=O)(=O)C2=CC=C(C=C2)C(=O)O
DMWBVMH	IK	JJLJZGDGOYIKBT-MDZDMXLPSA-N
DMWBVMH	IU	4-[4-[(E)-2-nitroethenyl]phenoxy]sulfonylbenzoic acid
DMWBVMH	DE	Discovery agent

DMA9TCD	ID	DMA9TCD
DMA9TCD	DN	4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol
DMA9TCD	HS	Investigative
DMA9TCD	SN	4-{[4-(4-nitrophenyl)-1,3-thiazol-2-yl]amino}phenol; CHEMBL559270; BDBM91658; ZINC36627530; STL255714; AKOS002279368; MCULE-8884798678; N-aryl-4-aryl-1,3-thiazole-2-amine, 6
DMA9TCD	DT	Small molecular drug
DMA9TCD	PC	16645659
DMA9TCD	MW	313.3
DMA9TCD	FM	C15H11N3O3S
DMA9TCD	IC	InChI=1S/C15H11N3O3S/c19-13-7-3-11(4-8-13)16-15-17-14(9-22-15)10-1-5-12(6-2-10)18(20)21/h1-9,19H,(H,16,17)
DMA9TCD	CS	C1=CC(=CC=C1C2=CSC(=N2)NC3=CC=C(C=C3)O)[N+](=O)[O-]
DMA9TCD	IK	PXYPXTOUOYAWOU-UHFFFAOYSA-N
DMA9TCD	IU	4-[[4-(4-nitrophenyl)-1,3-thiazol-2-yl]amino]phenol
DMA9TCD	DE	Discovery agent

DM6KIG0	ID	DM6KIG0
DM6KIG0	DN	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid
DM6KIG0	HS	Investigative
DM6KIG0	SN	CHEMBL373275; 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid; BDBM50180608
DM6KIG0	DT	Small molecular drug
DM6KIG0	PC	44406790
DM6KIG0	MW	314.4
DM6KIG0	FM	C20H26O3
DM6KIG0	IC	InChI=1S/C20H26O3/c1-2-3-4-5-6-7-8-9-10-17-11-13-18(14-12-17)19(21)15-16-20(22)23/h11-14H,2-8,15-16H2,1H3,(H,22,23)
DM6KIG0	CS	CCCCCCCCC#CC1=CC=C(C=C1)C(=O)CCC(=O)O
DM6KIG0	IK	JJPRJMIBECZYNN-UHFFFAOYSA-N
DM6KIG0	IU	4-(4-dec-1-ynylphenyl)-4-oxobutanoic acid
DM6KIG0	DE	Discovery agent

DMYXHUO	ID	DMYXHUO
DMYXHUO	DN	4-(4-(pentyloxy)phenoxy)phenol
DMYXHUO	HS	Investigative
DMYXHUO	SN	4-(4-(pentyloxy)phenoxy)phenol; CHEMBL500079
DMYXHUO	DT	Small molecular drug
DMYXHUO	PC	44562857
DMYXHUO	MW	272.34
DMYXHUO	FM	C17H20O3
DMYXHUO	IC	InChI=1S/C17H20O3/c1-2-3-4-13-19-15-9-11-17(12-10-15)20-16-7-5-14(18)6-8-16/h5-12,18H,2-4,13H2,1H3
DMYXHUO	CS	CCCCCOC1=CC=C(C=C1)OC2=CC=C(C=C2)O
DMYXHUO	IK	JYQOLNAVBLFGQA-UHFFFAOYSA-N
DMYXHUO	IU	4-(4-pentoxyphenoxy)phenol
DMYXHUO	DE	Discovery agent

DMVXJU6	ID	DMVXJU6
DMVXJU6	DN	4-(4-(thiophen-2-yl)benzyl)pyridine
DMVXJU6	HS	Investigative
DMVXJU6	SN	CHEMBL1214736; 4-(4-(thiophen-2-yl)benzyl)pyridine; SCHEMBL18770350
DMVXJU6	DT	Small molecular drug
DMVXJU6	PC	46901783
DMVXJU6	MW	251.3
DMVXJU6	FM	C16H13NS
DMVXJU6	IC	InChI=1S/C16H13NS/c1-2-16(18-11-1)15-5-3-13(4-6-15)12-14-7-9-17-10-8-14/h1-11H,12H2
DMVXJU6	CS	C1=CSC(=C1)C2=CC=C(C=C2)CC3=CC=NC=C3
DMVXJU6	IK	ORQOALYZYXEWJV-UHFFFAOYSA-N
DMVXJU6	IU	4-[(4-thiophen-2-ylphenyl)methyl]pyridine
DMVXJU6	DE	Discovery agent

DM7I21V	ID	DM7I21V
DM7I21V	DN	4-(4-(thiophen-3-yl)benzyl)pyridine
DM7I21V	HS	Investigative
DM7I21V	SN	CHEMBL1214735; 4-(4-(thiophen-3-yl)benzyl)pyridine; SCHEMBL18770375
DM7I21V	DT	Small molecular drug
DM7I21V	PC	46901784
DM7I21V	MW	251.3
DM7I21V	FM	C16H13NS
DM7I21V	IC	InChI=1S/C16H13NS/c1-3-15(16-7-10-18-12-16)4-2-13(1)11-14-5-8-17-9-6-14/h1-10,12H,11H2
DM7I21V	CS	C1=CC(=CC=C1CC2=CC=NC=C2)C3=CSC=C3
DM7I21V	IK	JZVKRZVTIHAZFG-UHFFFAOYSA-N
DM7I21V	IU	4-[(4-thiophen-3-ylphenyl)methyl]pyridine
DM7I21V	DE	Discovery agent

DMOF0J1	ID	DMOF0J1
DMOF0J1	DN	4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate
DMOF0J1	HS	Investigative
DMOF0J1	SN	CHEMBL457882; AC1MCGW6; 4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate; MolPort-002-923-829; HMS1669K08; ZINC4394394; BDBM50274981; CCG-56239; MCULE-6668458781; SR-01000645209-1; [4-(4,5-dihydro-1,3-thiazol-2-yl)phenyl] N-butylcarbamate
DMOF0J1	DT	Small molecular drug
DMOF0J1	PC	2743568
DMOF0J1	MW	278.37
DMOF0J1	FM	C14H18N2O2S
DMOF0J1	IC	InChI=1S/C14H18N2O2S/c1-2-3-8-16-14(17)18-12-6-4-11(5-7-12)13-15-9-10-19-13/h4-7H,2-3,8-10H2,1H3,(H,16,17)
DMOF0J1	CS	CCCCNC(=O)OC1=CC=C(C=C1)C2=NCCS2
DMOF0J1	IK	OUBMDYCXTDANEM-UHFFFAOYSA-N
DMOF0J1	IU	[4-(4,5-dihydro-1,3-thiazol-2-yl)phenyl] N-butylcarbamate
DMOF0J1	DE	Discovery agent

DMI1598	ID	DMI1598
DMI1598	DN	4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine
DMI1598	HS	Investigative
DMI1598	SN	CHEMBL200844; 4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine
DMI1598	DT	Small molecular drug
DMI1598	PC	44405257
DMI1598	MW	362.32
DMI1598	FM	C14H10N4O6S
DMI1598	IC	InChI=1S/C14H10N4O6S/c15-9-1-3-11(4-2-9)25(23,24)16-6-5-12-13(16)7-10(17(19)20)8-14(12)18(21)22/h1-8H,15H2
DMI1598	CS	C1=CC(=CC=C1N)S(=O)(=O)N2C=CC3=C2C=C(C=C3[N+](=O)[O-])[N+](=O)[O-]
DMI1598	IK	NMGNRDGVTLTPFO-UHFFFAOYSA-N
DMI1598	IU	4-(4,6-dinitroindol-1-yl)sulfonylaniline
DMI1598	DE	Discovery agent

DMETK18	ID	DMETK18
DMETK18	DN	4-(4,6-diphenylpyridin-2-yl)phenol
DMETK18	HS	Investigative
DMETK18	DT	Small molecular drug
DMETK18	PC	135838975
DMETK18	MW	323.4
DMETK18	FM	C23H17NO
DMETK18	IC	InChI=1S/C23H17NO/c25-21-13-11-19(12-14-21)23-16-20(17-7-3-1-4-8-17)15-22(24-23)18-9-5-2-6-10-18/h1-16,25H
DMETK18	CS	C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC=C(C=C3)O)C4=CC=CC=C4
DMETK18	IK	LARDQALKCMOPHD-UHFFFAOYSA-N
DMETK18	IU	4-(4,6-diphenylpyridin-2-yl)phenol
DMETK18	DE	Discovery agent

DMGOTYC	ID	DMGOTYC
DMGOTYC	DN	4'-(4-Aminobenzensulfonamide)-4-hydroxychalcone
DMGOTYC	HS	Investigative
DMGOTYC	SN	CHEMBL1087578; SCHEMBL3484498; BDBM50316856; 4''-(4-Aminobenzensulfonamide)-4-hydroxychalcone
DMGOTYC	DT	Small molecular drug
DMGOTYC	PC	24989956
DMGOTYC	MW	394.4
DMGOTYC	FM	C21H18N2O4S
DMGOTYC	IC	InChI=1S/C21H18N2O4S/c22-17-6-12-20(13-7-17)28(26,27)23-18-8-4-16(5-9-18)21(25)14-3-15-1-10-19(24)11-2-15/h1-14,23-24H,22H2/b14-3+
DMGOTYC	CS	C1=CC(=CC=C1/C=C/C(=O)C2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)N)O
DMGOTYC	IK	HMCALLLWIUWUTM-LZWSPWQCSA-N
DMGOTYC	IU	4-amino-N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]benzenesulfonamide
DMGOTYC	DE	Discovery agent

DMK1IWD	ID	DMK1IWD
DMK1IWD	DN	4-(4-aminophenyl)-1H-indazol-3yl-amine
DMK1IWD	HS	Investigative
DMK1IWD	SN	4-(4-aminophenyl)-1H-indazol-3-amine; 819058-89-4; CHEMBL222778; Flt3 Inhibitor IV; 4-(4-aminophenyl)-1H-indazol-3yl-amine; SCHEMBL421242; DTXSID90583110; 3-amino-4-(4-aminophenyl)indazole; BDBM50207472; ZINC35324130; AKOS025401748; QC-1103; AC-25079; 1H-Indazol-3-amine,4-(4-aminophenyl)-
DMK1IWD	DT	Small molecular drug
DMK1IWD	PC	16125106
DMK1IWD	MW	224.26
DMK1IWD	FM	C13H12N4
DMK1IWD	IC	InChI=1S/C13H12N4/c14-9-6-4-8(5-7-9)10-2-1-3-11-12(10)13(15)17-16-11/h1-7H,14H2,(H3,15,16,17)
DMK1IWD	CS	C1=CC(=C2C(=C1)NN=C2N)C3=CC=C(C=C3)N
DMK1IWD	IK	KHQLSBOHZQJRPC-UHFFFAOYSA-N
DMK1IWD	IU	4-(4-aminophenyl)-1H-indazol-3-amine
DMK1IWD	CA	CAS 819058-89-4
DMK1IWD	DE	Discovery agent

DMP0G1W	ID	DMP0G1W
DMP0G1W	DN	4-(4-benzenesulfonamidophenyl)piperazine
DMP0G1W	HS	Investigative
DMP0G1W	SN	4-(4-benzenesulfonamidophenyl)piperazine; CHEMBL426332; SCHEMBL18553766
DMP0G1W	DT	Small molecular drug
DMP0G1W	PC	11849789
DMP0G1W	MW	317.4
DMP0G1W	FM	C16H19N3O2S
DMP0G1W	IC	InChI=1S/C16H19N3O2S/c20-22(21,16-4-2-1-3-5-16)18-14-6-8-15(9-7-14)19-12-10-17-11-13-19/h1-9,17-18H,10-13H2
DMP0G1W	CS	C1CN(CCN1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC=CC=C3
DMP0G1W	IK	LHOHHFFMBNKDDU-UHFFFAOYSA-N
DMP0G1W	IU	N-(4-piperazin-1-ylphenyl)benzenesulfonamide
DMP0G1W	DE	Discovery agent

DM0DZFX	ID	DM0DZFX
DM0DZFX	DN	4-(4-benzenesulfonylphenyl)piperazine
DM0DZFX	HS	Investigative
DM0DZFX	SN	4-(4-benzenesulfonylphenyl)piperazine; CHEMBL211577; 1-[4-(benzenesulfonyl)phenyl]piperazine; AC1NOI8E; SCHEMBL4573254; 4-(1-Piperazinyl)diphenyl sulfone; ZINC3716178; BDBM50193458; AKOS025215167; MCULE-7301402628
DM0DZFX	DT	Small molecular drug
DM0DZFX	PC	5113605
DM0DZFX	MW	302.4
DM0DZFX	FM	C16H18N2O2S
DM0DZFX	IC	InChI=1S/C16H18N2O2S/c19-21(20,15-4-2-1-3-5-15)16-8-6-14(7-9-16)18-12-10-17-11-13-18/h1-9,17H,10-13H2
DM0DZFX	CS	C1CN(CCN1)C2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3
DM0DZFX	IK	SZAOHADKAZDUGT-UHFFFAOYSA-N
DM0DZFX	IU	1-[4-(benzenesulfonyl)phenyl]piperazine
DM0DZFX	DE	Discovery agent

DMT2S9U	ID	DMT2S9U
DMT2S9U	DN	4-(4-benzyl-1H-1,2,3-triazol-1-yl)phenol
DMT2S9U	HS	Investigative
DMT2S9U	SN	CHEMBL1288977
DMT2S9U	DT	Small molecular drug
DMT2S9U	PC	52947733
DMT2S9U	MW	251.28
DMT2S9U	FM	C15H13N3O
DMT2S9U	IC	InChI=1S/C15H13N3O/c19-15-8-6-14(7-9-15)18-11-13(16-17-18)10-12-4-2-1-3-5-12/h1-9,11,19H,10H2
DMT2S9U	CS	C1=CC=C(C=C1)CC2=CN(N=N2)C3=CC=C(C=C3)O
DMT2S9U	IK	ZSQDQVRTOOCIEW-UHFFFAOYSA-N
DMT2S9U	IU	4-(4-benzyltriazol-1-yl)phenol
DMT2S9U	DE	Discovery agent

DME3PUT	ID	DME3PUT
DME3PUT	DN	4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine
DME3PUT	HS	Investigative
DME3PUT	SN	benzylamine 6; CHEMBL179938; BDBM13580
DME3PUT	DT	Small molecular drug
DME3PUT	PC	23646462
DME3PUT	MW	361.4
DME3PUT	FM	C22H23N3O2
DME3PUT	IC	InChI=1S/C22H23N3O2/c1-26-21-13-17(14-25-19-10-8-18(9-11-19)22(23)24)7-12-20(21)27-15-16-5-3-2-4-6-16/h2-13,25H,14-15H2,1H3,(H3,23,24)
DME3PUT	CS	COC1=C(C=CC(=C1)CNC2=CC=C(C=C2)C(=N)N)OCC3=CC=CC=C3
DME3PUT	IK	YPLDWUAEABIXKN-UHFFFAOYSA-N
DME3PUT	IU	4-[(3-methoxy-4-phenylmethoxyphenyl)methylamino]benzenecarboximidamide
DME3PUT	DE	Discovery agent

DMXAEW9	ID	DMXAEW9
DMXAEW9	DN	4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole
DMXAEW9	HS	Investigative
DMXAEW9	SN	CHEMBL88837; 4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole
DMXAEW9	DT	Small molecular drug
DMXAEW9	PC	44323762
DMXAEW9	MW	292.4
DMXAEW9	FM	C18H20N4
DMXAEW9	IC	InChI=1S/C18H20N4/c1-2-5-15(6-3-1)13-21-9-11-22(12-10-21)17-8-4-7-16-18(17)20-14-19-16/h1-8,14H,9-13H2,(H,19,20)
DMXAEW9	CS	C1CN(CCN1CC2=CC=CC=C2)C3=CC=CC4=C3N=CN4
DMXAEW9	IK	ZNBOBGDGUIWKPE-UHFFFAOYSA-N
DMXAEW9	IU	4-(4-benzylpiperazin-1-yl)-1H-benzimidazole
DMXAEW9	DE	Discovery agent

DMWR0AS	ID	DMWR0AS
DMWR0AS	DN	4-(4-Benzyl-piperazin-1-yl)-1H-indole
DMWR0AS	HS	Investigative
DMWR0AS	SN	4-(4-Benzyl-piperazin-1-yl)-1H-indole; CHEMBL328051; Maybridge2_000682; AC1MBNW0; Oprea1_014756; SCHEMBL2161609; JLZIBIQTDGMAFZ-UHFFFAOYSA-N; BDBM50071857; ZINC53006914
DMWR0AS	DT	Small molecular drug
DMWR0AS	PC	2728532
DMWR0AS	MW	291.4
DMWR0AS	FM	C19H21N3
DMWR0AS	IC	InChI=1S/C19H21N3/c1-2-5-16(6-3-1)15-21-11-13-22(14-12-21)19-8-4-7-18-17(19)9-10-20-18/h1-10,20H,11-15H2
DMWR0AS	CS	C1CN(CCN1CC2=CC=CC=C2)C3=CC=CC4=C3C=CN4
DMWR0AS	IK	JLZIBIQTDGMAFZ-UHFFFAOYSA-N
DMWR0AS	IU	4-(4-benzylpiperazin-1-yl)-1H-indole
DMWR0AS	DE	Discovery agent

DMZ4237	ID	DMZ4237
DMZ4237	DN	4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole
DMZ4237	HS	Investigative
DMZ4237	SN	CHEMBL311539; 4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole
DMZ4237	DT	Small molecular drug
DMZ4237	PC	44323978
DMZ4237	MW	325.8
DMZ4237	FM	C19H20ClN3
DMZ4237	IC	InChI=1S/C19H20ClN3/c20-17-6-7-18-16(8-9-21-18)19(17)23-12-10-22(11-13-23)14-15-4-2-1-3-5-15/h1-9,21H,10-14H2
DMZ4237	CS	C1CN(CCN1CC2=CC=CC=C2)C3=C(C=CC4=C3C=CN4)Cl
DMZ4237	IK	IRFLVVGRMBDQSJ-UHFFFAOYSA-N
DMZ4237	IU	4-(4-benzylpiperazin-1-yl)-5-chloro-1H-indole
DMZ4237	DE	Discovery agent

DMVAB7U	ID	DMVAB7U
DMVAB7U	DN	4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole
DMVAB7U	HS	Investigative
DMVAB7U	SN	CHEMBL90476; 4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole
DMVAB7U	DT	Small molecular drug
DMVAB7U	PC	44323962
DMVAB7U	MW	370.3
DMVAB7U	FM	C19H20BrN3
DMVAB7U	IC	InChI=1S/C19H20BrN3/c20-17-6-7-18(16-8-9-21-19(16)17)23-12-10-22(11-13-23)14-15-4-2-1-3-5-15/h1-9,21H,10-14H2
DMVAB7U	CS	C1CN(CCN1CC2=CC=CC=C2)C3=C4C=CNC4=C(C=C3)Br
DMVAB7U	IK	RBUDKKJLRVBPDA-UHFFFAOYSA-N
DMVAB7U	IU	4-(4-benzylpiperazin-1-yl)-7-bromo-1H-indole
DMVAB7U	DE	Discovery agent

DMHWIMO	ID	DMHWIMO
DMHWIMO	DN	4-(4-bromobenzylthio)-2-aminobutanoic acid
DMHWIMO	HS	Investigative
DMHWIMO	SN	CHEMBL203746; 4-(4-bromobenzylthio)-2-aminobutanoic acid; BDBM50179700
DMHWIMO	DT	Small molecular drug
DMHWIMO	PC	44408329
DMHWIMO	MW	304.21
DMHWIMO	FM	C11H14BrNO2S
DMHWIMO	IC	InChI=1S/C11H14BrNO2S/c12-9-3-1-8(2-4-9)7-16-6-5-10(13)11(14)15/h1-4,10H,5-7,13H2,(H,14,15)
DMHWIMO	CS	C1=CC(=CC=C1CSCCC(C(=O)O)N)Br
DMHWIMO	IK	XUFONRLUGMPMHQ-UHFFFAOYSA-N
DMHWIMO	IU	2-amino-4-[(4-bromophenyl)methylsulfanyl]butanoic acid
DMHWIMO	DE	Discovery agent

DMFEBCO	ID	DMFEBCO
DMFEBCO	DN	4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole
DMFEBCO	HS	Investigative
DMFEBCO	SN	4-(4-BROMOPHENYL)-1H-1,2,3-TRIAZOLE-5-CARBONITRILE; CHEMBL238828; 1119392-12-9; AC1O4QZZ; 5-(4-bromophenyl)-2H-triazole-4-carbonitrile; 4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL4105736; CTK7C5822; MolPort-006-755-219; ZINC6448351; BDBM50200765; AKOS022169659; MS-8537; KS-000029L0; 4-(4-Bromophenyl)-1H-1,2,3-triazole-5-carbonitrile, AldrichCPR
DMFEBCO	DT	Small molecular drug
DMFEBCO	PC	6411478
DMFEBCO	MW	249.07
DMFEBCO	FM	C9H5BrN4
DMFEBCO	IC	InChI=1S/C9H5BrN4/c10-7-3-1-6(2-4-7)9-8(5-11)12-14-13-9/h1-4H,(H,12,13,14)
DMFEBCO	CS	C1=CC(=CC=C1C2=NNN=C2C#N)Br
DMFEBCO	IK	SKCRCHJZYFYITH-UHFFFAOYSA-N
DMFEBCO	IU	5-(4-bromophenyl)-2H-triazole-4-carbonitrile
DMFEBCO	DE	Discovery agent

DMI2EM5	ID	DMI2EM5
DMI2EM5	DN	4-(4-butoxyphenoxy)phenol
DMI2EM5	HS	Investigative
DMI2EM5	SN	4-(4-butoxyphenoxy)phenol; CHEMBL467374
DMI2EM5	DT	Small molecular drug
DMI2EM5	PC	44562814
DMI2EM5	MW	258.31
DMI2EM5	FM	C16H18O3
DMI2EM5	IC	InChI=1S/C16H18O3/c1-2-3-12-18-14-8-10-16(11-9-14)19-15-6-4-13(17)5-7-15/h4-11,17H,2-3,12H2,1H3
DMI2EM5	CS	CCCCOC1=CC=C(C=C1)OC2=CC=C(C=C2)O
DMI2EM5	IK	WZNRRCAQHKVCHJ-UHFFFAOYSA-N
DMI2EM5	IU	4-(4-butoxyphenoxy)phenol
DMI2EM5	DE	Discovery agent

DMNGDOM	ID	DMNGDOM
DMNGDOM	DN	4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide
DMNGDOM	HS	Investigative
DMNGDOM	SN	CHEMBL197632; 4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide
DMNGDOM	DT	Small molecular drug
DMNGDOM	PC	44404521
DMNGDOM	MW	265.3
DMNGDOM	FM	C14H19NO4
DMNGDOM	IC	InChI=1S/C14H19NO4/c1-2-3-10-19-12-6-4-11(5-7-12)13(16)8-9-14(17)15-18/h4-7,18H,2-3,8-10H2,1H3,(H,15,17)
DMNGDOM	CS	CCCCOC1=CC=C(C=C1)C(=O)CCC(=O)NO
DMNGDOM	IK	SFIUVAFWSBUQJK-UHFFFAOYSA-N
DMNGDOM	IU	4-(4-butoxyphenyl)-N-hydroxy-4-oxobutanamide
DMNGDOM	DE	Discovery agent

DMM9X0G	ID	DMM9X0G
DMM9X0G	DN	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G	HS	Investigative
DMM9X0G	SN	4-(4-Butylpiperidin-1-yl)-1-o-tolylbutan-1-one; AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one
DMM9X0G	DT	Small molecular drug
DMM9X0G	PC	9948320
DMM9X0G	MW	301.5
DMM9X0G	FM	C20H31NO
DMM9X0G	IC	InChI=1S/C20H31NO/c1-3-4-9-18-12-15-21(16-13-18)14-7-11-20(22)19-10-6-5-8-17(19)2/h5-6,8,10,18H,3-4,7,9,11-16H2,1-2H3
DMM9X0G	CS	CCCCC1CCN(CC1)CCCC(=O)C2=CC=CC=C2C
DMM9X0G	IK	ANTKBACNWQHQJE-UHFFFAOYSA-N
DMM9X0G	IU	4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one
DMM9X0G	DE	Discovery agent

DM14I6C	ID	DM14I6C
DM14I6C	DN	4-(4-chloro-2-cyclohexylphenoxy)butanoic acid
DM14I6C	HS	Investigative
DM14I6C	SN	CHEMBL394496; 4-(4-chloro-2-cyclohexylphenoxy)butanoic acid; BDBM50213928
DM14I6C	DT	Small molecular drug
DM14I6C	PC	43169594
DM14I6C	MW	296.79
DM14I6C	FM	C16H21ClO3
DM14I6C	IC	InChI=1S/C16H21ClO3/c17-13-8-9-15(20-10-4-7-16(18)19)14(11-13)12-5-2-1-3-6-12/h8-9,11-12H,1-7,10H2,(H,18,19)
DM14I6C	CS	C1CCC(CC1)C2=C(C=CC(=C2)Cl)OCCCC(=O)O
DM14I6C	IK	BDEUQTBTFVDWEA-UHFFFAOYSA-N
DM14I6C	IU	4-(4-chloro-2-cyclohexylphenoxy)butanoic acid
DM14I6C	DE	Discovery agent

DMRBEZD	ID	DMRBEZD
DMRBEZD	DN	4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one
DMRBEZD	HS	Investigative
DMRBEZD	SN	CHEMBL207277; 4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one; BDBM50183665; 2-allyl-4-[(4-chlorophenyl)methyl]phthalazin-1-one; 1(2H)-Phthalazinone, 4-[(4-chlorophenyl)methyl]-2-allyl-
DMRBEZD	DT	Small molecular drug
DMRBEZD	PC	15959119
DMRBEZD	MW	310.8
DMRBEZD	FM	C18H15ClN2O
DMRBEZD	IC	InChI=1S/C18H15ClN2O/c1-2-11-21-18(22)16-6-4-3-5-15(16)17(20-21)12-13-7-9-14(19)10-8-13/h2-10H,1,11-12H2
DMRBEZD	CS	C=CCN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=C(C=C3)Cl
DMRBEZD	IK	OHEWOPKEAKDVRX-UHFFFAOYSA-N
DMRBEZD	IU	4-[(4-chlorophenyl)methyl]-2-prop-2-enylphthalazin-1-one
DMRBEZD	DE	Discovery agent

DMNYQGV	ID	DMNYQGV
DMNYQGV	DN	4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one
DMNYQGV	HS	Investigative
DMNYQGV	SN	CHEMBL67457; 4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-methyl-phthalazin-1-one; BDBM50131411; 4-(4-Chloro-benzyl)-2-methyl-2H-phthalazin-1-one; 2-Methyl-4-(4-chlorobenzyl)-1,2-dihydrophthalazine-1-one; 1(2H)-Phthalazinone, 4-[(4-chlorophenyl)methyl]-2-methyl-
DMNYQGV	DT	Small molecular drug
DMNYQGV	PC	11522042
DMNYQGV	MW	284.74
DMNYQGV	FM	C16H13ClN2O
DMNYQGV	IC	InChI=1S/C16H13ClN2O/c1-19-16(20)14-5-3-2-4-13(14)15(18-19)10-11-6-8-12(17)9-7-11/h2-9H,10H2,1H3
DMNYQGV	CS	CN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=C(C=C3)Cl
DMNYQGV	IK	QZOXWSKLFOUEKD-UHFFFAOYSA-N
DMNYQGV	IU	4-[(4-chlorophenyl)methyl]-2-methylphthalazin-1-one
DMNYQGV	DE	Discovery agent

DM9AEF0	ID	DM9AEF0
DM9AEF0	DN	4-(4-chlorobenzyl)phthalazin-1(2H)-one
DM9AEF0	HS	Investigative
DM9AEF0	SN	53242-88-9; 4-(4-chlorobenzyl)phthalazin-1(2H)-one; 4-(4-Chloro-benzyl)-2H-phthalazin-1-one; 4-[(4-chlorophenyl)methyl]-2H-phthalazin-1-one; UNII-56DW142LLX; MLS000547504; 4-(4-chlorobenzyl)phthalazin-1-ol; CHEMBL63976; 4-(4-chlorobenzyl)-1(2H)-phthalazinone; 56DW142LLX; 4-[(4-CHLOROPHENYL)METHYL]PHTHALAZIN-1(2H)-ONE; SMR000113649; 4-(4-Chlorobenzyl)-2H-phthalazin-1-one; 4-[(4-Chlorophenyl)methyl]-1(2H)-phthalazinone; 4-((4-Chlorophenyl)methyl)phthalazin-1(2H)-one; W-109042; 4-{[4-chlorophenyl]methyl}-1(2H)-phthalazinone
DM9AEF0	DT	Small molecular drug
DM9AEF0	PC	104452
DM9AEF0	MW	270.71
DM9AEF0	FM	C15H11ClN2O
DM9AEF0	IC	InChI=1S/C15H11ClN2O/c16-11-7-5-10(6-8-11)9-14-12-3-1-2-4-13(12)15(19)18-17-14/h1-8H,9H2,(H,18,19)
DM9AEF0	CS	C1=CC=C2C(=C1)C(=NNC2=O)CC3=CC=C(C=C3)Cl
DM9AEF0	IK	NLXGCQIEVZYDRS-UHFFFAOYSA-N
DM9AEF0	IU	4-[(4-chlorophenyl)methyl]-2H-phthalazin-1-one
DM9AEF0	CA	CAS 53242-88-9
DM9AEF0	DE	Discovery agent

DMENLUP	ID	DMENLUP
DMENLUP	DN	4-(4-chlorobenzylthio)-2-aminobutanoic acid
DMENLUP	HS	Investigative
DMENLUP	SN	CHEMBL377079; 4-(4-chlorobenzylthio)-2-aminobutanoic acid; BDBM50179703
DMENLUP	DT	Small molecular drug
DMENLUP	PC	44408321
DMENLUP	MW	259.75
DMENLUP	FM	C11H14ClNO2S
DMENLUP	IC	InChI=1S/C11H14ClNO2S/c12-9-3-1-8(2-4-9)7-16-6-5-10(13)11(14)15/h1-4,10H,5-7,13H2,(H,14,15)
DMENLUP	CS	C1=CC(=CC=C1CSCCC(C(=O)O)N)Cl
DMENLUP	IK	ALRMSMDJCRNGNM-UHFFFAOYSA-N
DMENLUP	IU	2-amino-4-[(4-chlorophenyl)methylsulfanyl]butanoic acid
DMENLUP	DE	Discovery agent

DMJI6QH	ID	DMJI6QH
DMJI6QH	DN	4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole
DMJI6QH	HS	Investigative
DMJI6QH	SN	CHEMBL206705
DMJI6QH	DT	Small molecular drug
DMJI6QH	PC	44408653
DMJI6QH	MW	255.7
DMJI6QH	FM	C14H10ClN3
DMJI6QH	IC	InChI=1S/C14H10ClN3/c15-13-6-4-11(5-7-13)12-9-17-18(10-12)14-3-1-2-8-16-14/h1-10H
DMJI6QH	CS	C1=CC=NC(=C1)N2C=C(C=N2)C3=CC=C(C=C3)Cl
DMJI6QH	IK	NJMIDEUMQUSYDE-UHFFFAOYSA-N
DMJI6QH	IU	2-[4-(4-chlorophenyl)pyrazol-1-yl]pyridine
DMJI6QH	DE	Discovery agent

DMODVGN	ID	DMODVGN
DMODVGN	DN	4-(4-Chlorophenyl)-5-(4-methoxyphenyl)isothiazole
DMODVGN	HS	Investigative
DMODVGN	SN	CHEMBL522624; 4-(4-Chlorophenyl)-5-(4-methoxyphenyl)isothiazole
DMODVGN	DT	Small molecular drug
DMODVGN	PC	44564458
DMODVGN	MW	301.8
DMODVGN	FM	C16H12ClNOS
DMODVGN	IC	InChI=1S/C16H12ClNOS/c1-19-14-8-4-12(5-9-14)16-15(10-18-20-16)11-2-6-13(17)7-3-11/h2-10H,1H3
DMODVGN	CS	COC1=CC=C(C=C1)C2=C(C=NS2)C3=CC=C(C=C3)Cl
DMODVGN	IK	OORIOMOWZWWCHX-UHFFFAOYSA-N
DMODVGN	IU	4-(4-chlorophenyl)-5-(4-methoxyphenyl)-1,2-thiazole
DMODVGN	DE	Discovery agent

DMVN7GC	ID	DMVN7GC
DMVN7GC	DN	4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole
DMVN7GC	HS	Investigative
DMVN7GC	SN	CHEMBL393014; 5-(4-CHLORO-PHENYL)-3H-[1,2,3]TRIAZOLE-4-CARBONITRILE; 50710-06-0; 4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969183; CTK1G7781; BDBM50200758; ZINC22004877; AKOS015967718; FCH1390661; ACM50710060
DMVN7GC	DT	Small molecular drug
DMVN7GC	PC	11183327
DMVN7GC	MW	204.61
DMVN7GC	FM	C9H5ClN4
DMVN7GC	IC	InChI=1S/C9H5ClN4/c10-7-3-1-6(2-4-7)9-8(5-11)12-14-13-9/h1-4H,(H,12,13,14)
DMVN7GC	CS	C1=CC(=CC=C1C2=NNN=C2C#N)Cl
DMVN7GC	IK	KBDVIKMDRWVMPM-UHFFFAOYSA-N
DMVN7GC	IU	5-(4-chlorophenyl)-2H-triazole-4-carbonitrile
DMVN7GC	DE	Discovery agent

DMZBEYO	ID	DMZBEYO
DMZBEYO	DN	4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole
DMZBEYO	HS	Investigative
DMZBEYO	SN	CHEMBL471171; 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole
DMZBEYO	DT	Small molecular drug
DMZBEYO	PC	24884693
DMZBEYO	MW	332.7
DMZBEYO	FM	C16H12ClNSe
DMZBEYO	IC	InChI=1S/C16H12ClNSe/c1-11-2-4-13(5-3-11)16-15(10-18-19-16)12-6-8-14(17)9-7-12/h2-10H,1H3
DMZBEYO	CS	CC1=CC=C(C=C1)C2=C(C=N[Se]2)C3=CC=C(C=C3)Cl
DMZBEYO	IK	NMKXOVXYAQBXPT-UHFFFAOYSA-N
DMZBEYO	IU	4-(4-chlorophenyl)-5-(4-methylphenyl)-1,2-selenazole
DMZBEYO	DE	Discovery agent

DMVDF9Q	ID	DMVDF9Q
DMVDF9Q	DN	4-(4-Chlorophenyl)-5-p-tolyl-3H-1,2-dithiol-3-one
DMVDF9Q	HS	Investigative
DMVDF9Q	SN	CHEMBL504541; 4-(4-Chlorophenyl)-5-p-tolyl-3H-1,2-dithiol-3-one
DMVDF9Q	DT	Small molecular drug
DMVDF9Q	PC	44564004
DMVDF9Q	MW	318.8
DMVDF9Q	FM	C16H11ClOS2
DMVDF9Q	IC	InChI=1S/C16H11ClOS2/c1-10-2-4-12(5-3-10)15-14(16(18)20-19-15)11-6-8-13(17)9-7-11/h2-9H,1H3
DMVDF9Q	CS	CC1=CC=C(C=C1)C2=C(C(=O)SS2)C3=CC=C(C=C3)Cl
DMVDF9Q	IK	NLGIFTIQVVCDPR-UHFFFAOYSA-N
DMVDF9Q	IU	4-(4-chlorophenyl)-5-(4-methylphenyl)dithiol-3-one
DMVDF9Q	DE	Discovery agent

DMMK9RC	ID	DMMK9RC
DMMK9RC	DN	4-(4-Chlorophenyl)-5-p-tolylisothiazole
DMMK9RC	HS	Investigative
DMMK9RC	SN	CHEMBL490889; 4-(4-Chlorophenyl)-5-p-tolylisothiazole
DMMK9RC	DT	Small molecular drug
DMMK9RC	PC	44564455
DMMK9RC	MW	285.8
DMMK9RC	FM	C16H12ClNS
DMMK9RC	IC	InChI=1S/C16H12ClNS/c1-11-2-4-13(5-3-11)16-15(10-18-19-16)12-6-8-14(17)9-7-12/h2-10H,1H3
DMMK9RC	CS	CC1=CC=C(C=C1)C2=C(C=NS2)C3=CC=C(C=C3)Cl
DMMK9RC	IK	YLLFNDIXMCYHET-UHFFFAOYSA-N
DMMK9RC	IU	4-(4-chlorophenyl)-5-(4-methylphenyl)-1,2-thiazole
DMMK9RC	DE	Discovery agent

DM9YRHW	ID	DM9YRHW
DM9YRHW	DN	4-(4-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine
DM9YRHW	HS	Investigative
DM9YRHW	SN	CHEMBL208731; 4-(4-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine; 4-[(4-chlorophenyl)thio]-2-pyridin-2-ylpyrimidine; SCHEMBL8280517; BDBM50182822
DM9YRHW	DT	Small molecular drug
DM9YRHW	PC	11381029
DM9YRHW	MW	299.8
DM9YRHW	FM	C15H10ClN3S
DM9YRHW	IC	InChI=1S/C15H10ClN3S/c16-11-4-6-12(7-5-11)20-14-8-10-18-15(19-14)13-3-1-2-9-17-13/h1-10H
DM9YRHW	CS	C1=CC=NC(=C1)C2=NC=CC(=N2)SC3=CC=C(C=C3)Cl
DM9YRHW	IK	GJICJCYMPFHBPO-UHFFFAOYSA-N
DM9YRHW	IU	4-(4-chlorophenyl)sulfanyl-2-pyridin-2-ylpyrimidine
DM9YRHW	DE	Discovery agent

DMNEAJH	ID	DMNEAJH
DMNEAJH	DN	4-(4-Cyanophenoxy)-3-pyridinesulfonamide
DMNEAJH	HS	Investigative
DMNEAJH	SN	CHEMBL1164572; 4-(4-Cyanophenoxy)-3-pyridinesulfonamide; BDBM50320503
DMNEAJH	DT	Small molecular drug
DMNEAJH	PC	46703769
DMNEAJH	MW	275.29
DMNEAJH	FM	C12H9N3O3S
DMNEAJH	IC	InChI=1S/C12H9N3O3S/c13-7-9-1-3-10(4-2-9)18-11-5-6-15-8-12(11)19(14,16)17/h1-6,8H,(H2,14,16,17)
DMNEAJH	CS	C1=CC(=CC=C1C#N)OC2=C(C=NC=C2)S(=O)(=O)N
DMNEAJH	IK	SUYXGHCYAUOKRH-UHFFFAOYSA-N
DMNEAJH	IU	4-(4-cyanophenoxy)pyridine-3-sulfonamide
DMNEAJH	DE	Discovery agent

DMSYH8R	ID	DMSYH8R
DMSYH8R	DN	4-(4-cyclohexylthiosemicarbazono)methyl-phenol
DMSYH8R	HS	Investigative
DMSYH8R	DT	Small molecular drug
DMSYH8R	PC	135562887
DMSYH8R	MW	277.39
DMSYH8R	FM	C14H19N3OS
DMSYH8R	IC	InChI=1S/C14H19N3OS/c18-13-8-6-11(7-9-13)10-15-17-14(19)16-12-4-2-1-3-5-12/h6-10,12,18H,1-5H2,(H2,16,17,19)/b15-10+
DMSYH8R	CS	C1CCC(CC1)NC(=S)N/N=C/C2=CC=C(C=C2)O
DMSYH8R	IK	GRDLPUUYRVMQPX-XNTDXEJSSA-N
DMSYH8R	IU	1-cyclohexyl-3-[(E)-(4-hydroxyphenyl)methylideneamino]thiourea
DMSYH8R	DE	Discovery agent

DMCDKHJ	ID	DMCDKHJ
DMCDKHJ	DN	4-(4-Decyloxy-phenyl)-1,1,1-trifluoro-butan-2-one
DMCDKHJ	HS	Investigative
DMCDKHJ	SN	CHEMBL462600
DMCDKHJ	DT	Small molecular drug
DMCDKHJ	PC	25059818
DMCDKHJ	MW	358.4
DMCDKHJ	FM	C20H29F3O2
DMCDKHJ	IC	InChI=1S/C20H29F3O2/c1-2-3-4-5-6-7-8-9-16-25-18-13-10-17(11-14-18)12-15-19(24)20(21,22)23/h10-11,13-14H,2-9,12,15-16H2,1H3
DMCDKHJ	CS	CCCCCCCCCCOC1=CC=C(C=C1)CCC(=O)C(F)(F)F
DMCDKHJ	IK	DJDSHOVBFZKIEK-UHFFFAOYSA-N
DMCDKHJ	IU	4-(4-decoxyphenyl)-1,1,1-trifluorobutan-2-one
DMCDKHJ	DE	Discovery agent

DMA6E28	ID	DMA6E28
DMA6E28	DN	4'-(4-Fluorobenzensulfonamide)-4-hydroxychalcone
DMA6E28	HS	Investigative
DMA6E28	SN	CHEMBL1087448; SCHEMBL3483870; BDBM50316857
DMA6E28	DT	Small molecular drug
DMA6E28	PC	24757297
DMA6E28	MW	397.4
DMA6E28	FM	C21H16FNO4S
DMA6E28	IC	InChI=1S/C21H16FNO4S/c22-17-6-12-20(13-7-17)28(26,27)23-18-8-4-16(5-9-18)21(25)14-3-15-1-10-19(24)11-2-15/h1-14,23-24H/b14-3+
DMA6E28	CS	C1=CC(=CC=C1/C=C/C(=O)C2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)F)O
DMA6E28	IK	SRDYAWAEKAHCHN-LZWSPWQCSA-N
DMA6E28	IU	4-fluoro-N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]benzenesulfonamide
DMA6E28	DE	Discovery agent

DMW8IN3	ID	DMW8IN3
DMW8IN3	DN	4-(4-FLUOROBENZYL)PIPERIDINE
DMW8IN3	HS	Investigative
DMW8IN3	SN	4-(4'-Fluorobenzyl)piperidine; 92822-02-1; 4-[(4-fluorophenyl)methyl]piperidine; 4-(4-fluorobenzyl)piperidine; 4-(4-fluoro-benzyl)-piperidine; PIPERIDINE, 4-[(4-FLUOROPHENYL)METHYL]-; CHEMBL144527; piperidine 4; PubChem12570; AC1Q4MDN; chembrdg-bb 4010301; AC1MWI24; SCHEMBL895063; 4-(4-fluorobenzyl)-piperidine; 4-(4'-fluorobenzyl) piperidine; CTK8F5377; BDBM15788; DTXSID30395219; JLAKCHGEEBPDQI-UHFFFAOYSA-N; MolPort-002-053-743; HMS3604B15; 4-(4-flourophenylmethyl)piperidine; ZINC2512916; ALBB-014951; KS-00002B8F
DMW8IN3	DT	Small molecular drug
DMW8IN3	PC	3699841
DMW8IN3	MW	193.26
DMW8IN3	FM	C12H16FN
DMW8IN3	IC	InChI=1S/C12H16FN/c13-12-3-1-10(2-4-12)9-11-5-7-14-8-6-11/h1-4,11,14H,5-9H2
DMW8IN3	CS	C1CNCCC1CC2=CC=C(C=C2)F
DMW8IN3	IK	JLAKCHGEEBPDQI-UHFFFAOYSA-N
DMW8IN3	IU	4-[(4-fluorophenyl)methyl]piperidine
DMW8IN3	CA	CAS 92822-02-1
DMW8IN3	DE	Discovery agent

DM4NEOU	ID	DM4NEOU
DM4NEOU	DN	4-(4-Fluoro-benzyl)-piperidine hydrochloride
DM4NEOU	HS	Investigative
DM4NEOU	SN	4-(4-Fluorobenzyl)piperidine hydrochloride; 92822-03-2; 193357-52-7; C12H17ClFN; CHEMBL1204355; 4-(4-Fluoro-benzyl)-piperidine hydrochloride; 4-(4'-FLUOROBENZYL)PIPERIDINE HYDROCHLORIDE; Piperidine, 4-[(4-fluorophenyl)methyl]-, hydrochloride; 4-(4-FLUOROBENZYL)PIPERIDINE HCL; AK134910; 4-[(4-fluorophenyl)methyl]piperidine Hydrochloride; 4-(4-FLUOROBENZYL)PIPERIDINE HYDROCHLORIDE Salt; SCHEMBL4247331; KS-00000DOL; CTK7C0359; DTXSID30588780; MolPort-001-778-599; OJKWWANXBGLGQN-UHFFFAOYSA-N; 4NPA-Q05-1; ZX-AV000292; ZX-CM003409
DM4NEOU	DT	Small molecular drug
DM4NEOU	PC	17039492
DM4NEOU	MW	229.72
DM4NEOU	FM	C12H17ClFN
DM4NEOU	IC	InChI=1S/C12H16FN.ClH/c13-12-3-1-10(2-4-12)9-11-5-7-14-8-6-11;/h1-4,11,14H,5-9H2;1H
DM4NEOU	CS	C1CNCCC1CC2=CC=C(C=C2)F.Cl
DM4NEOU	IK	OJKWWANXBGLGQN-UHFFFAOYSA-N
DM4NEOU	IU	4-[(4-fluorophenyl)methyl]piperidine;hydrochloride
DM4NEOU	CA	CAS 193357-52-7
DM4NEOU	DE	Discovery agent

DMRJD75	ID	DMRJD75
DMRJD75	DN	4-(4-fluoro-benzylideneamino)-benzenesulfonamide
DMRJD75	HS	Investigative
DMRJD75	SN	CHEMBL427835; 4-[(4-fluorobenzylidene)amino]benzenesulfonamide; 4-{[(e)-(4-fluorophenyl)methylidene]amino}benzenesulfonamide; NSC720519; AC1L8N2R; SCHEMBL5311683; CTK7B9640; BKZPDMSMFWCHPI-UHFFFAOYSA-N; MolPort-003-705-944; ZINC18102137; BDBM50371768; ZINC95919526; AKOS001613042; ZINC253618202; AKOS016038195; NSC-720519; MCULE-4378033729; ST009698; KB-117288; N-(4-Fluorobenzylidene)-4-sulfamoylaniline; EU-0002043; SR-01000079257; SR-01000079257-1; 4-[(4-Fluoro-benzylidene)-amino]-benzenesulfonamide
DMRJD75	DT	Small molecular drug
DMRJD75	PC	404324
DMRJD75	MW	278.3
DMRJD75	FM	C13H11FN2O2S
DMRJD75	IC	InChI=1S/C13H11FN2O2S/c14-11-3-1-10(2-4-11)9-16-12-5-7-13(8-6-12)19(15,17)18/h1-9H,(H2,15,17,18)
DMRJD75	CS	C1=CC(=CC=C1C=NC2=CC=C(C=C2)S(=O)(=O)N)F
DMRJD75	IK	BKZPDMSMFWCHPI-UHFFFAOYSA-N
DMRJD75	IU	4-[(4-fluorophenyl)methylideneamino]benzenesulfonamide
DMRJD75	DE	Discovery agent

DM52NMU	ID	DM52NMU
DM52NMU	DN	4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine
DM52NMU	HS	Investigative
DM52NMU	SN	CHEMBL1215732; BDBM50324616
DM52NMU	DT	Small molecular drug
DM52NMU	PC	49864196
DM52NMU	MW	263.3
DM52NMU	FM	C18H14FN
DM52NMU	IC	InChI=1S/C18H14FN/c19-18-3-1-2-17(13-18)16-6-4-14(5-7-16)12-15-8-10-20-11-9-15/h1-11,13H,12H2
DM52NMU	CS	C1=CC(=CC(=C1)F)C2=CC=C(C=C2)CC3=CC=NC=C3
DM52NMU	IK	NDUUGOAGHNLAIZ-UHFFFAOYSA-N
DM52NMU	IU	4-[[4-(3-fluorophenyl)phenyl]methyl]pyridine
DM52NMU	DE	Discovery agent

DMRJLAP	ID	DMRJLAP
DMRJLAP	DN	4-(4-Fluorophenoxy)-3-pyridinesulfonamide
DMRJLAP	HS	Investigative
DMRJLAP	SN	4-(4-Fluorophenoxy)-3-pyridinesulfonamide; CHEMBL1163599; BDBM50320502
DMRJLAP	DT	Small molecular drug
DMRJLAP	PC	46703770
DMRJLAP	MW	268.27
DMRJLAP	FM	C11H9FN2O3S
DMRJLAP	IC	InChI=1S/C11H9FN2O3S/c12-8-1-3-9(4-2-8)17-10-5-6-14-7-11(10)18(13,15)16/h1-7H,(H2,13,15,16)
DMRJLAP	CS	C1=CC(=CC=C1OC2=C(C=NC=C2)S(=O)(=O)N)F
DMRJLAP	IK	AJOXYVWAKWQVRZ-UHFFFAOYSA-N
DMRJLAP	IU	4-(4-fluorophenoxy)pyridine-3-sulfonamide
DMRJLAP	DE	Discovery agent

DMK8DCF	ID	DMK8DCF
DMK8DCF	DN	4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide
DMK8DCF	HS	Investigative
DMK8DCF	SN	CHEMBL272622; SCHEMBL5312313; JAKLWQFGJXPTHN-UHFFFAOYSA-N; BDBM50371742
DMK8DCF	DT	Small molecular drug
DMK8DCF	PC	21862753
DMK8DCF	MW	278.3
DMK8DCF	FM	C13H11FN2O2S
DMK8DCF	IC	InChI=1S/C13H11FN2O2S/c14-11-3-5-12(6-4-11)16-9-10-1-7-13(8-2-10)19(15,17)18/h1-9H,(H2,15,17,18)
DMK8DCF	CS	C1=CC(=CC=C1C=NC2=CC=C(C=C2)F)S(=O)(=O)N
DMK8DCF	IK	JAKLWQFGJXPTHN-UHFFFAOYSA-N
DMK8DCF	IU	4-[(4-fluorophenyl)iminomethyl]benzenesulfonamide
DMK8DCF	DE	Discovery agent

DMR9TBW	ID	DMR9TBW
DMR9TBW	DN	4-(4-hexylphenyl)-4-oxobut-2-enoic acid
DMR9TBW	HS	Investigative
DMR9TBW	SN	CHEMBL237601; SCHEMBL16227167
DMR9TBW	DT	Small molecular drug
DMR9TBW	PC	53881633
DMR9TBW	MW	260.329
DMR9TBW	FM	C16H20O3
DMR9TBW	IC	InChI=1S/C16H20O3/c1-2-3-4-5-6-13-7-9-14(10-8-13)15(17)11-12-16(18)19/h7-12H,2-6H2,1H3,(H,18,19)
DMR9TBW	CS	CCCCCCC1=CC=C(C=C1)C(=O)C=CC(=O)O
DMR9TBW	IK	HKEVTQICMJNUNY-UHFFFAOYSA-N
DMR9TBW	IU	4-(4-hexylphenyl)-4-oxobut-2-enoic acid
DMR9TBW	DE	Discovery agent

DMNY0I5	ID	DMNY0I5
DMNY0I5	DN	4-(4-hydroxy-benzylideneamino)-benzenesulfonamide
DMNY0I5	HS	Investigative
DMNY0I5	SN	4-(4-hydroxybenzylideneamino)benzenesulfonamide
DMNY0I5	PC	404202
DMNY0I5	MW	276.31
DMNY0I5	FM	C13H12N2O3S
DMNY0I5	IC	InChI=1S/C13H12N2O3S/c14-19(17,18)13-7-3-11(4-8-13)15-9-10-1-5-12(16)6-2-10/h1-9,16H,(H2,14,17,18)
DMNY0I5	CS	C1=CC(=CC=C1C=NC2=CC=C(C=C2)S(=O)(=O)N)O
DMNY0I5	IK	QEZYWFVOEUVTBF-UHFFFAOYSA-N
DMNY0I5	IU	4-[(4-hydroxyphenyl)methylideneamino]benzenesulfonamide
DMNY0I5	CA	CAS 66667-58-1
DMNY0I5	DE	Discovery agent

DML357W	ID	DML357W
DML357W	DN	4-(4-hydroxybenzylideneamino)benzoic acid
DML357W	HS	Investigative
DML357W	DT	Small molecular drug
DML357W	PC	2306645
DML357W	MW	241.24
DML357W	FM	C14H11NO3
DML357W	IC	InChI=1S/C14H11NO3/c16-13-7-1-10(2-8-13)9-15-12-5-3-11(4-6-12)14(17)18/h1-9,16H,(H,17,18)
DML357W	CS	C1=CC(=CC=C1C=NC2=CC=C(C=C2)C(=O)O)O
DML357W	IK	HRLVVRLMLAPCBI-UHFFFAOYSA-N
DML357W	IU	4-[(4-hydroxyphenyl)methylideneamino]benzoic acid
DML357W	CA	CAS 60027-82-9
DML357W	DE	Discovery agent

DMZT6HL	ID	DMZT6HL
DMZT6HL	DN	4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
DMZT6HL	HS	Investigative
DMZT6HL	DT	Small molecular drug
DMZT6HL	PC	135440536
DMZT6HL	MW	263.29
DMZT6HL	FM	C17H13NO2
DMZT6HL	IC	InChI=1S/C17H13NO2/c19-14-8-5-12(6-9-14)16-10-7-13(11-18-20)15-3-1-2-4-17(15)16/h1-11,19-20H/b18-11+
DMZT6HL	CS	C1=CC=C2C(=C1)C(=CC=C2C3=CC=C(C=C3)O)/C=N/O
DMZT6HL	IK	VYQQTWUZKPWPRL-WOJGMQOQSA-N
DMZT6HL	IU	4-[4-[(E)-hydroxyiminomethyl]naphthalen-1-yl]phenol
DMZT6HL	CA	CAS 799765-95-0
DMZT6HL	DE	Discovery agent

DMC9Z45	ID	DMC9Z45
DMC9Z45	DN	4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol
DMC9Z45	HS	Investigative
DMC9Z45	SN	CHEMBL268881; NSC622468; 4-(4-Isopropyl-2-morpholinyl)-1,2-benzenediol hydrochloride; AC1L7GLH; AC1Q7ACF; 4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol; BDBM50000499; AKOS022660109; NCI60_006589; 4-(4-isopropylmorpholin-2-yl)benzene-1,2-diol; 4-(4-propan-2-ylmorpholin-2-yl)benzene-1,2-diol; 1,2-benzenediol, 4-[4-(1-methylethyl)-2-morpholinyl]-
DMC9Z45	DT	Small molecular drug
DMC9Z45	PC	360400
DMC9Z45	MW	237.29
DMC9Z45	FM	C13H19NO3
DMC9Z45	IC	InChI=1S/C13H19NO3/c1-9(2)14-5-6-17-13(8-14)10-3-4-11(15)12(16)7-10/h3-4,7,9,13,15-16H,5-6,8H2,1-2H3
DMC9Z45	CS	CC(C)N1CCOC(C1)C2=CC(=C(C=C2)O)O
DMC9Z45	IK	SUYJAACXNVNFGP-UHFFFAOYSA-N
DMC9Z45	IU	4-(4-propan-2-ylmorpholin-2-yl)benzene-1,2-diol
DMC9Z45	DE	Discovery agent

DMRGM21	ID	DMRGM21
DMRGM21	DN	4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole
DMRGM21	HS	Investigative
DMRGM21	SN	CHEMBL239895; 4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969081
DMRGM21	DT	Small molecular drug
DMRGM21	PC	44437844
DMRGM21	MW	212.25
DMRGM21	FM	C12H12N4
DMRGM21	IC	InChI=1S/C12H12N4/c1-8(2)9-3-5-10(6-4-9)12-11(7-13)14-16-15-12/h3-6,8H,1-2H3,(H,14,15,16)
DMRGM21	CS	CC(C)C1=CC=C(C=C1)C2=NNN=C2C#N
DMRGM21	IK	WEMPWGDVLUDOBY-UHFFFAOYSA-N
DMRGM21	IU	5-(4-propan-2-ylphenyl)-2H-triazole-4-carbonitrile
DMRGM21	DE	Discovery agent

DMA7LEO	ID	DMA7LEO
DMA7LEO	DN	4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DMA7LEO	HS	Investigative
DMA7LEO	SN	CHEMBL379273; 4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DMA7LEO	DT	Small molecular drug
DMA7LEO	PC	44413494
DMA7LEO	MW	302.4
DMA7LEO	FM	C15H14N2O3S
DMA7LEO	IC	InChI=1S/C15H14N2O3S/c1-20-15-4-2-3-14-13(15)9-10-17(14)21(18,19)12-7-5-11(16)6-8-12/h2-10H,16H2,1H3
DMA7LEO	CS	COC1=CC=CC2=C1C=CN2S(=O)(=O)C3=CC=C(C=C3)N
DMA7LEO	IK	ITHFAYACRWTMMR-UHFFFAOYSA-N
DMA7LEO	IU	4-(4-methoxyindol-1-yl)sulfonylaniline
DMA7LEO	DE	Discovery agent

DM5PTB9	ID	DM5PTB9
DM5PTB9	DN	4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol
DM5PTB9	HS	Investigative
DM5PTB9	SN	CHEMBL172912; 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol; SCHEMBL7212305
DM5PTB9	DT	Small molecular drug
DM5PTB9	PC	15516780
DM5PTB9	MW	260.399
DM5PTB9	FM	C11H16O3S2
DM5PTB9	IC	InChI=1S/C11H16O3S2/c1-9(15)7-8-16(12,13)11-5-3-10(14-2)4-6-11/h3-6,9,15H,7-8H2,1-2H3
DM5PTB9	CS	CC(CCS(=O)(=O)C1=CC=C(C=C1)OC)S
DM5PTB9	IK	UXTQFUKVODXBBJ-UHFFFAOYSA-N
DM5PTB9	IU	4-(4-methoxyphenyl)sulfonylbutane-2-thiol
DM5PTB9	DE	Discovery agent

DM2OR8E	ID	DM2OR8E
DM2OR8E	DN	4-(4-methoxy-benzylideneamino)-benzenesulfonamide
DM2OR8E	HS	Investigative
DM2OR8E	SN	CHEMBL271911; N-(4-Methoxybenzylidene)-4-sulfamoylaniline; 66667-56-9; AC1LCE5G; CBDivE_014997; SCHEMBL1517619; 4-[(4-methoxyphenyl)methylideneamino]benzenesulfonamide; CTK1J4463; DTXSID70347792; MolPort-000-519-122; MLUHDVSELBSKPI-UHFFFAOYSA-N; MLUHDVSELBSKPI-MHWRWJLKSA-N; ZINC131008; BDBM50371762; STK790787; AKOS001583663; MCULE-9167737347; MCULE-3795342438; ST016434; 4-(4-Methoxybenzylideneamino)benzenesulfonamide; Benzenesulfonamide, 4-(4-methoxybenzylideneamino)-; 4-((4-METHOXYBENZYLIDENE)AMINO)BENZENESULFONAMIDE
DM2OR8E	DT	Small molecular drug
DM2OR8E	PC	625902
DM2OR8E	MW	290.34
DM2OR8E	FM	C14H14N2O3S
DM2OR8E	IC	InChI=1S/C14H14N2O3S/c1-19-13-6-2-11(3-7-13)10-16-12-4-8-14(9-5-12)20(15,17)18/h2-10H,1H3,(H2,15,17,18)
DM2OR8E	CS	COC1=CC=C(C=C1)C=NC2=CC=C(C=C2)S(=O)(=O)N
DM2OR8E	IK	MLUHDVSELBSKPI-UHFFFAOYSA-N
DM2OR8E	IU	4-[(4-methoxyphenyl)methylideneamino]benzenesulfonamide
DM2OR8E	CA	CAS 66667-56-9
DM2OR8E	DE	Discovery agent

DMZSQ04	ID	DMZSQ04
DMZSQ04	DN	4-(4-methyl-benzylideneamino)-benzenesulfonamide
DMZSQ04	HS	Investigative
DMZSQ04	SN	CHEMBL429915; AC1LEQSK; SCHEMBL5312741; SOHFVFXITPDEDK-UHFFFAOYSA-N; ZINC95919525; ZINC18036434; BDBM50371763; ZINC253618240; AKOS016038193; AKOS003632590; MCULE-3900521489; ST009696; N-(4-Methylbenzylidene)-4-sulfamoylaniline; J3.552.121F; 4-[[(E)-4-Methylbenzylidene]amino]benzenesulfonamide; 4-[(4-methylphenyl)methylideneamino]benzenesulfonamide; 4-[(1E)-2-(4-methylphenyl)-1-azavinyl]benzenesulfonamide
DMZSQ04	DT	Small molecular drug
DMZSQ04	PC	690836
DMZSQ04	MW	274.34
DMZSQ04	FM	C14H14N2O2S
DMZSQ04	IC	InChI=1S/C14H14N2O2S/c1-11-2-4-12(5-3-11)10-16-13-6-8-14(9-7-13)19(15,17)18/h2-10H,1H3,(H2,15,17,18)
DMZSQ04	CS	CC1=CC=C(C=C1)C=NC2=CC=C(C=C2)S(=O)(=O)N
DMZSQ04	IK	SOHFVFXITPDEDK-UHFFFAOYSA-N
DMZSQ04	IU	4-[(4-methylphenyl)methylideneamino]benzenesulfonamide
DMZSQ04	DE	Discovery agent

DMYZHXR	ID	DMYZHXR
DMYZHXR	DN	4-(4-Methyl-indan-1-yl)-1H-imidazole
DMYZHXR	HS	Investigative
DMYZHXR	SN	SCHEMBL7035172; CHEMBL102763; 1H-Imidazole, 5-(2,3-dihydro-4-methyl-1H-inden-1-yl)-; AKOS006291239; 4-(4-methylindan-1-yl)-1h-imidazole; 192208-31-4; L016358
DMYZHXR	DT	Small molecular drug
DMYZHXR	PC	9990325
DMYZHXR	MW	198.26
DMYZHXR	FM	C13H14N2
DMYZHXR	IC	InChI=1S/C13H14N2/c1-9-3-2-4-11-10(9)5-6-12(11)13-7-14-8-15-13/h2-4,7-8,12H,5-6H2,1H3,(H,14,15)
DMYZHXR	CS	CC1=C2CCC(C2=CC=C1)C3=CN=CN3
DMYZHXR	IK	XXQLSAWUSXSJTK-UHFFFAOYSA-N
DMYZHXR	IU	5-(4-methyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazole
DMYZHXR	DE	Discovery agent

DMV0S4U	ID	DMV0S4U
DMV0S4U	DN	4-(4-methyl-phenyliminomethyl)-benzenesulfonamide
DMV0S4U	HS	Investigative
DMV0S4U	SN	CHEMBL271962; SCHEMBL5309671; GFCNORPCMFOXDQ-UHFFFAOYSA-N; BDBM50371756
DMV0S4U	DT	Small molecular drug
DMV0S4U	PC	21862824
DMV0S4U	MW	274.34
DMV0S4U	FM	C14H14N2O2S
DMV0S4U	IC	InChI=1S/C14H14N2O2S/c1-11-2-6-13(7-3-11)16-10-12-4-8-14(9-5-12)19(15,17)18/h2-10H,1H3,(H2,15,17,18)
DMV0S4U	CS	CC1=CC=C(C=C1)N=CC2=CC=C(C=C2)S(=O)(=O)N
DMV0S4U	IK	GFCNORPCMFOXDQ-UHFFFAOYSA-N
DMV0S4U	IU	4-[(4-methylphenyl)iminomethyl]benzenesulfonamide
DMV0S4U	DE	Discovery agent

DMS74F2	ID	DMS74F2
DMS74F2	DN	4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one
DMS74F2	HS	Investigative
DMS74F2	SN	CHEMBL373210; 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one
DMS74F2	DT	Small molecular drug
DMS74F2	PC	44403404
DMS74F2	MW	287.36
DMS74F2	FM	C16H21N3O2
DMS74F2	IC	InChI=1S/C16H21N3O2/c20-16-14-6-2-1-5-13(14)15(17-18-16)7-3-4-8-19-9-11-21-12-10-19/h1-2,5-6H,3-4,7-12H2,(H,18,20)
DMS74F2	CS	C1COCCN1CCCCC2=NNC(=O)C3=CC=CC=C32
DMS74F2	IK	BMGFFXOJQJDSQN-UHFFFAOYSA-N
DMS74F2	IU	4-(4-morpholin-4-ylbutyl)-2H-phthalazin-1-one
DMS74F2	DE	Discovery agent

DM3KCL1	ID	DM3KCL1
DM3KCL1	DN	4-(4-m-Tolylamino-phthalazin-1-yl)-benzamide
DM3KCL1	HS	Investigative
DM3KCL1	SN	CHEMBL196025; AC1LR1ZB; 4-(4-m-Tolylamino-phthalazin-1-yl)-benzamide; Oprea1_451204; MolPort-002-560-372; MolPort-000-703-859; ZINC1297754; BDBM50173029; STK846512; AKOS030511153; AKOS005626717; MCULE-6513504515; 4-(4-(m-tolylamino)phthalazin-1-yl)benzamide; AB00109646-01; 4-[4-(3-methylanilino)phthalazin-1-yl]benzamide
DM3KCL1	DT	Small molecular drug
DM3KCL1	PC	1416247
DM3KCL1	MW	354.4
DM3KCL1	FM	C22H18N4O
DM3KCL1	IC	InChI=1S/C22H18N4O/c1-14-5-4-6-17(13-14)24-22-19-8-3-2-7-18(19)20(25-26-22)15-9-11-16(12-10-15)21(23)27/h2-13H,1H3,(H2,23,27)(H,24,26)
DM3KCL1	CS	CC1=CC(=CC=C1)NC2=NN=C(C3=CC=CC=C32)C4=CC=C(C=C4)C(=O)N
DM3KCL1	IK	JBCRRCQSLMCSLQ-UHFFFAOYSA-N
DM3KCL1	IU	4-[4-(3-methylanilino)phthalazin-1-yl]benzamide
DM3KCL1	DE	Discovery agent

DMHB1N6	ID	DMHB1N6
DMHB1N6	DN	4'-(4-Nitrobenzensulfonamide)-4-hydroxychalcone
DMHB1N6	HS	Investigative
DMHB1N6	SN	CHEMBL1087324; SCHEMBL3484304; BDBM50316855
DMHB1N6	DT	Small molecular drug
DMHB1N6	PC	24989566
DMHB1N6	MW	424.4
DMHB1N6	FM	C21H16N2O6S
DMHB1N6	IC	InChI=1S/C21H16N2O6S/c24-19-10-1-15(2-11-19)3-14-21(25)16-4-6-17(7-5-16)22-30(28,29)20-12-8-18(9-13-20)23(26)27/h1-14,22,24H/b14-3+
DMHB1N6	CS	C1=CC(=CC=C1/C=C/C(=O)C2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)[N+](=O)[O-])O
DMHB1N6	IK	WQIGNJDEMJBAFL-LZWSPWQCSA-N
DMHB1N6	IU	N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]-4-nitrobenzenesulfonamide
DMHB1N6	DE	Discovery agent

DMM86YK	ID	DMM86YK
DMM86YK	DN	4-(4-nitro-benzylideneamino)-benzenesulfonamide
DMM86YK	HS	Investigative
DMM86YK	SN	CHEMBL255175; 66667-60-5; 4-[(1E)-2-(4-nitrophenyl)-1-azavinyl]benzenesulfonamide; AC1LBU0E; 4-[(4-nitrophenyl)methylideneamino]benzenesulfonamide; SCHEMBL12416808; CTK5I3043; CTK1J4461; DTXSID10340363; IJEQJCKQAKELNC-OQLLNIDSSA-N; MolPort-001-818-097; ZINC131032; BDBM50371746; STK790732; SBB006116; AKOS001719928; MCULE-1611993564; MCULE-9098092341; ST016439; EU-0084260; 4-(4-Nitrobenzylideneamino)Benzenesulfonamide; 4-[(4-Nitrobenzylidene)amino]benzenesulfonamide; Benzenesulfonamide, 4-(4-nitrobenzylidenamino)-
DMM86YK	DT	Small molecular drug
DMM86YK	PC	564225
DMM86YK	MW	305.31
DMM86YK	FM	C13H11N3O4S
DMM86YK	IC	InChI=1S/C13H11N3O4S/c14-21(19,20)13-7-3-11(4-8-13)15-9-10-1-5-12(6-2-10)16(17)18/h1-9H,(H2,14,19,20)
DMM86YK	CS	C1=CC(=CC=C1C=NC2=CC=C(C=C2)S(=O)(=O)N)[N+](=O)[O-]
DMM86YK	IK	IJEQJCKQAKELNC-UHFFFAOYSA-N
DMM86YK	IU	4-[(4-nitrophenyl)methylideneamino]benzenesulfonamide
DMM86YK	CA	CAS 66667-60-5
DMM86YK	DE	Discovery agent

DMGVNE3	ID	DMGVNE3
DMGVNE3	DN	4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide
DMGVNE3	HS	Investigative
DMGVNE3	SN	azo-sulfonamide, 1c; CHEMBL571371; BDBM33268; 4-[(E)-[4-(methylamino)phenyl]azo]benzenesulfonamide
DMGVNE3	DT	Small molecular drug
DMGVNE3	PC	44246261
DMGVNE3	MW	290.34
DMGVNE3	FM	C13H14N4O2S
DMGVNE3	IC	InChI=1S/C13H14N4O2S/c1-15-10-2-4-11(5-3-10)16-17-12-6-8-13(9-7-12)20(14,18)19/h2-9,15H,1H3,(H2,14,18,19)
DMGVNE3	CS	CNC1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)N
DMGVNE3	IK	RMLHDMTUTOMVIX-UHFFFAOYSA-N
DMGVNE3	IU	4-[[4-(methylamino)phenyl]diazenyl]benzenesulfonamide
DMGVNE3	DE	Discovery agent

DMOHB6U	ID	DMOHB6U
DMOHB6U	DN	4-(4-phenoxybenzoyl)benzoic acid
DMOHB6U	HS	Investigative
DMOHB6U	SN	4-(4-phenoxybenzoyl)benzoic Acid; CHEMBL36392; SCHEMBL7822422; BDBM50180894; 4-(4-Phenoxy-benzoyl)-benzoic acid
DMOHB6U	DT	Small molecular drug
DMOHB6U	PC	10087225
DMOHB6U	MW	318.3
DMOHB6U	FM	C20H14O4
DMOHB6U	IC	InChI=1S/C20H14O4/c21-19(14-6-8-16(9-7-14)20(22)23)15-10-12-18(13-11-15)24-17-4-2-1-3-5-17/h1-13H,(H,22,23)
DMOHB6U	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DMOHB6U	IK	SQQFOBWKPOREAO-UHFFFAOYSA-N
DMOHB6U	IU	4-(4-phenoxybenzoyl)benzoic acid
DMOHB6U	DE	Discovery agent

DMQ0JWZ	ID	DMQ0JWZ
DMQ0JWZ	DN	4-(4-phenoxybenzoyl)phenylacetic acid
DMQ0JWZ	HS	Investigative
DMQ0JWZ	SN	4-(4-phenoxybenzoyl)phenylacetic acid; CHEMBL370016
DMQ0JWZ	DT	Small molecular drug
DMQ0JWZ	PC	11695657
DMQ0JWZ	MW	332.3
DMQ0JWZ	FM	C21H16O4
DMQ0JWZ	IC	InChI=1S/C21H16O4/c22-20(23)14-15-6-8-16(9-7-15)21(24)17-10-12-19(13-11-17)25-18-4-2-1-3-5-18/h1-13H,14H2,(H,22,23)
DMQ0JWZ	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)CC(=O)O
DMQ0JWZ	IK	VRBHQDUOTOPSLA-UHFFFAOYSA-N
DMQ0JWZ	IU	2-[4-(4-phenoxybenzoyl)phenyl]acetic acid
DMQ0JWZ	DE	Discovery agent

DMKMH5L	ID	DMKMH5L
DMKMH5L	DN	4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one
DMKMH5L	HS	Investigative
DMKMH5L	SN	5-(4-Phenoxybutoxy)psoralen; 870653-45-5; UNII-A62C114Q0Q; CHEMBL444449; A62C114Q0Q; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-(4-phenoxybutoxy)-; 4-(4-phenoxybutoxy)furo[3,2-g]chromen-7-one; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-(4-phenoxybutoxy)-; C21H18O5; 4-(4-Phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one; 7h-furo[3; 4-(4-phenoxybutoxy)-; 2-g][1]benzopyran-7-one; 5-(4-phenoxybutoxy) psoralen; GTPL2554; SCHEMBL2585454; CTK8F0318; DTXSID80461776; 5-(4-phenoxybutoxy)psoralen
DMKMH5L	DT	Small molecular drug
DMKMH5L	PC	11302540
DMKMH5L	MW	350.4
DMKMH5L	FM	C21H18O5
DMKMH5L	IC	InChI=1S/C21H18O5/c22-20-9-8-16-19(26-20)14-18-17(10-13-24-18)21(16)25-12-5-4-11-23-15-6-2-1-3-7-15/h1-3,6-10,13-14H,4-5,11-12H2
DMKMH5L	CS	C1=CC=C(C=C1)OCCCCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4
DMKMH5L	IK	KINMYBBFQRSVLL-UHFFFAOYSA-N
DMKMH5L	IU	4-(4-phenoxybutoxy)furo[3,2-g]chromen-7-one
DMKMH5L	CA	CAS 870653-45-5
DMKMH5L	DE	Discovery agent

DMBZHUA	ID	DMBZHUA
DMBZHUA	DN	4-(4-propoxyphenoxy)phenol
DMBZHUA	HS	Investigative
DMBZHUA	SN	4-(4-propoxyphenoxy)phenol; CHEMBL472893; SCHEMBL19848981
DMBZHUA	DT	Small molecular drug
DMBZHUA	PC	44562813
DMBZHUA	MW	244.28
DMBZHUA	FM	C15H16O3
DMBZHUA	IC	InChI=1S/C15H16O3/c1-2-11-17-13-7-9-15(10-8-13)18-14-5-3-12(16)4-6-14/h3-10,16H,2,11H2,1H3
DMBZHUA	CS	CCCOC1=CC=C(C=C1)OC2=CC=C(C=C2)O
DMBZHUA	IK	FNAGBMSBTIDLJO-UHFFFAOYSA-N
DMBZHUA	IU	4-(4-propoxyphenoxy)phenol
DMBZHUA	DE	Discovery agent

DM6ESXB	ID	DM6ESXB
DM6ESXB	DN	4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide
DM6ESXB	HS	Investigative
DM6ESXB	SN	CHEMBL194747; 4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide; BAS 02999388; AC1LR1JT; Oprea1_289700; Oprea1_093859; SCHEMBL3021915; MolPort-000-702-961; MolPort-001-909-424; ZINC1297142; BDBM50173017; STL148635; STL483208; AKOS005748394; AKOS000665050; MCULE-9763616884; 4-(4-(p-tolylamino)phthalazin-1-yl)benzamide; 4-[4-(4-methylanilino)phthalazin-1-yl]benzamide; 4-{4-[(4-methylphenyl)amino]phthalazin-1-yl}benzamide
DM6ESXB	DT	Small molecular drug
DM6ESXB	PC	1416020
DM6ESXB	MW	354.4
DM6ESXB	FM	C22H18N4O
DM6ESXB	IC	InChI=1S/C22H18N4O/c1-14-6-12-17(13-7-14)24-22-19-5-3-2-4-18(19)20(25-26-22)15-8-10-16(11-9-15)21(23)27/h2-13H,1H3,(H2,23,27)(H,24,26)
DM6ESXB	CS	CC1=CC=C(C=C1)NC2=NN=C(C3=CC=CC=C32)C4=CC=C(C=C4)C(=O)N
DM6ESXB	IK	UTDXGHMGCXLCKT-UHFFFAOYSA-N
DM6ESXB	IU	4-[4-(4-methylanilino)phthalazin-1-yl]benzamide
DM6ESXB	DE	Discovery agent

DMFLH2G	ID	DMFLH2G
DMFLH2G	DN	4-(4-tert-butylbenzylideneamino)benzoic acid
DMFLH2G	HS	Investigative
DMFLH2G	SN	CHEMBL567821; 4-(4-tert-butylbenzylideneamino)benzoic acid
DMFLH2G	DT	Small molecular drug
DMFLH2G	PC	45483280
DMFLH2G	MW	281.3
DMFLH2G	FM	C18H19NO2
DMFLH2G	IC	InChI=1S/C18H19NO2/c1-18(2,3)15-8-4-13(5-9-15)12-19-16-10-6-14(7-11-16)17(20)21/h4-12H,1-3H3,(H,20,21)
DMFLH2G	CS	CC(C)(C)C1=CC=C(C=C1)C=NC2=CC=C(C=C2)C(=O)O
DMFLH2G	IK	CZLMLVYXQCJOGH-UHFFFAOYSA-N
DMFLH2G	IU	4-[(4-tert-butylphenyl)methylideneamino]benzoic acid
DMFLH2G	DE	Discovery agent

DMG6DV9	ID	DMG6DV9
DMG6DV9	DN	4-(4-tert-butylbenzylthio)-2-aminobutanoic acid
DMG6DV9	HS	Investigative
DMG6DV9	SN	CHEMBL383441; 4-(4-tert-butylbenzylthio)-2-aminobutanoic acid; BDBM50179698
DMG6DV9	DT	Small molecular drug
DMG6DV9	PC	44408220
DMG6DV9	MW	281.4
DMG6DV9	FM	C15H23NO2S
DMG6DV9	IC	InChI=1S/C15H23NO2S/c1-15(2,3)12-6-4-11(5-7-12)10-19-9-8-13(16)14(17)18/h4-7,13H,8-10,16H2,1-3H3,(H,17,18)
DMG6DV9	CS	CC(C)(C)C1=CC=C(C=C1)CSCCC(C(=O)O)N
DMG6DV9	IK	BAHGAZBQXUXBJR-UHFFFAOYSA-N
DMG6DV9	IU	2-amino-4-[(4-tert-butylphenyl)methylsulfanyl]butanoic acid
DMG6DV9	DE	Discovery agent

DMGHVW7	ID	DMGHVW7
DMGHVW7	DN	4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol
DMGHVW7	HS	Investigative
DMGHVW7	SN	CHEMBL205512; 4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol
DMGHVW7	DT	Small molecular drug
DMGHVW7	PC	44408965
DMGHVW7	MW	281.4
DMGHVW7	FM	C17H15NOS
DMGHVW7	IC	InChI=1S/C17H15NOS/c1-18-14-6-2-12(3-7-14)16-10-11-17(20-16)13-4-8-15(19)9-5-13/h2-11,18-19H,1H3
DMGHVW7	CS	CNC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)O
DMGHVW7	IK	CXLILFMFVYDZLM-UHFFFAOYSA-N
DMGHVW7	IU	4-[5-[4-(methylamino)phenyl]thiophen-2-yl]phenol
DMGHVW7	DE	Discovery agent

DMOGMJ9	ID	DMOGMJ9
DMOGMJ9	DN	4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine
DMOGMJ9	HS	Investigative
DMOGMJ9	SN	CHEMBL382007; 2,5-bis(4-aminophenyl)thiophene; 4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine; SCHEMBL6751854; ZINC28571226; BDBM50178547; 70010-49-0
DMOGMJ9	DT	Small molecular drug
DMOGMJ9	PC	21788024
DMOGMJ9	MW	266.4
DMOGMJ9	FM	C16H14N2S
DMOGMJ9	IC	InChI=1S/C16H14N2S/c17-13-5-1-11(2-6-13)15-9-10-16(19-15)12-3-7-14(18)8-4-12/h1-10H,17-18H2
DMOGMJ9	CS	C1=CC(=CC=C1C2=CC=C(S2)C3=CC=C(C=C3)N)N
DMOGMJ9	IK	QUVIYFJRWXKEKM-UHFFFAOYSA-N
DMOGMJ9	IU	4-[5-(4-aminophenyl)thiophen-2-yl]aniline
DMOGMJ9	DE	Discovery agent

DM1UX89	ID	DM1UX89
DM1UX89	DN	4-(5-(4-aminophenyl)thiophen-2-yl)phenol
DM1UX89	HS	Investigative
DM1UX89	SN	CHEMBL205824; 4-(5-(4-aminophenyl)thiophen-2-yl)phenol; SCHEMBL12973258
DM1UX89	DT	Small molecular drug
DM1UX89	PC	44408840
DM1UX89	MW	267.3
DM1UX89	FM	C16H13NOS
DM1UX89	IC	InChI=1S/C16H13NOS/c17-13-5-1-11(2-6-13)15-9-10-16(19-15)12-3-7-14(18)8-4-12/h1-10,18H,17H2
DM1UX89	CS	C1=CC(=CC=C1C2=CC=C(S2)C3=CC=C(C=C3)O)N
DM1UX89	IK	NTAJNMDKXYZMKZ-UHFFFAOYSA-N
DM1UX89	IU	4-[5-(4-aminophenyl)thiophen-2-yl]phenol
DM1UX89	DE	Discovery agent

DMK1ZF2	ID	DMK1ZF2
DMK1ZF2	DN	4-(5-(4-Hydroxyphenyl)isothiazol-4-yl)phenol
DMK1ZF2	HS	Investigative
DMK1ZF2	DT	Small molecular drug
DMK1ZF2	PC	136036233
DMK1ZF2	MW	269.3
DMK1ZF2	FM	C15H11NO2S
DMK1ZF2	IC	InChI=1S/C15H11NO2S/c17-12-5-1-10(2-6-12)14-9-16-19-15(14)11-3-7-13(18)8-4-11/h1-9,17-18H
DMK1ZF2	CS	C1=CC(=CC=C1C2=C(SN=C2)C3=CC=C(C=C3)O)O
DMK1ZF2	IK	OCBISDMDUBGFSN-UHFFFAOYSA-N
DMK1ZF2	IU	4-[5-(4-hydroxyphenyl)-1,2-thiazol-4-yl]phenol
DMK1ZF2	DE	Discovery agent

DMO9YH0	ID	DMO9YH0
DMO9YH0	DN	4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine
DMO9YH0	HS	Investigative
DMO9YH0	SN	CHEMBL203320; 4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine; SCHEMBL12973259
DMO9YH0	DT	Small molecular drug
DMO9YH0	PC	44408839
DMO9YH0	MW	281.4
DMO9YH0	FM	C17H15NOS
DMO9YH0	IC	InChI=1S/C17H15NOS/c1-19-15-8-4-13(5-9-15)17-11-10-16(20-17)12-2-6-14(18)7-3-12/h2-11H,18H2,1H3
DMO9YH0	CS	COC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)N
DMO9YH0	IK	JJUWIYUCBOADAD-UHFFFAOYSA-N
DMO9YH0	IU	4-[5-(4-methoxyphenyl)thiophen-2-yl]aniline
DMO9YH0	DE	Discovery agent

DMCNLBZ	ID	DMCNLBZ
DMCNLBZ	DN	4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol
DMCNLBZ	HS	Investigative
DMCNLBZ	SN	CHEMBL381991; 4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol
DMCNLBZ	DT	Small molecular drug
DMCNLBZ	PC	44408738
DMCNLBZ	MW	282.4
DMCNLBZ	FM	C17H14O2S
DMCNLBZ	IC	InChI=1S/C17H14O2S/c1-19-15-8-4-13(5-9-15)17-11-10-16(20-17)12-2-6-14(18)7-3-12/h2-11,18H,1H3
DMCNLBZ	CS	COC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)O
DMCNLBZ	IK	WNCPZRMABGADNX-UHFFFAOYSA-N
DMCNLBZ	IU	4-[5-(4-methoxyphenyl)thiophen-2-yl]phenol
DMCNLBZ	DE	Discovery agent

DMJKUQI	ID	DMJKUQI
DMJKUQI	DN	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine
DMJKUQI	HS	Investigative
DMJKUQI	SN	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine; Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872
DMJKUQI	DT	Small molecular drug
DMJKUQI	PC	10017019
DMJKUQI	MW	289.13
DMJKUQI	FM	C12H9BrN4
DMJKUQI	IC	InChI=1S/C12H9BrN4/c13-7-1-2-10-8(5-7)9(6-16-10)11-3-4-15-12(14)17-11/h1-6,16H,(H2,14,15,17)
DMJKUQI	CS	C1=CC2=C(C=C1Br)C(=CN2)C3=NC(=NC=C3)N
DMJKUQI	IK	PKQJCYXKRNGUKQ-UHFFFAOYSA-N
DMJKUQI	IU	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine
DMJKUQI	CA	CAS 213473-00-8
DMJKUQI	DE	Discovery agent

DMLSGU1	ID	DMLSGU1
DMLSGU1	DN	4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline
DMLSGU1	HS	Investigative
DMLSGU1	SN	CHEMBL473320; 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline; SCHEMBL5616932
DMLSGU1	DT	Small molecular drug
DMLSGU1	PC	11696664
DMLSGU1	MW	384.2
DMLSGU1	FM	C18H14BrN3O2
DMLSGU1	IC	InChI=1S/C18H14BrN3O2/c1-23-16-6-12-15(7-17(16)24-2)21-9-22-18(12)13-8-20-14-4-3-10(19)5-11(13)14/h3-9,20H,1-2H3
DMLSGU1	CS	COC1=C(C=C2C(=C1)C(=NC=N2)C3=CNC4=C3C=C(C=C4)Br)OC
DMLSGU1	IK	MWBJNWJINFGNLQ-UHFFFAOYSA-N
DMLSGU1	IU	4-(5-bromo-1H-indol-3-yl)-6,7-dimethoxyquinazoline
DMLSGU1	DE	Discovery agent

DMDYBIC	ID	DMDYBIC
DMDYBIC	DN	4'-(5-Chloro-2-thienyl)biphenyl-3-ol
DMDYBIC	HS	Investigative
DMDYBIC	SN	CHEMBL1099312; BDBM50318418
DMDYBIC	DT	Small molecular drug
DMDYBIC	PC	46887551
DMDYBIC	MW	286.8
DMDYBIC	FM	C16H11ClOS
DMDYBIC	IC	InChI=1S/C16H11ClOS/c17-16-9-8-15(19-16)12-6-4-11(5-7-12)13-2-1-3-14(18)10-13/h1-10,18H
DMDYBIC	CS	C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC=C(S3)Cl
DMDYBIC	IK	ABAQWDXYFZGNGR-UHFFFAOYSA-N
DMDYBIC	IU	3-[4-(5-chlorothiophen-2-yl)phenyl]phenol
DMDYBIC	DE	Discovery agent

DM1EANV	ID	DM1EANV
DM1EANV	DN	4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol
DM1EANV	HS	Investigative
DM1EANV	DT	Small molecular drug
DM1EANV	PC	135486039
DM1EANV	MW	243.21
DM1EANV	FM	C13H9NO4
DM1EANV	IC	InChI=1S/C13H9NO4/c15-7-2-4-12-10(5-7)14-13(18-12)9-3-1-8(16)6-11(9)17/h1-6,15-17H
DM1EANV	CS	C1=CC(=C(C=C1O)O)C2=NC3=C(O2)C=CC(=C3)O
DM1EANV	IK	RGXSSCFRVTXICH-UHFFFAOYSA-N
DM1EANV	IU	4-(5-hydroxy-1,3-benzoxazol-2-yl)benzene-1,3-diol
DM1EANV	DE	Discovery agent

DMIWT60	ID	DMIWT60
DMIWT60	DN	4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine
DMIWT60	HS	Investigative
DMIWT60	SN	5-Substituted 1-Phenylbenzimidazole 22; AC1NS4PO; SCHEMBL7989819; CHEMBL309035; BDBM3933; AKOS023129997; 4-(5-methoxybenzimidazol-1-yl)aniline; 5-Methoxy-1-(4-aminophenyl)-1H-benzimidazole; 4-(5-methoxy-1H-1,3-benzodiazol-1-yl)aniline; 1-(4-aminophenyl)-5-methoxybenzimidazole dihydrochloride
DMIWT60	DT	Small molecular drug
DMIWT60	PC	5328512
DMIWT60	MW	239.27
DMIWT60	FM	C14H13N3O
DMIWT60	IC	InChI=1S/C14H13N3O/c1-18-12-6-7-14-13(8-12)16-9-17(14)11-4-2-10(15)3-5-11/h2-9H,15H2,1H3
DMIWT60	CS	COC1=CC2=C(C=C1)N(C=N2)C3=CC=C(C=C3)N
DMIWT60	IK	KLJLVCKIKCKKEA-UHFFFAOYSA-N
DMIWT60	IU	4-(5-methoxybenzimidazol-1-yl)aniline
DMIWT60	DE	Discovery agent

DMKT20Q	ID	DMKT20Q
DMKT20Q	DN	4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide
DMKT20Q	HS	Investigative
DMKT20Q	SN	CHEMBL1163382; 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide
DMKT20Q	DT	Small molecular drug
DMKT20Q	PC	46704077
DMKT20Q	MW	240.28
DMKT20Q	FM	C9H12N4O2S
DMKT20Q	IC	InChI=1S/C9H12N4O2S/c1-7-2-5-12-13(7)8-3-4-11-6-9(8)16(10,14)15/h3-7H,2H2,1H3,(H2,10,14,15)
DMKT20Q	CS	CC1CC=NN1C2=C(C=NC=C2)S(=O)(=O)N
DMKT20Q	IK	LMKCKKHGIIIBOX-UHFFFAOYSA-N
DMKT20Q	IU	4-(3-methyl-3,4-dihydropyrazol-2-yl)pyridine-3-sulfonamide
DMKT20Q	DE	Discovery agent

DMXHIK5	ID	DMXHIK5
DMXHIK5	DN	4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one
DMXHIK5	HS	Investigative
DMXHIK5	SN	CHEMBL194684; 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one
DMXHIK5	DT	Small molecular drug
DMXHIK5	PC	44403402
DMXHIK5	MW	301.4
DMXHIK5	FM	C17H23N3O2
DMXHIK5	IC	InChI=1S/C17H23N3O2/c21-17-15-7-4-3-6-14(15)16(18-19-17)8-2-1-5-9-20-10-12-22-13-11-20/h3-4,6-7H,1-2,5,8-13H2,(H,19,21)
DMXHIK5	CS	C1COCCN1CCCCCC2=NNC(=O)C3=CC=CC=C32
DMXHIK5	IK	OSFRDFHBAQDMGC-UHFFFAOYSA-N
DMXHIK5	IU	4-(5-morpholin-4-ylpentyl)-2H-phthalazin-1-one
DMXHIK5	DE	Discovery agent

DMUHQ0J	ID	DMUHQ0J
DMUHQ0J	DN	4-(5-Nitro-indol-1-ylmethyl)-benzamidine
DMUHQ0J	HS	Investigative
DMUHQ0J	SN	CHEMBL100296; 4-(5-Nitro-indol-1-ylmethyl)-benzamidine
DMUHQ0J	DT	Small molecular drug
DMUHQ0J	PC	44331823
DMUHQ0J	MW	294.31
DMUHQ0J	FM	C16H14N4O2
DMUHQ0J	IC	InChI=1S/C16H14N4O2/c17-16(18)12-3-1-11(2-4-12)10-19-8-7-13-9-14(20(21)22)5-6-15(13)19/h1-9H,10H2,(H3,17,18)
DMUHQ0J	CS	C1=CC(=CC=C1CN2C=CC3=C2C=CC(=C3)[N+](=O)[O-])C(=N)N
DMUHQ0J	IK	TYZQZZRAPZQXLG-UHFFFAOYSA-N
DMUHQ0J	IU	4-[(5-nitroindol-1-yl)methyl]benzenecarboximidamide
DMUHQ0J	DE	Discovery agent

DM3N9O5	ID	DM3N9O5
DM3N9O5	DN	4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide
DM3N9O5	HS	Investigative
DM3N9O5	SN	GW572399X; 4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide; 2-Anilino-5-aryloxazole 15; AC1NS7RK; CHEMBL194062; BDBM5854; HMS3303D13; HMS3305L11; NCGC00242064-01; AB01092072-01
DM3N9O5	DT	Small molecular drug
DM3N9O5	PC	5329850
DM3N9O5	MW	315.3
DM3N9O5	FM	C15H13N3O3S
DM3N9O5	IC	InChI=1S/C15H13N3O3S/c16-22(19,20)13-8-6-12(7-9-13)18-15-17-10-14(21-15)11-4-2-1-3-5-11/h1-10H,(H,17,18)(H2,16,19,20)
DM3N9O5	CS	C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=C(C=C3)S(=O)(=O)N
DM3N9O5	IK	OKFOIEMZTIOWQH-UHFFFAOYSA-N
DM3N9O5	IU	4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide
DM3N9O5	DE	Discovery agent

DMZ1DW0	ID	DMZ1DW0
DMZ1DW0	DN	4-(5-tert-Butyl-[1,3]dithian-2-yl)-benzonitrile
DMZ1DW0	HS	Investigative
DMZ1DW0	SN	CHEMBL90342; SCHEMBL8950639; ZINC584599047; ZINC584599044
DMZ1DW0	DT	Small molecular drug
DMZ1DW0	PC	10039485
DMZ1DW0	MW	277.5
DMZ1DW0	FM	C15H19NS2
DMZ1DW0	IC	InChI=1S/C15H19NS2/c1-15(2,3)13-9-17-14(18-10-13)12-6-4-11(8-16)5-7-12/h4-7,13-14H,9-10H2,1-3H3
DMZ1DW0	CS	CC(C)(C)C1CSC(SC1)C2=CC=C(C=C2)C#N
DMZ1DW0	IK	JBVUMTNJGGTVQA-UHFFFAOYSA-N
DMZ1DW0	IU	4-(5-tert-butyl-1,3-dithian-2-yl)benzonitrile
DMZ1DW0	DE	Discovery agent

DM8A6UH	ID	DM8A6UH
DM8A6UH	DN	4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid
DM8A6UH	HS	Investigative
DM8A6UH	SN	CHEMBL66868; 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid; SCHEMBL8172493; ZINC13737718
DM8A6UH	DT	Small molecular drug
DM8A6UH	PC	10244811
DM8A6UH	MW	309.3
DM8A6UH	FM	C18H15NO4
DM8A6UH	IC	InChI=1S/C18H15NO4/c1-22-16-8-13-7-14(10-19-15(13)9-17(16)23-2)11-3-5-12(6-4-11)18(20)21/h3-10H,1-2H3,(H,20,21)
DM8A6UH	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=C(C=C3)C(=O)O
DM8A6UH	IK	YEEIRSIWKQULLK-UHFFFAOYSA-N
DM8A6UH	IU	4-(6,7-dimethoxyquinolin-3-yl)benzoic acid
DM8A6UH	DE	Discovery agent

DM9RNUX	ID	DM9RNUX
DM9RNUX	DN	4-(6,7-Dimethoxy-quinolin-3-yl)-phenol
DM9RNUX	HS	Investigative
DM9RNUX	SN	CHEMBL303704; 4-(6,7-dimethoxyquinolin-3-yl)phenol; 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol; ZINC3834025
DM9RNUX	DT	Small molecular drug
DM9RNUX	PC	11778467
DM9RNUX	MW	281.3
DM9RNUX	FM	C17H15NO3
DM9RNUX	IC	InChI=1S/C17H15NO3/c1-20-16-8-12-7-13(11-3-5-14(19)6-4-11)10-18-15(12)9-17(16)21-2/h3-10,19H,1-2H3
DM9RNUX	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=C(C=C3)O
DM9RNUX	IK	GVQYSEHILFQSHO-UHFFFAOYSA-N
DM9RNUX	IU	4-(6,7-dimethoxyquinolin-3-yl)phenol
DM9RNUX	DE	Discovery agent

DMPD9GE	ID	DMPD9GE
DMPD9GE	DN	4-(6-Cyclohexyl-hex-3-ynyl)-1H-imidazole
DMPD9GE	HS	Investigative
DMPD9GE	SN	CHEMBL15000; 4-(6-Cyclohexyl-hex-3-ynyl)-1H-imidazole; SCHEMBL7621912; LATXTZVCBBIDBM-UHFFFAOYSA-N; ZINC2001873; PDSP2_000104; BDBM50070211; PDSP1_000104; GT 2260; GT-2260; 1-[1H-imidazol-4-yl]-6-cyclohexyl-3-hexyne
DMPD9GE	DT	Small molecular drug
DMPD9GE	PC	10220233
DMPD9GE	MW	230.35
DMPD9GE	FM	C15H22N2
DMPD9GE	IC	InChI=1S/C15H22N2/c1(2-7-11-15-12-16-13-17-15)4-8-14-9-5-3-6-10-14/h12-14H,3-11H2,(H,16,17)
DMPD9GE	CS	C1CCC(CC1)CCC#CCCC2=CN=CN2
DMPD9GE	IK	LATXTZVCBBIDBM-UHFFFAOYSA-N
DMPD9GE	IU	5-(6-cyclohexylhex-3-ynyl)-1H-imidazole
DMPD9GE	DE	Discovery agent

DM4EC0J	ID	DM4EC0J
DM4EC0J	DN	4-(6-Cyclopentyl-hex-3-ynyl)-1H-imidazole
DM4EC0J	HS	Investigative
DM4EC0J	SN	CHEMBL274977; 4-(6-Cyclopentyl-hex-3-ynyl)-1H-imidazole; SCHEMBL7621345; PDSP1_000105; ZINC13795227; BDBM50070220; PDSP2_000105; GT-2286; GT 2286
DM4EC0J	DT	Small molecular drug
DM4EC0J	PC	9794398
DM4EC0J	MW	216.32
DM4EC0J	FM	C14H20N2
DM4EC0J	IC	InChI=1S/C14H20N2/c1(3-7-13-8-5-6-9-13)2-4-10-14-11-15-12-16-14/h11-13H,3-10H2,(H,15,16)
DM4EC0J	CS	C1CCC(C1)CCC#CCCC2=CN=CN2
DM4EC0J	IK	XFHACGZTJUJXHB-UHFFFAOYSA-N
DM4EC0J	IU	5-(6-cyclopentylhex-3-ynyl)-1H-imidazole
DM4EC0J	DE	Discovery agent

DMHGRPB	ID	DMHGRPB
DMHGRPB	DN	4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
DMHGRPB	HS	Investigative
DMHGRPB	DT	Small molecular drug
DMHGRPB	PC	135566322
DMHGRPB	MW	242.23
DMHGRPB	FM	C13H10N2O3
DMHGRPB	IC	InChI=1S/C13H10N2O3/c16-7-1-3-9-11(5-7)14-15-13(9)10-4-2-8(17)6-12(10)18/h1-6,16-18H,(H,14,15)
DMHGRPB	CS	C1=CC2=C(C=C1O)NN=C2C3=C(C=C(C=C3)O)O
DMHGRPB	IK	WLDZDEMGKFWJNR-UHFFFAOYSA-N
DMHGRPB	IU	4-(6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol
DMHGRPB	CA	CAS 117767-16-5
DMHGRPB	DE	Discovery agent

DM38YZ4	ID	DM38YZ4
DM38YZ4	DN	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DM38YZ4	HS	Investigative
DM38YZ4	DT	Small molecular drug
DM38YZ4	PC	135545334
DM38YZ4	MW	243.21
DM38YZ4	FM	C13H9NO4
DM38YZ4	IC	InChI=1S/C13H9NO4/c15-8-2-3-9-12(6-8)18-13(14-9)7-1-4-10(16)11(17)5-7/h1-6,15-17H
DM38YZ4	CS	C1=CC(=C(C=C1C2=NC3=C(O2)C=C(C=C3)O)O)O
DM38YZ4	IK	QSWPVNMCVFYCHT-UHFFFAOYSA-N
DM38YZ4	IU	4-(6-hydroxy-1,3-benzoxazol-2-yl)benzene-1,2-diol
DM38YZ4	DE	Discovery agent

DM07NT9	ID	DM07NT9
DM07NT9	DN	4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol
DM07NT9	HS	Investigative
DM07NT9	DT	Small molecular drug
DM07NT9	PC	135522275
DM07NT9	MW	243.21
DM07NT9	FM	C13H9NO4
DM07NT9	IC	InChI=1S/C13H9NO4/c15-7-1-3-9(11(17)5-7)13-14-10-4-2-8(16)6-12(10)18-13/h1-6,15-17H
DM07NT9	CS	C1=CC(=C(C=C1O)O)C2=NC3=C(O2)C=C(C=C3)O
DM07NT9	IK	FLDXQSCXJKEXJF-UHFFFAOYSA-N
DM07NT9	IU	4-(6-hydroxy-1,3-benzoxazol-2-yl)benzene-1,3-diol
DM07NT9	DE	Discovery agent

DM4SPV7	ID	DM4SPV7
DM4SPV7	DN	4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DM4SPV7	HS	Investigative
DM4SPV7	SN	HS-1793; CHEMBL248499; 927885-00-5; 4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol; 4-(6-hydroxy-2-naphthyl)-1,3-benzenediol; AOB4534; BCP17387; ZINC28878526; BDBM50197244
DM4SPV7	DT	Small molecular drug
DM4SPV7	PC	16215105
DM4SPV7	MW	252.26
DM4SPV7	FM	C16H12O3
DM4SPV7	IC	InChI=1S/C16H12O3/c17-13-4-3-10-7-12(2-1-11(10)8-13)15-6-5-14(18)9-16(15)19/h1-9,17-19H
DM4SPV7	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=C(C=C(C=C3)O)O
DM4SPV7	IK	BXZJBSHLEZAMOP-UHFFFAOYSA-N
DM4SPV7	IU	4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DM4SPV7	DE	Discovery agent

DM3L5I6	ID	DM3L5I6
DM3L5I6	DN	4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DM3L5I6	HS	Investigative
DM3L5I6	SN	CHEMBL209724; 4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DM3L5I6	DT	Small molecular drug
DM3L5I6	PC	44413495
DM3L5I6	MW	302.4
DM3L5I6	FM	C15H14N2O3S
DM3L5I6	IC	InChI=1S/C15H14N2O3S/c1-20-13-5-2-11-8-9-17(15(11)10-13)21(18,19)14-6-3-12(16)4-7-14/h2-10H,16H2,1H3
DM3L5I6	CS	COC1=CC2=C(C=C1)C=CN2S(=O)(=O)C3=CC=C(C=C3)N
DM3L5I6	IK	DMQUSAAOCWRTQX-UHFFFAOYSA-N
DM3L5I6	IU	4-(6-methoxyindol-1-yl)sulfonylaniline
DM3L5I6	DE	Discovery agent

DM3ACVD	ID	DM3ACVD
DM3ACVD	DN	4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DM3ACVD	HS	Investigative
DM3ACVD	SN	4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 11; AC1O70HL; SCHEMBL4513739; CHEMBL425054; BDBM8897
DM3ACVD	DT	Small molecular drug
DM3ACVD	PC	6540055
DM3ACVD	MW	237.3
DM3ACVD	FM	C16H15NO
DM3ACVD	IC	InChI=1S/C16H15NO/c1-18-16-5-4-14-10-13(2-3-15(14)11-16)12-6-8-17-9-7-12/h4-11H,2-3H2,1H3
DM3ACVD	CS	COC1=CC2=C(C=C1)C=C(CC2)C3=CC=NC=C3
DM3ACVD	IK	QCWIENOGGDTTEN-UHFFFAOYSA-N
DM3ACVD	IU	4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DM3ACVD	DE	Discovery agent

DMRPU0V	ID	DMRPU0V
DMRPU0V	DN	4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline
DMRPU0V	HS	Investigative
DMRPU0V	SN	CHEMBL525785; 4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline
DMRPU0V	DT	Small molecular drug
DMRPU0V	PC	25034427
DMRPU0V	MW	299.4
DMRPU0V	FM	C21H17NO
DMRPU0V	IC	InChI=1S/C21H17NO/c1-14-9-17-10-18(23-2)8-7-15(17)11-20(14)21-13-22-12-16-5-3-4-6-19(16)21/h3-13H,1-2H3
DMRPU0V	CS	CC1=CC2=C(C=CC(=C2)OC)C=C1C3=CN=CC4=CC=CC=C43
DMRPU0V	IK	PVTDLLYLEPRYDL-UHFFFAOYSA-N
DMRPU0V	IU	4-(6-methoxy-3-methylnaphthalen-2-yl)isoquinoline
DMRPU0V	DE	Discovery agent

DM51XDA	ID	DM51XDA
DM51XDA	DN	4-(6-Methoxynaphthalen-2-yl)isoquinoline
DM51XDA	HS	Investigative
DM51XDA	SN	CHEMBL500394; 4-(6-Methoxynaphthalen-2-yl)isoquinoline; BDBM50272368
DM51XDA	DT	Small molecular drug
DM51XDA	PC	24754344
DM51XDA	MW	285.3
DM51XDA	FM	C20H15NO
DM51XDA	IC	InChI=1S/C20H15NO/c1-22-18-9-8-14-10-16(7-6-15(14)11-18)20-13-21-12-17-4-2-3-5-19(17)20/h2-13H,1H3
DM51XDA	CS	COC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC4=CC=CC=C43
DM51XDA	IK	SGBOBLSELUHWRG-UHFFFAOYSA-N
DM51XDA	IU	4-(6-methoxynaphthalen-2-yl)isoquinoline
DM51XDA	DE	Discovery agent

DM4B73F	ID	DM4B73F
DM4B73F	DN	4'-(6-Methoxypyridin-3-yl)biphenyl-3-ol
DM4B73F	HS	Investigative
DM4B73F	SN	CHEMBL1097417; BDBM50318417
DM4B73F	DT	Small molecular drug
DM4B73F	PC	46887511
DM4B73F	MW	277.3
DM4B73F	FM	C18H15NO2
DM4B73F	IC	InChI=1S/C18H15NO2/c1-21-18-10-9-16(12-19-18)14-7-5-13(6-8-14)15-3-2-4-17(20)11-15/h2-12,20H,1H3
DM4B73F	CS	COC1=NC=C(C=C1)C2=CC=C(C=C2)C3=CC(=CC=C3)O
DM4B73F	IK	JEDOKEGGMJNKGY-UHFFFAOYSA-N
DM4B73F	IU	3-[4-(6-methoxypyridin-3-yl)phenyl]phenol
DM4B73F	DE	Discovery agent

DM9O8VY	ID	DM9O8VY
DM9O8VY	DN	4-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM9O8VY	HS	Investigative
DM9O8VY	SN	CHEMBL222765; 4-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM9O8VY	DT	Small molecular drug
DM9O8VY	PC	16203359
DM9O8VY	MW	282.29
DM9O8VY	FM	C16H14N2O3
DM9O8VY	IC	InChI=1S/C16H14N2O3/c17-11-12-1-3-13(4-2-12)15-9-14(19)10-16(21-15)18-5-7-20-8-6-18/h1-4,9-10H,5-8H2
DM9O8VY	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=CC=C(C=C3)C#N
DM9O8VY	IK	GGAAWYRRMFPEHA-UHFFFAOYSA-N
DM9O8VY	IU	4-(6-morpholin-4-yl-4-oxopyran-2-yl)benzonitrile
DM9O8VY	DE	Discovery agent

DM1Z3N6	ID	DM1Z3N6
DM1Z3N6	DN	4-(6-morpholino-9H-purin-2-yl)phenol
DM1Z3N6	HS	Investigative
DM1Z3N6	DT	Small molecular drug
DM1Z3N6	PC	135955186
DM1Z3N6	MW	297.31
DM1Z3N6	FM	C15H15N5O2
DM1Z3N6	IC	InChI=1S/C15H15N5O2/c21-11-3-1-10(2-4-11)13-18-14-12(16-9-17-14)15(19-13)20-5-7-22-8-6-20/h1-4,9,21H,5-8H2,(H,16,17,18,19)
DM1Z3N6	CS	C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC=C(C=C4)O
DM1Z3N6	IK	PSGSPCJHCOUEEU-UHFFFAOYSA-N
DM1Z3N6	IU	4-(6-morpholin-4-yl-7H-purin-2-yl)phenol
DM1Z3N6	DE	Discovery agent

DMJ81IL	ID	DMJ81IL
DMJ81IL	DN	4-(6-phenyl-2,4'-bipyridin-4-yl)phenol
DMJ81IL	HS	Investigative
DMJ81IL	DT	Small molecular drug
DMJ81IL	PC	46887286
DMJ81IL	DE	Discovery agent

DMIY5QU	ID	DMIY5QU
DMIY5QU	DN	4-(7,7-Dimethyl-oct-3-ynyl)-1H-imidazole
DMIY5QU	HS	Investigative
DMIY5QU	SN	CHEMBL280076; 4-(7,7-Dimethyl-oct-3-ynyl)-1H-imidazole; 1H-Imidazole, 5-(7,7-dimethyl-3-octyn-1-yl)-; SCHEMBL7619037; PDSP1_000108; BDBM50070214; PDSP2_000108; GT 2293; 209599-16-6
DMIY5QU	DT	Small molecular drug
DMIY5QU	PC	10219888
DMIY5QU	MW	204.31
DMIY5QU	FM	C13H20N2
DMIY5QU	IC	InChI=1S/C13H20N2/c1-13(2,3)9-7-5-4-6-8-12-10-14-11-15-12/h10-11H,6-9H2,1-3H3,(H,14,15)
DMIY5QU	CS	CC(C)(C)CCC#CCCC1=CN=CN1
DMIY5QU	IK	CNQBABLURIQXNU-UHFFFAOYSA-N
DMIY5QU	IU	5-(7,7-dimethyloct-3-ynyl)-1H-imidazole
DMIY5QU	DE	Discovery agent

DMUXZOM	ID	DMUXZOM
DMUXZOM	DN	4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol
DMUXZOM	HS	Investigative
DMUXZOM	DT	Small molecular drug
DMUXZOM	PC	135525228
DMUXZOM	MW	326.8
DMUXZOM	FM	C19H19ClN2O
DMUXZOM	IC	InChI=1S/C19H19ClN2O/c20-17-8-4-7-16-18(13-9-11-15(23)12-10-13)21-22(19(16)17)14-5-2-1-3-6-14/h4,7-12,14,23H,1-3,5-6H2
DMUXZOM	CS	C1CCC(CC1)N2C3=C(C=CC=C3Cl)C(=N2)C4=CC=C(C=C4)O
DMUXZOM	IK	JFMIDTYLHCPZPL-UHFFFAOYSA-N
DMUXZOM	IU	4-(7-chloro-1-cyclohexylindazol-3-yl)phenol
DMUXZOM	CA	CAS 680611-05-6
DMUXZOM	DE	Discovery agent

DM0X5SY	ID	DM0X5SY
DM0X5SY	DN	4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol
DM0X5SY	HS	Investigative
DM0X5SY	DT	Small molecular drug
DM0X5SY	PC	135476471
DM0X5SY	MW	312.8
DM0X5SY	FM	C18H17ClN2O
DM0X5SY	IC	InChI=1S/C18H17ClN2O/c19-16-7-3-6-15-17(12-8-10-14(22)11-9-12)20-21(18(15)16)13-4-1-2-5-13/h3,6-11,13,22H,1-2,4-5H2
DM0X5SY	CS	C1CCC(C1)N2C3=C(C=CC=C3Cl)C(=N2)C4=CC=C(C=C4)O
DM0X5SY	IK	NDUBFDHNGRZGIL-UHFFFAOYSA-N
DM0X5SY	IU	4-(7-chloro-1-cyclopentylindazol-3-yl)phenol
DM0X5SY	CA	CAS 680611-61-4
DM0X5SY	DE	Discovery agent

DMEYUH0	ID	DMEYUH0
DMEYUH0	DN	4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol
DMEYUH0	HS	Investigative
DMEYUH0	DT	Small molecular drug
DMEYUH0	PC	135407148
DMEYUH0	MW	286.75
DMEYUH0	FM	C16H15ClN2O
DMEYUH0	IC	InChI=1S/C16H15ClN2O/c1-2-10-19-16-13(4-3-5-14(16)17)15(18-19)11-6-8-12(20)9-7-11/h3-9,20H,2,10H2,1H3
DMEYUH0	CS	CCCN1C2=C(C=CC=C2Cl)C(=N1)C3=CC=C(C=C3)O
DMEYUH0	IK	OEWGFWIYFTVVAZ-UHFFFAOYSA-N
DMEYUH0	IU	4-(7-chloro-1-propylindazol-3-yl)phenol
DMEYUH0	CA	CAS 680611-44-3
DMEYUH0	DE	Discovery agent

DMX2K8R	ID	DMX2K8R
DMX2K8R	DN	4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol
DMX2K8R	HS	Investigative
DMX2K8R	DT	Small molecular drug
DMX2K8R	PC	135511848
DMX2K8R	MW	266.34
DMX2K8R	FM	C17H18N2O
DMX2K8R	IC	InChI=1S/C17H18N2O/c1-3-11-19-17-12(2)5-4-6-15(17)16(18-19)13-7-9-14(20)10-8-13/h4-10,20H,3,11H2,1-2H3
DMX2K8R	CS	CCCN1C2=C(C=CC=C2C(=N1)C3=CC=C(C=C3)O)C
DMX2K8R	IK	KGNRBLHSFFCQIN-UHFFFAOYSA-N
DMX2K8R	IU	4-(7-methyl-1-propylindazol-3-yl)phenol
DMX2K8R	CA	CAS 680611-32-9
DMX2K8R	DE	Discovery agent

DMJ86OS	ID	DMJ86OS
DMJ86OS	DN	4-(7-Methyl-oct-3-ynyl)-1H-imidazole
DMJ86OS	HS	Investigative
DMJ86OS	SN	CHEMBL14497; 4-(7-Methyl-oct-3-ynyl)-1H-imidazole; 1H-Imidazole, 5-(7-methyl-3-octyn-1-yl)-; SCHEMBL7618441; BDBM50070212; 4-(7-Methyl-3-octynyl)-1H-imidazole
DMJ86OS	DT	Small molecular drug
DMJ86OS	PC	10012754
DMJ86OS	MW	190.28
DMJ86OS	FM	C12H18N2
DMJ86OS	IC	InChI=1S/C12H18N2/c1-11(2)7-5-3-4-6-8-12-9-13-10-14-12/h9-11H,5-8H2,1-2H3,(H,13,14)
DMJ86OS	CS	CC(C)CCC#CCCC1=CN=CN1
DMJ86OS	IK	FGSZNBGTIGFMGN-UHFFFAOYSA-N
DMJ86OS	IU	5-(7-methyloct-3-ynyl)-1H-imidazole
DMJ86OS	DE	Discovery agent

DM27OGL	ID	DM27OGL
DM27OGL	DN	4-(8-Phenyl-oct-3-ynyl)-1H-imidazole
DM27OGL	HS	Investigative
DM27OGL	SN	CHEMBL14811; 4-(8-Phenyl-oct-3-ynyl)-1H-imidazole; SCHEMBL7621857; ZINC13795232; BDBM50070216
DM27OGL	DT	Small molecular drug
DM27OGL	PC	9794983
DM27OGL	MW	252.35
DM27OGL	FM	C17H20N2
DM27OGL	IC	InChI=1S/C17H20N2/c1(2-4-9-13-17-14-18-15-19-17)3-6-10-16-11-7-5-8-12-16/h5,7-8,11-12,14-15H,1,3,6,9-10,13H2,(H,18,19)
DM27OGL	CS	C1=CC=C(C=C1)CCCCC#CCCC2=CN=CN2
DM27OGL	IK	MSBRTBBFZFRZEJ-UHFFFAOYSA-N
DM27OGL	IU	5-(8-phenyloct-3-ynyl)-1H-imidazole
DM27OGL	DE	Discovery agent

DMR37FN	ID	DMR37FN
DMR37FN	DN	4-(Acetylamino)-3-Amino Benzoic Acid
DMR37FN	HS	Investigative
DMR37FN	SN	4-(Acetylamino)-3-Amino Benzoic Acid; 3-amino-4-acetamidobenzoic acid; CHEMBL109162; 4-acetylamino-3-aminobenzoic acid; 4-(Acetylamino)-3-aminobenzoic acid; 53484-10-9; ST3; BANA108; AC1L9JL6; BANA-108; SCHEMBL2344997; BANA 108; BDBM5274; 4-acetamido-3-aminobenzoic acid; 4-acetamido-3-amino-benzoic acid; 4-Acetylamino-3-amino-benzoic acid; AKOS012418429
DMR37FN	DT	Small molecular drug
DMR37FN	PC	446367
DMR37FN	MW	194.19
DMR37FN	FM	C9H10N2O3
DMR37FN	IC	InChI=1S/C9H10N2O3/c1-5(12)11-8-3-2-6(9(13)14)4-7(8)10/h2-4H,10H2,1H3,(H,11,12)(H,13,14)
DMR37FN	CS	CC(=O)NC1=C(C=C(C=C1)C(=O)O)N
DMR37FN	IK	MJMLUICFHWSBQZ-UHFFFAOYSA-N
DMR37FN	IU	4-acetamido-3-aminobenzoic acid
DMR37FN	DE	Discovery agent

DM8F0N5	ID	DM8F0N5
DM8F0N5	DN	4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID
DM8F0N5	HS	Investigative
DM8F0N5	SN	4-acetamido-3-hydroxy-5-nitrobenzoic acid; 162252-45-1; 4-(Acetylamino)-3-hydroxy-5-nitrobenzoic acid; ST1; BANA105; AC1MO7GF; SCHEMBL5571782; CHEMBL324455; BANA-105; CTK8C2119; DTXSID30391837; JIDRTCHFBHJIDG-UHFFFAOYSA-N; ZINC3833968; 8224AA; ANW-67849; AKOS016007095; DB08570; AJ-45807; TC-156594; AX8236797; KB-107355; 4-acetamido-3-hydroxy-5-nitro-benzoic acid; Benzoic acid,4-(acetylamino)-3-hydroxy-5-nitro-
DM8F0N5	DT	Small molecular drug
DM8F0N5	PC	3364665
DM8F0N5	MW	240.17
DM8F0N5	FM	C9H8N2O6
DM8F0N5	IC	InChI=1S/C9H8N2O6/c1-4(12)10-8-6(11(16)17)2-5(9(14)15)3-7(8)13/h2-3,13H,1H3,(H,10,12)(H,14,15)
DM8F0N5	CS	CC(=O)NC1=C(C=C(C=C1O)C(=O)O)[N+](=O)[O-]
DM8F0N5	IK	JIDRTCHFBHJIDG-UHFFFAOYSA-N
DM8F0N5	IU	4-acetamido-3-hydroxy-5-nitrobenzoic acid
DM8F0N5	CA	CAS 162252-45-1
DM8F0N5	DE	Discovery agent

DM1DKSV	ID	DM1DKSV
DM1DKSV	DN	4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID
DM1DKSV	HS	Investigative
DM1DKSV	SN	4-acetamido-3-amino-5-hydroxybenzoic acid; 162252-46-2; 4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID; 4-(Acetylamino)-3-amino-5-hydroxybenzoic acid; ST2; BANA106; AC1L9JL3; CHEMBL109005; BANA-106; SCHEMBL8375025; CTK8H1571; DTXSID70332224; ZINC3581100; 8225AA; AKOS016012208; DB08571; AJ-45035; 3-amino-4-acetamido-5-hydroxybenzoic acid; KB-239845; AX8247088; 4-acetamido-3-amino-5-hydroxy-benzoic acid; 3-Amino-4-(acetylamino)-5-hydroxybenzoic acid
DM1DKSV	DT	Small molecular drug
DM1DKSV	PC	446366
DM1DKSV	MW	210.19
DM1DKSV	FM	C9H10N2O4
DM1DKSV	IC	InChI=1S/C9H10N2O4/c1-4(12)11-8-6(10)2-5(9(14)15)3-7(8)13/h2-3,13H,10H2,1H3,(H,11,12)(H,14,15)
DM1DKSV	CS	CC(=O)NC1=C(C=C(C=C1O)C(=O)O)N
DM1DKSV	IK	CALDTVBHJMBRTM-UHFFFAOYSA-N
DM1DKSV	IU	4-acetamido-3-amino-5-hydroxybenzoic acid
DM1DKSV	CA	CAS 162252-46-2
DM1DKSV	DE	Discovery agent

DM6MQCI	ID	DM6MQCI
DM6MQCI	DN	4-(Allylamino)-3-pyridinesulfonamide
DM6MQCI	HS	Investigative
DM6MQCI	SN	4-(Allylamino)-3-pyridinesulfonamide; CHEMBL1164966; 76254-81-4; Oprea1_825745
DM6MQCI	DT	Small molecular drug
DM6MQCI	PC	25044690
DM6MQCI	MW	213.26
DM6MQCI	FM	C8H11N3O2S
DM6MQCI	IC	InChI=1S/C8H11N3O2S/c1-2-4-11-7-3-5-10-6-8(7)14(9,12)13/h2-3,5-6H,1,4H2,(H,10,11)(H2,9,12,13)
DM6MQCI	CS	C=CCNC1=C(C=NC=C1)S(=O)(=O)N
DM6MQCI	IK	HYUSVYAJBKXAKB-UHFFFAOYSA-N
DM6MQCI	IU	4-(prop-2-enylamino)pyridine-3-sulfonamide
DM6MQCI	DE	Discovery agent

DMTB80W	ID	DMTB80W
DMTB80W	DN	4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
DMTB80W	HS	Investigative
DMTB80W	SN	CHEMBL572533; 4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
DMTB80W	DT	Small molecular drug
DMTB80W	PC	44542042
DMTB80W	MW	281.3
DMTB80W	FM	C17H15NO3
DMTB80W	IC	InChI=1S/C17H15NO3/c18-10-13-8-17(19)21-16-9-14(6-7-15(13)16)20-11-12-4-2-1-3-5-12/h1-9H,10-11,18H2
DMTB80W	CS	C1=CC=C(C=C1)COC2=CC3=C(C=C2)C(=CC(=O)O3)CN
DMTB80W	IK	XCWHFSADYQMGEA-UHFFFAOYSA-N
DMTB80W	IU	4-(aminomethyl)-7-phenylmethoxychromen-2-one
DMTB80W	DE	Discovery agent

DML2EF4	ID	DML2EF4
DML2EF4	DN	4'-(Benzensulfonamide)-4-hydroxychalcone
DML2EF4	HS	Investigative
DML2EF4	SN	CHEMBL1087322; SCHEMBL3483693; BDBM50316853; 4''-(Benzensulfonamide)-4-hydroxychalcone
DML2EF4	DT	Small molecular drug
DML2EF4	PC	15176577
DML2EF4	MW	379.4
DML2EF4	FM	C21H17NO4S
DML2EF4	IC	InChI=1S/C21H17NO4S/c23-19-13-6-16(7-14-19)8-15-21(24)17-9-11-18(12-10-17)22-27(25,26)20-4-2-1-3-5-20/h1-15,22-23H/b15-8+
DML2EF4	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C(=O)/C=C/C3=CC=C(C=C3)O
DML2EF4	IK	CJSVUASMASROSS-OVCLIPMQSA-N
DML2EF4	IU	N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]benzenesulfonamide
DML2EF4	DE	Discovery agent

DMF6S3X	ID	DMF6S3X
DMF6S3X	DN	4-(Benzylamino)-1-naphthol
DMF6S3X	HS	Investigative
DMF6S3X	SN	CHEMBL569096; 4-(Benzylamino)-1-naphthol; SCHEMBL6677663
DMF6S3X	DT	Small molecular drug
DMF6S3X	PC	17937479
DMF6S3X	MW	249.31
DMF6S3X	FM	C17H15NO
DMF6S3X	IC	InChI=1S/C17H15NO/c19-17-11-10-16(14-8-4-5-9-15(14)17)18-12-13-6-2-1-3-7-13/h1-11,18-19H,12H2
DMF6S3X	CS	C1=CC=C(C=C1)CNC2=CC=C(C3=CC=CC=C32)O
DMF6S3X	IK	GXGORQOUKCMHGK-UHFFFAOYSA-N
DMF6S3X	IU	4-(benzylamino)naphthalen-1-ol
DMF6S3X	DE	Discovery agent

DM03BQD	ID	DM03BQD
DM03BQD	DN	4-(benzylideneamino)benzenesulfonamide
DM03BQD	HS	Investigative
DM03BQD	SN	4-benzylideneamino-benzenesulfonamide
DM03BQD	DT	Small molecular drug
DM03BQD	PC	308405
DM03BQD	MW	260.31
DM03BQD	FM	C13H12N2O2S
DM03BQD	IC	InChI=1S/C13H12N2O2S/c14-18(16,17)13-8-6-12(7-9-13)15-10-11-4-2-1-3-5-11/h1-10H,(H2,14,16,17)
DM03BQD	CS	C1=CC=C(C=C1)C=NC2=CC=C(C=C2)S(=O)(=O)N
DM03BQD	IK	OPUFYXLEFFRGSQ-UHFFFAOYSA-N
DM03BQD	IU	4-(benzylideneamino)benzenesulfonamide
DM03BQD	CA	CAS 5877-53-2
DM03BQD	DE	Discovery agent

DMJM2H1	ID	DMJM2H1
DMJM2H1	DN	4-(benzylideneamino)benzoic acid
DMJM2H1	HS	Investigative
DMJM2H1	SN	4-(benzylideneamino)benzoic Acid; CHEMBL567820; 820985-82-8; AC1LEKUN; SCHEMBL11027747; SCHEMBL10354517; ZINC56233; CTK3E2373; DTXSID10350765; MolPort-000-420-278; 4-(a-benzylideneamino)benzoic acid; benzylideneaniline-p-carboxylic acid; STK861975; BDBM50299292; AKOS002162184; MCULE-4796916281; 4-((1E)-2-phenyl-1-azavinyl)benzoic acid; ST45187403; 4-{[(E)-phenylmethylidene]amino}benzoic acid; Benzoic acid, 4-[(E)-(phenylmethylene)amino]-
DMJM2H1	DT	Small molecular drug
DMJM2H1	PC	687887
DMJM2H1	MW	225.24
DMJM2H1	FM	C14H11NO2
DMJM2H1	IC	InChI=1S/C14H11NO2/c16-14(17)12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-10H,(H,16,17)
DMJM2H1	CS	C1=CC=C(C=C1)C=NC2=CC=C(C=C2)C(=O)O
DMJM2H1	IK	MREPJQZHXSDMKL-UHFFFAOYSA-N
DMJM2H1	IU	4-(benzylideneamino)benzoic acid
DMJM2H1	CA	CAS 820985-82-8
DMJM2H1	DE	Discovery agent

DM1T95Y	ID	DM1T95Y
DM1T95Y	DN	4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol
DM1T95Y	HS	Investigative
DM1T95Y	SN	CHEMBL223324; 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol; BDBM50208721; J3.502.571E
DM1T95Y	DT	Small molecular drug
DM1T95Y	PC	16203494
DM1T95Y	MW	320.4
DM1T95Y	FM	C20H20N2O2
DM1T95Y	IC	InChI=1S/C20H20N2O2/c23-20-18(19(24-22-20)15-9-11-21-12-10-15)17-8-4-7-16(13-17)14-5-2-1-3-6-14/h1-8,13,15,21H,9-12H2,(H,22,23)
DM1T95Y	CS	C1CNCCC1C2=C(C(=O)NO2)C3=CC=CC(=C3)C4=CC=CC=C4
DM1T95Y	IK	KLKHVLINJXRNBG-UHFFFAOYSA-N
DM1T95Y	IU	4-(3-phenylphenyl)-5-piperidin-4-yl-1,2-oxazol-3-one
DM1T95Y	DE	Discovery agent

DMNE5H7	ID	DMNE5H7
DMNE5H7	DN	4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide
DMNE5H7	HS	Investigative
DMNE5H7	SN	CHEMBL601040; 4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide
DMNE5H7	DT	Small molecular drug
DMNE5H7	PC	46207013
DMNE5H7	MW	351.3
DMNE5H7	FM	C18H20Cl2N2O
DMNE5H7	IC	InChI=1S/C18H20Cl2N2O/c1-14-2-6-16(7-3-14)21-18(23)15-4-8-17(9-5-15)22(12-10-19)13-11-20/h2-9H,10-13H2,1H3,(H,21,23)
DMNE5H7	CS	CC1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N(CCCl)CCCl
DMNE5H7	IK	YUHSPIYJWBBMHU-UHFFFAOYSA-N
DMNE5H7	IU	4-[bis(2-chloroethyl)amino]-N-(4-methylphenyl)benzamide
DMNE5H7	DE	Discovery agent

DM3GUFI	ID	DM3GUFI
DM3GUFI	DN	4-(butyl(methyl)amino)-N-(quinolin-3-yl)benzamide
DM3GUFI	HS	Investigative
DM3GUFI	SN	CHEMBL258915; SCHEMBL845760
DM3GUFI	DT	Small molecular drug
DM3GUFI	PC	44450336
DM3GUFI	MW	333.4
DM3GUFI	FM	C21H23N3O
DM3GUFI	IC	InChI=1S/C21H23N3O/c1-3-4-13-24(2)19-11-9-16(10-12-19)21(25)23-18-14-17-7-5-6-8-20(17)22-15-18/h5-12,14-15H,3-4,13H2,1-2H3,(H,23,25)
DM3GUFI	CS	CCCCN(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM3GUFI	IK	UYXXRZNAVMFMMG-UHFFFAOYSA-N
DM3GUFI	IU	4-[butyl(methyl)amino]-N-quinolin-3-ylbenzamide
DM3GUFI	DE	Discovery agent

DM6SIA4	ID	DM6SIA4
DM6SIA4	DN	4-(butylthio)-2-(trifluoromethyl)benzonitrile
DM6SIA4	HS	Investigative
DM6SIA4	SN	CHEMBL462665; 4-(butylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247959
DM6SIA4	DT	Small molecular drug
DM6SIA4	PC	43615786
DM6SIA4	MW	259.29
DM6SIA4	FM	C12H12F3NS
DM6SIA4	IC	InChI=1S/C12H12F3NS/c1-2-3-6-17-10-5-4-9(8-16)11(7-10)12(13,14)15/h4-5,7H,2-3,6H2,1H3
DM6SIA4	CS	CCCCSC1=CC(=C(C=C1)C#N)C(F)(F)F
DM6SIA4	IK	FQVZVSZPULBOJM-UHFFFAOYSA-N
DM6SIA4	IU	4-butylsulfanyl-2-(trifluoromethyl)benzonitrile
DM6SIA4	DE	Discovery agent

DMH1AZV	ID	DMH1AZV
DMH1AZV	DN	4-(butylthio)-2-methoxybenzonitrile
DMH1AZV	HS	Investigative
DMH1AZV	SN	CHEMBL455566; 4-(butylthio)-2-methoxybenzonitrile
DMH1AZV	DT	Small molecular drug
DMH1AZV	PC	44564582
DMH1AZV	MW	221.32
DMH1AZV	FM	C12H15NOS
DMH1AZV	IC	InChI=1S/C12H15NOS/c1-3-4-7-15-11-6-5-10(9-13)12(8-11)14-2/h5-6,8H,3-4,7H2,1-2H3
DMH1AZV	CS	CCCCSC1=CC(=C(C=C1)C#N)OC
DMH1AZV	IK	RUUKMZBJVWOJEZ-UHFFFAOYSA-N
DMH1AZV	IU	4-butylsulfanyl-2-methoxybenzonitrile
DMH1AZV	DE	Discovery agent

DM12R4M	ID	DM12R4M
DM12R4M	DN	4-(Carbamolymethylthio)pyridine-3-sulfonamide
DM12R4M	HS	Investigative
DM12R4M	SN	CHEMBL1163376; 4-(carbamoylmethylthio)pyridine-3-sulfonamide; 1078160-11-8; 4-(Carbamolymethylthio)pyridine-3-sulfonamide
DM12R4M	DT	Small molecular drug
DM12R4M	PC	46907400
DM12R4M	MW	247.3
DM12R4M	FM	C7H9N3O3S2
DM12R4M	IC	InChI=1S/C7H9N3O3S2/c8-7(11)4-14-5-1-2-10-3-6(5)15(9,12)13/h1-3H,4H2,(H2,8,11)(H2,9,12,13)
DM12R4M	CS	C1=CN=CC(=C1SCC(=O)N)S(=O)(=O)N
DM12R4M	IK	GMEZLQXYYUCJAQ-UHFFFAOYSA-N
DM12R4M	IU	2-(3-sulfamoylpyridin-4-yl)sulfanylacetamide
DM12R4M	DE	Discovery agent

DMSG9LV	ID	DMSG9LV
DMSG9LV	DN	4-(Carboxyvin-2-Yl)Phenylboronic Acid
DMSG9LV	HS	Investigative
DMSG9LV	SN	159896-15-8; (E)-3-(4-Boronophenyl)acrylic acid; 4-(2-Carboxyvinyl)phenylboronic acid; 3-(4-Boronophenyl)Acrylic Acid; 4-Boronocinnamic acid; 4-(CARBOXYVIN-2-YL)PHENYLBORONIC ACID; 151169-68-5; 4-(E-2-Carboxyvinyl)phenylboronic acid; 4-(2-CARBOXYVINYL)BENZENEBORONIC ACID; C9H9BO4; CHEMBL139928; 4-phenylpropylester boronic acid; (2E)-3-[4-(DIHYDROXYBORANYL)PHENYL]PROP-2-ENOIC ACID; 4-(E-2-Carboxyvinyl)benzeneboronic acid; AC1NRANQ; 3-[4-(dihydroxyboranyl)phenyl]prop-2-enoic acid; MolPort-000-931-601
DMSG9LV	DT	Small molecular drug
DMSG9LV	PC	5288001
DMSG9LV	MW	191.98
DMSG9LV	FM	C9H9BO4
DMSG9LV	IC	InChI=1S/C9H9BO4/c11-9(12)6-3-7-1-4-8(5-2-7)10(13)14/h1-6,13-14H,(H,11,12)/b6-3+
DMSG9LV	CS	B(C1=CC=C(C=C1)/C=C/C(=O)O)(O)O
DMSG9LV	IK	IEMLKNHGGSYOMP-ZZXKWVIFSA-N
DMSG9LV	IU	(E)-3-(4-boronophenyl)prop-2-enoic acid
DMSG9LV	DE	Discovery agent

DMZP20H	ID	DMZP20H
DMZP20H	DN	4-(Cyanomethylthio)pyridine-3-sulfonamide
DMZP20H	HS	Investigative
DMZP20H	SN	4-(Cyanomethylthio)pyridine-3-sulfonamide; CHEMBL1164420; 1078160-09-4
DMZP20H	DT	Small molecular drug
DMZP20H	PC	46703932
DMZP20H	MW	229.3
DMZP20H	FM	C7H7N3O2S2
DMZP20H	IC	InChI=1S/C7H7N3O2S2/c8-2-4-13-6-1-3-10-5-7(6)14(9,11)12/h1,3,5H,4H2,(H2,9,11,12)
DMZP20H	CS	C1=CN=CC(=C1SCC#N)S(=O)(=O)N
DMZP20H	IK	JOIYJNZMYUXKRS-UHFFFAOYSA-N
DMZP20H	IU	4-(cyanomethylsulfanyl)pyridine-3-sulfonamide
DMZP20H	DE	Discovery agent

DMR69K2	ID	DMR69K2
DMR69K2	DN	4-(cyclobutylmethylthio)-2-methoxybenzonitrile
DMR69K2	HS	Investigative
DMR69K2	SN	CHEMBL453244; 4-(cyclobutylmethylthio)-2-methoxybenzonitrile
DMR69K2	DT	Small molecular drug
DMR69K2	PC	44564584
DMR69K2	MW	233.33
DMR69K2	FM	C13H15NOS
DMR69K2	IC	InChI=1S/C13H15NOS/c1-15-13-7-12(6-5-11(13)8-14)16-9-10-3-2-4-10/h5-7,10H,2-4,9H2,1H3
DMR69K2	CS	COC1=C(C=CC(=C1)SCC2CCC2)C#N
DMR69K2	IK	VLNPFRWDACXANC-UHFFFAOYSA-N
DMR69K2	IU	4-(cyclobutylmethylsulfanyl)-2-methoxybenzonitrile
DMR69K2	DE	Discovery agent

DMUOQN7	ID	DMUOQN7
DMUOQN7	DN	4-(Cyclohexylamino)-1-naphthol
DMUOQN7	HS	Investigative
DMUOQN7	SN	CHEMBL571437; 4-(Cyclohexylamino)-1-naphthol
DMUOQN7	DT	Small molecular drug
DMUOQN7	PC	45487176
DMUOQN7	MW	241.33
DMUOQN7	FM	C16H19NO
DMUOQN7	IC	InChI=1S/C16H19NO/c18-16-11-10-15(13-8-4-5-9-14(13)16)17-12-6-2-1-3-7-12/h4-5,8-12,17-18H,1-3,6-7H2
DMUOQN7	CS	C1CCC(CC1)NC2=CC=C(C3=CC=CC=C32)O
DMUOQN7	IK	JNIUFYOCOKGFDL-UHFFFAOYSA-N
DMUOQN7	IU	4-(cyclohexylamino)naphthalen-1-ol
DMUOQN7	DE	Discovery agent

DMWELVK	ID	DMWELVK
DMWELVK	DN	4-(cyclohexylamino)-N-(quinolin-3-yl)benzamide
DMWELVK	HS	Investigative
DMWELVK	SN	CHEMBL406573; SCHEMBL846014
DMWELVK	DT	Small molecular drug
DMWELVK	PC	44450288
DMWELVK	MW	345.4
DMWELVK	FM	C22H23N3O
DMWELVK	IC	InChI=1S/C22H23N3O/c26-22(25-20-14-17-6-4-5-9-21(17)23-15-20)16-10-12-19(13-11-16)24-18-7-2-1-3-8-18/h4-6,9-15,18,24H,1-3,7-8H2,(H,25,26)
DMWELVK	CS	C1CCC(CC1)NC2=CC=C(C=C2)C(=O)NC3=CC4=CC=CC=C4N=C3
DMWELVK	IK	SWEAAERORIFOIX-UHFFFAOYSA-N
DMWELVK	IU	4-(cyclohexylamino)-N-quinolin-3-ylbenzamide
DMWELVK	DE	Discovery agent

DMWYESB	ID	DMWYESB
DMWYESB	DN	4-(cyclohexylmethylcarbamoyloxy)benzoic acid
DMWYESB	HS	Investigative
DMWYESB	SN	CHEMBL465214; 4-(cyclohexylmethylcarbamoyloxy)benzoic acid
DMWYESB	DT	Small molecular drug
DMWYESB	PC	44589216
DMWYESB	MW	277.31
DMWYESB	FM	C15H19NO4
DMWYESB	IC	InChI=1S/C15H19NO4/c17-14(18)12-6-8-13(9-7-12)20-15(19)16-10-11-4-2-1-3-5-11/h6-9,11H,1-5,10H2,(H,16,19)(H,17,18)
DMWYESB	CS	C1CCC(CC1)CNC(=O)OC2=CC=C(C=C2)C(=O)O
DMWYESB	IK	UTXJJIRQAYXELZ-UHFFFAOYSA-N
DMWYESB	IU	4-(cyclohexylmethylcarbamoyloxy)benzoic acid
DMWYESB	DE	Discovery agent

DMCDZ7E	ID	DMCDZ7E
DMCDZ7E	DN	4-(cyclohexyloxy)quinazoline
DMCDZ7E	HS	Investigative
DMCDZ7E	SN	4-(cyclohexyloxy)quinazoline; CHEMBL471866
DMCDZ7E	DT	Small molecular drug
DMCDZ7E	PC	44591868
DMCDZ7E	MW	228.29
DMCDZ7E	FM	C14H16N2O
DMCDZ7E	IC	InChI=1S/C14H16N2O/c1-2-6-11(7-3-1)17-14-12-8-4-5-9-13(12)15-10-16-14/h4-5,8-11H,1-3,6-7H2
DMCDZ7E	CS	C1CCC(CC1)OC2=NC=NC3=CC=CC=C32
DMCDZ7E	IK	QNXOLVQGDILPJV-UHFFFAOYSA-N
DMCDZ7E	IU	4-cyclohexyloxyquinazoline
DMCDZ7E	DE	Discovery agent

DM43Z2J	ID	DM43Z2J
DM43Z2J	DN	4-(cyclopropylmethylthio)-2-methoxybenzonitrile
DM43Z2J	HS	Investigative
DM43Z2J	SN	CHEMBL504110; 4-(cyclopropylmethylthio)-2-methoxybenzonitrile
DM43Z2J	DT	Small molecular drug
DM43Z2J	PC	44564583
DM43Z2J	MW	219.3
DM43Z2J	FM	C12H13NOS
DM43Z2J	IC	InChI=1S/C12H13NOS/c1-14-12-6-11(5-4-10(12)7-13)15-8-9-2-3-9/h4-6,9H,2-3,8H2,1H3
DM43Z2J	CS	COC1=C(C=CC(=C1)SCC2CC2)C#N
DM43Z2J	IK	KLTYCOFPIFASIE-UHFFFAOYSA-N
DM43Z2J	IU	4-(cyclopropylmethylsulfanyl)-2-methoxybenzonitrile
DM43Z2J	DE	Discovery agent

DM68S9F	ID	DM68S9F
DM68S9F	DN	4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE
DM68S9F	HS	Investigative
DM68S9F	SN	4-(Dimethylamino)butyl carbamimidothioate; F 91488; UNII-1I4LVX494H; SKF 91488; F-91488; SKF-91488; 1I4LVX494H; 68643-23-2; [4-(carbamimidoylsulfanyl)butyl]dimethylamine; Carbamimidothioic acid, 4-(dimethylamino)butyl ester; 4DI; Tocris-0512; Lopac-S-145; AC1L1JVO; AC1Q1UAN; Lopac0_001172; carbamimidothioic acid 4-(dimethylamino)butyl ester; CHEMBL1230270; SCHEMBL12648461; CTK5C8308; ZINC29747245; AKOS006328360; DB07106; CCG-205246; NCGC00024626-01; NCGC00015911-02
DM68S9F	DT	Small molecular drug
DM68S9F	PC	5227
DM68S9F	MW	175.3
DM68S9F	FM	C7H17N3S
DM68S9F	IC	InChI=1S/C7H17N3S/c1-10(2)5-3-4-6-11-7(8)9/h3-6H2,1-2H3,(H3,8,9)
DM68S9F	CS	CN(C)CCCCSC(=N)N
DM68S9F	IK	UFYJLJINUGVUHO-UHFFFAOYSA-N
DM68S9F	IU	4-(dimethylamino)butyl carbamimidothioate
DM68S9F	CA	CAS 68643-23-2
DM68S9F	DE	Discovery agent

DMJP5YH	ID	DMJP5YH
DMJP5YH	DN	4-(dimethylamino)-N-(thiazol-2-yl)benzamide
DMJP5YH	HS	Investigative
DMJP5YH	SN	4-(dimethylamino)-N-(1,3-thiazol-2-yl)benzamide; AC1M7A6S; CHEMBL425124; MolPort-004-070-500; ZINC3346941; AKOS017059191; MCULE-5265697892; N-(Thiazole-2-yl)-4-(dimethylamino)benzamide; Z28173761
DMJP5YH	DT	Small molecular drug
DMJP5YH	PC	2463677
DMJP5YH	MW	247.32
DMJP5YH	FM	C12H13N3OS
DMJP5YH	IC	InChI=1S/C12H13N3OS/c1-15(2)10-5-3-9(4-6-10)11(16)14-12-13-7-8-17-12/h3-8H,1-2H3,(H,13,14,16)
DMJP5YH	CS	CN(C)C1=CC=C(C=C1)C(=O)NC2=NC=CS2
DMJP5YH	IK	RGXFQNTVZRGDNG-UHFFFAOYSA-N
DMJP5YH	IU	4-(dimethylamino)-N-(1,3-thiazol-2-yl)benzamide
DMJP5YH	DE	Discovery agent

DM14C9V	ID	DM14C9V
DM14C9V	DN	4-(ethylamino)naphthalen-1-ol
DM14C9V	HS	Investigative
DM14C9V	SN	CHEMBL577335; 4-(ethylamino)-1-naphthol; 4-(ethylamino)naphthalen-1-ol; SCHEMBL12599061; BDBM50303902; AKOS022516437
DM14C9V	DT	Small molecular drug
DM14C9V	PC	45487209
DM14C9V	MW	187.24
DM14C9V	FM	C12H13NO
DM14C9V	IC	InChI=1S/C12H13NO/c1-2-13-11-7-8-12(14)10-6-4-3-5-9(10)11/h3-8,13-14H,2H2,1H3
DM14C9V	CS	CCNC1=CC=C(C2=CC=CC=C21)O
DM14C9V	IK	SKQYPGROWSDIBN-UHFFFAOYSA-N
DM14C9V	IU	4-(ethylamino)naphthalen-1-ol
DM14C9V	DE	Discovery agent

DM0GCEK	ID	DM0GCEK
DM0GCEK	DN	4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine
DM0GCEK	HS	Investigative
DM0GCEK	SN	CHEMBL220445; 4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine
DM0GCEK	DT	Small molecular drug
DM0GCEK	PC	44420099
DM0GCEK	MW	232.31
DM0GCEK	FM	C11H12N4S
DM0GCEK	IC	InChI=1S/C11H12N4S/c1-2-16-11-14-9(13-10(12)15-11)8-6-4-3-5-7-8/h3-7H,2H2,1H3,(H2,12,13,14,15)
DM0GCEK	CS	CCSC1=NC(=NC(=N1)N)C2=CC=CC=C2
DM0GCEK	IK	UMHVGNHYSDRNNN-UHFFFAOYSA-N
DM0GCEK	IU	4-ethylsulfanyl-6-phenyl-1,3,5-triazin-2-amine
DM0GCEK	DE	Discovery agent

DMY7035	ID	DMY7035
DMY7035	DN	4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
DMY7035	HS	Investigative
DMY7035	SN	CHEMBL406499; 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamine; 442847-46-3; SCHEMBL4369855; 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine; SCHEMBL13668449; YOPVCNSOKMOXST-UHFFFAOYSA-N; BDBM50239028; J3.571.237B; L021771; 4-(2-Furyl)-7H-pyrrolo[2,3-d]pyrimidine-2-amine
DMY7035	DT	Small molecular drug
DMY7035	PC	21976428
DMY7035	MW	200.2
DMY7035	FM	C10H8N4O
DMY7035	IC	InChI=1S/C10H8N4O/c11-10-13-8(7-2-1-5-15-7)6-3-4-12-9(6)14-10/h1-5H,(H3,11,12,13,14)
DMY7035	CS	C1=COC(=C1)C2=C3C=CNC3=NC(=N2)N
DMY7035	IK	YOPVCNSOKMOXST-UHFFFAOYSA-N
DMY7035	IU	4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
DMY7035	DE	Discovery agent

DM7LVKP	ID	DM7LVKP
DM7LVKP	DN	4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine
DM7LVKP	HS	Investigative
DM7LVKP	SN	CHEMBL406298; Thieno[3,2-d]pyrimidin-2-amine, 4-(2-furanyl)-; SCHEMBL3678073; ARPSUXKIHNZLQL-UHFFFAOYSA-N; BDBM50377489; 443148-30-9
DM7LVKP	DT	Small molecular drug
DM7LVKP	PC	9964493
DM7LVKP	MW	217.25
DM7LVKP	FM	C10H7N3OS
DM7LVKP	IC	InChI=1S/C10H7N3OS/c11-10-12-6-3-5-15-9(6)8(13-10)7-2-1-4-14-7/h1-5H,(H2,11,12,13)
DM7LVKP	CS	C1=COC(=C1)C2=NC(=NC3=C2SC=C3)N
DM7LVKP	IK	ARPSUXKIHNZLQL-UHFFFAOYSA-N
DM7LVKP	IU	4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine
DM7LVKP	DE	Discovery agent

DMW4O31	ID	DMW4O31
DMW4O31	DN	4-(furan-3-yl)-2,6-di(thiophen-2-yl)pyridine
DMW4O31	HS	Investigative
DMW4O31	SN	CHEMBL601911
DMW4O31	DT	Small molecular drug
DMW4O31	PC	46224813
DMW4O31	MW	309.4
DMW4O31	FM	C17H11NOS2
DMW4O31	IC	InChI=1S/C17H11NOS2/c1-3-16(20-7-1)14-9-13(12-5-6-19-11-12)10-15(18-14)17-4-2-8-21-17/h1-11H
DMW4O31	CS	C1=CSC(=C1)C2=CC(=CC(=N2)C3=CC=CS3)C4=COC=C4
DMW4O31	IK	HCNMYINNCZEXQR-UHFFFAOYSA-N
DMW4O31	IU	4-(furan-3-yl)-2,6-dithiophen-2-ylpyridine
DMW4O31	DE	Discovery agent

DM70MRZ	ID	DM70MRZ
DM70MRZ	DN	4-(hexyl(methyl)amino)-N-(quinolin-3-yl)benzamide
DM70MRZ	HS	Investigative
DM70MRZ	SN	CHEMBL408637; SCHEMBL846538
DM70MRZ	DT	Small molecular drug
DM70MRZ	PC	44450322
DM70MRZ	MW	361.5
DM70MRZ	FM	C23H27N3O
DM70MRZ	IC	InChI=1S/C23H27N3O/c1-3-4-5-8-15-26(2)21-13-11-18(12-14-21)23(27)25-20-16-19-9-6-7-10-22(19)24-17-20/h6-7,9-14,16-17H,3-5,8,15H2,1-2H3,(H,25,27)
DM70MRZ	CS	CCCCCCN(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM70MRZ	IK	FIZXTSXGXVTGKK-UHFFFAOYSA-N
DM70MRZ	IU	4-[hexyl(methyl)amino]-N-quinolin-3-ylbenzamide
DM70MRZ	DE	Discovery agent

DMWJN73	ID	DMWJN73
DMWJN73	DN	4-(Hydroxymercury)Benzoic Acid
DMWJN73	HS	Investigative
DMWJN73	SN	p-hydroxymercuribenzoic acid; p-hydroxymercuribenzoate; (p-carboxyphenyl)hydroxymercury; 4-(HYDROXYMERCURY)BENZOIC ACID; mercury, (p-carboxyphenyl)hydroxy-; (4-carboxyphenyl)(hydroxy)mercury; (4-carboxylatophenyl)hydroxymercurate(1-) hydrogen; 1126-48-3; Sodium p-chloromercuribenzoate; Mercury, sodium salt; Mercury, monosodium salt; Mercurate(1-), sodium; SCHEMBL678164; CHEMBL78771; Mercurate(1-), (4-carboxylatophenyl)hydroxy-, hydrogen; CHEBI:49644; NSC1048; NSC-1048
DMWJN73	DT	Small molecular drug
DMWJN73	PC	14309
DMWJN73	MW	339.72
DMWJN73	FM	C7H7HgO3
DMWJN73	IC	InChI=1S/C7H5O2.Hg.H2O/c8-7(9)6-4-2-1-3-5-6;;/h2-5H,(H,8,9);;1H2
DMWJN73	CS	C1=CC(=CC=C1C(=O)O)[Hg].O
DMWJN73	IK	NBCQBGBECVUZMK-UHFFFAOYSA-N
DMWJN73	IU	(4-carboxyphenyl)mercury;hydrate
DMWJN73	CA	CAS 1126-48-3
DMWJN73	CB	CHEBI:49644
DMWJN73	DE	Discovery agent

DMR6VWL	ID	DMR6VWL
DMR6VWL	DN	4-(hydroxymethyl)benzenesulfonamide
DMR6VWL	HS	Investigative
DMR6VWL	SN	4-Hydroxymethyl-benzenesulfonamide
DMR6VWL	DT	Small molecular drug
DMR6VWL	PC	10081162
DMR6VWL	MW	187.22
DMR6VWL	FM	C7H9NO3S
DMR6VWL	IC	InChI=1S/C7H9NO3S/c8-12(10,11)7-3-1-6(5-9)2-4-7/h1-4,9H,5H2,(H2,8,10,11)
DMR6VWL	CS	C1=CC(=CC=C1CO)S(=O)(=O)N
DMR6VWL	IK	UULCVOIRJRJPQS-UHFFFAOYSA-N
DMR6VWL	IU	4-(hydroxymethyl)benzenesulfonamide
DMR6VWL	CA	CAS 67472-44-0
DMR6VWL	DE	Discovery agent

DMHI50W	ID	DMHI50W
DMHI50W	DN	4-(Indan-1-ylsulfanyl)-phenylamine
DMHI50W	HS	Investigative
DMHI50W	SN	CHEMBL191844; 4-(Indan-1-ylsulfanyl)-phenylamine
DMHI50W	DT	Small molecular drug
DMHI50W	PC	44401620
DMHI50W	MW	241.4
DMHI50W	FM	C15H15NS
DMHI50W	IC	InChI=1S/C15H15NS/c16-12-6-8-13(9-7-12)17-15-10-5-11-3-1-2-4-14(11)15/h1-4,6-9,15H,5,10,16H2
DMHI50W	CS	C1CC2=CC=CC=C2C1SC3=CC=C(C=C3)N
DMHI50W	IK	WWGLOFVWIRHNNH-UHFFFAOYSA-N
DMHI50W	IU	4-(2,3-dihydro-1H-inden-1-ylsulfanyl)aniline
DMHI50W	DE	Discovery agent

DM201UM	ID	DM201UM
DM201UM	DN	4-(Indane-1-sulfonyl)-phenylamine
DM201UM	HS	Investigative
DM201UM	SN	CHEMBL191972; 4-(Indane-1-sulfonyl)-phenylamine
DM201UM	DT	Small molecular drug
DM201UM	PC	44401621
DM201UM	MW	273.4
DM201UM	FM	C15H15NO2S
DM201UM	IC	InChI=1S/C15H15NO2S/c16-12-6-8-13(9-7-12)19(17,18)15-10-5-11-3-1-2-4-14(11)15/h1-4,6-9,15H,5,10,16H2
DM201UM	CS	C1CC2=CC=CC=C2C1S(=O)(=O)C3=CC=C(C=C3)N
DM201UM	IK	AJRGJBUDLAAWNT-UHFFFAOYSA-N
DM201UM	IU	4-(2,3-dihydro-1H-inden-1-ylsulfonyl)aniline
DM201UM	DE	Discovery agent

DMGSZB2	ID	DMGSZB2
DMGSZB2	DN	4-(isopentylthio)-2-(trifluoromethyl)benzonitrile
DMGSZB2	HS	Investigative
DMGSZB2	SN	CHEMBL503687; 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile
DMGSZB2	DT	Small molecular drug
DMGSZB2	PC	44564659
DMGSZB2	MW	273.32
DMGSZB2	FM	C13H14F3NS
DMGSZB2	IC	InChI=1S/C13H14F3NS/c1-9(2)5-6-18-11-4-3-10(8-17)12(7-11)13(14,15)16/h3-4,7,9H,5-6H2,1-2H3
DMGSZB2	CS	CC(C)CCSC1=CC(=C(C=C1)C#N)C(F)(F)F
DMGSZB2	IK	JCLWLTZDKYNAQH-UHFFFAOYSA-N
DMGSZB2	IU	4-(3-methylbutylsulfanyl)-2-(trifluoromethyl)benzonitrile
DMGSZB2	DE	Discovery agent

DML1G9S	ID	DML1G9S
DML1G9S	DN	4-(isopentylthio)-2-methoxybenzonitrile
DML1G9S	HS	Investigative
DML1G9S	SN	CHEMBL462663; 4-(isopentylthio)-2-methoxybenzonitrile
DML1G9S	DT	Small molecular drug
DML1G9S	PC	44564585
DML1G9S	MW	235.35
DML1G9S	FM	C13H17NOS
DML1G9S	IC	InChI=1S/C13H17NOS/c1-10(2)6-7-16-12-5-4-11(9-14)13(8-12)15-3/h4-5,8,10H,6-7H2,1-3H3
DML1G9S	CS	CC(C)CCSC1=CC(=C(C=C1)C#N)OC
DML1G9S	IK	XWPLSLIGOKRGBS-UHFFFAOYSA-N
DML1G9S	IU	2-methoxy-4-(3-methylbutylsulfanyl)benzonitrile
DML1G9S	DE	Discovery agent

DMJFSTX	ID	DMJFSTX
DMJFSTX	DN	4-(Isopropylamino)-1-naphthol
DMJFSTX	HS	Investigative
DMJFSTX	SN	CHEMBL578212; 4-(Isopropylamino)-1-naphthol; SCHEMBL12599062
DMJFSTX	DT	Small molecular drug
DMJFSTX	PC	44465702
DMJFSTX	MW	201.26
DMJFSTX	FM	C13H15NO
DMJFSTX	IC	InChI=1S/C13H15NO/c1-9(2)14-12-7-8-13(15)11-6-4-3-5-10(11)12/h3-9,14-15H,1-2H3
DMJFSTX	CS	CC(C)NC1=CC=C(C2=CC=CC=C21)O
DMJFSTX	IK	TWBKFLLEYLZFHH-UHFFFAOYSA-N
DMJFSTX	IU	4-(propan-2-ylamino)naphthalen-1-ol
DMJFSTX	DE	Discovery agent

DMVDHX1	ID	DMVDHX1
DMVDHX1	DN	4-(isopropylthio)-2-(trifluoromethyl)benzonitrile
DMVDHX1	HS	Investigative
DMVDHX1	SN	CHEMBL453740; 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247976
DMVDHX1	DT	Small molecular drug
DMVDHX1	PC	44157043
DMVDHX1	MW	245.27
DMVDHX1	FM	C11H10F3NS
DMVDHX1	IC	InChI=1S/C11H10F3NS/c1-7(2)16-9-4-3-8(6-15)10(5-9)11(12,13)14/h3-5,7H,1-2H3
DMVDHX1	CS	CC(C)SC1=CC(=C(C=C1)C#N)C(F)(F)F
DMVDHX1	IK	QPFAGTVKCMQHRW-UHFFFAOYSA-N
DMVDHX1	IU	4-propan-2-ylsulfanyl-2-(trifluoromethyl)benzonitrile
DMVDHX1	DE	Discovery agent

DMR5HNI	ID	DMR5HNI
DMR5HNI	DN	4-(isopropylthio)-2-methoxybenzonitrile
DMR5HNI	HS	Investigative
DMR5HNI	SN	CHEMBL445429; 4-(isopropylthio)-2-methoxybenzonitrile
DMR5HNI	DT	Small molecular drug
DMR5HNI	PC	44157042
DMR5HNI	MW	207.29
DMR5HNI	FM	C11H13NOS
DMR5HNI	IC	InChI=1S/C11H13NOS/c1-8(2)14-10-5-4-9(7-12)11(6-10)13-3/h4-6,8H,1-3H3
DMR5HNI	CS	CC(C)SC1=CC(=C(C=C1)C#N)OC
DMR5HNI	IK	MIAOMCWVGGHYSA-UHFFFAOYSA-N
DMR5HNI	IU	2-methoxy-4-propan-2-ylsulfanylbenzonitrile
DMR5HNI	DE	Discovery agent

DM8LODU	ID	DM8LODU
DM8LODU	DN	4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine
DM8LODU	HS	Investigative
DM8LODU	SN	CHEMBL202998; 4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine; BDBM50179884
DM8LODU	DT	Small molecular drug
DM8LODU	PC	44409436
DM8LODU	MW	362.4
DM8LODU	FM	C24H18N4
DM8LODU	IC	InChI=1S/C24H18N4/c1-16-6-4-8-18(14-16)26-24-22-10-3-2-9-21(22)23(27-28-24)20-11-5-7-17-15-25-13-12-19(17)20/h2-15H,1H3,(H,26,28)
DM8LODU	CS	CC1=CC(=CC=C1)NC2=NN=C(C3=CC=CC=C32)C4=CC=CC5=C4C=CN=C5
DM8LODU	IK	KGVVWWXTGNZBAX-UHFFFAOYSA-N
DM8LODU	IU	4-isoquinolin-5-yl-N-(3-methylphenyl)phthalazin-1-amine
DM8LODU	DE	Discovery agent

DMS30HQ	ID	DMS30HQ
DMS30HQ	DN	4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine
DMS30HQ	HS	Investigative
DMS30HQ	SN	CHEMBL204220; 4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine; BDBM50179895
DMS30HQ	DT	Small molecular drug
DMS30HQ	PC	44409370
DMS30HQ	MW	362.4
DMS30HQ	FM	C24H18N4
DMS30HQ	IC	InChI=1S/C24H18N4/c1-16-7-2-5-12-22(16)26-24-21-10-4-3-9-20(21)23(27-28-24)19-11-6-8-17-15-25-14-13-18(17)19/h2-15H,1H3,(H,26,28)
DMS30HQ	CS	CC1=CC=CC=C1NC2=NN=C(C3=CC=CC=C32)C4=CC=CC5=C4C=CN=C5
DMS30HQ	IK	AQWOEJFWZLDYCH-UHFFFAOYSA-N
DMS30HQ	IU	4-isoquinolin-5-yl-N-(2-methylphenyl)phthalazin-1-amine
DMS30HQ	DE	Discovery agent

DMQG57D	ID	DMQG57D
DMQG57D	DN	4-(mesityloxy)-2-(trifluoromethyl)benzonitrile
DMQG57D	HS	Investigative
DMQG57D	SN	CHEMBL513768; 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile; SCHEMBL4163778
DMQG57D	DT	Small molecular drug
DMQG57D	PC	11587567
DMQG57D	MW	305.29
DMQG57D	FM	C17H14F3NO
DMQG57D	IC	InChI=1S/C17H14F3NO/c1-10-6-11(2)16(12(3)7-10)22-14-5-4-13(9-21)15(8-14)17(18,19)20/h4-8H,1-3H3
DMQG57D	CS	CC1=CC(=C(C(=C1)C)OC2=CC(=C(C=C2)C#N)C(F)(F)F)C
DMQG57D	IK	XMMDWVWTOYZZAJ-UHFFFAOYSA-N
DMQG57D	IU	2-(trifluoromethyl)-4-(2,4,6-trimethylphenoxy)benzonitrile
DMQG57D	DE	Discovery agent

DMAI3NZ	ID	DMAI3NZ
DMAI3NZ	DN	4-(mesitylthio)-2-(trifluoromethyl)benzonitrile
DMAI3NZ	HS	Investigative
DMAI3NZ	SN	CHEMBL462234; 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile
DMAI3NZ	DT	Small molecular drug
DMAI3NZ	PC	44565205
DMAI3NZ	MW	321.4
DMAI3NZ	FM	C17H14F3NS
DMAI3NZ	IC	InChI=1S/C17H14F3NS/c1-10-6-11(2)16(12(3)7-10)22-14-5-4-13(9-21)15(8-14)17(18,19)20/h4-8H,1-3H3
DMAI3NZ	CS	CC1=CC(=C(C(=C1)C)SC2=CC(=C(C=C2)C#N)C(F)(F)F)C
DMAI3NZ	IK	ZDVOQQIVWWNKSG-UHFFFAOYSA-N
DMAI3NZ	IU	2-(trifluoromethyl)-4-(2,4,6-trimethylphenyl)sulfanylbenzonitrile
DMAI3NZ	DE	Discovery agent

DM1XK68	ID	DM1XK68
DM1XK68	DN	4-(mesitylthio)-2-methoxybenzonitrile
DM1XK68	HS	Investigative
DM1XK68	SN	CHEMBL462022; 4-(mesitylthio)-2-methoxybenzonitrile
DM1XK68	DT	Small molecular drug
DM1XK68	PC	44564580
DM1XK68	MW	283.4
DM1XK68	FM	C17H17NOS
DM1XK68	IC	InChI=1S/C17H17NOS/c1-11-7-12(2)17(13(3)8-11)20-15-6-5-14(10-18)16(9-15)19-4/h5-9H,1-4H3
DM1XK68	CS	CC1=CC(=C(C(=C1)C)SC2=CC(=C(C=C2)C#N)OC)C
DM1XK68	IK	YPJRESPHGOONFU-UHFFFAOYSA-N
DM1XK68	IU	2-methoxy-4-(2,4,6-trimethylphenyl)sulfanylbenzonitrile
DM1XK68	DE	Discovery agent

DMQCMFU	ID	DMQCMFU
DMQCMFU	DN	4-(methyl(4-phenylthiazol-2-yl)amino)phenol
DMQCMFU	HS	Investigative
DMQCMFU	SN	CHEMBL460515; 4-[Methyl-(4-phenyl-thiazol-2-yl)-amino]-phenol; 4-(methyl(4-phenylthiazol-2-yl)amino)phenol; AC1LDK73; MLS000075845; cid_649391; ZINC813364; HMS2534H13; BDBM50247460; AKOS000563578; SMR000014954; BAS 08769335; SR-01000322128; SR-01000322128-1
DMQCMFU	DT	Small molecular drug
DMQCMFU	PC	649391
DMQCMFU	MW	282.4
DMQCMFU	FM	C16H14N2OS
DMQCMFU	IC	InChI=1S/C16H14N2OS/c1-18(13-7-9-14(19)10-8-13)16-17-15(11-20-16)12-5-3-2-4-6-12/h2-11,19H,1H3
DMQCMFU	CS	CN(C1=CC=C(C=C1)O)C2=NC(=CS2)C3=CC=CC=C3
DMQCMFU	IK	XDKOSPFALAXPJO-UHFFFAOYSA-N
DMQCMFU	IU	4-[methyl-(4-phenyl-1,3-thiazol-2-yl)amino]phenol
DMQCMFU	DE	Discovery agent

DM3TF9Y	ID	DM3TF9Y
DM3TF9Y	DN	4-(methyl(nonyl)amino)-N-(quinolin-3-yl)benzamide
DM3TF9Y	HS	Investigative
DM3TF9Y	SN	CHEMBL407233; SCHEMBL846831
DM3TF9Y	DT	Small molecular drug
DM3TF9Y	PC	44450300
DM3TF9Y	MW	403.6
DM3TF9Y	FM	C26H33N3O
DM3TF9Y	IC	InChI=1S/C26H33N3O/c1-3-4-5-6-7-8-11-18-29(2)24-16-14-21(15-17-24)26(30)28-23-19-22-12-9-10-13-25(22)27-20-23/h9-10,12-17,19-20H,3-8,11,18H2,1-2H3,(H,28,30)
DM3TF9Y	CS	CCCCCCCCCN(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM3TF9Y	IK	KGQMIDBMCJPWMX-UHFFFAOYSA-N
DM3TF9Y	IU	4-[methyl(nonyl)amino]-N-quinolin-3-ylbenzamide
DM3TF9Y	DE	Discovery agent

DM1I0TA	ID	DM1I0TA
DM1I0TA	DN	4-(methyl(octyl)amino)-N-(quinolin-3-yl)benzamide
DM1I0TA	HS	Investigative
DM1I0TA	SN	CHEMBL259017; SCHEMBL846048
DM1I0TA	DT	Small molecular drug
DM1I0TA	PC	44450313
DM1I0TA	MW	389.5
DM1I0TA	FM	C25H31N3O
DM1I0TA	IC	InChI=1S/C25H31N3O/c1-3-4-5-6-7-10-17-28(2)23-15-13-20(14-16-23)25(29)27-22-18-21-11-8-9-12-24(21)26-19-22/h8-9,11-16,18-19H,3-7,10,17H2,1-2H3,(H,27,29)
DM1I0TA	CS	CCCCCCCCN(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM1I0TA	IK	YWPSOIQULJMWIC-UHFFFAOYSA-N
DM1I0TA	IU	4-[methyl(octyl)amino]-N-quinolin-3-ylbenzamide
DM1I0TA	DE	Discovery agent

DMF3O10	ID	DMF3O10
DMF3O10	DN	4-(methylamino)naphthalen-1-ol
DMF3O10	HS	Investigative
DMF3O10	SN	CHEMBL571240; 4-(methylamino)naphthalen-1-ol; SCHEMBL10158309; BDBM50303921
DMF3O10	DT	Small molecular drug
DMF3O10	PC	20029042
DMF3O10	MW	173.21
DMF3O10	FM	C11H11NO
DMF3O10	IC	InChI=1S/C11H11NO/c1-12-10-6-7-11(13)9-5-3-2-4-8(9)10/h2-7,12-13H,1H3
DMF3O10	CS	CNC1=CC=C(C2=CC=CC=C21)O
DMF3O10	IK	YEJJUWPHXGQPCZ-UHFFFAOYSA-N
DMF3O10	IU	4-(methylamino)naphthalen-1-ol
DMF3O10	DE	Discovery agent

DM4BPL1	ID	DM4BPL1
DM4BPL1	DN	4-(Methylhydrazino)-3-pyridinesulfonamide
DM4BPL1	HS	Investigative
DM4BPL1	SN	4-(Methylhydrazino)-3-pyridinesulfonamide; CHEMBL1164878; BDBM50320511
DM4BPL1	DT	Small molecular drug
DM4BPL1	PC	46704078
DM4BPL1	MW	202.24
DM4BPL1	FM	C6H10N4O2S
DM4BPL1	IC	InChI=1S/C6H10N4O2S/c1-8-10-5-2-3-9-4-6(5)13(7,11)12/h2-4,8H,1H3,(H,9,10)(H2,7,11,12)
DM4BPL1	CS	CNNC1=C(C=NC=C1)S(=O)(=O)N
DM4BPL1	IK	CKTSHDQZQGLANI-UHFFFAOYSA-N
DM4BPL1	IU	4-(2-methylhydrazinyl)pyridine-3-sulfonamide
DM4BPL1	DE	Discovery agent

DM8BWZO	ID	DM8BWZO
DM8BWZO	DN	4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile
DM8BWZO	HS	Investigative
DM8BWZO	SN	CHEMBL464764; 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile; BDBM50248553
DM8BWZO	DT	Small molecular drug
DM8BWZO	PC	43320723
DM8BWZO	MW	277.24
DM8BWZO	FM	C15H10F3NO
DM8BWZO	IC	InChI=1S/C15H10F3NO/c1-10-3-2-4-12(7-10)20-13-6-5-11(9-19)14(8-13)15(16,17)18/h2-8H,1H3
DM8BWZO	CS	CC1=CC(=CC=C1)OC2=CC(=C(C=C2)C#N)C(F)(F)F
DM8BWZO	IK	RKGPWAIQCDEIFV-UHFFFAOYSA-N
DM8BWZO	IU	4-(3-methylphenoxy)-2-(trifluoromethyl)benzonitrile
DM8BWZO	DE	Discovery agent

DMI5XB1	ID	DMI5XB1
DMI5XB1	DN	4-(Naphthalene-1-sulfonyl)-phenylamine
DMI5XB1	HS	Investigative
DMI5XB1	SN	CHEMBL181382; 4-(Naphthalene-1-sulfonyl)-phenylamine; SCHEMBL10775871
DMI5XB1	DT	Small molecular drug
DMI5XB1	PC	44390054
DMI5XB1	MW	283.3
DMI5XB1	FM	C16H13NO2S
DMI5XB1	IC	InChI=1S/C16H13NO2S/c17-13-8-10-14(11-9-13)20(18,19)16-7-3-5-12-4-1-2-6-15(12)16/h1-11H,17H2
DMI5XB1	CS	C1=CC=C2C(=C1)C=CC=C2S(=O)(=O)C3=CC=C(C=C3)N
DMI5XB1	IK	WJMHQZIDRDGGIY-UHFFFAOYSA-N
DMI5XB1	IU	4-naphthalen-1-ylsulfonylaniline
DMI5XB1	DE	Discovery agent

DMADWTI	ID	DMADWTI
DMADWTI	DN	4-(N-Methyl-hydrazino)-benzenesulfonamide
DMADWTI	HS	Investigative
DMADWTI	SN	CHEMBL183913; 4-(N-Methyl-hydrazino)-benzenesulfonamide; SCHEMBL13242579
DMADWTI	DT	Small molecular drug
DMADWTI	PC	44392435
DMADWTI	MW	201.25
DMADWTI	FM	C7H11N3O2S
DMADWTI	IC	InChI=1S/C7H11N3O2S/c1-10(8)6-2-4-7(5-3-6)13(9,11)12/h2-5H,8H2,1H3,(H2,9,11,12)
DMADWTI	CS	CN(C1=CC=C(C=C1)S(=O)(=O)N)N
DMADWTI	IK	XGAFGUJHKUYKIM-UHFFFAOYSA-N
DMADWTI	IU	4-[amino(methyl)amino]benzenesulfonamide
DMADWTI	DE	Discovery agent

DMYCV8E	ID	DMYCV8E
DMYCV8E	DN	4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide
DMYCV8E	HS	Investigative
DMYCV8E	SN	CHEMBL1165118; 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide
DMYCV8E	DT	Small molecular drug
DMYCV8E	PC	46703924
DMYCV8E	MW	283.3
DMYCV8E	FM	C10H9N3O3S2
DMYCV8E	IC	InChI=1S/C10H9N3O3S2/c11-18(15,16)9-7-12-5-4-8(9)17-10-3-1-2-6-13(10)14/h1-7H,(H2,11,15,16)
DMYCV8E	CS	C1=CC=[N+](C(=C1)SC2=C(C=NC=C2)S(=O)(=O)N)[O-]
DMYCV8E	IK	DQAURQJZVIJAAO-UHFFFAOYSA-N
DMYCV8E	IU	4-(1-oxidopyridin-1-ium-2-yl)sulfanylpyridine-3-sulfonamide
DMYCV8E	DE	Discovery agent

DMP43HI	ID	DMP43HI
DMP43HI	DN	4-(n-propyl)amino-3-nitrobenzoic acid
DMP43HI	HS	Investigative
DMP43HI	SN	compound 5c [PMID: 17931863]
DMP43HI	DT	Small molecular drug
DMP43HI	PC	11715556
DMP43HI	MW	224.21
DMP43HI	FM	C10H12N2O4
DMP43HI	IC	InChI=1S/C10H12N2O4/c1-2-5-11-8-4-3-7(10(13)14)6-9(8)12(15)16/h3-4,6,11H,2,5H2,1H3,(H,13,14)
DMP43HI	CS	CCCNC1=C(C=C(C=C1)C(=O)O)[N+](=O)[O-]
DMP43HI	IK	OVDGUTHABMXVMI-UHFFFAOYSA-N
DMP43HI	IU	3-nitro-4-(propylamino)benzoic acid
DMP43HI	CA	CAS 68740-31-8
DMP43HI	DE	Discovery agent

DM8I4B9	ID	DM8I4B9
DM8I4B9	DN	4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile
DM8I4B9	HS	Investigative
DM8I4B9	SN	CHEMBL499137; 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile; SCHEMBL4163678; BDBM50248552
DM8I4B9	DT	Small molecular drug
DM8I4B9	PC	11608821
DM8I4B9	MW	277.24
DM8I4B9	FM	C15H10F3NO
DM8I4B9	IC	InChI=1S/C15H10F3NO/c1-10-4-2-3-5-14(10)20-12-7-6-11(9-19)13(8-12)15(16,17)18/h2-8H,1H3
DM8I4B9	CS	CC1=CC=CC=C1OC2=CC(=C(C=C2)C#N)C(F)(F)F
DM8I4B9	IK	PEOSULIFVYUPML-UHFFFAOYSA-N
DM8I4B9	IU	4-(2-methylphenoxy)-2-(trifluoromethyl)benzonitrile
DM8I4B9	DE	Discovery agent

DM85XP6	ID	DM85XP6
DM85XP6	DN	4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile
DM85XP6	HS	Investigative
DM85XP6	SN	CHEMBL462025; 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile; BDBM50248593
DM85XP6	DT	Small molecular drug
DM85XP6	PC	44565202
DM85XP6	MW	293.31
DM85XP6	FM	C15H10F3NS
DM85XP6	IC	InChI=1S/C15H10F3NS/c1-10-4-2-3-5-14(10)20-12-7-6-11(9-19)13(8-12)15(16,17)18/h2-8H,1H3
DM85XP6	CS	CC1=CC=CC=C1SC2=CC(=C(C=C2)C#N)C(F)(F)F
DM85XP6	IK	RAJQECAXWDTUGF-UHFFFAOYSA-N
DM85XP6	IU	4-(2-methylphenyl)sulfanyl-2-(trifluoromethyl)benzonitrile
DM85XP6	DE	Discovery agent

DMHIDY6	ID	DMHIDY6
DMHIDY6	DN	4-(Pent-3-ylamino)-1-naphthol
DMHIDY6	HS	Investigative
DMHIDY6	SN	CHEMBL571980; 4-(Pent-3-ylamino)-1-naphthol; SCHEMBL12649391
DMHIDY6	DT	Small molecular drug
DMHIDY6	PC	45487171
DMHIDY6	MW	229.32
DMHIDY6	FM	C15H19NO
DMHIDY6	IC	InChI=1S/C15H19NO/c1-3-11(4-2)16-14-9-10-15(17)13-8-6-5-7-12(13)14/h5-11,16-17H,3-4H2,1-2H3
DMHIDY6	CS	CCC(CC)NC1=CC=C(C2=CC=CC=C21)O
DMHIDY6	IK	LZQSUKJAJXHQLF-UHFFFAOYSA-N
DMHIDY6	IU	4-(pentan-3-ylamino)naphthalen-1-ol
DMHIDY6	DE	Discovery agent

DM54MOP	ID	DM54MOP
DM54MOP	DN	4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine
DM54MOP	HS	Investigative
DM54MOP	DT	Small molecular drug
DM54MOP	PC	242623
DM54MOP	MW	202.22
DM54MOP	FM	C9H10N6
DM54MOP	IC	InChI=1S/C9H10N6/c10-8-7(9(11)15-14-8)13-12-6-4-2-1-3-5-6/h1-5H,(H5,10,11,14,15)
DM54MOP	CS	C1=CC=C(C=C1)N=NC2=C(NN=C2N)N
DM54MOP	IK	BLXRKDXUWQFGAW-UHFFFAOYSA-N
DM54MOP	IU	4-phenyldiazenyl-1H-pyrazole-3,5-diamine
DM54MOP	CA	CAS 3656-02-8
DM54MOP	DE	Discovery agent

DMM1RCS	ID	DMM1RCS
DMM1RCS	DN	4-(piperazin-1-yl)-1H-indole
DMM1RCS	HS	Investigative
DMM1RCS	SN	4-(1-Piperazinyl)-1H-indole; 84807-09-0; 4-(piperazin-1-yl)-1H-indole; 4-Piperazino-1H-indole; 1H-Indole, 4-(1-piperazinyl)-; 4-(Piperazino)indole; 4-piperazin-1-yl-1H-indole; 1-(4-indolyl)piperazine; CHEMBL200234; YZKSXUIOKWQABW-UHFFFAOYSA-N; AK-26360; W-206959; 1H-Indole-4-(1-piperazinyl)dihydrochloride; 4-piperazinoindole; 4-piperazino-indole; PubChem22668; AC1LC5AN; 1H-indol-4-ylpiperazine; 4-(1-piperazinyl)indole; 1-(indol-4yl)piperazine; 1-(indol-4yl)-piperazine; 1-(indol-4-yl)piperazine; 1-(4-indolyl)-piperazine
DMM1RCS	DT	Small molecular drug
DMM1RCS	PC	594590
DMM1RCS	MW	201.27
DMM1RCS	FM	C12H15N3
DMM1RCS	IC	InChI=1S/C12H15N3/c1-2-11-10(4-5-14-11)12(3-1)15-8-6-13-7-9-15/h1-5,13-14H,6-9H2
DMM1RCS	CS	C1CN(CCN1)C2=CC=CC3=C2C=CN3
DMM1RCS	IK	YZKSXUIOKWQABW-UHFFFAOYSA-N
DMM1RCS	IU	4-piperazin-1-yl-1H-indole
DMM1RCS	CA	CAS 84807-09-0
DMM1RCS	DE	Discovery agent

DM1HM3F	ID	DM1HM3F
DM1HM3F	DN	4-(piperazin-1-yl)-3-tosyl-1H-indazole
DM1HM3F	HS	Investigative
DM1HM3F	SN	CHEMBL1277834; 4-(piperazin-1-yl)-3-tosyl-1H-indazole
DM1HM3F	DT	Small molecular drug
DM1HM3F	PC	49836506
DM1HM3F	MW	356.4
DM1HM3F	FM	C18H20N4O2S
DM1HM3F	IC	InChI=1S/C18H20N4O2S/c1-13-5-7-14(8-6-13)25(23,24)18-17-15(20-21-18)3-2-4-16(17)22-11-9-19-10-12-22/h2-8,19H,9-12H2,1H3,(H,20,21)
DM1HM3F	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=C3C(=NN2)C=CC=C3N4CCNCC4
DM1HM3F	IK	SJAUEJQIVFASOP-UHFFFAOYSA-N
DM1HM3F	IU	3-(4-methylphenyl)sulfonyl-4-piperazin-1-yl-2H-indazole
DM1HM3F	DE	Discovery agent

DMTNVFZ	ID	DMTNVFZ
DMTNVFZ	DN	4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine
DMTNVFZ	HS	Investigative
DMTNVFZ	SN	252722-52-4; 4-(Piperazin-1-yl)-1H-pyrrolo[2,3-d]pyrimidine; 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine; 4-(1-Piperazinyl)-1H-pyrrolo[2,3-d]pyrimidine; CHEMBL595554; 1-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperazine; 6J9; SCHEMBL2251760; DTXSID20592472; MolPort-028-913-269; BDBM50304819; AKOS022175220; AKOS016374229; MCULE-3871238079; ACM252722524; NS-02114; DB-067363; AX8159612; KB-186079; AJ-103002
DMTNVFZ	DT	Small molecular drug
DMTNVFZ	PC	18008465
DMTNVFZ	MW	203.24
DMTNVFZ	FM	C10H13N5
DMTNVFZ	IC	InChI=1S/C10H13N5/c1-2-12-9-8(1)10(14-7-13-9)15-5-3-11-4-6-15/h1-2,7,11H,3-6H2,(H,12,13,14)
DMTNVFZ	CS	C1CN(CCN1)C2=NC=NC3=C2C=CN3
DMTNVFZ	IK	LZSXQBNNRGZPES-UHFFFAOYSA-N
DMTNVFZ	IU	4-piperazin-1-yl-7H-pyrrolo[2,3-d]pyrimidine
DMTNVFZ	CA	CAS 252722-52-4
DMTNVFZ	DE	Discovery agent

DMNM8VY	ID	DMNM8VY
DMNM8VY	DN	4-(piperazin-1-yl)furo[3,2-c]pyridine
DMNM8VY	HS	Investigative
DMNM8VY	SN	4-(piperazin-1-yl)furo[3,2-c]pyridine; 81078-84-4; 4-PIPERAZIN-1-YL-FURO[3,2-C]PYRIDINE; 1-{furo[3,2-c]pyridin-4-yl}piperazine; CHEMBL595555; Furo[3,2-c]pyridine, 4-(1-piperazinyl)-; AK-76639; CHEMBL543969; PubChem17312; AC1MDRY3; SCHEMBL1026755; KS-00000EXO; CTK5E8449; DTXSID10383432; MolPort-000-145-249; LUIZVTKJWSGSPA-UHFFFAOYSA-N; ZINC4287704; 4-piperazinylfurano[3,2-c]pyridine; ANW-49259; BDBM50016972; SBB093149; 4-piperazin-1-ylfuro[3,2-c]pyridine; AKOS015919593; FS-3269; 1-(4-furo[3,2-c]pyridinyl)piperazine
DMNM8VY	DT	Small molecular drug
DMNM8VY	PC	2794808
DMNM8VY	MW	203.24
DMNM8VY	FM	C11H13N3O
DMNM8VY	IC	InChI=1S/C11H13N3O/c1-3-13-11(9-2-8-15-10(1)9)14-6-4-12-5-7-14/h1-3,8,12H,4-7H2
DMNM8VY	CS	C1CN(CCN1)C2=NC=CC3=C2C=CO3
DMNM8VY	IK	LUIZVTKJWSGSPA-UHFFFAOYSA-N
DMNM8VY	IU	4-piperazin-1-ylfuro[3,2-c]pyridine
DMNM8VY	CA	CAS 81078-84-4
DMNM8VY	DE	Discovery agent

DMNU2RM	ID	DMNU2RM
DMNU2RM	DN	4-(piperazin-1-yl)thieno[2,3-d]pyrimidine
DMNU2RM	HS	Investigative
DMNU2RM	SN	4-(piperazin-1-yl)thieno[2,3-d]pyrimidine; 373356-48-0; 1-{thieno[2,3-d]pyrimidin-4-yl}piperazine; 4-piperazin-1-ylthieno[2,3-d]pyrimidine; CHEMBL596108; 1-(Thieno[2,3-d]pyrimidin-4-yl)piperazine; AC1Q1I4T; SCHEMBL4922800; CTK7D1707; MolPort-001-760-894; ZINC12954996; SBB095996; BDBM50304810; AKOS000123564; MCULE-6714459164; PS-3311; NE24045; KS-000029X0; 4-piperazinylthiopheno[2,3-d]pyrimidine; KB-85055; DA-06355; 4-Piperazin-1-yl-thieno[2,3-d]pyrimidine; KB-243074; FT-0727983; EN300-29445; Thieno[2,3-d]pyrimidine, 4-(1-piperaziny
DMNU2RM	DT	Small molecular drug
DMNU2RM	PC	16768198
DMNU2RM	MW	220.3
DMNU2RM	FM	C10H12N4S
DMNU2RM	IC	InChI=1S/C10H12N4S/c1-6-15-10-8(1)9(12-7-13-10)14-4-2-11-3-5-14/h1,6-7,11H,2-5H2
DMNU2RM	CS	C1CN(CCN1)C2=C3C=CSC3=NC=N2
DMNU2RM	IK	HFGUINASBGDWLY-UHFFFAOYSA-N
DMNU2RM	IU	4-piperazin-1-ylthieno[2,3-d]pyrimidine
DMNU2RM	CA	CAS 373356-48-0
DMNU2RM	DE	Discovery agent

DMJGTS7	ID	DMJGTS7
DMJGTS7	DN	4-(piperazin-1-yl)thieno[3,2-c]pyridine
DMJGTS7	HS	Investigative
DMJGTS7	SN	106261-27-2; 4-(piperazin-1-yl)thieno[3,2-c]pyridine; 1-{THIENO[3,2-C]PYRIDIN-4-YL}PIPERAZINE; Thieno[3,2-c]pyridine,4-(1-piperazinyl)-; Thieno[3,2-c]pyridine, 4-(1-piperazinyl)-; 4-Piperazin-1-yl-thieno[3,2-c]pyridine; CHEMBL608135; 4-Piperazin-1-ylthieno[3,2-c]pyridine; CHEMBL552833; 4-(1-piperazinyl)thieno[3,2-c]pyridine; 4-piperazine-1-yl-thieno[3,2-c]pyridine; 4-Piperazine-1-yl-thieno[2,3-c]pyridine hydrochloride; ACMC-1BO03; SCHEMBL616087; CTK4A4454; DTXSID10450113; MolPort-002-500-678; RVGRTFBJOXMFAX-UHFFFAOYSA-N
DMJGTS7	DT	Small molecular drug
DMJGTS7	PC	10966027
DMJGTS7	MW	219.31
DMJGTS7	FM	C11H13N3S
DMJGTS7	IC	InChI=1S/C11H13N3S/c1-3-13-11(9-2-8-15-10(1)9)14-6-4-12-5-7-14/h1-3,8,12H,4-7H2
DMJGTS7	CS	C1CN(CCN1)C2=NC=CC3=C2C=CS3
DMJGTS7	IK	RVGRTFBJOXMFAX-UHFFFAOYSA-N
DMJGTS7	IU	4-piperazin-1-ylthieno[3,2-c]pyridine
DMJGTS7	CA	CAS 106261-27-2
DMJGTS7	DE	Discovery agent

DM2KAG5	ID	DM2KAG5
DM2KAG5	DN	4-(piperazin-1-yl)thieno[3,2-d]pyrimidine
DM2KAG5	HS	Investigative
DM2KAG5	SN	683274-67-1; 4-(piperazin-1-yl)thieno[3,2-d]pyrimidine; 4-Piperazinothieno[3,2-d]pyrimidine; CHEMBL594477; 1-{thieno[3,2-d]pyrimidin-4-yl}piperazine; 1-(thieno[3,2-d]pyrimidin-4-yl)piperazine; AC1MC2NN; SCHEMBL1601613; CTK7D1709; GVNSLBIXJYZCCB-UHFFFAOYSA-N; MolPort-000-158-321; ZINC2513539; SBB095997; KM1197; BDBM50304815; 8099AE; AKOS009377421; FS-1502; MCULE-3522335295; KS-0000257Q; 4-piperazinylthiopheno[3,2-d]pyrimidine; 4-piperazin-1-ylthieno[3,2-d]pyrimidine; KB-86789; KB-193828; 4-piperazin-1-yl-thieno[3,2-d]pyrimidine
DM2KAG5	DT	Small molecular drug
DM2KAG5	PC	2760428
DM2KAG5	MW	220.3
DM2KAG5	FM	C10H12N4S
DM2KAG5	IC	InChI=1S/C10H12N4S/c1-6-15-9-8(1)12-7-13-10(9)14-4-2-11-3-5-14/h1,6-7,11H,2-5H2
DM2KAG5	CS	C1CN(CCN1)C2=NC=NC3=C2SC=C3
DM2KAG5	IK	GVNSLBIXJYZCCB-UHFFFAOYSA-N
DM2KAG5	IU	4-piperazin-1-ylthieno[3,2-d]pyrimidine
DM2KAG5	DE	Discovery agent

DMEAZFJ	ID	DMEAZFJ
DMEAZFJ	DN	4-(propylamino)naphthalen-1-ol
DMEAZFJ	HS	Investigative
DMEAZFJ	SN	CHEMBL572064; 4-(propylamino)naphthalen-1-ol; SCHEMBL12599065
DMEAZFJ	DT	Small molecular drug
DMEAZFJ	PC	45487219
DMEAZFJ	MW	201.26
DMEAZFJ	FM	C13H15NO
DMEAZFJ	IC	InChI=1S/C13H15NO/c1-2-9-14-12-7-8-13(15)11-6-4-3-5-10(11)12/h3-8,14-15H,2,9H2,1H3
DMEAZFJ	CS	CCCNC1=CC=C(C2=CC=CC=C21)O
DMEAZFJ	IK	FDQDPQDUXWRNKT-UHFFFAOYSA-N
DMEAZFJ	IU	4-(propylamino)naphthalen-1-ol
DMEAZFJ	DE	Discovery agent

DM8BZQ3	ID	DM8BZQ3
DM8BZQ3	DN	4-(propylthio)-2-(trifluoromethyl)benzonitrile
DM8BZQ3	HS	Investigative
DM8BZQ3	SN	CHEMBL462664; 4-(propylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247958
DM8BZQ3	DT	Small molecular drug
DM8BZQ3	PC	43138589
DM8BZQ3	MW	245.27
DM8BZQ3	FM	C11H10F3NS
DM8BZQ3	IC	InChI=1S/C11H10F3NS/c1-2-5-16-9-4-3-8(7-15)10(6-9)11(12,13)14/h3-4,6H,2,5H2,1H3
DM8BZQ3	CS	CCCSC1=CC(=C(C=C1)C#N)C(F)(F)F
DM8BZQ3	IK	CUMRETWHEPZEIN-UHFFFAOYSA-N
DM8BZQ3	IU	4-propylsulfanyl-2-(trifluoromethyl)benzonitrile
DM8BZQ3	DE	Discovery agent

DM8M0N9	ID	DM8M0N9
DM8M0N9	DN	4'-(p-toluenesulfonamide)-3,4-dihydroxy chalcone
DM8M0N9	HS	Investigative
DM8M0N9	SN	CHEMBL199829; Sulfonamide chalcone, 5; SCHEMBL3484418; BDBM50174837; 4''-(p-toluenesulfonamide)-3,4-dihydroxy chalcone
DM8M0N9	DT	Small molecular drug
DM8M0N9	PC	11668680
DM8M0N9	MW	409.5
DM8M0N9	FM	C22H19NO5S
DM8M0N9	IC	InChI=1S/C22H19NO5S/c1-15-2-10-19(11-3-15)29(27,28)23-18-8-6-17(7-9-18)20(24)12-4-16-5-13-21(25)22(26)14-16/h2-14,23,25-26H,1H3/b12-4+
DM8M0N9	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C(=O)/C=C/C3=CC(=C(C=C3)O)O
DM8M0N9	IK	XCEAUELSIXURQB-UUILKARUSA-N
DM8M0N9	IU	N-[4-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]phenyl]-4-methylbenzenesulfonamide
DM8M0N9	DE	Discovery agent

DMRFWE1	ID	DMRFWE1
DMRFWE1	DN	4'-(p-Toluenesulfonamide)-4-hydroxychalcone
DMRFWE1	HS	Investigative
DMRFWE1	SN	CHEMBL371723; TSAHC; Sulfonamide chalcone, 4; SCHEMBL3483827; BDBM50174835; 4''-(p-Toluenesulfonamide)-4-hydroxychalcone; 4''-(4-toluenesulfonamido)-4-hydroxychalcone
DMRFWE1	DT	Small molecular drug
DMRFWE1	PC	24757213
DMRFWE1	MW	393.5
DMRFWE1	FM	C22H19NO4S
DMRFWE1	IC	InChI=1S/C22H19NO4S/c1-16-2-13-21(14-3-16)28(26,27)23-19-9-7-18(8-10-19)22(25)15-6-17-4-11-20(24)12-5-17/h2-15,23-24H,1H3/b15-6+
DMRFWE1	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C(=O)/C=C/C3=CC=C(C=C3)O
DMRFWE1	IK	KDODYFOOJCIHGK-GIDUJCDVSA-N
DMRFWE1	IU	N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]-4-methylbenzenesulfonamide
DMRFWE1	DE	Discovery agent

DMQA0EJ	ID	DMQA0EJ
DMQA0EJ	DN	4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione
DMQA0EJ	HS	Investigative
DMQA0EJ	SN	CHEMBL204456; 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione
DMQA0EJ	DT	Small molecular drug
DMQA0EJ	PC	44409922
DMQA0EJ	MW	305.4
DMQA0EJ	FM	C20H19NO2
DMQA0EJ	IC	InChI=1S/C20H19NO2/c1-12(2)17-18(21-14-10-8-13(3)9-11-14)15-6-4-5-7-16(15)19(22)20(17)23/h4-12,21H,1-3H3
DMQA0EJ	CS	CC1=CC=C(C=C1)NC2=C(C(=O)C(=O)C3=CC=CC=C32)C(C)C
DMQA0EJ	IK	JFLZSYUNGPXQEX-UHFFFAOYSA-N
DMQA0EJ	IU	4-(4-methylanilino)-3-propan-2-ylnaphthalene-1,2-dione
DMQA0EJ	DE	Discovery agent

DMIOQJD	ID	DMIOQJD
DMIOQJD	DN	4-(p-Tolyl)spiro[chromene-2,4'-piperidine]
DMIOQJD	HS	Investigative
DMIOQJD	SN	CHEMBL492448; SCHEMBL471328; BDBM50252831
DMIOQJD	DT	Small molecular drug
DMIOQJD	PC	25129090
DMIOQJD	MW	291.4
DMIOQJD	FM	C20H21NO
DMIOQJD	IC	InChI=1S/C20H21NO/c1-15-6-8-16(9-7-15)18-14-20(10-12-21-13-11-20)22-19-5-3-2-4-17(18)19/h2-9,14,21H,10-13H2,1H3
DMIOQJD	CS	CC1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC=C42
DMIOQJD	IK	YDXKUUFNKUXOBE-UHFFFAOYSA-N
DMIOQJD	IU	4-(4-methylphenyl)spiro[chromene-2,4'-piperidine]
DMIOQJD	DE	Discovery agent

DMXK56P	ID	DMXK56P
DMXK56P	DN	4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile
DMXK56P	HS	Investigative
DMXK56P	SN	CHEMBL465539; 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile; BDBM50248554
DMXK56P	DT	Small molecular drug
DMXK56P	PC	43138559
DMXK56P	MW	277.24
DMXK56P	FM	C15H10F3NO
DMXK56P	IC	InChI=1S/C15H10F3NO/c1-10-2-5-12(6-3-10)20-13-7-4-11(9-19)14(8-13)15(16,17)18/h2-8H,1H3
DMXK56P	CS	CC1=CC=C(C=C1)OC2=CC(=C(C=C2)C#N)C(F)(F)F
DMXK56P	IK	NLEVNQCHSZMRKR-UHFFFAOYSA-N
DMXK56P	IU	4-(4-methylphenoxy)-2-(trifluoromethyl)benzonitrile
DMXK56P	DE	Discovery agent

DMZ0H5X	ID	DMZ0H5X
DMZ0H5X	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine
DMZ0H5X	HS	Investigative
DMZ0H5X	SN	CHEMBL1173327; SCHEMBL18770336; BDBM50322785
DMZ0H5X	DT	Small molecular drug
DMZ0H5X	PC	46901445
DMZ0H5X	MW	275.3
DMZ0H5X	FM	C18H17N3
DMZ0H5X	IC	InChI=1S/C18H17N3/c19-17-6-5-16(12-18(17)20)15-3-1-13(2-4-15)11-14-7-9-21-10-8-14/h1-10,12H,11,19-20H2
DMZ0H5X	CS	C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)N)N
DMZ0H5X	IK	SRXFPSNWVWAMBL-UHFFFAOYSA-N
DMZ0H5X	IU	4-[4-(pyridin-4-ylmethyl)phenyl]benzene-1,2-diamine
DMZ0H5X	DE	Discovery agent

DM6Z5EK	ID	DM6Z5EK
DM6Z5EK	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol
DM6Z5EK	HS	Investigative
DM6Z5EK	SN	CHEMBL1172779; SCHEMBL18770369; BDBM50322793
DM6Z5EK	DT	Small molecular drug
DM6Z5EK	PC	46901610
DM6Z5EK	MW	277.3
DM6Z5EK	FM	C18H15NO2
DM6Z5EK	IC	InChI=1S/C18H15NO2/c20-17-6-5-16(12-18(17)21)15-3-1-13(2-4-15)11-14-7-9-19-10-8-14/h1-10,12,20-21H,11H2
DM6Z5EK	CS	C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)O
DM6Z5EK	IK	KOYRCBKCALKGKO-UHFFFAOYSA-N
DM6Z5EK	IU	4-[4-(pyridin-4-ylmethyl)phenyl]benzene-1,2-diol
DM6Z5EK	DE	Discovery agent

DMR8O1B	ID	DMR8O1B
DMR8O1B	DN	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine
DMR8O1B	HS	Investigative
DMR8O1B	SN	CHEMBL1171987; SCHEMBL18770411; BDBM50322783
DMR8O1B	DT	Small molecular drug
DMR8O1B	PC	46901444
DMR8O1B	MW	260.3
DMR8O1B	FM	C18H16N2
DMR8O1B	IC	InChI=1S/C18H16N2/c19-18-3-1-2-17(13-18)16-6-4-14(5-7-16)12-15-8-10-20-11-9-15/h1-11,13H,12,19H2
DMR8O1B	CS	C1=CC(=CC(=C1)N)C2=CC=C(C=C2)CC3=CC=NC=C3
DMR8O1B	IK	MVDKLMQNQSJYHJ-UHFFFAOYSA-N
DMR8O1B	IU	3-[4-(pyridin-4-ylmethyl)phenyl]aniline
DMR8O1B	DE	Discovery agent

DM8HXYS	ID	DM8HXYS
DM8HXYS	DN	4'-(Pyridin-4-ylmethyl)biphenyl-4-amine
DM8HXYS	HS	Investigative
DM8HXYS	SN	CHEMBL1215665; BDBM50324612
DM8HXYS	DT	Small molecular drug
DM8HXYS	PC	46901443
DM8HXYS	MW	260.3
DM8HXYS	FM	C18H16N2
DM8HXYS	IC	InChI=1S/C18H16N2/c19-18-7-5-17(6-8-18)16-3-1-14(2-4-16)13-15-9-11-20-12-10-15/h1-12H,13,19H2
DM8HXYS	CS	C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC=C(C=C3)N
DM8HXYS	IK	DFRORZVGCQQRJH-UHFFFAOYSA-N
DM8HXYS	IU	4-[4-(pyridin-4-ylmethyl)phenyl]aniline
DM8HXYS	DE	Discovery agent

DMYXMT6	ID	DMYXMT6
DMYXMT6	DN	4'-(Pyridin-4-ylmethyl)biphenyl-4-carboxamide
DMYXMT6	HS	Investigative
DMYXMT6	SN	CHEMBL1215731; BDBM50324615
DMYXMT6	DT	Small molecular drug
DMYXMT6	PC	46901614
DMYXMT6	MW	288.3
DMYXMT6	FM	C19H16N2O
DMYXMT6	IC	InChI=1S/C19H16N2O/c20-19(22)18-7-5-17(6-8-18)16-3-1-14(2-4-16)13-15-9-11-21-12-10-15/h1-12H,13H2,(H2,20,22)
DMYXMT6	CS	C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC=C(C=C3)C(=O)N
DMYXMT6	IK	IYXGEVQAAIDJAA-UHFFFAOYSA-N
DMYXMT6	IU	4-[4-(pyridin-4-ylmethyl)phenyl]benzamide
DMYXMT6	DE	Discovery agent

DM4YFU5	ID	DM4YFU5
DM4YFU5	DN	4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine
DM4YFU5	HS	Investigative
DM4YFU5	SN	CHEMBL1080666
DM4YFU5	DT	Small molecular drug
DM4YFU5	PC	44820377
DM4YFU5	MW	312.4
DM4YFU5	FM	C20H16N4
DM4YFU5	IC	InChI=1S/C20H16N4/c1-14-6-8-17(9-7-14)23-20-21-11-10-19(24-20)16-12-15-4-2-3-5-18(15)22-13-16/h2-13H,1H3,(H,21,23,24)
DM4YFU5	CS	CC1=CC=C(C=C1)NC2=NC=CC(=N2)C3=CC4=CC=CC=C4N=C3
DM4YFU5	IK	DLSCDFDGOMZHSD-UHFFFAOYSA-N
DM4YFU5	IU	N-(4-methylphenyl)-4-quinolin-3-ylpyrimidin-2-amine
DM4YFU5	DE	Discovery agent

DMDW3SX	ID	DMDW3SX
DMDW3SX	DN	4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine
DMDW3SX	HS	Investigative
DMDW3SX	SN	CHEMBL1080023
DMDW3SX	DT	Small molecular drug
DMDW3SX	PC	44820374
DMDW3SX	MW	312.4
DMDW3SX	FM	C20H16N4
DMDW3SX	IC	InChI=1S/C20H16N4/c1-14-6-8-15(9-7-14)23-20-22-13-11-19(24-20)17-10-12-21-18-5-3-2-4-16(17)18/h2-13H,1H3,(H,22,23,24)
DMDW3SX	CS	CC1=CC=C(C=C1)NC2=NC=CC(=N2)C3=CC=NC4=CC=CC=C34
DMDW3SX	IK	HFJKLAQBWSUMDJ-UHFFFAOYSA-N
DMDW3SX	IU	N-(4-methylphenyl)-4-quinolin-4-ylpyrimidin-2-amine
DMDW3SX	DE	Discovery agent

DMPNXFA	ID	DMPNXFA
DMPNXFA	DN	4-(Quinolinoxy)-3-pyridinesulfonamide
DMPNXFA	HS	Investigative
DMPNXFA	SN	CHEMBL1165726; 4-(Quinolinoxy)-3-pyridinesulfonamide; BDBM50320501; NSC743333; NSC-743333
DMPNXFA	DT	Small molecular drug
DMPNXFA	PC	45028568
DMPNXFA	MW	301.32
DMPNXFA	FM	C14H11N3O3S
DMPNXFA	IC	InChI=1S/C14H11N3O3S/c15-21(18,19)13-9-16-8-6-11(13)20-12-5-1-3-10-4-2-7-17-14(10)12/h1-9H,(H2,15,18,19)
DMPNXFA	CS	C1=CC2=C(C(=C1)OC3=C(C=NC=C3)S(=O)(=O)N)N=CC=C2
DMPNXFA	IK	YEXUPIWQHCCQQA-UHFFFAOYSA-N
DMPNXFA	IU	4-quinolin-8-yloxypyridine-3-sulfonamide
DMPNXFA	DE	Discovery agent

DM0XDG6	ID	DM0XDG6
DM0XDG6	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide
DM0XDG6	HS	Investigative
DM0XDG6	SN	CHEMBL550063; SCHEMBL10266987; BDBM50297313
DM0XDG6	DT	Small molecular drug
DM0XDG6	PC	44254503
DM0XDG6	MW	320.4
DM0XDG6	FM	C20H20N2O2
DM0XDG6	IC	InChI=1S/C20H20N2O2/c21-19(23)15-7-5-14(6-8-15)17-13-20(9-11-22-12-10-20)24-18-4-2-1-3-16(17)18/h1-8,13,22H,9-12H2,(H2,21,23)
DM0XDG6	CS	C1CNCCC12C=C(C3=CC=CC=C3O2)C4=CC=C(C=C4)C(=O)N
DM0XDG6	IK	QQXCPIPMLCDOFK-UHFFFAOYSA-N
DM0XDG6	IU	4-spiro[chromene-2,4'-piperidine]-4-ylbenzamide
DM0XDG6	DE	Discovery agent

DM8ZRAE	ID	DM8ZRAE
DM8ZRAE	DN	4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol
DM8ZRAE	HS	Investigative
DM8ZRAE	SN	CHEMBL495074; SCHEMBL471335; BDBM50252834
DM8ZRAE	DT	Small molecular drug
DM8ZRAE	PC	25129433
DM8ZRAE	MW	293.4
DM8ZRAE	FM	C19H19NO2
DM8ZRAE	IC	InChI=1S/C19H19NO2/c21-15-7-5-14(6-8-15)17-13-19(9-11-20-12-10-19)22-18-4-2-1-3-16(17)18/h1-8,13,20-21H,9-12H2
DM8ZRAE	CS	C1CNCCC12C=C(C3=CC=CC=C3O2)C4=CC=C(C=C4)O
DM8ZRAE	IK	OZOVJRMTVPPLSS-UHFFFAOYSA-N
DM8ZRAE	IU	4-spiro[chromene-2,4'-piperidine]-4-ylphenol
DM8ZRAE	DE	Discovery agent

DMU5A2B	ID	DMU5A2B
DMU5A2B	DN	4-(tert-butylamino)naphthalen-1-ol
DMU5A2B	HS	Investigative
DMU5A2B	SN	CHEMBL568767; 4-(tert-butylamino)naphthalen-1-ol; SCHEMBL12599109
DMU5A2B	DT	Small molecular drug
DMU5A2B	PC	44465947
DMU5A2B	MW	215.29
DMU5A2B	FM	C14H17NO
DMU5A2B	IC	InChI=1S/C14H17NO/c1-14(2,3)15-12-8-9-13(16)11-7-5-4-6-10(11)12/h4-9,15-16H,1-3H3
DMU5A2B	CS	CC(C)(C)NC1=CC=C(C2=CC=CC=C21)O
DMU5A2B	IK	YZPHFECVIINFFI-UHFFFAOYSA-N
DMU5A2B	IU	4-(tert-butylamino)naphthalen-1-ol
DMU5A2B	DE	Discovery agent

DMSUM3C	ID	DMSUM3C
DMSUM3C	DN	4-(thiazol-2-yl)phenyl butylcarbamate
DMSUM3C	HS	Investigative
DMSUM3C	SN	CHEMBL376748; 4-(thiazol-2-yl)phenyl butylcarbamate
DMSUM3C	DT	Small molecular drug
DMSUM3C	PC	16007307
DMSUM3C	MW	276.36
DMSUM3C	FM	C14H16N2O2S
DMSUM3C	IC	InChI=1S/C14H16N2O2S/c1-2-3-8-16-14(17)18-12-6-4-11(5-7-12)13-15-9-10-19-13/h4-7,9-10H,2-3,8H2,1H3,(H,16,17)
DMSUM3C	CS	CCCCNC(=O)OC1=CC=C(C=C1)C2=NC=CS2
DMSUM3C	IK	HIQUBTZOYOZSPC-UHFFFAOYSA-N
DMSUM3C	IU	[4-(1,3-thiazol-2-yl)phenyl] N-butylcarbamate
DMSUM3C	DE	Discovery agent

DMK3J8Q	ID	DMK3J8Q
DMK3J8Q	DN	4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine
DMK3J8Q	HS	Investigative
DMK3J8Q	SN	CHEMBL259111; 4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine; 443148-62-7; SCHEMBL3684455
DMK3J8Q	DT	Small molecular drug
DMK3J8Q	PC	9813424
DMK3J8Q	MW	234.3
DMK3J8Q	FM	C9H6N4S2
DMK3J8Q	IC	InChI=1S/C9H6N4S2/c10-9-12-5-1-3-14-7(5)6(13-9)8-11-2-4-15-8/h1-4H,(H2,10,12,13)
DMK3J8Q	CS	C1=CSC2=C1N=C(N=C2C3=NC=CS3)N
DMK3J8Q	IK	CLNBBLGSLDNSMF-UHFFFAOYSA-N
DMK3J8Q	IU	4-(1,3-thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine
DMK3J8Q	DE	Discovery agent

DMMWZLC	ID	DMMWZLC
DMMWZLC	DN	4'-(trifluoromethyl)-4-biphenylol
DMMWZLC	HS	Investigative
DMMWZLC	SN	10355-13-2; 4-(4-TRIFLUOROMETHYLPHENYL)PHENOL; 4'-(Trifluoromethyl)[1,1'-biphenyl]-4-ol; CHEMBL244264; 4'-(trifluoromethyl)biphenyl-4-ol; 4'-(Trifluoromethyl)-[1,1'-biphenyl]-4-ol; [1,1'-Biphenyl]-4-ol, 4'-(trifluoromethyl)-; ACMC-1BRC7; SCHEMBL678508; CTK0D8481; DTXSID50573870; 4'-Trifluoromethyl-biphenyl-4-ol; AFPOYLCQXONCPX-UHFFFAOYSA-N; ZINC13840578; BDBM50220207; 4'-(trifluoromethyl) biphenyl-4-ol; 4''-(trifluoromethyl)-4-biphenylol; ANW-14928; AKOS004116417; SEL12447598; 4-hydroxy-4'-(trifluoromethyl)biphenyl; AJ-64481
DMMWZLC	DT	Small molecular drug
DMMWZLC	PC	15541180
DMMWZLC	MW	238.2
DMMWZLC	FM	C13H9F3O
DMMWZLC	IC	InChI=1S/C13H9F3O/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(17)8-4-10/h1-8,17H
DMMWZLC	CS	C1=CC(=CC=C1C2=CC=C(C=C2)O)C(F)(F)F
DMMWZLC	IK	AFPOYLCQXONCPX-UHFFFAOYSA-N
DMMWZLC	IU	4-[4-(trifluoromethyl)phenyl]phenol
DMMWZLC	CA	CAS 10355-13-2
DMMWZLC	DE	Discovery agent

DMLP67R	ID	DMLP67R
DMLP67R	DN	4'-(trifluoromethyl)-4-biphenylsulfonamide
DMLP67R	HS	Investigative
DMLP67R	SN	CHEMBL242783; WWPFVDFIDSAULR-UHFFFAOYSA-N; BDBM50220193; ZINC28711886; AKOS015966248; 4'-Trifluoromethylbiphenyl-4-O-sulfamate; 950500-72-8; 4'-(Trifluoromethyl)-4-biphenylsulfoamide; 4'-(trifluoromethyl)biphenyl-4-sulfonamide
DMLP67R	DT	Small molecular drug
DMLP67R	PC	23625979
DMLP67R	MW	301.29
DMLP67R	FM	C13H10F3NO2S
DMLP67R	IC	InChI=1S/C13H10F3NO2S/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(8-4-10)20(17,18)19/h1-8H,(H2,17,18,19)
DMLP67R	CS	C1=CC(=CC=C1C2=CC=C(C=C2)S(=O)(=O)N)C(F)(F)F
DMLP67R	IK	WWPFVDFIDSAULR-UHFFFAOYSA-N
DMLP67R	IU	4-[4-(trifluoromethyl)phenyl]benzenesulfonamide
DMLP67R	DE	Discovery agent

DMT3BX9	ID	DMT3BX9
DMT3BX9	DN	4'-(trifluoromethyl)-4-biphenylyl carbamate
DMT3BX9	HS	Investigative
DMT3BX9	SN	CHEMBL394512; BDBM50220194; 4''-(trifluoromethyl)-4-biphenylyl carbamate
DMT3BX9	DT	Small molecular drug
DMT3BX9	PC	23626139
DMT3BX9	MW	281.23
DMT3BX9	FM	C14H10F3NO2
DMT3BX9	IC	InChI=1S/C14H10F3NO2/c15-14(16,17)11-5-1-9(2-6-11)10-3-7-12(8-4-10)20-13(18)19/h1-8H,(H2,18,19)
DMT3BX9	CS	C1=CC(=CC=C1C2=CC=C(C=C2)OC(=O)N)C(F)(F)F
DMT3BX9	IK	ZIARVUIVYFGYIG-UHFFFAOYSA-N
DMT3BX9	IU	[4-[4-(trifluoromethyl)phenyl]phenyl] carbamate
DMT3BX9	DE	Discovery agent

DM8PTNR	ID	DM8PTNR
DM8PTNR	DN	4'-(trifluoromethyl)-4-biphenylyl sulfamate
DM8PTNR	HS	Investigative
DM8PTNR	SN	CHEMBL396794; SCHEMBL4665444; ZINC28711937; BDBM50220172; 4''-(trifluoromethyl)-4-biphenylyl sulfamate
DM8PTNR	DT	Small molecular drug
DM8PTNR	PC	15541181
DM8PTNR	MW	317.29
DM8PTNR	FM	C13H10F3NO3S
DM8PTNR	IC	InChI=1S/C13H10F3NO3S/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(8-4-10)20-21(17,18)19/h1-8H,(H2,17,18,19)
DM8PTNR	CS	C1=CC(=CC=C1C2=CC=C(C=C2)OS(=O)(=O)N)C(F)(F)F
DM8PTNR	IK	CRJUOWWINLUIRE-UHFFFAOYSA-N
DM8PTNR	IU	[4-[4-(trifluoromethyl)phenyl]phenyl] sulfamate
DM8PTNR	DE	Discovery agent

DMZ0AKP	ID	DMZ0AKP
DMZ0AKP	DN	4-(trifluoromethyl)biphenyl
DMZ0AKP	HS	Investigative
DMZ0AKP	SN	4-(trifluoromethyl)biphenyl; 398-36-7; 4-trifluoromethylbiphenyl; 4-(Trifluoromethyl)-1,1'-biphenyl; 1-phenyl-4-(trifluoromethyl)benzene; 4-(Trifluoromethyl)-biphenyl; CHEMBL242993; 4-Phenylbenzotrifluoride; p-Trifluoromethylbiphenyl; SCHEMBL163728; CTK4I1963; DTXSID20432208; MolPort-005-937-883; 4-(a,a,a-Trifluoromethyl)biphenyl; ZINC2529931; STL555310; 2494AE; BDBM50220191; BBL101514; 1,1'-Biphenyl,4-(trifluoromethyl)-; AKOS005259545; MCULE-3710616152; AN-44717; DS-11883; AC-18838; AK326586; AB0077698; TR-015900; KB-195437
DMZ0AKP	DT	Small molecular drug
DMZ0AKP	PC	9877863
DMZ0AKP	MW	222.2
DMZ0AKP	FM	C13H9F3
DMZ0AKP	IC	InChI=1S/C13H9F3/c14-13(15,16)12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9H
DMZ0AKP	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F
DMZ0AKP	IK	OUMKBAHMPRLISR-UHFFFAOYSA-N
DMZ0AKP	IU	1-phenyl-4-(trifluoromethyl)benzene
DMZ0AKP	CA	CAS 398-36-7
DMZ0AKP	DE	Discovery agent

DMADZQ9	ID	DMADZQ9
DMADZQ9	DN	4-(trifluoromethyl)phenylboronic acid
DMADZQ9	HS	Investigative
DMADZQ9	SN	128796-39-4; 4-(Trifluoromethyl)phenylboronic acid; 4-trifluoromethylphenylboronic acid; 4-(Trifluoromethyl)benzeneboronic acid; (4-(trifluoromethyl)phenyl)boronic acid; [4-(Trifluoromethyl)phenyl]boronic acid; (4-Trifluoromethylphenyl)boronic acid; [4-(trifluoromethyl)phenyl]boranediol; 4-Boronobenzotrifluoride; p-(trifluoromethyl)phenylboronic acid; CHEMBL143654; alpha,alpha,alpha-Trifluoro-p-tolylboronic acid; 4-trifluoromethylphenyl boronic acid; 4-trifluoromethylphenyl-boronic acid; MFCD00151855; Boronic acid, [4-(tr
DMADZQ9	DT	Small molecular drug
DMADZQ9	PC	2734389
DMADZQ9	MW	189.93
DMADZQ9	FM	C7H6BF3O2
DMADZQ9	IC	InChI=1S/C7H6BF3O2/c9-7(10,11)5-1-3-6(4-2-5)8(12)13/h1-4,12-13H
DMADZQ9	CS	B(C1=CC=C(C=C1)C(F)(F)F)(O)O
DMADZQ9	IK	ALMFIOZYDASRRC-UHFFFAOYSA-N
DMADZQ9	IU	[4-(trifluoromethyl)phenyl]boronic acid
DMADZQ9	CA	CAS 128796-39-4
DMADZQ9	DE	Discovery agent

DM2YAUX	ID	DM2YAUX
DM2YAUX	DN	4(Z)-(5'-Deoxyadenosin-5'-ylidene)butanoic acid
DM2YAUX	HS	Investigative
DM2YAUX	SN	CHEMBL525000
DM2YAUX	DT	Small molecular drug
DM2YAUX	PC	44576814
DM2YAUX	MW	335.32
DM2YAUX	FM	C14H17N5O5
DM2YAUX	IC	InChI=1S/C14H17N5O5/c15-12-9-13(17-5-16-12)19(6-18-9)14-11(23)10(22)7(24-14)3-1-2-4-8(20)21/h1,3,5-7,10-11,14,22-23H,2,4H2,(H,20,21)(H2,15,16,17)/b3-1-/t7-,10-,11-,14-/m1/s1
DM2YAUX	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)/C=C\\CCC(=O)O)O)O)N
DM2YAUX	IK	ZZPNPWVYLOIHPM-RSPDOVAOSA-N
DM2YAUX	IU	(Z)-5-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]pent-4-enoic acid
DM2YAUX	DE	Discovery agent

DMB5RJK	ID	DMB5RJK
DMB5RJK	DN	4,10-dimethyl-6H-benzo[c]chromene-3,8-diol
DMB5RJK	HS	Investigative
DMB5RJK	SN	CHEMBL206582; 4,10-dimethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6924719
DMB5RJK	DT	Small molecular drug
DMB5RJK	PC	10399473
DMB5RJK	MW	242.27
DMB5RJK	FM	C15H14O3
DMB5RJK	IC	InChI=1S/C15H14O3/c1-8-5-11(16)6-10-7-18-15-9(2)13(17)4-3-12(15)14(8)10/h3-6,16-17H,7H2,1-2H3
DMB5RJK	CS	CC1=CC(=CC2=C1C3=C(C(=C(C=C3)O)C)OC2)O
DMB5RJK	IK	UUVHCOKGCFXIER-UHFFFAOYSA-N
DMB5RJK	IU	4,10-dimethyl-6H-benzo[c]chromene-3,8-diol
DMB5RJK	DE	Discovery agent

DM1XTJC	ID	DM1XTJC
DM1XTJC	DN	4,12,17-dehydroxyriccardin C
DM1XTJC	HS	Investigative
DM1XTJC	SN	Deoxyriccardin C; 4,12,17-dehydroxyriccardin C; Riccardin C derivative, 22; CHEMBL410486; BDBM23854
DM1XTJC	DT	Small molecular drug
DM1XTJC	PC	24860516
DM1XTJC	MW	376.5
DM1XTJC	FM	C28H24O
DM1XTJC	IC	InChI=1S/C28H24O/c1-2-7-28-24(5-1)15-10-22-13-18-26(19-14-22)29-27-6-3-4-23(20-27)9-8-21-11-16-25(28)17-12-21/h1-7,11-14,16-20H,8-10,15H2
DM1XTJC	CS	C1CC2=CC(=CC=C2)OC3=CC=C(CCC4=CC=CC=C4C5=CC=C1C=C5)C=C3
DM1XTJC	IK	VHGMCOKOKWHSEA-UHFFFAOYSA-N
DM1XTJC	IU	14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2,4,6,10(29),11,13(28),15,17,19(27),22,25-dodecaene
DM1XTJC	DE	Discovery agent

DMIZ0GO	ID	DMIZ0GO
DMIZ0GO	DN	4,17-dehydroxyriccardin C
DMIZ0GO	HS	Investigative
DMIZ0GO	SN	4,17-dehydroxyriccardin C; Riccardin C derivative, 20f; CHEMBL411912; BDBM23853
DMIZ0GO	DT	Small molecular drug
DMIZ0GO	PC	24860515
DMIZ0GO	MW	392.5
DMIZ0GO	FM	C28H24O2
DMIZ0GO	IC	InChI=1S/C28H24O2/c29-28-19-22-9-8-21-4-3-6-25(18-21)30-24-15-11-20(12-16-24)10-14-23-5-1-2-7-26(23)27(28)17-13-22/h1-7,11-13,15-19,29H,8-10,14H2
DMIZ0GO	CS	C1CC2=CC=CC=C2C3=C(C=C(CCC4=CC(=CC=C4)OC5=CC=C1C=C5)C=C3)O
DMIZ0GO	IK	AWANYYTXBZWDHH-UHFFFAOYSA-N
DMIZ0GO	IU	14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2,4,6,10(29),11,13(28),15,17,19(27),22,25-dodecaen-24-ol
DMIZ0GO	DE	Discovery agent

DMBN4G6	ID	DMBN4G6
DMBN4G6	DN	4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl
DMBN4G6	HS	Investigative
DMBN4G6	SN	CHEMBL379687; BDBM50186763
DMBN4G6	DT	Small molecular drug
DMBN4G6	PC	11537051
DMBN4G6	MW	320.4
DMBN4G6	FM	C21H20O3
DMBN4G6	IC	InChI=1S/C21H20O3/c1-22-17-10-8-15(9-11-17)20-6-4-5-7-21(20)16-12-18(23-2)14-19(13-16)24-3/h4-14H,1-3H3
DMBN4G6	CS	COC1=CC=C(C=C1)C2=CC=CC=C2C3=CC(=CC(=C3)OC)OC
DMBN4G6	IK	YTEAKYDIQLKHMB-UHFFFAOYSA-N
DMBN4G6	IU	1,3-dimethoxy-5-[2-(4-methoxyphenyl)phenyl]benzene
DMBN4G6	DE	Discovery agent

DM40E1T	ID	DM40E1T
DM40E1T	DN	4,3'',5''-trimethoxy-[1,1':3',1'']-terphenyl
DM40E1T	HS	Investigative
DM40E1T	SN	CHEMBL206919; BDBM50186761
DM40E1T	DT	Small molecular drug
DM40E1T	PC	11594901
DM40E1T	MW	320.4
DM40E1T	FM	C21H20O3
DM40E1T	IC	InChI=1S/C21H20O3/c1-22-19-9-7-15(8-10-19)16-5-4-6-17(11-16)18-12-20(23-2)14-21(13-18)24-3/h4-14H,1-3H3
DM40E1T	CS	COC1=CC=C(C=C1)C2=CC(=CC=C2)C3=CC(=CC(=C3)OC)OC
DM40E1T	IK	MDKFFJFTEBNHAN-UHFFFAOYSA-N
DM40E1T	IU	1,3-dimethoxy-5-[3-(4-methoxyphenyl)phenyl]benzene
DM40E1T	DE	Discovery agent

DMJKWFI	ID	DMJKWFI
DMJKWFI	DN	4,4'-(4-phenylpyridine-2,6-diyl)diphenol
DMJKWFI	HS	Investigative
DMJKWFI	DT	Small molecular drug
DMJKWFI	PC	46887215
DMJKWFI	DE	Discovery agent

DM1NVEI	ID	DM1NVEI
DM1NVEI	DN	4,4'-(ethane-1,2-diyl)dibenzene-1,3-diol
DM1NVEI	HS	Investigative
DM1NVEI	SN	CHEMBL499124; SCHEMBL1397158; GTPL8785; Bibenzyl-2,2',4,4'-tetraol; BDBM50263336; compound 7 [PMID: 21334791]; 4,4''-(ethane-1,2-diyl)dibenzene-1,3-diol
DM1NVEI	DT	Small molecular drug
DM1NVEI	PC	24849532
DM1NVEI	MW	246.26
DM1NVEI	FM	C14H14O4
DM1NVEI	IC	InChI=1S/C14H14O4/c15-11-5-3-9(13(17)7-11)1-2-10-4-6-12(16)8-14(10)18/h3-8,15-18H,1-2H2
DM1NVEI	CS	C1=CC(=C(C=C1O)O)CCC2=C(C=C(C=C2)O)O
DM1NVEI	IK	WKIFTWPZTZUMRN-UHFFFAOYSA-N
DM1NVEI	IU	4-[2-(2,4-dihydroxyphenyl)ethyl]benzene-1,3-diol
DM1NVEI	DE	Discovery agent

DMFGQ02	ID	DMFGQ02
DMFGQ02	DN	4,4'-Biphenyldiboronic Acid
DMFGQ02	HS	Investigative
DMFGQ02	SN	44'-Biphenyldiboronic acid; SCHEMBL2460602; ZINC199832994; KB-187838; A825578; (1-borono-4-phenyl-1-cyclohexa-2,4-dienyl)boronic acid; [1-(dihydroxyboranyl)-4-phenyl-cyclohexa-2,4-dien-1-yl]boronic acid
DMFGQ02	DT	Small molecular drug
DMFGQ02	PC	2734608
DMFGQ02	MW	241.8
DMFGQ02	FM	C12H12B2O4
DMFGQ02	IC	InChI=1S/C12H12B2O4/c15-13(16)11-5-1-9(2-6-11)10-3-7-12(8-4-10)14(17)18/h1-8,15-18H
DMFGQ02	CS	B(C1=CC=C(C=C1)C2=CC=C(C=C2)B(O)O)(O)O
DMFGQ02	IK	SLHKDOGTVUCXKX-UHFFFAOYSA-N
DMFGQ02	IU	[4-(4-boronophenyl)phenyl]boronic acid
DMFGQ02	CA	CAS 4151-80-8
DMFGQ02	DE	Discovery agent

DMFPO16	ID	DMFPO16
DMFPO16	DN	4',4-Dihydroxychalcone
DMFPO16	HS	Investigative
DMFPO16	SN	4,4'-Dihydroxychalcone; UNII-CKY3J88Z94; CKY3J88Z94; CHEMBL145927; 1,3-bis(4-hydroxyphenyl)prop-2-en-1-one; 4',4-Dihydroxychalcone; 3600-61-1; 4,4'-Dihydroxybenzylidene acetophenone; RVC 588 (chalcone); 4,4''-dihydroxychalcone; 4'',4-Dihydroxychalcone; AC1NV3S6; (E)-1,3-bis(4-hydroxyphenyl)prop-2-en-1-one; Trans-4,4'-dihydroxychalcone; SCHEMBL773588; (E)-4,4'-Dihydroxychalcone; 4,4'-Dihydroxychalcone, (E)-; 1,3-bis(4-hydroxyphenyl)propenone; ZINC5843955; NSC652891; LMPK12120193; BDBM50068224; AKOS022660924; NSC-652891
DMFPO16	DT	Small molecular drug
DMFPO16	PC	5467477
DMFPO16	MW	240.25
DMFPO16	FM	C15H12O3
DMFPO16	IC	InChI=1S/C15H12O3/c16-13-6-1-11(2-7-13)3-10-15(18)12-4-8-14(17)9-5-12/h1-10,16-17H/b10-3+
DMFPO16	CS	C1=CC(=CC=C1/C=C/C(=O)C2=CC=C(C=C2)O)O
DMFPO16	IK	FZQLEXXZAVVCCA-XCVCLJGOSA-N
DMFPO16	IU	(E)-1,3-bis(4-hydroxyphenyl)prop-2-en-1-one
DMFPO16	CA	CAS 3600-61-1
DMFPO16	DE	Discovery agent

DM1ONBT	ID	DM1ONBT
DM1ONBT	DN	4,4'-dihydroxyoctafluoroazobenzene
DM1ONBT	HS	Investigative
DM1ONBT	DT	Small molecular drug
DM1ONBT	PC	136186019
DM1ONBT	MW	358.14
DM1ONBT	FM	C12H2F8N2O2
DM1ONBT	IC	InChI=1S/C12H2F8N2O2/c13-1-5(17)11(23)6(18)2(14)9(1)21-22-10-3(15)7(19)12(24)8(20)4(10)16/h23-24H
DM1ONBT	CS	C1(=C(C(=C(C(=C1F)F)O)F)F)N=NC2=C(C(=C(C(=C2F)F)O)F)F
DM1ONBT	IK	OLAUREFYJFRAJD-UHFFFAOYSA-N
DM1ONBT	IU	2,3,5,6-tetrafluoro-4-[(2,3,5,6-tetrafluoro-4-hydroxyphenyl)diazenyl]phenol
DM1ONBT	DE	Discovery agent

DMQ0TBX	ID	DMQ0TBX
DMQ0TBX	DN	4,4-Diphenylbutan-1-amine
DMQ0TBX	HS	Investigative
DMQ0TBX	SN	4,4-Diphenylbutylamine; 36765-74-9; EINECS 253-194-6; 4,4-Diphenylbutan-1-amine; diphenylbutylamine; AC1MI1YM; delta-Phenylbenzenebutanamine; Benzenebutanamine, d-phenyl-; SCHEMBL157808; diphenylalkylamine (DPA), 6a; CHEMBL593734; CTK4H7118; BDBM35935; DTXSID10190229; MAAQGZFMFXQVOG-UHFFFAOYSA-N; AKOS030583685
DMQ0TBX	DT	Small molecular drug
DMQ0TBX	PC	3015863
DMQ0TBX	MW	225.33
DMQ0TBX	FM	C16H19N
DMQ0TBX	IC	InChI=1S/C16H19N/c17-13-7-12-16(14-8-3-1-4-9-14)15-10-5-2-6-11-15/h1-6,8-11,16H,7,12-13,17H2
DMQ0TBX	CS	C1=CC=C(C=C1)C(CCCN)C2=CC=CC=C2
DMQ0TBX	IK	MAAQGZFMFXQVOG-UHFFFAOYSA-N
DMQ0TBX	IU	4,4-diphenylbutan-1-amine
DMQ0TBX	CA	CAS 36765-74-9
DMQ0TBX	DE	Discovery agent

DMM0H9Y	ID	DMM0H9Y
DMM0H9Y	DN	4,4-Diphenyl-N-(pyridin-3-yl)-butyramide
DMM0H9Y	HS	Investigative
DMM0H9Y	SN	CHEMBL565028; 4,4-Diphenyl-N-(pyridin-3-yl)-butyramide; SCHEMBL4617484; CEQRPUYSSDGEML-UHFFFAOYSA-N; BDBM50297404
DMM0H9Y	DT	Small molecular drug
DMM0H9Y	PC	11976417
DMM0H9Y	MW	316.4
DMM0H9Y	FM	C21H20N2O
DMM0H9Y	IC	InChI=1S/C21H20N2O/c24-21(23-19-12-7-15-22-16-19)14-13-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-12,15-16,20H,13-14H2,(H,23,24)
DMM0H9Y	CS	C1=CC=C(C=C1)C(CCC(=O)NC2=CN=CC=C2)C3=CC=CC=C3
DMM0H9Y	IK	CEQRPUYSSDGEML-UHFFFAOYSA-N
DMM0H9Y	IU	4,4-diphenyl-N-pyridin-3-ylbutanamide
DMM0H9Y	DE	Discovery agent

DM0K5JM	ID	DM0K5JM
DM0K5JM	DN	4,4'-thiodipyridine-3-sulfonamide
DM0K5JM	HS	Investigative
DM0K5JM	SN	4,4'-thiodipyridine-3-sulfonamide; CHEMBL1164504; 1078160-08-3; NSC743332; BDBM50320519; 4,4''-thiodipyridine-3-sulfonamide; 4,4'-Thiodi(pyridine-3-sulfonamide); NSC-743332
DM0K5JM	DT	Small molecular drug
DM0K5JM	PC	45028567
DM0K5JM	MW	346.4
DM0K5JM	FM	C10H10N4O4S3
DM0K5JM	IC	InChI=1S/C10H10N4O4S3/c11-20(15,16)9-5-13-3-1-7(9)19-8-2-4-14-6-10(8)21(12,17)18/h1-6H,(H2,11,15,16)(H2,12,17,18)
DM0K5JM	CS	C1=CN=CC(=C1SC2=C(C=NC=C2)S(=O)(=O)N)S(=O)(=O)N
DM0K5JM	IK	JYMNSJBFCKCLMB-UHFFFAOYSA-N
DM0K5JM	IU	4-(3-sulfamoylpyridin-4-yl)sulfanylpyridine-3-sulfonamide
DM0K5JM	DE	Discovery agent

DMUE4K3	ID	DMUE4K3
DMUE4K3	DN	4,5,6,7-tetrabromo-1H-benzimidazole
DMUE4K3	HS	Investigative
DMUE4K3	SN	4,5,6,7-tetrabromobenzimidazole; TBBz; 577779-57-8; 4,5,6,7-Tetrabromo-Benzimidazole; 4,5,6,7-tetrabromo-1H-benzo[d]imidazole; CHEMBL373937; 2oxy; AC1NP4E4; SCHEMBL406945; CTK5I6050; DTXSID80408803; MolPort-003-850-464; LOEIRDBRYBHAJB-UHFFFAOYSA-N; HMS3260K22; ZINC2528524; Tox21_500140; BDBM50156669; TBBz, &gt; MFCD04116202; 4,5,6,7-Tetrabromo-1Hbenzimidazole; LP00140; CCG-221444; NCGC00260825-01; NCGC00165910-02; NCGC00165910-01; RT-009016; FT-0674936
DMUE4K3	DT	Small molecular drug
DMUE4K3	PC	5149739
DMUE4K3	MW	433.72
DMUE4K3	FM	C7H2Br4N2
DMUE4K3	IC	InChI=1S/C7H2Br4N2/c8-2-3(9)5(11)7-6(4(2)10)12-1-13-7/h1H,(H,12,13)
DMUE4K3	CS	C1=NC2=C(N1)C(=C(C(=C2Br)Br)Br)Br
DMUE4K3	IK	LOEIRDBRYBHAJB-UHFFFAOYSA-N
DMUE4K3	IU	4,5,6,7-tetrabromo-1H-benzimidazole
DMUE4K3	CA	CAS 577779-57-8
DMUE4K3	DE	Discovery agent

DMN9YOB	ID	DMN9YOB
DMN9YOB	DN	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB	HS	Investigative
DMN9YOB	SN	4,5,6,7-tetrabromobenzotriazole
DMN9YOB	DT	Small molecular drug
DMN9YOB	PC	1694
DMN9YOB	MW	434.71
DMN9YOB	FM	C6HBr4N3
DMN9YOB	IC	InChI=1S/C6HBr4N3/c7-1-2(8)4(10)6-5(3(1)9)11-13-12-6/h(H,11,12,13)
DMN9YOB	CS	C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br
DMN9YOB	IK	OMZYUVOATZSGJY-UHFFFAOYSA-N
DMN9YOB	IU	4,5,6,7-tetrabromo-2H-benzotriazole
DMN9YOB	CA	CAS 17374-26-4
DMN9YOB	DE	Discovery agent

DMTC7J2	ID	DMTC7J2
DMTC7J2	DN	4,5,6,7-tetrafluoro-3-methyl-1H-indazole
DMTC7J2	HS	Investigative
DMTC7J2	SN	4,5,6,7-tetrafluoro-3-methyl-1H-indazole; 220057-70-5; CHEMBL593307; SCHEMBL13122192; ZINC34415295; AKOS024258260; FCH3137367; AJ-88433; AX8289182
DMTC7J2	DT	Small molecular drug
DMTC7J2	PC	10726859
DMTC7J2	MW	204.12
DMTC7J2	FM	C8H4F4N2
DMTC7J2	IC	InChI=1S/C8H4F4N2/c1-2-3-4(9)5(10)6(11)7(12)8(3)14-13-2/h1H3,(H,13,14)
DMTC7J2	CS	CC1=C2C(=C(C(=C(C2=NN1)F)F)F)F
DMTC7J2	IK	MEHLPQAUVAMMPE-UHFFFAOYSA-N
DMTC7J2	IU	4,5,6,7-tetrafluoro-3-methyl-2H-indazole
DMTC7J2	DE	Discovery agent

DMZEY31	ID	DMZEY31
DMZEY31	DN	4,5,6,7-tetrafluoro-3-perfluorophenyl-1H-indazole
DMZEY31	HS	Investigative
DMZEY31	SN	CHEMBL595197; 4,5,6,7-tetrafluoro-3-perfluorophenyl-1H-indazole; SCHEMBL20472960; BDBM50304151
DMZEY31	DT	Small molecular drug
DMZEY31	PC	44622822
DMZEY31	MW	356.15
DMZEY31	FM	C13HF9N2
DMZEY31	IC	InChI=1S/C13HF9N2/c14-3-1(4(15)7(18)9(20)6(3)17)12-2-5(16)8(19)10(21)11(22)13(2)24-23-12/h(H,23,24)
DMZEY31	CS	C12=C(NN=C1C(=C(C(=C2F)F)F)F)C3=C(C(=C(C(=C3F)F)F)F)F
DMZEY31	IK	BLRLNVDCKOMIHM-UHFFFAOYSA-N
DMZEY31	IU	4,5,6,7-tetrafluoro-3-(2,3,4,5,6-pentafluorophenyl)-2H-indazole
DMZEY31	DE	Discovery agent

DMDQL24	ID	DMDQL24
DMDQL24	DN	4,5,6,7-Tetrahydro-1H-indazole-3-carboxylic acid
DMDQL24	HS	Investigative
DMDQL24	SN	4,5,6,7-Tetrahydro-1H-indazole-3-carboxylic acid; 6076-13-7; 4,5,6,7-Tetrahydro-2H-indazole-3-carboxylic acid; 714255-28-4; CHEMBL338405; LWXNHFZBFJMHGU-UHFFFAOYSA-N; 2H-Indazole-3-carboxylicacid, 4,5,6,7-tetrahydro-; 1H-Indazole-3-carboxylic acid, 4,5,6,7-tetrahydro-; 2H-Indazole-3-carboxylic acid, 4,5,6,7-tetrahydro-; 1H-4,5,6,7-tetrahydroindazole-3-carboxylic acid; MLS000074645; AC1LDJ0A; ChemDiv2_003320; Oprea1_089683; AC1Q748E; SCHEMBL1808017; AC1Q72Q0; CTK2H6469; DTXSID00349466; MolPort-000-767-792; MolPort-000-149-162
DMDQL24	DT	Small molecular drug
DMDQL24	PC	648852
DMDQL24	MW	166.18
DMDQL24	FM	C8H10N2O2
DMDQL24	IC	InChI=1S/C8H10N2O2/c11-8(12)7-5-3-1-2-4-6(5)9-10-7/h1-4H2,(H,9,10)(H,11,12)
DMDQL24	CS	C1CCC2=C(C1)C(=NN2)C(=O)O
DMDQL24	IK	LWXNHFZBFJMHGU-UHFFFAOYSA-N
DMDQL24	IU	4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid
DMDQL24	CA	CAS 6076-13-7
DMDQL24	DE	Discovery agent

DMO91EH	ID	DMO91EH
DMO91EH	DN	4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridin-3-ol
DMO91EH	HS	Investigative
DMO91EH	SN	THIP hydrochloride; GABOXADOL HYDROCHLORIDE; 85118-33-8; UNII-478RVH3TVD; 478RVH3TVD; 4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrochloride; 4,5,6,7-TETRAHYDROISOXAZOLO[5,4-C]PYRIDIN-3-OL HCL, GABOXADOL-HCL; SR-01000075651; EINECS 285-687-7; THIP NIEaNI; THIP HCl; AC1NWAX4; Gaboxadol (hydrochloride); MLS002154080; SPECTRUM1503648; CHEMBL1255746; CTK8G3449; DTXSID90234251; AOB5024; MolPort-006-141-665; MolPort-003-666-496; HMS1571C05; Pharmakon1600-01503648; BCP16610; Tox21_501233; BN0520; NSC759585; CCG-39368
DMO91EH	DT	Small molecular drug
DMO91EH	PC	5702253
DMO91EH	MW	176.6
DMO91EH	FM	C6H9ClN2O2
DMO91EH	IC	InChI=1S/C6H8N2O2.ClH/c9-6-4-1-2-7-3-5(4)10-8-6;/h7H,1-3H2,(H,8,9);1H
DMO91EH	CS	C1CNCC2=C1C(=O)NO2.Cl
DMO91EH	IK	ZDZDSZQYRBZPNN-UHFFFAOYSA-N
DMO91EH	IU	4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one;hydrochloride
DMO91EH	CA	CAS 85118-33-8
DMO91EH	DE	Discovery agent

DMQFTJ7	ID	DMQFTJ7
DMQFTJ7	DN	4,5,6-trihydroxy-3-methylphthalide
DMQFTJ7	HS	Investigative
DMQFTJ7	SN	CHEMBL486813; 4,5,6-trihydroxy-3-methylphthalide; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one
DMQFTJ7	DT	Small molecular drug
DMQFTJ7	PC	11424128
DMQFTJ7	MW	196.16
DMQFTJ7	FM	C9H8O5
DMQFTJ7	IC	InChI=1S/C9H8O5/c1-3-6-4(9(13)14-3)2-5(10)7(11)8(6)12/h2-3,10-12H,1H3
DMQFTJ7	CS	CC1C2=C(C(=C(C=C2C(=O)O1)O)O)O
DMQFTJ7	IK	AGUVVAYMPQDJDX-UHFFFAOYSA-N
DMQFTJ7	IU	4,5,6-trihydroxy-3-methyl-3H-2-benzofuran-1-one
DMQFTJ7	DE	Discovery agent

DMXZ9PI	ID	DMXZ9PI
DMXZ9PI	DN	4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one
DMXZ9PI	HS	Investigative
DMXZ9PI	SN	CHEMBL147690
DMXZ9PI	DT	Small molecular drug
DMXZ9PI	PC	44364737
DMXZ9PI	MW	264.5
DMXZ9PI	FM	C9H4Cl3NO2
DMXZ9PI	IC	InChI=1S/C9H4Cl3NO2/c10-3-1-4(11)6-5(2-3)13-9(15)8(14)7(6)12/h1-2,14H,(H,13,15)
DMXZ9PI	CS	C1=C(C=C(C2=C1NC(=O)C(=C2Cl)O)Cl)Cl
DMXZ9PI	IK	NRMJPXWRZZNIDJ-UHFFFAOYSA-N
DMXZ9PI	IU	4,5,7-trichloro-3-hydroxy-1H-quinolin-2-one
DMXZ9PI	DE	Discovery agent

DM1RM3H	ID	DM1RM3H
DM1RM3H	DN	4',5,7-trihydroxy-6,8-dimethylisoflavone
DM1RM3H	HS	Investigative
DM1RM3H	SN	4',5,7-Trihydroxy-6,8-dimethylisoflavone; CHEMBL512579; AC1LCTEG; SCHEMBL571136; BDBM50250906; 4'',5,7-trihydroxy-6,8-dimethylisoflavone; 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethylchromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethyl-4H-chromen-4-one; 5,7-Dihydroxy-3-(4-hydroxy-phenyl)-6,8-dimethyl-chromen-4-one; 4H-1-benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethyl-
DM1RM3H	DT	Small molecular drug
DM1RM3H	PC	637048
DM1RM3H	MW	298.29
DM1RM3H	FM	C17H14O5
DM1RM3H	IC	InChI=1S/C17H14O5/c1-8-14(19)9(2)17-13(15(8)20)16(21)12(7-22-17)10-3-5-11(18)6-4-10/h3-7,18-20H,1-2H3
DM1RM3H	CS	CC1=C(C(=C2C(=C1O)C(=O)C(=CO2)C3=CC=C(C=C3)O)C)O
DM1RM3H	IK	VSEIMGCATUFLSE-UHFFFAOYSA-N
DM1RM3H	IU	5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethylchromen-4-one
DM1RM3H	DE	Discovery agent

DMIO254	ID	DMIO254
DMIO254	DN	4,5-Bis(4-chlorophenyl)-1,2-selenazole
DMIO254	HS	Investigative
DMIO254	SN	CHEMBL501676; 4,5-Bis(4-chlorophenyl)-1,2-selenazole
DMIO254	DT	Small molecular drug
DMIO254	PC	24884694
DMIO254	MW	353.1
DMIO254	FM	C15H9Cl2NSe
DMIO254	IC	InChI=1S/C15H9Cl2NSe/c16-12-5-1-10(2-6-12)14-9-18-19-15(14)11-3-7-13(17)8-4-11/h1-9H
DMIO254	CS	C1=CC(=CC=C1C2=C([Se]N=C2)C3=CC=C(C=C3)Cl)Cl
DMIO254	IK	QKBSSPQBZVKIAU-UHFFFAOYSA-N
DMIO254	IU	4,5-bis(4-chlorophenyl)-1,2-selenazole
DMIO254	DE	Discovery agent

DMENLFY	ID	DMENLFY
DMENLFY	DN	4,5-Bis(4-chlorophenyl)isothiazole
DMENLFY	HS	Investigative
DMENLFY	SN	4,5-Bis(4-chlorophenyl)isothiazole; CHEMBL491088
DMENLFY	DT	Small molecular drug
DMENLFY	PC	44564456
DMENLFY	MW	306.2
DMENLFY	FM	C15H9Cl2NS
DMENLFY	IC	InChI=1S/C15H9Cl2NS/c16-12-5-1-10(2-6-12)14-9-18-19-15(14)11-3-7-13(17)8-4-11/h1-9H
DMENLFY	CS	C1=CC(=CC=C1C2=C(SN=C2)C3=CC=C(C=C3)Cl)Cl
DMENLFY	IK	FCOMTKBRAKMDNZ-UHFFFAOYSA-N
DMENLFY	IU	4,5-bis(4-chlorophenyl)-1,2-thiazole
DMENLFY	DE	Discovery agent

DMKHD1M	ID	DMKHD1M
DMKHD1M	DN	4,5-Bis(4-methoxyphenyl)-1,2-selenazole
DMKHD1M	HS	Investigative
DMKHD1M	SN	CHEMBL470304; 4,5-Bis(4-methoxyphenyl)-1,2-selenazole
DMKHD1M	DT	Small molecular drug
DMKHD1M	PC	24884690
DMKHD1M	MW	344.3
DMKHD1M	FM	C17H15NO2Se
DMKHD1M	IC	InChI=1S/C17H15NO2Se/c1-19-14-7-3-12(4-8-14)16-11-18-21-17(16)13-5-9-15(20-2)10-6-13/h3-11H,1-2H3
DMKHD1M	CS	COC1=CC=C(C=C1)C2=C([Se]N=C2)C3=CC=C(C=C3)OC
DMKHD1M	IK	QSLNOYIPCSNQKT-UHFFFAOYSA-N
DMKHD1M	IU	4,5-bis(4-methoxyphenyl)-1,2-selenazole
DMKHD1M	DE	Discovery agent

DMI39QT	ID	DMI39QT
DMI39QT	DN	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one
DMI39QT	HS	Investigative
DMI39QT	SN	CHEMBL490292; 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one
DMI39QT	DT	Small molecular drug
DMI39QT	PC	13015959
DMI39QT	MW	330.4
DMI39QT	FM	C17H14O3S2
DMI39QT	IC	InChI=1S/C17H14O3S2/c1-19-13-7-3-11(4-8-13)15-16(21-22-17(15)18)12-5-9-14(20-2)10-6-12/h3-10H,1-2H3
DMI39QT	CS	COC1=CC=C(C=C1)C2=C(SSC2=O)C3=CC=C(C=C3)OC
DMI39QT	IK	HXHFMMHFTDDRIF-UHFFFAOYSA-N
DMI39QT	IU	4,5-bis(4-methoxyphenyl)dithiol-3-one
DMI39QT	DE	Discovery agent

DMPW145	ID	DMPW145
DMPW145	DN	4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiole-3-thione
DMPW145	HS	Investigative
DMPW145	SN	CHEMBL489899; 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiole-3-thione
DMPW145	DT	Small molecular drug
DMPW145	PC	44564508
DMPW145	MW	346.5
DMPW145	FM	C17H14O2S3
DMPW145	IC	InChI=1S/C17H14O2S3/c1-18-13-7-3-11(4-8-13)15-16(21-22-17(15)20)12-5-9-14(19-2)10-6-12/h3-10H,1-2H3
DMPW145	CS	COC1=CC=C(C=C1)C2=C(SSC2=S)C3=CC=C(C=C3)OC
DMPW145	IK	CLEJIKNYKPUJCS-UHFFFAOYSA-N
DMPW145	IU	4,5-bis(4-methoxyphenyl)dithiole-3-thione
DMPW145	CA	CAS 35564-24-0
DMPW145	DE	Discovery agent

DM90DV6	ID	DM90DV6
DM90DV6	DN	4,5-Bis(4-methoxyphenyl)isothiazole
DM90DV6	HS	Investigative
DM90DV6	SN	4,5-Bis(4-methoxyphenyl)isothiazole; CHEMBL473946
DM90DV6	DT	Small molecular drug
DM90DV6	PC	44564415
DM90DV6	MW	297.4
DM90DV6	FM	C17H15NO2S
DM90DV6	IC	InChI=1S/C17H15NO2S/c1-19-14-7-3-12(4-8-14)16-11-18-21-17(16)13-5-9-15(20-2)10-6-13/h3-11H,1-2H3
DM90DV6	CS	COC1=CC=C(C=C1)C2=C(SN=C2)C3=CC=C(C=C3)OC
DM90DV6	IK	COPANKICKKUPAC-UHFFFAOYSA-N
DM90DV6	IU	4,5-bis(4-methoxyphenyl)-1,2-thiazole
DM90DV6	DE	Discovery agent

DMHURXY	ID	DMHURXY
DMHURXY	DN	4,5-dibenzylbenzene-1,2-diol
DMHURXY	HS	Investigative
DMHURXY	SN	4,5-dibenzylbenzene-1,2-diol; 4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154
DMHURXY	DT	Small molecular drug
DMHURXY	PC	379493
DMHURXY	MW	290.4
DMHURXY	FM	C20H18O2
DMHURXY	IC	InChI=1S/C20H18O2/c21-19-13-17(11-15-7-3-1-4-8-15)18(14-20(19)22)12-16-9-5-2-6-10-16/h1-10,13-14,21-22H,11-12H2
DMHURXY	CS	C1=CC=C(C=C1)CC2=CC(=C(C=C2CC3=CC=CC=C3)O)O
DMHURXY	IK	SQDMOCPHIXUCCE-UHFFFAOYSA-N
DMHURXY	IU	4,5-dibenzylbenzene-1,2-diol
DMHURXY	DE	Discovery agent

DMDM9UV	ID	DMDM9UV
DMDM9UV	DN	4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide
DMDM9UV	HS	Investigative
DMDM9UV	SN	CHEMBL356164; 34649-20-2; 4,5-dibromopyrrole-2-carboxamide; 4,5-dibromo-1h-pyrrole-2-carboxamide; 4,5-dibromopyrrole-2-carbonamide; 4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide; MLS001250248; 4,5-dibromopyrrole-2-carbamide; CTK1B1045; DTXSID30555154; BDBM50108773; SMR001216076; 1H-Pyrrole-2-carboxamide, 4,5-dibromo-; 4,5-Dibromo-1H-pyrrole-2-carboxylic acid
DMDM9UV	DT	Small molecular drug
DMDM9UV	PC	14056555
DMDM9UV	MW	267.91
DMDM9UV	FM	C5H4Br2N2O
DMDM9UV	IC	InChI=1S/C5H4Br2N2O/c6-2-1-3(5(8)10)9-4(2)7/h1,9H,(H2,8,10)
DMDM9UV	CS	C1=C(NC(=C1Br)Br)C(=O)N
DMDM9UV	IK	VTWHNVAKXBNGFV-UHFFFAOYSA-N
DMDM9UV	IU	4,5-dibromo-1H-pyrrole-2-carboxamide
DMDM9UV	CA	CAS 34649-20-2
DMDM9UV	DE	Discovery agent

DMX94EK	ID	DMX94EK
DMX94EK	DN	4,5-dichloro-1H-indole-2,3-dione
DMX94EK	HS	Investigative
DMX94EK	SN	4,5-Dichloroisatin; 1677-47-0; 4,5-dichloro-1H-indole-2,3-dione; 4,5-Dichloroindoline-2,3-dione; 1H-Indole-2,3-dione, 4,5-dichloro-; 4,5-dichloro-2,3-dihydro-1H-indole-2,3-dione; 4,5-Dichlorisatin; AC1NOKZI; AC1Q3HQG; Isatin-based compound, 49; SCHEMBL734955; CHEMBL385799; CTK4D2746; BDBM22829; DTXSID90408697; MolPort-001-828-451; WWSWHYAXEFLETD-UHFFFAOYSA-N; ZINC4530445; 8556AA; 4,5-dichloro-1H-indol-2,3-dione; ANW-58782; AKOS015850110; FCH1330653; 1H-Indole-2,3-dione,4,5-dichloro-; QC-9708; MCULE-6649049490; KB-35588; SY030680
DMX94EK	DT	Small molecular drug
DMX94EK	PC	5139980
DMX94EK	MW	216.02
DMX94EK	FM	C8H3Cl2NO2
DMX94EK	IC	InChI=1S/C8H3Cl2NO2/c9-3-1-2-4-5(6(3)10)7(12)8(13)11-4/h1-2H,(H,11,12,13)
DMX94EK	CS	C1=CC(=C(C2=C1NC(=O)C2=O)Cl)Cl
DMX94EK	IK	WWSWHYAXEFLETD-UHFFFAOYSA-N
DMX94EK	IU	4,5-dichloro-1H-indole-2,3-dione
DMX94EK	CA	CAS 1677-47-0
DMX94EK	DE	Discovery agent

DMG8KRN	ID	DMG8KRN
DMG8KRN	DN	4,5-Dihydroxy-10H-anthracen-9-one
DMG8KRN	HS	Investigative
DMG8KRN	SN	CHEMBL124951; Isoanthralin; 4,5-Dihydroxy-10H-anthracen-9-one; 1,8-dihydroxy-10-anthrone; ZINC13606497; BDBM50060858
DMG8KRN	DT	Small molecular drug
DMG8KRN	PC	13379482
DMG8KRN	MW	226.23
DMG8KRN	FM	C14H10O3
DMG8KRN	IC	InChI=1S/C14H10O3/c15-12-5-1-3-8-10(12)7-11-9(14(8)17)4-2-6-13(11)16/h1-6,15-16H,7H2
DMG8KRN	CS	C1C2=C(C=CC=C2O)C(=O)C3=C1C(=CC=C3)O
DMG8KRN	IK	BGECJMUUSSERAU-UHFFFAOYSA-N
DMG8KRN	IU	4,5-dihydroxy-10H-anthracen-9-one
DMG8KRN	DE	Discovery agent

DM34L89	ID	DM34L89
DM34L89	DN	4,5-Dimethoxy-10H-anthracen-9-one
DM34L89	HS	Investigative
DM34L89	SN	4,5-dimethoxy-10H-anthracen-9-one; CHEMBL125822; 76403-03-7; AC1NRZIP; CTK2G0639; DTXSID90416070; ZINC2540909; BDBM50060856; 4,5-Dimethoxyanthracen-9(10H)-one; 9(10H)-Anthracenone, 4,5-dimethoxy-
DM34L89	DT	Small molecular drug
DM34L89	PC	5325945
DM34L89	MW	254.28
DM34L89	FM	C16H14O3
DM34L89	IC	InChI=1S/C16H14O3/c1-18-14-7-3-5-10-12(14)9-13-11(16(10)17)6-4-8-15(13)19-2/h3-8H,9H2,1-2H3
DM34L89	CS	COC1=CC=CC2=C1CC3=C(C2=O)C=CC=C3OC
DM34L89	IK	YNXDXUPTUFLKRN-UHFFFAOYSA-N
DM34L89	IU	4,5-dimethoxy-10H-anthracen-9-one
DM34L89	CA	CAS 76403-03-7
DM34L89	DE	Discovery agent

DMB9CJM	ID	DMB9CJM
DMB9CJM	DN	4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMB9CJM	HS	Investigative
DMB9CJM	SN	CHEMBL185584; 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150924
DMB9CJM	DT	Small molecular drug
DMB9CJM	PC	10261068
DMB9CJM	MW	112.17
DMB9CJM	FM	C6H12N2
DMB9CJM	IC	InChI=1S/C6H12N2/c1-4-3-6(7)8-5(4)2/h4-5H,3H2,1-2H3,(H2,7,8)
DMB9CJM	CS	CC1CC(=NC1C)N
DMB9CJM	IK	HLFGYTAETWRDBS-UHFFFAOYSA-N
DMB9CJM	IU	2,3-dimethyl-3,4-dihydro-2H-pyrrol-5-amine
DMB9CJM	DE	Discovery agent

DMXNP2W	ID	DMXNP2W
DMXNP2W	DN	4,5-ISOBUDLEIN A
DMXNP2W	HS	Investigative
DMXNP2W	SN	4,5-isobudlein A
DMXNP2W	DT	Small molecular drug
DMXNP2W	PC	44409589
DMXNP2W	MW	374.4
DMXNP2W	FM	C20H22O7
DMXNP2W	IC	InChI=1S/C20H22O7/c1-6-9(2)18(23)25-13-8-20(5)14(21)7-12(27-20)10(3)16(22)17-15(13)11(4)19(24)26-17/h6-7,13,15-17,22H,3-4,8H2,1-2,5H3/b9-6-/t13-,15-,16+,17+,20-/m1/s1
DMXNP2W	CS	C/C=C(/C)\\C(=O)O[C@@H]1C[C@@]2(C(=O)C=C(O2)C(=C)[C@@H]([C@@H]3[C@@H]1C(=C)C(=O)O3)O)C
DMXNP2W	IK	LEMMNOMGQFFVKL-NPUWKFQTSA-N
DMXNP2W	IU	[(3S,4S,8R,9R,11R)-3-hydroxy-11-methyl-2,7-dimethylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradec-1(13)-en-9-yl] (Z)-2-methylbut-2-enoate
DMXNP2W	DE	Discovery agent

DM6N98E	ID	DM6N98E
DM6N98E	DN	4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol
DM6N98E	HS	Investigative
DM6N98E	SN	CHEMBL380362; 4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol
DM6N98E	DT	Small molecular drug
DM6N98E	PC	11777167
DM6N98E	MW	256.3
DM6N98E	FM	C16H16O3
DM6N98E	IC	InChI=1S/C16H16O3/c1-8-6-11(17)7-13-10(3)19-16-9(2)14(18)5-4-12(16)15(8)13/h4-7,10,17-18H,1-3H3
DM6N98E	CS	CC1C2=C(C(=CC(=C2)O)C)C3=C(O1)C(=C(C=C3)O)C
DM6N98E	IK	ACLQWAFSCNOYRE-UHFFFAOYSA-N
DM6N98E	IU	4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol
DM6N98E	DE	Discovery agent

DM14VI3	ID	DM14VI3
DM14VI3	DN	4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol
DM14VI3	HS	Investigative
DM14VI3	SN	CHEMBL204025; 4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6827956
DM14VI3	DT	Small molecular drug
DM14VI3	PC	9993278
DM14VI3	MW	270.32
DM14VI3	FM	C17H18O3
DM14VI3	IC	InChI=1S/C17H18O3/c1-9-13(18)7-5-11-12-6-8-14(19)10(2)16(12)20-17(3,4)15(9)11/h5-8,18-19H,1-4H3
DM14VI3	CS	CC1=C(C=CC2=C1C(OC3=C2C=CC(=C3C)O)(C)C)O
DM14VI3	IK	XQLSNCGISMACFD-UHFFFAOYSA-N
DM14VI3	IU	4,6,6,7-tetramethylbenzo[c]chromene-3,8-diol
DM14VI3	DE	Discovery agent

DMYN25U	ID	DMYN25U
DMYN25U	DN	4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol
DMYN25U	HS	Investigative
DMYN25U	SN	CHEMBL206584; SCHEMBL6830345; 4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol
DMYN25U	DT	Small molecular drug
DMYN25U	PC	10061675
DMYN25U	MW	270.32
DMYN25U	FM	C17H18O3
DMYN25U	IC	InChI=1S/C17H18O3/c1-8-7-14(19)9(2)16-11(4)20-17-10(3)13(18)6-5-12(17)15(8)16/h5-7,11,18-19H,1-4H3
DMYN25U	CS	CC1C2=C(C(=CC(=C2C)O)C)C3=C(O1)C(=C(C=C3)O)C
DMYN25U	IK	NXVCUJCNTBPNSZ-UHFFFAOYSA-N
DMYN25U	IU	4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol
DMYN25U	DE	Discovery agent

DMFECXI	ID	DMFECXI
DMFECXI	DN	4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol
DMFECXI	HS	Investigative
DMFECXI	SN	CHEMBL381337; 4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6828067
DMFECXI	DT	Small molecular drug
DMFECXI	PC	10060956
DMFECXI	MW	256.3
DMFECXI	FM	C16H16O3
DMFECXI	IC	InChI=1S/C16H16O3/c1-8-13(17)6-4-11-12-5-7-14(18)9(2)16(12)19-10(3)15(8)11/h4-7,10,17-18H,1-3H3
DMFECXI	CS	CC1C2=C(C=CC(=C2C)O)C3=C(O1)C(=C(C=C3)O)C
DMFECXI	IK	SKULOBHFUJYXEB-UHFFFAOYSA-N
DMFECXI	IU	4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol
DMFECXI	DE	Discovery agent

DMHBO17	ID	DMHBO17
DMHBO17	DN	4,6-dichloro-1H-indole-2,3-dione
DMHBO17	HS	Investigative
DMHBO17	SN	4,6-Dichloroisatin; 18711-15-4; 4,6-Dichloro-1H-indole-2,3-dione; 4,6-DICHLOROINDOLINE-2,3-DIONE; 4,6-dichloro-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione,4,6-dichloro-; CGCVHJCZBIYRQC-UHFFFAOYSA-N; 4,6-dichloro-1H-benzo[d]azoline-2,3-dione; 4,6-dichlorisatin; NSC72897; AC1L5KVQ; AC1Q3MQL; Isatin-based compound, 50; SCHEMBL124586; CHEMBL385800; Jsp003834; BDBM22830; CTK4D9417; 4,6-dichloroindolin-2,3-dione; DTXSID60291058; 4,6-Dichloro-2,3-indolinedione; MolPort-001-969-148; ACT09176; ZINC1698777; ZERO/005650; KS-00000J1A
DMHBO17	DT	Small molecular drug
DMHBO17	PC	251908
DMHBO17	MW	216.02
DMHBO17	FM	C8H3Cl2NO2
DMHBO17	IC	InChI=1S/C8H3Cl2NO2/c9-3-1-4(10)6-5(2-3)11-8(13)7(6)12/h1-2H,(H,11,12,13)
DMHBO17	CS	C1=C(C=C(C2=C1NC(=O)C2=O)Cl)Cl
DMHBO17	IK	CGCVHJCZBIYRQC-UHFFFAOYSA-N
DMHBO17	IU	4,6-dichloro-1H-indole-2,3-dione
DMHBO17	CA	CAS 18711-15-4
DMHBO17	DE	Discovery agent

DM62XC3	ID	DM62XC3
DM62XC3	DN	4,6-Dichloro-1H-indole-2-carboxylic acid
DM62XC3	HS	Investigative
DM62XC3	SN	101861-63-6; 4,6-dichloro-1H-indole-2-carboxylic acid; 4,6-Dichloroindole-2-carboxylic acid; CHEMBL301556; 1H-Indole-2-carboxylicacid, 4,6-dichloro-; 3-(4,6-Dichloro-2-carboxyindol-3-yl)propionic acid; 3-Dccip; KBio2_007460; PubChem7197; Spectrum_001822; SpecPlus_000800; 4,6-Dichloro-1H-indole-2-carboxylicacid; ACMC-1BPUR; AC1Q3MQM; AC1L2SZE; Maybridge1_006804; AC1Q73TA; Oprea1_268024; KBioSS_002327; SCHEMBL727389; DivK1c_006896; KBio2_004892; KBio2_002324; KBio1_001840; CTK0H4782; HMS560N06; DTXSID80144299; MolPort-000-147-351; Mdl-29951
DM62XC3	DT	Small molecular drug
DM62XC3	PC	127988
DM62XC3	MW	230.04
DM62XC3	FM	C9H5Cl2NO2
DM62XC3	IC	InChI=1S/C9H5Cl2NO2/c10-4-1-6(11)5-3-8(9(13)14)12-7(5)2-4/h1-3,12H,(H,13,14)
DM62XC3	CS	C1=C(C=C(C2=C1NC(=C2)C(=O)O)Cl)Cl
DM62XC3	IK	DHXISZKSSIWRLH-UHFFFAOYSA-N
DM62XC3	IU	4,6-dichloro-1H-indole-2-carboxylic acid
DM62XC3	CA	CAS 101861-63-6
DM62XC3	DE	Discovery agent

DMBZIG7	ID	DMBZIG7
DMBZIG7	DN	4,6-Dideoxy-4-Amino-Alpha-D-Glucose
DMBZIG7	HS	Investigative
DMBZIG7	SN	4,6-DIDEOXY-4-AMINO-ALPHA-D-GLUCOSE; AC1L9FSA; SCHEMBL1543515; DB03439; 4-amino-4,6-dideoxy-alpha-d-glucopyranose; AGL; (2S,3R,4S,5S,6R)-5-amino-6-methyloxane-2,3,4-triol
DMBZIG7	DT	Small molecular drug
DMBZIG7	PC	444139
DMBZIG7	MW	163.17
DMBZIG7	FM	C6H13NO4
DMBZIG7	IC	InChI=1S/C6H13NO4/c1-2-3(7)4(8)5(9)6(10)11-2/h2-6,8-10H,7H2,1H3/t2-,3-,4+,5-,6+/m1/s1
DMBZIG7	CS	C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)N
DMBZIG7	IK	RJKBJEZZABBYBA-DVKNGEFBSA-N
DMBZIG7	IU	(2S,3R,4S,5S,6R)-5-amino-6-methyloxane-2,3,4-triol
DMBZIG7	DE	Discovery agent

DMP5M9E	ID	DMP5M9E
DMP5M9E	DN	4,6-Dideoxyglucose
DMP5M9E	HS	Investigative
DMP5M9E	SN	4,6-DIDEOXYGLUCOSE; AC1NRBIQ; ZINC12501177; DB01841; 4,6-dideoxy-alpha-D-xylo-hexopyranose
DMP5M9E	DT	Small molecular drug
DMP5M9E	PC	5288437
DMP5M9E	MW	148.16
DMP5M9E	FM	C6H12O4
DMP5M9E	IC	InChI=1S/C6H12O4/c1-3-2-4(7)5(8)6(9)10-3/h3-9H,2H2,1H3/t3-,4+,5-,6+/m1/s1
DMP5M9E	CS	C[C@@H]1C[C@@H]([C@H]([C@H](O1)O)O)O
DMP5M9E	IK	BJBURJZEESAQPG-MOJAZDJTSA-N
DMP5M9E	IU	(2S,3R,4S,6R)-6-methyloxane-2,3,4-triol
DMP5M9E	DE	Discovery agent

DMIJ4VZ	ID	DMIJ4VZ
DMIJ4VZ	DN	4,6-Dinitro salicylic acid
DMIJ4VZ	HS	Investigative
DMIJ4VZ	SN	4,6-Dinitro salicylic acid; 4,6-dinitrosalicylic acid; CHEMBL447810; 65841-03-4; SCHEMBL8633874; 6-hydroxy-2,4-dinitrobenzoic acid; 2-Hydroxy-4,6-dinitrobenzoic acid
DMIJ4VZ	DT	Small molecular drug
DMIJ4VZ	PC	13443185
DMIJ4VZ	MW	228.12
DMIJ4VZ	FM	C7H4N2O7
DMIJ4VZ	IC	InChI=1S/C7H4N2O7/c10-5-2-3(8(13)14)1-4(9(15)16)6(5)7(11)12/h1-2,10H,(H,11,12)
DMIJ4VZ	CS	C1=C(C=C(C(=C1[N+](=O)[O-])C(=O)O)O)[N+](=O)[O-]
DMIJ4VZ	IK	AQBLBIVMAAUENI-UHFFFAOYSA-N
DMIJ4VZ	IU	2-hydroxy-4,6-dinitrobenzoic acid
DMIJ4VZ	DE	Discovery agent

DMWDYLR	ID	DMWDYLR
DMWDYLR	DN	4,6-dinitrobenzo[c][1,2,5]thiadiazole
DMWDYLR	HS	Investigative
DMWDYLR	SN	4,6-Dinitro-2,1,3-benzothiadiazole; 4,6-dinitrobenzo[c][1,2,5]thiadiazole; CHEMBL206140; 16408-06-3; NSC202427; AC1L76UW; AC1Q1Y7D; C6H2N4O4S; DTXSID90308123; MolPort-000-820-133; BYLOIWCTRDPRTP-UHFFFAOYSA-N; ZINC1736331; STK744333; BDBM50182130; 5,7-dinitro-2,1,3-benzothiadiazole; AKOS000544790; NSC-202427; MCULE-2301273439; 4,6-dinitrobenzo[c]1,2,5-thiadiazole; 4,6-Dinitro-benzo[1,2,5]thiadiazole; 2,1,3-Benzothiadiazole, 4,6-dinitro-; 4,6-Dinitro-2,1,3-benzothiadiazole #; NCI60_001699; ST032375; BAS 00731156
DMWDYLR	DT	Small molecular drug
DMWDYLR	PC	305451
DMWDYLR	MW	226.17
DMWDYLR	FM	C6H2N4O4S
DMWDYLR	IC	InChI=1S/C6H2N4O4S/c11-9(12)3-1-4-6(8-15-7-4)5(2-3)10(13)14/h1-2H
DMWDYLR	CS	C1=C(C=C(C2=NSN=C21)[N+](=O)[O-])[N+](=O)[O-]
DMWDYLR	IK	BYLOIWCTRDPRTP-UHFFFAOYSA-N
DMWDYLR	IU	4,6-dinitro-2,1,3-benzothiadiazole
DMWDYLR	CA	CAS 16408-06-3
DMWDYLR	DE	Discovery agent

DMEVK5F	ID	DMEVK5F
DMEVK5F	DN	4,7-dichloro-1H-indole-2,3-dione
DMEVK5F	HS	Investigative
DMEVK5F	SN	4,7-Dichloroisatin; 18711-13-2; 4,7-dichloroindoline-2,3-dione; 4,7-dichloro-1H-indole-2,3-dione; 4,7-dichloro isatin; 4,7-dichloro-isatin; 4,7-dichloro-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 4,7-dichloro-; 4,7-dichloroisatin;; 4,7-dichloroisatine;; AC1MC1Y2; Isatin-based compound, 51; ACMC-1C3I3; 4,7-Dichloroisatin, 97%; KSC494I6J; SCHEMBL281619; CHEMBL223039; 4,7-Dichloroindole-2,3-dione; CTK3J4464; BDBM22831; DTXSID90370507; 4,7-Dichloro-2,3-indolinedione; MolPort-001-766-630; 4,7-Dichloroindole-2,3-dione;
DMEVK5F	DT	Small molecular drug
DMEVK5F	PC	2734793
DMEVK5F	MW	216.02
DMEVK5F	FM	C8H3Cl2NO2
DMEVK5F	IC	InChI=1S/C8H3Cl2NO2/c9-3-1-2-4(10)6-5(3)7(12)8(13)11-6/h1-2H,(H,11,12,13)
DMEVK5F	CS	C1=CC(=C2C(=C1Cl)C(=O)C(=O)N2)Cl
DMEVK5F	IK	NUXYYWOWNFEMNH-UHFFFAOYSA-N
DMEVK5F	IU	4,7-dichloro-1H-indole-2,3-dione
DMEVK5F	CA	CAS 18711-13-2
DMEVK5F	DE	Discovery agent

DM67Z81	ID	DM67Z81
DM67Z81	DN	4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DM67Z81	HS	Investigative
DM67Z81	SN	CHEMBL378798; 4,7-dimethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6830103
DM67Z81	DT	Small molecular drug
DM67Z81	PC	9991961
DM67Z81	MW	242.27
DM67Z81	FM	C15H14O3
DM67Z81	IC	InChI=1S/C15H14O3/c1-8-12-7-18-15-9(2)14(17)6-4-11(15)10(12)3-5-13(8)16/h3-6,16-17H,7H2,1-2H3
DM67Z81	CS	CC1=C(C=CC2=C1COC3=C2C=CC(=C3C)O)O
DM67Z81	IK	UCANDFJLKWPIBP-UHFFFAOYSA-N
DM67Z81	IU	4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DM67Z81	DE	Discovery agent

DML5302	ID	DML5302
DML5302	DN	4,7-Dioxosebacic Acid
DML5302	HS	Investigative
DML5302	PC	1698
DML5302	MW	230.21
DML5302	FM	C10H14O6
DML5302	IC	InChI=1S/C10H14O6/c11-7(3-5-9(13)14)1-2-8(12)4-6-10(15)16/h1-6H2,(H,13,14)(H,15,16)
DML5302	CS	C(CC(=O)CCC(=O)O)C(=O)CCC(=O)O
DML5302	IK	DUAWJQCMZICMIK-UHFFFAOYSA-N
DML5302	IU	4,7-dioxodecanedioic acid
DML5302	DE	Discovery agent

DMQNXL1	ID	DMQNXL1
DMQNXL1	DN	4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin
DMQNXL1	HS	Investigative
DMQNXL1	SN	CHEMBL488917; 4,8-dimethyl-7-((2-oxocyclohexyl)oxy)-2H-chromen-2-one; 4,8-dimethyl-7-[(2-oxocyclohexyl)oxy]-2H-chromen-2-one; AC1N8LB1; MLS001213498; MolPort-000-837-574; HMS2863H04; STL528052; BDBM50246220; AKOS030497124; MCULE-3956285825; SMR000540525; 4,8-Dimethyl-7-(2''-oxocyclohexyloxy)coumarin; 4,8-dimethyl-7-(2-oxocyclohexyl)oxychromen-2-one
DMQNXL1	DT	Small molecular drug
DMQNXL1	PC	4297278
DMQNXL1	MW	286.32
DMQNXL1	FM	C17H18O4
DMQNXL1	IC	InChI=1S/C17H18O4/c1-10-9-16(19)21-17-11(2)14(8-7-12(10)17)20-15-6-4-3-5-13(15)18/h7-9,15H,3-6H2,1-2H3
DMQNXL1	CS	CC1=CC(=O)OC2=C1C=CC(=C2C)OC3CCCCC3=O
DMQNXL1	IK	WRTZCCCOMNOONZ-UHFFFAOYSA-N
DMQNXL1	IU	4,8-dimethyl-7-(2-oxocyclohexyl)oxychromen-2-one
DMQNXL1	DE	Discovery agent

DMEKI1B	ID	DMEKI1B
DMEKI1B	DN	4,9-anhydro-tetrodotoxin
DMEKI1B	HS	Investigative
DMEKI1B	SN	4,9-anhydro-TTX; 4,9-ah-TTX
DMEKI1B	DT	Small molecular drug
DMEKI1B	PC	73755148
DMEKI1B	MW	302.26
DMEKI1B	FM	C11H16N3O7+
DMEKI1B	IC	InChI=1S/C11H15N3O7/c12-8-13-6-2-4-9(17,1-15)5-3(16)10(2,14-8)7(19-6)11(18,20-4)21-5/h2-7,15-18H,1H2,(H3,12,13,14)/p+1
DMEKI1B	CS	C(C1(C2C3C4[NH+]=C(NC35C(C1OC(C5O4)(O2)O)O)N)O)O
DMEKI1B	IK	STNXQECXKDMLJK-UHFFFAOYSA-O
DMEKI1B	IU	7-amino-2-(hydroxymethyl)-10,13,15-trioxa-6-aza-8-azoniapentacyclo[7.4.1.13,12.05,11.05,14]pentadec-7-ene-2,4,12-triol
DMEKI1B	DE	Discovery agent

DM27HMT	ID	DM27HMT
DM27HMT	DN	4,9-Dihydro-3H-beta-carboline
DM27HMT	HS	Investigative
DM27HMT	SN	4894-26-2; 4,9-dihydro-3H-Pyrido[3,4-b]indole; 4,9-dihydro-3H-beta-carboline; 3H-Pyrido(3,4-b)indole, 4,9-dihydro-; 3,4-dihydro-beta-carboline; CHEMBL266221; 4,9-Dihydro-3H-pyrido(3,4-b)indole; 3H-Pyrido[3,4-b]indole, 4,9-dihydro-; AC1L3RVU; 3,4-dihydrobeta-carboline; SCHEMBL678673; CTK7D1379; DTXSID20197643; ZINC332024; BDBM50136506; SBB062953; FCH841675; AKOS006272808; ACM4894262; 3H,4H,9H-PYRIDO[3,4-B]INDOLE; TX-010240; FT-0698471
DM27HMT	DT	Small molecular drug
DM27HMT	PC	145772
DM27HMT	MW	170.21
DM27HMT	FM	C11H10N2
DM27HMT	IC	InChI=1S/C11H10N2/c1-2-4-10-8(3-1)9-5-6-12-7-11(9)13-10/h1-4,7,13H,5-6H2
DM27HMT	CS	C1CN=CC2=C1C3=CC=CC=C3N2
DM27HMT	IK	NTYXKFHKVREUMR-UHFFFAOYSA-N
DM27HMT	IU	4,9-dihydro-3H-pyrido[3,4-b]indole
DM27HMT	CA	CAS 4894-26-2
DM27HMT	DE	Discovery agent

DM8BPTQ	ID	DM8BPTQ
DM8BPTQ	DN	4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine
DM8BPTQ	HS	Investigative
DM8BPTQ	SN	CHEMBL1269156; 4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine; BDBM50330054; AKOS013124194
DM8BPTQ	DT	Small molecular drug
DM8BPTQ	PC	52949342
DM8BPTQ	MW	173.21
DM8BPTQ	FM	C10H11N3
DM8BPTQ	IC	InChI=1S/C10H11N3/c1-9-12-6-7-13(9)8-10-2-4-11-5-3-10/h2-7H,8H2,1H3
DM8BPTQ	CS	CC1=NC=CN1CC2=CC=NC=C2
DM8BPTQ	IK	MNSNMTASPOHKEI-UHFFFAOYSA-N
DM8BPTQ	IU	4-[(2-methylimidazol-1-yl)methyl]pyridine
DM8BPTQ	DE	Discovery agent

DMSKJ1X	ID	DMSKJ1X
DMSKJ1X	DN	4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X	HS	Investigative
DMSKJ1X	DT	Small molecular drug
DMSKJ1X	PC	9859248
DMSKJ1X	DE	Discovery agent

DM04MK7	ID	DM04MK7
DM04MK7	DN	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine
DM04MK7	HS	Investigative
DM04MK7	SN	CHEMBL1172882; SCHEMBL18770302; BDBM50322789; 4''-(pyridin-4-ylmethyl)biphenyl-3-ol
DM04MK7	DT	Small molecular drug
DM04MK7	PC	46901446
DM04MK7	MW	261.3
DM04MK7	FM	C18H15NO
DM04MK7	IC	InChI=1S/C18H15NO/c20-18-3-1-2-17(13-18)16-6-4-14(5-7-16)12-15-8-10-19-11-9-15/h1-11,13,20H,12H2
DM04MK7	CS	C1=CC(=CC(=C1)O)C2=CC=C(C=C2)CC3=CC=NC=C3
DM04MK7	IK	GFIBJCSJSOCGMM-UHFFFAOYSA-N
DM04MK7	IU	3-[4-(pyridin-4-ylmethyl)phenyl]phenol
DM04MK7	DE	Discovery agent

DMIEMWA	ID	DMIEMWA
DMIEMWA	DN	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine
DMIEMWA	HS	Investigative
DMIEMWA	SN	CHEMBL1215664; BDBM50324611
DMIEMWA	DT	Small molecular drug
DMIEMWA	PC	49864181
DMIEMWA	MW	277.3
DMIEMWA	FM	C18H15NO2
DMIEMWA	IC	InChI=1S/C18H15NO2/c20-17-7-5-14(6-8-17)13-1-3-15(4-2-13)18(21)16-9-11-19-12-10-16/h1-12,18,20-21H
DMIEMWA	CS	C1=CC(=CC=C1C2=CC=C(C=C2)O)C(C3=CC=NC=C3)O
DMIEMWA	IK	ABUNZHUAYBOXCN-UHFFFAOYSA-N
DMIEMWA	IU	4-[4-[hydroxy(pyridin-4-yl)methyl]phenyl]phenol
DMIEMWA	DE	Discovery agent

DMNMC9O	ID	DMNMC9O
DMNMC9O	DN	4-[(5-methoxy-2-methylphenoxy)methyl]pyridine
DMNMC9O	HS	Investigative
DMNMC9O	SN	4-[(5-methoxy-2-methylphenoxy)methyl]pyridine; DB07428
DMNMC9O	DT	Small molecular drug
DMNMC9O	PC	46937073
DMNMC9O	MW	229.27
DMNMC9O	FM	C14H15NO2
DMNMC9O	IC	InChI=1S/C14H15NO2/c1-11-3-4-13(16-2)9-14(11)17-10-12-5-7-15-8-6-12/h3-9H,10H2,1-2H3
DMNMC9O	CS	CC1=C(C=C(C=C1)OC)OCC2=CC=NC=C2
DMNMC9O	IK	MBHBRRBLXCXQKV-UHFFFAOYSA-N
DMNMC9O	IU	4-[(5-methoxy-2-methylphenoxy)methyl]pyridine
DMNMC9O	DE	Discovery agent

DMGRWEU	ID	DMGRWEU
DMGRWEU	DN	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
DMGRWEU	HS	Investigative
DMGRWEU	SN	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide; CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10
DMGRWEU	DT	Small molecular drug
DMGRWEU	PC	9994066
DMGRWEU	MW	284.72
DMGRWEU	FM	C10H9ClN4O2S
DMGRWEU	IC	InChI=1S/C10H9ClN4O2S/c11-9-5-13-6-10(15-9)14-7-1-3-8(4-2-7)18(12,16)17/h1-6H,(H,14,15)(H2,12,16,17)
DMGRWEU	CS	C1=CC(=CC=C1NC2=CN=CC(=N2)Cl)S(=O)(=O)N
DMGRWEU	IK	RSNSGNZRUMHXAY-UHFFFAOYSA-N
DMGRWEU	IU	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
DMGRWEU	DE	Discovery agent

DMT1PM4	ID	DMT1PM4
DMT1PM4	DN	4-[(diphenylmethyl)amino]-2-phenylquinazoline
DMT1PM4	HS	Investigative
DMT1PM4	SN	4-[(Diphenylmethyl)amino]-2-phenylquinazoline; CHEMBL305876; Benzhydryl-(2-phenyl-quinazolin-4-yl)-amine; SCHEMBL18388787; BDBM50116317
DMT1PM4	DT	Small molecular drug
DMT1PM4	PC	9930153
DMT1PM4	MW	387.5
DMT1PM4	FM	C27H21N3
DMT1PM4	IC	InChI=1S/C27H21N3/c1-4-12-20(13-5-1)25(21-14-6-2-7-15-21)29-27-23-18-10-11-19-24(23)28-26(30-27)22-16-8-3-9-17-22/h1-19,25H,(H,28,29,30)
DMT1PM4	CS	C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=N2)NC(C4=CC=CC=C4)C5=CC=CC=C5
DMT1PM4	IK	LJIQXEUCYVPWRY-UHFFFAOYSA-N
DMT1PM4	IU	N-benzhydryl-2-phenylquinazolin-4-amine
DMT1PM4	DE	Discovery agent

DMXKT6M	ID	DMXKT6M
DMXKT6M	DN	4-[(METHYLSULFONYL)AMINO]BENZOIC ACID
DMXKT6M	HS	Investigative
DMXKT6M	SN	4-(Methylsulfonamido)benzoic acid; 7151-76-0; 4-[(methylsulfonyl)amino]benzoic acid; 4-methanesulfonamidobenzoic acid; 4-Methanesulfonylamino-benzoic acid; 4-(METHANESULFONYLAMINO)BENZOIC ACID; Benzoic acid, 4-[(methylsulfonyl)amino]-; 4-(methanesulfonamido)benzoic acid; CHEMBL339996; SROHFTOYGFCJAF-UHFFFAOYSA-N; p-(Methylsulfonamido)benzoic acid; 2hds; methanesulfonamidobenzoicacid; AC1Q6VU0; AC1Q4GQ4; NCIOpen2_003463; Oprea1_337582; Oprea1_072870; SCHEMBL118340; AC1L5I58; 4-methylsulfonylaminobenzoic acid
DMXKT6M	DT	Small molecular drug
DMXKT6M	PC	250653
DMXKT6M	MW	215.23
DMXKT6M	FM	C8H9NO4S
DMXKT6M	IC	InChI=1S/C8H9NO4S/c1-14(12,13)9-7-4-2-6(3-5-7)8(10)11/h2-5,9H,1H3,(H,10,11)
DMXKT6M	CS	CS(=O)(=O)NC1=CC=C(C=C1)C(=O)O
DMXKT6M	IK	SROHFTOYGFCJAF-UHFFFAOYSA-N
DMXKT6M	IU	4-(methanesulfonamido)benzoic acid
DMXKT6M	CA	CAS 7151-76-0
DMXKT6M	DE	Discovery agent

DMTMLXU	ID	DMTMLXU
DMTMLXU	DN	4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol
DMTMLXU	HS	Investigative
DMTMLXU	SN	91221-46-4; 1,1-Bis(4-hydroxyphenyl)-2-phenylbut-1-ene; 1,1-Bis(4-hydroxyphenyl)-2-phenyl-1-butene; 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol; CHEMBL149791; 4,4'-(2-phenylbut-1-ene-1,1-diyl)diphenol; Tamoxifen bis-phenol; 1,1-Bhpe; Tamoxifenbisphenol; AC1L1YAG; SCHEMBL639225; CTK5G9076; DTXSID50238452; BPKSDMHGDYTXLI-UHFFFAOYSA-N; ZINC1849484; BDBM50121317; AKOS030254689; KB-09832; 4,4'-(2-Phenyl-1-butenylidene)bisphenol; B5114; FT-0663304; Phenol, 4,4'-(2-phenyl-1-butenylidene)bis-
DMTMLXU	DT	Small molecular drug
DMTMLXU	PC	63059
DMTMLXU	MW	316.4
DMTMLXU	FM	C22H20O2
DMTMLXU	IC	InChI=1S/C22H20O2/c1-2-21(16-6-4-3-5-7-16)22(17-8-12-19(23)13-9-17)18-10-14-20(24)15-11-18/h3-15,23-24H,2H2,1H3
DMTMLXU	CS	CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMTMLXU	IK	BPKSDMHGDYTXLI-UHFFFAOYSA-N
DMTMLXU	IU	4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol
DMTMLXU	CA	CAS 91221-46-4
DMTMLXU	DE	Discovery agent

DM30421	ID	DM30421
DM30421	DN	4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol
DM30421	HS	Investigative
DM30421	SN	CHEMBL356693; 4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol
DM30421	DT	Small molecular drug
DM30421	PC	10871661
DM30421	MW	344.4
DM30421	FM	C24H24O2
DM30421	IC	InChI=1S/C24H24O2/c1-2-3-9-23(18-7-5-4-6-8-18)24(19-10-14-21(25)15-11-19)20-12-16-22(26)17-13-20/h4-8,10-17,25-26H,2-3,9H2,1H3
DM30421	CS	CCCCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DM30421	IK	LOSAKSLRALRQMY-UHFFFAOYSA-N
DM30421	IU	4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol
DM30421	DE	Discovery agent

DMWHKLA	ID	DMWHKLA
DMWHKLA	DN	4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol
DMWHKLA	HS	Investigative
DMWHKLA	SN	CHEMBL357824; 4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol; SCHEMBL19158863; BDBM50121321
DMWHKLA	DT	Small molecular drug
DMWHKLA	PC	11782482
DMWHKLA	MW	330.4
DMWHKLA	FM	C23H22O2
DMWHKLA	IC	InChI=1S/C23H22O2/c1-2-6-22(17-7-4-3-5-8-17)23(18-9-13-20(24)14-10-18)19-11-15-21(25)16-12-19/h3-5,7-16,24-25H,2,6H2,1H3
DMWHKLA	CS	CCCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMWHKLA	IK	UTLLHWVRVATSPI-UHFFFAOYSA-N
DMWHKLA	IU	4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol
DMWHKLA	DE	Discovery agent

DMH1I32	ID	DMH1I32
DMH1I32	DN	4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol
DMH1I32	HS	Investigative
DMH1I32	SN	CHEMBL150461; 4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol; SCHEMBL18882768
DMH1I32	DT	Small molecular drug
DMH1I32	PC	11141183
DMH1I32	MW	302.4
DMH1I32	FM	C21H18O2
DMH1I32	IC	InChI=1S/C21H18O2/c1-15(16-5-3-2-4-6-16)21(17-7-11-19(22)12-8-17)18-9-13-20(23)14-10-18/h2-14,22-23H,1H3
DMH1I32	CS	CC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMH1I32	IK	VGWVLJXJHQENDY-UHFFFAOYSA-N
DMH1I32	IU	4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol
DMH1I32	DE	Discovery agent

DM4BFPE	ID	DM4BFPE
DM4BFPE	DN	4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol
DM4BFPE	HS	Investigative
DM4BFPE	SN	CHEMBL415864; 1,1-Bis(4-hydroxyphenyl)-2-phenylethylene; 4,4'-(2-Phenylethene-1,1-Diyl)diphenol; 66422-18-2; Bhpe-1,1; 4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol; SCHEMBL641985; AC1MI565; CTK5C4724; 4-(1,2-diphenyl-vinyl)-phenol; BDBM50023749; ZINC13492380; Phenol, 4,4'-(phenylethenylidene)bis-; 1,1-bis(4-hydroxyphenyl)-2-phenylethene; 4-[1-(4-hydroxyphenyl)-2-phenylethenyl]phenol
DM4BFPE	DT	Small molecular drug
DM4BFPE	PC	3017674
DM4BFPE	MW	288.3
DM4BFPE	FM	C20H16O2
DM4BFPE	IC	InChI=1S/C20H16O2/c21-18-10-6-16(7-11-18)20(14-15-4-2-1-3-5-15)17-8-12-19(22)13-9-17/h1-14,21-22H
DM4BFPE	CS	C1=CC=C(C=C1)C=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DM4BFPE	IK	CKNFKDYCAQZYBQ-UHFFFAOYSA-N
DM4BFPE	IU	4-[1-(4-hydroxyphenyl)-2-phenylethenyl]phenol
DM4BFPE	CA	CAS 66422-18-2
DM4BFPE	DE	Discovery agent

DM8IYG1	ID	DM8IYG1
DM8IYG1	DN	4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol
DM8IYG1	HS	Investigative
DM8IYG1	SN	Phenol, 4,4'-(3-methyl-1-butenylidene)bis-; 66422-07-9; CHEMBL156843; CTK1J4765; DTXSID70441143; ZINC13650255
DM8IYG1	DT	Small molecular drug
DM8IYG1	PC	10515117
DM8IYG1	MW	254.32
DM8IYG1	FM	C17H18O2
DM8IYG1	IC	InChI=1S/C17H18O2/c1-12(2)11-17(13-3-7-15(18)8-4-13)14-5-9-16(19)10-6-14/h3-12,18-19H,1-2H3
DM8IYG1	CS	CC(C)C=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O
DM8IYG1	IK	DDEWRRMILVWZOZ-UHFFFAOYSA-N
DM8IYG1	IU	4-[1-(4-hydroxyphenyl)-3-methylbut-1-enyl]phenol
DM8IYG1	CA	CAS 66422-07-9
DM8IYG1	DE	Discovery agent

DMCEABJ	ID	DMCEABJ
DMCEABJ	DN	4-[1-(4'-Methoxybiphenyl-4-yl)propyl]pyridine
DMCEABJ	HS	Investigative
DMCEABJ	SN	CHEMBL1215596; BDBM50324608
DMCEABJ	DT	Small molecular drug
DMCEABJ	PC	46901440
DMCEABJ	MW	303.4
DMCEABJ	FM	C21H21NO
DMCEABJ	IC	InChI=1S/C21H21NO/c1-3-21(19-12-14-22-15-13-19)18-6-4-16(5-7-18)17-8-10-20(23-2)11-9-17/h4-15,21H,3H2,1-2H3
DMCEABJ	CS	CCC(C1=CC=C(C=C1)C2=CC=C(C=C2)OC)C3=CC=NC=C3
DMCEABJ	IK	DURIQWOMVBEIPW-UHFFFAOYSA-N
DMCEABJ	IU	4-[1-[4-(4-methoxyphenyl)phenyl]propyl]pyridine
DMCEABJ	DE	Discovery agent

DMW1IXY	ID	DMW1IXY
DMW1IXY	DN	4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol
DMW1IXY	HS	Investigative
DMW1IXY	SN	CHEMBL37775
DMW1IXY	DT	Small molecular drug
DMW1IXY	PC	10246180
DMW1IXY	MW	332.4
DMW1IXY	FM	C22H20O3
DMW1IXY	IC	InChI=1S/C22H20O3/c1-2-21(15-3-9-18(23)10-4-15)22(16-5-11-19(24)12-6-16)17-7-13-20(25)14-8-17/h3-14,23-25H,2H2,1H3
DMW1IXY	CS	CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DMW1IXY	IK	CUXRGANZEHBODX-UHFFFAOYSA-N
DMW1IXY	IU	4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]phenol
DMW1IXY	DE	Discovery agent

DMTL6ES	ID	DMTL6ES
DMTL6ES	DN	4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol
DMTL6ES	HS	Investigative
DMTL6ES	SN	CHEMBL38222
DMTL6ES	DT	Small molecular drug
DMTL6ES	PC	10948394
DMTL6ES	MW	360.4
DMTL6ES	FM	C24H24O3
DMTL6ES	IC	InChI=1S/C24H24O3/c1-2-3-4-23(17-5-11-20(25)12-6-17)24(18-7-13-21(26)14-8-18)19-9-15-22(27)16-10-19/h5-16,25-27H,2-4H2,1H3
DMTL6ES	CS	CCCCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DMTL6ES	IK	QMNAADNBEBCAEQ-UHFFFAOYSA-N
DMTL6ES	IU	4-[1,1-bis(4-hydroxyphenyl)hex-1-en-2-yl]phenol
DMTL6ES	DE	Discovery agent

DMTHG0Y	ID	DMTHG0Y
DMTHG0Y	DN	4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol
DMTHG0Y	HS	Investigative
DMTHG0Y	SN	CHEMBL38266
DMTHG0Y	DT	Small molecular drug
DMTHG0Y	PC	11131781
DMTHG0Y	MW	346.4
DMTHG0Y	FM	C23H22O3
DMTHG0Y	IC	InChI=1S/C23H22O3/c1-2-3-22(16-4-10-19(24)11-5-16)23(17-6-12-20(25)13-7-17)18-8-14-21(26)15-9-18/h4-15,24-26H,2-3H2,1H3
DMTHG0Y	CS	CCCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DMTHG0Y	IK	OCRBCWNNWUOJIP-UHFFFAOYSA-N
DMTHG0Y	IU	4-[1,1-bis(4-hydroxyphenyl)pent-1-en-2-yl]phenol
DMTHG0Y	DE	Discovery agent

DMR7GP6	ID	DMR7GP6
DMR7GP6	DN	4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol
DMR7GP6	HS	Investigative
DMR7GP6	SN	CHEMBL34709
DMR7GP6	DT	Small molecular drug
DMR7GP6	PC	10881256
DMR7GP6	MW	304.3
DMR7GP6	FM	C20H16O3
DMR7GP6	IC	InChI=1S/C20H16O3/c21-17-7-1-14(2-8-17)13-20(15-3-9-18(22)10-4-15)16-5-11-19(23)12-6-16/h1-13,21-23H
DMR7GP6	CS	C1=CC(=CC=C1C=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)O
DMR7GP6	IK	LZHPXIZTZSFAAE-UHFFFAOYSA-N
DMR7GP6	IU	4-[2,2-bis(4-hydroxyphenyl)ethenyl]phenol
DMR7GP6	DE	Discovery agent

DM08CG7	ID	DM08CG7
DM08CG7	DN	4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine
DM08CG7	HS	Investigative
DM08CG7	SN	CHEMBL365697; 4-[2-(2-benzylphenoxy)ethyl]morpholine; AC1MGXJ0; 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine; BDBM50151042
DM08CG7	DT	Small molecular drug
DM08CG7	PC	2993172
DM08CG7	MW	297.4
DM08CG7	FM	C19H23NO2
DM08CG7	IC	InChI=1S/C19H23NO2/c1-2-6-17(7-3-1)16-18-8-4-5-9-19(18)22-15-12-20-10-13-21-14-11-20/h1-9H,10-16H2
DM08CG7	CS	C1COCCN1CCOC2=CC=CC=C2CC3=CC=CC=C3
DM08CG7	IK	DQESEABEPUDVEZ-UHFFFAOYSA-N
DM08CG7	IU	4-[2-(2-benzylphenoxy)ethyl]morpholine
DM08CG7	DE	Discovery agent

DMYESXB	ID	DMYESXB
DMYESXB	DN	4-[2-(2-Thienyl)acetamido]benzenesulfonamide
DMYESXB	HS	Investigative
DMYESXB	SN	N-(4-sulfamoylphenyl)-2-(thiophen-2-yl)acetamide; N-(4-Sulfamoyl-phenyl)-2-thiophen-2-yl-acetamide; 4-[2-(2-Thienyl)acetamido]benzenesulfonamide; sulfonamide deriv., 5a; AC1LDN6X; Cambridge id 6617099; Oprea1_255870; Oprea1_090963; MLS001212957; CHEMBL573127; ZINC30817; BDBM35726; MolPort-000-681-412; 3r16; HMS1588L03; HMS2848H14; CCG-19182; STK001094; AKOS000646514; MCULE-6253669570; 349432-97-9; SMR000518066; BAS 03030369; ST043878; N-(4-sulfamoylphenyl)-2-(2-thienyl)acetamide; N-(4-sulfamoylphenyl)-2-thiophen-2-ylacetamide
DMYESXB	DT	Small molecular drug
DMYESXB	PC	670143
DMYESXB	MW	296.4
DMYESXB	FM	C12H12N2O3S2
DMYESXB	IC	InChI=1S/C12H12N2O3S2/c13-19(16,17)11-5-3-9(4-6-11)14-12(15)8-10-2-1-7-18-10/h1-7H,8H2,(H,14,15)(H2,13,16,17)
DMYESXB	CS	C1=CSC(=C1)CC(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMYESXB	IK	ZQWXOBLMDBJRLY-UHFFFAOYSA-N
DMYESXB	IU	N-(4-sulfamoylphenyl)-2-thiophen-2-ylacetamide
DMYESXB	DE	Discovery agent

DMH3UPO	ID	DMH3UPO
DMH3UPO	DN	4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide
DMH3UPO	HS	Investigative
DMH3UPO	SN	ST044176; N-[2-(4-sulfamoylphenyl)ethyl]-2-(2-thienyl)acetamide; N-[2-(4-sulfamoylphenyl)ethyl]-2-(thiophen-2-yl)acetamide; N-[2-(4-Sulfamoyl-phenyl)-ethyl]-2-thiophen-2-yl-acetamide; 6613-83-8; NAPETA; sulfonamide deriv., 5f; AC1LDO3N; Oprea1_814072; Oprea1_120836; MLS001207920; CHEMBL583171; ZINC31727; BDBM35731; DTXSID20350014; MolPort-001-528-371; HMS2823O10; STK091085; AKOS000648562; MCULE-3510388823; BAS 03034092; 349537-90-2; SMR000518099; MLS-0291936.0001; SR-01000476637; SR-01000476637-1; Z30857856
DMH3UPO	DT	Small molecular drug
DMH3UPO	PC	670786
DMH3UPO	MW	324.4
DMH3UPO	FM	C14H16N2O3S2
DMH3UPO	IC	InChI=1S/C14H16N2O3S2/c15-21(18,19)13-5-3-11(4-6-13)7-8-16-14(17)10-12-2-1-9-20-12/h1-6,9H,7-8,10H2,(H,16,17)(H2,15,18,19)
DMH3UPO	CS	C1=CSC(=C1)CC(=O)NCCC2=CC=C(C=C2)S(=O)(=O)N
DMH3UPO	IK	DWGJCBRJYFGGNR-UHFFFAOYSA-N
DMH3UPO	IU	N-[2-(4-sulfamoylphenyl)ethyl]-2-thiophen-2-ylacetamide
DMH3UPO	CA	CAS 6613-83-8
DMH3UPO	DE	Discovery agent

DM4ENGI	ID	DM4ENGI
DM4ENGI	DN	4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine
DM4ENGI	HS	Investigative
DM4ENGI	SN	CHEMBL43013; 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine; SCHEMBL7047647; SCHEMBL7047642; BDBM50108054; ZINC13471766; AKOS015967530; 4-[(E)-3,5-Dimethoxystyryl]pyridine
DM4ENGI	DT	Small molecular drug
DM4ENGI	PC	11957947
DM4ENGI	MW	241.28
DM4ENGI	FM	C15H15NO2
DM4ENGI	IC	InChI=1S/C15H15NO2/c1-17-14-9-13(10-15(11-14)18-2)4-3-12-5-7-16-8-6-12/h3-11H,1-2H3/b4-3+
DM4ENGI	CS	COC1=CC(=CC(=C1)/C=C/C2=CC=NC=C2)OC
DM4ENGI	IK	HXJQPOSPRKZPGS-ONEGZZNKSA-N
DM4ENGI	IU	4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]pyridine
DM4ENGI	DE	Discovery agent

DM64WSV	ID	DM64WSV
DM64WSV	DN	4-[2-(3-Phenyl-propylamino)-ethyl]-phenol
DM64WSV	HS	Investigative
DM64WSV	SN	CHEMBL333339; 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol; SCHEMBL12009648; BDBM50066543; AKOS010487382
DM64WSV	DT	Small molecular drug
DM64WSV	PC	10565541
DM64WSV	MW	255.35
DM64WSV	FM	C17H21NO
DM64WSV	IC	InChI=1S/C17H21NO/c19-17-10-8-16(9-11-17)12-14-18-13-4-7-15-5-2-1-3-6-15/h1-3,5-6,8-11,18-19H,4,7,12-14H2
DM64WSV	CS	C1=CC=C(C=C1)CCCNCCC2=CC=C(C=C2)O
DM64WSV	IK	SJSNYEZWGGSNKY-UHFFFAOYSA-N
DM64WSV	IU	4-[2-(3-phenylpropylamino)ethyl]phenol
DM64WSV	DE	Discovery agent

DMGXM9C	ID	DMGXM9C
DMGXM9C	DN	4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide
DMGXM9C	HS	Investigative
DMGXM9C	SN	CHEMBL22374; ST50982048; 1-phenyl-3-[2-(4-sulfamoylphenyl)ethyl]urea; 10080-04-3; AC1N65GX; CTK0G8621; aromatic sulfonamide compound 21; BDBM16656; DTXSID80401056; ZINC6344454; AKOS024355000; 1-(4-Sulfamoylphenethyl)-3-phenylurea; MCULE-8492301896; N-(4-aminosulfonylphenylethyl)-N'-phenyl-urea; N-phenyl{[2-(4-sulfamoylphenyl)ethyl]amino}carboxamide; Benzenesulfonamide, 4-[2-[[(phenylamino)carbonyl]amino]ethyl]-
DMGXM9C	DT	Small molecular drug
DMGXM9C	PC	4229592
DMGXM9C	MW	319.4
DMGXM9C	FM	C15H17N3O3S
DMGXM9C	IC	InChI=1S/C15H17N3O3S/c16-22(20,21)14-8-6-12(7-9-14)10-11-17-15(19)18-13-4-2-1-3-5-13/h1-9H,10-11H2,(H2,16,20,21)(H2,17,18,19)
DMGXM9C	CS	C1=CC=C(C=C1)NC(=O)NCCC2=CC=C(C=C2)S(=O)(=O)N
DMGXM9C	IK	CQMWNAHSFVPGJL-UHFFFAOYSA-N
DMGXM9C	IU	1-phenyl-3-[2-(4-sulfamoylphenyl)ethyl]urea
DMGXM9C	CA	CAS 10080-04-3
DMGXM9C	DE	Discovery agent

DMDI32S	ID	DMDI32S
DMDI32S	DN	4-[2-(4-Benzylphenoxy)ethyl]pyridine
DMDI32S	HS	Investigative
DMDI32S	SN	CHEMBL578131; 4-[2-(4-Benzylphenoxy)ethyl]pyridine
DMDI32S	DT	Small molecular drug
DMDI32S	PC	44818625
DMDI32S	MW	289.4
DMDI32S	FM	C20H19NO
DMDI32S	IC	InChI=1S/C20H19NO/c1-2-4-18(5-3-1)16-19-6-8-20(9-7-19)22-15-12-17-10-13-21-14-11-17/h1-11,13-14H,12,15-16H2
DMDI32S	CS	C1=CC=C(C=C1)CC2=CC=C(C=C2)OCCC3=CC=NC=C3
DMDI32S	IK	PHONRHOSBJCBIH-UHFFFAOYSA-N
DMDI32S	IU	4-[2-(4-benzylphenoxy)ethyl]pyridine
DMDI32S	DE	Discovery agent

DM74G6Q	ID	DM74G6Q
DM74G6Q	DN	4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol
DM74G6Q	HS	Investigative
DM74G6Q	SN	CHEMBL54778; 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol; SCHEMBL7402131; BDBM50079386; Co-101071; 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol(Co 101071)
DM74G6Q	DT	Small molecular drug
DM74G6Q	PC	10086803
DM74G6Q	MW	311.4
DM74G6Q	FM	C20H25NO2
DM74G6Q	IC	InChI=1S/C20H25NO2/c22-19-6-8-20(9-7-19)23-15-14-21-12-10-18(11-13-21)16-17-4-2-1-3-5-17/h1-9,18,22H,10-16H2
DM74G6Q	CS	C1CN(CCC1CC2=CC=CC=C2)CCOC3=CC=C(C=C3)O
DM74G6Q	IK	CSOKNRXDEKJUFZ-UHFFFAOYSA-N
DM74G6Q	IU	4-[2-(4-benzylpiperidin-1-yl)ethoxy]phenol
DM74G6Q	DE	Discovery agent

DM9UGO0	ID	DM9UGO0
DM9UGO0	DN	4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine
DM9UGO0	HS	Investigative
DM9UGO0	SN	CHEMBL113018; 4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine; SCHEMBL14129876; BDBM50138231
DM9UGO0	DT	Small molecular drug
DM9UGO0	PC	44341256
DM9UGO0	MW	273.33
DM9UGO0	FM	C15H19N3O2
DM9UGO0	IC	InChI=1S/C15H19N3O2/c1-3-15(4-2-14(1)18-6-5-16-13-18)20-12-9-17-7-10-19-11-8-17/h1-6,13H,7-12H2
DM9UGO0	CS	C1COCCN1CCOC2=CC=C(C=C2)N3C=CN=C3
DM9UGO0	IK	PXFGMZGVHWPLCC-UHFFFAOYSA-N
DM9UGO0	IU	4-[2-(4-imidazol-1-ylphenoxy)ethyl]morpholine
DM9UGO0	DE	Discovery agent

DML8B3T	ID	DML8B3T
DML8B3T	DN	4-[2-(4-Phenyl-butoxy)-ethyl]-phenol
DML8B3T	HS	Investigative
DML8B3T	SN	CHEMBL119100; 4-[2-(4-phenylbutoxy)ethyl]phenol; 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol; BDBM50066548
DML8B3T	DT	Small molecular drug
DML8B3T	PC	10707190
DML8B3T	MW	270.4
DML8B3T	FM	C18H22O2
DML8B3T	IC	InChI=1S/C18H22O2/c19-18-11-9-17(10-12-18)13-15-20-14-5-4-8-16-6-2-1-3-7-16/h1-3,6-7,9-12,19H,4-5,8,13-15H2
DML8B3T	CS	C1=CC=C(C=C1)CCCCOCCC2=CC=C(C=C2)O
DML8B3T	IK	FCGUGQUECVRUCX-UHFFFAOYSA-N
DML8B3T	IU	4-[2-(4-phenylbutoxy)ethyl]phenol
DML8B3T	DE	Discovery agent

DMXLVJW	ID	DMXLVJW
DMXLVJW	DN	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol
DMXLVJW	HS	Investigative
DMXLVJW	SN	CHEMBL118969; 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol; SCHEMBL7379499; ZINC13781000; BDBM50066539
DMXLVJW	DT	Small molecular drug
DMXLVJW	PC	10707108
DMXLVJW	MW	269.4
DMXLVJW	FM	C18H23NO
DMXLVJW	IC	InChI=1S/C18H23NO/c20-18-11-9-17(10-12-18)13-15-19-14-5-4-8-16-6-2-1-3-7-16/h1-3,6-7,9-12,19-20H,4-5,8,13-15H2
DMXLVJW	CS	C1=CC=C(C=C1)CCCCNCCC2=CC=C(C=C2)O
DMXLVJW	IK	FNRAWMBUHCSCSX-UHFFFAOYSA-N
DMXLVJW	IU	4-[2-(4-phenylbutylamino)ethyl]phenol
DMXLVJW	DE	Discovery agent

DM8JM4Q	ID	DM8JM4Q
DM8JM4Q	DN	4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol
DM8JM4Q	HS	Investigative
DM8JM4Q	SN	CHEMBL100870; 763907-80-8; 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol; CTK2G7823; DTXSID50445220; BDBM50079384; 4-[2-(4-Phenylpiperidino)ethoxy]phenol; Phenol, 4-[2-(4-phenyl-1-piperidinyl)ethoxy]-
DM8JM4Q	DT	Small molecular drug
DM8JM4Q	PC	10806596
DM8JM4Q	MW	297.4
DM8JM4Q	FM	C19H23NO2
DM8JM4Q	IC	InChI=1S/C19H23NO2/c21-18-6-8-19(9-7-18)22-15-14-20-12-10-17(11-13-20)16-4-2-1-3-5-16/h1-9,17,21H,10-15H2
DM8JM4Q	CS	C1CN(CCC1C2=CC=CC=C2)CCOC3=CC=C(C=C3)O
DM8JM4Q	IK	JRNIKKDZNLWUQY-UHFFFAOYSA-N
DM8JM4Q	IU	4-[2-(4-phenylpiperidin-1-yl)ethoxy]phenol
DM8JM4Q	CA	CAS 763907-80-8
DM8JM4Q	DE	Discovery agent

DM5J7O8	ID	DM5J7O8
DM5J7O8	DN	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol
DM5J7O8	HS	Investigative
DM5J7O8	SN	CHEMBL119778; 790642-63-6; 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol; CTK2G4587; DTXSID40438363; BDBM50066544; 4-[2-[(5-Phenylpentyl)amino]ethyl]phenol; Phenol, 4-[2-[(5-phenylpentyl)amino]ethyl]-
DM5J7O8	DT	Small molecular drug
DM5J7O8	PC	10336113
DM5J7O8	MW	283.4
DM5J7O8	FM	C19H25NO
DM5J7O8	IC	InChI=1S/C19H25NO/c21-19-12-10-18(11-13-19)14-16-20-15-6-2-5-9-17-7-3-1-4-8-17/h1,3-4,7-8,10-13,20-21H,2,5-6,9,14-16H2
DM5J7O8	CS	C1=CC=C(C=C1)CCCCCNCCC2=CC=C(C=C2)O
DM5J7O8	IK	GMQWOUOTGDXTNP-UHFFFAOYSA-N
DM5J7O8	IU	4-[2-(5-phenylpentylamino)ethyl]phenol
DM5J7O8	CA	CAS 790642-63-6
DM5J7O8	DE	Discovery agent

DMLCIJX	ID	DMLCIJX
DMLCIJX	DN	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol
DMLCIJX	HS	Investigative
DMLCIJX	SN	CHEMBL420530; 765883-50-9; 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol; CTK2G7588; DTXSID10444870; BDBM50066547; 4-[2-[(6-Phenylhexyl)amino]ethyl]phenol; Phenol, 4-[2-[(6-phenylhexyl)amino]ethyl]-
DMLCIJX	DT	Small molecular drug
DMLCIJX	PC	10782907
DMLCIJX	MW	297.4
DMLCIJX	FM	C20H27NO
DMLCIJX	IC	InChI=1S/C20H27NO/c22-20-13-11-19(12-14-20)15-17-21-16-7-2-1-4-8-18-9-5-3-6-10-18/h3,5-6,9-14,21-22H,1-2,4,7-8,15-17H2
DMLCIJX	CS	C1=CC=C(C=C1)CCCCCCNCCC2=CC=C(C=C2)O
DMLCIJX	IK	GWYOLALPGDHNBU-UHFFFAOYSA-N
DMLCIJX	IU	4-[2-(6-phenylhexylamino)ethyl]phenol
DMLCIJX	CA	CAS 765883-50-9
DMLCIJX	DE	Discovery agent

DMS0HV6	ID	DMS0HV6
DMS0HV6	DN	4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol
DMS0HV6	HS	Investigative
DMS0HV6	SN	Ici-3188; 1,1,2-Tris(4-hydroxyphenyl)prop-1-ene; 68373-13-7; 4-[1,1-bis(4-hydroxyphenyl)prop-1-en-2-yl]phenol; Phenol, 4,4',4''-(1-methyl-1-ethenyl-2-ylidene)tris-; Ici 3188; AC1MJ4DX; CHEMBL38103; CTK2F3093; DTXSID20218504; AKOS030547870
DMS0HV6	DT	Small molecular drug
DMS0HV6	PC	3085373
DMS0HV6	MW	318.4
DMS0HV6	FM	C21H18O3
DMS0HV6	IC	InChI=1S/C21H18O3/c1-14(15-2-8-18(22)9-3-15)21(16-4-10-19(23)11-5-16)17-6-12-20(24)13-7-17/h2-13,22-24H,1H3
DMS0HV6	CS	CC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DMS0HV6	IK	FFGNPMKMQDXQJJ-UHFFFAOYSA-N
DMS0HV6	IU	4-[1,1-bis(4-hydroxyphenyl)prop-1-en-2-yl]phenol
DMS0HV6	CA	CAS 68373-13-7
DMS0HV6	DE	Discovery agent

DMOPRQ7	ID	DMOPRQ7
DMOPRQ7	DN	4-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide
DMOPRQ7	HS	Investigative
DMOPRQ7	SN	CHEMBL201718; 4-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide; BDBM50181477; 4-[(3-benzyloxy-2-pyridyl)carbamoylamino]benzamide; Benzamide, 4-[[[[3-(phenylmethoxy)-2-pyridinyl]amino]carbonyl]amino]-
DMOPRQ7	DT	Small molecular drug
DMOPRQ7	PC	11574097
DMOPRQ7	MW	362.4
DMOPRQ7	FM	C20H18N4O3
DMOPRQ7	IC	InChI=1S/C20H18N4O3/c21-18(25)15-8-10-16(11-9-15)23-20(26)24-19-17(7-4-12-22-19)27-13-14-5-2-1-3-6-14/h1-12H,13H2,(H2,21,25)(H2,22,23,24,26)
DMOPRQ7	CS	C1=CC=C(C=C1)COC2=C(N=CC=C2)NC(=O)NC3=CC=C(C=C3)C(=O)N
DMOPRQ7	IK	TWCYUPDQSZQMLM-UHFFFAOYSA-N
DMOPRQ7	IU	4-[(3-phenylmethoxypyridin-2-yl)carbamoylamino]benzamide
DMOPRQ7	DE	Discovery agent

DMFKRMG	ID	DMFKRMG
DMFKRMG	DN	4-[3-(4-Butyl-phenoxy)-propyl]-1H-imidazole
DMFKRMG	HS	Investigative
DMFKRMG	SN	CHEMBL419654; 4-[3-(4-Butyl-phenoxy)-propyl]-1H-imidazole; SCHEMBL7991257; NKIFZJYIQSBUEI-UHFFFAOYSA-N; BDBM50093221; [3-(4-Imidazolyl)propyl](4-butylphenyl) ether; 4-Butylphenyl 3-(1H-imidazol-4-yl)propyl ether
DMFKRMG	DT	Small molecular drug
DMFKRMG	PC	21193574
DMFKRMG	MW	258.36
DMFKRMG	FM	C16H22N2O
DMFKRMG	IC	InChI=1S/C16H22N2O/c1-2-3-5-14-7-9-16(10-8-14)19-11-4-6-15-12-17-13-18-15/h7-10,12-13H,2-6,11H2,1H3,(H,17,18)
DMFKRMG	CS	CCCCC1=CC=C(C=C1)OCCCC2=CN=CN2
DMFKRMG	IK	NKIFZJYIQSBUEI-UHFFFAOYSA-N
DMFKRMG	IU	5-[3-(4-butylphenoxy)propyl]-1H-imidazole
DMFKRMG	DE	Discovery agent

DMJI6AM	ID	DMJI6AM
DMJI6AM	DN	4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE
DMJI6AM	HS	Investigative
DMJI6AM	SN	4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE; 156336-70-8; 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]piperidine; CHEMBL75691; 4-(5-(4-chlorophenyl)-1H-pyrazol-3-yl)piperidine; L02; 1way; AC1L9MRB; Bionet2_000947; Oprea1_423246; MLS000706783; SCHEMBL2598428; KS-00001ZEP; MolPort-001-684-207; GELALLNTKKLQLM-UHFFFAOYSA-N; HMS2660H19; HMS1366L01; ZINC5974200; BDBM50059237; AKOS015868501; AKOS023968186; DB08061; MCULE-8931017804; SMR000334280; FT-0741308; 7L-015; 3-(4-Piperidinyl)-5-(4-chlorophenyl)pyrazole
DMJI6AM	DT	Small molecular drug
DMJI6AM	PC	449126
DMJI6AM	MW	261.75
DMJI6AM	FM	C14H16ClN3
DMJI6AM	IC	InChI=1S/C14H16ClN3/c15-12-3-1-10(2-4-12)13-9-14(18-17-13)11-5-7-16-8-6-11/h1-4,9,11,16H,5-8H2,(H,17,18)
DMJI6AM	CS	C1CNCCC1C2=CC(=NN2)C3=CC=C(C=C3)Cl
DMJI6AM	IK	GELALLNTKKLQLM-UHFFFAOYSA-N
DMJI6AM	IU	4-[3-(4-chlorophenyl)-1H-pyrazol-5-yl]piperidine
DMJI6AM	DE	Discovery agent

DMXBEYQ	ID	DMXBEYQ
DMXBEYQ	DN	4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole
DMXBEYQ	HS	Investigative
DMXBEYQ	SN	CHEMBL309600; 4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole; SCHEMBL7987317; FUB-470; BDBM50067472; L018291; 4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole (FUB 470)
DMXBEYQ	DT	Small molecular drug
DMXBEYQ	PC	10082417
DMXBEYQ	MW	226.27
DMXBEYQ	FM	C14H14N2O
DMXBEYQ	IC	InChI=1S/C14H14N2O/c1-2-12-5-7-14(8-6-12)17-9-3-4-13-10-15-11-16-13/h1,5-8,10-11H,3-4,9H2,(H,15,16)
DMXBEYQ	CS	C#CC1=CC=C(C=C1)OCCCC2=CN=CN2
DMXBEYQ	IK	LMKPPWNWUJXSAQ-UHFFFAOYSA-N
DMXBEYQ	IU	5-[3-(4-ethynylphenoxy)propyl]-1H-imidazole
DMXBEYQ	DE	Discovery agent

DM7LV5A	ID	DM7LV5A
DM7LV5A	DN	4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DM7LV5A	HS	Investigative
DM7LV5A	SN	CHEMBL113227; 4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine; SCHEMBL14130001; BDBM50138238
DM7LV5A	DT	Small molecular drug
DM7LV5A	PC	44341260
DM7LV5A	MW	279.34
DM7LV5A	FM	C17H17N3O
DM7LV5A	IC	InChI=1S/C17H17N3O/c1(2-15-7-9-18-10-8-15)13-21-17-5-3-16(4-6-17)20-12-11-19-14-20/h3-12,14H,1-2,13H2
DM7LV5A	CS	C1=CC(=CC=C1N2C=CN=C2)OCCCC3=CC=NC=C3
DM7LV5A	IK	PFAUOLMRDJNYLJ-UHFFFAOYSA-N
DM7LV5A	IU	4-[3-(4-imidazol-1-ylphenoxy)propyl]pyridine
DM7LV5A	DE	Discovery agent

DM4GU29	ID	DM4GU29
DM4GU29	DN	4-[3-(4-Methoxy-phenoxy)-propyl]-1H-imidazole
DM4GU29	HS	Investigative
DM4GU29	SN	CHEMBL369714; SCHEMBL7987297; DEZXFTGWFMDRDA-UHFFFAOYSA-N; BDBM50092844; 4-[3-(4-Methoxyphenoxy)propyl]-1H-imidazole; 3-(1H-Imidazol-4-yl)propyl 4-methoxyphenyl ether; 4-[3-(4-Methoxy-phenoxy)-propyl]-1H-imidazole; compound with but-2-enedioic acid(0.25M H2O)
DM4GU29	DT	Small molecular drug
DM4GU29	PC	10681081
DM4GU29	MW	232.28
DM4GU29	FM	C13H16N2O2
DM4GU29	IC	InChI=1S/C13H16N2O2/c1-16-12-4-6-13(7-5-12)17-8-2-3-11-9-14-10-15-11/h4-7,9-10H,2-3,8H2,1H3,(H,14,15)
DM4GU29	CS	COC1=CC=C(C=C1)OCCCC2=CN=CN2
DM4GU29	IK	DEZXFTGWFMDRDA-UHFFFAOYSA-N
DM4GU29	IU	5-[3-(4-methoxyphenoxy)propyl]-1H-imidazole
DM4GU29	DE	Discovery agent

DMOF9YN	ID	DMOF9YN
DMOF9YN	DN	4-[3-(4-Phenyl-butylamino)-propyl]-phenol
DMOF9YN	HS	Investigative
DMOF9YN	SN	CHEMBL42414; 4-[3-(4-Phenyl-butylamino)-propyl]-phenol; BDBM50066538
DMOF9YN	DT	Small molecular drug
DMOF9YN	PC	10853103
DMOF9YN	MW	283.4
DMOF9YN	FM	C19H25NO
DMOF9YN	IC	InChI=1S/C19H25NO/c21-19-13-11-18(12-14-19)10-6-16-20-15-5-4-9-17-7-2-1-3-8-17/h1-3,7-8,11-14,20-21H,4-6,9-10,15-16H2
DMOF9YN	CS	C1=CC=C(C=C1)CCCCNCCCC2=CC=C(C=C2)O
DMOF9YN	IK	NXJFACHOHAZIMY-UHFFFAOYSA-N
DMOF9YN	IU	4-[3-(4-phenylbutylamino)propyl]phenol
DMOF9YN	DE	Discovery agent

DMKDBHN	ID	DMKDBHN
DMKDBHN	DN	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol
DMKDBHN	HS	Investigative
DMKDBHN	SN	CHEMBL334003; 771459-50-8; 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol; CTK2G6876; DTXSID00441232; BDBM50066546; 4-[3-[(5-Phenylpentyl)amino]propyl]phenol; Phenol, 4-[3-[(5-phenylpentyl)amino]propyl]-
DMKDBHN	DT	Small molecular drug
DMKDBHN	PC	10520673
DMKDBHN	MW	297.4
DMKDBHN	FM	C20H27NO
DMKDBHN	IC	InChI=1S/C20H27NO/c22-20-14-12-19(13-15-20)11-7-17-21-16-6-2-5-10-18-8-3-1-4-9-18/h1,3-4,8-9,12-15,21-22H,2,5-7,10-11,16-17H2
DMKDBHN	CS	C1=CC=C(C=C1)CCCCCNCCCC2=CC=C(C=C2)O
DMKDBHN	IK	HCVJFVZXTLAHRT-UHFFFAOYSA-N
DMKDBHN	IU	4-[3-(5-phenylpentylamino)propyl]phenol
DMKDBHN	CA	CAS 771459-50-8
DMKDBHN	DE	Discovery agent

DMZU23D	ID	DMZU23D
DMZU23D	DN	4-[3-(benzyloxy)benzoyl]benzoic acid
DMZU23D	HS	Investigative
DMZU23D	SN	4-[3-(benzyloxy)benzoyl]benzoic acid; CHEMBL382649
DMZU23D	DT	Small molecular drug
DMZU23D	PC	11702714
DMZU23D	MW	332.3
DMZU23D	FM	C21H16O4
DMZU23D	IC	InChI=1S/C21H16O4/c22-20(16-9-11-17(12-10-16)21(23)24)18-7-4-8-19(13-18)25-14-15-5-2-1-3-6-15/h1-13H,14H2,(H,23,24)
DMZU23D	CS	C1=CC=C(C=C1)COC2=CC=CC(=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DMZU23D	IK	UBSDFPUNDIGYKJ-UHFFFAOYSA-N
DMZU23D	IU	4-(3-phenylmethoxybenzoyl)benzoic acid
DMZU23D	DE	Discovery agent

DMTIA27	ID	DMTIA27
DMTIA27	DN	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
DMTIA27	HS	Investigative
DMTIA27	SN	4-[3-Hydroxyanilino]-6,7-dimethoxyquinazoline; whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; 4-[3-HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3&amp; -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15; WHI-P180
DMTIA27	DT	Small molecular drug
DMTIA27	PC	5687
DMTIA27	MW	297.31
DMTIA27	FM	C16H15N3O3
DMTIA27	IC	InChI=1S/C16H15N3O3/c1-21-14-7-12-13(8-15(14)22-2)17-9-18-16(12)19-10-4-3-5-11(20)6-10/h3-9,20H,1-2H3,(H,17,18,19)
DMTIA27	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)O)OC
DMTIA27	IK	BNDYIYYKEIXHNK-UHFFFAOYSA-N
DMTIA27	IU	3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol
DMTIA27	DE	Discovery agent

DM62351	ID	DM62351
DM62351	DN	4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine
DM62351	HS	Investigative
DM62351	SN	CHEMBL1214738; 4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine; SCHEMBL18770313
DM62351	DT	Small molecular drug
DM62351	PC	46901928
DM62351	MW	325.4
DM62351	FM	C23H19NO
DM62351	IC	InChI=1S/C23H19NO/c1-25-23-9-8-21-15-20(6-7-22(21)16-23)19-4-2-17(3-5-19)14-18-10-12-24-13-11-18/h2-13,15-16H,14H2,1H3
DM62351	CS	COC1=CC2=C(C=C1)C=C(C=C2)C3=CC=C(C=C3)CC4=CC=NC=C4
DM62351	IK	XDUUJWUQYXFHEK-UHFFFAOYSA-N
DM62351	IU	4-[[4-(6-methoxynaphthalen-2-yl)phenyl]methyl]pyridine
DM62351	DE	Discovery agent

DM8MVE9	ID	DM8MVE9
DM8MVE9	DN	4-[4-(benzhydryloxy)benzoyl]benzoic acid
DM8MVE9	HS	Investigative
DM8MVE9	SN	4-[4-(benzhydryloxy)benzoyl]benzoic acid; CHEMBL203352
DM8MVE9	DT	Small molecular drug
DM8MVE9	PC	11509747
DM8MVE9	MW	408.4
DM8MVE9	FM	C27H20O4
DM8MVE9	IC	InChI=1S/C27H20O4/c28-25(19-11-13-23(14-12-19)27(29)30)20-15-17-24(18-16-20)31-26(21-7-3-1-4-8-21)22-9-5-2-6-10-22/h1-18,26H,(H,29,30)
DM8MVE9	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)OC3=CC=C(C=C3)C(=O)C4=CC=C(C=C4)C(=O)O
DM8MVE9	IK	RSHGTUVDNJDFHP-UHFFFAOYSA-N
DM8MVE9	IU	4-(4-benzhydryloxybenzoyl)benzoic acid
DM8MVE9	DE	Discovery agent

DM5Z64L	ID	DM5Z64L
DM5Z64L	DN	4-[4-(benzhydryloxy)piperidino]butyl benzoate
DM5Z64L	HS	Investigative
DM5Z64L	SN	CHEMBL228999; 4-[4-(benzhydryloxy)piperidino]butyl benzoate; SCHEMBL4020166
DM5Z64L	DT	Small molecular drug
DM5Z64L	PC	10275242
DM5Z64L	MW	443.6
DM5Z64L	FM	C29H33NO3
DM5Z64L	IC	InChI=1S/C29H33NO3/c31-29(26-16-8-3-9-17-26)32-23-11-10-20-30-21-18-27(19-22-30)33-28(24-12-4-1-5-13-24)25-14-6-2-7-15-25/h1-9,12-17,27-28H,10-11,18-23H2
DM5Z64L	CS	C1CN(CCC1OC(C2=CC=CC=C2)C3=CC=CC=C3)CCCCOC(=O)C4=CC=CC=C4
DM5Z64L	IK	SUQKPOGAPWZPRM-UHFFFAOYSA-N
DM5Z64L	IU	4-(4-benzhydryloxypiperidin-1-yl)butyl benzoate
DM5Z64L	DE	Discovery agent

DM9VPFL	ID	DM9VPFL
DM9VPFL	DN	4-[4-(benzoylamino)benzoyl]benzoic acid
DM9VPFL	HS	Investigative
DM9VPFL	SN	4-[4-(benzoylamino)benzoyl]benzoic acid
DM9VPFL	DT	Small molecular drug
DM9VPFL	PC	11681722
DM9VPFL	MW	345.3
DM9VPFL	FM	C21H15NO4
DM9VPFL	IC	InChI=1S/C21H15NO4/c23-19(14-6-8-17(9-7-14)21(25)26)15-10-12-18(13-11-15)22-20(24)16-4-2-1-3-5-16/h1-13H,(H,22,24)(H,25,26)
DM9VPFL	CS	C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DM9VPFL	IK	FKMULXSKUTZDBD-UHFFFAOYSA-N
DM9VPFL	IU	4-(4-benzamidobenzoyl)benzoic acid
DM9VPFL	DE	Discovery agent

DMQC5EH	ID	DMQC5EH
DMQC5EH	DN	4-[4-(benzylamino)benzoyl]benzoic acid
DMQC5EH	HS	Investigative
DMQC5EH	SN	4-[4-(benzylamino)benzoyl]benzoic Acid
DMQC5EH	DT	Small molecular drug
DMQC5EH	PC	11602388
DMQC5EH	MW	331.4
DMQC5EH	FM	C21H17NO3
DMQC5EH	IC	InChI=1S/C21H17NO3/c23-20(16-6-8-18(9-7-16)21(24)25)17-10-12-19(13-11-17)22-14-15-4-2-1-3-5-15/h1-13,22H,14H2,(H,24,25)
DMQC5EH	CS	C1=CC=C(C=C1)CNC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DMQC5EH	IK	HTOJJEGICHZIJA-UHFFFAOYSA-N
DMQC5EH	IU	4-[4-(benzylamino)benzoyl]benzoic acid
DMQC5EH	DE	Discovery agent

DMTDYHE	ID	DMTDYHE
DMTDYHE	DN	4-[4-(benzyloxy)piperidino]butyl benzoate
DMTDYHE	HS	Investigative
DMTDYHE	SN	4-[4-(benzyloxy)piperidino]butyl benzoate; CHEMBL228950; SCHEMBL4028855
DMTDYHE	DT	Small molecular drug
DMTDYHE	PC	9969234
DMTDYHE	MW	367.5
DMTDYHE	FM	C23H29NO3
DMTDYHE	IC	InChI=1S/C23H29NO3/c25-23(21-11-5-2-6-12-21)26-18-8-7-15-24-16-13-22(14-17-24)27-19-20-9-3-1-4-10-20/h1-6,9-12,22H,7-8,13-19H2
DMTDYHE	CS	C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC=CC=C3
DMTDYHE	IK	PIHTVJYRMYAPDJ-UHFFFAOYSA-N
DMTDYHE	IU	4-(4-phenylmethoxypiperidin-1-yl)butyl benzoate
DMTDYHE	DE	Discovery agent

DMIXRCS	ID	DMIXRCS
DMIXRCS	DN	4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate
DMIXRCS	HS	Investigative
DMIXRCS	SN	CHEMBL389049; 4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate; SCHEMBL4024650
DMIXRCS	DT	Small molecular drug
DMIXRCS	PC	10222714
DMIXRCS	MW	401.9
DMIXRCS	FM	C23H28ClNO3
DMIXRCS	IC	InChI=1S/C23H28ClNO3/c24-21-10-6-9-20(17-21)23(26)27-16-5-4-13-25-14-11-22(12-15-25)28-18-19-7-2-1-3-8-19/h1-3,6-10,17,22H,4-5,11-16,18H2
DMIXRCS	CS	C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC(=CC=C3)Cl
DMIXRCS	IK	NDGPQNPYSUGIAY-UHFFFAOYSA-N
DMIXRCS	IU	4-(4-phenylmethoxypiperidin-1-yl)butyl 3-chlorobenzoate
DMIXRCS	DE	Discovery agent

DM87AYP	ID	DM87AYP
DM87AYP	DN	4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate
DM87AYP	HS	Investigative
DM87AYP	SN	CHEMBL228359; 4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate; SCHEMBL4027386
DM87AYP	DT	Small molecular drug
DM87AYP	PC	10178151
DM87AYP	MW	385.5
DM87AYP	FM	C23H28FNO3
DM87AYP	IC	InChI=1S/C23H28FNO3/c24-21-10-6-9-20(17-21)23(26)27-16-5-4-13-25-14-11-22(12-15-25)28-18-19-7-2-1-3-8-19/h1-3,6-10,17,22H,4-5,11-16,18H2
DM87AYP	CS	C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC(=CC=C3)F
DM87AYP	IK	YJPYLKLJKPTNBQ-UHFFFAOYSA-N
DM87AYP	IU	4-(4-phenylmethoxypiperidin-1-yl)butyl 3-fluorobenzoate
DM87AYP	DE	Discovery agent

DM0V8MA	ID	DM0V8MA
DM0V8MA	DN	4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate
DM0V8MA	HS	Investigative
DM0V8MA	SN	CHEMBL389048; 4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate; SCHEMBL4020282
DM0V8MA	DT	Small molecular drug
DM0V8MA	PC	10135721
DM0V8MA	MW	401.9
DM0V8MA	FM	C23H28ClNO3
DM0V8MA	IC	InChI=1S/C23H28ClNO3/c24-21-10-8-20(9-11-21)23(26)27-17-5-4-14-25-15-12-22(13-16-25)28-18-19-6-2-1-3-7-19/h1-3,6-11,22H,4-5,12-18H2
DM0V8MA	CS	C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC=C(C=C3)Cl
DM0V8MA	IK	ZUARKRNDJKGEIT-UHFFFAOYSA-N
DM0V8MA	IU	4-(4-phenylmethoxypiperidin-1-yl)butyl 4-chlorobenzoate
DM0V8MA	DE	Discovery agent

DML7UQ1	ID	DML7UQ1
DML7UQ1	DN	4-[4-(benzyloxy)piperidino]butyl-4-fluorobenzoate
DML7UQ1	HS	Investigative
DML7UQ1	SN	CHEMBL229105; 4-[4-(benzyloxy)piperidino]butyl-4-fluorobenzoate; SCHEMBL4026157
DML7UQ1	DT	Small molecular drug
DML7UQ1	PC	10221700
DML7UQ1	MW	385.5
DML7UQ1	FM	C23H28FNO3
DML7UQ1	IC	InChI=1S/C23H28FNO3/c24-21-10-8-20(9-11-21)23(26)27-17-5-4-14-25-15-12-22(13-16-25)28-18-19-6-2-1-3-7-19/h1-3,6-11,22H,4-5,12-18H2
DML7UQ1	CS	C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC=C(C=C3)F
DML7UQ1	IK	WNLQOEBYDOWFBU-UHFFFAOYSA-N
DML7UQ1	IU	4-(4-phenylmethoxypiperidin-1-yl)butyl 4-fluorobenzoate
DML7UQ1	DE	Discovery agent

DMNOD2Q	ID	DMNOD2Q
DMNOD2Q	DN	4-[4-(benzyloxy)piperidino]butyl-4-nitrobenzoate
DMNOD2Q	HS	Investigative
DMNOD2Q	SN	CHEMBL228301; 4-[4-(benzyloxy)piperidino]butyl-4-nitrobenzoate; SCHEMBL4025407
DMNOD2Q	DT	Small molecular drug
DMNOD2Q	PC	10112356
DMNOD2Q	MW	412.5
DMNOD2Q	FM	C23H28N2O5
DMNOD2Q	IC	InChI=1S/C23H28N2O5/c26-23(20-8-10-21(11-9-20)25(27)28)29-17-5-4-14-24-15-12-22(13-16-24)30-18-19-6-2-1-3-7-19/h1-3,6-11,22H,4-5,12-18H2
DMNOD2Q	CS	C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC=C(C=C3)[N+](=O)[O-]
DMNOD2Q	IK	CBYWQHUSTLWEBJ-UHFFFAOYSA-N
DMNOD2Q	IU	4-(4-phenylmethoxypiperidin-1-yl)butyl 4-nitrobenzoate
DMNOD2Q	DE	Discovery agent

DMQ9IN4	ID	DMQ9IN4
DMQ9IN4	DN	4-[4-benzyloxy)benzoyl]benzoic acid
DMQ9IN4	HS	Investigative
DMQ9IN4	SN	CHEMBL202871; 4-[4-benzyloxy)benzoyl]benzoic acid
DMQ9IN4	DT	Small molecular drug
DMQ9IN4	PC	11616925
DMQ9IN4	MW	332.3
DMQ9IN4	FM	C21H16O4
DMQ9IN4	IC	InChI=1S/C21H16O4/c22-20(16-6-8-18(9-7-16)21(23)24)17-10-12-19(13-11-17)25-14-15-4-2-1-3-5-15/h1-13H,14H2,(H,23,24)
DMQ9IN4	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DMQ9IN4	IK	ZSVDQQIAIVOVRI-UHFFFAOYSA-N
DMQ9IN4	IU	4-(4-phenylmethoxybenzoyl)benzoic acid
DMQ9IN4	DE	Discovery agent

DMK4ICB	ID	DMK4ICB
DMK4ICB	DN	4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol
DMK4ICB	HS	Investigative
DMK4ICB	SN	1122660-25-6; 4-(5-(3-Hydroxyphenyl)thiophen-2-yl)-2-methylphenol; 3-(5-(4-hydroxy-3-methylphenyl)thiophen-2-yl)phenol; CHEMBL570596; AK160974; 3-(5-(4-Hydroxy-3-methylphenyl)-thiophen-2-yl)phenol; SCHEMBL1180399; 4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol; MolPort-028-616-334; ZINC45254284; BDBM50299633; AKOS024463871; DS-9818; QC-10086; AJ-110394; AX8293985
DMK4ICB	DT	Small molecular drug
DMK4ICB	PC	25192475
DMK4ICB	MW	282.4
DMK4ICB	FM	C17H14O2S
DMK4ICB	IC	InChI=1S/C17H14O2S/c1-11-9-13(5-6-15(11)19)17-8-7-16(20-17)12-3-2-4-14(18)10-12/h2-10,18-19H,1H3
DMK4ICB	CS	CC1=C(C=CC(=C1)C2=CC=C(S2)C3=CC(=CC=C3)O)O
DMK4ICB	IK	ICDRVGLMFQWTDX-UHFFFAOYSA-N
DMK4ICB	IU	4-[5-(3-hydroxyphenyl)thiophen-2-yl]-2-methylphenol
DMK4ICB	DE	Discovery agent

DMZHVFO	ID	DMZHVFO
DMZHVFO	DN	4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol
DMZHVFO	HS	Investigative
DMZHVFO	SN	CHEMBL573003; 4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol; SCHEMBL1180066
DMZHVFO	DT	Small molecular drug
DMZHVFO	PC	25192476
DMZHVFO	MW	284.3
DMZHVFO	FM	C16H12O3S
DMZHVFO	IC	InChI=1S/C16H12O3S/c17-12-3-1-2-10(8-12)15-6-7-16(20-15)11-4-5-13(18)14(19)9-11/h1-9,17-19H
DMZHVFO	CS	C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=C(C=C3)O)O
DMZHVFO	IK	URXFYOORYZACQY-UHFFFAOYSA-N
DMZHVFO	IU	4-[5-(3-hydroxyphenyl)thiophen-2-yl]benzene-1,2-diol
DMZHVFO	DE	Discovery agent

DM7ERYJ	ID	DM7ERYJ
DM7ERYJ	DN	4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol
DM7ERYJ	HS	Investigative
DM7ERYJ	SN	CHEMBL569862; 4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol; SCHEMBL1180208
DM7ERYJ	DT	Small molecular drug
DM7ERYJ	PC	25192621
DM7ERYJ	MW	282.4
DM7ERYJ	FM	C17H14O2S
DM7ERYJ	IC	InChI=1S/C17H14O2S/c1-11-7-12(5-6-16(11)19)14-9-17(20-10-14)13-3-2-4-15(18)8-13/h2-10,18-19H,1H3
DM7ERYJ	CS	CC1=C(C=CC(=C1)C2=CSC(=C2)C3=CC(=CC=C3)O)O
DM7ERYJ	IK	STFVOGWUKNAWOF-UHFFFAOYSA-N
DM7ERYJ	IU	4-[5-(3-hydroxyphenyl)thiophen-3-yl]-2-methylphenol
DM7ERYJ	DE	Discovery agent

DMI7YAQ	ID	DMI7YAQ
DMI7YAQ	DN	4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine
DMI7YAQ	HS	Investigative
DMI7YAQ	SN	(4-Pyridylmethylene)indane 10a; CHEMBL366773; BDBM8620; AC1O7063; 4-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMI7YAQ	DT	Small molecular drug
DMI7YAQ	PC	6539794
DMI7YAQ	MW	286.17
DMI7YAQ	FM	C15H12BrN
DMI7YAQ	IC	InChI=1S/C15H12BrN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9+
DMI7YAQ	CS	C1C/C(=C\\C2=CC=NC=C2)/C3=C1C=C(C=C3)Br
DMI7YAQ	IK	MNQUPNOEJZVKRD-FMIVXFBMSA-N
DMI7YAQ	IU	4-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMI7YAQ	DE	Discovery agent

DMQKHXN	ID	DMQKHXN
DMQKHXN	DN	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine
DMQKHXN	HS	Investigative
DMQKHXN	SN	CHEMBL179222; BDBM8621; (4-Pyridylmethylene)indane 10b; AC1O7065; 4-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMQKHXN	DT	Small molecular drug
DMQKHXN	PC	6539795
DMQKHXN	MW	286.17
DMQKHXN	FM	C15H12BrN
DMQKHXN	IC	InChI=1S/C15H12BrN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9-
DMQKHXN	CS	C1C/C(=C/C2=CC=NC=C2)/C3=C1C=C(C=C3)Br
DMQKHXN	IK	MNQUPNOEJZVKRD-XFXZXTDPSA-N
DMQKHXN	IU	4-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMQKHXN	DE	Discovery agent

DMZL8KN	ID	DMZL8KN
DMZL8KN	DN	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DMZL8KN	HS	Investigative
DMZL8KN	SN	(4-Pyridylmethylene)indane 8a; SCHEMBL4231646; CHEMBL175554; BDBM8618; SCHEMBL4231651; AC1O705Z; ZINC13610827; 4-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMZL8KN	DT	Small molecular drug
DMZL8KN	PC	6539792
DMZL8KN	MW	241.71
DMZL8KN	FM	C15H12ClN
DMZL8KN	IC	InChI=1S/C15H12ClN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9+
DMZL8KN	CS	C1C/C(=C\\C2=CC=NC=C2)/C3=C1C=C(C=C3)Cl
DMZL8KN	IK	NFCDNDMUSHGWSU-FMIVXFBMSA-N
DMZL8KN	IU	4-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMZL8KN	DE	Discovery agent

DM1Z3DG	ID	DM1Z3DG
DM1Z3DG	DN	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DM1Z3DG	HS	Investigative
DM1Z3DG	SN	(4-Pyridylmethylene)indane 8b; SCHEMBL4231649; CHEMBL175799; BDBM8619; AC1O7061; ZINC100056323; 4-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM1Z3DG	DT	Small molecular drug
DM1Z3DG	PC	6539793
DM1Z3DG	MW	241.71
DM1Z3DG	FM	C15H12ClN
DM1Z3DG	IC	InChI=1S/C15H12ClN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9-
DM1Z3DG	CS	C1C/C(=C/C2=CC=NC=C2)/C3=C1C=C(C=C3)Cl
DM1Z3DG	IK	NFCDNDMUSHGWSU-XFXZXTDPSA-N
DM1Z3DG	IU	4-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM1Z3DG	DE	Discovery agent

DMY08FE	ID	DMY08FE
DMY08FE	DN	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMY08FE	HS	Investigative
DMY08FE	SN	(4-Pyridylmethylene)indane 6a; BDBM8614; AC1O705R; SCHEMBL4231103; CHEMBL424960; SCHEMBL4231111; ZINC13535834; 4-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMY08FE	DT	Small molecular drug
DMY08FE	PC	6539788
DMY08FE	MW	225.26
DMY08FE	FM	C15H12FN
DMY08FE	IC	InChI=1S/C15H12FN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9+
DMY08FE	CS	C1C/C(=C\\C2=CC=NC=C2)/C3=C1C=C(C=C3)F
DMY08FE	IK	KVRYTKBSTLSXKC-FMIVXFBMSA-N
DMY08FE	IU	4-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMY08FE	DE	Discovery agent

DMHDZUO	ID	DMHDZUO
DMHDZUO	DN	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMHDZUO	HS	Investigative
DMHDZUO	SN	(4-Pyridylmethylene)indane 6b; SCHEMBL4231108; CHEMBL179144; AC1O705T; BDBM8615; ZINC100056302; 4-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMHDZUO	DT	Small molecular drug
DMHDZUO	PC	6539789
DMHDZUO	MW	225.26
DMHDZUO	FM	C15H12FN
DMHDZUO	IC	InChI=1S/C15H12FN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9-
DMHDZUO	CS	C1C/C(=C/C2=CC=NC=C2)/C3=C1C=C(C=C3)F
DMHDZUO	IK	KVRYTKBSTLSXKC-XFXZXTDPSA-N
DMHDZUO	IU	4-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMHDZUO	DE	Discovery agent

DM25GS6	ID	DM25GS6
DM25GS6	DN	4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM25GS6	HS	Investigative
DM25GS6	SN	(4-Pyridylmethylene)indane 12a; CHEMBL359942; BDBM8622; AC1O7067; 4-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM25GS6	DT	Small molecular drug
DM25GS6	PC	6539796
DM25GS6	MW	237.3
DM25GS6	FM	C16H15NO
DM25GS6	IC	InChI=1S/C16H15NO/c1-18-15-4-5-16-13(2-3-14(16)11-15)10-12-6-8-17-9-7-12/h4-11H,2-3H2,1H3/b13-10+
DM25GS6	CS	COC1=CC2=C(C=C1)/C(=C/C3=CC=NC=C3)/CC2
DM25GS6	IK	VDGYNVYFCLIMOF-JLHYYAGUSA-N
DM25GS6	IU	4-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM25GS6	DE	Discovery agent

DMLBX4Q	ID	DMLBX4Q
DMLBX4Q	DN	4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMLBX4Q	HS	Investigative
DMLBX4Q	SN	CHEMBL175609; BDBM8623; (4-Pyridylmethylene)indane 12b; AC1O7069; 4-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMLBX4Q	DT	Small molecular drug
DMLBX4Q	PC	6539797
DMLBX4Q	MW	237.3
DMLBX4Q	FM	C16H15NO
DMLBX4Q	IC	InChI=1S/C16H15NO/c1-18-15-4-5-16-13(2-3-14(16)11-15)10-12-6-8-17-9-7-12/h4-11H,2-3H2,1H3/b13-10-
DMLBX4Q	CS	COC1=CC2=C(C=C1)/C(=C\\C3=CC=NC=C3)/CC2
DMLBX4Q	IK	VDGYNVYFCLIMOF-RAXLEYEMSA-N
DMLBX4Q	IU	4-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMLBX4Q	DE	Discovery agent

DM3IR8Y	ID	DM3IR8Y
DM3IR8Y	DN	4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM3IR8Y	HS	Investigative
DM3IR8Y	SN	AC1O706F; CHEMBL365314; BDBM8626; (4-Pyridylmethylene)indane 16a; 4-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM3IR8Y	DT	Small molecular drug
DM3IR8Y	PC	6539800
DM3IR8Y	MW	237.3
DM3IR8Y	FM	C16H15NO
DM3IR8Y	IC	InChI=1S/C16H15NO/c1-18-15-5-4-13-2-3-14(16(13)11-15)10-12-6-8-17-9-7-12/h4-11H,2-3H2,1H3/b14-10+
DM3IR8Y	CS	COC1=CC\\2=C(CC/C2=C\\C3=CC=NC=C3)C=C1
DM3IR8Y	IK	VFFWGGPPTWJBON-GXDHUFHOSA-N
DM3IR8Y	IU	4-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM3IR8Y	DE	Discovery agent

DMIBZJC	ID	DMIBZJC
DMIBZJC	DN	4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMIBZJC	HS	Investigative
DMIBZJC	SN	(4-Pyridylmethylene)indane 16b; CHEMBL370281; AC1O706H; BDBM8627; 4-[(Z)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMIBZJC	DT	Small molecular drug
DMIBZJC	PC	6539801
DMIBZJC	MW	237.3
DMIBZJC	FM	C16H15NO
DMIBZJC	IC	InChI=1S/C16H15NO/c1-18-15-5-4-13-2-3-14(16(13)11-15)10-12-6-8-17-9-7-12/h4-11H,2-3H2,1H3/b14-10-
DMIBZJC	CS	COC1=CC\\2=C(CC/C2=C/C3=CC=NC=C3)C=C1
DMIBZJC	IK	VFFWGGPPTWJBON-UVTDQMKNSA-N
DMIBZJC	IU	4-[(Z)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMIBZJC	DE	Discovery agent

DMYGN1K	ID	DMYGN1K
DMYGN1K	DN	4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMYGN1K	HS	Investigative
DMYGN1K	SN	CHEMBL371742; BDBM8629; AC1O706L; (4-Pyridylmethylene)indane 22a; 4-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMYGN1K	DT	Small molecular drug
DMYGN1K	PC	6539803
DMYGN1K	MW	221.3
DMYGN1K	FM	C16H15N
DMYGN1K	IC	InChI=1S/C16H15N/c1-12-2-3-14-4-5-15(16(14)10-12)11-13-6-8-17-9-7-13/h2-3,6-11H,4-5H2,1H3/b15-11+
DMYGN1K	CS	CC1=CC\\2=C(CC/C2=C\\C3=CC=NC=C3)C=C1
DMYGN1K	IK	JRWJGUYEZHCVMC-RVDMUPIBSA-N
DMYGN1K	IU	4-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMYGN1K	DE	Discovery agent

DM5VN3D	ID	DM5VN3D
DM5VN3D	DN	4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DM5VN3D	HS	Investigative
DM5VN3D	SN	(4-Pyridylmethylene)indane 22b; AC1O706N; CHEMBL192077; BDBM8630; 4-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM5VN3D	DT	Small molecular drug
DM5VN3D	PC	6539804
DM5VN3D	MW	221.3
DM5VN3D	FM	C16H15N
DM5VN3D	IC	InChI=1S/C16H15N/c1-12-2-3-14-4-5-15(16(14)10-12)11-13-6-8-17-9-7-13/h2-3,6-11H,4-5H2,1H3/b15-11-
DM5VN3D	CS	CC1=CC\\2=C(CC/C2=C/C3=CC=NC=C3)C=C1
DM5VN3D	IK	JRWJGUYEZHCVMC-PTNGSMBKSA-N
DM5VN3D	IU	4-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM5VN3D	DE	Discovery agent

DMMGHNA	ID	DMMGHNA
DMMGHNA	DN	4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid
DMMGHNA	HS	Investigative
DMMGHNA	SN	4-{2-[(3-NITROBENZOYL)AMINO]PHENOXY}PHTHALIC ACID; CHEMBL326611; 4-[2-[(3-nitrobenzoyl)amino]phenoxy]phthalic acid; 1z6p; AC1LCW3D; SCHEMBL4323472; NAQUAVBNIYTIIS-UHFFFAOYSA-N; BDBM50149303; DB04044; 4-[2-(3-nitrobenzoylamino)phenoxy]phthalic acid; 4-[2-(3-nitrobenzoylamino)-phenoxy]phthalic acid; 4-[2-(3-nitrobenzoylamino)-phenoxyl]phthalic acid; 4-[2-(3-Nitro-benzoylamino)-phenoxy]-phthalic acid; 4-[2-(3-nitrobenzamido)phenoxy]benzene-1,2-dicarboxylic acid
DMMGHNA	DT	Small molecular drug
DMMGHNA	PC	657140
DMMGHNA	MW	422.3
DMMGHNA	FM	C21H14N2O8
DMMGHNA	IC	InChI=1S/C21H14N2O8/c24-19(12-4-3-5-13(10-12)23(29)30)22-17-6-1-2-7-18(17)31-14-8-9-15(20(25)26)16(11-14)21(27)28/h1-11H,(H,22,24)(H,25,26)(H,27,28)
DMMGHNA	CS	C1=CC=C(C(=C1)NC(=O)C2=CC(=CC=C2)[N+](=O)[O-])OC3=CC(=C(C=C3)C(=O)O)C(=O)O
DMMGHNA	IK	NAQUAVBNIYTIIS-UHFFFAOYSA-N
DMMGHNA	IU	4-[2-[(3-nitrobenzoyl)amino]phenoxy]phthalic acid
DMMGHNA	DE	Discovery agent

DMA21GM	ID	DMA21GM
DMA21GM	DN	4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol
DMA21GM	HS	Investigative
DMA21GM	SN	CHEMBL327075; 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol; SCHEMBL7374092; BDBM50066540; ZINC13781001
DMA21GM	DT	Small molecular drug
DMA21GM	PC	10685438
DMA21GM	MW	297.4
DMA21GM	FM	C20H27NO
DMA21GM	IC	InChI=1S/C20H27NO/c1-2-21(17-15-19-11-13-20(22)14-12-19)16-7-6-10-18-8-4-3-5-9-18/h3-5,8-9,11-14,22H,2,6-7,10,15-17H2,1H3
DMA21GM	CS	CCN(CCCCC1=CC=CC=C1)CCC2=CC=C(C=C2)O
DMA21GM	IK	CJODMSRSFMFSCO-UHFFFAOYSA-N
DMA21GM	IU	4-[2-[ethyl(4-phenylbutyl)amino]ethyl]phenol
DMA21GM	DE	Discovery agent

DMZUM95	ID	DMZUM95
DMZUM95	DN	4-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMZUM95	HS	Investigative
DMZUM95	SN	CHEMBL67175; 4-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate; SCHEMBL2501164
DMZUM95	DT	Small molecular drug
DMZUM95	PC	9885795
DMZUM95	MW	372.4
DMZUM95	FM	C13H12N2O7S2
DMZUM95	IC	InChI=1S/C13H12N2O7S2/c14-23(17,18)21-11-5-1-9(2-6-11)13(16)10-3-7-12(8-4-10)22-24(15,19)20/h1-8H,(H2,14,17,18)(H2,15,19,20)
DMZUM95	CS	C1=CC(=CC=C1C(=O)C2=CC=C(C=C2)OS(=O)(=O)N)OS(=O)(=O)N
DMZUM95	IK	NKZRLSJYBCVOGN-UHFFFAOYSA-N
DMZUM95	IU	[4-(4-sulfamoyloxybenzoyl)phenyl] sulfamate
DMZUM95	DE	Discovery agent

DMLE0I7	ID	DMLE0I7
DMLE0I7	DN	4557W
DMLE0I7	HS	Investigative
DMLE0I7	SN	EGFR/ErbB-2 Inhibitor; 179248-61-4; 4557W; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine
DMLE0I7	DT	Small molecular drug
DMLE0I7	PC	9843206
DMLE0I7	MW	387.4
DMLE0I7	FM	C23H21N3O3
DMLE0I7	IC	InChI=1S/C23H21N3O3/c1-27-21-12-19-20(13-22(21)28-2)24-15-25-23(19)26-17-8-10-18(11-9-17)29-14-16-6-4-3-5-7-16/h3-13,15H,14H2,1-2H3,(H,24,25,26)
DMLE0I7	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)OCC4=CC=CC=C4)OC
DMLE0I7	IK	DNOKYISWMVFYFA-UHFFFAOYSA-N
DMLE0I7	IU	6,7-dimethoxy-N-(4-phenylmethoxyphenyl)quinazolin-4-amine
DMLE0I7	CA	CAS 179248-61-4
DMLE0I7	DE	Discovery agent

DMN2TMS	ID	DMN2TMS
DMN2TMS	DN	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide
DMN2TMS	HS	Investigative
DMN2TMS	SN	CHEMBL200958
DMN2TMS	DT	Small molecular drug
DMN2TMS	PC	44406548
DMN2TMS	MW	361.19
DMN2TMS	FM	C16H13BrN2O3
DMN2TMS	IC	InChI=1S/C16H13BrN2O3/c1-2-15(21)18-12-6-7-13(14(20)9-12)16(22)19-11-5-3-4-10(17)8-11/h2-9,20H,1H2,(H,18,21)(H,19,22)
DMN2TMS	CS	C=CC(=O)NC1=CC(=C(C=C1)C(=O)NC2=CC(=CC=C2)Br)O
DMN2TMS	IK	RVPAGQILSYDDNT-UHFFFAOYSA-N
DMN2TMS	IU	N-(3-bromophenyl)-2-hydroxy-4-(prop-2-enoylamino)benzamide
DMN2TMS	DE	Discovery agent

DME24LV	ID	DME24LV
DME24LV	DN	4-adamantyl resorcinol
DME24LV	HS	Investigative
DME24LV	SN	4-adamantyl resorcinol; CHEMBL474953; 4-(adamant-1-yl)resorcin; 4-(1-Adamantyl)resorcinol; SCHEMBL2420330; NAJPJOQCMCYGLX-UHFFFAOYSA-N; 1-(2,4-dihydroxyphenyl)adamantane
DME24LV	DT	Small molecular drug
DME24LV	PC	15105171
DME24LV	MW	244.33
DME24LV	FM	C16H20O2
DME24LV	IC	InChI=1S/C16H20O2/c17-13-1-2-14(15(18)6-13)16-7-10-3-11(8-16)5-12(4-10)9-16/h1-2,6,10-12,17-18H,3-5,7-9H2
DME24LV	CS	C1C2CC3CC1CC(C2)(C3)C4=C(C=C(C=C4)O)O
DME24LV	IK	NAJPJOQCMCYGLX-UHFFFAOYSA-N
DME24LV	IU	4-(1-adamantyl)benzene-1,3-diol
DME24LV	DE	Discovery agent

DM9WT8M	ID	DM9WT8M
DM9WT8M	DN	4-Allyl-6-nitro-2-piperazin-1-yl-quinoline
DM9WT8M	HS	Investigative
DM9WT8M	SN	CHEMBL167358; 4-Allyl-6-nitro-2-piperazin-1-yl-quinoline; BDBM50110587
DM9WT8M	DT	Small molecular drug
DM9WT8M	PC	44379686
DM9WT8M	MW	298.34
DM9WT8M	FM	C16H18N4O2
DM9WT8M	IC	InChI=1S/C16H18N4O2/c1-2-3-12-10-16(19-8-6-17-7-9-19)18-15-5-4-13(20(21)22)11-14(12)15/h2,4-5,10-11,17H,1,3,6-9H2
DM9WT8M	CS	C=CCC1=CC(=NC2=C1C=C(C=C2)[N+](=O)[O-])N3CCNCC3
DM9WT8M	IK	MQKUUUQECTZPIV-UHFFFAOYSA-N
DM9WT8M	IU	6-nitro-2-piperazin-1-yl-4-prop-2-enylquinoline
DM9WT8M	DE	Discovery agent

DMGYK25	ID	DMGYK25
DMGYK25	DN	4ALPHA-(HYDROXYMETHYL)-4ALPHA-DEMETHYLTERRITREM B
DMGYK25	HS	Investigative
DMGYK25	SN	CHEMBL464537; 4alpha-(hydroxymethyl)-4alpha-demethylterritrem B; BDBM50292394; 4beta-Hyroxymethyl-4beta-demethylterritrem B
DMGYK25	DT	Small molecular drug
DMGYK25	PC	10030248
DMGYK25	MW	542.6
DMGYK25	FM	C29H34O10
DMGYK25	IC	InChI=1S/C29H34O10/c1-25(15-30)8-7-22(31)27(3)28(25,33)10-9-26(2)29(27,34)14-17-19(39-26)13-18(38-24(17)32)16-11-20(35-4)23(37-6)21(12-16)36-5/h7-8,11-13,30,33-34H,9-10,14-15H2,1-6H3/t25-,26+,27-,28+,29+/m0/s1
DMGYK25	CS	C[C@@]12CC[C@]3([C@](C=CC(=O)[C@@]3([C@]1(CC4=C(O2)C=C(OC4=O)C5=CC(=C(C(=C5)OC)OC)OC)O)C)(C)CO)O
DMGYK25	IK	PXIKKOJKOBCLTQ-XPLNXOJDSA-N
DMGYK25	IU	(1S,2S,6S,7R,10R)-1,7-dihydroxy-6-(hydroxymethyl)-2,6,10-trimethyl-14-(3,4,5-trimethoxyphenyl)-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-4,12(17),13-triene-3,16-dione
DMGYK25	DE	Discovery agent

DMTSPLX	ID	DMTSPLX
DMTSPLX	DN	4alpha-PDD
DMTSPLX	HS	Investigative
DMTSPLX	SN	4alpha-phorbol 12,13-didecanoate; 4alpha-phorbol-didecanoate
DMTSPLX	DT	Small molecular drug
DMTSPLX	PC	452544
DMTSPLX	MW	672.9
DMTSPLX	FM	C40H64O8
DMTSPLX	IC	InChI=1S/C40H64O8/c1-7-9-11-13-15-17-19-21-32(42)47-36-28(4)39(46)30(24-29(26-41)25-38(45)31(39)23-27(3)35(38)44)34-37(5,6)40(34,36)48-33(43)22-20-18-16-14-12-10-8-2/h23-24,28,30-31,34,36,41,45-46H,7-22,25-26H2,1-6H3/t28-,30+,31-,34-,36-,38+,39-,40-/m1/s1
DMTSPLX	CS	CCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)CCCCCCCCC)O)C
DMTSPLX	IK	DGOSGFYDFDYMCW-OEFRVDPMSA-N
DMTSPLX	IU	[(1S,2S,6S,10S,11R,13S,14R,15R)-13-decanoyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] decanoate
DMTSPLX	CA	CAS 27536-56-7
DMTSPLX	CB	CHEBI:139299
DMTSPLX	DE	Discovery agent

DMUOLES	ID	DMUOLES
DMUOLES	DN	4alpha-PDH
DMUOLES	HS	Investigative
DMUOLES	SN	4alpha-phorbol 12,13-dihexanoate
DMUOLES	DT	Small molecular drug
DMUOLES	PC	42638006
DMUOLES	MW	560.7
DMUOLES	FM	C32H48O8
DMUOLES	IC	InChI=1S/C32H48O8/c1-7-9-11-13-24(34)39-28-20(4)31(38)22(16-21(18-33)17-30(37)23(31)15-19(3)27(30)36)26-29(5,6)32(26,28)40-25(35)14-12-10-8-2/h15-16,20,22-23,26,28,33,37-38H,7-14,17-18H2,1-6H3/t20-,22+,23-,26-,28-,30+,31-,32-/m1/s1
DMUOLES	CS	CCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)CCCCC)O)C
DMUOLES	IK	XGPRSRGBAHBMAF-QYSBVNMQSA-N
DMUOLES	IU	[(1S,2S,6S,10S,11R,13S,14R,15R)-13-hexanoyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] hexanoate
DMUOLES	DE	Discovery agent

DMYNASR	ID	DMYNASR
DMYNASR	DN	4-AMBA
DMYNASR	HS	Investigative
DMYNASR	SN	4-(Aminomethyl)benzoic acid; 56-91-7; 4-Carboxybenzylamine; Pamba; 4-Aminomethylbenzoic acid; Styptopur; Gumbix; p-Aminomethylbenzoic acid; Aminomethylbenzoic acid; Benzoic acid, 4-(aminomethyl)-; Benzylamine-4-carboxylic acid; alpha-Amino-p-toluic acid; p-(Aminomethyl)benzoic acid; Aminomethyl benzoic acid; UNII-68WG9JKC7L; 4-Aminomethyl-benzoic acid; 4-(Aminomethyl)benzoesaeure; NSC41629; EINECS 200-297-9; NSC 41629; 68WG9JKC7L; .alpha.-Amino-p-toluic acid; CHEMBL328875; p-Toluic acid, .alpha.-amino-
DMYNASR	DT	Small molecular drug
DMYNASR	PC	65526
DMYNASR	MW	151.16
DMYNASR	FM	C8H9NO2
DMYNASR	IC	InChI=1S/C8H9NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h1-4H,5,9H2,(H,10,11)
DMYNASR	CS	C1=CC(=CC=C1CN)C(=O)O
DMYNASR	IK	QCTBMLYLENLHLA-UHFFFAOYSA-N
DMYNASR	IU	4-(aminomethyl)benzoic acid
DMYNASR	CA	CAS 56-91-7
DMYNASR	CB	CHEBI:134774
DMYNASR	DE	Discovery agent

DMYX34S	ID	DMYX34S
DMYX34S	DN	4-Amino Hexanoic Acid
DMYX34S	HS	Investigative
DMYX34S	SN	4-Aminohexanoic acid; 5415-99-6; Hexanoic acid, 4-amino-; g-aminocaproic acid; 4-ethyl aminobutyric acid; AC1L3CX4; SCHEMBL900872; CTK1H4537; MolPort-006-169-599; ALBB-018090; NSC11326; NSC-11326; AKOS000277394; AKOS017258812; Hexanoic acid, 4-amino-, hydrochloride
DMYX34S	DT	Small molecular drug
DMYX34S	PC	46936928
DMYX34S	MW	131.17
DMYX34S	FM	C6H13NO2
DMYX34S	IC	InChI=1S/C6H13NO2/c1-2-5(7)3-4-6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1
DMYX34S	CS	CC[C@@H](CCC(=O)O)N
DMYX34S	IK	ROFNJLCLYMMXCT-YFKPBYRVSA-N
DMYX34S	IU	(4S)-4-aminohexanoic acid
DMYX34S	CA	CAS 1334472-86-4
DMYX34S	DE	Discovery agent

DMNXSM2	ID	DMNXSM2
DMNXSM2	DN	4-amino-1,2,5-oxadiazole-3-carboximidamide
DMNXSM2	HS	Investigative
DMNXSM2	DT	Small molecular drug
DMNXSM2	PC	45078766
DMNXSM2	MW	127.11
DMNXSM2	FM	C3H5N5O
DMNXSM2	IC	InChI=1S/C3H5N5O/c4-2(5)1-3(6)8-9-7-1/h(H3,4,5)(H2,6,8)
DMNXSM2	CS	C1(=NON=C1N)C(=N)N
DMNXSM2	IK	YHIJOLKAHGHVML-UHFFFAOYSA-N
DMNXSM2	IU	4-amino-1,2,5-oxadiazole-3-carboximidamide
DMNXSM2	DE	Discovery agent

DMU49H6	ID	DMU49H6
DMU49H6	DN	4-amino-1,8-naphthalimide
DMU49H6	HS	Investigative
DMU49H6	SN	4-Amino-1,8-naphthalimide; 1742-95-6; 4-Aminonaphthalimide; 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE; 6-Amino-1H-benzo[de]isoquinoline-1,3(2H)-dione; 4-Aminonaphthalene-1,8-dicarboximide; Naphthalimide, 4-amino-; DFP 1; 1H-Benz[de]isoquinoline-1,3(2H)-dione, 6-amino-; EINECS 217-110-1; BRN 0177185; 6-aminobenzo[de]isoquinoline-1,3-dione; PARP Inhibitor V, 4-ANI; CHEMBL338790; CHEBI:40071; SSMIFVHARFVINF-UHFFFAOYSA-N; 6-Amino-1H-benz(de)isoquinoline-1,3(2H)-dione; 4-AMINO-1,8 NAPHTHALIMIDE
DMU49H6	DT	Small molecular drug
DMU49H6	PC	1720
DMU49H6	MW	212.2
DMU49H6	FM	C12H8N2O2
DMU49H6	IC	InChI=1S/C12H8N2O2/c13-9-5-4-8-10-6(9)2-1-3-7(10)11(15)14-12(8)16/h1-5H,13H2,(H,14,15,16)
DMU49H6	CS	C1=CC2=C(C=CC3=C2C(=C1)C(=O)NC3=O)N
DMU49H6	IK	SSMIFVHARFVINF-UHFFFAOYSA-N
DMU49H6	IU	6-aminobenzo[de]isoquinoline-1,3-dione
DMU49H6	CA	CAS 1742-95-6
DMU49H6	CB	CHEBI:40071
DMU49H6	DE	Discovery agent

DM7X59V	ID	DM7X59V
DM7X59V	DN	4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile
DM7X59V	HS	Investigative
DM7X59V	SN	MLS000055002; 4-amino-2,6-diphenylpyrimidine-5-carbonitrile; SMR000065808; 4-amino-2,6-diphenyl-5-pyrimidinecarbonitrile; AC1M4AA8; 4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile; CHEMBL260615; BDBM49037; cid_2303947; MolPort-003-996-370; HMS2490H05; ZINC3098930; AKOS003621107; MCULE-1850499298; 20954-77-2; FT-0711858; 4-azanyl-2,6-diphenyl-pyrimidine-5-carbonitrile
DM7X59V	DT	Small molecular drug
DM7X59V	PC	2303947
DM7X59V	MW	272.3
DM7X59V	FM	C17H12N4
DM7X59V	IC	InChI=1S/C17H12N4/c18-11-14-15(12-7-3-1-4-8-12)20-17(21-16(14)19)13-9-5-2-6-10-13/h1-10H,(H2,19,20,21)
DM7X59V	CS	C1=CC=C(C=C1)C2=C(C(=NC(=N2)C3=CC=CC=C3)N)C#N
DM7X59V	IK	RVAUJCJDJMOIOL-UHFFFAOYSA-N
DM7X59V	IU	4-amino-2,6-diphenylpyrimidine-5-carbonitrile
DM7X59V	DE	Discovery agent

DMINUHD	ID	DMINUHD
DMINUHD	DN	4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid
DMINUHD	HS	Investigative
DMINUHD	SN	130525-62-1; 4-amino-2-deoxy-2,3-dehydro-n-neuraminic acid; 4-AM-DANA; CHEMBL52270; 4-Amino-neu5Ac2en; 5-(Acetylamino)-4-amino-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic Acid; 4AM; Zanamivir Amine; (4S,5R,6R)-5-Acetylamino-4-amino-6-((1R,2R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid; (2R,3R,4S)-3-acetamido-4-amino-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DMINUHD	DT	Small molecular drug
DMINUHD	PC	445533
DMINUHD	MW	290.27
DMINUHD	FM	C11H18N2O7
DMINUHD	IC	InChI=1S/C11H18N2O7/c1-4(15)13-8-5(12)2-7(11(18)19)20-10(8)9(17)6(16)3-14/h2,5-6,8-10,14,16-17H,3,12H2,1H3,(H,13,15)(H,18,19)/t5-,6+,8+,9+,10+/m0/s1
DMINUHD	CS	CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)N
DMINUHD	IK	NKENBBIXEGPQLS-UFGQHTETSA-N
DMINUHD	IU	(2R,3R,4S)-3-acetamido-4-amino-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DMINUHD	CA	CAS 130525-62-1
DMINUHD	DE	Discovery agent

DM3MUF1	ID	DM3MUF1
DM3MUF1	DN	4-amino-2H-chromen-2-one
DM3MUF1	HS	Investigative
DM3MUF1	SN	4-Amino-chromen-2-one; 4-Aminocoumarin; 53348-92-8; 4-amino-2H-chromen-2-one; 4-Amino-2H-1-benzopyran-2-one; 2H-1-Benzopyran-2-one, 4-amino-; UNII-SCI2054E4F; CHEMBL240482; SCI2054E4F; Coumarin, 4-amino-; 4-aminochromen-2-one; AC1LGGAS; Coumarin, 4-amino- (7CI); SCHEMBL4396062; AC1Q69X0; CTK7H2649; DTXSID90201509; MolPort-000-000-981; AHZAKFLOHIRCDU-UHFFFAOYSA-N; ZINC337346; STL371135; BDBM50226833; 4-[Amino]-2H-1-benzopyran-2-one; AKOS004909244; FCH1162846; MCULE-3726196442; MB00371; LS-39436; DB-071668; KB-189290; FT-0740005; A58124
DM3MUF1	DT	Small molecular drug
DM3MUF1	PC	820807
DM3MUF1	MW	161.16
DM3MUF1	FM	C9H7NO2
DM3MUF1	IC	InChI=1S/C9H7NO2/c10-7-5-9(11)12-8-4-2-1-3-6(7)8/h1-5H,10H2
DM3MUF1	CS	C1=CC=C2C(=C1)C(=CC(=O)O2)N
DM3MUF1	IK	AHZAKFLOHIRCDU-UHFFFAOYSA-N
DM3MUF1	IU	4-aminochromen-2-one
DM3MUF1	CA	CAS 53348-92-8
DM3MUF1	DE	Discovery agent

DMOJTZD	ID	DMOJTZD
DMOJTZD	DN	4-amino-2-p-tolylisoindoline-1,3-dione
DMOJTZD	HS	Investigative
DMOJTZD	SN	4-Amino-2-p-tolylisoindole-1,3-dione; CHEMBL600405; 20871-07-2; 4-Amino-2-p-tolyl-isoindole-1,3-dione; 4-Amino-2-(p-tolyl)isoindoline-1,3-dione; 4-amino-2-p-tolylisoindoline-1,3-dione; AC1LHA6Z; Oprea1_716953; Oprea1_214378; MolPort-000-151-255; ZINC360744; BDBM50306747; AKOS000727908; MCULE-4928093173; BAS 00084697; KB-189090
DMOJTZD	DT	Small molecular drug
DMOJTZD	PC	834731
DMOJTZD	MW	252.27
DMOJTZD	FM	C15H12N2O2
DMOJTZD	IC	InChI=1S/C15H12N2O2/c1-9-5-7-10(8-6-9)17-14(18)11-3-2-4-12(16)13(11)15(17)19/h2-8H,16H2,1H3
DMOJTZD	CS	CC1=CC=C(C=C1)N2C(=O)C3=C(C2=O)C(=CC=C3)N
DMOJTZD	IK	LTZXDGYVXKFIET-UHFFFAOYSA-N
DMOJTZD	IU	4-amino-2-(4-methylphenyl)isoindole-1,3-dione
DMOJTZD	CA	CAS 20871-07-2
DMOJTZD	DE	Discovery agent

DMIX81A	ID	DMIX81A
DMIX81A	DN	4-Amino-3-(2-chloro-phenyl)-butyric acid
DMIX81A	HS	Investigative
DMIX81A	SN	CHEMBL83245; 28311-34-4; 4-Amino-3-(2-chloro-phenyl)-butyric acid; SCHEMBL349398; BDBM50007121; AKOS015157811; 4-Amino-3-(2-chlorophenyl)butyric acid; 4-amino-3-(2-chlorophenyl)butanoic acid; 4-amino-3-(-chlorophenyl)-butanoic acid; Benzenepropanoic acid, beta-(aminomethyl)-2-chloro-
DMIX81A	DT	Small molecular drug
DMIX81A	PC	21950279
DMIX81A	MW	213.66
DMIX81A	FM	C10H12ClNO2
DMIX81A	IC	InChI=1S/C10H12ClNO2/c11-9-4-2-1-3-8(9)7(6-12)5-10(13)14/h1-4,7H,5-6,12H2,(H,13,14)
DMIX81A	CS	C1=CC=C(C(=C1)C(CC(=O)O)CN)Cl
DMIX81A	IK	RNSIJRUPQJHCBR-UHFFFAOYSA-N
DMIX81A	IU	4-amino-3-(2-chlorophenyl)butanoic acid
DMIX81A	DE	Discovery agent

DMGI0YV	ID	DMGI0YV
DMGI0YV	DN	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid
DMGI0YV	HS	Investigative
DMGI0YV	SN	CHEMBL448246; 3-(4-Hexyloxy-phenyl)-succinamic acid; AC1LCKXS; SMR000008837; MLS000073581; 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid; cid_651854; HMS2162F22; HMS3313H20; BDBM50247490; AKOS000505159; AKOS030483668; BAS 00404306; 4-amino-3-(4-hexoxyphenyl)-4-oxobutanoic acid; SR-01000514729
DMGI0YV	DT	Small molecular drug
DMGI0YV	PC	651854
DMGI0YV	MW	293.36
DMGI0YV	FM	C16H23NO4
DMGI0YV	IC	InChI=1S/C16H23NO4/c1-2-3-4-5-10-21-13-8-6-12(7-9-13)14(16(17)20)11-15(18)19/h6-9,14H,2-5,10-11H2,1H3,(H2,17,20)(H,18,19)
DMGI0YV	CS	CCCCCCOC1=CC=C(C=C1)C(CC(=O)O)C(=O)N
DMGI0YV	IK	RRXQHLQCQYPPMF-UHFFFAOYSA-N
DMGI0YV	IU	4-amino-3-(4-hexoxyphenyl)-4-oxobutanoic acid
DMGI0YV	DE	Discovery agent

DMVKPF1	ID	DMVKPF1
DMVKPF1	DN	4-Amino-3-(4-fluoro-phenyl)-butyric acid
DMVKPF1	HS	Investigative
DMVKPF1	SN	(R)-4-AMINO-3-(4-FLUOROPHENYL)BUTANOIC ACID; 741217-33-4; CHEMBL301492; (3R)-4-amino-3-(4-fluorophenyl)butanoic acid; AK-87533; PubChem18292; SCHEMBL351702; CTK5D9380; KS-00000QGP; DTXSID00557064; MolPort-023-332-505; ZINC6093177; ANW-65813; 1505AC; BDBM50368295; AKOS006325793; LS30154; CA-2040; DS-2490; AC-22391; AJ-55750; TC-154558; AX8236708; KB-210177; ST24020736; (R)-3-(4-Fluorophenyl)-4-aminobutyric acid
DMVKPF1	DT	Small molecular drug
DMVKPF1	PC	103611
DMVKPF1	MW	197.21
DMVKPF1	FM	C10H12FNO2
DMVKPF1	IC	InChI=1S/C10H12FNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)
DMVKPF1	CS	C1=CC(=CC=C1C(CC(=O)O)CN)F
DMVKPF1	IK	QWHXHLDNSXLAPX-UHFFFAOYSA-N
DMVKPF1	IU	4-amino-3-(4-fluorophenyl)butanoic acid
DMVKPF1	CA	CAS 52237-19-1
DMVKPF1	DE	Discovery agent

DMTO8NV	ID	DMTO8NV
DMTO8NV	DN	4-Amino-3-(5-bromo-thiophen-2-yl)-butyric acid
DMTO8NV	HS	Investigative
DMTO8NV	SN	CHEMBL314177; 4-Amino-3-(5-bromo-thiophen-2-yl)-butyric acid; SCHEMBL340904; beta-(5-Bromo-2-thienyl)GABA; BDBM50007108; AKOS022983047; 4-amino-3-(5-bromothien-2-yl)butanoic acid
DMTO8NV	DT	Small molecular drug
DMTO8NV	PC	10220920
DMTO8NV	MW	264.14
DMTO8NV	FM	C8H10BrNO2S
DMTO8NV	IC	InChI=1S/C8H10BrNO2S/c9-7-2-1-6(13-7)5(4-10)3-8(11)12/h1-2,5H,3-4,10H2,(H,11,12)
DMTO8NV	CS	C1=C(SC(=C1)Br)C(CC(=O)O)CN
DMTO8NV	IK	AGSZIPFOQSAPON-UHFFFAOYSA-N
DMTO8NV	IU	4-amino-3-(5-bromothiophen-2-yl)butanoic acid
DMTO8NV	DE	Discovery agent

DM415DB	ID	DM415DB
DM415DB	DN	4-Amino-3-(5-chloro-thiophen-2-yl)-butyric acid
DM415DB	HS	Investigative
DM415DB	SN	133933-81-0; 4-amino-3-(5-chlorothiophen-2-yl)butanoic acid; CHEMBL87482; 4-AMINO-3- (5-CHLOROTHIEN-2-YL)BUTANOIC ACID; 2-Thiophenepropanoicacid, b-(aminomethyl)-5-chloro-; (+/-)-4-AMINO-3-(5-CHLORO-2-THIENYL)-BUTANOIC ACID; 4-Actba; KBio3_002901; ACMC-20mv5p; AC1L2PFH; Spectrum2_001171; Spectrum3_001889; Spectrum4_000231; Spectrum5_001875; 4-Amino-3-(5-chloro-2-thienyl)butyric acid; Biomol-NT_000250; BSPBio_003398; KBioGR_000921; 4-Amino-3-(5-chloro-thiophen-2-yl)-butyric acid; SCHEMBL342009; SPBio_001181; BPBio1_000706
DM415DB	DT	Small molecular drug
DM415DB	PC	125917
DM415DB	MW	219.69
DM415DB	FM	C8H10ClNO2S
DM415DB	IC	InChI=1S/C8H10ClNO2S/c9-7-2-1-6(13-7)5(4-10)3-8(11)12/h1-2,5H,3-4,10H2,(H,11,12)
DM415DB	CS	C1=C(SC(=C1)Cl)C(CC(=O)O)CN
DM415DB	IK	CDFQDLUHBLZCGL-UHFFFAOYSA-N
DM415DB	IU	4-amino-3-(5-chlorothiophen-2-yl)butanoic acid
DM415DB	CA	CAS 151563-54-1
DM415DB	DE	Discovery agent

DMEDRAX	ID	DMEDRAX
DMEDRAX	DN	4-Amino-3-(5-methyl-thiophen-2-yl)-butyric acid
DMEDRAX	HS	Investigative
DMEDRAX	SN	133933-77-4; CHEMBL86144; 4-amino-3-(5-methylthiophen-2-yl)butanoic acid; 4-Amtba; 4-Amino-3-(5-methyl-2-thienyl)butyric acid; AC1L2PFE; ACMC-1C1U4; 4-Amino-3-(5-methyl-thiophen-2-yl)-butyric acid; SCHEMBL341475; CTK0H6620; beta-(5-Methyl-2-thienyl)GABA; BDBM50007107; AKOS022919013; 4-amino-3-(5-methylthien-2-yl)butanoic acid; 2-Thiophenepropanoic acid, beta-(aminomethyl)-5-methyl-, (+-)-
DMEDRAX	DT	Small molecular drug
DMEDRAX	PC	125916
DMEDRAX	MW	199.27
DMEDRAX	FM	C9H13NO2S
DMEDRAX	IC	InChI=1S/C9H13NO2S/c1-6-2-3-8(13-6)7(5-10)4-9(11)12/h2-3,7H,4-5,10H2,1H3,(H,11,12)
DMEDRAX	CS	CC1=CC=C(S1)C(CC(=O)O)CN
DMEDRAX	IK	RPNWEWXYTFWDTR-UHFFFAOYSA-N
DMEDRAX	IU	4-amino-3-(5-methylthiophen-2-yl)butanoic acid
DMEDRAX	CA	CAS 133933-77-4
DMEDRAX	DE	Discovery agent

DMDCQAX	ID	DMDCQAX
DMDCQAX	DN	4-amino-3,5-dibromobenzenesulfonamide
DMDCQAX	HS	Investigative
DMDCQAX	SN	4-amino-3,5-dibromobenzenesulfonamide; 39150-45-3; 3,5-Dibromosulfanilamide; 2,6-Dibromosulfanilamide; 3,5-Dibromosulphanilamide; CHEMBL306195; DLXJPWSYRLLYSV-UHFFFAOYSA-N; AK109126; 4-amino-3,5-dibromobenzene-1-sulfonamide; Benzenesulfonamide, 4-amino-3,5-dibromo-; W-202619; EINECS 254-321-8; 4-Amino-3,5-dibromobenzenesulphonamide; ACMC-209j3o; AC1Q50HX; AC1MJ34Y; halogenosulfanilamide deriv. 12; SCHEMBL11136228; BDBM11611; CTK4I0998; DTXSID20192395; MolPort-001-780-206; ZINC2146706; ALBB-026584; ZX-AN025095; KS-00000NE9; 5104AB
DMDCQAX	DT	Small molecular drug
DMDCQAX	PC	3084733
DMDCQAX	MW	330
DMDCQAX	FM	C6H6Br2N2O2S
DMDCQAX	IC	InChI=1S/C6H6Br2N2O2S/c7-4-1-3(13(10,11)12)2-5(8)6(4)9/h1-2H,9H2,(H2,10,11,12)
DMDCQAX	CS	C1=C(C=C(C(=C1Br)N)Br)S(=O)(=O)N
DMDCQAX	IK	DLXJPWSYRLLYSV-UHFFFAOYSA-N
DMDCQAX	IU	4-amino-3,5-dibromobenzenesulfonamide
DMDCQAX	CA	CAS 39150-45-3
DMDCQAX	DE	Discovery agent

DM1IHCV	ID	DM1IHCV
DM1IHCV	DN	4-Amino-3-benzofuran-2-yl-butyric acid
DM1IHCV	HS	Investigative
DM1IHCV	SN	121838-28-6; CHEMBL349520; 4-Amino-3-benzo(b)furan-2-ylbutanoic acid; 2-Benzofuranpropanoicacid, b-(aminomethyl)-; 4-amino-3-benzo[b]furan-2-ylbutanoic acid; Bfg-butanoic acid; 4-Amino-3-benzofuran-2-yl-butyric acid; ACMC-20mpq1; AC1L2VQL; 4-amino-3-(1-benzofuran-2-yl)butanoic acid; 2-Benzofuranpropanoic acid, beta-(aminomethyl)-; CTK4B2770; BDBM50021756; AKOS015439841; KB-240006
DM1IHCV	DT	Small molecular drug
DM1IHCV	PC	129512
DM1IHCV	MW	219.24
DM1IHCV	FM	C12H13NO3
DM1IHCV	IC	InChI=1S/C12H13NO3/c13-7-9(6-12(14)15)11-5-8-3-1-2-4-10(8)16-11/h1-5,9H,6-7,13H2,(H,14,15)
DM1IHCV	CS	C1=CC=C2C(=C1)C=C(O2)C(CC(=O)O)CN
DM1IHCV	IK	SRLRWPSSQWUHQC-UHFFFAOYSA-N
DM1IHCV	IU	4-amino-3-(1-benzofuran-2-yl)butanoic acid
DM1IHCV	CA	CAS 121838-28-6
DM1IHCV	DE	Discovery agent

DMVUCZK	ID	DMVUCZK
DMVUCZK	DN	4-Amino-3-bromo-benzenesulfonamide
DMVUCZK	HS	Investigative
DMVUCZK	SN	4-amino-3-bromobenzenesulfonamide
DMVUCZK	PC	3526523
DMVUCZK	MW	251.1
DMVUCZK	FM	C6H7BrN2O2S
DMVUCZK	IC	InChI=1S/C6H7BrN2O2S/c7-5-3-4(12(9,10)11)1-2-6(5)8/h1-3H,8H2,(H2,9,10,11)
DMVUCZK	CS	C1=CC(=C(C=C1S(=O)(=O)N)Br)N
DMVUCZK	IK	KQEVQYJWCZRLTJ-UHFFFAOYSA-N
DMVUCZK	IU	4-amino-3-bromobenzenesulfonamide
DMVUCZK	CA	CAS 53297-69-1
DMVUCZK	DE	Discovery agent

DMERTQ4	ID	DMERTQ4
DMERTQ4	DN	4-Amino-3-chloro-benzenesulfonamide
DMERTQ4	HS	Investigative
DMERTQ4	SN	4-amino-3-chlorobenzenesulfonamide
DMERTQ4	DT	Small molecular drug
DMERTQ4	PC	1502014
DMERTQ4	MW	206.65
DMERTQ4	FM	C6H7ClN2O2S
DMERTQ4	IC	InChI=1S/C6H7ClN2O2S/c7-5-3-4(12(9,10)11)1-2-6(5)8/h1-3H,8H2,(H2,9,10,11)
DMERTQ4	CS	C1=CC(=C(C=C1S(=O)(=O)N)Cl)N
DMERTQ4	IK	LFIOFZKZCDMGFG-UHFFFAOYSA-N
DMERTQ4	IU	4-amino-3-chlorobenzenesulfonamide
DMERTQ4	CA	CAS 53297-68-0
DMERTQ4	DE	Discovery agent

DMR9M6H	ID	DMR9M6H
DMR9M6H	DN	4-amino-3-fluoro-5-iodobenzenesulfonamide
DMR9M6H	HS	Investigative
DMR9M6H	SN	CHEMBL69813; 4-amino-3-fluoro-5-iodobenzenesulfonamide; 4-amino-3-fluoro-5-iodobenzene-1-sulfonamide; halogenosulfanilamide deriv. 8
DMR9M6H	DT	Small molecular drug
DMR9M6H	PC	10903168
DMR9M6H	MW	316.09
DMR9M6H	FM	C6H6FIN2O2S
DMR9M6H	IC	InChI=1S/C6H6FIN2O2S/c7-4-1-3(13(10,11)12)2-5(8)6(4)9/h1-2H,9H2,(H2,10,11,12)
DMR9M6H	CS	C1=C(C=C(C(=C1F)N)I)S(=O)(=O)N
DMR9M6H	IK	KDXNVSMWRXCNMY-UHFFFAOYSA-N
DMR9M6H	IU	4-amino-3-fluoro-5-iodobenzenesulfonamide
DMR9M6H	DE	Discovery agent

DMIQ3VR	ID	DMIQ3VR
DMIQ3VR	DN	4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR	HS	Investigative
DMIQ3VR	SN	4-amino-3-fluorobenzenesulfonamide
DMIQ3VR	PC	4687472
DMIQ3VR	MW	190.2
DMIQ3VR	FM	C6H7FN2O2S
DMIQ3VR	IC	InChI=1S/C6H7FN2O2S/c7-5-3-4(12(9,10)11)1-2-6(5)8/h1-3H,8H2,(H2,9,10,11)
DMIQ3VR	CS	C1=CC(=C(C=C1S(=O)(=O)N)F)N
DMIQ3VR	IK	HVFBADWBKHAPKV-UHFFFAOYSA-N
DMIQ3VR	IU	4-amino-3-fluorobenzenesulfonamide
DMIQ3VR	CA	CAS 2368-84-5
DMIQ3VR	DE	Discovery agent

DMPY8D3	ID	DMPY8D3
DMPY8D3	DN	4-Amino-3-hydroxy-butyric acid
DMPY8D3	HS	Investigative
DMPY8D3	SN	4-Amino-3-hydroxybutanoic acid; 924-49-2; 4-Amino-3-hydroxybutyric acid; Gabob; DL-4-Amino-3-hydroxybutyric acid; 3-Hydroxy-GABA; Gamibetal; Gabomade; Gaboril; Idramina; Gaminal; Buksamin; Gabimex; Bogil; 352-21-6; Gamma-amino-beta-hydroxybutyric acid; Butanoic acid, 4-amino-3-hydroxy-; Buxamine; Buxamin; Gabobe; beta-Oxy-gaba; 3-Hydroxy-4-aminobutyric acid; Buxamine (VAN); NSC 40244; gamma-Amino-beta-hydroxybutyrate; beta-Hydroxy-gamma-aminobutyrate; 4-Amino-3-hydroxy-butyric acid; BUTYRIC ACID, 4-AMINO-3-HYDROXY-
DMPY8D3	DT	Small molecular drug
DMPY8D3	PC	2149
DMPY8D3	MW	119.12
DMPY8D3	FM	C4H9NO3
DMPY8D3	IC	InChI=1S/C4H9NO3/c5-2-3(6)1-4(7)8/h3,6H,1-2,5H2,(H,7,8)
DMPY8D3	CS	C(C(CN)O)C(=O)O
DMPY8D3	IK	YQGDEPYYFWUPGO-UHFFFAOYSA-N
DMPY8D3	IU	4-amino-3-hydroxybutanoic acid
DMPY8D3	CA	CAS 924-49-2
DMPY8D3	CB	CHEBI:16080
DMPY8D3	DE	Discovery agent

DMCOYHR	ID	DMCOYHR
DMCOYHR	DN	4-Amino-3-iodo-benzenesulfonamide
DMCOYHR	HS	Investigative
DMCOYHR	SN	4-amino-3-iodobenzenesulfonamide
DMCOYHR	PC	9861037
DMCOYHR	MW	298.1
DMCOYHR	FM	C6H7IN2O2S
DMCOYHR	IC	InChI=1S/C6H7IN2O2S/c7-5-3-4(12(9,10)11)1-2-6(5)8/h1-3H,8H2,(H2,9,10,11)
DMCOYHR	CS	C1=CC(=C(C=C1S(=O)(=O)N)I)N
DMCOYHR	IK	HCODCRHNVCTCTR-UHFFFAOYSA-N
DMCOYHR	IU	4-amino-3-iodobenzenesulfonamide
DMCOYHR	CA	CAS 60154-06-5
DMCOYHR	DE	Discovery agent

DMZJS2E	ID	DMZJS2E
DMZJS2E	DN	4-Amino-3-thiophen-2-yl-butyric acid
DMZJS2E	HS	Investigative
DMZJS2E	SN	4-Amino-3-(2-thienyl)butanoic acid; 133933-76-3; CHEMBL315476; 4-amino-3-(thien-2-yl)butanoic acid; 2-Thiophenepropanoicacid, b-(aminomethyl)-; 98593-59-0; 2-BTG; 4-amino-3-thiophen-2-ylbutanoic acid; 4-Amino-3-thiophen-2-yl-butyric acid; beta-(2-Thienyl)-gamma-aminobutyric acid; ACMC-1C0HP; AC1L2ZM2; SCHEMBL341042; CTK4B8884; BDBM50007117; 4-Amino-3-(2-thienyl)butyric acid; 4-amino-3-(2-thienyl) butyric acid; AKOS014313933
DMZJS2E	DT	Small molecular drug
DMZJS2E	PC	131689
DMZJS2E	MW	185.25
DMZJS2E	FM	C8H11NO2S
DMZJS2E	IC	InChI=1S/C8H11NO2S/c9-5-6(4-8(10)11)7-2-1-3-12-7/h1-3,6H,4-5,9H2,(H,10,11)
DMZJS2E	CS	C1=CSC(=C1)C(CC(=O)O)CN
DMZJS2E	IK	QDVRXIPQICAUFK-UHFFFAOYSA-N
DMZJS2E	IU	4-amino-3-thiophen-2-ylbutanoic acid
DMZJS2E	CA	CAS 98593-59-0
DMZJS2E	DE	Discovery agent

DMQ6EBR	ID	DMQ6EBR
DMQ6EBR	DN	4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMQ6EBR	HS	Investigative
DMQ6EBR	SN	CHEMBL391136; BDBM50213140
DMQ6EBR	DT	Small molecular drug
DMQ6EBR	PC	44431968
DMQ6EBR	MW	311.5
DMQ6EBR	FM	C21H29NO
DMQ6EBR	IC	InChI=1S/C21H29NO/c1-4-5-6-7-14-21(2,3)17-10-13-19(20(23)15-17)16-8-11-18(22)12-9-16/h8-13,15,23H,4-7,14,22H2,1-3H3
DMQ6EBR	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC=C(C=C2)N)O
DMQ6EBR	IK	SDBAMIYHTMYHHO-UHFFFAOYSA-N
DMQ6EBR	IU	2-(4-aminophenyl)-5-(2-methyloctan-2-yl)phenol
DMQ6EBR	DE	Discovery agent

DM9S5V0	ID	DM9S5V0
DM9S5V0	DN	4'-Amino-4-hydroxychalcone
DM9S5V0	HS	Investigative
DM9S5V0	SN	CHEMBL383563; 1-(4-aminophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 4''-Amino-4-hydroxychalcone; AC1O21K2; SCHEMBL3762443; MolPort-019-723-769; ZINC4099897; SBB099103; BDBM50174839; AN-308/25123008; (2E)-1-(4-aminophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
DM9S5V0	DT	Small molecular drug
DM9S5V0	PC	4525387
DM9S5V0	MW	239.27
DM9S5V0	FM	C15H13NO2
DM9S5V0	IC	InChI=1S/C15H13NO2/c16-13-6-4-12(5-7-13)15(18)10-3-11-1-8-14(17)9-2-11/h1-10,17H,16H2
DM9S5V0	CS	C1=CC(=CC=C1C=CC(=O)C2=CC=C(C=C2)N)O
DM9S5V0	IK	GJKSOGFGWQZGRL-UHFFFAOYSA-N
DM9S5V0	IU	1-(4-aminophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
DM9S5V0	DE	Discovery agent

DMZRM0Q	ID	DMZRM0Q
DMZRM0Q	DN	4-amino-6-(4-octylphenyl)hexanoic acid
DMZRM0Q	HS	Investigative
DMZRM0Q	SN	CHEMBL325050; 4-amino-6-(4-octylphenyl)hexanoic Acid; SCHEMBL5462898; BDBM50147701; 4-Amino-6-(4-octyl-phenyl)-hexanoic acid
DMZRM0Q	DT	Small molecular drug
DMZRM0Q	PC	10125714
DMZRM0Q	MW	319.5
DMZRM0Q	FM	C20H33NO2
DMZRM0Q	IC	InChI=1S/C20H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(21)15-16-20(22)23/h9-12,19H,2-8,13-16,21H2,1H3,(H,22,23)
DMZRM0Q	CS	CCCCCCCCC1=CC=C(C=C1)CCC(CCC(=O)O)N
DMZRM0Q	IK	UUODWPRHRNIITI-UHFFFAOYSA-N
DMZRM0Q	IU	4-amino-6-(4-octylphenyl)hexanoic acid
DMZRM0Q	DE	Discovery agent

DMIWGZS	ID	DMIWGZS
DMIWGZS	DN	4-amino-6-chlorobenzene-1,3-disulfonamide
DMIWGZS	HS	Investigative
DMIWGZS	SN	121-30-2; 4-Amino-6-chlorobenzene-1,3-disulfonamide; 4-Amino-6-chloro-1,3-benzenedisulfonamide; Chloraminophenamide; Idorese; Salmid; Chloroaminophenamide; 1,3-Benzenedisulfonamide, 4-amino-6-chloro-; 5-Chloro-2,4-disulfamylaniline; 4-Amino-6-chloro-m-benzenedisulfonamide; 3-Chloro-4,6-disulfamoylaniline; 5-Chloro-2,4-disulfamoylaniline; UNII-3A52O8YREJ; Su 5683; 4-Amino-6-Chloro-1,3-Benzendisulfonamide; 3A52O8YREJ; CHEBI:3602; CHEMBL266240; 4-Amino-6-chlorobenzene-1,3-disulphonamide
DMIWGZS	DT	Small molecular drug
DMIWGZS	PC	67136
DMIWGZS	MW	285.7
DMIWGZS	FM	C6H8ClN3O4S2
DMIWGZS	IC	InChI=1S/C6H8ClN3O4S2/c7-3-1-4(8)6(16(10,13)14)2-5(3)15(9,11)12/h1-2H,8H2,(H2,9,11,12)(H2,10,13,14)
DMIWGZS	CS	C1=C(C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N)N
DMIWGZS	IK	IHJCXVZDYSXXFT-UHFFFAOYSA-N
DMIWGZS	IU	4-amino-6-chlorobenzene-1,3-disulfonamide
DMIWGZS	CA	CAS 121-30-2
DMIWGZS	CB	CHEBI:3602
DMIWGZS	DE	Discovery agent

DMP2GN7	ID	DMP2GN7
DMP2GN7	DN	4-aminobenzoic acid hydrazide
DMP2GN7	HS	Investigative
DMP2GN7	SN	4-Aminobenzohydrazide; 5351-17-7; 4-Aminobenzhydrazide; 4-Aminobenzoic acid hydrazide; Amben hydrazide; p-Aminobenzhydrazide; Aminostimil; p-Aminobenzoic acid hydrazide; 4-Aminobenzoylhydrazine; p-Aminobenzoyl hydrazide; Benzoic acid, 4-amino-, hydrazide; p-Aminobenzoic hydrazide; p-Aminobenzoylhydrazine; para-Aminobenzhydrazide; NSC 640; BENZOIC ACID, p-AMINO-, HYDRAZIDE; EINECS 226-324-4; Myeloperoxidase Inhibitor-I; BRN 0639053; AI3-52435; CHEMBL2170241; (4-Aminobenzoyl)hydrazide, 95%; WPBZMCGPFHZRHJ-UHFFFAOYSA-N
DMP2GN7	DT	Small molecular drug
DMP2GN7	PC	21450
DMP2GN7	MW	151.17
DMP2GN7	FM	C7H9N3O
DMP2GN7	IC	InChI=1S/C7H9N3O/c8-6-3-1-5(2-4-6)7(11)10-9/h1-4H,8-9H2,(H,10,11)
DMP2GN7	CS	C1=CC(=CC=C1C(=O)NN)N
DMP2GN7	IK	WPBZMCGPFHZRHJ-UHFFFAOYSA-N
DMP2GN7	IU	4-aminobenzohydrazide
DMP2GN7	CA	CAS 5351-17-7
DMP2GN7	DE	Discovery agent

DMHDB70	ID	DMHDB70
DMHDB70	DN	4-amino-biphenyl-3-carboxylic acid amide
DMHDB70	HS	Investigative
DMHDB70	SN	CHEMBL207940; 5-phenylanthranilamide; 2-amino-5-phenylbenzamide; SCHEMBL3781950; Amino-substituted benzamide, 8c; BDBM27462; ZINC13686738
DMHDB70	DT	Small molecular drug
DMHDB70	PC	11600944
DMHDB70	MW	212.25
DMHDB70	FM	C13H12N2O
DMHDB70	IC	InChI=1S/C13H12N2O/c14-12-7-6-10(8-11(12)13(15)16)9-4-2-1-3-5-9/h1-8H,14H2,(H2,15,16)
DMHDB70	CS	C1=CC=C(C=C1)C2=CC(=C(C=C2)N)C(=O)N
DMHDB70	IK	KLDLPUIJJYDCEE-UHFFFAOYSA-N
DMHDB70	IU	2-amino-5-phenylbenzamide
DMHDB70	DE	Discovery agent

DM6PQ5V	ID	DM6PQ5V
DM6PQ5V	DN	4-amino-N-(2-chlorophenyl)benzenesulfonamide
DM6PQ5V	HS	Investigative
DM6PQ5V	SN	19837-85-5; 4-amino-N-(2-chlorophenyl)benzenesulfonamide; 4-amino-N-(2-chlorophenyl)benzene-1-sulfonamide; 4-Amino-N-(2-chloro-phenyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(2-chlorophenyl)-; AC1MP5DG; AC1Q51WZ; SCHEMBL1970942; n1-2-chlorophenylsulphanilamide; CHEMBL227597; CTK4E2501; DTXSID20392191; XZQHDUUDKCHQIL-UHFFFAOYSA-N; MolPort-002-463-078; ZINC3885452; STL420385; BBL034801; AKOS000115492; NE25153; MCULE-7275329899; KB-289984; FT-0719132; N-(2-Chlorophenyl)-4-aminobenzenesulfonamide; EN300-02335
DM6PQ5V	DT	Small molecular drug
DM6PQ5V	PC	3405810
DM6PQ5V	MW	282.75
DM6PQ5V	FM	C12H11ClN2O2S
DM6PQ5V	IC	InChI=1S/C12H11ClN2O2S/c13-11-3-1-2-4-12(11)15-18(16,17)10-7-5-9(14)6-8-10/h1-8,15H,14H2
DM6PQ5V	CS	C1=CC=C(C(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)Cl
DM6PQ5V	IK	XZQHDUUDKCHQIL-UHFFFAOYSA-N
DM6PQ5V	IU	4-amino-N-(2-chlorophenyl)benzenesulfonamide
DM6PQ5V	CA	CAS 19837-85-5
DM6PQ5V	DE	Discovery agent

DMCUSD4	ID	DMCUSD4
DMCUSD4	DN	4-amino-N-(4-chlorophenyl)benzenesulfonamide
DMCUSD4	HS	Investigative
DMCUSD4	SN	4-amino-N-(4-chlorophenyl)benzenesulfonamide; 16803-92-2; 4-Amino-N-(4-chloro-phenyl)-benzenesulfonamide; CHEMBL227413; Benzenesulfonamide, 4-amino-N-(4-chlorophenyl)-; 4-amino-n-(4-chlorophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-chlorophenyl)-; [(4-aminophenyl)sulfonyl](4-chlorophenyl)amine; BAS 02102352; AC1Q3REH; AC1LG33E; ARONIS021171; AC1Q51X9; SCHEMBL14093755; KS-00003SYR; CTK4D2850; DTXSID90354963; MolPort-000-164-113; ZINC286765; ALBB-000053; BDBM50197705; 5394AD; BBL037004; SBB009347; STK091555
DMCUSD4	DT	Small molecular drug
DMCUSD4	PC	788021
DMCUSD4	MW	282.75
DMCUSD4	FM	C12H11ClN2O2S
DMCUSD4	IC	InChI=1S/C12H11ClN2O2S/c13-9-1-5-11(6-2-9)15-18(16,17)12-7-3-10(14)4-8-12/h1-8,15H,14H2
DMCUSD4	CS	C1=CC(=CC=C1N)S(=O)(=O)NC2=CC=C(C=C2)Cl
DMCUSD4	IK	RBJGYDGKXTYSSL-UHFFFAOYSA-N
DMCUSD4	IU	4-amino-N-(4-chlorophenyl)benzenesulfonamide
DMCUSD4	CA	CAS 16803-92-2
DMCUSD4	DE	Discovery agent

DMN19QP	ID	DMN19QP
DMN19QP	DN	4-amino-N-(4-iodophenyl)benzenesulfonamide
DMN19QP	HS	Investigative
DMN19QP	SN	6965-75-9; NSC63371; 4-amino-N-(4-iodophenyl)benzenesulfonamide; 4-amino-n-(4-iodo-phenyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(4-iodophenyl)-; 4-amino-N-(4-iodophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-iodophenyl)-; NSC 63371; Enamine_003086; AC1Q6VVM; AC1Q51XD; AC1L6LA2; AC1Q51XC; 4-IODOSULFANILANILIDE; CHEMBL227416; CTK5D0764; DTXSID00219913; MolPort-001-833-979; HMS1402M06; ZINC537958; NSC-63371; STK063720; AKOS000115972; NE11209; MCULE-7780071880; KB-290010; EN300-02869; SR-01000033730
DMN19QP	DT	Small molecular drug
DMN19QP	PC	247908
DMN19QP	MW	374.2
DMN19QP	FM	C12H11IN2O2S
DMN19QP	IC	InChI=1S/C12H11IN2O2S/c13-9-1-5-11(6-2-9)15-18(16,17)12-7-3-10(14)4-8-12/h1-8,15H,14H2
DMN19QP	CS	C1=CC(=CC=C1N)S(=O)(=O)NC2=CC=C(C=C2)I
DMN19QP	IK	GNYYVWOTRVNKCO-UHFFFAOYSA-N
DMN19QP	IU	4-amino-N-(4-iodophenyl)benzenesulfonamide
DMN19QP	CA	CAS 6965-75-9
DMN19QP	DE	Discovery agent

DMJZNX6	ID	DMJZNX6
DMJZNX6	DN	4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMJZNX6	HS	Investigative
DMJZNX6	SN	CHEMBL266026; 4-[[(4-aminophenyl)sulfonylamino]methyl]benzenesulfonamide; AC1NA7ER; SCHEMBL3789773; BDBM10871; ZINC6392199; aromatic/heteroaromatic sulfonamide 16; AKOS024362676; MCULE-5136189306; ST50993685; N-(4-Sulfamoylbenzyl)-4-aminobenzenesulfonamide; 4-amino-N-[(4-sulfamoylphenyl)methyl]benzene-1-sulfonamide; 4-({[(4-aminophenyl)sulfonyl]amino}methyl)benzenesulfonamide; Benzenesulfonamide, 4-amino-N-[[4-(aminosulfonyl)phenyl]methyl]-
DMJZNX6	DT	Small molecular drug
DMJZNX6	PC	4422372
DMJZNX6	MW	341.4
DMJZNX6	FM	C13H15N3O4S2
DMJZNX6	IC	InChI=1S/C13H15N3O4S2/c14-11-3-7-13(8-4-11)22(19,20)16-9-10-1-5-12(6-2-10)21(15,17)18/h1-8,16H,9,14H2,(H2,15,17,18)
DMJZNX6	CS	C1=CC(=CC=C1CNS(=O)(=O)C2=CC=C(C=C2)N)S(=O)(=O)N
DMJZNX6	IK	HHCXOFYGBAPOJR-UHFFFAOYSA-N
DMJZNX6	IU	4-[[(4-aminophenyl)sulfonylamino]methyl]benzenesulfonamide
DMJZNX6	DE	Discovery agent

DMDX0VP	ID	DMDX0VP
DMDX0VP	DN	4-amino-N-[4-(benzyloxy)phenyl]butanamide
DMDX0VP	HS	Investigative
DMDX0VP	SN	4-Amino-N-[4-(benzyloxy)phenyl]butanamide; CHEMBL478718; Modified amino acid analog, 7a; BDBM24263; AKOS010509844; DB07104; N-[4-(Benzyloxy)phenyl]-4-aminobutanamide; J3603388F; 4-Amino-N-[4-(phenylmethoxy)phenyl]butanamide
DMDX0VP	DT	Small molecular drug
DMDX0VP	PC	22692237
DMDX0VP	MW	284.35
DMDX0VP	FM	C17H20N2O2
DMDX0VP	IC	InChI=1S/C17H20N2O2/c18-12-4-7-17(20)19-15-8-10-16(11-9-15)21-13-14-5-2-1-3-6-14/h1-3,5-6,8-11H,4,7,12-13,18H2,(H,19,20)
DMDX0VP	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CCCN
DMDX0VP	IK	QTWBKNVNGVYTNZ-UHFFFAOYSA-N
DMDX0VP	IU	4-amino-N-(4-phenylmethoxyphenyl)butanamide
DMDX0VP	DE	Discovery agent

DMIG82P	ID	DMIG82P
DMIG82P	DN	4-aminonaphthalen-1-ol
DMIG82P	HS	Investigative
DMIG82P	SN	4-Amino-1-naphthol; 2834-90-4; 4-Amino-1-naphthalenol; 1-Naphthalenol, 4-amino-; 1-AMINO-4-NAPHTHOL; UNII-02W29959D9; 4-amino-naphthalen-1-ol; CHEMBL576321; ABJQKDJOYSQVFX-UHFFFAOYSA-N; 4-Amino-1-naphtholhydrochloride; 02W29959D9; PCMD-CC-PAB-253; PC-0685415; 4-amino1-naphthol; 4-amino-1-naphtol; 4-azanylnaphthalen-1-ol; AC1L2AQW; 1-Amino-4-hydroxynaphthalene; SCHEMBL367092; AC1Q523Y; cid_2723858; BDBM43339; DTXSID30182580; 4-amino-1-naphthol; ZINC119431
DMIG82P	DT	Small molecular drug
DMIG82P	PC	17815
DMIG82P	MW	159.18
DMIG82P	FM	C10H9NO
DMIG82P	IC	InChI=1S/C10H9NO/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6,12H,11H2
DMIG82P	CS	C1=CC=C2C(=C1)C(=CC=C2O)N
DMIG82P	IK	ABJQKDJOYSQVFX-UHFFFAOYSA-N
DMIG82P	IU	4-aminonaphthalen-1-ol
DMIG82P	CA	CAS 2834-90-4
DMIG82P	DE	Discovery agent

DMLW651	ID	DMLW651
DMLW651	DN	4-amino-N-p-tolylbenzenesulfonamide
DMLW651	HS	Investigative
DMLW651	SN	4-Amino-N-(4-methylphenyl)benzenesulfonamide; 16803-95-5; 4-Amino-N-(p-tolyl)benzenesulfonamide; QXIZWXNTAVXJNC-UHFFFAOYSA-N; Benzenesulfonamide, 4-amino-N-(4-methylphenyl)-; AC1LC9K2; Oprea1_140477; CHEMBL389286; SCHEMBL2240008; CTK0E5316; DTXSID50341293; MolPort-002-788-929; ZINC265634; ALBB-005339; ZX-AN005271; BBL008295; STK288097; 4-Amino-N-p-tolyl-benzenesulfonamide; AKOS000151276; MCULE-6336197788; SEL11434898; TR-041978; TR-058746; AB0221486; ST45130422; R4223; EU-0099855; [(4-aminophenyl)sulfonyl](4-methylphenyl)amine
DMLW651	DT	Small molecular drug
DMLW651	PC	572102
DMLW651	MW	262.33
DMLW651	FM	C13H14N2O2S
DMLW651	IC	InChI=1S/C13H14N2O2S/c1-10-2-6-12(7-3-10)15-18(16,17)13-8-4-11(14)5-9-13/h2-9,15H,14H2,1H3
DMLW651	CS	CC1=CC=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMLW651	IK	QXIZWXNTAVXJNC-UHFFFAOYSA-N
DMLW651	IU	4-amino-N-(4-methylphenyl)benzenesulfonamide
DMLW651	CA	CAS 16803-95-5
DMLW651	DE	Discovery agent

DMYC1T6	ID	DMYC1T6
DMYC1T6	DN	4-AMINOPHENOL
DMYC1T6	HS	Investigative
DMYC1T6	SN	4-aminophenol; 123-30-8; p-aminophenol; 4-hydroxyaniline; p-hydroxyaniline; Phenol, 4-amino-; Paranol; Certinal; Citol; Azol; 4-aminobenzenol; Fouramine P; Ursol P Base; Rodinal; p-Hydroxyphenylamine; Benzofur P; Fourrine P Base; Pelagol P Base; Tertral P Base; Ursol P; Furro P Base; Nako Brown R; Durafur Brown RB; 4-Amino-1-hydroxybenzene; Renal AC; Fourrine 84; Phenol, p-amino-; Zoba Brown P Base; 4-AMINO-PHENOL; UNAL; C.I. Oxidation Base 6; 1-Amino-4-hydroxybenzene; Pelagol Grey P Base; BASF Ursol P Base; p-Aminofenol; Para-aminophenol
DMYC1T6	DT	Small molecular drug
DMYC1T6	PC	403
DMYC1T6	MW	109.13
DMYC1T6	FM	C6H7NO
DMYC1T6	IC	InChI=1S/C6H7NO/c7-5-1-3-6(8)4-2-5/h1-4,8H,7H2
DMYC1T6	CS	C1=CC(=CC=C1N)O
DMYC1T6	IK	PLIKAWJENQZMHA-UHFFFAOYSA-N
DMYC1T6	IU	4-aminophenol
DMYC1T6	CA	CAS 123-30-8
DMYC1T6	CB	CHEBI:17602
DMYC1T6	DE	Discovery agent

DMSE8NU	ID	DMSE8NU
DMSE8NU	DN	4-ANDROSTENE-3-17-DIONE
DMSE8NU	HS	Investigative
DMSE8NU	SN	Androstenedione; androstenedione; 4-Androstene-3,17-dione; Androst-4-ene-3,17-dione; 1963/5/8; 4-Androstenedione; Androtex; 3,17-Dioxoandrost-4-ene; delta-4-Androstenedione; SKF 2170; Fecundin; delta-4-Androsten-3,17-dione; delta-4-Androstene-3,17-dione; Androstendione; 4-Androsten-3,17-dione; NSC 9563; delta-(sup4)-Androsten-3,17-dione; delta(sup 4)-Androstene-3,17-dione; UNII-409J2J96VR; 17-Ketotestosterone; d4-androstenedione; CHEBI:16422; Androstenedione [JAN]; HSDB 7335; EINECS 200-554-5; MLS000028510; NSC9563; ANDROSTENEDIONE
DMSE8NU	DT	Small molecular drug
DMSE8NU	PC	6128
DMSE8NU	MW	286.4
DMSE8NU	FM	C19H26O2
DMSE8NU	IC	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1
DMSE8NU	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C
DMSE8NU	IK	AEMFNILZOJDQLW-QAGGRKNESA-N
DMSE8NU	IU	(8R,9S,10R,13S,14S)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMSE8NU	CA	CAS 63-05-8
DMSE8NU	CB	CHEBI:16422
DMSE8NU	DE	Discovery agent

DM1UXHE	ID	DM1UXHE
DM1UXHE	DN	4-APPES
DM1UXHE	HS	Investigative
DM1UXHE	SN	4-APPES; GTPL6258
DM1UXHE	DT	Small molecular drug
DM1UXHE	PC	11281345
DM1UXHE	MW	411.5
DM1UXHE	FM	C21H21N3O4S
DM1UXHE	IC	InChI=1S/C21H21N3O4S/c1-2-29(26,27)24(15-16-4-3-13-23-14-16)18-7-11-20(12-8-18)28-19-9-5-17(6-10-19)21(22)25/h3-14H,2,15H2,1H3,(H2,22,25)
DM1UXHE	CS	CCS(=O)(=O)N(CC1=CN=CC=C1)C2=CC=C(C=C2)OC3=CC=C(C=C3)C(=O)N
DM1UXHE	IK	VCBPWPYIGXFKDH-UHFFFAOYSA-N
DM1UXHE	IU	4-[4-[ethylsulfonyl(pyridin-3-ylmethyl)amino]phenoxy]benzamide
DM1UXHE	DE	Discovery agent

DM3UE42	ID	DM3UE42
DM3UE42	DN	4-arylphthalazin-1(2H)-3,4-Di-F
DM3UE42	HS	Investigative
DM3UE42	SN	CHEMBL1934835; 4-arylphthalazin-1(2H)-3,4-Di-F; GTPL7753; BDBM50360858
DM3UE42	DT	Small molecular drug
DM3UE42	PC	56835134
DM3UE42	MW	516.6
DM3UE42	FM	C30H30F2N4O2
DM3UE42	IC	InChI=1S/C30H30F2N4O2/c1-20(37)33-24-7-4-6-22(18-24)21-12-16-35(17-13-21)14-5-15-36-30(38)26-9-3-2-8-25(26)29(34-36)23-10-11-27(31)28(32)19-23/h2-4,6-11,18-19,21H,5,12-17H2,1H3,(H,33,37)
DM3UE42	CS	CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCN3C(=O)C4=CC=CC=C4C(=N3)C5=CC(=C(C=C5)F)F
DM3UE42	IK	YVVMAGRTTSOPEO-UHFFFAOYSA-N
DM3UE42	IU	N-[3-[1-[3-[4-(3,4-difluorophenyl)-1-oxophthalazin-2-yl]propyl]piperidin-4-yl]phenyl]acetamide
DM3UE42	DE	Discovery agent

DM7EQ06	ID	DM7EQ06
DM7EQ06	DN	4-azidobenzenesulfonamide
DM7EQ06	HS	Investigative
DM7EQ06	SN	4-azidobenzenesulfonamide; 4-azidobenzene-1-sulfonamide; CHEMBL222837; 36326-86-0; diazosulfanilamide; azide 1; AC1MSFSV; 4-azidophenylsulfonamide; 4-azido-benzenesulfonamide; SCHEMBL15155897; BDBM15222; MolPort-023-499-930; NSC80928; ZINC12410597; NSC-80928
DM7EQ06	DT	Small molecular drug
DM7EQ06	PC	3558590
DM7EQ06	MW	198.21
DM7EQ06	FM	C6H6N4O2S
DM7EQ06	IC	InChI=1S/C6H6N4O2S/c7-10-9-5-1-3-6(4-2-5)13(8,11)12/h1-4H,(H2,8,11,12)
DM7EQ06	CS	C1=CC(=CC=C1N=[N+]=[N-])S(=O)(=O)N
DM7EQ06	IK	UZEFHQIOSJWWSB-UHFFFAOYSA-N
DM7EQ06	IU	4-azidobenzenesulfonamide
DM7EQ06	CA	CAS 36326-86-0
DM7EQ06	DE	Discovery agent

DMACRHS	ID	DMACRHS
DMACRHS	DN	4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine
DMACRHS	HS	Investigative
DMACRHS	SN	CHEMBL148565; 4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine; BDBM50108708; ZINC13472074; 4-(Phenylsulfonyl)-1-hydrocinnamylpiperidine
DMACRHS	DT	Small molecular drug
DMACRHS	PC	10871642
DMACRHS	MW	343.5
DMACRHS	FM	C20H25NO2S
DMACRHS	IC	InChI=1S/C20H25NO2S/c22-24(23,19-11-5-2-6-12-19)20-13-16-21(17-14-20)15-7-10-18-8-3-1-4-9-18/h1-6,8-9,11-12,20H,7,10,13-17H2
DMACRHS	CS	C1CN(CCC1S(=O)(=O)C2=CC=CC=C2)CCCC3=CC=CC=C3
DMACRHS	IK	PZLOABUPAFZHAF-UHFFFAOYSA-N
DMACRHS	IU	4-(benzenesulfonyl)-1-(3-phenylpropyl)piperidine
DMACRHS	DE	Discovery agent

DMCKT3Q	ID	DMCKT3Q
DMCKT3Q	DN	4-Benzenesulfonyl-1-phenethyl-piperidine
DMCKT3Q	HS	Investigative
DMCKT3Q	SN	CHEMBL148280; 4-Benzenesulfonyl-1-phenethyl-piperidine; ZINC13472072; BDBM50108703; 4-(Phenylsulfonyl)-1-phenethylpiperidine
DMCKT3Q	DT	Small molecular drug
DMCKT3Q	PC	10991121
DMCKT3Q	MW	329.5
DMCKT3Q	FM	C19H23NO2S
DMCKT3Q	IC	InChI=1S/C19H23NO2S/c21-23(22,18-9-5-2-6-10-18)19-12-15-20(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19H,11-16H2
DMCKT3Q	CS	C1CN(CCC1S(=O)(=O)C2=CC=CC=C2)CCC3=CC=CC=C3
DMCKT3Q	IK	XFTLHKDSWBEMSE-UHFFFAOYSA-N
DMCKT3Q	IU	4-(benzenesulfonyl)-1-(2-phenylethyl)piperidine
DMCKT3Q	DE	Discovery agent

DMC7HKA	ID	DMC7HKA
DMC7HKA	DN	4-Benzenesulfonylamino-benzenesulfonamide
DMC7HKA	HS	Investigative
DMC7HKA	SN	4-Benzenesulfonylamino-benzenesulfonamide; CHEMBL23796; 4461-11-4; N4-(benzenesulfonyl)sulfanilamide; 4-(benzenesulfonamido)benzenesulfonamide; AC1LGK72; BDBM16658; aromatic sulfonamide compound 23; CTK1D2369; DTXSID20356379; MolPort-001-887-057; ZINC340351; AKOS001088105; 1-N-benzenebenzene-1,4-disulfonamide; MCULE-1421025287; 4-[(Phenylsulfonyl)amino]benzenesulfonamide; Benzenesulfonamide, N-[4-(aminosulfonyl)phenyl]-
DMC7HKA	DT	Small molecular drug
DMC7HKA	PC	822774
DMC7HKA	MW	312.4
DMC7HKA	FM	C12H12N2O4S2
DMC7HKA	IC	InChI=1S/C12H12N2O4S2/c13-19(15,16)11-8-6-10(7-9-11)14-20(17,18)12-4-2-1-3-5-12/h1-9,14H,(H2,13,15,16)
DMC7HKA	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMC7HKA	IK	FOOYRJIJNYBGIF-UHFFFAOYSA-N
DMC7HKA	IU	4-(benzenesulfonamido)benzenesulfonamide
DMC7HKA	CA	CAS 4461-11-4
DMC7HKA	DE	Discovery agent

DMM6UPD	ID	DMM6UPD
DMM6UPD	DN	4-Benzenesulfonylamino-N-hydroxy-benzamide
DMM6UPD	HS	Investigative
DMM6UPD	SN	CHEMBL98345; 4-Benzenesulfonylamino-N-hydroxy-benzamide; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid
DMM6UPD	DT	Small molecular drug
DMM6UPD	PC	44328873
DMM6UPD	MW	292.31
DMM6UPD	FM	C13H12N2O4S
DMM6UPD	IC	InChI=1S/C13H12N2O4S/c16-13(14-17)10-6-8-11(9-7-10)15-20(18,19)12-4-2-1-3-5-12/h1-9,15,17H,(H,14,16)
DMM6UPD	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C(=O)NO
DMM6UPD	IK	ZSIKBIFOAPITGF-UHFFFAOYSA-N
DMM6UPD	IU	4-(benzenesulfonamido)-N-hydroxybenzamide
DMM6UPD	DE	Discovery agent

DMVSNPB	ID	DMVSNPB
DMVSNPB	DN	4-benzhydryl-N-butylpiperazine-1-carboxamide
DMVSNPB	HS	Investigative
DMVSNPB	SN	4-benzhydryl-N-butylpiperazine-1-carboxamide; CHEMBL1087032; 681801-59-2; N-butyl-4-(diphenylmethyl)piperazine-1-carboxamide; (4-(DIPHENYLMETHYL)PIPERAZINYL)-N-BUTYLFORMAMIDE; AC1MDDX7; AC1Q2X1X; MLS001181725; MolPort-001-841-442; HMS2858M18; HMS1662P18; KS-000029IQ; BDBM50312580; ZINC19924797; AKOS022169771; MS-8361; MCULE-5902192289
DMVSNPB	DT	Small molecular drug
DMVSNPB	PC	2809754
DMVSNPB	MW	351.5
DMVSNPB	FM	C22H29N3O
DMVSNPB	IC	InChI=1S/C22H29N3O/c1-2-3-14-23-22(26)25-17-15-24(16-18-25)21(19-10-6-4-7-11-19)20-12-8-5-9-13-20/h4-13,21H,2-3,14-18H2,1H3,(H,23,26)
DMVSNPB	CS	CCCCNC(=O)N1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3
DMVSNPB	IK	QRGYLEAVFDZUPV-UHFFFAOYSA-N
DMVSNPB	IU	4-benzhydryl-N-butylpiperazine-1-carboxamide
DMVSNPB	DE	Discovery agent

DMASO86	ID	DMASO86
DMASO86	DN	4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
DMASO86	HS	Investigative
DMASO86	SN	CHEMBL1086903; 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide; MLS000532882; AC1LQXAP; CBMicro_028883; Oprea1_410069; Oprea1_118265; MolPort-001-490-660; HMS2484B06; STK413461; ZINC13468414; BDBM50312579; AKOS003253125; MCULE-2070823146; SMR000140320; BIM-0028795.P001; ST50914634; N-cyclohexyl-4-(diphenylmethyl)piperazine-1-carboxamide; N-cyclohexyl-4-(diphenylmethyl)-1-piperazinecarboxamide
DMASO86	DT	Small molecular drug
DMASO86	PC	1358608
DMASO86	MW	377.5
DMASO86	FM	C24H31N3O
DMASO86	IC	InChI=1S/C24H31N3O/c28-24(25-22-14-8-3-9-15-22)27-18-16-26(17-19-27)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-2,4-7,10-13,22-23H,3,8-9,14-19H2,(H,25,28)
DMASO86	CS	C1CCC(CC1)NC(=O)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4
DMASO86	IK	IRRGBCHOFRYUCB-UHFFFAOYSA-N
DMASO86	IU	4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
DMASO86	CA	CAS 401578-04-9
DMASO86	DE	Discovery agent

DM02Q8N	ID	DM02Q8N
DM02Q8N	DN	4-Benzo[b]thiophen-4-yl-1H-imidazole
DM02Q8N	HS	Investigative
DM02Q8N	SN	CHEMBL30534; 4-Benzo[b]thiophen-4-yl-1H-imidazole; 1H-Imidazole, 5-benzo[b]thien-4-yl-; SCHEMBL1502418; BDBM50085681; 4-(1H-Imidazole-4-yl)benzo[b]thiophene
DM02Q8N	DT	Small molecular drug
DM02Q8N	PC	10176567
DM02Q8N	MW	200.26
DM02Q8N	FM	C11H8N2S
DM02Q8N	IC	InChI=1S/C11H8N2S/c1-2-8(10-6-12-7-13-10)9-4-5-14-11(9)3-1/h1-7H,(H,12,13)
DM02Q8N	CS	C1=CC(=C2C=CSC2=C1)C3=CN=CN3
DM02Q8N	IK	QRRRICPYXPJYEH-UHFFFAOYSA-N
DM02Q8N	IU	5-(1-benzothiophen-4-yl)-1H-imidazole
DM02Q8N	DE	Discovery agent

DM1UG2A	ID	DM1UG2A
DM1UG2A	DN	4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol
DM1UG2A	HS	Investigative
DM1UG2A	DT	Small molecular drug
DM1UG2A	PC	135496123
DM1UG2A	MW	227.21
DM1UG2A	FM	C13H9NO3
DM1UG2A	IC	InChI=1S/C13H9NO3/c15-8-5-6-9(11(16)7-8)13-10-3-1-2-4-12(10)17-14-13/h1-7,15-16H
DM1UG2A	CS	C1=CC=C2C(=C1)C(=NO2)C3=C(C=C(C=C3)O)O
DM1UG2A	IK	JTGLWGSJTQMWBD-UHFFFAOYSA-N
DM1UG2A	IU	4-(1,2-benzoxazol-3-yl)benzene-1,3-diol
DM1UG2A	DE	Discovery agent

DM7AOGD	ID	DM7AOGD
DM7AOGD	DN	4-Benzoimidazol-1-yl-phenylamine
DM7AOGD	HS	Investigative
DM7AOGD	SN	4-(1H-benzimidazol-1-yl)aniline; 52708-36-8; 4-(1H-Benzo[d]imidazol-1-yl)aniline; 4-(1H-1,3-benzodiazol-1-yl)aniline; 4-benzimidazolylphenylamine; AC1NS4KU; 4-(benzimidazol-1-yl)aniline; AC1Q51W1; SCHEMBL1208951; BDBM3829; CHEMBL346870; CTK1H4832; DTXSID80416160; 1-Phenylbenzimidazole deriv. 46; MolPort-000-892-003; ZINC2538824; 7454AB; STK122023; 1-(4-Aminophenyl)-1H-benzimidazole; SBB022485; AKOS000200797; MCULE-3811873515; AJ-38769; DA-18573; Benzenamine, 4-(1H-benzimidazol-1-yl)-; KB-237102; ST45055167; FT-0748937; EN300-14992
DM7AOGD	DT	Small molecular drug
DM7AOGD	PC	5328453
DM7AOGD	MW	209.25
DM7AOGD	FM	C13H11N3
DM7AOGD	IC	InChI=1S/C13H11N3/c14-10-5-7-11(8-6-10)16-9-15-12-3-1-2-4-13(12)16/h1-9H,14H2
DM7AOGD	CS	C1=CC=C2C(=C1)N=CN2C3=CC=C(C=C3)N
DM7AOGD	IK	DWYMPMWWYZEKLQ-UHFFFAOYSA-N
DM7AOGD	IU	4-(benzimidazol-1-yl)aniline
DM7AOGD	CA	CAS 52708-36-8
DM7AOGD	DE	Discovery agent

DMA9DHE	ID	DMA9DHE
DMA9DHE	DN	4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane
DMA9DHE	HS	Investigative
DMA9DHE	SN	CHEMBL611082; 4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane; SCHEMBL373021; CXJLWJAYGMWLRR-UHFFFAOYSA-N; BDBM50309862
DMA9DHE	DT	Small molecular drug
DMA9DHE	PC	9794818
DMA9DHE	MW	243.3
DMA9DHE	FM	C14H17N3O
DMA9DHE	IC	InChI=1S/C14H17N3O/c1-2-4-13-12(3-1)15-14(18-13)17-10-9-16-7-5-11(17)6-8-16/h1-4,11H,5-10H2
DMA9DHE	CS	C1CN2CCC1N(CC2)C3=NC4=CC=CC=C4O3
DMA9DHE	IK	CXJLWJAYGMWLRR-UHFFFAOYSA-N
DMA9DHE	IU	2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-1,3-benzoxazole
DMA9DHE	DE	Discovery agent

DMYBPFS	ID	DMYBPFS
DMYBPFS	DN	4-Benzoylamino-N-hydroxy-benzamide
DMYBPFS	HS	Investigative
DMYBPFS	SN	SCHEMBL673678; CHEMBL191227
DMYBPFS	DT	Small molecular drug
DMYBPFS	PC	11817702
DMYBPFS	MW	256.26
DMYBPFS	FM	C14H12N2O3
DMYBPFS	IC	InChI=1S/C14H12N2O3/c17-13(10-4-2-1-3-5-10)15-12-8-6-11(7-9-12)14(18)16-19/h1-9,19H,(H,15,17)(H,16,18)
DMYBPFS	CS	C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
DMYBPFS	IK	QXGMQWWJCBVFOF-UHFFFAOYSA-N
DMYBPFS	IU	4-benzamido-N-hydroxybenzamide
DMYBPFS	DE	Discovery agent

DMQZ0D6	ID	DMQZ0D6
DMQZ0D6	DN	4-Benzyl-1-(2-phenoxy-ethyl)-piperidine
DMQZ0D6	HS	Investigative
DMQZ0D6	SN	4-benzyl-1-(2-phenoxyethyl)piperidine; CHEMBL102659; 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine; AC1LPA49; SCHEMBL5888854; HRBKFQYSVXXYDE-UHFFFAOYSA-N; ZINC1159765
DMQZ0D6	DT	Small molecular drug
DMQZ0D6	PC	1328600
DMQZ0D6	MW	295.4
DMQZ0D6	FM	C20H25NO
DMQZ0D6	IC	InChI=1S/C20H25NO/c1-3-7-18(8-4-1)17-19-11-13-21(14-12-19)15-16-22-20-9-5-2-6-10-20/h1-10,19H,11-17H2
DMQZ0D6	CS	C1CN(CCC1CC2=CC=CC=C2)CCOC3=CC=CC=C3
DMQZ0D6	IK	HRBKFQYSVXXYDE-UHFFFAOYSA-N
DMQZ0D6	IU	4-benzyl-1-(2-phenoxyethyl)piperidine
DMQZ0D6	DE	Discovery agent

DMIX6RG	ID	DMIX6RG
DMIX6RG	DN	4-Benzyl-1-[3-phenylpropoxy)propyl]piperidine
DMIX6RG	HS	Investigative
DMIX6RG	SN	CHEMBL513620; 4-Benzyl-1-[3-phenylpropoxy)propyl]piperidine
DMIX6RG	DT	Small molecular drug
DMIX6RG	PC	44563685
DMIX6RG	MW	351.5
DMIX6RG	FM	C24H33NO
DMIX6RG	IC	InChI=1S/C24H33NO/c1-3-9-22(10-4-1)13-7-19-26-20-8-16-25-17-14-24(15-18-25)21-23-11-5-2-6-12-23/h1-6,9-12,24H,7-8,13-21H2
DMIX6RG	CS	C1CN(CCC1CC2=CC=CC=C2)CCCOCCCC3=CC=CC=C3
DMIX6RG	IK	XBQBYNHFYXHMHB-UHFFFAOYSA-N
DMIX6RG	IU	4-benzyl-1-[3-(3-phenylpropoxy)propyl]piperidine
DMIX6RG	DE	Discovery agent

DM6XLZ0	ID	DM6XLZ0
DM6XLZ0	DN	4-Benzyl-1-chroman-2-ylmethyl-piperidine
DM6XLZ0	HS	Investigative
DM6XLZ0	SN	CHEMBL178650; 4-Benzyl-1-chroman-2-ylmethyl-piperidine
DM6XLZ0	DT	Small molecular drug
DM6XLZ0	PC	11220953
DM6XLZ0	MW	321.5
DM6XLZ0	FM	C22H27NO
DM6XLZ0	IC	InChI=1S/C22H27NO/c1-2-6-18(7-3-1)16-19-12-14-23(15-13-19)17-21-11-10-20-8-4-5-9-22(20)24-21/h1-9,19,21H,10-17H2
DM6XLZ0	CS	C1CC2=CC=CC=C2OC1CN3CCC(CC3)CC4=CC=CC=C4
DM6XLZ0	IK	XIEPNNMDKPLLAY-UHFFFAOYSA-N
DM6XLZ0	IU	4-benzyl-1-(3,4-dihydro-2H-chromen-2-ylmethyl)piperidine
DM6XLZ0	DE	Discovery agent

DMAZMPF	ID	DMAZMPF
DMAZMPF	DN	4-Benzyl-1-chroman-3-ylmethyl-piperidine
DMAZMPF	HS	Investigative
DMAZMPF	SN	CHEMBL179373; 4-Benzyl-1-chroman-3-ylmethyl-piperidine
DMAZMPF	DT	Small molecular drug
DMAZMPF	PC	11152527
DMAZMPF	MW	321.5
DMAZMPF	FM	C22H27NO
DMAZMPF	IC	InChI=1S/C22H27NO/c1-2-6-18(7-3-1)14-19-10-12-23(13-11-19)16-20-15-21-8-4-5-9-22(21)24-17-20/h1-9,19-20H,10-17H2
DMAZMPF	CS	C1CN(CCC1CC2=CC=CC=C2)CC3CC4=CC=CC=C4OC3
DMAZMPF	IK	SLJXLWDNADHNLA-UHFFFAOYSA-N
DMAZMPF	IU	4-benzyl-1-(3,4-dihydro-2H-chromen-3-ylmethyl)piperidine
DMAZMPF	DE	Discovery agent

DMES9AJ	ID	DMES9AJ
DMES9AJ	DN	4-Benzyl-1-indan-2-ylmethyl-piperidine
DMES9AJ	HS	Investigative
DMES9AJ	SN	CHEMBL179145; 4-Benzyl-1-indan-2-ylmethyl-piperidine
DMES9AJ	DT	Small molecular drug
DMES9AJ	PC	11336800
DMES9AJ	MW	305.5
DMES9AJ	FM	C22H27N
DMES9AJ	IC	InChI=1S/C22H27N/c1-2-6-18(7-3-1)14-19-10-12-23(13-11-19)17-20-15-21-8-4-5-9-22(21)16-20/h1-9,19-20H,10-17H2
DMES9AJ	CS	C1CN(CCC1CC2=CC=CC=C2)CC3CC4=CC=CC=C4C3
DMES9AJ	IK	YMEBJHPCSQTYQZ-UHFFFAOYSA-N
DMES9AJ	IU	4-benzyl-1-(2,3-dihydro-1H-inden-2-ylmethyl)piperidine
DMES9AJ	DE	Discovery agent

DMQKCGI	ID	DMQKCGI
DMQKCGI	DN	4-Benzyl-1-methyl-piperidine hydrochloride
DMQKCGI	HS	Investigative
DMQKCGI	DE	Discovery agent

DMAI6X2	ID	DMAI6X2
DMAI6X2	DN	4-Benzyl-1-phenethyl-piperidine hydrochloride
DMAI6X2	HS	Investigative
DMAI6X2	DE	Discovery agent

DM2Q0VB	ID	DM2Q0VB
DM2Q0VB	DN	4-benzyl-2,6-diisobutylamino-pyrimidine
DM2Q0VB	HS	Investigative
DM2Q0VB	SN	CHEMBL493703; 4-benzyl-2,6-diisobutylamino-pyrimidine
DM2Q0VB	DT	Small molecular drug
DM2Q0VB	PC	25130896
DM2Q0VB	MW	327.5
DM2Q0VB	FM	C19H29N5
DM2Q0VB	IC	InChI=1S/C19H29N5/c1-14(2)11-20-17-10-18(21-13-16-8-6-5-7-9-16)24-19(23-17)22-12-15(3)4/h5-10,14-15H,11-13H2,1-4H3,(H3,20,21,22,23,24)
DM2Q0VB	CS	CC(C)CNC1=NC(=NC(=C1)NCC2=CC=CC=C2)NCC(C)C
DM2Q0VB	IK	ZOQDUFOUNDLFCC-UHFFFAOYSA-N
DM2Q0VB	IU	6-N-benzyl-2-N,4-N-bis(2-methylpropyl)pyrimidine-2,4,6-triamine
DM2Q0VB	DE	Discovery agent

DM8MVU4	ID	DM8MVU4
DM8MVU4	DN	4-benzyl-2-methylphthalazin-1(2H)-one
DM8MVU4	HS	Investigative
DM8MVU4	SN	CHEMBL304747; AC1LDJCK; 4-benzyl-2-methylphthalazin-1(2H)-one; 4-Benzyl-2-methyl-1(2H)-phthalazinone; SCHEMBL8556390; KUTSOIMAOFABLX-UHFFFAOYSA-N; 4-benzyl-2-methylphthalazin-1-one; BDBM50131423; 4-Benzyl-2-methyl-2H-phthalazin-1-one; 4-Benzyl-2-methyl-1(2H)-phthalazinone #; 4-Benzyl-1,2-dihydro-2-methyl-1-oxophthalazine
DM8MVU4	DT	Small molecular drug
DM8MVU4	PC	619552
DM8MVU4	MW	250.29
DM8MVU4	FM	C16H14N2O
DM8MVU4	IC	InChI=1S/C16H14N2O/c1-18-16(19)14-10-6-5-9-13(14)15(17-18)11-12-7-3-2-4-8-12/h2-10H,11H2,1H3
DM8MVU4	CS	CN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=CC=C3
DM8MVU4	IK	KUTSOIMAOFABLX-UHFFFAOYSA-N
DM8MVU4	IU	4-benzyl-2-methylphthalazin-1-one
DM8MVU4	DE	Discovery agent

DMZ18OJ	ID	DMZ18OJ
DMZ18OJ	DN	4-benzyl-5-(4-piperidyl)isothiazol-3-ol
DMZ18OJ	HS	Investigative
DMZ18OJ	SN	CHEMBL203718; 4-benzyl-5-(4-piperidyl)isothiazol-3-ol
DMZ18OJ	DT	Small molecular drug
DMZ18OJ	PC	11515916
DMZ18OJ	MW	274.4
DMZ18OJ	FM	C15H18N2OS
DMZ18OJ	IC	InChI=1S/C15H18N2OS/c18-15-13(10-11-4-2-1-3-5-11)14(19-17-15)12-6-8-16-9-7-12/h1-5,12,16H,6-10H2,(H,17,18)
DMZ18OJ	CS	C1CNCCC1C2=C(C(=O)NS2)CC3=CC=CC=C3
DMZ18OJ	IK	VUKNNEXTWWCNCW-UHFFFAOYSA-N
DMZ18OJ	IU	4-benzyl-5-piperidin-4-yl-1,2-thiazol-3-one
DMZ18OJ	DE	Discovery agent

DMA4CZK	ID	DMA4CZK
DMA4CZK	DN	4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol
DMA4CZK	HS	Investigative
DMA4CZK	SN	CHEMBL144364; CHEMBL542896; 439944-86-2; CTK1C8001; DTXSID40440825; ZINC13473970; BDBM50113808; AKOS030538866; 4-Benzyl-5-(4-piperidinyl)isoxazole-3-ol; 3(2H)-Isoxazolone, 4-(phenylmethyl)-5-(4-piperidinyl)-
DMA4CZK	DT	Small molecular drug
DMA4CZK	PC	10491441
DMA4CZK	MW	258.32
DMA4CZK	FM	C15H18N2O2
DMA4CZK	IC	InChI=1S/C15H18N2O2/c18-15-13(10-11-4-2-1-3-5-11)14(19-17-15)12-6-8-16-9-7-12/h1-5,12,16H,6-10H2,(H,17,18)
DMA4CZK	CS	C1CNCCC1C2=C(C(=O)NO2)CC3=CC=CC=C3
DMA4CZK	IK	UQASDRGKIOGECB-UHFFFAOYSA-N
DMA4CZK	IU	4-benzyl-5-piperidin-4-yl-1,2-oxazol-3-one
DMA4CZK	CA	CAS 439944-86-2
DMA4CZK	DE	Discovery agent

DMOBC0F	ID	DMOBC0F
DMOBC0F	DN	4-Benzyl-6-nitro-2-piperazin-1-yl-quinoline
DMOBC0F	HS	Investigative
DMOBC0F	SN	CHEMBL422203; 4-Benzyl-6-nitro-2-piperazin-1-yl-quinoline; BDBM50110580
DMOBC0F	DT	Small molecular drug
DMOBC0F	PC	44379687
DMOBC0F	MW	348.4
DMOBC0F	FM	C20H20N4O2
DMOBC0F	IC	InChI=1S/C20H20N4O2/c25-24(26)17-6-7-19-18(14-17)16(12-15-4-2-1-3-5-15)13-20(22-19)23-10-8-21-9-11-23/h1-7,13-14,21H,8-12H2
DMOBC0F	CS	C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)CC4=CC=CC=C4
DMOBC0F	IK	SOYBGJFHGGERLE-UHFFFAOYSA-N
DMOBC0F	IU	4-benzyl-6-nitro-2-piperazin-1-ylquinoline
DMOBC0F	DE	Discovery agent

DMDC7TL	ID	DMDC7TL
DMDC7TL	DN	4-benzyloxy-2'-hydroxychalcone
DMDC7TL	HS	Investigative
DMDC7TL	SN	CHEMBL242078; (E)-3-(4-(benzyloxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; AC1O2DDI; SCHEMBL10768190; 4-benzyloxy-2''-hydroxychalcone; 2'-Hydroxy-4-(benzyloxy)chalcone; ZINC4775332; BDBM50241204; AKOS024335342; (E)-1-(2-hydroxyphenyl)-3-(4-phenylmethoxyphenyl)prop-2-en-1-one
DMDC7TL	DT	Small molecular drug
DMDC7TL	PC	6172473
DMDC7TL	MW	330.4
DMDC7TL	FM	C22H18O3
DMDC7TL	IC	InChI=1S/C22H18O3/c23-21-9-5-4-8-20(21)22(24)15-12-17-10-13-19(14-11-17)25-16-18-6-2-1-3-7-18/h1-15,23H,16H2/b15-12+
DMDC7TL	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)/C=C/C(=O)C3=CC=CC=C3O
DMDC7TL	IK	PQZKTWBQDPHGOU-NTCAYCPXSA-N
DMDC7TL	IU	(E)-1-(2-hydroxyphenyl)-3-(4-phenylmethoxyphenyl)prop-2-en-1-one
DMDC7TL	DE	Discovery agent

DM0T1NZ	ID	DM0T1NZ
DM0T1NZ	DN	4-Benzyloxybenzo[b]thiophene-2-carboxamidine
DM0T1NZ	HS	Investigative
DM0T1NZ	SN	CHEMBL598191; 4-Benzyloxybenzo[b]thiophene-2-carboxamidine; SCHEMBL13709500
DM0T1NZ	DT	Small molecular drug
DM0T1NZ	PC	24859718
DM0T1NZ	MW	282.4
DM0T1NZ	FM	C16H14N2OS
DM0T1NZ	IC	InChI=1S/C16H14N2OS/c17-16(18)15-9-12-13(7-4-8-14(12)20-15)19-10-11-5-2-1-3-6-11/h1-9H,10H2,(H3,17,18)
DM0T1NZ	CS	C1=CC=C(C=C1)COC2=C3C=C(SC3=CC=C2)C(=N)N
DM0T1NZ	IK	BMADCBRXHDOABZ-UHFFFAOYSA-N
DM0T1NZ	IU	4-phenylmethoxy-1-benzothiophene-2-carboximidamide
DM0T1NZ	DE	Discovery agent

DMA5FEM	ID	DMA5FEM
DMA5FEM	DN	4-benzylphthalazin-1(2H)-one
DMA5FEM	HS	Investigative
DMA5FEM	SN	4-Benzyl-1(2H)-phthalazinone; 4-benzylphthalazin-1(2H)-one; 32003-14-8; 4-Benzyl-2H-phthalazin-1-one; 4-benzyl-1,2-dihydrophthalazin-1-one; CHEMBL66761; JUCCMEHWBGPJKS-UHFFFAOYSA-N; benzylphthalazinone; phthalazinone, 1; 4-benzyl-phthalazone; AC1LDDNC; SMR000135223; AC1Q6GZZ; ChemDiv2_000142; Cambridge id 5241846; Oprea1_151142; Oprea1_623913; CBDivE_015258; MLS000530246; SCHEMBL863462; CTK4G8063; BDBM27660; DTXSID30346948; MolPort-001-796-654; HMS2379K10; HMS1369G10; 4-benzyl-2-hydrophthalazin-1-one; 4-Benzyl-1(2H)-phthalazinone #
DMA5FEM	DT	Small molecular drug
DMA5FEM	PC	616651
DMA5FEM	MW	236.27
DMA5FEM	FM	C15H12N2O
DMA5FEM	IC	InChI=1S/C15H12N2O/c18-15-13-9-5-4-8-12(13)14(16-17-15)10-11-6-2-1-3-7-11/h1-9H,10H2,(H,17,18)
DMA5FEM	CS	C1=CC=C(C=C1)CC2=NNC(=O)C3=CC=CC=C32
DMA5FEM	IK	JUCCMEHWBGPJKS-UHFFFAOYSA-N
DMA5FEM	IU	4-benzyl-2H-phthalazin-1-one
DMA5FEM	CA	CAS 32003-14-8
DMA5FEM	DE	Discovery agent

DMI1EFY	ID	DMI1EFY
DMI1EFY	DN	4-Benzythiopyridine-3-sulfonamide
DMI1EFY	HS	Investigative
DMI1EFY	SN	4-Benzythiopyridine-3-sulfonamide; CHEMBL1164472; 4-benzylsulfanylpyridine-3-sulfonamide; 4-(benzylsulfanyl)-3-pyridinesulfonamide; AC1LICQ3; Oprea1_561801; AJ-333/13050159; MolPort-002-817-660; ZINC481325; BDBM50320515; MCULE-9875266241
DMI1EFY	DT	Small molecular drug
DMI1EFY	PC	901953
DMI1EFY	MW	280.4
DMI1EFY	FM	C12H12N2O2S2
DMI1EFY	IC	InChI=1S/C12H12N2O2S2/c13-18(15,16)12-8-14-7-6-11(12)17-9-10-4-2-1-3-5-10/h1-8H,9H2,(H2,13,15,16)
DMI1EFY	CS	C1=CC=C(C=C1)CSC2=C(C=NC=C2)S(=O)(=O)N
DMI1EFY	IK	FUJBJSOIYVUFSM-UHFFFAOYSA-N
DMI1EFY	IU	4-benzylsulfanylpyridine-3-sulfonamide
DMI1EFY	DE	Discovery agent

DMDF3KJ	ID	DMDF3KJ
DMDF3KJ	DN	4beta,15-epoxy-miller-9E-enolide
DMDF3KJ	HS	Investigative
DMDF3KJ	SN	CHEMBL364742; (4R,5Z,10R,11R)-2,3,3abeta,4,7,8,9,10,11,11aalpha-Decahydro-2-oxo-3-methylene-11-hydroxy-4-(methacryloyloxy)spiro[cyclodeca[b]furan-10,2'-oxirane]-6-carbaldehyde
DMDF3KJ	DT	Small molecular drug
DMDF3KJ	PC	44398301
DMDF3KJ	MW	362.4
DMDF3KJ	FM	C19H22O7
DMDF3KJ	IC	InChI=1S/C19H22O7/c1-10(2)17(22)25-13-7-12(8-20)5-4-6-19(9-24-19)16(21)15-14(13)11(3)18(23)26-15/h7-8,13-16,21H,1,3-6,9H2,2H3/b12-7+/t13-,14-,15+,16-,19-/m1/s1
DMDF3KJ	CS	CC(=C)C(=O)O[C@@H]1/C=C(\\CCC[C@@]2(CO2)[C@@H]([C@@H]3[C@@H]1C(=C)C(=O)O3)O)/C=O
DMDF3KJ	IK	OGCMEEKAZKEDQP-USTFYIHISA-N
DMDF3KJ	IU	[(3aR,4R,5E,10R,11R,11aS)-6-formyl-11-hydroxy-3-methylidene-2-oxospiro[4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-10,2'-oxirane]-4-yl] 2-methylprop-2-enoate
DMDF3KJ	DE	Discovery agent

DMZ01SV	ID	DMZ01SV
DMZ01SV	DN	4beta,15-epoxy-miller-9Z-enolide
DMZ01SV	HS	Investigative
DMZ01SV	SN	CHEMBL205620
DMZ01SV	DT	Small molecular drug
DMZ01SV	PC	44409577
DMZ01SV	MW	362.4
DMZ01SV	FM	C19H22O7
DMZ01SV	IC	InChI=1S/C19H22O7/c1-10(2)17(22)25-13-7-12(8-20)5-4-6-19(9-24-19)16(21)15-14(13)11(3)18(23)26-15/h7-8,13-16,21H,1,3-6,9H2,2H3/b12-7-/t13-,14-,15+,16-,19-/m1/s1
DMZ01SV	CS	CC(=C)C(=O)O[C@@H]1/C=C(/CCC[C@@]2(CO2)[C@@H]([C@@H]3[C@@H]1C(=C)C(=O)O3)O)\\C=O
DMZ01SV	IK	OGCMEEKAZKEDQP-UPZPYLOFSA-N
DMZ01SV	IU	[(3aR,4R,5Z,10R,11R,11aS)-6-formyl-11-hydroxy-3-methylidene-2-oxospiro[4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-10,2'-oxirane]-4-yl] 2-methylprop-2-enoate
DMZ01SV	DE	Discovery agent

DM3B2TG	ID	DM3B2TG
DM3B2TG	DN	4-Biphenyl-2-ylethynyl-2-methyl-thiazole
DM3B2TG	HS	Investigative
DM3B2TG	SN	CHEMBL183608; 4-Biphenyl-2-ylethynyl-2-methyl-thiazole
DM3B2TG	DT	Small molecular drug
DM3B2TG	PC	44393041
DM3B2TG	MW	275.4
DM3B2TG	FM	C18H13NS
DM3B2TG	IC	InChI=1S/C18H13NS/c1-14-19-17(13-20-14)12-11-16-9-5-6-10-18(16)15-7-3-2-4-8-15/h2-10,13H,1H3
DM3B2TG	CS	CC1=NC(=CS1)C#CC2=CC=CC=C2C3=CC=CC=C3
DM3B2TG	IK	BXIUXCNGUNCOFW-UHFFFAOYSA-N
DM3B2TG	IU	2-methyl-4-[2-(2-phenylphenyl)ethynyl]-1,3-thiazole
DM3B2TG	DE	Discovery agent

DMYUL9J	ID	DMYUL9J
DMYUL9J	DN	4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline
DMYUL9J	HS	Investigative
DMYUL9J	SN	CHEMBL250924; 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline; BDBM50222419
DMYUL9J	DT	Small molecular drug
DMYUL9J	PC	44442180
DMYUL9J	MW	366.4
DMYUL9J	FM	C24H18N2O2
DMYUL9J	IC	InChI=1S/C24H18N2O2/c1-27-23-14-20-21(25-16-26-22(20)15-24(23)28-2)13-12-18-10-6-7-11-19(18)17-8-4-3-5-9-17/h3-11,14-16H,1-2H3
DMYUL9J	CS	COC1=C(C=C2C(=C1)C(=NC=N2)C#CC3=CC=CC=C3C4=CC=CC=C4)OC
DMYUL9J	IK	ZUBUFJOEYHKFCQ-UHFFFAOYSA-N
DMYUL9J	IU	6,7-dimethoxy-4-[2-(2-phenylphenyl)ethynyl]quinazoline
DMYUL9J	DE	Discovery agent

DML6PTX	ID	DML6PTX
DML6PTX	DN	4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole
DML6PTX	HS	Investigative
DML6PTX	SN	CHEMBL332257; SCHEMBL4817122
DML6PTX	DT	Small molecular drug
DML6PTX	PC	10109974
DML6PTX	MW	374.6
DML6PTX	FM	C26H34N2
DML6PTX	IC	InChI=1S/C26H34N2/c1-3-5-8-14-24(15-9-6-4-2)26-27-20-25(28-26)23-18-16-22(17-19-23)21-12-10-7-11-13-21/h7,10-13,16-20,24H,3-6,8-9,14-15H2,1-2H3,(H,27,28)
DML6PTX	CS	CCCCCC(CCCCC)C1=NC=C(N1)C2=CC=C(C=C2)C3=CC=CC=C3
DML6PTX	IK	FAJKZAIMTCYING-UHFFFAOYSA-N
DML6PTX	IU	5-(4-phenylphenyl)-2-undecan-6-yl-1H-imidazole
DML6PTX	DE	Discovery agent

DM2I13S	ID	DM2I13S
DM2I13S	DN	4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole
DM2I13S	HS	Investigative
DM2I13S	SN	CHEMBL118682; SCHEMBL4811439
DM2I13S	DT	Small molecular drug
DM2I13S	PC	9923013
DM2I13S	MW	318.5
DM2I13S	FM	C22H26N2
DM2I13S	IC	InChI=1S/C22H26N2/c1-3-8-20(9-4-2)22-23-16-21(24-22)19-14-12-18(13-15-19)17-10-6-5-7-11-17/h5-7,10-16,20H,3-4,8-9H2,1-2H3,(H,23,24)
DM2I13S	CS	CCCC(CCC)C1=NC=C(N1)C2=CC=C(C=C2)C3=CC=CC=C3
DM2I13S	IK	VAJCFLBVVHOAAW-UHFFFAOYSA-N
DM2I13S	IU	2-heptan-4-yl-5-(4-phenylphenyl)-1H-imidazole
DM2I13S	DE	Discovery agent

DMLSUXD	ID	DMLSUXD
DMLSUXD	DN	4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole
DMLSUXD	HS	Investigative
DMLSUXD	SN	CHEMBL334104; SCHEMBL4821982
DMLSUXD	DT	Small molecular drug
DMLSUXD	PC	9966703
DMLSUXD	MW	316.4
DMLSUXD	FM	C22H24N2
DMLSUXD	IC	InChI=1S/C22H24N2/c1-3-7-17(8-4-1)15-22-23-16-21(24-22)20-13-11-19(12-14-20)18-9-5-2-6-10-18/h2,5-6,9-14,16-17H,1,3-4,7-8,15H2,(H,23,24)
DMLSUXD	CS	C1CCC(CC1)CC2=NC=C(N2)C3=CC=C(C=C3)C4=CC=CC=C4
DMLSUXD	IK	LAHDQEJNOQBNSA-UHFFFAOYSA-N
DMLSUXD	IU	2-(cyclohexylmethyl)-5-(4-phenylphenyl)-1H-imidazole
DMLSUXD	DE	Discovery agent

DMPIH4L	ID	DMPIH4L
DMPIH4L	DN	4-Biphenyl-4-yl-2-hexyl-1H-imidazole
DMPIH4L	HS	Investigative
DMPIH4L	SN	CHEMBL118603; SCHEMBL4814536
DMPIH4L	DT	Small molecular drug
DMPIH4L	PC	9922499
DMPIH4L	MW	304.4
DMPIH4L	FM	C21H24N2
DMPIH4L	IC	InChI=1S/C21H24N2/c1-2-3-4-8-11-21-22-16-20(23-21)19-14-12-18(13-15-19)17-9-6-5-7-10-17/h5-7,9-10,12-16H,2-4,8,11H2,1H3,(H,22,23)
DMPIH4L	CS	CCCCCCC1=NC=C(N1)C2=CC=C(C=C2)C3=CC=CC=C3
DMPIH4L	IK	LLLKBKRUIUYVOU-UHFFFAOYSA-N
DMPIH4L	IU	2-hexyl-5-(4-phenylphenyl)-1H-imidazole
DMPIH4L	DE	Discovery agent

DMNLC2Y	ID	DMNLC2Y
DMNLC2Y	DN	4-Biphenyl-4-yl-2-methyl-1H-imidazole
DMNLC2Y	HS	Investigative
DMNLC2Y	SN	CHEMBL330800; SCHEMBL3669956
DMNLC2Y	DT	Small molecular drug
DMNLC2Y	PC	44344607
DMNLC2Y	MW	234.29
DMNLC2Y	FM	C16H14N2
DMNLC2Y	IC	InChI=1S/C16H14N2/c1-12-17-11-16(18-12)15-9-7-14(8-10-15)13-5-3-2-4-6-13/h2-11H,1H3,(H,17,18)
DMNLC2Y	CS	CC1=NC=C(N1)C2=CC=C(C=C2)C3=CC=CC=C3
DMNLC2Y	IK	MBBDOQNKURHTFH-UHFFFAOYSA-N
DMNLC2Y	IU	2-methyl-5-(4-phenylphenyl)-1H-imidazole
DMNLC2Y	DE	Discovery agent

DMCQYKO	ID	DMCQYKO
DMCQYKO	DN	4-Biphenyl-4-ylethynyl-2-methyl-thiazole
DMCQYKO	HS	Investigative
DMCQYKO	SN	CHEMBL185078; 4-Biphenyl-4-ylethynyl-2-methyl-thiazole
DMCQYKO	DT	Small molecular drug
DMCQYKO	PC	44392959
DMCQYKO	MW	275.4
DMCQYKO	FM	C18H13NS
DMCQYKO	IC	InChI=1S/C18H13NS/c1-14-19-18(13-20-14)12-9-15-7-10-17(11-8-15)16-5-3-2-4-6-16/h2-8,10-11,13H,1H3
DMCQYKO	CS	CC1=NC(=CS1)C#CC2=CC=C(C=C2)C3=CC=CC=C3
DMCQYKO	IK	DGRLZFWNJWSHOX-UHFFFAOYSA-N
DMCQYKO	IU	2-methyl-4-[2-(4-phenylphenyl)ethynyl]-1,3-thiazole
DMCQYKO	DE	Discovery agent

DMS0JVE	ID	DMS0JVE
DMS0JVE	DN	4BP-TQS
DMS0JVE	HS	Investigative
DMS0JVE	SN	360791-49-7; 4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide; AC1MEMT7; ChemDiv1_000271; Cambridge id 5647991; Oprea1_528880; ARONIS25331; GTPL3962; SCHEMBL17458811; HMS587M07; SYN5056; MolPort-002-160-471; STL289206; AKOS003520670; AKOS022133488; MCULE-3388310837; 4BP-TQS, &gt; KS-0000477C; ST042158; AS-16422; BB0293824; KB-268939; AB00091637-01; SR-01000388448; SR-01000388448-1; 4-(4-bromophenyl)-3H,3aH,4H,5H,9bH-cyclopenta[c]quinoline-8-sulfonamide
DMS0JVE	DT	Small molecular drug
DMS0JVE	PC	2857838
DMS0JVE	MW	405.3
DMS0JVE	FM	C18H17BrN2O2S
DMS0JVE	IC	InChI=1S/C18H17BrN2O2S/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(24(20,22)23)8-9-17(16)21-18/h1-2,4-10,14-15,18,21H,3H2,(H2,20,22,23)
DMS0JVE	CS	C1C=CC2C1C(NC3=C2C=C(C=C3)S(=O)(=O)N)C4=CC=C(C=C4)Br
DMS0JVE	IK	YNCXHXYZTLIZTO-UHFFFAOYSA-N
DMS0JVE	IU	4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide
DMS0JVE	DE	Discovery agent

DM81D90	ID	DM81D90
DM81D90	DN	4-bromo-1H-indazole
DM81D90	HS	Investigative
DM81D90	SN	4-bromo-1H-indazole; 186407-74-9; 4-Bromoindazole; 1H-Indazole, 4-bromo-; 4-BROMO (1H)INDAZOLE; 4-Bromo(1H)indazole; CHEMBL246393; 4-bromo-indazole; bromo-1h-indazole; PubChem7834; 4-bromo-2H-indazole; ACMC-1BZDS; 4-bromanyl-1H-indazole; KSC173Q8P; 4-BROMO-7AH-INDAZOLE; SCHEMBL155255; 4-Bromo-1H-indazole, 95%; IND084; AC1Q24I6; Jsp003814; 4-bromo-1h-indazole, 97+%; SCHEMBL16799950; CTK0H3887; HID1021; DTXSID30625169; KJIODOACRIRBPB-UHFFFAOYSA-N; MolPort-022-450-748; MolPort-000-002-423; BCP00013; ACN-S003168; SBB054645; BDBM50209241
DM81D90	DT	Small molecular drug
DM81D90	PC	22352548
DM81D90	MW	197.03
DM81D90	FM	C7H5BrN2
DM81D90	IC	InChI=1S/C7H5BrN2/c8-6-2-1-3-7-5(6)4-9-10-7/h1-4H,(H,9,10)
DM81D90	CS	C1=CC2=C(C=NN2)C(=C1)Br
DM81D90	IK	KJIODOACRIRBPB-UHFFFAOYSA-N
DM81D90	IU	4-bromo-1H-indazole
DM81D90	CA	CAS 186407-74-9
DM81D90	DE	Discovery agent

DMMVASI	ID	DMMVASI
DMMVASI	DN	4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one
DMMVASI	HS	Investigative
DMMVASI	SN	CHEMBL78322; 331684-13-0; 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one; CTK1B8690; DTXSID70440555; BDBM50097370; AKOS030562752; 1-(imidazol-1-ylmethyl)-4-bromo-9h-9-xanthenone; 1-(1H-Imidazole-1-ylmethyl)-4-bromo-9H-xanthene-9-one; 9H-Xanthen-9-one, 4-bromo-1-(1H-imidazol-1-ylmethyl)-
DMMVASI	DT	Small molecular drug
DMMVASI	PC	10473365
DMMVASI	MW	355.2
DMMVASI	FM	C17H11BrN2O2
DMMVASI	IC	InChI=1S/C17H11BrN2O2/c18-13-6-5-11(9-20-8-7-19-10-20)15-16(21)12-3-1-2-4-14(12)22-17(13)15/h1-8,10H,9H2
DMMVASI	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3O2)Br)CN4C=CN=C4
DMMVASI	IK	FSWPWGQUEZXZFV-UHFFFAOYSA-N
DMMVASI	IU	4-bromo-1-(imidazol-1-ylmethyl)xanthen-9-one
DMMVASI	CA	CAS 331684-13-0
DMMVASI	DE	Discovery agent

DMPSRAC	ID	DMPSRAC
DMPSRAC	DN	4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMPSRAC	HS	Investigative
DMPSRAC	SN	4-bromo-2-(4-hydroxyphenyl)quinolin-6-ol
DMPSRAC	PC	135454802
DMPSRAC	MW	316.15
DMPSRAC	FM	C15H10BrNO2
DMPSRAC	IC	InChI=1S/C15H10BrNO2/c16-13-8-15(9-1-3-10(18)4-2-9)17-14-6-5-11(19)7-12(13)14/h1-8,18-19H
DMPSRAC	CS	C1=CC(=CC=C1C2=NC3=C(C=C(C=C3)O)C(=C2)Br)O
DMPSRAC	IK	XRUZUCBHVAMRMC-UHFFFAOYSA-N
DMPSRAC	IU	4-bromo-2-(4-hydroxyphenyl)quinolin-6-ol
DMPSRAC	DE	Discovery agent

DMY8TLO	ID	DMY8TLO
DMY8TLO	DN	4-Bromo-2,6-diisopropyl-phenol
DMY8TLO	HS	Investigative
DMY8TLO	SN	4-Bromo-2,6-diisopropyl-phenol; 4-BROMO-2,6-DIISOPROPYLPHENOL; CHEMBL54497; 2432-03-3; SCHEMBL3640323; 2,6-Diisopropyl-4-bromophenol; CTK5I6265; 4-bromo-2,6-di-isopropylphenol; MolPort-002-462-054; QNJVELOLCDKQBN-UHFFFAOYSA-N; ZINC13779577; BDBM50064417; AKOS028112327; 4-bromo-2,6-bis(propan-2-yl)phenol; AS-3289; Phenol, 4-bromo-2,6-bis(1-methylethyl)-
DMY8TLO	DT	Small molecular drug
DMY8TLO	PC	10422572
DMY8TLO	MW	257.17
DMY8TLO	FM	C12H17BrO
DMY8TLO	IC	InChI=1S/C12H17BrO/c1-7(2)10-5-9(13)6-11(8(3)4)12(10)14/h5-8,14H,1-4H3
DMY8TLO	CS	CC(C)C1=CC(=CC(=C1O)C(C)C)Br
DMY8TLO	IK	QNJVELOLCDKQBN-UHFFFAOYSA-N
DMY8TLO	IU	4-bromo-2,6-di(propan-2-yl)phenol
DMY8TLO	DE	Discovery agent

DMK2PBJ	ID	DMK2PBJ
DMK2PBJ	DN	4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone
DMK2PBJ	HS	Investigative
DMK2PBJ	SN	CHEMBL209047; BDBM50191596; 4''-bromo-3-(imidazolylmethyl)-7-methoxyflavone
DMK2PBJ	DT	Small molecular drug
DMK2PBJ	PC	11847170
DMK2PBJ	MW	411.2
DMK2PBJ	FM	C20H15BrN2O3
DMK2PBJ	IC	InChI=1S/C20H15BrN2O3/c1-25-15-6-7-16-18(10-15)26-20(13-2-4-14(21)5-3-13)17(19(16)24)11-23-9-8-22-12-23/h2-10,12H,11H2,1H3
DMK2PBJ	CS	COC1=CC2=C(C=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)Br)CN4C=CN=C4
DMK2PBJ	IK	DWMSDWDWUCFTQZ-UHFFFAOYSA-N
DMK2PBJ	IU	2-(4-bromophenyl)-3-(imidazol-1-ylmethyl)-7-methoxychromen-4-one
DMK2PBJ	DE	Discovery agent

DM2V3S8	ID	DM2V3S8
DM2V3S8	DN	4'-bromo-3-(imidazolylmethyl)flavone
DM2V3S8	HS	Investigative
DM2V3S8	SN	CHEMBL377766; BDBM50191597; 4''-bromo-3-(imidazolylmethyl)flavone
DM2V3S8	DT	Small molecular drug
DM2V3S8	PC	11847318
DM2V3S8	MW	381.2
DM2V3S8	FM	C19H13BrN2O2
DM2V3S8	IC	InChI=1S/C19H13BrN2O2/c20-14-7-5-13(6-8-14)19-16(11-22-10-9-21-12-22)18(23)15-3-1-2-4-17(15)24-19/h1-10,12H,11H2
DM2V3S8	CS	C1=CC=C2C(=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)Br)CN4C=CN=C4
DM2V3S8	IK	VPZRWXUJDQPWSY-UHFFFAOYSA-N
DM2V3S8	IU	2-(4-bromophenyl)-3-(imidazol-1-ylmethyl)chromen-4-one
DM2V3S8	DE	Discovery agent

DMYOCFX	ID	DMYOCFX
DMYOCFX	DN	4-Bromo-3-hydroxy-1H-quinolin-2-one
DMYOCFX	HS	Investigative
DMYOCFX	SN	2(1H)-Quinolinone, 4-bromo-3-hydroxy-; CHEMBL146520; SCHEMBL15690621; BSYFERFWIZPSKL-UHFFFAOYSA-N; BDBM247011; 4-Bromo-3-hydroxyquinolin-2(1H)-one; 4-Bromo-3-hydroxyquinoline-2(1H)-one; 176170-14-2; US9701638, 2
DMYOCFX	DT	Small molecular drug
DMYOCFX	PC	44364603
DMYOCFX	MW	240.05
DMYOCFX	FM	C9H6BrNO2
DMYOCFX	IC	InChI=1S/C9H6BrNO2/c10-7-5-3-1-2-4-6(5)11-9(13)8(7)12/h1-4,12H,(H,11,13)
DMYOCFX	CS	C1=CC=C2C(=C1)C(=C(C(=O)N2)O)Br
DMYOCFX	IK	BSYFERFWIZPSKL-UHFFFAOYSA-N
DMYOCFX	IU	4-bromo-3-hydroxy-1H-quinolin-2-one
DMYOCFX	DE	Discovery agent

DM2QJ5A	ID	DM2QJ5A
DM2QJ5A	DN	4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one
DM2QJ5A	HS	Investigative
DM2QJ5A	SN	CHEMBL147398
DM2QJ5A	DT	Small molecular drug
DM2QJ5A	PC	44364764
DM2QJ5A	MW	308.94
DM2QJ5A	FM	C9H4BrCl2NO2
DM2QJ5A	IC	InChI=1S/C9H4BrCl2NO2/c10-7-6-4(12)1-3(11)2-5(6)13-9(15)8(7)14/h1-2,14H,(H,13,15)
DM2QJ5A	CS	C1=C(C=C(C2=C1NC(=O)C(=C2Br)O)Cl)Cl
DM2QJ5A	IK	HDPAPMXBVVKNAQ-UHFFFAOYSA-N
DM2QJ5A	IU	4-bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one
DM2QJ5A	DE	Discovery agent

DMH6OPI	ID	DMH6OPI
DMH6OPI	DN	4-Bromo-6-nitro-2-piperazin-1-yl-quinoline
DMH6OPI	HS	Investigative
DMH6OPI	SN	4-Bromo-6-nitroquipazine; 143954-73-8; CHEMBL167825; 4-Bromo-6-nitro-2-piperazin-1-yl-quinoline; Quinoline, 4-bromo-6-nitro-2-(1-piperazinyl)-; ACMC-20n3fo; SCHEMBL6364738; AC1L318Y; CTK0I3188; DTXSID50162581; NRCNLRMWSMFETI-UHFFFAOYSA-N; BDBM50110574
DMH6OPI	DT	Small molecular drug
DMH6OPI	PC	132590
DMH6OPI	MW	337.17
DMH6OPI	FM	C13H13BrN4O2
DMH6OPI	IC	InChI=1S/C13H13BrN4O2/c14-11-8-13(17-5-3-15-4-6-17)16-12-2-1-9(18(19)20)7-10(11)12/h1-2,7-8,15H,3-6H2
DMH6OPI	CS	C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)Br
DMH6OPI	IK	NRCNLRMWSMFETI-UHFFFAOYSA-N
DMH6OPI	IU	4-bromo-6-nitro-2-piperazin-1-ylquinoline
DMH6OPI	CA	CAS 143954-73-8
DMH6OPI	DE	Discovery agent

DMJFY9Z	ID	DMJFY9Z
DMJFY9Z	DN	4-Bromo-N-(4-phenyl-thiazol-2-yl)-benzamide
DMJFY9Z	HS	Investigative
DMJFY9Z	SN	CHEMBL61836; 4-Bromo-N-(4-phenyl-thiazol-2-yl)-benzamide; 4-bromo-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; AC1LKC2E; Oprea1_799831; SCHEMBL17107249; MolPort-001-934-338; ZINC5775827; BDBM50101783; AKOS000591432; MCULE-9538176345; BAS 00470402; N-(4-Phenyl-2-thiazolyl)-4-bromobenzamide; ST50002847
DMJFY9Z	DT	Small molecular drug
DMJFY9Z	PC	988802
DMJFY9Z	MW	359.2
DMJFY9Z	FM	C16H11BrN2OS
DMJFY9Z	IC	InChI=1S/C16H11BrN2OS/c17-13-8-6-12(7-9-13)15(20)19-16-18-14(10-21-16)11-4-2-1-3-5-11/h1-10H,(H,18,19,20)
DMJFY9Z	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=C(C=C3)Br
DMJFY9Z	IK	PJMUFKFWQNWHCY-UHFFFAOYSA-N
DMJFY9Z	IU	4-bromo-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMJFY9Z	DE	Discovery agent

DMF38M5	ID	DMF38M5
DMF38M5	DN	4-Bromo-N-hydroxy-benzamide
DMF38M5	HS	Investigative
DMF38M5	SN	4-Bromo-N-hydroxybenzamide; 4-Bromo-N-hydroxy-benzamide; 1836-27-7; CHEMBL351337; 4-bromobenzenecarbohydroxamic acid; p-Bromobenzohydroxamic acid; AC1LCOKZ; N-Hydroxy-4-bromobenzamide; p-bromophenylhydroxamic acid; 4-Bromo-N-hydroxybenzamide #; SCHEMBL8575405; Benzamide, 4-bromo-N-hydroxy-; CTK0E2598; DTXSID20345349; VESPFSJNQMGUCQ-UHFFFAOYSA-N; MolPort-002-985-506; ZINC5249551; STK249669; BDBM50015106; AKOS000175576; MCULE-4510290140; DA-16649; SC-53612; KB-290158; ST51029575; FT-0708429
DMF38M5	DT	Small molecular drug
DMF38M5	PC	603910
DMF38M5	MW	216.03
DMF38M5	FM	C7H6BrNO2
DMF38M5	IC	InChI=1S/C7H6BrNO2/c8-6-3-1-5(2-4-6)7(10)9-11/h1-4,11H,(H,9,10)
DMF38M5	CS	C1=CC(=CC=C1C(=O)NO)Br
DMF38M5	IK	VESPFSJNQMGUCQ-UHFFFAOYSA-N
DMF38M5	IU	4-bromo-N-hydroxybenzamide
DMF38M5	CA	CAS 1836-27-7
DMF38M5	DE	Discovery agent

DM2YN37	ID	DM2YN37
DM2YN37	DN	4-bromophenylboronic acid
DM2YN37	HS	Investigative
DM2YN37	SN	4-Bromophenylboronic acid; 5467-74-3; (4-Bromophenyl)boronic acid; 4-Bromobenzeneboronic acid; 4-Bromophenylboric acid; p-Bromophenylboronic acid; p-Bromophenylboric acid; p-Bromobenzeneboronic acid; Boronic acid, (4-bromophenyl)-; Benzeneboronic acid, p-bromo-; (p-Bromophenyl)boronic acid; 4-bromo phenyl boronic acid; 4-bromophenyl boronic acid; 4-bromo-phenylboronic acid; Dihydroxy-4-bromophenylborane; EINECS 226-779-9; NSC 25407; 4-bromo phenylboronic acid; BRN 2936347; CHEMBL20866; AI3-32763; Boronic acid,B-(4-romophenyl)
DM2YN37	DT	Small molecular drug
DM2YN37	PC	79599
DM2YN37	MW	200.83
DM2YN37	FM	C6H6BBrO2
DM2YN37	IC	InChI=1S/C6H6BBrO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4,9-10H
DM2YN37	CS	B(C1=CC=C(C=C1)Br)(O)O
DM2YN37	IK	QBLFZIBJXUQVRF-UHFFFAOYSA-N
DM2YN37	IU	(4-bromophenyl)boronic acid
DM2YN37	CA	CAS 5467-74-3
DM2YN37	DE	Discovery agent

DMMGK2B	ID	DMMGK2B
DMMGK2B	DN	4-Butoxy-N-hydroxycarbamoylmethyl-benzamide
DMMGK2B	HS	Investigative
DMMGK2B	SN	CHEMBL371715; 4-Butoxy-N-hydroxycarbamoylmethyl-benzamide
DMMGK2B	DT	Small molecular drug
DMMGK2B	PC	44404479
DMMGK2B	MW	266.29
DMMGK2B	FM	C13H18N2O4
DMMGK2B	IC	InChI=1S/C13H18N2O4/c1-2-3-8-19-11-6-4-10(5-7-11)13(17)14-9-12(16)15-18/h4-7,18H,2-3,8-9H2,1H3,(H,14,17)(H,15,16)
DMMGK2B	CS	CCCCOC1=CC=C(C=C1)C(=O)NCC(=O)NO
DMMGK2B	IK	BFVCLRFRELSADQ-UHFFFAOYSA-N
DMMGK2B	IU	4-butoxy-N-[2-(hydroxyamino)-2-oxoethyl]benzamide
DMMGK2B	DE	Discovery agent

DMFCB7L	ID	DMFCB7L
DMFCB7L	DN	4-Butoxy-N-hydroxy-N-methyl-benzamide
DMFCB7L	HS	Investigative
DMFCB7L	SN	CHEMBL177392; 4-Butoxy-N-hydroxy-N-methyl-benzamide; Benzamide, 4-butoxy-N-hydroxy-N-methyl-; BDBM50015090; 4-Butoxy-N-methylbenzohydroxamic acid
DMFCB7L	DT	Small molecular drug
DMFCB7L	PC	44387015
DMFCB7L	MW	223.27
DMFCB7L	FM	C12H17NO3
DMFCB7L	IC	InChI=1S/C12H17NO3/c1-3-4-9-16-11-7-5-10(6-8-11)12(14)13(2)15/h5-8,15H,3-4,9H2,1-2H3
DMFCB7L	CS	CCCCOC1=CC=C(C=C1)C(=O)N(C)O
DMFCB7L	IK	OFVDFLZBUJEGOQ-UHFFFAOYSA-N
DMFCB7L	IU	4-butoxy-N-hydroxy-N-methylbenzamide
DMFCB7L	DE	Discovery agent

DM6ADJM	ID	DM6ADJM
DM6ADJM	DN	4-Butyl-1-[3-(phenylpropoxy)propyl]piperidine
DM6ADJM	HS	Investigative
DM6ADJM	SN	CHEMBL460309; 4-Butyl-1-[3-(phenylpropoxy)propyl]piperidine
DM6ADJM	DT	Small molecular drug
DM6ADJM	PC	44563684
DM6ADJM	MW	317.5
DM6ADJM	FM	C21H35NO
DM6ADJM	IC	InChI=1S/C21H35NO/c1-2-3-9-21-13-16-22(17-14-21)15-8-19-23-18-7-12-20-10-5-4-6-11-20/h4-6,10-11,21H,2-3,7-9,12-19H2,1H3
DM6ADJM	CS	CCCCC1CCN(CC1)CCCOCCCC2=CC=CC=C2
DM6ADJM	IK	OFZZAFXTRYWAHX-UHFFFAOYSA-N
DM6ADJM	IU	4-butyl-1-[3-(3-phenylpropoxy)propyl]piperidine
DM6ADJM	DE	Discovery agent

DMZHGP6	ID	DMZHGP6
DMZHGP6	DN	4-butyl-N-(7-hydroxynaphthalen-1-yl)benzamide
DMZHGP6	HS	Investigative
DMZHGP6	SN	CHEMBL259601
DMZHGP6	DT	Small molecular drug
DMZHGP6	PC	44450356
DMZHGP6	MW	319.4
DMZHGP6	FM	C21H21NO2
DMZHGP6	IC	InChI=1S/C21H21NO2/c1-2-3-5-15-8-10-17(11-9-15)21(24)22-20-7-4-6-16-12-13-18(23)14-19(16)20/h4,6-14,23H,2-3,5H2,1H3,(H,22,24)
DMZHGP6	CS	CCCCC1=CC=C(C=C1)C(=O)NC2=CC=CC3=C2C=C(C=C3)O
DMZHGP6	IK	KSWNGABTIMONPN-UHFFFAOYSA-N
DMZHGP6	IU	4-butyl-N-(7-hydroxynaphthalen-1-yl)benzamide
DMZHGP6	DE	Discovery agent

DMHLQSE	ID	DMHLQSE
DMHLQSE	DN	4-butyl-N-(isoquinolin-5-yl)benzamide
DMHLQSE	HS	Investigative
DMHLQSE	SN	CHEMBL407762
DMHLQSE	DT	Small molecular drug
DMHLQSE	PC	44450355
DMHLQSE	MW	304.4
DMHLQSE	FM	C20H20N2O
DMHLQSE	IC	InChI=1S/C20H20N2O/c1-2-3-5-15-8-10-16(11-9-15)20(23)22-19-7-4-6-17-14-21-13-12-18(17)19/h4,6-14H,2-3,5H2,1H3,(H,22,23)
DMHLQSE	CS	CCCCC1=CC=C(C=C1)C(=O)NC2=CC=CC3=C2C=CN=C3
DMHLQSE	IK	FBFHYVLRXNNMSE-UHFFFAOYSA-N
DMHLQSE	IU	4-butyl-N-isoquinolin-5-ylbenzamide
DMHLQSE	DE	Discovery agent

DMGW9XJ	ID	DMGW9XJ
DMGW9XJ	DN	4-butyl-N-(pyridin-3-yl)benzamide
DMGW9XJ	HS	Investigative
DMGW9XJ	SN	CHEMBL259396; 4-butyl-N-pyridin-3-ylbenzamide; 4-butyl-N-(pyridin-3-yl)benzamide; AC1N7X0I; Oprea1_505737; MolPort-003-720-572; ZINC3899411; STK493059; BDBM50376254; AKOS001583267; MCULE-4107696507; (4-butylphenyl)-N-(3-pyridyl)carboxamide; ST50859128; SR-01000396349
DMGW9XJ	DT	Small molecular drug
DMGW9XJ	PC	4286311
DMGW9XJ	MW	254.33
DMGW9XJ	FM	C16H18N2O
DMGW9XJ	IC	InChI=1S/C16H18N2O/c1-2-3-5-13-7-9-14(10-8-13)16(19)18-15-6-4-11-17-12-15/h4,6-12H,2-3,5H2,1H3,(H,18,19)
DMGW9XJ	CS	CCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMGW9XJ	IK	KDHOWTVYQKITMO-UHFFFAOYSA-N
DMGW9XJ	IU	4-butyl-N-pyridin-3-ylbenzamide
DMGW9XJ	DE	Discovery agent

DMRMGWF	ID	DMRMGWF
DMRMGWF	DN	4-butyl-N-(quinolin-3-yl)benzamide
DMRMGWF	HS	Investigative
DMRMGWF	SN	CHEMBL259385; 4-butyl-N-(quinolin-3-yl)benzamide; AC1LXX0M; Oprea1_455948; SCHEMBL846651; 4-butyl-N-quinolin-3-ylbenzamide; MolPort-002-564-310; ZINC2228626; STL329914; BDBM50376281; AKOS022106211; MCULE-9844265532; ST020606; (4-butylphenyl)-N-(3-quinolyl)carboxamide; SR-01000396347
DMRMGWF	DT	Small molecular drug
DMRMGWF	PC	1860395
DMRMGWF	MW	304.4
DMRMGWF	FM	C20H20N2O
DMRMGWF	IC	InChI=1S/C20H20N2O/c1-2-3-6-15-9-11-16(12-10-15)20(23)22-18-13-17-7-4-5-8-19(17)21-14-18/h4-5,7-14H,2-3,6H2,1H3,(H,22,23)
DMRMGWF	CS	CCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DMRMGWF	IK	LEGBMUNFZPMJOG-UHFFFAOYSA-N
DMRMGWF	IU	4-butyl-N-quinolin-3-ylbenzamide
DMRMGWF	DE	Discovery agent

DMIMW1E	ID	DMIMW1E
DMIMW1E	DN	4-butyl-N-phenylbenzamide
DMIMW1E	HS	Investigative
DMIMW1E	SN	CHEMBL260465; BDBM50376283
DMIMW1E	DT	Small molecular drug
DMIMW1E	PC	44450366
DMIMW1E	MW	253.34
DMIMW1E	FM	C17H19NO
DMIMW1E	IC	InChI=1S/C17H19NO/c1-2-3-7-14-10-12-15(13-11-14)17(19)18-16-8-5-4-6-9-16/h4-6,8-13H,2-3,7H2,1H3,(H,18,19)
DMIMW1E	CS	CCCCC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2
DMIMW1E	IK	PNJHOPPVHVQWPM-UHFFFAOYSA-N
DMIMW1E	IU	4-butyl-N-phenylbenzamide
DMIMW1E	DE	Discovery agent

DMD9FZW	ID	DMD9FZW
DMD9FZW	DN	4-butylphenylboronic acid
DMD9FZW	HS	Investigative
DMD9FZW	SN	4-Butylphenylboronic acid; 145240-28-4; (4-butylphenyl)boronic Acid; 4-n-Butylphenylboronic acid; 4-Butylphenylboronicacid; 4-Butylbenzeneboronic Acid; 4-N-BUTYLBENZENEBORONIC ACID; (4-Butylphenyl)Boranediol; CHEMBL555064; Boronic acid, (4-butylphenyl)-; MFCD02093926; AK-47631; 4-n-Butylphenylboronic acid, 95%; Boronic acid, B-(4-butylphenyl)-; PubChem18523; ACMC-209cue; AC1N2RDA; 4-Butylphenylboranic acid; 4-n-Butylphenylboronicacid; 4-butylphenyl boronic acid; 4-butyl-phenylboronic acid; AC1Q2VE3; 4-butyl phenyl boronic acid
DMD9FZW	DT	Small molecular drug
DMD9FZW	PC	4100860
DMD9FZW	MW	178.04
DMD9FZW	FM	C10H15BO2
DMD9FZW	IC	InChI=1S/C10H15BO2/c1-2-3-4-9-5-7-10(8-6-9)11(12)13/h5-8,12-13H,2-4H2,1H3
DMD9FZW	CS	B(C1=CC=C(C=C1)CCCC)(O)O
DMD9FZW	IK	UGZUUTHZEATQAM-UHFFFAOYSA-N
DMD9FZW	IU	(4-butylphenyl)boronic acid
DMD9FZW	CA	CAS 145240-28-4
DMD9FZW	DE	Discovery agent

DMKU4TR	ID	DMKU4TR
DMKU4TR	DN	4-Butyl-thiazolidin-(2E)-ylideneamine
DMKU4TR	HS	Investigative
DMKU4TR	SN	CHEMBL363049; 4-Butyl-thiazolidin-(2E)-ylideneamine; SCHEMBL7090223
DMKU4TR	DT	Small molecular drug
DMKU4TR	PC	9812839
DMKU4TR	MW	158.27
DMKU4TR	FM	C7H14N2S
DMKU4TR	IC	InChI=1S/C7H14N2S/c1-2-3-4-6-5-10-7(8)9-6/h6H,2-5H2,1H3,(H2,8,9)
DMKU4TR	CS	CCCCC1CSC(=N1)N
DMKU4TR	IK	LRIFCAXPRJKRBE-UHFFFAOYSA-N
DMKU4TR	IU	4-butyl-4,5-dihydro-1,3-thiazol-2-amine
DMKU4TR	DE	Discovery agent

DMRY6B4	ID	DMRY6B4
DMRY6B4	DN	4-Butyrylamino-N-hydroxy-benzamide
DMRY6B4	HS	Investigative
DMRY6B4	SN	CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262
DMRY6B4	DT	Small molecular drug
DMRY6B4	PC	11287488
DMRY6B4	MW	222.24
DMRY6B4	FM	C11H14N2O3
DMRY6B4	IC	InChI=1S/C11H14N2O3/c1-2-3-10(14)12-9-6-4-8(5-7-9)11(15)13-16/h4-7,16H,2-3H2,1H3,(H,12,14)(H,13,15)
DMRY6B4	CS	CCCC(=O)NC1=CC=C(C=C1)C(=O)NO
DMRY6B4	IK	WASGGDMUCRMECJ-UHFFFAOYSA-N
DMRY6B4	IU	4-(butanoylamino)-N-hydroxybenzamide
DMRY6B4	CA	CAS 656261-22-2
DMRY6B4	DE	Discovery agent

DM74GWO	ID	DM74GWO
DM74GWO	DN	4-Carbazol-9-yl-butyric acid
DM74GWO	HS	Investigative
DM74GWO	SN	CARBAZOLE BUTANOIC ACID; 4-(9H-CARBAZOL-9-YL)BUTANOIC ACID; CHEMBL185595; CRZ; 90053-09-1; 4-Carbazol-9-yl-butyric acid; 1tow; AC1L9MBO; 4-carbazol-9-ylbutanoic acid; 9H-Carbazole-9-butanoic acid; SCHEMBL4314440; 4-(N-carbazolyl) butyric acid; CTK3I5050; DTXSID50332287; BDBM50152851; AKOS000153937
DM74GWO	DT	Small molecular drug
DM74GWO	PC	448769
DM74GWO	MW	253.29
DM74GWO	FM	C16H15NO2
DM74GWO	IC	InChI=1S/C16H15NO2/c18-16(19)10-5-11-17-14-8-3-1-6-12(14)13-7-2-4-9-15(13)17/h1-4,6-9H,5,10-11H2,(H,18,19)
DM74GWO	CS	C1=CC=C2C(=C1)C3=CC=CC=C3N2CCCC(=O)O
DM74GWO	IK	HQAKVYGASUTQHH-UHFFFAOYSA-N
DM74GWO	IU	4-carbazol-9-ylbutanoic acid
DM74GWO	CA	CAS 90053-09-1
DM74GWO	DE	Discovery agent

DMBIQV3	ID	DMBIQV3
DMBIQV3	DN	4-Carboxycinnamic Acid
DMBIQV3	HS	Investigative
DMBIQV3	PC	697959
DMBIQV3	MW	192.17
DMBIQV3	FM	C10H8O4
DMBIQV3	IC	InChI=1S/C10H8O4/c11-9(12)6-3-7-1-4-8(5-2-7)10(13)14/h1-6H,(H,11,12)(H,13,14)/b6-3+
DMBIQV3	CS	C1=CC(=CC=C1/C=C/C(=O)O)C(=O)O
DMBIQV3	IK	HAEJSGLKJYIYTB-ZZXKWVIFSA-N
DMBIQV3	IU	4-[(E)-2-carboxyethenyl]benzoic acid
DMBIQV3	CA	CAS 19675-63-9
DMBIQV3	DE	Discovery agent

DM8A2QO	ID	DM8A2QO
DM8A2QO	DN	4-Carboxyphenylboronic Acid
DM8A2QO	HS	Investigative
DM8A2QO	SN	62729-39-9; 4-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)benzoic acid; Benzoic acid,4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-; SCHEMBL8083423; CTK5B5787; DTXSID00656960; ZX-AT029551; ZINC169807903; AKOS027380718; FCH2811826; AB29398
DM8A2QO	DT	Small molecular drug
DM8A2QO	PC	312183
DM8A2QO	MW	165.94
DM8A2QO	FM	C7H7BO4
DM8A2QO	IC	InChI=1S/C7H7BO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4,11-12H,(H,9,10)
DM8A2QO	CS	B(C1=CC=C(C=C1)C(=O)O)(O)O
DM8A2QO	IK	SIAVMDKGVRXFAX-UHFFFAOYSA-N
DM8A2QO	IU	4-boronobenzoic acid
DM8A2QO	CA	CAS 14047-29-1
DM8A2QO	DE	Discovery agent

DMMIA36	ID	DMMIA36
DMMIA36	DN	4-chloro-1-guanidino-7-isoquinolinesulphonamide
DMMIA36	HS	Investigative
DMMIA36	SN	223671-02-1; 1-GUANIDINO-4-CHLORO-7-SULFAMOYL-ISOQUINOLINE; 4-chloro-1-guanidino-7-isoquinolinesulphonamide; 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine; CHEMBL227782; SCHEMBL6437735; CTK4E9305; BDBM16132; DTXSID90586545; FXVHAOFNNRNCRJ-UHFFFAOYSA-N; AKOS015966420; 1-guanidino-7-sulfonamidoisoquinoline 6; ACM223671021; 4-chloro-1-guanidino-7-sulphamoylisoquinoline
DMMIA36	DT	Small molecular drug
DMMIA36	PC	16658353
DMMIA36	MW	299.74
DMMIA36	FM	C10H10ClN5O2S
DMMIA36	IC	InChI=1S/C10H10ClN5O2S/c11-8-4-15-9(16-10(12)13)7-3-5(19(14,17)18)1-2-6(7)8/h1-4H,(H2,14,17,18)(H4,12,13,15,16)
DMMIA36	CS	C1=CC2=C(C=C1S(=O)(=O)N)C(=NC=C2Cl)N=C(N)N
DMMIA36	IK	FXVHAOFNNRNCRJ-UHFFFAOYSA-N
DMMIA36	IU	2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine
DMMIA36	CA	CAS 223671-02-1
DMMIA36	DE	Discovery agent

DMHNSXP	ID	DMHNSXP
DMHNSXP	DN	4-chloro-1H-indazole
DMHNSXP	HS	Investigative
DMHNSXP	SN	4-Chloro-1H-indazole; 13096-96-3; 4-CHLOROINDAZOLE; 1H-Indazole, 4-chloro-; 4-Chloro-2H-indazole; NSC694315; 4-CHLORO(1H)INDAZOLE; CHEMBL246533; MFCD00211065; 4-Chloro-1H-indazole, AldrichCPR; 4-chloro-indazole; zlchem 748; NSC 694315; PubChem21945; AC1Q3RSH; ACMC-1BUW0; AC1L95AW; SCHEMBL476854; 4-Chloro-1H-indazole, 97%; 4-CHLORO (1H)INDAZOLE; CTK0H7106; DTXSID40156818; ZLD0205; CQTGQYVQJOJQCM-UHFFFAOYSA-N; MolPort-001-767-756; 4-CHLORO-3-(1H)INDAZOLE; ACT06078; BCP27008; ZINC5543816; KS-00000O0T; CS-M0440; STL556259; SBB054691; QC-206
DMHNSXP	DT	Small molecular drug
DMHNSXP	PC	393037
DMHNSXP	MW	152.58
DMHNSXP	FM	C7H5ClN2
DMHNSXP	IC	InChI=1S/C7H5ClN2/c8-6-2-1-3-7-5(6)4-9-10-7/h1-4H,(H,9,10)
DMHNSXP	CS	C1=CC2=C(C=NN2)C(=C1)Cl
DMHNSXP	IK	CQTGQYVQJOJQCM-UHFFFAOYSA-N
DMHNSXP	IU	4-chloro-1H-indazole
DMHNSXP	CA	CAS 13096-96-3
DMHNSXP	DE	Discovery agent

DM9HXPR	ID	DM9HXPR
DM9HXPR	DN	4-chloro-1H-indole-2,3-dione
DM9HXPR	HS	Investigative
DM9HXPR	SN	4-Chloroisatin; 6344-05-4; 4-chloro-1H-indole-2,3-dione; 4-chloroindoline-2,3-dione; 4-chloro-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 4-chloro-; 4-Chloroindole-2,3-dione; 4-Chloro-2,3-indolinedione; Indole-2,3-dione, 4-chloro-; HSYFISNDMZKGRS-UHFFFAOYSA-N; 4-chloro isatin; NSC49794; PubChem13911; AC1Q3HWJ; AC1L3VNL; ACMC-2097je; AC1Q3P5R; Isatin-based compound, 29; AC1Q3KG8; KSC492I4L; SCHEMBL282066; CHEMBL376228; KS-00000DIY; HSYFISNDMZKGRS-UHFFFAOYSA-; CTK3J2445; BDBM22809; DTXSID90212852; MolPort-001-797-339
DM9HXPR	DT	Small molecular drug
DM9HXPR	PC	96047
DM9HXPR	MW	181.57
DM9HXPR	FM	C8H4ClNO2
DM9HXPR	IC	InChI=1S/C8H4ClNO2/c9-4-2-1-3-5-6(4)7(11)8(12)10-5/h1-3H,(H,10,11,12)
DM9HXPR	CS	C1=CC2=C(C(=C1)Cl)C(=O)C(=O)N2
DM9HXPR	IK	HSYFISNDMZKGRS-UHFFFAOYSA-N
DM9HXPR	IU	4-chloro-1H-indole-2,3-dione
DM9HXPR	CA	CAS 6344-05-4
DM9HXPR	DE	Discovery agent

DMKJ18X	ID	DMKJ18X
DMKJ18X	DN	4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMKJ18X	HS	Investigative
DMKJ18X	SN	4-chloro-2-(4-hydroxyphenyl)quinolin-6-ol
DMKJ18X	PC	135519319
DMKJ18X	MW	271.7
DMKJ18X	FM	C15H10ClNO2
DMKJ18X	IC	InChI=1S/C15H10ClNO2/c16-13-8-15(9-1-3-10(18)4-2-9)17-14-6-5-11(19)7-12(13)14/h1-8,18-19H
DMKJ18X	CS	C1=CC(=CC=C1C2=NC3=C(C=C(C=C3)O)C(=C2)Cl)O
DMKJ18X	IK	MJJDANHWHHWHME-UHFFFAOYSA-N
DMKJ18X	IU	4-chloro-2-(4-hydroxyphenyl)quinolin-6-ol
DMKJ18X	DE	Discovery agent

DM9VN21	ID	DM9VN21
DM9VN21	DN	4-Chloro-2,6-diisopropyl-phenol
DM9VN21	HS	Investigative
DM9VN21	SN	CHEMBL292402; 2,6-diisopropyl-4-chlorophenol; 91561-75-0; 4-chloro-2,6-diisopropylphenol; 4-Chloro-2,6-diisopropyl-phenol; SCHEMBL4714270; ZINC13779576; BDBM50064419; DA-01221
DM9VN21	DT	Small molecular drug
DM9VN21	PC	10059055
DM9VN21	MW	212.71
DM9VN21	FM	C12H17ClO
DM9VN21	IC	InChI=1S/C12H17ClO/c1-7(2)10-5-9(13)6-11(8(3)4)12(10)14/h5-8,14H,1-4H3
DM9VN21	CS	CC(C)C1=CC(=CC(=C1O)C(C)C)Cl
DM9VN21	IK	ZRTAKZQCHCQFAB-UHFFFAOYSA-N
DM9VN21	IU	4-chloro-2,6-di(propan-2-yl)phenol
DM9VN21	DE	Discovery agent

DMIYVJX	ID	DMIYVJX
DMIYVJX	DN	4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN
DMIYVJX	HS	Investigative
DMIYVJX	SN	3,3-BIS(3-BROMO-4-HYDROXYPHENYL)-7-CHLORO-1H,3H-BENZO[DE]ISOCHROMEN-1-ONE; 4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN; BDBM18753; DB04696; 4-CHLORO-3',3"-DIBROMOPHENOL-1,8-NAPHTHALEIN; 4,4-bis(3-bromo-4-hydroxyphenyl)-10-chloro-3-oxatricyclo[7.3.1.0;{5,13}]trideca-1(12),5(13),6,8,10-pentaen-2-one
DMIYVJX	DT	Small molecular drug
DMIYVJX	PC	5288329
DMIYVJX	MW	560.6
DMIYVJX	FM	C24H13Br2ClO4
DMIYVJX	IC	InChI=1S/C24H13Br2ClO4/c25-17-10-12(4-8-20(17)28)24(13-5-9-21(29)18(26)11-13)16-3-1-2-14-19(27)7-6-15(22(14)16)23(30)31-24/h1-11,28-29H
DMIYVJX	CS	C1=CC2=C(C=CC3=C2C(=C1)C(OC3=O)(C4=CC(=C(C=C4)O)Br)C5=CC(=C(C=C5)O)Br)Cl
DMIYVJX	IK	GFGZCXHXQCQRFP-UHFFFAOYSA-N
DMIYVJX	IU	4,4-bis(3-bromo-4-hydroxyphenyl)-10-chloro-3-oxatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-2-one
DMIYVJX	DE	Discovery agent

DMMALY3	ID	DMMALY3
DMMALY3	DN	4-Chloro-3-hydroxy-1H-quinolin-2-one
DMMALY3	HS	Investigative
DMMALY3	DE	Discovery agent

DMI580M	ID	DMI580M
DMI580M	DN	4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine
DMI580M	HS	Investigative
DMI580M	SN	4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine; 4-chloro-5,7-diphenylpyrrolo[2,3-d]pyrimidine; 287177-10-0; CHEMBL426229; AC1M1GSW; MolPort-000-510-379; ZINC2455203; BDBM50088916; SBB039474; BBL001718; STL115578; AKOS000267629; MCULE-6403159172; ST45174715; H6707; L-3752
DMI580M	DT	Small molecular drug
DMI580M	PC	2049536
DMI580M	MW	305.8
DMI580M	FM	C18H12ClN3
DMI580M	IC	InChI=1S/C18H12ClN3/c19-17-16-15(13-7-3-1-4-8-13)11-22(18(16)21-12-20-17)14-9-5-2-6-10-14/h1-12H
DMI580M	CS	C1=CC=C(C=C1)C2=CN(C3=C2C(=NC=N3)Cl)C4=CC=CC=C4
DMI580M	IK	INLZGZMAUAHURP-UHFFFAOYSA-N
DMI580M	IU	4-chloro-5,7-diphenylpyrrolo[2,3-d]pyrimidine
DMI580M	DE	Discovery agent

DM04OFE	ID	DM04OFE
DM04OFE	DN	4-Chloro-6-nitro-2-piperazin-1-yl-quinoline
DM04OFE	HS	Investigative
DM04OFE	SN	4-CHLORO-6-NITRO-2-(PIPERAZIN-1-YL)QUINOLINE; 437708-76-4; CHEMBL423269; 4-chloro-6-nitro-2-piperazin-1-yl-quinoline; SCHEMBL6365676; CTK4I7722; DTXSID00438329; ZINC13439731; BDBM50110578; AKOS027381012; 2-Piperazino-4-chloro-6-nitroquinoline; ACM437708764; KB-334255
DM04OFE	DT	Small molecular drug
DM04OFE	PC	10334554
DM04OFE	MW	292.72
DM04OFE	FM	C13H13ClN4O2
DM04OFE	IC	InChI=1S/C13H13ClN4O2/c14-11-8-13(17-5-3-15-4-6-17)16-12-2-1-9(18(19)20)7-10(11)12/h1-2,7-8,15H,3-6H2
DM04OFE	CS	C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)Cl
DM04OFE	IK	HADJVDJPSUSVPZ-UHFFFAOYSA-N
DM04OFE	IU	4-chloro-6-nitro-2-piperazin-1-ylquinoline
DM04OFE	CA	CAS 437708-76-4
DM04OFE	DE	Discovery agent

DM16P3N	ID	DM16P3N
DM16P3N	DN	4-chloro-7-methyl-1H-indole-2,3-dione
DM16P3N	HS	Investigative
DM16P3N	SN	61258-72-8; 4-Chloro-7-methyl isatin; 4-Chloro-7-methyl-1H-indole-2,3-dione; 4-chloro-7-methylisatin; 4-chloro-7-methylindoline-2,3-dione; 4-chloro-7-methyl-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione,4-chloro-7-methyl-; 1H-Indole-2,3-dione, 4-chloro-7-methyl-; AC1LXYLJ; AC1Q2GPB; Isatin-based compound, 55; Cambridge id 5226020; MLS002473344; SCHEMBL950949; CHEMBL373715; CTK5B2947; BDBM22835; DTXSID20365244; MolPort-002-111-842; MWCJCUFHPFXQLS-UHFFFAOYSA-N; HMS2228G20; ZINC2169011; ALBB-024400; SBB066723; BBL005527
DM16P3N	DT	Small molecular drug
DM16P3N	PC	1810509
DM16P3N	MW	195.6
DM16P3N	FM	C9H6ClNO2
DM16P3N	IC	InChI=1S/C9H6ClNO2/c1-4-2-3-5(10)6-7(4)11-9(13)8(6)12/h2-3H,1H3,(H,11,12,13)
DM16P3N	CS	CC1=C2C(=C(C=C1)Cl)C(=O)C(=O)N2
DM16P3N	IK	MWCJCUFHPFXQLS-UHFFFAOYSA-N
DM16P3N	IU	4-chloro-7-methyl-1H-indole-2,3-dione
DM16P3N	CA	CAS 61258-72-8
DM16P3N	DE	Discovery agent

DM9SVEB	ID	DM9SVEB
DM9SVEB	DN	4-Chloro-7-methyl-2-phenyl-[1,8]naphthyridine
DM9SVEB	HS	Investigative
DM9SVEB	SN	CHEMBL97778; 4-chloro-7-methyl-2-phenyl-1,8-naphthyridine; 4-Chloro-7-methyl-2-phenyl-[1,8]naphthyridine; SCHEMBL1536334; BDBM50090689; ZINC13579501
DM9SVEB	DT	Small molecular drug
DM9SVEB	PC	12431921
DM9SVEB	MW	254.71
DM9SVEB	FM	C15H11ClN2
DM9SVEB	IC	InChI=1S/C15H11ClN2/c1-10-7-8-12-13(16)9-14(18-15(12)17-10)11-5-3-2-4-6-11/h2-9H,1H3
DM9SVEB	CS	CC1=NC2=C(C=C1)C(=CC(=N2)C3=CC=CC=C3)Cl
DM9SVEB	IK	CMSOCFLZPHQUAD-UHFFFAOYSA-N
DM9SVEB	IU	4-chloro-7-methyl-2-phenyl-1,8-naphthyridine
DM9SVEB	DE	Discovery agent

DMKTSPM	ID	DMKTSPM
DMKTSPM	DN	4-Chlorobenzenemethanethiol
DMKTSPM	HS	Investigative
DMKTSPM	SN	4-Chlorobenzyl mercaptan; 6258-66-8; 4-Chlorobenzenemethanethiol; 4-Chlorobenzylmercaptan; (4-Chlorophenyl)methanethiol; p-Chlorobenzyl mercaptan; Benzenemethanethiol, 4-chloro-; p-Chlorotoluene-alpha-thiol; 4-Chloro benzyl mercaptan; 4-chloro-alpha-toluenethiol; CHEMBL1224555; GKQXPTHQTXCXEV-UHFFFAOYSA-N; EINECS 228-395-7; 4-chlor-benzylthiol; 4-chlorobenzyl thiol; p-chlorobenzylmercaptan; PubChem6838; NSC 108735; 4-chloro-benzylmercaptan; AC1L2ZDM; 4-chlorophenylmethanethiol; ACMC-1BE9W; 4-chlorophenyl methanethiol; AC1Q3NX5
DMKTSPM	DT	Small molecular drug
DMKTSPM	PC	80409
DMKTSPM	MW	158.65
DMKTSPM	FM	C7H7ClS
DMKTSPM	IC	InChI=1S/C7H7ClS/c8-7-3-1-6(5-9)2-4-7/h1-4,9H,5H2
DMKTSPM	CS	C1=CC(=CC=C1CS)Cl
DMKTSPM	IK	GKQXPTHQTXCXEV-UHFFFAOYSA-N
DMKTSPM	IU	(4-chlorophenyl)methanethiol
DMKTSPM	CA	CAS 6258-66-8
DMKTSPM	DE	Discovery agent

DMHL9V3	ID	DMHL9V3
DMHL9V3	DN	4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide
DMHL9V3	HS	Investigative
DMHL9V3	SN	4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide; CHEMBL560605; AC1LEF7J; Oprea1_805046; Oprea1_782408; MolPort-001-927-690; ZINC102805; BDBM50297549; STK201761; AKOS000609413; MCULE-5386572276; 2',4,5'-Trichloro-3-nitrobenzanilide; BAS 00368876; 91822-09-2; ST011043; AG-690/09694020; 4-Chloro-N-(2,5-dichloro-phenyl)-3-nitro-benzamide
DMHL9V3	DT	Small molecular drug
DMHL9V3	PC	711259
DMHL9V3	MW	345.6
DMHL9V3	FM	C13H7Cl3N2O3
DMHL9V3	IC	InChI=1S/C13H7Cl3N2O3/c14-8-2-4-9(15)11(6-8)17-13(19)7-1-3-10(16)12(5-7)18(20)21/h1-6H,(H,17,19)
DMHL9V3	CS	C1=CC(=C(C=C1C(=O)NC2=C(C=CC(=C2)Cl)Cl)[N+](=O)[O-])Cl
DMHL9V3	IK	FYQHDHBGADAFGF-UHFFFAOYSA-N
DMHL9V3	IU	4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide
DMHL9V3	DE	Discovery agent

DMVJ61A	ID	DMVJ61A
DMVJ61A	DN	4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide
DMVJ61A	HS	Investigative
DMVJ61A	SN	AC1LJL3L; CHEMBL189826; MolPort-000-293-674; ZINC617836; AKOS002786758; MCULE-4723966083; 2-chloro-N-(4-chlorophenyl)sulfonylbenzamide; SR-01000270508
DMVJ61A	DT	Small molecular drug
DMVJ61A	PC	975893
DMVJ61A	MW	330.2
DMVJ61A	FM	C13H9Cl2NO3S
DMVJ61A	IC	InChI=1S/C13H9Cl2NO3S/c14-9-5-7-10(8-6-9)20(18,19)16-13(17)11-3-1-2-4-12(11)15/h1-8H,(H,16,17)
DMVJ61A	CS	C1=CC=C(C(=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl)Cl
DMVJ61A	IK	XWHYBUXHQMUOJE-UHFFFAOYSA-N
DMVJ61A	IU	2-chloro-N-(4-chlorophenyl)sulfonylbenzamide
DMVJ61A	DE	Discovery agent

DM6SI78	ID	DM6SI78
DM6SI78	DN	4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide
DM6SI78	HS	Investigative
DM6SI78	SN	CHEMBL187769; MolPort-000-480-083; ZINC16740680; AKOS016874521; MCULE-6213547895; N-(4-chlorobenzenesulfonyl)-2-methylbenzamide; Z56665599
DM6SI78	DT	Small molecular drug
DM6SI78	PC	11266872
DM6SI78	MW	309.8
DM6SI78	FM	C14H12ClNO3S
DM6SI78	IC	InChI=1S/C14H12ClNO3S/c1-10-4-2-3-5-13(10)14(17)16-20(18,19)12-8-6-11(15)7-9-12/h2-9H,1H3,(H,16,17)
DM6SI78	CS	CC1=CC=CC=C1C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl
DM6SI78	IK	JQSONZDJELNSLQ-UHFFFAOYSA-N
DM6SI78	IU	N-(4-chlorophenyl)sulfonyl-2-methylbenzamide
DM6SI78	DE	Discovery agent

DMVCLP8	ID	DMVCLP8
DMVCLP8	DN	4-Chloro-N-(2-morpholinoethyl)nicotinamide
DMVCLP8	HS	Investigative
DMVCLP8	SN	4-Chloro-N-(2-morpholinoethyl)nicotinamide; CHEMBL598187; BDBM50307210; AKOS019796958
DMVCLP8	DT	Small molecular drug
DMVCLP8	PC	46233361
DMVCLP8	MW	269.73
DMVCLP8	FM	C12H16ClN3O2
DMVCLP8	IC	InChI=1S/C12H16ClN3O2/c13-11-1-2-14-9-10(11)12(17)15-3-4-16-5-7-18-8-6-16/h1-2,9H,3-8H2,(H,15,17)
DMVCLP8	CS	C1COCCN1CCNC(=O)C2=C(C=CN=C2)Cl
DMVCLP8	IK	FJZDMBYDDXBLAU-UHFFFAOYSA-N
DMVCLP8	IU	4-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMVCLP8	DE	Discovery agent

DMI3OR9	ID	DMI3OR9
DMI3OR9	DN	4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide
DMI3OR9	HS	Investigative
DMI3OR9	SN	CHEMBL359783
DMI3OR9	DT	Small molecular drug
DMI3OR9	PC	11174891
DMI3OR9	MW	330.2
DMI3OR9	FM	C13H9Cl2NO3S
DMI3OR9	IC	InChI=1S/C13H9Cl2NO3S/c14-10-4-6-12(7-5-10)20(18,19)16-13(17)9-2-1-3-11(15)8-9/h1-8H,(H,16,17)
DMI3OR9	CS	C1=CC(=CC(=C1)Cl)C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl
DMI3OR9	IK	OPPZHIMBWGDCCT-UHFFFAOYSA-N
DMI3OR9	IU	3-chloro-N-(4-chlorophenyl)sulfonylbenzamide
DMI3OR9	DE	Discovery agent

DMM8G6H	ID	DMM8G6H
DMM8G6H	DN	4-Chloro-N-(3-morpholinopropyl)nicotinamide
DMM8G6H	HS	Investigative
DMM8G6H	SN	4-Chloro-N-(3-morpholinopropyl)nicotinamide; CHEMBL598586; SCHEMBL1613255; XYKBQKHBJFXZSH-UHFFFAOYSA-N; BDBM50307197; AKOS019797554
DMM8G6H	DT	Small molecular drug
DMM8G6H	PC	46233458
DMM8G6H	MW	283.75
DMM8G6H	FM	C13H18ClN3O2
DMM8G6H	IC	InChI=1S/C13H18ClN3O2/c14-12-2-4-15-10-11(12)13(18)16-3-1-5-17-6-8-19-9-7-17/h2,4,10H,1,3,5-9H2,(H,16,18)
DMM8G6H	CS	C1COCCN1CCCNC(=O)C2=C(C=CN=C2)Cl
DMM8G6H	IK	XYKBQKHBJFXZSH-UHFFFAOYSA-N
DMM8G6H	IU	4-chloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DMM8G6H	DE	Discovery agent

DMTDX2S	ID	DMTDX2S
DMTDX2S	DN	4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide
DMTDX2S	HS	Investigative
DMTDX2S	SN	BAS 00692952; AC1LHFP5; Oprea1_686071; 4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide; Oprea1_072837; CHEMBL365275; SCHEMBL10989349; MolPort-000-293-593; ZINC364345; AKOS001022179; MCULE-2798437162; 4-chloro-N-(4-chlorophenyl)sulfonylbenzamide; 4-chloro-N-((4-chlorophenyl)sulfonyl)benzamide; SR-01000319886; SR-01000319886-1
DMTDX2S	DT	Small molecular drug
DMTDX2S	PC	837182
DMTDX2S	MW	330.2
DMTDX2S	FM	C13H9Cl2NO3S
DMTDX2S	IC	InChI=1S/C13H9Cl2NO3S/c14-10-3-1-9(2-4-10)13(17)16-20(18,19)12-7-5-11(15)6-8-12/h1-8H,(H,16,17)
DMTDX2S	CS	C1=CC(=CC=C1C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl)Cl
DMTDX2S	IK	IZIJDUMIQKCMGD-UHFFFAOYSA-N
DMTDX2S	IU	4-chloro-N-(4-chlorophenyl)sulfonylbenzamide
DMTDX2S	CA	CAS 14068-02-1
DMTDX2S	DE	Discovery agent

DMM0TL6	ID	DMM0TL6
DMM0TL6	DN	4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide
DMM0TL6	HS	Investigative
DMM0TL6	SN	CHEMBL436085; 36965-16-9; CTK1A9789; DTXSID10465969; ZINC16740685; AKOS002221762; Benzamide, N-[(4-chlorophenyl)sulfonyl]-4-nitro-
DMM0TL6	DT	Small molecular drug
DMM0TL6	PC	11439243
DMM0TL6	MW	340.74
DMM0TL6	FM	C13H9ClN2O5S
DMM0TL6	IC	InChI=1S/C13H9ClN2O5S/c14-10-3-7-12(8-4-10)22(20,21)15-13(17)9-1-5-11(6-2-9)16(18)19/h1-8H,(H,15,17)
DMM0TL6	CS	C1=CC(=CC=C1C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl)[N+](=O)[O-]
DMM0TL6	IK	NOPPJNVGKXKZSN-UHFFFAOYSA-N
DMM0TL6	IU	N-(4-chlorophenyl)sulfonyl-4-nitrobenzamide
DMM0TL6	CA	CAS 36965-16-9
DMM0TL6	DE	Discovery agent

DMVKU4L	ID	DMVKU4L
DMVKU4L	DN	4-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMVKU4L	HS	Investigative
DMVKU4L	SN	4-chloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; CHEMBL62078; 4-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide; 103966-00-3; (Z)-4-chloro-N-(4-phenylthiazol-2(3H)-ylidene)benzamide; AC1LF4A9; Oprea1_546006; SCHEMBL17107148; MolPort-000-422-245; MolPort-003-009-218; CCG-1056; ZINC4693069; STK514420; BDBM50101787; AKOS024573977; AKOS000620846; MCULE-1729549249; BAS 00444248; ST45229639; N-(4-Phenyl-2-thiazolyl)-4-chlorobenzamide; AH-034/06884044; SR-01000394981; SR-01000394981-1; F0013-0438
DMVKU4L	DT	Small molecular drug
DMVKU4L	PC	697415
DMVKU4L	MW	314.8
DMVKU4L	FM	C16H11ClN2OS
DMVKU4L	IC	InChI=1S/C16H11ClN2OS/c17-13-8-6-12(7-9-13)15(20)19-16-18-14(10-21-16)11-4-2-1-3-5-11/h1-10H,(H,18,19,20)
DMVKU4L	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=C(C=C3)Cl
DMVKU4L	IK	ZLQJUNKKCMQVHA-UHFFFAOYSA-N
DMVKU4L	IU	4-chloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMVKU4L	DE	Discovery agent

DM5AVG3	ID	DM5AVG3
DM5AVG3	DN	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DM5AVG3	HS	Investigative
DM5AVG3	SN	CHEMBL143734; NSC718168; 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid
DM5AVG3	DT	Small molecular drug
DM5AVG3	PC	403373
DM5AVG3	MW	284.74
DM5AVG3	FM	C13H17ClN2O3
DM5AVG3	IC	InChI=1S/C13H17ClN2O3/c14-11-7-5-10(6-8-11)13(18)15-9-3-1-2-4-12(17)16-19/h5-8,19H,1-4,9H2,(H,15,18)(H,16,17)
DM5AVG3	CS	C1=CC(=CC=C1C(=O)NCCCCCC(=O)NO)Cl
DM5AVG3	IK	YYCQNZBMCNSCKG-UHFFFAOYSA-N
DM5AVG3	IU	4-chloro-N-[6-(hydroxyamino)-6-oxohexyl]benzamide
DM5AVG3	DE	Discovery agent

DM2UYCS	ID	DM2UYCS
DM2UYCS	DN	4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide
DM2UYCS	HS	Investigative
DM2UYCS	SN	CHEMBL364127; 4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide; BDBM50155552
DM2UYCS	DT	Small molecular drug
DM2UYCS	PC	44395685
DM2UYCS	MW	350.8
DM2UYCS	FM	C16H15ClN2O3S
DM2UYCS	IC	InChI=1S/C16H15ClN2O3S/c17-13-4-1-10(2-5-13)16(20)19-14-7-11-3-6-15(23(18,21)22)9-12(11)8-14/h1-6,9,14H,7-8H2,(H,19,20)(H2,18,21,22)
DM2UYCS	CS	C1C(CC2=C1C=CC(=C2)S(=O)(=O)N)NC(=O)C3=CC=C(C=C3)Cl
DM2UYCS	IK	BJLRENUWWOPZIL-UHFFFAOYSA-N
DM2UYCS	IU	4-chloro-N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)benzamide
DM2UYCS	DE	Discovery agent

DMPINBR	ID	DMPINBR
DMPINBR	DN	4-chlorophenyl 10H-phenothiazine-10-carboxylate
DMPINBR	HS	Investigative
DMPINBR	SN	CHEMBL481530; 4-chlorophenyl 10H-phenothiazine-10-carboxylate; SCHEMBL4442850; ZINC27529769; BDBM50292625; AKOS002279099; 4-chlorophenyl phenothiazine-10-carboxylate
DMPINBR	DT	Small molecular drug
DMPINBR	PC	16645663
DMPINBR	MW	353.8
DMPINBR	FM	C19H12ClNO2S
DMPINBR	IC	InChI=1S/C19H12ClNO2S/c20-13-9-11-14(12-10-13)23-19(22)21-15-5-1-3-7-17(15)24-18-8-4-2-6-16(18)21/h1-12H
DMPINBR	CS	C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)OC4=CC=C(C=C4)Cl
DMPINBR	IK	OTLLKYSWTVZPOJ-UHFFFAOYSA-N
DMPINBR	IU	(4-chlorophenyl) phenothiazine-10-carboxylate
DMPINBR	DE	Discovery agent

DMWGF9R	ID	DMWGF9R
DMWGF9R	DN	4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone
DMWGF9R	HS	Investigative
DMWGF9R	SN	CHEMBL377626; BDBM50191601; 4''-cyano-3-(imidazolylmethyl)-7-methoxyflavone
DMWGF9R	DT	Small molecular drug
DMWGF9R	PC	11847171
DMWGF9R	MW	357.4
DMWGF9R	FM	C21H15N3O3
DMWGF9R	IC	InChI=1S/C21H15N3O3/c1-26-16-6-7-17-19(10-16)27-21(15-4-2-14(11-22)3-5-15)18(20(17)25)12-24-9-8-23-13-24/h2-10,13H,12H2,1H3
DMWGF9R	CS	COC1=CC2=C(C=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)C#N)CN4C=CN=C4
DMWGF9R	IK	MFAAEVRNWGIQOT-UHFFFAOYSA-N
DMWGF9R	IU	4-[3-(imidazol-1-ylmethyl)-7-methoxy-4-oxochromen-2-yl]benzonitrile
DMWGF9R	DE	Discovery agent

DMUJS4R	ID	DMUJS4R
DMUJS4R	DN	4'-cyano-3-(imidazolylmethyl)flavone
DMUJS4R	HS	Investigative
DMUJS4R	SN	CHEMBL209731; BDBM50191602; 4''-cyano-3-(imidazolylmethyl)flavone
DMUJS4R	DT	Small molecular drug
DMUJS4R	PC	11847319
DMUJS4R	MW	327.3
DMUJS4R	FM	C20H13N3O2
DMUJS4R	IC	InChI=1S/C20H13N3O2/c21-11-14-5-7-15(8-6-14)20-17(12-23-10-9-22-13-23)19(24)16-3-1-2-4-18(16)25-20/h1-10,13H,12H2
DMUJS4R	CS	C1=CC=C2C(=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)C#N)CN4C=CN=C4
DMUJS4R	IK	IOBDYJIIOAQKGQ-UHFFFAOYSA-N
DMUJS4R	IU	4-[3-(imidazol-1-ylmethyl)-4-oxochromen-2-yl]benzonitrile
DMUJS4R	DE	Discovery agent

DMJ610E	ID	DMJ610E
DMJ610E	DN	4-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMJ610E	HS	Investigative
DMJ610E	SN	CHEMBL378434; 4-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; MLS002153000; SCHEMBL3677412; HMS2198C07; BDBM50187632
DMJ610E	DT	Small molecular drug
DMJ610E	PC	11574130
DMJ610E	MW	364.4
DMJ610E	FM	C23H16N4O
DMJ610E	IC	InChI=1S/C23H16N4O/c24-16-17-11-13-19(14-12-17)23(28)25-22-15-21(18-7-3-1-4-8-18)26-27(22)20-9-5-2-6-10-20/h1-15H,(H,25,28)
DMJ610E	CS	C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC=C(C=C3)C#N)C4=CC=CC=C4
DMJ610E	IK	YOQRDFGCIVWWAO-UHFFFAOYSA-N
DMJ610E	IU	4-cyano-N-(2,5-diphenylpyrazol-3-yl)benzamide
DMJ610E	DE	Discovery agent

DMN12EX	ID	DMN12EX
DMN12EX	DN	4-CYANOPHENOL
DMN12EX	HS	Investigative
DMN12EX	SN	4-Hydroxybenzonitrile; 4-Cyanophenol; 767-00-0; p-Hydroxybenzonitrile; P-CYANOPHENOL; Benzonitrile, 4-hydroxy-; Benzonitrile, p-hydroxy-; 4-CYANO PHENOL; 4-Hydroxybenzoic acid nitrile; 4-hydroxy-benzonitrile; 4-Hydroxy benzonitrile; 4-hydroxybenzenecarbonitrile; UNII-1S13529YJU; EINECS 212-175-2; C7H5NO; NSC 400524; AI3-52392; CHEBI:38622; CVNOWLNNPYYEOH-UHFFFAOYSA-N; 1S13529YJU; 4-Cyanophenol, 99%; paracyanophenol; p-cyano-phenol; 4-cyano-phenol; 4 -cyanophenol; para-cyanophenol;; 4-hydroxybezonitrile; p-hydroxybenzo-nitrile
DMN12EX	DT	Small molecular drug
DMN12EX	PC	13019
DMN12EX	MW	119.12
DMN12EX	FM	C7H5NO
DMN12EX	IC	InChI=1S/C7H5NO/c8-5-6-1-3-7(9)4-2-6/h1-4,9H
DMN12EX	CS	C1=CC(=CC=C1C#N)O
DMN12EX	IK	CVNOWLNNPYYEOH-UHFFFAOYSA-N
DMN12EX	IU	4-hydroxybenzonitrile
DMN12EX	CA	CAS 767-00-0
DMN12EX	CB	CHEBI:38622
DMN12EX	DE	Discovery agent

DMEP80Q	ID	DMEP80Q
DMEP80Q	DN	4-cyanophenyl ethyl dodecylphosphonate
DMEP80Q	HS	Investigative
DMEP80Q	SN	4-cyanophenyl ethyl dodecylphosphonate; CHEMBL462582
DMEP80Q	DT	Small molecular drug
DMEP80Q	PC	44563662
DMEP80Q	MW	379.5
DMEP80Q	FM	C21H34NO3P
DMEP80Q	IC	InChI=1S/C21H34NO3P/c1-3-5-6-7-8-9-10-11-12-13-18-26(23,24-4-2)25-21-16-14-20(19-22)15-17-21/h14-17H,3-13,18H2,1-2H3
DMEP80Q	CS	CCCCCCCCCCCCP(=O)(OCC)OC1=CC=C(C=C1)C#N
DMEP80Q	IK	FHIBETIKXBGJPS-UHFFFAOYSA-N
DMEP80Q	IU	4-[dodecyl(ethoxy)phosphoryl]oxybenzonitrile
DMEP80Q	DE	Discovery agent

DMOLFHZ	ID	DMOLFHZ
DMOLFHZ	DN	4-cyanophenylboronic acid
DMOLFHZ	HS	Investigative
DMOLFHZ	SN	4-Cyanophenylboronic acid; 126747-14-6; (4-cyanophenyl)boronic Acid; 4-Cyanobenzeneboronic Acid; 4-cyanophenyl boronic acid; 4-cyano-phenyl-boronic acid; 4-Boronobenzonitrile; 4-(dihydroxyboranyl)benzonitrile; p-cyanophenylboronic acid; 4-cyanobenzene boronic acid; (4-cyano-phenyl)boronic acid; CEBAHYWORUOILU-UHFFFAOYSA-N; MFCD01318968; BORONIC ACID, (4-CYANOPHENYL)-; 4-Cyanophenylboronic acid, 97%; ACMC-209bbp; AC1MC0VB; 4-cyanoplienylboronic acid; 4-cyano phenylboronic acid; 4-cyano-phenylboronic acid; 4-cyanophenyl-boronic 
DMOLFHZ	DT	Small molecular drug
DMOLFHZ	PC	2734326
DMOLFHZ	MW	146.94
DMOLFHZ	FM	C7H6BNO2
DMOLFHZ	IC	InChI=1S/C7H6BNO2/c9-5-6-1-3-7(4-2-6)8(10)11/h1-4,10-11H
DMOLFHZ	CS	B(C1=CC=C(C=C1)C#N)(O)O
DMOLFHZ	IK	CEBAHYWORUOILU-UHFFFAOYSA-N
DMOLFHZ	IU	(4-cyanophenyl)boronic acid
DMOLFHZ	CA	CAS 126747-14-6
DMOLFHZ	DE	Discovery agent

DMNT5BF	ID	DMNT5BF
DMNT5BF	DN	4-cycloheptyl-6-propylpyrimidine-2-carbonitrile
DMNT5BF	HS	Investigative
DMNT5BF	SN	CHEMBL1085423; 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile; SCHEMBL5796281
DMNT5BF	DT	Small molecular drug
DMNT5BF	PC	11694425
DMNT5BF	MW	243.35
DMNT5BF	FM	C15H21N3
DMNT5BF	IC	InChI=1S/C15H21N3/c1-2-7-13-10-14(18-15(11-16)17-13)12-8-5-3-4-6-9-12/h10,12H,2-9H2,1H3
DMNT5BF	CS	CCCC1=CC(=NC(=N1)C#N)C2CCCCCC2
DMNT5BF	IK	UOAUUFFKQMFGTJ-UHFFFAOYSA-N
DMNT5BF	IU	4-cycloheptyl-6-propylpyrimidine-2-carbonitrile
DMNT5BF	DE	Discovery agent

DM4LIUC	ID	DM4LIUC
DM4LIUC	DN	4-cycloheptyliden(4-hydroxyphenyl)methylphenol
DM4LIUC	HS	Investigative
DM4LIUC	SN	4,4'-(Cycloheptylidenemethylene)diphenol; 4,4'-(Cycloheptylidenemethanediyl)diphenol; 14303-48-1; 4-cycloheptyliden(4-hydroxyphenyl)methylphenol; CHEMBL154947; SCHEMBL3468370; CTK0F0060; DTXSID10469043; XVTAYJKFHUKWSR-UHFFFAOYSA-N; 4,4'-(Cycloheptylidenemethylene)bis(phenol); Phenol, 4-[cycloheptylidene(4-hydroxyphenyl)methyl]-
DM4LIUC	DT	Small molecular drug
DM4LIUC	PC	11587420
DM4LIUC	MW	294.4
DM4LIUC	FM	C20H22O2
DM4LIUC	IC	InChI=1S/C20H22O2/c21-18-11-7-16(8-12-18)20(15-5-3-1-2-4-6-15)17-9-13-19(22)14-10-17/h7-14,21-22H,1-6H2
DM4LIUC	CS	C1CCCC(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)CC1
DM4LIUC	IK	XVTAYJKFHUKWSR-UHFFFAOYSA-N
DM4LIUC	IU	4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenol
DM4LIUC	CA	CAS 14303-48-1
DM4LIUC	DE	Discovery agent

DMTFL5J	ID	DMTFL5J
DMTFL5J	DN	4-Cyclohexyl-4-hydroxy-but-2-enoic acid
DMTFL5J	HS	Investigative
DMTFL5J	SN	CHEMBL171331; 4-cyclohexyl-4-hydroxybut-2-enoic acid; NSC400155; AC1NTOGK; AC1Q5T8F; BDBM50023573; AKOS022641700; NSC-400155; 4-Cyclohexyl-4-hydroxy-but-2-enoic acid; (E)-4-cyclohexyl-4-hydroxybut-2-enoic acid
DMTFL5J	DT	Small molecular drug
DMTFL5J	PC	5385144
DMTFL5J	MW	184.23
DMTFL5J	FM	C10H16O3
DMTFL5J	IC	InChI=1S/C10H16O3/c11-9(6-7-10(12)13)8-4-2-1-3-5-8/h6-9,11H,1-5H2,(H,12,13)/b7-6+
DMTFL5J	CS	C1CCC(CC1)C(/C=C/C(=O)O)O
DMTFL5J	IK	CGIACWYLNZMXMN-VOTSOKGWSA-N
DMTFL5J	IU	(E)-4-cyclohexyl-4-hydroxybut-2-enoic acid
DMTFL5J	DE	Discovery agent

DM10U6S	ID	DM10U6S
DM10U6S	DN	4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
DM10U6S	HS	Investigative
DM10U6S	SN	CHEMBL1085896; 4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
DM10U6S	DT	Small molecular drug
DM10U6S	PC	11622731
DM10U6S	MW	229.32
DM10U6S	FM	C14H19N3
DM10U6S	IC	InChI=1S/C14H19N3/c1-2-6-12-9-13(17-14(10-15)16-12)11-7-4-3-5-8-11/h9,11H,2-8H2,1H3
DM10U6S	CS	CCCC1=CC(=NC(=N1)C#N)C2CCCCC2
DM10U6S	IK	WGTHPYHNMKDPLN-UHFFFAOYSA-N
DM10U6S	IU	4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
DM10U6S	DE	Discovery agent

DMGVIXW	ID	DMGVIXW
DMGVIXW	DN	4-cyclohexylamino-pyrimidine-2-carbonitrile
DMGVIXW	HS	Investigative
DMGVIXW	SN	2-Cyano-pyrimidine, 5; 4-(cyclohexylamino)pyrimidine-2-carbonitrile; CHEMBL221591; BDBM19749; 927176-94-1; 2-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-
DMGVIXW	DT	Small molecular drug
DMGVIXW	PC	16108884
DMGVIXW	MW	202.26
DMGVIXW	FM	C11H14N4
DMGVIXW	IC	InChI=1S/C11H14N4/c12-8-11-13-7-6-10(15-11)14-9-4-2-1-3-5-9/h6-7,9H,1-5H2,(H,13,14,15)
DMGVIXW	CS	C1CCC(CC1)NC2=NC(=NC=C2)C#N
DMGVIXW	IK	UWPRHHHJGYCNGK-UHFFFAOYSA-N
DMGVIXW	IU	4-(cyclohexylamino)pyrimidine-2-carbonitrile
DMGVIXW	DE	Discovery agent

DM8BLK2	ID	DM8BLK2
DM8BLK2	DN	4-cyclohexyliden(4-hydroxyphenyl)methylphenol
DM8BLK2	HS	Investigative
DM8BLK2	SN	4,4'-(cyclohexylidenemethylene)diphenol; 5189-40-2; Cyclofenil diphenol; 4,4'-Cyclohexylidenemethylenediphenol; UNII-00W4083OML; EINECS 225-972-5; BRN 2055864; F 6060; 4-[cyclohexylidene(4-hydroxyphenyl)methyl]phenol; 4-(Cyclohexylidene(4-hydroxyphenyl)methyl)phenol; 00W4083OML; 4,4-Cyclohexylidenemethylenediphenol; Phenol, 4-(cyclohexylidene(4-hydroxyphenyl)methyl)-; alpha-Cyclohexylidene-alpha-(p-hydroxyphenyl)-p-cresol; p-CRESOL, alpha-CYCLOHEXYLIDENE-alpha-(p-HYDROXYPHENYL)-; AC1L2HYB
DM8BLK2	DT	Small molecular drug
DM8BLK2	PC	21260
DM8BLK2	MW	280.4
DM8BLK2	FM	C19H20O2
DM8BLK2	IC	InChI=1S/C19H20O2/c20-17-10-6-15(7-11-17)19(14-4-2-1-3-5-14)16-8-12-18(21)13-9-16/h6-13,20-21H,1-5H2
DM8BLK2	CS	C1CCC(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)CC1
DM8BLK2	IK	POEZOFHZEJTFHF-UHFFFAOYSA-N
DM8BLK2	IU	4-[cyclohexylidene-(4-hydroxyphenyl)methyl]phenol
DM8BLK2	CA	CAS 5189-40-2
DM8BLK2	DE	Discovery agent

DMS42TN	ID	DMS42TN
DMS42TN	DN	4-cyclooctyl-6-propylpyrimidine-2-carbonitrile
DMS42TN	HS	Investigative
DMS42TN	SN	CHEMBL1077194; 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile
DMS42TN	DT	Small molecular drug
DMS42TN	PC	46881498
DMS42TN	MW	257.37
DMS42TN	FM	C16H23N3
DMS42TN	IC	InChI=1S/C16H23N3/c1-2-8-14-11-15(19-16(12-17)18-14)13-9-6-4-3-5-7-10-13/h11,13H,2-10H2,1H3
DMS42TN	CS	CCCC1=CC(=NC(=N1)C#N)C2CCCCCCC2
DMS42TN	IK	AWOXPJKLDJGFMS-UHFFFAOYSA-N
DMS42TN	IU	4-cyclooctyl-6-propylpyrimidine-2-carbonitrile
DMS42TN	DE	Discovery agent

DM7LN53	ID	DM7LN53
DM7LN53	DN	4-cyclopentyliden(4-hydroxyphenyl)methylphenol
DM7LN53	HS	Investigative
DM7LN53	SN	4-cyclopentyliden(4-hydroxyphenyl)methylphenol; 66422-10-4; SCHEMBL3902681; CHEMBL352015; CTK1J4764; DTXSID00468323; ZINC13650257; bis(4-hydroxyphenyl)methylidenecyclopentane; 4,4'-(Cyclopentylidenemethylene)bis(phenol); Phenol, 4-[cyclopentylidene(4-hydroxyphenyl)methyl]-
DM7LN53	DT	Small molecular drug
DM7LN53	PC	11543532
DM7LN53	MW	266.3
DM7LN53	FM	C18H18O2
DM7LN53	IC	InChI=1S/C18H18O2/c19-16-9-5-14(6-10-16)18(13-3-1-2-4-13)15-7-11-17(20)12-8-15/h5-12,19-20H,1-4H2
DM7LN53	CS	C1CCC(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)C1
DM7LN53	IK	GIGYKXHGYNZBEN-UHFFFAOYSA-N
DM7LN53	IU	4-[cyclopentylidene-(4-hydroxyphenyl)methyl]phenol
DM7LN53	CA	CAS 66422-10-4
DM7LN53	DE	Discovery agent

DMZIUQ2	ID	DMZIUQ2
DMZIUQ2	DN	4-DAMP
DMZIUQ2	HS	Investigative
DMZIUQ2	SN	4-Diphenylacetoxy-1,1-dimethylpiperidinium; CHEMBL168067; 81405-11-0; CHEBI:73467; CHEMBL76897; 4-Damp methobromide; C21H26NO2; Tocris-0482; Lopac-D-104; AC1Q60WY; AC1L1C4C; 4-[(diphenylacetyl)oxy]-1,1-dimethylpiperidinium; Lopac0_000407; GTPL307; SCHEMBL2730650; 1952-15-4 (iodide); CTK3E9884; DTXSID70231086; 4-DAMP(1+); ZINC2555356; BDBM50176065; CCG-204500; NCGC00024611-02; NCGC00015304-04; NCGC00015304-03; NCGC00163244-01; NCGC00024611-01; NCGC00015304-02; NCGC00015304-01; LS-177624; N,N-dimethyl-4-(diphenylacetoxy)piperidinium
DMZIUQ2	DT	Small molecular drug
DMZIUQ2	PC	3014059
DMZIUQ2	MW	451.3
DMZIUQ2	FM	C21H26INO2
DMZIUQ2	IC	InChI=1S/C21H26NO2.HI/c1-22(2)15-13-19(14-16-22)24-21(23)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;/h3-12,19-20H,13-16H2,1-2H3;1H/q+1;/p-1
DMZIUQ2	CS	C[N+]1(CCC(CC1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C.[I-]
DMZIUQ2	IK	WWJHRSCUAQPFQO-UHFFFAOYSA-M
DMZIUQ2	IU	(1,1-dimethylpiperidin-1-ium-4-yl) 2,2-diphenylacetate;iodide
DMZIUQ2	CA	CAS 1952-15-4
DMZIUQ2	CB	CHEBI:73340
DMZIUQ2	DE	Discovery agent

DMGQTF9	ID	DMGQTF9
DMGQTF9	DN	4-decyl-N-(pyridin-3-yl)benzamide
DMGQTF9	HS	Investigative
DMGQTF9	SN	CHEMBL259102
DMGQTF9	DT	Small molecular drug
DMGQTF9	PC	44450381
DMGQTF9	MW	338.5
DMGQTF9	FM	C22H30N2O
DMGQTF9	IC	InChI=1S/C22H30N2O/c1-2-3-4-5-6-7-8-9-11-19-13-15-20(16-14-19)22(25)24-21-12-10-17-23-18-21/h10,12-18H,2-9,11H2,1H3,(H,24,25)
DMGQTF9	CS	CCCCCCCCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMGQTF9	IK	QIODTOXMQFMJNV-UHFFFAOYSA-N
DMGQTF9	IU	4-decyl-N-pyridin-3-ylbenzamide
DMGQTF9	DE	Discovery agent

DM93DQG	ID	DM93DQG
DM93DQG	DN	4-dehydroxyriccardin C
DM93DQG	HS	Investigative
DM93DQG	SN	4-dehydroxyriccardin C; Riccardin C derivative, 20d; CHEMBL411246; BDBM23851; 2',4-(Ethylene-1,4-phenylene-oxy-1,3-phenylene-ethylene)-1,1'-biphenyl-2,4'-diol
DM93DQG	DT	Small molecular drug
DM93DQG	PC	24860513
DM93DQG	MW	408.5
DM93DQG	FM	C28H24O3
DM93DQG	IC	InChI=1S/C28H24O3/c29-23-11-15-26-22(18-23)10-6-19-7-12-24(13-8-19)31-25-3-1-2-20(16-25)4-5-21-9-14-27(26)28(30)17-21/h1-3,7-9,11-18,29-30H,4-6,10H2
DM93DQG	CS	C1CC2=C(C=CC(=C2)O)C3=C(C=C(CCC4=CC(=CC=C4)OC5=CC=C1C=C5)C=C3)O
DM93DQG	IK	ZCEPVFMKRVLFDX-UHFFFAOYSA-N
DM93DQG	IU	14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2(7),3,5,10(29),11,13(28),15,17,19(27),22,25-dodecaene-5,24-diol
DM93DQG	DE	Discovery agent

DMQWHLM	ID	DMQWHLM
DMQWHLM	DN	4'-Demethyl-4beta-amino-4-desoxypodophyllotoxin
DMQWHLM	HS	Investigative
DMQWHLM	SN	CHEMBL32083; SCHEMBL4854498; WZTRSUUEQXXWCN-JHQYFNNDSA-N; (5R,5aR,8aS,9S)-9-amino-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; (5R,5aR,8aS,9S)-9-amino-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one
DMQWHLM	DT	Small molecular drug
DMQWHLM	PC	10927468
DMQWHLM	MW	399.4
DMQWHLM	FM	C21H21NO7
DMQWHLM	IC	InChI=1S/C21H21NO7/c1-25-15-3-9(4-16(26-2)20(15)23)17-10-5-13-14(29-8-28-13)6-11(10)19(22)12-7-27-21(24)18(12)17/h3-6,12,17-19,23H,7-8,22H2,1-2H3/t12-,17+,18-,19+/m0/s1
DMQWHLM	CS	COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)N
DMQWHLM	IK	WZTRSUUEQXXWCN-JHQYFNNDSA-N
DMQWHLM	IU	(5S,5aS,8aR,9R)-5-amino-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMQWHLM	DE	Discovery agent

DMIWX3B	ID	DMIWX3B
DMIWX3B	DN	4'-Demethyl-epipodophyllotoxin
DMIWX3B	HS	Investigative
DMIWX3B	SN	4'-Demethylepipodophyllotoxin; 6559-91-7; 4'-DMEP; 4-Demethylepipodophyllotoxin; UNII-X0S6I23X6L; (-)-4'-Demethylepipodophyllotoxin; BRN 1358259; X0S6I23X6L; CHEBI:74422; C21H20O8; (5R,5aR,8aR,9S)-9-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one; (5s,5ar,8ar,9r)-9-(3,5-Dimethoxy-4-Oxidanyl-Phenyl)-5-Oxidanyl-5a,6,8a,9-Tetrahydro-5h-[2]benzofuro[6,5-F][1,3]benzodioxol-8-One; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydrox
DMIWX3B	DT	Small molecular drug
DMIWX3B	PC	122797
DMIWX3B	MW	400.4
DMIWX3B	FM	C21H20O8
DMIWX3B	IC	InChI=1S/C21H20O8/c1-25-15-3-9(4-16(26-2)20(15)23)17-10-5-13-14(29-8-28-13)6-11(10)19(22)12-7-27-21(24)18(12)17/h3-6,12,17-19,22-23H,7-8H2,1-2H3/t12-,17+,18-,19+/m0/s1
DMIWX3B	CS	COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O
DMIWX3B	IK	YVCVYCSAAZQOJI-JHQYFNNDSA-N
DMIWX3B	IU	(5S,5aR,8aR,9R)-5-hydroxy-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMIWX3B	CA	CAS 6559-91-7
DMIWX3B	CB	CHEBI:74422
DMIWX3B	DE	Discovery agent

DMEC1PS	ID	DMEC1PS
DMEC1PS	DN	4-Dimethylamino-2,6-diisopropyl-phenol
DMEC1PS	HS	Investigative
DMEC1PS	SN	CHEMBL55136; ZINC13779581
DMEC1PS	DT	Small molecular drug
DMEC1PS	PC	10727719
DMEC1PS	MW	221.34
DMEC1PS	FM	C14H23NO
DMEC1PS	IC	InChI=1S/C14H23NO/c1-9(2)12-7-11(15(5)6)8-13(10(3)4)14(12)16/h7-10,16H,1-6H3
DMEC1PS	CS	CC(C)C1=CC(=CC(=C1O)C(C)C)N(C)C
DMEC1PS	IK	BOEKREBRMTXRRJ-UHFFFAOYSA-N
DMEC1PS	IU	4-(dimethylamino)-2,6-di(propan-2-yl)phenol
DMEC1PS	DE	Discovery agent

DM0M8G5	ID	DM0M8G5
DM0M8G5	DN	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide
DM0M8G5	HS	Investigative
DM0M8G5	SN	CHEMBL324126
DM0M8G5	DT	Small molecular drug
DM0M8G5	PC	11277483
DM0M8G5	MW	280.4
DM0M8G5	FM	C15H24N2OS
DM0M8G5	IC	InChI=1S/C15H24N2OS/c1-17(2)14-9-7-13(8-10-14)15(18)16-11-5-3-4-6-12-19/h7-10,19H,3-6,11-12H2,1-2H3,(H,16,18)
DM0M8G5	CS	CN(C)C1=CC=C(C=C1)C(=O)NCCCCCCS
DM0M8G5	IK	XMUAFOWTSHBASP-UHFFFAOYSA-N
DM0M8G5	IU	4-(dimethylamino)-N-(6-sulfanylhexyl)benzamide
DM0M8G5	DE	Discovery agent

DMKEHLD	ID	DMKEHLD
DMKEHLD	DN	4-Dipropylamino-cyclohex-1-enecarbonitrile
DMKEHLD	HS	Investigative
DMKEHLD	SN	CHEMBL164631; 4-Dipropylamino-cyclohex-1-enecarbonitrile; SCHEMBL153730
DMKEHLD	DT	Small molecular drug
DMKEHLD	PC	10420539
DMKEHLD	MW	206.33
DMKEHLD	FM	C13H22N2
DMKEHLD	IC	InChI=1S/C13H22N2/c1-3-9-15(10-4-2)13-7-5-12(11-14)6-8-13/h5,13H,3-4,6-10H2,1-2H3
DMKEHLD	CS	CCCN(CCC)C1CCC(=CC1)C#N
DMKEHLD	IK	WKFNOWSGTCBYBL-UHFFFAOYSA-N
DMKEHLD	IU	4-(dipropylamino)cyclohexene-1-carbonitrile
DMKEHLD	DE	Discovery agent

DMD6ROZ	ID	DMD6ROZ
DMD6ROZ	DN	4E2Rcat
DMD6ROZ	HS	Investigative
DMD6ROZ	SN	CAS 432499-63-3
DMD6ROZ	TC	Antiviral Agents
DMD6ROZ	DT	Small molecular drug
DMD6ROZ	PC	2287236
DMD6ROZ	MW	455.9
DMD6ROZ	FM	C22H14ClNO4S2
DMD6ROZ	IC	InChI=1S/C22H14ClNO4S2/c23-17-8-6-14(10-16(17)21(26)27)18-9-7-15(28-18)11-19-20(25)24(22(29)30-19)12-13-4-2-1-3-5-13/h1-11H,12H2,(H,26,27)/b19-11-
DMD6ROZ	CS	C1=CC=C(C=C1)CN2C(=O)/C(=C/C3=CC=C(O3)C4=CC(=C(C=C4)Cl)C(=O)O)/SC2=S
DMD6ROZ	IK	WOBPZFKXPCYOLU-ODLFYWEKSA-N
DMD6ROZ	IU	5-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]-2-chlorobenzoic acid
DMD6ROZ	DE	Coronavirus Disease 2019 (COVID-19)

DM8WAOR	ID	DM8WAOR
DM8WAOR	DN	4-Ethoxy-3-pyridinesulfonamide
DM8WAOR	HS	Investigative
DM8WAOR	SN	CHEMBL1165319; 4-Ethoxy-3-pyridinesulfonamide; 4-ethoxypyridine-3-sulfonamide; SCHEMBL20610078; MolPort-038-948-438; BDBM50320504; ZINC49803276
DM8WAOR	DT	Small molecular drug
DM8WAOR	PC	46703768
DM8WAOR	MW	202.23
DM8WAOR	FM	C7H10N2O3S
DM8WAOR	IC	InChI=1S/C7H10N2O3S/c1-2-12-6-3-4-9-5-7(6)13(8,10)11/h3-5H,2H2,1H3,(H2,8,10,11)
DM8WAOR	CS	CCOC1=C(C=NC=C1)S(=O)(=O)N
DM8WAOR	IK	MQJPVIGZIDYFMM-UHFFFAOYSA-N
DM8WAOR	IU	4-ethoxypyridine-3-sulfonamide
DM8WAOR	CA	CAS 1229666-21-0
DM8WAOR	DE	Discovery agent

DM8642Z	ID	DM8642Z
DM8642Z	DN	4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one
DM8642Z	HS	Investigative
DM8642Z	SN	CHEMBL76874; MRS1066; GTPL396; MRS-1066; BDBM50051338; AKOS030557417
DM8642Z	DT	Small molecular drug
DM8642Z	PC	10806465
DM8642Z	MW	332.3
DM8642Z	FM	C21H16O4
DM8642Z	IC	InChI=1S/C21H16O4/c1-2-23-21-16-10-11-24-18(16)13-19-20(21)17(22)12-15(25-19)9-8-14-6-4-3-5-7-14/h3-13H,2H2,1H3/b9-8+
DM8642Z	CS	CCOC1=C2C=COC2=CC3=C1C(=O)C=C(O3)/C=C/C4=CC=CC=C4
DM8642Z	IK	TZRUAYHMQMKKLT-CMDGGOBGSA-N
DM8642Z	IU	4-ethoxy-7-[(E)-2-phenylethenyl]furo[3,2-g]chromen-5-one
DM8642Z	DE	Discovery agent

DMUN7KC	ID	DMUN7KC
DMUN7KC	DN	4-ethoxynaphthalene-1,2-dione
DMUN7KC	HS	Investigative
DMUN7KC	SN	4-ethoxynaphthalene-1,2-dione; 4-ethoxy-1,2-naphthoquinone; CHEMBL50620; 4-Ethoxy-[1,2]naphthoquinone; 7473-19-0; NSC400247; AC1L7Z1H; 4-Ethoxy-1,2-naphthalenedione; SCHEMBL5595641; DTXSID70322029; XPXODXIULRDWNT-UHFFFAOYSA-N; 1,2-Naphthalenedione, 4-ethoxy-; ZINC1593117; BDBM50099736
DMUN7KC	DT	Small molecular drug
DMUN7KC	PC	343759
DMUN7KC	MW	202.21
DMUN7KC	FM	C12H10O3
DMUN7KC	IC	InChI=1S/C12H10O3/c1-2-15-11-7-10(13)12(14)9-6-4-3-5-8(9)11/h3-7H,2H2,1H3
DMUN7KC	CS	CCOC1=CC(=O)C(=O)C2=CC=CC=C21
DMUN7KC	IK	XPXODXIULRDWNT-UHFFFAOYSA-N
DMUN7KC	IU	4-ethoxynaphthalene-1,2-dione
DMUN7KC	CA	CAS 7473-19-0
DMUN7KC	DE	Discovery agent

DMTIY89	ID	DMTIY89
DMTIY89	DN	4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMTIY89	HS	Investigative
DMTIY89	SN	4-ethyl-2-(4-hydroxyphenyl)quinolin-6-ol
DMTIY89	PC	135430317
DMTIY89	MW	265.31
DMTIY89	FM	C17H15NO2
DMTIY89	IC	InChI=1S/C17H15NO2/c1-2-11-9-17(12-3-5-13(19)6-4-12)18-16-8-7-14(20)10-15(11)16/h3-10,19-20H,2H2,1H3
DMTIY89	CS	CCC1=CC(=NC2=C1C=C(C=C2)O)C3=CC=C(C=C3)O
DMTIY89	IK	JHGHNHLKUJDBRE-UHFFFAOYSA-N
DMTIY89	IU	4-ethyl-2-(4-hydroxyphenyl)quinolin-6-ol
DMTIY89	DE	Discovery agent

DMHDN25	ID	DMHDN25
DMHDN25	DN	4-ethyl-3,4-dihydroquinazolin-2-amine
DMHDN25	HS	Investigative
DMHDN25	SN	CHEMBL270841
DMHDN25	DT	Small molecular drug
DMHDN25	PC	44455986
DMHDN25	MW	175.23
DMHDN25	FM	C10H13N3
DMHDN25	IC	InChI=1S/C10H13N3/c1-2-8-7-5-3-4-6-9(7)13-10(11)12-8/h3-6,8H,2H2,1H3,(H3,11,12,13)
DMHDN25	CS	CCC1C2=CC=CC=C2NC(=N1)N
DMHDN25	IK	FUFWGLRRMNVLPD-UHFFFAOYSA-N
DMHDN25	IU	4-ethyl-1,4-dihydroquinazolin-2-amine
DMHDN25	DE	Discovery agent

DM5G3NU	ID	DM5G3NU
DM5G3NU	DN	4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine
DM5G3NU	HS	Investigative
DM5G3NU	SN	CHEMBL184798; 4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150930
DM5G3NU	DT	Small molecular drug
DM5G3NU	PC	19049061
DM5G3NU	MW	126.2
DM5G3NU	FM	C7H14N2
DM5G3NU	IC	InChI=1S/C7H14N2/c1-3-6-4-9-7(8)5(6)2/h5-6H,3-4H2,1-2H3,(H2,8,9)
DM5G3NU	CS	CCC1CN=C(C1C)N
DM5G3NU	IK	BIWSZTWZJHYWGX-UHFFFAOYSA-N
DM5G3NU	IU	3-ethyl-4-methyl-3,4-dihydro-2H-pyrrol-5-amine
DM5G3NU	DE	Discovery agent

DMTM1VD	ID	DMTM1VD
DMTM1VD	DN	4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine
DMTM1VD	HS	Investigative
DMTM1VD	SN	CHEMBL260277; 4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine; BDBM50237936; AKOS006359116; 4-Ethyl-1,2,5,6-tetrahydropyridine-2-imine
DMTM1VD	DT	Small molecular drug
DMTM1VD	PC	10130105
DMTM1VD	MW	124.18
DMTM1VD	FM	C7H12N2
DMTM1VD	IC	InChI=1S/C7H12N2/c1-2-6-3-4-9-7(8)5-6/h5H,2-4H2,1H3,(H2,8,9)
DMTM1VD	CS	CCC1=CC(=NCC1)N
DMTM1VD	IK	PZWTXXAVOPPTGW-UHFFFAOYSA-N
DMTM1VD	IU	4-ethyl-2,3-dihydropyridin-6-amine
DMTM1VD	DE	Discovery agent

DMOAQ1E	ID	DMOAQ1E
DMOAQ1E	DN	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine
DMOAQ1E	HS	Investigative
DMOAQ1E	SN	CHEMBL363477; 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150933
DMOAQ1E	DT	Small molecular drug
DMOAQ1E	PC	19049121
DMOAQ1E	MW	126.2
DMOAQ1E	FM	C7H14N2
DMOAQ1E	IC	InChI=1S/C7H14N2/c1-3-6-4-7(8)9-5(6)2/h5-6H,3-4H2,1-2H3,(H2,8,9)
DMOAQ1E	CS	CCC1CC(=NC1C)N
DMOAQ1E	IK	NMCNOZCNKVOIET-UHFFFAOYSA-N
DMOAQ1E	IU	3-ethyl-2-methyl-3,4-dihydro-2H-pyrrol-5-amine
DMOAQ1E	DE	Discovery agent

DMYO2GP	ID	DMYO2GP
DMYO2GP	DN	4-Ethyl-5-piperidin-4-yl-isoxazol-3-ol
DMYO2GP	HS	Investigative
DMYO2GP	SN	CHEMBL143993; 439944-80-6; 3(2H)-Isoxazolone, 4-ethyl-5-(4-piperidinyl)-; CHEMBL543365; 4-ethyl-5-piperidin-4-yl-isoxazol-3-ol; CTK1C8002; DTXSID50445689; BDBM50113809; AKOS030538897; AKOS015904779; 4-ethyl-5-(4-piperidinyl)-3-isoxazolol; 4-Ethyl-5-(4-piperidinyl)isoxazole-3-ol; I14-23452; 4-Ethyl-5-piperidin-4-yl-isoxazol-3-ol
DMYO2GP	DT	Small molecular drug
DMYO2GP	PC	10845560
DMYO2GP	MW	196.25
DMYO2GP	FM	C10H16N2O2
DMYO2GP	IC	InChI=1S/C10H16N2O2/c1-2-8-9(14-12-10(8)13)7-3-5-11-6-4-7/h7,11H,2-6H2,1H3,(H,12,13)
DMYO2GP	CS	CCC1=C(ONC1=O)C2CCNCC2
DMYO2GP	IK	NKLHMQIBLBZVKZ-UHFFFAOYSA-N
DMYO2GP	IU	4-ethyl-5-piperidin-4-yl-1,2-oxazol-3-one
DMYO2GP	CA	CAS 439944-80-6
DMYO2GP	DE	Discovery agent

DMG0Y3W	ID	DMG0Y3W
DMG0Y3W	DN	4-Ethyl-oxazolidin-(2Z)-ylideneamine
DMG0Y3W	HS	Investigative
DMG0Y3W	SN	CHEMBL108788; 4-Ethyl-oxazolidin-(2Z)-ylideneamine; 4-Ethyloxazolidine-2-imine; SCHEMBL10211233; BDBM50138188; AKOS013533141
DMG0Y3W	DT	Small molecular drug
DMG0Y3W	PC	44337211
DMG0Y3W	MW	114.15
DMG0Y3W	FM	C5H10N2O
DMG0Y3W	IC	InChI=1S/C5H10N2O/c1-2-4-3-8-5(6)7-4/h4H,2-3H2,1H3,(H2,6,7)
DMG0Y3W	CS	CCC1COC(=N1)N
DMG0Y3W	IK	JTEWXLMHFCOPAX-UHFFFAOYSA-N
DMG0Y3W	IU	4-ethyl-4,5-dihydro-1,3-oxazol-2-amine
DMG0Y3W	DE	Discovery agent

DMYIWAH	ID	DMYIWAH
DMYIWAH	DN	4-Ethyl-pyrrolidin-(2Z)-ylideneamine
DMYIWAH	HS	Investigative
DMYIWAH	SN	CHEMBL360616; CHEMBL543886; 4-Ethylpyrrolidine-2-imine; SCHEMBL7593608; BDBM50066783; AKOS006353400; 4-Ethyl-pyrrolidin-(2E)-ylideneamine
DMYIWAH	DT	Small molecular drug
DMYIWAH	PC	10725313
DMYIWAH	MW	112.17
DMYIWAH	FM	C6H12N2
DMYIWAH	IC	InChI=1S/C6H12N2/c1-2-5-3-6(7)8-4-5/h5H,2-4H2,1H3,(H2,7,8)
DMYIWAH	CS	CCC1CC(=NC1)N
DMYIWAH	IK	YDJLYZDTIUKJQI-UHFFFAOYSA-N
DMYIWAH	IU	3-ethyl-3,4-dihydro-2H-pyrrol-5-amine
DMYIWAH	DE	Discovery agent

DMIF1D6	ID	DMIF1D6
DMIF1D6	DN	4-ethynyl benzene sulfonamide
DMIF1D6	HS	Investigative
DMIF1D6	SN	4-ethynylbenzenesulfonamide; 1788-08-5; 4-Ethynylbenzene-1-sulfonamide; 4-Ethynybenzenesulfonamide; 4-ethynyl benzene sulfonamide; Benzenesulfonamide, 4-ethynyl-; CHEMBL272881; benzenesulfonamide, 4-ethynyl- (9ci); P-Ethynylbenzenesulfonamide; 4-ethvnylbenzenesulfonamide; 4-ethynylbenzene sulfonamide; 4-ethynyl-benzenesulfonamide; Benzenesulfonamide,4-ethynyl-; SCHEMBL1066580; CTK4D6902; DTXSID80659176; OQPUCENNUFNCQO-UHFFFAOYSA-N; MolPort-004-759-802; KS-00000L2U; ANW-45086; BDBM50236140; ZINC29134554; FC0779; AKOS006308323
DMIF1D6	DT	Small molecular drug
DMIF1D6	PC	44457221
DMIF1D6	MW	181.21
DMIF1D6	FM	C8H7NO2S
DMIF1D6	IC	InChI=1S/C8H7NO2S/c1-2-7-3-5-8(6-4-7)12(9,10)11/h1,3-6H,(H2,9,10,11)
DMIF1D6	CS	C#CC1=CC=C(C=C1)S(=O)(=O)N
DMIF1D6	IK	OQPUCENNUFNCQO-UHFFFAOYSA-N
DMIF1D6	IU	4-ethynylbenzenesulfonamide
DMIF1D6	CA	CAS 1788-08-5
DMIF1D6	DE	Discovery agent

DMXLZAT	ID	DMXLZAT
DMXLZAT	DN	4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMXLZAT	HS	Investigative
DMXLZAT	SN	4-ethynyl-2-(4-hydroxyphenyl)quinolin-6-ol
DMXLZAT	PC	135524856
DMXLZAT	MW	261.269
DMXLZAT	FM	C17H11NO2
DMXLZAT	IC	InChI=1S/C17H11NO2/c1-2-11-9-17(12-3-5-13(19)6-4-12)18-16-8-7-14(20)10-15(11)16/h1,3-10,19-20H
DMXLZAT	CS	C#CC1=CC(=NC2=C1C=C(C=C2)O)C3=CC=C(C=C3)O
DMXLZAT	IK	LZRCWCHYOCKNED-UHFFFAOYSA-N
DMXLZAT	IU	4-ethynyl-2-(4-hydroxyphenyl)quinolin-6-ol
DMXLZAT	DE	Discovery agent

DMNDS19	ID	DMNDS19
DMNDS19	DN	4-Flourobenzenesulfonamide
DMNDS19	HS	Investigative
DMNDS19	SN	4-Fluorobenzenesulfonamide; 402-46-0; p-Fluorobenzenesulfonamide; 4-fluorobenzenesulphonamide; 4-fluorobenzene-1-sulfonamide; p-Fluorobenzenesulphonamide; 4-FLOUROBENZENESULFONAMIDE; EINECS 206-946-2; 4-fluoro-benzenesulfonamide; BRN 2832246; Benzenesulfonamide, p-fluoro-; Benzenesulfonamide, 4-fluoro-; PubChem2167; ACMC-1ACSJ; 4-Fuloro sulfonamide, C; 4-fluorobenzene sulfonamide; Cambridge id 5135296; AC1Q55BS; AC1L3QD2; 4-fluoranylbenzenesulfonamide; 4-fluoro benzene sulfonamide; Benzenesulfonamide,4-fluoro-; 4-11-00-00102 (Be
DMNDS19	DT	Small molecular drug
DMNDS19	PC	120231
DMNDS19	MW	175.18
DMNDS19	FM	C6H6FNO2S
DMNDS19	IC	InChI=1S/C6H6FNO2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,(H2,8,9,10)
DMNDS19	CS	C1=CC(=CC=C1F)S(=O)(=O)N
DMNDS19	IK	LFLSATHZMYYIAQ-UHFFFAOYSA-N
DMNDS19	IU	4-fluorobenzenesulfonamide
DMNDS19	CA	CAS 402-46-0
DMNDS19	DE	Discovery agent

DMW9I1X	ID	DMW9I1X
DMW9I1X	DN	4-Fluoren-9-ylidenemethyl-pyridine
DMW9I1X	HS	Investigative
DMW9I1X	SN	MLS002694154; 4-(9H-fluoren-9-ylidenemethyl)pyridine; 4-Fluoren-9-ylidenemethyl-pyridine; NSC83319; AC1L5UM6; NCIOpen2_004593; Oprea1_438447; Oprea1_732020; BDBM8644; CHEMBL383145; 9-(4-pyridylmethylene)fluorene; SCHEMBL8276094; CTK7D1435; (4-Pyridylmethylene)fluorene 34; HMS3088F22; 4-(fluoren-9-ylidenemethyl)pyridine; ZINC13283063; NSC-83319; AKOS000634958; Pyridine, 4-(fluoren-9-ylidenemethyl)-; 4-(9H-Fluorene-9-ylidenemethyl)pyridine; SMR001560085; BAS 00004846; SR-01000321373
DMW9I1X	DT	Small molecular drug
DMW9I1X	PC	256445
DMW9I1X	MW	255.3
DMW9I1X	FM	C19H13N
DMW9I1X	IC	InChI=1S/C19H13N/c1-3-7-17-15(5-1)16-6-2-4-8-18(16)19(17)13-14-9-11-20-12-10-14/h1-13H
DMW9I1X	CS	C1=CC=C2C(=C1)C3=CC=CC=C3C2=CC4=CC=NC=C4
DMW9I1X	IK	YVNXZDHQCSSQMR-UHFFFAOYSA-N
DMW9I1X	IU	4-(fluoren-9-ylidenemethyl)pyridine
DMW9I1X	DE	Discovery agent

DM0INZX	ID	DM0INZX
DM0INZX	DN	4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol
DM0INZX	HS	Investigative
DM0INZX	SN	CHEMBL570102; BDBM50299654
DM0INZX	DT	Small molecular drug
DM0INZX	PC	44543260
DM0INZX	MW	280.3
DM0INZX	FM	C18H13FO2
DM0INZX	IC	InChI=1S/C18H13FO2/c19-17-9-8-15(11-18(17)21)13-6-4-12(5-7-13)14-2-1-3-16(20)10-14/h1-11,20-21H
DM0INZX	CS	C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC(=C(C=C3)F)O
DM0INZX	IK	MCDQJOWWXZILHP-UHFFFAOYSA-N
DM0INZX	IU	2-fluoro-5-[4-(3-hydroxyphenyl)phenyl]phenol
DM0INZX	DE	Discovery agent

DMQ1D9A	ID	DMQ1D9A
DMQ1D9A	DN	4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID
DMQ1D9A	HS	Investigative
DMQ1D9A	SN	5731-10-2; 4-(4-Fluorophenyl)benzoic acid; 4'-Fluoro-biphenyl-4-carboxylic acid; 4'-fluorobiphenyl-4-carboxylic acid; 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID; 4'-Fluoro-biphenyl-4-carboxylic aci; 4'-Fluoro-[1,1'-biphenyl]-4-carboxylic acid; CHEMBL106708; MFCD01631909; 4-(4-Fluorophenyl)benzoic acid, 97%; 4'-fluoro[1,1'-biphenyl]-4-carboxylic acid; 4FC; 4'-fluoro(1,1'-biphenyl)-4-carboxylic acid; 1ysg; 4-Biphenyl-4'-fluoro-carboxylicacid; 4-Biphenyl-4'-fluoro-carboxylic acid; PubChem10277; 1,5-dibenzoyloxybenzene
DMQ1D9A	DT	Small molecular drug
DMQ1D9A	PC	2782689
DMQ1D9A	MW	216.21
DMQ1D9A	FM	C13H9FO2
DMQ1D9A	IC	InChI=1S/C13H9FO2/c14-12-7-5-10(6-8-12)9-1-3-11(4-2-9)13(15)16/h1-8H,(H,15,16)
DMQ1D9A	CS	C1=CC(=CC=C1C2=CC=C(C=C2)F)C(=O)O
DMQ1D9A	IK	LXWNTLBMNCXRQN-UHFFFAOYSA-N
DMQ1D9A	IU	4-(4-fluorophenyl)benzoic acid
DMQ1D9A	CA	CAS 5731-10-2
DMQ1D9A	DE	Discovery agent

DM2N4BJ	ID	DM2N4BJ
DM2N4BJ	DN	4-fluorobenzaldehyde O-benzoyloxime
DM2N4BJ	HS	Investigative
DM2N4BJ	SN	4-fluorobenzaldehyde O-benzoyloxime; CHEMBL180720; SCHEMBL3225285; SCHEMBL3225274
DM2N4BJ	DT	Small molecular drug
DM2N4BJ	PC	11368513
DM2N4BJ	MW	243.23
DM2N4BJ	FM	C14H10FNO2
DM2N4BJ	IC	InChI=1S/C14H10FNO2/c15-13-8-6-11(7-9-13)10-16-18-14(17)12-4-2-1-3-5-12/h1-10H/b16-10+
DM2N4BJ	CS	C1=CC=C(C=C1)C(=O)O/N=C/C2=CC=C(C=C2)F
DM2N4BJ	IK	DIEBAKUPBFEXAP-MHWRWJLKSA-N
DM2N4BJ	IU	[(E)-(4-fluorophenyl)methylideneamino] benzoate
DM2N4BJ	DE	Discovery agent

DMS6RHD	ID	DMS6RHD
DMS6RHD	DN	4-Fluorobenzenemethanethiol
DMS6RHD	HS	Investigative
DMS6RHD	SN	4-Fluorobenzyl mercaptan; 15894-04-9; (4-Fluorophenyl)methanethiol; 4-Fluoro benzyl mercaptan; 4-fluorobenzylmercaptan; 4-Fluorobenzenemethanethiol; p-Fluorotoluene-alpha-thiol; 4-fluorophenylmethanethiol; 4-fluoro-alpha-toluenethiol; Benzenemethanethiol, 4-fluoro-; (4-fluoro-phenyl)-methanethiol; CHEMBL1224558; 4-Fluorobenzyl mercaptan, 96%; RKTRHMNWVZRZJQ-UHFFFAOYSA-N; 4-fluorobenzylthiol; EINECS 240-031-9; 4-fluorobenzyl thiol; PubChem6855; 4-fluorobenzylmercaptane; AC1Q4NST; p-fluorobenzenemethanethiol; ACMC-209dj5
DMS6RHD	DT	Small molecular drug
DMS6RHD	PC	85171
DMS6RHD	MW	142.2
DMS6RHD	FM	C7H7FS
DMS6RHD	IC	InChI=1S/C7H7FS/c8-7-3-1-6(5-9)2-4-7/h1-4,9H,5H2
DMS6RHD	CS	C1=CC(=CC=C1CS)F
DMS6RHD	IK	RKTRHMNWVZRZJQ-UHFFFAOYSA-N
DMS6RHD	IU	(4-fluorophenyl)methanethiol
DMS6RHD	CA	CAS 15894-04-9
DMS6RHD	DE	Discovery agent

DMWD42N	ID	DMWD42N
DMWD42N	DN	4-fluorobenzoyl-Phe-Gly-Leu-Arg-Trp-NH2
DMWD42N	HS	Investigative
DMWD42N	SN	CHEMBL388586; Peptide analogue, 1; SCHEMBL4132720; BDBM26338; FTM-080; N-[(4-fluorophenyl)carbonyl]-L-phenylalanylglycyl-L-leucyl-L-arginyl-L-tryptophanamide
DMWD42N	DT	Small molecular drug
DMWD42N	PC	16735569
DMWD42N	MW	798.9
DMWD42N	FM	C41H51FN10O6
DMWD42N	IC	InChI=1S/C41H51FN10O6/c1-24(2)19-33(49-35(53)23-48-38(56)34(20-25-9-4-3-5-10-25)52-37(55)26-14-16-28(42)17-15-26)40(58)50-31(13-8-18-46-41(44)45)39(57)51-32(36(43)54)21-27-22-47-30-12-7-6-11-29(27)30/h3-7,9-12,14-17,22,24,31-34,47H,8,13,18-21,23H2,1-2H3,(H2,43,54)(H,48,56)(H,49,53)(H,50,58)(H,51,57)(H,52,55)(H4,44,45,46)/t31-,32-,33-,34-/m0/s1
DMWD42N	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N)NC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)C4=CC=C(C=C4)F
DMWD42N	IK	CSDUUNOZBMGMHZ-CUPIEXAXSA-N
DMWD42N	IU	N-[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-4-fluorobenzamide
DMWD42N	DE	Discovery agent

DMV6M5U	ID	DMV6M5U
DMV6M5U	DN	4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline
DMV6M5U	HS	Investigative
DMV6M5U	SN	CHEMBL1240925; 4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline
DMV6M5U	DT	Small molecular drug
DMV6M5U	PC	46937407
DMV6M5U	MW	265.31
DMV6M5U	FM	C13H12FNO2S
DMV6M5U	IC	InChI=1S/C13H12FNO2S/c1-18(16,17)13-8-6-12(7-9-13)15-11-4-2-10(14)3-5-11/h2-9,15H,1H3
DMV6M5U	CS	CS(=O)(=O)C1=CC=C(C=C1)NC2=CC=C(C=C2)F
DMV6M5U	IK	QTRCGPBYCSHGJM-UHFFFAOYSA-N
DMV6M5U	IU	4-fluoro-N-(4-methylsulfonylphenyl)aniline
DMV6M5U	DE	Discovery agent

DMGBKN7	ID	DMGBKN7
DMGBKN7	DN	4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMGBKN7	HS	Investigative
DMGBKN7	SN	CHEMBL511186; 4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide; 4-({[(4-fluorophenyl)sulfonyl]amino}methyl)benzenesulfonamide; 4-[[[(4-Fluorophenyl)sulfonyl]amino]methyl]benzenesulfonamide; BAS 02065178; AC1LG4NC; Cambridge id 6100956; Oprea1_631950; Oprea1_795607; MolPort-001-510-834; ZINC288074; STK396016; BDBM50247721; AKOS000644386; MCULE-1179145360; ST50706913; AB00102538-01; Z45537946; N-[4-(aminosulfonyl)benzyl]-4-fluoro-1-benzenesulfonamide; 4-[[(4-fluorophenyl)sulfonylamino]methyl]benzenesulfonamide
DMGBKN7	DT	Small molecular drug
DMGBKN7	PC	788811
DMGBKN7	MW	344.4
DMGBKN7	FM	C13H13FN2O4S2
DMGBKN7	IC	InChI=1S/C13H13FN2O4S2/c14-11-3-7-13(8-4-11)22(19,20)16-9-10-1-5-12(6-2-10)21(15,17)18/h1-8,16H,9H2,(H2,15,17,18)
DMGBKN7	CS	C1=CC(=CC=C1CNS(=O)(=O)C2=CC=C(C=C2)F)S(=O)(=O)N
DMGBKN7	IK	RXAAVLURIXEENO-UHFFFAOYSA-N
DMGBKN7	IU	4-[[(4-fluorophenyl)sulfonylamino]methyl]benzenesulfonamide
DMGBKN7	DE	Discovery agent

DMZV3MD	ID	DMZV3MD
DMZV3MD	DN	4-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate
DMZV3MD	HS	Investigative
DMZV3MD	SN	CHEMBL604388; 4-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate; SCHEMBL5215965
DMZV3MD	DT	Small molecular drug
DMZV3MD	PC	20872768
DMZV3MD	MW	345.4
DMZV3MD	FM	C20H24FNO3
DMZV3MD	IC	InChI=1S/C20H24FNO3/c1-3-5-14-24-17-10-6-15(7-11-17)19(4-2)22-20(23)25-18-12-8-16(21)9-13-18/h6-13,19H,3-5,14H2,1-2H3,(H,22,23)
DMZV3MD	CS	CCCCOC1=CC=C(C=C1)C(CC)NC(=O)OC2=CC=C(C=C2)F
DMZV3MD	IK	IEKBPHHXDXKATO-UHFFFAOYSA-N
DMZV3MD	IU	(4-fluorophenyl) N-[1-(4-butoxyphenyl)propyl]carbamate
DMZV3MD	DE	Discovery agent

DMCRJ54	ID	DMCRJ54
DMCRJ54	DN	4-fluorophenyl 4-butoxybenzylcarbamate
DMCRJ54	HS	Investigative
DMCRJ54	SN	4-fluorophenyl 4-butoxybenzylcarbamate; CHEMBL607558; SCHEMBL5216504
DMCRJ54	DT	Small molecular drug
DMCRJ54	PC	20872770
DMCRJ54	MW	317.4
DMCRJ54	FM	C18H20FNO3
DMCRJ54	IC	InChI=1S/C18H20FNO3/c1-2-3-12-22-16-8-4-14(5-9-16)13-20-18(21)23-17-10-6-15(19)7-11-17/h4-11H,2-3,12-13H2,1H3,(H,20,21)
DMCRJ54	CS	CCCCOC1=CC=C(C=C1)CNC(=O)OC2=CC=C(C=C2)F
DMCRJ54	IK	BVPXJSVMJYBIRX-UHFFFAOYSA-N
DMCRJ54	IU	(4-fluorophenyl) N-[(4-butoxyphenyl)methyl]carbamate
DMCRJ54	DE	Discovery agent

DMI03KV	ID	DMI03KV
DMI03KV	DN	4-fluorophenyl-2,2-diphenylacetamide
DMI03KV	HS	Investigative
DMI03KV	SN	CHEMBL258604; SCHEMBL2337394
DMI03KV	DT	Small molecular drug
DMI03KV	PC	9879550
DMI03KV	MW	305.3
DMI03KV	FM	C20H16FNO
DMI03KV	IC	InChI=1S/C20H16FNO/c21-18-13-11-17(12-14-18)20(19(22)23,15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-14H,(H2,22,23)
DMI03KV	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=C(C=C3)F)C(=O)N
DMI03KV	IK	JHPLFDBQYVMFCT-UHFFFAOYSA-N
DMI03KV	IU	2-(4-fluorophenyl)-2,2-diphenylacetamide
DMI03KV	DE	Discovery agent

DMD5LXQ	ID	DMD5LXQ
DMD5LXQ	DN	4-fluorophenylboronic acid
DMD5LXQ	HS	Investigative
DMD5LXQ	SN	4-Fluorophenylboronic acid; 1765-93-1; 4-Fluorobenzeneboronic acid; (4-fluorophenyl)boronic acid; 4-Fluorophenyl boronic acid; (4-fluorophenyl)boranediol; p-fluorophenylboronic acid; 4-fluorophenylbornic acid; 4-Fluorophenylboric acid; (4-FLUOROPHENYL)DIHYDROXYBORON; p-fluorobenzeneboronic acid; 4-fluoro phenylboronic acid; C6H6BFO2; 4-Fluoro Phenyl Boronic Acid; CHEMBL344890; (4-fluorophenyl)dihydroxyborane; CHEBI:48661; Boronic acid, (4-fluorophenyl)-; LBUNNMJLXWQQBY-UHFFFAOYSA-N; (P-FLUOROPHENYL)BORIC ACID
DMD5LXQ	DT	Small molecular drug
DMD5LXQ	PC	285645
DMD5LXQ	MW	139.92
DMD5LXQ	FM	C6H6BFO2
DMD5LXQ	IC	InChI=1S/C6H6BFO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4,9-10H
DMD5LXQ	CS	B(C1=CC=C(C=C1)F)(O)O
DMD5LXQ	IK	LBUNNMJLXWQQBY-UHFFFAOYSA-N
DMD5LXQ	IU	(4-fluorophenyl)boronic acid
DMD5LXQ	CA	CAS 1765-93-1
DMD5LXQ	CB	CHEBI:48661
DMD5LXQ	DE	Discovery agent

DMRC49E	ID	DMRC49E
DMRC49E	DN	4-fluoroselegiline
DMRC49E	HS	Investigative
DMRC49E	SN	CH-175; SR-96516; P-Fluoro-Selegiline; P-Fluoro-Selegiline hydrochloride
DMRC49E	CP	Chinoin Gyogyszer Es Vegyeszeti
DMRC49E	DE	Dementia

DM1VNEF	ID	DM1VNEF
DM1VNEF	DN	4-formylphenyl-O-beta-Dglucopyranoside
DM1VNEF	HS	Investigative
DM1VNEF	SN	Helicid; 26993-16-8; HELECIN; 4-formylphenyl b-d-glucopyranoside; 4-Formylphenyl beta-D-glucopyranoside; CHEMBL461515; 4-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde; 4-formylphenyl-O-beta-Dglucopyranoside; helicin hydrate; 4'-Formylphenyl-beta-d-glucopyranoside; Gastrodin Impurity 1; AC1OPT9G; SCHEMBL987981; CTK8F5959; MolPort-000-629-575; ZINC5234422; BDBM50245886; AKOS015960450; AC-7974; 4-formylphenyl-O-beta-D-glucopyranoside; 4-(beta-d-glucopyranosyloxy)benzaldehyde
DM1VNEF	DT	Small molecular drug
DM1VNEF	PC	7573800
DM1VNEF	MW	284.26
DM1VNEF	FM	C13H16O7
DM1VNEF	IC	InChI=1S/C13H16O7/c14-5-7-1-3-8(4-2-7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-5,9-13,15-18H,6H2/t9-,10-,11+,12-,13-/m1/s1
DM1VNEF	CS	C1=CC(=CC=C1C=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM1VNEF	IK	OLZAGZCCJJBKNZ-UJPOAAIJSA-N
DM1VNEF	IU	4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzaldehyde
DM1VNEF	DE	Discovery agent

DM7DW0G	ID	DM7DW0G
DM7DW0G	DN	4-formylphenyl-O-beta-D-ribopyranoside
DM7DW0G	HS	Investigative
DM7DW0G	SN	CHEMBL499285; 4-formylphenyl-O-beta-D-ribopyranoside; 4-formylphenyl beta-d-ribopyranoside; BDBM50245887
DM7DW0G	DT	Small molecular drug
DM7DW0G	PC	24796254
DM7DW0G	MW	254.24
DM7DW0G	FM	C12H14O6
DM7DW0G	IC	InChI=1S/C12H14O6/c13-5-7-1-3-8(4-2-7)18-12-11(16)10(15)9(14)6-17-12/h1-5,9-12,14-16H,6H2/t9-,10-,11-,12+/m1/s1
DM7DW0G	CS	C1[C@H]([C@H]([C@H]([C@@H](O1)OC2=CC=C(C=C2)C=O)O)O)O
DM7DW0G	IK	QGBRWWHJQCFYEI-KKOKHZNYSA-N
DM7DW0G	IU	4-[(2S,3R,4R,5R)-3,4,5-trihydroxyoxan-2-yl]oxybenzaldehyde
DM7DW0G	DE	Discovery agent

DMKT915	ID	DMKT915
DMKT915	DN	4-Furan-2-yl-6-nitro-2-piperazin-1-yl-quinoline
DMKT915	HS	Investigative
DMKT915	SN	CHEMBL166948; 4-Furan-2-yl-6-nitro-2-piperazin-1-yl-quinoline; SCHEMBL6364878; APJKUNDSNZQZPA-UHFFFAOYSA-N; BDBM50110576; 2-Piperazino-4-(2-furyl)-6-nitroquinoline
DMKT915	DT	Small molecular drug
DMKT915	PC	44379696
DMKT915	MW	324.33
DMKT915	FM	C17H16N4O3
DMKT915	IC	InChI=1S/C17H16N4O3/c22-21(23)12-3-4-15-13(10-12)14(16-2-1-9-24-16)11-17(19-15)20-7-5-18-6-8-20/h1-4,9-11,18H,5-8H2
DMKT915	CS	C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)C4=CC=CO4
DMKT915	IK	APJKUNDSNZQZPA-UHFFFAOYSA-N
DMKT915	IU	4-(furan-2-yl)-6-nitro-2-piperazin-1-ylquinoline
DMKT915	DE	Discovery agent

DMRF9NH	ID	DMRF9NH
DMRF9NH	DN	4'-GALACTOSYLLACTOSE
DMRF9NH	HS	Investigative
DMRF9NH	SN	O-beta-D-Galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-D-glucose; 4'-GL
DMRF9NH	DT	Small molecular drug
DMRF9NH	PC	10874809
DMRF9NH	MW	504.4
DMRF9NH	FM	C18H32O16
DMRF9NH	IC	InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13-,14-,15+,16?,17+,18+/m1/s1
DMRF9NH	CS	C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)O)O
DMRF9NH	IK	FYGDTMLNYKFZSV-YXENHOCSSA-N
DMRF9NH	IU	(2S,3R,4S,5R,6R)-2-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMRF9NH	CA	CAS 157240-67-0
DMRF9NH	CB	CHEBI:63141
DMRF9NH	DE	Hyperlipidaemia

DM5MHO6	ID	DM5MHO6
DM5MHO6	DN	4-Hept-3-ynyl-1H-imidazole
DM5MHO6	HS	Investigative
DM5MHO6	SN	CHEMBL276804; 4-Hept-3-ynyl-1H-imidazole; 1H-Imidazole, 5-(3-heptyn-1-yl)-; SCHEMBL7620435; 4-(3-Heptynyl)-1H-imidazole; BDBM50070215
DM5MHO6	DT	Small molecular drug
DM5MHO6	PC	10630835
DM5MHO6	MW	162.23
DM5MHO6	FM	C10H14N2
DM5MHO6	IC	InChI=1S/C10H14N2/c1-2-3-4-5-6-7-10-8-11-9-12-10/h8-9H,2-3,6-7H2,1H3,(H,11,12)
DM5MHO6	CS	CCCC#CCCC1=CN=CN1
DM5MHO6	IK	UDXIRDIVFQGLKT-UHFFFAOYSA-N
DM5MHO6	IU	5-hept-3-ynyl-1H-imidazole
DM5MHO6	DE	Discovery agent

DMA3MX5	ID	DMA3MX5
DMA3MX5	DN	4-heptyl-N-(pyridin-3-yl)benzamide
DMA3MX5	HS	Investigative
DMA3MX5	SN	CHEMBL263921
DMA3MX5	DT	Small molecular drug
DMA3MX5	PC	44450346
DMA3MX5	MW	296.4
DMA3MX5	FM	C19H24N2O
DMA3MX5	IC	InChI=1S/C19H24N2O/c1-2-3-4-5-6-8-16-10-12-17(13-11-16)19(22)21-18-9-7-14-20-15-18/h7,9-15H,2-6,8H2,1H3,(H,21,22)
DMA3MX5	CS	CCCCCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMA3MX5	IK	XRYFRVDOZOSYGN-UHFFFAOYSA-N
DMA3MX5	IU	4-heptyl-N-pyridin-3-ylbenzamide
DMA3MX5	CA	CAS 1029437-48-6
DMA3MX5	DE	Discovery agent

DMAHLF6	ID	DMAHLF6
DMAHLF6	DN	4-heptyl-N-(quinolin-3-yl)benzamide
DMAHLF6	HS	Investigative
DMAHLF6	SN	CHEMBL406860; AC1MYO1K; SCHEMBL846864; 4-heptyl-N-quinolin-3-ylbenzamide; BDBM50376279
DMAHLF6	DT	Small molecular drug
DMAHLF6	PC	3884807
DMAHLF6	MW	346.5
DMAHLF6	FM	C23H26N2O
DMAHLF6	IC	InChI=1S/C23H26N2O/c1-2-3-4-5-6-9-18-12-14-19(15-13-18)23(26)25-21-16-20-10-7-8-11-22(20)24-17-21/h7-8,10-17H,2-6,9H2,1H3,(H,25,26)
DMAHLF6	CS	CCCCCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DMAHLF6	IK	VJFYODCLTPGLMR-UHFFFAOYSA-N
DMAHLF6	IU	4-heptyl-N-quinolin-3-ylbenzamide
DMAHLF6	DE	Discovery agent

DMYNTJ0	ID	DMYNTJ0
DMYNTJ0	DN	4-Hex-3-ynyl-1H-imidazole
DMYNTJ0	HS	Investigative
DMYNTJ0	SN	CHEMBL14721; 4-Hex-3-ynyl-1H-imidazole; SCHEMBL7627737; 4-(3-Hexynyl)-1H-imidazole; BDBM50070219
DMYNTJ0	DT	Small molecular drug
DMYNTJ0	PC	10749338
DMYNTJ0	MW	148.2
DMYNTJ0	FM	C9H12N2
DMYNTJ0	IC	InChI=1S/C9H12N2/c1-2-3-4-5-6-9-7-10-8-11-9/h7-8H,2,5-6H2,1H3,(H,10,11)
DMYNTJ0	CS	CCC#CCCC1=CN=CN1
DMYNTJ0	IK	KXZPBLYVPNSMHH-UHFFFAOYSA-N
DMYNTJ0	IU	5-hex-3-ynyl-1H-imidazole
DMYNTJ0	DE	Discovery agent

DM36JUD	ID	DM36JUD
DM36JUD	DN	4-hexyl resorcinol
DM36JUD	HS	Investigative
DM36JUD	SN	hexylresorcinol; 4-Hexylresorcinol; 4-hexylbenzene-1,3-diol; 136-77-6; Ascarinol; Antascarin; 4-Hexyl-1,3-benzenediol; Ascaricid; p-Hexylresorcinol; 4-n-Hexylresorcinol; Hidesol; Caprokol; Adrover; Oxana; Crystoids; Prensol; 4-Hexylresorcine; 1,3-Benzenediol, 4-hexyl-; Sucrets; Hexylresorcin; Gelovermin; Ascaryl; 4-Hexyl-1,3-dihydroxybenzene; 4-(1-Hexyl)resorcinol; Cystoids anthelmintic; 1,3-Dihydroxy-4-hexylbenzene; Worm-agen; Resorcinol, 4-hexyl-; Hexylresorzin; Mycoderm; 1,3-Dihydroxy-4-n-hexylbenzene; NCI-C55787
DM36JUD	DT	Small molecular drug
DM36JUD	PC	3610
DM36JUD	MW	194.27
DM36JUD	FM	C12H18O2
DM36JUD	IC	InChI=1S/C12H18O2/c1-2-3-4-5-6-10-7-8-11(13)9-12(10)14/h7-9,13-14H,2-6H2,1H3
DM36JUD	CS	CCCCCCC1=C(C=C(C=C1)O)O
DM36JUD	IK	WFJIVOKAWHGMBH-UHFFFAOYSA-N
DM36JUD	IU	4-hexylbenzene-1,3-diol
DM36JUD	CA	CAS 136-77-6
DM36JUD	CB	CHEBI:93749
DM36JUD	DE	Discovery agent

DM5E03C	ID	DM5E03C
DM5E03C	DN	4-hexyl-N-(quinolin-3-yl)benzamide
DM5E03C	HS	Investigative
DM5E03C	SN	CHEMBL258623; SCHEMBL846650
DM5E03C	DT	Small molecular drug
DM5E03C	PC	44450347
DM5E03C	MW	332.4
DM5E03C	FM	C22H24N2O
DM5E03C	IC	InChI=1S/C22H24N2O/c1-2-3-4-5-8-17-11-13-18(14-12-17)22(25)24-20-15-19-9-6-7-10-21(19)23-16-20/h6-7,9-16H,2-5,8H2,1H3,(H,24,25)
DM5E03C	CS	CCCCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM5E03C	IK	RTKCLHOLWGNTOT-UHFFFAOYSA-N
DM5E03C	IU	4-hexyl-N-quinolin-3-ylbenzamide
DM5E03C	DE	Discovery agent

DMONZ0Y	ID	DMONZ0Y
DMONZ0Y	DN	4-hexylphenyl propiolate
DMONZ0Y	HS	Investigative
DMONZ0Y	SN	4-hexylphenyl propiolate; 4-hexylphenyl prop-2-ynoate; Propiolic acid derivative, 8b; CHEMBL236338; BDBM18854
DMONZ0Y	DT	Small molecular drug
DMONZ0Y	PC	23635856
DMONZ0Y	MW	230.3
DMONZ0Y	FM	C15H18O2
DMONZ0Y	IC	InChI=1S/C15H18O2/c1-3-5-6-7-8-13-9-11-14(12-10-13)17-15(16)4-2/h2,9-12H,3,5-8H2,1H3
DMONZ0Y	CS	CCCCCCC1=CC=C(C=C1)OC(=O)C#C
DMONZ0Y	IK	IAEVDNHEIHTNJR-UHFFFAOYSA-N
DMONZ0Y	IU	(4-hexylphenyl) prop-2-ynoate
DMONZ0Y	DE	Discovery agent

DMSZMQU	ID	DMSZMQU
DMSZMQU	DN	4-Hydrazino-3-pyridinesulfonamide
DMSZMQU	HS	Investigative
DMSZMQU	SN	4-hydrazinylpyridine-3-sulfonamide; 73742-76-4; CHEMBL1164967; 4-Hydrazino-3-pyridinesulfonamide; 4-Hydrazinopyridine-3-sulfonamide; MolPort-004-759-861; 3-pyridinesulfonamide,4-hydrazino-; ZINC39054028; BDBM50320510; AKOS006341241; AJ-97667; 3-Pyridinesulfonamide,4-hydrazino-(9CI); KB-184865; ST24043768; FT-0705130
DMSZMQU	DT	Small molecular drug
DMSZMQU	PC	12554666
DMSZMQU	MW	188.21
DMSZMQU	FM	C5H8N4O2S
DMSZMQU	IC	InChI=1S/C5H8N4O2S/c6-9-4-1-2-8-3-5(4)12(7,10)11/h1-3H,6H2,(H,8,9)(H2,7,10,11)
DMSZMQU	CS	C1=CN=CC(=C1NN)S(=O)(=O)N
DMSZMQU	IK	PTRSDYFZXIJRKG-UHFFFAOYSA-N
DMSZMQU	IU	4-hydrazinylpyridine-3-sulfonamide
DMSZMQU	DE	Discovery agent

DM49B18	ID	DM49B18
DM49B18	DN	4-Hydrazino-benzenesulfonamide
DM49B18	HS	Investigative
DM49B18	SN	4-hydrazinylbenzenesulfonamide
DM49B18	DT	Small molecular drug
DM49B18	PC	78105
DM49B18	MW	187.22
DM49B18	FM	C6H9N3O2S
DM49B18	IC	InChI=1S/C6H9N3O2S/c7-9-5-1-3-6(4-2-5)12(8,10)11/h1-4,9H,7H2,(H2,8,10,11)
DM49B18	CS	C1=CC(=CC=C1NN)S(=O)(=O)N
DM49B18	IK	NBJSNAGTUCWQRO-UHFFFAOYSA-N
DM49B18	IU	4-hydrazinylbenzenesulfonamide
DM49B18	CA	CAS 4392-54-5
DM49B18	DE	Discovery agent

DM8PBEJ	ID	DM8PBEJ
DM8PBEJ	DN	4-Hydrazinocarbonyl-benzenesulfonamide
DM8PBEJ	HS	Investigative
DM8PBEJ	SN	4-(hydrazinecarbonyl)benzenesulfonamide; 35264-29-0; 4-(hydrazinecarbonyl)benzene-1-sulfonamide; JIDAHYHCQJXNTD-UHFFFAOYSA-N; 4-(hydrazinylcarbonyl)benzenesulfonamide; 4-   benzenesulfonamide; 4-HYDRAZINOCARBONYL-BENZENE-SULFONAMIDE; hydrazide 2; p-Sulfamylbenzoic acid hydrazide; AC1L7XIP; CHEMBL180323; SCHEMBL4616920; BDBM12136; CTK4H4135; DTXSID60312358; 4-Sulfamoylbenzoic acid hydrazide; MolPort-000-887-192; ZINC1556993; STK349231; SBB021016; 4376AB; NSC252930; AKOS000305291; MCULE-5832659214
DM8PBEJ	DT	Small molecular drug
DM8PBEJ	PC	318174
DM8PBEJ	MW	215.23
DM8PBEJ	FM	C7H9N3O3S
DM8PBEJ	IC	InChI=1S/C7H9N3O3S/c8-10-7(11)5-1-3-6(4-2-5)14(9,12)13/h1-4H,8H2,(H,10,11)(H2,9,12,13)
DM8PBEJ	CS	C1=CC(=CC=C1C(=O)NN)S(=O)(=O)N
DM8PBEJ	IK	JIDAHYHCQJXNTD-UHFFFAOYSA-N
DM8PBEJ	IU	4-(hydrazinecarbonyl)benzenesulfonamide
DM8PBEJ	CA	CAS 35264-29-0
DM8PBEJ	DE	Discovery agent

DM6WJ4K	ID	DM6WJ4K
DM6WJ4K	DN	4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid
DM6WJ4K	HS	Investigative
DM6WJ4K	SN	4-HYDROXY-1,2,5-OXADIAZOLE-3-CARBOXYLIC ACID; 4-Hydroxy-furazan-3-carboxylic acid; 66313-36-8; OXQ; AC1L9M6V; 1,2,5-oxadiazole, OXD1; SCHEMBL1043406; CTK8F6043; CTK7J1234; BDBM23232; MolPort-002-679-216; ZINC6523895; FCH841687; AKOS030214651; AKOS000301440; DB02401; MCULE-2928095407; ST077901; TR-055247; AX8302019; 4-oxo-1,2,5-oxadiazole-3-carboxylic acid; BB 0257536
DM6WJ4K	DT	Small molecular drug
DM6WJ4K	PC	448650
DM6WJ4K	MW	130.06
DM6WJ4K	FM	C3H2N2O4
DM6WJ4K	IC	InChI=1S/C3H2N2O4/c6-2-1(3(7)8)4-9-5-2/h(H,5,6)(H,7,8)
DM6WJ4K	CS	C1(=NONC1=O)C(=O)O
DM6WJ4K	IK	IBRWUZLLHSXPKL-UHFFFAOYSA-N
DM6WJ4K	IU	4-oxo-1,2,5-oxadiazole-3-carboxylic acid
DM6WJ4K	CA	CAS 66313-36-8
DM6WJ4K	DE	Discovery agent

DME29PX	ID	DME29PX
DME29PX	DN	4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid
DME29PX	HS	Investigative
DME29PX	SN	4-HYDROXY-1,2,5-THIADIAZOLE-3-CARBOXYLIC ACID; LDHA Inhibitor, 1; 45654-48-6; GBD; AC1L9M6Z; C3H2N2O3S; 1,2,5-Thiadiazole, TDA1; SCHEMBL2573610; CHEMBL1232973; BDBM23251; MolPort-006-168-875; ZINC6523896; AKOS006380523; DB03162; 4-oxo-1,2,5-thiadiazole-3-carboxylic acid; Z2467454497; 4-oxo-4,5-dihydro-1,2,5-thiadiazole-3-carboxylic acid
DME29PX	DT	Small molecular drug
DME29PX	PC	448652
DME29PX	MW	146.13
DME29PX	FM	C3H2N2O3S
DME29PX	IC	InChI=1S/C3H2N2O3S/c6-2-1(3(7)8)4-9-5-2/h(H,5,6)(H,7,8)
DME29PX	CS	C1(=NSNC1=O)C(=O)O
DME29PX	IK	FVZITYNLUYJDOE-UHFFFAOYSA-N
DME29PX	IU	4-oxo-1,2,5-thiadiazole-3-carboxylic acid
DME29PX	CA	CAS 45654-48-6
DME29PX	DE	Discovery agent

DMTZ9G3	ID	DMTZ9G3
DMTZ9G3	DN	4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone
DMTZ9G3	HS	Investigative
DMTZ9G3	PC	285836
DMTZ9G3	MW	323.4
DMTZ9G3	FM	C21H25NO2
DMTZ9G3	IC	InChI=1S/C21H25NO2/c1-15-4-8-17(9-5-15)20(23)19-14-22(3)13-12-21(19,24)18-10-6-16(2)7-11-18/h4-11,19,24H,12-14H2,1-3H3
DMTZ9G3	CS	CC1=CC=C(C=C1)C(=O)C2CN(CCC2(C3=CC=C(C=C3)C)O)C
DMTZ9G3	IK	SWFNNRQTSSTAGB-UHFFFAOYSA-N
DMTZ9G3	IU	[4-hydroxy-1-methyl-4-(4-methylphenyl)piperidin-3-yl]-(4-methylphenyl)methanone
DMTZ9G3	DE	Discovery agent

DM7BQ65	ID	DM7BQ65
DM7BQ65	DN	4-Hydroxy-2-Butanone
DM7BQ65	HS	Investigative
DM7BQ65	SN	4-Hydroxy-2-butanone; 4-Hydroxybutan-2-one; 590-90-9; 2-Butanone, 4-hydroxy-; Methylolacetone; 3-Oxo-1-butanol; 3-Oxobutanol; 3-Ketobutan-1-ol; Monomethylolacetone; 4-Butanol-2-one; UNII-TCM0BJ44MF; 2-Hydroxyethyl methyl ketone; NSC 41219; TCM0BJ44MF; CH3C(O)CH2CH2OH; LVSQXDHWDCMMRJ-UHFFFAOYSA-N; BUQ; Ketones, C4-6, beta-hydroxy; 3-ketobutanol; 4-hydroxy butanone; EINECS 209-693-6; 1-hydroxy-3-butanone; 4-oxidanylbutan-2-one; 1d7j; 1 -hydroxy-3-butanone; 4-hydroxy-butan-2-one; AI3-11747; EC 209-693-6; ACMC-1B12A
DM7BQ65	DT	Small molecular drug
DM7BQ65	PC	111509
DM7BQ65	MW	88.11
DM7BQ65	FM	C4H8O2
DM7BQ65	IC	InChI=1S/C4H8O2/c1-4(6)2-3-5/h5H,2-3H2,1H3
DM7BQ65	CS	CC(=O)CCO
DM7BQ65	IK	LVSQXDHWDCMMRJ-UHFFFAOYSA-N
DM7BQ65	IU	4-hydroxybutan-2-one
DM7BQ65	CA	CAS 590-90-9
DM7BQ65	CB	CHEBI:41268
DM7BQ65	DE	Discovery agent

DM2LJFZ	ID	DM2LJFZ
DM2LJFZ	DN	4-hydroxy-2-nonenal
DM2LJFZ	HS	Investigative
DM2LJFZ	SN	4-Hydroxynonenal; 4-Hydroxy-2-nonenal; 4-hydroxynon-2-enal; trans-4-Hydroxy-2-nonenal; 4-Hydroxy-2,3-nonenal; 4-HNE; 75899-68-2; 4-hydroxy-2E-nonenal; (E)-4-hydroxynon-2-enal; CCRIS 9028; CCRIS 1781; 29343-52-0; 128946-65-6; 2-NONENAL, 4-HYDROXY-; HNE; (E)-4-hydroxy-2-nonenal; (2E)-4-hydroxynon-2-enal; (2E)-4-Hydroxy-2-nonenal; CHEMBL454280; CHEBI:58968; C9H16O2; (+/-)4-HYDROXYNON-2-ENAL; NCGC00161254-02; 4-hydroxynonen-2-al; CHEBI:32585; CCRIS 6927; 4 hydroxynonenal; (E)-4-Hydroxynonenal; AC1Q2VOQ; 4HNE; SCHEMBL3920; AC1Q6PP5; AC1NR22M
DM2LJFZ	DT	Small molecular drug
DM2LJFZ	PC	5283344
DM2LJFZ	MW	156.22
DM2LJFZ	FM	C9H16O2
DM2LJFZ	IC	InChI=1S/C9H16O2/c1-2-3-4-6-9(11)7-5-8-10/h5,7-9,11H,2-4,6H2,1H3/b7-5+
DM2LJFZ	CS	CCCCCC(/C=C/C=O)O
DM2LJFZ	IK	JVJFIQYAHPMBBX-FNORWQNLSA-N
DM2LJFZ	IU	(E)-4-hydroxynon-2-enal
DM2LJFZ	CA	CAS 75899-68-2
DM2LJFZ	CB	CHEBI:58968
DM2LJFZ	DE	Discovery agent

DMY3OHK	ID	DMY3OHK
DMY3OHK	DN	4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one
DMY3OHK	HS	Investigative
DMY3OHK	SN	SCHEMBL7353536; CHEMBL582933; BDBM35549; 4-hydroxy-2H-chromen-2-one core, 25
DMY3OHK	DT	Small molecular drug
DMY3OHK	PC	54711585
DMY3OHK	MW	302.3
DMY3OHK	FM	C20H14O3
DMY3OHK	IC	InChI=1S/C20H14O3/c21-19-16-10-3-4-11-18(16)23-20(22)17(19)12-14-8-5-7-13-6-1-2-9-15(13)14/h1-11,21H,12H2
DMY3OHK	CS	C1=CC=C2C(=C1)C=CC=C2CC3=C(C4=CC=CC=C4OC3=O)O
DMY3OHK	IK	PRHLSJVWKOFWSE-UHFFFAOYSA-N
DMY3OHK	IU	4-hydroxy-3-(naphthalen-1-ylmethyl)chromen-2-one
DMY3OHK	DE	Discovery agent

DMM3QPL	ID	DMM3QPL
DMM3QPL	DN	4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one
DMM3QPL	HS	Investigative
DMM3QPL	SN	CHEMBL571283; SCHEMBL7354617; BDBM35550; 4-hydroxy-2H-chromen-2-one core, 26
DMM3QPL	DT	Small molecular drug
DMM3QPL	PC	54724899
DMM3QPL	MW	302.3
DMM3QPL	FM	C20H14O3
DMM3QPL	IC	InChI=1S/C20H14O3/c21-19-16-7-3-4-8-18(16)23-20(22)17(19)12-13-9-10-14-5-1-2-6-15(14)11-13/h1-11,21H,12H2
DMM3QPL	CS	C1=CC=C2C=C(C=CC2=C1)CC3=C(C4=CC=CC=C4OC3=O)O
DMM3QPL	IK	UHCUHNQBQRRJOC-UHFFFAOYSA-N
DMM3QPL	IU	4-hydroxy-3-(naphthalen-2-ylmethyl)chromen-2-one
DMM3QPL	DE	Discovery agent

DM2PS89	ID	DM2PS89
DM2PS89	DN	4-Hydroxy-3,5-diisopropyl-benzaldehyde
DM2PS89	HS	Investigative
DM2PS89	SN	4-hydroxy-3,5-diisopropylbenzaldehyde; 10537-86-7; 4-Hydroxy-3,5-bis(isopropyl)benzaldehyde; 4-hydroxy-3,5-di(propan-2-yl)benzaldehyde; 3,5-diisopropyl-4-hydroxybenzaldehyde; WVGDLTQPAQUBMO-UHFFFAOYSA-N; EINECS 234-111-2; CDS1_003950; CBMicro_017454; Cambridge id 5318853; AC1L33YK; CHEMBL55354; DivK1c_004990; AC1Q6Q36; SCHEMBL2597919; CTK4A3796; DTXSID50147095; MolPort-002-144-464; ZINC297726; CCG-6041; ANW-58021; CD-932; 3,5-diisopropy-4-hydroxylbenzaldehyde; AKOS000100686; MCULE-9155785460; 3,5-diisopropyl-4-hydroxylbenzaldehyde
DM2PS89	DT	Small molecular drug
DM2PS89	PC	82712
DM2PS89	MW	206.28
DM2PS89	FM	C13H18O2
DM2PS89	IC	InChI=1S/C13H18O2/c1-8(2)11-5-10(7-14)6-12(9(3)4)13(11)15/h5-9,15H,1-4H3
DM2PS89	CS	CC(C)C1=CC(=CC(=C1O)C(C)C)C=O
DM2PS89	IK	WVGDLTQPAQUBMO-UHFFFAOYSA-N
DM2PS89	IU	4-hydroxy-3,5-di(propan-2-yl)benzaldehyde
DM2PS89	CA	CAS 10537-86-7
DM2PS89	DE	Discovery agent

DMWDBHC	ID	DMWDBHC
DMWDBHC	DN	4-Hydroxy-3-methyl-but-2-enoic acid
DMWDBHC	HS	Investigative
DMWDBHC	SN	44647-19-0; (E)-4-hydroxy-3-methylbut-2-enoic acid; CHEMBL353481; SCHEMBL6282205; SCHEMBL8370948; 4-hydroxy-3-methylcrotonic acid; 3-(Hydroxymethyl)-2-butenoic acid; 4-hydroxy-3-methylbut-2-enoic acid; AKOS013086986; FCH4103824; FCH2609833; BBV-37850347; (E)-4-Hydroxy-3-methyl-2-butenoic acid; (2E)-4-hydroxy-3-methylbut-2-enoic acid
DMWDBHC	DT	Small molecular drug
DMWDBHC	PC	11389379
DMWDBHC	MW	116.11
DMWDBHC	FM	C5H8O3
DMWDBHC	IC	InChI=1S/C5H8O3/c1-4(3-6)2-5(7)8/h2,6H,3H2,1H3,(H,7,8)/b4-2+
DMWDBHC	CS	C/C(=C\\C(=O)O)/CO
DMWDBHC	IK	BERUOTKXCOOJJM-DUXPYHPUSA-N
DMWDBHC	IU	(E)-4-hydroxy-3-methylbut-2-enoic acid
DMWDBHC	DE	Discovery agent

DM6AHO4	ID	DM6AHO4
DM6AHO4	DN	4-Hydroxy-3-methyl-butyric acid
DM6AHO4	HS	Investigative
DM6AHO4	SN	4-Hydroxyisovaleric acid; 4-Hydroxyisovalerate; 4-Hydroxyisopentanoate; 4-Hydroxyisopentanoic acid; 4-hydroxy-3-methylbutanoic acid; 4-hydroxy-isovaleric acid; 77220-86-1; CHEBI:90005; 3-methyl-4-hydroxy-butanoic acid; AC1Q5V9X; AC1Q2B3C; AC1L2ZR2; SCHEMBL43435; CHEMBL353863; CTK5E4050; Butanoic acid,4-hydroxy-3-methyl-; Butanoic acid, 4-hydroxy-3-methyl-; LMFA01050399; AKOS006373039; 4-Hydroxyisovaleric acid sodium salt hydrate, analytical standard
DM6AHO4	DT	Small molecular drug
DM6AHO4	PC	131760
DM6AHO4	MW	118.13
DM6AHO4	FM	C5H10O3
DM6AHO4	IC	InChI=1S/C5H10O3/c1-4(3-6)2-5(7)8/h4,6H,2-3H2,1H3,(H,7,8)
DM6AHO4	CS	CC(CC(=O)O)CO
DM6AHO4	IK	ZGYGEPZZMAXSKH-UHFFFAOYSA-N
DM6AHO4	IU	4-hydroxy-3-methylbutanoic acid
DM6AHO4	CA	CAS 77220-86-1
DM6AHO4	CB	CHEBI:90005
DM6AHO4	DE	Discovery agent

DMR0S8X	ID	DMR0S8X
DMR0S8X	DN	4-hydroxy-3-nitrobenzaldehyde
DMR0S8X	HS	Investigative
DMR0S8X	SN	4-Hydroxy-3-nitrobenzaldehyde; 3011-34-5; Benzaldehyde, 4-hydroxy-3-nitro-; 3-nitro-4-hydroxybenzaldehyde; CHEMBL378361; 4-hydroxy-3-nitro-benzaldehyde; 4-FORMYL-2-NITROPHENOL; YTHJCZRFJGXPTL-UHFFFAOYSA-N; 4-Hydroxy-3-nitrobenzaldehyde, 97%; EINECS 221-141-6; NSC138267; NSC 138267; PubChem8135; ACMC-1CJNU; AC1L2BHN; 4-hydroxy-3-nitrobenzaldeyde; KSC223K5F; SCHEMBL244093; 4-hydroxyl-3-nitrobenzaldehyde; 4-Hydroxy-3-nitro benzaldehyde; Jsp005694; KS-00000AYN; CTK1C3552; DTXSID80184195; MolPort-000-156-359; ZINC562702; ACT01022
DMR0S8X	DT	Small molecular drug
DMR0S8X	PC	18169
DMR0S8X	MW	167.12
DMR0S8X	FM	C7H5NO4
DMR0S8X	IC	InChI=1S/C7H5NO4/c9-4-5-1-2-7(10)6(3-5)8(11)12/h1-4,10H
DMR0S8X	CS	C1=CC(=C(C=C1C=O)[N+](=O)[O-])O
DMR0S8X	IK	YTHJCZRFJGXPTL-UHFFFAOYSA-N
DMR0S8X	IU	4-hydroxy-3-nitrobenzaldehyde
DMR0S8X	CA	CAS 3011-34-5
DMR0S8X	DE	Discovery agent

DMDEMV8	ID	DMDEMV8
DMDEMV8	DN	4-Hydroxy-3-nonanoyl-6-octyl-pyran-2-one
DMDEMV8	HS	Investigative
DMDEMV8	SN	CHEMBL7816; 4-Hydroxy-3-nonanoyl-6-octyl-pyran-2-one; SCHEMBL10337787
DMDEMV8	DT	Small molecular drug
DMDEMV8	PC	54737457
DMDEMV8	MW	364.5
DMDEMV8	FM	C22H36O4
DMDEMV8	IC	InChI=1S/C22H36O4/c1-3-5-7-9-11-13-15-18-17-20(24)21(22(25)26-18)19(23)16-14-12-10-8-6-4-2/h17,24H,3-16H2,1-2H3
DMDEMV8	CS	CCCCCCCCC1=CC(=C(C(=O)O1)C(=O)CCCCCCCC)O
DMDEMV8	IK	NLATVPVYSKNDRM-UHFFFAOYSA-N
DMDEMV8	IU	4-hydroxy-3-nonanoyl-6-octylpyran-2-one
DMDEMV8	DE	Discovery agent

DMIVQGW	ID	DMIVQGW
DMIVQGW	DN	4-Hydroxy-4-phenyl-but-2-enoic acid
DMIVQGW	HS	Investigative
DMIVQGW	SN	4-hydroxy-4-phenylbut-2-enoic acid; 99389-54-5; CHEMBL435474
DMIVQGW	DT	Small molecular drug
DMIVQGW	PC	14168401
DMIVQGW	MW	178.18
DMIVQGW	FM	C10H10O3
DMIVQGW	IC	InChI=1S/C10H10O3/c11-9(6-7-10(12)13)8-4-2-1-3-5-8/h1-7,9,11H,(H,12,13)/b7-6+
DMIVQGW	CS	C1=CC=C(C=C1)C(/C=C/C(=O)O)O
DMIVQGW	IK	JJTRLNDAHGRZGZ-VOTSOKGWSA-N
DMIVQGW	IU	(E)-4-hydroxy-4-phenylbut-2-enoic acid
DMIVQGW	DE	Discovery agent

DMDWGS9	ID	DMDWGS9
DMDWGS9	DN	4-Hydroxy-4-phenyl-butyric acid
DMDWGS9	HS	Investigative
DMDWGS9	SN	4-Hydroxy-4-phenyl-butyric acid; 4-hydroxy-4-phenylbutanoic acid; 34674-93-6; BAS 00281341; AC1O5G7Z; SCHEMBL258372; CHEMBL170514; 4-Hydroxy-4-phenylbutyric acid; gamma-Hydroxybenzenebutanoic acid; CTK7J6414; SBB010649; AKOS016038533; AKOS000301399; MCULE-4325680851; BBV-183857; TR-045028; BB0266635; ST50341916
DMDWGS9	DT	Small molecular drug
DMDWGS9	PC	6483718
DMDWGS9	MW	180.2
DMDWGS9	FM	C10H12O3
DMDWGS9	IC	InChI=1S/C10H12O3/c11-9(6-7-10(12)13)8-4-2-1-3-5-8/h1-5,9,11H,6-7H2,(H,12,13)
DMDWGS9	CS	C1=CC=C(C=C1)C(CCC(=O)O)O
DMDWGS9	IK	OGQGIKZPOBBMNO-UHFFFAOYSA-N
DMDWGS9	IU	4-hydroxy-4-phenylbutanoic acid
DMDWGS9	DE	Discovery agent

DMVFKSX	ID	DMVFKSX
DMVFKSX	DN	4-Hydroxy-5-methoxy-10H-anthracen-9-one
DMVFKSX	HS	Investigative
DMVFKSX	SN	CHEMBL123148; 4-hydroxy-5-methoxy-10H-anthracen-9-one; ZINC13606502; BDBM50060871
DMVFKSX	DT	Small molecular drug
DMVFKSX	PC	10776422
DMVFKSX	MW	240.25
DMVFKSX	FM	C15H12O3
DMVFKSX	IC	InChI=1S/C15H12O3/c1-18-14-7-3-5-10-12(14)8-11-9(15(10)17)4-2-6-13(11)16/h2-7,16H,8H2,1H3
DMVFKSX	CS	COC1=CC=CC2=C1CC3=C(C2=O)C=CC=C3O
DMVFKSX	IK	ZLLAABQSJKWBDB-UHFFFAOYSA-N
DMVFKSX	IU	4-hydroxy-5-methoxy-10H-anthracen-9-one
DMVFKSX	DE	Discovery agent

DMT3H2X	ID	DMT3H2X
DMT3H2X	DN	4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one
DMT3H2X	HS	Investigative
DMT3H2X	SN	CHEMBL414672; 4-hydroxy-5-phenyl-Thieno[2,3-b]pyridin-6(7H)-one; 179337-87-2; SCHEMBL1077245; SCHEMBL16776799; CTK7H0273; ZINC13679983; AKOS015965514; DA-09113; 4-Hydroxy-5-phenyl-7H-thieno[2,3-b]; FT-0762488
DMT3H2X	DT	Small molecular drug
DMT3H2X	PC	54688796
DMT3H2X	MW	243.28
DMT3H2X	FM	C13H9NO2S
DMT3H2X	IC	InChI=1S/C13H9NO2S/c15-11-9-6-7-17-13(9)14-12(16)10(11)8-4-2-1-3-5-8/h1-7H,(H2,14,15,16)
DMT3H2X	CS	C1=CC=C(C=C1)C2=C(C3=C(NC2=O)SC=C3)O
DMT3H2X	IK	LLZJLIULTBEDHM-UHFFFAOYSA-N
DMT3H2X	IU	4-hydroxy-5-phenyl-7H-thieno[2,3-b]pyridin-6-one
DMT3H2X	DE	Discovery agent

DM7PWOL	ID	DM7PWOL
DM7PWOL	DN	4'-hydroxy-6,3',5'-triprenylisoflavonone
DM7PWOL	HS	Investigative
DM7PWOL	SN	CHEMBL465773; BDBM50292387; AKOS025289213
DM7PWOL	DT	Small molecular drug
DM7PWOL	PC	129847997
DM7PWOL	MW	458.6
DM7PWOL	FM	C30H34O4
DM7PWOL	IC	InChI=1S/C30H34O4/c1-18(2)7-10-21-11-14-26-25(15-21)29(32)27(30(33)34-26)24-16-22(12-8-19(3)4)28(31)23(17-24)13-9-20(5)6/h7-9,11,14-17,27,31H,10,12-13H2,1-6H3
DM7PWOL	CS	CC(=CCC1=CC2=C(C=C1)OC(=O)C(C2=O)C3=CC(=C(C(=C3)CC=C(C)C)O)CC=C(C)C)C
DM7PWOL	IK	XVMLCODOINIZIF-UHFFFAOYSA-N
DM7PWOL	IU	3-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]-6-(3-methylbut-2-enyl)chromene-2,4-dione
DM7PWOL	DE	Discovery agent

DMH78QU	ID	DMH78QU
DMH78QU	DN	4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one
DMH78QU	HS	Investigative
DMH78QU	SN	CHEMBL413773; 4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one; SCHEMBL4469573; ZINC36185238; BDBM50189455
DMH78QU	DT	Small molecular drug
DMH78QU	PC	54737894
DMH78QU	MW	282.25
DMH78QU	FM	C15H10N2O4
DMH78QU	IC	InChI=1S/C15H10N2O4/c18-14-11-8-10(17(20)21)6-7-12(11)16-15(19)13(14)9-4-2-1-3-5-9/h1-8H,(H2,16,18,19)
DMH78QU	CS	C1=CC=C(C=C1)C2=C(C3=C(C=CC(=C3)[N+](=O)[O-])NC2=O)O
DMH78QU	IK	FHJYCGCXAYLWFD-UHFFFAOYSA-N
DMH78QU	IU	4-hydroxy-6-nitro-3-phenyl-1H-quinolin-2-one
DMH78QU	DE	Discovery agent

DMD3OV8	ID	DMD3OV8
DMD3OV8	DN	4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one
DMD3OV8	HS	Investigative
DMD3OV8	SN	CHEMBL377646; 4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one; SCHEMBL4456699; BDBM50189477; 2(1H)-Quinolinone, 4-hydroxy-8-nitro-3-phenyl-
DMD3OV8	DT	Small molecular drug
DMD3OV8	PC	54737904
DMD3OV8	MW	282.25
DMD3OV8	FM	C15H10N2O4
DMD3OV8	IC	InChI=1S/C15H10N2O4/c18-14-10-7-4-8-11(17(20)21)13(10)16-15(19)12(14)9-5-2-1-3-6-9/h1-8H,(H2,16,18,19)
DMD3OV8	CS	C1=CC=C(C=C1)C2=C(C3=C(C(=CC=C3)[N+](=O)[O-])NC2=O)O
DMD3OV8	IK	XWRIMEVQDODFAZ-UHFFFAOYSA-N
DMD3OV8	IU	4-hydroxy-8-nitro-3-phenyl-1H-quinolin-2-one
DMD3OV8	DE	Discovery agent

DMT8L5R	ID	DMT8L5R
DMT8L5R	DN	4-Hydroxy-Aconitate Ion
DMT8L5R	HS	Investigative
DMT8L5R	SN	4-hydroxy-aconitate ion; ATH; AC1NRA5R; DB03964; (E,3R)-3-hydroxyprop-1-ene-1,2,3-tricarboxylate
DMT8L5R	DT	Small molecular drug
DMT8L5R	PC	5287714
DMT8L5R	MW	187.08
DMT8L5R	FM	C6H3O7-3
DMT8L5R	IC	InChI=1S/C6H6O7/c7-3(8)1-2(5(10)11)4(9)6(12)13/h1,4,9H,(H,7,8)(H,10,11)(H,12,13)/p-3/b2-1+/t4-/m1/s1
DMT8L5R	CS	C(=C(\\[C@H](C(=O)[O-])O)/C(=O)[O-])\\C(=O)[O-]
DMT8L5R	IK	WUUVSJBKHXDKBS-ROFOPDMZSA-K
DMT8L5R	IU	(E,3R)-3-hydroxyprop-1-ene-1,2,3-tricarboxylate
DMT8L5R	DE	Discovery agent

DM7WPGN	ID	DM7WPGN
DM7WPGN	DN	4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME
DM7WPGN	HS	Investigative
DM7WPGN	DT	Small molecular drug
DM7WPGN	PC	135566316
DM7WPGN	MW	247.29
DM7WPGN	FM	C14H17NO3
DM7WPGN	IC	InChI=1S/C14H17NO3/c16-13-8-6-11(7-9-13)10-15-18-14(17)12-4-2-1-3-5-12/h6-10,12,16H,1-5H2/b15-10-
DM7WPGN	CS	C1CCC(CC1)C(=O)O/N=C\\C2=CC=C(C=C2)O
DM7WPGN	IK	YWZBYSBZDQWXGQ-GDNBJRDFSA-N
DM7WPGN	IU	[(Z)-(4-hydroxyphenyl)methylideneamino] cyclohexanecarboxylate
DM7WPGN	DE	Discovery agent

DMJVPF0	ID	DMJVPF0
DMJVPF0	DN	4-hydroxybenzylamine
DMJVPF0	HS	Investigative
DMJVPF0	SN	4-Hydroxybenzylamine; 4-(aminomethyl)phenol; 696-60-6; 4-Aminomethyl-phenol; para-Hydroxybenzylamine; UNII-7J7F85B7BI; 4-aminomethylphenol; CHEMBL202519; 7J7F85B7BI; (4-HYDROXYPHENYL)METHANAMINIUM BROMIDE; 4-Hydroxybenzylamine hydrate, 97%; a-Amino-p-cresol; p-hydroxybenzylamine; 4-hyroxybenzylamine; 4-hydroxylbenzylamine; NSC 125720; 4-hydroxybenzyl amine; 4-hydroxy benzylamine; 4-(amino methyl)phenol; 4-(Aminomethyl)-Phenol; ACMC-1AXW9; Phenol, 4-(aminomethyl)-; AC1Q7A8B; AC1L3YL9; SCHEMBL63123; (4-Hydroxyphenyl)methylamine
DMJVPF0	DT	Small molecular drug
DMJVPF0	PC	97472
DMJVPF0	MW	123.15
DMJVPF0	FM	C7H9NO
DMJVPF0	IC	InChI=1S/C7H9NO/c8-5-6-1-3-7(9)4-2-6/h1-4,9H,5,8H2
DMJVPF0	CS	C1=CC(=CC=C1CN)O
DMJVPF0	IK	RQJDUEKERVZLLU-UHFFFAOYSA-N
DMJVPF0	IU	4-(aminomethyl)phenol
DMJVPF0	CA	CAS 696-60-6
DMJVPF0	DE	Discovery agent

DMCA2XQ	ID	DMCA2XQ
DMCA2XQ	DN	4-hydroxy-but-2-enoate
DMCA2XQ	HS	Investigative
DMCA2XQ	SN	CHEMBL354804
DMCA2XQ	DT	Small molecular drug
DMCA2XQ	PC	23699047
DMCA2XQ	MW	124.07
DMCA2XQ	FM	C4H5NaO3
DMCA2XQ	IC	InChI=1S/C4H6O3.Na/c5-3-1-2-4(6)7;/h1-2,5H,3H2,(H,6,7);/q;+1/p-1/b2-1+;
DMCA2XQ	CS	C(/C=C/C(=O)[O-])O.[Na+]
DMCA2XQ	IK	PUAFPEZXZZJTBR-TYYBGVCCSA-M
DMCA2XQ	IU	sodium;(E)-4-hydroxybut-2-enoate
DMCA2XQ	DE	Discovery agent

DM36PHM	ID	DM36PHM
DM36PHM	DN	4-hydroxylonchocarpin
DM36PHM	HS	Investigative
DM36PHM	SN	Isobavachromene; 4-Hydroxylonchocarpin; 56083-03-5; CHEMBL362378; 4-Hydroxylonchocharpin; AC1NYR2W; SCHEMBL19960679; MolPort-003-804-213; BDBM50240945; ZINC14557836; LMPK12120077; 52801-22-6; 1-(5-Hydroxy-2,2-dimethyl-2H-chromen-6-yl)-3-(4-hydroxy-phenyl)-propenone; (E)-1-(5-hydroxy-2,2-dimethyl-2H-chromen-6-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-(5-hydroxy-2,2-dimethyl-chromen-6-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one
DM36PHM	DT	Small molecular drug
DM36PHM	PC	5889042
DM36PHM	MW	322.4
DM36PHM	FM	C20H18O4
DM36PHM	IC	InChI=1S/C20H18O4/c1-20(2)12-11-16-18(24-20)10-8-15(19(16)23)17(22)9-5-13-3-6-14(21)7-4-13/h3-12,21,23H,1-2H3/b9-5+
DM36PHM	CS	CC1(C=CC2=C(O1)C=CC(=C2O)C(=O)/C=C/C3=CC=C(C=C3)O)C
DM36PHM	IK	IQHPDUUSMBMDGN-WEVVVXLNSA-N
DM36PHM	IU	(E)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one
DM36PHM	DE	Discovery agent

DMULOHZ	ID	DMULOHZ
DMULOHZ	DN	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DMULOHZ	HS	Investigative
DMULOHZ	SN	CHEMBL167455
DMULOHZ	DT	Small molecular drug
DMULOHZ	PC	11086699
DMULOHZ	MW	266.29
DMULOHZ	FM	C13H18N2O4
DMULOHZ	IC	InChI=1S/C13H18N2O4/c16-11-7-5-10(6-8-11)13(18)14-9-3-1-2-4-12(17)15-19/h5-8,16,19H,1-4,9H2,(H,14,18)(H,15,17)
DMULOHZ	CS	C1=CC(=CC=C1C(=O)NCCCCCC(=O)NO)O
DMULOHZ	IK	JORFILXLFWALBT-UHFFFAOYSA-N
DMULOHZ	IU	4-hydroxy-N-[6-(hydroxyamino)-6-oxohexyl]benzamide
DMULOHZ	DE	Discovery agent

DMXPQ5H	ID	DMXPQ5H
DMXPQ5H	DN	4-hydroxy-N,N-diphenylbenzenesulfonamide
DMXPQ5H	HS	Investigative
DMXPQ5H	SN	CHEMBL203061; 4-hydroxy-N,N-diphenylbenzenesulfonamide; SCHEMBL2114599
DMXPQ5H	DT	Small molecular drug
DMXPQ5H	PC	23582387
DMXPQ5H	MW	325.4
DMXPQ5H	FM	C18H15NO3S
DMXPQ5H	IC	InChI=1S/C18H15NO3S/c20-17-11-13-18(14-12-17)23(21,22)19(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-14,20H
DMXPQ5H	CS	C1=CC=C(C=C1)N(C2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)O
DMXPQ5H	IK	KLZORRIEDRGOHR-UHFFFAOYSA-N
DMXPQ5H	IU	4-hydroxy-N,N-diphenylbenzenesulfonamide
DMXPQ5H	DE	Discovery agent

DMVAP9U	ID	DMVAP9U
DMVAP9U	DN	4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide
DMVAP9U	HS	Investigative
DMVAP9U	SN	CHEMBL204664; 4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide
DMVAP9U	DT	Small molecular drug
DMVAP9U	PC	44407886
DMVAP9U	MW	291.4
DMVAP9U	FM	C15H17NO3S
DMVAP9U	IC	InChI=1S/C15H17NO3S/c1-12(2)16(13-6-4-3-5-7-13)20(18,19)15-10-8-14(17)9-11-15/h3-12,17H,1-2H3
DMVAP9U	CS	CC(C)N(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DMVAP9U	IK	QYGYTGVIRJYHLA-UHFFFAOYSA-N
DMVAP9U	IU	4-hydroxy-N-phenyl-N-propan-2-ylbenzenesulfonamide
DMVAP9U	DE	Discovery agent

DM8XOJC	ID	DM8XOJC
DM8XOJC	DN	4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide
DM8XOJC	HS	Investigative
DM8XOJC	SN	CHEMBL203515; 4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide
DM8XOJC	DT	Small molecular drug
DM8XOJC	PC	44407806
DM8XOJC	MW	319.4
DM8XOJC	FM	C17H21NO3S
DM8XOJC	IC	InChI=1S/C17H21NO3S/c1-17(2,3)13-18(14-7-5-4-6-8-14)22(20,21)16-11-9-15(19)10-12-16/h4-12,19H,13H2,1-3H3
DM8XOJC	CS	CC(C)(C)CN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DM8XOJC	IK	QKNCIALYEAWCOU-UHFFFAOYSA-N
DM8XOJC	IU	N-(2,2-dimethylpropyl)-4-hydroxy-N-phenylbenzenesulfonamide
DM8XOJC	DE	Discovery agent

DM5TU98	ID	DM5TU98
DM5TU98	DN	4-hydroxy-N-phenyl-N-propylbenzenesulfonamide
DM5TU98	HS	Investigative
DM5TU98	SN	CHEMBL205070; 4-hydroxy-N-phenyl-N-propylbenzenesulfonamide
DM5TU98	DT	Small molecular drug
DM5TU98	PC	44407885
DM5TU98	MW	291.4
DM5TU98	FM	C15H17NO3S
DM5TU98	IC	InChI=1S/C15H17NO3S/c1-2-12-16(13-6-4-3-5-7-13)20(18,19)15-10-8-14(17)9-11-15/h3-11,17H,2,12H2,1H3
DM5TU98	CS	CCCN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DM5TU98	IK	VUUWGEGTDFUSTR-UHFFFAOYSA-N
DM5TU98	IU	4-hydroxy-N-phenyl-N-propylbenzenesulfonamide
DM5TU98	DE	Discovery agent

DMNMJDL	ID	DMNMJDL
DMNMJDL	DN	4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN
DMNMJDL	HS	Investigative
DMNMJDL	SN	4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN; AC1NUV4X; DB08480; (1R)-1-(prop-2-enylideneamino)-2,3-dihydro-1H-inden-4-ol; (1R)-1-[(E)-prop-2-en-1-ylideneamino]-2,3-dihydro-1H-inden-4-ol
DMNMJDL	DT	Small molecular drug
DMNMJDL	PC	5494443
DMNMJDL	MW	187.24
DMNMJDL	FM	C12H13NO
DMNMJDL	IC	InChI=1S/C12H13NO/c1-2-8-13-11-7-6-10-9(11)4-3-5-12(10)14/h2-5,8,11,14H,1,6-7H2/t11-/m1/s1
DMNMJDL	CS	C=CC=N[C@@H]1CCC2=C1C=CC=C2O
DMNMJDL	IK	OFWOPQIDDNCCLL-LLVKDONJSA-N
DMNMJDL	IU	(1R)-1-(prop-2-enylideneamino)-2,3-dihydro-1H-inden-4-ol
DMNMJDL	DE	Discovery agent

DM5ZQK1	ID	DM5ZQK1
DM5ZQK1	DN	4-Hydroxy-pent-2-enoic acid
DM5ZQK1	HS	Investigative
DM5ZQK1	SN	CHEMBL171595; (E)-4-hydroxypent-2-enoic acid; YANJKPZKTWMMOF-NSCUHMNNSA-N; 4-Hydroxy-pent-2-enoic acid; trans-4-hydroxypent-2-enoic acid; AC1NSI5H; 4-hydroxy-2-pentenoic acid; SCHEMBL166635; 2-Pentenoic acid, 4-hydroxy-; BDBM50023574; (2E)-4-Hydroxy-2-pentenoic acid #; AKOS022632862
DM5ZQK1	DT	Small molecular drug
DM5ZQK1	PC	5363658
DM5ZQK1	MW	116.11
DM5ZQK1	FM	C5H8O3
DM5ZQK1	IC	InChI=1S/C5H8O3/c1-4(6)2-3-5(7)8/h2-4,6H,1H3,(H,7,8)/b3-2+
DM5ZQK1	CS	CC(/C=C/C(=O)O)O
DM5ZQK1	IK	YANJKPZKTWMMOF-NSCUHMNNSA-N
DM5ZQK1	IU	(E)-4-hydroxypent-2-enoic acid
DM5ZQK1	DE	Discovery agent

DMDGKFV	ID	DMDGKFV
DMDGKFV	DN	4-Hydroxy-pentanoic acid
DMDGKFV	HS	Investigative
DMDGKFV	SN	4-Hydroxypentanoic acid; 4-Hydroxyvaleric acid; 4-hydroxy-pentanoic acid; gamma-Hydroxyvaleric acid; 13532-37-1; 4-hydroxy-valeric acid; Pentanoic acid, 4-hydroxy-; 103712-26-1; Pentanoic acid, 4-hydroxy-, (S)-; EINECS 236-884-1; ACMC-20m6jh; AC1Q5VUF; Pentanoic acid,4-hydroxy-; AC1L3FK5; AC1Q2BV5; SCHEMBL27394; CHEMBL169219; CTK4B9757; FMHKPLXYWVCLME-UHFFFAOYSA-N; MolPort-006-120-502; LMFA01050009; AKOS008148154; MCULE-6352217997; TX-017030
DMDGKFV	DT	Small molecular drug
DMDGKFV	PC	114539
DMDGKFV	MW	118.13
DMDGKFV	FM	C5H10O3
DMDGKFV	IC	InChI=1S/C5H10O3/c1-4(6)2-3-5(7)8/h4,6H,2-3H2,1H3,(H,7,8)
DMDGKFV	CS	CC(CCC(=O)O)O
DMDGKFV	IK	FMHKPLXYWVCLME-UHFFFAOYSA-N
DMDGKFV	IU	4-hydroxypentanoic acid
DMDGKFV	CA	CAS 13532-37-1
DMDGKFV	DE	Discovery agent

DMJ7G0E	ID	DMJ7G0E
DMJ7G0E	DN	4-hydroxyphenethyl 3,4,5-trihydroxybenzoate
DMJ7G0E	HS	Investigative
DMJ7G0E	SN	CHEMBL147069; 4-hydroxyphenethyl 3,4,5-trihydroxybenzoate; 2-(4-hydroxyphenyl)ethyl 3,4,5-trihydroxybenzoate; AC1NQOM4; SCHEMBL4738028; Gallic acid 4-hydroxyphenethyl ester; BDBM50109690; 2-(4-hydroxyphenyl) ethyl 3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxy-benzoic acid 2-(4-hydroxy-phenyl)-ethyl ester; Benzoic acid, 3,4,5-trihydroxy-, 2-(4-hydroxyphenyl)ethyl ester
DMJ7G0E	DT	Small molecular drug
DMJ7G0E	PC	5276405
DMJ7G0E	MW	290.27
DMJ7G0E	FM	C15H14O6
DMJ7G0E	IC	InChI=1S/C15H14O6/c16-11-3-1-9(2-4-11)5-6-21-15(20)10-7-12(17)14(19)13(18)8-10/h1-4,7-8,16-19H,5-6H2
DMJ7G0E	CS	C1=CC(=CC=C1CCOC(=O)C2=CC(=C(C(=C2)O)O)O)O
DMJ7G0E	IK	WSPSAXWXELZFQI-UHFFFAOYSA-N
DMJ7G0E	IU	2-(4-hydroxyphenyl)ethyl 3,4,5-trihydroxybenzoate
DMJ7G0E	DE	Discovery agent

DM0564K	ID	DM0564K
DM0564K	DN	4-hydroxyphenylpyruvic acid
DM0564K	HS	Investigative
DM0564K	SN	4-Hydroxyphenylpyruvic acid; 156-39-8; 3-(4-Hydroxyphenyl)-2-oxopropanoic acid; Testacid; p-Hydroxyphenylpyruvic acid; 4-hydroxyphenylpyruvate; Testacide; 3-(4-Hydroxyphenyl)pyruvic acid; (P-HYDROXYPHENYL)PYRUVIC ACID; 3-(p-Hydroxyphenyl)pyruvic acid; 3-(p-Hydroxyphenyl)-2-oxopropanoic acid; 3-(4-HYDROXY-PHENYL)PYRUVIC ACID; (p-hydroxyphenyl)-pyruvic acid; Pyruvic acid, p-hydroxyphenyl-; NSC 100738; 4-Hydroxy alpha-oxobenzenepropanoic acid; Pyruvic acid, (p-hydroxyphenyl)-; p-hydroxyphenylpyruvate;  4-hydroxyphenylpyruvate
DM0564K	DT	Small molecular drug
DM0564K	PC	979
DM0564K	MW	180.16
DM0564K	FM	C9H8O4
DM0564K	IC	InChI=1S/C9H8O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,10H,5H2,(H,12,13)
DM0564K	CS	C1=CC(=CC=C1CC(=O)C(=O)O)O
DM0564K	IK	KKADPXVIOXHVKN-UHFFFAOYSA-N
DM0564K	IU	3-(4-hydroxyphenyl)-2-oxopropanoic acid
DM0564K	CA	CAS 156-39-8
DM0564K	CB	CHEBI:15999
DM0564K	DE	Discovery agent

DM9VQ0T	ID	DM9VQ0T
DM9VQ0T	DN	4-Hydroxy-piperidine-3-carboxylic acid
DM9VQ0T	HS	Investigative
DM9VQ0T	SN	CHEMBL277372; SCHEMBL5426302; ZINC26898692; BDBM50223874; AKOS006353852; (3S)-4alpha-Hydroxypiperidine-3alpha-carboxylic acid
DM9VQ0T	DT	Small molecular drug
DM9VQ0T	PC	21125089
DM9VQ0T	MW	145.16
DM9VQ0T	FM	C6H11NO3
DM9VQ0T	IC	InChI=1S/C6H11NO3/c8-5-1-2-7-3-4(5)6(9)10/h4-5,7-8H,1-3H2,(H,9,10)/t4-,5+/m0/s1
DM9VQ0T	CS	C1CNC[C@@H]([C@@H]1O)C(=O)O
DM9VQ0T	IK	DAMFVOCECLPLSI-CRCLSJGQSA-N
DM9VQ0T	IU	(3S,4R)-4-hydroxypiperidine-3-carboxylic acid
DM9VQ0T	DE	Discovery agent

DMPIV6J	ID	DMPIV6J
DMPIV6J	DN	4-hydroxysaprothoquinone
DMPIV6J	HS	Investigative
DMPIV6J	SN	4-hydroxysaprothoquinone; CHEMBL453303; 4-Hydroxysaprorthoquinone; AC1NRZ82; BDBM50242319; 8-(4-hydroxy-4-methylpentyl)-7-methyl-3-propan-2-ylnaphthalene-1,2-dione
DMPIV6J	DT	Small molecular drug
DMPIV6J	PC	5325817
DMPIV6J	MW	314.4
DMPIV6J	FM	C20H26O3
DMPIV6J	IC	InChI=1S/C20H26O3/c1-12(2)16-11-14-9-8-13(3)15(7-6-10-20(4,5)23)17(14)19(22)18(16)21/h8-9,11-12,23H,6-7,10H2,1-5H3
DMPIV6J	CS	CC1=C(C2=C(C=C1)C=C(C(=O)C2=O)C(C)C)CCCC(C)(C)O
DMPIV6J	IK	QJYXXTULLNTAEX-UHFFFAOYSA-N
DMPIV6J	IU	8-(4-hydroxy-4-methylpentyl)-7-methyl-3-propan-2-ylnaphthalene-1,2-dione
DMPIV6J	DE	Discovery agent

DMJKF17	ID	DMJKF17
DMJKF17	DN	4-Imidazol-1-yl-2-phenyl-chroman-7-ol
DMJKF17	HS	Investigative
DMJKF17	SN	CHEMBL95919; 4-imidazol-1-yl-2-phenyl-chroman-7-ol
DMJKF17	DT	Small molecular drug
DMJKF17	PC	11779089
DMJKF17	MW	292.3
DMJKF17	FM	C18H16N2O2
DMJKF17	IC	InChI=1S/C18H16N2O2/c21-14-6-7-15-16(20-9-8-19-12-20)11-17(22-18(15)10-14)13-4-2-1-3-5-13/h1-10,12,16-17,21H,11H2
DMJKF17	CS	C1C(C2=C(C=C(C=C2)O)OC1C3=CC=CC=C3)N4C=CN=C4
DMJKF17	IK	ZVMPYRSCCMHXRC-UHFFFAOYSA-N
DMJKF17	IU	4-imidazol-1-yl-2-phenyl-3,4-dihydro-2H-chromen-7-ol
DMJKF17	DE	Discovery agent

DM28DEU	ID	DM28DEU
DM28DEU	DN	4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one
DM28DEU	HS	Investigative
DM28DEU	SN	CHEMBL1083665; 4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one
DM28DEU	DT	Small molecular drug
DM28DEU	PC	46867540
DM28DEU	MW	337.4
DM28DEU	FM	C17H11N3O3S
DM28DEU	IC	InChI=1S/C17H11N3O3S/c21-16-12-3-1-2-4-14(12)24-17-11(9-19-8-7-18-10-19)5-6-13(15(16)17)20(22)23/h1-8,10H,9H2
DM28DEU	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3S2)CN4C=CN=C4)[N+](=O)[O-]
DM28DEU	IK	OCFFNJCKSSDREB-UHFFFAOYSA-N
DM28DEU	IU	4-(imidazol-1-ylmethyl)-1-nitrothioxanthen-9-one
DM28DEU	DE	Discovery agent

DMZLVIF	ID	DMZLVIF
DMZLVIF	DN	4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one
DMZLVIF	HS	Investigative
DMZLVIF	SN	aromatase inhibitor i; CHEMBL159073; 4-(Imidazolylmethyl)-1-nitro-9H-9-xanthenone; 4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one; AC1L1D8C; CTK5I3006; BDBM50097366; 4-(imidazol-1-ylmethyl)-1-nitroxanthen-9-one; 4-(1H-imidazol-1-ylmethyl)-1-nitro-9H-xanthen-9-one; 4-((1H-imidazol-1-yl)methyl)-1-nitro-9H-xanthen-9-one; 1-Nitro-4-(1H-imidazole-1-ylmethyl)-9H-xanthene-9-one
DMZLVIF	DT	Small molecular drug
DMZLVIF	PC	2238
DMZLVIF	MW	321.29
DMZLVIF	FM	C17H11N3O4
DMZLVIF	IC	InChI=1S/C17H11N3O4/c21-16-12-3-1-2-4-14(12)24-17-11(9-19-8-7-18-10-19)5-6-13(15(16)17)20(22)23/h1-8,10H,9H2
DMZLVIF	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3O2)CN4C=CN=C4)[N+](=O)[O-]
DMZLVIF	IK	JLTNBMDVMUSXHQ-UHFFFAOYSA-N
DMZLVIF	IU	4-(imidazol-1-ylmethyl)-1-nitroxanthen-9-one
DMZLVIF	DE	Discovery agent

DM6FMO1	ID	DM6FMO1
DM6FMO1	DN	4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one
DM6FMO1	HS	Investigative
DM6FMO1	SN	CHEMBL1083663; 4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one
DM6FMO1	DT	Small molecular drug
DM6FMO1	PC	46867416
DM6FMO1	MW	321.29
DM6FMO1	FM	C17H11N3O4
DM6FMO1	IC	InChI=1S/C17H11N3O4/c21-16-13-3-1-2-4-15(13)24-17-11(9-19-6-5-18-10-19)7-12(20(22)23)8-14(16)17/h1-8,10H,9H2
DM6FMO1	CS	C1=CC=C2C(=C1)C(=O)C3=CC(=CC(=C3O2)CN4C=CN=C4)[N+](=O)[O-]
DM6FMO1	IK	FTWURRJWFIOKBA-UHFFFAOYSA-N
DM6FMO1	IU	4-(imidazol-1-ylmethyl)-2-nitroxanthen-9-one
DM6FMO1	DE	Discovery agent

DM8KZQN	ID	DM8KZQN
DM8KZQN	DN	4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one
DM8KZQN	HS	Investigative
DM8KZQN	SN	CHEMBL1083664; 4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one
DM8KZQN	DT	Small molecular drug
DM8KZQN	PC	46867417
DM8KZQN	MW	321.29
DM8KZQN	FM	C17H11N3O4
DM8KZQN	IC	InChI=1S/C17H11N3O4/c21-16-11-3-1-2-4-15(11)24-17-12(16)5-6-14(20(22)23)13(17)9-19-8-7-18-10-19/h1-8,10H,9H2
DM8KZQN	CS	C1=CC=C2C(=C1)C(=O)C3=C(O2)C(=C(C=C3)[N+](=O)[O-])CN4C=CN=C4
DM8KZQN	IK	SRBZAHSXFAWSRK-UHFFFAOYSA-N
DM8KZQN	IU	4-(imidazol-1-ylmethyl)-3-nitroxanthen-9-one
DM8KZQN	DE	Discovery agent

DMVUSMP	ID	DMVUSMP
DMVUSMP	DN	4-Imidazol-1-ylmethylthioxanthen-9-one
DMVUSMP	HS	Investigative
DMVUSMP	SN	CHEMBL1083353; 4-Imidazol-1-ylmethylthioxanthen-9-one
DMVUSMP	DT	Small molecular drug
DMVUSMP	PC	46867543
DMVUSMP	MW	292.4
DMVUSMP	FM	C17H12N2OS
DMVUSMP	IC	InChI=1S/C17H12N2OS/c20-16-13-5-1-2-7-15(13)21-17-12(4-3-6-14(16)17)10-19-9-8-18-11-19/h1-9,11H,10H2
DMVUSMP	CS	C1=CC=C2C(=C1)C(=O)C3=CC=CC(=C3S2)CN4C=CN=C4
DMVUSMP	IK	QHPHZBRQVQYOFQ-UHFFFAOYSA-N
DMVUSMP	IU	4-(imidazol-1-ylmethyl)thioxanthen-9-one
DMVUSMP	DE	Discovery agent

DMM8HK0	ID	DMM8HK0
DMM8HK0	DN	4-Imidazol-1-ylmethylxanthen-9-one
DMM8HK0	HS	Investigative
DMM8HK0	SN	CHEMBL1083971; 4-Imidazol-1-ylmethylxanthen-9-one
DMM8HK0	DT	Small molecular drug
DMM8HK0	PC	46867542
DMM8HK0	MW	276.29
DMM8HK0	FM	C17H12N2O2
DMM8HK0	IC	InChI=1S/C17H12N2O2/c20-16-13-5-1-2-7-15(13)21-17-12(4-3-6-14(16)17)10-19-9-8-18-11-19/h1-9,11H,10H2
DMM8HK0	CS	C1=CC=C2C(=C1)C(=O)C3=CC=CC(=C3O2)CN4C=CN=C4
DMM8HK0	IK	SWNOXHJBMDOXFE-UHFFFAOYSA-N
DMM8HK0	IU	4-(imidazol-1-ylmethyl)xanthen-9-one
DMM8HK0	DE	Discovery agent

DMFRCQS	ID	DMFRCQS
DMFRCQS	DN	4-Indan-(1E)-ylidenemethyl-pyridine
DMFRCQS	HS	Investigative
DMFRCQS	SN	(4-Pyridylmethylene)indane 2a; SCHEMBL4230787; BDBM8616; CHEMBL175962; SCHEMBL4230798; AC1O705V; ZINC13610822; 4-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 4-[(1E)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 4-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Oxalate
DMFRCQS	DT	Small molecular drug
DMFRCQS	PC	6539790
DMFRCQS	MW	207.27
DMFRCQS	FM	C15H13N
DMFRCQS	IC	InChI=1S/C15H13N/c1-2-4-15-13(3-1)5-6-14(15)11-12-7-9-16-10-8-12/h1-4,7-11H,5-6H2/b14-11+
DMFRCQS	CS	C1C/C(=C\\C2=CC=NC=C2)/C3=CC=CC=C31
DMFRCQS	IK	ZHGWOEHABOMOSV-SDNWHVSQSA-N
DMFRCQS	IU	4-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine
DMFRCQS	DE	Discovery agent

DM25DR7	ID	DM25DR7
DM25DR7	DN	4-Indan-(1Z)-ylidenemethyl-pyridine
DM25DR7	HS	Investigative
DM25DR7	SN	(4-Pyridylmethylene)indane 2b; SCHEMBL4230792; CHEMBL179149; BDBM8612; AC1O705N; 4-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 4-[(1Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 4-[(Z)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Oxalate
DM25DR7	DT	Small molecular drug
DM25DR7	PC	6539786
DM25DR7	MW	207.27
DM25DR7	FM	C15H13N
DM25DR7	IC	InChI=1S/C15H13N/c1-2-4-15-13(3-1)5-6-14(15)11-12-7-9-16-10-8-12/h1-4,7-11H,5-6H2/b14-11-
DM25DR7	CS	C1C/C(=C/C2=CC=NC=C2)/C3=CC=CC=C31
DM25DR7	IK	ZHGWOEHABOMOSV-KAMYIIQDSA-N
DM25DR7	IU	4-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine
DM25DR7	DE	Discovery agent

DM6YON7	ID	DM6YON7
DM6YON7	DN	4-Indan-1-ylmethyl-phenylamine
DM6YON7	HS	Investigative
DM6YON7	SN	CHEMBL364089; 4-Indan-1-ylmethyl-phenylamine
DM6YON7	DT	Small molecular drug
DM6YON7	PC	44401390
DM6YON7	MW	223.31
DM6YON7	FM	C16H17N
DM6YON7	IC	InChI=1S/C16H17N/c17-15-9-5-12(6-10-15)11-14-8-7-13-3-1-2-4-16(13)14/h1-6,9-10,14H,7-8,11,17H2
DM6YON7	CS	C1CC2=CC=CC=C2C1CC3=CC=C(C=C3)N
DM6YON7	IK	IFNMCDJEFWXUCT-UHFFFAOYSA-N
DM6YON7	IU	4-(2,3-dihydro-1H-inden-1-ylmethyl)aniline
DM6YON7	DE	Discovery agent

DM23E0R	ID	DM23E0R
DM23E0R	DN	4-Inden-(1E)-ylidenemethyl-phenylamine
DM23E0R	HS	Investigative
DM23E0R	SN	4-(1H-Inden-1-ylidenemethyl)aniline; NSC83092; 4-[(E)-inden-1-ylidenemethyl]aniline; CHEMBL193376; 487-61-6; 1-(4-Aminobenzylidene)indene; p-Toluidine, .alpha.-inden-1-ylidene-; 4-(1H-Inden-1-ylidenemethyl)phenylamine; Benzenamine, 4-(1H-inden-1-ylidenemethyl)-; MLS002694146; WLN: L56 BYJ BU1R DZ; 4-Inden-(1E)-ylidenemethyl-phenylamine; AC1O53IW; AC1Q1HQ2; cid_98148; BDBM50164749; NSC-83092; AKOS030547084; ZINC100425076; NCGC00186285-13; NCGC00186285-07; NCGC00186285-06; NCGC00186285-01; NCGC00186285-11; NCGC00186285-09
DM23E0R	DT	Small molecular drug
DM23E0R	PC	6476992
DM23E0R	MW	219.28
DM23E0R	FM	C16H13N
DM23E0R	IC	InChI=1S/C16H13N/c17-15-9-5-12(6-10-15)11-14-8-7-13-3-1-2-4-16(13)14/h1-11H,17H2/b14-11+
DM23E0R	CS	C1=CC=C\\2C(=C1)C=C/C2=C\\C3=CC=C(C=C3)N
DM23E0R	IK	GISMNWZLKDONAA-SDNWHVSQSA-N
DM23E0R	IU	4-[(E)-inden-1-ylidenemethyl]aniline
DM23E0R	CA	CAS 487-61-6
DM23E0R	DE	Discovery agent

DMG9JSK	ID	DMG9JSK
DMG9JSK	DN	4-Indol-1-ylmethyl-benzamidine
DMG9JSK	HS	Investigative
DMG9JSK	SN	1-(4-Amidinobenzyl)indole; 83783-25-9; CHEMBL100569; 4-ABI; 4-Indol-1-ylmethyl-benzamidine; 4-(1h-indol-1-ylmethyl)benzenecarboximidamide; AC1L34FF; AC1Q1U95; CTK5F1124; DTXSID50232637; ZINC5162918; BDBM50027305; AKOS030584119; 4-((1h-indol-1-yl)methyl)benzimidamide; 4-(indol-1-ylmethyl)benzenecarboximidamide; KB-214170; Benzenecarboximidamide,4-(1H-indol-1-ylmethyl)-; Benzenecarboximidamide, 4-(1H-indol-1-ylmethyl)-
DMG9JSK	DT	Small molecular drug
DMG9JSK	PC	134348
DMG9JSK	MW	249.31
DMG9JSK	FM	C16H15N3
DMG9JSK	IC	InChI=1S/C16H15N3/c17-16(18)14-7-5-12(6-8-14)11-19-10-9-13-3-1-2-4-15(13)19/h1-10H,11H2,(H3,17,18)
DMG9JSK	CS	C1=CC=C2C(=C1)C=CN2CC3=CC=C(C=C3)C(=N)N
DMG9JSK	IK	VKEKMIKRPJWXHO-UHFFFAOYSA-N
DMG9JSK	IU	4-(indol-1-ylmethyl)benzenecarboximidamide
DMG9JSK	CA	CAS 83783-25-9
DMG9JSK	DE	Discovery agent

DMKZQ3I	ID	DMKZQ3I
DMKZQ3I	DN	4-iodo-1H-indazole
DMKZQ3I	HS	Investigative
DMKZQ3I	SN	4-iodo-1H-indazole; 885522-11-2; 4-Iodoindazole; 4-IODO (1H)INDAZOLE; CHEMBL246534; zlchem 1146; PubChem21944; SCHEMBL358061; 4-Iodo-1H-indazole, 95%; 4-IODO-(1H)-iNDAZOLE; 1H-INDAZOLE, 4-IODO-; CTK8B7170; ZLD0614; DTXSID10646276; MolPort-009-197-588; CJQXSPSUIGJNJX-UHFFFAOYSA-N; ZX-RL006042; BCP26449; ZINC14983484; BDBM50209235; ANW-56585; CI-483; AKOS015853740; FCH1325887; VI20042; QC-2871; PB27826; RP05951; AS-50534; AJ-65949; EN002531; KB-39256; OR308061; AK-27887; TC-062829; DB-023141; AB0037276; ST1100625; AX8158792; Y4536; AM20041322
DMKZQ3I	DT	Small molecular drug
DMKZQ3I	PC	24728219
DMKZQ3I	MW	244.03
DMKZQ3I	FM	C7H5IN2
DMKZQ3I	IC	InChI=1S/C7H5IN2/c8-6-2-1-3-7-5(6)4-9-10-7/h1-4H,(H,9,10)
DMKZQ3I	CS	C1=CC2=C(C=NN2)C(=C1)I
DMKZQ3I	IK	CJQXSPSUIGJNJX-UHFFFAOYSA-N
DMKZQ3I	IU	4-iodo-1H-indazole
DMKZQ3I	CA	CAS 885522-11-2
DMKZQ3I	DE	Discovery agent

DMIPENJ	ID	DMIPENJ
DMIPENJ	DN	4-Iodo-2,6-diisopropyl-phenol
DMIPENJ	HS	Investigative
DMIPENJ	SN	4-Iodopropofol; 169255-48-5; 4-IODO-2,6-BIS(ISOPROPYL)PHENOL; CHEMBL53267; 4-Iodo-2,6-diisopropyl-phenol; Bobel 4; Phenol, 4-iodo-2,6-bis(1-methylethyl)-; 4-Iodo-2,6-diisopropylphenol; ZINC8678; SCHEMBL1163939; DTXSID10432353; MolPort-009-677-266; ZX-AT014004; BDBM50064424; 2,6-Bis(prop-2-yl)-4-iodophenol; AKOS025310281; OR54368; FCH1363142; 2,6-Bis(isopropyl)-4-iodophenol 97%
DMIPENJ	DT	Small molecular drug
DMIPENJ	PC	9882905
DMIPENJ	MW	304.17
DMIPENJ	FM	C12H17IO
DMIPENJ	IC	InChI=1S/C12H17IO/c1-7(2)10-5-9(13)6-11(8(3)4)12(10)14/h5-8,14H,1-4H3
DMIPENJ	CS	CC(C)C1=CC(=CC(=C1O)C(C)C)I
DMIPENJ	IK	JMJHJCFWTNRPEI-UHFFFAOYSA-N
DMIPENJ	IU	4-iodo-2,6-di(propan-2-yl)phenol
DMIPENJ	CA	CAS 169255-48-5
DMIPENJ	DE	Discovery agent

DMC8D4R	ID	DMC8D4R
DMC8D4R	DN	4-Iodo-6-nitro-2-piperazin-1-yl-quinoline
DMC8D4R	HS	Investigative
DMC8D4R	SN	CHEMBL167475; 4-Iodo-6-nitro-2-piperazin-1-yl-quinoline; SCHEMBL6365240; BDBM50110579
DMC8D4R	DT	Small molecular drug
DMC8D4R	PC	44379433
DMC8D4R	MW	384.17
DMC8D4R	FM	C13H13IN4O2
DMC8D4R	IC	InChI=1S/C13H13IN4O2/c14-11-8-13(17-5-3-15-4-6-17)16-12-2-1-9(18(19)20)7-10(11)12/h1-2,7-8,15H,3-6H2
DMC8D4R	CS	C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)I
DMC8D4R	IK	ABNBXDNNSDJWKN-UHFFFAOYSA-N
DMC8D4R	IU	4-iodo-6-nitro-2-piperazin-1-ylquinoline
DMC8D4R	DE	Discovery agent

DMYNVLZ	ID	DMYNVLZ
DMYNVLZ	DN	4-iodo-6-phenylpyrimidine
DMYNVLZ	HS	Investigative
DMYNVLZ	SN	41270-96-6; CHEMBL497802; AC-907/25004997; AC1LG8ZQ; SCHEMBL244108; CHEBI:91213; CTK7C3610; MolPort-003-800-888; ZINC331218; BDBM50265608; AKOS005266491; FCH1331127; 4-IPP, &gt
DMYNVLZ	DT	Small molecular drug
DMYNVLZ	PC	817368
DMYNVLZ	MW	282.08
DMYNVLZ	FM	C10H7IN2
DMYNVLZ	IC	InChI=1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H
DMYNVLZ	CS	C1=CC=C(C=C1)C2=CC(=NC=N2)I
DMYNVLZ	IK	ZTCJXHNJVLUUMR-UHFFFAOYSA-N
DMYNVLZ	IU	4-iodo-6-phenylpyrimidine
DMYNVLZ	CB	CHEBI:91213
DMYNVLZ	DE	Solid tumour/cancer

DMFSH2I	ID	DMFSH2I
DMFSH2I	DN	4-iodo-acetamido phenylboronic acid
DMFSH2I	HS	Investigative
DMFSH2I	SN	4-IODO-ACETAMIDO PHENYLBORONIC ACID; Boronic acid, [3-[(iodoacetyl)amino]phenyl]-; 87199-19-7; AC1NE0SC; [3-[(2-iodoacetyl)amino]phenyl]boronic acid; C8H9BINO3; SCHEMBL7744399; CTK2I2732; DTXSID90405045; AKOS030568788; DB02122; {3-[(iodoacetyl)amino]phenyl}boronic acid
DMFSH2I	DT	Small molecular drug
DMFSH2I	PC	4634714
DMFSH2I	MW	304.88
DMFSH2I	FM	C8H9BINO3
DMFSH2I	IC	InChI=1S/C8H9BINO3/c10-5-8(12)11-7-3-1-2-6(4-7)9(13)14/h1-4,13-14H,5H2,(H,11,12)
DMFSH2I	CS	B(C1=CC(=CC=C1)NC(=O)CI)(O)O
DMFSH2I	IK	LMHXPDZPXBIIEX-UHFFFAOYSA-N
DMFSH2I	IU	[3-[(2-iodoacetyl)amino]phenyl]boronic acid
DMFSH2I	CA	CAS 87199-19-7
DMFSH2I	DE	Discovery agent

DMXAEGF	ID	DMXAEGF
DMXAEGF	DN	4-iodobenzo[b]thiophene 2-carboxamidine
DMXAEGF	HS	Investigative
DMXAEGF	SN	amino(4-iodo-1-benzothiophen-2-yl)methaniminium; ESI; AC1L1C5C; CTK7C3490; BDBM14169; APC-6860; CRA-6860; DB03136; [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium
DMXAEGF	DT	Small molecular drug
DMXAEGF	PC	1746
DMXAEGF	MW	303.14
DMXAEGF	FM	C9H8IN2S+
DMXAEGF	IC	InChI=1S/C9H7IN2S/c10-6-2-1-3-7-5(6)4-8(13-7)9(11)12/h1-4H,(H3,11,12)/p+1
DMXAEGF	CS	C1=CC2=C(C=C(S2)C(=[NH2+])N)C(=C1)I
DMXAEGF	IK	YERQOXAYAFWFEJ-UHFFFAOYSA-O
DMXAEGF	IU	[amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium

DMJMOAI	ID	DMJMOAI
DMJMOAI	DN	4-iodophenyl-alaninyl-(S)-2-cyano-pyrrolidine
DMJMOAI	HS	Investigative
DMJMOAI	SN	SCHEMBL3260399; CHEMBL199881; BDBM11116; 4-substituted phenylalanine cyano-(S)-pyrrolidine deriv. 3
DMJMOAI	DT	Small molecular drug
DMJMOAI	PC	23645372
DMJMOAI	MW	369.2
DMJMOAI	FM	C14H16IN3O
DMJMOAI	IC	InChI=1S/C14H16IN3O/c15-11-5-3-10(4-6-11)8-13(17)14(19)18-7-1-2-12(18)9-16/h3-6,12-13H,1-2,7-8,17H2/t12-,13-/m0/s1
DMJMOAI	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)I)N)C#N
DMJMOAI	IK	PQFUJTFHVDWNOF-STQMWFEESA-N
DMJMOAI	IU	(2S)-1-[(2S)-2-amino-3-(4-iodophenyl)propanoyl]pyrrolidine-2-carbonitrile
DMJMOAI	DE	Discovery agent

DMF3CLX	ID	DMF3CLX
DMF3CLX	DN	4-Iodopyrazole
DMF3CLX	HS	Investigative
DMF3CLX	SN	4-Iodopyrazole; 4-Iodo-1H-pyrazole; 3469-69-0; 1H-Pyrazole, 4-iodo-; 4-iodo-pyrazole; Pyrazole, 4-iodo; LLNQWPTUJJYTTE-UHFFFAOYSA-N; 4-Iodopyrazole, 98%; 4-iod-1h-pyrazol; 4-iodo pyrazole; sFtHCQVILimKP@; zlchem 55; EINECS 222-434-1; 4-iodo-1H-pyrazol; PubChem13295; ACMC-1CSZW; 4-Iodopyrazole, 99%; AC1Q4PAD; AC1L2S6R; AC1Q1GT3; SCHEMBL71959; AMTH001; KSC225I2F; Jsp006281; LLNQWPTUJJYTTE-UHFFFAOYSA-; CTK1C5422; CHEBI:45260; ZLB0042; DTXSID30188244; MolPort-000-156-497; BM019; KS-000004PJ; ALBB-013400; ACT01776; ZINC2046962; ACN-P000781
DMF3CLX	DT	Small molecular drug
DMF3CLX	PC	77022
DMF3CLX	MW	193.97
DMF3CLX	FM	C3H3IN2
DMF3CLX	IC	InChI=1S/C3H3IN2/c4-3-1-5-6-2-3/h1-2H,(H,5,6)
DMF3CLX	CS	C1=C(C=NN1)I
DMF3CLX	IK	LLNQWPTUJJYTTE-UHFFFAOYSA-N
DMF3CLX	IU	4-iodo-1H-pyrazole
DMF3CLX	CA	CAS 3469-69-0
DMF3CLX	CB	CHEBI:45260
DMF3CLX	DE	Discovery agent

DMQ95EG	ID	DMQ95EG
DMQ95EG	DN	4-Iodyl-benzoic acid
DMQ95EG	HS	Investigative
DMQ95EG	SN	4-iodylbenzoic Acid; 4-Iodyl-benzoic acid; CHEMBL119805; AC1MW5HG; SCHEMBL3123027
DMQ95EG	DT	Small molecular drug
DMQ95EG	PC	3718733
DMQ95EG	MW	280.02
DMQ95EG	FM	C7H5IO4
DMQ95EG	IC	InChI=1S/C7H5IO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4H,(H,9,10)
DMQ95EG	CS	C1=CC(=CC=C1C(=O)O)I(=O)=O
DMQ95EG	IK	OCPGBAXIXDSOBI-UHFFFAOYSA-N
DMQ95EG	IU	4-iodylbenzoic acid
DMQ95EG	DE	Discovery agent

DM7F38J	ID	DM7F38J
DM7F38J	DN	4-isopropyl-2-(phenoxymethyl)morpholine
DM7F38J	HS	Investigative
DM7F38J	SN	CHEMBL510654; 4-isopropyl-2-(phenoxymethyl)morpholine; BDBM50293194
DM7F38J	DT	Small molecular drug
DM7F38J	PC	12226582
DM7F38J	MW	235.32
DM7F38J	FM	C14H21NO2
DM7F38J	IC	InChI=1S/C14H21NO2/c1-12(2)15-8-9-16-14(10-15)11-17-13-6-4-3-5-7-13/h3-7,12,14H,8-11H2,1-2H3
DM7F38J	CS	CC(C)N1CCOC(C1)COC2=CC=CC=C2
DM7F38J	IK	WCHHCBBPGSWTOB-UHFFFAOYSA-N
DM7F38J	IU	2-(phenoxymethyl)-4-propan-2-ylmorpholine
DM7F38J	DE	Discovery agent

DMW1T93	ID	DMW1T93
DMW1T93	DN	4-isopropyl-N-(naphthalen-1-yl)thiazol-2-amine
DMW1T93	HS	Investigative
DMW1T93	SN	CHEMBL207589; 4-isopropyl-N-(naphthalen-1-yl)thiazol-2-amine; SCHEMBL14433285
DMW1T93	DT	Small molecular drug
DMW1T93	PC	9814022
DMW1T93	MW	268.4
DMW1T93	FM	C16H16N2S
DMW1T93	IC	InChI=1S/C16H16N2S/c1-11(2)15-10-19-16(18-15)17-14-9-5-7-12-6-3-4-8-13(12)14/h3-11H,1-2H3,(H,17,18)
DMW1T93	CS	CC(C)C1=CSC(=N1)NC2=CC=CC3=CC=CC=C32
DMW1T93	IK	UZYASSJTIRFKFN-UHFFFAOYSA-N
DMW1T93	IU	N-naphthalen-1-yl-4-propan-2-yl-1,3-thiazol-2-amine
DMW1T93	DE	Discovery agent

DMMDGR2	ID	DMMDGR2
DMMDGR2	DN	4-ISOPROPYLPHENSERINE
DMMDGR2	HS	Investigative
DMMDGR2	SN	Cymserine; cymserinetartaric acid; 145209-39-8; CHEMBL129837; BDBM10960; DTXSID10432696; 4-Isopropylphenylcarbamic acid (3aS)-1,3aalpha,8-trimethyl-1,2,3,3a,8,8aalpha-hexahydropyrrolo[2,3-b]indole-5-yl ester; (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl
DMMDGR2	DT	Small molecular drug
DMMDGR2	PC	9907847
DMMDGR2	MW	379.5
DMMDGR2	FM	C23H29N3O2
DMMDGR2	IC	InChI=1S/C23H29N3O2/c1-15(2)16-6-8-17(9-7-16)24-22(27)28-18-10-11-20-19(14-18)23(3)12-13-25(4)21(23)26(20)5/h6-11,14-15,21H,12-13H2,1-5H3,(H,24,27)/t21-,23+/m1/s1
DMMDGR2	CS	CC(C)C1=CC=C(C=C1)NC(=O)OC2=CC3=C(C=C2)N([C@@H]4[C@]3(CCN4C)C)C
DMMDGR2	IK	NKJRRVBTMYRXRB-GGAORHGYSA-N
DMMDGR2	IU	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(4-propan-2-ylphenyl)carbamate
DMMDGR2	CA	CAS 145209-39-8
DMMDGR2	DE	Discovery agent

DMVTEOQ	ID	DMVTEOQ
DMVTEOQ	DN	4-Isopropyl-pyrrolidin-(2Z)-ylideneamine
DMVTEOQ	HS	Investigative
DMVTEOQ	SN	CHEMBL365637; 4-Isopropyl-pyrrolidin-(2Z)-ylideneamine; SCHEMBL7598537; SCHEMBL10077978; BDBM50150914
DMVTEOQ	DT	Small molecular drug
DMVTEOQ	PC	18983431
DMVTEOQ	MW	126.2
DMVTEOQ	FM	C7H14N2
DMVTEOQ	IC	InChI=1S/C7H14N2/c1-5(2)6-3-7(8)9-4-6/h5-6H,3-4H2,1-2H3,(H2,8,9)
DMVTEOQ	CS	CC(C)C1CC(=NC1)N
DMVTEOQ	IK	PUOKLNVZFQOPOS-UHFFFAOYSA-N
DMVTEOQ	IU	3-propan-2-yl-3,4-dihydro-2H-pyrrol-5-amine
DMVTEOQ	DE	Discovery agent

DMBK67H	ID	DMBK67H
DMBK67H	DN	4-isothiocyanatobenzenesulfonamide
DMBK67H	HS	Investigative
DMBK67H	SN	4-Isothiocyanatobenzenesulfonamide; 51908-29-3; 4-isothiocyanatobenzene-1-sulfonamide; 4-Isothiocyanato-benzenesulfonamide; Benzenesulfonamide, 4-isothiocyanato-; CHEMBL144818; IMDUFDNFSJWYQT-UHFFFAOYSA-N; 4-Isothiocyanatobenzene sulfonamide; 4-Icsa; AC1LAVHK; SCHEMBL1476527; CTK4J5100; DTXSID90199871; MolPort-000-156-692; KS-00000HK9; ZINC2571868; ALBB-003064; 4-(Isothiocyanato)benzenesulfonamide; Benzenesulfonamide,4-isothiocyanato-; GEO-03379; BDBM50094812; ANW-51072; STK501629; 4-(aminosulfonyl)phenylisothiocyanate; SBB046978
DMBK67H	DT	Small molecular drug
DMBK67H	PC	521359
DMBK67H	MW	214.3
DMBK67H	FM	C7H6N2O2S2
DMBK67H	IC	InChI=1S/C7H6N2O2S2/c8-13(10,11)7-3-1-6(2-4-7)9-5-12/h1-4H,(H2,8,10,11)
DMBK67H	CS	C1=CC(=CC=C1N=C=S)S(=O)(=O)N
DMBK67H	IK	IMDUFDNFSJWYQT-UHFFFAOYSA-N
DMBK67H	IU	4-isothiocyanatobenzenesulfonamide
DMBK67H	CA	CAS 51908-29-3
DMBK67H	DE	Discovery agent

DMNCVIP	ID	DMNCVIP
DMNCVIP	DN	4-MA
DMNCVIP	HS	Investigative
DMNCVIP	SN	4-Methylbenzoic acid; P-TOLUIC ACID; 99-94-5; 4-Toluic acid; Crithminic acid; p-Methylbenzoic acid; p-Toluylic acid; Benzoic acid, 4-methyl-; p-Carboxytoluene; para-Toluic acid; 4-Methyl-Benzoic Acid; Toluate; Toluenecarboxylic acid; p-Toluate; UNII-A26GBX5SSV; para toluic acid; NSC 2215; p-Toluic acid, 98%; EINECS 202-803-3; A26GBX5SSV; BRN 0507600; AI3-15627; CHEBI:36635; 2420-97-5 (cadmium salt); LPNBBFKOUUSUDB-UHFFFAOYSA-N; p-toluicacid; 4MA; Crithmic acid; rho-toluic acid; 4-Carboxytoluene; 4-MethylbenzoicAcid; 4-methylbenzic acid
DMNCVIP	DT	Small molecular drug
DMNCVIP	PC	6917653
DMNCVIP	MW	388.6
DMNCVIP	FM	C24H40N2O2
DMNCVIP	IC	InChI=1S/C24H40N2O2/c1-6-26(7-2)22(28)19-10-9-17-16-8-11-20-24(4,15-13-21(27)25(20)5)18(16)12-14-23(17,19)3/h16-20H,6-15H2,1-5H3/t16-,17-,18-,19+,20+,23-,24+/m0/s1
DMNCVIP	CS	CCN(CC)C(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=O)N4C)C)C
DMNCVIP	IK	GNWBLLYJQXKPIP-ZOGIJGBBSA-N
DMNCVIP	IU	(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-1-carboxamide
DMNCVIP	CA	CAS 73671-86-0
DMNCVIP	DE	Discovery agent

DMPH4C8	ID	DMPH4C8
DMPH4C8	DN	4-Methanesulfonylamino-benzenesulfonamide
DMPH4C8	HS	Investigative
DMPH4C8	SN	4-Methanesulfonylamino-benzenesulfonamide; 4-(methanesulfonamido)benzenesulfonamide; CHEMBL193648; 4426-90-8; 4-[(methylsulfonyl)amino]benzenesulfonamide; AC1MDJCY; Oprea1_082411; SCHEMBL6401783; DTXSID60385527; MolPort-001-489-118; ZINC3191876; BDBM50174035; STK416772; BBL020042; AKOS002973885; MCULE-3544784326; 4-(Methylsulfonylamino)benzenesulfonamide
DMPH4C8	DT	Small molecular drug
DMPH4C8	PC	2837872
DMPH4C8	MW	250.3
DMPH4C8	FM	C7H10N2O4S2
DMPH4C8	IC	InChI=1S/C7H10N2O4S2/c1-14(10,11)9-6-2-4-7(5-3-6)15(8,12)13/h2-5,9H,1H3,(H2,8,12,13)
DMPH4C8	CS	CS(=O)(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DMPH4C8	IK	KPLRLDFXFOARQY-UHFFFAOYSA-N
DMPH4C8	IU	4-(methanesulfonamido)benzenesulfonamide
DMPH4C8	CA	CAS 4426-90-8
DMPH4C8	DE	Discovery agent

DM97B2G	ID	DM97B2G
DM97B2G	DN	4-Methoxy-2-phenyl-2H-pyrazolo[4,3-c]quinoline
DM97B2G	HS	Investigative
DM97B2G	SN	CHEMBL188052; 4-Methoxy-2-phenyl-2H-pyrazolo[4,3-c]quinoline
DM97B2G	DT	Small molecular drug
DM97B2G	PC	11196622
DM97B2G	MW	275.3
DM97B2G	FM	C17H13N3O
DM97B2G	IC	InChI=1S/C17H13N3O/c1-21-17-14-11-20(12-7-3-2-4-8-12)19-16(14)13-9-5-6-10-15(13)18-17/h2-11H,1H3
DM97B2G	CS	COC1=NC2=CC=CC=C2C3=NN(C=C31)C4=CC=CC=C4
DM97B2G	IK	LBRDTSFKAURCRO-UHFFFAOYSA-N
DM97B2G	IU	4-methoxy-2-phenylpyrazolo[4,3-c]quinoline
DM97B2G	DE	Discovery agent

DMJIX7H	ID	DMJIX7H
DMJIX7H	DN	4-Methoxy-3-pyridinesulfonamide
DMJIX7H	HS	Investigative
DMJIX7H	SN	CHEMBL1165321; 4-Methoxy-3-pyridinesulfonamide
DMJIX7H	DT	Small molecular drug
DMJIX7H	PC	46703766
DMJIX7H	MW	188.21
DMJIX7H	FM	C6H8N2O3S
DMJIX7H	IC	InChI=1S/C6H8N2O3S/c1-11-5-2-3-8-4-6(5)12(7,9)10/h2-4H,1H3,(H2,7,9,10)
DMJIX7H	CS	COC1=C(C=NC=C1)S(=O)(=O)N
DMJIX7H	IK	YLDUTJXETDRGDZ-UHFFFAOYSA-N
DMJIX7H	IU	4-methoxypyridine-3-sulfonamide
DMJIX7H	DE	Discovery agent

DM5FRV2	ID	DM5FRV2
DM5FRV2	DN	4'-Methoxy-5,3'-dipropyl-biphenyl-2ol
DM5FRV2	HS	Investigative
DM5FRV2	SN	CHEMBL555297; Magreth-1; ZINC42966087; BDBM50295920
DM5FRV2	DT	Small molecular drug
DM5FRV2	PC	45267389
DM5FRV2	MW	284.4
DM5FRV2	FM	C19H24O2
DM5FRV2	IC	InChI=1S/C19H24O2/c1-4-6-14-8-10-18(20)17(12-14)15-9-11-19(21-3)16(13-15)7-5-2/h8-13,20H,4-7H2,1-3H3
DM5FRV2	CS	CCCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)OC)CCC
DM5FRV2	IK	HFEJJSAHPYKAPW-UHFFFAOYSA-N
DM5FRV2	IU	2-(4-methoxy-3-propylphenyl)-4-propylphenol
DM5FRV2	DE	Discovery agent

DMID40H	ID	DMID40H
DMID40H	DN	4-Methoxy-5-phenyl-6-thia-10b-aza-benzo[e]azulene
DMID40H	HS	Investigative
DMID40H	SN	CHEMBL142639; 4-Methoxy-5-phenyl-6-thia-10b-aza-benzo[e]azulene; ZINC13603872; BDBM50029753
DMID40H	DT	Small molecular drug
DMID40H	PC	10494803
DMID40H	MW	305.4
DMID40H	FM	C19H15NOS
DMID40H	IC	InChI=1S/C19H15NOS/c1-21-18-16-11-7-13-20(16)15-10-5-6-12-17(15)22-19(18)14-8-3-2-4-9-14/h2-13H,1H3
DMID40H	CS	COC1=C(SC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DMID40H	IK	AWMKYXNZIQHXIW-UHFFFAOYSA-N
DMID40H	IU	7-methoxy-6-phenylpyrrolo[2,1-d][1,5]benzothiazepine
DMID40H	DE	Discovery agent

DM54A3W	ID	DM54A3W
DM54A3W	DN	4-methoxy-9-aminomethyl-9,10-dihydroanthracene
DM54A3W	HS	Investigative
DM54A3W	SN	CHEMBL454491; 4-methoxy-9-aminomethyl-9,10-dihydroanthracene; BDBM50264950
DM54A3W	DT	Small molecular drug
DM54A3W	PC	44580318
DM54A3W	MW	239.31
DM54A3W	FM	C16H17NO
DM54A3W	IC	InChI=1S/C16H17NO/c1-18-16-8-4-7-13-14(16)9-11-5-2-3-6-12(11)15(13)10-17/h2-8,15H,9-10,17H2,1H3
DM54A3W	CS	COC1=CC=CC2=C1CC3=CC=CC=C3C2CN
DM54A3W	IK	ZJILWLYMMRQWLR-UHFFFAOYSA-N
DM54A3W	IU	(4-methoxy-9,10-dihydroanthracen-9-yl)methanamine
DM54A3W	DE	Discovery agent

DMVFLCM	ID	DMVFLCM
DMVFLCM	DN	4-Methoxybenzenemethanethiol
DMVFLCM	HS	Investigative
DMVFLCM	SN	6258-60-2; 4-Methoxy-alpha-toluenethiol; 4-Methoxybenzyl mercaptan; 4-methoxybenzylmercaptan; (4-Methoxyphenyl)methanethiol; 4-Methoxy Benzylmercaptan; Benzenemethanethiol, 4-methoxy-; p-Methoxybenzyl Mercaptan; 4-Methoxy benzyl mercaptan; 4-Methoxy-; p-Methoxybenzylthiol; p-Methoxybenzylmercaptan; p-Methoxy-.alpha.-toluenethiol; 4-Methoxy-.alpha.-toluenethiol; CHEMBL1224560; PTDVPWWJRCOIIO-UHFFFAOYSA-N; 4-Methoxy-alpha-toluenethiol, 95%; 4-methoxybenzylthiol; EINECS 228-393-6
DMVFLCM	DT	Small molecular drug
DMVFLCM	PC	80407
DMVFLCM	MW	154.23
DMVFLCM	FM	C8H10OS
DMVFLCM	IC	InChI=1S/C8H10OS/c1-9-8-4-2-7(6-10)3-5-8/h2-5,10H,6H2,1H3
DMVFLCM	CS	COC1=CC=C(C=C1)CS
DMVFLCM	IK	PTDVPWWJRCOIIO-UHFFFAOYSA-N
DMVFLCM	IU	(4-methoxyphenyl)methanethiol
DMVFLCM	CA	CAS 6258-60-2
DMVFLCM	DE	Discovery agent

DMCS83F	ID	DMCS83F
DMCS83F	DN	4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline
DMCS83F	HS	Investigative
DMCS83F	SN	CHEMBL83581; 4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline
DMCS83F	DT	Small molecular drug
DMCS83F	PC	10711377
DMCS83F	MW	328.4
DMCS83F	FM	C19H24N2O3
DMCS83F	IC	InChI=1S/C19H24N2O3/c1-4-8-23-13-6-7-16-14(10-13)18-15(12-22-3)19(24-9-5-2)20-11-17(18)21-16/h6-7,10-11,21H,4-5,8-9,12H2,1-3H3
DMCS83F	CS	CCCOC1=CC2=C(C=C1)NC3=CN=C(C(=C23)COC)OCCC
DMCS83F	IK	BTCRVOSPHNKQGJ-UHFFFAOYSA-N
DMCS83F	IU	4-(methoxymethyl)-3,6-dipropoxy-9H-pyrido[3,4-b]indole
DMCS83F	DE	Discovery agent

DMF079L	ID	DMF079L
DMF079L	DN	4-methoxy-N'-(2-phenylacetyl)benzohydrazide
DMF079L	HS	Investigative
DMF079L	SN	4-methoxy-N'-(phenylacetyl)benzohydrazide; 4-methoxy-N'-(2-phenylacetyl)benzohydrazide; benzohydrazide, 15; AC1LEZHC; CHEMBL244921; ARONIS002261; BDBM23731; ZINC68809; KS-00003VJE; MolPort-000-681-545; STK056698; AKOS000492246; MCULE-6943344531; ST040019; 4-methoxy-N -(phenylacetyl)benzohydrazide; KB-115318; 4-methoxy-N''-(2-phenylacetyl)benzohydrazide
DMF079L	DT	Small molecular drug
DMF079L	PC	695069
DMF079L	MW	284.31
DMF079L	FM	C16H16N2O3
DMF079L	IC	InChI=1S/C16H16N2O3/c1-21-14-9-7-13(8-10-14)16(20)18-17-15(19)11-12-5-3-2-4-6-12/h2-10H,11H2,1H3,(H,17,19)(H,18,20)
DMF079L	CS	COC1=CC=C(C=C1)C(=O)NNC(=O)CC2=CC=CC=C2
DMF079L	IK	BJVRKPCYZSFHDT-UHFFFAOYSA-N
DMF079L	IU	4-methoxy-N'-(2-phenylacetyl)benzohydrazide
DMF079L	DE	Discovery agent

DMFKN1M	ID	DMFKN1M
DMFKN1M	DN	4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide
DMFKN1M	HS	Investigative
DMFKN1M	SN	CHEMBL62075; 4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide; BDBM50097446
DMFKN1M	DT	Small molecular drug
DMFKN1M	PC	10760609
DMFKN1M	MW	354.4
DMFKN1M	FM	C23H18N2O2
DMFKN1M	IC	InChI=1S/C23H18N2O2/c1-27-19-13-11-17(12-14-19)23(26)25-22-20-10-6-5-9-18(20)15-21(24-22)16-7-3-2-4-8-16/h2-15H,1H3,(H,24,25,26)
DMFKN1M	CS	COC1=CC=C(C=C1)C(=O)NC2=NC(=CC3=CC=CC=C32)C4=CC=CC=C4
DMFKN1M	IK	MJZBWCOZBVDNSM-UHFFFAOYSA-N
DMFKN1M	IU	4-methoxy-N-(3-phenylisoquinolin-1-yl)benzamide
DMFKN1M	DE	Discovery agent

DMPQKGY	ID	DMPQKGY
DMPQKGY	DN	4-methoxy-N-(thiazol-2-yl)benzamide
DMPQKGY	HS	Investigative
DMPQKGY	SN	4-Methoxy-N-thiazol-2-yl-benzamide; 4-methoxy-N-1,3-thiazol-2-ylbenzamide; 4-methoxy-benzoic acid thiazol-2-ylamide; 4-methoxy-N-(1,3-thiazol-2-yl)benzamide; 303122-55-6; BAS 00626024; Oprea1_481467; Oprea1_830630; MLS001209223; ARONIS023447; CHEMBL387618; AC1Q49Y5; AC1LF170; MolPort-001-004-838; ZINC123532; HMS2848F19; STK031490; AKOS001320075; MCULE-9448418356; KS-0000469Q; ST089107; SMR000514833; KB-115289; 4-methoxy-N~1~-(1,3-thiazol-2-yl)benzamide
DMPQKGY	DT	Small molecular drug
DMPQKGY	PC	721308
DMPQKGY	MW	234.28
DMPQKGY	FM	C11H10N2O2S
DMPQKGY	IC	InChI=1S/C11H10N2O2S/c1-15-9-4-2-8(3-5-9)10(14)13-11-12-6-7-16-11/h2-7H,1H3,(H,12,13,14)
DMPQKGY	CS	COC1=CC=C(C=C1)C(=O)NC2=NC=CS2
DMPQKGY	IK	PPERAEKJEHRHOY-UHFFFAOYSA-N
DMPQKGY	IU	4-methoxy-N-(1,3-thiazol-2-yl)benzamide
DMPQKGY	DE	Discovery agent

DMBS61O	ID	DMBS61O
DMBS61O	DN	4-methoxynaphthalen-1-amine
DMBS61O	HS	Investigative
DMBS61O	SN	4-methoxynaphthalen-1-amine; 16430-99-2; 1-Naphthalenamine, 4-methoxy-; 1-amino-4-methoxynaphthalene; CHEMBL572058; JVMUPDOMGALPOW-UHFFFAOYSA-N; F2146-0572; 4-methoxy naphthylamine; ACMC-209dqv; 4-methoxy-1-naphthalenamine; 1-methoxy-4-naphthalenamine; SCHEMBL331453; 1 -amino-4-methoxy-naphthalene; CTK8B0935; DTXSID80454284; ZINC11919966; BDBM50303938; ANW-22085; AKOS009236876; MCULE-9788991699; 4-methoxynaphthalen-1-amine, AldrichCPR; CJ-13724; AJ-60498; TC-110830; FT-0750226
DMBS61O	DT	Small molecular drug
DMBS61O	PC	11074644
DMBS61O	MW	173.21
DMBS61O	FM	C11H11NO
DMBS61O	IC	InChI=1S/C11H11NO/c1-13-11-7-6-10(12)8-4-2-3-5-9(8)11/h2-7H,12H2,1H3
DMBS61O	CS	COC1=CC=C(C2=CC=CC=C21)N
DMBS61O	IK	JVMUPDOMGALPOW-UHFFFAOYSA-N
DMBS61O	IU	4-methoxynaphthalen-1-amine
DMBS61O	CA	CAS 16430-99-2
DMBS61O	DE	Discovery agent

DM739SQ	ID	DM739SQ
DM739SQ	DN	4-methoxyphenyl 1-(4-butoxyphenyl)propylcarbamate
DM739SQ	HS	Investigative
DM739SQ	SN	CHEMBL591447; 4-methoxyphenyl 1-(4-butoxyphenyl)propylcarbamate; SCHEMBL5214948
DM739SQ	DT	Small molecular drug
DM739SQ	PC	20872773
DM739SQ	MW	357.4
DM739SQ	FM	C21H27NO4
DM739SQ	IC	InChI=1S/C21H27NO4/c1-4-6-15-25-18-9-7-16(8-10-18)20(5-2)22-21(23)26-19-13-11-17(24-3)12-14-19/h7-14,20H,4-6,15H2,1-3H3,(H,22,23)
DM739SQ	CS	CCCCOC1=CC=C(C=C1)C(CC)NC(=O)OC2=CC=C(C=C2)OC
DM739SQ	IK	SOBJGOKNEOSMPL-UHFFFAOYSA-N
DM739SQ	IU	(4-methoxyphenyl) N-[1-(4-butoxyphenyl)propyl]carbamate
DM739SQ	DE	Discovery agent

DM3L76R	ID	DM3L76R
DM3L76R	DN	4-methoxyphenyl 10H-phenothiazine-10-carboxylate
DM3L76R	HS	Investigative
DM3L76R	SN	CHEMBL481872; 4-methoxyphenyl 10H-phenothiazine-10-carboxylate; SCHEMBL4453079; MolPort-004-877-802; BDBM50292614; STK354315; ZINC20085903; AKOS005442135
DM3L76R	DT	Small molecular drug
DM3L76R	PC	24905597
DM3L76R	MW	349.4
DM3L76R	FM	C20H15NO3S
DM3L76R	IC	InChI=1S/C20H15NO3S/c1-23-14-10-12-15(13-11-14)24-20(22)21-16-6-2-4-8-18(16)25-19-9-5-3-7-17(19)21/h2-13H,1H3
DM3L76R	CS	COC1=CC=C(C=C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM3L76R	IK	OFQHJDQONOGHGC-UHFFFAOYSA-N
DM3L76R	IU	(4-methoxyphenyl) phenothiazine-10-carboxylate
DM3L76R	DE	Discovery agent

DMP5YFQ	ID	DMP5YFQ
DMP5YFQ	DN	4-methoxyphenylboronic acid
DMP5YFQ	HS	Investigative
DMP5YFQ	SN	4-Methoxyphenylboronic acid; 5720-07-0; (4-Methoxyphenyl)boronic acid; 4-Methoxybenzeneboronic acid; 4-Methoxyphenyl boronic acid; p-Anisylboronic acid; p-Methoxyphenylboronic acid; 45713-46-0; p-Methoxybenzeneboronic acid; (4-Methoxyphenyl)Boranediol; Benzeneboronic acid, p-methoxy-; 4-Boronoanisole; Boronic acid, p-methoxyphenyl-; 4-methoxy boronic acid; BRN 2936912; CHEMBL21427; BORONIC ACID, (4-METHOXYPHENYL)-; 4-methoxy-phenyl-boronic acid; AI3-61385; (4-METHOXYPHENYL)BORANE; MFCD00039139; 4-Methoxyphenylboronic acid, 97%
DMP5YFQ	DT	Small molecular drug
DMP5YFQ	PC	201262
DMP5YFQ	MW	151.96
DMP5YFQ	FM	C7H9BO3
DMP5YFQ	IC	InChI=1S/C7H9BO3/c1-11-7-4-2-6(3-5-7)8(9)10/h2-5,9-10H,1H3
DMP5YFQ	CS	B(C1=CC=C(C=C1)OC)(O)O
DMP5YFQ	IK	VOAAEKKFGLPLLU-UHFFFAOYSA-N
DMP5YFQ	IU	(4-methoxyphenyl)boronic acid
DMP5YFQ	CA	CAS 5720-07-0
DMP5YFQ	DE	Discovery agent

DMVW8KN	ID	DMVW8KN
DMVW8KN	DN	4-methoxyphenylsulfamide
DMVW8KN	HS	Investigative
DMVW8KN	SN	4-methoxyphenylsulfamide; N-(4-methoxyphenyl)sulfamide; CHEMBL165878; 10539-83-0; (4-methoxylphenyl)sulfamide; SCHEMBL1645328; CTK8G5045; N-(4-methoxyphenyl)sulfuric diamide; BDBM50124171; ZINC13488096; 1-methoxy-4-(sulfamoylamino)-benzene; AKOS027393897; DA-48085; KB-299500; FT-0726752; 79495-EP2305698A2; 79495-EP2305697A2; 79495-EP2305696A2
DMVW8KN	DT	Small molecular drug
DMVW8KN	PC	12033284
DMVW8KN	MW	202.23
DMVW8KN	FM	C7H10N2O3S
DMVW8KN	IC	InChI=1S/C7H10N2O3S/c1-12-7-4-2-6(3-5-7)9-13(8,10)11/h2-5,9H,1H3,(H2,8,10,11)
DMVW8KN	CS	COC1=CC=C(C=C1)NS(=O)(=O)N
DMVW8KN	IK	ICWBFSCBEZAOCT-UHFFFAOYSA-N
DMVW8KN	IU	1-methoxy-4-(sulfamoylamino)benzene
DMVW8KN	DE	Discovery agent

DM2IZA3	ID	DM2IZA3
DM2IZA3	DN	4-Methyl-1,1':4',1''-terphenyl-3,4''-diol
DM2IZA3	HS	Investigative
DM2IZA3	SN	CHEMBL568945; BDBM50299638
DM2IZA3	DT	Small molecular drug
DM2IZA3	PC	44543257
DM2IZA3	MW	276.3
DM2IZA3	FM	C19H16O2
DM2IZA3	IC	InChI=1S/C19H16O2/c1-13-11-17(9-10-19(13)21)15-7-5-14(6-8-15)16-3-2-4-18(20)12-16/h2-12,20-21H,1H3
DM2IZA3	CS	CC1=C(C=CC(=C1)C2=CC=C(C=C2)C3=CC(=CC=C3)O)O
DM2IZA3	IK	NXOBKCKXSAATAY-UHFFFAOYSA-N
DM2IZA3	IU	4-[4-(3-hydroxyphenyl)phenyl]-2-methylphenol
DM2IZA3	DE	Discovery agent

DMKRHQ3	ID	DMKRHQ3
DMKRHQ3	DN	4-methyl-2H-benzofuro[3,2-g]chromen-2-one
DMKRHQ3	HS	Investigative
DMKRHQ3	SN	CHEMBL201777; 105290-13-9; 2H-Benzofuro(3,2-g)-1-benzopyran-2-one, 4-methyl-; 4-Methyl-(1)benzofuro(3,2-g)chromen-2-one; 2H-Benzofuro[3,2-g]-1-benzopyran-2-one, 4-methyl-; 4-methyl-[1]benzofuro[3,2-g]chromen-2-one; 4-methyl-2H-benzofuro[3,2-g]chromen-2-one; ACMC-20c6p3; AC1Q6A2V; AC1L4EY2; 4-methyl-2h-[1]benzofuro[3,2-g]chromen-2-one; CTK0G5617; DTXSID00147060; ZINC6069630; BDBM50181850
DMKRHQ3	DT	Small molecular drug
DMKRHQ3	PC	184462
DMKRHQ3	MW	250.25
DMKRHQ3	FM	C16H10O3
DMKRHQ3	IC	InChI=1S/C16H10O3/c1-9-6-16(17)19-14-8-15-12(7-11(9)14)10-4-2-3-5-13(10)18-15/h2-8H,1H3
DMKRHQ3	CS	CC1=CC(=O)OC2=CC3=C(C=C12)C4=CC=CC=C4O3
DMKRHQ3	IK	MOTTUNALIBKKNF-UHFFFAOYSA-N
DMKRHQ3	IU	4-methyl-[1]benzofuro[3,2-g]chromen-2-one
DMKRHQ3	CA	CAS 105290-13-9
DMKRHQ3	DE	Discovery agent

DMH6QZO	ID	DMH6QZO
DMH6QZO	DN	4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid
DMH6QZO	HS	Investigative
DMH6QZO	SN	CHEMBL124880; 88072-24-6; 4-Methyl-3-(2-oxoazetidin-1-yl)benzoic acid; 4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid; CTK3B8559; DTXSID20539468; BDBM50022785; Benzoic acid, 4-methyl-3-(2-oxo-1-azetidinyl)-
DMH6QZO	DT	Small molecular drug
DMH6QZO	PC	13400034
DMH6QZO	MW	205.21
DMH6QZO	FM	C11H11NO3
DMH6QZO	IC	InChI=1S/C11H11NO3/c1-7-2-3-8(11(14)15)6-9(7)12-5-4-10(12)13/h2-3,6H,4-5H2,1H3,(H,14,15)
DMH6QZO	CS	CC1=C(C=C(C=C1)C(=O)O)N2CCC2=O
DMH6QZO	IK	XLQAIEGAEHIXRJ-UHFFFAOYSA-N
DMH6QZO	IU	4-methyl-3-(2-oxoazetidin-1-yl)benzoic acid
DMH6QZO	CA	CAS 88072-24-6
DMH6QZO	DE	Discovery agent

DM5FWYG	ID	DM5FWYG
DM5FWYG	DN	4-Methyl-3,6-dihydro-1H-pyridin-(2Z)-ylideneamine
DM5FWYG	HS	Investigative
DM5FWYG	SN	AKOS006358726
DM5FWYG	DT	Small molecular drug
DM5FWYG	PC	44313256
DM5FWYG	MW	110.16
DM5FWYG	FM	C6H10N2
DM5FWYG	IC	InChI=1S/C6H10N2/c1-5-2-3-8-6(7)4-5/h2H,3-4H2,1H3,(H2,7,8)
DM5FWYG	CS	CC1=CCN=C(C1)N
DM5FWYG	IK	ZOKOWWYVKANQNJ-UHFFFAOYSA-N
DM5FWYG	IU	4-methyl-2,5-dihydropyridin-6-amine
DM5FWYG	DE	Discovery agent

DMV19HC	ID	DMV19HC
DMV19HC	DN	4-Methyl-5-(4-piperidyl)isothiazol-3-ol
DMV19HC	HS	Investigative
DMV19HC	SN	CHEMBL204110; 4-Methyl-5-(4-piperidyl)isothiazol-3-ol
DMV19HC	DT	Small molecular drug
DMV19HC	PC	11507406
DMV19HC	MW	198.29
DMV19HC	FM	C9H14N2OS
DMV19HC	IC	InChI=1S/C9H14N2OS/c1-6-8(13-11-9(6)12)7-2-4-10-5-3-7/h7,10H,2-5H2,1H3,(H,11,12)
DMV19HC	CS	CC1=C(SNC1=O)C2CCNCC2
DMV19HC	IK	TVYLWJFICSYNFD-UHFFFAOYSA-N
DMV19HC	IU	4-methyl-5-piperidin-4-yl-1,2-thiazol-3-one
DMV19HC	DE	Discovery agent

DMUP8NS	ID	DMUP8NS
DMUP8NS	DN	4-Methyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine
DMUP8NS	HS	Investigative
DMUP8NS	SN	CHEMBL75304; 479668-33-2; 5,6-dihydro-4-methyl-2-Pyridinamine; ZINC2002913; BDBM50116666; AKOS006359115; FCH1123804; ACM479668332; DB-070901; FT-0749169; 2-Pyridinamine,5,6-dihydro-4-methyl-(9CI)
DMUP8NS	DT	Small molecular drug
DMUP8NS	PC	9793827
DMUP8NS	MW	110.16
DMUP8NS	FM	C6H10N2
DMUP8NS	IC	InChI=1S/C6H10N2/c1-5-2-3-8-6(7)4-5/h4H,2-3H2,1H3,(H2,7,8)
DMUP8NS	CS	CC1=CC(=NCC1)N
DMUP8NS	IK	SRTDZDDEFUNXJL-UHFFFAOYSA-N
DMUP8NS	IU	4-methyl-2,3-dihydropyridin-6-amine
DMUP8NS	DE	Discovery agent

DM7LPON	ID	DM7LPON
DM7LPON	DN	4-Methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one
DM7LPON	HS	Investigative
DM7LPON	SN	CHEMBL124849; 4-Methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one; SCHEMBL6942608; ZINC27211803
DM7LPON	DT	Small molecular drug
DM7LPON	PC	12969973
DM7LPON	MW	211.26
DM7LPON	FM	C14H13NO
DM7LPON	IC	InChI=1S/C14H13NO/c1-10-12-7-6-11-4-2-3-5-13(11)15(12)9-8-14(10)16/h2-5,8-9H,6-7H2,1H3
DM7LPON	CS	CC1=C2CCC3=CC=CC=C3N2C=CC1=O
DM7LPON	IK	POEIHRYHSHOMRL-UHFFFAOYSA-N
DM7LPON	IU	4-methyl-5,6-dihydrobenzo[f]quinolizin-3-one
DM7LPON	DE	Discovery agent

DM0ZA7T	ID	DM0ZA7T
DM0ZA7T	DN	4-Methyl-5-piperidin-4-yl-isoxazol-3-ol
DM0ZA7T	HS	Investigative
DM0ZA7T	SN	CHEMBL144416; CHEMBL553129; 439944-42-0; 3(2H)-Isoxazolone, 4-methyl-5-(4-piperidinyl)-; BDBM50113803; BDBM50020029; AKOS022705739; 4-Methyl-5-(4-piperidinyl)isoxazole-3-ol; 4-Methyl-5-piperidin-4-yl-isoxazol-3-ol
DM0ZA7T	DT	Small molecular drug
DM0ZA7T	PC	10797510
DM0ZA7T	MW	182.22
DM0ZA7T	FM	C9H14N2O2
DM0ZA7T	IC	InChI=1S/C9H14N2O2/c1-6-8(13-11-9(6)12)7-2-4-10-5-3-7/h7,10H,2-5H2,1H3,(H,11,12)
DM0ZA7T	CS	CC1=C(ONC1=O)C2CCNCC2
DM0ZA7T	IK	PACUXLHRGQUIQZ-UHFFFAOYSA-N
DM0ZA7T	IU	4-methyl-5-piperidin-4-yl-1,2-oxazol-3-one
DM0ZA7T	DE	Discovery agent

DMN8Z3C	ID	DMN8Z3C
DMN8Z3C	DN	4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine
DMN8Z3C	HS	Investigative
DMN8Z3C	SN	CHEMBL186142; CHEMBL541081; BDBM50066785; AKOS006377665; 4-Methyl-5-propyl-pyrrolidin-(2E)-ylideneamine
DMN8Z3C	DT	Small molecular drug
DMN8Z3C	PC	19049123
DMN8Z3C	MW	140.23
DMN8Z3C	FM	C8H16N2
DMN8Z3C	IC	InChI=1S/C8H16N2/c1-3-4-7-6(2)5-8(9)10-7/h6-7H,3-5H2,1-2H3,(H2,9,10)
DMN8Z3C	CS	CCCC1C(CC(=N1)N)C
DMN8Z3C	IK	TYAICJLSMGBRPT-UHFFFAOYSA-N
DMN8Z3C	IU	3-methyl-2-propyl-3,4-dihydro-2H-pyrrol-5-amine
DMN8Z3C	DE	Discovery agent

DMW7YHS	ID	DMW7YHS
DMW7YHS	DN	4-Methyl-6-(2-methylprop-1-enyl)pyridin-2-amine
DMW7YHS	HS	Investigative
DMW7YHS	SN	4-Methyl-6-(2-methylprop-1-enyl)pyridin-2-amine; CHEMBL464556; 1146620-61-2; SCHEMBL13040624
DMW7YHS	DT	Small molecular drug
DMW7YHS	PC	42625621
DMW7YHS	MW	162.23
DMW7YHS	FM	C10H14N2
DMW7YHS	IC	InChI=1S/C10H14N2/c1-7(2)4-9-5-8(3)6-10(11)12-9/h4-6H,1-3H3,(H2,11,12)
DMW7YHS	CS	CC1=CC(=NC(=C1)N)C=C(C)C
DMW7YHS	IK	BHPPONCQQUIFAK-UHFFFAOYSA-N
DMW7YHS	IU	4-methyl-6-(2-methylprop-1-enyl)pyridin-2-amine
DMW7YHS	DE	Discovery agent

DMY04D1	ID	DMY04D1
DMY04D1	DN	4-methyl-6-propylpyridin-2-amine
DMY04D1	HS	Investigative
DMY04D1	SN	4-Methyl-6-propylpyridin-2-amine; CHEMBL302657; 2-amino-4-methyl-6-propylpyridine; 179555-24-9; SCHEMBL7051196; QGCCHDIBMYPTPX-UHFFFAOYSA-N; BDBM50091817; 4-Methyl-6-propyl-pyridin-2-ylamine; 2-Pyridinamine, 4-methyl-6-propyl-; AKOS027400844; 4-Methyl-6-propylpyridin-2-amine, 7
DMY04D1	DT	Small molecular drug
DMY04D1	PC	9855524
DMY04D1	MW	150.22
DMY04D1	FM	C9H14N2
DMY04D1	IC	InChI=1S/C9H14N2/c1-3-4-8-5-7(2)6-9(10)11-8/h5-6H,3-4H2,1-2H3,(H2,10,11)
DMY04D1	CS	CCCC1=NC(=CC(=C1)C)N
DMY04D1	IK	QGCCHDIBMYPTPX-UHFFFAOYSA-N
DMY04D1	IU	4-methyl-6-propylpyridin-2-amine
DMY04D1	DE	Discovery agent

DM9K7CQ	ID	DM9K7CQ
DM9K7CQ	DN	4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one
DM9K7CQ	HS	Investigative
DM9K7CQ	SN	CHEMBL372943; 4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one; CTK7H3804; BDBM50181856; AKOS015965448; 4-Methyl-7-(2-oxo-cyclopentyloxy)-c
DM9K7CQ	DT	Small molecular drug
DM9K7CQ	PC	44407281
DM9K7CQ	MW	258.269
DM9K7CQ	FM	C15H14O4
DM9K7CQ	IC	InChI=1S/C15H14O4/c1-9-7-15(17)19-14-8-10(5-6-11(9)14)18-13-4-2-3-12(13)16/h5-8,13H,2-4H2,1H3
DM9K7CQ	CS	CC1=CC(=O)OC2=C1C=CC(=C2)OC3CCCC3=O
DM9K7CQ	IK	UDCMJKJFGCMHHR-UHFFFAOYSA-N
DM9K7CQ	IU	4-methyl-7-(2-oxocyclopentyl)oxychromen-2-one
DM9K7CQ	DE	Discovery agent

DM5XMI9	ID	DM5XMI9
DM5XMI9	DN	4-Methylamino-benzenesulfonamide
DM5XMI9	HS	Investigative
DM5XMI9	SN	4-(Methylamino)Benzenesulfonamide; 4-(methylamino)benzene-1-sulfonamide; 16891-79-5; 4-Methylamino-benzenesulfonamide; CHEMBL174847; AC1Q40XN; SCHEMBL3521509; p-methylaminobenzene sulphonamide; CTK4D3153; DTXSID40562172; FJVAYUUWTJKKNC-UHFFFAOYSA-N; MolPort-004-759-881; Benzenesulfonamide,4-(methylamino)-; ZINC28098746; BDBM50160668; Benzenesulfonamide, 4-(methylamino)-; AKOS009323835; MCULE-7909074599; NE62186; DA-09438; KB-289209; FT-0749810; EN300-58198
DM5XMI9	DT	Small molecular drug
DM5XMI9	PC	14612854
DM5XMI9	MW	186.23
DM5XMI9	FM	C7H10N2O2S
DM5XMI9	IC	InChI=1S/C7H10N2O2S/c1-9-6-2-4-7(5-3-6)12(8,10)11/h2-5,9H,1H3,(H2,8,10,11)
DM5XMI9	CS	CNC1=CC=C(C=C1)S(=O)(=O)N
DM5XMI9	IK	FJVAYUUWTJKKNC-UHFFFAOYSA-N
DM5XMI9	IU	4-(methylamino)benzenesulfonamide
DM5XMI9	CA	CAS 16891-79-5
DM5XMI9	DE	Discovery agent

DMI1L6Q	ID	DMI1L6Q
DMI1L6Q	DN	4-methylaminomethyl-7-methoxycoumarin
DMI1L6Q	HS	Investigative
DMI1L6Q	SN	4-Methylaminomethyl-7-methoxycoumarin; AC1PGYCB; 7-methoxy-4-(methylaminomethyl)chromen-2-one; SCHEMBL5022816; CHEMBL1080339; BDBM26482; GWMGUFTYUOYYQV-UHFFFAOYSA-N; 4-(Methylaminomethyl)-7-methoxycoumarin; 7-Methoxy-4-(methylaminomethyl)coumarin
DMI1L6Q	DT	Small molecular drug
DMI1L6Q	PC	8931837
DMI1L6Q	MW	219.24
DMI1L6Q	FM	C12H13NO3
DMI1L6Q	IC	InChI=1S/C12H13NO3/c1-13-7-8-5-12(14)16-11-6-9(15-2)3-4-10(8)11/h3-6,13H,7H2,1-2H3
DMI1L6Q	CS	CNCC1=CC(=O)OC2=C1C=CC(=C2)OC
DMI1L6Q	IK	GWMGUFTYUOYYQV-UHFFFAOYSA-N
DMI1L6Q	IU	7-methoxy-4-(methylaminomethyl)chromen-2-one
DMI1L6Q	DE	Discovery agent

DM3S2P8	ID	DM3S2P8
DM3S2P8	DN	4-Methylbenzenemethanethiol
DM3S2P8	HS	Investigative
DM3S2P8	SN	4498-99-1; 4-Methylbenzyl Mercaptan; (4-Methylphenyl)methanethiol; p-Xylene-alpha-thiol; alpha-Mercapto-p-xylene; 4-Methylbenzenemethanethiol; 4-Methylbenzylmercaptan; Benzenemethanethiol, 4-methyl-; CHEMBL1224559; AGFYZLVFPSGUIX-UHFFFAOYSA-N; P-Xylyl Mercaptan; (4-methylphenyl)methane-1-thiol; p-tolylmethanethiol; NSC79870; EINECS 224-796-6; AC1L2UTO; AC1Q7GOJ; ACMC-1AQT2; 4-Methyl-alpha-toluenethiol; SCHEMBL385561; PARA-XYLENE-ALPHA-THIOL; (4-Methylphenyl)methanethiol #; CTK3J1384; DTXSID30196349; MolPort-000-146-954
DM3S2P8	DT	Small molecular drug
DM3S2P8	PC	78252
DM3S2P8	MW	138.23
DM3S2P8	FM	C8H10S
DM3S2P8	IC	InChI=1S/C8H10S/c1-7-2-4-8(6-9)5-3-7/h2-5,9H,6H2,1H3
DM3S2P8	CS	CC1=CC=C(C=C1)CS
DM3S2P8	IK	AGFYZLVFPSGUIX-UHFFFAOYSA-N
DM3S2P8	IU	(4-methylphenyl)methanethiol
DM3S2P8	CA	CAS 4498-99-1
DM3S2P8	DE	Discovery agent

DMABMPQ	ID	DMABMPQ
DMABMPQ	DN	4-methylhistamine
DMABMPQ	HS	Investigative
DMABMPQ	SN	4-Methylhistamine; 5-Methylhistamine; 36507-31-0; 5(4)-Methylhistamine; 1H-Imidazole-4-ethanamine, 5-methyl-; 2-(5-methyl-1H-imidazol-4-yl)ethanamine; UNII-54ST71P9EE; 1H-Imidazo-4-ethanamine, 5-methyl-; 54ST71P9EE; CHEBI:74760; IMIDAZOLE, 4-(2-AMINOETHYL)-5-METHYL-; 2-(5-Methyl-4-imidazolyl)ethylamine; 2-(4-METHYL-1H-IMIDAZOL-5-YL)ETHANAMINE; p-methylhistamine; Methylhistamine-4; 5-(2-Aminoethyl)-4-methylimidazole; AC1L1XS2; SCHEMBL606803; CHEMBL275443; GTPL1269; SCHEMBL11452941; BDBM22880; UGYXPZQILZRKJJ-UHFFFAOYSA-N
DMABMPQ	DT	Small molecular drug
DMABMPQ	PC	37463
DMABMPQ	MW	125.17
DMABMPQ	FM	C6H11N3
DMABMPQ	IC	InChI=1S/C6H11N3/c1-5-6(2-3-7)9-4-8-5/h4H,2-3,7H2,1H3,(H,8,9)
DMABMPQ	CS	CC1=C(N=CN1)CCN
DMABMPQ	IK	UGYXPZQILZRKJJ-UHFFFAOYSA-N
DMABMPQ	IU	2-(5-methyl-1H-imidazol-4-yl)ethanamine
DMABMPQ	CA	CAS 36507-31-0
DMABMPQ	CB	CHEBI:74760
DMABMPQ	DE	Discovery agent

DM45N6U	ID	DM45N6U
DM45N6U	DN	4-Methylimidazole
DM45N6U	HS	Investigative
DM45N6U	SN	4-Methylimidazole; 4-Methyl-1H-imidazole; 822-36-6; 5-Methyl-1H-imidazole; 1H-Imidazole, 4-methyl-; 4(5)-Methylimidazole; 4-Me-i; 5-Methylimidazole; IMIDAZOLE, 4-METHYL-; 4(or 5)-Methylimidazole; 4-MEI; 4-methylimidazol; UNII-Q64GF9FV4I; 1H-Imidazole, 5-methyl-; 4-methyl imidazole; EINECS 212-497-3; NSC 40744; Q64GF9FV4I; AI3-08274; CHEBI:40035; XLSZMDLNRCVEIJ-UHFFFAOYSA-N; 4-Methylimidazole, 98%; 4-Methyl-d3-imidazole; 88054-16-4; 4MI; 4MZ; InChI=1/C4H6N2/c1-4-2-5-3-6-4/h2-3H,1H3,(H,5,6; CCRIS 8912; HSDB 7757; 4-methyl-imidazole
DM45N6U	DT	Small molecular drug
DM45N6U	PC	13195
DM45N6U	MW	82.1
DM45N6U	FM	C4H6N2
DM45N6U	IC	InChI=1S/C4H6N2/c1-4-2-5-3-6-4/h2-3H,1H3,(H,5,6)
DM45N6U	CS	CC1=CN=CN1
DM45N6U	IK	XLSZMDLNRCVEIJ-UHFFFAOYSA-N
DM45N6U	IU	5-methyl-1H-imidazole
DM45N6U	CA	CAS 822-36-6
DM45N6U	CB	CHEBI:40035
DM45N6U	DE	Discovery agent

DMSF5DR	ID	DMSF5DR
DMSF5DR	DN	4-Methyl-N-(4-phenyl-thiazol-2-yl)-benzamide
DMSF5DR	HS	Investigative
DMSF5DR	SN	4-Methyl-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; CHEMBL294175; 4-Methyl-N-(4-phenyl-thiazol-2-yl)-benzamide; NERONVMZIDSIRT-UHFFFAOYSA-N; 87614-00-4; (Z)-4-methyl-N-(4-phenylthiazol-2(3H)-ylidene)benzamide; AC1Q2JVA; AC1LB6OY; Oprea1_598164; Oprea1_751162; Oprea1_000114; SCHEMBL233522; ARONIS019641; 2-[(4-methylphenyl)carboxamido]-4-phenyl-1,3-thiazole; KS-00004BJP; MolPort-003-009-217; MolPort-001-029-741; ZINC4031557; BDBM50101781; STK084905; AKOS024573976; AKOS000486758; MCULE-8350259880; ST036564
DMSF5DR	DT	Small molecular drug
DMSF5DR	PC	577347
DMSF5DR	MW	294.4
DMSF5DR	FM	C17H14N2OS
DMSF5DR	IC	InChI=1S/C17H14N2OS/c1-12-7-9-14(10-8-12)16(20)19-17-18-15(11-21-17)13-5-3-2-4-6-13/h2-11H,1H3,(H,18,19,20)
DMSF5DR	CS	CC1=CC=C(C=C1)C(=O)NC2=NC(=CS2)C3=CC=CC=C3
DMSF5DR	IK	NERONVMZIDSIRT-UHFFFAOYSA-N
DMSF5DR	IU	4-methyl-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMSF5DR	DE	Discovery agent

DMFRASQ	ID	DMFRASQ
DMFRASQ	DN	4-methyl-N-(naphthalen-1-yl)thiazol-2-amine
DMFRASQ	HS	Investigative
DMFRASQ	SN	CHEMBL383736; AC1LEV1N; Maybridge1_006094; 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine; SCHEMBL14433296; HMS558M22; CCG-716; MolPort-000-432-043; ZINC5730833; BDBM50183094; AKOS002285219; MCULE-5807523116; ST50046832; (4-methyl(1,3-thiazol-2-yl))naphthylamine
DMFRASQ	DT	Small molecular drug
DMFRASQ	PC	692856
DMFRASQ	MW	240.33
DMFRASQ	FM	C14H12N2S
DMFRASQ	IC	InChI=1S/C14H12N2S/c1-10-9-17-14(15-10)16-13-8-4-6-11-5-2-3-7-12(11)13/h2-9H,1H3,(H,15,16)
DMFRASQ	CS	CC1=CSC(=N1)NC2=CC=CC3=CC=CC=C32
DMFRASQ	IK	QNKLFDFMOINNIW-UHFFFAOYSA-N
DMFRASQ	IU	4-methyl-N-naphthalen-1-yl-1,3-thiazol-2-amine
DMFRASQ	DE	Discovery agent

DMN45EH	ID	DMN45EH
DMN45EH	DN	4-methyl-N-propyl-3,4-dihydroquinazolin-2-amine
DMN45EH	HS	Investigative
DMN45EH	DT	Small molecular drug
DMN45EH	PC	44456463
DMN45EH	DE	Discovery agent

DME7W0Q	ID	DME7W0Q
DME7W0Q	DN	4-Methyl-oxazolidin-(2Z)-ylideneamine
DME7W0Q	HS	Investigative
DME7W0Q	SN	CHEMBL105823; 4-methyl-4,5-dihydro-1,3-oxazol-2-amine; 68210-17-3; 4-Methyl-oxazolidin-(2Z)-ylideneamine; 4-Methyloxazolidine-2-imine; SCHEMBL6593982; SCHEMBL11825446; MolPort-004-802-126; BDBM50138202; AKOS006363611; NE17732
DME7W0Q	DT	Small molecular drug
DME7W0Q	PC	18376830
DME7W0Q	MW	100.12
DME7W0Q	FM	C4H8N2O
DME7W0Q	IC	InChI=1S/C4H8N2O/c1-3-2-7-4(5)6-3/h3H,2H2,1H3,(H2,5,6)
DME7W0Q	CS	CC1COC(=N1)N
DME7W0Q	IK	PIXPFRMNXPKTFS-UHFFFAOYSA-N
DME7W0Q	IU	4-methyl-4,5-dihydro-1,3-oxazol-2-amine
DME7W0Q	DE	Discovery agent

DMR5NLM	ID	DMR5NLM
DMR5NLM	DN	4-methylphenyl-difluoromethanesulfonamide
DMR5NLM	HS	Investigative
DMR5NLM	SN	4-methylphenyl-difluoromethanesulfonamide; CHEMBL199464; 803728-11-2; CTK5E7727; DTXSID60658763; BDBM50175011; AKOS027416710; Benzenemethanesulfonamide,a,a-difluoro-4-methyl-; 1,1-Difluoro-1-(4-methylphenyl)methanesulfonamide
DMR5NLM	DT	Small molecular drug
DMR5NLM	PC	44405177
DMR5NLM	MW	221.23
DMR5NLM	FM	C8H9F2NO2S
DMR5NLM	IC	InChI=1S/C8H9F2NO2S/c1-6-2-4-7(5-3-6)8(9,10)14(11,12)13/h2-5H,1H3,(H2,11,12,13)
DMR5NLM	CS	CC1=CC=C(C=C1)C(F)(F)S(=O)(=O)N
DMR5NLM	IK	QPMHTUPJLAWJAW-UHFFFAOYSA-N
DMR5NLM	IU	difluoro-(4-methylphenyl)methanesulfonamide
DMR5NLM	CA	CAS 803728-11-2
DMR5NLM	DE	Discovery agent

DMNMXCE	ID	DMNMXCE
DMNMXCE	DN	4-Methyl-piperidin-(2E)-ylideneamine
DMNMXCE	HS	Investigative
DMNMXCE	SN	CHEMBL6808; 2-imino-4-methylpiperidine; 2-PYRIDINAMINE, 3,4,5,6-TETRAHYDRO-4-METHYL-; 165383-71-1; 4-Methyl-piperidin-(2E)-ylideneamine; AC1MMWW1; 4-methylpiperidin-2-imine; 4-methyl-3,4,5,6-tetrahydropyridin-2-amine; 4-Methyl-2-piperidinimine; SCHEMBL4103569; CTK0A9019; DTXSID00390857; BDBM50062133; 4-Methyl-piperidin-(2Z)-ylideneamine; AKOS006348873; FT-0722141; 4-methyl-2,3,4,5-tetrahydropyridin-6-amine
DMNMXCE	DT	Small molecular drug
DMNMXCE	PC	3268009
DMNMXCE	MW	112.17
DMNMXCE	FM	C6H12N2
DMNMXCE	IC	InChI=1S/C6H12N2/c1-5-2-3-8-6(7)4-5/h5H,2-4H2,1H3,(H2,7,8)
DMNMXCE	CS	CC1CCN=C(C1)N
DMNMXCE	IK	GGDLOMFAKKVDPT-UHFFFAOYSA-N
DMNMXCE	IU	4-methyl-2,3,4,5-tetrahydropyridin-6-amine
DMNMXCE	CA	CAS 165383-71-1
DMNMXCE	DE	Discovery agent

DME6UOM	ID	DME6UOM
DME6UOM	DN	4-Methyl-pyridine
DME6UOM	HS	Investigative
DME6UOM	SN	4-METHYLPYRIDINE; 4-Picoline; 108-89-4; Pyridine, 4-methyl-; p-Picoline; gamma-Picoline; p-Methylpyridine; 4-methyl-pyridine; gamma-Methylpyridine; Ba 35846; UNII-TJD6V9SSO7; .gamma.-Picoline; NSC 18252; 4-Mepy; CCRIS 1723; .gamma.-Methylpyridine; HSDB 5386; EINECS 203-626-4; TJD6V9SSO7; AI3-24111; CHEBI:32547; FKNQCJSGGFJEIZ-UHFFFAOYSA-N; 4-Picoline, 99%; DSSTox_CID_1892; DSSTox_RID_76389; DSSTox_GSID_21892; 4-methyl pyridine; CAS-108-89-4; gamma-picolin; 4-Pyridylmethyl; 4-pi-coline; para-Methylpyridine; Methyl, 4-pyridinyl-; 4-Picoline 
DME6UOM	DT	Small molecular drug
DME6UOM	PC	7963
DME6UOM	MW	93.13
DME6UOM	FM	C6H7N
DME6UOM	IC	InChI=1S/C6H7N/c1-6-2-4-7-5-3-6/h2-5H,1H3
DME6UOM	CS	CC1=CC=NC=C1
DME6UOM	IK	FKNQCJSGGFJEIZ-UHFFFAOYSA-N
DME6UOM	IU	4-methylpyridine
DME6UOM	CA	CAS 108-89-4
DME6UOM	CB	CHEBI:32547
DME6UOM	DE	Discovery agent

DM0YS36	ID	DM0YS36
DM0YS36	DN	4-Methyl-pyrrolidin-(2Z)-ylideneamine
DM0YS36	HS	Investigative
DM0YS36	SN	CHEMBL183012; CHEMBL541090; 4-Methylpyrrolidine-2-imine; BDBM50066780; AKOS006351281; 4-Methyl-pyrrolidin-(2E)-ylideneamine
DM0YS36	DT	Small molecular drug
DM0YS36	PC	15887953
DM0YS36	MW	98.15
DM0YS36	FM	C5H10N2
DM0YS36	IC	InChI=1S/C5H10N2/c1-4-2-5(6)7-3-4/h4H,2-3H2,1H3,(H2,6,7)
DM0YS36	CS	CC1CC(=NC1)N
DM0YS36	IK	IAGJRVCMUDBZSN-UHFFFAOYSA-N
DM0YS36	IU	3-methyl-3,4-dihydro-2H-pyrrol-5-amine
DM0YS36	DE	Discovery agent

DMVMHBL	ID	DMVMHBL
DMVMHBL	DN	4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMVMHBL	HS	Investigative
DMVMHBL	SN	CHEMBL380940; 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5828673
DMVMHBL	DT	Small molecular drug
DMVMHBL	PC	44407566
DMVMHBL	MW	250.25
DMVMHBL	FM	C15H10N2O2
DMVMHBL	IC	InChI=1S/C15H10N2O2/c1-7-6-10-12(8-4-2-3-5-9(8)16-10)13-11(7)14(18)17-15(13)19/h2-6,16H,1H3,(H,17,18,19)
DMVMHBL	CS	CC1=CC2=C(C3=CC=CC=C3N2)C4=C1C(=O)NC4=O
DMVMHBL	IK	DSCSSQAANWCYAP-UHFFFAOYSA-N
DMVMHBL	IU	4-methyl-6H-pyrrolo[3,4-c]carbazole-1,3-dione
DMVMHBL	DE	Discovery agent

DMW0Y29	ID	DMW0Y29
DMW0Y29	DN	4-methylstyrylboronic acid
DMW0Y29	HS	Investigative
DMW0Y29	SN	72316-17-7; trans-2-(4-Methylphenyl)vinylboronic acid; 4-methylstyrylboronic acid; (4-Methylstyryl)boronic acid; (E)-(4-Methylstyryl)boronic acid; CHEMBL551649; AK-96341; AC1O0LYH; AC1Q2JL5; SCHEMBL350162; JJOBVKVXRDHVRP-VOTSOKGWSA-N; [(E)-4-Methylstyryl]boronic acid; 1219AC; BDBM50294579; ZINC169876972; AKOS015893172; AB15070; FCH1119774; FCH4624789; OR360466; KB-61861; BBV-43860393; AX8240132; TX-012607; TC-143527; (E)-2-(4-methylphenyl)ethenylboronic acid; [(E)-2-(4-methylphenyl)ethenyl]boranediol
DMW0Y29	DT	Small molecular drug
DMW0Y29	PC	6019835
DMW0Y29	MW	162
DMW0Y29	FM	C9H11BO2
DMW0Y29	IC	InChI=1S/C9H11BO2/c1-8-2-4-9(5-3-8)6-7-10(11)12/h2-7,11-12H,1H3/b7-6+
DMW0Y29	CS	B(/C=C/C1=CC=C(C=C1)C)(O)O
DMW0Y29	IK	JJOBVKVXRDHVRP-VOTSOKGWSA-N
DMW0Y29	IU	[(E)-2-(4-methylphenyl)ethenyl]boronic acid
DMW0Y29	CA	CAS 214907-11-6
DMW0Y29	DE	Discovery agent

DMEB5XP	ID	DMEB5XP
DMEB5XP	DN	4-Methylthiopyridine-3-sulfonamide
DMEB5XP	HS	Investigative
DMEB5XP	SN	4-Methylthiopyridine-3-sulfonamide; CHEMBL1165117; 1078160-10-7
DMEB5XP	DT	Small molecular drug
DMEB5XP	PC	46703929
DMEB5XP	MW	204.3
DMEB5XP	FM	C6H8N2O2S2
DMEB5XP	IC	InChI=1S/C6H8N2O2S2/c1-11-5-2-3-8-4-6(5)12(7,9)10/h2-4H,1H3,(H2,7,9,10)
DMEB5XP	CS	CSC1=C(C=NC=C1)S(=O)(=O)N
DMEB5XP	IK	PLOUCIVACOBALV-UHFFFAOYSA-N
DMEB5XP	IU	4-methylsulfanylpyridine-3-sulfonamide
DMEB5XP	DE	Discovery agent

DM049QO	ID	DM049QO
DM049QO	DN	4-Morpholin-2-yl-benzene-1,2-diol
DM049QO	HS	Investigative
DM049QO	SN	4-(2-Morpholinyl)pyrocatechol; 1,2-Benzenediol, 4-(2-morpholinyl)-; BRN 0170116; Pyrocatechol, 4-(2-morpholinyl)-; CHEMBL7681; 54826-84-5; 2-(3,4-Dioxyphenyl)tetrahydro-1,4-oxazin [German]; 4-Morpholin-2-yl-benzene-1,2-diol; AC1MIECG; 2-(3,4-Dioxyphenyl)tetrahydro-1,4-oxazin; 3,4-Dioxyphenyl-Morpholin; SCHEMBL17632965; CTK5A2632; 4-morpholin-2-ylbenzene-1,2-diol; BDBM50000502; AKOS022644999; UK-42620; LS-136459
DM049QO	DT	Small molecular drug
DM049QO	PC	3042920
DM049QO	MW	195.21
DM049QO	FM	C10H13NO3
DM049QO	IC	InChI=1S/C10H13NO3/c12-8-2-1-7(5-9(8)13)10-6-11-3-4-14-10/h1-2,5,10-13H,3-4,6H2
DM049QO	CS	C1COC(CN1)C2=CC(=C(C=C2)O)O
DM049QO	IK	GYJRRQRGZZEHEB-UHFFFAOYSA-N
DM049QO	IU	4-morpholin-2-ylbenzene-1,2-diol
DM049QO	CA	CAS 54826-84-5
DM049QO	DE	Discovery agent

DMEJ6G9	ID	DMEJ6G9
DMEJ6G9	DN	4-Morpholin-4-yl-benzo[g]chromen-2-one
DMEJ6G9	HS	Investigative
DMEJ6G9	SN	CHEMBL177279; 4-Morpholin-4-yl-benzo[g]chromen-2-one
DMEJ6G9	DT	Small molecular drug
DMEJ6G9	PC	11346540
DMEJ6G9	MW	281.3
DMEJ6G9	FM	C17H15NO3
DMEJ6G9	IC	InChI=1S/C17H15NO3/c19-17-11-15(18-5-7-20-8-6-18)14-9-12-3-1-2-4-13(12)10-16(14)21-17/h1-4,9-11H,5-8H2
DMEJ6G9	CS	C1COCCN1C2=CC(=O)OC3=CC4=CC=CC=C4C=C23
DMEJ6G9	IK	NEEAOCHOCYXDSE-UHFFFAOYSA-N
DMEJ6G9	IU	4-morpholin-4-ylbenzo[g]chromen-2-one
DMEJ6G9	DE	Discovery agent

DMW2MRP	ID	DMW2MRP
DMW2MRP	DN	4-Morpholin-4-yl-benzo[h]chromen-2-one
DMW2MRP	HS	Investigative
DMW2MRP	SN	CHEMBL179641; 4-Morpholin-4-yl-benzo[h]chromen-2-one; BDBM50159617
DMW2MRP	DT	Small molecular drug
DMW2MRP	PC	11471539
DMW2MRP	MW	281.3
DMW2MRP	FM	C17H15NO3
DMW2MRP	IC	InChI=1S/C17H15NO3/c19-16-11-15(18-7-9-20-10-8-18)14-6-5-12-3-1-2-4-13(12)17(14)21-16/h1-6,11H,7-10H2
DMW2MRP	CS	C1COCCN1C2=CC(=O)OC3=C2C=CC4=CC=CC=C43
DMW2MRP	IK	QPPKEHFJUVBRAD-UHFFFAOYSA-N
DMW2MRP	IU	4-morpholin-4-ylbenzo[h]chromen-2-one
DMW2MRP	DE	Discovery agent

DM7T3CU	ID	DM7T3CU
DM7T3CU	DN	4-Morpholin-4-yl-chromen-2-one
DM7T3CU	HS	Investigative
DM7T3CU	SN	4-Morpholin-4-yl-chromen-2-one; 4-morpholin-4-ylchromen-2-one; CHEMBL367262; 65625-83-4; 4-morpholinyl coumarin; SMR000116476; AC1LFJN6; CBMicro_022351; Oprea1_628619; Oprea1_860966; MLS000526002; SCHEMBL11450752; 4-morpholino-2H-chromen-2-one; CTK1I2254; DTXSID30355510; MolPort-001-959-554; ZINC312514; HMS2490I17; CCG-9410; BDBM50159613; AKOS000639877; 4-(4-morpholinyl)-2H-chromen-2-one; MCULE-8859511318; BAS 01256112; BIM-0022285.P001; ST50008215; 2H-1-Benzopyran-2-one, 4-(4-morpholinyl)-; SR-01000312410; AI-204/31682008
DM7T3CU	DT	Small molecular drug
DM7T3CU	PC	804048
DM7T3CU	MW	231.25
DM7T3CU	FM	C13H13NO3
DM7T3CU	IC	InChI=1S/C13H13NO3/c15-13-9-11(14-5-7-16-8-6-14)10-3-1-2-4-12(10)17-13/h1-4,9H,5-8H2
DM7T3CU	CS	C1COCCN1C2=CC(=O)OC3=CC=CC=C32
DM7T3CU	IK	YJXJQEJDZPLPTQ-UHFFFAOYSA-N
DM7T3CU	IU	4-morpholin-4-ylchromen-2-one
DM7T3CU	CA	CAS 65625-83-4
DM7T3CU	DE	Discovery agent

DM8QPTJ	ID	DM8QPTJ
DM8QPTJ	DN	4-morpholino-6-phenyl-2H-pyran-2-one
DM8QPTJ	HS	Investigative
DM8QPTJ	SN	CHEMBL221409; 4-morpholino-6-phenyl-2H-pyran-2-one; SCHEMBL3542543
DM8QPTJ	DT	Small molecular drug
DM8QPTJ	PC	21106428
DM8QPTJ	MW	257.279
DM8QPTJ	FM	C15H15NO3
DM8QPTJ	IC	InChI=1S/C15H15NO3/c17-15-11-13(16-6-8-18-9-7-16)10-14(19-15)12-4-2-1-3-5-12/h1-5,10-11H,6-9H2
DM8QPTJ	CS	C1COCCN1C2=CC(=O)OC(=C2)C3=CC=CC=C3
DM8QPTJ	IK	VKOGCIIARBRLEC-UHFFFAOYSA-N
DM8QPTJ	IU	4-morpholin-4-yl-6-phenylpyran-2-one
DM8QPTJ	DE	Discovery agent

DM4E6HW	ID	DM4E6HW
DM4E6HW	DN	4-MPPTS
DM4E6HW	HS	Investigative
DM4E6HW	SN	LY487379; LY-487379
DM4E6HW	DT	Small molecular drug
DM4E6HW	PC	9825084
DM4E6HW	MW	452.4
DM4E6HW	FM	C21H19F3N2O4S
DM4E6HW	IC	InChI=1S/C21H19F3N2O4S/c1-29-19-6-2-3-7-20(19)30-18-10-8-17(9-11-18)26(14-16-5-4-12-25-13-16)31(27,28)15-21(22,23)24/h2-13H,14-15H2,1H3
DM4E6HW	CS	COC1=CC=CC=C1OC2=CC=C(C=C2)N(CC3=CN=CC=C3)S(=O)(=O)CC(F)(F)F
DM4E6HW	IK	ALMACYDZFBMGOR-UHFFFAOYSA-N
DM4E6HW	IU	2,2,2-trifluoro-N-[4-(2-methoxyphenoxy)phenyl]-N-(pyridin-3-ylmethyl)ethanesulfonamide
DM4E6HW	CA	CAS 353231-17-1
DM4E6HW	DE	Discovery agent

DMEIA3L	ID	DMEIA3L
DMEIA3L	DN	4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol
DMEIA3L	HS	Investigative
DMEIA3L	SN	CHEMBL370714; 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol; BDBM50159229
DMEIA3L	DT	Small molecular drug
DMEIA3L	PC	11303367
DMEIA3L	MW	294.3
DMEIA3L	FM	C18H18N2O2
DMEIA3L	IC	InChI=1S/C18H18N2O2/c21-18-16(17(22-20-18)13-8-10-19-11-9-13)15-7-3-5-12-4-1-2-6-14(12)15/h1-7,13,19H,8-11H2,(H,20,21)
DMEIA3L	CS	C1CNCCC1C2=C(C(=O)NO2)C3=CC=CC4=CC=CC=C43
DMEIA3L	IK	WDMOSRJVOUIQMD-UHFFFAOYSA-N
DMEIA3L	IU	4-naphthalen-1-yl-5-piperidin-4-yl-1,2-oxazol-3-one
DMEIA3L	DE	Discovery agent

DM9O8UM	ID	DM9O8UM
DM9O8UM	DN	4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol
DM9O8UM	HS	Investigative
DM9O8UM	SN	CHEMBL382320; 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol; BDBM50159237; J3.626.536A; 4-(naphthalen-2-yl)-5-(piperidin-4-yl)isoxazol-3-ol
DM9O8UM	DT	Small molecular drug
DM9O8UM	PC	11303369
DM9O8UM	MW	294.3
DM9O8UM	FM	C18H18N2O2
DM9O8UM	IC	InChI=1S/C18H18N2O2/c21-18-16(17(22-20-18)13-7-9-19-10-8-13)15-6-5-12-3-1-2-4-14(12)11-15/h1-6,11,13,19H,7-10H2,(H,20,21)
DM9O8UM	CS	C1CNCCC1C2=C(C(=O)NO2)C3=CC4=CC=CC=C4C=C3
DM9O8UM	IK	PWDALQSYHZMANN-UHFFFAOYSA-N
DM9O8UM	IU	4-naphthalen-2-yl-5-piperidin-4-yl-1,2-oxazol-3-one
DM9O8UM	DE	Discovery agent

DMKPNSH	ID	DMKPNSH
DMKPNSH	DN	4-Naphthalen-2-yl-phenol
DMKPNSH	HS	Investigative
DMKPNSH	SN	4-(naphthalen-2-yl)phenol; 6336-82-9; 4-Naphthalen-2-yl-phenol; 4-(2-Naphthyl)phenol; 4-naphthalen-2-ylphenol; CHEMBL194772; NSC-39892; 2-(4-HYDROXYPHENYL)NAPHTHALENE; NSC39892; AC1L5XK9; AC1Q7B9I; SCHEMBL234529; KS-00000ORV; CTK5B8841; DTXSID70284931; NIRHUNSXEDESLN-UHFFFAOYSA-N; MolPort-015-145-553; ZINC1671629; MFCD18312886; KM0737; BDBM50168385; ANW-73541; AKOS016007751; IMED1575423883; KB-40006; AK-50357; AJ-29221; TC-162286; AX8212912; 4CH-024303
DMKPNSH	DT	Small molecular drug
DMKPNSH	PC	236868
DMKPNSH	MW	220.26
DMKPNSH	FM	C16H12O
DMKPNSH	IC	InChI=1S/C16H12O/c17-16-9-7-13(8-10-16)15-6-5-12-3-1-2-4-14(12)11-15/h1-11,17H
DMKPNSH	CS	C1=CC=C2C=C(C=CC2=C1)C3=CC=C(C=C3)O
DMKPNSH	IK	NIRHUNSXEDESLN-UHFFFAOYSA-N
DMKPNSH	IU	4-naphthalen-2-ylphenol
DMKPNSH	CA	CAS 6336-82-9
DMKPNSH	DE	Discovery agent

DMZY8UW	ID	DMZY8UW
DMZY8UW	DN	4-Nitro-benzenesulfonamide
DMZY8UW	HS	Investigative
DMZY8UW	SN	4-NITROBENZENESULFONAMIDE; 6325-93-5; Benzenesulfonamide, 4-nitro-; p-Nitrobenzenesulfonamide; 4-Nitrobenzolesulfamide; p-Nitrophenylsulfonamide; 4-Nitrobenzenesulphonamide; Benzenesulfonamide, p-nitro-; 4-Nitro-benzenesulfonamide; UNII-TUF52O8Y8B; EINECS 228-691-6; NSC 31148; BRN 2214218; TUF52O8Y8B; CHEMBL282157; 4-Nitrobenzenesulfonamide, 97%; QWKKYJLAUWFPDB-UHFFFAOYSA-N; NsNH2; 4-nitrophenylsulfonamid; 3m8t; 4-Nitrobenzolsulfonamide; p-nitrophenyl sulfonamide; WLN: ZSWR DNW; p-nitrobenzene sulphonamide; AC1Q55AA; Cambridge id 5
DMZY8UW	DT	Small molecular drug
DMZY8UW	PC	22784
DMZY8UW	MW	202.19
DMZY8UW	FM	C6H6N2O4S
DMZY8UW	IC	InChI=1S/C6H6N2O4S/c7-13(11,12)6-3-1-5(2-4-6)8(9)10/h1-4H,(H2,7,11,12)
DMZY8UW	CS	C1=CC(=CC=C1[N+](=O)[O-])S(=O)(=O)N
DMZY8UW	IK	QWKKYJLAUWFPDB-UHFFFAOYSA-N
DMZY8UW	IU	4-nitrobenzenesulfonamide
DMZY8UW	CA	CAS 6325-93-5
DMZY8UW	DE	Discovery agent

DMKZJ1V	ID	DMKZJ1V
DMKZJ1V	DN	4-nitrobenzo[c][1,2,5]thiadiazole
DMKZJ1V	HS	Investigative
DMKZJ1V	SN	4-Nitro-2,1,3-benzothiadiazole; 6583-06-8; 4-nitrobenzo[c][1,2,5]thiadiazole; 4-Nitropiazthiole; 2,1,3-Benzothiadiazole, 4-nitro-; NSC404747; CHEMBL383084; 4-Nitro-1,2,3-benzothiadiazole; 4-Nitro-benzo[1,2,5]thiadiazole; 4-nitrobenzo[c]1,2,5-thiadiazole; ACMC-1B59L; Oprea1_370043; 4-Bromo-2,8-dimethylphenol; C6H3N3O2S; 4-Nitro-2,3-benzothiadiazole; SCHEMBL2213406; AC1Q202C; AC1L30J9; CTK5C3163; DTXSID10216019; 4-nitrobenzo-2,1,3-thiadiazole; MolPort-004-288-376; IWQKAMJGVIHECB-UHFFFAOYSA-N; MolPort-001-779-862
DMKZJ1V	DT	Small molecular drug
DMKZJ1V	PC	81062
DMKZJ1V	MW	181.17
DMKZJ1V	FM	C6H3N3O2S
DMKZJ1V	IC	InChI=1S/C6H3N3O2S/c10-9(11)5-3-1-2-4-6(5)8-12-7-4/h1-3H
DMKZJ1V	CS	C1=CC2=NSN=C2C(=C1)[N+](=O)[O-]
DMKZJ1V	IK	IWQKAMJGVIHECB-UHFFFAOYSA-N
DMKZJ1V	IU	4-nitro-2,1,3-benzothiadiazole
DMKZJ1V	CA	CAS 6583-06-8
DMKZJ1V	DE	Discovery agent

DMKZUWY	ID	DMKZUWY
DMKZUWY	DN	4-Nitro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMKZUWY	HS	Investigative
DMKZUWY	SN	4-Nitro-N-(4-phenyl-thiazol-2-yl)-benzamide; CHEMBL60027; 4-nitro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; AC1LEVE1; Oprea1_616019; Oprea1_578616; Oprea1_274027; MolPort-001-016-564; ZINC1506439; BDBM50101782; STK401913; AKOS000523323; MCULE-9071819567; BAS 00417263; N-(4-Phenyl-2-thiazolyl)-4-nitrobenzamide; ST50002539; SR-01000394982; SR-01000394982-1
DMKZUWY	DT	Small molecular drug
DMKZUWY	PC	718622
DMKZUWY	MW	325.3
DMKZUWY	FM	C16H11N3O3S
DMKZUWY	IC	InChI=1S/C16H11N3O3S/c20-15(12-6-8-13(9-7-12)19(21)22)18-16-17-14(10-23-16)11-4-2-1-3-5-11/h1-10H,(H,17,18,20)
DMKZUWY	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=C(C=C3)[N+](=O)[O-]
DMKZUWY	IK	LLSUVHOZHQEGJS-UHFFFAOYSA-N
DMKZUWY	IU	4-nitro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMKZUWY	DE	Discovery agent

DMLJDU5	ID	DMLJDU5
DMLJDU5	DN	4-nitro-N-(quinolin-8-yl)benzenesulfonamide
DMLJDU5	HS	Investigative
DMLJDU5	SN	CHEMBL540966; 33757-62-9; AC1NAKSM; SCHEMBL13485922; CTK1B1556; DTXSID90403445; MolPort-007-041-512; ZINC5681580; BDBM50372514; AKOS024374275; MCULE-8526334160; NCGC00161718-01; 4-nitro-N-quinolin-8-ylbenzenesulfonamide; N-(8-Quinolyl)-4-nitrobenzenesulfonamide; 4-nitro-N-(8-quinolyl)benzenesulfonamide; [(4-nitrophenyl)sulfonyl]-8-quinolylamine; ST51013795; Benzenesulfonamide, 4-nitro-N-8-quinolinyl-; 4-nitro-N-(quinolin-8-yl)benzene-1-sulfonamide; CU-00000000141-1
DMLJDU5	DT	Small molecular drug
DMLJDU5	PC	4453505
DMLJDU5	MW	329.3
DMLJDU5	FM	C15H11N3O4S
DMLJDU5	IC	InChI=1S/C15H11N3O4S/c19-18(20)12-6-8-13(9-7-12)23(21,22)17-14-5-1-3-11-4-2-10-16-15(11)14/h1-10,17H
DMLJDU5	CS	C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)[N+](=O)[O-])N=CC=C2
DMLJDU5	IK	HXWOKTOKXJLLRZ-UHFFFAOYSA-N
DMLJDU5	IU	4-nitro-N-quinolin-8-ylbenzenesulfonamide
DMLJDU5	CA	CAS 33757-62-9
DMLJDU5	DE	Discovery agent

DMTJ3F9	ID	DMTJ3F9
DMTJ3F9	DN	4-Nitrophenyl 4-Benzylpiperazine-1-carboxylate
DMTJ3F9	HS	Investigative
DMTJ3F9	SN	CHEMBL597700; 4-Nitrophenyl 4-Benzylpiperazine-1-carboxylate; SCHEMBL12794615
DMTJ3F9	DT	Small molecular drug
DMTJ3F9	PC	45104861
DMTJ3F9	MW	341.4
DMTJ3F9	FM	C18H19N3O4
DMTJ3F9	IC	InChI=1S/C18H19N3O4/c22-18(25-17-8-6-16(7-9-17)21(23)24)20-12-10-19(11-13-20)14-15-4-2-1-3-5-15/h1-9H,10-14H2
DMTJ3F9	CS	C1CN(CCN1CC2=CC=CC=C2)C(=O)OC3=CC=C(C=C3)[N+](=O)[O-]
DMTJ3F9	IK	HNIDATBYDXCKRE-UHFFFAOYSA-N
DMTJ3F9	IU	(4-nitrophenyl) 4-benzylpiperazine-1-carboxylate
DMTJ3F9	DE	Discovery agent

DMBX4UJ	ID	DMBX4UJ
DMBX4UJ	DN	4-nitrophenyl phosphate
DMBX4UJ	HS	Investigative
DMBX4UJ	SN	4-nitrophenyl phosphate; 4-Nitrophenyl dihydrogen phosphate; 330-13-2; Nitrophenylphosphate; Phosphoric acid, mono(4-nitrophenyl) ester; p-nitrophenyl phosphate; p-Nitrophenyl dihydrogen phosphate; p-Nitrophenol phosphate; p-Nitrophenylphosphate; (4-nitrophenyl) dihydrogen phosphate; PNPP; NSC 404086; Phenol, p-nitro-, dihydrogen phosphate; CHEMBL24231; (4-nitrophenoxy)phosphonic acid; CHEBI:17440; XZKIHKMTEMTJQX-UHFFFAOYSA-N; pNPP Alkaline Phosphatase Substrate; Phosphoric acid, mono(p-nitrophenyl) ester (8CI); Phosphoric ac
DMBX4UJ	DT	Small molecular drug
DMBX4UJ	PC	378
DMBX4UJ	MW	219.09
DMBX4UJ	FM	C6H6NO6P
DMBX4UJ	IC	InChI=1S/C6H6NO6P/c8-7(9)5-1-3-6(4-2-5)13-14(10,11)12/h1-4H,(H2,10,11,12)
DMBX4UJ	CS	C1=CC(=CC=C1[N+](=O)[O-])OP(=O)(O)O
DMBX4UJ	IK	XZKIHKMTEMTJQX-UHFFFAOYSA-N
DMBX4UJ	IU	(4-nitrophenyl) dihydrogen phosphate
DMBX4UJ	CA	CAS 330-13-2
DMBX4UJ	CB	CHEBI:17440
DMBX4UJ	DE	Discovery agent

DMO6XK2	ID	DMO6XK2
DMO6XK2	DN	4-nitrophenylboronic acid
DMO6XK2	HS	Investigative
DMO6XK2	SN	4-Nitrophenylboronic acid; 24067-17-2; (4-nitrophenyl)boronic Acid; 4-Nitrobenzeneboronic acid; p-nitrophenylboronic acid; 4-Nitrophenyl boronic acid; p-nitrophenyl boronic acid; 4-Nitro phenyl boronic acid; Boronic acid, (4-nitrophenyl)-; MFCD00161360; 4-Nitrophenylboronic acid, 97%; 4-Nitrophenylboronicacid; 4-Borononitrobenzene; PubChem24079; 4-nitrobenzenboronic acid; (4-nitrophenyl)boranediol; 4-nitro-phenylboronic acid; ACMC-209g8k; para-nitrophenylboronic acid; 4-nitrobenzene boronic acid; AC1MCN49; SCHEMBL5993
DMO6XK2	DT	Small molecular drug
DMO6XK2	PC	2773552
DMO6XK2	MW	166.93
DMO6XK2	FM	C6H6BNO4
DMO6XK2	IC	InChI=1S/C6H6BNO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4,9-10H
DMO6XK2	CS	B(C1=CC=C(C=C1)[N+](=O)[O-])(O)O
DMO6XK2	IK	NSFJAFZHYOAMHL-UHFFFAOYSA-N
DMO6XK2	IU	(4-nitrophenyl)boronic acid
DMO6XK2	CA	CAS 24067-17-2
DMO6XK2	DE	Discovery agent

DM9ETMD	ID	DM9ETMD
DM9ETMD	DN	4-nitrophenyl-difluoromethanesulfonamide
DM9ETMD	HS	Investigative
DM9ETMD	SN	4-nitrophenyl-difluoromethanesulfonamide; CHEMBL370159; BDBM50175001
DM9ETMD	DT	Small molecular drug
DM9ETMD	PC	44405178
DM9ETMD	MW	252.2
DM9ETMD	FM	C7H6F2N2O4S
DM9ETMD	IC	InChI=1S/C7H6F2N2O4S/c8-7(9,16(10,14)15)5-1-3-6(4-2-5)11(12)13/h1-4H,(H2,10,14,15)
DM9ETMD	CS	C1=CC(=CC=C1C(F)(F)S(=O)(=O)N)[N+](=O)[O-]
DM9ETMD	IK	WUEDWPOZFNFODO-UHFFFAOYSA-N
DM9ETMD	IU	difluoro-(4-nitrophenyl)methanesulfonamide
DM9ETMD	DE	Discovery agent

DM47IFL	ID	DM47IFL
DM47IFL	DN	4-nitrophenylsulfamide
DM47IFL	HS	Investigative
DM47IFL	SN	4-nitrophenylsulfamide; N-(4-Nitrophenyl)sulfamide; CHEMBL168778; 70466-80-7; AC1LD5GZ; N-(4-Nitrophenyl)sulfamide #; Sulphamide, N-(4-nitrophenyl)-; RAXPQAODVUNKFW-UHFFFAOYSA-N; 1-nitro-4-(sulfamoylamino)benzene; BDBM50124157
DM47IFL	DT	Small molecular drug
DM47IFL	PC	612414
DM47IFL	MW	217.21
DM47IFL	FM	C6H7N3O4S
DM47IFL	IC	InChI=1S/C6H7N3O4S/c7-14(12,13)8-5-1-3-6(4-2-5)9(10)11/h1-4,8H,(H2,7,12,13)
DM47IFL	CS	C1=CC(=CC=C1NS(=O)(=O)N)[N+](=O)[O-]
DM47IFL	IK	RAXPQAODVUNKFW-UHFFFAOYSA-N
DM47IFL	IU	1-nitro-4-(sulfamoylamino)benzene
DM47IFL	DE	Discovery agent

DMOW8TM	ID	DMOW8TM
DMOW8TM	DN	4-nonyl-N-(quinolin-3-yl)benzamide
DMOW8TM	HS	Investigative
DMOW8TM	SN	CHEMBL261848; AC1N8TZO; SCHEMBL846134; 4-nonyl-N-quinolin-3-ylbenzamide
DMOW8TM	DT	Small molecular drug
DMOW8TM	PC	4375060
DMOW8TM	MW	374.5
DMOW8TM	FM	C25H30N2O
DMOW8TM	IC	InChI=1S/C25H30N2O/c1-2-3-4-5-6-7-8-11-20-14-16-21(17-15-20)25(28)27-23-18-22-12-9-10-13-24(22)26-19-23/h9-10,12-19H,2-8,11H2,1H3,(H,27,28)
DMOW8TM	CS	CCCCCCCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DMOW8TM	IK	LTHZASJBAIGTJL-UHFFFAOYSA-N
DMOW8TM	IU	4-nonyl-N-quinolin-3-ylbenzamide
DMOW8TM	DE	Discovery agent

DMBF5KW	ID	DMBF5KW
DMBF5KW	DN	4-nonylphenylboronic acid
DMBF5KW	HS	Investigative
DMBF5KW	SN	256383-45-6; 4-N-Nonylphenylboronic acid; 4-Nonylphenylboronic acid; (4-nonylphenyl)boronic Acid; 4-N-NONYLBENZENEBORONIC ACID; 4-N-Nonylphenylboronicacid; VONVJOGSLHAKOX-UHFFFAOYSA-N; AC1NEAO1; (4-nonylphenyl)boranediol; 4-nonylbenzene boronic acid; B-(4-Nonylphenyl)boronic acid; SCHEMBL3405525; CHEMBL485946; 4-(n-Nonyl)benzeneboronic Acid; BDBM26134; CTK8B1318; 1-Borono-4-(non-1-yl)benzene; DTXSID10404611; MolPort-000-931-545; Boronic acid,B-(4-nonylphenyl)-; 4-(Non-1-yl)benzeneboronic acid; ZX-AT001529; OR7244; CN-219
DMBF5KW	DT	Small molecular drug
DMBF5KW	PC	4589192
DMBF5KW	MW	248.17
DMBF5KW	FM	C15H25BO2
DMBF5KW	IC	InChI=1S/C15H25BO2/c1-2-3-4-5-6-7-8-9-14-10-12-15(13-11-14)16(17)18/h10-13,17-18H,2-9H2,1H3
DMBF5KW	CS	B(C1=CC=C(C=C1)CCCCCCCCC)(O)O
DMBF5KW	IK	VONVJOGSLHAKOX-UHFFFAOYSA-N
DMBF5KW	IU	(4-nonylphenyl)boronic acid
DMBF5KW	CA	CAS 256383-45-6
DMBF5KW	DE	Discovery agent

DMNSU1H	ID	DMNSU1H
DMNSU1H	DN	4-octyl-N-(pyridin-3-yl)benzamide
DMNSU1H	HS	Investigative
DMNSU1H	SN	CHEMBL405990
DMNSU1H	DT	Small molecular drug
DMNSU1H	PC	44450380
DMNSU1H	MW	310.4
DMNSU1H	FM	C20H26N2O
DMNSU1H	IC	InChI=1S/C20H26N2O/c1-2-3-4-5-6-7-9-17-11-13-18(14-12-17)20(23)22-19-10-8-15-21-16-19/h8,10-16H,2-7,9H2,1H3,(H,22,23)
DMNSU1H	CS	CCCCCCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMNSU1H	IK	ONPWXUJVJZCKSY-UHFFFAOYSA-N
DMNSU1H	IU	4-octyl-N-pyridin-3-ylbenzamide
DMNSU1H	DE	Discovery agent

DMOGM3H	ID	DMOGM3H
DMOGM3H	DN	4-octyl-N-(quinolin-3-yl)benzamide
DMOGM3H	HS	Investigative
DMOGM3H	SN	CHEMBL406859; AC1MZP51; SCHEMBL846096; 4-octyl-N-quinolin-3-ylbenzamide; BDBM50376278
DMOGM3H	DT	Small molecular drug
DMOGM3H	PC	3904199
DMOGM3H	MW	360.5
DMOGM3H	FM	C24H28N2O
DMOGM3H	IC	InChI=1S/C24H28N2O/c1-2-3-4-5-6-7-10-19-13-15-20(16-14-19)24(27)26-22-17-21-11-8-9-12-23(21)25-18-22/h8-9,11-18H,2-7,10H2,1H3,(H,26,27)
DMOGM3H	CS	CCCCCCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DMOGM3H	IK	QXGPHMISVLJYDS-UHFFFAOYSA-N
DMOGM3H	IU	4-octyl-N-quinolin-3-ylbenzamide
DMOGM3H	DE	Discovery agent

DM7GW4P	ID	DM7GW4P
DM7GW4P	DN	4-oxo-4H-chromene-3-carboxylic acid
DM7GW4P	HS	Investigative
DM7GW4P	SN	Chromone-3-carboxylic acid; 39079-62-4; 4-oxo-4H-chromene-3-carboxylic acid; 4-Oxo-4H-1-benzopyran-3-carboxylic acid; 4-oxochromene-3-carboxylic acid; CHEMBL315361; PCIITXGDSHXTSN-UHFFFAOYSA-N; MFCD00017338; Maybridge1_005842; 3-carboxychromone; ACMC-1AD65; SCHEMBL1253672; AC1L49D2; CTK1C4919; ZINC57725; HMS558B12; DTXSID90192327; MolPort-000-145-536; 4-oxo-chromene-3-carboxylic acid; Chromone-3-carboxylic acid, 97%; CC-721; BDBM50131081; 4H-Chromen-4-one-3-carboxylic acid; SBB017525; AKOS001044083; CS-W015906; VZ31583
DM7GW4P	DT	Small molecular drug
DM7GW4P	PC	181620
DM7GW4P	MW	190.15
DM7GW4P	FM	C10H6O4
DM7GW4P	IC	InChI=1S/C10H6O4/c11-9-6-3-1-2-4-8(6)14-5-7(9)10(12)13/h1-5H,(H,12,13)
DM7GW4P	CS	C1=CC=C2C(=C1)C(=O)C(=CO2)C(=O)O
DM7GW4P	IK	PCIITXGDSHXTSN-UHFFFAOYSA-N
DM7GW4P	IU	4-oxochromene-3-carboxylic acid
DM7GW4P	CA	CAS 39079-62-4
DM7GW4P	CB	CHEBI:166522
DM7GW4P	DE	Discovery agent

DMPX1J9	ID	DMPX1J9
DMPX1J9	DN	4-oxo-nonenal
DMPX1J9	HS	Investigative
DMPX1J9	SN	4-oxo-2E-nonenal
DMPX1J9	DT	Small molecular drug
DMPX1J9	PC	6445537
DMPX1J9	MW	154.21
DMPX1J9	FM	C9H14O2
DMPX1J9	IC	InChI=1S/C9H14O2/c1-2-3-4-6-9(11)7-5-8-10/h5,7-8H,2-4,6H2,1H3/b7-5+
DMPX1J9	CS	CCCCCC(=O)/C=C/C=O
DMPX1J9	IK	SEPPVOUBHWNCAW-FNORWQNLSA-N
DMPX1J9	IU	(E)-4-oxonon-2-enal
DMPX1J9	CA	CAS 103560-62-9
DMPX1J9	CB	CHEBI:58972
DMPX1J9	DE	Discovery agent

DMADSUY	ID	DMADSUY
DMADSUY	DN	4-Oxosebacic Acid
DMADSUY	HS	Investigative
DMADSUY	SN	4-OXOSEBACIC ACID; Decanedioic acid, 4-oxo-; 3-Oxo-1,8-octanedicarboxylic acid; AC1L1C60; SCHEMBL1053787; CTK7G1425; XTQIBFVBYWIHIP-UHFFFAOYSA-N; ZINC3074811; AKOS024339724; DB02260; MCULE-8689766454
DMADSUY	DT	Small molecular drug
DMADSUY	PC	1755
DMADSUY	MW	216.23
DMADSUY	FM	C10H16O5
DMADSUY	IC	InChI=1S/C10H16O5/c11-8(6-7-10(14)15)4-2-1-3-5-9(12)13/h1-7H2,(H,12,13)(H,14,15)
DMADSUY	CS	C(CCC(=O)CCC(=O)O)CCC(=O)O
DMADSUY	IK	XTQIBFVBYWIHIP-UHFFFAOYSA-N
DMADSUY	IU	4-oxodecanedioic acid
DMADSUY	DE	Discovery agent

DMN1XMK	ID	DMN1XMK
DMN1XMK	DN	4-Pentadeca-1,3,6-trienylsulfanyl-butyric acid
DMN1XMK	HS	Investigative
DMN1XMK	SN	CHEMBL16979; 4-Pentadeca-1,3,6-trienylsulfanyl-butyric acid; ZINC36222955
DMN1XMK	DT	Small molecular drug
DMN1XMK	PC	14632697
DMN1XMK	MW	324.5
DMN1XMK	FM	C19H32O2S
DMN1XMK	IC	InChI=1S/C19H32O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-22-18-15-16-19(20)21/h9-10,12-14,17H,2-8,11,15-16,18H2,1H3,(H,20,21)/b10-9-,13-12-,17-14+
DMN1XMK	CS	CCCCCCCC/C=C\\C/C=C\\C=C\\SCCCC(=O)O
DMN1XMK	IK	YRBDHTFMZHCRCL-MPAZIYIRSA-N
DMN1XMK	IU	4-[(1E,3Z,6Z)-pentadeca-1,3,6-trienyl]sulfanylbutanoic acid
DMN1XMK	DE	Discovery agent

DMW198G	ID	DMW198G
DMW198G	DN	4-pentyl-N-pyridin-3-yl benzamide
DMW198G	HS	Investigative
DMW198G	SN	CHEMBL321932; 4-pentyl-N-pyridin-3-yl benzamide; AC1MDVHQ; 4-pentyl-N-pyridin-3-ylbenzamide; MolPort-002-889-076; ZINC3128742; 4-Pentyl-N-pyridin-3-yl-benzamide; BDBM50147079
DMW198G	DT	Small molecular drug
DMW198G	PC	2796370
DMW198G	MW	268.35
DMW198G	FM	C17H20N2O
DMW198G	IC	InChI=1S/C17H20N2O/c1-2-3-4-6-14-8-10-15(11-9-14)17(20)19-16-7-5-12-18-13-16/h5,7-13H,2-4,6H2,1H3,(H,19,20)
DMW198G	CS	CCCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMW198G	IK	DZLXEBWNAFQZQI-UHFFFAOYSA-N
DMW198G	IU	4-pentyl-N-pyridin-3-ylbenzamide
DMW198G	DE	Discovery agent

DMIPQTW	ID	DMIPQTW
DMIPQTW	DN	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
DMIPQTW	HS	Investigative
DMIPQTW	SN	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE; CHEMBL199237; CHEBI:41135; 4-phenoxy-N-[(pyridin-2-yl)methyl]benzamide; BI5; 1zyj; AC1M5EGY; Oprea1_773674; MolPort-004-000-036; HMS3604L15; BDBM50174097; ZINC13284470; AKOS027682522; MCULE-5005773275; DB07459; Z30166389
DMIPQTW	DT	Small molecular drug
DMIPQTW	PC	2352168
DMIPQTW	MW	304.3
DMIPQTW	FM	C19H16N2O2
DMIPQTW	IC	InChI=1S/C19H16N2O2/c22-19(21-14-16-6-4-5-13-20-16)15-9-11-18(12-10-15)23-17-7-2-1-3-8-17/h1-13H,14H2,(H,21,22)
DMIPQTW	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC=CC=N3
DMIPQTW	IK	HVLSCZSVTCNAQX-UHFFFAOYSA-N
DMIPQTW	IU	4-phenoxy-N-(pyridin-2-ylmethyl)benzamide
DMIPQTW	CB	CHEBI:41135
DMIPQTW	DE	Discovery agent

DMMWYI9	ID	DMMWYI9
DMMWYI9	DN	4-phenoxyphenylboronic acid
DMMWYI9	HS	Investigative
DMMWYI9	SN	4-Phenoxyphenylboronic acid; 51067-38-0; (4-phenoxyphenyl)boronic acid; 4-Phenoxybenzeneboronic acid; (4-Phenoxyphenyl)Boranediol; CHEMBL459151; Boronic acid, (4-phenoxyphenyl)-; MFCD00093312; 4-Phenoxyphenylboronic acid, 95+%; 4-phenoxyphenyl boronic acid; PubChem7890; phenoxyphenylboronic acid; ACMC-209krn; AC1MC0ZX; SCHEMBL9285; 4-phenyoxyphenylboronic acid; 4-phenoxy-phenylboronic acid; 4-Phenoxyphenyl-boronic acid; KSC489K8J; 4-phenoxy-phenyl boronic acid; AC1Q715Q; (4-phenoxyphenyl) boronic acid
DMMWYI9	DT	Small molecular drug
DMMWYI9	PC	2734377
DMMWYI9	MW	214.03
DMMWYI9	FM	C12H11BO3
DMMWYI9	IC	InChI=1S/C12H11BO3/c14-13(15)10-6-8-12(9-7-10)16-11-4-2-1-3-5-11/h1-9,14-15H
DMMWYI9	CS	B(C1=CC=C(C=C1)OC2=CC=CC=C2)(O)O
DMMWYI9	IK	KFXUHRXGLWUOJT-UHFFFAOYSA-N
DMMWYI9	IU	(4-phenoxyphenyl)boronic acid
DMMWYI9	CA	CAS 51067-38-0
DMMWYI9	DE	Discovery agent

DMVCIJB	ID	DMVCIJB
DMVCIJB	DN	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB	HS	Investigative
DMVCIJB	SN	CHEMBL230145; 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB	DT	Small molecular drug
DMVCIJB	PC	44426807
DMVCIJB	MW	309.4
DMVCIJB	FM	C21H27NO
DMVCIJB	IC	InChI=1S/C21H27NO/c1-2-9-20(18-10-5-3-6-11-18)22-16-14-21(23,15-17-22)19-12-7-4-8-13-19/h3-8,10-13,20,23H,2,9,14-17H2,1H3
DMVCIJB	CS	CCCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMVCIJB	IK	HVKSQGJIDXVAKX-UHFFFAOYSA-N
DMVCIJB	IU	4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB	DE	Discovery agent

DM6EFLV	ID	DM6EFLV
DM6EFLV	DN	4-phenyl-1-(1-phenylethyl)piperidin-4-ol
DM6EFLV	HS	Investigative
DM6EFLV	SN	CHEMBL230249; 4-phenyl-1-(1-phenylethyl)piperidin-4-ol
DM6EFLV	DT	Small molecular drug
DM6EFLV	PC	9925737
DM6EFLV	MW	281.4
DM6EFLV	FM	C19H23NO
DM6EFLV	IC	InChI=1S/C19H23NO/c1-16(17-8-4-2-5-9-17)20-14-12-19(21,13-15-20)18-10-6-3-7-11-18/h2-11,16,21H,12-15H2,1H3
DM6EFLV	CS	CC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DM6EFLV	IK	PKTJCXJTMHJHNK-UHFFFAOYSA-N
DM6EFLV	IU	4-phenyl-1-(1-phenylethyl)piperidin-4-ol
DM6EFLV	DE	Discovery agent

DMISTXQ	ID	DMISTXQ
DMISTXQ	DN	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ	HS	Investigative
DMISTXQ	SN	CHEMBL231607; 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ	DT	Small molecular drug
DMISTXQ	PC	44426812
DMISTXQ	MW	351.5
DMISTXQ	FM	C24H33NO
DMISTXQ	IC	InChI=1S/C24H33NO/c1-2-3-4-11-16-23(21-12-7-5-8-13-21)25-19-17-24(26,18-20-25)22-14-9-6-10-15-22/h5-10,12-15,23,26H,2-4,11,16-20H2,1H3
DMISTXQ	CS	CCCCCCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMISTXQ	IK	VSTFKYJXYVRGDG-UHFFFAOYSA-N
DMISTXQ	IU	4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ	DE	Discovery agent

DM1GRWY	ID	DM1GRWY
DM1GRWY	DN	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY	HS	Investigative
DM1GRWY	SN	CHEMBL230253; 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY	DT	Small molecular drug
DM1GRWY	PC	44426810
DM1GRWY	MW	337.5
DM1GRWY	FM	C23H31NO
DM1GRWY	IC	InChI=1S/C23H31NO/c1-2-3-6-15-22(20-11-7-4-8-12-20)24-18-16-23(25,17-19-24)21-13-9-5-10-14-21/h4-5,7-14,22,25H,2-3,6,15-19H2,1H3
DM1GRWY	CS	CCCCCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DM1GRWY	IK	AHZUGQDNSYDLNN-UHFFFAOYSA-N
DM1GRWY	IU	4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY	DE	Discovery agent

DMZQ7DP	ID	DMZQ7DP
DMZQ7DP	DN	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP	HS	Investigative
DMZQ7DP	SN	CHEMBL390882; 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP	DT	Small molecular drug
DMZQ7DP	PC	44426808
DMZQ7DP	MW	323.5
DMZQ7DP	FM	C22H29NO
DMZQ7DP	IC	InChI=1S/C22H29NO/c1-2-3-14-21(19-10-6-4-7-11-19)23-17-15-22(24,16-18-23)20-12-8-5-9-13-20/h4-13,21,24H,2-3,14-18H2,1H3
DMZQ7DP	CS	CCCCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMZQ7DP	IK	WQECIXIOLXNRTH-UHFFFAOYSA-N
DMZQ7DP	IU	4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP	DE	Discovery agent

DM491FJ	ID	DM491FJ
DM491FJ	DN	4-phenyl-1-(1-phenylpropan-2-yl)piperidin-4-ol
DM491FJ	HS	Investigative
DM491FJ	SN	CHEMBL230140
DM491FJ	DT	Small molecular drug
DM491FJ	PC	44426805
DM491FJ	MW	295.4
DM491FJ	FM	C20H25NO
DM491FJ	IC	InChI=1S/C20H25NO/c1-17(16-18-8-4-2-5-9-18)21-14-12-20(22,13-15-21)19-10-6-3-7-11-19/h2-11,17,22H,12-16H2,1H3
DM491FJ	CS	CC(CC1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DM491FJ	IK	DBTIAPBSTRWDLH-UHFFFAOYSA-N
DM491FJ	IU	4-phenyl-1-(1-phenylpropan-2-yl)piperidin-4-ol
DM491FJ	DE	Discovery agent

DMALIQ8	ID	DMALIQ8
DMALIQ8	DN	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol
DMALIQ8	HS	Investigative
DMALIQ8	SN	CHEMBL433814; 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol; SCHEMBL9520650
DMALIQ8	DT	Small molecular drug
DMALIQ8	PC	44426806
DMALIQ8	MW	295.4
DMALIQ8	FM	C20H25NO
DMALIQ8	IC	InChI=1S/C20H25NO/c1-2-19(17-9-5-3-6-10-17)21-15-13-20(22,14-16-21)18-11-7-4-8-12-18/h3-12,19,22H,2,13-16H2,1H3
DMALIQ8	CS	CCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMALIQ8	IK	YUOJNJIUXXIUHY-UHFFFAOYSA-N
DMALIQ8	IU	4-phenyl-1-(1-phenylpropyl)piperidin-4-ol
DMALIQ8	DE	Discovery agent

DMM8O1X	ID	DMM8O1X
DMM8O1X	DN	4-phenyl-1-(3-phenylpropyl)piperidin-4-ol
DMM8O1X	HS	Investigative
DMM8O1X	SN	CHEMBL115508; 4-phenyl-1-(3-phenylpropyl)piperidin-4-ol; SCHEMBL8096481; BDBM50007398
DMM8O1X	DT	Small molecular drug
DMM8O1X	PC	15723894
DMM8O1X	MW	295.4
DMM8O1X	FM	C20H25NO
DMM8O1X	IC	InChI=1S/C20H25NO/c22-20(19-11-5-2-6-12-19)13-16-21(17-14-20)15-7-10-18-8-3-1-4-9-18/h1-6,8-9,11-12,22H,7,10,13-17H2
DMM8O1X	CS	C1CN(CCC1(C2=CC=CC=C2)O)CCCC3=CC=CC=C3
DMM8O1X	IK	ZZUJERGWKSXINO-UHFFFAOYSA-N
DMM8O1X	IU	4-phenyl-1-(3-phenylpropyl)piperidin-4-ol
DMM8O1X	DE	Discovery agent

DMFV0JC	ID	DMFV0JC
DMFV0JC	DN	4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol
DMFV0JC	HS	Investigative
DMFV0JC	SN	CHEMBL390279; 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol
DMFV0JC	DT	Small molecular drug
DMFV0JC	PC	44426827
DMFV0JC	MW	357.5
DMFV0JC	FM	C25H27NO
DMFV0JC	IC	InChI=1S/C25H27NO/c1-20-9-8-12-22(19-20)24(21-10-4-2-5-11-21)26-17-15-25(27,16-18-26)23-13-6-3-7-14-23/h2-14,19,24,27H,15-18H2,1H3
DMFV0JC	CS	CC1=CC(=CC=C1)C(C2=CC=CC=C2)N3CCC(CC3)(C4=CC=CC=C4)O
DMFV0JC	IK	ODFDCTDNLNJAAY-UHFFFAOYSA-N
DMFV0JC	IU	1-[(3-methylphenyl)-phenylmethyl]-4-phenylpiperidin-4-ol
DMFV0JC	DE	Discovery agent

DM2MPWC	ID	DM2MPWC
DM2MPWC	DN	4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol
DM2MPWC	HS	Investigative
DM2MPWC	SN	CHEMBL388123; 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol
DM2MPWC	DT	Small molecular drug
DM2MPWC	PC	9863568
DM2MPWC	MW	357.5
DM2MPWC	FM	C25H27NO
DM2MPWC	IC	InChI=1S/C25H27NO/c1-20-10-8-9-15-23(20)24(21-11-4-2-5-12-21)26-18-16-25(27,17-19-26)22-13-6-3-7-14-22/h2-15,24,27H,16-19H2,1H3
DM2MPWC	CS	CC1=CC=CC=C1C(C2=CC=CC=C2)N3CCC(CC3)(C4=CC=CC=C4)O
DM2MPWC	IK	GBDUIWBXAKZJPC-UHFFFAOYSA-N
DM2MPWC	IU	1-[(2-methylphenyl)-phenylmethyl]-4-phenylpiperidin-4-ol
DM2MPWC	DE	Discovery agent

DM5R6T4	ID	DM5R6T4
DM5R6T4	DN	4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol
DM5R6T4	HS	Investigative
DM5R6T4	SN	CHEMBL228793; 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol
DM5R6T4	DT	Small molecular drug
DM5R6T4	PC	44426828
DM5R6T4	MW	357.5
DM5R6T4	FM	C25H27NO
DM5R6T4	IC	InChI=1S/C25H27NO/c1-20-12-14-22(15-13-20)24(21-8-4-2-5-9-21)26-18-16-25(27,17-19-26)23-10-6-3-7-11-23/h2-15,24,27H,16-19H2,1H3
DM5R6T4	CS	CC1=CC=C(C=C1)C(C2=CC=CC=C2)N3CCC(CC3)(C4=CC=CC=C4)O
DM5R6T4	IK	RKHFFYFBKRWGAL-UHFFFAOYSA-N
DM5R6T4	IU	1-[(4-methylphenyl)-phenylmethyl]-4-phenylpiperidin-4-ol
DM5R6T4	DE	Discovery agent

DMV6WC4	ID	DMV6WC4
DMV6WC4	DN	4-phenyl-1,2,3,6-tetrahydropyridine
DMV6WC4	HS	Investigative
DMV6WC4	SN	4-Phenyl-1,2,3,6-tetrahydropyridine; 10338-69-9; 4-Phenyl-1,2,3,6-tetrahydro-pyridine; 1,2,3,6-tetrahydro-4-phenyl-pyridine; 1,2,3,6-Tetrahydro-4-phenylpyridine; Pyridine, 1,2,3,6-tetrahydro-4-phenyl-; CHEMBL6224; OMPXTQYWYRWWPH-UHFFFAOYSA-N; 4-phenyl-1,2,3,6-tetrahydro pyridine; Oprea1_874761; NSC 54451; AC1Q1IN6; AC1L33NE; AC1Q1GX2; SCHEMBL415545; DTXSID2065040; CTK4A2038; MolPort-001-794-494; 43064-12-6 (hydrochloride); ZINC1295150; NSC54451; 4-Phenyl-1,3,6-tetrahydropyridine; STK535809; NSC-54451; BDBM50036718; BBL027886
DMV6WC4	DT	Small molecular drug
DMV6WC4	PC	82553
DMV6WC4	MW	159.23
DMV6WC4	FM	C11H13N
DMV6WC4	IC	InChI=1S/C11H13N/c1-2-4-10(5-3-1)11-6-8-12-9-7-11/h1-6,12H,7-9H2
DMV6WC4	CS	C1CNCC=C1C2=CC=CC=C2
DMV6WC4	IK	OMPXTQYWYRWWPH-UHFFFAOYSA-N
DMV6WC4	IU	4-phenyl-1,2,3,6-tetrahydropyridine
DMV6WC4	CA	CAS 10338-69-9
DMV6WC4	DE	Discovery agent

DMONKDQ	ID	DMONKDQ
DMONKDQ	DN	4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile
DMONKDQ	HS	Investigative
DMONKDQ	SN	CHEMBL411829; 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile; SCHEMBL6033918
DMONKDQ	DT	Small molecular drug
DMONKDQ	PC	18516979
DMONKDQ	MW	272.3
DMONKDQ	FM	C17H12N4
DMONKDQ	IC	InChI=1S/C17H12N4/c18-11-14-12-19-17(20-15-9-5-2-6-10-15)21-16(14)13-7-3-1-4-8-13/h1-10,12H,(H,19,20,21)
DMONKDQ	CS	C1=CC=C(C=C1)C2=NC(=NC=C2C#N)NC3=CC=CC=C3
DMONKDQ	IK	KLNVGLIZGCKXCE-UHFFFAOYSA-N
DMONKDQ	IU	2-anilino-4-phenylpyrimidine-5-carbonitrile
DMONKDQ	DE	Discovery agent

DMPY4G1	ID	DMPY4G1
DMPY4G1	DN	4-phenyl-4-[1H-imidazol-2-yl]-piperidine
DMPY4G1	HS	Investigative
DMPY4G1	SN	CHEMBL382326; 4-phenyl-4-[1H-imidazol-2-yl]-piperidine; SCHEMBL14173644
DMPY4G1	DT	Small molecular drug
DMPY4G1	PC	44406272
DMPY4G1	MW	436.5
DMPY4G1	FM	C28H28N4O
DMPY4G1	IC	InChI=1S/C28H28N4O/c33-27(30-25-14-8-3-9-15-25)31-19-16-28(17-20-31,24-12-6-2-7-13-24)26-29-18-21-32(26)22-23-10-4-1-5-11-23/h1-15,18,21H,16-17,19-20,22H2,(H,30,33)
DMPY4G1	CS	C1CN(CCC1(C2=CC=CC=C2)C3=NC=CN3CC4=CC=CC=C4)C(=O)NC5=CC=CC=C5
DMPY4G1	IK	SSXWGBNGZDJNOZ-UHFFFAOYSA-N
DMPY4G1	IU	4-(1-benzylimidazol-2-yl)-N,4-diphenylpiperidine-1-carboxamide
DMPY4G1	DE	Discovery agent

DM7E4JU	ID	DM7E4JU
DM7E4JU	DN	4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol
DM7E4JU	HS	Investigative
DM7E4JU	SN	4-phenyl-5-(4-piperidyl)-3-isoxazolol
DM7E4JU	PC	11404581
DM7E4JU	MW	244.29
DM7E4JU	FM	C14H16N2O2
DM7E4JU	IC	InChI=1S/C14H16N2O2/c17-14-12(10-4-2-1-3-5-10)13(18-16-14)11-6-8-15-9-7-11/h1-5,11,15H,6-9H2,(H,16,17)
DM7E4JU	CS	C1CNCCC1C2=C(C(=O)NO2)C3=CC=CC=C3
DM7E4JU	IK	QTEBXBALJGPXEP-UHFFFAOYSA-N
DM7E4JU	IU	4-phenyl-5-piperidin-4-yl-1,2-oxazol-3-one
DM7E4JU	DE	Discovery agent

DMMIB0R	ID	DMMIB0R
DMMIB0R	DN	4-phenyl-6-propylpyrimidine-2-carbonitrile
DMMIB0R	HS	Investigative
DMMIB0R	SN	CHEMBL1077366; 4-phenyl-6-propylpyrimidine-2-carbonitrile; SCHEMBL4442260
DMMIB0R	DT	Small molecular drug
DMMIB0R	PC	46882093
DMMIB0R	MW	223.27
DMMIB0R	FM	C14H13N3
DMMIB0R	IC	InChI=1S/C14H13N3/c1-2-6-12-9-13(17-14(10-15)16-12)11-7-4-3-5-8-11/h3-5,7-9H,2,6H2,1H3
DMMIB0R	CS	CCCC1=CC(=NC(=N1)C#N)C2=CC=CC=C2
DMMIB0R	IK	IUPDRSKJKKTVKP-UHFFFAOYSA-N
DMMIB0R	IU	4-phenyl-6-propylpyrimidine-2-carbonitrile
DMMIB0R	DE	Discovery agent

DMLZSH1	ID	DMLZSH1
DMLZSH1	DN	4-Phenyl-benzo[b]thiophene-2-carboxamidine
DMLZSH1	HS	Investigative
DMLZSH1	SN	CHEMBL591931; 4-Phenyl-benzo[b]thiophene-2-carboxamidine; SCHEMBL13709464
DMLZSH1	DT	Small molecular drug
DMLZSH1	PC	15230353
DMLZSH1	MW	252.3
DMLZSH1	FM	C15H12N2S
DMLZSH1	IC	InChI=1S/C15H12N2S/c16-15(17)14-9-12-11(7-4-8-13(12)18-14)10-5-2-1-3-6-10/h1-9H,(H3,16,17)
DMLZSH1	CS	C1=CC=C(C=C1)C2=C3C=C(SC3=CC=C2)C(=N)N
DMLZSH1	IK	HKXOXDHVUZHJFV-UHFFFAOYSA-N
DMLZSH1	IU	4-phenyl-1-benzothiophene-2-carboximidamide
DMLZSH1	DE	Discovery agent

DM871ZE	ID	DM871ZE
DM871ZE	DN	4-Phenylbutylcarbamic Acid Biphenyl-3-yl Ester
DM871ZE	HS	Investigative
DM871ZE	SN	CHEMBL486492; 4-Phenylbutylcarbamic Acid Biphenyl-3-yl Ester
DM871ZE	DT	Small molecular drug
DM871ZE	PC	24881743
DM871ZE	MW	345.4
DM871ZE	FM	C23H23NO2
DM871ZE	IC	InChI=1S/C23H23NO2/c25-23(24-17-8-7-12-19-10-3-1-4-11-19)26-22-16-9-15-21(18-22)20-13-5-2-6-14-20/h1-6,9-11,13-16,18H,7-8,12,17H2,(H,24,25)
DM871ZE	CS	C1=CC=C(C=C1)CCCCNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DM871ZE	IK	WZSGWNPOHRAUQO-UHFFFAOYSA-N
DM871ZE	IU	(3-phenylphenyl) N-(4-phenylbutyl)carbamate
DM871ZE	DE	Discovery agent

DMCZKN7	ID	DMCZKN7
DMCZKN7	DN	4-Phenylbutyrohydroxamic acid
DMCZKN7	HS	Investigative
DMCZKN7	SN	N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; 4-Phenylbutyrohydroxamic acid; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596
DMCZKN7	DT	Small molecular drug
DMCZKN7	PC	279980
DMCZKN7	MW	179.22
DMCZKN7	FM	C10H13NO2
DMCZKN7	IC	InChI=1S/C10H13NO2/c12-10(11-13)8-4-7-9-5-2-1-3-6-9/h1-3,5-6,13H,4,7-8H2,(H,11,12)
DMCZKN7	CS	C1=CC=C(C=C1)CCCC(=O)NO
DMCZKN7	IK	UPHXPXYRKPCXHK-UHFFFAOYSA-N
DMCZKN7	IU	N-hydroxy-4-phenylbutanamide
DMCZKN7	CA	CAS 32153-46-1
DMCZKN7	DE	Discovery agent

DM5UNBW	ID	DM5UNBW
DM5UNBW	DN	4-Phenylimidazole
DM5UNBW	HS	Investigative
DM5UNBW	SN	4-Phenylimidazole; 670-95-1; 4-PHENYL-1H-IMIDAZOLE; 5-Phenyl-1H-imidazole; 4(5)-Phenylimidazole; 1H-Imidazole, 4-phenyl-; Imidazole, 4-phenyl-; 5-phenylimidazole; 4-PHENYL IMIDAZOLE; CHEMBL14145; XHLKOHSAWQPOFO-UHFFFAOYSA-N; MFCD00005197; NSC-195337; F1918-0054; PIM; 4-phenyl-1h-imidazol; 4-phenyl-imidazole; EINECS 211-580-1; PubChem7224; NSC 195337; ACMC-209nxp; 4-phenylimidazole, 4-PI; 4-Phenylimidazole, 97%; 1H-Imidazole, 5-phenyl-; AC1L2C7W; AC1Q4YD1; SCHEMBL37563; KSC696A2D; Imidazole, 4-phenyl- (8CI); AMBZ0133; CTK5J6021
DM5UNBW	DT	Small molecular drug
DM5UNBW	PC	69590
DM5UNBW	MW	144.17
DM5UNBW	FM	C9H8N2
DM5UNBW	IC	InChI=1S/C9H8N2/c1-2-4-8(5-3-1)9-6-10-7-11-9/h1-7H,(H,10,11)
DM5UNBW	CS	C1=CC=C(C=C1)C2=CN=CN2
DM5UNBW	IK	XHLKOHSAWQPOFO-UHFFFAOYSA-N
DM5UNBW	IU	5-phenyl-1H-imidazole
DM5UNBW	CA	CAS 670-95-1
DM5UNBW	DE	Discovery agent

DM9J5TZ	ID	DM9J5TZ
DM9J5TZ	DN	4-phenyliminomethyl-benzenesulfonamide
DM9J5TZ	HS	Investigative
DM9J5TZ	SN	4-phenyliminomethyl-benzenesulfonamide; CHEMBL407019; SCHEMBL5311443
DM9J5TZ	DT	Small molecular drug
DM9J5TZ	PC	44456679
DM9J5TZ	MW	260.31
DM9J5TZ	FM	C13H12N2O2S
DM9J5TZ	IC	InChI=1S/C13H12N2O2S/c14-18(16,17)13-8-6-11(7-9-13)10-15-12-4-2-1-3-5-12/h1-10H,(H2,14,16,17)
DM9J5TZ	CS	C1=CC=C(C=C1)N=CC2=CC=C(C=C2)S(=O)(=O)N
DM9J5TZ	IK	XUMZYVTUPBUWOY-UHFFFAOYSA-N
DM9J5TZ	IU	4-(phenyliminomethyl)benzenesulfonamide
DM9J5TZ	DE	Discovery agent

DMW46K7	ID	DMW46K7
DMW46K7	DN	4-Phenylspiro[chromene-2,4'-piperidine]
DMW46K7	HS	Investigative
DMW46K7	SN	CHEMBL492447; SCHEMBL467151; BDBM50252830
DMW46K7	DT	Small molecular drug
DMW46K7	PC	25129089
DMW46K7	MW	277.4
DMW46K7	FM	C19H19NO
DMW46K7	IC	InChI=1S/C19H19NO/c1-2-6-15(7-3-1)17-14-19(10-12-20-13-11-19)21-18-9-5-4-8-16(17)18/h1-9,14,20H,10-13H2
DMW46K7	CS	C1CNCCC12C=C(C3=CC=CC=C3O2)C4=CC=CC=C4
DMW46K7	IK	AWYPHZMWGAOGIC-UHFFFAOYSA-N
DMW46K7	IU	4-phenylspiro[chromene-2,4'-piperidine]
DMW46K7	DE	Discovery agent

DMHANXD	ID	DMHANXD
DMHANXD	DN	4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine
DMHANXD	HS	Investigative
DMHANXD	SN	4-(Phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine; 736142-84-0; 7h-pyrrolo[2,3-d]pyrimidine,4-(phenylthio)-; SCHEMBL191691; CHEMBL360302; TUBUPSQEQADRHY-UHFFFAOYSA-N; ZINC13608572; KB-270401; 7H-Pyrrolo[2,3-d]pyrimidine, 4-(phenylthio)-
DMHANXD	DT	Small molecular drug
DMHANXD	PC	11481564
DMHANXD	MW	227.29
DMHANXD	FM	C12H9N3S
DMHANXD	IC	InChI=1S/C12H9N3S/c1-2-4-9(5-3-1)16-12-10-6-7-13-11(10)14-8-15-12/h1-8H,(H,13,14,15)
DMHANXD	CS	C1=CC=C(C=C1)SC2=NC=NC3=C2C=CN3
DMHANXD	IK	TUBUPSQEQADRHY-UHFFFAOYSA-N
DMHANXD	IU	4-phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine
DMHANXD	DE	Discovery agent

DM3B1CE	ID	DM3B1CE
DM3B1CE	DN	4-phenylthiazole-2-thiol
DM3B1CE	HS	Investigative
DM3B1CE	SN	4-Phenylthiazole-2-thiol; 2103-88-0; 2-Mercapto-4-phenylthiazole; 4-Phenyl-2-thiazolethiol; 4-Phenyl-1,3-thiazole-2-thiol; 2(3H)-Thiazolethione, 4-phenyl-; 4-Phenyl-2-mercaptothiazole; 4-Thiazoline-2-thione, 4-phenyl-; 2-Thiazolethiol, 4-phenyl-; 4-phenyl-thiazole-2-thiol; CHEMBL571436; 4-Phenylthiazole-2(3H)-thione; NSC 678; CYCKHTAVNBPQDB-UHFFFAOYSA-N; EINECS 218-274-7; 4-phenyl-3H-1,3-thiazole-2-thione; NSC678; zlchem 830; AC1MHDCC; ACMC-1CJ8W; 2-mercapto-4-phenylthiazol; MLS001006837; SCHEMBL178051; SCHEMBL11460891
DM3B1CE	DT	Small molecular drug
DM3B1CE	PC	3000729
DM3B1CE	MW	193.3
DM3B1CE	FM	C9H7NS2
DM3B1CE	IC	InChI=1S/C9H7NS2/c11-9-10-8(6-12-9)7-4-2-1-3-5-7/h1-6H,(H,10,11)
DM3B1CE	CS	C1=CC=C(C=C1)C2=CSC(=S)N2
DM3B1CE	IK	CYCKHTAVNBPQDB-UHFFFAOYSA-N
DM3B1CE	IU	4-phenyl-3H-1,3-thiazole-2-thione
DM3B1CE	CA	CAS 2103-88-0
DM3B1CE	CB	CHEBI:109516
DM3B1CE	DE	Discovery agent

DMW4KXQ	ID	DMW4KXQ
DMW4KXQ	DN	4-phospho-D-erythronate
DMW4KXQ	HS	Investigative
DMW4KXQ	SN	4-Phospho-D-erythronate; 4-phosphoerythronate; 4-phospho-D-erythronic acid; 4-Phospho D-Erythronate; 57229-25-1; CHEBI:49003; 4-O-phosphono-D-erythronic acid; (2R,3R)-2,3-dihydroxy-4-(phosphonooxy)butanoic acid; 2bet; AC1L9MYX; SCHEMBL420471; CHEMBL1160945; CTK1E1186; DTXSID70332305; ZINC3869897; DER; AKOS030570437; DB03108; FT-0673861; C03393; (2R,3R)-2,3-dihydroxy-4-phosphonooxybutanoic acid; [R-(R*,R*)]-2,3-Dihydroxy-4-(phosphonooxy)butanoic Acid; Butanoic acid, 2,3-dihydroxy-4-(phosphonooxy)-, (2R,3R)-
DMW4KXQ	DT	Small molecular drug
DMW4KXQ	PC	449304
DMW4KXQ	MW	216.08
DMW4KXQ	FM	C4H9O8P
DMW4KXQ	IC	InChI=1S/C4H9O8P/c5-2(3(6)4(7)8)1-12-13(9,10)11/h2-3,5-6H,1H2,(H,7,8)(H2,9,10,11)/t2-,3-/m1/s1
DMW4KXQ	CS	C([C@H]([C@H](C(=O)O)O)O)OP(=O)(O)O
DMW4KXQ	IK	ZCZXOHUILRHRQJ-PWNYCUMCSA-N
DMW4KXQ	IU	(2R,3R)-2,3-dihydroxy-4-phosphonooxybutanoic acid
DMW4KXQ	CA	CAS 57229-25-1
DMW4KXQ	CB	CHEBI:49003
DMW4KXQ	DE	Discovery agent

DMJ0A4Z	ID	DMJ0A4Z
DMJ0A4Z	DN	4'-Phosphopantetheine
DMJ0A4Z	HS	Investigative
DMJ0A4Z	SN	4'-phosphopantetheine; Phosphopantetheine; Psh-4'-P; Pantetheine-4'-phosphate; D-Pantetheine 4'-phosphate; UNII-NM39WU8OFM; 2226-71-3; NM39WU8OFM; O(4)-phosphono-D-pantethein; (2R)-2-Hydroxy-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethyl-4-(phosphonooxy)butanamide; PNS; N(3)-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-N-(2-sulfanylethyl)-beta-alaninamide; P-PantSH; AC1L3GTE; SCHEMBL106050; CHEBI:4222; JDMUPRLRUUMCTL-VIFPVBQESA-N; AKOS027326509; DB03912; C01134; Butanamide, 2-hydroxy-N-(3-((2-mercaptoethyl)a
DMJ0A4Z	DT	Small molecular drug
DMJ0A4Z	PC	115254
DMJ0A4Z	MW	358.35
DMJ0A4Z	FM	C11H23N2O7PS
DMJ0A4Z	IC	InChI=1S/C11H23N2O7PS/c1-11(2,7-20-21(17,18)19)9(15)10(16)13-4-3-8(14)12-5-6-22/h9,15,22H,3-7H2,1-2H3,(H,12,14)(H,13,16)(H2,17,18,19)/t9-/m0/s1
DMJ0A4Z	CS	CC(C)(COP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCS)O
DMJ0A4Z	IK	JDMUPRLRUUMCTL-VIFPVBQESA-N
DMJ0A4Z	IU	[(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] dihydrogen phosphate
DMJ0A4Z	CA	CAS 2226-71-3
DMJ0A4Z	CB	CHEBI:4222
DMJ0A4Z	DE	Discovery agent

DMOHDRS	ID	DMOHDRS
DMOHDRS	DN	4-Piperidin-1-yl-chromen-2-one
DMOHDRS	HS	Investigative
DMOHDRS	SN	4-Piperidin-1-yl-chromen-2-one; CHEMBL176114; 4-piperidinocoumarin; AC1LEH6J; 4-piperidylchromen-2-one; Oprea1_207466; Oprea1_800231; MLS000711082; 4-piperidin-1-ylchromen-2-one; ZINC53303; HMS2627L16; BDBM50159626; AKOS003620982; MCULE-1716733202; 4-(1-piperidinyl)-2H-chromen-2-one; BAS 01052429; SMR000280849; ST50993947; EU-0085678; SR-01000527828
DMOHDRS	DT	Small molecular drug
DMOHDRS	PC	686127
DMOHDRS	MW	229.27
DMOHDRS	FM	C14H15NO2
DMOHDRS	IC	InChI=1S/C14H15NO2/c16-14-10-12(15-8-4-1-5-9-15)11-6-2-3-7-13(11)17-14/h2-3,6-7,10H,1,4-5,8-9H2
DMOHDRS	CS	C1CCN(CC1)C2=CC(=O)OC3=CC=CC=C32
DMOHDRS	IK	AZAXRUNIGYYEKS-UHFFFAOYSA-N
DMOHDRS	IU	4-piperidin-1-ylchromen-2-one
DMOHDRS	DE	Discovery agent

DMONGDX	ID	DMONGDX
DMONGDX	DN	4-Piperidino-Piperidine
DMONGDX	HS	Investigative
DMONGDX	SN	4-Piperidinopiperidine; 4897-50-1; 1,4'-Bipiperidine; 4-PIPERIDINO-PIPERIDINE; 1,4'-Bipiperidyl; 1,4-Bipiperidine; [1,4']BIPIPERIDINYL; 4-(1-piperidinyl)piperidine; 1-(piperidin-4-yl)piperidine; 4-(piperidin-1-yl)piperidine; 4-Piperidino piperidine; 4-piperidin-1-ylpiperidine; 1-(4-PIPERIDYL)PIPERIDINE; CHEMBL174391; CHEBI:40117; QDVBKXJMLILLLB-UHFFFAOYSA-N; N-(4-PIPERIDINO)PIPERIDINE; MFCD00006475; 4-piperidylpiperidine; {1,4'}bipiperidinyl; 4PN; 1,4'-bipiperidin; 4-Piperidinopiperidine, 95%, tech.
DMONGDX	DT	Small molecular drug
DMONGDX	PC	78607
DMONGDX	MW	168.28
DMONGDX	FM	C10H20N2
DMONGDX	IC	InChI=1S/C10H20N2/c1-2-8-12(9-3-1)10-4-6-11-7-5-10/h10-11H,1-9H2
DMONGDX	CS	C1CCN(CC1)C2CCNCC2
DMONGDX	IK	QDVBKXJMLILLLB-UHFFFAOYSA-N
DMONGDX	IU	1-piperidin-4-ylpiperidine
DMONGDX	CA	CAS 4897-50-1
DMONGDX	CB	CHEBI:40117
DMONGDX	DE	Discovery agent

DMEMN0W	ID	DMEMN0W
DMEMN0W	DN	4P-PDOT
DMEMN0W	HS	Investigative
DMEMN0W	SN	N-(4-phenyltetralin-2-yl)propanamide; 4-phenyl-2-propionamidotetraline
DMEMN0W	DT	Small molecular drug
DMEMN0W	PC	3976006
DMEMN0W	MW	279.4
DMEMN0W	FM	C19H21NO
DMEMN0W	IC	InChI=1S/C19H21NO/c1-2-19(21)20-16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,2,12-13H2,1H3,(H,20,21)
DMEMN0W	CS	CCC(=O)NC1CC(C2=CC=CC=C2C1)C3=CC=CC=C3
DMEMN0W	IK	RCYLUNPFECYGDW-UHFFFAOYSA-N
DMEMN0W	IU	N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
DMEMN0W	CA	CAS 134865-74-0
DMEMN0W	CB	CHEBI:110160
DMEMN0W	DE	Discovery agent

DMDBC1K	ID	DMDBC1K
DMDBC1K	DN	4-Propyl-1-[3-(phenylpropoxy)propyl]piperidine
DMDBC1K	HS	Investigative
DMDBC1K	SN	CHEMBL462598; 4-Propyl-1-[3-(phenylpropoxy)propyl]piperidine
DMDBC1K	DT	Small molecular drug
DMDBC1K	PC	44563683
DMDBC1K	MW	303.5
DMDBC1K	FM	C20H33NO
DMDBC1K	IC	InChI=1S/C20H33NO/c1-2-8-19-12-15-21(16-13-19)14-7-18-22-17-6-11-20-9-4-3-5-10-20/h3-5,9-10,19H,2,6-8,11-18H2,1H3
DMDBC1K	CS	CCCC1CCN(CC1)CCCOCCCC2=CC=CC=C2
DMDBC1K	IK	STTDWMNBHHXZBO-UHFFFAOYSA-N
DMDBC1K	IU	1-[3-(3-phenylpropoxy)propyl]-4-propylpiperidine
DMDBC1K	DE	Discovery agent

DMRYCL6	ID	DMRYCL6
DMRYCL6	DN	4-propyl-3,4-dihydroquinazolin-2-amine
DMRYCL6	HS	Investigative
DMRYCL6	SN	CHEMBL270840
DMRYCL6	DT	Small molecular drug
DMRYCL6	PC	44455983
DMRYCL6	MW	189.26
DMRYCL6	FM	C11H15N3
DMRYCL6	IC	InChI=1S/C11H15N3/c1-2-5-9-8-6-3-4-7-10(8)14-11(12)13-9/h3-4,6-7,9H,2,5H2,1H3,(H3,12,13,14)
DMRYCL6	CS	CCCC1C2=CC=CC=C2NC(=N1)N
DMRYCL6	IK	GMMVLHFFOQJVPH-UHFFFAOYSA-N
DMRYCL6	IU	4-propyl-1,4-dihydroquinazolin-2-amine
DMRYCL6	DE	Discovery agent

DMNM4GE	ID	DMNM4GE
DMNM4GE	DN	4-propyl-6-m-tolylpyrimidine-2-carbonitrile
DMNM4GE	HS	Investigative
DMNM4GE	SN	CHEMBL1082859; 4-propyl-6-m-tolylpyrimidine-2-carbonitrile; SCHEMBL4453859
DMNM4GE	DT	Small molecular drug
DMNM4GE	PC	46881451
DMNM4GE	MW	237.3
DMNM4GE	FM	C15H15N3
DMNM4GE	IC	InChI=1S/C15H15N3/c1-3-5-13-9-14(18-15(10-16)17-13)12-7-4-6-11(2)8-12/h4,6-9H,3,5H2,1-2H3
DMNM4GE	CS	CCCC1=CC(=NC(=N1)C#N)C2=CC=CC(=C2)C
DMNM4GE	IK	LWTLVKKUNGVFHE-UHFFFAOYSA-N
DMNM4GE	IU	4-(3-methylphenyl)-6-propylpyrimidine-2-carbonitrile
DMNM4GE	DE	Discovery agent

DM4FLK6	ID	DM4FLK6
DM4FLK6	DN	4-propyl-N-(quinolin-3-yl)benzamide
DM4FLK6	HS	Investigative
DM4FLK6	SN	CHEMBL259600; ChemDiv2_003456; AC1N8MZ4; Oprea1_836743; SCHEMBL846554; 4-propyl-N-(3-quinolyl)benzamide; ZINC188371; HMS1378N02; 4-propyl-N-quinolin-3-ylbenzamide; BDBM50376280; AKOS001583305; MCULE-1509884615; EU-0034321; SR-01000396314
DM4FLK6	DT	Small molecular drug
DM4FLK6	PC	4298023
DM4FLK6	MW	290.4
DM4FLK6	FM	C19H18N2O
DM4FLK6	IC	InChI=1S/C19H18N2O/c1-2-5-14-8-10-15(11-9-14)19(22)21-17-12-16-6-3-4-7-18(16)20-13-17/h3-4,6-13H,2,5H2,1H3,(H,21,22)
DM4FLK6	CS	CCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM4FLK6	IK	ACMQNRGXOSFSMZ-UHFFFAOYSA-N
DM4FLK6	IU	4-propyl-N-quinolin-3-ylbenzamide
DM4FLK6	DE	Discovery agent

DMY8ZLM	ID	DMY8ZLM
DMY8ZLM	DN	4-Pyridin-2-yl-5-quinolin-2-yl-thiazol-2-ylamine
DMY8ZLM	HS	Investigative
DMY8ZLM	SN	CHEMBL186966; 4-Pyridin-2-yl-5-quinolin-2-yl-thiazol-2-ylamine
DMY8ZLM	DT	Small molecular drug
DMY8ZLM	PC	11403950
DMY8ZLM	MW	304.4
DMY8ZLM	FM	C17H12N4S
DMY8ZLM	IC	InChI=1S/C17H12N4S/c18-17-21-15(13-7-3-4-10-19-13)16(22-17)14-9-8-11-5-1-2-6-12(11)20-14/h1-10H,(H2,18,21)
DMY8ZLM	CS	C1=CC=C2C(=C1)C=CC(=N2)C3=C(N=C(S3)N)C4=CC=CC=N4
DMY8ZLM	IK	XYMCAGVJYOESBU-UHFFFAOYSA-N
DMY8ZLM	IU	4-pyridin-2-yl-5-quinolin-2-yl-1,3-thiazol-2-amine
DMY8ZLM	DE	Discovery agent

DM6RVB3	ID	DM6RVB3
DM6RVB3	DN	4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine
DM6RVB3	HS	Investigative
DM6RVB3	SN	CHEMBL181640; SCHEMBL410002; 4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine; UPYLCJSMNYCTLZ-UHFFFAOYSA-N; BDBM50151348; 4-(pyridin-2-yl)-5-(quinolin-4-yl)thiazol-2-amine
DM6RVB3	DT	Small molecular drug
DM6RVB3	PC	9796486
DM6RVB3	MW	304.4
DM6RVB3	FM	C17H12N4S
DM6RVB3	IC	InChI=1S/C17H12N4S/c18-17-21-15(14-7-3-4-9-19-14)16(22-17)12-8-10-20-13-6-2-1-5-11(12)13/h1-10H,(H2,18,21)
DM6RVB3	CS	C1=CC=C2C(=C1)C(=CC=N2)C3=C(N=C(S3)N)C4=CC=CC=N4
DM6RVB3	IK	UPYLCJSMNYCTLZ-UHFFFAOYSA-N
DM6RVB3	IU	4-pyridin-2-yl-5-quinolin-4-yl-1,3-thiazol-2-amine
DM6RVB3	DE	Discovery agent

DMFC8Q4	ID	DMFC8Q4
DMFC8Q4	DN	4-Pyridin-2-yl-piperazine-1-carboxylic acid amide
DMFC8Q4	HS	Investigative
DMFC8Q4	SN	CHEMBL296963; SCHEMBL1270156; CTK7D3440; BDBM50224176; AKOS000158821; 4-(2-pyridyl)piperazine-1-carboxamide
DMFC8Q4	DT	Small molecular drug
DMFC8Q4	PC	22418783
DMFC8Q4	MW	206.24
DMFC8Q4	FM	C10H14N4O
DMFC8Q4	IC	InChI=1S/C10H14N4O/c11-10(15)14-7-5-13(6-8-14)9-3-1-2-4-12-9/h1-4H,5-8H2,(H2,11,15)
DMFC8Q4	CS	C1CN(CCN1C2=CC=CC=N2)C(=O)N
DMFC8Q4	IK	XYIDWLYTWKIZQC-UHFFFAOYSA-N
DMFC8Q4	IU	4-pyridin-2-ylpiperazine-1-carboxamide
DMFC8Q4	DE	Discovery agent

DM06AV8	ID	DM06AV8
DM06AV8	DN	4-Pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine
DM06AV8	HS	Investigative
DM06AV8	SN	CHEMBL359724; 4-Pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine; BDBM50151364
DM06AV8	DT	Small molecular drug
DM06AV8	PC	11231979
DM06AV8	MW	304.4
DM06AV8	FM	C17H12N4S
DM06AV8	IC	InChI=1S/C17H12N4S/c18-17-21-15(11-4-3-8-19-10-11)16(22-17)13-7-9-20-14-6-2-1-5-12(13)14/h1-10H,(H2,18,21)
DM06AV8	CS	C1=CC=C2C(=C1)C(=CC=N2)C3=C(N=C(S3)N)C4=CN=CC=C4
DM06AV8	IK	SSOAVUCQSQRZGQ-UHFFFAOYSA-N
DM06AV8	IU	4-pyridin-3-yl-5-quinolin-4-yl-1,3-thiazol-2-amine
DM06AV8	DE	Discovery agent

DMUGFS3	ID	DMUGFS3
DMUGFS3	DN	4r-Fluoro-N6-Ethanimidoyl-L-Lysine
DMUGFS3	HS	Investigative
DMUGFS3	SN	4R-FLUORO-N6-ETHANIMIDOYL-L-LYSINE; I58; AC1L9LS8; SCHEMBL4308483; DB01835; (4R)-N~6~-[(1Z)-ethanimidoyl]-4-fluoro-L-lysine; (2S,4R)-2-amino-6-ethanimidamido-4-fluorohexanoic acid; (2S,4R)-2-amino-6-(1-aminoethylideneamino)-4-fluorohexanoic acid
DMUGFS3	DT	Small molecular drug
DMUGFS3	PC	448269
DMUGFS3	MW	205.23
DMUGFS3	FM	C8H16FN3O2
DMUGFS3	IC	InChI=1S/C8H16FN3O2/c1-5(10)12-3-2-6(9)4-7(11)8(13)14/h6-7H,2-4,11H2,1H3,(H2,10,12)(H,13,14)/t6-,7+/m1/s1
DMUGFS3	CS	CC(=NCC[C@H](C[C@@H](C(=O)O)N)F)N
DMUGFS3	IK	LTCJJIZTKXNFGK-RQJHMYQMSA-N
DMUGFS3	IU	(2S,4R)-2-amino-6-(1-aminoethylideneamino)-4-fluorohexanoic acid
DMUGFS3	DE	Discovery agent

DMQNT8D	ID	DMQNT8D
DMQNT8D	DN	4S-4,5-Diamino-N-(4-phenoxyphenyl)pentanamide
DMQNT8D	HS	Investigative
DMQNT8D	SN	CHEMBL477275; BDBM24292; Modified amino acid analog, 12b
DMQNT8D	DT	Small molecular drug
DMQNT8D	PC	24901637
DMQNT8D	MW	299.37
DMQNT8D	FM	C17H21N3O2
DMQNT8D	IC	InChI=1S/C17H21N3O2/c18-12-13(19)6-11-17(21)20-14-7-9-16(10-8-14)22-15-4-2-1-3-5-15/h1-5,7-10,13H,6,11-12,18-19H2,(H,20,21)/t13-/m0/s1
DMQNT8D	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](CN)N
DMQNT8D	IK	YUSYHJFOQGXULG-ZDUSSCGKSA-N
DMQNT8D	IU	(4S)-4,5-diamino-N-(4-phenoxyphenyl)pentanamide
DMQNT8D	DE	Discovery agent

DMELGKY	ID	DMELGKY
DMELGKY	DN	4-substituted 2,4-dioxobutanoic acids
DMELGKY	HS	Investigative
DMELGKY	SN	Guvacine; 1,2,5,6-tetrahydropyridine-3-carboxylic acid; 498-96-4; 1,2,5,6-Tetrahydro-3-pyridinecarboxylic acid; UNII-41538P325K; 1,2,5,6-Tetrahydronicotinic acid; CHEBI:5576; 1,2,3,6-tetrahydropyridine-5-carboxylic acid; 41538P325K; 1,2,5,6-Tetrahydro-pyridine-3-carboxylic acid; MLS000859975; SMR000326834; Spectrum_001426; Tocris-0234; SpecPlus_000808; Lopac-G-007; AC1Q5RCN; Spectrum2_001474; Spectrum4_001753; Spectrum3_001511; Spectrum5_000606; Biomol-NT_000253; C10149; AC1L1G5E; Lopac0_000571; BSPBio_003181; KBioSS_001906
DMELGKY	DT	Small molecular drug
DMELGKY	PC	3532
DMELGKY	MW	127.14
DMELGKY	FM	C6H9NO2
DMELGKY	IC	InChI=1S/C6H9NO2/c8-6(9)5-2-1-3-7-4-5/h2,7H,1,3-4H2,(H,8,9)
DMELGKY	CS	C1CNCC(=C1)C(=O)O
DMELGKY	IK	QTDZOWFRBNTPQR-UHFFFAOYSA-N
DMELGKY	IU	1,2,3,6-tetrahydropyridine-5-carboxylic acid
DMELGKY	CA	CAS 498-96-4
DMELGKY	CB	CHEBI:5576
DMELGKY	DE	Discovery agent

DMWH2NT	ID	DMWH2NT
DMWH2NT	DN	4-Sulfamoyloxy-benzoic acid butyl ester
DMWH2NT	HS	Investigative
DMWH2NT	SN	4-Sulfamoyloxy-benzoic acid butyl ester; CHEMBL76374; BDBM50116810; 4-(Sulfamoyloxy)benzoic acid butyl ester
DMWH2NT	DT	Small molecular drug
DMWH2NT	PC	10880277
DMWH2NT	MW	273.31
DMWH2NT	FM	C11H15NO5S
DMWH2NT	IC	InChI=1S/C11H15NO5S/c1-2-3-8-16-11(13)9-4-6-10(7-5-9)17-18(12,14)15/h4-7H,2-3,8H2,1H3,(H2,12,14,15)
DMWH2NT	CS	CCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMWH2NT	IK	DTGVRFABWYOAMJ-UHFFFAOYSA-N
DMWH2NT	IU	butyl 4-sulfamoyloxybenzoate
DMWH2NT	DE	Discovery agent

DMDNRCU	ID	DMDNRCU
DMDNRCU	DN	4-Sulfamoyloxy-benzoic acid cycloheptyl ester
DMDNRCU	HS	Investigative
DMDNRCU	SN	CHEMBL349091; 4-Sulfamoyloxy-benzoic acid cycloheptyl ester; BDBM50139113; 4-(Sulfamoyloxy)benzoic acid cycloheptyl ester
DMDNRCU	DT	Small molecular drug
DMDNRCU	PC	10018465
DMDNRCU	MW	313.37
DMDNRCU	FM	C14H19NO5S
DMDNRCU	IC	InChI=1S/C14H19NO5S/c15-21(17,18)20-13-9-7-11(8-10-13)14(16)19-12-5-3-1-2-4-6-12/h7-10,12H,1-6H2,(H2,15,17,18)
DMDNRCU	CS	C1CCCC(CC1)OC(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMDNRCU	IK	ZJGRMZILHPHGTJ-UHFFFAOYSA-N
DMDNRCU	IU	cycloheptyl 4-sulfamoyloxybenzoate
DMDNRCU	DE	Discovery agent

DMIX0UN	ID	DMIX0UN
DMIX0UN	DN	4-Sulfamoyloxy-benzoic acid cyclohexyl ester
DMIX0UN	HS	Investigative
DMIX0UN	SN	CHEMBL443552; 4-Sulfamoyloxy-benzoic acid cyclohexyl ester; BDBM50139116; 4-(Sulfamoyloxy)benzoic acid cyclohexyl ester
DMIX0UN	DT	Small molecular drug
DMIX0UN	PC	44371205
DMIX0UN	MW	299.34
DMIX0UN	FM	C13H17NO5S
DMIX0UN	IC	InChI=1S/C13H17NO5S/c14-20(16,17)19-12-8-6-10(7-9-12)13(15)18-11-4-2-1-3-5-11/h6-9,11H,1-5H2,(H2,14,16,17)
DMIX0UN	CS	C1CCC(CC1)OC(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMIX0UN	IK	VMBLTTIYVBQGQH-UHFFFAOYSA-N
DMIX0UN	IU	cyclohexyl 4-sulfamoyloxybenzoate
DMIX0UN	DE	Discovery agent

DMG4LD9	ID	DMG4LD9
DMG4LD9	DN	4-Sulfamoyloxy-benzoic acid cyclooctyl ester
DMG4LD9	HS	Investigative
DMG4LD9	SN	CHEMBL155465; 4-Sulfamoyloxy-benzoic acid cyclooctyl ester; BDBM50139114; 4-(Sulfamoyloxy)benzoic acid cyclooctyl ester
DMG4LD9	DT	Small molecular drug
DMG4LD9	PC	10065009
DMG4LD9	MW	327.4
DMG4LD9	FM	C15H21NO5S
DMG4LD9	IC	InChI=1S/C15H21NO5S/c16-22(18,19)21-14-10-8-12(9-11-14)15(17)20-13-6-4-2-1-3-5-7-13/h8-11,13H,1-7H2,(H2,16,18,19)
DMG4LD9	CS	C1CCCC(CCC1)OC(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMG4LD9	IK	AGVIMIWKQHZOFR-UHFFFAOYSA-N
DMG4LD9	IU	cyclooctyl 4-sulfamoyloxybenzoate
DMG4LD9	DE	Discovery agent

DMF3C71	ID	DMF3C71
DMF3C71	DN	4-Sulfamoyloxy-benzoic acid cyclopentyl ester
DMF3C71	HS	Investigative
DMF3C71	SN	CHEMBL347202; 4-Sulfamoyloxy-benzoic acid cyclopentyl ester; BDBM50139115; 4-(Sulfamoyloxy)benzoic acid cyclopentyl ester
DMF3C71	DT	Small molecular drug
DMF3C71	PC	44370998
DMF3C71	MW	285.32
DMF3C71	FM	C12H15NO5S
DMF3C71	IC	InChI=1S/C12H15NO5S/c13-19(15,16)18-11-7-5-9(6-8-11)12(14)17-10-3-1-2-4-10/h5-8,10H,1-4H2,(H2,13,15,16)
DMF3C71	CS	C1CCC(C1)OC(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMF3C71	IK	UOISMBVIIRRGNN-UHFFFAOYSA-N
DMF3C71	IU	cyclopentyl 4-sulfamoyloxybenzoate
DMF3C71	DE	Discovery agent

DMTC25W	ID	DMTC25W
DMTC25W	DN	4-Sulfamoyloxy-benzoic acid heptyl ester
DMTC25W	HS	Investigative
DMTC25W	SN	4-Sulfamoyloxy-benzoic acid heptyl ester; CHEMBL420395; BDBM50116818; 4-(Sulfamoyloxy)benzoic acid heptyl ester
DMTC25W	DT	Small molecular drug
DMTC25W	PC	9796948
DMTC25W	MW	315.39
DMTC25W	FM	C14H21NO5S
DMTC25W	IC	InChI=1S/C14H21NO5S/c1-2-3-4-5-6-11-19-14(16)12-7-9-13(10-8-12)20-21(15,17)18/h7-10H,2-6,11H2,1H3,(H2,15,17,18)
DMTC25W	CS	CCCCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMTC25W	IK	XTVXDGYXZNQKRA-UHFFFAOYSA-N
DMTC25W	IU	heptyl 4-sulfamoyloxybenzoate
DMTC25W	DE	Discovery agent

DMU784M	ID	DMU784M
DMU784M	DN	4-Sulfamoyloxy-benzoic acid hexyl ester
DMU784M	HS	Investigative
DMU784M	SN	4-Sulfamoyloxy-benzoic acid hexyl ester; CHEMBL78282; BDBM50116815; 4-(Sulfamoyloxy)benzoic acid hexyl ester
DMU784M	DT	Small molecular drug
DMU784M	PC	9879424
DMU784M	MW	301.36
DMU784M	FM	C13H19NO5S
DMU784M	IC	InChI=1S/C13H19NO5S/c1-2-3-4-5-10-18-13(15)11-6-8-12(9-7-11)19-20(14,16)17/h6-9H,2-5,10H2,1H3,(H2,14,16,17)
DMU784M	CS	CCCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMU784M	IK	PJIPMHPXRQOHKO-UHFFFAOYSA-N
DMU784M	IU	hexyl 4-sulfamoyloxybenzoate
DMU784M	DE	Discovery agent

DM4Z7TU	ID	DM4Z7TU
DM4Z7TU	DN	4-Sulfamoyloxy-benzoic acid nonyl ester
DM4Z7TU	HS	Investigative
DM4Z7TU	SN	4-Sulfamoyloxy-benzoic acid nonyl ester; CHEMBL80330; BDBM50116813; 4-(Sulfamoyloxy)benzoic acid nonyl ester
DM4Z7TU	DT	Small molecular drug
DM4Z7TU	PC	10914878
DM4Z7TU	MW	343.4
DM4Z7TU	FM	C16H25NO5S
DM4Z7TU	IC	InChI=1S/C16H25NO5S/c1-2-3-4-5-6-7-8-13-21-16(18)14-9-11-15(12-10-14)22-23(17,19)20/h9-12H,2-8,13H2,1H3,(H2,17,19,20)
DM4Z7TU	CS	CCCCCCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DM4Z7TU	IK	MIEAOZZHVJFVJY-UHFFFAOYSA-N
DM4Z7TU	IU	nonyl 4-sulfamoyloxybenzoate
DM4Z7TU	DE	Discovery agent

DMQMSW3	ID	DMQMSW3
DMQMSW3	DN	4-Sulfamoyloxy-benzoic acid octyl ester
DMQMSW3	HS	Investigative
DMQMSW3	SN	4-Sulfamoyloxy-benzoic acid octyl ester; CHEMBL421505; BDBM50116814; 4-(Sulfamoyloxy)benzoic acid octyl ester
DMQMSW3	DT	Small molecular drug
DMQMSW3	PC	10958461
DMQMSW3	MW	329.4
DMQMSW3	FM	C15H23NO5S
DMQMSW3	IC	InChI=1S/C15H23NO5S/c1-2-3-4-5-6-7-12-20-15(17)13-8-10-14(11-9-13)21-22(16,18)19/h8-11H,2-7,12H2,1H3,(H2,16,18,19)
DMQMSW3	CS	CCCCCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMQMSW3	IK	YDCCVRPKBUQXHB-UHFFFAOYSA-N
DMQMSW3	IU	octyl 4-sulfamoyloxybenzoate
DMQMSW3	DE	Discovery agent

DMZIFW7	ID	DMZIFW7
DMZIFW7	DN	4-Sulfamoyloxy-benzoic acid pentyl ester
DMZIFW7	HS	Investigative
DMZIFW7	SN	4-Sulfamoyloxy-benzoic acid pentyl ester; CHEMBL306782; BDBM50116811; 4-(Sulfamoyloxy)benzoic acid pentyl ester
DMZIFW7	DT	Small molecular drug
DMZIFW7	PC	11822292
DMZIFW7	MW	287.33
DMZIFW7	FM	C12H17NO5S
DMZIFW7	IC	InChI=1S/C12H17NO5S/c1-2-3-4-9-17-12(14)10-5-7-11(8-6-10)18-19(13,15)16/h5-8H,2-4,9H2,1H3,(H2,13,15,16)
DMZIFW7	CS	CCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMZIFW7	IK	ZFWKNIDIWKSQEP-UHFFFAOYSA-N
DMZIFW7	IU	pentyl 4-sulfamoyloxybenzoate
DMZIFW7	DE	Discovery agent

DMRILJC	ID	DMRILJC
DMRILJC	DN	4-Sulfamoyloxy-benzoic acid propyl ester
DMRILJC	HS	Investigative
DMRILJC	SN	4-Sulfamoyloxy-benzoic acid propyl ester; CHEMBL77121; BDBM50116817; 4-(Sulfamoyloxy)benzoic acid propyl ester
DMRILJC	DT	Small molecular drug
DMRILJC	PC	10858185
DMRILJC	MW	259.279
DMRILJC	FM	C10H13NO5S
DMRILJC	IC	InChI=1S/C10H13NO5S/c1-2-7-15-10(12)8-3-5-9(6-4-8)16-17(11,13)14/h3-6H,2,7H2,1H3,(H2,11,13,14)
DMRILJC	CS	CCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMRILJC	IK	LUBKCXRNDIXVCG-UHFFFAOYSA-N
DMRILJC	IU	propyl 4-sulfamoyloxybenzoate
DMRILJC	DE	Discovery agent

DM61CJK	ID	DM61CJK
DM61CJK	DN	4-Sulfonamide-[1-(4-Aminobutane)]Benzamide
DM61CJK	HS	Investigative
DM61CJK	SN	4-sulfonamide-[1-(4-aminobutane)]benzamide; N-(4-aminobutyl)-4-sulfamoylbenzamide; AC1L1C69; CHEMBL331282; DB03697
DM61CJK	DT	Small molecular drug
DM61CJK	PC	1758
DM61CJK	MW	271.34
DM61CJK	FM	C11H17N3O3S
DM61CJK	IC	InChI=1S/C11H17N3O3S/c12-7-1-2-8-14-11(15)9-3-5-10(6-4-9)18(13,16)17/h3-6H,1-2,7-8,12H2,(H,14,15)(H2,13,16,17)
DM61CJK	CS	C1=CC(=CC=C1C(=O)NCCCCN)S(=O)(=O)N
DM61CJK	IK	ZDYFRIZTYRFPJC-UHFFFAOYSA-N
DM61CJK	IU	N-(4-aminobutyl)-4-sulfamoylbenzamide
DM61CJK	DE	Discovery agent

DMGCYS1	ID	DMGCYS1
DMGCYS1	DN	4-TERT-BUTYLBENZENESULFONIC ACID
DMGCYS1	HS	Investigative
DMGCYS1	SN	4-TERT-BUTYLBENZENESULFONIC ACID; 1133-17-1; AC1L8AOG; SCHEMBL196750; DTXSID80314995; ZINC1565641; 4-tert-butylbenzene-1-sulfonic acid; NSC290811; AKOS022773375; NSC-290811; MCULE-2120234795; DB07440; AJ-27135; BBS; 4-tert-Butylbenzenesulfonic acid, AldrichCPR
DMGCYS1	DT	Small molecular drug
DMGCYS1	PC	324690
DMGCYS1	MW	214.28
DMGCYS1	FM	C10H14O3S
DMGCYS1	IC	InChI=1S/C10H14O3S/c1-10(2,3)8-4-6-9(7-5-8)14(11,12)13/h4-7H,1-3H3,(H,11,12,13)
DMGCYS1	CS	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)O
DMGCYS1	IK	LZQMCUIWYRQLOG-UHFFFAOYSA-N
DMGCYS1	IU	4-tert-butylbenzenesulfonic acid
DMGCYS1	CA	CAS 1133-17-1
DMGCYS1	DE	Discovery agent

DMDWRE5	ID	DMDWRE5
DMDWRE5	DN	4-tert-butyl-N-(2-isopropylphenyl)thiazol-2-amine
DMDWRE5	HS	Investigative
DMDWRE5	SN	CHEMBL206788; 4-tert-butyl-N-(2-isopropylphenyl)thiazol-2-amine
DMDWRE5	DT	Small molecular drug
DMDWRE5	PC	44411266
DMDWRE5	MW	274.4
DMDWRE5	FM	C16H22N2S
DMDWRE5	IC	InChI=1S/C16H22N2S/c1-11(2)12-8-6-7-9-13(12)17-15-18-14(10-19-15)16(3,4)5/h6-11H,1-5H3,(H,17,18)
DMDWRE5	CS	CC(C)C1=CC=CC=C1NC2=NC(=CS2)C(C)(C)C
DMDWRE5	IK	XGRAMFLJGHKCSV-UHFFFAOYSA-N
DMDWRE5	IU	4-tert-butyl-N-(2-propan-2-ylphenyl)-1,3-thiazol-2-amine
DMDWRE5	DE	Discovery agent

DMLFZ6Q	ID	DMLFZ6Q
DMLFZ6Q	DN	4-tert-Butyl-N-(4-phenyl-thiazol-2-yl)-benzamide
DMLFZ6Q	HS	Investigative
DMLFZ6Q	SN	4-tert-Butyl-N-(4-phenyl-thiazol-2-yl)-benzamide; CHEMBL293635; 4-tert-butyl-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; BAS 03572060; AC1Q1LYP; AC1LGN92; Oprea1_621031; Oprea1_258896; MolPort-001-030-330; ZINC342768; BDBM50101785; STK401915; AKOS000569708; MCULE-2080665457; ST50017828; N-(4-Phenyl-2-thiazolyl)-4-tert-butylbenzamide; AG-690/09665053
DMLFZ6Q	DT	Small molecular drug
DMLFZ6Q	PC	824266
DMLFZ6Q	MW	336.5
DMLFZ6Q	FM	C20H20N2OS
DMLFZ6Q	IC	InChI=1S/C20H20N2OS/c1-20(2,3)16-11-9-15(10-12-16)18(23)22-19-21-17(13-24-19)14-7-5-4-6-8-14/h4-13H,1-3H3,(H,21,22,23)
DMLFZ6Q	CS	CC(C)(C)C1=CC=C(C=C1)C(=O)NC2=NC(=CS2)C3=CC=CC=C3
DMLFZ6Q	IK	JXOGYJOCFUSOPS-UHFFFAOYSA-N
DMLFZ6Q	IU	4-tert-butyl-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMLFZ6Q	DE	Discovery agent

DM5U6ZW	ID	DM5U6ZW
DM5U6ZW	DN	4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine
DM5U6ZW	HS	Investigative
DM5U6ZW	SN	CHEMBL206878; 4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine
DM5U6ZW	DT	Small molecular drug
DM5U6ZW	PC	44411037
DM5U6ZW	MW	266.34
DM5U6ZW	FM	C17H18N2O
DM5U6ZW	IC	InChI=1S/C17H18N2O/c1-17(2,3)15-11-20-16(19-15)18-14-10-6-8-12-7-4-5-9-13(12)14/h4-11H,1-3H3,(H,18,19)
DM5U6ZW	CS	CC(C)(C)C1=COC(=N1)NC2=CC=CC3=CC=CC=C32
DM5U6ZW	IK	RDWFLGKWZJPVFQ-UHFFFAOYSA-N
DM5U6ZW	IU	4-tert-butyl-N-naphthalen-1-yl-1,3-oxazol-2-amine
DM5U6ZW	DE	Discovery agent

DMBUZ75	ID	DMBUZ75
DMBUZ75	DN	4-tert-butyl-N-(naphthalen-1-yl)thiazol-2-amine
DMBUZ75	HS	Investigative
DMBUZ75	SN	CHEMBL379460; 4-tert-butyl-N-(naphthalen-1-yl)thiazol-2-amine; SCHEMBL14433284; ZINC36159661
DMBUZ75	DT	Small molecular drug
DMBUZ75	PC	9814340
DMBUZ75	MW	282.4
DMBUZ75	FM	C17H18N2S
DMBUZ75	IC	InChI=1S/C17H18N2S/c1-17(2,3)15-11-20-16(19-15)18-14-10-6-8-12-7-4-5-9-13(12)14/h4-11H,1-3H3,(H,18,19)
DMBUZ75	CS	CC(C)(C)C1=CSC(=N1)NC2=CC=CC3=CC=CC=C32
DMBUZ75	IK	TXEFBOQHGSOELC-UHFFFAOYSA-N
DMBUZ75	IU	4-tert-butyl-N-naphthalen-1-yl-1,3-thiazol-2-amine
DMBUZ75	DE	Discovery agent

DM1OBHQ	ID	DM1OBHQ
DM1OBHQ	DN	4-tert-butyl-N-(quinolin-3-yl)benzamide
DM1OBHQ	HS	Investigative
DM1OBHQ	SN	CHEMBL258917; 331850-72-7; 4-tert-butyl-N-(quinolin-3-yl)benzamide; AC1LGMQ4; Oprea1_306931; Oprea1_506548; SCHEMBL846396; CTK1B8678; DTXSID30355358; MolPort-001-496-766; ZINC302143; BDBM50376277; AKOS000637295; MCULE-9209807944; 4-tert-butyl-N-quinolin-3-ylbenzamide; 4-tert-Butyl-N-quinolin-3-yl-benzamide; BAS 00631860; ST45006323; [4-(tert-butyl)phenyl]-N-(3-quinolyl)carboxamide; Benzamide, 4-(1,1-dimethylethyl)-N-3-quinolinyl-
DM1OBHQ	DT	Small molecular drug
DM1OBHQ	PC	797382
DM1OBHQ	MW	304.4
DM1OBHQ	FM	C20H20N2O
DM1OBHQ	IC	InChI=1S/C20H20N2O/c1-20(2,3)16-10-8-14(9-11-16)19(23)22-17-12-15-6-4-5-7-18(15)21-13-17/h4-13H,1-3H3,(H,22,23)
DM1OBHQ	CS	CC(C)(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM1OBHQ	IK	MUZWQZALZQTMBA-UHFFFAOYSA-N
DM1OBHQ	IU	4-tert-butyl-N-quinolin-3-ylbenzamide
DM1OBHQ	CA	CAS 331850-72-7
DM1OBHQ	DE	Discovery agent

DMUWTPX	ID	DMUWTPX
DMUWTPX	DN	4-tert-butyl-N-hydroxybenzamide
DMUWTPX	HS	Investigative
DMUWTPX	SN	4-tert-butyl-N-hydroxybenzamide; 62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279
DMUWTPX	DT	Small molecular drug
DMUWTPX	PC	21397854
DMUWTPX	MW	193.24
DMUWTPX	FM	C11H15NO2
DMUWTPX	IC	InChI=1S/C11H15NO2/c1-11(2,3)9-6-4-8(5-7-9)10(13)12-14/h4-7,14H,1-3H3,(H,12,13)
DMUWTPX	CS	CC(C)(C)C1=CC=C(C=C1)C(=O)NO
DMUWTPX	IK	HVTKRCPHQXJOFW-UHFFFAOYSA-N
DMUWTPX	IU	4-tert-butyl-N-hydroxybenzamide
DMUWTPX	CA	CAS 62034-73-5
DMUWTPX	DE	Discovery agent

DM9K27Q	ID	DM9K27Q
DM9K27Q	DN	4-tert-butyl-N-m-tolylthiazol-2-amine
DM9K27Q	HS	Investigative
DM9K27Q	SN	CHEMBL438248; 4-tert-butyl-N-m-tolylthiazol-2-amine; ZINC36159723
DM9K27Q	DT	Small molecular drug
DM9K27Q	PC	44411325
DM9K27Q	MW	246.37
DM9K27Q	FM	C14H18N2S
DM9K27Q	IC	InChI=1S/C14H18N2S/c1-10-6-5-7-11(8-10)15-13-16-12(9-17-13)14(2,3)4/h5-9H,1-4H3,(H,15,16)
DM9K27Q	CS	CC1=CC(=CC=C1)NC2=NC(=CS2)C(C)(C)C
DM9K27Q	IK	JCIZSRYCZWHMQK-UHFFFAOYSA-N
DM9K27Q	IU	4-tert-butyl-N-(3-methylphenyl)-1,3-thiazol-2-amine
DM9K27Q	DE	Discovery agent

DMJQFD5	ID	DMJQFD5
DMJQFD5	DN	4-tert-butyl-N-o-tolylthiazol-2-amine
DMJQFD5	HS	Investigative
DMJQFD5	SN	CHEMBL382244; 4-tert-butyl-N-o-tolylthiazol-2-amine; BDBM50183109
DMJQFD5	DT	Small molecular drug
DMJQFD5	PC	44411322
DMJQFD5	MW	246.37
DMJQFD5	FM	C14H18N2S
DMJQFD5	IC	InChI=1S/C14H18N2S/c1-10-7-5-6-8-11(10)15-13-16-12(9-17-13)14(2,3)4/h5-9H,1-4H3,(H,15,16)
DMJQFD5	CS	CC1=CC=CC=C1NC2=NC(=CS2)C(C)(C)C
DMJQFD5	IK	LGKMKCIPKKOAPX-UHFFFAOYSA-N
DMJQFD5	IU	4-tert-butyl-N-(2-methylphenyl)-1,3-thiazol-2-amine
DMJQFD5	DE	Discovery agent

DM5CPBK	ID	DM5CPBK
DM5CPBK	DN	4-tert-butyl-N-phenylthiazol-2-amine
DM5CPBK	HS	Investigative
DM5CPBK	SN	CHEMBL206103; 4-tert-butyl-N-phenylthiazol-2-amine; SCHEMBL5486145; ZINC2161671; BDBM50183112; N-Phenyl-4-tert-butyl-2-thiazolamine
DM5CPBK	DT	Small molecular drug
DM5CPBK	PC	9899450
DM5CPBK	MW	232.35
DM5CPBK	FM	C13H16N2S
DM5CPBK	IC	InChI=1S/C13H16N2S/c1-13(2,3)11-9-16-12(15-11)14-10-7-5-4-6-8-10/h4-9H,1-3H3,(H,14,15)
DM5CPBK	CS	CC(C)(C)C1=CSC(=N1)NC2=CC=CC=C2
DM5CPBK	IK	OZPRKERRJSPXIW-UHFFFAOYSA-N
DM5CPBK	IU	4-tert-butyl-N-phenyl-1,3-thiazol-2-amine
DM5CPBK	DE	Discovery agent

DMUGMVI	ID	DMUGMVI
DMUGMVI	DN	4-Thiocyanato-benzenesulfonamide
DMUGMVI	HS	Investigative
DMUGMVI	SN	4-Thiocyanato-benzenesulfonamide; CHEMBL363086; NSC166291; AC1L6PWF; (4-sulfamoylphenyl) thiocyanate; SCHEMBL16407107; ZINC1655602; BDBM50155502; NSC-166291
DMUGMVI	DT	Small molecular drug
DMUGMVI	PC	296284
DMUGMVI	MW	214.3
DMUGMVI	FM	C7H6N2O2S2
DMUGMVI	IC	InChI=1S/C7H6N2O2S2/c8-5-12-6-1-3-7(4-2-6)13(9,10)11/h1-4H,(H2,9,10,11)
DMUGMVI	CS	C1=CC(=CC=C1SC#N)S(=O)(=O)N
DMUGMVI	IK	JAOXYZVWRQDPGB-UHFFFAOYSA-N
DMUGMVI	IU	(4-sulfamoylphenyl) thiocyanate
DMUGMVI	DE	Discovery agent

DMA8SHN	ID	DMA8SHN
DMA8SHN	DN	4-Thiomorpholin-4-yl-benzo[g]chromen-2-one
DMA8SHN	HS	Investigative
DMA8SHN	SN	CHEMBL179640; 4-Thiomorpholin-4-yl-benzo[g]chromen-2-one
DMA8SHN	DT	Small molecular drug
DMA8SHN	PC	11358426
DMA8SHN	MW	297.4
DMA8SHN	FM	C17H15NO2S
DMA8SHN	IC	InChI=1S/C17H15NO2S/c19-17-11-15(18-5-7-21-8-6-18)14-9-12-3-1-2-4-13(12)10-16(14)20-17/h1-4,9-11H,5-8H2
DMA8SHN	CS	C1CSCCN1C2=CC(=O)OC3=CC4=CC=CC=C4C=C23
DMA8SHN	IK	UYBNTAODFKOXIU-UHFFFAOYSA-N
DMA8SHN	IU	4-thiomorpholin-4-ylbenzo[g]chromen-2-one
DMA8SHN	DE	Discovery agent

DM7YOXW	ID	DM7YOXW
DM7YOXW	DN	4-thio-UTP
DM7YOXW	HS	Investigative
DM7YOXW	SN	4-S-UTP; 4-thiouridine triphosphate
DM7YOXW	DT	Small molecular drug
DM7YOXW	PC	3033941
DM7YOXW	MW	500.21
DM7YOXW	FM	C9H15N2O14P3S
DM7YOXW	IC	InChI=1S/C9H15N2O14P3S/c12-6-4(3-22-27(18,19)25-28(20,21)24-26(15,16)17)23-8(7(6)13)11-2-1-5(29)10-9(11)14/h1-2,4,6-8,12-13H,3H2,(H,18,19)(H,20,21)(H,10,14,29)(H2,15,16,17)/t4-,6-,7-,8-/m1/s1
DM7YOXW	CS	C1=CN(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DM7YOXW	IK	GKVHYBAWZAYQDO-XVFCMESISA-N
DM7YOXW	IU	[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-oxo-4-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM7YOXW	CA	CAS 31556-28-2
DM7YOXW	DE	Discovery agent

DMT81SD	ID	DMT81SD
DMT81SD	DN	4'-trifluoromethyl-biphenyl-4-ylamine
DMT81SD	HS	Investigative
DMT81SD	SN	57688-34-3; 4'-(trifluoromethyl)-[1,1'-biphenyl]-4-amine; 4'-trifluoromethylbiphenyl-4-ylamine; 4-[4-(trifluoromethyl)phenyl]aniline; 4'-trifluoromethyl-biphenyl-4-ylamine; [1,1'-biphenyl]-4-amine, 4'-(trifluoromethyl)-; CHEMBL242142; 4'-(trifluoromethyl)biphenyl-4-amine; 4'-(trifluoromethyl)[1,1'-biphenyl]-4-amine; [1,1'-Biphenyl]-4-amine,4'-(trifluoromethyl)-; ACMC-1AWVA; AC1MD2WS; SCHEMBL2655246; CTK5A7284; DTXSID50382227; PDKIAMYXBRKPBW-UHFFFAOYSA-N; MolPort-000-159-036; 4-amino-4'-trifluoromethyldiphenyl; ZINC2574122
DMT81SD	DT	Small molecular drug
DMT81SD	PC	2782709
DMT81SD	MW	237.22
DMT81SD	FM	C13H10F3N
DMT81SD	IC	InChI=1S/C13H10F3N/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(17)8-4-10/h1-8H,17H2
DMT81SD	CS	C1=CC(=CC=C1C2=CC=C(C=C2)N)C(F)(F)F
DMT81SD	IK	PDKIAMYXBRKPBW-UHFFFAOYSA-N
DMT81SD	IU	4-[4-(trifluoromethyl)phenyl]aniline
DMT81SD	CA	CAS 57688-34-3
DMT81SD	DE	Discovery agent

DML4DSG	ID	DML4DSG
DML4DSG	DN	5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline
DML4DSG	HS	Investigative
DML4DSG	SN	CHEMBL53068; dihydroquinoline 44; BDBM10025; ZINC13808186; 5-(1H-imidazol-1-ylmethyl)-7,8-dihydroquinoline; 5-[(Imidazol-1-yl)methyl]-7,8-dihydroquinoline
DML4DSG	DT	Small molecular drug
DML4DSG	PC	10774864
DML4DSG	MW	211.26
DML4DSG	FM	C13H13N3
DML4DSG	IC	InChI=1S/C13H13N3/c1-3-11(9-16-8-7-14-10-16)12-4-2-6-15-13(12)5-1/h2-4,6-8,10H,1,5,9H2
DML4DSG	CS	C1CC2=C(C=CC=N2)C(=C1)CN3C=CN=C3
DML4DSG	IK	DVAOHPCQHIOCSM-UHFFFAOYSA-N
DML4DSG	IU	5-(imidazol-1-ylmethyl)-7,8-dihydroquinoline
DML4DSG	DE	Discovery agent

DMBSFLW	ID	DMBSFLW
DMBSFLW	DN	5-((6-Methylpyridin-2-yl)ethynyl)nicotinonitrile
DMBSFLW	HS	Investigative
DMBSFLW	SN	CHEMBL1098656; 5-((6-Methylpyridin-2-yl)ethynyl)nicotinonitrile
DMBSFLW	DT	Small molecular drug
DMBSFLW	PC	46861851
DMBSFLW	MW	219.24
DMBSFLW	FM	C14H9N3
DMBSFLW	IC	InChI=1S/C14H9N3/c1-11-3-2-4-14(17-11)6-5-12-7-13(8-15)10-16-9-12/h2-4,7,9-10H,1H3
DMBSFLW	CS	CC1=NC(=CC=C1)C#CC2=CC(=CN=C2)C#N
DMBSFLW	IK	ZWOWJRDKGWIZDL-UHFFFAOYSA-N
DMBSFLW	IU	5-[2-(6-methylpyridin-2-yl)ethynyl]pyridine-3-carbonitrile
DMBSFLW	DE	Discovery agent

DMH0QA7	ID	DMH0QA7
DMH0QA7	DN	5-((E)-Styryl)-quinazoline-2,4-diamine
DMH0QA7	HS	Investigative
DMH0QA7	SN	CHEMBL164845; 5-((E)-Styryl)-quinazoline-2,4-diamine; AC1O6QWN; ZINC5974460; BDBM50036484
DMH0QA7	DT	Small molecular drug
DMH0QA7	PC	6532431
DMH0QA7	MW	262.31
DMH0QA7	FM	C16H14N4
DMH0QA7	IC	InChI=1S/C16H14N4/c17-15-14-12(10-9-11-5-2-1-3-6-11)7-4-8-13(14)19-16(18)20-15/h1-10H,(H4,17,18,19,20)/b10-9+
DMH0QA7	CS	C1=CC=C(C=C1)/C=C/C2=C3C(=CC=C2)N=C(N=C3N)N
DMH0QA7	IK	YPIDSPOROIRHIL-MDZDMXLPSA-N
DMH0QA7	IU	5-[(E)-2-phenylethenyl]quinazoline-2,4-diamine
DMH0QA7	DE	Discovery agent

DMT6D5V	ID	DMT6D5V
DMT6D5V	DN	5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine
DMT6D5V	HS	Investigative
DMT6D5V	SN	123642-27-3; AC1O6FAJ; SCHEMBL13092296; 2-[[[(Z)-4-aminobut-2-enyl]-methylamino]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol
DMT6D5V	DT	Small molecular drug
DMT6D5V	PC	6474401
DMT6D5V	MW	349.39
DMT6D5V	FM	C15H23N7O3
DMT6D5V	IC	InChI=1S/C15H23N7O3/c1-21(5-3-2-4-16)6-9-11(23)12(24)15(25-9)22-8-20-10-13(17)18-7-19-14(10)22/h2-3,7-9,11-12,15,23-24H,4-6,16H2,1H3,(H2,17,18,19)/b3-2-
DMT6D5V	CS	CN(C/C=C\\CN)CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O
DMT6D5V	IK	YWJCZGDVJQLZET-IHWYPQMZSA-N
DMT6D5V	IU	2-[[[(Z)-4-aminobut-2-enyl]-methylamino]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol
DMT6D5V	DE	Discovery agent

DMS31H9	ID	DMS31H9
DMS31H9	DN	5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol
DMS31H9	HS	Investigative
DMS31H9	SN	CHEMBL234207; 5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol; SCHEMBL4888568; OYBDWAVFBKZYIO-UHFFFAOYSA-N; BDBM50213139; 5-(1,1-Dimethylheptyl)-2-pyridin-3-yl phenol
DMS31H9	DT	Small molecular drug
DMS31H9	PC	11551123
DMS31H9	MW	297.4
DMS31H9	FM	C20H27NO
DMS31H9	IC	InChI=1S/C20H27NO/c1-4-5-6-7-12-20(2,3)17-10-11-18(19(22)14-17)16-9-8-13-21-15-16/h8-11,13-15,22H,4-7,12H2,1-3H3
DMS31H9	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CN=CC=C2)O
DMS31H9	IK	OYBDWAVFBKZYIO-UHFFFAOYSA-N
DMS31H9	IU	5-(2-methyloctan-2-yl)-2-pyridin-3-ylphenol
DMS31H9	DE	Discovery agent

DMMSK9W	ID	DMMSK9W
DMMSK9W	DN	5-(1-Methyl-pyrrolidin-2-yl)-2-phenethyl-pyridine
DMMSK9W	HS	Investigative
DMMSK9W	SN	CHEMBL190295; 5-(1-Methyl-pyrrolidin-2-yl)-2-phenethyl-pyridine; SCHEMBL11307517; (+/-)6-(2-Phenylethyl)nicotine
DMMSK9W	DT	Small molecular drug
DMMSK9W	PC	11644688
DMMSK9W	MW	266.4
DMMSK9W	FM	C18H22N2
DMMSK9W	IC	InChI=1S/C18H22N2/c1-20-13-5-8-18(20)16-10-12-17(19-14-16)11-9-15-6-3-2-4-7-15/h2-4,6-7,10,12,14,18H,5,8-9,11,13H2,1H3
DMMSK9W	CS	CN1CCCC1C2=CN=C(C=C2)CCC3=CC=CC=C3
DMMSK9W	IK	YJFYNYHEHYBROJ-UHFFFAOYSA-N
DMMSK9W	IU	5-(1-methylpyrrolidin-2-yl)-2-(2-phenylethyl)pyridine
DMMSK9W	DE	Discovery agent

DMA2GIE	ID	DMA2GIE
DMA2GIE	DN	5-(2-(1H-imidazol-1-yl)ethyl)quinoline
DMA2GIE	HS	Investigative
DMA2GIE	SN	CHEMBL54803; quinoline 33; BDBM10028; ZINC13808193; 5-[2-(Imidazol-1-yl)ethyl]quinoline; 5-[2-(1H-imidazol-1-yl)ethyl]quinoline
DMA2GIE	DT	Small molecular drug
DMA2GIE	PC	10751574
DMA2GIE	MW	223.27
DMA2GIE	FM	C14H13N3
DMA2GIE	IC	InChI=1S/C14H13N3/c1-3-12(6-9-17-10-8-15-11-17)13-4-2-7-16-14(13)5-1/h1-5,7-8,10-11H,6,9H2
DMA2GIE	CS	C1=CC(=C2C=CC=NC2=C1)CCN3C=CN=C3
DMA2GIE	IK	AVFNKJKCERQPJI-UHFFFAOYSA-N
DMA2GIE	IU	5-(2-imidazol-1-ylethyl)quinoline
DMA2GIE	DE	Discovery agent

DMCFKGW	ID	DMCFKGW
DMCFKGW	DN	5-(2-(2,5-dimethylphenyl)ethynyl)pyrimidine
DMCFKGW	HS	Investigative
DMCFKGW	SN	CHEMBL453979; 5-(2-(2,5-dimethylphenyl)ethynyl)pyrimidine
DMCFKGW	DT	Small molecular drug
DMCFKGW	PC	44560633
DMCFKGW	MW	208.26
DMCFKGW	FM	C14H12N2
DMCFKGW	IC	InChI=1S/C14H12N2/c1-11-3-4-12(2)14(7-11)6-5-13-8-15-10-16-9-13/h3-4,7-10H,1-2H3
DMCFKGW	CS	CC1=CC(=C(C=C1)C)C#CC2=CN=CN=C2
DMCFKGW	IK	XOIZHMAWDAZINA-UHFFFAOYSA-N
DMCFKGW	IU	5-[2-(2,5-dimethylphenyl)ethynyl]pyrimidine
DMCFKGW	DE	Discovery agent

DM3XMKJ	ID	DM3XMKJ
DM3XMKJ	DN	5-(2-(3,5-difluorophenyl)ethynyl)pyrimidine
DM3XMKJ	HS	Investigative
DM3XMKJ	SN	CHEMBL488233; 5-(2-(3,5-difluorophenyl)ethynyl)pyrimidine
DM3XMKJ	DT	Small molecular drug
DM3XMKJ	PC	44560631
DM3XMKJ	MW	216.19
DM3XMKJ	FM	C12H6F2N2
DM3XMKJ	IC	InChI=1S/C12H6F2N2/c13-11-3-9(4-12(14)5-11)1-2-10-6-15-8-16-7-10/h3-8H
DM3XMKJ	CS	C1=C(C=C(C=C1F)F)C#CC2=CN=CN=C2
DM3XMKJ	IK	AFBRTODAYUUWDJ-UHFFFAOYSA-N
DM3XMKJ	IU	5-[2-(3,5-difluorophenyl)ethynyl]pyrimidine
DM3XMKJ	DE	Discovery agent

DM37KG6	ID	DM37KG6
DM37KG6	DN	5-(2-(3-chlorophenyl)ethynyl)pyrimidine
DM37KG6	HS	Investigative
DM37KG6	SN	CHEMBL487870; 5-(2-(3-chlorophenyl)ethynyl)pyrimidine; SCHEMBL13732174
DM37KG6	DT	Small molecular drug
DM37KG6	PC	24894086
DM37KG6	MW	214.65
DM37KG6	FM	C12H7ClN2
DM37KG6	IC	InChI=1S/C12H7ClN2/c13-12-3-1-2-10(6-12)4-5-11-7-14-9-15-8-11/h1-3,6-9H
DM37KG6	CS	C1=CC(=CC(=C1)Cl)C#CC2=CN=CN=C2
DM37KG6	IK	BYUKCJHVLPJKLQ-UHFFFAOYSA-N
DM37KG6	IU	5-[2-(3-chlorophenyl)ethynyl]pyrimidine
DM37KG6	DE	Discovery agent

DMRS1Q5	ID	DMRS1Q5
DMRS1Q5	DN	5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine
DMRS1Q5	HS	Investigative
DMRS1Q5	SN	CHEMBL488232; 5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine
DMRS1Q5	DT	Small molecular drug
DMRS1Q5	PC	44560630
DMRS1Q5	MW	212.22
DMRS1Q5	FM	C13H9FN2
DMRS1Q5	IC	InChI=1S/C13H9FN2/c1-10-6-11(4-5-13(10)14)2-3-12-7-15-9-16-8-12/h4-9H,1H3
DMRS1Q5	CS	CC1=C(C=CC(=C1)C#CC2=CN=CN=C2)F
DMRS1Q5	IK	DCUICHQOGTUMNS-UHFFFAOYSA-N
DMRS1Q5	IU	5-[2-(4-fluoro-3-methylphenyl)ethynyl]pyrimidine
DMRS1Q5	DE	Discovery agent

DMXAF7Y	ID	DMXAF7Y
DMXAF7Y	DN	5-(2-(pyrrolidin-1-yl)ethyl)isothiazole
DMXAF7Y	HS	Investigative
DMXAF7Y	SN	CHEMBL272131
DMXAF7Y	DT	Small molecular drug
DMXAF7Y	PC	44456451
DMXAF7Y	MW	182.29
DMXAF7Y	FM	C9H14N2S
DMXAF7Y	IC	InChI=1S/C9H14N2S/c1-2-7-11(6-1)8-4-9-3-5-10-12-9/h3,5H,1-2,4,6-8H2
DMXAF7Y	CS	C1CCN(C1)CCC2=CC=NS2
DMXAF7Y	IK	GRXWPIZSBSTAQX-UHFFFAOYSA-N
DMXAF7Y	IU	5-(2-pyrrolidin-1-ylethyl)-1,2-thiazole
DMXAF7Y	DE	Discovery agent

DM149IX	ID	DM149IX
DM149IX	DN	5-(2-1H-indenyl)-1,3-benzodioxole
DM149IX	HS	Investigative
DM149IX	SN	CHEMBL229139; 5-(2-1H-indenyl)-1,3-benzodioxole; BDBM50217118
DM149IX	DT	Small molecular drug
DM149IX	PC	44424411
DM149IX	MW	236.26
DM149IX	FM	C16H12O2
DM149IX	IC	InChI=1S/C16H12O2/c1-2-4-12-8-14(7-11(12)3-1)13-5-6-15-16(9-13)18-10-17-15/h1-7,9H,8,10H2
DM149IX	CS	C1C2=CC=CC=C2C=C1C3=CC4=C(C=C3)OCO4
DM149IX	IK	JPKHJTXWUUOHEF-UHFFFAOYSA-N
DM149IX	IU	5-(1H-inden-2-yl)-1,3-benzodioxole
DM149IX	DE	Discovery agent

DMJXI65	ID	DMJXI65
DMJXI65	DN	5-(2-Amino-ethyl)-2-chloro-phenol hydrobromide
DMJXI65	HS	Investigative
DMJXI65	DE	Discovery agent

DMQCYEK	ID	DMQCYEK
DMQCYEK	DN	5-(2-fluorobenzyloxy)quinazoline-2,4-diamine
DMQCYEK	HS	Investigative
DMQCYEK	SN	CHEMBL251427; 5-(2-fluorobenzyloxy)quinazoline-2,4-diamine; SCHEMBL1154761
DMQCYEK	DT	Small molecular drug
DMQCYEK	PC	24778025
DMQCYEK	MW	284.29
DMQCYEK	FM	C15H13FN4O
DMQCYEK	IC	InChI=1S/C15H13FN4O/c16-10-5-2-1-4-9(10)8-21-12-7-3-6-11-13(12)14(17)20-15(18)19-11/h1-7H,8H2,(H4,17,18,19,20)
DMQCYEK	CS	C1=CC=C(C(=C1)COC2=CC=CC3=C2C(=NC(=N3)N)N)F
DMQCYEK	IK	SFJOSBAEWKPKPY-UHFFFAOYSA-N
DMQCYEK	IU	5-[(2-fluorophenyl)methoxy]quinazoline-2,4-diamine
DMQCYEK	DE	Discovery agent

DMHBD1T	ID	DMHBD1T
DMHBD1T	DN	5-(2-hydroxyethyl)nonane-1,9-diol
DMHBD1T	HS	Investigative
DMHBD1T	SN	5-(2-Hydroxyethyl)nonane-1,9-Diol; DB07171
DMHBD1T	DT	Small molecular drug
DMHBD1T	PC	25058136
DMHBD1T	MW	204.31
DMHBD1T	FM	C11H24O3
DMHBD1T	IC	InChI=1S/C11H24O3/c12-8-3-1-5-11(7-10-14)6-2-4-9-13/h11-14H,1-10H2
DMHBD1T	CS	C(CCO)CC(CCCCO)CCO
DMHBD1T	IK	VICIXNZSEUYGFV-UHFFFAOYSA-N
DMHBD1T	IU	5-(2-hydroxyethyl)nonane-1,9-diol
DMHBD1T	DE	Discovery agent

DMCP5U8	ID	DMCP5U8
DMCP5U8	DN	5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline
DMCP5U8	HS	Investigative
DMCP5U8	SN	CHEMBL293122; dihydroquinoline 31; BDBM10027; ZINC13808192; 5-[2-(Imidazol-1-yl)ethyl]-7,8-dihydroquinoline; 5-[2-(1H-imidazol-1-yl)ethyl]-7,8-dihydroquinoline
DMCP5U8	DT	Small molecular drug
DMCP5U8	PC	10561174
DMCP5U8	MW	225.29
DMCP5U8	FM	C14H15N3
DMCP5U8	IC	InChI=1S/C14H15N3/c1-3-12(6-9-17-10-8-15-11-17)13-4-2-7-16-14(13)5-1/h2-4,7-8,10-11H,1,5-6,9H2
DMCP5U8	CS	C1CC2=C(C=CC=N2)C(=C1)CCN3C=CN=C3
DMCP5U8	IK	DJMSMHXCSIBVSA-UHFFFAOYSA-N
DMCP5U8	IU	5-(2-imidazol-1-ylethyl)-7,8-dihydroquinoline
DMCP5U8	DE	Discovery agent

DMV3KBE	ID	DMV3KBE
DMV3KBE	DN	5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline
DMV3KBE	HS	Investigative
DMV3KBE	SN	1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine; 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 84477-87-2; H-7; 5-(2-methylpiperazine-1-sulfonyl)isoquinoline; H 7; H7; Piperazine, 1-(5-isoquinolinylsulfonyl)-2-methyl-; BRN 5482740; MLS000069615; CHEMBL323556; CHEBI:43385; Isoquinoline,5-[(2-methyl-1-piperazinyl)sulfonyl]-,hydrochloride (1:2); 5-[(2-methylpiperazin-1-yl)sulfonyl]isoquinoline; SMR000058749; Isoquinoline-5-sulfonic 2-methyl-1-piperazide; 5-(2-methylpiperazin-1-yl)sulfonylisoquinoline; Piperazine, 1-(5-isoquino
DMV3KBE	DT	Small molecular drug
DMV3KBE	PC	3542
DMV3KBE	MW	291.37
DMV3KBE	FM	C14H17N3O2S
DMV3KBE	IC	InChI=1S/C14H17N3O2S/c1-11-9-16-7-8-17(11)20(18,19)14-4-2-3-12-10-15-6-5-13(12)14/h2-6,10-11,16H,7-9H2,1H3
DMV3KBE	CS	CC1CNCCN1S(=O)(=O)C2=CC=CC3=C2C=CN=C3
DMV3KBE	IK	BDVFVCGFMNCYPV-UHFFFAOYSA-N
DMV3KBE	IU	5-(2-methylpiperazin-1-yl)sulfonylisoquinoline
DMV3KBE	CA	CAS 84477-87-2
DMV3KBE	CB	CHEBI:43385
DMV3KBE	DE	Discovery agent

DMIQJM4	ID	DMIQJM4
DMIQJM4	DN	5-(2-Methylquinolin-7-yl)-2-phenylbenzonitrile
DMIQJM4	HS	Investigative
DMIQJM4	SN	CHEMBL1099113; 5-(2-Methylquinolin-7-yl)-2-phenylbenzonitrile
DMIQJM4	DT	Small molecular drug
DMIQJM4	PC	46888045
DMIQJM4	MW	320.4
DMIQJM4	FM	C23H16N2
DMIQJM4	IC	InChI=1S/C23H16N2/c1-16-7-8-18-9-10-20(14-23(18)25-16)19-11-12-22(21(13-19)15-24)17-5-3-2-4-6-17/h2-14H,1H3
DMIQJM4	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=C(C=C3)C4=CC=CC=C4)C#N
DMIQJM4	IK	AGKCPUQJKJZENU-UHFFFAOYSA-N
DMIQJM4	IU	5-(2-methylquinolin-7-yl)-2-phenylbenzonitrile
DMIQJM4	DE	Discovery agent

DMO74HX	ID	DMO74HX
DMO74HX	DN	5-(2-Methylquinolin-7-yl)-2-phenylnicotinonitrile
DMO74HX	HS	Investigative
DMO74HX	SN	CHEMBL1096197; 5-(2-Methylquinolin-7-yl)-2-phenylnicotinonitrile
DMO74HX	DT	Small molecular drug
DMO74HX	PC	46888089
DMO74HX	MW	321.4
DMO74HX	FM	C22H15N3
DMO74HX	IC	InChI=1S/C22H15N3/c1-15-7-8-16-9-10-18(12-21(16)25-15)20-11-19(13-23)22(24-14-20)17-5-3-2-4-6-17/h2-12,14H,1H3
DMO74HX	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=C(N=C3)C4=CC=CC=C4)C#N
DMO74HX	IK	NENPIXNGFVWRLL-UHFFFAOYSA-N
DMO74HX	IU	5-(2-methylquinolin-7-yl)-2-phenylpyridine-3-carbonitrile
DMO74HX	DE	Discovery agent

DMMX69H	ID	DMMX69H
DMMX69H	DN	5-(2-methylquinolin-7-yl)isophthalonitrile
DMMX69H	HS	Investigative
DMMX69H	SN	CHEMBL231788; 5-(2-methylquinolin-7-yl)isophthalonitrile; SCHEMBL4304888
DMMX69H	DT	Small molecular drug
DMMX69H	PC	44432677
DMMX69H	MW	269.3
DMMX69H	FM	C18H11N3
DMMX69H	IC	InChI=1S/C18H11N3/c1-12-2-3-15-4-5-16(9-18(15)21-12)17-7-13(10-19)6-14(8-17)11-20/h2-9H,1H3
DMMX69H	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)C#N
DMMX69H	IK	KVBFHKKSOXHZCJ-UHFFFAOYSA-N
DMMX69H	IU	5-(2-methylquinolin-7-yl)benzene-1,3-dicarbonitrile
DMMX69H	DE	Discovery agent

DM8LN2X	ID	DM8LN2X
DM8LN2X	DN	5-(2-methylquinolin-7-yl)nicotinonitrile
DM8LN2X	HS	Investigative
DM8LN2X	SN	CHEMBL233418; 5-(2-methylquinolin-7-yl)nicotinonitrile
DM8LN2X	DT	Small molecular drug
DM8LN2X	PC	44178396
DM8LN2X	MW	245.28
DM8LN2X	FM	C16H11N3
DM8LN2X	IC	InChI=1S/C16H11N3/c1-11-2-3-13-4-5-14(7-16(13)19-11)15-6-12(8-17)9-18-10-15/h2-7,9-10H,1H3
DM8LN2X	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CN=CC(=C3)C#N
DM8LN2X	IK	AYJCNPHACWMDIG-UHFFFAOYSA-N
DM8LN2X	IU	5-(2-methylquinolin-7-yl)pyridine-3-carbonitrile
DM8LN2X	DE	Discovery agent

DMO5WG8	ID	DMO5WG8
DMO5WG8	DN	5-(2-m-tolylethynyl)pyrimidine
DMO5WG8	HS	Investigative
DMO5WG8	SN	5-(M-Tolylethynyl)Pyrimidine; CHEMBL508497; 5-(2-m-tolylethynyl)pyrimidine
DMO5WG8	DT	Small molecular drug
DMO5WG8	PC	24894087
DMO5WG8	MW	194.23
DMO5WG8	FM	C13H10N2
DMO5WG8	IC	InChI=1S/C13H10N2/c1-11-3-2-4-12(7-11)5-6-13-8-14-10-15-9-13/h2-4,7-10H,1H3
DMO5WG8	CS	CC1=CC(=CC=C1)C#CC2=CN=CN=C2
DMO5WG8	IK	WDWDORGIXVCIQC-UHFFFAOYSA-N
DMO5WG8	IU	5-[2-(3-methylphenyl)ethynyl]pyrimidine
DMO5WG8	DE	Discovery agent

DMR7OHB	ID	DMR7OHB
DMR7OHB	DN	5-(2-oxoindolin-5-yl)-1H-pyrrole-2-carbonitrile
DMR7OHB	HS	Investigative
DMR7OHB	SN	CHEMBL270909
DMR7OHB	DT	Small molecular drug
DMR7OHB	PC	24824217
DMR7OHB	MW	223.23
DMR7OHB	FM	C13H9N3O
DMR7OHB	IC	InChI=1S/C13H9N3O/c14-7-10-2-4-11(15-10)8-1-3-12-9(5-8)6-13(17)16-12/h1-5,15H,6H2,(H,16,17)
DMR7OHB	CS	C1C2=C(C=CC(=C2)C3=CC=C(N3)C#N)NC1=O
DMR7OHB	IK	TVDRXBFEEAXOTN-UHFFFAOYSA-N
DMR7OHB	IU	5-(2-oxo-1,3-dihydroindol-5-yl)-1H-pyrrole-2-carbonitrile
DMR7OHB	DE	Discovery agent

DM07P5E	ID	DM07P5E
DM07P5E	DN	5-(2-phenethylpiperazin-1-yl)-1H-indazole
DM07P5E	HS	Investigative
DM07P5E	SN	CHEMBL1170373; 5-(2-phenethylpiperazin-1-yl)-1H-indazole; SCHEMBL2944873
DM07P5E	DT	Small molecular drug
DM07P5E	PC	49798218
DM07P5E	MW	306.4
DM07P5E	FM	C19H22N4
DM07P5E	IC	InChI=1S/C19H22N4/c1-2-4-15(5-3-1)6-7-18-14-20-10-11-23(18)17-8-9-19-16(12-17)13-21-22-19/h1-5,8-9,12-13,18,20H,6-7,10-11,14H2,(H,21,22)
DM07P5E	CS	C1CN(C(CN1)CCC2=CC=CC=C2)C3=CC4=C(C=C3)NN=C4
DM07P5E	IK	OOXRIQOVBUMMQG-UHFFFAOYSA-N
DM07P5E	IU	5-[2-(2-phenylethyl)piperazin-1-yl]-1H-indazole
DM07P5E	DE	Discovery agent

DMR35OM	ID	DMR35OM
DMR35OM	DN	5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole
DMR35OM	HS	Investigative
DMR35OM	SN	CHEMBL513258; 5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole; SCHEMBL982062
DMR35OM	DT	Small molecular drug
DMR35OM	PC	44230874
DMR35OM	MW	294.4
DMR35OM	FM	C19H19FN2
DMR35OM	IC	InChI=1S/C19H19FN2/c20-17-4-1-14(2-5-17)12-19(8-10-21-13-19)16-3-6-18-15(11-16)7-9-22-18/h1-7,9,11,21-22H,8,10,12-13H2
DMR35OM	CS	C1CNCC1(CC2=CC=C(C=C2)F)C3=CC4=C(C=C3)NC=C4
DMR35OM	IK	RBNFIIOAQFISLC-UHFFFAOYSA-N
DMR35OM	IU	5-[3-[(4-fluorophenyl)methyl]pyrrolidin-3-yl]-1H-indole
DMR35OM	DE	Discovery agent

DMRF0PS	ID	DMRF0PS
DMRF0PS	DN	5-(3,4-dichlorophenyl)-1H-pyrazol-3-ol
DMRF0PS	HS	Investigative
DMRF0PS	SN	MLS000066902; SMR000078902; CHEMBL566068; 3-(3,4-Dichlorophenyl)-1H-pyrazol-5-ol; 5-(3,4-dichlorophenyl)-1,2-dihydropyrazol-3-one; AC1LCBRY; cid_598633; BDBM59701; MolPort-002-279-649; ANMVQJHGOQOZLG-UHFFFAOYSA-N; HMS2187N05; KUC104342N; KSC-10-40; 5-(3,4-dichlorophenyl)-3-pyrazolin-3-one; 3-(3,4-Dichlorophenyl)-1H-pyrazol-5-ol #; 2H-Pyrazol-3-ol, 5-(3,4-dichlorophenyl)-; SR-01000617714
DMRF0PS	DT	Small molecular drug
DMRF0PS	PC	598633
DMRF0PS	MW	229.06
DMRF0PS	FM	C9H6Cl2N2O
DMRF0PS	IC	InChI=1S/C9H6Cl2N2O/c10-6-2-1-5(3-7(6)11)8-4-9(14)13-12-8/h1-4H,(H2,12,13,14)
DMRF0PS	CS	C1=CC(=C(C=C1C2=CC(=O)NN2)Cl)Cl
DMRF0PS	IK	ANMVQJHGOQOZLG-UHFFFAOYSA-N
DMRF0PS	IU	5-(3,4-dichlorophenyl)-1,2-dihydropyrazol-3-one
DMRF0PS	DE	Discovery agent

DMZK4AH	ID	DMZK4AH
DMZK4AH	DN	5-(3-benzylpyrrolidin-3-yl)-1h-indole (structural mix)
DMZK4AH	HS	Investigative
DMZK4AH	SN	CHEMBL487355; 5-(3-BENZYLPYRROLIDIN-3-YL)-1H-INDOLE (STRUCTURAL MIX); SCHEMBL982204; UZKWACFLBGIUSH-UHFFFAOYSA-N; BDBM50275438; 5-(3-benzylpyrrolidin-3-yl)-1H-indole; 5-(3-benzyl-pyrrolidin-3-yl)-1H-indole; (-)-5-(3-benzylpyrrolidin-3-yl)-1H-indole
DMZK4AH	DT	Small molecular drug
DMZK4AH	PC	44230732
DMZK4AH	MW	276.4
DMZK4AH	FM	C19H20N2
DMZK4AH	IC	InChI=1S/C19H20N2/c1-2-4-15(5-3-1)13-19(9-11-20-14-19)17-6-7-18-16(12-17)8-10-21-18/h1-8,10,12,20-21H,9,11,13-14H2
DMZK4AH	CS	C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4
DMZK4AH	IK	UZKWACFLBGIUSH-UHFFFAOYSA-N
DMZK4AH	IU	5-(3-benzylpyrrolidin-3-yl)-1H-indole
DMZK4AH	DE	Discovery agent

DM2ZUFO	ID	DM2ZUFO
DM2ZUFO	DN	5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole
DM2ZUFO	HS	Investigative
DM2ZUFO	SN	CHEMBL459176; 5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole; SCHEMBL981431
DM2ZUFO	DT	Small molecular drug
DM2ZUFO	PC	44230733
DM2ZUFO	MW	290.4
DM2ZUFO	FM	C20H22N2
DM2ZUFO	IC	InChI=1S/C20H22N2/c1-22-12-9-17-13-18(7-8-19(17)22)20(10-11-21-15-20)14-16-5-3-2-4-6-16/h2-9,12-13,21H,10-11,14-15H2,1H3
DM2ZUFO	CS	CN1C=CC2=C1C=CC(=C2)C3(CCNC3)CC4=CC=CC=C4
DM2ZUFO	IK	OSXVIZKTSFAUPG-UHFFFAOYSA-N
DM2ZUFO	IU	5-(3-benzylpyrrolidin-3-yl)-1-methylindole
DM2ZUFO	DE	Discovery agent

DMPKGJC	ID	DMPKGJC
DMPKGJC	DN	5-(3-butylpyrrolidin-3-yl)-1H-indole
DMPKGJC	HS	Investigative
DMPKGJC	SN	CHEMBL463585; 5-(3-butylpyrrolidin-3-yl)-1H-indole; SCHEMBL983150
DMPKGJC	DT	Small molecular drug
DMPKGJC	PC	25224941
DMPKGJC	MW	242.36
DMPKGJC	FM	C16H22N2
DMPKGJC	IC	InChI=1S/C16H22N2/c1-2-3-7-16(8-10-17-12-16)14-4-5-15-13(11-14)6-9-18-15/h4-6,9,11,17-18H,2-3,7-8,10,12H2,1H3
DMPKGJC	CS	CCCCC1(CCNC1)C2=CC3=C(C=C2)NC=C3
DMPKGJC	IK	FIIZGBLPZZYXCS-UHFFFAOYSA-N
DMPKGJC	IU	5-(3-butylpyrrolidin-3-yl)-1H-indole
DMPKGJC	DE	Discovery agent

DMCR9KX	ID	DMCR9KX
DMCR9KX	DN	5-(3-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid
DMCR9KX	HS	Investigative
DMCR9KX	SN	CHEMBL394441; 595610-55-2; 1H-Pyrazole-3-carboxylic acid, 5-[(3-chlorophenyl)methyl]-; SCHEMBL569462; 5-(3-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid; CTK1D9284; DTXSID30472377; BDBM50216550; AKOS030620128; 5-meta-chlorobenzyl-3-carboxyl-pyrazole; 5-(3-Chlorobenzyl)-1H-pyrazole-3-carboxylic acid; 3-(3-chlorobenzyl)-1H-pyrazole-5-carboxylic acid
DMCR9KX	DT	Small molecular drug
DMCR9KX	PC	11776293
DMCR9KX	MW	236.65
DMCR9KX	FM	C11H9ClN2O2
DMCR9KX	IC	InChI=1S/C11H9ClN2O2/c12-8-3-1-2-7(4-8)5-9-6-10(11(15)16)14-13-9/h1-4,6H,5H2,(H,13,14)(H,15,16)
DMCR9KX	CS	C1=CC(=CC(=C1)Cl)CC2=CC(=NN2)C(=O)O
DMCR9KX	IK	UYMDSFKYOCEPFN-UHFFFAOYSA-N
DMCR9KX	IU	5-[(3-chlorophenyl)methyl]-1H-pyrazole-3-carboxylic acid
DMCR9KX	CA	CAS 595610-55-2
DMCR9KX	DE	Discovery agent

DMABSOC	ID	DMABSOC
DMABSOC	DN	5-(3-chlorophenylethynyl)-5-methyl[1,2,4]triazine
DMABSOC	HS	Investigative
DMABSOC	SN	CHEMBL390802; 5-(3-chlorophenylethynyl)-5-methyl[1,2,4]triazine; SCHEMBL4290682; 1,2,4-Triazine, 3-[2-(3-chlorophenyl)ethynyl]-5-methyl-; BDBM50215448; 945915-51-5
DMABSOC	DT	Small molecular drug
DMABSOC	PC	16736031
DMABSOC	MW	229.66
DMABSOC	FM	C12H8ClN3
DMABSOC	IC	InChI=1S/C12H8ClN3/c1-9-8-14-16-12(15-9)6-5-10-3-2-4-11(13)7-10/h2-4,7-8H,1H3
DMABSOC	CS	CC1=CN=NC(=N1)C#CC2=CC(=CC=C2)Cl
DMABSOC	IK	KPQLYWIRBOHKMO-UHFFFAOYSA-N
DMABSOC	IU	3-[2-(3-chlorophenyl)ethynyl]-5-methyl-1,2,4-triazine
DMABSOC	DE	Discovery agent

DMPC9DV	ID	DMPC9DV
DMPC9DV	DN	5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMPC9DV	HS	Investigative
DMPC9DV	SN	CHEMBL574666; SCHEMBL5613445; BDBM50300481; 5-(3''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMPC9DV	DT	Small molecular drug
DMPC9DV	PC	45483018
DMPC9DV	MW	295.3
DMPC9DV	FM	C18H17NO3
DMPC9DV	IC	InChI=1S/C18H17NO3/c19-12-14-2-1-3-16(10-14)15-7-4-13(5-8-15)6-9-17(20)11-18(21)22/h1-5,7-8,10,17,20H,6,9,11H2,(H,21,22)
DMPC9DV	CS	C1=CC(=CC(=C1)C2=CC=C(C=C2)CCC(CC(=O)O)O)C#N
DMPC9DV	IK	WILNYVYWCSPWAP-UHFFFAOYSA-N
DMPC9DV	IU	5-[4-(3-cyanophenyl)phenyl]-3-hydroxypentanoic acid
DMPC9DV	DE	Discovery agent

DM2H9ND	ID	DM2H9ND
DM2H9ND	DN	5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
DM2H9ND	HS	Investigative
DM2H9ND	SN	3-(5-Mercapto-[1,3,4]oxadiazol-2-yl)-phenol; 3-(5-mercapto-1,3,4-oxadiazol-2-yl)phenol; 299465-12-6; 3-(5-sulfanyl-1,3,4-oxadiazol-2-yl)phenol; CHEMBL595356; 3-(5-Mercapto-1,3,4-Oxadiazol-2-Yl)-Phenol; AO-365/08835025; 5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione; 5-[3-Hydroxyphenyl]-1,3,4-oxadiazole-2(3H)-thione; NSC524085; AC1LF1GV; Oprea1_836042; CTK8F4715; CTK8A0072; MolPort-000-932-334; ZX-AN016552; ZINC1605604; BB_SC-06098; CCG-15357; STK506749; FCH842308; BDBM50320729; BBL000571; AKOS000564154; FCH2245445; NSC-524085
DM2H9ND	DT	Small molecular drug
DM2H9ND	PC	745318
DM2H9ND	MW	194.21
DM2H9ND	FM	C8H6N2O2S
DM2H9ND	IC	InChI=1S/C8H6N2O2S/c11-6-3-1-2-5(4-6)7-9-10-8(13)12-7/h1-4,11H,(H,10,13)
DM2H9ND	CS	C1=CC(=CC(=C1)O)C2=NNC(=S)O2
DM2H9ND	IK	CNOGHDSTUCQSOV-UHFFFAOYSA-N
DM2H9ND	IU	5-(3-hydroxyphenyl)-3H-1,3,4-oxadiazole-2-thione
DM2H9ND	DE	Discovery agent

DMPCFA6	ID	DMPCFA6
DMPCFA6	DN	5-(3-Phenyl-propyl)-1H-pyrazole-3-carboxylic acid
DMPCFA6	HS	Investigative
DMPCFA6	SN	CHEMBL129326; 5-(3-Phenyl-propyl)-1H-pyrazole-3-carboxylic acid; ZINC13526614
DMPCFA6	DT	Small molecular drug
DMPCFA6	PC	11746440
DMPCFA6	MW	230.26
DMPCFA6	FM	C13H14N2O2
DMPCFA6	IC	InChI=1S/C13H14N2O2/c16-13(17)12-9-11(14-15-12)8-4-7-10-5-2-1-3-6-10/h1-3,5-6,9H,4,7-8H2,(H,14,15)(H,16,17)
DMPCFA6	CS	C1=CC=C(C=C1)CCCC2=CC(=NN2)C(=O)O
DMPCFA6	IK	JDCXDGHZXKZHQL-UHFFFAOYSA-N
DMPCFA6	IU	5-(3-phenylpropyl)-1H-pyrazole-3-carboxylic acid
DMPCFA6	DE	Discovery agent

DMZYE8W	ID	DMZYE8W
DMZYE8W	DN	5-(4-((phenethylamino)methyl)phenoxy)picolinamide
DMZYE8W	HS	Investigative
DMZYE8W	SN	CHEMBL236376; 5-(4-((phenethylamino)methyl)phenoxy)picolinamide; SCHEMBL3771658
DMZYE8W	DT	Small molecular drug
DMZYE8W	PC	44434951
DMZYE8W	MW	347.4
DMZYE8W	FM	C21H21N3O2
DMZYE8W	IC	InChI=1S/C21H21N3O2/c22-21(25)20-11-10-19(15-24-20)26-18-8-6-17(7-9-18)14-23-13-12-16-4-2-1-3-5-16/h1-11,15,23H,12-14H2,(H2,22,25)
DMZYE8W	CS	C1=CC=C(C=C1)CCNCC2=CC=C(C=C2)OC3=CN=C(C=C3)C(=O)N
DMZYE8W	IK	RDWUBDSRHFANBO-UHFFFAOYSA-N
DMZYE8W	IU	5-[4-[(2-phenylethylamino)methyl]phenoxy]pyridine-2-carboxamide
DMZYE8W	DE	Discovery agent

DM6KSN9	ID	DM6KSN9
DM6KSN9	DN	5-(4'-benzoylbiphenyl-4-yl)-2-furoic acid
DM6KSN9	HS	Investigative
DM6KSN9	SN	CHEMBL222717
DM6KSN9	DT	Small molecular drug
DM6KSN9	PC	16202985
DM6KSN9	MW	368.4
DM6KSN9	FM	C24H16O4
DM6KSN9	IC	InChI=1S/C24H16O4/c25-23(19-4-2-1-3-5-19)20-12-8-17(9-13-20)16-6-10-18(11-7-16)21-14-15-22(28-21)24(26)27/h1-15H,(H,26,27)
DM6KSN9	CS	C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C4=CC=C(O4)C(=O)O
DM6KSN9	IK	UKLDRYNCWUIPPD-UHFFFAOYSA-N
DM6KSN9	IU	5-[4-(4-benzoylphenyl)phenyl]furan-2-carboxylic acid
DM6KSN9	DE	Discovery agent

DMT4856	ID	DMT4856
DMT4856	DN	5-(4-bromophenyl)-2-furaldehyde thiosemicarbazone
DMT4856	HS	Investigative
DMT4856	SN	5-(4-bromophenyl)-2-furaldehyde thiosemicarbazone; AC1LF4XJ; CTK7D4016; AKOS017263438; MCULE-1426418015
DMT4856	DT	Small molecular drug
DMT4856	PC	6870109
DMT4856	MW	324.2
DMT4856	FM	C12H10BrN3OS
DMT4856	IC	InChI=1S/C12H10BrN3OS/c13-9-3-1-8(2-4-9)11-6-5-10(17-11)7-15-16-12(14)18/h1-7H,(H3,14,16,18)/b15-7+
DMT4856	CS	C1=CC(=CC=C1C2=CC=C(O2)/C=N/NC(=S)N)Br
DMT4856	IK	ZCUMFDMDQURMSL-VIZOYTHASA-N
DMT4856	IU	[(E)-[5-(4-bromophenyl)furan-2-yl]methylideneamino]thiourea
DMT4856	DE	Discovery agent

DMDCNZE	ID	DMDCNZE
DMDCNZE	DN	5-(4-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid
DMDCNZE	HS	Investigative
DMDCNZE	SN	CHEMBL341520; 5-(4-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid; 1H-Pyrazole-3-carboxylic acid, 5-[(4-chlorophenyl)methyl]-; BDBM50132144
DMDCNZE	DT	Small molecular drug
DMDCNZE	PC	10857469
DMDCNZE	MW	236.65
DMDCNZE	FM	C11H9ClN2O2
DMDCNZE	IC	InChI=1S/C11H9ClN2O2/c12-8-3-1-7(2-4-8)5-9-6-10(11(15)16)14-13-9/h1-4,6H,5H2,(H,13,14)(H,15,16)
DMDCNZE	CS	C1=CC(=CC=C1CC2=CC(=NN2)C(=O)O)Cl
DMDCNZE	IK	YKKXGQMJMUSFFP-UHFFFAOYSA-N
DMDCNZE	IU	5-[(4-chlorophenyl)methyl]-1H-pyrazole-3-carboxylic acid
DMDCNZE	CA	CAS 595610-52-9
DMDCNZE	DE	Discovery agent

DMJKAF0	ID	DMJKAF0
DMJKAF0	DN	5-(4-Chloro-phenyl)-1-methyl-piperidin-2-one
DMJKAF0	HS	Investigative
DMJKAF0	SN	CHEMBL294630; 5-(4-Chloro-phenyl)-1-methyl-piperidin-2-one; BDBM50091709
DMJKAF0	DT	Small molecular drug
DMJKAF0	PC	12012177
DMJKAF0	MW	223.7
DMJKAF0	FM	C12H14ClNO
DMJKAF0	IC	InChI=1S/C12H14ClNO/c1-14-8-10(4-7-12(14)15)9-2-5-11(13)6-3-9/h2-3,5-6,10H,4,7-8H2,1H3
DMJKAF0	CS	CN1CC(CCC1=O)C2=CC=C(C=C2)Cl
DMJKAF0	IK	QCCANQQHOCXGTL-UHFFFAOYSA-N
DMJKAF0	IU	5-(4-chlorophenyl)-1-methylpiperidin-2-one
DMJKAF0	DE	Discovery agent

DMQB1UI	ID	DMQB1UI
DMQB1UI	DN	5-(4-Chloro-phenyl)-1-methyl-piperidine-2-thione
DMQB1UI	HS	Investigative
DMQB1UI	SN	CHEMBL56517; 5-(4-Chloro-phenyl)-1-methyl-piperidine-2-thione; BDBM50091711
DMQB1UI	DT	Small molecular drug
DMQB1UI	PC	12012178
DMQB1UI	MW	239.76
DMQB1UI	FM	C12H14ClNS
DMQB1UI	IC	InChI=1S/C12H14ClNS/c1-14-8-10(4-7-12(14)15)9-2-5-11(13)6-3-9/h2-3,5-6,10H,4,7-8H2,1H3
DMQB1UI	CS	CN1CC(CCC1=S)C2=CC=C(C=C2)Cl
DMQB1UI	IK	FTCLELCCXKHRQL-UHFFFAOYSA-N
DMQB1UI	IU	5-(4-chlorophenyl)-1-methylpiperidine-2-thione
DMQB1UI	DE	Discovery agent

DMSTG03	ID	DMSTG03
DMSTG03	DN	5-(4-Chlorophenyl)-4-(4-methoxyphenyl)isothiazole
DMSTG03	HS	Investigative
DMSTG03	SN	CHEMBL491089; 5-(4-Chlorophenyl)-4-(4-methoxyphenyl)isothiazole
DMSTG03	DT	Small molecular drug
DMSTG03	PC	44564457
DMSTG03	MW	301.8
DMSTG03	FM	C16H12ClNOS
DMSTG03	IC	InChI=1S/C16H12ClNOS/c1-19-14-8-4-11(5-9-14)15-10-18-20-16(15)12-2-6-13(17)7-3-12/h2-10H,1H3
DMSTG03	CS	COC1=CC=C(C=C1)C2=C(SN=C2)C3=CC=C(C=C3)Cl
DMSTG03	IK	XGOLGQNTCHMSDA-UHFFFAOYSA-N
DMSTG03	IU	5-(4-chlorophenyl)-4-(4-methoxyphenyl)-1,2-thiazole
DMSTG03	DE	Discovery agent

DMY0P86	ID	DMY0P86
DMY0P86	DN	5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole
DMY0P86	HS	Investigative
DMY0P86	SN	CHEMBL513405; 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole
DMY0P86	DT	Small molecular drug
DMY0P86	PC	24884692
DMY0P86	MW	332.7
DMY0P86	FM	C16H12ClNSe
DMY0P86	IC	InChI=1S/C16H12ClNSe/c1-11-2-4-12(5-3-11)15-10-18-19-16(15)13-6-8-14(17)9-7-13/h2-10H,1H3
DMY0P86	CS	CC1=CC=C(C=C1)C2=C([Se]N=C2)C3=CC=C(C=C3)Cl
DMY0P86	IK	SIYWUUCHURNUOK-UHFFFAOYSA-N
DMY0P86	IU	5-(4-chlorophenyl)-4-(4-methylphenyl)-1,2-selenazole
DMY0P86	DE	Discovery agent

DMFYEL8	ID	DMFYEL8
DMFYEL8	DN	5-(4-Chlorophenyl)-4-p-tolyl-3H-1,2-dithiol-3-one
DMFYEL8	HS	Investigative
DMFYEL8	SN	CHEMBL475545; 5-(4-Chlorophenyl)-4-p-tolyl-3H-1,2-dithiol-3-one
DMFYEL8	DT	Small molecular drug
DMFYEL8	PC	44564003
DMFYEL8	MW	318.8
DMFYEL8	FM	C16H11ClOS2
DMFYEL8	IC	InChI=1S/C16H11ClOS2/c1-10-2-4-11(5-3-10)14-15(19-20-16(14)18)12-6-8-13(17)9-7-12/h2-9H,1H3
DMFYEL8	CS	CC1=CC=C(C=C1)C2=C(SSC2=O)C3=CC=C(C=C3)Cl
DMFYEL8	IK	CUFDVUQUYHTZLD-UHFFFAOYSA-N
DMFYEL8	IU	5-(4-chlorophenyl)-4-(4-methylphenyl)dithiol-3-one
DMFYEL8	DE	Discovery agent

DMA1N75	ID	DMA1N75
DMA1N75	DN	5-(4-Chlorophenyl)-4-p-tolylisothiazole
DMA1N75	HS	Investigative
DMA1N75	SN	CHEMBL524133; 5-(4-Chlorophenyl)-4-p-tolylisothiazole
DMA1N75	DT	Small molecular drug
DMA1N75	PC	44564454
DMA1N75	MW	285.8
DMA1N75	FM	C16H12ClNS
DMA1N75	IC	InChI=1S/C16H12ClNS/c1-11-2-4-12(5-3-11)15-10-18-19-16(15)13-6-8-14(17)9-7-13/h2-10H,1H3
DMA1N75	CS	CC1=CC=C(C=C1)C2=C(SN=C2)C3=CC=C(C=C3)Cl
DMA1N75	IK	LELNOQBBNOVPJP-UHFFFAOYSA-N
DMA1N75	IU	5-(4-chlorophenyl)-4-(4-methylphenyl)-1,2-thiazole
DMA1N75	DE	Discovery agent

DMV7HA1	ID	DMV7HA1
DMV7HA1	DN	5-(4-chlorophenyl)-N-(2-methylbenzyl)nicotinamide
DMV7HA1	HS	Investigative
DMV7HA1	SN	CHEMBL1269882; 5-(4-chlorophenyl)-N-(2-methylbenzyl)nicotinamide
DMV7HA1	DT	Small molecular drug
DMV7HA1	PC	52945923
DMV7HA1	MW	336.8
DMV7HA1	FM	C20H17ClN2O
DMV7HA1	IC	InChI=1S/C20H17ClN2O/c1-14-4-2-3-5-16(14)13-23-20(24)18-10-17(11-22-12-18)15-6-8-19(21)9-7-15/h2-12H,13H2,1H3,(H,23,24)
DMV7HA1	CS	CC1=CC=CC=C1CNC(=O)C2=CN=CC(=C2)C3=CC=C(C=C3)Cl
DMV7HA1	IK	MLDMXXWILKZITA-UHFFFAOYSA-N
DMV7HA1	IU	5-(4-chlorophenyl)-N-[(2-methylphenyl)methyl]pyridine-3-carboxamide
DMV7HA1	DE	Discovery agent

DM6CRVS	ID	DM6CRVS
DM6CRVS	DN	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
DM6CRVS	HS	Investigative
DM6CRVS	SN	CHEMBL84288
DM6CRVS	DT	Small molecular drug
DM6CRVS	PC	11528707
DM6CRVS	MW	227.69
DM6CRVS	FM	C11H14ClNO2
DM6CRVS	IC	InChI=1S/C11H14ClNO2/c12-10-7-5-9(6-8-10)3-1-2-4-11(14)13-15/h5-8,15H,1-4H2,(H,13,14)
DM6CRVS	CS	C1=CC(=CC=C1CCCCC(=O)NO)Cl
DM6CRVS	IK	PRMXJXDYJXBBPT-UHFFFAOYSA-N
DM6CRVS	IU	5-(4-chlorophenyl)-N-hydroxypentanamide
DM6CRVS	DE	Discovery agent

DMTDNX3	ID	DMTDNX3
DMTDNX3	DN	5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMTDNX3	HS	Investigative
DMTDNX3	SN	CHEMBL583588; SCHEMBL5613483; BDBM50300472; 5-(4''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMTDNX3	DT	Small molecular drug
DMTDNX3	PC	44626352
DMTDNX3	MW	295.3
DMTDNX3	FM	C18H17NO3
DMTDNX3	IC	InChI=1S/C18H17NO3/c19-12-14-3-8-16(9-4-14)15-6-1-13(2-7-15)5-10-17(20)11-18(21)22/h1-4,6-9,17,20H,5,10-11H2,(H,21,22)
DMTDNX3	CS	C1=CC(=CC=C1CCC(CC(=O)O)O)C2=CC=C(C=C2)C#N
DMTDNX3	IK	YDAZWMGCTBJQEO-UHFFFAOYSA-N
DMTDNX3	IU	5-[4-(4-cyanophenyl)phenyl]-3-hydroxypentanoic acid
DMTDNX3	DE	Discovery agent

DMISOLU	ID	DMISOLU
DMISOLU	DN	5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid
DMISOLU	HS	Investigative
DMISOLU	SN	CHEMBL216668; 5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid
DMISOLU	DT	Small molecular drug
DMISOLU	PC	44418518
DMISOLU	MW	269.29
DMISOLU	FM	C16H15NO3
DMISOLU	IC	InChI=1S/C16H15NO3/c1-10-5-14(18)6-11(2)15(10)4-3-12-7-13(16(19)20)9-17-8-12/h3-9,18H,1-2H3,(H,19,20)/b4-3+
DMISOLU	CS	CC1=CC(=CC(=C1/C=C/C2=CC(=CN=C2)C(=O)O)C)O
DMISOLU	IK	QHRQJLLCYNFCCT-ONEGZZNKSA-N
DMISOLU	IU	5-[(E)-2-(4-hydroxy-2,6-dimethylphenyl)ethenyl]pyridine-3-carboxylic acid
DMISOLU	DE	Discovery agent

DMB2GLE	ID	DMB2GLE
DMB2GLE	DN	5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
DMB2GLE	HS	Investigative
DMB2GLE	DT	Small molecular drug
DMB2GLE	PC	739395
DMB2GLE	MW	194.21
DMB2GLE	FM	C8H6N2O2S
DMB2GLE	IC	InChI=1S/C8H6N2O2S/c11-6-3-1-5(2-4-6)7-9-10-8(13)12-7/h1-4,11H,(H,10,13)
DMB2GLE	CS	C1=CC(=CC=C1C2=NNC(=S)O2)O
DMB2GLE	IK	NGBOFOYNPCHKQQ-UHFFFAOYSA-N
DMB2GLE	IU	5-(4-hydroxyphenyl)-3H-1,3,4-oxadiazole-2-thione
DMB2GLE	CA	CAS 69829-90-9
DMB2GLE	DE	Discovery agent

DM7KQXL	ID	DM7KQXL
DM7KQXL	DN	5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
DM7KQXL	HS	Investigative
DM7KQXL	DT	Small molecular drug
DM7KQXL	PC	3082127
DM7KQXL	MW	226.3
DM7KQXL	FM	C9H6OS3
DM7KQXL	IC	InChI=1S/C9H6OS3/c10-7-3-1-6(2-4-7)8-5-9(11)13-12-8/h1-5,10H
DM7KQXL	CS	C1=CC(=CC=C1C2=CC(=S)SS2)O
DM7KQXL	IK	IWBBKLMHAILHAR-UHFFFAOYSA-N
DM7KQXL	IU	5-(4-hydroxyphenyl)dithiole-3-thione
DM7KQXL	CA	CAS 18274-81-2
DM7KQXL	DE	Discovery agent

DM3SQEY	ID	DM3SQEY
DM3SQEY	DN	5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine
DM3SQEY	HS	Investigative
DM3SQEY	SN	5-(4-METHOXYPHENOXY)-2,4-QUINAZOLINEDIAMINE; 5-(4-methoxyphenoxy)quinazoline-2,4-diamine; AC1L9KGI; SCHEMBL2128429
DM3SQEY	DT	Small molecular drug
DM3SQEY	PC	447098
DM3SQEY	MW	282.3
DM3SQEY	FM	C15H14N4O2
DM3SQEY	IC	InChI=1S/C15H14N4O2/c1-20-9-5-7-10(8-6-9)21-12-4-2-3-11-13(12)14(16)19-15(17)18-11/h2-8H,1H3,(H4,16,17,18,19)
DM3SQEY	CS	COC1=CC=C(C=C1)OC2=CC=CC3=C2C(=NC(=N3)N)N
DM3SQEY	IK	CPZJZAIZIMCJRC-UHFFFAOYSA-N
DM3SQEY	IU	5-(4-methoxyphenoxy)quinazoline-2,4-diamine
DM3SQEY	DE	Discovery agent

DMCMNKA	ID	DMCMNKA
DMCMNKA	DN	5-(4-Methoxy-phenyl)-1-phenyl-1H-benzoimidazole
DMCMNKA	HS	Investigative
DMCMNKA	SN	benzimidazole 2; AC1NS6L8; CHEMBL81026; SCHEMBL7683792; BDBM5295; MolPort-028-745-333; ZINC13536068; 5-(4-methoxyphenyl)-1-phenylbenzimidazole; 1-Phenyl-5-(4-methoxyphenyl)-1H-benzimidazole
DMCMNKA	DT	Small molecular drug
DMCMNKA	PC	5329338
DMCMNKA	MW	300.4
DMCMNKA	FM	C20H16N2O
DMCMNKA	IC	InChI=1S/C20H16N2O/c1-23-18-10-7-15(8-11-18)16-9-12-20-19(13-16)21-14-22(20)17-5-3-2-4-6-17/h2-14H,1H3
DMCMNKA	CS	COC1=CC=C(C=C1)C2=CC3=C(C=C2)N(C=N3)C4=CC=CC=C4
DMCMNKA	IK	OPGUZRRLMQSMAQ-UHFFFAOYSA-N
DMCMNKA	IU	5-(4-methoxyphenyl)-1-phenylbenzimidazole
DMCMNKA	DE	Discovery agent

DMEV8WS	ID	DMEV8WS
DMEV8WS	DN	5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole
DMEV8WS	HS	Investigative
DMEV8WS	SN	CHEMBL452730; 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole
DMEV8WS	DT	Small molecular drug
DMEV8WS	PC	24884691
DMEV8WS	MW	328.3
DMEV8WS	FM	C17H15NOSe
DMEV8WS	IC	InChI=1S/C17H15NOSe/c1-12-3-5-13(6-4-12)16-11-18-20-17(16)14-7-9-15(19-2)10-8-14/h3-11H,1-2H3
DMEV8WS	CS	CC1=CC=C(C=C1)C2=C([Se]N=C2)C3=CC=C(C=C3)OC
DMEV8WS	IK	ZTXIFGCFDLCGKN-UHFFFAOYSA-N
DMEV8WS	IU	5-(4-methoxyphenyl)-4-(4-methylphenyl)-1,2-selenazole
DMEV8WS	DE	Discovery agent

DMJSTCK	ID	DMJSTCK
DMJSTCK	DN	5-(4-Methoxyphenyl)-4-p-tolylisothiazole
DMJSTCK	HS	Investigative
DMJSTCK	SN	CHEMBL514950; 5-(4-Methoxyphenyl)-4-p-tolylisothiazole
DMJSTCK	DT	Small molecular drug
DMJSTCK	PC	44564416
DMJSTCK	MW	281.4
DMJSTCK	FM	C17H15NOS
DMJSTCK	IC	InChI=1S/C17H15NOS/c1-12-3-5-13(6-4-12)16-11-18-20-17(16)14-7-9-15(19-2)10-8-14/h3-11H,1-2H3
DMJSTCK	CS	CC1=CC=C(C=C1)C2=C(SN=C2)C3=CC=C(C=C3)OC
DMJSTCK	IK	KPYJYWIFJYUIBB-UHFFFAOYSA-N
DMJSTCK	IU	5-(4-methoxyphenyl)-4-(4-methylphenyl)-1,2-thiazole
DMJSTCK	DE	Discovery agent

DMNSIF2	ID	DMNSIF2
DMNSIF2	DN	5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole
DMNSIF2	HS	Investigative
DMNSIF2	SN	CHEMBL1276926; 5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole
DMNSIF2	DT	Small molecular drug
DMNSIF2	PC	49836621
DMNSIF2	MW	370.5
DMNSIF2	FM	C19H22N4O2S
DMNSIF2	IC	InChI=1S/C19H22N4O2S/c1-14-3-6-16(7-4-14)26(24,25)19-17-13-15(5-8-18(17)20-21-19)23-11-9-22(2)10-12-23/h3-8,13H,9-12H2,1-2H3,(H,20,21)
DMNSIF2	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=C3C=C(C=CC3=NN2)N4CCN(CC4)C
DMNSIF2	IK	DAXBNFVWZYVXTC-UHFFFAOYSA-N
DMNSIF2	IU	3-(4-methylphenyl)sulfonyl-5-(4-methylpiperazin-1-yl)-2H-indazole
DMNSIF2	DE	Discovery agent

DM05OMF	ID	DM05OMF
DM05OMF	DN	5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione
DM05OMF	HS	Investigative
DM05OMF	SN	CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione
DM05OMF	DT	Small molecular drug
DM05OMF	PC	53742316
DM05OMF	MW	296.28
DM05OMF	FM	C16H12N2O4
DM05OMF	IC	InChI=1S/C16H12N2O4/c19-14-13(15(20)18-16(21)17-14)10-6-8-12(9-7-10)22-11-4-2-1-3-5-11/h1-9H,(H3,17,18,19,20,21)
DM05OMF	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=C(NC(=O)NC3=O)O
DM05OMF	IK	CVMFBMDAPZFQBR-UHFFFAOYSA-N
DM05OMF	IU	6-hydroxy-5-(4-phenoxyphenyl)-1H-pyrimidine-2,4-dione
DM05OMF	DE	Discovery agent

DM3QFCV	ID	DM3QFCV
DM3QFCV	DN	5-(4-Phenylbutoxy)psoralen
DM3QFCV	HS	Investigative
DM3QFCV	SN	4-(4-Phenylbutoxy)furo[3,2-g]chromen-7-one; Psora-4; Psora 4; 724709-68-6; 4-(4-phenylbutoxy)furo[3,2-g]chromen-7-one; CHEMBL1256851; 4-(4-Phenylbutoxy)-7H-furo[3,2-g]chromen-7-one; 4-(4-Phenylbutoxy)-7H-furo[3,2-g][1]benzopyran-7-one; NCGC00015863-01; Lopac-P-9872; SCHEMBL2801777; GTPL9583; AC1O7G66; CTK8F0317; DTXSID10424970; MolPort-023-277-165; HMS3260K16; ZINC7997390; Psora-4, &gt; Tox21_500137; BDBM50331458; AKOS024458119; LP00137; CCG-204232; NCGC00015863-02; NCGC00015863-03; NCGC00093627-02; NCGC00260822-01; NCGC00093627-01
DM3QFCV	DT	Small molecular drug
DM3QFCV	PC	6603977
DM3QFCV	MW	334.4
DM3QFCV	FM	C21H18O4
DM3QFCV	IC	InChI=1S/C21H18O4/c22-20-10-9-16-19(25-20)14-18-17(11-13-23-18)21(16)24-12-5-4-8-15-6-2-1-3-7-15/h1-3,6-7,9-11,13-14H,4-5,8,12H2
DM3QFCV	CS	C1=CC=C(C=C1)CCCCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4
DM3QFCV	IK	JJAWGNIQEOFURP-UHFFFAOYSA-N
DM3QFCV	IU	4-(4-phenylbutoxy)furo[3,2-g]chromen-7-one
DM3QFCV	CA	CAS 724709-68-6
DM3QFCV	DE	Discovery agent

DMZ7K5G	ID	DMZ7K5G
DMZ7K5G	DN	5-(4-piperidyl)-4-propylisothiazol-3-ol
DMZ7K5G	HS	Investigative
DMZ7K5G	SN	CHEMBL382791; 5-(4-piperidyl)-4-propylisothiazol-3-ol
DMZ7K5G	DT	Small molecular drug
DMZ7K5G	PC	11515063
DMZ7K5G	MW	226.34
DMZ7K5G	FM	C11H18N2OS
DMZ7K5G	IC	InChI=1S/C11H18N2OS/c1-2-3-9-10(15-13-11(9)14)8-4-6-12-7-5-8/h8,12H,2-7H2,1H3,(H,13,14)
DMZ7K5G	CS	CCCC1=C(SNC1=O)C2CCNCC2
DMZ7K5G	IK	INIXNNKFVDXPBJ-UHFFFAOYSA-N
DMZ7K5G	IU	5-piperidin-4-yl-4-propyl-1,2-thiazol-3-one
DMZ7K5G	DE	Discovery agent

DMVMBG0	ID	DMVMBG0
DMVMBG0	DN	5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one
DMVMBG0	HS	Investigative
DMVMBG0	SN	CHEMBL66981; SCHEMBL8176516; 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one; ZINC9633633; BDBM50039067
DMVMBG0	DT	Small molecular drug
DMVMBG0	PC	11778521
DMVMBG0	MW	282.29
DMVMBG0	FM	C16H14N2O3
DMVMBG0	IC	InChI=1S/C16H14N2O3/c1-20-14-6-11-5-12(10-3-4-16(19)18-8-10)9-17-13(11)7-15(14)21-2/h3-9H,1-2H3,(H,18,19)
DMVMBG0	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CNC(=O)C=C3
DMVMBG0	IK	RWZAFECYIQQVPG-UHFFFAOYSA-N
DMVMBG0	IU	5-(6,7-dimethoxyquinolin-3-yl)-1H-pyridin-2-one
DMVMBG0	DE	Discovery agent

DM0K7U5	ID	DM0K7U5
DM0K7U5	DN	5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid
DM0K7U5	HS	Investigative
DM0K7U5	SN	compound 39 [PMID: 23581530]
DM0K7U5	DT	Small molecular drug
DM0K7U5	PC	71655222
DM0K7U5	MW	349.8
DM0K7U5	FM	C19H24ClNO3
DM0K7U5	IC	InChI=1S/C19H24ClNO3/c1-2-3-4-5-7-16-12-14-10-11-15(20)13-17(14)21(16)18(22)8-6-9-19(23)24/h10-13H,2-9H2,1H3,(H,23,24)
DM0K7U5	CS	CCCCCCC1=CC2=C(N1C(=O)CCCC(=O)O)C=C(C=C2)Cl
DM0K7U5	IK	KNTPSPKZGNVRML-UHFFFAOYSA-N
DM0K7U5	IU	5-(6-chloro-2-hexylindol-1-yl)-5-oxopentanoic acid
DM0K7U5	DE	Discovery agent

DMIB9AX	ID	DMIB9AX
DMIB9AX	DN	5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol
DMIB9AX	HS	Investigative
DMIB9AX	SN	CHEMBL246045; 5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol; BDBM50197243
DMIB9AX	DT	Small molecular drug
DMIB9AX	PC	25062609
DMIB9AX	MW	268.26
DMIB9AX	FM	C16H12O4
DMIB9AX	IC	InChI=1S/C16H12O4/c17-13-4-3-9-5-10(1-2-11(9)6-13)12-7-14(18)16(20)15(19)8-12/h1-8,17-20H
DMIB9AX	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C(=C3)O)O)O
DMIB9AX	IK	PBTSXIZGBMXUHW-UHFFFAOYSA-N
DMIB9AX	IU	5-(6-hydroxynaphthalen-2-yl)benzene-1,2,3-triol
DMIB9AX	DE	Discovery agent

DMJWIPS	ID	DMJWIPS
DMJWIPS	DN	5-(6-hydroxy-2-naphthyl)pyridin-3-ol
DMJWIPS	HS	Investigative
DMJWIPS	SN	CHEMBL261427; SCHEMBL3002838; RTRRNSMMHNFJIV-UHFFFAOYSA-N; BDBM50373034
DMJWIPS	DT	Small molecular drug
DMJWIPS	PC	24827431
DMJWIPS	MW	237.25
DMJWIPS	FM	C15H11NO2
DMJWIPS	IC	InChI=1S/C15H11NO2/c17-14-4-3-10-5-11(1-2-12(10)6-14)13-7-15(18)9-16-8-13/h1-9,17-18H
DMJWIPS	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=CN=C3)O
DMJWIPS	IK	RTRRNSMMHNFJIV-UHFFFAOYSA-N
DMJWIPS	IU	5-(6-hydroxynaphthalen-2-yl)pyridin-3-ol
DMJWIPS	DE	Discovery agent

DMJRBKO	ID	DMJRBKO
DMJRBKO	DN	5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DMJRBKO	HS	Investigative
DMJRBKO	SN	CHEMBL197892; 5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol; SCHEMBL1741908; ZINC28527773; BDBM50186767; 5-(6-hydroxy-2-naphthyl)benzene-1,3-diol; 5-(6-Hydroxy-naphthalen-2-yl)-benzene-1,3-diol
DMJRBKO	DT	Small molecular drug
DMJRBKO	PC	11514345
DMJRBKO	MW	252.26
DMJRBKO	FM	C16H12O3
DMJRBKO	IC	InChI=1S/C16H12O3/c17-14-4-3-10-5-11(1-2-12(10)6-14)13-7-15(18)9-16(19)8-13/h1-9,17-19H
DMJRBKO	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=CC(=C3)O)O
DMJRBKO	IK	CKQUMNKKOYTAST-UHFFFAOYSA-N
DMJRBKO	IU	5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DMJRBKO	DE	Discovery agent

DMMPAWD	ID	DMMPAWD
DMMPAWD	DN	5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol
DMMPAWD	HS	Investigative
DMMPAWD	SN	CHEMBL500636; 5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol; ZINC40425010
DMMPAWD	DT	Small molecular drug
DMMPAWD	PC	25034344
DMMPAWD	MW	251.28
DMMPAWD	FM	C16H13NO2
DMMPAWD	IC	InChI=1S/C16H13NO2/c1-19-16-5-4-11-6-12(2-3-13(11)8-16)14-7-15(18)10-17-9-14/h2-10,18H,1H3
DMMPAWD	CS	COC1=CC2=C(C=C1)C=C(C=C2)C3=CC(=CN=C3)O
DMMPAWD	IK	YXTBYYAJCILARD-UHFFFAOYSA-N
DMMPAWD	IU	5-(6-methoxynaphthalen-2-yl)pyridin-3-ol
DMMPAWD	DE	Discovery agent

DMGIO3R	ID	DMGIO3R
DMGIO3R	DN	5-(azepan-1-ylsulfonyl)indoline-2,3-dione
DMGIO3R	HS	Investigative
DMGIO3R	SN	1H-Azepine, 1-[(2,3-dihydro-2,3-dioxo-1H-indol-5-yl)sulfonyl]hexahydro-; 220510-14-5; Isatin Sulfonamide 22; 5-(azepan-1-ylsulfonyl)-1H-indole-2,3-dione; CHEMBL302461; SCHEMBL6535562; CTK0I8877; BDBM10311; DTXSID20431675; 5-(azepane-1-sulfonyl)-2,3-dihydro-1H-indole-2,3-dione
DMGIO3R	DT	Small molecular drug
DMGIO3R	PC	9839586
DMGIO3R	MW	308.35
DMGIO3R	FM	C14H16N2O4S
DMGIO3R	IC	InChI=1S/C14H16N2O4S/c17-13-11-9-10(5-6-12(11)15-14(13)18)21(19,20)16-7-3-1-2-4-8-16/h5-6,9H,1-4,7-8H2,(H,15,17,18)
DMGIO3R	CS	C1CCCN(CC1)S(=O)(=O)C2=CC3=C(C=C2)NC(=O)C3=O
DMGIO3R	IK	MLWAHVYFMDBXBL-UHFFFAOYSA-N
DMGIO3R	IU	5-(azepan-1-ylsulfonyl)-1H-indole-2,3-dione
DMGIO3R	CA	CAS 220510-14-5
DMGIO3R	DE	Discovery agent

DMJIVLY	ID	DMJIVLY
DMJIVLY	DN	5-(azetidin-1-ylsulfonyl)indoline-2,3-dione
DMJIVLY	HS	Investigative
DMJIVLY	SN	5-[1-(Azetidinyl)sulfonyl]isatin; Isatin Sulfonamide 19; 1H-Indole-2,3-dione, 5-(1-azetidinylsulfonyl)-; CHEMBL64789; SCHEMBL6535690; BDBM10308; 220510-08-7; 5-(Azetidine-1-ylsulfonyl)indoline-2,3-dione
DMJIVLY	DT	Small molecular drug
DMJIVLY	PC	9903426
DMJIVLY	MW	266.28
DMJIVLY	FM	C11H10N2O4S
DMJIVLY	IC	InChI=1S/C11H10N2O4S/c14-10-8-6-7(2-3-9(8)12-11(10)15)18(16,17)13-4-1-5-13/h2-3,6H,1,4-5H2,(H,12,14,15)
DMJIVLY	CS	C1CN(C1)S(=O)(=O)C2=CC3=C(C=C2)NC(=O)C3=O
DMJIVLY	IK	VEHTUFDNCGHBFH-UHFFFAOYSA-N
DMJIVLY	IU	5-(azetidin-1-ylsulfonyl)-1H-indole-2,3-dione
DMJIVLY	DE	Discovery agent

DMJAG7M	ID	DMJAG7M
DMJAG7M	DN	5-(biphenyl-4-yl)-3-methoxypentanoic acid
DMJAG7M	HS	Investigative
DMJAG7M	SN	CHEMBL583771; 5-(biphenyl-4-yl)-3-methoxypentanoic acid
DMJAG7M	DT	Small molecular drug
DMJAG7M	PC	45482998
DMJAG7M	MW	284.3
DMJAG7M	FM	C18H20O3
DMJAG7M	IC	InChI=1S/C18H20O3/c1-21-17(13-18(19)20)12-9-14-7-10-16(11-8-14)15-5-3-2-4-6-15/h2-8,10-11,17H,9,12-13H2,1H3,(H,19,20)
DMJAG7M	CS	COC(CCC1=CC=C(C=C1)C2=CC=CC=C2)CC(=O)O
DMJAG7M	IK	KYPWLTXIHUQMGA-UHFFFAOYSA-N
DMJAG7M	IU	3-methoxy-5-(4-phenylphenyl)pentanoic acid
DMJAG7M	DE	Discovery agent

DMQKU9H	ID	DMQKU9H
DMQKU9H	DN	5-(biphenyl-4-yl)-3-oxopentanoic acid
DMQKU9H	HS	Investigative
DMQKU9H	SN	CHEMBL572979; 5-(biphenyl-4-yl)-3-oxopentanoic acid
DMQKU9H	DT	Small molecular drug
DMQKU9H	PC	45483008
DMQKU9H	MW	268.31
DMQKU9H	FM	C17H16O3
DMQKU9H	IC	InChI=1S/C17H16O3/c18-16(12-17(19)20)11-8-13-6-9-15(10-7-13)14-4-2-1-3-5-14/h1-7,9-10H,8,11-12H2,(H,19,20)
DMQKU9H	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCC(=O)CC(=O)O
DMQKU9H	IK	HDXADAWBGFXTBW-UHFFFAOYSA-N
DMQKU9H	IU	3-oxo-5-(4-phenylphenyl)pentanoic acid
DMQKU9H	DE	Discovery agent

DMPQSZN	ID	DMPQSZN
DMPQSZN	DN	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide
DMPQSZN	HS	Investigative
DMPQSZN	SN	CHEMBL541239; 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide; SCHEMBL7045815
DMPQSZN	DT	Small molecular drug
DMPQSZN	PC	22915475
DMPQSZN	MW	269.34
DMPQSZN	FM	C17H19NO2
DMPQSZN	IC	InChI=1S/C17H19NO2/c19-17(18-20)9-5-4-6-14-10-12-16(13-11-14)15-7-2-1-3-8-15/h1-3,7-8,10-13,20H,4-6,9H2,(H,18,19)
DMPQSZN	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCCCC(=O)NO
DMPQSZN	IK	QQLOLMJSVXGPGC-UHFFFAOYSA-N
DMPQSZN	IU	N-hydroxy-5-(4-phenylphenyl)pentanamide
DMPQSZN	DE	Discovery agent

DMPFX0S	ID	DMPFX0S
DMPFX0S	DN	5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID
DMPFX0S	HS	Investigative
DMPFX0S	SN	5-(dimethylamino)naphthalene-2-sulfonic acid; AC1NBV3O; 5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID; SCHEMBL18300795; DB07684; 5-dimethyl-aminonaphthalene-2-sulfonic acid
DMPFX0S	DT	Small molecular drug
DMPFX0S	PC	4474224
DMPFX0S	MW	251.3
DMPFX0S	FM	C12H13NO3S
DMPFX0S	IC	InChI=1S/C12H13NO3S/c1-13(2)12-5-3-4-9-8-10(17(14,15)16)6-7-11(9)12/h3-8H,1-2H3,(H,14,15,16)
DMPFX0S	CS	CN(C)C1=CC=CC2=C1C=CC(=C2)S(=O)(=O)O
DMPFX0S	IK	VENHBDIMAAXWKI-UHFFFAOYSA-N
DMPFX0S	IU	5-(dimethylamino)naphthalene-2-sulfonic acid
DMPFX0S	DE	Discovery agent

DM1IGOD	ID	DM1IGOD
DM1IGOD	DN	5(E)-(5'-Deoxyadenosin-5'-ylidene)pentanoic acid
DM1IGOD	HS	Investigative
DM1IGOD	SN	CHEMBL496927
DM1IGOD	DT	Small molecular drug
DM1IGOD	PC	44576817
DM1IGOD	MW	349.34
DM1IGOD	FM	C15H19N5O5
DM1IGOD	IC	InChI=1S/C15H19N5O5/c16-13-10-14(18-6-17-13)20(7-19-10)15-12(24)11(23)8(25-15)4-2-1-3-5-9(21)22/h2,4,6-8,11-12,15,23-24H,1,3,5H2,(H,21,22)(H2,16,17,18)/b4-2+/t8-,11-,12-,15-/m1/s1
DM1IGOD	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)/C=C/CCCC(=O)O)O)O)N
DM1IGOD	IK	HAGCQDHTBHGTQC-VLCWARKCSA-N
DM1IGOD	IU	(E)-6-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]hex-5-enoic acid
DM1IGOD	DE	Discovery agent

DM45VRX	ID	DM45VRX
DM45VRX	DN	5-(isopropylamino)quinolin-8-ol
DM45VRX	HS	Investigative
DM45VRX	SN	CHEMBL571661; 5-(isopropylamino)quinolin-8-ol; 8-Quinolinol, 5-[(1-methylethyl)amino]-; SCHEMBL12599076; BDBM50303920
DM45VRX	DT	Small molecular drug
DM45VRX	PC	44466195
DM45VRX	MW	202.25
DM45VRX	FM	C12H14N2O
DM45VRX	IC	InChI=1S/C12H14N2O/c1-8(2)14-10-5-6-11(15)12-9(10)4-3-7-13-12/h3-8,14-15H,1-2H3
DM45VRX	CS	CC(C)NC1=C2C=CC=NC2=C(C=C1)O
DM45VRX	IK	BRXAKDWFCHQCDT-UHFFFAOYSA-N
DM45VRX	IU	5-(propan-2-ylamino)quinolin-8-ol
DM45VRX	DE	Discovery agent

DMYLIX9	ID	DMYLIX9
DMYLIX9	DN	5-(methylthio)thiophene-2-carboxylic acid
DMYLIX9	HS	Investigative
DMYLIX9	SN	20873-58-9; 5-methylsulfanylthiophene-2-carboxylic acid; 5-(methylthio)thiophene-2-carboxylic acid; 5-(methylsulfanyl)thiophene-2-carboxylic acid; CHEMBL450866; 2-thiophenecarboxylic acid, 5-(methylthio)-; 2-Thiophenecarboxylicacid, 5-(methylthio)-; 5-methylthiothiophene-2-carboxylic acid; ZERO/008316; AC1Q5UIM; Maybridge1_007717; ChemDiv2_000116; AC1Q4H1V; AC1LEM73; Cambridge id 5103856; SCHEMBL2723219; KS-00000KTP; HMS563G17; CTK1A1236; DTXSID70351935; FWFWUSLBIIIIEN-UHFFFAOYSA-N; MolPort-000-146-385; ZINC109304; HMS1369F06
DMYLIX9	DT	Small molecular drug
DMYLIX9	PC	714372
DMYLIX9	MW	174.2
DMYLIX9	FM	C6H6O2S2
DMYLIX9	IC	InChI=1S/C6H6O2S2/c1-9-5-3-2-4(10-5)6(7)8/h2-3H,1H3,(H,7,8)
DMYLIX9	CS	CSC1=CC=C(S1)C(=O)O
DMYLIX9	IK	FWFWUSLBIIIIEN-UHFFFAOYSA-N
DMYLIX9	IU	5-methylsulfanylthiophene-2-carboxylic acid
DMYLIX9	CA	CAS 20873-58-9
DMYLIX9	DE	Discovery agent

DM3TPMO	ID	DM3TPMO
DM3TPMO	DN	5'-(N-ethyl-N-isopropyl)amiloride
DM3TPMO	HS	Investigative
DM3TPMO	SN	EIPA; 5-(N-Ethyl-N-isopropyl)amiloride; 1154-25-2; Ethylisopropylamiloride; 5-(Ethylisopropyl)amiloride; Ethyl isopropyl amiloride; 5-(N-ethyl-N-isopropyl)-Amiloride; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-[ethyl(1-methylethyl)amino]-2-pyrazinecarboxamide; N-Amidino-3-amino-5-ethylisopropylamino-6-chloropyrazine carboxamide; C11H18ClN7O; CHEMBL517986; 5-(N-Ethyl-N-isopropyl) Amiloride; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-(ethyl(1-methylethyl)amino)pyrazinecarboxamide
DM3TPMO	DT	Small molecular drug
DM3TPMO	PC	1795
DM3TPMO	MW	299.76
DM3TPMO	FM	C11H18ClN7O
DM3TPMO	IC	InChI=1S/C11H18ClN7O/c1-4-19(5(2)3)9-7(12)16-6(8(13)17-9)10(20)18-11(14)15/h5H,4H2,1-3H3,(H2,13,17)(H4,14,15,18,20)
DM3TPMO	CS	CCN(C1=NC(=C(N=C1Cl)C(=O)N=C(N)N)N)C(C)C
DM3TPMO	IK	QDERNBXNXJCIQK-UHFFFAOYSA-N
DM3TPMO	IU	3-amino-6-chloro-N-(diaminomethylidene)-5-[ethyl(propan-2-yl)amino]pyrazine-2-carboxamide
DM3TPMO	CA	CAS 1154-25-2
DM3TPMO	CB	CHEBI:136538
DM3TPMO	DE	Discovery agent

DMG2VQB	ID	DMG2VQB
DMG2VQB	DN	5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-ol
DMG2VQB	HS	Investigative
DMG2VQB	DT	Small molecular drug
DMG2VQB	PC	135546485
DMG2VQB	MW	255.4
DMG2VQB	FM	C10H13N3OS2
DMG2VQB	IC	InChI=1S/C10H13N3OS2/c1-2-3-4-5-15-10-12-8-7(9(14)13-10)16-6-11-8/h6H,2-5H2,1H3,(H,12,13,14)
DMG2VQB	CS	CCCCCSC1=NC2=C(C(=O)N1)SC=N2
DMG2VQB	IK	QONMYXCFINJDMT-UHFFFAOYSA-N
DMG2VQB	IU	5-pentylsulfanyl-6H-[1,3]thiazolo[4,5-d]pyrimidin-7-one
DMG2VQB	DE	Discovery agent

DMP4RO3	ID	DMP4RO3
DMP4RO3	DN	5-(phenylethynyl)pyrimidine
DMP4RO3	HS	Investigative
DMP4RO3	SN	5-(phenylethynyl)pyrimidine; 71418-88-7; CHEMBL486244; 5-(2-phenylethynyl)pyrimidine; 5-phenylethynylpyrimidine; SCHEMBL4860070; DTXSID50399052; ZINC198515; AC1N4263; BDBM50243108; AKOS001674343; MCULE-6083144775; FCH1171193; AJ-17844; AX8280340; SR-01000501737; SR-01000501737-1
DMP4RO3	DT	Small molecular drug
DMP4RO3	PC	4074142
DMP4RO3	MW	180.2
DMP4RO3	FM	C12H8N2
DMP4RO3	IC	InChI=1S/C12H8N2/c1-2-4-11(5-3-1)6-7-12-8-13-10-14-9-12/h1-5,8-10H
DMP4RO3	CS	C1=CC=C(C=C1)C#CC2=CN=CN=C2
DMP4RO3	IK	HSQDWKSXSIUOJC-UHFFFAOYSA-N
DMP4RO3	IU	5-(2-phenylethynyl)pyrimidine
DMP4RO3	CA	CAS 71418-88-7
DMP4RO3	DE	Discovery agent

DMT60AM	ID	DMT60AM
DMT60AM	DN	5-(piperidin-1-ylsulfonyl)indoline-2,3-dione
DMT60AM	HS	Investigative
DMT60AM	SN	329905-79-5; 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione; 5-(piperidin-1-ylsulfonyl)-1H-indole-2,3-dione; 5-(Piperidine-1-sulfonyl)-1H-indole-2,3-dione; 5-[1-(Piperidinyl)sulfonyl]isatin; Isatin Sulfonamide 21; AC1N3S5Q; CHEMBL61320; BDBM10310; DTXSID40399501; MolPort-000-149-258; ZX-BK002316; ZINC2944779; MIX-0755; STK894352; BBL021638; 2990AJ; AKOS005144288; MCULE-6394963078; 5-(Piperidinosulfonyl)indoline-2,3-dione; AJ-44313; ACM329905795; AX8291419; H8238; 5-(piperidinosulfonyl)-1H-indole-2,3-dione
DMT60AM	DT	Small molecular drug
DMT60AM	PC	4117383
DMT60AM	MW	294.33
DMT60AM	FM	C13H14N2O4S
DMT60AM	IC	InChI=1S/C13H14N2O4S/c16-12-10-8-9(4-5-11(10)14-13(12)17)20(18,19)15-6-2-1-3-7-15/h4-5,8H,1-3,6-7H2,(H,14,16,17)
DMT60AM	CS	C1CCN(CC1)S(=O)(=O)C2=CC3=C(C=C2)NC(=O)C3=O
DMT60AM	IK	YATIWPMEKYVTAO-UHFFFAOYSA-N
DMT60AM	IU	5-piperidin-1-ylsulfonyl-1H-indole-2,3-dione
DMT60AM	CA	CAS 329905-79-5
DMT60AM	CB	CHEBI:149998
DMT60AM	DE	Discovery agent

DM4XGFW	ID	DM4XGFW
DM4XGFW	DN	5-(piperidin-4-yl)isothiazol-3-ol
DM4XGFW	HS	Investigative
DM4XGFW	SN	CHEMBL109209; 5-(piperidin-4-yl)isothiazol-3-ol; Thio-4-PIOL; SCHEMBL2046840; 5-(4-Piperidyl)isothiazole-3-ol; 5-Piperidin-4-yl-isothiazol-3-ol; BDBM50032951; PDSP2_001589
DM4XGFW	DT	Small molecular drug
DM4XGFW	PC	10035301
DM4XGFW	MW	184.26
DM4XGFW	FM	C8H12N2OS
DM4XGFW	IC	InChI=1S/C8H12N2OS/c11-8-5-7(12-10-8)6-1-3-9-4-2-6/h5-6,9H,1-4H2,(H,10,11)
DM4XGFW	CS	C1CNCCC1C2=CC(=O)NS2
DM4XGFW	IK	WUINUICOEAZPLK-UHFFFAOYSA-N
DM4XGFW	IU	5-piperidin-4-yl-1,2-thiazol-3-one
DM4XGFW	DE	Discovery agent

DM6GO2I	ID	DM6GO2I
DM6GO2I	DN	5-(piperidin-4-yl)isoxazol-3-ol
DM6GO2I	HS	Investigative
DM6GO2I	SN	5-Piperidin-4-yl-isoxazol-3-ol
DM6GO2I	DT	Small molecular drug
DM6GO2I	PC	125520
DM6GO2I	MW	168.19
DM6GO2I	FM	C8H12N2O2
DM6GO2I	IC	InChI=1S/C8H12N2O2/c11-8-5-7(12-10-8)6-1-3-9-4-2-6/h5-6,9H,1-4H2,(H,10,11)
DM6GO2I	CS	C1CNCCC1C2=CC(=O)NO2
DM6GO2I	IK	YYOYGSTYWVHCJR-UHFFFAOYSA-N
DM6GO2I	IU	5-piperidin-4-yl-1,2-oxazol-3-one
DM6GO2I	CA	CAS 132033-91-1
DM6GO2I	CB	CHEBI:34433
DM6GO2I	DE	Discovery agent

DM93MAX	ID	DM93MAX
DM93MAX	DN	5-(pyridin-4-yl)-1,3,4-oxadiazole-2(3H)-thione
DM93MAX	HS	Investigative
DM93MAX	SN	15264-63-8; 5-(4-Pyridyl)-1,3,4-oxadiazole-2-thiol; 5-(pyridin-4-yl)-1,3,4-oxadiazole-2-thiol; 5-pyridin-4-yl-[1,3,4]oxadiazole-2-thiol; 5-(pyridin-4-yl)-1,3,4-oxadiazole-2(3H)-thione; CHEMBL571513; 5-pyridin-4-yl-1,3,4-oxadiazole-2-thiol; 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol; TXCXZVFDWQYTIC-UHFFFAOYSA-N; 1,3,4-Oxadiazole-2(3H)-thione,5-(4-pyridinyl)-; 1,3,4-Oxadiazole-2-thiol, 5-(4-pyridinyl)-; ZERO/005315; AC1LGNJA; ChemDiv2_000174; AC1Q7F3J; Oprea1_812023; Oprea1_290121; SCHEMBL987340; SCHEMBL17065364; CTK4C7526
DM93MAX	DT	Small molecular drug
DM93MAX	PC	774383
DM93MAX	MW	179.2
DM93MAX	FM	C7H5N3OS
DM93MAX	IC	InChI=1S/C7H5N3OS/c12-7-10-9-6(11-7)5-1-3-8-4-2-5/h1-4H,(H,10,12)
DM93MAX	CS	C1=CN=CC=C1C2=NNC(=S)O2
DM93MAX	IK	TXCXZVFDWQYTIC-UHFFFAOYSA-N
DM93MAX	IU	5-pyridin-4-yl-3H-1,3,4-oxadiazole-2-thione
DM93MAX	CA	CAS 15264-63-8
DM93MAX	DE	Discovery agent

DMEL8XU	ID	DMEL8XU
DMEL8XU	DN	5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione
DMEL8XU	HS	Investigative
DMEL8XU	SN	13581-25-4; 5-(pyridin-4-yl)-1,3,4-thiadiazole-2-thiol; CHEMBL596214; 5-(4-pyridyl)-1,3,4-thiadiazole-2-thiol; 5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione; 5-pyridin-4-yl-1,3,4-thiadiazole-2-thiol; 5-mercapto-2-(pyridin-4-yl)-1,3,4-thiadiazole; 1,3,4-Thiadiazole-2(3H)-thione, 5-(4-pyridinyl)-; AC1NRXV6; 5-pyridin-4-yl-3H-1,3,4-thiadiazole-2-thione; SCHEMBL969939; CTK0F4035; DTXSID70415420; MolPort-002-738-405; BDBM50304604; ZINC13532584; STK328652; AKOS030229631; AKOS005174322; MCULE-1265725983; KB-243965; R9200; ST45106367
DMEL8XU	DT	Small molecular drug
DMEL8XU	PC	5300214
DMEL8XU	MW	195.3
DMEL8XU	FM	C7H5N3S2
DMEL8XU	IC	InChI=1S/C7H5N3S2/c11-7-10-9-6(12-7)5-1-3-8-4-2-5/h1-4H,(H,10,11)
DMEL8XU	CS	C1=CN=CC=C1C2=NNC(=S)S2
DMEL8XU	IK	BSPHQWQMWIUIPM-UHFFFAOYSA-N
DMEL8XU	IU	5-pyridin-4-yl-3H-1,3,4-thiadiazole-2-thione
DMEL8XU	CA	CAS 13581-25-4
DMEL8XU	DE	Discovery agent

DMJBK7F	ID	DMJBK7F
DMJBK7F	DN	5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione
DMJBK7F	HS	Investigative
DMJBK7F	SN	5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione; 220510-17-8; 5-(Pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione; Isatin Sulfonamide 20; 5-pyrrolidinylsulfonylisatin; AC1N3S5K; 5-pyrrolidin-1-ylsulfonyl-1H-indole-2,3-dione; SCHEMBL2486952; CHEMBL305545; BDBM10309; DTXSID80399500; QKCWUYHXHMXOLG-UHFFFAOYSA-N; ZINC2944777; 5-[1-(pyrrolidinyl)sulfonyl]isatin; 2991AJ; AKOS024262065; AJ-44312; 5-(Pyrrolizinosulfonyl)indoline-2,3-dione; AX8291337; FT-0734877; 5-(Pyrrolidin-1-ylsulfonyl)-1H-indole-2,3-dione
DMJBK7F	DT	Small molecular drug
DMJBK7F	PC	4117381
DMJBK7F	MW	280.3
DMJBK7F	FM	C12H12N2O4S
DMJBK7F	IC	InChI=1S/C12H12N2O4S/c15-11-9-7-8(3-4-10(9)13-12(11)16)19(17,18)14-5-1-2-6-14/h3-4,7H,1-2,5-6H2,(H,13,15,16)
DMJBK7F	CS	C1CCN(C1)S(=O)(=O)C2=CC3=C(C=C2)NC(=O)C3=O
DMJBK7F	IK	QKCWUYHXHMXOLG-UHFFFAOYSA-N
DMJBK7F	IU	5-pyrrolidin-1-ylsulfonyl-1H-indole-2,3-dione
DMJBK7F	CA	CAS 220510-17-8
DMJBK7F	DE	Discovery agent

DMK3TEV	ID	DMK3TEV
DMK3TEV	DN	5-(trifluoromethoxy)-1H-indole-2,3-dione
DMK3TEV	HS	Investigative
DMK3TEV	SN	5-(Trifluoromethoxy)isatin; 169037-23-4; 5-(TRIFLUOROMETHOXY)INDOLINE-2,3-DIONE; 5-(trifluoromethoxy)-1H-indole-2,3-dione; 5-trifluoromethoxyisatin; 5-Trifluoromethoxy-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 5-(trifluoromethoxy)-; MFCD00192524; 5-(Trifluoromethoxy)-2,3-indolinedione; AK-33632; 5-(Trifluoromethoxy)isatin, 97%; AC1MBXBJ; 5-trifluoromethoxy isatin; buttpark 34\07-90; ACMC-209dz9; Isatin-based compound, 36; 5-(trifluoromethoxy)-isatin; KSC498C3D; SCHEMBL457929; CHEMBL116649; KS-00000IZD; BDBM22816
DMK3TEV	DT	Small molecular drug
DMK3TEV	PC	2732752
DMK3TEV	MW	231.13
DMK3TEV	FM	C9H4F3NO3
DMK3TEV	IC	InChI=1S/C9H4F3NO3/c10-9(11,12)16-4-1-2-6-5(3-4)7(14)8(15)13-6/h1-3H,(H,13,14,15)
DMK3TEV	CS	C1=CC2=C(C=C1OC(F)(F)F)C(=O)C(=O)N2
DMK3TEV	IK	XHAJMVPMNOBILF-UHFFFAOYSA-N
DMK3TEV	IU	5-(trifluoromethoxy)-1H-indole-2,3-dione
DMK3TEV	CA	CAS 169037-23-4
DMK3TEV	DE	Discovery agent

DMM7N6K	ID	DMM7N6K
DMM7N6K	DN	5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine
DMM7N6K	HS	Investigative
DMM7N6K	DT	Small molecular drug
DMM7N6K	PC	135468219
DMM7N6K	MW	305.29
DMM7N6K	FM	C16H11N5O2
DMM7N6K	IC	InChI=1S/C16H11N5O2/c17-14-13-16(19-15(18-14)10-6-2-1-3-7-10)21(23)12-9-5-4-8-11(12)20(13)22/h1-9H,(H2,17,18,19)
DMM7N6K	CS	C1=CC=C(C=C1)C2=NC3=[N+](C4=CC=CC=C4[N+](=C3C(=N2)N)[O-])[O-]
DMM7N6K	IK	YWSUTRFYAQHJFZ-UHFFFAOYSA-N
DMM7N6K	IU	5,10-dioxido-2-phenylbenzo[g]pteridine-5,10-diium-4-amine
DMM7N6K	DE	Discovery agent

DMAQDK9	ID	DMAQDK9
DMAQDK9	DN	5,10-Methylene-6-Hydrofolic Acid
DMAQDK9	HS	Investigative
DMAQDK9	DT	Small molecular drug
DMAQDK9	PC	135403830
DMAQDK9	MW	455.4
DMAQDK9	FM	C20H21N7O6
DMAQDK9	IC	InChI=1S/C20H21N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,7,12-13H,5-6,8-9H2,(H,23,30)(H,28,29)(H,32,33)(H3,21,24,25,31)/t12-,13-/m1/s1
DMAQDK9	CS	C1[C@H]2C=NC3=C(N2CN1C4=CC=C(C=C4)C(=O)N[C@H](CCC(=O)O)C(=O)O)C(=O)NC(=N3)N
DMAQDK9	IK	BHJAPJNOACHPNI-CHWSQXEVSA-N
DMAQDK9	IU	(2R)-2-[[4-[(6aS)-3-amino-1-oxo-2,6a,7,9-tetrahydroimidazo[1,5-f]pteridin-8-yl]benzoyl]amino]pentanedioic acid
DMAQDK9	DE	Discovery agent

DMWSLTB	ID	DMWSLTB
DMWSLTB	DN	5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
DMWSLTB	HS	Investigative
DMWSLTB	SN	9-Hydroxyellipticine; 9-Hydroxyellipticin; 51131-85-2; 5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol; Hydroxyellipticine; ELLIPTICINE, 9-HYDROXY-; UNII-9G4A3ET6XG; IGIG 929; Hydroxy-9 ellipticine [French]; EINECS 257-000-0; NSC 237070; NSC 210717; 9G4A3ET6XG; CHEMBL26559; CHEBI:88297; C17H14N2O; 5,11-Dimethyl-6H-pyrido(4,3-b)carbazol-9-ol; 6H-Pyrido(4,3-b)carbazol-9-ol, 5,11-dimethyl-; 6H-Pyrido[4,3-b]carbazol-9-ol, 5,11-dimethyl-; 9-hydroxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; Hydroxy-9 ellipticine
DMWSLTB	DT	Small molecular drug
DMWSLTB	PC	91643
DMWSLTB	MW	262.3
DMWSLTB	FM	C17H14N2O
DMWSLTB	IC	InChI=1S/C17H14N2O/c1-9-14-8-18-6-5-12(14)10(2)17-16(9)13-7-11(20)3-4-15(13)19-17/h3-8,19-20H,1-2H3
DMWSLTB	CS	CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C
DMWSLTB	IK	QZTWUDDGLIDXSE-UHFFFAOYSA-N
DMWSLTB	IU	5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
DMWSLTB	CA	CAS 51131-85-2
DMWSLTB	CB	CHEBI:88297
DMWSLTB	DE	Discovery agent

DMJRXLD	ID	DMJRXLD
DMJRXLD	DN	5,3'-Dipropyl-biphenyl-2,4'-diol
DMJRXLD	HS	Investigative
DMJRXLD	SN	CHEMBL330227; 35406-31-6; Magreth-2; SCHEMBL12319404; CTK1B6970; DTXSID90432573; 3',5-Dipropylbiphenyl-2,4'-diol; BDBM50157312; AKOS030533140; 5,3''-Dipropyl-biphenyl-2,4''-diol; 5,3''''-Dipropyl-biphenyl-2,4''''-diol; [1,1'-Biphenyl]-2,4'-diol, 3',5-dipropyl-
DMJRXLD	DT	Small molecular drug
DMJRXLD	PC	9900113
DMJRXLD	MW	270.4
DMJRXLD	FM	C18H22O2
DMJRXLD	IC	InChI=1S/C18H22O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h7-12,19-20H,3-6H2,1-2H3
DMJRXLD	CS	CCCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CCC
DMJRXLD	IK	PJBHWFHBOPMXAM-UHFFFAOYSA-N
DMJRXLD	IU	2-(4-hydroxy-3-propylphenyl)-4-propylphenol
DMJRXLD	CA	CAS 35406-31-6
DMJRXLD	DE	Discovery agent

DMWL1UY	ID	DMWL1UY
DMWL1UY	DN	5,5-diethyl-2-(phenethylamino)oxazol-4(5H)-one
DMWL1UY	HS	Investigative
DMWL1UY	DT	Small molecular drug
DMWL1UY	PC	135950108
DMWL1UY	MW	260.329
DMWL1UY	FM	C15H20N2O2
DMWL1UY	IC	InChI=1S/C15H20N2O2/c1-3-15(4-2)13(18)17-14(19-15)16-11-10-12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3,(H,16,17,18)
DMWL1UY	CS	CCC1(C(=O)NC(=NCCC2=CC=CC=C2)O1)CC
DMWL1UY	IK	ARZSETSNEBJNMA-UHFFFAOYSA-N
DMWL1UY	IU	5,5-diethyl-2-(2-phenylethylimino)-1,3-oxazolidin-4-one
DMWL1UY	DE	Discovery agent

DM28LNV	ID	DM28LNV
DM28LNV	DN	5,5-Diphenyl-2-iminohydantoin
DM28LNV	HS	Investigative
DM28LNV	SN	CHEMBL291784; 5,5-Diphenyl-2-iminohydantoin; SCHEMBL4237550; 2-amino-3-methyl-5,5-diphenyl-3,5-dihydro-imidazol-4-one; BDBM50300229; 26975-80-4; 2-Imino-3-methyl-5,5-diphenylimidazolidin-4-one; 2-Imino-3-methyl-5,5-diphenyl-imidazolidin-4-one; 1-methyl-4,4-diphenyl-4,5-dihydro-1H-imidazol-2-amine
DM28LNV	DT	Small molecular drug
DM28LNV	PC	15054176
DM28LNV	MW	265.31
DM28LNV	FM	C16H15N3O
DM28LNV	IC	InChI=1S/C16H15N3O/c1-19-14(20)16(18-15(19)17,12-8-4-2-5-9-12)13-10-6-3-7-11-13/h2-11H,1H3,(H2,17,18)
DM28LNV	CS	CN1C(=O)C(N=C1N)(C2=CC=CC=C2)C3=CC=CC=C3
DM28LNV	IK	RNWLAFWLSSMCLN-UHFFFAOYSA-N
DM28LNV	IU	2-amino-3-methyl-5,5-diphenylimidazol-4-one
DM28LNV	DE	Discovery agent

DMPVBC2	ID	DMPVBC2
DMPVBC2	DN	5,5'-methylenebis(1,3,4-oxadiazole-2(3H)-thione)
DMPVBC2	HS	Investigative
DMPVBC2	SN	CHEMBL608132; bis-(5-mercapto-1,3,4-oxadiazol-2-yl)-methane; BDBM50304603; 90748-72-4; Bis(1,3,4-oxadiazol-2-methyl)-5-thione
DMPVBC2	DT	Small molecular drug
DMPVBC2	PC	14711339
DMPVBC2	MW	216.2
DMPVBC2	FM	C5H4N4O2S2
DMPVBC2	IC	InChI=1S/C5H4N4O2S2/c12-4-8-6-2(10-4)1-3-7-9-5(13)11-3/h1H2,(H,8,12)(H,9,13)
DMPVBC2	CS	C(C1=NNC(=S)O1)C2=NNC(=S)O2
DMPVBC2	IK	FIBRGBFKOVAXHJ-UHFFFAOYSA-N
DMPVBC2	IU	5-[(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)methyl]-3H-1,3,4-oxadiazole-2-thione
DMPVBC2	DE	Discovery agent

DMW13SO	ID	DMW13SO
DMW13SO	DN	5,5'-methylenebis(1,3,4-thiadiazole-2(3H)-thione)
DMW13SO	HS	Investigative
DMW13SO	SN	CHEMBL595241; 70066-79-4; SCHEMBL737372; CTK2G3163; DTXSID80673150; BDBM50320717; Bis(1,3,4-thiadiazole-2-methyl)-5-thione; 5,5'-Methylenedi(1,3,4-thiadiazole-2(3H)-thione); 1,3,4-Thiadiazole-2(3H)-thione, 5,5'-methylenebis-
DMW13SO	DT	Small molecular drug
DMW13SO	PC	46225958
DMW13SO	MW	248.4
DMW13SO	FM	C5H4N4S4
DMW13SO	IC	InChI=1S/C5H4N4S4/c10-4-8-6-2(12-4)1-3-7-9-5(11)13-3/h1H2,(H,8,10)(H,9,11)
DMW13SO	CS	C(C1=NNC(=S)S1)C2=NNC(=S)S2
DMW13SO	IK	XUFJHTRVFXOZOI-UHFFFAOYSA-N
DMW13SO	IU	5-[(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)methyl]-3H-1,3,4-thiadiazole-2-thione
DMW13SO	CA	CAS 70066-79-4
DMW13SO	DE	Discovery agent

DMZ693W	ID	DMZ693W
DMZ693W	DN	5,5'-methylenebis(3,4-dibromobenzene-1,2-diol)
DMZ693W	HS	Investigative
DMZ693W	SN	CHEMBL253690; 65487-76-5; CTK1J6652; DTXSID90466393; BDBM50329688; 3,4-dibromo-5-[(2,3-dibromo-4,5-dihydroxy-phenyl)methyl]benzene-1,2-diol; 5,5'-Methylenebis(3,4-dibromopyrocatechol); 1,2-Benzenediol, 4,4'-methylenebis[5,6-dibromo-; 5,5''-methylenebis(3,4-dibromobenzene-1,2-diol); 2,2',3,3'-tetrabromo-4,4',5,5'-tetrahydroxy-diphenylmethane
DMZ693W	DT	Small molecular drug
DMZ693W	PC	11455599
DMZ693W	MW	547.8
DMZ693W	FM	C13H8Br4O4
DMZ693W	IC	InChI=1S/C13H8Br4O4/c14-8-4(2-6(18)12(20)10(8)16)1-5-3-7(19)13(21)11(17)9(5)15/h2-3,18-21H,1H2
DMZ693W	CS	C1=C(C(=C(C(=C1O)O)Br)Br)CC2=CC(=C(C(=C2Br)Br)O)O
DMZ693W	IK	WIAKRAUTQVUHHL-UHFFFAOYSA-N
DMZ693W	IU	3,4-dibromo-5-[(2,3-dibromo-4,5-dihydroxyphenyl)methyl]benzene-1,2-diol
DMZ693W	CA	CAS 65487-76-5
DMZ693W	DE	Discovery agent

DMIQAO9	ID	DMIQAO9
DMIQAO9	DN	5,6,7,8-tetrahydroanthracene-1,4-dione
DMIQAO9	HS	Investigative
DMIQAO9	SN	CHEMBL508233; 5,6,7,8-tetrahydroanthracene-1,4-dione; SCHEMBL11038167
DMIQAO9	DT	Small molecular drug
DMIQAO9	PC	44582382
DMIQAO9	MW	212.24
DMIQAO9	FM	C14H12O2
DMIQAO9	IC	InChI=1S/C14H12O2/c15-13-5-6-14(16)12-8-10-4-2-1-3-9(10)7-11(12)13/h5-8H,1-4H2
DMIQAO9	CS	C1CCC2=CC3=C(C=C2C1)C(=O)C=CC3=O
DMIQAO9	IK	DWXLNXHEUIUNRF-UHFFFAOYSA-N
DMIQAO9	IU	5,6,7,8-tetrahydroanthracene-1,4-dione
DMIQAO9	DE	Discovery agent

DMTL4S9	ID	DMTL4S9
DMTL4S9	DN	5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione
DMTL4S9	HS	Investigative
DMTL4S9	SN	5,6,7-trichloro-1,4-dihydroquinoxaline-2,3-dione; CHEMBL43846; 172215-97-3; 5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione; SCHEMBL8904175
DMTL4S9	DT	Small molecular drug
DMTL4S9	PC	10849325
DMTL4S9	MW	265.5
DMTL4S9	FM	C8H3Cl3N2O2
DMTL4S9	IC	InChI=1S/C8H3Cl3N2O2/c9-2-1-3-6(5(11)4(2)10)13-8(15)7(14)12-3/h1H,(H,12,14)(H,13,15)
DMTL4S9	CS	C1=C2C(=C(C(=C1Cl)Cl)Cl)NC(=O)C(=O)N2
DMTL4S9	IK	MVCXAPXDPCEJBN-UHFFFAOYSA-N
DMTL4S9	IU	5,6,7-trichloro-1,4-dihydroquinoxaline-2,3-dione
DMTL4S9	DE	Discovery agent

DM53CLY	ID	DM53CLY
DM53CLY	DN	5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline
DM53CLY	HS	Investigative
DM53CLY	SN	CHEMBL86717; 5,6,7-trimethoxy-3-pyridin-4-yl-quinoline; BDBM50039649
DM53CLY	DT	Small molecular drug
DM53CLY	PC	9994707
DM53CLY	MW	296.32
DM53CLY	FM	C17H16N2O3
DM53CLY	IC	InChI=1S/C17H16N2O3/c1-20-15-9-14-13(16(21-2)17(15)22-3)8-12(10-19-14)11-4-6-18-7-5-11/h4-10H,1-3H3
DM53CLY	CS	COC1=C(C(=C2C=C(C=NC2=C1)C3=CC=NC=C3)OC)OC
DM53CLY	IK	FQVDOOFEQQAHPX-UHFFFAOYSA-N
DM53CLY	IU	5,6,7-trimethoxy-3-pyridin-4-ylquinoline
DM53CLY	DE	Discovery agent

DM6VPF4	ID	DM6VPF4
DM6VPF4	DN	5,6,7-Trimethyl-2-p-tolyl-chromen-4-one
DM6VPF4	HS	Investigative
DM6VPF4	SN	CHEMBL168080; 5,6,7-Trimethyl-2-p-tolyl-chromen-4-one; 4',5,6,7-Tetramethylflavone
DM6VPF4	DT	Small molecular drug
DM6VPF4	PC	44378768
DM6VPF4	MW	278.3
DM6VPF4	FM	C19H18O2
DM6VPF4	IC	InChI=1S/C19H18O2/c1-11-5-7-15(8-6-11)17-10-16(20)19-14(4)13(3)12(2)9-18(19)21-17/h5-10H,1-4H3
DM6VPF4	CS	CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3C)C)C
DM6VPF4	IK	CMMLREBGPOOVPU-UHFFFAOYSA-N
DM6VPF4	IU	5,6,7-trimethyl-2-(4-methylphenyl)chromen-4-one
DM6VPF4	DE	Discovery agent

DMDCE1M	ID	DMDCE1M
DMDCE1M	DN	5,6,8-trichloroquinoline-4-one-3-carboxylic acid
DMDCE1M	HS	Investigative
DMDCE1M	SN	5,6,8-trichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; AC1LEUE0; Oprea1_066465; CHEMBL553336; 5,6,8-trichloro-4-oxo-1H-quinoline-3-carboxylic Acid; SCHEMBL19615682; MolPort-000-563-469; ZINC117346; STK970936
DMDCE1M	DT	Small molecular drug
DMDCE1M	PC	718154
DMDCE1M	MW	292.5
DMDCE1M	FM	C10H4Cl3NO3
DMDCE1M	IC	InChI=1S/C10H4Cl3NO3/c11-4-1-5(12)8-6(7(4)13)9(15)3(2-14-8)10(16)17/h1-2H,(H,14,15)(H,16,17)
DMDCE1M	CS	C1=C(C2=C(C(=C1Cl)Cl)C(=O)C(=CN2)C(=O)O)Cl
DMDCE1M	IK	DIMMLVONVUPWHB-UHFFFAOYSA-N
DMDCE1M	IU	5,6,8-trichloro-4-oxo-1H-quinoline-3-carboxylic acid
DMDCE1M	CA	CAS 302553-01-1
DMDCE1M	DE	Discovery agent

DMNHT7Q	ID	DMNHT7Q
DMNHT7Q	DN	5,6,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one
DMNHT7Q	HS	Investigative
DMNHT7Q	SN	5,6,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one; casimiroin analogue, 1p; CHEMBL449065; BDBM29227; MolPort-028-745-486; ZINC40829644; 1,4-Dimethyl-5,6,8-trimethoxyquinolin-2(1H)-one
DMNHT7Q	DT	Small molecular drug
DMNHT7Q	PC	15306617
DMNHT7Q	MW	263.29
DMNHT7Q	FM	C14H17NO4
DMNHT7Q	IC	InChI=1S/C14H17NO4/c1-8-6-11(16)15(2)13-9(17-3)7-10(18-4)14(19-5)12(8)13/h6-7H,1-5H3
DMNHT7Q	CS	CC1=CC(=O)N(C2=C1C(=C(C=C2OC)OC)OC)C
DMNHT7Q	IK	PJUNWPXRLZUYPB-UHFFFAOYSA-N
DMNHT7Q	IU	5,6,8-trimethoxy-1,4-dimethylquinolin-2-one
DMNHT7Q	DE	Discovery agent

DM97XZ1	ID	DM97XZ1
DM97XZ1	DN	5,6,8-Trimethoxy-4-methylquinolin-2(1H)-one
DM97XZ1	HS	Investigative
DM97XZ1	SN	5,6,8-Trimethoxy-4-methylquinolin-2(1H)-one; casimiroin analogue, 1o; CHEMBL493181; BDBM29226; MolPort-028-745-485; ZINC40957356; 4-Methyl-5,6,8-trimethoxyquinolin-2(1H)-one
DM97XZ1	DT	Small molecular drug
DM97XZ1	PC	15306616
DM97XZ1	MW	249.26
DM97XZ1	FM	C13H15NO4
DM97XZ1	IC	InChI=1S/C13H15NO4/c1-7-5-10(15)14-12-8(16-2)6-9(17-3)13(18-4)11(7)12/h5-6H,1-4H3,(H,14,15)
DM97XZ1	CS	CC1=CC(=O)NC2=C1C(=C(C=C2OC)OC)OC
DM97XZ1	IK	YRUICGVVPDTGCH-UHFFFAOYSA-N
DM97XZ1	IU	5,6,8-trimethoxy-4-methyl-1H-quinolin-2-one
DM97XZ1	DE	Discovery agent

DM6A4LM	ID	DM6A4LM
DM6A4LM	DN	5,6-Bis-p-tolylamino-isoindole-1,3-dione
DM6A4LM	HS	Investigative
DM6A4LM	SN	CHEMBL7914; 5,6-Bis-p-tolylamino-isoindole-1,3-dione; SCHEMBL8834183; BDBM50040920
DM6A4LM	DT	Small molecular drug
DM6A4LM	PC	10360970
DM6A4LM	MW	357.4
DM6A4LM	FM	C22H19N3O2
DM6A4LM	IC	InChI=1S/C22H19N3O2/c1-13-3-7-15(8-4-13)23-19-11-17-18(22(27)25-21(17)26)12-20(19)24-16-9-5-14(2)6-10-16/h3-12,23-24H,1-2H3,(H,25,26,27)
DM6A4LM	CS	CC1=CC=C(C=C1)NC2=C(C=C3C(=C2)C(=O)NC3=O)NC4=CC=C(C=C4)C
DM6A4LM	IK	KSZXNFIEZNOXCC-UHFFFAOYSA-N
DM6A4LM	IU	5,6-bis(4-methylanilino)isoindole-1,3-dione
DM6A4LM	DE	Discovery agent

DMDE7XJ	ID	DMDE7XJ
DMDE7XJ	DN	5,6-Cyclic-Tetrahydropteridine
DMDE7XJ	HS	Investigative
DMDE7XJ	DT	Small molecular drug
DMDE7XJ	PC	135509077
DMDE7XJ	MW	223.19
DMDE7XJ	FM	C8H9N5O3
DMDE7XJ	IC	InChI=1S/C8H9N5O3/c9-7-11-5-4(6(14)12-7)13-3(1-10-5)2-16-8(13)15/h3H,1-2H2,(H4,9,10,11,12,14)/t3-/m1/s1
DMDE7XJ	CS	C1[C@@H]2COC(=O)N2C3=C(N1)N=C(NC3=O)N
DMDE7XJ	IK	XAZOBOCYEGBXHD-GSVOUGTGSA-N
DMDE7XJ	IU	(6aR)-3-amino-5,6,6a,7-tetrahydro-2H-[1,3]oxazolo[3,4-f]pteridine-1,9-dione
DMDE7XJ	DE	Discovery agent

DM3JB6S	ID	DM3JB6S
DM3JB6S	DN	5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
DM3JB6S	HS	Investigative
DM3JB6S	SN	53-85-0; 5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole; NSC 401575; Dichlororibofuranosylbenzimidazole; DRB; C12H12Cl2N2O4; 5,6-Dichlorobenzimidazole riboside; BRN 0039123; CHEMBL375530; UNII-8153319T3Q; 5,6-Dichloro-1-Beta-D-Ribofuranosyl-1h-Benzimidazole; 8153319T3Q; (2R,3R,4S,5R)-2-(5,6-Dichloro-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; Benzimidazole, 5,6-dichloro-1-beta-D-ribofuranosyl-; 5,6-Dichloro-1-.beta.-D-ribofuranosylbenzimidazole
DM3JB6S	DT	Small molecular drug
DM3JB6S	PC	5894
DM3JB6S	MW	319.14
DM3JB6S	FM	C12H12Cl2N2O4
DM3JB6S	IC	InChI=1S/C12H12Cl2N2O4/c13-5-1-7-8(2-6(5)14)16(4-15-7)12-11(19)10(18)9(3-17)20-12/h1-2,4,9-12,17-19H,3H2/t9-,10-,11-,12-/m1/s1
DM3JB6S	CS	C1=C2C(=CC(=C1Cl)Cl)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DM3JB6S	IK	XHSQDZXAVJRBMX-DDHJBXDOSA-N
DM3JB6S	IU	(2R,3R,4S,5R)-2-(5,6-dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM3JB6S	CA	CAS 53-85-0
DM3JB6S	DE	Discovery agent

DMN1S35	ID	DMN1S35
DMN1S35	DN	5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35	HS	Investigative
DMN1S35	SN	Anagrelide impurity 5; 2-Amino-5,6-dichloro-3,4-dihydroquinazoline; 444904-63-6; CHEMBL1548; 2-Quinazolinamine, 5,6-dichloro-1,4-dihydro-; W-202785; SCHEMBL1569300; CTK1D2410; DTXSID80432648; VBKOTIVQMCTTAQ-UHFFFAOYSA-N; ZINC29130869; BDBM50371434; AKOS030254941; 5,6-Dichloro-1,4-dihydro-2-quinazolinamine; 2-amino-5,6-dichloro-3,4dihydroquinazoline; FT-0722369
DMN1S35	DT	Small molecular drug
DMN1S35	PC	9904281
DMN1S35	MW	216.06
DMN1S35	FM	C8H7Cl2N3
DMN1S35	IC	InChI=1S/C8H7Cl2N3/c9-5-1-2-6-4(7(5)10)3-12-8(11)13-6/h1-2H,3H2,(H3,11,12,13)
DMN1S35	CS	C1C2=C(C=CC(=C2Cl)Cl)NC(=N1)N
DMN1S35	IK	VBKOTIVQMCTTAQ-UHFFFAOYSA-N
DMN1S35	IU	5,6-dichloro-1,4-dihydroquinazolin-2-amine
DMN1S35	CA	CAS 444904-63-6
DMN1S35	DE	Discovery agent

DMR2OMU	ID	DMR2OMU
DMR2OMU	DN	5,6-Dichloro-N-(2-morpholinoethyl)nicotinamide
DMR2OMU	HS	Investigative
DMR2OMU	SN	5,6-Dichloro-N-(2-morpholinoethyl)nicotinamide; CHEMBL589770; MolPort-005-210-928; ZINC21809540; BDBM50307191; AKOS005859120; 1039842-02-8; Z32410257
DMR2OMU	DT	Small molecular drug
DMR2OMU	PC	29786172
DMR2OMU	MW	304.17
DMR2OMU	FM	C12H15Cl2N3O2
DMR2OMU	IC	InChI=1S/C12H15Cl2N3O2/c13-10-7-9(8-16-11(10)14)12(18)15-1-2-17-3-5-19-6-4-17/h7-8H,1-6H2,(H,15,18)
DMR2OMU	CS	C1COCCN1CCNC(=O)C2=CC(=C(N=C2)Cl)Cl
DMR2OMU	IK	BNRXERZZOCTDMX-UHFFFAOYSA-N
DMR2OMU	IU	5,6-dichloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMR2OMU	DE	Discovery agent

DMZL87A	ID	DMZL87A
DMZL87A	DN	5,6-Dichloro-N-(3-morpholinopropyl)nicotinamide
DMZL87A	HS	Investigative
DMZL87A	SN	CHEMBL597764; 5,6-Dichloro-N-(3-morpholinopropyl)nicotinamide; BDBM50307204
DMZL87A	DT	Small molecular drug
DMZL87A	PC	43236315
DMZL87A	MW	318.2
DMZL87A	FM	C13H17Cl2N3O2
DMZL87A	IC	InChI=1S/C13H17Cl2N3O2/c14-11-8-10(9-17-12(11)15)13(19)16-2-1-3-18-4-6-20-7-5-18/h8-9H,1-7H2,(H,16,19)
DMZL87A	CS	C1COCCN1CCCNC(=O)C2=CC(=C(N=C2)Cl)Cl
DMZL87A	IK	TZOXTUGEEZYMTF-UHFFFAOYSA-N
DMZL87A	IU	5,6-dichloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DMZL87A	DE	Discovery agent

DM94V8D	ID	DM94V8D
DM94V8D	DN	5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one
DM94V8D	HS	Investigative
DM94V8D	SN	5,6-dihydroxy-7-nitro-1-indanone; 383382-47-6; CHEMBL9039; SCHEMBL7432202; ULOQNEJBWLIGHK-UHFFFAOYSA-N; 5,6-Dihydroxy-7-nitro-indan-1-one
DM94V8D	DT	Small molecular drug
DM94V8D	PC	9920742
DM94V8D	MW	209.16
DM94V8D	FM	C9H7NO5
DM94V8D	IC	InChI=1S/C9H7NO5/c11-5-2-1-4-3-6(12)9(13)8(7(4)5)10(14)15/h3,12-13H,1-2H2
DM94V8D	CS	C1CC(=O)C2=C(C(=C(C=C21)O)O)[N+](=O)[O-]
DM94V8D	IK	ULOQNEJBWLIGHK-UHFFFAOYSA-N
DM94V8D	IU	5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one
DM94V8D	DE	Discovery agent

DM07HYA	ID	DM07HYA
DM07HYA	DN	5,6-dinitroacenaphthoquinone
DM07HYA	HS	Investigative
DM07HYA	SN	5,6-dinitroacenaphthoquinone; 5,6-dinitroacenaphthylene-1,2-dione; AC1MQHVL; 5,6-dinitroacenaphthenequinone; CHEMBL235289; SCHEMBL2699746; BDBM22854; MolPort-003-895-771; 1,2-Dione-Based Compound, 11; AKOS024343013; MCULE-5132922926; 27471-02-9; 5,6-dinitro-1,2-dihydroacenaphthylenedione
DM07HYA	DT	Small molecular drug
DM07HYA	PC	3477013
DM07HYA	MW	272.17
DM07HYA	FM	C12H4N2O6
DM07HYA	IC	InChI=1S/C12H4N2O6/c15-11-5-1-3-7(13(17)18)10-8(14(19)20)4-2-6(9(5)10)12(11)16/h1-4H
DM07HYA	CS	C1=CC(=C2C(=CC=C3C2=C1C(=O)C3=O)[N+](=O)[O-])[N+](=O)[O-]
DM07HYA	IK	HKNXJYVCBQHLBT-UHFFFAOYSA-N
DM07HYA	IU	5,6-dinitroacenaphthylene-1,2-dione
DM07HYA	DE	Discovery agent

DMXTYCU	ID	DMXTYCU
DMXTYCU	DN	5,6-epoxyeicosatrienoic acid
DMXTYCU	HS	Investigative
DMXTYCU	SN	(+/-)5,6-EpETrE; (+/-)5,6-epoxy-8Z,11Z,14Z-eicosatrienoic acid
DMXTYCU	DT	Small molecular drug
DMXTYCU	PC	5283202
DMXTYCU	MW	320.5
DMXTYCU	FM	C20H32O3
DMXTYCU	IC	InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-19(23-18)16-14-17-20(21)22/h6-7,9-10,12-13,18-19H,2-5,8,11,14-17H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-
DMXTYCU	CS	CCCCC/C=C\\C/C=C\\C/C=C\\CC1C(O1)CCCC(=O)O
DMXTYCU	IK	VBQNSZQZRAGRIX-QNEBEIHSSA-N
DMXTYCU	IU	4-[3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trienyl]oxiran-2-yl]butanoic acid
DMXTYCU	CA	CAS 81246-84-6
DMXTYCU	CB	CHEBI:34450
DMXTYCU	DE	Discovery agent

DMA50BQ	ID	DMA50BQ
DMA50BQ	DN	5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione
DMA50BQ	HS	Investigative
DMA50BQ	SN	CHEMBL336017; 5,7-Dibromo-1,4-dihydro-2,3-quinoxalinedione; 153504-78-0; 5,7-dibromo-1,4-dihydroquinoxaline-2,3-dione; Oprea1_150165; SCHEMBL2638792; SCHEMBL8557193; KAMOVQVEAFPAHG-UHFFFAOYSA-N
DMA50BQ	DT	Small molecular drug
DMA50BQ	PC	10591750
DMA50BQ	MW	319.94
DMA50BQ	FM	C8H4Br2N2O2
DMA50BQ	IC	InChI=1S/C8H4Br2N2O2/c9-3-1-4(10)6-5(2-3)11-7(13)8(14)12-6/h1-2H,(H,11,13)(H,12,14)
DMA50BQ	CS	C1=C(C=C(C2=C1NC(=O)C(=O)N2)Br)Br
DMA50BQ	IK	KAMOVQVEAFPAHG-UHFFFAOYSA-N
DMA50BQ	IU	5,7-dibromo-1,4-dihydroquinoxaline-2,3-dione
DMA50BQ	DE	Discovery agent

DMZLOVB	ID	DMZLOVB
DMZLOVB	DN	5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol
DMZLOVB	HS	Investigative
DMZLOVB	SN	7-Bromoeudistomine D; 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol; 7-bromo-eudistomin D; CHEMBL272185; 101927-49-5; Bromo-eudistomin D; Bromoeudistomin D; AC1L2SZQ; 5,7-Dibromo-9H-prido(3,4-b)indol-6-ol; SCHEMBL7085913; DTXSID80144350; BDBM50207817; 9H-Prido(3,4-b)indol-6-ol, 5,7-dibromo-
DMZLOVB	DT	Small molecular drug
DMZLOVB	PC	127993
DMZLOVB	MW	341.99
DMZLOVB	FM	C11H6Br2N2O
DMZLOVB	IC	InChI=1S/C11H6Br2N2O/c12-6-3-7-9(10(13)11(6)16)5-1-2-14-4-8(5)15-7/h1-4,15-16H
DMZLOVB	CS	C1=CN=CC2=C1C3=C(C(=C(C=C3N2)Br)O)Br
DMZLOVB	IK	UNIUKKWPGRGSRQ-UHFFFAOYSA-N
DMZLOVB	IU	5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol
DMZLOVB	CA	CAS 101927-49-5
DMZLOVB	DE	Discovery agent

DMOJ5LM	ID	DMOJ5LM
DMOJ5LM	DN	5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione
DMOJ5LM	HS	Investigative
DMOJ5LM	SN	CHEMBL282003; 5,7-dichloroquinoxaline-2,3-diol; 5,7-Dichloro-quinoxaline-2,3-diol; BAS 01357242; 5,7-dichloro-1,4-dihydroquinoxaline-2,3-dione; 5,7-Dichloro-1,4-dihydro-2,3-quinoxalinedione; MLS000026787; AC1LCHFV; 5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione; Oprea1_426848; SCHEMBL7345532; SCHEMBL2639494; MolPort-002-737-915; DBSHFABBWSZJLZ-UHFFFAOYSA-N; HMS2397P18; ZINC12428297; STK782684; BDBM50008757; AKOS022421131; AKOS005619834; AKOS000543707; MCULE-5094494417; ST088493; ST042190; SMR000010423; 4029-54-3
DMOJ5LM	DT	Small molecular drug
DMOJ5LM	PC	650260
DMOJ5LM	MW	231.03
DMOJ5LM	FM	C8H4Cl2N2O2
DMOJ5LM	IC	InChI=1S/C8H4Cl2N2O2/c9-3-1-4(10)6-5(2-3)11-7(13)8(14)12-6/h1-2H,(H,11,13)(H,12,14)
DMOJ5LM	CS	C1=C(C=C(C2=C1NC(=O)C(=O)N2)Cl)Cl
DMOJ5LM	IK	DBSHFABBWSZJLZ-UHFFFAOYSA-N
DMOJ5LM	IU	5,7-dichloro-1,4-dihydroquinoxaline-2,3-dione
DMOJ5LM	DE	Discovery agent

DMFHDWG	ID	DMFHDWG
DMFHDWG	DN	5,7-dichloro-1H-indole-2,3-dione
DMFHDWG	HS	Investigative
DMFHDWG	SN	5,7-Dichloroisatin; 6374-92-1; 5,7-Dichloroindoline-2,3-dione; 5,7-Dichloro-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 5,7-dichloro-; NSC26045; 5,7-dichloro-2,3-dihydro-1H-indole-2,3-dione; MLS002639083; AYGGQJHJRFZDFH-UHFFFAOYSA-N; 5,7-dichloro-1H-benzo[d]azolidine-2,3-dione; 5,7-dichlor-1h-indol-2,3-dion; EINECS 228-928-3; Indole-2,3-dione, 5,7-dichloro-; Isatin,7-dichloro-; PubChem22561; AC1Q3MQY; Isatin, 5,7-dichloro-; ACMC-1B7TC; NCIMech_000038; Isatin-based compound, 53; Cambridge id 5228213; AC1Q3I9X; CBDivE_012174
DMFHDWG	DT	Small molecular drug
DMFHDWG	PC	80771
DMFHDWG	MW	216.02
DMFHDWG	FM	C8H3Cl2NO2
DMFHDWG	IC	InChI=1S/C8H3Cl2NO2/c9-3-1-4-6(5(10)2-3)11-8(13)7(4)12/h1-2H,(H,11,12,13)
DMFHDWG	CS	C1=C(C=C(C2=C1C(=O)C(=O)N2)Cl)Cl
DMFHDWG	IK	AYGGQJHJRFZDFH-UHFFFAOYSA-N
DMFHDWG	IU	5,7-dichloro-1H-indole-2,3-dione
DMFHDWG	CA	CAS 6374-92-1
DMFHDWG	DE	Discovery agent

DMUADN4	ID	DMUADN4
DMUADN4	DN	5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMUADN4	HS	Investigative
DMUADN4	PC	23354226
DMUADN4	MW	247.03
DMUADN4	FM	C8H4Cl2N2O3
DMUADN4	IC	InChI=1S/C8H4Cl2N2O3/c9-3-1-4(10)6-5(2-3)11-8(14)12(15)7(6)13/h1-2,15H,(H,11,14)
DMUADN4	CS	C1=C(C=C(C2=C1NC(=O)N(C2=O)O)Cl)Cl
DMUADN4	IK	MVMRFDFKPNDLQJ-UHFFFAOYSA-N
DMUADN4	IU	5,7-dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMUADN4	DE	Discovery agent

DMZJKIU	ID	DMZJKIU
DMZJKIU	DN	5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one
DMZJKIU	HS	Investigative
DMZJKIU	SN	CHEMBL104298
DMZJKIU	DT	Small molecular drug
DMZJKIU	PC	54710618
DMZJKIU	MW	306.1
DMZJKIU	FM	C15H9Cl2NO2
DMZJKIU	IC	InChI=1S/C15H9Cl2NO2/c16-9-6-10(17)13-11(7-9)18-15(20)12(14(13)19)8-4-2-1-3-5-8/h1-7H,(H2,18,19,20)
DMZJKIU	CS	C1=CC=C(C=C1)C2=C(C3=C(C=C(C=C3Cl)Cl)NC2=O)O
DMZJKIU	IK	ZIMBGBQTQUNKLP-UHFFFAOYSA-N
DMZJKIU	IU	5,7-dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one
DMZJKIU	DE	Discovery agent

DMHKQ1L	ID	DMHKQ1L
DMHKQ1L	DN	5,7-Dichlorokynurenic Acid
DMHKQ1L	HS	Investigative
DMHKQ1L	SN	Dcka
DMHKQ1L	DT	Small molecular drug
DMHKQ1L	PC	1779
DMHKQ1L	MW	258.05
DMHKQ1L	FM	C10H5Cl2NO3
DMHKQ1L	IC	InChI=1S/C10H5Cl2NO3/c11-4-1-5(12)9-6(2-4)13-7(10(15)16)3-8(9)14/h1-3H,(H,13,14)(H,15,16)
DMHKQ1L	CS	C1=C(C=C(C2=C1NC(=CC2=O)C(=O)O)Cl)Cl
DMHKQ1L	IK	BGKFPRIGXAVYNX-UHFFFAOYSA-N
DMHKQ1L	IU	5,7-dichloro-4-oxo-1H-quinoline-2-carboxylic acid
DMHKQ1L	CA	CAS 131123-76-7
DMHKQ1L	CB	CHEBI:107660
DMHKQ1L	DE	Discovery agent

DMA61I2	ID	DMA61I2
DMA61I2	DN	5,7-dihydroxy-3-phenyl-3H-quinazolin-4-one
DMA61I2	HS	Investigative
DMA61I2	SN	3-arylquinazolinone, 1au; CHEMBL378572; BDBM19929
DMA61I2	DT	Small molecular drug
DMA61I2	PC	11579722
DMA61I2	MW	254.24
DMA61I2	FM	C14H10N2O3
DMA61I2	IC	InChI=1S/C14H10N2O3/c17-10-6-11-13(12(18)7-10)14(19)16(8-15-11)9-4-2-1-3-5-9/h1-8,17-18H
DMA61I2	CS	C1=CC=C(C=C1)N2C=NC3=C(C2=O)C(=CC(=C3)O)O
DMA61I2	IK	LUBZIRZXRMLBKH-UHFFFAOYSA-N
DMA61I2	IU	5,7-dihydroxy-3-phenylquinazolin-4-one
DMA61I2	DE	Discovery agent

DM724JF	ID	DM724JF
DM724JF	DN	5,7-Dimethoxy-3-pyridin-4-yl-quinoline
DM724JF	HS	Investigative
DM724JF	SN	5,7-Dimethoxy-3-(4-pyridinyl)quinoline; 137206-97-4; 5,7-dimethoxy-3-(pyridin-4-yl)quinoline; CHEMBL68423; Quinoline,5,7-dimethoxy-3-(4-pyridinyl)-; 5,7-Dmpq; Bio1_000429; Tocris-1222; 5,7-Dimethoxy-3-pyridin-4-yl-quinoline; ACMC-20c86u; AC1L1F9B; AC1Q4YD3; SCHEMBL3652915; CTK4C0691; DTXSID90160107; Bio1_001407; Bio1_000918; ZINC2581408; BDBM50039655; AKOS030239521; 5,7-Dimethoxy-3-(4-pyridyl)quinoline; 5,7-dimethoxy-3-pyridin-4-ylquinoline; NCGC00025053-01; AJ-43025; KB-291722; DB-063190
DM724JF	DT	Small molecular drug
DM724JF	PC	3139
DM724JF	MW	266.29
DM724JF	FM	C16H14N2O2
DM724JF	IC	InChI=1S/C16H14N2O2/c1-19-13-8-15-14(16(9-13)20-2)7-12(10-18-15)11-3-5-17-6-4-11/h3-10H,1-2H3
DM724JF	CS	COC1=CC2=C(C=C(C=N2)C3=CC=NC=C3)C(=C1)OC
DM724JF	IK	HBXDLZBPKJEWHZ-UHFFFAOYSA-N
DM724JF	IU	5,7-dimethoxy-3-pyridin-4-ylquinoline
DM724JF	CA	CAS 137206-97-4
DM724JF	DE	Discovery agent

DMJAQ41	ID	DMJAQ41
DMJAQ41	DN	5,7-Dimethoxy-3-thiophen-3-yl-quinoline
DMJAQ41	HS	Investigative
DMJAQ41	SN	CHEMBL66071; 5,7-dimethoxy-3-thiophen-3-yl-quinoline; ZINC3834026
DMJAQ41	DT	Small molecular drug
DMJAQ41	PC	10355832
DMJAQ41	MW	271.3
DMJAQ41	FM	C15H13NO2S
DMJAQ41	IC	InChI=1S/C15H13NO2S/c1-17-12-6-14-13(15(7-12)18-2)5-11(8-16-14)10-3-4-19-9-10/h3-9H,1-2H3
DMJAQ41	CS	COC1=CC2=C(C=C(C=N2)C3=CSC=C3)C(=C1)OC
DMJAQ41	IK	OOSYGDRIWJDGFV-UHFFFAOYSA-N
DMJAQ41	IU	5,7-dimethoxy-3-thiophen-3-ylquinoline
DMJAQ41	DE	Discovery agent

DMU618S	ID	DMU618S
DMU618S	DN	5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMU618S	HS	Investigative
DMU618S	SN	NSC676189; AC1NV5AO; SCHEMBL7921784; CHEMBL102019; ZINC6491121; NSC-676189; NCI60_026916; 5,7-dimethyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMU618S	DT	Small molecular drug
DMU618S	PC	5468783
DMU618S	MW	264.32
DMU618S	FM	C17H16N2O
DMU618S	IC	InChI=1S/C17H16N2O/c1-10-5-4-6-13(7-10)14-9-15(20)16-11(2)8-12(3)18-17(16)19-14/h4-9H,1-3H3,(H,18,19,20)
DMU618S	CS	CC1=CC(=CC=C1)C2=CC(=O)C3=C(N2)N=C(C=C3C)C
DMU618S	IK	RXJJJRMOQDHINF-UHFFFAOYSA-N
DMU618S	IU	5,7-dimethyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMU618S	DE	Discovery agent

DM3P79O	ID	DM3P79O
DM3P79O	DN	5,7-Dimethyl-3-thiophen-3-yl-quinoline
DM3P79O	HS	Investigative
DM3P79O	SN	CHEMBL304333; 5,7-dimethyl-3-thiophen-3-yl-quinoline; SCHEMBL8501282; ZINC3832218
DM3P79O	DT	Small molecular drug
DM3P79O	PC	10060170
DM3P79O	MW	239.3
DM3P79O	FM	C15H13NS
DM3P79O	IC	InChI=1S/C15H13NS/c1-10-5-11(2)14-7-13(8-16-15(14)6-10)12-3-4-17-9-12/h3-9H,1-2H3
DM3P79O	CS	CC1=CC(=C2C=C(C=NC2=C1)C3=CSC=C3)C
DM3P79O	IK	YXZQRTLGEGYVTJ-UHFFFAOYSA-N
DM3P79O	IU	5,7-dimethyl-3-thiophen-3-ylquinoline
DM3P79O	DE	Discovery agent

DMG4UCX	ID	DMG4UCX
DMG4UCX	DN	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione
DMG4UCX	HS	Investigative
DMG4UCX	SN	5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione; CHEMBL323335; 136529-54-9; Biomol-NT_000208; SCHEMBL8123057; SCHEMBL8114607; SCHEMBL4706926; BPBio1_001268; BDBM50038162; NCGC00163270-01; 5,7-Dinitroquinoxaline-2,3(1H,4H)-dione
DMG4UCX	DT	Small molecular drug
DMG4UCX	PC	16760018
DMG4UCX	MW	252.14
DMG4UCX	FM	C8H4N4O6
DMG4UCX	IC	InChI=1S/C8H4N4O6/c13-7-8(14)10-6-4(9-7)1-3(11(15)16)2-5(6)12(17)18/h1-2H,(H,9,13)(H,10,14)
DMG4UCX	CS	C1=C(C=C(C2=C1NC(=O)C(=O)N2)[N+](=O)[O-])[N+](=O)[O-]
DMG4UCX	IK	YUVRBZPHIDJESL-UHFFFAOYSA-N
DMG4UCX	IU	5,7-dinitro-1,4-dihydroquinoxaline-2,3-dione
DMG4UCX	DE	Discovery agent

DM4TIXY	ID	DM4TIXY
DM4TIXY	DN	5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol
DM4TIXY	HS	Investigative
DM4TIXY	SN	CHEMBL374938; 5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol; SCHEMBL14164225; BDBM50205282
DM4TIXY	DT	Small molecular drug
DM4TIXY	PC	11150373
DM4TIXY	MW	287.3
DM4TIXY	FM	C18H13N3O
DM4TIXY	IC	InChI=1S/C18H13N3O/c22-18-20-16-14(12-7-3-1-4-8-12)11-15(19-17(16)21-18)13-9-5-2-6-10-13/h1-11H,(H2,19,20,21,22)
DM4TIXY	CS	C1=CC=C(C=C1)C2=CC(=NC3=C2NC(=O)N3)C4=CC=CC=C4
DM4TIXY	IK	SHTZPAWLYJASHR-UHFFFAOYSA-N
DM4TIXY	IU	5,7-diphenyl-1,3-dihydroimidazo[4,5-b]pyridin-2-one
DM4TIXY	DE	Discovery agent

DMKXIWQ	ID	DMKXIWQ
DMKXIWQ	DN	5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol
DMKXIWQ	HS	Investigative
DMKXIWQ	DT	Small molecular drug
DMKXIWQ	PC	135463744
DMKXIWQ	MW	287.3
DMKXIWQ	FM	C18H13N3O
DMKXIWQ	IC	InChI=1S/C18H13N3O/c22-18-16-15(13-7-3-1-4-8-13)11-21(17(16)19-12-20-18)14-9-5-2-6-10-14/h1-12H,(H,19,20,22)
DMKXIWQ	CS	C1=CC=C(C=C1)C2=CN(C3=C2C(=O)NC=N3)C4=CC=CC=C4
DMKXIWQ	IK	YTLWLZPZXNOVGS-UHFFFAOYSA-N
DMKXIWQ	IU	5,7-diphenyl-3H-pyrrolo[2,3-d]pyrimidin-4-one
DMKXIWQ	DE	Discovery agent

DMOCEPA	ID	DMOCEPA
DMOCEPA	DN	5,8-Dihydroxy-1,4-naphthoquinone
DMOCEPA	HS	Investigative
DMOCEPA	SN	Naphthazarin; 475-38-7; Naphthazarine; 5,8-dihydroxynaphthalene-1,4-dione; Naphthazarone; 5,8-Dihydroxynaphthoquinone; 5,8-Dihydroxy-1,4-naphthalenedione; NAPHTHAZALIN; 5,8-Dihydroxynaphthalene-1,4(4aH,8aH)-dione; 5,8-Dihydroxy-1,4-naphthosemiquinone; CCRIS 6670; Dihydroxynaphthoquinone; EINECS 207-495-4; NSC 26647; UNII-S9IX5I5C0K; S9IX5I5C0K; CHEMBL274056; CHEBI:28849; 1,4-NAPHTHOQUINONE, 5,8-DIHYDROXY-; NSC26647; 5,8-Dihydroxy-[1,4]naphthoquinone; NSC344555
DMOCEPA	DT	Small molecular drug
DMOCEPA	PC	10141
DMOCEPA	MW	190.15
DMOCEPA	FM	C10H6O4
DMOCEPA	IC	InChI=1S/C10H6O4/c11-5-1-2-6(12)10-8(14)4-3-7(13)9(5)10/h1-4,11-12H
DMOCEPA	CS	C1=CC(=C2C(=O)C=CC(=O)C2=C1O)O
DMOCEPA	IK	RQNVIKXOOKXAJQ-UHFFFAOYSA-N
DMOCEPA	IU	5,8-dihydroxynaphthalene-1,4-dione
DMOCEPA	CA	CAS 475-38-7
DMOCEPA	CB	CHEBI:28849
DMOCEPA	DE	Malaria

DMJ1IRO	ID	DMJ1IRO
DMJ1IRO	DN	5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
DMJ1IRO	HS	Investigative
DMJ1IRO	SN	5,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one; 5,8-dimethoxy-1,4-dimethylquinolin-2-one; 131451-78-0; BAS 13027560; casimiroin analogue, 1l; AC1LT9OM; 5,8-Dimethoxy-1,4-dimethyl-1H-quinolin-2-one; CHEMBL490867; BDBM29223; MolPort-002-024-473; FTGZPMFPUDKJBX-UHFFFAOYSA-N; HMS3604K14; ZINC1423886; STK736911; AKOS000643970; DB08228; MCULE-6770591553; ST4106238; 5,8-dimethoxy-1,4-dimethylhydroquinolin-2-one; 5,8-dimethoxy-1,4-dimethyl-2(1H)-quinolinone; 1,4-Dimethyl-5,8-dimethoxyquinolin-2(1H)-one; 1H-Quinolin-2-one, 5,8-dimethoxy-1
DMJ1IRO	DT	Small molecular drug
DMJ1IRO	PC	1504717
DMJ1IRO	MW	233.26
DMJ1IRO	FM	C13H15NO3
DMJ1IRO	IC	InChI=1S/C13H15NO3/c1-8-7-11(15)14(2)13-10(17-4)6-5-9(16-3)12(8)13/h5-7H,1-4H3
DMJ1IRO	CS	CC1=CC(=O)N(C2=C(C=CC(=C12)OC)OC)C
DMJ1IRO	IK	FTGZPMFPUDKJBX-UHFFFAOYSA-N
DMJ1IRO	IU	5,8-dimethoxy-1,4-dimethylquinolin-2-one
DMJ1IRO	DE	Discovery agent

DMEMBKW	ID	DMEMBKW
DMEMBKW	DN	5,8-Dimethoxy-4-methylquinolin-2(1H)-one
DMEMBKW	HS	Investigative
DMEMBKW	SN	5,8-Dimethoxy-4-methylquinolin-2(1H)-one; 23947-41-3; 2(1h)-quinolinone, 5,8-dimethoxy-4-methyl-; 5,8-dimethoxy-4-methyl-2-quinolinol; 5,8-dimethoxy-4-methylquinolin-2-ol; ST056710; 5,8-dimethoxy-4-methylhydroquinolin-2-one; 2(1H)-Quinolinone,5,8-dimethoxy-4-methyl-; MZX; NSC109761; casimiroin analogue, 1k; AC1L6LUU; AC1Q6I1R; TimTec1_003888; Oprea1_236890; Oprea1_728115; CHEMBL493174; BDBM29222; CTK4F2623; DTXSID30296530; MolPort-000-699-993; MolPort-002-514-269; BUHDAIGNGIXQJO-UHFFFAOYSA-N; HMS1545A16; ZINC8817671; ALBB-032301
DMEMBKW	DT	Small molecular drug
DMEMBKW	PC	269167
DMEMBKW	MW	219.24
DMEMBKW	FM	C12H13NO3
DMEMBKW	IC	InChI=1S/C12H13NO3/c1-7-6-10(14)13-12-9(16-3)5-4-8(15-2)11(7)12/h4-6H,1-3H3,(H,13,14)
DMEMBKW	CS	CC1=CC(=O)NC2=C(C=CC(=C12)OC)OC
DMEMBKW	IK	BUHDAIGNGIXQJO-UHFFFAOYSA-N
DMEMBKW	IU	5,8-dimethoxy-4-methyl-1H-quinolin-2-one
DMEMBKW	CA	CAS 23947-41-3
DMEMBKW	DE	Discovery agent

DM1SO62	ID	DM1SO62
DM1SO62	DN	5,8-hydroxy-naphthoquinone
DM1SO62	HS	Investigative
DM1SO62	DE	Discovery agent

DM3MSZN	ID	DM3MSZN
DM3MSZN	DN	5,N-Dihydroxythalidomide
DM3MSZN	HS	Investigative
DM3MSZN	SN	5,N-Dihydroxythalidomide; 5,1'-Dihydroxythalidomide; 5,1'-Dihydroxy thalidomide; 5,1'-Dihydroxy thalidomide, (+/-)-; CHEMBL479546; 1H-Isoindole-1,3(2H)-dione, 5-hydroxy-2-(1-hydroxy-2,6-dioxo-3-piperidinyl)-; 478785-12-5
DM3MSZN	DT	Small molecular drug
DM3MSZN	PC	10356851
DM3MSZN	MW	290.23
DM3MSZN	FM	C13H10N2O6
DM3MSZN	IC	InChI=1S/C13H10N2O6/c16-6-1-2-7-8(5-6)12(19)14(11(7)18)9-3-4-10(17)15(21)13(9)20/h1-2,5,9,16,21H,3-4H2
DM3MSZN	CS	C1CC(=O)N(C(=O)C1N2C(=O)C3=C(C2=O)C=C(C=C3)O)O
DM3MSZN	IK	RLBGOICZNMULCW-UHFFFAOYSA-N
DM3MSZN	IU	5-hydroxy-2-(1-hydroxy-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
DM3MSZN	CA	CAS 478785-12-5
DM3MSZN	DE	Discovery agent

DM23PL4	ID	DM23PL4
DM23PL4	DN	5-[(1R)-1-ammonioethyl]isoxazol-3-olate
DM23PL4	HS	Investigative
DM23PL4	SN	CHEMBL283019; (r)-5-(1-aminoethyl)-3-isoxazolol
DM23PL4	DT	Small molecular drug
DM23PL4	PC	44278344
DM23PL4	MW	128.13
DM23PL4	FM	C5H8N2O2
DM23PL4	IC	InChI=1S/C5H8N2O2/c1-3(6)4-2-5(8)7-9-4/h2-3H,6H2,1H3,(H,7,8)/t3-/m1/s1
DM23PL4	CS	C[C@H](C1=CC(=O)NO1)N
DM23PL4	IK	ICRYUJPBYIPXQF-GSVOUGTGSA-N
DM23PL4	IU	5-[(1R)-1-aminoethyl]-1,2-oxazol-3-one
DM23PL4	DE	Discovery agent

DMYAPLT	ID	DMYAPLT
DMYAPLT	DN	5-[(1S)-1-ammonioethyl]isoxazol-3-olate
DMYAPLT	HS	Investigative
DMYAPLT	SN	CHEMBL285783; 5-[(S)-1-Aminoethyl]isoxazol-3-ol; AKOS022719281
DMYAPLT	DT	Small molecular drug
DMYAPLT	PC	44279120
DMYAPLT	MW	128.13
DMYAPLT	FM	C5H8N2O2
DMYAPLT	IC	InChI=1S/C5H8N2O2/c1-3(6)4-2-5(8)7-9-4/h2-3H,6H2,1H3,(H,7,8)/t3-/m0/s1
DMYAPLT	CS	C[C@@H](C1=CC(=O)NO1)N
DMYAPLT	IK	ICRYUJPBYIPXQF-VKHMYHEASA-N
DMYAPLT	IU	5-[(1S)-1-aminoethyl]-1,2-oxazol-3-one
DMYAPLT	DE	Discovery agent

DMM9GCA	ID	DMM9GCA
DMM9GCA	DN	5-[(2-methyl-4-thiazolyl)ethynyl]pyrimidine
DMM9GCA	HS	Investigative
DMM9GCA	SN	CHEMBL202042; 5-[(2-methyl-4-thiazolyl)ethynyl]pyrimidine; SCHEMBL4144583
DMM9GCA	DT	Small molecular drug
DMM9GCA	PC	11600877
DMM9GCA	MW	201.25
DMM9GCA	FM	C10H7N3S
DMM9GCA	IC	InChI=1S/C10H7N3S/c1-8-13-10(6-14-8)3-2-9-4-11-7-12-5-9/h4-7H,1H3
DMM9GCA	CS	CC1=NC(=CS1)C#CC2=CN=CN=C2
DMM9GCA	IK	ILVDLPMGOZQXLY-UHFFFAOYSA-N
DMM9GCA	IU	2-methyl-4-(2-pyrimidin-5-ylethynyl)-1,3-thiazole
DMM9GCA	DE	Discovery agent

DMLFY2T	ID	DMLFY2T
DMLFY2T	DN	5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole
DMLFY2T	HS	Investigative
DMLFY2T	SN	5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole; 3fuj; DB06828; 5-[2-(pyrrol-1-yl)ethoxy]-1H-indole
DMLFY2T	DT	Small molecular drug
DMLFY2T	PC	44129621
DMLFY2T	MW	226.27
DMLFY2T	FM	C14H14N2O
DMLFY2T	IC	InChI=1S/C14H14N2O/c1-2-8-16(7-1)9-10-17-13-3-4-14-12(11-13)5-6-15-14/h1-8,11,15H,9-10H2
DMLFY2T	CS	C1=CN(C=C1)CCOC2=CC3=C(C=C2)NC=C3
DMLFY2T	IK	NSZDJRLPCLOQAM-UHFFFAOYSA-N
DMLFY2T	IU	5-(2-pyrrol-1-ylethoxy)-1H-indole
DMLFY2T	DE	Discovery agent

DM1KO7U	ID	DM1KO7U
DM1KO7U	DN	5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol
DM1KO7U	HS	Investigative
DM1KO7U	SN	Dihydroresveratrol; 58436-28-5; 5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol; 3,4',5-Trihydroxybibenzyl; CHEMBL111234; CHEBI:4582; 5-(4-hydroxyphenethyl)benzene-1,3-diol; Dihydroresveratol; 3ftu; Dihydro-Resveratrol; RE2; a, b-Dihydroresveratrol; AC1L4HRG; C10255; 5-[2-(4-hydroxyphenyl)ethyl]-1,3-Benzenediol; 3,5,4'-trihydroxybibenzyl; 3,4'',5-trihydroxybibenzyl; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethyl)-; SCHEMBL716856; AC1Q79W7; CTK5A8302; MolPort-035-706-156; ZINC899123; LMPK13090035; BDBM50085531; NSC723534; AKOS030555676
DM1KO7U	DT	Small molecular drug
DM1KO7U	PC	185914
DM1KO7U	MW	230.26
DM1KO7U	FM	C14H14O3
DM1KO7U	IC	InChI=1S/C14H14O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h3-9,15-17H,1-2H2
DM1KO7U	CS	C1=CC(=CC=C1CCC2=CC(=CC(=C2)O)O)O
DM1KO7U	IK	HITJFUSPLYBJPE-UHFFFAOYSA-N
DM1KO7U	IU	5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol
DM1KO7U	CA	CAS 58436-28-5
DM1KO7U	CB	CHEBI:4582
DM1KO7U	DE	Discovery agent

DMW8RLN	ID	DMW8RLN
DMW8RLN	DN	5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole
DMW8RLN	HS	Investigative
DMW8RLN	SN	CHEMBL1214737; 5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole; ZINC58581744
DMW8RLN	DT	Small molecular drug
DMW8RLN	PC	46901927
DMW8RLN	MW	284.4
DMW8RLN	FM	C20H16N2
DMW8RLN	IC	InChI=1S/C20H16N2/c1-3-17(18-5-6-20-19(14-18)9-12-22-20)4-2-15(1)13-16-7-10-21-11-8-16/h1-12,14,22H,13H2
DMW8RLN	CS	C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC4=C(C=C3)NC=C4
DMW8RLN	IK	VVBPUVXDCLUNKF-UHFFFAOYSA-N
DMW8RLN	IU	5-[4-(pyridin-4-ylmethyl)phenyl]-1H-indole
DMW8RLN	DE	Discovery agent

DMV7QU3	ID	DMV7QU3
DMV7QU3	DN	5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole
DMV7QU3	HS	Investigative
DMV7QU3	SN	Imidazolylmethyleneindane 9a; AC1O70GV; BDBM8883; SCHEMBL4231848; CHEMBL177293; 5-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]-1H-imidazole; 5-[(E)-(5-Bromo-2,3-dihydro-1H-inden-1-ylidene)methyl]-1H-imidazole
DMV7QU3	DT	Small molecular drug
DMV7QU3	PC	6540042
DMV7QU3	MW	275.14
DMV7QU3	FM	C13H11BrN2
DMV7QU3	IC	InChI=1S/C13H11BrN2/c14-11-3-4-13-9(5-11)1-2-10(13)6-12-7-15-8-16-12/h3-8H,1-2H2,(H,15,16)/b10-6+
DMV7QU3	CS	C1C/C(=C\\C2=CN=CN2)/C3=C1C=C(C=C3)Br
DMV7QU3	IK	SNWLVVNOSVKKRA-UXBLZVDNSA-N
DMV7QU3	IU	5-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]-1H-imidazole
DMV7QU3	DE	Discovery agent

DMZICL8	ID	DMZICL8
DMZICL8	DN	5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole
DMZICL8	HS	Investigative
DMZICL8	SN	AC1O70GX; SCHEMBL4231849; CHEMBL174579
DMZICL8	DT	Small molecular drug
DMZICL8	PC	6540043
DMZICL8	MW	275.14
DMZICL8	FM	C13H11BrN2
DMZICL8	IC	InChI=1S/C13H11BrN2/c14-11-3-4-13-9(5-11)1-2-10(13)6-12-7-15-8-16-12/h3-8H,1-2H2,(H,15,16)/b10-6-
DMZICL8	CS	C1C/C(=C/C2=CN=CN2)/C3=C1C=C(C=C3)Br
DMZICL8	IK	SNWLVVNOSVKKRA-POHAHGRESA-N
DMZICL8	IU	5-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]-1H-imidazole
DMZICL8	DE	Discovery agent

DM2RIHT	ID	DM2RIHT
DM2RIHT	DN	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine
DM2RIHT	HS	Investigative
DM2RIHT	SN	AC1O706P; CHEMBL195248; SCHEMBL4225537; SCHEMBL4225546; BDBM8631; (5-pyrimidylmethylene)indane 28a; ZINC13535842; 5-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine
DM2RIHT	DT	Small molecular drug
DM2RIHT	PC	6539805
DM2RIHT	MW	226.25
DM2RIHT	FM	C14H11FN2
DM2RIHT	IC	InChI=1S/C14H11FN2/c15-13-3-4-14-11(1-2-12(14)6-13)5-10-7-16-9-17-8-10/h3-9H,1-2H2/b11-5+
DM2RIHT	CS	C1C/C(=C\\C2=CN=CN=C2)/C3=C1C=C(C=C3)F
DM2RIHT	IK	LEJPKWXGQFBXRX-VZUCSPMQSA-N
DM2RIHT	IU	5-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine
DM2RIHT	DE	Discovery agent

DMQGX2Z	ID	DMQGX2Z
DMQGX2Z	DN	5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine
DMQGX2Z	HS	Investigative
DMQGX2Z	SN	(5-pyrimidylmethylene)indane 28b; SCHEMBL4225541; AC1O706V; CHEMBL364956; BDBM8634; 5-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine
DMQGX2Z	DT	Small molecular drug
DMQGX2Z	PC	6539808
DMQGX2Z	MW	226.25
DMQGX2Z	FM	C14H11FN2
DMQGX2Z	IC	InChI=1S/C14H11FN2/c15-13-3-4-14-11(1-2-12(14)6-13)5-10-7-16-9-17-8-10/h3-9H,1-2H2/b11-5-
DMQGX2Z	CS	C1C/C(=C/C2=CN=CN=C2)/C3=C1C=C(C=C3)F
DMQGX2Z	IK	LEJPKWXGQFBXRX-WZUFQYTHSA-N
DMQGX2Z	IU	5-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine
DMQGX2Z	DE	Discovery agent

DM5FA74	ID	DM5FA74
DM5FA74	DN	5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole
DM5FA74	HS	Investigative
DM5FA74	SN	(5-Thiazolemethylene)indane 27a; BDBM8632; CHEMBL192155; AC1O706R; 5-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]-1,3-thiazole
DM5FA74	DT	Small molecular drug
DM5FA74	PC	6539806
DM5FA74	MW	243.33
DM5FA74	FM	C14H13NOS
DM5FA74	IC	InChI=1S/C14H13NOS/c1-16-12-4-5-14-10(6-12)2-3-11(14)7-13-8-15-9-17-13/h4-9H,2-3H2,1H3/b11-7+
DM5FA74	CS	COC1=CC2=C(C=C1)/C(=C/C3=CN=CS3)/CC2
DM5FA74	IK	YBVSJXCRZPLUNH-YRNVUSSQSA-N
DM5FA74	IU	5-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]-1,3-thiazole
DM5FA74	DE	Discovery agent

DMPDN63	ID	DMPDN63
DMPDN63	DN	5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole
DMPDN63	HS	Investigative
DMPDN63	SN	CHEMBL195354; BDBM8633; AC1O706T; (5-Thiazolemethylene)indane 27b; 5-{[(1Z)-5-methoxy-2,3-dihydro-1H-inden-1-ylidene]methyl}-1,3-thiazole
DMPDN63	DT	Small molecular drug
DMPDN63	PC	6539807
DMPDN63	MW	243.33
DMPDN63	FM	C14H13NOS
DMPDN63	IC	InChI=1S/C14H13NOS/c1-16-12-4-5-14-10(6-12)2-3-11(14)7-13-8-15-9-17-13/h4-9H,2-3H2,1H3/b11-7-
DMPDN63	CS	COC1=CC2=C(C=C1)/C(=C\\C3=CN=CS3)/CC2
DMPDN63	IK	YBVSJXCRZPLUNH-XFFZJAGNSA-N
DMPDN63	IU	5-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]-1,3-thiazole
DMPDN63	DE	Discovery agent

DMSZ3T6	ID	DMSZ3T6
DMSZ3T6	DN	5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol
DMSZ3T6	HS	Investigative
DMSZ3T6	SN	Cardol triene; CHEMBL459603; 5-(8Z,11Z,14-Pentadecatrienyl)resorcinol; 79473-24-8; CHEBI:52680; 5-(pentadeca-8,11,14-trien-1-yl)resorcinol; 5-[(8Z,11Z)-pentadeca-8,11,14-trien-1-yl]benzene-1,3-diol; (8Z,11Z)-5-(pentadeca-8,11,14-trien-1-yl)resorcinol; 5-pentadecatrienyl resorcinol; 5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol; 5-((8Z,11Z)-pentadeca-8,11,14-trien-1-yl)benzene-1,3-diol; SCHEMBL2467234; MEGxp0_000811; ACon1_000596; DTXSID30872873; MolPort-001-740-965; 1,3-Benzenediol, 5-(8Z,11Z)-8,11,14-pentadecatrienyl-
DMSZ3T6	DT	Small molecular drug
DMSZ3T6	PC	13259919
DMSZ3T6	MW	314.5
DMSZ3T6	FM	C21H30O2
DMSZ3T6	IC	InChI=1S/C21H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-16-20(22)18-21(23)17-19/h2,4-5,7-8,16-18,22-23H,1,3,6,9-15H2/b5-4-,8-7-
DMSZ3T6	CS	C=CC/C=C\\C/C=C\\CCCCCCCC1=CC(=CC(=C1)O)O
DMSZ3T6	IK	OOXBEOHCOCMKAC-UTOQUPLUSA-N
DMSZ3T6	IU	5-[(8Z,11Z)-pentadeca-8,11,14-trienyl]benzene-1,3-diol
DMSZ3T6	CA	CAS 79473-24-8
DMSZ3T6	CB	CHEBI:52680
DMSZ3T6	DE	Discovery agent

DM0EBWR	ID	DM0EBWR
DM0EBWR	DN	5-{8(Z),11(Z)-pentadecadienyl}resorcinol
DM0EBWR	HS	Investigative
DM0EBWR	SN	5-{8(Z),11(Z)-pentadecadienyl}resorcinol; CHEMBL459604; 5-(8,11-Pentadecadienyl)-1,3-benzenediol; 5-[(8Z,11Z)-pentadeca-8,11-dien-1-yl]benzene-1,3-diol; Cardoldiene; 5-((8Z,11Z)-pentadeca-8,11-dien-1-yl)benzene-1,3-diol; SCHEMBL9475761; DTXSID70872872; MolPort-005-944-663; 79473-25-9; ZINC31157863; LMPK15030021; BDBM50292428; AKOS030555484; MCULE-2398296746; RESORCINOL(15:2(8Z,11Z)); 5-(pentadeca-8,11-dienyl)benzene-1,3-diol; 5-((8Z,11Z)-pentadeca-8,11-dien-1-yl)resorcinol
DM0EBWR	DT	Small molecular drug
DM0EBWR	PC	11702450
DM0EBWR	MW	316.5
DM0EBWR	FM	C21H32O2
DM0EBWR	IC	InChI=1S/C21H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-16-20(22)18-21(23)17-19/h4-5,7-8,16-18,22-23H,2-3,6,9-15H2,1H3/b5-4-,8-7-
DM0EBWR	CS	CCC/C=C\\C/C=C\\CCCCCCCC1=CC(=CC(=C1)O)O
DM0EBWR	IK	UFMJCOLGRWKUKO-UTOQUPLUSA-N
DM0EBWR	IU	5-[(8Z,11Z)-pentadeca-8,11-dienyl]benzene-1,3-diol
DM0EBWR	CA	CAS 79473-25-9
DM0EBWR	DE	Discovery agent

DMNRWEV	ID	DMNRWEV
DMNRWEV	DN	5-{8(Z),-pentadecenyl}resorcinol
DMNRWEV	HS	Investigative
DMNRWEV	SN	Bilobol; 5-[(8Z)-pentadec-8-en-1-yl]benzene-1,3-diol; 5-[(8Z)-pentadec-8-enyl]resorcinol; CHEBI:3104; CHEMBL461628; 5-(8Z-Pentadecenyl)resorcinol; 22910-86-7; 5-[(Z)-pentadec-8-enyl]benzene-1,3-diol; (Z)-5-(Pentadec-8-en-1-yl)benzene-1,3-diol; Trifurcatol A2; Cardol monoene; 5-{8(Z),-pentadecenyl}resorcinol; Bilobol C15:1; AC1NQZ6L; 21:1-.omega.7-Cardol; SCHEMBL164545; 5-(8'Z-heptadecenyl)resorcinol; DTXSID90872874; TUGAUFMQYWZJAB-FPLPWBNLSA-N; MolPort-005-945-917; ZINC8234356; 5-[8'(Z)-Pentadecenyl]Resorcinol
DMNRWEV	DT	Small molecular drug
DMNRWEV	PC	5281852
DMNRWEV	MW	318.5
DMNRWEV	FM	C21H34O2
DMNRWEV	IC	InChI=1S/C21H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-16-20(22)18-21(23)17-19/h7-8,16-18,22-23H,2-6,9-15H2,1H3/b8-7-
DMNRWEV	CS	CCCCCC/C=C\\CCCCCCCC1=CC(=CC(=C1)O)O
DMNRWEV	IK	TUGAUFMQYWZJAB-FPLPWBNLSA-N
DMNRWEV	IU	5-[(Z)-pentadec-8-enyl]benzene-1,3-diol
DMNRWEV	CA	CAS 22910-86-7
DMNRWEV	CB	CHEBI:3104
DMNRWEV	DE	Discovery agent

DMB7R95	ID	DMB7R95
DMB7R95	DN	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide
DMB7R95	HS	Investigative
DMB7R95	SN	CHEMBL382537
DMB7R95	DT	Small molecular drug
DMB7R95	PC	11717472
DMB7R95	MW	361.19
DMB7R95	FM	C16H13BrN2O3
DMB7R95	IC	InChI=1S/C16H13BrN2O3/c1-2-15(21)18-12-6-7-14(20)13(9-12)16(22)19-11-5-3-4-10(17)8-11/h2-9,20H,1H2,(H,18,21)(H,19,22)
DMB7R95	CS	C=CC(=O)NC1=CC(=C(C=C1)O)C(=O)NC2=CC(=CC=C2)Br
DMB7R95	IK	BVFCILADOWKWJB-UHFFFAOYSA-N
DMB7R95	IU	N-(3-bromophenyl)-2-hydroxy-5-(prop-2-enoylamino)benzamide
DMB7R95	DE	Discovery agent

DMHI7Y2	ID	DMHI7Y2
DMHI7Y2	DN	5alpha-Androstan-3,17-Dione
DMHI7Y2	HS	Investigative
DMHI7Y2	SN	Androstanedione; 5alpha-Androstane-3,17-dione; 846-46-8; 5alpha-Androstan-3,17-dione; 5a-Androstanedione; 5-alpha-Androstane-3,17-dione; Dihydroandrostendione; 5alpha-Androstanedione; UNII-2KR72RNR8Z; Androstane-3,17-dione; 5.alpha.-Androstanedione; dihydroandrostenedione; 5a-Androstane-3,17-dione; 2KR72RNR8Z; A-androstane-3,17-dione; CHEMBL1230438; CHEBI:15994; 5.alpha.-Androsta-3,17-dione; RAJWOBJTTGJROA-WZNAKSSCSA-N; Androstane-3,17-dione, (5alpha)-; 5.alpha.-Androstane-3,17-dione; Androstane-3, (5.alpha.)-
DMHI7Y2	DT	Small molecular drug
DMHI7Y2	PC	222865
DMHI7Y2	MW	288.4
DMHI7Y2	FM	C19H28O2
DMHI7Y2	IC	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-16H,3-11H2,1-2H3/t12-,14-,15-,16-,18-,19-/m0/s1
DMHI7Y2	CS	C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C
DMHI7Y2	IK	RAJWOBJTTGJROA-WZNAKSSCSA-N
DMHI7Y2	IU	(5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMHI7Y2	CA	CAS 846-46-8
DMHI7Y2	CB	CHEBI:15994
DMHI7Y2	DE	Discovery agent

DMGA47N	ID	DMGA47N
DMGA47N	DN	5-Amino-[1,3,4]thiadiazole-2-thiol
DMGA47N	HS	Investigative
DMGA47N	SN	5-Amino-1,3,4-thiadiazole-2-thiol; 2349-67-9; 2-Amino-5-mercapto-1,3,4-thiadiazole; USAF PD-25; 1,3,4-Thiadiazole-2(3H)-thione, 5-amino-; NSC 21402; 5-Amino-1,3,4-thiadiazole-2(3H)-thione; 5-Amino-2-mercapto-1,3,4-thiadiazole; UNII-B1HEG7V21S; 2-AMINO-1,3,4-THIADIAZOLE-5-THIOL; 2-Thiol-5-amino-1,3,4-thiadiazole; NSC 209061; CCRIS 6893; 5-Amino-1,3,4-thiadiazoline-2-thione; 2-Mercapto-5-amino-1,3,4-thiadiazole; 1,3,4-Thiadiazole-2-thiol, 5-amino-; EINECS 219-078-4; B1HEG7V21S; 5-amino-3H-1,3,4-thiadiazole-2-thione
DMGA47N	DT	Small molecular drug
DMGA47N	PC	2723847
DMGA47N	MW	133.2
DMGA47N	FM	C2H3N3S2
DMGA47N	IC	InChI=1S/C2H3N3S2/c3-1-4-5-2(6)7-1/h(H2,3,4)(H,5,6)
DMGA47N	CS	C1(=NNC(=S)S1)N
DMGA47N	IK	GDGIVSREGUOIJZ-UHFFFAOYSA-N
DMGA47N	IU	5-amino-3H-1,3,4-thiadiazole-2-thione
DMGA47N	CA	CAS 2349-67-9
DMGA47N	DE	Discovery agent

DMX37ZC	ID	DMX37ZC
DMX37ZC	DN	5-amino-2-phenyl-oxazole-4-carboxylic acid amide
DMX37ZC	HS	Investigative
DMX37ZC	SN	CHEMBL207987; 5-amino-2-phenyloxazole-4-carboxylic acid amide; 99185-68-9; 5-amino-2-phenyl-oxazole-4-carboxylic acid amide
DMX37ZC	DT	Small molecular drug
DMX37ZC	PC	11708263
DMX37ZC	MW	203.2
DMX37ZC	FM	C10H9N3O2
DMX37ZC	IC	InChI=1S/C10H9N3O2/c11-8(14)7-9(12)15-10(13-7)6-4-2-1-3-5-6/h1-5H,12H2,(H2,11,14)
DMX37ZC	CS	C1=CC=C(C=C1)C2=NC(=C(O2)N)C(=O)N
DMX37ZC	IK	UPWLRKVVLBSIPK-UHFFFAOYSA-N
DMX37ZC	IU	5-amino-2-phenyl-1,3-oxazole-4-carboxamide
DMX37ZC	DE	Discovery agent

DM4SWJ7	ID	DM4SWJ7
DM4SWJ7	DN	5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide
DM4SWJ7	HS	Investigative
DM4SWJ7	SN	5-amino-2-(4-methylphenyl)-1,3-oxazole-4-carboxamide; CHEMBL382993; 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide; CTK6B8237; MolPort-000-894-518; SBB024037; BDBM50186628; STK351079; ZINC12394806; AKOS000313592; MCULE-2038651256
DM4SWJ7	DT	Small molecular drug
DM4SWJ7	PC	11543063
DM4SWJ7	MW	217.22
DM4SWJ7	FM	C11H11N3O2
DM4SWJ7	IC	InChI=1S/C11H11N3O2/c1-6-2-4-7(5-3-6)11-14-8(9(12)15)10(13)16-11/h2-5H,13H2,1H3,(H2,12,15)
DM4SWJ7	CS	CC1=CC=C(C=C1)C2=NC(=C(O2)N)C(=O)N
DM4SWJ7	IK	RSMHDVYJLCPVNY-UHFFFAOYSA-N
DM4SWJ7	IU	5-amino-2-(4-methylphenyl)-1,3-oxazole-4-carboxamide
DM4SWJ7	DE	Discovery agent

DMJKQ5I	ID	DMJKQ5I
DMJKQ5I	DN	5-amino-3-(N-methylpiperidin-4-yl)-1H-indole
DMJKQ5I	HS	Investigative
DMJKQ5I	SN	3-(1-methyl-4-piperidyl)indole-5-ylamine; CHEMBL521235; 3-(1-methylpiperidin-4-yl)-1h-indol-5-amine; 5-amino-3-(N-methylpiperidin-4-yl)-1H-indole; SCHEMBL427406; CTK6I2276; CKBJZDHVHHKARV-UHFFFAOYSA-N; BDBM50271135; AKOS024098950; 182564-38-1; 5-amino-3-(1-methylpiperidin-4-yl)-1H-indole; 3-(1-Methyl-4-piperidinyl)-5-amino-1H-indole
DMJKQ5I	DT	Small molecular drug
DMJKQ5I	PC	11831220
DMJKQ5I	MW	229.32
DMJKQ5I	FM	C14H19N3
DMJKQ5I	IC	InChI=1S/C14H19N3/c1-17-6-4-10(5-7-17)13-9-16-14-3-2-11(15)8-12(13)14/h2-3,8-10,16H,4-7,15H2,1H3
DMJKQ5I	CS	CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)N
DMJKQ5I	IK	CKBJZDHVHHKARV-UHFFFAOYSA-N
DMJKQ5I	IU	3-(1-methylpiperidin-4-yl)-1H-indol-5-amine
DMJKQ5I	DE	Discovery agent

DMR853M	ID	DMR853M
DMR853M	DN	5-amino-3,4-dihydroisoquinolin-1(2H)-one
DMR853M	HS	Investigative
DMR853M	SN	5-amino-3,4-dihydroisoquinolin-1(2H)-one; 129075-53-2; CHEMBL594759; SCHEMBL7581623; RTPKPVYTPRJRBY-UHFFFAOYSA-N; ZINC45353622; BDBM50306284; AKOS023598631; AB53700; FCH1123505; KS-9128; CM10348; AJ-110485; 5-amino-3,4-dihydro-1(2H)-isoquinolinone; EN300-254419
DMR853M	DT	Small molecular drug
DMR853M	PC	18369509
DMR853M	MW	162.19
DMR853M	FM	C9H10N2O
DMR853M	IC	InChI=1S/C9H10N2O/c10-8-3-1-2-7-6(8)4-5-11-9(7)12/h1-3H,4-5,10H2,(H,11,12)
DMR853M	CS	C1CNC(=O)C2=C1C(=CC=C2)N
DMR853M	IK	RTPKPVYTPRJRBY-UHFFFAOYSA-N
DMR853M	IU	5-amino-3,4-dihydro-2H-isoquinolin-1-one
DMR853M	CA	CAS 129075-53-2
DMR853M	DE	Discovery agent

DMBF42W	ID	DMBF42W
DMBF42W	DN	5'-amino-5'-deoxy-alpha-D-thymidine
DMBF42W	HS	Investigative
DMBF42W	SN	CHEMBL428720; BDBM50223794; ZINC17000414
DMBF42W	DT	Small molecular drug
DMBF42W	PC	27469877
DMBF42W	MW	241.24
DMBF42W	FM	C10H15N3O4
DMBF42W	IC	InChI=1S/C10H15N3O4/c1-5-4-13(10(16)12-9(5)15)8-2-6(14)7(3-11)17-8/h4,6-8,14H,2-3,11H2,1H3,(H,12,15,16)/t6-,7+,8-/m0/s1
DMBF42W	CS	CC1=CN(C(=O)NC1=O)[C@@H]2C[C@@H]([C@H](O2)CN)O
DMBF42W	IK	PYWLBQPICCQJFF-RNJXMRFFSA-N
DMBF42W	IU	1-[(2S,4S,5R)-5-(aminomethyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMBF42W	DE	Discovery agent

DMVPSXW	ID	DMVPSXW
DMVPSXW	DN	5-aminoisoquinolin-1(2H)-one
DMVPSXW	HS	Investigative
DMVPSXW	SN	5-aminoisoquinolin-1(2H)-one; 93117-08-9; 5-amino-2H-isoquinolin-1-one; 5-AMINOISOQUINOLIN-1-OL; 5-amino-1,2-dihydroisoquinolin-1-one; 5-AIQ; CHEMBL446240; 5-Amino-2H-isoquinoin-1-one; 5-AMINO-1(2H)-ISOQUINOLINONE; 5-aminoisoquinolinone; 4pnq; 32X; AC1Q6DVG; AC1L1CUR; 5-Amino-1-isoquinolinol; SCHEMBL215327; 5-Amino-1-hydroxyisoquinoline; BDBM27503; 5-amino-isoquinolin-1(2h)-one; 5-amino isoquinolin-1(2h)-one; CTK5H2122; DTXSID90274354; 1(2H)-Isoquinolinone,5-amino-; MolPort-008-423-043; MolPort-004-803-197
DMVPSXW	DT	Small molecular drug
DMVPSXW	PC	2072
DMVPSXW	MW	160.17
DMVPSXW	FM	C9H8N2O
DMVPSXW	IC	InChI=1S/C9H8N2O/c10-8-3-1-2-7-6(8)4-5-11-9(7)12/h1-5H,10H2,(H,11,12)
DMVPSXW	CS	C1=CC2=C(C=CNC2=O)C(=C1)N
DMVPSXW	IK	SVASVGVAQIVSEZ-UHFFFAOYSA-N
DMVPSXW	IU	5-amino-2H-isoquinolin-1-one
DMVPSXW	CA	CAS 93117-08-9
DMVPSXW	CB	CHEBI:103965
DMVPSXW	DE	Discovery agent

DMWDUVC	ID	DMWDUVC
DMWDUVC	DN	5-Aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMWDUVC	HS	Investigative
DMWDUVC	SN	CHEMBL17643; 5-Aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one; 2-Oxazolidinone, 5-(aminomethyl)-3-(1H-pyrrol-1-yl)-, (5R)-; BDBM50110724; 406934-17-6
DMWDUVC	DT	Small molecular drug
DMWDUVC	PC	11008547
DMWDUVC	MW	181.19
DMWDUVC	FM	C8H11N3O2
DMWDUVC	IC	InChI=1S/C8H11N3O2/c9-5-7-6-11(8(12)13-7)10-3-1-2-4-10/h1-4,7H,5-6,9H2/t7-/m0/s1
DMWDUVC	CS	C1[C@@H](OC(=O)N1N2C=CC=C2)CN
DMWDUVC	IK	OZSRSVNLPCHFKO-ZETCQYMHSA-N
DMWDUVC	IU	(5S)-5-(aminomethyl)-3-pyrrol-1-yl-1,3-oxazolidin-2-one
DMWDUVC	DE	Discovery agent

DMZK8V5	ID	DMZK8V5
DMZK8V5	DN	5-Aminomethyl-4,5-dihydro-isoxazol-3-ol
DMZK8V5	HS	Investigative
DMZK8V5	SN	Dihydromuscimol; 72241-46-4; CHEMBL40363; (RS)-4,5-Dihydromuscimol; 5-(aminomethyl)-1,2-oxazolidin-3-one; 3-isoxazolol, 5-(aminomethyl)-4,5-dihydro-; AC1L4Y9G; SCHEMBL2924224; AC1Q6H18; SCHEMBL12477033; CTK5D5767; 5-aminomethyl-isoxazolidin-3-one; ZHCZZTNIHDWRNS-UHFFFAOYSA-N; 5-(Aminomethyl)-3-isoxazolidinone; 3-Isoxazolidinone,5-(aminomethyl)-; BDBM50225363; 3-Isoxazolidinone, 5-(aminomethyl)-
DMZK8V5	DT	Small molecular drug
DMZK8V5	PC	14601455
DMZK8V5	MW	116.12
DMZK8V5	FM	C4H8N2O2
DMZK8V5	IC	InChI=1S/C4H8N2O2/c5-2-3-1-4(7)6-8-3/h3H,1-2,5H2,(H,6,7)/t3-/m0/s1
DMZK8V5	CS	C1[C@H](ONC1=O)CN
DMZK8V5	IK	ZHCZZTNIHDWRNS-VKHMYHEASA-N
DMZK8V5	IU	(5S)-5-(aminomethyl)-1,2-oxazolidin-3-one
DMZK8V5	DE	Discovery agent

DMTP9DB	ID	DMTP9DB
DMTP9DB	DN	5-Aminomethyl-naphthalen-2-ol
DMTP9DB	HS	Investigative
DMTP9DB	SN	5-Aminomethyl-naphthalen-2-ol; 5-(aminomethyl)naphthalen-2-ol; CHEMBL131174; 170244-98-1; SCHEMBL15345565; CTK4D3537; DTXSID00658388; BDBM50061315; ZINC13766764; 1-(Aminomethyl)-6-hydroxynaphthalene; AKOS027292253; SC-29498; 1,2-Anthracenediol,10-(aminomethyl)-9,10-dihydro-
DMTP9DB	DT	Small molecular drug
DMTP9DB	PC	44352201
DMTP9DB	MW	173.21
DMTP9DB	FM	C11H11NO
DMTP9DB	IC	InChI=1S/C11H11NO/c12-7-9-3-1-2-8-6-10(13)4-5-11(8)9/h1-6,13H,7,12H2
DMTP9DB	CS	C1=CC2=C(C=CC(=C2)O)C(=C1)CN
DMTP9DB	IK	PFFJJFRURKJERG-UHFFFAOYSA-N
DMTP9DB	IU	5-(aminomethyl)naphthalen-2-ol
DMTP9DB	DE	Discovery agent

DMYTUNE	ID	DMYTUNE
DMYTUNE	DN	5-AMINO-NAPHTALENE-2-MONOSULFONATE
DMYTUNE	HS	Investigative
DMYTUNE	SN	119-79-9; 5-Amino-2-naphthalenesulfonic acid; 5-aminonaphthalene-2-sulfonic acid; 1,6-Cleve's acid; 1-Aminonaphthalene-6-sulfonic acid; 2-Naphthalenesulfonic acid, 5-amino-; 1-NAPHTHYLAMINE-6-SULFONIC ACID; Kyselina cleve; 1-Amino-6-naphthalenesulfonic acid; 5-Aminonaphthalene-2-sulphonic acid; Cleve's acid-1,6; 5-Naphthylamine-2-sulfonic acid; 1-Amino-6-sulfonaphthalene; Cleve's beta-acid; Cleve's acid, mixed; Kyselina cleve [Czech]; Kyselina 1-naftylamin-6-sulfonova; 51548-48-2; NSC 31506; UNII-59G56TB11B; Cleve's .beta.-aci
DMYTUNE	DT	Small molecular drug
DMYTUNE	PC	8408
DMYTUNE	MW	223.25
DMYTUNE	FM	C10H9NO3S
DMYTUNE	IC	InChI=1S/C10H9NO3S/c11-10-3-1-2-7-6-8(15(12,13)14)4-5-9(7)10/h1-6H,11H2,(H,12,13,14)
DMYTUNE	CS	C1=CC2=C(C=CC(=C2)S(=O)(=O)O)C(=C1)N
DMYTUNE	IK	UWPJYQYRSWYIGZ-UHFFFAOYSA-N
DMYTUNE	IU	5-aminonaphthalene-2-sulfonic acid
DMYTUNE	CA	CAS 119-79-9
DMYTUNE	CB	CHEBI:44188
DMYTUNE	DE	Discovery agent

DMIBHP5	ID	DMIBHP5
DMIBHP5	DN	5-aminoquinolin-8-ol
DMIBHP5	HS	Investigative
DMIBHP5	SN	5-aminoquinolin-8-ol; 13207-66-4; 5-Amino-8-hydroxyquinoline; 8-Quinolinol, 5-amino-; 5-Amino-8-quinolinol; 5-Amino-quinolin-8-ol; 5-azanylquinolin-8-ol; YDEUKNRKEYICTH-UHFFFAOYSA-N; AS-0308-225; 5-aminoquinoline-8-ol; AC1L9ASV; 5-Amino-8-quinolinol #; SCHEMBL688655; 5'-amino-8'-hydroxyquinoline; CHEMBL449298; AMOT0046; AC1Q523Z; cid_416002; BDBM32142; CTK0H3311; DTXSID20328975; MolPort-000-000-986; ZINC120515; ALBB-024871; 5-Amino-8-hydroxyquinoline HClsalt; ANW-61190; 5928AA; BBL028356; STK737829; SBB005680; AKOS000111586
DMIBHP5	DT	Small molecular drug
DMIBHP5	PC	416002
DMIBHP5	MW	160.17
DMIBHP5	FM	C9H8N2O
DMIBHP5	IC	InChI=1S/C9H8N2O/c10-7-3-4-8(12)9-6(7)2-1-5-11-9/h1-5,12H,10H2
DMIBHP5	CS	C1=CC2=C(C=CC(=C2N=C1)O)N
DMIBHP5	IK	YDEUKNRKEYICTH-UHFFFAOYSA-N
DMIBHP5	IU	5-aminoquinolin-8-ol
DMIBHP5	CA	CAS 13207-66-4
DMIBHP5	DE	Discovery agent

DMURTHE	ID	DMURTHE
DMURTHE	DN	5-Azido-6-benzyl-2-methyl-[1,8]naphthyridine
DMURTHE	HS	Investigative
DMURTHE	SN	CHEMBL194401; 5-Azido-6-benzyl-2-methyl-[1,8]naphthyridine
DMURTHE	DT	Small molecular drug
DMURTHE	PC	44403591
DMURTHE	MW	275.31
DMURTHE	FM	C16H13N5
DMURTHE	IC	InChI=1S/C16H13N5/c1-11-7-8-14-15(20-21-17)13(10-18-16(14)19-11)9-12-5-3-2-4-6-12/h2-8,10H,9H2,1H3
DMURTHE	CS	CC1=NC2=NC=C(C(=C2C=C1)N=[N+]=[N-])CC3=CC=CC=C3
DMURTHE	IK	GFTOIPQCHLKALF-UHFFFAOYSA-N
DMURTHE	IU	5-azido-6-benzyl-2-methyl-1,8-naphthyridine
DMURTHE	DE	Discovery agent

DM0HO6C	ID	DM0HO6C
DM0HO6C	DN	5-Azidomethyl-3-pyrrol-1-yl-oxazolidin-2-one
DM0HO6C	HS	Investigative
DM0HO6C	SN	CHEMBL18019; 5-Azidomethyl-3-pyrrol-1-yl-oxazolidin-2-one; BDBM50110717
DM0HO6C	DT	Small molecular drug
DM0HO6C	PC	11074575
DM0HO6C	MW	207.19
DM0HO6C	FM	C8H9N5O2
DM0HO6C	IC	InChI=1S/C8H9N5O2/c9-11-10-5-7-6-13(8(14)15-7)12-3-1-2-4-12/h1-4,7H,5-6H2/t7-/m1/s1
DM0HO6C	CS	C1[C@H](OC(=O)N1N2C=CC=C2)CN=[N+]=[N-]
DM0HO6C	IK	RJURJCGAHMMGOY-SSDOTTSWSA-N
DM0HO6C	IU	(5S)-5-(azidomethyl)-3-pyrrol-1-yl-1,3-oxazolidin-2-one
DM0HO6C	DE	Discovery agent

DM65WZ7	ID	DM65WZ7
DM65WZ7	DN	5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione
DM65WZ7	HS	Investigative
DM65WZ7	SN	CHEMBL593832; 5-benzhydryl-1,3,4-oxadiazole-2-thiol; 93073-39-3; 5-(diphenylmethyl)-1,3,4-oxadiazole-2-thiol; AC1MJWI7; 5-benzhydryl-3H-1,3,4-oxadiazole-2-thione; 5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione; MolPort-001-902-005; ZINC17946026; STK803293; BDBM50320727; BBL012648; AKOS002344283; MCULE-6937439472; BAS 00805225; 5-Benzhydryl-[1,3,4]oxadiazole-2-thiol; SR-01000312098; 5-Diphenylmethyl-1,3,4-oxadiazole-2(3H)-thione
DM65WZ7	DT	Small molecular drug
DM65WZ7	PC	3119329
DM65WZ7	MW	268.3
DM65WZ7	FM	C15H12N2OS
DM65WZ7	IC	InChI=1S/C15H12N2OS/c19-15-17-16-14(18-15)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13H,(H,17,19)
DM65WZ7	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=NNC(=S)O3
DM65WZ7	IK	YCCKTVQLIQQBMK-UHFFFAOYSA-N
DM65WZ7	IU	5-benzhydryl-3H-1,3,4-oxadiazole-2-thione
DM65WZ7	DE	Discovery agent

DMBQ5HV	ID	DMBQ5HV
DMBQ5HV	DN	5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione
DMBQ5HV	HS	Investigative
DMBQ5HV	SN	CHEMBL593062; 5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione; BDBM50320720
DMBQ5HV	DT	Small molecular drug
DMBQ5HV	PC	46225813
DMBQ5HV	MW	284.4
DMBQ5HV	FM	C15H12N2S2
DMBQ5HV	IC	InChI=1S/C15H12N2S2/c18-15-17-16-14(19-15)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13H,(H,17,18)
DMBQ5HV	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=NNC(=S)S3
DMBQ5HV	IK	NYLCTMQHPFIJCL-UHFFFAOYSA-N
DMBQ5HV	IU	5-benzhydryl-3H-1,3,4-thiadiazole-2-thione
DMBQ5HV	DE	Discovery agent

DM8QK2O	ID	DM8QK2O
DM8QK2O	DN	5-benzyl-1,3,4-oxadiazole-2(3H)-thione
DM8QK2O	HS	Investigative
DM8QK2O	SN	5-benzyl-1,3,4-oxadiazole-2-thiol; 23288-90-6; 5-Benzyl-[1,3,4]oxadiazole-2-thiol; CHEMBL1164364; 5-Benzyl-1,3,4-oxadiazol-2-yl hydrosulfide; 1,3,4-Oxadiazole-2(3H)-thione,5-(phenylmethyl)-; 2-benzyl-1,3,4-oxadiazole-5-thiol; AC1Q7GGP; 5-benzyl-1,3,4-oxadiazole-2(3H)-thione; ChemDiv2_001277; AC1M00UR; SCHEMBL7023603; SCHEMBL11835354; CTK4F1247; DTXSID60365768; MolPort-000-473-148; HMS1649K04; HMS1372M01; ZINC2379869; BDBM50320724; STK498480; CCG-21122; BBL007772; AKOS000100218; AKOS001054851; MCULE-7500395690
DM8QK2O	DT	Small molecular drug
DM8QK2O	PC	1987817
DM8QK2O	MW	192.24
DM8QK2O	FM	C9H8N2OS
DM8QK2O	IC	InChI=1S/C9H8N2OS/c13-9-11-10-8(12-9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,11,13)
DM8QK2O	CS	C1=CC=C(C=C1)CC2=NNC(=S)O2
DM8QK2O	IK	ARGIBMBTIISQNH-UHFFFAOYSA-N
DM8QK2O	IU	5-benzyl-3H-1,3,4-oxadiazole-2-thione
DM8QK2O	CA	CAS 23288-90-6
DM8QK2O	DE	Discovery agent

DMJVGUZ	ID	DMJVGUZ
DMJVGUZ	DN	5-Benzyl-1H-pyrazole-3-carboxylic acid
DMJVGUZ	HS	Investigative
DMJVGUZ	SN	5-benzyl-1H-pyrazole-3-carboxylic Acid; 1H-Pyrazole-3-carboxylic acid, 5-(phenylmethyl)-; CHEMBL247317; 595610-51-8; 3-benzyl-1H-pyrazole-5-carboxylic acid; SCHEMBL12703568; MolPort-035-831-532; MolPort-022-664-582; ZINC13526594; BDBM50216537; AKOS026575568
DMJVGUZ	DT	Small molecular drug
DMJVGUZ	PC	11041813
DMJVGUZ	MW	202.21
DMJVGUZ	FM	C11H10N2O2
DMJVGUZ	IC	InChI=1S/C11H10N2O2/c14-11(15)10-7-9(12-13-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H,12,13)(H,14,15)
DMJVGUZ	CS	C1=CC=C(C=C1)CC2=CC(=NN2)C(=O)O
DMJVGUZ	IK	YYEOXPLPYNYVRY-UHFFFAOYSA-N
DMJVGUZ	IU	5-benzyl-1H-pyrazole-3-carboxylic acid
DMJVGUZ	DE	Discovery agent

DM5MJ3I	ID	DM5MJ3I
DM5MJ3I	DN	5-benzyl-2-(2,4-dichlorophenoxy)phenol
DM5MJ3I	HS	Investigative
DM5MJ3I	SN	5-benzyl-2-(2,4-dichlorophenoxy)phenol; Triclosan derivative, 20; CHEMBL405973; BDBM25419
DM5MJ3I	DT	Small molecular drug
DM5MJ3I	PC	25023969
DM5MJ3I	MW	345.2
DM5MJ3I	FM	C19H14Cl2O2
DM5MJ3I	IC	InChI=1S/C19H14Cl2O2/c20-15-7-9-18(16(21)12-15)23-19-8-6-14(11-17(19)22)10-13-4-2-1-3-5-13/h1-9,11-12,22H,10H2
DM5MJ3I	CS	C1=CC=C(C=C1)CC2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DM5MJ3I	IK	LUMKUDPYQGEIPU-UHFFFAOYSA-N
DM5MJ3I	IU	5-benzyl-2-(2,4-dichlorophenoxy)phenol
DM5MJ3I	DE	Discovery agent

DMCKODQ	ID	DMCKODQ
DMCKODQ	DN	5-benzyl-6-chloropyrimidine-2,4(1H,3H)-dione
DMCKODQ	HS	Investigative
DMCKODQ	SN	5-benzyl-6-chloropyrimidine-2,4(1H,3H)-dione; 18493-82-8; Oprea1_007440; SCHEMBL2672214; CHEMBL394673; BDBM20060; LWRITIARHSTBLU-UHFFFAOYSA-N; 5-Substituted-6-chlorouracil, 5g; 5-benzyl-6-chloro-1H-pyrimidine-2,4-dione; SR-01000516321; SR-01000516321-1
DMCKODQ	DT	Small molecular drug
DMCKODQ	PC	23648513
DMCKODQ	MW	236.65
DMCKODQ	FM	C11H9ClN2O2
DMCKODQ	IC	InChI=1S/C11H9ClN2O2/c12-9-8(10(15)14-11(16)13-9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H2,13,14,15,16)
DMCKODQ	CS	C1=CC=C(C=C1)CC2=C(NC(=O)NC2=O)Cl
DMCKODQ	IK	LWRITIARHSTBLU-UHFFFAOYSA-N
DMCKODQ	IU	5-benzyl-6-chloro-1H-pyrimidine-2,4-dione
DMCKODQ	DE	Discovery agent

DM8WB96	ID	DM8WB96
DM8WB96	DN	5-Benzyloxy-benzo[b]thiophene-2-carboxamidine
DM8WB96	HS	Investigative
DM8WB96	SN	CHEMBL598385; 5-Benzyloxy-benzo[b]thiophene-2-carboxamidine; SCHEMBL13709665
DM8WB96	DT	Small molecular drug
DM8WB96	PC	46233192
DM8WB96	MW	358.5
DM8WB96	FM	C22H18N2OS
DM8WB96	IC	InChI=1S/C22H18N2OS/c23-22(24)21-13-18-12-17(8-11-20(18)26-21)16-6-9-19(10-7-16)25-14-15-4-2-1-3-5-15/h1-13H,14H2,(H3,23,24)
DM8WB96	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)C3=CC4=C(C=C3)SC(=C4)C(=N)N
DM8WB96	IK	VZVHZNRYOZAOJD-UHFFFAOYSA-N
DM8WB96	IU	5-(4-phenylmethoxyphenyl)-1-benzothiophene-2-carboximidamide
DM8WB96	DE	Discovery agent

DMOM35G	ID	DMOM35G
DMOM35G	DN	5-Benzyloxytryptamine
DMOM35G	HS	Investigative
DMOM35G	SN	5-Benzyloxytryptamine; 20776-45-8; 2-(5-Benzyloxy-1H-indol-3-yl)-ethylamine; 5-Benzyloxytriptamine; 2-[5-(benzyloxy)-1H-indol-3-yl]ethanamine; 3-(2-aminoethyl)-5-benzyloxyindole; 5-BT; CHEMBL1288652; 2-(5-(Benzyloxy)-1H-indol-3-yl)ethanamine; WKPDXBXNJWWWGQ-UHFFFAOYSA-N; 5-Benzyloxy-3-(2-ethylamino)indole hydrochloride; 1H-Indole-3-ethanamine,5-(phenylmethoxy)-; 1H-Indole-3-ethanamine, 5-(phenylmethoxy)-; B-2100; 2-[5-(benzyloxy)-1H-indol-3-yl]ethanamine hydrochloride; 2-[5-(phenylmethoxy)indol-3-yl]ethylamine; EINECS 244-
DMOM35G	DT	Small molecular drug
DMOM35G	PC	89576
DMOM35G	MW	266.34
DMOM35G	FM	C17H18N2O
DMOM35G	IC	InChI=1S/C17H18N2O/c18-9-8-14-11-19-17-7-6-15(10-16(14)17)20-12-13-4-2-1-3-5-13/h1-7,10-11,19H,8-9,12,18H2
DMOM35G	CS	C1=CC=C(C=C1)COC2=CC3=C(C=C2)NC=C3CCN
DMOM35G	IK	WKPDXBXNJWWWGQ-UHFFFAOYSA-N
DMOM35G	IU	2-(5-phenylmethoxy-1H-indol-3-yl)ethanamine
DMOM35G	CA	CAS 20776-45-8
DMOM35G	DE	Discovery agent

DMFAITE	ID	DMFAITE
DMFAITE	DN	5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione
DMFAITE	HS	Investigative
DMFAITE	SN	CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-
DMFAITE	DT	Small molecular drug
DMFAITE	PC	2220392
DMFAITE	MW	308.3
DMFAITE	FM	C18H16N2O3
DMFAITE	IC	InChI=1S/C18H16N2O3/c1-2-18(15(21)19-17(23)20-16(18)22)14-10-8-13(9-11-14)12-6-4-3-5-7-12/h3-11H,2H2,1H3,(H2,19,20,21,22,23)
DMFAITE	CS	CCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMFAITE	IK	XWZIZWWEAJZAMO-UHFFFAOYSA-N
DMFAITE	IU	5-ethyl-5-(4-phenylphenyl)-1,3-diazinane-2,4,6-trione
DMFAITE	CA	CAS 94209-48-0
DMFAITE	DE	Discovery agent

DMI2PXO	ID	DMI2PXO
DMI2PXO	DN	5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione
DMI2PXO	HS	Investigative
DMI2PXO	SN	CHEMBL175282; 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione; BDBM50099116
DMI2PXO	DT	Small molecular drug
DMI2PXO	PC	44385624
DMI2PXO	MW	364.4
DMI2PXO	FM	C22H24N2O3
DMI2PXO	IC	InChI=1S/C22H24N2O3/c1-2-3-4-8-15-22(19(25)23-21(27)24-20(22)26)18-13-11-17(12-14-18)16-9-6-5-7-10-16/h5-7,9-14H,2-4,8,15H2,1H3,(H2,23,24,25,26,27)
DMI2PXO	CS	CCCCCCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMI2PXO	IK	KYTLMUVGULFASG-UHFFFAOYSA-N
DMI2PXO	IU	5-hexyl-5-(4-phenylphenyl)-1,3-diazinane-2,4,6-trione
DMI2PXO	DE	Discovery agent

DMMG9PV	ID	DMMG9PV
DMMG9PV	DN	5-Biphenyl-4-ylethynyl-pyrimidine
DMMG9PV	HS	Investigative
DMMG9PV	SN	CHEMBL447469; 5-Biphenyl-4-ylethynyl-pyrimidine
DMMG9PV	DT	Small molecular drug
DMMG9PV	PC	44560632
DMMG9PV	MW	256.3
DMMG9PV	FM	C18H12N2
DMMG9PV	IC	InChI=1S/C18H12N2/c1-2-4-17(5-3-1)18-10-8-15(9-11-18)6-7-16-12-19-14-20-13-16/h1-5,8-14H
DMMG9PV	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C#CC3=CN=CN=C3
DMMG9PV	IK	WSPLFBLWQURLSJ-UHFFFAOYSA-N
DMMG9PV	IU	5-[2-(4-phenylphenyl)ethynyl]pyrimidine
DMMG9PV	DE	Discovery agent

DM6W0QI	ID	DM6W0QI
DM6W0QI	DN	5-Biphenyl-4-ylmethyl-1-isobutyl-1H-tetrazole
DM6W0QI	HS	Investigative
DM6W0QI	SN	CHEMBL255903
DM6W0QI	DT	Small molecular drug
DM6W0QI	PC	44448616
DM6W0QI	MW	292.4
DM6W0QI	FM	C18H20N4
DM6W0QI	IC	InChI=1S/C18H20N4/c1-14(2)13-22-18(19-20-21-22)12-15-8-10-17(11-9-15)16-6-4-3-5-7-16/h3-11,14H,12-13H2,1-2H3
DM6W0QI	CS	CC(C)CN1C(=NN=N1)CC2=CC=C(C=C2)C3=CC=CC=C3
DM6W0QI	IK	GASXPOWMPRTYRR-UHFFFAOYSA-N
DM6W0QI	IU	1-(2-methylpropyl)-5-[(4-phenylphenyl)methyl]tetrazole
DM6W0QI	DE	Discovery agent

DMCPIK5	ID	DMCPIK5
DMCPIK5	DN	5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole
DMCPIK5	HS	Investigative
DMCPIK5	SN	CHEMBL255904
DMCPIK5	DT	Small molecular drug
DMCPIK5	PC	44448617
DMCPIK5	MW	292.4
DMCPIK5	FM	C18H20N4
DMCPIK5	IC	InChI=1S/C18H20N4/c1-14(2)13-22-20-18(19-21-22)12-15-8-10-17(11-9-15)16-6-4-3-5-7-16/h3-11,14H,12-13H2,1-2H3
DMCPIK5	CS	CC(C)CN1N=C(N=N1)CC2=CC=C(C=C2)C3=CC=CC=C3
DMCPIK5	IK	PPXBPBABGOMYLY-UHFFFAOYSA-N
DMCPIK5	IU	2-(2-methylpropyl)-5-[(4-phenylphenyl)methyl]tetrazole
DMCPIK5	DE	Discovery agent

DM7BWG5	ID	DM7BWG5
DM7BWG5	DN	5-BODMT
DM7BWG5	HS	Investigative
DM7BWG5	SN	5-N-butyryloxy-N,N-dimethyltryptamine; compound 10 [PMID 21422162]
DM7BWG5	DT	Small molecular drug
DM7BWG5	PC	91827360
DM7BWG5	MW	272.4
DM7BWG5	FM	C17H24N2O
DM7BWG5	IC	InChI=1S/C17H24N2O/c1-4-5-15(20)10-13-6-7-17-16(11-13)14(12-18-17)8-9-19(2)3/h6-7,11-12,18H,4-5,8-10H2,1-3H3
DM7BWG5	CS	CCCC(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
DM7BWG5	IK	OQDBJMBOPCUBGS-UHFFFAOYSA-N
DM7BWG5	IU	1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]pentan-2-one
DM7BWG5	DE	Discovery agent

DMPITR9	ID	DMPITR9
DMPITR9	DN	5-boronothiophene-2-carboxylic acid
DMPITR9	HS	Investigative
DMPITR9	SN	465515-31-5; 2-Carboxythiophene-5-boronic acid; 5-Carboxythiophene-2-boronic acid; 5-boronothiophene-2-carboxylic acid; 5-(dihydroxyboryl)thiophene-2-carboxylic acid; 5-(Dihydroxyboryl)-2-thiophenecarboxylic acid; C5H5BO4S; CHEMBL573906; 5-(dihydroxyboranyl)thiophene-2-carboxylic acid; AF-399/25053010; AK-26004; PubChem7851; AC1MCWDJ; ACMC-1AP1P; SCHEMBL363172; KS-00000JEI; CTK1D5505; 2-Carboxythiophene-5-boronicacid; DTXSID90381557; MolPort-000-144-982; OQGIKNPOYTVNNF-UHFFFAOYSA-N; 2-Carboxy-5-thiopheneboronic acid
DMPITR9	DT	Small molecular drug
DMPITR9	PC	2779807
DMPITR9	MW	171.97
DMPITR9	FM	C5H5BO4S
DMPITR9	IC	InChI=1S/C5H5BO4S/c7-5(8)3-1-2-4(11-3)6(9)10/h1-2,9-10H,(H,7,8)
DMPITR9	CS	B(C1=CC=C(S1)C(=O)O)(O)O
DMPITR9	IK	OQGIKNPOYTVNNF-UHFFFAOYSA-N
DMPITR9	IU	5-boronothiophene-2-carboxylic acid
DMPITR9	CA	CAS 465515-31-5
DMPITR9	DE	Discovery agent

DM0HCG6	ID	DM0HCG6
DM0HCG6	DN	5-bromo orotate
DM0HCG6	HS	Investigative
DM0HCG6	DE	Discovery agent

DM2QPHE	ID	DM2QPHE
DM2QPHE	DN	5-bromo-1H-indazole
DM2QPHE	HS	Investigative
DM2QPHE	SN	5-bromo-1H-indazole; 5-Bromoindazole; 53857-57-1; 5-Bromo-2H-indazole; 1h-indazole, 5-bromo-; 465529-55-9; CHEMBL16425; 5-Bromo-1H-indazole, 97%; 5-brom-1h-indazol; MLS000088501; 5-bromoazaindole; 5-bromo-indazole; 5- Bromoindazole; 5-bromo-azaindole; 5-bromo-1hindazole; AC1LFXVY; 4-Nitrotrityl chloride; PubChem15628; 5-bromo-1 h-indazole; ACMC-209lal; 5-bromanyl-1H-indazole; 2H-Indazole, 5-bromo-; SCHEMBL5562; AC1Q1H9U; KSC269G3N; cid_761929; AMBZ0279; CTK1G9336; DTXSID50354020; HID1020; STVHMYNPQCLUNJ-UHFFFAOYSA-N; MolPort-029-084-055
DM2QPHE	DT	Small molecular drug
DM2QPHE	PC	761929
DM2QPHE	MW	197.03
DM2QPHE	FM	C7H5BrN2
DM2QPHE	IC	InChI=1S/C7H5BrN2/c8-6-1-2-7-5(3-6)4-9-10-7/h1-4H,(H,9,10)
DM2QPHE	CS	C1=CC2=C(C=C1Br)C=NN2
DM2QPHE	IK	STVHMYNPQCLUNJ-UHFFFAOYSA-N
DM2QPHE	IU	5-bromo-1H-indazole
DM2QPHE	CA	CAS 53857-57-1
DM2QPHE	DE	Discovery agent

DM4WVSB	ID	DM4WVSB
DM4WVSB	DN	5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid
DM4WVSB	HS	Investigative
DM4WVSB	SN	5-bromo-2-{[(4-chlorophenyl)sulfonyl]amino}benzoic acid; AC1LLKZK; BAS 00347593; sulfonamide compound, 1; CBDivE_004908; SCHEMBL5925257; CHEMBL212522; BDBM17595; MolPort-001-926-487; ZINC754636; HMS3604C20; STL325205; AKOS000541754; DB07309; MCULE-4831129771; 107143-69-1; ST50224787; EU-0033636; SR-01000389963; A193400; 5-bromo-2-(4-chlorobenzenesulfonamido)benzoic acid; SR-01000389963-1; 5-bromo-2-[(4-chlorobenzene)sulfonamido]benzoic acid; 5-bromo-2-[(4-chlorophenyl)sulfonylamino]benzoic acid
DM4WVSB	DT	Small molecular drug
DM4WVSB	PC	1069140
DM4WVSB	MW	390.64
DM4WVSB	FM	C13H9BrClNO4S
DM4WVSB	IC	InChI=1S/C13H9BrClNO4S/c14-8-1-6-12(11(7-8)13(17)18)16-21(19,20)10-4-2-9(15)3-5-10/h1-7,16H,(H,17,18)
DM4WVSB	CS	C1=CC(=CC=C1S(=O)(=O)NC2=C(C=C(C=C2)Br)C(=O)O)Cl
DM4WVSB	IK	JDVLYAYDIMUAAC-UHFFFAOYSA-N
DM4WVSB	IU	5-bromo-2-[(4-chlorophenyl)sulfonylamino]benzoic acid
DM4WVSB	DE	Discovery agent

DM2YL0T	ID	DM2YL0T
DM2YL0T	DN	5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol
DM2YL0T	HS	Investigative
DM2YL0T	DT	Small molecular drug
DM2YL0T	PC	135421237
DM2YL0T	MW	316.15
DM2YL0T	FM	C15H10BrNO2
DM2YL0T	IC	InChI=1S/C15H10BrNO2/c16-15-11-5-6-12(9-1-3-10(18)4-2-9)17-13(11)7-8-14(15)19/h1-8,18-19H
DM2YL0T	CS	C1=CC(=CC=C1C2=NC3=C(C=C2)C(=C(C=C3)O)Br)O
DM2YL0T	IK	BLXVDNNULRNBGB-UHFFFAOYSA-N
DM2YL0T	IU	5-bromo-2-(4-hydroxyphenyl)quinolin-6-ol
DM2YL0T	DE	Discovery agent

DMMI4H3	ID	DMMI4H3
DMMI4H3	DN	5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMMI4H3	HS	Investigative
DMMI4H3	SN	CHEMBL6426; 5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline; BDBM50136501; AKOS023651923
DMMI4H3	DT	Small molecular drug
DMMI4H3	PC	44264094
DMMI4H3	MW	251.12
DMMI4H3	FM	C11H11BrN2
DMMI4H3	IC	InChI=1S/C11H11BrN2/c12-8-2-1-3-9-11(8)7-4-5-13-6-10(7)14-9/h1-3,13-14H,4-6H2
DMMI4H3	CS	C1CNCC2=C1C3=C(N2)C=CC=C3Br
DMMI4H3	IK	AOMJWOGZKNQVBI-UHFFFAOYSA-N
DMMI4H3	IU	5-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMMI4H3	DE	Discovery agent

DM2SEFR	ID	DM2SEFR
DM2SEFR	DN	5-Bromo-4,9-dihydro-3H-beta-carboline
DM2SEFR	HS	Investigative
DM2SEFR	SN	CHEMBL267599; 5-Bromo-4,9-dihydro-3H-beta-carboline; BDBM50136504
DM2SEFR	DT	Small molecular drug
DM2SEFR	PC	44264263
DM2SEFR	MW	249.11
DM2SEFR	FM	C11H9BrN2
DM2SEFR	IC	InChI=1S/C11H9BrN2/c12-8-2-1-3-9-11(8)7-4-5-13-6-10(7)14-9/h1-3,6,14H,4-5H2
DM2SEFR	CS	C1CN=CC2=C1C3=C(N2)C=CC=C3Br
DM2SEFR	IK	FTDSATOEKTYHMK-UHFFFAOYSA-N
DM2SEFR	IU	5-bromo-4,9-dihydro-3H-pyrido[3,4-b]indole
DM2SEFR	DE	Discovery agent

DMRY0OL	ID	DMRY0OL
DMRY0OL	DN	5-bromo-6-(cyclopropylamino)uracil hydrochloride
DMRY0OL	HS	Investigative
DMRY0OL	SN	CHEMBL537864
DMRY0OL	DT	Small molecular drug
DMRY0OL	PC	45263353
DMRY0OL	MW	282.52
DMRY0OL	FM	C7H9BrClN3O2
DMRY0OL	IC	InChI=1S/C7H8BrN3O2.ClH/c8-4-5(9-3-1-2-3)10-7(13)11-6(4)12;/h3H,1-2H2,(H3,9,10,11,12,13);1H
DMRY0OL	CS	C1CC1NC2=C(C(=O)NC(=O)N2)Br.Cl
DMRY0OL	IK	CUQFSKAHEOAMRH-UHFFFAOYSA-N
DMRY0OL	IU	5-bromo-6-(cyclopropylamino)-1H-pyrimidine-2,4-dione;hydrochloride
DMRY0OL	DE	Discovery agent

DMZJE6M	ID	DMZJE6M
DMZJE6M	DN	5-bromo-6-hydrazinouracil hydrochloride
DMZJE6M	HS	Investigative
DMZJE6M	SN	CHEMBL536284
DMZJE6M	DT	Small molecular drug
DMZJE6M	PC	45263378
DMZJE6M	MW	257.47
DMZJE6M	FM	C4H6BrClN4O2
DMZJE6M	IC	InChI=1S/C4H5BrN4O2.ClH/c5-1-2(9-6)7-4(11)8-3(1)10;/h6H2,(H3,7,8,9,10,11);1H
DMZJE6M	CS	C1(=C(NC(=O)NC1=O)NN)Br.Cl
DMZJE6M	IK	FSNHPVKPJNIXAD-UHFFFAOYSA-N
DMZJE6M	IU	5-bromo-6-hydrazinyl-1H-pyrimidine-2,4-dione;hydrochloride
DMZJE6M	DE	Discovery agent

DM157OQ	ID	DM157OQ
DM157OQ	DN	5-Bromo-6-methoxy-9H-beta-carboline
DM157OQ	HS	Investigative
DM157OQ	SN	5-bromo-6-methoxy-beta-carboline; CHEMBL310975; 5-Bromo-6-methoxy-9H-beta-carboline; SCHEMBL6465779; BDBM50130233
DM157OQ	DT	Small molecular drug
DM157OQ	PC	11414735
DM157OQ	MW	277.12
DM157OQ	FM	C12H9BrN2O
DM157OQ	IC	InChI=1S/C12H9BrN2O/c1-16-10-3-2-8-11(12(10)13)7-4-5-14-6-9(7)15-8/h2-6,15H,1H3
DM157OQ	CS	COC1=C(C2=C(C=C1)NC3=C2C=CN=C3)Br
DM157OQ	IK	NXKWYFQQPHBFII-UHFFFAOYSA-N
DM157OQ	IU	5-bromo-6-methoxy-9H-pyrido[3,4-b]indole
DM157OQ	DE	Discovery agent

DMTPRIW	ID	DMTPRIW
DMTPRIW	DN	5-Bromo-6-p-tolylamino-1H-pyrimidine-2,4-dione
DMTPRIW	HS	Investigative
DMTPRIW	SN	CHEMBL353575; 5-bromo-6-(p-toluidino)uracil; 100763-66-4; 5-Bromo-6-p-tolylamino-1H-pyrimidine-2,4-dione
DMTPRIW	DT	Small molecular drug
DMTPRIW	PC	44374273
DMTPRIW	MW	296.12
DMTPRIW	FM	C11H10BrN3O2
DMTPRIW	IC	InChI=1S/C11H10BrN3O2/c1-6-2-4-7(5-3-6)13-9-8(12)10(16)15-11(17)14-9/h2-5H,1H3,(H3,13,14,15,16,17)
DMTPRIW	CS	CC1=CC=C(C=C1)NC2=C(C(=O)NC(=O)N2)Br
DMTPRIW	IK	XCZQWOVVHWQUMF-UHFFFAOYSA-N
DMTPRIW	IU	5-bromo-6-(4-methylanilino)-1H-pyrimidine-2,4-dione
DMTPRIW	DE	Discovery agent

DM09Y72	ID	DM09Y72
DM09Y72	DN	5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one
DM09Y72	HS	Investigative
DM09Y72	SN	CHEMBL161530; 5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one; BDBM50097371; 8-((1H-imidazol-1-yl)methyl)-5-bromo-4H-chromen-4-one
DM09Y72	DT	Small molecular drug
DM09Y72	PC	10566470
DM09Y72	MW	305.13
DM09Y72	FM	C13H9BrN2O2
DM09Y72	IC	InChI=1S/C13H9BrN2O2/c14-10-2-1-9(7-16-5-4-15-8-16)13-12(10)11(17)3-6-18-13/h1-6,8H,7H2
DM09Y72	CS	C1=CC(=C2C(=O)C=COC2=C1CN3C=CN=C3)Br
DM09Y72	IK	QYFIAVSWVXIKAW-UHFFFAOYSA-N
DM09Y72	IU	5-bromo-8-(imidazol-1-ylmethyl)chromen-4-one
DM09Y72	DE	Discovery agent

DMSVCJM	ID	DMSVCJM
DMSVCJM	DN	5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine
DMSVCJM	HS	Investigative
DMSVCJM	SN	CHEMBL123566; 5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine; BDBM50002150; 143591-65-5; 5-Bromo-8-(1-piperazinyl)imidazo[1,2-a]pyrazine; Imidazo[1,2-a]pyrazine, 5-bromo-8-(1-piperazinyl)-
DMSVCJM	DT	Small molecular drug
DMSVCJM	PC	10379016
DMSVCJM	MW	282.14
DMSVCJM	FM	C10H12BrN5
DMSVCJM	IC	InChI=1S/C10H12BrN5/c11-8-7-14-9(10-13-3-6-16(8)10)15-4-1-12-2-5-15/h3,6-7,12H,1-2,4-5H2
DMSVCJM	CS	C1CN(CCN1)C2=NC=C(N3C2=NC=C3)Br
DMSVCJM	IK	SOIWQJOBNCOQPP-UHFFFAOYSA-N
DMSVCJM	IU	5-bromo-8-piperazin-1-ylimidazo[1,2-a]pyrazine
DMSVCJM	DE	Discovery agent

DMH908V	ID	DMH908V
DMH908V	DN	5-Bromomethyl-oxazolidin-(2Z)-ylideneamine
DMH908V	HS	Investigative
DMH908V	SN	5-Bromomethyl-4,5-dihydro-oxazol-2-ylamine; CHEMBL447832; 52886-60-9; 5-(bromomethyl)-4,5-dihydro-1,3-oxazol-2-amine; AC1MJII5; 5-Bromomethyl-oxazolidin-(2Z)-ylideneamine; SCHEMBL11817450; MolPort-001-940-341; 5-(Bromomethyl)oxazolidine-2-imine; SBB010634; BDBM50138186; AKOS016344418; AKOS000301813; BAS 00615750; 5-(bromomethyl)-1,3-oxazoline-2-ylamine; BB 0261596
DMH908V	DT	Small molecular drug
DMH908V	PC	3112983
DMH908V	MW	179.02
DMH908V	FM	C4H7BrN2O
DMH908V	IC	InChI=1S/C4H7BrN2O/c5-1-3-2-7-4(6)8-3/h3H,1-2H2,(H2,6,7)
DMH908V	CS	C1C(OC(=N1)N)CBr
DMH908V	IK	DCJDVEKKUOXALB-UHFFFAOYSA-N
DMH908V	IU	5-(bromomethyl)-4,5-dihydro-1,3-oxazol-2-amine
DMH908V	DE	Discovery agent

DM37T5L	ID	DM37T5L
DM37T5L	DN	5-bromo-N-(quinolin-8-yl)thiophene-2-sulfonamide
DM37T5L	HS	Investigative
DM37T5L	SN	5-bromo-N-quinolin-8-ylthiophene-2-sulfonamide; 5-bromo-N-(quinolin-8-yl)thiophene-2-sulfonamide; 620103-87-9; CHEMBL401504; AC1M3N93; SCHEMBL11995751; CTK5I7875; MolPort-000-693-109; ZINC2888883; ALBB-010070; STK506180; BDBM50372503; BBL018066; AKOS001440266; MCULE-3903306629; NCGC00161700-01; TR-061560; TR-039409; R9130; 2-Thiophenesulfonamide, 5-bromo-N-8-quinolinyl-
DM37T5L	DT	Small molecular drug
DM37T5L	PC	2240993
DM37T5L	MW	369.3
DM37T5L	FM	C13H9BrN2O2S2
DM37T5L	IC	InChI=1S/C13H9BrN2O2S2/c14-11-6-7-12(19-11)20(17,18)16-10-5-1-3-9-4-2-8-15-13(9)10/h1-8,16H
DM37T5L	CS	C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(S3)Br)N=CC=C2
DM37T5L	IK	BWZPDZRPJIBWAU-UHFFFAOYSA-N
DM37T5L	IU	5-bromo-N-quinolin-8-ylthiophene-2-sulfonamide
DM37T5L	DE	Discovery agent

DMZ8X3H	ID	DMZ8X3H
DMZ8X3H	DN	5-Bromothienyldeoxyuridine
DMZ8X3H	HS	Investigative
DMZ8X3H	SN	5-BROMOTHIENYLDEOXYURIDINE; CHEMBL1231486; 5-(5-Bromo-2-thienyl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-2'-deoxyuridine; BTD; 134333-70-3; BTDU; Uridine,5-(5-bromo-2-thienyl)-2'-deoxy-; AC1L9K0Y; SCHEMBL1636648; CHEMBL358374; CTK4B9107; BDBM50054768; DB03804; 5-(5-Bromothien-2-yl)-2'-deoxyuridine-; 5-(5-bromothiophen-2-yl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-1- (.beta.-D-2-deoxyribofuranos-1-yl)uracil; 5-(5-Bromo-thiophen-2-yl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione
DMZ8X3H	DT	Small molecular drug
DMZ8X3H	PC	446725
DMZ8X3H	MW	389.22
DMZ8X3H	FM	C13H13BrN2O5S
DMZ8X3H	IC	InChI=1S/C13H13BrN2O5S/c14-10-2-1-9(22-10)6-4-16(13(20)15-12(6)19)11-3-7(18)8(5-17)21-11/h1-2,4,7-8,11,17-18H,3,5H2,(H,15,19,20)/t7-,8+,11+/m0/s1
DMZ8X3H	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C3=CC=C(S3)Br)CO)O
DMZ8X3H	IK	IGUZFFOBAZCVRK-VAOFZXAKSA-N
DMZ8X3H	IU	5-(5-bromothiophen-2-yl)-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMZ8X3H	DE	Discovery agent

DMEVRH4	ID	DMEVRH4
DMEVRH4	DN	5BrUTP
DMEVRH4	HS	Investigative
DMEVRH4	SN	5-bromouridine triphosphate; bromouridine 5'-triphosphate; 5-bromo-UTP
DMEVRH4	DT	Small molecular drug
DMEVRH4	PC	9872620
DMEVRH4	MW	563.04
DMEVRH4	FM	C9H14BrN2O15P3
DMEVRH4	IC	InChI=1S/C9H14BrN2O15P3/c10-3-1-12(9(16)11-7(3)15)8-6(14)5(13)4(25-8)2-24-29(20,21)27-30(22,23)26-28(17,18)19/h1,4-6,8,13-14H,2H2,(H,20,21)(H,22,23)(H,11,15,16)(H2,17,18,19)/t4-,5-,6-,8-/m1/s1
DMEVRH4	CS	C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)Br
DMEVRH4	IK	IWFHOSULCAJGRM-UAKXSSHOSA-N
DMEVRH4	IU	[[(2R,3S,4R,5R)-5-(5-bromo-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMEVRH4	CA	CAS 3398-50-3
DMEVRH4	CB	CHEBI:88358
DMEVRH4	DE	Discovery agent

DMXKQFM	ID	DMXKQFM
DMXKQFM	DN	5-Butyl-1H-pyrazole-3-carboxylic acid
DMXKQFM	HS	Investigative
DMXKQFM	SN	5-Butyl-1H-pyrazole-3-carboxylic acid; 92933-48-7; 5-Butyl-2H-pyrazole-3-carboxylic acid; 3-butyl-1H-pyrazole-5-carboxylic acid; CHEMBL428730; 890624-89-2; 3-butylpyrazole-5-carboxylic acid; 5-n-butyl-1H-pyrazole-3-carboxylic acid; BAS 13299640; AC1O5JK4; GTPL1591; SCHEMBL1527555; CTK8F6771; CTK6D6234; MolPort-027-640-734; ZJTXSGLJNBAMJS-UHFFFAOYSA-N; MolPort-002-026-457; ZX-AV000908; ZINC4386887; STL257894; BDBM50220842; BBL030719; 2213AF; SBB027985; AKOS024458395; 5-butyl-1H-pyrazol-3-carboxylic acid; AKOS000301963; CHM0075795
DMXKQFM	DT	Small molecular drug
DMXKQFM	PC	6485181
DMXKQFM	MW	168.19
DMXKQFM	FM	C8H12N2O2
DMXKQFM	IC	InChI=1S/C8H12N2O2/c1-2-3-4-6-5-7(8(11)12)10-9-6/h5H,2-4H2,1H3,(H,9,10)(H,11,12)
DMXKQFM	CS	CCCCC1=CC(=NN1)C(=O)O
DMXKQFM	IK	ZJTXSGLJNBAMJS-UHFFFAOYSA-N
DMXKQFM	IU	5-butyl-1H-pyrazole-3-carboxylic acid
DMXKQFM	CA	CAS 92933-48-7
DMXKQFM	DE	Discovery agent

DMCNU6I	ID	DMCNU6I
DMCNU6I	DN	5-butyl-2-(2,4-dichlorophenoxy)phenol
DMCNU6I	HS	Investigative
DMCNU6I	SN	5-butyl-2-(2,4-dichlorophenoxy)phenol; Triclosan derivative, 10; CHEMBL405402
DMCNU6I	DT	Small molecular drug
DMCNU6I	PC	25023960
DMCNU6I	MW	311.2
DMCNU6I	FM	C16H16Cl2O2
DMCNU6I	IC	InChI=1S/C16H16Cl2O2/c1-2-3-4-11-5-7-16(14(19)9-11)20-15-8-6-12(17)10-13(15)18/h5-10,19H,2-4H2,1H3
DMCNU6I	CS	CCCCC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DMCNU6I	IK	YJSDMDYNCMZAED-UHFFFAOYSA-N
DMCNU6I	IU	5-butyl-2-(2,4-dichlorophenoxy)phenol
DMCNU6I	DE	Discovery agent

DMI7DSM	ID	DMI7DSM
DMI7DSM	DN	5-butyl-2-(phenylsulfonamido)benzoic acid
DMI7DSM	HS	Investigative
DMI7DSM	SN	sulfonamide compound, 8; SCHEMBL3983649; CHEMBL425776; BDBM17602; 2-benzenesulfonamido-5-butylbenzoic acid
DMI7DSM	DT	Small molecular drug
DMI7DSM	PC	10246233
DMI7DSM	MW	333.4
DMI7DSM	FM	C17H19NO4S
DMI7DSM	IC	InChI=1S/C17H19NO4S/c1-2-3-7-13-10-11-16(15(12-13)17(19)20)18-23(21,22)14-8-5-4-6-9-14/h4-6,8-12,18H,2-3,7H2,1H3,(H,19,20)
DMI7DSM	CS	CCCCC1=CC(=C(C=C1)NS(=O)(=O)C2=CC=CC=C2)C(=O)O
DMI7DSM	IK	GUFYXBDBRAROGG-UHFFFAOYSA-N
DMI7DSM	IU	2-(benzenesulfonamido)-5-butylbenzoic acid
DMI7DSM	DE	Discovery agent

DMFKMYV	ID	DMFKMYV
DMFKMYV	DN	5-butyl-6-chloropyrimidine-2,4(1H,3H)-dione
DMFKMYV	HS	Investigative
DMFKMYV	SN	5-butyl-6-chloropyrimidine-2,4(1H,3H)-dione; 18493-80-6; CHEMBL237996; BDBM20056; 5-Substituted-6-chlorouracil, 5c
DMFKMYV	DT	Small molecular drug
DMFKMYV	PC	14956545
DMFKMYV	MW	202.64
DMFKMYV	FM	C8H11ClN2O2
DMFKMYV	IC	InChI=1S/C8H11ClN2O2/c1-2-3-4-5-6(9)10-8(13)11-7(5)12/h2-4H2,1H3,(H2,10,11,12,13)
DMFKMYV	CS	CCCCC1=C(NC(=O)NC1=O)Cl
DMFKMYV	IK	CYNWJDGCUODOPW-UHFFFAOYSA-N
DMFKMYV	IU	5-butyl-6-chloro-1H-pyrimidine-2,4-dione
DMFKMYV	DE	Discovery agent

DM2EPFZ	ID	DM2EPFZ
DM2EPFZ	DN	5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine
DM2EPFZ	HS	Investigative
DM2EPFZ	DT	Small molecular drug
DM2EPFZ	PC	135457998
DM2EPFZ	MW	292.34
DM2EPFZ	FM	C16H16N6
DM2EPFZ	IC	InChI=1S/C16H16N6/c1-2-3-9-12-19-15-13(17-10-18-15)16-20-14(21-22(12)16)11-7-5-4-6-8-11/h4-8,10H,2-3,9H2,1H3,(H,17,18)
DM2EPFZ	CS	CCCCC1=NC2=C(C3=NC(=NN13)C4=CC=CC=C4)NC=N2
DM2EPFZ	IK	LTQQXOYFDPLYHI-UHFFFAOYSA-N
DM2EPFZ	IU	5-butyl-8-phenyl-1H-[1,2,4]triazolo[5,1-f]purine
DM2EPFZ	DE	Discovery agent

DM0VGCX	ID	DM0VGCX
DM0VGCX	DN	5-butyl-methyl immidazole carboxylate 30
DM0VGCX	HS	Investigative
DM0VGCX	SN	compound 30 [PMID: 22889560]
DM0VGCX	DT	Small molecular drug
DM0VGCX	PC	73755250
DM0VGCX	MW	348.4
DM0VGCX	FM	C22H24N2O2
DM0VGCX	IC	InChI=1S/C22H24N2O2/c1-3-4-8-19-14-23-21(22(25)26)24(19)15-17-10-12-18(13-11-17)20-9-6-5-7-16(20)2/h5-7,9-14H,3-4,8,15H2,1-2H3,(H,25,26)
DM0VGCX	CS	CCCCC1=CN=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C)C(=O)O
DM0VGCX	IK	ZCAMCVJTCSXPMT-UHFFFAOYSA-N
DM0VGCX	IU	5-butyl-1-[[4-(2-methylphenyl)phenyl]methyl]imidazole-2-carboxylic acid
DM0VGCX	DE	Discovery agent

DM04WVH	ID	DM04WVH
DM04WVH	DN	5-Carbazol-9-yl-pentanoic acid
DM04WVH	HS	Investigative
DM04WVH	SN	CHEMBL184795; 5-Carbazol-9-yl-pentanoic acid; SCHEMBL12951764; BDBM50152858
DM04WVH	DT	Small molecular drug
DM04WVH	PC	28971834
DM04WVH	MW	267.32
DM04WVH	FM	C17H17NO2
DM04WVH	IC	InChI=1S/C17H17NO2/c19-17(20)11-5-6-12-18-15-9-3-1-7-13(15)14-8-2-4-10-16(14)18/h1-4,7-10H,5-6,11-12H2,(H,19,20)
DM04WVH	CS	C1=CC=C2C(=C1)C3=CC=CC=C3N2CCCCC(=O)O
DM04WVH	IK	YEPJVQJMLQBLOE-UHFFFAOYSA-N
DM04WVH	IU	5-carbazol-9-ylpentanoic acid
DM04WVH	DE	Discovery agent

DMIH7W1	ID	DMIH7W1
DMIH7W1	DN	5-Chloro-1-(4-chloro-benzyl)-1H-indole-2,3-dione
DMIH7W1	HS	Investigative
DMIH7W1	SN	5-chloro-1-(4-chlorobenzyl)-1H-indole-2,3-dione; CHEMBL333067; 87423-59-4; AC1M2SUT; Cambridge id 7142603; 5-Chloro-1-(4-chloro-benzyl)-1H-indole-2,3-dione; SCHEMBL11186018; KS-00001SNW; MolPort-000-407-830; ZINC2813807; BDBM50133622; STK394570; BBL005671; AKOS001662460; MCULE-8294112694; 12F-374S; H3079; ST50867327; 5-chloro-1-[(4-chlorophenyl)methyl]indole-2,3-dione; 5-chloro-1-[(4-chlorophenyl)methyl]benzo[d]azoline-2,3-dione; 1-(4-Chlorobenzyl)-5-chloro-2,3-dihydro-1H-indole-2,3-dione
DMIH7W1	DT	Small molecular drug
DMIH7W1	PC	2175573
DMIH7W1	MW	306.1
DMIH7W1	FM	C15H9Cl2NO2
DMIH7W1	IC	InChI=1S/C15H9Cl2NO2/c16-10-3-1-9(2-4-10)8-18-13-6-5-11(17)7-12(13)14(19)15(18)20/h1-7H,8H2
DMIH7W1	CS	C1=CC(=CC=C1CN2C3=C(C=C(C=C3)Cl)C(=O)C2=O)Cl
DMIH7W1	IK	NWUYWKYKVCEBTP-UHFFFAOYSA-N
DMIH7W1	IU	5-chloro-1-[(4-chlorophenyl)methyl]indole-2,3-dione
DMIH7W1	DE	Discovery agent

DMTJNY0	ID	DMTJNY0
DMTJNY0	DN	5-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DMTJNY0	HS	Investigative
DMTJNY0	SN	CHEMBL369661; 5-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine; SCHEMBL12043414; ZINC27993222; BDBM50280623; AKOS011477647
DMTJNY0	DT	Small molecular drug
DMTJNY0	PC	44381944
DMTJNY0	MW	232.71
DMTJNY0	FM	C13H13ClN2
DMTJNY0	IC	InChI=1S/C13H13ClN2/c14-10-6-3-5-9-12(15)8-4-1-2-7-11(8)16-13(9)10/h3,5-6H,1-2,4,7H2,(H2,15,16)
DMTJNY0	CS	C1CCC2=C(C1)C(=C3C=CC=C(C3=N2)Cl)N
DMTJNY0	IK	DREAHDLCWZKIJL-UHFFFAOYSA-N
DMTJNY0	IU	5-chloro-1,2,3,4-tetrahydroacridin-9-amine
DMTJNY0	DE	Discovery agent

DMOCYDU	ID	DMOCYDU
DMOCYDU	DN	5-chloro-1H-indazole
DMOCYDU	HS	Investigative
DMOCYDU	SN	5-Chloro-1H-indazole; 698-26-0; 1H-Indazole, 5-chloro-; 5-Chloroindazole; 5-CHLORO INDAZOLE; EINECS 211-812-1; NSC 78434; BRN 0003260; CHEMBL246746; FVNCILPDWNBPLK-UHFFFAOYSA-N; AK-23822; 5-chloro-indazole; 2H-Indazole, 5-chloro-; NSC78434; 5-chloro-2H-indazole; AC1L2CF8; 5-23-06-00175 (Beilstein Handbook Reference); 5-CHLORO(1H)INDAZOLE; SCHEMBL3540025; SCHEMBL16523221; CTK2F6769; DTXSID70220091; MolPort-000-002-983; 5-Chloro-1H-indazole, AldrichCPR; ZX-CM006597; ZX-AT013670; ZINC4876880; BCP00023; ACT10091; FCH837623; BDBM50209242
DMOCYDU	DT	Small molecular drug
DMOCYDU	PC	69681
DMOCYDU	MW	152.58
DMOCYDU	FM	C7H5ClN2
DMOCYDU	IC	InChI=1S/C7H5ClN2/c8-6-1-2-7-5(3-6)4-9-10-7/h1-4H,(H,9,10)
DMOCYDU	CS	C1=CC2=C(C=C1Cl)C=NN2
DMOCYDU	IK	FVNCILPDWNBPLK-UHFFFAOYSA-N
DMOCYDU	IU	5-chloro-1H-indazole
DMOCYDU	CA	CAS 698-26-0
DMOCYDU	DE	Discovery agent

DMQ350F	ID	DMQ350F
DMQ350F	DN	5-chloro-1H-indole-2,3-dione
DMQ350F	HS	Investigative
DMQ350F	SN	5-Chloroisatin; 17630-76-1; 5-chloroindoline-2,3-dione; 5-Chloro-1H-indole-2,3-dione; 5-chlorisatin; 1H-Indole-2,3-dione, 5-chloro-; 5-chloro-2,3-dihydro-1H-indole-2,3-dione; 5-CHLORO ISATIN; 5-chlor-2,3-dioxoindolin; NSC 135811; XHDJYQWGFIBCEP-UHFFFAOYSA-N; MFCD00014567; 5-chlor-1h-indol-2,3-dion; 2HQ; EINECS 241-614-0; NSC135811; PubChem13607; ACMC-209zyf; 5-Chloroisatin, 97%; AC1Q3MRO; AC1Q3KL6; Isatin-based compound, 33; AC1Q3KL5; AC1L3D5R; 5-chloro-2,3-dioxoindolin; 5-Chloroindolin-2,3-dione; 1H-Indole-2, 5-chloro-; KSC174O1F
DMQ350F	DT	Small molecular drug
DMQ350F	PC	87203
DMQ350F	MW	181.57
DMQ350F	FM	C8H4ClNO2
DMQ350F	IC	InChI=1S/C8H4ClNO2/c9-4-1-2-6-5(3-4)7(11)8(12)10-6/h1-3H,(H,10,11,12)
DMQ350F	CS	C1=CC2=C(C=C1Cl)C(=O)C(=O)N2
DMQ350F	IK	XHDJYQWGFIBCEP-UHFFFAOYSA-N
DMQ350F	IU	5-chloro-1H-indole-2,3-dione
DMQ350F	CA	CAS 17630-76-1
DMQ350F	CB	CHEBI:149904
DMQ350F	DE	Discovery agent

DMDZ8NA	ID	DMDZ8NA
DMDZ8NA	DN	5-chloro-2-(2-chloro-4-hydroxyphenoxy)phenol
DMDZ8NA	HS	Investigative
DMDZ8NA	SN	CHEMBL200379; 5-chloro-2-(2-chloro-4-hydroxyphenoxy)phenol; 656833-26-0; SCHEMBL10539354; CTK1J6007; DTXSID70611844; BDBM50174768; 2-(2-Chloro-4-hydroxyphenoxy)-5-chlorophenol; 3-chloro-4-(4-chloro-2-hydroxy-phenoxy)phenol; Phenol, 5-chloro-2-(2-chloro-4-hydroxyphenoxy)-
DMDZ8NA	DT	Small molecular drug
DMDZ8NA	PC	21272512
DMDZ8NA	MW	271.09
DMDZ8NA	FM	C12H8Cl2O3
DMDZ8NA	IC	InChI=1S/C12H8Cl2O3/c13-7-1-3-12(10(16)5-7)17-11-4-2-8(15)6-9(11)14/h1-6,15-16H
DMDZ8NA	CS	C1=CC(=C(C=C1O)Cl)OC2=C(C=C(C=C2)Cl)O
DMDZ8NA	IK	JVFMLMMBAJXPOQ-UHFFFAOYSA-N
DMDZ8NA	IU	3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenol
DMDZ8NA	CA	CAS 656833-26-0
DMDZ8NA	DE	Discovery agent

DMAJ8BS	ID	DMAJ8BS
DMAJ8BS	DN	5-chloro-2-(2-chloro-4-nitrophenoxy)phenol
DMAJ8BS	HS	Investigative
DMAJ8BS	SN	5-CHLORO-2-(2-CHLORO-4-NITROPHENOXY)PHENOL; CHEMBL370595; TN2; AC1OA9SQ; Phenol, 5-chloro-2-(2-chloro-4-nitrophenoxy)-; BDBM50174770; 36859-73-1; 5-chloro-(2-chloro-4-nitrophenoxy)phenol
DMAJ8BS	DT	Small molecular drug
DMAJ8BS	PC	6852143
DMAJ8BS	MW	300.09
DMAJ8BS	FM	C12H7Cl2NO4
DMAJ8BS	IC	InChI=1S/C12H7Cl2NO4/c13-7-1-3-12(10(16)5-7)19-11-4-2-8(15(17)18)6-9(11)14/h1-6,16H
DMAJ8BS	CS	C1=CC(=C(C=C1[N+](=O)[O-])Cl)OC2=C(C=C(C=C2)Cl)O
DMAJ8BS	IK	DEDBMNCDHFNYKX-UHFFFAOYSA-N
DMAJ8BS	IU	5-chloro-2-(2-chloro-4-nitrophenoxy)phenol
DMAJ8BS	DE	Discovery agent

DMH4SLZ	ID	DMH4SLZ
DMH4SLZ	DN	5-Chloro-2-(2-methylquinolin-7-yl)benzonitrile
DMH4SLZ	HS	Investigative
DMH4SLZ	SN	CHEMBL1099112; 5-Chloro-2-(2-methylquinolin-7-yl)benzonitrile
DMH4SLZ	DT	Small molecular drug
DMH4SLZ	PC	46888044
DMH4SLZ	MW	278.7
DMH4SLZ	FM	C17H11ClN2
DMH4SLZ	IC	InChI=1S/C17H11ClN2/c1-11-2-3-12-4-5-13(9-17(12)20-11)16-7-6-15(18)8-14(16)10-19/h2-9H,1H3
DMH4SLZ	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=C(C=C(C=C3)Cl)C#N
DMH4SLZ	IK	BYFVDRQULSVRKZ-UHFFFAOYSA-N
DMH4SLZ	IU	5-chloro-2-(2-methylquinolin-7-yl)benzonitrile
DMH4SLZ	DE	Discovery agent

DMCFIZN	ID	DMCFIZN
DMCFIZN	DN	5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol
DMCFIZN	HS	Investigative
DMCFIZN	DT	Small molecular drug
DMCFIZN	PC	135495079
DMCFIZN	MW	261.66
DMCFIZN	FM	C13H8ClNO3
DMCFIZN	IC	InChI=1S/C13H8ClNO3/c14-9-5-10-12(6-11(9)17)18-13(15-10)7-1-3-8(16)4-2-7/h1-6,16-17H
DMCFIZN	CS	C1=CC(=CC=C1C2=NC3=CC(=C(C=C3O2)O)Cl)O
DMCFIZN	IK	BXCKDNMAGMSBHF-UHFFFAOYSA-N
DMCFIZN	IU	5-chloro-2-(4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DMCFIZN	DE	Discovery agent

DMXNPSB	ID	DMXNPSB
DMXNPSB	DN	5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMXNPSB	HS	Investigative
DMXNPSB	DT	Small molecular drug
DMXNPSB	PC	135502634
DMXNPSB	MW	271.7
DMXNPSB	FM	C15H10ClNO2
DMXNPSB	IC	InChI=1S/C15H10ClNO2/c16-15-11-5-6-12(9-1-3-10(18)4-2-9)17-13(11)7-8-14(15)19/h1-8,18-19H
DMXNPSB	CS	C1=CC(=CC=C1C2=NC3=C(C=C2)C(=C(C=C3)O)Cl)O
DMXNPSB	IK	FGSBNIBNUVNBIW-UHFFFAOYSA-N
DMXNPSB	IU	5-chloro-2-(4-hydroxyphenyl)quinolin-6-ol
DMXNPSB	DE	Discovery agent

DM9QBAZ	ID	DM9QBAZ
DM9QBAZ	DN	5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione
DM9QBAZ	HS	Investigative
DM9QBAZ	SN	CHEMBL397849
DM9QBAZ	DT	Small molecular drug
DM9QBAZ	PC	44440475
DM9QBAZ	MW	313.8
DM9QBAZ	FM	C18H16ClNO2
DM9QBAZ	IC	InChI=1S/C18H16ClNO2/c19-14-9-10-15-16(12-14)18(22)20(17(15)21)11-5-4-8-13-6-2-1-3-7-13/h1-3,6-7,9-10,12H,4-5,8,11H2
DM9QBAZ	CS	C1=CC=C(C=C1)CCCCN2C(=O)C3=C(C2=O)C=C(C=C3)Cl
DM9QBAZ	IK	QQYWRVQHDFXEFG-UHFFFAOYSA-N
DM9QBAZ	IU	5-chloro-2-(4-phenylbutyl)isoindole-1,3-dione
DM9QBAZ	DE	Discovery agent

DMJBHR9	ID	DMJBHR9
DMJBHR9	DN	5-chloro-2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMJBHR9	HS	Investigative
DMJBHR9	SN	63053-15-6; 6-chloro-2-(pyridin-2-yl)-1H-1,3-benzodiazole; 1H-Benzimidazole, 6-chloro-2-(2-pyridinyl)-; CHEMBL166127; 5-chloro-2-pyridin-2-yl-3H-benzoimidazole; 5-chlor-2-(2-pyridinyl)-1h-benzimidazol; AC1L4JHX; AC1Q3S8V; 5-chloro-2-(pyridin-2-yl)-1H-benzo[d]imidazole; SCHEMBL124391; CTK2F4016; MolPort-006-709-924; KS-00001PG4; BDBM50180732; ZINC13679488; AKOS008957084; AKOS005256857; NE28766; MCULE-2896710700; 6-chloro-2-pyridin-2-yl-1H-benzimidazole; 2-(2-Pyridyl)-5-chloro-1H-benzoimidazole
DMJBHR9	DT	Small molecular drug
DMJBHR9	PC	186763
DMJBHR9	MW	229.66
DMJBHR9	FM	C12H8ClN3
DMJBHR9	IC	InChI=1S/C12H8ClN3/c13-8-4-5-9-11(7-8)16-12(15-9)10-3-1-2-6-14-10/h1-7H,(H,15,16)
DMJBHR9	CS	C1=CC=NC(=C1)C2=NC3=C(N2)C=C(C=C3)Cl
DMJBHR9	IK	AIASBFLKLNIZOK-UHFFFAOYSA-N
DMJBHR9	IU	6-chloro-2-pyridin-2-yl-1H-benzimidazole
DMJBHR9	CA	CAS 63053-15-6
DMJBHR9	DE	Discovery agent

DM6YBZR	ID	DM6YBZR
DM6YBZR	DN	5-Chloro-2-methyl-3H-quinazolin-4-one
DM6YBZR	HS	Investigative
DM6YBZR	DT	Small molecular drug
DM6YBZR	PC	135875707
DM6YBZR	MW	194.62
DM6YBZR	FM	C9H7ClN2O
DM6YBZR	IC	InChI=1S/C9H7ClN2O/c1-5-11-7-4-2-3-6(10)8(7)9(13)12-5/h2-4H,1H3,(H,11,12,13)
DM6YBZR	CS	CC1=NC2=C(C(=CC=C2)Cl)C(=O)N1
DM6YBZR	IK	GKDIFKSYPXLUJS-UHFFFAOYSA-N
DM6YBZR	IU	5-chloro-2-methyl-3H-quinazolin-4-one
DM6YBZR	CA	CAS 19407-56-8
DM6YBZR	DE	Discovery agent

DMKEFJ0	ID	DMKEFJ0
DMKEFJ0	DN	5-chloro-3,4-dihydroquinazolin-2-amine
DMKEFJ0	HS	Investigative
DMKEFJ0	SN	CHEMBL401541; 2-Amino-5-chlor-3,4-dihydrochinazolin; 109319-86-0
DMKEFJ0	DT	Small molecular drug
DMKEFJ0	PC	13702393
DMKEFJ0	MW	181.62
DMKEFJ0	FM	C8H8ClN3
DMKEFJ0	IC	InChI=1S/C8H8ClN3/c9-6-2-1-3-7-5(6)4-11-8(10)12-7/h1-3H,4H2,(H3,10,11,12)
DMKEFJ0	CS	C1C2=C(C=CC=C2Cl)NC(=N1)N
DMKEFJ0	IK	UDUQYNVUNNDSEJ-UHFFFAOYSA-N
DMKEFJ0	IU	5-chloro-1,4-dihydroquinazolin-2-amine
DMKEFJ0	DE	Discovery agent

DM207CQ	ID	DM207CQ
DM207CQ	DN	5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole
DM207CQ	HS	Investigative
DM207CQ	SN	CHEMBL300907; 181116-12-1; 5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole; CTK0A6482; DTXSID30658199; BDBM50127987; ZINC13489982; AKOS030619591; 5-Chloro-3-ethyl-1-(4-fluorophenyl)-1H-indole; 1H-Indole, 5-chloro-3-ethyl-1-(4-fluorophenyl)-
DM207CQ	DT	Small molecular drug
DM207CQ	PC	44297094
DM207CQ	MW	273.73
DM207CQ	FM	C16H13ClFN
DM207CQ	IC	InChI=1S/C16H13ClFN/c1-2-11-10-19(14-6-4-13(18)5-7-14)16-8-3-12(17)9-15(11)16/h3-10H,2H2,1H3
DM207CQ	CS	CCC1=CN(C2=C1C=C(C=C2)Cl)C3=CC=C(C=C3)F
DM207CQ	IK	APVXBLPJSJGGAJ-UHFFFAOYSA-N
DM207CQ	IU	5-chloro-3-ethyl-1-(4-fluorophenyl)indole
DM207CQ	CA	CAS 181116-12-1
DM207CQ	DE	Discovery agent

DMGDTNI	ID	DMGDTNI
DMGDTNI	DN	5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine
DMGDTNI	HS	Investigative
DMGDTNI	SN	CHEMBL270176; 918134-92-6; 2-Quinazolinamine, 5-chloro-4-ethyl-1,4-dihydro-; 5-Chloro-4-ethyl-1,4-dihydroquinazolin-2-amine; SCHEMBL3570857; CTK3H8593; DTXSID00659173
DMGDTNI	DT	Small molecular drug
DMGDTNI	PC	44455973
DMGDTNI	MW	209.67
DMGDTNI	FM	C10H12ClN3
DMGDTNI	IC	InChI=1S/C10H12ClN3/c1-2-7-9-6(11)4-3-5-8(9)14-10(12)13-7/h3-5,7H,2H2,1H3,(H3,12,13,14)
DMGDTNI	CS	CCC1C2=C(C=CC=C2Cl)NC(=N1)N
DMGDTNI	IK	MICIQKQOEFSTDP-UHFFFAOYSA-N
DMGDTNI	IU	5-chloro-4-ethyl-1,4-dihydroquinazolin-2-amine
DMGDTNI	CA	CAS 918134-92-6
DMGDTNI	DE	Discovery agent

DM7FZU2	ID	DM7FZU2
DM7FZU2	DN	5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine
DM7FZU2	HS	Investigative
DM7FZU2	SN	CHEMBL270177; 918134-82-4; 2-Quinazolinamine, 5-chloro-1,4-dihydro-4-methyl-; 5-Chloro-4-methyl-1,4-dihydroquinazolin-2-amine; SCHEMBL1381915; CTK3H8599; DTXSID00581041; XFMPGBXLGWZMQP-UHFFFAOYSA-N; BDBM50371466
DM7FZU2	DT	Small molecular drug
DM7FZU2	PC	16006492
DM7FZU2	MW	195.65
DM7FZU2	FM	C9H10ClN3
DM7FZU2	IC	InChI=1S/C9H10ClN3/c1-5-8-6(10)3-2-4-7(8)13-9(11)12-5/h2-5H,1H3,(H3,11,12,13)
DM7FZU2	CS	CC1C2=C(C=CC=C2Cl)NC(=N1)N
DM7FZU2	IK	XFMPGBXLGWZMQP-UHFFFAOYSA-N
DM7FZU2	IU	5-chloro-4-methyl-1,4-dihydroquinazolin-2-amine
DM7FZU2	CA	CAS 918134-82-4
DM7FZU2	DE	Discovery agent

DMRS82Q	ID	DMRS82Q
DMRS82Q	DN	5-chloro-4-nitrothiophene-2-sulfonamide
DMRS82Q	HS	Investigative
DMRS82Q	SN	5-chloro-4-nitrothiophene-2-sulfonamide; 61714-46-3; 2-Chloro-3-nitrothiophene-5-sulfonamide; CHEMBL1170927; 2-Thiophenesulfonamide,5-chloro-4-nitro-; 2-chloro-3-nitrothiophene-5-sulphonamide; C4H3ClN2O4S2; AC1MC43M; SCHEMBL1185703; AC1Q558E; CTK5B3617; DTXSID50370942; CKMLFNQCVNTKHN-UHFFFAOYSA-N; MolPort-000-153-347; ZINC4253283; 9258AB; SBB099627; BDBM50321449; AKOS016010801; MCULE-8003873982; 5-chloro-4-nitro-2-thiophenesulfonamide; AJ-49707; 5-chloro-4-nitro-thiophene-2-sulfonamide; DB-053977; KB-229486; FT-0640779
DMRS82Q	DT	Small molecular drug
DMRS82Q	PC	2735782
DMRS82Q	MW	242.7
DMRS82Q	FM	C4H3ClN2O4S2
DMRS82Q	IC	InChI=1S/C4H3ClN2O4S2/c5-4-2(7(8)9)1-3(12-4)13(6,10)11/h1H,(H2,6,10,11)
DMRS82Q	CS	C1=C(SC(=C1[N+](=O)[O-])Cl)S(=O)(=O)N
DMRS82Q	IK	CKMLFNQCVNTKHN-UHFFFAOYSA-N
DMRS82Q	IU	5-chloro-4-nitrothiophene-2-sulfonamide
DMRS82Q	CA	CAS 61714-46-3
DMRS82Q	DE	Discovery agent

DMMT7WO	ID	DMMT7WO
DMMT7WO	DN	5-chloro-6-hydrazinouracil hydrochloride
DMMT7WO	HS	Investigative
DMMT7WO	SN	CHEMBL558777
DMMT7WO	DT	Small molecular drug
DMMT7WO	PC	45263377
DMMT7WO	MW	213.02
DMMT7WO	FM	C4H6Cl2N4O2
DMMT7WO	IC	InChI=1S/C4H5ClN4O2.ClH/c5-1-2(9-6)7-4(11)8-3(1)10;/h6H2,(H3,7,8,9,10,11);1H
DMMT7WO	CS	C1(=C(NC(=O)NC1=O)NN)Cl.Cl
DMMT7WO	IK	CEUAYFMFBGNGQD-UHFFFAOYSA-N
DMMT7WO	IU	5-chloro-6-hydrazinyl-1H-pyrimidine-2,4-dione;hydrochloride
DMMT7WO	DE	Discovery agent

DM2SKP7	ID	DM2SKP7
DM2SKP7	DN	5-Chloro-N-(4-ethylphenyl)benzo[d]oxazol-2-amine
DM2SKP7	HS	Investigative
DM2SKP7	SN	CHEMBL1269621; 5-Chloro-N-(4-ethylphenyl)benzo[d]oxazol-2-amine; SCHEMBL12095512
DM2SKP7	DT	Small molecular drug
DM2SKP7	PC	49843567
DM2SKP7	MW	272.73
DM2SKP7	FM	C15H13ClN2O
DM2SKP7	IC	InChI=1S/C15H13ClN2O/c1-2-10-3-6-12(7-4-10)17-15-18-13-9-11(16)5-8-14(13)19-15/h3-9H,2H2,1H3,(H,17,18)
DM2SKP7	CS	CCC1=CC=C(C=C1)NC2=NC3=C(O2)C=CC(=C3)Cl
DM2SKP7	IK	CKVTZZTZMCGPHV-UHFFFAOYSA-N
DM2SKP7	IU	5-chloro-N-(4-ethylphenyl)-1,3-benzoxazol-2-amine
DM2SKP7	DE	Discovery agent

DMZ5MDY	ID	DMZ5MDY
DMZ5MDY	DN	5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide
DMZ5MDY	HS	Investigative
DMZ5MDY	SN	CHEMBL290395; 5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide; SCHEMBL8527508; BYXYRVSXGVLRKM-UHFFFAOYSA-N; BDBM50321877; 5-Chloro-1-(3-pyridylcarbamoyl)indoline; N-(3-Pyridinyl)-5-chloro-2,3-dihydro-1H-indole-1-carboxamide; 5-Chloro-2,3-dihydro-indole-1-carboxylic acid pyridin-3-ylamide
DMZ5MDY	DT	Small molecular drug
DMZ5MDY	PC	10826147
DMZ5MDY	MW	273.72
DMZ5MDY	FM	C14H12ClN3O
DMZ5MDY	IC	InChI=1S/C14H12ClN3O/c15-11-3-4-13-10(8-11)5-7-18(13)14(19)17-12-2-1-6-16-9-12/h1-4,6,8-9H,5,7H2,(H,17,19)
DMZ5MDY	CS	C1CN(C2=C1C=C(C=C2)Cl)C(=O)NC3=CN=CC=C3
DMZ5MDY	IK	BYXYRVSXGVLRKM-UHFFFAOYSA-N
DMZ5MDY	IU	5-chloro-N-pyridin-3-yl-2,3-dihydroindole-1-carboxamide
DMZ5MDY	DE	Discovery agent

DMMV931	ID	DMMV931
DMMV931	DN	5-chloro-N-(quinolin-8-yl)thiophene-2-sulfonamide
DMMV931	HS	Investigative
DMMV931	SN	CHEMBL257446; 620103-77-7; 5-chloro-N-(quinolin-8-yl)thiophene-2-sulfonamide; AC1NGSHS; SCHEMBL13633877; CTK1I9417; DTXSID80406061; MolPort-003-263-222; ZINC6858682; BDBM50372504; AKOS001150619; MCULE-4753456414; NCGC00163030-02; NCGC00163030-01; 5-chloro-N-quinolin-8-ylthiophene-2-sulfonamide; 2-Thiophenesulfonamide, 5-chloro-N-8-quinolinyl-; CU-00000000281-1
DMMV931	DT	Small molecular drug
DMMV931	PC	4729240
DMMV931	MW	324.8
DMMV931	FM	C13H9ClN2O2S2
DMMV931	IC	InChI=1S/C13H9ClN2O2S2/c14-11-6-7-12(19-11)20(17,18)16-10-5-1-3-9-4-2-8-15-13(9)10/h1-8,16H
DMMV931	CS	C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(S3)Cl)N=CC=C2
DMMV931	IK	SNSCETRSXPPXIM-UHFFFAOYSA-N
DMMV931	IU	5-chloro-N-quinolin-8-ylthiophene-2-sulfonamide
DMMV931	CA	CAS 620103-77-7
DMMV931	DE	Discovery agent

DMVQLFB	ID	DMVQLFB
DMVQLFB	DN	5-Chloro-N-phenylbenzo[d]oxazol-2-amine
DMVQLFB	HS	Investigative
DMVQLFB	SN	CHEMBL1269620; 79558-94-4; 2-Benzoxazolamine, 5-chloro-N-phenyl-; 5-Chloro-N-phenylbenzo[d]oxazol-2-amine; AC1NKL9S; 5-chloro-N-phenyl-1,3-benzoxazol-2-amine; SCHEMBL3474865; CTK2G4049; DTXSID50406795; BDBM50329393; ZINC33559155; N-Phenyl-5-chlorobenzoxazole-2-amine; VU0404023-1; J3.559.656I
DMVQLFB	DT	Small molecular drug
DMVQLFB	PC	4915226
DMVQLFB	MW	244.67
DMVQLFB	FM	C13H9ClN2O
DMVQLFB	IC	InChI=1S/C13H9ClN2O/c14-9-6-7-12-11(8-9)16-13(17-12)15-10-4-2-1-3-5-10/h1-8H,(H,15,16)
DMVQLFB	CS	C1=CC=C(C=C1)NC2=NC3=C(O2)C=CC(=C3)Cl
DMVQLFB	IK	YWNAVPSABPGECL-UHFFFAOYSA-N
DMVQLFB	IU	5-chloro-N-phenyl-1,3-benzoxazol-2-amine
DMVQLFB	CA	CAS 79558-94-4
DMVQLFB	DE	Discovery agent

DMH397E	ID	DMH397E
DMH397E	DN	5-Chlorosalicylic Acid
DMH397E	HS	Investigative
DMH397E	SN	5-CHLOROSALICYLIC ACID; 5-Chloro-2-hydroxybenzoic acid; 321-14-2; Benzoic acid, 5-chloro-2-hydroxy-; 2-Hydroxy-5-chlorobenzoic acid; 5 CSA; Salicylic acid, 5-chloro-; 5-Chlorosalicyclic acid; 5-chloro salicylic acid; 5-Chloro-2-hydroxy-benzoic acid; UNII-J2YFG68VCZ; CCRIS 4485; EINECS 206-283-9; NSC 30111; J2YFG68VCZ; BRN 2046665; CHEMBL1375; AI3-22259; CHEBI:420128; NKBASRXWGAGQDP-UHFFFAOYSA-N; 5-chloro-salicylic acid; 5-chloro-salicyclic acid; ACMC-209hr2; Oprea1_451559; 5-chloro-2-hydroxy-benzoate; 4-10-00-00207 (Beilstein Handb
DMH397E	DT	Small molecular drug
DMH397E	PC	9447
DMH397E	MW	172.56
DMH397E	FM	C7H5ClO3
DMH397E	IC	InChI=1S/C7H5ClO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,(H,10,11)
DMH397E	CS	C1=CC(=C(C=C1Cl)C(=O)O)O
DMH397E	IK	NKBASRXWGAGQDP-UHFFFAOYSA-N
DMH397E	IU	5-chloro-2-hydroxybenzoic acid
DMH397E	CA	CAS 321-14-2
DMH397E	CB	CHEBI:420128
DMH397E	DE	Discovery agent

DMWS3D6	ID	DMWS3D6
DMWS3D6	DN	5-Chloryl-2,4,6-Quinazolinetriamine
DMWS3D6	HS	Investigative
DMWS3D6	SN	2,4,6-Triamino-5-chloroquinazoline; 17511-20-5; CHEMBL6708; CLZ; AC1L47X8; SCHEMBL1611666; CTK4D5160; DTXSID70169931; MolPort-003-808-568; JZWXVYNQIJJTKF-UHFFFAOYSA-N; BDBM50404662; 5-chloroquinazoline-2,4,6-triamine; ZINC13282329; AKOS022649928; 2,4,6-Quinazolinetriamine,5-chloro-; 2,4,6-Quinazolinetriamine, 5-chloro-
DMWS3D6	DT	Small molecular drug
DMWS3D6	PC	4627204
DMWS3D6	MW	241.63
DMWS3D6	FM	C8H8ClN5O2
DMWS3D6	IC	InChI=1S/C8H8ClN5O2/c10-3-1-2-4-5(6(3)9(15)16)7(11)14-8(12)13-4/h1-2H,10H2,(H4,11,12,13,14)
DMWS3D6	CS	C1=CC2=C(C(=C1N)Cl(=O)=O)C(=NC(=N2)N)N
DMWS3D6	IK	AOIWFGJNGXKHGL-UHFFFAOYSA-N
DMWS3D6	IU	5-chlorylquinazoline-2,4,6-triamine
DMWS3D6	DE	Discovery agent

DM109IL	ID	DM109IL
DM109IL	DN	5-Cl-5-deoxy-(+/-)-ENBA
DM109IL	HS	Investigative
DM109IL	SN	GTPL6560; 5-Cl-5-deoxy-(plusmn)-ENBA; (  )-5'-Chloro-5'-deoxy-ENBA; 2-[6-({bicyclo[2.2.1]heptan-2-yl}amino)-9H-purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol
DM109IL	DT	Small molecular drug
DM109IL	PC	15599147
DM109IL	MW	379.8
DM109IL	FM	C17H22ClN5O3
DM109IL	IC	InChI=1S/C17H22ClN5O3/c18-5-11-13(24)14(25)17(26-11)23-7-21-12-15(19-6-20-16(12)23)22-10-4-8-1-2-9(10)3-8/h6-11,13-14,17,24-25H,1-5H2,(H,19,20,22)
DM109IL	CS	C1CC2CC1CC2NC3=C4C(=NC=N3)N(C=N4)C5C(C(C(O5)CCl)O)O
DM109IL	IK	PVJGDYDNVNCGBT-UHFFFAOYSA-N
DM109IL	IU	2-[6-(2-bicyclo[2.2.1]heptanylamino)purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol
DM109IL	CA	CAS 103626-26-2
DM109IL	DE	Discovery agent

DM260KD	ID	DM260KD
DM260KD	DN	5-CT
DM260KD	HS	Investigative
DM260KD	SN	5-carboxamidotryptamine
DM260KD	DT	Small molecular drug
DM260KD	PC	1809
DM260KD	MW	203.24
DM260KD	FM	C11H13N3O
DM260KD	IC	InChI=1S/C11H13N3O/c12-4-3-8-6-14-10-2-1-7(11(13)15)5-9(8)10/h1-2,5-6,14H,3-4,12H2,(H2,13,15)
DM260KD	CS	C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN
DM260KD	IK	WKZLNEWVIAGNAW-UHFFFAOYSA-N
DM260KD	IU	3-(2-aminoethyl)-1H-indole-5-carboxamide
DM260KD	CA	CAS 74885-09-9
DM260KD	CB	CHEBI:48292
DM260KD	DE	Discovery agent

DMMYENH	ID	DMMYENH
DMMYENH	DN	5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione
DMMYENH	HS	Investigative
DMMYENH	SN	5-cyclohexyl-1,3,4-oxadiazole-2-thiol; 173589-87-2; 5-Cyclohexyl-[1,3,4]oxadiazole-2-thiol; CHEMBL456586; 5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione; 1,3,4-Oxadiazole-2(3H)-thione, 5-cyclohexyl-; BAS 09627004; AC1Q7GLG; AC1MWQ13; MLS000719170; SCHEMBL13401036; CTK0A7651; DTXSID20396654; MolPort-000-932-255; HMS1700P22; HMS2732D23; ZINC6675630; BDBM50320725; AKOS000669727; MCULE-5633296933; SMR000291438; KB-124591; 5-cyclohexyl-3H-1,3,4-oxadiazole-2-thione; EN300-10672; 5-Cyclohexyl-3H-[1,3,4]oxadiazole-2-thione; K-5320
DMMYENH	DT	Small molecular drug
DMMYENH	PC	3803233
DMMYENH	MW	184.26
DMMYENH	FM	C8H12N2OS
DMMYENH	IC	InChI=1S/C8H12N2OS/c12-8-10-9-7(11-8)6-4-2-1-3-5-6/h6H,1-5H2,(H,10,12)
DMMYENH	CS	C1CCC(CC1)C2=NNC(=S)O2
DMMYENH	IK	ONBUSMDUKULCRC-UHFFFAOYSA-N
DMMYENH	IU	5-cyclohexyl-3H-1,3,4-oxadiazole-2-thione
DMMYENH	CA	CAS 173589-87-2
DMMYENH	DE	Discovery agent

DMRFH9U	ID	DMRFH9U
DMRFH9U	DN	5'-deoxy-4'-hydroxy-5'-methylthio-DADMe-ImmH
DMRFH9U	HS	Investigative
DMRFH9U	DT	Small molecular drug
DMRFH9U	PC	11722921
DMRFH9U	DE	Discovery agent

DMR28HG	ID	DMR28HG
DMR28HG	DN	5'-Deoxy-5'-(Methylthio)-Tubercidin
DMR28HG	HS	Investigative
DMR28HG	SN	5'-methylthiotubercidin; 5'-DEOXY-5'-(METHYLTHIO)-TUBERCIDIN; 2-(4-AMINO-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-METHYLSULFANYLMETHYL-TETRAHYDRO-FURAN-3,4-DIOL; MTH; 2qtg; 7-(5-S-methyl-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; 7-(5-S-methyl-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 61893-98-9; 1nc1; AC1Q7DT3; AC1L4MN1; 5'-(methylsulfanyl)tubercidin; CHEMBL551561; DB02933; 7-(5-s-methyl-5-thio-; A-d-ribofuranosyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine; 7H-Pyrrolo(2,3-d)pyrimidin-4-amine, 
DMR28HG	DT	Small molecular drug
DMR28HG	PC	188350
DMR28HG	MW	296.35
DMR28HG	FM	C12H16N4O3S
DMR28HG	IC	InChI=1S/C12H16N4O3S/c1-20-4-7-8(17)9(18)12(19-7)16-3-2-6-10(13)14-5-15-11(6)16/h2-3,5,7-9,12,17-18H,4H2,1H3,(H2,13,14,15)/t7-,8-,9-,12-/m1/s1
DMR28HG	CS	CSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC3=C(N=CN=C32)N)O)O
DMR28HG	IK	WBPLMFVTQMIPLW-MFYTUXHUSA-N
DMR28HG	IU	(2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(methylsulfanylmethyl)oxolane-3,4-diol
DMR28HG	CA	CAS 61893-98-9
DMR28HG	DE	Discovery agent

DMOHSY0	ID	DMOHSY0
DMOHSY0	DN	5'-Deoxy-5'-(N,N-dimethylamino)-8-methyladenosine
DMOHSY0	HS	Investigative
DMOHSY0	SN	5'-deoxy-5'-(dimethylamino)-8-methyladenosine; SCHEMBL955366; 5'-Deoxy-5'-(N,N-dimethylamino)-8-methyladenosine; CHEMBL516214; AdoMet substrate analogue, 23a; BDBM28452; BDRUNDKEQQVJJG-QYVSTXNMSA-N; (2R,3R,4S,5R)-2-(6-amino-8-methyl-9H-purin-9-yl)-5-[(dimethylamino)methyl]oxolane-3,4-diol
DMOHSY0	DT	Small molecular drug
DMOHSY0	PC	25231308
DMOHSY0	MW	308.34
DMOHSY0	FM	C13H20N6O3
DMOHSY0	IC	InChI=1S/C13H20N6O3/c1-6-17-8-11(14)15-5-16-12(8)19(6)13-10(21)9(20)7(22-13)4-18(2)3/h5,7,9-10,13,20-21H,4H2,1-3H3,(H2,14,15,16)/t7-,9-,10-,13-/m1/s1
DMOHSY0	CS	CC1=NC2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CN(C)C)O)O)N
DMOHSY0	IK	BDRUNDKEQQVJJG-QYVSTXNMSA-N
DMOHSY0	IU	(2R,3R,4S,5R)-2-(6-amino-8-methylpurin-9-yl)-5-[(dimethylamino)methyl]oxolane-3,4-diol
DMOHSY0	DE	Discovery agent

DMF7JPO	ID	DMF7JPO
DMF7JPO	DN	5'-Deoxy-5'-(N,N-dimethylamino)adenosine
DMF7JPO	HS	Investigative
DMF7JPO	SN	5'-Deoxy-5'-(Dimethylamino)adenosine; 5'-Deoxy-5'-(N,N-dimethylamino)adenosine; SCHEMBL952928; CHEMBL472733; AdoMet substrate analogue, 23b; BDBM28453; SLNWRDWGFHZRAQ-WOUKDFQISA-N; ZINC40914070; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-[(dimethylamino)methyl]oxolane-3,4-diol
DMF7JPO	DT	Small molecular drug
DMF7JPO	PC	25231309
DMF7JPO	MW	294.31
DMF7JPO	FM	C12H18N6O3
DMF7JPO	IC	InChI=1S/C12H18N6O3/c1-17(2)3-6-8(19)9(20)12(21-6)18-5-16-7-10(13)14-4-15-11(7)18/h4-6,8-9,12,19-20H,3H2,1-2H3,(H2,13,14,15)/t6-,8-,9-,12-/m1/s1
DMF7JPO	CS	CN(C)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMF7JPO	IK	SLNWRDWGFHZRAQ-WOUKDFQISA-N
DMF7JPO	IU	(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[(dimethylamino)methyl]oxolane-3,4-diol
DMF7JPO	DE	Discovery agent

DM6HGUL	ID	DM6HGUL
DM6HGUL	DN	5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine
DM6HGUL	HS	Investigative
DM6HGUL	SN	MHZPA; 112621-42-8; 5'-Deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine; 5'-Deoxy-5'-(N-methyl-N-(3-hydrazinopropyl)amino)adenosine; 5'-Deoxy-5'-((3-hydrazinopropyl)methylamino)adenosine; Adenosine, 5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]-; MHZ; Adenosine, 5'-deoxy-5'-((3-hydrazinopropyl)methylamino)-; AC1L3TYJ; SCHEMBL952217; Adenosine,5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]- (9CI); CTK4A7899; DTXSID50150125; AKOS030589592; 5'-[(3-Hydrazinopropyl)methylamino]-5'-deoxyadenosine
DM6HGUL	DT	Small molecular drug
DM6HGUL	PC	122092
DM6HGUL	MW	352.39
DM6HGUL	FM	C14H24N8O3
DM6HGUL	IC	InChI=1S/C14H24N8O3/c1-21(4-2-3-20-16)5-8-10(23)11(24)14(25-8)22-7-19-9-12(15)17-6-18-13(9)22/h6-8,10-11,14,20,23-24H,2-5,16H2,1H3,(H2,15,17,18)/t8-,10-,11-,14-/m1/s1
DM6HGUL	CS	CN(CCCNN)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DM6HGUL	IK	MYNRDUPGBPOWQT-IDTAVKCVSA-N
DM6HGUL	IU	(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[3-hydrazinylpropyl(methyl)amino]methyl]oxolane-3,4-diol
DM6HGUL	CA	CAS 112621-42-8
DM6HGUL	DE	Discovery agent

DM1NAMK	ID	DM1NAMK
DM1NAMK	DN	5'-Deoxy-5'-dimethylsulfonioadenosine chloride
DM1NAMK	HS	Investigative
DM1NAMK	SN	SCHEMBL952519
DM1NAMK	DT	Small molecular drug
DM1NAMK	PC	25231315
DM1NAMK	MW	347.82
DM1NAMK	FM	C12H18ClN5O3S
DM1NAMK	IC	InChI=1S/C12H18N5O3S.ClH/c1-21(2)3-6-8(18)9(19)12(20-6)17-5-16-7-10(13)14-4-15-11(7)17;/h4-6,8-9,12,18-19H,3H2,1-2H3,(H2,13,14,15);1H/q+1;/p-1/t6-,8-,9-,12-;/m1./s1
DM1NAMK	CS	C[S+](C)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O.[Cl-]
DM1NAMK	IK	UQRXECZPKCIHRJ-OUTCZKRVSA-M
DM1NAMK	IU	[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-dimethylsulfanium;chloride
DM1NAMK	DE	Discovery agent

DMU4MCK	ID	DMU4MCK
DMU4MCK	DN	5'-Deoxy-5'-phenyladenophostin A
DMU4MCK	HS	Investigative
DMU4MCK	SN	CHEMBL1161890; 3'-O-(3-O,4-O-Diphosphono-alpha-D-glucopyranosyl)-5'-phenyl-5'-deoxy-2'-adenylic acid
DMU4MCK	DT	Small molecular drug
DMU4MCK	PC	44416175
DMU4MCK	MW	723.4
DMU4MCK	FM	C22H24N5O17P3-6
DMU4MCK	IC	InChI=1S/C22H30N5O17P3/c23-19-13-20(25-8-24-19)27(9-26-13)21-18(44-47(36,37)38)15(11(39-21)6-10-4-2-1-3-5-10)41-22-14(29)17(43-46(33,34)35)16(12(7-28)40-22)42-45(30,31)32/h1-5,8-9,11-12,14-18,21-22,28-29H,6-7H2,(H2,23,24,25)(H2,30,31,32)(H2,33,34,35)(H2,36,37,38)/p-6/t11-,12-,14-,15-,16-,17-,18-,21-,22-/m1/s1
DMU4MCK	CS	C1=CC=C(C=C1)C[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)OP(=O)([O-])[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)OP(=O)([O-])[O-])OP(=O)([O-])[O-])O
DMU4MCK	IK	HQEPXXWNKLEIRE-NYCICKCISA-H
DMU4MCK	IU	[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-benzyl-4-[(2R,3R,4R,5R,6R)-3-hydroxy-6-(hydroxymethyl)-4,5-diphosphonatooxyoxan-2-yl]oxyoxolan-3-yl] phosphate
DMU4MCK	DE	Discovery agent

DM65XZJ	ID	DM65XZJ
DM65XZJ	DN	5-deoxy-5-phosphono-D-arabinonate
DM65XZJ	HS	Investigative
DM65XZJ	DT	Small molecular drug
DM65XZJ	PC	56603745
DM65XZJ	MW	227.09
DM65XZJ	FM	C5H8O8P-3
DM65XZJ	IC	InChI=1S/C5H11O8P/c6-2(1-14(11,12)13)3(7)4(8)5(9)10/h2-4,6-8H,1H2,(H,9,10)(H2,11,12,13)/p-3
DM65XZJ	CS	C(C(C(C(C(=O)[O-])O)O)O)P(=O)([O-])[O-]
DM65XZJ	IK	XCBNBIPHASXSKG-UHFFFAOYSA-K
DM65XZJ	IU	2,3,4-trihydroxy-5-phosphonatopentanoate
DM65XZJ	DE	Discovery agent

DM8IQX4	ID	DM8IQX4
DM8IQX4	DN	5'-deoxy-5'-ureidoadenosine
DM8IQX4	HS	Investigative
DM8IQX4	SN	CHEMBL231952; 5''-deoxy-5''-ureidoadenosine
DM8IQX4	DT	Small molecular drug
DM8IQX4	PC	23661679
DM8IQX4	MW	309.28
DM8IQX4	FM	C11H15N7O4
DM8IQX4	IC	InChI=1S/C11H15N7O4/c12-8-5-9(16-2-15-8)18(3-17-5)10-7(20)6(19)4(22-10)1-14-11(13)21/h2-4,6-7,10,19-20H,1H2,(H2,12,15,16)(H3,13,14,21)/t4-,6-,7-,10-/m1/s1
DM8IQX4	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CNC(=O)N)O)O)N
DM8IQX4	IK	MRVWQDQRJFAPMW-KQYNXXCUSA-N
DM8IQX4	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylurea
DM8IQX4	DE	Discovery agent

DM1Q0BF	ID	DM1Q0BF
DM1Q0BF	DN	5-deoxyabyssinin II
DM1Q0BF	HS	Investigative
DM1Q0BF	SN	5-deoxyabyssinin II; CHEMBL229670
DM1Q0BF	DT	Small molecular drug
DM1Q0BF	PC	44424649
DM1Q0BF	MW	354.4
DM1Q0BF	FM	C21H22O5
DM1Q0BF	IC	InChI=1S/C21H22O5/c1-12(2)4-5-13-8-14(9-20(25-3)21(13)24)18-11-17(23)16-7-6-15(22)10-19(16)26-18/h4,6-10,18,22,24H,5,11H2,1-3H3/t18-/m0/s1
DM1Q0BF	CS	CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(O2)C=C(C=C3)O)OC)O)C
DM1Q0BF	IK	GZTDFKLABHOHBU-SFHVURJKSA-N
DM1Q0BF	IU	(2S)-7-hydroxy-2-[4-hydroxy-3-methoxy-5-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DM1Q0BF	DE	Discovery agent

DMR48NG	ID	DMR48NG
DMR48NG	DN	5'-deoxythymidine
DMR48NG	HS	Investigative
DMR48NG	SN	5'-Deoxythymidine; 3458-14-8; Thymidine, 5'-deoxy-; 5'-Ddthd; 2',5'-Dideoxythymidine; 5'-Deoxythymidine, 98%; AC1L22MY; SCHEMBL2056693; CHEMBL465901; CTK1C3983; DTXSID70188127; MolPort-003-930-221; ZINC5765072; AKOS015892581; 5 inverted exclamation marka-Deoxythymidine; FT-0772769; C-44347; I03-1540; 5''-Deoxythymidine; AC1L22MY; SureCN2056693;; 2 inverted exclamation marka,5 inverted exclamation marka-Dideoxythymidine; 1-[(2R,4S,5R)-4-hydroxy-5-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR48NG	DT	Small molecular drug
DMR48NG	PC	65120
DMR48NG	MW	226.23
DMR48NG	FM	C10H14N2O4
DMR48NG	IC	InChI=1S/C10H14N2O4/c1-5-4-12(10(15)11-9(5)14)8-3-7(13)6(2)16-8/h4,6-8,13H,3H2,1-2H3,(H,11,14,15)/t6-,7+,8-/m1/s1
DMR48NG	CS	C[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)O
DMR48NG	IK	UGUILUGCFSCUKR-GJMOJQLCSA-N
DMR48NG	IU	1-[(2R,4S,5R)-4-hydroxy-5-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR48NG	CA	CAS 3458-14-8
DMR48NG	DE	Discovery agent

DM6TM1L	ID	DM6TM1L
DM6TM1L	DN	5-desgalloylstachyurin
DM6TM1L	HS	Investigative
DM6TM1L	SN	5-desgalloylstachyurin; CHEMBL488110
DM6TM1L	DT	Small molecular drug
DM6TM1L	PC	10417809
DM6TM1L	MW	784.5
DM6TM1L	FM	C34H24O22
DM6TM1L	IC	InChI=1S/C34H24O22/c35-8-1-5-12(21(42)18(8)39)13-6(2-9(36)19(40)22(13)43)32(50)54-28(11(38)4-53-31(5)49)30-29-26(47)17-16(34(52)55-29)15(24(45)27(48)25(17)46)14-7(33(51)56-30)3-10(37)20(41)23(14)44/h1-3,11,26,28-30,35-48H,4H2/t11-,26+,28-,29+,30+/m1/s1
DM6TM1L	CS	C1[C@H]([C@@H](OC(=O)C2=CC(=C(C(=C2C3=C(C(=C(C=C3C(=O)O1)O)O)O)O)O)O)[C@H]4[C@@H]5[C@H](C6=C(C(=C(C(=C6C(=O)O5)C7=C(C(=C(C=C7C(=O)O4)O)O)O)O)O)O)O)O
DM6TM1L	IK	CHBITXAMNKHJCR-VGYCLGPVSA-N
DM6TM1L	IU	(14R,15S,19S)-14-[(10R,11R)-3,4,5,11,17,18,19-heptahydroxy-8,14-dioxo-9,13-dioxatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]-2,3,4,7,8,9,19-heptahydroxy-13,16-dioxatetracyclo[13.3.1.05,18.06,11]nonadeca-1,3,5(18),6,8,10-hexaene-12,17-dione
DM6TM1L	DE	Discovery agent

DMX64E3	ID	DMX64E3
DMX64E3	DN	5-ethyl-2-(2-(pyrrolidin-1-yl)ethyl)pyridine
DMX64E3	HS	Investigative
DMX64E3	SN	CHEMBL271300; SCHEMBL13990825; ZINC29131629
DMX64E3	DT	Small molecular drug
DMX64E3	PC	44456496
DMX64E3	MW	204.31
DMX64E3	FM	C13H20N2
DMX64E3	IC	InChI=1S/C13H20N2/c1-2-12-5-6-13(14-11-12)7-10-15-8-3-4-9-15/h5-6,11H,2-4,7-10H2,1H3
DMX64E3	CS	CCC1=CN=C(C=C1)CCN2CCCC2
DMX64E3	IK	LTRFAPGENZNRNS-UHFFFAOYSA-N
DMX64E3	IU	5-ethyl-2-(2-pyrrolidin-1-ylethyl)pyridine
DMX64E3	DE	Discovery agent

DM0E9O1	ID	DM0E9O1
DM0E9O1	DN	5-ethyl-2-(phenylsulfonamido)benzoic acid
DM0E9O1	HS	Investigative
DM0E9O1	SN	Benzoic acid, 5-ethyl-2-[(phenylsulfonyl)amino]-; 677290-35-6; sulfonamide compound, 6; SCHEMBL3979169; CHEMBL377012; CTK1H6802; BDBM17600; DTXSID80439379; BUWBVEJQFXVJCT-UHFFFAOYSA-N; 2-benzenesulfonamido-5-ethylbenzoic acid; 5-ethyl-2-[(phenylsulfonyl)amino]benzoic acid
DM0E9O1	DT	Small molecular drug
DM0E9O1	PC	10402833
DM0E9O1	MW	305.4
DM0E9O1	FM	C15H15NO4S
DM0E9O1	IC	InChI=1S/C15H15NO4S/c1-2-11-8-9-14(13(10-11)15(17)18)16-21(19,20)12-6-4-3-5-7-12/h3-10,16H,2H2,1H3,(H,17,18)
DM0E9O1	CS	CCC1=CC(=C(C=C1)NS(=O)(=O)C2=CC=CC=C2)C(=O)O
DM0E9O1	IK	BUWBVEJQFXVJCT-UHFFFAOYSA-N
DM0E9O1	IU	2-(benzenesulfonamido)-5-ethylbenzoic acid
DM0E9O1	CA	CAS 677290-35-6
DM0E9O1	DE	Discovery agent

DMK57W2	ID	DMK57W2
DMK57W2	DN	5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole
DMK57W2	HS	Investigative
DMK57W2	SN	CHEMBL49048; 5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole; SCHEMBL8506288; PWLIYMBPGFVKOO-UHFFFAOYSA-N; BDBM50090520; 3-(2-Pyrrolizinoethyl)-5-ethyl-1H-indole; 5-ethyl-3-(2-pyrrolidinylethyl) -1H-indole
DMK57W2	DT	Small molecular drug
DMK57W2	PC	15870567
DMK57W2	MW	242.36
DMK57W2	FM	C16H22N2
DMK57W2	IC	InChI=1S/C16H22N2/c1-2-13-5-6-16-15(11-13)14(12-17-16)7-10-18-8-3-4-9-18/h5-6,11-12,17H,2-4,7-10H2,1H3
DMK57W2	CS	CCC1=CC2=C(C=C1)NC=C2CCN3CCCC3
DMK57W2	IK	PWLIYMBPGFVKOO-UHFFFAOYSA-N
DMK57W2	IU	5-ethyl-3-(2-pyrrolidin-1-ylethyl)-1H-indole
DMK57W2	DE	Discovery agent

DMRIGXA	ID	DMRIGXA
DMRIGXA	DN	5-Ethyl-3,4-diphenyl-isoxazole
DMRIGXA	HS	Investigative
DMRIGXA	SN	CHEMBL361504; 5-Ethyl-3,4-diphenyl-isoxazole; 3,4-diphenyl-5-ethylisoxazole; SCHEMBL2279510; MXTWADCRLRQMDW-UHFFFAOYSA-N; ZINC13583259
DMRIGXA	DT	Small molecular drug
DMRIGXA	PC	10377376
DMRIGXA	MW	249.31
DMRIGXA	FM	C17H15NO
DMRIGXA	IC	InChI=1S/C17H15NO/c1-2-15-16(13-9-5-3-6-10-13)17(18-19-15)14-11-7-4-8-12-14/h3-12H,2H2,1H3
DMRIGXA	CS	CCC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=CC=C3
DMRIGXA	IK	MXTWADCRLRQMDW-UHFFFAOYSA-N
DMRIGXA	IU	5-ethyl-3,4-diphenyl-1,2-oxazole
DMRIGXA	DE	Discovery agent

DMYD8GP	ID	DMYD8GP
DMYD8GP	DN	5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione
DMYD8GP	HS	Investigative
DMYD8GP	SN	CHEMBL41666; 5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione; BDBM50227231; 68475-20-7
DMYD8GP	DT	Small molecular drug
DMYD8GP	PC	12488718
DMYD8GP	MW	219.24
DMYD8GP	FM	C12H13NO3
DMYD8GP	IC	InChI=1S/C12H13NO3/c1-3-12(9-7-5-4-6-8-9)10(14)13(2)11(15)16-12/h4-8H,3H2,1-2H3
DMYD8GP	CS	CCC1(C(=O)N(C(=O)O1)C)C2=CC=CC=C2
DMYD8GP	IK	BWNMMRKYEBCJHN-UHFFFAOYSA-N
DMYD8GP	IU	5-ethyl-3-methyl-5-phenyl-1,3-oxazolidine-2,4-dione
DMYD8GP	DE	Discovery agent

DMS9TFC	ID	DMS9TFC
DMS9TFC	DN	5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine
DMS9TFC	HS	Investigative
DMS9TFC	SN	CHEMBL185585; 5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine; SCHEMBL12617784; BDBM50150915
DMS9TFC	DT	Small molecular drug
DMS9TFC	PC	17892465
DMS9TFC	MW	126.2
DMS9TFC	FM	C7H14N2
DMS9TFC	IC	InChI=1S/C7H14N2/c1-3-6-4-5(2)7(8)9-6/h5-6H,3-4H2,1-2H3,(H2,8,9)
DMS9TFC	CS	CCC1CC(C(=N1)N)C
DMS9TFC	IK	WPWKHPKZOKESJR-UHFFFAOYSA-N
DMS9TFC	IU	2-ethyl-4-methyl-3,4-dihydro-2H-pyrrol-5-amine
DMS9TFC	DE	Discovery agent

DMQWOIG	ID	DMQWOIG
DMQWOIG	DN	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine
DMQWOIG	HS	Investigative
DMQWOIG	SN	CHEMBL185024; CHEMBL552935; 190909-71-8; SCHEMBL7624096; BDBM50066778; AKOS027401526; AKOS006376472; DA-08771; FT-0744003; 2-ethyl-3,4-dihydro-3-methyl-2H-Pyrrol-5-amine; 5-Ethyl-4-methyl-pyrrolidin-(2E)-ylideneamine
DMQWOIG	DT	Small molecular drug
DMQWOIG	PC	10396852
DMQWOIG	MW	126.2
DMQWOIG	FM	C7H14N2
DMQWOIG	IC	InChI=1S/C7H14N2/c1-3-6-5(2)4-7(8)9-6/h5-6H,3-4H2,1-2H3,(H2,8,9)
DMQWOIG	CS	CCC1C(CC(=N1)N)C
DMQWOIG	IK	APKCAWUHKKJFRX-UHFFFAOYSA-N
DMQWOIG	IU	2-ethyl-3-methyl-3,4-dihydro-2H-pyrrol-5-amine
DMQWOIG	DE	Discovery agent

DMSA8X2	ID	DMSA8X2
DMSA8X2	DN	5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine
DMSA8X2	HS	Investigative
DMSA8X2	SN	CHEMBL360009; 5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine
DMSA8X2	DT	Small molecular drug
DMSA8X2	PC	19049087
DMSA8X2	MW	154.25
DMSA8X2	FM	C9H18N2
DMSA8X2	IC	InChI=1S/C9H18N2/c1-3-5-7-6-9(10)11-8(7)4-2/h7-8H,3-6H2,1-2H3,(H2,10,11)
DMSA8X2	CS	CCCC1CC(=NC1CC)N
DMSA8X2	IK	ZRHQCTSUMZLGON-UHFFFAOYSA-N
DMSA8X2	IU	2-ethyl-3-propyl-3,4-dihydro-2H-pyrrol-5-amine
DMSA8X2	DE	Discovery agent

DM8Y4G5	ID	DM8Y4G5
DM8Y4G5	DN	5-Ethyl-oxazolidin-(2Z)-ylideneamine
DM8Y4G5	HS	Investigative
DM8Y4G5	SN	CHEMBL108352; 5-Ethyl-oxazolidin-(2Z)-ylideneamine; 5-Ethyloxazolidine-2-imine; SCHEMBL8968728; BDBM50138193; AKOS013533140; AKOS006375671
DM8Y4G5	DT	Small molecular drug
DM8Y4G5	PC	19096426
DM8Y4G5	MW	114.15
DM8Y4G5	FM	C5H10N2O
DM8Y4G5	IC	InChI=1S/C5H10N2O/c1-2-4-3-7-5(6)8-4/h4H,2-3H2,1H3,(H2,6,7)
DM8Y4G5	CS	CCC1CN=C(O1)N
DM8Y4G5	IK	MFMHWQFUMUNREN-UHFFFAOYSA-N
DM8Y4G5	IU	5-ethyl-4,5-dihydro-1,3-oxazol-2-amine
DM8Y4G5	DE	Discovery agent

DMLSC10	ID	DMLSC10
DMLSC10	DN	5-Fluoro orotate
DMLSC10	HS	Investigative
DMLSC10	SN	5-Fluoroorotic acid; 703-95-7; 5-Fluoroorotate; 5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid; Fluoroorotic acid; Orotic acid, 5-fluoro-; 5-FOA; 5-Fluoro orotic acid; NSC 31712; ENT-26398; Ro 2-9945; 5-Fluorouracil-4-carboxylic acid; UNII-7IA9OUC93E; WR 152520; 5-Fluoroorotic acid (VAN); MLS000737636; EINECS 211-876-0; 4-Pyrimidinecarboxylic acid, 5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-; 7IA9OUC93E; AI3-26398; FOA; 5-Fluorouracil-6-carboxylic Acid; SEHFUALWMUWDKS-UHFFFAOYSA-N
DMLSC10	DT	Small molecular drug
DMLSC10	PC	69711
DMLSC10	MW	174.09
DMLSC10	FM	C5H3FN2O4
DMLSC10	IC	InChI=1S/C5H3FN2O4/c6-1-2(4(10)11)7-5(12)8-3(1)9/h(H,10,11)(H2,7,8,9,12)
DMLSC10	CS	C1(=C(NC(=O)NC1=O)C(=O)O)F
DMLSC10	IK	SEHFUALWMUWDKS-UHFFFAOYSA-N
DMLSC10	IU	5-fluoro-2,4-dioxo-1H-pyrimidine-6-carboxylic acid
DMLSC10	CA	CAS 703-95-7
DMLSC10	DE	Discovery agent

DM9U1HV	ID	DM9U1HV
DM9U1HV	DN	5-fluoro-1H-indole-2-carboxylic acid
DM9U1HV	HS	Investigative
DM9U1HV	SN	5-Fluoroindole-2-carboxylic acid; 399-76-8; 5-Fluoro-1H-indole-2-carboxylic acid; 2-Carboxy-5-fluoroindole; 1H-Indole-2-carboxylic acid, 5-fluoro-; CHEMBL23507; MLS000080089; WTXBRZCVLDTWLP-UHFFFAOYSA-N; MFCD00005612; SMR000037735; 5-Fluoroindole-2-carboxylic acid, 98%; Spectrum_001495; EINECS 206-919-5; PubChem1683; SpecPlus_000678; Spectrum5_001733; Opera_ID_1340; Spectrum4_001182; Spectrum3_001043; Spectrum2_001469; ACMC-209j9k; AC1Q4NE3; Lopac-265128; cid_1820; AC1Q73TI; AC1L1CB9; AC1Q73TJ; Lopac0_000071; Oprea1_012690
DM9U1HV	DT	Small molecular drug
DM9U1HV	PC	1820
DM9U1HV	MW	179.15
DM9U1HV	FM	C9H6FNO2
DM9U1HV	IC	InChI=1S/C9H6FNO2/c10-6-1-2-7-5(3-6)4-8(11-7)9(12)13/h1-4,11H,(H,12,13)
DM9U1HV	CS	C1=CC2=C(C=C1F)C=C(N2)C(=O)O
DM9U1HV	IK	WTXBRZCVLDTWLP-UHFFFAOYSA-N
DM9U1HV	IU	5-fluoro-1H-indole-2-carboxylic acid
DM9U1HV	CA	CAS 399-76-8
DM9U1HV	CB	CHEBI:111276
DM9U1HV	DE	Glioma; Melanoma

DMEA8WP	ID	DMEA8WP
DMEA8WP	DN	5-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMEA8WP	HS	Investigative
DMEA8WP	SN	875468-81-8; CHEMBL199982; 5-FLUORO-2-(2-PYRIDYL)-1H-BENZIMIDAZOLE; 1H-Benzimidazole, 6-fluoro-2-(2-pyridinyl)-; 6-fluoro-2-(pyridin-2-yl)-1H-1,3-benzodiazole; 5-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazole; SCHEMBL124265; DTXSID90470258; MolPort-009-677-335; MolPort-027-941-496; ZINC13679485; BDBM50180735; AKOS010206775; NE40467; PC450144; KB-87704; BC4242268; 5-fluoro-2-pyridin-2-yl-1H-benzoimidazole; TL80090069; US8748618, LD-1-31
DMEA8WP	DT	Small molecular drug
DMEA8WP	PC	11665659
DMEA8WP	MW	213.21
DMEA8WP	FM	C12H8FN3
DMEA8WP	IC	InChI=1S/C12H8FN3/c13-8-4-5-9-11(7-8)16-12(15-9)10-3-1-2-6-14-10/h1-7H,(H,15,16)
DMEA8WP	CS	C1=CC=NC(=C1)C2=NC3=C(N2)C=C(C=C3)F
DMEA8WP	IK	AUSVDSQFCRIAEX-UHFFFAOYSA-N
DMEA8WP	IU	6-fluoro-2-pyridin-2-yl-1H-benzimidazole
DMEA8WP	CA	CAS 875468-81-8
DMEA8WP	DE	Discovery agent

DME1AGO	ID	DME1AGO
DME1AGO	DN	5-Fluoro-2'-Deoxyuridine-5'-Monophosphate
DME1AGO	HS	Investigative
DME1AGO	SN	5-fluorodeoxyuridine monophosphate; FLUORODEOXYURIDYLATE; 5-fluoro-2'-deoxyuridine-5'-monophosphate; F-dUMP; 134-46-3; FdUMP; CHEMBL886; CHEBI:2129; UNII-7CJ707H131; 7CJ707H131; 88410-68-8; 5-FLUORO-2-DEOXYURIDINE MONOPHOSPHATE (FDUMP); [(2R,3S,5R)-5-(5-fluoro-2,4-dioxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methyl dihydrogen phosphate; UFP; Poly(dF5U); Poly(5'-FU); Poly(5-fluoro-2'-deoxyuridylic acid); 5FdUMP; DB03761; 5'-Uridylic acid, 2'-deoxy-5-fluoro-; AC1L1RES; 5'-Uridylic acid,2'-deoxy-5-fluoro-, homopolymer
DME1AGO	DT	Small molecular drug
DME1AGO	PC	8642
DME1AGO	MW	326.17
DME1AGO	FM	C9H12FN2O8P
DME1AGO	IC	InChI=1S/C9H12FN2O8P/c10-4-2-12(9(15)11-8(4)14)7-1-5(13)6(20-7)3-19-21(16,17)18/h2,5-7,13H,1,3H2,(H,11,14,15)(H2,16,17,18)/t5-,6+,7+/m0/s1
DME1AGO	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)COP(=O)(O)O)O
DME1AGO	IK	HFEKDTCAMMOLQP-RRKCRQDMSA-N
DME1AGO	IU	[(2R,3S,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DME1AGO	CA	CAS 134-46-3
DME1AGO	CB	CHEBI:2129
DME1AGO	DE	Discovery agent

DMOI7ME	ID	DMOI7ME
DMOI7ME	DN	5-Fluoro-2-hydroxy-N-isopropyl-benzamide
DMOI7ME	HS	Investigative
DMOI7ME	SN	CHEMBL84730; 5-Fluoro-2-hydroxy-N-isopropyl-benzamide; BDBM50084016; AKOS018088189
DMOI7ME	DT	Small molecular drug
DMOI7ME	PC	44321262
DMOI7ME	MW	197.21
DMOI7ME	FM	C10H12FNO2
DMOI7ME	IC	InChI=1S/C10H12FNO2/c1-6(2)12-10(14)8-5-7(11)3-4-9(8)13/h3-6,13H,1-2H3,(H,12,14)
DMOI7ME	CS	CC(C)NC(=O)C1=C(C=CC(=C1)F)O
DMOI7ME	IK	OQHZTWFYOJLOMH-UHFFFAOYSA-N
DMOI7ME	IU	5-fluoro-2-hydroxy-N-propan-2-ylbenzamide
DMOI7ME	DE	Discovery agent

DMUCLAV	ID	DMUCLAV
DMUCLAV	DN	5-Fluoro-2-sulfanyl-phenylphosphonic acid
DMUCLAV	HS	Investigative
DMUCLAV	SN	CHEMBL1170425; 5-Fluoro-2-sulfanyl-phenylphosphonic acid
DMUCLAV	DT	Small molecular drug
DMUCLAV	PC	49799138
DMUCLAV	MW	208.15
DMUCLAV	FM	C6H6FO3PS
DMUCLAV	IC	InChI=1S/C6H6FO3PS/c7-4-1-2-6(12)5(3-4)11(8,9)10/h1-3,12H,(H2,8,9,10)
DMUCLAV	CS	C1=CC(=C(C=C1F)P(=O)(O)O)S
DMUCLAV	IK	RDAVYJKCJHOMSD-UHFFFAOYSA-N
DMUCLAV	IU	(5-fluoro-2-sulfanylphenyl)phosphonic acid
DMUCLAV	DE	Discovery agent

DM0OQTJ	ID	DM0OQTJ
DM0OQTJ	DN	5-Fluoro-3-thiophen-3-yl-quinoline
DM0OQTJ	HS	Investigative
DM0OQTJ	SN	CHEMBL305056; 5-fluoro-3-thiophen-3-yl-quinoline; SCHEMBL8501434; ZINC3834023
DM0OQTJ	DT	Small molecular drug
DM0OQTJ	PC	10421346
DM0OQTJ	MW	229.27
DM0OQTJ	FM	C13H8FNS
DM0OQTJ	IC	InChI=1S/C13H8FNS/c14-12-2-1-3-13-11(12)6-10(7-15-13)9-4-5-16-8-9/h1-8H
DM0OQTJ	CS	C1=CC2=C(C=C(C=N2)C3=CSC=C3)C(=C1)F
DM0OQTJ	IK	BEVNNTNJJJWQAK-UHFFFAOYSA-N
DM0OQTJ	IU	5-fluoro-3-thiophen-3-ylquinoline
DM0OQTJ	DE	Discovery agent

DMEV0GO	ID	DMEV0GO
DMEV0GO	DN	5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil
DMEV0GO	HS	Investigative
DMEV0GO	SN	CHEMBL1080896; 5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil
DMEV0GO	DT	Small molecular drug
DMEV0GO	PC	44632008
DMEV0GO	MW	225.18
DMEV0GO	FM	C8H8FN5O2
DMEV0GO	IC	InChI=1S/C8H8FN5O2/c9-5-4(12-8(16)13-6(5)15)3-14-2-1-11-7(14)10/h1-2H,3H2,(H2,10,11)(H2,12,13,15,16)
DMEV0GO	CS	C1=CN(C(=N1)N)CC2=C(C(=O)NC(=O)N2)F
DMEV0GO	IK	SFEMKOUUPCFITA-UHFFFAOYSA-N
DMEV0GO	IU	6-[(2-aminoimidazol-1-yl)methyl]-5-fluoro-1H-pyrimidine-2,4-dione
DMEV0GO	DE	Discovery agent

DM6QHIA	ID	DM6QHIA
DM6QHIA	DN	5-fluoro-6-amino-UMP
DM6QHIA	HS	Investigative
DM6QHIA	SN	6-Amino-5-Fluorouridine 5'-(Dihydrogen Phosphate); FNU; uridine derivative, 42; SCHEMBL1363501; CHEMBL474165; BDBM27945; {[(2R,3S,4R,5R)-5-(6-amino-5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
DM6QHIA	DT	Small molecular drug
DM6QHIA	PC	16666487
DM6QHIA	MW	357.19
DM6QHIA	FM	C9H13FN3O9P
DM6QHIA	IC	InChI=1S/C9H13FN3O9P/c10-3-6(11)13(9(17)12-7(3)16)8-5(15)4(14)2(22-8)1-21-23(18,19)20/h2,4-5,8,14-15H,1,11H2,(H,12,16,17)(H2,18,19,20)/t2-,4-,5-,8-/m1/s1
DM6QHIA	CS	C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=C(C(=O)NC2=O)F)N)O)O)OP(=O)(O)O
DM6QHIA	IK	OLBMCLUPWOAIRA-UMMCILCDSA-N
DM6QHIA	IU	[(2R,3S,4R,5R)-5-(6-amino-5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM6QHIA	DE	Discovery agent

DMZLJRS	ID	DMZLJRS
DMZLJRS	DN	5-fluoro-6-azido-UMP
DMZLJRS	HS	Investigative
DMZLJRS	SN	uridine derivative, 41; CHEMBL514166; SCHEMBL15189843; BDBM27944; {[(2R,3S,4R,5R)-5-(6-azido-5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
DMZLJRS	DT	Small molecular drug
DMZLJRS	PC	16666489
DMZLJRS	MW	383.18
DMZLJRS	FM	C9H11FN5O9P
DMZLJRS	IC	InChI=1S/C9H11FN5O9P/c10-3-6(13-14-11)15(9(19)12-7(3)18)8-5(17)4(16)2(24-8)1-23-25(20,21)22/h2,4-5,8,16-17H,1H2,(H,12,18,19)(H2,20,21,22)/t2-,4-,5-,8-/m1/s1
DMZLJRS	CS	C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=C(C(=O)NC2=O)F)N=[N+]=[N-])O)O)OP(=O)(O)O
DMZLJRS	IK	ARRBQQMKVQEOHQ-UMMCILCDSA-N
DMZLJRS	IU	[(2R,3S,4R,5R)-5-(6-azido-5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMZLJRS	DE	Discovery agent

DMTAZ71	ID	DMTAZ71
DMTAZ71	DN	5-Fluoro-6-ethyluridine-5'-O-monophosphate
DMTAZ71	HS	Investigative
DMTAZ71	SN	uridine derivative, 43; CHEMBL473587; SCHEMBL3219344; BDBM27946; {[(2R,3S,4R,5R)-5-(6-ethyl-5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
DMTAZ71	DT	Small molecular drug
DMTAZ71	PC	25027092
DMTAZ71	MW	370.22
DMTAZ71	FM	C11H16FN2O9P
DMTAZ71	IC	InChI=1S/C11H16FN2O9P/c1-2-4-6(12)9(17)13-11(18)14(4)10-8(16)7(15)5(23-10)3-22-24(19,20)21/h5,7-8,10,15-16H,2-3H2,1H3,(H,13,17,18)(H2,19,20,21)/t5-,7-,8-,10-/m1/s1
DMTAZ71	CS	CCC1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)F
DMTAZ71	IK	JBBLQWFDKGRNST-VPCXQMTMSA-N
DMTAZ71	IU	[(2R,3S,4R,5R)-5-(6-ethyl-5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMTAZ71	DE	Discovery agent

DM3LMIS	ID	DM3LMIS
DM3LMIS	DN	5-fluoro-6-iodo-UMP
DM3LMIS	HS	Investigative
DM3LMIS	SN	SCHEMBL1364021
DM3LMIS	DT	Small molecular drug
DM3LMIS	PC	16124514
DM3LMIS	MW	468.07
DM3LMIS	FM	C9H11FIN2O9P
DM3LMIS	IC	InChI=1S/C9H11FIN2O9P/c10-3-6(11)13(9(17)12-7(3)16)8-5(15)4(14)2(22-8)1-21-23(18,19)20/h2,4-5,8,14-15H,1H2,(H,12,16,17)(H2,18,19,20)/t2-,4-,5-,8-/m1/s1
DM3LMIS	CS	C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=C(C(=O)NC2=O)F)I)O)O)OP(=O)(O)O
DM3LMIS	IK	NJSVPTGGTXIMLP-UMMCILCDSA-N
DM3LMIS	IU	[(2R,3S,4R,5R)-5-(5-fluoro-6-iodo-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM3LMIS	DE	Discovery agent

DMDV48S	ID	DMDV48S
DMDV48S	DN	5-Fluorolevulinic Acid
DMDV48S	HS	Investigative
DMDV48S	SN	5-FLUOROLEVULINIC ACID; 5-Fluoro-4-oxopentanoic acid; 76385-49-4; 1gzg; LAF; 5-Fluoro-4-oxopentanoate; 5-Fluoro-4-ketopentanoic acid; Substrate analogue, 9; AC1L2YNX; AC1Q4OPQ; SCHEMBL1053778; Pentanoic acid,5-fluoro-4-oxo-; BDBM82192; CTK5E2869; DTXSID40227219; Pentanoic acid, 5-fluoro-4-oxo-
DMDV48S	DT	Small molecular drug
DMDV48S	PC	131153
DMDV48S	MW	134.11
DMDV48S	FM	C5H7FO3
DMDV48S	IC	InChI=1S/C5H7FO3/c6-3-4(7)1-2-5(8)9/h1-3H2,(H,8,9)
DMDV48S	CS	C(CC(=O)O)C(=O)CF
DMDV48S	IK	MBVLGMJBSFUHKW-UHFFFAOYSA-N
DMDV48S	IU	5-fluoro-4-oxopentanoic acid
DMDV48S	CA	CAS 76385-49-4
DMDV48S	DE	Discovery agent

DM371WE	ID	DM371WE
DM371WE	DN	5-Formyl-6-Hydrofolic Acid
DM371WE	HS	Investigative
DM371WE	DT	Small molecular drug
DM371WE	PC	136122640
DM371WE	MW	471.4
DM371WE	FM	C20H21N7O7
DM371WE	IC	InChI=1S/C20H21N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,8-9,12-13,22H,5-7H2,(H,24,31)(H,29,30)(H,33,34)(H3,21,25,26,32)/t12-,13-/m1/s1
DM371WE	CS	C1=CC(=CC=C1C(=O)N[C@H](CCC(=O)O)C(=O)O)NC[C@@H]2C=NC3=C(N2C=O)C(=O)NC(=N3)N
DM371WE	IK	CJLRPFSRJZBYFE-CHWSQXEVSA-N
DM371WE	IU	(2R)-2-[[4-[[(6R)-2-amino-5-formyl-4-oxo-3,6-dihydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
DM371WE	DE	Discovery agent

DMIARG7	ID	DMIARG7
DMIARG7	DN	5'-Guanosine-Diphosphate-Monothiophosphate
DMIARG7	HS	Investigative
DMIARG7	DT	Small molecular drug
DMIARG7	PC	135398675
DMIARG7	MW	539.25
DMIARG7	FM	C10H16N5O13P3S
DMIARG7	IC	InChI=1S/C10H16N5O13P3S/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(26-9)1-25-29(19,20)27-30(21,22)28-31(23,24)32/h2-3,5-6,9,16-17H,1H2,(H,19,20)(H,21,22)(H2,23,24,32)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1
DMIARG7	CS	C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N=C(NC2=O)N
DMIARG7	IK	XOFLBQFBSOEHOG-UUOKFMHZSA-N
DMIARG7	IU	[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphinothioyl hydrogen phosphate
DMIARG7	CA	CAS 37589-80-3
DMIARG7	CB	CHEBI:43000
DMIARG7	DE	Discovery agent

DM1SON5	ID	DM1SON5
DM1SON5	DN	5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DM1SON5	HS	Investigative
DM1SON5	SN	MLS000038106; SMR000040050; 5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide; 5H-6-thia-4,5-diaza-chrysene 6,6-dioxide; Oprea1_666568; CBDivE_011354; CHEMBL428064; cid_659101; AC1LD057; CHEMBL1589921; SCHEMBL11973195; BDBM36894; CHEBI:93609; MolPort-002-134-452; CYSOFAOLQAYKGU-UHFFFAOYSA-N; HMS2479M21; ZINC230033; DNDI1318477; STL328289; AKOS022139691; MCULE-7323909600; NCGC00070544-03; EU-0033328; SR-01000388300; 5H-quino[8,7-c][1,2]benzothiazine 6,6-dioxide; SR-01000388300-1
DM1SON5	DT	Small molecular drug
DM1SON5	PC	659101
DM1SON5	MW	282.3
DM1SON5	FM	C15H10N2O2S
DM1SON5	IC	InChI=1S/C15H10N2O2S/c18-20(19)13-6-2-1-5-11(13)12-8-7-10-4-3-9-16-14(10)15(12)17-20/h1-9,17H
DM1SON5	CS	C1=CC=C2C(=C1)C3=C(C4=C(C=CC=N4)C=C3)NS2(=O)=O
DM1SON5	IK	CYSOFAOLQAYKGU-UHFFFAOYSA-N
DM1SON5	IU	5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide
DM1SON5	CB	CHEBI:93609
DM1SON5	DE	Discovery agent

DMKUT6A	ID	DMKUT6A
DMKUT6A	DN	5-HEAT
DMKUT6A	HS	Investigative
DMKUT6A	SN	5-hydroxyethoxy-N-acetyltryptamine
DMKUT6A	DT	Small molecular drug
DMKUT6A	PC	10849065
DMKUT6A	MW	262.3
DMKUT6A	FM	C14H18N2O3
DMKUT6A	IC	InChI=1S/C14H18N2O3/c1-10(18)15-5-4-11-9-16-14-3-2-12(8-13(11)14)19-7-6-17/h2-3,8-9,16-17H,4-7H2,1H3,(H,15,18)
DMKUT6A	CS	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OCCO
DMKUT6A	IK	CZPLTTWZQPLXMQ-UHFFFAOYSA-N
DMKUT6A	IU	N-[2-[5-(2-hydroxyethoxy)-1H-indol-3-yl]ethyl]acetamide
DMKUT6A	CA	CAS 214416-49-6
DMKUT6A	DE	Discovery agent

DMICKOU	ID	DMICKOU
DMICKOU	DN	5-Heptyl-5-phenyl-imidazolidine-2,4-dione
DMICKOU	HS	Investigative
DMICKOU	SN	CHEMBL417155; SCHEMBL13946578
DMICKOU	DT	Small molecular drug
DMICKOU	PC	10659949
DMICKOU	MW	274.36
DMICKOU	FM	C16H22N2O2
DMICKOU	IC	InChI=1S/C16H22N2O2/c1-2-3-4-5-9-12-16(13-10-7-6-8-11-13)14(19)17-15(20)18-16/h6-8,10-11H,2-5,9,12H2,1H3,(H2,17,18,19,20)
DMICKOU	CS	CCCCCCCC1(C(=O)NC(=O)N1)C2=CC=CC=C2
DMICKOU	IK	UKJJKBMGJSMVEV-UHFFFAOYSA-N
DMICKOU	IU	5-heptyl-5-phenylimidazolidine-2,4-dione
DMICKOU	DE	Discovery agent

DM49F6Z	ID	DM49F6Z
DM49F6Z	DN	5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione
DM49F6Z	HS	Investigative
DM49F6Z	SN	5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE; AC1NRAPN; DB07636; 5-Heptyl-6-hydroxybenzothiazole-4,7-dione; 5-n-heptyl-6-hydroxy-4,7-dioxobenzothiazole
DM49F6Z	DT	Small molecular drug
DM49F6Z	PC	5288033
DM49F6Z	MW	279.36
DM49F6Z	FM	C14H17NO3S
DM49F6Z	IC	InChI=1S/C14H17NO3S/c1-2-3-4-5-6-7-9-11(16)10-14(19-8-15-10)13(18)12(9)17/h8,16H,2-7H2,1H3
DM49F6Z	CS	CCCCCCCC1=C(C2=C(C(=O)C1=O)SC=N2)O
DM49F6Z	IK	PJALLUJRPFUWAF-UHFFFAOYSA-N
DM49F6Z	IU	5-heptyl-4-hydroxy-1,3-benzothiazole-6,7-dione
DM49F6Z	CA	CAS 611207-02-4
DM49F6Z	DE	Discovery agent

DMHGQRF	ID	DMHGQRF
DMHGQRF	DN	5-Hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole
DMHGQRF	HS	Investigative
DMHGQRF	SN	CHEMBL14331; 5-Hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole
DMHGQRF	DT	Small molecular drug
DMHGQRF	PC	14106263
DMHGQRF	MW	277.5
DMHGQRF	FM	C19H35N
DMHGQRF	IC	InChI=1S/C19H35N/c1-3-5-7-9-10-11-13-15-19-17-16-18(20-19)14-12-8-6-4-2/h4,19H,2-3,5-17H2,1H3
DMHGQRF	CS	CCCCCCCCCC1CCC(=N1)CCCCC=C
DMHGQRF	IK	NNAFMHTUNBLVDA-UHFFFAOYSA-N
DMHGQRF	IU	5-hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole
DMHGQRF	DE	Discovery agent

DM0OJZF	ID	DM0OJZF
DM0OJZF	DN	5-hexyl-2-(2-nitrophenoxy)phenol
DM0OJZF	HS	Investigative
DM0OJZF	SN	CHEMBL264415; 5-hexyl-2-(2-nitrophenoxy)phenol
DM0OJZF	DT	Small molecular drug
DM0OJZF	PC	44450122
DM0OJZF	MW	315.4
DM0OJZF	FM	C18H21NO4
DM0OJZF	IC	InChI=1S/C18H21NO4/c1-2-3-4-5-8-14-11-12-18(16(20)13-14)23-17-10-7-6-9-15(17)19(21)22/h6-7,9-13,20H,2-5,8H2,1H3
DM0OJZF	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2[N+](=O)[O-])O
DM0OJZF	IK	ASCHWJRXPZBPHV-UHFFFAOYSA-N
DM0OJZF	IU	5-hexyl-2-(2-nitrophenoxy)phenol
DM0OJZF	DE	Discovery agent

DM7EBQL	ID	DM7EBQL
DM7EBQL	DN	5-hexyl-2-(3-nitrophenoxy)phenol
DM7EBQL	HS	Investigative
DM7EBQL	SN	CHEMBL264416
DM7EBQL	DT	Small molecular drug
DM7EBQL	PC	44450123
DM7EBQL	MW	315.4
DM7EBQL	FM	C18H21NO4
DM7EBQL	IC	InChI=1S/C18H21NO4/c1-2-3-4-5-7-14-10-11-18(17(20)12-14)23-16-9-6-8-15(13-16)19(21)22/h6,8-13,20H,2-5,7H2,1H3
DM7EBQL	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=CC(=C2)[N+](=O)[O-])O
DM7EBQL	IK	ZPFZCOJDEYCPSH-UHFFFAOYSA-N
DM7EBQL	IU	5-hexyl-2-(3-nitrophenoxy)phenol
DM7EBQL	DE	Discovery agent

DMNBLPA	ID	DMNBLPA
DMNBLPA	DN	5-hexyl-2-(4-nitrophenoxy)phenol
DMNBLPA	HS	Investigative
DMNBLPA	SN	5-hexyl-2-(4-nitrophenoxy)phenol; CHEMBL264417; JA1
DMNBLPA	DT	Small molecular drug
DMNBLPA	PC	44450124
DMNBLPA	MW	315.4
DMNBLPA	FM	C18H21NO4
DMNBLPA	IC	InChI=1S/C18H21NO4/c1-2-3-4-5-6-14-7-12-18(17(20)13-14)23-16-10-8-15(9-11-16)19(21)22/h7-13,20H,2-6H2,1H3
DMNBLPA	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=C(C=C2)[N+](=O)[O-])O
DMNBLPA	IK	NNNQXCYHIVPZRH-UHFFFAOYSA-N
DMNBLPA	IU	5-hexyl-2-(4-nitrophenoxy)phenol
DMNBLPA	DE	Discovery agent

DM9263J	ID	DM9263J
DM9263J	DN	5-hexyl-2-(pyrazin-2-yloxy)phenol
DM9263J	HS	Investigative
DM9263J	SN	CHEMBL258932
DM9263J	DT	Small molecular drug
DM9263J	PC	16063378
DM9263J	MW	272.34
DM9263J	FM	C16H20N2O2
DM9263J	IC	InChI=1S/C16H20N2O2/c1-2-3-4-5-6-13-7-8-15(14(19)11-13)20-16-12-17-9-10-18-16/h7-12,19H,2-6H2,1H3
DM9263J	CS	CCCCCCC1=CC(=C(C=C1)OC2=NC=CN=C2)O
DM9263J	IK	DIBZNKWLKFDWAC-UHFFFAOYSA-N
DM9263J	IU	5-hexyl-2-pyrazin-2-yloxyphenol
DM9263J	DE	Discovery agent

DMLIMOP	ID	DMLIMOP
DMLIMOP	DN	5-hexyl-2-(pyridin-2-yloxy)phenol
DMLIMOP	HS	Investigative
DMLIMOP	SN	CHEMBL264679
DMLIMOP	DT	Small molecular drug
DMLIMOP	PC	44450183
DMLIMOP	MW	271.35
DMLIMOP	FM	C17H21NO2
DMLIMOP	IC	InChI=1S/C17H21NO2/c1-2-3-4-5-8-14-10-11-16(15(19)13-14)20-17-9-6-7-12-18-17/h6-7,9-13,19H,2-5,8H2,1H3
DMLIMOP	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=N2)O
DMLIMOP	IK	GGLAALKBNDMDTG-UHFFFAOYSA-N
DMLIMOP	IU	5-hexyl-2-pyridin-2-yloxyphenol
DMLIMOP	DE	Discovery agent

DMHZT1S	ID	DMHZT1S
DMHZT1S	DN	5-hexyl-2-(pyridin-3-yloxy)phenol
DMHZT1S	HS	Investigative
DMHZT1S	SN	CHEMBL405655
DMHZT1S	DT	Small molecular drug
DMHZT1S	PC	44450159
DMHZT1S	MW	271.35
DMHZT1S	FM	C17H21NO2
DMHZT1S	IC	InChI=1S/C17H21NO2/c1-2-3-4-5-7-14-9-10-17(16(19)12-14)20-15-8-6-11-18-13-15/h6,8-13,19H,2-5,7H2,1H3
DMHZT1S	CS	CCCCCCC1=CC(=C(C=C1)OC2=CN=CC=C2)O
DMHZT1S	IK	MMFBADBXBVJXTO-UHFFFAOYSA-N
DMHZT1S	IU	5-hexyl-2-pyridin-3-yloxyphenol
DMHZT1S	DE	Discovery agent

DMP6U3L	ID	DMP6U3L
DMP6U3L	DN	5-hexyl-2-(pyridin-4-yloxy)phenol
DMP6U3L	HS	Investigative
DMP6U3L	SN	CHEMBL259138
DMP6U3L	DT	Small molecular drug
DMP6U3L	PC	44450160
DMP6U3L	MW	271.35
DMP6U3L	FM	C17H21NO2
DMP6U3L	IC	InChI=1S/C17H21NO2/c1-2-3-4-5-6-14-7-8-17(16(19)13-14)20-15-9-11-18-12-10-15/h7-13,19H,2-6H2,1H3
DMP6U3L	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=NC=C2)O
DMP6U3L	IK	YVUSUCCKZBSLJS-UHFFFAOYSA-N
DMP6U3L	IU	5-hexyl-2-pyridin-4-yloxyphenol
DMP6U3L	DE	Discovery agent

DMNYOV3	ID	DMNYOV3
DMNYOV3	DN	5-hexyl-2-(pyrimidin-2-yloxy)phenol
DMNYOV3	HS	Investigative
DMNYOV3	SN	CHEMBL258931
DMNYOV3	DT	Small molecular drug
DMNYOV3	PC	44450156
DMNYOV3	MW	272.34
DMNYOV3	FM	C16H20N2O2
DMNYOV3	IC	InChI=1S/C16H20N2O2/c1-2-3-4-5-7-13-8-9-15(14(19)12-13)20-16-17-10-6-11-18-16/h6,8-12,19H,2-5,7H2,1H3
DMNYOV3	CS	CCCCCCC1=CC(=C(C=C1)OC2=NC=CC=N2)O
DMNYOV3	IK	CWDKJRBSXCNZHS-UHFFFAOYSA-N
DMNYOV3	IU	5-hexyl-2-pyrimidin-2-yloxyphenol
DMNYOV3	DE	Discovery agent

DMHNRXT	ID	DMHNRXT
DMHNRXT	DN	5-hexyl-2-phenoxyphenol
DMHNRXT	HS	Investigative
DMHNRXT	SN	5-hexyl-2-phenoxyphenol; 5-Hexyl-2-phenoxy-phenol; 6PP; AIDS227446; AC1NRXEM; 2-Phenoxy-5-hexylphenol; 5-hexyl-2-phenoxylphenol; SCHEMBL2878546; PT04; CHEMBL264682; BDBM16297; SXGQGHHNOWYMRT-UHFFFAOYSA-N
DMHNRXT	DT	Small molecular drug
DMHNRXT	PC	5274977
DMHNRXT	MW	270.4
DMHNRXT	FM	C18H22O2
DMHNRXT	IC	InChI=1S/C18H22O2/c1-2-3-4-6-9-15-12-13-18(17(19)14-15)20-16-10-7-5-8-11-16/h5,7-8,10-14,19H,2-4,6,9H2,1H3
DMHNRXT	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2)O
DMHNRXT	IK	SXGQGHHNOWYMRT-UHFFFAOYSA-N
DMHNRXT	IU	5-hexyl-2-phenoxyphenol
DMHNRXT	DE	Discovery agent

DMCDUO1	ID	DMCDUO1
DMCDUO1	DN	5-Hexyl-5-phenyl-imidazolidine-2,4-dione
DMCDUO1	HS	Investigative
DMCDUO1	SN	CHEMBL289499
DMCDUO1	DT	Small molecular drug
DMCDUO1	PC	44285898
DMCDUO1	MW	260.329
DMCDUO1	FM	C15H20N2O2
DMCDUO1	IC	InChI=1S/C15H20N2O2/c1-2-3-4-8-11-15(12-9-6-5-7-10-12)13(18)16-14(19)17-15/h5-7,9-10H,2-4,8,11H2,1H3,(H2,16,17,18,19)
DMCDUO1	CS	CCCCCCC1(C(=O)NC(=O)N1)C2=CC=CC=C2
DMCDUO1	IK	QUCQUPBUCULYGF-UHFFFAOYSA-N
DMCDUO1	IU	5-hexyl-5-phenylimidazolidine-2,4-dione
DMCDUO1	DE	Discovery agent

DM4S86L	ID	DM4S86L
DM4S86L	DN	5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione
DM4S86L	HS	Investigative
DM4S86L	SN	5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512
DM4S86L	DT	Small molecular drug
DM4S86L	PC	49292
DM4S86L	MW	288.34
DM4S86L	FM	C16H20N2O3
DM4S86L	IC	InChI=1S/C16H20N2O3/c1-2-3-4-8-11-16(12-9-6-5-7-10-12)13(19)17-15(21)18-14(16)20/h5-7,9-10H,2-4,8,11H2,1H3,(H2,17,18,19,20,21)
DM4S86L	CS	CCCCCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
DM4S86L	IK	LWBGXTORWSRDHX-UHFFFAOYSA-N
DM4S86L	IU	5-hexyl-5-phenyl-1,3-diazinane-2,4,6-trione
DM4S86L	CA	CAS 67051-21-2
DM4S86L	DE	Discovery agent

DM98OEQ	ID	DM98OEQ
DM98OEQ	DN	5-hydroxy-1H-indole-3-acetic acid
DM98OEQ	HS	Investigative
DM98OEQ	SN	5-Hydroxyindole-3-acetic acid; 54-16-0; 5-HIAA; 2-(5-hydroxy-1H-indol-3-yl)acetic acid; 5-Hydroxyindoleacetic acid; 5-Hydroxyheteroauxin; (5-Hydroxy-1H-indol-3-yl)acetic acid; 5-Oxyindoleacetic acid; 5-Hydroxy-IAA; 5-Hydroxyindolacetic acid; 5-Hydroxy-3-indoleacetic acid; 5-Hydroxyindol-3-ylacetic acid; Hydroxyindoleacetic acid; 5-Hydroxy-1H-indole-3-acetic acid; 5-Hydroxyindolylacetic acid; 1H-Indole-3-acetic acid, 5-hydroxy-; 1321-73-9; Indole-3-acetic acid, 5-hydroxy-; 5-Hydroxyindoleacetate; UNII-YHC763JY1P; NSC 90432
DM98OEQ	DT	Small molecular drug
DM98OEQ	PC	1826
DM98OEQ	MW	191.18
DM98OEQ	FM	C10H9NO3
DM98OEQ	IC	InChI=1S/C10H9NO3/c12-7-1-2-9-8(4-7)6(5-11-9)3-10(13)14/h1-2,4-5,11-12H,3H2,(H,13,14)
DM98OEQ	CS	C1=CC2=C(C=C1O)C(=CN2)CC(=O)O
DM98OEQ	IK	DUUGKQCEGZLZNO-UHFFFAOYSA-N
DM98OEQ	IU	2-(5-hydroxy-1H-indol-3-yl)acetic acid
DM98OEQ	CA	CAS 54-16-0
DM98OEQ	CB	CHEBI:27823
DM98OEQ	DE	Discovery agent

DM5RI4H	ID	DM5RI4H
DM5RI4H	DN	5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one
DM5RI4H	HS	Investigative
DM5RI4H	SN	CHEMBL1163554; 5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one; BDBM50321257
DM5RI4H	DT	Small molecular drug
DM5RI4H	PC	46871781
DM5RI4H	MW	253.28
DM5RI4H	FM	C11H11NO4S
DM5RI4H	IC	InChI=1S/C11H11NO4S/c1-8-2-4-9(5-3-8)17(15,16)12-10(13)6-7-11(12)14/h2-7,10,13H,1H3
DM5RI4H	CS	CC1=CC=C(C=C1)S(=O)(=O)N2C(C=CC2=O)O
DM5RI4H	IK	LASNBXWNXQRYSO-UHFFFAOYSA-N
DM5RI4H	IU	2-hydroxy-1-(4-methylphenyl)sulfonyl-2H-pyrrol-5-one
DM5RI4H	DE	Discovery agent

DM8KON3	ID	DM8KON3
DM8KON3	DN	5-hydroxy-2-(4-aminophenyl)benzofuran
DM8KON3	HS	Investigative
DM8KON3	SN	CHEMBL380476; 5-hydroxy-2-(4-aminophenyl)benzofuran; CTK7D7241; ZINC13686340; BDBM50185949; 2-(4-Amino-phenyl)-benzofuran-5-ol
DM8KON3	DT	Small molecular drug
DM8KON3	PC	11499570
DM8KON3	MW	225.24
DM8KON3	FM	C14H11NO2
DM8KON3	IC	InChI=1S/C14H11NO2/c15-11-3-1-9(2-4-11)14-8-10-7-12(16)5-6-13(10)17-14/h1-8,16H,15H2
DM8KON3	CS	C1=CC(=CC=C1C2=CC3=C(O2)C=CC(=C3)O)N
DM8KON3	IK	JDGXRZSZWVUFMN-UHFFFAOYSA-N
DM8KON3	IU	2-(4-aminophenyl)-1-benzofuran-5-ol
DM8KON3	CA	CAS 888703-99-9
DM8KON3	DE	Discovery agent

DMYL0ZF	ID	DMYL0ZF
DMYL0ZF	DN	5-hydroxy-2-(4-dimethylaminophenyl)benzofuran
DMYL0ZF	HS	Investigative
DMYL0ZF	SN	CHEMBL204414; 5-hydroxy-2-(4-dimethylaminophenyl)benzofuran; CTK7J9733; ZINC13686356; BDBM50185950; AKOS015966036
DMYL0ZF	DT	Small molecular drug
DMYL0ZF	PC	11543378
DMYL0ZF	MW	253.29
DMYL0ZF	FM	C16H15NO2
DMYL0ZF	IC	InChI=1S/C16H15NO2/c1-17(2)13-5-3-11(4-6-13)16-10-12-9-14(18)7-8-15(12)19-16/h3-10,18H,1-2H3
DMYL0ZF	CS	CN(C)C1=CC=C(C=C1)C2=CC3=C(O2)C=CC(=C3)O
DMYL0ZF	IK	ZEWYMVJDOSXOEG-UHFFFAOYSA-N
DMYL0ZF	IU	2-[4-(dimethylamino)phenyl]-1-benzofuran-5-ol
DMYL0ZF	DE	Discovery agent

DM4QC0R	ID	DM4QC0R
DM4QC0R	DN	5-hydroxy-2-(4-methylaminophenyl)benzofuran
DM4QC0R	HS	Investigative
DM4QC0R	SN	CHEMBL204829; 2-(4-methylaminophenyl)benzofuran-5-ol; 5-hydroxy-2-(4-methylaminophenyl)benzofuran; CTK6I4824; BDBM50185948; ZINC13686348; AKOS015966035
DM4QC0R	DT	Small molecular drug
DM4QC0R	PC	11550464
DM4QC0R	MW	239.27
DM4QC0R	FM	C15H13NO2
DM4QC0R	IC	InChI=1S/C15H13NO2/c1-16-12-4-2-10(3-5-12)15-9-11-8-13(17)6-7-14(11)18-15/h2-9,16-17H,1H3
DM4QC0R	CS	CNC1=CC=C(C=C1)C2=CC3=C(O2)C=CC(=C3)O
DM4QC0R	IK	ZNESXKIPTICLME-UHFFFAOYSA-N
DM4QC0R	IU	2-[4-(methylamino)phenyl]-1-benzofuran-5-ol
DM4QC0R	DE	Discovery agent

DMTO2L3	ID	DMTO2L3
DMTO2L3	DN	5-hydroxy-2-(pentylthiomethyl)-4H-pyran-4-one
DMTO2L3	HS	Investigative
DMTO2L3	SN	CHEMBL1269399; 5-hydroxy-2-(pentylthiomethyl)-4H-pyran-4-one
DMTO2L3	DT	Small molecular drug
DMTO2L3	PC	52945274
DMTO2L3	MW	228.31
DMTO2L3	FM	C11H16O3S
DMTO2L3	IC	InChI=1S/C11H16O3S/c1-2-3-4-5-15-8-9-6-10(12)11(13)7-14-9/h6-7,13H,2-5,8H2,1H3
DMTO2L3	CS	CCCCCSCC1=CC(=O)C(=CO1)O
DMTO2L3	IK	BSUYJCKSLPFPSA-UHFFFAOYSA-N
DMTO2L3	IU	5-hydroxy-2-(pentylsulfanylmethyl)pyran-4-one
DMTO2L3	DE	Discovery agent

DM7M1RZ	ID	DM7M1RZ
DM7M1RZ	DN	5-hydroxy-2-(propylthiomethyl)-4H-pyran-4-one
DM7M1RZ	HS	Investigative
DM7M1RZ	SN	CHEMBL1269350; 5-hydroxy-2-(propylthiomethyl)-4H-pyran-4-one
DM7M1RZ	DT	Small molecular drug
DM7M1RZ	PC	23273746
DM7M1RZ	MW	200.26
DM7M1RZ	FM	C9H12O3S
DM7M1RZ	IC	InChI=1S/C9H12O3S/c1-2-3-13-6-7-4-8(10)9(11)5-12-7/h4-5,11H,2-3,6H2,1H3
DM7M1RZ	CS	CCCSCC1=CC(=O)C(=CO1)O
DM7M1RZ	IK	DKYLUTJQQPXXLM-UHFFFAOYSA-N
DM7M1RZ	IU	5-hydroxy-2-(propylsulfanylmethyl)pyran-4-one
DM7M1RZ	DE	Discovery agent

DMLZKNF	ID	DMLZKNF
DMLZKNF	DN	5-hydroxy-2-phenylisoindoline-1,3-dione
DMLZKNF	HS	Investigative
DMLZKNF	SN	CHEMBL276030; 4-Hydroxy-N-phenylphthalimide; 3975-50-6; 5-hydroxy-2-phenylisoindoline-1,3-dione; 5-hydroxy-2-phenyl-isoindole-1,3-dione; SCHEMBL8615277; CTK1B3719; DTXSID80445430; HCUAWJNHCZEMJS-UHFFFAOYSA-N; ZINC26020837; BDBM50088673; 5-hydroxy-2-phenyl-1H-isoindole-1,3(2H)-dione; 1H-Isoindole-1,3(2H)-dione, 5-hydroxy-2-phenyl-
DMLZKNF	DT	Small molecular drug
DMLZKNF	PC	10823890
DMLZKNF	MW	239.23
DMLZKNF	FM	C14H9NO3
DMLZKNF	IC	InChI=1S/C14H9NO3/c16-10-6-7-11-12(8-10)14(18)15(13(11)17)9-4-2-1-3-5-9/h1-8,16H
DMLZKNF	CS	C1=CC=C(C=C1)N2C(=O)C3=C(C2=O)C=C(C=C3)O
DMLZKNF	IK	HCUAWJNHCZEMJS-UHFFFAOYSA-N
DMLZKNF	IU	5-hydroxy-2-phenylisoindole-1,3-dione
DMLZKNF	CA	CAS 3975-50-6
DMLZKNF	DE	Discovery agent

DMI0GMB	ID	DMI0GMB
DMI0GMB	DN	5-hydroxyindole
DMI0GMB	HS	Investigative
DMI0GMB	SN	5-Hydroxyindole; 1H-Indol-5-ol; 1953-54-4; INDOL-5-OL; 5-Hydroxy-1H-indole; Hydroxy-5 indole; 5-Indolol; UNII-320UN7XZYN; Hydroxy-5-indole; Hydroxy-5 indole [French]; CCRIS 4422; 5-Hydroxyindole, 97%; EINECS 217-782-6; MFCD00005677; NSC 87503; BRN 0112349; 320UN7XZYN; CHEBI:89649; LMIQERWZRIFWNZ-UHFFFAOYSA-N; NSC-87503; 5-hydroxy-indole; Hydroxy-5 indole  [French]; 5-hydroxylindole; 5-hydroxy-indol; 5-hydroxy indole; 3fuh; 5H1; zlchem 359; 5Hydroxy-1H-indole; PubChem7263; 1-H-indol-5-ol; 1H-indol-5-ol.; 4b3c; ACMC-1BQT3; WLN: T56 BMJ GQ
DMI0GMB	DT	Small molecular drug
DMI0GMB	PC	16054
DMI0GMB	MW	133.15
DMI0GMB	FM	C8H7NO
DMI0GMB	IC	InChI=1S/C8H7NO/c10-7-1-2-8-6(5-7)3-4-9-8/h1-5,9-10H
DMI0GMB	CS	C1=CC2=C(C=CN2)C=C1O
DMI0GMB	IK	LMIQERWZRIFWNZ-UHFFFAOYSA-N
DMI0GMB	IU	1H-indol-5-ol
DMI0GMB	CA	CAS 1953-54-4
DMI0GMB	CB	CHEBI:89649
DMI0GMB	DE	Discovery agent

DMDWZGJ	ID	DMDWZGJ
DMDWZGJ	DN	5-hydroxy-L-tryptophan
DMDWZGJ	HS	Investigative
DMDWZGJ	SN	5-hydroxytryptophan
DMDWZGJ	DT	Small molecular drug
DMDWZGJ	PC	439280
DMDWZGJ	MW	220.22
DMDWZGJ	FM	C11H12N2O3
DMDWZGJ	IC	InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)/t9-/m0/s1
DMDWZGJ	CS	C1=CC2=C(C=C1O)C(=CN2)C[C@@H](C(=O)O)N
DMDWZGJ	IK	LDCYZAJDBXYCGN-VIFPVBQESA-N
DMDWZGJ	IU	(2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid
DMDWZGJ	CA	CAS 4350-09-8
DMDWZGJ	CB	CHEBI:17780
DMDWZGJ	DE	Discovery agent

DMT9FQN	ID	DMT9FQN
DMT9FQN	DN	5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMT9FQN	HS	Investigative
DMT9FQN	SN	CHEMBL17653; 406934-09-6; 2-Oxazolidinone, 5-(hydroxymethyl)-3-(1H-pyrrol-1-yl)-, (5R)-; 5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one; CTK1C9350; DTXSID00452964; BDBM50110714; BDBM50370193
DMT9FQN	DT	Small molecular drug
DMT9FQN	PC	11095251
DMT9FQN	MW	182.18
DMT9FQN	FM	C8H10N2O3
DMT9FQN	IC	InChI=1S/C8H10N2O3/c11-6-7-5-10(8(12)13-7)9-3-1-2-4-9/h1-4,7,11H,5-6H2/t7-/m0/s1
DMT9FQN	CS	C1[C@H](OC(=O)N1N2C=CC=C2)CO
DMT9FQN	IK	SITMGBVDSOSSTH-ZETCQYMHSA-N
DMT9FQN	IU	(5S)-5-(hydroxymethyl)-3-pyrrol-1-yl-1,3-oxazolidin-2-one
DMT9FQN	DE	Discovery agent

DMN9FPV	ID	DMN9FPV
DMN9FPV	DN	5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid
DMN9FPV	HS	Investigative
DMN9FPV	SN	CHEMBL395398; Boronic acid, B-(5-hydroxybenzo[b]thien-2-yl)-; 959636-67-0; 5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid; BDBM50225392
DMN9FPV	DT	Small molecular drug
DMN9FPV	PC	44435712
DMN9FPV	MW	194.02
DMN9FPV	FM	C8H7BO3S
DMN9FPV	IC	InChI=1S/C8H7BO3S/c10-6-1-2-7-5(3-6)4-8(13-7)9(11)12/h1-4,10-12H
DMN9FPV	CS	B(C1=CC2=C(S1)C=CC(=C2)O)(O)O
DMN9FPV	IK	VDCIKADVYWVDGT-UHFFFAOYSA-N
DMN9FPV	IU	(5-hydroxy-1-benzothiophen-2-yl)boronic acid
DMN9FPV	CA	CAS 959636-67-0
DMN9FPV	DE	Discovery agent

DMZHVRW	ID	DMZHVRW
DMZHVRW	DN	5-Hydroxymethyl-Chonduritol
DMZHVRW	HS	Investigative
DMZHVRW	SN	Valienol; 5-HYDROXYMETHYL-CHONDURITOL; (1S,2S,3S,4R)-5-(hydroxymethyl)cyclohex-5-ene-1,2,3,4-tetrol; 111136-25-5; AC1NRBPE; CHEMBL1233349; DTXSID50415342
DMZHVRW	DT	Small molecular drug
DMZHVRW	PC	5288564
DMZHVRW	MW	176.17
DMZHVRW	FM	C7H12O5
DMZHVRW	IC	InChI=1S/C7H12O5/c8-2-3-1-4(9)6(11)7(12)5(3)10/h1,4-12H,2H2/t4-,5+,6-,7-/m0/s1
DMZHVRW	CS	C1=C([C@H]([C@@H]([C@H]([C@H]1O)O)O)O)CO
DMZHVRW	IK	PJPGMULJEYSZBS-VZFHVOOUSA-N
DMZHVRW	IU	(1S,2S,3S,4R)-5-(hydroxymethyl)cyclohex-5-ene-1,2,3,4-tetrol
DMZHVRW	CA	CAS 111136-25-5
DMZHVRW	DE	Discovery agent

DMWVCJ1	ID	DMWVCJ1
DMWVCJ1	DN	5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate
DMWVCJ1	HS	Investigative
DMWVCJ1	DT	Small molecular drug
DMWVCJ1	PC	447206
DMWVCJ1	MW	338.21
DMWVCJ1	FM	C10H15N2O9P
DMWVCJ1	IC	InChI=1S/C10H15N2O9P/c13-3-5-2-12(10(16)11-9(5)15)8-1-6(14)7(21-8)4-20-22(17,18)19/h2,6-8,13-14H,1,3-4H2,(H,11,15,16)(H2,17,18,19)/t6-,7+,8+/m0/s1
DMWVCJ1	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)CO)COP(=O)(O)O)O
DMWVCJ1	IK	WEBVWKFGRVLCNS-XLPZGREQSA-N
DMWVCJ1	IU	[(2R,3S,5R)-3-hydroxy-5-[5-(hydroxymethyl)-2,4-dioxopyrimidin-1-yl]oxolan-2-yl]methyl dihydrogen phosphate
DMWVCJ1	DE	Discovery agent

DMMF57V	ID	DMMF57V
DMMF57V	DN	5-hydroxynaphthalene-1-sulfonamide
DMMF57V	HS	Investigative
DMMF57V	SN	5-hydroxynaphthalene-1-sulfonamide; 17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211
DMMF57V	DT	Small molecular drug
DMMF57V	PC	87031
DMMF57V	MW	223.25
DMMF57V	FM	C10H9NO3S
DMMF57V	IC	InChI=1S/C10H9NO3S/c11-15(13,14)10-6-2-3-7-8(10)4-1-5-9(7)12/h1-6,12H,(H2,11,13,14)
DMMF57V	CS	C1=CC2=C(C=CC=C2S(=O)(=O)N)C(=C1)O
DMMF57V	IK	NFVBVKHGDDDCEA-UHFFFAOYSA-N
DMMF57V	IU	5-hydroxynaphthalene-1-sulfonamide
DMMF57V	CA	CAS 17286-26-9
DMMF57V	DE	Discovery agent

DMJQFZH	ID	DMJQFZH
DMJQFZH	DN	5-hydroxy-pentanoate
DMJQFZH	HS	Investigative
DMJQFZH	SN	sodium 5-hydroxypentanoate; 37435-69-1; 5-Hydroxypentanoic Acid Sodium Salt; Pentanoic acid, 5-hydroxy-, monosodium salt; sodium 5-hydroxyvalerate; C5H9O3.Na; Sodium 5-Hydroxy-Pentanoate; SCHEMBL311152; 5-hydroxypentanoic acid sodium; CHEMBL170082; 5-HydroxypentanoicAcidSodiumSalt; MolPort-027-844-925; ZJDDLWNQIJLIQU-UHFFFAOYSA-M; 5-Hydroxyvaleric acid sodium salt; 6374AJ; AKOS022186958; KS-0000090D; SY019284; BC621003; AK146710; KB-269943; CS-0047732; K-8251; MFCD22192345 (95+%)
DMJQFZH	DT	Small molecular drug
DMJQFZH	PC	23695195
DMJQFZH	MW	140.11
DMJQFZH	FM	C5H9NaO3
DMJQFZH	IC	InChI=1S/C5H10O3.Na/c6-4-2-1-3-5(7)8;/h6H,1-4H2,(H,7,8);/q;+1/p-1
DMJQFZH	CS	C(CCO)CC(=O)[O-].[Na+]
DMJQFZH	IK	ZJDDLWNQIJLIQU-UHFFFAOYSA-M
DMJQFZH	IU	sodium;5-hydroxypentanoate
DMJQFZH	DE	Discovery agent

DMIXQG6	ID	DMIXQG6
DMIXQG6	DN	5-hydroxyvaleric acid
DMIXQG6	HS	Investigative
DMIXQG6	SN	5-HYDROXYPENTANOIC ACID; 5-Hydroxyvaleric acid; 13392-69-3; 5-Hydroxyvalerate; 5-hydroxy-pentanoic acid; delta-Hydroxypentanoic acid; Pentanoic acid, 5-hydroxy-; 5-hydroxy valeric acid; 5-Hydroxy-pentansaeure; omega-hydroxyvaleric acid; delta-hydroxyvaleric acid; 5-Hydroxy-valeriansaeure; 4-Oxy-butan-carbonsaeure; omega-hydroxypentanoic acid; Pentanoic acid,5-hydroxy-; 5-HYDROXYLAEVULINIC ACID; CHEBI:45564; delta-hydroxyvalerate; Omega-hydroxyvalerate; Omega-hydroxypentanoate; delta-Hydroxypentanoate
DMIXQG6	DT	Small molecular drug
DMIXQG6	PC	25945
DMIXQG6	MW	118.13
DMIXQG6	FM	C5H10O3
DMIXQG6	IC	InChI=1S/C5H10O3/c6-4-2-1-3-5(7)8/h6H,1-4H2,(H,7,8)
DMIXQG6	CS	C(CCO)CC(=O)O
DMIXQG6	IK	PHOJOSOUIAQEDH-UHFFFAOYSA-N
DMIXQG6	IU	5-hydroxypentanoic acid
DMIXQG6	CA	CAS 13392-69-3
DMIXQG6	CB	CHEBI:45564
DMIXQG6	DE	Discovery agent

DMVSBHU	ID	DMVSBHU
DMVSBHU	DN	5-Imidazol-1-yl-5,6,7,8-tetrahydro-quinoline
DMVSBHU	HS	Investigative
DMVSBHU	SN	Quinoline, 5,6,7,8-tetrahydro-5-(1H-imidazol-1-yl)-; 273930-06-6; tetrahydroquinoline 40; CHEMBL52509; BDBM10023; 5-(Imidazol-1-yl)-5,6,7,8-tetrahydroquinoline; 5-(1H-imidazol-1-yl)-5,6,7,8-tetrahydroquinoline
DMVSBHU	DT	Small molecular drug
DMVSBHU	PC	10703161
DMVSBHU	MW	199.25
DMVSBHU	FM	C12H13N3
DMVSBHU	IC	InChI=1S/C12H13N3/c1-4-11-10(3-2-6-14-11)12(5-1)15-8-7-13-9-15/h2-3,6-9,12H,1,4-5H2
DMVSBHU	CS	C1CC(C2=C(C1)N=CC=C2)N3C=CN=C3
DMVSBHU	IK	QFNKKYLTOSVDJG-UHFFFAOYSA-N
DMVSBHU	IU	5-imidazol-1-yl-5,6,7,8-tetrahydroquinoline
DMVSBHU	DE	Discovery agent

DMW8AOM	ID	DMW8AOM
DMW8AOM	DN	5-Indan-(1E)-ylidenemethyl-1H-imidazole
DMW8AOM	HS	Investigative
DMW8AOM	SN	Imidazolylmethyleneindane 2a; AC1O70GB; SCHEMBL4235335; BDBM8873; CHEMBL177468; SCHEMBL13877092; 5-[(E)-2,3-dihydroinden-1-ylidenemethyl]-1H-imidazole; 5-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]-1H-imidazole
DMW8AOM	DT	Small molecular drug
DMW8AOM	PC	6540032
DMW8AOM	MW	196.25
DMW8AOM	FM	C13H12N2
DMW8AOM	IC	InChI=1S/C13H12N2/c1-2-4-13-10(3-1)5-6-11(13)7-12-8-14-9-15-12/h1-4,7-9H,5-6H2,(H,14,15)/b11-7+
DMW8AOM	CS	C1C/C(=C\\C2=CN=CN2)/C3=CC=CC=C31
DMW8AOM	IK	FXLOWXDBTSZJFZ-YRNVUSSQSA-N
DMW8AOM	IU	5-[(E)-2,3-dihydroinden-1-ylidenemethyl]-1H-imidazole
DMW8AOM	DE	Discovery agent

DMKLY20	ID	DMKLY20
DMKLY20	DN	5-Indan-(1Z)-ylidenemethyl-1H-imidazole
DMKLY20	HS	Investigative
DMKLY20	SN	AC1O70GD; SCHEMBL4236847; CHEMBL178036; SCHEMBL4235344
DMKLY20	DT	Small molecular drug
DMKLY20	PC	6540033
DMKLY20	MW	196.25
DMKLY20	FM	C13H12N2
DMKLY20	IC	InChI=1S/C13H12N2/c1-2-4-13-10(3-1)5-6-11(13)7-12-8-14-9-15-12/h1-4,7-9H,5-6H2,(H,14,15)/b11-7-
DMKLY20	CS	C1C/C(=C/C2=CN=CN2)/C3=CC=CC=C31
DMKLY20	IK	FXLOWXDBTSZJFZ-XFFZJAGNSA-N
DMKLY20	IU	5-[(Z)-2,3-dihydroinden-1-ylidenemethyl]-1H-imidazole
DMKLY20	DE	Discovery agent

DMDKFIO	ID	DMDKFIO
DMDKFIO	DN	5-iodo orotate
DMDKFIO	HS	Investigative
DMDKFIO	DE	Discovery agent

DMVT2LW	ID	DMVT2LW
DMVT2LW	DN	5-iodo,5'-deoxytubercidin
DMVT2LW	HS	Investigative
DMVT2LW	SN	CHEMBL66280; 7-(5-Deoxy-Beta-D-Ribofuranosyl)-5-Iodo-7h-Pyrrolo[2,3-D]pyrimidin-4-Amine; 5-iodo,5'-deoxytubercidin; 2i6a; 5-Iodo-5-deoxytubercidin; 5-Iodo-5'-deoxytubercidin; SCHEMBL6236636; BDBM14486; DB07173; 5I5; (2R,3R,4S,5R)-2-{4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl}-5-methyloxolane-3,4-diol; 5'-DEOXY-5-IODOTUBERCIDIN; (2R,3R,4S,5R)-2-(4-AMINO-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-(METHYL)TETRAHYDROFURAN-3,4-DIOL; (2R,3R,4S,5R)-2-{4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-5-methyloxolane-3,4-diol
DMVT2LW	DT	Small molecular drug
DMVT2LW	PC	9842606
DMVT2LW	MW	376.15
DMVT2LW	FM	C11H13IN4O3
DMVT2LW	IC	InChI=1S/C11H13IN4O3/c1-4-7(17)8(18)11(19-4)16-2-5(12)6-9(13)14-3-15-10(6)16/h2-4,7-8,11,17-18H,1H3,(H2,13,14,15)/t4-,7-,8-,11-/m1/s1
DMVT2LW	CS	C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C3=C(N=CN=C32)N)I)O)O
DMVT2LW	IK	NTXUAWGNGBSCRS-TZQXKBMNSA-N
DMVT2LW	IU	(2R,3R,4S,5R)-2-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)-5-methyloxolane-3,4-diol
DMVT2LW	DE	Discovery agent

DM4NQY6	ID	DM4NQY6
DM4NQY6	DN	5-iodo-1H-indazole
DM4NQY6	HS	Investigative
DM4NQY6	SN	5-Iodo-1H-indazole; 55919-82-9; 5-IODOINDAZOLE; 5-IODO (1H)INDAZOLE; 5-iodanyl-1H-indazole; 1H-INDAZOLE, 5-IODO-; CHEMBL391348; AK-27902; 5-Iodo-1H-indazole, 95%; 5-Iodo(1H)indazole; 5-iodio-1H-indazole; PubChem20575; SCHEMBL264176; 5-IODO-(1H)-INDAZOLE; CTK5A4375; DTXSID00619590; CGCHCLICSHIAAM-UHFFFAOYSA-N; MolPort-000-004-505; BCP27249; CS-D1249; ZX-AT020681; KS-000003HB; OR2756; ANW-50835; ZINC14983580; CI-264; BDBM50209243; RW3195; AKOS007930518; QC-2142; CM10802; RP05949; PB10471; VI20054; TRA0057528; FCH1323980; AS-8203; CJ-14773
DM4NQY6	DT	Small molecular drug
DM4NQY6	PC	21894739
DM4NQY6	MW	244.03
DM4NQY6	FM	C7H5IN2
DM4NQY6	IC	InChI=1S/C7H5IN2/c8-6-1-2-7-5(3-6)4-9-10-7/h1-4H,(H,9,10)
DM4NQY6	CS	C1=CC2=C(C=C1I)C=NN2
DM4NQY6	IK	CGCHCLICSHIAAM-UHFFFAOYSA-N
DM4NQY6	IU	5-iodo-1H-indazole
DM4NQY6	CA	CAS 55919-82-9
DM4NQY6	DE	Discovery agent

DMZACXG	ID	DMZACXG
DMZACXG	DN	5-Iodo-2'-Deoxyuridine-5'-Monophosphate
DMZACXG	HS	Investigative
DMZACXG	SN	AC1L52UF; [(2R,3S)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMZACXG	DT	Small molecular drug
DMZACXG	PC	449489
DMZACXG	MW	434.08
DMZACXG	FM	C9H12IN2O8P
DMZACXG	IC	InChI=1S/C9H12IN2O8P/c10-4-2-12(9(15)11-8(4)14)7-1-5(13)6(20-7)3-19-21(16,17)18/h2,5-7,13H,1,3H2,(H,11,14,15)(H2,16,17,18)/t5-,6+,7+/m0/s1
DMZACXG	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)COP(=O)(O)O)O
DMZACXG	IK	WXFYBFRZROJDLL-RRKCRQDMSA-N
DMZACXG	IU	[(2R,3S,5R)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMZACXG	CA	CAS 1763-02-6
DMZACXG	DE	Discovery agent

DMQINY5	ID	DMQINY5
DMQINY5	DN	5'-iodoresiniferatoxin
DMQINY5	HS	Investigative
DMQINY5	SN	TZUJORCXGLGWDV-DZBJMWFRSA-N; Iodoresiniferatoxin; 5'-Iodoresiniferatoxin; CHEMBL595069; 535974-91-5; 5-Iodoesiniferatoxin; 5-Iodo-Resiniferatoxin; GTPL4109; ZINC95537470; BDBM50305278; LS-28832;  I-RTX; IODORESINIFERATOXIN
DMQINY5	DT	Small molecular drug
DMQINY5	PC	6324614
DMQINY5	MW	754.6
DMQINY5	FM	C37H39IO9
DMQINY5	IC	InChI=1S/C37H39IO9/c1-20(2)35-16-22(4)37-26(33(35)45-36(46-35,47-37)18-23-9-7-6-8-10-23)12-25(17-34(42)29(37)11-21(3)32(34)41)19-44-30(39)15-24-13-27(38)31(40)28(14-24)43-5/h6-14,22,26,29,33,40,42H,1,15-19H2,2-5H3/t22-,26+,29-,33-,34-,35-,36-,37-/m1/s1
DMQINY5	CS	C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5(CC(=C4)COC(=O)CC6=CC(=C(C(=C6)I)O)OC)O)C)O[C@](O3)(O2)CC7=CC=CC=C7)C(=C)C
DMQINY5	IK	TZUJORCXGLGWDV-DZBJMWFRSA-N
DMQINY5	IU	[(1R,2R,6R,10S,11R,13S,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-iodo-5-methoxyphenyl)acetate
DMQINY5	CA	CAS 535974-91-5
DMQINY5	DE	Discovery agent

DML5ZEJ	ID	DML5ZEJ
DML5ZEJ	DN	5'-iodotubercidin
DML5ZEJ	HS	Investigative
DML5ZEJ	SN	5-Iodotubercidin; 24386-93-4; 5-iodotubericidin; 7-Deaza-7-iodoadenosine; 7-iodo-7-deazaadenosine; 7-iodotubercidin; (2R,3R,4S,5R)-2-(4-AMINO-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL; CHEMBL99203; CHEBI:40167; 5-iodo-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine; NSC 113939; 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,5-iodo-7-b-D-ribofuranosyl-; 7H-Pyrrolo(2,3-d)pyrimidin-4-amine, 5-iodo-7-beta-D-ribofuranosyl-
DML5ZEJ	DT	Small molecular drug
DML5ZEJ	PC	101649230
DML5ZEJ	MW	376.15
DML5ZEJ	FM	C11H13IN4O3
DML5ZEJ	IC	InChI=1S/C11H13IN4O3/c12-3-6-7(17)8(18)11(19-6)16-2-1-5-9(13)14-4-15-10(5)16/h1-2,4,6-8,11,17-18H,3H2,(H2,13,14,15)/t6-,7-,8-,11-/m1/s1
DML5ZEJ	CS	C1=CN(C2=NC=NC(=C21)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CI)O)O
DML5ZEJ	IK	RUOLUSLZJXGWAU-KCGFPETGSA-N
DML5ZEJ	IU	(2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(iodomethyl)oxolane-3,4-diol
DML5ZEJ	DE	Discovery agent

DM4O6I5	ID	DM4O6I5
DM4O6I5	DN	5-Iodouracil
DM4O6I5	HS	Investigative
DM4O6I5	SN	5-Iodouracil; 696-07-1; 5-iodopyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-iodo-; 5-iodopyrimidine-2,4-diol; Uracil, 5-iodo-; 2,4-Dihydroxy-5-iodopyrimidine; 5-iodo-1H-pyrimidine-2,4-dione; 5-iodo uracil; UNII-H59BRK500M; NSC 57848; CHEBI:43636; EINECS 211-788-2; CHEMBL1173; AI3-50390; H59BRK500M; KSNXJLQDQOIRIP-UHFFFAOYSA-N; 5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione; NSC57848; MFCD00006020; 5-Iodouracil, 99%; 5-iodo-1,3-dihydropyrimidine-2,4-dione; IUR; 5909-21-7; 5-Iodo-uracil; 5- Iodouracil; zlchem 530
DM4O6I5	DT	Small molecular drug
DM4O6I5	PC	69672
DM4O6I5	MW	237.98
DM4O6I5	FM	C4H3IN2O2
DM4O6I5	IC	InChI=1S/C4H3IN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
DM4O6I5	CS	C1=C(C(=O)NC(=O)N1)I
DM4O6I5	IK	KSNXJLQDQOIRIP-UHFFFAOYSA-N
DM4O6I5	IU	5-iodo-1H-pyrimidine-2,4-dione
DM4O6I5	CA	CAS 696-07-1
DM4O6I5	CB	CHEBI:43636
DM4O6I5	DE	Discovery agent

DME6BX5	ID	DME6BX5
DME6BX5	DN	5-Isopropyl-1H-pyrazole-3-carboxylic acid
DME6BX5	HS	Investigative
DME6BX5	SN	5-isopropyl-1H-pyrazole-3-carboxylic acid; 92933-47-6; 5-Isopropyl-2H-pyrazole-3-carboxylic acid; 3-isopropyl-1H-pyrazole-5-carboxylic acid; 5-ISOPROPYLPYRAZOLE-3-CARBOXYLIC ACID; 3-(propan-2-yl)-1H-pyrazole-5-carboxylic acid; CHEMBL238002; CHWXKAHFWLSLOQ-UHFFFAOYSA-N; 1H-Pyrazole-3-carboxylic acid, 5-(1-methylethyl)-; 890590-91-7; 5-isopropyl-1H-pyrazol-3-carboxylic acid; 5-(propan-2-yl)-1H-pyrazole-3-carboxylic acid; 3-(methylethyl)pyrazole-5-carboxylic acid; PubChem22754; BAS 15375081; ACMC-20cbo3; AC1Q5UGZ; AC1Q1OGL
DME6BX5	DT	Small molecular drug
DME6BX5	PC	776421
DME6BX5	MW	154.17
DME6BX5	FM	C7H10N2O2
DME6BX5	IC	InChI=1S/C7H10N2O2/c1-4(2)5-3-6(7(10)11)9-8-5/h3-4H,1-2H3,(H,8,9)(H,10,11)
DME6BX5	CS	CC(C)C1=CC(=NN1)C(=O)O
DME6BX5	IK	CHWXKAHFWLSLOQ-UHFFFAOYSA-N
DME6BX5	IU	5-propan-2-yl-1H-pyrazole-3-carboxylic acid
DME6BX5	DE	Discovery agent

DM2TNWO	ID	DM2TNWO
DM2TNWO	DN	5-isopropyl-2-(phenylamino)thiazol-4(5H)-one
DM2TNWO	HS	Investigative
DM2TNWO	DT	Small molecular drug
DM2TNWO	PC	90788829
DM2TNWO	MW	234.32
DM2TNWO	FM	C12H14N2OS
DM2TNWO	IC	InChI=1S/C12H14N2OS/c1-8(2)10-11(15)14-12(16-10)13-9-6-4-3-5-7-9/h3-8,15H,1-2H3,(H,13,14)
DM2TNWO	CS	CC(C)C1=C(N=C(S1)NC2=CC=CC=C2)O
DM2TNWO	IK	RCZXLRFUEUEYCI-UHFFFAOYSA-N
DM2TNWO	IU	2-anilino-5-propan-2-yl-1,3-thiazol-4-ol
DM2TNWO	DE	Discovery agent

DMXGRMB	ID	DMXGRMB
DMXGRMB	DN	5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole
DMXGRMB	HS	Investigative
DMXGRMB	SN	CHEMBL297660; 5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole; SCHEMBL8507362; BDBM50090518; 3-(2-Pyrrolizinoethyl)-5-isopropyl-1H-indole
DMXGRMB	DT	Small molecular drug
DMXGRMB	PC	10912152
DMXGRMB	MW	256.399
DMXGRMB	FM	C17H24N2
DMXGRMB	IC	InChI=1S/C17H24N2/c1-13(2)14-5-6-17-16(11-14)15(12-18-17)7-10-19-8-3-4-9-19/h5-6,11-13,18H,3-4,7-10H2,1-2H3
DMXGRMB	CS	CC(C)C1=CC2=C(C=C1)NC=C2CCN3CCCC3
DMXGRMB	IK	BCHGFZYQLYUXBO-UHFFFAOYSA-N
DMXGRMB	IU	5-propan-2-yl-3-(2-pyrrolidin-1-ylethyl)-1H-indole
DMXGRMB	DE	Discovery agent

DMXVPL1	ID	DMXVPL1
DMXVPL1	DN	5-ketodihydromevinolin
DMXVPL1	HS	Investigative
DMXVPL1	SN	compound 69 [PMID: 3656359]
DMXVPL1	DT	Small molecular drug
DMXVPL1	PC	44298287
DMXVPL1	MW	422.6
DMXVPL1	FM	C24H38O6
DMXVPL1	IC	InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,14-17,19-21,23,26H,5,8-13H2,1-4H3,(H,27,28)/t14-,15-,16-,17-,19+,20-,21-,23?/m0/s1
DMXVPL1	CS	CC[C@H](C)C(=O)O[C@H]1C[C@H](C[C@H]2C1[C@H]([C@H](C=C2)C)CCC(=O)C[C@H](CC(=O)O)O)C
DMXVPL1	IK	OOKAZRDERJMRCJ-KOUAFAAESA-N
DMXVPL1	IU	(3R)-7-[(1S,2S,4aR,6S,8S)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid
DMXVPL1	DE	Discovery agent

DMFZN7J	ID	DMFZN7J
DMFZN7J	DN	5-Me-IAA
DMFZN7J	HS	Investigative
DMFZN7J	SN	5-methy-1H-imidazole-4-acetic acid
DMFZN7J	DT	Small molecular drug
DMFZN7J	PC	22359367
DMFZN7J	MW	140.14
DMFZN7J	FM	C6H8N2O2
DMFZN7J	IC	InChI=1S/C6H8N2O2/c1-4-5(2-6(9)10)8-3-7-4/h3H,2H2,1H3,(H,7,8)(H,9,10)
DMFZN7J	CS	CC1=C(N=CN1)CC(=O)O
DMFZN7J	IK	BINCHKHDIQXADS-UHFFFAOYSA-N
DMFZN7J	IU	2-(5-methyl-1H-imidazol-4-yl)acetic acid
DMFZN7J	DE	Discovery agent

DMG0EL7	ID	DMG0EL7
DMG0EL7	DN	5-MEO-DMT
DMG0EL7	HS	Investigative
DMG0EL7	SN	N,N-Dimethyl-5-methoxytryptamine; 5-Methoxy-N,N-dimethyltryptamine; 1019-45-0; Methoxybufotenin; O-Methylbufotenine; Methylbufotenine; MeODMT; 5-MeO-DMT; 5-Methoxydimethyltryptamine; Bufotenine, O-methyl-; 3-(2-Dimethylaminoethyl)-5-methoxyindole; 2-(5-Methoxy-1H-indol-3-yl)-N,N-dimethylethanamine; CT 4334; Methoxydimethyltryptamines; UNII-X0MKX3GWU9; 1H-Indole-3-ethanamine, 5-methoxy-N,N-dimethyl-; NSC 88624; 5-Methoxy-N,N-dimethyl-1H-indole-3-ethanamine; 5-OMe-DMT; INDOLE, 3-(2-(N,N-DIMETHYLAMINO)ETHYL)-5-METHOXY-
DMG0EL7	DT	Small molecular drug
DMG0EL7	PC	1832
DMG0EL7	MW	218.29
DMG0EL7	FM	C13H18N2O
DMG0EL7	IC	InChI=1S/C13H18N2O/c1-15(2)7-6-10-9-14-13-5-4-11(16-3)8-12(10)13/h4-5,8-9,14H,6-7H2,1-3H3
DMG0EL7	CS	CN(C)CCC1=CNC2=C1C=C(C=C2)OC
DMG0EL7	IK	ZSTKHSQDNIGFLM-UHFFFAOYSA-N
DMG0EL7	IU	2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine
DMG0EL7	CA	CAS 1019-45-0
DMG0EL7	CB	CHEBI:2086
DMG0EL7	DE	Discovery agent

DM7YGJO	ID	DM7YGJO
DM7YGJO	DN	5-Mercapto-pentanoic acid
DM7YGJO	HS	Investigative
DM7YGJO	SN	5-sulfanylpentanoic Acid; 5-Mercaptopentanoic Acid; 30247-98-4; 5-Mercapto-pentanoic acid; Pentanoic acid, 5-mercapto-; CHEMBL294565; 5-mercaptovaleric acid; SCHEMBL204062; CTK1C0536; DTXSID90447945; GCIZMJUHGHGRNW-UHFFFAOYSA-N; MolPort-013-659-967; BDBM50127619; ZINC13519063; AKOS010615958
DM7YGJO	DT	Small molecular drug
DM7YGJO	PC	10909614
DM7YGJO	MW	134.2
DM7YGJO	FM	C5H10O2S
DM7YGJO	IC	InChI=1S/C5H10O2S/c6-5(7)3-1-2-4-8/h8H,1-4H2,(H,6,7)
DM7YGJO	CS	C(CCS)CC(=O)O
DM7YGJO	IK	GCIZMJUHGHGRNW-UHFFFAOYSA-N
DM7YGJO	IU	5-sulfanylpentanoic acid
DM7YGJO	CA	CAS 30247-98-4
DM7YGJO	DE	Discovery agent

DMET3OJ	ID	DMET3OJ
DMET3OJ	DN	5-Mercapto-pentanoic acid phenylamide
DMET3OJ	HS	Investigative
DMET3OJ	SN	5-Mercapto-pentanoic acid phenylamide; N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-
DMET3OJ	DT	Small molecular drug
DMET3OJ	PC	11608171
DMET3OJ	MW	209.31
DMET3OJ	FM	C11H15NOS
DMET3OJ	IC	InChI=1S/C11H15NOS/c13-11(8-4-5-9-14)12-10-6-2-1-3-7-10/h1-3,6-7,14H,4-5,8-9H2,(H,12,13)
DMET3OJ	CS	C1=CC=C(C=C1)NC(=O)CCCCS
DMET3OJ	IK	AGRMYYLOBIRRKQ-UHFFFAOYSA-N
DMET3OJ	IU	N-phenyl-5-sulfanylpentanamide
DMET3OJ	DE	Discovery agent

DMPEKWD	ID	DMPEKWD
DMPEKWD	DN	5-Methoxy-1-phenyl-1H-benzoimidazole
DMPEKWD	HS	Investigative
DMPEKWD	SN	1H-Benzimidazole, 5-methoxy-1-phenyl-; 38205-85-5; 1-Phenylbenzimidazole deriv. 64; AC1NS4LX; CHEMBL76202; BDBM3847; SCHEMBL8006768; 5-methoxy-1-phenylbenzimidazole; CTK1B5049; DTXSID40416161; 5-Methoxy-1-phenyl-1H-benzimidazole; AKOS023169650; 5-Substituted 1-Phenylbenzimidazole 6
DMPEKWD	DT	Small molecular drug
DMPEKWD	PC	5328466
DMPEKWD	MW	224.26
DMPEKWD	FM	C14H12N2O
DMPEKWD	IC	InChI=1S/C14H12N2O/c1-17-12-7-8-14-13(9-12)15-10-16(14)11-5-3-2-4-6-11/h2-10H,1H3
DMPEKWD	CS	COC1=CC2=C(C=C1)N(C=N2)C3=CC=CC=C3
DMPEKWD	IK	BMNCXCJXZKZJII-UHFFFAOYSA-N
DMPEKWD	IU	5-methoxy-1-phenylbenzimidazole
DMPEKWD	CA	CAS 38205-85-5
DMPEKWD	DE	Discovery agent

DMX1LY3	ID	DMX1LY3
DMX1LY3	DN	5-methoxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole
DMX1LY3	HS	Investigative
DMX1LY3	SN	CHEMBL403264
DMX1LY3	DT	Small molecular drug
DMX1LY3	PC	44456023
DMX1LY3	MW	244.33
DMX1LY3	FM	C15H20N2O
DMX1LY3	IC	InChI=1S/C15H20N2O/c1-18-14-4-5-15-12(11-14)10-13(16-15)6-9-17-7-2-3-8-17/h4-5,10-11,16H,2-3,6-9H2,1H3
DMX1LY3	CS	COC1=CC2=C(C=C1)NC(=C2)CCN3CCCC3
DMX1LY3	IK	UXDACHZONACAIV-UHFFFAOYSA-N
DMX1LY3	IU	5-methoxy-2-(2-pyrrolidin-1-ylethyl)-1H-indole
DMX1LY3	DE	Discovery agent

DMG2HSU	ID	DMG2HSU
DMG2HSU	DN	5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole
DMG2HSU	HS	Investigative
DMG2HSU	SN	CHEMBL565567; 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole
DMG2HSU	DT	Small molecular drug
DMG2HSU	PC	45484514
DMG2HSU	MW	301.4
DMG2HSU	FM	C16H15NO3S
DMG2HSU	IC	InChI=1S/C16H15NO3S/c1-20-13-5-8-15-12(9-13)10-16(17-15)11-3-6-14(7-4-11)21(2,18)19/h3-10,17H,1-2H3
DMG2HSU	CS	COC1=CC2=C(C=C1)NC(=C2)C3=CC=C(C=C3)S(=O)(=O)C
DMG2HSU	IK	RQIQNXKCKAJTPF-UHFFFAOYSA-N
DMG2HSU	IU	5-methoxy-2-(4-methylsulfonylphenyl)-1H-indole
DMG2HSU	DE	Discovery agent

DMW7IXL	ID	DMW7IXL
DMW7IXL	DN	5-methoxy-2-(4-aminophenyl)benzofuran
DMW7IXL	HS	Investigative
DMW7IXL	SN	CHEMBL205221; 5-methoxy-2-(4-aminophenyl)benzofuran; CTK7A8117; ZINC13686334; BDBM50185946; AKOS015965959; KB-238624; 4-(5-methoxybenzo[b]furan-2-yl)phenylamine
DMW7IXL	DT	Small molecular drug
DMW7IXL	PC	11579589
DMW7IXL	MW	239.27
DMW7IXL	FM	C15H13NO2
DMW7IXL	IC	InChI=1S/C15H13NO2/c1-17-13-6-7-14-11(8-13)9-15(18-14)10-2-4-12(16)5-3-10/h2-9H,16H2,1H3
DMW7IXL	CS	COC1=CC2=C(C=C1)OC(=C2)C3=CC=C(C=C3)N
DMW7IXL	IK	GICMHQJTKXNMGB-UHFFFAOYSA-N
DMW7IXL	IU	4-(5-methoxy-1-benzofuran-2-yl)aniline
DMW7IXL	DE	Discovery agent

DM3NUMG	ID	DM3NUMG
DM3NUMG	DN	5-methoxy-2-(4-dimethylaminophenyl)benzofuran
DM3NUMG	HS	Investigative
DM3NUMG	SN	CHEMBL383116; 5-methoxy-2-(4-dimethylaminophenyl)benzofuran; ZINC13686352; BDBM50185945; AKOS015965999; KB-289042
DM3NUMG	DT	Small molecular drug
DM3NUMG	PC	11673398
DM3NUMG	MW	267.32
DM3NUMG	FM	C17H17NO2
DM3NUMG	IC	InChI=1S/C17H17NO2/c1-18(2)14-6-4-12(5-7-14)17-11-13-10-15(19-3)8-9-16(13)20-17/h4-11H,1-3H3
DM3NUMG	CS	CN(C)C1=CC=C(C=C1)C2=CC3=C(O2)C=CC(=C3)OC
DM3NUMG	IK	KKKKLHNEZMGUPC-UHFFFAOYSA-N
DM3NUMG	IU	4-(5-methoxy-1-benzofuran-2-yl)-N,N-dimethylaniline
DM3NUMG	DE	Discovery agent

DM5N1JX	ID	DM5N1JX
DM5N1JX	DN	5-methoxy-2-(4-methylaminophenyl)benzofuran
DM5N1JX	HS	Investigative
DM5N1JX	SN	CHEMBL208212; 5-methoxy-2-(4-methylaminophenyl)benzofuran; BDBM50185947; ZINC13686344
DM5N1JX	DT	Small molecular drug
DM5N1JX	PC	11708629
DM5N1JX	MW	253.29
DM5N1JX	FM	C16H15NO2
DM5N1JX	IC	InChI=1S/C16H15NO2/c1-17-13-5-3-11(4-6-13)16-10-12-9-14(18-2)7-8-15(12)19-16/h3-10,17H,1-2H3
DM5N1JX	CS	CNC1=CC=C(C=C1)C2=CC3=C(O2)C=CC(=C3)OC
DM5N1JX	IK	UPVZXZTUTQNNFR-UHFFFAOYSA-N
DM5N1JX	IU	4-(5-methoxy-1-benzofuran-2-yl)-N-methylaniline
DM5N1JX	DE	Discovery agent

DMNRSYA	ID	DMNRSYA
DMNRSYA	DN	5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMNRSYA	HS	Investigative
DMNRSYA	SN	5-Methoxytryptoline; 30439-19-1; CHEMBL6586; 1H-Pyrido(3,4-b)indole, 2,3,4,9-tetrahydro-5-methoxy-; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-5-methoxy-; 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline; SCHEMBL4525164; CTK4G5204; DTXSID10184522; VPZWHBCLJCKHGZ-UHFFFAOYSA-N; AC1Q5856; AC1L5390; BDBM50136499; AKOS023631742; 1,2,3,4-Tetrahydro-5-methoxy-beta-carboline; 5-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMNRSYA	DT	Small molecular drug
DMNRSYA	PC	169160
DMNRSYA	MW	202.25
DMNRSYA	FM	C12H14N2O
DMNRSYA	IC	InChI=1S/C12H14N2O/c1-15-11-4-2-3-9-12(11)8-5-6-13-7-10(8)14-9/h2-4,13-14H,5-7H2,1H3
DMNRSYA	CS	COC1=CC=CC2=C1C3=C(N2)CNCC3
DMNRSYA	IK	VPZWHBCLJCKHGZ-UHFFFAOYSA-N
DMNRSYA	IU	5-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMNRSYA	CA	CAS 30439-19-1
DMNRSYA	DE	Discovery agent

DMW9D30	ID	DMW9D30
DMW9D30	DN	5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one
DMW9D30	HS	Investigative
DMW9D30	SN	CHEMBL505327; 5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one
DMW9D30	DT	Small molecular drug
DMW9D30	PC	44592117
DMW9D30	MW	296.3
DMW9D30	FM	C18H16O4
DMW9D30	IC	InChI=1S/C18H16O4/c1-20-15-7-4-3-6-12(15)10-13-11-14-16(21-2)8-5-9-17(14)22-18(13)19/h3-9,11H,10H2,1-2H3
DMW9D30	CS	COC1=CC=CC=C1CC2=CC3=C(C=CC=C3OC)OC2=O
DMW9D30	IK	PUMXCXWQMAPHFQ-UHFFFAOYSA-N
DMW9D30	IU	5-methoxy-3-[(2-methoxyphenyl)methyl]chromen-2-one
DMW9D30	DE	Discovery agent

DMBOMZE	ID	DMBOMZE
DMBOMZE	DN	5-Methoxy-4,9-dihydro-3H-beta-carboline
DMBOMZE	HS	Investigative
DMBOMZE	SN	CHEMBL6591; 5-Methoxy-4,9-dihydro-3H-beta-carboline; SCHEMBL19407272; BDBM50136491
DMBOMZE	DT	Small molecular drug
DMBOMZE	PC	11424197
DMBOMZE	MW	200.24
DMBOMZE	FM	C12H12N2O
DMBOMZE	IC	InChI=1S/C12H12N2O/c1-15-11-4-2-3-9-12(11)8-5-6-13-7-10(8)14-9/h2-4,7,14H,5-6H2,1H3
DMBOMZE	CS	COC1=CC=CC2=C1C3=C(N2)C=NCC3
DMBOMZE	IK	UXOCVYNVGBOVRY-UHFFFAOYSA-N
DMBOMZE	IU	5-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole
DMBOMZE	DE	Discovery agent

DMCZSP3	ID	DMCZSP3
DMCZSP3	DN	5-methoxycarbonylamino-N-acetyltryptamine
DMCZSP3	HS	Investigative
DMCZSP3	SN	5-Methoxycarbonylamino-N-acetyltryptamine; GR 135531; 190277-13-5; 5-MCA-NAT; 5MCA-NAT; CHEMBL504585; methyl 3-(2-acetamidoethyl)-1H-indol-5-ylcarbamate; methyl N-[3-(2-acetamidoethyl)-1H-indol-5-yl]carbamate; Methyl {3-[2-(Acetylamino)ethyl]-1h-Indol-5-Yl}carbamate; Methyl [3-[2-(acetylamino)ethyl]-1H-indol-5-yl]carbamate; Tocris-0896; AC1N7T0H; GTPL3393; SCHEMBL4655625; CTK6J2921; CHEBI:93457; DTXSID70401560; MPZVHKLZCUEJFO-UHFFFAOYSA-N; MolPort-003-848-587; HMS3266P16; ZINC2567732; BN0231; BDBM50260394; PDSP2_001790
DMCZSP3	DT	Small molecular drug
DMCZSP3	PC	4284525
DMCZSP3	MW	275.3
DMCZSP3	FM	C14H17N3O3
DMCZSP3	IC	InChI=1S/C14H17N3O3/c1-9(18)15-6-5-10-8-16-13-4-3-11(7-12(10)13)17-14(19)20-2/h3-4,7-8,16H,5-6H2,1-2H3,(H,15,18)(H,17,19)
DMCZSP3	CS	CC(=O)NCCC1=CNC2=C1C=C(C=C2)NC(=O)OC
DMCZSP3	IK	MPZVHKLZCUEJFO-UHFFFAOYSA-N
DMCZSP3	IU	methyl N-[3-(2-acetamidoethyl)-1H-indol-5-yl]carbamate
DMCZSP3	CA	CAS 190277-13-5
DMCZSP3	CB	CHEBI:93457
DMCZSP3	DE	Discovery agent

DMQX3V9	ID	DMQX3V9
DMQX3V9	DN	5-Methoxyflavone
DMQX3V9	HS	Investigative
DMQX3V9	SN	5-Methoxyflavone; 42079-78-7; 5-methoxy-2-phenyl-4h-chromen-4-one; 5-methoxy-2-phenylchromen-4-one; 5-Methoxy-2-phenyl-4-benzopyrone; CHEMBL16685; 4H-1-Benzopyran-4-one, 5-methoxy-2-phenyl-; 5-Methoxy-2-phenyl-chromen-4-one; MFCD00016942; ST069360; EINECS 255-652-0; 5 - Methoxyflavone; ACMC-20am2h; AC1Q6AKD; AC1L3SE9; Oprea1_859852; Oprea1_842256; BIDD:ER0473; ghl.PD_Mitscher_leg0.1155; ZINC5954; MEGxp0_001704; SCHEMBL1629391; ACon1_000175; DTXSID40194917; XRQSPUXANRGDAV-UHFFFAOYSA-N; MolPort-001-742-472; KS-000014KU; BDBM50296862
DMQX3V9	DT	Small molecular drug
DMQX3V9	PC	94525
DMQX3V9	MW	252.26
DMQX3V9	FM	C16H12O3
DMQX3V9	IC	InChI=1S/C16H12O3/c1-18-13-8-5-9-14-16(13)12(17)10-15(19-14)11-6-3-2-4-7-11/h2-10H,1H3
DMQX3V9	CS	COC1=CC=CC2=C1C(=O)C=C(O2)C3=CC=CC=C3
DMQX3V9	IK	XRQSPUXANRGDAV-UHFFFAOYSA-N
DMQX3V9	IU	5-methoxy-2-phenylchromen-4-one
DMQX3V9	CA	CAS 42079-78-7
DMQX3V9	DE	Discovery agent

DMUXTWC	ID	DMUXTWC
DMUXTWC	DN	5-methoxy-luzindole
DMUXTWC	HS	Investigative
DMUXTWC	SN	5-methoxyluzindole
DMUXTWC	DT	Small molecular drug
DMUXTWC	PC	129776
DMUXTWC	MW	322.4
DMUXTWC	FM	C20H22N2O2
DMUXTWC	IC	InChI=1S/C20H22N2O2/c1-14(23)21-11-10-17-18-13-16(24-2)8-9-19(18)22-20(17)12-15-6-4-3-5-7-15/h3-9,13,22H,10-12H2,1-2H3,(H,21,23)
DMUXTWC	CS	CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)CC3=CC=CC=C3
DMUXTWC	IK	MUQOTEHRXIKHKR-UHFFFAOYSA-N
DMUXTWC	IU	N-[2-(2-benzyl-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMUXTWC	CA	CAS 122853-28-5
DMUXTWC	DE	Discovery agent

DMJ1HX2	ID	DMJ1HX2
DMJ1HX2	DN	5-Methoxymethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMJ1HX2	HS	Investigative
DMJ1HX2	SN	CHEMBL18334; 5-Methoxymethyl-3-pyrrol-1-yl-oxazolidin-2-one; BDBM50110719; 2-Oxazolidinone, 5-(methoxymethyl)-3-(1H-pyrrol-1-yl)-, (5R)-; 406934-10-9
DMJ1HX2	DT	Small molecular drug
DMJ1HX2	PC	11019781
DMJ1HX2	MW	196.2
DMJ1HX2	FM	C9H12N2O3
DMJ1HX2	IC	InChI=1S/C9H12N2O3/c1-13-7-8-6-11(9(12)14-8)10-4-2-3-5-10/h2-5,8H,6-7H2,1H3/t8-/m0/s1
DMJ1HX2	CS	COC[C@@H]1CN(C(=O)O1)N2C=CC=C2
DMJ1HX2	IK	RWCYHUWSHCXNRR-QMMMGPOBSA-N
DMJ1HX2	IU	(5S)-5-(methoxymethyl)-3-pyrrol-1-yl-1,3-oxazolidin-2-one
DMJ1HX2	DE	Discovery agent

DM98EQX	ID	DM98EQX
DM98EQX	DN	5-Methoxy-N-phenylbenzo[d]oxazol-2-amine
DM98EQX	HS	Investigative
DM98EQX	SN	CHEMBL1269705; 5-Methoxy-N-phenylbenzo[d]oxazol-2-amine
DM98EQX	DT	Small molecular drug
DM98EQX	PC	16117802
DM98EQX	MW	240.26
DM98EQX	FM	C14H12N2O2
DM98EQX	IC	InChI=1S/C14H12N2O2/c1-17-11-7-8-13-12(9-11)16-14(18-13)15-10-5-3-2-4-6-10/h2-9H,1H3,(H,15,16)
DM98EQX	CS	COC1=CC2=C(C=C1)OC(=N2)NC3=CC=CC=C3
DM98EQX	IK	PZJKFSCOZOTZRO-UHFFFAOYSA-N
DM98EQX	IU	5-methoxy-N-phenyl-1,3-benzoxazol-2-amine
DM98EQX	DE	Discovery agent

DMARCKD	ID	DMARCKD
DMARCKD	DN	5-METHOXYTRYPTAMINE
DMARCKD	HS	Investigative
DMARCKD	SN	5-METHOXYTRYPTAMINE; 608-07-1; 2-(5-Methoxy-1H-indol-3-yl)ethanamine; Mexamine; Methoxytryptamine; 3-(2-Aminoethyl)-5-methoxyindole; Mexamine base; 5MOT; 5-Mot; 1H-Indole-3-ethanamine, 5-methoxy-; 2-(5-Methoxyindol-3-yl)ethylamine; Meksamin; Meksamin (free base); 5-MeOT; O-Methylserotonin; 2-(5-Methoxy-1H-Indol-3-Yl)Ethan-1-Amine; NSC 56422; 5-MT; UNII-3VMW6141KC; INDOLE, 3-(2-AMINOETHYL)-5-METHOXY-; 5-methoxy-1H-indole-3-ethanamine; EINECS 210-153-7; Lopac-M-6628; 5-Methoxytryptamine, 97%; BRN 0145587; CHEMBL8165; 3VMW6141KC
DMARCKD	DT	Small molecular drug
DMARCKD	PC	1833
DMARCKD	MW	190.24
DMARCKD	FM	C11H14N2O
DMARCKD	IC	InChI=1S/C11H14N2O/c1-14-9-2-3-11-10(6-9)8(4-5-12)7-13-11/h2-3,6-7,13H,4-5,12H2,1H3
DMARCKD	CS	COC1=CC2=C(C=C1)NC=C2CCN
DMARCKD	IK	JTEJPPKMYBDEMY-UHFFFAOYSA-N
DMARCKD	IU	2-(5-methoxy-1H-indol-3-yl)ethanamine
DMARCKD	CA	CAS 608-07-1
DMARCKD	CB	CHEBI:2089
DMARCKD	DE	Discovery agent

DM0AIOW	ID	DM0AIOW
DM0AIOW	DN	5-methyl nicotinic acid
DM0AIOW	HS	Investigative
DM0AIOW	SN	5-Methylnicotinic acid; 3222-49-9; 5-methylpyridine-3-carboxylic acid; 5-Methyl-nicotinic acid; 5-methyl nicotinic acid; CHEMBL247132; DJDHHXDFKSLEQY-UHFFFAOYSA-N; MFCD00829036; 3-Pyridinecarboxylic acid, 5-methyl-; 5-METHYL-3-PYRIDINECARBOXYLIC ACID; 5-Methylnicotinic acid, 97%; 5-methyinicotinic acid; PubChem11961; ACMC-1AFVP; 5-methyl nicotinic aicd; EC 608-720-2; AC1L5U3L; Nicotinic acid, 5-methyl-; AC1Q5UC0; NCIOpen2_001043; 5-METHYLNICOTIC ACID; KSC222G7T; SCHEMBL185789; GTPL1592; Jsp005966; CTK1C2379; DTXSID60292444
DM0AIOW	DT	Small molecular drug
DM0AIOW	PC	256208
DM0AIOW	MW	137.14
DM0AIOW	FM	C7H7NO2
DM0AIOW	IC	InChI=1S/C7H7NO2/c1-5-2-6(7(9)10)4-8-3-5/h2-4H,1H3,(H,9,10)
DM0AIOW	CS	CC1=CC(=CN=C1)C(=O)O
DM0AIOW	IK	DJDHHXDFKSLEQY-UHFFFAOYSA-N
DM0AIOW	IU	5-methylpyridine-3-carboxylic acid
DM0AIOW	CA	CAS 3222-49-9
DM0AIOW	DE	Discovery agent

DMYNFIP	ID	DMYNFIP
DMYNFIP	DN	5-methyl orotate
DMYNFIP	HS	Investigative
DMYNFIP	SN	AC1LAAV1; SCHEMBL15531476; 4-[4-[[11-butyl-9-[(R)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid
DMYNFIP	DT	Small molecular drug
DMYNFIP	PC	464989
DMYNFIP	MW	577.7
DMYNFIP	FM	C33H43N3O6
DMYNFIP	IC	InChI=1S/C33H43N3O6/c1-2-3-19-36-30(38)28(29(37)24-7-5-4-6-8-24)34-32(41)33(36)17-20-35(21-18-33)22-23-9-13-26(14-10-23)42-27-15-11-25(12-16-27)31(39)40/h9-16,24,28-29,37H,2-8,17-22H2,1H3,(H,34,41)(H,39,40)/t28?,29-/m1/s1
DMYNFIP	CS	CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@@H](C5CCCCC5)O
DMYNFIP	IK	GWNOTCOIYUNTQP-YPJJGMIRSA-N
DMYNFIP	IU	4-[4-[[1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid
DMYNFIP	DE	Discovery agent

DM0E1Y9	ID	DM0E1Y9
DM0E1Y9	DN	5-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM0E1Y9	HS	Investigative
DM0E1Y9	SN	CHEMBL319551; 2H-Imidazo[4,5-b]quinolin-2-one, 1,3-dihydro-5-methyl-; BDBM50229556
DM0E1Y9	DT	Small molecular drug
DM0E1Y9	PC	15065143
DM0E1Y9	MW	199.21
DM0E1Y9	FM	C11H9N3O
DM0E1Y9	IC	InChI=1S/C11H9N3O/c1-6-3-2-4-7-5-8-10(13-9(6)7)14-11(15)12-8/h2-5H,1H3,(H2,12,13,14,15)
DM0E1Y9	CS	CC1=C2C(=CC=C1)C=C3C(=N2)NC(=O)N3
DM0E1Y9	IK	YZNZOJPHYDBVIZ-UHFFFAOYSA-N
DM0E1Y9	IU	5-methyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DM0E1Y9	DE	Discovery agent

DMC10HG	ID	DMC10HG
DMC10HG	DN	5-methyl-2-(phenylsulfonamido)benzoic acid
DMC10HG	HS	Investigative
DMC10HG	SN	5-Methyl-2-[(phenylsulfonyl)amino]benzoic acid; 5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID; 2-benzenesulfonamido-5-methylbenzoic acid; A41; 1yw7; sulfonamide compound, 4; AC1O0UU4; SCHEMBL2009251; CHEMBL378927; Anthranilic Acid Sulfonamide, 4; BDBM17477; MolPort-004-356-849; HMS3604F08; STK978137; ZINC14964411; AKOS000202786; MCULE-6409447208; DB07313; 138964-56-4; 2-(benzenesulfonamido)-5-methylbenzoic acid; A444148
DMC10HG	DT	Small molecular drug
DMC10HG	PC	6102684
DMC10HG	MW	291.32
DMC10HG	FM	C14H13NO4S
DMC10HG	IC	InChI=1S/C14H13NO4S/c1-10-7-8-13(12(9-10)14(16)17)15-20(18,19)11-5-3-2-4-6-11/h2-9,15H,1H3,(H,16,17)
DMC10HG	CS	CC1=CC(=C(C=C1)NS(=O)(=O)C2=CC=CC=C2)C(=O)O
DMC10HG	IK	HXQLTRSIZRSFTR-UHFFFAOYSA-N
DMC10HG	IU	2-(benzenesulfonamido)-5-methylbenzoic acid
DMC10HG	DE	Discovery agent

DMAR4ZF	ID	DMAR4ZF
DMAR4ZF	DN	5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMAR4ZF	HS	Investigative
DMAR4ZF	SN	CHEMBL352049; 5-Methyl-2-pyridin-2-yl-1H-benzoimidazole; 7471-12-7; NSC403547; AC1L83HW; TimTec1_008296; 5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole; SCHEMBL124267; SCHEMBL12119033; DTXSID20323304; HMS1557J02; CCG-24525; BDBM50180733; ZINC12481420; AKOS002999038; AKOS000636609; NSC-403547; BAS 06347449; 6-methyl-2-pyridin-2-yl-1H-benzimidazole; 6-Methyl-2-(2-pyridyl)-1H-benzimidazole; KB-249126; US8748618, LD-2-11; 6-methyl-2-pyridin-2-yl-1h-benzo[d]imidazole
DMAR4ZF	DT	Small molecular drug
DMAR4ZF	PC	345772
DMAR4ZF	MW	209.25
DMAR4ZF	FM	C13H11N3
DMAR4ZF	IC	InChI=1S/C13H11N3/c1-9-5-6-10-12(8-9)16-13(15-10)11-4-2-3-7-14-11/h2-8H,1H3,(H,15,16)
DMAR4ZF	CS	CC1=CC2=C(C=C1)N=C(N2)C3=CC=CC=N3
DMAR4ZF	IK	HFYFOFMVURXVSD-UHFFFAOYSA-N
DMAR4ZF	IU	6-methyl-2-pyridin-2-yl-1H-benzimidazole
DMAR4ZF	CA	CAS 7471-12-7
DMAR4ZF	DE	Discovery agent

DMH1IVN	ID	DMH1IVN
DMH1IVN	DN	5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMH1IVN	HS	Investigative
DMH1IVN	SN	NSC676186; AC1L8OZL; CHEMBL317272; SCHEMBL7920133; CTK8D2147; ZINC5504116; NSC-676186; NCI60_026913; 5-methyl-2-(3-methylphenyl)-1,8-naphthyridin-4-ol; 5-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMH1IVN	DT	Small molecular drug
DMH1IVN	PC	385182
DMH1IVN	MW	250.29
DMH1IVN	FM	C16H14N2O
DMH1IVN	IC	InChI=1S/C16H14N2O/c1-10-4-3-5-12(8-10)13-9-14(19)15-11(2)6-7-17-16(15)18-13/h3-9H,1-2H3,(H,17,18,19)
DMH1IVN	CS	CC1=CC(=CC=C1)C2=CC(=O)C3=C(C=CN=C3N2)C
DMH1IVN	IK	ZLZNSSZWWMBAMD-UHFFFAOYSA-N
DMH1IVN	IU	5-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMH1IVN	DE	Discovery agent

DMIE9BG	ID	DMIE9BG
DMIE9BG	DN	5-Methyl-2-p-tolyl-thiazol-4-ol
DMIE9BG	HS	Investigative
DMIE9BG	SN	CHEMBL69094; 5-Methyl-2-p-tolyl-thiazol-4-ol; 4-Thiazolol, 5-methyl-2-(4-methylphenyl)-; SCHEMBL9629237; BDBM50012393; 131786-76-0
DMIE9BG	DT	Small molecular drug
DMIE9BG	PC	15691812
DMIE9BG	MW	205.28
DMIE9BG	FM	C11H11NOS
DMIE9BG	IC	InChI=1S/C11H11NOS/c1-7-3-5-9(6-4-7)11-12-10(13)8(2)14-11/h3-6,13H,1-2H3
DMIE9BG	CS	CC1=CC=C(C=C1)C2=NC(=C(S2)C)O
DMIE9BG	IK	CKXYNXQZWQQOOO-UHFFFAOYSA-N
DMIE9BG	IU	5-methyl-2-(4-methylphenyl)-1,3-thiazol-4-ol
DMIE9BG	DE	Discovery agent

DM0G2N5	ID	DM0G2N5
DM0G2N5	DN	5-Methyl-3,4-diphenyl-isoxazole
DM0G2N5	HS	Investigative
DM0G2N5	SN	5-Methyl-3,4-diphenylisoxazole; 37928-17-9; 5-Methyl-3,4-diphenyl-isoxazole; 5-methyl-3,4-diphenyl-1,2-oxazole; CHEMBL365033; Isoxazole, 5-methyl-3,4-diphenyl-; AK110518; SCHEMBL2277199; 3,4-Diphenyl-5-methylisoxazole; DTXSID40433813; 3,4-diphenyl-5-methyl isoxazole; 5-methyl-3,4-diphenyl isoxazole; 3,4-diphenyl-5-methyl-isoxazole; ZXIRUKJWLADSJS-UHFFFAOYSA-N; MolPort-027-835-429; KS-00000PQ9; Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate); ZINC12352313; BDBM50153036; AKOS016008848; VO10067; DS-4629; LS40778
DM0G2N5	DT	Small molecular drug
DM0G2N5	PC	9991673
DM0G2N5	MW	235.28
DM0G2N5	FM	C16H13NO
DM0G2N5	IC	InChI=1S/C16H13NO/c1-12-15(13-8-4-2-5-9-13)16(17-18-12)14-10-6-3-7-11-14/h2-11H,1H3
DM0G2N5	CS	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=CC=C3
DM0G2N5	IK	ZXIRUKJWLADSJS-UHFFFAOYSA-N
DM0G2N5	IU	5-methyl-3,4-diphenyl-1,2-oxazole
DM0G2N5	CA	CAS 37928-17-9
DM0G2N5	DE	Discovery agent

DMF0IJ2	ID	DMF0IJ2
DMF0IJ2	DN	5-methyl-3-phenylethynyl[1,2,4]triazine
DMF0IJ2	HS	Investigative
DMF0IJ2	SN	CHEMBL227199; 5-methyl-3-phenylethynyl[1,2,4]triazine; 1,2,4-Triazine, 5-methyl-3-(2-phenylethynyl)-; BDBM50215455; 945915-49-1
DMF0IJ2	DT	Small molecular drug
DMF0IJ2	PC	16736030
DMF0IJ2	MW	195.22
DMF0IJ2	FM	C12H9N3
DMF0IJ2	IC	InChI=1S/C12H9N3/c1-10-9-13-15-12(14-10)8-7-11-5-3-2-4-6-11/h2-6,9H,1H3
DMF0IJ2	CS	CC1=CN=NC(=N1)C#CC2=CC=CC=C2
DMF0IJ2	IK	PXUGAXNBWJVVQY-UHFFFAOYSA-N
DMF0IJ2	IU	5-methyl-3-(2-phenylethynyl)-1,2,4-triazine
DMF0IJ2	CA	CAS 945915-49-1
DMF0IJ2	DE	Discovery agent

DM6DEOC	ID	DM6DEOC
DM6DEOC	DN	5-Methyl-4-propyl-pyrrolidin-(2Z)-ylideneamine
DM6DEOC	HS	Investigative
DM6DEOC	SN	CHEMBL362366; 5-Methyl-4-propyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150912
DM6DEOC	DT	Small molecular drug
DM6DEOC	PC	19049152
DM6DEOC	MW	140.23
DM6DEOC	FM	C8H16N2
DM6DEOC	IC	InChI=1S/C8H16N2/c1-3-4-7-5-8(9)10-6(7)2/h6-7H,3-5H2,1-2H3,(H2,9,10)
DM6DEOC	CS	CCCC1CC(=NC1C)N
DM6DEOC	IK	KBOKLILFNBAIHC-UHFFFAOYSA-N
DM6DEOC	IU	2-methyl-3-propyl-3,4-dihydro-2H-pyrrol-5-amine
DM6DEOC	DE	Discovery agent

DMO37W4	ID	DMO37W4
DMO37W4	DN	5-methyl-5-(5-methylthiophen-3-yl)-4-oxo-4,5-dihydrofuran-2-carboxylic acid
DMO37W4	HS	Investigative
DMO37W4	SN	compound 5aj [PMID: 17358052]
DMO37W4	DT	Small molecular drug
DMO37W4	PC	11436345
DMO37W4	MW	238.26
DMO37W4	FM	C11H10O4S
DMO37W4	IC	InChI=1S/C11H10O4S/c1-6-3-7(5-16-6)11(2)9(12)4-8(15-11)10(13)14/h3-5H,1-2H3,(H,13,14)
DMO37W4	CS	CC1=CC(=CS1)C2(C(=O)C=C(O2)C(=O)O)C
DMO37W4	IK	NNWGOUJBCKZULC-UHFFFAOYSA-N
DMO37W4	IU	5-methyl-5-(5-methylthiophen-3-yl)-4-oxofuran-2-carboxylic acid
DMO37W4	DE	Discovery agent

DMRMKXD	ID	DMRMKXD
DMRMKXD	DN	5-Methyl-5-phenyl-pyrimidine-2,4,6-trione
DMRMKXD	HS	Investigative
DMRMKXD	SN	Heptobarbital; Mephebarbital; Eudan; Phenylmethylbarbituric acid; Rutonal; Methylphenylbarbital; 5-Methyl-5-phenylbarbituric acid; 5-Methyl-5-phenylbarbityric acid; 76-94-8; 5-Phenyl-5-methylbarbituric acid; NSC 80543; Barbituric acid, 5-methyl-5-phenyl-; UNII-GFR227X6YY; 5-Methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; EINECS 200-994-8; BRN 0201825; GFR227X6YY; CHEMBL329617; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-methyl-5-phenyl-; 5-methyl-5-phenyl-barbituric acid; C11H10N2O3; 5-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMRMKXD	DT	Small molecular drug
DMRMKXD	PC	66160
DMRMKXD	MW	218.21
DMRMKXD	FM	C11H10N2O3
DMRMKXD	IC	InChI=1S/C11H10N2O3/c1-11(7-5-3-2-4-6-7)8(14)12-10(16)13-9(11)15/h2-6H,1H3,(H2,12,13,14,15,16)
DMRMKXD	CS	CC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
DMRMKXD	IK	LSAOZCAKUIANSQ-UHFFFAOYSA-N
DMRMKXD	IU	5-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMRMKXD	CA	CAS 76-94-8
DMRMKXD	CB	CHEBI:134900
DMRMKXD	DE	Discovery agent

DMLJVB7	ID	DMLJVB7
DMLJVB7	DN	5-methyl-benzo[b]thiophen-2-ylboronic acid
DMLJVB7	HS	Investigative
DMLJVB7	SN	5-methylbenzo[b]thiophene-2-boronic acid; 136099-65-5; 5-METHYLBENZOTHIPHENE-2-BORONIC ACID; 5-methylbenzo[b]thiophen-2-ylboronic acid; CHEMBL238243; 5-METHYLBENZOTHIOPHENE-2-BORONIC ACID; (5-methyl-1-benzothiophen-2-yl)boronic acid; 5-methyl-1-benzothiophen-2-ylboronic acid; (5-methylbenzothiophen-2-yl)boronic Acid; AC1MDRK8; 5-methyl-benzo[b]thiophen-2-ylboronic acid; C9H9BO2S; SCHEMBL289762; CTK6C0387; DTXSID20383286; MolPort-000-145-050; DHNHZPQPQAINDI-UHFFFAOYSA-N; 2-Borono-5-methylbenzo[b]thiophene; 6437AA; SBB091358
DMLJVB7	DT	Small molecular drug
DMLJVB7	PC	2794641
DMLJVB7	MW	192.05
DMLJVB7	FM	C9H9BO2S
DMLJVB7	IC	InChI=1S/C9H9BO2S/c1-6-2-3-8-7(4-6)5-9(13-8)10(11)12/h2-5,11-12H,1H3
DMLJVB7	CS	B(C1=CC2=C(S1)C=CC(=C2)C)(O)O
DMLJVB7	IK	DHNHZPQPQAINDI-UHFFFAOYSA-N
DMLJVB7	IU	(5-methyl-1-benzothiophen-2-yl)boronic acid
DMLJVB7	CA	CAS 136099-65-5
DMLJVB7	DE	Discovery agent

DMRC8SO	ID	DMRC8SO
DMRC8SO	DN	5-methyl-cyclosal-d4TMP
DMRC8SO	HS	Investigative
DMRC8SO	SN	CHEMBL223807; BDBM50206639; 5-methyl-cyclosal-d4TMP; 5-Methyl-1-[(2R,5S)-5-(6-methyl-2-oxo-4H-2lambda*5*-benzo[1,3,2]dioxaphosphinin-2-yloxymethyl)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione; 5-Me-CycloSal-d4TMP; AC1LABZ0; CHEMBL8458; BDBM50064051; 5-methyl-1-[(2R,5S)-5-[(6-methyl-2-oxo-4H-1,3,2; 5-Methyl-1-[5-(6-methyl-2-oxo-4H-2lambda*5*-benzo[1,3,2]dioxaphosphinin-2-yloxymethyl)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione
DMRC8SO	DT	Small molecular drug
DMRC8SO	PC	465615
DMRC8SO	MW	406.3
DMRC8SO	FM	C18H19N2O7P
DMRC8SO	IC	InChI=1S/C18H19N2O7P/c1-11-3-5-15-13(7-11)9-24-28(23,27-15)25-10-14-4-6-16(26-14)20-8-12(2)17(21)19-18(20)22/h3-8,14,16H,9-10H2,1-2H3,(H,19,21,22)/t14-,16+,28?/m0/s1
DMRC8SO	CS	CC1=CC2=C(C=C1)OP(=O)(OC2)OC[C@@H]3C=C[C@@H](O3)N4C=C(C(=O)NC4=O)C
DMRC8SO	IK	XCQZHNHBKUHUEJ-NIGMZYBYSA-N
DMRC8SO	IU	5-methyl-1-[(2R,5S)-5-[(6-methyl-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl)oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione
DMRC8SO	DE	Discovery agent

DMIQ1X3	ID	DMIQ1X3
DMIQ1X3	DN	5-methylenearisteromycin
DMIQ1X3	HS	Investigative
DMIQ1X3	SN	CHEMBL262063; 5-methylenearisteromycin; 5'-Methylenearisteromycin; BDBM50373100
DMIQ1X3	DT	Small molecular drug
DMIQ1X3	PC	11737492
DMIQ1X3	MW	277.28
DMIQ1X3	FM	C12H15N5O3
DMIQ1X3	IC	InChI=1S/C12H15N5O3/c1-5-6(2-18)9(19)10(20)8(5)17-4-16-7-11(13)14-3-15-12(7)17/h3-4,6,8-10,18-20H,1-2H2,(H2,13,14,15)/t6-,8+,9+,10-/m0/s1
DMIQ1X3	CS	C=C1[C@@H]([C@H]([C@H]([C@@H]1N2C=NC3=C(N=CN=C32)N)O)O)CO
DMIQ1X3	IK	REGXGANNNMTWAW-ZQNVIIHSSA-N
DMIQ1X3	IU	(1R,2S,3R,5R)-3-(6-aminopurin-9-yl)-5-(hydroxymethyl)-4-methylidenecyclopentane-1,2-diol
DMIQ1X3	DE	Discovery agent

DMNJ0XZ	ID	DMNJ0XZ
DMNJ0XZ	DN	5-Methyl-N-phenylbenzo[d]oxazol-2-amine
DMNJ0XZ	HS	Investigative
DMNJ0XZ	SN	CHEMBL1269622; 5-Methyl-N-phenylbenzo[d]oxazol-2-amine; SCHEMBL13436713; BDBM50329396; N-Phenyl-5-methylbenzoxazole-2-amine; (5-methyl-benzooxazol-2-yl)-phenyl-amine; 5-methyl-N-phenyl-1,3-benzoxazol-2-amine
DMNJ0XZ	DT	Small molecular drug
DMNJ0XZ	PC	12751500
DMNJ0XZ	MW	224.26
DMNJ0XZ	FM	C14H12N2O
DMNJ0XZ	IC	InChI=1S/C14H12N2O/c1-10-7-8-13-12(9-10)16-14(17-13)15-11-5-3-2-4-6-11/h2-9H,1H3,(H,15,16)
DMNJ0XZ	CS	CC1=CC2=C(C=C1)OC(=N2)NC3=CC=CC=C3
DMNJ0XZ	IK	SJERMAXXFIXBCQ-UHFFFAOYSA-N
DMNJ0XZ	IU	5-methyl-N-phenyl-1,3-benzoxazol-2-amine
DMNJ0XZ	DE	Discovery agent

DMBQS31	ID	DMBQS31
DMBQS31	DN	5-Methyl-oxazolidin-(2Z)-ylideneamine
DMBQS31	HS	Investigative
DMBQS31	SN	CHEMBL107413; 5-Methyl-oxazolidin-(2Z)-ylideneamine; 2-imino-5-methyloxazolidine; 5-Methyl-2-iminooxazolidine; SCHEMBL8968765; SCHEMBL6592796; BDBM50138201; AKOS006350070; AKOS013498557; 5-methyl-4,5-dihydro-oxazol-2-ylamine
DMBQS31	DT	Small molecular drug
DMBQS31	PC	12495134
DMBQS31	MW	100.12
DMBQS31	FM	C4H8N2O
DMBQS31	IC	InChI=1S/C4H8N2O/c1-3-2-6-4(5)7-3/h3H,2H2,1H3,(H2,5,6)
DMBQS31	CS	CC1CN=C(O1)N
DMBQS31	IK	ZHFKVNRMZIOKGZ-UHFFFAOYSA-N
DMBQS31	IU	5-methyl-4,5-dihydro-1,3-oxazol-2-amine
DMBQS31	DE	Discovery agent

DM4QB3G	ID	DM4QB3G
DM4QB3G	DN	5-Methyl-pyrrolidin-(2Z)-ylideneamine
DM4QB3G	HS	Investigative
DM4QB3G	SN	CHEMBL182305; CHEMBL555587; 5-Methylpyrrolidine-2-imine; BDBM50066782; AKOS006365094; 5-Methyl-pyrrolidin-(2E)-ylideneamine
DM4QB3G	DT	Small molecular drug
DM4QB3G	PC	12778906
DM4QB3G	MW	98.15
DM4QB3G	FM	C5H10N2
DM4QB3G	IC	InChI=1S/C5H10N2/c1-4-2-3-5(6)7-4/h4H,2-3H2,1H3,(H2,6,7)
DM4QB3G	CS	CC1CCC(=N1)N
DM4QB3G	IK	DDQFWSHGBVMBEM-UHFFFAOYSA-N
DM4QB3G	IU	2-methyl-3,4-dihydro-2H-pyrrol-5-amine
DM4QB3G	DE	Discovery agent

DMYERNM	ID	DMYERNM
DMYERNM	DN	5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMYERNM	HS	Investigative
DMYERNM	SN	CHEMBL201723; 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMYERNM	DT	Small molecular drug
DMYERNM	PC	44407565
DMYERNM	MW	250.25
DMYERNM	FM	C15H10N2O2
DMYERNM	IC	InChI=1S/C15H10N2O2/c1-7-6-9-12(15(19)17-14(9)18)11-8-4-2-3-5-10(8)16-13(7)11/h2-6,16H,1H3,(H,17,18,19)
DMYERNM	CS	CC1=CC2=C(C3=C1NC4=CC=CC=C43)C(=O)NC2=O
DMYERNM	IK	IMEDEXINTFAKNV-UHFFFAOYSA-N
DMYERNM	IU	5-methyl-6H-pyrrolo[3,4-c]carbazole-1,3-dione
DMYERNM	DE	Discovery agent

DM3MVSD	ID	DM3MVSD
DM3MVSD	DN	5-Methylsulfanyl-thiophene-2-carboxamidine
DM3MVSD	HS	Investigative
DM3MVSD	SN	CHEMBL28890; 5-Methylsulfanyl-thiophene-2-carboxamidine; 2-Thiophenecarboximidamide, 5-(methylthio)-; SCHEMBL5982145; AXSQTCBARFBKPH-UHFFFAOYSA-N; BDBM50099912; 5-methylthiothiophene-2-carboxamidine
DM3MVSD	DT	Small molecular drug
DM3MVSD	PC	10313318
DM3MVSD	MW	172.3
DM3MVSD	FM	C6H8N2S2
DM3MVSD	IC	InChI=1S/C6H8N2S2/c1-9-5-3-2-4(10-5)6(7)8/h2-3H,1H3,(H3,7,8)
DM3MVSD	CS	CSC1=CC=C(S1)C(=N)N
DM3MVSD	IK	AXSQTCBARFBKPH-UHFFFAOYSA-N
DM3MVSD	IU	5-methylsulfanylthiophene-2-carboximidamide
DM3MVSD	DE	Discovery agent

DM3LY0Q	ID	DM3LY0Q
DM3LY0Q	DN	5'-Methylthio-ImmH
DM3LY0Q	HS	Investigative
DM3LY0Q	DT	Small molecular drug
DM3LY0Q	PC	135509131
DM3LY0Q	MW	296.35
DM3LY0Q	FM	C12H16N4O3S
DM3LY0Q	IC	InChI=1S/C12H16N4O3S/c1-20-3-6-10(17)11(18)8(16-6)5-2-13-9-7(5)14-4-15-12(9)19/h2,4,6,8,10-11,13,16-18H,3H2,1H3,(H,14,15,19)/t6-,8+,10-,11+/m1/s1
DM3LY0Q	CS	CSC[C@@H]1[C@H]([C@H]([C@@H](N1)C2=CNC3=C2N=CNC3=O)O)O
DM3LY0Q	IK	CEGIKIXYDFDYDN-RXDXJJGDSA-N
DM3LY0Q	IU	7-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(methylsulfanylmethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DM3LY0Q	DE	Discovery agent

DMK52UH	ID	DMK52UH
DMK52UH	DN	5'-methylthio-immucillin-H
DMK52UH	HS	Investigative
DMK52UH	PC	136002688
DMK52UH	MW	282.32
DMK52UH	FM	C11H14N4O3S
DMK52UH	IC	InChI=1S/C11H14N4O3S/c1-19-11-9(17)8(16)6(15-11)5-2-4-7(14-5)10(18)13-3-12-4/h2-3,6,8-9,11,14-17H,1H3,(H,12,13,18)/t6-,8-,9-,11+/m0/s1
DMK52UH	CS	CS[C@@H]1[C@H]([C@H]([C@@H](N1)C2=CC3=C(N2)C(=O)NC=N3)O)O
DMK52UH	IK	ZXECYVBSYKBAAH-MRQALGCZSA-N
DMK52UH	IU	6-[(2S,3S,4S,5R)-3,4-dihydroxy-5-methylsulfanylpyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMK52UH	DE	Discovery agent

DMCX9WN	ID	DMCX9WN
DMCX9WN	DN	5-methylurapidil
DMCX9WN	HS	Investigative
DMCX9WN	SN	5 methylurapidil; 5-methyl-urapidil
DMCX9WN	DT	Small molecular drug
DMCX9WN	PC	5640
DMCX9WN	MW	401.5
DMCX9WN	FM	C21H31N5O3
DMCX9WN	IC	InChI=1S/C21H31N5O3/c1-16-19(23(2)21(28)24(3)20(16)27)22-10-7-11-25-12-14-26(15-13-25)17-8-5-6-9-18(17)29-4/h5-6,8-9,22H,7,10-15H2,1-4H3
DMCX9WN	CS	CC1=C(N(C(=O)N(C1=O)C)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC
DMCX9WN	IK	HIHZDNKKIUQQSC-UHFFFAOYSA-N
DMCX9WN	IU	6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3,5-trimethylpyrimidine-2,4-dione
DMCX9WN	CA	CAS 34661-85-3
DMCX9WN	DE	Discovery agent

DMX0EAK	ID	DMX0EAK
DMX0EAK	DN	5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine
DMX0EAK	HS	Investigative
DMX0EAK	SN	5--MONOPHOSPHATE-9-BETA-D-RIBOFURANOSYL XANTHINE; AC1O43SS; DB02309; 5-MONOPHOSPHATE-9-BETA-D-RIBOFURANOSYL XANTHINE; [(2R,3S,4R,5R)-5-(2,6-dioxo-3,7-dihydropurin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMX0EAK	DT	Small molecular drug
DMX0EAK	PC	6323540
DMX0EAK	MW	365.21
DMX0EAK	FM	C10H14N4O9P+
DMX0EAK	IC	InChI=1S/C10H13N4O9P/c15-5-3(1-22-24(19,20)21)23-9(6(5)16)14-2-11-4-7(14)12-10(18)13-8(4)17/h2-3,5-6,9,15-16H,1H2,(H4,12,13,17,18,19,20,21)/p+1/t3-,5-,6-,9-/m1/s1
DMX0EAK	CS	C1=[N+](C2=C(N1)C(=O)NC(=O)N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
DMX0EAK	IK	XHDARDSMKMUDDI-UUOKFMHZSA-O
DMX0EAK	IU	[(2R,3S,4R,5R)-5-(2,6-dioxo-3,7-dihydropurin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMX0EAK	DE	Discovery agent

DMSRGTI	ID	DMSRGTI
DMSRGTI	DN	5-MPEP
DMSRGTI	HS	Investigative
DMSRGTI	SN	5-Methyl-2-(phenylethynyl)pyridine; 124300-38-5; 5MPEP; 5-MPEP; GTPL1419; SCHEMBL3955825; CTK8E1822; 2-(Phenylethynyl)-5-methylpyridine; ZINC65731259; 6379AJ; 5-methyl-2-(2-phenylethynyl)pyridine; AKOS022184010; SY015649; KB-73636; AX8280780; AJ-115560; TC-307922; MFCD18205120 (95%)
DMSRGTI	DT	Small molecular drug
DMSRGTI	PC	14343211
DMSRGTI	MW	193.24
DMSRGTI	FM	C14H11N
DMSRGTI	IC	InChI=1S/C14H11N/c1-12-7-9-14(15-11-12)10-8-13-5-3-2-4-6-13/h2-7,9,11H,1H3
DMSRGTI	CS	CC1=CN=C(C=C1)C#CC2=CC=CC=C2
DMSRGTI	IK	HESJPHOOGDBABM-UHFFFAOYSA-N
DMSRGTI	IU	5-methyl-2-(2-phenylethynyl)pyridine
DMSRGTI	DE	Discovery agent

DMOSKJ8	ID	DMOSKJ8
DMOSKJ8	DN	5-N-Allyl-Arginine
DMOSKJ8	HS	Investigative
DMOSKJ8	SN	5-N-ALLYL-ARGININE; ARV; AC1NRA56; DB03892; N-[(1Z)-amino{[(4S)-4-amino-4-carboxybutyl]amino}methylidene]prop-2-en-1-aminium
DMOSKJ8	DT	Small molecular drug
DMOSKJ8	PC	5287706
DMOSKJ8	MW	215.27
DMOSKJ8	FM	C9H19N4O2+
DMOSKJ8	IC	InChI=1S/C9H18N4O2/c1-2-5-12-9(11)13-6-3-4-7(10)8(14)15/h2,7H,1,3-6,10H2,(H,14,15)(H3,11,12,13)/p+1/t7-/m0/s1
DMOSKJ8	CS	C=CCNC(=[NH+]CCC[C@@H](C(=O)O)N)N
DMOSKJ8	IK	ZPQWZDPOLXVMOU-ZETCQYMHSA-O
DMOSKJ8	IU	[(4S)-4-amino-4-carboxybutyl]-[amino-(prop-2-enylamino)methylidene]azanium
DMOSKJ8	DE	Discovery agent

DMK0PAL	ID	DMK0PAL
DMK0PAL	DN	5-Naphthalen-2-yl-1H-imidazole
DMK0PAL	HS	Investigative
DMK0PAL	SN	SCHEMBL2369049; BDBM8931; CHEMBL370822; 5-(2-Naphthyl)-1H-imidazole; 4-(2-Naphthyl)-1H-imidazole; BDBM220125; 5-(naphthalen-2-yl)-1h-imidazole; Imidazole-substituted naphthalene 27; ZINC13674488; US9271963, 27
DMK0PAL	DT	Small molecular drug
DMK0PAL	PC	21772021
DMK0PAL	MW	194.23
DMK0PAL	FM	C13H10N2
DMK0PAL	IC	InChI=1S/C13H10N2/c1-2-4-11-7-12(6-5-10(11)3-1)13-8-14-9-15-13/h1-9H,(H,14,15)
DMK0PAL	CS	C1=CC=C2C=C(C=CC2=C1)C3=CN=CN3
DMK0PAL	IK	CTUKWPHHWRYGEH-UHFFFAOYSA-N
DMK0PAL	IU	5-naphthalen-2-yl-1H-imidazole
DMK0PAL	DE	Discovery agent

DMTH3BW	ID	DMTH3BW
DMTH3BW	DN	5-Naphthalen-2-yl-oxazole
DMTH3BW	HS	Investigative
DMTH3BW	SN	143659-20-5; 5-(naphthalen-2-yl)-1,3-oxazole; 5-(2-naphthalenyl)Oxazole; 5-(Naphthalen-2-yl)oxazole; Oxazole,5-(2-naphthalenyl)-; 5-(2-naphthyl)-1,3-oxazole; 5-(2-Naphthyl)oxazole; ACMC-1C0FI; 5-(2-naph-thyl-)oxazol; SCHEMBL4500585; BDBM8928; CHEMBL193653; 5-Naphth-2-yl-1,3-oxazole; CTK4C3747; DTXSID10460853; MolPort-001-758-948; UQGCSVOKHFBQIP-UHFFFAOYSA-N; oxazole-substituted naphthalene 29; KS-00001PB5; ZX-AT019030; ZINC13674492; AKOS005254941; MCULE-4854701546; OR12565; GL-1006; KB-269976; AX8104945; DB-057999
DMTH3BW	DT	Small molecular drug
DMTH3BW	PC	11275595
DMTH3BW	MW	195.22
DMTH3BW	FM	C13H9NO
DMTH3BW	IC	InChI=1S/C13H9NO/c1-2-4-11-7-12(6-5-10(11)3-1)13-8-14-9-15-13/h1-9H
DMTH3BW	CS	C1=CC=C2C=C(C=CC2=C1)C3=CN=CO3
DMTH3BW	IK	UQGCSVOKHFBQIP-UHFFFAOYSA-N
DMTH3BW	IU	5-naphthalen-2-yl-1,3-oxazole
DMTH3BW	CA	CAS 143659-20-5
DMTH3BW	DE	Discovery agent

DMTS06Z	ID	DMTS06Z
DMTS06Z	DN	5-Nitro-1H-indole-2,3-dione
DMTS06Z	HS	Investigative
DMTS06Z	SN	5-Nitroisatin; 611-09-6; 5-Nitroindoline-2,3-dione; 5-Nitroindole-2,3-dione; 5-Nitro-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 5-nitro-; N-Nitroisatin; Isatin, 5-nitro-; INDOLE-2,3-DIONE, 5-NITRO-; CCRIS 4031; UNII-J4J633881Z; 5-Nitroisatin, 97%; EINECS 210-252-5; NSC 525798; 2,3-Dihydro-5-nitroindole-2,3-dione; BRN 0180223; CHEMBL118305; UNMYHYODJHKLOC-UHFFFAOYSA-N; J4J633881Z; 5-nitro-2,3-dihydro-1H-indole-2,3-dione; 5-Nitro isatin; Isatin, 5-nitro- (6CI); 5-nitroisatine; Isatin analog 3; NSC525798; PubChem15514; Indole-2, 5-nitro
DMTS06Z	DT	Small molecular drug
DMTS06Z	PC	4669250
DMTS06Z	MW	192.13
DMTS06Z	FM	C8H4N2O4
DMTS06Z	IC	InChI=1S/C8H4N2O4/c11-7-5-3-4(10(13)14)1-2-6(5)9-8(7)12/h1-3H,(H,9,11,12)
DMTS06Z	CS	C1=CC2=C(C=C1[N+](=O)[O-])C(=O)C(=O)N2
DMTS06Z	IK	UNMYHYODJHKLOC-UHFFFAOYSA-N
DMTS06Z	IU	5-nitro-1H-indole-2,3-dione
DMTS06Z	CA	CAS 611-09-6
DMTS06Z	CB	CHEBI:149791
DMTS06Z	DE	Discovery agent

DM26MIC	ID	DM26MIC
DM26MIC	DN	5-Nitro-2-(4-phenoxy-phenyl)-1H-benzoimidazole
DM26MIC	HS	Investigative
DM26MIC	SN	CHEMBL175481; 5-Nitro-2-(4-phenoxy-phenyl)-1H-benzoimidazole
DM26MIC	DT	Small molecular drug
DM26MIC	PC	11325003
DM26MIC	MW	331.3
DM26MIC	FM	C19H13N3O3
DM26MIC	IC	InChI=1S/C19H13N3O3/c23-22(24)14-8-11-17-18(12-14)21-19(20-17)13-6-9-16(10-7-13)25-15-4-2-1-3-5-15/h1-12H,(H,20,21)
DM26MIC	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=NC4=C(N3)C=C(C=C4)[N+](=O)[O-]
DM26MIC	IK	ZBWXPJPIZQAKGA-UHFFFAOYSA-N
DM26MIC	IU	6-nitro-2-(4-phenoxyphenyl)-1H-benzimidazole
DM26MIC	DE	Discovery agent

DMH7SIX	ID	DMH7SIX
DMH7SIX	DN	5-Nitroindazole
DMH7SIX	HS	Investigative
DMH7SIX	SN	5-Nitro-1H-indazole; 5401-94-5; 1H-INDAZOLE, 5-NITRO-; UNII-235Y7P37ZD; CCRIS 4134; NSC 5032; EINECS 226-451-5; BRN 0007936; CHEMBL165372; WSGURAYTCUVDQL-UHFFFAOYSA-N; 235Y7P37ZD; MFCD00005693; 5NI; 2H-Indazole, 5-nitro-; 5-Nitroindazol; 5-nitro indazole; 5-nitro-indazole; 5-nitro-1H-indazol; 5-nitro-IH-indazole; 5-nitro-2H-indazole; PubChem15672; 4lm0; AC1L2IGS; ACMC-209lc9; DSSTox_RID_83391; DSSTox_CID_29272; 5-Nitroindazole, &gt; DSSTox_GSID_49316; KSC490O7N; 5-Nitro-1H-indazole 99%; MLS000728712; 5-23-06-00180 (B
DMH7SIX	DT	Small molecular drug
DMH7SIX	PC	21501
DMH7SIX	MW	163.13
DMH7SIX	FM	C7H5N3O2
DMH7SIX	IC	InChI=1S/C7H5N3O2/c11-10(12)6-1-2-7-5(3-6)4-8-9-7/h1-4H,(H,8,9)
DMH7SIX	CS	C1=CC2=C(C=C1[N+](=O)[O-])C=NN2
DMH7SIX	IK	WSGURAYTCUVDQL-UHFFFAOYSA-N
DMH7SIX	IU	5-nitro-1H-indazole
DMH7SIX	CA	CAS 5401-94-5
DMH7SIX	DE	Discovery agent

DM4K8N2	ID	DM4K8N2
DM4K8N2	DN	5-nitroindirubin-3'-oxime
DM4K8N2	HS	Investigative
DM4K8N2	DT	Small molecular drug
DM4K8N2	PC	11450099
DM4K8N2	DE	Discovery agent

DM2DWUQ	ID	DM2DWUQ
DM2DWUQ	DN	5-Nonyl-5-phenyl-imidazolidine-2,4-dione
DM2DWUQ	HS	Investigative
DM2DWUQ	SN	CHEMBL39043
DM2DWUQ	DT	Small molecular drug
DM2DWUQ	PC	10518486
DM2DWUQ	MW	302.4
DM2DWUQ	FM	C18H26N2O2
DM2DWUQ	IC	InChI=1S/C18H26N2O2/c1-2-3-4-5-6-7-11-14-18(15-12-9-8-10-13-15)16(21)19-17(22)20-18/h8-10,12-13H,2-7,11,14H2,1H3,(H2,19,20,21,22)
DM2DWUQ	CS	CCCCCCCCCC1(C(=O)NC(=O)N1)C2=CC=CC=C2
DM2DWUQ	IK	YDNZJQWFOGASIE-UHFFFAOYSA-N
DM2DWUQ	IU	5-nonyl-5-phenylimidazolidine-2,4-dione
DM2DWUQ	DE	Discovery agent

DM74JL8	ID	DM74JL8
DM74JL8	DN	5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole
DM74JL8	HS	Investigative
DM74JL8	SN	UHDBT; 6-Hydroxy-5-undecyl-4,7-benzothiazoledione; 43152-58-5; 5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole; 4,7-Benzothiazoledione, 6-hydroxy-5-undecyl-; 6-HYDROXY-5-UNDECYL-1,3-BENZOTHIAZOLE-4,7-DIONE; 3-UNDECYL-2-HYDROXYDIOXOBENZOTHIAZOL; AC1MI2XQ; SCHEMBL6672079; CTK1D6913; DB04799; 4-hydroxy-5-undecyl-1,3-benzothiazole-6,7-dione; 3-UNDECYL-2-HYDROXYDIOXOBENZOTHIAZOL
DM74JL8	DT	Small molecular drug
DM74JL8	PC	3016416
DM74JL8	MW	335.5
DM74JL8	FM	C18H25NO3S
DM74JL8	IC	InChI=1S/C18H25NO3S/c1-2-3-4-5-6-7-8-9-10-11-13-15(20)14-18(23-12-19-14)17(22)16(13)21/h12,20H,2-11H2,1H3
DM74JL8	CS	CCCCCCCCCCCC1=C(C2=C(C(=O)C1=O)SC=N2)O
DM74JL8	IK	VSIBLXWNANVQDH-UHFFFAOYSA-N
DM74JL8	IU	4-hydroxy-5-undecyl-1,3-benzothiazole-6,7-dione
DM74JL8	CA	CAS 43152-58-5
DM74JL8	DE	Discovery agent

DM20X8C	ID	DM20X8C
DM20X8C	DN	5'-O-[(L-Methionyl)-Sulphamoyl]Adenosine
DM20X8C	HS	Investigative
DM20X8C	SN	CHEMBL1163059; 1pfy; AC1L9LA4; SCHEMBL4308351; BDBM50222901; 5'-O-[N-(L-Methionyl)-sulfamoyl]adenosine; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl N-[(2S)-2-amino-4-methylsulfanylbutanoyl]sulfamate
DM20X8C	DT	Small molecular drug
DM20X8C	PC	46936326
DM20X8C	MW	479.5
DM20X8C	FM	C15H25N7O7S2
DM20X8C	IC	InChI=1S/C15H25N7O7S2/c1-30-3-2-7(16)14(25)21-31(26,27)28-4-8-10(23)11(24)15(29-8)22-6-20-9-12(17)18-5-19-13(9)22/h5-8,10-11,13,15,23-24H,2-4,16-17H2,1H3,(H,18,19)(H,21,25)/t7-,8+,10+,11-,13+,15-/m1/s1
DM20X8C	CS	CSCC[C@H](C(=O)NS(=O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N2C=NC3=C(NC=N[C@H]32)N)O)O)N
DM20X8C	IK	SQDXXTAOGLOMRP-JJWYTCDVSA-N
DM20X8C	IU	[(2S,3R,4R,5R)-5-[(4S)-6-amino-1,4-dihydropurin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl N-[(2R)-2-amino-4-methylsulfanylbutanoyl]sulfamate
DM20X8C	DE	Discovery agent

DMAXHEU	ID	DMAXHEU
DMAXHEU	DN	5-octyl-2-phenoxyphenol
DMAXHEU	HS	Investigative
DMAXHEU	SN	5-OCTYL-2-PHENOXYPHENOL; 5-Octyl-2-phenoxy-phenol; CHEMBL505886; 8PS; 8PP; AC1NRXEO; 2-Phenoxy-5-octylphenol; 5-octyl-2-phenoxy phenol; 5-heptyl-2-phenoxylphenol; SCHEMBL2873469; PT05; BDBM16298; JOWYBLIPWAMIHM-UHFFFAOYSA-N
DMAXHEU	DT	Small molecular drug
DMAXHEU	PC	5274979
DMAXHEU	MW	298.4
DMAXHEU	FM	C20H26O2
DMAXHEU	IC	InChI=1S/C20H26O2/c1-2-3-4-5-6-8-11-17-14-15-20(19(21)16-17)22-18-12-9-7-10-13-18/h7,9-10,12-16,21H,2-6,8,11H2,1H3
DMAXHEU	CS	CCCCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2)O
DMAXHEU	IK	JOWYBLIPWAMIHM-UHFFFAOYSA-N
DMAXHEU	IU	5-octyl-2-phenoxyphenol
DMAXHEU	DE	Discovery agent

DMZT6JR	ID	DMZT6JR
DMZT6JR	DN	5-OH-DPAT
DMZT6JR	HS	Investigative
DMZT6JR	SN	5-OH-Dpat; CHEMBL273273; 68593-96-4; 6-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol; 6-dipropylaminotetralin-1-ol; 5-Hydroxy-2-N,N-dipropylaminotetralin; 5-Hydroxy-2-(di-n-propylamino)tetralin; (-)-5-hydroxy-2-(dipropylamino)tetralin; 6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol; GTPL128; SCHEMBL279021; AC1L58V4; 2-Dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene; 5-hydroxy-2-(dipropylamino)tetralin; BDBM50020221; 5-hydroxy-N,N-dipropyl-2-aminotetralin; L000957; 1-Naphthalenol,;  6-dipropylaminotetralin-1-ol
DMZT6JR	DT	Small molecular drug
DMZT6JR	PC	172267
DMZT6JR	MW	247.38
DMZT6JR	FM	C16H25NO
DMZT6JR	IC	InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-8-9-15-13(12-14)6-5-7-16(15)18/h5-7,14,18H,3-4,8-12H2,1-2H3
DMZT6JR	CS	CCCN(CCC)C1CCC2=C(C1)C=CC=C2O
DMZT6JR	IK	MDBWEQVKJDMEMK-UHFFFAOYSA-N
DMZT6JR	IU	6-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
DMZT6JR	CA	CAS 68593-96-4
DMZT6JR	DE	Discovery agent

DME62OQ	ID	DME62OQ
DME62OQ	DN	5-oxo-1-2-4-oxadiazol biphenyl
DME62OQ	HS	Investigative
DME62OQ	SN	compound 1c [PMID: 22410249]
DME62OQ	DT	Small molecular drug
DME62OQ	PC	136218976
DME62OQ	MW	423.5
DME62OQ	FM	C23H25N3O5
DME62OQ	IC	InChI=1S/C23H25N3O5/c1-3-7-19(22(28)29)26(20(27)4-2)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)21-24-23(30)31-25-21/h5-6,8-13,19H,3-4,7,14H2,1-2H3,(H,28,29)(H,24,25,30)/t19-/m0/s1
DME62OQ	CS	CCC[C@@H](C(=O)O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NOC(=O)N3)C(=O)CC
DME62OQ	IK	FXELTRKWYHPHAE-IBGZPJMESA-N
DME62OQ	IU	(2S)-2-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl-propanoylamino]pentanoic acid
DME62OQ	DE	Discovery agent

DMLABR9	ID	DMLABR9
DMLABR9	DN	5-oxo-12-HETE
DMLABR9	HS	Investigative
DMLABR9	SN	5-oxo-12S-hydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid
DMLABR9	DT	Small molecular drug
DMLABR9	PC	10568747
DMLABR9	MW	334.4
DMLABR9	FM	C20H30O4
DMLABR9	IC	InChI=1S/C20H30O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18,21H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7-,9-6-,14-10+,15-11+/t18-/m0/s1
DMLABR9	CS	CCCCC/C=C\\C[C@@H](/C=C/C=C\\C=C\\C(=O)CCCC(=O)O)O
DMLABR9	IK	MLZJFLKEKVDNAZ-XPKTZJOPSA-N
DMLABR9	IU	(6E,8Z,10E,12S,14Z)-12-hydroxy-5-oxoicosa-6,8,10,14-tetraenoic acid
DMLABR9	CB	CHEBI:137749
DMLABR9	DE	Discovery agent

DM9ZC7B	ID	DM9ZC7B
DM9ZC7B	DN	5-oxo-15-HETE
DM9ZC7B	HS	Investigative
DM9ZC7B	SN	5-oxo-15-hydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid
DM9ZC7B	DT	Small molecular drug
DM9ZC7B	PC	6438757
DM9ZC7B	MW	334.4
DM9ZC7B	FM	C20H30O4
DM9ZC7B	IC	InChI=1S/C20H30O4/c1-2-3-9-13-18(21)14-10-7-5-4-6-8-11-15-19(22)16-12-17-20(23)24/h5-8,10-11,14-15,18,21H,2-4,9,12-13,16-17H2,1H3,(H,23,24)/b7-5-,8-6-,14-10+,15-11+/t18-/m0/s1
DM9ZC7B	CS	CCCCC[C@@H](/C=C/C=C\\C/C=C\\C=C\\C(=O)CCCC(=O)O)O
DM9ZC7B	IK	RIUDRKHGFDAKPO-WWWYWCMOSA-N
DM9ZC7B	IU	(6E,8Z,11Z,13E,15S)-15-hydroxy-5-oxoicosa-6,8,11,13-tetraenoic acid
DM9ZC7B	CA	CAS 142828-12-4
DM9ZC7B	CB	CHEBI:137746
DM9ZC7B	DE	Discovery agent

DMQ94BX	ID	DMQ94BX
DMQ94BX	DN	5-oxo-1-tosyl-2,5-dihydro-1Hpyrrol-2-yl acetate
DMQ94BX	HS	Investigative
DMQ94BX	SN	CHEMBL1164744; 5-oxo-1-tosyl-2,5-dihydro-1Hpyrrol-2-yl acetate
DMQ94BX	DT	Small molecular drug
DMQ94BX	PC	46871782
DMQ94BX	MW	295.31
DMQ94BX	FM	C13H13NO5S
DMQ94BX	IC	InChI=1S/C13H13NO5S/c1-9-3-5-11(6-4-9)20(17,18)14-12(16)7-8-13(14)19-10(2)15/h3-8,13H,1-2H3
DMQ94BX	CS	CC1=CC=C(C=C1)S(=O)(=O)N2C(C=CC2=O)OC(=O)C
DMQ94BX	IK	JVIFWMPUUHEQPE-UHFFFAOYSA-N
DMQ94BX	IU	[1-(4-methylphenyl)sulfonyl-5-oxo-2H-pyrrol-2-yl] acetate
DMQ94BX	DE	Discovery agent

DM493GU	ID	DM493GU
DM493GU	DN	5-oxo-20-HETE
DM493GU	HS	Investigative
DM493GU	SN	5-oxo-20-hydroxy-6E, 8Z,11Z, 14Z-eicosatetraenoic acid
DM493GU	DT	Small molecular drug
DM493GU	PC	73755178
DM493GU	MW	334.4
DM493GU	FM	C20H30O4
DM493GU	IC	InChI=1S/C20H30O4/c21-18-13-11-9-7-5-3-1-2-4-6-8-10-12-15-19(22)16-14-17-20(23)24/h2-5,8,10,12,15,21H,1,6-7,9,11,13-14,16-18H2,(H,23,24)/b4-2-,5-3-,10-8-,15-12+
DM493GU	CS	C(CC/C=C\\C/C=C\\C/C=C\\C=C\\C(=O)CCCC(=O)O)CCO
DM493GU	IK	DTSRZRUIWKDHMR-DHYYJNSCSA-N
DM493GU	IU	(6E,8Z,11Z,14Z)-20-hydroxy-5-oxoicosa-6,8,11,14-tetraenoic acid
DM493GU	DE	Discovery agent

DM6FSUW	ID	DM6FSUW
DM6FSUW	DN	5-oxo-C20:3
DM6FSUW	HS	Investigative
DM6FSUW	SN	5-oxo-6e,8z,11z-eicosatrienoic acid; 5-oxo-ETrE
DM6FSUW	DT	Small molecular drug
DM6FSUW	PC	56947094
DM6FSUW	MW	320.5
DM6FSUW	FM	C20H32O3
DM6FSUW	IC	InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h9-10,12-14,16H,2-8,11,15,17-18H2,1H3,(H,22,23)/b10-9-,13-12-,16-14-
DM6FSUW	CS	CCCCCCCC/C=C\\C/C=C\\C=C/C(=O)CCCC(=O)O
DM6FSUW	IK	ULMVEQWNDGUUBR-IEQFDQMRSA-N
DM6FSUW	IU	(6Z,8Z,11Z)-5-oxoicosa-6,8,11-trienoic acid
DM6FSUW	DE	Discovery agent

DM56TVA	ID	DM56TVA
DM56TVA	DN	5-oxo-ODE
DM56TVA	HS	Investigative
DM56TVA	SN	5-oxo-(6E,8Z)-octadecadienoic acid
DM56TVA	DT	Small molecular drug
DM56TVA	PC	71751402
DM56TVA	MW	294.4
DM56TVA	FM	C18H30O3
DM56TVA	IC	InChI=1S/C18H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-14-17(19)15-13-16-18(20)21/h10-12,14H,2-9,13,15-16H2,1H3,(H,20,21)/b11-10-,14-12+
DM56TVA	CS	CCCCCCCCC/C=C\\C=C\\C(=O)CCCC(=O)O
DM56TVA	IK	YVWMHFYOIJMUMN-HSINTONASA-N
DM56TVA	IU	(6E,8Z)-5-oxooctadeca-6,8-dienoic acid
DM56TVA	CA	CAS 1021188-25-9
DM56TVA	CB	CHEBI:137754
DM56TVA	DE	Discovery agent

DMPLB3S	ID	DMPLB3S
DMPLB3S	DN	5PAM523
DMPLB3S	HS	Investigative
DMPLB3S	SN	5PAM523; SCHEMBL600403; GTPL6414; JOBPCEDWVKYVKZ-OCCSQVGLSA-N; 5-fluoro-2-{3-[(3S,6R)-1-[(4-fluorophenyl)carbonyl]-6-methylpiperidin-3-yl]-1,2,4-oxadiazol-5-yl}pyridine; 4-fluorophenyl((2r,5s)-5-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-2-methylpiperidin-1-yl)methanone
DMPLB3S	DT	Small molecular drug
DMPLB3S	PC	46946406
DMPLB3S	MW	384.4
DMPLB3S	FM	C20H18F2N4O2
DMPLB3S	IC	InChI=1S/C20H18F2N4O2/c1-12-2-3-14(11-26(12)20(27)13-4-6-15(21)7-5-13)18-24-19(28-25-18)17-9-8-16(22)10-23-17/h4-10,12,14H,2-3,11H2,1H3/t12-,14+/m1/s1
DMPLB3S	CS	C[C@@H]1CC[C@@H](CN1C(=O)C2=CC=C(C=C2)F)C3=NOC(=N3)C4=NC=C(C=C4)F
DMPLB3S	IK	JOBPCEDWVKYVKZ-OCCSQVGLSA-N
DMPLB3S	IU	(4-fluorophenyl)-[(2R,5S)-5-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-2-methylpiperidin-1-yl]methanone
DMPLB3S	DE	Discovery agent

DMKHFV4	ID	DMKHFV4
DMKHFV4	DN	5-PENTYL-2-PHENOXYPHENOL
DMKHFV4	HS	Investigative
DMKHFV4	SN	5-PENTYL-2-PHENOXYPHENOL; 5-Pentyl-2-phenoxy-phenol; 5PP; AC1NRXEL; 5-pentyl-2-phenoxylphenol; SCHEMBL2873530; PT03; CHEMBL1224745; BDBM16296; AIDS227445
DMKHFV4	DT	Small molecular drug
DMKHFV4	PC	5274976
DMKHFV4	MW	256.339
DMKHFV4	FM	C17H20O2
DMKHFV4	IC	InChI=1S/C17H20O2/c1-2-3-5-8-14-11-12-17(16(18)13-14)19-15-9-6-4-7-10-15/h4,6-7,9-13,18H,2-3,5,8H2,1H3
DMKHFV4	CS	CCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2)O
DMKHFV4	IK	OJLYTHOKCYLPMA-UHFFFAOYSA-N
DMKHFV4	IU	5-pentyl-2-phenoxyphenol
DMKHFV4	DE	Discovery agent

DMZKJF8	ID	DMZKJF8
DMZKJF8	DN	5-Phenethyl-1H-pyrazole-3-carboxylic acid
DMZKJF8	HS	Investigative
DMZKJF8	SN	5-phenethyl-1H-pyrazole-3-carboxylic Acid; 595610-56-3; CHEMBL129385; 3-(2-phenylethyl)-1H-pyrazole-5-carboxylic acid; 1H-Pyrazole-3-carboxylic acid, 5-(2-phenylethyl)-; SCHEMBL1149172; SCHEMBL17672395; CTK7I6521; DTXSID50474116; MolPort-022-664-580; MolPort-022-231-591; BDBM50132146; STL426411; ZINC13526610; BBL035265; AKOS016013666; AKOS022947847; AJ-64058; 3-phenethyl-1H-pyrazole-5-carboxylic acid; AX8249620; 5-(2-phenylethyl)-1h-pyrazole-3-carboxylic acid
DMZKJF8	DT	Small molecular drug
DMZKJF8	PC	11830866
DMZKJF8	MW	216.24
DMZKJF8	FM	C12H12N2O2
DMZKJF8	IC	InChI=1S/C12H12N2O2/c15-12(16)11-8-10(13-14-11)7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H,13,14)(H,15,16)
DMZKJF8	CS	C1=CC=C(C=C1)CCC2=CC(=NN2)C(=O)O
DMZKJF8	IK	HHEBXMNODWRUEV-UHFFFAOYSA-N
DMZKJF8	IU	5-(2-phenylethyl)-1H-pyrazole-3-carboxylic acid
DMZKJF8	CA	CAS 595610-56-3
DMZKJF8	DE	Discovery agent

DMWI7XJ	ID	DMWI7XJ
DMWI7XJ	DN	5-Phenethyl-quinazoline-2,4-diamine
DMWI7XJ	HS	Investigative
DMWI7XJ	SN	CHEMBL341703; 5-phenethylquinazoline-2,4-diamine; 5-Phenethyl-quinazoline-2,4-diamine; AC1LALFL; CTK7E0789; BDBM50036483; ZINC13740535; 5-(2-phenylethyl)quinazoline-2,4-diamine; 5-(2-phenylethyl)-2,4-quinazolinediamine; 2,4-Diamino-5-(2-phenylethyl)-quinazoline; (2-amino-5-phenethyl-quinazolin-4-yl)-amine; 2,4-Quinazolinediamine, 5-(2-phenylethyl)-
DMWI7XJ	DT	Small molecular drug
DMWI7XJ	PC	490662
DMWI7XJ	MW	264.32
DMWI7XJ	FM	C16H16N4
DMWI7XJ	IC	InChI=1S/C16H16N4/c17-15-14-12(10-9-11-5-2-1-3-6-11)7-4-8-13(14)19-16(18)20-15/h1-8H,9-10H2,(H4,17,18,19,20)
DMWI7XJ	CS	C1=CC=C(C=C1)CCC2=C3C(=CC=C2)N=C(N=C3N)N
DMWI7XJ	IK	UIHMRPRVKDDARV-UHFFFAOYSA-N
DMWI7XJ	IU	5-(2-phenylethyl)quinazoline-2,4-diamine
DMWI7XJ	DE	Discovery agent

DMZ6TRV	ID	DMZ6TRV
DMZ6TRV	DN	5-phenyl-1,3,4-oxadiazole-2(3H)-thione
DMZ6TRV	HS	Investigative
DMZ6TRV	SN	3004-42-0; 5-Phenyl-1,3,4-oxadiazole-2-thiol; 5-Phenyl-1,3,4-oxadiazole-2(3H)-thione; 1,3,4-Oxadiazole-2(3H)-thione, 5-phenyl-; 2-Phenyl-1,3,4-oxadiazole-5-thiol; 1,3,4-oxadiazole-2-thiol, 5-phenyl-; EINECS 221-103-9; 5-Phenyl-[1,3,4]oxadiazole-2-thiol; 2-Fenil-5-mercapto-1,3,4-ossadiazolo; CHEMBL1164316; 1,3,4-OXADIAZOLE-5-THIOL, 2-PHENYL-; FOHWXVBZGSVUGO-UHFFFAOYSA-N; 2-Fenil-5-mercapto-1,3,4-ossadiazolo [Italian]; 5-phenyl-1,3,4-oxadiazole-2-thione; 2-Phenyl-1,3,4--oxadiazol-5-thiol
DMZ6TRV	DT	Small molecular drug
DMZ6TRV	PC	735254
DMZ6TRV	MW	178.21
DMZ6TRV	FM	C8H6N2OS
DMZ6TRV	IC	InChI=1S/C8H6N2OS/c12-8-10-9-7(11-8)6-4-2-1-3-5-6/h1-5H,(H,10,12)
DMZ6TRV	CS	C1=CC=C(C=C1)C2=NNC(=S)O2
DMZ6TRV	IK	FOHWXVBZGSVUGO-UHFFFAOYSA-N
DMZ6TRV	IU	5-phenyl-3H-1,3,4-oxadiazole-2-thione
DMZ6TRV	CA	CAS 3004-42-0
DMZ6TRV	DE	Discovery agent

DMCKBQY	ID	DMCKBQY
DMCKBQY	DN	5-phenyl-1,3,4-thiadiazole-2(3H)-thione
DMCKBQY	HS	Investigative
DMCKBQY	SN	5-Phenyl-1,3,4-thiadiazole-2-thiol; 5585-19-3; 1,3,4-Thiadiazole-2-thiol, 5-phenyl-; L 1542; 2-Mercapto-5-fenil-1,3,4-tiadiazolo [Italian]; 5-Phenyl-1,3,4-thiadiazole-2(3H)-thione; CHEMBL596215; 2-mercapto-5-phenyl-1,3,4-thiadiazole; 2-Mercapto-5-fenil-1,3,4-tiadiazolo; AC1Q7GLK; AC1MHZ9V; SCHEMBL969040; DTXSID40204444; ZTLMHGOWADYAHM-UHFFFAOYSA-N; MolPort-000-932-663; ZINC13532595; MFCD01681863; BDBM50320718; 5-phenyl-1,3,4-thiadiazol-2-thiol; AKOS003056166; MCULE-7311616477; NE54511; LS-150315
DMCKBQY	DT	Small molecular drug
DMCKBQY	PC	3035373
DMCKBQY	MW	194.3
DMCKBQY	FM	C8H6N2S2
DMCKBQY	IC	InChI=1S/C8H6N2S2/c11-8-10-9-7(12-8)6-4-2-1-3-5-6/h1-5H,(H,10,11)
DMCKBQY	CS	C1=CC=C(C=C1)C2=NNC(=S)S2
DMCKBQY	IK	ZTLMHGOWADYAHM-UHFFFAOYSA-N
DMCKBQY	IU	5-phenyl-3H-1,3,4-thiadiazole-2-thione
DMCKBQY	CA	CAS 5585-19-3
DMCKBQY	DE	Discovery agent

DMWF4HX	ID	DMWF4HX
DMWF4HX	DN	5-phenyl-1H-1,2,3-triazole
DMWF4HX	HS	Investigative
DMWF4HX	SN	1680-44-0; 5-phenyl-1H-1,2,3-triazole; 4-Phenyl-1H-1,2,3-triazole; 4-Phenyl-1H-[1,2,3]triazole; 4-Phenyl-1,2,3-triazole; 1H-1,2,3-Triazole, 4-phenyl-; 4-phenyl-2H-triazole; v-Triazole, 4-phenyl-; 4-phenyl-2H-[1,2,3]triazole; LUEYUHCBBXWTQT-UHFFFAOYSA-N; 4-phenyl-1h-1,2,3,-triazole; 5-Phenyl-1H-[1,2,3]triazole; 112614-96-7; phenyltriazole; 4-phenyltriazole; NSC83125; SCHEMBL9868; AC1L3A0F; 5-phenyl-1,2,3-triazole; SCHEMBL8221447; CHEMBL193664; 1,2,3-triazole analogue, 4; 1,2,3-Triazole, 4-phenyl-; ZINC27320; BDBM17448; CTK4D2851
DMWF4HX	DT	Small molecular drug
DMWF4HX	PC	137153
DMWF4HX	MW	145.16
DMWF4HX	FM	C8H7N3
DMWF4HX	IC	InChI=1S/C8H7N3/c1-2-4-7(5-3-1)8-6-9-11-10-8/h1-6H,(H,9,10,11)
DMWF4HX	CS	C1=CC=C(C=C1)C2=NNN=C2
DMWF4HX	IK	LUEYUHCBBXWTQT-UHFFFAOYSA-N
DMWF4HX	IU	4-phenyl-2H-triazole
DMWF4HX	CA	CAS 1680-44-0
DMWF4HX	DE	Discovery agent

DMJBEIF	ID	DMJBEIF
DMJBEIF	DN	5-phenyl-1H-indazol-3-amine
DMJBEIF	HS	Investigative
DMJBEIF	SN	5-phenyl-1H-indazol-3-amine; CHEMBL500779; SCHEMBL3359889; 3e63; BDBM50254831; DB07161
DMJBEIF	DT	Small molecular drug
DMJBEIF	PC	11492186
DMJBEIF	MW	209.25
DMJBEIF	FM	C13H11N3
DMJBEIF	IC	InChI=1S/C13H11N3/c14-13-11-8-10(6-7-12(11)15-16-13)9-4-2-1-3-5-9/h1-8H,(H3,14,15,16)
DMJBEIF	CS	C1=CC=C(C=C1)C2=CC3=C(C=C2)NN=C3N
DMJBEIF	IK	ZCUSNQPYUNLATP-UHFFFAOYSA-N
DMJBEIF	IU	5-phenyl-1H-indazol-3-amine
DMJBEIF	DE	Discovery agent

DMQHU0J	ID	DMQHU0J
DMQHU0J	DN	5-phenyl-2-(4-(piperidin-1-yl)butyl)oxazole
DMQHU0J	HS	Investigative
DMQHU0J	SN	CHEMBL1257573; 5-phenyl-2-(4-(piperidin-1-yl)butyl)oxazole
DMQHU0J	DT	Small molecular drug
DMQHU0J	PC	52946272
DMQHU0J	MW	284.4
DMQHU0J	FM	C18H24N2O
DMQHU0J	IC	InChI=1S/C18H24N2O/c1-3-9-16(10-4-1)17-15-19-18(21-17)11-5-8-14-20-12-6-2-7-13-20/h1,3-4,9-10,15H,2,5-8,11-14H2
DMQHU0J	CS	C1CCN(CC1)CCCCC2=NC=C(O2)C3=CC=CC=C3
DMQHU0J	IK	XJINDZCEGQZNLD-UHFFFAOYSA-N
DMQHU0J	IU	5-phenyl-2-(4-piperidin-1-ylbutyl)-1,3-oxazole
DMQHU0J	DE	Discovery agent

DMLK2VT	ID	DMLK2VT
DMLK2VT	DN	5-Phenyl-6-thia-10b-aza-benzo[e]azulen-4-one
DMLK2VT	HS	Investigative
DMLK2VT	SN	NSC675284; CHEMBL32718; 6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-one; 6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7(6h)-one; AC1L8OAU; 5-Phenyl-6-thia-10b-aza-benzo[e]azulen-4-one; CTK8D2539; BDBM50041512; NSC-675284
DMLK2VT	DT	Small molecular drug
DMLK2VT	PC	384831
DMLK2VT	MW	291.4
DMLK2VT	FM	C18H13NOS
DMLK2VT	IC	InChI=1S/C18H13NOS/c20-17-15-10-6-12-19(15)14-9-4-5-11-16(14)21-18(17)13-7-2-1-3-8-13/h1-12,18H
DMLK2VT	CS	C1=CC=C(C=C1)C2C(=O)C3=CC=CN3C4=CC=CC=C4S2
DMLK2VT	IK	NZZPYZUATMBWAV-UHFFFAOYSA-N
DMLK2VT	IU	6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-one
DMLK2VT	DE	Discovery agent

DMUBCVL	ID	DMUBCVL
DMUBCVL	DN	5-Phenyl-6-thia-10b-aza-benzo[e]azulene
DMUBCVL	HS	Investigative
DMUBCVL	SN	CHEMBL358133; 5-Phenyl-6-thia-10b-aza-benzo[e]azulene; ZINC13603874; BDBM50029752
DMUBCVL	DT	Small molecular drug
DMUBCVL	PC	13057872
DMUBCVL	MW	275.4
DMUBCVL	FM	C18H13NS
DMUBCVL	IC	InChI=1S/C18H13NS/c1-2-7-14(8-3-1)18-13-15-9-6-12-19(15)16-10-4-5-11-17(16)20-18/h1-13H
DMUBCVL	CS	C1=CC=C(C=C1)C2=CC3=CC=CN3C4=CC=CC=C4S2
DMUBCVL	IK	XBVRXEAOFZWJAH-UHFFFAOYSA-N
DMUBCVL	IU	6-phenylpyrrolo[2,1-d][1,5]benzothiazepine
DMUBCVL	DE	Discovery agent

DMX6R0H	ID	DMX6R0H
DMX6R0H	DN	5-phenylamino-4-cyano-3-hydroxy-isothiazole
DMX6R0H	HS	Investigative
DMX6R0H	SN	CHEMBL209793; 1137-65-1; 4-Isothiazolecarbonitrile, 2,3-dihydro-3-oxo-5-(phenylamino)-; AC1MBJGN; Maybridge4_002946; 5-phenylamino-4-cyano-3-hydroxy-isothiazole; 5-anilino-3-oxo-1,2-thiazole-4-carbonitrile; Oprea1_090337; MLS000850692; SCHEMBL3527060; CTK0G1139; DTXSID30369410; CHEBI:107126; MolPort-002-913-499; GHXPCAXQBVCFNU-UHFFFAOYSA-N; HMS2799B08; HMS1529F20; CCG-1976; ZINC15924361; BDBM50187849; AKOS022652528; AKOS030549246; MCULE-9694822584; NCGC00176381-01; SMR000456709; 5-anilino-3-oxo-isothiazole-4-carbonitrile
DMX6R0H	DT	Small molecular drug
DMX6R0H	PC	2726555
DMX6R0H	MW	217.25
DMX6R0H	FM	C10H7N3OS
DMX6R0H	IC	InChI=1S/C10H7N3OS/c11-6-8-9(14)13-15-10(8)12-7-4-2-1-3-5-7/h1-5,12H,(H,13,14)
DMX6R0H	CS	C1=CC=C(C=C1)NC2=C(C(=O)NS2)C#N
DMX6R0H	IK	GHXPCAXQBVCFNU-UHFFFAOYSA-N
DMX6R0H	IU	5-anilino-3-oxo-1,2-thiazole-4-carbonitrile
DMX6R0H	CA	CAS 1137-65-1
DMX6R0H	CB	CHEBI:107126
DMX6R0H	DE	Discovery agent

DM3B6A8	ID	DM3B6A8
DM3B6A8	DN	5-Phenyl-pentanoic acid benzyl-hydroxy-amide
DM3B6A8	HS	Investigative
DM3B6A8	SN	N-benzyl-N-hydroxy-5-phenylpentanamide; 158999-12-3; N-Benzyl-N-hydroxy-5-phenylpentamide; CHEMBL301253; N-Bhpp; AC1L4IPK; N-Hydroxy-N-(phenylmethyl)benzenepentanamide; 5-Phenyl-pentanoic acid benzyl-hydroxy-amide; SCHEMBL1271129; DTXSID60166550; ZINC5138973; BDBM50016680; KB-301817; Benzenepentanamide, N-hydroxy-N-(phenylmethyl)-
DM3B6A8	DT	Small molecular drug
DM3B6A8	PC	157806
DM3B6A8	MW	283.4
DM3B6A8	FM	C18H21NO2
DM3B6A8	IC	InChI=1S/C18H21NO2/c20-18(19(21)15-17-12-5-2-6-13-17)14-8-7-11-16-9-3-1-4-10-16/h1-6,9-10,12-13,21H,7-8,11,14-15H2
DM3B6A8	CS	C1=CC=C(C=C1)CCCCC(=O)N(CC2=CC=CC=C2)O
DM3B6A8	IK	MXZUASJHVOWCLX-UHFFFAOYSA-N
DM3B6A8	IU	N-benzyl-N-hydroxy-5-phenylpentanamide
DM3B6A8	CA	CAS 158999-12-3
DM3B6A8	DE	Discovery agent

DMMWYFR	ID	DMMWYFR
DMMWYFR	DN	5-Phenylsulfanyl-2,4-Quinazolinediamine
DMMWYFR	HS	Investigative
DMMWYFR	SN	5-Phenylsulfanyl-2,4-quinazolinediamine; 5-PHENYLSULFANYL-2,4-QUINAZOLINEDIAMINE; TCMDC-131943; 5-(phenylsulfanyl)quinazoline-2,4-diamine; 5-phenylsulfanylquinazoline-2,4-diamine; TQ3; AC1L9JD6; SCHEMBL2125192; CHEMBL100239; BDBM18045; GW997; ZINC5974663; 5-Phenylthioquinazoline-2,4-diamine; 2,4-Diamino-5-phenylthio-quinazoline; DB04163; 5-Phenylsulfanyl-quinazoline-2,4-diamine
DMMWYFR	DT	Small molecular drug
DMMWYFR	PC	446244
DMMWYFR	MW	268.34
DMMWYFR	FM	C14H12N4S
DMMWYFR	IC	InChI=1S/C14H12N4S/c15-13-12-10(17-14(16)18-13)7-4-8-11(12)19-9-5-2-1-3-6-9/h1-8H,(H4,15,16,17,18)
DMMWYFR	CS	C1=CC=C(C=C1)SC2=CC=CC3=C2C(=NC(=N3)N)N
DMMWYFR	IK	BUFDQCGCADQQQY-UHFFFAOYSA-N
DMMWYFR	IU	5-phenylsulfanylquinazoline-2,4-diamine
DMMWYFR	DE	Discovery agent

DMQMZ0Y	ID	DMQMZ0Y
DMQMZ0Y	DN	5'-phenylthio-ImmH
DMQMZ0Y	HS	Investigative
DMQMZ0Y	DT	Small molecular drug
DMQMZ0Y	PC	135981935
DMQMZ0Y	MW	358.4
DMQMZ0Y	FM	C17H18N4O3S
DMQMZ0Y	IC	InChI=1S/C17H18N4O3S/c22-15-11(7-25-9-4-2-1-3-5-9)21-13(16(15)23)10-6-18-14-12(10)19-8-20-17(14)24/h1-6,8,11,13,15-16,18,21-23H,7H2,(H,19,20,24)/t11-,13+,15-,16+/m1/s1
DMQMZ0Y	CS	C1=CC=C(C=C1)SC[C@@H]2[C@H]([C@H]([C@@H](N2)C3=CNC4=C3N=CNC4=O)O)O
DMQMZ0Y	IK	RILVLBFFRDXSEY-JMGFVUJMSA-N
DMQMZ0Y	IU	7-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(phenylsulfanylmethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMQMZ0Y	DE	Discovery agent

DMGK05W	ID	DMGK05W
DMGK05W	DN	5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate
DMGK05W	HS	Investigative
DMGK05W	SN	5-PHOSPHORIBOSYL-1-(BETA-METHYLENE) PYROPHOSPHATE; AC1L9LOK; DB04294; 1-O-[(R)-hydroxy(phosphonomethyl)phosphoryl]-5-O-phosphono-alpha-D-ribofuranose; [[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]oxy-hydroxyphosphoryl]methylphosphonic acid
DMGK05W	DT	Small molecular drug
DMGK05W	PC	448176
DMGK05W	MW	388.1
DMGK05W	FM	C6H15O13P3
DMGK05W	IC	InChI=1S/C6H15O13P3/c7-4-3(1-17-22(14,15)16)18-6(5(4)8)19-21(12,13)2-20(9,10)11/h3-8H,1-2H2,(H,12,13)(H2,9,10,11)(H2,14,15,16)/t3-,4-,5-,6-/m1/s1
DMGK05W	CS	C([C@@H]1[C@H]([C@H]([C@H](O1)OP(=O)(CP(=O)(O)O)O)O)O)OP(=O)(O)O
DMGK05W	IK	JFMKBQDEISBIPL-KVTDHHQDSA-N
DMGK05W	IU	[[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]oxy-hydroxyphosphoryl]methylphosphonic acid
DMGK05W	DE	Discovery agent

DM6A902	ID	DM6A902
DM6A902	DN	5-propenyl-2'-deoxyuridine triphosphate
DM6A902	HS	Investigative
DM6A902	DE	Discovery agent

DM762FY	ID	DM762FY
DM762FY	DN	5-propenyl-arabinofuranosyluracil 5'-triphosphate
DM762FY	HS	Investigative
DM762FY	DT	Small molecular drug
DM762FY	PC	56603747
DM762FY	MW	524.2
DM762FY	FM	C12H19N2O15P3
DM762FY	IC	InChI=1S/C12H19N2O15P3/c1-2-3-6(27-31(22,23)29-32(24,25)28-30(19,20)21)10-8(16)9(17)11(26-10)14-5-4-7(15)13-12(14)18/h2-6,8-11,16-17H,1H3,(H,22,23)(H,24,25)(H,13,15,18)(H2,19,20,21)/b3-2+/t6?,8-,9-,10+,11?/m0/s1
DM762FY	CS	C/C=C/C([C@@H]1[C@H]([C@@H](C(O1)N2C=CC(=O)NC2=O)O)O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O
DM762FY	IK	XLORWTLPILWCFG-GPJQKZQFSA-N
DM762FY	IU	[[(E)-1-[(2S,3S,4S)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]but-2-enoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate
DM762FY	DE	Discovery agent

DMSPVXM	ID	DMSPVXM
DMSPVXM	DN	5-Propyl-1H-pyrazole-3-carboxylic acid
DMSPVXM	HS	Investigative
DMSPVXM	SN	3-propyl-1H-pyrazole-5-carboxylic acid; 76424-47-0; 5-Propyl-1H-pyrazole-3-carboxylic acid; 5-Propyl-2H-pyrazole-3-carboxylic acid; CHEMBL237788; 3-n-propyl-1H-pyrazole-5-carboxylic acid; AC1LDWNQ; BAS 01543590; SCHEMBL1092; AC1Q2V2W; Oprea1_206890; ZINC39600; CTK6D4610; KS-00003OFY; CTK2H6772; DTXSID20350296; MolPort-001-965-385; QYPSYPPSHXDFLV-UHFFFAOYSA-N; MolPort-000-929-573; HMS1697E16; 3-propylpyrazole-5-carboxylic acid; BDBM50220850; BBL031087; STL244838; KM1764; 9410AE; AKOS000136076; AKOS000646963; MS-2036; MCULE-2411097064
DMSPVXM	DT	Small molecular drug
DMSPVXM	PC	676464
DMSPVXM	MW	154.17
DMSPVXM	FM	C7H10N2O2
DMSPVXM	IC	InChI=1S/C7H10N2O2/c1-2-3-5-4-6(7(10)11)9-8-5/h4H,2-3H2,1H3,(H,8,9)(H,10,11)
DMSPVXM	CS	CCCC1=CC(=NN1)C(=O)O
DMSPVXM	IK	QYPSYPPSHXDFLV-UHFFFAOYSA-N
DMSPVXM	IU	5-propyl-1H-pyrazole-3-carboxylic acid
DMSPVXM	CA	CAS 76424-47-0
DMSPVXM	DE	Discovery agent

DM9IHV6	ID	DM9IHV6
DM9IHV6	DN	5-propyl-2'-deoxyuridine
DM9IHV6	HS	Investigative
DM9IHV6	SN	5-Propyl-2'-deoxyuridine; 27826-74-0; CHEMBL221982; 5-Propyldeoxyuridine; 2'-Deoxy-5-propyluridine; 5-Propyl-dUrd; 5-Propyl-2'-desoxyuridine; AC1L4N4W; 2'-deoxy-5-n-propyluridine; Uridine,2'-deoxy-5-propyl-; Uridine, 2'-deoxy-5-propyl-; SCHEMBL2396529; CTK4G0305; DTXSID30182141; MBERTAKFBYOAHR-IVZWLZJFSA-N; BDBM50375778; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione
DM9IHV6	DT	Small molecular drug
DM9IHV6	PC	160155
DM9IHV6	MW	270.28
DM9IHV6	FM	C12H18N2O5
DM9IHV6	IC	InChI=1S/C12H18N2O5/c1-2-3-7-5-14(12(18)13-11(7)17)10-4-8(16)9(6-15)19-10/h5,8-10,15-16H,2-4,6H2,1H3,(H,13,17,18)/t8-,9+,10+/m0/s1
DM9IHV6	CS	CCCC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O
DM9IHV6	IK	MBERTAKFBYOAHR-IVZWLZJFSA-N
DM9IHV6	IU	1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione
DM9IHV6	CA	CAS 27826-74-0
DM9IHV6	DE	Discovery agent

DM2W0AD	ID	DM2W0AD
DM2W0AD	DN	5-p-Tolyl-1H-[1,2,3]triazole
DM2W0AD	HS	Investigative
DM2W0AD	SN	4-(p-Tolyl)-1H-1,2,3-triazole; 5301-96-2; 4-(p-Tolyl)-2H-1,2,3-triazole; 5-(4-methylphenyl)-1H-1,2,3-triazole; 1H-1,2,3-Triazole, 4-(4-methylphenyl)-; 4-(4-methylphenyl)-2H-triazole; 5-(p-Tolyl)-1H-1,2,3-triazole; 59066-81-8; v-Triazole, 4-p-tolyl-; AC1LC4W8; SCHEMBL20848; 1,2,3-triazole analogue, 3; CHEMBL193610; CTK1G1560; BDBM17447; DTXSID60344093; ZPCIKQLLQORQCV-UHFFFAOYSA-N; MolPort-023-332-536; 4-p-tolyl-1H-1,2,3-triazole; ZINC13671868; ANW-65599; AKOS015907809; FCH4165656; KS-0000101Z; SC-23256; AJ-64294; AK-90097
DM2W0AD	DT	Small molecular drug
DM2W0AD	PC	594397
DM2W0AD	MW	159.19
DM2W0AD	FM	C9H9N3
DM2W0AD	IC	InChI=1S/C9H9N3/c1-7-2-4-8(5-3-7)9-6-10-12-11-9/h2-6H,1H3,(H,10,11,12)
DM2W0AD	CS	CC1=CC=C(C=C1)C2=NNN=C2
DM2W0AD	IK	ZPCIKQLLQORQCV-UHFFFAOYSA-N
DM2W0AD	IU	4-(4-methylphenyl)-2H-triazole
DM2W0AD	CA	CAS 29385-43-1
DM2W0AD	DE	Discovery agent

DMV4ICS	ID	DMV4ICS
DMV4ICS	DN	5-p-Tolylsulfanyl-quinazoline-2,4-diamine
DMV4ICS	HS	Investigative
DMV4ICS	SN	5-(4-Tolylthio)-2,4-diaminoquinazoline; 168910-32-5; 5-[(4-METHYLPHENYL)SULFANYL]-2,4-QUINAZOLINEDIAMINE; CHEMBL83547; 5-[(4-methylphenyl)sulfanyl]quinazoline-2,4-diamine; TQ4; Maybridge3_004364; AC1L9JD9; Oprea1_160965; SCHEMBL2126685; BDBM18046; CTK0E5148; DTXSID80332215; MolPort-002-910-071; HMS1443G08; GW578; ZINC172633; HMS3604M19; CCG-44692; AKOS027447345; MCULE-8600056307; DB04306; IDI1_015751; 5-(p-Tolylthio)quinazoline-2,4-diamine; RT-010103; 5-(p-tolylsulfanyl)quinazoline-2,4-diamine; FT-0675290
DMV4ICS	DT	Small molecular drug
DMV4ICS	PC	446245
DMV4ICS	MW	282.4
DMV4ICS	FM	C15H14N4S
DMV4ICS	IC	InChI=1S/C15H14N4S/c1-9-5-7-10(8-6-9)20-12-4-2-3-11-13(12)14(16)19-15(17)18-11/h2-8H,1H3,(H4,16,17,18,19)
DMV4ICS	CS	CC1=CC=C(C=C1)SC2=CC=CC3=C2C(=NC(=N3)N)N
DMV4ICS	IK	UOJFGEAPSYQDIP-UHFFFAOYSA-N
DMV4ICS	IU	5-(4-methylphenyl)sulfanylquinazoline-2,4-diamine
DMV4ICS	CA	CAS 168910-32-5
DMV4ICS	DE	Discovery agent

DMLRM9Z	ID	DMLRM9Z
DMLRM9Z	DN	5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one
DMLRM9Z	HS	Investigative
DMLRM9Z	SN	CHEMBL459071; 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one; 5-(pyrid-3-yl)-2h-indolin-2-one; SCHEMBL748904; SCHEMBL6840746; LRXSVYIRRDZVNQ-UHFFFAOYSA-N; BDBM50273706; 220904-98-3
DMLRM9Z	DT	Small molecular drug
DMLRM9Z	PC	12050204
DMLRM9Z	MW	210.23
DMLRM9Z	FM	C13H10N2O
DMLRM9Z	IC	InChI=1S/C13H10N2O/c16-13-7-11-6-9(3-4-12(11)15-13)10-2-1-5-14-8-10/h1-6,8H,7H2,(H,15,16)
DMLRM9Z	CS	C1C2=C(C=CC(=C2)C3=CN=CC=C3)NC1=O
DMLRM9Z	IK	LRXSVYIRRDZVNQ-UHFFFAOYSA-N
DMLRM9Z	IU	5-pyridin-3-yl-1,3-dihydroindol-2-one
DMLRM9Z	DE	Discovery agent

DMQYIBC	ID	DMQYIBC
DMQYIBC	DN	5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one
DMQYIBC	HS	Investigative
DMQYIBC	SN	5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one; CHEMBL448743; 5-(pyridin-3-yl)-2,3-dihydroinden-1-one; 5-Pyridin-3-yl-1-indanone; 5-(3-Pyridyl)-1-indanone; SCHEMBL6205709; CTK8E5276; QNSOPUXDEXJMIY-UHFFFAOYSA-N; BDBM50273704; ZINC40829496; 255895-87-5; TX-011073
DMQYIBC	DT	Small molecular drug
DMQYIBC	PC	18407230
DMQYIBC	MW	209.24
DMQYIBC	FM	C14H11NO
DMQYIBC	IC	InChI=1S/C14H11NO/c16-14-6-4-11-8-10(3-5-13(11)14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2
DMQYIBC	CS	C1CC(=O)C2=C1C=C(C=C2)C3=CN=CC=C3
DMQYIBC	IK	QNSOPUXDEXJMIY-UHFFFAOYSA-N
DMQYIBC	IU	5-pyridin-3-yl-2,3-dihydroinden-1-one
DMQYIBC	DE	Discovery agent

DMZQPTU	ID	DMZQPTU
DMZQPTU	DN	5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime
DMZQPTU	HS	Investigative
DMZQPTU	SN	SCHEMBL3649264; 2-Thiophenecarboxaldehyde, 5-(3-pyridinyl)-, oxime
DMZQPTU	DT	Small molecular drug
DMZQPTU	PC	91196339
DMZQPTU	MW	204.25
DMZQPTU	FM	C10H8N2OS
DMZQPTU	IC	InChI=1S/C10H8N2OS/c13-12-7-9-3-4-10(14-9)8-2-1-5-11-6-8/h1-6H,7H2
DMZQPTU	CS	C1=CC(=CN=C1)C2=CC=C(S2)CN=O
DMZQPTU	IK	JUZUBCBEFKWHQP-UHFFFAOYSA-N
DMZQPTU	IU	3-[5-(nitrosomethyl)thiophen-2-yl]pyridine
DMZQPTU	DE	Discovery agent

DMNYQGS	ID	DMNYQGS
DMNYQGS	DN	5''-Quinolin-4-yl-[2,4'']bithiazolyl-2''-ylamine
DMNYQGS	HS	Investigative
DMNYQGS	SN	CHEMBL362710; BDBM50151351; 5''-(quinolin-4-yl)-2,4''-bithiazol-2''-amine
DMNYQGS	DT	Small molecular drug
DMNYQGS	PC	11197671
DMNYQGS	MW	310.4
DMNYQGS	FM	C15H10N4S2
DMNYQGS	IC	InChI=1S/C15H10N4S2/c16-15-19-12(14-18-7-8-20-14)13(21-15)10-5-6-17-11-4-2-1-3-9(10)11/h1-8H,(H2,16,19)
DMNYQGS	CS	C1=CC=C2C(=C1)C(=CC=N2)C3=C(N=C(S3)N)C4=NC=CS4
DMNYQGS	IK	JHZIIPPDVRVCNU-UHFFFAOYSA-N
DMNYQGS	IU	5-quinolin-4-yl-4-(1,3-thiazol-2-yl)-1,3-thiazol-2-amine
DMNYQGS	DE	Discovery agent

DMVX063	ID	DMVX063
DMVX063	DN	5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
DMVX063	HS	Investigative
DMVX063	SN	5-Quinoxalin-6-ylmethylene-thiazolidine-2,4-dione; AS-605240; 648450-29-7; AS605240; AS 605240; CHEMBL568150; (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione; (5E)-5-(QUINOXALIN-6-YLMETHYLENE)-1,3-THIAZOLIDINE-2,4-DIONE; 5-(6-QUINOXALINYLMETHYLENE)-2,4-THIAZOLIDINEDIONE; QYT; (Z)-5-(Quinoxalin-6-ylmethylene)thiazolidine-2,4-dione; PI 3-Kg inhibitor; 2a5u; AC1NRCY0; 5-(quinoxalin-6-ylmethylene)thiazolidine-2,4-dione; SCHEMBL668616; GTPL6023; AOB3848; MolPort-006-169-944; HMS3650I15
DMVX063	DT	Small molecular drug
DMVX063	PC	5289247
DMVX063	MW	257.269
DMVX063	FM	C12H7N3O2S
DMVX063	IC	InChI=1S/C12H7N3O2S/c16-11-10(18-12(17)15-11)6-7-1-2-8-9(5-7)14-4-3-13-8/h1-6H,(H,15,16,17)/b10-6-
DMVX063	CS	C1=CC2=NC=CN=C2C=C1/C=C\\3/C(=O)NC(=O)S3
DMVX063	IK	SQWZFLMPDUSYGV-POHAHGRESA-N
DMVX063	IU	(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
DMVX063	CB	CHEBI:45302
DMVX063	DE	Discovery agent

DM0PQH1	ID	DM0PQH1
DM0PQH1	DN	5'-S-ethyl-5'-thioadenosine
DM0PQH1	HS	Investigative
DM0PQH1	SN	5'-S-ethyl-5'-thioadenosine; S-adenosylethane; 5'-ethylthioadenosine; CHEBI:74046; SCHEMBL998091; CHEMBL195660; 5'-Deoxy-5'-(ethylthio)adenosine; DB07052; (2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-[(ethylsulfanyl)methyl]oxolane-3,4-diol
DM0PQH1	DT	Small molecular drug
DM0PQH1	PC	10041129
DM0PQH1	MW	311.36
DM0PQH1	FM	C12H17N5O3S
DM0PQH1	IC	InChI=1S/C12H17N5O3S/c1-2-21-3-6-8(18)9(19)12(20-6)17-5-16-7-10(13)14-4-15-11(7)17/h4-6,8-9,12,18-19H,2-3H2,1H3,(H2,13,14,15)/t6-,8-,9-,12-/m1/s1
DM0PQH1	CS	CCSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DM0PQH1	IK	HMXHURAGFHWODC-WOUKDFQISA-N
DM0PQH1	IU	(2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-(ethylsulfanylmethyl)oxolane-3,4-diol
DM0PQH1	CB	CHEBI:74046
DM0PQH1	DE	Discovery agent

DM3Z6G4	ID	DM3Z6G4
DM3Z6G4	DN	5S-HETE
DM3Z6G4	HS	Investigative
DM3Z6G4	SN	5-Hydroxyeicosatetraenoic acid; 5(S)-HETE; 5-Hete; 5-Hydroxyeicosatetraenoate; 5-Hydroxy-6,8,11,14-eicosatetraenoic acid; UNII-467RNW8T91; 70608-72-9; CHEMBL164813; CHEBI:28209; 5(S)-hydroxyeicosatetraenoic acid; 467RNW8T91; 6,8,11,14-Eicosatetraenoic acid, 5-hydroxy-, (S-(E,Z,Z,Z))-; (5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoic acid; 5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; (6E,8Z,11Z,14Z)-(5S)-5-Hydroxyicosa-6,8,11,14-tetraenoic acid; 5-(S)-hydroxyeicosatetraenoic acid; AC1NQXIH; BSPBio_001443;  5-(S)-hydroxyeicosatetraenoic acid
DM3Z6G4	DT	Small molecular drug
DM3Z6G4	PC	5280733
DM3Z6G4	MW	320.5
DM3Z6G4	FM	C20H32O3
DM3Z6G4	IC	InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h6-7,9-10,12-14,16,19,21H,2-5,8,11,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,13-12-,16-14+/t19-/m1/s1
DM3Z6G4	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C=C\\[C@H](CCCC(=O)O)O
DM3Z6G4	IK	KGIJOOYOSFUGPC-JGKLHWIESA-N
DM3Z6G4	IU	(5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoic acid
DM3Z6G4	CA	CAS 330796-62-8
DM3Z6G4	CB	CHEBI:28209
DM3Z6G4	DE	Discovery agent

DME1304	ID	DME1304
DME1304	DN	5S-HPETE
DME1304	HS	Investigative
DME1304	SN	5-(S)-hydroperoxyeicosatetraenoic acid; 5S-HpETE
DME1304	DT	Small molecular drug
DME1304	PC	5280778
DME1304	MW	336.5
DME1304	FM	C20H32O4
DME1304	IC	InChI=1S/C20H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(24-23)17-15-18-20(21)22/h6-7,9-10,12-14,16,19,23H,2-5,8,11,15,17-18H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-14+/t19-/m1/s1
DME1304	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C=C\\[C@H](CCCC(=O)O)OO
DME1304	IK	JNUUNUQHXIOFDA-JGKLHWIESA-N
DME1304	IU	(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoic acid
DME1304	CA	CAS 71774-08-8
DME1304	CB	CHEBI:15632
DME1304	DE	Discovery agent

DMCG6EK	ID	DMCG6EK
DMCG6EK	DN	5-tert-Butyl-2-(4-ethynyl-phenyl)-[1,3]dithiane
DMCG6EK	HS	Investigative
DMCG6EK	SN	120076-03-1; 1,3-Dithiane, 5-(1,1-dimethylethyl)-2-(4-ethynylphenyl)-, trans-; ACMC-20mopv; CHEMBL90399; SCHEMBL8950548; CTK0F9221; DTXSID40625630; HKLYPSSDHPAOJM-UHFFFAOYSA-N; 2-(4-ethynylphenyl)-5-t-butyl-1,3-dithiane; 5-tert-Butyl-2-(4-ethynylphenyl)-1,3-dithiane
DMCG6EK	DT	Small molecular drug
DMCG6EK	PC	22421021
DMCG6EK	MW	276.5
DMCG6EK	FM	C16H20S2
DMCG6EK	IC	InChI=1S/C16H20S2/c1-5-12-6-8-13(9-7-12)15-17-10-14(11-18-15)16(2,3)4/h1,6-9,14-15H,10-11H2,2-4H3
DMCG6EK	CS	CC(C)(C)C1CSC(SC1)C2=CC=C(C=C2)C#C
DMCG6EK	IK	HKLYPSSDHPAOJM-UHFFFAOYSA-N
DMCG6EK	IU	5-tert-butyl-2-(4-ethynylphenyl)-1,3-dithiane
DMCG6EK	CA	CAS 120076-03-1
DMCG6EK	DE	Discovery agent

DMQK32F	ID	DMQK32F
DMQK32F	DN	5-tert-Butyl-2-(4-fluoro-phenyl)-[1,3]dithiane
DMQK32F	HS	Investigative
DMQK32F	SN	CHEMBL315953; ZINC584614859; ZINC584614855
DMQK32F	DT	Small molecular drug
DMQK32F	PC	10015993
DMQK32F	MW	270.4
DMQK32F	FM	C14H19FS2
DMQK32F	IC	InChI=1S/C14H19FS2/c1-14(2,3)11-8-16-13(17-9-11)10-4-6-12(15)7-5-10/h4-7,11,13H,8-9H2,1-3H3
DMQK32F	CS	CC(C)(C)C1CSC(SC1)C2=CC=C(C=C2)F
DMQK32F	IK	MFJQBAHBCVIQEE-UHFFFAOYSA-N
DMQK32F	IU	5-tert-butyl-2-(4-fluorophenyl)-1,3-dithiane
DMQK32F	DE	Discovery agent

DMF4RGW	ID	DMF4RGW
DMF4RGW	DN	5-thia-8,11,14,17-eicosatetraenoic acid
DMF4RGW	HS	Investigative
DMF4RGW	SN	CHEMBL460444; 5-thia-8,11,14,17-eicosatetraenoic acid; BDBM50242353; (8Z,11Z,14Z,17Z)-5-Thia-8,11,14,17-icosatetraenoic acid
DMF4RGW	DT	Small molecular drug
DMF4RGW	PC	10019057
DMF4RGW	MW	322.5
DMF4RGW	FM	C19H30O2S
DMF4RGW	IC	InChI=1S/C19H30O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-22-18-15-16-19(20)21/h3-4,6-7,9-10,12-13H,2,5,8,11,14-18H2,1H3,(H,20,21)/b4-3-,7-6-,10-9-,13-12-
DMF4RGW	CS	CC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCSCCCC(=O)O
DMF4RGW	IK	JUGSAWFPXQSLMJ-LTKCOYKYSA-N
DMF4RGW	IU	4-[(3Z,6Z,9Z,12Z)-pentadeca-3,6,9,12-tetraenyl]sulfanylbutanoic acid
DMF4RGW	DE	Discovery agent

DMTB91D	ID	DMTB91D
DMTB91D	DN	5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one
DMTB91D	HS	Investigative
DMTB91D	SN	CHEMBL498086; 24127-35-3; KCIOJLFKVQHRPU-UHFFFAOYSA-N; 5,6-dihydro-5-(p-tolylsulfonyl)-7h-dibenz[b,d]azepin-7-one; 5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one; AC1LCKZQ; TimTec1_004880; Oprea1_188679; SCHEMBL3034555; CTK8H7702; HMS1547N18; 7H-Dibenz[b,d]azepin-7-one, 5,6-dihydro-5-(p-tolylsulfonyl)-; BDBM50279063; KB-310270; 5-(4-methylphenyl)sulfonyl-6H-benzo[d][1]benzazepin-7-one; 5-(Toluene-4-sulfonyl)-5,6-dihydro-dibenzo[b,d]azepin-7-one; 5-[(4-Methylphenyl)sulfonyl]-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one #
DMTB91D	DT	Small molecular drug
DMTB91D	PC	602095
DMTB91D	MW	363.4
DMTB91D	FM	C21H17NO3S
DMTB91D	IC	InChI=1S/C21H17NO3S/c1-15-10-12-16(13-11-15)26(24,25)22-14-21(23)19-8-3-2-6-17(19)18-7-4-5-9-20(18)22/h2-13H,14H2,1H3
DMTB91D	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CC(=O)C3=CC=CC=C3C4=CC=CC=C42
DMTB91D	IK	KCIOJLFKVQHRPU-UHFFFAOYSA-N
DMTB91D	IU	5-(4-methylphenyl)sulfonyl-6H-benzo[d][1]benzazepin-7-one
DMTB91D	DE	Discovery agent

DMOR04W	ID	DMOR04W
DMOR04W	DN	6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione
DMOR04W	HS	Investigative
DMOR04W	DE	Discovery agent

DM5RX0K	ID	DM5RX0K
DM5RX0K	DN	6-(1H-Benzoimidazol-2-yl)-benzocyclohepten-7-one
DM5RX0K	HS	Investigative
DM5RX0K	SN	benzoannulenone 1; AC1NS6NT; CHEMBL327029; BDBM5326; 6-(1H-benzimidazol-2-yl)benzo[7]annulen-7-one
DM5RX0K	DT	Small molecular drug
DM5RX0K	PC	5329369
DM5RX0K	MW	272.3
DM5RX0K	FM	C18H12N2O
DM5RX0K	IC	InChI=1S/C18H12N2O/c21-17-10-9-12-5-1-2-6-13(12)11-14(17)18-19-15-7-3-4-8-16(15)20-18/h1-11H,(H,19,20)
DM5RX0K	CS	C1=CC=C2C=C(C(=O)C=CC2=C1)C3=NC4=CC=CC=C4N3
DM5RX0K	IK	OZPIXWTVOIXFBH-UHFFFAOYSA-N
DM5RX0K	IU	6-(1H-benzimidazol-2-yl)benzo[7]annulen-7-one
DM5RX0K	DE	Discovery agent

DM1TOFD	ID	DM1TOFD
DM1TOFD	DN	6-(1H-Indole-2-sulfonyl)-2H-pyridazin-3-one
DM1TOFD	HS	Investigative
DM1TOFD	SN	indole, 20; CHEMBL72278; SCHEMBL4454291; BDBM16454; HXNAGYMCTAINEA-UHFFFAOYSA-N; Heterocyclic Sulfonylpyridazinone, 19a; 6-(indole-2-sulfonyl)-2H-pyridazin-3-one
DM1TOFD	DT	Small molecular drug
DM1TOFD	PC	9856809
DM1TOFD	MW	275.29
DM1TOFD	FM	C12H9N3O3S
DM1TOFD	IC	InChI=1S/C12H9N3O3S/c16-10-5-6-11(15-14-10)19(17,18)12-7-8-3-1-2-4-9(8)13-12/h1-7,13H,(H,14,16)
DM1TOFD	CS	C1=CC=C2C(=C1)C=C(N2)S(=O)(=O)C3=NNC(=O)C=C3
DM1TOFD	IK	HXNAGYMCTAINEA-UHFFFAOYSA-N
DM1TOFD	IU	3-(1H-indol-2-ylsulfonyl)-1H-pyridazin-6-one
DM1TOFD	DE	Discovery agent

DMRU963	ID	DMRU963
DMRU963	DN	6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMRU963	HS	Investigative
DMRU963	SN	CHEMBL195289; 6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3930290; VLJUOFGVEJAFFK-UHFFFAOYSA-N; ZINC13645040; BDBM50168359
DMRU963	DT	Small molecular drug
DMRU963	PC	10308206
DMRU963	MW	272.24
DMRU963	FM	C16H10F2O2
DMRU963	IC	InChI=1S/C16H10F2O2/c17-14-8-16(20)15(18)7-13(14)11-2-1-10-6-12(19)4-3-9(10)5-11/h1-8,19-20H
DMRU963	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C=C3F)O)F
DMRU963	IK	VLJUOFGVEJAFFK-UHFFFAOYSA-N
DMRU963	IU	6-(2,5-difluoro-4-hydroxyphenyl)naphthalen-2-ol
DMRU963	DE	Discovery agent

DMFALTY	ID	DMFALTY
DMFALTY	DN	6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMFALTY	HS	Investigative
DMFALTY	SN	CHEMBL192621; 6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3924515; AUZLISXBMGKYGA-UHFFFAOYSA-N; ZINC13645047; BDBM50168333
DMFALTY	DT	Small molecular drug
DMFALTY	PC	10214708
DMFALTY	MW	272.24
DMFALTY	FM	C16H10F2O2
DMFALTY	IC	InChI=1S/C16H10F2O2/c17-14-7-13(20)8-15(18)16(14)11-2-1-10-6-12(19)4-3-9(10)5-11/h1-8,19-20H
DMFALTY	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=C(C=C(C=C3F)O)F
DMFALTY	IK	AUZLISXBMGKYGA-UHFFFAOYSA-N
DMFALTY	IU	6-(2,6-difluoro-4-hydroxyphenyl)naphthalen-2-ol
DMFALTY	DE	Discovery agent

DMA9LFR	ID	DMA9LFR
DMA9LFR	DN	6-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMA9LFR	HS	Investigative
DMA9LFR	SN	CHEMBL381869
DMA9LFR	DT	Small molecular drug
DMA9LFR	PC	11552020
DMA9LFR	MW	349.4
DMA9LFR	FM	C21H19NO4
DMA9LFR	IC	InChI=1S/C21H19NO4/c1-14(23)16-4-2-3-5-17(16)15-6-7-20-18(12-15)19(24)13-21(26-20)22-8-10-25-11-9-22/h2-7,12-13H,8-11H2,1H3
DMA9LFR	CS	CC(=O)C1=CC=CC=C1C2=CC3=C(C=C2)OC(=CC3=O)N4CCOCC4
DMA9LFR	IK	IMYDVWVTZRVBCX-UHFFFAOYSA-N
DMA9LFR	IU	6-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMA9LFR	DE	Discovery agent

DMO724D	ID	DMO724D
DMO724D	DN	6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol
DMO724D	HS	Investigative
DMO724D	SN	CHEMBL57470; ZINC29557762; BDBM50025207
DMO724D	DT	Small molecular drug
DMO724D	PC	44299852
DMO724D	MW	245.27
DMO724D	FM	C14H15NO3
DMO724D	IC	InChI=1S/C14H15NO3/c15-8-7-10-3-6-12(17)14(18)13(10)9-1-4-11(16)5-2-9/h1-6,16-18H,7-8,15H2
DMO724D	CS	C1=CC(=CC=C1C2=C(C=CC(=C2O)O)CCN)O
DMO724D	IK	AHHHSPLFRASFOU-UHFFFAOYSA-N
DMO724D	IU	4-(2-aminoethyl)-3-(4-hydroxyphenyl)benzene-1,2-diol
DMO724D	DE	Discovery agent

DMI8KOF	ID	DMI8KOF
DMI8KOF	DN	6-(2-Amino-ethyl)-biphenyl-2,3-diol
DMI8KOF	HS	Investigative
DMI8KOF	SN	CHEMBL299511; 6-(2-Amino-ethyl)-biphenyl-2,3-diol; BDBM50025204
DMI8KOF	DT	Small molecular drug
DMI8KOF	PC	13678304
DMI8KOF	MW	229.27
DMI8KOF	FM	C14H15NO2
DMI8KOF	IC	InChI=1S/C14H15NO2/c15-9-8-11-6-7-12(16)14(17)13(11)10-4-2-1-3-5-10/h1-7,16-17H,8-9,15H2
DMI8KOF	CS	C1=CC=C(C=C1)C2=C(C=CC(=C2O)O)CCN
DMI8KOF	IK	DAKLNHHLHPIOPS-UHFFFAOYSA-N
DMI8KOF	IU	4-(2-aminoethyl)-3-phenylbenzene-1,2-diol
DMI8KOF	DE	Discovery agent

DMXFRW9	ID	DMXFRW9
DMXFRW9	DN	6-(2-aminophenoxy)benzo[d]isothiazol-3-amine
DMXFRW9	HS	Investigative
DMXFRW9	SN	CHEMBL458612; 6-(2-aminophenoxy)benzo[d]isothiazol-3-amine; SCHEMBL14241034; ZINC3818486; BDBM50274720; AKOS022180470; AJ-45722
DMXFRW9	DT	Small molecular drug
DMXFRW9	PC	44224215
DMXFRW9	MW	257.31
DMXFRW9	FM	C13H11N3OS
DMXFRW9	IC	InChI=1S/C13H11N3OS/c14-10-3-1-2-4-11(10)17-8-5-6-9-12(7-8)18-16-13(9)15/h1-7H,14H2,(H2,15,16)
DMXFRW9	CS	C1=CC=C(C(=C1)N)OC2=CC3=C(C=C2)C(=NS3)N
DMXFRW9	IK	HQCTTYOADNAJJR-UHFFFAOYSA-N
DMXFRW9	IU	6-(2-aminophenoxy)-1,2-benzothiazol-3-amine
DMXFRW9	DE	Discovery agent

DMUD2R9	ID	DMUD2R9
DMUD2R9	DN	6-(2-benzylisoindolin-5-yloxy)nicotinamide
DMUD2R9	HS	Investigative
DMUD2R9	SN	CHEMBL238362; 6-(2-benzylisoindolin-5-yloxy)nicotinamide; SCHEMBL3690327; GGVSFVBTUMOASO-UHFFFAOYSA-N; BDBM50226248
DMUD2R9	DT	Small molecular drug
DMUD2R9	PC	44434060
DMUD2R9	MW	345.4
DMUD2R9	FM	C21H19N3O2
DMUD2R9	IC	InChI=1S/C21H19N3O2/c22-21(25)16-7-9-20(23-11-16)26-19-8-6-17-13-24(14-18(17)10-19)12-15-4-2-1-3-5-15/h1-11H,12-14H2,(H2,22,25)
DMUD2R9	CS	C1C2=C(CN1CC3=CC=CC=C3)C=C(C=C2)OC4=NC=C(C=C4)C(=O)N
DMUD2R9	IK	GGVSFVBTUMOASO-UHFFFAOYSA-N
DMUD2R9	IU	6-[(2-benzyl-1,3-dihydroisoindol-5-yl)oxy]pyridine-3-carboxamide
DMUD2R9	DE	Discovery agent

DM9LKXD	ID	DM9LKXD
DM9LKXD	DN	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide
DM9LKXD	HS	Investigative
DM9LKXD	SN	CHEMBL344920; 651767-99-6; 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-
DM9LKXD	DT	Small molecular drug
DM9LKXD	PC	9927379
DM9LKXD	MW	327.22
DM9LKXD	FM	C14H19BrN2O2
DM9LKXD	IC	InChI=1S/C14H19BrN2O2/c15-11-14(19)16-10-6-2-5-9-13(18)17-12-7-3-1-4-8-12/h1,3-4,7-8H,2,5-6,9-11H2,(H,16,19)(H,17,18)
DM9LKXD	CS	C1=CC=C(C=C1)NC(=O)CCCCCNC(=O)CBr
DM9LKXD	IK	HWYLREOMBVUGJQ-UHFFFAOYSA-N
DM9LKXD	IU	6-[(2-bromoacetyl)amino]-N-phenylhexanamide
DM9LKXD	CA	CAS 651767-99-6
DM9LKXD	DE	Discovery agent

DMYDHLN	ID	DMYDHLN
DMYDHLN	DN	6-(2-Bromo-benzenesulfonyl)-2H-pyridazin-3-one
DMYDHLN	HS	Investigative
DMYDHLN	SN	CHEMBL74579; SCHEMBL6206670; BDBM16445; 6-phenylsulfonylpyridazin-2H-3-one, 7; Phenyl-Substituted Sulfonylpyridazinone, 8a
DMYDHLN	DT	Small molecular drug
DMYDHLN	PC	9901432
DMYDHLN	MW	315.15
DMYDHLN	FM	C10H7BrN2O3S
DMYDHLN	IC	InChI=1S/C10H7BrN2O3S/c11-7-3-1-2-4-8(7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DMYDHLN	CS	C1=CC=C(C(=C1)S(=O)(=O)C2=NNC(=O)C=C2)Br
DMYDHLN	IK	MLFKNCYUUMLHTD-UHFFFAOYSA-N
DMYDHLN	IU	3-(2-bromophenyl)sulfonyl-1H-pyridazin-6-one
DMYDHLN	DE	Discovery agent

DMTPAMS	ID	DMTPAMS
DMTPAMS	DN	6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol
DMTPAMS	HS	Investigative
DMTPAMS	SN	CHEMBL195311; 6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3932692; FNSIACDWDZGUHN-UHFFFAOYSA-N; BDBM50168347; ZINC13645053
DMTPAMS	DT	Small molecular drug
DMTPAMS	PC	10308197
DMTPAMS	MW	270.71
DMTPAMS	FM	C16H11ClO2
DMTPAMS	IC	InChI=1S/C16H11ClO2/c17-16-9-14(19)5-6-15(16)12-2-1-11-8-13(18)4-3-10(11)7-12/h1-9,18-19H
DMTPAMS	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=C(C=C(C=C3)O)Cl
DMTPAMS	IK	FNSIACDWDZGUHN-UHFFFAOYSA-N
DMTPAMS	IU	6-(2-chloro-4-hydroxyphenyl)naphthalen-2-ol
DMTPAMS	DE	Discovery agent

DM2Y9O4	ID	DM2Y9O4
DM2Y9O4	DN	6-(2-Chloro-benzenesulfonyl)-2H-pyridazin-3-one
DM2Y9O4	HS	Investigative
DM2Y9O4	SN	CHEMBL72699; SCHEMBL6207180; BDBM16444; 6-phenylsulfonylpyridazin-2H-3-one, 6; Phenyl-Substituted Sulfonylpyridazinone, 8c
DM2Y9O4	DT	Small molecular drug
DM2Y9O4	PC	9921581
DM2Y9O4	MW	270.69
DM2Y9O4	FM	C10H7ClN2O3S
DM2Y9O4	IC	InChI=1S/C10H7ClN2O3S/c11-7-3-1-2-4-8(7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DM2Y9O4	CS	C1=CC=C(C(=C1)S(=O)(=O)C2=NNC(=O)C=C2)Cl
DM2Y9O4	IK	FTLDTGWMVVXYAM-UHFFFAOYSA-N
DM2Y9O4	IU	3-(2-chlorophenyl)sulfonyl-1H-pyridazin-6-one
DM2Y9O4	DE	Discovery agent

DM3VME7	ID	DM3VME7
DM3VME7	DN	6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol
DM3VME7	HS	Investigative
DM3VME7	SN	CHEMBL60861; BDBM50025203
DM3VME7	DT	Small molecular drug
DM3VME7	PC	13678327
DM3VME7	MW	329.4
DM3VME7	FM	C20H27NO3
DM3VME7	IC	InChI=1S/C20H27NO3/c1-3-12-21(13-4-2)14-11-16-7-10-18(23)20(24)19(16)15-5-8-17(22)9-6-15/h5-10,22-24H,3-4,11-14H2,1-2H3
DM3VME7	CS	CCCN(CCC)CCC1=C(C(=C(C=C1)O)O)C2=CC=C(C=C2)O
DM3VME7	IK	NTNWFRQRDDNMJY-UHFFFAOYSA-N
DM3VME7	IU	4-[2-(dipropylamino)ethyl]-3-(4-hydroxyphenyl)benzene-1,2-diol
DM3VME7	DE	Discovery agent

DMNQWZO	ID	DMNQWZO
DMNQWZO	DN	6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol
DMNQWZO	HS	Investigative
DMNQWZO	SN	CHEMBL300995; 6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol
DMNQWZO	DT	Small molecular drug
DMNQWZO	PC	13678325
DMNQWZO	MW	313.4
DMNQWZO	FM	C20H27NO2
DMNQWZO	IC	InChI=1S/C20H27NO2/c1-3-13-21(14-4-2)15-12-17-10-11-18(22)20(23)19(17)16-8-6-5-7-9-16/h5-11,22-23H,3-4,12-15H2,1-2H3
DMNQWZO	CS	CCCN(CCC)CCC1=C(C(=C(C=C1)O)O)C2=CC=CC=C2
DMNQWZO	IK	HDPTVXIDWCYRQU-UHFFFAOYSA-N
DMNQWZO	IU	4-[2-(dipropylamino)ethyl]-3-phenylbenzene-1,2-diol
DMNQWZO	DE	Discovery agent

DM6Q3M7	ID	DM6Q3M7
DM6Q3M7	DN	6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DM6Q3M7	HS	Investigative
DM6Q3M7	SN	CHEMBL195878; 6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3926652; MAFQDFZNSVYFEW-UHFFFAOYSA-N; ZINC13645034; BDBM50168350
DM6Q3M7	DT	Small molecular drug
DM6Q3M7	PC	10125290
DM6Q3M7	MW	254.25
DM6Q3M7	FM	C16H11FO2
DM6Q3M7	IC	InChI=1S/C16H11FO2/c17-16-9-14(19)5-6-15(16)12-2-1-11-8-13(18)4-3-10(11)7-12/h1-9,18-19H
DM6Q3M7	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=C(C=C(C=C3)O)F
DM6Q3M7	IK	MAFQDFZNSVYFEW-UHFFFAOYSA-N
DM6Q3M7	IU	6-(2-fluoro-4-hydroxyphenyl)naphthalen-2-ol
DM6Q3M7	DE	Discovery agent

DMQKR2W	ID	DMQKR2W
DMQKR2W	DN	6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one
DMQKR2W	HS	Investigative
DMQKR2W	SN	6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one; CHEMBL198119; SCHEMBL6205793; BDBM16600; AEDNYZQZIZUZTP-UHFFFAOYSA-N; Phenyl-Substituted Sulfonylpyridazinone, 8f
DMQKR2W	DT	Small molecular drug
DMQKR2W	PC	9943009
DMQKR2W	MW	254.24
DMQKR2W	FM	C10H7FN2O3S
DMQKR2W	IC	InChI=1S/C10H7FN2O3S/c11-7-3-1-2-4-8(7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DMQKR2W	CS	C1=CC=C(C(=C1)F)S(=O)(=O)C2=NNC(=O)C=C2
DMQKR2W	IK	AEDNYZQZIZUZTP-UHFFFAOYSA-N
DMQKR2W	IU	3-(2-fluorophenyl)sulfonyl-1H-pyridazin-6-one
DMQKR2W	DE	Discovery agent

DME1JLM	ID	DME1JLM
DME1JLM	DN	6-(2-Fluoropropyl)-4-methylpyridin-2-amine
DME1JLM	HS	Investigative
DME1JLM	SN	6-(2-Fluoropropyl)-4-methylpyridin-2-amine; CHEMBL450726; 1146620-35-0; SCHEMBL13040574; BDBM50267272; 2-Pyridinamine, 6-(2-fluoropropyl)-4-methyl-
DME1JLM	DT	Small molecular drug
DME1JLM	PC	42625451
DME1JLM	MW	168.21
DME1JLM	FM	C9H13FN2
DME1JLM	IC	InChI=1S/C9H13FN2/c1-6-3-8(5-7(2)10)12-9(11)4-6/h3-4,7H,5H2,1-2H3,(H2,11,12)
DME1JLM	CS	CC1=CC(=NC(=C1)N)CC(C)F
DME1JLM	IK	MBHRCNFCHFHUKZ-UHFFFAOYSA-N
DME1JLM	IU	6-(2-fluoropropyl)-4-methylpyridin-2-amine
DME1JLM	CA	CAS 1146620-35-0
DME1JLM	DE	Discovery agent

DMA2CPG	ID	DMA2CPG
DMA2CPG	DN	6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE
DMA2CPG	HS	Investigative
DMA2CPG	SN	6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE; GR157368; 1qhr; AC1O43NS; DB06861; (6R)-6-[(1R,2S)-2-hydroxycyclopentyl]-7-oxoheptanimidamide
DMA2CPG	DT	Small molecular drug
DMA2CPG	PC	6323178
DMA2CPG	MW	226.32
DMA2CPG	FM	C12H22N2O2
DMA2CPG	IC	InChI=1S/C12H22N2O2/c13-12(14)7-2-1-4-9(8-15)10-5-3-6-11(10)16/h8-11,16H,1-7H2,(H3,13,14)/t9-,10+,11-/m0/s1
DMA2CPG	CS	C1C[C@@H]([C@H](C1)O)[C@@H](CCCCC(=N)N)C=O
DMA2CPG	IK	FCDJKFJACUMSOZ-AXFHLTTASA-N
DMA2CPG	IU	(6R)-6-[(1R,2S)-2-hydroxycyclopentyl]-7-oxoheptanimidamide
DMA2CPG	DE	Discovery agent

DMM3798	ID	DMM3798
DMM3798	DN	6-(2-Hydroxy-phenyl)-naphthalen-2-ol
DMM3798	HS	Investigative
DMM3798	SN	CHEMBL195058; 6-(2-hydroxyphenyl)-2-naphthol; 6-(2-Hydroxy-phenyl)-naphthalen-2-ol; 2-methyl-6-o-tolylnaphthalene; SCHEMBL3016027; SMFVAKMYNVSVKJ-UHFFFAOYSA-N; BDBM50168378
DMM3798	DT	Small molecular drug
DMM3798	PC	11368353
DMM3798	MW	236.26
DMM3798	FM	C16H12O2
DMM3798	IC	InChI=1S/C16H12O2/c17-14-8-7-11-9-13(6-5-12(11)10-14)15-3-1-2-4-16(15)18/h1-10,17-18H
DMM3798	CS	C1=CC=C(C(=C1)C2=CC3=C(C=C2)C=C(C=C3)O)O
DMM3798	IK	SMFVAKMYNVSVKJ-UHFFFAOYSA-N
DMM3798	IU	6-(2-hydroxyphenyl)naphthalen-2-ol
DMM3798	DE	Discovery agent

DMXZWOA	ID	DMXZWOA
DMXZWOA	DN	6-(2-Imidazol-1-yl-vinyl)-1H-quinolin-2-one
DMXZWOA	HS	Investigative
DMXZWOA	SN	CHEMBL347379; 6-(2-Imidazol-1-yl-vinyl)-1H-quinolin-2-one; SCHEMBL10461779
DMXZWOA	DT	Small molecular drug
DMXZWOA	PC	14373279
DMXZWOA	MW	237.26
DMXZWOA	FM	C14H11N3O
DMXZWOA	IC	InChI=1S/C14H11N3O/c18-14-4-2-12-9-11(1-3-13(12)16-14)5-7-17-8-6-15-10-17/h1-10H,(H,16,18)/b7-5+
DMXZWOA	CS	C1=CC2=C(C=CC(=O)N2)C=C1/C=C/N3C=CN=C3
DMXZWOA	IK	ULTZJAJIZBBKSG-FNORWQNLSA-N
DMXZWOA	IU	6-[(E)-2-imidazol-1-ylethenyl]-1H-quinolin-2-one
DMXZWOA	DE	Discovery agent

DM9P4LB	ID	DM9P4LB
DM9P4LB	DN	6-(2-mercaptoacetamido)-N-phenylhexanamide
DM9P4LB	HS	Investigative
DM9P4LB	SN	CHEMBL178727; 6-(2-Mercaptoacetylamino)-N-Phenylhexanamide; 824970-14-1; 6-(2-mercaptoacetamido)-N-phenylhexanamide; 4cqf; SCHEMBL5998899; CTK3D8890; DTXSID50465903; ZINC13609328; BDBM50157884; AKOS030603047; N-phenyl-6-[(sulfanylacetyl)amino]hexanamide; N-Phenyl-6-[(mercaptoacetyl)amino]hexanamide; Hexanamide, 6-[(mercaptoacetyl)amino]-N-phenyl-; 6-(2-Mercapto-acetylamino)-hexanoic acid phenylamide
DM9P4LB	DT	Small molecular drug
DM9P4LB	PC	11437457
DM9P4LB	MW	280.39
DM9P4LB	FM	C14H20N2O2S
DM9P4LB	IC	InChI=1S/C14H20N2O2S/c17-13(16-12-7-3-1-4-8-12)9-5-2-6-10-15-14(18)11-19/h1,3-4,7-8,19H,2,5-6,9-11H2,(H,15,18)(H,16,17)
DM9P4LB	CS	C1=CC=C(C=C1)NC(=O)CCCCCNC(=O)CS
DM9P4LB	IK	ICMLRCZXRBTKLJ-UHFFFAOYSA-N
DM9P4LB	IU	N-phenyl-6-[(2-sulfanylacetyl)amino]hexanamide
DM9P4LB	CA	CAS 824970-14-1
DM9P4LB	DE	Discovery agent

DMQOJBN	ID	DMQOJBN
DMQOJBN	DN	6-(2-phenethylisoindolin-5-yloxy)nicotinamide
DMQOJBN	HS	Investigative
DMQOJBN	SN	CHEMBL235154; 6-(2-phenethylisoindolin-5-yloxy)nicotinamide; SCHEMBL3696847
DMQOJBN	DT	Small molecular drug
DMQOJBN	PC	44434061
DMQOJBN	MW	359.4
DMQOJBN	FM	C22H21N3O2
DMQOJBN	IC	InChI=1S/C22H21N3O2/c23-22(26)17-7-9-21(24-13-17)27-20-8-6-18-14-25(15-19(18)12-20)11-10-16-4-2-1-3-5-16/h1-9,12-13H,10-11,14-15H2,(H2,23,26)
DMQOJBN	CS	C1C2=C(CN1CCC3=CC=CC=C3)C=C(C=C2)OC4=NC=C(C=C4)C(=O)N
DMQOJBN	IK	ACAQNMZIFFSQCU-UHFFFAOYSA-N
DMQOJBN	IU	6-[[2-(2-phenylethyl)-1,3-dihydroisoindol-5-yl]oxy]pyridine-3-carboxamide
DMQOJBN	DE	Discovery agent

DMKXNP0	ID	DMKXNP0
DMKXNP0	DN	6-(2-Phenylsulfanyl-ethyl)-pteridine-2,4-diamine
DMKXNP0	HS	Investigative
DMKXNP0	SN	CHEMBL50379; 6-(2-phenylsulfanylethyl)pteridine-2,4-diamine; AC1L9YC2; 6-(2-Phenylsulfanyl-ethyl)-pteridine-2,4-diamine; BDBM50127151; 2,4-Pteridinediamine, 6-[2-(phenylthio)ethyl]-
DMKXNP0	DT	Small molecular drug
DMKXNP0	PC	504032
DMKXNP0	MW	298.37
DMKXNP0	FM	C14H14N6S
DMKXNP0	IC	InChI=1S/C14H14N6S/c15-12-11-13(20-14(16)19-12)17-8-9(18-11)6-7-21-10-4-2-1-3-5-10/h1-5,8H,6-7H2,(H4,15,16,17,19,20)
DMKXNP0	CS	C1=CC=C(C=C1)SCCC2=CN=C3C(=N2)C(=NC(=N3)N)N
DMKXNP0	IK	OVPXUMDQGFGLQK-UHFFFAOYSA-N
DMKXNP0	IU	6-(2-phenylsulfanylethyl)pteridine-2,4-diamine
DMKXNP0	DE	Discovery agent

DMA8TWC	ID	DMA8TWC
DMA8TWC	DN	6-(3-(pyridin-4-yl)phenyl)naphthalen-2-ol
DMA8TWC	HS	Investigative
DMA8TWC	SN	CHEMBL254326
DMA8TWC	DT	Small molecular drug
DMA8TWC	PC	24936181
DMA8TWC	MW	297.3
DMA8TWC	FM	C21H15NO
DMA8TWC	IC	InChI=1S/C21H15NO/c23-21-7-6-19-13-18(4-5-20(19)14-21)17-3-1-2-16(12-17)15-8-10-22-11-9-15/h1-14,23H
DMA8TWC	CS	C1=CC(=CC(=C1)C2=CC3=C(C=C2)C=C(C=C3)O)C4=CC=NC=C4
DMA8TWC	IK	JKPUOZDSUARXRX-UHFFFAOYSA-N
DMA8TWC	IU	6-(3-pyridin-4-ylphenyl)naphthalen-2-ol
DMA8TWC	DE	Discovery agent

DMDYQE2	ID	DMDYQE2
DMDYQE2	DN	6-(3-(trifluoromethyl)phenyl)picolinonitrile
DMDYQE2	HS	Investigative
DMDYQE2	SN	6-(3-(trifluoromethyl)phenyl)picolinonitrile; CHEMBL1210691; 833457-45-7; SCHEMBL9954071; CTK3D2833; DTXSID80678807; BDBM50322920; 6-[3-(Trifluoromethyl)phenyl]pyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 6-[3-(trifluoromethyl)phenyl]-
DMDYQE2	DT	Small molecular drug
DMDYQE2	PC	49863205
DMDYQE2	MW	248.2
DMDYQE2	FM	C13H7F3N2
DMDYQE2	IC	InChI=1S/C13H7F3N2/c14-13(15,16)10-4-1-3-9(7-10)12-6-2-5-11(8-17)18-12/h1-7H
DMDYQE2	CS	C1=CC(=CC(=C1)C(F)(F)F)C2=CC=CC(=N2)C#N
DMDYQE2	IK	FYQRYAIHFASLNM-UHFFFAOYSA-N
DMDYQE2	IU	6-[3-(trifluoromethyl)phenyl]pyridine-2-carbonitrile
DMDYQE2	CA	CAS 833457-45-7
DMDYQE2	DE	Discovery agent

DMZHFWX	ID	DMZHFWX
DMZHFWX	DN	6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)
DMZHFWX	HS	Investigative
DMZHFWX	SN	CHEMBL1173087; 6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX); BDBM50322696; rac-6-(3,4-dichlorophenyl)-5-methoxy-1-1-methoxybut-3-enyl)-3-azabicyclo[4.1.0]heptane
DMZHFWX	DT	Small molecular drug
DMZHFWX	PC	49799108
DMZHFWX	MW	326.3
DMZHFWX	FM	C17H21Cl2NO
DMZHFWX	IC	InChI=1S/C17H21Cl2NO/c1-3-4-15(21-2)17-10-16(17,7-8-20-11-17)12-5-6-13(18)14(19)9-12/h3,5-6,9,15,20H,1,4,7-8,10-11H2,2H3/t15?,16-,17+/m1/s1
DMZHFWX	CS	COC(CC=C)[C@@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl
DMZHFWX	IK	AOUKQWFJPNRGAH-FGJGXXMFSA-N
DMZHFWX	IU	(1S,6S)-6-(3,4-dichlorophenyl)-1-(1-methoxybut-3-enyl)-3-azabicyclo[4.1.0]heptane
DMZHFWX	DE	Discovery agent

DMKJOL6	ID	DMKJOL6
DMKJOL6	DN	6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMKJOL6	HS	Investigative
DMKJOL6	SN	CHEMBL191716; 6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3934682; DZGRIHNLLUZLTL-UHFFFAOYSA-N; BDBM50168366; ZINC13645080
DMKJOL6	DT	Small molecular drug
DMKJOL6	PC	10308207
DMKJOL6	MW	272.24
DMKJOL6	FM	C16H10F2O2
DMKJOL6	IC	InChI=1S/C16H10F2O2/c17-14-7-12(8-15(18)16(14)20)10-1-2-11-6-13(19)4-3-9(11)5-10/h1-8,19-20H
DMKJOL6	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C(=C3)F)O)F
DMKJOL6	IK	DZGRIHNLLUZLTL-UHFFFAOYSA-N
DMKJOL6	IU	6-(3,5-difluoro-4-hydroxyphenyl)naphthalen-2-ol
DMKJOL6	DE	Discovery agent

DMIXT2L	ID	DMIXT2L
DMIXT2L	DN	6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol
DMIXT2L	HS	Investigative
DMIXT2L	SN	CHEMBL362997; 6-(3,5-Dimethoxy-phenyl)-naphthalen-2-ol; BDBM50186758
DMIXT2L	DT	Small molecular drug
DMIXT2L	PC	11536458
DMIXT2L	MW	280.3
DMIXT2L	FM	C18H16O3
DMIXT2L	IC	InChI=1S/C18H16O3/c1-20-17-9-15(10-18(11-17)21-2)13-3-4-14-8-16(19)6-5-12(14)7-13/h3-11,19H,1-2H3
DMIXT2L	CS	COC1=CC(=CC(=C1)C2=CC3=C(C=C2)C=C(C=C3)O)OC
DMIXT2L	IK	HYWKEQNSMAOKKU-UHFFFAOYSA-N
DMIXT2L	IU	6-(3,5-dimethoxyphenyl)naphthalen-2-ol
DMIXT2L	DE	Discovery agent

DMJ92W0	ID	DMJ92W0
DMJ92W0	DN	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine
DMJ92W0	HS	Investigative
DMJ92W0	SN	O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine
DMJ92W0	DT	Small molecular drug
DMJ92W0	PC	5329517
DMJ92W0	MW	256.26
DMJ92W0	FM	C12H12N6O
DMJ92W0	IC	InChI=1S/C12H12N6O/c13-8-3-1-2-7(4-8)5-19-11-9-10(16-6-15-9)17-12(14)18-11/h1-4,6H,5,13H2,(H3,14,15,16,17,18)
DMJ92W0	CS	C1=CC(=CC(=C1)N)COC2=NC(=NC3=C2NC=N3)N
DMJ92W0	IK	QCEFDVCKQLVMCW-UHFFFAOYSA-N
DMJ92W0	IU	6-[(3-aminophenyl)methoxy]-7H-purin-2-amine
DMJ92W0	DE	Discovery agent

DMYA4D2	ID	DMYA4D2
DMYA4D2	DN	6-(3-aminopropyl)benzo[h]isoquinolin-1(2H)-one
DMYA4D2	HS	Investigative
DMYA4D2	SN	CHEMBL250222; 6-(3-aminopropyl)benzo[h]isoquinolin-1(2H)-one; SCHEMBL13659560
DMYA4D2	DT	Small molecular drug
DMYA4D2	PC	44443516
DMYA4D2	MW	252.31
DMYA4D2	FM	C16H16N2O
DMYA4D2	IC	InChI=1S/C16H16N2O/c17-8-3-4-11-10-12-7-9-18-16(19)15(12)14-6-2-1-5-13(11)14/h1-2,5-7,9-10H,3-4,8,17H2,(H,18,19)
DMYA4D2	CS	C1=CC=C2C(=C1)C(=CC3=C2C(=O)NC=C3)CCCN
DMYA4D2	IK	LBNJYZFAUIDIPA-UHFFFAOYSA-N
DMYA4D2	IU	6-(3-aminopropyl)-2H-benzo[h]isoquinolin-1-one
DMYA4D2	DE	Discovery agent

DMKFDQ7	ID	DMKFDQ7
DMKFDQ7	DN	6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline
DMKFDQ7	HS	Investigative
DMKFDQ7	SN	CHEMBL503444; 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline; SCHEMBL3471202
DMKFDQ7	DT	Small molecular drug
DMKFDQ7	PC	25166858
DMKFDQ7	MW	210.27
DMKFDQ7	FM	C14H14N2
DMKFDQ7	IC	InChI=1S/C14H14N2/c1-2-10-6-11(3-4-13(10)16-5-1)14-7-12(14)8-15-9-14/h1-6,12,15H,7-9H2
DMKFDQ7	CS	C1C2C1(CNC2)C3=CC4=C(C=C3)N=CC=C4
DMKFDQ7	IK	RJVNCNHNNCNEMX-UHFFFAOYSA-N
DMKFDQ7	IU	6-(3-azabicyclo[3.1.0]hexan-1-yl)quinoline
DMKFDQ7	DE	Discovery agent

DMQZTS3	ID	DMQZTS3
DMQZTS3	DN	6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide
DMQZTS3	HS	Investigative
DMQZTS3	SN	UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235
DMQZTS3	DT	Small molecular drug
DMQZTS3	PC	11449246
DMQZTS3	MW	293.32
DMQZTS3	FM	C14H19N3O4
DMQZTS3	IC	InChI=1S/C14H19N3O4/c18-12(17-21)9-5-2-6-10-15-14(20)16-13(19)11-7-3-1-4-8-11/h1,3-4,7-8,21H,2,5-6,9-10H2,(H,17,18)(H2,15,16,19,20)
DMQZTS3	CS	C1=CC=C(C=C1)C(=O)NC(=O)NCCCCCC(=O)NO
DMQZTS3	IK	VQLQZMGNGMOMPU-UHFFFAOYSA-N
DMQZTS3	IU	N-[[6-(hydroxyamino)-6-oxohexyl]carbamoyl]benzamide
DMQZTS3	CA	CAS 851365-34-9
DMQZTS3	DE	Discovery agent

DM89LF5	ID	DM89LF5
DM89LF5	DN	6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
DM89LF5	HS	Investigative
DM89LF5	SN	6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE; 6-(3-bromonaphthalen-2-yl)-1,3,5-triazine-2,4-diamine; 2qf6; HSP90 Inhibitor, 1; SCHEMBL10822557; BDBM81729; DB07319
DM89LF5	DT	Small molecular drug
DM89LF5	PC	13373715
DM89LF5	MW	316.16
DM89LF5	FM	C13H10BrN5
DM89LF5	IC	InChI=1S/C13H10BrN5/c14-10-6-8-4-2-1-3-7(8)5-9(10)11-17-12(15)19-13(16)18-11/h1-6H,(H4,15,16,17,18,19)
DM89LF5	CS	C1=CC=C2C=C(C(=CC2=C1)C3=NC(=NC(=N3)N)N)Br
DM89LF5	IK	RXSSKAZHCZWJPP-UHFFFAOYSA-N
DM89LF5	IU	6-(3-bromonaphthalen-2-yl)-1,3,5-triazine-2,4-diamine
DM89LF5	DE	Discovery agent

DMMFWYX	ID	DMMFWYX
DMMFWYX	DN	6-(3-Bromo-phenylamino)-1H-pyrimidine-2,4-dione
DMMFWYX	HS	Investigative
DMMFWYX	SN	CHEMBL291461; 6-(3-Bromo-phenylamino)-1H-pyrimidine-2,4-dione; 72255-49-3; 2,4(1H,3H)-Pyrimidinedione, 6-[(3-bromophenyl)amino]-; 6-[(3-bromophenyl)amino]pyrimidine-2,4(1H,3H)-dione; AC1LFXXC; Oprea1_136416; Oprea1_839686; MLS000713738; CTK2H2676; DTXSID30355636; MolPort-001-933-580; ZINC322347; HMS3363I15; HMS2635L06; HMS1673K06; BDBM50028343; STK385018; AKOS000541603; MCULE-5935337788; SMR000273219; BAS 00450422; ST50002707; 6-(3-bromoanilino)-1H-pyrimidine-2,4-dione; AB00091424-01
DMMFWYX	DT	Small molecular drug
DMMFWYX	PC	810824
DMMFWYX	MW	282.09
DMMFWYX	FM	C10H8BrN3O2
DMMFWYX	IC	InChI=1S/C10H8BrN3O2/c11-6-2-1-3-7(4-6)12-8-5-9(15)14-10(16)13-8/h1-5H,(H3,12,13,14,15,16)
DMMFWYX	CS	C1=CC(=CC(=C1)Br)NC2=CC(=O)NC(=O)N2
DMMFWYX	IK	CFLHCISOVMSSHJ-UHFFFAOYSA-N
DMMFWYX	IU	6-(3-bromoanilino)-1H-pyrimidine-2,4-dione
DMMFWYX	CA	CAS 72255-49-3
DMMFWYX	DE	Discovery agent

DM4YP3Q	ID	DM4YP3Q
DM4YP3Q	DN	6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol
DM4YP3Q	HS	Investigative
DM4YP3Q	SN	CHEMBL365999; 6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL4012132; UVRXGDFVCKYIGU-UHFFFAOYSA-N; BDBM50168370; ZINC13645074
DM4YP3Q	DT	Small molecular drug
DM4YP3Q	PC	10286087
DM4YP3Q	MW	270.71
DM4YP3Q	FM	C16H11ClO2
DM4YP3Q	IC	InChI=1S/C16H11ClO2/c17-15-9-13(4-6-16(15)19)10-1-2-12-8-14(18)5-3-11(12)7-10/h1-9,18-19H
DM4YP3Q	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C=C3)O)Cl
DM4YP3Q	IK	UVRXGDFVCKYIGU-UHFFFAOYSA-N
DM4YP3Q	IU	6-(3-chloro-4-hydroxyphenyl)naphthalen-2-ol
DM4YP3Q	CA	CAS 550997-74-5
DM4YP3Q	DE	Discovery agent

DMJO4I7	ID	DMJO4I7
DMJO4I7	DN	6-(3-Chloro-benzenesulfonyl)-2H-pyridazin-3-one
DMJO4I7	HS	Investigative
DMJO4I7	SN	6-(3-Chloro-benzenesulfonyl)-2H-pyridazin-3-one; SCHEMBL6206394; CHEMBL197924; BDBM16598; JORLLGPOJPMFRS-UHFFFAOYSA-N; Phenyl-Substituted Sulfonylpyridazinone, 8d
DMJO4I7	DT	Small molecular drug
DMJO4I7	PC	9943365
DMJO4I7	MW	270.69
DMJO4I7	FM	C10H7ClN2O3S
DMJO4I7	IC	InChI=1S/C10H7ClN2O3S/c11-7-2-1-3-8(6-7)17(15,16)10-5-4-9(14)12-13-10/h1-6H,(H,12,14)
DMJO4I7	CS	C1=CC(=CC(=C1)Cl)S(=O)(=O)C2=NNC(=O)C=C2
DMJO4I7	IK	JORLLGPOJPMFRS-UHFFFAOYSA-N
DMJO4I7	IU	3-(3-chlorophenyl)sulfonyl-1H-pyridazin-6-one
DMJO4I7	DE	Discovery agent

DMKUHN9	ID	DMKUHN9
DMKUHN9	DN	6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione
DMKUHN9	HS	Investigative
DMKUHN9	SN	CHEMBL51750; 72255-48-2; 2,4(1H,3H)-Pyrimidinedione, 6-[(3-ethylphenyl)amino]-; 6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione; CTK2H2677; DTXSID90658211; BDBM50028320
DMKUHN9	DT	Small molecular drug
DMKUHN9	PC	44297884
DMKUHN9	MW	231.25
DMKUHN9	FM	C12H13N3O2
DMKUHN9	IC	InChI=1S/C12H13N3O2/c1-2-8-4-3-5-9(6-8)13-10-7-11(16)15-12(17)14-10/h3-7H,2H2,1H3,(H3,13,14,15,16,17)
DMKUHN9	CS	CCC1=CC(=CC=C1)NC2=CC(=O)NC(=O)N2
DMKUHN9	IK	RFKOQVWQIOZRDE-UHFFFAOYSA-N
DMKUHN9	IU	6-(3-ethylanilino)-1H-pyrimidine-2,4-dione
DMKUHN9	CA	CAS 72255-48-2
DMKUHN9	DE	Discovery agent

DMAJEDG	ID	DMAJEDG
DMAJEDG	DN	6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMAJEDG	HS	Investigative
DMAJEDG	SN	CHEMBL193727; 6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3924993; QTDYCKGQBCKMGC-UHFFFAOYSA-N; ZINC13645068; BDBM50168372
DMAJEDG	DT	Small molecular drug
DMAJEDG	PC	10236221
DMAJEDG	MW	254.25
DMAJEDG	FM	C16H11FO2
DMAJEDG	IC	InChI=1S/C16H11FO2/c17-15-9-13(4-6-16(15)19)10-1-2-12-8-14(18)5-3-11(12)7-10/h1-9,18-19H
DMAJEDG	CS	C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C=C3)O)F
DMAJEDG	IK	QTDYCKGQBCKMGC-UHFFFAOYSA-N
DMAJEDG	IU	6-(3-fluoro-4-hydroxyphenyl)naphthalen-2-ol
DMAJEDG	DE	Discovery agent

DMTJPZU	ID	DMTJPZU
DMTJPZU	DN	6-(3-Fluoropropyl)-4-methylpyridin-2-amine
DMTJPZU	HS	Investigative
DMTJPZU	SN	6-(3-Fluoropropyl)-4-methylpyridin-2-amine; CHEMBL443862; 1146620-54-3; SCHEMBL13040676
DMTJPZU	DT	Small molecular drug
DMTJPZU	PC	42625617
DMTJPZU	MW	168.21
DMTJPZU	FM	C9H13FN2
DMTJPZU	IC	InChI=1S/C9H13FN2/c1-7-5-8(3-2-4-10)12-9(11)6-7/h5-6H,2-4H2,1H3,(H2,11,12)
DMTJPZU	CS	CC1=CC(=NC(=C1)N)CCCF
DMTJPZU	IK	UWBOFUBWKXYIJF-UHFFFAOYSA-N
DMTJPZU	IU	6-(3-fluoropropyl)-4-methylpyridin-2-amine
DMTJPZU	DE	Discovery agent

DMMZENV	ID	DMMZENV
DMMZENV	DN	6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol
DMMZENV	HS	Investigative
DMMZENV	SN	CHEMBL469227; 6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol; SCHEMBL3008799
DMMZENV	DT	Small molecular drug
DMMZENV	PC	24894072
DMMZENV	MW	312.4
DMMZENV	FM	C22H16O2
DMMZENV	IC	InChI=1S/C22H16O2/c23-19-8-4-7-16(14-19)17-9-11-20-18(13-17)10-12-21(24)22(20)15-5-2-1-3-6-15/h1-14,23-24H
DMMZENV	CS	C1=CC=C(C=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O
DMMZENV	IK	ZYOIQICRHUXCRL-UHFFFAOYSA-N
DMMZENV	IU	6-(3-hydroxyphenyl)-1-phenylnaphthalen-2-ol
DMMZENV	DE	Discovery agent

DM28DPY	ID	DM28DPY
DM28DPY	DN	6-(3-hydroxyphenyl)-2-morpholino-4H-chromen-4-one
DM28DPY	HS	Investigative
DM28DPY	SN	CHEMBL427009
DM28DPY	DT	Small molecular drug
DM28DPY	PC	11558836
DM28DPY	MW	323.3
DM28DPY	FM	C19H17NO4
DM28DPY	IC	InChI=1S/C19H17NO4/c21-15-3-1-2-13(10-15)14-4-5-18-16(11-14)17(22)12-19(24-18)20-6-8-23-9-7-20/h1-5,10-12,21H,6-9H2
DM28DPY	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC(=CC=C4)O
DM28DPY	IK	PLPMLPUPRLWRRG-UHFFFAOYSA-N
DM28DPY	IU	6-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DM28DPY	DE	Discovery agent

DMMHRVO	ID	DMMHRVO
DMMHRVO	DN	6-(3-Hydroxy-phenyl)-naphthalen-1-ol
DMMHRVO	HS	Investigative
DMMHRVO	SN	CHEMBL193010; 6-(3-hydroxyphenyl)-1-naphthol; 6-(3-Hydroxy-phenyl)-naphthalen-1-ol; SCHEMBL3010784; HXKYTCGOCJUQSE-UHFFFAOYSA-N; ZINC13644987
DMMHRVO	DT	Small molecular drug
DMMHRVO	PC	11447703
DMMHRVO	MW	236.26
DMMHRVO	FM	C16H12O2
DMMHRVO	IC	InChI=1S/C16H12O2/c17-14-5-1-3-11(10-14)12-7-8-15-13(9-12)4-2-6-16(15)18/h1-10,17-18H
DMMHRVO	CS	C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=CC=C3)O
DMMHRVO	IK	HXKYTCGOCJUQSE-UHFFFAOYSA-N
DMMHRVO	IU	6-(3-hydroxyphenyl)naphthalen-1-ol
DMMHRVO	DE	Discovery agent

DMH8WA2	ID	DMH8WA2
DMH8WA2	DN	6-(3-Hydroxy-phenyl)-naphthalen-2-ol
DMH8WA2	HS	Investigative
DMH8WA2	SN	6-(3-hydroxyphenyl)-2-naphthol; 6-(3-hydroxyphenyl)naphthalen-2-ol
DMH8WA2	PC	10192730
DMH8WA2	MW	236.26
DMH8WA2	FM	C16H12O2
DMH8WA2	IC	InChI=1S/C16H12O2/c17-15-3-1-2-11(9-15)12-4-5-14-10-16(18)7-6-13(14)8-12/h1-10,17-18H
DMH8WA2	CS	C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C=C(C=C3)O
DMH8WA2	IK	VHWBXEUHUQDHDH-UHFFFAOYSA-N
DMH8WA2	IU	6-(3-hydroxyphenyl)naphthalen-2-ol
DMH8WA2	DE	Discovery agent

DMISV5A	ID	DMISV5A
DMISV5A	DN	6-(3-Iodo-phenylamino)-1H-pyrimidine-2,4-dione
DMISV5A	HS	Investigative
DMISV5A	SN	CHEMBL300465; 72255-50-6; 6-(3-Iodo-phenylamino)-1H-pyrimidine-2,4-dione; CTK2H2675; DTXSID50658212; BDBM50028331; 6-(3-Iodoanilino)pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-[(3-iodophenyl)amino]-
DMISV5A	DT	Small molecular drug
DMISV5A	PC	44297894
DMISV5A	MW	329.09
DMISV5A	FM	C10H8IN3O2
DMISV5A	IC	InChI=1S/C10H8IN3O2/c11-6-2-1-3-7(4-6)12-8-5-9(15)14-10(16)13-8/h1-5H,(H3,12,13,14,15,16)
DMISV5A	CS	C1=CC(=CC(=C1)I)NC2=CC(=O)NC(=O)N2
DMISV5A	IK	NUGFPABWAOETRO-UHFFFAOYSA-N
DMISV5A	IU	6-(3-iodoanilino)-1H-pyrimidine-2,4-dione
DMISV5A	CA	CAS 72255-50-6
DMISV5A	DE	Discovery agent

DMSW3KN	ID	DMSW3KN
DMSW3KN	DN	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine
DMSW3KN	HS	Investigative
DMSW3KN	SN	O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine
DMSW3KN	DT	Small molecular drug
DMSW3KN	PC	5329516
DMSW3KN	MW	255.28
DMSW3KN	FM	C13H13N5O
DMSW3KN	IC	InChI=1S/C13H13N5O/c1-8-3-2-4-9(5-8)6-19-12-10-11(16-7-15-10)17-13(14)18-12/h2-5,7H,6H2,1H3,(H3,14,15,16,17,18)
DMSW3KN	CS	CC1=CC(=CC=C1)COC2=NC(=NC3=C2NC=N3)N
DMSW3KN	IK	WSSNDTDMMVLPHS-UHFFFAOYSA-N
DMSW3KN	IU	6-[(3-methylphenyl)methoxy]-7H-purin-2-amine
DMSW3KN	DE	Discovery agent

DM83VN6	ID	DM83VN6
DM83VN6	DN	6-(3-Nitro-phenyl)-3H-benzothiazol-2-one
DM83VN6	HS	Investigative
DM83VN6	SN	CHEMBL315445; 6-(3-Nitro-phenyl)-3H-benzothiazol-2-one; SCHEMBL6541670; NGWRFPUBBONZGG-UHFFFAOYSA-N; BDBM50105566
DM83VN6	DT	Small molecular drug
DM83VN6	PC	10221123
DM83VN6	MW	272.28
DM83VN6	FM	C13H8N2O3S
DM83VN6	IC	InChI=1S/C13H8N2O3S/c16-13-14-11-5-4-9(7-12(11)19-13)8-2-1-3-10(6-8)15(17)18/h1-7H,(H,14,16)
DM83VN6	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC3=C(C=C2)NC(=O)S3
DM83VN6	IK	NGWRFPUBBONZGG-UHFFFAOYSA-N
DM83VN6	IU	6-(3-nitrophenyl)-3H-1,3-benzothiazol-2-one
DM83VN6	DE	Discovery agent

DMEM1BA	ID	DMEM1BA
DMEM1BA	DN	6-(4-((benzylamino)methyl)phenoxy)nicotinamide
DMEM1BA	HS	Investigative
DMEM1BA	SN	CHEMBL238316; 6-(4-((benzylamino)methyl)phenoxy)nicotinamide; SCHEMBL3700197; LUBVSQAMVPXMBJ-UHFFFAOYSA-N; BDBM50219916
DMEM1BA	DT	Small molecular drug
DMEM1BA	PC	44434949
DMEM1BA	MW	333.4
DMEM1BA	FM	C20H19N3O2
DMEM1BA	IC	InChI=1S/C20H19N3O2/c21-20(24)17-8-11-19(23-14-17)25-18-9-6-16(7-10-18)13-22-12-15-4-2-1-3-5-15/h1-11,14,22H,12-13H2,(H2,21,24)
DMEM1BA	CS	C1=CC=C(C=C1)CNCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(=O)N
DMEM1BA	IK	LUBVSQAMVPXMBJ-UHFFFAOYSA-N
DMEM1BA	IU	6-[4-[(benzylamino)methyl]phenoxy]pyridine-3-carboxamide
DMEM1BA	DE	Discovery agent

DM9VD4W	ID	DM9VD4W
DM9VD4W	DN	6-(4-((phenethylamino)methyl)phenoxy)nicotinamide
DM9VD4W	HS	Investigative
DM9VD4W	SN	CHEMBL238361; 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide; SCHEMBL3702187
DM9VD4W	DT	Small molecular drug
DM9VD4W	PC	44434058
DM9VD4W	MW	347.4
DM9VD4W	FM	C21H21N3O2
DM9VD4W	IC	InChI=1S/C21H21N3O2/c22-21(25)18-8-11-20(24-15-18)26-19-9-6-17(7-10-19)14-23-13-12-16-4-2-1-3-5-16/h1-11,15,23H,12-14H2,(H2,22,25)
DM9VD4W	CS	C1=CC=C(C=C1)CCNCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(=O)N
DM9VD4W	IK	XPIWSPZHJZLUGI-UHFFFAOYSA-N
DM9VD4W	IU	6-[4-[(2-phenylethylamino)methyl]phenoxy]pyridine-3-carboxamide
DM9VD4W	DE	Discovery agent

DMDKOWP	ID	DMDKOWP
DMDKOWP	DN	6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide
DMDKOWP	HS	Investigative
DMDKOWP	SN	CHEMBL237066; 6-[4-(2-benzylamino-ethyl)-phenoxy]-nicotinamide; 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide; SCHEMBL3698270; FCDWJNPFPYAKET-UHFFFAOYSA-N; BDBM50219925
DMDKOWP	DT	Small molecular drug
DMDKOWP	PC	44434057
DMDKOWP	MW	347.4
DMDKOWP	FM	C21H21N3O2
DMDKOWP	IC	InChI=1S/C21H21N3O2/c22-21(25)18-8-11-20(24-15-18)26-19-9-6-16(7-10-19)12-13-23-14-17-4-2-1-3-5-17/h1-11,15,23H,12-14H2,(H2,22,25)
DMDKOWP	CS	C1=CC=C(C=C1)CNCCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(=O)N
DMDKOWP	IK	FCDWJNPFPYAKET-UHFFFAOYSA-N
DMDKOWP	IU	6-[4-[2-(benzylamino)ethyl]phenoxy]pyridine-3-carboxamide
DMDKOWP	DE	Discovery agent

DMOSDM2	ID	DMOSDM2
DMOSDM2	DN	6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide
DMOSDM2	HS	Investigative
DMOSDM2	SN	CHEMBL235560; 6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide; SCHEMBL3702023; JKDWSAGAQLISRL-UHFFFAOYSA-N; BDBM50219927
DMOSDM2	DT	Small molecular drug
DMOSDM2	PC	44434931
DMOSDM2	MW	347.4
DMOSDM2	FM	C21H21N3O2
DMOSDM2	IC	InChI=1S/C21H21N3O2/c22-21(25)19-7-4-8-20(24-19)26-18-11-9-16(10-12-18)13-14-23-15-17-5-2-1-3-6-17/h1-12,23H,13-15H2,(H2,22,25)
DMOSDM2	CS	C1=CC=C(C=C1)CNCCC2=CC=C(C=C2)OC3=CC=CC(=N3)C(=O)N
DMOSDM2	IK	JKDWSAGAQLISRL-UHFFFAOYSA-N
DMOSDM2	IU	6-[4-[2-(benzylamino)ethyl]phenoxy]pyridine-2-carboxamide
DMOSDM2	DE	Discovery agent

DMDTMB7	ID	DMDTMB7
DMDTMB7	DN	6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide
DMDTMB7	HS	Investigative
DMDTMB7	SN	CHEMBL236170; 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide; SCHEMBL3697663; FZBJOVYOONJNIG-UHFFFAOYSA-N; BDBM50219917
DMDTMB7	DT	Small molecular drug
DMDTMB7	PC	44434946
DMDTMB7	MW	361.4
DMDTMB7	FM	C22H23N3O2
DMDTMB7	IC	InChI=1S/C22H23N3O2/c23-22(26)19-10-13-21(25-16-19)27-20-11-8-17(9-12-20)7-4-14-24-15-18-5-2-1-3-6-18/h1-3,5-6,8-13,16,24H,4,7,14-15H2,(H2,23,26)
DMDTMB7	CS	C1=CC=C(C=C1)CNCCCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(=O)N
DMDTMB7	IK	FZBJOVYOONJNIG-UHFFFAOYSA-N
DMDTMB7	IU	6-[4-[3-(benzylamino)propyl]phenoxy]pyridine-3-carboxamide
DMDTMB7	DE	Discovery agent

DM9K8DY	ID	DM9K8DY
DM9K8DY	DN	6-(4-Bromo-benzenesulfonyl)-2H-pyridazin-3-one
DM9K8DY	HS	Investigative
DM9K8DY	SN	CHEMBL413566; BDBM16597; MolPort-035-757-148; HMS3437C04; ZINC11536222; AKOS024439117; AKOS001782802; MCULE-5808217949; Phenyl-Substituted Sulfonylpyridazinone, 8b; 6-[(4-bromophenyl)sulfonyl]-3(2H)-pyridazinone
DM9K8DY	DT	Small molecular drug
DM9K8DY	PC	11674065
DM9K8DY	MW	315.15
DM9K8DY	FM	C10H7BrN2O3S
DM9K8DY	IC	InChI=1S/C10H7BrN2O3S/c11-7-1-3-8(4-2-7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DM9K8DY	CS	C1=CC(=CC=C1S(=O)(=O)C2=NNC(=O)C=C2)Br
DM9K8DY	IK	MKFSHYSDCZFZEZ-UHFFFAOYSA-N
DM9K8DY	IU	3-(4-bromophenyl)sulfonyl-1H-pyridazin-6-one
DM9K8DY	DE	Discovery agent

DMCYQDU	ID	DMCYQDU
DMCYQDU	DN	6-(4-Bromo-phenylamino)-1H-pyrimidine-2,4-dione
DMCYQDU	HS	Investigative
DMCYQDU	SN	CHEMBL293964; 6-(4-Bromo-phenylamino)-1H-pyrimidine-2,4-dione; 21333-03-9; NSC212333; Cambridge id 5630405; AC1L7G1A; Oprea1_831727; Oprea1_666298; DTXSID70309572; 2,4(1H,3H)-Pyrimidinedione, 6-[(4-bromophenyl)amino]-; MolPort-001-898-229; ZINC245008; BDBM50028349; AKOS000541604; MCULE-6634356270; NSC-212333; BAS 00450423; 6-(4-bromoanilino)-1H-pyrimidine-2,4-dione
DMCYQDU	DT	Small molecular drug
DMCYQDU	PC	309876
DMCYQDU	MW	282.09
DMCYQDU	FM	C10H8BrN3O2
DMCYQDU	IC	InChI=1S/C10H8BrN3O2/c11-6-1-3-7(4-2-6)12-8-5-9(15)14-10(16)13-8/h1-5H,(H3,12,13,14,15,16)
DMCYQDU	CS	C1=CC(=CC=C1NC2=CC(=O)NC(=O)N2)Br
DMCYQDU	IK	KVJLEUZMCGNFGQ-UHFFFAOYSA-N
DMCYQDU	IU	6-(4-bromoanilino)-1H-pyrimidine-2,4-dione
DMCYQDU	CA	CAS 21333-03-9
DMCYQDU	DE	Discovery agent

DMNAHVB	ID	DMNAHVB
DMNAHVB	DN	6-(4-Chloro-benzenesulfonyl)-2H-pyridazin-3-one
DMNAHVB	HS	Investigative
DMNAHVB	SN	SCHEMBL6205548; CHEMBL425745; BDBM16599; MolPort-008-421-579; ZINC11536219; AKOS004915123; AKOS001782171; MCULE-3139216379; CCG-127350; 454181-53-4; Phenyl-Substituted Sulfonylpyridazinone, 8e; 6-[(4-chlorophenyl)sulfonyl]-3-pyridazinol; 6-[(4-chlorophenyl)sulfonyl]-3(2H)-pyridazinone; 3(2H)-Pyridazinone, 6-[(4-chlorophenyl)sulfonyl]-
DMNAHVB	DT	Small molecular drug
DMNAHVB	PC	9878572
DMNAHVB	MW	270.69
DMNAHVB	FM	C10H7ClN2O3S
DMNAHVB	IC	InChI=1S/C10H7ClN2O3S/c11-7-1-3-8(4-2-7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DMNAHVB	CS	C1=CC(=CC=C1S(=O)(=O)C2=NNC(=O)C=C2)Cl
DMNAHVB	IK	MLRLSUWJTAHEKD-UHFFFAOYSA-N
DMNAHVB	IU	3-(4-chlorophenyl)sulfonyl-1H-pyridazin-6-one
DMNAHVB	DE	Discovery agent

DMSO2JW	ID	DMSO2JW
DMSO2JW	DN	6-(4-chlorophenyl)-2-morpholin-4-ylpyridin-4-ol
DMSO2JW	HS	Investigative
DMSO2JW	SN	CHEMBL225150; 6-(4-chlorophenyl)-2-morpholin-4-ylpyridin-4-ol
DMSO2JW	DT	Small molecular drug
DMSO2JW	PC	16203826
DMSO2JW	MW	290.74
DMSO2JW	FM	C15H15ClN2O2
DMSO2JW	IC	InChI=1S/C15H15ClN2O2/c16-12-3-1-11(2-4-12)14-9-13(19)10-15(17-14)18-5-7-20-8-6-18/h1-4,9-10H,5-8H2,(H,17,19)
DMSO2JW	CS	C1COCCN1C2=CC(=O)C=C(N2)C3=CC=C(C=C3)Cl
DMSO2JW	IK	PETWHCAMQFMDRM-UHFFFAOYSA-N
DMSO2JW	IU	2-(4-chlorophenyl)-6-morpholin-4-yl-1H-pyridin-4-one
DMSO2JW	DE	Discovery agent

DMMTG7L	ID	DMMTG7L
DMMTG7L	DN	6-(4-chlorophenyl)-4-morpholino-2H-pyran-2-one
DMMTG7L	HS	Investigative
DMMTG7L	SN	CHEMBL222821; 6-(4-chlorophenyl)-4-morpholino-2H-pyran-2-one; SCHEMBL3537608
DMMTG7L	DT	Small molecular drug
DMMTG7L	PC	21106425
DMMTG7L	MW	291.73
DMMTG7L	FM	C15H14ClNO3
DMMTG7L	IC	InChI=1S/C15H14ClNO3/c16-12-3-1-11(2-4-12)14-9-13(10-15(18)20-14)17-5-7-19-8-6-17/h1-4,9-10H,5-8H2
DMMTG7L	CS	C1COCCN1C2=CC(=O)OC(=C2)C3=CC=C(C=C3)Cl
DMMTG7L	IK	QAPAFHWHAZOAOB-UHFFFAOYSA-N
DMMTG7L	IU	6-(4-chlorophenyl)-4-morpholin-4-ylpyran-2-one
DMMTG7L	DE	Discovery agent

DM0C1FX	ID	DM0C1FX
DM0C1FX	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM0C1FX	HS	Investigative
DM0C1FX	SN	CHEMBL1082305; 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX); BDBM50320178
DM0C1FX	DT	Small molecular drug
DM0C1FX	PC	46891274
DM0C1FX	MW	461.8
DM0C1FX	FM	C23H19Cl3N2O2
DM0C1FX	IC	InChI=1S/C23H19Cl3N2O2/c1-23(2)11-18(21(27)29)17-10-16(12-3-5-13(24)6-4-12)20(28-22(17)30-23)15-8-7-14(25)9-19(15)26/h3-10,18H,11H2,1-2H3,(H2,27,29)
DM0C1FX	CS	CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)C(=O)N)C
DM0C1FX	IK	YYFWEVOTTPIJNN-UHFFFAOYSA-N
DM0C1FX	IU	6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridine-4-carboxamide
DM0C1FX	DE	Discovery agent

DM1N46J	ID	DM1N46J
DM1N46J	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM1N46J	HS	Investigative
DM1N46J	SN	CHEMBL1082650; 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX); BDBM50320181
DM1N46J	DT	Small molecular drug
DM1N46J	PC	46891372
DM1N46J	MW	518.9
DM1N46J	FM	C26H26Cl3N3O2
DM1N46J	IC	InChI=1S/C26H26Cl3N3O2/c1-14(33)30-25(34)21-13-26(2,3)32(4)24-20(21)12-19(15-5-7-16(27)8-6-15)23(31-24)18-10-9-17(28)11-22(18)29/h5-12,14,21,33H,13H2,1-4H3,(H,30,34)/t14-,21?/m1/s1
DM1N46J	CS	C[C@H](NC(=O)C1CC(N(C2=C1C=C(C(=N2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl)C)(C)C)O
DM1N46J	IK	DIDXRIJBHXOGGD-CKAQCJTGSA-N
DM1N46J	IU	6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-N-[(1R)-1-hydroxyethyl]-1,2,2-trimethyl-3,4-dihydro-1,8-naphthyridine-4-carboxamide
DM1N46J	DE	Discovery agent

DM5H4KE	ID	DM5H4KE
DM5H4KE	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM5H4KE	HS	Investigative
DM5H4KE	SN	CHEMBL1082321; 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX); SCHEMBL1404688; BDBM50320179
DM5H4KE	DT	Small molecular drug
DM5H4KE	PC	24992763
DM5H4KE	MW	533.9
DM5H4KE	FM	C27H27Cl3N2O3
DM5H4KE	IC	InChI=1S/C27H27Cl3N2O3/c1-26(2,14-33)32-24(34)21-13-27(3,4)35-25-20(21)12-19(15-5-7-16(28)8-6-15)23(31-25)18-10-9-17(29)11-22(18)30/h5-12,21,33H,13-14H2,1-4H3,(H,32,34)
DM5H4KE	CS	CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)C(=O)NC(C)(C)CO)C
DM5H4KE	IK	JUNWVTKDXNTEJW-UHFFFAOYSA-N
DM5H4KE	IU	6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-N-(1-hydroxy-2-methylpropan-2-yl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridine-4-carboxamide
DM5H4KE	DE	Discovery agent

DMEJ83H	ID	DMEJ83H
DMEJ83H	DN	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DMEJ83H	HS	Investigative
DMEJ83H	SN	CHEMBL1082330; 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX); BDBM50320180
DMEJ83H	DT	Small molecular drug
DMEJ83H	PC	46891330
DMEJ83H	MW	504.8
DMEJ83H	FM	C25H24Cl3N3O2
DMEJ83H	IC	InChI=1S/C25H24Cl3N3O2/c1-25(2)12-20(24(33)29-13-32)19-11-18(14-4-6-15(26)7-5-14)22(30-23(19)31(25)3)17-9-8-16(27)10-21(17)28/h4-11,20,32H,12-13H2,1-3H3,(H,29,33)
DMEJ83H	CS	CC1(CC(C2=C(N1C)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)C(=O)NCO)C
DMEJ83H	IK	URTQOVWDFKPXTI-UHFFFAOYSA-N
DMEJ83H	IU	6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-N-(hydroxymethyl)-1,2,2-trimethyl-3,4-dihydro-1,8-naphthyridine-4-carboxamide
DMEJ83H	DE	Ovarian cancer

DM5LUF4	ID	DM5LUF4
DM5LUF4	DN	6-(4-Chloro-phenylamino)-1H-pyrimidine-2,4-dione
DM5LUF4	HS	Investigative
DM5LUF4	SN	CHEMBL51694; 6-(4-Chloro-phenylamino)-1H-pyrimidine-2,4-dione; STK374802; 21333-02-8; 6-[(4-chlorophenyl)amino]pyrimidine-2,4(1H,3H)-dione; NSC210499; AC1L7DC5; Oprea1_449957; Oprea1_000118; SCHEMBL5309531; 2,4(1H,3H)-Pyrimidinedione, 6-[(4-chlorophenyl)amino]-; DTXSID10308968; MolPort-002-117-140; ZINC169555; BDBM50028338; AKOS001620570; NSC-210499; MCULE-2076182094; BAS 00450419; ST50876537; 6-(4-chloroanilino)-1H-pyrimidine-2,4-dione; AB00091363-01; 6-(4-chlorophenylamino)pyrimidine-2,4(1H,3H)-dione
DM5LUF4	DT	Small molecular drug
DM5LUF4	PC	308646
DM5LUF4	MW	237.64
DM5LUF4	FM	C10H8ClN3O2
DM5LUF4	IC	InChI=1S/C10H8ClN3O2/c11-6-1-3-7(4-2-6)12-8-5-9(15)14-10(16)13-8/h1-5H,(H3,12,13,14,15,16)
DM5LUF4	CS	C1=CC(=CC=C1NC2=CC(=O)NC(=O)N2)Cl
DM5LUF4	IK	POKMZWROIKHVLE-UHFFFAOYSA-N
DM5LUF4	IU	6-(4-chloroanilino)-1H-pyrimidine-2,4-dione
DM5LUF4	CA	CAS 21333-02-8
DM5LUF4	DE	Discovery agent

DMOZFU5	ID	DMOZFU5
DMOZFU5	DN	6-(4-chlorophenylamino)-N,N-diethylnicotinamide
DMOZFU5	HS	Investigative
DMOZFU5	SN	CHEMBL596589; 6-(4-chlorophenylamino)-N,N-diethylnicotinamide; BDBM50305021
DMOZFU5	DT	Small molecular drug
DMOZFU5	PC	23725212
DMOZFU5	MW	303.78
DMOZFU5	FM	C16H18ClN3O
DMOZFU5	IC	InChI=1S/C16H18ClN3O/c1-3-20(4-2)16(21)12-5-10-15(18-11-12)19-14-8-6-13(17)7-9-14/h5-11H,3-4H2,1-2H3,(H,18,19)
DMOZFU5	CS	CCN(CC)C(=O)C1=CN=C(C=C1)NC2=CC=C(C=C2)Cl
DMOZFU5	IK	UEKPAIMMZMCKSL-UHFFFAOYSA-N
DMOZFU5	IU	6-(4-chloroanilino)-N,N-diethylpyridine-3-carboxamide
DMOZFU5	DE	Discovery agent

DMYQB5R	ID	DMYQB5R
DMYQB5R	DN	6-(4-Decyloxy-phenyl)-1,1,1-trifluoro-hexan-2-one
DMYQB5R	HS	Investigative
DMYQB5R	SN	CHEMBL513627
DMYQB5R	DT	Small molecular drug
DMYQB5R	PC	25059557
DMYQB5R	MW	386.5
DMYQB5R	FM	C22H33F3O2
DMYQB5R	IC	InChI=1S/C22H33F3O2/c1-2-3-4-5-6-7-8-11-18-27-20-16-14-19(15-17-20)12-9-10-13-21(26)22(23,24)25/h14-17H,2-13,18H2,1H3
DMYQB5R	CS	CCCCCCCCCCOC1=CC=C(C=C1)CCCCC(=O)C(F)(F)F
DMYQB5R	IK	LRMSMLKRXXVPRC-UHFFFAOYSA-N
DMYQB5R	IU	6-(4-decoxyphenyl)-1,1,1-trifluorohexan-2-one
DMYQB5R	DE	Discovery agent

DM7WYNT	ID	DM7WYNT
DM7WYNT	DN	6-(4-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one
DM7WYNT	HS	Investigative
DM7WYNT	SN	SCHEMBL6206599; CHEMBL425922; BDBM16601; 454181-47-6; Phenyl-Substituted Sulfonylpyridazinone, 8g; 3(2H)-Pyridazinone, 6-[(4-fluorophenyl)sulfonyl]-
DM7WYNT	DT	Small molecular drug
DM7WYNT	PC	9856396
DM7WYNT	MW	254.24
DM7WYNT	FM	C10H7FN2O3S
DM7WYNT	IC	InChI=1S/C10H7FN2O3S/c11-7-1-3-8(4-2-7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DM7WYNT	CS	C1=CC(=CC=C1F)S(=O)(=O)C2=NNC(=O)C=C2
DM7WYNT	IK	OVAVDZRNJWQJPL-UHFFFAOYSA-N
DM7WYNT	IU	3-(4-fluorophenyl)sulfonyl-1H-pyridazin-6-one
DM7WYNT	DE	Discovery agent

DM3EDBO	ID	DM3EDBO
DM3EDBO	DN	6-(4-Fluorobutyl)-4-methylpyridin-2-amine
DM3EDBO	HS	Investigative
DM3EDBO	SN	CHEMBL509542; 6-(4-Fluorobutyl)-4-methylpyridin-2-amine; 2-Pyridinamine, 6-(4-fluorobutyl)-4-methyl-; BDBM50267355
DM3EDBO	DT	Small molecular drug
DM3EDBO	PC	42625618
DM3EDBO	MW	182.24
DM3EDBO	FM	C10H15FN2
DM3EDBO	IC	InChI=1S/C10H15FN2/c1-8-6-9(4-2-3-5-11)13-10(12)7-8/h6-7H,2-5H2,1H3,(H2,12,13)
DM3EDBO	CS	CC1=CC(=NC(=C1)N)CCCCF
DM3EDBO	IK	OTKWRERYYAYGSY-UHFFFAOYSA-N
DM3EDBO	IU	6-(4-fluorobutyl)-4-methylpyridin-2-amine
DM3EDBO	DE	Discovery agent

DM5JWEY	ID	DM5JWEY
DM5JWEY	DN	6-(4-Fluoro-phenylsulfanyl)-9H-purine
DM5JWEY	HS	Investigative
DM5JWEY	SN	6-(4-fluorophenylsulfanyl)-9H-purine; 736142-69-1; CHEMBL175603
DM5JWEY	DT	Small molecular drug
DM5JWEY	PC	11265091
DM5JWEY	MW	246.27
DM5JWEY	FM	C11H7FN4S
DM5JWEY	IC	InChI=1S/C11H7FN4S/c12-7-1-3-8(4-2-7)17-11-9-10(14-5-13-9)15-6-16-11/h1-6H,(H,13,14,15,16)
DM5JWEY	CS	C1=CC(=CC=C1F)SC2=NC=NC3=C2NC=N3
DM5JWEY	IK	MTSKQGGVBOTGLP-UHFFFAOYSA-N
DM5JWEY	IU	6-(4-fluorophenyl)sulfanyl-7H-purine
DM5JWEY	DE	Discovery agent

DMKGTRF	ID	DMKGTRF
DMKGTRF	DN	6-(4-fluorostyryl)-2-morpholino-4H-chromen-4-one
DMKGTRF	HS	Investigative
DMKGTRF	SN	CHEMBL426654
DMKGTRF	DT	Small molecular drug
DMKGTRF	PC	11717289
DMKGTRF	MW	351.4
DMKGTRF	FM	C21H18FNO3
DMKGTRF	IC	InChI=1S/C21H18FNO3/c22-17-6-3-15(4-7-17)1-2-16-5-8-20-18(13-16)19(24)14-21(26-20)23-9-11-25-12-10-23/h1-8,13-14H,9-12H2/b2-1+
DMKGTRF	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)/C=C/C4=CC=C(C=C4)F
DMKGTRF	IK	MGIIGLFUKQWDHF-OWOJBTEDSA-N
DMKGTRF	IU	6-[(E)-2-(4-fluorophenyl)ethenyl]-2-morpholin-4-ylchromen-4-one
DMKGTRF	DE	Discovery agent

DMYM3EW	ID	DMYM3EW
DMYM3EW	DN	6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol
DMYM3EW	HS	Investigative
DMYM3EW	SN	CHEMBL427180; 6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol; SCHEMBL3932725; TWSSGPRRAGPVKD-UHFFFAOYSA-N; BDBM50168373; ZINC13645059
DMYM3EW	DT	Small molecular drug
DMYM3EW	PC	10125342
DMYM3EW	MW	266.29
DMYM3EW	FM	C17H14O3
DMYM3EW	IC	InChI=1S/C17H14O3/c1-20-17-10-15(19)6-7-16(17)13-3-2-12-9-14(18)5-4-11(12)8-13/h2-10,18-19H,1H3
DMYM3EW	CS	COC1=C(C=CC(=C1)O)C2=CC3=C(C=C2)C=C(C=C3)O
DMYM3EW	IK	TWSSGPRRAGPVKD-UHFFFAOYSA-N
DMYM3EW	IU	6-(4-hydroxy-2-methoxyphenyl)naphthalen-2-ol
DMYM3EW	DE	Discovery agent

DMYEIRH	ID	DMYEIRH
DMYEIRH	DN	6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol
DMYEIRH	HS	Investigative
DMYEIRH	SN	CHEMBL195389; 6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol; SCHEMBL4077781; YIKDKHNOMWERET-UHFFFAOYSA-N; ZINC13645062; BDBM50168377
DMYEIRH	DT	Small molecular drug
DMYEIRH	PC	10192794
DMYEIRH	MW	250.29
DMYEIRH	FM	C17H14O2
DMYEIRH	IC	InChI=1S/C17H14O2/c1-11-8-15(18)6-7-17(11)14-3-2-13-10-16(19)5-4-12(13)9-14/h2-10,18-19H,1H3
DMYEIRH	CS	CC1=C(C=CC(=C1)O)C2=CC3=C(C=C2)C=C(C=C3)O
DMYEIRH	IK	YIKDKHNOMWERET-UHFFFAOYSA-N
DMYEIRH	IU	6-(4-hydroxy-2-methylphenyl)naphthalen-2-ol
DMYEIRH	DE	Discovery agent

DMBG5Y8	ID	DMBG5Y8
DMBG5Y8	DN	6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol
DMBG5Y8	HS	Investigative
DMBG5Y8	SN	CHEMBL195786; 6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol; SCHEMBL5980579; DSBWWPDVDPKMHN-UHFFFAOYSA-N; ZINC13645027; BDBM50168344
DMBG5Y8	DT	Small molecular drug
DMBG5Y8	PC	11414445
DMBG5Y8	MW	266.29
DMBG5Y8	FM	C17H14O3
DMBG5Y8	IC	InChI=1S/C17H14O3/c1-20-17-15-8-4-12(10-13(15)5-9-16(17)19)11-2-6-14(18)7-3-11/h2-10,18-19H,1H3
DMBG5Y8	CS	COC1=C(C=CC2=C1C=CC(=C2)C3=CC=C(C=C3)O)O
DMBG5Y8	IK	DSBWWPDVDPKMHN-UHFFFAOYSA-N
DMBG5Y8	IU	6-(4-hydroxyphenyl)-1-methoxynaphthalen-2-ol
DMBG5Y8	DE	Discovery agent

DMGLT0N	ID	DMGLT0N
DMGLT0N	DN	6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol
DMGLT0N	HS	Investigative
DMGLT0N	SN	CHEMBL372030; 6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol; SCHEMBL3927148; FGIUXCLAHODWKV-UHFFFAOYSA-N; BDBM50168320; ZINC13645024
DMGLT0N	DT	Small molecular drug
DMGLT0N	PC	10308075
DMGLT0N	MW	250.29
DMGLT0N	FM	C17H14O2
DMGLT0N	IC	InChI=1S/C17H14O2/c1-11-16-8-4-13(10-14(16)5-9-17(11)19)12-2-6-15(18)7-3-12/h2-10,18-19H,1H3
DMGLT0N	CS	CC1=C(C=CC2=C1C=CC(=C2)C3=CC=C(C=C3)O)O
DMGLT0N	IK	FGIUXCLAHODWKV-UHFFFAOYSA-N
DMGLT0N	IU	6-(4-hydroxyphenyl)-1-methylnaphthalen-2-ol
DMGLT0N	DE	Discovery agent

DMGC84U	ID	DMGC84U
DMGC84U	DN	6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol
DMGC84U	HS	Investigative
DMGC84U	SN	CHEMBL195788; 6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol; SCHEMBL3935673; MYVOVZDBAWARDP-UHFFFAOYSA-N; ZINC13645031; BDBM50168340
DMGC84U	DT	Small molecular drug
DMGC84U	PC	10308268
DMGC84U	MW	281.26
DMGC84U	FM	C16H11NO4
DMGC84U	IC	InChI=1S/C16H11NO4/c18-13-5-1-10(2-6-13)11-3-7-14-12(9-11)4-8-15(19)16(14)17(20)21/h1-9,18-19H
DMGC84U	CS	C1=CC(=CC=C1C2=CC3=C(C=C2)C(=C(C=C3)O)[N+](=O)[O-])O
DMGC84U	IK	MYVOVZDBAWARDP-UHFFFAOYSA-N
DMGC84U	IU	6-(4-hydroxyphenyl)-1-nitronaphthalen-2-ol
DMGC84U	DE	Discovery agent

DMI6UVN	ID	DMI6UVN
DMI6UVN	DN	6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol
DMI6UVN	HS	Investigative
DMI6UVN	SN	CHEMBL192102; 6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol; SCHEMBL3927262; INNGVLJQICTRAF-UHFFFAOYSA-N; BDBM50168362
DMI6UVN	DT	Small molecular drug
DMI6UVN	PC	10171886
DMI6UVN	MW	312.4
DMI6UVN	FM	C22H16O2
DMI6UVN	IC	InChI=1S/C22H16O2/c23-19-10-6-15(7-11-19)17-8-12-20-18(14-17)9-13-21(24)22(20)16-4-2-1-3-5-16/h1-14,23-24H
DMI6UVN	CS	C1=CC=C(C=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC=C(C=C4)O)O
DMI6UVN	IK	INNGVLJQICTRAF-UHFFFAOYSA-N
DMI6UVN	IU	6-(4-hydroxyphenyl)-1-phenylnaphthalen-2-ol
DMI6UVN	DE	Discovery agent

DMTYWCS	ID	DMTYWCS
DMTYWCS	DN	6-(4-hydroxyphenyl)-2-morpholino-4H-chromen-4-one
DMTYWCS	HS	Investigative
DMTYWCS	SN	CHEMBL371103
DMTYWCS	DT	Small molecular drug
DMTYWCS	PC	11623973
DMTYWCS	MW	323.3
DMTYWCS	FM	C19H17NO4
DMTYWCS	IC	InChI=1S/C19H17NO4/c21-15-4-1-13(2-5-15)14-3-6-18-16(11-14)17(22)12-19(24-18)20-7-9-23-10-8-20/h1-6,11-12,21H,7-10H2
DMTYWCS	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=C(C=C4)O
DMTYWCS	IK	JERFBKBQDMCBEI-UHFFFAOYSA-N
DMTYWCS	IU	6-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DMTYWCS	DE	Discovery agent

DM2V9XI	ID	DM2V9XI
DM2V9XI	DN	6-(4-Hydroxy-phenyl)-naphthalen-1-ol
DM2V9XI	HS	Investigative
DM2V9XI	SN	6-(4-hydroxyphenyl)-1-naphthol
DM2V9XI	PC	10308021
DM2V9XI	MW	236.26
DM2V9XI	FM	C16H12O2
DM2V9XI	IC	InChI=1S/C16H12O2/c17-14-7-4-11(5-8-14)12-6-9-15-13(10-12)2-1-3-16(15)18/h1-10,17-18H
DM2V9XI	CS	C1=CC2=C(C=CC(=C2)C3=CC=C(C=C3)O)C(=C1)O
DM2V9XI	IK	MBESMLNJQCOTRU-UHFFFAOYSA-N
DM2V9XI	IU	6-(4-hydroxyphenyl)naphthalen-1-ol
DM2V9XI	DE	Discovery agent

DM3L2OI	ID	DM3L2OI
DM3L2OI	DN	6-(4-Hydroxy-phenyl)-naphthalen-2-ol
DM3L2OI	HS	Investigative
DM3L2OI	SN	CHEMBL191974; 6-(4-hydroxyphenyl)-2-naphthol; 6-(4-Hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL2699234; SKPPZWVFPOQPOT-UHFFFAOYSA-N; ZINC13644983
DM3L2OI	DT	Small molecular drug
DM3L2OI	PC	11459006
DM3L2OI	MW	236.26
DM3L2OI	FM	C16H12O2
DM3L2OI	IC	InChI=1S/C16H12O2/c17-15-6-3-11(4-7-15)12-1-2-14-10-16(18)8-5-13(14)9-12/h1-10,17-18H
DM3L2OI	CS	C1=CC(=CC=C1C2=CC3=C(C=C2)C=C(C=C3)O)O
DM3L2OI	IK	SKPPZWVFPOQPOT-UHFFFAOYSA-N
DM3L2OI	IU	6-(4-hydroxyphenyl)naphthalen-2-ol
DM3L2OI	DE	Discovery agent

DM5LBCH	ID	DM5LBCH
DM5LBCH	DN	6-(4-Methoxy-benzenesulfonyl)-2H-pyridazin-3-one
DM5LBCH	HS	Investigative
DM5LBCH	SN	CHEMBL74785; SCHEMBL6207869; BDBM16446; ZINC11536216; AKOS001782172; AKOS015830989; MCULE-9943571795; CCG-127351; 6-phenylsulfonylpyridazin-2H-3-one, 8; 454181-51-2; Phenyl-Substituted Sulfonylpyridazinone, 8h; 6-[(4-methoxyphenyl)sulfonyl]pyridazin-3(2H)-one; 3(2H)-Pyridazinone, 6-[(4-methoxyphenyl)sulfonyl]-
DM5LBCH	DT	Small molecular drug
DM5LBCH	PC	9921499
DM5LBCH	MW	266.28
DM5LBCH	FM	C11H10N2O4S
DM5LBCH	IC	InChI=1S/C11H10N2O4S/c1-17-8-2-4-9(5-3-8)18(15,16)11-7-6-10(14)12-13-11/h2-7H,1H3,(H,12,14)
DM5LBCH	CS	COC1=CC=C(C=C1)S(=O)(=O)C2=NNC(=O)C=C2
DM5LBCH	IK	KLWAIVHFGCYFDO-UHFFFAOYSA-N
DM5LBCH	IU	3-(4-methoxyphenyl)sulfonyl-1H-pyridazin-6-one
DM5LBCH	DE	Discovery agent

DMUHCO8	ID	DMUHCO8
DMUHCO8	DN	6-(4-methoxyphenyl)-4-morpholino-2H-pyran-2-one
DMUHCO8	HS	Investigative
DMUHCO8	SN	CHEMBL221410; 6-(4-methoxyphenyl)-4-morpholino-2H-pyran-2-one; SCHEMBL3538432
DMUHCO8	DT	Small molecular drug
DMUHCO8	PC	21106426
DMUHCO8	MW	287.31
DMUHCO8	FM	C16H17NO4
DMUHCO8	IC	InChI=1S/C16H17NO4/c1-19-14-4-2-12(3-5-14)15-10-13(11-16(18)21-15)17-6-8-20-9-7-17/h2-5,10-11H,6-9H2,1H3
DMUHCO8	CS	COC1=CC=C(C=C1)C2=CC(=CC(=O)O2)N3CCOCC3
DMUHCO8	IK	PRPSUNXAZLZCBS-UHFFFAOYSA-N
DMUHCO8	IU	6-(4-methoxyphenyl)-4-morpholin-4-ylpyran-2-one
DMUHCO8	DE	Discovery agent

DMWITYU	ID	DMWITYU
DMWITYU	DN	6-(4-Methylpiperazin-1-yl)-9H-purin-2-amine
DMWITYU	HS	Investigative
DMWITYU	SN	6-(4-Methylpiperazin-1-yl)-9H-purin-2-amine; CHEMBL594694; 1196993-60-8; SCHEMBL20093538; MolPort-039-193-873; BBL036459; STL490826; ZINC45352375; BDBM50304514
DMWITYU	DT	Small molecular drug
DMWITYU	PC	46228161
DMWITYU	MW	233.27
DMWITYU	FM	C10H15N7
DMWITYU	IC	InChI=1S/C10H15N7/c1-16-2-4-17(5-3-16)9-7-8(13-6-12-7)14-10(11)15-9/h6H,2-5H2,1H3,(H3,11,12,13,14,15)
DMWITYU	CS	CN1CCN(CC1)C2=NC(=NC3=C2NC=N3)N
DMWITYU	IK	HZZXEPZFOVOWIN-UHFFFAOYSA-N
DMWITYU	IU	6-(4-methylpiperazin-1-yl)-7H-purin-2-amine
DMWITYU	DE	Discovery agent

DMA3FQP	ID	DMA3FQP
DMA3FQP	DN	6-(4-methylpiperazin-1-yl)-9Hpurine
DMA3FQP	HS	Investigative
DMA3FQP	SN	6-(4-methylpiperazin-1-yl)-9H-purine; 6-(4-methylpiperazin-1-yl)-7H-purine; CHEMBL594152; 99172-01-7; SDCCGMLS-0065440.P001; 6-(4-methylpiperazin-1-yl)-9Hpurine; AC1LFNRL; Oprea1_666011; MLS000419169; 6-(4-methylpiperazinyl)purine; SCHEMBL13718480; MolPort-000-847-583; MolPort-000-384-358; HMS2684L19; ZINC213869; HMS1650E09; CCG-26902; BBL036787; STK630143; BDBM50304512; NSC510935; AKOS001427557; AKOS005562847; NSC-510935; MCULE-5386395090; SMR000319851; ST45178781; AB00588487-02; SR-01000104630; SR-01000104630-1; Z57745256
DMA3FQP	DT	Small molecular drug
DMA3FQP	PC	756701
DMA3FQP	MW	218.26
DMA3FQP	FM	C10H14N6
DMA3FQP	IC	InChI=1S/C10H14N6/c1-15-2-4-16(5-3-15)10-8-9(12-6-11-8)13-7-14-10/h6-7H,2-5H2,1H3,(H,11,12,13,14)
DMA3FQP	CS	CN1CCN(CC1)C2=NC=NC3=C2NC=N3
DMA3FQP	IK	AXPCNBLIEMWMMG-UHFFFAOYSA-N
DMA3FQP	IU	6-(4-methylpiperazin-1-yl)-7H-purine
DMA3FQP	DE	Discovery agent

DM1HAWR	ID	DM1HAWR
DM1HAWR	DN	6-(4-Methyl-piperazin-1-yl)-phenanthridine
DM1HAWR	HS	Investigative
DM1HAWR	SN	CHEMBL43193; 23441-13-6; 6-(4-methylpiperazin-1-yl)phenanthridine; 6-(4-Methyl-piperazin-1-yl)-phenanthridine; CTK0I7937; DTXSID50433889; ZINC13778637; BDBM50063258; 6-(4-Methylpiperazino)phenanthridine; Phenanthridine, 6-(4-methyl-1-piperazinyl)-
DM1HAWR	DT	Small molecular drug
DM1HAWR	PC	9993659
DM1HAWR	MW	277.4
DM1HAWR	FM	C18H19N3
DM1HAWR	IC	InChI=1S/C18H19N3/c1-20-10-12-21(13-11-20)18-16-8-3-2-6-14(16)15-7-4-5-9-17(15)19-18/h2-9H,10-13H2,1H3
DM1HAWR	CS	CN1CCN(CC1)C2=NC3=CC=CC=C3C4=CC=CC=C42
DM1HAWR	IK	ZVJIBTNUNUXAIO-UHFFFAOYSA-N
DM1HAWR	IU	6-(4-methylpiperazin-1-yl)phenanthridine
DM1HAWR	CA	CAS 23441-13-6
DM1HAWR	DE	Discovery agent

DMYAS2V	ID	DMYAS2V
DMYAS2V	DN	6-(4-Methylpiperazin-1-yl)pyrimidine-2,4-diamine
DMYAS2V	HS	Investigative
DMYAS2V	SN	CHEMBL473662; 6-(4-Methylpiperazin-1-yl)pyrimidine-2,4-diamine; BAS 06575347; AC1LFG9R; 2,4-Pyrimidinediamine, 6-(4-methyl-1-piperazinyl)-; SCHEMBL2169898; MolPort-002-005-545; ZINC205303; BDBM50304501; CCG-24528; AKOS000670805; 4940-96-9; VU0047515-1
DMYAS2V	DT	Small molecular drug
DMYAS2V	PC	753256
DMYAS2V	MW	208.26
DMYAS2V	FM	C9H16N6
DMYAS2V	IC	InChI=1S/C9H16N6/c1-14-2-4-15(5-3-14)8-6-7(10)12-9(11)13-8/h6H,2-5H2,1H3,(H4,10,11,12,13)
DMYAS2V	CS	CN1CCN(CC1)C2=NC(=NC(=C2)N)N
DMYAS2V	IK	RBHNSRTVBDSNLG-UHFFFAOYSA-N
DMYAS2V	IU	6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine
DMYAS2V	DE	Discovery agent

DMTV753	ID	DMTV753
DMTV753	DN	6-(4-Methylpyridin-3-yl)-2-naphthonitrile
DMTV753	HS	Investigative
DMTV753	SN	CHEMBL500665; 6-(4-Methylpyridin-3-yl)-2-naphthonitrile; BDBM50272247
DMTV753	DT	Small molecular drug
DMTV753	PC	25034343
DMTV753	MW	244.29
DMTV753	FM	C17H12N2
DMTV753	IC	InChI=1S/C17H12N2/c1-12-6-7-19-11-17(12)16-5-4-14-8-13(10-18)2-3-15(14)9-16/h2-9,11H,1H3
DMTV753	CS	CC1=C(C=NC=C1)C2=CC3=C(C=C2)C=C(C=C3)C#N
DMTV753	IK	BVEDDOVOLJETRX-UHFFFAOYSA-N
DMTV753	IU	6-(4-methylpyridin-3-yl)naphthalene-2-carbonitrile
DMTV753	DE	Discovery agent

DMPL5XV	ID	DMPL5XV
DMPL5XV	DN	6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine
DMPL5XV	HS	Investigative
DMPL5XV	SN	CHEMBL362511; 6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine
DMPL5XV	DT	Small molecular drug
DMPL5XV	PC	11165248
DMPL5XV	MW	391.4
DMPL5XV	FM	C20H17N5O2S
DMPL5XV	IC	InChI=1S/C20H17N5O2S/c26-25(27)17-8-6-16(7-9-17)12-28-20-18-19(21-13-22-20)24(14-23-18)11-10-15-4-2-1-3-5-15/h1-9,13-14H,10-12H2
DMPL5XV	CS	C1=CC=C(C=C1)CCN2C=NC3=C2N=CN=C3SCC4=CC=C(C=C4)[N+](=O)[O-]
DMPL5XV	IK	RXUAVXPJZWEMTE-UHFFFAOYSA-N
DMPL5XV	IU	6-[(4-nitrophenyl)methylsulfanyl]-9-(2-phenylethyl)purine
DMPL5XV	DE	Discovery agent

DMVMDJ3	ID	DMVMDJ3
DMVMDJ3	DN	6-(9H-carbazol-9-yl)-N-hydroxyhexanamide
DMVMDJ3	HS	Investigative
DMVMDJ3	SN	CHEMBL1290142; A1-02262; 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1
DMVMDJ3	DT	Small molecular drug
DMVMDJ3	PC	46918725
DMVMDJ3	MW	296.4
DMVMDJ3	FM	C18H20N2O2
DMVMDJ3	IC	InChI=1S/C18H20N2O2/c21-18(19-22)12-2-1-7-13-20-16-10-5-3-8-14(16)15-9-4-6-11-17(15)20/h3-6,8-11,22H,1-2,7,12-13H2,(H,19,21)
DMVMDJ3	CS	C1=CC=C2C(=C1)C3=CC=CC=C3N2CCCCCC(=O)NO
DMVMDJ3	IK	SOMDVJCUFVPZKM-UHFFFAOYSA-N
DMVMDJ3	IU	6-carbazol-9-yl-N-hydroxyhexanamide
DMVMDJ3	DE	Discovery agent

DMYMJHF	ID	DMYMJHF
DMYMJHF	DN	6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol
DMYMJHF	HS	Investigative
DMYMJHF	SN	CHEMBL171118
DMYMJHF	DT	Small molecular drug
DMYMJHF	PC	44382932
DMYMJHF	MW	337.5
DMYMJHF	FM	C23H31NO
DMYMJHF	IC	InChI=1S/C23H31NO/c1-5-17-24(4)19(3)18-23(22(25)6-2,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h5,7-16,19,22,25H,1,6,17-18H2,2-4H3
DMYMJHF	CS	CCC(C(CC(C)N(C)CC=C)(C1=CC=CC=C1)C2=CC=CC=C2)O
DMYMJHF	IK	HXWBPTAZQDKQKI-UHFFFAOYSA-N
DMYMJHF	IU	6-[methyl(prop-2-enyl)amino]-4,4-diphenylheptan-3-ol
DMYMJHF	DE	Discovery agent

DMJU9TG	ID	DMJU9TG
DMJU9TG	DN	6-(aminomethyl)-2H-chromen-2-one
DMJU9TG	HS	Investigative
DMJU9TG	SN	CHEMBL567139; 6-aminomethylcoumarin; 927173-90-8; 6-(aminomethyl)-2H-chromen-2-one; 6-(Aminomethyl)coumarin; BDBM50303497
DMJU9TG	DT	Small molecular drug
DMJU9TG	PC	45485270
DMJU9TG	MW	175.18
DMJU9TG	FM	C10H9NO2
DMJU9TG	IC	InChI=1S/C10H9NO2/c11-6-7-1-3-9-8(5-7)2-4-10(12)13-9/h1-5H,6,11H2
DMJU9TG	CS	C1=CC2=C(C=CC(=O)O2)C=C1CN
DMJU9TG	IK	MXXNUQUOHJMQEU-UHFFFAOYSA-N
DMJU9TG	IU	6-(aminomethyl)chromen-2-one
DMJU9TG	DE	Discovery agent

DM2GFI3	ID	DM2GFI3
DM2GFI3	DN	6-(Benzofuran-2-sulfonyl)-2H-pyridazin-3-one
DM2GFI3	HS	Investigative
DM2GFI3	SN	CHEMBL241777; benzofuran, 22; SCHEMBL4448826; BDBM16456; Heterocyclic Sulfonylpyridazinone, 19h
DM2GFI3	DT	Small molecular drug
DM2GFI3	PC	11807954
DM2GFI3	MW	276.27
DM2GFI3	FM	C12H8N2O4S
DM2GFI3	IC	InChI=1S/C12H8N2O4S/c15-10-5-6-11(14-13-10)19(16,17)12-7-8-3-1-2-4-9(8)18-12/h1-7H,(H,13,15)
DM2GFI3	CS	C1=CC=C2C(=C1)C=C(O2)S(=O)(=O)C3=NNC(=O)C=C3
DM2GFI3	IK	RBZSSTPBYFHRSR-UHFFFAOYSA-N
DM2GFI3	IU	3-(1-benzofuran-2-ylsulfonyl)-1H-pyridazin-6-one
DM2GFI3	DE	Discovery agent

DMXLDHR	ID	DMXLDHR
DMXLDHR	DN	6-(Benzothiazole-2-sulfonyl)-2H-pyridazin-3-one
DMXLDHR	HS	Investigative
DMXLDHR	SN	benzothiazole, 19; 6-(Benzothiazole-2-sulfonyl)-2H-pyridazin-3-one; CHEMBL73330; BDBM16453; Heterocyclic Sulfonylpyridazinone, 19z
DMXLDHR	DT	Small molecular drug
DMXLDHR	PC	10902449
DMXLDHR	MW	293.3
DMXLDHR	FM	C11H7N3O3S2
DMXLDHR	IC	InChI=1S/C11H7N3O3S2/c15-9-5-6-10(14-13-9)19(16,17)11-12-7-3-1-2-4-8(7)18-11/h1-6H,(H,13,15)
DMXLDHR	CS	C1=CC=C2C(=C1)N=C(S2)S(=O)(=O)C3=NNC(=O)C=C3
DMXLDHR	IK	AWYKKLWCTAPMDK-UHFFFAOYSA-N
DMXLDHR	IU	3-(1,3-benzothiazol-2-ylsulfonyl)-1H-pyridazin-6-one
DMXLDHR	DE	Discovery agent

DM7BIJH	ID	DM7BIJH
DM7BIJH	DN	6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile
DM7BIJH	HS	Investigative
DM7BIJH	SN	Compound 3{8,12}; 6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile; CHEMBL255079
DM7BIJH	DT	Small molecular drug
DM7BIJH	PC	24777047
DM7BIJH	MW	306.4
DM7BIJH	FM	C17H18N6
DM7BIJH	IC	InChI=1S/C17H18N6/c1-2-3-9-23-12-20-15-16(21-14(10-18)22-17(15)23)19-11-13-7-5-4-6-8-13/h4-8,12H,2-3,9,11H2,1H3,(H,19,21,22)
DM7BIJH	CS	CCCCN1C=NC2=C(N=C(N=C21)C#N)NCC3=CC=CC=C3
DM7BIJH	IK	OJVVVZACBFLFEJ-UHFFFAOYSA-N
DM7BIJH	IU	6-(benzylamino)-9-butylpurine-2-carbonitrile
DM7BIJH	DE	Discovery agent

DM4KMDB	ID	DM4KMDB
DM4KMDB	DN	6-(Biphenyl-2-sulfonyl)-2H-pyridazin-3-one
DM4KMDB	HS	Investigative
DM4KMDB	SN	CHEMBL72752; SCHEMBL6207186; BDBM16448; 6-phenylsulfonylpyridazin-2H-3-one, 10; Phenyl-Substituted Sulfonylpyridazinone, 8j
DM4KMDB	DT	Small molecular drug
DM4KMDB	PC	10267673
DM4KMDB	MW	312.3
DM4KMDB	FM	C16H12N2O3S
DM4KMDB	IC	InChI=1S/C16H12N2O3S/c19-15-10-11-16(18-17-15)22(20,21)14-9-5-4-8-13(14)12-6-2-1-3-7-12/h1-11H,(H,17,19)
DM4KMDB	CS	C1=CC=C(C=C1)C2=CC=CC=C2S(=O)(=O)C3=NNC(=O)C=C3
DM4KMDB	IK	PICCQCWBQAQOHS-UHFFFAOYSA-N
DM4KMDB	IU	3-(2-phenylphenyl)sulfonyl-1H-pyridazin-6-one
DM4KMDB	DE	Discovery agent

DMAYWIN	ID	DMAYWIN
DMAYWIN	DN	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine
DMAYWIN	HS	Investigative
DMAYWIN	SN	CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine
DMAYWIN	DT	Small molecular drug
DMAYWIN	PC	5329512
DMAYWIN	MW	245.28
DMAYWIN	FM	C12H15N5O
DMAYWIN	IC	InChI=1S/C12H15N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-2,7-8H,3-6H2,(H3,13,14,15,16,17)
DMAYWIN	CS	C1CC(CC=C1)COC2=NC(=NC3=C2NC=N3)N
DMAYWIN	IK	RXNXVXFFAAPSTR-UHFFFAOYSA-N
DMAYWIN	IU	6-(cyclohex-3-en-1-ylmethoxy)-7H-purin-2-amine
DMAYWIN	DE	Discovery agent

DMQPTL5	ID	DMQPTL5
DMQPTL5	DN	6-(Dihydroxy-Isobutyl)-Thymine
DMQPTL5	HS	Investigative
DMQPTL5	SN	6-(DIHYDROXY-ISOBUTYL)-THYMINE; DHBT; 6-(1,3-dihydroxyisobutyl)thymine; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methylpyrimidine-2,4(1H,3H)-dione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-2,4(1h,3h)-pyrimidinedione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]thymine; CCV; AC1L1CE0; CTK8A1595; CHEBI:41485; DB02500; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione
DMQPTL5	DT	Small molecular drug
DMQPTL5	PC	1855
DMQPTL5	MW	214.22
DMQPTL5	FM	C9H14N2O4
DMQPTL5	IC	InChI=1S/C9H14N2O4/c1-5-7(2-6(3-12)4-13)10-9(15)11-8(5)14/h6,12-13H,2-4H2,1H3,(H2,10,11,14,15)
DMQPTL5	CS	CC1=C(NC(=O)NC1=O)CC(CO)CO
DMQPTL5	IK	CLCPDSJUXHDRGX-UHFFFAOYSA-N
DMQPTL5	IU	6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione
DMQPTL5	CB	CHEBI:41485
DMQPTL5	DE	Discovery agent

DMOYCBH	ID	DMOYCBH
DMOYCBH	DN	6-(furan-2-yl)-9H-purin-2-amine
DMOYCBH	HS	Investigative
DMOYCBH	SN	CHEMBL404447; 6-(2-furanyl)-9h-purin-2-amine; 442682-77-1; 6-(furan-2-yl)-9H-purin-2-amine; SCHEMBL3272888; 6-(furanyl)-9h-purin-2-amine; JZSMPSCWNAYWOI-UHFFFAOYSA-N; 6-(2-furyl)1H-purine-2-amine; 6-(2-Furyl)-1H-purine-2-amine
DMOYCBH	DT	Small molecular drug
DMOYCBH	PC	9834240
DMOYCBH	MW	201.18
DMOYCBH	FM	C9H7N5O
DMOYCBH	IC	InChI=1S/C9H7N5O/c10-9-13-6(5-2-1-3-15-5)7-8(14-9)12-4-11-7/h1-4H,(H3,10,11,12,13,14)
DMOYCBH	CS	C1=COC(=C1)C2=C3C(=NC(=N2)N)N=CN3
DMOYCBH	IK	JZSMPSCWNAYWOI-UHFFFAOYSA-N
DMOYCBH	IU	6-(furan-2-yl)-7H-purin-2-amine
DMOYCBH	DE	Discovery agent

DM5TOX2	ID	DM5TOX2
DM5TOX2	DN	6-(hydroxymethyl)-2H-chromen-2-one
DM5TOX2	HS	Investigative
DM5TOX2	SN	6-(hydroxymethyl)-2H-chromen-2-one; CHEMBL571738; 2H-1-Benzopyran-2-one, 6-(hydroxymethyl)-; 6,7-hydroxy-4-methyl coumarin; SCHEMBL10350668; BDBM50303496; AKOS006293254
DM5TOX2	DT	Small molecular drug
DM5TOX2	PC	20195365
DM5TOX2	MW	176.17
DM5TOX2	FM	C10H8O3
DM5TOX2	IC	InChI=1S/C10H8O3/c11-6-7-1-3-9-8(5-7)2-4-10(12)13-9/h1-5,11H,6H2
DM5TOX2	CS	C1=CC2=C(C=CC(=O)O2)C=C1CO
DM5TOX2	IK	BPTGMUVORRVIEP-UHFFFAOYSA-N
DM5TOX2	IU	6-(hydroxymethyl)chromen-2-one
DM5TOX2	DE	Discovery agent

DMSH107	ID	DMSH107
DMSH107	DN	6-(Indan-5-ylamino)-1H-pyrimidine-2,4-dione
DMSH107	HS	Investigative
DMSH107	SN	CHEMBL54950; 64054-69-9; 6-(Indan-5-ylamino)-1H-pyrimidine-2,4-dione; 6-[(5-Indanyl)amino]uracil; SCHEMBL3971654; CTK2A7431; DTXSID80591769; BDBM50022163; ZINC13798089; 6-[(3,4-trimethylene)anilino]uracil; 2,4(1H,3H)-Pyrimidinedione, 6-[(2,3-dihydro-1H-inden-5-yl)amino]-
DMSH107	DT	Small molecular drug
DMSH107	PC	17960612
DMSH107	MW	243.26
DMSH107	FM	C13H13N3O2
DMSH107	IC	InChI=1S/C13H13N3O2/c17-12-7-11(15-13(18)16-12)14-10-5-4-8-2-1-3-9(8)6-10/h4-7H,1-3H2,(H3,14,15,16,17,18)
DMSH107	CS	C1CC2=C(C1)C=C(C=C2)NC3=CC(=O)NC(=O)N3
DMSH107	IK	CVUMGFDAIXWWCV-UHFFFAOYSA-N
DMSH107	IU	6-(2,3-dihydro-1H-inden-5-ylamino)-1H-pyrimidine-2,4-dione
DMSH107	CA	CAS 64054-69-9
DMSH107	DE	Discovery agent

DMM2TFX	ID	DMM2TFX
DMM2TFX	DN	6-(Naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione
DMM2TFX	HS	Investigative
DMM2TFX	SN	CHEMBL124937; 6-(Naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione; 21333-09-5; NSC212338; AC1L7G1P; Oprea1_822744; Oprea1_362386; DTXSID70309577; ZINC322361; BDBM50028361; NSC-212338
DMM2TFX	DT	Small molecular drug
DMM2TFX	PC	309881
DMM2TFX	MW	253.26
DMM2TFX	FM	C14H11N3O2
DMM2TFX	IC	InChI=1S/C14H11N3O2/c18-13-8-12(16-14(19)17-13)15-11-6-5-9-3-1-2-4-10(9)7-11/h1-8H,(H3,15,16,17,18,19)
DMM2TFX	CS	C1=CC=C2C=C(C=CC2=C1)NC3=CC(=O)NC(=O)N3
DMM2TFX	IK	KADGSGKDRXSVOE-UHFFFAOYSA-N
DMM2TFX	IU	6-(naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione
DMM2TFX	CA	CAS 21333-09-5
DMM2TFX	DE	Discovery agent

DMXSCQE	ID	DMXSCQE
DMXSCQE	DN	6-(Naphthalene-1-sulfonyl)-2H-pyridazin-3-one
DMXSCQE	HS	Investigative
DMXSCQE	SN	CHEMBL194582; SCHEMBL6206673
DMXSCQE	DT	Small molecular drug
DMXSCQE	PC	9943757
DMXSCQE	MW	286.31
DMXSCQE	FM	C14H10N2O3S
DMXSCQE	IC	InChI=1S/C14H10N2O3S/c17-13-8-9-14(16-15-13)20(18,19)12-7-3-5-10-4-1-2-6-11(10)12/h1-9H,(H,15,17)
DMXSCQE	CS	C1=CC=C2C(=C1)C=CC=C2S(=O)(=O)C3=NNC(=O)C=C3
DMXSCQE	IK	HJXKXDILPXEWJY-UHFFFAOYSA-N
DMXSCQE	IU	3-naphthalen-1-ylsulfonyl-1H-pyridazin-6-one
DMXSCQE	DE	Discovery agent

DMCIA63	ID	DMCIA63
DMCIA63	DN	6-(Naphthalene-2-sulfonyl)-2H-pyridazin-3-one
DMCIA63	HS	Investigative
DMCIA63	SN	CHEMBL369911
DMCIA63	DT	Small molecular drug
DMCIA63	PC	11673647
DMCIA63	MW	286.31
DMCIA63	FM	C14H10N2O3S
DMCIA63	IC	InChI=1S/C14H10N2O3S/c17-13-7-8-14(16-15-13)20(18,19)12-6-5-10-3-1-2-4-11(10)9-12/h1-9H,(H,15,17)
DMCIA63	CS	C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)C3=NNC(=O)C=C3
DMCIA63	IK	HXEYVOPGUKCHBE-UHFFFAOYSA-N
DMCIA63	IU	3-naphthalen-2-ylsulfonyl-1H-pyridazin-6-one
DMCIA63	DE	Discovery agent

DMHM0RW	ID	DMHM0RW
DMHM0RW	DN	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine
DMHM0RW	HS	Investigative
DMHM0RW	SN	6-(N-PHENYLCARBAMYL)-2-NAPHTHALENECARBOXAMIDINE; CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide
DMHM0RW	DT	Small molecular drug
DMHM0RW	PC	447732
DMHM0RW	MW	289.3
DMHM0RW	FM	C18H15N3O
DMHM0RW	IC	InChI=1S/C18H15N3O/c19-17(20)14-8-6-13-11-15(9-7-12(13)10-14)18(22)21-16-4-2-1-3-5-16/h1-11H,(H3,19,20)(H,21,22)
DMHM0RW	CS	C1=CC=C(C=C1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=N)N
DMHM0RW	IK	AECPTICWHONWNW-UHFFFAOYSA-N
DMHM0RW	IU	6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide
DMHM0RW	DE	Discovery agent

DM1LY0S	ID	DM1LY0S
DM1LY0S	DN	6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
DM1LY0S	HS	Investigative
DM1LY0S	SN	6-(OXALYL-AMINO)-1H-INDOLE-5-CARBOXYLIC ACID; CHEMBL342478; 243967-44-4; 1H-Indole-5-carboxylic acid, 6-[(carboxycarbonyl)amino]-; 6-(carboxyformamido)-1H-indole-5-carboxylic acid; OAI; AC1L9GUL; SCHEMBL4318827; CTK0J4951; DTXSID50332166; 1c83; BDBM50118796; DB04001; N-(5-Carboxy-1H-indole-6-yl)oxamidic acid; 6-(oxaloamino)-1H-indole-5-carboxylic acid; 6-[(carboxycarbonyl)amino]-1H-indole-5-carboxylic acid
DM1LY0S	DT	Small molecular drug
DM1LY0S	PC	444763
DM1LY0S	MW	248.19
DM1LY0S	FM	C11H8N2O5
DM1LY0S	IC	InChI=1S/C11H8N2O5/c14-9(11(17)18)13-8-4-7-5(1-2-12-7)3-6(8)10(15)16/h1-4,12H,(H,13,14)(H,15,16)(H,17,18)
DM1LY0S	CS	C1=CNC2=CC(=C(C=C21)C(=O)O)NC(=O)C(=O)O
DM1LY0S	IK	AHWMERGBWWROMM-UHFFFAOYSA-N
DM1LY0S	IU	6-(oxaloamino)-1H-indole-5-carboxylic acid
DM1LY0S	CA	CAS 243967-44-4
DM1LY0S	DE	Discovery agent

DMM9G0J	ID	DMM9G0J
DMM9G0J	DN	6-(piperazin-1-yl)-3-tosyl-1H-indazole
DMM9G0J	HS	Investigative
DMM9G0J	SN	CHEMBL1277286; 6-(piperazin-1-yl)-3-tosyl-1H-indazole
DMM9G0J	DT	Small molecular drug
DMM9G0J	PC	49836719
DMM9G0J	MW	356.4
DMM9G0J	FM	C18H20N4O2S
DMM9G0J	IC	InChI=1S/C18H20N4O2S/c1-13-2-5-15(6-3-13)25(23,24)18-16-7-4-14(12-17(16)20-21-18)22-10-8-19-9-11-22/h2-7,12,19H,8-11H2,1H3,(H,20,21)
DMM9G0J	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=C3C=CC(=CC3=NN2)N4CCNCC4
DMM9G0J	IK	HACUZCXCVMCHQD-UHFFFAOYSA-N
DMM9G0J	IU	3-(4-methylphenyl)sulfonyl-6-piperazin-1-yl-2H-indazole
DMM9G0J	CA	CAS 744219-47-4
DMM9G0J	DE	Discovery agent

DMUNWJR	ID	DMUNWJR
DMUNWJR	DN	6-(piperazin-1-yl)-9-propyl-9H-purine
DMUNWJR	HS	Investigative
DMUNWJR	SN	CHEMBL594489; 6-(piperazin-1-yl)-9-propyl-9H-purine
DMUNWJR	DT	Small molecular drug
DMUNWJR	PC	46228441
DMUNWJR	MW	246.31
DMUNWJR	FM	C12H18N6
DMUNWJR	IC	InChI=1S/C12H18N6/c1-2-5-18-9-16-10-11(14-8-15-12(10)18)17-6-3-13-4-7-17/h8-9,13H,2-7H2,1H3
DMUNWJR	CS	CCCN1C=NC2=C1N=CN=C2N3CCNCC3
DMUNWJR	IK	BWJIAIMMFVYUQA-UHFFFAOYSA-N
DMUNWJR	IU	6-piperazin-1-yl-9-propylpurine
DMUNWJR	DE	Discovery agent

DMBQKGY	ID	DMBQKGY
DMBQKGY	DN	6-(piperidin-4-ylmethoxy)-2-naphthonitrile
DMBQKGY	HS	Investigative
DMBQKGY	SN	CHEMBL469552; 6-(piperidin-4-ylmethoxy)-2-naphthonitrile
DMBQKGY	DT	Small molecular drug
DMBQKGY	PC	44592200
DMBQKGY	MW	266.34
DMBQKGY	FM	C17H18N2O
DMBQKGY	IC	InChI=1S/C17H18N2O/c18-11-14-1-2-16-10-17(4-3-15(16)9-14)20-12-13-5-7-19-8-6-13/h1-4,9-10,13,19H,5-8,12H2
DMBQKGY	CS	C1CNCCC1COC2=CC3=C(C=C2)C=C(C=C3)C#N
DMBQKGY	IK	SHJHTXWKDLOBQS-UHFFFAOYSA-N
DMBQKGY	IU	6-(piperidin-4-ylmethoxy)naphthalene-2-carbonitrile
DMBQKGY	DE	Discovery agent

DMC3SJI	ID	DMC3SJI
DMC3SJI	DN	6-(pyridin-3-yl)-2-naphthonitrile
DMC3SJI	HS	Investigative
DMC3SJI	SN	CHEMBL196796; SCHEMBL4511285; BDBM8909; 6-pyridin-3-yl-2-naphthonitrile; Pyridine-substituted naphthalene 8; ZINC13674459
DMC3SJI	DT	Small molecular drug
DMC3SJI	PC	11601068
DMC3SJI	MW	230.26
DMC3SJI	FM	C16H10N2
DMC3SJI	IC	InChI=1S/C16H10N2/c17-10-12-3-4-14-9-15(6-5-13(14)8-12)16-2-1-7-18-11-16/h1-9,11H
DMC3SJI	CS	C1=CC(=CN=C1)C2=CC3=C(C=C2)C=C(C=C3)C#N
DMC3SJI	IK	BRNSTMOAGOETDI-UHFFFAOYSA-N
DMC3SJI	IU	6-pyridin-3-ylnaphthalene-2-carbonitrile
DMC3SJI	DE	Discovery agent

DMV3MF4	ID	DMV3MF4
DMV3MF4	DN	6-(Toluene-4-sulfonyl)-2H-pyridazin-3-one
DMV3MF4	HS	Investigative
DMV3MF4	SN	CHEMBL72368; 6-tosylpyridazin-3(2H)-one; BDBM16447; ZINC11536215; AKOS015830955; AKOS001773373; MCULE-5757912617; CCG-126887; 6-phenylsulfonylpyridazin-2H-3-one, 9; 99985-09-8; Phenyl-Substituted Sulfonylpyridazinone, 8i; 3(2H)-Pyridazinone, 6-[(4-methylphenyl)sulfonyl]-; F6548-0368
DMV3MF4	DT	Small molecular drug
DMV3MF4	PC	22424988
DMV3MF4	MW	250.28
DMV3MF4	FM	C11H10N2O3S
DMV3MF4	IC	InChI=1S/C11H10N2O3S/c1-8-2-4-9(5-3-8)17(15,16)11-7-6-10(14)12-13-11/h2-7H,1H3,(H,12,14)
DMV3MF4	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=NNC(=O)C=C2
DMV3MF4	IK	SGMDNRFRSNYBCA-UHFFFAOYSA-N
DMV3MF4	IU	3-(4-methylphenyl)sulfonyl-1H-pyridazin-6-one
DMV3MF4	DE	Discovery agent

DMSB8WQ	ID	DMSB8WQ
DMSB8WQ	DN	6,11-dihydro-5H-benzo[a]carbazole
DMSB8WQ	HS	Investigative
DMSB8WQ	SN	6,11-dihydro-5H-benzo[a]carbazole; 21064-49-3; 5H-Benzo[a]carbazole, 6,11-dihydro-; 1,2,7-trihydrobenzo[a]4aH-carbazole; ST076800; 5,11-Dihydro-6H-benzo[a]carbazole; 5,11-DIHYDRO-6H-BENZO(A)CARBAZOLE; NSC168810; AC1L6RUQ; Maybridge1_006237; AC1Q1H7M; CHEMBL239937; Aza-heterocyclic Derivative, 7; SCHEMBL12126575; HMS559D11; CTK0J8060; BDBM19186; DTXSID40305026; MolPort-000-737-601; ZX-AN022290; ALBB-023776; ZINC1023865; CCG-20433; STK874208; BBL028411; 5,6-Dihydro-11H-benzo[a]carbazole; AKOS000547063; MCULE-4710620349; NSC-168810; RH 00
DMSB8WQ	DT	Small molecular drug
DMSB8WQ	PC	297591
DMSB8WQ	MW	219.28
DMSB8WQ	FM	C16H13N
DMSB8WQ	IC	InChI=1S/C16H13N/c1-2-6-12-11(5-1)9-10-14-13-7-3-4-8-15(13)17-16(12)14/h1-8,17H,9-10H2
DMSB8WQ	CS	C1CC2=C(C3=CC=CC=C31)NC4=CC=CC=C24
DMSB8WQ	IK	UPUQYBJFFYMNQK-UHFFFAOYSA-N
DMSB8WQ	IU	6,11-dihydro-5H-benzo[a]carbazole
DMSB8WQ	CA	CAS 21064-49-3
DMSB8WQ	DE	Discovery agent

DM0RB53	ID	DM0RB53
DM0RB53	DN	6,11-dihydrothiochromeno[4,3-b]indol-8-ol
DM0RB53	HS	Investigative
DM0RB53	SN	CHEMBL210924; 6,11-dihydrothiochromeno[4,3-b]indol-8-ol; SCHEMBL1986592; BVGUKMAMOJMOFD-UHFFFAOYSA-N; BDBM50185203
DM0RB53	DT	Small molecular drug
DM0RB53	PC	44411868
DM0RB53	MW	253.32
DM0RB53	FM	C15H11NOS
DM0RB53	IC	InChI=1S/C15H11NOS/c17-9-5-6-13-11(7-9)12-8-18-14-4-2-1-3-10(14)15(12)16-13/h1-7,16-17H,8H2
DM0RB53	CS	C1C2=C(C3=CC=CC=C3S1)NC4=C2C=C(C=C4)O
DM0RB53	IK	BVGUKMAMOJMOFD-UHFFFAOYSA-N
DM0RB53	IU	6,11-dihydrothiochromeno[4,3-b]indol-8-ol
DM0RB53	DE	Discovery agent

DMMZTE3	ID	DMMZTE3
DMMZTE3	DN	6,6-dimethyl-1-phenyl-3-aza-bicyclo[3.1.0]hexane
DMMZTE3	HS	Investigative
DMMZTE3	SN	CHEMBL488639; 6,6-dimethyl-1-phenyl-3-aza-bicyclo[3.1.0]hexane
DMMZTE3	DT	Small molecular drug
DMMZTE3	PC	44561134
DMMZTE3	MW	187.28
DMMZTE3	FM	C13H17N
DMMZTE3	IC	InChI=1S/C13H17N/c1-12(2)11-8-14-9-13(11,12)10-6-4-3-5-7-10/h3-7,11,14H,8-9H2,1-2H3
DMMZTE3	CS	CC1(C2C1(CNC2)C3=CC=CC=C3)C
DMMZTE3	IK	GCPODIFNAITRSC-UHFFFAOYSA-N
DMMZTE3	IU	6,6-dimethyl-1-phenyl-3-azabicyclo[3.1.0]hexane
DMMZTE3	DE	Discovery agent

DMOIFAP	ID	DMOIFAP
DMOIFAP	DN	6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DMOIFAP	HS	Investigative
DMOIFAP	SN	2-Oxaspiro[4.4]nonan-1-one, 6,6-dimethyl-; CHEMBL94885; 153579-89-6
DMOIFAP	DT	Small molecular drug
DMOIFAP	PC	10352086
DMOIFAP	MW	168.23
DMOIFAP	FM	C10H16O2
DMOIFAP	IC	InChI=1S/C10H16O2/c1-9(2)4-3-5-10(9)6-7-12-8(10)11/h3-7H2,1-2H3
DMOIFAP	CS	CC1(CCCC12CCOC2=O)C
DMOIFAP	IK	FHWLTPUPKBUBCF-UHFFFAOYSA-N
DMOIFAP	IU	9,9-dimethyl-2-oxaspiro[4.4]nonan-1-one
DMOIFAP	DE	Discovery agent

DMNOI7B	ID	DMNOI7B
DMNOI7B	DN	6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene
DMNOI7B	HS	Investigative
DMNOI7B	SN	2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine; 58980-39-5; 2,3,4,5-tetrahydro-1,4-benzothiazepine; CHEMBL333343; 6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene; 1,4-Benzothiazepine, 2,3,4,5-tetrahydro-; SCHEMBL2589907; CTK1D9777; DTXSID50483283; SUBDEKBXSIKCSA-UHFFFAOYSA-N; MolPort-022-153-088; BDBM50052886; 8761AB; ANW-63665; ZINC13757904; AKOS015856597; AJ-64367; AS-36127; KB-224927; TR-072578; AB0052636; ST24021452; FT-0733802; 2,3,4,5-tetrahydrobenzo[f]-1,4-thiazepine; X-3109; I14-16090
DMNOI7B	DT	Small molecular drug
DMNOI7B	PC	12269106
DMNOI7B	MW	165.26
DMNOI7B	FM	C9H11NS
DMNOI7B	IC	InChI=1S/C9H11NS/c1-2-4-9-8(3-1)7-10-5-6-11-9/h1-4,10H,5-7H2
DMNOI7B	CS	C1CSC2=CC=CC=C2CN1
DMNOI7B	IK	SUBDEKBXSIKCSA-UHFFFAOYSA-N
DMNOI7B	IU	2,3,4,5-tetrahydro-1,4-benzothiazepine
DMNOI7B	CA	CAS 58980-39-5
DMNOI7B	DE	Discovery agent

DMAMD87	ID	DMAMD87
DMAMD87	DN	6,7,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one
DMAMD87	HS	Investigative
DMAMD87	SN	6,7,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one; casimiroin analogue, 1n; CHEMBL492382; BDBM29225
DMAMD87	DT	Small molecular drug
DMAMD87	PC	42618033
DMAMD87	MW	263.29
DMAMD87	FM	C14H17NO4
DMAMD87	IC	InChI=1S/C14H17NO4/c1-8-6-11(16)15(2)12-9(8)7-10(17-3)13(18-4)14(12)19-5/h6-7H,1-5H3
DMAMD87	CS	CC1=CC(=O)N(C2=C(C(=C(C=C12)OC)OC)OC)C
DMAMD87	IK	QKOJIFYKROBOKN-UHFFFAOYSA-N
DMAMD87	IU	6,7,8-trimethoxy-1,4-dimethylquinolin-2-one
DMAMD87	DE	Discovery agent

DMJX9NQ	ID	DMJX9NQ
DMJX9NQ	DN	6,7,8-Trimethoxy-4-methylquinolin-2(1H)-one
DMJX9NQ	HS	Investigative
DMJX9NQ	SN	6,7,8-Trimethoxy-4-methylquinolin-2(1H)-one; casimiroin analogue, 1m; CHEMBL454226; BDBM29224
DMJX9NQ	DT	Small molecular drug
DMJX9NQ	PC	42618032
DMJX9NQ	MW	249.26
DMJX9NQ	FM	C13H15NO4
DMJX9NQ	IC	InChI=1S/C13H15NO4/c1-7-5-10(15)14-11-8(7)6-9(16-2)12(17-3)13(11)18-4/h5-6H,1-4H3,(H,14,15)
DMJX9NQ	CS	CC1=CC(=O)NC2=C(C(=C(C=C12)OC)OC)OC
DMJX9NQ	IK	JAKHLWMOJRMVRW-UHFFFAOYSA-N
DMJX9NQ	IU	6,7,8-trimethoxy-4-methyl-1H-quinolin-2-one
DMJX9NQ	DE	Discovery agent

DMDO083	ID	DMDO083
DMDO083	DN	6,7-dibromoquinoline-5,8-dione
DMDO083	HS	Investigative
DMDO083	SN	6,7-dibromoquinoline-5,8-dione; CHEMBL488961; 18633-05-1; 6,7-Dibrom-5,8-dihydrochinolin-5,8-dion; NSC82128; AC1L5TKN; SCHEMBL6866292; AC1Q6K93; 6,7-dibromo-5,8-quinolindion; CTK4D9216; DTXSID40292366; CPZKOUMVYNIHQE-UHFFFAOYSA-N; BDBM50264041; NSC-82128
DMDO083	DT	Small molecular drug
DMDO083	PC	255964
DMDO083	MW	316.93
DMDO083	FM	C9H3Br2NO2
DMDO083	IC	InChI=1S/C9H3Br2NO2/c10-5-6(11)9(14)7-4(8(5)13)2-1-3-12-7/h1-3H
DMDO083	CS	C1=CC2=C(C(=O)C(=C(C2=O)Br)Br)N=C1
DMDO083	IK	CPZKOUMVYNIHQE-UHFFFAOYSA-N
DMDO083	IU	6,7-dibromoquinoline-5,8-dione
DMDO083	CA	CAS 18633-05-1
DMDO083	DE	Discovery agent

DMMX1QJ	ID	DMMX1QJ
DMMX1QJ	DN	6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione
DMMX1QJ	HS	Investigative
DMMX1QJ	SN	25983-13-5; 6,7-Dichloroquinoxaline-2,3(1H,4H)-dione; DCQX; 6,7-dichloroquinoxaline-2,3-diol; 6,7-DICHLORO-1,4-DIHYDRO-2,3-QUINOXALINEDIONE; 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione; 2,3-Dihydroxy-6,7-dichloroquinoxaline; 6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione; CHEMBL284028; Spectrum_001661; ACMC-209gnv; SpecPlus_000650; Lopac-D-133; AC1L1CDC; Spectrum5_001426; Spectrum4_000630; Spectrum3_001668; Spectrum2_000537; Biomol-NT_000181; AC1Q3Q7M; Lopac0_000418; KBioSS_002141; KBioGR_001220; BSPBio_003455; Benzil-related co
DMMX1QJ	DT	Small molecular drug
DMMX1QJ	PC	1845
DMMX1QJ	MW	231.03
DMMX1QJ	FM	C8H4Cl2N2O2
DMMX1QJ	IC	InChI=1S/C8H4Cl2N2O2/c9-3-1-5-6(2-4(3)10)12-8(14)7(13)11-5/h1-2H,(H,11,13)(H,12,14)
DMMX1QJ	CS	C1=C2C(=CC(=C1Cl)Cl)NC(=O)C(=O)N2
DMMX1QJ	IK	AVBSIKMUAFYZAV-UHFFFAOYSA-N
DMMX1QJ	IU	6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione
DMMX1QJ	CA	CAS 25983-13-5
DMMX1QJ	CB	CHEBI:113553
DMMX1QJ	DE	Discovery agent

DMZHDFM	ID	DMZHDFM
DMZHDFM	DN	6,7-dichloro-1H-indole-2,3-dione
DMZHDFM	HS	Investigative
DMZHDFM	SN	6,7-dichloro-1H-indole-2,3-dione; 18711-12-1; 6,7-Dichloroindoline-2,3-dione; 1H-Indole-2,3-dione,6,7-dichloro-; 6,7-dichloro-2,3-dihydro-1H-indole-2,3-dione; 6,7-dichlorisatin; 6,7-dichloroisatin; AC1Q3HQA; Isatin-based compound, 54; SCHEMBL1248801; CHEMBL222292; CTK4D9416; BDBM22834; DTXSID30588487; MolPort-004-304-808; XTXIILHWOQZVAQ-UHFFFAOYSA-N; STL381782; ZINC14979616; AKOS000139553; MCULE-1304306967; 1H-Indole-2,3-dione, 6,7-dichloro-; AJ-65537; KB-335070; FT-0620847; EN300-36024; Y-0718
DMZHDFM	DT	Small molecular drug
DMZHDFM	PC	16786802
DMZHDFM	MW	216.02
DMZHDFM	FM	C8H3Cl2NO2
DMZHDFM	IC	InChI=1S/C8H3Cl2NO2/c9-4-2-1-3-6(5(4)10)11-8(13)7(3)12/h1-2H,(H,11,12,13)
DMZHDFM	CS	C1=CC(=C(C2=C1C(=O)C(=O)N2)Cl)Cl
DMZHDFM	IK	XTXIILHWOQZVAQ-UHFFFAOYSA-N
DMZHDFM	IU	6,7-dichloro-1H-indole-2,3-dione
DMZHDFM	CA	CAS 18711-12-1
DMZHDFM	DE	Discovery agent

DM592FB	ID	DM592FB
DM592FB	DN	6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine
DM592FB	HS	Investigative
DM592FB	SN	6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine; CHEMBL262862; 180160-89-8; SCHEMBL7885461; WMCWIMZEYWNBOQ-UHFFFAOYSA-N; BDBM50375903; L021806
DM592FB	DT	Small molecular drug
DM592FB	PC	9813197
DM592FB	MW	216.1
DM592FB	FM	C10H11Cl2N
DM592FB	IC	InChI=1S/C10H11Cl2N/c11-9-2-1-7-3-5-13-6-4-8(7)10(9)12/h1-2,13H,3-6H2
DM592FB	CS	C1CNCCC2=C1C=CC(=C2Cl)Cl
DM592FB	IK	WMCWIMZEYWNBOQ-UHFFFAOYSA-N
DM592FB	IU	6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine
DM592FB	DE	Discovery agent

DMNEJ8W	ID	DMNEJ8W
DMNEJ8W	DN	6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMNEJ8W	HS	Investigative
DMNEJ8W	SN	CHEMBL77569; 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMNEJ8W	DT	Small molecular drug
DMNEJ8W	PC	44315523
DMNEJ8W	MW	247.03
DMNEJ8W	FM	C8H4Cl2N2O3
DMNEJ8W	IC	InChI=1S/C8H4Cl2N2O3/c9-4-1-3-6(2-5(4)10)11-8(14)12(15)7(3)13/h1-2,15H,(H,11,14)
DMNEJ8W	CS	C1=C2C(=CC(=C1Cl)Cl)NC(=O)N(C2=O)O
DMNEJ8W	IK	URXMQPMLTVUBON-UHFFFAOYSA-N
DMNEJ8W	IU	6,7-dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMNEJ8W	DE	Discovery agent

DMJNHSL	ID	DMJNHSL
DMJNHSL	DN	6,7-Dichloro-3-thiophen-3-yl-quinoline
DMJNHSL	HS	Investigative
DMJNHSL	SN	CHEMBL66718; 6,7-dichloro-3-thiophen-3-yl-quinoline; SCHEMBL8503219; ZINC13737709
DMJNHSL	DT	Small molecular drug
DMJNHSL	PC	10265642
DMJNHSL	MW	280.2
DMJNHSL	FM	C13H7Cl2NS
DMJNHSL	IC	InChI=1S/C13H7Cl2NS/c14-11-4-9-3-10(8-1-2-17-7-8)6-16-13(9)5-12(11)15/h1-7H
DMJNHSL	CS	C1=CSC=C1C2=CN=C3C=C(C(=CC3=C2)Cl)Cl
DMJNHSL	IK	KNQSFKNTYMKKOR-UHFFFAOYSA-N
DMJNHSL	IU	6,7-dichloro-3-thiophen-3-ylquinoline
DMJNHSL	DE	Discovery agent

DMI7FVJ	ID	DMI7FVJ
DMI7FVJ	DN	6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline
DMI7FVJ	HS	Investigative
DMI7FVJ	SN	CHEMBL399371; 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline
DMI7FVJ	DT	Small molecular drug
DMI7FVJ	PC	44442182
DMI7FVJ	MW	348.4
DMI7FVJ	FM	C22H24N2O2
DMI7FVJ	IC	InChI=1S/C22H24N2O2/c1-3-25-21-14-18-19(13-9-8-12-17-10-6-5-7-11-17)23-16-24-20(18)15-22(21)26-4-2/h5-7,9-11,13-16H,3-4,8,12H2,1-2H3/b13-9+
DMI7FVJ	CS	CCOC1=C(C=C2C(=C1)C(=NC=N2)/C=C/CCC3=CC=CC=C3)OCC
DMI7FVJ	IK	TYVCCOFEERYUGD-UKTHLTGXSA-N
DMI7FVJ	IU	6,7-diethoxy-4-[(E)-4-phenylbut-1-enyl]quinazoline
DMI7FVJ	DE	Discovery agent

DMFVT8A	ID	DMFVT8A
DMFVT8A	DN	6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline
DMFVT8A	HS	Investigative
DMFVT8A	SN	CHEMBL251123; 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline
DMFVT8A	DT	Small molecular drug
DMFVT8A	PC	44442183
DMFVT8A	MW	362.5
DMFVT8A	FM	C23H26N2O2
DMFVT8A	IC	InChI=1S/C23H26N2O2/c1-3-26-22-15-19-20(24-17-25-21(19)16-23(22)27-4-2)14-10-6-9-13-18-11-7-5-8-12-18/h5,7-8,10-12,14-17H,3-4,6,9,13H2,1-2H3/b14-10+
DMFVT8A	CS	CCOC1=C(C=C2C(=C1)C(=NC=N2)/C=C/CCCC3=CC=CC=C3)OCC
DMFVT8A	IK	QLOYTAAAUVDJCT-GXDHUFHOSA-N
DMFVT8A	IU	6,7-diethoxy-4-[(E)-5-phenylpent-1-enyl]quinazoline
DMFVT8A	DE	Discovery agent

DMVR4OW	ID	DMVR4OW
DMVR4OW	DN	6,7-diethoxy-4-styrylquinazoline
DMVR4OW	HS	Investigative
DMVR4OW	SN	CHEMBL250925; 6,7-diethoxy-4-styrylquinazoline
DMVR4OW	DT	Small molecular drug
DMVR4OW	PC	44442181
DMVR4OW	MW	320.4
DMVR4OW	FM	C20H20N2O2
DMVR4OW	IC	InChI=1S/C20H20N2O2/c1-3-23-19-12-16-17(11-10-15-8-6-5-7-9-15)21-14-22-18(16)13-20(19)24-4-2/h5-14H,3-4H2,1-2H3/b11-10+
DMVR4OW	CS	CCOC1=C(C=C2C(=C1)C(=NC=N2)/C=C/C3=CC=CC=C3)OCC
DMVR4OW	IK	MVIQZBWZLCMZGF-ZHACJKMWSA-N
DMVR4OW	IU	6,7-diethoxy-4-[(E)-2-phenylethenyl]quinazoline
DMVR4OW	DE	Discovery agent

DMUZYXQ	ID	DMUZYXQ
DMUZYXQ	DN	6,7-Difluoro-3-thiophen-3-yl-quinoline
DMUZYXQ	HS	Investigative
DMUZYXQ	SN	CHEMBL68184; 6,7-difluoro-3-thiophen-3-yl-quinoline; SCHEMBL8501272; ZINC13737708
DMUZYXQ	DT	Small molecular drug
DMUZYXQ	PC	10106010
DMUZYXQ	MW	247.26
DMUZYXQ	FM	C13H7F2NS
DMUZYXQ	IC	InChI=1S/C13H7F2NS/c14-11-4-9-3-10(8-1-2-17-7-8)6-16-13(9)5-12(11)15/h1-7H
DMUZYXQ	CS	C1=CSC=C1C2=CN=C3C=C(C(=CC3=C2)F)F
DMUZYXQ	IK	RAEOQRGQVOSWAJ-UHFFFAOYSA-N
DMUZYXQ	IU	6,7-difluoro-3-thiophen-3-ylquinoline
DMUZYXQ	DE	Discovery agent

DMF08UT	ID	DMF08UT
DMF08UT	DN	6,7-Dihydroxy-2-phenyl-chromen-4-one
DMF08UT	HS	Investigative
DMF08UT	SN	6,7-dihydroxyflavone; 38183-04-9; 6,7-dihydroxy-2-phenyl-4H-chromen-4-one; 6,7-Dihydroxy-2-phenyl-chromen-4-one; 6,7-dihydroxy flavone; 4H-1-Benzopyran-4-one, 6,7-dihydroxy-2-phenyl-; CHEMBL300814; 6,7-dihydroxy-2-phenylchromen-4-one; SR-05000002250; PubChem9843; 6,7 - Dihydroxyflavone; AC1NS43N; SPECTRUM1500718; SCHEMBL980197; DivK1c_000421; CTK4H9455; KBio1_000421; HMS501F03; DTXSID60191569; NINDS_000421; GSAOUZGPXSGVRS-UHFFFAOYSA-N; ZINC3871176; BDBM50077318; AKOS024283483; CCG-208431; MCULE-6698063887; IDI1_000421; ACM38183049
DMF08UT	DT	Small molecular drug
DMF08UT	PC	5353357
DMF08UT	MW	254.24
DMF08UT	FM	C15H10O4
DMF08UT	IC	InChI=1S/C15H10O4/c16-11-7-14(9-4-2-1-3-5-9)19-15-8-13(18)12(17)6-10(11)15/h1-8,17-18H
DMF08UT	CS	C1=CC=C(C=C1)C2=CC(=O)C3=CC(=C(C=C3O2)O)O
DMF08UT	IK	GSAOUZGPXSGVRS-UHFFFAOYSA-N
DMF08UT	IU	6,7-dihydroxy-2-phenylchromen-4-one
DMF08UT	CA	CAS 38183-04-9
DMF08UT	DE	Discovery agent

DM9JLUS	ID	DM9JLUS
DM9JLUS	DN	6,7-dihydroxy-8-nitro-1-tetralone
DM9JLUS	HS	Investigative
DM9JLUS	SN	383382-48-7; 1(2h)-naphthalenone,3,4-dihydro-6,7-dihydroxy-8-nitro-; CHEMBL8752; SCHEMBL7428171; CTK8I5216; 1(2H)-Naphthalenone, 3,4-dihydro-6,7-dihydroxy-8-nitro-; ZINC25989269
DM9JLUS	DT	Small molecular drug
DM9JLUS	PC	9877868
DM9JLUS	MW	223.18
DM9JLUS	FM	C10H9NO5
DM9JLUS	IC	InChI=1S/C10H9NO5/c12-6-3-1-2-5-4-7(13)10(14)9(8(5)6)11(15)16/h4,13-14H,1-3H2
DM9JLUS	CS	C1CC2=CC(=C(C(=C2C(=O)C1)[N+](=O)[O-])O)O
DM9JLUS	IK	CXOQHHVPOJWTNP-UHFFFAOYSA-N
DM9JLUS	IU	6,7-dihydroxy-8-nitro-3,4-dihydro-2H-naphthalen-1-one
DM9JLUS	DE	Discovery agent

DMSM0QV	ID	DMSM0QV
DMSM0QV	DN	6,7-Dimethoxy-3-((E)-styryl)-quinoline
DMSM0QV	HS	Investigative
DMSM0QV	SN	CHEMBL70149; 6,7-Dimethoxy-3-((E)-styryl)-quinoline; ZINC3834019; BDBM50039041
DMSM0QV	DT	Small molecular drug
DMSM0QV	PC	10017166
DMSM0QV	MW	291.3
DMSM0QV	FM	C19H17NO2
DMSM0QV	IC	InChI=1S/C19H17NO2/c1-21-18-11-16-10-15(9-8-14-6-4-3-5-7-14)13-20-17(16)12-19(18)22-2/h3-13H,1-2H3/b9-8+
DMSM0QV	CS	COC1=CC2=CC(=CN=C2C=C1OC)/C=C/C3=CC=CC=C3
DMSM0QV	IK	NQVBNOPSVRCGSI-CMDGGOBGSA-N
DMSM0QV	IU	6,7-dimethoxy-3-[(E)-2-phenylethenyl]quinoline
DMSM0QV	DE	Discovery agent

DMPYGK9	ID	DMPYGK9
DMPYGK9	DN	6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline
DMPYGK9	HS	Investigative
DMPYGK9	SN	CHEMBL419248; 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline; ZINC13737710
DMPYGK9	DT	Small molecular drug
DMPYGK9	PC	10085862
DMPYGK9	MW	295.3
DMPYGK9	FM	C18H17NO3
DMPYGK9	IC	InChI=1S/C18H17NO3/c1-20-16-7-5-4-6-14(16)13-8-12-9-17(21-2)18(22-3)10-15(12)19-11-13/h4-11H,1-3H3
DMPYGK9	CS	COC1=CC=CC=C1C2=CN=C3C=C(C(=CC3=C2)OC)OC
DMPYGK9	IK	ZGHJQSABDREYEE-UHFFFAOYSA-N
DMPYGK9	IU	6,7-dimethoxy-3-(2-methoxyphenyl)quinoline
DMPYGK9	DE	Discovery agent

DMDENVF	ID	DMDENVF
DMDENVF	DN	6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline
DMDENVF	HS	Investigative
DMDENVF	SN	CHEMBL308466; 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline; ZINC13737704
DMDENVF	DT	Small molecular drug
DMDENVF	PC	10447210
DMDENVF	MW	295.3
DMDENVF	FM	C18H17NO3
DMDENVF	IC	InChI=1S/C18H17NO3/c1-20-15-6-4-5-12(8-15)14-7-13-9-17(21-2)18(22-3)10-16(13)19-11-14/h4-11H,1-3H3
DMDENVF	CS	COC1=CC=CC(=C1)C2=CN=C3C=C(C(=CC3=C2)OC)OC
DMDENVF	IK	RIQQTUOYRGIOFQ-UHFFFAOYSA-N
DMDENVF	IU	6,7-dimethoxy-3-(3-methoxyphenyl)quinoline
DMDENVF	DE	Discovery agent

DM12DVT	ID	DM12DVT
DM12DVT	DN	6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline
DM12DVT	HS	Investigative
DM12DVT	SN	CHEMBL70130; 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline; SCHEMBL8501467; ZINC8074; BDBM50039071
DM12DVT	DT	Small molecular drug
DM12DVT	PC	9882618
DM12DVT	MW	295.3
DM12DVT	FM	C18H17NO3
DM12DVT	IC	InChI=1S/C18H17NO3/c1-20-15-6-4-12(5-7-15)14-8-13-9-17(21-2)18(22-3)10-16(13)19-11-14/h4-11H,1-3H3
DM12DVT	CS	COC1=CC=C(C=C1)C2=CN=C3C=C(C(=CC3=C2)OC)OC
DM12DVT	IK	UNALZVYBWFUPTL-UHFFFAOYSA-N
DM12DVT	IU	6,7-dimethoxy-3-(4-methoxyphenyl)quinoline
DM12DVT	DE	Discovery agent

DMM7NHI	ID	DMM7NHI
DMM7NHI	DN	6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline
DMM7NHI	HS	Investigative
DMM7NHI	SN	CHEMBL69585; 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline; ZINC3834037
DMM7NHI	DT	Small molecular drug
DMM7NHI	PC	11722903
DMM7NHI	MW	310.3
DMM7NHI	FM	C17H14N2O4
DMM7NHI	IC	InChI=1S/C17H14N2O4/c1-22-16-8-12-7-13(10-18-15(12)9-17(16)23-2)11-3-5-14(6-4-11)19(20)21/h3-10H,1-2H3
DMM7NHI	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=C(C=C3)[N+](=O)[O-]
DMM7NHI	IK	FLEDIDSHIXDOQR-UHFFFAOYSA-N
DMM7NHI	IU	6,7-dimethoxy-3-(4-nitrophenyl)quinoline
DMM7NHI	DE	Discovery agent

DMFRXDT	ID	DMFRXDT
DMFRXDT	DN	6,7-Dimethoxy-3-phenylethynyl-quinoline
DMFRXDT	HS	Investigative
DMFRXDT	SN	CHEMBL67059; 6,7-Dimethoxy-3-phenylethynyl-quinoline; ZINC3834029
DMFRXDT	DT	Small molecular drug
DMFRXDT	PC	10446889
DMFRXDT	MW	289.3
DMFRXDT	FM	C19H15NO2
DMFRXDT	IC	InChI=1S/C19H15NO2/c1-21-18-11-16-10-15(9-8-14-6-4-3-5-7-14)13-20-17(16)12-19(18)22-2/h3-7,10-13H,1-2H3
DMFRXDT	CS	COC1=CC2=CC(=CN=C2C=C1OC)C#CC3=CC=CC=C3
DMFRXDT	IK	FIWNVHIDDOMDBP-UHFFFAOYSA-N
DMFRXDT	IU	6,7-dimethoxy-3-(2-phenylethynyl)quinoline
DMFRXDT	DE	Discovery agent

DM516B4	ID	DM516B4
DM516B4	DN	6,7-Dimethoxy-3-phenyl-quinoline
DM516B4	HS	Investigative
DM516B4	SN	CHEMBL66063; 6,7-dimethoxy-3-phenyl-quinoline; SCHEMBL8177777; ZINC3834036
DM516B4	DT	Small molecular drug
DM516B4	PC	10422972
DM516B4	MW	265.31
DM516B4	FM	C17H15NO2
DM516B4	IC	InChI=1S/C17H15NO2/c1-19-16-9-13-8-14(12-6-4-3-5-7-12)11-18-15(13)10-17(16)20-2/h3-11H,1-2H3
DM516B4	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=CC=C3
DM516B4	IK	NZSMBYIPLGDVEM-UHFFFAOYSA-N
DM516B4	IU	6,7-dimethoxy-3-phenylquinoline
DM516B4	DE	Discovery agent

DMM7IAK	ID	DMM7IAK
DMM7IAK	DN	6,7-Dimethoxy-3-p-tolyl-quinoline
DMM7IAK	HS	Investigative
DMM7IAK	SN	CHEMBL67219; 6,7-Dimethoxy-3-p-tolyl-quinoline; ZINC13737715
DMM7IAK	DT	Small molecular drug
DMM7IAK	PC	10401378
DMM7IAK	MW	279.3
DMM7IAK	FM	C18H17NO2
DMM7IAK	IC	InChI=1S/C18H17NO2/c1-12-4-6-13(7-5-12)15-8-14-9-17(20-2)18(21-3)10-16(14)19-11-15/h4-11H,1-3H3
DMM7IAK	CS	CC1=CC=C(C=C1)C2=CN=C3C=C(C(=CC3=C2)OC)OC
DMM7IAK	IK	CMEIVVNDSVPQKC-UHFFFAOYSA-N
DMM7IAK	IU	6,7-dimethoxy-3-(4-methylphenyl)quinoline
DMM7IAK	DE	Discovery agent

DMSG1AY	ID	DMSG1AY
DMSG1AY	DN	6,7-Dimethoxy-3-pyridin-3-yl-quinoline
DMSG1AY	HS	Investigative
DMSG1AY	SN	CHEMBL304668; 6,7-dimethoxy-3-pyridin-3-yl-quinoline; SCHEMBL8170900; KYJQMVJJOORKLO-UHFFFAOYSA-N; ZINC3832247; BDBM50039050; 3-(6,7-dimethoxyquinolin-3-yl)pyridine; 6,7-dimethoxy-3-(3-pyridinyl)quinoline
DMSG1AY	DT	Small molecular drug
DMSG1AY	PC	10445611
DMSG1AY	MW	266.29
DMSG1AY	FM	C16H14N2O2
DMSG1AY	IC	InChI=1S/C16H14N2O2/c1-19-15-7-12-6-13(11-4-3-5-17-9-11)10-18-14(12)8-16(15)20-2/h3-10H,1-2H3
DMSG1AY	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CN=CC=C3
DMSG1AY	IK	KYJQMVJJOORKLO-UHFFFAOYSA-N
DMSG1AY	IU	6,7-dimethoxy-3-pyridin-3-ylquinoline
DMSG1AY	DE	Discovery agent

DMW7K5P	ID	DMW7K5P
DMW7K5P	DN	6,7-Dimethoxy-3-pyridin-4-yl-quinoline
DMW7K5P	HS	Investigative
DMW7K5P	SN	CHEMBL280069; 6,7-dimethoxy-3-pyridin-4-yl-quinoline; BDBM50039650
DMW7K5P	DT	Small molecular drug
DMW7K5P	PC	10061448
DMW7K5P	MW	266.29
DMW7K5P	FM	C16H14N2O2
DMW7K5P	IC	InChI=1S/C16H14N2O2/c1-19-15-8-12-7-13(11-3-5-17-6-4-11)10-18-14(12)9-16(15)20-2/h3-10H,1-2H3
DMW7K5P	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=NC=C3
DMW7K5P	IK	GDUOSVIOUNAARR-UHFFFAOYSA-N
DMW7K5P	IU	6,7-dimethoxy-3-pyridin-4-ylquinoline
DMW7K5P	DE	Discovery agent

DM6WD8T	ID	DM6WD8T
DM6WD8T	DN	6,7-Dimethoxy-3-thiophen-2-yl-quinoline
DM6WD8T	HS	Investigative
DM6WD8T	SN	CHEMBL304336; 6,7-dimethoxy-3-thiophen-2-yl-quinoline; SCHEMBL8501345; ZINC3834034
DM6WD8T	DT	Small molecular drug
DM6WD8T	PC	10468421
DM6WD8T	MW	271.3
DM6WD8T	FM	C15H13NO2S
DM6WD8T	IC	InChI=1S/C15H13NO2S/c1-17-13-7-10-6-11(15-4-3-5-19-15)9-16-12(10)8-14(13)18-2/h3-9H,1-2H3
DM6WD8T	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=CS3
DM6WD8T	IK	DWCZKFGISHBMCE-UHFFFAOYSA-N
DM6WD8T	IU	6,7-dimethoxy-3-thiophen-2-ylquinoline
DM6WD8T	DE	Discovery agent

DMU15YV	ID	DMU15YV
DMU15YV	DN	6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline
DMU15YV	HS	Investigative
DMU15YV	SN	CHEMBL415501; 6,7-Dimethoxy-4-(2-methoxyphenoxy)quinoline; 190726-38-6; 6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline; SCHEMBL7487419; CTK0E1594; DTXSID50622690; ZTLZYKICAWTOKI-UHFFFAOYSA-N; BDBM50290848; Quinoline, 6,7-dimethoxy-4-(2-methoxyphenoxy)-
DMU15YV	DT	Small molecular drug
DMU15YV	PC	22132763
DMU15YV	MW	311.3
DMU15YV	FM	C18H17NO4
DMU15YV	IC	InChI=1S/C18H17NO4/c1-20-15-6-4-5-7-16(15)23-14-8-9-19-13-11-18(22-3)17(21-2)10-12(13)14/h4-11H,1-3H3
DMU15YV	CS	COC1=CC=CC=C1OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMU15YV	IK	ZTLZYKICAWTOKI-UHFFFAOYSA-N
DMU15YV	IU	6,7-dimethoxy-4-(2-methoxyphenoxy)quinoline
DMU15YV	CA	CAS 190726-38-6
DMU15YV	DE	Discovery agent

DMQTHV7	ID	DMQTHV7
DMQTHV7	DN	6,7-dimethoxy-4-(2-phenylethynyl)quinazoline
DMQTHV7	HS	Investigative
DMQTHV7	SN	CHEMBL250315; 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline; SCHEMBL6180450; BDBM50222433
DMQTHV7	DT	Small molecular drug
DMQTHV7	PC	18770812
DMQTHV7	MW	290.3
DMQTHV7	FM	C18H14N2O2
DMQTHV7	IC	InChI=1S/C18H14N2O2/c1-21-17-10-14-15(9-8-13-6-4-3-5-7-13)19-12-20-16(14)11-18(17)22-2/h3-7,10-12H,1-2H3
DMQTHV7	CS	COC1=C(C=C2C(=C1)C(=NC=N2)C#CC3=CC=CC=C3)OC
DMQTHV7	IK	ASHKAXPHUUQQTC-UHFFFAOYSA-N
DMQTHV7	IU	6,7-dimethoxy-4-(2-phenylethynyl)quinazoline
DMQTHV7	DE	Discovery agent

DMPS2GX	ID	DMPS2GX
DMPS2GX	DN	6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline
DMPS2GX	HS	Investigative
DMPS2GX	SN	CHEMBL98583; 6,7-Dimethoxy-4-(3-methoxyphenoxy)quinoline; 6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline; SCHEMBL7481076; SORFICSDHDADIC-UHFFFAOYSA-N
DMPS2GX	DT	Small molecular drug
DMPS2GX	PC	22132666
DMPS2GX	MW	311.3
DMPS2GX	FM	C18H17NO4
DMPS2GX	IC	InChI=1S/C18H17NO4/c1-20-12-5-4-6-13(9-12)23-16-7-8-19-15-11-18(22-3)17(21-2)10-14(15)16/h4-11H,1-3H3
DMPS2GX	CS	COC1=CC(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMPS2GX	IK	SORFICSDHDADIC-UHFFFAOYSA-N
DMPS2GX	IU	6,7-dimethoxy-4-(3-methoxyphenoxy)quinoline
DMPS2GX	DE	Discovery agent

DM3YSNX	ID	DM3YSNX
DM3YSNX	DN	6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline
DM3YSNX	HS	Investigative
DM3YSNX	SN	CHEMBL99272; 6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline; SCHEMBL7482913; OMYGYNKHKZLDSH-UHFFFAOYSA-N; BDBM50290844
DM3YSNX	DT	Small molecular drug
DM3YSNX	PC	22132767
DM3YSNX	MW	326.3
DM3YSNX	FM	C17H14N2O5
DM3YSNX	IC	InChI=1S/C17H14N2O5/c1-22-16-9-13-14(10-17(16)23-2)18-7-6-15(13)24-12-5-3-4-11(8-12)19(20)21/h3-10H,1-2H3
DM3YSNX	CS	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=CC(=C3)[N+](=O)[O-]
DM3YSNX	IK	OMYGYNKHKZLDSH-UHFFFAOYSA-N
DM3YSNX	IU	6,7-dimethoxy-4-(3-nitrophenoxy)quinoline
DM3YSNX	DE	Discovery agent

DMKO8QT	ID	DMKO8QT
DMKO8QT	DN	6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline
DMKO8QT	HS	Investigative
DMKO8QT	SN	CHEMBL250523; 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline; BDBM50222432
DMKO8QT	DT	Small molecular drug
DMKO8QT	PC	44442168
DMKO8QT	MW	320.3
DMKO8QT	FM	C19H16N2O3
DMKO8QT	IC	InChI=1S/C19H16N2O3/c1-22-18-11-15-16(20-13-21-17(15)12-19(18)23-2)9-6-10-24-14-7-4-3-5-8-14/h3-5,7-8,11-13H,10H2,1-2H3
DMKO8QT	CS	COC1=C(C=C2C(=C1)C(=NC=N2)C#CCOC3=CC=CC=C3)OC
DMKO8QT	IK	SKJFTWBCHDIBAC-UHFFFAOYSA-N
DMKO8QT	IU	6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline
DMKO8QT	DE	Discovery agent

DMX2VFP	ID	DMX2VFP
DMX2VFP	DN	6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline
DMX2VFP	HS	Investigative
DMX2VFP	SN	CHEMBL98584; 6,7-Dimethoxy-4-(4-methoxyphenoxy)quinoline; 6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline; SCHEMBL7486400; GBYWCVLXEHHOFE-UHFFFAOYSA-N
DMX2VFP	DT	Small molecular drug
DMX2VFP	PC	22132780
DMX2VFP	MW	311.3
DMX2VFP	FM	C18H17NO4
DMX2VFP	IC	InChI=1S/C18H17NO4/c1-20-12-4-6-13(7-5-12)23-16-8-9-19-15-11-18(22-3)17(21-2)10-14(15)16/h4-11H,1-3H3
DMX2VFP	CS	COC1=CC=C(C=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMX2VFP	IK	GBYWCVLXEHHOFE-UHFFFAOYSA-N
DMX2VFP	IU	6,7-dimethoxy-4-(4-methoxyphenoxy)quinoline
DMX2VFP	DE	Discovery agent

DMBI40Y	ID	DMBI40Y
DMBI40Y	DN	6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline
DMBI40Y	HS	Investigative
DMBI40Y	SN	CHEMBL250318; 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline; BDBM50222435
DMBI40Y	DT	Small molecular drug
DMBI40Y	PC	44442165
DMBI40Y	MW	318.4
DMBI40Y	FM	C20H18N2O2
DMBI40Y	IC	InChI=1S/C20H18N2O2/c1-23-19-12-16-17(21-14-22-18(16)13-20(19)24-2)11-7-6-10-15-8-4-3-5-9-15/h3-5,8-9,12-14H,6,10H2,1-2H3
DMBI40Y	CS	COC1=C(C=C2C(=C1)C(=NC=N2)C#CCCC3=CC=CC=C3)OC
DMBI40Y	IK	UJTHKWFURJCQDD-UHFFFAOYSA-N
DMBI40Y	IU	6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline
DMBI40Y	DE	Discovery agent

DMEMGPU	ID	DMEMGPU
DMEMGPU	DN	6,7-Dimethoxy-4-m-tolyloxy-quinoline
DMEMGPU	HS	Investigative
DMEMGPU	SN	CHEMBL98839; 6,7-Dimethoxy-4-m-tolyloxy-quinoline; SCHEMBL19373176
DMEMGPU	DT	Small molecular drug
DMEMGPU	PC	44331325
DMEMGPU	MW	295.3
DMEMGPU	FM	C18H17NO3
DMEMGPU	IC	InChI=1S/C18H17NO3/c1-12-5-4-6-13(9-12)22-16-7-8-19-15-11-18(21-3)17(20-2)10-14(15)16/h4-11H,1-3H3
DMEMGPU	CS	CC1=CC(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMEMGPU	IK	DKQOYJJIXRSARC-UHFFFAOYSA-N
DMEMGPU	IU	6,7-dimethoxy-4-(3-methylphenoxy)quinoline
DMEMGPU	DE	Discovery agent

DMBZP3I	ID	DMBZP3I
DMBZP3I	DN	6,7-Dimethoxy-4-phenoxy-quinoline
DMBZP3I	HS	Investigative
DMBZP3I	SN	CHEMBL327534; 6,7-Dimethoxy-4-phenoxy-quinoline; SCHEMBL17117826
DMBZP3I	DT	Small molecular drug
DMBZP3I	PC	13085778
DMBZP3I	MW	281.3
DMBZP3I	FM	C17H15NO3
DMBZP3I	IC	InChI=1S/C17H15NO3/c1-19-16-10-13-14(11-17(16)20-2)18-9-8-15(13)21-12-6-4-3-5-7-12/h3-11H,1-2H3
DMBZP3I	CS	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=CC=C3
DMBZP3I	IK	ZQNTXGWAYYJCOZ-UHFFFAOYSA-N
DMBZP3I	IU	6,7-dimethoxy-4-phenoxyquinoline
DMBZP3I	DE	Discovery agent

DMP8LXB	ID	DMP8LXB
DMP8LXB	DN	6,7-dimethoxy-N-m-tolylquinazolin-4-amine
DMP8LXB	HS	Investigative
DMP8LXB	SN	CHEMBL56802; 6,7-dimethoxy-N-m-tolylquinazolin-4-amine; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine
DMP8LXB	DT	Small molecular drug
DMP8LXB	PC	2808977
DMP8LXB	MW	295.34
DMP8LXB	FM	C17H17N3O2
DMP8LXB	IC	InChI=1S/C17H17N3O2/c1-11-5-4-6-12(7-11)20-17-13-8-15(21-2)16(22-3)9-14(13)18-10-19-17/h4-10H,1-3H3,(H,18,19,20)
DMP8LXB	CS	CC1=CC(=CC=C1)NC2=NC=NC3=CC(=C(C=C32)OC)OC
DMP8LXB	IK	RSVNNWQHWIOIOC-UHFFFAOYSA-N
DMP8LXB	IU	6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine
DMP8LXB	DE	Discovery agent

DM7U8ID	ID	DM7U8ID
DM7U8ID	DN	6,7-Diphenyl-pteridine-2,4-diamine
DM7U8ID	HS	Investigative
DM7U8ID	SN	6,7-diphenylpteridine-2,4-diamine; 18181-93-6; 2,4-DIAMINO-6,7-DIPHENYL-PTERIDINE; NSC10922; CHEMBL48296; 2,4-Diamino-6,7-diphenylpteridine; AC1Q4WHR; AC1L5CHW; diphenylpteridine-2,4-diamine; SCHEMBL3746280; diaminopteridine derivative, 24; CTK4D7985; BDBM25101; DTXSID80278987; DDZJPETYMUJLIW-UHFFFAOYSA-N; ZINC1712532; NSC-10922; 2,4-Pteridinediamine,6,7-diphenyl-; 6,7-Diphenyl-2,4-pteridinediamine #; 2,4-Pteridinediamine, 6,7-diphenyl-; ACM18181936; DB-081833
DM7U8ID	DT	Small molecular drug
DM7U8ID	PC	223355
DM7U8ID	MW	314.3
DM7U8ID	FM	C18H14N6
DM7U8ID	IC	InChI=1S/C18H14N6/c19-16-15-17(24-18(20)23-16)22-14(12-9-5-2-6-10-12)13(21-15)11-7-3-1-4-8-11/h1-10H,(H4,19,20,22,23,24)
DM7U8ID	CS	C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2C4=CC=CC=C4)N)N
DM7U8ID	IK	DDZJPETYMUJLIW-UHFFFAOYSA-N
DM7U8ID	IU	6,7-diphenylpteridine-2,4-diamine
DM7U8ID	CA	CAS 18181-93-6
DM7U8ID	DE	Discovery agent

DMT09YC	ID	DMT09YC
DMT09YC	DN	6,7'-oxybis(2-phenyl-4H-chromen-4-one)
DMT09YC	HS	Investigative
DMT09YC	SN	CHEMBL466800; BDBM50254285
DMT09YC	DT	Small molecular drug
DMT09YC	PC	44569786
DMT09YC	MW	458.5
DMT09YC	FM	C30H18O5
DMT09YC	IC	InChI=1S/C30H18O5/c31-25-17-29(20-9-5-2-6-10-20)35-30-16-22(11-13-23(25)30)33-21-12-14-27-24(15-21)26(32)18-28(34-27)19-7-3-1-4-8-19/h1-18H
DMT09YC	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)OC4=CC5=C(C=C4)C(=O)C=C(O5)C6=CC=CC=C6
DMT09YC	IK	IGRXBHDMCKHQQC-UHFFFAOYSA-N
DMT09YC	IU	7-(4-oxo-2-phenylchromen-6-yl)oxy-2-phenylchromen-4-one
DMT09YC	DE	Discovery agent

DMUEFDM	ID	DMUEFDM
DMUEFDM	DN	6,8-Dichloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DMUEFDM	HS	Investigative
DMUEFDM	SN	CHEMBL48643; Tacrine deriv. 2; 6,8-dichloro-1,2,3,4-tetrahydroacridin-9-amine; SCHEMBL15168338; BDBM10516; ZINC13492737; AKOS011484747
DMUEFDM	DT	Small molecular drug
DMUEFDM	PC	10858442
DMUEFDM	MW	267.15
DMUEFDM	FM	C13H12Cl2N2
DMUEFDM	IC	InChI=1S/C13H12Cl2N2/c14-7-5-9(15)12-11(6-7)17-10-4-2-1-3-8(10)13(12)16/h5-6H,1-4H2,(H2,16,17)
DMUEFDM	CS	C1CCC2=NC3=C(C(=CC(=C3)Cl)Cl)C(=C2C1)N
DMUEFDM	IK	ISUJWDYWYFLQFP-UHFFFAOYSA-N
DMUEFDM	IU	6,8-dichloro-1,2,3,4-tetrahydroacridin-9-amine
DMUEFDM	DE	Discovery agent

DMAFP18	ID	DMAFP18
DMAFP18	DN	6,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one
DMAFP18	HS	Investigative
DMAFP18	SN	6,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one; casimiroin analogue, 1j; CHEMBL493173; BDBM29221; MolPort-028-745-489; ZINC40955907; 1,4-Dimethyl-6,8-dimethoxyquinoline-2(1H)-one
DMAFP18	DT	Small molecular drug
DMAFP18	PC	42618031
DMAFP18	MW	233.26
DMAFP18	FM	C13H15NO3
DMAFP18	IC	InChI=1S/C13H15NO3/c1-8-5-12(15)14(2)13-10(8)6-9(16-3)7-11(13)17-4/h5-7H,1-4H3
DMAFP18	CS	CC1=CC(=O)N(C2=C1C=C(C=C2OC)OC)C
DMAFP18	IK	BYYQQWLTZFBHIQ-UHFFFAOYSA-N
DMAFP18	IU	6,8-dimethoxy-1,4-dimethylquinolin-2-one
DMAFP18	DE	Discovery agent

DMYKSTZ	ID	DMYKSTZ
DMYKSTZ	DN	6,8-Dimethoxy-4-methylquinolin-2(1H)-one
DMYKSTZ	HS	Investigative
DMYKSTZ	SN	casimiroin analogue, 1i; 2(1H)-Quinolinone, 6,8-dimethoxy-4-methyl-; CHEMBL476126; BDBM29220; MolPort-028-745-488; ZINC40429907; 249737-05-1
DMYKSTZ	DT	Small molecular drug
DMYKSTZ	PC	42618030
DMYKSTZ	MW	219.24
DMYKSTZ	FM	C12H13NO3
DMYKSTZ	IC	InChI=1S/C12H13NO3/c1-7-4-11(14)13-12-9(7)5-8(15-2)6-10(12)16-3/h4-6H,1-3H3,(H,13,14)
DMYKSTZ	CS	CC1=CC(=O)NC2=C1C=C(C=C2OC)OC
DMYKSTZ	IK	TZVDVDRNKWYRNO-UHFFFAOYSA-N
DMYKSTZ	IU	6,8-dimethoxy-4-methyl-1H-quinolin-2-one
DMYKSTZ	DE	Discovery agent

DME4193	ID	DME4193
DME4193	DN	6,8-Dinitro-2-piperazin-1-yl-quinoline
DME4193	HS	Investigative
DME4193	SN	CHEMBL37739; 6,8-Dinitro-2-piperazin-1-yl-quinoline; 2-Piperazino-6,8-dinitroquinoline
DME4193	DT	Small molecular drug
DME4193	PC	12044726
DME4193	MW	303.27
DME4193	FM	C13H13N5O4
DME4193	IC	InChI=1S/C13H13N5O4/c19-17(20)10-7-9-1-2-12(16-5-3-14-4-6-16)15-13(9)11(8-10)18(21)22/h1-2,7-8,14H,3-6H2
DME4193	CS	C1CN(CCN1)C2=NC3=C(C=C(C=C3C=C2)[N+](=O)[O-])[N+](=O)[O-]
DME4193	IK	LDLAXAIDSVRAEY-UHFFFAOYSA-N
DME4193	IU	6,8-dinitro-2-piperazin-1-ylquinoline
DME4193	DE	Discovery agent

DM7FMWS	ID	DM7FMWS
DM7FMWS	DN	6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DM7FMWS	HS	Investigative
DM7FMWS	DT	Small molecular drug
DM7FMWS	PC	44329120
DM7FMWS	MW	168.23
DM7FMWS	FM	C10H16O2
DM7FMWS	IC	InChI=1S/C10H16O2/c1-7-3-4-8(2)10(7)5-6-12-9(10)11/h7-8H,3-6H2,1-2H3
DM7FMWS	CS	CC1CCC(C12CCOC2=O)C
DM7FMWS	IK	CQORSWAIFJDWPQ-UHFFFAOYSA-N
DM7FMWS	IU	6,9-dimethyl-2-oxaspiro[4.4]nonan-1-one
DM7FMWS	DE	Discovery agent

DMDNG8F	ID	DMDNG8F
DMDNG8F	DN	6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine
DMDNG8F	HS	Investigative
DMDNG8F	SN	SCHEMBL6660879
DMDNG8F	DT	Small molecular drug
DMDNG8F	PC	44387948
DMDNG8F	MW	240.24
DMDNG8F	FM	C13H9FN4
DMDNG8F	IC	InChI=1S/C13H9FN4/c14-10-4-1-9(2-5-10)3-6-11-12-13(17-7-15-11)18-8-16-12/h1-8H,(H,15,16,17,18)/b6-3+
DMDNG8F	CS	C1=CC(=CC=C1/C=C/C2=C3C(=NC=N2)N=CN3)F
DMDNG8F	IK	QUTNZZOCHSVJRB-ZZXKWVIFSA-N
DMDNG8F	IU	6-[(E)-2-(4-fluorophenyl)ethenyl]-7H-purine
DMDNG8F	DE	Discovery agent

DMNJPCD	ID	DMNJPCD
DMNJPCD	DN	6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE
DMNJPCD	HS	Investigative
DMNJPCD	SN	6IP
DMNJPCD	DT	Small molecular drug
DMNJPCD	PC	11586735
DMNJPCD	MW	237.3
DMNJPCD	FM	C15H15N3
DMNJPCD	IC	InChI=1S/C15H15N3/c16-15-3-1-2-13(18-15)7-5-11-4-6-12-8-9-17-14(12)10-11/h1-4,6,8-10,17H,5,7H2,(H2,16,18)
DMNJPCD	CS	C1=CC(=NC(=C1)N)CCC2=CC3=C(C=C2)C=CN3
DMNJPCD	IK	OSHSZKRWKLQZBV-UHFFFAOYSA-N
DMNJPCD	IU	6-[2-(1H-indol-6-yl)ethyl]pyridin-2-amine
DMNJPCD	DE	Discovery agent

DM40LQ9	ID	DM40LQ9
DM40LQ9	DN	6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol
DM40LQ9	HS	Investigative
DM40LQ9	SN	CHEMBL1214739; 6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol; SCHEMBL18770333
DM40LQ9	DT	Small molecular drug
DM40LQ9	PC	46901929
DM40LQ9	MW	311.4
DM40LQ9	FM	C22H17NO
DM40LQ9	IC	InChI=1S/C22H17NO/c24-22-8-7-20-14-19(5-6-21(20)15-22)18-3-1-16(2-4-18)13-17-9-11-23-12-10-17/h1-12,14-15,24H,13H2
DM40LQ9	CS	C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC4=C(C=C3)C=C(C=C4)O
DM40LQ9	IK	OCQPVXWUPNNJIV-UHFFFAOYSA-N
DM40LQ9	IU	6-[4-(pyridin-4-ylmethyl)phenyl]naphthalen-2-ol
DM40LQ9	DE	Discovery agent

DM1G7P9	ID	DM1G7P9
DM1G7P9	DN	6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID
DM1G7P9	HS	Investigative
DM1G7P9	SN	6-[(cyclohexylcarbamoyl)amino]hexanoic acid; 6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID; CHEMBL434374; 6-(3-cyclohexylureido)hexanoic acid; 4-(3-CYCLOHEXYLURIEDO)-HEXANOIC ACID; NC6; 479413-50-8; 1zd4; AC1O4WJZ; MolPort-004-305-491; HMS3604D15; ZINC13493677; BDBM50192966; AKOS000144586; DB08258; NE37451; MCULE-4614457618; 6-(cyclohexylcarbamoylamino)hexanoic acid; EN300-77810
DM1G7P9	DT	Small molecular drug
DM1G7P9	PC	6420120
DM1G7P9	MW	256.339
DM1G7P9	FM	C13H24N2O3
DM1G7P9	IC	InChI=1S/C13H24N2O3/c16-12(17)9-5-2-6-10-14-13(18)15-11-7-3-1-4-8-11/h11H,1-10H2,(H,16,17)(H2,14,15,18)
DM1G7P9	CS	C1CCC(CC1)NC(=O)NCCCCCC(=O)O
DM1G7P9	IK	KFTVEPYSUSWBRD-UHFFFAOYSA-N
DM1G7P9	IU	6-(cyclohexylcarbamoylamino)hexanoic acid
DM1G7P9	DE	Discovery agent

DM7D52Z	ID	DM7D52Z
DM7D52Z	DN	677T
DM7D52Z	HS	Investigative
DM7D52Z	TC	Antisense
DM7D52Z	DT	Antisense drug
DM7D52Z	DE	Discovery agent

DMERKGH	ID	DMERKGH
DMERKGH	DN	6-Acetyl-7-ethoxy-2H-chromen-2-one
DMERKGH	HS	Investigative
DMERKGH	SN	CHEMBL1288559; 6-Acetyl-7-ethoxy-2H-chromen-2-one
DMERKGH	DT	Small molecular drug
DMERKGH	PC	52949265
DMERKGH	MW	232.23
DMERKGH	FM	C13H12O4
DMERKGH	IC	InChI=1S/C13H12O4/c1-3-16-12-7-11-9(4-5-13(15)17-11)6-10(12)8(2)14/h4-7H,3H2,1-2H3
DMERKGH	CS	CCOC1=C(C=C2C=CC(=O)OC2=C1)C(=O)C
DMERKGH	IK	YPWNHEXIUIFWSP-UHFFFAOYSA-N
DMERKGH	IU	6-acetyl-7-ethoxychromen-2-one
DMERKGH	DE	Discovery agent

DM1K0E2	ID	DM1K0E2
DM1K0E2	DN	6-Acetyl-7-hydroxy-2H-chromen-2-one
DM1K0E2	HS	Investigative
DM1K0E2	SN	CHEMBL1288534; 6-Acetyl-7-hydroxy-2H-1-benzopyran-2-one; 6835-55-8; 6-Acetyl-7-hydroxy-2H-chromen-2-one; AC1NWHPN; 6-acetyl-7-hydroxycoumarin; 2H-1-Benzopyran-2-one, 6-acetyl-7-hydroxy-; SCHEMBL4640781; 6-acetyl-7-hydroxychromen-2-one; ZINC3848612; BDBM50332033
DM1K0E2	DT	Small molecular drug
DM1K0E2	PC	5705744
DM1K0E2	MW	204.18
DM1K0E2	FM	C11H8O4
DM1K0E2	IC	InChI=1S/C11H8O4/c1-6(12)8-4-7-2-3-11(14)15-10(7)5-9(8)13/h2-5,13H,1H3
DM1K0E2	CS	CC(=O)C1=C(C=C2C(=C1)C=CC(=O)O2)O
DM1K0E2	IK	MYJIZBGGFRMXEM-UHFFFAOYSA-N
DM1K0E2	IU	6-acetyl-7-hydroxychromen-2-one
DM1K0E2	DE	Discovery agent

DMXOB2K	ID	DMXOB2K
DMXOB2K	DN	6-acetyl-7-methoxy-2H-chromen-2-one
DMXOB2K	HS	Investigative
DMXOB2K	SN	6-acetyl-7-methoxychromen-2-one; CHEMBL1288558; 16850-94-5; 6-acetyl-7-methoxy-2H-chromen-2-one; AC1LGQHB; MolPort-002-843-897; ZINC384856
DMXOB2K	DT	Small molecular drug
DMXOB2K	PC	850202
DMXOB2K	MW	218.2
DMXOB2K	FM	C12H10O4
DMXOB2K	IC	InChI=1S/C12H10O4/c1-7(13)9-5-8-3-4-12(14)16-10(8)6-11(9)15-2/h3-6H,1-2H3
DMXOB2K	CS	CC(=O)C1=C(C=C2C(=C1)C=CC(=O)O2)OC
DMXOB2K	IK	QDWMZGNQFSIPKO-UHFFFAOYSA-N
DMXOB2K	IU	6-acetyl-7-methoxychromen-2-one
DMXOB2K	DE	Discovery agent

DMCG8BJ	ID	DMCG8BJ
DMCG8BJ	DN	6-acetyl-7-propoxy-2H-chromen-2-one
DMCG8BJ	HS	Investigative
DMCG8BJ	SN	CHEMBL1288560; 6-acetyl-7-propoxy-2H-chromen-2-one
DMCG8BJ	DT	Small molecular drug
DMCG8BJ	PC	52940758
DMCG8BJ	MW	246.26
DMCG8BJ	FM	C14H14O4
DMCG8BJ	IC	InChI=1S/C14H14O4/c1-3-6-17-13-8-12-10(4-5-14(16)18-12)7-11(13)9(2)15/h4-5,7-8H,3,6H2,1-2H3
DMCG8BJ	CS	CCCOC1=C(C=C2C=CC(=O)OC2=C1)C(=O)C
DMCG8BJ	IK	VIKCPCBUFQJHPC-UHFFFAOYSA-N
DMCG8BJ	IU	6-acetyl-7-propoxychromen-2-one
DMCG8BJ	DE	Discovery agent

DMI2XUQ	ID	DMI2XUQ
DMI2XUQ	DN	6-Allyloxy-9H-purin-2-ylamine
DMI2XUQ	HS	Investigative
DMI2XUQ	SN	CHEMBL325053; 50663-54-2; O6-Allylguanine; O6-Substituted Guanine Deriv. 15; 6-prop-2-enoxy-7H-purin-2-amine; NU 2028; AC1L45IB; SCHEMBL1263549; BDBM5475; 6-(prop-2-en-1-yloxy)-9H-purin-2-amine; 9H-Purin-2-amine, 6-(2-propen-1-yloxy)-
DMI2XUQ	DT	Small molecular drug
DMI2XUQ	PC	179571
DMI2XUQ	MW	191.19
DMI2XUQ	FM	C8H9N5O
DMI2XUQ	IC	InChI=1S/C8H9N5O/c1-2-3-14-7-5-6(11-4-10-5)12-8(9)13-7/h2,4H,1,3H2,(H3,9,10,11,12,13)
DMI2XUQ	CS	C=CCOC1=NC(=NC2=C1NC=N2)N
DMI2XUQ	IK	HJMGFQNIHIHSCQ-UHFFFAOYSA-N
DMI2XUQ	IU	6-prop-2-enoxy-7H-purin-2-amine
DMI2XUQ	CA	CAS 50663-54-2
DMI2XUQ	DE	Discovery agent

DMMUE05	ID	DMMUE05
DMMUE05	DN	6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid
DMMUE05	HS	Investigative
DMMUE05	SN	CHEMBL65910; 6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid; SCHEMBL7257200
DMMUE05	DT	Small molecular drug
DMMUE05	PC	10035600
DMMUE05	MW	197.23
DMMUE05	FM	C9H15N3O2
DMMUE05	IC	InChI=1S/C9H15N3O2/c10-4-2-1-3-7(9(13)14)8-5-11-6-12-8/h5-7H,1-4,10H2,(H,11,12)(H,13,14)
DMMUE05	CS	C1=C(NC=N1)C(CCCCN)C(=O)O
DMMUE05	IK	ATNHCKIPIWIEGH-UHFFFAOYSA-N
DMMUE05	IU	6-amino-2-(1H-imidazol-5-yl)hexanoic acid
DMMUE05	DE	Discovery agent

DMC5M76	ID	DMC5M76
DMC5M76	DN	6-amino-4-trifluoromethylquinolin-2(1H)-one
DMC5M76	HS	Investigative
DMC5M76	SN	6-amino-4-trifluoromethylquinolin-2(1H)-one; 328955-57-3; 6-amino-4-(trifluoromethyl)quinolin-2(1H)-one; 2(1H)-Quinolinone, 6-amino-4-(trifluoromethyl)-; SCHEMBL1770828; CHEMBL385509; SCHEMBL19680530; CTK8B4763; BDBM18526; DTXSID60582115; LMXZMEMPGRLDIG-UHFFFAOYSA-N; ANW-46096; ZINC12349446; AKOS015951346; AK-41783; AC-27434; SC-50493; AJ-61229; AB1009151; AB0024239; ST2406401; AX8208563; W5464; CS-0084832; FT-0688581; 6-Amino-4-trifluoromethyl-2(1H)-quinolinone; 6-Amino-4-(trifluoromethyl)-quinolin-2(1h)-one
DMC5M76	DT	Small molecular drug
DMC5M76	PC	16090308
DMC5M76	MW	228.17
DMC5M76	FM	C10H7F3N2O
DMC5M76	IC	InChI=1S/C10H7F3N2O/c11-10(12,13)7-4-9(16)15-8-2-1-5(14)3-6(7)8/h1-4H,14H2,(H,15,16)
DMC5M76	CS	C1=CC2=C(C=C1N)C(=CC(=O)N2)C(F)(F)F
DMC5M76	IK	LMXZMEMPGRLDIG-UHFFFAOYSA-N
DMC5M76	IU	6-amino-4-(trifluoromethyl)-1H-quinolin-2-one
DMC5M76	CA	CAS 328955-57-3
DMC5M76	DE	Discovery agent

DM5SZHR	ID	DM5SZHR
DM5SZHR	DN	6-amino-5-bromouracil
DM5SZHR	HS	Investigative
DM5SZHR	SN	6312-73-8; 5-Bromo-6-aminouracil; 6-Amino-5-bromouracil; 6-Amino-5-bromopyrimidine-2,4(1H,3H)-dione; 6-Amino-5-bromo-1H-pyrimidine-2,4-dione; 6-amino-5-bromo-1,2,3,4-tetrahydropyrimidine-2,4-dione; CHEMBL64909; 6-amino-5-bromopyrimidine-2,4-diol; 6-amino-5-bromo-2,4(1H,3H)-pyrimidinedione; 6-amino-5-bromo-1,3-dihydropyrimidine-2,4-dione; NSC40394; EINECS 228-638-7; NSC 27652; NSC 40394; AC1Q24DM; AC1Q50HI; AC1L2ZP9; SCHEMBL2894070; CTK5B7686; KS-00001QBO; DTXSID60212460; MolPort-000-873-593; FSLBEEVCUZFKRL-UHFFFAOYSA-N
DM5SZHR	DT	Small molecular drug
DM5SZHR	PC	80578
DM5SZHR	MW	206
DM5SZHR	FM	C4H4BrN3O2
DM5SZHR	IC	InChI=1S/C4H4BrN3O2/c5-1-2(6)7-4(10)8-3(1)9/h(H4,6,7,8,9,10)
DM5SZHR	CS	C1(=C(NC(=O)NC1=O)N)Br
DM5SZHR	IK	FSLBEEVCUZFKRL-UHFFFAOYSA-N
DM5SZHR	IU	6-amino-5-bromo-1H-pyrimidine-2,4-dione
DM5SZHR	CA	CAS 6312-73-8
DM5SZHR	DE	Discovery agent

DMFPCSJ	ID	DMFPCSJ
DMFPCSJ	DN	6-amino-5-chlorouracil hydrochloride
DMFPCSJ	HS	Investigative
DMFPCSJ	SN	CHEMBL541900
DMFPCSJ	DT	Small molecular drug
DMFPCSJ	PC	45265835
DMFPCSJ	MW	198
DMFPCSJ	FM	C4H5Cl2N3O2
DMFPCSJ	IC	InChI=1S/C4H4ClN3O2.ClH/c5-1-2(6)7-4(10)8-3(1)9;/h(H4,6,7,8,9,10);1H
DMFPCSJ	CS	C1(=C(NC(=O)NC1=O)N)Cl.Cl
DMFPCSJ	IK	LZWPDUHEHWOBPF-UHFFFAOYSA-N
DMFPCSJ	IU	6-amino-5-chloro-1H-pyrimidine-2,4-dione;hydrochloride
DMFPCSJ	DE	Discovery agent

DMU1CV4	ID	DMU1CV4
DMU1CV4	DN	6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one
DMU1CV4	HS	Investigative
DMU1CV4	SN	CHEMBL504356; 6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one
DMU1CV4	DT	Small molecular drug
DMU1CV4	PC	44563082
DMU1CV4	MW	231.2
DMU1CV4	FM	C12H9NO4
DMU1CV4	IC	InChI=1S/C12H9NO4/c1-15-11-9-6(2-3-16-9)4-7-5-8(13)12(14)17-10(7)11/h2-5H,13H2,1H3
DMU1CV4	CS	COC1=C2C(=CC3=C1OC(=O)C(=C3)N)C=CO2
DMU1CV4	IK	YFAQAXXPQHHTHA-UHFFFAOYSA-N
DMU1CV4	IU	6-amino-9-methoxyfuro[3,2-g]chromen-7-one
DMU1CV4	DE	Discovery agent

DMWPELS	ID	DMWPELS
DMWPELS	DN	6-Amino-benzothiazole-2-sulfonic acid amide
DMWPELS	HS	Investigative
DMWPELS	SN	6-aminobenzo[d]thiazole-2-sulfonamide; 6-Amino-2-benzothiazolesulfonamide; 94641-11-9; MR69RTSOVN; UNII-MR69RTSOVN; CHEMBL35118; Aminozolamide; AC1L3QBY; 6-Amino-benzothiazole-2-sulfonic acid amide; SCHEMBL9459715; OFSGGVHHSMAUEI-UHFFFAOYSA-N; 6-aminobenzothiazole-2-sulfonamide; ZINC5162075; BDBM50079035; 2-Benzothiazolesulfonamide, 6-amino-; AKOS022656973; FCH1394039; 6-amino-1,3-benzothiazole-2-sulfonamide; AX8292464
DMWPELS	DT	Small molecular drug
DMWPELS	PC	93505
DMWPELS	MW	229.3
DMWPELS	FM	C7H7N3O2S2
DMWPELS	IC	InChI=1S/C7H7N3O2S2/c8-4-1-2-5-6(3-4)13-7(10-5)14(9,11)12/h1-3H,8H2,(H2,9,11,12)
DMWPELS	CS	C1=CC2=C(C=C1N)SC(=N2)S(=O)(=O)N
DMWPELS	IK	OFSGGVHHSMAUEI-UHFFFAOYSA-N
DMWPELS	IU	6-amino-1,3-benzothiazole-2-sulfonamide
DMWPELS	CA	CAS 94641-11-9
DMWPELS	DE	Discovery agent

DMEHG2F	ID	DMEHG2F
DMEHG2F	DN	6-amino-N-(2,4-dichlorobenzyl)nicotinamide
DMEHG2F	HS	Investigative
DMEHG2F	SN	CHEMBL567109; 6-amino-N-(2,4-dichlorobenzyl)nicotinamide
DMEHG2F	DT	Small molecular drug
DMEHG2F	PC	45487830
DMEHG2F	MW	296.15
DMEHG2F	FM	C13H11Cl2N3O
DMEHG2F	IC	InChI=1S/C13H11Cl2N3O/c14-10-3-1-8(11(15)5-10)6-18-13(19)9-2-4-12(16)17-7-9/h1-5,7H,6H2,(H2,16,17)(H,18,19)
DMEHG2F	CS	C1=CC(=C(C=C1Cl)Cl)CNC(=O)C2=CN=C(C=C2)N
DMEHG2F	IK	PWGDOYQXBPVPGB-UHFFFAOYSA-N
DMEHG2F	IU	6-amino-N-[(2,4-dichlorophenyl)methyl]pyridine-3-carboxamide
DMEHG2F	DE	Discovery agent

DMYI5GU	ID	DMYI5GU
DMYI5GU	DN	6-amino-N-(3,3-diphenylpropyl)nicotinamide
DMYI5GU	HS	Investigative
DMYI5GU	SN	CHEMBL568773; 6-amino-N-(3,3-diphenylpropyl)nicotinamide; SCHEMBL5947733
DMYI5GU	DT	Small molecular drug
DMYI5GU	PC	11976309
DMYI5GU	MW	331.4
DMYI5GU	FM	C21H21N3O
DMYI5GU	IC	InChI=1S/C21H21N3O/c22-20-12-11-18(15-24-20)21(25)23-14-13-19(16-7-3-1-4-8-16)17-9-5-2-6-10-17/h1-12,15,19H,13-14H2,(H2,22,24)(H,23,25)
DMYI5GU	CS	C1=CC=C(C=C1)C(CCNC(=O)C2=CN=C(C=C2)N)C3=CC=CC=C3
DMYI5GU	IK	DZGHCDWBFODWBC-UHFFFAOYSA-N
DMYI5GU	IU	6-amino-N-(3,3-diphenylpropyl)pyridine-3-carboxamide
DMYI5GU	DE	Discovery agent

DMUZOYN	ID	DMUZOYN
DMUZOYN	DN	6-amino-uridine monophosphate
DMUZOYN	HS	Investigative
DMUZOYN	DT	Small molecular drug
DMUZOYN	PC	11843563
DMUZOYN	MW	339.2
DMUZOYN	FM	C9H14N3O9P
DMUZOYN	IC	InChI=1S/C9H14N3O9P/c10-4-1-5(13)11-9(16)12(4)8-7(15)6(14)3(21-8)2-20-22(17,18)19/h1,3,6-8,14-15H,2,10H2,(H,11,13,16)(H2,17,18,19)/t3-,6-,7-,8-/m1/s1
DMUZOYN	CS	C1=C(N(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)N
DMUZOYN	IK	DUFXRFNPGXQQOI-YXZULKJRSA-N
DMUZOYN	IU	[(2R,3S,4R,5R)-5-(6-amino-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMUZOYN	DE	Discovery agent

DM7WYCM	ID	DM7WYCM
DM7WYCM	DN	6-aza-uridine monophosphate
DM7WYCM	HS	Investigative
DM7WYCM	SN	6-Aza-ump; 6-Azauridine-5'-monophosphate; 6-aza uridine 5'-monophosphate; 1los; UP6; [(2R,3S,4R,5R)-5-(3,5-dioxo-1,2,4-triazin-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate; aza UMP; 6-Azauridine-5'-phosphate; 6-Azauridine 5'M; NSC47549; 6-Azauridine 5'MP; 6-azauridine 5'-phosphate; AC1L45DF; 6-aza-uridine monophosphate; C6-Uridine Derivative, 18; 6-Azauridine-5-monophosphate; CHEMBL463480; SCHEMBL3214622; BDBM21340; 6-Azauridine 5'-phosphoric acid; ZINC12503861; AKOS027381721; DB03718; W-201761
DM7WYCM	DT	Small molecular drug
DM7WYCM	PC	150959
DM7WYCM	MW	325.17
DM7WYCM	FM	C8H12N3O9P
DM7WYCM	IC	InChI=1S/C8H12N3O9P/c12-4-1-9-11(8(15)10-4)7-6(14)5(13)3(20-7)2-19-21(16,17)18/h1,3,5-7,13-14H,2H2,(H,10,12,15)(H2,16,17,18)/t3-,5-,6-,7-/m1/s1
DM7WYCM	CS	C1=NN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O
DM7WYCM	IK	LRVZOSYMNMNQFR-SHUUEZRQSA-N
DM7WYCM	IU	[(2R,3S,4R,5R)-5-(3,5-dioxo-1,2,4-triazin-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM7WYCM	CA	CAS 2018-19-1
DM7WYCM	CB	CHEBI:46319
DM7WYCM	DE	Discovery agent

DM8BNWH	ID	DM8BNWH
DM8BNWH	DN	6-Azido-8-(3-iodo-phenyl)-quinoline
DM8BNWH	HS	Investigative
DM8BNWH	SN	CHEMBL124575; 6-azido-8-(3-iodophenyl)quinoline; 6-Azido-8-(3-iodo-phenyl)-quinoline
DM8BNWH	DT	Small molecular drug
DM8BNWH	PC	10547238
DM8BNWH	MW	372.16
DM8BNWH	FM	C15H9IN4
DM8BNWH	IC	InChI=1S/C15H9IN4/c16-12-5-1-3-10(7-12)14-9-13(19-20-17)8-11-4-2-6-18-15(11)14/h1-9H
DM8BNWH	CS	C1=CC(=CC(=C1)I)C2=C3C(=CC(=C2)N=[N+]=[N-])C=CC=N3
DM8BNWH	IK	FZNQYXTXKRWFRF-UHFFFAOYSA-N
DM8BNWH	IU	6-azido-8-(3-iodophenyl)quinoline
DM8BNWH	DE	Discovery agent

DM2I95Z	ID	DM2I95Z
DM2I95Z	DN	6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z	HS	Investigative
DM2I95Z	SN	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4; 6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z	DT	Small molecular drug
DM2I95Z	PC	11694528
DM2I95Z	MW	255.34
DM2I95Z	FM	C12H17NO3S
DM2I95Z	IC	InChI=1S/C12H17NO3S/c14-12(13-15)9-5-2-6-10-17(16)11-7-3-1-4-8-11/h1,3-4,7-8,15H,2,5-6,9-10H2,(H,13,14)
DM2I95Z	CS	C1=CC=C(C=C1)S(=O)CCCCCC(=O)NO
DM2I95Z	IK	LIZWRHXVIWNMIS-UHFFFAOYSA-N
DM2I95Z	IU	6-(benzenesulfinyl)-N-hydroxyhexanamide
DM2I95Z	DE	Discovery agent

DM81DTC	ID	DM81DTC
DM81DTC	DN	6-Benzenesulfonyl-2H-pyridazin-3-one
DM81DTC	HS	Investigative
DM81DTC	SN	6-(benzenesulfonyl)-2,3-dihydropyridazin-3-one; 141060-78-8; 3(2H)-Pyridazinone, 6-(phenylsulfonyl)-; AC1Q6GZS; CHEMBL74814; SCHEMBL7295107; BDBM16442; ZICCKDUVBPQRQT-UHFFFAOYSA-N; MolPort-007-599-834; ZINC11536236; AKOS001782098; MCULE-8830355611; NE56517; 6-phenylsulfonylpyridazin-2H-3-one, 1; 6-phenylsulfonyl-3-oxo-2,3-dihydropyridazine; EN300-72670
DM81DTC	DT	Small molecular drug
DM81DTC	PC	11701437
DM81DTC	MW	236.25
DM81DTC	FM	C10H8N2O3S
DM81DTC	IC	InChI=1S/C10H8N2O3S/c13-9-6-7-10(12-11-9)16(14,15)8-4-2-1-3-5-8/h1-7H,(H,11,13)
DM81DTC	CS	C1=CC=C(C=C1)S(=O)(=O)C2=NNC(=O)C=C2
DM81DTC	IK	ZICCKDUVBPQRQT-UHFFFAOYSA-N
DM81DTC	IU	3-(benzenesulfonyl)-1H-pyridazin-6-one
DM81DTC	DE	Discovery agent

DMY9IK8	ID	DMY9IK8
DMY9IK8	DN	6-benzenesulfonylhexanoic acid hydroxamide
DMY9IK8	HS	Investigative
DMY9IK8	SN	6-benzenesulfonylhexanoic acid hydroxamide; CHEMBL203207
DMY9IK8	DT	Small molecular drug
DMY9IK8	PC	11572583
DMY9IK8	MW	271.33
DMY9IK8	FM	C12H17NO4S
DMY9IK8	IC	InChI=1S/C12H17NO4S/c14-12(13-15)9-5-2-6-10-18(16,17)11-7-3-1-4-8-11/h1,3-4,7-8,15H,2,5-6,9-10H2,(H,13,14)
DMY9IK8	CS	C1=CC=C(C=C1)S(=O)(=O)CCCCCC(=O)NO
DMY9IK8	IK	CUUZMQZWMSHEAR-UHFFFAOYSA-N
DMY9IK8	IU	6-(benzenesulfonyl)-N-hydroxyhexanamide
DMY9IK8	DE	Discovery agent

DM0CZ1F	ID	DM0CZ1F
DM0CZ1F	DN	6-Benzyl-2-cyclohexylsulfanyl-3H-pyrimidin-4-one
DM0CZ1F	HS	Investigative
DM0CZ1F	DT	Small molecular drug
DM0CZ1F	PC	467334
DM0CZ1F	DE	Discovery agent

DMZRQEF	ID	DMZRQEF
DMZRQEF	DN	6-Benzyl-2-cyclopentylsulfanyl-3H-pyrimidin-4-one
DMZRQEF	HS	Investigative
DMZRQEF	DT	Small molecular drug
DMZRQEF	PC	467333
DMZRQEF	DE	Discovery agent

DMI5RNJ	ID	DMI5RNJ
DMI5RNJ	DN	6-Benzyl-2-isobutylsulfanyl-3H-pyrimidin-4-one
DMI5RNJ	HS	Investigative
DMI5RNJ	DT	Small molecular drug
DMI5RNJ	PC	467331
DMI5RNJ	DE	Discovery agent

DM7ANE3	ID	DM7ANE3
DM7ANE3	DN	6-Benzyl-2-sec-butylsulfanyl-3H-pyrimidin-4-one
DM7ANE3	HS	Investigative
DM7ANE3	DT	Small molecular drug
DM7ANE3	PC	467332
DM7ANE3	DE	Discovery agent

DMICRFQ	ID	DMICRFQ
DMICRFQ	DN	6-benzyl-3-ethoxycarbonyl-4-quinolone
DMICRFQ	HS	Investigative
DMICRFQ	SN	CHEMBL381059; 6-benzyl-3-ethoxycarbonyl-4-quinolone; SCHEMBL7728970; WQYYZNGOTUCWQX-UHFFFAOYSA-N; BDBM50185292; ZINC13685782; ethyl 6-benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylate; ethyl 6-benzyl-1,4-dihydro-4-oxoquinoline-3-carboxylate; 6-Benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid EthylEster
DMICRFQ	DT	Small molecular drug
DMICRFQ	PC	11529633
DMICRFQ	MW	307.3
DMICRFQ	FM	C19H17NO3
DMICRFQ	IC	InChI=1S/C19H17NO3/c1-2-23-19(22)16-12-20-17-9-8-14(11-15(17)18(16)21)10-13-6-4-3-5-7-13/h3-9,11-12H,2,10H2,1H3,(H,20,21)
DMICRFQ	CS	CCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC3=CC=CC=C3
DMICRFQ	IK	WQYYZNGOTUCWQX-UHFFFAOYSA-N
DMICRFQ	IU	ethyl 6-benzyl-4-oxo-1H-quinoline-3-carboxylate
DMICRFQ	DE	Discovery agent

DMXMI5E	ID	DMXMI5E
DMXMI5E	DN	6-benzyl-3-propoxycarbonyl-4-quinolone
DMXMI5E	HS	Investigative
DMXMI5E	SN	CHEMBL425590
DMXMI5E	DT	Small molecular drug
DMXMI5E	PC	11594914
DMXMI5E	MW	321.4
DMXMI5E	FM	C20H19NO3
DMXMI5E	IC	InChI=1S/C20H19NO3/c1-2-10-24-20(23)17-13-21-18-9-8-15(12-16(18)19(17)22)11-14-6-4-3-5-7-14/h3-9,12-13H,2,10-11H2,1H3,(H,21,22)
DMXMI5E	CS	CCCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC3=CC=CC=C3
DMXMI5E	IK	JIOMLDXNFGNQFW-UHFFFAOYSA-N
DMXMI5E	IU	propyl 6-benzyl-4-oxo-1H-quinoline-3-carboxylate
DMXMI5E	DE	Discovery agent

DM7HNPJ	ID	DM7HNPJ
DM7HNPJ	DN	6-benzyl-3-propylaminocarbonyl-4-quinolone
DM7HNPJ	HS	Investigative
DM7HNPJ	SN	CHEMBL380906
DM7HNPJ	DT	Small molecular drug
DM7HNPJ	PC	44409492
DM7HNPJ	MW	320.4
DM7HNPJ	FM	C20H20N2O2
DM7HNPJ	IC	InChI=1S/C20H20N2O2/c1-2-10-21-20(24)17-13-22-18-9-8-15(12-16(18)19(17)23)11-14-6-4-3-5-7-14/h3-9,12-13H,2,10-11H2,1H3,(H,21,24)(H,22,23)
DM7HNPJ	CS	CCCNC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC3=CC=CC=C3
DM7HNPJ	IK	RZALWHUVJLYKIZ-UHFFFAOYSA-N
DM7HNPJ	IU	6-benzyl-4-oxo-N-propyl-1H-quinoline-3-carboxamide
DM7HNPJ	DE	Discovery agent

DM8FUZL	ID	DM8FUZL
DM8FUZL	DN	6-Benzylamino-1H-pyrimidine-2,4-dione
DM8FUZL	HS	Investigative
DM8FUZL	SN	CHEMBL86482; 6-(Benzylamino)uracil; 6-(benzylamino)pyrimidine-2,4(1H,3H)-dione; 5759-80-8; 6-benzylaminouracil; NSC210509; 6-Benzylamino-1H-pyrimidine-2,4-dione; 6-(benzylamino)-1H-pyrimidine-2,4-dione; AC1L7DCT; ChemDiv2_000645; Oprea1_763542; Oprea1_040277; MLS001143323; SCHEMBL7563397; DTXSID80308975; MolPort-002-324-866; ZINC169533; HMS2799M09; HMS1370N07; STK385017; BDBM50022154; AKOS000627145; MCULE-8157405299; NSC-210509; CCG-107711; SMR000473158; ST50859108; EU-0040004; 6-(benzylamino)-2,4(1H,3H)-pyrimidinedione
DM8FUZL	DT	Small molecular drug
DM8FUZL	PC	308654
DM8FUZL	MW	217.22
DM8FUZL	FM	C11H11N3O2
DM8FUZL	IC	InChI=1S/C11H11N3O2/c15-10-6-9(13-11(16)14-10)12-7-8-4-2-1-3-5-8/h1-6H,7H2,(H3,12,13,14,15,16)
DM8FUZL	CS	C1=CC=C(C=C1)CNC2=CC(=O)NC(=O)N2
DM8FUZL	IK	NORSBFZJRBPBQZ-UHFFFAOYSA-N
DM8FUZL	IU	6-(benzylamino)-1H-pyrimidine-2,4-dione
DM8FUZL	CA	CAS 5759-80-8
DM8FUZL	DE	Discovery agent

DMGJYWF	ID	DMGJYWF
DMGJYWF	DN	6-Benzylamino-5-bromo-1H-pyrimidine-2,4-dione
DMGJYWF	HS	Investigative
DMGJYWF	SN	CHEMBL161517; 28484-80-2; 5-bromo-6-(benzylamino)uracil; NSC212354; AC1L7G2Y; 6-Benzylamino-5-bromo-1H-pyrimidine-2,4-dione; 6-(benzylamino)-5-bromo-1H-pyrimidine-2,4-dione; DTXSID60309581; BDBM50022146
DMGJYWF	DT	Small molecular drug
DMGJYWF	PC	309896
DMGJYWF	MW	296.12
DMGJYWF	FM	C11H10BrN3O2
DMGJYWF	IC	InChI=1S/C11H10BrN3O2/c12-8-9(14-11(17)15-10(8)16)13-6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,13,14,15,16,17)
DMGJYWF	CS	C1=CC=C(C=C1)CNC2=C(C(=O)NC(=O)N2)Br
DMGJYWF	IK	SLPLXDQXLWOWDS-UHFFFAOYSA-N
DMGJYWF	IU	6-(benzylamino)-5-bromo-1H-pyrimidine-2,4-dione
DMGJYWF	CA	CAS 28484-80-2
DMGJYWF	DE	Discovery agent

DM8FTNC	ID	DM8FTNC
DM8FTNC	DN	6-Benzylamino-5-iodo-1H-pyrimidine-2,4-dione
DM8FTNC	HS	Investigative
DM8FTNC	SN	5-iodo-6-(benzylamino)uracil; CHEMBL161515; 100763-62-0; 6-Benzylamino-5-iodo-1H-pyrimidine-2,4-dione
DM8FTNC	DT	Small molecular drug
DM8FTNC	PC	44374075
DM8FTNC	MW	343.12
DM8FTNC	FM	C11H10IN3O2
DM8FTNC	IC	InChI=1S/C11H10IN3O2/c12-8-9(14-11(17)15-10(8)16)13-6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,13,14,15,16,17)
DM8FTNC	CS	C1=CC=C(C=C1)CNC2=C(C(=O)NC(=O)N2)I
DM8FTNC	IK	XDTXBEGCSPNEIV-UHFFFAOYSA-N
DM8FTNC	IU	6-(benzylamino)-5-iodo-1H-pyrimidine-2,4-dione
DM8FTNC	DE	Discovery agent

DMK8XIO	ID	DMK8XIO
DMK8XIO	DN	6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine
DMK8XIO	HS	Investigative
DMK8XIO	SN	CHEMBL121479; 127116-64-7; 2,4-Pyrimidinediamine, 5-nitro-6-(phenylmethoxy)-; ACMC-20msby; 6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine; SCHEMBL3309544; CTK0F6457; DTXSID40431990; VLVHHGNPHBVEIG-UHFFFAOYSA-N; BDBM50062813; AKOS030620964; 6-Benzyloxy-5-nitropyrimidine-2,4-diamine; 2,4-Diamino-6-benzyloxy-5-nitropyrimidine
DMK8XIO	DT	Small molecular drug
DMK8XIO	PC	9860003
DMK8XIO	MW	261.24
DMK8XIO	FM	C11H11N5O3
DMK8XIO	IC	InChI=1S/C11H11N5O3/c12-9-8(16(17)18)10(15-11(13)14-9)19-6-7-4-2-1-3-5-7/h1-5H,6H2,(H4,12,13,14,15)
DMK8XIO	CS	C1=CC=C(C=C1)COC2=NC(=NC(=C2[N+](=O)[O-])N)N
DMK8XIO	IK	VLVHHGNPHBVEIG-UHFFFAOYSA-N
DMK8XIO	IU	5-nitro-6-phenylmethoxypyrimidine-2,4-diamine
DMK8XIO	CA	CAS 127116-64-7
DMK8XIO	DE	Discovery agent

DMUFSE2	ID	DMUFSE2
DMUFSE2	DN	6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine
DMUFSE2	HS	Investigative
DMUFSE2	SN	101724-61-2; 2,4-Pyrimidinediamine, 5-nitroso-6-(phenylmethoxy)-; CHEMBL71484; 6-(benzyloxy)-5-nitrosopyrimidine-2,4-diamine; pyrimidine deriv. 1g; NU 6039; 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine; AC1L48AH; 5-nitroso-6-phenylmethoxypyrimidine-2,4-diamine; BDBM5573; SCHEMBL2054835; DTXSID50144145; MBQPVHNJEDDVCF-UHFFFAOYSA-N; ZINC6096446; AKOS028111161; 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine; 2,6-Diamino-4-benzyloxy-5-nitrosopyrimidine; 2,4-Diamino-5-nitroso-6-benzyloxypyrimidine
DMUFSE2	DT	Small molecular drug
DMUFSE2	PC	181029
DMUFSE2	MW	245.24
DMUFSE2	FM	C11H11N5O2
DMUFSE2	IC	InChI=1S/C11H11N5O2/c12-9-8(16-17)10(15-11(13)14-9)18-6-7-4-2-1-3-5-7/h1-5H,6H2,(H4,12,13,14,15)
DMUFSE2	CS	C1=CC=C(C=C1)COC2=NC(=NC(=C2N=O)N)N
DMUFSE2	IK	MBQPVHNJEDDVCF-UHFFFAOYSA-N
DMUFSE2	IU	5-nitroso-6-phenylmethoxypyrimidine-2,4-diamine
DMUFSE2	CA	CAS 101724-61-2
DMUFSE2	DE	Discovery agent

DMFI7A8	ID	DMFI7A8
DMFI7A8	DN	6-Benzyloxy-9H-purin-2-ylamine
DMFI7A8	HS	Investigative
DMFI7A8	SN	6-O-Benzylguanine; 19916-73-5; 6-(Benzyloxy)-7H-purin-2-amine; 2-amino-6-benzyloxypurine; 6-(benzyloxy)-9H-purin-2-amine; 2-Amino-6-(benzyloxy)purine; O(6)-Bgua; 6-(Benzyloxy)guanine; 6-Benzyloxyguanine; 6-Benzyloxy guanine; 6-(Phenylmethoxy)-1H-purin-2-amine; 2-Amino-6-(phenylmethoxy)-9H-purine; O6-BG; UNII-01KC87F8FE; 1H-Purin-2-amine, 6-(phenylmethoxy)-; 6-BENZYLGUANINE; Purine, 2-amino-6-(benzyloxy)-; NSC 637037; CHEMBL407874; 01KC87F8FE; 6-benzyloxy-7H-purin-2-amine
DMFI7A8	DT	Small molecular drug
DMFI7A8	PC	4578
DMFI7A8	MW	241.25
DMFI7A8	FM	C12H11N5O
DMFI7A8	IC	InChI=1S/C12H11N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,13,14,15,16,17)
DMFI7A8	CS	C1=CC=C(C=C1)COC2=NC(=NC3=C2NC=N3)N
DMFI7A8	IK	KRWMERLEINMZFT-UHFFFAOYSA-N
DMFI7A8	IU	6-phenylmethoxy-7H-purin-2-amine
DMFI7A8	CA	CAS 19916-73-5
DMFI7A8	DE	Discovery agent

DMARP3M	ID	DMARP3M
DMARP3M	DN	6-Benzyloxybenzo[b]thiophene-2-carboxamidine
DMARP3M	HS	Investigative
DMARP3M	SN	CHEMBL598170; 6-Benzyloxybenzo[b]thiophene-2-carboxamidine; SCHEMBL13709671
DMARP3M	DT	Small molecular drug
DMARP3M	PC	46233193
DMARP3M	MW	358.5
DMARP3M	FM	C22H18N2OS
DMARP3M	IC	InChI=1S/C22H18N2OS/c23-22(24)21-13-18-11-17(9-10-20(18)26-21)16-7-4-8-19(12-16)25-14-15-5-2-1-3-6-15/h1-13H,14H2,(H3,23,24)
DMARP3M	CS	C1=CC=C(C=C1)COC2=CC=CC(=C2)C3=CC4=C(C=C3)SC(=C4)C(=N)N
DMARP3M	IK	HCMFEDPYXOWDMW-UHFFFAOYSA-N
DMARP3M	IU	5-(3-phenylmethoxyphenyl)-1-benzothiophene-2-carboximidamide
DMARP3M	DE	Discovery agent

DMI7FNZ	ID	DMI7FNZ
DMI7FNZ	DN	6-Benzylsulfanyl-9H-purine
DMI7FNZ	HS	Investigative
DMI7FNZ	SN	Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-benzylsulfanyl-9H-purine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine
DMI7FNZ	DT	Small molecular drug
DMI7FNZ	PC	93558
DMI7FNZ	MW	242.3
DMI7FNZ	FM	C12H10N4S
DMI7FNZ	IC	InChI=1S/C12H10N4S/c1-2-4-9(5-3-1)6-17-12-10-11(14-7-13-10)15-8-16-12/h1-5,7-8H,6H2,(H,13,14,15,16)
DMI7FNZ	CS	C1=CC=C(C=C1)CSC2=NC=NC3=C2NC=N3
DMI7FNZ	IK	ULIQGBPQLPCTAJ-UHFFFAOYSA-N
DMI7FNZ	IU	6-benzylsulfanyl-7H-purine
DMI7FNZ	CA	CAS 724-34-5
DMI7FNZ	DE	Discovery agent

DMNXGZP	ID	DMNXGZP
DMNXGZP	DN	6-Benzylthioinosine
DMNXGZP	HS	Investigative
DMNXGZP	SN	6-Benzylthioinosine; NSC26273; 6-Benzylthionebularine; MLS002702829; CHEMBL178704; 6-Benzylthiopurine ribonucleoside; 6165-03-3; NSC-26273; 6-(benzylsulfanyl)-9-pentofuranosyl-9h-purine; AC1L3TX3; AC1Q4YP0; cid_95263; ChEMBL_299712; SCHEMBL15427008; CTK5B3520; NSC 26273; BDBM50159129; SMR001566656; NCI60_002098; AI3-50272; Inosine,6-S-(phenylmethyl)-6-thio- (9CI); 9H-Purine, 6-(benzylthio)-9-.beta.-D-ribofuranosyl-; 9H-Purine, 6-(benzylthio)-9-beta-D-ribofuranosyl- (8CI); 9H-Purine, 6-((phenylmethyl)thio)-9-beta-D-ribofuranosyl-
DMNXGZP	DT	Small molecular drug
DMNXGZP	PC	95263
DMNXGZP	MW	374.4
DMNXGZP	FM	C17H18N4O4S
DMNXGZP	IC	InChI=1S/C17H18N4O4S/c22-6-11-13(23)14(24)17(25-11)21-9-20-12-15(21)18-8-19-16(12)26-7-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,22-24H,6-7H2
DMNXGZP	CS	C1=CC=C(C=C1)CSC2=NC=NC3=C2N=CN3C4C(C(C(O4)CO)O)O
DMNXGZP	IK	OMJRXFOHHLLDFR-UHFFFAOYSA-N
DMNXGZP	IU	2-(6-benzylsulfanylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMNXGZP	CA	CAS 6165-03-3
DMNXGZP	DE	Discovery agent

DMZ8PBE	ID	DMZ8PBE
DMZ8PBE	DN	6beta-naltrexol HCl
DMZ8PBE	HS	Investigative
DMZ8PBE	SN	CHEMBL558140; UNII-765G11MG24; 765G11MG24; 55488-86-3; Naltrexone metabolite 6; A-Naltrexol (hydrochloride); 6beta-Naltrexol hydrochloride; HY-G0019; 6beta-Hydroxynaltrexone hydrochloride; Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, hydrochloride, (5alpha,6beta)-; Naltrexone metabolite 6AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade markAfA centA centasA notA em leaderA inverted exclamation mark-Naltrexol (hydrochloride)
DMZ8PBE	DT	Small molecular drug
DMZ8PBE	PC	45110000
DMZ8PBE	MW	379.9
DMZ8PBE	FM	C20H26ClNO4
DMZ8PBE	IC	InChI=1S/C20H25NO4.ClH/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;/h3-4,11,14-15,18,22-24H,1-2,5-10H2;1H/t14-,15-,18+,19+,20-;/m1./s1
DMZ8PBE	CS	C1C[C@]2([C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@@H]1O)OC5=C(C=C4)O)O.Cl
DMZ8PBE	IK	FSQFFCPJTDFOAN-CDHBEYIESA-N
DMZ8PBE	IU	(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol;hydrochloride
DMZ8PBE	CA	CAS 55488-86-3
DMZ8PBE	DE	Discovery agent

DMZPY69	ID	DMZPY69
DMZPY69	DN	6-biphenyl-2-yl-2-morpholin-4-yl-chromen-4-one
DMZPY69	HS	Investigative
DMZPY69	SN	CHEMBL200678
DMZPY69	DT	Small molecular drug
DMZPY69	PC	11603381
DMZPY69	MW	383.4
DMZPY69	FM	C25H21NO3
DMZPY69	IC	InChI=1S/C25H21NO3/c27-23-17-25(26-12-14-28-15-13-26)29-24-11-10-19(16-22(23)24)21-9-5-4-8-20(21)18-6-2-1-3-7-18/h1-11,16-17H,12-15H2
DMZPY69	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=CC=C4C5=CC=CC=C5
DMZPY69	IK	RYQNUEMYQYWYOR-UHFFFAOYSA-N
DMZPY69	IU	2-morpholin-4-yl-6-(2-phenylphenyl)chromen-4-one
DMZPY69	DE	Discovery agent

DMU9WG0	ID	DMU9WG0
DMU9WG0	DN	6-bromo-1H-indazole
DMU9WG0	HS	Investigative
DMU9WG0	SN	6-bromo-1H-indazole; 79762-54-2; 6-Bromoindazole; 6-Bromo-2H-indazole; 1H-Indazole, 6-bromo-; CHEMBL247365; 1H-INDAZOLE,6-BROMO-; 1788080-23-8; 6-Bromo-1H-indazole, 97%; 6- Bromoindazole; PubChem7831; zlchem 1237; 6-broMo-1H indazole; 6-bromo-1-H-indazole; 6-bromanyl-1H-indazole; ACMC-209pi5; SCHEMBL5902; KSC376S4P; 6-Bromo-1H-indazole, 95%; AMBZ0200; AC1Q251Y; CTK2H6947; ZLE0012; DTXSID80591229; MolPort-029-084-056; WMKDUJVLNZANRN-UHFFFAOYSA-N; MolPort-000-001-819; ZINC8764137; KS-000002SJ; CS-D0757; BCP00386; ACN-S003161; ACT06505
DMU9WG0	DT	Small molecular drug
DMU9WG0	PC	17842471
DMU9WG0	MW	197.03
DMU9WG0	FM	C7H5BrN2
DMU9WG0	IC	InChI=1S/C7H5BrN2/c8-6-2-1-5-4-9-10-7(5)3-6/h1-4H,(H,9,10)
DMU9WG0	CS	C1=CC2=C(C=C1Br)NN=C2
DMU9WG0	IK	WMKDUJVLNZANRN-UHFFFAOYSA-N
DMU9WG0	IU	6-bromo-1H-indazole
DMU9WG0	CA	CAS 79762-54-2
DMU9WG0	DE	Discovery agent

DMM9GOR	ID	DMM9GOR
DMM9GOR	DN	6-bromo-1-methyl-3-(pyridin-4-yl)-1H-indole
DMM9GOR	HS	Investigative
DMM9GOR	SN	CHEMBL383060
DMM9GOR	DT	Small molecular drug
DMM9GOR	PC	44410801
DMM9GOR	MW	287.15
DMM9GOR	FM	C14H11BrN2
DMM9GOR	IC	InChI=1S/C14H11BrN2/c1-17-9-13(10-4-6-16-7-5-10)12-3-2-11(15)8-14(12)17/h2-9H,1H3
DMM9GOR	CS	CN1C=C(C2=C1C=C(C=C2)Br)C3=CC=NC=C3
DMM9GOR	IK	FSWMKLCDACNCRN-UHFFFAOYSA-N
DMM9GOR	IU	6-bromo-1-methyl-3-pyridin-4-ylindole
DMM9GOR	DE	Discovery agent

DM7U58O	ID	DM7U58O
DM7U58O	DN	6-Bromo-2-(2-nitro-phenyl)-chromen-4-one
DM7U58O	HS	Investigative
DM7U58O	SN	CHEMBL56906
DM7U58O	DT	Small molecular drug
DM7U58O	PC	44298955
DM7U58O	MW	346.13
DM7U58O	FM	C15H8BrNO4
DM7U58O	IC	InChI=1S/C15H8BrNO4/c16-9-5-6-14-11(7-9)13(18)8-15(21-14)10-3-1-2-4-12(10)17(19)20/h1-8H
DM7U58O	CS	C1=CC=C(C(=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)Br)[N+](=O)[O-]
DM7U58O	IK	GXUSNZYZTBJMIT-UHFFFAOYSA-N
DM7U58O	IU	6-bromo-2-(2-nitrophenyl)chromen-4-one
DM7U58O	DE	Discovery agent

DMTJRF3	ID	DMTJRF3
DMTJRF3	DN	6-Bromo-2-(3-bromo-phenyl)-chromen-4-one
DMTJRF3	HS	Investigative
DMTJRF3	SN	CHEMBL54878; 6,3'-Dibromoflavone; 3',6-Dibromoflavone; SCHEMBL6652108
DMTJRF3	DT	Small molecular drug
DMTJRF3	PC	10045305
DMTJRF3	MW	380.03
DMTJRF3	FM	C15H8Br2O2
DMTJRF3	IC	InChI=1S/C15H8Br2O2/c16-10-3-1-2-9(6-10)15-8-13(18)12-7-11(17)4-5-14(12)19-15/h1-8H
DMTJRF3	CS	C1=CC(=CC(=C1)Br)C2=CC(=O)C3=C(O2)C=CC(=C3)Br
DMTJRF3	IK	UIPGLQFPZVUUQW-UHFFFAOYSA-N
DMTJRF3	IU	6-bromo-2-(3-bromophenyl)chromen-4-one
DMTJRF3	DE	Discovery agent

DMP8ZVS	ID	DMP8ZVS
DMP8ZVS	DN	6-Bromo-2-(3-nitro-phenyl)-chromen-4-one
DMP8ZVS	HS	Investigative
DMP8ZVS	SN	6-bromo-2-(3-nitrophenyl)chromen-4-one; AC1MVVK1; 6-bromo-3'-nitroflavone; 3'-Nitro-6-bromoflavone; CHEMBL54341
DMP8ZVS	DT	Small molecular drug
DMP8ZVS	PC	3714237
DMP8ZVS	MW	346.13
DMP8ZVS	FM	C15H8BrNO4
DMP8ZVS	IC	InChI=1S/C15H8BrNO4/c16-10-4-5-14-12(7-10)13(18)8-15(21-14)9-2-1-3-11(6-9)17(19)20/h1-8H
DMP8ZVS	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=O)C3=C(O2)C=CC(=C3)Br
DMP8ZVS	IK	IPHSQMSRIWZULE-UHFFFAOYSA-N
DMP8ZVS	IU	6-bromo-2-(3-nitrophenyl)chromen-4-one
DMP8ZVS	DE	Discovery agent

DMCX3TM	ID	DMCX3TM
DMCX3TM	DN	6-Bromo-2-(4-nitro-phenyl)-chromen-4-one
DMCX3TM	HS	Investigative
DMCX3TM	SN	CHEMBL55023; 6-bromo-4'-nitroflavone; SCHEMBL4990126; GMVMGIYPRPPNMB-UHFFFAOYSA-N; ZINC29544424
DMCX3TM	DT	Small molecular drug
DMCX3TM	PC	11688794
DMCX3TM	MW	346.13
DMCX3TM	FM	C15H8BrNO4
DMCX3TM	IC	InChI=1S/C15H8BrNO4/c16-10-3-6-14-12(7-10)13(18)8-15(21-14)9-1-4-11(5-2-9)17(19)20/h1-8H
DMCX3TM	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=CC(=C3)Br)[N+](=O)[O-]
DMCX3TM	IK	GMVMGIYPRPPNMB-UHFFFAOYSA-N
DMCX3TM	IU	6-bromo-2-(4-nitrophenyl)chromen-4-one
DMCX3TM	DE	Discovery agent

DMXQ8K1	ID	DMXQ8K1
DMXQ8K1	DN	6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMXQ8K1	HS	Investigative
DMXQ8K1	SN	6-Bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 23046-69-7; CHEMBL6427; 6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline; 6-Bromo-1,2,3,4-tetrahydro-beta-carboline; AO-800/41069736; SCHEMBL1872944; CTK8H7143; MolPort-022-860-053; WUTVTUWSFMYRJK-UHFFFAOYSA-N; ZINC13587966; BDBM50136495; AKOS022471446; FCH1329538; AJ-64213; KB-205649
DMXQ8K1	DT	Small molecular drug
DMXQ8K1	PC	14680201
DMXQ8K1	MW	251.12
DMXQ8K1	FM	C11H11BrN2
DMXQ8K1	IC	InChI=1S/C11H11BrN2/c12-7-1-2-10-9(5-7)8-3-4-13-6-11(8)14-10/h1-2,5,13-14H,3-4,6H2
DMXQ8K1	CS	C1CNCC2=C1C3=C(N2)C=CC(=C3)Br
DMXQ8K1	IK	WUTVTUWSFMYRJK-UHFFFAOYSA-N
DMXQ8K1	IU	6-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMXQ8K1	DE	Discovery agent

DM39VT6	ID	DM39VT6
DM39VT6	DN	6-bromo-2'-de-N-methylaplysinopsin
DM39VT6	HS	Investigative
DM39VT6	DT	Small molecular drug
DM39VT6	PC	10336056
DM39VT6	DE	Discovery agent

DMMCNQI	ID	DMMCNQI
DMMCNQI	DN	6-Bromo-2-phenyl-chromen-4-one
DMMCNQI	HS	Investigative
DMMCNQI	SN	6-Bromoflavone; 1218-80-0; 6-bromo-2-phenyl-4H-chromen-4-one; 6-Bromo-2-phenyl-4H-1-benzopyran-4-one; 6-Bromo-2-phenyl-(4H)-4-benzopyranone; 6-bromo-2-phenylchromen-4-one; 6-Bromo-2-phenyl-chromen-4-one; ACMC-20alzx; AC1LAD8N; MLS002473413; CHEMBL52825; SCHEMBL4449962; ZINC58081; DTXSID00332792; HMS3343M11; HMS2224K05; 5956AH; MFCD00276169; AKOS015889624; MCULE-7797339727; ZB002311; ST059081; SMR001397504; KB-247810; TX-017285; 4H-1-Benzopyran-4-one, 6-bromo-2-phenyl-; K-1651; 6-Bromo-2-phenyl-(4H)-4-benzopyranone, 97%
DMMCNQI	DT	Small molecular drug
DMMCNQI	PC	466276
DMMCNQI	MW	301.13
DMMCNQI	FM	C15H9BrO2
DMMCNQI	IC	InChI=1S/C15H9BrO2/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-9H
DMMCNQI	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)Br
DMMCNQI	IK	LPOZDKMXSPAATL-UHFFFAOYSA-N
DMMCNQI	IU	6-bromo-2-phenylchromen-4-one
DMMCNQI	CA	CAS 1218-80-0
DMMCNQI	DE	Discovery agent

DMLT01H	ID	DMLT01H
DMLT01H	DN	6-Bromo-2-piperazin-1-yl-quinoline
DMLT01H	HS	Investigative
DMLT01H	SN	124782-95-2; 6-Bromo-2-piperazin-1-yl-quinoline; 6-bromo-2-(piperazin-1-yl)quinoline; 6-Bromoquipazine; 6-bromo-2-piperazin-1-ylquinoline; Quinoline, 6-bromo-2-(1-piperazinyl)-; CHEMBL39164; Quinoline,6-bromo-2-(1-piperazinyl)-; ACMC-20mr6z; AC1L2X2K; SCHEMBL5912936; CTK4B4077; DTXSID90154485; MKIHFWMBAKJYJL-UHFFFAOYSA-N; ZINC2527449; BDBM50090213; 6-bromo-2-(1-piperazinyl)quinoline; 3453AJ; AKOS022401899; AB19846; 6-bromanyl-2-piperazin-1-yl-quinoline; AJ-83658; DB-062320; AX8027344; FT-0713002; Z-6757; A805296
DMLT01H	DT	Small molecular drug
DMLT01H	PC	130261
DMLT01H	MW	292.17
DMLT01H	FM	C13H14BrN3
DMLT01H	IC	InChI=1S/C13H14BrN3/c14-11-2-3-12-10(9-11)1-4-13(16-12)17-7-5-15-6-8-17/h1-4,9,15H,5-8H2
DMLT01H	CS	C1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)Br
DMLT01H	IK	MKIHFWMBAKJYJL-UHFFFAOYSA-N
DMLT01H	IU	6-bromo-2-piperazin-1-ylquinoline
DMLT01H	CA	CAS 124782-95-2
DMLT01H	DE	Discovery agent

DMVWX62	ID	DMVWX62
DMVWX62	DN	6-bromo-3-(pyridin-4-yl)-1H-indole
DMVWX62	HS	Investigative
DMVWX62	SN	CHEMBL206257; 6-bromo-3-(pyridin-4-yl)-1H-indole
DMVWX62	DT	Small molecular drug
DMVWX62	PC	44410796
DMVWX62	MW	273.13
DMVWX62	FM	C13H9BrN2
DMVWX62	IC	InChI=1S/C13H9BrN2/c14-10-1-2-11-12(8-16-13(11)7-10)9-3-5-15-6-4-9/h1-8,16H
DMVWX62	CS	C1=CC2=C(C=C1Br)NC=C2C3=CC=NC=C3
DMVWX62	IK	KLYDZCDPTMADJL-UHFFFAOYSA-N
DMVWX62	IU	6-bromo-3-pyridin-4-yl-1H-indole
DMVWX62	DE	Discovery agent

DM4HRIX	ID	DM4HRIX
DM4HRIX	DN	6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone
DM4HRIX	HS	Investigative
DM4HRIX	SN	CHEMBL206762; 88960-40-1; 3-Quinolinecarboxylic acid, 6-bromo-4-hydroxy-2-methyl-, ethyl ester; ACMC-20lfhk; CTK3A4318; DTXSID10469528
DM4HRIX	DT	Small molecular drug
DM4HRIX	PC	11616547
DM4HRIX	MW	310.14
DM4HRIX	FM	C13H12BrNO3
DM4HRIX	IC	InChI=1S/C13H12BrNO3/c1-3-18-13(17)11-7(2)15-10-5-4-8(14)6-9(10)12(11)16/h4-6H,3H2,1-2H3,(H,15,16)
DM4HRIX	CS	CCOC(=O)C1=C(NC2=C(C1=O)C=C(C=C2)Br)C
DM4HRIX	IK	OWQFPNVJMALXNK-UHFFFAOYSA-N
DM4HRIX	IU	ethyl 6-bromo-2-methyl-4-oxo-1H-quinoline-3-carboxylate
DM4HRIX	CA	CAS 88960-40-1
DM4HRIX	DE	Discovery agent

DM0MQHP	ID	DM0MQHP
DM0MQHP	DN	6-bromo-3-ethoxycarbonyl-4-quinolone
DM0MQHP	HS	Investigative
DM0MQHP	SN	ethyl 6-bromo-4-hydroxyquinoline-3-carboxylate; 122794-99-4; 79607-23-1; ethyl 6-bromo-4-oxo-1,4-dihydroquinoline-3-carboxylate; 6-Bromo-4-hydroxyquinoline-3-carboxylic acid ethyl ester; Ethyl 6-bromo-4-hydroxy-3-quinolinecarboxylate; ethyl 6-bromo-4-oxo-1H-quinoline-3-carboxylate; 6-bromo-4-hydroxy-quinoline-3-carboxylic acid ethyl ester; CHEMBL205257; 3-QUINOLINECARBOXYLIC ACID, 6-BROMO-4-HYDROXY-, ETHYL ESTER; 6-BROMO-4-HYDROXY-3-QUINOLINECARBOXYLIC ACID ETHYL ESTER; 3-Quinolinecarboxylic acid, 6-bromo-1,4-dihydro-
DM0MQHP	DT	Small molecular drug
DM0MQHP	PC	689824
DM0MQHP	MW	296.12
DM0MQHP	FM	C12H10BrNO3
DM0MQHP	IC	InChI=1S/C12H10BrNO3/c1-2-17-12(16)9-6-14-10-4-3-7(13)5-8(10)11(9)15/h3-6H,2H2,1H3,(H,14,15)
DM0MQHP	CS	CCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)Br
DM0MQHP	IK	IVZIOBTVAJBBAS-UHFFFAOYSA-N
DM0MQHP	IU	ethyl 6-bromo-4-oxo-1H-quinoline-3-carboxylate
DM0MQHP	CA	CAS 122794-99-4
DM0MQHP	DE	Discovery agent

DM64KOZ	ID	DM64KOZ
DM64KOZ	DN	6-Bromo-4,9-dihydro-3H-beta-carboline
DM64KOZ	HS	Investigative
DM64KOZ	SN	CHEMBL6626; 6-Bromo-4,9-dihydro-3H-beta-carboline; BDBM50136508; 6-Bromo-3,4-dihydro-beta-carboline
DM64KOZ	DT	Small molecular drug
DM64KOZ	PC	42281505
DM64KOZ	MW	249.11
DM64KOZ	FM	C11H9BrN2
DM64KOZ	IC	InChI=1S/C11H9BrN2/c12-7-1-2-10-9(5-7)8-3-4-13-6-11(8)14-10/h1-2,5-6,14H,3-4H2
DM64KOZ	CS	C1CN=CC2=C1C3=C(N2)C=CC(=C3)Br
DM64KOZ	IK	PAHAIWFYCZHWKN-UHFFFAOYSA-N
DM64KOZ	IU	6-bromo-4,9-dihydro-3H-pyrido[3,4-b]indole
DM64KOZ	DE	Discovery agent

DMFZ2PI	ID	DMFZ2PI
DMFZ2PI	DN	6-bromo-5-methyl-1H-indole-2,3-dione
DMFZ2PI	HS	Investigative
DMFZ2PI	SN	6-bromo-5-methyl-1H-indole-2,3-dione; 6-BROMO-5-METHYLISATIN; 306325-13-3; 6-bromo-5-methylindoline-2,3-dione; 6-bromo-5-methyl-2,3-dihydro-1H-indole-2,3-dione; 6-bromo-5-methyl-1H-benzo[d]azolidine-2,3-dione; AC1LW5IO; CBMicro_014209; Isatin-based compound, 58; SCHEMBL5526009; AC1Q2O90; CHEMBL221830; ARONIS016716; CTK7H5981; BDBM22838; BBC/891; MolPort-001-022-207; DQZFCBOXZKQQPM-UHFFFAOYSA-N; ALBB-012856; ZX-AN011645; ZINC2052963; SMSF0004612; STK042825; SBB071631; AKOS000484014; MCULE-6005372434; FCH1317267; CB09212; KS-000049B7
DMFZ2PI	DT	Small molecular drug
DMFZ2PI	PC	1718647
DMFZ2PI	MW	240.05
DMFZ2PI	FM	C9H6BrNO2
DMFZ2PI	IC	InChI=1S/C9H6BrNO2/c1-4-2-5-7(3-6(4)10)11-9(13)8(5)12/h2-3H,1H3,(H,11,12,13)
DMFZ2PI	CS	CC1=CC2=C(C=C1Br)NC(=O)C2=O
DMFZ2PI	IK	DQZFCBOXZKQQPM-UHFFFAOYSA-N
DMFZ2PI	IU	6-bromo-5-methyl-1H-indole-2,3-dione
DMFZ2PI	DE	Discovery agent

DM8A1ZU	ID	DM8A1ZU
DM8A1ZU	DN	6-bromo-5-phenylpyrimidine-2,4(1H,3H)-dione
DM8A1ZU	HS	Investigative
DM8A1ZU	SN	CHEMBL235666; BDBM20076; 6-Bromo-5-phenylpyrimidine-2,4(1H,3H)-dione, 23
DM8A1ZU	DT	Small molecular drug
DM8A1ZU	PC	23648528
DM8A1ZU	MW	267.08
DM8A1ZU	FM	C10H7BrN2O2
DM8A1ZU	IC	InChI=1S/C10H7BrN2O2/c11-8-7(6-4-2-1-3-5-6)9(14)13-10(15)12-8/h1-5H,(H2,12,13,14,15)
DM8A1ZU	CS	C1=CC=C(C=C1)C2=C(NC(=O)NC2=O)Br
DM8A1ZU	IK	XSEDFSJHHTXVPL-UHFFFAOYSA-N
DM8A1ZU	IU	6-bromo-5-phenyl-1H-pyrimidine-2,4-dione
DM8A1ZU	DE	Discovery agent

DMZJ6M8	ID	DMZJ6M8
DMZJ6M8	DN	6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine
DMZJ6M8	HS	Investigative
DMZJ6M8	SN	CHEMBL609595; 6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine; BDBM50304813
DMZJ6M8	DT	Small molecular drug
DMZJ6M8	PC	46228424
DMZJ6M8	MW	282.14
DMZJ6M8	FM	C10H12BrN5
DMZJ6M8	IC	InChI=1S/C10H12BrN5/c11-8-7-16-6-3-13-9(16)10(14-8)15-4-1-12-2-5-15/h3,6-7,12H,1-2,4-5H2
DMZJ6M8	CS	C1CN(CCN1)C2=NC(=CN3C2=NC=C3)Br
DMZJ6M8	IK	XNILOZDQMHSDIZ-UHFFFAOYSA-N
DMZJ6M8	IU	6-bromo-8-piperazin-1-ylimidazo[1,2-a]pyrazine
DMZJ6M8	DE	Discovery agent

DMQGB70	ID	DMQGB70
DMQGB70	DN	6-bromoaplysinopsin
DMQGB70	HS	Investigative
DMQGB70	DT	Small molecular drug
DMQGB70	PC	135433933
DMQGB70	MW	333.18
DMQGB70	FM	C14H13BrN4O
DMQGB70	IC	InChI=1S/C14H13BrN4O/c1-18-12(13(20)19(2)14(18)16)5-8-7-17-11-6-9(15)3-4-10(8)11/h3-7,16,20H,1-2H3/b8-5+,16-14?
DMQGB70	CS	CN1C(=C(N(C1=N)C)O)/C=C/2\\C=NC3=C2C=CC(=C3)Br
DMQGB70	IK	RZEXTWCYINCKES-JENRKBSESA-N
DMQGB70	IU	5-[(Z)-(6-bromoindol-3-ylidene)methyl]-2-imino-1,3-dimethylimidazol-4-ol
DMQGB70	CA	CAS 85079-45-4
DMQGB70	DE	Discovery agent

DM12WYV	ID	DM12WYV
DM12WYV	DN	6-bromoindirubin-3-oxime
DM12WYV	HS	Investigative
DM12WYV	SN	6-bromoindirubin-3'-oxime (BIO)
DM12WYV	DT	Small molecular drug
DM12WYV	PC	448949
DM12WYV	MW	356.17
DM12WYV	FM	C16H10BrN3O2
DM12WYV	IC	InChI=1S/C16H10BrN3O2/c17-8-5-6-9-12(7-8)19-16(21)13(9)15-14(20-22)10-3-1-2-4-11(10)18-15/h1-7,18-19,21H
DM12WYV	CS	C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=CC(=C4)Br)O)N=O
DM12WYV	IK	SAQUSDSPQYQNBG-UHFFFAOYSA-N
DM12WYV	IU	6-bromo-3-(3-nitroso-1H-indol-2-yl)-1H-indol-2-ol
DM12WYV	CA	CAS 667463-62-9
DM12WYV	CB	CHEBI:86290
DM12WYV	DE	Discovery agent

DMP9O7G	ID	DMP9O7G
DMP9O7G	DN	6-bromo-N-(3-bromophenyl)quinazolin-4-amine
DMP9O7G	HS	Investigative
DMP9O7G	SN	CHEMBL1081536; 6-bromo-N-(3-bromophenyl)quinazolin-4-amine
DMP9O7G	DT	Small molecular drug
DMP9O7G	PC	46879644
DMP9O7G	MW	379.05
DMP9O7G	FM	C14H9Br2N3
DMP9O7G	IC	InChI=1S/C14H9Br2N3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DMP9O7G	CS	C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=C(C=C3)Br
DMP9O7G	IK	GBBRIESLSQOJQX-UHFFFAOYSA-N
DMP9O7G	IU	6-bromo-N-(3-bromophenyl)quinazolin-4-amine
DMP9O7G	DE	Discovery agent

DM0A3DB	ID	DM0A3DB
DM0A3DB	DN	6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
DM0A3DB	HS	Investigative
DM0A3DB	SN	6-bromo-N-(3-chlorophenyl)quinazolin-4-amine; CHEMBL1079374; AC1LEZQW; C14H9BrClN3; ChemDiv1_028574; Oprea1_590274; Neuro1_000364; MLS000572427; cid_720635; SCHEMBL4783154; HMS668C18; MolPort-000-660-268; ZINC122236; HMS2493B23; BDBM50311887; STK965864; AKOS002348868; MCULE-5418328745; SMR000194385; EU-0077259; ST50477345; 6-bromo-N-(3-chlorophenyl)-4-quinazolinamine; (6-bromoquinazolin-4-yl)(3-chlorophenyl)amine; SR-01000485096; SR-01000485096-1
DM0A3DB	DT	Small molecular drug
DM0A3DB	PC	720635
DM0A3DB	MW	334.6
DM0A3DB	FM	C14H9BrClN3
DM0A3DB	IC	InChI=1S/C14H9BrClN3/c15-9-4-5-13-12(6-9)14(18-8-17-13)19-11-3-1-2-10(16)7-11/h1-8H,(H,17,18,19)
DM0A3DB	CS	C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)Br
DM0A3DB	IK	LYKXFKUSOXETGV-UHFFFAOYSA-N
DM0A3DB	IU	6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
DM0A3DB	DE	Discovery agent

DM2IP5F	ID	DM2IP5F
DM2IP5F	DN	6-bromo-N-(3-fluorophenyl)quinazolin-4-amine
DM2IP5F	HS	Investigative
DM2IP5F	SN	CHEMBL1079375; 6-bromo-N-(3-fluorophenyl)quinazolin-4-amine; ZINC32540960; BDBM50311885; AKOS002366762
DM2IP5F	DT	Small molecular drug
DM2IP5F	PC	21002513
DM2IP5F	MW	318.14
DM2IP5F	FM	C14H9BrFN3
DM2IP5F	IC	InChI=1S/C14H9BrFN3/c15-9-4-5-13-12(6-9)14(18-8-17-13)19-11-3-1-2-10(16)7-11/h1-8H,(H,17,18,19)
DM2IP5F	CS	C1=CC(=CC(=C1)F)NC2=NC=NC3=C2C=C(C=C3)Br
DM2IP5F	IK	ALKMBIXEONKULX-UHFFFAOYSA-N
DM2IP5F	IU	6-bromo-N-(3-fluorophenyl)quinazolin-4-amine
DM2IP5F	DE	Discovery agent

DM2MJ9F	ID	DM2MJ9F
DM2MJ9F	DN	6-bromo-N-m-tolylquinazolin-4-amine
DM2MJ9F	HS	Investigative
DM2MJ9F	SN	CHEMBL1081537; 6-bromo-N-m-tolylquinazolin-4-amine; AC1LEZQQ; Oprea1_147022; Neuro1_000540; MLS000684595; SCHEMBL4349199; MolPort-000-660-263; HMS3380E09; HMS2596L23; ZINC122234; BDBM50311883; AKOS002348862; MCULE-2560701920; SMR000268469; ST50477342; EU-0043981; 6-bromo-N-(3-methylphenyl)quinazolin-4-amine; 6-bromo-N-(3-methylphenyl)-4-quinazolinamine; (6-bromoquinazolin-4-yl)(3-methylphenyl)amine; SR-01000485095
DM2MJ9F	DT	Small molecular drug
DM2MJ9F	PC	720633
DM2MJ9F	MW	314.18
DM2MJ9F	FM	C15H12BrN3
DM2MJ9F	IC	InChI=1S/C15H12BrN3/c1-10-3-2-4-12(7-10)19-15-13-8-11(16)5-6-14(13)17-9-18-15/h2-9H,1H3,(H,17,18,19)
DM2MJ9F	CS	CC1=CC(=CC=C1)NC2=NC=NC3=C2C=C(C=C3)Br
DM2MJ9F	IK	CGCSONSXFOSORP-UHFFFAOYSA-N
DM2MJ9F	IU	6-bromo-N-(3-methylphenyl)quinazolin-4-amine
DM2MJ9F	DE	Discovery agent

DM46GLQ	ID	DM46GLQ
DM46GLQ	DN	6-butyl-2,4-dipropylaminopyrimidine
DM46GLQ	HS	Investigative
DM46GLQ	SN	CHEMBL352024; 6-butyl-2,4-dipropylaminopyrimidine; BDBM50138883; ZINC13559144
DM46GLQ	DT	Small molecular drug
DM46GLQ	PC	11276767
DM46GLQ	MW	250.38
DM46GLQ	FM	C14H26N4
DM46GLQ	IC	InChI=1S/C14H26N4/c1-4-7-8-12-11-13(15-9-5-2)18-14(17-12)16-10-6-3/h11H,4-10H2,1-3H3,(H2,15,16,17,18)
DM46GLQ	CS	CCCCC1=CC(=NC(=N1)NCCC)NCCC
DM46GLQ	IK	UYWCDBMUBBSZOJ-UHFFFAOYSA-N
DM46GLQ	IU	6-butyl-2-N,4-N-dipropylpyrimidine-2,4-diamine
DM46GLQ	DE	Discovery agent

DMWTMDH	ID	DMWTMDH
DMWTMDH	DN	6-Carboxyfluorescein
DMWTMDH	HS	Investigative
DMWTMDH	SN	3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-1,9'-xanthene]-6-carboxylic acid; 3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-6-carboxylic acid; 5(6)-carboxy fluorescein; 6-Carboxyfluorescein; 6-Carboxyfluorescein, 96%; 6-FAM; FLUOS; J-100061; Spiro(isobenzofuran-1(3H),9'-(9H)xanthene)-6-carboxylic acid, 3',6'-dihydroxy-3-oxo-; Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-6-carboxylic acid, 3',6'-dihydroxy-3-oxo-; carboxyfluorescein
DMWTMDH	DT	Small molecular drug
DMWTMDH	PC	76806
DMWTMDH	MW	376.32
DMWTMDH	FM	C21H12O7
DMWTMDH	IC	InChI=1S/C21H12O7/c22-11-2-5-14-17(8-11)27-18-9-12(23)3-6-15(18)21(14)16-7-10(19(24)25)1-4-13(16)20(26)28-21/h1-9,22-23H,(H,24,25)
DMWTMDH	CS	C1=CC2=C(C=C1C(=O)O)C3(C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O)OC2=O
DMWTMDH	IK	BZTDTCNHAFUJOG-UHFFFAOYSA-N
DMWTMDH	IU	3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carboxylic acid
DMWTMDH	CA	CAS 3301-79-9
DMWTMDH	CB	ChEBI:39073

DM9MPDK	ID	DM9MPDK
DM9MPDK	DN	6-Carboxymethyluracil
DM9MPDK	HS	Investigative
DM9MPDK	SN	6-Carboxymethyluracil; 4628-39-1; URACIL-6-ACETIC ACID; Uracil-4-acetic acid; (2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetic acid; 1,2,3,6-Tetrahydro-2,6-dioxo-4-pyrimidineacetic acid; 2-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetic acid; uracil-6-ylacetic acid; NSC13201; 4-Pyrimidineacetic acid, 1,2,3,6-tetrahydro-2,6-dioxo-; (2,6-Dioxo-1,2,3,6-tetrahydro-pyrimidin-4-yl)-acetic acid; CHEBI:46371; 2-(2,6-dihydroxypyrimidin-4-yl)acetic acid; 2-(2,4-dioxo-1H-pyrimidin-6-yl)acetic acid; 4-Pyrimidineaceticacid, 1,2,
DM9MPDK	DT	Small molecular drug
DM9MPDK	PC	73271
DM9MPDK	MW	170.12
DM9MPDK	FM	C6H6N2O4
DM9MPDK	IC	InChI=1S/C6H6N2O4/c9-4-1-3(2-5(10)11)7-6(12)8-4/h1H,2H2,(H,10,11)(H2,7,8,9,12)
DM9MPDK	CS	C1=C(NC(=O)NC1=O)CC(=O)O
DM9MPDK	IK	NQAUNZZEYKWTHM-UHFFFAOYSA-N
DM9MPDK	IU	2-(2,4-dioxo-1H-pyrimidin-6-yl)acetic acid
DM9MPDK	CA	CAS 4628-39-1
DM9MPDK	CB	CHEBI:46371
DM9MPDK	DE	Discovery agent

DMW6320	ID	DMW6320
DMW6320	DN	6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole
DMW6320	HS	Investigative
DMW6320	SN	CHEMBL288445; 6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole; BDBM50108303; AKOS022692451
DMW6320	DT	Small molecular drug
DMW6320	PC	44287208
DMW6320	MW	206.67
DMW6320	FM	C11H11ClN2
DMW6320	IC	InChI=1S/C11H11ClN2/c12-10-3-1-2-8-6-9-7-13-4-5-14(9)11(8)10/h1-3,6,13H,4-5,7H2
DMW6320	CS	C1CN2C(=CC3=C2C(=CC=C3)Cl)CN1
DMW6320	IK	AWEHDQNNOZXHOU-UHFFFAOYSA-N
DMW6320	IU	6-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole
DMW6320	DE	Discovery agent

DMURJ34	ID	DMURJ34
DMURJ34	DN	6-Chloro-1,4-dihydro-quinoxaline-2,3-dione
DMURJ34	HS	Investigative
DMURJ34	SN	6-chloroquinoxaline-2,3-diol; 6639-79-8; 2,3-Dihydroxy-6-chloroquinoxaline; 6-Chloro-1,4-dihydroquinoxaline-2,3-dione; 6-Chloroquinoxaline-2,3(1H,4H)-dione; 6-Chloro-2,3-dihydroxyquinoxaline; 6-Chloro-1,2,3,4-tetrahydroquinoxaline-2,3-dione; 169-14-2; 2,3-Quinoxalinedione, 6-chloro-1,4-dihydro-; CHEMBL21641; 6-CHLORO-2,3-DIOXO-1,2,3,4-TETRAHYDROQUINOXALINE; 6-chloro-1,4-dihydro-2,3-quinoxalinedione; Oprea1_205811; 2,3-Quinoxalinediol, 6-chloro-; EINECS 229-647-9; NSC 48940; PubChem15426; 2, 6-chloro-; AC1Q3ORE
DMURJ34	DT	Small molecular drug
DMURJ34	PC	81143
DMURJ34	MW	196.59
DMURJ34	FM	C8H5ClN2O2
DMURJ34	IC	InChI=1S/C8H5ClN2O2/c9-4-1-2-5-6(3-4)11-8(13)7(12)10-5/h1-3H,(H,10,12)(H,11,13)
DMURJ34	CS	C1=CC2=C(C=C1Cl)NC(=O)C(=O)N2
DMURJ34	IK	RNOLFZACEWWIHP-UHFFFAOYSA-N
DMURJ34	IU	6-chloro-1,4-dihydroquinoxaline-2,3-dione
DMURJ34	CA	CAS 6639-79-8
DMURJ34	DE	Discovery agent

DMKCBIL	ID	DMKCBIL
DMKCBIL	DN	6-chloro-1H-indazole
DMKCBIL	HS	Investigative
DMKCBIL	SN	6-Chloro-1H-indazole; 698-25-9; 6-Chloroindazole; 1H-Indazole, 6-chloro-; 1H-INDAZOLE,6-CHLORO-; CHEMBL392184; VUZQHUVRBPILAX-UHFFFAOYSA-N; AK-27924; 6-chloroazaindole; 6-chloro-indazole; NSC92743; PubChem20592; AC1L9DR4; SCHEMBL3533806; SCHEMBL16523332; CTK2F6854; DTXSID70329119; MolPort-000-002-984; HMS1629J03; 6-Chloro-1H-indazole, AldrichCPR; ACT06345; ZINC4878475; BCP00929; EBD48419; NSC-92743; BDBM50209236; BBL101057; STL554851; ANW-50721; FCH835101; AKOS005256021; AKOS024124978; RP01765; CS-W005017; VI20061; FS-2891; QC-2958; PB34228
DMKCBIL	DT	Small molecular drug
DMKCBIL	PC	417524
DMKCBIL	MW	152.58
DMKCBIL	FM	C7H5ClN2
DMKCBIL	IC	InChI=1S/C7H5ClN2/c8-6-2-1-5-4-9-10-7(5)3-6/h1-4H,(H,9,10)
DMKCBIL	CS	C1=CC2=C(C=C1Cl)NN=C2
DMKCBIL	IK	VUZQHUVRBPILAX-UHFFFAOYSA-N
DMKCBIL	IU	6-chloro-1H-indazole
DMKCBIL	CA	CAS 698-25-9
DMKCBIL	DE	Discovery agent

DMTWBOV	ID	DMTWBOV
DMTWBOV	DN	6-Chloro-2-(3-nitro-phenyl)-chromen-4-one
DMTWBOV	HS	Investigative
DMTWBOV	SN	CHEMBL59263; 127767-40-2; 4H-1-Benzopyran-4-one, 6-chloro-2-(3-nitrophenyl)-; 6-chloro-2-(3-nitrophenyl)chromen-4-one; ACMC-20mskm; 3'-Nitro-6-chloroflavone; AC1NMK14; 6-chloro-3' -nitroflavone; CTK0C1861; DTXSID20407496; AKOS001600357; EU-0068162; SR-01000400460
DMTWBOV	DT	Small molecular drug
DMTWBOV	PC	5011228
DMTWBOV	MW	301.68
DMTWBOV	FM	C15H8ClNO4
DMTWBOV	IC	InChI=1S/C15H8ClNO4/c16-10-4-5-14-12(7-10)13(18)8-15(21-14)9-2-1-3-11(6-9)17(19)20/h1-8H
DMTWBOV	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=O)C3=C(O2)C=CC(=C3)Cl
DMTWBOV	IK	DKCAUMRZSZVJCP-UHFFFAOYSA-N
DMTWBOV	IU	6-chloro-2-(3-nitrophenyl)chromen-4-one
DMTWBOV	CA	CAS 127767-40-2
DMTWBOV	DE	Discovery agent

DMLMOC0	ID	DMLMOC0
DMLMOC0	DN	6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMLMOC0	HS	Investigative
DMLMOC0	DT	Small molecular drug
DMLMOC0	PC	135546593
DMLMOC0	MW	261.66
DMLMOC0	FM	C13H8ClNO3
DMLMOC0	IC	InChI=1S/C13H8ClNO3/c14-9-5-12-10(6-11(9)17)15-13(18-12)7-1-3-8(16)4-2-7/h1-6,16-17H
DMLMOC0	CS	C1=CC(=CC=C1C2=NC3=CC(=C(C=C3O2)Cl)O)O
DMLMOC0	IK	FXPRHFKNZLXHRN-UHFFFAOYSA-N
DMLMOC0	IU	6-chloro-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMLMOC0	DE	Discovery agent

DM5FZDI	ID	DM5FZDI
DM5FZDI	DN	6-Chloro-2-phenyl-chromen-4-one
DM5FZDI	HS	Investigative
DM5FZDI	SN	6-chloroflavone; 10420-73-2; 6-Chloro-2-phenyl-4H-chromen-4-one; 6-Chloro-2-phenyl-chromen-4-one; MLS002701775; CHEMBL293478; 6-chloro-2-phenylchromen-4-one; NSC63999; 4l2f; AC1L6LIW; Maybridge4_000538; AC1Q3RN7; NCIOpen2_003001; Oprea1_047009; SCHEMBL4649891; ZINC58093; DTXSID10289783; MolPort-002-893-915; IFNDLWHUYFSXBK-UHFFFAOYSA-N; HMS1522I10; KS-000017VJ; MRS-1131; NSC621450; BDBM50051364; NSC-63999; 5979AH; AKOS000603599; MCULE-8596095757; MB00919; CCG-233377; NSC-621450; IDI1_031120; NCGC00177472-01; SMR001565369; ZB002315
DM5FZDI	DT	Small molecular drug
DM5FZDI	PC	248021
DM5FZDI	MW	256.68
DM5FZDI	FM	C15H9ClO2
DM5FZDI	IC	InChI=1S/C15H9ClO2/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-9H
DM5FZDI	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)Cl
DM5FZDI	IK	IFNDLWHUYFSXBK-UHFFFAOYSA-N
DM5FZDI	IU	6-chloro-2-phenylchromen-4-one
DM5FZDI	CA	CAS 10420-73-2
DM5FZDI	DE	Discovery agent

DMM41AQ	ID	DMM41AQ
DMM41AQ	DN	6-Chloro-2-piperazin-1-yl-quinoline
DMM41AQ	HS	Investigative
DMM41AQ	SN	6-chloro-2-piperazin-1-yl-quinoline; 78060-46-5; 6-Chloro-2-(piperazin-1-yl)quinoline; 6-chloro-2-piperazin-1-ylquinoline; 6-chloro-2-(1-piperazinyl)quinoline; CHEMBL290537; AC1Q3JZ5; 2-Piperazino-6-chloroquinoline; SCHEMBL4182196; CTK5E5334; DTXSID60437575; GSFXEINORRSYJW-UHFFFAOYSA-N; ZINC2527450; 3506AJ; BDBM50090216; AKOS022401900; AB19847; 6-chloranyl-2-piperazin-1-yl-quinoline; Quinoline,6-chloro-2-(1-piperazinyl)-; AJ-83656; AX8029614; KB-248323; DB-075405; FT-0719429; Z-5014
DMM41AQ	DT	Small molecular drug
DMM41AQ	PC	10264015
DMM41AQ	MW	247.72
DMM41AQ	FM	C13H14ClN3
DMM41AQ	IC	InChI=1S/C13H14ClN3/c14-11-2-3-12-10(9-11)1-4-13(16-12)17-7-5-15-6-8-17/h1-4,9,15H,5-8H2
DMM41AQ	CS	C1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)Cl
DMM41AQ	IK	GSFXEINORRSYJW-UHFFFAOYSA-N
DMM41AQ	IU	6-chloro-2-piperazin-1-ylquinoline
DMM41AQ	CA	CAS 78060-46-5
DMM41AQ	DE	Discovery agent

DMHJIN0	ID	DMHJIN0
DMHJIN0	DN	6-Chloro-4-morpholin-4-yl-chromen-2-one
DMHJIN0	HS	Investigative
DMHJIN0	SN	CHEMBL179591; 6-chloro-4-morpholin-4-yl-chromen-2-one
DMHJIN0	DT	Small molecular drug
DMHJIN0	PC	11459783
DMHJIN0	MW	265.69
DMHJIN0	FM	C13H12ClNO3
DMHJIN0	IC	InChI=1S/C13H12ClNO3/c14-9-1-2-12-10(7-9)11(8-13(16)18-12)15-3-5-17-6-4-15/h1-2,7-8H,3-6H2
DMHJIN0	CS	C1COCCN1C2=CC(=O)OC3=C2C=C(C=C3)Cl
DMHJIN0	IK	IKOYKMNERRYCAN-UHFFFAOYSA-N
DMHJIN0	IU	6-chloro-4-morpholin-4-ylchromen-2-one
DMHJIN0	DE	Discovery agent

DMSZML2	ID	DMSZML2
DMSZML2	DN	6-chloro-5-(2-thienyl)pyrimidine-2,4(1H,3H)-dione
DMSZML2	HS	Investigative
DMSZML2	SN	6-chloro-5-(2-thienyl)pyrimidine-2,4(1H,3H)-dione; 1000680-81-8; CHEMBL397364; BDBM20069; 5-Substituted-6-chlorouracil, 10e
DMSZML2	DT	Small molecular drug
DMSZML2	PC	23648522
DMSZML2	MW	228.66
DMSZML2	FM	C8H5ClN2O2S
DMSZML2	IC	InChI=1S/C8H5ClN2O2S/c9-6-5(4-2-1-3-14-4)7(12)11-8(13)10-6/h1-3H,(H2,10,11,12,13)
DMSZML2	CS	C1=CSC(=C1)C2=C(NC(=O)NC2=O)Cl
DMSZML2	IK	DPKZWAVQBQNTIP-UHFFFAOYSA-N
DMSZML2	IU	6-chloro-5-thiophen-2-yl-1H-pyrimidine-2,4-dione
DMSZML2	DE	Discovery agent

DMASFR6	ID	DMASFR6
DMASFR6	DN	6-chloro-5-heptylpyrimidine-2,4(1H,3H)-dione
DMASFR6	HS	Investigative
DMASFR6	SN	CHEMBL435558; BDBM20059; 5-Substituted-6-chlorouracil, 5f
DMASFR6	DT	Small molecular drug
DMASFR6	PC	23648512
DMASFR6	MW	244.72
DMASFR6	FM	C11H17ClN2O2
DMASFR6	IC	InChI=1S/C11H17ClN2O2/c1-2-3-4-5-6-7-8-9(12)13-11(16)14-10(8)15/h2-7H2,1H3,(H2,13,14,15,16)
DMASFR6	CS	CCCCCCCC1=C(NC(=O)NC1=O)Cl
DMASFR6	IK	CIAJCIKDDKGJBP-UHFFFAOYSA-N
DMASFR6	IU	6-chloro-5-heptyl-1H-pyrimidine-2,4-dione
DMASFR6	DE	Discovery agent

DMP4V8Y	ID	DMP4V8Y
DMP4V8Y	DN	6-chloro-5-hexylpyrimidine-2,4(1H,3H)-dione
DMP4V8Y	HS	Investigative
DMP4V8Y	SN	CHEMBL234997; BDBM20058; 5-Substituted-6-chlorouracil, 5e
DMP4V8Y	DT	Small molecular drug
DMP4V8Y	PC	23648511
DMP4V8Y	MW	230.69
DMP4V8Y	FM	C10H15ClN2O2
DMP4V8Y	IC	InChI=1S/C10H15ClN2O2/c1-2-3-4-5-6-7-8(11)12-10(15)13-9(7)14/h2-6H2,1H3,(H2,12,13,14,15)
DMP4V8Y	CS	CCCCCCC1=C(NC(=O)NC1=O)Cl
DMP4V8Y	IK	KRFZZHACLHGMCH-UHFFFAOYSA-N
DMP4V8Y	IU	6-chloro-5-hexyl-1H-pyrimidine-2,4-dione
DMP4V8Y	DE	Discovery agent

DMUJSP7	ID	DMUJSP7
DMUJSP7	DN	6-chloro-5-pentylpyrimidine-2,4(1H,3H)-dione
DMUJSP7	HS	Investigative
DMUJSP7	SN	CHEMBL238183; BDBM20057; 5-Substituted-6-chlorouracil, 5d
DMUJSP7	DT	Small molecular drug
DMUJSP7	PC	23648510
DMUJSP7	MW	216.66
DMUJSP7	FM	C9H13ClN2O2
DMUJSP7	IC	InChI=1S/C9H13ClN2O2/c1-2-3-4-5-6-7(10)11-9(14)12-8(6)13/h2-5H2,1H3,(H2,11,12,13,14)
DMUJSP7	CS	CCCCCC1=C(NC(=O)NC1=O)Cl
DMUJSP7	IK	XCFUGRSUKUUBGJ-UHFFFAOYSA-N
DMUJSP7	IU	6-chloro-5-pentyl-1H-pyrimidine-2,4-dione
DMUJSP7	DE	Discovery agent

DM90JMN	ID	DM90JMN
DM90JMN	DN	6-chloro-5-phenylpyrimidine-2,4(1H,3H)-dione
DM90JMN	HS	Investigative
DM90JMN	SN	6-chloro-5-phenylpyrimidine-2,4(1H,3H)-dione; 1000680-77-2; CHEMBL235001; BDBM20065; 5-Substituted-6-chlorouracil, 10a
DM90JMN	DT	Small molecular drug
DM90JMN	PC	23648518
DM90JMN	MW	222.63
DM90JMN	FM	C10H7ClN2O2
DM90JMN	IC	InChI=1S/C10H7ClN2O2/c11-8-7(6-4-2-1-3-5-6)9(14)13-10(15)12-8/h1-5H,(H2,12,13,14,15)
DM90JMN	CS	C1=CC=C(C=C1)C2=C(NC(=O)NC2=O)Cl
DM90JMN	IK	ORRYLQRWCPCGJZ-UHFFFAOYSA-N
DM90JMN	IU	6-chloro-5-phenyl-1H-pyrimidine-2,4-dione
DM90JMN	DE	Discovery agent

DMB24LJ	ID	DMB24LJ
DMB24LJ	DN	6-chloro-5-propylpyrimidine-2,4(1H,3H)-dione
DMB24LJ	HS	Investigative
DMB24LJ	SN	6-chloro-5-propylpyrimidine-2,4(1H,3H)-dione; 19030-76-3; 5-propyl-6-chloro-uracil; CHEMBL394425; BDBM20055; 5-Substituted-6-chlorouracil, 5b
DMB24LJ	DT	Small molecular drug
DMB24LJ	PC	11095381
DMB24LJ	MW	188.61
DMB24LJ	FM	C7H9ClN2O2
DMB24LJ	IC	InChI=1S/C7H9ClN2O2/c1-2-3-4-5(8)9-7(12)10-6(4)11/h2-3H2,1H3,(H2,9,10,11,12)
DMB24LJ	CS	CCCC1=C(NC(=O)NC1=O)Cl
DMB24LJ	IK	DTSULQDNDBSJQV-UHFFFAOYSA-N
DMB24LJ	IU	6-chloro-5-propyl-1H-pyrimidine-2,4-dione
DMB24LJ	CA	CAS 19030-76-3
DMB24LJ	DE	Discovery agent

DM10A9S	ID	DM10A9S
DM10A9S	DN	6-Chloro-N-(2-morpholinoethyl)nicotinamide
DM10A9S	HS	Investigative
DM10A9S	SN	6-Chloro-N-(2-morpholinoethyl)nicotinamide; CHEMBL596768; 446269-58-5; 6-chloro-N-[2-(morpholin-4-yl)ethyl]pyridine-3-carboxamide; AC1LNWHD; Oprea1_139589; MLS001010907; CTK6H1374; cid_1228702; 6-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide; MolPort-000-431-678; HMS2765K07; ZINC19397174; BDBM50307188; AKOS000162940; MCULE-8413919053; SMR000352965; ST50046456; 6-chloro-N-(2-morpholin-4-ylethyl)nicotinamide; Z32410126; F1077-0095
DM10A9S	DT	Small molecular drug
DM10A9S	PC	1228702
DM10A9S	MW	269.73
DM10A9S	FM	C12H16ClN3O2
DM10A9S	IC	InChI=1S/C12H16ClN3O2/c13-11-2-1-10(9-15-11)12(17)14-3-4-16-5-7-18-8-6-16/h1-2,9H,3-8H2,(H,14,17)
DM10A9S	CS	C1COCCN1CCNC(=O)C2=CN=C(C=C2)Cl
DM10A9S	IK	DWSIBMFUHQAQMK-UHFFFAOYSA-N
DM10A9S	IU	6-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DM10A9S	DE	Discovery agent

DMPIFLA	ID	DMPIFLA
DMPIFLA	DN	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine
DMPIFLA	HS	Investigative
DMPIFLA	SN	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine; 4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397
DMPIFLA	DT	Small molecular drug
DMPIFLA	PC	5328819
DMPIFLA	MW	290.1
DMPIFLA	FM	C14H9Cl2N3
DMPIFLA	IC	InChI=1S/C14H9Cl2N3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DMPIFLA	CS	C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)Cl
DMPIFLA	IK	QKCFZLIUAVWYRM-UHFFFAOYSA-N
DMPIFLA	IU	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine
DMPIFLA	DE	Discovery agent

DM78I4P	ID	DM78I4P
DM78I4P	DN	6-Chloro-N-(3-morpholinopropyl)nicotinamide
DM78I4P	HS	Investigative
DM78I4P	SN	CHEMBL610499; 6-Chloro-N-(3-morpholinopropyl)nicotinamide; BDBM50307201
DM78I4P	DT	Small molecular drug
DM78I4P	PC	17144214
DM78I4P	MW	283.75
DM78I4P	FM	C13H18ClN3O2
DM78I4P	IC	InChI=1S/C13H18ClN3O2/c14-12-3-2-11(10-16-12)13(18)15-4-1-5-17-6-8-19-9-7-17/h2-3,10H,1,4-9H2,(H,15,18)
DM78I4P	CS	C1COCCN1CCCNC(=O)C2=CN=C(C=C2)Cl
DM78I4P	IK	CNQVNEPLCSJWDF-UHFFFAOYSA-N
DM78I4P	IU	6-chloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DM78I4P	DE	Discovery agent

DMUY9TF	ID	DMUY9TF
DMUY9TF	DN	6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide
DMUY9TF	HS	Investigative
DMUY9TF	SN	CHEMBL38911; 6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide; SCHEMBL8526818; LOMPSBWQXLVHJX-UHFFFAOYSA-N; BDBM50321876; 6-Chloro-1-(3-pyridylcarbamoyl)indoline; N-(3-Pyridinyl)-6-chloro-2,3-dihydro-1H-indole-1-carboxamide; 6-Chloro-2,3-dihydro-indole-1-carboxylic acid pyridin-3-ylamide
DMUY9TF	DT	Small molecular drug
DMUY9TF	PC	10730997
DMUY9TF	MW	273.72
DMUY9TF	FM	C14H12ClN3O
DMUY9TF	IC	InChI=1S/C14H12ClN3O/c15-11-4-3-10-5-7-18(13(10)8-11)14(19)17-12-2-1-6-16-9-12/h1-4,6,8-9H,5,7H2,(H,17,19)
DMUY9TF	CS	C1CN(C2=C1C=CC(=C2)Cl)C(=O)NC3=CN=CC=C3
DMUY9TF	IK	LOMPSBWQXLVHJX-UHFFFAOYSA-N
DMUY9TF	IU	6-chloro-N-pyridin-3-yl-2,3-dihydroindole-1-carboxamide
DMUY9TF	DE	Discovery agent

DMWB43U	ID	DMWB43U
DMWB43U	DN	6-Chloropurine Riboside, 5'-Monophosphate
DMWB43U	HS	Investigative
DMWB43U	SN	6-Cl-Purine Ribotide; CHEMBL1683023; 6-Chloropurine riboside 5'-phosphate; 6-Chloropurine riboside 5'-monophosphate; 6-Chloropurine ribotide; AC1L4ML7; AC1Q3SV8; 6-Chloroinosine monophosphate; SCHEMBL622623; 6-chloro-9-(5-o-phosphono-; A-d-ribofuranosyl)-9h-purine; ALOBOMYIOYNCBS-KQYNXXCUSA-N; ZINC13526959; BDBM50222697; A8843; 6-Chloropurine 9-beta-D-ribofuranosyl 5'-monophosphate; 6-Chloro-9-(5-O-phosphono-beta-D-ribofuranosyl)-9H-purine; [(2R,3S,4R,5R)-5-(6-chloropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen pho
DMWB43U	DT	Small molecular drug
DMWB43U	PC	17753915
DMWB43U	MW	367.66
DMWB43U	FM	C10H13ClN4O7P+
DMWB43U	IC	InChI=1S/C10H12ClN4O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,18,19,20)/p+1/t4-,6-,7-,10-/m1/s1
DMWB43U	CS	C1=[N+](C2=C(N1)C(=NC=N2)Cl)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
DMWB43U	IK	ALOBOMYIOYNCBS-KQYNXXCUSA-O
DMWB43U	IU	[(2R,3S,4R,5R)-5-(6-chloro-7H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMWB43U	DE	Discovery agent

DMV0C69	ID	DMV0C69
DMV0C69	DN	6-chlorotacrine hydrochloride
DMV0C69	HS	Investigative
DMV0C69	SN	6-chlorotacrine; 5778-84-7; 9-AMINO-6-CHLORO-1,2,3,4-TETRAHYDRO-ACRIDINE; Tacrine Analogue 4; 6-chlorotacrine.HCl; 6-Chlorotacrine HCl; 6-chloro-1,2,3,4-tetrahydroacridin-9-amine; SCHEMBL4271238; BDBM8987; ZINC5689; CHEMBL292314; GQZMDBQRGRRPMS-UHFFFAOYSA-N
DMV0C69	DT	Small molecular drug
DMV0C69	PC	10399068
DMV0C69	MW	232.71
DMV0C69	FM	C13H13ClN2
DMV0C69	IC	InChI=1S/C13H13ClN2/c14-8-5-6-10-12(7-8)16-11-4-2-1-3-9(11)13(10)15/h5-7H,1-4H2,(H2,15,16)
DMV0C69	CS	C1CCC2=NC3=C(C=CC(=C3)Cl)C(=C2C1)N
DMV0C69	IK	GQZMDBQRGRRPMS-UHFFFAOYSA-N
DMV0C69	IU	6-chloro-1,2,3,4-tetrahydroacridin-9-amine
DMV0C69	DE	Discovery agent

DMPULH3	ID	DMPULH3
DMPULH3	DN	6-cinnamoylhernandine
DMPULH3	HS	Investigative
DMPULH3	SN	6-cinnamoylhernandine; CHEMBL1097804
DMPULH3	DT	Small molecular drug
DMPULH3	PC	46888587
DMPULH3	MW	521.6
DMPULH3	FM	C29H31NO8
DMPULH3	IC	InChI=1S/C29H31NO8/c1-30-22(31)16-27-14-21(37-23(32)13-10-17-8-6-5-7-9-17)26(35-3)29(36-4)28(27,30)15-20(38-29)18-11-12-19(34-2)25(33)24(18)27/h5-13,20-21,26,33H,14-16H2,1-4H3/b13-10+/t20-,21-,26-,27+,28-,29+/m0/s1
DMPULH3	CS	CN1C(=O)C[C@@]23[C@]14C[C@@H](C5=C2C(=C(C=C5)OC)O)O[C@@]4([C@H]([C@H](C3)OC(=O)/C=C/C6=CC=CC=C6)OC)OC
DMPULH3	IK	KOKWRSAOHLOSAI-HXHZFJGXSA-N
DMPULH3	IU	[(1R,8S,10S,11S,12S,13S)-3-hydroxy-4,11,12-trimethoxy-17-methyl-16-oxo-18-oxa-17-azapentacyclo[8.4.3.18,11.01,10.02,7]octadeca-2(7),3,5-trien-13-yl] (E)-3-phenylprop-2-enoate
DMPULH3	DE	Discovery agent

DMPXS9F	ID	DMPXS9F
DMPXS9F	DN	6-cinnamoyl-N-methylstephasunoline
DMPXS9F	HS	Investigative
DMPXS9F	SN	CHEMBL1098354; 6-cinnamoyl-N-methylstephasunoline
DMPXS9F	DT	Small molecular drug
DMPXS9F	PC	46888570
DMPXS9F	MW	553.6
DMPXS9F	FM	C30H35NO9
DMPXS9F	IC	InChI=1S/C30H35NO9/c1-31-13-12-28-15-23(39-24(33)11-7-17-6-9-20(35-2)19(32)14-17)27(37-4)30(38-5)29(28,31)16-22(40-30)18-8-10-21(36-3)26(34)25(18)28/h6-11,14,22-23,27,32,34H,12-13,15-16H2,1-5H3/b11-7+/t22-,23-,27-,28-,29-,30+/m0/s1
DMPXS9F	CS	CN1CC[C@@]23[C@]14C[C@@H](C5=C2C(=C(C=C5)OC)O)O[C@@]4([C@H]([C@H](C3)OC(=O)/C=C/C6=CC(=C(C=C6)OC)O)OC)OC
DMPXS9F	IK	CDTWAPXUQYEAIP-YYRBTORNSA-N
DMPXS9F	IU	[(1S,8S,10S,11S,12S,13S)-3-hydroxy-4,11,12-trimethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.18,11.01,10.02,7]octadeca-2(7),3,5-trien-13-yl] (E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoate
DMPXS9F	DE	Discovery agent

DMNTDFV	ID	DMNTDFV
DMNTDFV	DN	6-Cl-IMP
DMNTDFV	HS	Investigative
DMNTDFV	SN	Hadacidin; N-FORMYL-N-HYDROXYGLYCINE; 689-13-4; Hadacidine; Asymmetrin; Hadacin; Nfhaa; N-Formyl hydroxyaminoacetic acid; UNII-BFO5P1010A; Glycine,N-formyl-N-hydroxy-; 2-(N-Hydroxyformamido)acetic acid; GLYCINE, N-FORMYL-N-HYDROXY-; NSC 72962; BRN 1927168; N-hydroxyformamidoacetic acid; CHEMBL331373; BFO5P1010A; CHEBI:43040; [formyl(hydroxy)amino]acetic acid; NSC 521778; N-formyl-N- hydroxyaminoacetic acid; hadicidine; SCHEMBL2115651; AC1L207A; DTXSID1043962; CTK5C8639; (Formyl-hydroxy-amino)-acetic acid; ZINC1482078
DMNTDFV	DT	Small molecular drug
DMNTDFV	PC	12717
DMNTDFV	MW	119.08
DMNTDFV	FM	C3H5NO4
DMNTDFV	IC	InChI=1S/C3H5NO4/c5-2-4(8)1-3(6)7/h2,8H,1H2,(H,6,7)
DMNTDFV	CS	C(C(=O)O)N(C=O)O
DMNTDFV	IK	URJHVPKUWOUENU-UHFFFAOYSA-N
DMNTDFV	IU	2-[formyl(hydroxy)amino]acetic acid
DMNTDFV	CA	CAS 689-13-4
DMNTDFV	CB	CHEBI:43040
DMNTDFV	DE	Discovery agent

DMKNOLV	ID	DMKNOLV
DMKNOLV	DN	6-Cl-MLT
DMKNOLV	HS	Investigative
DMKNOLV	SN	6-Cl-melatonin; 6-chloromelatonin
DMKNOLV	DT	Small molecular drug
DMKNOLV	PC	1858
DMKNOLV	MW	266.72
DMKNOLV	FM	C13H15ClN2O2
DMKNOLV	IC	InChI=1S/C13H15ClN2O2/c1-8(17)15-4-3-9-7-16-12-6-11(14)13(18-2)5-10(9)12/h5-7,16H,3-4H2,1-2H3,(H,15,17)
DMKNOLV	CS	CC(=O)NCCC1=CNC2=CC(=C(C=C21)OC)Cl
DMKNOLV	IK	LUINDDOUWHRIPW-UHFFFAOYSA-N
DMKNOLV	IU	N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKNOLV	CA	CAS 63762-74-3
DMKNOLV	CB	CHEBI:109545
DMKNOLV	DE	Discovery agent

DMACTDZ	ID	DMACTDZ
DMACTDZ	DN	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
DMACTDZ	HS	Investigative
DMACTDZ	SN	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-
DMACTDZ	DT	Small molecular drug
DMACTDZ	PC	4565
DMACTDZ	MW	357.8
DMACTDZ	FM	C18H20ClN5O
DMACTDZ	IC	InChI=1S/C18H20ClN5O/c19-13-7-4-8-14(9-13)22-18-23-16-15(20-11-21-16)17(24-18)25-10-12-5-2-1-3-6-12/h4,7-9,11-12H,1-3,5-6,10H2,(H2,20,21,22,23,24)
DMACTDZ	CS	C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)NC4=CC(=CC=C4)Cl
DMACTDZ	IK	OUEGMEMDEAOAEG-UHFFFAOYSA-N
DMACTDZ	IU	N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine
DMACTDZ	CA	CAS 444722-81-0
DMACTDZ	DE	Discovery agent

DM9IHYS	ID	DM9IHYS
DM9IHYS	DN	6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine
DM9IHYS	HS	Investigative
DM9IHYS	SN	6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N
DM9IHYS	DT	Small molecular drug
DM9IHYS	PC	5329597
DM9IHYS	MW	237.3
DM9IHYS	FM	C11H19N5O
DM9IHYS	IC	InChI=1S/C11H19N5O/c12-8-9(13)15-11(14)16-10(8)17-6-7-4-2-1-3-5-7/h7H,1-6,12H2,(H4,13,14,15,16)
DM9IHYS	CS	C1CCC(CC1)COC2=NC(=NC(=C2N)N)N
DM9IHYS	IK	IMNSQZHRHASLAR-UHFFFAOYSA-N
DM9IHYS	IU	6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine
DM9IHYS	DE	Discovery agent

DM6UP25	ID	DM6UP25
DM6UP25	DN	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine
DM6UP25	HS	Investigative
DM6UP25	SN	6-Cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine; CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine
DM6UP25	DT	Small molecular drug
DM6UP25	PC	447649
DM6UP25	MW	339.4
DM6UP25	FM	C18H21N5O2
DM6UP25	IC	InChI=1S/C18H21N5O2/c24-14-8-6-13(7-9-14)21-18-22-16-15(19-11-20-16)17(23-18)25-10-12-4-2-1-3-5-12/h6-9,11-12,24H,1-5,10H2,(H2,19,20,21,22,23)
DM6UP25	CS	C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)NC4=CC=C(C=C4)O
DM6UP25	IK	RFSDQDHHBKYQOD-UHFFFAOYSA-N
DM6UP25	IU	4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]phenol
DM6UP25	DE	Discovery agent

DM9HBY5	ID	DM9HBY5
DM9HBY5	DN	6-Deoxy-Alpha-D-Glucose
DM9HBY5	HS	Investigative
DM9HBY5	SN	alpha-D-Quinovopyranose; 6-deoxy-alpha-D-glucopyranose; UNII-68BDH91OBS; 68BDH91OBS; Isorhodeose; Isorhamnose; D-Epifucose; D-Glucomethylose; D-Chinovose; 6-DEOXY-ALPHA-D-GLUCOSE; 551-63-3; alpha-D-quinovose; 3h-6-deoxyglucose; alpha-D-Quinovose pyranose; AC1L9B8Y; SCHEMBL79180; CHEBI:42606; alpha-D-Glucopyranose, 6-deoxy-; ZINC2042980; DB03773; C08352; (2S,3R,4S,5S,6R)-6-methyloxane-2,3,4,5-tetrol
DM9HBY5	DT	Small molecular drug
DM9HBY5	PC	6713579
DM9HBY5	MW	164.16
DM9HBY5	FM	C6H12O5
DM9HBY5	IC	InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3-,4+,5-,6-/m0/s1
DM9HBY5	CS	C[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)O)O)O)O
DM9HBY5	IK	SHZGCJCMOBCMKK-QYESYBIKSA-N
DM9HBY5	IU	(2S,3S,4R,5R,6S)-6-methyloxane-2,3,4,5-tetrol
DM9HBY5	CA	CAS 71116-61-5
DM9HBY5	DE	Discovery agent

DMKPWN0	ID	DMKPWN0
DMKPWN0	DN	6-deoxymanzamine X
DMKPWN0	HS	Investigative
DMKPWN0	DT	Small molecular drug
DMKPWN0	PC	44445400
DMKPWN0	MW	564.8
DMKPWN0	FM	C36H44N4O2
DMKPWN0	IC	InChI=1S/C36H44N4O2/c41-35-16-7-3-1-2-4-8-19-39-21-15-29(34(24-39)23-36-17-13-25(42-36)10-9-20-40(36)33(34)35)28(22-35)31-32-27(14-18-37-31)26-11-5-6-12-30(26)38-32/h1,3,5-6,11-12,14,18,22,25,29,33,38,41H,2,4,7-10,13,15-17,19-21,23-24H2/b3-1-/t25-,29?,33+,34-,35-,36+/m0/s1
DMKPWN0	CS	C1CCN2CCC3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@]56N4CCC[C@H](O5)CC6)O)C7=NC=CC8=C7NC9=CC=CC=C89
DMKPWN0	IK	CLKZPQNKNPCQGL-NZGBLPSWSA-N
DMKPWN0	IU	(2R,4R,7S,12R,13S,16Z)-25-(9H-pyrido[3,4-b]indol-1-yl)-28-oxa-11,22-diazahexacyclo[11.11.2.12,22.14,7.02,12.04,11]octacosa-16,25-dien-13-ol
DMKPWN0	DE	Discovery agent

DMGZQNS	ID	DMGZQNS
DMGZQNS	DN	6-desoxonaltrexone
DMGZQNS	HS	Investigative
DMGZQNS	SN	6-desoxonaltrexone; CHEMBL511816; SCHEMBL3825815; XBPQMXFKKJADMC-WOUAJJJCSA-N; BDBM50278385; 3,14-Dihydroxy-17-cyclopropylmethyl-4,5alpha-epoxymorphinan
DMGZQNS	DT	Small molecular drug
DMGZQNS	PC	13374610
DMGZQNS	MW	327.4
DMGZQNS	FM	C20H25NO3
DMGZQNS	IC	InChI=1S/C20H25NO3/c22-14-6-5-13-10-15-20(23)7-1-2-16-19(20,17(13)18(14)24-16)8-9-21(15)11-12-3-4-12/h5-6,12,15-16,22-23H,1-4,7-11H2/t15-,16+,19-,20-/m1/s1
DMGZQNS	CS	C1C[C@H]2[C@@]34CCN([C@@H]([C@@]3(C1)O)CC5=C4C(=C(C=C5)O)O2)CC6CC6
DMGZQNS	IK	XBPQMXFKKJADMC-WOUAJJJCSA-N
DMGZQNS	IU	(4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DMGZQNS	DE	Discovery agent

DML2AC1	ID	DML2AC1
DML2AC1	DN	6-Dimethylamino-2-methyl-hex-4-ynal oxime
DML2AC1	HS	Investigative
DML2AC1	DT	Small molecular drug
DML2AC1	PC	91934661
DML2AC1	MW	168.24
DML2AC1	FM	C9H16N2O
DML2AC1	IC	InChI=1S/C9H16N2O/c1-9(8-10-12)6-4-5-7-11(2)3/h9H,6-8H2,1-3H3
DML2AC1	CS	CC(CC#CCN(C)C)CN=O
DML2AC1	IK	DMQFXDRNMHZPER-UHFFFAOYSA-N
DML2AC1	IU	N,N,5-trimethyl-6-nitrosohex-2-yn-1-amine
DML2AC1	DE	Discovery agent

DMBMRUI	ID	DMBMRUI
DMBMRUI	DN	6-ethyl-2,4-diisobutylaminopyrimidine
DMBMRUI	HS	Investigative
DMBMRUI	SN	CHEMBL484451; 6-ethyl-2,4-diisobutylaminopyrimidine
DMBMRUI	DT	Small molecular drug
DMBMRUI	PC	25133613
DMBMRUI	MW	250.38
DMBMRUI	FM	C14H26N4
DMBMRUI	IC	InChI=1S/C14H26N4/c1-6-12-7-13(15-8-10(2)3)18-14(17-12)16-9-11(4)5/h7,10-11H,6,8-9H2,1-5H3,(H2,15,16,17,18)
DMBMRUI	CS	CCC1=CC(=NC(=N1)NCC(C)C)NCC(C)C
DMBMRUI	IK	MQGNVQNFJZWUAO-UHFFFAOYSA-N
DMBMRUI	IU	6-ethyl-2-N,4-N-bis(2-methylpropyl)pyrimidine-2,4-diamine
DMBMRUI	DE	Discovery agent

DMUHOF4	ID	DMUHOF4
DMUHOF4	DN	6-Ethyl-2-phenyl-chromen-4-one
DMUHOF4	HS	Investigative
DMUHOF4	SN	CHEMBL134732; 288401-00-3; 6-Ethylflavone; CTK4G2218; DTXSID80451374; ZINC2573995; AKOS030553658
DMUHOF4	DT	Small molecular drug
DMUHOF4	PC	10999458
DMUHOF4	MW	250.29
DMUHOF4	FM	C17H14O2
DMUHOF4	IC	InChI=1S/C17H14O2/c1-2-12-8-9-16-14(10-12)15(18)11-17(19-16)13-6-4-3-5-7-13/h3-11H,2H2,1H3
DMUHOF4	CS	CCC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3
DMUHOF4	IK	ILUYTTQELSQWNA-UHFFFAOYSA-N
DMUHOF4	IU	6-ethyl-2-phenylchromen-4-one
DMUHOF4	CA	CAS 288401-00-3
DMUHOF4	DE	Discovery agent

DMLEUP2	ID	DMLEUP2
DMLEUP2	DN	6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone
DMLEUP2	HS	Investigative
DMLEUP2	SN	CHEMBL383080
DMLEUP2	DT	Small molecular drug
DMLEUP2	PC	11580305
DMLEUP2	MW	301.4
DMLEUP2	FM	C18H23NO3
DMLEUP2	IC	InChI=1S/C18H23NO3/c1-4-12(5-2)11-22-18(21)15-10-19-16-8-7-13(6-3)9-14(16)17(15)20/h7-10,12H,4-6,11H2,1-3H3,(H,19,20)
DMLEUP2	CS	CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCC(CC)CC
DMLEUP2	IK	ANYBYQLGVQJDTI-UHFFFAOYSA-N
DMLEUP2	IU	2-ethylbutyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMLEUP2	DE	Discovery agent

DMESU53	ID	DMESU53
DMESU53	DN	6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone
DMESU53	HS	Investigative
DMESU53	SN	CHEMBL377719
DMESU53	DT	Small molecular drug
DMESU53	PC	11529369
DMESU53	MW	287.35
DMESU53	FM	C17H21NO3
DMESU53	IC	InChI=1S/C17H21NO3/c1-4-11(3)10-21-17(20)14-9-18-15-7-6-12(5-2)8-13(15)16(14)19/h6-9,11H,4-5,10H2,1-3H3,(H,18,19)
DMESU53	CS	CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCC(C)CC
DMESU53	IK	CXKHROTTYJSKQI-UHFFFAOYSA-N
DMESU53	IU	2-methylbutyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMESU53	DE	Discovery agent

DM1POEA	ID	DM1POEA
DM1POEA	DN	6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone
DM1POEA	HS	Investigative
DM1POEA	SN	CHEMBL206071; 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone
DM1POEA	DT	Small molecular drug
DM1POEA	PC	11587331
DM1POEA	MW	287.35
DM1POEA	FM	C17H21NO3
DM1POEA	IC	InChI=1S/C17H21NO3/c1-4-12-5-6-15-13(9-12)16(19)14(10-18-15)17(20)21-8-7-11(2)3/h5-6,9-11H,4,7-8H2,1-3H3,(H,18,19)
DM1POEA	CS	CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCCC(C)C
DM1POEA	IK	YQYRRRVQWIMSFP-UHFFFAOYSA-N
DM1POEA	IU	3-methylbutyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DM1POEA	DE	Discovery agent

DMG05V1	ID	DMG05V1
DMG05V1	DN	6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone
DMG05V1	HS	Investigative
DMG05V1	SN	CHEMBL205528
DMG05V1	DT	Small molecular drug
DMG05V1	PC	11716193
DMG05V1	MW	287.35
DMG05V1	FM	C17H21NO3
DMG05V1	IC	InChI=1S/C17H21NO3/c1-4-11-7-8-15-13(9-11)16(19)14(10-18-15)17(20)21-12(5-2)6-3/h7-10,12H,4-6H2,1-3H3,(H,18,19)
DMG05V1	CS	CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OC(CC)CC
DMG05V1	IK	OLWFMJLLBYGGKS-UHFFFAOYSA-N
DMG05V1	IU	pentan-3-yl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMG05V1	DE	Discovery agent

DML9EU7	ID	DML9EU7
DML9EU7	DN	6-ethyl-3-i-propoxycarbonyl-4-quinolone
DML9EU7	HS	Investigative
DML9EU7	SN	CHEMBL205724
DML9EU7	DT	Small molecular drug
DML9EU7	PC	11586960
DML9EU7	MW	259.3
DML9EU7	FM	C15H17NO3
DML9EU7	IC	InChI=1S/C15H17NO3/c1-4-10-5-6-13-11(7-10)14(17)12(8-16-13)15(18)19-9(2)3/h5-9H,4H2,1-3H3,(H,16,17)
DML9EU7	CS	CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OC(C)C
DML9EU7	IK	XGNSUAGLUGPMKD-UHFFFAOYSA-N
DML9EU7	IU	propan-2-yl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DML9EU7	DE	Discovery agent

DMSGJM6	ID	DMSGJM6
DMSGJM6	DN	6-ethyl-3-pentoxycarbonyl-4-quinolone
DMSGJM6	HS	Investigative
DMSGJM6	SN	CHEMBL205252
DMSGJM6	DT	Small molecular drug
DMSGJM6	PC	11492986
DMSGJM6	MW	287.35
DMSGJM6	FM	C17H21NO3
DMSGJM6	IC	InChI=1S/C17H21NO3/c1-3-5-6-9-21-17(20)14-11-18-15-8-7-12(4-2)10-13(15)16(14)19/h7-8,10-11H,3-6,9H2,1-2H3,(H,18,19)
DMSGJM6	CS	CCCCCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DMSGJM6	IK	DEHHQRSKBIBSBX-UHFFFAOYSA-N
DMSGJM6	IU	pentyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMSGJM6	DE	Discovery agent

DMGVI08	ID	DMGVI08
DMGVI08	DN	6-ethyl-3-propoxycarbonyl-4-quinolone
DMGVI08	HS	Investigative
DMGVI08	SN	CHEMBL206068
DMGVI08	DT	Small molecular drug
DMGVI08	PC	11715856
DMGVI08	MW	259.3
DMGVI08	FM	C15H17NO3
DMGVI08	IC	InChI=1S/C15H17NO3/c1-3-7-19-15(18)12-9-16-13-6-5-10(4-2)8-11(13)14(12)17/h5-6,8-9H,3-4,7H2,1-2H3,(H,16,17)
DMGVI08	CS	CCCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DMGVI08	IK	RSBPUSKIUBSGGR-UHFFFAOYSA-N
DMGVI08	IU	propyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMGVI08	DE	Discovery agent

DMC1F2E	ID	DMC1F2E
DMC1F2E	DN	6-ethyl-3-propylaminocarbonyl-4-quinolone
DMC1F2E	HS	Investigative
DMC1F2E	SN	CHEMBL204566
DMC1F2E	DT	Small molecular drug
DMC1F2E	PC	11521736
DMC1F2E	MW	258.32
DMC1F2E	FM	C15H18N2O2
DMC1F2E	IC	InChI=1S/C15H18N2O2/c1-3-7-16-15(19)12-9-17-13-6-5-10(4-2)8-11(13)14(12)18/h5-6,8-9H,3-4,7H2,1-2H3,(H,16,19)(H,17,18)
DMC1F2E	CS	CCCNC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DMC1F2E	IK	YTLATZVRJZTHRQ-UHFFFAOYSA-N
DMC1F2E	IU	6-ethyl-4-oxo-N-propyl-1H-quinoline-3-carboxamide
DMC1F2E	DE	Discovery agent

DMOGETD	ID	DMOGETD
DMOGETD	DN	6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DMOGETD	HS	Investigative
DMOGETD	SN	CHEMBL206547; 6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6828050
DMOGETD	DT	Small molecular drug
DMOGETD	PC	10445833
DMOGETD	MW	270.32
DMOGETD	FM	C17H18O3
DMOGETD	IC	InChI=1S/C17H18O3/c1-4-15-16-9(2)13(18)7-5-11(16)12-6-8-14(19)10(3)17(12)20-15/h5-8,15,18-19H,4H2,1-3H3
DMOGETD	CS	CCC1C2=C(C=CC(=C2C)O)C3=C(O1)C(=C(C=C3)O)C
DMOGETD	IK	IAFZPZLQCDKQGG-UHFFFAOYSA-N
DMOGETD	IU	6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DMOGETD	DE	Discovery agent

DM9OD7U	ID	DM9OD7U
DM9OD7U	DN	6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE
DM9OD7U	HS	Investigative
DM9OD7U	SN	6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE; 2,4-Diamino-5-phenyl-6-ethylpyrimidine; UNII-KMJ59LN22F; 2,4-Diamino-6-ethyl-5-phenylpyrimidine; TCMDC-124296; Pyrimidine, 2,4-diamino-6-ethyl-5-phenyl-; 27653-49-2; BRN 0190097; KMJ59LN22F; GNF-PF-26; CHEMBL22148; Diamino-5-phenyl-6-ethylpyrimidine, 2,4-; CP7; 2,4-Pyrimidinediamine, 6-ethyl-5-phenyl-; AC1L3PJ1; Oprea1_813184; SCHEMBL3498787; CTK8H9609; BDBM18788; DTXSID70182029; XREDUPOVEQDQQS-UHFFFAOYSA-N; MolPort-002-484-045; ZINC13282257; AKOS003622581; MCULE-8548953211; DB07577
DM9OD7U	DT	Small molecular drug
DM9OD7U	PC	93114
DM9OD7U	MW	214.27
DM9OD7U	FM	C12H14N4
DM9OD7U	IC	InChI=1S/C12H14N4/c1-2-9-10(8-6-4-3-5-7-8)11(13)16-12(14)15-9/h3-7H,2H2,1H3,(H4,13,14,15,16)
DM9OD7U	CS	CCC1=C(C(=NC(=N1)N)N)C2=CC=CC=C2
DM9OD7U	IK	XREDUPOVEQDQQS-UHFFFAOYSA-N
DM9OD7U	IU	6-ethyl-5-phenylpyrimidine-2,4-diamine
DM9OD7U	CA	CAS 27653-49-2
DM9OD7U	DE	Discovery agent

DME4GBS	ID	DME4GBS
DME4GBS	DN	6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine
DME4GBS	HS	Investigative
DME4GBS	DT	Small molecular drug
DME4GBS	PC	44420925
DME4GBS	MW	424.5
DME4GBS	FM	C21H24N6O4
DME4GBS	IC	InChI=1S/C21H24N6O4/c1-2-14-16(28)17(29)20(31-14)27-10-24-15-18(22)25-21(26-19(15)27)30-8-7-11-9-23-13-6-4-3-5-12(11)13/h3-6,9-10,14,16-17,20,23,28-29H,2,7-8H2,1H3,(H2,22,25,26)/t14-,16-,17-,20-/m1/s1
DME4GBS	CS	CC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)OCCC4=CNC5=CC=CC=C54)N)O)O
DME4GBS	IK	USRXNKLXHDLOMQ-WVSUBDOOSA-N
DME4GBS	IU	(2R,3R,4S,5R)-2-[6-amino-2-[2-(1H-indol-3-yl)ethoxy]purin-9-yl]-5-ethyloxolane-3,4-diol
DME4GBS	DE	Discovery agent

DMPZIV0	ID	DMPZIV0
DMPZIV0	DN	6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one
DMPZIV0	HS	Investigative
DMPZIV0	SN	CHEMBL55412; AKOS003616217
DMPZIV0	DT	Small molecular drug
DMPZIV0	PC	21239768
DMPZIV0	MW	285.23
DMPZIV0	FM	C15H8FNO4
DMPZIV0	IC	InChI=1S/C15H8FNO4/c16-10-4-5-14-12(7-10)13(18)8-15(21-14)9-2-1-3-11(6-9)17(19)20/h1-8H
DMPZIV0	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=O)C3=C(O2)C=CC(=C3)F
DMPZIV0	IK	QKZNNAUSAVZXNE-UHFFFAOYSA-N
DMPZIV0	IU	6-fluoro-2-(3-nitrophenyl)chromen-4-one
DMPZIV0	DE	Discovery agent

DM2DTHV	ID	DM2DTHV
DM2DTHV	DN	6-fluoro-2-methyl-9H-carbazole
DM2DTHV	HS	Investigative
DM2DTHV	SN	CHEMBL1172721; 6-fluoro-2-methyl-9H-carbazole
DM2DTHV	DT	Small molecular drug
DM2DTHV	PC	44191658
DM2DTHV	MW	199.22
DM2DTHV	FM	C13H10FN
DM2DTHV	IC	InChI=1S/C13H10FN/c1-8-2-4-10-11-7-9(14)3-5-12(11)15-13(10)6-8/h2-7,15H,1H3
DM2DTHV	CS	CC1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)F
DM2DTHV	IK	YMJCUFBPZUBEGB-UHFFFAOYSA-N
DM2DTHV	IU	6-fluoro-2-methyl-9H-carbazole
DM2DTHV	DE	Discovery agent

DM4Q5TX	ID	DM4Q5TX
DM4Q5TX	DN	6-fluoro-5-phenylpyrimidine-2,4(1H,3H)-dione
DM4Q5TX	HS	Investigative
DM4Q5TX	SN	CHEMBL395907; BDBM20075; 6-Fluoro-5-phenylpyrimidine-2,4(1H,3H)-dione, 21
DM4Q5TX	DT	Small molecular drug
DM4Q5TX	PC	23648527
DM4Q5TX	MW	206.17
DM4Q5TX	FM	C10H7FN2O2
DM4Q5TX	IC	InChI=1S/C10H7FN2O2/c11-8-7(6-4-2-1-3-5-6)9(14)13-10(15)12-8/h1-5H,(H2,12,13,14,15)
DM4Q5TX	CS	C1=CC=C(C=C1)C2=C(NC(=O)NC2=O)F
DM4Q5TX	IK	BMLADZLRZDTUAA-UHFFFAOYSA-N
DM4Q5TX	IU	6-fluoro-5-phenyl-1H-pyrimidine-2,4-dione
DM4Q5TX	DE	Discovery agent

DMKFUO0	ID	DMKFUO0
DMKFUO0	DN	6-Fluoromelatonin
DMKFUO0	HS	Investigative
DMKFUO0	SN	6-Fluoromelatonin; 62106-00-7; CHEMBL333886; N-(2-(6-Fluoro-5-methoxy-1H-indol-3-yl)ethyl)acetamide; N-[2-(6-fluoro-5-methoxy-1H-indol-3-yl)ethyl]acetamide; ACETAMIDE, N-(2-(6-FLUORO-5-METHOXY-1H-INDOL-3-YL)ETHYL)-; AC1L2ASC; SCHEMBL1772618; SCHEMBL1772619; DTXSID10211165; BTTITVUHHXXLFM-UHFFFAOYSA-N; ZINC2032560; BDBM50330858; LS-9627; N-[2-(5-methoxy-6-fluoroindol-3-yl)ethyl]acetamide
DMKFUO0	DT	Small molecular drug
DMKFUO0	PC	43922
DMKFUO0	MW	250.27
DMKFUO0	FM	C13H15FN2O2
DMKFUO0	IC	InChI=1S/C13H15FN2O2/c1-8(17)15-4-3-9-7-16-12-6-11(14)13(18-2)5-10(9)12/h5-7,16H,3-4H2,1-2H3,(H,15,17)
DMKFUO0	CS	CC(=O)NCCC1=CNC2=CC(=C(C=C21)OC)F
DMKFUO0	IK	BTTITVUHHXXLFM-UHFFFAOYSA-N
DMKFUO0	IU	N-[2-(6-fluoro-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKFUO0	CA	CAS 62106-00-7
DMKFUO0	DE	Discovery agent

DMPZ92X	ID	DMPZ92X
DMPZ92X	DN	6-fluoromevalonate 5-diphosphate
DMPZ92X	HS	Investigative
DMPZ92X	SN	GTPL3205; 6-fluoro-3-hydroxy-5-{[hydroxy(phosphonooxy)phosphoryl]oxy}-3-methylhexanoic acid
DMPZ92X	DT	Small molecular drug
DMPZ92X	PC	56947062
DMPZ92X	MW	340.13
DMPZ92X	FM	C7H15FO10P2
DMPZ92X	IC	InChI=1S/C7H15FO10P2/c1-7(11,3-6(9)10)2-5(4-8)17-20(15,16)18-19(12,13)14/h5,11H,2-4H2,1H3,(H,9,10)(H,15,16)(H2,12,13,14)
DMPZ92X	CS	CC(CC(CF)OP(=O)(O)OP(=O)(O)O)(CC(=O)O)O
DMPZ92X	IK	YGLNCOGHKIHKSA-UHFFFAOYSA-N
DMPZ92X	IU	6-fluoro-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylhexanoic acid
DMPZ92X	DE	Discovery agent

DMZ26LS	ID	DMZ26LS
DMZ26LS	DN	6-fluoromevalonate pyrophosphate
DMZ26LS	HS	Investigative
DMZ26LS	SN	6-FMevPP
DMZ26LS	DT	Small molecular drug
DMZ26LS	PC	44306087
DMZ26LS	MW	326.11
DMZ26LS	FM	C6H13FO10P2
DMZ26LS	IC	InChI=1S/C6H13FO10P2/c7-4-6(10,3-5(8)9)1-2-16-19(14,15)17-18(11,12)13/h10H,1-4H2,(H,8,9)(H,14,15)(H2,11,12,13)/t6-/m1/s1
DMZ26LS	CS	C(COP(=O)(O)OP(=O)(O)O)[C@@](CC(=O)O)(CF)O
DMZ26LS	IK	YIGLDWRZXXHIGZ-ZCFIWIBFSA-N
DMZ26LS	IU	(3R)-3-(fluoromethyl)-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxypentanoic acid
DMZ26LS	DE	Discovery agent

DMA1QH0	ID	DMA1QH0
DMA1QH0	DN	6-Fluoro-N-(2-morpholinoethyl)nicotinamide
DMA1QH0	HS	Investigative
DMA1QH0	SN	6-Fluoro-N-(2-morpholinoethyl)nicotinamide; CHEMBL611061; BDBM50307187; AKOS013288891
DMA1QH0	DT	Small molecular drug
DMA1QH0	PC	46233363
DMA1QH0	MW	253.27
DMA1QH0	FM	C12H16FN3O2
DMA1QH0	IC	InChI=1S/C12H16FN3O2/c13-11-2-1-10(9-15-11)12(17)14-3-4-16-5-7-18-8-6-16/h1-2,9H,3-8H2,(H,14,17)
DMA1QH0	CS	C1COCCN1CCNC(=O)C2=CN=C(C=C2)F
DMA1QH0	IK	GHLPFUPTLVEUTA-UHFFFAOYSA-N
DMA1QH0	IU	6-fluoro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMA1QH0	DE	Discovery agent

DMVADTP	ID	DMVADTP
DMVADTP	DN	6-fluoro-N-m-tolylquinazolin-4-amine
DMVADTP	HS	Investigative
DMVADTP	SN	CHEMBL1079598; 6-fluoro-N-m-tolylquinazolin-4-amine; SCHEMBL8427296; BDBM50311857
DMVADTP	DT	Small molecular drug
DMVADTP	PC	21847810
DMVADTP	MW	253.27
DMVADTP	FM	C15H12FN3
DMVADTP	IC	InChI=1S/C15H12FN3/c1-10-3-2-4-12(7-10)19-15-13-8-11(16)5-6-14(13)17-9-18-15/h2-9H,1H3,(H,17,18,19)
DMVADTP	CS	CC1=CC(=CC=C1)NC2=NC=NC3=C2C=C(C=C3)F
DMVADTP	IK	UBPLAEHESGUBAD-UHFFFAOYSA-N
DMVADTP	IU	6-fluoro-N-(3-methylphenyl)quinazolin-4-amine
DMVADTP	DE	Discovery agent

DMF2RGY	ID	DMF2RGY
DMF2RGY	DN	6-fluoro-noradrenaline
DMF2RGY	HS	Investigative
DMF2RGY	SN	6-fluoronorepinephrine; 6-fluoro-NE
DMF2RGY	DT	Small molecular drug
DMF2RGY	PC	1862
DMF2RGY	MW	187.17
DMF2RGY	FM	C8H10FNO3
DMF2RGY	IC	InChI=1S/C8H10FNO3/c9-5-2-7(12)6(11)1-4(5)8(13)3-10/h1-2,8,11-13H,3,10H2
DMF2RGY	CS	C1=C(C(=CC(=C1O)O)F)C(CN)O
DMF2RGY	IK	SBUQBFTXTZSRMH-UHFFFAOYSA-N
DMF2RGY	IU	4-(2-amino-1-hydroxyethyl)-5-fluorobenzene-1,2-diol
DMF2RGY	CA	CAS 86820-21-5
DMF2RGY	CB	CHEBI:125398
DMF2RGY	DE	Discovery agent

DMPWXI8	ID	DMPWXI8
DMPWXI8	DN	6-fluoronorepinehprine
DMPWXI8	HS	Investigative
DMPWXI8	SN	6-fluoronorepinehprine; CHEMBL295072; 2-Fluoronorepinephrine; fluoronorepinephrine; BDBM50087518
DMPWXI8	DT	Small molecular drug
DMPWXI8	PC	10352428
DMPWXI8	MW	187.17
DMPWXI8	FM	C8H10FNO3
DMPWXI8	IC	InChI=1S/C8H10FNO3/c9-7-4(6(12)3-10)1-2-5(11)8(7)13/h1-2,6,11-13H,3,10H2/t6-/m0/s1
DMPWXI8	CS	C1=CC(=C(C(=C1[C@H](CN)O)F)O)O
DMPWXI8	IK	FOTRTWXNJQSQJS-LURJTMIESA-N
DMPWXI8	IU	4-[(1R)-2-amino-1-hydroxyethyl]-3-fluorobenzene-1,2-diol
DMPWXI8	DE	Discovery agent

DMS325C	ID	DMS325C
DMS325C	DN	6-fluoropyridin-3-ylboronic acid
DMS325C	HS	Investigative
DMS325C	SN	351019-18-6; 2-Fluoropyridine-5-boronic acid; 2-Fluoro-5-pyridylboronic acid; (6-fluoropyridin-3-yl)boronic Acid; 6-fluoropyridine-3-boronic acid; 2-fluoro-5-pyridineboronic acid; 2-fluoropyridin-5-ylboronic acid; 6-fluoropyridin-3-ylboronic acid; 2-fluoropyridin-5-boronic acid; 6-Fluoro-3-pyridinylboronic acid; 6-Fluoro-3-pyridylboronic Acid; 6-fluoropyridin-3-yl-3-boronic acid; 6-FLUORO-3-PYRIDINEBORONIC ACID; (6-fluoropyridin-3-yl)boranediol; BORONIC ACID, (6-FLUORO-3-PYRIDINYL)-; (6-fluoro-3-pyridyl)boronic acid
DMS325C	DT	Small molecular drug
DMS325C	PC	2783397
DMS325C	MW	140.91
DMS325C	FM	C5H5BFNO2
DMS325C	IC	InChI=1S/C5H5BFNO2/c7-5-2-1-4(3-8-5)6(9)10/h1-3,9-10H
DMS325C	CS	B(C1=CN=C(C=C1)F)(O)O
DMS325C	IK	OJBYZWHAPXIJID-UHFFFAOYSA-N
DMS325C	IU	(6-fluoropyridin-3-yl)boronic acid
DMS325C	CA	CAS 351019-18-6
DMS325C	DE	Discovery agent

DM6YD3U	ID	DM6YD3U
DM6YD3U	DN	6-fluorotryptophan
DM6YD3U	HS	Investigative
DM6YD3U	SN	6-Fluoro-DL-tryptophan; 7730-20-3; 6-fluorotryptophan; 2-amino-3-(6-fluoro-1H-indol-3-yl)propanoic acid; DL-Tryptophan, 6-fluoro-; DL-6-Fluorotryptophane; (+-)-6-Fluorotryptophan; Tryptophan, 6-fluoro-, DL-; NSC 9364; 6-fluoro-D,L-tryptophan; EINECS 231-788-6; BRN 0482552; Tryptophan, 6-fluoro-; ST072163; 2-amino-3-(6-fluoroindol-3-yl)propanoic acid; 6-Fluoro-DL-tryptophan, 97%; D-Tryptophan, 6-fluoro-; 343-92-0; 6-Fluorotryptophan, DL-; ACMC-20mbi4; AC1Q5S5W; SCHEMBL248870; GTPL5126; CHEMBL472222; AC1L3T80; SCHEMBL18029199
DM6YD3U	DT	Small molecular drug
DM6YD3U	PC	94937
DM6YD3U	MW	222.22
DM6YD3U	FM	C11H11FN2O2
DM6YD3U	IC	InChI=1S/C11H11FN2O2/c12-7-1-2-8-6(3-9(13)11(15)16)5-14-10(8)4-7/h1-2,4-5,9,14H,3,13H2,(H,15,16)
DM6YD3U	CS	C1=CC2=C(C=C1F)NC=C2CC(C(=O)O)N
DM6YD3U	IK	YMEXGEAJNZRQEH-UHFFFAOYSA-N
DM6YD3U	IU	2-amino-3-(6-fluoro-1H-indol-3-yl)propanoic acid
DM6YD3U	CA	CAS 7730-20-3
DM6YD3U	DE	Discovery agent

DMN84RM	ID	DMN84RM
DMN84RM	DN	6-Formylindolo[3,2-b]carbazole
DMN84RM	HS	Investigative
DMN84RM	SN	Indolo[3,2-b]carbazole-6-carbaldehyde; 1555757-10-2; indolo[3,2-b]carbazole-12-carbaldehyde; SCHEMBL528518; ANW-57186; MFCD23140892; ZINC39957465; AKOS015837457; AKOS025396684; FT-0678209
DMN84RM	DT	Small molecular drug
DMN84RM	PC	22245026
DMN84RM	MW	282.3
DMN84RM	FM	C19H10N2O
DMN84RM	IC	InChI=1S/C19H10N2O/c22-10-14-18-12-6-2-4-8-16(12)20-17(18)9-13-11-5-1-3-7-15(11)21-19(13)14/h1-10H
DMN84RM	CS	C1=CC2=C3C=C4C(=C5C=CC=CC5=N4)C(=C3N=C2C=C1)C=O
DMN84RM	IK	OTWFDHQTFRXSAK-UHFFFAOYSA-N
DMN84RM	IU	indolo[3,2-b]carbazole-12-carbaldehyde
DMN84RM	DE	Dermatitis

DMOLIW4	ID	DMOLIW4
DMOLIW4	DN	6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine
DMOLIW4	HS	Investigative
DMOLIW4	SN	CHEMBL194383; 6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine; SCHEMBL3272682
DMOLIW4	DT	Small molecular drug
DMOLIW4	PC	44401799
DMOLIW4	MW	305.33
DMOLIW4	FM	C17H15N5O
DMOLIW4	IC	InChI=1S/C17H15N5O/c18-17-20-14(13-7-4-10-23-13)15-16(21-17)22(11-19-15)9-8-12-5-2-1-3-6-12/h1-7,10-11H,8-9H2,(H2,18,20,21)
DMOLIW4	CS	C1=CC=C(C=C1)CCN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DMOLIW4	IK	LOCNLYLIABVQFH-UHFFFAOYSA-N
DMOLIW4	IU	6-(furan-2-yl)-9-(2-phenylethyl)purin-2-amine
DMOLIW4	DE	Discovery agent

DMSJP6T	ID	DMSJP6T
DMSJP6T	DN	6-Furan-2-yl-9-phenyl-9H-purin-2-ylamine
DMSJP6T	HS	Investigative
DMSJP6T	SN	CHEMBL439336; 6-Furan-2-yl-9-phenyl-9H-purin-2-ylamine
DMSJP6T	DT	Small molecular drug
DMSJP6T	PC	44401937
DMSJP6T	MW	277.28
DMSJP6T	FM	C15H11N5O
DMSJP6T	IC	InChI=1S/C15H11N5O/c16-15-18-12(11-7-4-8-21-11)13-14(19-15)20(9-17-13)10-5-2-1-3-6-10/h1-9H,(H2,16,18,19)
DMSJP6T	CS	C1=CC=C(C=C1)N2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DMSJP6T	IK	VEZSQJIGMFDZRT-UHFFFAOYSA-N
DMSJP6T	IU	6-(furan-2-yl)-9-phenylpurin-2-amine
DMSJP6T	DE	Discovery agent

DMM86PK	ID	DMM86PK
DMM86PK	DN	6-guanidino-2-(3''-indolylethyloxy)adenosine
DMM86PK	HS	Investigative
DMM86PK	DT	Small molecular drug
DMM86PK	PC	44420924
DMM86PK	MW	438.4
DMM86PK	FM	C20H22N8O4
DMM86PK	IC	InChI=1S/C20H22N8O4/c21-16(22)15-13(29)14(30)19(32-15)28-8-25-12-17(23)26-20(27-18(12)28)31-6-5-9-7-24-11-4-2-1-3-10(9)11/h1-4,7-8,13-15,19,24,29-30H,5-6H2,(H3,21,22)(H2,23,26,27)/t13-,14+,15-,19+/m0/s1
DMM86PK	CS	C1=CC=C2C(=C1)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)C(=N)N)O)O)N
DMM86PK	IK	AWBHOELFSQMGIY-QCUYGVNKSA-N
DMM86PK	IU	(2R,3S,4R,5R)-5-[6-amino-2-[2-(1H-indol-3-yl)ethoxy]purin-9-yl]-3,4-dihydroxyoxolane-2-carboximidamide
DMM86PK	DE	Discovery agent

DMF3W15	ID	DMF3W15
DMF3W15	DN	6-Heptyl-4-hydroxy-3-octanoyl-pyran-2-one
DMF3W15	HS	Investigative
DMF3W15	SN	CHEMBL269138; 6-Heptyl-4-hydroxy-3-octanoyl-pyran-2-one; SCHEMBL10337594; BDBM50024653
DMF3W15	DT	Small molecular drug
DMF3W15	PC	54678949
DMF3W15	MW	336.5
DMF3W15	FM	C20H32O4
DMF3W15	IC	InChI=1S/C20H32O4/c1-3-5-7-9-11-13-16-15-18(22)19(20(23)24-16)17(21)14-12-10-8-6-4-2/h15,22H,3-14H2,1-2H3
DMF3W15	CS	CCCCCCCC1=CC(=C(C(=O)O1)C(=O)CCCCCCC)O
DMF3W15	IK	UXMFHBGEDUHLJO-UHFFFAOYSA-N
DMF3W15	IU	6-heptyl-4-hydroxy-3-octanoylpyran-2-one
DMF3W15	DE	Discovery agent

DMWLN2Y	ID	DMWLN2Y
DMWLN2Y	DN	6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium
DMWLN2Y	HS	Investigative
DMWLN2Y	SN	CHEMBL441868; 6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium
DMWLN2Y	DT	Small molecular drug
DMWLN2Y	PC	44419706
DMWLN2Y	MW	227.28
DMWLN2Y	FM	C14H15N2O+
DMWLN2Y	IC	InChI=1S/C14H14N2O/c1-9-14-11(6-7-15(9)2)12-8-10(17)4-5-13(12)16(14)3/h4-8H,1-3H3/p+1
DMWLN2Y	CS	CC1=[N+](C=CC2=C1N(C3=C2C=C(C=C3)O)C)C
DMWLN2Y	IK	CHMZSXAIQRLCLX-UHFFFAOYSA-O
DMWLN2Y	IU	1,2,9-trimethylpyrido[3,4-b]indol-2-ium-6-ol
DMWLN2Y	DE	Discovery agent

DM20DAG	ID	DM20DAG
DM20DAG	DN	6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DM20DAG	HS	Investigative
DM20DAG	SN	CHEMBL375862; 6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DM20DAG	DT	Small molecular drug
DM20DAG	PC	44419702
DM20DAG	MW	213.25
DM20DAG	FM	C13H13N2O+
DM20DAG	IC	InChI=1S/C13H12N2O/c1-8-13-10(5-6-15(8)2)11-7-9(16)3-4-12(11)14-13/h3-7,16H,1-2H3/p+1
DM20DAG	CS	CC1=[N+](C=CC2=C1NC3=C2C=C(C=C3)O)C
DM20DAG	IK	ICPRLZDLIOARIN-UHFFFAOYSA-O
DM20DAG	IU	1,2-dimethyl-9H-pyrido[3,4-b]indol-2-ium-6-ol
DM20DAG	DE	Discovery agent

DMPSOIF	ID	DMPSOIF
DMPSOIF	DN	6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE
DMPSOIF	HS	Investigative
DMPSOIF	SN	6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE; 6-Hydroxy-2-benzothiazolesulfonamide; CHEMBL6685; 6-Hydroxybenzothiazole-2-sulfonamide; ZEC; 1zfq; AC1OA9RN; SCHEMBL160105; BDBM10874; NOOBQTYVTDBXTL-UHFFFAOYSA-N; AKOS022657291; aromatic/heteroaromatic sulfonamide 19; DB08765
DMPSOIF	DT	Small molecular drug
DMPSOIF	PC	6852129
DMPSOIF	MW	230.3
DMPSOIF	FM	C7H6N2O3S2
DMPSOIF	IC	InChI=1S/C7H6N2O3S2/c8-14(11,12)7-9-5-2-1-4(10)3-6(5)13-7/h1-3,10H,(H2,8,11,12)
DMPSOIF	CS	C1=CC2=C(C=C1O)SC(=N2)S(=O)(=O)N
DMPSOIF	IK	NOOBQTYVTDBXTL-UHFFFAOYSA-N
DMPSOIF	IU	6-hydroxy-1,3-benzothiazole-2-sulfonamide
DMPSOIF	CA	CAS 29927-14-8
DMPSOIF	DE	Discovery agent

DMUD1CG	ID	DMUD1CG
DMUD1CG	DN	6-Hydroxy-1,6-Dihydro Purine Nucleoside
DMUD1CG	HS	Investigative
DMUD1CG	SN	6-Hydroxy-1,6-Dihydro Purine Nucleoside; PRH; AC1NRCV9; DB03015; (6S)-6-hydroxy-9-beta-D-ribofuranosyl-6,9-dihydro-1H-purin-7-ium
DMUD1CG	DT	Small molecular drug
DMUD1CG	PC	5289205
DMUD1CG	MW	271.25
DMUD1CG	FM	C10H15N4O5+
DMUD1CG	IC	InChI=1S/C10H14N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,9-10,15-18H,1H2,(H,11,12)/p+1/t4-,6-,7-,9+,10-/m1/s1
DMUD1CG	CS	C1=N[C@H](C2=C(N1)[N+](=CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O
DMUD1CG	IK	WGRXVKRHIMUTPD-YOHZANMFSA-O
DMUD1CG	IU	(2R,3R,4S,5R)-2-[(6S)-6-hydroxy-6,7-dihydro-3H-purin-9-ium-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMUD1CG	DE	Discovery agent

DMU1CGD	ID	DMU1CGD
DMU1CGD	DN	6-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one
DMU1CGD	HS	Investigative
DMU1CGD	SN	CHEMBL56345; 6-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one; BDBM50077322
DMU1CGD	DT	Small molecular drug
DMU1CGD	PC	10539813
DMU1CGD	MW	268.26
DMU1CGD	FM	C16H12O4
DMU1CGD	IC	InChI=1S/C16H12O4/c17-11-3-1-10(2-4-11)7-13-9-15(19)14-8-12(18)5-6-16(14)20-13/h1-6,8-9,17-18H,7H2
DMU1CGD	CS	C1=CC(=CC=C1CC2=CC(=O)C3=C(O2)C=CC(=C3)O)O
DMU1CGD	IK	LSIKXKVRDNWDKN-UHFFFAOYSA-N
DMU1CGD	IU	6-hydroxy-2-[(4-hydroxyphenyl)methyl]chromen-4-one
DMU1CGD	DE	Discovery agent

DMNA2M6	ID	DMNA2M6
DMNA2M6	DN	6-hydroxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMNA2M6	HS	Investigative
DMNA2M6	SN	CHEMBL373651; 6-hydroxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMNA2M6	DT	Small molecular drug
DMNA2M6	PC	44419701
DMNA2M6	MW	213.25
DMNA2M6	FM	C13H13N2O+
DMNA2M6	IC	InChI=1S/C13H12N2O/c1-14-6-5-10-11-7-9(16)3-4-12(11)15(2)13(10)8-14/h3-8H,1-2H3/p+1
DMNA2M6	CS	CN1C2=C(C=C(C=C2)O)C3=C1C=[N+](C=C3)C
DMNA2M6	IK	OEJPDCAOADNKRJ-UHFFFAOYSA-O
DMNA2M6	IU	2,9-dimethylpyrido[3,4-b]indol-2-ium-6-ol
DMNA2M6	DE	Discovery agent

DMAK35M	ID	DMAK35M
DMAK35M	DN	6-hydroxy-2-methyl-9H-beta-carbolin-2-ium
DMAK35M	HS	Investigative
DMAK35M	SN	6-hydroxy-2-methyl-9H-beta-carbolin-2-ium; CHEMBL220905; 2-methyl-beta-carbolinium-6-ol; CHEBI:59956; 2-methyl-9H-pyrido[3,4-b]indol-2-ium-6-ol
DMAK35M	DT	Small molecular drug
DMAK35M	PC	44419700
DMAK35M	MW	199.23
DMAK35M	FM	C12H11N2O+
DMAK35M	IC	InChI=1S/C12H10N2O/c1-14-5-4-9-10-6-8(15)2-3-11(10)13-12(9)7-14/h2-7,15H,1H3/p+1
DMAK35M	CS	C[N+]1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)O
DMAK35M	IK	FTXCPBMJKVPYRT-UHFFFAOYSA-O
DMAK35M	IU	2-methyl-9H-pyrido[3,4-b]indol-2-ium-6-ol
DMAK35M	CB	CHEBI:59956
DMAK35M	DE	Discovery agent

DM4F5OG	ID	DM4F5OG
DM4F5OG	DN	6-hydroxy-3-(3',5'-dihydroxyphenyl)coumarin
DM4F5OG	HS	Investigative
DM4F5OG	SN	CHEMBL199397; BDBM50176526
DM4F5OG	DT	Small molecular drug
DM4F5OG	PC	11536337
DM4F5OG	MW	270.24
DM4F5OG	FM	C15H10O5
DM4F5OG	IC	InChI=1S/C15H10O5/c16-10-1-2-14-9(5-10)6-13(15(19)20-14)8-3-11(17)7-12(18)4-8/h1-7,16-18H
DM4F5OG	CS	C1=CC2=C(C=C1O)C=C(C(=O)O2)C3=CC(=CC(=C3)O)O
DM4F5OG	IK	DKFCOAXLNVHDTF-UHFFFAOYSA-N
DM4F5OG	IU	3-(3,5-dihydroxyphenyl)-6-hydroxychromen-2-one
DM4F5OG	DE	Discovery agent

DM0CVTI	ID	DM0CVTI
DM0CVTI	DN	6-Hydroxy-5,7-dimethyl-beta-carboline
DM0CVTI	HS	Investigative
DM0CVTI	SN	CHEMBL458558; 6-Hydroxy-5,7-dimethyl-beta-carboline
DM0CVTI	DT	Small molecular drug
DM0CVTI	PC	44567438
DM0CVTI	MW	212.25
DM0CVTI	FM	C13H12N2O
DM0CVTI	IC	InChI=1S/C13H12N2O/c1-7-5-10-12(8(2)13(7)16)9-3-4-14-6-11(9)15-10/h3-6,15-16H,1-2H3
DM0CVTI	CS	CC1=CC2=C(C(=C1O)C)C3=C(N2)C=NC=C3
DM0CVTI	IK	RRUTVQQPPTZUTL-UHFFFAOYSA-N
DM0CVTI	IU	5,7-dimethyl-9H-pyrido[3,4-b]indol-6-ol
DM0CVTI	DE	Discovery agent

DMNM1EZ	ID	DMNM1EZ
DMNM1EZ	DN	6-Hydroxy-7,8-Dihydro Purine Nucleoside
DMNM1EZ	HS	Investigative
DMNM1EZ	DT	Small molecular drug
DMNM1EZ	PC	136254582
DMNM1EZ	MW	270.24
DMNM1EZ	FM	C10H14N4O5
DMNM1EZ	IC	InChI=1S/C10H14N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2,4,6-7,10,13,15-17H,1,3H2,(H,11,12,18)/t4-,6-,7+,10+/m0/s1
DMNM1EZ	CS	C1NC2=C(N1[C@H]3[C@@H]([C@H]([C@@H](O3)CO)O)O)N=CNC2=O
DMNM1EZ	IK	ZWTNXGIZBOQCAJ-FCIPNVEPSA-N
DMNM1EZ	IU	9-[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-1H-purin-6-one
DMNM1EZ	DE	Discovery agent

DMPQTNK	ID	DMPQTNK
DMPQTNK	DN	6-hydroxy-7,9-octadecadiynoic acid
DMPQTNK	HS	Investigative
DMPQTNK	SN	6-hydroxy-7,9-octadecadiynoic acid; CHEMBL448462; SCHEMBL3199736; 6-Hydroxyoctadeca-7,9-diynoic acid; LMFA01031024
DMPQTNK	DT	Small molecular drug
DMPQTNK	PC	14309408
DMPQTNK	MW	292.4
DMPQTNK	FM	C18H28O3
DMPQTNK	IC	InChI=1S/C18H28O3/c1-2-3-4-5-6-7-8-9-10-11-14-17(19)15-12-13-16-18(20)21/h17,19H,2-8,12-13,15-16H2,1H3,(H,20,21)
DMPQTNK	CS	CCCCCCCCC#CC#CC(CCCCC(=O)O)O
DMPQTNK	IK	APWVQFPFWVNZPF-UHFFFAOYSA-N
DMPQTNK	IU	6-hydroxyoctadeca-7,9-diynoic acid
DMPQTNK	DE	Discovery agent

DMDRSNH	ID	DMDRSNH
DMDRSNH	DN	6-hydroxybenzo[d][1,3]oxathiol-2-one
DMDRSNH	HS	Investigative
DMDRSNH	SN	Tioxolone; 4991-65-5; 6-Hydroxy-1,3-benzoxathiol-2-one; Thioxolone; 6-hydroxybenzo[d][1,3]oxathiol-2-one; Camyna; Tioxolon; Thioxalone; Tioxolonum; Tioxolona; 1,3-Benzoxathiol-2-one, 6-hydroxy-; Tioxolonum [INN-Latin]; UNII-S0FAJ1R9CD; Tioxolona [INN-Spanish]; 6-Hydro-2-oxo-1,3-benzoxathiole; C7H4O3S; 6-hydroxy-2H-1,3-benzoxathiol-2-one; EINECS 225-653-0; S0FAJ1R9CD; CHEMBL442687; CHEBI:568021; SLYPOVJCSQHITR-UHFFFAOYSA-N; NCGC00095003-01; Acnosan; 5-Hydroxy-1,3-benzothioxol-2-one; 6-hydroxybenzo[d]1,3-oxathiolen-2-one
DMDRSNH	DT	Small molecular drug
DMDRSNH	PC	72139
DMDRSNH	MW	168.17
DMDRSNH	FM	C7H4O3S
DMDRSNH	IC	InChI=1S/C7H4O3S/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3,8H
DMDRSNH	CS	C1=CC2=C(C=C1O)OC(=O)S2
DMDRSNH	IK	SLYPOVJCSQHITR-UHFFFAOYSA-N
DMDRSNH	IU	6-hydroxy-1,3-benzoxathiol-2-one
DMDRSNH	CA	CAS 4991-65-5
DMDRSNH	CB	CHEBI:568021
DMDRSNH	DE	Discovery agent

DM2B4S5	ID	DM2B4S5
DM2B4S5	DN	6-Hydroxy-benzothiazole-2-sulfonic acid amide
DM2B4S5	HS	Investigative
DM2B4S5	SN	6-hydroxybenzo[d]thiazole-2-sulfonamide
DM2B4S5	DE	Discovery agent

DM7M58P	ID	DM7M58P
DM7M58P	DN	6-hydroxydopa quinone
DM7M58P	HS	Investigative
DM7M58P	SN	Topa quinone; topaquinone; 6-hydroxydopa quinone; L-topaquinone; 6-Hydroxydopaquinone; 2,4,5-trihydroxyphenylalanine quinone; 135791-48-9; 64192-68-3; 3-(6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl)-l-alanine; 5-(2-CARBOXY-2-AMINOETHYL)-2-HYDROXY-1,4-BENZOQUINONE; (2S)-2-amino-3-(6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl)propanoic acid; o-Topaquinone; 6-Hydroxyphenylalanine-3,4-dione; L-topaquinone residue; 5-(2-CARBOXY-2-AMINOETHYL)-4-HYDROXY-1,2-BENZOQUINONE; AC1Q6BVC; AC1L3XGD; TPQ; 2',4',5'-topaquinone; SCHEMBL1781673
DM7M58P	DT	Small molecular drug
DM7M58P	PC	123871
DM7M58P	MW	211.17
DM7M58P	FM	C9H9NO5
DM7M58P	IC	InChI=1S/C9H9NO5/c10-5(9(14)15)1-4-2-7(12)8(13)3-6(4)11/h2-3,5,11H,1,10H2,(H,14,15)/t5-/m0/s1
DM7M58P	CS	C1=C(C(=CC(=O)C1=O)O)C[C@@H](C(=O)O)N
DM7M58P	IK	YWRFBISQAMHSIX-YFKPBYRVSA-N
DM7M58P	IU	(2S)-2-amino-3-(6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl)propanoic acid
DM7M58P	CA	CAS 64192-68-3
DM7M58P	CB	CHEBI:36076
DM7M58P	DE	Discovery agent

DM6FNVC	ID	DM6FNVC
DM6FNVC	DN	6-Hydroxyflavanone
DM6FNVC	HS	Investigative
DM6FNVC	SN	6-Hydroxyflavanone; 4250-77-5; 6-hydroxy-2-phenylchroman-4-one; 6-hydroxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; 6-Hydroxy-Flavanone; CHEMBL195033; 4H-1-Benzopyran-4-one, 2,3-dihydro-6-hydroxy-2-phenyl-; CHEBI:34471; XYHWPQUEOOBIOW-UHFFFAOYSA-N; 6-hydroxy-2-phenyl-chroman-4-one; MFCD00017485; 6-hydroxy-2-phenyl-2,3-dihydrochromen-4-one; Flavanone, 6-hydroxy-; (+/-)-6-Hydroxyflavanone; 6 - Hydroxyflavanone; ACMC-209jpu; AC1MC1GQ; Maybridge3_000570; 6-Hydroxyflavanone, 99%; bmse000985; C14221; Oprea1_761592; SCHEMBL126598
DM6FNVC	DT	Small molecular drug
DM6FNVC	PC	2734580
DM6FNVC	MW	240.25
DM6FNVC	FM	C15H12O3
DM6FNVC	IC	InChI=1S/C15H12O3/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-8,15-16H,9H2
DM6FNVC	CS	C1C(OC2=C(C1=O)C=C(C=C2)O)C3=CC=CC=C3
DM6FNVC	IK	XYHWPQUEOOBIOW-UHFFFAOYSA-N
DM6FNVC	IU	6-hydroxy-2-phenyl-2,3-dihydrochromen-4-one
DM6FNVC	CA	CAS 4250-77-5
DM6FNVC	CB	CHEBI:34471
DM6FNVC	DE	Discovery agent

DM89YV7	ID	DM89YV7
DM89YV7	DN	6-hydroxymelatonin
DM89YV7	HS	Investigative
DM89YV7	SN	6-OH-MLT; 6-OH-melatonin
DM89YV7	DT	Small molecular drug
DM89YV7	PC	1864
DM89YV7	MW	248.28
DM89YV7	FM	C13H16N2O3
DM89YV7	IC	InChI=1S/C13H16N2O3/c1-8(16)14-4-3-9-7-15-11-6-12(17)13(18-2)5-10(9)11/h5-7,15,17H,3-4H2,1-2H3,(H,14,16)
DM89YV7	CS	CC(=O)NCCC1=CNC2=CC(=C(C=C21)OC)O
DM89YV7	IK	OMYMRCXOJJZYKE-UHFFFAOYSA-N
DM89YV7	IU	N-[2-(6-hydroxy-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DM89YV7	CA	CAS 2208-41-5
DM89YV7	CB	CHEBI:2198
DM89YV7	DE	Discovery agent

DMYF60K	ID	DMYF60K
DMYF60K	DN	6-Hydroxymethyl-7,8-Dihydropterin
DMYF60K	HS	Investigative
DMYF60K	DT	Small molecular drug
DMYF60K	PC	135398568
DMYF60K	MW	195.18
DMYF60K	FM	C7H9N5O2
DMYF60K	IC	InChI=1S/C7H9N5O2/c8-7-11-5-4(6(14)12-7)10-3(2-13)1-9-5/h13H,1-2H2,(H4,8,9,11,12,14)
DMYF60K	CS	C1C(=NC2=C(N1)N=C(NC2=O)N)CO
DMYF60K	IK	CQQNNQTXUGLUEV-UHFFFAOYSA-N
DMYF60K	IU	2-amino-6-(hydroxymethyl)-7,8-dihydro-3H-pteridin-4-one
DMYF60K	CA	CAS 3672-03-5
DMYF60K	CB	CHEBI:17083
DMYF60K	DE	Discovery agent

DM7EWDN	ID	DM7EWDN
DM7EWDN	DN	6-Hydroxymethylpterin
DM7EWDN	HS	Investigative
DM7EWDN	DT	Small molecular drug
DM7EWDN	PC	135415975
DM7EWDN	MW	193.16
DM7EWDN	FM	C7H7N5O2
DM7EWDN	IC	InChI=1S/C7H7N5O2/c8-7-11-5-4(6(14)12-7)10-3(2-13)1-9-5/h1,13H,2H2,(H3,8,9,11,12,14)
DM7EWDN	CS	C1=C(N=C2C(=O)NC(=NC2=N1)N)CO
DM7EWDN	IK	XGWIBNWDLMIPNF-UHFFFAOYSA-N
DM7EWDN	IU	2-amino-6-(hydroxymethyl)-3H-pteridin-4-one
DM7EWDN	CA	CAS 712-29-8
DM7EWDN	DE	Discovery agent

DM6KVO0	ID	DM6KVO0
DM6KVO0	DN	6-Hydroxy-N-(2-morpholinoethyl)nicotinamide
DM6KVO0	HS	Investigative
DM6KVO0	SN	6-Hydroxy-N-(2-morpholinoethyl)nicotinamide; CHEMBL596971; BDBM50307189; AKOS008932018; AKOS027598195
DM6KVO0	DT	Small molecular drug
DM6KVO0	PC	28826303
DM6KVO0	MW	251.28
DM6KVO0	FM	C12H17N3O3
DM6KVO0	IC	InChI=1S/C12H17N3O3/c16-11-2-1-10(9-14-11)12(17)13-3-4-15-5-7-18-8-6-15/h1-2,9H,3-8H2,(H,13,17)(H,14,16)
DM6KVO0	CS	C1COCCN1CCNC(=O)C2=CNC(=O)C=C2
DM6KVO0	IK	BNPSDTRXYVPPCU-UHFFFAOYSA-N
DM6KVO0	IU	N-(2-morpholin-4-ylethyl)-6-oxo-1H-pyridine-3-carboxamide
DM6KVO0	DE	Discovery agent

DMVRFU5	ID	DMVRFU5
DMVRFU5	DN	6-Hydroxypropylthymine
DMVRFU5	HS	Investigative
DMVRFU5	SN	6-hydroxypropylthymine; 6-(3-hydroxypropyl)thymine; 6-(3-hydroxypropyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-(3-hydroxypropyl)-5-methyl-; 156569-47-0; AC1L1CEO; SCHEMBL4315838; CHEBI:43299; CTK8A4001; DB04139
DMVRFU5	DT	Small molecular drug
DMVRFU5	PC	1865
DMVRFU5	MW	184.19
DMVRFU5	FM	C8H12N2O3
DMVRFU5	IC	InChI=1S/C8H12N2O3/c1-5-6(3-2-4-11)9-8(13)10-7(5)12/h11H,2-4H2,1H3,(H2,9,10,12,13)
DMVRFU5	CS	CC1=C(NC(=O)NC1=O)CCCO
DMVRFU5	IK	OIEJBPVNLZZLGQ-UHFFFAOYSA-N
DMVRFU5	IU	6-(3-hydroxypropyl)-5-methyl-1H-pyrimidine-2,4-dione
DMVRFU5	CB	CHEBI:43299
DMVRFU5	DE	Discovery agent

DMDMNQV	ID	DMDMNQV
DMDMNQV	DN	6-Hydroxyuridine-5'-Phosphate
DMDMNQV	HS	Investigative
DMDMNQV	SN	6-hydroxy-UMP; 6-HYDROXYURIDINE-5'-PHOSPHATE; 6-hydroxyuridine 5'-(dihydrogen phosphate); CHEMBL383923; 29741-00-2; Prfb acid; 1lor; 1dqx; 1eix; 6-hydroxyuridine 5'-phosphate; AC1Q69HY; AC1L4PT5; 5'-Uridylic acid,6-hydroxy-; SCHEMBL2130675; 5'-Uridylic acid, 6-hydroxy-; CTK4G3746; DTXSID50183892; Phosphoribofuranosylbarbituric acid; BDBM50199178; 6-Hydroxyuridine 5'-phosphoric acid; DB02890; 6-HYDROXYURIDINE-5''-PHOSPHATE; Barbituric acid ribonucleoside 5'-phosphate; 1-beta-D-ribofuranosyl(3H)pyrimidine-2,4,6-trione 5''-monophosp
DMDMNQV	DT	Small molecular drug
DMDMNQV	PC	161647
DMDMNQV	MW	340.18
DMDMNQV	FM	C9H13N2O10P
DMDMNQV	IC	InChI=1S/C9H13N2O10P/c12-4-1-5(13)11(9(16)10-4)8-7(15)6(14)3(21-8)2-20-22(17,18)19/h1,3,6-8,13-15H,2H2,(H,10,12,16)(H2,17,18,19)/t3-,6-,7-,8-/m1/s1
DMDMNQV	CS	C1=C(N(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)O
DMDMNQV	IK	UDOBICLZEKUKCV-YXZULKJRSA-N
DMDMNQV	IU	[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMDMNQV	CA	CAS 29741-00-2
DMDMNQV	DE	Discovery agent

DMQF8JG	ID	DMQF8JG
DMQF8JG	DN	6-ile-ustiloxin
DMQF8JG	HS	Investigative
DMQF8JG	DT	Small molecular drug
DMQF8JG	PC	56661181
DMQF8JG	MW	508.6
DMQF8JG	FM	C24H36N4O8
DMQF8JG	IC	InChI=1S/C24H36N4O8/c1-6-12(3)17-21(33)28-20(23(35)26-11-16(30)31)24(4,7-2)36-15-10-13(8-9-14(15)29)19(32)18(25-5)22(34)27-17/h8-10,12,17-20,25,29,32H,6-7,11H2,1-5H3,(H,26,35)(H,27,34)(H,28,33)(H,30,31)/t12-,17+,18+,19-,20-,24-/m1/s1
DMQF8JG	CS	CC[C@@H](C)[C@H]1C(=O)N[C@@H]([C@@](OC2=C(C=CC(=C2)[C@H]([C@@H](C(=O)N1)NC)O)O)(C)CC)C(=O)NCC(=O)O
DMQF8JG	IK	HXTMSBIVCTYGAS-NBNOUWLYSA-N
DMQF8JG	IU	2-[[(3R,4S,7S,10S,11R)-7-[(2R)-butan-2-yl]-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(15),12(16),13-triene-4-carbonyl]amino]acetic acid
DMQF8JG	DE	Discovery agent

DMRMSU5	ID	DMRMSU5
DMRMSU5	DN	6-Imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one
DMRMSU5	HS	Investigative
DMRMSU5	SN	CHEMBL17516; 119924-94-6; 3,4-dihydro-6-(1H-imidazol-1-yl)quinolin-2(1H)-one; 2(1H)-Quinolinone, 3,4-dihydro-6-(1H-imidazol-1-yl)-; ACMC-20momi; 6-Imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one; SCHEMBL10463333; CTK0F9353; DTXSID20551867; BDMKPUAZENLRDY-UHFFFAOYSA-N; BDBM50000309; 6-(imidazol-1-yl)-3,4-dihydrocarbostyril
DMRMSU5	DT	Small molecular drug
DMRMSU5	PC	13885278
DMRMSU5	MW	213.23
DMRMSU5	FM	C12H11N3O
DMRMSU5	IC	InChI=1S/C12H11N3O/c16-12-4-1-9-7-10(2-3-11(9)14-12)15-6-5-13-8-15/h2-3,5-8H,1,4H2,(H,14,16)
DMRMSU5	CS	C1CC(=O)NC2=C1C=C(C=C2)N3C=CN=C3
DMRMSU5	IK	BDMKPUAZENLRDY-UHFFFAOYSA-N
DMRMSU5	IU	6-imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one
DMRMSU5	CA	CAS 119924-94-6
DMRMSU5	DE	Discovery agent

DMQXL1Y	ID	DMQXL1Y
DMQXL1Y	DN	6-Imidazol-1-yl-isoquinoline
DMQXL1Y	HS	Investigative
DMQXL1Y	SN	6-(1H-imidazol-1-yl)isoquinoline
DMQXL1Y	DT	Small molecular drug
DMQXL1Y	PC	10845522
DMQXL1Y	MW	195.22
DMQXL1Y	FM	C12H9N3
DMQXL1Y	IC	InChI=1S/C12H9N3/c1-2-12(15-6-5-14-9-15)7-10-3-4-13-8-11(1)10/h1-9H
DMQXL1Y	CS	C1=CC2=C(C=CN=C2)C=C1N3C=CN=C3
DMQXL1Y	IK	YACWDKFXWATANA-UHFFFAOYSA-N
DMQXL1Y	IU	6-imidazol-1-ylisoquinoline
DMQXL1Y	DE	Discovery agent

DMBQ3HV	ID	DMBQ3HV
DMBQ3HV	DN	6-Imidazol-1-ylmethyl-8-phenyl-quinoline
DMBQ3HV	HS	Investigative
DMBQ3HV	SN	CHEMBL419416; 6-Imidazol-1-ylmethyl-8-phenyl-quinoline; BDBM50092624
DMBQ3HV	DT	Small molecular drug
DMBQ3HV	PC	10565073
DMBQ3HV	MW	285.3
DMBQ3HV	FM	C19H15N3
DMBQ3HV	IC	InChI=1S/C19H15N3/c1-2-5-16(6-3-1)18-12-15(13-22-10-9-20-14-22)11-17-7-4-8-21-19(17)18/h1-12,14H,13H2
DMBQ3HV	CS	C1=CC=C(C=C1)C2=C3C(=CC(=C2)CN4C=CN=C4)C=CC=N3
DMBQ3HV	IK	PBPLGORPOONLEQ-UHFFFAOYSA-N
DMBQ3HV	IU	6-(imidazol-1-ylmethyl)-8-phenylquinoline
DMBQ3HV	DE	Discovery agent

DM31VLA	ID	DM31VLA
DM31VLA	DN	6-Iodo-2-piperazin-1-yl-quinoline
DM31VLA	HS	Investigative
DM31VLA	SN	6-Iodo-2-piperazin-1-yl-quinoline; 296759-25-6; 6-Iodo-2-(piperazin-1-yl)quinoline; CHEMBL38466; 2-Piperazino-6-iodoquinoline; SCHEMBL6364907; C13H14IN3; DTXSID00476408; ZINC2527444; 3556AJ; BDBM50090210; AKOS024260375; NE63975; AB19831; ACM296759256; AJ-83657; AX8289444; DB-068143
DM31VLA	DT	Small molecular drug
DM31VLA	PC	12044728
DM31VLA	MW	339.17
DM31VLA	FM	C13H14IN3
DM31VLA	IC	InChI=1S/C13H14IN3/c14-11-2-3-12-10(9-11)1-4-13(16-12)17-7-5-15-6-8-17/h1-4,9,15H,5-8H2
DM31VLA	CS	C1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)I
DM31VLA	IK	BZVOKNDAJHHFPT-UHFFFAOYSA-N
DM31VLA	IU	6-iodo-2-piperazin-1-ylquinoline
DM31VLA	CA	CAS 296759-25-6
DM31VLA	DE	Discovery agent

DMAL1UH	ID	DMAL1UH
DMAL1UH	DN	6-iodo-4'-dimethyaminoflavone
DMAL1UH	HS	Investigative
DMAL1UH	SN	871101-31-4; 2-(4-DIMETHYLAMINOPHENYL)-6-IODO-4-CHROMENONE; CHEMBL375934; 2-(4-dimethylaminophenyl)-6-iodo-chromen-4-one; 2-[4-(Dimethylamino)phenyl]-6-iodo-4H-1-benzopyran-4-one; SCHEMBL4985743; 6-iodo-4'-dimethylaminoflavone; 6-iodo-4''-dimethyaminoflavone; CTK8E3396; DTXSID30468831; MVKVWWKDDYBNOJ-UHFFFAOYSA-N; BDBM50176892; ZINC13675691; RT-007109
DMAL1UH	DT	Small molecular drug
DMAL1UH	PC	11574659
DMAL1UH	MW	391.2
DMAL1UH	FM	C17H14INO2
DMAL1UH	IC	InChI=1S/C17H14INO2/c1-19(2)13-6-3-11(4-7-13)17-10-15(20)14-9-12(18)5-8-16(14)21-17/h3-10H,1-2H3
DMAL1UH	CS	CN(C)C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)I
DMAL1UH	IK	MVKVWWKDDYBNOJ-UHFFFAOYSA-N
DMAL1UH	IU	2-[4-(dimethylamino)phenyl]-6-iodochromen-4-one
DMAL1UH	CA	CAS 871101-31-4
DMAL1UH	DE	Discovery agent

DM5FZBI	ID	DM5FZBI
DM5FZBI	DN	6-iodo-4'-hydroxyflavone
DM5FZBI	HS	Investigative
DM5FZBI	SN	CHEMBL388844; 6-iodo-4''-hydroxyflavone; SCHEMBL10144252
DM5FZBI	DT	Small molecular drug
DM5FZBI	PC	11703303
DM5FZBI	MW	364.13
DM5FZBI	FM	C15H9IO3
DM5FZBI	IC	InChI=1S/C15H9IO3/c16-10-3-6-14-12(7-10)13(18)8-15(19-14)9-1-4-11(17)5-2-9/h1-8,17H
DM5FZBI	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=CC(=C3)I)O
DM5FZBI	IK	IFAJNNUYROKKPW-UHFFFAOYSA-N
DM5FZBI	IU	2-(4-hydroxyphenyl)-6-iodochromen-4-one
DM5FZBI	DE	Discovery agent

DM6U9CY	ID	DM6U9CY
DM6U9CY	DN	6-iodo-4'-methoxyflavone
DM6U9CY	HS	Investigative
DM6U9CY	SN	CHEMBL224064; 6-iodo-2-(4-methoxyphenyl)chromen-4-one; 1033-44-9; 4h-1-benzopyran-4-one,6-iodo-2-(4-methoxyphenyl)-; 6-iodo-4'-methoxyflavone; AC1LAD9Q; 6-iodo-4''-methoxyflavone; 4'-Methoxy-6-iodoflavanone; SCHEMBL4983190; BYDBCAPACOXVEH-UHFFFAOYSA-N; ZINC6484552; BDBM50176894
DM6U9CY	DT	Small molecular drug
DM6U9CY	PC	466289
DM6U9CY	MW	378.16
DM6U9CY	FM	C16H11IO3
DM6U9CY	IC	InChI=1S/C16H11IO3/c1-19-12-5-2-10(3-6-12)16-9-14(18)13-8-11(17)4-7-15(13)20-16/h2-9H,1H3
DM6U9CY	CS	COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)I
DM6U9CY	IK	BYDBCAPACOXVEH-UHFFFAOYSA-N
DM6U9CY	IU	6-iodo-2-(4-methoxyphenyl)chromen-4-one
DM6U9CY	DE	Discovery agent

DM9GJAY	ID	DM9GJAY
DM9GJAY	DN	6-iodo-4'-methylaminoflavone
DM9GJAY	HS	Investigative
DM9GJAY	SN	6-iodo-4'-methylaminoflavone; 871101-30-3; CHEMBL224643; 6-iodo-2-(4-methylaminophenyl)-chromen-4-one; SCHEMBL4991516; 6-iodo-4''-methylaminoflavone; DTXSID20469771; QIZWRTNISFPGTO-UHFFFAOYSA-N; ZINC13675690; BDBM50176896; KB-248886
DM9GJAY	DT	Small molecular drug
DM9GJAY	PC	11632242
DM9GJAY	MW	377.18
DM9GJAY	FM	C16H12INO2
DM9GJAY	IC	InChI=1S/C16H12INO2/c1-18-12-5-2-10(3-6-12)16-9-14(19)13-8-11(17)4-7-15(13)20-16/h2-9,18H,1H3
DM9GJAY	CS	CNC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)I
DM9GJAY	IK	QIZWRTNISFPGTO-UHFFFAOYSA-N
DM9GJAY	IU	6-iodo-2-[4-(methylamino)phenyl]chromen-4-one
DM9GJAY	CA	CAS 871101-30-3
DM9GJAY	DE	Discovery agent

DM0GSRL	ID	DM0GSRL
DM0GSRL	DN	6'-Iodononivamide
DM0GSRL	HS	Investigative
DM0GSRL	SN	859171-97-4; CHEMBL177809; Tocris-1975; NCGC00025334-01; AC1NP3A0; CTK8E7732; DTXSID70408796; MolPort-003-983-501; CHEBI:107654; HMS3268B17; ZINC8036052; MFCD09878233; BN0036; BDBM50170053; AKOS024456886; RT-010669; N-(4-hydroxy-2-iodo-5-methoxybenzyl)nonanamide; N-(2-Iodo-4-hydroxy-5-methoxybenzyl)nonanamide; 6-Iodonordihydrocapsaicin, &gt; SR-01000597523; SR-01000597523-1; BRD-K49236613-001-01-5; Nonanoic acid 4-hydroxy-2-iodo-5-methoxy-benzylamide
DM0GSRL	DT	Small molecular drug
DM0GSRL	PC	5149140
DM0GSRL	MW	419.3
DM0GSRL	FM	C17H26INO3
DM0GSRL	IC	InChI=1S/C17H26INO3/c1-3-4-5-6-7-8-9-17(21)19-12-13-10-16(22-2)15(20)11-14(13)18/h10-11,20H,3-9,12H2,1-2H3,(H,19,21)
DM0GSRL	CS	CCCCCCCCC(=O)NCC1=CC(=C(C=C1I)O)OC
DM0GSRL	IK	AAORACFZMYMFCG-UHFFFAOYSA-N
DM0GSRL	IU	N-[(4-hydroxy-2-iodo-5-methoxyphenyl)methyl]nonanamide
DM0GSRL	CA	CAS 859171-97-4
DM0GSRL	CB	CHEBI:107654
DM0GSRL	DE	Discovery agent

DM1S9DB	ID	DM1S9DB
DM1S9DB	DN	6-iodo-nordihydrocapsaicin
DM1S9DB	HS	Investigative
DM1S9DB	SN	GTPL4110
DM1S9DB	DT	Small molecular drug
DM1S9DB	PC	24881008
DM1S9DB	MW	419.3
DM1S9DB	FM	C17H26INO3
DM1S9DB	IC	InChI=1S/C17H26INO3/c1-12(2)7-5-4-6-8-17(21)19-11-13-9-16(22-3)15(20)10-14(13)18/h9-10,12,20H,4-8,11H2,1-3H3,(H,19,21)
DM1S9DB	CS	CC(C)CCCCCC(=O)NCC1=CC(=C(C=C1I)O)OC
DM1S9DB	IK	MGJQSBQUFTWMOG-UHFFFAOYSA-N
DM1S9DB	IU	N-[(4-hydroxy-2-iodo-5-methoxyphenyl)methyl]-7-methyloctanamide
DM1S9DB	DE	Discovery agent

DM2XB68	ID	DM2XB68
DM2XB68	DN	6-isobutyl-4-methylpyridin-2-amine
DM2XB68	HS	Investigative
DM2XB68	SN	CHEMBL294609; 6-isobutyl-4-methylpyridin-2-amine; SCHEMBL7052362; VMTPVCVORKDABN-UHFFFAOYSA-N; BDBM50091801; 2-Amino-4-methyl-6-isobutylpyridine; 6-Isobutyl-4-methyl-pyridin-2-ylamine; 179555-28-3; 2-amino-4-methyl-6-(2-methylpropyl)pyridine; 2-Pyridinamine, 4-methyl-6-(2-methylpropyl)-
DM2XB68	DT	Small molecular drug
DM2XB68	PC	10197851
DM2XB68	MW	164.25
DM2XB68	FM	C10H16N2
DM2XB68	IC	InChI=1S/C10H16N2/c1-7(2)4-9-5-8(3)6-10(11)12-9/h5-7H,4H2,1-3H3,(H2,11,12)
DM2XB68	CS	CC1=CC(=NC(=C1)N)CC(C)C
DM2XB68	IK	VMTPVCVORKDABN-UHFFFAOYSA-N
DM2XB68	IU	4-methyl-6-(2-methylpropyl)pyridin-2-amine
DM2XB68	DE	Discovery agent

DMGXMZL	ID	DMGXMZL
DMGXMZL	DN	6-isopropyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMGXMZL	HS	Investigative
DMGXMZL	SN	CHEMBL222929; 6-isopropyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMGXMZL	DT	Small molecular drug
DMGXMZL	PC	16203712
DMGXMZL	MW	239.34
DMGXMZL	FM	C12H17NO2S
DMGXMZL	IC	InChI=1S/C12H17NO2S/c1-9(2)11-7-10(14)8-12(16-11)13-3-5-15-6-4-13/h7-9H,3-6H2,1-2H3
DMGXMZL	CS	CC(C)C1=CC(=O)C=C(S1)N2CCOCC2
DMGXMZL	IK	AWDQFPIPWUUVQD-UHFFFAOYSA-N
DMGXMZL	IU	2-morpholin-4-yl-6-propan-2-ylthiopyran-4-one
DMGXMZL	DE	Discovery agent

DMO2F8L	ID	DMO2F8L
DMO2F8L	DN	6-Isopropyl-2-phenyl-chromen-4-one
DMO2F8L	HS	Investigative
DMO2F8L	SN	288401-05-8; 6-ISO-PROPYLFLAVONE; 6-Isopropylflavone; CHEMBL133949; CTK4G2222; DTXSID70658395; ZINC2573996; AKOS030553653; 2-Phenyl-6-(propan-2-yl)-4H-1-benzopyran-4-one
DMO2F8L	DT	Small molecular drug
DMO2F8L	PC	44355253
DMO2F8L	MW	264.3
DMO2F8L	FM	C18H16O2
DMO2F8L	IC	InChI=1S/C18H16O2/c1-12(2)14-8-9-17-15(10-14)16(19)11-18(20-17)13-6-4-3-5-7-13/h3-12H,1-2H3
DMO2F8L	CS	CC(C)C1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3
DMO2F8L	IK	APJYDAHXYGPDII-UHFFFAOYSA-N
DMO2F8L	IU	2-phenyl-6-propan-2-ylchromen-4-one
DMO2F8L	CA	CAS 288401-05-8
DMO2F8L	DE	Discovery agent

DM2WUZP	ID	DM2WUZP
DM2WUZP	DN	6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one
DM2WUZP	HS	Investigative
DM2WUZP	SN	CHEMBL456390; 6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one; SCHEMBL1120250; BDBM50273813
DM2WUZP	DT	Small molecular drug
DM2WUZP	PC	25147692
DM2WUZP	MW	274.3
DM2WUZP	FM	C18H14N2O
DM2WUZP	IC	InChI=1S/C18H14N2O/c21-18-8-6-13-9-12(5-7-17(13)20-18)16-11-19-10-14-3-1-2-4-15(14)16/h1-5,7,9-11H,6,8H2,(H,20,21)
DM2WUZP	CS	C1CC(=O)NC2=C1C=C(C=C2)C3=CN=CC4=CC=CC=C43
DM2WUZP	IK	TVVPAZUMRVMIFM-UHFFFAOYSA-N
DM2WUZP	IU	6-isoquinolin-4-yl-3,4-dihydro-1H-quinolin-2-one
DM2WUZP	DE	Discovery agent

DMD2FW9	ID	DMD2FW9
DMD2FW9	DN	6-Mercapto-hexanoic acid phenylamide
DMD2FW9	HS	Investigative
DMD2FW9	SN	6-Mercapto-hexanoic acid phenylamide; CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600
DMD2FW9	DT	Small molecular drug
DMD2FW9	PC	11436024
DMD2FW9	MW	223.34
DMD2FW9	FM	C12H17NOS
DMD2FW9	IC	InChI=1S/C12H17NOS/c14-12(9-5-2-6-10-15)13-11-7-3-1-4-8-11/h1,3-4,7-8,15H,2,5-6,9-10H2,(H,13,14)
DMD2FW9	CS	C1=CC=C(C=C1)NC(=O)CCCCCS
DMD2FW9	IK	IFUHTURYMZWNNJ-UHFFFAOYSA-N
DMD2FW9	IU	N-phenyl-6-sulfanylhexanamide
DMD2FW9	DE	Discovery agent

DMJUT70	ID	DMJUT70
DMJUT70	DN	6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DMJUT70	HS	Investigative
DMJUT70	SN	CHEMBL374729; 6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DMJUT70	DT	Small molecular drug
DMJUT70	PC	44419695
DMJUT70	MW	227.28
DMJUT70	FM	C14H15N2O+
DMJUT70	IC	InChI=1S/C14H14N2O/c1-9-14-11(6-7-16(9)2)12-8-10(17-3)4-5-13(12)15-14/h4-8H,1-3H3/p+1
DMJUT70	CS	CC1=[N+](C=CC2=C1NC3=C2C=C(C=C3)OC)C
DMJUT70	IK	GKOBEAWUMYEQIP-UHFFFAOYSA-O
DMJUT70	IU	6-methoxy-1,2-dimethyl-9H-pyrido[3,4-b]indol-2-ium
DMJUT70	DE	Discovery agent

DMOHWPD	ID	DMOHWPD
DMOHWPD	DN	6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole
DMOHWPD	HS	Investigative
DMOHWPD	SN	6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole; CHEMBL375077; AC1L4QAL; SCHEMBL20159056; BDBM50194445; 22574-29-4
DMOHWPD	DT	Small molecular drug
DMOHWPD	PC	211174
DMOHWPD	MW	226.27
DMOHWPD	FM	C14H14N2O
DMOHWPD	IC	InChI=1S/C14H14N2O/c1-9-14-11(6-7-15-9)12-8-10(17-3)4-5-13(12)16(14)2/h4-8H,1-3H3
DMOHWPD	CS	CC1=NC=CC2=C1N(C3=C2C=C(C=C3)OC)C
DMOHWPD	IK	AJSYZGYPCGTQSU-UHFFFAOYSA-N
DMOHWPD	IU	6-methoxy-1,9-dimethylpyrido[3,4-b]indole
DMOHWPD	DE	Discovery agent

DMZP3XJ	ID	DMZP3XJ
DMZP3XJ	DN	6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole
DMZP3XJ	HS	Investigative
DMZP3XJ	SN	CHEMBL67196
DMZP3XJ	DT	Small molecular drug
DMZP3XJ	PC	9797585
DMZP3XJ	MW	330.4
DMZP3XJ	FM	C21H18N2O2
DMZP3XJ	IC	InChI=1S/C21H18N2O2/c1-24-18-11-12-19-20(14-18)23-21(22-19)13-15-7-9-17(10-8-15)25-16-5-3-2-4-6-16/h2-12,14H,13H2,1H3,(H,22,23)
DMZP3XJ	CS	COC1=CC2=C(C=C1)N=C(N2)CC3=CC=C(C=C3)OC4=CC=CC=C4
DMZP3XJ	IK	QXVTTYRBOJXPRC-UHFFFAOYSA-N
DMZP3XJ	IU	6-methoxy-2-[(4-phenoxyphenyl)methyl]-1H-benzimidazole
DMZP3XJ	DE	Discovery agent

DMSA367	ID	DMSA367
DMSA367	DN	6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMSA367	HS	Investigative
DMSA367	SN	20315-68-8; 6-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 6-methoxytryptoline; 6-Methoxy-1,2,3,4-tetrahydro-beta-carboline; pinoline; 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole; 6-MeOthbc; 6-methoxy-2,3,4,9-tetrahydro-1H-beta-carboline; 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4b] indole; 6-Methoxytetrahydro-beta-carboline; 2,3,4,9-Tetrahydro-6-methoxy-1H-pyrido(3,4-b)indole; BRN 0172873; CHEMBL266084; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-6-methoxy-; QYMDEOQLJUUNOF-UHFFFAOYSA-N
DMSA367	DT	Small molecular drug
DMSA367	PC	1868
DMSA367	MW	202.25
DMSA367	FM	C12H14N2O
DMSA367	IC	InChI=1S/C12H14N2O/c1-15-8-2-3-11-10(6-8)9-4-5-13-7-12(9)14-11/h2-3,6,13-14H,4-5,7H2,1H3
DMSA367	CS	COC1=CC2=C(C=C1)NC3=C2CCNC3
DMSA367	IK	QYMDEOQLJUUNOF-UHFFFAOYSA-N
DMSA367	IU	6-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMSA367	CA	CAS 20315-68-8
DMSA367	DE	Discovery agent

DMG3F7D	ID	DMG3F7D
DMG3F7D	DN	6-methoxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMG3F7D	HS	Investigative
DMG3F7D	SN	CHEMBL385778; 6-methoxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMG3F7D	DT	Small molecular drug
DMG3F7D	PC	44419694
DMG3F7D	MW	227.28
DMG3F7D	FM	C14H15N2O+
DMG3F7D	IC	InChI=1S/C14H15N2O/c1-15-7-6-11-12-8-10(17-3)4-5-13(12)16(2)14(11)9-15/h4-9H,1-3H3/q+1
DMG3F7D	CS	CN1C2=C(C=C(C=C2)OC)C3=C1C=[N+](C=C3)C
DMG3F7D	IK	DSZQQMUYRCNRKS-UHFFFAOYSA-N
DMG3F7D	IU	6-methoxy-2,9-dimethylpyrido[3,4-b]indol-2-ium
DMG3F7D	DE	Discovery agent

DMHITF8	ID	DMHITF8
DMHITF8	DN	6-methoxy-2-methyl-9H-beta-carbolin-2-ium
DMHITF8	HS	Investigative
DMHITF8	SN	CHEMBL376434; AC1NSY4Y; 6-methoxy-2-methyl-9H-beta-carbolin-2-ium; BDBM50194438
DMHITF8	DT	Small molecular drug
DMHITF8	PC	5319470
DMHITF8	MW	213.25
DMHITF8	FM	C13H13N2O+
DMHITF8	IC	InChI=1S/C13H12N2O/c1-15-6-5-10-11-7-9(16-2)3-4-12(11)14-13(10)8-15/h3-8H,1-2H3/p+1
DMHITF8	CS	C[N+]1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)OC
DMHITF8	IK	UXIBWQLCPYHBSH-UHFFFAOYSA-O
DMHITF8	IU	6-methoxy-2-methyl-9H-pyrido[3,4-b]indol-2-ium
DMHITF8	DE	Discovery agent

DM7WH82	ID	DM7WH82
DM7WH82	DN	6-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DM7WH82	HS	Investigative
DM7WH82	SN	6-Methoxy-2-oxo-2H-chromene-3-carboxylic acid; 35924-44-8; 6-methoxy-2-oxochromene-3-carboxylic acid; CHEMBL568416; 6-methoxy-2-oxo-2H-1-benzopyran-3-carboxylic acid; MLS000061036; AC1LEG8M; CBMicro_000141; Oprea1_705276; Oprea1_357602; 6-methoxy-3-carboxy-coumarin; SCHEMBL978456; CTK1B0306; DTXSID90351856; XIQQAIQZABTSNZ-UHFFFAOYSA-N; MolPort-000-467-024; ZINC103684; HMS2443I11; HMS1607B10; SMSF0006060; ZX-AL001956; STL553633; SBB043625; BDBM50303489; AKOS000274154; CB01296; MCULE-7757033841; BAS 00518708; SMR000069802
DM7WH82	DT	Small molecular drug
DM7WH82	PC	711717
DM7WH82	MW	220.18
DM7WH82	FM	C11H8O5
DM7WH82	IC	InChI=1S/C11H8O5/c1-15-7-2-3-9-6(4-7)5-8(10(12)13)11(14)16-9/h2-5H,1H3,(H,12,13)
DM7WH82	CS	COC1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)O
DM7WH82	IK	XIQQAIQZABTSNZ-UHFFFAOYSA-N
DM7WH82	IU	6-methoxy-2-oxochromene-3-carboxylic acid
DM7WH82	CA	CAS 35924-44-8
DM7WH82	DE	Discovery agent

DM52SDO	ID	DM52SDO
DM52SDO	DN	6-Methoxy-3-pyridin-4-yl-quinoline
DM52SDO	HS	Investigative
DM52SDO	SN	CHEMBL90780; 6-methoxy-3-pyridin-4-yl-quinoline; 6-Methoxy-3-(4-pyridyl)quinoline
DM52SDO	DT	Small molecular drug
DM52SDO	PC	10354094
DM52SDO	MW	236.27
DM52SDO	FM	C15H12N2O
DM52SDO	IC	InChI=1S/C15H12N2O/c1-18-14-2-3-15-12(9-14)8-13(10-17-15)11-4-6-16-7-5-11/h2-10H,1H3
DM52SDO	CS	COC1=CC2=CC(=CN=C2C=C1)C3=CC=NC=C3
DM52SDO	IK	BGNDYXHAEMNSOM-UHFFFAOYSA-N
DM52SDO	IU	6-methoxy-3-pyridin-4-ylquinoline
DM52SDO	DE	Discovery agent

DMOYL71	ID	DMOYL71
DMOYL71	DN	6-Methoxy-3-thiophen-3-yl-quinoline
DMOYL71	HS	Investigative
DMOYL71	SN	CHEMBL303184; 6-methoxy-3-thiophen-3-yl-quinoline; ZINC3832230
DMOYL71	DT	Small molecular drug
DMOYL71	PC	10083051
DMOYL71	MW	241.31
DMOYL71	FM	C14H11NOS
DMOYL71	IC	InChI=1S/C14H11NOS/c1-16-13-2-3-14-11(7-13)6-12(8-15-14)10-4-5-17-9-10/h2-9H,1H3
DMOYL71	CS	COC1=CC2=CC(=CN=C2C=C1)C3=CSC=C3
DMOYL71	IK	SQHKULNLQJHPDX-UHFFFAOYSA-N
DMOYL71	IU	6-methoxy-3-thiophen-3-ylquinoline
DMOYL71	DE	Discovery agent

DM98FQO	ID	DM98FQO
DM98FQO	DN	6-Methoxy-4,9-dihydro-3H-beta-carboline
DM98FQO	HS	Investigative
DM98FQO	SN	6-Methoxy-4,9-dihydro-3H-beta-carboline; CHEMBL6717; SCHEMBL8369162; BDBM50136505; AKOS023554679; 3,4-Dihydro-6-methoxy-beta-carboline
DM98FQO	DT	Small molecular drug
DM98FQO	PC	15160217
DM98FQO	MW	200.24
DM98FQO	FM	C12H12N2O
DM98FQO	IC	InChI=1S/C12H12N2O/c1-15-8-2-3-11-10(6-8)9-4-5-13-7-12(9)14-11/h2-3,6-7,14H,4-5H2,1H3
DM98FQO	CS	COC1=CC2=C(C=C1)NC3=C2CCN=C3
DM98FQO	IK	BJODVFITWMPYMU-UHFFFAOYSA-N
DM98FQO	IU	6-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole
DM98FQO	DE	Discovery agent

DMPB9MY	ID	DMPB9MY
DMPB9MY	DN	6-Methoxy-4-morpholin-4-yl-chromen-2-one
DMPB9MY	HS	Investigative
DMPB9MY	SN	CHEMBL175510; NU-7031; 79105-88-7; 6-methoxy-4-morpholin-4-yl-chromen-2-one; 6-methoxy-4-morpholino-2H-chromen-2-one; SCHEMBL3666851; BDBM50159679
DMPB9MY	DT	Small molecular drug
DMPB9MY	PC	11196279
DMPB9MY	MW	261.269
DMPB9MY	FM	C14H15NO4
DMPB9MY	IC	InChI=1S/C14H15NO4/c1-17-10-2-3-13-11(8-10)12(9-14(16)19-13)15-4-6-18-7-5-15/h2-3,8-9H,4-7H2,1H3
DMPB9MY	CS	COC1=CC2=C(C=C1)OC(=O)C=C2N3CCOCC3
DMPB9MY	IK	UEDWCBYLFYRZFY-UHFFFAOYSA-N
DMPB9MY	IU	6-methoxy-4-morpholin-4-ylchromen-2-one
DMPB9MY	DE	Discovery agent

DMHO7TZ	ID	DMHO7TZ
DMHO7TZ	DN	6-Methoxy-5-oxazol-5-yl-2-phenyl-1H-indole
DMHO7TZ	HS	Investigative
DMHO7TZ	SN	CHEMBL23590; 569352-88-1; 6-Methoxy-5-oxazol-5-yl-2-phenyl-1H-indole; SCHEMBL5832036; CTK1F3437; DTXSID60623678; BDBM50126004; 2-Phenyl-5-(5-oxazolyl)-6-methoxy-1H-indole; 1H-Indole, 6-methoxy-5-(5-oxazolyl)-2-phenyl-
DMHO7TZ	DT	Small molecular drug
DMHO7TZ	PC	22238483
DMHO7TZ	MW	290.3
DMHO7TZ	FM	C18H14N2O2
DMHO7TZ	IC	InChI=1S/C18H14N2O2/c1-21-17-9-16-13(7-14(17)18-10-19-11-22-18)8-15(20-16)12-5-3-2-4-6-12/h2-11,20H,1H3
DMHO7TZ	CS	COC1=C(C=C2C=C(NC2=C1)C3=CC=CC=C3)C4=CN=CO4
DMHO7TZ	IK	BESGGLGAKGKEOC-UHFFFAOYSA-N
DMHO7TZ	IU	5-(6-methoxy-2-phenyl-1H-indol-5-yl)-1,3-oxazole
DMHO7TZ	CA	CAS 569352-88-1
DMHO7TZ	DE	Discovery agent

DM5JB9D	ID	DM5JB9D
DM5JB9D	DN	6-methoxykaempferol 3-O-beta-D-robinobioside
DM5JB9D	HS	Investigative
DM5JB9D	SN	6-methoxykaempferol 3-O-beta-D-robinobioside; 90706-64-2; AC1NUSLN; CHEMBL445993; AKOS030567035; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one; 4H-1-Benzopyran-4-one, 3-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-galactopyranosyl)oxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-
DM5JB9D	DT	Small molecular drug
DM5JB9D	PC	5491783
DM5JB9D	MW	624.5
DM5JB9D	FM	C28H32O16
DM5JB9D	IC	InChI=1S/C28H32O16/c1-9-16(31)20(35)22(37)27(41-9)40-8-14-17(32)21(36)23(38)28(43-14)44-26-19(34)15-13(7-12(30)25(39-2)18(15)33)42-24(26)10-3-5-11(29)6-4-10/h3-7,9,14,16-17,20-23,27-33,35-38H,8H2,1-2H3/t9-,14+,16-,17-,20+,21-,22+,23+,27+,28-/m0/s1
DM5JB9D	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=C(C3=O)C(=C(C(=C4)O)OC)O)C5=CC=C(C=C5)O)O)O)O)O)O)O
DM5JB9D	IK	FPVLVSUOCXHCMR-GBNKVCQDSA-N
DM5JB9D	IU	5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
DM5JB9D	CA	CAS 90706-64-2
DM5JB9D	DE	Discovery agent

DMOIC64	ID	DMOIC64
DMOIC64	DN	6-Methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
DMOIC64	HS	Investigative
DMOIC64	SN	6-Methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one; 6-Methyl[1,3]dioxolo[4,5-H]quinolin-8(9h)-One; 1137557-67-5; casimiroin analogue, 1a; CHEMBL482693; BDBM29212
DMOIC64	DT	Small molecular drug
DMOIC64	PC	42618026
DMOIC64	MW	203.19
DMOIC64	FM	C11H9NO3
DMOIC64	IC	InChI=1S/C11H9NO3/c1-6-4-9(13)12-10-7(6)2-3-8-11(10)15-5-14-8/h2-4H,5H2,1H3,(H,12,13)
DMOIC64	CS	CC1=CC(=O)NC2=C1C=CC3=C2OCO3
DMOIC64	IK	XCKXJOHJSMHNFE-UHFFFAOYSA-N
DMOIC64	IU	6-methyl-9H-[1,3]dioxolo[4,5-h]quinolin-8-one
DMOIC64	DE	Discovery agent

DMAQGZR	ID	DMAQGZR
DMAQGZR	DN	6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMAQGZR	HS	Investigative
DMAQGZR	SN	CHEMBL49016; NSC676187; AC1L8OZO; 6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one; SCHEMBL7921815; CTK8D2137; ZINC5504117; BDBM50059977; NSC-676187; NCI60_026914; 2-(3-Methylphenyl)-6-methyl-1,8-naphthyridin-4(1H)-one; 6-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMAQGZR	DT	Small molecular drug
DMAQGZR	PC	385183
DMAQGZR	MW	250.29
DMAQGZR	FM	C16H14N2O
DMAQGZR	IC	InChI=1S/C16H14N2O/c1-10-4-3-5-12(6-10)14-8-15(19)13-7-11(2)9-17-16(13)18-14/h3-9H,1-2H3,(H,17,18,19)
DMAQGZR	CS	CC1=CC(=CC=C1)C2=CC(=O)C3=C(N2)N=CC(=C3)C
DMAQGZR	IK	KDLJOBRGZSEPQS-UHFFFAOYSA-N
DMAQGZR	IU	6-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMAQGZR	DE	Discovery agent

DMNJRFP	ID	DMNJRFP
DMNJRFP	DN	6-Methyl-2-oxa-spiro[4.4]nonan-1-one
DMNJRFP	HS	Investigative
DMNJRFP	SN	CHEMBL97469
DMNJRFP	DT	Small molecular drug
DMNJRFP	PC	10511073
DMNJRFP	MW	154.21
DMNJRFP	FM	C9H14O2
DMNJRFP	IC	InChI=1S/C9H14O2/c1-7-3-2-4-9(7)5-6-11-8(9)10/h7H,2-6H2,1H3
DMNJRFP	CS	CC1CCCC12CCOC2=O
DMNJRFP	IK	IDYXKZWAEUMDEE-UHFFFAOYSA-N
DMNJRFP	IU	9-methyl-2-oxaspiro[4.4]nonan-1-one
DMNJRFP	DE	Discovery agent

DMZ6HQL	ID	DMZ6HQL
DMZ6HQL	DN	6-methyl-2-oxo-2H-chromene-3-carboxylic acid
DMZ6HQL	HS	Investigative
DMZ6HQL	SN	10242-13-4; 6-methyl-2-oxo-2H-chromene-3-carboxylic acid; 2H-1-BENZOPYRAN-3-CARBOXYLIC ACID, 6-METHYL-2-OXO-; BRN 0172386; 6-Methyl-2-oxo-2H-1-benzopyran-3-carboxylic acid; 6-methyl-2-oxochromene-3-carboxylic acid; CHEMBL577123; AC1L18EL; 5-18-08-00343 (Beilstein Handbook Reference); SCHEMBL2808135; CTK0H8591; DTXSID00145066; MolPort-007-984-853; FJICLQQBBFWGMZ-UHFFFAOYSA-N; HMS1622M11; ZINC2023765; SBB077427; BDBM50303488; AKOS002679479; MCULE-8314622881; LS-39185; VU0511228-1; 2-Oxo-6-methyl-2H-1-benzopyran-3-carboxylic acid
DMZ6HQL	DT	Small molecular drug
DMZ6HQL	PC	25090
DMZ6HQL	MW	204.18
DMZ6HQL	FM	C11H8O4
DMZ6HQL	IC	InChI=1S/C11H8O4/c1-6-2-3-9-7(4-6)5-8(10(12)13)11(14)15-9/h2-5H,1H3,(H,12,13)
DMZ6HQL	CS	CC1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)O
DMZ6HQL	IK	FJICLQQBBFWGMZ-UHFFFAOYSA-N
DMZ6HQL	IU	6-methyl-2-oxochromene-3-carboxylic acid
DMZ6HQL	CA	CAS 10242-13-4
DMZ6HQL	DE	Discovery agent

DMAXBOU	ID	DMAXBOU
DMAXBOU	DN	6-Methyl-2-phenyl-chromen-4-one
DMAXBOU	HS	Investigative
DMAXBOU	SN	6-Methylflavone; 29976-75-8; 6-methyl-2-phenyl-4H-chromen-4-one; 6-methyl-2-phenylchromen-4-one; ST069348; 4H-1-Benzopyran-4-one,6-methyl-2-phenyl-; AC1Q6AKA; AC1LEN9R; Maybridge3_003437; Cambridge id 5479507; Oprea1_512723; BIDD:ER0442; SCHEMBL4648879; CHEMBL134291; ZINC58123; CTK4G4151; DTXSID40351008; MolPort-000-648-469; NOQJBXPAMJLUSS-UHFFFAOYSA-N; HMS1440M05; HY-N6630; KS-000017TV; SBB012439; 6019AH; AKOS002387497; MCULE-3565329436; CCG-250475; IDI1_014824; NCGC00142612-01; ZB002324; 6-Methylflavone solution, 20 mM in DMSO
DMAXBOU	DT	Small molecular drug
DMAXBOU	PC	689013
DMAXBOU	MW	236.26
DMAXBOU	FM	C16H12O2
DMAXBOU	IC	InChI=1S/C16H12O2/c1-11-7-8-15-13(9-11)14(17)10-16(18-15)12-5-3-2-4-6-12/h2-10H,1H3
DMAXBOU	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3
DMAXBOU	IK	NOQJBXPAMJLUSS-UHFFFAOYSA-N
DMAXBOU	IU	6-methyl-2-phenylchromen-4-one
DMAXBOU	CA	CAS 29976-75-8
DMAXBOU	DE	Discovery agent

DM8KMEG	ID	DM8KMEG
DM8KMEG	DN	6-Methyl-2-p-tolyl-chromen-4-one
DM8KMEG	HS	Investigative
DM8KMEG	SN	88952-74-3; CHEMBL133226; 6-methyl-2-(4-methylphenyl)chromen-4-one; 6-methyl-2-(4-methylphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 6-methyl-2-(4-methylphenyl)-; 6-Methyl-2-p-tolyl-chromen-4-one; ACMC-20lfbb; AC1LFDMB; 4',6-Dimethylflavone; BAS 01121723; Oprea1_016511; Oprea1_052018; SCHEMBL10024074; CTK3A4544; DTXSID70354567; MolPort-000-450-864; ZINC265995; STK888587; AKOS000603226; MCULE-9170697941; NCGC00320777-01; 6-methyl-2-(p-tolyl)-4H-chromen-4-one; ST45177106; AB00086662-03; AB00086662-01
DM8KMEG	DT	Small molecular drug
DM8KMEG	PC	776388
DM8KMEG	MW	250.29
DM8KMEG	FM	C17H14O2
DM8KMEG	IC	InChI=1S/C17H14O2/c1-11-3-6-13(7-4-11)17-10-15(18)14-9-12(2)5-8-16(14)19-17/h3-10H,1-2H3
DM8KMEG	CS	CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)C
DM8KMEG	IK	RDMTVGAVRNFIEE-UHFFFAOYSA-N
DM8KMEG	IU	6-methyl-2-(4-methylphenyl)chromen-4-one
DM8KMEG	CA	CAS 88952-74-3
DM8KMEG	DE	Discovery agent

DMFMK6Y	ID	DMFMK6Y
DMFMK6Y	DN	6-Methyl-2-pyridin-3-yl-chromen-4-one
DMFMK6Y	HS	Investigative
DMFMK6Y	SN	CHEMBL337443
DMFMK6Y	DT	Small molecular drug
DMFMK6Y	PC	10988288
DMFMK6Y	MW	237.25
DMFMK6Y	FM	C15H11NO2
DMFMK6Y	IC	InChI=1S/C15H11NO2/c1-10-4-5-14-12(7-10)13(17)8-15(18-14)11-3-2-6-16-9-11/h2-9H,1H3
DMFMK6Y	CS	CC1=CC2=C(C=C1)OC(=CC2=O)C3=CN=CC=C3
DMFMK6Y	IK	KPZRGUDQIYLPKX-UHFFFAOYSA-N
DMFMK6Y	IU	6-methyl-2-pyridin-3-ylchromen-4-one
DMFMK6Y	DE	Discovery agent

DMOVUP2	ID	DMOVUP2
DMOVUP2	DN	6-Methyl-4-(4-benzoylpiperazin-1-yl)coumarin
DMOVUP2	HS	Investigative
DMOVUP2	SN	CHEMBL461382; 6-Methyl-4-(4-benzoylpiperazin-1-yl)coumarin
DMOVUP2	DT	Small molecular drug
DMOVUP2	PC	44561935
DMOVUP2	MW	348.4
DMOVUP2	FM	C21H20N2O3
DMOVUP2	IC	InChI=1S/C21H20N2O3/c1-15-7-8-19-17(13-15)18(14-20(24)26-19)22-9-11-23(12-10-22)21(25)16-5-3-2-4-6-16/h2-8,13-14H,9-12H2,1H3
DMOVUP2	CS	CC1=CC2=C(C=C1)OC(=O)C=C2N3CCN(CC3)C(=O)C4=CC=CC=C4
DMOVUP2	IK	LSXVWZHPJRTGIV-UHFFFAOYSA-N
DMOVUP2	IU	4-(4-benzoylpiperazin-1-yl)-6-methylchromen-2-one
DMOVUP2	DE	Discovery agent

DMN0SYW	ID	DMN0SYW
DMN0SYW	DN	6-Methyl-4-(4-o-tolylpiperazin-1-yl)coumarin
DMN0SYW	HS	Investigative
DMN0SYW	SN	CHEMBL509670; 6-Methyl-4-(4-o-tolylpiperazin-1-yl)coumarin
DMN0SYW	DT	Small molecular drug
DMN0SYW	PC	44561860
DMN0SYW	MW	334.4
DMN0SYW	FM	C21H22N2O2
DMN0SYW	IC	InChI=1S/C21H22N2O2/c1-15-7-8-20-17(13-15)19(14-21(24)25-20)23-11-9-22(10-12-23)18-6-4-3-5-16(18)2/h3-8,13-14H,9-12H2,1-2H3
DMN0SYW	CS	CC1=CC2=C(C=C1)OC(=O)C=C2N3CCN(CC3)C4=CC=CC=C4C
DMN0SYW	IK	WISLSRMHRCKWLA-UHFFFAOYSA-N
DMN0SYW	IU	6-methyl-4-[4-(2-methylphenyl)piperazin-1-yl]chromen-2-one
DMN0SYW	DE	Discovery agent

DMU7E3O	ID	DMU7E3O
DMU7E3O	DN	6-Methyl-4-(4-phenylpiperazin-1-yl)coumarin
DMU7E3O	HS	Investigative
DMU7E3O	SN	CHEMBL461305; 6-Methyl-4-(4-phenylpiperazin-1-yl)coumarin
DMU7E3O	DT	Small molecular drug
DMU7E3O	PC	25141417
DMU7E3O	MW	320.4
DMU7E3O	FM	C20H20N2O2
DMU7E3O	IC	InChI=1S/C20H20N2O2/c1-15-7-8-19-17(13-15)18(14-20(23)24-19)22-11-9-21(10-12-22)16-5-3-2-4-6-16/h2-8,13-14H,9-12H2,1H3
DMU7E3O	CS	CC1=CC2=C(C=C1)OC(=O)C=C2N3CCN(CC3)C4=CC=CC=C4
DMU7E3O	IK	FYWXEEJKGHDKBJ-UHFFFAOYSA-N
DMU7E3O	IU	6-methyl-4-(4-phenylpiperazin-1-yl)chromen-2-one
DMU7E3O	DE	Discovery agent

DM1LW62	ID	DM1LW62
DM1LW62	DN	6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine
DM1LW62	HS	Investigative
DM1LW62	SN	CHEMBL596328; 6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine
DM1LW62	DT	Small molecular drug
DM1LW62	PC	46228435
DM1LW62	MW	218.26
DM1LW62	FM	C11H14N4O
DM1LW62	IC	InChI=1S/C11H14N4O/c1-8-6-9-10(13-7-14-11(9)16-8)15-4-2-12-3-5-15/h6-7,12H,2-5H2,1H3
DM1LW62	CS	CC1=CC2=C(N=CN=C2O1)N3CCNCC3
DM1LW62	IK	MNCCXFCOQHVIEX-UHFFFAOYSA-N
DM1LW62	IU	6-methyl-4-piperazin-1-ylfuro[2,3-d]pyrimidine
DM1LW62	DE	Discovery agent

DMO7RPW	ID	DMO7RPW
DMO7RPW	DN	6-Methyl-4-morpholin-4-yl-chromen-2-one
DMO7RPW	HS	Investigative
DMO7RPW	SN	CHEMBL361588; 6-methyl-4-morpholin-4-yl-chromen-2-one; 6-Methyl-4-morpholino-coumarin; MolPort-000-485-396; BDBM50159606; ZINC13608106; STK908587; AKOS002216573; MCULE-4100962736; NCGC00327351-01; 6-methyl-4-morpholin-4-ylchromen-2-one; ST096430; AB01322204-02
DMO7RPW	DT	Small molecular drug
DMO7RPW	PC	11075707
DMO7RPW	MW	245.27
DMO7RPW	FM	C14H15NO3
DMO7RPW	IC	InChI=1S/C14H15NO3/c1-10-2-3-13-11(8-10)12(9-14(16)18-13)15-4-6-17-7-5-15/h2-3,8-9H,4-7H2,1H3
DMO7RPW	CS	CC1=CC2=C(C=C1)OC(=O)C=C2N3CCOCC3
DMO7RPW	IK	XWKCKOOKHALUIU-UHFFFAOYSA-N
DMO7RPW	IU	6-methyl-4-morpholin-4-ylchromen-2-one
DMO7RPW	DE	Discovery agent

DMSLT3I	ID	DMSLT3I
DMSLT3I	DN	6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine
DMSLT3I	HS	Investigative
DMSLT3I	SN	2-amino-5,6-dihydro-6-methyl-4h-1,3-thiazine; 1121-91-1; 6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; (+/-)-AMT hydrochloride; 4H-1,3-Thiazin-2-amine, 5,6-dihydro-6-methyl-; AC1L1BOF; Lopac0_000085; SCHEMBL523755; CHEMBL106322; CHEBI:91610; MolPort-009-018-788; BATVOUKHGLKDGQ-UHFFFAOYSA-N; FCH842002; AKOS006274541; CCG-204180; NCGC00024834-02; NCGC00015114-03; NCGC00015114-04; KB-19997; 5,6-dihydro-6-methyl-4h-1,3-thiazin-2-amine; C-41564
DMSLT3I	DT	Small molecular drug
DMSLT3I	PC	1534
DMSLT3I	MW	130.21
DMSLT3I	FM	C5H10N2S
DMSLT3I	IC	InChI=1S/C5H10N2S/c1-4-2-3-7-5(6)8-4/h4H,2-3H2,1H3,(H2,6,7)
DMSLT3I	CS	CC1CCN=C(S1)N
DMSLT3I	IK	BATVOUKHGLKDGQ-UHFFFAOYSA-N
DMSLT3I	IU	6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine
DMSLT3I	CB	CHEBI:91610
DMSLT3I	DE	Discovery agent

DMN6IDK	ID	DMN6IDK
DMN6IDK	DN	6-Methylamino-5-Nitroisocytosine
DMN6IDK	HS	Investigative
DMN6IDK	DT	Small molecular drug
DMN6IDK	PC	135509070
DMN6IDK	MW	185.14
DMN6IDK	FM	C5H7N5O3
DMN6IDK	IC	InChI=1S/C5H7N5O3/c1-7-3-2(10(12)13)4(11)9-5(6)8-3/h1H3,(H4,6,7,8,9,11)
DMN6IDK	CS	CNC1=C(C(=O)NC(=N1)N)[N+](=O)[O-]
DMN6IDK	IK	NMCMUSAXKISTKW-UHFFFAOYSA-N
DMN6IDK	IU	2-amino-4-(methylamino)-5-nitro-1H-pyrimidin-6-one
DMN6IDK	DE	Discovery agent

DMTG8D0	ID	DMTG8D0
DMTG8D0	DN	6'-methylepibatidine
DMTG8D0	HS	Investigative
DMTG8D0	SN	CHEMBL235261; 6'-methylepibatidine; 6''-methylepibatidine; SCHEMBL6359134
DMTG8D0	DT	Small molecular drug
DMTG8D0	PC	9816611
DMTG8D0	MW	222.71
DMTG8D0	FM	C12H15ClN2
DMTG8D0	IC	InChI=1S/C12H15ClN2/c1-7-9(3-5-12(13)14-7)10-6-8-2-4-11(10)15-8/h3,5,8,10-11,15H,2,4,6H2,1H3
DMTG8D0	CS	CC1=C(C=CC(=N1)Cl)C2CC3CCC2N3
DMTG8D0	IK	CEIOZCMVGWULLM-UHFFFAOYSA-N
DMTG8D0	IU	2-(6-chloro-2-methylpyridin-3-yl)-7-azabicyclo[2.2.1]heptane
DMTG8D0	DE	Discovery agent

DMTNZKU	ID	DMTNZKU
DMTNZKU	DN	6-MORPHOLIN-4-YL-9H-PURINE
DMTNZKU	HS	Investigative
DMTNZKU	SN	2846-96-0; 6-Morpholinopurine; 6-(morpholin-4-yl)-9H-purine; 6-Morpholin-4-Yl-9h-Purine; 4-(1H-Purin-6-yl)morpholine; 4-(9h-purin-6-yl)morpholine; 4-(7H-purin-6-yl)morpholine; SMR000017638; MLS000080575; 2wmu; EINECS 220-645-3; 4-purin-6-ylmorpholine; 6-morpholino-9H-purine; 6-Morpholino-1H-purine; AC1Q4X9J; AC1Q1I5S; Oprea1_261650; Oprea1_519977; MLS000104086; SCHEMBL336612; CHEMBL271138; AC1L2Q64; BDBM33210; CTK4G1553; 9H-Purine,6-(4-morpholinyl)-; DTXSID80182656; MEOMXKNIFWDDGZ-UHFFFAOYSA-N; MolPort-002-610-718; HMS2298A04
DMTNZKU	DT	Small molecular drug
DMTNZKU	PC	76098
DMTNZKU	MW	205.22
DMTNZKU	FM	C9H11N5O
DMTNZKU	IC	InChI=1S/C9H11N5O/c1-3-15-4-2-14(1)9-7-8(11-5-10-7)12-6-13-9/h5-6H,1-4H2,(H,10,11,12,13)
DMTNZKU	CS	C1COCCN1C2=NC=NC3=C2NC=N3
DMTNZKU	IK	MEOMXKNIFWDDGZ-UHFFFAOYSA-N
DMTNZKU	IU	4-(7H-purin-6-yl)morpholine
DMTNZKU	CA	CAS 2846-96-0
DMTNZKU	DE	Discovery agent

DMHU78R	ID	DMHU78R
DMHU78R	DN	6-m-Tolyl-pteridine-2,4,7-triamine
DMHU78R	HS	Investigative
DMHU78R	SN	6-(3-methylphenyl)pteridine-2,4,7-triamine; 2853-70-5; UNII-Y75RNL3DWL; Y75RNL3DWL; CHEMBL48189; NSC19443; NSC 19443; 6-m-Tolyl-pteridine-2,4,7-triamine; NSC 639358; AC1Q4WBT; AC1L5FLS; CTK4G1672; DTXSID00182754; ZINC1566881; 6-meta-tolylpteridine-2,7-triamine; NSC639358; NSC-19443; BDBM50127144; 6-(m-tolyl)pteridine-2,4,7-triamine
DMHU78R	DT	Small molecular drug
DMHU78R	PC	227595
DMHU78R	MW	267.29
DMHU78R	FM	C13H13N7
DMHU78R	IC	InChI=1S/C13H13N7/c1-6-3-2-4-7(5-6)8-10(14)18-12-9(17-8)11(15)19-13(16)20-12/h2-5H,1H3,(H6,14,15,16,18,19,20)
DMHU78R	CS	CC1=CC(=CC=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N
DMHU78R	IK	YCKFHKBIDNIARX-UHFFFAOYSA-N
DMHU78R	IU	6-(3-methylphenyl)pteridine-2,4,7-triamine
DMHU78R	CA	CAS 2853-70-5
DMHU78R	DE	Discovery agent

DM84CTA	ID	DM84CTA
DM84CTA	DN	6-Nitro-1,4-dihydro-quinoxaline-2,3-dione
DM84CTA	HS	Investigative
DM84CTA	SN	6-nitroquinoxaline-2,3-diol; 1,4-Dihydro-6-nitroquinoxaline-2,3-dione; 6-Nitro-1,4-dihydroquinoxaline-2,3-dione; 6-Nitro-2,3-dihydroxyquinoxaline; 6-Nitro-2,3-quinoxalinediol; 2,3-Dihydroxy-6-nitroquinoxaline; 6-nitro-1,2,3,4-tetrahydroquinoxaline-2,3-dione; RYMLSFWVYNAKAR-UHFFFAOYSA-N; 6-Nitroquinoxaline-2,3(1H,4H)-dione; AC1N1YFP; 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione; AC1Q1Y5W; Oprea1_565337; CHEMBL23044; ACMC-209g63; 6-nitro quinoxaline-2,3-dion; SCHEMBL1259529; SCHEMBL14385403; 6-Nitro-2,3-quinoxalinediol #
DM84CTA	DT	Small molecular drug
DM84CTA	PC	4038142
DM84CTA	MW	207.14
DM84CTA	FM	C8H5N3O4
DM84CTA	IC	InChI=1S/C8H5N3O4/c12-7-8(13)10-6-3-4(11(14)15)1-2-5(6)9-7/h1-3H,(H,9,12)(H,10,13)
DM84CTA	CS	C1=CC2=C(C=C1[N+](=O)[O-])NC(=O)C(=O)N2
DM84CTA	IK	RYMLSFWVYNAKAR-UHFFFAOYSA-N
DM84CTA	IU	6-nitro-1,4-dihydroquinoxaline-2,3-dione
DM84CTA	DE	Discovery agent

DMRCTBA	ID	DMRCTBA
DMRCTBA	DN	6-Nitro-2-(3-nitro-phenyl)-chromen-4-one
DMRCTBA	HS	Investigative
DMRCTBA	SN	6,3'-Dinitroflavone; 3',6-Dinitroflavone; 100914-36-1; 4H-1-Benzopyran-4-one,6-nitro-2-(3-nitrophenyl)-; 6-3'-Dinitroflavone; ACMC-20m3ym; AC1L2SI8; 6-Nitro-2-(3-nitrophenyl)-4H-1-benzopyran-4-one; SCHEMBL4607216; CHEMBL292868; CTK3J9355; DTXSID90143576; AKOS030553659
DMRCTBA	DT	Small molecular drug
DMRCTBA	PC	127714
DMRCTBA	MW	312.23
DMRCTBA	FM	C15H8N2O6
DMRCTBA	IC	InChI=1S/C15H8N2O6/c18-13-8-15(9-2-1-3-10(6-9)16(19)20)23-14-5-4-11(17(21)22)7-12(13)14/h1-8H
DMRCTBA	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-]
DMRCTBA	IK	CNVQMRWAJHEFGZ-UHFFFAOYSA-N
DMRCTBA	IU	6-nitro-2-(3-nitrophenyl)chromen-4-one
DMRCTBA	CA	CAS 100914-36-1
DMRCTBA	DE	Discovery agent

DMM635K	ID	DMM635K
DMM635K	DN	6-Nitro-2-(4-nitro-phenyl)-chromen-4-one
DMM635K	HS	Investigative
DMM635K	SN	CHEMBL64704; 158555-11-4; 4',6-Dinitroflavone; 6-Nitro-2-(4-nitro-phenyl)-chromen-4-one; SCHEMBL7538912; CTK0B0325; DTXSID60437292; BDBM50037398; AKOS030553425; 4H-1-Benzopyran-4-one, 6-nitro-2-(4-nitrophenyl)-
DMM635K	DT	Small molecular drug
DMM635K	PC	10244983
DMM635K	MW	312.23
DMM635K	FM	C15H8N2O6
DMM635K	IC	InChI=1S/C15H8N2O6/c18-13-8-15(9-1-3-10(4-2-9)16(19)20)23-14-6-5-11(17(21)22)7-12(13)14/h1-8H
DMM635K	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-])[N+](=O)[O-]
DMM635K	IK	FPLQIUAPEQSTCP-UHFFFAOYSA-N
DMM635K	IU	6-nitro-2-(4-nitrophenyl)chromen-4-one
DMM635K	CA	CAS 158555-11-4
DMM635K	DE	Discovery agent

DMZTXDV	ID	DMZTXDV
DMZTXDV	DN	6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole
DMZTXDV	HS	Investigative
DMZTXDV	SN	CHEMBL63146
DMZTXDV	DT	Small molecular drug
DMZTXDV	PC	9950054
DMZTXDV	MW	345.4
DMZTXDV	FM	C20H15N3O3
DMZTXDV	IC	InChI=1S/C20H15N3O3/c24-23(25)15-8-11-18-19(13-15)22-20(21-18)12-14-6-9-17(10-7-14)26-16-4-2-1-3-5-16/h1-11,13H,12H2,(H,21,22)
DMZTXDV	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=C(N3)C=C(C=C4)[N+](=O)[O-]
DMZTXDV	IK	VRLHOPLBQZRORF-UHFFFAOYSA-N
DMZTXDV	IU	6-nitro-2-[(4-phenoxyphenyl)methyl]-1H-benzimidazole
DMZTXDV	DE	Discovery agent

DMVLID9	ID	DMVLID9
DMVLID9	DN	6-Nitro-2-phenyl-chromen-4-one
DMVLID9	HS	Investigative
DMVLID9	SN	6-Nitroflavone; CHEMBL26742
DMVLID9	DT	Small molecular drug
DMVLID9	PC	15731470
DMVLID9	MW	267.24
DMVLID9	FM	C15H9NO4
DMVLID9	IC	InChI=1S/C15H9NO4/c17-13-9-15(10-4-2-1-3-5-10)20-14-7-6-11(16(18)19)8-12(13)14/h1-9H
DMVLID9	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-]
DMVLID9	IK	ZDFHPVOEUNRYMP-UHFFFAOYSA-N
DMVLID9	IU	6-nitro-2-phenylchromen-4-one
DMVLID9	DE	Discovery agent

DMAOUQI	ID	DMAOUQI
DMAOUQI	DN	6-Nitro-2-piperazin-1-yl-4-vinyl-quinoline
DMAOUQI	HS	Investigative
DMAOUQI	SN	CHEMBL166870; 6-Nitro-2-piperazin-1-yl-4-vinyl-quinoline; SCHEMBL6365141; BFHGMHUBVIINKT-UHFFFAOYSA-N; BDBM50110583; 2-Piperazino-4-vinyl-6-nitroquinoline
DMAOUQI	DT	Small molecular drug
DMAOUQI	PC	44379685
DMAOUQI	MW	284.31
DMAOUQI	FM	C15H16N4O2
DMAOUQI	IC	InChI=1S/C15H16N4O2/c1-2-11-9-15(18-7-5-16-6-8-18)17-14-4-3-12(19(20)21)10-13(11)14/h2-4,9-10,16H,1,5-8H2
DMAOUQI	CS	C=CC1=CC(=NC2=C1C=C(C=C2)[N+](=O)[O-])N3CCNCC3
DMAOUQI	IK	BFHGMHUBVIINKT-UHFFFAOYSA-N
DMAOUQI	IU	4-ethenyl-6-nitro-2-piperazin-1-ylquinoline
DMAOUQI	DE	Discovery agent

DMCEG6V	ID	DMCEG6V
DMCEG6V	DN	6-Nitro-4-phenyl-2-piperazin-1-yl-quinoline
DMCEG6V	HS	Investigative
DMCEG6V	SN	CHEMBL167487; 6-Nitro-4-phenyl-2-piperazin-1-yl-quinoline; BDBM50110575
DMCEG6V	DT	Small molecular drug
DMCEG6V	PC	44379683
DMCEG6V	MW	334.4
DMCEG6V	FM	C19H18N4O2
DMCEG6V	IC	InChI=1S/C19H18N4O2/c24-23(25)15-6-7-18-17(12-15)16(14-4-2-1-3-5-14)13-19(21-18)22-10-8-20-9-11-22/h1-7,12-13,20H,8-11H2
DMCEG6V	CS	C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)C4=CC=CC=C4
DMCEG6V	IK	VABDCPDEFUPFHF-UHFFFAOYSA-N
DMCEG6V	IU	6-nitro-4-phenyl-2-piperazin-1-ylquinoline
DMCEG6V	DE	Discovery agent

DMYP7UG	ID	DMYP7UG
DMYP7UG	DN	6-Nitro-benzothiazole-2-sulfonic acid amide
DMYP7UG	HS	Investigative
DMYP7UG	SN	CHEMBL186335; 6-nitro-2-benzothiazolesulfonamide; 6-Nitro-benzothiazole-2-sulfonic acid amide; SCHEMBL10347981; VDPWQQORTOWPSP-UHFFFAOYSA-N; 6-nitrobenzothiazole-2-sulfonamide; BDBM50155503
DMYP7UG	DT	Small molecular drug
DMYP7UG	PC	13393427
DMYP7UG	MW	259.3
DMYP7UG	FM	C7H5N3O4S2
DMYP7UG	IC	InChI=1S/C7H5N3O4S2/c8-16(13,14)7-9-5-2-1-4(10(11)12)3-6(5)15-7/h1-3H,(H2,8,13,14)
DMYP7UG	CS	C1=CC2=C(C=C1[N+](=O)[O-])SC(=N2)S(=O)(=O)N
DMYP7UG	IK	VDPWQQORTOWPSP-UHFFFAOYSA-N
DMYP7UG	IU	6-nitro-1,3-benzothiazole-2-sulfonamide
DMYP7UG	DE	Discovery agent

DM2WZCX	ID	DM2WZCX
DM2WZCX	DN	6-Nitroindazole
DM2WZCX	HS	Investigative
DM2WZCX	SN	6-Nitro-1H-indazole; 6-Nitroindazole; 7597-18-4; 6-Nitro-2H-indazole; 6-Nitroisoindazole; 1H-INDAZOLE, 6-NITRO-; 65750-02-9; 2H-Indazole, 6-nitro-; CCRIS 3263; EINECS 231-500-9; NSC 35066; NSC 56816; BRN 0007812; CHEMBL54277; MLS000069593; ORZRMRUXSPNQQL-UHFFFAOYSA-N; SMR000059016; 6NI; 6-nitro-indazol; indazole,6-nitro; Tocris-0710; PubChem20594; Opera_ID_909; 2H-Indazole,6-nitro-; AC1Q1XVW; 6-Nitroindazole, 97%; ACMC-209p0z; AC1L2NB1; AC1Q1Y5L; MLS001148387; KSC379M3P; 5-23-06-00183 (Beilstein Handbook Reference); SCHEMBL271522
DM2WZCX	DT	Small molecular drug
DM2WZCX	PC	24239
DM2WZCX	MW	163.13
DM2WZCX	FM	C7H5N3O2
DM2WZCX	IC	InChI=1S/C7H5N3O2/c11-10(12)6-2-1-5-4-8-9-7(5)3-6/h1-4H,(H,8,9)
DM2WZCX	CS	C1=CC2=C(C=C1[N+](=O)[O-])NN=C2
DM2WZCX	IK	ORZRMRUXSPNQQL-UHFFFAOYSA-N
DM2WZCX	IU	6-nitro-1H-indazole
DM2WZCX	CA	CAS 7597-18-4
DM2WZCX	DE	Discovery agent

DMXJFCQ	ID	DMXJFCQ
DMXJFCQ	DN	6-n-octylaminouracil
DMXJFCQ	HS	Investigative
DMXJFCQ	SN	6-n-octyl aminouracil
DMXJFCQ	DT	Small molecular drug
DMXJFCQ	PC	10354234
DMXJFCQ	MW	239.31
DMXJFCQ	FM	C12H21N3O2
DMXJFCQ	IC	InChI=1S/C12H21N3O2/c1-2-3-4-5-6-7-8-13-10-9-11(16)15-12(17)14-10/h9H,2-8H2,1H3,(H3,13,14,15,16,17)
DMXJFCQ	CS	CCCCCCCCNC1=CC(=O)NC(=O)N1
DMXJFCQ	IK	PFSWASUQURIOOR-UHFFFAOYSA-N
DMXJFCQ	IU	6-(octylamino)-1H-pyrimidine-2,4-dione
DMXJFCQ	DE	Discovery agent

DMDPA2T	ID	DMDPA2T
DMDPA2T	DN	6-N-propyl -4-trifluoromethylquinolin-2(1H)-one
DMDPA2T	HS	Investigative
DMDPA2T	SN	SCHEMBL1771502; CHEMBL405835; BDBM18527; ZINC14968235; 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-one, 4a; 4-(Trifluoromethyl)-6-(propylamino)quinoline-2(1H)-one
DMDPA2T	DT	Small molecular drug
DMDPA2T	PC	9903530
DMDPA2T	MW	270.25
DMDPA2T	FM	C13H13F3N2O
DMDPA2T	IC	InChI=1S/C13H13F3N2O/c1-2-5-17-8-3-4-11-9(6-8)10(13(14,15)16)7-12(19)18-11/h3-4,6-7,17H,2,5H2,1H3,(H,18,19)
DMDPA2T	CS	CCCNC1=CC2=C(C=C1)NC(=O)C=C2C(F)(F)F
DMDPA2T	IK	YGYHGNGCPLCHQH-UHFFFAOYSA-N
DMDPA2T	IU	6-(propylamino)-4-(trifluoromethyl)-1H-quinolin-2-one
DMDPA2T	DE	Discovery agent

DMDIW08	ID	DMDIW08
DMDIW08	DN	6-O-Cyclohexylmethyl Guanine
DMDIW08	HS	Investigative
DMDIW08	SN	6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 6-(cyclohexylmethoxy)-9H-purin-2-amine; 6-O-CYCLOHEXYLMETHYL GUANINE; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06
DMDIW08	DT	Small molecular drug
DMDIW08	PC	4564
DMDIW08	MW	247.3
DMDIW08	FM	C12H17N5O
DMDIW08	IC	InChI=1S/C12H17N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h7-8H,1-6H2,(H3,13,14,15,16,17)
DMDIW08	CS	C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)N
DMDIW08	IK	MWGXGTJJAOZBNW-UHFFFAOYSA-N
DMDIW08	IU	6-(cyclohexylmethoxy)-7H-purin-2-amine
DMDIW08	DE	Discovery agent

DM6YHBR	ID	DM6YHBR
DM6YHBR	DN	6-O-Phosphoryl Inosine Monophosphate
DM6YHBR	HS	Investigative
DM6YHBR	SN	6-o-phosphoryl inosine monophosphate; IMO; AC1L9GY0; SCHEMBL4321566; DB03510; 6-(phosphonooxy)-9-(5-O-phosphono-beta-D-ribofuranosyl)-9H-purine; [9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl] dihydrogen phosphate
DM6YHBR	DT	Small molecular drug
DM6YHBR	PC	444818
DM6YHBR	MW	428.19
DM6YHBR	FM	C10H14N4O11P2
DM6YHBR	IC	InChI=1S/C10H14N4O11P2/c15-6-4(1-23-26(17,18)19)24-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)25-27(20,21)22/h2-4,6-7,10,15-16H,1H2,(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1
DM6YHBR	CS	C1=NC2=C(C(=N1)OP(=O)(O)O)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
DM6YHBR	IK	RXRZOKQPANIEDW-KQYNXXCUSA-N
DM6YHBR	IU	[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl] dihydrogen phosphate
DM6YHBR	DE	Discovery agent

DM4TX9O	ID	DM4TX9O
DM4TX9O	DN	6-o-tolylquinazolin-2-amine
DM4TX9O	HS	Investigative
DM4TX9O	SN	6-o-tolylquinazolin-2-amine; CHEMBL215952; SCHEMBL5494575; RAWAQXBVMDKSIO-UHFFFAOYSA-N; ZINC35049815
DM4TX9O	DT	Small molecular drug
DM4TX9O	PC	16086113
DM4TX9O	MW	235.28
DM4TX9O	FM	C15H13N3
DM4TX9O	IC	InChI=1S/C15H13N3/c1-10-4-2-3-5-13(10)11-6-7-14-12(8-11)9-17-15(16)18-14/h2-9H,1H3,(H2,16,17,18)
DM4TX9O	CS	CC1=CC=CC=C1C2=CC3=CN=C(N=C3C=C2)N
DM4TX9O	IK	RAWAQXBVMDKSIO-UHFFFAOYSA-N
DM4TX9O	IU	6-(2-methylphenyl)quinazolin-2-amine
DM4TX9O	DE	Discovery agent

DMPBE5H	ID	DMPBE5H
DMPBE5H	DN	6-oxo-16-formyl-estrone
DMPBE5H	HS	Investigative
DMPBE5H	SN	CHEMBL202432
DMPBE5H	DT	Small molecular drug
DMPBE5H	PC	44407480
DMPBE5H	MW	312.4
DMPBE5H	FM	C19H20O4
DMPBE5H	IC	InChI=1S/C19H20O4/c1-19-5-4-13-12-3-2-11(21)7-15(12)17(22)8-14(13)16(19)6-10(9-20)18(19)23/h2-3,7,9,13-14,16,20-21H,4-6,8H2,1H3/b10-9-/t13?,14?,16?,19-/m0/s1
DMPBE5H	CS	C[C@]12CCC3C(C1C/C(=C/O)/C2=O)CC(=O)C4=C3C=CC(=C4)O
DMPBE5H	IK	ZRLTUTFRAVMGPJ-SSNSBQRSSA-N
DMPBE5H	IU	(13S,16Z)-3-hydroxy-16-(hydroxymethylidene)-13-methyl-8,9,11,12,14,15-hexahydro-7H-cyclopenta[a]phenanthrene-6,17-dione
DMPBE5H	DE	Discovery agent

DMKMYAJ	ID	DMKMYAJ
DMKMYAJ	DN	6-oxo-estrone
DMKMYAJ	HS	Investigative
DMKMYAJ	SN	6-Ketoestrone; 1476-34-2; 6-Oxoestrone; 6-Keto Estrone; CHEMBL1628005; 3-Hydroxyestra-1,3,5(10)-triene-6,17-dione; 6-oxo-estrone; Estra-1,3,5(10)-triene-6,17-dione, 3-hydroxy-; SCHEMBL1977286; DTXSID50514400; JOVYPIGRPWIXHQ-ONUSSAAZSA-N; MFCD00056399; BDBM50370698; ZINC13547985; 1,3,5(10)-Estratrien-3-ol-6,17-dione; C-44091; 3-Hydroxyestra-1,3,5(10)-triene-6,17-dione #
DMKMYAJ	DT	Small molecular drug
DMKMYAJ	PC	12985714
DMKMYAJ	MW	284.3
DMKMYAJ	FM	C18H20O3
DMKMYAJ	IC	InChI=1S/C18H20O3/c1-18-7-6-12-11-3-2-10(19)8-14(11)16(20)9-13(12)15(18)4-5-17(18)21/h2-3,8,12-13,15,19H,4-7,9H2,1H3/t12-,13-,15+,18+/m1/s1
DMKMYAJ	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=O)C4=C3C=CC(=C4)O
DMKMYAJ	IK	JOVYPIGRPWIXHQ-ONUSSAAZSA-N
DMKMYAJ	IU	(8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-6,17-dione
DMKMYAJ	CA	CAS 1476-34-2
DMKMYAJ	DE	Discovery agent

DMVYIN2	ID	DMVYIN2
DMVYIN2	DN	6-Phenoxy-hexane-1-thiol
DMVYIN2	HS	Investigative
DMVYIN2	SN	CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089
DMVYIN2	DT	Small molecular drug
DMVYIN2	PC	11298778
DMVYIN2	MW	210.34
DMVYIN2	FM	C12H18OS
DMVYIN2	IC	InChI=1S/C12H18OS/c14-11-7-2-1-6-10-13-12-8-4-3-5-9-12/h3-5,8-9,14H,1-2,6-7,10-11H2
DMVYIN2	CS	C1=CC=C(C=C1)OCCCCCCS
DMVYIN2	IK	QUBILGABLBGKPV-UHFFFAOYSA-N
DMVYIN2	IU	6-phenoxyhexane-1-thiol
DMVYIN2	DE	Discovery agent

DM3UBR5	ID	DM3UBR5
DM3UBR5	DN	6-phenyl-3-(pyridin-4-yl)-1H-indole
DM3UBR5	HS	Investigative
DM3UBR5	SN	CHEMBL207621; 6-phenyl-3-(pyridin-4-yl)-1H-indole
DM3UBR5	DT	Small molecular drug
DM3UBR5	PC	44410733
DM3UBR5	MW	270.3
DM3UBR5	FM	C19H14N2
DM3UBR5	IC	InChI=1S/C19H14N2/c1-2-4-14(5-3-1)16-6-7-17-18(13-21-19(17)12-16)15-8-10-20-11-9-15/h1-13,21H
DM3UBR5	CS	C1=CC=C(C=C1)C2=CC3=C(C=C2)C(=CN3)C4=CC=NC=C4
DM3UBR5	IK	QPUYBWAAFGEKSG-UHFFFAOYSA-N
DM3UBR5	IU	6-phenyl-3-pyridin-4-yl-1H-indole
DM3UBR5	DE	Discovery agent

DMG6PZT	ID	DMG6PZT
DMG6PZT	DN	6-Phenylaminomethyl-quinazoline-2,4-diamine
DMG6PZT	HS	Investigative
DMG6PZT	SN	CHEMBL80746; 6-(anilinomethyl)quinazoline-2,4-diamine; 27133-39-7; AC1LAG5J; 6-Phenylaminomethyl-quinazoline-2,4-diamine; SCHEMBL4788363; CTK0I5781; DTXSID30333156; ZINC3814839; BDBM50101637; [(2,4-Diaminoquinazolin-6-yl)methyl]phenylamine; 2,4-Quinazolinediamine, 6-[(phenylamino)methyl]-
DMG6PZT	DT	Small molecular drug
DMG6PZT	PC	487412
DMG6PZT	MW	265.31
DMG6PZT	FM	C15H15N5
DMG6PZT	IC	InChI=1S/C15H15N5/c16-14-12-8-10(6-7-13(12)19-15(17)20-14)9-18-11-4-2-1-3-5-11/h1-8,18H,9H2,(H4,16,17,19,20)
DMG6PZT	CS	C1=CC=C(C=C1)NCC2=CC3=C(C=C2)N=C(N=C3N)N
DMG6PZT	IK	SQHNSLWKFCXHKZ-UHFFFAOYSA-N
DMG6PZT	IU	6-(anilinomethyl)quinazoline-2,4-diamine
DMG6PZT	CA	CAS 27133-39-7
DMG6PZT	DE	Discovery agent

DMIKRP6	ID	DMIKRP6
DMIKRP6	DN	6-phenylethynyl-nicotinic acid methyl ester
DMIKRP6	HS	Investigative
DMIKRP6	SN	6-phenylethynyl-nicotinic acid methyl ester; CHEMBL400735; BDBM50231751; 6-(Phenylethynyl)pyridine-3-carboxylic acid methyl ester
DMIKRP6	DT	Small molecular drug
DMIKRP6	PC	14343219
DMIKRP6	MW	237.25
DMIKRP6	FM	C15H11NO2
DMIKRP6	IC	InChI=1S/C15H11NO2/c1-18-15(17)13-8-10-14(16-11-13)9-7-12-5-3-2-4-6-12/h2-6,8,10-11H,1H3
DMIKRP6	CS	COC(=O)C1=CN=C(C=C1)C#CC2=CC=CC=C2
DMIKRP6	IK	DRFBUAIOGNADQC-UHFFFAOYSA-N
DMIKRP6	IU	methyl 6-(2-phenylethynyl)pyridine-3-carboxylate
DMIKRP6	DE	Discovery agent

DMLJN8Z	ID	DMLJN8Z
DMLJN8Z	DN	6-Phenylhexylcarbamic Acid Biphenyl-3-yl Ester
DMLJN8Z	HS	Investigative
DMLJN8Z	SN	CHEMBL486493; 6-Phenylhexylcarbamic Acid Biphenyl-3-yl Ester
DMLJN8Z	DT	Small molecular drug
DMLJN8Z	PC	24881806
DMLJN8Z	MW	373.5
DMLJN8Z	FM	C25H27NO2
DMLJN8Z	IC	InChI=1S/C25H27NO2/c27-25(26-19-10-2-1-5-12-21-13-6-3-7-14-21)28-24-18-11-17-23(20-24)22-15-8-4-9-16-22/h3-4,6-9,11,13-18,20H,1-2,5,10,12,19H2,(H,26,27)
DMLJN8Z	CS	C1=CC=C(C=C1)CCCCCCNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMLJN8Z	IK	MGXPWHVQDGCMAC-UHFFFAOYSA-N
DMLJN8Z	IU	(3-phenylphenyl) N-(6-phenylhexyl)carbamate
DMLJN8Z	DE	Discovery agent

DMPA534	ID	DMPA534
DMPA534	DN	6-Phenylmethanesulfonyl-2H-pyridazin-3-one
DMPA534	HS	Investigative
DMPA534	SN	6-Phenylmethanesulfonyl-2H-pyridazin-3-one; 92016-73-4; CHEMBL199028; BDBM16611; Benzyl-Substituted Sulfonylpyridazinone, 15
DMPA534	DT	Small molecular drug
DMPA534	PC	23647383
DMPA534	MW	250.28
DMPA534	FM	C11H10N2O3S
DMPA534	IC	InChI=1S/C11H10N2O3S/c14-10-6-7-11(13-12-10)17(15,16)8-9-4-2-1-3-5-9/h1-7H,8H2,(H,12,14)
DMPA534	CS	C1=CC=C(C=C1)CS(=O)(=O)C2=NNC(=O)C=C2
DMPA534	IK	QUZYPEPCSQAPEU-UHFFFAOYSA-N
DMPA534	IU	3-benzylsulfonyl-1H-pyridazin-6-one
DMPA534	DE	Discovery agent

DMEYOF7	ID	DMEYOF7
DMEYOF7	DN	6-Phenyl-naphthalen-2-ol
DMEYOF7	HS	Investigative
DMEYOF7	SN	6-phenyl-2-naphthol; 6-Phenylnaphthalene-2-ol; CHEMBL191714; 6-Phenyl-naphthalen-2-ol; SCHEMBL3019399; PZOXFBPKKGTQDZ-UHFFFAOYSA-N; ZINC13644999
DMEYOF7	DT	Small molecular drug
DMEYOF7	PC	10125182
DMEYOF7	MW	220.26
DMEYOF7	FM	C16H12O
DMEYOF7	IC	InChI=1S/C16H12O/c17-16-9-8-14-10-13(6-7-15(14)11-16)12-4-2-1-3-5-12/h1-11,17H
DMEYOF7	CS	C1=CC=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)O
DMEYOF7	IK	PZOXFBPKKGTQDZ-UHFFFAOYSA-N
DMEYOF7	IU	6-phenylnaphthalen-2-ol
DMEYOF7	DE	Discovery agent

DMXTV1B	ID	DMXTV1B
DMXTV1B	DN	6-phenylpyridazin-3-yl thiophene-2-carboxylate
DMXTV1B	HS	Investigative
DMXTV1B	SN	CHEMBL1253380; AC1O4BXS; 6-phenylpyridazin-3-yl thiophene-2-carboxylate; MolPort-002-097-410; HMS1597J02; ZINC1059557; BDBM50326574; MCULE-6134548476; (6-phenylpyridazin-3-yl) thiophene-2-carboxylate
DMXTV1B	DT	Small molecular drug
DMXTV1B	PC	6403448
DMXTV1B	MW	282.3
DMXTV1B	FM	C15H10N2O2S
DMXTV1B	IC	InChI=1S/C15H10N2O2S/c18-15(13-7-4-10-20-13)19-14-9-8-12(16-17-14)11-5-2-1-3-6-11/h1-10H
DMXTV1B	CS	C1=CC=C(C=C1)C2=NN=C(C=C2)OC(=O)C3=CC=CS3
DMXTV1B	IK	WIJDBDCYFCOSHK-UHFFFAOYSA-N
DMXTV1B	IU	(6-phenylpyridazin-3-yl) thiophene-2-carboxylate
DMXTV1B	DE	Discovery agent

DMZ76NQ	ID	DMZ76NQ
DMZ76NQ	DN	6-Phenylsulfanyl-9H-purine
DMZ76NQ	HS	Investigative
DMZ76NQ	SN	Purine, 6-(phenylthio)-; 6-(Phenylthio)purine; 1H-Purine, 6-(phenylthio)-; 5450-35-1; NSC 15746; UNII-3KH11DU8DY; 6-phenylsulfanyl-7H-purine; BRN 0013668; 3KH11DU8DY; AI3-52068; AC1Q4XUH; AC1L3TI0; 4-26-00-01985 (Beilstein Handbook Reference); 9H-Purine,6-(phenylthio)-; SCHEMBL796397; 6-(phenylsulfanyl)-7H-purine; CHEMBL175600; 9H-Purine, 6-(phenylthio)-; CTK5A1336; DTXSID20202908; NSC15746; ZINC13608565; NSC-15746; AKOS030562402
DMZ76NQ	DT	Small molecular drug
DMZ76NQ	PC	95065
DMZ76NQ	MW	228.28
DMZ76NQ	FM	C11H8N4S
DMZ76NQ	IC	InChI=1S/C11H8N4S/c1-2-4-8(5-3-1)16-11-9-10(13-6-12-9)14-7-15-11/h1-7H,(H,12,13,14,15)
DMZ76NQ	CS	C1=CC=C(C=C1)SC2=NC=NC3=C2NC=N3
DMZ76NQ	IK	CTDPZFBZKUUAED-UHFFFAOYSA-N
DMZ76NQ	IU	6-phenylsulfanyl-7H-purine
DMZ76NQ	CA	CAS 5450-35-1
DMZ76NQ	DE	Discovery agent

DM3OLM6	ID	DM3OLM6
DM3OLM6	DN	6-phenylsulfanylhexanoic acid hydroxamide
DM3OLM6	HS	Investigative
DM3OLM6	SN	Hexanamide, N-hydroxy-6-(phenylthio)-; 6-phenylsulfanylhexanoic acid hydroxamide; CHEMBL203028; SCHEMBL7317658
DM3OLM6	DT	Small molecular drug
DM3OLM6	PC	11637291
DM3OLM6	MW	239.34
DM3OLM6	FM	C12H17NO2S
DM3OLM6	IC	InChI=1S/C12H17NO2S/c14-12(13-15)9-5-2-6-10-16-11-7-3-1-4-8-11/h1,3-4,7-8,15H,2,5-6,9-10H2,(H,13,14)
DM3OLM6	CS	C1=CC=C(C=C1)SCCCCCC(=O)NO
DM3OLM6	IK	RFQHGQGHSXXDPZ-UHFFFAOYSA-N
DM3OLM6	IU	N-hydroxy-6-phenylsulfanylhexanamide
DM3OLM6	DE	Discovery agent

DM6GWRB	ID	DM6GWRB
DM6GWRB	DN	6-Phenylsulfanylmethyl-pteridine-2,4-diamine
DM6GWRB	HS	Investigative
DM6GWRB	SN	NSC232965; 57963-58-3; UNII-D5VU87D2MN; D5VU87D2MN; 2,4-Diamino-6-phenylthiomethyl-pteridine; CHEMBL279243; 6-(phenylsulfanylmethyl)pteridine-2,4-diamine; 2,4-Pteridinediamine, 6-((phenylthio)methyl)-; 2,4-Pteridinediamine, 6-[(phenylthio)methyl]-; NSC 232965; AC1L7PXP; 6-Phenylsulfanylmethyl-pteridine-2,4-diamine; ZINC5088; SCHEMBL11630631; DTXSID30206699; BDBM50049602; NSC-232965; 6-(Phenylthiomethyl)pteridine-2,4-diamine
DM6GWRB	DT	Small molecular drug
DM6GWRB	PC	314604
DM6GWRB	MW	284.34
DM6GWRB	FM	C13H12N6S
DM6GWRB	IC	InChI=1S/C13H12N6S/c14-11-10-12(19-13(15)18-11)16-6-8(17-10)7-20-9-4-2-1-3-5-9/h1-6H,7H2,(H4,14,15,16,18,19)
DM6GWRB	CS	C1=CC=C(C=C1)SCC2=CN=C3C(=N2)C(=NC(=N3)N)N
DM6GWRB	IK	ZJOATKLQTCGUSP-UHFFFAOYSA-N
DM6GWRB	IU	6-(phenylsulfanylmethyl)pteridine-2,4-diamine
DM6GWRB	CA	CAS 57963-58-3
DM6GWRB	DE	Discovery agent

DME230I	ID	DME230I
DME230I	DN	6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine
DME230I	HS	Investigative
DME230I	SN	6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamine; CHEMBL311108; CTK7E1320; ZINC13588156; BDBM50137196; AKOS015965750; 6-phenylthieno[3,2-d]pyrimidin-4-ylamine
DME230I	DT	Small molecular drug
DME230I	PC	11499583
DME230I	MW	227.29
DME230I	FM	C12H9N3S
DME230I	IC	InChI=1S/C12H9N3S/c13-12-11-9(14-7-15-12)6-10(16-11)8-4-2-1-3-5-8/h1-7H,(H2,13,14,15)
DME230I	CS	C1=CC=C(C=C1)C2=CC3=C(S2)C(=NC=N3)N
DME230I	IK	WQVHTLKGGYMXIO-UHFFFAOYSA-N
DME230I	IU	6-phenylthieno[3,2-d]pyrimidin-4-amine
DME230I	DE	Discovery agent

DMB1QCY	ID	DMB1QCY
DMB1QCY	DN	6-Phosphogluconic Acid
DMB1QCY	HS	Investigative
DMB1QCY	SN	6-phosphogluconic acid; 6-Phosphogluconate; 921-62-0; 6-phospho-D-gluconic acid; 6-phospho-D-gluconate; 6-O-phosphono-D-gluconic acid; Gluconic acid-6-phosphate; (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(phosphonooxy)hexanoic acid; UNII-W31WK7B8U0; D-Gluconic acid 6-(dihydrogen phosphate); CHEBI:48928; W31WK7B8U0; CHEMBL1230513; BIRSGZKFKXLSJQ-SQOUGZDYSA-N; 1pgp; 6PG; 6-phosphogluconic acid barium salt; C6H13O10P; 6-p-gluconate; EINECS 213-069-9; D-Gluconic acid, 6-(dihydrogen phosphate); bmse000198; AC1Q6RV2; AC1L3M6P; SCHEMBL50297
DMB1QCY	DT	Small molecular drug
DMB1QCY	PC	91493
DMB1QCY	MW	276.14
DMB1QCY	FM	C6H13O10P
DMB1QCY	IC	InChI=1S/C6H13O10P/c7-2(1-16-17(13,14)15)3(8)4(9)5(10)6(11)12/h2-5,7-10H,1H2,(H,11,12)(H2,13,14,15)/t2-,3-,4+,5-/m1/s1
DMB1QCY	CS	C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)OP(=O)(O)O
DMB1QCY	IK	BIRSGZKFKXLSJQ-SQOUGZDYSA-N
DMB1QCY	IU	(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-phosphonooxyhexanoic acid
DMB1QCY	CA	CAS 921-62-0
DMB1QCY	CB	CHEBI:48928
DMB1QCY	DE	Discovery agent

DMIAQUC	ID	DMIAQUC
DMIAQUC	DN	6-p-Tolylamino-1H-pyrimidine-2,4-dione
DMIAQUC	HS	Investigative
DMIAQUC	SN	CHEMBL57397; 6-p-Tolylamino-1H-pyrimidine-2,4-dione; 6948-11-4; 6-[(4-methylphenyl)amino]pyrimidine-2,4(1h,3h)-dione; NSC55724; AC1Q6LTF; CBMicro_020485; Oprea1_316803; Oprea1_212741; SCHEMBL5298937; AC1L6E57; CTK5D0097; 2,4(1H,3H)-Pyrimidinedione, 6-[(4-methylphenyl)amino]-; MolPort-003-722-204; ZINC227430; CCG-8301; NSC-55724; BDBM50022161; AKOS001620102; MCULE-6764538026; BIM-0020481.P001; EU-0034750; SR-01000400155; SR-01000400155-1
DMIAQUC	DT	Small molecular drug
DMIAQUC	PC	244640
DMIAQUC	MW	217.22
DMIAQUC	FM	C11H11N3O2
DMIAQUC	IC	InChI=1S/C11H11N3O2/c1-7-2-4-8(5-3-7)12-9-6-10(15)14-11(16)13-9/h2-6H,1H3,(H3,12,13,14,15,16)
DMIAQUC	CS	CC1=CC=C(C=C1)NC2=CC(=O)NC(=O)N2
DMIAQUC	IK	QKHUPPJBNXWLJB-UHFFFAOYSA-N
DMIAQUC	IU	6-(4-methylanilino)-1H-pyrimidine-2,4-dione
DMIAQUC	CA	CAS 6948-11-4
DMIAQUC	DE	Discovery agent

DM86XG5	ID	DM86XG5
DM86XG5	DN	6-Pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol
DM86XG5	HS	Investigative
DM86XG5	SN	CHEMBL461458; 6-Pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol
DM86XG5	DT	Small molecular drug
DM86XG5	PC	25180104
DM86XG5	MW	225.28
DM86XG5	FM	C15H15NO
DM86XG5	IC	InChI=1S/C15H15NO/c17-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-16-10-14/h1-4,7-8,10,15,17H,5-6,9H2
DM86XG5	CS	C1CC2=C(CC1O)C=CC(=C2)C3=CN=CC=C3
DM86XG5	IK	ROYVUWJYYRTBSK-UHFFFAOYSA-N
DM86XG5	IU	6-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol
DM86XG5	DE	Discovery agent

DMG5ABT	ID	DMG5ABT
DMG5ABT	DN	6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one
DMG5ABT	HS	Investigative
DMG5ABT	SN	6-Pyridin-3-yl-3,4-dihydroquinolin-2(1H)-on
DMG5ABT	PC	13728862
DMG5ABT	MW	224.26
DMG5ABT	FM	C14H12N2O
DMG5ABT	IC	InChI=1S/C14H12N2O/c17-14-6-4-11-8-10(3-5-13(11)16-14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2,(H,16,17)
DMG5ABT	CS	C1CC(=O)NC2=C1C=C(C=C2)C3=CN=CC=C3
DMG5ABT	IK	MPGBYGNPFRLHAO-UHFFFAOYSA-N
DMG5ABT	IU	6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one
DMG5ABT	CA	CAS 99471-41-7
DMG5ABT	DE	Discovery agent

DMIM5DL	ID	DMIM5DL
DMIM5DL	DN	6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one
DMIM5DL	HS	Investigative
DMIM5DL	SN	CHEMBL462093; 6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one; 2(1H)-Naphthalenone,3,4-dihydro-6-(3-pyridinyl)-; BDBM50273703
DMIM5DL	DT	Small molecular drug
DMIM5DL	PC	25180108
DMIM5DL	MW	223.27
DMIM5DL	FM	C15H13NO
DMIM5DL	IC	InChI=1S/C15H13NO/c17-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-16-10-14/h1-4,7-8,10H,5-6,9H2
DMIM5DL	CS	C1CC2=C(CC1=O)C=CC(=C2)C3=CN=CC=C3
DMIM5DL	IK	XMIVJNDWTQQRAQ-UHFFFAOYSA-N
DMIM5DL	IU	6-pyridin-3-yl-3,4-dihydro-1H-naphthalen-2-one
DMIM5DL	DE	Discovery agent

DMHAS2B	ID	DMHAS2B
DMHAS2B	DN	6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione
DMHAS2B	HS	Investigative
DMHAS2B	SN	CHEMBL511329; 6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione; SCHEMBL1119425; BBIRVEDVKRWBOZ-UHFFFAOYSA-N; BDBM50273815; ZINC40380214; 6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione
DMHAS2B	DT	Small molecular drug
DMHAS2B	PC	25180300
DMHAS2B	MW	240.33
DMHAS2B	FM	C14H12N2S
DMHAS2B	IC	InChI=1S/C14H12N2S/c17-14-6-4-11-8-10(3-5-13(11)16-14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2,(H,16,17)
DMHAS2B	CS	C1CC(=S)NC2=C1C=C(C=C2)C3=CN=CC=C3
DMHAS2B	IK	BBIRVEDVKRWBOZ-UHFFFAOYSA-N
DMHAS2B	IU	6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione
DMHAS2B	DE	Discovery agent

DMGWNDB	ID	DMGWNDB
DMGWNDB	DN	6-Pyridin-3-yl-naphthalen-2-ol
DMGWNDB	HS	Investigative
DMGWNDB	SN	6-pyridin-3-ylnaphthalen-2-ol; CHEMBL195571; SCHEMBL3008490; BDBM8906; Pyridine-substituted naphthalene 3; 6-(pyridin-3-yl)naphthalen-2-ol
DMGWNDB	DT	Small molecular drug
DMGWNDB	PC	11514074
DMGWNDB	MW	221.25
DMGWNDB	FM	C15H11NO
DMGWNDB	IC	InChI=1S/C15H11NO/c17-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-16-10-14/h1-10,17H
DMGWNDB	CS	C1=CC(=CN=C1)C2=CC3=C(C=C2)C=C(C=C3)O
DMGWNDB	IK	MDXMZUQFVFTPDO-UHFFFAOYSA-N
DMGWNDB	IU	6-pyridin-3-ylnaphthalen-2-ol
DMGWNDB	DE	Discovery agent

DMIA7ND	ID	DMIA7ND
DMIA7ND	DN	6s-5,6,7,8-Tetrahydrobiopterin
DMIA7ND	HS	Investigative
DMIA7ND	DT	Small molecular drug
DMIA7ND	PC	135509079
DMIA7ND	MW	241.25
DMIA7ND	FM	C9H15N5O3
DMIA7ND	IC	InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4-,6-/m1/s1
DMIA7ND	CS	C[C@H]([C@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DMIA7ND	IK	FNKQXYHWGSIFBK-ZMIZWQJLSA-N
DMIA7ND	IU	(6R)-2-amino-6-[(1S,2R)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one
DMIA7ND	DE	Discovery agent

DMDO13Y	ID	DMDO13Y
DMDO13Y	DN	6-Styryl-naphthalene-2-carboxamidine
DMDO13Y	HS	Investigative
DMDO13Y	SN	CHEMBL185345; 6-Styryl-naphthalene-2-carboxamidine; ZINC28365935
DMDO13Y	DT	Small molecular drug
DMDO13Y	PC	21707121
DMDO13Y	MW	272.3
DMDO13Y	FM	C19H16N2
DMDO13Y	IC	InChI=1S/C19H16N2/c20-19(21)18-11-10-16-12-15(8-9-17(16)13-18)7-6-14-4-2-1-3-5-14/h1-13H,(H3,20,21)/b7-6+
DMDO13Y	CS	C1=CC=C(C=C1)/C=C/C2=CC3=C(C=C2)C=C(C=C3)C(=N)N
DMDO13Y	IK	YRAFBVUQILDIDH-VOTSOKGWSA-N
DMDO13Y	IU	6-[(E)-2-phenylethenyl]naphthalene-2-carboximidamide
DMDO13Y	DE	Discovery agent

DMQAG1B	ID	DMQAG1B
DMQAG1B	DN	6-tert-Butyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMQAG1B	HS	Investigative
DMQAG1B	SN	CHEMBL224827; 6-tert-Butyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMQAG1B	DT	Small molecular drug
DMQAG1B	PC	16204165
DMQAG1B	MW	253.36
DMQAG1B	FM	C13H19NO2S
DMQAG1B	IC	InChI=1S/C13H19NO2S/c1-13(2,3)11-8-10(15)9-12(17-11)14-4-6-16-7-5-14/h8-9H,4-7H2,1-3H3
DMQAG1B	CS	CC(C)(C)C1=CC(=O)C=C(S1)N2CCOCC2
DMQAG1B	IK	HCEFXOMYHGQVRM-UHFFFAOYSA-N
DMQAG1B	IU	2-tert-butyl-6-morpholin-4-ylthiopyran-4-one
DMQAG1B	DE	Discovery agent

DM9EA3C	ID	DM9EA3C
DM9EA3C	DN	6-tert-butyl-m-cresol
DM9EA3C	HS	Investigative
DM9EA3C	SN	6-tert-Butyl-m-cresol; 2-tert-Butyl-5-methylphenol; 88-60-8; 6-tert-Butyl-3-methylphenol; 2-(tert-butyl)-5-methylphenol; m-Cresol, 6-tert-butyl-; Phenol, 2-(1,1-dimethylethyl)-5-methyl-; 5-Methyl-2-tert-butylphenol; 3-Methyl-6-tert-butylphenol; UNII-UXV32MJ2CA; 2-tert-butyl-5-methyl-phenol; 6-t-butyl-m-cresol; HSDB 5260; EINECS 201-842-3; NSC 48467; UXV32MJ2CA; 2-t-Butyl-5-methylphenol; BRN 1908225; Benzene, 1-tert-butyl-2-hydroxy-4-methyl-; 2-(1,1-DIMETHYLETHYL)-5-METHYLPHENOL; Phenol, 2-tert-butyl-5-methyl-
DM9EA3C	DT	Small molecular drug
DM9EA3C	PC	6937
DM9EA3C	MW	164.24
DM9EA3C	FM	C11H16O
DM9EA3C	IC	InChI=1S/C11H16O/c1-8-5-6-9(10(12)7-8)11(2,3)4/h5-7,12H,1-4H3
DM9EA3C	CS	CC1=CC(=C(C=C1)C(C)(C)C)O
DM9EA3C	IK	XOUQAVYLRNOXDO-UHFFFAOYSA-N
DM9EA3C	IU	2-tert-butyl-5-methylphenol
DM9EA3C	CA	CAS 88-60-8
DM9EA3C	DE	Discovery agent

DMVGC7H	ID	DMVGC7H
DMVGC7H	DN	6-Thia-10b-aza-benzo[e]azulen-4-one
DMVGC7H	HS	Investigative
DMVGC7H	SN	80008-53-3; NSC363827; Pyrrolo(2,1-d)(1,5)benzothiazepin-7(6H)-one; pyrrolo[2,1-d][1,5]benzothiazepin-7-one; CHEMBL286138; Pyrrolo[2,1-d][1,5]benzothiazepin-7(6H)-one; NSC 363827; 6-Thia-10b-aza-benzo[e]azulen-4-one; AC1L7OX1; CTK3F0749; DTXSID30230010; ZINC1585392; BDBM50041484
DMVGC7H	DT	Small molecular drug
DMVGC7H	PC	338956
DMVGC7H	MW	215.27
DMVGC7H	FM	C12H9NOS
DMVGC7H	IC	InChI=1S/C12H9NOS/c14-11-8-15-12-6-2-1-4-10(12)13-7-3-5-9(11)13/h1-7H,8H2
DMVGC7H	CS	C1C(=O)C2=CC=CN2C3=CC=CC=C3S1
DMVGC7H	IK	WRMQVQBFXFIZIY-UHFFFAOYSA-N
DMVGC7H	IU	pyrrolo[2,1-d][1,5]benzothiazepin-7-one
DMVGC7H	CA	CAS 80008-53-3
DMVGC7H	DE	Discovery agent

DMC013U	ID	DMC013U
DMC013U	DN	6-Thiophen-2-yl-imidazo[2,1-b]thiazole
DMC013U	HS	Investigative
DMC013U	SN	6-(thiophen-2-yl)imidazo[2,1-b][1,3]thiazole; AC1Q7FWK; AC1N51XV; CHEMBL12113; IFLab2_000013; IFLab1_003798; MolPort-000-476-548; HMS1422M14; ZINC406855; STL115074; CCG-22586; AKOS002232733; MCULE-2716534216; 6-(2-Thienyl)imidazo[2,1-b]thiazole; IDI1_019039; IDI1_009905; imidazo[2,1-b]thiazole,6-(2-thienyl)-; KB-305118; EU-0080970; ST50113084; 6-(2-thienyl)imidazo[2,1-b]1,3-thiazoline; 6-thiophen-2-ylimidazo[2,1-b][1,3]thiazole; SR-01000506671
DMC013U	DT	Small molecular drug
DMC013U	PC	4164759
DMC013U	MW	206.3
DMC013U	FM	C9H6N2S2
DMC013U	IC	InChI=1S/C9H6N2S2/c1-2-8(12-4-1)7-6-11-3-5-13-9(11)10-7/h1-6H
DMC013U	CS	C1=CSC(=C1)C2=CN3C=CSC3=N2
DMC013U	IK	YKINBJCTANWRJC-UHFFFAOYSA-N
DMC013U	IU	6-thiophen-2-ylimidazo[2,1-b][1,3]thiazole
DMC013U	DE	Discovery agent

DM90VJ6	ID	DM90VJ6
DM90VJ6	DN	6-Thiophen-3-yl-imidazo[2,1-b]thiazole
DM90VJ6	HS	Investigative
DM90VJ6	SN	6-Thiophen-3-yl-imidazo[2,1-b]thiazole; 163851-59-0; CHEMBL273842; AKOS005145119
DM90VJ6	DT	Small molecular drug
DM90VJ6	PC	10352957
DM90VJ6	MW	206.3
DM90VJ6	FM	C9H6N2S2
DM90VJ6	IC	InChI=1S/C9H6N2S2/c1-3-12-6-7(1)8-5-11-2-4-13-9(11)10-8/h1-6H
DM90VJ6	CS	C1=CSC=C1C2=CN3C=CSC3=N2
DM90VJ6	IK	QNYBFCDYFVERKH-UHFFFAOYSA-N
DM90VJ6	IU	6-thiophen-3-ylimidazo[2,1-b][1,3]thiazole
DM90VJ6	DE	Discovery agent

DMVL218	ID	DMVL218
DMVL218	DN	6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole
DMVL218	HS	Investigative
DMVL218	SN	CHEMBL479349; 6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole
DMVL218	DT	Small molecular drug
DMVL218	PC	44567986
DMVL218	MW	340.4
DMVL218	FM	C19H20N2O2S
DMVL218	IC	InChI=1S/C19H20N2O2S/c1-14-6-8-15(9-7-14)24(22,23)21-18-5-3-2-4-16(18)17-10-12-20-13-11-19(17)21/h2-9,20H,10-13H2,1H3
DMVL218	CS	CC1=CC=C(C=C1)S(=O)(=O)N2C3=C(CCNCC3)C4=CC=CC=C42
DMVL218	IK	LXDIYGJJOWTGAR-UHFFFAOYSA-N
DMVL218	IU	6-(4-methylphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-azepino[4,5-b]indole
DMVL218	DE	Discovery agent

DM2UTEA	ID	DM2UTEA
DM2UTEA	DN	7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one
DM2UTEA	HS	Investigative
DM2UTEA	SN	CHEMBL224649; Coumarin deriv. 27; BDBM9478; ZINC13586720
DM2UTEA	DT	Small molecular drug
DM2UTEA	PC	11401873
DM2UTEA	MW	226.23
DM2UTEA	FM	C13H10N2O2
DM2UTEA	IC	InChI=1S/C13H10N2O2/c16-13-4-3-11-2-1-10(7-12(11)17-13)8-15-6-5-14-9-15/h1-7,9H,8H2
DM2UTEA	CS	C1=CC(=CC2=C1C=CC(=O)O2)CN3C=CN=C3
DM2UTEA	IK	HXFIMHPPOABVMO-UHFFFAOYSA-N
DM2UTEA	IU	7-(imidazol-1-ylmethyl)chromen-2-one
DM2UTEA	DE	Discovery agent

DMOS4ZQ	ID	DMOS4ZQ
DMOS4ZQ	DN	7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one
DMOS4ZQ	HS	Investigative
DMOS4ZQ	SN	CHEMBL158984; 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one; ZINC13861991; BDBM50097369; 7-Imidazol-1-ylmethyl-chromen-4-one
DMOS4ZQ	DT	Small molecular drug
DMOS4ZQ	PC	10585323
DMOS4ZQ	MW	226.23
DMOS4ZQ	FM	C13H10N2O2
DMOS4ZQ	IC	InChI=1S/C13H10N2O2/c16-12-3-6-17-13-7-10(1-2-11(12)13)8-15-5-4-14-9-15/h1-7,9H,8H2
DMOS4ZQ	CS	C1=CC2=C(C=C1CN3C=CN=C3)OC=CC2=O
DMOS4ZQ	IK	KLOFOSXNENLIKT-UHFFFAOYSA-N
DMOS4ZQ	IU	7-(imidazol-1-ylmethyl)chromen-4-one
DMOS4ZQ	DE	Discovery agent

DM9ID4T	ID	DM9ID4T
DM9ID4T	DN	7-((1H-imidazol-1-yl)methyl)isoquinoline
DM9ID4T	HS	Investigative
DM9ID4T	SN	CHEMBL298720; isoquinoline 56; BDBM10041; ZINC13808228; 7-[(Imidazol-1-yl)methyl]isoquinoline; 7-(1H-imidazol-1-ylmethyl)isoquinoline
DM9ID4T	DT	Small molecular drug
DM9ID4T	PC	10750911
DM9ID4T	MW	209.25
DM9ID4T	FM	C13H11N3
DM9ID4T	IC	InChI=1S/C13H11N3/c1-2-12-3-4-14-8-13(12)7-11(1)9-16-6-5-15-10-16/h1-8,10H,9H2
DM9ID4T	CS	C1=CC(=CC2=C1C=CN=C2)CN3C=CN=C3
DM9ID4T	IK	SIZZGSWTNCSETD-UHFFFAOYSA-N
DM9ID4T	IU	7-(imidazol-1-ylmethyl)isoquinoline
DM9ID4T	DE	Discovery agent

DMRPFNU	ID	DMRPFNU
DMRPFNU	DN	7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol
DMRPFNU	HS	Investigative
DMRPFNU	SN	CHEMBL505550; 7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol
DMRPFNU	DT	Small molecular drug
DMRPFNU	PC	44586828
DMRPFNU	MW	276.3
DMRPFNU	FM	C18H16N2O
DMRPFNU	IC	InChI=1S/C18H16N2O/c1-12(20-7-6-19-11-20)13-2-4-17-14(8-13)9-15-10-16(21)3-5-18(15)17/h2-8,10-12,21H,9H2,1H3
DMRPFNU	CS	CC(C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)O)N4C=CN=C4
DMRPFNU	IK	LVWQDZJSHTWZHR-UHFFFAOYSA-N
DMRPFNU	IU	7-(1-imidazol-1-ylethyl)-9H-fluoren-2-ol
DMRPFNU	DE	Discovery agent

DMOZV9W	ID	DMOZV9W
DMOZV9W	DN	7-(1H-indol-5-yloxy)-N-hydroxyheptanamide
DMOZV9W	HS	Investigative
DMOZV9W	SN	CHEMBL426516; 7-(1H-indol-5-yloxy)-N-hydroxyheptanamide
DMOZV9W	DT	Small molecular drug
DMOZV9W	PC	44418145
DMOZV9W	MW	276.33
DMOZV9W	FM	C15H20N2O3
DMOZV9W	IC	InChI=1S/C15H20N2O3/c18-15(17-19)5-3-1-2-4-10-20-13-6-7-14-12(11-13)8-9-16-14/h6-9,11,16,19H,1-5,10H2,(H,17,18)
DMOZV9W	CS	C1=CC2=C(C=CN2)C=C1OCCCCCCC(=O)NO
DMOZV9W	IK	YJOHRQFBXILUHS-UHFFFAOYSA-N
DMOZV9W	IU	N-hydroxy-7-(1H-indol-5-yloxy)heptanamide
DMOZV9W	DE	Discovery agent

DM4HUO1	ID	DM4HUO1
DM4HUO1	DN	7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one
DM4HUO1	HS	Investigative
DM4HUO1	SN	Coumarin deriv. 29; CHEMBL390152; BDBM9480
DM4HUO1	DT	Small molecular drug
DM4HUO1	PC	11230598
DM4HUO1	MW	256.26
DM4HUO1	FM	C14H12N2O3
DM4HUO1	IC	InChI=1S/C14H12N2O3/c17-14-4-2-11-1-3-12(9-13(11)19-14)18-8-7-16-6-5-15-10-16/h1-6,9-10H,7-8H2
DM4HUO1	CS	C1=CC(=CC2=C1C=CC(=O)O2)OCCN3C=CN=C3
DM4HUO1	IK	JUOCDQIZOPYANC-UHFFFAOYSA-N
DM4HUO1	IU	7-(2-imidazol-1-ylethoxy)chromen-2-one
DM4HUO1	DE	Discovery agent

DMPV674	ID	DMPV674
DMPV674	DN	7-(2-Amino-ethyl)-4-hydroxy-3H-benzothiazol-2-one
DMPV674	HS	Investigative
DMPV674	SN	CHEMBL17357; 108773-04-2; 7-(2-Amino-ethyl)-4-hydroxy-3H-benzothiazol-2-one; SCHEMBL4740762; 2(3H)-BENZOTHIAZOLONE,7-(2-AMINOETHYL)-4-HYDROXY-; ZINC26894070; BDBM50020679; AKOS027394867; KB-293910; 7-(2-Aminoethyl)-1,3-benzothiazole-2,4-diol; 2(3H)-Benzothiazolone, 7-(2-aminoethyl)-4-hydroxy-
DMPV674	DT	Small molecular drug
DMPV674	PC	10856744
DMPV674	MW	210.26
DMPV674	FM	C9H10N2O2S
DMPV674	IC	InChI=1S/C9H10N2O2S/c10-4-3-5-1-2-6(12)7-8(5)14-9(13)11-7/h1-2,12H,3-4,10H2,(H,11,13)
DMPV674	CS	C1=CC(=C2C(=C1CCN)SC(=O)N2)O
DMPV674	IK	YPLJLRNXOFWVTL-UHFFFAOYSA-N
DMPV674	IU	7-(2-aminoethyl)-4-hydroxy-3H-1,3-benzothiazol-2-one
DMPV674	DE	Discovery agent

DMWXGLE	ID	DMWXGLE
DMWXGLE	DN	7-(2-Dipropylamino-ethyl)-3H-benzothiazol-2-one
DMWXGLE	HS	Investigative
DMWXGLE	SN	CHEMBL418548; 7-(2-Dipropylamino-ethyl)-3H-benzothiazol-2-one; SCHEMBL10986865
DMWXGLE	DT	Small molecular drug
DMWXGLE	PC	13814264
DMWXGLE	MW	278.4
DMWXGLE	FM	C15H22N2OS
DMWXGLE	IC	InChI=1S/C15H22N2OS/c1-3-9-17(10-4-2)11-8-12-6-5-7-13-14(12)19-15(18)16-13/h5-7H,3-4,8-11H2,1-2H3,(H,16,18)
DMWXGLE	CS	CCCN(CCC)CCC1=C2C(=CC=C1)NC(=O)S2
DMWXGLE	IK	ZAHKGALZXMOXJH-UHFFFAOYSA-N
DMWXGLE	IU	7-[2-(dipropylamino)ethyl]-3H-1,3-benzothiazol-2-one
DMWXGLE	DE	Discovery agent

DMBIY98	ID	DMBIY98
DMBIY98	DN	7-(2-Hydroxyethyl)-3-O-rhamnosylicariin
DMBIY98	HS	Investigative
DMBIY98	SN	CHEMBL504656; 7-(2-Hydroxyethyl)-3-O-rhamnosylicariin
DMBIY98	DT	Small molecular drug
DMBIY98	PC	44587253
DMBIY98	MW	558.6
DMBIY98	FM	C29H34O11
DMBIY98	IC	InChI=1S/C29H34O11/c1-14(2)5-10-18-20(37-12-11-30)13-19(31)21-23(33)28(40-29-25(35)24(34)22(32)15(3)38-29)26(39-27(18)21)16-6-8-17(36-4)9-7-16/h5-9,13,15,22,24-25,29-32,34-35H,10-12H2,1-4H3/t15-,22-,24+,25+,29+/m1/s1
DMBIY98	CS	C[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)OCCO)O)C4=CC=C(C=C4)OC)O)O)O
DMBIY98	IK	MMEHTVTVEQHORK-NXPCAARESA-N
DMBIY98	IU	5-hydroxy-7-(2-hydroxyethoxy)-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DMBIY98	DE	Discovery agent

DMO8DYW	ID	DMO8DYW
DMO8DYW	DN	7-(2-methoxyphenyl)-2-methylquinoline
DMO8DYW	HS	Investigative
DMO8DYW	SN	CHEMBL231991; 7-(2-methoxyphenyl)-2-methylquinoline
DMO8DYW	DT	Small molecular drug
DMO8DYW	PC	44432672
DMO8DYW	MW	249.31
DMO8DYW	FM	C17H15NO
DMO8DYW	IC	InChI=1S/C17H15NO/c1-12-7-8-13-9-10-14(11-16(13)18-12)15-5-3-4-6-17(15)19-2/h3-11H,1-2H3
DMO8DYW	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC=C3OC
DMO8DYW	IK	JLXDREZJLZGNTK-UHFFFAOYSA-N
DMO8DYW	IU	7-(2-methoxyphenyl)-2-methylquinoline
DMO8DYW	DE	Discovery agent

DMK28IS	ID	DMK28IS
DMK28IS	DN	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine
DMK28IS	HS	Investigative
DMK28IS	SN	CHEMBL315194; 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine; SCHEMBL6980573; BDBM50104649
DMK28IS	DT	Small molecular drug
DMK28IS	PC	10375155
DMK28IS	MW	185.22
DMK28IS	FM	C8H15N3O2
DMK28IS	IC	InChI=1S/C8H15N3O2/c9-8-4-2-1-3-7(10-8)5-6-11(12)13/h7H,1-6H2,(H2,9,10)
DMK28IS	CS	C1CCC(=NC(C1)CC[N+](=O)[O-])N
DMK28IS	IK	ILALABPIKINZAM-UHFFFAOYSA-N
DMK28IS	IU	2-(2-nitroethyl)-3,4,5,6-tetrahydro-2H-azepin-7-amine
DMK28IS	DE	Discovery agent

DMYNLOI	ID	DMYNLOI
DMYNLOI	DN	7-(3-(methoxymethyl)phenyl)-2-methylquinoline
DMYNLOI	HS	Investigative
DMYNLOI	SN	CHEMBL231985; 7-(3-(methoxymethyl)phenyl)-2-methylquinoline
DMYNLOI	DT	Small molecular drug
DMYNLOI	PC	44432664
DMYNLOI	MW	263.3
DMYNLOI	FM	C18H17NO
DMYNLOI	IC	InChI=1S/C18H17NO/c1-13-6-7-15-8-9-17(11-18(15)19-13)16-5-3-4-14(10-16)12-20-2/h3-11H,12H2,1-2H3
DMYNLOI	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC(=C3)COC
DMYNLOI	IK	JADKCVGREWVUKV-UHFFFAOYSA-N
DMYNLOI	IU	7-[3-(methoxymethyl)phenyl]-2-methylquinoline
DMYNLOI	DE	Discovery agent

DM9BS5L	ID	DM9BS5L
DM9BS5L	DN	7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol
DM9BS5L	HS	Investigative
DM9BS5L	SN	CHEMBL392209; 7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol
DM9BS5L	DT	Small molecular drug
DM9BS5L	PC	44438240
DM9BS5L	MW	268.26
DM9BS5L	FM	C16H12O4
DM9BS5L	IC	InChI=1S/C16H12O4/c17-12-4-11(5-13(18)7-12)9-1-2-10-3-14(19)8-16(20)15(10)6-9/h1-8,17-20H
DM9BS5L	CS	C1=CC(=CC2=C(C=C(C=C21)O)O)C3=CC(=CC(=C3)O)O
DM9BS5L	IK	VMEOGCASIHYHCW-UHFFFAOYSA-N
DM9BS5L	IU	7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol
DM9BS5L	DE	Discovery agent

DM2RFOB	ID	DM2RFOB
DM2RFOB	DN	7-(3,5-dimethoxyphenyl)-1,6-naphthyridine
DM2RFOB	HS	Investigative
DM2RFOB	SN	CHEMBL236262; 7-(3,5-dimethoxyphenyl)-1,6-naphthyridine; MLS002402797; HMS3344J20; HMS2201J14; BDBM50224927
DM2RFOB	DT	Small molecular drug
DM2RFOB	PC	44142284
DM2RFOB	MW	266.29
DM2RFOB	FM	C16H14N2O2
DM2RFOB	IC	InChI=1S/C16H14N2O2/c1-19-13-6-12(7-14(8-13)20-2)16-9-15-11(10-18-16)4-3-5-17-15/h3-10H,1-2H3
DM2RFOB	CS	COC1=CC(=CC(=C1)C2=NC=C3C=CC=NC3=C2)OC
DM2RFOB	IK	HVIBISIIVPOREN-UHFFFAOYSA-N
DM2RFOB	IU	7-(3,5-dimethoxyphenyl)-1,6-naphthyridine
DM2RFOB	DE	Discovery agent

DMNQW2B	ID	DMNQW2B
DMNQW2B	DN	7-(3,6,9,12-tetraoxatricos-22-enyl)theophylline
DMNQW2B	HS	Investigative
DMNQW2B	SN	CHEMBL591242; 7-(3,6,9,12-tetraoxatricos-22-enyl)theophylline
DMNQW2B	DT	Small molecular drug
DMNQW2B	PC	46229111
DMNQW2B	MW	508.7
DMNQW2B	FM	C26H44N4O6
DMNQW2B	IC	InChI=1S/C26H44N4O6/c1-4-5-6-7-8-9-10-11-12-14-33-16-18-35-20-21-36-19-17-34-15-13-30-22-27-24-23(30)25(31)29(3)26(32)28(24)2/h4,22H,1,5-21H2,2-3H3
DMNQW2B	CS	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCOCCOCCOCCOCCCCCCCCCC=C
DMNQW2B	IK	VWEZUVSKUQSAQQ-UHFFFAOYSA-N
DMNQW2B	IU	1,3-dimethyl-7-[2-[2-[2-(2-undec-10-enoxyethoxy)ethoxy]ethoxy]ethyl]purine-2,6-dione
DMNQW2B	DE	Discovery agent

DMCFV0X	ID	DMCFV0X
DMCFV0X	DN	7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide
DMCFV0X	HS	Investigative
DMCFV0X	SN	CHEMBL1083440; 7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide; SCHEMBL4922807
DMCFV0X	DT	Small molecular drug
DMCFV0X	PC	11426781
DMCFV0X	MW	307.34
DMCFV0X	FM	C15H21N3O4
DMCFV0X	IC	InChI=1S/C15H21N3O4/c19-13(18-22)10-6-1-2-7-11-16-15(21)17-14(20)12-8-4-3-5-9-12/h3-5,8-9,22H,1-2,6-7,10-11H2,(H,18,19)(H2,16,17,20,21)
DMCFV0X	CS	C1=CC=C(C=C1)C(=O)NC(=O)NCCCCCCC(=O)NO
DMCFV0X	IK	XEBCJLKRZJZBNT-UHFFFAOYSA-N
DMCFV0X	IU	N-[[7-(hydroxyamino)-7-oxoheptyl]carbamoyl]benzamide
DMCFV0X	DE	Discovery agent

DM762G3	ID	DM762G3
DM762G3	DN	7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin
DM762G3	HS	Investigative
DM762G3	SN	7-[(3-Chlorobenzyl)oxy]-2-Oxo-2h-Chromene-4-Carbaldehyde; C17; CHEMBL239508; BDBM19189; DB07512; 7-(3-Chlorobenzyloxy)-4-carboxaldehyde-coumarin, 3; 7-[(3-chlorophenyl)methoxy]-2-oxochromene-4-carbaldehyde
DM762G3	DT	Small molecular drug
DM762G3	PC	16750123
DM762G3	MW	314.7
DM762G3	FM	C17H11ClO4
DM762G3	IC	InChI=1S/C17H11ClO4/c18-13-3-1-2-11(6-13)10-21-14-4-5-15-12(9-19)7-17(20)22-16(15)8-14/h1-9H,10H2
DM762G3	CS	C1=CC(=CC(=C1)Cl)COC2=CC3=C(C=C2)C(=CC(=O)O3)C=O
DM762G3	IK	ZOCADHRNWNJARU-UHFFFAOYSA-N
DM762G3	IU	7-[(3-chlorophenyl)methoxy]-2-oxochromene-4-carbaldehyde
DM762G3	DE	Discovery agent

DM0Q56N	ID	DM0Q56N
DM0Q56N	DN	7-(3-chlorophenyl)-2-methylquinoline
DM0Q56N	HS	Investigative
DM0Q56N	SN	CHEMBL231987; 7-(3-chlorophenyl)-2-methylquinoline
DM0Q56N	DT	Small molecular drug
DM0Q56N	PC	44432666
DM0Q56N	MW	253.72
DM0Q56N	FM	C16H12ClN
DM0Q56N	IC	InChI=1S/C16H12ClN/c1-11-5-6-12-7-8-14(10-16(12)18-11)13-3-2-4-15(17)9-13/h2-10H,1H3
DM0Q56N	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)Cl
DM0Q56N	IK	HNAVWOSKROEPOM-UHFFFAOYSA-N
DM0Q56N	IU	7-(3-chlorophenyl)-2-methylquinoline
DM0Q56N	DE	Discovery agent

DME2VD7	ID	DME2VD7
DME2VD7	DN	7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine
DME2VD7	HS	Investigative
DME2VD7	SN	CHEMBL238389; 7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine
DME2VD7	DT	Small molecular drug
DME2VD7	PC	44434723
DME2VD7	MW	238.26
DME2VD7	FM	C15H11FN2
DME2VD7	IC	InChI=1S/C15H11FN2/c1-10-5-12(7-13(16)6-10)15-8-14-11(9-18-15)3-2-4-17-14/h2-9H,1H3
DME2VD7	CS	CC1=CC(=CC(=C1)F)C2=NC=C3C=CC=NC3=C2
DME2VD7	IK	ZJIGDEYNCCHRKX-UHFFFAOYSA-N
DME2VD7	IU	7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine
DME2VD7	DE	Discovery agent

DMDXOBH	ID	DMDXOBH
DMDXOBH	DN	7-(3-fluorophenyl)-2-methylquinoline
DMDXOBH	HS	Investigative
DMDXOBH	SN	CHEMBL231764; 7-(3-fluorophenyl)-2-methylquinoline
DMDXOBH	DT	Small molecular drug
DMDXOBH	PC	44432661
DMDXOBH	MW	237.27
DMDXOBH	FM	C16H12FN
DMDXOBH	IC	InChI=1S/C16H12FN/c1-11-5-6-12-7-8-14(10-16(12)18-11)13-3-2-4-15(17)9-13/h2-10H,1H3
DMDXOBH	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)F
DMDXOBH	IK	BBNRSYMDJKFBOU-UHFFFAOYSA-N
DMDXOBH	IU	7-(3-fluorophenyl)-2-methylquinoline
DMDXOBH	DE	Discovery agent

DM2I91C	ID	DM2I91C
DM2I91C	DN	7-(3-Hydroxy-phenyl)-naphthalen-2-ol
DM2I91C	HS	Investigative
DM2I91C	SN	7-(3-hydroxyphenyl)-2-naphthol
DM2I91C	PC	10171410
DM2I91C	MW	236.26
DM2I91C	FM	C16H12O2
DM2I91C	IC	InChI=1S/C16H12O2/c17-15-3-1-2-12(9-15)13-5-4-11-6-7-16(18)10-14(11)8-13/h1-10,17-18H
DM2I91C	CS	C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C=CC(=C3)O
DM2I91C	IK	VEQWNMMVQWDERW-UHFFFAOYSA-N
DM2I91C	IU	7-(3-hydroxyphenyl)naphthalen-2-ol
DM2I91C	DE	Discovery agent

DMEC9YK	ID	DMEC9YK
DMEC9YK	DN	7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine
DMEC9YK	HS	Investigative
DMEC9YK	SN	CHEMBL238139; 7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine
DMEC9YK	DT	Small molecular drug
DMEC9YK	PC	44434751
DMEC9YK	MW	250.29
DMEC9YK	FM	C16H14N2O
DMEC9YK	IC	InChI=1S/C16H14N2O/c1-11-6-7-13-10-17-15(9-16(13)18-11)12-4-3-5-14(8-12)19-2/h3-10H,1-2H3
DMEC9YK	CS	CC1=NC2=CC(=NC=C2C=C1)C3=CC(=CC=C3)OC
DMEC9YK	IK	FNFGNQRSMXJCIJ-UHFFFAOYSA-N
DMEC9YK	IU	7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine
DMEC9YK	DE	Discovery agent

DMW6LCH	ID	DMW6LCH
DMW6LCH	DN	7-(3-methoxyphenyl)-2-methylquinoline
DMW6LCH	HS	Investigative
DMW6LCH	SN	CHEMBL394876; 7-(3-methoxyphenyl)-2-methylquinoline
DMW6LCH	DT	Small molecular drug
DMW6LCH	PC	44432660
DMW6LCH	MW	249.31
DMW6LCH	FM	C17H15NO
DMW6LCH	IC	InChI=1S/C17H15NO/c1-12-6-7-13-8-9-15(11-17(13)18-12)14-4-3-5-16(10-14)19-2/h3-11H,1-2H3
DMW6LCH	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)OC
DMW6LCH	IK	JQAHRDJGLFSZFY-UHFFFAOYSA-N
DMW6LCH	IU	7-(3-methoxyphenyl)-2-methylquinoline
DMW6LCH	DE	Discovery agent

DM2TNCK	ID	DM2TNCK
DM2TNCK	DN	7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide
DM2TNCK	HS	Investigative
DM2TNCK	SN	CHEMBL265479; 7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide
DM2TNCK	DT	Small molecular drug
DM2TNCK	PC	44418155
DM2TNCK	MW	280.36
DM2TNCK	FM	C15H24N2O3
DM2TNCK	IC	InChI=1S/C15H24N2O3/c1-17(2)13-8-10-14(11-9-13)20-12-6-4-3-5-7-15(18)16-19/h8-11,19H,3-7,12H2,1-2H3,(H,16,18)
DM2TNCK	CS	CN(C)C1=CC=C(C=C1)OCCCCCCC(=O)NO
DM2TNCK	IK	UVUVYSYWSTVIBF-UHFFFAOYSA-N
DM2TNCK	IU	7-[4-(dimethylamino)phenoxy]-N-hydroxyheptanamide
DM2TNCK	DE	Discovery agent

DMHXMY5	ID	DMHXMY5
DMHXMY5	DN	7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline
DMHXMY5	HS	Investigative
DMHXMY5	SN	CHEMBL245235; 7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline
DMHXMY5	DT	Small molecular drug
DMHXMY5	PC	44427383
DMHXMY5	MW	281.31
DMHXMY5	FM	C16H15N3O2
DMHXMY5	IC	InChI=1S/C16H15N3O2/c1-10-4-5-11-6-7-12(8-13(11)17-10)16-18-14(20-2)9-15(19-16)21-3/h4-9H,1-3H3
DMHXMY5	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=NC(=CC(=N3)OC)OC
DMHXMY5	IK	BWVPGOLPFZULHO-UHFFFAOYSA-N
DMHXMY5	IU	7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline
DMHXMY5	DE	Discovery agent

DMQFBTW	ID	DMQFBTW
DMQFBTW	DN	7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline
DMQFBTW	HS	Investigative
DMQFBTW	SN	CHEMBL245236; 7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline
DMQFBTW	DT	Small molecular drug
DMQFBTW	PC	44427384
DMQFBTW	MW	249.31
DMQFBTW	FM	C16H15N3
DMQFBTW	IC	InChI=1S/C16H15N3/c1-10-4-5-13-6-7-14(9-15(13)17-10)16-18-11(2)8-12(3)19-16/h4-9H,1-3H3
DMQFBTW	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=NC(=CC(=N3)C)C
DMQFBTW	IK	QOOQRVAAEYZPDS-UHFFFAOYSA-N
DMQFBTW	IU	7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline
DMQFBTW	DE	Discovery agent

DMM9IXB	ID	DMM9IXB
DMM9IXB	DN	7-(4-Hydroxy-phenyl)-naphthalen-2-ol
DMM9IXB	HS	Investigative
DMM9IXB	SN	CHEMBL191715; 7-(4-Hydroxyphenyl)-2-naphthol; 7-(4-Hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3932603; NSCZTZNRMFWAIY-UHFFFAOYSA-N; ZINC13645002; BDBM50168330
DMM9IXB	DT	Small molecular drug
DMM9IXB	PC	10171409
DMM9IXB	MW	236.26
DMM9IXB	FM	C16H12O2
DMM9IXB	IC	InChI=1S/C16H12O2/c17-15-6-3-11(4-7-15)13-2-1-12-5-8-16(18)10-14(12)9-13/h1-10,17-18H
DMM9IXB	CS	C1=CC(=CC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O
DMM9IXB	IK	NSCZTZNRMFWAIY-UHFFFAOYSA-N
DMM9IXB	IU	7-(4-hydroxyphenyl)naphthalen-2-ol
DMM9IXB	DE	Discovery agent

DMBT1KS	ID	DMBT1KS
DMBT1KS	DN	7-(4-methoxyphenyl)-2-methylquinoline
DMBT1KS	HS	Investigative
DMBT1KS	SN	CHEMBL396134; 7-(4-methoxyphenyl)-2-methylquinoline
DMBT1KS	DT	Small molecular drug
DMBT1KS	PC	44432673
DMBT1KS	MW	249.31
DMBT1KS	FM	C17H15NO
DMBT1KS	IC	InChI=1S/C17H15NO/c1-12-3-4-14-5-6-15(11-17(14)18-12)13-7-9-16(19-2)10-8-13/h3-11H,1-2H3
DMBT1KS	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=C(C=C3)OC
DMBT1KS	IK	NCNHXSMXZZAGHM-UHFFFAOYSA-N
DMBT1KS	IU	7-(4-methoxyphenyl)-2-methylquinoline
DMBT1KS	DE	Discovery agent

DMLIYUJ	ID	DMLIYUJ
DMLIYUJ	DN	7-(4-methoxyphenyl)pteridine-2,4-diol
DMLIYUJ	HS	Investigative
DMLIYUJ	SN	CHEMBL511249; AC1NTQMH; 7-(4-methoxyphenyl)pteridine-2,4-diol; 7-(4-methoxyphenyl)-2,4-pteridinediol; 7-(4-methoxyphenyl)-1H-pteridine-2,4-dione; SCHEMBL13401704; MolPort-002-799-584; ZINC6493631; BDBM50262040; MCULE-1306601038
DMLIYUJ	DT	Small molecular drug
DMLIYUJ	PC	5409710
DMLIYUJ	MW	270.24
DMLIYUJ	FM	C13H10N4O3
DMLIYUJ	IC	InChI=1S/C13H10N4O3/c1-20-8-4-2-7(3-5-8)9-6-14-10-11(15-9)16-13(19)17-12(10)18/h2-6H,1H3,(H2,15,16,17,18,19)
DMLIYUJ	CS	COC1=CC=C(C=C1)C2=CN=C3C(=N2)NC(=O)NC3=O
DMLIYUJ	IK	LQVUFGDEIPMWPT-UHFFFAOYSA-N
DMLIYUJ	IU	7-(4-methoxyphenyl)-1H-pteridine-2,4-dione
DMLIYUJ	DE	Discovery agent

DMSRKF0	ID	DMSRKF0
DMSRKF0	DN	7-(4-methoxypyrimidin-2-yl)-2-methylquinoline
DMSRKF0	HS	Investigative
DMSRKF0	SN	CHEMBL395327; 7-(4-methoxypyrimidin-2-yl)-2-methylquinoline
DMSRKF0	DT	Small molecular drug
DMSRKF0	PC	44427382
DMSRKF0	MW	251.28
DMSRKF0	FM	C15H13N3O
DMSRKF0	IC	InChI=1S/C15H13N3O/c1-10-3-4-11-5-6-12(9-13(11)17-10)15-16-8-7-14(18-15)19-2/h3-9H,1-2H3
DMSRKF0	CS	CC1=NC2=C(C=C1)C=CC(=C2)C3=NC=CC(=N3)OC
DMSRKF0	IK	RMLLQYDXXOIJNH-UHFFFAOYSA-N
DMSRKF0	IU	7-(4-methoxypyrimidin-2-yl)-2-methylquinoline
DMSRKF0	DE	Discovery agent

DMTKFPW	ID	DMTKFPW
DMTKFPW	DN	7-(benzyloxy)-2H-chromen-2-one
DMTKFPW	HS	Investigative
DMTKFPW	SN	7-(benzyloxy)-2H-chromen-2-one; 7-BENZYLOXYCOUMARIN; CHEMBL145781; 31005-04-6; 7-phenylmethoxychromen-2-one; AC1LIRVN; AC1Q6HKT; 7-benzyloxychromen-2-one; ChemDiv3_006648; Oprea1_123644; MLS001198544; CM16; SCHEMBL3901170; BEN294; 7-(phenylmethoxy)chromen-2-one; CTK1C0068; DTXSID30358687; QDLFCBKKECTJSK-UHFFFAOYSA-N; MolPort-001-573-426; ZINC493069; HMS2864P20; HMS1491O04; CCG-25276; STK373844; BDBM50378564; AKOS001064953; MCULE-8905496403; IDI1_024558; SMR000558913; ST50429120; 2H-1-Benzopyran-2-one, 7-(phenylmethoxy)
DMTKFPW	DT	Small molecular drug
DMTKFPW	PC	910172
DMTKFPW	MW	252.26
DMTKFPW	FM	C16H12O3
DMTKFPW	IC	InChI=1S/C16H12O3/c17-16-9-7-13-6-8-14(10-15(13)19-16)18-11-12-4-2-1-3-5-12/h1-10H,11H2
DMTKFPW	CS	C1=CC=C(C=C1)COC2=CC3=C(C=C2)C=CC(=O)O3
DMTKFPW	IK	QDLFCBKKECTJSK-UHFFFAOYSA-N
DMTKFPW	IU	7-phenylmethoxychromen-2-one
DMTKFPW	CA	CAS 31005-04-6
DMTKFPW	DE	Discovery agent

DMLCGSY	ID	DMLCGSY
DMLCGSY	DN	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one
DMLCGSY	HS	Investigative
DMLCGSY	SN	CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone
DMLCGSY	DT	Small molecular drug
DMLCGSY	PC	44350718
DMLCGSY	MW	349.4
DMLCGSY	FM	C22H23NO3
DMLCGSY	IC	InChI=1S/C22H23NO3/c24-21(22-23-14-16-26-22)13-6-1-2-7-15-25-20-12-8-11-19(17-20)18-9-4-3-5-10-18/h3-5,8-12,14,16-17H,1-2,6-7,13,15H2
DMLCGSY	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)OCCCCCCC(=O)C3=NC=CO3
DMLCGSY	IK	HWZHDGRMABBYOV-UHFFFAOYSA-N
DMLCGSY	IU	1-(1,3-oxazol-2-yl)-7-(3-phenylphenoxy)heptan-1-one
DMLCGSY	DE	Discovery agent

DM28GZ7	ID	DM28GZ7
DM28GZ7	DN	7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one
DM28GZ7	HS	Investigative
DM28GZ7	SN	CHEMBL326529; SCHEMBL7365237; BDBM50217957
DM28GZ7	DT	Small molecular drug
DM28GZ7	PC	44342825
DM28GZ7	MW	336.3
DM28GZ7	FM	C19H19F3O2
DM28GZ7	IC	InChI=1S/C19H19F3O2/c20-19(21,22)18(23)9-5-2-6-14-24-17-12-10-16(11-13-17)15-7-3-1-4-8-15/h1,3-4,7-8,10-13H,2,5-6,9,14H2
DM28GZ7	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCC(=O)C(F)(F)F
DM28GZ7	IK	JQEVPQYABGWLCL-UHFFFAOYSA-N
DM28GZ7	IU	1,1,1-trifluoro-7-(4-phenylphenoxy)heptan-2-one
DM28GZ7	DE	Discovery agent

DMY027P	ID	DMY027P
DMY027P	DN	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one
DMY027P	HS	Investigative
DMY027P	SN	CHEMBL126355; BDBM50222394
DMY027P	DT	Small molecular drug
DMY027P	PC	44350626
DMY027P	MW	349.4
DMY027P	FM	C22H23NO3
DMY027P	IC	InChI=1S/C22H23NO3/c24-21(22-23-15-17-26-22)10-6-1-2-7-16-25-20-13-11-19(12-14-20)18-8-4-3-5-9-18/h3-5,8-9,11-15,17H,1-2,6-7,10,16H2
DMY027P	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCC(=O)C3=NC=CO3
DMY027P	IK	ASDDHZUEOBVPNO-UHFFFAOYSA-N
DMY027P	IU	1-(1,3-oxazol-2-yl)-7-(4-phenylphenoxy)heptan-1-one
DMY027P	DE	Discovery agent

DMO4YLA	ID	DMO4YLA
DMO4YLA	DN	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide
DMO4YLA	HS	Investigative
DMO4YLA	SN	CHEMBL114184; SCHEMBL3383144
DMO4YLA	DT	Small molecular drug
DMO4YLA	PC	22915465
DMO4YLA	MW	313.4
DMO4YLA	FM	C19H23NO3
DMO4YLA	IC	InChI=1S/C19H23NO3/c21-19(20-22)10-6-1-2-7-15-23-18-13-11-17(12-14-18)16-8-4-3-5-9-16/h3-5,8-9,11-14,22H,1-2,6-7,10,15H2,(H,20,21)
DMO4YLA	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCC(=O)NO
DMO4YLA	IK	KASXKFPWIZYBSG-UHFFFAOYSA-N
DMO4YLA	IU	N-hydroxy-7-(4-phenylphenoxy)heptanamide
DMO4YLA	DE	Discovery agent

DMU74R8	ID	DMU74R8
DMU74R8	DN	7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine
DMU74R8	HS	Investigative
DMU74R8	SN	CHEMBL385112; 1,2,4-Benzotriazin-3-amine,7-(2-naphthalenyl)-; 7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine; BDBM50193895
DMU74R8	DT	Small molecular drug
DMU74R8	PC	44419363
DMU74R8	MW	272.3
DMU74R8	FM	C17H12N4
DMU74R8	IC	InChI=1S/C17H12N4/c18-17-19-15-8-7-14(10-16(15)20-21-17)13-6-5-11-3-1-2-4-12(11)9-13/h1-10H,(H2,18,19,21)
DMU74R8	CS	C1=CC=C2C=C(C=CC2=C1)C3=CC4=C(C=C3)N=C(N=N4)N
DMU74R8	IK	XEBDWUZHTXSJGH-UHFFFAOYSA-N
DMU74R8	IU	7-naphthalen-2-yl-1,2,4-benzotriazin-3-amine
DMU74R8	DE	Discovery agent

DM4VQN8	ID	DM4VQN8
DM4VQN8	DN	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one
DM4VQN8	HS	Investigative
DM4VQN8	SN	CHEMBL127328
DM4VQN8	DT	Small molecular drug
DM4VQN8	PC	44350703
DM4VQN8	MW	323.4
DM4VQN8	FM	C20H21NO3
DM4VQN8	IC	InChI=1S/C20H21NO3/c22-19(20-21-12-14-24-20)9-3-1-2-6-13-23-18-11-10-16-7-4-5-8-17(16)15-18/h4-5,7-8,10-12,14-15H,1-3,6,9,13H2
DM4VQN8	CS	C1=CC=C2C=C(C=CC2=C1)OCCCCCCC(=O)C3=NC=CO3
DM4VQN8	IK	BKNPQEYYRAPRRP-UHFFFAOYSA-N
DM4VQN8	IU	7-naphthalen-2-yloxy-1-(1,3-oxazol-2-yl)heptan-1-one
DM4VQN8	DE	Discovery agent

DM6I5K1	ID	DM6I5K1
DM6I5K1	DN	7-(piperidin-4-ylmethoxy)-2-naphthonitrile
DM6I5K1	HS	Investigative
DM6I5K1	SN	CHEMBL444985; 7-(piperidin-4-ylmethoxy)-2-naphthonitrile
DM6I5K1	DT	Small molecular drug
DM6I5K1	PC	44592241
DM6I5K1	MW	266.34
DM6I5K1	FM	C17H18N2O
DM6I5K1	IC	InChI=1S/C17H18N2O/c18-11-14-1-2-15-3-4-17(10-16(15)9-14)20-12-13-5-7-19-8-6-13/h1-4,9-10,13,19H,5-8,12H2
DM6I5K1	CS	C1CNCCC1COC2=CC3=C(C=CC(=C3)C#N)C=C2
DM6I5K1	IK	ZINGRQZUIVEPKX-UHFFFAOYSA-N
DM6I5K1	IU	7-(piperidin-4-ylmethoxy)naphthalene-2-carbonitrile
DM6I5K1	DE	Discovery agent

DM46VT2	ID	DM46VT2
DM46VT2	DN	7-(trifluoromethyl)-1H-indole-2,3-dione
DM46VT2	HS	Investigative
DM46VT2	SN	391-12-8; 7-Trifluoromethylisatin; 7-(Trifluoromethyl)isatin; 7-(Trifluoromethyl)indoline-2,3-dione; 7-(Trifluoromethyl)-1H-indole-2,3-dione; 7-trifluoromethyl-1h-indole-2,3-dione; 7-(trifluoromethyl)-2,3-dihydro-1h-indole-2,3-dione; MXLDJTXXAYVWDF-UHFFFAOYSA-N; 1H-INDOLE-2,3-DIONE, 7-(TRIFLUOROMETHYL)-; 7-(trifluoromethyl)-1~{H}-indole-2,3-dione; 7-Trifluoroisatin; PubChem9557; AC1LCPWB; ACMC-1CLGD; 7-trifluoromethyl-isatin; Isatin-based compound, 45; AC1Q4IR6; KSC493C7F; SCHEMBL594546; CHEMBL376435; Jsp006801; CTK3J3172
DM46VT2	DT	Small molecular drug
DM46VT2	PC	604575
DM46VT2	MW	215.13
DM46VT2	FM	C9H4F3NO2
DM46VT2	IC	InChI=1S/C9H4F3NO2/c10-9(11,12)5-3-1-2-4-6(5)13-8(15)7(4)14/h1-3H,(H,13,14,15)
DM46VT2	CS	C1=CC2=C(C(=C1)C(F)(F)F)NC(=O)C2=O
DM46VT2	IK	MXLDJTXXAYVWDF-UHFFFAOYSA-N
DM46VT2	IU	7-(trifluoromethyl)-1H-indole-2,3-dione
DM46VT2	CA	CAS 391-12-8
DM46VT2	DE	Discovery agent

DM3FXRC	ID	DM3FXRC
DM3FXRC	DN	7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene
DM3FXRC	HS	Investigative
DM3FXRC	SN	CHEMBL301605; 7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene; 7,12-dihydropyrido[3,2-b:5,4-b']diindole; NCI60_006891; AC1L7HBP; AC1Q4YR3; CTK5J6980; ZINC12941871
DM3FXRC	DT	Small molecular drug
DM3FXRC	PC	360772
DM3FXRC	MW	257.29
DM3FXRC	FM	C17H11N3
DM3FXRC	IC	InChI=1S/C17H11N3/c1-3-7-12-10(5-1)15-14(19-12)9-18-16-11-6-2-4-8-13(11)20-17(15)16/h1-9,19-20H
DM3FXRC	CS	C1=CC=C2C(=C1)C3=C4C(=NC=C3N2)C5=CC=CC=C5N4
DM3FXRC	IK	UFTKNTUWDMJOIX-UHFFFAOYSA-N
DM3FXRC	IU	9,12,20-triazapentacyclo[11.7.0.02,10.03,8.014,19]icosa-1(13),2(10),3,5,7,11,14,16,18-nonaene
DM3FXRC	DE	Discovery agent

DMTZ943	ID	DMTZ943
DMTZ943	DN	7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene
DMTZ943	HS	Investigative
DMTZ943	SN	5,12-Dihydroindolo[3,2-a]carbazole; 111296-91-4; 5,12-dihydroindolo[3,2-c]carbazole; Indolo[3,2-]arbazole, 5,12-ihydro-; Indolo[3,2-a]carbazole, 5,12-dihydro-; 5H,12H-Indolo[3,2-a]carbazole; AC1NFSZ0; SCHEMBL224017; CHEMBL53230; DTXSID80405771; QQWXDAWSMPLECU-UHFFFAOYSA-N; MolPort-027-835-190; ZINC13490703; 2059AA; AKOS016009131; 5,12-dihydro-indolo[3,2-a]carbazole; Indolo[3,2-a]carbazole,5,12-dihydro-; SC-48298; AJ-63955; AX8227529
DMTZ943	DT	Small molecular drug
DMTZ943	PC	4713445
DMTZ943	MW	256.3
DMTZ943	FM	C18H12N2
DMTZ943	IC	InChI=1S/C18H12N2/c1-3-7-14-11(5-1)12-9-10-16-17(18(12)20-14)13-6-2-4-8-15(13)19-16/h1-10,19-20H
DMTZ943	CS	C1=CC=C2C(=C1)C3=C(N2)C4=C(C=C3)NC5=CC=CC=C54
DMTZ943	IK	QQWXDAWSMPLECU-UHFFFAOYSA-N
DMTZ943	IU	5,12-dihydroindolo[3,2-c]carbazole
DMTZ943	CA	CAS 111296-91-4
DMTZ943	DE	Discovery agent

DM5JV8G	ID	DM5JV8G
DM5JV8G	DN	7,3',4'-trihydroxyisoflavone
DM5JV8G	HS	Investigative
DM5JV8G	SN	3',4',7-Trihydroxyisoflavone; 3'-Hydroxydaidzein; 485-63-2; 3-(3,4-Dihydroxyphenyl)-7-hydroxy-4H-chromen-4-one; 7,3',4'-Trihydroxyisoflavone; UNII-T08Y239E7Y; CHEMBL13486; CHEBI:50399; 3',4',7-trihydroxy isoflavone; DDKGKOOLFLYZDL-UHFFFAOYSA-N; 3'',4'',7-trihydroxyisoflavone; T08Y239E7Y; 3-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one; 3-(3,4-dihydroxyphenyl)-7-hydroxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3,4-dihydroxyphenyl)-7-hydroxy-; 47X; Orita-13; 3l5r; AC1NR4TZ; SCHEMBL73012; BIDD:ER0118; GTPL9985
DM5JV8G	DT	Small molecular drug
DM5JV8G	PC	5284648
DM5JV8G	MW	270.24
DM5JV8G	FM	C15H10O5
DM5JV8G	IC	InChI=1S/C15H10O5/c16-9-2-3-10-14(6-9)20-7-11(15(10)19)8-1-4-12(17)13(18)5-8/h1-7,16-18H
DM5JV8G	CS	C1=CC(=C(C=C1C2=COC3=C(C2=O)C=CC(=C3)O)O)O
DM5JV8G	IK	DDKGKOOLFLYZDL-UHFFFAOYSA-N
DM5JV8G	IU	3-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one
DM5JV8G	CA	CAS 485-63-2
DM5JV8G	CB	CHEBI:50399
DM5JV8G	DE	Discovery agent

DMXQ1K0	ID	DMXQ1K0
DMXQ1K0	DN	7,4'-Dihydroxyflavone
DMXQ1K0	HS	Investigative
DMXQ1K0	SN	7,4'-Dihydroxyflavone; 4',7-Dihydroxyflavone; 2196-14-7; 7-Hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-2-(4-hydroxyphenyl)-; FLAVONE, 4',7-DIHYDROXY-; UNII-53ZZF57X0U; CHEMBL294878; 53ZZF57X0U; 7-hydroxy-2-(4-hydroxyphenyl)chromen-4-one; CHEBI:29503; LCAWNFIFMLXZPQ-UHFFFAOYSA-N; BRN 0224356; PubChem9844; AC1NQZG5; 7, 4'-Dihydroxyflavone; Spectrum4_001280; 7,4''-Dihydroxyflavone; 7,4' - Dihydroxyflavone; C12123; 7,4&amp;#39-dihydroxyflavone; KBioGR_001900; SPECTRUM1500721; SCHEMBL157723
DMXQ1K0	DT	Small molecular drug
DMXQ1K0	PC	5282073
DMXQ1K0	MW	254.24
DMXQ1K0	FM	C15H10O4
DMXQ1K0	IC	InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-8,16-17H
DMXQ1K0	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=C(C=C3)O)O
DMXQ1K0	IK	LCAWNFIFMLXZPQ-UHFFFAOYSA-N
DMXQ1K0	IU	7-hydroxy-2-(4-hydroxyphenyl)chromen-4-one
DMXQ1K0	CA	CAS 2196-14-7
DMXQ1K0	CB	CHEBI:29503
DMXQ1K0	DE	Discovery agent

DMOBEL9	ID	DMOBEL9
DMOBEL9	DN	7,8,3',4'-tetrahydroxyflavone
DMOBEL9	HS	Investigative
DMOBEL9	SN	7,8,3',4'-tetrahydroxyflavone; 3440-24-2; 2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-4H-chromen-4-one; 3',4',7,8-Tetrahydroxyflavone; CHEMBL222541; ARYCMKPCDNHQCL-UHFFFAOYSA-N; ST059620; 2-(3,4-dihydroxyphenyl)-7,8-dihydroxychromen-4-one; AC1LEMTC; AC1Q6AJ1; SCHEMBL35318; CTK4H2335; ZINC57844; DTXSID20350973; 2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-4h-chromen-4-on; CHEBI:125596; 7,8,3'',4''-tetrahydroxyflavone; BDBM50157547; AKOS024283046; ACM3440242; MCULE-5496936655; ZB002260; DB-048618; FT-0614178; C-57754
DMOBEL9	DT	Small molecular drug
DMOBEL9	PC	688798
DMOBEL9	MW	286.24
DMOBEL9	FM	C15H10O6
DMOBEL9	IC	InChI=1S/C15H10O6/c16-9-3-1-7(5-12(9)19)13-6-11(18)8-2-4-10(17)14(20)15(8)21-13/h1-6,16-17,19-20H
DMOBEL9	CS	C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C(=C(C=C3)O)O)O)O
DMOBEL9	IK	ARYCMKPCDNHQCL-UHFFFAOYSA-N
DMOBEL9	IU	2-(3,4-dihydroxyphenyl)-7,8-dihydroxychromen-4-one
DMOBEL9	CA	CAS 3440-24-2
DMOBEL9	CB	CHEBI:125596
DMOBEL9	DE	Discovery agent

DM80GFL	ID	DM80GFL
DM80GFL	DN	7,8,4'-trihydroxyisoflavone
DM80GFL	HS	Investigative
DM80GFL	SN	7,8,4'-Trihydroxyisoflavone; 8-Hydroxydaidzein; 75187-63-2; 4',7,8-Trihydroxyisoflavone; 7,8-Dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; 7,8-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one; 7,8-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; NSC678112; CHEMBL242739; NSC 678112; 4H-1-Benzopyran-4-one, 7,8-dihydroxy-3-(4-hydroxyphenyl)-; 7,4'-Trihydroxyisoflavone; AC1NV1M1; SCHEMBL571127; 7,8,4''-trihydroxyisoflavone; 4'',7,8-trihydroxyisoflavone; CTK5E1244; DTXSID20226169; MolPort-000-165-583; BMZFZTMWBCFKSS-UHFFFAOYSA-N
DM80GFL	DT	Small molecular drug
DM80GFL	PC	5466139
DM80GFL	MW	270.24
DM80GFL	FM	C15H10O5
DM80GFL	IC	InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-15-10(13(11)18)5-6-12(17)14(15)19/h1-7,16-17,19H
DM80GFL	CS	C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3O)O)O
DM80GFL	IK	BMZFZTMWBCFKSS-UHFFFAOYSA-N
DM80GFL	IU	7,8-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
DM80GFL	CA	CAS 75187-63-2
DM80GFL	DE	Discovery agent

DMIMLUO	ID	DMIMLUO
DMIMLUO	DN	7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine
DMIMLUO	HS	Investigative
DMIMLUO	SN	CHEMBL261490; BDBM50375901
DMIMLUO	DT	Small molecular drug
DMIMLUO	PC	44451373
DMIMLUO	MW	187.24
DMIMLUO	FM	C12H13NO
DMIMLUO	IC	InChI=1S/C12H13NO/c1-2-10-5-8-14-12(10)11-4-7-13-6-3-9(1)11/h1-2,5,8,13H,3-4,6-7H2
DMIMLUO	CS	C1CNCCC2=C1C=CC3=C2OC=C3
DMIMLUO	IK	QDAAIWYKQLAISZ-UHFFFAOYSA-N
DMIMLUO	IU	7,8,9,10-tetrahydro-6H-furo[3,2-i][3]benzazepine
DMIMLUO	DE	Discovery agent

DMVZA27	ID	DMVZA27
DMVZA27	DN	7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine
DMVZA27	HS	Investigative
DMVZA27	SN	CHEMBL261489
DMVZA27	DT	Small molecular drug
DMVZA27	PC	44451369
DMVZA27	MW	187.24
DMVZA27	FM	C12H13NO
DMVZA27	IC	InChI=1S/C12H13NO/c1-2-12-11(5-8-14-12)10-4-7-13-6-3-9(1)10/h1-2,5,8,13H,3-4,6-7H2
DMVZA27	CS	C1CNCCC2=C1C=CC3=C2C=CO3
DMVZA27	IK	BGHAWUGGSCZWBN-UHFFFAOYSA-N
DMVZA27	IU	7,8,9,10-tetrahydro-6H-furo[2,3-i][3]benzazepine
DMVZA27	DE	Discovery agent

DMKNQW4	ID	DMKNQW4
DMKNQW4	DN	7,8-dichloroquinoline-4-one-3-carboxylic acid
DMKNQW4	HS	Investigative
DMKNQW4	SN	300675-28-9; 7,8-DICHLORO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID; 144061-33-6; 7,8-dichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7,8-dichloro-4-oxo-1H-quinoline-3-carboxylic Acid; CHEMBL218566; 7,8-Dichloro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid; J-650168; 7,8-dichloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; AC1LEVOV; Oprea1_635608; Oprea1_583373; SCHEMBL9654331; SCHEMBL17502115; CTK7I6370; CHEBI:94582; DTXSID00351180; MolPort-000-680-344; MolPort-000-651-074; ZINC3945161; STK539875; MFCD01909987
DMKNQW4	DT	Small molecular drug
DMKNQW4	PC	693139
DMKNQW4	MW	258.05
DMKNQW4	FM	C10H5Cl2NO3
DMKNQW4	IC	InChI=1S/C10H5Cl2NO3/c11-6-2-1-4-8(7(6)12)13-3-5(9(4)14)10(15)16/h1-3H,(H,13,14)(H,15,16)
DMKNQW4	CS	C1=CC(=C(C2=C1C(=O)C(=CN2)C(=O)O)Cl)Cl
DMKNQW4	IK	HVXHDYSWCHQWBD-UHFFFAOYSA-N
DMKNQW4	IU	7,8-dichloro-4-oxo-1H-quinoline-3-carboxylic acid
DMKNQW4	CA	CAS 144061-33-6
DMKNQW4	CB	CHEBI:94582
DMKNQW4	DE	Discovery agent

DMQU4XM	ID	DMQU4XM
DMQU4XM	DN	7,8-dihydrobiopterin
DMQU4XM	HS	Investigative
DMQU4XM	SN	Quinonoid dihydrobiopterin; q-BH2; L-erythro-q-dihydrobiopterin; dihydrobiopterin; L-erythro-7,8-Dihydrobiopterin; L-erythro-dihydrobiopterin; 7,8-Dihydro-L-biopterin; 6779-87-9; 2-amino-6-((1r,2s)-1,2-dihydroxypropyl)-7,8-dihydro-4(1h)-pteridinone; 2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-7,8-dihydropteridin-4(3H)-one; 2toh; 4(1H)-pteridinone, 2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-7,8-dihydro-; 4(1H)-Pteridinone, 2-amino-6-(1,2-dihydroxypropyl)-7,8-dihydro-, [S-(R*,S*)]-; 4(1H)-Pteridinone; 7,8-Dihydro-L-Biopterin
DMQU4XM	DT	Small molecular drug
DMQU4XM	PC	135398687
DMQU4XM	MW	239.23
DMQU4XM	FM	C9H13N5O3
DMQU4XM	IC	InChI=1S/C9H13N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3,6,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,6-/m0/s1
DMQU4XM	CS	C[C@@H]([C@@H](C1=NC2=C(NC1)N=C(NC2=O)N)O)O
DMQU4XM	IK	FEMXZDUTFRTWPE-DZSWIPIPSA-N
DMQU4XM	IU	2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-7,8-dihydro-3H-pteridin-4-one
DMQU4XM	CA	CAS 6779-87-9
DMQU4XM	CB	CHEBI:43029
DMQU4XM	DE	Discovery agent

DM5TXY1	ID	DM5TXY1
DM5TXY1	DN	7,8-Dihydroneopterin
DM5TXY1	HS	Investigative
DM5TXY1	DT	Small molecular drug
DM5TXY1	PC	135398602
DM5TXY1	MW	255.23
DM5TXY1	FM	C9H13N5O4
DM5TXY1	IC	InChI=1S/C9H13N5O4/c10-9-13-7-5(8(18)14-9)12-3(1-11-7)6(17)4(16)2-15/h4,6,15-17H,1-2H2,(H4,10,11,13,14,18)/t4-,6+/m1/s1
DM5TXY1	CS	C1C(=NC2=C(N1)N=C(NC2=O)N)[C@@H]([C@@H](CO)O)O
DM5TXY1	IK	YQIFAMYNGGOTFB-XINAWCOVSA-N
DM5TXY1	IU	2-amino-6-[(1S,2R)-1,2,3-trihydroxypropyl]-7,8-dihydro-3H-pteridin-4-one
DM5TXY1	CA	CAS 1218-98-0
DM5TXY1	CB	CHEBI:17001
DM5TXY1	DE	Discovery agent

DMUB5E8	ID	DMUB5E8
DMUB5E8	DN	7,8-dihydroxy-4-phenyl-2H-chromen-2-one
DMUB5E8	HS	Investigative
DMUB5E8	SN	7,8-dihydroxy-4-phenyl-2H-chromen-2-one; 842-01-3; 7,8-Dihydroxy-4-phenylcoumarin; 7,8-dihydroxy-4-phenylchromen-2-one; 2zvj; AC1NTWI0; AC1Q78GB; Oprea1_803491; IFLab1_001650; SCHEMBL1181304; CHEMBL1233867; 4-phenyl-7,8-dihydroxycoumarin; CTK5F1973; 4-phenyl-7,8-dihydroxycoumarine; DTXSID10419942; MolPort-000-852-912; JRVIIPJSVKTPBK-UHFFFAOYSA-N; ZINC406883; HMS1416K22; DNDI1417012; ALBB-015578; BBL029555; 0375AF; STL372126; AKOS005175244; MCULE-8639896630; DB08049; 7,8-dihydroxy-4-phenyl-chromen-2-one; 7,8-DIHYDROXY-4-PHENYL COUMARIN
DMUB5E8	DT	Small molecular drug
DMUB5E8	PC	5413034
DMUB5E8	MW	254.24
DMUB5E8	FM	C15H10O4
DMUB5E8	IC	InChI=1S/C15H10O4/c16-12-7-6-10-11(9-4-2-1-3-5-9)8-13(17)19-15(10)14(12)18/h1-8,16,18H
DMUB5E8	CS	C1=CC=C(C=C1)C2=CC(=O)OC3=C2C=CC(=C3O)O
DMUB5E8	IK	JRVIIPJSVKTPBK-UHFFFAOYSA-N
DMUB5E8	IU	7,8-dihydroxy-4-phenylchromen-2-one
DMUB5E8	CA	CAS 842-01-3
DMUB5E8	DE	Discovery agent

DMPF6MD	ID	DMPF6MD
DMPF6MD	DN	7,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one
DMPF6MD	HS	Investigative
DMPF6MD	SN	7,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one; casimiroin analogue, 1h; CHEMBL453233
DMPF6MD	DT	Small molecular drug
DMPF6MD	PC	42618029
DMPF6MD	MW	233.26
DMPF6MD	FM	C13H15NO3
DMPF6MD	IC	InChI=1S/C13H15NO3/c1-8-7-11(15)14(2)12-9(8)5-6-10(16-3)13(12)17-4/h5-7H,1-4H3
DMPF6MD	CS	CC1=CC(=O)N(C2=C1C=CC(=C2OC)OC)C
DMPF6MD	IK	DHJBSOKLGMWDBA-UHFFFAOYSA-N
DMPF6MD	IU	7,8-dimethoxy-1,4-dimethylquinolin-2-one
DMPF6MD	DE	Discovery agent

DMO8GEI	ID	DMO8GEI
DMO8GEI	DN	7,9-octadecadiynoic acid
DMO8GEI	HS	Investigative
DMO8GEI	SN	7,9-Octadecadiynoic acid; CHEMBL485858; 33128-25-5; LMFA01030532; AC1NSN9N; octadeca-7,9-diynoic acid; CTK1B8718; DTXSID00415579
DMO8GEI	DT	Small molecular drug
DMO8GEI	PC	5312662
DMO8GEI	MW	276.4
DMO8GEI	FM	C18H28O2
DMO8GEI	IC	InChI=1S/C18H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-8,13-17H2,1H3,(H,19,20)
DMO8GEI	CS	CCCCCCCCC#CC#CCCCCCC(=O)O
DMO8GEI	IK	LDZUDUYCHODRLO-UHFFFAOYSA-N
DMO8GEI	IU	octadeca-7,9-diynoic acid
DMO8GEI	CA	CAS 33128-25-5
DMO8GEI	DE	Discovery agent

DMPEXTB	ID	DMPEXTB
DMPEXTB	DN	7,9-tetradecadiynoic acid
DMPEXTB	HS	Investigative
DMPEXTB	SN	7,9-tetradecadiynoic acid; CHEMBL501307; 7,9-Tetradecadiyneoic acid; Tetradecan-7,9-diynoic acid; LMFA01031094; BDBM50292399
DMPEXTB	DT	Small molecular drug
DMPEXTB	PC	14309406
DMPEXTB	MW	220.31
DMPEXTB	FM	C14H20O2
DMPEXTB	IC	InChI=1S/C14H20O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-4,9-13H2,1H3,(H,15,16)
DMPEXTB	CS	CCCCC#CC#CCCCCCC(=O)O
DMPEXTB	IK	UDDQRZKIDJCZJF-UHFFFAOYSA-N
DMPEXTB	IU	tetradeca-7,9-diynoic acid
DMPEXTB	DE	Discovery agent

DMNGLM1	ID	DMNGLM1
DMNGLM1	DN	7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one
DMNGLM1	HS	Investigative
DMNGLM1	SN	CHEMBL157925; 7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one; 4H-1-Benzopyran-4-one, 7-(4H-1,2,4-triazol-4-ylmethyl)-; BDBM50097361; 331684-17-4
DMNGLM1	DT	Small molecular drug
DMNGLM1	PC	10823163
DMNGLM1	MW	227.22
DMNGLM1	FM	C12H9N3O2
DMNGLM1	IC	InChI=1S/C12H9N3O2/c16-11-3-4-17-12-5-9(1-2-10(11)12)6-15-7-13-14-8-15/h1-5,7-8H,6H2
DMNGLM1	CS	C1=CC2=C(C=C1CN3C=NN=C3)OC=CC2=O
DMNGLM1	IK	QNCWBRMMGXVBEU-UHFFFAOYSA-N
DMNGLM1	IU	7-(1,2,4-triazol-4-ylmethyl)chromen-4-one
DMNGLM1	DE	Discovery agent

DMQCDT1	ID	DMQCDT1
DMQCDT1	DN	7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin
DMQCDT1	HS	Investigative
DMQCDT1	SN	307550-03-4; CHEMBL488073; 4-METHYL-3-(2-OXOPROPOXY)-7,8,9,10-TETRAHYDRO-6H-BENZO[C]CHROMEN-6-ONE; CHEMBRDG-BB 6148717; AC1LDV7A; CBMicro_031517; 7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin; ZINC83523; CTK4G5861; DTXSID00351504; MolPort-000-688-897; ZX-CM016547; STL303255; BDBM50246265; AKOS002377920; MCULE-4345433569; AJ-10643; ACM307550034; BIM-0031568.P001; W-8890; SR-01000229174; SR-01000229174-1; 4-methyl-3-(2-oxopropoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one; 6H-Dibenzo[b,d]pyran-6-one, 7,8,9,10-tetrahydro-4-methyl-3-
DMQCDT1	DT	Small molecular drug
DMQCDT1	PC	701943
DMQCDT1	MW	286.32
DMQCDT1	FM	C17H18O4
DMQCDT1	IC	InChI=1S/C17H18O4/c1-10(18)9-20-15-8-7-13-12-5-3-4-6-14(12)17(19)21-16(13)11(15)2/h7-8H,3-6,9H2,1-2H3
DMQCDT1	CS	CC1=C(C=CC2=C1OC(=O)C3=C2CCCC3)OCC(=O)C
DMQCDT1	IK	FPBPSCOEWNGWAT-UHFFFAOYSA-N
DMQCDT1	IU	4-methyl-3-(2-oxopropoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one
DMQCDT1	CA	CAS 307550-03-4
DMQCDT1	DE	Discovery agent

DMQMTSX	ID	DMQMTSX
DMQMTSX	DN	7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin
DMQMTSX	HS	Investigative
DMQMTSX	SN	307548-94-3; CHEMBL488076; 6-methyl-7-(2-oxopropoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one; 6-METHYL-7-(2-OXOPROPOXY)-2,3-DIHYDROCYCLOPENTA(C)CHROMEN-4(1H)-ONE; CHEMBRDG-BB 6159766; AC1MY6ZC; CBMicro_001748; 7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin; CTK4G5858; DTXSID20397328; MolPort-000-688-742; ZX-CM016564; SMSF0015818; ZINC4387711; STK829219; BDBM50246264; AKOS001021363; CB03533; MCULE-6433360521; ACM307548943; AJ-51032; BIM-0001876.P001; W-8723; SR-01000229477; SR-01000229477-1
DMQMTSX	DT	Small molecular drug
DMQMTSX	PC	3852139
DMQMTSX	MW	272.29
DMQMTSX	FM	C16H16O4
DMQMTSX	IC	InChI=1S/C16H16O4/c1-9(17)8-19-14-7-6-12-11-4-3-5-13(11)16(18)20-15(12)10(14)2/h6-7H,3-5,8H2,1-2H3
DMQMTSX	CS	CC1=C(C=CC2=C1OC(=O)C3=C2CCC3)OCC(=O)C
DMQMTSX	IK	JLYIBZRYQJEBHZ-UHFFFAOYSA-N
DMQMTSX	IU	6-methyl-7-(2-oxopropoxy)-2,3-dihydro-1H-cyclopenta[c]chromen-4-one
DMQMTSX	CA	CAS 307548-94-3
DMQMTSX	DE	Discovery agent

DMYSNQO	ID	DMYSNQO
DMYSNQO	DN	7-acetonyloxy-3-acetylamino-8-methoxycoumarin
DMYSNQO	HS	Investigative
DMYSNQO	SN	CHEMBL201250; 7-acetonyloxy-3-acetylamino-8-methoxycoumarin; CTK6J4706; BDBM50181853; AKOS015965518; N-[8-Methoxy-2-oxo-7-(2-oxo-propoxy; N-(8-methoxy-2-oxo-7-(2-oxopropoxy)-2H-chromen-3-yl)acetamide
DMYSNQO	DT	Small molecular drug
DMYSNQO	PC	11623661
DMYSNQO	MW	305.28
DMYSNQO	FM	C15H15NO6
DMYSNQO	IC	InChI=1S/C15H15NO6/c1-8(17)7-21-12-5-4-10-6-11(16-9(2)18)15(19)22-13(10)14(12)20-3/h4-6H,7H2,1-3H3,(H,16,18)
DMYSNQO	CS	CC(=O)COC1=C(C2=C(C=C1)C=C(C(=O)O2)NC(=O)C)OC
DMYSNQO	IK	BPSQKFACFYVPBO-UHFFFAOYSA-N
DMYSNQO	IU	N-[8-methoxy-2-oxo-7-(2-oxopropoxy)chromen-3-yl]acetamide
DMYSNQO	DE	Discovery agent

DMPRBO1	ID	DMPRBO1
DMPRBO1	DN	7-Allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
DMPRBO1	HS	Investigative
DMPRBO1	SN	7-Allyltheophylline; Theophylline, 7-allyl-; 61444-26-6; UNII-NC789Z71XR; BRN 0226015; CHEMBL24289; NC789Z71XR; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-7-(2-propenyl)-; 7-Allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione; 7-allyl-1,3-dimethylxanthine; 7-Allyl-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 1,3-dimethyl-7-(prop-2-en-1-yl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione; NSC521015; AC1L2QUV; ChemDiv2_003783; 1,3-dimethyl-7-prop-2-enylpurine-2,6-dione; Cambridge id 6249500; AC1Q3ZA3; SCHEMBL316279
DMPRBO1	DT	Small molecular drug
DMPRBO1	PC	101446
DMPRBO1	MW	220.23
DMPRBO1	FM	C10H12N4O2
DMPRBO1	IC	InChI=1S/C10H12N4O2/c1-4-5-14-6-11-8-7(14)9(15)13(3)10(16)12(8)2/h4,6H,1,5H2,2-3H3
DMPRBO1	CS	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC=C
DMPRBO1	IK	ZGIBYCLLIMGXEZ-UHFFFAOYSA-N
DMPRBO1	IU	1,3-dimethyl-7-prop-2-enylpurine-2,6-dione
DMPRBO1	CA	CAS 61444-26-6
DMPRBO1	DE	Discovery agent

DMHJ6TU	ID	DMHJ6TU
DMHJ6TU	DN	7-Allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione
DMHJ6TU	HS	Investigative
DMHJ6TU	SN	CHEMBL284860; 7-Allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; BDBM50025571
DMHJ6TU	DT	Small molecular drug
DMHJ6TU	PC	44274626
DMHJ6TU	MW	276.33
DMHJ6TU	FM	C14H20N4O2
DMHJ6TU	IC	InChI=1S/C14H20N4O2/c1-4-7-16-10-15-12-11(16)13(19)18(9-6-3)14(20)17(12)8-5-2/h4,10H,1,5-9H2,2-3H3
DMHJ6TU	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)N(C=N2)CC=C
DMHJ6TU	IK	NRUARHUVQRNQPB-UHFFFAOYSA-N
DMHJ6TU	IU	7-prop-2-enyl-1,3-dipropylpurine-2,6-dione
DMHJ6TU	DE	Discovery agent

DMSRQ1L	ID	DMSRQ1L
DMSRQ1L	DN	7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMSRQ1L	HS	Investigative
DMSRQ1L	DT	Small molecular drug
DMSRQ1L	PC	135458122
DMSRQ1L	MW	267.28
DMSRQ1L	FM	C16H13NO3
DMSRQ1L	IC	InChI=1S/C16H13NO3/c1-2-3-11-8-13(19)9-14-15(11)20-16(17-14)10-4-6-12(18)7-5-10/h2,4-9,18-19H,1,3H2
DMSRQ1L	CS	C=CCC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMSRQ1L	IK	XQORYXRHJJULMI-UHFFFAOYSA-N
DMSRQ1L	IU	2-(4-hydroxyphenyl)-7-prop-2-enyl-1,3-benzoxazol-5-ol
DMSRQ1L	DE	Discovery agent

DM2N8TW	ID	DM2N8TW
DM2N8TW	DN	7alpha,25-dihydroxycholesterol
DM2N8TW	HS	Investigative
DM2N8TW	SN	7alpha-25-OHC
DM2N8TW	DT	Small molecular drug
DM2N8TW	PC	11954197
DM2N8TW	MW	418.7
DM2N8TW	FM	C27H46O3
DM2N8TW	IC	InChI=1S/C27H46O3/c1-17(7-6-12-25(2,3)30)20-8-9-21-24-22(11-14-27(20,21)5)26(4)13-10-19(28)15-18(26)16-23(24)29/h16-17,19-24,28-30H,6-15H2,1-5H3/t17-,19+,20-,21+,22+,23-,24+,26+,27-/m1/s1
DM2N8TW	CS	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DM2N8TW	IK	BQMSKLCEWBSPPY-IKVTXIKFSA-N
DM2N8TW	IU	(3S,7S,8S,9S,10R,13R,14S,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DM2N8TW	CA	CAS 64907-22-8
DM2N8TW	CB	CHEBI:37623
DM2N8TW	DE	Discovery agent

DM52UOM	ID	DM52UOM
DM52UOM	DN	7alpha,27-dihydroxycholesterol
DM52UOM	HS	Investigative
DM52UOM	SN	7alpha, 27-OHC
DM52UOM	DT	Small molecular drug
DM52UOM	PC	440985
DM52UOM	MW	418.7
DM52UOM	FM	C27H46O3
DM52UOM	IC	InChI=1S/C27H46O3/c1-17(16-28)6-5-7-18(2)21-8-9-22-25-23(11-13-27(21,22)4)26(3)12-10-20(29)14-19(26)15-24(25)30/h15,17-18,20-25,28-30H,5-14,16H2,1-4H3/t17?,18-,20+,21-,22+,23+,24-,25+,26+,27-/m1/s1
DM52UOM	CS	C[C@H](CCCC(C)CO)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DM52UOM	IK	RXMHNAKZMGJANZ-DTTSCKGMSA-N
DM52UOM	IU	(3S,7S,8S,9S,10R,13R,14S,17R)-17-[(2R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DM52UOM	CA	CAS 4725-24-0
DM52UOM	CB	CHEBI:18431
DM52UOM	DE	Discovery agent

DMD6UC9	ID	DMD6UC9
DMD6UC9	DN	7alpha-Cl-ginkgolide B
DMD6UC9	HS	Investigative
DMD6UC9	SN	7alpha-Cl-ginkgolide B; 7alpha-Cl-GB
DMD6UC9	DT	Small molecular drug
DMD6UC9	PC	73755014
DMD6UC9	MW	458.8
DMD6UC9	FM	C20H23ClO10
DMD6UC9	IC	InChI=1S/C20H23ClO10/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,22-23,27H,1-4H3/t5?,6?,7?,8?,9-,10?,11-,15?,17?,18?,19+,20-/m0/s1
DMD6UC9	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C(C5Cl)C(C)(C)C)O
DMD6UC9	IK	GXEIWFYPUUOBJY-UUSFTXJGSA-N
DMD6UC9	IU	(1S,6R,13S,17R)-8-tert-butyl-9-chloro-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMD6UC9	DE	Discovery agent

DMRQ24A	ID	DMRQ24A
DMRQ24A	DN	7alpha-F-ginkgolide B
DMRQ24A	HS	Investigative
DMRQ24A	SN	7alpha-F-ginkgolide B; 7alpha-F-GB
DMRQ24A	DT	Small molecular drug
DMRQ24A	PC	73755015
DMRQ24A	MW	442.4
DMRQ24A	FM	C20H23FO10
DMRQ24A	IC	InChI=1S/C20H23FO10/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,22-23,27H,1-4H3/t5?,6?,7?,8?,9-,10?,11-,15?,17?,18?,19+,20-/m0/s1
DMRQ24A	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C(C5F)C(C)(C)C)O
DMRQ24A	IK	NKHCTSYWTBHOAK-UUSFTXJGSA-N
DMRQ24A	IU	(1S,6R,13S,17R)-8-tert-butyl-9-fluoro-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMRQ24A	DE	Discovery agent

DMH6LD0	ID	DMH6LD0
DMH6LD0	DN	7alpha-hydroxycholesterol
DMH6LD0	HS	Investigative
DMH6LD0	SN	7-alpha-OHC
DMH6LD0	DT	Small molecular drug
DMH6LD0	PC	107722
DMH6LD0	MW	402.7
DMH6LD0	FM	C27H46O2
DMH6LD0	IC	InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24-,25+,26+,27-/m1/s1
DMH6LD0	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DMH6LD0	IK	OYXZMSRRJOYLLO-RVOWOUOISA-N
DMH6LD0	IU	(3S,7S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMH6LD0	CA	CAS 566-26-7
DMH6LD0	CB	CHEBI:17500
DMH6LD0	DE	Discovery agent

DMGNWBV	ID	DMGNWBV
DMGNWBV	DN	7alpha-N3-ginkgolide B
DMGNWBV	HS	Investigative
DMGNWBV	SN	7alpha-N3-ginkgolide B; 7alpha-N3-GB
DMGNWBV	DT	Small molecular drug
DMGNWBV	PC	73755016
DMGNWBV	MW	465.4
DMGNWBV	FM	C20H23N3O10
DMGNWBV	IC	InChI=1S/C20H23N3O10/c1-5-12(26)30-11-8(24)18-10-6(22-23-21)7(16(2,3)4)17(18)9(25)13(27)32-15(17)33-20(18,14(28)31-10)19(5,11)29/h5-11,15,24-25,29H,1-4H3/t5?,6-,7?,8?,9-,10?,11-,15?,17?,18?,19+,20-/m0/s1
DMGNWBV	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@@H]5N=[N+]=[N-])C(C)(C)C)O
DMGNWBV	IK	GLXZEIIDXFBXMR-AQPRMESZSA-N
DMGNWBV	IU	(1S,6R,9S,13S,17R)-9-azido-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMGNWBV	DE	Discovery agent

DMZUYX1	ID	DMZUYX1
DMZUYX1	DN	7alpha-NH2-ginkgolide B
DMZUYX1	HS	Investigative
DMZUYX1	SN	7alpha-NH2-ginkgolide B; 7alpha-NH2-GB
DMZUYX1	DT	Small molecular drug
DMZUYX1	PC	73755017
DMZUYX1	MW	439.4
DMZUYX1	FM	C20H25NO10
DMZUYX1	IC	InChI=1S/C20H25NO10/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,22-23,27H,21H2,1-4H3/t5?,6-,7?,8?,9-,10?,11-,15?,17?,18?,19+,20-/m0/s1
DMZUYX1	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@@H]5N)C(C)(C)C)O
DMZUYX1	IK	OONDPNQTNMFTRA-AQPRMESZSA-N
DMZUYX1	IU	(1S,6R,9S,13S,17R)-9-amino-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMZUYX1	DE	Discovery agent

DMWAB7F	ID	DMWAB7F
DMWAB7F	DN	7alpha-NHEt-ginkgolide B
DMWAB7F	HS	Investigative
DMWAB7F	SN	7alpha-NHEt-ginkgolide B; 7alpha-NHEt-GB
DMWAB7F	DT	Small molecular drug
DMWAB7F	PC	73755018
DMWAB7F	MW	467.5
DMWAB7F	FM	C22H29NO10
DMWAB7F	IC	InChI=1S/C22H29NO10/c1-6-23-8-9(18(3,4)5)19-11(25)15(27)32-17(19)33-22-16(28)31-12(8)20(19,22)10(24)13-21(22,29)7(2)14(26)30-13/h7-13,17,23-25,29H,6H2,1-5H3/t7?,8-,9?,10?,11-,12?,13-,17?,19?,20?,21+,22-/m0/s1
DMWAB7F	CS	CCN[C@H]1C(C23[C@H](C(=O)OC2O[C@]45C3(C1OC4=O)C([C@H]6[C@@]5(C(C(=O)O6)C)O)O)O)C(C)(C)C
DMWAB7F	IK	UIERCQIWSNGSNJ-YUTHRBKVSA-N
DMWAB7F	IU	(1S,6R,9S,13S,17R)-8-tert-butyl-9-(ethylamino)-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMWAB7F	DE	Discovery agent

DMSPLYF	ID	DMSPLYF
DMSPLYF	DN	7alpha-NHMe-ginkgolide B
DMSPLYF	HS	Investigative
DMSPLYF	SN	7alpha-NHMe-ginkgolide B; 7alpha-NHMe-GB
DMSPLYF	DT	Small molecular drug
DMSPLYF	PC	73755019
DMSPLYF	MW	453.4
DMSPLYF	FM	C21H27NO10
DMSPLYF	IC	InChI=1S/C21H27NO10/c1-6-13(25)29-12-9(23)19-11-7(22-5)8(17(2,3)4)18(19)10(24)14(26)31-16(18)32-21(19,15(27)30-11)20(6,12)28/h6-12,16,22-24,28H,1-5H3/t6?,7-,8?,9?,10-,11?,12-,16?,18?,19?,20+,21-/m0/s1
DMSPLYF	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@@H]5NC)C(C)(C)C)O
DMSPLYF	IK	IFVRBXXBLQUPAA-WOBCBQRJSA-N
DMSPLYF	IU	(1S,6R,9S,13S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-9-(methylamino)-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMSPLYF	DE	Discovery agent

DMN1U56	ID	DMN1U56
DMN1U56	DN	7alpha-OAc-ginkgolide B
DMN1U56	HS	Investigative
DMN1U56	SN	7alpha-OAc-ginkgolide B; 7alpha-OAc-GB
DMN1U56	DT	Small molecular drug
DMN1U56	PC	73755020
DMN1U56	MW	482.4
DMN1U56	FM	C22H26O12
DMN1U56	IC	InChI=1S/C22H26O12/c1-6-14(26)31-13-10(24)20-12-8(30-7(2)23)9(18(3,4)5)19(20)11(25)15(27)33-17(19)34-22(20,16(28)32-12)21(6,13)29/h6,8-13,17,24-25,29H,1-5H3/t6?,8?,9?,10?,11-,12?,13-,17?,19?,20?,21+,22-/m0/s1
DMN1U56	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C(C5OC(=O)C)C(C)(C)C)O
DMN1U56	IK	PTVXMWRAVPFHBG-OIYCRRHPSA-N
DMN1U56	IU	[(1S,6R,13S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-5,15,18-trioxo-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecan-9-yl] acetate
DMN1U56	DE	Discovery agent

DMGAPCD	ID	DMGAPCD
DMGAPCD	DN	7alpha-OCOCH2Ph-ginkgolide B
DMGAPCD	HS	Investigative
DMGAPCD	SN	7alpha-OCOCH2Ph-ginkgolide B; 7alpha-OCOCH2Ph-GB
DMGAPCD	DT	Small molecular drug
DMGAPCD	PC	73755021
DMGAPCD	MW	558.5
DMGAPCD	FM	C28H30O12
DMGAPCD	IC	InChI=1S/C28H30O12/c1-11-20(32)37-19-16(30)26-18-14(36-13(29)10-12-8-6-5-7-9-12)15(24(2,3)4)25(26)17(31)21(33)39-23(25)40-28(26,22(34)38-18)27(11,19)35/h5-9,11,14-19,23,30-31,35H,10H2,1-4H3/t11?,14-,15?,16?,17-,18?,19-,23?,25?,26?,27+,28-/m0/s1
DMGAPCD	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@@H]5OC(=O)CC7=CC=CC=C7)C(C)(C)C)O
DMGAPCD	IK	IYWGNBBAQNQGIC-MAVMKJRYSA-N
DMGAPCD	IU	[(1S,6R,9S,13S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-5,15,18-trioxo-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecan-9-yl] 2-phenylacetate
DMGAPCD	DE	Discovery agent

DMDUB63	ID	DMDUB63
DMDUB63	DN	7-amino-4-hydroxy-2-naphthalenesulfonic acid
DMDUB63	HS	Investigative
DMDUB63	SN	87-02-5; J acid; 7-AMINO-4-HYDROXY-2-NAPHTHALENESULFONIC ACID; 7-amino-4-hydroxynaphthalene-2-sulfonic acid; Isogamma acid; I acid; 2-Naphthalenesulfonic acid, 7-amino-4-hydroxy-; Kyselina I; 2-Amino-5-naphthol-7-sulfonic Acid; Kyselina I [Czech]; Aminonaphthol sulfonic acid J; 6-Amino-1-naphthol-3-sulfonic acid; CCRIS 8989; EINECS 201-718-9; NSC 31510; Kyselina 2-amino-5-naftol-7-sulfonova; BRN 2217192; UNII-9A1IU1C93L; MLS002638012; CHEMBL220259; 9A1IU1C93L; CHEBI:87316; 7-Amino-4-hydroxynaphthalene-2-sulphonic acid; Kyselina 6
DMDUB63	DT	Small molecular drug
DMDUB63	PC	6868
DMDUB63	MW	239.25
DMDUB63	FM	C10H9NO4S
DMDUB63	IC	InChI=1S/C10H9NO4S/c11-7-1-2-9-6(3-7)4-8(5-10(9)12)16(13,14)15/h1-5,12H,11H2,(H,13,14,15)
DMDUB63	CS	C1=CC2=C(C=C(C=C2C=C1N)S(=O)(=O)O)O
DMDUB63	IK	KYARBIJYVGJZLB-UHFFFAOYSA-N
DMDUB63	IU	7-amino-4-hydroxynaphthalene-2-sulfonic acid
DMDUB63	CA	CAS 87-02-5
DMDUB63	CB	CHEBI:87316
DMDUB63	DE	Discovery agent

DMC8O3Z	ID	DMC8O3Z
DMC8O3Z	DN	7-AMINO-4-METHYL-CHROMEN-2-ONE
DMC8O3Z	HS	Investigative
DMC8O3Z	SN	7-Amino-4-methylcoumarin; 26093-31-2; Coumarin 120; 7-Amino-4-methyl-2H-chromen-2-one; 4-Methyl-7-aminocoumarin; 2H-1-Benzopyran-2-one, 7-amino-4-methyl-; Coumarin, 7-amino-4-methyl-; 7-AMINO-4-METHYL-CHROMEN-2-ONE; UNII-OCY3JCT44X; CCRIS 4961; 7-amino-4-methylchromen-2-one; EINECS 247-454-8; NSC 45796; OCY3JCT44X; 7-amino-4-methyl-coumarin; MLS000057660; AMC; CHEBI:51771; GLNDAGDHSLMOKX-UHFFFAOYSA-N; NSC45796; MFCD00006868; GEO-02697; SMR000067752; AK-34405; 7-amino-4-methyl-2H-1-Benzopyran-2-one; A-6591; A1-00199; J-100007
DMC8O3Z	DT	Small molecular drug
DMC8O3Z	PC	92249
DMC8O3Z	MW	175.18
DMC8O3Z	FM	C10H9NO2
DMC8O3Z	IC	InChI=1S/C10H9NO2/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9/h2-5H,11H2,1H3
DMC8O3Z	CS	CC1=CC(=O)OC2=C1C=CC(=C2)N
DMC8O3Z	IK	GLNDAGDHSLMOKX-UHFFFAOYSA-N
DMC8O3Z	IU	7-amino-4-methylchromen-2-one
DMC8O3Z	CA	CAS 26093-31-2
DMC8O3Z	CB	CHEBI:51771
DMC8O3Z	DE	Discovery agent

DMZDP5S	ID	DMZDP5S
DMZDP5S	DN	7-benzoyloxy-2-(morpholin-4-yl)-chromen-4-one
DMZDP5S	HS	Investigative
DMZDP5S	SN	CHEMBL198944; 7-benzoyloxy-2-(morpholin-4-yl)-chromen-4-one; SCHEMBL3534476
DMZDP5S	DT	Small molecular drug
DMZDP5S	PC	11508573
DMZDP5S	MW	351.4
DMZDP5S	FM	C20H17NO5
DMZDP5S	IC	InChI=1S/C20H17NO5/c22-17-13-19(21-8-10-24-11-9-21)26-18-12-15(6-7-16(17)18)25-20(23)14-4-2-1-3-5-14/h1-7,12-13H,8-11H2
DMZDP5S	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)OC(=O)C4=CC=CC=C4
DMZDP5S	IK	GIEJDWWZPMOULL-UHFFFAOYSA-N
DMZDP5S	IU	(2-morpholin-4-yl-4-oxochromen-7-yl) benzoate
DMZDP5S	DE	Discovery agent

DMCJED6	ID	DMCJED6
DMCJED6	DN	7-benzylidenenaltrexone
DMCJED6	HS	Investigative
DMCJED6	SN	Bntx-7; CHEMBL101519; Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-7-(phenylmethylene)-, (5alpha)-; C27H27NO4; 7-BNTX; 129468-28-6; (Z)-7-Benzylidenenaltrexone; GTPL1634; SCHEMBL15354616; CHEBI:125500; BDBM50450986; LS-172729
DMCJED6	DT	Small molecular drug
DMCJED6	PC	5310988
DMCJED6	MW	429.5
DMCJED6	FM	C27H27NO4
DMCJED6	IC	InChI=1S/C27H27NO4/c29-20-9-8-18-13-21-27(31)14-19(12-16-4-2-1-3-5-16)23(30)25-26(27,22(18)24(20)32-25)10-11-28(21)15-17-6-7-17/h1-5,8-9,12,17,21,25,29,31H,6-7,10-11,13-15H2/b19-12+/t21-,25+,26+,27-/m1/s1
DMCJED6	CS	C1CC1CN2CC[C@]34[C@@H]5C(=O)/C(=C/C6=CC=CC=C6)/C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O
DMCJED6	IK	WXOUFNFMPVMGFZ-BDQAUFNLSA-N
DMCJED6	IU	(4R,4aS,6E,7aR,12bS)-6-benzylidene-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMCJED6	CB	CHEBI:138855
DMCJED6	DE	Discovery agent

DMMXAEN	ID	DMMXAEN
DMMXAEN	DN	7-benzyloxy-2-(morpholin-4-yl)-chromen-4-one
DMMXAEN	HS	Investigative
DMMXAEN	SN	CHEMBL95298; 7-benzyloxy-2-(morpholin-4-yl)-chromen-4-one; SCHEMBL3536307; BDBM50178028; 7-Benzyloxy-2-morpholin-4-yl-chromen-4-one
DMMXAEN	DT	Small molecular drug
DMMXAEN	PC	11522900
DMMXAEN	MW	337.4
DMMXAEN	FM	C20H19NO4
DMMXAEN	IC	InChI=1S/C20H19NO4/c22-18-13-20(21-8-10-23-11-9-21)25-19-12-16(6-7-17(18)19)24-14-15-4-2-1-3-5-15/h1-7,12-13H,8-11,14H2
DMMXAEN	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)OCC4=CC=CC=C4
DMMXAEN	IK	KUCJYOZKCJHLND-UHFFFAOYSA-N
DMMXAEN	IU	2-morpholin-4-yl-7-phenylmethoxychromen-4-one
DMMXAEN	DE	Discovery agent

DMYKXWE	ID	DMYKXWE
DMYKXWE	DN	7beta, 25-dihydroxycholesterol
DMYKXWE	HS	Investigative
DMYKXWE	SN	CHEMBL3311219; (3S,7R,8S,9S,10R,13R,14S,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol; 7beta,25-dihydroxycholesterol; 7beta, 25-dihydroxycholesterol; AC1LAQHU; GTPL4355; SCHEMBL2485860; 7.beta.,25-Dihydroxycholesterol; BDBM50045543; (3.beta.,7.beta.)-7,25-Dihydroxycholest-5-en-3-ol
DMYKXWE	DT	Small molecular drug
DMYKXWE	PC	473142
DMYKXWE	MW	418.7
DMYKXWE	FM	C27H46O3
DMYKXWE	IC	InChI=1S/C27H46O3/c1-17(7-6-12-25(2,3)30)20-8-9-21-24-22(11-14-27(20,21)5)26(4)13-10-19(28)15-18(26)16-23(24)29/h16-17,19-24,28-30H,6-15H2,1-5H3/t17-,19+,20-,21+,22+,23+,24+,26+,27-/m1/s1
DMYKXWE	CS	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DMYKXWE	IK	BQMSKLCEWBSPPY-CGSQRZAOSA-N
DMYKXWE	IU	(3S,7R,8S,9S,10R,13R,14S,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMYKXWE	DE	Discovery agent

DMSDINR	ID	DMSDINR
DMSDINR	DN	7beta, 27-dihydroxycholesterol
DMSDINR	HS	Investigative
DMSDINR	SN	7beta,26-dihydroxycholesterol
DMSDINR	DT	Small molecular drug
DMSDINR	PC	52931518
DMSDINR	MW	418.7
DMSDINR	FM	C27H46O3
DMSDINR	IC	InChI=1S/C27H46O3/c1-17(16-28)6-5-7-18(2)21-8-9-22-25-23(11-13-27(21,22)4)26(3)12-10-20(29)14-19(26)15-24(25)30/h15,17-18,20-25,28-30H,5-14,16H2,1-4H3/t17-,18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1
DMSDINR	CS	C[C@H](CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C)CO
DMSDINR	IK	RXMHNAKZMGJANZ-BMOLSTJGSA-N
DMSDINR	IU	(3S,7R,8S,9S,10R,13R,14S,17R)-17-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMSDINR	DE	Discovery agent

DMPHJZU	ID	DMPHJZU
DMPHJZU	DN	7beta-hydroxycholesterol
DMPHJZU	HS	Investigative
DMPHJZU	SN	7-beta-OHC
DMPHJZU	DT	Small molecular drug
DMPHJZU	PC	473141
DMPHJZU	MW	402.7
DMPHJZU	FM	C27H46O2
DMPHJZU	IC	InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1
DMPHJZU	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DMPHJZU	IK	OYXZMSRRJOYLLO-KGZHIOMZSA-N
DMPHJZU	IU	(3S,7R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMPHJZU	CA	CAS 566-27-8
DMPHJZU	CB	CHEBI:42989
DMPHJZU	DE	Discovery agent

DMV54MT	ID	DMV54MT
DMV54MT	DN	7-Biphenyl-4-yl-heptanoic acid hydroxyamide
DMV54MT	HS	Investigative
DMV54MT	SN	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid
DMV54MT	DT	Small molecular drug
DMV54MT	PC	44349481
DMV54MT	MW	297.4
DMV54MT	FM	C19H23NO2
DMV54MT	IC	InChI=1S/C19H23NO2/c21-19(20-22)11-7-2-1-4-8-16-12-14-18(15-13-16)17-9-5-3-6-10-17/h3,5-6,9-10,12-15,22H,1-2,4,7-8,11H2,(H,20,21)
DMV54MT	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCCCCCC(=O)NO
DMV54MT	IK	UDSUAIGMNDAMBQ-UHFFFAOYSA-N
DMV54MT	IU	N-hydroxy-7-(4-phenylphenyl)heptanamide
DMV54MT	DE	Discovery agent

DMYBNCO	ID	DMYBNCO
DMYBNCO	DN	7-bromo-1H-indazole
DMYBNCO	HS	Investigative
DMYBNCO	SN	7-bromo-1H-indazole; 53857-58-2; 7-Bromoindazole; 7-Bromo-2H-indazole; 845751-59-9; 1H-Indazole, 7-bromo-; 1H-INDAZOLE,7-BROMO-; CHEMBL439566; AK-26850; PubChem14406; 2H-Indazole, 7-bromo-; ACMC-1B1ZL; BROMOINDAZOLE(7-); T56 BMNJ IE; KSC268A6L; 7-Bromo-1H-indazole, 97%; SCHEMBL1855857; CTK1G8065; MolPort-027-946-828; MolPort-006-717-407; KMHHWCPTROQUFM-UHFFFAOYSA-N; ZX-AT005164; BCP00108; STL555654; 2999AC; FCH835100; ANW-31868; ZINC14007945; MFCD07371564; BBL101857; SBB092096; BDBM50209239; AKOS016013628; AKOS005072291; RTC-062730; RP04094
DMYBNCO	DT	Small molecular drug
DMYBNCO	PC	20323899
DMYBNCO	MW	197.03
DMYBNCO	FM	C7H5BrN2
DMYBNCO	IC	InChI=1S/C7H5BrN2/c8-6-3-1-2-5-4-9-10-7(5)6/h1-4H,(H,9,10)
DMYBNCO	CS	C1=CC2=C(C(=C1)Br)NN=C2
DMYBNCO	IK	KMHHWCPTROQUFM-UHFFFAOYSA-N
DMYBNCO	IU	7-bromo-1H-indazole
DMYBNCO	CA	CAS 53857-58-2
DMYBNCO	DE	Discovery agent

DMA8DXG	ID	DMA8DXG
DMA8DXG	DN	7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol
DMA8DXG	HS	Investigative
DMA8DXG	SN	CHEMBL183782; 7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol; SCHEMBL3927964; UBYHIUUMRHTEFF-UHFFFAOYSA-N
DMA8DXG	DT	Small molecular drug
DMA8DXG	PC	10286352
DMA8DXG	MW	305.12
DMA8DXG	FM	C14H9BrO3
DMA8DXG	IC	InChI=1S/C14H9BrO3/c15-12-7-11(17)5-9-6-13(18-14(9)12)8-1-3-10(16)4-2-8/h1-7,16-17H
DMA8DXG	CS	C1=CC(=CC=C1C2=CC3=CC(=CC(=C3O2)Br)O)O
DMA8DXG	IK	UBYHIUUMRHTEFF-UHFFFAOYSA-N
DMA8DXG	IU	7-bromo-2-(4-hydroxyphenyl)-1-benzofuran-5-ol
DMA8DXG	DE	Discovery agent

DMVTH0Q	ID	DMVTH0Q
DMVTH0Q	DN	7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMVTH0Q	HS	Investigative
DMVTH0Q	SN	7-Bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 108061-47-8; CHEMBL441891; 7-Bromo-1,2,3,4-tetrahydro-beta-carboline; 7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline; CS-WAA0033; SCHEMBL3476066; CTK8C1152; DTXSID00434588; XAHAQVIJZAMMLO-UHFFFAOYSA-N; ZINC13587967; BDBM50136507; 1620AA; ANW-65970; AKOS016005623; CB-3796; FCH1610363; CS-15602; AJ-64214; TC-154715; KB-249517; AX8236304
DMVTH0Q	DT	Small molecular drug
DMVTH0Q	PC	10037784
DMVTH0Q	MW	251.12
DMVTH0Q	FM	C11H11BrN2
DMVTH0Q	IC	InChI=1S/C11H11BrN2/c12-7-1-2-8-9-3-4-13-6-11(9)14-10(8)5-7/h1-2,5,13-14H,3-4,6H2
DMVTH0Q	CS	C1CNCC2=C1C3=C(N2)C=C(C=C3)Br
DMVTH0Q	IK	XAHAQVIJZAMMLO-UHFFFAOYSA-N
DMVTH0Q	IU	7-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMVTH0Q	CA	CAS 108061-47-8
DMVTH0Q	DE	Discovery agent

DMG8ZJA	ID	DMG8ZJA
DMG8ZJA	DN	7-Bromo-2-phenyl-[1,8]naphthyridin-4-ol
DMG8ZJA	HS	Investigative
DMG8ZJA	SN	CHEMBL97687; 7-Bromo-2-phenyl-[1,8]naphthyridin-4-ol; BDBM50090700; ZINC13579521; 7-bromo-2-phenyl-1,8-naphthyridin-4-ol
DMG8ZJA	DT	Small molecular drug
DMG8ZJA	PC	10402581
DMG8ZJA	MW	301.14
DMG8ZJA	FM	C14H9BrN2O
DMG8ZJA	IC	InChI=1S/C14H9BrN2O/c15-13-7-6-10-12(18)8-11(16-14(10)17-13)9-4-2-1-3-5-9/h1-8H,(H,16,17,18)
DMG8ZJA	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(N2)N=C(C=C3)Br
DMG8ZJA	IK	ZVIMMGQTBAKKGA-UHFFFAOYSA-N
DMG8ZJA	IU	7-bromo-2-phenyl-1H-1,8-naphthyridin-4-one
DMG8ZJA	DE	Discovery agent

DMCWYT7	ID	DMCWYT7
DMCWYT7	DN	7-Bromo-4,9-dihydro-3H-beta-carboline
DMCWYT7	HS	Investigative
DMCWYT7	SN	CHEMBL428999; 7-Bromo-4,9-dihydro-3H-beta-carboline; BDBM50136497
DMCWYT7	DT	Small molecular drug
DMCWYT7	PC	44264453
DMCWYT7	MW	249.11
DMCWYT7	FM	C11H9BrN2
DMCWYT7	IC	InChI=1S/C11H9BrN2/c12-7-1-2-8-9-3-4-13-6-11(9)14-10(8)5-7/h1-2,5-6,14H,3-4H2
DMCWYT7	CS	C1CN=CC2=C1C3=C(N2)C=C(C=C3)Br
DMCWYT7	IK	NTZLLWPDAQVIOA-UHFFFAOYSA-N
DMCWYT7	IU	7-bromo-4,9-dihydro-3H-pyrido[3,4-b]indole
DMCWYT7	DE	Discovery agent

DMX85IF	ID	DMX85IF
DMX85IF	DN	7-bromo-6H-chromeno[4,3-b]quinoline-3,9-diol
DMX85IF	HS	Investigative
DMX85IF	DT	Small molecular drug
DMX85IF	PC	135520118
DMX85IF	MW	344.16
DMX85IF	FM	C16H10BrNO3
DMX85IF	IC	InChI=1S/C16H10BrNO3/c17-15-11-5-8(19)2-4-13(11)18-16-10-3-1-9(20)6-14(10)21-7-12(15)16/h1-6,19-20H,7H2
DMX85IF	CS	C1C2=C(C3=C(C=CC(=C3)O)N=C2C4=C(O1)C=C(C=C4)O)Br
DMX85IF	IK	UHDQHUPIXKORDL-UHFFFAOYSA-N
DMX85IF	IU	7-bromo-6H-chromeno[4,3-b]quinoline-3,9-diol
DMX85IF	DE	Discovery agent

DM3G8I7	ID	DM3G8I7
DM3G8I7	DN	7-bromoindirubin-3-acetoxime
DM3G8I7	HS	Investigative
DM3G8I7	DT	Small molecular drug
DM3G8I7	PC	136104465
DM3G8I7	MW	398.2
DM3G8I7	FM	C18H12BrN3O3
DM3G8I7	IC	InChI=1S/C18H12BrN3O3/c1-9(23)25-22-16-10-5-2-3-8-13(10)20-17(16)14-11-6-4-7-12(19)15(11)21-18(14)24/h2-8,21,24H,1H3/b22-16-
DM3G8I7	CS	CC(=O)O/N=C\\1/C2=CC=CC=C2N=C1C3=C(NC4=C3C=CC=C4Br)O
DM3G8I7	IK	CHULSJBNZJIYCG-JWGURIENSA-N
DM3G8I7	IU	[(Z)-[2-(7-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate
DM3G8I7	DE	Discovery agent

DM07QD3	ID	DM07QD3
DM07QD3	DN	7-bromoindirubin-3-oxime
DM07QD3	HS	Investigative
DM07QD3	DT	Small molecular drug
DM07QD3	PC	91936028
DM07QD3	MW	356.17
DM07QD3	FM	C16H10BrN3O2
DM07QD3	IC	InChI=1S/C16H10BrN3O2/c17-10-6-3-5-9-12(16(21)19-13(9)10)15-14(20-22)8-4-1-2-7-11(8)18-15/h1-7,12,18H,(H,19,21)
DM07QD3	CS	C1=CC=C2C(=C1)C(=C(N2)C3C4=C(C(=CC=C4)Br)NC3=O)N=O
DM07QD3	IK	GMRAFJUVKHMGPN-UHFFFAOYSA-N
DM07QD3	IU	7-bromo-3-(3-nitroso-1H-indol-2-yl)-1,3-dihydroindol-2-one
DM07QD3	DE	Discovery agent

DML8PH7	ID	DML8PH7
DML8PH7	DN	7-bromo-N-(3-bromophenyl)isoquinolin-1-amine
DML8PH7	HS	Investigative
DML8PH7	SN	CHEMBL1080277; 7-bromo-N-(3-bromophenyl)isoquinolin-1-amine
DML8PH7	DT	Small molecular drug
DML8PH7	PC	46879685
DML8PH7	MW	378.06
DML8PH7	FM	C15H10Br2N2
DML8PH7	IC	InChI=1S/C15H10Br2N2/c16-11-2-1-3-13(8-11)19-15-14-9-12(17)5-4-10(14)6-7-18-15/h1-9H,(H,18,19)
DML8PH7	CS	C1=CC(=CC(=C1)Br)NC2=NC=CC3=C2C=C(C=C3)Br
DML8PH7	IK	FGMDNVCIUONADU-UHFFFAOYSA-N
DML8PH7	IU	7-bromo-N-(3-bromophenyl)isoquinolin-1-amine
DML8PH7	DE	Discovery agent

DM78C5A	ID	DM78C5A
DM78C5A	DN	7-butoxy-2H-chromen-2-one
DM78C5A	HS	Investigative
DM78C5A	SN	7-butoxy-2H-chromen-2-one; 7-BUTOXYCOUMARIN; 7-butoxychromen-2-one; 2H-1-Benzopyran-2-one, 7-butoxy-; CHEMBL571514; 71783-00-1; CBMicro_045472; AC1L4FS0; SCHEMBL6686295; DTXSID40221994; MolPort-002-085-798; ZINC2950199; STK371317; BDBM50303502; AKOS001064182; MCULE-1530014848; BIM-0045671.P001; ST50462808; SR-01000227430
DM78C5A	DT	Small molecular drug
DM78C5A	PC	156219
DM78C5A	MW	218.25
DM78C5A	FM	C13H14O3
DM78C5A	IC	InChI=1S/C13H14O3/c1-2-3-8-15-11-6-4-10-5-7-13(14)16-12(10)9-11/h4-7,9H,2-3,8H2,1H3
DM78C5A	CS	CCCCOC1=CC2=C(C=C1)C=CC(=O)O2
DM78C5A	IK	BDOGTORASJEUBW-UHFFFAOYSA-N
DM78C5A	IU	7-butoxychromen-2-one
DM78C5A	CA	CAS 71783-00-1
DM78C5A	DE	Discovery agent

DMQ8BIX	ID	DMQ8BIX
DMQ8BIX	DN	7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMQ8BIX	HS	Investigative
DMQ8BIX	DT	Small molecular drug
DMQ8BIX	PC	135499774
DMQ8BIX	MW	283.32
DMQ8BIX	FM	C17H17NO3
DMQ8BIX	IC	InChI=1S/C17H17NO3/c1-2-3-4-12-9-14(20)10-15-16(12)21-17(18-15)11-5-7-13(19)8-6-11/h5-10,19-20H,2-4H2,1H3
DMQ8BIX	CS	CCCCC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMQ8BIX	IK	MEBUPUARJUIPAP-UHFFFAOYSA-N
DMQ8BIX	IU	7-butyl-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMQ8BIX	DE	Discovery agent

DMVTK0A	ID	DMVTK0A
DMVTK0A	DN	7-Butyl-azepan-(2Z)-ylideneamine
DMVTK0A	HS	Investigative
DMVTK0A	SN	CHEMBL89288; CHEMBL543514; SCHEMBL7628313; BDBM50064011; 2-Imino-7-butylhexahydro-1H-azepine; 7-Butyl-azepan-(2Z)-ylideneamine
DMVTK0A	DT	Small molecular drug
DMVTK0A	PC	10104379
DMVTK0A	MW	168.28
DMVTK0A	FM	C10H20N2
DMVTK0A	IC	InChI=1S/C10H20N2/c1-2-3-6-9-7-4-5-8-10(11)12-9/h9H,2-8H2,1H3,(H2,11,12)
DMVTK0A	CS	CCCCC1CCCCC(=N1)N
DMVTK0A	IK	LXZWIIJORJEBKG-UHFFFAOYSA-N
DMVTK0A	IU	2-butyl-3,4,5,6-tetrahydro-2H-azepin-7-amine
DMVTK0A	DE	Discovery agent

DM1SEXA	ID	DM1SEXA
DM1SEXA	DN	7-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DM1SEXA	HS	Investigative
DM1SEXA	SN	7-chloro-1,2,3,4-tetrahydroacridin-9-amine; BRN 0394541; ACRIDINE, 1,2,3,4-TETRAHYDRO-9-AMINO-7-CHLORO-; 6115-67-9; 9-Amino-7-chloro-1,2,3,4-tetrahydroacridine; Tacrine Analogue 3; AC1L2KHB; CHEMBL62084; BDBM8986; DTXSID20210043; ZINC2034186; AKOS011482955; LS-14463
DM1SEXA	DT	Small molecular drug
DM1SEXA	PC	22493
DM1SEXA	MW	232.71
DM1SEXA	FM	C13H13ClN2
DM1SEXA	IC	InChI=1S/C13H13ClN2/c14-8-5-6-12-10(7-8)13(15)9-3-1-2-4-11(9)16-12/h5-7H,1-4H2,(H2,15,16)
DM1SEXA	CS	C1CCC2=NC3=C(C=C(C=C3)Cl)C(=C2C1)N
DM1SEXA	IK	PUKKYURTEBJMKJ-UHFFFAOYSA-N
DM1SEXA	IU	7-chloro-1,2,3,4-tetrahydroacridin-9-amine
DM1SEXA	CA	CAS 6115-67-9
DM1SEXA	DE	Discovery agent

DMP5JF8	ID	DMP5JF8
DMP5JF8	DN	7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole
DMP5JF8	HS	Investigative
DMP5JF8	SN	7-chloro-1H,2H,3H,4H-pyrazino[1,2-a]indole; CHEMBL290779; 287384-61-6; 7-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole; 7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole; SCHEMBL5619809; PSLRQWHMXFDQNK-UHFFFAOYSA-N; MolPort-022-445-854; BDBM50108315; ZINC13586841; AKOS022692453; NE33360
DMP5JF8	DT	Small molecular drug
DMP5JF8	PC	21868720
DMP5JF8	MW	206.67
DMP5JF8	FM	C11H11ClN2
DMP5JF8	IC	InChI=1S/C11H11ClN2/c12-9-2-1-8-5-10-7-13-3-4-14(10)11(8)6-9/h1-2,5-6,13H,3-4,7H2
DMP5JF8	CS	C1CN2C(=CC3=C2C=C(C=C3)Cl)CN1
DMP5JF8	IK	PSLRQWHMXFDQNK-UHFFFAOYSA-N
DMP5JF8	IU	7-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole
DMP5JF8	DE	Discovery agent

DMWUS5Q	ID	DMWUS5Q
DMWUS5Q	DN	7-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DMWUS5Q	HS	Investigative
DMWUS5Q	SN	CHEMBL98851; 7-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one; SCHEMBL10758208; 2H-Imidazo[4,5-b]quinolin-2-one, 7-chloro-1,3-dihydro-; BDBM50007221
DMWUS5Q	DT	Small molecular drug
DMWUS5Q	PC	13936972
DMWUS5Q	MW	219.63
DMWUS5Q	FM	C10H6ClN3O
DMWUS5Q	IC	InChI=1S/C10H6ClN3O/c11-6-1-2-7-5(3-6)4-8-9(12-7)14-10(15)13-8/h1-4H,(H2,12,13,14,15)
DMWUS5Q	CS	C1=CC2=NC3=C(C=C2C=C1Cl)NC(=O)N3
DMWUS5Q	IK	OSBMKBWTTUTUMA-UHFFFAOYSA-N
DMWUS5Q	IU	7-chloro-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMWUS5Q	DE	Discovery agent

DMPJWIB	ID	DMPJWIB
DMPJWIB	DN	7-chloro-1,3-dihydroxyacridone
DMPJWIB	HS	Investigative
DMPJWIB	DE	Discovery agent

DMX8DZM	ID	DMX8DZM
DMX8DZM	DN	7-chloro-1H-indazole
DMX8DZM	HS	Investigative
DMX8DZM	SN	7-chloro-1H-indazole; 37435-12-4; 7-Chloroindazole; 1H-Indazole, 7-chloro-; CHEMBL247367; AK-24465; 7-chlor-1H-indazol; ACMC-1AG86; SCHEMBL104360; SCHEMBL19152469; CTK1C1806; DTXSID80455690; WIYOYUQVNPTVQG-UHFFFAOYSA-N; MolPort-001-767-757; 7-Chloro-1H-indazole, AldrichCPR; ZX-AT002536; BCP27378; BDBM50209244; ZINC12336533; STL554161; SBB054730; MFCD07368214; ANW-28635; OR3680; FCH921470; BBL100367; AKOS024124979; AKOS005072025; VI20076; RP01758; MCULE-5657266195; CB-0833; PB17411; ACM37435124; KB-46237; SC-27673; QC-11238; BL000561; AN-17144
DMX8DZM	DT	Small molecular drug
DMX8DZM	PC	11116249
DMX8DZM	MW	152.58
DMX8DZM	FM	C7H5ClN2
DMX8DZM	IC	InChI=1S/C7H5ClN2/c8-6-3-1-2-5-4-9-10-7(5)6/h1-4H,(H,9,10)
DMX8DZM	CS	C1=CC2=C(C(=C1)Cl)NN=C2
DMX8DZM	IK	WIYOYUQVNPTVQG-UHFFFAOYSA-N
DMX8DZM	IU	7-chloro-1H-indazole
DMX8DZM	CA	CAS 37435-12-4
DMX8DZM	DE	Discovery agent

DMCZLKA	ID	DMCZLKA
DMCZLKA	DN	7-chloro-1H-indole-2,3-dione
DMCZLKA	HS	Investigative
DMCZLKA	SN	7-Chloroisatin; 7477-63-6; 7-chloro-1H-indole-2,3-dione; 7-chloroindoline-2,3-dione; 7-chloro-2,3-dihydro-1H-indole-2,3-dione; 7-chloro-2,3-indolinedione; MLS003171490; 1H-INDOLE-2,3-DIONE, 7-CHLORO-; 1H-Indole-2,3-dione,7-chloro-; MFCD00022796; 7-chloro-1H-benzo[d]azolidine-2,3-dione; 7-chlorisatin; 7-chloro isatin; NSC400868; PubChem15537; 7-Chloroisatin, 97%; AC1Q3HYB; AC1L7ZVK; AC1Q3KGY; ACMC-209zr4; 7-Chloroindole-2,3-dione; Isatin-based compound, 43; KSC640I8T; 7-chloro-indoline-2,3-dione; SCHEMBL1247382; CHEMBL222190
DMCZLKA	DT	Small molecular drug
DMCZLKA	PC	344135
DMCZLKA	MW	181.57
DMCZLKA	FM	C8H4ClNO2
DMCZLKA	IC	InChI=1S/C8H4ClNO2/c9-5-3-1-2-4-6(5)10-8(12)7(4)11/h1-3H,(H,10,11,12)
DMCZLKA	CS	C1=CC2=C(C(=C1)Cl)NC(=O)C2=O
DMCZLKA	IK	MPLXQMMMGDYXIT-UHFFFAOYSA-N
DMCZLKA	IU	7-chloro-1H-indole-2,3-dione
DMCZLKA	CA	CAS 7477-63-6
DMCZLKA	DE	Discovery agent

DM38HKE	ID	DM38HKE
DM38HKE	DN	7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol
DM38HKE	HS	Investigative
DM38HKE	SN	CHEMBL184448; 7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol; SCHEMBL3922992
DM38HKE	DT	Small molecular drug
DM38HKE	PC	10236250
DM38HKE	MW	260.67
DM38HKE	FM	C14H9ClO3
DM38HKE	IC	InChI=1S/C14H9ClO3/c15-12-7-11(17)5-9-6-13(18-14(9)12)8-1-3-10(16)4-2-8/h1-7,16-17H
DM38HKE	CS	C1=CC(=CC=C1C2=CC3=CC(=CC(=C3O2)Cl)O)O
DM38HKE	IK	OCILFYQUCSGLEE-UHFFFAOYSA-N
DM38HKE	IU	7-chloro-2-(4-hydroxyphenyl)-1-benzofuran-5-ol
DM38HKE	DE	Discovery agent

DM9TZH4	ID	DM9TZH4
DM9TZH4	DN	7-Chloro-2-phenyl-[1,8]naphthyridin-4-ol
DM9TZH4	HS	Investigative
DM9TZH4	SN	7-Chloro-4-hydroxy-2-phenyl-1,8-naphthyridine; CHEMBL97760; 286411-09-4; NCGC00015250-01; Lopac-C-5982; 7-Chloro-2-phenyl-[1,8]naphthyridin-4-ol; AC1O0Y6J; Lopac0_000305; SCHEMBL378998; CTK8F7271; CTK8E5517; HMS3260N12; ZINC8582290; Tox21_500305; BDBM50090697; AKOS028113015; TRA0054236; LP00305; CCG-204400; NCGC00093754-02; NCGC00015250-03; NCGC00260990-01; NCGC00093754-01; NCGC00015250-05; NCGC00015250-02; NCGC00015250-04; 7-chloro-2-phenyl-1,8-naphthyridin-4-ol; TX-017366; KB-270267; 2-Phenyl-7-chloro-1,8-naphthyridine-4-ol
DM9TZH4	DT	Small molecular drug
DM9TZH4	PC	6105572
DM9TZH4	MW	256.68
DM9TZH4	FM	C14H9ClN2O
DM9TZH4	IC	InChI=1S/C14H9ClN2O/c15-13-7-6-10-12(18)8-11(16-14(10)17-13)9-4-2-1-3-5-9/h1-8H,(H,16,17,18)
DM9TZH4	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(N2)N=C(C=C3)Cl
DM9TZH4	IK	JSCUNIPKMPNPFX-UHFFFAOYSA-N
DM9TZH4	IU	7-chloro-2-phenyl-1H-1,8-naphthyridin-4-one
DM9TZH4	DE	Discovery agent

DM3OMLU	ID	DM3OMLU
DM3OMLU	DN	7-chloro-3-hydroxyquinazoline-2,4-dione
DM3OMLU	HS	Investigative
DM3OMLU	SN	CHEMBL80594; 3-hydroxy-7-chloro-1H-quinazoline-2,4-dione; 705977-20-4; 7-chloro-3-hydroxyquinazoline-2,4-dione; BDBM50144806
DM3OMLU	DT	Small molecular drug
DM3OMLU	PC	44315786
DM3OMLU	MW	212.59
DM3OMLU	FM	C8H5ClN2O3
DM3OMLU	IC	InChI=1S/C8H5ClN2O3/c9-4-1-2-5-6(3-4)10-8(13)11(14)7(5)12/h1-3,14H,(H,10,13)
DM3OMLU	CS	C1=CC2=C(C=C1Cl)NC(=O)N(C2=O)O
DM3OMLU	IK	CRTPJJNXJPKDEZ-UHFFFAOYSA-N
DM3OMLU	IU	7-chloro-3-hydroxy-1H-quinazoline-2,4-dione
DM3OMLU	DE	Discovery agent

DM53A1R	ID	DM53A1R
DM53A1R	DN	7-Chloro-3-pyridin-4-yl-quinoline
DM53A1R	HS	Investigative
DM53A1R	SN	CHEMBL86664; 7-chloro-3-pyridin-4-yl-quinoline; 7-Chloro-3-(4-pyridyl)quinoline
DM53A1R	DT	Small molecular drug
DM53A1R	PC	10354294
DM53A1R	MW	240.69
DM53A1R	FM	C14H9ClN2
DM53A1R	IC	InChI=1S/C14H9ClN2/c15-13-2-1-11-7-12(9-17-14(11)8-13)10-3-5-16-6-4-10/h1-9H
DM53A1R	CS	C1=CC(=CC2=NC=C(C=C21)C3=CC=NC=C3)Cl
DM53A1R	IK	WMECTFBVYBAOOF-UHFFFAOYSA-N
DM53A1R	IU	7-chloro-3-pyridin-4-ylquinoline
DM53A1R	DE	Discovery agent

DMRNZYQ	ID	DMRNZYQ
DMRNZYQ	DN	7-chloro-6H-chromeno[4,3-b]quinoline-3,9-diol
DMRNZYQ	HS	Investigative
DMRNZYQ	DT	Small molecular drug
DMRNZYQ	PC	135466468
DMRNZYQ	MW	299.71
DMRNZYQ	FM	C16H10ClNO3
DMRNZYQ	IC	InChI=1S/C16H10ClNO3/c17-15-11-5-8(19)2-4-13(11)18-16-10-3-1-9(20)6-14(10)21-7-12(15)16/h1-6,19-20H,7H2
DMRNZYQ	CS	C1C2=C(C3=C(C=CC(=C3)O)N=C2C4=C(O1)C=C(C=C4)O)Cl
DMRNZYQ	IK	RYBHKLZSHRZGQK-UHFFFAOYSA-N
DMRNZYQ	IU	7-chloro-6H-chromeno[4,3-b]quinoline-3,9-diol
DMRNZYQ	DE	Discovery agent

DM28NAB	ID	DM28NAB
DM28NAB	DN	7-chloroindirubin-3-oxime
DM28NAB	HS	Investigative
DM28NAB	DT	Small molecular drug
DM28NAB	PC	11845976
DM28NAB	DE	Discovery agent

DM2MIJY	ID	DM2MIJY
DM2MIJY	DN	7-Cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one
DM2MIJY	HS	Investigative
DM2MIJY	SN	SCHEMBL1700973
DM2MIJY	DT	Small molecular drug
DM2MIJY	PC	46914767
DM2MIJY	MW	322.4
DM2MIJY	FM	C20H18O4
DM2MIJY	IC	InChI=1S/C20H18O4/c21-14-7-5-13(6-8-14)18-12-23-19-11-16(9-10-17(19)20(18)22)24-15-3-1-2-4-15/h5-12,15,21H,1-4H2
DM2MIJY	CS	C1CCC(C1)OC2=CC3=C(C=C2)C(=O)C(=CO3)C4=CC=C(C=C4)O
DM2MIJY	IK	RFDBJXQLCPTPCX-UHFFFAOYSA-N
DM2MIJY	IU	7-cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one
DM2MIJY	DE	Discovery agent

DMANYSO	ID	DMANYSO
DMANYSO	DN	7-Diazonium-naphthalene-1-sulfonic acid anion
DMANYSO	HS	Investigative
DMANYSO	SN	CHEMBL71830
DMANYSO	DT	Small molecular drug
DMANYSO	PC	13948289
DMANYSO	MW	234.23
DMANYSO	FM	C10H6N2O3S
DMANYSO	IC	InChI=1S/C10H6N2O3S/c11-12-8-5-4-7-2-1-3-10(9(7)6-8)16(13,14)15/h1-6H
DMANYSO	CS	C1=CC2=C(C=C(C=C2)[N+]#N)C(=C1)S(=O)(=O)[O-]
DMANYSO	IK	ABQHTWPSSABLIQ-UHFFFAOYSA-N
DMANYSO	IU	7-diazonionaphthalene-1-sulfonate
DMANYSO	DE	Discovery agent

DMNEAU0	ID	DMNEAU0
DMNEAU0	DN	7-Dimethylamino-2-phenyl-[1,8]naphthyridin-4-ol
DMNEAU0	HS	Investigative
DMNEAU0	SN	CHEMBL102429; 7-Dimethylamino-2-phenyl-[1,8]naphthyridin-4-ol; ZINC13579545; BDBM50147858
DMNEAU0	DT	Small molecular drug
DMNEAU0	PC	10378184
DMNEAU0	MW	265.31
DMNEAU0	FM	C16H15N3O
DMNEAU0	IC	InChI=1S/C16H15N3O/c1-19(2)15-9-8-12-14(20)10-13(17-16(12)18-15)11-6-4-3-5-7-11/h3-10H,1-2H3,(H,17,18,20)
DMNEAU0	CS	CN(C)C1=NC2=C(C=C1)C(=O)C=C(N2)C3=CC=CC=C3
DMNEAU0	IK	BEMRWFAUJDRLIY-UHFFFAOYSA-N
DMNEAU0	IU	7-(dimethylamino)-2-phenyl-1H-1,8-naphthyridin-4-one
DMNEAU0	DE	Discovery agent

DMDY2PQ	ID	DMDY2PQ
DMDY2PQ	DN	7-Dimethylamino-3-methyl-hept-5-yn-2-one
DMDY2PQ	HS	Investigative
DMDY2PQ	SN	CHEMBL165985
DMDY2PQ	DT	Small molecular drug
DMDY2PQ	PC	15685978
DMDY2PQ	MW	167.25
DMDY2PQ	FM	C10H17NO
DMDY2PQ	IC	InChI=1S/C10H17NO/c1-9(10(2)12)7-5-6-8-11(3)4/h9H,7-8H2,1-4H3
DMDY2PQ	CS	CC(CC#CCN(C)C)C(=O)C
DMDY2PQ	IK	PDSSGGXKHZHTIQ-UHFFFAOYSA-N
DMDY2PQ	IU	7-(dimethylamino)-3-methylhept-5-yn-2-one
DMDY2PQ	DE	Discovery agent

DMH782V	ID	DMH782V
DMH782V	DN	7-Dimethylamino-hept-5-yn-2-one
DMH782V	HS	Investigative
DMH782V	SN	CHEMBL166736; 7-(dimethylamino)hept-5-yn-2-one; 7-Dimethylamino-hept-5-yn-2-one; AC1L2EXE; AC1Q5H3K
DMH782V	DT	Small molecular drug
DMH782V	PC	19816
DMH782V	MW	153.22
DMH782V	FM	C9H15NO
DMH782V	IC	InChI=1S/C9H15NO/c1-9(11)7-5-4-6-8-10(2)3/h5,7-8H2,1-3H3
DMH782V	CS	CC(=O)CCC#CCN(C)C
DMH782V	IK	UYTLBASHEWACKP-UHFFFAOYSA-N
DMH782V	IU	7-(dimethylamino)hept-5-yn-2-one
DMH782V	DE	Discovery agent

DMRAZDW	ID	DMRAZDW
DMRAZDW	DN	7-epi-ginkgolide C
DMRAZDW	HS	Investigative
DMRAZDW	SN	7-epi-GC
DMRAZDW	DT	Small molecular drug
DMRAZDW	PC	58761009
DMRAZDW	MW	440.4
DMRAZDW	FM	C20H24O11
DMRAZDW	IC	InChI=1S/C20H24O11/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,21-23,27H,1-4H3/t5?,6-,7?,8?,9+,10?,11+,15?,17?,18?,19-,20+/m1/s1
DMRAZDW	CS	CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@H]5O)C(C)(C)C)O
DMRAZDW	IK	AMOGMTLMADGEOQ-RNOCTPMTSA-N
DMRAZDW	IU	(1S,6R,9R,13S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMRAZDW	DE	Discovery agent

DMI16MD	ID	DMI16MD
DMI16MD	DN	7-Ethoxy-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DMI16MD	HS	Investigative
DMI16MD	SN	CHEMBL98812; SCHEMBL10760128; 2H-Imidazo[4,5-b]quinolin-2-one, 7-ethoxy-1,3-dihydro-; BDBM50229572
DMI16MD	DT	Small molecular drug
DMI16MD	PC	13936989
DMI16MD	MW	229.23
DMI16MD	FM	C12H11N3O2
DMI16MD	IC	InChI=1S/C12H11N3O2/c1-2-17-8-3-4-9-7(5-8)6-10-11(13-9)15-12(16)14-10/h3-6H,2H2,1H3,(H2,13,14,15,16)
DMI16MD	CS	CCOC1=CC2=CC3=C(NC(=O)N3)N=C2C=C1
DMI16MD	IK	SBMFEGWRZYIWGG-UHFFFAOYSA-N
DMI16MD	IU	7-ethoxy-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMI16MD	DE	Discovery agent

DMYJBPI	ID	DMYJBPI
DMYJBPI	DN	7-ethoxy-8-propionyl-2H-chromen-2-one
DMYJBPI	HS	Investigative
DMYJBPI	SN	CHEMBL1288622; 7-ethoxy-8-propionyl-2H-chromen-2-one
DMYJBPI	DT	Small molecular drug
DMYJBPI	PC	52949288
DMYJBPI	MW	246.26
DMYJBPI	FM	C14H14O4
DMYJBPI	IC	InChI=1S/C14H14O4/c1-3-10(15)13-11(17-4-2)7-5-9-6-8-12(16)18-14(9)13/h5-8H,3-4H2,1-2H3
DMYJBPI	CS	CCC(=O)C1=C(C=CC2=C1OC(=O)C=C2)OCC
DMYJBPI	IK	LJTVZULEIDSNAK-UHFFFAOYSA-N
DMYJBPI	IU	7-ethoxy-8-propanoylchromen-2-one
DMYJBPI	DE	Discovery agent

DMUMN4B	ID	DMUMN4B
DMUMN4B	DN	7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMUMN4B	HS	Investigative
DMUMN4B	DT	Small molecular drug
DMUMN4B	PC	135442585
DMUMN4B	MW	255.27
DMUMN4B	FM	C15H13NO3
DMUMN4B	IC	InChI=1S/C15H13NO3/c1-2-9-7-12(18)8-13-14(9)19-15(16-13)10-3-5-11(17)6-4-10/h3-8,17-18H,2H2,1H3
DMUMN4B	CS	CCC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMUMN4B	IK	PRIKKCCDYUBJIV-UHFFFAOYSA-N
DMUMN4B	IU	7-ethyl-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMUMN4B	DE	Discovery agent

DMSFODU	ID	DMSFODU
DMSFODU	DN	7-ethyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMSFODU	HS	Investigative
DMSFODU	DT	Small molecular drug
DMSFODU	PC	135466462
DMSFODU	MW	293.3
DMSFODU	FM	C18H15NO3
DMSFODU	IC	InChI=1S/C18H15NO3/c1-2-12-14-7-10(20)4-6-16(14)19-18-13-5-3-11(21)8-17(13)22-9-15(12)18/h3-8,20-21H,2,9H2,1H3
DMSFODU	CS	CCC1=C2COC3=C(C2=NC4=C1C=C(C=C4)O)C=CC(=C3)O
DMSFODU	IK	OGDCTCUVBBYZTK-UHFFFAOYSA-N
DMSFODU	IU	7-ethyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMSFODU	DE	Discovery agent

DMXM2G7	ID	DMXM2G7
DMXM2G7	DN	7-ethyloxyethoxy-2-morpholin-4-yl-chromen-4-one
DMXM2G7	HS	Investigative
DMXM2G7	SN	CHEMBL196920; 7-ethyloxyethoxy-2-morpholin-4-yl-chromen-4-one
DMXM2G7	DT	Small molecular drug
DMXM2G7	PC	11529823
DMXM2G7	MW	319.4
DMXM2G7	FM	C17H21NO5
DMXM2G7	IC	InChI=1S/C17H21NO5/c1-2-20-9-10-22-13-3-4-14-15(19)12-17(23-16(14)11-13)18-5-7-21-8-6-18/h3-4,11-12H,2,5-10H2,1H3
DMXM2G7	CS	CCOCCOC1=CC2=C(C=C1)C(=O)C=C(O2)N3CCOCC3
DMXM2G7	IK	ICGVDPFEKFHPNV-UHFFFAOYSA-N
DMXM2G7	IU	7-(2-ethoxyethoxy)-2-morpholin-4-ylchromen-4-one
DMXM2G7	DE	Discovery agent

DM92EG5	ID	DM92EG5
DM92EG5	DN	7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DM92EG5	HS	Investigative
DM92EG5	DT	Small molecular drug
DM92EG5	PC	135409723
DM92EG5	MW	251.24
DM92EG5	FM	C15H9NO3
DM92EG5	IC	InChI=1S/C15H9NO3/c1-2-9-7-12(18)8-13-14(9)19-15(16-13)10-3-5-11(17)6-4-10/h1,3-8,17-18H
DM92EG5	CS	C#CC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DM92EG5	IK	UASSHNIRIMIZTA-UHFFFAOYSA-N
DM92EG5	IU	7-ethynyl-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DM92EG5	DE	Discovery agent

DMJWCAH	ID	DMJWCAH
DMJWCAH	DN	7-ethynyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMJWCAH	HS	Investigative
DMJWCAH	DT	Small molecular drug
DMJWCAH	PC	135453199
DMJWCAH	MW	289.3
DMJWCAH	FM	C18H11NO3
DMJWCAH	IC	InChI=1S/C18H11NO3/c1-2-12-14-7-10(20)4-6-16(14)19-18-13-5-3-11(21)8-17(13)22-9-15(12)18/h1,3-8,20-21H,9H2
DMJWCAH	CS	C#CC1=C2COC3=C(C2=NC4=C1C=C(C=C4)O)C=CC(=C3)O
DMJWCAH	IK	NFDYBNVVFHAKIV-UHFFFAOYSA-N
DMJWCAH	IU	7-ethynyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMJWCAH	DE	Discovery agent

DMNRCDI	ID	DMNRCDI
DMNRCDI	DN	7-Fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DMNRCDI	HS	Investigative
DMNRCDI	SN	CHEMBL323071; 7-Fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one; SCHEMBL10757077; 2H-Imidazo[4,5-b]quinolin-2-one, 7-fluoro-1,3-dihydro-; BDBM50007234
DMNRCDI	DT	Small molecular drug
DMNRCDI	PC	13936969
DMNRCDI	MW	203.17
DMNRCDI	FM	C10H6FN3O
DMNRCDI	IC	InChI=1S/C10H6FN3O/c11-6-1-2-7-5(3-6)4-8-9(12-7)14-10(15)13-8/h1-4H,(H2,12,13,14,15)
DMNRCDI	CS	C1=CC2=NC3=C(C=C2C=C1F)NC(=O)N3
DMNRCDI	IK	XTXHKKBSLRGOJD-UHFFFAOYSA-N
DMNRCDI	IU	7-fluoro-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMNRCDI	DE	Discovery agent

DM4HJZI	ID	DM4HJZI
DM4HJZI	DN	7-fluoro-2-(4-fluorophenyl)-4H-chromene-4-thione
DM4HJZI	HS	Investigative
DM4HJZI	SN	CHEMBL599545; 7-fluoro-2-(4-fluorophenyl)-4H-chromene-4-thione
DM4HJZI	DT	Small molecular drug
DM4HJZI	PC	46231935
DM4HJZI	MW	274.29
DM4HJZI	FM	C15H8F2OS
DM4HJZI	IC	InChI=1S/C15H8F2OS/c16-10-3-1-9(2-4-10)13-8-15(19)12-6-5-11(17)7-14(12)18-13/h1-8H
DM4HJZI	CS	C1=CC(=CC=C1C2=CC(=S)C3=C(O2)C=C(C=C3)F)F
DM4HJZI	IK	JDKXGUUVCBWLSB-UHFFFAOYSA-N
DM4HJZI	IU	7-fluoro-2-(4-fluorophenyl)chromene-4-thione
DM4HJZI	DE	Discovery agent

DMUPXBJ	ID	DMUPXBJ
DMUPXBJ	DN	7-fluoro-2-(4-methoxyphenyl)-4H-chromen-4-one
DMUPXBJ	HS	Investigative
DMUPXBJ	SN	7-fluoro-2-(4-methoxyphenyl)-4H-chromen-4-one; CHEMBL599149; 7-fluoro-2-(4-methoxyphenyl)chromen-4-one; AC1LAD85; 4'-Methoxy-7-fluoroflavanone; BDBM50310186; MB10522
DMUPXBJ	DT	Small molecular drug
DMUPXBJ	PC	466270
DMUPXBJ	MW	270.25
DMUPXBJ	FM	C16H11FO3
DMUPXBJ	IC	InChI=1S/C16H11FO3/c1-19-12-5-2-10(3-6-12)15-9-14(18)13-7-4-11(17)8-16(13)20-15/h2-9H,1H3
DMUPXBJ	CS	COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)F
DMUPXBJ	IK	STGBQHUMAHPOBT-UHFFFAOYSA-N
DMUPXBJ	IU	7-fluoro-2-(4-methoxyphenyl)chromen-4-one
DMUPXBJ	DE	Discovery agent

DMFOU8G	ID	DMFOU8G
DMFOU8G	DN	7-fluoro-2-p-tolyl-4H-chromen-4-one
DMFOU8G	HS	Investigative
DMFOU8G	SN	CHEMBL599148; 7-fluoro-2-p-tolyl-4H-chromen-4-one
DMFOU8G	DT	Small molecular drug
DMFOU8G	PC	46231795
DMFOU8G	MW	254.25
DMFOU8G	FM	C16H11FO2
DMFOU8G	IC	InChI=1S/C16H11FO2/c1-10-2-4-11(5-3-10)15-9-14(18)13-7-6-12(17)8-16(13)19-15/h2-9H,1H3
DMFOU8G	CS	CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)F
DMFOU8G	IK	NGYCVQPULTXSDL-UHFFFAOYSA-N
DMFOU8G	IU	7-fluoro-2-(4-methylphenyl)chromen-4-one
DMFOU8G	DE	Discovery agent

DMJFXKA	ID	DMJFXKA
DMJFXKA	DN	7-fluoro-2-p-tolyl-4H-chromene-4-thione
DMJFXKA	HS	Investigative
DMJFXKA	SN	CHEMBL599547; 7-fluoro-2-p-tolyl-4H-chromene-4-thione
DMJFXKA	DT	Small molecular drug
DMJFXKA	PC	46231936
DMJFXKA	MW	270.3
DMJFXKA	FM	C16H11FOS
DMJFXKA	IC	InChI=1S/C16H11FOS/c1-10-2-4-11(5-3-10)14-9-16(19)13-7-6-12(17)8-15(13)18-14/h2-9H,1H3
DMJFXKA	CS	CC1=CC=C(C=C1)C2=CC(=S)C3=C(O2)C=C(C=C3)F
DMJFXKA	IK	SJJJFWHFSTWMGP-UHFFFAOYSA-N
DMJFXKA	IU	7-fluoro-2-(4-methylphenyl)chromene-4-thione
DMJFXKA	DE	Discovery agent

DM0QI8V	ID	DM0QI8V
DM0QI8V	DN	7-Fluoro-3-thiophen-3-yl-quinoline
DM0QI8V	HS	Investigative
DM0QI8V	SN	CHEMBL307093; 7-fluoro-3-thiophen-3-yl-quinoline; ZINC3834021
DM0QI8V	DT	Small molecular drug
DM0QI8V	PC	10398928
DM0QI8V	MW	229.27
DM0QI8V	FM	C13H8FNS
DM0QI8V	IC	InChI=1S/C13H8FNS/c14-12-2-1-9-5-11(7-15-13(9)6-12)10-3-4-16-8-10/h1-8H
DM0QI8V	CS	C1=CC(=CC2=NC=C(C=C21)C3=CSC=C3)F
DM0QI8V	IK	OQYVAKAMHRACJL-UHFFFAOYSA-N
DM0QI8V	IU	7-fluoro-3-thiophen-3-ylquinoline
DM0QI8V	DE	Discovery agent

DMQ2ZTJ	ID	DMQ2ZTJ
DMQ2ZTJ	DN	7-fluorochromone-2-carboxamide
DMQ2ZTJ	HS	Investigative
DMQ2ZTJ	SN	CHEMBL214021; 7-fluorochromone-2-carboxamide; GTPL1303; SCHEMBL2669492; BDBM50197139; LS-193885; N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide; N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxochromene-2-carboxamide
DMQ2ZTJ	DT	Small molecular drug
DMQ2ZTJ	PC	11539096
DMQ2ZTJ	MW	424.4
DMQ2ZTJ	FM	C23H21FN2O5
DMQ2ZTJ	IC	InChI=1S/C23H21FN2O5/c24-15-2-3-17-18(27)11-22(31-20(17)10-15)23(28)25-16-5-7-26(8-6-16)12-14-1-4-19-21(9-14)30-13-29-19/h1-4,9-11,16H,5-8,12-13H2,(H,25,28)
DMQ2ZTJ	CS	C1CN(CCC1NC(=O)C2=CC(=O)C3=C(O2)C=C(C=C3)F)CC4=CC5=C(C=C4)OCO5
DMQ2ZTJ	IK	FVFURMJFTAJXRH-UHFFFAOYSA-N
DMQ2ZTJ	IU	N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxochromene-2-carboxamide
DMQ2ZTJ	DE	Discovery agent

DM70I3V	ID	DM70I3V
DM70I3V	DN	7-fluoroindirubin-3-acetoxime
DM70I3V	HS	Investigative
DM70I3V	DT	Small molecular drug
DM70I3V	PC	136104466
DM70I3V	MW	337.3
DM70I3V	FM	C18H12FN3O3
DM70I3V	IC	InChI=1S/C18H12FN3O3/c1-9(23)25-22-16-10-5-2-3-8-13(10)20-17(16)14-11-6-4-7-12(19)15(11)21-18(14)24/h2-8,21,24H,1H3/b22-16-
DM70I3V	CS	CC(=O)O/N=C\\1/C2=CC=CC=C2N=C1C3=C(NC4=C3C=CC=C4F)O
DM70I3V	IK	NFIUKUJUBYCMTC-JWGURIENSA-N
DM70I3V	IU	[(Z)-[2-(7-fluoro-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate
DM70I3V	DE	Discovery agent

DMQD34N	ID	DMQD34N
DMQD34N	DN	7-fluoroindirubin-3-oxime
DMQD34N	HS	Investigative
DMQD34N	DT	Small molecular drug
DMQD34N	PC	11845975
DMQD34N	DE	Discovery agent

DMEGSZD	ID	DMEGSZD
DMEGSZD	DN	7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine
DMEGSZD	HS	Investigative
DMEGSZD	DT	Small molecular drug
DMEGSZD	PC	334409
DMEGSZD	MW	199.21
DMEGSZD	FM	C10H9N5
DMEGSZD	IC	InChI=1S/C10H9N5/c11-9-8-5-3-4-13-6(5)1-2-7(8)14-10(12)15-9/h1-4H,11H2,(H3,12,14,15)
DMEGSZD	CS	C1=C2C(=C(N=C(N2)N)N)C3=CC=NC3=C1
DMEGSZD	IK	TYJMBWNFQVCGFT-UHFFFAOYSA-N
DMEGSZD	IU	4H-pyrrolo[3,2-f]quinazoline-1,3-diamine
DMEGSZD	CA	CAS 65795-37-1
DMEGSZD	DE	Discovery agent

DMKSJE3	ID	DMKSJE3
DMKSJE3	DN	7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one
DMKSJE3	HS	Investigative
DMKSJE3	SN	CHEMBL377622; 7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one
DMKSJE3	DT	Small molecular drug
DMKSJE3	PC	44412953
DMKSJE3	MW	200.23
DMKSJE3	FM	C13H12O2
DMKSJE3	IC	InChI=1S/C13H12O2/c14-10-3-4-12-9(6-10)5-8-1-2-11(15)7-13(8)12/h3-4,6-8,14H,1-2,5H2
DMKSJE3	CS	C1CC(=O)C=C2C1CC3=C2C=CC(=C3)O
DMKSJE3	IK	TVWXDDLDMKKZJT-UHFFFAOYSA-N
DMKSJE3	IU	7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one
DMKSJE3	DE	Discovery agent

DMXBUNV	ID	DMXBUNV
DMXBUNV	DN	7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one
DMXBUNV	HS	Investigative
DMXBUNV	SN	CHEMBL255110; 62252-06-6; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-(3-hydroxyphenyl)-; AC1LDLCQ; CTK2C3909; DTXSID60347362; MXNJBOFUFMJXOB-UHFFFAOYSA-N; BDBM50374256; AKOS030552838; 7-hydroxy-2-(3-hydroxyphenyl)-2,3-dihydrochromen-4-one; 2,3-Dihydro-7-hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-Hydroxy-2-(3-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one #
DMXBUNV	DT	Small molecular drug
DMXBUNV	PC	620596
DMXBUNV	MW	256.25
DMXBUNV	FM	C15H12O4
DMXBUNV	IC	InChI=1S/C15H12O4/c16-10-3-1-2-9(6-10)14-8-13(18)12-5-4-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2
DMXBUNV	CS	C1C(OC2=C(C1=O)C=CC(=C2)O)C3=CC(=CC=C3)O
DMXBUNV	IK	MXNJBOFUFMJXOB-UHFFFAOYSA-N
DMXBUNV	IU	7-hydroxy-2-(3-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMXBUNV	CA	CAS 62252-06-6
DMXBUNV	DE	Discovery agent

DMCB2IM	ID	DMCB2IM
DMCB2IM	DN	7-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one
DMCB2IM	HS	Investigative
DMCB2IM	SN	CHEMBL56650; 7-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one; ZINC13797581; BDBM50077320; 2-(4-Hydroxybenzyl)-7-hydroxychromone
DMCB2IM	DT	Small molecular drug
DMCB2IM	PC	10084377
DMCB2IM	MW	268.26
DMCB2IM	FM	C16H12O4
DMCB2IM	IC	InChI=1S/C16H12O4/c17-11-3-1-10(2-4-11)7-13-9-15(19)14-6-5-12(18)8-16(14)20-13/h1-6,8-9,17-18H,7H2
DMCB2IM	CS	C1=CC(=CC=C1CC2=CC(=O)C3=C(O2)C=C(C=C3)O)O
DMCB2IM	IK	ZUDKQDRWUFGUDQ-UHFFFAOYSA-N
DMCB2IM	IU	7-hydroxy-2-[(4-hydroxyphenyl)methyl]chromen-4-one
DMCB2IM	DE	Discovery agent

DM2BV6P	ID	DM2BV6P
DM2BV6P	DN	7-Hydroxy-2-(4-methoxy-benzyl)-chromen-4-one
DM2BV6P	HS	Investigative
DM2BV6P	SN	CHEMBL56447; 7-Hydroxy-2-(4-methoxy-benzyl)-chromen-4-one; ZINC13797575; BDBM50077321
DM2BV6P	DT	Small molecular drug
DM2BV6P	PC	10708015
DM2BV6P	MW	282.29
DM2BV6P	FM	C17H14O4
DM2BV6P	IC	InChI=1S/C17H14O4/c1-20-13-5-2-11(3-6-13)8-14-10-16(19)15-7-4-12(18)9-17(15)21-14/h2-7,9-10,18H,8H2,1H3
DM2BV6P	CS	COC1=CC=C(C=C1)CC2=CC(=O)C3=C(O2)C=C(C=C3)O
DM2BV6P	IK	SKFOCRVUNCGDHR-UHFFFAOYSA-N
DM2BV6P	IU	7-hydroxy-2-[(4-methoxyphenyl)methyl]chromen-4-one
DM2BV6P	DE	Discovery agent

DMIKSTL	ID	DMIKSTL
DMIKSTL	DN	7-hydroxy-2-(morpholin-4-yl)chromen-4-one
DMIKSTL	HS	Investigative
DMIKSTL	SN	CHEMBL197536; 7-hydroxy-2-(morpholin-4-yl)chromen-4-one; SCHEMBL3533604; ULTRFFGNTUDFJW-UHFFFAOYSA-N; BDBM50178123
DMIKSTL	DT	Small molecular drug
DMIKSTL	PC	11715743
DMIKSTL	MW	247.25
DMIKSTL	FM	C13H13NO4
DMIKSTL	IC	InChI=1S/C13H13NO4/c15-9-1-2-10-11(16)8-13(18-12(10)7-9)14-3-5-17-6-4-14/h1-2,7-8,15H,3-6H2
DMIKSTL	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)O
DMIKSTL	IK	ULTRFFGNTUDFJW-UHFFFAOYSA-N
DMIKSTL	IU	7-hydroxy-2-morpholin-4-ylchromen-4-one
DMIKSTL	DE	Discovery agent

DM4UW65	ID	DM4UW65
DM4UW65	DN	7-hydroxy-2-phenylchroman-4-one
DM4UW65	HS	Investigative
DM4UW65	SN	7-Hydroxyflavanone; 6515-36-2; 7-Hydroxy-2-phenylchroman-4-one; 7-Hydroxyflavanone, 98%; CHEMBL97542; CHEBI:34483; SWAJPHCXKPCPQZ-UHFFFAOYSA-N; 7-hydroxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; MFCD00017487; 2,3-dihydro-7-hydroxy-2-phenyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-phenyl-; 7-hydroxy-2-phenyl-4-chromanone; 2545-13-3; 7-hydroxy-flavanone; AC1L1CGO; AC1Q6KJV; ACMC-1B5B3; Oprea1_401356; MLS001181922; SCHEMBL130266; DTXSID0022430; CTK4F5779; MolPort-002-903-717; HMS2865F07; HMS1664L06
DM4UW65	DT	Small molecular drug
DM4UW65	PC	1890
DM4UW65	MW	240.25
DM4UW65	FM	C15H12O3
DM4UW65	IC	InChI=1S/C15H12O3/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14,16H,9H2
DM4UW65	CS	C1C(OC2=C(C1=O)C=CC(=C2)O)C3=CC=CC=C3
DM4UW65	IK	SWAJPHCXKPCPQZ-UHFFFAOYSA-N
DM4UW65	IU	7-hydroxy-2-phenyl-2,3-dihydrochromen-4-one
DM4UW65	CA	CAS 6515-36-2
DM4UW65	CB	CHEBI:34483
DM4UW65	DE	Discovery agent

DMS2NZA	ID	DMS2NZA
DMS2NZA	DN	7-Hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile
DMS2NZA	HS	Investigative
DMS2NZA	SN	7-Hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile; SCHEMBL3020111; CHEMBL467183; UXJULIKCAFGFJL-UHFFFAOYSA-N
DMS2NZA	DT	Small molecular drug
DMS2NZA	PC	24950551
DMS2NZA	MW	261.269
DMS2NZA	FM	C17H11NO2
DMS2NZA	IC	InChI=1S/C17H11NO2/c18-10-14-7-13(11-2-1-3-15(19)8-11)6-12-4-5-16(20)9-17(12)14/h1-9,19-20H
DMS2NZA	CS	C1=CC(=CC(=C1)O)C2=CC(=C3C=C(C=CC3=C2)O)C#N
DMS2NZA	IK	UXJULIKCAFGFJL-UHFFFAOYSA-N
DMS2NZA	IU	7-hydroxy-3-(3-hydroxyphenyl)naphthalene-1-carbonitrile
DMS2NZA	DE	Discovery agent

DM46J2H	ID	DM46J2H
DM46J2H	DN	7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one
DM46J2H	HS	Investigative
DM46J2H	SN	3-arylquinazolinone, 1as; CHEMBL203370; SCHEMBL1795123; BDBM19927; AKOS002674620
DM46J2H	DT	Small molecular drug
DM46J2H	PC	11579721
DM46J2H	MW	254.24
DM46J2H	FM	C14H10N2O3
DM46J2H	IC	InChI=1S/C14H10N2O3/c17-10-3-1-9(2-4-10)16-8-15-13-7-11(18)5-6-12(13)14(16)19/h1-8,17-18H
DM46J2H	CS	C1=CC(=CC=C1N2C=NC3=C(C2=O)C=CC(=C3)O)O
DM46J2H	IK	NECCEJFVHJYYDA-UHFFFAOYSA-N
DM46J2H	IU	7-hydroxy-3-(4-hydroxyphenyl)quinazolin-4-one
DM46J2H	DE	Discovery agent

DM2ZE8U	ID	DM2ZE8U
DM2ZE8U	DN	7-hydroxy-3-phenyl-2H-chromen-2-one
DM2ZE8U	HS	Investigative
DM2ZE8U	SN	7-hydroxy-3-phenyl-2H-chromen-2-one; 6468-96-8; 3-Phenylumbelliferone; 7-Hydroxy-3-phenylcoumarin; 7-hydroxy-3-phenylchromen-2-one; 3-phenyl-7-hydroxycoumarin; CHEMBL153505; 7-Hydroxy-3-phenyl-2H-1-benzopyran-2-one; 2H-1-Benzopyran-2-one,7-hydroxy-3-phenyl-; 7-Hydroxy-3-phenyl-chromen-2-one; EN300-36438; AE-641/01995035; AC1NU2DD; MLS001167019; SCHEMBL591688; AC1Q797K; ZINC58069; CTK5C1589; cid_5393176; DTXSID60419831; MolPort-000-870-829; RIPZCQZTVDNJHQ-UHFFFAOYSA-N; HMS2955O07; BB_NC-01950; SBB042221; STL033560; MFCD00037574
DM2ZE8U	DT	Small molecular drug
DM2ZE8U	PC	5393176
DM2ZE8U	MW	238.24
DM2ZE8U	FM	C15H10O3
DM2ZE8U	IC	InChI=1S/C15H10O3/c16-12-7-6-11-8-13(10-4-2-1-3-5-10)15(17)18-14(11)9-12/h1-9,16H
DM2ZE8U	CS	C1=CC=C(C=C1)C2=CC3=C(C=C(C=C3)O)OC2=O
DM2ZE8U	IK	RIPZCQZTVDNJHQ-UHFFFAOYSA-N
DM2ZE8U	IU	7-hydroxy-3-phenylchromen-2-one
DM2ZE8U	CA	CAS 6468-96-8
DM2ZE8U	DE	Discovery agent

DM3T612	ID	DM3T612
DM3T612	DN	7-Hydroxy-4-phenylcoumarin
DM3T612	HS	Investigative
DM3T612	SN	7-Hydroxy-4-phenylcoumarin; 2555-30-8; 7-hydroxy-4-phenyl-2H-chromen-2-one; 7-hydroxy-4-phenylchromen-2-one; NSC78474; 4-Phenyl-7-hydroxycoumarin; UNII-L0487H6Q0H; CHEMBL325841; L0487H6Q0H; 7-Hydroxy-4-phenyl-chromen-2-one; 7-oxidanyl-4-phenyl-chromen-2-one; NSC-78474; 2H-1-Benzopyran-2-one,7-hydroxy-4-phenyl-; 2H-1-Benzopyran-2-one, 7-hydroxy-4-phenyl-; 4-Phenylumbelliferone; PubChem8691; Coumarin derivative, 3c; AC1NSAV1; 7-Hydroxy4-phenylcoumarin; Oprea1_774373; 7-hydroxy-4-phenyl coumarin; MLS001143868; SCHEMBL2987658
DM3T612	DT	Small molecular drug
DM3T612	PC	5357479
DM3T612	MW	238.24
DM3T612	FM	C15H10O3
DM3T612	IC	InChI=1S/C15H10O3/c16-11-6-7-12-13(10-4-2-1-3-5-10)9-15(17)18-14(12)8-11/h1-9,16H
DM3T612	CS	C1=CC=C(C=C1)C2=CC(=O)OC3=C2C=CC(=C3)O
DM3T612	IK	IVJMJRRORVMRJJ-UHFFFAOYSA-N
DM3T612	IU	7-hydroxy-4-phenylchromen-2-one
DM3T612	CA	CAS 2555-30-8
DM3T612	DE	Discovery agent

DM49RWY	ID	DM49RWY
DM49RWY	DN	7-Hydroxy-6-nitro-2-phenyl-chromen-4-one
DM49RWY	HS	Investigative
DM49RWY	SN	CHEMBL56730; 7-hydroxy-6-nitro-2-phenyl-chromen-4-one; 6-Nitro-7-hydroxyflavone
DM49RWY	DT	Small molecular drug
DM49RWY	PC	10755384
DM49RWY	MW	283.23
DM49RWY	FM	C15H9NO5
DM49RWY	IC	InChI=1S/C15H9NO5/c17-12-7-14(9-4-2-1-3-5-9)21-15-8-13(18)11(16(19)20)6-10(12)15/h1-8,18H
DM49RWY	CS	C1=CC=C(C=C1)C2=CC(=O)C3=CC(=C(C=C3O2)O)[N+](=O)[O-]
DM49RWY	IK	KJSLXXZBGFZOAH-UHFFFAOYSA-N
DM49RWY	IU	7-hydroxy-6-nitro-2-phenylchromen-4-one
DM49RWY	DE	Discovery agent

DMQ3RVK	ID	DMQ3RVK
DMQ3RVK	DN	7-hydroxy-6-propionyl-2H-chromen-2-one
DMQ3RVK	HS	Investigative
DMQ3RVK	SN	7-hydroxy-6-propanoylcoumarin; CHEMBL1288535; 144582-52-5; 7-hydroxy-6-propionyl-2H-chromen-2-one
DMQ3RVK	DT	Small molecular drug
DMQ3RVK	PC	52949920
DMQ3RVK	MW	218.2
DMQ3RVK	FM	C12H10O4
DMQ3RVK	IC	InChI=1S/C12H10O4/c1-2-9(13)8-5-7-3-4-12(15)16-11(7)6-10(8)14/h3-6,14H,2H2,1H3
DMQ3RVK	CS	CCC(=O)C1=C(C=C2C(=C1)C=CC(=O)O2)O
DMQ3RVK	IK	GJOCMGDMAGUOKE-UHFFFAOYSA-N
DMQ3RVK	IU	7-hydroxy-6-propanoylchromen-2-one
DMQ3RVK	DE	Discovery agent

DMFKSMW	ID	DMFKSMW
DMFKSMW	DN	7-hydroxy-8-propionyl-2H-chromen-2-one
DMFKSMW	HS	Investigative
DMFKSMW	SN	7-hydroxy-8-propionyl-coumarin; CHEMBL1288557; 67752-18-5; 7-hydroxy-8-propionyl-2H-chromen-2-one; 7-hydroxy-8-propionylcoumarin
DMFKSMW	DT	Small molecular drug
DMFKSMW	PC	52943164
DMFKSMW	MW	218.2
DMFKSMW	FM	C12H10O4
DMFKSMW	IC	InChI=1S/C12H10O4/c1-2-8(13)11-9(14)5-3-7-4-6-10(15)16-12(7)11/h3-6,14H,2H2,1H3
DMFKSMW	CS	CCC(=O)C1=C(C=CC2=C1OC(=O)C=C2)O
DMFKSMW	IK	DVLIOVBNBOBBGS-UHFFFAOYSA-N
DMFKSMW	IU	7-hydroxy-8-propanoylchromen-2-one
DMFKSMW	DE	Discovery agent

DMZXMB7	ID	DMZXMB7
DMZXMB7	DN	7-hydroxycholesterol
DMZXMB7	HS	Investigative
DMZXMB7	SN	7-hydroxy-cholesterol; 7-OHC; SCHEMBL281943; GTPL3432; KB-200035
DMZXMB7	DT	Small molecular drug
DMZXMB7	PC	15571093
DMZXMB7	MW	402.7
DMZXMB7	FM	C27H46O2
DMZXMB7	IC	InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24?,25+,26+,27-/m1/s1
DMZXMB7	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C(C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DMZXMB7	IK	OYXZMSRRJOYLLO-UOQFGJKXSA-N
DMZXMB7	IU	(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMZXMB7	DE	Discovery agent

DMV0PT8	ID	DMV0PT8
DMV0PT8	DN	7-hydroxycostunolide
DMV0PT8	HS	Investigative
DMV0PT8	SN	7-hydroxycostunolide; NSC711176; AC1NV7KU; CHEMBL206443; CHEMBL1976955; NSC-711176; Cyclodeca[b]furan-2(3H)-one,4,5,8,9,11a-hexahydro-3a-hydroxy- 6,10-dimethyl-3-methylene-, stereoisomer
DMV0PT8	DT	Small molecular drug
DMV0PT8	PC	5471440
DMV0PT8	MW	248.32
DMV0PT8	FM	C15H20O3
DMV0PT8	IC	InChI=1S/C15H20O3/c1-10-5-4-6-11(2)9-13-15(17,8-7-10)12(3)14(16)18-13/h5,9,13,17H,3-4,6-8H2,1-2H3/b10-5+,11-9+/t13-,15-/m1/s1
DMV0PT8	CS	C/C/1=C\\CC/C(=C/[C@@H]2[C@@](CC1)(C(=C)C(=O)O2)O)/C
DMV0PT8	IK	AZKRCCHLNBJNOK-HZAIZTQPSA-N
DMV0PT8	IU	(3aR,6E,10E,11aR)-3a-hydroxy-6,10-dimethyl-3-methylidene-5,8,9,11a-tetrahydro-4H-cyclodeca[b]furan-2-one
DMV0PT8	DE	Discovery agent

DMTMNO7	ID	DMTMNO7
DMTMNO7	DN	7-hydroxycoumarin
DMTMNO7	HS	Investigative
DMTMNO7	SN	Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510; UMBELLIFERONE
DMTMNO7	DT	Small molecular drug
DMTMNO7	PC	5281426
DMTMNO7	MW	162.14
DMTMNO7	FM	C9H6O3
DMTMNO7	IC	InChI=1S/C9H6O3/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5,10H
DMTMNO7	CS	C1=CC(=CC2=C1C=CC(=O)O2)O
DMTMNO7	IK	ORHBXUUXSCNDEV-UHFFFAOYSA-N
DMTMNO7	IU	7-hydroxychromen-2-one
DMTMNO7	CA	CAS 93-35-6
DMTMNO7	CB	CHEBI:27510
DMTMNO7	DE	Discovery agent

DMV39XT	ID	DMV39XT
DMV39XT	DN	7-Hydroxy-Pyrazolo[4,3-D]Pyrimidine
DMV39XT	HS	Investigative
DMV39XT	DT	Small molecular drug
DMV39XT	PC	135460353
DMV39XT	MW	136.11
DMV39XT	FM	C5H4N4O
DMV39XT	IC	InChI=1S/C5H4N4O/c10-5-4-3(1-8-9-4)6-2-7-5/h1-2H,(H,8,9)(H,6,7,10)
DMV39XT	CS	C1=NNC2=C1N=CNC2=O
DMV39XT	IK	JFZSDNLQDTYVEE-UHFFFAOYSA-N
DMV39XT	IU	1,6-dihydropyrazolo[4,3-d]pyrimidin-7-one
DMV39XT	CA	CAS 13877-55-9
DMV39XT	DE	Discovery agent

DM6K5NF	ID	DM6K5NF
DM6K5NF	DN	7-Iodo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one
DM6K5NF	HS	Investigative
DM6K5NF	DT	Small molecular drug
DM6K5NF	PC	14177141
DM6K5NF	DE	Discovery agent

DMNFI02	ID	DMNFI02
DMNFI02	DN	7-iodoindirubin-3-oxime
DMNFI02	HS	Investigative
DMNFI02	DT	Small molecular drug
DMNFI02	PC	11846149
DMNFI02	DE	Discovery agent

DMVSF0O	ID	DMVSF0O
DMVSF0O	DN	7-Isopropyl-7H-adenine
DMVSF0O	HS	Investigative
DMVSF0O	SN	7-Isopropyl-7H-adenine; CHEMBL448396; 55146-09-3; SCHEMBL756635
DMVSF0O	DT	Small molecular drug
DMVSF0O	PC	23562742
DMVSF0O	MW	177.21
DMVSF0O	FM	C8H11N5
DMVSF0O	IC	InChI=1S/C8H11N5/c1-5(2)13-4-12-8-6(13)7(9)10-3-11-8/h3-5H,1-2H3,(H2,9,10,11)
DMVSF0O	CS	CC(C)N1C=NC2=NC=NC(=C21)N
DMVSF0O	IK	WAPXYHTXSGPYEX-UHFFFAOYSA-N
DMVSF0O	IU	7-propan-2-ylpurin-6-amine
DMVSF0O	DE	Discovery agent

DMPYTHV	ID	DMPYTHV
DMPYTHV	DN	7-Mercapto-heptanoic acid benzothiazol-2-ylamide
DMPYTHV	HS	Investigative
DMPYTHV	SN	CHEMBL178779
DMPYTHV	DT	Small molecular drug
DMPYTHV	PC	11346934
DMPYTHV	MW	294.4
DMPYTHV	FM	C14H18N2OS2
DMPYTHV	IC	InChI=1S/C14H18N2OS2/c17-13(9-3-1-2-6-10-18)16-14-15-11-7-4-5-8-12(11)19-14/h4-5,7-8,18H,1-3,6,9-10H2,(H,15,16,17)
DMPYTHV	CS	C1=CC=C2C(=C1)N=C(S2)NC(=O)CCCCCCS
DMPYTHV	IK	QMWKKGIVGMUWJC-UHFFFAOYSA-N
DMPYTHV	IU	N-(1,3-benzothiazol-2-yl)-7-sulfanylheptanamide
DMPYTHV	DE	Discovery agent

DMEQKPO	ID	DMEQKPO
DMEQKPO	DN	7-Mercapto-heptanoic acid biphenyl-3-ylamide
DMEQKPO	HS	Investigative
DMEQKPO	SN	CHEMBL320323
DMEQKPO	DT	Small molecular drug
DMEQKPO	PC	11449823
DMEQKPO	MW	313.5
DMEQKPO	FM	C19H23NOS
DMEQKPO	IC	InChI=1S/C19H23NOS/c21-19(13-6-1-2-7-14-22)20-18-12-8-11-17(15-18)16-9-4-3-5-10-16/h3-5,8-12,15,22H,1-2,6-7,13-14H2,(H,20,21)
DMEQKPO	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)CCCCCCS
DMEQKPO	IK	VJSUVWGNKFMQET-UHFFFAOYSA-N
DMEQKPO	IU	N-(3-phenylphenyl)-7-sulfanylheptanamide
DMEQKPO	DE	Discovery agent

DMJMOUK	ID	DMJMOUK
DMJMOUK	DN	7-Mercapto-heptanoic acid biphenyl-4-ylamide
DMJMOUK	HS	Investigative
DMJMOUK	SN	CHEMBL112311
DMJMOUK	DT	Small molecular drug
DMJMOUK	PC	11220728
DMJMOUK	MW	313.5
DMJMOUK	FM	C19H23NOS
DMJMOUK	IC	InChI=1S/C19H23NOS/c21-19(10-6-1-2-7-15-22)20-18-13-11-17(12-14-18)16-8-4-3-5-9-16/h3-5,8-9,11-14,22H,1-2,6-7,10,15H2,(H,20,21)
DMJMOUK	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)CCCCCCS
DMJMOUK	IK	QTXIBRBGYJCFEU-UHFFFAOYSA-N
DMJMOUK	IU	N-(4-phenylphenyl)-7-sulfanylheptanamide
DMJMOUK	DE	Discovery agent

DM4912P	ID	DM4912P
DM4912P	DN	7-Mercapto-heptanoic acid phenylamide
DM4912P	HS	Investigative
DM4912P	SN	7-Mercapto-heptanoic acid phenylamide; Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692
DM4912P	DT	Small molecular drug
DM4912P	PC	11379392
DM4912P	MW	237.36
DM4912P	FM	C13H19NOS
DM4912P	IC	InChI=1S/C13H19NOS/c15-13(10-6-1-2-7-11-16)14-12-8-4-3-5-9-12/h3-5,8-9,16H,1-2,6-7,10-11H2,(H,14,15)
DM4912P	CS	C1=CC=C(C=C1)NC(=O)CCCCCCS
DM4912P	IK	CFKBMXXDXYFDET-UHFFFAOYSA-N
DM4912P	IU	N-phenyl-7-sulfanylheptanamide
DM4912P	DE	Discovery agent

DMQ9PLA	ID	DMQ9PLA
DMQ9PLA	DN	7-Mercapto-heptanoic acid pyridin-3-ylamide
DMQ9PLA	HS	Investigative
DMQ9PLA	SN	CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653
DMQ9PLA	DT	Small molecular drug
DMQ9PLA	PC	11345433
DMQ9PLA	MW	238.35
DMQ9PLA	FM	C12H18N2OS
DMQ9PLA	IC	InChI=1S/C12H18N2OS/c15-12(7-3-1-2-4-9-16)14-11-6-5-8-13-10-11/h5-6,8,10,16H,1-4,7,9H2,(H,14,15)
DMQ9PLA	CS	C1=CC(=CN=C1)NC(=O)CCCCCCS
DMQ9PLA	IK	SHPVLBRAGPXPLH-UHFFFAOYSA-N
DMQ9PLA	IU	N-pyridin-3-yl-7-sulfanylheptanamide
DMQ9PLA	DE	Discovery agent

DMTAGJ1	ID	DMTAGJ1
DMTAGJ1	DN	7-Mercapto-heptanoic acid quinolin-3-ylamide
DMTAGJ1	HS	Investigative
DMTAGJ1	SN	CHEMBL112234
DMTAGJ1	DT	Small molecular drug
DMTAGJ1	PC	10379373
DMTAGJ1	MW	288.4
DMTAGJ1	FM	C16H20N2OS
DMTAGJ1	IC	InChI=1S/C16H20N2OS/c19-16(9-3-1-2-6-10-20)18-14-11-13-7-4-5-8-15(13)17-12-14/h4-5,7-8,11-12,20H,1-3,6,9-10H2,(H,18,19)
DMTAGJ1	CS	C1=CC=C2C(=C1)C=C(C=N2)NC(=O)CCCCCCS
DMTAGJ1	IK	XAFIWTHVBLRJFM-UHFFFAOYSA-N
DMTAGJ1	IU	N-quinolin-3-yl-7-sulfanylheptanamide
DMTAGJ1	DE	Discovery agent

DM03XYF	ID	DM03XYF
DM03XYF	DN	7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide
DM03XYF	HS	Investigative
DM03XYF	SN	CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide
DM03XYF	DT	Small molecular drug
DM03XYF	PC	11427204
DM03XYF	MW	320.5
DM03XYF	FM	C16H20N2OS2
DM03XYF	IC	InChI=1S/C16H20N2OS2/c19-15(10-6-1-2-7-11-20)18-16-17-14(12-21-16)13-8-4-3-5-9-13/h3-5,8-9,12,20H,1-2,6-7,10-11H2,(H,17,18,19)
DM03XYF	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)CCCCCCS
DM03XYF	IK	LUXAHBUKMVESIS-UHFFFAOYSA-N
DM03XYF	IU	N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide
DM03XYF	DE	Discovery agent

DMTFBCU	ID	DMTFBCU
DMTFBCU	DN	7-Methoxy-1H-indazole
DMTFBCU	HS	Investigative
DMTFBCU	SN	7-methoxy-1H-indazole; 133841-05-1; 1H-Indazole, 7-methoxy-; CHEMBL15921; ACMC-20aa2r; 7-METHOXYINDAZOLE; SCHEMBL5483794; SCHEMBL18003573; CTK0H0012; KS-00000DHI; DTXSID90439880; QCBANHQTMCETBI-UHFFFAOYSA-N; MolPort-009-199-308; BDBM50099399; ANW-63985; ZINC26894532; AKOS024124789; AKOS006290288; TRA0059918; AS-8550; RP01575; PB32675; RTC-062053; AN-6943; KB-46446; AC-29510; SY032798; SC-54780; AK-58155; AJ-82859; 1429222-35-4; TC-062053; DB-062996; Y7436; ST24045679; FT-0767863; 4CH-023995; CS-0043993; AM20020408; MFCD08752584 (97%); Q-2252
DMTFBCU	DT	Small molecular drug
DMTFBCU	PC	10441839
DMTFBCU	MW	148.16
DMTFBCU	FM	C8H8N2O
DMTFBCU	IC	InChI=1S/C8H8N2O/c1-11-7-4-2-3-6-5-9-10-8(6)7/h2-5H,1H3,(H,9,10)
DMTFBCU	CS	COC1=CC=CC2=C1NN=C2
DMTFBCU	IK	QCBANHQTMCETBI-UHFFFAOYSA-N
DMTFBCU	IU	7-methoxy-1H-indazole
DMTFBCU	CA	CAS 133841-05-1
DMTFBCU	DE	Discovery agent

DM3MXI5	ID	DM3MXI5
DM3MXI5	DN	7-methoxy-1-naphthylpiperazine
DM3MXI5	HS	Investigative
DM3MXI5	SN	7-methoxy-1-naphthylpiperazine; GTPL6; SCHEMBL9478699; oxiran-2-ylmethyl N-[2-(dimethyl-trimethylsilylsilyl)ethyl]carbamate
DM3MXI5	DT	Small molecular drug
DM3MXI5	PC	14533720
DM3MXI5	MW	275.49
DM3MXI5	FM	C11H25NO3Si2
DM3MXI5	IC	InChI=1S/C11H25NO3Si2/c1-16(2,3)17(4,5)7-6-12-11(13)15-9-10-8-14-10/h10H,6-9H2,1-5H3,(H,12,13)
DM3MXI5	CS	C[Si](C)(C)[Si](C)(C)CCNC(=O)OCC1CO1
DM3MXI5	IK	RMYUPIFLALKWOD-UHFFFAOYSA-N
DM3MXI5	IU	oxiran-2-ylmethyl N-[2-[dimethyl(trimethylsilyl)silyl]ethyl]carbamate
DM3MXI5	DE	Discovery agent

DMQ1BE8	ID	DMQ1BE8
DMQ1BE8	DN	7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMQ1BE8	HS	Investigative
DMQ1BE8	SN	CHEMBL6310; 7-Methoxy-1,2,3,4-tetrahydro-beta-carboline; AC1LCCZT; 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline; 7-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole; SCIRNASYBOGBOO-UHFFFAOYSA-N; BDBM50132097; ZINC13587968; AKOS004119616; 91566-22-2; 7-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; Methyl 2,3,4,9-tetrahydro-1H-beta-carbolin-7-yl ether #
DMQ1BE8	DT	Small molecular drug
DMQ1BE8	PC	599482
DMQ1BE8	MW	202.25
DMQ1BE8	FM	C12H14N2O
DMQ1BE8	IC	InChI=1S/C12H14N2O/c1-15-8-2-3-9-10-4-5-13-7-12(10)14-11(9)6-8/h2-3,6,13-14H,4-5,7H2,1H3
DMQ1BE8	CS	COC1=CC2=C(C=C1)C3=C(N2)CNCC3
DMQ1BE8	IK	SCIRNASYBOGBOO-UHFFFAOYSA-N
DMQ1BE8	IU	7-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMQ1BE8	DE	Discovery agent

DMR713M	ID	DMR713M
DMR713M	DN	7-Methoxy-2-morpholin-4-yl-chromen-4-one
DMR713M	HS	Investigative
DMR713M	SN	CHEMBL175459; 130735-66-9; 4H-1-Benzopyran-4-one, 7-methoxy-2-(4-morpholinyl)-; 7-methoxy-2-morpholin-4-yl-chromen-4-one; ACMC-20mts5; 4H-1-Benzopyran-4-one,7-methoxy-2-(4-morpholinyl)-; SCHEMBL3536694; CTK0C1164; DTXSID00466243; BDBM50159634
DMR713M	DT	Small molecular drug
DMR713M	PC	11448366
DMR713M	MW	261.269
DMR713M	FM	C14H15NO4
DMR713M	IC	InChI=1S/C14H15NO4/c1-17-10-2-3-11-12(16)9-14(19-13(11)8-10)15-4-6-18-7-5-15/h2-3,8-9H,4-7H2,1H3
DMR713M	CS	COC1=CC2=C(C=C1)C(=O)C=C(O2)N3CCOCC3
DMR713M	IK	TVHCBKPEOVWUEQ-UHFFFAOYSA-N
DMR713M	IU	7-methoxy-2-morpholin-4-ylchromen-4-one
DMR713M	CA	CAS 130735-66-9
DMR713M	DE	Discovery agent

DMJITU0	ID	DMJITU0
DMJITU0	DN	7-methoxy-2-oxo-2H-chromene-4-carboxylic acid
DMJITU0	HS	Investigative
DMJITU0	SN	CHEMBL12567; 7-Methoxy-2-oxo-2H-chromene-4-carboxylic acid; 2H-1-Benzopyran-4-carboxylic acid, 7-methoxy-2-oxo-; BDBM50022188; 74802-00-9; 2-Oxo-7-methoxy-2H-1-benzopyran-4-carboxylic acid
DMJITU0	DT	Small molecular drug
DMJITU0	PC	44268050
DMJITU0	MW	220.18
DMJITU0	FM	C11H8O5
DMJITU0	IC	InChI=1S/C11H8O5/c1-15-6-2-3-7-8(11(13)14)5-10(12)16-9(7)4-6/h2-5H,1H3,(H,13,14)
DMJITU0	CS	COC1=CC2=C(C=C1)C(=CC(=O)O2)C(=O)O
DMJITU0	IK	IHHLDCASADSHEG-UHFFFAOYSA-N
DMJITU0	IU	7-methoxy-2-oxochromene-4-carboxylic acid
DMJITU0	DE	Discovery agent

DME5WZQ	ID	DME5WZQ
DME5WZQ	DN	7-methoxy-2-p-tolyl-4H-chromen-4-one
DME5WZQ	HS	Investigative
DME5WZQ	SN	CHEMBL17052; 7-methoxy-2-(4-methylphenyl)chromen-4-one; 7-methoxy-2-(4-methylphenyl)-4H-chromen-4-one; 108980-49-0; 7-methoxy-2-p-tolyl-4H-chromen-4-one; AC1LIGD7; MolPort-000-450-862; ZINC522064; STK893155; BDBM50310185; 7-Methoxy-2-p-tolyl-chromen-4-one; AKOS002182021; MCULE-3043616847; NCGC00318207-01; 7-methoxy-2-(p-tolyl)-4H-chromen-4-one; ST50070846; VU0510077-1; AB01311569-01; 2-(4-Methylphenyl)-7-methoxy-4H-1-benzopyran-4-one
DME5WZQ	DT	Small molecular drug
DME5WZQ	PC	930709
DME5WZQ	MW	266.29
DME5WZQ	FM	C17H14O3
DME5WZQ	IC	InChI=1S/C17H14O3/c1-11-3-5-12(6-4-11)16-10-15(18)14-8-7-13(19-2)9-17(14)20-16/h3-10H,1-2H3
DME5WZQ	CS	CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)OC
DME5WZQ	IK	OBNQAKAHHNLJHT-UHFFFAOYSA-N
DME5WZQ	IU	7-methoxy-2-(4-methylphenyl)chromen-4-one
DME5WZQ	DE	Discovery agent

DM4WMGK	ID	DM4WMGK
DM4WMGK	DN	7-methoxy-2-p-tolyl-4H-chromene-4-thione
DM4WMGK	HS	Investigative
DM4WMGK	SN	CHEMBL597716; 7-methoxy-2-p-tolyl-4H-chromene-4-thione
DM4WMGK	DT	Small molecular drug
DM4WMGK	PC	46232008
DM4WMGK	MW	282.4
DM4WMGK	FM	C17H14O2S
DM4WMGK	IC	InChI=1S/C17H14O2S/c1-11-3-5-12(6-4-11)15-10-17(20)14-8-7-13(18-2)9-16(14)19-15/h3-10H,1-2H3
DM4WMGK	CS	CC1=CC=C(C=C1)C2=CC(=S)C3=C(O2)C=C(C=C3)OC
DM4WMGK	IK	HJUOMZBCQPCXHZ-UHFFFAOYSA-N
DM4WMGK	IU	7-methoxy-2-(4-methylphenyl)chromene-4-thione
DM4WMGK	DE	Discovery agent

DMUZIDT	ID	DMUZIDT
DMUZIDT	DN	7-Methoxy-3-pyridin-4-yl-quinoline
DMUZIDT	HS	Investigative
DMUZIDT	SN	CHEMBL329622; 7-methoxy-3-pyridin-4-yl-quinoline; 7-Methoxy-3-(4-pyridyl)quinoline
DMUZIDT	DT	Small molecular drug
DMUZIDT	PC	11776270
DMUZIDT	MW	236.27
DMUZIDT	FM	C15H12N2O
DMUZIDT	IC	InChI=1S/C15H12N2O/c1-18-14-3-2-12-8-13(10-17-15(12)9-14)11-4-6-16-7-5-11/h2-10H,1H3
DMUZIDT	CS	COC1=CC2=NC=C(C=C2C=C1)C3=CC=NC=C3
DMUZIDT	IK	NGPCGERQDPJHQQ-UHFFFAOYSA-N
DMUZIDT	IU	7-methoxy-3-pyridin-4-ylquinoline
DMUZIDT	DE	Discovery agent

DM9QKLC	ID	DM9QKLC
DM9QKLC	DN	7-Methoxy-3-thiophen-3-yl-quinoline
DM9QKLC	HS	Investigative
DM9QKLC	SN	CHEMBL68185; 7-methoxy-3-thiophen-3-yl-quinoline; SCHEMBL8500071; ZINC8076
DM9QKLC	DT	Small molecular drug
DM9QKLC	PC	10331922
DM9QKLC	MW	241.31
DM9QKLC	FM	C14H11NOS
DM9QKLC	IC	InChI=1S/C14H11NOS/c1-16-13-3-2-10-6-12(8-15-14(10)7-13)11-4-5-17-9-11/h2-9H,1H3
DM9QKLC	CS	COC1=CC2=NC=C(C=C2C=C1)C3=CSC=C3
DM9QKLC	IK	AOLUUEDZXBVWED-UHFFFAOYSA-N
DM9QKLC	IU	7-methoxy-3-thiophen-3-ylquinoline
DM9QKLC	DE	Discovery agent

DMNFIZD	ID	DMNFIZD
DMNFIZD	DN	7-Methoxy-4-morpholin-4-yl-chromen-2-one
DMNFIZD	HS	Investigative
DMNFIZD	SN	CHEMBL177241; 7-methoxy-4-morpholin-4-yl-chromen-2-one; BDBM50159670
DMNFIZD	DT	Small molecular drug
DMNFIZD	PC	11357448
DMNFIZD	MW	261.269
DMNFIZD	FM	C14H15NO4
DMNFIZD	IC	InChI=1S/C14H15NO4/c1-17-10-2-3-11-12(15-4-6-18-7-5-15)9-14(16)19-13(11)8-10/h2-3,8-9H,4-7H2,1H3
DMNFIZD	CS	COC1=CC2=C(C=C1)C(=CC(=O)O2)N3CCOCC3
DMNFIZD	IK	DRJQJIYPCHBMLO-UHFFFAOYSA-N
DMNFIZD	IU	7-methoxy-4-morpholin-4-ylchromen-2-one
DMNFIZD	DE	Discovery agent

DMH0UVE	ID	DMH0UVE
DMH0UVE	DN	7-methoxy-8-propionyl-2H-chromen-2-one
DMH0UVE	HS	Investigative
DMH0UVE	SN	CHEMBL1288621; 7-methoxy-8-propionyl-2H-chromen-2-one
DMH0UVE	DT	Small molecular drug
DMH0UVE	PC	52950111
DMH0UVE	MW	232.23
DMH0UVE	FM	C13H12O4
DMH0UVE	IC	InChI=1S/C13H12O4/c1-3-9(14)12-10(16-2)6-4-8-5-7-11(15)17-13(8)12/h4-7H,3H2,1-2H3
DMH0UVE	CS	CCC(=O)C1=C(C=CC2=C1OC(=O)C=C2)OC
DMH0UVE	IK	XQJPTVQKFUWDCL-UHFFFAOYSA-N
DMH0UVE	IU	7-methoxy-8-propanoylchromen-2-one
DMH0UVE	DE	Discovery agent

DMHKMU1	ID	DMHKMU1
DMHKMU1	DN	7-Methoxy-9H-beta-carboline
DMHKMU1	HS	Investigative
DMHKMU1	SN	NORHARMINE; 7-Methoxy-9H-pyrido[3,4-b]indole; 6253-19-6; CHEMBL6470; SCHEMBL4823690; CTK5B5241; DTXSID30431161
DMHKMU1	DT	Small molecular drug
DMHKMU1	PC	9815570
DMHKMU1	MW	198.22
DMHKMU1	FM	C12H10N2O
DMHKMU1	IC	InChI=1S/C12H10N2O/c1-15-8-2-3-9-10-4-5-13-7-12(10)14-11(9)6-8/h2-7,14H,1H3
DMHKMU1	CS	COC1=CC2=C(C=C1)C3=C(N2)C=NC=C3
DMHKMU1	IK	LMDPJJFWLNRVEH-UHFFFAOYSA-N
DMHKMU1	IU	7-methoxy-9H-pyrido[3,4-b]indole
DMHKMU1	CA	CAS 6253-19-6
DMHKMU1	DE	Discovery agent

DMUCJA6	ID	DMUCJA6
DMUCJA6	DN	7-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMUCJA6	HS	Investigative
DMUCJA6	SN	CHEMBL365202; 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7682273; BDBM50155792
DMUCJA6	DT	Small molecular drug
DMUCJA6	PC	15552206
DMUCJA6	MW	144.24
DMUCJA6	FM	C6H12N2S
DMUCJA6	IC	InChI=1S/C6H12N2S/c1-5-4-6(7)8-2-3-9-5/h5H,2-4H2,1H3,(H2,7,8)
DMUCJA6	CS	CC1CC(=NCCS1)N
DMUCJA6	IK	JXQWNOBSLLRHKM-UHFFFAOYSA-N
DMUCJA6	IU	7-methyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMUCJA6	DE	Discovery agent

DM5EQJU	ID	DM5EQJU
DM5EQJU	DN	7-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM5EQJU	HS	Investigative
DM5EQJU	SN	CHEMBL98738; 7-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one; SCHEMBL10758549
DM5EQJU	DT	Small molecular drug
DM5EQJU	PC	13936971
DM5EQJU	MW	199.21
DM5EQJU	FM	C11H9N3O
DM5EQJU	IC	InChI=1S/C11H9N3O/c1-6-2-3-8-7(4-6)5-9-10(12-8)14-11(15)13-9/h2-5H,1H3,(H2,12,13,14,15)
DM5EQJU	CS	CC1=CC2=CC3=C(NC(=O)N3)N=C2C=C1
DM5EQJU	IK	BSAKVJKPJIQKNP-UHFFFAOYSA-N
DM5EQJU	IU	7-methyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DM5EQJU	DE	Discovery agent

DM7LGDC	ID	DM7LGDC
DM7LGDC	DN	7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DM7LGDC	HS	Investigative
DM7LGDC	SN	CHEMBL45620; NSC676188; AC1NV5AM; 7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one; SCHEMBL7920165; ZINC6491122; BDBM50059974; NSC-676188; NCI60_026915; 2-(3-Methylphenyl)-7-methyl-1,8-naphthyridin-4(1H)-one
DM7LGDC	DT	Small molecular drug
DM7LGDC	PC	5468782
DM7LGDC	MW	250.29
DM7LGDC	FM	C16H14N2O
DM7LGDC	IC	InChI=1S/C16H14N2O/c1-10-4-3-5-12(8-10)14-9-15(19)13-7-6-11(2)17-16(13)18-14/h3-9H,1-2H3,(H,17,18,19)
DM7LGDC	CS	CC1=CC(=CC=C1)C2=CC(=O)C3=C(N2)N=C(C=C3)C
DM7LGDC	IK	WHANICGPAJMUTA-UHFFFAOYSA-N
DM7LGDC	IU	7-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DM7LGDC	DE	Discovery agent

DMCV891	ID	DMCV891
DMCV891	DN	7-methyl-2-m-tolylpyrido[2,3-d]pyrimidine
DMCV891	HS	Investigative
DMCV891	SN	CHEMBL238552; 7-methyl-2-m-tolylpyrido[2,3-d]pyrimidine
DMCV891	DT	Small molecular drug
DMCV891	PC	44435026
DMCV891	MW	235.28
DMCV891	FM	C15H13N3
DMCV891	IC	InChI=1S/C15H13N3/c1-10-4-3-5-12(8-10)14-16-9-13-7-6-11(2)17-15(13)18-14/h3-9H,1-2H3
DMCV891	CS	CC1=CC(=CC=C1)C2=NC=C3C=CC(=NC3=N2)C
DMCV891	IK	AHSIQPYQWYRYSS-UHFFFAOYSA-N
DMCV891	IU	7-methyl-2-(3-methylphenyl)pyrido[2,3-d]pyrimidine
DMCV891	DE	Discovery agent

DMJ4G27	ID	DMJ4G27
DMJ4G27	DN	7-methyl-2-phenylpyrido[2,3-d]pyrimidine
DMJ4G27	HS	Investigative
DMJ4G27	SN	CHEMBL394304; 7-methyl-2-phenylpyrido[2,3-d]pyrimidine
DMJ4G27	DT	Small molecular drug
DMJ4G27	PC	44435020
DMJ4G27	MW	221.26
DMJ4G27	FM	C14H11N3
DMJ4G27	IC	InChI=1S/C14H11N3/c1-10-7-8-12-9-15-13(17-14(12)16-10)11-5-3-2-4-6-11/h2-9H,1H3
DMJ4G27	CS	CC1=NC2=NC(=NC=C2C=C1)C3=CC=CC=C3
DMJ4G27	IK	KWVJWWRUSUZAGY-UHFFFAOYSA-N
DMJ4G27	IU	7-methyl-2-phenylpyrido[2,3-d]pyrimidine
DMJ4G27	DE	Discovery agent

DMGB9IE	ID	DMGB9IE
DMGB9IE	DN	7-Methyl-2-propyl-[1,8]naphthyridin-4-ol
DMGB9IE	HS	Investigative
DMGB9IE	SN	CHEMBL103150; 7-Methyl-2-propyl-[1,8]naphthyridin-4-ol; 1,8-Naphthyridin-4-ol, 7-methyl-2-propyl-; BDBM50147877; 718624-73-8
DMGB9IE	DT	Small molecular drug
DMGB9IE	PC	13155595
DMGB9IE	MW	202.25
DMGB9IE	FM	C12H14N2O
DMGB9IE	IC	InChI=1S/C12H14N2O/c1-3-4-9-7-11(15)10-6-5-8(2)13-12(10)14-9/h5-7H,3-4H2,1-2H3,(H,13,14,15)
DMGB9IE	CS	CCCC1=CC(=O)C2=C(N1)N=C(C=C2)C
DMGB9IE	IK	JAFFZYFREVCDTP-UHFFFAOYSA-N
DMGB9IE	IU	7-methyl-2-propyl-1H-1,8-naphthyridin-4-one
DMGB9IE	DE	Discovery agent

DMB9YA8	ID	DMB9YA8
DMB9YA8	DN	7-methyl-2-p-tolyl-4H-chromene-4-thione
DMB9YA8	HS	Investigative
DMB9YA8	SN	CHEMBL592642; 7-methyl-2-p-tolyl-4H-chromene-4-thione
DMB9YA8	DT	Small molecular drug
DMB9YA8	PC	46232005
DMB9YA8	MW	266.4
DMB9YA8	FM	C17H14OS
DMB9YA8	IC	InChI=1S/C17H14OS/c1-11-3-6-13(7-4-11)15-10-17(19)14-8-5-12(2)9-16(14)18-15/h3-10H,1-2H3
DMB9YA8	CS	CC1=CC=C(C=C1)C2=CC(=S)C3=C(O2)C=C(C=C3)C
DMB9YA8	IK	LDIMKSQQZFWQLA-UHFFFAOYSA-N
DMB9YA8	IU	7-methyl-2-(4-methylphenyl)chromene-4-thione
DMB9YA8	DE	Discovery agent

DMZKO14	ID	DMZKO14
DMZKO14	DN	7-Methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine
DMZKO14	HS	Investigative
DMZKO14	SN	TCMDC-139863; 7-Methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; CHEMBL174414; 7-methylpyrrolo[3,2-f]quinazoline-1,3-diamine; AC1LAG62; SCHEMBL11612134; 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine, 7-methyl-; WSISEVQVCUARDZ-UHFFFAOYSA-N; BDBM50049900; 65796-02-3
DMZKO14	DT	Small molecular drug
DMZKO14	PC	467889
DMZKO14	MW	213.24
DMZKO14	FM	C11H11N5
DMZKO14	IC	InChI=1S/C11H11N5/c1-16-5-4-6-8(16)3-2-7-9(6)10(12)15-11(13)14-7/h2-5H,1H3,(H4,12,13,14,15)
DMZKO14	CS	CN1C=CC2=C1C=CC3=C2C(=NC(=N3)N)N
DMZKO14	IK	WSISEVQVCUARDZ-UHFFFAOYSA-N
DMZKO14	IU	7-methylpyrrolo[3,2-f]quinazoline-1,3-diamine
DMZKO14	DE	Discovery agent

DMMENDC	ID	DMMENDC
DMMENDC	DN	7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (3,5-BIS-TRIFLUOROMETHYL-BENZYL)-METHYL-AMIDE (STRUCTURAL MIX)
DMMENDC	HS	Investigative
DMMENDC	SN	CHEMBL107172; SCHEMBL7850311; TAK-622; BDBM50030589; N-Methyl-N-[3,5-bis(trifluoromethyl)benzyl]-7-methyl-8-oxo-5-(4-methylphenyl)-1,7-naphthyridine-6-carboxamide
DMMENDC	DT	Small molecular drug
DMMENDC	PC	9871754
DMMENDC	MW	533.5
DMMENDC	FM	C27H21F6N3O2
DMMENDC	IC	InChI=1S/C27H21F6N3O2/c1-15-6-8-17(9-7-15)21-20-5-4-10-34-22(20)24(37)36(3)23(21)25(38)35(2)14-16-11-18(26(28,29)30)13-19(12-16)27(31,32)33/h4-13H,14H2,1-3H3
DMMENDC	CS	CC1=CC=C(C=C1)C2=C(N(C(=O)C3=C2C=CC=N3)C)C(=O)N(C)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMMENDC	IK	GIAQQXUCTFYCHO-UHFFFAOYSA-N
DMMENDC	IU	N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide
DMMENDC	DE	Discovery agent

DMO0RGL	ID	DMO0RGL
DMO0RGL	DN	7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(R)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX)
DMO0RGL	HS	Investigative
DMO0RGL	SN	CHEMBL135572; 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(R)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX); BDBM50067521; 5-(4-Methylphenyl)-7,N-dimethyl-N-[(R)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl]-8-oxo-7,8-dihydro-1,7-naphthyridine-6-carboxamide; 7-Methyl-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid (S)-[(R)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide
DMO0RGL	DT	Small molecular drug
DMO0RGL	PC	10650263
DMO0RGL	MW	547.5
DMO0RGL	FM	C28H23F6N3O2
DMO0RGL	IC	InChI=1S/C28H23F6N3O2/c1-15-7-9-17(10-8-15)22-21-6-5-11-35-23(21)25(38)37(4)24(22)26(39)36(3)16(2)18-12-19(27(29,30)31)14-20(13-18)28(32,33)34/h5-14,16H,1-4H3/t16-/m1/s1
DMO0RGL	CS	CC1=CC=C(C=C1)C2=C(N(C(=O)C3=C2C=CC=N3)C)C(=O)N(C)[C@H](C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMO0RGL	IK	TTZWDLZPHOQUAU-MRXNPFEDSA-N
DMO0RGL	IU	N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide
DMO0RGL	DE	Discovery agent

DMOAJ0E	ID	DMOAJ0E
DMOAJ0E	DN	7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(S)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX)
DMOAJ0E	HS	Investigative
DMOAJ0E	SN	CHEMBL336589; 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(S)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX); BDBM50067516; 7-Methyl-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid (S)-[(S)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide; 7-Methyl-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid (R)-[(S)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide
DMOAJ0E	DT	Small molecular drug
DMOAJ0E	PC	10053205
DMOAJ0E	MW	547.5
DMOAJ0E	FM	C28H23F6N3O2
DMOAJ0E	IC	InChI=1S/C28H23F6N3O2/c1-15-7-9-17(10-8-15)22-21-6-5-11-35-23(21)25(38)37(4)24(22)26(39)36(3)16(2)18-12-19(27(29,30)31)14-20(13-18)28(32,33)34/h5-14,16H,1-4H3/t16-/m0/s1
DMOAJ0E	CS	CC1=CC=C(C=C1)C2=C(N(C(=O)C3=C2C=CC=N3)C)C(=O)N(C)[C@@H](C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMOAJ0E	IK	TTZWDLZPHOQUAU-INIZCTEOSA-N
DMOAJ0E	IU	N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide
DMOAJ0E	DE	Discovery agent

DME39U2	ID	DME39U2
DME39U2	DN	7-Methyl-Gpppa
DME39U2	HS	Investigative
DME39U2	DT	Small molecular drug
DME39U2	PC	135415790
DME39U2	MW	787.4
DME39U2	FM	C21H30N10O17P3+
DME39U2	IC	InChI=1S/C21H29N10O17P3/c1-29-6-31(17-10(29)18(36)28-21(23)27-17)20-14(35)12(33)8(46-20)3-44-50(39,40)48-51(41,42)47-49(37,38)43-2-7-11(32)13(34)19(45-7)30-5-26-9-15(22)24-4-25-16(9)30/h4-8,11-14,19-20,32-35H,2-3H2,1H3,(H7-,22,23,24,25,27,28,36,37,38,39,40,41,42)/p+1/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1
DME39U2	CS	CN1C=[N+](C2=C1C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O
DME39U2	IK	QQOHNVHGNZYSBP-XPWFQUROSA-O
DME39U2	IU	[[(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DME39U2	DE	Discovery agent

DMCGNUO	ID	DMCGNUO
DMCGNUO	DN	7-Methyl-Guanosine-5'-Triphosphate
DMCGNUO	HS	Investigative
DMCGNUO	DT	Small molecular drug
DMCGNUO	PC	135419182
DMCGNUO	MW	538.22
DMCGNUO	FM	C11H19N5O14P3+
DMCGNUO	IC	InChI=1S/C11H18N5O14P3/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(28-10)2-27-32(23,24)30-33(25,26)29-31(20,21)22/h3-4,6-7,10,17-18H,2H2,1H3,(H6-,12,13,14,19,20,21,22,23,24,25,26)/p+1/t4-,6-,7-,10-/m1/s1
DMCGNUO	CS	CN1C=[N+](C2=C1C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMCGNUO	IK	DKVRNHPCAOHRSI-KQYNXXCUSA-O
DMCGNUO	IU	[[(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMCGNUO	CB	CHEBI:50226
DMCGNUO	DE	Discovery agent

DMBDFP2	ID	DMBDFP2
DMBDFP2	DN	7-m-tolyl-1,6-naphthyridine
DMBDFP2	HS	Investigative
DMBDFP2	SN	CHEMBL238388; 7-m-tolyl-1,6-naphthyridine
DMBDFP2	DT	Small molecular drug
DMBDFP2	PC	44434721
DMBDFP2	MW	220.27
DMBDFP2	FM	C15H12N2
DMBDFP2	IC	InChI=1S/C15H12N2/c1-11-4-2-5-12(8-11)14-9-15-13(10-17-14)6-3-7-16-15/h2-10H,1H3
DMBDFP2	CS	CC1=CC(=CC=C1)C2=NC=C3C=CC=NC3=C2
DMBDFP2	IK	QFKQBMHTZFGQHK-UHFFFAOYSA-N
DMBDFP2	IU	7-(3-methylphenyl)-1,6-naphthyridine
DMBDFP2	DE	Discovery agent

DMX3UV1	ID	DMX3UV1
DMX3UV1	DN	7-Nitro-1,2,3,4-tetrahydro-isoquinoline
DMX3UV1	HS	Investigative
DMX3UV1	SN	7-Nitro-1,2,3,4-tetrahydroisoquinoline; 42923-79-5; 7-Nitro-1,2,3,4-tetrahydro-isoquinoline; 1,2,3,4-Tetrahydro-7-nitroisoquinoline; CHEMBL281289; YPRWYZSUBZXORL-UHFFFAOYSA-N; ISOQUINOLINE, 1,2,3,4-TETRAHYDRO-7-NITRO-; N90100; 7-nitrotetrahydroisoquinoline; SCHEMBL324460; 7-Nitro-tetrahydroisoquinoline; AC1O502M; SCHEMBL10066165; CTK4I6796; DTXSID30423728; MolPort-003-886-230; BCP09681; KS-00000DK2; ACT10738; CS-D0150; ANW-50594; ZINC13686846; BDBM50072991; AKOS005259136; QC-5046; AB21318; RP03102; MCULE-4384372233; AC-9598
DMX3UV1	DT	Small molecular drug
DMX3UV1	PC	6424833
DMX3UV1	MW	178.19
DMX3UV1	FM	C9H10N2O2
DMX3UV1	IC	InChI=1S/C9H10N2O2/c12-11(13)9-2-1-7-3-4-10-6-8(7)5-9/h1-2,5,10H,3-4,6H2
DMX3UV1	CS	C1CNCC2=C1C=CC(=C2)[N+](=O)[O-]
DMX3UV1	IK	YPRWYZSUBZXORL-UHFFFAOYSA-N
DMX3UV1	IU	7-nitro-1,2,3,4-tetrahydroisoquinoline
DMX3UV1	CA	CAS 42923-79-5
DMX3UV1	DE	Discovery agent

DMW4XKQ	ID	DMW4XKQ
DMW4XKQ	DN	7-nitro-1H-indazole
DMW4XKQ	HS	Investigative
DMW4XKQ	SN	7-Nitroindazole; 7-nitroindazole; 7-Nitro-1H-indazole; 2942-42-9; 1H-Indazole, 7-nitro-; 7-nitro-indazole; 7-NI; UNII-UX0N37CMVH; CCRIS 3309; EINECS 220-934-4; NSC 72843; UX0N37CMVH; BRN 0006809; MLS000028452; CHEMBL247378; PQCAUHUKTBHUSA-UHFFFAOYSA-N; MFCD00022789; SMR000058266; 7NI; 2h-indazole,7-nitro-; SR-01000075512; 7- Nitroindazole; 7-Nitroisoindazole; Tocris-0602; PubChem14009; AC1L1CGU; Spectrum3_001980; Spectrum2_001715; Opera_ID_1690; Lopac-N-7778; ACMC-209h8w; AC1Q1Y3U; 7-Nitroindazole, &gt; NCIOpen2_000477; Lopac0_000839; BSPBio_003580
DMW4XKQ	DT	Small molecular drug
DMW4XKQ	PC	1893
DMW4XKQ	MW	163.13
DMW4XKQ	FM	C7H5N3O2
DMW4XKQ	IC	InChI=1S/C7H5N3O2/c11-10(12)6-3-1-2-5-4-8-9-7(5)6/h1-4H,(H,8,9)
DMW4XKQ	CS	C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2
DMW4XKQ	IK	PQCAUHUKTBHUSA-UHFFFAOYSA-N
DMW4XKQ	IU	7-nitro-1H-indazole
DMW4XKQ	CA	CAS 2942-42-9
DMW4XKQ	DE	Discovery agent

DMGLWOM	ID	DMGLWOM
DMGLWOM	DN	7-Nitroindazole-2-Carboxamidine
DMGLWOM	HS	Investigative
DMGLWOM	SN	7-nitroindazole-2-carboxamidine; 7-nitro-2h-indazole-2-carboximidamide; 7I2; AC1L1CGX; SCHEMBL4315825; CTK5I3867; 7-nitroindazole-2-carboximidamide; 7-Nitro-2H-indazole-2-carboxamidine
DMGLWOM	DT	Small molecular drug
DMGLWOM	PC	1894
DMGLWOM	MW	205.17
DMGLWOM	FM	C8H7N5O2
DMGLWOM	IC	InChI=1S/C8H7N5O2/c9-8(10)12-4-5-2-1-3-6(13(14)15)7(5)11-12/h1-4H,(H3,9,10)
DMGLWOM	CS	C1=CC2=CN(N=C2C(=C1)[N+](=O)[O-])C(=N)N
DMGLWOM	IK	GFYAZUABYOOPCN-UHFFFAOYSA-N
DMGLWOM	IU	7-nitroindazole-2-carboximidamide
DMGLWOM	DE	Discovery agent

DM2403T	ID	DM2403T
DM2403T	DN	7n-Methyl-8-Hydroguanosine-5'-Diphosphate
DM2403T	HS	Investigative
DM2403T	DT	Small molecular drug
DM2403T	PC	135509116
DM2403T	MW	459.24
DM2403T	FM	C11H19N5O11P2
DM2403T	IC	InChI=1S/C11H19N5O11P2/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(26-10)2-25-29(23,24)27-28(20,21)22/h4,6-7,10,17-18H,2-3H2,1H3,(H,23,24)(H2,20,21,22)(H3,12,13,14,19)/t4-,6-,7-,10-/m1/s1
DM2403T	CS	CN1CN(C2=C1C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O
DM2403T	IK	QQODJOAVWUWVHJ-KQYNXXCUSA-N
DM2403T	IU	[(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1,8-dihydropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DM2403T	CA	CAS 104809-16-7
DM2403T	CB	CHEBI:43977
DM2403T	DE	Discovery agent

DM8IY3D	ID	DM8IY3D
DM8IY3D	DN	7-O-b-D-Glucopyranosyl-a-homonojirimycin
DM8IY3D	HS	Investigative
DM8IY3D	SN	CHEMBL478209; NSC630254; 104343-33-1; MDL-25637; 7-O-b-D-Glucopyranosyl-a-homonojirimycin; AC1L9X0M; SCHEMBL305712; BDBM50263042; 2,6-Dideoxy-2,6-imino-7-O-.beta.-D-glucopyranosyl-D-glycero-L-gulo-heptitol hydrochloride hydrate; (2R,3R,4S,5S,6R)-2-(hydroxymethyl)-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]piperidine-3,4,5-triol; .beta.-D-glucopyranoside, [(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-piperidinyl]methyl
DM8IY3D	DT	Small molecular drug
DM8IY3D	PC	457676
DM8IY3D	MW	355.34
DM8IY3D	FM	C13H25NO10
DM8IY3D	IC	InChI=1S/C13H25NO10/c15-1-4-7(17)10(20)8(18)5(14-4)3-23-13-12(22)11(21)9(19)6(2-16)24-13/h4-22H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11+,12-,13-/m1/s1
DM8IY3D	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](N1)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O
DM8IY3D	IK	VCIPQQCYKMORDY-KBYFLBCBSA-N
DM8IY3D	IU	(2R,3R,4S,5S,6R)-2-(hydroxymethyl)-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]piperidine-3,4,5-triol
DM8IY3D	CA	CAS 104343-33-1
DM8IY3D	DE	Discovery agent

DMJZR0A	ID	DMJZR0A
DMJZR0A	DN	7-Oxo-7H-dibenzo[de,g]quinoline
DMJZR0A	HS	Investigative
DMJZR0A	SN	CHEMBL559502; 38750-39-9; 7-Oxo-7H-dibenzo[de,g]quinoline; NSC296570; AC1L6XTV; CTK1C6162; DTXSID80315725; 7H-Dibenzo[de,g]quinolin-7-one; 7H-Dibenzo[de,g]quinoline-7-one; BDBM50293443
DMJZR0A	DT	Small molecular drug
DMJZR0A	PC	326183
DMJZR0A	MW	231.25
DMJZR0A	FM	C16H9NO
DMJZR0A	IC	InChI=1S/C16H9NO/c18-16-13-6-2-1-5-11(13)12-7-3-4-10-8-9-17-15(16)14(10)12/h1-9H
DMJZR0A	CS	C1=CC=C2C(=C1)C3=CC=CC4=C3C(=NC=C4)C2=O
DMJZR0A	IK	GHWKWAMIXPOYPG-UHFFFAOYSA-N
DMJZR0A	IU	10-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2,4,6,9,11,13(17),14-octaen-8-one
DMJZR0A	CA	CAS 38750-39-9
DMJZR0A	DE	Discovery agent

DM8Q267	ID	DM8Q267
DM8Q267	DN	7-phenethoxy-2H-chromen-2-one
DM8Q267	HS	Investigative
DM8Q267	SN	CHEMBL567544; 7-phenethoxy-2H-chromen-2-one
DM8Q267	DT	Small molecular drug
DM8Q267	PC	45485279
DM8Q267	MW	250.29
DM8Q267	FM	C17H14O2
DM8Q267	IC	InChI=1S/C17H14O2/c18-17-11-10-15-9-8-14(12-16(15)19-17)7-6-13-4-2-1-3-5-13/h1-5,8-12H,6-7H2
DM8Q267	CS	C1=CC=C(C=C1)CCC2=CC3=C(C=C2)C=CC(=O)O3
DM8Q267	IK	FQWWPSNGCTYUHH-UHFFFAOYSA-N
DM8Q267	IU	7-(2-phenylethyl)chromen-2-one
DM8Q267	DE	Discovery agent

DM1FL5G	ID	DM1FL5G
DM1FL5G	DN	7-Phenoxy-heptanoic acid hydroxyamide
DM1FL5G	HS	Investigative
DM1FL5G	SN	7-Phenoxy-heptanoic acid hydroxyamide; CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid
DM1FL5G	DT	Small molecular drug
DM1FL5G	PC	25798548
DM1FL5G	MW	237.29
DM1FL5G	FM	C13H19NO3
DM1FL5G	IC	InChI=1S/C13H19NO3/c15-13(14-16)10-6-1-2-7-11-17-12-8-4-3-5-9-12/h3-5,8-9,16H,1-2,6-7,10-11H2,(H,14,15)
DM1FL5G	CS	C1=CC=C(C=C1)OCCCCCCC(=O)NO
DM1FL5G	IK	IHTQKNINBYXIDN-UHFFFAOYSA-N
DM1FL5G	IU	N-hydroxy-7-phenoxyheptanamide
DM1FL5G	DE	Discovery agent

DMQMRGD	ID	DMQMRGD
DMQMRGD	DN	7-Phenyl-1-(1,3,4-thiadiazol-2-yl)-heptan-1-one
DMQMRGD	HS	Investigative
DMQMRGD	SN	CHEMBL477371; SCHEMBL2162232; 7-Phenyl-1-(1,3,4-thiadiazol-2-yl)-heptan-1-one
DMQMRGD	DT	Small molecular drug
DMQMRGD	PC	24951315
DMQMRGD	MW	274.4
DMQMRGD	FM	C15H18N2OS
DMQMRGD	IC	InChI=1S/C15H18N2OS/c18-14(15-17-16-12-19-15)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMQMRGD	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NN=CS2
DMQMRGD	IK	QUVXRHLPGVMXRU-UHFFFAOYSA-N
DMQMRGD	IU	7-phenyl-1-(1,3,4-thiadiazol-2-yl)heptan-1-one
DMQMRGD	DE	Discovery agent

DMEABGI	ID	DMEABGI
DMEABGI	DN	7-Phenyl-1-(2H-tetrazol-5-yl)-heptan-1-one
DMEABGI	HS	Investigative
DMEABGI	SN	CHEMBL456450; 7-Phenyl-1-(2H-tetrazol-5-yl)-heptan-1-one; SCHEMBL2161929; ZINC40380109; BDBM50274982
DMEABGI	DT	Small molecular drug
DMEABGI	PC	24950683
DMEABGI	MW	258.32
DMEABGI	FM	C14H18N4O
DMEABGI	IC	InChI=1S/C14H18N4O/c19-13(14-15-17-18-16-14)11-7-2-1-4-8-12-9-5-3-6-10-12/h3,5-6,9-10H,1-2,4,7-8,11H2,(H,15,16,17,18)
DMEABGI	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NNN=N2
DMEABGI	IK	JVOYAZCLPXVADL-UHFFFAOYSA-N
DMEABGI	IU	7-phenyl-1-(2H-tetrazol-5-yl)heptan-1-one
DMEABGI	DE	Discovery agent

DM62PAU	ID	DM62PAU
DM62PAU	DN	7-phenyl-1-(4-phenyloxazol-2-yl)heptan-1-one
DM62PAU	HS	Investigative
DM62PAU	SN	CHEMBL460316; 7-phenyl-1-(4-phenyloxazol-2-yl)heptan-1-one; SCHEMBL2162579
DM62PAU	DT	Small molecular drug
DM62PAU	PC	44554614
DM62PAU	MW	333.4
DM62PAU	FM	C22H23NO2
DM62PAU	IC	InChI=1S/C22H23NO2/c24-21(16-10-2-1-5-11-18-12-6-3-7-13-18)22-23-20(17-25-22)19-14-8-4-9-15-19/h3-4,6-9,12-15,17H,1-2,5,10-11,16H2
DM62PAU	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C3=CC=CC=C3
DM62PAU	IK	XOLGPHAVLXMSGU-UHFFFAOYSA-N
DM62PAU	IU	7-phenyl-1-(4-phenyl-1,3-oxazol-2-yl)heptan-1-one
DM62PAU	DE	Discovery agent

DM9SGBW	ID	DM9SGBW
DM9SGBW	DN	7-phenyl-1-(5-phenyloxazol-2-yl)heptan-1-one
DM9SGBW	HS	Investigative
DM9SGBW	SN	CHEMBL173992; 7-phenyl-1-(5-phenyloxazol-2-yl)heptan-1-one; 7-phenyl-1-(5-phenyl-1,3-oxazol-2-yl)heptan-1-one; BDBM50163187
DM9SGBW	DT	Small molecular drug
DM9SGBW	PC	11279040
DM9SGBW	MW	333.4
DM9SGBW	FM	C22H23NO2
DM9SGBW	IC	InChI=1S/C22H23NO2/c24-20(16-10-2-1-5-11-18-12-6-3-7-13-18)22-23-17-21(25-22)19-14-8-4-9-15-19/h3-4,6-9,12-15,17H,1-2,5,10-11,16H2
DM9SGBW	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=C(O2)C3=CC=CC=C3
DM9SGBW	IK	GEHXWVPLQWJJQM-UHFFFAOYSA-N
DM9SGBW	IU	7-phenyl-1-(5-phenyl-1,3-oxazol-2-yl)heptan-1-one
DM9SGBW	DE	Discovery agent

DMG1PNX	ID	DMG1PNX
DMG1PNX	DN	7-Phenyl-1-(pyridazin-3-yl)-heptan-1-one
DMG1PNX	HS	Investigative
DMG1PNX	SN	CHEMBL455556; 7-Phenyl-1-(pyridazin-3-yl)-heptan-1-one; SCHEMBL2161875; BDBM50262479
DMG1PNX	DT	Small molecular drug
DMG1PNX	PC	24951319
DMG1PNX	MW	268.35
DMG1PNX	FM	C17H20N2O
DMG1PNX	IC	InChI=1S/C17H20N2O/c20-17(16-12-8-14-18-19-16)13-7-2-1-4-9-15-10-5-3-6-11-15/h3,5-6,8,10-12,14H,1-2,4,7,9,13H2
DMG1PNX	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NN=CC=C2
DMG1PNX	IK	DXGZKZUTNHLJNE-UHFFFAOYSA-N
DMG1PNX	IU	7-phenyl-1-pyridazin-3-ylheptan-1-one
DMG1PNX	DE	Discovery agent

DMLHI5T	ID	DMLHI5T
DMLHI5T	DN	7-Phenyl-1-(thiazol-2-yl)-heptan-1-one
DMLHI5T	HS	Investigative
DMLHI5T	SN	CHEMBL468221; 7-Phenyl-1-(thiazol-2-yl)-heptan-1-one; SCHEMBL2161939
DMLHI5T	DT	Small molecular drug
DMLHI5T	PC	24951160
DMLHI5T	MW	273.4
DMLHI5T	FM	C16H19NOS
DMLHI5T	IC	InChI=1S/C16H19NOS/c18-15(16-17-12-13-19-16)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,12-13H,1-2,4,7-8,11H2
DMLHI5T	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=CS2
DMLHI5T	IK	BBVVJTRLCDWSMU-UHFFFAOYSA-N
DMLHI5T	IU	7-phenyl-1-(1,3-thiazol-2-yl)heptan-1-one
DMLHI5T	DE	Discovery agent

DMEDOFB	ID	DMEDOFB
DMEDOFB	DN	7-phenylethoxy-2-morpholin-4-yl-chromen-4-one
DMEDOFB	HS	Investigative
DMEDOFB	SN	CHEMBL199127; 7-phenylethoxy-2-morpholin-4-yl-chromen-4-one
DMEDOFB	DT	Small molecular drug
DMEDOFB	PC	11624481
DMEDOFB	MW	351.4
DMEDOFB	FM	C21H21NO4
DMEDOFB	IC	InChI=1S/C21H21NO4/c23-19-15-21(22-9-12-24-13-10-22)26-20-14-17(6-7-18(19)20)25-11-8-16-4-2-1-3-5-16/h1-7,14-15H,8-13H2
DMEDOFB	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)OCCC4=CC=CC=C4
DMEDOFB	IK	KIOBMXIHRJGBLA-UHFFFAOYSA-N
DMEDOFB	IU	2-morpholin-4-yl-7-(2-phenylethoxy)chromen-4-one
DMEDOFB	DE	Discovery agent

DM1WJFR	ID	DM1WJFR
DM1WJFR	DN	7-Phenyl-naphthalen-2-ol
DM1WJFR	HS	Investigative
DM1WJFR	SN	7-Phenyl-naphthalen-2-ol; CHEMBL194718; 7-Phenyl-2-naphthol; 7-Phenylnaphthalene-2-ol; SCHEMBL5981104; MLFRZWHPLMDWES-UHFFFAOYSA-N; BDBM50168338
DM1WJFR	DT	Small molecular drug
DM1WJFR	PC	11458674
DM1WJFR	MW	220.26
DM1WJFR	FM	C16H12O
DM1WJFR	IC	InChI=1S/C16H12O/c17-16-9-8-13-6-7-14(10-15(13)11-16)12-4-2-1-3-5-12/h1-11,17H
DM1WJFR	CS	C1=CC=C(C=C1)C2=CC3=C(C=C2)C=CC(=C3)O
DM1WJFR	IK	MLFRZWHPLMDWES-UHFFFAOYSA-N
DM1WJFR	IU	7-phenylnaphthalen-2-ol
DM1WJFR	DE	Discovery agent

DMSBJ4M	ID	DMSBJ4M
DMSBJ4M	DN	7-phenyloxyethoxy-2-morpholin-4-yl-chromen-4-one
DMSBJ4M	HS	Investigative
DMSBJ4M	SN	CHEMBL372804; 7-phenyloxyethoxy-2-morpholin-4-yl-chromen-4-one; SCHEMBL9535095
DMSBJ4M	DT	Small molecular drug
DMSBJ4M	PC	11566823
DMSBJ4M	MW	367.4
DMSBJ4M	FM	C21H21NO5
DMSBJ4M	IC	InChI=1S/C21H21NO5/c23-19-15-21(22-8-10-24-11-9-22)27-20-14-17(6-7-18(19)20)26-13-12-25-16-4-2-1-3-5-16/h1-7,14-15H,8-13H2
DMSBJ4M	CS	C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)OCCOC4=CC=CC=C4
DMSBJ4M	IK	WZUWDKBMBHSVAZ-UHFFFAOYSA-N
DMSBJ4M	IU	2-morpholin-4-yl-7-(2-phenoxyethoxy)chromen-4-one
DMSBJ4M	DE	Discovery agent

DM19I62	ID	DM19I62
DM19I62	DN	7-Phloroethol
DM19I62	HS	Investigative
DM19I62	SN	7-Phloroeckol; 7-Phloroethol; UNII-97GCC12YF0; CHEMBL456228; 97GCC12YF0; CHEBI:65790; 4-(3,5-dihydroxyphenoxy)-8-(2,4,6-trihydroxyphenoxy)oxanthrene-1,3,6-triol; 1-(3',5'-Dihydroxyphenoxy)-7-(2'',4'',6''-trihydroxyphenoxy)-2,4,9-trihydroxydibenzo-1,4-dioxin; 7-Phloroglucinoleckol; SCHEMBL10271928; BDBM50276826; 4-(3,5-Dihydroxyphenoxy)-8-(2,4,6-trihydroxyphenoxy)dibenzo(b,E)(1,4)dioxin-1,3,6-triol; [(2,4,9-Trihydroxydibenzo-p-dioxin-1,7-diyl)dioxydibenzene]-2',3,4',5,6'-pentol; Dibenzo(b,E)(1,4)dioxin-1,3,6-triol, 4-(3,
DM19I62	DT	Small molecular drug
DM19I62	PC	10480940
DM19I62	MW	496.4
DM19I62	FM	C24H16O12
DM19I62	IC	InChI=1S/C24H16O12/c25-9-1-10(26)3-12(2-9)34-22-17(31)8-18(32)23-24(22)36-21-16(30)6-13(7-19(21)35-23)33-20-14(28)4-11(27)5-15(20)29/h1-8,25-32H
DM19I62	CS	C1=C(C=C(C=C1O)OC2=C(C=C(C3=C2OC4=C(C=C(C=C4O3)OC5=C(C=C(C=C5O)O)O)O)O)O)O
DM19I62	IK	JLEVVQRBEATTCM-UHFFFAOYSA-N
DM19I62	IU	4-(3,5-dihydroxyphenoxy)-8-(2,4,6-trihydroxyphenoxy)dibenzo-p-dioxin-1,3,6-triol
DM19I62	CA	CAS 662165-35-7
DM19I62	CB	CHEBI:65790
DM19I62	DE	Discovery agent

DMO8WB2	ID	DMO8WB2
DMO8WB2	DN	7-propoxy-2-(morpholin-4-yl)-chromen-4-one
DMO8WB2	HS	Investigative
DMO8WB2	SN	CHEMBL426099; 7-propoxy-2-(morpholin-4-yl)-chromen-4-one; SCHEMBL3537201
DMO8WB2	DT	Small molecular drug
DMO8WB2	PC	11630658
DMO8WB2	MW	289.33
DMO8WB2	FM	C16H19NO4
DMO8WB2	IC	InChI=1S/C16H19NO4/c1-2-7-20-12-3-4-13-14(18)11-16(21-15(13)10-12)17-5-8-19-9-6-17/h3-4,10-11H,2,5-9H2,1H3
DMO8WB2	CS	CCCOC1=CC2=C(C=C1)C(=O)C=C(O2)N3CCOCC3
DMO8WB2	IK	RXAXOVGTCLFYCQ-UHFFFAOYSA-N
DMO8WB2	IU	2-morpholin-4-yl-7-propoxychromen-4-one
DMO8WB2	DE	Discovery agent

DMD5CB6	ID	DMD5CB6
DMD5CB6	DN	7-propoxy-2H-chromen-2-one
DMD5CB6	HS	Investigative
DMD5CB6	SN	7-Propoxy-chromen-2-one; 7-propoxy-2H-chromen-2-one; 6093-73-8; 7-PROPOXYCOUMARIN; 2H-1-Benzopyran-2-one, 7-propoxy-; CHEMBL568516; 7-Propoxy-2H-1-benzopyran-2-one; AC1LUIIJ; 7-propoxychromen-2-one; CBMicro_001394; SCHEMBL6690398; CTK6E6140; DTXSID90209762; MolPort-000-158-388; ZINC1893420; SMSF0015515; BDBM50303501; STK829267; AKOS001042495; MCULE-7191883680; CB03116; RP26084; KB-46577; CJ-30724; BIM-0001595.P001; DB-072872; FT-0687986
DMD5CB6	DT	Small molecular drug
DMD5CB6	PC	1631814
DMD5CB6	MW	204.22
DMD5CB6	FM	C12H12O3
DMD5CB6	IC	InChI=1S/C12H12O3/c1-2-7-14-10-5-3-9-4-6-12(13)15-11(9)8-10/h3-6,8H,2,7H2,1H3
DMD5CB6	CS	CCCOC1=CC2=C(C=C1)C=CC(=O)O2
DMD5CB6	IK	FCCCOTWGEKNZMI-UHFFFAOYSA-N
DMD5CB6	IU	7-propoxychromen-2-one
DMD5CB6	CA	CAS 6093-73-8
DMD5CB6	DE	Discovery agent

DM4I0B1	ID	DM4I0B1
DM4I0B1	DN	7-Propyl-7H-adenine
DM4I0B1	HS	Investigative
DM4I0B1	SN	CHEMBL449108; 7-Propyl-7H-adenine; 7H-Purin-6-amine, 7-propyl-; BDBM50256892
DM4I0B1	DT	Small molecular drug
DM4I0B1	PC	44572291
DM4I0B1	MW	177.21
DM4I0B1	FM	C8H11N5
DM4I0B1	IC	InChI=1S/C8H11N5/c1-2-3-13-5-12-8-6(13)7(9)10-4-11-8/h4-5H,2-3H2,1H3,(H2,9,10,11)
DM4I0B1	CS	CCCN1C=NC2=NC=NC(=C21)N
DM4I0B1	IK	RKILQGBFRKICCA-UHFFFAOYSA-N
DM4I0B1	IU	7-propylpurin-6-amine
DM4I0B1	DE	Discovery agent

DMW8XME	ID	DMW8XME
DMW8XME	DN	7-Pyridin-3-yl-2H-1,4-benzothiazin-3(4H)-one
DMW8XME	HS	Investigative
DMW8XME	SN	CHEMBL509971; 7-Pyridin-3-yl-2H-1,4-benzothiazin-3(4H)-one; SCHEMBL1119417
DMW8XME	DT	Small molecular drug
DMW8XME	PC	25180103
DMW8XME	MW	242.3
DMW8XME	FM	C13H10N2OS
DMW8XME	IC	InChI=1S/C13H10N2OS/c16-13-8-17-12-6-9(3-4-11(12)15-13)10-2-1-5-14-7-10/h1-7H,8H2,(H,15,16)
DMW8XME	CS	C1C(=O)NC2=C(S1)C=C(C=C2)C3=CN=CC=C3
DMW8XME	IK	QVFBOIKMDDLOQP-UHFFFAOYSA-N
DMW8XME	IU	7-pyridin-3-yl-4H-1,4-benzothiazin-3-one
DMW8XME	DE	Discovery agent

DMQJ26K	ID	DMQJ26K
DMQJ26K	DN	7-Pyrrolidin-1-yl-hept-5-yn-2-one
DMQJ26K	HS	Investigative
DMQJ26K	SN	CHEMBL167419; 7-pyrrolidin-1-ylhept-5-yn-2-one; AC1Q5CHA; AC1L2EX8; BDBM50212578
DMQJ26K	DT	Small molecular drug
DMQJ26K	PC	19814
DMQJ26K	MW	179.26
DMQJ26K	FM	C11H17NO
DMQJ26K	IC	InChI=1S/C11H17NO/c1-11(13)7-3-2-4-8-12-9-5-6-10-12/h3,5-10H2,1H3
DMQJ26K	CS	CC(=O)CCC#CCN1CCCC1
DMQJ26K	IK	DBUFGNBWZXFABF-UHFFFAOYSA-N
DMQJ26K	IU	7-pyrrolidin-1-ylhept-5-yn-2-one
DMQJ26K	DE	Discovery agent

DMSU06X	ID	DMSU06X
DMSU06X	DN	7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30)
DMSU06X	HS	Investigative
DMSU06X	SN	Hemicholinium; 16478-59-4; 2,2'-(Biphenyl)-4,4'-diylbis(2-hydroxy-4,4-dimethylmorpholinium); 2,2'-(4,4'-Biphenylene)bis(2-hydroxy-4,4-dimethylmorpholinium); 2-[4-[4-(2-hydroxy-4,4-dimethylmorpholin-4-ium-2-yl)phenyl]phenyl]-4,4-dimethylmorpholin-4-ium-2-ol; Morpholinium, 2,2'-(4,4'-biphenylene)bis(2-hydroxy-4,4-dimethyl-; Prestwick3_000393; Prestwick0_000393; Prestwick1_000393; Prestwick2_000393; AC1L1G9B; Lopac0_000578; BSPBio_000605; SPBio_002526; CHEMBL268697; BPBio1_000667; GTPL4494; SCHEMBL12638596; 8-amino-5'-deoxy-5'-chloroguanosine
DMSU06X	DT	Small molecular drug
DMSU06X	PC	3585
DMSU06X	MW	414.5
DMSU06X	FM	C24H34N2O4+2
DMSU06X	IC	InChI=1S/C24H34N2O4/c1-25(2)13-15-29-23(27,17-25)21-9-5-19(6-10-21)20-7-11-22(12-8-20)24(28)18-26(3,4)14-16-30-24/h5-12,27-28H,13-18H2,1-4H3/q+2
DMSU06X	CS	C[N+]1(CCOC(C1)(C2=CC=C(C=C2)C3=CC=C(C=C3)C4(C[N+](CCO4)(C)C)O)O)C
DMSU06X	IK	JIWUESGGKYLPPG-UHFFFAOYSA-N
DMSU06X	IU	2-[4-[4-(2-hydroxy-4,4-dimethylmorpholin-4-ium-2-yl)phenyl]phenyl]-4,4-dimethylmorpholin-4-ium-2-ol
DMSU06X	CA	CAS 16478-59-4
DMSU06X	CB	CHEBI:94343
DMSU06X	DE	Discovery agent

DMD7Q1R	ID	DMD7Q1R
DMD7Q1R	DN	7-tert-butyl-9H-carbazole-3-carboxylic acid
DMD7Q1R	HS	Investigative
DMD7Q1R	SN	CHEMBL1171078; 7-tert-butyl-9H-carbazole-3-carboxylic acid
DMD7Q1R	DT	Small molecular drug
DMD7Q1R	PC	46855215
DMD7Q1R	MW	267.32
DMD7Q1R	FM	C17H17NO2
DMD7Q1R	IC	InChI=1S/C17H17NO2/c1-17(2,3)11-5-6-12-13-8-10(16(19)20)4-7-14(13)18-15(12)9-11/h4-9,18H,1-3H3,(H,19,20)
DMD7Q1R	CS	CC(C)(C)C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)C(=O)O
DMD7Q1R	IK	DIDFDNKTXWWCAJ-UHFFFAOYSA-N
DMD7Q1R	IU	7-tert-butyl-9H-carbazole-3-carboxylic acid
DMD7Q1R	DE	Discovery agent

DMMU5SO	ID	DMMU5SO
DMMU5SO	DN	7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline
DMMU5SO	HS	Investigative
DMMU5SO	SN	CHEMBL69378; 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline; ZINC3832255
DMMU5SO	DT	Small molecular drug
DMMU5SO	PC	10083695
DMMU5SO	MW	255.29
DMMU5SO	FM	C14H9NO2S
DMMU5SO	IC	InChI=1S/C14H9NO2S/c1-2-18-7-9(1)11-3-10-4-13-14(17-8-16-13)5-12(10)15-6-11/h1-7H,8H2
DMMU5SO	CS	C1OC2=CC3=CC(=CN=C3C=C2O1)C4=CSC=C4
DMMU5SO	IK	YSBLLMHIZDPXPM-UHFFFAOYSA-N
DMMU5SO	IU	7-thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline
DMMU5SO	DE	Discovery agent

DMOQMA0	ID	DMOQMA0
DMOQMA0	DN	7-trans-OH-PIPAT
DMOQMA0	HS	Investigative
DMOQMA0	SN	8-OH-PIPAT
DMOQMA0	DT	Small molecular drug
DMOQMA0	PC	6604758
DMOQMA0	MW	371.26
DMOQMA0	FM	C16H22INO
DMOQMA0	IC	InChI=1S/C16H22INO/c1-2-10-18(11-4-9-17)14-8-7-13-5-3-6-16(19)15(13)12-14/h3-6,9,14,19H,2,7-8,10-12H2,1H3/b9-4-/t14-/m1/s1
DMOQMA0	CS	CCCN(C/C=C\\I)[C@@H]1CCC2=C(C1)C(=CC=C2)O
DMOQMA0	IK	QBXHUZJZYDSLRH-RXTQTKKPSA-N
DMOQMA0	IU	(7R)-7-[[(Z)-3-iodoprop-2-enyl]-propylamino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMOQMA0	DE	Discovery agent

DM14OHR	ID	DM14OHR
DM14OHR	DN	7-vinyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DM14OHR	HS	Investigative
DM14OHR	DT	Small molecular drug
DM14OHR	PC	135438472
DM14OHR	MW	291.3
DM14OHR	FM	C18H13NO3
DM14OHR	IC	InChI=1S/C18H13NO3/c1-2-12-14-7-10(20)4-6-16(14)19-18-13-5-3-11(21)8-17(13)22-9-15(12)18/h2-8,20-21H,1,9H2
DM14OHR	CS	C=CC1=C2COC3=C(C2=NC4=C1C=C(C=C4)O)C=CC(=C3)O
DM14OHR	IK	SDQIIVSWOGDEKO-UHFFFAOYSA-N
DM14OHR	IU	7-ethenyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DM14OHR	DE	Discovery agent

DMUE15B	ID	DMUE15B
DMUE15B	DN	8-(1,2-Dimethyl-propoxy)-quinolin-2-ylamine
DMUE15B	HS	Investigative
DMUE15B	SN	CHEMBL185095; 8-(1,2-Dimethyl-propoxy)-quinolin-2-ylamine; SCHEMBL5883706
DMUE15B	DT	Small molecular drug
DMUE15B	PC	10466406
DMUE15B	MW	230.31
DMUE15B	FM	C14H18N2O
DMUE15B	IC	InChI=1S/C14H18N2O/c1-9(2)10(3)17-12-6-4-5-11-7-8-13(15)16-14(11)12/h4-10H,1-3H3,(H2,15,16)
DMUE15B	CS	CC(C)C(C)OC1=CC=CC2=C1N=C(C=C2)N
DMUE15B	IK	UQTSQIVXJFEZMJ-UHFFFAOYSA-N
DMUE15B	IU	8-(3-methylbutan-2-yloxy)quinolin-2-amine
DMUE15B	DE	Discovery agent

DMGS7CE	ID	DMGS7CE
DMGS7CE	DN	8-(1,3,3-Trimethyl-butoxy)-quinolin-2-ylamine
DMGS7CE	HS	Investigative
DMGS7CE	SN	CHEMBL183159; 8-(1,3,3-Trimethyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884151; ZDVPLVAZUCNXKZ-UHFFFAOYSA-N; BDBM50152425
DMGS7CE	DT	Small molecular drug
DMGS7CE	PC	10083869
DMGS7CE	MW	258.36
DMGS7CE	FM	C16H22N2O
DMGS7CE	IC	InChI=1S/C16H22N2O/c1-11(10-16(2,3)4)19-13-7-5-6-12-8-9-14(17)18-15(12)13/h5-9,11H,10H2,1-4H3,(H2,17,18)
DMGS7CE	CS	CC(CC(C)(C)C)OC1=CC=CC2=C1N=C(C=C2)N
DMGS7CE	IK	ZDVPLVAZUCNXKZ-UHFFFAOYSA-N
DMGS7CE	IU	8-(4,4-dimethylpentan-2-yloxy)quinolin-2-amine
DMGS7CE	DE	Discovery agent

DMYERNW	ID	DMYERNW
DMYERNW	DN	8-(1-Ethyl-propoxy)-quinolin-2-ylamine
DMYERNW	HS	Investigative
DMYERNW	SN	CHEMBL185096; 8-(1-Ethyl-propoxy)-quinolin-2-ylamine; SCHEMBL5884073
DMYERNW	DT	Small molecular drug
DMYERNW	PC	10353807
DMYERNW	MW	230.31
DMYERNW	FM	C14H18N2O
DMYERNW	IC	InChI=1S/C14H18N2O/c1-3-11(4-2)17-12-7-5-6-10-8-9-13(15)16-14(10)12/h5-9,11H,3-4H2,1-2H3,(H2,15,16)
DMYERNW	CS	CCC(CC)OC1=CC=CC2=C1N=C(C=C2)N
DMYERNW	IK	ZYSOQSQXCCTFTO-UHFFFAOYSA-N
DMYERNW	IU	8-pentan-3-yloxyquinolin-2-amine
DMYERNW	DE	Discovery agent

DMMBH9N	ID	DMMBH9N
DMMBH9N	DN	8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one
DMMBH9N	HS	Investigative
DMMBH9N	SN	CHEMBL200567; 8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one
DMMBH9N	DT	Small molecular drug
DMMBH9N	PC	11501108
DMMBH9N	MW	346.4
DMMBH9N	FM	C21H18N2O3
DMMBH9N	IC	InChI=1S/C21H18N2O3/c24-19-13-20(23-8-10-25-11-9-23)26-21-16(2-1-3-17(19)21)14-4-5-18-15(12-14)6-7-22-18/h1-7,12-13,22H,8-11H2
DMMBH9N	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC5=C(C=C4)NC=C5
DMMBH9N	IK	LXMAOXUZAUDVCG-UHFFFAOYSA-N
DMMBH9N	IU	8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one
DMMBH9N	DE	Discovery agent

DM7VT3P	ID	DM7VT3P
DM7VT3P	DN	8-(1-Methyl-butoxy)-quinolin-2-ylamine
DM7VT3P	HS	Investigative
DM7VT3P	SN	CHEMBL187702; 8-(1-Methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884359
DM7VT3P	DT	Small molecular drug
DM7VT3P	PC	11776033
DM7VT3P	MW	230.31
DM7VT3P	FM	C14H18N2O
DM7VT3P	IC	InChI=1S/C14H18N2O/c1-3-5-10(2)17-12-7-4-6-11-8-9-13(15)16-14(11)12/h4,6-10H,3,5H2,1-2H3,(H2,15,16)
DM7VT3P	CS	CCCC(C)OC1=CC=CC2=C1N=C(C=C2)N
DM7VT3P	IK	KMEFXXMANWGJCR-UHFFFAOYSA-N
DM7VT3P	IU	8-pentan-2-yloxyquinolin-2-amine
DM7VT3P	DE	Discovery agent

DMV5FZO	ID	DMV5FZO
DMV5FZO	DN	8-(2,2-dimethylpropyl)naringenin
DMV5FZO	HS	Investigative
DMV5FZO	SN	8-(2,2-dimethylpropyl)naringenin
DMV5FZO	DT	Small molecular drug
DMV5FZO	PC	16066665
DMV5FZO	MW	342.4
DMV5FZO	FM	C20H22O5
DMV5FZO	IC	InChI=1S/C20H22O5/c1-20(2,3)10-13-14(22)8-15(23)18-16(24)9-17(25-19(13)18)11-4-6-12(21)7-5-11/h4-8,17,21-23H,9-10H2,1-3H3/t17-/m0/s1
DMV5FZO	CS	CC(C)(C)CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMV5FZO	IK	SBFJMGDUIWYKMQ-KRWDZBQOSA-N
DMV5FZO	IU	(2S)-8-(2,2-dimethylpropyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMV5FZO	DE	Discovery agent

DM3QV95	ID	DM3QV95
DM3QV95	DN	8-(2,3,4-trimethoxyphenyl)-9H-purine-2,6-diamine
DM3QV95	HS	Investigative
DM3QV95	SN	8-(2,3,4-trimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL105759; AC1LAR8U; CTK7A1388; BDBM50059922; 2,6-Diamino-8-(2',3',4'-trimethoxyphenyl)purine; 8-(2,3,4-Trimethoxy-phenyl)-9H-purine-2,6-diamine; 8-(2,3,4-trimethoxyphenyl)-7H-purine-2,6-diamine
DM3QV95	DT	Small molecular drug
DM3QV95	PC	473567
DM3QV95	MW	316.32
DM3QV95	FM	C14H16N6O3
DM3QV95	IC	InChI=1S/C14H16N6O3/c1-21-7-5-4-6(9(22-2)10(7)23-3)12-17-8-11(15)18-14(16)20-13(8)19-12/h4-5H,1-3H3,(H5,15,16,17,18,19,20)
DM3QV95	CS	COC1=C(C(=C(C=C1)C2=NC3=NC(=NC(=C3N2)N)N)OC)OC
DM3QV95	IK	PMHAERKHAISVTI-UHFFFAOYSA-N
DM3QV95	IU	8-(2,3,4-trimethoxyphenyl)-7H-purine-2,6-diamine
DM3QV95	DE	Discovery agent

DM4KP5M	ID	DM4KP5M
DM4KP5M	DN	8-(2,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine
DM4KP5M	HS	Investigative
DM4KP5M	SN	8-(2,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine; 1H-Purine-2,6-diamine, 8-(3,4,5-trimethoxyphenyl)-; CHEMBL105523; 194613-10-0; 8-(2,4,5-trimethoxyphenyl)-3h-purine-2,6-diamine; 2,6-Diamino-8-(2',4',5'-trimethoxyphenyl)purine; AC1Q4FDE; AC1LAR90; CTK4E1570; DTXSID40173101; BDBM50059923; AKOS030559902; 8-(2,4,5-trimethoxyphenyl)-7H-purine-2,6-diamine
DM4KP5M	DT	Small molecular drug
DM4KP5M	PC	473569
DM4KP5M	MW	316.32
DM4KP5M	FM	C14H16N6O3
DM4KP5M	IC	InChI=1S/C14H16N6O3/c1-21-7-5-9(23-3)8(22-2)4-6(7)12-17-10-11(15)18-14(16)20-13(10)19-12/h4-5H,1-3H3,(H5,15,16,17,18,19,20)
DM4KP5M	CS	COC1=CC(=C(C=C1C2=NC3=NC(=NC(=C3N2)N)N)OC)OC
DM4KP5M	IK	RPTOJQVHIPKIRX-UHFFFAOYSA-N
DM4KP5M	IU	8-(2,4,5-trimethoxyphenyl)-7H-purine-2,6-diamine
DM4KP5M	CA	CAS 194613-10-0
DM4KP5M	DE	Discovery agent

DM5TSJF	ID	DM5TSJF
DM5TSJF	DN	8-(2,4,6-trimethoxyphenyl)-9H-purine-2,6-diamine
DM5TSJF	HS	Investigative
DM5TSJF	SN	8-(2,4,6-trimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL103474; AC1LAR8X; CTK6J8980; BDBM50059931; 2,6-Diamino-8-(2',4',6'-trimethoxyphenyl)purine; 8-(2,4,6-trimethoxyphenyl)-7H-purine-2,6-diamine; 8-(2,4,6-trimethoxyphenyl)-3h-purine-2,6-diamine
DM5TSJF	DT	Small molecular drug
DM5TSJF	PC	473568
DM5TSJF	MW	316.32
DM5TSJF	FM	C14H16N6O3
DM5TSJF	IC	InChI=1S/C14H16N6O3/c1-21-6-4-7(22-2)9(8(5-6)23-3)12-17-10-11(15)18-14(16)20-13(10)19-12/h4-5H,1-3H3,(H5,15,16,17,18,19,20)
DM5TSJF	CS	COC1=CC(=C(C(=C1)OC)C2=NC3=NC(=NC(=C3N2)N)N)OC
DM5TSJF	IK	DGDMBWNOPVGWKG-UHFFFAOYSA-N
DM5TSJF	IU	8-(2,4,6-trimethoxyphenyl)-7H-purine-2,6-diamine
DM5TSJF	DE	Discovery agent

DMJPYIZ	ID	DMJPYIZ
DMJPYIZ	DN	8-(2,4-dimethoxyphenyl)-9H-purine-2,6-diamine
DMJPYIZ	HS	Investigative
DMJPYIZ	SN	8-(2,4-Dimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL421594; AC1L9X4S; SCHEMBL2947301; BDBM50059921; 8-(2,4-dimethoxyphenyl)-7H-purine-2,6-diamine
DMJPYIZ	DT	Small molecular drug
DMJPYIZ	PC	457736
DMJPYIZ	MW	286.29
DMJPYIZ	FM	C13H14N6O2
DMJPYIZ	IC	InChI=1S/C13H14N6O2/c1-20-6-3-4-7(8(5-6)21-2)11-16-9-10(14)17-13(15)19-12(9)18-11/h3-5H,1-2H3,(H5,14,15,16,17,18,19)
DMJPYIZ	CS	COC1=CC(=C(C=C1)C2=NC3=NC(=NC(=C3N2)N)N)OC
DMJPYIZ	IK	GCFWRZGRJQMBPE-UHFFFAOYSA-N
DMJPYIZ	IU	8-(2,4-dimethoxyphenyl)-7H-purine-2,6-diamine
DMJPYIZ	DE	Discovery agent

DM0MIGU	ID	DM0MIGU
DM0MIGU	DN	8-(2,5-dimethoxyphenyl)-9H-purine-2,6-diamine
DM0MIGU	HS	Investigative
DM0MIGU	SN	8-(2,5-dimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL106070; AC1LAR93; CTK7A0688; BDBM50059939; 2,6-Diamino-8-(2',5'-dimethoxyphenyl)purine; 8-(2,5-dimethoxyphenyl)-3h-purine-2,6-diamine; 8-(2,5-dimethoxyphenyl)-7H-purine-2,6-diamine
DM0MIGU	DT	Small molecular drug
DM0MIGU	PC	473570
DM0MIGU	MW	286.29
DM0MIGU	FM	C13H14N6O2
DM0MIGU	IC	InChI=1S/C13H14N6O2/c1-20-6-3-4-8(21-2)7(5-6)11-16-9-10(14)17-13(15)19-12(9)18-11/h3-5H,1-2H3,(H5,14,15,16,17,18,19)
DM0MIGU	CS	COC1=CC(=C(C=C1)OC)C2=NC3=NC(=NC(=C3N2)N)N
DM0MIGU	IK	FFAMOOJMNMXIFW-UHFFFAOYSA-N
DM0MIGU	IU	8-(2,5-dimethoxyphenyl)-7H-purine-2,6-diamine
DM0MIGU	DE	Discovery agent

DMECWL1	ID	DMECWL1
DMECWL1	DN	8-(2,6-Dichloro-phenyl)-9H-purine-2,6-diamine
DMECWL1	HS	Investigative
DMECWL1	SN	CHEMBL318601; 8-(2,6-dichlorophenyl)-9H-purine-2,6-diamine; 8-(2,6-dichlorophenyl)-7H-purine-2,6-diamine; AC1LAR9F; 8-(2,6-Dichloro-phenyl)-9H-purine-2,6-diamine; CTK7E1079; BDBM50059926
DMECWL1	DT	Small molecular drug
DMECWL1	PC	473574
DMECWL1	MW	295.12
DMECWL1	FM	C11H8Cl2N6
DMECWL1	IC	InChI=1S/C11H8Cl2N6/c12-4-2-1-3-5(13)6(4)9-16-7-8(14)17-11(15)19-10(7)18-9/h1-3H,(H5,14,15,16,17,18,19)
DMECWL1	CS	C1=CC(=C(C(=C1)Cl)C2=NC3=NC(=NC(=C3N2)N)N)Cl
DMECWL1	IK	ZBIYAIOEBKNMQY-UHFFFAOYSA-N
DMECWL1	IU	8-(2,6-dichlorophenyl)-7H-purine-2,6-diamine
DMECWL1	DE	Discovery agent

DM8SRM0	ID	DM8SRM0
DM8SRM0	DN	8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DM8SRM0	HS	Investigative
DM8SRM0	SN	CHEMBL197284; 8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DM8SRM0	DT	Small molecular drug
DM8SRM0	PC	11609954
DM8SRM0	MW	349.4
DM8SRM0	FM	C21H19NO4
DM8SRM0	IC	InChI=1S/C21H19NO4/c1-14(23)15-5-2-3-6-16(15)17-7-4-8-18-19(24)13-20(26-21(17)18)22-9-11-25-12-10-22/h2-8,13H,9-12H2,1H3
DM8SRM0	CS	CC(=O)C1=CC=CC=C1C2=CC=CC3=C2OC(=CC3=O)N4CCOCC4
DM8SRM0	IK	GMTPLPJMRGXINX-UHFFFAOYSA-N
DM8SRM0	IU	8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DM8SRM0	DE	Discovery agent

DMJKL3Z	ID	DMJKL3Z
DMJKL3Z	DN	8-(2-Cyclopropyl-ethoxy)-quinolin-2-ylamine
DMJKL3Z	HS	Investigative
DMJKL3Z	SN	CHEMBL186949; 8-(2-Cyclopropyl-ethoxy)-quinolin-2-ylamine; SCHEMBL5884150
DMJKL3Z	DT	Small molecular drug
DMJKL3Z	PC	22254580
DMJKL3Z	MW	228.29
DMJKL3Z	FM	C14H16N2O
DMJKL3Z	IC	InChI=1S/C14H16N2O/c15-13-7-6-11-2-1-3-12(14(11)16-13)17-9-8-10-4-5-10/h1-3,6-7,10H,4-5,8-9H2,(H2,15,16)
DMJKL3Z	CS	C1CC1CCOC2=CC=CC3=C2N=C(C=C3)N
DMJKL3Z	IK	YLXQVSWEPLSGKN-UHFFFAOYSA-N
DMJKL3Z	IU	8-(2-cyclopropylethoxy)quinolin-2-amine
DMJKL3Z	DE	Discovery agent

DMOB8XT	ID	DMOB8XT
DMOB8XT	DN	8-(2-Ethoxy-1-methyl-ethoxy)-quinolin-2-ylamine
DMOB8XT	HS	Investigative
DMOB8XT	SN	CHEMBL184001; 8-(2-Ethoxy-1-methyl-ethoxy)-quinolin-2-ylamine; SCHEMBL5884055
DMOB8XT	DT	Small molecular drug
DMOB8XT	PC	10399674
DMOB8XT	MW	246.3
DMOB8XT	FM	C14H18N2O2
DMOB8XT	IC	InChI=1S/C14H18N2O2/c1-3-17-9-10(2)18-12-6-4-5-11-7-8-13(15)16-14(11)12/h4-8,10H,3,9H2,1-2H3,(H2,15,16)
DMOB8XT	CS	CCOCC(C)OC1=CC=CC2=C1N=C(C=C2)N
DMOB8XT	IK	NPQHPGOWIVAOJW-UHFFFAOYSA-N
DMOB8XT	IU	8-(1-ethoxypropan-2-yloxy)quinolin-2-amine
DMOB8XT	DE	Discovery agent

DMSKTVW	ID	DMSKTVW
DMSKTVW	DN	8-(2-Ethyl-1-methyl-butoxy)-quinolin-2-ylamine
DMSKTVW	HS	Investigative
DMSKTVW	SN	CHEMBL365459; 8-(2-Ethyl-1-methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884532
DMSKTVW	DT	Small molecular drug
DMSKTVW	PC	10377822
DMSKTVW	MW	258.36
DMSKTVW	FM	C16H22N2O
DMSKTVW	IC	InChI=1S/C16H22N2O/c1-4-12(5-2)11(3)19-14-8-6-7-13-9-10-15(17)18-16(13)14/h6-12H,4-5H2,1-3H3,(H2,17,18)
DMSKTVW	CS	CCC(CC)C(C)OC1=CC=CC2=C1N=C(C=C2)N
DMSKTVW	IK	UMDWRYRCTHHCNV-UHFFFAOYSA-N
DMSKTVW	IU	8-(3-ethylpentan-2-yloxy)quinolin-2-amine
DMSKTVW	DE	Discovery agent

DMA5K04	ID	DMA5K04
DMA5K04	DN	8-(2-Methoxy-1-methyl-ethoxy)-quinolin-2-ylamine
DMA5K04	HS	Investigative
DMA5K04	SN	CHEMBL363011; 8-(2-Methoxy-1-methyl-ethoxy)-quinolin-2-ylamine; SCHEMBL5884451
DMA5K04	DT	Small molecular drug
DMA5K04	PC	10466478
DMA5K04	MW	232.28
DMA5K04	FM	C13H16N2O2
DMA5K04	IC	InChI=1S/C13H16N2O2/c1-9(8-16-2)17-11-5-3-4-10-6-7-12(14)15-13(10)11/h3-7,9H,8H2,1-2H3,(H2,14,15)
DMA5K04	CS	CC(COC)OC1=CC=CC2=C1N=C(C=C2)N
DMA5K04	IK	HFVYCRXMQPWHFZ-UHFFFAOYSA-N
DMA5K04	IU	8-(1-methoxypropan-2-yloxy)quinolin-2-amine
DMA5K04	DE	Discovery agent

DMVBRMF	ID	DMVBRMF
DMVBRMF	DN	8-(2-Methyl-butoxy)-quinolin-2-ylamine
DMVBRMF	HS	Investigative
DMVBRMF	SN	CHEMBL362720; 8-(2-Methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884531
DMVBRMF	DT	Small molecular drug
DMVBRMF	PC	10466405
DMVBRMF	MW	230.31
DMVBRMF	FM	C14H18N2O
DMVBRMF	IC	InChI=1S/C14H18N2O/c1-3-10(2)9-17-12-6-4-5-11-7-8-13(15)16-14(11)12/h4-8,10H,3,9H2,1-2H3,(H2,15,16)
DMVBRMF	CS	CCC(C)COC1=CC=CC2=C1N=C(C=C2)N
DMVBRMF	IK	YLIRVLXATQGNTR-UHFFFAOYSA-N
DMVBRMF	IU	8-(2-methylbutoxy)quinolin-2-amine
DMVBRMF	DE	Discovery agent

DMUIFJY	ID	DMUIFJY
DMUIFJY	DN	8-(2-Methyl-cyclohexyloxy)-quinolin-2-ylamine
DMUIFJY	HS	Investigative
DMUIFJY	SN	CHEMBL362713; 8-(2-Methyl-cyclohexyloxy)-quinolin-2-ylamine; SCHEMBL5884370
DMUIFJY	DT	Small molecular drug
DMUIFJY	PC	22254604
DMUIFJY	MW	256.339
DMUIFJY	FM	C16H20N2O
DMUIFJY	IC	InChI=1S/C16H20N2O/c1-11-5-2-3-7-13(11)19-14-8-4-6-12-9-10-15(17)18-16(12)14/h4,6,8-11,13H,2-3,5,7H2,1H3,(H2,17,18)
DMUIFJY	CS	CC1CCCCC1OC2=CC=CC3=C2N=C(C=C3)N
DMUIFJY	IK	MXXMNBSDHISKHW-UHFFFAOYSA-N
DMUIFJY	IU	8-(2-methylcyclohexyl)oxyquinolin-2-amine
DMUIFJY	DE	Discovery agent

DMQUZSJ	ID	DMQUZSJ
DMQUZSJ	DN	8-(2-methylpropyl)naringenin
DMQUZSJ	HS	Investigative
DMQUZSJ	SN	8-(2-methylpropyl)naringenin
DMQUZSJ	DT	Small molecular drug
DMQUZSJ	PC	44418729
DMQUZSJ	MW	328.4
DMQUZSJ	FM	C19H20O5
DMQUZSJ	IC	InChI=1S/C19H20O5/c1-10(2)7-13-14(21)8-15(22)18-16(23)9-17(24-19(13)18)11-3-5-12(20)6-4-11/h3-6,8,10,17,20-22H,7,9H2,1-2H3/t17-/m0/s1
DMQUZSJ	CS	CC(C)CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMQUZSJ	IK	ZYVQEHNABDHJGN-KRWDZBQOSA-N
DMQUZSJ	IU	(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(2-methylpropyl)-2,3-dihydrochromen-4-one
DMQUZSJ	DE	Discovery agent

DMRUP0A	ID	DMRUP0A
DMRUP0A	DN	8-(3,3,3-trifluoropropoxy)quinolin-2-amine
DMRUP0A	HS	Investigative
DMRUP0A	SN	CHEMBL187165; 8-(3,3,3-trifluoropropoxy)quinolin-2-amine; SCHEMBL5884488
DMRUP0A	DT	Small molecular drug
DMRUP0A	PC	22254540
DMRUP0A	MW	256.22
DMRUP0A	FM	C12H11F3N2O
DMRUP0A	IC	InChI=1S/C12H11F3N2O/c13-12(14,15)6-7-18-9-3-1-2-8-4-5-10(16)17-11(8)9/h1-5H,6-7H2,(H2,16,17)
DMRUP0A	CS	C1=CC2=C(C(=C1)OCCC(F)(F)F)N=C(C=C2)N
DMRUP0A	IK	ZGZSZXFSLMTFBX-UHFFFAOYSA-N
DMRUP0A	IU	8-(3,3,3-trifluoropropoxy)quinolin-2-amine
DMRUP0A	DE	Discovery agent

DM72EM9	ID	DM72EM9
DM72EM9	DN	8-(3,3-Dimethyl-butoxy)-quinolin-2-ylamine
DM72EM9	HS	Investigative
DM72EM9	SN	CHEMBL364104; 8-(3,3-Dimethyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884452
DM72EM9	DT	Small molecular drug
DM72EM9	PC	10421933
DM72EM9	MW	244.33
DM72EM9	FM	C15H20N2O
DM72EM9	IC	InChI=1S/C15H20N2O/c1-15(2,3)9-10-18-12-6-4-5-11-7-8-13(16)17-14(11)12/h4-8H,9-10H2,1-3H3,(H2,16,17)
DM72EM9	CS	CC(C)(C)CCOC1=CC=CC2=C1N=C(C=C2)N
DM72EM9	IK	GUJKDUVYIJMAPL-UHFFFAOYSA-N
DM72EM9	IU	8-(3,3-dimethylbutoxy)quinolin-2-amine
DM72EM9	DE	Discovery agent

DMV63G1	ID	DMV63G1
DMV63G1	DN	8-(3,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine
DMV63G1	HS	Investigative
DMV63G1	SN	8-(3,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL431257; AC1LAR8R; CTK6J4531; BDBM50059933; 2,6-Diamino-8-(3',4',5'-trimethoxyphenyl)purine; 8-(3,4,5-trimethoxyphenyl)-3h-purine-2,6-diamine; 8-(3,4,5-trimethoxyphenyl)-7H-purine-2,6-diamine
DMV63G1	DT	Small molecular drug
DMV63G1	PC	473566
DMV63G1	MW	316.32
DMV63G1	FM	C14H16N6O3
DMV63G1	IC	InChI=1S/C14H16N6O3/c1-21-7-4-6(5-8(22-2)10(7)23-3)12-17-9-11(15)18-14(16)20-13(9)19-12/h4-5H,1-3H3,(H5,15,16,17,18,19,20)
DMV63G1	CS	COC1=CC(=CC(=C1OC)OC)C2=NC3=NC(=NC(=C3N2)N)N
DMV63G1	IK	QPWGTISXOSFSHJ-UHFFFAOYSA-N
DMV63G1	IU	8-(3,4,5-trimethoxyphenyl)-7H-purine-2,6-diamine
DMV63G1	DE	Discovery agent

DMZU0YF	ID	DMZU0YF
DMZU0YF	DN	8-(3,4-dichlorophenyl)-9H-purine-2,6-diamine
DMZU0YF	HS	Investigative
DMZU0YF	SN	8-(3,4-dichlorophenyl)-9H-purine-2,6-diamine; CHEMBL312688; 8-(3,4-dichlorophenyl)-7H-purine-2,6-diamine; AC1LAR9C; CTK7E1080; BDBM50059929; 2,6-Diamino-8-(3',4'-dichlorophenyl)purine
DMZU0YF	DT	Small molecular drug
DMZU0YF	PC	473573
DMZU0YF	MW	295.12
DMZU0YF	FM	C11H8Cl2N6
DMZU0YF	IC	InChI=1S/C11H8Cl2N6/c12-5-2-1-4(3-6(5)13)9-16-7-8(14)17-11(15)19-10(7)18-9/h1-3H,(H5,14,15,16,17,18,19)
DMZU0YF	CS	C1=CC(=C(C=C1C2=NC3=NC(=NC(=C3N2)N)N)Cl)Cl
DMZU0YF	IK	GZDRYQKQDXYCQK-UHFFFAOYSA-N
DMZU0YF	IU	8-(3,4-dichlorophenyl)-7H-purine-2,6-diamine
DMZU0YF	DE	Discovery agent

DMYZC3I	ID	DMYZC3I
DMYZC3I	DN	8-(3,4-dimethoxyphenyl)-9H-purine-2,6-diamine
DMYZC3I	HS	Investigative
DMYZC3I	SN	8-(3,4-dimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL102518; AC1LAR99; CTK7A7284; BDBM50059936; 2,6-Diamino-8-(3',4'-dimethoxyphenyl)purine; 8-(3,4-dimethoxyphenyl)-3h-purine-2,6-diamine; 8-(3,4-dimethoxyphenyl)-7H-purine-2,6-diamine
DMYZC3I	DT	Small molecular drug
DMYZC3I	PC	473572
DMYZC3I	MW	286.29
DMYZC3I	FM	C13H14N6O2
DMYZC3I	IC	InChI=1S/C13H14N6O2/c1-20-7-4-3-6(5-8(7)21-2)11-16-9-10(14)17-13(15)19-12(9)18-11/h3-5H,1-2H3,(H5,14,15,16,17,18,19)
DMYZC3I	CS	COC1=C(C=C(C=C1)C2=NC3=NC(=NC(=C3N2)N)N)OC
DMYZC3I	IK	LXQDFGKWPJDZOK-UHFFFAOYSA-N
DMYZC3I	IU	8-(3,4-dimethoxyphenyl)-7H-purine-2,6-diamine
DMYZC3I	DE	Discovery agent

DM920XR	ID	DM920XR
DM920XR	DN	8-(3,5-dimethoxyphenyl)-9H-purine-2,6-diamine
DM920XR	HS	Investigative
DM920XR	SN	8-(3,5-dimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL105323; AC1LAR96; CTK6J9242; BDBM50059940; 2,6-Diamino-8-(3',5'-dimethoxyphenyl)purine; 8-(3,5-dimethoxyphenyl)-7H-purine-2,6-diamine; 8-(3,5-dimethoxyphenyl)-3h-purine-2,6-diamine
DM920XR	DT	Small molecular drug
DM920XR	PC	473571
DM920XR	MW	286.29
DM920XR	FM	C13H14N6O2
DM920XR	IC	InChI=1S/C13H14N6O2/c1-20-7-3-6(4-8(5-7)21-2)11-16-9-10(14)17-13(15)19-12(9)18-11/h3-5H,1-2H3,(H5,14,15,16,17,18,19)
DM920XR	CS	COC1=CC(=CC(=C1)C2=NC3=NC(=NC(=C3N2)N)N)OC
DM920XR	IK	CFTYJGDHKCKXBN-UHFFFAOYSA-N
DM920XR	IU	8-(3,5-dimethoxyphenyl)-7H-purine-2,6-diamine
DM920XR	DE	Discovery agent

DM9J2LT	ID	DM9J2LT
DM9J2LT	DN	8-(3-Azido-phenyl)-6-iodo-quinoline
DM9J2LT	HS	Investigative
DM9J2LT	SN	CHEMBL127994; 8-(3-Azido-phenyl)-6-iodo-quinoline; 6-Iodo-8-(3-azidophenyl)quinoline
DM9J2LT	DT	Small molecular drug
DM9J2LT	PC	10642995
DM9J2LT	MW	372.16
DM9J2LT	FM	C15H9IN4
DM9J2LT	IC	InChI=1S/C15H9IN4/c16-12-7-11-4-2-6-18-15(11)14(9-12)10-3-1-5-13(8-10)19-20-17/h1-9H
DM9J2LT	CS	C1=CC(=CC(=C1)N=[N+]=[N-])C2=C3C(=CC(=C2)I)C=CC=N3
DM9J2LT	IK	PBIQIEZSLAPKDM-UHFFFAOYSA-N
DM9J2LT	IU	8-(3-azidophenyl)-6-iodoquinoline
DM9J2LT	DE	Discovery agent

DMON7RZ	ID	DMON7RZ
DMON7RZ	DN	8-(3-Azido-phenyl)-6-pyridin-4-ylmethyl-quinoline
DMON7RZ	HS	Investigative
DMON7RZ	SN	CHEMBL339083; 8-(3-Azido-phenyl)-6-pyridin-4-ylmethyl-quinoline; BDBM50092630
DMON7RZ	DT	Small molecular drug
DMON7RZ	PC	10404815
DMON7RZ	MW	337.4
DMON7RZ	FM	C21H15N5
DMON7RZ	IC	InChI=1S/C21H15N5/c22-26-25-19-5-1-3-17(14-19)20-13-16(11-15-6-9-23-10-7-15)12-18-4-2-8-24-21(18)20/h1-10,12-14H,11H2
DMON7RZ	CS	C1=CC(=CC(=C1)N=[N+]=[N-])C2=C3C(=CC(=C2)CC4=CC=NC=C4)C=CC=N3
DMON7RZ	IK	SJSUBWZFLWXJFL-UHFFFAOYSA-N
DMON7RZ	IU	8-(3-azidophenyl)-6-(pyridin-4-ylmethyl)quinoline
DMON7RZ	DE	Discovery agent

DMW2NJR	ID	DMW2NJR
DMW2NJR	DN	8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide
DMW2NJR	HS	Investigative
DMW2NJR	SN	CHEMBL1083441; 8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N
DMW2NJR	DT	Small molecular drug
DMW2NJR	PC	11381650
DMW2NJR	MW	321.37
DMW2NJR	FM	C16H23N3O4
DMW2NJR	IC	InChI=1S/C16H23N3O4/c20-14(19-23)11-7-2-1-3-8-12-17-16(22)18-15(21)13-9-5-4-6-10-13/h4-6,9-10,23H,1-3,7-8,11-12H2,(H,19,20)(H2,17,18,21,22)
DMW2NJR	CS	C1=CC=C(C=C1)C(=O)NC(=O)NCCCCCCCC(=O)NO
DMW2NJR	IK	WUKFQTZVXXYEAB-UHFFFAOYSA-N
DMW2NJR	IU	N-[[8-(hydroxyamino)-8-oxooctyl]carbamoyl]benzamide
DMW2NJR	DE	Discovery agent

DM2RA4N	ID	DM2RA4N
DM2RA4N	DN	8-(3-Bromobenzyloxy)caffeine
DM2RA4N	HS	Investigative
DM2RA4N	SN	8-(3-Bromobenzyloxy)caffeine; CHEMBL602464
DM2RA4N	DT	Small molecular drug
DM2RA4N	PC	46232852
DM2RA4N	MW	379.21
DM2RA4N	FM	C15H15BrN4O3
DM2RA4N	IC	InChI=1S/C15H15BrN4O3/c1-18-11-12(19(2)15(22)20(3)13(11)21)17-14(18)23-8-9-5-4-6-10(16)7-9/h4-7H,8H2,1-3H3
DM2RA4N	CS	CN1C2=C(N=C1OCC3=CC(=CC=C3)Br)N(C(=O)N(C2=O)C)C
DM2RA4N	IK	UMXJQISLIGIYPW-UHFFFAOYSA-N
DM2RA4N	IU	8-[(3-bromophenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione
DM2RA4N	DE	Discovery agent

DM7HMNP	ID	DM7HMNP
DM7HMNP	DN	8-(3-Chlorobenzyloxy)caffeine
DM7HMNP	HS	Investigative
DM7HMNP	SN	8-(3-Chlorobenzyloxy)caffeine; CHEMBL602260
DM7HMNP	DT	Small molecular drug
DM7HMNP	PC	46232851
DM7HMNP	MW	334.76
DM7HMNP	FM	C15H15ClN4O3
DM7HMNP	IC	InChI=1S/C15H15ClN4O3/c1-18-11-12(19(2)15(22)20(3)13(11)21)17-14(18)23-8-9-5-4-6-10(16)7-9/h4-7H,8H2,1-3H3
DM7HMNP	CS	CN1C2=C(N=C1OCC3=CC(=CC=C3)Cl)N(C(=O)N(C2=O)C)C
DM7HMNP	IK	XCVMGVIPMZLFEU-UHFFFAOYSA-N
DM7HMNP	IU	8-[(3-chlorophenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione
DM7HMNP	DE	Discovery agent

DME85GS	ID	DME85GS
DME85GS	DN	8-(3-Fluorobenzyloxy)caffeine
DME85GS	HS	Investigative
DME85GS	SN	8-(3-Fluorobenzyloxy)caffeine; CHEMBL602465
DME85GS	DT	Small molecular drug
DME85GS	PC	46232853
DME85GS	MW	318.3
DME85GS	FM	C15H15FN4O3
DME85GS	IC	InChI=1S/C15H15FN4O3/c1-18-11-12(19(2)15(22)20(3)13(11)21)17-14(18)23-8-9-5-4-6-10(16)7-9/h4-7H,8H2,1-3H3
DME85GS	CS	CN1C2=C(N=C1OCC3=CC(=CC=C3)F)N(C(=O)N(C2=O)C)C
DME85GS	IK	YAQZRUHNOYDFHZ-UHFFFAOYSA-N
DME85GS	IU	8-[(3-fluorophenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione
DME85GS	DE	Discovery agent

DMLQPVH	ID	DMLQPVH
DMLQPVH	DN	8-(3-Fluoro-phenyl)-9-methyl-9H-purin-6-ylamine
DMLQPVH	HS	Investigative
DMLQPVH	SN	CHEMBL48682
DMLQPVH	DT	Small molecular drug
DMLQPVH	PC	10633978
DMLQPVH	MW	243.24
DMLQPVH	FM	C12H10FN5
DMLQPVH	IC	InChI=1S/C12H10FN5/c1-18-11(7-3-2-4-8(13)5-7)17-9-10(14)15-6-16-12(9)18/h2-6H,1H3,(H2,14,15,16)
DMLQPVH	CS	CN1C(=NC2=C(N=CN=C21)N)C3=CC(=CC=C3)F
DMLQPVH	IK	JXJYLIUAIVDUNX-UHFFFAOYSA-N
DMLQPVH	IU	8-(3-fluorophenyl)-9-methylpurin-6-amine
DMLQPVH	DE	Discovery agent

DM15LVG	ID	DM15LVG
DM15LVG	DN	8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DM15LVG	HS	Investigative
DM15LVG	SN	CHEMBL200685; 8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one; SCHEMBL5258643; WPUKKEMHTVGTFK-UHFFFAOYSA-N; BDBM50178081
DM15LVG	DT	Small molecular drug
DM15LVG	PC	11609490
DM15LVG	MW	323.3
DM15LVG	FM	C19H17NO4
DM15LVG	IC	InChI=1S/C19H17NO4/c21-14-4-1-3-13(11-14)15-5-2-6-16-17(22)12-18(24-19(15)16)20-7-9-23-10-8-20/h1-6,11-12,21H,7-10H2
DM15LVG	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC(=CC=C4)O
DM15LVG	IK	WPUKKEMHTVGTFK-UHFFFAOYSA-N
DM15LVG	IU	8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DM15LVG	DE	Discovery agent

DM3WEQA	ID	DM3WEQA
DM3WEQA	DN	8-(3-Methoxy-3-methyl-butoxy)-quinolin-2-ylamine
DM3WEQA	HS	Investigative
DM3WEQA	SN	CHEMBL361288; 8-(3-Methoxy-3-methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884407
DM3WEQA	DT	Small molecular drug
DM3WEQA	PC	10377914
DM3WEQA	MW	260.329
DM3WEQA	FM	C15H20N2O2
DM3WEQA	IC	InChI=1S/C15H20N2O2/c1-15(2,18-3)9-10-19-12-6-4-5-11-7-8-13(16)17-14(11)12/h4-8H,9-10H2,1-3H3,(H2,16,17)
DM3WEQA	CS	CC(C)(CCOC1=CC=CC2=C1N=C(C=C2)N)OC
DM3WEQA	IK	LPHQANHABFNXJD-UHFFFAOYSA-N
DM3WEQA	IU	8-(3-methoxy-3-methylbutoxy)quinolin-2-amine
DM3WEQA	DE	Discovery agent

DMLY46X	ID	DMLY46X
DMLY46X	DN	8-(3-Methoxybenzyloxy)caffeine
DMLY46X	HS	Investigative
DMLY46X	SN	8-(3-Methoxybenzyloxy)caffeine; CHEMBL602880; AC1LCY7O; Oprea1_481626; MLS000038017; MolPort-002-545-851; ZINC497710; HMS2326N19; BDBM50306702; AKOS030507253; MCULE-4574508539; NCGC00020867-02; NCGC00020867-01; SMR000039153; 8-[(3-methoxyphenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione; 8-((3-methoxybenzyl)oxy)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione
DMLY46X	DT	Small molecular drug
DMLY46X	PC	658198
DMLY46X	MW	330.34
DMLY46X	FM	C16H18N4O4
DMLY46X	IC	InChI=1S/C16H18N4O4/c1-18-12-13(19(2)16(22)20(3)14(12)21)17-15(18)24-9-10-6-5-7-11(8-10)23-4/h5-8H,9H2,1-4H3
DMLY46X	CS	CN1C2=C(N=C1OCC3=CC(=CC=C3)OC)N(C(=O)N(C2=O)C)C
DMLY46X	IK	SDEMBXFOALFRQD-UHFFFAOYSA-N
DMLY46X	IU	8-[(3-methoxyphenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione
DMLY46X	DE	Discovery agent

DMB9645	ID	DMB9645
DMB9645	DN	8-(3-Methylbenzyloxy)caffeine
DMB9645	HS	Investigative
DMB9645	SN	8-(3-Methylbenzyloxy)caffeine; CHEMBL589765
DMB9645	DT	Small molecular drug
DMB9645	PC	46232855
DMB9645	MW	314.34
DMB9645	FM	C16H18N4O3
DMB9645	IC	InChI=1S/C16H18N4O3/c1-10-6-5-7-11(8-10)9-23-15-17-13-12(18(15)2)14(21)20(4)16(22)19(13)3/h5-8H,9H2,1-4H3
DMB9645	CS	CC1=CC(=CC=C1)COC2=NC3=C(N2C)C(=O)N(C(=O)N3C)C
DMB9645	IK	AFSVTGXZVYXITM-UHFFFAOYSA-N
DMB9645	IU	1,3,7-trimethyl-8-[(3-methylphenyl)methoxy]purine-2,6-dione
DMB9645	DE	Discovery agent

DMNYPCQ	ID	DMNYPCQ
DMNYPCQ	DN	8-(3-Methyl-butoxy)-quinolin-2-ylamine
DMNYPCQ	HS	Investigative
DMNYPCQ	SN	CHEMBL184476; 8-(3-Methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884316
DMNYPCQ	DT	Small molecular drug
DMNYPCQ	PC	10443853
DMNYPCQ	MW	230.31
DMNYPCQ	FM	C14H18N2O
DMNYPCQ	IC	InChI=1S/C14H18N2O/c1-10(2)8-9-17-12-5-3-4-11-6-7-13(15)16-14(11)12/h3-7,10H,8-9H2,1-2H3,(H2,15,16)
DMNYPCQ	CS	CC(C)CCOC1=CC=CC2=C1N=C(C=C2)N
DMNYPCQ	IK	RGLJKEQVQXDAIT-UHFFFAOYSA-N
DMNYPCQ	IU	8-(3-methylbutoxy)quinolin-2-amine
DMNYPCQ	DE	Discovery agent

DM2VAJE	ID	DM2VAJE
DM2VAJE	DN	8-(3-methylbutyl)naringenin
DM2VAJE	HS	Investigative
DM2VAJE	SN	8-(3-methylbutyl)naringenin
DM2VAJE	DT	Small molecular drug
DM2VAJE	PC	44418728
DM2VAJE	MW	342.4
DM2VAJE	FM	C20H22O5
DM2VAJE	IC	InChI=1S/C20H22O5/c1-11(2)3-8-14-15(22)9-16(23)19-17(24)10-18(25-20(14)19)12-4-6-13(21)7-5-12/h4-7,9,11,18,21-23H,3,8,10H2,1-2H3/t18-/m0/s1
DM2VAJE	CS	CC(C)CCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DM2VAJE	IK	UKBYGNGSGOXLFO-SFHVURJKSA-N
DM2VAJE	IU	(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbutyl)-2,3-dihydrochromen-4-one
DM2VAJE	DE	Discovery agent

DMPMJHV	ID	DMPMJHV
DMPMJHV	DN	8-(3-Methyl-cyclohexyloxy)-quinolin-2-ylamine
DMPMJHV	HS	Investigative
DMPMJHV	SN	CHEMBL183932; 8-(3-Methyl-cyclohexyloxy)-quinolin-2-ylamine; SCHEMBL5883847
DMPMJHV	DT	Small molecular drug
DMPMJHV	PC	10038053
DMPMJHV	MW	256.339
DMPMJHV	FM	C16H20N2O
DMPMJHV	IC	InChI=1S/C16H20N2O/c1-11-4-2-6-13(10-11)19-14-7-3-5-12-8-9-15(17)18-16(12)14/h3,5,7-9,11,13H,2,4,6,10H2,1H3,(H2,17,18)
DMPMJHV	CS	CC1CCCC(C1)OC2=CC=CC3=C2N=C(C=C3)N
DMPMJHV	IK	AZGLOGDXDJFQFK-UHFFFAOYSA-N
DMPMJHV	IU	8-(3-methylcyclohexyl)oxyquinolin-2-amine
DMPMJHV	DE	Discovery agent

DM8N314	ID	DM8N314
DM8N314	DN	8-(3-Methyl-cyclopentyloxy)-quinolin-2-ylamine
DM8N314	HS	Investigative
DM8N314	SN	CHEMBL183739; 8-(3-Methyl-cyclopentyloxy)-quinolin-2-ylamine; SCHEMBL5883724
DM8N314	DT	Small molecular drug
DM8N314	PC	10083101
DM8N314	MW	242.32
DM8N314	FM	C15H18N2O
DM8N314	IC	InChI=1S/C15H18N2O/c1-10-5-7-12(9-10)18-13-4-2-3-11-6-8-14(16)17-15(11)13/h2-4,6,8,10,12H,5,7,9H2,1H3,(H2,16,17)
DM8N314	CS	CC1CCC(C1)OC2=CC=CC3=C2N=C(C=C3)N
DM8N314	IK	XSBYTVRYECCAPQ-UHFFFAOYSA-N
DM8N314	IU	8-(3-methylcyclopentyl)oxyquinolin-2-amine
DM8N314	DE	Discovery agent

DMP6Z3R	ID	DMP6Z3R
DMP6Z3R	DN	8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine
DMP6Z3R	HS	Investigative
DMP6Z3R	SN	CHEMBL161465; 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine; 8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine; SCHEMBL7015917; SRVUGPYWYLBZNI-UHFFFAOYSA-N; ZINC13805266
DMP6Z3R	DT	Small molecular drug
DMP6Z3R	PC	10711281
DMP6Z3R	MW	327.3
DMP6Z3R	FM	C20H13N3O2
DMP6Z3R	IC	InChI=1S/C20H13N3O2/c24-23(25)17-10-4-8-15(12-17)20-19-16(9-5-11-21-19)13-18(22-20)14-6-2-1-3-7-14/h1-13H
DMP6Z3R	CS	C1=CC=C(C=C1)C2=NC(=C3C(=C2)C=CC=N3)C4=CC(=CC=C4)[N+](=O)[O-]
DMP6Z3R	IK	SRVUGPYWYLBZNI-UHFFFAOYSA-N
DMP6Z3R	IU	8-(3-nitrophenyl)-6-phenyl-1,7-naphthyridine
DMP6Z3R	DE	Discovery agent

DM0N68L	ID	DM0N68L
DM0N68L	DN	8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline
DM0N68L	HS	Investigative
DM0N68L	SN	8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline; 159925-31-2; RS-14203; CHEMBL127944; 8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline; 8-(3-nitrophenyl)-6-(4-pyridinylmethyl)Quinoline; ZINC6165; SCHEMBL3698956; DTXSID20431317; XRSKAWJXBDACRF-UHFFFAOYSA-N; 3g58; 3g45; BDBM50092632; AKOS022171718; 4CA-1115; KB-74213; DA-09714; AJ-08271; AX8257760; FT-0733089
DM0N68L	DT	Small molecular drug
DM0N68L	PC	9819356
DM0N68L	MW	341.4
DM0N68L	FM	C21H15N3O2
DM0N68L	IC	InChI=1S/C21H15N3O2/c25-24(26)19-5-1-3-17(14-19)20-13-16(11-15-6-9-22-10-7-15)12-18-4-2-8-23-21(18)20/h1-10,12-14H,11H2
DM0N68L	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=C3C(=CC(=C2)CC4=CC=NC=C4)C=CC=N3
DM0N68L	IK	XRSKAWJXBDACRF-UHFFFAOYSA-N
DM0N68L	IU	8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline
DM0N68L	CA	CAS 159925-31-2
DM0N68L	DE	Discovery agent

DMAK0P3	ID	DMAK0P3
DMAK0P3	DN	8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMAK0P3	HS	Investigative
DMAK0P3	SN	CHEMBL197218; 8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMAK0P3	DT	Small molecular drug
DMAK0P3	PC	11710022
DMAK0P3	MW	349.4
DMAK0P3	FM	C21H19NO4
DMAK0P3	IC	InChI=1S/C21H19NO4/c1-14(23)15-5-7-16(8-6-15)17-3-2-4-18-19(24)13-20(26-21(17)18)22-9-11-25-12-10-22/h2-8,13H,9-12H2,1H3
DMAK0P3	CS	CC(=O)C1=CC=C(C=C1)C2=CC=CC3=C2OC(=CC3=O)N4CCOCC4
DMAK0P3	IK	OEHLKVQEMZKDOJ-UHFFFAOYSA-N
DMAK0P3	IU	8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMAK0P3	DE	Discovery agent

DMVOCWY	ID	DMVOCWY
DMVOCWY	DN	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide
DMVOCWY	HS	Investigative
DMVOCWY	SN	CHEMBL319070; 8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide
DMVOCWY	DT	Small molecular drug
DMVOCWY	PC	11120992
DMVOCWY	MW	328.2
DMVOCWY	FM	C14H18BrNO3
DMVOCWY	IC	InChI=1S/C14H18BrNO3/c15-12-9-7-11(8-10-12)13(17)5-3-1-2-4-6-14(18)16-19/h7-10,19H,1-6H2,(H,16,18)
DMVOCWY	CS	C1=CC(=CC=C1C(=O)CCCCCCC(=O)NO)Br
DMVOCWY	IK	RFYYZRFJBNAHCG-UHFFFAOYSA-N
DMVOCWY	IU	8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide
DMVOCWY	DE	Discovery agent

DM4186A	ID	DM4186A
DM4186A	DN	8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one
DM4186A	HS	Investigative
DM4186A	SN	CHEMBL200733; 8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one
DM4186A	DT	Small molecular drug
DM4186A	PC	11515664
DM4186A	MW	341.8
DM4186A	FM	C19H16ClNO3
DM4186A	IC	InChI=1S/C19H16ClNO3/c20-14-6-4-13(5-7-14)15-2-1-3-16-17(22)12-18(24-19(15)16)21-8-10-23-11-9-21/h1-7,12H,8-11H2
DM4186A	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=C(C=C4)Cl
DM4186A	IK	HYBIQRLHJUFHFC-UHFFFAOYSA-N
DM4186A	IU	8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one
DM4186A	DE	Discovery agent

DMLANGY	ID	DMLANGY
DMLANGY	DN	8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DMLANGY	HS	Investigative
DMLANGY	SN	CHEMBL200517; 8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DMLANGY	DT	Small molecular drug
DMLANGY	PC	11652716
DMLANGY	MW	323.3
DMLANGY	FM	C19H17NO4
DMLANGY	IC	InChI=1S/C19H17NO4/c21-14-6-4-13(5-7-14)15-2-1-3-16-17(22)12-18(24-19(15)16)20-8-10-23-11-9-20/h1-7,12,21H,8-11H2
DMLANGY	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=C(C=C4)O
DMLANGY	IK	WSNZUFRPSRSILZ-UHFFFAOYSA-N
DMLANGY	IU	8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DMLANGY	DE	Discovery agent

DMPVQN3	ID	DMPVQN3
DMPVQN3	DN	8-(4-Methyl-cyclohexyloxy)-quinolin-2-ylamine
DMPVQN3	HS	Investigative
DMPVQN3	SN	CHEMBL184573; 8-(4-Methyl-cyclohexyloxy)-quinolin-2-ylamine; SCHEMBL5884069
DMPVQN3	DT	Small molecular drug
DMPVQN3	PC	10244148
DMPVQN3	MW	256.339
DMPVQN3	FM	C16H20N2O
DMPVQN3	IC	InChI=1S/C16H20N2O/c1-11-5-8-13(9-6-11)19-14-4-2-3-12-7-10-15(17)18-16(12)14/h2-4,7,10-11,13H,5-6,8-9H2,1H3,(H2,17,18)
DMPVQN3	CS	CC1CCC(CC1)OC2=CC=CC3=C2N=C(C=C3)N
DMPVQN3	IK	OQURIDUAVDCPLT-UHFFFAOYSA-N
DMPVQN3	IU	8-(4-methylcyclohexyl)oxyquinolin-2-amine
DMPVQN3	DE	Discovery agent

DMH3SDO	ID	DMH3SDO
DMH3SDO	DN	8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one
DMH3SDO	HS	Investigative
DMH3SDO	SN	CHEMBL116023; SCHEMBL7368359; BDBM50218558
DMH3SDO	DT	Small molecular drug
DMH3SDO	PC	44343094
DMH3SDO	MW	350.4
DMH3SDO	FM	C20H21F3O2
DMH3SDO	IC	InChI=1S/C20H21F3O2/c21-20(22,23)19(24)13-6-1-2-7-14-25-18-12-8-11-17(15-18)16-9-4-3-5-10-16/h3-5,8-12,15H,1-2,6-7,13-14H2
DMH3SDO	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)OCCCCCCC(=O)C(F)(F)F
DMH3SDO	IK	OFSLRFDWUPANFG-UHFFFAOYSA-N
DMH3SDO	IU	1,1,1-trifluoro-8-(3-phenylphenoxy)octan-2-one
DMH3SDO	DE	Discovery agent

DMD6VSY	ID	DMD6VSY
DMD6VSY	DN	8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide
DMD6VSY	HS	Investigative
DMD6VSY	SN	CHEMBL95313; 8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide
DMD6VSY	DT	Small molecular drug
DMD6VSY	PC	10314237
DMD6VSY	MW	325.4
DMD6VSY	FM	C20H23NO3
DMD6VSY	IC	InChI=1S/C20H23NO3/c22-19(10-6-1-2-7-11-20(23)21-24)18-14-12-17(13-15-18)16-8-4-3-5-9-16/h3-5,8-9,12-15,24H,1-2,6-7,10-11H2,(H,21,23)
DMD6VSY	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCCCCCC(=O)NO
DMD6VSY	IK	LZZJBJLIOVNVKE-UHFFFAOYSA-N
DMD6VSY	IU	N-hydroxy-8-oxo-8-(4-phenylphenyl)octanamide
DMD6VSY	DE	Discovery agent

DM23XGW	ID	DM23XGW
DM23XGW	DN	8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one
DM23XGW	HS	Investigative
DM23XGW	SN	CHEMBL112148; SCHEMBL7364383; BDBM50218532
DM23XGW	DT	Small molecular drug
DM23XGW	PC	44341053
DM23XGW	MW	350.4
DM23XGW	FM	C20H21F3O2
DM23XGW	IC	InChI=1S/C20H21F3O2/c21-20(22,23)19(24)10-6-1-2-7-15-25-18-13-11-17(12-14-18)16-8-4-3-5-9-16/h3-5,8-9,11-14H,1-2,6-7,10,15H2
DM23XGW	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCC(=O)C(F)(F)F
DM23XGW	IK	LRVOZKXSFOOZRP-UHFFFAOYSA-N
DM23XGW	IU	1,1,1-trifluoro-8-(4-phenylphenoxy)octan-2-one
DM23XGW	DE	Discovery agent

DMDIGPW	ID	DMDIGPW
DMDIGPW	DN	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid
DMDIGPW	HS	Investigative
DMDIGPW	SN	CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-
DMDIGPW	DT	Small molecular drug
DMDIGPW	PC	44341224
DMDIGPW	MW	326.4
DMDIGPW	FM	C20H22O4
DMDIGPW	IC	InChI=1S/C20H22O4/c21-19(20(22)23)10-6-1-2-7-15-24-18-13-11-17(12-14-18)16-8-4-3-5-9-16/h3-5,8-9,11-14H,1-2,6-7,10,15H2,(H,22,23)
DMDIGPW	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCC(=O)C(=O)O
DMDIGPW	IK	VREZMJDAPPMITK-UHFFFAOYSA-N
DMDIGPW	IU	2-oxo-8-(4-phenylphenoxy)octanoic acid
DMDIGPW	CA	CAS 436150-72-0
DMDIGPW	DE	Discovery agent

DMT1NW2	ID	DMT1NW2
DMT1NW2	DN	8(S)-amino-2(R)-methyl-7-oxononanoic acid
DMT1NW2	HS	Investigative
DMT1NW2	SN	8(S)-Amino-2(R)-methyl-7-oxononanoic acid; CHEMBL465576; Nonanoic acid, 8-amino-2-methyl-7-oxo-, (S-(R*,S*))-; 181886-81-7; SCHEMBL4098289; AC1L42P6; DTXSID90171213; BDBM50292361; (2R,8S)-8-amino-2-methyl-7-oxononanoic acid; (2R,8S)-2-Methyl-7-oxo-8-aminononanoic acid
DMT1NW2	DT	Small molecular drug
DMT1NW2	PC	177363
DMT1NW2	MW	201.26
DMT1NW2	FM	C10H19NO3
DMT1NW2	IC	InChI=1S/C10H19NO3/c1-7(10(13)14)5-3-4-6-9(12)8(2)11/h7-8H,3-6,11H2,1-2H3,(H,13,14)/t7-,8+/m1/s1
DMT1NW2	CS	C[C@H](CCCCC(=O)[C@H](C)N)C(=O)O
DMT1NW2	IK	YBWPFLPQZXWNNM-SFYZADRCSA-N
DMT1NW2	IU	(2R,8S)-8-amino-2-methyl-7-oxononanoic acid
DMT1NW2	CA	CAS 181886-81-7
DMT1NW2	DE	Discovery agent

DMT3IOB	ID	DMT3IOB
DMT3IOB	DN	8-[(3-Trifluoromethyl)benzyloxy]caffeine
DMT3IOB	HS	Investigative
DMT3IOB	SN	8-[(3-Trifluoromethyl)benzyloxy]caffeine; CHEMBL602466
DMT3IOB	DT	Small molecular drug
DMT3IOB	PC	46232854
DMT3IOB	MW	368.31
DMT3IOB	FM	C16H15F3N4O3
DMT3IOB	IC	InChI=1S/C16H15F3N4O3/c1-21-11-12(22(2)15(25)23(3)13(11)24)20-14(21)26-8-9-5-4-6-10(7-9)16(17,18)19/h4-7H,8H2,1-3H3
DMT3IOB	CS	CN1C2=C(N=C1OCC3=CC(=CC=C3)C(F)(F)F)N(C(=O)N(C2=O)C)C
DMT3IOB	IK	MJKQEGLZEOPZNY-UHFFFAOYSA-N
DMT3IOB	IU	1,3,7-trimethyl-8-[[3-(trifluoromethyl)phenyl]methoxy]purine-2,6-dione
DMT3IOB	DE	Discovery agent

DM4R2EX	ID	DM4R2EX
DM4R2EX	DN	8-acetyl-7-(benzyloxy)-2H-chromen-2-one
DM4R2EX	HS	Investigative
DM4R2EX	SN	CHEMBL1290111; 65535-49-1; 8-acetyl-7-(benzyloxy)-2H-chromen-2-one; SCHEMBL7518570; CTK1J6469; DTXSID60555920; BDBM50332028; 8-Acetyl-7-(benzyloxy)-2H-1-benzopyran-2-one; 2H-1-Benzopyran-2-one, 8-acetyl-7-(phenylmethoxy)-
DM4R2EX	DT	Small molecular drug
DM4R2EX	PC	14101447
DM4R2EX	MW	294.3
DM4R2EX	FM	C18H14O4
DM4R2EX	IC	InChI=1S/C18H14O4/c1-12(19)17-15(21-11-13-5-3-2-4-6-13)9-7-14-8-10-16(20)22-18(14)17/h2-10H,11H2,1H3
DM4R2EX	CS	CC(=O)C1=C(C=CC2=C1OC(=O)C=C2)OCC3=CC=CC=C3
DM4R2EX	IK	QMLSJCDSHGYBMT-UHFFFAOYSA-N
DM4R2EX	IU	8-acetyl-7-phenylmethoxychromen-2-one
DM4R2EX	CA	CAS 65535-49-1
DM4R2EX	DE	Discovery agent

DMCTWBL	ID	DMCTWBL
DMCTWBL	DN	8-acetyl-7-butoxy-2H-chromen-2-one
DMCTWBL	HS	Investigative
DMCTWBL	SN	CHEMBL1288620; 8-acetyl-7-butoxy-2H-chromen-2-one
DMCTWBL	DT	Small molecular drug
DMCTWBL	PC	52943193
DMCTWBL	MW	260.279
DMCTWBL	FM	C15H16O4
DMCTWBL	IC	InChI=1S/C15H16O4/c1-3-4-9-18-12-7-5-11-6-8-13(17)19-15(11)14(12)10(2)16/h5-8H,3-4,9H2,1-2H3
DMCTWBL	CS	CCCCOC1=C(C2=C(C=C1)C=CC(=O)O2)C(=O)C
DMCTWBL	IK	ULYJCIVHEFSJIF-UHFFFAOYSA-N
DMCTWBL	IU	8-acetyl-7-butoxychromen-2-one
DMCTWBL	DE	Discovery agent

DMDV8UT	ID	DMDV8UT
DMDV8UT	DN	8-acetyl-7-ethoxy-2H-chromen-2-one
DMDV8UT	HS	Investigative
DMDV8UT	SN	CHEMBL1288595; 8-acetyl-7-ethoxy-2H-chromen-2-one
DMDV8UT	DT	Small molecular drug
DMDV8UT	PC	50925425
DMDV8UT	MW	232.23
DMDV8UT	FM	C13H12O4
DMDV8UT	IC	InChI=1S/C13H12O4/c1-3-16-10-6-4-9-5-7-11(15)17-13(9)12(10)8(2)14/h4-7H,3H2,1-2H3
DMDV8UT	CS	CCOC1=C(C2=C(C=C1)C=CC(=O)O2)C(=O)C
DMDV8UT	IK	KWMPAFCHEJYQEQ-UHFFFAOYSA-N
DMDV8UT	IU	8-acetyl-7-ethoxychromen-2-one
DMDV8UT	DE	Discovery agent

DMAMJW2	ID	DMAMJW2
DMAMJW2	DN	8-Acetyl-7-hydroxy-2H-chromen-2-one
DMAMJW2	HS	Investigative
DMAMJW2	SN	8-Acetyl-7-hydroxycoumarin; 6748-68-1; 8-acetyl-7-hydroxy-2H-chromen-2-one; 7-hydroxy-8-acetylcoumarin; CHEMBL446518; AN-829/13872055; AC1NTTTW; SCHEMBL4639845; CTK5C6237; 8-acetyl-7-hydroxychromen-2-one; DTXSID40419935; MolPort-003-821-703; 8-acetyl-7-hydroxy-2-oxochromene; ZINC366861; 8-acetyl-7-hydroxy-chromen-2-one; 8-Acetyl-7-hydroxycoumarin, 97%; BDBM50332038; MFCD00270162; 8 - Acetyl - 7 - hydroxycoumarin; AKOS022647720; OR345001; KB-200256; ST50309088; Z3067; 2H-1-Benzopyran-2-one, 8-acetyl-7-hydroxy-
DMAMJW2	DT	Small molecular drug
DMAMJW2	PC	5411574
DMAMJW2	MW	204.18
DMAMJW2	FM	C11H8O4
DMAMJW2	IC	InChI=1S/C11H8O4/c1-6(12)10-8(13)4-2-7-3-5-9(14)15-11(7)10/h2-5,13H,1H3
DMAMJW2	CS	CC(=O)C1=C(C=CC2=C1OC(=O)C=C2)O
DMAMJW2	IK	XWYMACPLPPQCHC-UHFFFAOYSA-N
DMAMJW2	IU	8-acetyl-7-hydroxychromen-2-one
DMAMJW2	CA	CAS 6748-68-1
DMAMJW2	DE	Discovery agent

DMZSJRC	ID	DMZSJRC
DMZSJRC	DN	8-acetyl-7-methoxy-2H-chromen-2-one
DMZSJRC	HS	Investigative
DMZSJRC	SN	8-Acetyl-7-methoxycoumarin; 8-acetyl-7-methoxy-2H-chromen-2-one; 89019-07-8; CHEMBL1288594; 8-Acetyl-7-methoxy-chromen-2-one; 2H-1-Benzopyran-2-one,8-acetyl-7-methoxy-; acetyl methoxycoumarin; ACMC-20lgfq; acetyl-7-methoxycoumarin, 8-; SCHEMBL16283617; CTK5G2445; DTXSID20556130; 8-acetyl-7-methoxy-2-oxochromene; 8-acetyl-7-methoxycoumarin ,98%; ZINC2562448; MFCD00270164; 8 - Acetyl - 7 - methoxycoumarin; BDBM50332024; 7-methoxy-8-coumarinul methyl ketone; AKOS016009510; RP27113; ST085908; AJ-40748; DB-078289; KB-200257; AX8111029
DMZSJRC	DT	Small molecular drug
DMZSJRC	PC	14116752
DMZSJRC	MW	218.2
DMZSJRC	FM	C12H10O4
DMZSJRC	IC	InChI=1S/C12H10O4/c1-7(13)11-9(15-2)5-3-8-4-6-10(14)16-12(8)11/h3-6H,1-2H3
DMZSJRC	CS	CC(=O)C1=C(C=CC2=C1OC(=O)C=C2)OC
DMZSJRC	IK	OTYBDEHZHXKGBO-UHFFFAOYSA-N
DMZSJRC	IU	8-acetyl-7-methoxychromen-2-one
DMZSJRC	CA	CAS 89019-07-8
DMZSJRC	DE	Discovery agent

DMGRK3V	ID	DMGRK3V
DMGRK3V	DN	8-acetyl-7-propoxy-2H-chromen-2-one
DMGRK3V	HS	Investigative
DMGRK3V	SN	CHEMBL1288596; 8-acetyl-7-propoxy-2H-chromen-2-one
DMGRK3V	DT	Small molecular drug
DMGRK3V	PC	52946829
DMGRK3V	MW	246.26
DMGRK3V	FM	C14H14O4
DMGRK3V	IC	InChI=1S/C14H14O4/c1-3-8-17-11-6-4-10-5-7-12(16)18-14(10)13(11)9(2)15/h4-7H,3,8H2,1-2H3
DMGRK3V	CS	CCCOC1=C(C2=C(C=C1)C=CC(=O)O2)C(=O)C
DMGRK3V	IK	XDGJEUMPGBUXDY-UHFFFAOYSA-N
DMGRK3V	IU	8-acetyl-7-propoxychromen-2-one
DMGRK3V	DE	Discovery agent

DM7K2DN	ID	DM7K2DN
DM7K2DN	DN	8alpha,19-dihydroxylabd-13 E-en-15-oic acid
DM7K2DN	HS	Investigative
DM7K2DN	SN	CHEBI:65789; (2E)-5-[(1R,2R,4aR,5R,8aS)-2-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyldecahydronaphthalen-1-yl]-3-methylpent-2-enoic acid; CHEMBL507405; 8alpha-19-dihydroxylabd-13E-ene-15-oic acid; 8alpha,19-dihydroxylabd-13E-ene-15-oic acid; (13E)-8,18-Dihydroxylabda-13-ene-15-oic acid
DM7K2DN	DT	Small molecular drug
DM7K2DN	PC	24899923
DM7K2DN	MW	338.5
DM7K2DN	FM	C20H34O4
DM7K2DN	IC	InChI=1S/C20H34O4/c1-14(12-17(22)23)6-7-16-19(3)10-5-9-18(2,13-21)15(19)8-11-20(16,4)24/h12,15-16,21,24H,5-11,13H2,1-4H3,(H,22,23)/b14-12+/t15-,16+,18-,19-,20+/m0/s1
DM7K2DN	CS	C/C(=C\\C(=O)O)/CC[C@@H]1[C@]2(CCC[C@@]([C@@H]2CC[C@@]1(C)O)(C)CO)C
DM7K2DN	IK	IYSBWLRXTOIYFZ-KBLZDMJYSA-N
DM7K2DN	IU	(E)-5-[(1R,2R,4aR,5R,8aS)-2-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enoic acid
DM7K2DN	CB	CHEBI:65789
DM7K2DN	DE	Discovery agent

DM84D9W	ID	DM84D9W
DM84D9W	DN	8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione
DM84D9W	HS	Investigative
DM84D9W	SN	8-Aminotheophylline; 8-Aminoteofiliny; Theophylline, 8-amino-; 19410-53-8; 8-Aminoteofiliny [Polish]; 8-AMINO-1,3-DIMETHYL-3,7-DIHYDROPURINE-2,6-DIONE; 1H-Purine-2,6-dione, 8-amino-3,7-dihydro-1,3-dimethyl-; 8-Amino-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-amino-1,3-dimethyl-7H-purine-2,6-dione; 8-amino-1,3-dimethyl-3,9-dihydro-1H-purine-2,6-dione; 8-amino-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 8-Aminotheophyline; 1rs2; AC1L3TFO; AC1Q6LC1; Oprea1_659892; Oprea1_298061; Oprea1_442990; CHEMBL298737
DM84D9W	DT	Small molecular drug
DM84D9W	PC	95034
DM84D9W	MW	195.18
DM84D9W	FM	C7H9N5O2
DM84D9W	IC	InChI=1S/C7H9N5O2/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h1-2H3,(H3,8,9,10)
DM84D9W	CS	CN1C2=C(C(=O)N(C1=O)C)NC(=N2)N
DM84D9W	IK	ZZESAIGPDOBLKZ-UHFFFAOYSA-N
DM84D9W	IU	8-amino-1,3-dimethyl-7H-purine-2,6-dione
DM84D9W	CA	CAS 19410-53-8
DM84D9W	DE	Discovery agent

DMTRBDP	ID	DMTRBDP
DMTRBDP	DN	8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMTRBDP	HS	Investigative
DMTRBDP	SN	SCHEMBL4662780; CHEMBL363363; BDBM27514; LQEYAIKMIJUZNT-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2a; ZINC13652898; 5,6-Dihydro-5-oxo-8-amino-indeno[1,2-c]isoquinoline
DMTRBDP	DT	Small molecular drug
DMTRBDP	PC	11736764
DMTRBDP	MW	248.28
DMTRBDP	FM	C16H12N2O
DMTRBDP	IC	InChI=1S/C16H12N2O/c17-10-6-5-9-7-14-11-3-1-2-4-12(11)16(19)18-15(14)13(9)8-10/h1-6,8H,7,17H2,(H,18,19)
DMTRBDP	CS	C1C2=C(C=C(C=C2)N)C3=C1C4=CC=CC=C4C(=O)N3
DMTRBDP	IK	LQEYAIKMIJUZNT-UHFFFAOYSA-N
DMTRBDP	IU	8-amino-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DMTRBDP	DE	Discovery agent

DMSNG7M	ID	DMSNG7M
DMSNG7M	DN	8-amino-9-benzylguanine
DMSNG7M	HS	Investigative
DMSNG7M	SN	8-Amino-9-benzylguanine; 100890-94-6; NSC650999; CHEMBL8230; NSC-650999; 6H-Purin-6-one,2,8-diamino-1,9-dihydro-9-(phenylmethyl)-; 8-Amino-9-benzyl-guanine; 8-ABG; 2,8-diamino-9-benzyl-3H-purin-6-one; ACMC-20m3xx; AC1L2SFN; SCHEMBL6359274; CTK3J9334; ZINC16958226; BDBM50005799; AKOS030559033; NCI60_017833; 2-amino-9-benzyl-8-imino-7H-purin-6-ol; 2-Amino-9-benzyl-8-imino-8,9-dihydro-7H-purin-6-ol; 6H-Purin-6-one,
DMSNG7M	DT	Small molecular drug
DMSNG7M	PC	135408972
DMSNG7M	MW	256.26
DMSNG7M	FM	C12H12N6O
DMSNG7M	IC	InChI=1S/C12H12N6O/c13-11-16-9-8(10(19)17-11)15-12(14)18(9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H2,14,15)(H3,13,16,17,19)
DMSNG7M	CS	C1=CC=C(C=C1)CN2C3=C(C(=O)NC(=N3)N)N=C2N
DMSNG7M	IK	DPDYTYOWSIRPMB-UHFFFAOYSA-N
DMSNG7M	IU	2,8-diamino-9-benzyl-1H-purin-6-one
DMSNG7M	CA	CAS 100890-94-6

DMYXJG7	ID	DMYXJG7
DMYXJG7	DN	8-AMINOGUANINE
DMYXJG7	HS	Investigative
DMYXJG7	DT	Small molecular drug
DMYXJG7	PC	135421887
DMYXJG7	MW	166.14
DMYXJG7	FM	C5H6N6O
DMYXJG7	IC	InChI=1S/C5H6N6O/c6-4-8-1-2(9-4)10-5(7)11-3(1)12/h(H6,6,7,8,9,10,11,12)
DMYXJG7	CS	C12=C(N=C(N1)N)N=C(NC2=O)N
DMYXJG7	IK	WYDKPTZGVLTYPG-UHFFFAOYSA-N
DMYXJG7	IU	2,8-diamino-1,7-dihydropurin-6-one
DMYXJG7	CA	CAS 28128-41-8
DMYXJG7	DE	Discovery agent

DM0JEA6	ID	DM0JEA6
DM0JEA6	DN	8-aminoguanosine
DM0JEA6	HS	Investigative
DM0JEA6	DT	Small molecular drug
DM0JEA6	PC	135518164
DM0JEA6	MW	298.26
DM0JEA6	FM	C10H14N6O5
DM0JEA6	IC	InChI=1S/C10H14N6O5/c11-9-14-6-3(7(20)15-9)13-10(12)16(6)8-5(19)4(18)2(1-17)21-8/h2,4-5,8,17-19H,1H2,(H2,12,13)(H3,11,14,15,20)/t2-,4-,5-,8-/m1/s1
DM0JEA6	CS	C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=C(C(=O)NC(=N3)N)N=C2N)O)O)O
DM0JEA6	IK	FNXPTCITVCRFRK-UMMCILCDSA-N
DM0JEA6	IU	2,8-diamino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DM0JEA6	CA	CAS 3868-32-4
DM0JEA6	DE	Discovery agent

DMN8QAF	ID	DMN8QAF
DMN8QAF	DN	8-aminoquinolines
DMN8QAF	HS	Investigative
DMN8QAF	SN	Hexamethonium; hexamethonium; Hexonium; Benzohexamethonium; Hexamethonum; Bistrium; Hexanium; 60-26-4; UNII-3C9PSP36Z2; Esametonio [Italian]; CHEMBL100622; CHEBI:5700; 3C9PSP36Z2; N,N,N,N',N',N'-hexamethylhexane-1,6-diaminium; NCGC00163239-01; Hexane-1,6-bis(trimethylammonium); 1,6-Hexanediaminium, N,N,N,N',N',N'-hexamethyl-; DSSTox_RID_80651; DSSTox_CID_25053; DSSTox_GSID_45053; BRN 1760389; Esametonio; CHEMBL332524; CAS-60-26-4; Hexamethonium [INN]; Ammonium, hexamethylenebis(trimethyl-; trimethyl-[6-(trimethylazaniumyl)hexyl]azanium
DMN8QAF	DT	Small molecular drug
DMN8QAF	PC	3604
DMN8QAF	MW	202.38
DMN8QAF	FM	C12H30N2+2
DMN8QAF	IC	InChI=1S/C12H30N2/c1-13(2,3)11-9-7-8-10-12-14(4,5)6/h7-12H2,1-6H3/q+2
DMN8QAF	CS	C[N+](C)(C)CCCCCC[N+](C)(C)C
DMN8QAF	IK	VZJFGSRCJCXDSG-UHFFFAOYSA-N
DMN8QAF	IU	trimethyl-[6-(trimethylazaniumyl)hexyl]azanium
DMN8QAF	CA	CAS 60-26-4
DMN8QAF	CB	CHEBI:5700
DMN8QAF	DE	Discovery agent

DMYBPGA	ID	DMYBPGA
DMYBPGA	DN	8-aza-11-deoxyprostaglandin E1
DMYBPGA	HS	Investigative
DMYBPGA	SN	CHEMBL42027; 8-aza-11-deoxyprostaglandin E1; BDBM50142481; 7-[(R)-2-((E)-(S)-3-Hydroxy-oct-1-enyl)-5-oxo-pyrrolidin-1-yl]-heptanoic acid
DMYBPGA	DT	Small molecular drug
DMYBPGA	PC	44289922
DMYBPGA	MW	339.5
DMYBPGA	FM	C19H33NO4
DMYBPGA	IC	InChI=1S/C19H33NO4/c1-2-3-6-9-17(21)13-11-16-12-14-18(22)20(16)15-8-5-4-7-10-19(23)24/h11,13,16-17,21H,2-10,12,14-15H2,1H3,(H,23,24)/b13-11+/t16-,17-/m0/s1
DMYBPGA	CS	CCCCC[C@@H](/C=C/[C@H]1CCC(=O)N1CCCCCCC(=O)O)O
DMYBPGA	IK	XOPMUDZOEKPBQZ-NSNJOPQOSA-N
DMYBPGA	IU	7-[(2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid
DMYBPGA	DE	Discovery agent

DMQMSZR	ID	DMQMSZR
DMQMSZR	DN	8-azabicyclo[3.2.1]octan-3-yloxy-benzamide
DMQMSZR	HS	Investigative
DMQMSZR	SN	CHEMBL1257578; CHEMBL1223815; SCHEMBL15031381; BDBM50325848; BDBM50327244; AZ-MTAB, &gt; ZINC101363709
DMQMSZR	DT	Small molecular drug
DMQMSZR	PC	49765077
DMQMSZR	MW	356.5
DMQMSZR	FM	C20H24N2O2S
DMQMSZR	IC	InChI=1S/C20H24N2O2S/c1-13-5-8-19(25-13)12-22-15-6-7-16(22)11-18(10-15)24-17-4-2-3-14(9-17)20(21)23/h2-5,8-9,15-16,18H,6-7,10-12H2,1H3,(H2,21,23)/t15-,16+,18?
DMQMSZR	CS	CC1=CC=C(S1)CN2[C@@H]3CC[C@H]2CC(C3)OC4=CC=CC(=C4)C(=O)N
DMQMSZR	IK	RLHOWHVHHMGIKE-BYICEURKSA-N
DMQMSZR	IU	3-[[(1S,5R)-8-[(5-methylthiophen-2-yl)methyl]-8-azabicyclo[3.2.1]octan-3-yl]oxy]benzamide
DMQMSZR	DE	Discovery agent

DMBVFKR	ID	DMBVFKR
DMBVFKR	DN	8-aza-DADMe-ImmH
DMBVFKR	HS	Investigative
DMBVFKR	DT	Small molecular drug
DMBVFKR	PC	56603748
DMBVFKR	DE	Discovery agent

DM7VP90	ID	DM7VP90
DM7VP90	DN	8-Azaguanine
DM7VP90	HS	Investigative
DM7VP90	DT	Small molecular drug
DM7VP90	PC	135403646
DM7VP90	MW	152.11
DM7VP90	FM	C4H4N6O
DM7VP90	IC	InChI=1S/C4H4N6O/c5-4-6-2-1(3(11)7-4)8-10-9-2/h(H4,5,6,7,8,9,10,11)
DM7VP90	CS	C12=NNN=C1N=C(NC2=O)N
DM7VP90	IK	LPXQRXLUHJKZIE-UHFFFAOYSA-N
DM7VP90	IU	5-amino-2,6-dihydrotriazolo[4,5-d]pyrimidin-7-one
DM7VP90	CA	CAS 134-58-7
DM7VP90	CB	CHEBI:63486
DM7VP90	DE	Discovery agent

DMT8QAP	ID	DMT8QAP
DMT8QAP	DN	8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
DMT8QAP	HS	Investigative
DMT8QAP	SN	8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-; CHEMBL326564; PU6; 8-(1,3-benzodioxol-5-ylmethyl)-9-butyl-9H-purin-6-amine; 1uy9; Purine-Based Inhibitor 4; AC1L9MK7; BDBM15377; DB08436; 8-(1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(2H-1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(1,3-Benzodioxole-5-ylmethyl)-9-butyl-9H-purine-6-amine
DMT8QAP	DT	Small molecular drug
DMT8QAP	PC	448968
DMT8QAP	MW	325.4
DMT8QAP	FM	C17H19N5O2
DMT8QAP	IC	InChI=1S/C17H19N5O2/c1-2-3-6-22-14(21-15-16(18)19-9-20-17(15)22)8-11-4-5-12-13(7-11)24-10-23-12/h4-5,7,9H,2-3,6,8,10H2,1H3,(H2,18,19,20)
DMT8QAP	CS	CCCCN1C(=NC2=C(N=CN=C21)N)CC3=CC4=C(C=C3)OCO4
DMT8QAP	IK	JCDXXNIRWRRGBX-UHFFFAOYSA-N
DMT8QAP	IU	8-(1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine
DMT8QAP	DE	Discovery agent

DM32OQB	ID	DM32OQB
DM32OQB	DN	8-benzyl-9H-purine-2,6-diamine
DM32OQB	HS	Investigative
DM32OQB	SN	8-Benzyl-9H-purine-2,6-diamine; CHEMBL102303; 9H-Purine-2,6-diamine, 8-(phenylmethyl)-; AC1L9X4P; SCHEMBL3923325; 8-benzyl-7H-purine-2,6-diamine; BDBM50059941
DM32OQB	DT	Small molecular drug
DM32OQB	PC	457735
DM32OQB	MW	240.26
DM32OQB	FM	C12H12N6
DM32OQB	IC	InChI=1S/C12H12N6/c13-10-9-11(18-12(14)17-10)16-8(15-9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H5,13,14,15,16,17,18)
DM32OQB	CS	C1=CC=C(C=C1)CC2=NC3=NC(=NC(=C3N2)N)N
DM32OQB	IK	AFWYNOWVYKOMGZ-UHFFFAOYSA-N
DM32OQB	IU	8-benzyl-7H-purine-2,6-diamine
DM32OQB	DE	Discovery agent

DMKHF87	ID	DMKHF87
DMKHF87	DN	8-benzylnaringenin
DMKHF87	HS	Investigative
DMKHF87	SN	8-benzylnaringenin
DMKHF87	DT	Small molecular drug
DMKHF87	PC	44418733
DMKHF87	MW	362.4
DMKHF87	FM	C22H18O5
DMKHF87	IC	InChI=1S/C22H18O5/c23-15-8-6-14(7-9-15)20-12-19(26)21-18(25)11-17(24)16(22(21)27-20)10-13-4-2-1-3-5-13/h1-9,11,20,23-25H,10,12H2/t20-/m0/s1
DMKHF87	CS	C1[C@H](OC2=C(C(=CC(=C2C1=O)O)O)CC3=CC=CC=C3)C4=CC=C(C=C4)O
DMKHF87	IK	JCMOCGVRZVEPSS-FQEVSTJZSA-N
DMKHF87	IU	(2S)-8-benzyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMKHF87	DE	Discovery agent

DMJQ8AP	ID	DMJQ8AP
DMJQ8AP	DN	8-Benzyloxycaffeine
DMJQ8AP	HS	Investigative
DMJQ8AP	SN	8-Benzyloxycaffeine; CHEMBL602259; 8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1h-purine-2,6-dione; 5422-51-5; NSC11301; AC1L5CNO; ChemDiv2_004644; AC1Q6NU8; MLS000115142; cid_223566; SCHEMBL15648367; CTK5A0068; DTXSID60279114; HMS1382D02; HMS2252G09; NSC-11301; BDBM50306696; ZINC37868689; AKOS001694622; CCG-117368; IDI1_003359; SMR000092353
DMJQ8AP	DT	Small molecular drug
DMJQ8AP	PC	223566
DMJQ8AP	MW	300.31
DMJQ8AP	FM	C15H16N4O3
DMJQ8AP	IC	InChI=1S/C15H16N4O3/c1-17-11-12(18(2)15(21)19(3)13(11)20)16-14(17)22-9-10-7-5-4-6-8-10/h4-8H,9H2,1-3H3
DMJQ8AP	CS	CN1C2=C(N=C1OCC3=CC=CC=C3)N(C(=O)N(C2=O)C)C
DMJQ8AP	IK	LSJWXGMOPMJCHP-UHFFFAOYSA-N
DMJQ8AP	IU	1,3,7-trimethyl-8-phenylmethoxypurine-2,6-dione
DMJQ8AP	CA	CAS 5422-51-5
DMJQ8AP	DE	Discovery agent

DMMCAZG	ID	DMMCAZG
DMMCAZG	DN	8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one
DMMCAZG	HS	Investigative
DMMCAZG	SN	CHEMBL425391; 8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one
DMMCAZG	DT	Small molecular drug
DMMCAZG	PC	11552705
DMMCAZG	MW	383.4
DMMCAZG	FM	C25H21NO3
DMMCAZG	IC	InChI=1S/C25H21NO3/c27-23-17-24(26-13-15-28-16-14-26)29-25-21(11-6-12-22(23)25)20-10-5-4-9-19(20)18-7-2-1-3-8-18/h1-12,17H,13-16H2
DMMCAZG	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4C5=CC=CC=C5
DMMCAZG	IK	VKLCRMQPVMPSKE-UHFFFAOYSA-N
DMMCAZG	IU	2-morpholin-4-yl-8-(2-phenylphenyl)chromen-4-one
DMMCAZG	DE	Discovery agent

DMVPIYG	ID	DMVPIYG
DMVPIYG	DN	8-Br-adenine
DMVPIYG	HS	Investigative
DMVPIYG	SN	8-Bromoadenine; 8-bromo-7H-purin-6-amine; 6974-78-3; 8-Bromo-9H-purin-6-amine; 8-Br-adenine; 8-Bromo-1H-adenine; 6-Amino-8-bromopurine; 8-bromopurine-6-ylamine; EINECS 230-225-1; NSC 21697; CHEMBL65747; 8-Bromo-9H-purin-6-ylamine; FVXHPCVBOXMRJP-UHFFFAOYSA-N; W-203555; 1H-Purin-6-amine, 8-bromo-; 8-bromo-1h-purin-6-amine; 8-bromadenin; 8-Bromo adenine; SCHEMBL8565; AC1L31DI; Oprea1_043695; 8-Bromo-9H-purine-6-amine; 9H-Purin-6-amine,2-bromo-; 9H-Purin-6-amine,8-bromo-; 8-Bromo-9H-purin-6-amine #; CTK4G0895; DTXSID70220036
DMVPIYG	DT	Small molecular drug
DMVPIYG	PC	81457
DMVPIYG	MW	214.02
DMVPIYG	FM	C5H4BrN5
DMVPIYG	IC	InChI=1S/C5H4BrN5/c6-5-10-2-3(7)8-1-9-4(2)11-5/h1H,(H3,7,8,9,10,11)
DMVPIYG	CS	C1=NC(=C2C(=N1)N=C(N2)Br)N
DMVPIYG	IK	FVXHPCVBOXMRJP-UHFFFAOYSA-N
DMVPIYG	IU	8-bromo-7H-purin-6-amine
DMVPIYG	CA	CAS 6974-78-3
DMVPIYG	DE	Discovery agent

DMALRU4	ID	DMALRU4
DMALRU4	DN	8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMALRU4	HS	Investigative
DMALRU4	SN	8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline; CHEMBL6857; BDBM50136494; AKOS022804102
DMALRU4	DT	Small molecular drug
DMALRU4	PC	10467319
DMALRU4	MW	251.12
DMALRU4	FM	C11H11BrN2
DMALRU4	IC	InChI=1S/C11H11BrN2/c12-9-3-1-2-8-7-4-5-13-6-10(7)14-11(8)9/h1-3,13-14H,4-6H2
DMALRU4	CS	C1CNCC2=C1C3=C(N2)C(=CC=C3)Br
DMALRU4	IK	QDAJATJOFYZEDN-UHFFFAOYSA-N
DMALRU4	IU	8-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMALRU4	DE	Discovery agent

DMPVU7H	ID	DMPVU7H
DMPVU7H	DN	8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMPVU7H	HS	Investigative
DMPVU7H	SN	SCHEMBL9007836; CHEMBL143380
DMPVU7H	DT	Small molecular drug
DMPVU7H	PC	10400801
DMPVU7H	MW	268.06
DMPVU7H	FM	C10H6BrNO3
DMPVU7H	IC	InChI=1S/C10H6BrNO3/c11-5-1-2-6-7(3-5)12-10(15)9(14)4-8(6)13/h1-4,13H,(H,12,14,15)
DMPVU7H	CS	C1=CC2=C(C=C1Br)NC(=O)C(=O)C=C2O
DMPVU7H	IK	VCORQELOMRIIBS-UHFFFAOYSA-N
DMPVU7H	IU	8-bromo-5-hydroxy-1H-1-benzazepine-2,3-dione
DMPVU7H	DE	Discovery agent

DM4V5RU	ID	DM4V5RU
DM4V5RU	DN	8-Bromo-4,9-dihydro-3H-beta-carboline
DM4V5RU	HS	Investigative
DM4V5RU	SN	CHEMBL6746; 8-Bromo-4,9-dihydro-3H-beta-carboline; BDBM50136503
DM4V5RU	DT	Small molecular drug
DM4V5RU	PC	44264251
DM4V5RU	MW	249.11
DM4V5RU	FM	C11H9BrN2
DM4V5RU	IC	InChI=1S/C11H9BrN2/c12-9-3-1-2-8-7-4-5-13-6-10(7)14-11(8)9/h1-3,6,14H,4-5H2
DM4V5RU	CS	C1CN=CC2=C1C3=C(N2)C(=CC=C3)Br
DM4V5RU	IK	BHLUQLWTEJKCOP-UHFFFAOYSA-N
DM4V5RU	IU	8-bromo-4,9-dihydro-3H-pyrido[3,4-b]indole
DM4V5RU	DE	Discovery agent

DM51FL9	ID	DM51FL9
DM51FL9	DN	8-Bromo-6-methyl-3-(4'-methoxyphenyl)coumarin
DM51FL9	HS	Investigative
DM51FL9	SN	CHEMBL1221980; SCHEMBL17857193; BDBM50324964
DM51FL9	DT	Small molecular drug
DM51FL9	PC	46933990
DM51FL9	MW	345.2
DM51FL9	FM	C17H13BrO3
DM51FL9	IC	InChI=1S/C17H13BrO3/c1-10-7-12-9-14(11-3-5-13(20-2)6-4-11)17(19)21-16(12)15(18)8-10/h3-9H,1-2H3
DM51FL9	CS	CC1=CC2=C(C(=C1)Br)OC(=O)C(=C2)C3=CC=C(C=C3)OC
DM51FL9	IK	QMFYGKBIXCRXNB-UHFFFAOYSA-N
DM51FL9	IU	8-bromo-3-(4-methoxyphenyl)-6-methylchromen-2-one
DM51FL9	DE	Discovery agent

DMD1LM8	ID	DMD1LM8
DMD1LM8	DN	8-Bromo-6-methyl-3-phenylcoumarin
DMD1LM8	HS	Investigative
DMD1LM8	SN	CHEMBL1221930; 8-Bromo-6-methyl-3-phenylcoumarin; SCHEMBL17857186; 8-bromo-3-phenyl-6-methylcumarin
DMD1LM8	DT	Small molecular drug
DMD1LM8	PC	46933989
DMD1LM8	MW	315.16
DMD1LM8	FM	C16H11BrO2
DMD1LM8	IC	InChI=1S/C16H11BrO2/c1-10-7-12-9-13(11-5-3-2-4-6-11)16(18)19-15(12)14(17)8-10/h2-9H,1H3
DMD1LM8	CS	CC1=CC2=C(C(=C1)Br)OC(=O)C(=C2)C3=CC=CC=C3
DMD1LM8	IK	TYLXEMSZGAPZTD-UHFFFAOYSA-N
DMD1LM8	IU	8-bromo-6-methyl-3-phenylchromen-2-one
DMD1LM8	DE	Discovery agent

DMKU06T	ID	DMKU06T
DMKU06T	DN	8-Bromo-6-styryl-naphthalene-2-carboxamidine
DMKU06T	HS	Investigative
DMKU06T	SN	CHEMBL360703; 8-Bromo-6-styryl-naphthalene-2-carboxamidine; BDBM50157086
DMKU06T	DT	Small molecular drug
DMKU06T	PC	44392405
DMKU06T	MW	351.2
DMKU06T	FM	C19H15BrN2
DMKU06T	IC	InChI=1S/C19H15BrN2/c20-18-11-14(7-6-13-4-2-1-3-5-13)10-15-8-9-16(19(21)22)12-17(15)18/h1-12H,(H3,21,22)/b7-6+
DMKU06T	CS	C1=CC=C(C=C1)/C=C/C2=CC(=C3C=C(C=CC3=C2)C(=N)N)Br
DMKU06T	IK	QHYGSRQJBXWIGI-VOTSOKGWSA-N
DMKU06T	IU	8-bromo-6-[(E)-2-phenylethenyl]naphthalene-2-carboximidamide
DMKU06T	DE	Discovery agent

DMMQ79W	ID	DMMQ79W
DMMQ79W	DN	8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine
DMMQ79W	HS	Investigative
DMMQ79W	SN	CHEMBL505633; 3-(6-amino-8-bromopurin-9-yl)propane-1,2-diol; 3-(6-Amino-8-bromo-purin-9-yl)-propane-1,2-diol; AC1MCMJY; 8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine; C8H10BrN5O2; Oprea1_182885; Oprea1_060925; MolPort-000-712-951; 3-(6-AMINO-8-BROMO-9H-PURIN-9-YL)PROPANE-1,2-DIOL; STL558390; CCG-18677; BDBM50257096; AKOS001644314; MCULE-9507586118; BAS 00110783; 69369-04-6; ST50975882
DMMQ79W	DT	Small molecular drug
DMMQ79W	PC	2773172
DMMQ79W	MW	288.1
DMMQ79W	FM	C8H10BrN5O2
DMMQ79W	IC	InChI=1S/C8H10BrN5O2/c9-8-13-5-6(10)11-3-12-7(5)14(8)1-4(16)2-15/h3-4,15-16H,1-2H2,(H2,10,11,12)
DMMQ79W	CS	C1=NC(=C2C(=N1)N(C(=N2)Br)CC(CO)O)N
DMMQ79W	IK	XXTHNUCUAMMCPB-UHFFFAOYSA-N
DMMQ79W	IU	3-(6-amino-8-bromopurin-9-yl)propane-1,2-diol
DMMQ79W	DE	Discovery agent

DM5DCPF	ID	DM5DCPF
DM5DCPF	DN	8-Bromo-9-(2-butyl)-9H-adenine
DM5DCPF	HS	Investigative
DM5DCPF	SN	CHEMBL505089; 202136-43-4; (8-bromo-9-butyl-9H-purin-6-yl)amine; 8-Bromo-9-(2-butyl)-9H-adenine; 8-bromo-9-butyladenine; SCHEMBL1965296; CTK4E3576; DTXSID80469393; FKNNQOCJLMQVAV-UHFFFAOYSA-N; BDBM50256953; AKOS015965383; 9H-Purin-6-amine,8-bromo-9-butyl-
DM5DCPF	DT	Small molecular drug
DM5DCPF	PC	11608719
DM5DCPF	MW	270.13
DM5DCPF	FM	C9H12BrN5
DM5DCPF	IC	InChI=1S/C9H12BrN5/c1-2-3-4-15-8-6(14-9(15)10)7(11)12-5-13-8/h5H,2-4H2,1H3,(H2,11,12,13)
DM5DCPF	CS	CCCCN1C2=NC=NC(=C2N=C1Br)N
DM5DCPF	IK	FKNNQOCJLMQVAV-UHFFFAOYSA-N
DM5DCPF	IU	8-bromo-9-butylpurin-6-amine
DM5DCPF	CA	CAS 202136-43-4
DM5DCPF	DE	Discovery agent

DMKW2PE	ID	DMKW2PE
DMKW2PE	DN	8-Bromo-9-(2-hydroxypropyl)-9H-adenine
DMKW2PE	HS	Investigative
DMKW2PE	SN	8-Bromo-9-(2-hydroxypropyl)-9H-adenine; CHEMBL475617; 98411-78-0
DMKW2PE	DT	Small molecular drug
DMKW2PE	PC	44572473
DMKW2PE	MW	272.1
DMKW2PE	FM	C8H10BrN5O
DMKW2PE	IC	InChI=1S/C8H10BrN5O/c1-4(15)2-14-7-5(13-8(14)9)6(10)11-3-12-7/h3-4,15H,2H2,1H3,(H2,10,11,12)
DMKW2PE	CS	CC(CN1C2=NC=NC(=C2N=C1Br)N)O
DMKW2PE	IK	MMKXSEBGGSBLDX-UHFFFAOYSA-N
DMKW2PE	IU	1-(6-amino-8-bromopurin-9-yl)propan-2-ol
DMKW2PE	DE	Discovery agent

DMA258T	ID	DMA258T
DMA258T	DN	8-Bromo-9-(3-hydroxypropyl)-9H-adenine
DMA258T	HS	Investigative
DMA258T	SN	8-Bromo-9-(3-hydroxypropyl)-9H-adenine; CHEMBL475455; 98411-75-7
DMA258T	DT	Small molecular drug
DMA258T	PC	44572471
DMA258T	MW	272.1
DMA258T	FM	C8H10BrN5O
DMA258T	IC	InChI=1S/C8H10BrN5O/c9-8-13-5-6(10)11-4-12-7(5)14(8)2-1-3-15/h4,15H,1-3H2,(H2,10,11,12)
DMA258T	CS	C1=NC(=C2C(=N1)N(C(=N2)Br)CCCO)N
DMA258T	IK	MUZYIFHIQGFDMZ-UHFFFAOYSA-N
DMA258T	IU	3-(6-amino-8-bromopurin-9-yl)propan-1-ol
DMA258T	DE	Discovery agent

DMXNF3V	ID	DMXNF3V
DMXNF3V	DN	8-Bromo-9-(but-3-enyl)-9H-adenine
DMXNF3V	HS	Investigative
DMXNF3V	SN	CHEMBL508561; 8-Bromo-9-(but-3-enyl)-9H-adenine
DMXNF3V	DT	Small molecular drug
DMXNF3V	PC	44572357
DMXNF3V	MW	268.11
DMXNF3V	FM	C9H10BrN5
DMXNF3V	IC	InChI=1S/C9H10BrN5/c1-2-3-4-15-8-6(14-9(15)10)7(11)12-5-13-8/h2,5H,1,3-4H2,(H2,11,12,13)
DMXNF3V	CS	C=CCCN1C2=NC=NC(=C2N=C1Br)N
DMXNF3V	IK	PZPGDJLTSOBNOR-UHFFFAOYSA-N
DMXNF3V	IU	8-bromo-9-but-3-enylpurin-6-amine
DMXNF3V	DE	Discovery agent

DMSQPFM	ID	DMSQPFM
DMSQPFM	DN	8-Bromo-9-(sec-butyl)-9H-adenine
DMSQPFM	HS	Investigative
DMSQPFM	SN	CHEMBL509367; 8-Bromo-9-(sec-butyl)-9H-adenine
DMSQPFM	DT	Small molecular drug
DMSQPFM	PC	44572295
DMSQPFM	MW	270.13
DMSQPFM	FM	C9H12BrN5
DMSQPFM	IC	InChI=1S/C9H12BrN5/c1-3-5(2)15-8-6(14-9(15)10)7(11)12-4-13-8/h4-5H,3H2,1-2H3,(H2,11,12,13)
DMSQPFM	CS	CCC(C)N1C2=NC=NC(=C2N=C1Br)N
DMSQPFM	IK	HDNHXVSBLXMYPH-UHFFFAOYSA-N
DMSQPFM	IU	8-bromo-9-butan-2-ylpurin-6-amine
DMSQPFM	DE	Discovery agent

DMUTV76	ID	DMUTV76
DMUTV76	DN	8-Bromo-9-cyclobutyl-9H-adenine
DMUTV76	HS	Investigative
DMUTV76	SN	CHEMBL515419; 8-Bromo-9-cyclobutyl-9H-adenine
DMUTV76	DT	Small molecular drug
DMUTV76	PC	44572409
DMUTV76	MW	268.11
DMUTV76	FM	C9H10BrN5
DMUTV76	IC	InChI=1S/C9H10BrN5/c10-9-14-6-7(11)12-4-13-8(6)15(9)5-2-1-3-5/h4-5H,1-3H2,(H2,11,12,13)
DMUTV76	CS	C1CC(C1)N2C3=NC=NC(=C3N=C2Br)N
DMUTV76	IK	ODVHXPRTEZXIFW-UHFFFAOYSA-N
DMUTV76	IU	8-bromo-9-cyclobutylpurin-6-amine
DMUTV76	DE	Discovery agent

DMLVCON	ID	DMLVCON
DMLVCON	DN	8-Bromo-9-cyclohexyl-9H-adenine
DMLVCON	HS	Investigative
DMLVCON	SN	8-Bromo-9-cyclohexyl-9H-adenine; CHEMBL516238; BDBM50256952
DMLVCON	DT	Small molecular drug
DMLVCON	PC	44572356
DMLVCON	MW	296.17
DMLVCON	FM	C11H14BrN5
DMLVCON	IC	InChI=1S/C11H14BrN5/c12-11-16-8-9(13)14-6-15-10(8)17(11)7-4-2-1-3-5-7/h6-7H,1-5H2,(H2,13,14,15)
DMLVCON	CS	C1CCC(CC1)N2C3=NC=NC(=C3N=C2Br)N
DMLVCON	IK	IVKXIMVGTFMPDF-UHFFFAOYSA-N
DMLVCON	IU	8-bromo-9-cyclohexylpurin-6-amine
DMLVCON	DE	Discovery agent

DMCK0O1	ID	DMCK0O1
DMCK0O1	DN	8-Bromo-9-cyclopentyl-9H-adenine
DMCK0O1	HS	Investigative
DMCK0O1	SN	CHEMBL449924; 8-Bromo-9-cyclopentyl-9H-adenine; SCHEMBL5732373
DMCK0O1	DT	Small molecular drug
DMCK0O1	PC	12016633
DMCK0O1	MW	282.14
DMCK0O1	FM	C10H12BrN5
DMCK0O1	IC	InChI=1S/C10H12BrN5/c11-10-15-7-8(12)13-5-14-9(7)16(10)6-3-1-2-4-6/h5-6H,1-4H2,(H2,12,13,14)
DMCK0O1	CS	C1CCC(C1)N2C3=NC=NC(=C3N=C2Br)N
DMCK0O1	IK	UIZPGNXMMMDTHD-UHFFFAOYSA-N
DMCK0O1	IU	8-bromo-9-cyclopentylpurin-6-amine
DMCK0O1	DE	Discovery agent

DM4YAD6	ID	DM4YAD6
DM4YAD6	DN	8-Bromo-9-ethyl-9H-adenine
DM4YAD6	HS	Investigative
DM4YAD6	SN	8-bromo-9-ethyladenine; CHEMBL468633; 21031-79-8; 8-Bromo-9-ethyl-9H-adenine; AC1NRVH3; SCHEMBL1755068; ANR-82; 8-bromo-9-ethylpurin-6-amine
DM4YAD6	DT	Small molecular drug
DM4YAD6	PC	5248753
DM4YAD6	MW	242.08
DM4YAD6	FM	C7H8BrN5
DM4YAD6	IC	InChI=1S/C7H8BrN5/c1-2-13-6-4(12-7(13)8)5(9)10-3-11-6/h3H,2H2,1H3,(H2,9,10,11)
DM4YAD6	CS	CCN1C2=NC=NC(=C2N=C1Br)N
DM4YAD6	IK	GACDSQLJMZANKT-UHFFFAOYSA-N
DM4YAD6	IU	8-bromo-9-ethylpurin-6-amine
DM4YAD6	DE	Discovery agent

DMZF3UN	ID	DMZF3UN
DMZF3UN	DN	8-bromo-9-isobutyl-9H-purin-6-amine
DMZF3UN	HS	Investigative
DMZF3UN	SN	CHEMBL474207; 8-bromo-9-isobutyl-9H-purin-6-amine; 8-Bromo-9-isobutyl-9H-adenine
DMZF3UN	DT	Small molecular drug
DMZF3UN	PC	44572355
DMZF3UN	MW	270.13
DMZF3UN	FM	C9H12BrN5
DMZF3UN	IC	InChI=1S/C9H12BrN5/c1-5(2)3-15-8-6(14-9(15)10)7(11)12-4-13-8/h4-5H,3H2,1-2H3,(H2,11,12,13)
DMZF3UN	CS	CC(C)CN1C2=NC=NC(=C2N=C1Br)N
DMZF3UN	IK	RLPKQFORPDRBQT-UHFFFAOYSA-N
DMZF3UN	IU	8-bromo-9-(2-methylpropyl)purin-6-amine
DMZF3UN	DE	Discovery agent

DMIN9HC	ID	DMIN9HC
DMIN9HC	DN	8-Bromo-9-isopropyl-9H-adenine
DMIN9HC	HS	Investigative
DMIN9HC	SN	CHEMBL446264; 8-Bromo-9-isopropyl-9H-adenine; BDBM50256895
DMIN9HC	DT	Small molecular drug
DMIN9HC	PC	44572292
DMIN9HC	MW	256.1
DMIN9HC	FM	C8H10BrN5
DMIN9HC	IC	InChI=1S/C8H10BrN5/c1-4(2)14-7-5(13-8(14)9)6(10)11-3-12-7/h3-4H,1-2H3,(H2,10,11,12)
DMIN9HC	CS	CC(C)N1C2=NC=NC(=C2N=C1Br)N
DMIN9HC	IK	AFKIJCJUVRTHPD-UHFFFAOYSA-N
DMIN9HC	IU	8-bromo-9-propan-2-ylpurin-6-amine
DMIN9HC	DE	Discovery agent

DM1DS3B	ID	DM1DS3B
DM1DS3B	DN	8-Bromo-9-methyl-9H-adenine
DM1DS3B	HS	Investigative
DM1DS3B	SN	8-Bromo-9-methyl-9H-adenine; 8-bromo-9-methyladenine; CHEMBL510288; 56489-40-8; AC1LGJ6D; Oprea1_555380; SCHEMBL8832637; 8-bromo-9-methylpurin-6-amine; CTK1E1875; DTXSID90356366; ICJDGKILGBQWGF-UHFFFAOYSA-N; BDBM50256842; AKOS022687396; 6-Amino-8-bromo-9-methyl-9H-purine; 9H-Purin-6-amine, 8-bromo-9-methyl-
DM1DS3B	DT	Small molecular drug
DM1DS3B	PC	822296
DM1DS3B	MW	228.05
DM1DS3B	FM	C6H6BrN5
DM1DS3B	IC	InChI=1S/C6H6BrN5/c1-12-5-3(11-6(12)7)4(8)9-2-10-5/h2H,1H3,(H2,8,9,10)
DM1DS3B	CS	CN1C2=NC=NC(=C2N=C1Br)N
DM1DS3B	IK	ICJDGKILGBQWGF-UHFFFAOYSA-N
DM1DS3B	IU	8-bromo-9-methylpurin-6-amine
DM1DS3B	CA	CAS 56489-40-8
DM1DS3B	DE	Discovery agent

DMB7EWZ	ID	DMB7EWZ
DMB7EWZ	DN	8-Bromo-9-phenylethyl-9H-adenine
DMB7EWZ	HS	Investigative
DMB7EWZ	SN	CHEMBL503376; 8-Bromo-9-phenylethyl-9H-adenine; SCHEMBL5364361
DMB7EWZ	DT	Small molecular drug
DMB7EWZ	PC	12016636
DMB7EWZ	MW	318.17
DMB7EWZ	FM	C13H12BrN5
DMB7EWZ	IC	InChI=1S/C13H12BrN5/c14-13-18-10-11(15)16-8-17-12(10)19(13)7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H2,15,16,17)
DMB7EWZ	CS	C1=CC=C(C=C1)CCN2C3=NC=NC(=C3N=C2Br)N
DMB7EWZ	IK	LQIMXMMBTNEKMZ-UHFFFAOYSA-N
DMB7EWZ	IU	8-bromo-9-(2-phenylethyl)purin-6-amine
DMB7EWZ	DE	Discovery agent

DMRIPU5	ID	DMRIPU5
DMRIPU5	DN	8-Bromo-9-propyl-9H-adenine
DMRIPU5	HS	Investigative
DMRIPU5	SN	CHEMBL506450; 8-bromo-9-propyl-9H-purin-6-ylamine; 908355-66-8; 8-Bromo-9-propyl-9H-adenine; BDBM50256893; 8-Bromo-9-propyl-9H-purine-6-amine
DMRIPU5	DT	Small molecular drug
DMRIPU5	PC	11849871
DMRIPU5	MW	256.1
DMRIPU5	FM	C8H10BrN5
DMRIPU5	IC	InChI=1S/C8H10BrN5/c1-2-3-14-7-5(13-8(14)9)6(10)11-4-12-7/h4H,2-3H2,1H3,(H2,10,11,12)
DMRIPU5	CS	CCCN1C2=NC=NC(=C2N=C1Br)N
DMRIPU5	IK	ATNWURROUOXVHM-UHFFFAOYSA-N
DMRIPU5	IU	8-bromo-9-propylpurin-6-amine
DMRIPU5	DE	Discovery agent

DM4CV1E	ID	DM4CV1E
DM4CV1E	DN	8-Bromo-Adenosine-5'-Monophosphate
DM4CV1E	HS	Investigative
DM4CV1E	SN	8-Bromoadenosine 5'-monophosphate; 8-BROMO-ADENOSINE-5'-MONOPHOSPHATE; 8-Bromoadenosine 5'-(dihydrogen phosphate); 23567-96-6; 8-Br-AMP; CHEMBL1230617; 8-Bromo-Adenosine Mono Phosphate; 50828-34-7; Poly 8-bromoadenylic acid; 8BR; Poly(8-bra); Poly(8-bromoriboadenylic acid); 8-Bromo-AMP; Adenosine, 8-bromo-, 5'-(dihydrogen phosphate); AC1L518I; SCHEMBL4315602; AC1Q270V; CTK4J3218; 23567-96-6 (monomer); DNPIJKNXFSPNNY-UUOKFMHZSA-N; 8-bromoadenosine-5'-monophosphate; 50828-34-7 (Parent); ZINC13527361; MFCD00056945; BDBM50222467
DM4CV1E	DT	Small molecular drug
DM4CV1E	PC	168120
DM4CV1E	MW	426.12
DM4CV1E	FM	C10H13BrN5O7P
DM4CV1E	IC	InChI=1S/C10H13BrN5O7P/c11-10-15-4-7(12)13-2-14-8(4)16(10)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,13,14)(H2,19,20,21)/t3-,5-,6-,9-/m1/s1
DM4CV1E	CS	C1=NC(=C2C(=N1)N(C(=N2)Br)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N
DM4CV1E	IK	DNPIJKNXFSPNNY-UUOKFMHZSA-N
DM4CV1E	IU	[(2R,3S,4R,5R)-5-(6-amino-8-bromopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM4CV1E	CA	CAS 23567-96-6
DM4CV1E	DE	Discovery agent

DM5RFCN	ID	DM5RFCN
DM5RFCN	DN	8-Butoxy-quinolin-2-ylamine
DM5RFCN	HS	Investigative
DM5RFCN	SN	CHEMBL186659; 8-Butoxy-quinolin-2-ylamine; SCHEMBL5884456
DM5RFCN	DT	Small molecular drug
DM5RFCN	PC	10443307
DM5RFCN	MW	216.28
DM5RFCN	FM	C13H16N2O
DM5RFCN	IC	InChI=1S/C13H16N2O/c1-2-3-9-16-11-6-4-5-10-7-8-12(14)15-13(10)11/h4-8H,2-3,9H2,1H3,(H2,14,15)
DM5RFCN	CS	CCCCOC1=CC=CC2=C1N=C(C=C2)N
DM5RFCN	IK	RANHBKGFWNIVKN-UHFFFAOYSA-N
DM5RFCN	IU	8-butoxyquinolin-2-amine
DM5RFCN	DE	Discovery agent

DMD18V5	ID	DMD18V5
DMD18V5	DN	8-carboxamidocyclazocine
DMD18V5	HS	Investigative
DMD18V5	SN	8-carboxamidocyclazocine; CHEMBL58646; 8-CAC; SCHEMBL12014004; (6S,11R)-3-Cyclopropylmethyl-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-8-carboxylic acid amide; PDSP1_000954; PDSP2_000939
DMD18V5	DT	Small molecular drug
DMD18V5	PC	10086063
DMD18V5	MW	298.4
DMD18V5	FM	C19H26N2O
DMD18V5	IC	InChI=1S/C19H26N2O/c1-12-17-10-14-5-6-15(18(20)22)9-16(14)19(12,2)7-8-21(17)11-13-3-4-13/h5-6,9,12-13,17H,3-4,7-8,10-11H2,1-2H3,(H2,20,22)/t12-,17?,19-/m0/s1
DMD18V5	CS	C[C@H]1C2CC3=C([C@]1(CCN2CC4CC4)C)C=C(C=C3)C(=O)N
DMD18V5	IK	FAVQVALXVLMHLE-BKBNBNODSA-N
DMD18V5	IU	(1S,13R)-10-(cyclopropylmethyl)-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-triene-4-carboxamide
DMD18V5	DE	Discovery agent

DMS7DA3	ID	DMS7DA3
DMS7DA3	DN	8-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DMS7DA3	HS	Investigative
DMS7DA3	SN	CHEMBL134057; 8-chloro-1,2,3,4-tetrahydroacridin-9-amine; 122994-74-5; 8-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine; SCHEMBL9584574; MolPort-039-242-295; ZINC27416388; BDBM50279984; AKOS033887449; 9-Amino-8-chloro-1,2,3,4-tetrahydro-acridinium
DMS7DA3	DT	Small molecular drug
DMS7DA3	PC	19770285
DMS7DA3	MW	232.71
DMS7DA3	FM	C13H13ClN2
DMS7DA3	IC	InChI=1S/C13H13ClN2/c14-9-5-3-7-11-12(9)13(15)8-4-1-2-6-10(8)16-11/h3,5,7H,1-2,4,6H2,(H2,15,16)
DMS7DA3	CS	C1CCC2=NC3=C(C(=CC=C3)Cl)C(=C2C1)N
DMS7DA3	IK	KVGMGGLTJLJDFE-UHFFFAOYSA-N
DMS7DA3	IU	8-chloro-1,2,3,4-tetrahydroacridin-9-amine
DMS7DA3	DE	Discovery agent

DMFW6Q0	ID	DMFW6Q0
DMFW6Q0	DN	8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole
DMFW6Q0	HS	Investigative
DMFW6Q0	SN	CHEMBL443258; 8-chloro-1H,2H,3H,4H-pyrazino[1,2-a]indole; 126718-22-7; 8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole; SCHEMBL5917499; MolPort-022-445-855; BDBM50108304; ZINC13586842; AKOS022692454; MCULE-6563903231; NE39901; 8-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole
DMFW6Q0	DT	Small molecular drug
DMFW6Q0	PC	14595512
DMFW6Q0	MW	206.67
DMFW6Q0	FM	C11H11ClN2
DMFW6Q0	IC	InChI=1S/C11H11ClN2/c12-9-1-2-11-8(5-9)6-10-7-13-3-4-14(10)11/h1-2,5-6,13H,3-4,7H2
DMFW6Q0	CS	C1CN2C(=CC3=C2C=CC(=C3)Cl)CN1
DMFW6Q0	IK	QKGDOWUCRMVFPY-UHFFFAOYSA-N
DMFW6Q0	IU	8-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole
DMFW6Q0	DE	Discovery agent

DM5IGOL	ID	DM5IGOL
DM5IGOL	DN	8-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM5IGOL	HS	Investigative
DM5IGOL	SN	CHEMBL98373; SCHEMBL10757832; 2H-Imidazo[4,5-b]quinolin-2-one, 8-chloro-1,3-dihydro-; BDBM50229559
DM5IGOL	DT	Small molecular drug
DM5IGOL	PC	15065155
DM5IGOL	MW	219.63
DM5IGOL	FM	C10H6ClN3O
DM5IGOL	IC	InChI=1S/C10H6ClN3O/c11-6-2-1-3-7-5(6)4-8-9(12-7)14-10(15)13-8/h1-4H,(H2,12,13,14,15)
DM5IGOL	CS	C1=CC2=NC3=C(C=C2C(=C1)Cl)NC(=O)N3
DM5IGOL	IK	VZXBGYRONYENIL-UHFFFAOYSA-N
DM5IGOL	IU	8-chloro-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DM5IGOL	DE	Discovery agent

DM61VJO	ID	DM61VJO
DM61VJO	DN	8-chloro-3,4-dihydroquinazolin-2-amine
DM61VJO	HS	Investigative
DM61VJO	SN	CHEMBL272752
DM61VJO	DT	Small molecular drug
DM61VJO	PC	44456244
DM61VJO	MW	181.62
DM61VJO	FM	C8H8ClN3
DM61VJO	IC	InChI=1S/C8H8ClN3/c9-6-3-1-2-5-4-11-8(10)12-7(5)6/h1-3H,4H2,(H3,10,11,12)
DM61VJO	CS	C1C2=C(C(=CC=C2)Cl)NC(=N1)N
DM61VJO	IK	AWSSYPVAGZEEAA-UHFFFAOYSA-N
DM61VJO	IU	8-chloro-1,4-dihydroquinazolin-2-amine
DM61VJO	DE	Discovery agent

DM842L6	ID	DM842L6
DM842L6	DN	8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DM842L6	HS	Investigative
DM842L6	SN	CHEMBL93798; 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione; 1H-1-Benzazepine-2,5-dione, 8-chloro-3-hydroxy-; SCHEMBL7350621; PUWRZSGQAPPNEC-UHFFFAOYSA-N; BDBM50054631; 144066-23-9; 3-Hydroxy-8-chloro-1H-1-benzazepine-2,5-dione; 8-chloro-3-hydroxy-2,5-dihydro-1h-benzazepine-2,5-dione
DM842L6	DT	Small molecular drug
DM842L6	PC	9815930
DM842L6	MW	223.61
DM842L6	FM	C10H6ClNO3
DM842L6	IC	InChI=1S/C10H6ClNO3/c11-5-1-2-6-7(3-5)12-10(15)9(14)4-8(6)13/h1-4,13H,(H,12,14,15)
DM842L6	CS	C1=CC2=C(C=C1Cl)NC(=O)C(=O)C=C2O
DM842L6	IK	CPGVEVDFZYFBBP-UHFFFAOYSA-N
DM842L6	IU	8-chloro-5-hydroxy-1H-1-benzazepine-2,3-dione
DM842L6	DE	Discovery agent

DMB76ZN	ID	DMB76ZN
DMB76ZN	DN	8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMB76ZN	HS	Investigative
DMB76ZN	SN	CHEMBL363367; 8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3923941; IVJIWGTXXHDRCU-UHFFFAOYSA-N; BDBM50168384; ZINC13645099
DMB76ZN	DT	Small molecular drug
DMB76ZN	PC	10214699
DMB76ZN	MW	270.71
DMB76ZN	FM	C16H11ClO2
DMB76ZN	IC	InChI=1S/C16H11ClO2/c17-16-8-12(10-1-4-13(18)5-2-10)7-11-3-6-14(19)9-15(11)16/h1-9,18-19H
DMB76ZN	CS	C1=CC(=CC=C1C2=CC(=C3C=C(C=CC3=C2)O)Cl)O
DMB76ZN	IK	IVJIWGTXXHDRCU-UHFFFAOYSA-N
DMB76ZN	IU	8-chloro-6-(4-hydroxyphenyl)naphthalen-2-ol
DMB76ZN	DE	Discovery agent

DMFNUHQ	ID	DMFNUHQ
DMFNUHQ	DN	8-chloro-quinoline-3-carbonitrile
DMFNUHQ	HS	Investigative
DMFNUHQ	SN	CHEMBL436817; Cyanoquinoline, 11; SCHEMBL6071997; BDBM21898; CHEBI:94979; BRD-K00088062-001-01-3; 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(1H-imidazole-5-ylmethyl)amino]-8-chloro-3-quinolinecarbonitrile
DMFNUHQ	DT	Small molecular drug
DMFNUHQ	PC	17759555
DMFNUHQ	MW	427.3
DMFNUHQ	FM	C20H13Cl2FN6
DMFNUHQ	IC	InChI=1S/C20H13Cl2FN6/c21-16-4-12(1-2-18(16)23)29-19-11(6-24)7-27-20-15(19)3-13(5-17(20)22)26-9-14-8-25-10-28-14/h1-5,7-8,10,26H,9H2,(H,25,28)(H,27,29)
DMFNUHQ	CS	C1=CC(=C(C=C1NC2=C3C=C(C=C(C3=NC=C2C#N)Cl)NCC4=CN=CN4)Cl)F
DMFNUHQ	IK	ONXROKMQGCSOMG-UHFFFAOYSA-N
DMFNUHQ	IU	8-chloro-4-(3-chloro-4-fluoroanilino)-6-(1H-imidazol-5-ylmethylamino)quinoline-3-carbonitrile
DMFNUHQ	CB	CHEBI:94979
DMFNUHQ	DE	Discovery agent

DM4VTM2	ID	DM4VTM2
DM4VTM2	DN	8-Cyclobutylmethoxy-quinolin-2-ylamine
DM4VTM2	HS	Investigative
DM4VTM2	SN	CHEMBL184980; 8-Cyclobutylmethoxy-quinolin-2-ylamine; SCHEMBL5883878
DM4VTM2	DT	Small molecular drug
DM4VTM2	PC	22254575
DM4VTM2	MW	228.29
DM4VTM2	FM	C14H16N2O
DM4VTM2	IC	InChI=1S/C14H16N2O/c15-13-8-7-11-5-2-6-12(14(11)16-13)17-9-10-3-1-4-10/h2,5-8,10H,1,3-4,9H2,(H2,15,16)
DM4VTM2	CS	C1CC(C1)COC2=CC=CC3=C2N=C(C=C3)N
DM4VTM2	IK	LOSCSSHHWRUJGD-UHFFFAOYSA-N
DM4VTM2	IU	8-(cyclobutylmethoxy)quinolin-2-amine
DM4VTM2	DE	Discovery agent

DMEBYRW	ID	DMEBYRW
DMEBYRW	DN	8-Cycloheptyloxy-quinolin-2-ylamine
DMEBYRW	HS	Investigative
DMEBYRW	SN	CHEMBL184394; 8-Cycloheptyloxy-quinolin-2-ylamine; SCHEMBL5884483
DMEBYRW	DT	Small molecular drug
DMEBYRW	PC	10332650
DMEBYRW	MW	256.339
DMEBYRW	FM	C16H20N2O
DMEBYRW	IC	InChI=1S/C16H20N2O/c17-15-11-10-12-6-5-9-14(16(12)18-15)19-13-7-3-1-2-4-8-13/h5-6,9-11,13H,1-4,7-8H2,(H2,17,18)
DMEBYRW	CS	C1CCCC(CC1)OC2=CC=CC3=C2N=C(C=C3)N
DMEBYRW	IK	MGAFXFCQBHUFIL-UHFFFAOYSA-N
DMEBYRW	IU	8-cycloheptyloxyquinolin-2-amine
DMEBYRW	DE	Discovery agent

DM79VQM	ID	DM79VQM
DM79VQM	DN	8-cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine
DM79VQM	HS	Investigative
DM79VQM	SN	CHEMBL381112; 8-cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine
DM79VQM	DT	Small molecular drug
DM79VQM	PC	11610347
DM79VQM	MW	368.5
DM79VQM	FM	C24H24N4
DM79VQM	IC	InChI=1S/C24H24N4/c1-16-12-14-17(15-13-16)20-21-24(27-22(25-20)18-8-4-2-5-9-18)28-23(26-21)19-10-6-3-7-11-19/h2,4-5,8-9,12-15,19H,3,6-7,10-11H2,1H3,(H,25,26,27,28)
DM79VQM	CS	CC1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=CC=C4)N=C(N3)C5CCCCC5
DM79VQM	IK	JOTMQRFWDYAWIE-UHFFFAOYSA-N
DM79VQM	IU	8-cyclohexyl-6-(4-methylphenyl)-2-phenyl-7H-purine
DM79VQM	DE	Discovery agent

DMKT0YQ	ID	DMKT0YQ
DMKT0YQ	DN	8-Cyclohexyloxy-quinolin-2-ylamine
DMKT0YQ	HS	Investigative
DMKT0YQ	SN	CHEMBL185235; 8-Cyclohexyloxy-quinolin-2-ylamine; SCHEMBL5883787
DMKT0YQ	DT	Small molecular drug
DMKT0YQ	PC	10399494
DMKT0YQ	MW	242.32
DMKT0YQ	FM	C15H18N2O
DMKT0YQ	IC	InChI=1S/C15H18N2O/c16-14-10-9-11-5-4-8-13(15(11)17-14)18-12-6-2-1-3-7-12/h4-5,8-10,12H,1-3,6-7H2,(H2,16,17)
DMKT0YQ	CS	C1CCC(CC1)OC2=CC=CC3=C2N=C(C=C3)N
DMKT0YQ	IK	MPHNEJNPZMBSBN-UHFFFAOYSA-N
DMKT0YQ	IU	8-cyclohexyloxyquinolin-2-amine
DMKT0YQ	DE	Discovery agent

DM16KZS	ID	DM16KZS
DM16KZS	DN	8-Cyclopentylmethoxy-quinolin-2-ylamine
DM16KZS	HS	Investigative
DM16KZS	SN	CHEMBL186770; 8-Cyclopentylmethoxy-quinolin-2-ylamine; SCHEMBL5883835
DM16KZS	DT	Small molecular drug
DM16KZS	PC	22254582
DM16KZS	MW	242.32
DM16KZS	FM	C15H18N2O
DM16KZS	IC	InChI=1S/C15H18N2O/c16-14-9-8-12-6-3-7-13(15(12)17-14)18-10-11-4-1-2-5-11/h3,6-9,11H,1-2,4-5,10H2,(H2,16,17)
DM16KZS	CS	C1CCC(C1)COC2=CC=CC3=C2N=C(C=C3)N
DM16KZS	IK	KGRRNRLJYPHJMT-UHFFFAOYSA-N
DM16KZS	IU	8-(cyclopentylmethoxy)quinolin-2-amine
DM16KZS	DE	Discovery agent

DMMITAJ	ID	DMMITAJ
DMMITAJ	DN	8-cyclopentyltheophylline
DMMITAJ	HS	Investigative
DMMITAJ	SN	8-Cyclopentyl-1,3-dimethylxanthine; 8-cyclopentyltheophylline; 35873-49-5; 8-Cyclopentyl theophylline; UNII-U7PWT4CPL5; U7PWT4CPL5; 8-cyclopentyl-1,3-dimethyl-7H-purine-2,6-dione; NSC 101806; BRN 1133199; Xanthine, 8-cyclopentyl-1,3-dimethyl-; Theophylline, 8-cyclopentyl-; CHEMBL106265; 8-Cyclopentyl-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione; 1,3-dimethyl-8-cyclopentylxanthine; Spectrum_000351; Lopac-C-102; AC1Q6LAU; AC1L1CIO; Spectrum4_000760; Spectrum2_001734; Spectrum5_001769; Spectrum3_000658; NCIOpen2_006919; Lopac0_000391
DMMITAJ	DT	Small molecular drug
DMMITAJ	PC	1917
DMMITAJ	MW	248.28
DMMITAJ	FM	C12H16N4O2
DMMITAJ	IC	InChI=1S/C12H16N4O2/c1-15-10-8(11(17)16(2)12(15)18)13-9(14-10)7-5-3-4-6-7/h7H,3-6H2,1-2H3,(H,13,14)
DMMITAJ	CS	CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C3CCCC3
DMMITAJ	IK	SCVHFRLUNIOSGI-UHFFFAOYSA-N
DMMITAJ	IU	8-cyclopentyl-1,3-dimethyl-7H-purine-2,6-dione
DMMITAJ	CA	CAS 35873-49-5
DMMITAJ	CB	CHEBI:109538
DMMITAJ	DE	Discovery agent

DMEOP4J	ID	DMEOP4J
DMEOP4J	DN	8-DEOXYGARTANIN
DMEOP4J	HS	Investigative
DMEOP4J	SN	8-Desoxygartanin; 8-DEOXYGARTANIN; 33390-41-9; CHEMBL488606; 1,3,5-trihydroxy-2,4-bis(3-methylbut-2-enyl)xanthen-9-one; 1,3,5-trihydroxy-2,4-bis(3-methylbut-2-en-1-yl)-9h-xanthen-9-one; 9H-Xanthen-9-one, 1,3,5-trihydroxy-2,4-bis(3-methyl-2-butenyl)-; Deoxygartinin; Desoxygartanin,8-; NSC692944; AC1L944B; SCHEMBL17056909; CTK8C7216; MolPort-039-052-631; ZINC5849312; BDBM50311742; AKOS028108663; NSC-692944; FT-0686569; 390D419; 1,3,5-Trihydroxy-2,4-bis(3-methyl-2-butenyl)-9H-xanthen-9-one
DMEOP4J	DT	Small molecular drug
DMEOP4J	PC	392450
DMEOP4J	MW	380.4
DMEOP4J	FM	C23H24O5
DMEOP4J	IC	InChI=1S/C23H24O5/c1-12(2)8-10-14-19(25)16(11-9-13(3)4)23-18(20(14)26)21(27)15-6-5-7-17(24)22(15)28-23/h5-9,24-26H,10-11H2,1-4H3
DMEOP4J	CS	CC(=CCC1=C(C(=C2C(=C1O)C(=O)C3=C(O2)C(=CC=C3)O)CC=C(C)C)O)C
DMEOP4J	IK	GVQOVMKBYJKZSY-UHFFFAOYSA-N
DMEOP4J	IU	1,3,5-trihydroxy-2,4-bis(3-methylbut-2-enyl)xanthen-9-one
DMEOP4J	CA	CAS 33390-41-9
DMEOP4J	DE	Discovery agent

DM7YW3B	ID	DM7YW3B
DM7YW3B	DN	8-deoxy-neodysiherbaine
DM7YW3B	HS	Investigative
DM7YW3B	SN	8-deoxy-neoDH
DM7YW3B	DT	Small molecular drug
DM7YW3B	PC	73755079
DM7YW3B	MW	274.25
DM7YW3B	FM	C11H16NO7-
DM7YW3B	IC	InChI=1S/C11H17NO7/c12-6(9(14)15)2-11(10(16)17)3-8-7(19-11)1-5(13)4-18-8/h5-8,13H,1-4,12H2,(H,14,15)(H,16,17)/p-1/t5-,6-,7?,8?,11+/m0/s1
DM7YW3B	CS	C1[C@@H](COC2C1O[C@@](C2)(C[C@@H](C(=O)[O-])[NH3+])C(=O)[O-])O
DM7YW3B	IK	JVLNPAVKDNEYGY-SCTSMQQKSA-M
DM7YW3B	IU	(2R,6S)-2-[(2S)-2-azaniumyl-2-carboxylatoethyl]-6-hydroxy-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-carboxylate
DM7YW3B	DE	Discovery agent

DMQJA4F	ID	DMQJA4F
DMQJA4F	DN	8-Diazonium-naphthalene-1-sulfonic acid anion
DMQJA4F	HS	Investigative
DMQJA4F	SN	CHEMBL304774
DMQJA4F	DT	Small molecular drug
DMQJA4F	PC	13948288
DMQJA4F	MW	234.23
DMQJA4F	FM	C10H6N2O3S
DMQJA4F	IC	InChI=1S/C10H6N2O3S/c11-12-8-5-1-3-7-4-2-6-9(10(7)8)16(13,14)15/h1-6H
DMQJA4F	CS	C1=CC2=C(C(=C1)[N+]#N)C(=CC=C2)S(=O)(=O)[O-]
DMQJA4F	IK	FBINSYHNLCGKLZ-UHFFFAOYSA-N
DMQJA4F	IU	8-diazonionaphthalene-1-sulfonate
DMQJA4F	DE	Discovery agent

DMUR97N	ID	DMUR97N
DMUR97N	DN	8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one
DMUR97N	HS	Investigative
DMUR97N	SN	CHEMBL186048; 503468-92-6; 8-(dibenzo[b,d]furan-4-yl)-2-morpholino-4H-chromen-4-one; 8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one; 8-dibenzofuran-4-yl-2-morpholin-4-yl-chromen-4-one; SCHEMBL13346347; CTK1G6916; DTXSID50470335; BDBM50156503; AKOS030553517; 4H-1-Benzopyran-4-one, 8-(4-dibenzofuranyl)-2-(4-morpholinyl)-
DMUR97N	DT	Small molecular drug
DMUR97N	PC	11668417
DMUR97N	MW	397.4
DMUR97N	FM	C25H19NO4
DMUR97N	IC	InChI=1S/C25H19NO4/c27-21-15-23(26-11-13-28-14-12-26)30-25-19(8-4-9-20(21)25)18-7-3-6-17-16-5-1-2-10-22(16)29-24(17)18/h1-10,15H,11-14H2
DMUR97N	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4OC6=CC=CC=C56
DMUR97N	IK	LEWYWLXLBNVBFP-UHFFFAOYSA-N
DMUR97N	IU	8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one
DMUR97N	CA	CAS 503468-92-6
DMUR97N	DE	Discovery agent

DMY8W0K	ID	DMY8W0K
DMY8W0K	DN	8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMY8W0K	HS	Investigative
DMY8W0K	SN	1H-1-Benzazepine-2,5-dione, 8-ethyl-3-hydroxy-; SCHEMBL9389409; CHEMBL143292; 183663-81-2
DMY8W0K	DT	Small molecular drug
DMY8W0K	PC	10680274
DMY8W0K	MW	217.22
DMY8W0K	FM	C12H11NO3
DMY8W0K	IC	InChI=1S/C12H11NO3/c1-2-7-3-4-8-9(5-7)13-12(16)11(15)6-10(8)14/h3-6,14H,2H2,1H3,(H,13,15,16)
DMY8W0K	CS	CCC1=CC2=C(C=C1)C(=CC(=O)C(=O)N2)O
DMY8W0K	IK	FPLGJFSMGRDPES-UHFFFAOYSA-N
DMY8W0K	IU	8-ethyl-5-hydroxy-1H-1-benzazepine-2,3-dione
DMY8W0K	DE	Discovery agent

DMBZSAO	ID	DMBZSAO
DMBZSAO	DN	8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMBZSAO	HS	Investigative
DMBZSAO	SN	1H-1-Benzazepine-2,5-dione, 8-fluoro-3-hydroxy-; SCHEMBL9007832; CHEMBL142890; 144066-26-2
DMBZSAO	DT	Small molecular drug
DMBZSAO	PC	15029643
DMBZSAO	MW	207.16
DMBZSAO	FM	C10H6FNO3
DMBZSAO	IC	InChI=1S/C10H6FNO3/c11-5-1-2-6-7(3-5)12-10(15)9(14)4-8(6)13/h1-4,13H,(H,12,14,15)
DMBZSAO	CS	C1=CC2=C(C=C1F)NC(=O)C(=O)C=C2O
DMBZSAO	IK	ZAZQJJXYILGMQL-UHFFFAOYSA-N
DMBZSAO	IU	8-fluoro-5-hydroxy-1H-1-benzazepine-2,3-dione
DMBZSAO	DE	Discovery agent

DMGJ3L6	ID	DMGJ3L6
DMGJ3L6	DN	8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMGJ3L6	HS	Investigative
DMGJ3L6	SN	CHEMBL192386; 8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3924505; KBQSRNQTSRTYGN-UHFFFAOYSA-N; ZINC13645086; BDBM50168353
DMGJ3L6	DT	Small molecular drug
DMGJ3L6	PC	10308090
DMGJ3L6	MW	254.25
DMGJ3L6	FM	C16H11FO2
DMGJ3L6	IC	InChI=1S/C16H11FO2/c17-16-8-12(10-1-4-13(18)5-2-10)7-11-3-6-14(19)9-15(11)16/h1-9,18-19H
DMGJ3L6	CS	C1=CC(=CC=C1C2=CC(=C3C=C(C=CC3=C2)O)F)O
DMGJ3L6	IK	KBQSRNQTSRTYGN-UHFFFAOYSA-N
DMGJ3L6	IU	8-fluoro-6-(4-hydroxyphenyl)naphthalen-2-ol
DMGJ3L6	DE	Discovery agent

DMKPMFJ	ID	DMKPMFJ
DMKPMFJ	DN	8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMKPMFJ	HS	Investigative
DMKPMFJ	SN	CHEMBL370045; BDBM27512; indeno[1,2-c]isoquinolinone, 1d; ZINC13652896; 8-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one
DMKPMFJ	DT	Small molecular drug
DMKPMFJ	PC	25190931
DMKPMFJ	MW	251.25
DMKPMFJ	FM	C16H10FNO
DMKPMFJ	IC	InChI=1S/C16H10FNO/c17-10-6-5-9-7-14-11-3-1-2-4-12(11)16(19)18-15(14)13(9)8-10/h1-6,8H,7H2,(H,18,19)
DMKPMFJ	CS	C1C2=C(C=C(C=C2)F)C3=C1C4=CC=CC=C4C(=O)N3
DMKPMFJ	IK	JDHAGQFOPJNKLS-UHFFFAOYSA-N
DMKPMFJ	IU	8-fluoro-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DMKPMFJ	DE	Discovery agent

DMPY9OI	ID	DMPY9OI
DMPY9OI	DN	8-furan-2-yl-2-morpholin-4-ylchromen-4-one
DMPY9OI	HS	Investigative
DMPY9OI	SN	CHEMBL369990; 8-furan-2-yl-2-morpholin-4-ylchromen-4-one
DMPY9OI	DT	Small molecular drug
DMPY9OI	PC	11637964
DMPY9OI	MW	297.3
DMPY9OI	FM	C17H15NO4
DMPY9OI	IC	InChI=1S/C17H15NO4/c19-14-11-16(18-6-9-20-10-7-18)22-17-12(14)3-1-4-13(17)15-5-2-8-21-15/h1-5,8,11H,6-7,9-10H2
DMPY9OI	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CO4
DMPY9OI	IK	KEXLPFOPRBRYIA-UHFFFAOYSA-N
DMPY9OI	IU	8-(furan-2-yl)-2-morpholin-4-ylchromen-4-one
DMPY9OI	DE	Discovery agent

DMFNCG8	ID	DMFNCG8
DMFNCG8	DN	8-Furan-3-yl-6-styryl-naphthalene-2-carboxamidine
DMFNCG8	HS	Investigative
DMFNCG8	SN	CHEMBL360195; 8-Furan-3-yl-6-styryl-naphthalene-2-carboxamidine
DMFNCG8	DT	Small molecular drug
DMFNCG8	PC	44392430
DMFNCG8	MW	338.4
DMFNCG8	FM	C23H18N2O
DMFNCG8	IC	InChI=1S/C23H18N2O/c24-23(25)19-9-8-18-12-17(7-6-16-4-2-1-3-5-16)13-21(22(18)14-19)20-10-11-26-15-20/h1-15H,(H3,24,25)/b7-6+
DMFNCG8	CS	C1=CC=C(C=C1)/C=C/C2=CC(=C3C=C(C=CC3=C2)C(=N)N)C4=COC=C4
DMFNCG8	IK	VWKDMGIRFQHGHQ-VOTSOKGWSA-N
DMFNCG8	IU	8-(furan-3-yl)-6-[(E)-2-phenylethenyl]naphthalene-2-carboximidamide
DMFNCG8	DE	Discovery agent

DM7PJN9	ID	DM7PJN9
DM7PJN9	DN	8-Hexyloxy-quinolin-2-ylamine
DM7PJN9	HS	Investigative
DM7PJN9	SN	CHEMBL187295; 8-Hexyloxy-quinolin-2-ylamine; SCHEMBL5884086
DM7PJN9	DT	Small molecular drug
DM7PJN9	PC	10421932
DM7PJN9	MW	244.33
DM7PJN9	FM	C15H20N2O
DM7PJN9	IC	InChI=1S/C15H20N2O/c1-2-3-4-5-11-18-13-8-6-7-12-9-10-14(16)17-15(12)13/h6-10H,2-5,11H2,1H3,(H2,16,17)
DM7PJN9	CS	CCCCCCOC1=CC=CC2=C1N=C(C=C2)N
DM7PJN9	IK	SBZZEIZRHJBKKE-UHFFFAOYSA-N
DM7PJN9	IU	8-hexoxyquinolin-2-amine
DM7PJN9	DE	Discovery agent

DMNE52B	ID	DMNE52B
DMNE52B	DN	8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one
DMNE52B	HS	Investigative
DMNE52B	DT	Small molecular drug
DMNE52B	PC	135492389
DMNE52B	MW	283.24
DMNE52B	FM	C14H9N3O4
DMNE52B	IC	InChI=1S/C14H9N3O4/c18-11-3-1-2-10-12(11)15-13(16-14(10)19)8-4-6-9(7-5-8)17(20)21/h1-7,18H,(H,15,16,19)
DMNE52B	CS	C1=CC2=C(C(=C1)O)N=C(NC2=O)C3=CC=C(C=C3)[N+](=O)[O-]
DMNE52B	IK	FKPMZNSEGYFIDN-UHFFFAOYSA-N
DMNE52B	IU	8-hydroxy-2-(4-nitrophenyl)-3H-quinazolin-4-one
DMNE52B	CA	CAS 172462-88-3
DMNE52B	DE	Discovery agent

DMKD2Q4	ID	DMKD2Q4
DMKD2Q4	DN	8-Hydroxy-2-phenyl-3H-quinazolin-4-one
DMKD2Q4	HS	Investigative
DMKD2Q4	DT	Small molecular drug
DMKD2Q4	PC	135528341
DMKD2Q4	MW	238.24
DMKD2Q4	FM	C14H10N2O2
DMKD2Q4	IC	InChI=1S/C14H10N2O2/c17-11-8-4-7-10-12(11)15-13(16-14(10)18)9-5-2-1-3-6-9/h1-8,17H,(H,15,16,18)
DMKD2Q4	CS	C1=CC=C(C=C1)C2=NC3=C(C=CC=C3O)C(=O)N2
DMKD2Q4	IK	JRDFYUFZPYBDNH-UHFFFAOYSA-N
DMKD2Q4	IU	8-hydroxy-2-phenyl-3H-quinazolin-4-one
DMKD2Q4	DE	Discovery agent

DMG4W2C	ID	DMG4W2C
DMG4W2C	DN	8-Hydroxy-5,7,9-trimethyl-delta-carboline
DMG4W2C	HS	Investigative
DMG4W2C	SN	CHEMBL458947; 8-Hydroxy-5,7,9-trimethyl-delta-carboline
DMG4W2C	DT	Small molecular drug
DMG4W2C	PC	44567454
DMG4W2C	MW	226.27
DMG4W2C	FM	C14H14N2O
DMG4W2C	IC	InChI=1S/C14H14N2O/c1-8-7-11-12(9(2)14(8)17)13-10(16(11)3)5-4-6-15-13/h4-7,17H,1-3H3
DMG4W2C	CS	CC1=CC2=C(C(=C1O)C)C3=C(N2C)C=CC=N3
DMG4W2C	IK	HGIQNBUVVTWBSJ-UHFFFAOYSA-N
DMG4W2C	IU	5,7,9-trimethylpyrido[3,2-b]indol-8-ol
DMG4W2C	DE	Discovery agent

DMFL46R	ID	DMFL46R
DMFL46R	DN	8-Hydroxy-7,9-dimethyl-delta-carboline
DMFL46R	HS	Investigative
DMFL46R	SN	CHEMBL458465; 8-Hydroxy-7,9-dimethyl-delta-carboline
DMFL46R	DT	Small molecular drug
DMFL46R	PC	25113696
DMFL46R	MW	212.25
DMFL46R	FM	C13H12N2O
DMFL46R	IC	InChI=1S/C13H12N2O/c1-7-6-10-11(8(2)13(7)16)12-9(15-10)4-3-5-14-12/h3-6,15-16H,1-2H3
DMFL46R	CS	CC1=CC2=C(C(=C1O)C)C3=C(N2)C=CC=N3
DMFL46R	IK	ISLNUDFCPIKSRK-UHFFFAOYSA-N
DMFL46R	IU	7,9-dimethyl-5H-pyrido[3,2-b]indol-8-ol
DMFL46R	DE	Discovery agent

DMT9BPN	ID	DMT9BPN
DMT9BPN	DN	8-hydroxyguanine
DMT9BPN	HS	Investigative
DMT9BPN	DT	Small molecular drug
DMT9BPN	PC	135420630
DMT9BPN	MW	167.13
DMT9BPN	FM	C5H5N5O2
DMT9BPN	IC	InChI=1S/C5H5N5O2/c6-4-8-2-1(3(11)10-4)7-5(12)9-2/h(H5,6,7,8,9,10,11,12)
DMT9BPN	CS	C12=C(NC(=O)N1)N=C(NC2=O)N
DMT9BPN	IK	CLGFIVUFZRGQRP-UHFFFAOYSA-N
DMT9BPN	IU	2-amino-7,9-dihydro-1H-purine-6,8-dione
DMT9BPN	CA	CAS 5614-64-2
DMT9BPN	CB	CHEBI:52617
DMT9BPN	DE	Discovery agent

DMA26L4	ID	DMA26L4
DMA26L4	DN	8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one
DMA26L4	HS	Investigative
DMA26L4	SN	CHEMBL351167; 8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one; BDBM50097362; 8-((1H-imidazol-1-yl)methyl)-5-nitro-4H-chromen-4-one
DMA26L4	DT	Small molecular drug
DMA26L4	PC	10659706
DMA26L4	MW	271.23
DMA26L4	FM	C13H9N3O4
DMA26L4	IC	InChI=1S/C13H9N3O4/c17-11-3-6-20-13-9(7-15-5-4-14-8-15)1-2-10(12(11)13)16(18)19/h1-6,8H,7H2
DMA26L4	CS	C1=CC(=C2C(=O)C=COC2=C1CN3C=CN=C3)[N+](=O)[O-]
DMA26L4	IK	YKATXTHPSQAGQZ-UHFFFAOYSA-N
DMA26L4	IU	8-(imidazol-1-ylmethyl)-5-nitrochromen-4-one
DMA26L4	DE	Discovery agent

DM3K1EO	ID	DM3K1EO
DM3K1EO	DN	8-Iodo-Guanine
DM3K1EO	HS	Investigative
DM3K1EO	DT	Small molecular drug
DM3K1EO	PC	135431972
DM3K1EO	MW	277.02
DM3K1EO	FM	C5H4IN5O
DM3K1EO	IC	InChI=1S/C5H4IN5O/c6-4-8-1-2(9-4)10-5(7)11-3(1)12/h(H4,7,8,9,10,11,12)
DM3K1EO	CS	C12=C(N=C(NC1=O)N)N=C(N2)I
DM3K1EO	IK	SXGFECRAKVVEJT-UHFFFAOYSA-N
DM3K1EO	IU	2-amino-8-iodo-1,7-dihydropurin-6-one
DM3K1EO	DE	Discovery agent

DMBIAGJ	ID	DMBIAGJ
DMBIAGJ	DN	8-Isopropoxy-quinolin-2-ylamine
DMBIAGJ	HS	Investigative
DMBIAGJ	SN	CHEMBL365254; 8-Isopropoxy-quinolin-2-ylamine; 2-Quinolinamine, 8-(1-methylethoxy)-; SCHEMBL5884565; BDBM50152417
DMBIAGJ	DT	Small molecular drug
DMBIAGJ	PC	10198125
DMBIAGJ	MW	202.25
DMBIAGJ	FM	C12H14N2O
DMBIAGJ	IC	InChI=1S/C12H14N2O/c1-8(2)15-10-5-3-4-9-6-7-11(13)14-12(9)10/h3-8H,1-2H3,(H2,13,14)
DMBIAGJ	CS	CC(C)OC1=CC=CC2=C1N=C(C=C2)N
DMBIAGJ	IK	IJQWZUBUZMKYCW-UHFFFAOYSA-N
DMBIAGJ	IU	8-propan-2-yloxyquinolin-2-amine
DMBIAGJ	DE	Discovery agent

DMD3FWU	ID	DMD3FWU
DMD3FWU	DN	8-Mercapto-octanoic acid phenylamide
DMD3FWU	HS	Investigative
DMD3FWU	SN	8-Mercapto-octanoic acid phenylamide; 8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343
DMD3FWU	DT	Small molecular drug
DMD3FWU	PC	11149404
DMD3FWU	MW	251.39
DMD3FWU	FM	C14H21NOS
DMD3FWU	IC	InChI=1S/C14H21NOS/c16-14(11-7-2-1-3-8-12-17)15-13-9-5-4-6-10-13/h4-6,9-10,17H,1-3,7-8,11-12H2,(H,15,16)
DMD3FWU	CS	C1=CC=C(C=C1)NC(=O)CCCCCCCS
DMD3FWU	IK	VTVJPXWTXILBGK-UHFFFAOYSA-N
DMD3FWU	IU	N-phenyl-8-sulfanyloctanamide
DMD3FWU	DE	Discovery agent

DMY50UR	ID	DMY50UR
DMY50UR	DN	8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline
DMY50UR	HS	Investigative
DMY50UR	SN	CHEMBL338311; 8-methoxy-1,2,3,4-tetrahydrobenzo[h]isoquinoline; 8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline; BDBM50061314; ZINC13766766
DMY50UR	DT	Small molecular drug
DMY50UR	PC	44352179
DMY50UR	MW	213.27
DMY50UR	FM	C14H15NO
DMY50UR	IC	InChI=1S/C14H15NO/c1-16-12-4-5-13-11(8-12)3-2-10-6-7-15-9-14(10)13/h2-5,8,15H,6-7,9H2,1H3
DMY50UR	CS	COC1=CC2=C(C=C1)C3=C(CCNC3)C=C2
DMY50UR	IK	LTVUTAZPBISUIF-UHFFFAOYSA-N
DMY50UR	IU	8-methoxy-1,2,3,4-tetrahydrobenzo[h]isoquinoline
DMY50UR	DE	Discovery agent

DMFOM10	ID	DMFOM10
DMFOM10	DN	8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine
DMFOM10	HS	Investigative
DMFOM10	SN	8-Methoxy-2-aminotetralin; 3880-77-1; 8-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine; 8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine; CHEMBL26688; ACMC-20msdp; ACMC-20mscg; 2-amino-8-methoxytetralin; 8-methoxytetralin-2-amine; 8-methoxy-2-amino-tetralin; 2-Naphthalenamine,1,2,3,4-tetrahydro-8-methoxy-, (2R)-; 2-Naphthalenamine,1,2,3,4-tetrahydro-8-methoxy-, (2S)-; SCHEMBL266921; CTK4I0515; 2-NAPHTHALENAMINE, 1,2,3,4-TETRAHYDRO-8-METHOXY-; RVKOHSCTEHZRRT-UHFFFAOYSA-N; MFCD00906373; BDBM50016733; AKOS022393176; FCH1122360
DMFOM10	DT	Small molecular drug
DMFOM10	PC	10197933
DMFOM10	MW	177.24
DMFOM10	FM	C11H15NO
DMFOM10	IC	InChI=1S/C11H15NO/c1-13-11-4-2-3-8-5-6-9(12)7-10(8)11/h2-4,9H,5-7,12H2,1H3
DMFOM10	CS	COC1=CC=CC2=C1CC(CC2)N
DMFOM10	IK	RVKOHSCTEHZRRT-UHFFFAOYSA-N
DMFOM10	IU	8-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine
DMFOM10	CA	CAS 3880-77-1
DMFOM10	DE	Discovery agent

DM0Y52J	ID	DM0Y52J
DM0Y52J	DN	8-Methoxy-1,4-dimethylquinolin-2(1H)-one
DM0Y52J	HS	Investigative
DM0Y52J	SN	8-Methoxy-1,4-dimethylquinolin-2(1H)-one; 8-methoxy-1,4-dimethyl-1h-quinolin-2-one; 63791-96-8; casimiroin analogue, 1f; AC1NT5XU; CHEMBL506858; SCHEMBL17509827; BDBM29217; NCNFIHNRVBJRPR-UHFFFAOYSA-N; MolPort-028-745-487; ZINC33835729; 8-methoxy-1,4-dimethylquinolin-2-one; 1,4-Dimethyl-8-methoxyquinoline-2(1H)-one
DM0Y52J	DT	Small molecular drug
DM0Y52J	PC	5324988
DM0Y52J	MW	203.24
DM0Y52J	FM	C12H13NO2
DM0Y52J	IC	InChI=1S/C12H13NO2/c1-8-7-11(14)13(2)12-9(8)5-4-6-10(12)15-3/h4-7H,1-3H3
DM0Y52J	CS	CC1=CC(=O)N(C2=C1C=CC=C2OC)C
DM0Y52J	IK	NCNFIHNRVBJRPR-UHFFFAOYSA-N
DM0Y52J	IU	8-methoxy-1,4-dimethylquinolin-2-one
DM0Y52J	DE	Discovery agent

DMQIFZC	ID	DMQIFZC
DMQIFZC	DN	8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline
DMQIFZC	HS	Investigative
DMQIFZC	SN	CHEMBL80775; 8-Methoxy-N-methylquipazine; 8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline; BDBM50025469
DMQIFZC	DT	Small molecular drug
DMQIFZC	PC	44316216
DMQIFZC	MW	257.329
DMQIFZC	FM	C15H19N3O
DMQIFZC	IC	InChI=1S/C15H19N3O/c1-17-8-10-18(11-9-17)14-7-6-12-4-3-5-13(19-2)15(12)16-14/h3-7H,8-11H2,1-2H3
DMQIFZC	CS	CN1CCN(CC1)C2=NC3=C(C=CC=C3OC)C=C2
DMQIFZC	IK	XPBCUYLZAWCBJJ-UHFFFAOYSA-N
DMQIFZC	IU	8-methoxy-2-(4-methylpiperazin-1-yl)quinoline
DMQIFZC	DE	Discovery agent

DMSN0ZE	ID	DMSN0ZE
DMSN0ZE	DN	8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one
DMSN0ZE	HS	Investigative
DMSN0ZE	DT	Small molecular drug
DMSN0ZE	PC	135417274
DMSN0ZE	MW	297.26
DMSN0ZE	FM	C15H11N3O4
DMSN0ZE	IC	InChI=1S/C15H11N3O4/c1-22-12-4-2-3-11-13(12)16-14(17-15(11)19)9-5-7-10(8-6-9)18(20)21/h2-8H,1H3,(H,16,17,19)
DMSN0ZE	CS	COC1=CC=CC2=C1N=C(NC2=O)C3=CC=C(C=C3)[N+](=O)[O-]
DMSN0ZE	IK	PGAMJHQYVDYIQX-UHFFFAOYSA-N
DMSN0ZE	IU	8-methoxy-2-(4-nitrophenyl)-3H-quinazolin-4-one
DMSN0ZE	DE	Discovery agent

DMHE7J5	ID	DMHE7J5
DMHE7J5	DN	8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMHE7J5	HS	Investigative
DMHE7J5	SN	CHEMBL269571; 8-Methoxy-1,2,3,4-tetrahydro-beta-carboline; 8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline; BDBM50136502; AKOS022647299; 122835-07-8
DMHE7J5	DT	Small molecular drug
DMHE7J5	PC	14355088
DMHE7J5	MW	202.25
DMHE7J5	FM	C12H14N2O
DMHE7J5	IC	InChI=1S/C12H14N2O/c1-15-11-4-2-3-9-8-5-6-13-7-10(8)14-12(9)11/h2-4,13-14H,5-7H2,1H3
DMHE7J5	CS	COC1=CC=CC2=C1NC3=C2CCNC3
DMHE7J5	IK	KKTKOWJABJYACN-UHFFFAOYSA-N
DMHE7J5	IU	8-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMHE7J5	DE	Discovery agent

DMOPN4K	ID	DMOPN4K
DMOPN4K	DN	8-Methoxy-2-methyl-3H-quinazolin-4-one
DMOPN4K	HS	Investigative
DMOPN4K	DT	Small molecular drug
DMOPN4K	PC	135411146
DMOPN4K	MW	190.2
DMOPN4K	FM	C10H10N2O2
DMOPN4K	IC	InChI=1S/C10H10N2O2/c1-6-11-9-7(10(13)12-6)4-3-5-8(9)14-2/h3-5H,1-2H3,(H,11,12,13)
DMOPN4K	CS	CC1=NC2=C(C=CC=C2OC)C(=O)N1
DMOPN4K	IK	ZWCBMSNYXIFTCM-UHFFFAOYSA-N
DMOPN4K	IU	8-methoxy-2-methyl-3H-quinazolin-4-one
DMOPN4K	CA	CAS 90915-45-0
DMOPN4K	DE	Discovery agent

DMYE1X2	ID	DMYE1X2
DMYE1X2	DN	8-Methoxy-2-morpholin-4-yl-chromen-4-one
DMYE1X2	HS	Investigative
DMYE1X2	SN	CHEMBL97024; 8-methoxy-2-morpholin-4-yl-chromen-4-one; SCHEMBL3542889; BDBM50159658
DMYE1X2	DT	Small molecular drug
DMYE1X2	PC	11482391
DMYE1X2	MW	261.269
DMYE1X2	FM	C14H15NO4
DMYE1X2	IC	InChI=1S/C14H15NO4/c1-17-12-4-2-3-10-11(16)9-13(19-14(10)12)15-5-7-18-8-6-15/h2-4,9H,5-8H2,1H3
DMYE1X2	CS	COC1=CC=CC2=C1OC(=CC2=O)N3CCOCC3
DMYE1X2	IK	USIRKXHEGVTPLO-UHFFFAOYSA-N
DMYE1X2	IU	8-methoxy-2-morpholin-4-ylchromen-4-one
DMYE1X2	DE	Discovery agent

DMHCWY8	ID	DMHCWY8
DMHCWY8	DN	8-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DMHCWY8	HS	Investigative
DMHCWY8	SN	8-Methoxy-2-oxo-2H-chromene-3-carboxylic acid; 2555-20-6; 8-methoxy-2-oxochromene-3-carboxylic acid; 8-methoxycoumarin-3-carboxylic acid; CHEMBL568348; SFAPWVZFUHJZIC-UHFFFAOYSA-N; 2H-1-Benzopyran-3-carboxylic acid, 8-methoxy-2-oxo-; NSC34647; AC1L5SHQ; AC1Q5T4B; 3-Carboxy-8-methoxycoumarin; Oprea1_510137; Oprea1_497732; 8-methoxy-3-carboxy-coumarin; SCHEMBL980310; methoxyoxochromenecarboxylicacid; SCHEMBL3659230; ZINC84532; KS-00001VYM; CTK4F6014; DTXSID30283980; MolPort-000-145-720; ALBB-000306; NSC-34647; STK411116; BBL013903
DMHCWY8	DT	Small molecular drug
DMHCWY8	PC	234562
DMHCWY8	MW	220.18
DMHCWY8	FM	C11H8O5
DMHCWY8	IC	InChI=1S/C11H8O5/c1-15-8-4-2-3-6-5-7(10(12)13)11(14)16-9(6)8/h2-5H,1H3,(H,12,13)
DMHCWY8	CS	COC1=CC=CC2=C1OC(=O)C(=C2)C(=O)O
DMHCWY8	IK	SFAPWVZFUHJZIC-UHFFFAOYSA-N
DMHCWY8	IU	8-methoxy-2-oxochromene-3-carboxylic acid
DMHCWY8	CA	CAS 2555-20-6
DMHCWY8	DE	Discovery agent

DM56EW7	ID	DM56EW7
DM56EW7	DN	8-Methoxy-2-phenyl-3H-quinazolin-4-one
DM56EW7	HS	Investigative
DM56EW7	DT	Small molecular drug
DM56EW7	PC	135439437
DM56EW7	MW	252.27
DM56EW7	FM	C15H12N2O2
DM56EW7	IC	InChI=1S/C15H12N2O2/c1-19-12-9-5-8-11-13(12)16-14(17-15(11)18)10-6-3-2-4-7-10/h2-9H,1H3,(H,16,17,18)
DM56EW7	CS	COC1=CC=CC2=C1N=C(NC2=O)C3=CC=CC=C3
DM56EW7	IK	XMLHWESTKAFTNA-UHFFFAOYSA-N
DM56EW7	IU	8-methoxy-2-phenyl-3H-quinazolin-4-one
DM56EW7	CA	CAS 172462-89-4
DM56EW7	DE	Discovery agent

DMNWC29	ID	DMNWC29
DMNWC29	DN	8-Methoxy-2-piperazin-1-yl-quinoline
DMNWC29	HS	Investigative
DMNWC29	SN	8-Methoxy-2-piperazin-1-yl-quinoline; CHEMBL80691; Quinoline, 8-methoxy-2-(1-piperazinyl)-; 104090-79-1; 8-Methoxyquipazine; ACMC-20m6vj; SCHEMBL6767019; CTK0G6599; DTXSID30627183; CUULVNAZRYFNIT-UHFFFAOYSA-N; ZINC26467647; BDBM50025465; AKOS022401904
DMNWC29	DT	Small molecular drug
DMNWC29	PC	22636319
DMNWC29	MW	243.3
DMNWC29	FM	C14H17N3O
DMNWC29	IC	InChI=1S/C14H17N3O/c1-18-12-4-2-3-11-5-6-13(16-14(11)12)17-9-7-15-8-10-17/h2-6,15H,7-10H2,1H3
DMNWC29	CS	COC1=CC=CC2=C1N=C(C=C2)N3CCNCC3
DMNWC29	IK	CUULVNAZRYFNIT-UHFFFAOYSA-N
DMNWC29	IU	8-methoxy-2-piperazin-1-ylquinoline
DMNWC29	CA	CAS 104090-79-1
DMNWC29	DE	Discovery agent

DM8MBSN	ID	DM8MBSN
DM8MBSN	DN	8-Methoxy-4,9-dihydro-3H-beta-carboline
DM8MBSN	HS	Investigative
DM8MBSN	SN	CHEMBL269367; 8-Methoxy-4,9-dihydro-3H-beta-carboline; BDBM50136509; 8-Methoxy-3,4-dihydro-beta-carboline
DM8MBSN	DT	Small molecular drug
DM8MBSN	PC	14355089
DM8MBSN	MW	200.24
DM8MBSN	FM	C12H12N2O
DM8MBSN	IC	InChI=1S/C12H12N2O/c1-15-11-4-2-3-9-8-5-6-13-7-10(8)14-12(9)11/h2-4,7,14H,5-6H2,1H3
DM8MBSN	CS	COC1=CC=CC2=C1NC3=C2CCN=C3
DM8MBSN	IK	LIUNAKJFUYIJFE-UHFFFAOYSA-N
DM8MBSN	IU	8-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole
DM8MBSN	DE	Discovery agent

DMK6U2V	ID	DMK6U2V
DMK6U2V	DN	8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine
DMK6U2V	HS	Investigative
DMK6U2V	SN	CHEMBL408152; SCHEMBL1382388; SCKPQZMXGISHHF-UHFFFAOYSA-N; BDBM50371445; 918136-34-2; 8-Methoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamine; 2-Quinazolinamine, 1,4-dihydro-8-methoxy-4-methyl-
DMK6U2V	DT	Small molecular drug
DMK6U2V	PC	16006606
DMK6U2V	MW	191.23
DMK6U2V	FM	C10H13N3O
DMK6U2V	IC	InChI=1S/C10H13N3O/c1-6-7-4-3-5-8(14-2)9(7)13-10(11)12-6/h3-6H,1-2H3,(H3,11,12,13)
DMK6U2V	CS	CC1C2=C(C(=CC=C2)OC)NC(=N1)N
DMK6U2V	IK	SCKPQZMXGISHHF-UHFFFAOYSA-N
DMK6U2V	IU	8-methoxy-4-methyl-1,4-dihydroquinazolin-2-amine
DMK6U2V	DE	Discovery agent

DMHLKAE	ID	DMHLKAE
DMHLKAE	DN	8-Methoxy-4-morpholin-4-yl-chromen-2-one
DMHLKAE	HS	Investigative
DMHLKAE	SN	CHEMBL176325; 8-methoxy-4-morpholin-4-yl-chromen-2-one
DMHLKAE	DT	Small molecular drug
DMHLKAE	PC	11346012
DMHLKAE	MW	261.269
DMHLKAE	FM	C14H15NO4
DMHLKAE	IC	InChI=1S/C14H15NO4/c1-17-12-4-2-3-10-11(9-13(16)19-14(10)12)15-5-7-18-8-6-15/h2-4,9H,5-8H2,1H3
DMHLKAE	CS	COC1=CC=CC2=C1OC(=O)C=C2N3CCOCC3
DMHLKAE	IK	QMOLGKOGXTXVPG-UHFFFAOYSA-N
DMHLKAE	IU	8-methoxy-4-morpholin-4-ylchromen-2-one
DMHLKAE	DE	Discovery agent

DMHZ5SB	ID	DMHZ5SB
DMHZ5SB	DN	8-Methoxy-quinolin-2-ylamine
DMHZ5SB	HS	Investigative
DMHZ5SB	SN	2-Quinolinamine, 8-methoxy-; 8-Methoxyquinolin-2-amine; 104090-86-0; CHEMBL77072; 8-Methoxy-quinolin-2-ylamine; ACMC-20m6vk; SCHEMBL1655715; CTK0G6598; DTXSID90624077; MolPort-020-915-686; PMXFKGCLUAFLMH-UHFFFAOYSA-N; 2-AMINO-8-METHOXYQUINOLINE; ZINC26399714; BDBM50025466; AKOS013465271
DMHZ5SB	DT	Small molecular drug
DMHZ5SB	PC	22266820
DMHZ5SB	MW	174.2
DMHZ5SB	FM	C10H10N2O
DMHZ5SB	IC	InChI=1S/C10H10N2O/c1-13-8-4-2-3-7-5-6-9(11)12-10(7)8/h2-6H,1H3,(H2,11,12)
DMHZ5SB	CS	COC1=CC=CC2=C1N=C(C=C2)N
DMHZ5SB	IK	PMXFKGCLUAFLMH-UHFFFAOYSA-N
DMHZ5SB	IU	8-methoxyquinolin-2-amine
DMHZ5SB	CA	CAS 104090-86-0
DMHZ5SB	DE	Discovery agent

DM92XPO	ID	DM92XPO
DM92XPO	DN	8-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM92XPO	HS	Investigative
DM92XPO	SN	CHEMBL97922; SCHEMBL10757167
DM92XPO	DT	Small molecular drug
DM92XPO	PC	15065156
DM92XPO	MW	199.21
DM92XPO	FM	C11H9N3O
DM92XPO	IC	InChI=1S/C11H9N3O/c1-6-3-2-4-8-7(6)5-9-10(12-8)14-11(15)13-9/h2-5H,1H3,(H2,12,13,14,15)
DM92XPO	CS	CC1=C2C=C3C(=NC2=CC=C1)NC(=O)N3
DM92XPO	IK	NFWDGDAZJTYAHA-UHFFFAOYSA-N
DM92XPO	IU	8-methyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DM92XPO	DE	Discovery agent

DM7FSZM	ID	DM7FSZM
DM7FSZM	DN	8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one
DM7FSZM	HS	Investigative
DM7FSZM	DT	Small molecular drug
DM7FSZM	PC	135457978
DM7FSZM	MW	281.27
DM7FSZM	FM	C15H11N3O3
DM7FSZM	IC	InChI=1S/C15H11N3O3/c1-9-3-2-4-12-13(9)16-14(17-15(12)19)10-5-7-11(8-6-10)18(20)21/h2-8H,1H3,(H,16,17,19)
DM7FSZM	CS	CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=C(C=C3)[N+](=O)[O-]
DM7FSZM	IK	NSQTWPGTGYHDIM-UHFFFAOYSA-N
DM7FSZM	IU	8-methyl-2-(4-nitrophenyl)-3H-quinazolin-4-one
DM7FSZM	DE	Discovery agent

DMLQ90D	ID	DMLQ90D
DMLQ90D	DN	8-Methyl-2-morpholin-4-yl-chromen-4-one
DMLQ90D	HS	Investigative
DMLQ90D	SN	CHEMBL179635; 8-methyl-2-morpholin-4-yl-chromen-4-one; SCHEMBL3539026; BDBM50159667
DMLQ90D	DT	Small molecular drug
DMLQ90D	PC	10083230
DMLQ90D	MW	245.27
DMLQ90D	FM	C14H15NO3
DMLQ90D	IC	InChI=1S/C14H15NO3/c1-10-3-2-4-11-12(16)9-13(18-14(10)11)15-5-7-17-8-6-15/h2-4,9H,5-8H2,1H3
DMLQ90D	CS	CC1=C2C(=CC=C1)C(=O)C=C(O2)N3CCOCC3
DMLQ90D	IK	OHUSJSSDFKPFTJ-UHFFFAOYSA-N
DMLQ90D	IU	8-methyl-2-morpholin-4-ylchromen-4-one
DMLQ90D	DE	Discovery agent

DMWZ27A	ID	DMWZ27A
DMWZ27A	DN	8-methyl-2-morpholino-7-phenoxy-4H-chromen-4-one
DMWZ27A	HS	Investigative
DMWZ27A	SN	CHEMBL203942
DMWZ27A	DT	Small molecular drug
DMWZ27A	PC	23586753
DMWZ27A	MW	337.4
DMWZ27A	FM	C20H19NO4
DMWZ27A	IC	InChI=1S/C20H19NO4/c1-14-18(24-15-5-3-2-4-6-15)8-7-16-17(22)13-19(25-20(14)16)21-9-11-23-12-10-21/h2-8,13H,9-12H2,1H3
DMWZ27A	CS	CC1=C(C=CC2=C1OC(=CC2=O)N3CCOCC3)OC4=CC=CC=C4
DMWZ27A	IK	OOXOMHKMWGSWSD-UHFFFAOYSA-N
DMWZ27A	IU	8-methyl-2-morpholin-4-yl-7-phenoxychromen-4-one
DMWZ27A	DE	Discovery agent

DMUI1YZ	ID	DMUI1YZ
DMUI1YZ	DN	8-methyl-2-morpholino-7-phenyl-4H-chromen-4-one
DMUI1YZ	HS	Investigative
DMUI1YZ	SN	CHEMBL95782
DMUI1YZ	DT	Small molecular drug
DMUI1YZ	PC	21460270
DMUI1YZ	MW	321.4
DMUI1YZ	FM	C20H19NO3
DMUI1YZ	IC	InChI=1S/C20H19NO3/c1-14-16(15-5-3-2-4-6-15)7-8-17-18(22)13-19(24-20(14)17)21-9-11-23-12-10-21/h2-8,13H,9-12H2,1H3
DMUI1YZ	CS	CC1=C(C=CC2=C1OC(=CC2=O)N3CCOCC3)C4=CC=CC=C4
DMUI1YZ	IK	ZMYPEBFYGCAKQT-UHFFFAOYSA-N
DMUI1YZ	IU	8-methyl-2-morpholin-4-yl-7-phenylchromen-4-one
DMUI1YZ	DE	Discovery agent

DMEM6Q0	ID	DMEM6Q0
DMEM6Q0	DN	8-Methyl-2-phenyl-3H-quinazolin-4-one
DMEM6Q0	HS	Investigative
DMEM6Q0	DT	Small molecular drug
DMEM6Q0	PC	135531482
DMEM6Q0	MW	236.27
DMEM6Q0	FM	C15H12N2O
DMEM6Q0	IC	InChI=1S/C15H12N2O/c1-10-6-5-9-12-13(10)16-14(17-15(12)18)11-7-3-2-4-8-11/h2-9H,1H3,(H,16,17,18)
DMEM6Q0	CS	CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=CC=C3
DMEM6Q0	IK	WLZJEOODSSBWMB-UHFFFAOYSA-N
DMEM6Q0	IU	8-methyl-2-phenyl-3H-quinazolin-4-one
DMEM6Q0	DE	Discovery agent

DMOM4VS	ID	DMOM4VS
DMOM4VS	DN	8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane
DMOM4VS	HS	Investigative
DMOM4VS	SN	CHEMBL82027; 130342-81-3; ACMC-20mtlb; 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane; SCHEMBL12959169; 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester; 8-Azabicyclo[3.2.1]octane-2-carboxylicacid, 8-methyl-3-(4-methylphenyl)-, methyl ester, (1R,2S,3S,5S)-
DMOM4VS	DT	Small molecular drug
DMOM4VS	PC	9881979
DMOM4VS	MW	273.37
DMOM4VS	FM	C17H23NO2
DMOM4VS	IC	InChI=1S/C17H23NO2/c1-11-4-6-12(7-5-11)14-10-13-8-9-15(18(13)2)16(14)17(19)20-3/h4-7,13-16H,8-10H2,1-3H3
DMOM4VS	CS	CC1=CC=C(C=C1)C2CC3CCC(C2C(=O)OC)N3C
DMOM4VS	IK	MMKZDDDDODERSJ-UHFFFAOYSA-N
DMOM4VS	IU	methyl 8-methyl-3-(4-methylphenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
DMOM4VS	DE	Discovery agent

DMA28OL	ID	DMA28OL
DMA28OL	DN	8-methyl-4H,7H-indolo[6,5,4-cd]indol-5-one
DMA28OL	HS	Investigative
DMA28OL	SN	CHEMBL388936; 8-methyl-4H,7H-indolo[6,5,4-cd]indol-5-one
DMA28OL	DT	Small molecular drug
DMA28OL	PC	44425819
DMA28OL	MW	222.24
DMA28OL	FM	C14H10N2O
DMA28OL	IC	InChI=1S/C14H10N2O/c1-7-5-9-8-3-2-4-11-13(8)10(14(17)16-11)6-12(9)15-7/h2-6,15H,1H3,(H,16,17)
DMA28OL	CS	CC1=CC2=C(N1)C=C3C4=C2C=CC=C4NC3=O
DMA28OL	IK	ACTSTIBGWRUXHI-UHFFFAOYSA-N
DMA28OL	IU	4-methyl-5,10-diazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(15),2(6),3,7,11,13-hexaen-9-one
DMA28OL	DE	Discovery agent

DMVAOIG	ID	DMVAOIG
DMVAOIG	DN	8-Methyl-4-morpholin-4-yl-chromen-2-one
DMVAOIG	HS	Investigative
DMVAOIG	SN	CHEMBL369452; 8-methyl-4-morpholin-4-yl-chromen-2-one
DMVAOIG	DT	Small molecular drug
DMVAOIG	PC	10857738
DMVAOIG	MW	245.27
DMVAOIG	FM	C14H15NO3
DMVAOIG	IC	InChI=1S/C14H15NO3/c1-10-3-2-4-11-12(9-13(16)18-14(10)11)15-5-7-17-8-6-15/h2-4,9H,5-8H2,1H3
DMVAOIG	CS	CC1=C2C(=CC=C1)C(=CC(=O)O2)N3CCOCC3
DMVAOIG	IK	HXUJEFDGGXBUQX-UHFFFAOYSA-N
DMVAOIG	IU	8-methyl-4-morpholin-4-ylchromen-2-one
DMVAOIG	DE	Discovery agent

DMK63P2	ID	DMK63P2
DMK63P2	DN	8-methylnaringenin
DMK63P2	HS	Investigative
DMK63P2	SN	8-methylnaringenin; CHEMBL426154; MolPort-039-339-073; ZINC14814929; 5,7,4'-Trihydroxy-8-methylflavanone
DMK63P2	DT	Small molecular drug
DMK63P2	PC	44418717
DMK63P2	MW	286.28
DMK63P2	FM	C16H14O5
DMK63P2	IC	InChI=1S/C16H14O5/c1-8-11(18)6-12(19)15-13(20)7-14(21-16(8)15)9-2-4-10(17)5-3-9/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1
DMK63P2	CS	CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMK63P2	IK	GMVYLXBMPRDZDR-AWEZNQCLSA-N
DMK63P2	IU	(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-methyl-2,3-dihydrochromen-4-one
DMK63P2	DE	Discovery agent

DMWMVI3	ID	DMWMVI3
DMWMVI3	DN	8-n-heptylnaringenin
DMWMVI3	HS	Investigative
DMWMVI3	SN	8-n-heptylnaringenin
DMWMVI3	DT	Small molecular drug
DMWMVI3	PC	44418724
DMWMVI3	MW	370.4
DMWMVI3	FM	C22H26O5
DMWMVI3	IC	InChI=1S/C22H26O5/c1-2-3-4-5-6-7-16-17(24)12-18(25)21-19(26)13-20(27-22(16)21)14-8-10-15(23)11-9-14/h8-12,20,23-25H,2-7,13H2,1H3/t20-/m0/s1
DMWMVI3	CS	CCCCCCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMWMVI3	IK	JDJYVQUSVHXJHY-FQEVSTJZSA-N
DMWMVI3	IU	(2S)-8-heptyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMWMVI3	DE	Discovery agent

DM5L40C	ID	DM5L40C
DM5L40C	DN	8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one
DM5L40C	HS	Investigative
DM5L40C	SN	SCHEMBL4661629; CHEMBL370673; BDBM27510; SWBDUXDIPMGDNO-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 1b; ZINC13652894; 5,6-dihydro-5-oxo-8-nitro-indeno[1,2-c]isoquinoline; 8-Nitro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one
DM5L40C	DT	Small molecular drug
DM5L40C	PC	25190929
DM5L40C	MW	278.26
DM5L40C	FM	C16H10N2O3
DM5L40C	IC	InChI=1S/C16H10N2O3/c19-16-12-4-2-1-3-11(12)14-7-9-5-6-10(18(20)21)8-13(9)15(14)17-16/h1-6,8H,7H2,(H,17,19)
DM5L40C	CS	C1C2=C(C=C(C=C2)[N+](=O)[O-])C3=C1C4=CC=CC=C4C(=O)N3
DM5L40C	IK	SWBDUXDIPMGDNO-UHFFFAOYSA-N
DM5L40C	IU	8-nitro-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DM5L40C	DE	Discovery agent

DMC2JLQ	ID	DMC2JLQ
DMC2JLQ	DN	8-n-nonylnaringenin
DMC2JLQ	HS	Investigative
DMC2JLQ	SN	8-n-nonylnaringenin
DMC2JLQ	DT	Small molecular drug
DMC2JLQ	PC	44418725
DMC2JLQ	MW	398.5
DMC2JLQ	FM	C24H30O5
DMC2JLQ	IC	InChI=1S/C24H30O5/c1-2-3-4-5-6-7-8-9-18-19(26)14-20(27)23-21(28)15-22(29-24(18)23)16-10-12-17(25)13-11-16/h10-14,22,25-27H,2-9,15H2,1H3/t22-/m0/s1
DMC2JLQ	CS	CCCCCCCCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMC2JLQ	IK	PGTXFXPDRFSQPT-QFIPXVFZSA-N
DMC2JLQ	IU	(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-nonyl-2,3-dihydrochromen-4-one
DMC2JLQ	DE	Discovery agent

DMRDOP0	ID	DMRDOP0
DMRDOP0	DN	8-n-pentylnaringenin
DMRDOP0	HS	Investigative
DMRDOP0	SN	8-n-pentylnaringenin
DMRDOP0	DT	Small molecular drug
DMRDOP0	PC	44418723
DMRDOP0	MW	342.4
DMRDOP0	FM	C20H22O5
DMRDOP0	IC	InChI=1S/C20H22O5/c1-2-3-4-5-14-15(22)10-16(23)19-17(24)11-18(25-20(14)19)12-6-8-13(21)9-7-12/h6-10,18,21-23H,2-5,11H2,1H3/t18-/m0/s1
DMRDOP0	CS	CCCCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMRDOP0	IK	NKWHELZNPRCJAS-SFHVURJKSA-N
DMRDOP0	IU	(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-pentyl-2,3-dihydrochromen-4-one
DMRDOP0	DE	Discovery agent

DMDOW5S	ID	DMDOW5S
DMDOW5S	DN	8-n-propylnaringenin
DMDOW5S	HS	Investigative
DMDOW5S	SN	8-n-propylnaringenin
DMDOW5S	DT	Small molecular drug
DMDOW5S	PC	44418722
DMDOW5S	MW	314.3
DMDOW5S	FM	C18H18O5
DMDOW5S	IC	InChI=1S/C18H18O5/c1-2-3-12-13(20)8-14(21)17-15(22)9-16(23-18(12)17)10-4-6-11(19)7-5-10/h4-8,16,19-21H,2-3,9H2,1H3/t16-/m0/s1
DMDOW5S	CS	CCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMDOW5S	IK	PFCDDRUHZAMKHP-INIZCTEOSA-N
DMDOW5S	IU	(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-propyl-2,3-dihydrochromen-4-one
DMDOW5S	DE	Discovery agent

DMXURM8	ID	DMXURM8
DMXURM8	DN	8-n-undecylnaringenin
DMXURM8	HS	Investigative
DMXURM8	SN	8-n-undecylnaringenin
DMXURM8	DT	Small molecular drug
DMXURM8	PC	44418726
DMXURM8	MW	426.5
DMXURM8	FM	C26H34O5
DMXURM8	IC	InChI=1S/C26H34O5/c1-2-3-4-5-6-7-8-9-10-11-20-21(28)16-22(29)25-23(30)17-24(31-26(20)25)18-12-14-19(27)15-13-18/h12-16,24,27-29H,2-11,17H2,1H3/t24-/m0/s1
DMXURM8	CS	CCCCCCCCCCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMXURM8	IK	MQGTUCCMXKRAMD-DEOSSOPVSA-N
DMXURM8	IU	(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-undecyl-2,3-dihydrochromen-4-one
DMXURM8	DE	Discovery agent

DMDRPLA	ID	DMDRPLA
DMDRPLA	DN	8-O-(4-bromobenzenesulfonyl)manzamine F
DMDRPLA	HS	Investigative
DMDRPLA	SN	CHEMBL414128; 8-O-(4-bromobenzenesulfonyl)manzamine F
DMDRPLA	DT	Small molecular drug
DMDRPLA	PC	23643732
DMDRPLA	MW	799.8
DMDRPLA	FM	C42H47BrN4O5S
DMDRPLA	IC	InChI=1S/C42H47BrN4O5S/c43-28-12-16-31(17-13-28)53(50,51)52-36-11-7-10-32-33-18-21-44-38(39(33)45-37(32)36)34-26-42(49)20-5-3-1-2-4-6-22-46-24-19-35(34)41(27-46)25-29-14-15-30(48)9-8-23-47(29)40(41)42/h1,3,7,10-13,16-18,21,26,29,35,40,45,49H,2,4-6,8-9,14-15,19-20,22-25,27H2/b3-1-/t29-,35?,40+,41-,42-/m0/s1
DMDRPLA	CS	C1CCN2CCC3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]5N4CCCC(=O)CC5)O)C6=NC=CC7=C6NC8=C7C=CC=C8OS(=O)(=O)C9=CC=C(C=C9)Br
DMDRPLA	IK	WYQZODVBTOVVOF-WXPZYUJUSA-N
DMDRPLA	IU	[1-[(2R,4S,12R,13S,16Z)-13-hydroxy-7-oxo-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-16,25-dien-25-yl]-9H-pyrido[3,4-b]indol-8-yl] 4-bromobenzenesulfonate
DMDRPLA	DE	Discovery agent

DM48JMC	ID	DM48JMC
DM48JMC	DN	8-O-(4-chlorobenzenesulfonyl)manzamine F
DM48JMC	HS	Investigative
DM48JMC	SN	CHEMBL400717; 8-O-(4-chlorobenzenesulfonyl)manzamine F
DM48JMC	DT	Small molecular drug
DM48JMC	PC	23643731
DM48JMC	MW	755.4
DM48JMC	FM	C42H47ClN4O5S
DM48JMC	IC	InChI=1S/C42H47ClN4O5S/c43-28-12-16-31(17-13-28)53(50,51)52-36-11-7-10-32-33-18-21-44-38(39(33)45-37(32)36)34-26-42(49)20-5-3-1-2-4-6-22-46-24-19-35(34)41(27-46)25-29-14-15-30(48)9-8-23-47(29)40(41)42/h1,3,7,10-13,16-18,21,26,29,35,40,45,49H,2,4-6,8-9,14-15,19-20,22-25,27H2/b3-1-/t29-,35?,40+,41-,42-/m0/s1
DM48JMC	CS	C1CCN2CCC3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]5N4CCCC(=O)CC5)O)C6=NC=CC7=C6NC8=C7C=CC=C8OS(=O)(=O)C9=CC=C(C=C9)Cl
DM48JMC	IK	MSUMHGMGRZWLMN-WXPZYUJUSA-N
DM48JMC	IU	[1-[(2R,4S,12R,13S,16Z)-13-hydroxy-7-oxo-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-16,25-dien-25-yl]-9H-pyrido[3,4-b]indol-8-yl] 4-chlorobenzenesulfonate
DM48JMC	DE	Discovery agent

DM249GI	ID	DM249GI
DM249GI	DN	8-O-(4-toluenesulfonyl)manzamine A
DM249GI	HS	Investigative
DM249GI	SN	CHEMBL403561
DM249GI	DT	Small molecular drug
DM249GI	PC	101437199
DM249GI	MW	718.9
DM249GI	FM	C43H50N4O4S
DM249GI	IC	InChI=1S/C43H50N4O4S/c1-30-16-18-32(19-17-30)52(49,50)51-37-15-12-14-33-34-20-23-44-39(40(34)45-38(33)37)35-28-43(48)22-9-5-2-3-6-10-24-46-26-21-36(35)42(29-46)27-31-13-8-4-7-11-25-47(31)41(42)43/h2,5,8,12-20,23,28,31,36,41,45,48H,3-4,6-7,9-11,21-22,24-27,29H2,1H3/b5-2-,13-8-/t31-,36-,41+,42-,43-/m0/s1
DM249GI	CS	CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=CC3=C2NC4=C3C=CN=C4C5=C[C@]6(CC/C=C\\CCCCN7CC[C@@H]5[C@]8(C7)[C@H]6N9CCCC/C=C\\[C@H]9C8)O
DM249GI	IK	YYODILDWWWVNHZ-PPDYSKKASA-N
DM249GI	IU	[1-[(1R,2R,4R,5Z,12R,13S,16Z)-13-hydroxy-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-25-yl]-9H-pyrido[3,4-b]indol-8-yl] 4-methylbenzenesulfonate
DM249GI	DE	Discovery agent

DM4Z15M	ID	DM4Z15M
DM4Z15M	DN	8-Octyl-benzolactam-V9
DM4Z15M	HS	Investigative
DM4Z15M	SN	CHEMBL206866; 8-Octyl-benzolactam-V9; 8-Octylbenzolactam-V9
DM4Z15M	DT	Small molecular drug
DM4Z15M	PC	11574614
DM4Z15M	MW	388.6
DM4Z15M	FM	C24H40N2O2
DM4Z15M	IC	InChI=1S/C24H40N2O2/c1-5-6-7-8-9-10-12-19-13-11-14-22-21(19)16-15-20(17-27)25-24(28)23(18(2)3)26(22)4/h11,13-14,18,20,23,27H,5-10,12,15-17H2,1-4H3,(H,25,28)/t20-,23-/m0/s1
DM4Z15M	CS	CCCCCCCCC1=C2CC[C@H](NC(=O)[C@@H](N(C2=CC=C1)C)C(C)C)CO
DM4Z15M	IK	IDVIOLNZWSXZGL-REWPJTCUSA-N
DM4Z15M	IU	(2S,5S)-5-(hydroxymethyl)-1-methyl-8-octyl-2-propan-2-yl-4,5,6,7-tetrahydro-2H-1,4-benzodiazonin-3-one
DM4Z15M	DE	Discovery agent

DM4QYEF	ID	DM4QYEF
DM4QYEF	DN	8-OH-MANZAMINE A
DM4QYEF	HS	Investigative
DM4QYEF	SN	8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; 8-OH-MANZAMINE A; (+)8-Hydroxymanzamine A; CHEBI:66669
DM4QYEF	DT	Small molecular drug
DM4QYEF	PC	5270765
DM4QYEF	MW	564.8
DM4QYEF	FM	C36H44N4O2
DM4QYEF	IC	InChI=1S/C36H44N4O2/c41-30-14-11-13-26-27-15-18-37-32(33(27)38-31(26)30)28-23-36(42)17-8-4-1-2-5-9-19-39-21-16-29(28)35(24-39)22-25-12-7-3-6-10-20-40(25)34(35)36/h1,4,7,11-15,18,23,25,29,34,38,41-42H,2-3,5-6,8-10,16-17,19-22,24H2/b4-1-,12-7-/t25-,29-,34+,35-,36-/m0/s1
DM4QYEF	CS	C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]/5N4CCCC/C=C5)O)C6=NC=CC7=C6NC8=C7C=CC=C8O
DM4QYEF	IK	AMSNINGPDSUBHZ-WAUQNXBMSA-N
DM4QYEF	IU	(1R,2R,4R,5Z,12R,13S,16Z)-25-(8-hydroxy-9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DM4QYEF	CA	CAS 154466-37-2
DM4QYEF	CB	CHEBI:66669
DM4QYEF	DE	Discovery agent

DMXDQ25	ID	DMXDQ25
DMXDQ25	DN	8-Oxo-8-phenyl-octanoic acid
DMXDQ25	HS	Investigative
DMXDQ25	SN	8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837
DMXDQ25	DT	Small molecular drug
DMXDQ25	PC	298878
DMXDQ25	MW	234.29
DMXDQ25	FM	C14H18O3
DMXDQ25	IC	InChI=1S/C14H18O3/c15-13(12-8-4-3-5-9-12)10-6-1-2-7-11-14(16)17/h3-5,8-9H,1-2,6-7,10-11H2,(H,16,17)
DMXDQ25	CS	C1=CC=C(C=C1)C(=O)CCCCCCC(=O)O
DMXDQ25	IK	UMCSRRHQLAVYRS-UHFFFAOYSA-N
DMXDQ25	IU	8-oxo-8-phenyloctanoic acid
DMXDQ25	CA	CAS 24314-23-6
DMXDQ25	DE	Discovery agent

DMWM1UL	ID	DMWM1UL
DMWM1UL	DN	8-Oxo-8-phenyl-octanoic acid hydroxyamide
DMWM1UL	HS	Investigative
DMWM1UL	SN	CHEMBL95959; 8-Oxo-8-phenyl-octanoic acid hydroxyamide; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide
DMWM1UL	DT	Small molecular drug
DMWM1UL	PC	11075845
DMWM1UL	MW	249.3
DMWM1UL	FM	C14H19NO3
DMWM1UL	IC	InChI=1S/C14H19NO3/c16-13(12-8-4-3-5-9-12)10-6-1-2-7-11-14(17)15-18/h3-5,8-9,18H,1-2,6-7,10-11H2,(H,15,17)
DMWM1UL	CS	C1=CC=C(C=C1)C(=O)CCCCCCC(=O)NO
DMWM1UL	IK	DPHGSTLAQCKOFV-UHFFFAOYSA-N
DMWM1UL	IU	N-hydroxy-8-oxo-8-phenyloctanamide
DMWM1UL	DE	Discovery agent

DME8S0R	ID	DME8S0R
DME8S0R	DN	8-Pentyloxy-quinolin-2-ylamine
DME8S0R	HS	Investigative
DME8S0R	SN	CHEMBL186481; 8-Pentyloxy-quinolin-2-ylamine; SCHEMBL5883752
DME8S0R	DT	Small molecular drug
DME8S0R	PC	10353806
DME8S0R	MW	230.31
DME8S0R	FM	C14H18N2O
DME8S0R	IC	InChI=1S/C14H18N2O/c1-2-3-4-10-17-12-7-5-6-11-8-9-13(15)16-14(11)12/h5-9H,2-4,10H2,1H3,(H2,15,16)
DME8S0R	CS	CCCCCOC1=CC=CC2=C1N=C(C=C2)N
DME8S0R	IK	CTMPUINXCIZFAU-UHFFFAOYSA-N
DME8S0R	IU	8-pentoxyquinolin-2-amine
DME8S0R	DE	Discovery agent

DMFGUCY	ID	DMFGUCY
DMFGUCY	DN	8-PHENYL THEOPHYLLINE
DMFGUCY	HS	Investigative
DMFGUCY	SN	8-Phenyltheophylline; 1,3-Dimethyl-8-phenylxanthine; 961-45-5; Theophylline, 8-phenyl-; UNII-E6M543P3BL; NSC 14127; CHEMBL62350; E6M543P3BL; MFCD00005582; 1,3-dimethyl-8-phenyl-3,7-dihydro-1H-purine-2,6-dione; 1,3-dimethyl-8-phenyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione, 2,3,6,7-tetrahydro-1,3-dimethyl-8-phenyl-; AC1L1CIX; Lopac-P-2278; Oprea1_390706; Lopac0_000917; MLS000069624; SCHEMBL516432; 8-PT; 8-Phenyl-1,3-dimethylxanthine; 1,3-dimethyl-8-phenyl-1H-purine-2,6(3H,7H)-dione; BDBM82015; DTXSID90242119; MolPort-002-605-303
DMFGUCY	DT	Small molecular drug
DMFGUCY	PC	1922
DMFGUCY	MW	256.26
DMFGUCY	FM	C13H12N4O2
DMFGUCY	IC	InChI=1S/C13H12N4O2/c1-16-11-9(12(18)17(2)13(16)19)14-10(15-11)8-6-4-3-5-7-8/h3-7H,1-2H3,(H,14,15)
DMFGUCY	CS	CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C3=CC=CC=C3
DMFGUCY	IK	PJFMAVHETLRJHJ-UHFFFAOYSA-N
DMFGUCY	IU	1,3-dimethyl-8-phenyl-7H-purine-2,6-dione
DMFGUCY	CA	CAS 961-45-5
DMFGUCY	DE	Discovery agent

DMHQGOC	ID	DMHQGOC
DMHQGOC	DN	8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione
DMHQGOC	HS	Investigative
DMHQGOC	SN	CHEMBL274855; propyl-8-phenyl xanthine; 1-Propyl-8-phenylxanthine; 8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione
DMHQGOC	DT	Small molecular drug
DMHQGOC	PC	15627855
DMHQGOC	MW	270.29
DMHQGOC	FM	C14H14N4O2
DMHQGOC	IC	InChI=1S/C14H14N4O2/c1-2-8-18-13(19)10-12(17-14(18)20)16-11(15-10)9-6-4-3-5-7-9/h3-7H,2,8H2,1H3,(H,15,16)(H,17,20)
DMHQGOC	CS	CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=CC=C3
DMHQGOC	IK	LNATVXLECNOWHK-UHFFFAOYSA-N
DMHQGOC	IU	8-phenyl-1-propyl-3,7-dihydropurine-2,6-dione
DMHQGOC	DE	Discovery agent

DM29L4D	ID	DM29L4D
DM29L4D	DN	8-Phenyl-2-piperidin-1-yl-chromen-4-one
DM29L4D	HS	Investigative
DM29L4D	SN	CHEMBL176064; 8-Phenyl-2-piperidin-1-yl-chromen-4-one; SCHEMBL259239
DM29L4D	DT	Small molecular drug
DM29L4D	PC	11185819
DM29L4D	MW	305.4
DM29L4D	FM	C20H19NO2
DM29L4D	IC	InChI=1S/C20H19NO2/c22-18-14-19(21-12-5-2-6-13-21)23-20-16(10-7-11-17(18)20)15-8-3-1-4-9-15/h1,3-4,7-11,14H,2,5-6,12-13H2
DM29L4D	CS	C1CCN(CC1)C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DM29L4D	IK	OSJZAQVQDRSBPT-UHFFFAOYSA-N
DM29L4D	IU	8-phenyl-2-piperidin-1-ylchromen-4-one
DM29L4D	CA	CAS 154447-39-9
DM29L4D	DE	Discovery agent

DMJMWOE	ID	DMJMWOE
DMJMWOE	DN	8-Phenyl-2-thiomorpholin-4-yl-chromen-4-one
DMJMWOE	HS	Investigative
DMJMWOE	SN	CHEMBL175944; 8-phenyl-2-thiomorpholin-4-yl-chromen-4-one
DMJMWOE	DT	Small molecular drug
DMJMWOE	PC	11324758
DMJMWOE	MW	323.4
DMJMWOE	FM	C19H17NO2S
DMJMWOE	IC	InChI=1S/C19H17NO2S/c21-17-13-18(20-9-11-23-12-10-20)22-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2
DMJMWOE	CS	C1CSCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DMJMWOE	IK	BJZCLUNKKGYDPF-UHFFFAOYSA-N
DMJMWOE	IU	8-phenyl-2-thiomorpholin-4-ylchromen-4-one
DMJMWOE	CA	CAS 154447-37-7
DMJMWOE	DE	Discovery agent

DMJB1NI	ID	DMJB1NI
DMJB1NI	DN	8-Phenyl-3,7-dihydro-purine-2,6-dione
DMJB1NI	HS	Investigative
DMJB1NI	SN	8-Phenylxanthine; 2879-14-3; UNII-0S2BVG6C31; CHEMBL285191; 0S2BVG6C31; 1H-Purine-2,6-dione, 3,9-dihydro-8-phenyl-; 1H-Purine-2,6-dione, 3,7-dihydro-8-phenyl-; Xanthine, 8-phenyl-; 8-Phenyl-3,7-dihydro-purine-2,6-dione; SCHEMBL378879; CTK0J1822; DTXSID50485464; BDBM50042214; ZINC13472986; 8-Phenyl-1H-purine-2,6(3H,7H)-dione
DMJB1NI	DT	Small molecular drug
DMJB1NI	PC	12295530
DMJB1NI	MW	228.21
DMJB1NI	FM	C11H8N4O2
DMJB1NI	IC	InChI=1S/C11H8N4O2/c16-10-7-9(14-11(17)15-10)13-8(12-7)6-4-2-1-3-5-6/h1-5H,(H3,12,13,14,15,16,17)
DMJB1NI	CS	C1=CC=C(C=C1)C2=NC3=C(N2)C(=O)NC(=O)N3
DMJB1NI	IK	ACCCXSZCOGNLFL-UHFFFAOYSA-N
DMJB1NI	IU	8-phenyl-3,7-dihydropurine-2,6-dione
DMJB1NI	CA	CAS 2879-14-3
DMJB1NI	DE	Discovery agent

DM516NE	ID	DM516NE
DM516NE	DN	8-Phenyl-octanoic acid hydroxyamide
DM516NE	HS	Investigative
DM516NE	SN	8-Phenyl-octanoic acid hydroxyamide; CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174
DM516NE	DT	Small molecular drug
DM516NE	PC	14098189
DM516NE	MW	235.32
DM516NE	FM	C14H21NO2
DM516NE	IC	InChI=1S/C14H21NO2/c16-14(15-17)12-8-3-1-2-5-9-13-10-6-4-7-11-13/h4,6-7,10-11,17H,1-3,5,8-9,12H2,(H,15,16)
DM516NE	CS	C1=CC=C(C=C1)CCCCCCCC(=O)NO
DM516NE	IK	JUCDFXVDGUXPMJ-UHFFFAOYSA-N
DM516NE	IU	N-hydroxy-8-phenyloctanamide
DM516NE	DE	Discovery agent

DM4TWRJ	ID	DM4TWRJ
DM4TWRJ	DN	8-Phenyloctylcarbamic Acid Biphenyl-3-yl Ester
DM4TWRJ	HS	Investigative
DM4TWRJ	SN	CHEMBL486701; 8-Phenyloctylcarbamic Acid Biphenyl-3-yl Ester
DM4TWRJ	DT	Small molecular drug
DM4TWRJ	PC	24881808
DM4TWRJ	MW	401.5
DM4TWRJ	FM	C27H31NO2
DM4TWRJ	IC	InChI=1S/C27H31NO2/c29-27(30-26-20-13-19-25(22-26)24-17-10-6-11-18-24)28-21-12-4-2-1-3-7-14-23-15-8-5-9-16-23/h5-6,8-11,13,15-20,22H,1-4,7,12,14,21H2,(H,28,29)
DM4TWRJ	CS	C1=CC=C(C=C1)CCCCCCCCNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DM4TWRJ	IK	IKKKZTIUGOILBU-UHFFFAOYSA-N
DM4TWRJ	IU	(3-phenylphenyl) N-(8-phenyloctyl)carbamate
DM4TWRJ	DE	Discovery agent

DM958EN	ID	DM958EN
DM958EN	DN	8-Piperazin-1-yl-imidazo[1,2-a]pyrazine
DM958EN	HS	Investigative
DM958EN	SN	76537-53-6; 8-(1-Piperazinyl)imidazo(1,2-a)pyrazine; 8-(1-piperazinyl)imidazo[1,2-a]pyrazine; CHEMBL331036; 8-piperazin-1-ylimidazo[1,2-a]pyrazine; 8-Pdpr; Imidazo(1,2-a)pyrazine, 8-(1-piperazinyl)-; Imidazo[1,2-a]pyrazine, 8-(1-piperazinyl)-; 8-Piperazin-1-yl-imidazo[1,2-a]pyrazine; AC1L2YVL; 8-(piperazin-1-yl)imidazo[1,2-a]pyrazine; AC1Q4X6M; SCHEMBL5496661; AC1Q1I52; CTK5E3085; DTXSID50227346; ZINC5117657; BDBM50002151; AKOS024075563; FT-0756627; Imidazo[1,2-a]pyrazine,8-(1-piperazinyl)-; A839966
DM958EN	DT	Small molecular drug
DM958EN	PC	131268
DM958EN	MW	203.24
DM958EN	FM	C10H13N5
DM958EN	IC	InChI=1S/C10H13N5/c1-5-14(6-2-11-1)9-10-13-4-8-15(10)7-3-12-9/h3-4,7-8,11H,1-2,5-6H2
DM958EN	CS	C1CN(CCN1)C2=NC=CN3C2=NC=C3
DM958EN	IK	NSHLOJVJEGEMSF-UHFFFAOYSA-N
DM958EN	IU	8-piperazin-1-ylimidazo[1,2-a]pyrazine
DM958EN	CA	CAS 76537-53-6
DM958EN	DE	Discovery agent

DM2VC0E	ID	DM2VC0E
DM2VC0E	DN	8-prenylapigenin
DM2VC0E	HS	Investigative
DM2VC0E	SN	Licoflavone C; 8-Prenylapigenin; 72357-31-4; UNII-0DQ85982ZY; 4',5,7-Trihydroxy-8-prenylflavone; CHEMBL371562; 0DQ85982ZY; SCHEMBL1231403; MEGxp0_002023; ACon1_001079; ZINC21406; MolPort-001-742-698; 4,5,7-trihydroxy-8-prenylflavone; LMPK12110422; BDBM50240972; 5,7,4'-Trihydroxy-8-prenylflavone; AKOS027326549; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methyl-2-buten-1-yl)-; NCGC00169697-01; BRD-K74687851-001-01-8
DM2VC0E	DT	Small molecular drug
DM2VC0E	PC	10246505
DM2VC0E	MW	338.4
DM2VC0E	FM	C20H18O5
DM2VC0E	IC	InChI=1S/C20H18O5/c1-11(2)3-8-14-15(22)9-16(23)19-17(24)10-18(25-20(14)19)12-4-6-13(21)7-5-12/h3-7,9-10,21-23H,8H2,1-2H3
DM2VC0E	CS	CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C=C(O2)C3=CC=C(C=C3)O)C
DM2VC0E	IK	MEHHCBRCXIDGKZ-UHFFFAOYSA-N
DM2VC0E	IU	5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
DM2VC0E	CA	CAS 72357-31-4
DM2VC0E	DE	Discovery agent

DMZC1SV	ID	DMZC1SV
DMZC1SV	DN	8-prenylquercetin
DMZC1SV	HS	Investigative
DMZC1SV	SN	8-prenylquercetin; CHEMBL193059; 8-prenyl-quercetin; SCHEMBL2686819; BDBM50240974
DMZC1SV	DT	Small molecular drug
DMZC1SV	PC	9799499
DMZC1SV	MW	370.4
DMZC1SV	FM	C20H18O7
DMZC1SV	IC	InChI=1S/C20H18O7/c1-9(2)3-5-11-13(22)8-15(24)16-17(25)18(26)19(27-20(11)16)10-4-6-12(21)14(23)7-10/h3-4,6-8,21-24,26H,5H2,1-2H3
DMZC1SV	CS	CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC(=C(C=C3)O)O)O)C
DMZC1SV	IK	ZHTTWVRMGWQEOH-UHFFFAOYSA-N
DMZC1SV	IU	2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-8-(3-methylbut-2-enyl)chromen-4-one
DMZC1SV	CA	CAS 143724-75-8
DMZC1SV	DE	Discovery agent

DMKWYJX	ID	DMKWYJX
DMKWYJX	DN	8-Propionyl-7-propoxy-2H-chromen-2-one
DMKWYJX	HS	Investigative
DMKWYJX	SN	CHEMBL1288623; 8-Propionyl-7-propoxy-2H-chromen-2-one
DMKWYJX	DT	Small molecular drug
DMKWYJX	PC	52946831
DMKWYJX	MW	260.279
DMKWYJX	FM	C15H16O4
DMKWYJX	IC	InChI=1S/C15H16O4/c1-3-9-18-12-7-5-10-6-8-13(17)19-15(10)14(12)11(16)4-2/h5-8H,3-4,9H2,1-2H3
DMKWYJX	CS	CCCOC1=C(C2=C(C=C1)C=CC(=O)O2)C(=O)CC
DMKWYJX	IK	CVYSNMWNCSOWAN-UHFFFAOYSA-N
DMKWYJX	IU	8-propanoyl-7-propoxychromen-2-one
DMKWYJX	DE	Discovery agent

DM0TVL5	ID	DM0TVL5
DM0TVL5	DN	8-Propoxy-quinolin-2-ylamine
DM0TVL5	HS	Investigative
DM0TVL5	SN	CHEMBL427153; 8-Propoxy-quinolin-2-ylamine; SCHEMBL5884205; BDBM50152441
DM0TVL5	DT	Small molecular drug
DM0TVL5	PC	10420382
DM0TVL5	MW	202.25
DM0TVL5	FM	C12H14N2O
DM0TVL5	IC	InChI=1S/C12H14N2O/c1-2-8-15-10-5-3-4-9-6-7-11(13)14-12(9)10/h3-7H,2,8H2,1H3,(H2,13,14)
DM0TVL5	CS	CCCOC1=CC=CC2=C1N=C(C=C2)N
DM0TVL5	IK	SZBXIIUHFFFWME-UHFFFAOYSA-N
DM0TVL5	IU	8-propoxyquinolin-2-amine
DM0TVL5	DE	Discovery agent

DMT6YUF	ID	DMT6YUF
DMT6YUF	DN	8-propyl-2,6-diphenyl-9H-purine
DMT6YUF	HS	Investigative
DMT6YUF	SN	CHEMBL424869; 8-propyl-2,6-diphenyl-9H-purine
DMT6YUF	DT	Small molecular drug
DMT6YUF	PC	11565892
DMT6YUF	MW	314.4
DMT6YUF	FM	C20H18N4
DMT6YUF	IC	InChI=1S/C20H18N4/c1-2-9-16-21-18-17(14-10-5-3-6-11-14)23-19(24-20(18)22-16)15-12-7-4-8-13-15/h3-8,10-13H,2,9H2,1H3,(H,21,22,23,24)
DMT6YUF	CS	CCCC1=NC2=NC(=NC(=C2N1)C3=CC=CC=C3)C4=CC=CC=C4
DMT6YUF	IK	LIJDFWULFIYULY-UHFFFAOYSA-N
DMT6YUF	IU	2,6-diphenyl-8-propyl-7H-purine
DMT6YUF	DE	Discovery agent

DM1I25F	ID	DM1I25F
DM1I25F	DN	8-Pyridin-4-yl-9H-purine-2,6-diamine
DM1I25F	HS	Investigative
DM1I25F	SN	CHEMBL317618; 8-Pyridin-4-yl-9H-purine-2,6-diamine; 9H-Purine-2,6-diamine, 8-(4-pyridinyl)-; AC1L9X4Y; BDBM50059928; 2,6-Diamino-8-(4'-pyridinyl)purine; 8-pyridin-4-yl-7H-purine-2,6-diamine; 8-(4-pyridyl)-9H-purine-2,6-diamine; 194613-23-5
DM1I25F	DT	Small molecular drug
DM1I25F	PC	457739
DM1I25F	MW	227.23
DM1I25F	FM	C10H9N7
DM1I25F	IC	InChI=1S/C10H9N7/c11-7-6-9(17-10(12)15-7)16-8(14-6)5-1-3-13-4-2-5/h1-4H,(H5,11,12,14,15,16,17)
DM1I25F	CS	C1=CN=CC=C1C2=NC3=NC(=NC(=C3N2)N)N
DM1I25F	IK	FRFATUHEQSVWHE-UHFFFAOYSA-N
DM1I25F	IU	8-pyridin-4-yl-7H-purine-2,6-diamine
DM1I25F	DE	Discovery agent

DML9HDA	ID	DML9HDA
DML9HDA	DN	8R-hydroxylobel-9-ene
DML9HDA	HS	Investigative
DML9HDA	SN	CHEMBL425617; 8R-hydroxylobel-9-ene; SCHEMBL13845050
DML9HDA	DT	Small molecular drug
DML9HDA	PC	12018178
DML9HDA	MW	321.5
DML9HDA	FM	C22H27NO
DML9HDA	IC	InChI=1S/C22H27NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,15-16,20-22,24H,8,13-14,17H2,1H3/b16-15+/t20-,21+,22+/m0/s1
DML9HDA	CS	CN1[C@H](CCC[C@H]1/C=C/C2=CC=CC=C2)C[C@H](C3=CC=CC=C3)O
DML9HDA	IK	IKYXUFYHDWVXST-OWHMEISOSA-N
DML9HDA	IU	(1R)-2-[(2R,6S)-1-methyl-6-[(E)-2-phenylethenyl]piperidin-2-yl]-1-phenylethanol
DML9HDA	DE	Discovery agent

DMJ82TO	ID	DMJ82TO
DMJ82TO	DN	8R-hydroxylobelane
DMJ82TO	HS	Investigative
DMJ82TO	SN	8R-hydroxylobelane; CHEMBL125511; SCHEMBL14178948; BDBM50080821; (R)-1-Phenyl-2-(1-methyl-6beta-phenethyl-2beta-piperidinyl)ethanol
DMJ82TO	DT	Small molecular drug
DMJ82TO	PC	10782198
DMJ82TO	MW	323.5
DMJ82TO	FM	C22H29NO
DMJ82TO	IC	InChI=1S/C22H29NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,20-22,24H,8,13-17H2,1H3/t20-,21+,22+/m0/s1
DMJ82TO	CS	CN1[C@@H](CCC[C@@H]1C[C@H](C2=CC=CC=C2)O)CCC3=CC=CC=C3
DMJ82TO	IK	MUSFCRGEWKAWEE-BHDDXSALSA-N
DMJ82TO	IU	(1R)-2-[(2R,6S)-1-methyl-6-(2-phenylethyl)piperidin-2-yl]-1-phenylethanol
DMJ82TO	DE	Discovery agent

DMLK4WO	ID	DMLK4WO
DMLK4WO	DN	8R-Lisuride
DMLK4WO	HS	Investigative
DMLK4WO	SN	BKRGVLQUQGGVSM-RDTXWAMCSA-N; S-(-)-Lisuride; 8R-lisuride; NCGC00163158-01; Biomol-NT_000024; Lopac0_000781; BPBio1_001092; CHEMBL1528238; CHEBI:93550; BDBM22867; CCG-204866; L-122; EU-0100781; SR-01000075971; SR-01000075971-1; BRD-K88871508-001-01-9; 1,1-diethyl-3-(9,10-didehydro-6-methyl-8beta-ergolinyl)urea; N'-(9,10-Didehydro-6-methylergoline-8beta-yl)-N,N-diethylurea; 1,1-diethyl-3-[(8beta)-6-methyl-9,10-didehydroergolin-8-yl]urea; S(-)-N'-[(8a)-9,10-Didehydro-6-methylergolin-8-yl]-N,N-diethyl-urea
DMLK4WO	DT	Small molecular drug
DMLK4WO	PC	11957615
DMLK4WO	MW	338.4
DMLK4WO	FM	C20H26N4O
DMLK4WO	IC	InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18-/m1/s1
DMLK4WO	CS	CCN(CC)C(=O)N[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMLK4WO	IK	BKRGVLQUQGGVSM-RDTXWAMCSA-N
DMLK4WO	IU	3-[(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
DMLK4WO	CA	CAS 140387-89-9
DMLK4WO	CB	CHEBI:93550
DMLK4WO	DE	Discovery agent

DMFPWJL	ID	DMFPWJL
DMFPWJL	DN	8-sec-Butoxy-quinolin-2-ylamine
DMFPWJL	HS	Investigative
DMFPWJL	SN	CHEMBL186818; 8-sec-Butoxy-quinolin-2-ylamine; SCHEMBL5883697
DMFPWJL	DT	Small molecular drug
DMFPWJL	PC	10262766
DMFPWJL	MW	216.28
DMFPWJL	FM	C13H16N2O
DMFPWJL	IC	InChI=1S/C13H16N2O/c1-3-9(2)16-11-6-4-5-10-7-8-12(14)15-13(10)11/h4-9H,3H2,1-2H3,(H2,14,15)
DMFPWJL	CS	CCC(C)OC1=CC=CC2=C1N=C(C=C2)N
DMFPWJL	IK	RDHSHZSWPBWALB-UHFFFAOYSA-N
DMFPWJL	IU	8-butan-2-yloxyquinolin-2-amine
DMFPWJL	DE	Discovery agent

DMT9SAC	ID	DMT9SAC
DMT9SAC	DN	8S-HETE
DMT9SAC	HS	Investigative
DMT9SAC	SN	8-hydroxyeicosatetraenoic acid
DMT9SAC	DT	Small molecular drug
DMT9SAC	PC	5283154
DMT9SAC	MW	320.5
DMT9SAC	FM	C20H32O3
DMT9SAC	IC	InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-13-16-19(21)17-14-11-12-15-18-20(22)23/h6-7,9-11,13-14,16,19,21H,2-5,8,12,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,14-11-,16-13+/t19-/m1/s1
DMT9SAC	CS	CCCCC/C=C\\C/C=C\\C=C\\[C@H](C/C=C\\CCCC(=O)O)O
DMT9SAC	IK	NLUNAYAEIJYXRB-VYOQERLCSA-N
DMT9SAC	IU	(5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoic acid
DMT9SAC	CA	CAS 98462-03-4
DMT9SAC	CB	CHEBI:34486
DMT9SAC	DE	Discovery agent

DMRL3BK	ID	DMRL3BK
DMRL3BK	DN	8S-hydroxylobel-9-ene
DMRL3BK	HS	Investigative
DMRL3BK	SN	CHEMBL213613; 8S-hydroxylobel-9-ene; SCHEMBL14178965
DMRL3BK	DT	Small molecular drug
DMRL3BK	PC	12018177
DMRL3BK	MW	321.5
DMRL3BK	FM	C22H27NO
DMRL3BK	IC	InChI=1S/C22H27NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,15-16,20-22,24H,8,13-14,17H2,1H3/b16-15+/t20-,21+,22-/m0/s1
DMRL3BK	CS	CN1[C@H](CCC[C@H]1/C=C/C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O
DMRL3BK	IK	IKYXUFYHDWVXST-HTNBDEJSSA-N
DMRL3BK	IU	(1S)-2-[(2R,6S)-1-methyl-6-[(E)-2-phenylethenyl]piperidin-2-yl]-1-phenylethanol
DMRL3BK	DE	Discovery agent

DMLONTS	ID	DMLONTS
DMLONTS	DN	8S-hydroxylobelane
DMLONTS	HS	Investigative
DMLONTS	SN	8S-hydroxylobelane; CHEMBL377539; SCHEMBL14178958
DMLONTS	DT	Small molecular drug
DMLONTS	PC	44416452
DMLONTS	MW	323.5
DMLONTS	FM	C22H29NO
DMLONTS	IC	InChI=1S/C22H29NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,20-22,24H,8,13-17H2,1H3/t20-,21+,22-/m0/s1
DMLONTS	CS	CN1[C@@H](CCC[C@@H]1C[C@@H](C2=CC=CC=C2)O)CCC3=CC=CC=C3
DMLONTS	IK	MUSFCRGEWKAWEE-BDTNDASRSA-N
DMLONTS	IU	(1S)-2-[(2R,6S)-1-methyl-6-(2-phenylethyl)piperidin-2-yl]-1-phenylethanol
DMLONTS	DE	Discovery agent

DMOHB3Z	ID	DMOHB3Z
DMOHB3Z	DN	8-sulfophenyl theophylline
DMOHB3Z	HS	Investigative
DMOHB3Z	SN	8-(p-Sulfophenyl)theophylline; 8-(4-Sulfophenyl)theophylline; 80206-91-3; 8-SPT; 4-(1,3-dimethyl-2,6-dioxo-2,3,6,9-tetrahydro-1H-purin-8-yl)benzenesulfonic acid; CHEMBL8488; Psp-theophylline; 8-Sulphophenyltheophylline; Lopac-A-013; AC1Q6X0T; AC1L1CI3; Lopac0_000135; 8-(P-Sulfophenyl)Thiophylline; SCHEMBL1320226; 8-(p-Sulfophenyl)-theophylline; CTK6I1750; BDBM82023; CTK3E8290; DTXSID90230152; LXJSJIXZOAMHTG-UHFFFAOYSA-N; MolPort-006-068-692; HMS3260K12; ALBB-009371; ZX-AN008233; ZINC5322904; NSC_1908; Tox21_500135; PDSP1_000449
DMOHB3Z	DT	Small molecular drug
DMOHB3Z	PC	1908
DMOHB3Z	MW	336.33
DMOHB3Z	FM	C13H12N4O5S
DMOHB3Z	IC	InChI=1S/C13H12N4O5S/c1-16-11-9(12(18)17(2)13(16)19)14-10(15-11)7-3-5-8(6-4-7)23(20,21)22/h3-6H,1-2H3,(H,14,15)(H,20,21,22)
DMOHB3Z	CS	CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C3=CC=C(C=C3)S(=O)(=O)O
DMOHB3Z	IK	LXJSJIXZOAMHTG-UHFFFAOYSA-N
DMOHB3Z	IU	4-(1,3-dimethyl-2,6-dioxo-7H-purin-8-yl)benzenesulfonic acid
DMOHB3Z	CA	CAS 80206-91-3
DMOHB3Z	DE	Discovery agent

DM4Y9U3	ID	DM4Y9U3
DM4Y9U3	DN	9-(2-aminoethyl)-9,10-dihydroanthracene
DM4Y9U3	HS	Investigative
DM4Y9U3	SN	CHEMBL160893; 9-(2-aminoethyl)-9,10-dihydroanthracene; BDBM35923; 9,10-dihydroanthracene(DHA), 2a
DM4Y9U3	DT	Small molecular drug
DM4Y9U3	PC	44373221
DM4Y9U3	MW	223.31
DM4Y9U3	FM	C16H17N
DM4Y9U3	IC	InChI=1S/C16H17N/c17-10-9-16-14-7-3-1-5-12(14)11-13-6-2-4-8-15(13)16/h1-8,16H,9-11,17H2
DM4Y9U3	CS	C1C2=CC=CC=C2C(C3=CC=CC=C31)CCN
DM4Y9U3	IK	OWPHKTVZEZNCMB-UHFFFAOYSA-N
DM4Y9U3	IU	2-(9,10-dihydroanthracen-9-yl)ethanamine
DM4Y9U3	DE	Discovery agent

DMND39P	ID	DMND39P
DMND39P	DN	9-(2-aminopropyl)-9,10-dihydroanthracene
DMND39P	HS	Investigative
DMND39P	SN	CHEMBL158780; 9-(2-aminopropyl)-9,10-dihydroanthracene; BDBM35926; 9,10-dihydroanthracene(DHA), 3a; 9-(3-Aminopropyl)-9,10-dihydroanthracene
DMND39P	DT	Small molecular drug
DMND39P	PC	10354158
DMND39P	MW	237.34
DMND39P	FM	C17H19N
DMND39P	IC	InChI=1S/C17H19N/c18-11-5-10-17-15-8-3-1-6-13(15)12-14-7-2-4-9-16(14)17/h1-4,6-9,17H,5,10-12,18H2
DMND39P	CS	C1C2=CC=CC=C2C(C3=CC=CC=C31)CCCN
DMND39P	IK	AUTKMGMMFJXIDV-UHFFFAOYSA-N
DMND39P	IU	3-(9,10-dihydroanthracen-9-yl)propan-1-amine
DMND39P	DE	Discovery agent

DMYUMHG	ID	DMYUMHG
DMYUMHG	DN	9-(2-Hydroxyethyl)-9H-adenine
DMYUMHG	HS	Investigative
DMYUMHG	SN	2-(6-aminopurin-9-yl)ethanol; 707-99-3; 9-(2-Hydroxyethyl)adenine; 9h-purine-9-ethanol, 6-amino-; 9-(2-hydroxyethyl) adenine; CHEMBL95897; 6-Amino-9H-purin-9-ethanol; VAQOTZQDXZDBJK-UHFFFAOYSA-N; 6-Amino-9-(2-hydroxyethyl)purine; 2-(6-Amino-9H-purin-9-yl)ethanol; 9-(2-Hydroxyethyl)-9H-adenine; NSC51467; N9 -hydroxyethyladenine; AC1Q4VHV; 9-(2hydroxyethyl)adenine; ACMC-209og5; TimTec1_003634; 9-(2'-hydroxyethyl)adenine; 9-(2-Hydroxyethyl)adenine.; SCHEMBL984944; 6-Amino-9h-purine-9-ethanol; AC1L69W8; ZINC36416; KS-00000VZR
DMYUMHG	DT	Small molecular drug
DMYUMHG	PC	242652
DMYUMHG	MW	179.18
DMYUMHG	FM	C7H9N5O
DMYUMHG	IC	InChI=1S/C7H9N5O/c8-6-5-7(10-3-9-6)12(1-2-13)4-11-5/h3-4,13H,1-2H2,(H2,8,9,10)
DMYUMHG	CS	C1=NC(=C2C(=N1)N(C=N2)CCO)N
DMYUMHG	IK	VAQOTZQDXZDBJK-UHFFFAOYSA-N
DMYUMHG	IU	2-(6-aminopurin-9-yl)ethanol
DMYUMHG	CA	CAS 707-99-3
DMYUMHG	DE	Discovery agent

DM2UQ0R	ID	DM2UQ0R
DM2UQ0R	DN	9-(2-Hydroxypropyl)-9H-adenine
DM2UQ0R	HS	Investigative
DM2UQ0R	SN	9-(2-Hydroxypropyl)adenine; 1-(6-aminopurin-9-yl)propan-2-ol; CHEMBL504495; MJZYTEBKXLVLMY-UHFFFAOYSA-N; 9-(2-Hydroxypropyl)-9H-adenine; AC1L1CKL; 9H-Purine-9-ethanol, 6-amino-.alpha.-methyl-; SCHEMBL904363; CTK6A8458; 9-(2-Hydroxy-1-propyl)adenine; BCP14341; BDBM50257055; 3-(6-Amino-9-purinyl)-2-propanol; AKOS010941288; TRA0093894; AN-7936; 1-(6-Amino-purin-9-yl)-propan-2-ol; SY022843; A3032; 4CH-024207; 4CH-018216; 1-(6-Amino-9H-purin-9-yl)-2-propanol #; MFCD07369451 (97+%)
DM2UQ0R	DT	Small molecular drug
DM2UQ0R	PC	1942
DM2UQ0R	MW	193.21
DM2UQ0R	FM	C8H11N5O
DM2UQ0R	IC	InChI=1S/C8H11N5O/c1-5(14)2-13-4-12-6-7(9)10-3-11-8(6)13/h3-5,14H,2H2,1H3,(H2,9,10,11)
DM2UQ0R	CS	CC(CN1C=NC2=C(N=CN=C21)N)O
DM2UQ0R	IK	MJZYTEBKXLVLMY-UHFFFAOYSA-N
DM2UQ0R	IU	1-(6-aminopurin-9-yl)propan-2-ol
DM2UQ0R	DE	Discovery agent

DMDYZCH	ID	DMDYZCH
DMDYZCH	DN	9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DMDYZCH	HS	Investigative
DMDYZCH	SN	CHEMBL260788; SCHEMBL3268186; XBESCJVITPKCJA-UHFFFAOYSA-N; BDBM50377513
DMDYZCH	DT	Small molecular drug
DMDYZCH	PC	9836155
DMDYZCH	MW	306.32
DMDYZCH	FM	C16H14N6O
DMDYZCH	IC	InChI=1S/C16H14N6O/c17-11-4-1-3-10(7-11)8-22-9-19-14-13(12-5-2-6-23-12)20-16(18)21-15(14)22/h1-7,9H,8,17H2,(H2,18,20,21)
DMDYZCH	CS	C1=CC(=CC(=C1)N)CN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DMDYZCH	IK	XBESCJVITPKCJA-UHFFFAOYSA-N
DMDYZCH	IU	9-[(3-aminophenyl)methyl]-6-(furan-2-yl)purin-2-amine
DMDYZCH	DE	Discovery agent

DM51MRV	ID	DM51MRV
DM51MRV	DN	9-(3-aminopropoxy)-7H-furo[3,2-g]chromen-7-one
DM51MRV	HS	Investigative
DM51MRV	SN	CHEMBL382645; 119802-72-1; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-(3-aminopropoxy)-; ACMC-20moke; 9-(3-aminopropoxy)-7H-furo[3,2-g]chromen-7-one; SCHEMBL17373028; CTK0F9398; DTXSID90470955
DM51MRV	DT	Small molecular drug
DM51MRV	PC	11708692
DM51MRV	MW	259.26
DM51MRV	FM	C14H13NO4
DM51MRV	IC	InChI=1S/C14H13NO4/c15-5-1-6-17-14-12-10(4-7-18-12)8-9-2-3-11(16)19-13(9)14/h2-4,7-8H,1,5-6,15H2
DM51MRV	CS	C1=CC(=O)OC2=C(C3=C(C=CO3)C=C21)OCCCN
DM51MRV	IK	ZTTJBZXILLQBLD-UHFFFAOYSA-N
DM51MRV	IU	9-(3-aminopropoxy)furo[3,2-g]chromen-7-one
DM51MRV	CA	CAS 119802-72-1
DM51MRV	DE	Discovery agent

DM80MTI	ID	DM80MTI
DM80MTI	DN	9-(3-Hydroxypropyl)-9H-adenine
DM80MTI	HS	Investigative
DM80MTI	SN	711-64-8; 9H-Purine-9-propanol, 6-amino-; CHEMBL445974; 9-(3-Hydroxypropyl)-9H-adenine; 3-(6-Amino-9H-purin-9-yl)propan-1-ol; 9-(3-Hydroxypropyl)adenine; Oprea1_108729; 9-(3'-hydroxypropyl)adenine; SCHEMBL1635576; CTK2H3970; DTXSID10500041; MolPort-014-160-140; ZINC5391161; BDBM50257052; 3-(6-aminopurin-9-yl)propan-1-ol; AKOS010941287; 3-(6-Amino-9H-purine-9-yl)-1-propanol
DM80MTI	DT	Small molecular drug
DM80MTI	PC	12486289
DM80MTI	MW	193.21
DM80MTI	FM	C8H11N5O
DM80MTI	IC	InChI=1S/C8H11N5O/c9-7-6-8(11-4-10-7)13(5-12-6)2-1-3-14/h4-5,14H,1-3H2,(H2,9,10,11)
DM80MTI	CS	C1=NC(=C2C(=N1)N(C=N2)CCCO)N
DM80MTI	IK	BLZBVHFRNUTFCH-UHFFFAOYSA-N
DM80MTI	IU	3-(6-aminopurin-9-yl)propan-1-ol
DM80MTI	CA	CAS 711-64-8
DM80MTI	DE	Discovery agent

DMOP5AJ	ID	DMOP5AJ
DMOP5AJ	DN	9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE
DMOP5AJ	HS	Investigative
DMOP5AJ	SN	9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE; I40; N-[(3-iodophenyl)methyl]-1,2,3,4-tetrahydroacridin-9-amine; 1qon; AC1L9LOA; SCHEMBL3361969; DB07940
DMOP5AJ	DT	Small molecular drug
DMOP5AJ	PC	448167
DMOP5AJ	MW	414.3
DMOP5AJ	FM	C20H19IN2
DMOP5AJ	IC	InChI=1S/C20H19IN2/c21-15-7-5-6-14(12-15)13-22-20-16-8-1-3-10-18(16)23-19-11-4-2-9-17(19)20/h1,3,5-8,10,12H,2,4,9,11,13H2,(H,22,23)
DMOP5AJ	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCC4=CC(=CC=C4)I
DMOP5AJ	IK	ZUCWQTWGZGIYPV-UHFFFAOYSA-N
DMOP5AJ	IU	N-[(3-iodophenyl)methyl]-1,2,3,4-tetrahydroacridin-9-amine
DMOP5AJ	DE	Discovery agent

DM4X18V	ID	DM4X18V
DM4X18V	DN	9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DM4X18V	HS	Investigative
DM4X18V	SN	CHEMBL260790; SCHEMBL3268445; LYSMIARHRJVSBZ-UHFFFAOYSA-N; BDBM50377515
DM4X18V	DT	Small molecular drug
DM4X18V	PC	44449695
DM4X18V	MW	336.3
DM4X18V	FM	C16H12N6O3
DM4X18V	IC	InChI=1S/C16H12N6O3/c17-16-19-13(12-5-2-6-25-12)14-15(20-16)21(9-18-14)8-10-3-1-4-11(7-10)22(23)24/h1-7,9H,8H2,(H2,17,19,20)
DM4X18V	CS	C1=CC(=CC(=C1)[N+](=O)[O-])CN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DM4X18V	IK	LYSMIARHRJVSBZ-UHFFFAOYSA-N
DM4X18V	IU	6-(furan-2-yl)-9-[(3-nitrophenyl)methyl]purin-2-amine
DM4X18V	DE	Discovery agent

DMUIRS1	ID	DMUIRS1
DMUIRS1	DN	9-(3-n-Pentylureido)non-4(Z)-enoic acid
DMUIRS1	HS	Investigative
DMUIRS1	SN	CHEMBL551899; 9-(3-n-Pentylureido)non-4(Z)-enoic acid
DMUIRS1	DT	Small molecular drug
DMUIRS1	PC	44235414
DMUIRS1	MW	284.39
DMUIRS1	FM	C15H28N2O3
DMUIRS1	IC	InChI=1S/C15H28N2O3/c1-2-3-9-12-16-15(20)17-13-10-7-5-4-6-8-11-14(18)19/h4,6H,2-3,5,7-13H2,1H3,(H,18,19)(H2,16,17,20)/b6-4-
DMUIRS1	CS	CCCCCNC(=O)NCCCC/C=C\\CCC(=O)O
DMUIRS1	IK	ABERTDKHAIMZFF-XQRVVYSFSA-N
DMUIRS1	IU	(Z)-9-(pentylcarbamoylamino)non-4-enoic acid
DMUIRS1	DE	Discovery agent

DMJYMFE	ID	DMJYMFE
DMJYMFE	DN	9-(3-n-Pentylureido)non-4-ynoic acid
DMJYMFE	HS	Investigative
DMJYMFE	SN	CHEMBL551900; 9-(3-n-Pentylureido)non-4-ynoic acid
DMJYMFE	DT	Small molecular drug
DMJYMFE	PC	44235634
DMJYMFE	MW	282.38
DMJYMFE	FM	C15H26N2O3
DMJYMFE	IC	InChI=1S/C15H26N2O3/c1-2-3-9-12-16-15(20)17-13-10-7-5-4-6-8-11-14(18)19/h2-3,5,7-13H2,1H3,(H,18,19)(H2,16,17,20)
DMJYMFE	CS	CCCCCNC(=O)NCCCCC#CCCC(=O)O
DMJYMFE	IK	RYPHFFFUDQDRHY-UHFFFAOYSA-N
DMJYMFE	IU	9-(pentylcarbamoylamino)non-4-ynoic acid
DMJYMFE	DE	Discovery agent

DMW2NY9	ID	DMW2NY9
DMW2NY9	DN	9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine
DMW2NY9	HS	Investigative
DMW2NY9	SN	CHEMBL176245
DMW2NY9	DT	Small molecular drug
DMW2NY9	PC	11175093
DMW2NY9	MW	336.4
DMW2NY9	FM	C18H13FN4S
DMW2NY9	IC	InChI=1S/C18H13FN4S/c19-14-8-6-13(7-9-14)10-23-12-22-16-17(23)20-11-21-18(16)24-15-4-2-1-3-5-15/h1-9,11-12H,10H2
DMW2NY9	CS	C1=CC=C(C=C1)SC2=NC=NC3=C2N=CN3CC4=CC=C(C=C4)F
DMW2NY9	IK	IHJWHIRJWNFCOO-UHFFFAOYSA-N
DMW2NY9	IU	9-[(4-fluorophenyl)methyl]-6-phenylsulfanylpurine
DMW2NY9	DE	Discovery agent

DMLKJD9	ID	DMLKJD9
DMLKJD9	DN	9-(4-Hydroxybutyl)-N2-Phenylguanine
DMLKJD9	HS	Investigative
DMLKJD9	SN	9-(4-HYDROXYBUTYL)-N2-PHENYLGUANINE; HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one
DMLKJD9	DT	Small molecular drug
DMLKJD9	PC	135415618
DMLKJD9	MW	299.33
DMLKJD9	FM	C15H17N5O2
DMLKJD9	IC	InChI=1S/C15H17N5O2/c21-9-5-4-8-20-10-16-12-13(20)18-15(19-14(12)22)17-11-6-2-1-3-7-11/h1-3,6-7,10,21H,4-5,8-9H2,(H2,17,18,19,22)
DMLKJD9	CS	C1=CC=C(C=C1)NC2=NC3=C(C(=O)N2)N=CN3CCCCO
DMLKJD9	IK	JHBXNPBKSPYOFT-UHFFFAOYSA-N
DMLKJD9	IU	2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one
DMLKJD9	CA	CAS 161363-19-5
DMLKJD9	DE	Discovery agent

DMOL01E	ID	DMOL01E
DMOL01E	DN	9-(4-Hydroxyphenyl)-2,7-Phenanthroline
DMOL01E	HS	Investigative
DMOL01E	DT	Small molecular drug
DMOL01E	PC	447874
DMOL01E	MW	272.3
DMOL01E	FM	C18H12N2O
DMOL01E	IC	InChI=1S/C18H12N2O/c21-15-4-1-12(2-5-15)14-9-16-17-11-19-8-7-13(17)3-6-18(16)20-10-14/h1-11,21H
DMOL01E	CS	C1=CC2=C(C=C(C=N2)C3=CC=C(C=C3)O)C4=C1C=CN=C4
DMOL01E	IK	IUSSGTWHFMSCOY-UHFFFAOYSA-N
DMOL01E	IU	4-(2,7-phenanthrolin-9-yl)phenol
DMOL01E	CB	CHEBI:40444
DMOL01E	DE	Discovery agent

DMURKL9	ID	DMURKL9
DMURKL9	DN	9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DMURKL9	HS	Investigative
DMURKL9	SN	CHEMBL410445; SCHEMBL3269368
DMURKL9	DT	Small molecular drug
DMURKL9	PC	44449696
DMURKL9	MW	336.3
DMURKL9	FM	C16H12N6O3
DMURKL9	IC	InChI=1S/C16H12N6O3/c17-16-19-13(12-2-1-7-25-12)14-15(20-16)21(9-18-14)8-10-3-5-11(6-4-10)22(23)24/h1-7,9H,8H2,(H2,17,19,20)
DMURKL9	CS	C1=COC(=C1)C2=C3C(=NC(=N2)N)N(C=N3)CC4=CC=C(C=C4)[N+](=O)[O-]
DMURKL9	IK	QAQYSXUIQQIGHU-UHFFFAOYSA-N
DMURKL9	IU	6-(furan-2-yl)-9-[(4-nitrophenyl)methyl]purin-2-amine
DMURKL9	DE	Discovery agent

DMGFQLE	ID	DMGFQLE
DMGFQLE	DN	9-(5,5-Difluoro-5-Phosphonopentyl)Guanine
DMGFQLE	HS	Investigative
DMGFQLE	SN	9-(5,5-DIFLUORO-5-PHOSPHONOPENTYL)GUANINE; CHEMBL236708; HA1; 5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-1,1-difluoropentylphosphonate; AC1L9MLH; SCHEMBL2230046; 1v48; BDBM50214705; DB04260; 9-(5'',5''-difluoro-5''-phosphonopentyl)guanine; 5-(2-amino-6-oxo-1H-purin-9-yl)-1,1-difluoropentylphosphonic acid; [5-(2-amino-6-oxo-3H-purin-9-yl)-1,1-difluoropentyl]phosphonic acid; [5-(2-Amino-6-oxo-1,6-dihydro-purin-9-yl)-1,1-difluoro-pentyl]-phosphonic acid; 9-(5',5'-difluoro-5'-phosphonopentyl)guanine
DMGFQLE	DT	Small molecular drug
DMGFQLE	PC	135460987
DMGFQLE	MW	337.22
DMGFQLE	FM	C10H14F2N5O4P
DMGFQLE	IC	InChI=1S/C10H14F2N5O4P/c11-10(12,22(19,20)21)3-1-2-4-17-5-14-6-7(17)15-9(13)16-8(6)18/h5H,1-4H2,(H2,19,20,21)(H3,13,15,16,18)
DMGFQLE	CS	C1=NC2=C(N1CCCCC(F)(F)P(=O)(O)O)N=C(NC2=O)N
DMGFQLE	IK	JANQQPWTLXUSCD-UHFFFAOYSA-N
DMGFQLE	IU	[5-(2-amino-6-oxo-1H-purin-9-yl)-1,1-difluoropentyl]phosphonic acid
DMGFQLE	DE	Discovery agent

DM6QDNH	ID	DM6QDNH
DM6QDNH	DN	9-(Aminomethyl)-9,10-dihydroanthracene
DM6QDNH	HS	Investigative
DM6QDNH	SN	C-(9,10-Dihydro-anthracen-9-yl)-methylamine
DM6QDNH	DT	Small molecular drug
DM6QDNH	PC	10398175
DM6QDNH	MW	209.29
DM6QDNH	FM	C15H15N
DM6QDNH	IC	InChI=1S/C15H15N/c16-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)15/h1-8,15H,9-10,16H2
DM6QDNH	CS	C1C2=CC=CC=C2C(C3=CC=CC=C31)CN
DM6QDNH	IK	GEICAQNIOJFRQN-UHFFFAOYSA-N
DM6QDNH	IU	9,10-dihydroanthracen-9-ylmethanamine
DM6QDNH	CA	CAS 22136-76-1
DM6QDNH	DE	Discovery agent

DMIY3D6	ID	DMIY3D6
DMIY3D6	DN	9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one
DMIY3D6	HS	Investigative
DMIY3D6	SN	SCHEMBL7373122; CHEMBL116578
DMIY3D6	DT	Small molecular drug
DMIY3D6	PC	44342872
DMIY3D6	MW	364.4
DMIY3D6	FM	C21H23F3O2
DMIY3D6	IC	InChI=1S/C21H23F3O2/c22-21(23,24)20(25)11-7-2-1-3-8-16-26-19-14-12-18(13-15-19)17-9-5-4-6-10-17/h4-6,9-10,12-15H,1-3,7-8,11,16H2
DMIY3D6	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCCC(=O)C(F)(F)F
DMIY3D6	IK	SJSZPXVUCDJGAB-UHFFFAOYSA-N
DMIY3D6	IU	1,1,1-trifluoro-9-(4-phenylphenoxy)nonan-2-one
DMIY3D6	DE	Discovery agent

DMA2RCD	ID	DMA2RCD
DMA2RCD	DN	9-(N-benzylaminomethyl)-9,10-dihydroanthracene
DMA2RCD	HS	Investigative
DMA2RCD	SN	CHEMBL349543; 9-(N-benzylaminomethyl)-9,10-dihydroanthracene; BDBM50097644; 9-(Benzylaminomethyl)-9,10-dihydroanthracene
DMA2RCD	DT	Small molecular drug
DMA2RCD	PC	44373281
DMA2RCD	MW	299.4
DMA2RCD	FM	C22H21N
DMA2RCD	IC	InChI=1S/C22H21N/c1-2-8-17(9-3-1)15-23-16-22-20-12-6-4-10-18(20)14-19-11-5-7-13-21(19)22/h1-13,22-23H,14-16H2
DMA2RCD	CS	C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCC4=CC=CC=C4
DMA2RCD	IK	PJLWLZAKVLPHRL-UHFFFAOYSA-N
DMA2RCD	IU	N-benzyl-1-(9,10-dihydroanthracen-9-yl)methanamine
DMA2RCD	DE	Discovery agent

DMFKVPA	ID	DMFKVPA
DMFKVPA	DN	9-(sec-Butyl)-9H-adenine
DMFKVPA	HS	Investigative
DMFKVPA	SN	CHEMBL466044; 9-(sec-Butyl)-9H-adenine; SCHEMBL240049
DMFKVPA	DT	Small molecular drug
DMFKVPA	PC	44572293
DMFKVPA	MW	191.23
DMFKVPA	FM	C9H13N5
DMFKVPA	IC	InChI=1S/C9H13N5/c1-3-6(2)14-5-13-7-8(10)11-4-12-9(7)14/h4-6H,3H2,1-2H3,(H2,10,11,12)
DMFKVPA	CS	CCC(C)N1C=NC2=C(N=CN=C21)N
DMFKVPA	IK	WUUGZXPFGNZPJO-UHFFFAOYSA-N
DMFKVPA	IU	9-butan-2-ylpurin-6-amine
DMFKVPA	DE	Discovery agent

DMVBCID	ID	DMVBCID
DMVBCID	DN	9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide
DMVBCID	HS	Investigative
DMVBCID	SN	9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553
DMVBCID	DT	Small molecular drug
DMVBCID	PC	9882812
DMVBCID	MW	301.3
DMVBCID	FM	C15H18F3NO2
DMVBCID	IC	InChI=1S/C15H18F3NO2/c16-15(17,18)13(20)10-6-1-2-7-11-14(21)19-12-8-4-3-5-9-12/h3-5,8-9H,1-2,6-7,10-11H2,(H,19,21)
DMVBCID	CS	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)C(F)(F)F
DMVBCID	IK	KRCXZGYVOZSCSF-UHFFFAOYSA-N
DMVBCID	IU	9,9,9-trifluoro-8-oxo-N-phenylnonanamide
DMVBCID	DE	Discovery agent

DMOGD42	ID	DMOGD42
DMOGD42	DN	9-[2-(1-Phosphonobutan-2-yloxy)ethyl]guanine
DMOGD42	HS	Investigative
DMOGD42	DT	Small molecular drug
DMOGD42	PC	135867624
DMOGD42	MW	331.27
DMOGD42	FM	C11H18N5O5P
DMOGD42	IC	InChI=1S/C11H18N5O5P/c1-2-7(5-22(18,19)20)21-4-3-16-6-13-8-9(16)14-11(12)15-10(8)17/h6-7H,2-5H2,1H3,(H2,18,19,20)(H3,12,14,15,17)
DMOGD42	CS	CCC(CP(=O)(O)O)OCCN1C=NC2=C1N=C(NC2=O)N
DMOGD42	IK	RGMQGNHVNYSQHV-UHFFFAOYSA-N
DMOGD42	IU	2-[2-(2-amino-6-oxo-1H-purin-9-yl)ethoxy]butylphosphonic acid
DMOGD42	DE	Discovery agent

DMKHXT9	ID	DMKHXT9
DMKHXT9	DN	9-[2-(1-Phosphonobutan-2-yloxy)ethyl]hypoxanthine
DMKHXT9	HS	Investigative
DMKHXT9	DT	Small molecular drug
DMKHXT9	PC	135867626
DMKHXT9	MW	316.25
DMKHXT9	FM	C11H17N4O5P
DMKHXT9	IC	InChI=1S/C11H17N4O5P/c1-2-8(5-21(17,18)19)20-4-3-15-7-14-9-10(15)12-6-13-11(9)16/h6-8H,2-5H2,1H3,(H,12,13,16)(H2,17,18,19)
DMKHXT9	CS	CCC(CP(=O)(O)O)OCCN1C=NC2=C1N=CNC2=O
DMKHXT9	IK	WLWRLYCRISPQDH-UHFFFAOYSA-N
DMKHXT9	IU	2-[2-(6-oxo-1H-purin-9-yl)ethoxy]butylphosphonic acid
DMKHXT9	DE	Discovery agent

DMCXN6R	ID	DMCXN6R
DMCXN6R	DN	9-[2-(1-Phosphonopropan-2-yloxy)ethyl]guanine
DMCXN6R	HS	Investigative
DMCXN6R	DT	Small molecular drug
DMCXN6R	PC	135867622
DMCXN6R	MW	317.24
DMCXN6R	FM	C10H16N5O5P
DMCXN6R	IC	InChI=1S/C10H16N5O5P/c1-6(4-21(17,18)19)20-3-2-15-5-12-7-8(15)13-10(11)14-9(7)16/h5-6H,2-4H2,1H3,(H2,17,18,19)(H3,11,13,14,16)
DMCXN6R	CS	CC(CP(=O)(O)O)OCCN1C=NC2=C1N=C(NC2=O)N
DMCXN6R	IK	XUOAETDFEFTPTL-UHFFFAOYSA-N
DMCXN6R	IU	2-[2-(2-amino-6-oxo-1H-purin-9-yl)ethoxy]propylphosphonic acid
DMCXN6R	DE	Discovery agent

DMFR3SD	ID	DMFR3SD
DMFR3SD	DN	9-[5-(beta-Carboline-9-yl)pentyl]-beta-carboline
DMFR3SD	HS	Investigative
DMFR3SD	SN	CHEMBL1098470; 9-[5-(beta-Carboline-9-yl)pentyl]-beta-carboline; SCHEMBL17502362
DMFR3SD	DT	Small molecular drug
DMFR3SD	PC	46223112
DMFR3SD	MW	404.5
DMFR3SD	FM	C27H24N4
DMFR3SD	IC	InChI=1S/C27H24N4/c1(6-16-30-24-10-4-2-8-20(24)22-12-14-28-18-26(22)30)7-17-31-25-11-5-3-9-21(25)23-13-15-29-19-27(23)31/h2-5,8-15,18-19H,1,6-7,16-17H2
DMFR3SD	CS	C1=CC=C2C(=C1)C3=C(N2CCCCCN4C5=CC=CC=C5C6=C4C=NC=C6)C=NC=C3
DMFR3SD	IK	MRZCXQWEBCLSNO-UHFFFAOYSA-N
DMFR3SD	IU	9-(5-pyrido[3,4-b]indol-9-ylpentyl)pyrido[3,4-b]indole
DMFR3SD	DE	Discovery agent

DM6M5A4	ID	DM6M5A4
DM6M5A4	DN	9-[9-(beta-Carboline-9-yl)nonyl]-beta-carboline
DM6M5A4	HS	Investigative
DM6M5A4	SN	CHEMBL1098471; 9-[9-(beta-Carboline-9-yl)nonyl]-beta-carboline; BDBM50317203
DM6M5A4	DT	Small molecular drug
DM6M5A4	PC	46223113
DM6M5A4	MW	460.6
DM6M5A4	FM	C31H32N4
DM6M5A4	IC	InChI=1S/C31H32N4/c1(2-4-10-20-34-28-14-8-6-12-24(28)26-16-18-32-22-30(26)34)3-5-11-21-35-29-15-9-7-13-25(29)27-17-19-33-23-31(27)35/h6-9,12-19,22-23H,1-5,10-11,20-21H2
DM6M5A4	CS	C1=CC=C2C(=C1)C3=C(N2CCCCCCCCCN4C5=CC=CC=C5C6=C4C=NC=C6)C=NC=C3
DM6M5A4	IK	JJAATQLWMKLMJU-UHFFFAOYSA-N
DM6M5A4	IU	9-(9-pyrido[3,4-b]indol-9-ylnonyl)pyrido[3,4-b]indole
DM6M5A4	DE	Discovery agent

DMJ1VAE	ID	DMJ1VAE
DMJ1VAE	DN	98mTc-CIM-ANT
DMJ1VAE	HS	Investigative
DMJ1VAE	SN	99mTC-chelator SSTR2 antagonist (radiolabeled, neuroendocrine tumor imaging), Molecular Insight
DMJ1VAE	CP	Molecular Insight Pharmaceuticals Inc
DMJ1VAE	DE	Neuroendocrine cancer

DMAGTL1	ID	DMAGTL1
DMAGTL1	DN	99mTc-EC-0652
DMAGTL1	HS	Investigative
DMAGTL1	SN	EC-0652; PSMA-targeted imaging agent (prostate cancer), Endocyte; Prostate-specific membrane antigen targeted imaging agent (prostate cancer), Endocyte
DMAGTL1	CP	Endocyte Inc
DMAGTL1	DE	Prostate cancer

DMQOFX2	ID	DMQOFX2
DMQOFX2	DN	99mTc-MIP-1340
DMQOFX2	HS	Investigative
DMQOFX2	SN	MIP-1340; MIP-1340-[99mTc]; Technetium-99m-MIP-1340
DMQOFX2	CP	Molecular Insight Pharmaceuticals Inc
DMQOFX2	DE	Prostate cancer

DMYPD5L	ID	DMYPD5L
DMYPD5L	DN	99mTc-MIP-1407
DMYPD5L	HS	Investigative
DMYPD5L	SN	MIP-1407; MIP-1407-[99mTc]; Somatostatin receptor modulator imaging agent (neuroendocrine cancer), Molecular Insight; Technetium-99m-MIP-1407
DMYPD5L	CP	Molecular Insight Pharmaceuticals Inc
DMYPD5L	DE	Neuroendocrine cancer

DM8VZIY	ID	DM8VZIY
DM8VZIY	DN	9-Allyl-8-bromo-9H-adenine
DM8VZIY	HS	Investigative
DM8VZIY	SN	CHEMBL506888; 9-Allyl-8-bromo-9H-adenine; 8-Brom-9-allyladenin
DM8VZIY	DT	Small molecular drug
DM8VZIY	PC	44572408
DM8VZIY	MW	254.09
DM8VZIY	FM	C8H8BrN5
DM8VZIY	IC	InChI=1S/C8H8BrN5/c1-2-3-14-7-5(13-8(14)9)6(10)11-4-12-7/h2,4H,1,3H2,(H2,10,11,12)
DM8VZIY	CS	C=CCN1C2=NC=NC(=C2N=C1Br)N
DM8VZIY	IK	RSFSQISQTSQYRO-UHFFFAOYSA-N
DM8VZIY	IU	8-bromo-9-prop-2-enylpurin-6-amine
DM8VZIY	DE	Discovery agent

DMO9R6T	ID	DMO9R6T
DMO9R6T	DN	9alpha-acetoxy-miller-1(10)Z-enolide
DMO9R6T	HS	Investigative
DMO9R6T	SN	CHEMBL433971
DMO9R6T	DT	Small molecular drug
DMO9R6T	PC	44398369
DMO9R6T	MW	404.4
DMO9R6T	FM	C21H24O8
DMO9R6T	IC	InChI=1S/C21H24O8/c1-10(2)20(25)29-19-15-12(4)21(26)28-18(15)16(24)11(3)7-6-8-14(9-22)17(19)27-13(5)23/h8-9,15-19,24H,1,3-4,6-7H2,2,5H3/b14-8-/t15-,16-,17-,18-,19-/m0/s1
DMO9R6T	CS	CC(=C)C(=O)O[C@H]1[C@@H]2[C@@H]([C@H](C(=C)CC/C=C(\\[C@@H]1OC(=O)C)/C=O)O)OC(=O)C2=C
DMO9R6T	IK	QCTYKEDNIPKZDW-QHWUSFJTSA-N
DMO9R6T	IU	[(3aS,4S,5S,6E,11S,11aS)-5-acetyloxy-6-formyl-11-hydroxy-3,10-dimethylidene-2-oxo-4,5,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DMO9R6T	DE	Discovery agent

DMNHZFG	ID	DMNHZFG
DMNHZFG	DN	9-Amino-1,2,3,4-tetrahydro-acridine-1,7-diol
DMNHZFG	HS	Investigative
DMNHZFG	SN	CHEMBL354601; 1,7-Dihydroxytacrine; 9-Amino-1,2,3,4-tetrahydro-acridine-1,7-diol; SCHEMBL10846147
DMNHZFG	DT	Small molecular drug
DMNHZFG	PC	15043995
DMNHZFG	MW	230.26
DMNHZFG	FM	C13H14N2O2
DMNHZFG	IC	InChI=1S/C13H14N2O2/c14-13-8-6-7(16)4-5-9(8)15-10-2-1-3-11(17)12(10)13/h4-6,11,16-17H,1-3H2,(H2,14,15)
DMNHZFG	CS	C1CC(C2=C(C3=C(C=CC(=C3)O)N=C2C1)N)O
DMNHZFG	IK	RIGISKTXVJDQAZ-UHFFFAOYSA-N
DMNHZFG	IU	9-amino-1,2,3,4-tetrahydroacridine-1,7-diol
DMNHZFG	DE	Discovery agent

DMUL6QR	ID	DMUL6QR
DMUL6QR	DN	9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMUL6QR	HS	Investigative
DMUL6QR	SN	9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one; CHEMBL194155; SCHEMBL4078284; BDBM27515; BIBLEFNXUYTZIB-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2b; ZINC13652899; 5,6-Dihydro-5-oxo-9-amino-indeno[1,2-c]isoquinoline
DMUL6QR	DT	Small molecular drug
DMUL6QR	PC	11288114
DMUL6QR	MW	248.28
DMUL6QR	FM	C16H12N2O
DMUL6QR	IC	InChI=1S/C16H12N2O/c17-10-5-6-11-9(7-10)8-14-12-3-1-2-4-13(12)16(19)18-15(11)14/h1-7H,8,17H2,(H,18,19)
DMUL6QR	CS	C1C2=C(C=CC(=C2)N)C3=C1C4=CC=CC=C4C(=O)N3
DMUL6QR	IK	BIBLEFNXUYTZIB-UHFFFAOYSA-N
DMUL6QR	IU	9-amino-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DMUL6QR	DE	Discovery agent

DMNMVCZ	ID	DMNMVCZ
DMNMVCZ	DN	9-amino-7H-dibenzo[de,h]quinolin-7-one
DMNMVCZ	HS	Investigative
DMNMVCZ	SN	CHEMBL246681; 9-amino-7H-dibenzo[de,h]quinolin-7-one; 9-Amino-1-azabenzanthrone; SCHEMBL18573118; BDBM50211247; 9-amino-1-aza-benzo[de]anthracen-7-one
DMNMVCZ	DT	Small molecular drug
DMNMVCZ	PC	44440937
DMNMVCZ	MW	246.26
DMNMVCZ	FM	C16H10N2O
DMNMVCZ	IC	InChI=1S/C16H10N2O/c17-10-4-5-11-13(8-10)16(19)12-3-1-2-9-6-7-18-15(11)14(9)12/h1-8H,17H2
DMNMVCZ	CS	C1=CC2=C3C(=C1)C(=O)C4=C(C3=NC=C2)C=CC(=C4)N
DMNMVCZ	IK	SWTAISDIUOZWOE-UHFFFAOYSA-N
DMNMVCZ	IU	5-amino-16-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17),14-octaen-8-one
DMNMVCZ	DE	Discovery agent

DM9123M	ID	DM9123M
DM9123M	DN	9-Aminomethyl-9H-fluorene-2,5,6-triol
DM9123M	HS	Investigative
DM9123M	SN	9-(Aminomethyl)-9H-fluorene-2,5,6-triol; CHEMBL57672; 103692-55-3; 9H-Fluorene-2,5,6-triol,9-(aminomethyl)-; 2,5,6-Tfma; 9-Aminomethyl-9H-fluorene-2,5,6-triol; AC1L3YRM; ACMC-1C8EO; 2,5,6-Trihydroxy-9H-fluorene-9-methanamine; CTK4A2322; BDBM50025202; 9H-Fluorene-2,5,6-triol, 9-(aminomethyl)-
DM9123M	DT	Small molecular drug
DM9123M	PC	124618
DM9123M	MW	243.26
DM9123M	FM	C14H13NO3
DM9123M	IC	InChI=1S/C14H13NO3/c15-6-11-9-3-4-12(17)14(18)13(9)8-2-1-7(16)5-10(8)11/h1-5,11,16-18H,6,15H2
DM9123M	CS	C1=CC2=C(C=C1O)C(C3=C2C(=C(C=C3)O)O)CN
DM9123M	IK	KQVZVMZWAHAQGC-UHFFFAOYSA-N
DM9123M	IU	9-(aminomethyl)-9H-fluorene-2,5,6-triol
DM9123M	CA	CAS 103692-55-3
DM9123M	DE	Discovery agent

DMNG6O7	ID	DMNG6O7
DMNG6O7	DN	9-Aminomethyl-9H-fluorene-3,4-diol
DMNG6O7	HS	Investigative
DMNG6O7	SN	103692-53-1; CHEMBL55693; 9H-Fluorene-3,4-diol,9-(aminomethyl)-; 3,4-Dfma; F 103243; 9-(aminomethyl)-9H-fluorene-3,4-diol; Skf 103243; F-103243; ACMC-20m6ix; 3,4-Dihydroxy-9H-fluorene-9-methanamine; AC1L2TS9; CTK4A2321; BDBM50025201; 9H-Fluorene-3,4-diol, 9-(aminomethyl)-
DMNG6O7	DT	Small molecular drug
DMNG6O7	PC	128434
DMNG6O7	MW	227.26
DMNG6O7	FM	C14H13NO2
DMNG6O7	IC	InChI=1S/C14H13NO2/c15-7-11-8-3-1-2-4-9(8)13-10(11)5-6-12(16)14(13)17/h1-6,11,16-17H,7,15H2
DMNG6O7	CS	C1=CC=C2C(=C1)C(C3=C2C(=C(C=C3)O)O)CN
DMNG6O7	IK	YLOTUMWDVNOPBU-UHFFFAOYSA-N
DMNG6O7	IU	9-(aminomethyl)-9H-fluorene-3,4-diol
DMNG6O7	CA	CAS 103692-53-1
DMNG6O7	DE	Discovery agent

DMGCVT2	ID	DMGCVT2
DMGCVT2	DN	9-anthroic acid
DMGCVT2	HS	Investigative
DMGCVT2	SN	anthracene-10-carboxylic acid; 9-AC
DMGCVT2	DT	Small molecular drug
DMGCVT2	PC	2201
DMGCVT2	MW	222.24
DMGCVT2	FM	C15H10O2
DMGCVT2	IC	InChI=1S/C15H10O2/c16-15(17)14-12-7-3-1-5-10(12)9-11-6-2-4-8-13(11)14/h1-9H,(H,16,17)
DMGCVT2	CS	C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C(=O)O
DMGCVT2	IK	XGWFJBFNAQHLEF-UHFFFAOYSA-N
DMGCVT2	IU	anthracene-9-carboxylic acid
DMGCVT2	CA	CAS 723-62-6
DMGCVT2	CB	CHEBI:34507
DMGCVT2	DE	Discovery agent

DM8Q0D9	ID	DM8Q0D9
DM8Q0D9	DN	9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine
DM8Q0D9	HS	Investigative
DM8Q0D9	SN	SCHEMBL6659707
DM8Q0D9	DT	Small molecular drug
DM8Q0D9	PC	11336624
DM8Q0D9	MW	336.4
DM8Q0D9	FM	C18H13FN4S
DM8Q0D9	IC	InChI=1S/C18H13FN4S/c19-14-6-8-15(9-7-14)24-18-16-17(20-11-21-18)23(12-22-16)10-13-4-2-1-3-5-13/h1-9,11-12H,10H2
DM8Q0D9	CS	C1=CC=C(C=C1)CN2C=NC3=C2N=CN=C3SC4=CC=C(C=C4)F
DM8Q0D9	IK	MYVLGUBXADPZJM-UHFFFAOYSA-N
DM8Q0D9	IU	9-benzyl-6-(4-fluorophenyl)sulfanylpurine
DM8Q0D9	DE	Discovery agent

DM4JG60	ID	DM4JG60
DM4JG60	DN	9-benzyl-6-(4-methylpiperazin-1-yl)-9H-purine
DM4JG60	HS	Investigative
DM4JG60	SN	CHEMBL594468; 9-benzyl-6-(4-methylpiperazin-1-yl)-9H-purine
DM4JG60	DT	Small molecular drug
DM4JG60	PC	46228160
DM4JG60	MW	308.4
DM4JG60	FM	C17H20N6
DM4JG60	IC	InChI=1S/C17H20N6/c1-21-7-9-22(10-8-21)16-15-17(19-12-18-16)23(13-20-15)11-14-5-3-2-4-6-14/h2-6,12-13H,7-11H2,1H3
DM4JG60	CS	CN1CCN(CC1)C2=NC=NC3=C2N=CN3CC4=CC=CC=C4
DM4JG60	IK	JSSGUCJSJQMEEQ-UHFFFAOYSA-N
DM4JG60	IU	9-benzyl-6-(4-methylpiperazin-1-yl)purine
DM4JG60	DE	Discovery agent

DMNY5P1	ID	DMNY5P1
DMNY5P1	DN	9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine
DMNY5P1	HS	Investigative
DMNY5P1	SN	CHEMBL362047; 9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine; SCHEMBL2965769
DMNY5P1	DT	Small molecular drug
DMNY5P1	PC	10237315
DMNY5P1	MW	377.4
DMNY5P1	FM	C19H15N5O2S
DMNY5P1	IC	InChI=1S/C19H15N5O2S/c25-24(26)16-8-6-15(7-9-16)11-27-19-17-18(20-12-21-19)23(13-22-17)10-14-4-2-1-3-5-14/h1-9,12-13H,10-11H2
DMNY5P1	CS	C1=CC=C(C=C1)CN2C=NC3=C2N=CN=C3SCC4=CC=C(C=C4)[N+](=O)[O-]
DMNY5P1	IK	VKPWNJKIHUERPQ-UHFFFAOYSA-N
DMNY5P1	IU	9-benzyl-6-[(4-nitrophenyl)methylsulfanyl]purine
DMNY5P1	DE	Discovery agent

DMUMOE2	ID	DMUMOE2
DMUMOE2	DN	9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile
DMUMOE2	HS	Investigative
DMUMOE2	SN	Compound 3{8,17}; 9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile; CHEMBL400454
DMUMOE2	DT	Small molecular drug
DMUMOE2	PC	24778186
DMUMOE2	MW	340.4
DMUMOE2	FM	C20H16N6
DMUMOE2	IC	InChI=1S/C20H16N6/c21-11-17-24-19(22-12-15-7-3-1-4-8-15)18-20(25-17)26(14-23-18)13-16-9-5-2-6-10-16/h1-10,14H,12-13H2,(H,22,24,25)
DMUMOE2	CS	C1=CC=C(C=C1)CNC2=C3C(=NC(=N2)C#N)N(C=N3)CC4=CC=CC=C4
DMUMOE2	IK	VVLPZPSTQWLQHU-UHFFFAOYSA-N
DMUMOE2	IU	9-benzyl-6-(benzylamino)purine-2-carbonitrile
DMUMOE2	DE	Discovery agent

DMO6CB7	ID	DMO6CB7
DMO6CB7	DN	9-benzyl-6-(furan-2-yl)-9H-purin-2-amine
DMO6CB7	HS	Investigative
DMO6CB7	SN	CHEMBL196436; 9-benzyl-6-(furan-2-yl)-9H-purin-2-amine; SCHEMBL3268454; 2-amino-6-furyl-9-benzyl purine; BDBM50165066
DMO6CB7	DT	Small molecular drug
DMO6CB7	PC	44401938
DMO6CB7	MW	291.31
DMO6CB7	FM	C16H13N5O
DMO6CB7	IC	InChI=1S/C16H13N5O/c17-16-19-13(12-7-4-8-22-12)14-15(20-16)21(10-18-14)9-11-5-2-1-3-6-11/h1-8,10H,9H2,(H2,17,19,20)
DMO6CB7	CS	C1=CC=C(C=C1)CN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DMO6CB7	IK	FZKKCBUDFSOYPA-UHFFFAOYSA-N
DMO6CB7	IU	9-benzyl-6-(furan-2-yl)purin-2-amine
DMO6CB7	DE	Discovery agent

DMNCL5G	ID	DMNCL5G
DMNCL5G	DN	9-Benzyl-6-phenylsulfanyl-9H-purine
DMNCL5G	HS	Investigative
DMNCL5G	SN	SCHEMBL6662063
DMNCL5G	DT	Small molecular drug
DMNCL5G	PC	11347708
DMNCL5G	MW	318.4
DMNCL5G	FM	C18H14N4S
DMNCL5G	IC	InChI=1S/C18H14N4S/c1-3-7-14(8-4-1)11-22-13-21-16-17(22)19-12-20-18(16)23-15-9-5-2-6-10-15/h1-10,12-13H,11H2
DMNCL5G	CS	C1=CC=C(C=C1)CN2C=NC3=C2N=CN=C3SC4=CC=CC=C4
DMNCL5G	IK	ADCGNZUTMCMTDC-UHFFFAOYSA-N
DMNCL5G	IU	9-benzyl-6-phenylsulfanylpurine
DMNCL5G	DE	Discovery agent

DMMWGVI	ID	DMMWGVI
DMMWGVI	DN	9-Benzyl-8-bromo-9H-adenine
DMMWGVI	HS	Investigative
DMMWGVI	SN	9-benzyl-8-bromoadenine; CHEMBL151071; 9-benzyl-8-bromo-9H-purin-6-amine; 56046-34-5; 9-Benzyl-8-bromo-9H-adenine; 8-bromo-9-benzyladenine; N9-benzyl-8-bromoadenine; 8-Bromo-N9-benzyladenine; SCHEMBL4341941; OUPAEJUFVKPEHM-UHFFFAOYSA-N; BDBM50240851; 6-Amino-8-bromo-9-benzyl-9H-purine; 9-Benzyl-8-bromo-9H-purin-6-ylamine; 9-benzyl-8-bromo-9H-purin-6-yl amine
DMMWGVI	DT	Small molecular drug
DMMWGVI	PC	9904551
DMMWGVI	MW	304.15
DMMWGVI	FM	C12H10BrN5
DMMWGVI	IC	InChI=1S/C12H10BrN5/c13-12-17-9-10(14)15-7-16-11(9)18(12)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H2,14,15,16)
DMMWGVI	CS	C1=CC=C(C=C1)CN2C3=NC=NC(=C3N=C2Br)N
DMMWGVI	IK	OUPAEJUFVKPEHM-UHFFFAOYSA-N
DMMWGVI	IU	9-benzyl-8-bromopurin-6-amine
DMMWGVI	DE	Discovery agent

DMONCUL	ID	DMONCUL
DMONCUL	DN	9-BENZYL-9H-ADENINE
DMONCUL	HS	Investigative
DMONCUL	SN	9-Benzyladenine; 4261-14-7; 9-benzyl-9H-purin-6-amine; N9-Benzyladenine; 9-Benzylaminopurine; ADENINE, 9-BENZYL-; 9-Bap; 9-Benzyl-6-aminopurine; N(sup 9)-Benzyladenine; 9-BENZYL-9H-ADENINE; 9-Benzyl-9H-purin-6-ylamine; 9H-Purin-6-amine, 9-(phenylmethyl)-; CCRIS 6908; SQ 21611; 9-benzylpurin-6-amine; NSC 35649; 9-(Phenylmethyl)-9H-purin-6-amine; CHEMBL266094; 9H-Purin-6-amine,9-(phenylmethyl)-; AC1L2FWA; MLS000660735; SCHEMBL104932; 9-Benzyl-9H-purine-6-amine; CTK4I6467; DTXSID70195371; MRHCSNNEUHXNIC-UHFFFAOYSA-N; HMS2676M21
DMONCUL	DT	Small molecular drug
DMONCUL	PC	20262
DMONCUL	MW	225.25
DMONCUL	FM	C12H11N5
DMONCUL	IC	InChI=1S/C12H11N5/c13-11-10-12(15-7-14-11)17(8-16-10)6-9-4-2-1-3-5-9/h1-5,7-8H,6H2,(H2,13,14,15)
DMONCUL	CS	C1=CC=C(C=C1)CN2C=NC3=C(N=CN=C32)N
DMONCUL	IK	MRHCSNNEUHXNIC-UHFFFAOYSA-N
DMONCUL	IU	9-benzylpurin-6-amine
DMONCUL	CA	CAS 4261-14-7
DMONCUL	DE	Discovery agent

DMQEO7F	ID	DMQEO7F
DMQEO7F	DN	9-Bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMQEO7F	HS	Investigative
DMQEO7F	SN	9-Bromoellipticine; Ellipticine, 9-bromo-; 9-Bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; 18073-34-2; NSC 98927; BRN 0543507; CHEMBL194474; NSC98927; 9-Bromo-5,11-dimethyl-6H-pyrido(4,3-b)carbazole; 6H-Pyrido(4,3-b)carbazole, 9-bromo-5,11-dimethyl-; AC1L3XSF; 5-23-09-00418 (Beilstein Handbook Reference); DTXSID80171005; ZINC13284221; NSC-98927; BDBM50174409; ACM18073342; 6H-Pyrido[4, 9-bromo-5,11-dimethyl-
DMQEO7F	DT	Small molecular drug
DMQEO7F	PC	97080
DMQEO7F	MW	325.2
DMQEO7F	FM	C17H13BrN2
DMQEO7F	IC	InChI=1S/C17H13BrN2/c1-9-14-8-19-6-5-12(14)10(2)17-16(9)13-7-11(18)3-4-15(13)20-17/h3-8,20H,1-2H3
DMQEO7F	CS	CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=C(C=C4)Br)C
DMQEO7F	IK	OSDDZVXUCKZOQA-UHFFFAOYSA-N
DMQEO7F	IU	9-bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMQEO7F	CA	CAS 18073-34-2
DMQEO7F	DE	Discovery agent

DMSWQY7	ID	DMSWQY7
DMSWQY7	DN	9-But-3-enyl-9H-adenine
DMSWQY7	HS	Investigative
DMSWQY7	SN	CHEMBL510907; 9-But-3-enyl-9H-adenine; BDBM50256954
DMSWQY7	DT	Small molecular drug
DMSWQY7	PC	13789211
DMSWQY7	MW	189.22
DMSWQY7	FM	C9H11N5
DMSWQY7	IC	InChI=1S/C9H11N5/c1-2-3-4-14-6-13-7-8(10)11-5-12-9(7)14/h2,5-6H,1,3-4H2,(H2,10,11,12)
DMSWQY7	CS	C=CCCN1C=NC2=C(N=CN=C21)N
DMSWQY7	IK	LMZZJSTVOIDJFV-UHFFFAOYSA-N
DMSWQY7	IU	9-but-3-enylpurin-6-amine
DMSWQY7	DE	Discovery agent

DMXU90T	ID	DMXU90T
DMXU90T	DN	9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
DMXU90T	HS	Investigative
DMXU90T	SN	9-BUTYL-8-(3-METHOXYBENZYL)-9H-PURIN-6-AMINE; CHEMBL109612; AC1NRCWL; 1uy8; Purine-Based Inhibitor 3; SCHEMBL1966787; BDBM15376; BWLWUGBHOXIUBP-UHFFFAOYSA-N; DB03809; 8-(3-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(3-methoxyphenyl)methyl]purin-6-amine; 9-Butyl-8-(3-methoxy-benzyl)-9H-purin-6-ylamine
DMXU90T	DT	Small molecular drug
DMXU90T	PC	5289228
DMXU90T	MW	311.4
DMXU90T	FM	C17H21N5O
DMXU90T	IC	InChI=1S/C17H21N5O/c1-3-4-8-22-14(10-12-6-5-7-13(9-12)23-2)21-15-16(18)19-11-20-17(15)22/h5-7,9,11H,3-4,8,10H2,1-2H3,(H2,18,19,20)
DMXU90T	CS	CCCCN1C(=NC2=C(N=CN=C21)N)CC3=CC(=CC=C3)OC
DMXU90T	IK	BWLWUGBHOXIUBP-UHFFFAOYSA-N
DMXU90T	IU	9-butyl-8-[(3-methoxyphenyl)methyl]purin-6-amine
DMXU90T	DE	Discovery agent

DMKHPAE	ID	DMKHPAE
DMKHPAE	DN	9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
DMKHPAE	HS	Investigative
DMKHPAE	SN	9-BUTYL-8-(4-METHOXYBENZYL)-9H-PURIN-6-AMINE; CHEMBL112834; 9-butyl-8-[(4-methoxyphenyl)methyl]purin-6-amine; 376629-53-7; PU4; AC1NRCWI; 1uy7; Purine-Based Inhibitor 2; SCHEMBL4320278; CTK1A9432; BDBM15375; DTXSID80415355; AKOS030562187; DB03899; 8-(4-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(4-methoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(4-methoxyphenyl)methyl]-
DMKHPAE	DT	Small molecular drug
DMKHPAE	PC	5289227
DMKHPAE	MW	311.4
DMKHPAE	FM	C17H21N5O
DMKHPAE	IC	InChI=1S/C17H21N5O/c1-3-4-9-22-14(10-12-5-7-13(23-2)8-6-12)21-15-16(18)19-11-20-17(15)22/h5-8,11H,3-4,9-10H2,1-2H3,(H2,18,19,20)
DMKHPAE	CS	CCCCN1C(=NC2=C(N=CN=C21)N)CC3=CC=C(C=C3)OC
DMKHPAE	IK	NVYATAJRTRFKSW-UHFFFAOYSA-N
DMKHPAE	IU	9-butyl-8-[(4-methoxyphenyl)methyl]purin-6-amine
DMKHPAE	CA	CAS 376629-53-7
DMKHPAE	DE	Discovery agent

DMZQLBD	ID	DMZQLBD
DMZQLBD	DN	9-Butyl-9H-adenine
DMZQLBD	HS	Investigative
DMZQLBD	SN	2715-70-0; 9-butyl-9H-purin-6-ylamine; 9H-Purin-6-amine, 9-butyl-; 9-Butyl-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl- (9CI); CHEMBL449628; 9-Butyl-9H-adenine; 9-butylpurin-6-amine; 9-butyladenine; NSC19094; NSC 19094; Adenine, 9-butyl-; AC1L2PTM; AC1Q4VHO; 9H-Purin-6-amine,9-butyl-; SCHEMBL1074972; CTK4F9171; DTXSID10181617; MolPort-011-342-029; BKXMJMZKKNIYRD-UHFFFAOYSA-N; ZINC1562338; NSC-19094; BDBM50256951; AKOS012922662; MCULE-9977877843; 9-Butyl-9H-purin-6-amine, AldrichCPR
DMZQLBD	DT	Small molecular drug
DMZQLBD	PC	75929
DMZQLBD	MW	191.23
DMZQLBD	FM	C9H13N5
DMZQLBD	IC	InChI=1S/C9H13N5/c1-2-3-4-14-6-13-7-8(10)11-5-12-9(7)14/h5-6H,2-4H2,1H3,(H2,10,11,12)
DMZQLBD	CS	CCCCN1C=NC2=C(N=CN=C21)N
DMZQLBD	IK	BKXMJMZKKNIYRD-UHFFFAOYSA-N
DMZQLBD	IU	9-butylpurin-6-amine
DMZQLBD	CA	CAS 2715-70-0
DMZQLBD	DE	Discovery agent

DMK5DUA	ID	DMK5DUA
DMK5DUA	DN	9-chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DMK5DUA	HS	Investigative
DMK5DUA	SN	CHEMBL429599; 9-chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide; SCHEMBL11973725; JVPPTVNJBXFSPQ-UHFFFAOYSA-N; BDBM50372498; NCGC00163054-01; CU-00000000357-1; 2-(8-Amino*-7-quinolinyl)-4-chlorobenzenesulfonic acid sultam
DMK5DUA	DT	Small molecular drug
DMK5DUA	PC	16759933
DMK5DUA	MW	316.8
DMK5DUA	FM	C15H9ClN2O2S
DMK5DUA	IC	InChI=1S/C15H9ClN2O2S/c16-10-4-6-13-12(8-10)11-5-3-9-2-1-7-17-14(9)15(11)18-21(13,19)20/h1-8,18H
DMK5DUA	CS	C1=CC2=C(C3=C(C=C2)C4=C(C=CC(=C4)Cl)S(=O)(=O)N3)N=C1
DMK5DUA	IK	JVPPTVNJBXFSPQ-UHFFFAOYSA-N
DMK5DUA	IU	9-chloro-5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide
DMK5DUA	DE	Discovery agent

DM6EFN2	ID	DM6EFN2
DM6EFN2	DN	9-chlorobenzo[h]isoquinolin-1(2H)-one
DM6EFN2	HS	Investigative
DM6EFN2	SN	9-chlorobenzo[h]isoquinolin-1(2H)-one; CHEMBL248988; 919290-40-7; SCHEMBL4296798; CTK3H3900; DTXSID50475406; XSQDWQSZUGGKPF-UHFFFAOYSA-N; ZINC28955758; BDBM50223471; Benz[h]isoquinolin-1(2H)-one, 9-chloro-
DM6EFN2	DT	Small molecular drug
DM6EFN2	PC	11993732
DM6EFN2	MW	229.66
DM6EFN2	FM	C13H8ClNO
DM6EFN2	IC	InChI=1S/C13H8ClNO/c14-10-4-3-8-1-2-9-5-6-15-13(16)12(9)11(8)7-10/h1-7H,(H,15,16)
DM6EFN2	CS	C1=CC2=C(C3=C1C=CC(=C3)Cl)C(=O)NC=C2
DM6EFN2	IK	XSQDWQSZUGGKPF-UHFFFAOYSA-N
DM6EFN2	IU	9-chloro-2H-benzo[h]isoquinolin-1-one
DM6EFN2	CA	CAS 919290-40-7
DM6EFN2	DE	Discovery agent

DM04QWX	ID	DM04QWX
DM04QWX	DN	9-Cyclobutyl-9H-adenine
DM04QWX	HS	Investigative
DM04QWX	SN	9-Cyclobutyladenine; 9-Cyclobutyl-9H-adenine; 9-cBuA; 9H-Purin-6-amine, 9-cyclobutyl-; 132406-73-6; 9-cyclobutylpurin-6-amine; CHEMBL455493; AC1L9QF6; 9-Cyclobutyl-9H-purin-6-amine; CTK4B7898; DTXSID80157526; BDBM50257000
DM04QWX	DT	Small molecular drug
DM04QWX	PC	452612
DM04QWX	MW	189.22
DM04QWX	FM	C9H11N5
DM04QWX	IC	InChI=1S/C9H11N5/c10-8-7-9(12-4-11-8)14(5-13-7)6-2-1-3-6/h4-6H,1-3H2,(H2,10,11,12)
DM04QWX	CS	C1CC(C1)N2C=NC3=C(N=CN=C32)N
DM04QWX	IK	JGFAEEKLMAWINF-UHFFFAOYSA-N
DM04QWX	IU	9-cyclobutylpurin-6-amine
DM04QWX	CA	CAS 132406-73-6
DM04QWX	DE	Discovery agent

DMP8VM2	ID	DMP8VM2
DMP8VM2	DN	9-Cycloheptyl-9H-adenine
DMP8VM2	HS	Investigative
DMP8VM2	SN	9-cycloheptylpurin-6-amine; 9-cycloheptyl-9h-purin-6-amine; CHEMBL62835; 6961-60-0; 9-Cycloheptyl-9H-adenine; NSC62733; AC1L6KRZ; AC1Q4VH9; CTK5D0614; DTXSID20289678; 6-Amino-9-cycloheptyl-9H-purine; 9-Cycloheptyl-9H-purin-6-ylamine; 9H-Purin-6-amine, 9-cycloheptyl-; BDBM50013702; NSC-62733
DMP8VM2	DT	Small molecular drug
DMP8VM2	PC	247678
DMP8VM2	MW	231.3
DMP8VM2	FM	C12H17N5
DMP8VM2	IC	InChI=1S/C12H17N5/c13-11-10-12(15-7-14-11)17(8-16-10)9-5-3-1-2-4-6-9/h7-9H,1-6H2,(H2,13,14,15)
DMP8VM2	CS	C1CCCC(CC1)N2C=NC3=C(N=CN=C32)N
DMP8VM2	IK	FHZRSYFMJLJWBS-UHFFFAOYSA-N
DMP8VM2	IU	9-cycloheptylpurin-6-amine
DMP8VM2	CA	CAS 6961-60-0
DMP8VM2	DE	Discovery agent

DMSGU2L	ID	DMSGU2L
DMSGU2L	DN	9-Cyclopentyl-9H-adenine
DMSGU2L	HS	Investigative
DMSGU2L	SN	9-Cyclopentyl-9H-purin-6-ylamine
DMSGU2L	DT	Small molecular drug
DMSGU2L	PC	12852
DMSGU2L	MW	203.24
DMSGU2L	FM	C10H13N5
DMSGU2L	IC	InChI=1S/C10H13N5/c11-9-8-10(13-5-12-9)15(6-14-8)7-3-1-2-4-7/h5-7H,1-4H2,(H2,11,12,13)
DMSGU2L	CS	C1CCC(C1)N2C=NC3=C(N=CN=C32)N
DMSGU2L	IK	KTJWHJNBTXITCB-UHFFFAOYSA-N
DMSGU2L	IU	9-cyclopentylpurin-6-amine
DMSGU2L	CA	CAS 715-91-3
DMSGU2L	DE	Discovery agent

DMAFCZL	ID	DMAFCZL
DMAFCZL	DN	9-Cyclopropyl-9H-adenine
DMAFCZL	HS	Investigative
DMAFCZL	SN	CHEMBL469409; 9-Cyclopropyl-9H-adenine; 9-cyclopropylpurin-6-amine; AC1L987W
DMAFCZL	DT	Small molecular drug
DMAFCZL	PC	414708
DMAFCZL	MW	175.19
DMAFCZL	FM	C8H9N5
DMAFCZL	IC	InChI=1S/C8H9N5/c9-7-6-8(11-3-10-7)13(4-12-6)5-1-2-5/h3-5H,1-2H2,(H2,9,10,11)
DMAFCZL	CS	C1CC1N2C=NC3=C(N=CN=C32)N
DMAFCZL	IK	QKMZACGKMJHVSI-UHFFFAOYSA-N
DMAFCZL	IU	9-cyclopropylpurin-6-amine
DMAFCZL	DE	Discovery agent

DM68IPZ	ID	DM68IPZ
DM68IPZ	DN	9-Deazaguanine
DM68IPZ	HS	Investigative
DM68IPZ	DT	Small molecular drug
DM68IPZ	PC	135461003
DM68IPZ	MW	150.14
DM68IPZ	FM	C6H6N4O
DM68IPZ	IC	InChI=1S/C6H6N4O/c7-6-9-3-1-2-8-4(3)5(11)10-6/h1-2,8H,(H3,7,9,10,11)
DM68IPZ	CS	C1=CNC2=C1N=C(NC2=O)N
DM68IPZ	IK	FFYPRJYSJODFFD-UHFFFAOYSA-N
DM68IPZ	IU	2-amino-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DM68IPZ	CA	CAS 65996-58-9
DM68IPZ	DE	Discovery agent

DM3G6LY	ID	DM3G6LY
DM3G6LY	DN	9-Deazahypoxanthine
DM3G6LY	HS	Investigative
DM3G6LY	DT	Small molecular drug
DM3G6LY	PC	135488881
DM3G6LY	MW	135.12
DM3G6LY	FM	C6H5N3O
DM3G6LY	IC	InChI=1S/C6H5N3O/c10-6-5-4(1-2-7-5)8-3-9-6/h1-3,7H,(H,8,9,10)
DM3G6LY	CS	C1=CNC2=C1N=CNC2=O
DM3G6LY	IK	UWMXUDUWVFWJPX-UHFFFAOYSA-N
DM3G6LY	IU	3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DM3G6LY	DE	Discovery agent

DME7ONQ	ID	DME7ONQ
DME7ONQ	DN	9-Deazainosine
DME7ONQ	HS	Investigative
DME7ONQ	DT	Small molecular drug
DME7ONQ	PC	135483765
DME7ONQ	MW	267.24
DME7ONQ	FM	C11H13N3O5
DME7ONQ	IC	InChI=1S/C11H13N3O5/c15-2-5-8(16)9(17)10(19-5)4-1-12-7-6(4)13-3-14-11(7)18/h1,3,5,8-10,12,15-17H,2H2,(H,13,14,18)/t5-,8-,9-,10+/m1/s1
DME7ONQ	CS	C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DME7ONQ	IK	WKDMPDYUJKSXBW-KBHCAIDQSA-N
DME7ONQ	IU	7-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DME7ONQ	CA	CAS 89458-19-5
DME7ONQ	DE	Discovery agent

DM9BCDT	ID	DM9BCDT
DM9BCDT	DN	9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE
DM9BCDT	HS	Investigative
DM9BCDT	DT	Small molecular drug
DM9BCDT	PC	135464487
DM9BCDT	MW	373.25
DM9BCDT	FM	C13H16N3O8P
DM9BCDT	IC	InChI=1S/C13H16N3O8P/c17-2-6-11-12(24-7(23-11)3-25(19,20)21)10(22-6)5-1-14-9-8(5)15-4-16-13(9)18/h1,4,6-7,10-12,14,17H,2-3H2,(H,15,16,18)(H2,19,20,21)/t6-,7-,10+,11-,12+/m1/s1
DM9BCDT	CS	C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@H]4[C@@H]([C@H](O3)CO)O[C@H](O4)CP(=O)(O)O
DM9BCDT	IK	ZOEDLCUBOBTIHG-USQSKNHBSA-N
DM9BCDT	IU	[(2S,3aS,4S,6R,6aR)-6-(hydroxymethyl)-4-(4-oxo-3,5-dihydropyrrolo[3,2-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-2-yl]methylphosphonic acid
DM9BCDT	DE	Discovery agent

DM70MPJ	ID	DM70MPJ
DM70MPJ	DN	9-Ethyl-2-methyl-beta-carboline-2-ium iodide
DM70MPJ	HS	Investigative
DM70MPJ	SN	CHEMBL1097826
DM70MPJ	DT	Small molecular drug
DM70MPJ	PC	46223109
DM70MPJ	MW	211.28
DM70MPJ	FM	C14H15N2+
DM70MPJ	IC	InChI=1S/C14H15N2/c1-3-16-13-7-5-4-6-11(13)12-8-9-15(2)10-14(12)16/h4-10H,3H2,1-2H3/q+1
DM70MPJ	CS	CCN1C2=CC=CC=C2C3=C1C=[N+](C=C3)C
DM70MPJ	IK	UYPDJRFFVNWZQV-UHFFFAOYSA-N
DM70MPJ	IU	9-ethyl-2-methylpyrido[3,4-b]indol-2-ium
DM70MPJ	DE	Discovery agent

DMRVS2D	ID	DMRVS2D
DMRVS2D	DN	9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine
DMRVS2D	HS	Investigative
DMRVS2D	SN	CHEMBL61259; 9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine; 8-phenylethynyl-9-ethyladenine; BDBM50102169
DMRVS2D	DT	Small molecular drug
DMRVS2D	PC	44300688
DMRVS2D	MW	263.3
DMRVS2D	FM	C15H13N5
DMRVS2D	IC	InChI=1S/C15H13N5/c1-2-20-12(9-8-11-6-4-3-5-7-11)19-13-14(16)17-10-18-15(13)20/h3-7,10H,2H2,1H3,(H2,16,17,18)
DMRVS2D	CS	CCN1C(=NC2=C(N=CN=C21)N)C#CC3=CC=CC=C3
DMRVS2D	IK	AXENMZHFYBPHQF-UHFFFAOYSA-N
DMRVS2D	IU	9-ethyl-8-(2-phenylethynyl)purin-6-amine
DMRVS2D	DE	Discovery agent

DMWV8YX	ID	DMWV8YX
DMWV8YX	DN	9-Ethyl-9H-adenine
DMWV8YX	HS	Investigative
DMWV8YX	SN	9-ethyl-9h-purin-6-amine; 2715-68-6; 9-Ethyladenine; 9H-Purin-6-amine,9-ethyl; N9-Ethyladenine; 9-ethylpurin-6-amine; 9H-Purin-6-amine, 9-ethyl-; 9-ethyl adenine; 9-Ethyl-9H-purin-6-ylamine; 9H-Purin-6-amine,9-ethyl-; CHEMBL304009; Adenine, 9-ethyl-; 9-Ethyl-9H-adenine; N9 -ethyladenine; NSC 14580; 6-Amino-9-ethylpurine; AC1Q4VHH; ACMC-1CJP6; (9-ethylpurin-6-yl)amine; Adenine, 9-ethyl- (8CI); AC1L189M; SCHEMBL1924594; CTK4F9170; DTXSID50181616; MUIPLRMGAXZWSQ-UHFFFAOYSA-N; MolPort-004-964-357; ZINC402896; NSC14580; KS-000000ID
DMWV8YX	DT	Small molecular drug
DMWV8YX	PC	7
DMWV8YX	MW	163.18
DMWV8YX	FM	C7H9N5
DMWV8YX	IC	InChI=1S/C7H9N5/c1-2-12-4-11-5-6(8)9-3-10-7(5)12/h3-4H,2H2,1H3,(H2,8,9,10)
DMWV8YX	CS	CCN1C=NC2=C(N=CN=C21)N
DMWV8YX	IK	MUIPLRMGAXZWSQ-UHFFFAOYSA-N
DMWV8YX	IU	9-ethylpurin-6-amine
DMWV8YX	CA	CAS 2715-68-6
DMWV8YX	DE	Discovery agent

DMHKUO9	ID	DMHKUO9
DMHKUO9	DN	9-Ethyl-beta-carboline
DMHKUO9	HS	Investigative
DMHKUO9	SN	9-Ethyl-beta-carboline; CHEMBL1097825; SCHEMBL2220005; BMGUCVPPDGYFRV-UHFFFAOYSA-N
DMHKUO9	DT	Small molecular drug
DMHKUO9	PC	14221745
DMHKUO9	MW	196.25
DMHKUO9	FM	C13H12N2
DMHKUO9	IC	InChI=1S/C13H12N2/c1-2-15-12-6-4-3-5-10(12)11-7-8-14-9-13(11)15/h3-9H,2H2,1H3
DMHKUO9	CS	CCN1C2=CC=CC=C2C3=C1C=NC=C3
DMHKUO9	IK	BMGUCVPPDGYFRV-UHFFFAOYSA-N
DMHKUO9	IU	9-ethylpyrido[3,4-b]indole
DMHKUO9	DE	Discovery agent

DMLK0TX	ID	DMLK0TX
DMLK0TX	DN	9-fluoro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DMLK0TX	HS	Investigative
DMLK0TX	SN	CHEMBL270799; 9-fluoro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide; SCHEMBL11972977; KNMYXLXOQAHLHK-UHFFFAOYSA-N; BDBM50372499; NCGC00163040-01
DMLK0TX	DT	Small molecular drug
DMLK0TX	PC	16759921
DMLK0TX	MW	300.31
DMLK0TX	FM	C15H9FN2O2S
DMLK0TX	IC	InChI=1S/C15H9FN2O2S/c16-10-4-6-13-12(8-10)11-5-3-9-2-1-7-17-14(9)15(11)18-21(13,19)20/h1-8,18H
DMLK0TX	CS	C1=CC2=C(C3=C(C=C2)C4=C(C=CC(=C4)F)S(=O)(=O)N3)N=C1
DMLK0TX	IK	KNMYXLXOQAHLHK-UHFFFAOYSA-N
DMLK0TX	IU	9-fluoro-5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide
DMLK0TX	DE	Discovery agent

DMGAE9Z	ID	DMGAE9Z
DMGAE9Z	DN	9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMGAE9Z	HS	Investigative
DMGAE9Z	SN	CHEMBL190895; BDBM27513; indeno[1,2-c]isoquinolinone, 1e; 9-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one
DMGAE9Z	DT	Small molecular drug
DMGAE9Z	PC	25190932
DMGAE9Z	MW	251.25
DMGAE9Z	FM	C16H10FNO
DMGAE9Z	IC	InChI=1S/C16H10FNO/c17-10-5-6-11-9(7-10)8-14-12-3-1-2-4-13(12)16(19)18-15(11)14/h1-7H,8H2,(H,18,19)
DMGAE9Z	CS	C1C2=C(C=CC(=C2)F)C3=C1C4=CC=CC=C4C(=O)N3
DMGAE9Z	IK	YZRNXEMHDKXRRA-UHFFFAOYSA-N
DMGAE9Z	IU	9-fluoro-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DMGAE9Z	DE	Discovery agent

DMBWAMR	ID	DMBWAMR
DMBWAMR	DN	9H-beta-Carbolin-3-ol
DMBWAMR	HS	Investigative
DMBWAMR	SN	3-hydroxy-beta-carboline; 91985-78-3; 3H-Pyrido[3,4-b]indol-3-one, 2,9-dihydro-; beta-Carbolin-3-ol; ACMC-20lva1; CHEMBL443140; CHEMBL299662; SCHEMBL10644440; CTK3H2577; 9H-pyrido[3,4-b]indol-3-ol; DTXSID90556566; UDTDJSXOXQLKGM-UHFFFAOYSA-N; AKOS006373463
DMBWAMR	DT	Small molecular drug
DMBWAMR	PC	14146438
DMBWAMR	MW	184.19
DMBWAMR	FM	C11H8N2O
DMBWAMR	IC	InChI=1S/C11H8N2O/c14-11-5-8-7-3-1-2-4-9(7)13-10(8)6-12-11/h1-6,13H,(H,12,14)
DMBWAMR	CS	C1=CC=C2C(=C1)C3=CC(=O)NC=C3N2
DMBWAMR	IK	UDTDJSXOXQLKGM-UHFFFAOYSA-N
DMBWAMR	IU	2,9-dihydropyrido[3,4-b]indol-3-one
DMBWAMR	CA	CAS 91985-78-3
DMBWAMR	DE	Discovery agent

DMBLEI7	ID	DMBLEI7
DMBLEI7	DN	9H-beta-Carbolin-6-ylamine
DMBLEI7	HS	Investigative
DMBLEI7	SN	9H-pyrido[3,4-b]indol-6-amine; 6-amino-beta-carboline; 6453-27-6; NSC248004; AC1L7VIB; CHEMBL164120; SCHEMBL10642567; PPCJCNSRVOYTKC-UHFFFAOYSA-N; AKOS022912596
DMBLEI7	DT	Small molecular drug
DMBLEI7	PC	317218
DMBLEI7	MW	183.21
DMBLEI7	FM	C11H9N3
DMBLEI7	IC	InChI=1S/C11H9N3/c12-7-1-2-10-9(5-7)8-3-4-13-6-11(8)14-10/h1-6,14H,12H2
DMBLEI7	CS	C1=CC2=C(C=C1N)C3=C(N2)C=NC=C3
DMBLEI7	IK	PPCJCNSRVOYTKC-UHFFFAOYSA-N
DMBLEI7	IU	9H-pyrido[3,4-b]indol-6-amine
DMBLEI7	DE	Discovery agent

DMK459I	ID	DMK459I
DMK459I	DN	9H-beta-Carboline-3-carboxylic acid ethyl ester
DMK459I	HS	Investigative
DMK459I	SN	Ethyl beta-carboline-3-carboxylate; beta-CCE; 74214-62-3; Ethyl 9H-pyrido[3,4-b]indole-3-carboxylate; beta-Carboline-3-carboxylic acid ethyl ester; UNII-HYW8K5N21Y; Ethyl 9H-pyrido(3,4-b)indole-3-carboxylate; HYW8K5N21Y; Ro 15-2538; CHEMBL11709; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, ethyl ester; MLS000069492; CHEMBL454606; KOVRZNUMIKACTB-UHFFFAOYSA-N; SMR000059107; 9H-Pyrido[3,4-b]indole-3-carboxylic acid, ethyl ester; b-cce; Ethylbeta-carboline-3-carboxylate; Beta CCE
DMK459I	DT	Small molecular drug
DMK459I	PC	105078
DMK459I	MW	240.26
DMK459I	FM	C14H12N2O2
DMK459I	IC	InChI=1S/C14H12N2O2/c1-2-18-14(17)12-7-10-9-5-3-4-6-11(9)16-13(10)8-15-12/h3-8,16H,2H2,1H3
DMK459I	CS	CCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMK459I	IK	KOVRZNUMIKACTB-UHFFFAOYSA-N
DMK459I	IU	ethyl 9H-pyrido[3,4-b]indole-3-carboxylate
DMK459I	CA	CAS 74214-62-3
DMK459I	CB	CHEBI:92850
DMK459I	DE	Discovery agent

DMMUH98	ID	DMMUH98
DMMUH98	DN	9H-beta-Carboline-3-carboxylic acid propyl ester
DMMUH98	HS	Investigative
DMMUH98	SN	beta-Ccp; 76808-18-9; beta-Carboline-3-carboxylic acid propyl ester; propyl beta-carboline-3-carboxylate; Pbc-3-C; propyl 9H-pyrido[3,4-b]indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, propyl ester; C15H14N2O2; Beta CCP; Biomol-NT_000275; AC1Q2Y9C; AC1L3X2D; AC1Q66NN; .beta.-Carboline-3-carboxylic acid propyl ester; SCHEMBL2348263; 9H-B-CARBOLINE-3-CARBOXYLIC ACID PROPYL ESTER; CHEMBL274847; BPBio1_001101; CTK5E3459; CHEBI:93491; BDBM84992; DTXSID30227627; WGRVAGIQTHEEQW-UHFFFAOYSA-N; ZINC2391117; PDSP2_001744
DMMUH98	DT	Small molecular drug
DMMUH98	PC	123662
DMMUH98	MW	254.28
DMMUH98	FM	C15H14N2O2
DMMUH98	IC	InChI=1S/C15H14N2O2/c1-2-7-19-15(18)13-8-11-10-5-3-4-6-12(10)17-14(11)9-16-13/h3-6,8-9,17H,2,7H2,1H3
DMMUH98	CS	CCCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMMUH98	IK	WGRVAGIQTHEEQW-UHFFFAOYSA-N
DMMUH98	IU	propyl 9H-pyrido[3,4-b]indole-3-carboxylate
DMMUH98	CA	CAS 76808-18-9
DMMUH98	CB	CHEBI:93491
DMMUH98	DE	Discovery agent

DM6WHIA	ID	DM6WHIA
DM6WHIA	DN	9H-carbazole-2-carbaldehyde
DM6WHIA	HS	Investigative
DM6WHIA	SN	9H-CARBAZOLE-2-CARBALDEHYDE; 9H-Carbazole-2-carboxaldehyde; 99585-18-9; CHEMBL1172395; SCHEMBL7963280; CTK3I5755; DTXSID90479100; LCENSQOWDHIKAN-UHFFFAOYSA-N; ZINC22003786; BDBM50322588; AKOS006329833; DB-080615; AB0108318
DM6WHIA	DT	Small molecular drug
DM6WHIA	PC	12169810
DM6WHIA	MW	195.22
DM6WHIA	FM	C13H9NO
DM6WHIA	IC	InChI=1S/C13H9NO/c15-8-9-5-6-11-10-3-1-2-4-12(10)14-13(11)7-9/h1-8,14H
DM6WHIA	CS	C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)C=O
DM6WHIA	IK	LCENSQOWDHIKAN-UHFFFAOYSA-N
DM6WHIA	IU	9H-carbazole-2-carbaldehyde
DM6WHIA	CA	CAS 99585-18-9
DM6WHIA	DE	Discovery agent

DM0HNU3	ID	DM0HNU3
DM0HNU3	DN	9H-carbazole-3-carbaldehyde
DM0HNU3	HS	Investigative
DM0HNU3	SN	9H-Carbazole-3-carbaldehyde; 9H-Carbazole-3-carboxaldehyde; 3-Formylcarbazole; 51761-07-0; CHEMBL1172392; 3-Formyl-9H-carbazole; AC1L9YEB; 2-Formylcarbazole (obsol.); SCHEMBL2775335; CTK1G4153; DTXSID70333418; WRBOHOGDAJPJOQ-UHFFFAOYSA-N; ZINC3641069; BDBM50322592; STL367222; BBL026891; AKOS000113618; AB51127
DM0HNU3	DT	Small molecular drug
DM0HNU3	PC	504067
DM0HNU3	MW	195.22
DM0HNU3	FM	C13H9NO
DM0HNU3	IC	InChI=1S/C13H9NO/c15-8-9-5-6-13-11(7-9)10-3-1-2-4-12(10)14-13/h1-8,14H
DM0HNU3	CS	C1=CC=C2C(=C1)C3=C(N2)C=CC(=C3)C=O
DM0HNU3	IK	WRBOHOGDAJPJOQ-UHFFFAOYSA-N
DM0HNU3	IU	9H-carbazole-3-carbaldehyde
DM0HNU3	CA	CAS 51761-07-0
DM0HNU3	DE	Discovery agent

DMF1XLZ	ID	DMF1XLZ
DMF1XLZ	DN	9H-purine derivative
DMF1XLZ	HS	Investigative
DMF1XLZ	DE	Discovery agent

DMOX21P	ID	DMOX21P
DMOX21P	DN	9-hydrazino-1,2,3,4-tetrahydroacridine
DMOX21P	HS	Investigative
DMOX21P	SN	9-hydrazino-1,2,3,4-tetrahydroacridine; CHEMBL219388; ZINC40576784; AKOS011534842
DMOX21P	DT	Small molecular drug
DMOX21P	PC	12383029
DMOX21P	MW	213.28
DMOX21P	FM	C13H15N3
DMOX21P	IC	InChI=1S/C13H15N3/c14-16-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8,14H2,(H,15,16)
DMOX21P	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NN
DMOX21P	IK	DUEMTPVZWKGXAY-UHFFFAOYSA-N
DMOX21P	IU	1,2,3,4-tetrahydroacridin-9-ylhydrazine
DMOX21P	DE	Discovery agent

DMH72MU	ID	DMH72MU
DMH72MU	DN	9-Hydroxy-7,8-benzoflavone
DMH72MU	HS	Investigative
DMH72MU	SN	CHEMBL1097042; 9-Hydroxy-7,8-benzoflavone
DMH72MU	DT	Small molecular drug
DMH72MU	PC	46887421
DMH72MU	MW	288.3
DMH72MU	FM	C19H12O3
DMH72MU	IC	InChI=1S/C19H12O3/c20-15-8-4-7-13-9-10-14-16(21)11-17(22-19(14)18(13)15)12-5-2-1-3-6-12/h1-11,20H
DMH72MU	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=C(C=CC=C4O)C=C3
DMH72MU	IK	UQEKEVFKEDHKOB-UHFFFAOYSA-N
DMH72MU	IU	10-hydroxy-2-phenylbenzo[h]chromen-4-one
DMH72MU	DE	Discovery agent

DM0FWNJ	ID	DM0FWNJ
DM0FWNJ	DN	9-hydroxyoctadecadienoic acid
DM0FWNJ	HS	Investigative
DM0FWNJ	SN	(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid; 9(S)-HODE; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid; alpha-dimorphecolic acid; 9S-HODE; (9S)-Hydroxyoctadecadienoic acid; UNII-42KE04U9BM; 9S-hydroxy-10E,12Z-octadecadienoic acid; 42KE04U9BM; CHEBI:34496; (9S)-Hydroxyoctadecadinoiec acid; 73543-67-6; (10E,12Z)-(9S)-9-Hydroxyoctadeca-10,12-dienoic acid; (9s,10e,12z)-9-hydroxy-10,12-octadecadienoic acid; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoate; 9(S)-hydroxyoctadecadienoic acid; Alpha-dimorphecolic; AC1NSNNN; (9S)-Hydroxyoctadecadienoate; (+)-alpha-Dimorphecolic;  9(S)-HODE
DM0FWNJ	DT	Small molecular drug
DM0FWNJ	PC	5312830
DM0FWNJ	MW	296.4
DM0FWNJ	FM	C18H32O3
DM0FWNJ	IC	InChI=1S/C18H32O3/c1-2-3-4-5-6-8-11-14-17(19)15-12-9-7-10-13-16-18(20)21/h6,8,11,14,17,19H,2-5,7,9-10,12-13,15-16H2,1H3,(H,20,21)/b8-6-,14-11+/t17-/m1/s1
DM0FWNJ	CS	CCCCC/C=C\\C=C\\[C@H](CCCCCCCC(=O)O)O
DM0FWNJ	IK	NPDSHTNEKLQQIJ-UINYOVNOSA-N
DM0FWNJ	IU	(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
DM0FWNJ	CA	CAS 73543-67-6
DM0FWNJ	CB	CHEBI:34496
DM0FWNJ	DE	Discovery agent

DMB9FCK	ID	DMB9FCK
DMB9FCK	DN	9-Hydroxypropyladenine, R-Isomer
DMB9FCK	HS	Investigative
DMB9FCK	SN	14047-28-0; (R)-9-(2-Hydroxypropyl)adenine; (R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; (R)-(+)-9-(2-HYDROXYPROPYL)ADENINE; (2R)-1-(6-aminopurin-9-yl)propan-2-ol; UNII-43H6SBP55W; 9-HYDROXYPROPYLADENINE, R-ISOMER; (R)-9-(2-hydroxypropyl) adenine; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaR)-; 43H6SBP55W; AK-59150; (2R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; ARP; W-201193; 9-(2-Hydroxypropyl)adenine, (R)-; PubChem9984; R-9-(2-hydroxypropyl)adenine [WHO-DD]; AC1L9HLR; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, D-
DMB9FCK	DT	Small molecular drug
DMB9FCK	PC	445211
DMB9FCK	MW	193.21
DMB9FCK	FM	C8H11N5O
DMB9FCK	IC	InChI=1S/C8H11N5O/c1-5(14)2-13-4-12-6-7(9)10-3-11-8(6)13/h3-5,14H,2H2,1H3,(H2,9,10,11)/t5-/m1/s1
DMB9FCK	CS	C[C@H](CN1C=NC2=C(N=CN=C21)N)O
DMB9FCK	IK	MJZYTEBKXLVLMY-RXMQYKEDSA-N
DMB9FCK	IU	(2R)-1-(6-aminopurin-9-yl)propan-2-ol
DMB9FCK	CA	CAS 14047-28-0
DMB9FCK	DE	Discovery agent

DM8QJUH	ID	DM8QJUH
DM8QJUH	DN	9-Hydroxypropyladenine, S-Isomer
DM8QJUH	HS	Investigative
DM8QJUH	SN	(S)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; 14047-27-9; 9-hydroxypropyladenine, s-isomer; (S)-9-(2-Hydroxypropyl)adenine; (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol; AC1L9HLO; Tenofovir Related Compound 9; S-9-(2-hydroxypropyl)adenine; SCHEMBL5810639; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaS)-; CTK8C2128; DTXSID60332177; MolPort-003-848-032; ZINC2046907; ANW-67863; 6827AA; DB03000; SC-43410; AK-82057; AJ-33425; KB-106920; TX-015702; (2S)-1-(6-aminopurin-9-yl)propan-2-ol; AX8236781; FT-0696938; ST24035731
DM8QJUH	DT	Small molecular drug
DM8QJUH	PC	445210
DM8QJUH	MW	193.21
DM8QJUH	FM	C8H11N5O
DM8QJUH	IC	InChI=1S/C8H11N5O/c1-5(14)2-13-4-12-6-7(9)10-3-11-8(6)13/h3-5,14H,2H2,1H3,(H2,9,10,11)/t5-/m0/s1
DM8QJUH	CS	C[C@@H](CN1C=NC2=C(N=CN=C21)N)O
DM8QJUH	IK	MJZYTEBKXLVLMY-YFKPBYRVSA-N
DM8QJUH	IU	(2S)-1-(6-aminopurin-9-yl)propan-2-ol
DM8QJUH	CA	CAS 14047-27-9
DM8QJUH	DE	Discovery agent

DMGCX7E	ID	DMGCX7E
DMGCX7E	DN	9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMGCX7E	HS	Investigative
DMGCX7E	SN	CHEMBL209907; 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5829446; IJHAYZZOYYQESB-UHFFFAOYSA-N; BDBM50192426
DMGCX7E	DT	Small molecular drug
DMGCX7E	PC	11844342
DMGCX7E	MW	252.22
DMGCX7E	FM	C14H8N2O3
DMGCX7E	IC	InChI=1S/C14H8N2O3/c17-6-1-3-9-8(5-6)11-10(15-9)4-2-7-12(11)14(19)16-13(7)18/h1-5,15,17H,(H,16,18,19)
DMGCX7E	CS	C1=CC2=C(C=C1O)C3=C(N2)C=CC4=C3C(=O)NC4=O
DMGCX7E	IK	IJHAYZZOYYQESB-UHFFFAOYSA-N
DMGCX7E	IU	9-hydroxy-6H-pyrrolo[3,4-c]carbazole-1,3-dione
DMGCX7E	DE	Discovery agent

DMBQLAI	ID	DMBQLAI
DMBQLAI	DN	9-Isopropyl-9H-adenine
DMBQLAI	HS	Investigative
DMBQLAI	SN	CHEMBL67199; 9-isopropyl-9H-purin-6-amine; 31601-35-1; 9-Isopropyl-9H-adenine; 9-propan-2-ylpurin-6-amine; SCHEMBL754007; AC1L987T; 6-Amino-9-isopropyl-9H-purine; 9-Isopropyl-9H-purin-6-ylamine; BDBM50013685; AKOS022639673; 9H-Purin-6-amine, 9-(1-methylethyl)-
DMBQLAI	DT	Small molecular drug
DMBQLAI	PC	414707
DMBQLAI	MW	177.21
DMBQLAI	FM	C8H11N5
DMBQLAI	IC	InChI=1S/C8H11N5/c1-5(2)13-4-12-6-7(9)10-3-11-8(6)13/h3-5H,1-2H3,(H2,9,10,11)
DMBQLAI	CS	CC(C)N1C=NC2=C(N=CN=C21)N
DMBQLAI	IK	BCMZIPWCRGOWEV-UHFFFAOYSA-N
DMBQLAI	IU	9-propan-2-ylpurin-6-amine
DMBQLAI	DE	Discovery agent

DMW905K	ID	DMW905K
DMW905K	DN	9-mercapto-8-oxo-N-phenylnonanamide
DMW905K	HS	Investigative
DMW905K	SN	CHEMBL402451
DMW905K	DT	Small molecular drug
DMW905K	PC	11964503
DMW905K	MW	279.4
DMW905K	FM	C15H21NO2S
DMW905K	IC	InChI=1S/C15H21NO2S/c17-14(12-19)10-6-1-2-7-11-15(18)16-13-8-4-3-5-9-13/h3-5,8-9,19H,1-2,6-7,10-12H2,(H,16,18)
DMW905K	CS	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)CS
DMW905K	IK	UJRMRSNAFIQQLD-UHFFFAOYSA-N
DMW905K	IU	8-oxo-N-phenyl-9-sulfanylnonanamide
DMW905K	DE	Discovery agent

DMM2GQC	ID	DMM2GQC
DMM2GQC	DN	9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid
DMM2GQC	HS	Investigative
DMM2GQC	SN	CHEMBL333720; 9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid; SCHEMBL7391643
DMM2GQC	DT	Small molecular drug
DMM2GQC	PC	19930853
DMM2GQC	MW	245.34
DMM2GQC	FM	C11H19NO3S
DMM2GQC	IC	InChI=1S/C11H19NO3S/c13-10-8(7-16)5-3-1-2-4-6-9(12-10)11(14)15/h8-9,16H,1-7H2,(H,12,13)(H,14,15)
DMM2GQC	CS	C1CCCC(NC(=O)C(CC1)CS)C(=O)O
DMM2GQC	IK	MWNHNWDDMZYRSH-UHFFFAOYSA-N
DMM2GQC	IU	10-oxo-9-(sulfanylmethyl)azecane-2-carboxylic acid
DMM2GQC	DE	Discovery agent

DM1YK42	ID	DM1YK42
DM1YK42	DN	9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine
DM1YK42	HS	Investigative
DM1YK42	SN	CHEMBL64303; 9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine; SCHEMBL8406908
DM1YK42	DT	Small molecular drug
DM1YK42	PC	10775682
DM1YK42	MW	227.3
DM1YK42	FM	C15H17NO
DM1YK42	IC	InChI=1S/C15H17NO/c1-17-15-13-5-3-2-4-10(13)8-11-6-7-12(16)9-14(11)15/h2-5,8,12H,6-7,9,16H2,1H3
DM1YK42	CS	COC1=C2CC(CCC2=CC3=CC=CC=C31)N
DM1YK42	IK	XZOPIEFNQZTGHL-UHFFFAOYSA-N
DM1YK42	IU	9-methoxy-1,2,3,4-tetrahydroanthracen-2-amine
DM1YK42	CA	CAS 179041-74-8
DM1YK42	DE	Discovery agent

DMDW267	ID	DMDW267
DMDW267	DN	9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMDW267	HS	Investigative
DMDW267	SN	9-Methoxyellipticine; Methoxyelliptione; Methoxyellipticine; 9-Methoxyellipticin; 9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; 10371-86-5; ICI 180 base; Ellipticine, 9-methoxy-; AT 181; ICIG 772; NSC69187; NSC 69187; B 656501 K003; 9-Methoxy-Ellipticine; UNII-U0924292N9; EINECS 233-812-0; BRN 0279742; 9-Methoxy-5,11-dimethyl-6H-pyrido(4,3-b)carbazole; CHEMBL19954; MLS000736760; C18H16N2O; BKRMCDAOAQWNTG-UHFFFAOYSA-N; NSC-69187; 6H-Pyrido[4,3-b]carbazole, 9-methoxy-5,11-dimethyl-; 6H-Pyrido(4,3-b)carbazole, 5,11-dimethyl-9-me
DMDW267	DT	Small molecular drug
DMDW267	PC	72512
DMDW267	MW	276.3
DMDW267	FM	C18H16N2O
DMDW267	IC	InChI=1S/C18H16N2O/c1-10-15-9-19-7-6-13(15)11(2)18-17(10)14-8-12(21-3)4-5-16(14)20-18/h4-9,20H,1-3H3
DMDW267	CS	CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=C(C=C4)OC)C
DMDW267	IK	BKRMCDAOAQWNTG-UHFFFAOYSA-N
DMDW267	IU	9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMDW267	CA	CAS 10371-86-5
DMDW267	DE	Discovery agent

DMKLTD5	ID	DMKLTD5
DMKLTD5	DN	9-methyl-2-(trifluoromethyl)-9H-carbazole
DMKLTD5	HS	Investigative
DMKLTD5	SN	CHEMBL1173162; 9-methyl-2-(trifluoromethyl)-9H-carbazole; ZINC53295380
DMKLTD5	DT	Small molecular drug
DMKLTD5	PC	49799223
DMKLTD5	MW	249.23
DMKLTD5	FM	C14H10F3N
DMKLTD5	IC	InChI=1S/C14H10F3N/c1-18-12-5-3-2-4-10(12)11-7-6-9(8-13(11)18)14(15,16)17/h2-8H,1H3
DMKLTD5	CS	CN1C2=CC=CC=C2C3=C1C=C(C=C3)C(F)(F)F
DMKLTD5	IK	XEEUWRNTJAAJOP-UHFFFAOYSA-N
DMKLTD5	IU	9-methyl-2-(trifluoromethyl)carbazole
DMKLTD5	DE	Discovery agent

DMF7QS5	ID	DMF7QS5
DMF7QS5	DN	9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline
DMF7QS5	HS	Investigative
DMF7QS5	SN	16502-02-6; 9-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-9-methyl-; 9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline; SCHEMBL967629; CHEMBL263883; STMNLEHELVDDKF-UHFFFAOYSA-N; AKOS022703460; AS-53673; 9-Methyl-1,2,3,4-tetrahydro-beta-carboline
DMF7QS5	DT	Small molecular drug
DMF7QS5	PC	10997754
DMF7QS5	MW	186.25
DMF7QS5	FM	C12H14N2
DMF7QS5	IC	InChI=1S/C12H14N2/c1-14-11-5-3-2-4-9(11)10-6-7-13-8-12(10)14/h2-5,13H,6-8H2,1H3
DMF7QS5	CS	CN1C2=C(CCNC2)C3=CC=CC=C31
DMF7QS5	IK	STMNLEHELVDDKF-UHFFFAOYSA-N
DMF7QS5	IU	9-methyl-1,2,3,4-tetrahydropyrido[3,4-b]indole
DMF7QS5	DE	Discovery agent

DMKD0ZP	ID	DMKD0ZP
DMKD0ZP	DN	9-methyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DMKD0ZP	HS	Investigative
DMKD0ZP	SN	CHEMBL271669; 9-methyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide; SCHEMBL11973219; CHEBI:94994; KYPLTYNYSYVGGA-UHFFFAOYSA-N; BDBM50372501; NCGC00163045-01; CU-00000000359-1
DMKD0ZP	DT	Small molecular drug
DMKD0ZP	PC	16759925
DMKD0ZP	MW	296.3
DMKD0ZP	FM	C16H12N2O2S
DMKD0ZP	IC	InChI=1S/C16H12N2O2S/c1-10-4-7-14-13(9-10)12-6-5-11-3-2-8-17-15(11)16(12)18-21(14,19)20/h2-9,18H,1H3
DMKD0ZP	CS	CC1=CC2=C(C=C1)S(=O)(=O)NC3=C2C=CC4=C3N=CC=C4
DMKD0ZP	IK	KYPLTYNYSYVGGA-UHFFFAOYSA-N
DMKD0ZP	IU	9-methyl-5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide
DMKD0ZP	CB	CHEBI:94994
DMKD0ZP	DE	Discovery agent

DMO4CSP	ID	DMO4CSP
DMO4CSP	DN	9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine
DMO4CSP	HS	Investigative
DMO4CSP	SN	CHEMBL194728; SCHEMBL4462539; 9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine; BDBM50176057; 496955-70-5; 9H-Purin-6-amine, 9-methyl-8-(2H-1,2,3-triazol-2-yl)-
DMO4CSP	DT	Small molecular drug
DMO4CSP	PC	9877796
DMO4CSP	MW	216.2
DMO4CSP	FM	C8H8N8
DMO4CSP	IC	InChI=1S/C8H8N8/c1-15-7-5(6(9)10-4-11-7)14-8(15)16-12-2-3-13-16/h2-4H,1H3,(H2,9,10,11)
DMO4CSP	CS	CN1C2=NC=NC(=C2N=C1N3N=CC=N3)N
DMO4CSP	IK	ZTJZVOMEMRNYKF-UHFFFAOYSA-N
DMO4CSP	IU	9-methyl-8-(triazol-2-yl)purin-6-amine
DMO4CSP	DE	Discovery agent

DM6DOVL	ID	DM6DOVL
DM6DOVL	DN	9-Methyl-9H-adenine
DM6DOVL	HS	Investigative
DM6DOVL	SN	9-Methyl-9H-purin-6-ylamine
DM6DOVL	DT	Small molecular drug
DM6DOVL	PC	69689
DM6DOVL	MW	149.15
DM6DOVL	FM	C6H7N5
DM6DOVL	IC	InChI=1S/C6H7N5/c1-11-3-10-4-5(7)8-2-9-6(4)11/h2-3H,1H3,(H2,7,8,9)
DM6DOVL	CS	CN1C=NC2=C(N=CN=C21)N
DM6DOVL	IK	WRXCXOUDSPTXNX-UHFFFAOYSA-N
DM6DOVL	IU	9-methylpurin-6-amine
DM6DOVL	CA	CAS 700-00-5
DM6DOVL	CB	CHEBI:40526
DM6DOVL	DE	Discovery agent

DM54FRI	ID	DM54FRI
DM54FRI	DN	9-Methylguanine
DM54FRI	HS	Investigative
DM54FRI	DT	Small molecular drug
DM54FRI	PC	135403591
DM54FRI	MW	165.15
DM54FRI	FM	C6H7N5O
DM54FRI	IC	InChI=1S/C6H7N5O/c1-11-2-8-3-4(11)9-6(7)10-5(3)12/h2H,1H3,(H3,7,9,10,12)
DM54FRI	CS	CN1C=NC2=C1N=C(NC2=O)N
DM54FRI	IK	UUWJNBOCAPUTBK-UHFFFAOYSA-N
DM54FRI	IU	2-amino-9-methyl-1H-purin-6-one
DM54FRI	CA	CAS 5502-78-3
DM54FRI	DE	Discovery agent

DMPXLEU	ID	DMPXLEU
DMPXLEU	DN	9-N-ETHYL-8-ETHOXY-MANZAMINE A
DMPXLEU	HS	Investigative
DMPXLEU	SN	9-N-ethyl-8-ethoxy-manzamine A; CHEMBL403562
DMPXLEU	DT	Small molecular drug
DMPXLEU	PC	23643537
DMPXLEU	MW	620.9
DMPXLEU	FM	C40H52N4O2
DMPXLEU	IC	InChI=1S/C40H52N4O2/c1-3-43-36-30(17-15-18-34(36)46-4-2)31-19-22-41-35(37(31)43)32-27-40(45)21-12-8-5-6-9-13-23-42-25-20-33(32)39(28-42)26-29-16-11-7-10-14-24-44(29)38(39)40/h5,8,11,15-19,22,27,29,33,38,45H,3-4,6-7,9-10,12-14,20-21,23-26,28H2,1-2H3/b8-5-,16-11-/t29-,33?,38+,39-,40-/m0/s1
DMPXLEU	CS	CCN1C2=C(C=CC=C2OCC)C3=C1C(=NC=C3)C4=C[C@]5(CC/C=C\\CCCCN6CCC4[C@]7(C6)[C@H]5N8CCCC/C=C\\[C@H]8C7)O
DMPXLEU	IK	ZOZMQOQRAXCUJA-OGIDAHSQSA-N
DMPXLEU	IU	(2R,4R,5Z,12R,13S,16Z)-25-(8-ethoxy-9-ethylpyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DMPXLEU	DE	Discovery agent

DM8LUYM	ID	DM8LUYM
DM8LUYM	DN	9-Nitropaullone
DM8LUYM	HS	Investigative
DM8LUYM	SN	Alsterpaullone; alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444
DM8LUYM	DT	Small molecular drug
DM8LUYM	PC	5005498
DM8LUYM	MW	293.28
DM8LUYM	FM	C16H11N3O3
DM8LUYM	IC	InChI=1S/C16H11N3O3/c20-15-8-12-11-7-9(19(21)22)5-6-14(11)18-16(12)10-3-1-2-4-13(10)17-15/h1-7,18H,8H2,(H,17,20)
DM8LUYM	CS	C1C2=C(C3=CC=CC=C3NC1=O)NC4=C2C=C(C=C4)[N+](=O)[O-]
DM8LUYM	IK	OLUKILHGKRVDCT-UHFFFAOYSA-N
DM8LUYM	IU	9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one
DM8LUYM	CA	CAS 237430-03-4
DM8LUYM	CB	CHEBI:138488
DM8LUYM	DE	Discovery agent

DM1YUBX	ID	DM1YUBX
DM1YUBX	DN	9-N-METHYL-8-METHOXY-MANZAMINE A
DM1YUBX	HS	Investigative
DM1YUBX	SN	9-N-methyl-8-methoxy-manzamine A
DM1YUBX	DT	Small molecular drug
DM1YUBX	PC	23643639
DM1YUBX	MW	592.8
DM1YUBX	FM	C38H48N4O2
DM1YUBX	IC	InChI=1S/C38H48N4O2/c1-40-34-28(15-13-16-32(34)44-2)29-17-20-39-33(35(29)40)30-25-38(43)19-10-6-3-4-7-11-21-41-23-18-31(30)37(26-41)24-27-14-9-5-8-12-22-42(27)36(37)38/h3,6,9,13-17,20,25,27,31,36,43H,4-5,7-8,10-12,18-19,21-24,26H2,1-2H3/b6-3-,14-9-/t27-,31?,36+,37-,38-/m0/s1
DM1YUBX	CS	CN1C2=C(C=CC=C2OC)C3=C1C(=NC=C3)C4=C[C@]5(CC/C=C\\CCCCN6CCC4[C@]7(C6)[C@H]5N8CCCC/C=C\\[C@H]8C7)O
DM1YUBX	IK	LANFUCOONSVQMQ-MCMDJTBWSA-N
DM1YUBX	IU	(2R,4R,5Z,12R,13S,16Z)-25-(8-methoxy-9-methylpyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DM1YUBX	DE	Discovery agent

DMGMD1K	ID	DMGMD1K
DMGMD1K	DN	9-N-Phenylmethylamino-Tacrine
DMGMD1K	HS	Investigative
DMGMD1K	SN	9-N-PHENYLMETHYLAMINO-TACRINE; N-benzyl-1,2,3,4-tetrahydroacridin-9-amine; 9-(3-phenylmethylamino)-1,2,3,4-tetrahydroacridine; AC1L1CJU; SCHEMBL3366446; CHEMBL215344; BDBM199182; DB03672; 9-benzylamino-1,2,3,4-tetrahydroacridine; N-Benzyl-1,2,3,4-tetrahydroacridine-9-amine; N-benzyl-1,2,3,4-tetrahydroacridin-9-amine (8a); 9-Acridinamine, 1,2,3,4-tetrahydro-N-(phenylmethyl)-
DMGMD1K	DT	Small molecular drug
DMGMD1K	PC	1933
DMGMD1K	MW	288.4
DMGMD1K	FM	C20H20N2
DMGMD1K	IC	InChI=1S/C20H20N2/c1-2-8-15(9-3-1)14-21-20-16-10-4-6-12-18(16)22-19-13-7-5-11-17(19)20/h1-4,6,8-10,12H,5,7,11,13-14H2,(H,21,22)
DMGMD1K	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCC4=CC=CC=C4
DMGMD1K	IK	JYJAEHAURXXPSD-UHFFFAOYSA-N
DMGMD1K	IU	N-benzyl-1,2,3,4-tetrahydroacridin-9-amine
DMGMD1K	DE	Discovery agent

DMYXEJ8	ID	DMYXEJ8
DMYXEJ8	DN	9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide
DMYXEJ8	HS	Investigative
DMYXEJ8	SN	CHEMBL602662
DMYXEJ8	DT	Small molecular drug
DMYXEJ8	PC	46232033
DMYXEJ8	MW	442.5
DMYXEJ8	FM	C27H24NO5+
DMYXEJ8	IC	InChI=1S/C27H24NO5/c1-29-24-8-7-18-13-23-21-15-26-25(32-17-33-26)14-19(21)9-10-28(23)16-22(18)27(24)31-12-11-30-20-5-3-2-4-6-20/h2-8,13-16H,9-12,17H2,1H3/q+1
DMYXEJ8	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCOC6=CC=CC=C6
DMYXEJ8	IK	BTWWJBNJLCMOGS-UHFFFAOYSA-N
DMYXEJ8	IU	17-methoxy-16-(2-phenoxyethoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMYXEJ8	DE	Discovery agent

DM081G2	ID	DM081G2
DM081G2	DN	9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide
DM081G2	HS	Investigative
DM081G2	SN	CHEMBL605344
DM081G2	DT	Small molecular drug
DM081G2	PC	46232101
DM081G2	MW	498.6
DM081G2	FM	C31H32NO5+
DM081G2	IC	InChI=1S/C31H32NO5/c1-33-28-12-11-22-17-27-25-19-30-29(36-21-37-30)18-23(25)13-14-32(27)20-26(22)31(28)35-16-8-3-2-7-15-34-24-9-5-4-6-10-24/h4-6,9-12,17-20H,2-3,7-8,13-16,21H2,1H3/q+1
DM081G2	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCCCOC6=CC=CC=C6
DM081G2	IK	LXNXNTQFJHYTEN-UHFFFAOYSA-N
DM081G2	IU	17-methoxy-16-(6-phenoxyhexoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM081G2	DE	Discovery agent

DMHRV2A	ID	DMHRV2A
DMHRV2A	DN	9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide
DMHRV2A	HS	Investigative
DMHRV2A	SN	CHEMBL1163829
DMHRV2A	DT	Small molecular drug
DMHRV2A	PC	46906661
DMHRV2A	MW	471.5
DMHRV2A	FM	C28H27N2O5+
DMHRV2A	IC	InChI=1S/C28H27N2O5/c1-31-24-8-7-19-14-23-21-16-26-25(34-18-35-26)15-20(21)9-11-30(23)17-22(19)28(24)33-13-5-4-12-32-27-6-2-3-10-29-27/h2-3,6-8,10,14-17H,4-5,9,11-13,18H2,1H3/q+1
DMHRV2A	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=CC=CC=N6
DMHRV2A	IK	MZPIENUCQFUDBE-UHFFFAOYSA-N
DMHRV2A	IU	17-methoxy-16-(4-pyridin-2-yloxybutoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMHRV2A	DE	Discovery agent

DM4JG9S	ID	DM4JG9S
DM4JG9S	DN	9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide
DM4JG9S	HS	Investigative
DM4JG9S	SN	CHEMBL1163985
DM4JG9S	DT	Small molecular drug
DM4JG9S	PC	46906615
DM4JG9S	MW	549.4
DM4JG9S	FM	C29H27BrNO5+
DM4JG9S	IC	InChI=1S/C29H27BrNO5/c1-32-26-9-4-19-14-25-23-16-28-27(35-18-36-28)15-20(23)10-11-31(25)17-24(19)29(26)34-13-3-2-12-33-22-7-5-21(30)6-8-22/h4-9,14-17H,2-3,10-13,18H2,1H3/q+1
DM4JG9S	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=CC=C(C=C6)Br
DM4JG9S	IK	XSYYQOISAKERBC-UHFFFAOYSA-N
DM4JG9S	IU	16-[4-(4-bromophenoxy)butoxy]-17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM4JG9S	DE	Discovery agent

DMWVSPH	ID	DMWVSPH
DMWVSPH	DN	9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide
DMWVSPH	HS	Investigative
DMWVSPH	SN	CHEMBL1165676
DMWVSPH	DT	Small molecular drug
DMWVSPH	PC	46906659
DMWVSPH	MW	515.5
DMWVSPH	FM	C29H27N2O7+
DMWVSPH	IC	InChI=1S/C29H27N2O7/c1-34-26-9-4-19-14-25-23-16-28-27(37-18-38-28)15-20(23)10-11-30(25)17-24(19)29(26)36-13-3-2-12-35-22-7-5-21(6-8-22)31(32)33/h4-9,14-17H,2-3,10-13,18H2,1H3/q+1
DMWVSPH	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=CC=C(C=C6)[N+](=O)[O-]
DMWVSPH	IK	APBFBLUUWLQIQX-UHFFFAOYSA-N
DMWVSPH	IU	17-methoxy-16-[4-(4-nitrophenoxy)butoxy]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMWVSPH	DE	Discovery agent

DMKPUWX	ID	DMKPUWX
DMKPUWX	DN	9-O-[3-(Phenylamino)propyl]-berberine bromide
DMKPUWX	HS	Investigative
DMKPUWX	SN	CHEMBL1164163
DMKPUWX	DT	Small molecular drug
DMKPUWX	PC	46906703
DMKPUWX	MW	455.5
DMKPUWX	FM	C28H27N2O4+
DMKPUWX	IC	InChI=1S/C28H27N2O4/c1-31-25-9-8-19-14-24-22-16-27-26(33-18-34-27)15-20(22)10-12-30(24)17-23(19)28(25)32-13-5-11-29-21-6-3-2-4-7-21/h2-4,6-9,14-17,29H,5,10-13,18H2,1H3/q+1
DMKPUWX	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCNC6=CC=CC=C6
DMKPUWX	IK	BRNHZXILANUSDI-UHFFFAOYSA-N
DMKPUWX	IU	N-[3-[(17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-yl)oxy]propyl]aniline
DMKPUWX	DE	Discovery agent

DM0FNUX	ID	DM0FNUX
DM0FNUX	DN	9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide
DM0FNUX	HS	Investigative
DM0FNUX	SN	CHEMBL602663
DM0FNUX	DT	Small molecular drug
DM0FNUX	PC	46232035
DM0FNUX	MW	456.5
DM0FNUX	FM	C28H26NO5+
DM0FNUX	IC	InChI=1S/C28H26NO5/c1-30-25-9-8-19-14-24-22-16-27-26(33-18-34-27)15-20(22)10-11-29(24)17-23(19)28(25)32-13-5-12-31-21-6-3-2-4-7-21/h2-4,6-9,14-17H,5,10-13,18H2,1H3/q+1
DM0FNUX	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCOC6=CC=CC=C6
DM0FNUX	IK	GGIRCXOFADOIHD-UHFFFAOYSA-N
DM0FNUX	IU	17-methoxy-16-(3-phenoxypropoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM0FNUX	DE	Discovery agent

DM58XF6	ID	DM58XF6
DM58XF6	DN	9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide
DM58XF6	HS	Investigative
DM58XF6	SN	CHEMBL602861
DM58XF6	DT	Small molecular drug
DM58XF6	PC	46232037
DM58XF6	MW	470.5
DM58XF6	FM	C29H28NO5+
DM58XF6	IC	InChI=1S/C29H28NO5/c1-31-26-10-9-20-15-25-23-17-28-27(34-19-35-28)16-21(23)11-12-30(25)18-24(20)29(26)33-14-6-5-13-32-22-7-3-2-4-8-22/h2-4,7-10,15-18H,5-6,11-14,19H2,1H3/q+1
DM58XF6	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=CC=CC=C6
DM58XF6	IK	BKMOSBYJXKOCTP-UHFFFAOYSA-N
DM58XF6	IU	17-methoxy-16-(4-phenoxybutoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM58XF6	DE	Discovery agent

DMPZTG9	ID	DMPZTG9
DMPZTG9	DN	9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide
DMPZTG9	HS	Investigative
DMPZTG9	SN	CHEMBL598528
DMPZTG9	DT	Small molecular drug
DMPZTG9	PC	46232099
DMPZTG9	MW	484.6
DMPZTG9	FM	C30H30NO5+
DMPZTG9	IC	InChI=1S/C30H30NO5/c1-32-27-11-10-21-16-26-24-18-29-28(35-20-36-29)17-22(24)12-13-31(26)19-25(21)30(27)34-15-7-3-6-14-33-23-8-4-2-5-9-23/h2,4-5,8-11,16-19H,3,6-7,12-15,20H2,1H3/q+1
DMPZTG9	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCCOC6=CC=CC=C6
DMPZTG9	IK	DIJNAHNGFYBCMU-UHFFFAOYSA-N
DMPZTG9	IU	17-methoxy-16-(5-phenoxypentoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMPZTG9	DE	Discovery agent

DM1DYU4	ID	DM1DYU4
DM1DYU4	DN	9-octadecynoic acid
DM1DYU4	HS	Investigative
DM1DYU4	SN	Stearolic acid; 9-Octadecynoic acid; Octadec-9-ynoic acid; 506-24-1; 9-Stearolic acid; Delta(9)-octadecynoic acid; CHEMBL482804; CHEBI:28801; RGTIBVZDHOMOKC-UHFFFAOYSA-N; Stearolsaeure; Octadec-9-insaeure; EINECS 208-030-8; Octadeca-9-ynoic acid; 9-ODYA; 9-ODA; SCHEMBL196385; AC1L296J; MEGxp0_001740; AC1Q5W60; CTK1H2272; ACon1_002039; DTXSID90198647; MolPort-001-742-497; ZINC8221125; SBB069546; BDBM50292401; MFCD00014386; LMFA01030455; AKOS025117038; NCGC00179891-01; AN-45417; 9a-18:1; FT-0621682; C08459; 506S241; C-51779
DM1DYU4	DT	Small molecular drug
DM1DYU4	PC	68167
DM1DYU4	MW	280.4
DM1DYU4	FM	C18H32O2
DM1DYU4	IC	InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-8,11-17H2,1H3,(H,19,20)
DM1DYU4	CS	CCCCCCCCC#CCCCCCCCC(=O)O
DM1DYU4	IK	RGTIBVZDHOMOKC-UHFFFAOYSA-N
DM1DYU4	IU	octadec-9-ynoic acid
DM1DYU4	CA	CAS 506-24-1
DM1DYU4	CB	CHEBI:28801
DM1DYU4	DE	Discovery agent

DMGORXQ	ID	DMGORXQ
DMGORXQ	DN	9-OH-risperidone
DMGORXQ	HS	Investigative
DMGORXQ	SN	9-hydroxy-risperidone
DMGORXQ	DT	Small molecular drug
DMGORXQ	PC	475100
DMGORXQ	MW	426.5
DMGORXQ	FM	C23H27FN4O3
DMGORXQ	IC	InChI=1S/C23H27FN4O3/c1-14-18(23(30)28-13-17(29)3-5-21(28)25-14)8-11-27-9-6-15(7-10-27)22-19-4-2-16(24)12-20(19)31-26-22/h2,4,12,15,17,29H,3,5-11,13H2,1H3
DMGORXQ	CS	CC1=C(C(=O)N2CC(CCC2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
DMGORXQ	IK	ABWPQNZPAOAQSG-UHFFFAOYSA-N
DMGORXQ	IU	3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-7-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
DMGORXQ	CA	CAS 147663-04-5
DMGORXQ	DE	Discovery agent

DMJFBQ1	ID	DMJFBQ1
DMJFBQ1	DN	9-phenanthrol
DMJFBQ1	HS	Investigative
DMJFBQ1	SN	Phenanthren-9-ol; 9-PHENANTHROL; 9-Hydroxyphenanthrene; 9-Phenanthrenol; 484-17-3; UNII-9FYU45OV9H; NSC 50554; CCRIS 1840; EINECS 207-602-4; BRN 2047057; 9FYU45OV9H; CHEBI:28820; DZKIUEHLEXLYKM-UHFFFAOYSA-N; AC1Q7B0Z; AC1L1UR8; DSSTox_RID_82439; DSSTox_CID_27592; ACMC-1AD67; DSSTox_GSID_47592; 4-06-00-04937 (Beilstein Handbook Reference); SCHEMBL508755; 9-Phenanthrol, technical grade; GTPL4114; CHEMBL2407182; DTXSID9047592; CTK1D6170; DZKIUEHLEXLYKM-UHFFFAOYSA-; MolPort-001-787-230; ZINC967824; KS-000018CG; NSC50554; AC1Q7986
DMJFBQ1	DT	Small molecular drug
DMJFBQ1	PC	10229
DMJFBQ1	MW	194.23
DMJFBQ1	FM	C14H10O
DMJFBQ1	IC	InChI=1S/C14H10O/c15-14-9-10-5-1-2-6-11(10)12-7-3-4-8-13(12)14/h1-9,15H
DMJFBQ1	CS	C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)O
DMJFBQ1	IK	DZKIUEHLEXLYKM-UHFFFAOYSA-N
DMJFBQ1	IU	phenanthren-9-ol
DMJFBQ1	CA	CAS 484-17-3
DMJFBQ1	CB	CHEBI:28820
DMJFBQ1	DE	Discovery agent

DMRCM7Q	ID	DMRCM7Q
DMRCM7Q	DN	9-Phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine
DMRCM7Q	HS	Investigative
DMRCM7Q	SN	CHEMBL279297; 9-Phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine
DMRCM7Q	DT	Small molecular drug
DMRCM7Q	PC	15830914
DMRCM7Q	MW	245.3
DMRCM7Q	FM	C18H15N
DMRCM7Q	IC	InChI=1S/C18H15N/c1-2-6-13(7-3-1)18-16-9-5-4-8-14(16)15-10-11-19-12-17(15)18/h1-10,19H,11-12H2
DMRCM7Q	CS	C1C=C2C(=C(C3=CC=CC=C23)C4=CC=CC=C4)CN1
DMRCM7Q	IK	KIUIXTNMEMKNGK-UHFFFAOYSA-N
DMRCM7Q	IU	9-phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine
DMRCM7Q	DE	Discovery agent

DM73O2A	ID	DM73O2A
DM73O2A	DN	9-Phenyl-9H-purin-6-ylamine
DM73O2A	HS	Investigative
DM73O2A	SN	9-phenylpurin-6-amine; CHEMBL62756; 20145-09-9; 9-phenyladenine; 9-Phenyl-9H-purin-6-ylamine; 9H-Purin-6-amine, 9-phenyl-; NSC516599; AC1L6X8K; 6-Amino-9-phenyl-9H-purine; SCHEMBL5146335; CTK1A5420; DTXSID30325733; ZINC1604448; BDBM50009689; AKOS030561953
DM73O2A	DT	Small molecular drug
DM73O2A	PC	350901
DM73O2A	MW	211.22
DM73O2A	FM	C11H9N5
DM73O2A	IC	InChI=1S/C11H9N5/c12-10-9-11(14-6-13-10)16(7-15-9)8-4-2-1-3-5-8/h1-7H,(H2,12,13,14)
DM73O2A	CS	C1=CC=C(C=C1)N2C=NC3=C(N=CN=C32)N
DM73O2A	IK	QOZYZBRNUYGQNF-UHFFFAOYSA-N
DM73O2A	IU	9-phenylpurin-6-amine
DM73O2A	CA	CAS 20145-09-9
DM73O2A	DE	Discovery agent

DMO17J0	ID	DMO17J0
DMO17J0	DN	9-Phenylethyl-9H-adenine
DMO17J0	HS	Investigative
DMO17J0	SN	9-Phenethyladenine; CHEMBL445696; 7051-86-7; 9-Phenylethyl-9H-adenine; NSC211638; AC1L7EWL; Maybridge3_003004; 9-phenethylpurin-6-amine; 9-(2-phenylethyl)adenine; MLS001181918; SCHEMBL1230786; 6-Amino-9-phenethyl-9H-purine; DTXSID10309298; MolPort-002-902-800; ZINC158322; HMS1439I12; HMS2852H03; BDBM50257097; CCG-51741; AKOS012923591; NSC-211638; MCULE-7488166280; IDI1_014391; SMR000567667
DMO17J0	DT	Small molecular drug
DMO17J0	PC	309375
DMO17J0	MW	239.28
DMO17J0	FM	C13H13N5
DMO17J0	IC	InChI=1S/C13H13N5/c14-12-11-13(16-8-15-12)18(9-17-11)7-6-10-4-2-1-3-5-10/h1-5,8-9H,6-7H2,(H2,14,15,16)
DMO17J0	CS	C1=CC=C(C=C1)CCN2C=NC3=C(N=CN=C32)N
DMO17J0	IK	MALQBKDZBRRFOM-UHFFFAOYSA-N
DMO17J0	IU	9-(2-phenylethyl)purin-6-amine
DMO17J0	CA	CAS 7051-86-7
DMO17J0	DE	Discovery agent

DMQTEPY	ID	DMQTEPY
DMQTEPY	DN	9-Propyl-9H-adenine
DMQTEPY	HS	Investigative
DMQTEPY	SN	9-propyl-9h-purin-6-amine; CHEMBL475023; 707-98-2; 9-propyl-9H-purin-6-ylamine; 9-Propyl-9H-adenine; 9-propylpurin-6-amine; 9-propyladenine; NSC61961; AC1Q4VHN; AC1L6K9K; SCHEMBL233405; 9-Propyl-9H-purine-6-amine; CTK5D3013; DTXSID10289561; BDBM50256891; NSC-61961
DMQTEPY	DT	Small molecular drug
DMQTEPY	PC	247436
DMQTEPY	MW	177.21
DMQTEPY	FM	C8H11N5
DMQTEPY	IC	InChI=1S/C8H11N5/c1-2-3-13-5-12-6-7(9)10-4-11-8(6)13/h4-5H,2-3H2,1H3,(H2,9,10,11)
DMQTEPY	CS	CCCN1C=NC2=C(N=CN=C21)N
DMQTEPY	IK	QTULKOMMYIUZQD-UHFFFAOYSA-N
DMQTEPY	IU	9-propylpurin-6-amine
DMQTEPY	CA	CAS 707-98-2
DMQTEPY	DE	Discovery agent

DM1H3FJ	ID	DM1H3FJ
DM1H3FJ	DN	A 137491
DM1H3FJ	HS	Investigative
DM1H3FJ	SN	ABT 491
DM1H3FJ	DT	Small molecular drug
DM1H3FJ	PC	154086
DM1H3FJ	MW	516
DM1H3FJ	FM	C28H23ClFN5O2
DM1H3FJ	IC	InChI=1S/C28H22FN5O2.ClH/c1-5-18-7-6-8-25-26(18)21(16-34(25)28(36)32(3)4)27(35)19-9-10-20(22(29)13-19)15-33-17(2)31-23-14-30-12-11-24(23)33;/h1,6-14,16H,15H2,2-4H3;1H
DM1H3FJ	CS	CC1=NC2=C(N1CC3=C(C=C(C=C3)C(=O)C4=CN(C5=CC=CC(=C54)C#C)C(=O)N(C)C)F)C=CN=C2.Cl
DM1H3FJ	IK	AWRGBOKANQBIBM-UHFFFAOYSA-N
DM1H3FJ	IU	4-ethynyl-3-[3-fluoro-4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]benzoyl]-N,N-dimethylindole-1-carboxamide;hydrochloride
DM1H3FJ	CA	CAS 189689-94-9
DM1H3FJ	DE	Discovery agent

DMHSPRE	ID	DMHSPRE
DMHSPRE	DN	A-058
DMHSPRE	HS	Investigative
DMHSPRE	SN	A-095; A-166; A-167; A-168; A-169; A-448; A-510; A-521; A-524; A-526; A-629; A-640; A-644; A-850; A-874; A-972; HCV NS5b polymerase inhibitors, Arrow Therapeutics
DMHSPRE	CP	Arrow Therapeutics Ltd
DMHSPRE	DE	Hepatitis C virus infection

DM1DWRN	ID	DM1DWRN
DM1DWRN	DN	A-119637
DM1DWRN	HS	Investigative
DM1DWRN	SN	A-119637; CHEMBL268758; A119637; GTPL490; SCHEMBL7837611; BDBM50099322; A 119637; 3-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-5-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione; 3-[2-[4-(2-Methoxyphenyl)piperazino]ethyl]-5-phenyl-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-2,4-dione
DM1DWRN	DT	Small molecular drug
DM1DWRN	PC	9890547
DM1DWRN	MW	462.6
DM1DWRN	FM	C25H26N4O3S
DM1DWRN	IC	InChI=1S/C25H26N4O3S/c1-32-21-10-6-5-9-20(21)28-14-11-27(12-15-28)13-16-29-24(30)22-19(18-7-3-2-4-8-18)17-33-23(22)26-25(29)31/h2-10,17H,11-16H2,1H3,(H,26,31)
DM1DWRN	CS	COC1=CC=CC=C1N2CCN(CC2)CCN3C(=O)C4=C(NC3=O)SC=C4C5=CC=CC=C5
DM1DWRN	IK	HLVQBOYEHQRWHG-UHFFFAOYSA-N
DM1DWRN	IU	3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-5-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione
DM1DWRN	DE	Discovery agent

DMZ51UJ	ID	DMZ51UJ
DMZ51UJ	DN	A-123189
DMZ51UJ	HS	Investigative
DMZ51UJ	SN	A-123189; CHEMBL13856; GTPL491; SCHEMBL7834335; BDBM50099325; A123189; A 123189; 3-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-5-m-tolyl-1H-thieno[2,3-d]pyrimidine-2,4-dione; 3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-5-(3-methylphenyl)-1H-thieno[3,2-e]pyrimidine-2,4-dione
DMZ51UJ	DT	Small molecular drug
DMZ51UJ	PC	9891167
DMZ51UJ	MW	476.6
DMZ51UJ	FM	C26H28N4O3S
DMZ51UJ	IC	InChI=1S/C26H28N4O3S/c1-18-6-5-7-19(16-18)20-17-34-24-23(20)25(31)30(26(32)27-24)15-12-28-10-13-29(14-11-28)21-8-3-4-9-22(21)33-2/h3-9,16-17H,10-15H2,1-2H3,(H,27,32)
DMZ51UJ	CS	CC1=CC(=CC=C1)C2=CSC3=C2C(=O)N(C(=O)N3)CCN4CCN(CC4)C5=CC=CC=C5OC
DMZ51UJ	IK	PANBMHHKBRMYAL-UHFFFAOYSA-N
DMZ51UJ	IU	3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-5-(3-methylphenyl)-1H-thieno[2,3-d]pyrimidine-2,4-dione
DMZ51UJ	DE	Discovery agent

DMV03NS	ID	DMV03NS
DMV03NS	DN	A-192558
DMV03NS	HS	Investigative
DMV03NS	SN	A-192558; UNII-SQ95TK2P11; CHEMBL19309; SQ95TK2P11; 4-Amino-1-(ethyl-isopropyl-carbamoyl)-5-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidine-3-carboxylic acid; BDBM50098745; 341969-96-8; 3-Pyrrolidinecarboxylic acid, 4-amino-1-((ethyl(1-methylethyl)amino)carbonyl)-5-(((2,2,2-trifluoroacetyl)amino)methyl)-, (3R,4R,5S)-; 1-[(Ethylisopropylamino)carbonyl]-2beta-[(trifluoroacetylamino)methyl]-3alpha-aminopyrrolidine-4alpha-carboxylic acid; 3-Pyrrolidinecarboxylic acid, 4-amino-1-((ethyl(1-methylethyl)amino)carbonyl)-5
DMV03NS	DT	Small molecular drug
DMV03NS	PC	9885589
DMV03NS	MW	368.35
DMV03NS	FM	C14H23F3N4O4
DMV03NS	IC	InChI=1S/C14H23F3N4O4/c1-4-20(7(2)3)13(25)21-6-8(11(22)23)10(18)9(21)5-19-12(24)14(15,16)17/h7-10H,4-6,18H2,1-3H3,(H,19,24)(H,22,23)/t8-,9+,10-/m1/s1
DMV03NS	CS	CCN(C(C)C)C(=O)N1C[C@H]([C@H]([C@@H]1CNC(=O)C(F)(F)F)N)C(=O)O
DMV03NS	IK	KRSIVMHLZOHCGR-KXUCPTDWSA-N
DMV03NS	IU	(3R,4R,5S)-4-amino-1-[ethyl(propan-2-yl)carbamoyl]-5-[[(2,2,2-trifluoroacetyl)amino]methyl]pyrrolidine-3-carboxylic acid
DMV03NS	CA	CAS 341969-96-8
DMV03NS	DE	Discovery agent

DMV8AH6	ID	DMV8AH6
DMV8AH6	DN	A192621
DMV8AH6	HS	Investigative
DMV8AH6	SN	A-192621; A 192621
DMV8AH6	DT	Small molecular drug
DMV8AH6	PC	5310991
DMV8AH6	MW	558.7
DMV8AH6	FM	C33H38N2O6
DMV8AH6	IC	InChI=1S/C33H38N2O6/c1-4-16-39-25-13-10-23(11-14-25)32-30(33(37)38)26(24-12-15-27-28(17-24)41-20-40-27)18-35(32)19-29(36)34-31-21(5-2)8-7-9-22(31)6-3/h7-15,17,26,30,32H,4-6,16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m1/s1
DMV8AH6	CS	CCCOC1=CC=C(C=C1)[C@H]2[C@@H]([C@H](CN2CC(=O)NC3=C(C=CC=C3CC)CC)C4=CC5=C(C=C4)OCO5)C(=O)O
DMV8AH6	IK	LQEHCKYYIXQEBM-FUKIBTTHSA-N
DMV8AH6	IU	(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(2,6-diethylanilino)-2-oxoethyl]-2-(4-propoxyphenyl)pyrrolidine-3-carboxylic acid
DMV8AH6	CA	CAS 195529-54-5
DMV8AH6	DE	Discovery agent

DM5VQ8E	ID	DM5VQ8E
DM5VQ8E	DN	A-224940
DM5VQ8E	HS	Investigative
DM5VQ8E	SN	CHEMBL364377; A-224940; 635755-66-7; SCHEMBL5884420; CTK2A8845; DTXSID90623944; BDBM50152424; 8-(cyclohexylmethoxy)quinolin-2-amine; 8-Cyclohexylmethoxy-quinolin-2-ylamine; 2-Quinolinamine, 8-(cyclohexylmethoxy)-
DM5VQ8E	DT	Small molecular drug
DM5VQ8E	PC	22254551
DM5VQ8E	MW	256.339
DM5VQ8E	FM	C16H20N2O
DM5VQ8E	IC	InChI=1S/C16H20N2O/c17-15-10-9-13-7-4-8-14(16(13)18-15)19-11-12-5-2-1-3-6-12/h4,7-10,12H,1-3,5-6,11H2,(H2,17,18)
DM5VQ8E	CS	C1CCC(CC1)COC2=CC=CC3=C2N=C(C=C3)N
DM5VQ8E	IK	OTJOSBTUERTNPP-UHFFFAOYSA-N
DM5VQ8E	IU	8-(cyclohexylmethoxy)quinolin-2-amine
DM5VQ8E	CA	CAS 635755-66-7
DM5VQ8E	DE	Discovery agent

DM98VFW	ID	DM98VFW
DM98VFW	DN	A-286982
DM98VFW	HS	Investigative
DM98VFW	SN	A-286982; 280749-17-9; UNII-5I8WFS075A; A 286982; CHEMBL19677; 5I8WFS075A; C24H27N3O4S; (2E)-1-(4-Acetyl-1-piperazinyl)-3-[4-[[2-(1-methylethyl)phenyl]thio]-3-nitrophenyl]-2-propen-1-one; SCHEMBL5829786; GTPL6592; SCHEMBL12063498; AOB1772; SYN5060; MolPort-023-277-110; ZINC602716; BDBM50092956; AKOS024458044; API0010263; Piperazine, 1-acetyl-4-((2E)-3-(4-((2-(1-methylethyl)phenyl)thio)-3-nitrophenyl)-1-oxo-2-propenyl)-; (E)-1-(4-acetylpiperazin-1-yl)-3-[3-nitro-4-(2-propan-2-ylphenyl)sulfanylphenyl]prop-2-en-1-one; AS-16426
DM98VFW	DT	Small molecular drug
DM98VFW	PC	9846729
DM98VFW	MW	453.6
DM98VFW	FM	C24H27N3O4S
DM98VFW	IC	InChI=1S/C24H27N3O4S/c1-17(2)20-6-4-5-7-22(20)32-23-10-8-19(16-21(23)27(30)31)9-11-24(29)26-14-12-25(13-15-26)18(3)28/h4-11,16-17H,12-15H2,1-3H3/b11-9+
DM98VFW	CS	CC(C)C1=CC=CC=C1SC2=C(C=C(C=C2)/C=C/C(=O)N3CCN(CC3)C(=O)C)[N+](=O)[O-]
DM98VFW	IK	HTGGAYLWTDOFDK-PKNBQFBNSA-N
DM98VFW	IU	(E)-1-(4-acetylpiperazin-1-yl)-3-[3-nitro-4-(2-propan-2-ylphenyl)sulfanylphenyl]prop-2-en-1-one
DM98VFW	CA	CAS 280749-17-9
DM98VFW	DE	Discovery agent

DMK4OD7	ID	DMK4OD7
DMK4OD7	DN	A2P5P
DMK4OD7	HS	Investigative
DMK4OD7	SN	2,5-ADP; adenosine 2',5'-bisphosphate; adenosine-2'-5'-diphosphate
DMK4OD7	DT	Small molecular drug
DMK4OD7	PC	440141
DMK4OD7	MW	427.2
DMK4OD7	FM	C10H15N5O10P2
DMK4OD7	IC	InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(25-27(20,21)22)6(16)4(24-10)1-23-26(17,18)19/h2-4,6-7,10,16H,1H2,(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1
DMK4OD7	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)OP(=O)(O)O)N
DMK4OD7	IK	AEOBEOJCBAYXBA-KQYNXXCUSA-N
DMK4OD7	IU	[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate
DMK4OD7	CA	CAS 3805-37-6
DMK4OD7	DE	Discovery agent

DMPI0YX	ID	DMPI0YX
DMPI0YX	DN	A-304121
DMPI0YX	HS	Investigative
DMPI0YX	SN	A304121; A 304121
DMPI0YX	DT	Small molecular drug
DMPI0YX	PC	9906860
DMPI0YX	MW	359.5
DMPI0YX	FM	C20H29N3O3
DMPI0YX	IC	InChI=1S/C20H29N3O3/c1-15(21)20(25)23-12-10-22(11-13-23)9-2-14-26-18-7-5-17(6-8-18)19(24)16-3-4-16/h5-8,15-16H,2-4,9-14,21H2,1H3/t15-/m1/s1
DMPI0YX	CS	C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
DMPI0YX	IK	KPXVCGPCRXEDLT-OAHLLOKOSA-N
DMPI0YX	IU	(2R)-2-amino-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]propan-1-one
DMPI0YX	CA	CAS 360551-71-9
DMPI0YX	DE	Discovery agent

DML4P6O	ID	DML4P6O
DML4P6O	DN	A-313326
DML4P6O	HS	Investigative
DML4P6O	SN	CHEMBL41748; A-313326; SCHEMBL7083765; BDBM13389; A313326; 4-[alpha-(1-Methyl-1H-imidazole-5-yl)-3-(1-naphthyl)-4-cyanobenzyloxymethyl]benzonitrile
DML4P6O	DT	Small molecular drug
DML4P6O	PC	23646371
DML4P6O	MW	454.5
DML4P6O	FM	C30H22N4O
DML4P6O	IC	InChI=1S/C30H22N4O/c1-34-20-33-18-29(34)30(35-19-22-11-9-21(16-31)10-12-22)24-13-14-25(17-32)28(15-24)27-8-4-6-23-5-2-3-7-26(23)27/h2-15,18,20,30H,19H2,1H3
DML4P6O	CS	CN1C=NC=C1C(C2=CC(=C(C=C2)C#N)C3=CC=CC4=CC=CC=C43)OCC5=CC=C(C=C5)C#N
DML4P6O	IK	ZBRVJLSHNVWEKS-UHFFFAOYSA-N
DML4P6O	IU	4-[(4-cyanophenyl)methoxy-(3-methylimidazol-4-yl)methyl]-2-naphthalen-1-ylbenzonitrile
DML4P6O	DE	Discovery agent

DMV8MKP	ID	DMV8MKP
DMV8MKP	DN	A-315456
DMV8MKP	HS	Investigative
DMV8MKP	SN	CHEMBL362863; N-[3-(cyclohexylidene(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide; NCGC00015076-01; AC1O7FZN; Lopac-A-6351; Lopac0_000059; MLS002153477; CTK8F7477; HMS3370M22; HMS3260K19; HMS2235H14; ZINC9229227; Tox21_500059; BDBM50160163; LP00059; CCG-204154; NCGC00093573-02; NCGC00015076-03; NCGC00093573-01; NCGC00015076-02; NCGC00260744-01; NCGC00015076-04; SMR001230830; EU-0100059; A-315456, &gt; A 6351; SR-01000076218; SR-01000076218-1
DMV8MKP	DT	Small molecular drug
DMV8MKP	PC	6603710
DMV8MKP	MW	345.5
DMV8MKP	FM	C18H23N3O2S
DMV8MKP	IC	InChI=1S/C18H23N3O2S/c1-2-24(22,23)21-16-10-6-9-15(11-16)18(17-12-19-13-20-17)14-7-4-3-5-8-14/h6,9-13,21H,2-5,7-8H2,1H3,(H,19,20)
DMV8MKP	CS	CCS(=O)(=O)NC1=CC=CC(=C1)C(=C2CCCCC2)C3=CN=CN3
DMV8MKP	IK	MTZVJHSZYMWIAG-UHFFFAOYSA-N
DMV8MKP	IU	N-[3-[cyclohexylidene(1H-imidazol-5-yl)methyl]phenyl]ethanesulfonamide
DMV8MKP	DE	Discovery agent

DMSQLZF	ID	DMSQLZF
DMSQLZF	DN	A-315675
DMSQLZF	HS	Investigative
DMSQLZF	SN	UNII-H8E590FKGW; A-315675; H8E590FKGW; CHEMBL473062; A 315675; 335679-69-1; 5-((2S,1R)-1-(Acetylamino)-2-methoxy-2-methylpentyl)(4S,2R)-4-(prop-1-enyl)pyrrolidine-2-carboxylic acid; D-Proline, 5-((1R,2S)-1-(acetylamino)-2-methoxy-2-methylpentyl)-4-(1Z)-1-propenyl-, (4S,5R)-; D-Proline, 5-[(1R,2S)-1-(acetylamino)-2-methoxy-2-methylpentyl]-4-(1Z)-1-propenyl-, (4S,5R)-; 5-[(2S,1R)-1-(Acetylamino)-2-methoxy-2-methylpentyl](4S,2R)-4-(prop-1-enyl)pyrrolidine-2-carboxylic acid; AC1O52P7; SCHEMBL6696713; BDBM50371257
DMSQLZF	DT	Small molecular drug
DMSQLZF	PC	6451053
DMSQLZF	MW	326.4
DMSQLZF	FM	C17H30N2O4
DMSQLZF	IC	InChI=1S/C17H30N2O4/c1-6-8-12-10-13(16(21)22)19-14(12)15(18-11(3)20)17(4,23-5)9-7-2/h6,8,12-15,19H,7,9-10H2,1-5H3,(H,18,20)(H,21,22)/b8-6-/t12-,13-,14-,15-,17+/m1/s1
DMSQLZF	CS	CCC[C@@](C)([C@@H]([C@H]1[C@@H](C[C@@H](N1)C(=O)O)/C=C\\C)NC(=O)C)OC
DMSQLZF	IK	UUVKABIGWGMYCE-FLMGFEAJSA-N
DMSQLZF	IU	(2R,4S,5R)-5-[(1R,2S)-1-acetamido-2-methoxy-2-methylpentyl]-4-[(Z)-prop-1-enyl]pyrrolidine-2-carboxylic acid
DMSQLZF	CA	CAS 335679-69-1
DMSQLZF	DE	Discovery agent

DMGWO9J	ID	DMGWO9J
DMGWO9J	DN	A-317567
DMGWO9J	HS	Investigative
DMGWO9J	SN	A317567; A 317567
DMGWO9J	DT	Small molecular drug
DMGWO9J	PC	10200844
DMGWO9J	MW	397.6
DMGWO9J	FM	C27H31N3
DMGWO9J	IC	InChI=1S/C27H31N3/c1-16(2)26-25-14-21(7-4-17(25)10-11-30(26)3)24-15-23(24)20-8-5-19-13-22(27(28)29)9-6-18(19)12-20/h4-9,12-14,16,23-24,26H,10-11,15H2,1-3H3,(H3,28,29)
DMGWO9J	CS	CC(C)C1C2=C(CCN1C)C=CC(=C2)C3CC3C4=CC5=C(C=C4)C=C(C=C5)C(=N)N
DMGWO9J	IK	FEPIUXBUJVISNN-UHFFFAOYSA-N
DMGWO9J	IU	6-[2-(2-methyl-1-propan-2-yl-3,4-dihydro-1H-isoquinolin-7-yl)cyclopropyl]naphthalene-2-carboximidamide
DMGWO9J	DE	Discovery agent

DM124K5	ID	DM124K5
DM124K5	DN	A-317920
DM124K5	HS	Investigative
DM124K5	SN	UNII-5P909HKP24; A 317920; A-317920; CHEMBL361355; 360551-59-3; 5P909HKP24; A317920; SCHEMBL7244823; GTPL1216; DTXSID00189622; BDBM50158601; N-[(2R)-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]-1-oxopropan-2-yl]furan-2-carboxamide; Furan-2-carboxylic acid ((R)-2-{4-[3-(4-cyclopropanecarbonyl-phenoxy)-propyl]-piperazin-1-yl}-1-methyl-2-oxo-ethyl)-amide; N-(2-(4-(3-(4-(Cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide; 2-Furancarboxamide, N-((1R)-2-(4-(3-(4-     (cyclopro
DM124K5	CP	Abbott
DM124K5	DT	Small molecular drug
DM124K5	PC	10389213
DM124K5	MW	453.5
DM124K5	FM	C25H31N3O5
DM124K5	IC	InChI=1S/C25H31N3O5/c1-18(26-24(30)22-4-2-16-33-22)25(31)28-14-12-27(13-15-28)11-3-17-32-21-9-7-20(8-10-21)23(29)19-5-6-19/h2,4,7-10,16,18-19H,3,5-6,11-15,17H2,1H3,(H,26,30)/t18-/m1/s1
DM124K5	CS	C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC(=O)C4=CC=CO4
DM124K5	IK	RTRADBQSZJIRMT-GOSISDBHSA-N
DM124K5	IU	N-[(2R)-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]-1-oxopropan-2-yl]furan-2-carboxamide
DM124K5	CA	CAS 360551-59-3
DM124K5	DE	Attention deficit hyperactivity disorder

DMPU3QR	ID	DMPU3QR
DMPU3QR	DN	A-331440
DMPU3QR	HS	Investigative
DMPU3QR	SN	A-331440; UNII-45WZM2FLYQ; 392338-13-5; A 331440; 45WZM2FLYQ; CHEMBL319000; GTPL4023; SCHEMBL5216650; ZINC22452295; BDBM50240709; 4-[4-[3-[(3R)-3-dimethylaminopyrrolidin-1-yl]propoxy]phenyl]benzonitrile; 4'-(3-((3R)-3-(Dimethylamino)pyrrolidinyl)propoxy)(1,1'-biphenyl)-4-carbonitrile; (1,1'-Biphenyl)-4-carbonitrile, 4'-(3-((3R)-3-(dimethylamino)-1-pyrrolidinyl)propoxy)-; KB-74351; A331440; 4''-[3-((R)-3-Dimethylamino-pyrrolidin-1-yl)-propoxy]-biphenyl-4-carbonitrile
DMPU3QR	CP	Abbott
DMPU3QR	DT	Small molecular drug
DMPU3QR	PC	9884746
DMPU3QR	MW	349.5
DMPU3QR	FM	C22H27N3O
DMPU3QR	IC	InChI=1S/C22H27N3O/c1-24(2)21-12-14-25(17-21)13-3-15-26-22-10-8-20(9-11-22)19-6-4-18(16-23)5-7-19/h4-11,21H,3,12-15,17H2,1-2H3/t21-/m1/s1
DMPU3QR	CS	CN(C)[C@@H]1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
DMPU3QR	IK	FXIPXWLVYIHFEP-OAQYLSRUSA-N
DMPU3QR	IU	4-[4-[3-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]phenyl]benzonitrile
DMPU3QR	CA	CAS 392338-13-5
DMPU3QR	DE	Obesity

DMFNR3Y	ID	DMFNR3Y
DMFNR3Y	DN	A35566-A
DMFNR3Y	HS	Investigative
DMFNR3Y	SN	A35566-B
DMFNR3Y	CP	Sankyo Co Ltd
DMFNR3Y	DE	Solid tumour/cancer

DMZHDWN	ID	DMZHDWN
DMZHDWN	DN	A-357300
DMZHDWN	HS	Investigative
DMZHDWN	DT	Small molecular drug
DMZHDWN	PC	448285
DMZHDWN	MW	359.9
DMZHDWN	FM	C15H22ClN3O3S
DMZHDWN	IC	InChI=1S/C15H22ClN3O3S/c1-9(2)23-7-6-12(17)13(20)15(22)19-18-14(21)10-4-3-5-11(16)8-10/h3-5,8-9,12-13,20H,6-7,17H2,1-2H3,(H,18,21)(H,19,22)/t12-,13+/m1/s1
DMZHDWN	CS	CC(C)SCC[C@H]([C@@H](C(=O)NNC(=O)C1=CC(=CC=C1)Cl)O)N
DMZHDWN	IK	BYBVYIPUGPZRSX-OLZOCXBDSA-N
DMZHDWN	IU	N'-[(2S,3R)-3-amino-2-hydroxy-5-propan-2-ylsulfanylpentanoyl]-3-chlorobenzohydrazide
DMZHDWN	DE	Discovery agent

DMI4TVB	ID	DMI4TVB
DMI4TVB	DN	A-381393
DMI4TVB	HS	Investigative
DMI4TVB	SN	CHEMBL127257; A-381393; GTPL8441; BDBM50150141; A 381393; A-381,393; 2-[[4-(3,4-dimethylphenyl)piperazin-1-yl]methyl]-1H-benzimidazole; 2-[4-(3,4-dimethylphenyl)piperazin-1-ylmethyl]-1h-benzimidazole
DMI4TVB	DT	Small molecular drug
DMI4TVB	PC	11301655
DMI4TVB	MW	320.4
DMI4TVB	FM	C20H24N4
DMI4TVB	IC	InChI=1S/C20H24N4/c1-15-7-8-17(13-16(15)2)24-11-9-23(10-12-24)14-20-21-18-5-3-4-6-19(18)22-20/h3-8,13H,9-12,14H2,1-2H3,(H,21,22)
DMI4TVB	CS	CC1=C(C=C(C=C1)N2CCN(CC2)CC3=NC4=CC=CC=C4N3)C
DMI4TVB	IK	SAQMCVDGOIRQTC-UHFFFAOYSA-N
DMI4TVB	IU	2-[[4-(3,4-dimethylphenyl)piperazin-1-yl]methyl]-1H-benzimidazole
DMI4TVB	DE	Discovery agent

DMSTZ14	ID	DMSTZ14
DMSTZ14	DN	A-395
DMSTZ14	HS	Investigative
DMSTZ14	SN	CHEMBL4104741; (3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine; GTPL9525; SCHEMBL19549392; BDBM223987; BDBM50241662; A-395 hydrochloride, >=98% (HPLC); HY-101512; CS-0021615; J3.609.234C; A-395 (5); A392089148-72-9; (3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-[4-(4-methylsulfonylpiperazin-1-yl)phenyl]pyrrolidin-3-amine; 2089148-71-8; rac-(3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine (4); rel-(3R,4S)-1-(7-Fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine
DMSTZ14	DT	Small molecular drug
DMSTZ14	PC	123132213
DMSTZ14	MW	486.6
DMSTZ14	FM	C26H35FN4O2S
DMSTZ14	IC	InChI=1S/C26H35FN4O2S/c1-28(2)25-18-30(24-12-9-20-5-4-6-23(27)26(20)24)17-22(25)19-7-10-21(11-8-19)29-13-15-31(16-14-29)34(3,32)33/h4-8,10-11,22,24-25H,9,12-18H2,1-3H3/t22-,24?,25+/m1/s1
DMSTZ14	CS	CN(C)[C@H]1CN(C[C@@H]1C2=CC=C(C=C2)N3CCN(CC3)S(=O)(=O)C)C4CCC5=C4C(=CC=C5)F
DMSTZ14	IK	REVJNSVNICWODC-KIDMSAQOSA-N
DMSTZ14	IU	(3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-[4-(4-methylsulfonylpiperazin-1-yl)phenyl]pyrrolidin-3-amine
DMSTZ14	DE	Discovery agent

DMKY9G5	ID	DMKY9G5
DMKY9G5	DN	A412997
DMKY9G5	HS	Investigative
DMKY9G5	SN	A-412,997; A-412997
DMKY9G5	DT	Small molecular drug
DMKY9G5	PC	10425450
DMKY9G5	MW	309.4
DMKY9G5	FM	C19H23N3O
DMKY9G5	IC	InChI=1S/C19H23N3O/c1-15-5-4-6-17(13-15)21-19(23)14-22-11-8-16(9-12-22)18-7-2-3-10-20-18/h2-7,10,13,16H,8-9,11-12,14H2,1H3,(H,21,23)
DMKY9G5	CS	CC1=CC(=CC=C1)NC(=O)CN2CCC(CC2)C3=CC=CC=N3
DMKY9G5	IK	JFCDMGGMCUKHST-UHFFFAOYSA-N
DMKY9G5	IU	N-(3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide
DMKY9G5	CA	CAS 630116-49-3
DMKY9G5	DE	Discovery agent

DM7HSCI	ID	DM7HSCI
DM7HSCI	DN	A-420983
DM7HSCI	HS	Investigative
DM7HSCI	SN	CHEMBL314627; A-420983; N-(4-{4-Amino-1-[4-(4-Methylpiperazin-1-Yl)-Trans-Cyclohexyl]-1h-Pyrazolo[3,4-D]pyrimidin-3-Yl}-2-Methoxyphenyl)-1-Methyl-1h-Indole-2-Carboxamide; SCHEMBL6221049; SCHEMBL5803074; SCHEMBL19999345; SCHEMBL14106773; SCHEMBL16752208; STVKLDUINKMZFE-RQNOJGIXSA-N; STVKLDUINKMZFE-PSWAGMNNSA-N; BDBM50145571; L1G; N-(4-(4-amino-1-((trans)-4-(4-methylpiperazin-1-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide
DM7HSCI	DT	Small molecular drug
DM7HSCI	PC	9549183
DM7HSCI	MW	593.7
DM7HSCI	FM	C33H39N9O2
DM7HSCI	IC	InChI=1S/C33H39N9O2/c1-39-14-16-41(17-15-39)23-9-11-24(12-10-23)42-32-29(31(34)35-20-36-32)30(38-42)22-8-13-25(28(19-22)44-3)37-33(43)27-18-21-6-4-5-7-26(21)40(27)2/h4-8,13,18-20,23-24H,9-12,14-17H2,1-3H3,(H,37,43)(H2,34,35,36)
DM7HSCI	CS	CN1CCN(CC1)C2CCC(CC2)N3C4=NC=NC(=C4C(=N3)C5=CC(=C(C=C5)NC(=O)C6=CC7=CC=CC=C7N6C)OC)N
DM7HSCI	IK	STVKLDUINKMZFE-UHFFFAOYSA-N
DM7HSCI	IU	N-[4-[4-amino-1-[4-(4-methylpiperazin-1-yl)cyclohexyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methylindole-2-carboxamide
DM7HSCI	DE	Discovery agent

DMM5XD6	ID	DMM5XD6
DMM5XD6	DN	A-425444
DMM5XD6	HS	Investigative
DMM5XD6	SN	CHEMBL219179; A-425444; SCHEMBL4809015; CBDXXUZXRDBOGH-UHFFFAOYSA-N; BDBM50200029; LS-193223; 6-[4-(1H-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridin-3-ol; 6-[4-(1H-Benzoimidazole-2-ylmethyl)piperazino]-3-pyridinol
DMM5XD6	DT	Small molecular drug
DMM5XD6	PC	9861462
DMM5XD6	MW	309.4
DMM5XD6	FM	C17H19N5O
DMM5XD6	IC	InChI=1S/C17H19N5O/c23-13-5-6-17(18-11-13)22-9-7-21(8-10-22)12-16-19-14-3-1-2-4-15(14)20-16/h1-6,11,23H,7-10,12H2,(H,19,20)
DMM5XD6	CS	C1CN(CCN1CC2=NC3=CC=CC=C3N2)C4=NC=C(C=C4)O
DMM5XD6	IK	CBDXXUZXRDBOGH-UHFFFAOYSA-N
DMM5XD6	IU	6-[4-(1H-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridin-3-ol
DMM5XD6	DE	Discovery agent

DMQHKIA	ID	DMQHKIA
DMQHKIA	DN	A-432411
DMQHKIA	HS	Investigative
DMQHKIA	SN	43A; (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; 2ayp; indolinone analog 13; A-432411; CHEMBL202930; SCHEMBL6674605; BDBM14649; DB07078; 29690-EP2311842A2; 29690-EP2289868A1; 29690-EP2289894A2; (3Z)-6-(4-hydroxy-3-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; (3Z)-6-(4-hydroxy-3-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one
DMQHKIA	DT	Small molecular drug
DMQHKIA	PC	10125830
DMQHKIA	MW	332.4
DMQHKIA	FM	C20H16N2O3
DMQHKIA	IC	InChI=1S/C20H16N2O3/c1-25-19-10-13(5-7-18(19)23)12-4-6-15-16(11-14-3-2-8-21-14)20(24)22-17(15)9-12/h2-11,21,23H,1H3,(H,22,24)/b16-11-
DMQHKIA	CS	COC1=C(C=CC(=C1)C2=CC3=C(C=C2)/C(=C/C4=CC=CN4)/C(=O)N3)O
DMQHKIA	IK	AYSXURJZVXBSRV-WJDWOHSUSA-N
DMQHKIA	IU	(3Z)-6-(4-hydroxy-3-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
DMQHKIA	DE	Discovery agent

DMUBM8X	ID	DMUBM8X
DMUBM8X	DN	A438079
DMUBM8X	HS	Investigative
DMUBM8X	SN	A-438079; A 438079
DMUBM8X	DT	Small molecular drug
DMUBM8X	PC	11673921
DMUBM8X	MW	306.15
DMUBM8X	FM	C13H9Cl2N5
DMUBM8X	IC	InChI=1S/C13H9Cl2N5/c14-11-5-1-4-10(12(11)15)13-17-18-19-20(13)8-9-3-2-6-16-7-9/h1-7H,8H2
DMUBM8X	CS	C1=CC(=C(C(=C1)Cl)Cl)C2=NN=NN2CC3=CN=CC=C3
DMUBM8X	IK	MMPAULQSJLVKHP-UHFFFAOYSA-N
DMUBM8X	IU	3-[[5-(2,3-dichlorophenyl)tetrazol-1-yl]methyl]pyridine
DMUBM8X	DE	Discovery agent

DMLMU63	ID	DMLMU63
DMLMU63	DN	A-443654
DMLMU63	HS	Investigative
DMLMU63	SN	A-4436554
DMLMU63	DT	Small molecular drug
DMLMU63	PC	10172943
DMLMU63	MW	397.5
DMLMU63	FM	C24H23N5O
DMLMU63	IC	InChI=1S/C24H23N5O/c1-15-22-10-16(6-7-24(22)29-28-15)17-9-20(13-26-11-17)30-14-19(25)8-18-12-27-23-5-3-2-4-21(18)23/h2-7,9-13,19,27H,8,14,25H2,1H3,(H,28,29)/t19-/m0/s1
DMLMU63	CS	CC1=C2C=C(C=CC2=NN1)C3=CC(=CN=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N
DMLMU63	IK	YWTBGJGMTBHQTM-IBGZPJMESA-N
DMLMU63	IU	(2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine
DMLMU63	CA	CAS 552325-16-3
DMLMU63	CB	CHEBI:91351
DMLMU63	DE	Discovery agent

DMN320E	ID	DMN320E
DMN320E	DN	A-558693
DMN320E	HS	Investigative
DMN320E	SN	A-705239; A-705253; Calpain inhibitors (neurological disorders); Calpain inhibitors, Knoll; Calpain inhibitors (neurological disorders), Abbott
DMN320E	CP	Knoll GmbH
DMN320E	DE	Neurological disorder

DM7R8DJ	ID	DM7R8DJ
DM7R8DJ	DN	A-582941
DM7R8DJ	HS	Investigative
DM7R8DJ	SN	A582941; A 582941
DM7R8DJ	DT	Small molecular drug
DM7R8DJ	PC	11173546
DM7R8DJ	MW	280.37
DM7R8DJ	FM	C17H20N4
DM7R8DJ	IC	InChI=1S/C17H20N4/c1-20-9-14-11-21(12-15(14)10-20)17-8-7-16(18-19-17)13-5-3-2-4-6-13/h2-8,14-15H,9-12H2,1H3
DM7R8DJ	CS	CN1CC2CN(CC2C1)C3=NN=C(C=C3)C4=CC=CC=C4
DM7R8DJ	IK	GTMRUYCIJSNXGB-UHFFFAOYSA-N
DM7R8DJ	IU	2-methyl-5-(6-phenylpyridazin-3-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole
DM7R8DJ	DE	Discovery agent

DM7W2ME	ID	DM7W2ME
DM7W2ME	DN	A61603
DM7W2ME	HS	Investigative
DM7W2ME	SN	A-61603; A 61603
DM7W2ME	DT	Small molecular drug
DM7W2ME	PC	4038180
DM7W2ME	MW	309.39
DM7W2ME	FM	C14H19N3O3S
DM7W2ME	IC	InChI=1S/C14H19N3O3S/c1-21(19,20)17-13-10-3-2-4-11(14-15-7-8-16-14)9(10)5-6-12(13)18/h5-6,11,17-18H,2-4,7-8H2,1H3,(H,15,16)
DM7W2ME	CS	CS(=O)(=O)NC1=C(C=CC2=C1CCCC2C3=NCCN3)O
DM7W2ME	IK	OQFCXJDXHCDLHX-UHFFFAOYSA-N
DM7W2ME	IU	N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide
DM7W2ME	CB	CHEBI:103854
DM7W2ME	DE	Discovery agent

DM9SXDI	ID	DM9SXDI
DM9SXDI	DN	A-620223
DM9SXDI	HS	Investigative
DM9SXDI	SN	A-866111; A-966492; ABT-472; ABT-999; PARP inhibitor, Abbott; PARP inhibitors, Abbott; Poly (ADP)ribose polymer inhibitor, Abbott; Poly (ADP)ribose inhibitors (cancer), Abbott
DM9SXDI	CP	Abbott Laboratories
DM9SXDI	DT	Small molecular drug
DM9SXDI	PC	9925908
DM9SXDI	MW	286.37
DM9SXDI	FM	C16H22N4O
DM9SXDI	IC	InChI=1S/C16H22N4O/c1-2-8-20-9-6-11(7-10-20)16-18-13-5-3-4-12(15(17)21)14(13)19-16/h3-5,11H,2,6-10H2,1H3,(H2,17,21)(H,18,19)
DM9SXDI	CS	CCCN1CCC(CC1)C2=NC3=C(C=CC=C3N2)C(=O)N
DM9SXDI	IK	KXSIHXHEHABEJX-UHFFFAOYSA-N
DM9SXDI	IU	2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide
DM9SXDI	CA	CAS 272769-49-0
DM9SXDI	DE	Solid tumour/cancer

DMJ6IMZ	ID	DMJ6IMZ
DMJ6IMZ	DN	A-62824
DMJ6IMZ	HS	Investigative
DMJ6IMZ	SN	A-62824; CHEMBL202864; SCHEMBL607791; BDBM50178926; 111279-87-9
DMJ6IMZ	DT	Small molecular drug
DMJ6IMZ	PC	10406223
DMJ6IMZ	MW	360.4
DMJ6IMZ	FM	C17H17FN4O2S
DMJ6IMZ	IC	InChI=1S/C17H17FN4O2S/c18-11-7-10-12(8-13(11)21-5-3-19-4-6-21)22(9-1-2-9)17-14(15(10)23)16(24)20-25-17/h7-9,19H,1-6H2,(H,20,24)
DMJ6IMZ	CS	C1CC1N2C3=CC(=C(C=C3C(=O)C4=C2SNC4=O)F)N5CCNCC5
DMJ6IMZ	IK	BEZDZMQEVWAVTH-UHFFFAOYSA-N
DMJ6IMZ	IU	9-cyclopropyl-6-fluoro-7-piperazin-1-yl-[1,2]thiazolo[5,4-b]quinoline-3,4-dione
DMJ6IMZ	DE	Discovery agent

DM5JSXI	ID	DM5JSXI
DM5JSXI	DN	A-641359
DM5JSXI	HS	Investigative
DM5JSXI	SN	CHEMBL381203; A-641359; N-(4-{4-Amino-1-[1-(Tetrahydro-2h-Pyran-4-Yl)piperidin-4-Yl]-1h-Pyrazolo[3,4-D]pyrimidin-3-Yl}-2-Methoxyphenyl)-1-Methyl-1h-Indole-2-Carboxamide; N-(4-(4-amino-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide; SCHEMBL4822105; BDBM50175207
DM5JSXI	DT	Small molecular drug
DM5JSXI	PC	9549185
DM5JSXI	MW	580.7
DM5JSXI	FM	C32H36N8O3
DM5JSXI	IC	InChI=1S/C32H36N8O3/c1-38-25-6-4-3-5-20(25)17-26(38)32(41)36-24-8-7-21(18-27(24)42-2)29-28-30(33)34-19-35-31(28)40(37-29)23-9-13-39(14-10-23)22-11-15-43-16-12-22/h3-8,17-19,22-23H,9-16H2,1-2H3,(H,36,41)(H2,33,34,35)
DM5JSXI	CS	CN1C2=CC=CC=C2C=C1C(=O)NC3=C(C=C(C=C3)C4=NN(C5=NC=NC(=C45)N)C6CCN(CC6)C7CCOCC7)OC
DM5JSXI	IK	CMFPSTWYLODPNE-UHFFFAOYSA-N
DM5JSXI	IU	N-[4-[4-amino-1-[1-(oxan-4-yl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methylindole-2-carboxamide
DM5JSXI	DE	Discovery agent

DMJ83LK	ID	DMJ83LK
DMJ83LK	DN	A-674563
DMJ83LK	HS	Investigative
DMJ83LK	SN	A 674563; A674563
DMJ83LK	DT	Small molecular drug
DMJ83LK	PC	11314340
DMJ83LK	MW	358.4
DMJ83LK	FM	C22H22N4O
DMJ83LK	IC	InChI=1S/C22H22N4O/c1-15-21-11-17(7-8-22(21)26-25-15)18-10-20(13-24-12-18)27-14-19(23)9-16-5-3-2-4-6-16/h2-8,10-13,19H,9,14,23H2,1H3,(H,25,26)/t19-/m0/s1
DMJ83LK	CS	CC1=C2C=C(C=CC2=NN1)C3=CC(=CN=C3)OC[C@H](CC4=CC=CC=C4)N
DMJ83LK	IK	BPNUQXPIQBZCMR-IBGZPJMESA-N
DMJ83LK	IU	(2S)-1-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxy-3-phenylpropan-2-amine
DMJ83LK	CA	CAS 552325-73-2
DMJ83LK	DE	Discovery agent

DMT6A7G	ID	DMT6A7G
DMT6A7G	DN	A-690344
DMT6A7G	HS	Investigative
DMT6A7G	SN	CHEMBL201115; A-690344; BDBM50177356
DMT6A7G	DT	Small molecular drug
DMT6A7G	PC	9806160
DMT6A7G	MW	468.5
DMT6A7G	FM	C22H31F3N6O2
DMT6A7G	IC	InChI=1S/C22H31F3N6O2/c1-15-14-31(20(33)28-18(15)32)8-6-5-7-29-9-11-30(12-10-29)17-13-16(22(23,24)25)26-19(27-17)21(2,3)4/h13-14H,5-12H2,1-4H3,(H,28,32,33)
DMT6A7G	CS	CC1=CN(C(=O)NC1=O)CCCCN2CCN(CC2)C3=NC(=NC(=C3)C(F)(F)F)C(C)(C)C
DMT6A7G	IK	LRAYIUHUAWSEDX-UHFFFAOYSA-N
DMT6A7G	IU	1-[4-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-5-methylpyrimidine-2,4-dione
DMT6A7G	DE	Schizophrenia

DMXOPFU	ID	DMXOPFU
DMXOPFU	DN	A-706149
DMXOPFU	HS	Investigative
DMXOPFU	SN	CHEMBL201232; A-706149; SCHEMBL3290844; FKHBHNWGBJHKGW-UHFFFAOYSA-N; BDBM50176440; 1-(4-(4-(2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)butyl)-3,4-dihydro-1H-benzo[b]azepine-2,5-dione
DMXOPFU	DT	Small molecular drug
DMXOPFU	PC	11237664
DMXOPFU	MW	517.6
DMXOPFU	FM	C27H34F3N5O2
DMXOPFU	IC	InChI=1S/C27H34F3N5O2/c1-26(2,3)25-31-22(27(28,29)30)18-23(32-25)34-16-14-33(15-17-34)12-6-7-13-35-20-9-5-4-8-19(20)21(36)10-11-24(35)37/h4-5,8-9,18H,6-7,10-17H2,1-3H3
DMXOPFU	CS	CC(C)(C)C1=NC(=CC(=N1)N2CCN(CC2)CCCCN3C(=O)CCC(=O)C4=CC=CC=C43)C(F)(F)F
DMXOPFU	IK	FKHBHNWGBJHKGW-UHFFFAOYSA-N
DMXOPFU	IU	1-[4-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-3,4-dihydro-1-benzazepine-2,5-dione
DMXOPFU	DE	Discovery agent

DMI7J1L	ID	DMI7J1L
DMI7J1L	DN	A-740003
DMI7J1L	HS	Investigative
DMI7J1L	SN	A-740003; 861393-28-4; A 740003; n-(1-(((cyanoamino)(5-quinolinylimino)methyl)amino)-2,2-dimethylpropyl)-3,4-dimethoxybenzeneacetamide; (E)-N-(1-((cyanamido(quinolin-5-ylamino)methylene)amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide; CHEMBL255787; SCHEMBL3357263; MolPort-044-567-676; EX-A1789; AKOS022184697; RL05324; CS-0297; Benzeneacetamide, N-(1-(((cyanoamino)(5-quinolinylamino)methylene)amino)-2,2-dimethylpropyl)-3,4-dimethoxy-; HY-50697; Benzeneacetamide, N-(1-(((cyanoamino)(5-quinolinylimino)methyl)ami
DMI7J1L	DT	Small molecular drug
DMI7J1L	PC	23232014
DMI7J1L	MW	474.6
DMI7J1L	FM	C26H30N6O3
DMI7J1L	IC	InChI=1S/C26H30N6O3/c1-26(2,3)24(31-23(33)15-17-11-12-21(34-4)22(14-17)35-5)32-25(29-16-27)30-20-10-6-9-19-18(20)8-7-13-28-19/h6-14,24H,15H2,1-5H3,(H,31,33)(H2,29,30,32)
DMI7J1L	CS	CC(C)(C)C(NC(=O)CC1=CC(=C(C=C1)OC)OC)/N=C(/NC#N)\\NC2=CC=CC3=C2C=CC=N3
DMI7J1L	IK	PUHSRMSFDASMAE-UHFFFAOYSA-N
DMI7J1L	IU	N-[1-[(E)-[(cyanoamino)-(quinolin-5-ylamino)methylidene]amino]-2,2-dimethylpropyl]-2-(3,4-dimethoxyphenyl)acetamide
DMI7J1L	CA	CAS 861393-28-4
DMI7J1L	DE	Discovery agent

DMT9N1I	ID	DMT9N1I
DMT9N1I	DN	A-76341
DMT9N1I	HS	Investigative
DMT9N1I	CP	Sankyo Co Ltd
DMT9N1I	DE	Diabetic complication

DMP78JY	ID	DMP78JY
DMP78JY	DN	A-770041
DMP78JY	HS	Investigative
DMP78JY	SN	A-770041; 869748-10-7; UNII-U9855G2ZPR; U9855G2ZPR; CHEMBL197603; KIN001-111; N-(4-{1-[4-(4-Acetylpiperazin-1-Yl)-Trans-Cyclohexyl]-4-Amino-1h-Pyrazolo[3,4-D]pyrimidin-3-Yl}-2-Methoxyphenyl)-1-Methyl-1h-Indole-2-Carboxamide; A 770041; Kinome_3267; 2c0o; MLS006010241; CHEMBL1970879; SCHEMBL15705796; CHEBI:91457; MolPort-039-139-535; C34H39N9O3; 3413AH; ZINC14210723; BDBM50175196; ABP001109; AKOS030526954; ZINC253387967; CS-0057; NCGC00386613-01; NCGC00346955-01; SMR004701317; HY-11011; L2G; 1H-Indole-2-carboxamide, N-(4-(1-(trans-4-(4-
DMP78JY	DT	Small molecular drug
DMP78JY	PC	9549184
DMP78JY	MW	621.7
DMP78JY	FM	C34H39N9O3
DMP78JY	IC	InChI=1S/C34H39N9O3/c1-21(44)41-14-16-42(17-15-41)24-9-11-25(12-10-24)43-33-30(32(35)36-20-37-33)31(39-43)23-8-13-26(29(19-23)46-3)38-34(45)28-18-22-6-4-5-7-27(22)40(28)2/h4-8,13,18-20,24-25H,9-12,14-17H2,1-3H3,(H,38,45)(H2,35,36,37)
DMP78JY	CS	CC(=O)N1CCN(CC1)C2CCC(CC2)N3C4=NC=NC(=C4C(=N3)C5=CC(=C(C=C5)NC(=O)C6=CC7=CC=CC=C7N6C)OC)N
DMP78JY	IK	ZMNWFTYYYCSSTF-UHFFFAOYSA-N
DMP78JY	IU	N-[4-[1-[4-(4-acetylpiperazin-1-yl)cyclohexyl]-4-aminopyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methylindole-2-carboxamide
DMP78JY	CA	CAS 869748-10-7
DMP78JY	CB	CHEBI:91457
DMP78JY	DE	Discovery agent

DMG6ZHO	ID	DMG6ZHO
DMG6ZHO	DN	A778317
DMG6ZHO	HS	Investigative
DMG6ZHO	SN	A-778317; A 778317
DMG6ZHO	DT	Small molecular drug
DMG6ZHO	PC	17757384
DMG6ZHO	MW	359.5
DMG6ZHO	FM	C23H25N3O
DMG6ZHO	IC	InChI=1S/C23H25N3O/c1-23(2,3)17-8-9-18-15(13-17)7-10-21(18)26-22(27)25-20-6-4-5-16-14-24-12-11-19(16)20/h4-6,8-9,11-14,21H,7,10H2,1-3H3,(H2,25,26,27)/t21-/m1/s1
DMG6ZHO	CS	CC(C)(C)C1=CC2=C(C=C1)[C@@H](CC2)NC(=O)NC3=CC=CC4=C3C=CN=C4
DMG6ZHO	IK	VPSCJCQPUGKRNC-OAQYLSRUSA-N
DMG6ZHO	IU	1-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-3-isoquinolin-5-ylurea
DMG6ZHO	DE	Discovery agent

DM6BRTF	ID	DM6BRTF
DM6BRTF	DN	A-794278
DM6BRTF	HS	Investigative
DM6BRTF	SN	compound 1ac [PMID: 16279797]; A 794278; A794278
DM6BRTF	DT	Small molecular drug
DM6BRTF	PC	11537456
DM6BRTF	MW	342.5
DM6BRTF	FM	C18H22N4OS
DM6BRTF	IC	InChI=1S/C18H22N4OS/c1-21(2)13-9-10-19-17-14(13)15-16(24-17)18(23)22(11-20-15)12-7-5-3-4-6-8-12/h9-12H,3-8H2,1-2H3
DM6BRTF	CS	CN(C)C1=C2C3=C(C(=O)N(C=N3)C4CCCCCC4)SC2=NC=C1
DM6BRTF	IK	WOADNNTWYZOWNV-UHFFFAOYSA-N
DM6BRTF	IU	5-cycloheptyl-13-(dimethylamino)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DM6BRTF	DE	Discovery agent

DMU965M	ID	DMU965M
DMU965M	DN	A-794282
DMU965M	HS	Investigative
DMU965M	SN	compound 1n [PMID: 16279797]; A 794282; A794282
DMU965M	DT	Small molecular drug
DMU965M	PC	11530404
DMU965M	MW	350.4
DMU965M	FM	C19H18N4OS
DMU965M	IC	InChI=1S/C19H18N4OS/c1-4-12-5-7-13(8-6-12)23-11-21-16-15-14(22(2)3)9-10-20-18(15)25-17(16)19(23)24/h5-11H,4H2,1-3H3
DMU965M	CS	CCC1=CC=C(C=C1)N2C=NC3=C(C2=O)SC4=NC=CC(=C34)N(C)C
DMU965M	IK	VCUKKMIXURRDKL-UHFFFAOYSA-N
DMU965M	IU	13-(dimethylamino)-5-(4-ethylphenyl)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMU965M	CA	CAS 869802-44-8
DMU965M	DE	Discovery agent

DM2W4IQ	ID	DM2W4IQ
DM2W4IQ	DN	A-795614
DM2W4IQ	HS	Investigative
DM2W4IQ	SN	CHEMBL520995; A-795614; SCHEMBL1862020; BDBM50264581; (R)-1-(1H-indazol-4-yl)-3-(5-(piperidin-1-yl)-2,3-dihydro-1H-inden-1-yl)urea
DM2W4IQ	DT	Small molecular drug
DM2W4IQ	PC	11451659
DM2W4IQ	MW	375.5
DM2W4IQ	FM	C22H25N5O
DM2W4IQ	IC	InChI=1S/C22H25N5O/c28-22(24-19-5-4-6-21-18(19)14-23-26-21)25-20-10-7-15-13-16(8-9-17(15)20)27-11-2-1-3-12-27/h4-6,8-9,13-14,20H,1-3,7,10-12H2,(H,23,26)(H2,24,25,28)/t20-/m1/s1
DM2W4IQ	CS	C1CCN(CC1)C2=CC3=C(C=C2)[C@@H](CC3)NC(=O)NC4=CC=CC5=C4C=NN5
DM2W4IQ	IK	SVYGRCSOIPQXGO-HXUWFJFHSA-N
DM2W4IQ	IU	1-(1H-indazol-4-yl)-3-[(1R)-5-piperidin-1-yl-2,3-dihydro-1H-inden-1-yl]urea
DM2W4IQ	DE	Discovery agent

DMHFPRJ	ID	DMHFPRJ
DMHFPRJ	DN	A-796260
DMHFPRJ	HS	Investigative
DMHFPRJ	SN	895155-26-7; (1-(2-morpholinoethyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; A-796260; UNII-5N69DXA53Z; CHEMBL262865; 5N69DXA53Z; A 796260; A-796,260; ZCFHOMLAFTWDFM-UHFFFAOYSA-N; A796260; Morpholino-ethyl analogue, 32; SCHEMBL2076954; CTK8B4187; BDBM21311; MolPort-023-278-969; ZINC14975818; ANW-44204; AKOS015999103; (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; KB-74376; AJ-65531; AS-19178; AX8228482; TC-132949; ST24020055; X5014; J3.566.431I
DMHFPRJ	DT	Small molecular drug
DMHFPRJ	PC	11584525
DMHFPRJ	MW	354.5
DMHFPRJ	FM	C22H30N2O2
DMHFPRJ	IC	InChI=1S/C22H30N2O2/c1-21(2)20(22(21,3)4)19(25)17-15-24(18-8-6-5-7-16(17)18)10-9-23-11-13-26-14-12-23/h5-8,15,20H,9-14H2,1-4H3
DMHFPRJ	CS	CC1(C(C1(C)C)C(=O)C2=CN(C3=CC=CC=C32)CCN4CCOCC4)C
DMHFPRJ	IK	ZCFHOMLAFTWDFM-UHFFFAOYSA-N
DMHFPRJ	IU	[1-(2-morpholin-4-ylethyl)indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone
DMHFPRJ	CA	CAS 895155-26-7
DMHFPRJ	DE	Pain

DML20N9	ID	DML20N9
DML20N9	DN	A-80040
DML20N9	HS	Investigative
DML20N9	SN	CHEMBL378186; A-80040; SCHEMBL16705052; BDBM50189633
DML20N9	DT	Small molecular drug
DML20N9	PC	11675600
DML20N9	MW	395.4
DML20N9	FM	C20H17N3O4S
DML20N9	IC	InChI=1S/C20H17N3O4S/c1-14(23(25)19(21)24)7-12-18-13-22-20(28-18)27-17-10-8-16(9-11-17)26-15-5-3-2-4-6-15/h2-6,8-11,13-14,25H,1H3,(H2,21,24)
DML20N9	CS	CC(C#CC1=CN=C(S1)OC2=CC=C(C=C2)OC3=CC=CC=C3)N(C(=O)N)O
DML20N9	IK	MCMUCDFOFIZPSA-UHFFFAOYSA-N
DML20N9	IU	1-hydroxy-1-[4-[2-(4-phenoxyphenoxy)-1,3-thiazol-5-yl]but-3-yn-2-yl]urea
DML20N9	DE	Discovery agent

DMWGRL8	ID	DMWGRL8
DMWGRL8	DN	A-803467
DMWGRL8	HS	Investigative
DMWGRL8	SN	A-803467; 944261-79-4; A 803467; UNII-339LBH1395; A803467; 5-(4-chlorophenyl)-N-(3,5-dimethoxyphenyl)furan-2-carboxamide; 5-(4-CHLOROPHENYL)-N-(3,5-DIMETHOXYPHENYL)-2-FURANCARBOXAMIDE; CHEMBL250699; 339LBH1395; 5-4(-Chlorophenyl)-N-(3,5-dimethoxyphenyl)furan-2-carboxamide; MLS006011118; GTPL5734; SCHEMBL9275137; CTK5H6562; EX-A083; DTXSID90241480; AOB2888; MolPort-006-069-060; HMS3656L08; BCP04519; 2-Furancarboxamide, 5-(4-chlorophenyl)-N-(3,5-dimethoxyphenyl)-; BN0738; ABP001000; ZINC14982453; MFCD10574689; BDBM50212239; s2785
DMWGRL8	TC	Analgesics
DMWGRL8	DT	Small molecular drug
DMWGRL8	PC	16038374
DMWGRL8	MW	357.8
DMWGRL8	FM	C19H16ClNO4
DMWGRL8	IC	InChI=1S/C19H16ClNO4/c1-23-15-9-14(10-16(11-15)24-2)21-19(22)18-8-7-17(25-18)12-3-5-13(20)6-4-12/h3-11H,1-2H3,(H,21,22)
DMWGRL8	CS	COC1=CC(=CC(=C1)NC(=O)C2=CC=C(O2)C3=CC=C(C=C3)Cl)OC
DMWGRL8	IK	VHKBTPQDHDSBSP-UHFFFAOYSA-N
DMWGRL8	IU	5-(4-chlorophenyl)-N-(3,5-dimethoxyphenyl)furan-2-carboxamide
DMWGRL8	CA	CAS 944261-79-4
DMWGRL8	DE	Pain

DMLC7HE	ID	DMLC7HE
DMLC7HE	DN	A804598
DMLC7HE	HS	Investigative
DMLC7HE	SN	A-804598; A 804598
DMLC7HE	DT	Small molecular drug
DMLC7HE	PC	53325874
DMLC7HE	MW	315.4
DMLC7HE	FM	C19H17N5
DMLC7HE	IC	InChI=1S/C19H17N5/c1-14(15-7-3-2-4-8-15)23-19(22-13-20)24-18-11-5-10-17-16(18)9-6-12-21-17/h2-12,14H,1H3,(H2,22,23,24)/t14-/m0/s1
DMLC7HE	CS	C[C@@H](C1=CC=CC=C1)N=C(NC#N)NC2=CC=CC3=C2C=CC=N3
DMLC7HE	IK	PQYCRDPLPKGSME-AWEZNQCLSA-N
DMLC7HE	IU	1-cyano-2-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine

DMQ5AJW	ID	DMQ5AJW
DMQ5AJW	DN	A-82186
DMQ5AJW	HS	Investigative
DMQ5AJW	SN	IDDB7311
DMQ5AJW	CP	Abbott Laboratories
DMQ5AJW	DE	Hypertension

DMPXKOE	ID	DMPXKOE
DMPXKOE	DN	A839977
DMPXKOE	HS	Investigative
DMPXKOE	SN	A-839977; A 839977
DMPXKOE	DT	Small molecular drug
DMPXKOE	PC	53325875
DMPXKOE	MW	413.3
DMPXKOE	FM	C19H14Cl2N6O
DMPXKOE	IC	InChI=1S/C19H14Cl2N6O/c20-14-7-5-8-15(18(14)21)27-19(24-25-26-27)23-12-13-6-1-2-9-16(13)28-17-10-3-4-11-22-17/h1-11H,12H2,(H,23,24,26)
DMPXKOE	CS	C1=CC=C(C(=C1)CNC2=NN=NN2C3=C(C(=CC=C3)Cl)Cl)OC4=CC=CC=N4
DMPXKOE	IK	GMVNBKZQJFRFAR-UHFFFAOYSA-N
DMPXKOE	IU	1-(2,3-dichlorophenyl)-N-[(2-pyridin-2-yloxyphenyl)methyl]tetrazol-5-amine
DMPXKOE	DE	Discovery agent

DM5TDEW	ID	DM5TDEW
DM5TDEW	DN	A-846714
DM5TDEW	HS	Investigative
DM5TDEW	SN	JMC516547 Compound 2; A-846714; 2-Aminopyrimidine analog., 4; SCHEMBL2166660; CHEMBL494678; BDBM26229
DM5TDEW	DT	Small molecular drug
DM5TDEW	PC	25130235
DM5TDEW	MW	294.35
DM5TDEW	FM	C16H18N6
DM5TDEW	IC	InChI=1S/C16H18N6/c1-21-6-8-22(9-7-21)15-10-14(19-16(18)20-15)13-4-2-12(11-17)3-5-13/h2-5,10H,6-9H2,1H3,(H2,18,19,20)
DM5TDEW	CS	CN1CCN(CC1)C2=NC(=NC(=C2)C3=CC=C(C=C3)C#N)N
DM5TDEW	IK	QFKQUMBUFVKQBH-UHFFFAOYSA-N
DM5TDEW	IU	4-[2-amino-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]benzonitrile
DM5TDEW	DE	Discovery agent

DMJBPR3	ID	DMJBPR3
DMJBPR3	DN	A-849531
DMJBPR3	HS	Investigative
DMJBPR3	CP	Abbott Laboratories
DMJBPR3	DE	Metabolic disorder

DMJCPSD	ID	DMJCPSD
DMJCPSD	DN	A-850002
DMJCPSD	HS	Investigative
DMJCPSD	SN	compound 28b [PMID: 16279797]; A 850002; A850002
DMJCPSD	DT	Small molecular drug
DMJCPSD	PC	11515548
DMJCPSD	MW	336.4
DMJCPSD	FM	C18H16N4OS
DMJCPSD	IC	InChI=1S/C18H16N4OS/c1-11-4-6-12(7-5-11)22-10-20-16-15-13(21(2)3)8-19-9-14(15)24-17(16)18(22)23/h4-10H,1-3H3
DMJCPSD	CS	CC1=CC=C(C=C1)N2C=NC3=C(C2=O)SC4=C3C(=CN=C4)N(C)C
DMJCPSD	IK	LPWKFUVWWQYLOD-UHFFFAOYSA-N
DMJCPSD	IU	13-(dimethylamino)-5-(4-methylphenyl)-8-thia-3,5,11-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,10,12-pentaen-6-one
DMJCPSD	DE	Discovery agent

DM96F8U	ID	DM96F8U
DM96F8U	DN	A-867744
DM96F8U	HS	Investigative
DM96F8U	SN	A867744; A 867744
DM96F8U	DT	Small molecular drug
DM96F8U	PC	23642319
DM96F8U	MW	402.9
DM96F8U	FM	C20H19ClN2O3S
DM96F8U	IC	InChI=1S/C20H19ClN2O3S/c1-3-20(24)18-12-19(14-4-6-15(21)7-5-14)23(13(18)2)16-8-10-17(11-9-16)27(22,25)26/h4-12H,3H2,1-2H3,(H2,22,25,26)
DM96F8U	CS	CCC(=O)C1=C(N(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)S(=O)(=O)N)C
DM96F8U	IK	ABACVOXFUHDKNZ-UHFFFAOYSA-N
DM96F8U	IU	4-[5-(4-chlorophenyl)-2-methyl-3-propanoylpyrrol-1-yl]benzenesulfonamide
DM96F8U	CA	CAS 1000279-69-5
DM96F8U	DE	Discovery agent

DM8IWUE	ID	DM8IWUE
DM8IWUE	DN	A-887755
DM8IWUE	HS	Investigative
DM8IWUE	CP	Abbott Laboratories
DM8IWUE	DE	Alzheimer disease

DMBF1OY	ID	DMBF1OY
DMBF1OY	DN	A-935142
DMBF1OY	HS	Investigative
DMBF1OY	SN	A935142; A 935142
DMBF1OY	DT	Small molecular drug
DMBF1OY	PC	25125452
DMBF1OY	MW	352.4
DMBF1OY	FM	C18H19F3N2O2
DMBF1OY	IC	InChI=1S/C18H19F3N2O2/c19-18(20,21)16-10-15(22-23-16)14-7-5-13(6-8-14)12-3-1-11(2-4-12)9-17(24)25/h5-8,10-12H,1-4,9H2,(H,22,23)(H,24,25)
DMBF1OY	CS	C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NNC(=C3)C(F)(F)F
DMBF1OY	IK	YPHFQSYEKIEMNC-UHFFFAOYSA-N
DMBF1OY	IU	2-[4-[4-[5-(trifluoromethyl)-1H-pyrazol-3-yl]phenyl]cyclohexyl]acetic acid
DMBF1OY	DE	Discovery agent

DMROD7Q	ID	DMROD7Q
DMROD7Q	DN	A-943931
DMROD7Q	HS	Investigative
DMROD7Q	SN	UNII-Q598HK01AO; A-943931; Q598HK01AO; 1027330-97-7; SCHEMBL602812; CHEMBL502347; BDBM26396; MolPort-035-936-414; SDTRYHWIXVHTLM-GFCCVEGCSA-N; ZINC40977166; NCGC00370827-02; 5H-Benzo(6,7)cyclohepta(1,2-d)pyrimidin-2-amine, 4-((3R)-3-amino-1-pyrrolidinyl)-6,7-dihydro-; 2,4-diamino-5,6-disubstituted pyrimidine, 10; 6-[(3R)-3-aminopyrrolidin-1-yl]-3,5-diazatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2(7),3,5,11,13-hexaen-4-amine
DMROD7Q	DT	Small molecular drug
DMROD7Q	PC	25068753
DMROD7Q	MW	295.4
DMROD7Q	FM	C17H21N5
DMROD7Q	IC	InChI=1S/C17H21N5/c18-12-8-9-22(10-12)16-14-7-3-5-11-4-1-2-6-13(11)15(14)20-17(19)21-16/h1-2,4,6,12H,3,5,7-10,18H2,(H2,19,20,21)/t12-/m1/s1
DMROD7Q	CS	C1CC2=CC=CC=C2C3=C(C1)C(=NC(=N3)N)N4CC[C@H](C4)N
DMROD7Q	IK	SDTRYHWIXVHTLM-GFCCVEGCSA-N
DMROD7Q	IU	6-[(3R)-3-aminopyrrolidin-1-yl]-3,5-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,5,11,13-hexaen-4-amine
DMROD7Q	CA	CAS 1027330-97-7
DMROD7Q	DE	Discovery agent

DMOY7TF	ID	DMOY7TF
DMOY7TF	DN	A-967079
DMOY7TF	HS	Investigative
DMOY7TF	SN	TRPA1 receptor antagonist (pain), Abbott
DMOY7TF	CP	Abbott Laboratories
DMOY7TF	DT	Small molecular drug
DMOY7TF	PC	60150207
DMOY7TF	MW	207.24
DMOY7TF	FM	C12H14FNO
DMOY7TF	IC	InChI=1S/C12H14FNO/c1-3-12(14-15)9(2)8-10-4-6-11(13)7-5-10/h4-8,15H,3H2,1-2H3/b9-8+,14-12-
DMOY7TF	CS	CC/C(=N/O)/C(=C/C1=CC=C(C=C1)F)/C
DMOY7TF	IK	HKROEBDHHKMNBZ-BYKJOZEVSA-N
DMOY7TF	IU	(NZ)-N-[(E)-1-(4-fluorophenyl)-2-methylpent-1-en-3-ylidene]hydroxylamine
DMOY7TF	DE	Pain

DMU34BK	ID	DMU34BK
DMU34BK	DN	A-987306
DMU34BK	HS	Investigative
DMU34BK	SN	SCHEMBL604437; CHEMBL519240; BDBM26226; MolPort-023-276-880; DJKJVWJQAVGLHJ-YPMHNXCESA-N; ZINC42887577; AKOS024457726; NCGC00370852-01; UNII-6BVK16R925 component DJKJVWJQAVGLHJ-YPMHNXCESA-N; (12S,17S)-6-(piperazin-1-yl)-11-oxa-3,5-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-1(10),2(7),3,5-tetraen-4-amine; (-)-(7aS*,11aS*)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3h]quinazolin-2-amine; (+/-)-(7aR*,11aR*)-5,6,7a,8,9,10,11,11a-Octahydro-4-(1-piperazinyl)-benzofuran[2,3-h]quinazolin-2-amine
DMU34BK	DT	Small molecular drug
DMU34BK	PC	44538833
DMU34BK	MW	327.4
DMU34BK	FM	C18H25N5O
DMU34BK	IC	InChI=1S/C18H25N5O/c19-18-21-16-12(17(22-18)23-9-7-20-8-10-23)5-6-14-15(16)11-3-1-2-4-13(11)24-14/h11,13,20H,1-10H2,(H2,19,21,22)/t11-,13+/m0/s1
DMU34BK	CS	C1CC[C@@H]2[C@H](C1)C3=C(O2)CCC4=C3N=C(N=C4N5CCNCC5)N
DMU34BK	IK	DJKJVWJQAVGLHJ-WCQYABFASA-N
DMU34BK	IU	(7aR,11aR)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro-[1]benzofuro[2,3-h]quinazolin-2-amine
DMU34BK	CA	CAS 1082954-71-9
DMU34BK	DE	Discovery agent

DME4ULA	ID	DME4ULA
DME4ULA	DN	A-993610
DME4ULA	HS	Investigative
DME4ULA	CP	Abbott
DME4ULA	TC	Analgesics
DME4ULA	PC	25224408
DME4ULA	MW	395.8
DME4ULA	FM	C19H17ClF3N3O
DME4ULA	IC	InChI=1S/C19H17ClF3N3O/c1-12-11-26(17-16(20)3-2-9-24-17)10-8-15(12)18(27)25-14-6-4-13(5-7-14)19(21,22)23/h2-9,12H,10-11H2,1H3,(H,25,27)/t12-/m1/s1
DME4ULA	CS	C[C@@H]1CN(CC=C1C(=O)NC2=CC=C(C=C2)C(F)(F)F)C3=C(C=CC=N3)Cl
DME4ULA	IK	IYXRQYVHUISAIP-GFCCVEGCSA-N
DME4ULA	IU	(3S)-1-(3-chloropyridin-2-yl)-3-methyl-N-[4-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-4-carboxamide
DME4ULA	DE	Pain

DMW73A8	ID	DMW73A8
DMW73A8	DN	AA-123
DMW73A8	HS	Investigative
DMW73A8	SN	BMP agonist (prostate cancer), Thrasos Therapeutics
DMW73A8	CP	Thrasos Therapeutics Inc
DMW73A8	DE	Prostate cancer

DM2BMAZ	ID	DM2BMAZ
DM2BMAZ	DN	AA-166
DM2BMAZ	HS	Investigative
DM2BMAZ	SN	BMP agonist (cartilage repair), Thrasos Therapeutics
DM2BMAZ	CP	Thrasos Therapeutics Inc
DM2BMAZ	DE	Articular cartilage disorder

DMCN4ZD	ID	DMCN4ZD
DMCN4ZD	DN	AA-184
DMCN4ZD	HS	Investigative
DMCN4ZD	SN	BMP agonist (acute kidney injury), Thrasos Therapeutics
DMCN4ZD	CP	Thrasos Therapeutics Inc
DMCN4ZD	DE	Kidney injury

DMBGTX9	ID	DMBGTX9
DMBGTX9	DN	AA-204
DMBGTX9	HS	Investigative
DMBGTX9	SN	BMP agonist (chronic kidney disease), Thrasos Therapeutics
DMBGTX9	CP	Thrasos Therapeutics Inc
DMBGTX9	DE	Kidney disease

DMI59T7	ID	DMI59T7
DMI59T7	DN	AA-29504
DMI59T7	HS	Investigative
DMI59T7	SN	Retigabine analogs (depression), Lundbeck
DMI59T7	CP	Lundbeck Research USA Inc
DMI59T7	DE	Major depressive disorder

DMNO51B	ID	DMNO51B
DMNO51B	DN	AAE-M-PBP-amine
DMNO51B	HS	Investigative
DMNO51B	SN	acetylaminoethyl-methyl-phenylbutoxyphenyl-amine
DMNO51B	DT	Small molecular drug
DMNO51B	PC	24763223
DMNO51B	MW	340.5
DMNO51B	FM	C21H28N2O2
DMNO51B	IC	InChI=1S/C21H28N2O2/c1-18(24)22-14-15-23(2)20-12-8-13-21(17-20)25-16-7-6-11-19-9-4-3-5-10-19/h3-5,8-10,12-13,17H,6-7,11,14-16H2,1-2H3,(H,22,24)
DMNO51B	CS	CC(=O)NCCN(C)C1=CC(=CC=C1)OCCCCC2=CC=CC=C2
DMNO51B	IK	VJIVACBGAAEDPS-UHFFFAOYSA-N
DMNO51B	IU	N-[2-[N-methyl-3-(4-phenylbutoxy)anilino]ethyl]acetamide
DMNO51B	DE	Discovery agent

DM35RFH	ID	DM35RFH
DM35RFH	DN	AAL-993
DM35RFH	HS	Investigative
DM35RFH	SN	AAL-993; 269390-77-4; CHEMBL153843; 2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl] benzamide; 2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide; 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide; 2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide; 2-[(pyridin-4-ylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide; 2-((pyridin-4-ylmethyl)amino)-N-(3-(trifluoromethyl)phenyl)benzamide; BLAFVGLBBOPRLP-UHFFFAOYSA-N; AC1O4QQI; anthranyl amide derivative C
DM35RFH	DT	Small molecular drug
DM35RFH	PC	6398883
DM35RFH	MW	371.4
DM35RFH	FM	C20H16F3N3O
DM35RFH	IC	InChI=1S/C20H16F3N3O/c21-20(22,23)15-4-3-5-16(12-15)26-19(27)17-6-1-2-7-18(17)25-13-14-8-10-24-11-9-14/h1-12,25H,13H2,(H,26,27)
DM35RFH	CS	C1=CC=C(C(=C1)C(=O)NC2=CC=CC(=C2)C(F)(F)F)NCC3=CC=NC=C3
DM35RFH	IK	BLAFVGLBBOPRLP-UHFFFAOYSA-N
DM35RFH	IU	2-(pyridin-4-ylmethylamino)-N-[3-(trifluoromethyl)phenyl]benzamide
DM35RFH	DE	Discovery agent

DMDBWT6	ID	DMDBWT6
DMDBWT6	DN	Abbott 14c
DMDBWT6	HS	Investigative
DMDBWT6	SN	2,4-diaminopyrimidine-based antagonist, 14c
DMDBWT6	DT	Small molecular drug
DMDBWT6	PC	11441554
DMDBWT6	MW	420.5
DMDBWT6	FM	C23H28N6O2
DMDBWT6	IC	InChI=1S/C23H28N6O2/c1-23(2,3)29-22(30)26-17-11-9-16(10-12-17)19-18(27-21(25)28-20(19)24)14-31-13-15-7-5-4-6-8-15/h4-12H,13-14H2,1-3H3,(H2,26,29,30)(H4,24,25,27,28)
DMDBWT6	CS	CC(C)(C)NC(=O)NC1=CC=C(C=C1)C2=C(N=C(N=C2N)N)COCC3=CC=CC=C3
DMDBWT6	IK	MLBYOWASRACYDH-UHFFFAOYSA-N
DMDBWT6	IU	1-tert-butyl-3-[4-[2,4-diamino-6-(phenylmethoxymethyl)pyrimidin-5-yl]phenyl]urea
DMDBWT6	DE	Discovery agent

DMHRPAM	ID	DMHRPAM
DMHRPAM	DN	ABBV-744
DMHRPAM	HS	Investigative
DMHRPAM	SN	ABBV744; UNII-9MX546E2SF; 9MX546E2SF; HWV; ABBV 744; SCHEMBL19463409
DMHRPAM	TC	Antiviral Agents
DMHRPAM	DT	Small molecular drug
DMHRPAM	PC	132010322
DMHRPAM	MW	491.6
DMHRPAM	FM	C28H30FN3O4
DMHRPAM	IC	InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)
DMHRPAM	CS	CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=C(C=CC(=C3)C(C)(C)O)OC4=C(C=C(C=C4C)F)C)C
DMHRPAM	IK	OEDSFMUSNZDJFD-UHFFFAOYSA-N
DMHRPAM	IU	N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
DMHRPAM	CA	CAS 2138861-99-9
DMHRPAM	DE	Coronavirus Disease 2019 (COVID-19)

DMA01OF	ID	DMA01OF
DMA01OF	DN	ABC-4
DMA01OF	HS	Investigative
DMA01OF	SN	FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma
DMA01OF	CP	XOMA Ltd
DMA01OF	DT	Antibody
DMA01OF	DE	Solid tumour/cancer

DM2AIE9	ID	DM2AIE9
DM2AIE9	DN	ABC-7
DM2AIE9	HS	Investigative
DM2AIE9	SN	RON tyrosine kinase targeted antibody (solid tumor), XOMA; Recepteur d'origine nantais tyrosine kinase targeted antibody (solid tumor), XOMA
DM2AIE9	CP	XOMA Ltd
DM2AIE9	DT	Antibody
DM2AIE9	DE	Solid tumour/cancer

DMW1Y2G	ID	DMW1Y2G
DMW1Y2G	DN	Abietic acid
DMW1Y2G	HS	Investigative
DMW1Y2G	SN	ABIETIC ACID; 514-10-3; Sylvic acid; Abietate; l-Abietic acid; Rosin Acid; 7,13-Abietadien-18-oic acid; Kyselina abietova; Kyselina abietova [Czech]; UNII-V3DHX33184; CCRIS 3183; Abieta-7,13-dien-18-oic acid; Abietic acid, technical; 13-Isopropylpodocarpa-7,13-dien-15-oic acid; EINECS 208-178-3; NSC 25149; Abietinic acid; AI3-17273; CHEBI:28987; V3DHX33184; NSC25149; (-)-Abietic acid; MFCD03423567; Abietic acid, 85%; NCGC00166273-01; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,6,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-,
DMW1Y2G	DT	Small molecular drug
DMW1Y2G	PC	10569
DMW1Y2G	MW	302.5
DMW1Y2G	FM	C20H30O2
DMW1Y2G	IC	InChI=1S/C20H30O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h7,12-13,16-17H,5-6,8-11H2,1-4H3,(H,21,22)/t16-,17+,19+,20+/m0/s1
DMW1Y2G	CS	CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCC[C@@]3(C)C(=O)O)C
DMW1Y2G	IK	RSWGJHLUYNHPMX-ONCXSQPRSA-N
DMW1Y2G	IU	(1R,4aR,4bR,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid
DMW1Y2G	CA	CAS 514-10-3
DMW1Y2G	CB	CHEBI:28987
DMW1Y2G	DE	Discovery agent

DM0LUOM	ID	DM0LUOM
DM0LUOM	DN	ABIO 09-01
DM0LUOM	HS	Investigative
DM0LUOM	SN	Antidepressants, Abiogen; BTG-1675A
DM0LUOM	CP	BTG plc
DM0LUOM	DE	Anxiety disorder

DMRC3A5	ID	DMRC3A5
DMRC3A5	DN	ABL127
DMRC3A5	HS	Investigative
DMRC3A5	SN	ABL-127; ABL 127
DMRC3A5	DT	Small molecular drug
DMRC3A5	PC	24856225
DMRC3A5	MW	332.4
DMRC3A5	FM	C17H20N2O5
DMRC3A5	IC	InChI=1S/C17H20N2O5/c1-23-15(21)18-14(20)17(13-10-6-7-11-13,19(18)16(22)24-2)12-8-4-3-5-9-12/h3-5,8-9,13H,6-7,10-11H2,1-2H3/t17-/m0/s1
DMRC3A5	CS	COC(=O)N1C(=O)[C@@](N1C(=O)OC)(C2CCCC2)C3=CC=CC=C3
DMRC3A5	IK	ZRHWCAFAIHTQKD-KRWDZBQOSA-N
DMRC3A5	IU	dimethyl (3R)-3-cyclopentyl-4-oxo-3-phenyldiazetidine-1,2-dicarboxylate
DMRC3A5	DE	Discovery agent

DMKN10X	ID	DMKN10X
DMKN10X	DN	Abloid
DMKN10X	HS	Investigative
DMKN10X	SN	Amyloid protein deposition inhibitor (Alzheimer's disease), Virionics
DMKN10X	CP	Virionics Corp
DMKN10X	DE	Alzheimer disease

DMQPHFU	ID	DMQPHFU
DMQPHFU	DN	AB-MECA
DMQPHFU	HS	Investigative
DMQPHFU	SN	AB-MECA; 152918-26-8; (2S,3S,4R,5R)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide; AB-MECA, solid; AC1NSJSB; [3H]AB-MECA; GTPL416; SCHEMBL16585151; CTK8E8476; BDBM21242; DTXSID70415501; LDYMCRRFCMRFKB-MOROJQBDSA-N; MolPort-003-940-100; ZINC4475069; AKOS030526575; CS-5220; NCGC00162075-03; NCGC00162075-02; NCGC00162075-01; HY-19365; RT-011146; N6-(4-Aminobenzyl)-N-methylcarboxamidoadenosine; J-008959; 5'-Methylamino-N-(4-aminobenzyl)-5'-oxo-5'-deoxyadenosine
DMQPHFU	DT	Small molecular drug
DMQPHFU	PC	5310992
DMQPHFU	MW	399.4
DMQPHFU	FM	C18H21N7O4
DMQPHFU	IC	InChI=1S/C18H21N7O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-2-4-10(19)5-3-9/h2-5,7-8,12-14,18,26-27H,6,19H2,1H3,(H,20,28)(H,21,22,23)/t12-,13+,14-,18+/m0/s1
DMQPHFU	CS	CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)N)O)O
DMQPHFU	IK	LDYMCRRFCMRFKB-MOROJQBDSA-N
DMQPHFU	IU	(2S,3S,4R,5R)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
DMQPHFU	CA	CAS 152918-26-8
DMQPHFU	DE	Discovery agent

DME8G7F	ID	DME8G7F
DME8G7F	DN	AB-NECA
DME8G7F	HS	Investigative
DME8G7F	SN	aminobenzyl-5'-N-ethylcarboxamidoadenosine
DME8G7F	DT	Small molecular drug
DME8G7F	PC	57340157
DME8G7F	MW	457.4
DME8G7F	FM	C20H23N7O6
DME8G7F	IC	InChI=1S/C20H23N7O6/c1-2-21-17(31)18(32)26-20-24-15(23-10-6-4-3-5-7-10)12-16(25-20)27(9-22-12)19-14(30)13(29)11(8-28)33-19/h3-7,9,11,13-14,19,28-30H,2,8H2,1H3,(H,21,31)(H2,23,24,25,26,32)/t11-,13-,14-,19-/m1/s1
DME8G7F	CS	CCNC(=O)C(=O)NC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NC4=CC=CC=C4
DME8G7F	IK	ZLZSAUQLHYWSOL-HLFSEMCJSA-N
DME8G7F	IU	N'-[6-anilino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-ethyloxamide
DME8G7F	DE	Discovery agent

DMV6DAO	ID	DMV6DAO
DMV6DAO	DN	abnormal cannabidiol
DMV6DAO	HS	Investigative
DMV6DAO	SN	Abn-CBD; CAY10429
DMV6DAO	DT	Small molecular drug
DMV6DAO	PC	89949
DMV6DAO	MW	314.5
DMV6DAO	FM	C21H30O2
DMV6DAO	IC	InChI=1S/C21H30O2/c1-5-6-7-8-16-12-17(22)13-20(23)21(16)19-11-15(4)9-10-18(19)14(2)3/h11-13,18-19,22-23H,2,5-10H2,1,3-4H3/t18-,19+/m0/s1
DMV6DAO	CS	CCCCCC1=C(C(=CC(=C1)O)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C
DMV6DAO	IK	YWEZXUNAYVCODW-RBUKOAKNSA-N
DMV6DAO	IU	4-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
DMV6DAO	CA	CAS 22972-55-0
DMV6DAO	DE	Discovery agent

DMJ6MUE	ID	DMJ6MUE
DMJ6MUE	DN	ABT-116
DMJ6MUE	HS	Investigative
DMJ6MUE	SN	A-1165442
DMJ6MUE	CP	Abbott Laboratories
DMJ6MUE	PC	46890602
DMJ6MUE	MW	432.5
DMJ6MUE	FM	C23H27F3N4O
DMJ6MUE	IC	InChI=1S/C23H27F3N4O/c1-22(2,3)11-10-15-12-17(23(24,25)26)9-8-16(15)13-27-21(31)29-19-6-5-7-20-18(19)14-28-30(20)4/h5-9,12,14H,10-11,13H2,1-4H3,(H2,27,29,31)
DMJ6MUE	CS	CC(C)(C)CCC1=C(C=CC(=C1)C(F)(F)F)CNC(=O)NC2=C3C=NN(C3=CC=C2)C
DMJ6MUE	IK	SMJCAASNPAKOIB-UHFFFAOYSA-N
DMJ6MUE	IU	1-[[2-(3,3-dimethylbutyl)-4-(trifluoromethyl)phenyl]methyl]-3-(1-methylindazol-4-yl)urea
DMJ6MUE	CA	CAS 1008529-42-7
DMJ6MUE	DE	Pain

DMZ3YTO	ID	DMZ3YTO
DMZ3YTO	DN	ABT-341
DMZ3YTO	HS	Investigative
DMZ3YTO	SN	CHEMBL437341
DMZ3YTO	DT	Small molecular drug
DMZ3YTO	PC	11974440
DMZ3YTO	MW	445.4
DMZ3YTO	FM	C19H17F6N5O
DMZ3YTO	IC	InChI=1S/C19H17F6N5O/c20-12-7-14(22)13(21)6-11(12)10-2-1-9(5-15(10)26)17(31)29-3-4-30-16(8-29)27-28-18(30)19(23,24)25/h1,6-7,10,15H,2-5,8,26H2/t10-,15+/m1/s1
DMZ3YTO	CS	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C3=CC[C@@H]([C@H](C3)N)C4=CC(=C(C=C4F)F)F
DMZ3YTO	IK	NVVSPGQEXMJZIR-BMIGLBTASA-N
DMZ3YTO	IU	[(4R,5S)-5-amino-4-(2,4,5-trifluorophenyl)cyclohexen-1-yl]-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone
DMZ3YTO	CA	CAS 913623-69-5
DMZ3YTO	DE	Discovery agent

DM6J57N	ID	DM6J57N
DM6J57N	DN	ABT-670
DM6J57N	HS	Investigative
DM6J57N	SN	ABT-670; UNII-4L6071XH2J; CHEMBL219182; 630119-43-6; 4L6071XH2J; GTPL8439; ABT670; SCHEMBL4010523; CTK2B0090; DTXSID30212235; ABT 670; ZINC35075418; BDBM50200050; compound 6b [PMID 17149874]; CS-6805; 3-methyl-n-(1-oxy-3',4',5',6'-tetrahydro-2'h-(2,4'-bipyridine)-1'-ylmethyl)benzamide; HY-19483; 3-methyl-N-[[4-(1-oxidopyridin-1-ium-2-yl)piperidin-1-yl]methyl]benzamide; Benzamide, 3-methyl-N-[[4-(1-oxido-2-pyridinyl)-1-piperidinyl]methyl]-
DM6J57N	DT	Small molecular drug
DM6J57N	PC	16094676
DM6J57N	MW	325.4
DM6J57N	FM	C19H23N3O2
DM6J57N	IC	InChI=1S/C19H23N3O2/c1-15-5-4-6-17(13-15)19(23)20-14-21-11-8-16(9-12-21)18-7-2-3-10-22(18)24/h2-7,10,13,16H,8-9,11-12,14H2,1H3,(H,20,23)
DM6J57N	CS	CC1=CC(=CC=C1)C(=O)NCN2CCC(CC2)C3=CC=CC=[N+]3[O-]
DM6J57N	IK	PUMMPCXNEPHBNN-UHFFFAOYSA-N
DM6J57N	IU	3-methyl-N-[[4-(1-oxidopyridin-1-ium-2-yl)piperidin-1-yl]methyl]benzamide
DM6J57N	CA	CAS 630119-43-6
DM6J57N	DE	Discovery agent

DM79DSN	ID	DM79DSN
DM79DSN	DN	ABTAA
DM79DSN	HS	Investigative
DM79DSN	DT	Antibody
DM79DSN	DE	Sepsis

DMC02FP	ID	DMC02FP
DMC02FP	DN	Abyssinin I
DMC02FP	HS	Investigative
DMC02FP	SN	CHEMBL389736
DMC02FP	DT	Small molecular drug
DMC02FP	PC	10761522
DMC02FP	MW	368.4
DMC02FP	FM	C21H20O6
DMC02FP	IC	InChI=1S/C21H20O6/c1-21(2)5-4-11-6-12(7-18(25-3)20(11)27-21)16-10-15(24)19-14(23)8-13(22)9-17(19)26-16/h4-9,16,22-23H,10H2,1-3H3/t16-/m0/s1
DMC02FP	CS	CC1(C=CC2=C(O1)C(=CC(=C2)[C@@H]3CC(=O)C4=C(C=C(C=C4O3)O)O)OC)C
DMC02FP	IK	SDUMAACMVUGGAC-INIZCTEOSA-N
DMC02FP	IU	(2S)-5,7-dihydroxy-2-(8-methoxy-2,2-dimethylchromen-6-yl)-2,3-dihydrochromen-4-one
DMC02FP	DE	Discovery agent

DMR7IGZ	ID	DMR7IGZ
DMR7IGZ	DN	Abyssinin II
DMR7IGZ	HS	Investigative
DMR7IGZ	SN	5'-Prenylhomoeriodictyol; abyssinin II; CHEMBL388722; 671781-82-1; Abyssinoflavanone II; AC1L9CV8; SCHEMBL4743888; DTXSID10331832; ZINC4098362; LMPK12140439; BDBM50212397; C09831
DMR7IGZ	DT	Small molecular drug
DMR7IGZ	PC	442457
DMR7IGZ	MW	370.4
DMR7IGZ	FM	C21H22O6
DMR7IGZ	IC	InChI=1S/C21H22O6/c1-11(2)4-5-12-6-13(7-19(26-3)21(12)25)17-10-16(24)20-15(23)8-14(22)9-18(20)27-17/h4,6-9,17,22-23,25H,5,10H2,1-3H3/t17-/m0/s1
DMR7IGZ	CS	CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)OC)O)C
DMR7IGZ	IK	UQFQODVSORPELA-KRWDZBQOSA-N
DMR7IGZ	IU	(2S)-5,7-dihydroxy-2-[4-hydroxy-3-methoxy-5-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DMR7IGZ	CA	CAS 671781-82-1
DMR7IGZ	DE	Discovery agent

DMEYQF9	ID	DMEYQF9
DMEYQF9	DN	Abyssinoflavanone VI
DMEYQF9	HS	Investigative
DMEYQF9	SN	CHEMBL389650
DMEYQF9	DT	Small molecular drug
DMEYQF9	PC	10551087
DMEYQF9	MW	440.5
DMEYQF9	FM	C25H28O7
DMEYQF9	IC	InChI=1S/C25H28O7/c1-24(2)6-5-12-7-14(15-10-20(29)25(3,4)32-23(15)22(12)31-24)18-11-17(28)21-16(27)8-13(26)9-19(21)30-18/h7-9,18,20,26-27,29H,5-6,10-11H2,1-4H3
DMEYQF9	CS	CC1(CCC2=CC(=C3CC(C(OC3=C2O1)(C)C)O)C4CC(=O)C5=C(C=C(C=C5O4)O)O)C
DMEYQF9	IK	ZAGCAZVMJBNNSU-UHFFFAOYSA-N
DMEYQF9	IU	5,7-dihydroxy-2-(3-hydroxy-2,2,9,9-tetramethyl-3,4,7,8-tetrahydropyrano[3,2-h]chromen-5-yl)-2,3-dihydrochromen-4-one
DMEYQF9	DE	Discovery agent

DMTVQSL	ID	DMTVQSL
DMTVQSL	DN	Abyssinoflavanone VII
DMTVQSL	HS	Investigative
DMTVQSL	SN	abyssinoflavanone VII; CHEMBL229220
DMTVQSL	DT	Small molecular drug
DMTVQSL	PC	16737250
DMTVQSL	MW	424.5
DMTVQSL	FM	C25H28O6
DMTVQSL	IC	InChI=1S/C25H28O6/c1-13(2)5-6-15-7-16(8-17(25(15)30)9-19(27)14(3)4)22-12-21(29)24-20(28)10-18(26)11-23(24)31-22/h5,7-8,10-11,19,22,26-28,30H,3,6,9,12H2,1-2,4H3/t19?,22-/m0/s1
DMTVQSL	CS	CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)CC(C(=C)C)O)O)C
DMTVQSL	IK	FZUJHUDJFJCWMT-BPARTEKVSA-N
DMTVQSL	IU	(2S)-5,7-dihydroxy-2-[4-hydroxy-3-(2-hydroxy-3-methylbut-3-enyl)-5-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DMTVQSL	DE	Discovery agent

DMH3CK2	ID	DMH3CK2
DMH3CK2	DN	ABYSSINONE V
DMH3CK2	HS	Investigative
DMH3CK2	SN	5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one; NSC618154; NSC 618154; AC1L2QBU; CHEMBL454332; CTK5E4111; NSC-618154; 5,7,4'-trihydroxy-3',5'-diprenylflavanone; 4H-1-Benzopyran-4-one,3-Dihydro-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl]-, (S)-; 4H-1-Benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methyl-2-buten-1-yl)phenyl]-,(2S)-; 4H-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl)-, (S)-
DMH3CK2	DT	Small molecular drug
DMH3CK2	PC	442153
DMH3CK2	MW	408.5
DMH3CK2	FM	C25H28O5
DMH3CK2	IC	InChI=1S/C25H28O5/c1-14(2)5-7-16-9-18(10-17(25(16)29)8-6-15(3)4)22-13-21(28)24-20(27)11-19(26)12-23(24)30-22/h5-6,9-12,22,26-27,29H,7-8,13H2,1-4H3/t22-/m0/s1
DMH3CK2	CS	CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)C
DMH3CK2	IK	LQHKFMYWTKORCE-QFIPXVFZSA-N
DMH3CK2	IU	(2S)-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DMH3CK2	CA	CAS 77263-11-7
DMH3CK2	CB	CHEBI:2368
DMH3CK2	DE	Discovery agent

DM9YAVX	ID	DM9YAVX
DM9YAVX	DN	Abyssinone-IV
DM9YAVX	HS	Investigative
DM9YAVX	SN	CHEMBL470454; Abyssinone IV; abyssinone-IV; AC1OK505; ZINC4716488; BDBM50241806
DM9YAVX	DT	Small molecular drug
DM9YAVX	PC	7330513
DM9YAVX	MW	392.5
DM9YAVX	FM	C25H28O4
DM9YAVX	IC	InChI=1S/C25H28O4/c1-15(2)5-7-17-11-19(12-18(25(17)28)8-6-16(3)4)23-14-22(27)21-10-9-20(26)13-24(21)29-23/h5-6,9-13,23,26,28H,7-8,14H2,1-4H3/t23-/m0/s1
DM9YAVX	CS	CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)[C@@H]2CC(=O)C3=C(O2)C=C(C=C3)O)C
DM9YAVX	IK	JBQLRZGPTDOWQA-QHCPKHFHSA-N
DM9YAVX	IU	(2S)-7-hydroxy-2-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DM9YAVX	DE	Discovery agent

DMZUY93	ID	DMZUY93
DMZUY93	DN	Abyssinone-VI-4-O-methyl ether
DMZUY93	HS	Investigative
DMZUY93	SN	CHEMBL470865; abyssinone-VI-4-O-methyl ether; Abyssinone VI 4-O-methyl ether
DMZUY93	DT	Small molecular drug
DMZUY93	PC	11995582
DMZUY93	MW	406.5
DMZUY93	FM	C26H30O4
DMZUY93	IC	InChI=1S/C26H30O4/c1-17(2)6-9-20-14-19(15-21(26(20)30-5)10-7-18(3)4)8-13-24(28)23-12-11-22(27)16-25(23)29/h6-8,11-16,27,29H,9-10H2,1-5H3/b13-8+
DMZUY93	CS	CC(=CCC1=CC(=CC(=C1OC)CC=C(C)C)/C=C/C(=O)C2=C(C=C(C=C2)O)O)C
DMZUY93	IK	AHQPCANDOCWXDN-MDWZMJQESA-N
DMZUY93	IU	(E)-1-(2,4-dihydroxyphenyl)-3-[4-methoxy-3,5-bis(3-methylbut-2-enyl)phenyl]prop-2-en-1-one
DMZUY93	DE	Discovery agent

DMZ0RP5	ID	DMZ0RP5
DMZ0RP5	DN	AC-(D)PHE-PRO-BOROHOMOLYS-OH
DMZ0RP5	HS	Investigative
DMZ0RP5	SN	AC-(D)PHE-PRO-BOROHOMOLYS-OH; AC1NRARZ; DB07659; N-acetyl-D-phenylalanyl-N-[(1R)-6-amino-1-(dihydroxyboranyl)hexyl]-L-prolinamide; (1R)-6-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}hexylboronic acid; [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-6-aminohexyl]boronic acid
DMZ0RP5	DT	Small molecular drug
DMZ0RP5	PC	5288066
DMZ0RP5	MW	446.4
DMZ0RP5	FM	C22H35BN4O5
DMZ0RP5	IC	InChI=1S/C22H35BN4O5/c1-16(28)25-18(15-17-9-4-2-5-10-17)22(30)27-14-8-11-19(27)21(29)26-20(23(31)32)12-6-3-7-13-24/h2,4-5,9-10,18-20,31-32H,3,6-8,11-15,24H2,1H3,(H,25,28)(H,26,29)/t18-,19+,20+/m1/s1
DMZ0RP5	CS	B([C@H](CCCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DMZ0RP5	IK	AILSWIBFGYYZTK-AABGKKOBSA-N
DMZ0RP5	IU	[(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-6-aminohexyl]boronic acid
DMZ0RP5	DE	Discovery agent

DMPHV7K	ID	DMPHV7K
DMPHV7K	DN	AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH
DMPHV7K	HS	Investigative
DMPHV7K	SN	AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH; AC1NRAS2; DB07660; N-acetyl-D-phenylalanyl-N-[(1R)-4-amino-1-(dihydroxyboranyl)butyl]-L-prolinamide; (1R)-4-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}butylboronic acid; [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-aminobutyl]boronic acid
DMPHV7K	DT	Small molecular drug
DMPHV7K	PC	5288067
DMPHV7K	MW	418.3
DMPHV7K	FM	C20H31BN4O5
DMPHV7K	IC	InChI=1S/C20H31BN4O5/c1-14(26)23-16(13-15-7-3-2-4-8-15)20(28)25-12-6-9-17(25)19(27)24-18(21(29)30)10-5-11-22/h2-4,7-8,16-18,29-30H,5-6,9-13,22H2,1H3,(H,23,26)(H,24,27)/t16-,17+,18+/m1/s1
DMPHV7K	CS	B([C@H](CCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DMPHV7K	IK	YKWKWNKWBGQECF-SQNIBIBYSA-N
DMPHV7K	IU	[(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-aminobutyl]boronic acid
DMPHV7K	DE	Discovery agent

DM2YWRL	ID	DM2YWRL
DM2YWRL	DN	AC-(D)PHE-PRO-BOROLYS-OH
DM2YWRL	HS	Investigative
DM2YWRL	SN	AC-(D)PHE-PRO-BOROLYS-OH; CHEMBL100109; AC1NRART; BDBM50288414; DB07658; N-acetyl-D-phenylalanyl-N-[(1R)-5-amino-1-(dihydroxyboranyl)pentyl]-L-prolinamide; 1-(2-Acetylamino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid (5-amino-1-dihydroxyboranyl-pentyl)-amide; [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-aminopentyl]boronic acid; (1R)-5-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}pentylboronic acid
DM2YWRL	DT	Small molecular drug
DM2YWRL	PC	5288064
DM2YWRL	MW	432.3
DM2YWRL	FM	C21H33BN4O5
DM2YWRL	IC	InChI=1S/C21H33BN4O5/c1-15(27)24-17(14-16-8-3-2-4-9-16)21(29)26-13-7-10-18(26)20(28)25-19(22(30)31)11-5-6-12-23/h2-4,8-9,17-19,30-31H,5-7,10-14,23H2,1H3,(H,24,27)(H,25,28)/t17-,18+,19+/m1/s1
DM2YWRL	CS	B([C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DM2YWRL	IK	UCQIHCRMWNRFNP-QYZOEREBSA-N
DM2YWRL	IU	[(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-aminopentyl]boronic acid
DM2YWRL	DE	Discovery agent

DMRLOGP	ID	DMRLOGP
DMRLOGP	DN	Ac-[CEHdFRWC]-NH2
DMRLOGP	HS	Investigative
DMRLOGP	SN	CHEMBL385556; Ac-[CEHdFRWC]-NH2
DMRLOGP	PC	44400398
DMRLOGP	MW	1019.2
DMRLOGP	FM	C45H58N14O10S2
DMRLOGP	IC	InChI=1S/C45H58N14O10S2/c1-24(60)53-36-22-71-70-21-35(38(46)63)59-42(67)33(17-26-19-51-29-11-6-5-10-28(26)29)57-39(64)30(12-7-15-50-45(47)48)54-41(66)32(16-25-8-3-2-4-9-25)56-43(68)34(18-27-20-49-23-52-27)58-40(65)31(55-44(36)69)13-14-37(61)62/h2-6,8-11,19-20,23,30-36,51H,7,12-18,21-22H2,1H3,(H2,46,63)(H,49,52)(H,53,60)(H,54,66)(H,55,69)(H,56,68)(H,57,64)(H,58,65)(H,59,67)(H,61,62)(H4,47,48,50)/t30-,31+,32-,33+,34-,35+,36+/m0/s1
DMRLOGP	CS	CC(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC1=O)CCC(=O)O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N
DMRLOGP	IK	DCRRHKOGXQUJTJ-VCFUPWAGSA-N
DMRLOGP	IU	3-[(4S,7R,10S,13S,16S,19R,22S)-22-acetamido-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMRLOGP	DE	Discovery agent

DM9IN4T	ID	DM9IN4T
DM9IN4T	DN	Ac-[CFWKFC]-NH2
DM9IN4T	HS	Investigative
DM9IN4T	SN	CHEMBL1163471; Ac-[CFWKFC]-NH2
DM9IN4T	DT	Small molecular drug
DM9IN4T	PC	11125778
DM9IN4T	MW	872.1
DM9IN4T	FM	C43H53N9O7S2
DM9IN4T	IC	InChI=1S/C43H53N9O7S2/c1-26(53)47-37-25-61-60-24-36(38(45)54)52-41(57)34(21-28-14-6-3-7-15-28)49-39(55)32(18-10-11-19-44)48-42(58)35(22-29-23-46-31-17-9-8-16-30(29)31)51-40(56)33(50-43(37)59)20-27-12-4-2-5-13-27/h2-9,12-17,23,32-37,46H,10-11,18-22,24-25,44H2,1H3,(H2,45,54)(H,47,53)(H,48,58)(H,49,55)(H,50,59)(H,51,56)(H,52,57)/t32-,33-,34-,35-,36-,37-/m0/s1
DM9IN4T	CS	CC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC=CC=C2)CC3=CNC4=CC=CC=C43)CCCCN)CC5=CC=CC=C5)C(=O)N
DM9IN4T	IK	PRZDRTMXFMEFAP-DUGSHLAESA-N
DM9IN4T	IU	(4R,7S,10S,13S,16S,19R)-19-acetamido-10-(4-aminobutyl)-7,16-dibenzyl-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM9IN4T	DE	Discovery agent

DMW24UH	ID	DMW24UH
DMW24UH	DN	Ac-[CFWkYC]-NH2
DMW24UH	HS	Investigative
DMW24UH	SN	CHEMBL1163477; Ac-[CFWKYC]-NH2
DMW24UH	DT	Small molecular drug
DMW24UH	PC	11007453
DMW24UH	MW	888.1
DMW24UH	FM	C43H53N9O8S2
DMW24UH	IC	InChI=1S/C43H53N9O8S2/c1-25(53)47-37-24-62-61-23-36(38(45)55)52-41(58)34(20-27-14-16-29(54)17-15-27)49-39(56)32(13-7-8-18-44)48-42(59)35(21-28-22-46-31-12-6-5-11-30(28)31)51-40(57)33(50-43(37)60)19-26-9-3-2-4-10-26/h2-6,9-12,14-17,22,32-37,46,54H,7-8,13,18-21,23-24,44H2,1H3,(H2,45,55)(H,47,53)(H,48,59)(H,49,56)(H,50,60)(H,51,57)(H,52,58)/t32-,33-,34+,35-,36-,37-/m0/s1
DMW24UH	CS	CC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC=CC=C2)CC3=CNC4=CC=CC=C43)CCCCN)CC5=CC=C(C=C5)O)C(=O)N
DMW24UH	IK	UHSPHALTSYXFRP-PCRAMSICSA-N
DMW24UH	IU	(4R,7R,10S,13S,16S,19R)-19-acetamido-10-(4-aminobutyl)-16-benzyl-7-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMW24UH	DE	Discovery agent

DMFKV97	ID	DMFKV97
DMFKV97	DN	AC1LG8KT
DMFKV97	HS	Investigative
DMFKV97	SN	BAS 01816608; TCS JNK 5a
DMFKV97	DT	Small molecular drug
DMFKV97	PC	766949
DMFKV97	MW	332.4
DMFKV97	FM	C20H16N2OS
DMFKV97	IC	InChI=1S/C20H16N2OS/c21-12-17-15-9-3-4-11-18(15)24-20(17)22-19(23)16-10-5-7-13-6-1-2-8-14(13)16/h1-2,5-8,10H,3-4,9,11H2,(H,22,23)
DMFKV97	CS	C1CCC2=C(C1)C(=C(S2)NC(=O)C3=CC=CC4=CC=CC=C43)C#N
DMFKV97	IK	WQGDQGAFSDMBLA-UHFFFAOYSA-N
DMFKV97	IU	N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)naphthalene-1-carboxamide
DMFKV97	CA	CAS 312917-14-9
DMFKV97	CB	CHEBI:91453
DMFKV97	DE	Discovery agent

DMSKE1I	ID	DMSKE1I
DMSKE1I	DN	AC261066
DMSKE1I	HS	Investigative
DMSKE1I	SN	AC 261066; AC-261066
DMSKE1I	DT	Small molecular drug
DMSKE1I	PC	11530459
DMSKE1I	MW	353.4
DMSKE1I	FM	C17H20FNO4S
DMSKE1I	IC	InChI=1S/C17H20FNO4S/c1-3-4-7-22-8-9-23-15-11(2)24-16(19-15)12-5-6-13(17(20)21)14(18)10-12/h5-6,10H,3-4,7-9H2,1-2H3,(H,20,21)
DMSKE1I	CS	CCCCOCCOC1=C(SC(=N1)C2=CC(=C(C=C2)C(=O)O)F)C
DMSKE1I	IK	HSAOETBFVAWNRP-UHFFFAOYSA-N
DMSKE1I	IU	4-[4-(2-butoxyethoxy)-5-methyl-1,3-thiazol-2-yl]-2-fluorobenzoic acid
DMSKE1I	CA	CAS 870773-76-5
DMSKE1I	DE	Discovery agent

DM4G60V	ID	DM4G60V
DM4G60V	DN	AC265347
DM4G60V	HS	Investigative
DM4G60V	SN	AC-265347; AC 265347
DM4G60V	DT	Small molecular drug
DM4G60V	PC	52943938
DM4G60V	MW	283.4
DM4G60V	FM	C17H17NOS
DM4G60V	IC	InChI=1S/C17H17NOS/c1-11-8-9-13(12(2)10-11)17(3,19)16-18-14-6-4-5-7-15(14)20-16/h4-10,19H,1-3H3
DM4G60V	CS	CC1=CC(=C(C=C1)C(C)(C2=NC3=CC=CC=C3S2)O)C
DM4G60V	IK	IGSZVEPQZANNAB-UHFFFAOYSA-N
DM4G60V	IU	1-(1,3-benzothiazol-2-yl)-1-(2,4-dimethylphenyl)ethanol
DM4G60V	DE	Discovery agent

DMNUE4H	ID	DMNUE4H
DMNUE4H	DN	AC-3174
DMNUE4H	HS	Investigative
DMNUE4H	SN	GLP-1 agonist (type 2 diabetes), Amylin Pharmaceuticals; Glucagon-like peptide-1 receptor agonist (type 2diabetes/non-alcoholic steatohepatitis), Amylin Pharmaceuticals; (Leu14)exendin-4
DMNUE4H	CP	Amylin Pharmaceuticals Inc
DMNUE4H	DT	Small molecular drug
DMNUE4H	PC	817098
DMNUE4H	MW	192.44
DMNUE4H	FM	C5H3BrClN
DMNUE4H	IC	InChI=1S/C5H3BrClN/c6-5-2-1-4(7)3-8-5/h1-3H
DMNUE4H	CS	C1=CC(=NC=C1Cl)Br
DMNUE4H	IK	BZUUVQCSPHPUQA-UHFFFAOYSA-N
DMNUE4H	IU	2-bromo-5-chloropyridine
DMNUE4H	CA	CAS 40473-01-6
DMNUE4H	DE	Non-alcoholic steatohepatitis

DM4JNY9	ID	DM4JNY9
DM4JNY9	DN	AC55649
DM4JNY9	HS	Investigative
DM4JNY9	SN	AC 55649; AC-55649
DM4JNY9	DT	Small molecular drug
DM4JNY9	PC	1714884
DM4JNY9	MW	310.4
DM4JNY9	FM	C21H26O2
DM4JNY9	IC	InChI=1S/C21H26O2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)19-13-15-20(16-14-19)21(22)23/h9-16H,2-8H2,1H3,(H,22,23)
DM4JNY9	CS	CCCCCCCCC1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)O
DM4JNY9	IK	HXBKPYIEQLLNBK-UHFFFAOYSA-N
DM4JNY9	IU	4-(4-octylphenyl)benzoic acid
DM4JNY9	CA	CAS 59662-49-6
DM4JNY9	CB	CHEBI:95048
DM4JNY9	DE	Discovery agent

DMXS72J	ID	DMXS72J
DMXS72J	DN	AC-710
DMXS72J	HS	Investigative
DMXS72J	SN	CSF1R inhibitor (cancer), Ambit Biosciences; CSF1R inhibitor (cancer/autoimmune/inflammatory disease), Ambit Biosciences
DMXS72J	CP	Ambit Biosciences Corp
DMXS72J	DT	Small molecular drug
DMXS72J	PC	54760053
DMXS72J	MW	562.7
DMXS72J	FM	C31H42N6O4
DMXS72J	IC	InChI=1S/C31H42N6O4/c1-9-37-30(5,6)17-23(18-31(37,7)8)40-22-14-15-24(32-19-22)27(38)33-20-10-12-21(13-11-20)34-28(39)35-26-16-25(41-36-26)29(2,3)4/h10-16,19,23H,9,17-18H2,1-8H3,(H,33,38)(H2,34,35,36,39)
DMXS72J	CS	CCN1C(CC(CC1(C)C)OC2=CN=C(C=C2)C(=O)NC3=CC=C(C=C3)NC(=O)NC4=NOC(=C4)C(C)(C)C)(C)C
DMXS72J	IK	JVCWPUFNLFSKFS-UHFFFAOYSA-N
DMXS72J	IU	N-[4-[(5-tert-butyl-1,2-oxazol-3-yl)carbamoylamino]phenyl]-5-(1-ethyl-2,2,6,6-tetramethylpiperidin-4-yl)oxypyridine-2-carboxamide
DMXS72J	DE	Autoimmune diabetes

DM367MF	ID	DM367MF
DM367MF	DN	AC-7954
DM367MF	HS	Investigative
DM367MF	SN	AC7954; AC 7954
DM367MF	DT	Small molecular drug
DM367MF	PC	9797568
DM367MF	MW	329.8
DM367MF	FM	C19H20ClNO2
DM367MF	IC	InChI=1S/C19H20ClNO2/c1-21(2)12-11-19(15-7-9-16(20)10-8-15)13-14-5-3-4-6-17(14)18(22)23-19/h3-10H,11-13H2,1-2H3
DM367MF	CS	CN(C)CCC1(CC2=CC=CC=C2C(=O)O1)C3=CC=C(C=C3)Cl
DM367MF	IK	HIVBATDUVFEJFZ-UHFFFAOYSA-N
DM367MF	IU	3-(4-chlorophenyl)-3-[2-(dimethylamino)ethyl]-4H-isochromen-1-one
DM367MF	CB	CHEBI:103978
DM367MF	DE	Discovery agent

DM09BJ4	ID	DM09BJ4
DM09BJ4	DN	AC-8632
DM09BJ4	HS	Investigative
DM09BJ4	SN	5-(Tetradecyloxy)-2-furoic acid; TOFA; 54857-86-2; 5-(Tetradecyloxy)-2-furancarboxylic acid; 5-Tetradecyloxy-2-furonic acid; Rmi 14514; UNII-BI12FRY055; 2-Furancarboxylic acid, 5-(tetradecyloxy)-; MDL 14514; RMI-14514; BRN 0539681; 5-(tetradecyloxy)furan-2-carboxylic acid; BI12FRY055; CHEBI:77936; C19H32O4; 2-Furancarboxylic acid,5-(tetradecyloxy)-; AC1Q5UHU; AC1L3GNQ; 5-(tetradecyloxy)furoic acid; SCHEMBL543676; 5-tetradecyloxy-2-furoic acid; GTPL5280; CHEMBL1562779; TOFA, RMI 14514; CTK5A2675; DTXSID60203338;  Acetyl-coenzyme A carboxylase inhibitor (Parkinson's disease), Accera; Acetyl-coenzyme A carboxylase inhibitor (Parkinson's disease), Neuera
DM09BJ4	CP	Accera Inc
DM09BJ4	DT	Small molecular drug
DM09BJ4	PC	115175
DM09BJ4	MW	324.5
DM09BJ4	FM	C19H32O4
DM09BJ4	IC	InChI=1S/C19H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22-18-15-14-17(23-18)19(20)21/h14-15H,2-13,16H2,1H3,(H,20,21)
DM09BJ4	CS	CCCCCCCCCCCCCCOC1=CC=C(O1)C(=O)O
DM09BJ4	IK	CZRCFAOMWRAFIC-UHFFFAOYSA-N
DM09BJ4	IU	5-tetradecoxyfuran-2-carboxylic acid
DM09BJ4	CA	CAS 54857-86-2
DM09BJ4	CB	CHEBI:77936
DM09BJ4	DE	Parkinson disease

DMACYPW	ID	DMACYPW
DMACYPW	DN	ACAA
DMACYPW	HS	Investigative
DMACYPW	SN	ACA
DMACYPW	DT	Small molecular drug
DMACYPW	PC	5353376
DMACYPW	MW	337.4
DMACYPW	FM	C21H23NO3
DMACYPW	IC	InChI=1S/C21H23NO3/c1-2-3-4-7-16-10-12-17(13-11-16)14-15-20(23)22-19-9-6-5-8-18(19)21(24)25/h5-6,8-15H,2-4,7H2,1H3,(H,22,23)(H,24,25)/b15-14+
DMACYPW	CS	CCCCCC1=CC=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O
DMACYPW	IK	GAMRBCZMOOMBSQ-CCEZHUSRSA-N
DMACYPW	IU	2-[[(E)-3-(4-pentylphenyl)prop-2-enoyl]amino]benzoic acid
DMACYPW	CA	CAS 99196-74-4
DMACYPW	CB	CHEBI:114200
DMACYPW	DE	Discovery agent

DMQOB0X	ID	DMQOB0X
DMQOB0X	DN	Acacetin
DMQOB0X	HS	Investigative
DMQOB0X	SN	acacetin; 480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; Acacetine; 4'-Methoxyapigenin; Buddleoflavonol; Linarisenin; Akatsetin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; ACAETIN; 4'-Methoxy-5,7-dihydroxyflavone; NSC76061; EINECS 207-552-3; KWI7J0A2CC
DMQOB0X	DT	Small molecular drug
DMQOB0X	PC	5280442
DMQOB0X	MW	284.26
DMQOB0X	FM	C16H12O5
DMQOB0X	IC	InChI=1S/C16H12O5/c1-20-11-4-2-9(3-5-11)14-8-13(19)16-12(18)6-10(17)7-15(16)21-14/h2-8,17-18H,1H3
DMQOB0X	CS	COC1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O
DMQOB0X	IK	DANYIYRPLHHOCZ-UHFFFAOYSA-N
DMQOB0X	IU	5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one
DMQOB0X	CA	CAS 480-44-4
DMQOB0X	CB	CHEBI:15335
DMQOB0X	DE	Discovery agent

DMJ3C20	ID	DMJ3C20
DMJ3C20	DN	Ac-Ala-Pro-Val-(2-benzoxazole)
DMJ3C20	HS	Investigative
DMJ3C20	SN	CHEMBL438709
DMJ3C20	DT	Small molecular drug
DMJ3C20	PC	44454029
DMJ3C20	MW	428.5
DMJ3C20	FM	C22H28N4O5
DMJ3C20	IC	InChI=1S/C22H28N4O5/c1-12(2)18(19(28)21-24-15-8-5-6-10-17(15)31-21)25-20(29)16-9-7-11-26(16)22(30)13(3)23-14(4)27/h5-6,8,10,12-13,16,18H,7,9,11H2,1-4H3,(H,23,27)(H,25,29)/t13-,16-,18-/m0/s1
DMJ3C20	CS	C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)C2=NC3=CC=CC=C3O2)NC(=O)C
DMJ3C20	IK	BITOROACNLSRME-OWQGQXMQSA-N
DMJ3C20	IU	(2S)-1-[(2S)-2-acetamidopropanoyl]-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]pyrrolidine-2-carboxamide
DMJ3C20	DE	Discovery agent

DMZDFRI	ID	DMZDFRI
DMZDFRI	DN	Acanthus ilicifolius Linn
DMZDFRI	HS	Investigative
DMZDFRI	SN	AC1L1B2B; CBiol_001885; KBioGR_000483; KBioSS_000483; BSPBio_001143; (-)-Huperzine A-d5 (Major); CHEMBL3184073; KBio3_000886; CTK8E6796; KBio2_003051; BDBM10441; KBio2_005619; KBio2_000483; KBio3_000885; Bio2_000402; Bio1_001149; Bio1_000660; HMS1990I05; Bio2_000882; Bio1_000171; AKOS032962044; AN-1052; KS-0000000G; IDI1_002157; NCGC00163246-01; FT-0642946; N1881; Acarviostatin III03; Acarviostatin IV03
DMZDFRI	DT	Small molecular drug
DMZDFRI	PC	1253
DMZDFRI	MW	242.32
DMZDFRI	FM	C15H18N2O
DMZDFRI	IC	InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)
DMZDFRI	CS	CC=C1C2CC3=C(C1(CC(=C2)C)N)C=CC(=O)N3
DMZDFRI	IK	ZRJBHWIHUMBLCN-UHFFFAOYSA-N
DMZDFRI	IU	1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one
DMZDFRI	CA	CAS 102518-79-6
DMZDFRI	DE	Discovery agent

DMS9COH	ID	DMS9COH
DMS9COH	DN	Acarbose Derived Hexasaccharide
DMS9COH	HS	Investigative
DMS9COH	DT	Small molecular drug
DMS9COH	PC	46936851
DMS9COH	MW	969.9
DMS9COH	FM	C37H63NO28
DMS9COH	IC	InChI=1S/C37H63NO28/c1-8-15(19(46)26(53)35(59-8)65-31-12(5-41)62-34(28(55)23(31)50)58-7-14-18(45)20(47)25(52)33(57)60-14)38-10-2-9(3-39)30(22(49)16(10)43)64-37-29(56)24(51)32(13(6-42)63-37)66-36-27(54)21(48)17(44)11(4-40)61-36/h2,8,10-57H,3-7H2,1H3/t8-,10+,11+,12+,13-,14+,15-,16-,17+,18+,19+,20-,21-,22+,23-,24-,25+,26-,27+,28-,29-,30-,31-,32-,33+,34-,35+,36-,37+/m1/s1
DMS9COH	CS	C[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@@H](O[C@H]([C@@H]([C@H]2O)O)OC[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)O)O)O)O)CO)O)O)N[C@H]4C=C([C@H]([C@H]([C@@H]4O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O[C@@H]6[C@H]([C@@H]([C@H]([C@@H](O6)CO)O)O)O)O)O)CO
DMS9COH	IK	MBNITLCAVXHYER-AGOKNQOUSA-N
DMS9COH	IU	(2S,3S,4R,5R,6S)-6-[[(2R,3R,4R,5S,6S)-5-[(2S,3R,4S,5S,6R)-5-[[(1S,4R,5S,6R)-4-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5,6-dihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]-3,4-dihydroxy-6-methyloxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
DMS9COH	DE	Discovery agent

DMYHADT	ID	DMYHADT
DMYHADT	DN	Ac-Asp-Arg-Leu-Asp-Ser-OH
DMYHADT	HS	Investigative
DMYHADT	SN	CHEMBL238484; Ac-Asp-Arg-Leu-Asp-Ser-OH; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420
DMYHADT	DT	Small molecular drug
DMYHADT	PC	11764797
DMYHADT	MW	646.6
DMYHADT	FM	C25H42N8O12
DMYHADT	IC	InChI=1S/C25H42N8O12/c1-11(2)7-14(21(41)32-16(9-19(38)39)23(43)33-17(10-34)24(44)45)31-20(40)13(5-4-6-28-25(26)27)30-22(42)15(8-18(36)37)29-12(3)35/h11,13-17,34H,4-10H2,1-3H3,(H,29,35)(H,30,42)(H,31,40)(H,32,41)(H,33,43)(H,36,37)(H,38,39)(H,44,45)(H4,26,27,28)/t13-,14-,15-,16-,17-/m0/s1
DMYHADT	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMYHADT	IK	MBZXDXZGPJKBRJ-WOYTXXSLSA-N
DMYHADT	IU	(3S)-3-acetamido-4-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMYHADT	DE	Discovery agent

DMT74F5	ID	DMT74F5
DMT74F5	DN	AcAsp-D-Gla-Leu-Ile-Cha-Cys
DMT74F5	HS	Investigative
DMT74F5	SN	CHEMBL179084; AcAsp-D-Gla-Leu-Ile-Cha-Cys; AC1NX3UI; BDBM50158804; (4S)-4-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-[[(2S)-1-[[(2S,3R)-1-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMT74F5	DT	Small molecular drug
DMT74F5	PC	5742851
DMT74F5	MW	786.9
DMT74F5	FM	C35H58N6O12S
DMT74F5	IC	InChI=1S/C35H58N6O12S/c1-6-19(4)29(34(51)39-24(15-21-10-8-7-9-11-21)31(48)40-26(17-54)35(52)53)41-33(50)23(14-18(2)3)38-30(47)22(12-13-27(43)44)37-32(49)25(16-28(45)46)36-20(5)42/h18-19,21-26,29,54H,6-17H2,1-5H3,(H,36,42)(H,37,49)(H,38,47)(H,39,51)(H,40,48)(H,41,50)(H,43,44)(H,45,46)(H,52,53)/t19-,22+,23+,24+,25+,26+,29+/m1/s1
DMT74F5	CS	CC[C@@H](C)[C@@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMT74F5	IK	CSWPZICAVWHBCE-ZZOXDLJQSA-N
DMT74F5	IU	(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMT74F5	DE	Discovery agent

DMDC71B	ID	DMDC71B
DMDC71B	DN	AcAsp-D-Glu-Leu-Glu-Cha-Cys
DMDC71B	HS	Investigative
DMDC71B	SN	AcAsp-D-Glu-Leu-Glu-Cha-Cys; CHEMBL60967; AC1LAOO4; BDBM50096410; AcAsp-D-Glu-Leu-Glu-.beta.-Cyclohexylalanine-Cys; Ac-L-Asp-D-Glu-L-Leu-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-[[(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDC71B	DT	Small molecular drug
DMDC71B	PC	492320
DMDC71B	MW	802.9
DMDC71B	FM	C34H54N6O14S
DMDC71B	IC	InChI=1S/C34H54N6O14S/c1-17(2)13-22(38-29(48)20(9-11-26(42)43)37-33(52)24(15-28(46)47)35-18(3)41)31(50)36-21(10-12-27(44)45)30(49)39-23(14-19-7-5-4-6-8-19)32(51)40-25(16-55)34(53)54/h17,19-25,55H,4-16H2,1-3H3,(H,35,41)(H,36,50)(H,37,52)(H,38,48)(H,39,49)(H,40,51)(H,42,43)(H,44,45)(H,46,47)(H,53,54)/t20-,21+,22+,23+,24+,25+/m1/s1
DMDC71B	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMDC71B	IK	SYHFABLPDKKGNQ-RFXJPFPRSA-N
DMDC71B	IU	(4S)-4-[[(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDC71B	DE	Discovery agent

DMXQATR	ID	DMXQATR
DMXQATR	DN	AcAsp-Gla-Leu-Ile-Cha-Cys
DMXQATR	HS	Investigative
DMXQATR	DT	Small molecular drug
DMXQATR	PC	44305052
DMXQATR	MW	830.9
DMXQATR	FM	C36H58N6O14S
DMXQATR	IC	InChI=1S/C36H58N6O14S/c1-6-18(4)28(33(51)39-23(13-20-10-8-7-9-11-20)30(48)40-25(16-57)36(55)56)41-31(49)22(12-17(2)3)38-34(52)29(21(35(53)54)14-26(44)45)42-32(50)24(15-27(46)47)37-19(5)43/h17-18,20-25,28-29,57H,6-16H2,1-5H3,(H,37,43)(H,38,52)(H,39,51)(H,40,48)(H,41,49)(H,42,50)(H,44,45)(H,46,47)(H,53,54)(H,55,56)/t18?,21?,22-,23-,24-,25-,28-,29+/m0/s1
DMXQATR	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C(CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMXQATR	IK	SBWANKMZZMQXKQ-JHOOERKCSA-N
DMXQATR	IU	2-[(1R)-1-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]butanedioic acid
DMXQATR	DE	Discovery agent

DMHZ5W3	ID	DMHZ5W3
DMHZ5W3	DN	AcAsp-Glu-Cha-Val-Prb-Cpg
DMHZ5W3	HS	Investigative
DMHZ5W3	SN	CHEMBL360983; AcAsp-Glu-Cha-Val-Prb-Cpg
DMHZ5W3	DT	Small molecular drug
DMHZ5W3	PC	44388180
DMHZ5W3	MW	842.9
DMHZ5W3	FM	C41H58N6O13
DMHZ5W3	IC	InChI=1S/C41H58N6O13/c1-23(2)34(39(57)47-21-27(60-22-26-12-8-5-9-13-26)19-31(47)38(56)46-41(16-17-41)40(58)59)45-37(55)29(18-25-10-6-4-7-11-25)44-35(53)28(14-15-32(49)50)43-36(54)30(20-33(51)52)42-24(3)48/h5,8-9,12-13,23,25,27-31,34H,4,6-7,10-11,14-22H2,1-3H3,(H,42,48)(H,43,54)(H,44,53)(H,45,55)(H,46,56)(H,49,50)(H,51,52)(H,58,59)/t27-,28-,29-,30-,31-,34-/m0/s1
DMHZ5W3	CS	CC(C)[C@@H](C(=O)N1C[C@H](C[C@H]1C(=O)NC2(CC2)C(=O)O)OCC3=CC=CC=C3)NC(=O)[C@H](CC4CCCCC4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMHZ5W3	IK	DDYNDQYNGBVAAZ-HWKKFYSMSA-N
DMHZ5W3	IU	1-[[(2S,4S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-cyclohexylpropanoyl]amino]-3-methylbutanoyl]-4-phenylmethoxypyrrolidine-2-carbonyl]amino]cyclopropane-1-carboxylic acid
DMHZ5W3	DE	Discovery agent

DMDH5EJ	ID	DMDH5EJ
DMDH5EJ	DN	AcAsp-Glu-Cha-Val-Prb-Cys
DMDH5EJ	HS	Investigative
DMDH5EJ	SN	AcAsp-Glu-Cha-Val-Prb-Cys; CHEMBL179963
DMDH5EJ	DT	Small molecular drug
DMDH5EJ	PC	44388179
DMDH5EJ	MW	863
DMDH5EJ	FM	C40H58N6O13S
DMDH5EJ	IC	InChI=1S/C40H58N6O13S/c1-22(2)34(39(56)46-19-26(59-20-25-12-8-5-9-13-25)17-31(46)38(55)44-30(21-60)40(57)58)45-37(54)28(16-24-10-6-4-7-11-24)43-35(52)27(14-15-32(48)49)42-36(53)29(18-33(50)51)41-23(3)47/h5,8-9,12-13,22,24,26-31,34,60H,4,6-7,10-11,14-21H2,1-3H3,(H,41,47)(H,42,53)(H,43,52)(H,44,55)(H,45,54)(H,48,49)(H,50,51)(H,57,58)/t26-,27+,28+,29+,30?,31+,34+/m1/s1
DMDH5EJ	CS	CC(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)NC(CS)C(=O)O)OCC2=CC=CC=C2)NC(=O)[C@H](CC3CCCCC3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMDH5EJ	IK	UINXWQSPCZCPNY-MKVQYLHRSA-N
DMDH5EJ	IU	(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S,4R)-2-[(1-carboxy-2-sulfanylethyl)carbamoyl]-4-phenylmethoxypyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDH5EJ	DE	Discovery agent

DMEB8UA	ID	DMEB8UA
DMEB8UA	DN	AcAsp-Glu-Dif-Glu-Cha-Cys
DMEB8UA	HS	Investigative
DMEB8UA	SN	CHEMBL417559; Ac-Asp-Glu-Dif-Glu-Cha-Cys-OH; AcAsp-Glu-Dif-Glu-Cha-Cys; (4S)-4-[[(2S)-2-acetamido-4-hydroxy-4-oxo-butanoyl]amino]-5-[[(1S)-1-benzhydryl-2-[[(1S)-1-[[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-2-hydroxy-2-oxo-1-(sulfanylmethyl)ethyl]amino]-2-oxo-ethyl]carbamoyl]-4-hydroxy-4-oxo-butyl]amino]-2-oxo-ethyl]amino]-5-oxo-pentanoic acid; AC1LA689; BDBM50084685; Ac-Asp-Glu-3,3-Diphenylalanine-GLu-beta-Cyclohexylalanine-Cys-OH; Ac-L-Asp-L-Glu-3,3-Diphenyl-L-Ala-L-Glu-3-cyclohexyl-L-Ala-L-Cys-OH
DMEB8UA	DT	Small molecular drug
DMEB8UA	PC	482211
DMEB8UA	MW	913
DMEB8UA	FM	C43H56N6O14S
DMEB8UA	IC	InChI=1S/C43H56N6O14S/c1-24(50)44-31(22-35(55)56)41(60)45-29(18-20-34(53)54)39(58)49-37(36(26-13-7-3-8-14-26)27-15-9-4-10-16-27)42(61)46-28(17-19-33(51)52)38(57)47-30(21-25-11-5-2-6-12-25)40(59)48-32(23-64)43(62)63/h3-4,7-10,13-16,25,28-32,36-37,64H,2,5-6,11-12,17-23H2,1H3,(H,44,50)(H,45,60)(H,46,61)(H,47,57)(H,48,59)(H,49,58)(H,51,52)(H,53,54)(H,55,56)(H,62,63)/t28-,29-,30-,31-,32-,37-/m0/s1
DMEB8UA	CS	CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CS)C(=O)O
DMEB8UA	IK	UJAUCRPOZPWCGV-XJJOYFJPSA-N
DMEB8UA	IU	(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DMEB8UA	DE	Discovery agent

DMPQ8Z9	ID	DMPQ8Z9
DMPQ8Z9	DN	AcAsp-Glu-Dif-Glu-Cha-Fab
DMPQ8Z9	HS	Investigative
DMPQ8Z9	SN	CHEMBL349186; AcAsp-Glu-Dif-Glu-Cha-Fab; AC1L9WIG; BDBM50110121; Ac-L-Asp-L-Glu-3,3-Diphenyl-L-Ala-L-Glu-3-cyclohexyl-L-Ala-[(3S)-2-oxo-3-(2,2-difluoroethyl)-betaAla-]-OH; 3-[2-(2-{2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino}-4-carboxy-butyrylamino)-3-cyclohexyl-propionylamino]-5,5-difluoro-2-oxo-pentanoic acid
DMPQ8Z9	DT	Small molecular drug
DMPQ8Z9	PC	457393
DMPQ8Z9	MW	959
DMPQ8Z9	FM	C45H56F2N6O15
DMPQ8Z9	IC	InChI=1S/C45H56F2N6O15/c1-24(54)48-32(23-36(59)60)43(65)49-29(18-20-35(57)58)41(63)53-38(37(26-13-7-3-8-14-26)27-15-9-4-10-16-27)44(66)50-28(17-19-34(55)56)40(62)52-31(21-25-11-5-2-6-12-25)42(64)51-30(22-33(46)47)39(61)45(67)68/h3-4,7-10,13-16,25,28-33,37-38H,2,5-6,11-12,17-23H2,1H3,(H,48,54)(H,49,65)(H,50,66)(H,51,64)(H,52,62)(H,53,63)(H,55,56)(H,57,58)(H,59,60)(H,67,68)/t28-,29-,30-,31-,32-,38-/m0/s1
DMPQ8Z9	CS	CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O
DMPQ8Z9	IK	FIGPTAABOPCRSH-BHTNCQBCSA-N
DMPQ8Z9	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3,3-diphenylpropanoyl]amino]-4-carboxybutanoyl]amino]-3-cyclohexylpropanoyl]amino]-5,5-difluoro-2-oxopentanoic acid
DMPQ8Z9	DE	Discovery agent

DM6IP17	ID	DM6IP17
DM6IP17	DN	AcAsp-Glu-Dif-Ile-Cha-Cys
DM6IP17	HS	Investigative
DM6IP17	SN	CHEMBL61390; AcAsp-Glu-Dif-Ile-Cha-Cys
DM6IP17	DT	Small molecular drug
DM6IP17	PC	44305085
DM6IP17	MW	897
DM6IP17	FM	C44H60N6O12S
DM6IP17	IC	InChI=1S/C44H60N6O12S/c1-4-25(2)37(42(59)47-31(22-27-14-8-5-9-15-27)40(57)48-33(24-63)44(61)62)49-43(60)38(36(28-16-10-6-11-17-28)29-18-12-7-13-19-29)50-39(56)30(20-21-34(52)53)46-41(58)32(23-35(54)55)45-26(3)51/h6-7,10-13,16-19,25,27,30-33,36-38,63H,4-5,8-9,14-15,20-24H2,1-3H3,(H,45,51)(H,46,58)(H,47,59)(H,48,57)(H,49,60)(H,50,56)(H,52,53)(H,54,55)(H,61,62)/t25-,30+,31+,32+,33-,37-,38+/m1/s1
DM6IP17	CS	CC[C@@H](C)[C@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](CS)C(=O)O)NC(=O)[C@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DM6IP17	IK	ZZXPMGNPISOZPV-IFWKXTFSSA-N
DM6IP17	IU	(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2R,3R)-1-[[(2S)-1-[[(1S)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM6IP17	DE	Discovery agent

DM3W68X	ID	DM3W68X
DM3W68X	DN	AcAsp-Glu-Dif-Ile-Cha-Cys-Iqc-Nle-Thr-TyrNH2
DM3W68X	HS	Investigative
DM3W68X	SN	N-{[(3R)-2-(N-Acetyl-L-alpha-aspartyl-L-alpha-glutamyl-3,3-diphenyl-L-alanyl-L-alloisoleucyl-3-cyclohexyl-L-alanyl-L-cysteinyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]carbonyl}-L-norleucyl-L-seryl-L-tyrosinamide
DM3W68X	PC	16133705
DM3W68X	MW	1418.7
DM3W68X	FM	C72H95N11O17S
DM3W68X	IC	InChI=1S/C72H95N11O17S/c1-5-7-27-50(64(92)79-55(39-84)68(96)77-52(63(73)91)34-44-28-30-49(86)31-29-44)76-69(97)57-36-47-25-17-18-26-48(47)38-83(57)72(100)56(40-101)80-66(94)53(35-43-19-11-8-12-20-43)78-70(98)61(41(3)6-2)81-71(99)62(60(45-21-13-9-14-22-45)46-23-15-10-16-24-46)82-65(93)51(32-33-58(87)88)75-67(95)54(37-59(89)90)74-42(4)85/h9-10,13-18,21-26,28-31,41,43,50-57,60-62,84,86,101H,5-8,11-12,19-20,27,32-40H2,1-4H3,(H2,73,91)(H,74,85)(H,75,95)(H,76,97)(H,77,96)(H,78,98)(H,79,92)(H,80,94)(H,81,99)(H,82,93)(H,87,88)(H,89,90)/t41?,50-,51-,52-,53-,54-,55-,56-,57+,61-,62-/m0/s1
DM3W68X	CS	CCCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H]2CC3=CC=CC=C3CN2C(=O)[C@H](CS)NC(=O)[C@H](CC4CCCCC4)NC(=O)[C@H](C(C)CC)NC(=O)[C@H](C(C5=CC=CC=C5)C6=CC=CC=C6)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DM3W68X	IK	NAFMHFOWWVFCTM-BPJKRSAYSA-N
DM3W68X	IU	(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[(3R)-3-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-3,4-dihydro-1H-isoquinolin-2-yl]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM3W68X	DE	Discovery agent

DMCIJ6Q	ID	DMCIJ6Q
DMCIJ6Q	DN	AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Cha-Asp-ValNH2
DMCIJ6Q	HS	Investigative
DMCIJ6Q	PC	44388155
DMCIJ6Q	MW	1360.6
DMCIJ6Q	FM	C67H97N11O17S
DMCIJ6Q	IC	InChI=1S/C67H97N11O17S/c1-6-38(4)56(76-66(94)57(54(42-24-15-9-16-25-42)43-26-17-10-18-27-43)77-59(87)44(29-30-51(80)81)70-62(90)47(34-52(82)83)69-39(5)79)65(93)73-46(33-41-22-13-8-14-23-41)61(89)74-49(36-96)67(95)78-31-19-28-50(78)64(92)72-45(32-40-20-11-7-12-21-40)60(88)71-48(35-53(84)85)63(91)75-55(37(2)3)58(68)86/h9-10,15-18,24-27,37-38,40-41,44-50,54-57,96H,6-8,11-14,19-23,28-36H2,1-5H3,(H2,68,86)(H,69,79)(H,70,90)(H,71,88)(H,72,92)(H,73,93)(H,74,89)(H,75,91)(H,76,94)(H,77,87)(H,80,81)(H,82,83)(H,84,85)/t38?,44-,45?,46-,47-,48-,49-,50+,55-,56-,57-/m0/s1
DMCIJ6Q	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)NC(CC3CCCCC3)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](C(C4=CC=CC=C4)C5=CC=CC=C5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMCIJ6Q	IK	HHWSXWBIJCFKKB-VQTAYXAZSA-N
DMCIJ6Q	IU	(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[(2R)-2-[[1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DMCIJ6Q	DE	Discovery agent

DMA7ZSY	ID	DMA7ZSY
DMA7ZSY	DN	AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Nle-Asp-ValNH2
DMA7ZSY	HS	Investigative
DMA7ZSY	PC	44388154
DMA7ZSY	MW	1320.6
DMA7ZSY	FM	C64H93N11O17S
DMA7ZSY	IC	InChI=1S/C64H93N11O17S/c1-7-9-26-41(56(84)69-45(33-50(81)82)60(88)72-52(35(3)4)55(65)83)68-61(89)47-27-19-30-75(47)64(92)46(34-93)71-58(86)43(31-38-20-13-10-14-21-38)70-62(90)53(36(5)8-2)73-63(91)54(51(39-22-15-11-16-23-39)40-24-17-12-18-25-40)74-57(85)42(28-29-48(77)78)67-59(87)44(32-49(79)80)66-37(6)76/h11-12,15-18,22-25,35-36,38,41-47,51-54,93H,7-10,13-14,19-21,26-34H2,1-6H3,(H2,65,83)(H,66,76)(H,67,87)(H,68,89)(H,69,84)(H,70,90)(H,71,86)(H,72,88)(H,73,91)(H,74,85)(H,77,78)(H,79,80)(H,81,82)/t36?,41?,42-,43-,44-,45-,46-,47+,52-,53-,54-/m0/s1
DMA7ZSY	CS	CCCCC(C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](C(C)CC)NC(=O)[C@H](C(C3=CC=CC=C3)C4=CC=CC=C4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMA7ZSY	IK	BZVYIEQNRWILPS-CPLDFCFASA-N
DMA7ZSY	IU	(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[(2R)-2-[[1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DMA7ZSY	DE	Discovery agent

DM6PZ45	ID	DM6PZ45
DM6PZ45	DN	AcAsp-Glu-Dif-Lys-Cha-Cys
DM6PZ45	HS	Investigative
DM6PZ45	SN	CHEMBL294440; AcAsp-Glu-Dif-Lys-Cha-Cys; AC1LAAJ1; BDBM50096413; AcAsp-Glu-Dif(3,3-diphenylalanine)-Lys-Cha-(beta-cyclohexylalanine)-Cys; Ac-L-Asp-L-Glu-3,3-Diphenyl-L-Ala-L-Lys-3-cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM6PZ45	DT	Small molecular drug
DM6PZ45	PC	484572
DM6PZ45	MW	912.1
DM6PZ45	FM	C44H61N7O12S
DM6PZ45	IC	InChI=1S/C44H61N7O12S/c1-26(52)46-33(24-36(55)56)42(60)47-31(20-21-35(53)54)40(58)51-38(37(28-15-7-3-8-16-28)29-17-9-4-10-18-29)43(61)48-30(19-11-12-22-45)39(57)49-32(23-27-13-5-2-6-14-27)41(59)50-34(25-64)44(62)63/h3-4,7-10,15-18,27,30-34,37-38,64H,2,5-6,11-14,19-25,45H2,1H3,(H,46,52)(H,47,60)(H,48,61)(H,49,57)(H,50,59)(H,51,58)(H,53,54)(H,55,56)(H,62,63)/t30-,31-,32-,33-,34-,38-/m0/s1
DM6PZ45	CS	CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CS)C(=O)O
DM6PZ45	IK	MMHRSDHCRGNWNY-PHPRXEDMSA-N
DM6PZ45	IU	(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM6PZ45	DE	Discovery agent

DMKDZH4	ID	DMKDZH4
DMKDZH4	DN	AcAsp-Glu-Leu-Glu-Cha-Cys
DMKDZH4	HS	Investigative
DMKDZH4	SN	AcAsp-Glu-Leu-Glu-Cha-Cys; CHEMBL305570; AC1LAON7; Ac-Asp-Glu-Leu-Glu-Cha-Cys-OH; BDBM50096404; AcAsp-Glu-Leu-Glu-.beta.-Cyclohexylalanine-Cys; Ac-Asp-Glu-Leu-Glu-beta-Cyclohexylalanine-Cys-OH; Ac-L-Asp-Glu-L-Leu-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMKDZH4	DT	Small molecular drug
DMKDZH4	PC	492309
DMKDZH4	MW	802.9
DMKDZH4	FM	C34H54N6O14S
DMKDZH4	IC	InChI=1S/C34H54N6O14S/c1-17(2)13-22(38-29(48)20(9-11-26(42)43)37-33(52)24(15-28(46)47)35-18(3)41)31(50)36-21(10-12-27(44)45)30(49)39-23(14-19-7-5-4-6-8-19)32(51)40-25(16-55)34(53)54/h17,19-25,55H,4-16H2,1-3H3,(H,35,41)(H,36,50)(H,37,52)(H,38,48)(H,39,49)(H,40,51)(H,42,43)(H,44,45)(H,46,47)(H,53,54)/t20-,21-,22-,23-,24-,25-/m0/s1
DMKDZH4	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMKDZH4	IK	SYHFABLPDKKGNQ-OOPVGHQCSA-N
DMKDZH4	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMKDZH4	DE	Discovery agent

DMOMI91	ID	DMOMI91
DMOMI91	DN	AcAsp-Glu-Met-Glu-Cha-Cys
DMOMI91	HS	Investigative
DMOMI91	SN	CHEMBL64867; AcAsp-Glu-Met-Glu-Cha-Cys; AC1LAAJ4; BDBM50096409; AcAsp-Glu-Met-Glu-Nal(2-naphthylalanine)-Cys; Ac-L-Asp-L-Glu-L-Met-L-Glu-3-(2-Naphthyl)-L-Ala-L-Cys-OH; (R)-2-[(S)-2-((S)-2-{(S)-2-[(S)-2-((S)-2-Acetylamino-3-carboxy-propanoylamino)-4-carboxy-butanoylamino]-4-methylsulfanyl-butanoylamino}-4-carboxy-butanoylamino)-3-naphthalen-2-yl-propanoylamino]-3-mercapto-propionic acid
DMOMI91	DT	Small molecular drug
DMOMI91	PC	484573
DMOMI91	MW	864.9
DMOMI91	FM	C37H48N6O14S2
DMOMI91	IC	InChI=1S/C37H48N6O14S2/c1-19(44)38-27(17-31(49)50)36(55)40-23(9-11-29(45)46)32(51)41-25(13-14-59-2)34(53)39-24(10-12-30(47)48)33(52)42-26(35(54)43-28(18-58)37(56)57)16-20-7-8-21-5-3-4-6-22(21)15-20/h3-8,15,23-28,58H,9-14,16-18H2,1-2H3,(H,38,44)(H,39,53)(H,40,55)(H,41,51)(H,42,52)(H,43,54)(H,45,46)(H,47,48)(H,49,50)(H,56,57)/t23-,24-,25-,26-,27-,28-/m0/s1
DMOMI91	CS	CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](CS)C(=O)O
DMOMI91	IK	FCGQLGIFPLXKQV-QUQVWLGBSA-N
DMOMI91	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMOMI91	DE	Discovery agent

DMIVFZE	ID	DMIVFZE
DMIVFZE	DN	AcAsp-Glu-Met-Glu-Glu-Cys
DMIVFZE	HS	Investigative
DMIVFZE	SN	CHEMBL62717; AcAsp-Glu-Met-Glu-Glu-Cys; AC1LA8TV; Ac-Asp-Glu-Met-Glu-Glu-Cys-OH; BDBM50084634; 4-(2-Acetylamino-3-carboxy-propionylamino)-4-(1-{3-carboxy-1-[3-carboxy-1-(1-carboxy-2-mercapto-ethylcarbamoyl)-propylcarbamoyl]-propylcarbamoyl}-3-methylsulfanyl-propylcarbamoyl)-butyric acid(NS4A-NS4B)
DMIVFZE	DT	Small molecular drug
DMIVFZE	PC	483675
DMIVFZE	MW	796.8
DMIVFZE	FM	C29H44N6O16S2
DMIVFZE	IC	InChI=1S/C29H44N6O16S2/c1-13(36)30-18(11-23(43)44)28(49)33-15(4-7-21(39)40)25(46)34-17(9-10-53-2)27(48)32-14(3-6-20(37)38)24(45)31-16(5-8-22(41)42)26(47)35-19(12-52)29(50)51/h14-19,52H,3-12H2,1-2H3,(H,30,36)(H,31,45)(H,32,48)(H,33,49)(H,34,46)(H,35,47)(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,50,51)/t14-,15-,16-,17-,18-,19-/m0/s1
DMIVFZE	CS	CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O
DMIVFZE	IK	VGFHUYLCQHZNFZ-DYKIIFRCSA-N
DMIVFZE	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-4-carboxy-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMIVFZE	DE	Discovery agent

DMBGHX7	ID	DMBGHX7
DMBGHX7	DN	AcAsp-Glu-Met-Glu-Nal-Cyse
DMBGHX7	HS	Investigative
DMBGHX7	SN	CHEMBL64618; Ac-Asp-Glu-Met-Glu-Cha-Cys-OH; AcAsp-Glu-Met-Glu-Nal-Cyse; AC1LAAIY; BDBM50096405; AcAsp-Glu-Met-GLu-Cha(beta-cyclohexylalanine)-Cys; Ac-Asp-Glu-Met-Glu-beta-Cyclohexylalanine-Cys-OH; Ac-L-Asp-L-Glu-L-Met-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMBGHX7	DT	Small molecular drug
DMBGHX7	PC	484571
DMBGHX7	MW	820.9
DMBGHX7	FM	C33H52N6O14S2
DMBGHX7	IC	InChI=1S/C33H52N6O14S2/c1-17(40)34-23(15-27(45)46)32(51)36-19(8-10-25(41)42)28(47)37-21(12-13-55-2)30(49)35-20(9-11-26(43)44)29(48)38-22(14-18-6-4-3-5-7-18)31(50)39-24(16-54)33(52)53/h18-24,54H,3-16H2,1-2H3,(H,34,40)(H,35,49)(H,36,51)(H,37,47)(H,38,48)(H,39,50)(H,41,42)(H,43,44)(H,45,46)(H,52,53)/t19-,20-,21-,22-,23-,24-/m0/s1
DMBGHX7	CS	CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O
DMBGHX7	IK	QFFHVIGQVJVQSD-BTNSXGMBSA-N
DMBGHX7	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMBGHX7	DE	Discovery agent

DM4KQUS	ID	DM4KQUS
DM4KQUS	DN	Ac-Asp-Glu-Val-Asp-CHO
DM4KQUS	HS	Investigative
DM4KQUS	SN	ICE INHIBITOR; AC1L1HX4; SCHEMBL13194679; AL010; AKOS015916330; AN-30897; N-Acetyl-Asp-Glu-Val-Asp-al, &gt; =95%, powder; I14-51535; 4-[(2-acetamido-4-hydroxy-4-oxobutanoyl)amino]-5-[[1-[(4-hydroxy-1,4-dioxobutan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid; 4-(3-carboxy-2-acetamidopropanamido)-4-({1-[(1-carboxy-3-oxopropan-2-yl)carbamoyl]-2-methylpropyl}carbamoyl)butanoic acid
DM4KQUS	DT	Small molecular drug
DM4KQUS	PC	4330
DM4KQUS	MW	502.5
DM4KQUS	FM	C20H30N4O11
DM4KQUS	IC	InChI=1S/C20H30N4O11/c1-9(2)17(20(35)22-11(8-25)6-15(29)30)24-18(33)12(4-5-14(27)28)23-19(34)13(7-16(31)32)21-10(3)26/h8-9,11-13,17H,4-7H2,1-3H3,(H,21,26)(H,22,35)(H,23,34)(H,24,33)(H,27,28)(H,29,30)(H,31,32)
DM4KQUS	CS	CC(C)C(C(=O)NC(CC(=O)O)C=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C
DM4KQUS	IK	UMBVAPCONCILTL-UHFFFAOYSA-N
DM4KQUS	IU	4-[(2-acetamido-3-carboxypropanoyl)amino]-5-[[1-[(1-carboxy-3-oxopropan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM4KQUS	DE	Discovery agent

DM1KDJV	ID	DM1KDJV
DM1KDJV	DN	Ac-bhg-F-N-Y-Y-W
DM1KDJV	HS	Investigative
DM1KDJV	SN	CHEMBL385405; Ac-bhg-F-N-Y-Y-W
DM1KDJV	PC	44371670
DM1KDJV	MW	1083.2
DM1KDJV	FM	C61H62N8O11
DM1KDJV	IC	InChI=1S/C61H62N8O11/c1-35(70)64-55(54-45-16-7-5-13-39(45)23-24-40-14-6-8-17-46(40)54)60(78)68-50(29-36-11-3-2-4-12-36)57(75)67-51(33-53(62)73)59(77)66-48(30-37-19-25-42(71)26-20-37)56(74)65-49(31-38-21-27-43(72)28-22-38)58(76)69-52(61(79)80)32-41-34-63-47-18-10-9-15-44(41)47/h2-22,25-28,34,48-52,54-55,63,71-72H,23-24,29-33H2,1H3,(H2,62,73)(H,64,70)(H,65,74)(H,66,77)(H,67,75)(H,68,78)(H,69,76)(H,79,80)/t48-,49-,50-,51-,52-,55-/m0/s1
DM1KDJV	CS	CC(=O)N[C@@H](C1C2=CC=CC=C2CCC3=CC=CC=C13)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)O
DM1KDJV	IK	DTNUUCGDOGDUBL-NHTZSVLLSA-N
DM1KDJV	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)acetyl]amino]-3-phenylpropanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DM1KDJV	DE	Discovery agent

DMSE29N	ID	DMSE29N
DMSE29N	DN	Ac-Bth-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSE29N	HS	Investigative
DMSE29N	SN	CHEMBL380685; Ac-Bth-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSE29N	DT	Small molecular drug
DMSE29N	PC	44409592
DMSE29N	MW	879.9
DMSE29N	FM	C41H50N7O11PS
DMSE29N	IC	InChI=1S/C41H50N7O11PS/c1-23(59-60(56,57)58)36(47-39(53)32(44-24(2)49)21-28-22-61-34-13-6-5-11-29(28)34)41(55)48-18-8-7-12-33(48)40(54)46-31(38(52)45-30(37(43)51)16-17-35(42)50)20-25-14-15-26-9-3-4-10-27(26)19-25/h3-6,9-11,13-15,19,22-23,30-33,36H,7-8,12,16-18,20-21H2,1-2H3,(H2,42,50)(H2,43,51)(H,44,49)(H,45,52)(H,46,54)(H,47,53)(H2,56,57,58)/t23-,30+,31+,32+,33-,36+/m1/s1
DMSE29N	CS	C[C@H]([C@@H](C(=O)N1CCCC[C@@H]1C(=O)N[C@@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC4=CSC5=CC=CC=C54)NC(=O)C)OP(=O)(O)O
DMSE29N	IK	WPZGCIDLTHYADD-YIVWXNOFSA-N
DMSE29N	IU	[(2R,3S)-3-[[(2S)-2-acetamido-3-(1-benzothiophen-3-yl)propanoyl]amino]-4-[(2R)-2-[[(2S)-1-[[(2S)-1,5-diamino-1,5-dioxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]piperidin-1-yl]-4-oxobutan-2-yl] dihydrogen phosphate
DMSE29N	DE	Discovery agent

DMH0SQC	ID	DMH0SQC
DMH0SQC	DN	Ac-Cys-Ile-cyclo[Phe-Lys]-Tyr-Tyr
DMH0SQC	HS	Investigative
DMH0SQC	DE	Discovery agent

DMG19LW	ID	DMG19LW
DMG19LW	DN	Ac-Cys-Ile-Phe(4-NO2)-Lys-Phe(4-NO2)-Tyr
DMG19LW	HS	Investigative
DMG19LW	DT	Small molecular drug
DMG19LW	PC	44412036
DMG19LW	MW	952
DMG19LW	FM	C44H57N9O13S
DMG19LW	IC	InChI=1S/C44H57N9O13S/c1-4-25(2)38(51-42(59)37(24-67)46-26(3)54)43(60)49-35(22-28-10-16-31(17-11-28)53(65)66)40(57)47-33(7-5-6-20-45)39(56)48-34(21-27-8-14-30(15-9-27)52(63)64)41(58)50-36(44(61)62)23-29-12-18-32(55)19-13-29/h8-19,25,33-38,55,67H,4-7,20-24,45H2,1-3H3,(H,46,54)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMG19LW	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)[N+](=O)[O-])C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)[N+](=O)[O-])C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMG19LW	IK	BQZNGWRLXCQNSI-LBNFHWTGSA-N
DMG19LW	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMG19LW	DE	Discovery agent

DMORPDV	ID	DMORPDV
DMORPDV	DN	Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Phe(4-NO2)
DMORPDV	HS	Investigative
DMORPDV	DT	Small molecular drug
DMORPDV	PC	44412129
DMORPDV	MW	952
DMORPDV	FM	C44H57N9O13S
DMORPDV	IC	InChI=1S/C44H57N9O13S/c1-4-25(2)38(51-42(59)37(24-67)46-26(3)54)43(60)49-35(21-27-8-14-30(15-9-27)52(63)64)40(57)47-33(7-5-6-20-45)39(56)48-34(22-29-12-18-32(55)19-13-29)41(58)50-36(44(61)62)23-28-10-16-31(17-11-28)53(65)66/h8-19,25,33-38,55,67H,4-7,20-24,45H2,1-3H3,(H,46,54)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMORPDV	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)[N+](=O)[O-])C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMORPDV	IK	YSCBRLXTMTYHMK-LBNFHWTGSA-N
DMORPDV	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-nitrophenyl)propanoic acid
DMORPDV	DE	Discovery agent

DMK7YIG	ID	DMK7YIG
DMK7YIG	DN	Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Tyr
DMK7YIG	HS	Investigative
DMK7YIG	DT	Small molecular drug
DMK7YIG	PC	44412137
DMK7YIG	MW	923
DMK7YIG	FM	C44H58N8O12S
DMK7YIG	IC	InChI=1S/C44H58N8O12S/c1-4-25(2)38(51-42(59)37(24-65)46-26(3)53)43(60)49-35(21-27-8-14-30(15-9-27)52(63)64)40(57)47-33(7-5-6-20-45)39(56)48-34(22-28-10-16-31(54)17-11-28)41(58)50-36(44(61)62)23-29-12-18-32(55)19-13-29/h8-19,25,33-38,54-55,65H,4-7,20-24,45H2,1-3H3,(H,46,53)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMK7YIG	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)[N+](=O)[O-])C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMK7YIG	IK	IFJPPNMSIWSRDX-LBNFHWTGSA-N
DMK7YIG	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMK7YIG	DE	Discovery agent

DMUWI2F	ID	DMUWI2F
DMUWI2F	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-Cl)-Tyr
DMUWI2F	HS	Investigative
DMUWI2F	DT	Small molecular drug
DMUWI2F	PC	44412001
DMUWI2F	MW	912.5
DMUWI2F	FM	C44H58ClN7O10S
DMUWI2F	IC	InChI=1S/C44H58ClN7O10S/c1-4-25(2)38(52-42(59)37(24-63)47-26(3)53)43(60)50-35(22-28-10-16-31(54)17-11-28)40(57)48-33(7-5-6-20-46)39(56)49-34(21-27-8-14-30(45)15-9-27)41(58)51-36(44(61)62)23-29-12-18-32(55)19-13-29/h8-19,25,33-38,54-55,63H,4-7,20-24,46H2,1-3H3,(H,47,53)(H,48,57)(H,49,56)(H,50,60)(H,51,58)(H,52,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMUWI2F	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)Cl)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMUWI2F	IK	MJPZCPCJFBXRAJ-LBNFHWTGSA-N
DMUWI2F	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMUWI2F	DE	Discovery agent

DMNW7GR	ID	DMNW7GR
DMNW7GR	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-CN)-Tyr
DMNW7GR	HS	Investigative
DMNW7GR	DT	Small molecular drug
DMNW7GR	PC	44412118
DMNW7GR	MW	903.1
DMNW7GR	FM	C45H58N8O10S
DMNW7GR	IC	InChI=1S/C45H58N8O10S/c1-4-26(2)39(53-43(60)38(25-64)48-27(3)54)44(61)51-36(22-29-12-16-32(55)17-13-29)41(58)49-34(7-5-6-20-46)40(57)50-35(21-28-8-10-31(24-47)11-9-28)42(59)52-37(45(62)63)23-30-14-18-33(56)19-15-30/h8-19,26,34-39,55-56,64H,4-7,20-23,25,46H2,1-3H3,(H,48,54)(H,49,58)(H,50,57)(H,51,61)(H,52,59)(H,53,60)(H,62,63)/t26?,34-,35-,36-,37-,38-,39-/m0/s1
DMNW7GR	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)C#N)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMNW7GR	IK	HMZZZPUDXBITDY-QCGUVPLXSA-N
DMNW7GR	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-cyanophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMNW7GR	DE	Discovery agent

DMO4MYI	ID	DMO4MYI
DMO4MYI	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-I)-Tyr
DMO4MYI	HS	Investigative
DMO4MYI	PC	44412037
DMO4MYI	MW	1003.9
DMO4MYI	FM	C44H58IN7O10S
DMO4MYI	IC	InChI=1S/C44H58IN7O10S/c1-4-25(2)38(52-42(59)37(24-63)47-26(3)53)43(60)50-35(22-28-10-16-31(54)17-11-28)40(57)48-33(7-5-6-20-46)39(56)49-34(21-27-8-14-30(45)15-9-27)41(58)51-36(44(61)62)23-29-12-18-32(55)19-13-29/h8-19,25,33-38,54-55,63H,4-7,20-24,46H2,1-3H3,(H,47,53)(H,48,57)(H,49,56)(H,50,60)(H,51,58)(H,52,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMO4MYI	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)I)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMO4MYI	IK	SFPMFCZXYBGJAR-LBNFHWTGSA-N
DMO4MYI	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-iodophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMO4MYI	DE	Discovery agent

DME4FZD	ID	DME4FZD
DME4FZD	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-N3)-Tyr
DME4FZD	HS	Investigative
DME4FZD	DT	Small molecular drug
DME4FZD	PC	44412139
DME4FZD	MW	919.1
DME4FZD	FM	C44H58N10O10S
DME4FZD	IC	InChI=1S/C44H58N10O10S/c1-4-25(2)38(52-42(61)37(24-65)47-26(3)55)43(62)50-35(22-28-10-16-31(56)17-11-28)40(59)48-33(7-5-6-20-45)39(58)49-34(21-27-8-14-30(15-9-27)53-54-46)41(60)51-36(44(63)64)23-29-12-18-32(57)19-13-29/h8-19,25,33-38,56-57,65H,4-7,20-24,45H2,1-3H3,(H,47,55)(H,48,59)(H,49,58)(H,50,62)(H,51,60)(H,52,61)(H,63,64)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DME4FZD	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)N=[N+]=[N-])C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DME4FZD	IK	YGJYKNHKRWZTIL-LBNFHWTGSA-N
DME4FZD	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-azidophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DME4FZD	DE	Discovery agent

DM856JM	ID	DM856JM
DM856JM	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Phe(4-NO2)
DM856JM	HS	Investigative
DM856JM	DT	Small molecular drug
DM856JM	PC	44412138
DM856JM	MW	952
DM856JM	FM	C44H57N9O13S
DM856JM	IC	InChI=1S/C44H57N9O13S/c1-4-25(2)38(51-42(59)37(24-67)46-26(3)54)43(60)49-35(22-29-12-18-32(55)19-13-29)40(57)47-33(7-5-6-20-45)39(56)48-34(21-27-8-14-30(15-9-27)52(63)64)41(58)50-36(44(61)62)23-28-10-16-31(17-11-28)53(65)66/h8-19,25,33-38,55,67H,4-7,20-24,45H2,1-3H3,(H,46,54)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DM856JM	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)[N+](=O)[O-])C(=O)N[C@@H](CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DM856JM	IK	YTKNXUJJRVGMTM-LBNFHWTGSA-N
DM856JM	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-3-(4-nitrophenyl)propanoic acid
DM856JM	DE	Discovery agent

DMU2PT1	ID	DMU2PT1
DMU2PT1	DN	Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Tyr-Phe
DMU2PT1	HS	Investigative
DMU2PT1	PC	44412130
DMU2PT1	MW	1070.2
DMU2PT1	FM	C53H67N9O13S
DMU2PT1	IC	InChI=1S/C53H67N9O13S/c1-4-31(2)46(61-51(70)45(30-76)55-32(3)63)52(71)59-43(28-36-17-23-39(65)24-18-36)48(67)56-40(12-8-9-25-54)47(66)57-41(26-34-13-19-37(20-14-34)62(74)75)49(68)58-42(27-35-15-21-38(64)22-16-35)50(69)60-44(53(72)73)29-33-10-6-5-7-11-33/h5-7,10-11,13-24,31,40-46,64-65,76H,4,8-9,12,25-30,54H2,1-3H3,(H,55,63)(H,56,67)(H,57,66)(H,58,68)(H,59,71)(H,60,69)(H,61,70)(H,72,73)/t31?,40-,41-,42-,43-,44-,45-,46-/m0/s1
DMU2PT1	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)[N+](=O)[O-])C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMU2PT1	IK	NYGFMHJKDBNTFT-GLNKEJAVSA-N
DMU2PT1	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoic acid
DMU2PT1	DE	Discovery agent

DM4MP69	ID	DM4MP69
DM4MP69	DN	Ac-Cys-Ile-Tyr-Lys-Tyr-Phe(4-NO2)
DM4MP69	HS	Investigative
DM4MP69	DT	Small molecular drug
DM4MP69	PC	44412128
DM4MP69	MW	923
DM4MP69	FM	C44H58N8O12S
DM4MP69	IC	InChI=1S/C44H58N8O12S/c1-4-25(2)38(51-42(59)37(24-65)46-26(3)53)43(60)49-35(22-29-12-18-32(55)19-13-29)40(57)47-33(7-5-6-20-45)39(56)48-34(21-28-10-16-31(54)17-11-28)41(58)50-36(44(61)62)23-27-8-14-30(15-9-27)52(63)64/h8-19,25,33-38,54-55,65H,4-7,20-24,45H2,1-3H3,(H,46,53)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DM4MP69	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DM4MP69	IK	FNBOPWDKOOFHTM-LBNFHWTGSA-N
DM4MP69	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-nitrophenyl)propanoic acid
DM4MP69	DE	Discovery agent

DMW02H7	ID	DMW02H7
DMW02H7	DN	Ac-DEVD-CHO
DMW02H7	HS	Investigative
DMW02H7	SN	169332-60-9; Caspase-3 Inhibitor I; N-acetyl-asp-glu-val-asp-al; acetyl-aspartyl-glutamyl-valyl-aspartal; Ac-Asp-Glu-Val-Asp-Aldehyde; AC-ASP-GLU-VAL-ASP-H; CHEMBL417149; CHEBI:59385; 184179-08-6; (4S,7S,10S,13S)-7-(2-carboxyethyl)-4-(carboxymethyl)-13-formyl-10-isopropyl-2,5,8,11-tetraoxo-3,6,9,12-tetraazapentadecan-15-oic acid; acetyl-Asp-Glu-Val-Asp-aldehyde; acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp-aldehyde
DMW02H7	DT	Small molecular drug
DMW02H7	PC	644345
DMW02H7	MW	502.5
DMW02H7	FM	C20H30N4O11
DMW02H7	IC	InChI=1S/C20H30N4O11/c1-9(2)17(20(35)22-11(8-25)6-15(29)30)24-18(33)12(4-5-14(27)28)23-19(34)13(7-16(31)32)21-10(3)26/h8-9,11-13,17H,4-7H2,1-3H3,(H,21,26)(H,22,35)(H,23,34)(H,24,33)(H,27,28)(H,29,30)(H,31,32)/t11-,12-,13-,17-/m0/s1
DMW02H7	CS	CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMW02H7	IK	UMBVAPCONCILTL-MRHIQRDNSA-N
DMW02H7	IU	(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMW02H7	CB	CHEBI:59385
DMW02H7	DE	Discovery agent

DMKDEWH	ID	DMKDEWH
DMKDEWH	DN	AcDif-Glu-Cha-Cys
DMKDEWH	HS	Investigative
DMKDEWH	SN	CHEMBL62433; AcDif-Glu-Cha-Cys; AC1LAAI7; Ac-Dif-Glu-Cha-Cys-OH; BDBM50096401; Ac-3,3-Diphenyl-L-Ala-L-Glu-3-cyclohexyl-L-Ala-L-Cys-OH; AcDif(3,3-diphenylalanine)-Glu-Cha(beta-cyclohexylalanine)-Cys; (4S)-4-[[(2S)-2-acetamido-3,3-diphenylpropanoyl]amino]-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMKDEWH	DT	Small molecular drug
DMKDEWH	PC	484562
DMKDEWH	MW	668.8
DMKDEWH	FM	C34H44N4O8S
DMKDEWH	IC	InChI=1S/C34H44N4O8S/c1-21(39)35-30(29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)33(44)36-25(17-18-28(40)41)31(42)37-26(19-22-11-5-2-6-12-22)32(43)38-27(20-47)34(45)46/h3-4,7-10,13-16,22,25-27,29-30,47H,2,5-6,11-12,17-20H2,1H3,(H,35,39)(H,36,44)(H,37,42)(H,38,43)(H,40,41)(H,45,46)/t25-,26-,27-,30-/m0/s1
DMKDEWH	CS	CC(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CS)C(=O)O
DMKDEWH	IK	CJVPMARHOWZLLI-YRUYCOJQSA-N
DMKDEWH	IU	(4S)-4-[[(2S)-2-acetamido-3,3-diphenylpropanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMKDEWH	DE	Discovery agent

DM1DWCP	ID	DM1DWCP
DM1DWCP	DN	AcDif-Ile-Cha-Cys
DM1DWCP	HS	Investigative
DM1DWCP	SN	CHEMBL293631; AcDif-Ile-Cha-Cys
DM1DWCP	DT	Small molecular drug
DM1DWCP	PC	44305023
DM1DWCP	MW	652.8
DM1DWCP	FM	C35H48N4O6S
DM1DWCP	IC	InChI=1S/C35H48N4O6S/c1-4-22(2)30(33(42)37-27(20-24-14-8-5-9-15-24)32(41)38-28(21-46)35(44)45)39-34(43)31(36-23(3)40)29(25-16-10-6-11-17-25)26-18-12-7-13-19-26/h6-7,10-13,16-19,22,24,27-31,46H,4-5,8-9,14-15,20-21H2,1-3H3,(H,36,40)(H,37,42)(H,38,41)(H,39,43)(H,44,45)/t22-,27+,28-,30-,31+/m1/s1
DM1DWCP	CS	CC[C@@H](C)[C@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](CS)C(=O)O)NC(=O)[C@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NC(=O)C
DM1DWCP	IK	IIYOAVWUFJFCOP-SHQUAMPASA-N
DM1DWCP	IU	(2S)-2-[[(2S)-2-[[(2R,3R)-2-[[(2S)-2-acetamido-3,3-diphenylpropanoyl]amino]-3-methylpentanoyl]amino]-3-cyclohexylpropanoyl]amino]-3-sulfanylpropanoic acid
DM1DWCP	DE	Discovery agent

DMPMH7Z	ID	DMPMH7Z
DMPMH7Z	DN	ACDPP
DMPMH7Z	HS	Investigative
DMPMH7Z	SN	3-amino-6-chloro-5-(dimethylamino)-N-(pyridin-3-yl)pyrazine-2-carboxamide; GTPL3388; CHEMBL1616372; CHEBI:104024; ZINC7992851; BRD-K68633617-003-01-1
DMPMH7Z	DT	Small molecular drug
DMPMH7Z	PC	16759169
DMPMH7Z	MW	292.72
DMPMH7Z	FM	C12H13ClN6O
DMPMH7Z	IC	InChI=1S/C12H13ClN6O/c1-19(2)11-9(13)17-8(10(14)18-11)12(20)16-7-4-3-5-15-6-7/h3-6H,1-2H3,(H2,14,18)(H,16,20)
DMPMH7Z	CS	CN(C)C1=NC(=C(N=C1Cl)C(=O)NC2=CN=CC=C2)N
DMPMH7Z	IK	RNGRUHWJJPTYNR-UHFFFAOYSA-N
DMPMH7Z	IU	3-amino-6-chloro-5-(dimethylamino)-N-pyridin-3-ylpyrazine-2-carboxamide
DMPMH7Z	CB	CHEBI:104024
DMPMH7Z	DE	Discovery agent

DMVDH4I	ID	DMVDH4I
DMVDH4I	DN	Ac-D-pro-L-Phe-D-trp-L-Phe-NH2
DMVDH4I	HS	Investigative
DMVDH4I	SN	CHEMBL450818; Ac-D-pro-L-Phe-D-trp-L-Phe-NH2
DMVDH4I	DT	Small molecular drug
DMVDH4I	PC	44583427
DMVDH4I	MW	636.7
DMVDH4I	FM	C36H40N6O5
DMVDH4I	IC	InChI=1S/C36H40N6O5/c1-23(43)42-18-10-17-32(42)36(47)41-30(20-25-13-6-3-7-14-25)34(45)40-31(21-26-22-38-28-16-9-8-15-27(26)28)35(46)39-29(33(37)44)19-24-11-4-2-5-12-24/h2-9,11-16,22,29-32,38H,10,17-21H2,1H3,(H2,37,44)(H,39,46)(H,40,45)(H,41,47)/t29-,30-,31+,32+/m0/s1
DMVDH4I	CS	CC(=O)N1CCC[C@@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N
DMVDH4I	IK	WEBVKDVBAOYUMD-GASGPIRDSA-N
DMVDH4I	IU	(2R)-1-acetyl-N-[(2S)-1-[[(2R)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMVDH4I	DE	Discovery agent

DM7XY41	ID	DM7XY41
DM7XY41	DN	Ac-dR[CEHdFRWC]-NH2
DM7XY41	HS	Investigative
DM7XY41	SN	CHEMBL267900; Ac-dR[CEHdFRWC]-NH2
DM7XY41	PC	44400402
DM7XY41	MW	1175.4
DM7XY41	FM	C51H70N18O11S2
DM7XY41	IC	InChI=1S/C51H70N18O11S2/c1-27(70)62-33(13-7-17-58-50(53)54)43(74)69-40-25-82-81-24-39(42(52)73)68-47(78)37(20-29-22-60-32-12-6-5-11-31(29)32)66-44(75)34(14-8-18-59-51(55)56)63-46(77)36(19-28-9-3-2-4-10-28)65-48(79)38(21-30-23-57-26-61-30)67-45(76)35(64-49(40)80)15-16-41(71)72/h2-6,9-12,22-23,26,33-40,60H,7-8,13-21,24-25H2,1H3,(H2,52,73)(H,57,61)(H,62,70)(H,63,77)(H,64,80)(H,65,79)(H,66,75)(H,67,76)(H,68,78)(H,69,74)(H,71,72)(H4,53,54,58)(H4,55,56,59)/t33-,34+,35-,36+,37-,38+,39-,40-/m0/s1
DM7XY41	CS	CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCC(=O)O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N
DM7XY41	IK	UNXFCHHFXJFRRB-ABRXVHCYSA-N
DM7XY41	IU	3-[(4R,7S,10R,13R,16R,19S,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DM7XY41	DE	Discovery agent

DM9MDBO	ID	DM9MDBO
DM9MDBO	DN	AcDRGDS
DM9MDBO	HS	Investigative
DM9MDBO	SN	CHEMBL241297; AcDRGDS; Acetyl-Asp-Arg-Gly-Asp-Ser-OH
DM9MDBO	DT	Small molecular drug
DM9MDBO	PC	10415998
DM9MDBO	MW	590.5
DM9MDBO	FM	C21H34N8O12
DM9MDBO	IC	InChI=1S/C21H34N8O12/c1-9(31)26-11(5-15(33)34)18(38)28-10(3-2-4-24-21(22)23)17(37)25-7-14(32)27-12(6-16(35)36)19(39)29-13(8-30)20(40)41/h10-13,30H,2-8H2,1H3,(H,25,37)(H,26,31)(H,27,32)(H,28,38)(H,29,39)(H,33,34)(H,35,36)(H,40,41)(H4,22,23,24)/t10-,11-,12-,13-/m0/s1
DM9MDBO	CS	CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O
DM9MDBO	IK	SSQXWSYTLDJJAP-CYDGBPFRSA-N
DM9MDBO	IU	(3S)-3-acetamido-4-[[(2S)-1-[[2-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DM9MDBO	DE	Discovery agent

DMOJGF3	ID	DMOJGF3
DMOJGF3	DN	ACE-435
DMOJGF3	HS	Investigative
DMOJGF3	SN	RAP-435; TGF beta protein superfamily signaling inhibitor (cancer cachexia/metabolic disease/age-related muscle loss), Acceleron
DMOJGF3	CP	Acceleron Pharma Inc
DMOJGF3	DE	Cachexia

DMWX3HT	ID	DMWX3HT
DMWX3HT	DN	ACEA
DMWX3HT	HS	Investigative
DMWX3HT	SN	Arachidonyl-2-chloroethylamide; arachidonyl-2-chloroethylamide; Arachidonyl-2'-chloroethylamide; CHEMBL151167; (5Z,8Z,11Z,14Z)-N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide; C22H36ClNO; Arachidonoyl-2-chloroethylamide; AC1NSJTE; GTPL738; SCHEMBL1517676; MolPort-003-940-362; HMS3649N11; MFCD02683581; BN0049; BDBM50072769; ZINC13675373; 1595AH; AKOS024456526; Arachidonyl-2'-chloroethylamide hydrate; NCGC00162406-01; LS-63778; ACM273734079; SR-01000946682; L000112; SR-01000946682-1; N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide
DMWX3HT	DT	Small molecular drug
DMWX3HT	PC	5311006
DMWX3HT	MW	366
DMWX3HT	FM	C22H36ClNO
DMWX3HT	IC	InChI=1S/C22H36ClNO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)24-21-20-23/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,24,25)/b7-6-,10-9-,13-12-,16-15-
DMWX3HT	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCCl
DMWX3HT	IK	SCJNCDSAIRBRIA-DOFZRALJSA-N
DMWX3HT	IU	(5Z,8Z,11Z,14Z)-N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
DMWX3HT	CA	CAS 220556-69-4
DMWX3HT	DE	Discovery agent

DMVTSM8	ID	DMVTSM8
DMVTSM8	DN	Acefylline
DMVTSM8	HS	Investigative
DMVTSM8	SN	Carboxymethyltheophylline; Theophyllin-7-ylacetic acid; Theophylline-7-acetic acid; Theophyllineacetic acid; (1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid; 1,3-Dimethylxanthine-7-acetic acid; 2-(1,3-Dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)acetic acid; 652-37-9; 7-(Carboxymethyl)theophylline; 7-Theophyllineacetic acid; 7-Theophyllinessigsaeure; 7-Theophyllinylacetic acid; 7-Theophyllinylessigsaeure; Acefylline; Acephylline; BRN 0279221; EINECS 211-490-2; MFCD00022832; NSC 52996; UNII-M494UE2YEP
DMVTSM8	PC	69550
DMVTSM8	MW	238.2
DMVTSM8	FM	C9H10N4O4
DMVTSM8	IC	HCYFGRCYSCXKNQ-UHFFFAOYSA-N
DMVTSM8	CS	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O
DMVTSM8	IK	1S/C9H10N4O4/c1-11-7-6(8(16)12(2)9(11)17)13(4-10-7)3-5(14)15/h4H,3H2,1-2H3,(H,14,15)
DMVTSM8	IU	2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid
DMVTSM8	CA	CAS 652-37-9
DMVTSM8	CB	CHEBI:94615
DMVTSM8	DE	Discovery agent

DMU9O7K	ID	DMU9O7K
DMU9O7K	DN	Acenanthrene-9,10-dione
DMU9O7K	HS	Investigative
DMU9O7K	SN	1,2-Aceanthrylenedione; Aceanthrenequinone; 6373-11-1; 1,2-Aceanthrenedione; aceanthrylene-1,2-dione; acenanthrene-9,10-dione; Aceanthrenchinon; NSC245130; AC1L7ULB; Aceanthrenequinone, 96%; ACMC-20ap73; SCHEMBL579274; CHEMBL235503; CTK2F3554; BDBM22859; DTXSID90311753; YAIBDWAANBTYIA-UHFFFAOYSA-N; MolPort-002-800-851; 1,2-Dione-Based Compound, 16; 1,2-dihydroaceanthrylene-1,2-dione; MFCD00035767; AKOS015902885; NSC-245130; MCULE-7113625880; VZ20381; CJ-29850; CC-02809; KB-64253; TC-172326; DB-054531; ST50825822; AE-641/00376058; 373A111
DMU9O7K	DT	Small molecular drug
DMU9O7K	PC	316765
DMU9O7K	MW	232.23
DMU9O7K	FM	C16H8O2
DMU9O7K	IC	InChI=1S/C16H8O2/c17-15-12-7-3-5-10-8-9-4-1-2-6-11(9)14(13(10)12)16(15)18/h1-8H
DMU9O7K	CS	C1=CC=C2C(=C1)C=C3C=CC=C4C3=C2C(=O)C4=O
DMU9O7K	IK	YAIBDWAANBTYIA-UHFFFAOYSA-N
DMU9O7K	IU	aceanthrylene-1,2-dione
DMU9O7K	CA	CAS 6373-11-1
DMU9O7K	DE	Discovery agent

DMT3QYZ	ID	DMT3QYZ
DMT3QYZ	DN	Acenaphthenol
DMT3QYZ	HS	Investigative
DMT3QYZ	SN	GEO-00001; MXUCIEHYJYRTLT-UHFFFAOYSA-; MXUCIEHYJYRTLT-UHFFFAOYSA-N; SCHEMBL345448; W-200056; 1,2-Dihydro-1-acenaphthylenol; 1,2-dihydroacenaphthylen-1-ol; 1-ACENAPHTHENOL; 1-Acenaphthalenol; 1-Acenaphthenol, 99%; 1-Acenaphthylenol, 1,2-dihydro-; 1-Acenaphthylenol,1,2-dihydro-; 1-Acenaphthylenol,2-dihydro-; 1-Hydroxyacenaphthene; 28807-94-5; 7-Acenaphthenol; AC1L2L0C; AC1Q7A0H; ACMC-1B4IN; Acenaphthen-1-ol; Acenaphthene-1-ol; 1-Acenaphthenol; Acenaphthenol-1; Acenaphthylenol, 1,2-dihydro-; DTXSID20951449; HMS1666F13
DMT3QYZ	PC	22750
DMT3QYZ	MW	170.21
DMT3QYZ	FM	C12H10O
DMT3QYZ	IC	MXUCIEHYJYRTLT-UHFFFAOYSA-N
DMT3QYZ	CS	C1C(C2=CC=CC3=C2C1=CC=C3)O
DMT3QYZ	IK	1S/C12H10O/c13-11-7-9-5-1-3-8-4-2-6-10(11)12(8)9/h1-6,11,13H,7H2
DMT3QYZ	IU	1,2-dihydroacenaphthylen-1-ol
DMT3QYZ	CA	CAS 6306-07-6
DMT3QYZ	DE	Discovery agent

DMU3DMH	ID	DMU3DMH
DMU3DMH	DN	ACENAPHTHOQUINONE
DMU3DMH	HS	Investigative
DMU3DMH	SN	Acenaphthenequinone; 82-86-0; Acenaphthoquinone; acenaphthylene-1,2-dione; 1,2-ACENAPHTHYLENEDIONE; Acenaphthenedione; 1,2-Acenaphthenequinone; 1,2-Acenaphthenedione; Acenaphthaquinone; Acenaphthylene-1,2-quinone; Acenaphthylenequinone; acenaphthodione; 1,2-Diketoacenaphthene; acenaphthene-1,2-dione; diketoacenaphthene; acenaphthylenedione; UNII-3950D6UEIQ; acenaphthene quinone; CCRIS 5318; CHEBI:15342; HSDB 2660; NSC 7656; EINECS 201-441-3; 1,2-dihydroacenaphthylene-1,2-dione; BRN 0879172; 3950D6UEIQ; AFPRJLBZLPBTPZ-UHFFFAOYSA-N
DMU3DMH	DT	Small molecular drug
DMU3DMH	PC	6724
DMU3DMH	MW	182.17
DMU3DMH	FM	C12H6O2
DMU3DMH	IC	InChI=1S/C12H6O2/c13-11-8-5-1-3-7-4-2-6-9(10(7)8)12(11)14/h1-6H
DMU3DMH	CS	C1=CC2=C3C(=C1)C(=O)C(=O)C3=CC=C2
DMU3DMH	IK	AFPRJLBZLPBTPZ-UHFFFAOYSA-N
DMU3DMH	IU	acenaphthylene-1,2-dione
DMU3DMH	CA	CAS 82-86-0
DMU3DMH	CB	CHEBI:15342
DMU3DMH	DE	Discovery agent

DM4BWMO	ID	DM4BWMO
DM4BWMO	DN	Acerogenin A
DM4BWMO	HS	Investigative
DM4BWMO	SN	acerogenin A; CHEMBL516665; SCHEMBL10048511
DM4BWMO	DT	Small molecular drug
DM4BWMO	PC	12000158
DM4BWMO	MW	298.4
DM4BWMO	FM	C19H22O3
DM4BWMO	IC	InChI=1S/C19H22O3/c20-16-4-2-1-3-15-8-12-18(21)19(13-15)22-17-10-6-14(5-9-16)7-11-17/h6-8,10-13,16,20-21H,1-5,9H2/t16-/m1/s1
DM4BWMO	CS	C1CCC2=CC(=C(C=C2)O)OC3=CC=C(CC[C@@H](C1)O)C=C3
DM4BWMO	IK	JHRMYLCWJWLUQL-MRXNPFEDSA-N
DM4BWMO	IU	(12R)-2-oxatricyclo[13.2.2.13,7]icosa-1(17),3,5,7(20),15,18-hexaene-4,12-diol
DM4BWMO	CA	CAS 60503-28-8
DM4BWMO	DE	Discovery agent

DMVQ30P	ID	DMVQ30P
DMVQ30P	DN	Acerogenin B
DMVQ30P	HS	Investigative
DMVQ30P	SN	acerogenin B
DMVQ30P	DT	Small molecular drug
DMVQ30P	PC	10913542
DMVQ30P	MW	298.4
DMVQ30P	FM	C19H22O3
DMVQ30P	IC	InChI=1S/C19H22O3/c20-16-4-2-1-3-14-6-10-17(11-7-14)22-19-13-15(5-9-16)8-12-18(19)21/h6-8,10-13,16,20-21H,1-5,9H2/t16-/m0/s1
DMVQ30P	CS	C1CCC2=CC=C(C=C2)OC3=C(C=CC(=C3)CC[C@H](C1)O)O
DMVQ30P	IK	BDTAPCJUUZRFKY-INIZCTEOSA-N
DMVQ30P	IU	(10S)-2-oxatricyclo[13.2.2.13,7]icosa-1(17),3,5,7(20),15,18-hexaene-4,10-diol
DMVQ30P	DE	Discovery agent

DMNETSX	ID	DMNETSX
DMNETSX	DN	Acerogenin C
DMNETSX	HS	Investigative
DMNETSX	SN	acerogenin C; SCHEMBL4112475
DMNETSX	DT	Small molecular drug
DMNETSX	PC	10040223
DMNETSX	MW	296.4
DMNETSX	FM	C19H20O3
DMNETSX	IC	InChI=1S/C19H20O3/c20-16-4-2-1-3-15-8-12-18(21)19(13-15)22-17-10-6-14(5-9-16)7-11-17/h6-8,10-13,21H,1-5,9H2
DMNETSX	CS	C1CCC2=CC(=C(C=C2)O)OC3=CC=C(CCC(=O)C1)C=C3
DMNETSX	IK	DMCJCKWHLCLVNV-UHFFFAOYSA-N
DMNETSX	IU	4-hydroxy-2-oxatricyclo[13.2.2.13,7]icosa-1(17),3,5,7(20),15,18-hexaen-12-one
DMNETSX	DE	Discovery agent

DMB2463	ID	DMB2463
DMB2463	DN	ACET
DMB2463	HS	Investigative
DMB2463	SN	CHEMBL373429; 3-({3-[(2s)-2-Amino-2-Carboxyethyl]-5-Methyl-2,6-Dioxo-3,6-Dihydropyrimidin-1(2h)-Yl}methyl)-5-Phenylthiophene-2-Carboxylic Acid; (S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxy-5-phenylthiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione; GTPL4123; MolPort-023-276-559; ZINC35324127; BDBM50207591; AKOS024457262; NCGC00378702-01; UBE; 3-({3-[(2S)-2-amino-2-carboxyethyl]-5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl}methyl)-5-phenylthiophene-2-carboxylic acid
DMB2463	DT	Small molecular drug
DMB2463	PC	16125102
DMB2463	MW	429.4
DMB2463	FM	C20H19N3O6S
DMB2463	IC	InChI=1S/C20H19N3O6S/c1-11-8-22(10-14(21)18(25)26)20(29)23(17(11)24)9-13-7-15(30-16(13)19(27)28)12-5-3-2-4-6-12/h2-8,14H,9-10,21H2,1H3,(H,25,26)(H,27,28)/t14-/m0/s1
DMB2463	CS	CC1=CN(C(=O)N(C1=O)CC2=C(SC(=C2)C3=CC=CC=C3)C(=O)O)C[C@@H](C(=O)O)N
DMB2463	IK	LCZDCKMQSBGXAH-AWEZNQCLSA-N
DMB2463	IU	3-[[3-[(2S)-2-amino-2-carboxyethyl]-5-methyl-2,6-dioxopyrimidin-1-yl]methyl]-5-phenylthiophene-2-carboxylic acid
DMB2463	DE	Discovery agent

DMJFKG4	ID	DMJFKG4
DMJFKG4	DN	Acetaldehyde
DMJFKG4	HS	Investigative
DMJFKG4	SN	acetic aldehyde; ethanal; ethyl aldehyde; NSC 7594
DMJFKG4	DT	Small molecular drug
DMJFKG4	PC	177
DMJFKG4	MW	44.05
DMJFKG4	FM	C2H4O
DMJFKG4	IC	InChI=1S/C2H4O/c1-2-3/h2H,1H3
DMJFKG4	CS	CC=O
DMJFKG4	IK	IKHGUXGNUITLKF-UHFFFAOYSA-N
DMJFKG4	IU	acetaldehyde
DMJFKG4	CA	CAS 75-07-0
DMJFKG4	CB	CHEBI:15343
DMJFKG4	DE	Discovery agent

DMD08RH	ID	DMD08RH
DMD08RH	DN	Acetate Ion
DMD08RH	HS	Investigative
DMD08RH	SN	acetate; Acetate Ion; Acetic acid, ion(1-); Acetate ions; 71-50-1; monoacetate; MeCO2 anion; UNII-569DQM74SC; ethanoate; Acetat; 569DQM74SC; Shotgun; Ethanoat; CHEMBL1354; racemic acetate; Azetat; acetyl hydroxide; Acetic acid ion; Acetic cid glacial; TCLP extraction fluid 2; AC1Q1J9D; AC1Q1J2O; CH3-COO(-); AC1L18N9; DTXSID1037694; CTK5D4394; CHEBI:30089; MolPort-006-169-563; QTBSBXVTEAMEQO-UHFFFAOYSA-M; STL282721; CMC_13391; BDBM50159793; AKOS022101130; AN-25008; AN-23801; LS-189936; 1395-EP2380874A2; 1395-EP2380661A2; 1395-EP2316837A1
DMD08RH	DT	Small molecular drug
DMD08RH	PC	175
DMD08RH	MW	59.04
DMD08RH	FM	C2H3O2-
DMD08RH	IC	InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)/p-1
DMD08RH	CS	CC(=O)[O-]
DMD08RH	IK	QTBSBXVTEAMEQO-UHFFFAOYSA-M
DMD08RH	IU	acetate
DMD08RH	CA	CAS 71-50-1
DMD08RH	CB	CHEBI:30089
DMD08RH	DE	Discovery agent

DMBP5L4	ID	DMBP5L4
DMBP5L4	DN	Acetic acid 2,6-diisopropyl-phenyl ester
DMBP5L4	HS	Investigative
DMBP5L4	SN	2,6-Diisopropylphenyl acetate; UVYYQAXNOURFPH-UHFFFAOYSA-N; [2,6-di(propan-2-yl)phenyl] acetate; Acetic acid 2,6-diisopropyl-phenyl ester; AC1LC89D; CHEMBL56587; SCHEMBL1927023; UVYYQAXNOURFPH-UHFFFAOYSA-; ZINC13779584; InChI=1/C14H20O2/c1-9(2)12-7-6-8-13(10(3)4)14(12)16-11(5)15/h6-10H,1-5H3
DMBP5L4	DT	Small molecular drug
DMBP5L4	PC	596091
DMBP5L4	MW	220.31
DMBP5L4	FM	C14H20O2
DMBP5L4	IC	InChI=1S/C14H20O2/c1-9(2)12-7-6-8-13(10(3)4)14(12)16-11(5)15/h6-10H,1-5H3
DMBP5L4	CS	CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)C
DMBP5L4	IK	UVYYQAXNOURFPH-UHFFFAOYSA-N
DMBP5L4	IU	[2,6-di(propan-2-yl)phenyl] acetate
DMBP5L4	DE	Discovery agent

DM97DJL	ID	DM97DJL
DM97DJL	DN	Acetic acid 2-hept-2-ynylsulfanyl-phenyl ester
DM97DJL	HS	Investigative
DM97DJL	SN	aphs; 209125-28-0; 2-(2-Heptynylthio)phenol Acetate; (2-hept-2-ynylsulfanylphenyl) acetate; CHEMBL345018; o-(Acetophenyl)hept-2-ynyl sulphide; Phenol, 2-(2-heptynylthio)-, acetate; Acetic acid 2-hept-2-ynylsulfanyl-phenyl ester; AC1L1D69; SCHEMBL3842943; DTXSID40175069; ZINC1903162; BDBM50068160; o-(Acetoxyphenyl)hept-2-ynyl sulphide; RT-011298; FT-0669138
DM97DJL	DT	Small molecular drug
DM97DJL	PC	2211
DM97DJL	MW	262.4
DM97DJL	FM	C15H18O2S
DM97DJL	IC	InChI=1S/C15H18O2S/c1-3-4-5-6-9-12-18-15-11-8-7-10-14(15)17-13(2)16/h7-8,10-11H,3-5,12H2,1-2H3
DM97DJL	CS	CCCCC#CCSC1=CC=CC=C1OC(=O)C
DM97DJL	IK	GXMBHQRROXQUJS-UHFFFAOYSA-N
DM97DJL	IU	(2-hept-2-ynylsulfanylphenyl) acetate
DM97DJL	CA	CAS 209125-28-0
DM97DJL	DE	Discovery agent

DMD89A1	ID	DMD89A1
DMD89A1	DN	Acetic acid 2-hept-3-ynylsulfanyl-phenyl ester
DMD89A1	HS	Investigative
DMD89A1	SN	CHEMBL145412; Acetic acid 2-hept-3-ynylsulfanyl-phenyl ester; ZINC13782091; BDBM50068194; Acetic acid 2-(3-heptynylthio)phenyl ester
DMD89A1	DT	Small molecular drug
DMD89A1	PC	9965111
DMD89A1	MW	262.4
DMD89A1	FM	C15H18O2S
DMD89A1	IC	InChI=1S/C15H18O2S/c1-3-4-5-6-9-12-18-15-11-8-7-10-14(15)17-13(2)16/h7-8,10-11H,3-4,9,12H2,1-2H3
DMD89A1	CS	CCCC#CCCSC1=CC=CC=C1OC(=O)C
DMD89A1	IK	DWPABKWGLDPTEB-UHFFFAOYSA-N
DMD89A1	IU	(2-hept-3-ynylsulfanylphenyl) acetate
DMD89A1	DE	Discovery agent

DM50BTA	ID	DM50BTA
DM50BTA	DN	Acetic acid 2-heptylselanyl-phenyl ester
DM50BTA	HS	Investigative
DM50BTA	SN	Acetic acid 2-heptylselanyl-phenyl ester; CHEMBL342799; BDBM50068185; Acetic acid 2-(heptylseleno)phenyl ester
DM50BTA	DT	Small molecular drug
DM50BTA	PC	9944615
DM50BTA	MW	313.3
DM50BTA	FM	C15H22O2Se
DM50BTA	IC	InChI=1S/C15H22O2Se/c1-3-4-5-6-9-12-18-15-11-8-7-10-14(15)17-13(2)16/h7-8,10-11H,3-6,9,12H2,1-2H3
DM50BTA	CS	CCCCCCC[Se]C1=CC=CC=C1OC(=O)C
DM50BTA	IK	FDXGTFIBPBOUCY-UHFFFAOYSA-N
DM50BTA	IU	(2-heptylselanylphenyl) acetate
DM50BTA	DE	Discovery agent

DMLPRIG	ID	DMLPRIG
DMLPRIG	DN	Acetic acid 2-heptylsulfanyl-phenyl ester
DMLPRIG	HS	Investigative
DMLPRIG	SN	Acetic acid 2-heptylsulfanyl-phenyl ester; CHEMBL143339; SCHEMBL6535129; BDBM50068166
DMLPRIG	DT	Small molecular drug
DMLPRIG	PC	9965195
DMLPRIG	MW	266.4
DMLPRIG	FM	C15H22O2S
DMLPRIG	IC	InChI=1S/C15H22O2S/c1-3-4-5-6-9-12-18-15-11-8-7-10-14(15)17-13(2)16/h7-8,10-11H,3-6,9,12H2,1-2H3
DMLPRIG	CS	CCCCCCCSC1=CC=CC=C1OC(=O)C
DMLPRIG	IK	FBOXARNCZRHBOP-UHFFFAOYSA-N
DMLPRIG	IU	(2-heptylsulfanylphenyl) acetate
DMLPRIG	DE	Discovery agent

DMFQE1C	ID	DMFQE1C
DMFQE1C	DN	Acetic acid 2-hex-2-ynylsulfanyl-phenyl ester
DMFQE1C	HS	Investigative
DMFQE1C	SN	CHEMBL144920; Acetic acid 2-hex-2-ynylsulfanyl-phenyl ester; ZINC13782090; BDBM50068198; Acetic acid 2-(2-hexynylthio)phenyl ester
DMFQE1C	DT	Small molecular drug
DMFQE1C	PC	9813643
DMFQE1C	MW	248.34
DMFQE1C	FM	C14H16O2S
DMFQE1C	IC	InChI=1S/C14H16O2S/c1-3-4-5-8-11-17-14-10-7-6-9-13(14)16-12(2)15/h6-7,9-10H,3-4,11H2,1-2H3
DMFQE1C	CS	CCCC#CCSC1=CC=CC=C1OC(=O)C
DMFQE1C	IK	MMWWBFVDWFUERO-UHFFFAOYSA-N
DMFQE1C	IU	(2-hex-2-ynylsulfanylphenyl) acetate
DMFQE1C	DE	Discovery agent

DMAKNUH	ID	DMAKNUH
DMAKNUH	DN	Acetic acid 2-hexylsulfanyl-phenyl ester
DMAKNUH	HS	Investigative
DMAKNUH	SN	Acetic acid 2-hexylsulfanyl-phenyl ester; CHEMBL144218; ZINC13782080
DMAKNUH	DT	Small molecular drug
DMAKNUH	PC	10220627
DMAKNUH	MW	252.37
DMAKNUH	FM	C14H20O2S
DMAKNUH	IC	InChI=1S/C14H20O2S/c1-3-4-5-8-11-17-14-10-7-6-9-13(14)16-12(2)15/h6-7,9-10H,3-5,8,11H2,1-2H3
DMAKNUH	CS	CCCCCCSC1=CC=CC=C1OC(=O)C
DMAKNUH	IK	IIONGZARVQOSAZ-UHFFFAOYSA-N
DMAKNUH	IU	(2-hexylsulfanylphenyl) acetate
DMAKNUH	DE	Discovery agent

DMFKRIH	ID	DMFKRIH
DMFKRIH	DN	Acetic acid 2-pentylsulfanyl-phenyl ester
DMFKRIH	HS	Investigative
DMFKRIH	SN	Acetic acid 2-pentylsulfanyl-phenyl ester; CHEMBL144806; SCHEMBL13659627; BDBM50068195
DMFKRIH	DT	Small molecular drug
DMFKRIH	PC	9837624
DMFKRIH	MW	238.35
DMFKRIH	FM	C13H18O2S
DMFKRIH	IC	InChI=1S/C13H18O2S/c1-3-4-7-10-16-13-9-6-5-8-12(13)15-11(2)14/h5-6,8-9H,3-4,7,10H2,1-2H3
DMFKRIH	CS	CCCCCSC1=CC=CC=C1OC(=O)C
DMFKRIH	IK	QCBPAZOETZPVCH-UHFFFAOYSA-N
DMFKRIH	IU	(2-pentylsulfanylphenyl) acetate
DMFKRIH	DE	Discovery agent

DMUYKIE	ID	DMUYKIE
DMUYKIE	DN	Acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester
DMUYKIE	HS	Investigative
DMUYKIE	SN	CHEMBL413975; Acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester; SCHEMBL9629413; BDBM50012407; Acetic acid 2-phenyl-5-propyl-4-thiazolyl ester
DMUYKIE	DT	Small molecular drug
DMUYKIE	PC	15691791
DMUYKIE	MW	261.339
DMUYKIE	FM	C14H15NO2S
DMUYKIE	IC	InChI=1S/C14H15NO2S/c1-3-7-12-13(17-10(2)16)15-14(18-12)11-8-5-4-6-9-11/h4-6,8-9H,3,7H2,1-2H3
DMUYKIE	CS	CCCC1=C(N=C(S1)C2=CC=CC=C2)OC(=O)C
DMUYKIE	IK	PNDOMGBHENBUGB-UHFFFAOYSA-N
DMUYKIE	IU	(2-phenyl-5-propyl-1,3-thiazol-4-yl) acetate
DMUYKIE	DE	Discovery agent

DM95QEA	ID	DM95QEA
DM95QEA	DN	Acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester
DM95QEA	HS	Investigative
DM95QEA	SN	CHEMBL303221; Acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester; SCHEMBL9630562; BDBM50012410; Acetic acid 5-butyl-2-phenyl-4-thiazolyl ester
DM95QEA	DT	Small molecular drug
DM95QEA	PC	15691792
DM95QEA	MW	275.4
DM95QEA	FM	C15H17NO2S
DM95QEA	IC	InChI=1S/C15H17NO2S/c1-3-4-10-13-14(18-11(2)17)16-15(19-13)12-8-6-5-7-9-12/h5-9H,3-4,10H2,1-2H3
DM95QEA	CS	CCCCC1=C(N=C(S1)C2=CC=CC=C2)OC(=O)C
DM95QEA	IK	NEOJOUJFNJKBMX-UHFFFAOYSA-N
DM95QEA	IU	(5-butyl-2-phenyl-1,3-thiazol-4-yl) acetate
DM95QEA	DE	Discovery agent

DMVEH40	ID	DMVEH40
DMVEH40	DN	Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMVEH40	HS	Investigative
DMVEH40	SN	CHEMBL64000; Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester; BDBM50064609
DMVEH40	DT	Small molecular drug
DMVEH40	PC	9815331
DMVEH40	MW	169.22
DMVEH40	FM	C9H15NO2
DMVEH40	IC	InChI=1S/C9H15NO2/c1-6(11)12-9-5-7-3-2-4-8(9)10-7/h7-10H,2-5H2,1H3
DMVEH40	CS	CC(=O)OC1CC2CCCC1N2
DMVEH40	IK	HHXDJDWQQPSWHW-UHFFFAOYSA-N
DMVEH40	IU	8-azabicyclo[3.2.1]octan-6-yl acetate
DMVEH40	DE	Discovery agent

DMLTNHY	ID	DMLTNHY
DMLTNHY	DN	Acetic Acid Salicyloyl-Amino-Ester
DMLTNHY	HS	Investigative
DMLTNHY	SN	O-Acetylsalicylhydroxamic Acid; ACETIC ACID SALICYLOYL-AMINO-ESTER; 199854-00-7; C9H9NO4; O-Acetyl Salicylhydroxamic Acid; N-(Acetyloxy)-2-hydroxybenzamide; SCL; N-Acetoxysalicylamide; AC1L9HR3; SCHEMBL4318044; CTK0A0021; PCFWLDHLJWUGSU-UHFFFAOYSA-N; MolPort-003-844-411; [(2-hydroxybenzoyl)amino] acetate; ZINC2046853; FCH850362; 1962AH; Benzamide, N-(acetyloxy)-2-hydroxy-; AKOS006293238; DB03667; AB22745; ACM199854007; (2-HYDROXYPHENYL)FORMAMIDO ACETATE; RT-014810; FT-0661357; 1846-EP2298783A1
DMLTNHY	DT	Small molecular drug
DMLTNHY	PC	445302
DMLTNHY	MW	195.17
DMLTNHY	FM	C9H9NO4
DMLTNHY	IC	InChI=1S/C9H9NO4/c1-6(11)14-10-9(13)7-4-2-3-5-8(7)12/h2-5,12H,1H3,(H,10,13)
DMLTNHY	CS	CC(=O)ONC(=O)C1=CC=CC=C1O
DMLTNHY	IK	PCFWLDHLJWUGSU-UHFFFAOYSA-N
DMLTNHY	IU	[(2-hydroxybenzoyl)amino] acetate
DMLTNHY	DE	Discovery agent

DM3HYU8	ID	DM3HYU8
DM3HYU8	DN	Acetoacetyl-Coenzyme A
DM3HYU8	HS	Investigative
DM3HYU8	SN	acetoacetyl-CoA; Acetoacetyl coenzyme A; acetoacetyl-coenzyme a; 3-acetoacetyl-CoA; Acetoacetyl coa; S-Acetoacetyl-CoA; S-Acetoacetylcoenzyme A; 1420-36-6; S-Acetoacetyl-coenzym A; S-acetoacetyl-coenzyme A; OJFDKHTZOUZBOS-CITAKDKDSA-N; acetoacetyl-S-CoA; S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-oxobutanethioate; s-acetoacetyl coenzyme a; bofuranosyl]-; 1dub
DM3HYU8	DT	Small molecular drug
DM3HYU8	PC	92153
DM3HYU8	MW	851.6
DM3HYU8	FM	C25H40N7O18P3S
DM3HYU8	IC	InChI=1S/C25H40N7O18P3S/c1-13(33)8-16(35)54-7-6-27-15(34)4-5-28-23(38)20(37)25(2,3)10-47-53(44,45)50-52(42,43)46-9-14-19(49-51(39,40)41)18(36)24(48-14)32-12-31-17-21(26)29-11-30-22(17)32/h11-12,14,18-20,24,36-37H,4-10H2,1-3H3,(H,27,34)(H,28,38)(H,42,43)(H,44,45)(H2,26,29,30)(H2,39,40,41)/t14-,18-,19-,20+,24-/m1/s1
DM3HYU8	CS	CC(=O)CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DM3HYU8	IK	OJFDKHTZOUZBOS-CITAKDKDSA-N
DM3HYU8	IU	S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-oxobutanethioate
DM3HYU8	CA	CAS 1420-36-6
DM3HYU8	CB	CHEBI:15345
DM3HYU8	DE	Discovery agent

DMH65Q8	ID	DMH65Q8
DMH65Q8	DN	Acetyl Coa
DMH65Q8	HS	Investigative
DMH65Q8	SN	acetyl coenzyme A; S-acetyl coenzyme A; acetylCoA; acetyl-CoA
DMH65Q8	DT	Small molecular drug
DMH65Q8	PC	444493
DMH65Q8	MW	809.6
DMH65Q8	FM	C23H38N7O17P3S
DMH65Q8	IC	InChI=1S/C23H38N7O17P3S/c1-12(31)51-7-6-25-14(32)4-5-26-21(35)18(34)23(2,3)9-44-50(41,42)47-49(39,40)43-8-13-17(46-48(36,37)38)16(33)22(45-13)30-11-29-15-19(24)27-10-28-20(15)30/h10-11,13,16-18,22,33-34H,4-9H2,1-3H3,(H,25,32)(H,26,35)(H,39,40)(H,41,42)(H2,24,27,28)(H2,36,37,38)/t13-,16-,17-,18+,22-/m1/s1
DMH65Q8	CS	CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DMH65Q8	IK	ZSLZBFCDCINBPY-ZSJPKINUSA-N
DMH65Q8	IU	S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] ethanethioate
DMH65Q8	CA	CAS 72-89-9
DMH65Q8	CB	CHEBI:15351
DMH65Q8	DE	Discovery agent

DMUH4N7	ID	DMUH4N7
DMUH4N7	DN	Acetyl ethylene
DMUH4N7	HS	Investigative
DMUH4N7	SN	Acetone, methylene-; 3-Buten-2-one; Butenone; Ketone, methyl vinyl; METHYL VINYL KETONE; Methyl ethenyl ketone; Methyl-vinyl-cetone; Methyl-vinyl-cetone [French]; Methylene acetone; Methylvinyl ketone; Methylvinylketon; Methylvinylketon [German]; Methylvinylketone; Vinyl methyl ketone; but-1-en-3-one; but-3-en-2-one; delta(sup 3)-2-Butenone; gamma-Oxo-alpha-butylene; methylvinylcetone; 1-Buten-3-one; 2-Butenone; 3-Butene-2-one; 3-Butenone-2; 3-oxo-1-butene; 78-94-4; CCRIS 3423; HSDB 716; NSC 4853; UNII-AR7642I1MP
DMUH4N7	PC	6570
DMUH4N7	MW	70.09
DMUH4N7	FM	C4H6O
DMUH4N7	IC	FUSUHKVFWTUUBE-UHFFFAOYSA-N
DMUH4N7	CS	CC(=O)C=C
DMUH4N7	IK	1S/C4H6O/c1-3-4(2)5/h3H,1H2,2H3
DMUH4N7	IU	but-3-en-2-one
DMUH4N7	CA	CAS 78-94-4
DMUH4N7	CB	CHEBI:48058
DMUH4N7	DE	Discovery agent

DMFZJRN	ID	DMFZJRN
DMFZJRN	DN	Acetyl-Ala-Ala-Pro-Ala-trifluromethane
DMFZJRN	HS	Investigative
DMFZJRN	SN	CHEMBL130128; Acetyl-Ala-Ala-Pro-Ala-trifluromethane; BDBM50014742
DMFZJRN	DT	Small molecular drug
DMFZJRN	PC	44353386
DMFZJRN	MW	422.4
DMFZJRN	FM	C17H25F3N4O5
DMFZJRN	IC	InChI=1S/C17H25F3N4O5/c1-8(13(26)17(18,19)20)22-15(28)12-6-5-7-24(12)16(29)10(3)23-14(27)9(2)21-11(4)25/h8-10,12H,5-7H2,1-4H3,(H,21,25)(H,22,28)(H,23,27)/t8-,9-,10-,12-/m0/s1
DMFZJRN	CS	C[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)C
DMFZJRN	IK	WGJCUKQNQHAXLF-GMOBBJLQSA-N
DMFZJRN	IU	(2S)-1-[(2S)-2-[[(2S)-2-acetamidopropanoyl]amino]propanoyl]-N-[(2S)-4,4,4-trifluoro-3-oxobutan-2-yl]pyrrolidine-2-carboxamide
DMFZJRN	DE	Discovery agent

DM1VE6S	ID	DM1VE6S
DM1VE6S	DN	Acetyl-Ile-Glu-Thr-Asp-aldehyde
DM1VE6S	HS	Investigative
DM1VE6S	SN	Ac-IETD-CHO; 191338-86-0; CHEMBL478695; Ac-Ile-Glu-Thr-Asp-CHO; SCHEMBL20257131; N-acetyl-Ile-Glu-Thr-Asp-aldehyde; ZINC14947181; BDBM50340547; Acetyl-isoleucyl-glutamyl-threonyl-aspartal; 338A860; N-Acetyl-Ile-Glu-Thr-Asp-al, ~99% (TLC), powder; (4S)-4-{[(1S,2R)-1-{[(2S)-1-carboxy-3-oxopropan-2-yl]carbamoyl}-2-hydroxypropyl]carbamoyl}-4-[(2S,3S)-2-acetamido-3-methylpentanamido]butanoic acid
DM1VE6S	DT	Small molecular drug
DM1VE6S	PC	11466200
DM1VE6S	MW	502.5
DM1VE6S	FM	C21H34N4O10
DM1VE6S	IC	InChI=1S/C21H34N4O10/c1-5-10(2)17(22-12(4)28)20(34)24-14(6-7-15(29)30)19(33)25-18(11(3)27)21(35)23-13(9-26)8-16(31)32/h9-11,13-14,17-18,27H,5-8H2,1-4H3,(H,22,28)(H,23,35)(H,24,34)(H,25,33)(H,29,30)(H,31,32)/t10-,11+,13-,14-,17-,18-/m0/s1
DM1VE6S	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)C
DM1VE6S	IK	AXTKTZHLZLOIIO-PBEPODTISA-N
DM1VE6S	IU	(4S)-4-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-5-[[(2S,3R)-1-[[(2S)-1-carboxy-3-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM1VE6S	DE	Discovery agent

DM74HGJ	ID	DM74HGJ
DM74HGJ	DN	Acetyl-L-carnitine
DM74HGJ	HS	Investigative
DM74HGJ	SN	UNII-521T0J13MA; acetyl-d-carnitine; 521T0J13MA; (3S)-3-acetoxy-4-(trimethylammonio)butyrate; 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, inner salt, (2S)-; 4398-79-2; O-acetylcarnitine; CAR(2:0); Acylcarnitine C2:0; O-acetyl-D-carnitine; AC1L2BM0; Acetylcarnitine, (R)-Isomer; SCHEMBL677128; C9H18NO4; GTPL4520; CHEBI:86045; DTXSID90196007; 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, hydroxide, inner salt, (R)-; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, acetate, L-
DM74HGJ	DT	Small molecular drug
DM74HGJ	PC	7045767
DM74HGJ	MW	203.24
DM74HGJ	FM	C9H17NO4
DM74HGJ	IC	InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1
DM74HGJ	CS	CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C
DM74HGJ	IK	RDHQFKQIGNGIED-MRVPVSSYSA-N
DM74HGJ	IU	(3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate
DM74HGJ	CA	CAS 3040-38-8
DM74HGJ	CB	CHEBI:57589
DM74HGJ	DE	Discovery agent

DMGTPFY	ID	DMGTPFY
DMGTPFY	DN	acetyl-podocarpic dimer
DMGTPFY	HS	Investigative
DMGTPFY	SN	acetyl podocarpic acid anhydride
DMGTPFY	DT	Small molecular drug
DMGTPFY	PC	9830426
DMGTPFY	MW	614.8
DMGTPFY	FM	C38H46O7
DMGTPFY	IC	InChI=1S/C38H46O7/c1-23(39)43-27-13-9-25-11-15-31-35(3,29(25)21-27)17-7-19-37(31,5)33(41)45-34(42)38(6)20-8-18-36(4)30-22-28(44-24(2)40)14-10-26(30)12-16-32(36)38/h9-10,13-14,21-22,31-32H,7-8,11-12,15-20H2,1-6H3/t31-,32-,35-,36-,37+,38+/m1/s1
DMGTPFY	CS	CC(=O)OC1=CC2=C(CC[C@@H]3[C@@]2(CCC[C@]3(C)C(=O)OC(=O)[C@]4(CCC[C@]5([C@H]4CCC6=C5C=C(C=C6)OC(=O)C)C)C)C)C=C1
DMGTPFY	IK	OUJQRQRBNRGQTC-SPGSYPTKSA-N
DMGTPFY	IU	[(1S,4aS,10aR)-6-acetyloxy-1,4a-dimethyl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carbonyl] (1S,4aS,10aR)-6-acetyloxy-1,4a-dimethyl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate
DMGTPFY	DE	Discovery agent

DMN5Z0F	ID	DMN5Z0F
DMN5Z0F	DN	Acetyl-Pro-Ala-Pro-Ala-trifluoro methane
DMN5Z0F	HS	Investigative
DMN5Z0F	SN	CHEMBL130718; Acetyl-Pro-Ala-Pro-Ala-trifluoro methane; BDBM50014740
DMN5Z0F	DT	Small molecular drug
DMN5Z0F	PC	44353385
DMN5Z0F	MW	448.4
DMN5Z0F	FM	C19H27F3N4O5
DMN5Z0F	IC	InChI=1S/C19H27F3N4O5/c1-10(15(28)19(20,21)22)23-17(30)14-7-5-9-26(14)18(31)11(2)24-16(29)13-6-4-8-25(13)12(3)27/h10-11,13-14H,4-9H2,1-3H3,(H,23,30)(H,24,29)/t10-,11-,13-,14-/m0/s1
DMN5Z0F	CS	C[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)C
DMN5Z0F	IK	DLOFUPNOARUTLN-IMIFBBOLSA-N
DMN5Z0F	IU	(2S)-1-acetyl-N-[(2S)-1-oxo-1-[(2S)-2-[[(2S)-4,4,4-trifluoro-3-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]propan-2-yl]pyrrolidine-2-carboxamide
DMN5Z0F	DE	Discovery agent

DMG8P24	ID	DMG8P24
DMG8P24	DN	ACETYLSULFANILAMIDE
DMG8P24	HS	Investigative
DMG8P24	SN	4-Acetamidobenzenesulfonamide; 121-61-9; N-(4-Sulfamoylphenyl)acetamide; Acetylsulfanilamide; Neotherapol; p-Sulfamylacetanilide; N4-ACETYLSULFANILAMIDE; Erytrin; N4-Acetsulfanilamide; 4-Acetylaminobenzenesulfonamide; 4'-Sulfamylacetanilide; 4'-Sulfamoylacetanilide; Sulfanilamide-N4-acetate; p-Sulfamoylacetanilide; p-Acetamidobenzenesulfonamide; N'-Acetylsulphanilamide; 4'-Sulphamoylacetanilide; N-(4-Sulphamoylphenyl)acetamide; Benzenesulfonamide, p-acetamido-; p-(Acetylamino)benzenesulfonamide; Acetanilide, 4'-sulfamoyl-
DMG8P24	DT	Small molecular drug
DMG8P24	PC	8482
DMG8P24	MW	214.24
DMG8P24	FM	C8H10N2O3S
DMG8P24	IC	InChI=1S/C8H10N2O3S/c1-6(11)10-7-2-4-8(5-3-7)14(9,12)13/h2-5H,1H3,(H,10,11)(H2,9,12,13)
DMG8P24	CS	CC(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DMG8P24	IK	PKOFBDHYTMYVGJ-UHFFFAOYSA-N
DMG8P24	IU	N-(4-sulfamoylphenyl)acetamide
DMG8P24	CA	CAS 121-61-9
DMG8P24	DE	Discovery agent

DM3XHIY	ID	DM3XHIY
DM3XHIY	DN	Ac-FWKY-NH2
DM3XHIY	HS	Investigative
DM3XHIY	SN	CHEMBL1165795
DM3XHIY	DT	Small molecular drug
DM3XHIY	PC	10985299
DM3XHIY	MW	683.8
DM3XHIY	FM	C37H45N7O6
DM3XHIY	IC	InChI=1S/C37H45N7O6/c1-23(45)41-32(20-24-9-3-2-4-10-24)36(49)44-33(21-26-22-40-29-12-6-5-11-28(26)29)37(50)42-30(13-7-8-18-38)35(48)43-31(34(39)47)19-25-14-16-27(46)17-15-25/h2-6,9-12,14-17,22,30-33,40,46H,7-8,13,18-21,38H2,1H3,(H2,39,47)(H,41,45)(H,42,50)(H,43,48)(H,44,49)/t30-,31-,32-,33-/m0/s1
DM3XHIY	CS	CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N
DM3XHIY	IK	YBFQDCKGFBIRPS-YRCZKMHPSA-N
DM3XHIY	IU	(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-amino-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]hexanamide
DM3XHIY	DE	Discovery agent

DMAI43O	ID	DMAI43O
DMAI43O	DN	AcGlu-Asp-Val-Val-Leu-Cys-Iqc-Nle-Thr-TyrNH2
DMAI43O	HS	Investigative
DMAI43O	SN	CHEMBL386885; AcGlu-Asp-Val-Val-Leu-Cys-Iqc-Nle-Thr-TyrNH2
DMAI43O	PC	44388164
DMAI43O	MW	1254.5
DMAI43O	FM	C59H87N11O17S
DMAI43O	IC	InChI=1S/C59H87N11O17S/c1-9-10-15-38(51(79)66-43(28-71)55(83)64-41(50(60)78)25-34-16-18-37(73)19-17-34)63-56(84)45-26-35-13-11-12-14-36(35)27-70(45)59(87)44(29-88)67-54(82)42(24-30(2)3)65-57(85)48(31(4)5)69-58(86)49(32(6)7)68-53(81)40(21-23-47(76)77)62-52(80)39(61-33(8)72)20-22-46(74)75/h11-14,16-19,30-32,38-45,48-49,71,73,88H,9-10,15,20-29H2,1-8H3,(H2,60,78)(H,61,72)(H,62,80)(H,63,84)(H,64,83)(H,65,85)(H,66,79)(H,67,82)(H,68,81)(H,69,86)(H,74,75)(H,76,77)/t38-,39-,40-,41-,42-,43-,44-,45+,48-,49-/m0/s1
DMAI43O	CS	CCCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H]2CC3=CC=CC=C3CN2C(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)C
DMAI43O	IK	HGLKSJLIZCXTFK-SEAKOTFTSA-N
DMAI43O	IU	(4S)-4-acetamido-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[(3R)-3-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-3,4-dihydro-1H-isoquinolin-2-yl]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMAI43O	DE	Discovery agent

DM6T09B	ID	DM6T09B
DM6T09B	DN	Ac-Glu-Cha-Cys
DM6T09B	HS	Investigative
DM6T09B	SN	CHEMBL303340; Ac-Glu-Cha-Cys; AcGlu-Cha-Cys; AC1NRQFL; AcGlu-.beta.-Cyclohexylalanine-Cys; BDBM50096406; Ac-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-acetamido-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid; (4S)-4-acetamido-5-[[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-2-hydroxy-2-oxo-1-(sulfanylmethyl)ethyl]amino]-2-oxo-ethyl]amino]-5-oxo-pentanoic acid
DM6T09B	DT	Small molecular drug
DM6T09B	PC	5271014
DM6T09B	MW	445.5
DM6T09B	FM	C19H31N3O7S
DM6T09B	IC	InChI=1S/C19H31N3O7S/c1-11(23)20-13(7-8-16(24)25)17(26)21-14(9-12-5-3-2-4-6-12)18(27)22-15(10-30)19(28)29/h12-15,30H,2-10H2,1H3,(H,20,23)(H,21,26)(H,22,27)(H,24,25)(H,28,29)/t13-,14-,15-/m0/s1
DM6T09B	CS	CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O
DM6T09B	IK	JOZDKRPORTUAIW-KKUMJFAQSA-N
DM6T09B	IU	(4S)-4-acetamido-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM6T09B	DE	Discovery agent

DM0BV9I	ID	DM0BV9I
DM0BV9I	DN	AcGlu-Dif-Glu-Cha-Cys
DM0BV9I	HS	Investigative
DM0BV9I	SN	CHEMBL431559; AcGlu-Dif-Glu-Cha-Cys; AC1LAAI4; Ac-Glu-Dif-Glu-Cha-Cys-OH; BDBM50096407; Ac-L-Glu-3,3-Diphenyl-L-Ala-L-Glu-3-cyclohexyl-L-Ala-L-Cys-OH; AcGlu-Dif(3,3-diphenylalanine)-Glu-Cha(beta-cychohexylalanine)-Cys; (4S)-4-acetamido-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-hydroxy-1,5-dioxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM0BV9I	DT	Small molecular drug
DM0BV9I	PC	484561
DM0BV9I	MW	797.9
DM0BV9I	FM	C39H51N5O11S
DM0BV9I	IC	InChI=1S/C39H51N5O11S/c1-23(45)40-27(17-19-31(46)47)36(51)44-34(33(25-13-7-3-8-14-25)26-15-9-4-10-16-26)38(53)41-28(18-20-32(48)49)35(50)42-29(21-24-11-5-2-6-12-24)37(52)43-30(22-56)39(54)55/h3-4,7-10,13-16,24,27-30,33-34,56H,2,5-6,11-12,17-22H2,1H3,(H,40,45)(H,41,53)(H,42,50)(H,43,52)(H,44,51)(H,46,47)(H,48,49)(H,54,55)/t27-,28-,29-,30-,34-/m0/s1
DM0BV9I	CS	CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CS)C(=O)O
DM0BV9I	IK	JVFCWJBRHCCRTF-ULYIESCMSA-N
DM0BV9I	IU	(4S)-4-acetamido-5-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM0BV9I	DE	Discovery agent

DMK6HGI	ID	DMK6HGI
DMK6HGI	DN	AcGlu-Dif-Ile-Cha-Cys
DMK6HGI	HS	Investigative
DMK6HGI	SN	CHEMBL304005; AcGlu-Dif-Ile-Cha-Cys
DMK6HGI	DT	Small molecular drug
DMK6HGI	PC	44304858
DMK6HGI	MW	782
DMK6HGI	FM	C40H55N5O9S
DMK6HGI	IC	InChI=1S/C40H55N5O9S/c1-4-24(2)34(38(51)42-30(22-26-14-8-5-9-15-26)37(50)43-31(23-55)40(53)54)44-39(52)35(45-36(49)29(41-25(3)46)20-21-32(47)48)33(27-16-10-6-11-17-27)28-18-12-7-13-19-28/h6-7,10-13,16-19,24,26,29-31,33-35,55H,4-5,8-9,14-15,20-23H2,1-3H3,(H,41,46)(H,42,51)(H,43,50)(H,44,52)(H,45,49)(H,47,48)(H,53,54)/t24-,29+,30+,31-,34-,35+/m1/s1
DMK6HGI	CS	CC[C@@H](C)[C@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](CS)C(=O)O)NC(=O)[C@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)C
DMK6HGI	IK	WLXMMKXNDCWWHB-KGIQSIOISA-N
DMK6HGI	IU	(4S)-4-acetamido-5-[[(2S)-1-[[(2R,3R)-1-[[(2S)-1-[[(1S)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DMK6HGI	DE	Discovery agent

DMMNQE3	ID	DMMNQE3
DMMNQE3	DN	ACH-702
DMMNQE3	HS	Investigative
DMMNQE3	SN	ACH-702; UNII-35QF8GE1L1; 35QF8GE1L1; CHEMBL1256993; ACH702; ACH 702; SCHEMBL728226; BDBM50330327; Isothiazolo(5,4-b)quinoline-3,4(2H,9H)-dione, 7-((3R)-3-(1-amino-1-methylethyl)-1-pyrrolidinyl)-9-cyclopropyl-6-fluoro-8-methoxy-; 922491-46-1; (R)-7-[3-(1-amino-1-methyl-ethyl)-pyrrolidin-1-yl]-9-cyclopropyl-6-fluoro-8-methoxy-9H isothiazolo[5,4-b]quinoline-3,4-dione; (r)-7-(3-(2-aminopropan-2-yl)pyrrolidin-1-yl)-9-cyclopropyl-6-fluoro-8-methoxyisothiazolo[5,4-b]quinoline-3,4(2h,9h)-dione
DMMNQE3	DT	Small molecular drug
DMMNQE3	PC	16048804
DMMNQE3	MW	432.5
DMMNQE3	FM	C21H25FN4O3S
DMMNQE3	IC	InChI=1S/C21H25FN4O3S/c1-21(2,23)10-6-7-25(9-10)16-13(22)8-12-15(18(16)29-3)26(11-4-5-11)20-14(17(12)27)19(28)24-30-20/h8,10-11H,4-7,9,23H2,1-3H3,(H,24,28)/t10-/m1/s1
DMMNQE3	CS	CC(C)([C@@H]1CCN(C1)C2=C(C=C3C(=C2OC)N(C4=C(C3=O)C(=O)NS4)C5CC5)F)N
DMMNQE3	IK	CECJUHKZSOSOJJ-SNVBAGLBSA-N
DMMNQE3	IU	7-[(3R)-3-(2-aminopropan-2-yl)pyrrolidin-1-yl]-9-cyclopropyl-6-fluoro-8-methoxy-[1,2]thiazolo[5,4-b]quinoline-3,4-dione
DMMNQE3	CA	CAS 922491-46-1
DMMNQE3	DE	Bacterial infection

DMUEBRN	ID	DMUEBRN
DMUEBRN	DN	Ac-His-DNal(2)-Arg-Trp-NH2
DMUEBRN	HS	Investigative
DMUEBRN	SN	CHEMBL454736; Ac-His-DNal(2)-Arg-Trp-NH2
DMUEBRN	DT	Small molecular drug
DMUEBRN	PC	44568851
DMUEBRN	MW	735.8
DMUEBRN	FM	C38H45N11O5
DMUEBRN	IC	InChI=1S/C38H45N11O5/c1-22(50)46-33(18-27-20-42-21-45-27)37(54)49-32(16-23-12-13-24-7-2-3-8-25(24)15-23)36(53)47-30(11-6-14-43-38(40)41)35(52)48-31(34(39)51)17-26-19-44-29-10-5-4-9-28(26)29/h2-5,7-10,12-13,15,19-21,30-33,44H,6,11,14,16-18H2,1H3,(H2,39,51)(H,42,45)(H,46,50)(H,47,53)(H,48,52)(H,49,54)(H4,40,41,43)/t30-,31-,32-,33+/m0/s1
DMUEBRN	CS	CC(=O)N[C@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N
DMUEBRN	IK	OHBCPCNJWIQQPW-ZWDYZTTJSA-N
DMUEBRN	IU	(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMUEBRN	DE	Discovery agent

DMR31Z9	ID	DMR31Z9
DMR31Z9	DN	Ac-His-DPhe(3,4-diCl)-Arg-Trp-NH2
DMR31Z9	HS	Investigative
DMR31Z9	SN	CHEMBL501394; Ac-His-DPhe(3,4-diCl)-Arg-Trp-NH2
DMR31Z9	DT	Small molecular drug
DMR31Z9	PC	25108218
DMR31Z9	MW	754.7
DMR31Z9	FM	C34H41Cl2N11O5
DMR31Z9	IC	InChI=1S/C34H41Cl2N11O5/c1-18(48)44-29(14-21-16-40-17-43-21)33(52)47-28(12-19-8-9-23(35)24(36)11-19)32(51)45-26(7-4-10-41-34(38)39)31(50)46-27(30(37)49)13-20-15-42-25-6-3-2-5-22(20)25/h2-3,5-6,8-9,11,15-17,26-29,42H,4,7,10,12-14H2,1H3,(H2,37,49)(H,40,43)(H,44,48)(H,45,51)(H,46,50)(H,47,52)(H4,38,39,41)/t26-,27-,28+,29-/m0/s1
DMR31Z9	CS	CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC(=C(C=C2)Cl)Cl)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DMR31Z9	IK	ULVZZVUTBBXNBL-FKWFRFQNSA-N
DMR31Z9	IU	(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(3,4-dichlorophenyl)propanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMR31Z9	DE	Discovery agent

DMXU5ZP	ID	DMXU5ZP
DMXU5ZP	DN	Ac-His-DPhe(pBr)-Arg-Trp-NH2
DMXU5ZP	HS	Investigative
DMXU5ZP	SN	CHEMBL502093; Ac-His-DPhe(pBr)-Arg-Trp-NH2
DMXU5ZP	DT	Small molecular drug
DMXU5ZP	PC	25108216
DMXU5ZP	MW	764.7
DMXU5ZP	FM	C34H42BrN11O5
DMXU5ZP	IC	InChI=1S/C34H42BrN11O5/c1-19(47)43-29(15-23-17-39-18-42-23)33(51)46-28(13-20-8-10-22(35)11-9-20)32(50)44-26(7-4-12-40-34(37)38)31(49)45-27(30(36)48)14-21-16-41-25-6-3-2-5-24(21)25/h2-3,5-6,8-11,16-18,26-29,41H,4,7,12-15H2,1H3,(H2,36,48)(H,39,42)(H,43,47)(H,44,50)(H,45,49)(H,46,51)(H4,37,38,40)/t26-,27-,28+,29-/m0/s1
DMXU5ZP	CS	CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=C(C=C2)Br)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DMXU5ZP	IK	UDLFTFKLQRVSSE-FKWFRFQNSA-N
DMXU5ZP	IU	(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-bromophenyl)propanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMXU5ZP	DE	Discovery agent

DMTA6I5	ID	DMTA6I5
DMTA6I5	DN	Ac-His-DPhe(pCF3)-Arg-Trp-NH2
DMTA6I5	HS	Investigative
DMTA6I5	SN	CHEMBL501679; Ac-His-DPhe(pCF3)-Arg-Trp-NH2
DMTA6I5	DT	Small molecular drug
DMTA6I5	PC	25108217
DMTA6I5	MW	753.8
DMTA6I5	FM	C35H42F3N11O5
DMTA6I5	IC	InChI=1S/C35H42F3N11O5/c1-19(50)46-29(15-23-17-42-18-45-23)33(54)49-28(13-20-8-10-22(11-9-20)35(36,37)38)32(53)47-26(7-4-12-43-34(40)41)31(52)48-27(30(39)51)14-21-16-44-25-6-3-2-5-24(21)25/h2-3,5-6,8-11,16-18,26-29,44H,4,7,12-15H2,1H3,(H2,39,51)(H,42,45)(H,46,50)(H,47,53)(H,48,52)(H,49,54)(H4,40,41,43)/t26-,27-,28+,29-/m0/s1
DMTA6I5	CS	CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=C(C=C2)C(F)(F)F)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DMTA6I5	IK	OBZQTNACJLTWOC-FKWFRFQNSA-N
DMTA6I5	IU	(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-[4-(trifluoromethyl)phenyl]propanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMTA6I5	DE	Discovery agent

DM3GSPX	ID	DM3GSPX
DM3GSPX	DN	Ac-His-DPhe(pI)-Arg-Trp-NH2
DM3GSPX	HS	Investigative
DM3GSPX	SN	CHEMBL322610; Ac-His-DPhe(pI)-Arg-Trp-NH2; BDBM50115373; JRH-322-18; 2-[2-[2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-(4-iodo-phenyl)-propionylamino]-5-guanidino-pentanoic acid [1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide
DM3GSPX	DT	Small molecular drug
DM3GSPX	PC	9875763
DM3GSPX	MW	811.7
DM3GSPX	FM	C34H42IN11O5
DM3GSPX	IC	InChI=1S/C34H42IN11O5/c1-19(47)43-29(15-23-17-39-18-42-23)33(51)46-28(13-20-8-10-22(35)11-9-20)32(50)44-26(7-4-12-40-34(37)38)31(49)45-27(30(36)48)14-21-16-41-25-6-3-2-5-24(21)25/h2-3,5-6,8-11,16-18,26-29,41H,4,7,12-15H2,1H3,(H2,36,48)(H,39,42)(H,43,47)(H,44,50)(H,45,49)(H,46,51)(H4,37,38,40)/t26-,27-,28+,29-/m0/s1
DM3GSPX	CS	CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=C(C=C2)I)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DM3GSPX	IK	OBADRSUMIBIHEX-FKWFRFQNSA-N
DM3GSPX	IU	(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-iodophenyl)propanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DM3GSPX	DE	Discovery agent

DMAQR29	ID	DMAQR29
DMAQR29	DN	Ac-His-D-Phe-Arg-2-Nal-NHCH3
DMAQR29	HS	Investigative
DMAQR29	SN	CHEMBL211699; Ac-His-D-Phe-Arg-2-Nal-NHCH3; BDBM50189018; (S)-2-{(R)-2-[(S)-2-acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid ((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide
DMAQR29	DT	Small molecular drug
DMAQR29	PC	44413876
DMAQR29	MW	710.8
DMAQR29	FM	C37H46N10O5
DMAQR29	IC	InChI=1S/C37H46N10O5/c1-23(48)44-32(20-28-21-41-22-43-28)36(52)47-31(18-24-9-4-3-5-10-24)35(51)45-29(13-8-16-42-37(38)39)34(50)46-30(33(49)40-2)19-25-14-15-26-11-6-7-12-27(26)17-25/h3-7,9-12,14-15,17,21-22,29-32H,8,13,16,18-20H2,1-2H3,(H,40,49)(H,41,43)(H,44,48)(H,45,51)(H,46,50)(H,47,52)(H4,38,39,42)/t29-,30-,31+,32-/m0/s1
DMAQR29	CS	CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NC
DMAQR29	IK	KXPKJVIQPPHENQ-IHZBLBIESA-N
DMAQR29	IU	(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)-N-[(2S)-1-(methylamino)-3-naphthalen-2-yl-1-oxopropan-2-yl]pentanamide
DMAQR29	DE	Discovery agent

DMMP0D8	ID	DMMP0D8
DMMP0D8	DN	Ac-His-DPhe-Arg-Trp-NH2
DMMP0D8	HS	Investigative
DMMP0D8	SN	Ac-His-Phe-Arg-Trp-NH2; CHEMBL50056; Ac-His-Phe-Arg-Trp-NH(2); L-Tryptophanamide, N-acetyl-L-histidyl-L-phenylalanyl-L-arginyl-; Ac-His-D-Phe-Arg-D-Trp-NH2; CTK0D4815; 2-{2-[2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid [1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide; 110392-38-6; BDBM50034910; (S)-2-{(S)-2-[(S)-2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid [(S)-1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide
DMMP0D8	DT	Small molecular drug
DMMP0D8	PC	11093672
DMMP0D8	MW	685.8
DMMP0D8	FM	C34H43N11O5
DMMP0D8	IC	InChI=1S/C34H43N11O5/c1-20(46)42-29(16-23-18-38-19-41-23)33(50)45-28(14-21-8-3-2-4-9-21)32(49)43-26(12-7-13-39-34(36)37)31(48)44-27(30(35)47)15-22-17-40-25-11-6-5-10-24(22)25/h2-6,8-11,17-19,26-29,40H,7,12-16H2,1H3,(H2,35,47)(H,38,41)(H,42,46)(H,43,49)(H,44,48)(H,45,50)(H4,36,37,39)/t26-,27-,28+,29-/m0/s1
DMMP0D8	CS	CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DMMP0D8	IK	DFCJPPDAOZROBS-FKWFRFQNSA-N
DMMP0D8	IU	(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMMP0D8	DE	Discovery agent

DMCA4QR	ID	DMCA4QR
DMCA4QR	DN	Ac-His-Trp-Ala-Val-Ala-His-Leu-Met-NH2
DMCA4QR	HS	Investigative
DMCA4QR	SN	CHEMBL438290; Ac-His-Trp-Ala-Val-Ala-His-Leu-Met-NH2
DMCA4QR	PC	44306522
DMCA4QR	MW	1005.2
DMCA4QR	FM	C47H68N14O9S
DMCA4QR	IC	InChI=1S/C47H68N14O9S/c1-24(2)15-35(44(67)57-34(40(48)63)13-14-71-8)59-46(69)38(18-31-21-50-23-53-31)58-41(64)26(5)55-47(70)39(25(3)4)61-42(65)27(6)54-43(66)36(16-29-19-51-33-12-10-9-11-32(29)33)60-45(68)37(56-28(7)62)17-30-20-49-22-52-30/h9-12,19-27,34-39,51H,13-18H2,1-8H3,(H2,48,63)(H,49,52)(H,50,53)(H,54,66)(H,55,70)(H,56,62)(H,57,67)(H,58,64)(H,59,69)(H,60,68)(H,61,65)/t26-,27-,34-,35-,36-,37-,38-,39-/m0/s1
DMCA4QR	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C
DMCA4QR	IK	FLMAIOAFTCGWGR-YDDHTLEASA-N
DMCA4QR	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpentanamide
DMCA4QR	DE	Discovery agent

DMUINVT	ID	DMUINVT
DMUINVT	DN	Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2
DMUINVT	HS	Investigative
DMUINVT	SN	CHEMBL263873; Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2
DMUINVT	PC	44306563
DMUINVT	MW	1005.2
DMUINVT	FM	C47H68N14O9S
DMUINVT	IC	InChI=1S/C47H68N14O9S/c1-24(2)15-35(44(67)57-34(40(48)63)13-14-71-8)59-46(69)38(18-31-21-50-23-53-31)58-41(64)26(5)55-47(70)39(25(3)4)61-42(65)27(6)54-43(66)36(16-29-19-51-33-12-10-9-11-32(29)33)60-45(68)37(56-28(7)62)17-30-20-49-22-52-30/h9-12,19-27,34-39,51H,13-18H2,1-8H3,(H2,48,63)(H,49,52)(H,50,53)(H,54,66)(H,55,70)(H,56,62)(H,57,67)(H,58,64)(H,59,69)(H,60,68)(H,61,65)/t26-,27+,34+,35+,36+,37+,38+,39+/m1/s1
DMUINVT	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C
DMUINVT	IK	FLMAIOAFTCGWGR-UGUXQERMSA-N
DMUINVT	IU	(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpentanamide
DMUINVT	DE	Discovery agent

DMUGO9M	ID	DMUGO9M
DMUGO9M	DN	Ac-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
DMUGO9M	HS	Investigative
DMUGO9M	SN	CHEMBL274874; Ac-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2; Acetyl-GRP(20-27); BDBM50012306; ZINC169366208
DMUGO9M	DT	Small molecular drug
DMUGO9M	PC	13049019
DMUGO9M	MW	991.2
DMUGO9M	FM	C46H66N14O9S
DMUGO9M	IC	InChI=1S/C46H66N14O9S/c1-24(2)14-34(43(66)57-33(40(47)63)12-13-70-7)58-45(68)37(17-30-20-49-23-53-30)56-38(62)21-51-46(69)39(25(3)4)60-41(64)26(5)54-42(65)35(15-28-18-50-32-11-9-8-10-31(28)32)59-44(67)36(55-27(6)61)16-29-19-48-22-52-29/h8-11,18-20,22-26,33-37,39,50H,12-17,21H2,1-7H3,(H2,47,63)(H,48,52)(H,49,53)(H,51,69)(H,54,65)(H,55,61)(H,56,62)(H,57,66)(H,58,68)(H,59,67)(H,60,64)/t26-,33-,34-,35-,36-,37-,39-/m0/s1
DMUGO9M	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C
DMUGO9M	IK	PESSCGOLEUORDO-IFIOYJEKSA-N
DMUGO9M	IU	(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpentanamide
DMUGO9M	DE	Discovery agent

DMZO5Y7	ID	DMZO5Y7
DMZO5Y7	DN	ACHP
DMZO5Y7	HS	Investigative
DMZO5Y7	DT	Small molecular drug
DMZO5Y7	PC	135465539
DMZO5Y7	MW	364.4
DMZO5Y7	FM	C21H24N4O2
DMZO5Y7	IC	InChI=1S/C21H24N4O2/c22-11-16-15(14-6-8-24-9-7-14)10-17(25-21(16)23)20-18(26)2-1-3-19(20)27-12-13-4-5-13/h1-3,10,13-14,24,26H,4-9,12H2,(H2,23,25)
DMZO5Y7	CS	C1CC1COC2=CC=CC(=C2C3=NC(=C(C(=C3)C4CCNCC4)C#N)N)O
DMZO5Y7	IK	DYVFBWXIOCLHPP-UHFFFAOYSA-N
DMZO5Y7	IU	2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-ylpyridine-3-carbonitrile
DMZO5Y7	CB	CHEBI:91445
DMZO5Y7	DE	Multiple myeloma

DMU7SBD	ID	DMU7SBD
DMU7SBD	DN	Ac-hPhe-Leu-Ala-LeuVSMe
DMU7SBD	HS	Investigative
DMU7SBD	SN	CHEMBL207579; Ac-hPhe-Leu-Ala-LeuVSMe
DMU7SBD	DT	Small molecular drug
DMU7SBD	PC	11556056
DMU7SBD	MW	578.8
DMU7SBD	FM	C29H46N4O6S
DMU7SBD	IC	InChI=1S/C29H46N4O6S/c1-19(2)17-24(15-16-40(7,38)39)32-27(35)21(5)30-29(37)26(18-20(3)4)33-28(36)25(31-22(6)34)14-13-23-11-9-8-10-12-23/h8-12,15-16,19-21,24-26H,13-14,17-18H2,1-7H3,(H,30,37)(H,31,34)(H,32,35)(H,33,36)/b16-15+/t21-,24+,25-,26-/m0/s1
DMU7SBD	CS	C[C@@H](C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)C
DMU7SBD	IK	WUQZWLVEKPBGGU-WXIXLNPNSA-N
DMU7SBD	IU	(2S)-2-[[(2S)-2-acetamido-4-phenylbutanoyl]amino]-4-methyl-N-[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]pentanamide
DMU7SBD	DE	Discovery agent

DMH2SU4	ID	DMH2SU4
DMH2SU4	DN	Ac-hPhe-Leu-Gly-LeuVSMe
DMH2SU4	HS	Investigative
DMH2SU4	SN	CHEMBL209243; Ac-hPhe-Leu-Gly-LeuVSMe
DMH2SU4	DT	Small molecular drug
DMH2SU4	PC	11713852
DMH2SU4	MW	564.7
DMH2SU4	FM	C28H44N4O6S
DMH2SU4	IC	InChI=1S/C28H44N4O6S/c1-19(2)16-23(14-15-39(6,37)38)31-26(34)18-29-27(35)25(17-20(3)4)32-28(36)24(30-21(5)33)13-12-22-10-8-7-9-11-22/h7-11,14-15,19-20,23-25H,12-13,16-18H2,1-6H3,(H,29,35)(H,30,33)(H,31,34)(H,32,36)/b15-14+/t23-,24+,25+/m1/s1
DMH2SU4	CS	CC(C)C[C@@H](/C=C/S(=O)(=O)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)C
DMH2SU4	IK	NYFDCVWCYDTELB-GNEZGTDISA-N
DMH2SU4	IU	(2S)-2-[[(2S)-2-acetamido-4-phenylbutanoyl]amino]-4-methyl-N-[2-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-2-oxoethyl]pentanamide
DMH2SU4	DE	Discovery agent

DMMDJPC	ID	DMMDJPC
DMMDJPC	DN	Ac-hPhe-Leu-Phe-LeuVSMe
DMMDJPC	HS	Investigative
DMMDJPC	SN	CHEMBL379669; Ac-hPhe-Leu-Phe-LeuVSMe; BDBM50186702
DMMDJPC	DT	Small molecular drug
DMMDJPC	PC	11693148
DMMDJPC	MW	654.9
DMMDJPC	FM	C35H50N4O6S
DMMDJPC	IC	InChI=1S/C35H50N4O6S/c1-24(2)21-29(19-20-46(6,44)45)37-34(42)32(23-28-15-11-8-12-16-28)39-35(43)31(22-25(3)4)38-33(41)30(36-26(5)40)18-17-27-13-9-7-10-14-27/h7-16,19-20,24-25,29-32H,17-18,21-23H2,1-6H3,(H,36,40)(H,37,42)(H,38,41)(H,39,43)/b20-19+/t29-,30+,31+,32+/m1/s1
DMMDJPC	CS	CC(C)C[C@@H](/C=C/S(=O)(=O)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC2=CC=CC=C2)NC(=O)C
DMMDJPC	IK	UIUWSHIRBDIYGM-QLEUBDALSA-N
DMMDJPC	IU	(2S)-2-[[(2S)-2-acetamido-4-phenylbutanoyl]amino]-4-methyl-N-[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]pentanamide
DMMDJPC	DE	Discovery agent

DMV58GQ	ID	DMV58GQ
DMV58GQ	DN	Ac-HSDAVFTDQYTRLRKQVAAKKYLQSIKQKRYC
DMV58GQ	HS	Investigative
DMV58GQ	PC	91936071
DMV58GQ	MW	3916
DMV58GQ	FM	C174H280N52O49S
DMV58GQ	IC	InChI=1S/C174H280N52O49S/c1-17-90(10)137(168(271)209-109(40-25-30-68-179)146(249)205-113(56-60-129(180)235)151(254)202-106(37-22-27-65-176)144(247)203-111(42-32-70-192-173(186)187)149(252)214-120(76-99-46-52-103(233)53-47-99)159(262)221-128(84-276)171(274)275)224-165(268)127(83-228)219-153(256)115(58-62-131(182)237)207-157(260)118(73-87(4)5)212-158(261)119(75-98-44-50-102(232)51-45-98)213-148(251)108(39-24-29-67-178)201-143(246)105(36-21-26-64-175)199-141(244)92(12)195-140(243)91(11)197-166(269)135(88(6)7)223-154(257)116(59-63-132(183)238)206-145(248)107(38-23-28-66-177)200-147(250)110(41-31-69-191-172(184)185)204-156(259)117(72-86(2)3)211-150(253)112(43-33-71-193-174(188)189)210-169(272)138(94(14)229)225-162(265)121(77-100-48-54-104(234)55-49-100)215-152(255)114(57-61-130(181)236)208-161(264)125(80-134(241)242)218-170(273)139(95(15)230)226-163(266)122(74-97-34-19-18-20-35-97)217-167(270)136(89(8)9)222-142(245)93(13)196-155(258)124(79-133(239)240)216-164(267)126(82-227)220-160(263)123(198-96(16)231)78-101-81-190-85-194-101/h18-20,34-35,44-55,81,85-95,105-128,135-139,227-230,232-234,276H,17,21-33,36-43,56-80,82-84,175-179H2,1-16H3,(H2,180,235)(H2,181,236)(H2,182,237)(H2,183,238)(H,190,194)(H,195,243)(H,196,258)(H,197,269)(H,198,231)(H,199,244)(H,200,250)(H,201,246)(H,202,254)(H,203,247)(H,204,259)(H,205,249)(H,206,248)(H,207,260)(H,208,264)(H,209,271)(H,210,272)(H,211,253)(H,212,261)(H,213,251)(H,214,252)(H,215,255)(H,216,267)(H,217,270)(H,218,273)(H,219,256)(H,220,263)(H,221,262)(H,222,245)(H,223,257)(H,224,268)(H,225,265)(H,226,266)(H,239,240)(H,241,242)(H,274,275)(H4,184,185,191)(H4,186,187,192)(H4,188,189,193)/t90-,91-,92-,93-,94+,95+,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,135-,136-,137-,138-,139-/m0/s1
DMV58GQ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CN=CN5)NC(=O)C
DMV58GQ	IK	IBAUXWGAMLDSHW-KCQDCZGMSA-N
DMV58GQ	IU	(3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMV58GQ	DE	Discovery agent

DMJVRPD	ID	DMJVRPD
DMJVRPD	DN	Ac-I[CV(1Nal)QDWGAHRC]T
DMJVRPD	HS	Investigative
DMJVRPD	PC	91933231
DMJVRPD	MW	1625.8
DMJVRPD	FM	C73H100N20O19S2
DMJVRPD	IC	InChI=1S/C73H100N20O19S2/c1-8-36(4)59(83-39(7)95)71(110)91-54-33-114-113-32-53(69(108)93-60(38(6)94)72(111)112)90-63(102)47(21-14-24-78-73(75)76)84-66(105)51(27-43-30-77-34-81-43)86-61(100)37(5)82-56(97)31-80-62(101)49(26-42-29-79-46-20-12-11-19-45(42)46)87-67(106)52(28-57(98)99)88-64(103)48(22-23-55(74)96)85-65(104)50(89-70(109)58(35(2)3)92-68(54)107)25-41-17-13-16-40-15-9-10-18-44(40)41/h9-13,15-20,29-30,34-38,47-54,58-60,79,94H,8,14,21-28,31-33H2,1-7H3,(H2,74,96)(H,77,81)(H,80,101)(H,82,97)(H,83,95)(H,84,105)(H,85,104)(H,86,100)(H,87,106)(H,88,103)(H,89,109)(H,90,102)(H,91,110)(H,92,107)(H,93,108)(H,98,99)(H,111,112)(H4,75,76,78)/t36-,37-,38+,47-,48-,49-,50-,51+,52+,53-,54-,58-,59-,60-/m0/s1
DMJVRPD	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=CC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMJVRPD	IK	ACANXZYPSQGZJT-UZUHPOSNSA-N
DMJVRPD	IU	(2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-28-(naphthalen-1-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMJVRPD	DE	Discovery agent

DM14DEL	ID	DM14DEL
DM14DEL	DN	Ac-I[CV(2Igl)QDWGAHRC]T
DM14DEL	HS	Investigative
DM14DEL	PC	91933237
DM14DEL	MW	1601.8
DM14DEL	FM	C71H100N20O19S2
DM14DEL	IC	InChI=1S/C71H100N20O19S2/c1-8-34(4)56(81-37(7)93)68(107)88-51-31-112-111-30-50(66(105)90-57(36(6)92)70(109)110)87-61(100)45(18-13-23-76-71(73)74)82-63(102)48(25-40-28-75-32-79-40)84-59(98)35(5)80-53(95)29-78-60(99)47(24-39-27-77-44-17-12-11-16-42(39)44)85-64(103)49(26-54(96)97)86-62(101)46(21-22-52(72)94)83-69(108)58(43-20-19-38-14-9-10-15-41(38)43)91-67(106)55(33(2)3)89-65(51)104/h9-12,14-17,27-28,32-36,43,45-51,55-58,77,92H,8,13,18-26,29-31H2,1-7H3,(H2,72,94)(H,75,79)(H,78,99)(H,80,95)(H,81,93)(H,82,102)(H,83,108)(H,84,98)(H,85,103)(H,86,101)(H,87,100)(H,88,107)(H,89,104)(H,90,105)(H,91,106)(H,96,97)(H,109,110)(H4,73,74,76)/t34-,35-,36+,43?,45-,46-,47-,48+,49+,50-,51-,55-,56-,57-,58-/m0/s1
DM14DEL	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)C2CCC3=CC=CC=C23)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DM14DEL	IK	HDGDWRFDJRCNRO-FUQOBRPNSA-N
DM14DEL	IU	(2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-28-(2,3-dihydro-1H-inden-1-yl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DM14DEL	DE	Discovery agent

DMQISG6	ID	DMQISG6
DMQISG6	DN	Ac-I[CV(2Igl)QDWGAHRC]T-NH2
DMQISG6	HS	Investigative
DMQISG6	PC	91933239
DMQISG6	MW	1600.8
DMQISG6	FM	C71H101N21O18S2
DMQISG6	IC	InChI=1S/C71H101N21O18S2/c1-8-34(4)56(82-37(7)94)69(109)89-51-31-112-111-30-50(67(107)91-57(36(6)93)59(73)99)88-62(102)45(18-13-23-77-71(74)75)83-64(104)48(25-40-28-76-32-80-40)85-60(100)35(5)81-53(96)29-79-61(101)47(24-39-27-78-44-17-12-11-16-42(39)44)86-65(105)49(26-54(97)98)87-63(103)46(21-22-52(72)95)84-70(110)58(43-20-19-38-14-9-10-15-41(38)43)92-68(108)55(33(2)3)90-66(51)106/h9-12,14-17,27-28,32-36,43,45-51,55-58,78,93H,8,13,18-26,29-31H2,1-7H3,(H2,72,95)(H2,73,99)(H,76,80)(H,79,101)(H,81,96)(H,82,94)(H,83,104)(H,84,110)(H,85,100)(H,86,105)(H,87,103)(H,88,102)(H,89,109)(H,90,106)(H,91,107)(H,92,108)(H,97,98)(H4,74,75,77)/t34-,35-,36+,43?,45-,46-,47-,48+,49+,50-,51-,55-,56-,57-,58-/m0/s1
DMQISG6	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)C2CCC3=CC=CC=C23)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMQISG6	IK	YYPFHDDBPCSRKO-FUQOBRPNSA-N
DMQISG6	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-28-(2,3-dihydro-1H-inden-1-yl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMQISG6	DE	Discovery agent

DM20PEO	ID	DM20PEO
DM20PEO	DN	Ac-I[CV(2Nal)QDWGAHRC]T
DM20PEO	HS	Investigative
DM20PEO	PC	91933249
DM20PEO	MW	1625.8
DM20PEO	FM	C73H100N20O19S2
DM20PEO	IC	InChI=1S/C73H100N20O19S2/c1-8-36(4)59(83-39(7)95)71(110)91-54-33-114-113-32-53(69(108)93-60(38(6)94)72(111)112)90-63(102)47(18-13-23-78-73(75)76)84-66(105)51(27-44-30-77-34-81-44)86-61(100)37(5)82-56(97)31-80-62(101)50(26-43-29-79-46-17-12-11-16-45(43)46)87-67(106)52(28-57(98)99)88-64(103)48(21-22-55(74)96)85-65(104)49(89-70(109)58(35(2)3)92-68(54)107)25-40-19-20-41-14-9-10-15-42(41)24-40/h9-12,14-17,19-20,24,29-30,34-38,47-54,58-60,79,94H,8,13,18,21-23,25-28,31-33H2,1-7H3,(H2,74,96)(H,77,81)(H,80,101)(H,82,97)(H,83,95)(H,84,105)(H,85,104)(H,86,100)(H,87,106)(H,88,103)(H,89,109)(H,90,102)(H,91,110)(H,92,107)(H,93,108)(H,98,99)(H,111,112)(H4,75,76,78)/t36-,37-,38+,47-,48-,49-,50-,51+,52+,53-,54-,58-,59-,60-/m0/s1
DM20PEO	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC3=CC=CC=C3C=C2)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DM20PEO	IK	UCWQZBKPQJMNPR-UZUHPOSNSA-N
DM20PEO	IU	(2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-28-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DM20PEO	DE	Discovery agent

DMX2IRY	ID	DMX2IRY
DMX2IRY	DN	Ac-I[CV(2Nal)QDWGAHRC]T-NH2
DMX2IRY	HS	Investigative
DMX2IRY	PC	91933228
DMX2IRY	MW	1624.8
DMX2IRY	FM	C73H101N21O18S2
DMX2IRY	IC	InChI=1S/C73H101N21O18S2/c1-8-36(4)59(84-39(7)96)72(112)92-54-33-114-113-32-53(70(110)94-60(38(6)95)61(75)101)91-64(104)47(18-13-23-79-73(76)77)85-67(107)51(27-44-30-78-34-82-44)87-62(102)37(5)83-56(98)31-81-63(103)50(26-43-29-80-46-17-12-11-16-45(43)46)88-68(108)52(28-57(99)100)89-65(105)48(21-22-55(74)97)86-66(106)49(90-71(111)58(35(2)3)93-69(54)109)25-40-19-20-41-14-9-10-15-42(41)24-40/h9-12,14-17,19-20,24,29-30,34-38,47-54,58-60,80,95H,8,13,18,21-23,25-28,31-33H2,1-7H3,(H2,74,97)(H2,75,101)(H,78,82)(H,81,103)(H,83,98)(H,84,96)(H,85,107)(H,86,106)(H,87,102)(H,88,108)(H,89,105)(H,90,111)(H,91,104)(H,92,112)(H,93,109)(H,94,110)(H,99,100)(H4,76,77,79)/t36-,37-,38+,47-,48-,49-,50-,51+,52+,53-,54-,58-,59-,60-/m0/s1
DMX2IRY	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC3=CC=CC=C3C=C2)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMX2IRY	IK	BFGQANAKHJAOQY-UZUHPOSNSA-N
DMX2IRY	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-28-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMX2IRY	DE	Discovery agent

DMDFKU3	ID	DMDFKU3
DMDFKU3	DN	Ac-I[CV(Bpa)QDWGAHRC]T
DMDFKU3	HS	Investigative
DMDFKU3	PC	91933244
DMDFKU3	MW	1679.9
DMDFKU3	FM	C76H102N20O20S2
DMDFKU3	IC	InChI=1S/C76H102N20O20S2/c1-8-38(4)61(86-41(7)98)74(114)94-56-35-118-117-34-55(72(112)96-62(40(6)97)75(115)116)93-66(106)49(19-14-26-81-76(78)79)87-69(109)53(29-46-32-80-36-84-46)89-64(104)39(5)85-58(100)33-83-65(105)52(28-45-31-82-48-18-13-12-17-47(45)48)90-70(110)54(30-59(101)102)91-67(107)50(24-25-57(77)99)88-68(108)51(92-73(113)60(37(2)3)95-71(56)111)27-42-20-22-44(23-21-42)63(103)43-15-10-9-11-16-43/h9-13,15-18,20-23,31-32,36-40,49-56,60-62,82,97H,8,14,19,24-30,33-35H2,1-7H3,(H2,77,99)(H,80,84)(H,83,105)(H,85,100)(H,86,98)(H,87,109)(H,88,108)(H,89,104)(H,90,110)(H,91,107)(H,92,113)(H,93,106)(H,94,114)(H,95,111)(H,96,112)(H,101,102)(H,115,116)(H4,78,79,81)/t38-,39-,40+,49-,50-,51-,52-,53+,54?,55-,56-,60-,61-,62-/m0/s1
DMDFKU3	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)C(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=C(C=C2)C(=O)C3=CC=CC=C3)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMDFKU3	IK	PWSUDTBGJHZYGB-MPCJNSQXSA-N
DMDFKU3	IU	(2S,3R)-2-[[(4R,7S,10R,13S,19S,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-28-[(4-benzoylphenyl)methyl]-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMDFKU3	DE	Discovery agent

DMZG46O	ID	DMZG46O
DMZG46O	DN	Ac-I[CV(Bpa)QDWGAHRC]T-NH2
DMZG46O	HS	Investigative
DMZG46O	PC	91933235
DMZG46O	MW	1678.9
DMZG46O	FM	C76H103N21O19S2
DMZG46O	IC	InChI=1S/C76H103N21O19S2/c1-8-38(4)61(87-41(7)99)75(116)95-56-35-118-117-34-55(73(114)97-62(40(6)98)64(78)105)94-67(108)49(19-14-26-82-76(79)80)88-70(111)53(29-46-32-81-36-85-46)90-65(106)39(5)86-58(101)33-84-66(107)52(28-45-31-83-48-18-13-12-17-47(45)48)91-71(112)54(30-59(102)103)92-68(109)50(24-25-57(77)100)89-69(110)51(93-74(115)60(37(2)3)96-72(56)113)27-42-20-22-44(23-21-42)63(104)43-15-10-9-11-16-43/h9-13,15-18,20-23,31-32,36-40,49-56,60-62,83,98H,8,14,19,24-30,33-35H2,1-7H3,(H2,77,100)(H2,78,105)(H,81,85)(H,84,107)(H,86,101)(H,87,99)(H,88,111)(H,89,110)(H,90,106)(H,91,112)(H,92,109)(H,93,115)(H,94,108)(H,95,116)(H,96,113)(H,97,114)(H,102,103)(H4,79,80,82)/t38-,39-,40+,49-,50-,51-,52-,53+,54+,55-,56-,60-,61-,62-/m0/s1
DMZG46O	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=C(C=C2)C(=O)C3=CC=CC=C3)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMZG46O	IK	WGQRWXBFHFOWBH-SORWEXASSA-N
DMZG46O	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-28-[(4-benzoylphenyl)methyl]-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMZG46O	DE	Discovery agent

DM5NMVP	ID	DM5NMVP
DM5NMVP	DN	Ac-I[CV(Bta)QDWGAHRC]T
DM5NMVP	HS	Investigative
DM5NMVP	PC	91933248
DM5NMVP	MW	1631.9
DM5NMVP	FM	C71H98N20O19S3
DM5NMVP	IC	InChI=1S/C71H98N20O19S3/c1-9-34(4)56(81-37(7)93)66(106)87-50-31-113-112-30-49(65(105)90-57(36(6)92)68(108)109)86-60(100)44(18-14-22-76-70(73)74)82-62(102)47(24-39-27-75-32-79-39)83-58(98)35(5)80-53(95)28-78-59(99)46(23-38-26-77-43-17-12-10-15-40(38)43)84-63(103)48(25-54(96)97)85-61(101)45(20-21-52(72)94)88-69(110)71(8,42-29-111-51-19-13-11-16-41(42)51)91-67(107)55(33(2)3)89-64(50)104/h10-13,15-17,19,26-27,29,32-36,44-50,55-57,77,92H,9,14,18,20-25,28,30-31H2,1-8H3,(H2,72,94)(H,75,79)(H,78,99)(H,80,95)(H,81,93)(H,82,102)(H,83,98)(H,84,103)(H,85,101)(H,86,100)(H,87,106)(H,88,110)(H,89,104)(H,90,105)(H,91,107)(H,96,97)(H,108,109)(H4,73,74,76)/t34-,35-,36+,44-,45-,46-,47+,48+,49-,50-,55-,56-,57-,71-/m0/s1
DM5NMVP	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@](NC(=O)[C@@H](NC1=O)C(C)C)(C)C2=CSC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DM5NMVP	IK	JSPKWLRQUPIDRS-NWJDZPOUSA-N
DM5NMVP	IU	(2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-28-(1-benzothiophen-3-yl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,28-dimethyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DM5NMVP	DE	Discovery agent

DMFLA5T	ID	DMFLA5T
DMFLA5T	DN	Ac-I[CV(Bta)QDWGAHRC]T-NH2
DMFLA5T	HS	Investigative
DMFLA5T	PC	91933234
DMFLA5T	MW	1630.9
DMFLA5T	FM	C71H99N21O18S3
DMFLA5T	IC	InChI=1S/C71H99N21O18S3/c1-9-34(4)56(82-37(7)94)67(108)88-50-31-113-112-30-49(66(107)91-57(36(6)93)58(73)99)87-61(102)44(18-14-22-77-70(74)75)83-63(104)47(24-39-27-76-32-80-39)84-59(100)35(5)81-53(96)28-79-60(101)46(23-38-26-78-43-17-12-10-15-40(38)43)85-64(105)48(25-54(97)98)86-62(103)45(20-21-52(72)95)89-69(110)71(8,42-29-111-51-19-13-11-16-41(42)51)92-68(109)55(33(2)3)90-65(50)106/h10-13,15-17,19,26-27,29,32-36,44-50,55-57,78,93H,9,14,18,20-25,28,30-31H2,1-8H3,(H2,72,95)(H2,73,99)(H,76,80)(H,79,101)(H,81,96)(H,82,94)(H,83,104)(H,84,100)(H,85,105)(H,86,103)(H,87,102)(H,88,108)(H,89,110)(H,90,106)(H,91,107)(H,92,109)(H,97,98)(H4,74,75,77)/t34-,35-,36+,44-,45-,46-,47+,48+,49-,50-,55-,56-,57-,71-/m0/s1
DMFLA5T	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@](NC(=O)[C@@H](NC1=O)C(C)C)(C)C2=CSC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMFLA5T	IK	OCTUQYZUSWCCJV-NWJDZPOUSA-N
DMFLA5T	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-28-(1-benzothiophen-3-yl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,28-dimethyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMFLA5T	DE	Discovery agent

DMO9VWH	ID	DMO9VWH
DMO9VWH	DN	Ac-I[CV(Dht)QDWGAHRC]T
DMO9VWH	HS	Investigative
DMO9VWH	PC	91933240
DMO9VWH	MW	1614.8
DMO9VWH	FM	C71H99N21O19S2
DMO9VWH	IC	InChI=1S/C71H99N21O19S2/c1-8-34(4)57(82-37(7)94)69(109)90-52-31-113-112-30-51(67(107)92-58(36(6)93)70(110)111)89-61(101)45(18-13-21-76-71(73)74)83-64(104)49(24-40-28-75-32-80-40)85-59(99)35(5)81-54(96)29-79-60(100)47(22-38-26-77-43-16-11-9-14-41(38)43)86-65(105)50(25-55(97)98)87-62(102)46(19-20-53(72)95)84-63(103)48(88-68(108)56(33(2)3)91-66(52)106)23-39-27-78-44-17-12-10-15-42(39)44/h9-12,14-17,26-28,32-36,45-52,56-58,77-78,93H,8,13,18-25,29-31H2,1-7H3,(H2,72,95)(H,75,80)(H,79,100)(H,81,96)(H,82,94)(H,83,104)(H,84,103)(H,85,99)(H,86,105)(H,87,102)(H,88,108)(H,89,101)(H,90,109)(H,91,106)(H,92,107)(H,97,98)(H,110,111)(H4,73,74,76)/t34-,35-,36+,45-,46-,47-,48-,49+,50+,51-,52-,56-,57-,58-/m0/s1
DMO9VWH	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMO9VWH	IK	XVHYFABBPDIZAN-YEKOCRBCSA-N
DMO9VWH	IU	(2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMO9VWH	DE	Discovery agent

DMY18ET	ID	DMY18ET
DMY18ET	DN	Ac-I[CV(Yphs)QDWGAHRC]I-NH2
DMY18ET	HS	Investigative
DMY18ET	PC	91933247
DMY18ET	MW	1682.8
DMY18ET	FM	C71H104N21O21PS2
DMY18ET	IC	InChI=1S/C71H104N21O21PS2/c1-9-35(5)57(59(73)98)92-68(107)51-31-115-116-32-52(90-70(109)58(36(6)10-2)82-38(8)93)67(106)91-56(34(3)4)69(108)88-47(24-39-17-19-42(20-18-39)113-114(110,111)112)64(103)84-46(21-22-53(72)94)63(102)87-50(27-55(96)97)66(105)86-48(25-40-28-78-44-15-12-11-14-43(40)44)61(100)79-30-54(95)81-37(7)60(99)85-49(26-41-29-76-33-80-41)65(104)83-45(62(101)89-51)16-13-23-77-71(74)75/h11-12,14-15,17-20,28-29,33-37,45-52,56-58,78H,9-10,13,16,21-27,30-32H2,1-8H3,(H2,72,94)(H2,73,98)(H,76,80)(H,79,100)(H,81,95)(H,82,93)(H,83,104)(H,84,103)(H,85,99)(H,86,105)(H,87,102)(H,88,108)(H,89,101)(H,90,109)(H,91,106)(H,92,107)(H,96,97)(H4,74,75,77)(H2,110,111,112)/t35-,36-,37-,45-,46-,47-,48-,49+,50+,51-,52-,56-,57-,58-/m0/s1
DMY18ET	CS	CC[C@H](C)[C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC2=CN=CN2)C)CC3=CNC4=CC=CC=C43)CC(=O)O)CCC(=O)N)CC5=CC=C(C=C5)OP(=O)(O)O)C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)C
DMY18ET	IK	GQCVZDSVWSDPKX-FWGFZLTPSA-N
DMY18ET	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-28-[(4-phosphonooxyphenyl)methyl]-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMY18ET	DE	Discovery agent

DMFOTYQ	ID	DMFOTYQ
DMFOTYQ	DN	Ac-I[CVFQDWGHHRC]T-NH2
DMFOTYQ	HS	Investigative
DMFOTYQ	PC	91933233
DMFOTYQ	MW	1640.9
DMFOTYQ	FM	C72H101N23O18S2
DMFOTYQ	IC	InChI=1S/C72H101N23O18S2/c1-7-36(4)58(84-38(6)97)71(113)93-53-32-115-114-31-52(69(111)95-59(37(5)96)60(74)102)92-62(104)45(18-13-21-79-72(75)76)86-66(108)50(25-42-29-78-34-83-42)89-65(107)49(24-41-28-77-33-82-41)85-55(99)30-81-61(103)48(23-40-27-80-44-17-12-11-16-43(40)44)88-67(109)51(26-56(100)101)90-63(105)46(19-20-54(73)98)87-64(106)47(22-39-14-9-8-10-15-39)91-70(112)57(35(2)3)94-68(53)110/h8-12,14-17,27-29,33-37,45-53,57-59,80,96H,7,13,18-26,30-32H2,1-6H3,(H2,73,98)(H2,74,102)(H,77,82)(H,78,83)(H,81,103)(H,84,97)(H,85,99)(H,86,108)(H,87,106)(H,88,109)(H,89,107)(H,90,105)(H,91,112)(H,92,104)(H,93,113)(H,94,110)(H,95,111)(H,100,101)(H4,75,76,79)/t36-,37+,45-,46-,47+,48-,49-,50+,51+,52-,53-,57-,58-,59-/m0/s1
DMFOTYQ	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=CC=C2)CCC(=O)N)CC(=O)O)CC3=CNC4=CC=CC=C43)CC5=CN=CN5)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMFOTYQ	IK	RBQLSOPILCDKPP-IJVDDTIBSA-N
DMFOTYQ	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-28-benzyl-7-(3-carbamimidamidopropyl)-10,13-bis(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMFOTYQ	DE	Discovery agent

DMLU3PZ	ID	DMLU3PZ
DMLU3PZ	DN	Ac-I[CVHQDWGHHRC]T-NH2
DMLU3PZ	HS	Investigative
DMLU3PZ	PC	91933241
DMLU3PZ	MW	1630.8
DMLU3PZ	FM	C69H99N25O18S2
DMLU3PZ	IC	InChI=1S/C69H99N25O18S2/c1-7-33(4)55(83-35(6)96)68(112)92-50-28-114-113-27-49(66(110)94-56(34(5)95)57(71)101)91-59(103)42(13-10-16-77-69(72)73)85-62(106)46(19-38-24-75-30-81-38)88-61(105)45(18-37-23-74-29-80-37)84-52(98)26-79-58(102)44(17-36-22-78-41-12-9-8-11-40(36)41)87-64(108)48(21-53(99)100)89-60(104)43(14-15-51(70)97)86-63(107)47(20-39-25-76-31-82-39)90-67(111)54(32(2)3)93-65(50)109/h8-9,11-12,22-25,29-34,42-50,54-56,78,95H,7,10,13-21,26-28H2,1-6H3,(H2,70,97)(H2,71,101)(H,74,80)(H,75,81)(H,76,82)(H,79,102)(H,83,96)(H,84,98)(H,85,106)(H,86,107)(H,87,108)(H,88,105)(H,89,104)(H,90,111)(H,91,103)(H,92,112)(H,93,109)(H,94,110)(H,99,100)(H4,72,73,77)/t33-,34+,42-,43-,44-,45-,46+,47+,48+,49-,50-,54-,55-,56-/m0/s1
DMLU3PZ	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CN=CN2)CCC(=O)N)CC(=O)O)CC3=CNC4=CC=CC=C43)CC5=CN=CN5)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMLU3PZ	IK	BOKLLRIGSLYOHT-OYMOBXHASA-N
DMLU3PZ	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10,13,28-tris(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMLU3PZ	DE	Discovery agent

DMDPSBQ	ID	DMDPSBQ
DMDPSBQ	DN	Ac-I[CVSQDWGHHRC]T-NH2
DMDPSBQ	HS	Investigative
DMDPSBQ	PC	91933246
DMDPSBQ	MW	1580.8
DMDPSBQ	FM	C66H97N23O19S2
DMDPSBQ	IC	InChI=1S/C66H97N23O19S2/c1-7-31(4)52(78-33(6)92)65(108)87-47-27-110-109-26-46(63(106)89-53(32(5)91)54(68)97)86-56(99)39(13-10-16-73-66(69)70)80-59(102)43(19-36-23-72-29-77-36)83-58(101)42(18-35-22-71-28-76-35)79-49(94)24-75-55(98)41(17-34-21-74-38-12-9-8-11-37(34)38)82-60(103)44(20-50(95)96)84-57(100)40(14-15-48(67)93)81-61(104)45(25-90)85-64(107)51(30(2)3)88-62(47)105/h8-9,11-12,21-23,28-32,39-47,51-53,74,90-91H,7,10,13-20,24-27H2,1-6H3,(H2,67,93)(H2,68,97)(H,71,76)(H,72,77)(H,75,98)(H,78,92)(H,79,94)(H,80,102)(H,81,104)(H,82,103)(H,83,101)(H,84,100)(H,85,107)(H,86,99)(H,87,108)(H,88,105)(H,89,106)(H,95,96)(H4,69,70,73)/t31-,32+,39-,40-,41-,42-,43+,44+,45+,46-,47-,51-,52-,53-/m0/s1
DMDPSBQ	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CO)CCC(=O)N)CC(=O)O)CC2=CNC3=CC=CC=C32)CC4=CN=CN4)CC5=CN=CN5)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMDPSBQ	IK	HZUYXHSRYLPHAY-PSEHRYLKSA-N
DMDPSBQ	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-28-(hydroxymethyl)-10,13-bis(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMDPSBQ	DE	Discovery agent

DMNVMB5	ID	DMNVMB5
DMNVMB5	DN	Ac-I[CVTQDWGHHRC]T-NH2
DMNVMB5	HS	Investigative
DMNVMB5	PC	91933229
DMNVMB5	MW	1594.8
DMNVMB5	FM	C67H99N23O19S2
DMNVMB5	IC	InChI=1S/C67H99N23O19S2/c1-8-31(4)52(79-34(7)93)65(108)87-47-27-111-110-26-46(63(106)89-53(32(5)91)55(69)98)86-57(100)40(14-11-17-74-67(70)71)81-60(103)44(20-37-24-73-29-78-37)84-59(102)43(19-36-23-72-28-77-36)80-49(95)25-76-56(99)42(18-35-22-75-39-13-10-9-12-38(35)39)83-61(104)45(21-50(96)97)85-58(101)41(15-16-48(68)94)82-66(109)54(33(6)92)90-64(107)51(30(2)3)88-62(47)105/h9-10,12-13,22-24,28-33,40-47,51-54,75,91-92H,8,11,14-21,25-27H2,1-7H3,(H2,68,94)(H2,69,98)(H,72,77)(H,73,78)(H,76,99)(H,79,93)(H,80,95)(H,81,103)(H,82,109)(H,83,104)(H,84,102)(H,85,101)(H,86,100)(H,87,108)(H,88,105)(H,89,106)(H,90,107)(H,96,97)(H4,70,71,74)/t31-,32+,33+,40-,41-,42-,43-,44+,45+,46-,47-,51-,52-,53-,54+/m0/s1
DMNVMB5	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)[C@@H](C)O)CCC(=O)N)CC(=O)O)CC2=CNC3=CC=CC=C32)CC4=CN=CN4)CC5=CN=CN5)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMNVMB5	IK	VOXWWAJOYBYONB-RTTZVKIOSA-N
DMNVMB5	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-28-[(1R)-1-hydroxyethyl]-10,13-bis(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMNVMB5	DE	Discovery agent

DMRSKIY	ID	DMRSKIY
DMRSKIY	DN	Ac-I[CVVQDWGAHRC]T-NH2
DMRSKIY	HS	Investigative
DMRSKIY	SN	CHEMBL269043; Ac-I[CVVQDWGAHRC]T-NH2
DMRSKIY	PC	44388602
DMRSKIY	MW	1526.7
DMRSKIY	FM	C65H99N21O18S2
DMRSKIY	IC	InChI=1S/C65H99N21O18S2/c1-10-31(6)51(76-34(9)88)64(104)83-45-27-106-105-26-44(61(101)86-52(33(8)87)53(67)93)82-56(96)39(16-13-19-71-65(68)69)77-58(98)42(21-36-24-70-28-74-36)79-54(94)32(7)75-47(90)25-73-55(95)41(20-35-23-72-38-15-12-11-14-37(35)38)80-59(99)43(22-48(91)92)81-57(97)40(17-18-46(66)89)78-62(102)49(29(2)3)85-63(103)50(30(4)5)84-60(45)100/h11-12,14-15,23-24,28-33,39-45,49-52,72,87H,10,13,16-22,25-27H2,1-9H3,(H2,66,89)(H2,67,93)(H,70,74)(H,73,95)(H,75,90)(H,76,88)(H,77,98)(H,78,102)(H,79,94)(H,80,99)(H,81,97)(H,82,96)(H,83,104)(H,84,100)(H,85,103)(H,86,101)(H,91,92)(H4,68,69,71)/t31-,32-,33+,39-,40-,41-,42+,43+,44-,45-,49+,50-,51-,52-/m0/s1
DMRSKIY	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)C(C)C)CCC(=O)N)CC(=O)O)CC2=CNC3=CC=CC=C32)C)CC4=CN=CN4)CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMRSKIY	IK	OSAZHXWZENYRCV-WKOWKQLHSA-N
DMRSKIY	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-28,31-di(propan-2-yl)-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMRSKIY	DE	Discovery agent

DMUW3T4	ID	DMUW3T4
DMUW3T4	DN	Ac-I[CVWQDWG(Abu)HRC]T-NH2
DMUW3T4	HS	Investigative
DMUW3T4	PC	91933232
DMUW3T4	MW	1628.8
DMUW3T4	FM	C72H101N21O19S2
DMUW3T4	IC	InChI=1S/C72H101N21O19S2/c1-8-35(5)58(82-37(7)95)70(110)91-53-32-114-113-31-52(68(108)93-59(36(6)94)71(111)112)90-62(102)46(19-14-22-77-72(74)75)84-65(105)50(25-40-29-76-33-81-40)87-61(101)43(9-2)83-55(97)30-80-60(100)48(23-38-27-78-44-17-12-10-15-41(38)44)86-66(106)51(26-56(98)99)88-63(103)47(20-21-54(73)96)85-64(104)49(89-69(109)57(34(3)4)92-67(53)107)24-39-28-79-45-18-13-11-16-42(39)45/h10-13,15-18,27-29,33-36,43,46-53,57-59,78-79,94H,8-9,14,19-26,30-32H2,1-7H3,(H2,73,96)(H,76,81)(H,80,100)(H,82,95)(H,83,97)(H,84,105)(H,85,104)(H,86,106)(H,87,101)(H,88,103)(H,89,109)(H,90,102)(H,91,110)(H,92,107)(H,93,108)(H,98,99)(H,111,112)(H4,74,75,77)/t35-,36+,43?,46+,47-,48-,49+,50-,51+,52+,53-,57-,58-,59-/m0/s1
DMUW3T4	CS	CCC1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CC2=CNC3=CC=CC=C32)CC(=O)O)CCC(=O)N)CC4=CNC5=CC=CC=C54)C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)CCCNC(=N)N)CC6=CN=CN6
DMUW3T4	IK	IRAHVUBILQLJJK-POSIHDSISA-N
DMUW3T4	IU	(2S,3R)-2-[[(4S,7R,10S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-13-ethyl-10-(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMUW3T4	DE	Discovery agent

DML5ZSJ	ID	DML5ZSJ
DML5ZSJ	DN	Ac-I[CVWQDWGAHRC]dT
DML5ZSJ	HS	Investigative
DML5ZSJ	PC	91933250
DML5ZSJ	MW	1614.8
DML5ZSJ	FM	C71H99N21O19S2
DML5ZSJ	IC	InChI=1S/C71H99N21O19S2/c1-8-34(4)57(82-37(7)94)69(109)90-52-31-113-112-30-51(67(107)92-58(36(6)93)70(110)111)89-61(101)45(18-13-21-76-71(73)74)83-64(104)49(24-40-28-75-32-80-40)85-59(99)35(5)81-54(96)29-79-60(100)47(22-38-26-77-43-16-11-9-14-41(38)43)86-65(105)50(25-55(97)98)87-62(102)46(19-20-53(72)95)84-63(103)48(88-68(108)56(33(2)3)91-66(52)106)23-39-27-78-44-17-12-10-15-42(39)44/h9-12,14-17,26-28,32-36,45-52,56-58,77-78,93H,8,13,18-25,29-31H2,1-7H3,(H2,72,95)(H,75,80)(H,79,100)(H,81,96)(H,82,94)(H,83,104)(H,84,103)(H,85,99)(H,86,105)(H,87,102)(H,88,108)(H,89,101)(H,90,109)(H,91,106)(H,92,107)(H,97,98)(H,110,111)(H4,73,74,76)/t34-,35-,36-,45-,46-,47-,48+,49+,50+,51-,52-,56-,57-,58-/m0/s1
DML5ZSJ	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@H](C)O)C(=O)O)NC(=O)C
DML5ZSJ	IK	XVHYFABBPDIZAN-AHNXIUSDSA-N
DML5ZSJ	IU	(2S,3S)-2-[[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DML5ZSJ	DE	Discovery agent

DMV3PC7	ID	DMV3PC7
DMV3PC7	DN	Ac-I[CVWQDWGAHRC]T
DMV3PC7	HS	Investigative
DMV3PC7	PC	91933222
DMV3PC7	MW	1614.8
DMV3PC7	FM	C71H99N21O19S2
DMV3PC7	IC	InChI=1S/C71H99N21O19S2/c1-8-34(4)57(82-37(7)94)69(109)90-52-31-113-112-30-51(67(107)92-58(36(6)93)70(110)111)89-61(101)45(18-13-21-76-71(73)74)83-64(104)49(24-40-28-75-32-80-40)85-59(99)35(5)81-54(96)29-79-60(100)47(22-38-26-77-43-16-11-9-14-41(38)43)86-65(105)50(25-55(97)98)87-62(102)46(19-20-53(72)95)84-63(103)48(88-68(108)56(33(2)3)91-66(52)106)23-39-27-78-44-17-12-10-15-42(39)44/h9-12,14-17,26-28,32-36,45-52,56-58,77-78,93H,8,13,18-25,29-31H2,1-7H3,(H2,72,95)(H,75,80)(H,79,100)(H,81,96)(H,82,94)(H,83,104)(H,84,103)(H,85,99)(H,86,105)(H,87,102)(H,88,108)(H,89,101)(H,90,109)(H,91,106)(H,92,107)(H,97,98)(H,110,111)(H4,73,74,76)/t34-,35-,36+,45-,46-,47-,48+,49+,50+,51-,52-,56-,57-,58-/m0/s1
DMV3PC7	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMV3PC7	IK	XVHYFABBPDIZAN-DRXBSEAFSA-N
DMV3PC7	IU	(2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMV3PC7	DE	Discovery agent

DMBA1LS	ID	DMBA1LS
DMBA1LS	DN	Ac-I[CVWQDWGHHRC]T-NH2
DMBA1LS	HS	Investigative
DMBA1LS	PC	91933238
DMBA1LS	MW	1679.9
DMBA1LS	FM	C74H102N24O18S2
DMBA1LS	IC	InChI=1S/C74H102N24O18S2/c1-7-36(4)60(87-38(6)100)73(116)96-55-32-118-117-31-54(71(114)98-61(37(5)99)62(76)105)95-64(107)47(17-12-20-81-74(77)78)89-68(111)52(24-42-29-80-34-86-42)92-67(110)51(23-41-28-79-33-85-41)88-57(102)30-84-63(106)49(21-39-26-82-45-15-10-8-13-43(39)45)91-69(112)53(25-58(103)104)93-65(108)48(18-19-56(75)101)90-66(109)50(94-72(115)59(35(2)3)97-70(55)113)22-40-27-83-46-16-11-9-14-44(40)46/h8-11,13-16,26-29,33-37,47-55,59-61,82-83,99H,7,12,17-25,30-32H2,1-6H3,(H2,75,101)(H2,76,105)(H,79,85)(H,80,86)(H,84,106)(H,87,100)(H,88,102)(H,89,111)(H,90,109)(H,91,112)(H,92,110)(H,93,108)(H,94,115)(H,95,107)(H,96,116)(H,97,113)(H,98,114)(H,103,104)(H4,77,78,81)/t36-,37+,47-,48-,49-,50+,51-,52+,53+,54-,55-,59-,60-,61-/m0/s1
DMBA1LS	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)CC6=CN=CN6)CC7=CN=CN7)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMBA1LS	IK	WCPUCPVVFQIWRA-BEXWAHHISA-N
DMBA1LS	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10,13-bis(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMBA1LS	DE	Discovery agent

DMDIUK6	ID	DMDIUK6
DMDIUK6	DN	Ac-I[CVWQDWGWHRC]T-NH2
DMDIUK6	HS	Investigative
DMDIUK6	PC	91933242
DMDIUK6	MW	1729
DMDIUK6	FM	C79H105N23O18S2
DMDIUK6	IC	InChI=1S/C79H105N23O18S2/c1-7-39(4)65(91-41(6)104)78(120)100-60-36-122-121-35-59(76(118)102-66(40(5)103)67(81)109)99-69(111)52(21-14-24-85-79(82)83)93-73(115)57(28-45-33-84-37-90-45)96-71(113)55(26-43-31-87-50-19-12-9-16-47(43)50)92-62(106)34-89-68(110)54(25-42-30-86-49-18-11-8-15-46(42)49)95-74(116)58(29-63(107)108)97-70(112)53(22-23-61(80)105)94-72(114)56(98-77(119)64(38(2)3)101-75(60)117)27-44-32-88-51-20-13-10-17-48(44)51/h8-13,15-20,30-33,37-40,52-60,64-66,86-88,103H,7,14,21-29,34-36H2,1-6H3,(H2,80,105)(H2,81,109)(H,84,90)(H,89,110)(H,91,104)(H,92,106)(H,93,115)(H,94,114)(H,95,116)(H,96,113)(H,97,112)(H,98,119)(H,99,111)(H,100,120)(H,101,117)(H,102,118)(H,107,108)(H4,82,83,85)/t39-,40+,52-,53-,54-,55-,56+,57+,58+,59-,60-,64-,65-,66-/m0/s1
DMDIUK6	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)CC6=CNC7=CC=CC=C76)CC8=CN=CN8)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMDIUK6	IK	FLYCCQRIADFTOH-RHIYSSTNSA-N
DMDIUK6	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-13,19,28-tris(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMDIUK6	DE	Discovery agent

DM3Q5SU	ID	DM3Q5SU
DM3Q5SU	DN	Ac-I[CVYQDWGAHRC]T-NH2
DM3Q5SU	HS	Investigative
DM3Q5SU	PC	44388582
DM3Q5SU	MW	1590.8
DM3Q5SU	FM	C69H99N21O19S2
DM3Q5SU	IC	InChI=1S/C69H99N21O19S2/c1-8-33(4)55(80-36(7)92)68(109)88-50-30-111-110-29-49(66(107)90-56(35(6)91)57(71)98)87-60(101)43(14-11-21-75-69(72)73)81-63(104)47(24-39-27-74-31-78-39)83-58(99)34(5)79-52(95)28-77-59(100)46(23-38-26-76-42-13-10-9-12-41(38)42)84-64(105)48(25-53(96)97)85-61(102)44(19-20-51(70)94)82-62(103)45(22-37-15-17-40(93)18-16-37)86-67(108)54(32(2)3)89-65(50)106/h9-10,12-13,15-18,26-27,31-35,43-50,54-56,76,91,93H,8,11,14,19-25,28-30H2,1-7H3,(H2,70,94)(H2,71,98)(H,74,78)(H,77,100)(H,79,95)(H,80,92)(H,81,104)(H,82,103)(H,83,99)(H,84,105)(H,85,102)(H,86,108)(H,87,101)(H,88,109)(H,89,106)(H,90,107)(H,96,97)(H4,72,73,75)/t33-,34-,35+,43-,44-,45+,46-,47+,48+,49-,50-,54-,55-,56-/m0/s1
DM3Q5SU	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=C(C=C2)O)CCC(=O)N)CC(=O)O)CC3=CNC4=CC=CC=C43)C)CC5=CNC=N5)CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DM3Q5SU	IK	PQVLDHFPSLWLQN-VEMXNSRSSA-N
DM3Q5SU	IU	2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-28-[(4-hydroxyphenyl)methyl]-10-(1H-imidazol-4-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DM3Q5SU	DE	Discovery agent

DMPLNTM	ID	DMPLNTM
DMPLNTM	DN	ACI-636
DMPLNTM	HS	Investigative
DMPLNTM	SN	Morphomers; ACI-140; Beta amyloid beta sheet formation inhibitor (CNS diseases), AC Immune; Beta-amyloid oligomer inhibitors (Alzheimer's disease), AC Immune
DMPLNTM	CP	AC Immune SA
DMPLNTM	DE	Alzheimer disease

DM351NL	ID	DM351NL
DM351NL	DN	Ac-ICV(1MeW)QDWGAHRCT-NH2
DM351NL	HS	Investigative
DM351NL	PC	77280229
DM351NL	MW	1648.8
DM351NL	FM	C72H102FN21O19S2
DM351NL	IC	InChI=1S/C72H102FN21O19S2/c1-9-34(4)58(83-37(7)96)70(111)91-52(31-115)67(108)92-57(33(2)3)69(110)89-48(22-39-29-94(8)53-15-11-10-13-42(39)53)64(105)85-46(18-19-54(74)97)63(104)88-50(25-56(99)100)66(107)87-47(21-38-26-79-44-17-16-40(73)23-43(38)44)61(102)80-28-55(98)82-35(5)60(101)86-49(24-41-27-77-32-81-41)65(106)84-45(14-12-20-78-72(75)76)62(103)90-51(30-114)68(109)93-59(36(6)95)71(112)113/h10-11,13,15-17,23,26-27,29,32-36,45-52,57-59,79,95,114-115H,9,12,14,18-22,24-25,28,30-31H2,1-8H3,(H2,74,97)(H,77,81)(H,80,102)(H,82,98)(H,83,96)(H,84,106)(H,85,105)(H,86,101)(H,87,107)(H,88,104)(H,89,110)(H,90,103)(H,91,111)(H,92,108)(H,93,109)(H,99,100)(H,112,113)(H4,75,76,78)/t34-,35-,36+,45-,46-,47-,48-,49-,50-,51-,52-,57-,58-,59-/m0/s1
DM351NL	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CNC4=C3C=C(C=C4)F)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CN=CN5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DM351NL	IK	ZTPZPGGQKAOPSL-ULRAUGTQSA-N
DM351NL	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(1-methylindol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(5-fluoro-1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DM351NL	DE	Discovery agent

DMQLPGA	ID	DMQLPGA
DMQLPGA	DN	Ac-ICV(5fW)QDWGAHRCT-NH2
DMQLPGA	HS	Investigative
DMQLPGA	PC	44413817
DMQLPGA	MW	1606.8
DMQLPGA	FM	C70H100FN21O18S2
DMQLPGA	IC	InChI=1S/C70H100FN21O18S2/c1-8-33(4)57(69(109)110-7)92-66(106)51(30-112)90-68(108)56(32(2)3)91-64(104)47(21-37-26-79-43-16-15-38(71)22-41(37)43)86-60(100)45(17-18-52(72)94)85-63(103)49(24-54(96)97)88-62(102)46(20-36-25-78-42-13-10-9-12-40(36)42)83-53(95)28-80-58(98)34(5)82-61(101)48(23-39-27-76-31-81-39)87-59(99)44(14-11-19-77-70(74)75)84-65(105)50(29-111)89-67(107)55(73)35(6)93/h9-10,12-13,15-16,22,25-27,31-35,44-51,55-57,78-79,93,111-112H,8,11,14,17-21,23-24,28-30,73H2,1-7H3,(H2,72,94)(H,76,81)(H,80,98)(H,82,101)(H,83,95)(H,84,105)(H,85,103)(H,86,100)(H,87,99)(H,88,102)(H,89,107)(H,90,108)(H,91,104)(H,92,106)(H,96,97)(H4,74,75,77)/t33?,34-,35+,44-,45-,46-,47-,48-,49-,50-,51-,55-,56-,57-/m0/s1
DMQLPGA	CS	CCC(C)[C@@H](C(=O)OC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=C1C=C(C=C2)F)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)N
DMQLPGA	IK	LNBPPCFNDRANJB-IIMWSTDNSA-N
DMQLPGA	IU	(3S)-4-[[(2S)-5-amino-1-[[(2S)-3-(5-fluoro-1H-indol-3-yl)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-methoxy-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoic acid
DMQLPGA	DE	Discovery agent

DM52T90	ID	DM52T90
DM52T90	DN	Ac-ICV(5MeW)QDWGAHRCT-NH2
DM52T90	HS	Investigative
DM52T90	PC	44413713
DM52T90	MW	1602.8
DM52T90	FM	C71H103N21O18S2
DM52T90	IC	InChI=1S/C71H103N21O18S2/c1-9-35(5)58(70(109)110-8)92-67(106)52(31-112)90-69(108)57(33(2)3)91-65(104)48(23-39-27-79-44-17-16-34(4)21-42(39)44)86-61(100)46(18-19-53(72)94)85-64(103)50(25-55(96)97)88-63(102)47(22-38-26-78-43-14-11-10-13-41(38)43)83-54(95)29-80-59(98)36(6)82-62(101)49(24-40-28-76-32-81-40)87-60(99)45(15-12-20-77-71(74)75)84-66(105)51(30-111)89-68(107)56(73)37(7)93/h10-11,13-14,16-17,21,26-28,32-33,35-37,45-52,56-58,78-79,93,111-112H,9,12,15,18-20,22-25,29-31,73H2,1-8H3,(H2,72,94)(H,76,81)(H,80,98)(H,82,101)(H,83,95)(H,84,105)(H,85,103)(H,86,100)(H,87,99)(H,88,102)(H,89,107)(H,90,108)(H,91,104)(H,92,106)(H,96,97)(H4,74,75,77)/t35?,36-,37+,45-,46-,47-,48-,49-,50-,51-,52-,56-,57-,58-/m0/s1
DM52T90	CS	CCC(C)[C@@H](C(=O)OC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=C1C=C(C=C2)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)N
DM52T90	IK	BZCORVKMPCMYEF-LXVAIGNUSA-N
DM52T90	IU	(3S)-3-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-methoxy-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(5-methyl-1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid
DM52T90	DE	Discovery agent

DMPK9LG	ID	DMPK9LG
DMPK9LG	DN	Ac-ICVWQD(5fW)GAHRCT-NH2
DMPK9LG	HS	Investigative
DMPK9LG	PC	77280228
DMPK9LG	MW	1634.8
DMPK9LG	FM	C71H100FN21O19S2
DMPK9LG	IC	InChI=1S/C71H100FN21O19S2/c1-8-33(4)57(83-36(7)95)69(110)91-52(30-114)66(107)92-56(32(2)3)68(109)89-48(20-37-25-78-43-13-10-9-12-41(37)43)63(104)85-46(17-18-53(73)96)62(103)88-50(24-55(98)99)65(106)87-47(21-38-26-79-44-16-15-39(72)22-42(38)44)60(101)80-28-54(97)82-34(5)59(100)86-49(23-40-27-76-31-81-40)64(105)84-45(14-11-19-77-71(74)75)61(102)90-51(29-113)67(108)93-58(35(6)94)70(111)112/h9-10,12-13,15-16,22,25-27,31-35,45-52,56-58,78-79,94,113-114H,8,11,14,17-21,23-24,28-30H2,1-7H3,(H2,73,96)(H,76,81)(H,80,101)(H,82,97)(H,83,95)(H,84,105)(H,85,104)(H,86,100)(H,87,106)(H,88,103)(H,89,109)(H,90,102)(H,91,110)(H,92,107)(H,93,108)(H,98,99)(H,111,112)(H4,74,75,77)/t33-,34-,35+,45-,46-,47-,48-,49-,50-,51-,52-,56-,57-,58-/m0/s1
DMPK9LG	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CNC4=C3C=C(C=C4)F)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CN=CN5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMPK9LG	IK	KSDNMEGNCSHTNC-MZUDAGKNSA-N
DMPK9LG	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(5-fluoro-1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMPK9LG	DE	Discovery agent

DMPSI26	ID	DMPSI26
DMPSI26	DN	Ac-ICVWQDWGAHRCT-NH2
DMPSI26	HS	Investigative
DMPSI26	PC	44413816
DMPSI26	MW	1588.8
DMPSI26	FM	C70H101N21O18S2
DMPSI26	IC	InChI=1S/C70H101N21O18S2/c1-8-34(4)57(69(108)109-7)91-66(105)51(31-111)89-68(107)56(33(2)3)90-64(103)47(23-38-27-78-43-17-12-10-15-41(38)43)85-60(99)45(19-20-52(71)93)84-63(102)49(25-54(95)96)87-62(101)46(22-37-26-77-42-16-11-9-14-40(37)42)82-53(94)29-79-58(97)35(5)81-61(100)48(24-39-28-75-32-80-39)86-59(98)44(18-13-21-76-70(73)74)83-65(104)50(30-110)88-67(106)55(72)36(6)92/h9-12,14-17,26-28,32-36,44-51,55-57,77-78,92,110-111H,8,13,18-25,29-31,72H2,1-7H3,(H2,71,93)(H,75,80)(H,79,97)(H,81,100)(H,82,94)(H,83,104)(H,84,102)(H,85,99)(H,86,98)(H,87,101)(H,88,106)(H,89,107)(H,90,103)(H,91,105)(H,95,96)(H4,73,74,76)/t34?,35-,36+,44-,45-,46-,47-,48-,49-,50-,51-,55-,56-,57-/m0/s1
DMPSI26	CS	CCC(C)[C@@H](C(=O)OC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)N
DMPSI26	IK	UQCBIVMMKZHRCG-CREZQNEJSA-N
DMPSI26	IU	(3S)-3-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-[[(2S)-5-amino-1-[[(2S)-3-(1H-indol-3-yl)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-methoxy-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid
DMPSI26	DE	Discovery agent

DMCU6XV	ID	DMCU6XV
DMCU6XV	DN	Acid blue 25
DMCU6XV	HS	Investigative
DMCU6XV	SN	Acid Blue 25; 6408-78-2; C.I. ACID BLUE 25; UNII-S2E15W6FSN; S2E15W6FSN; W-110136; CHEMBL256057; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-9,10-dioxo-4-(phenylamino)-, sodium salt (1:1); EINECS 229-068-1; EC 229-068-1; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-9,10-dioxo-4-(phenylamino)-, monosodium salt; C20H13N2NaO5S; SCHEMBL790822; DTXSID2044711; CTK8F7553; Sodium 1-amino-9,10-dioxo-4-phenylaminoanthracene-2-sulphonate; MFCD00001214; Acid Blue 25, Dye content 45 %; AKOS015894441; AN-19165; Q394; I04-8965; sodium 1
DMCU6XV	DT	Small molecular drug
DMCU6XV	PC	23675622
DMCU6XV	MW	416.4
DMCU6XV	FM	C20H13N2NaO5S
DMCU6XV	IC	InChI=1S/C20H14N2O5S.Na/c21-18-15(28(25,26)27)10-14(22-11-6-2-1-3-7-11)16-17(18)20(24)13-9-5-4-8-12(13)19(16)23;/h1-10,22H,21H2,(H,25,26,27);/q;+1/p-1
DMCU6XV	CS	C1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)[O-].[Na+]
DMCU6XV	IK	LIKZXCROQGHXTI-UHFFFAOYSA-M
DMCU6XV	IU	sodium;1-amino-4-anilino-9,10-dioxoanthracene-2-sulfonate
DMCU6XV	CA	CAS 6408-78-2
DMCU6XV	DE	Discovery agent

DMTOEJX	ID	DMTOEJX
DMTOEJX	DN	Acid-activated omeprazole
DMTOEJX	HS	Investigative
DMTOEJX	SN	Hydroxyfasudil; HYDROXYFASUDIL; 105628-72-6; Hydroxy-Fasudil; 1-(1-Hydroxy-5-isoquinolinesulfonyl)homopiperazine; HA 1100; HA-1100; 1-[(1,2-DIHYDRO-1-OXO-5-ISOQUINOLINYL)SULFONYL]HEXAHYDRO-1H-1,4-DIAZEPINE; CHEMBL1233300; Hexahydro-1-((1,2-dihydro-1-oxo-5-isoquinolinyl)sulfonyl)-1H-1,4-diazepine; 5-(1,4-diazepane-1-sulfonyl)-1,2-dihydroisoquinolin-1-one; HYDROXYFASUDIL;5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one; 1H-1,4-Diazepine, hexahydro-1-((1,2-dihydro-1-oxo-5-isoquinolinyl)sulfonyl)-; HFS; 2etk; 2erz; AC1MI8J4; SCHEMBL123699
DMTOEJX	DT	Small molecular drug
DMTOEJX	PC	3064778
DMTOEJX	MW	307.37
DMTOEJX	FM	C14H17N3O3S
DMTOEJX	IC	InChI=1S/C14H17N3O3S/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17/h1,3-5,7,15H,2,6,8-10H2,(H,16,18)
DMTOEJX	CS	C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CNC3=O
DMTOEJX	IK	ZAVGJDAFCZAWSZ-UHFFFAOYSA-N
DMTOEJX	IU	5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one
DMTOEJX	CA	CAS 105628-72-6
DMTOEJX	DE	Discovery agent

DMKVU8P	ID	DMKVU8P
DMKVU8P	DN	Ac-L-Phe-D-trp-L-Phe-D-pro-NH2
DMKVU8P	HS	Investigative
DMKVU8P	SN	CHEMBL442612; Ac-L-Phe-D-trp-L-Phe-D-pro-NH2
DMKVU8P	DT	Small molecular drug
DMKVU8P	PC	44583428
DMKVU8P	MW	636.7
DMKVU8P	FM	C36H40N6O5
DMKVU8P	IC	InChI=1S/C36H40N6O5/c1-23(43)39-29(19-24-11-4-2-5-12-24)34(45)40-30(21-26-22-38-28-16-9-8-15-27(26)28)35(46)41-31(20-25-13-6-3-7-14-25)36(47)42-18-10-17-32(42)33(37)44/h2-9,11-16,22,29-32,38H,10,17-21H2,1H3,(H2,37,44)(H,39,43)(H,40,45)(H,41,46)/t29-,30+,31-,32+/m0/s1
DMKVU8P	CS	CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N5CCC[C@@H]5C(=O)N
DMKVU8P	IK	FCKYLHYBJRMIPQ-MLMSKLGMSA-N
DMKVU8P	IU	(2R)-1-[(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMKVU8P	DE	Discovery agent

DMIAYTP	ID	DMIAYTP
DMIAYTP	DN	Ac-Lys-[Leu(8)]-des-Arg(9)-BK
DMIAYTP	HS	Investigative
DMIAYTP	SN	4-(5-AMINO-4-OXO-4H-PYRAZOL-3-YL)-2-BROMO-4,5,6,7-TETRAHYDRO-3AH-PYRROLO[2,3-C]AZEPIN-8-ONE; AC1L1GFH; CTK5I6002; 4-(2-amino-4-oxo-4h-imidazol-5-yl)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8(3ah)-one; 4-(2-amino-5-oxoimidazol-4-yl)-2-bromo-4,5,6,7-tetrahydro-3aH-pyrrolo[2,3-c]azepin-8-one; (3aR,4S)-4-(2-amino-4-oxo-4H-imidazol-5-yl)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8(3aH)-one
DMIAYTP	DT	Small molecular drug
DMIAYTP	PC	3660
DMIAYTP	MW	324.13
DMIAYTP	FM	C11H10BrN5O2
DMIAYTP	IC	InChI=1S/C11H10BrN5O2/c12-6-3-5-4(7-10(19)17-11(13)16-7)1-2-14-9(18)8(5)15-6/h3-5H,1-2H2,(H,14,18)(H2,13,17,19)
DMIAYTP	CS	C1CNC(=O)C2=NC(=CC2C1C3=NC(=NC3=O)N)Br
DMIAYTP	IK	QPCBNXNDVYOBIP-UHFFFAOYSA-N
DMIAYTP	IU	4-(2-amino-5-oxoimidazol-4-yl)-2-bromo-4,5,6,7-tetrahydro-3aH-pyrrolo[2,3-c]azepin-8-one
DMIAYTP	DE	Discovery agent

DMRQ70X	ID	DMRQ70X
DMRQ70X	DN	ACMC-1AKLT
DMRQ70X	HS	Investigative
DMRQ70X	SN	Maybridge1_006885; PubChem8688; SCHEMBL307508; ZINC57916; 2H-1-Benzopyran-2-one, 7-hydroxy-4-(trifluoromethyl)-; 4-(Trifluoromethyl)umbelliferone; 4-(trifluoromethyl)umbeilliferone; 575-03-1; 7,4-Hfc; 7-Hydroxy-4-(trifluoromethyl)-2H-chromen-2-one; 7-Hydroxy-4-(trifluoromethyl)coumarin; 7-Hydroxy-4-trifluoromethyl-chromen-2-one; 7-Hydroxy-4-trifluoromethylcoumarin; 7-hydroxy-4-(trifluoromethyl)chromen-2-one; AC1NT9P6; AC1Q795W; CCKWMCUOHJAVOL-UHFFFAOYSA-N; CHEMBL104679; CTK5A6979; HMS561A21; MFCD00037578; TFMU
DMRQ70X	PC	5375667
DMRQ70X	MW	230.14
DMRQ70X	FM	C10H5F3O3
DMRQ70X	IC	CCKWMCUOHJAVOL-UHFFFAOYSA-N
DMRQ70X	CS	C1=CC2=C(C=C1O)OC(=O)C=C2C(F)(F)F
DMRQ70X	IK	1S/C10H5F3O3/c11-10(12,13)7-4-9(15)16-8-3-5(14)1-2-6(7)8/h1-4,14H
DMRQ70X	IU	7-hydroxy-4-(trifluoromethyl)chromen-2-one
DMRQ70X	CA	CAS 575-03-1
DMRQ70X	DE	Discovery agent

DMQCSFB	ID	DMQCSFB
DMQCSFB	DN	ACMC-209cv7
DMQCSFB	HS	Investigative
DMQCSFB	SN	Ketone, phenyl 4-pyridyl; Methanone, phenyl-4-pyridinyl-; Phenyl 4-pyridyl ketone; Phenyl(4-pyridinyl)methanone; Pyridine, 4-benzoyl-; SKFLCXNDKRUHTA-UHFFFAOYSA-N; WLN: T6NJ DVR; gamma-Benzoylpyridine; phenyl 4-pyridinyl ketone; phenyl(pyridin-4-yl)methanone; .gamma.-Benzoylpyridine; 14548-46-0; 4-Benzoylpyridine; 4-Benzoylpyridine, 98%; 4-Pyridyl phenyl ketone; ChemDiv2_000073; 4-benzoyl pyridine; 524YQ3O21T; AC1L1BRW; AC1Q5CWK; BRN 0003864; Ba 33215; EINECS 238-586-7; NSC 9488; UNII-524YQ3O21T
DMQCSFB	PC	26731
DMQCSFB	MW	183.21
DMQCSFB	FM	C12H9NO
DMQCSFB	IC	SKFLCXNDKRUHTA-UHFFFAOYSA-N
DMQCSFB	CS	C1=CC=C(C=C1)C(=O)C2=CC=NC=C2
DMQCSFB	IK	1S/C12H9NO/c14-12(10-4-2-1-3-5-10)11-6-8-13-9-7-11/h1-9H
DMQCSFB	IU	phenyl(pyridin-4-yl)methanone
DMQCSFB	CA	CAS 14548-46-0
DMQCSFB	DE	Discovery agent

DM3E4QR	ID	DM3E4QR
DM3E4QR	DN	ACN-1052
DM3E4QR	HS	Investigative
DM3E4QR	SN	Adenosine A3 antagonists (ophthalmic, glaucoma), Acorn
DM3E4QR	CP	Acorn Biomedical Inc
DM3E4QR	DE	Glaucoma/ocular hypertension

DMLYGPW	ID	DMLYGPW
DMLYGPW	DN	Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2
DMLYGPW	HS	Investigative
DMLYGPW	SN	CHEMBL194552; BDBM50268798
DMLYGPW	PC	16724004
DMLYGPW	MW	1015.2
DMLYGPW	FM	C53H66N12O9
DMLYGPW	IC	InChI=1S/C53H66N12O9/c1-3-4-15-40(59-31(2)66)48(69)62-43-27-46(67)56-21-10-9-17-39(47(54)68)60-49(70)41(25-35-28-57-38-16-8-7-14-37(35)38)63-52(73)45-18-11-22-65(45)53(74)44(24-32-19-20-33-12-5-6-13-34(33)23-32)64-50(71)42(61-51(43)72)26-36-29-55-30-58-36/h5-8,12-14,16,19-20,23,28-30,39-45,57H,3-4,9-11,15,17-18,21-22,24-27H2,1-2H3,(H2,54,68)(H,55,58)(H,56,67)(H,59,66)(H,60,70)(H,61,72)(H,62,69)(H,63,73)(H,64,71)/t39-,40-,41-,42-,43-,44+,45-/m0/s1
DMLYGPW	CS	CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](NC(=O)[C@@H](NC1=O)CC3=CN=CN3)CC4=CC5=CC=CC=C5C=C4)CC6=CNC7=CC=CC=C76)C(=O)N)NC(=O)C
DMLYGPW	IK	NUEQNUVEEKTGQM-GTBIJRGCSA-N
DMLYGPW	IU	(3R,6S,9S,17S,20S,23S)-9-[[(2S)-2-acetamidohexanoyl]amino]-6-(1H-imidazol-5-ylmethyl)-20-(1H-indol-3-ylmethyl)-3-(naphthalen-2-ylmethyl)-2,5,8,11,19,22-hexaoxo-1,4,7,12,18,21-hexazabicyclo[21.3.0]hexacosane-17-carboxamide
DMLYGPW	DE	Discovery agent

DMOVI7Y	ID	DMOVI7Y
DMOVI7Y	DN	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2
DMOVI7Y	HS	Investigative
DMOVI7Y	PC	44366173
DMOVI7Y	MW	1074.2
DMOVI7Y	FM	C54H71N15O9
DMOVI7Y	IC	InChI=1S/C54H71N15O9/c1-3-4-15-40(63-31(2)70)48(73)69-45-27-46(71)59-21-10-9-17-39(47(55)72)64-51(76)43(25-35-28-61-38-16-8-7-14-37(35)38)67-49(74)41(18-11-22-60-54(56)57)65-50(75)42(24-32-19-20-33-12-5-6-13-34(33)23-32)66-52(77)44(68-53(45)78)26-36-29-58-30-62-36/h5-8,12-14,16,19-20,23,28-30,39-45,61H,3-4,9-11,15,17-18,21-22,24-27H2,1-2H3,(H2,55,72)(H,58,62)(H,59,71)(H,63,70)(H,64,76)(H,65,75)(H,66,77)(H,67,74)(H,68,78)(H,69,73)(H4,56,57,60)/t39-,40+,41+,42-,43-,44?,45+/m0/s1
DMOVI7Y	CS	CCCC[C@H](C(=O)N[C@@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC4=CC=CC=C4C=C3)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N)NC(=O)C
DMOVI7Y	IK	GGYWLZFXFKFWKL-ZCMLEEDBSA-N
DMOVI7Y	IU	(3S,6R,9S,15R,23S)-15-[[(2R)-2-acetamidohexanoyl]amino]-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-9-(naphthalen-2-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
DMOVI7Y	DE	Discovery agent

DMG418C	ID	DMG418C
DMG418C	DN	AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2
DMG418C	HS	Investigative
DMG418C	SN	CHEMBL501642; AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2
DMG418C	DT	Small molecular drug
DMG418C	PC	44158031
DMG418C	MW	965.1
DMG418C	FM	C49H64N12O9
DMG418C	IC	InChI=1S/C49H64N12O9/c1-3-4-16-36(55-29(2)62)44(65)58-39-25-42(63)52-20-11-10-18-35(43(50)64)56-45(66)37(23-31-26-53-34-17-9-8-15-33(31)34)59-48(69)41-19-12-21-61(41)49(70)40(22-30-13-6-5-7-14-30)60-46(67)38(57-47(39)68)24-32-27-51-28-54-32/h5-9,13-15,17,26-28,35-41,53H,3-4,10-12,16,18-25H2,1-2H3,(H2,50,64)(H,51,54)(H,52,63)(H,55,62)(H,56,66)(H,57,68)(H,58,65)(H,59,69)(H,60,67)/t35-,36-,37-,38-,39-,40+,41-/m0/s1
DMG418C	CS	CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](NC(=O)[C@@H](NC1=O)CC3=CN=CN3)CC4=CC=CC=C4)CC5=CNC6=CC=CC=C65)C(=O)N)NC(=O)C
DMG418C	IK	ZHWWUNQUSCAJKE-CQPWUTEUSA-N
DMG418C	IU	(3R,6S,9S,17S,20S,23S)-9-[[(2S)-2-acetamidohexanoyl]amino]-3-benzyl-6-(1H-imidazol-5-ylmethyl)-20-(1H-indol-3-ylmethyl)-2,5,8,11,19,22-hexaoxo-1,4,7,12,18,21-hexazabicyclo[21.3.0]hexacosane-17-carboxamide
DMG418C	DE	Discovery agent

DMZBOQW	ID	DMZBOQW
DMZBOQW	DN	AcNPY(25-36)
DMZBOQW	HS	Investigative
DMZBOQW	PC	91936053
DMZBOQW	MW	1698.9
DMZBOQW	FM	C76H119N27O18
DMZBOQW	IC	InChI=1S/C76H119N27O18/c1-6-40(4)61-73(121)97-52(68(116)93-49(14-10-30-89-75(82)83)64(112)96-51(24-26-58(77)107)67(115)94-50(15-11-31-90-76(84)85)65(113)98-53(62(79)110)33-42-16-20-45(105)21-17-42)25-27-60(109)87-28-8-7-12-48(66(114)102-57(36-59(78)108)71(119)99-54(32-39(2)3)72(120)103-61)95-69(117)55(34-43-18-22-46(106)23-19-43)100-70(118)56(35-44-37-86-38-91-44)101-63(111)47(92-41(5)104)13-9-29-88-74(80)81/h16-23,37-40,47-57,61,105-106H,6-15,24-36H2,1-5H3,(H2,77,107)(H2,78,108)(H2,79,110)(H,86,91)(H,87,109)(H,92,104)(H,93,116)(H,94,115)(H,95,117)(H,96,112)(H,97,121)(H,98,113)(H,99,119)(H,100,118)(H,101,111)(H,102,114)(H,103,120)(H4,80,81,88)(H4,82,83,89)(H4,84,85,90)/t40-,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,61+/m1/s1
DMZBOQW	CS	CC[C@@H](C)[C@H]1C(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(C)C)CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N
DMZBOQW	IK	RDOFKMDVEDQFIJ-WQSAXVMWSA-N
DMZBOQW	IU	(2S)-2-[[(2S)-2-[[(2S,5S,8S,11S,20S)-20-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-2-(2-amino-2-oxoethyl)-8-[(2R)-butan-2-yl]-5-(2-methylpropyl)-3,6,9,14,21-pentaoxo-1,4,7,10,15-pentazacyclohenicosane-11-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMZBOQW	DE	Discovery agent

DMQ0YW7	ID	DMQ0YW7
DMQ0YW7	DN	Acocantherin
DMQ0YW7	HS	Investigative
DMQ0YW7	SN	Ouabain; Ouabagenin L-Rhamnoside; Ouabagenin L-rhamnoside; Acocantherin; Acocantherine; Acolongifloroside K; Astrobain; G-Strophanthin; G-Strophanthin (JAN); G-Strophicor; Gratibain; Gratus strophanthin; Kombetin; O 3125; OBN; Ouabagenin-L-rhamnosid; Ouabagenin-L-rhamnosid [German]; Ouabain (anhydrous); Ouabain anhydrous; Ouabain octahydrate; Ouabain, Octahydrate; Ouabaine; Oubain; Purostrophan; Quabain; Rectobaina; Solufantina; Strodival; Strophalen; Strophanthin G; Strophanthin-G; Strophoperm; Strophosan; Uabaina; Uabanin
DMQ0YW7	TC	Antiviral Agents
DMQ0YW7	DT	Small molecular drug
DMQ0YW7	PC	439501
DMQ0YW7	MW	584.7
DMQ0YW7	FM	C29H44O12
DMQ0YW7	IC	InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
DMQ0YW7	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
DMQ0YW7	IK	LPMXVESGRSUGHW-HBYQJFLCSA-N
DMQ0YW7	IU	3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMQ0YW7	CA	CAS 630-60-4
DMQ0YW7	CB	CHEBI:472805
DMQ0YW7	DE	Atrial fibrillation; Heart failure; Middle East Respiratory Syndrome (MERS)

DMJ5U8C	ID	DMJ5U8C
DMJ5U8C	DN	Aconitate Ion
DMJ5U8C	HS	Investigative
DMJ5U8C	SN	Aconitate Ion; (E)-prop-1-ene-1,2,3-tricarboxylate; (1E)-prop-1-ene-1,2,3-tricarboxylate; trans-aconitate(3-); AC1NRDE4
DMJ5U8C	DT	Small molecular drug
DMJ5U8C	PC	5459816
DMJ5U8C	MW	171.08
DMJ5U8C	FM	C6H3O6-3
DMJ5U8C	IC	InChI=1S/C6H6O6/c7-4(8)1-3(6(11)12)2-5(9)10/h1H,2H2,(H,7,8)(H,9,10)(H,11,12)/p-3/b3-1-
DMJ5U8C	CS	C(/C(=C/C(=O)[O-])/C(=O)[O-])C(=O)[O-]
DMJ5U8C	IK	GTZCVFVGUGFEME-IWQZZHSRSA-K
DMJ5U8C	IU	(Z)-prop-1-ene-1,2,3-tricarboxylate
DMJ5U8C	CB	CHEBI:16383
DMJ5U8C	DE	Discovery agent

DMFOZ60	ID	DMFOZ60
DMFOZ60	DN	aconitine
DMFOZ60	HS	Investigative
DMFOZ60	SN	aconitine; 302-27-2; CHEBI:2430; Acetylbenzoylaconine; NSC56464; 20-ethyl-3alpha,13,15alpha-trihydroxy-1alpha,6alpha,16beta-trimethoxy-4-(methoxymethyl)aconitane-8,14alpha-diyl 8-acetate 14-benzoate; 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate; NCGC00163146-01; CAS-302-27-2; DSSTox_RID_81535; DSSTox_CID_26319; SCHEMBL73323; DSSTox_GSID_46319; GTPL2617; DTXSID4046319; CHEMBL1979562; MolPort-002-527-310; Tox21_112015; NSC-56464; AKOS032428256
DMFOZ60	DT	Small molecular drug
DMFOZ60	PC	245005
DMFOZ60	MW	645.7
DMFOZ60	FM	C34H47NO11
DMFOZ60	IC	InChI=1S/C34H47NO11/c1-7-35-15-31(16-41-3)20(37)13-21(42-4)33-19-14-32(40)28(45-30(39)18-11-9-8-10-12-18)22(19)34(46-17(2)36,27(38)29(32)44-6)23(26(33)35)24(43-5)25(31)33/h8-12,19-29,37-38,40H,7,13-16H2,1-6H3/t19-,20-,21+,22-,23+,24+,25-,26?,27+,28-,29+,31+,32-,33+,34-/m1/s1
DMFOZ60	CS	CCN1C[C@@]2([C@@H](C[C@@H]([C@@]34[C@@H]2[C@H]([C@@H](C31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC
DMFOZ60	IK	XFSBVAOIAHNAPC-XTHSEXKGSA-N
DMFOZ60	IU	[(1S,2R,3R,4R,5R,6S,7S,8R,9R,13R,14R,16S,17S,18R)-8-acetyloxy-11-ethyl-5,7,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate
DMFOZ60	CA	CAS 302-27-2
DMFOZ60	CB	CHEBI:2430
DMFOZ60	DE	Discovery agent

DMBVHLT	ID	DMBVHLT
DMBVHLT	DN	ACP-106
DMBVHLT	HS	Investigative
DMBVHLT	SN	5-HT2A inverse agonists (CNS disorders/sleep disorders), ACADIA
DMBVHLT	CP	ACADIA Pharmaceuticals Inc
DMBVHLT	DE	Central nervous system disease

DMAZLWR	ID	DMAZLWR
DMAZLWR	DN	ACPC
DMAZLWR	HS	Investigative
DMAZLWR	SN	1-Aminocyclopropanecarboxylic acid
DMAZLWR	DE	Neurological disorder

DM6ONY7	ID	DM6ONY7
DM6ONY7	DN	Ac-Phe-D-Thr(PO3H2)-Pip-Nal-Gln-NH2
DM6ONY7	HS	Investigative
DM6ONY7	SN	CHEMBL436759; Ac-Phe-D-Thr(PO3H2)-Pip-Nal-Gln-NH2
DM6ONY7	DT	Small molecular drug
DM6ONY7	PC	44409555
DM6ONY7	MW	823.8
DM6ONY7	FM	C39H50N7O11P
DM6ONY7	IC	InChI=1S/C39H50N7O11P/c1-23(57-58(54,55)56)34(45-37(51)30(42-24(2)47)21-25-10-4-3-5-11-25)39(53)46-19-9-8-14-32(46)38(52)44-31(36(50)43-29(35(41)49)17-18-33(40)48)22-26-15-16-27-12-6-7-13-28(27)20-26/h3-7,10-13,15-16,20,23,29-32,34H,8-9,14,17-19,21-22H2,1-2H3,(H2,40,48)(H2,41,49)(H,42,47)(H,43,50)(H,44,52)(H,45,51)(H2,54,55,56)/t23-,29-,30-,31-,32+,34+/m0/s1
DM6ONY7	CS	C[C@@H]([C@H](C(=O)N1CCCC[C@@H]1C(=O)N[C@@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)C)OP(=O)(O)O
DM6ONY7	IK	KZSGJDBAWAUUMC-DHQPFQMDSA-N
DM6ONY7	IU	[(2S,3R)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[(2R)-2-[[(2S)-1-[[(2S)-1,5-diamino-1,5-dioxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]piperidin-1-yl]-4-oxobutan-2-yl] dihydrogen phosphate
DM6ONY7	DE	Discovery agent

DMDXBQA	ID	DMDXBQA
DMDXBQA	DN	Ac-Phe-Phe-NH2
DMDXBQA	HS	Investigative
DMDXBQA	SN	CHEMBL464178; Ac-Phe-Phe-NH2; Ac-(Phe)2-CONH2; BDBM50308387; N-acetyl-l-phenylalanyl-l-phenylalanine amide
DMDXBQA	DT	Small molecular drug
DMDXBQA	PC	11100291
DMDXBQA	MW	353.4
DMDXBQA	FM	C20H23N3O3
DMDXBQA	IC	InChI=1S/C20H23N3O3/c1-14(24)22-18(13-16-10-6-3-7-11-16)20(26)23-17(19(21)25)12-15-8-4-2-5-9-15/h2-11,17-18H,12-13H2,1H3,(H2,21,25)(H,22,24)(H,23,26)/t17-,18-/m0/s1
DMDXBQA	CS	CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N
DMDXBQA	IK	MRIDWVSVNKEVEJ-ROUUACIJSA-N
DMDXBQA	IU	(2S)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-3-phenylpropanamide
DMDXBQA	DE	Discovery agent

DMSWTPX	ID	DMSWTPX
DMSWTPX	DN	Ac-Phe-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSWTPX	HS	Investigative
DMSWTPX	SN	CHEMBL383244; Ac-Phe-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSWTPX	DT	Small molecular drug
DMSWTPX	PC	44409591
DMSWTPX	MW	823.8
DMSWTPX	FM	C39H50N7O11P
DMSWTPX	IC	InChI=1S/C39H50N7O11P/c1-23(57-58(54,55)56)34(45-37(51)30(42-24(2)47)21-25-10-4-3-5-11-25)39(53)46-19-9-8-14-32(46)38(52)44-31(36(50)43-29(35(41)49)17-18-33(40)48)22-26-15-16-27-12-6-7-13-28(27)20-26/h3-7,10-13,15-16,20,23,29-32,34H,8-9,14,17-19,21-22H2,1-2H3,(H2,40,48)(H2,41,49)(H,42,47)(H,43,50)(H,44,52)(H,45,51)(H2,54,55,56)/t23-,29-,30-,31-,32+,34-/m0/s1
DMSWTPX	CS	C[C@@H]([C@@H](C(=O)N1CCCC[C@@H]1C(=O)N[C@@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)C)OP(=O)(O)O
DMSWTPX	IK	KZSGJDBAWAUUMC-UHZLREMTSA-N
DMSWTPX	IU	[(2S,3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[(2R)-2-[[(2S)-1-[[(2S)-1,5-diamino-1,5-dioxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]piperidin-1-yl]-4-oxobutan-2-yl] dihydrogen phosphate
DMSWTPX	DE	Discovery agent

DM264XN	ID	DM264XN
DM264XN	DN	ACPT-I
DM264XN	HS	Investigative
DM264XN	SN	1-aminocyclopentane-1,3,4-tricarboxylic acid
DM264XN	DT	Small molecular drug
DM264XN	PC	6604820
DM264XN	MW	217.18
DM264XN	FM	C8H11NO6
DM264XN	IC	InChI=1S/C8H11NO6/c9-8(7(14)15)1-3(5(10)11)4(2-8)6(12)13/h3-4H,1-2,9H2,(H,10,11)(H,12,13)(H,14,15)/t3-,4+,8?
DM264XN	CS	C1[C@H]([C@H](CC1(C(=O)O)N)C(=O)O)C(=O)O
DM264XN	IK	FERIKTBTNCSGJS-OBLUMXEWSA-N
DM264XN	IU	(1R,2S)-4-aminocyclopentane-1,2,4-tricarboxylic acid
DM264XN	DE	Discovery agent

DMDEFPS	ID	DMDEFPS
DMDEFPS	DN	AcPYY(22-36)
DMDEFPS	HS	Investigative
DMDEFPS	PC	44342691
DMDEFPS	MW	1931.2
DMDEFPS	FM	C86H139N29O22
DMDEFPS	IC	InChI=1S/C86H139N29O22/c1-41(2)31-58(109-81(135)64(39-116)113-70(124)45(9)101-47(11)118)75(129)103-54(16-13-29-98-85(92)93)73(127)111-62(36-50-38-96-40-100-50)78(132)110-61(35-49-20-24-52(120)25-21-49)77(131)107-59(32-42(3)4)76(130)112-63(37-66(88)122)79(133)108-60(33-43(5)6)80(134)114-67(44(7)8)82(136)115-68(46(10)117)83(137)105-55(17-14-30-99-86(94)95)71(125)104-56(26-27-65(87)121)74(128)102-53(15-12-28-97-84(90)91)72(126)106-57(69(89)123)34-48-18-22-51(119)23-19-48/h18-25,38,40-46,53-64,67-68,116-117,119-120H,12-17,26-37,39H2,1-11H3,(H2,87,121)(H2,88,122)(H2,89,123)(H,96,100)(H,101,118)(H,102,128)(H,103,129)(H,104,125)(H,105,137)(H,106,126)(H,107,131)(H,108,133)(H,109,135)(H,110,132)(H,111,127)(H,112,130)(H,113,124)(H,114,134)(H,115,136)(H4,90,91,97)(H4,92,93,98)(H4,94,95,99)/t45-,46+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,67-,68-/m0/s1
DMDEFPS	CS	C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)C)O
DMDEFPS	IK	NDQIPMDOGHILHE-UXUJTPOBSA-N
DMDEFPS	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamidopropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMDEFPS	DE	Discovery agent

DMRSU2K	ID	DMRSU2K
DMRSU2K	DN	AcPYY(25-36)
DMRSU2K	HS	Investigative
DMRSU2K	PC	91936052
DMRSU2K	MW	1659.9
DMRSU2K	FM	C74H118N26O18
DMRSU2K	IC	InChI=1S/C74H118N26O18/c1-36(2)28-51(94-66(113)53(31-42-17-21-45(104)22-18-42)96-67(114)54(32-43-34-84-35-88-43)97-61(108)46(89-40(8)102)12-9-25-85-72(78)79)65(112)98-55(33-57(76)106)68(115)95-52(29-37(3)4)69(116)99-58(38(5)6)70(117)100-59(39(7)101)71(118)92-48(14-11-27-87-74(82)83)62(109)91-49(23-24-56(75)105)64(111)90-47(13-10-26-86-73(80)81)63(110)93-50(60(77)107)30-41-15-19-44(103)20-16-41/h15-22,34-39,46-55,58-59,101,103-104H,9-14,23-33H2,1-8H3,(H2,75,105)(H2,76,106)(H2,77,107)(H,84,88)(H,89,102)(H,90,111)(H,91,109)(H,92,118)(H,93,110)(H,94,113)(H,95,115)(H,96,114)(H,97,108)(H,98,112)(H,99,116)(H,100,117)(H4,78,79,85)(H4,80,81,86)(H4,82,83,87)/t39-,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,58+,59+/m1/s1
DMRSU2K	CS	C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)O
DMRSU2K	IK	AQWCJJKYINAYIM-QIRMFHLNSA-N
DMRSU2K	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMRSU2K	DE	Discovery agent

DM7RELC	ID	DM7RELC
DM7RELC	DN	AcPYY(26-36)
DM7RELC	HS	Investigative
DM7RELC	SN	CHEMBL397527
DM7RELC	PC	44439563
DM7RELC	MW	1503.7
DM7RELC	FM	C68H106N22O17
DM7RELC	IC	InChI=1S/C68H106N22O17/c1-33(2)25-47(85-61(102)49(28-39-15-19-42(94)20-16-39)87-62(103)50(80-37(8)92)29-40-31-76-32-79-40)60(101)88-51(30-53(70)96)63(104)86-48(26-34(3)4)64(105)89-54(35(5)6)65(106)90-55(36(7)91)66(107)83-44(12-10-24-78-68(74)75)57(98)82-45(21-22-52(69)95)59(100)81-43(11-9-23-77-67(72)73)58(99)84-46(56(71)97)27-38-13-17-41(93)18-14-38/h13-20,31-36,43-51,54-55,91,93-94H,9-12,21-30H2,1-8H3,(H2,69,95)(H2,70,96)(H2,71,97)(H,76,79)(H,80,92)(H,81,100)(H,82,98)(H,83,107)(H,84,99)(H,85,102)(H,86,104)(H,87,103)(H,88,101)(H,89,105)(H,90,106)(H4,72,73,77)(H4,74,75,78)/t36-,43+,44+,45+,46+,47+,48+,49+,50+,51+,54+,55+/m1/s1
DM7RELC	CS	C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)C)O
DM7RELC	IK	JFWAFYNFTBNEPH-XATDXXKLSA-N
DM7RELC	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DM7RELC	DE	Discovery agent

DMBFUD0	ID	DMBFUD0
DMBFUD0	DN	Ac-R[CEHdFRWC]-NH2
DMBFUD0	HS	Investigative
DMBFUD0	SN	CHEMBL408257; Ac-R[CEHdFRWC]-NH2
DMBFUD0	PC	44400401
DMBFUD0	MW	1175.4
DMBFUD0	FM	C51H70N18O11S2
DMBFUD0	IC	InChI=1S/C51H70N18O11S2/c1-27(70)62-33(13-7-17-58-50(53)54)43(74)69-40-25-82-81-24-39(42(52)73)68-47(78)37(20-29-22-60-32-12-6-5-11-31(29)32)66-44(75)34(14-8-18-59-51(55)56)63-46(77)36(19-28-9-3-2-4-10-28)65-48(79)38(21-30-23-57-26-61-30)67-45(76)35(64-49(40)80)15-16-41(71)72/h2-6,9-12,22-23,26,33-40,60H,7-8,13-21,24-25H2,1H3,(H2,52,73)(H,57,61)(H,62,70)(H,63,77)(H,64,80)(H,65,79)(H,66,75)(H,67,76)(H,68,78)(H,69,74)(H,71,72)(H4,53,54,58)(H4,55,56,59)/t33-,34-,35+,36-,37+,38-,39+,40+/m1/s1
DMBFUD0	CS	CC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCC(=O)O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N
DMBFUD0	IK	UNXFCHHFXJFRRB-VYZFECEFSA-N
DMBFUD0	IU	3-[(4R,7S,10R,13R,16R,19S,22R)-22-[[(2R)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMBFUD0	DE	Discovery agent

DMYZJ5B	ID	DMYZJ5B
DMYZJ5B	DN	Acriflavinium chloride
DMYZJ5B	HS	Investigative
DMYZJ5B	SN	Acriflavine (component of); Acriflavon; Burnol; Chromoflavine; Flavine; Flavosan; Gonacrine; Gonocrin; Neutroflavine; Panflavin; Trypaflavin; Xanthacridine; ACRIFLAVINIUM HYDROCHLORIDE; 10-methylacridine-3,6-diamine, chloride; 1TW3Q60E36; 3,6-DIAMINO-10-METHYLACRIDINIUM CHLORIDE; 3,6-diamino-10-methylacridin-10-ium chloride; 86-40-8; Acridinium, 3,6-diamino-10-methyl-, chloride; Acridinium, 3,6-diamino-10-methyl-, chloride (1:1); Avlon; C.I. 46000; CCRIS 2116; CHEBI:383703; EINECS 201-668-8; NSC 2755; NSC2755; UNII-1TW3Q60E36
DMYZJ5B	PC	6842
DMYZJ5B	MW	259.73
DMYZJ5B	FM	C14H14ClN3
DMYZJ5B	IC	KKAJSJJFBSOMGS-UHFFFAOYSA-N
DMYZJ5B	CS	C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.[Cl-]
DMYZJ5B	IK	1S/C14H13N3.ClH/c1-17-13-7-11(15)4-2-9(13)6-10-3-5-12(16)8-14(10)17;/h2-8H,1H3,(H3,15,16);1H
DMYZJ5B	IU	10-methylacridin-10-ium-3,6-diamine;chloride
DMYZJ5B	CA	CAS 86-40-8
DMYZJ5B	CB	CHEBI:383703
DMYZJ5B	DE	Trypanosomiasis

DMAMCSR	ID	DMAMCSR
DMAMCSR	DN	acrolein
DMAMCSR	HS	Investigative
DMAMCSR	SN	ACROLEIN; Acrylaldehyde; 2-Propenal; Propenal; 107-02-8; Acrylic aldehyde; Allyl aldehyde; prop-2-enal; Ethylene aldehyde; Acraldehyde; Aqualin; Magnacide H; 2-Propen-1-one; Aqualine; Slimicide; Crolean; Acquinite; Magnacide; Prop-2-en-1-al; Acrylaldehyd; Akroleina; Akrolein; Acroleine; Acroleina; Papite; Biocide; Aldeide acrilica; Aldehyde acrylique; Acraldehydeacroleina; polyacrolein; Propenaldehyde; trans-Acrolein; NSC 8819; Akrolein [Czech]; Propenal [Czech]; Rcra waste number P003; Magnacide H and B; Akroleina [Polish]; Acroleina [Italian]
DMAMCSR	DT	Small molecular drug
DMAMCSR	PC	7847
DMAMCSR	MW	56.06
DMAMCSR	FM	C3H4O
DMAMCSR	IC	InChI=1S/C3H4O/c1-2-3-4/h2-3H,1H2
DMAMCSR	CS	C=CC=O
DMAMCSR	IK	HGINCPLSRVDWNT-UHFFFAOYSA-N
DMAMCSR	IU	prop-2-enal
DMAMCSR	CA	CAS 107-02-8
DMAMCSR	CB	CHEBI:15368
DMAMCSR	DE	Discovery agent

DM512OP	ID	DM512OP
DM512OP	DN	Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG
DM512OP	HS	Investigative
DM512OP	SN	CHEMBL414736; Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG
DM512OP	PC	44416159
DM512OP	MW	2138.4
DM512OP	FM	C100H144N28O25
DM512OP	IC	InChI=1S/C100H144N28O25/c1-5-56(2)85(127-93(148)72(21-14-42-110-100(106)107)121-94(149)74(46-61-25-33-65(132)34-26-61)125-95(150)75(47-62-27-35-66(133)36-28-62)124-92(147)71(118-58(4)130)20-13-41-109-99(104)105)97(152)122-70(19-9-11-39-101)89(144)114-51-81(137)112-50-80(136)113-53-83(139)119-69(86(103)141)18-10-12-40-108-79(135)49-111-82(138)52-115-91(146)77(55-129)126-96(151)78-22-15-43-128(78)98(153)76(48-63-29-37-67(134)38-30-63)120-84(140)54-116-90(145)73(45-59-16-7-6-8-17-59)123-87(142)57(3)117-88(143)68(102)44-60-23-31-64(131)32-24-60/h6-8,16-17,23-38,56-57,68-78,85,129,131-134H,5,9-15,18-22,39-55,101-102H2,1-4H3,(H2,103,141)(H,108,135)(H,111,138)(H,112,137)(H,113,136)(H,114,144)(H,115,146)(H,116,145)(H,117,143)(H,118,130)(H,119,139)(H,120,140)(H,121,149)(H,122,152)(H,123,142)(H,124,147)(H,125,150)(H,126,151)(H,127,148)(H4,104,105,109)(H4,106,107,110)/t56-,57-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,85-/m0/s1
DM512OP	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCNC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DM512OP	IK	JSLWGMSGFRFMOR-GCASCPCBSA-N
DM512OP	IU	(2S)-N-[(2S)-1-[[2-[[2-[[(5S)-5-[[2-[[2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-6-aminohexanoyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-6-amino-6-oxohexyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DM512OP	DE	Discovery agent

DMAHQIV	ID	DMAHQIV
DMAHQIV	DN	Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG
DMAHQIV	HS	Investigative
DMAHQIV	SN	CHEMBL441930; Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG
DMAHQIV	PC	44416445
DMAHQIV	MW	1848.1
DMAHQIV	FM	C85H130N28O19
DMAHQIV	IC	InChI=1S/C85H130N28O19/c1-3-49(2)72(113-79(129)62(20-13-38-100-85(94)95)108-80(130)65(43-53-25-31-56(116)32-26-53)112-81(131)64(42-52-23-29-55(115)30-24-52)110-74(124)57(87)16-11-36-98-83(90)91)82(132)109-60(18-7-9-34-86)76(126)105-47-70(121)103-46-69(120)104-48-71(122)106-59(73(89)123)17-8-10-35-96-67(118)44-102-68(119)45-101-66(117)33-39-97-77(127)63(41-50-14-5-4-6-15-50)111-78(128)61(19-12-37-99-84(92)93)107-75(125)58(88)40-51-21-27-54(114)28-22-51/h4-6,14-15,21-32,49,57-65,72,114-116H,3,7-13,16-20,33-48,86-88H2,1-2H3,(H2,89,123)(H,96,118)(H,97,127)(H,101,117)(H,102,119)(H,103,121)(H,104,120)(H,105,126)(H,106,122)(H,107,125)(H,108,130)(H,109,132)(H,110,124)(H,111,128)(H,112,131)(H,113,129)(H4,90,91,98)(H4,92,93,99)(H4,94,95,100)/t49-,57-,58-,59-,60-,61+,62-,63-,64-,65-,72-/m0/s1
DMAHQIV	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCNC(=O)CNC(=O)CNC(=O)CCNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCN=C(N)N)N
DMAHQIV	IK	FJZYPQNKFGDFEG-NWGZXSTASA-N
DMAHQIV	IU	(2S)-6-amino-N-[2-[[2-[[2-[[(2S)-1-amino-6-[[2-[[2-[3-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]propanoylamino]acetyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMAHQIV	DE	Discovery agent

DM2ND3U	ID	DM2ND3U
DM2ND3U	DN	Ac-RYYRIK-K-(NH2)-YAFGYPS
DM2ND3U	HS	Investigative
DM2ND3U	SN	CHEMBL404792; Ac-RYYRIK-K-(NH2)-YAFGYPS
DM2ND3U	PC	44416158
DM2ND3U	MW	1853.1
DM2ND3U	FM	C90H129N23O20
DM2ND3U	IC	InChI=1S/C90H129N23O20/c1-5-51(2)75(112-83(128)67(21-14-42-100-90(96)97)106-84(129)69(46-56-25-33-60(117)34-26-56)110-85(130)70(47-57-27-35-61(118)36-28-57)109-81(126)65(103-53(4)115)20-13-41-99-89(94)95)87(132)107-66(19-9-11-39-91)82(127)105-64(76(93)121)18-10-12-40-98-80(125)72(50-114)111-86(131)73-22-15-43-113(73)88(133)71(48-58-29-37-62(119)38-30-58)104-74(120)49-101-79(124)68(45-54-16-7-6-8-17-54)108-77(122)52(3)102-78(123)63(92)44-55-23-31-59(116)32-24-55/h6-8,16-17,23-38,51-52,63-73,75,114,116-119H,5,9-15,18-22,39-50,91-92H2,1-4H3,(H2,93,121)(H,98,125)(H,101,124)(H,102,123)(H,103,115)(H,104,120)(H,105,127)(H,106,129)(H,107,132)(H,108,122)(H,109,126)(H,110,130)(H,111,131)(H,112,128)(H4,94,95,99)(H4,96,97,100)/t51-,52-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,75-/m0/s1
DM2ND3U	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DM2ND3U	IK	DHDRBUQCZPZXNW-IJPMLFLGSA-N
DM2ND3U	IU	(2S)-N-[(2S)-1-[[(5S)-5-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-amino-6-oxohexyl]amino]-3-hydroxy-1-oxopropan-2-yl]-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DM2ND3U	DE	Discovery agent

DMNA3F4	ID	DMNA3F4
DMNA3F4	DN	Ac-RYYRIK-K-(NH2)-YRFB
DMNA3F4	HS	Investigative
DMNA3F4	SN	CHEMBL412939; Ac-RYYRIK-K-(NH2)-YRFB
DMNA3F4	PC	44416444
DMNA3F4	MW	1604.9
DMNA3F4	FM	C77H117N23O15
DMNA3F4	IC	InChI=1S/C77H117N23O15/c1-4-45(2)64(100-71(112)59(21-14-39-91-77(85)86)95-72(113)61(43-49-24-30-52(103)31-25-49)99-73(114)62(44-50-26-32-53(104)33-27-50)98-68(109)56(92-46(3)101)19-12-37-89-75(81)82)74(115)96-57(18-8-10-35-78)69(110)93-55(65(80)106)17-9-11-36-87-63(105)34-40-88-67(108)60(42-47-15-6-5-7-16-47)97-70(111)58(20-13-38-90-76(83)84)94-66(107)54(79)41-48-22-28-51(102)29-23-48/h5-7,15-16,22-33,45,54-62,64,102-104H,4,8-14,17-21,34-44,78-79H2,1-3H3,(H2,80,106)(H,87,105)(H,88,108)(H,92,101)(H,93,110)(H,94,107)(H,95,113)(H,96,115)(H,97,111)(H,98,109)(H,99,114)(H,100,112)(H4,81,82,89)(H4,83,84,90)(H4,85,86,91)/t45-,54-,55-,56-,57-,58+,59-,60-,61-,62-,64-/m0/s1
DMNA3F4	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCNC(=O)CCNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DMNA3F4	IK	XLFHOYFYEWSAKV-OKFGKCNJSA-N
DMNA3F4	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-6-amino-N-[(2S)-1-amino-6-[3-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]propanoylamino]-1-oxohexan-2-yl]hexanamide
DMNA3F4	DE	Discovery agent

DMI87UE	ID	DMI87UE
DMI87UE	DN	Ac-RYYRIK-NH2
DMI87UE	HS	Investigative
DMI87UE	SN	Ac-RYYRIK-NH2; 200959-48-4; CHEMBL437723; Ac-Arg-Tyr-Tyr-Arg-Ile-Lys-NH(2); acetyl-Arg-Tyr-Tyr-Arg-Ile-Lys-NH(2); Ac-RYYRIK-NH; BDBM85192; BDBM50190305; ZINC169289387; AKOS024456481; CA-1321; CAS_200959-48-4
DMI87UE	DT	Small molecular drug
DMI87UE	PC	9963005
DMI87UE	MW	939.1
DMI87UE	FM	C44H70N14O9
DMI87UE	IC	InChI=1S/C44H70N14O9/c1-4-25(2)36(42(67)54-31(37(46)62)9-5-6-20-45)58-39(64)33(11-8-22-52-44(49)50)55-40(65)34(23-27-12-16-29(60)17-13-27)57-41(66)35(24-28-14-18-30(61)19-15-28)56-38(63)32(53-26(3)59)10-7-21-51-43(47)48/h12-19,25,31-36,60-61H,4-11,20-24,45H2,1-3H3,(H2,46,62)(H,53,59)(H,54,67)(H,55,65)(H,56,63)(H,57,66)(H,58,64)(H4,47,48,51)(H4,49,50,52)/t25-,31-,32-,33-,34-,35-,36-/m0/s1
DMI87UE	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DMI87UE	IK	WBBBVZGQADABSU-RERZDIOCSA-N
DMI87UE	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-6-aminohexanamide
DMI87UE	DE	Discovery agent

DM8XBR1	ID	DM8XBR1
DM8XBR1	DN	Ac-SFWKYS-NH2
DM8XBR1	HS	Investigative
DM8XBR1	SN	CHEMBL1163474
DM8XBR1	DT	Small molecular drug
DM8XBR1	PC	10974939
DM8XBR1	MW	858
DM8XBR1	FM	C43H55N9O10
DM8XBR1	IC	InChI=1S/C43H55N9O10/c1-25(55)47-37(24-54)43(62)50-33(19-26-9-3-2-4-10-26)40(59)51-35(21-28-22-46-31-12-6-5-11-30(28)31)42(61)48-32(13-7-8-18-44)39(58)49-34(20-27-14-16-29(56)17-15-27)41(60)52-36(23-53)38(45)57/h2-6,9-12,14-17,22,32-37,46,53-54,56H,7-8,13,18-21,23-24,44H2,1H3,(H2,45,57)(H,47,55)(H,48,61)(H,49,58)(H,50,62)(H,51,59)(H,52,60)/t32-,33-,34-,35-,36-,37-/m0/s1
DM8XBR1	CS	CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](CO)C(=O)N
DM8XBR1	IK	QNAVIRFMKUQHRS-DUGSHLAESA-N
DM8XBR1	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-amino-N-[(2S)-1-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]hexanamide
DM8XBR1	DE	Discovery agent

DMPHSU8	ID	DMPHSU8
DMPHSU8	DN	ACTB-1003
DMPHSU8	HS	Investigative
DMPHSU8	SN	Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer
DMPHSU8	CP	Bayer AG
DMPHSU8	PC	23653175
DMPHSU8	MW	591.5
DMPHSU8	FM	C27H26F5N7O3
DMPHSU8	IC	InChI=1S/C27H26F5N7O3/c1-41-13-17-22(12-38-6-8-42-9-7-38)39-24(25(33)34-14-35-39)23(17)15-2-5-20(19(29)10-15)36-26(40)37-21-11-16(27(30,31)32)3-4-18(21)28/h2-5,10-11,14H,6-9,12-13H2,1H3,(H2,33,34,35)(H2,36,37,40)
DMPHSU8	CS	COCC1=C(N2C(=C1C3=CC(=C(C=C3)NC(=O)NC4=C(C=CC(=C4)C(F)(F)F)F)F)C(=NC=N2)N)CN5CCOCC5
DMPHSU8	IK	GZPJCJKUZPUFAL-UHFFFAOYSA-N
DMPHSU8	IU	1-[4-[4-amino-6-(methoxymethyl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
DMPHSU8	CA	CAS 939805-30-8
DMPHSU8	DE	Solid tumour/cancer

DMXIDS9	ID	DMXIDS9
DMXIDS9	DN	ACTINOPLANIC ACID A
DMXIDS9	HS	Investigative
DMXIDS9	SN	CHEMBL100684; ACTINOPLANIC ACID A; SCHEMBL8909241; BDBM50059873; 3-Carboxy-pentanedioic acid mono-{(E)-10-[(14E,18Z)-4-carboxy-19-(6-carboxy-4-ethyl-3-oxo-heptyl)-12-hydroxy-11,13,15,17-tetramethyl-2,6-dioxo-1,7dioxa-cycloicosa-14,18-dien-8-yl]-1,4-dimethyl-dec-5-enyl} ester
DMXIDS9	DT	Small molecular drug
DMXIDS9	PC	10102380
DMXIDS9	MW	949.2
DMXIDS9	FM	C51H80O16
DMXIDS9	IC	InChI=1S/C51H80O16/c1-9-39(25-36(7)49(59)60)43(52)21-19-38-24-33(4)22-32(3)23-35(6)48(58)34(5)17-20-42(67-47(57)29-41(51(63)64)27-45(55)65-30-38)15-13-11-10-12-14-31(2)16-18-37(8)66-46(56)28-40(50(61)62)26-44(53)54/h12,14,23-24,31,33-37,39-42,48,58H,9-11,13,15-22,25-30H2,1-8H3,(H,53,54)(H,59,60)(H,61,62)(H,63,64)/b14-12+,32-23+,38-24-
DMXIDS9	CS	CCC(CC(C)C(=O)O)C(=O)CC/C/1=C/C(C/C(=C/C(C(C(CCC(OC(=O)CC(CC(=O)OC1)C(=O)O)CCCC/C=C/C(C)CCC(C)OC(=O)CC(CC(=O)O)C(=O)O)C)O)C)/C)C
DMXIDS9	IK	ZJCPEIGQYKMZFE-PXQKRTIOSA-N
DMXIDS9	IU	2-[2-[(E)-11-[(14E,18Z)-4-carboxy-19-(6-carboxy-4-ethyl-3-oxoheptyl)-12-hydroxy-11,13,15,17-tetramethyl-2,6-dioxo-1,7-dioxacycloicosa-14,18-dien-8-yl]-5-methylundec-6-en-2-yl]oxy-2-oxoethyl]butanedioic acid
DMXIDS9	DE	Discovery agent

DMIH5CD	ID	DMIH5CD
DMIH5CD	DN	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3
DMIH5CD	HS	Investigative
DMIH5CD	SN	CHEMBL202699; Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3; BDBM50179459; (S)-2-{(R)-2-[(S)-2-acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid ((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide
DMIH5CD	DT	Small molecular drug
DMIH5CD	PC	44409240
DMIH5CD	MW	736.9
DMIH5CD	FM	C40H48N8O6
DMIH5CD	IC	InChI=1S/C40H48N8O6/c1-25(49)45-34(23-27-15-18-31(50)19-16-27)38(53)48-35(22-26-9-4-3-5-10-26)39(54)46-32(13-8-20-44-40(41)42)37(52)47-33(36(51)43-2)24-28-14-17-29-11-6-7-12-30(29)21-28/h3-7,9-12,14-19,21,32-35,50H,8,13,20,22-24H2,1-2H3,(H,43,51)(H,45,49)(H,46,54)(H,47,52)(H,48,53)(H4,41,42,44)/t32-,33-,34-,35+/m0/s1
DMIH5CD	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NC
DMIH5CD	IK	QVTMGASDQFBYLJ-AYXCPNKJSA-N
DMIH5CD	IU	(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)-N-[(2S)-1-(methylamino)-3-naphthalen-2-yl-1-oxopropan-2-yl]pentanamide
DMIH5CD	DE	Discovery agent

DM7ZWRN	ID	DM7ZWRN
DM7ZWRN	DN	ACU-0101979
DM7ZWRN	HS	Investigative
DM7ZWRN	SN	HuC091; ACU-5A5; ADDL formation inhibitors, Acumen/Merck; Anti-ADDL antibodies (Alzheimers disease); Anti-ADDL antibodies (Alzheimers disease), Acumen/Merck & Co; Anti-ADDL vaccines (Alzheimers disease), Acumen/Merck & Co
DM7ZWRN	CP	Acumen Pharmaceuticals Inc
DM7ZWRN	DT	Vaccine
DM7ZWRN	DE	Alzheimer disease

DMR2MUG	ID	DMR2MUG
DMR2MUG	DN	ACULEACIN A
DMR2MUG	HS	Investigative
DMR2MUG	SN	Aculeacin A; 58814-86-1; AC1Q6G0M; AC1L3U84; YKPHLXGEPNYRPY-UHFFFAOYSA-N; LS-14909; n-{23-[1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis(1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}hexadecanamide; Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N(sup 2)-(1-oxohexadecyl)-L-ornithine)-
DMR2MUG	PC	14315169
DMR2MUG	MW	1036.2
DMR2MUG	FM	C50H81N7O16
DMR2MUG	IC	InChI=1S/C50H81N7O16/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-36(63)51-33-24-35(62)46(69)55-48(71)40-41(64)27(2)25-57(40)50(73)38(29(4)59)53-47(70)39(43(66)42(65)30-19-21-31(60)22-20-30)54-45(68)34-23-32(61)26-56(34)49(72)37(28(3)58)52-44(33)67/h19-22,27-29,32-35,37-43,46,58-62,64-66,69H,5-18,23-26H2,1-4H3,(H,51,63)(H,52,67)(H,53,70)(H,54,68)(H,55,71)/t27-,28+,29+,32+,33-,34-,35+,37-,38-,39-,40-,41-,42-,43-,46+/m0/s1
DMR2MUG	CS	CCCCCCCCCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H]([C@H](CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](C)O)C)O)O)O
DMR2MUG	IK	YKPHLXGEPNYRPY-ZIUFDZNVSA-N
DMR2MUG	IU	N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]hexadecanamide
DMR2MUG	DE	Discovery agent

DMMQKCV	ID	DMMQKCV
DMMQKCV	DN	Acurea
DMMQKCV	HS	Investigative
DMMQKCV	SN	tetrahydrohyperforin; AC1L1GFN; SCHEMBL8168239; CTK5J8870; KGSZHKRKHXOAMG-UHFFFAOYSA-N; Bicyclo[3.3.1]non-3-ene-2,9-dione,4-hydroxy-6-methyl-1,3,7-tris(3-methyl-2-buten-1-yl)-5-(2-methyl-1-oxopropyl)-6-(4-methyl-3-penten-1-yl)-,(1R,5S,6R,7S)-; VA11063; 2-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-2-ene-4,9-dione
DMMQKCV	DT	Small molecular drug
DMMQKCV	PC	3662
DMMQKCV	MW	536.8
DMMQKCV	FM	C35H52O4
DMMQKCV	IC	InChI=1S/C35H52O4/c1-22(2)13-12-19-33(11)27(16-14-23(3)4)21-34(20-18-25(7)8)30(37)28(17-15-24(5)6)31(38)35(33,32(34)39)29(36)26(9)10/h13-15,18,26-27,37H,12,16-17,19-21H2,1-11H3
DMMQKCV	CS	CC(C)C(=O)C12C(=O)C(=C(C(C1=O)(CC(C2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C
DMMQKCV	IK	KGSZHKRKHXOAMG-UHFFFAOYSA-N
DMMQKCV	IU	4-hydroxy-8-methyl-3,5,7-tris(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-1-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione
DMMQKCV	CA	CAS 11079-53-1
DMMQKCV	DE	Discovery agent

DMWOYCZ	ID	DMWOYCZ
DMWOYCZ	DN	Ac-VEID-CHO
DMWOYCZ	HS	Investigative
DMWOYCZ	SN	Ac-VEID-CHO; CHEMBL478081; Ac-Val-Glu-Ile-Asp-CHO; acetyl-Val-Ile-Asp-aldehyde; GTPL8566; SCHEMBL20257260; acetyl-Val-Glu-Ile-Asp-aldehyde; N-acetyl-Val-Glu-Ile-Asp-aldehyde; ZINC14947179; BDBM50340548; 319494-39-8; N-Acetyl-Val-Glu-Ile-Asp-al, ~99% (HPLC), powder; (4S)-4-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMWOYCZ	DT	Small molecular drug
DMWOYCZ	PC	15487887
DMWOYCZ	MW	500.5
DMWOYCZ	FM	C22H36N4O9
DMWOYCZ	IC	InChI=1S/C22H36N4O9/c1-6-12(4)19(22(35)24-14(10-27)9-17(31)32)26-20(33)15(7-8-16(29)30)25-21(34)18(11(2)3)23-13(5)28/h10-12,14-15,18-19H,6-9H2,1-5H3,(H,23,28)(H,24,35)(H,25,34)(H,26,33)(H,29,30)(H,31,32)/t12-,14-,15-,18-,19-/m0/s1
DMWOYCZ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)C
DMWOYCZ	IK	KYUFGGNCJRWMDN-GOYXDOSHSA-N
DMWOYCZ	IU	(4S)-4-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMWOYCZ	DE	Discovery agent

DML7Z1H	ID	DML7Z1H
DML7Z1H	DN	ACVR2B
DML7Z1H	HS	Investigative
DML7Z1H	SN	ACVR2B program (muscle atrophy); ACVR2B program (muscle atrophy), Rigel Pharmaceuticals; Activin type IIB receptorantagonist, (small molecule therapeutic, muscle atrophy), Rigel Pharmaceuticals
DML7Z1H	CP	Rigel Pharmaceuticals Inc
DML7Z1H	DE	Muscle wasting disease

DMO0W9V	ID	DMO0W9V
DMO0W9V	DN	Ac-VTHRLAGLLSRSGGVVKNNFVPTDVGPFAF-NH2
DMO0W9V	HS	Investigative
DMO0W9V	PC	91935699
DMO0W9V	MW	3197.6
DMO0W9V	FM	C146H230N42O39
DMO0W9V	IC	InChI=1S/C146H230N42O39/c1-71(2)53-92(166-108(197)66-159-120(203)79(17)163-126(209)93(54-72(3)4)171-124(207)89(44-33-49-156-145(151)152)167-130(213)97(59-87-63-155-70-162-87)177-143(226)118(82(20)192)186-140(223)113(75(9)10)165-83(21)193)128(211)172-94(55-73(5)6)129(212)180-102(69-190)135(218)168-90(45-34-50-157-146(153)154)125(208)179-101(68-189)122(205)160-64-107(196)158-65-109(198)181-114(76(11)12)141(224)183-115(77(13)14)139(222)169-88(43-31-32-48-147)123(206)174-98(60-105(148)194)132(215)175-99(61-106(149)195)131(214)173-96(58-86-41-29-24-30-42-86)133(216)184-116(78(15)16)144(227)188-52-36-47-104(188)137(220)185-117(81(19)191)142(225)178-100(62-111(200)201)134(217)182-112(74(7)8)138(221)161-67-110(199)187-51-35-46-103(187)136(219)176-95(57-85-39-27-23-28-40-85)127(210)164-80(18)121(204)170-91(119(150)202)56-84-37-25-22-26-38-84/h22-30,37-42,63,70-82,88-104,112-118,189-192H,31-36,43-62,64-69,147H2,1-21H3,(H2,148,194)(H2,149,195)(H2,150,202)(H,155,162)(H,158,196)(H,159,203)(H,160,205)(H,161,221)(H,163,209)(H,164,210)(H,165,193)(H,166,197)(H,167,213)(H,168,218)(H,169,222)(H,170,204)(H,171,207)(H,172,211)(H,173,214)(H,174,206)(H,175,215)(H,176,219)(H,177,226)(H,178,225)(H,179,208)(H,180,212)(H,181,198)(H,182,217)(H,183,224)(H,184,216)(H,185,220)(H,186,223)(H,200,201)(H4,151,152,156)(H4,153,154,157)/t79-,80-,81+,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,112-,113-,114-,115-,116-,117-,118-/m0/s1
DMO0W9V	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)C)O
DMO0W9V	IK	OYUUVTJIINDYIH-ZCHJXOKKSA-N
DMO0W9V	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMO0W9V	DE	Discovery agent

DMWJ2M5	ID	DMWJ2M5
DMWJ2M5	DN	Ac-VTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2
DMWJ2M5	HS	Investigative
DMWJ2M5	PC	91935700
DMWJ2M5	MW	3239.7
DMWJ2M5	FM	C148H236N44O38
DMWJ2M5	IC	InChI=1S/C148H236N44O38/c1-73(2)56-95(170-109(200)68-163-121(206)81(17)167-128(213)96(57-74(3)4)176-126(211)91(45-33-51-159-146(152)153)172-132(217)100(62-89-65-158-72-166-89)181-144(229)119(84(20)196)190-141(226)114(77(9)10)169-85(21)197)130(215)177-97(58-75(5)6)131(216)184-104(71-194)136(221)173-92(46-34-52-160-147(154)155)127(212)183-103(70-193)123(208)164-66-108(199)162-67-110(201)185-115(78(11)12)142(227)187-116(79(13)14)140(225)174-93(47-35-53-161-148(156)157)124(209)171-90(44-31-32-50-149)125(210)179-101(63-107(150)198)133(218)178-99(61-88-42-29-24-30-43-88)134(219)188-117(80(15)16)145(230)192-55-37-49-106(192)138(223)189-118(83(19)195)143(228)182-102(64-112(203)204)135(220)186-113(76(7)8)139(224)165-69-111(202)191-54-36-48-105(191)137(222)180-98(60-87-40-27-23-28-41-87)129(214)168-82(18)122(207)175-94(120(151)205)59-86-38-25-22-26-39-86/h22-30,38-43,65,72-84,90-106,113-119,193-196H,31-37,44-64,66-71,149H2,1-21H3,(H2,150,198)(H2,151,205)(H,158,166)(H,162,199)(H,163,206)(H,164,208)(H,165,224)(H,167,213)(H,168,214)(H,169,197)(H,170,200)(H,171,209)(H,172,217)(H,173,221)(H,174,225)(H,175,207)(H,176,211)(H,177,215)(H,178,218)(H,179,210)(H,180,222)(H,181,229)(H,182,228)(H,183,212)(H,184,216)(H,185,201)(H,186,220)(H,187,227)(H,188,219)(H,189,223)(H,190,226)(H,203,204)(H4,152,153,159)(H4,154,155,160)(H4,156,157,161)/t81-,82-,83+,84+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116-,117-,118-,119-/m0/s1
DMWJ2M5	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)C)O
DMWJ2M5	IK	KPPNHHWOHREFKE-POKONUJPSA-N
DMWJ2M5	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMWJ2M5	DE	Discovery agent

DMP89K4	ID	DMP89K4
DMP89K4	DN	Ac-w-F-F-N-Y-Y-W
DMP89K4	HS	Investigative
DMP89K4	SN	CHEMBL405677; Ac-W-F-F-N-Y-Y-W
DMP89K4	PC	44371613
DMP89K4	MW	1124.2
DMP89K4	FM	C63H65N9O11
DMP89K4	IC	InChI=1S/C63H65N9O11/c1-37(73)50(32-42-35-65-48-18-10-8-16-46(42)48)67-51(28-38-12-4-2-5-13-38)58(77)68-52(29-39-14-6-3-7-15-39)60(79)71-55(34-57(64)76)62(81)70-53(30-40-20-24-44(74)25-21-40)59(78)69-54(31-41-22-26-45(75)27-23-41)61(80)72-56(63(82)83)33-43-36-66-49-19-11-9-17-47(43)49/h2-27,35-36,50-56,65-67,74-75H,28-34H2,1H3,(H2,64,76)(H,68,77)(H,69,78)(H,70,81)(H,71,79)(H,72,80)(H,82,83)/t50-,51+,52+,53+,54+,55+,56+/m1/s1
DMP89K4	CS	CC(=O)[C@@H](CC1=CNC2=CC=CC=C21)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)O
DMP89K4	IK	JNMRBSLUOYEORH-GMXKVRHKSA-N
DMP89K4	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-1-(1H-indol-3-yl)-3-oxobutan-2-yl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMP89K4	DE	Discovery agent

DM7J9O6	ID	DM7J9O6
DM7J9O6	DN	Ac-WKY-NH2
DM7J9O6	HS	Investigative
DM7J9O6	SN	CHEMBL1164996
DM7J9O6	DT	Small molecular drug
DM7J9O6	PC	11006017
DM7J9O6	MW	536.6
DM7J9O6	FM	C28H36N6O5
DM7J9O6	IC	InChI=1S/C28H36N6O5/c1-17(35)32-25(15-19-16-31-22-7-3-2-6-21(19)22)28(39)33-23(8-4-5-13-29)27(38)34-24(26(30)37)14-18-9-11-20(36)12-10-18/h2-3,6-7,9-12,16,23-25,31,36H,4-5,8,13-15,29H2,1H3,(H2,30,37)(H,32,35)(H,33,39)(H,34,38)/t23-,24-,25-/m0/s1
DM7J9O6	CS	CC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N
DM7J9O6	IK	NIAKXWGYSYBRJH-SDHOMARFSA-N
DM7J9O6	IU	(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-6-amino-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]hexanamide
DM7J9O6	DE	Discovery agent

DM9W21L	ID	DM9W21L
DM9W21L	DN	Ac-WVEHRLKGELSRKGGVV[hArg]KNFVPTDVGPFAF-NH2
DM9W21L	HS	Investigative
DM9W21L	PC	91935709
DM9W21L	MW	3546.1
DM9W21L	FM	C166H254N48O39
DM9W21L	IC	InChI=1S/C166H254N48O39/c1-86(2)69-112-148(238)192-104(51-31-35-63-178-125(220)60-58-110(146(236)202-117(75-100-79-176-85-187-100)150(240)194-108(144(234)199-112)54-38-66-181-166(174)175)197-159(249)133(90(9)10)209-153(243)116(189-95(17)217)74-99-78-182-102-48-28-27-47-101(99)102)140(230)185-82-127(222)190-109-57-59-124(219)177-62-34-30-50-103(191-142(232)107(53-37-65-180-165(172)173)195-155(245)120(84-215)206-149(239)113(70-87(3)4)200-145(109)235)139(229)184-80-126(221)183-81-128(223)207-132(89(7)8)161(251)210-134(91(11)12)160(250)196-106(52-32-36-64-179-164(170)171)141(231)193-105(49-29-33-61-167)143(233)203-118(76-123(168)218)151(241)201-115(73-98-45-25-20-26-46-98)152(242)211-135(92(13)14)163(253)214-68-40-56-122(214)157(247)212-136(94(16)216)162(252)205-119(77-130(225)226)154(244)208-131(88(5)6)158(248)186-83-129(224)213-67-39-55-121(213)156(246)204-114(72-97-43-23-19-24-44-97)147(237)188-93(15)138(228)198-111(137(169)227)71-96-41-21-18-22-42-96/h18-28,41-48,78-79,85-94,103-122,131-136,182,215-216H,29-40,49-77,80-84,167H2,1-17H3,(H2,168,218)(H2,169,227)(H,176,187)(H,177,219)(H,178,220)(H,183,221)(H,184,229)(H,185,230)(H,186,248)(H,188,237)(H,189,217)(H,190,222)(H,191,232)(H,192,238)(H,193,231)(H,194,240)(H,195,245)(H,196,250)(H,197,249)(H,198,228)(H,199,234)(H,200,235)(H,201,241)(H,202,236)(H,203,233)(H,204,246)(H,205,252)(H,206,239)(H,207,223)(H,208,244)(H,209,243)(H,210,251)(H,211,242)(H,212,247)(H,225,226)(H4,170,171,179)(H4,172,173,180)(H4,174,175,181)/t93-,94+,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,131-,132-,133-,134-,135-,136-/m0/s1
DM9W21L	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H]6CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N6)CCCN=C(N)N)CO)CC(C)C)NC(=O)CNC(=O)[C@@H]7CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N7)CC(C)C)CCCN=C(N)N)CC8=CN=CN8)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC9=CNC1=CC=CC=C19)NC(=O)C)O
DM9W21L	IK	WKTOEIRIAWMLPL-KFCCYEGLSA-N
DM9W21L	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S,5S,8S,11S,20S)-20-[[2-[[(2S,5S,8S,11S,20S)-20-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-5-[3-(diaminomethylideneamino)propyl]-2-(1H-imidazol-5-ylmethyl)-8-(2-methylpropyl)-3,6,9,17,21-pentaoxo-1,4,7,10,16-pentazacyclohenicosane-11-carbonyl]amino]acetyl]amino]-8-[3-(diaminomethylideneamino)propyl]-5-(hydroxymethyl)-2-(2-methylpropyl)-3,6,9,17,21-pentaoxo-1,4,7,10,16-pentazacyclohenicosane-11-carbonyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM9W21L	DE	Discovery agent

DMJU4AM	ID	DMJU4AM
DMJU4AM	DN	Ac-WVTH[Cit]LAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2
DMJU4AM	HS	Investigative
DMJU4AM	PC	91935704
DMJU4AM	MW	3427.9
DMJU4AM	FM	C159H244N44O41
DMJU4AM	IC	InChI=1S/C159H244N44O41/c1-79(2)60-104(180-119(211)74-173-131(217)87(17)177-138(224)105(61-80(3)4)186-136(222)100(50-36-56-169-158(165)243)182-142(228)110(67-96-71-167-78-176-96)191-155(241)129(90(20)207)201-153(239)126(85(13)14)197-145(231)109(179-91(21)208)66-95-70-171-98-47-32-31-46-97(95)98)140(226)187-106(62-81(5)6)141(227)194-114(77-205)147(233)183-101(51-37-57-170-159(166)244)137(223)193-113(76-204)133(219)174-72-118(210)172-73-120(212)195-124(83(9)10)152(238)198-125(84(11)12)151(237)184-102(49-35-55-168-157(163)164)134(220)181-99(48-33-34-54-160)135(221)189-111(68-117(161)209)143(229)188-108(65-94-44-29-24-30-45-94)144(230)199-127(86(15)16)156(242)203-59-39-53-116(203)149(235)200-128(89(19)206)154(240)192-112(69-122(214)215)146(232)196-123(82(7)8)150(236)175-75-121(213)202-58-38-52-115(202)148(234)190-107(64-93-42-27-23-28-43-93)139(225)178-88(18)132(218)185-103(130(162)216)63-92-40-25-22-26-41-92/h22-32,40-47,70-71,78-90,99-116,123-129,171,204-207H,33-39,48-69,72-77,160H2,1-21H3,(H2,161,209)(H2,162,216)(H,167,176)(H,172,210)(H,173,217)(H,174,219)(H,175,236)(H,177,224)(H,178,225)(H,179,208)(H,180,211)(H,181,220)(H,182,228)(H,183,233)(H,184,237)(H,185,218)(H,186,222)(H,187,226)(H,188,229)(H,189,221)(H,190,234)(H,191,241)(H,192,240)(H,193,223)(H,194,227)(H,195,212)(H,196,232)(H,197,231)(H,198,238)(H,199,230)(H,200,235)(H,201,239)(H,214,215)(H4,163,164,168)(H3,165,169,243)(H3,166,170,244)/t87-,88-,89+,90+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMJU4AM	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DMJU4AM	IK	VDLYRUOYUCCKKR-BQWGFPJXSA-N
DMJU4AM	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMJU4AM	DE	Discovery agent

DMR1N53	ID	DMR1N53
DMR1N53	DN	Ac-WVTH[Cit]LAGLLSRSGGVVRKNFVPTDVGPFAF-NH2
DMR1N53	HS	Investigative
DMR1N53	PC	91935702
DMR1N53	MW	3426.9
DMR1N53	FM	C159H245N45O40
DMR1N53	IC	InChI=1S/C159H245N45O40/c1-79(2)60-104(181-119(212)74-174-131(218)87(17)178-138(225)105(61-80(3)4)187-136(223)100(51-37-57-171-159(167)244)183-142(229)110(67-96-71-168-78-177-96)192-155(242)129(90(20)208)202-153(240)126(85(13)14)198-145(232)109(180-91(21)209)66-95-70-172-98-47-32-31-46-97(95)98)140(227)188-106(62-81(5)6)141(228)195-114(77-206)147(234)184-101(49-35-55-169-157(163)164)137(224)194-113(76-205)133(220)175-72-118(211)173-73-120(213)196-124(83(9)10)152(239)199-125(84(11)12)151(238)185-102(50-36-56-170-158(165)166)134(221)182-99(48-33-34-54-160)135(222)190-111(68-117(161)210)143(230)189-108(65-94-44-29-24-30-45-94)144(231)200-127(86(15)16)156(243)204-59-39-53-116(204)149(236)201-128(89(19)207)154(241)193-112(69-122(215)216)146(233)197-123(82(7)8)150(237)176-75-121(214)203-58-38-52-115(203)148(235)191-107(64-93-42-27-23-28-43-93)139(226)179-88(18)132(219)186-103(130(162)217)63-92-40-25-22-26-41-92/h22-32,40-47,70-71,78-90,99-116,123-129,172,205-208H,33-39,48-69,72-77,160H2,1-21H3,(H2,161,210)(H2,162,217)(H,168,177)(H,173,211)(H,174,218)(H,175,220)(H,176,237)(H,178,225)(H,179,226)(H,180,209)(H,181,212)(H,182,221)(H,183,229)(H,184,234)(H,185,238)(H,186,219)(H,187,223)(H,188,227)(H,189,230)(H,190,222)(H,191,235)(H,192,242)(H,193,241)(H,194,224)(H,195,228)(H,196,213)(H,197,233)(H,198,232)(H,199,239)(H,200,231)(H,201,236)(H,202,240)(H,215,216)(H4,163,164,169)(H4,165,166,170)(H3,167,171,244)/t87-,88-,89+,90+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMR1N53	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DMR1N53	IK	CSCIPTVNDXPCSL-BQWGFPJXSA-N
DMR1N53	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMR1N53	DE	Discovery agent

DM19NMF	ID	DM19NMF
DM19NMF	DN	Ac-WVTH[hArg]LAGLLS[hArg]SGGVVRKNFVPTDVGPFAF-NH2
DM19NMF	HS	Investigative
DM19NMF	PC	91935706
DM19NMF	MW	3454
DM19NMF	FM	C161H250N46O39
DM19NMF	IC	InChI=1S/C161H250N46O39/c1-81(2)62-106(184-121(215)76-177-133(221)89(17)181-140(228)107(63-82(3)4)190-137(225)102(51-34-37-57-172-159(165)166)186-144(232)112(69-98-73-171-80-180-98)195-157(245)131(92(20)211)205-155(243)128(87(13)14)201-147(235)111(183-93(21)212)68-97-72-175-100-49-32-31-48-99(97)100)142(230)191-108(64-83(5)6)143(231)198-116(79-209)149(237)187-103(52-35-38-58-173-160(167)168)139(227)197-115(78-208)135(223)178-74-120(214)176-75-122(216)199-126(85(9)10)154(242)202-127(86(11)12)153(241)188-104(53-39-59-174-161(169)170)136(224)185-101(50-33-36-56-162)138(226)193-113(70-119(163)213)145(233)192-110(67-96-46-29-24-30-47-96)146(234)203-129(88(15)16)158(246)207-61-41-55-118(207)151(239)204-130(91(19)210)156(244)196-114(71-124(218)219)148(236)200-125(84(7)8)152(240)179-77-123(217)206-60-40-54-117(206)150(238)194-109(66-95-44-27-23-28-45-95)141(229)182-90(18)134(222)189-105(132(164)220)65-94-42-25-22-26-43-94/h22-32,42-49,72-73,80-92,101-118,125-131,175,208-211H,33-41,50-71,74-79,162H2,1-21H3,(H2,163,213)(H2,164,220)(H,171,180)(H,176,214)(H,177,221)(H,178,223)(H,179,240)(H,181,228)(H,182,229)(H,183,212)(H,184,215)(H,185,224)(H,186,232)(H,187,237)(H,188,241)(H,189,222)(H,190,225)(H,191,230)(H,192,233)(H,193,226)(H,194,238)(H,195,245)(H,196,244)(H,197,227)(H,198,231)(H,199,216)(H,200,236)(H,201,235)(H,202,242)(H,203,234)(H,204,239)(H,205,243)(H,218,219)(H4,165,166,172)(H4,167,168,173)(H4,169,170,174)/t89-,90-,91+,92+,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,125-,126-,127-,128-,129-,130-,131-/m0/s1
DM19NMF	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN=C(N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DM19NMF	IK	DJNZEIOMSBZSIW-DTFUFJKDSA-N
DM19NMF	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM19NMF	DE	Discovery agent

DM3BUP6	ID	DM3BUP6
DM3BUP6	DN	Ac-WVTHQLAGLLSQSGGVVRKNFVPTDVGPFAF-NH2
DM3BUP6	HS	Investigative
DM3BUP6	PC	91935705
DM3BUP6	MW	3369.8
DM3BUP6	FM	C157H238N42O41
DM3BUP6	IC	InChI=1S/C157H238N42O41/c1-77(2)58-102(176-119(209)72-169-131(215)85(17)173-138(222)103(59-78(3)4)182-136(220)99(50-52-115(159)205)178-142(226)108(65-94-69-165-76-172-94)187-155(239)129(88(20)203)197-153(237)126(83(13)14)193-145(229)107(175-89(21)204)64-93-68-167-96-45-32-31-44-95(93)96)140(224)183-104(60-79(5)6)141(225)190-112(75-201)147(231)179-100(51-53-116(160)206)137(221)189-111(74-200)133(217)170-70-118(208)168-71-120(210)191-124(81(9)10)152(236)194-125(82(11)12)151(235)180-98(47-35-55-166-157(163)164)134(218)177-97(46-33-34-54-158)135(219)185-109(66-117(161)207)143(227)184-106(63-92-42-29-24-30-43-92)144(228)195-127(84(15)16)156(240)199-57-37-49-114(199)149(233)196-128(87(19)202)154(238)188-110(67-122(212)213)146(230)192-123(80(7)8)150(234)171-73-121(211)198-56-36-48-113(198)148(232)186-105(62-91-40-27-23-28-41-91)139(223)174-86(18)132(216)181-101(130(162)214)61-90-38-25-22-26-39-90/h22-32,38-45,68-69,76-88,97-114,123-129,167,200-203H,33-37,46-67,70-75,158H2,1-21H3,(H2,159,205)(H2,160,206)(H2,161,207)(H2,162,214)(H,165,172)(H,168,208)(H,169,215)(H,170,217)(H,171,234)(H,173,222)(H,174,223)(H,175,204)(H,176,209)(H,177,218)(H,178,226)(H,179,231)(H,180,235)(H,181,216)(H,182,220)(H,183,224)(H,184,227)(H,185,219)(H,186,232)(H,187,239)(H,188,238)(H,189,221)(H,190,225)(H,191,210)(H,192,230)(H,193,229)(H,194,236)(H,195,228)(H,196,233)(H,197,237)(H,212,213)(H4,163,164,166)/t85-,86-,87+,88+,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DM3BUP6	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DM3BUP6	IK	NNTUVPALHRZTKJ-BHNOSDEFSA-N
DM3BUP6	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM3BUP6	DE	Discovery agent

DMKO982	ID	DMKO982
DMKO982	DN	Ac-WVTHRLAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2
DMKO982	HS	Investigative
DMKO982	PC	91935703
DMKO982	MW	3426.9
DMKO982	FM	C159H245N45O40
DMKO982	IC	InChI=1S/C159H245N45O40/c1-79(2)60-104(181-119(212)74-174-131(218)87(17)178-138(225)105(61-80(3)4)187-136(223)100(49-35-55-169-157(163)164)183-142(229)110(67-96-71-168-78-177-96)192-155(242)129(90(20)208)202-153(240)126(85(13)14)198-145(232)109(180-91(21)209)66-95-70-172-98-47-32-31-46-97(95)98)140(227)188-106(62-81(5)6)141(228)195-114(77-206)147(234)184-101(51-37-57-171-159(167)244)137(224)194-113(76-205)133(220)175-72-118(211)173-73-120(213)196-124(83(9)10)152(239)199-125(84(11)12)151(238)185-102(50-36-56-170-158(165)166)134(221)182-99(48-33-34-54-160)135(222)190-111(68-117(161)210)143(230)189-108(65-94-44-29-24-30-45-94)144(231)200-127(86(15)16)156(243)204-59-39-53-116(204)149(236)201-128(89(19)207)154(241)193-112(69-122(215)216)146(233)197-123(82(7)8)150(237)176-75-121(214)203-58-38-52-115(203)148(235)191-107(64-93-42-27-23-28-43-93)139(226)179-88(18)132(219)186-103(130(162)217)63-92-40-25-22-26-41-92/h22-32,40-47,70-71,78-90,99-116,123-129,172,205-208H,33-39,48-69,72-77,160H2,1-21H3,(H2,161,210)(H2,162,217)(H,168,177)(H,173,211)(H,174,218)(H,175,220)(H,176,237)(H,178,225)(H,179,226)(H,180,209)(H,181,212)(H,182,221)(H,183,229)(H,184,234)(H,185,238)(H,186,219)(H,187,223)(H,188,227)(H,189,230)(H,190,222)(H,191,235)(H,192,242)(H,193,241)(H,194,224)(H,195,228)(H,196,213)(H,197,233)(H,198,232)(H,199,239)(H,200,231)(H,201,236)(H,202,240)(H,215,216)(H4,163,164,169)(H4,165,166,170)(H3,167,171,244)/t87-,88-,89+,90+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMKO982	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DMKO982	IK	APWOLIUOOPBJRZ-BQWGFPJXSA-N
DMKO982	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMKO982	DE	Discovery agent

DMSMVK4	ID	DMSMVK4
DMSMVK4	DN	Ac-WVTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2
DMSMVK4	HS	Investigative
DMSMVK4	PC	91935701
DMSMVK4	MW	3425.9
DMSMVK4	FM	C159H246N46O39
DMSMVK4	IC	InChI=1S/C159H246N46O39/c1-79(2)60-104(182-119(213)74-175-131(219)87(17)179-138(226)105(61-80(3)4)188-136(224)100(49-35-55-170-157(163)164)184-142(230)110(67-96-71-169-78-178-96)193-155(243)129(90(20)209)203-153(241)126(85(13)14)199-145(233)109(181-91(21)210)66-95-70-173-98-47-32-31-46-97(95)98)140(228)189-106(62-81(5)6)141(229)196-114(77-207)147(235)185-101(50-36-56-171-158(165)166)137(225)195-113(76-206)133(221)176-72-118(212)174-73-120(214)197-124(83(9)10)152(240)200-125(84(11)12)151(239)186-102(51-37-57-172-159(167)168)134(222)183-99(48-33-34-54-160)135(223)191-111(68-117(161)211)143(231)190-108(65-94-44-29-24-30-45-94)144(232)201-127(86(15)16)156(244)205-59-39-53-116(205)149(237)202-128(89(19)208)154(242)194-112(69-122(216)217)146(234)198-123(82(7)8)150(238)177-75-121(215)204-58-38-52-115(204)148(236)192-107(64-93-42-27-23-28-43-93)139(227)180-88(18)132(220)187-103(130(162)218)63-92-40-25-22-26-41-92/h22-32,40-47,70-71,78-90,99-116,123-129,173,206-209H,33-39,48-69,72-77,160H2,1-21H3,(H2,161,211)(H2,162,218)(H,169,178)(H,174,212)(H,175,219)(H,176,221)(H,177,238)(H,179,226)(H,180,227)(H,181,210)(H,182,213)(H,183,222)(H,184,230)(H,185,235)(H,186,239)(H,187,220)(H,188,224)(H,189,228)(H,190,231)(H,191,223)(H,192,236)(H,193,243)(H,194,242)(H,195,225)(H,196,229)(H,197,214)(H,198,234)(H,199,233)(H,200,240)(H,201,232)(H,202,237)(H,203,241)(H,216,217)(H4,163,164,170)(H4,165,166,171)(H4,167,168,172)/t87-,88-,89+,90+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMSMVK4	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DMSMVK4	IK	LVJLXLXVWDOXCC-BQWGFPJXSA-N
DMSMVK4	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMSMVK4	DE	Discovery agent

DMAVPXL	ID	DMAVPXL
DMAVPXL	DN	Ac-YCit[CEHdFRWC]-NH2
DMAVPXL	HS	Investigative
DMAVPXL	SN	CHEMBL412494; Ac-YCit[CEHdFRWC]-NH2
DMAVPXL	PC	44400399
DMAVPXL	MW	1339.5
DMAVPXL	FM	C60H78N18O14S2
DMAVPXL	IC	InChI=1S/C60H78N18O14S2/c1-32(79)70-43(24-34-15-17-37(80)18-16-34)54(87)71-41(14-8-22-67-60(64)92)52(85)78-48-30-94-93-29-47(50(61)83)77-56(89)45(25-35-27-68-39-12-6-5-11-38(35)39)75-51(84)40(13-7-21-66-59(62)63)72-55(88)44(23-33-9-3-2-4-10-33)74-57(90)46(26-36-28-65-31-69-36)76-53(86)42(73-58(48)91)19-20-49(81)82/h2-6,9-12,15-18,27-28,31,40-48,68,80H,7-8,13-14,19-26,29-30H2,1H3,(H2,61,83)(H,65,69)(H,70,79)(H,71,87)(H,72,88)(H,73,91)(H,74,90)(H,75,84)(H,76,86)(H,77,89)(H,78,85)(H,81,82)(H4,62,63,66)(H3,64,67,92)/t40-,41-,42+,43-,44-,45+,46-,47+,48+/m0/s1
DMAVPXL	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=O)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMAVPXL	IK	OODHJMPCOPKKSM-XVRHLUALSA-N
DMAVPXL	IU	3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMAVPXL	DE	Discovery agent

DMC0TU5	ID	DMC0TU5
DMC0TU5	DN	Ac-YGGFL-NH2
DMC0TU5	HS	Investigative
DMC0TU5	SN	CHEMBL500212; Ac-YGGFL-NH2
DMC0TU5	DT	Small molecular drug
DMC0TU5	PC	15747210
DMC0TU5	MW	596.7
DMC0TU5	FM	C30H40N6O7
DMC0TU5	IC	InChI=1S/C30H40N6O7/c1-18(2)13-23(28(31)41)36-30(43)25(14-20-7-5-4-6-8-20)35-27(40)17-32-26(39)16-33-29(42)24(34-19(3)37)15-21-9-11-22(38)12-10-21/h4-12,18,23-25,38H,13-17H2,1-3H3,(H2,31,41)(H,32,39)(H,33,42)(H,34,37)(H,35,40)(H,36,43)/t23-,24-,25-/m0/s1
DMC0TU5	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)C
DMC0TU5	IK	GFXHMPKMESGSMX-SDHOMARFSA-N
DMC0TU5	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanamide
DMC0TU5	DE	Discovery agent

DM5SJX8	ID	DM5SJX8
DM5SJX8	DN	Ac-YK[CEHdFRWC]-NH2
DM5SJX8	HS	Investigative
DM5SJX8	SN	CHEMBL412495; Ac-YK[CEHdFRWC]-NH2
DM5SJX8	PC	44400400
DM5SJX8	MW	1310.5
DM5SJX8	FM	C60H79N17O13S2
DM5SJX8	IC	InChI=1S/C60H79N17O13S2/c1-33(78)69-44(25-35-16-18-38(79)19-17-35)55(86)70-41(14-7-8-22-61)53(84)77-49-31-92-91-30-48(51(62)82)76-57(88)46(26-36-28-67-40-13-6-5-12-39(36)40)74-52(83)42(15-9-23-66-60(63)64)71-56(87)45(24-34-10-3-2-4-11-34)73-58(89)47(27-37-29-65-32-68-37)75-54(85)43(72-59(49)90)20-21-50(80)81/h2-6,10-13,16-19,28-29,32,41-49,67,79H,7-9,14-15,20-27,30-31,61H2,1H3,(H2,62,82)(H,65,68)(H,69,78)(H,70,86)(H,71,87)(H,72,90)(H,73,89)(H,74,83)(H,75,85)(H,76,88)(H,77,84)(H,80,81)(H4,63,64,66)/t41-,42-,43+,44-,45-,46+,47-,48+,49+/m0/s1
DM5SJX8	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DM5SJX8	IK	ASUAOIWGQADQOH-PYPSSTHSSA-N
DM5SJX8	IU	3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DM5SJX8	DE	Discovery agent

DMIZ5VO	ID	DMIZ5VO
DMIZ5VO	DN	Acylated Ceftazidime
DMIZ5VO	HS	Investigative
DMIZ5VO	SN	ACYLATED CEFTAZIDIME; DB03530; (2R)-2-[(1R)-1-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-2-oxoethyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMIZ5VO	DT	Small molecular drug
DMIZ5VO	PC	9600404
DMIZ5VO	MW	469.5
DMIZ5VO	FM	C17H19N5O7S2
DMIZ5VO	IC	InChI=1S/C17H19N5O7S2/c1-7-5-30-13(21-10(7)14(25)26)8(4-23)19-12(24)11(9-6-31-16(18)20-9)22-29-17(2,3)15(27)28/h4,6,8,13H,1,5H2,2-3H3,(H2,18,20)(H,19,24)(H,25,26)(H,27,28)/b22-11-/t8-,13-/m1/s1
DMIZ5VO	CS	CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H](C=O)[C@@H]2N=C(C(=C)CS2)C(=O)O
DMIZ5VO	IK	VEHPZKIFULQYFS-BZXVCXBKSA-N
DMIZ5VO	IU	(2R)-2-[(1R)-1-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-2-oxoethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
DMIZ5VO	DE	Discovery agent

DM4CYKE	ID	DM4CYKE
DM4CYKE	DN	Acylureido penicillin mezlocillin
DM4CYKE	HS	Investigative
DM4CYKE	DE	Discovery agent

DMJK8QZ	ID	DMJK8QZ
DMJK8QZ	DN	Ac-YR[CE(1-Me-H)dFRWC]-NH2
DMJK8QZ	HS	Investigative
DMJK8QZ	SN	CHEMBL264132; Ac-YR[CE(1-Me-H)dFRWC]-NH2
DMJK8QZ	PC	44400322
DMJK8QZ	MW	1352.6
DMJK8QZ	FM	C61H81N19O13S2
DMJK8QZ	IC	InChI=1S/C61H81N19O13S2/c1-33(81)71-44(25-35-16-18-38(82)19-17-35)55(89)72-42(15-9-23-69-61(65)66)53(87)79-49-31-95-94-30-48(51(62)85)78-57(91)46(26-36-28-70-40-13-7-6-12-39(36)40)76-52(86)41(14-8-22-68-60(63)64)73-56(90)45(24-34-10-4-3-5-11-34)75-58(92)47(27-37-29-67-32-80(37)2)77-54(88)43(74-59(49)93)20-21-50(83)84/h3-7,10-13,16-19,28-29,32,41-49,70,82H,8-9,14-15,20-27,30-31H2,1-2H3,(H2,62,85)(H,71,81)(H,72,89)(H,73,90)(H,74,93)(H,75,92)(H,76,86)(H,77,88)(H,78,91)(H,79,87)(H,83,84)(H4,63,64,68)(H4,65,66,69)/t41-,42-,43+,44-,45-,46+,47-,48+,49+/m0/s1
DMJK8QZ	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3C)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMJK8QZ	IK	JCRBBWBYSVHLIT-PYPSSTHSSA-N
DMJK8QZ	IU	3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-7-(1H-indol-3-ylmethyl)-16-[(3-methylimidazol-4-yl)methyl]-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMJK8QZ	DE	Discovery agent

DMVQ4KG	ID	DMVQ4KG
DMVQ4KG	DN	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2
DMVQ4KG	HS	Investigative
DMVQ4KG	PC	91936743
DMVQ4KG	MW	1388.6
DMVQ4KG	FM	C64H81N19O13S2
DMVQ4KG	IC	InChI=1S/C64H81N19O13S2/c1-34(84)75-47(25-35-15-18-41(85)19-16-35)58(92)76-45(13-7-23-72-64(68)69)56(90)83-52-32-98-97-31-51(54(65)88)82-60(94)49(27-39-29-73-43-11-5-4-10-42(39)43)80-55(89)44(12-6-22-71-63(66)67)77-59(93)48(26-36-14-17-37-8-2-3-9-38(37)24-36)79-61(95)50(28-40-30-70-33-74-40)81-57(91)46(78-62(52)96)20-21-53(86)87/h2-5,8-11,14-19,24,29-30,33,44-52,73,85H,6-7,12-13,20-23,25-28,31-32H2,1H3,(H2,65,88)(H,70,74)(H,75,84)(H,76,92)(H,77,93)(H,78,96)(H,79,95)(H,80,89)(H,81,91)(H,82,94)(H,83,90)(H,86,87)(H4,66,67,71)(H4,68,69,72)/t44-,45-,46+,47-,48-,49+,50-,51+,52+/m0/s1
DMVQ4KG	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC5=CC=CC=C5C=C4)CCCNC(=N)N)CC6=CNC7=CC=CC=C76)C(=O)N
DMVQ4KG	IK	LZYYGZAXFMYSBE-UHFDWKIASA-N
DMVQ4KG	IU	3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-10-(3-carbamimidamidopropyl)-4-carbamoyl-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-13-(naphthalen-2-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMVQ4KG	DE	Discovery agent

DM25JXM	ID	DM25JXM
DM25JXM	DN	Ac-YR[CEH(pCl-dF)RWC]-NH2
DM25JXM	HS	Investigative
DM25JXM	SN	CHEMBL415661; Ac-YR[CEH(pCl-dF)RWC]-NH2
DM25JXM	PC	44400320
DM25JXM	MW	1373
DM25JXM	FM	C60H78ClN19O13S2
DM25JXM	IC	InChI=1S/C60H78ClN19O13S2/c1-31(81)72-43(22-33-12-16-37(82)17-13-33)54(89)73-41(9-5-21-69-60(65)66)52(87)80-48-29-95-94-28-47(50(62)85)79-56(91)45(24-34-26-70-39-7-3-2-6-38(34)39)77-51(86)40(8-4-20-68-59(63)64)74-55(90)44(23-32-10-14-35(61)15-11-32)76-57(92)46(25-36-27-67-30-71-36)78-53(88)42(75-58(48)93)18-19-49(83)84/h2-3,6-7,10-17,26-27,30,40-48,70,82H,4-5,8-9,18-25,28-29H2,1H3,(H2,62,85)(H,67,71)(H,72,81)(H,73,89)(H,74,90)(H,75,93)(H,76,92)(H,77,86)(H,78,88)(H,79,91)(H,80,87)(H,83,84)(H4,63,64,68)(H4,65,66,69)/t40-,41-,42+,43-,44-,45+,46-,47+,48+/m0/s1
DM25JXM	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=C(C=C4)Cl)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DM25JXM	IK	KIFNALNSUOJQPJ-XVRHLUALSA-N
DM25JXM	IU	3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-carbamoyl-13-[(4-chlorophenyl)methyl]-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DM25JXM	DE	Discovery agent

DMXCF9T	ID	DMXCF9T
DMXCF9T	DN	Ac-YR[CEH(pF-dF)RWC]-NH2
DMXCF9T	HS	Investigative
DMXCF9T	SN	CHEMBL407809; Ac-YR[CEH(pF-dF)RWC]-NH2
DMXCF9T	PC	44400321
DMXCF9T	MW	1356.5
DMXCF9T	FM	C60H78FN19O13S2
DMXCF9T	IC	InChI=1S/C60H78FN19O13S2/c1-31(81)72-43(22-33-12-16-37(82)17-13-33)54(89)73-41(9-5-21-69-60(65)66)52(87)80-48-29-95-94-28-47(50(62)85)79-56(91)45(24-34-26-70-39-7-3-2-6-38(34)39)77-51(86)40(8-4-20-68-59(63)64)74-55(90)44(23-32-10-14-35(61)15-11-32)76-57(92)46(25-36-27-67-30-71-36)78-53(88)42(75-58(48)93)18-19-49(83)84/h2-3,6-7,10-17,26-27,30,40-48,70,82H,4-5,8-9,18-25,28-29H2,1H3,(H2,62,85)(H,67,71)(H,72,81)(H,73,89)(H,74,90)(H,75,93)(H,76,92)(H,77,86)(H,78,88)(H,79,91)(H,80,87)(H,83,84)(H4,63,64,68)(H4,65,66,69)/t40-,41-,42+,43-,44-,45+,46-,47+,48+/m0/s1
DMXCF9T	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=C(C=C4)F)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMXCF9T	IK	CHBTZNAADZTZLP-XVRHLUALSA-N
DMXCF9T	IU	3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-13-[(4-fluorophenyl)methyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMXCF9T	DE	Discovery agent

DMBMY73	ID	DMBMY73
DMBMY73	DN	Ac-YR[CEHdFRWC]-NH2
DMBMY73	HS	Investigative
DMBMY73	SN	CHEMBL264352; Ac-YR[CEHdFRWC]-NH2
DMBMY73	PC	44400370
DMBMY73	MW	1338.5
DMBMY73	FM	C60H79N19O13S2
DMBMY73	IC	InChI=1S/C60H79N19O13S2/c1-32(80)71-43(24-34-15-17-37(81)18-16-34)54(88)72-41(14-8-22-68-60(64)65)52(86)79-48-30-94-93-29-47(50(61)84)78-56(90)45(25-35-27-69-39-12-6-5-11-38(35)39)76-51(85)40(13-7-21-67-59(62)63)73-55(89)44(23-33-9-3-2-4-10-33)75-57(91)46(26-36-28-66-31-70-36)77-53(87)42(74-58(48)92)19-20-49(82)83/h2-6,9-12,15-18,27-28,31,40-48,69,81H,7-8,13-14,19-26,29-30H2,1H3,(H2,61,84)(H,66,70)(H,71,80)(H,72,88)(H,73,89)(H,74,92)(H,75,91)(H,76,85)(H,77,87)(H,78,90)(H,79,86)(H,82,83)(H4,62,63,67)(H4,64,65,68)/t40-,41-,42+,43-,44-,45+,46-,47+,48+/m0/s1
DMBMY73	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMBMY73	IK	FEKXKTLLBDRSQH-XVRHLUALSA-N
DMBMY73	IU	3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMBMY73	DE	Discovery agent

DMDO468	ID	DMDO468
DMDO468	DN	Ac-YR[CEHdFRWC]SPPKD-NH2
DMDO468	HS	Investigative
DMDO468	SN	CHEMBL2373515; Ac-YR[CEHdFRWC]SPPKD-NH2; CHEMBL437086
DMDO468	PC	44400369
DMDO468	MW	1863.1
DMDO468	FM	C83H115N25O21S2
DMDO468	IC	InChI=1S/C83H115N25O21S2/c1-44(110)95-57(34-46-22-24-49(111)25-23-46)73(121)96-54(19-10-30-92-83(88)89)71(119)105-62-41-130-131-42-63(78(126)104-61(40-109)80(128)108-32-12-21-65(108)81(129)107-31-11-20-64(107)79(127)99-52(17-7-8-28-84)69(117)100-56(68(85)116)37-67(114)115)106-75(123)59(35-47-38-93-51-16-6-5-15-50(47)51)102-70(118)53(18-9-29-91-82(86)87)97-74(122)58(33-45-13-3-2-4-14-45)101-76(124)60(36-48-39-90-43-94-48)103-72(120)55(98-77(62)125)26-27-66(112)113/h2-6,13-16,22-25,38-39,43,52-65,93,109,111H,7-12,17-21,26-37,40-42,84H2,1H3,(H2,85,116)(H,90,94)(H,95,110)(H,96,121)(H,97,122)(H,98,125)(H,99,127)(H,100,117)(H,101,124)(H,102,118)(H,103,120)(H,104,126)(H,105,119)(H,106,123)(H,112,113)(H,114,115)(H4,86,87,91)(H4,88,89,92)/t52-,53-,54-,55+,56-,57-,58-,59+,60-,61-,62+,63+,64-,65-/m0/s1
DMDO468	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CNC=N3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CO)C(=O)N7CCC[C@H]7C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N
DMDO468	IK	PPKIGEMCDOLKEY-AURDXFKRSA-N
DMDO468	IU	(3S)-3-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-19-(2-carboxyethyl)-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-4-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoic acid
DMDO468	DE	Discovery agent

DMH0EAI	ID	DMH0EAI
DMH0EAI	DN	Ac-YR[CEHFRWC]-NH2
DMH0EAI	HS	Investigative
DMH0EAI	SN	CHEMBL410672; Ac-YR[CEHFRWC]-NH2
DMH0EAI	PC	44400371
DMH0EAI	MW	1338.5
DMH0EAI	FM	C60H79N19O13S2
DMH0EAI	IC	InChI=1S/C60H79N19O13S2/c1-32(80)71-43(24-34-15-17-37(81)18-16-34)54(88)72-41(14-8-22-68-60(64)65)52(86)79-48-30-94-93-29-47(50(61)84)78-56(90)45(25-35-27-69-39-12-6-5-11-38(35)39)76-51(85)40(13-7-21-67-59(62)63)73-55(89)44(23-33-9-3-2-4-10-33)75-57(91)46(26-36-28-66-31-70-36)77-53(87)42(74-58(48)92)19-20-49(82)83/h2-6,9-12,15-18,27-28,31,40-48,69,81H,7-8,13-14,19-26,29-30H2,1H3,(H2,61,84)(H,66,70)(H,71,80)(H,72,88)(H,73,89)(H,74,92)(H,75,91)(H,76,85)(H,77,87)(H,78,90)(H,79,86)(H,82,83)(H4,62,63,67)(H4,64,65,68)/t40-,41-,42+,43-,44+,45+,46-,47+,48+/m0/s1
DMH0EAI	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMH0EAI	IK	FEKXKTLLBDRSQH-JUYCQENKSA-N
DMH0EAI	IU	3-[(4S,7R,10S,13R,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMH0EAI	DE	Discovery agent

DMWJ8UR	ID	DMWJ8UR
DMWJ8UR	DN	Ac-YRC(Me)*EHdFRWC(Me)NH2
DMWJ8UR	HS	Investigative
DMWJ8UR	SN	CHEMBL427666; Ac-YRC(Me)*EHdFRWC(Me)NH2
DMWJ8UR	PC	25078242
DMWJ8UR	MW	1368.6
DMWJ8UR	FM	C62H85N19O13S2
DMWJ8UR	IC	InChI=1S/C62H85N19O13S2/c1-34(82)73-45(26-36-17-19-39(83)20-18-36)56(90)74-43(16-10-24-70-62(66)67)54(88)81-50(32-96-3)60(94)76-44(21-22-51(84)85)55(89)79-48(28-38-30-68-33-72-38)59(93)77-46(25-35-11-5-4-6-12-35)57(91)75-42(15-9-23-69-61(64)65)53(87)78-47(58(92)80-49(31-95-2)52(63)86)27-37-29-71-41-14-8-7-13-40(37)41/h4-8,11-14,17-20,29-30,33,42-50,71,83H,9-10,15-16,21-28,31-32H2,1-3H3,(H2,63,86)(H,68,72)(H,73,82)(H,74,90)(H,75,91)(H,76,94)(H,77,93)(H,78,87)(H,79,89)(H,80,92)(H,81,88)(H,84,85)(H4,64,65,69)(H4,66,67,70)/t42-,43-,44-,45-,46+,47-,48-,49-,50-/m0/s1
DMWJ8UR	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CSC)C(=O)N
DMWJ8UR	IK	PWVUYOZSIWYFJW-MYBKRMQRSA-N
DMWJ8UR	IU	(4S)-4-[[(2R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylsulfanylpropanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-amino-3-methylsulfanyl-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMWJ8UR	DE	Discovery agent

DMN2UKC	ID	DMN2UKC
DMN2UKC	DN	Ac-YRMEHdFRWG-NH2
DMN2UKC	HS	Investigative
DMN2UKC	SN	CHEMBL266879; Ac-YRMEHdFRWG-NH2
DMN2UKC	PC	25078192
DMN2UKC	MW	1322.5
DMN2UKC	FM	C61H83N19O13S
DMN2UKC	IC	InChI=1S/C61H83N19O13S/c1-34(81)73-46(27-36-16-18-39(82)19-17-36)57(91)74-42(14-8-23-68-60(63)64)53(87)77-45(22-25-94-2)56(90)76-44(20-21-51(84)85)55(89)80-49(29-38-31-67-33-72-38)59(93)78-47(26-35-10-4-3-5-11-35)58(92)75-43(15-9-24-69-61(65)66)54(88)79-48(52(86)71-32-50(62)83)28-37-30-70-41-13-7-6-12-40(37)41/h3-7,10-13,16-19,30-31,33,42-49,70,82H,8-9,14-15,20-29,32H2,1-2H3,(H2,62,83)(H,67,72)(H,71,86)(H,73,81)(H,74,91)(H,75,92)(H,76,90)(H,77,87)(H,78,93)(H,79,88)(H,80,89)(H,84,85)(H4,63,64,68)(H4,65,66,69)/t42-,43-,44-,45-,46-,47+,48-,49-/m0/s1
DMN2UKC	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)NCC(=O)N
DMN2UKC	IK	ZSONGANRJTVTCP-FHYJZJLOSA-N
DMN2UKC	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMN2UKC	DE	Discovery agent

DMDH5B3	ID	DMDH5B3
DMDH5B3	DN	Ac-YRMEHdFRWGSPPKD-NH2
DMDH5B3	HS	Investigative
DMDH5B3	PC	91936747
DMDH5B3	MW	1847.1
DMDH5B3	FM	C84H119N25O21S
DMDH5B3	IC	InChI=1S/C84H119N25O21S/c1-46(111)97-60(37-48-23-25-51(112)26-24-48)77(125)99-55(19-10-31-92-83(87)88)72(120)102-58(29-35-131-2)76(124)101-57(27-28-68(114)115)75(123)107-63(39-50-42-91-45-96-50)79(127)105-61(36-47-14-4-3-5-15-47)78(126)100-56(20-11-32-93-84(89)90)74(122)106-62(38-49-41-94-53-17-7-6-16-52(49)53)71(119)95-43-67(113)98-64(44-110)81(129)109-34-13-22-66(109)82(130)108-33-12-21-65(108)80(128)103-54(18-8-9-30-85)73(121)104-59(70(86)118)40-69(116)117/h3-7,14-17,23-26,41-42,45,54-66,94,110,112H,8-13,18-22,27-40,43-44,85H2,1-2H3,(H2,86,118)(H,91,96)(H,95,119)(H,97,111)(H,98,113)(H,99,125)(H,100,126)(H,101,124)(H,102,120)(H,103,128)(H,104,121)(H,105,127)(H,106,122)(H,107,123)(H,114,115)(H,116,117)(H4,87,88,92)(H4,89,90,93)/t54-,55-,56-,57-,58-,59-,60-,61+,62-,63-,64-,65-,66-/m0/s1
DMDH5B3	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)NCC(=O)N[C@@H](CO)C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N
DMDH5B3	IK	XDLJELQQEILLFZ-URRWLXDFSA-N
DMDH5B3	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDH5B3	DE	Discovery agent

DM23QND	ID	DM23QND
DM23QND	DN	AD-0802
DM23QND	HS	Investigative
DM23QND	SN	Humanized monoclonal antibody vaccine (Alzheimers disease), Bioarctic
DM23QND	CP	Bioarctic Neuroscience AB
DM23QND	DT	Vaccine
DM23QND	DE	Alzheimer disease

DMYLA29	ID	DMYLA29
DMYLA29	DN	AD10-1025
DMYLA29	HS	Investigative
DMYLA29	SN	AD10-369; AD10-371; AD10-797; AD10-798; Partial PPAR gamma agonist (oral, type 2 diabetes); Partial PPAR gamma agonist (oral, type 2 diabetes), Adamed SP; Phenyl propionic acid derivative 3 (oral, type 2 diabetes), Adamed SP; PPAR modulators (oral, hypercholesterolemia/NIDDM), Adamed
DMYLA29	CP	Adamed Sp zoo
DMYLA29	DE	Hypercholesterolaemia

DMJMCDP	ID	DMJMCDP
DMJMCDP	DN	AD-412
DMJMCDP	HS	Investigative
DMJMCDP	SN	JAK3 inhibitor (autoimmune disease/transplant rejection), INSERM
DMJMCDP	CP	INSERM
DMJMCDP	DE	Autoimmune diabetes

DM5WV13	ID	DM5WV13
DM5WV13	DN	AD-5061
DM5WV13	HS	Investigative
DM5WV13	SN	AD-7057; AD7057; AD 7057; AD5061; AD 5061
DM5WV13	DT	Small molecular drug
DM5WV13	PC	9953271
DM5WV13	MW	408.5
DM5WV13	FM	C22H20N2O4S
DM5WV13	IC	InChI=1S/C22H20N2O4S/c1-14-18(23-21(28-14)16-5-3-2-4-6-16)11-12-27-17-9-7-15(8-10-17)13-19-20(25)24-22(26)29-19/h2-10,19H,11-13H2,1H3,(H,24,25,26)
DM5WV13	CS	CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DM5WV13	IK	GUTCYOKMCPFRGH-UHFFFAOYSA-N
DM5WV13	IU	5-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM5WV13	DE	Discovery agent

DMV48L3	ID	DMV48L3
DMV48L3	DN	AD5-10
DMV48L3	HS	Investigative
DMV48L3	SN	Zaptuzumab; Death receptor 5 (DR5) human murine antibody (cancer), Chinese Academy of Medical Science
DMV48L3	CP	Chinese Academy of Medical Science
DMV48L3	DT	Antibody
DMV48L3	DE	Solid tumour/cancer

DMQW612	ID	DMQW612
DMQW612	DN	Ad5f35-LMPd1-2-transduced autologous dendritic cells
DMQW612	HS	Investigative
DMQW612	SN	AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI
DMQW612	CP	National Cancer Institute
DMQW612	DT	Vaccine
DMQW612	DE	Nasopharyngeal carcinoma

DMKDRVZ	ID	DMKDRVZ
DMKDRVZ	DN	Adamant-1-ylcarbamic Acid Biphenyl-3-yl Ester
DMKDRVZ	HS	Investigative
DMKDRVZ	SN	CHEMBL485883; Adamant-1-ylcarbamic Acid Biphenyl-3-yl Ester
DMKDRVZ	DT	Small molecular drug
DMKDRVZ	PC	24881677
DMKDRVZ	MW	347.4
DMKDRVZ	FM	C23H25NO2
DMKDRVZ	IC	InChI=1S/C23H25NO2/c25-22(24-23-13-16-9-17(14-23)11-18(10-16)15-23)26-21-8-4-7-20(12-21)19-5-2-1-3-6-19/h1-8,12,16-18H,9-11,13-15H2,(H,24,25)
DMKDRVZ	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)OC4=CC=CC(=C4)C5=CC=CC=C5
DMKDRVZ	IK	STNJKWWAIGCDRW-UHFFFAOYSA-N
DMKDRVZ	IU	(3-phenylphenyl) N-(1-adamantyl)carbamate
DMKDRVZ	DE	Discovery agent

DM4S279	ID	DM4S279
DM4S279	DN	Adamantan-1-yl-(4-ethyl-piperazin-1-yl)-methanone
DM4S279	HS	Investigative
DM4S279	SN	CHEMBL396928; AC1N8RTC; 1-adamantyl-(4-ethylpiperazin-1-yl)methanone; Oprea1_784934; adamantan-1-yl-(4-ethyl-piperazin-1-yl)-methanone; MolPort-005-510-679; BDBM50207776
DM4S279	DT	Small molecular drug
DM4S279	PC	4348598
DM4S279	MW	276.4
DM4S279	FM	C17H28N2O
DM4S279	IC	InChI=1S/C17H28N2O/c1-2-18-3-5-19(6-4-18)16(20)17-10-13-7-14(11-17)9-15(8-13)12-17/h13-15H,2-12H2,1H3
DM4S279	CS	CCN1CCN(CC1)C(=O)C23CC4CC(C2)CC(C4)C3
DM4S279	IK	XOWWNQSYPPTVEH-UHFFFAOYSA-N
DM4S279	IU	1-adamantyl-(4-ethylpiperazin-1-yl)methanone
DM4S279	DE	Discovery agent

DM5K0EI	ID	DM5K0EI
DM5K0EI	DN	Adamantan-1-yl-piperazin-1-yl-methanone
DM5K0EI	HS	Investigative
DM5K0EI	SN	1-(1-adamantylcarbonyl)piperazine; 29869-08-7; adamantanyl piperazinyl ketone; CHEMBL391335; piperazin-1-yl(tricyclo[3.3.1.1~3,7~]dec-1-yl)methanone; adamantan-1-yl-piperazin-1-yl-methanone; AC1Q5KAX; SCHEMBL1150471; CTK4G3954; DTXSID70589438; XAFSAELWLMDLKL-UHFFFAOYSA-N; MolPort-006-345-515; 1-(1-adamantanecarbonyl)piperazine; ALBB-024506; ZINC12343593; STL412114; BDBM50207783; SBB071957; BBL037233; AKOS009097513; MCULE-3925280273; ST072044; EN300-25317; AB00983558-01; piperazine, 1-(tricyclo[3.3.1.1~3,7~]dec-1-ylcarbonyl)-
DM5K0EI	DT	Small molecular drug
DM5K0EI	PC	17233943
DM5K0EI	MW	248.36
DM5K0EI	FM	C15H24N2O
DM5K0EI	IC	InChI=1S/C15H24N2O/c18-14(17-3-1-16-2-4-17)15-8-11-5-12(9-15)7-13(6-11)10-15/h11-13,16H,1-10H2
DM5K0EI	CS	C1CN(CCN1)C(=O)C23CC4CC(C2)CC(C4)C3
DM5K0EI	IK	XAFSAELWLMDLKL-UHFFFAOYSA-N
DM5K0EI	IU	1-adamantyl(piperazin-1-yl)methanone
DM5K0EI	CA	CAS 29869-08-7
DM5K0EI	DE	Discovery agent

DMTUL9J	ID	DMTUL9J
DMTUL9J	DN	Adamantan-1-yl-piperidin-1-yl-methanone
DMTUL9J	HS	Investigative
DMTUL9J	SN	Adamantan-1-yl-piperidin-1-yl-methanone; adamantanyl piperidyl ketone; CHEMBL245590; 1-adamantyl(piperidino)methanone; 22508-49-2; (3r,5r,7r)-adamantan-1-yl(piperidin-1-yl)methanone; 1-adamantyl(piperidin-1-yl)methanone; SMR000117086; AC1LBKY9; Maybridge1_008125; Oprea1_633750; Oprea1_290126; MLS000526612; Piperidino(1-adamantyl) ketone; SCHEMBL3457055; SCHEMBL19841773; CTK7F5375; HMS564J07; BURUIZXRHQWZQI-UHFFFAOYSA-N; MolPort-001-930-823; 1-(1-Adamantylcarbonyl)piperidine; HMS2178P18; ZINC4031797
DMTUL9J	DT	Small molecular drug
DMTUL9J	PC	584509
DMTUL9J	MW	247.38
DMTUL9J	FM	C16H25NO
DMTUL9J	IC	InChI=1S/C16H25NO/c18-15(17-4-2-1-3-5-17)16-9-12-6-13(10-16)8-14(7-12)11-16/h12-14H,1-11H2
DMTUL9J	CS	C1CCN(CC1)C(=O)C23CC4CC(C2)CC(C4)C3
DMTUL9J	IK	BURUIZXRHQWZQI-UHFFFAOYSA-N
DMTUL9J	IU	1-adamantyl(piperidin-1-yl)methanone
DMTUL9J	DE	Discovery agent

DMAEN9Y	ID	DMAEN9Y
DMAEN9Y	DN	Adamantan-1-yl-pyrrolidin-1-yl-methanone
DMAEN9Y	HS	Investigative
DMAEN9Y	SN	Adamantan-1-yl-pyrrolidin-1-yl-methanone; CHEMBL392866; 1-adamantyl(1-pyrrolidinyl)methanone; 22508-51-6; (3r,5r,7r)-adamantan-1-yl(pyrrolidin-1-yl)methanone; 1-adamantyl(pyrrolidin-1-yl)methanone; AC1MCDV9; CBMicro_007397; Cambridge id 5142982; Oprea1_111627; Oprea1_295021; MLS000526196; adamantanyl pyrrolidinyl ketone; SCHEMBL3456185; MolPort-001-930-821; HMS2477C05; HMS1608M03; ZINC4031845; SMSF0003738; STK091400; BDBM50207788; 1-(adamantane-1-carbonyl)pyrrolidine; AKOS000612243; CCG-246226; CB09819; MCULE-7009966643
DMAEN9Y	DT	Small molecular drug
DMAEN9Y	PC	2741656
DMAEN9Y	MW	233.35
DMAEN9Y	FM	C15H23NO
DMAEN9Y	IC	InChI=1S/C15H23NO/c17-14(16-3-1-2-4-16)15-8-11-5-12(9-15)7-13(6-11)10-15/h11-13H,1-10H2
DMAEN9Y	CS	C1CCN(C1)C(=O)C23CC4CC(C2)CC(C4)C3
DMAEN9Y	IK	RVXVNLMWQYKNHL-UHFFFAOYSA-N
DMAEN9Y	IU	1-adamantyl(pyrrolidin-1-yl)methanone
DMAEN9Y	CA	CAS 22508-51-6
DMAEN9Y	DE	Discovery agent

DMBRAV5	ID	DMBRAV5
DMBRAV5	DN	Adamantan-2-yl-piperidin-1-yl-methanone
DMBRAV5	HS	Investigative
DMBRAV5	SN	CHEMBL245393; adamantan-2-yl-piperidin-1-yl-methanone; MolPort-027-725-528; BDBM50207799; AKOS017280695
DMBRAV5	DT	Small molecular drug
DMBRAV5	PC	9450114
DMBRAV5	MW	247.38
DMBRAV5	FM	C16H25NO
DMBRAV5	IC	InChI=1S/C16H25NO/c18-16(17-4-2-1-3-5-17)15-13-7-11-6-12(9-13)10-14(15)8-11/h11-15H,1-10H2
DMBRAV5	CS	C1CCN(CC1)C(=O)C2C3CC4CC(C3)CC2C4
DMBRAV5	IK	AHSGKCRVZWMWDM-UHFFFAOYSA-N
DMBRAV5	IU	2-adamantyl(piperidin-1-yl)methanone
DMBRAV5	DE	Discovery agent

DM1MAVU	ID	DM1MAVU
DM1MAVU	DN	Ada-RYYRIK-NH2
DM1MAVU	HS	Investigative
DM1MAVU	SN	CHEMBL256687
DM1MAVU	PC	44456141
DM1MAVU	MW	1043.3
DM1MAVU	FM	C53H82N14O8
DM1MAVU	IC	InChI=1S/C53H82N14O8/c1-3-31(2)43(49(74)62-38(44(55)69)13-7-8-20-54)67-46(71)39(14-9-21-60-51(56)57)63-47(72)42(27-33-16-18-37(68)19-17-33)65-48(73)41(26-32-11-5-4-6-12-32)64-45(70)40(15-10-22-61-52(58)59)66-50(75)53-28-34-23-35(29-53)25-36(24-34)30-53/h4-6,11-12,16-19,31,34-36,38-43,68H,3,7-10,13-15,20-30,54H2,1-2H3,(H2,55,69)(H,62,74)(H,63,72)(H,64,70)(H,65,73)(H,66,75)(H,67,71)(H4,56,57,60)(H4,58,59,61)/t31-,34?,35?,36?,38-,39-,40-,41-,42-,43-,53?/m0/s1
DM1MAVU	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C34CC5CC(C3)CC(C5)C4
DM1MAVU	IK	CHQPBFJDZBBZJD-OGHQQVQQSA-N
DM1MAVU	IU	N-[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S,3S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]adamantane-1-carboxamide
DM1MAVU	DE	Discovery agent

DMJQM7H	ID	DMJQM7H
DMJQM7H	DN	ADC-1012
DMJQM7H	HS	Investigative
DMJQM7H	SN	IL-23 antagonist (protein recombinant, cancer/inflammation), Alligator Bioscience
DMJQM7H	CP	Alligator Bioscience AB
DMJQM7H	DE	Solid tumour/cancer

DMV761D	ID	DMV761D
DMV761D	DN	ADC-5510
DMV761D	HS	Investigative
DMV761D	SN	ADC-02265510; ADL-5510; Centrally acting mu opoid receptor antagonists, Adolor
DMV761D	CP	Adolor Corp
DMV761D	DE	Movement disorder

DM19KY6	ID	DM19KY6
DM19KY6	DN	ADC-7828
DM19KY6	HS	Investigative
DM19KY6	SN	Neutrophil elastase inhibitors (inhaled, CF/COPD); Neutrophil elastase inhibitor (inhaled, cystic fibrosis/chronic obstructive pulmonary disease), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Pulmagen
DM19KY6	CP	Argenta Discovery Ltd
DM19KY6	DE	Chronic obstructive pulmonary disease

DMY6PMJ	ID	DMY6PMJ
DMY6PMJ	DN	ADC-9971
DMY6PMJ	HS	Investigative
DMY6PMJ	SN	ADS-9971; CRTh2 antagonist (oral, COPD/allergic asthma/allergic rhinitis), Argenta Discovery; Prostaglandin D2 receptor antagonist (oral, allergic asthma/allergic rhinitis/COPD), Argenta Discovery
DMY6PMJ	CP	Argenta Discovery Ltd
DMY6PMJ	DE	Allergic rhinitis

DMZYJHV	ID	DMZYJHV
DMZYJHV	DN	AdcAhxArg4Lys(biotin)-PEG-OMe
DMZYJHV	HS	Investigative
DMZYJHV	SN	CHEMBL413173
DMZYJHV	PC	44387501
DMZYJHV	MW	1474.7
DMZYJHV	FM	C61H107N27O14S
DMZYJHV	IC	InChI=1S/C61H107N27O14S/c1-100-29-30-101-28-27-73-50(93)34(13-6-8-21-71-41(89)19-5-4-18-40-43-39(31-103-40)86-61(99)87-43)82-52(95)36(15-10-24-75-58(65)66)84-54(97)38(17-12-26-77-60(69)70)85-53(96)37(16-11-25-76-59(67)68)83-51(94)35(14-9-23-74-57(63)64)81-42(90)20-3-2-7-22-72-55(98)47-45(91)46(92)56(102-47)88-33-80-44-48(62)78-32-79-49(44)88/h32-40,43,45-47,56,91-92H,2-31H2,1H3,(H,71,89)(H,72,98)(H,73,93)(H,81,90)(H,82,95)(H,83,94)(H,84,97)(H,85,96)(H2,62,78,79)(H4,63,64,74)(H4,65,66,75)(H4,67,68,76)(H4,69,70,77)(H2,86,87,99)/t34?,35-,36-,37-,38-,39-,40-,43-,45-,46+,47-,56+/m0/s1
DMZYJHV	CS	COCCOCCNC(=O)C(CCCCNC(=O)CCCC[C@H]1[C@@H]2[C@H](CS1)NC(=O)N2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CCCCCNC(=O)[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O
DMZYJHV	IK	HKRIJYTUBFTJDB-GQHJETKOSA-N
DMZYJHV	IU	(2S,3S,4R,5R)-N-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-1-[2-(2-methoxyethoxy)ethylamino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-6-oxohexyl]-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carboxamide
DMZYJHV	DE	Discovery agent

DMQ2C8X	ID	DMQ2C8X
DMQ2C8X	DN	AdcAhxArg4Lys-PEGOMe
DMQ2C8X	HS	Investigative
DMQ2C8X	SN	CHEMBL426336
DMQ2C8X	PC	44387499
DMQ2C8X	MW	1248.4
DMQ2C8X	FM	C51H93N25O12
DMQ2C8X	IC	InChI=1S/C51H93N25O12/c1-86-25-26-87-24-23-63-41(80)29(11-4-5-17-52)72-43(82)31(13-8-20-65-49(56)57)74-45(84)33(15-10-22-67-51(60)61)75-44(83)32(14-9-21-66-50(58)59)73-42(81)30(12-7-19-64-48(54)55)71-34(77)16-3-2-6-18-62-46(85)38-36(78)37(79)47(88-38)76-28-70-35-39(53)68-27-69-40(35)76/h27-33,36-38,47,78-79H,2-26,52H2,1H3,(H,62,85)(H,63,80)(H,71,77)(H,72,82)(H,73,81)(H,74,84)(H,75,83)(H2,53,68,69)(H4,54,55,64)(H4,56,57,65)(H4,58,59,66)(H4,60,61,67)/t29?,30-,31-,32-,33-,36-,37+,38-,47+/m0/s1
DMQ2C8X	CS	COCCOCCNC(=O)C(CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CCCCCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMQ2C8X	IK	JBQKHDQXRCCDGW-NZDGIOGASA-N
DMQ2C8X	IU	(2S,3S,4R,5R)-N-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[6-amino-1-[2-(2-methoxyethoxy)ethylamino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-6-oxohexyl]-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carboxamide
DMQ2C8X	DE	Discovery agent

DMSYMRJ	ID	DMSYMRJ
DMSYMRJ	DN	AdcAhxArg4NH(CH2)6NH2
DMSYMRJ	HS	Investigative
DMSYMRJ	SN	CHEMBL263964
DMSYMRJ	PC	44387500
DMSYMRJ	MW	1117.3
DMSYMRJ	FM	C46H84N24O9
DMSYMRJ	IC	InChI=1S/C46H84N24O9/c47-17-5-1-2-6-18-57-37(74)26(12-8-20-59-43(49)50)67-39(76)28(14-10-22-61-45(53)54)69-40(77)29(15-11-23-62-46(55)56)68-38(75)27(13-9-21-60-44(51)52)66-30(71)16-4-3-7-19-58-41(78)34-32(72)33(73)42(79-34)70-25-65-31-35(48)63-24-64-36(31)70/h24-29,32-34,42,72-73H,1-23,47H2,(H,57,74)(H,58,78)(H,66,71)(H,67,76)(H,68,75)(H,69,77)(H2,48,63,64)(H4,49,50,59)(H4,51,52,60)(H4,53,54,61)(H4,55,56,62)/t26-,27-,28-,29-,32-,33+,34-,42+/m0/s1
DMSYMRJ	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCCCCN)O)O)N
DMSYMRJ	IK	AKYVNHGFJFUSDY-HYKQOWLKSA-N
DMSYMRJ	IU	(2S,3S,4R,5R)-N-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-(6-aminohexylamino)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-6-oxohexyl]-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carboxamide
DMSYMRJ	DE	Discovery agent

DM7J3K0	ID	DM7J3K0
DM7J3K0	DN	AdcAhxArg6
DM7J3K0	HS	Investigative
DM7J3K0	SN	CHEMBL438544
DM7J3K0	PC	10441484
DM7J3K0	MW	1331.5
DM7J3K0	FM	C52H94N30O12
DM7J3K0	IC	InChI=1S/C52H94N30O12/c53-37-33-38(74-24-73-37)82(25-75-33)45-35(85)34(84)36(94-45)44(91)66-17-3-1-2-16-32(83)76-26(10-4-18-67-47(54)55)39(86)77-27(11-5-19-68-48(56)57)40(87)78-28(12-6-20-69-49(58)59)41(88)79-29(13-7-21-70-50(60)61)42(89)80-30(14-8-22-71-51(62)63)43(90)81-31(46(92)93)15-9-23-72-52(64)65/h24-31,34-36,45,84-85H,1-23H2,(H,66,91)(H,76,83)(H,77,86)(H,78,87)(H,79,88)(H,80,89)(H,81,90)(H,92,93)(H2,53,73,74)(H4,54,55,67)(H4,56,57,68)(H4,58,59,69)(H4,60,61,70)(H4,62,63,71)(H4,64,65,72)/t26-,27-,28-,29-,30-,31-,34-,35+,36-,45+/m0/s1
DM7J3K0	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)O)O)N
DM7J3K0	IK	QLSCMEHEXBNFGR-HDLKDVBUSA-N
DM7J3K0	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[6-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]hexanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM7J3K0	DE	Discovery agent

DMV39AW	ID	DMV39AW
DMV39AW	DN	ADENOPHOSTIN A
DMV39AW	HS	Investigative
DMV39AW	SN	adenophostin a; 149091-92-9; Adenophostin; CHEMBL204385; AC1L3X4M; CHEBI:34524; 2'-Adenylic acid, 3'-O-(3,4-di-O-phosphono-alpha-D-glucopyranosyl)-; C16H26N5O18P3; GTPL4124; DTXSID10164167; BDBM50184325; LS-173343; C13727; 2-[5-(6-amino-9H-9-purinyl)-2-hydroxymethyl-4-oxyphosphate-(2R,3R,4R,5R)-tetrahydro-3-furanyloxy]-6-hydroxymethyl-4,5-dioxyphosphate-(2R,3R,4S,5R,6R)-tetrahydro-2H-3-pyranol
DMV39AW	DT	Small molecular drug
DMV39AW	PC	123695
DMV39AW	MW	669.3
DMV39AW	FM	C16H26N5O18P3
DMV39AW	IC	InChI=1S/C16H26N5O18P3/c17-13-7-14(19-3-18-13)21(4-20-7)15-12(39-42(31,32)33)9(5(1-22)34-15)36-16-8(24)11(38-41(28,29)30)10(6(2-23)35-16)37-40(25,26)27/h3-6,8-12,15-16,22-24H,1-2H2,(H2,17,18,19)(H2,25,26,27)(H2,28,29,30)(H2,31,32,33)/t5-,6-,8-,9-,10-,11-,12-,15-,16-/m1/s1
DMV39AW	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)OP(=O)(O)O)OP(=O)(O)O)O)OP(=O)(O)O)N
DMV39AW	IK	RENVITLQVBEFDT-MZQFDOALSA-N
DMV39AW	IU	[(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-[(2R,3R,4R,5R,6R)-3-hydroxy-6-(hydroxymethyl)-4,5-diphosphonooxyoxan-2-yl]oxy-5-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate
DMV39AW	CA	CAS 149091-92-9
DMV39AW	CB	CHEBI:34524
DMV39AW	DE	Discovery agent

DMFUHKP	ID	DMFUHKP
DMFUHKP	DN	adenosine diphosphate
DMFUHKP	HS	Investigative
DMFUHKP	SN	Adenosine diphosphate; 58-64-0; ADP; Adenosine 5'-(trihydrogen diphosphate); adenosine pyrophosphate; adenosine 5'-pyrophosphate; ADP (nucleotide); adenosine-diphosphate; 5'-Adenylphosphoric acid; 5'-Adp; Adenosindiphosphorsaeure; Adenosine 5'-pyrophosphoric acid; Adenosine-5'-diphosphat; Adenosine 5'-diphosphoric acid; Adenosine diphosphoric acid; Ado-5'-P-P; UNII-61D2G4IYVH; H3adp; BRN 0067722; CHEBI:16761; EINECS 200-392-5; 61D2G4IYVH; CHEMBL14830
DMFUHKP	DT	Small molecular drug
DMFUHKP	PC	6022
DMFUHKP	MW	427.2
DMFUHKP	FM	C10H15N5O10P2
DMFUHKP	IC	InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-27(21,22)25-26(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMFUHKP	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N
DMFUHKP	IK	XTWYTFMLZFPYCI-KQYNXXCUSA-N
DMFUHKP	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMFUHKP	CA	CAS 58-64-0
DMFUHKP	CB	CHEBI:16761

DMJZPSX	ID	DMJZPSX
DMJZPSX	DN	Adenosine Monotungstate
DMJZPSX	HS	Investigative
DMJZPSX	SN	ADENOSINE MONOTUNGSTATE
DMJZPSX	DT	Small molecular drug
DMJZPSX	PC	46936368
DMJZPSX	MW	501.1
DMJZPSX	FM	C10H15N5O7W
DMJZPSX	IC	InChI=1S/C10H13N5O4.2H2O.O.W/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10;;;;/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13);2*1H2;;/q;;;;+2/p-2/t4-,6-,7+,10+;;;;/m0..../s1
DMJZPSX	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@H]([C@@H](O3)CO)O)O)N.O[W](=O)O
DMJZPSX	IK	YGGXZRZCGFLZPM-LRDMJOKZSA-L
DMJZPSX	IU	(2R,3R,4R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol;dihydroxy(oxo)tungsten
DMJZPSX	DE	Discovery agent

DMSOVFD	ID	DMSOVFD
DMSOVFD	DN	adenosine-3'-5'-bisphosphate
DMSOVFD	HS	Investigative
DMSOVFD	SN	adenosine 3',5'-diphosphate; adenosine 3',5'-bisphosphate
DMSOVFD	DT	Small molecular drug
DMSOVFD	PC	159296
DMSOVFD	MW	427.2
DMSOVFD	FM	C10H15N5O10P2
DMSOVFD	IC	InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7(25-27(20,21)22)4(24-10)1-23-26(17,18)19/h2-4,6-7,10,16H,1H2,(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1
DMSOVFD	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)OP(=O)(O)O)O)N
DMSOVFD	IK	WHTCPDAXWFLDIH-KQYNXXCUSA-N
DMSOVFD	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate
DMSOVFD	CA	CAS 1053-73-2
DMSOVFD	CB	CHEBI:17985
DMSOVFD	DE	Discovery agent

DM96LBV	ID	DM96LBV
DM96LBV	DN	Adenosine-5-Diphosphoribose
DM96LBV	HS	Investigative
DM96LBV	SN	Adenosine-5-Diphosphoribose; [(2r,3s,4r,5r)-5-(6-Aminopurin-9-Yl)-3,4-Dihydroxy-Oxolan-2-Yl]methyl [hydroxy-[[(2r,3s,4r,5s)-3,4,5-Trihydroxyoxolan-2-Yl]methoxy]phosphoryl] Hydrogen Phosphate; 2bfq; AR6; AC1L9KEO; ZINC14880207; DB02059; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl [(2R,3S,4R,5S)-3,4,5-trihydroxytetrahydrof
DM96LBV	DT	Small molecular drug
DM96LBV	PC	447048
DM96LBV	MW	559.32
DM96LBV	FM	C15H23N5O14P2
DM96LBV	IC	InChI=1S/C15H23N5O14P2/c16-12-7-13(18-3-17-12)20(4-19-7)14-10(23)8(21)5(32-14)1-30-35(26,27)34-36(28,29)31-2-6-9(22)11(24)15(25)33-6/h3-6,8-11,14-15,21-25H,1-2H2,(H,26,27)(H,28,29)(H2,16,17,18)/t5-,6-,8-,9-,10-,11-,14-,15+/m1/s1
DM96LBV	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@H](O4)O)O)O)O)O)N
DM96LBV	IK	SRNWOUGRCWSEMX-ZQSHOCFMSA-N
DM96LBV	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM96LBV	DE	Discovery agent

DMJDO2F	ID	DMJDO2F
DMJDO2F	DN	Adenosine-5'-O-(2-thiodiphosphate)
DMJDO2F	HS	Investigative
DMJDO2F	SN	Adpbetas; adenosine 5'-O-(2-thiodiphosphate); beta-Thio-ADP; Adenosine-5'-O-(2-thiodiphosphate); CHEMBL335206; 35094-45-2; ADP-beta-S; 73536-95-5; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydroxyphosphinothioyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl dihydroxyphosphinothioyl hydrogen phosphate; ADP beta S; 5'-Adps; 5'-Adenosine diphosphate beta-S; ADP-gamma-S; AT4; EINECS 277-530-6; AC1NSJSN; (32S)Adenosine 5'-O-(2-thiodiphosphate)
DMJDO2F	DT	Small molecular drug
DMJDO2F	PC	5310996
DMJDO2F	MW	443.27
DMJDO2F	FM	C10H15N5O9P2S
DMJDO2F	IC	InChI=1S/C10H15N5O9P2S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(23-10)1-22-25(18,19)24-26(20,21)27/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H2,11,12,13)(H2,20,21,27)/t4-,6-,7-,10-/m1/s1
DMJDO2F	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=S)(O)O)O)O)N
DMJDO2F	IK	HCIKUKNAJRJFOW-KQYNXXCUSA-N
DMJDO2F	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydroxyphosphinothioyl hydrogen phosphate
DMJDO2F	CA	CAS 35094-45-2
DMJDO2F	DE	Discovery agent

DMKY7T8	ID	DMKY7T8
DMKY7T8	DN	Adenosine-5'-Rp-Alpha-Thio-Triphosphate
DMKY7T8	HS	Investigative
DMKY7T8	SN	ADENOSINE-5'-RP-ALPHA-THIO-TRIPHOSPHATE; ATP-alpha-S; AC1OAHXZ; SCHEMBL307389; CHEMBL3774733; adenosine 5'-O-(1-thiotriphosphate); DB02355; T99; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate
DMKY7T8	DT	Small molecular drug
DMKY7T8	PC	6858181
DMKY7T8	MW	523.25
DMKY7T8	FM	C10H16N5O12P3S
DMKY7T8	IC	InChI=1S/C10H16N5O12P3S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(25-10)1-24-30(23,31)27-29(21,22)26-28(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,31)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-,30?/m1/s1
DMKY7T8	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=S)(O)OP(=O)(O)OP(=O)(O)O)O)O)N
DMKY7T8	IK	ROYJKVPBJVNHCQ-VWJVIAGJSA-N
DMKY7T8	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate
DMKY7T8	DE	Discovery agent

DM0YQ2I	ID	DM0YQ2I
DM0YQ2I	DN	Adenylylsulfate
DM0YQ2I	HS	Investigative
DM0YQ2I	SN	ADENOSINE-5'-PHOSPHOSULFATE; Adenosine 5'-phosphosulfate; Adenosine 5'-sulfatophosphate; Adenosine sulfatophosphate; Adenylyl sulfate; Adenylylsulfate; Phosphosulphate; adenosine 5'-sulphatophosphate; adenosine phosphosulfate; adenylyl-sulfate; adenylyl-sulphate; phosphosulfate; sulfatophosphate; 485-84-7; 5'-Adenylic acid, monoanhydride with sulfuric acid; 5'-Adenylyl sulfate; AMPS; BRN 0067726; CHEBI:17709; [({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]sulfonic acid
DM0YQ2I	PC	10238
DM0YQ2I	MW	427.29
DM0YQ2I	FM	C10H14N5O10PS
DM0YQ2I	IC	IRLPACMLTUPBCL-KQYNXXCUSA-N
DM0YQ2I	CS	C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)OS(=O)(=O)O)O)O)N
DM0YQ2I	IK	1S/C10H14N5O10PS/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-26(18,19)25-27(20,21)22/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H2,11,12,13)(H,20,21,22)/t4-,6-,7-,10-/m1/s1
DM0YQ2I	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl sulfo hydrogen phosphate
DM0YQ2I	CA	CAS 485-84-7
DM0YQ2I	CB	CHEBI:17709
DM0YQ2I	DE	Discovery agent

DM2XI09	ID	DM2XI09
DM2XI09	DN	Adipate
DM2XI09	HS	Investigative
DM2XI09	SN	adipic acid; hexanedioic acid; 124-04-9; Adipinic acid; 1,4-Butanedicarboxylic acid; Adilactetten; Acifloctin; Acinetten; 1,6-Hexanedioic acid; Molten adipic acid; Kyselina adipova; Adipinsaure [German]; Acide adipique [French]; Kyselina adipova [Czech]; Hexanedioate; Adipinsaeure; FEMA Number 2011; Adi-pure; UNII-76A0JE0FKJ; NSC 7622; CCRIS 812; Adipic acid [NF]; FEMA No. 2011; HSDB 188; Adipic acid, 99%; Hexan-1,6-dicarboxylate; EINECS 204-673-3; BRN 1209788; 76A0JE0FKJ; AI3-03700; 1,6-HEXANE-DIOIC ACID; CHEBI:30832; NSC7622
DM2XI09	DT	Small molecular drug
DM2XI09	PC	200164
DM2XI09	MW	144.12
DM2XI09	FM	C6H8O4-2
DM2XI09	IC	InChI=1S/C6H10O4/c7-5(8)3-1-2-4-6(9)10/h1-4H2,(H,7,8)(H,9,10)/p-2
DM2XI09	CS	C(CCC(=O)[O-])CC(=O)[O-]
DM2XI09	IK	WNLRTRBMVRJNCN-UHFFFAOYSA-L
DM2XI09	IU	hexanedioate
DM2XI09	CA	CAS 764-65-8
DM2XI09	CB	CHEBI:17128
DM2XI09	DE	Discovery agent

DMW5HO0	ID	DMW5HO0
DMW5HO0	DN	AdoC(Ahx)Arg6
DMW5HO0	HS	Investigative
DMW5HO0	SN	CHEMBL610874
DMW5HO0	PC	46877390
DMW5HO0	MW	1331.5
DMW5HO0	FM	C52H94N30O12
DMW5HO0	IC	InChI=1S/C52H94N30O12/c53-37-33-38(74-24-73-37)82(25-75-33)45-35(85)34(84)36(94-45)44(91)66-17-3-1-2-16-32(83)76-26(10-4-18-67-47(54)55)39(86)77-27(11-5-19-68-48(56)57)40(87)78-28(12-6-20-69-49(58)59)41(88)79-29(13-7-21-70-50(60)61)42(89)80-30(14-8-22-71-51(62)63)43(90)81-31(46(92)93)15-9-23-72-52(64)65/h24-31,34-36,45,84-85H,1-23H2,(H,66,91)(H,76,83)(H,77,86)(H,78,87)(H,79,88)(H,80,89)(H,81,90)(H,92,93)(H2,53,73,74)(H4,54,55,67)(H4,56,57,68)(H4,58,59,69)(H4,60,61,70)(H4,62,63,71)(H4,64,65,72)/t26-,27-,28-,29-,30-,31-,34+,35-,36+,45?/m1/s1
DMW5HO0	CS	C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMW5HO0	IK	QLSCMEHEXBNFGR-FBEAYKSBSA-N
DMW5HO0	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[6-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]hexanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMW5HO0	DE	Discovery agent

DMRSCO2	ID	DMRSCO2
DMRSCO2	DN	AdoC(Aoc)Arg6
DMRSCO2	HS	Investigative
DMRSCO2	SN	CHEMBL610876
DMRSCO2	PC	46877392
DMRSCO2	MW	1359.6
DMRSCO2	FM	C54H98N30O12
DMRSCO2	IC	InChI=1S/C54H98N30O12/c55-39-35-40(76-26-75-39)84(27-77-35)47-37(87)36(86)38(96-47)46(93)68-19-5-3-1-2-4-18-34(85)78-28(12-6-20-69-49(56)57)41(88)79-29(13-7-21-70-50(58)59)42(89)80-30(14-8-22-71-51(60)61)43(90)81-31(15-9-23-72-52(62)63)44(91)82-32(16-10-24-73-53(64)65)45(92)83-33(48(94)95)17-11-25-74-54(66)67/h26-33,36-38,47,86-87H,1-25H2,(H,68,93)(H,78,85)(H,79,88)(H,80,89)(H,81,90)(H,82,91)(H,83,92)(H,94,95)(H2,55,75,76)(H4,56,57,69)(H4,58,59,70)(H4,60,61,71)(H4,62,63,72)(H4,64,65,73)(H4,66,67,74)/t28-,29-,30-,31-,32-,33-,36+,37-,38+,47?/m1/s1
DMRSCO2	CS	C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMRSCO2	IK	HBUMOBPTTFUJHS-FIYJFMLKSA-N
DMRSCO2	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[8-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]octanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMRSCO2	DE	Discovery agent

DMDLHAB	ID	DMDLHAB
DMDLHAB	DN	AdoC(Aun)Arg6
DMDLHAB	HS	Investigative
DMDLHAB	SN	CHEMBL611121
DMDLHAB	PC	46877396
DMDLHAB	MW	1401.6
DMDLHAB	FM	C57H104N30O12
DMDLHAB	IC	InChI=1S/C57H104N30O12/c58-42-38-43(79-29-78-42)87(30-80-38)50-40(90)39(89)41(99-50)49(96)71-22-8-6-4-2-1-3-5-7-21-37(88)81-31(15-9-23-72-52(59)60)44(91)82-32(16-10-24-73-53(61)62)45(92)83-33(17-11-25-74-54(63)64)46(93)84-34(18-12-26-75-55(65)66)47(94)85-35(19-13-27-76-56(67)68)48(95)86-36(51(97)98)20-14-28-77-57(69)70/h29-36,39-41,50,89-90H,1-28H2,(H,71,96)(H,81,88)(H,82,91)(H,83,92)(H,84,93)(H,85,94)(H,86,95)(H,97,98)(H2,58,78,79)(H4,59,60,72)(H4,61,62,73)(H4,63,64,74)(H4,65,66,75)(H4,67,68,76)(H4,69,70,77)/t31-,32-,33-,34-,35-,36-,39+,40-,41+,50?/m1/s1
DMDLHAB	CS	C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMDLHAB	IK	VPJLJWJUVPAMHK-MOSAXMBESA-N
DMDLHAB	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[11-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]undecanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMDLHAB	DE	Discovery agent

DMPUAFC	ID	DMPUAFC
DMPUAFC	DN	AdoC(beta-Ala)2AlaArg6
DMPUAFC	HS	Investigative
DMPUAFC	SN	CHEMBL610875
DMPUAFC	PC	46877391
DMPUAFC	MW	1431.6
DMPUAFC	FM	C55H98N32O14
DMPUAFC	IC	InChI=1S/C55H98N32O14/c1-26(80-34(89)15-22-69-33(88)14-23-70-47(98)38-36(90)37(91)48(101-38)87-25-79-35-39(56)77-24-78-40(35)87)41(92)81-27(8-2-16-71-50(57)58)42(93)82-28(9-3-17-72-51(59)60)43(94)83-29(10-4-18-73-52(61)62)44(95)84-30(11-5-19-74-53(63)64)45(96)85-31(12-6-20-75-54(65)66)46(97)86-32(49(99)100)13-7-21-76-55(67)68/h24-32,36-38,48,90-91H,2-23H2,1H3,(H,69,88)(H,70,98)(H,80,89)(H,81,92)(H,82,93)(H,83,94)(H,84,95)(H,85,96)(H,86,97)(H,99,100)(H2,56,77,78)(H4,57,58,71)(H4,59,60,72)(H4,61,62,73)(H4,63,64,74)(H4,65,66,75)(H4,67,68,76)/t26-,27-,28-,29-,30-,31-,32-,36+,37-,38+,48?/m1/s1
DMPUAFC	CS	C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)NC(=O)CCNC(=O)CCNC(=O)[C@@H]1[C@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)O
DMPUAFC	IK	QDXYEHKCQQMPGT-LSDLINHMSA-N
DMPUAFC	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[3-[3-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]propanoylamino]propanoylamino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMPUAFC	DE	Discovery agent

DMO8D4V	ID	DMO8D4V
DMO8D4V	DN	AdoC(beta-Ala)Arg6
DMO8D4V	HS	Investigative
DMO8D4V	SN	CHEMBL611122
DMO8D4V	PC	46877397
DMO8D4V	MW	1289.4
DMO8D4V	FM	C49H88N30O12
DMO8D4V	IC	InChI=1S/C49H88N30O12/c50-34-30-35(71-21-70-34)79(22-72-30)42-32(82)31(81)33(91-42)41(88)63-20-13-29(80)73-23(7-1-14-64-44(51)52)36(83)74-24(8-2-15-65-45(53)54)37(84)75-25(9-3-16-66-46(55)56)38(85)76-26(10-4-17-67-47(57)58)39(86)77-27(11-5-18-68-48(59)60)40(87)78-28(43(89)90)12-6-19-69-49(61)62/h21-28,31-33,42,81-82H,1-20H2,(H,63,88)(H,73,80)(H,74,83)(H,75,84)(H,76,85)(H,77,86)(H,78,87)(H,89,90)(H2,50,70,71)(H4,51,52,64)(H4,53,54,65)(H4,55,56,66)(H4,57,58,67)(H4,59,60,68)(H4,61,62,69)/t23-,24-,25-,26-,27-,28-,31+,32-,33+,42?/m1/s1
DMO8D4V	CS	C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMO8D4V	IK	SKHJPFQNPQEHHQ-VOMWTDLXSA-N
DMO8D4V	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[3-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]propanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMO8D4V	DE	Discovery agent

DM65B7Y	ID	DM65B7Y
DM65B7Y	DN	AdoC(betaAsp)2AlaArg6
DM65B7Y	HS	Investigative
DM65B7Y	SN	CHEMBL611127
DM65B7Y	PC	46877402
DM65B7Y	MW	1519.6
DM65B7Y	FM	C57H98N32O18
DM65B7Y	IC	InChI=1S/C57H98N32O18/c1-24(82-41(94)26(50(103)104)21-77-40(93)25(49(101)102)20-78-47(100)36-34(90)35(91)48(107-36)89-23-81-33-37(58)79-22-80-38(33)89)39(92)83-27(8-2-14-71-52(59)60)42(95)84-28(9-3-15-72-53(61)62)43(96)85-29(10-4-16-73-54(63)64)44(97)86-30(11-5-17-74-55(65)66)45(98)87-31(12-6-18-75-56(67)68)46(99)88-32(51(105)106)13-7-19-76-57(69)70/h22-32,34-36,48,90-91H,2-21H2,1H3,(H,77,93)(H,78,100)(H,82,94)(H,83,92)(H,84,95)(H,85,96)(H,86,97)(H,87,98)(H,88,99)(H,101,102)(H,103,104)(H,105,106)(H2,58,79,80)(H4,59,60,71)(H4,61,62,72)(H4,63,64,73)(H4,65,66,74)(H4,67,68,75)(H4,69,70,76)/t24-,25?,26?,27-,28-,29-,30-,31-,32-,34+,35-,36+,48?/m1/s1
DM65B7Y	CS	C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)NC(=O)C(CNC(=O)C(CNC(=O)[C@@H]1[C@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)O)C(=O)O)C(=O)O
DM65B7Y	IK	RAUBYAYMEJMYTN-VDLZJJBUSA-N
DM65B7Y	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[3-[[3-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]-2-carboxypropanoyl]amino]-2-carboxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM65B7Y	DE	Discovery agent

DM2TWSZ	ID	DM2TWSZ
DM2TWSZ	DN	AdoC(Dpr)2AlaArg6
DM2TWSZ	HS	Investigative
DM2TWSZ	SN	CHEMBL611120
DM2TWSZ	PC	46877395
DM2TWSZ	MW	1440.6
DM2TWSZ	FM	C58H101N31O13
DM2TWSZ	IC	InChI=1S/C58H101N31O13/c1-28(87-24-9-17-36(87)50(99)88-25-8-16-35(88)38(90)41-39(91)40(92)51(102-41)89-27-80-37-42(59)78-26-79-43(37)89)44(93)81-29(10-2-18-72-53(60)61)45(94)82-30(11-3-19-73-54(62)63)46(95)83-31(12-4-20-74-55(64)65)47(96)84-32(13-5-21-75-56(66)67)48(97)85-33(14-6-22-76-57(68)69)49(98)86-34(52(100)101)15-7-23-77-58(70)71/h26-36,39-41,51,91-92H,2-25H2,1H3,(H,81,93)(H,82,94)(H,83,95)(H,84,96)(H,85,97)(H,86,98)(H,100,101)(H2,59,78,79)(H4,60,61,72)(H4,62,63,73)(H4,64,65,74)(H4,66,67,75)(H4,68,69,76)(H4,70,71,77)/t28-,29-,30-,31-,32-,33-,34-,35-,36+,39+,40-,41-,51?/m1/s1
DM2TWSZ	CS	C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)N1CCC[C@H]1C(=O)N2CCC[C@@H]2C(=O)[C@@H]3[C@H]([C@H](C(O3)N4C=NC5=C(N=CN=C54)N)O)O
DM2TWSZ	IK	MKVGDINXVXQIHD-OALVHANWSA-N
DM2TWSZ	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[(2S)-2-[(2R)-2-[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM2TWSZ	DE	Discovery agent

DMMWNPT	ID	DMMWNPT
DMMWNPT	DN	AdoC(GABA)Arg6
DMMWNPT	HS	Investigative
DMMWNPT	SN	CHEMBL611125
DMMWNPT	PC	46877400
DMMWNPT	MW	1303.4
DMMWNPT	FM	C50H90N30O12
DMMWNPT	IC	InChI=1S/C50H90N30O12/c51-35-31-36(72-22-71-35)80(23-73-31)43-33(83)32(82)34(92-43)42(89)64-15-7-14-30(81)74-24(8-1-16-65-45(52)53)37(84)75-25(9-2-17-66-46(54)55)38(85)76-26(10-3-18-67-47(56)57)39(86)77-27(11-4-19-68-48(58)59)40(87)78-28(12-5-20-69-49(60)61)41(88)79-29(44(90)91)13-6-21-70-50(62)63/h22-29,32-34,43,82-83H,1-21H2,(H,64,89)(H,74,81)(H,75,84)(H,76,85)(H,77,86)(H,78,87)(H,79,88)(H,90,91)(H2,51,71,72)(H4,52,53,65)(H4,54,55,66)(H4,56,57,67)(H4,58,59,68)(H4,60,61,69)(H4,62,63,70)/t24-,25-,26-,27-,28-,29-,32+,33-,34+,43?/m1/s1
DMMWNPT	CS	C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMMWNPT	IK	RAWZLEKTUTUGLH-PYGBFABJSA-N
DMMWNPT	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[4-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]butanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMMWNPT	DE	Discovery agent

DMVQJP0	ID	DMVQJP0
DMVQJP0	DN	AdoCGlyArg6
DMVQJP0	HS	Investigative
DMVQJP0	SN	CHEMBL611123
DMVQJP0	PC	46877398
DMVQJP0	MW	1275.4
DMVQJP0	FM	C48H86N30O12
DMVQJP0	IC	InChI=1S/C48H86N30O12/c49-33-29-34(70-20-69-33)78(21-71-29)41-31(81)30(80)32(90-41)40(87)68-19-28(79)72-22(7-1-13-62-43(50)51)35(82)73-23(8-2-14-63-44(52)53)36(83)74-24(9-3-15-64-45(54)55)37(84)75-25(10-4-16-65-46(56)57)38(85)76-26(11-5-17-66-47(58)59)39(86)77-27(42(88)89)12-6-18-67-48(60)61/h20-27,30-32,41,80-81H,1-19H2,(H,68,87)(H,72,79)(H,73,82)(H,74,83)(H,75,84)(H,76,85)(H,77,86)(H,88,89)(H2,49,69,70)(H4,50,51,62)(H4,52,53,63)(H4,54,55,64)(H4,56,57,65)(H4,58,59,66)(H4,60,61,67)/t22-,23-,24-,25-,26-,27-,30+,31-,32+,41?/m1/s1
DMVQJP0	CS	C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMVQJP0	IK	RQOKDGUOYJQMIS-CUDNWQCBSA-N
DMVQJP0	IU	(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[2-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMVQJP0	DE	Discovery agent

DMPOU86	ID	DMPOU86
DMPOU86	DN	ADOCIAQUINONE B
DMPOU86	HS	Investigative
DMPOU86	SN	Adociaquinone B
DMPOU86	DT	Small molecular drug
DMPOU86	PC	11201041
DMPOU86	MW	423.4
DMPOU86	FM	C22H17NO6S
DMPOU86	IC	InChI=1S/C22H17NO6S/c1-22-4-2-3-10-9-29-20(15(10)22)18(25)13-7-11-12(8-14(13)22)19(26)21-16(17(11)24)23-5-6-30(21,27)28/h7-9,23H,2-6H2,1H3/t22-/m0/s1
DMPOU86	CS	C[C@@]12CCCC3=COC(=C31)C(=O)C4=C2C=C5C(=C4)C(=O)C6=C(C5=O)S(=O)(=O)CCN6
DMPOU86	IK	KJMXEMKLXNMFIG-QFIPXVFZSA-N
DMPOU86	IU	(1S)-1-methyl-7,7-dioxo-18-oxa-7lambda6-thia-10-azahexacyclo[15.6.1.02,15.04,13.06,11.020,24]tetracosa-2(15),3,6(11),13,17(24),19-hexaene-5,12,16-trione
DMPOU86	DE	Discovery agent

DM6MRSC	ID	DM6MRSC
DM6MRSC	DN	Adociasulfate-2
DM6MRSC	HS	Investigative
DM6MRSC	SN	adociasulfate-2; CHEMBL426141; Adociasulfate 2
DM6MRSC	DT	Small molecular drug
DM6MRSC	PC	10010225
DM6MRSC	MW	738.9
DM6MRSC	FM	C36H52Na2O9S2
DM6MRSC	IC	InChI=1S/C36H54O9S2.2Na/c1-31(2)15-8-16-36(7)25(31)11-18-34(5)27-12-17-33(4)26(32(27,3)20-14-29(34)43-36)13-19-35(6)28(33)21-22-23(44-46(37,38)39)9-10-24(30(22)35)45-47(40,41)42;;/h9-10,25-29H,8,11-21H2,1-7H3,(H,37,38,39)(H,40,41,42);;/q;2*+1/p-2/t25-,26+,27+,28-,29-,32+,33+,34-,35-,36-;;/m0../s1
DM6MRSC	CS	C[C@]12CC[C@H]3[C@]([C@@H]1CC[C@@]4([C@@H]2CC[C@]5([C@H]4CC6=C(C=CC(=C65)OS(=O)(=O)[O-])OS(=O)(=O)[O-])C)C)(CC[C@@H]7[C@@](O3)(CCCC7(C)C)C)C.[Na+].[Na+]
DM6MRSC	IK	LLFWGACFIWPWDA-TZYHAVDYSA-L
DM6MRSC	IU	disodium;[(1R,2S,5S,13S,14R,17R,18S,21S,26S,28S)-1,5,14,18,22,22,26-heptamethyl-7-sulfonatooxy-27-oxaheptacyclo[15.13.0.02,14.05,13.06,11.018,28.021,26]triaconta-6,8,10-trien-10-yl] sulfate
DM6MRSC	DE	Discovery agent

DM9IBHU	ID	DM9IBHU
DM9IBHU	DN	Ado-P-Ch2-P-Ps-Ado
DM9IBHU	HS	Investigative
DM9IBHU	SN	ADO-P-CH2-P-PS-ADO; p1-p2-methylene-p3-thio-diadenosine triphosphate; IB2; AC1OAHZQ; DB04389; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-hydroxyphosphoryl]methyl]phosphinic acid; Adenosine 5'-[[alpha,beta-methylene]diphosphoric acid beta-[5'-adenosyloxy(mercapto)phosphinyl]] ester
DM9IBHU	DT	Small molecular drug
DM9IBHU	PC	6858209
DM9IBHU	MW	770.5
DM9IBHU	FM	C21H29N10O14P3S
DM9IBHU	IC	InChI=1S/C21H29N10O14P3S/c22-16-10-18(26-3-24-16)30(5-28-10)20-14(34)12(32)8(43-20)1-41-46(36,37)7-47(38,39)45-48(40,49)42-2-9-13(33)15(35)21(44-9)31-6-29-11-17(23)25-4-27-19(11)31/h3-6,8-9,12-15,20-21,32-35H,1-2,7H2,(H,36,37)(H,38,39)(H,40,49)(H2,22,24,26)(H2,23,25,27)/t8-,9-,12-,13-,14-,15-,20-,21-,48?/m1/s1
DM9IBHU	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)OP(=S)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O)N
DM9IBHU	IK	UJCWOSLCGXVJOD-VEBDTVEDSA-N
DM9IBHU	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-hydroxyphosphoryl]methyl]phosphinic acid
DM9IBHU	DE	Discovery agent

DMQ1F7J	ID	DMQ1F7J
DMQ1F7J	DN	ADP ribose
DMQ1F7J	HS	Investigative
DMQ1F7J	SN	ADP Ribose; ADPR (nucleotide); Adenosine diphosphoribose; Ribose adenosinediphosphate; Adenosine pyrophosphate-ribose; [32P]-ADP-ribose; AC1L1J3O; GTPL2444; Adenosine 5'-diphosphate, D-ribose ester; Adenosine 5'-diphosphate, D-ribose ester (6CI); Adenosine 5'-pyrophosphate, 5'-5-ester with D-ribofuranose (7CI); Ribofuranose, 5-5'-ester with adenosine 5'-(trihydrogen pyrophosphate), D-; Adenosine 5'-(trihydrogen pyrophosphate), 5'-5-ester with D-ribofuranose; Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribo
DMQ1F7J	DT	Small molecular drug
DMQ1F7J	PC	30243
DMQ1F7J	MW	559.32
DMQ1F7J	FM	C15H23N5O14P2
DMQ1F7J	IC	InChI=1S/C15H23N5O14P2/c16-13-9-14(18-4-17-13)20(5-19-9)15-12(26)11(25)8(33-15)3-32-36(29,30)34-35(27,28)31-2-7(23)10(24)6(22)1-21/h1,4-8,10-12,15,22-26H,2-3H2,(H,27,28)(H,29,30)(H2,16,17,18)/t6-,7+,8+,10-,11+,12+,15+/m0/s1
DMQ1F7J	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC[C@H]([C@H]([C@H](C=O)O)O)O)O)O)N
DMQ1F7J	IK	PWJFNRJRHXWEPT-AOOZFPJJSA-N
DMQ1F7J	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4R)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate
DMQ1F7J	CA	CAS 20762-30-5
DMQ1F7J	DE	Discovery agent

DMVWM75	ID	DMVWM75
DMVWM75	DN	Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMVWM75	HS	Investigative
DMVWM75	PC	73345612
DMVWM75	MW	1696
DMVWM75	FM	C80H118N28O14
DMVWM75	IC	InChI=1S/C80H118N28O14/c1-3-13-55(69(115)101-59(21-11-35-95-79(89)90)73(119)105-61(65(83)111)37-43-23-27-47(109)28-24-43)99-71(117)57(19-9-33-93-77(85)86)103-75(121)63(39-45-41-97-53-17-7-5-15-49(45)53)107-67(113)51(81)31-32-52(82)68(114)108-64(40-46-42-98-54-18-8-6-16-50(46)54)76(122)104-58(20-10-34-94-78(87)88)72(118)100-56(14-4-2)70(116)102-60(22-12-36-96-80(91)92)74(120)106-62(66(84)112)38-44-25-29-48(110)30-26-44/h5-8,15-18,23-30,41-42,51-52,55-64,97-98,109-110H,3-4,9-14,19-22,31-40,81-82H2,1-2H3,(H2,83,111)(H2,84,112)(H,99,117)(H,100,118)(H,101,115)(H,102,116)(H,103,121)(H,104,122)(H,105,119)(H,106,120)(H,107,113)(H,108,114)(H4,85,86,93)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t51-,52-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1
DMVWM75	CS	CCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC[C@@H](C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N)N)N
DMVWM75	IK	TWBRLXCGQXCXSU-HCHGDIHTSA-N
DMVWM75	IU	(2S,5S)-2,5-diamino-N,N'-bis[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]hexanediamide
DMVWM75	DE	Discovery agent

DMQBCPK	ID	DMQBCPK
DMQBCPK	DN	ADR58
DMQBCPK	HS	Investigative
DMQBCPK	DT	Aptamer
DMQBCPK	DE	Rheumatoid arthritis

DMP8NSU	ID	DMP8NSU
DMP8NSU	DN	ADRENOGLOMERULOTROPIN
DMP8NSU	HS	Investigative
DMP8NSU	SN	Adrenoglomerulotropin; MMTC; 1210-56-6; BRN 0747865; 1-Methyl-6-methoxy-1,2,3,4-tetrahydro-beta-carboline; CHEMBL221811; RDUORFDQRFHYBF-UHFFFAOYSA-N; 6-Methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline; 9H-Pyrido(3,4-b)indole, 1,2,3,4-tetrahydro-6-methoxy-1-methyl-; 6-methoxy-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-6-methoxy-1-methyl-; 1-Methyl-6-methoxy-1,2,3,4-tetrahydro-2-carboline; 1H-Pyrido(3,4-b)indole, 2,3,4,9-tetrahydro-6-methoxy-1-methyl-; Mmthc
DMP8NSU	DT	Small molecular drug
DMP8NSU	PC	71028
DMP8NSU	MW	216.28
DMP8NSU	FM	C13H16N2O
DMP8NSU	IC	InChI=1S/C13H16N2O/c1-8-13-10(5-6-14-8)11-7-9(16-2)3-4-12(11)15-13/h3-4,7-8,14-15H,5-6H2,1-2H3
DMP8NSU	CS	CC1C2=C(CCN1)C3=C(N2)C=CC(=C3)OC
DMP8NSU	IK	RDUORFDQRFHYBF-UHFFFAOYSA-N
DMP8NSU	IU	6-methoxy-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMP8NSU	CA	CAS 1210-56-6
DMP8NSU	DE	Discovery agent

DMP7IS0	ID	DMP7IS0
DMP7IS0	DN	ADS-0101
DMP7IS0	HS	Investigative
DMP7IS0	SN	ADS-0102; DOM-0101; DOM-0102; Domain antibody therapy (inhalant formulation, COPD/respiratory disease); Domain antibody therapy (inhalant formulation, COPD/respiratory disease), Domantis; DAbs (inhalant formulation, COPD/respiratory disorders), Domantis/Argenta
DMP7IS0	CP	Domantis Ltd
DMP7IS0	DT	Antibody
DMP7IS0	DE	Chronic obstructive pulmonary disease

DM7U4OT	ID	DM7U4OT
DM7U4OT	DN	ADS-100380
DM7U4OT	HS	Investigative
DM7U4OT	SN	ADS-100380; CHEMBL216885; SCHEMBL5904027; BDBM50198221
DM7U4OT	DT	Small molecular drug
DM7U4OT	PC	44418141
DM7U4OT	MW	291.25
DM7U4OT	FM	C10H8F3N3O2S
DM7U4OT	IC	InChI=1S/C10H8F3N3O2S/c1-16-5(4-8(14-16)10(11,12)13)6-2-3-7(19-6)9(17)15-18/h2-4,18H,1H3,(H,15,17)
DM7U4OT	CS	CN1C(=CC(=N1)C(F)(F)F)C2=CC=C(S2)C(=O)NO
DM7U4OT	IK	CBAUPWKIZUBNOQ-UHFFFAOYSA-N
DM7U4OT	IU	N-hydroxy-5-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophene-2-carboxamide
DM7U4OT	DE	Discovery agent

DMEU6MH	ID	DMEU6MH
DMEU6MH	DN	ADS-102550
DMEU6MH	HS	Investigative
DMEU6MH	SN	ADS-102550; CHEMBL217716; SCHEMBL5903759; BDBM50198218
DMEU6MH	DT	Small molecular drug
DMEU6MH	PC	10452725
DMEU6MH	MW	386.4
DMEU6MH	FM	C18H18N4O4S
DMEU6MH	IC	InChI=1S/C18H18N4O4S/c23-18(21-24)17-4-3-16(27-17)13-5-7-22(20-13)8-6-19-10-12-1-2-14-15(9-12)26-11-25-14/h1-5,7,9,19,24H,6,8,10-11H2,(H,21,23)
DMEU6MH	CS	C1OC2=C(O1)C=C(C=C2)CNCCN3C=CC(=N3)C4=CC=C(S4)C(=O)NO
DMEU6MH	IK	CCCCPSHFLXQUBH-UHFFFAOYSA-N
DMEU6MH	IU	5-[1-[2-(1,3-benzodioxol-5-ylmethylamino)ethyl]pyrazol-3-yl]-N-hydroxythiophene-2-carboxamide
DMEU6MH	DE	Discovery agent

DMXD0C3	ID	DMXD0C3
DMXD0C3	DN	ADS-102891
DMXD0C3	HS	Investigative
DMXD0C3	SN	ADS-102891; CHEMBL424728; SCHEMBL6508765; BDBM50200792
DMXD0C3	DT	Small molecular drug
DMXD0C3	PC	11189610
DMXD0C3	MW	430.4
DMXD0C3	FM	C22H21F3N4O2
DMXD0C3	IC	InChI=1S/C22H21F3N4O2/c1-14-18-12-16(6-9-19(18)28-21(26-14)29-10-2-3-11-29)27-20(30)13-31-17-7-4-15(5-8-17)22(23,24)25/h4-9,12H,2-3,10-11,13H2,1H3,(H,27,30)
DMXD0C3	CS	CC1=C2C=C(C=CC2=NC(=N1)N3CCCC3)NC(=O)COC4=CC=C(C=C4)C(F)(F)F
DMXD0C3	IK	UPUPELYLRJEQHO-UHFFFAOYSA-N
DMXD0C3	IU	N-(4-methyl-2-pyrrolidin-1-ylquinazolin-6-yl)-2-[4-(trifluoromethyl)phenoxy]acetamide
DMXD0C3	DE	Discovery agent

DMMYUB9	ID	DMMYUB9
DMMYUB9	DN	ADS-103168
DMMYUB9	HS	Investigative
DMMYUB9	SN	ADS-103168; CHEMBL424739; SCHEMBL6532244; BDBM50200783
DMMYUB9	DT	Small molecular drug
DMMYUB9	PC	11153928
DMMYUB9	MW	404.4
DMMYUB9	FM	C20H19F3N4O2
DMMYUB9	IC	InChI=1S/C20H19F3N4O2/c21-20(22,23)13-3-6-15(7-4-13)29-12-18(28)24-14-5-8-16-17(11-14)26-19(25-16)27-9-1-2-10-27/h3-8,11H,1-2,9-10,12H2,(H,24,28)(H,25,26)
DMMYUB9	CS	C1CCN(C1)C2=NC3=C(N2)C=C(C=C3)NC(=O)COC4=CC=C(C=C4)C(F)(F)F
DMMYUB9	IK	UWZAIHJEZDRIJB-UHFFFAOYSA-N
DMMYUB9	IU	N-(2-pyrrolidin-1-yl-3H-benzimidazol-5-yl)-2-[4-(trifluoromethyl)phenoxy]acetamide
DMMYUB9	DE	Discovery agent

DMUMF0B	ID	DMUMF0B
DMUMF0B	DN	ADS-103214
DMUMF0B	HS	Investigative
DMUMF0B	SN	ADS-103214; CHEMBL216430; SCHEMBL3831809; BDBM50200793
DMUMF0B	DT	Small molecular drug
DMUMF0B	PC	11281523
DMUMF0B	MW	418.4
DMUMF0B	FM	C21H21F3N4O2
DMUMF0B	IC	InChI=1S/C21H21F3N4O2/c1-27-18-12-15(6-9-17(18)26-20(27)28-10-2-3-11-28)25-19(29)13-30-16-7-4-14(5-8-16)21(22,23)24/h4-9,12H,2-3,10-11,13H2,1H3,(H,25,29)
DMUMF0B	CS	CN1C2=C(C=CC(=C2)NC(=O)COC3=CC=C(C=C3)C(F)(F)F)N=C1N4CCCC4
DMUMF0B	IK	BHTNQFXUFJJYNG-UHFFFAOYSA-N
DMUMF0B	IU	N-(3-methyl-2-pyrrolidin-1-ylbenzimidazol-5-yl)-2-[4-(trifluoromethyl)phenoxy]acetamide
DMUMF0B	DE	Discovery agent

DMH9A4S	ID	DMH9A4S
DMH9A4S	DN	ADS-103253
DMH9A4S	HS	Investigative
DMH9A4S	SN	ADS-103253; CHEMBL216228; SCHEMBL6507329; BDBM50200788
DMH9A4S	DT	Small molecular drug
DMH9A4S	PC	11452268
DMH9A4S	MW	396.9
DMH9A4S	FM	C21H21ClN4O2
DMH9A4S	IC	InChI=1S/C21H21ClN4O2/c1-14-18-12-16(24-20(27)13-28-17-7-4-15(22)5-8-17)6-9-19(18)25-21(23-14)26-10-2-3-11-26/h4-9,12H,2-3,10-11,13H2,1H3,(H,24,27)
DMH9A4S	CS	CC1=C2C=C(C=CC2=NC(=N1)N3CCCC3)NC(=O)COC4=CC=C(C=C4)Cl
DMH9A4S	IK	MXDQNCXNQJMIEH-UHFFFAOYSA-N
DMH9A4S	IU	2-(4-chlorophenoxy)-N-(4-methyl-2-pyrrolidin-1-ylquinazolin-6-yl)acetamide
DMH9A4S	DE	Discovery agent

DMLIOV2	ID	DMLIOV2
DMLIOV2	DN	ADS-103254
DMLIOV2	HS	Investigative
DMLIOV2	SN	ADS-103254; CHEMBL217712; SCHEMBL6509918; BDBM50200785
DMLIOV2	DT	Small molecular drug
DMLIOV2	PC	11155432
DMLIOV2	MW	461.5
DMLIOV2	FM	C23H26F3N5O2
DMLIOV2	IC	InChI=1S/C23H26F3N5O2/c1-15-19-13-17(7-10-20(19)29-22(27-15)31(4)12-11-30(2)3)28-21(32)14-33-18-8-5-16(6-9-18)23(24,25)26/h5-10,13H,11-12,14H2,1-4H3,(H,28,32)
DMLIOV2	CS	CC1=C2C=C(C=CC2=NC(=N1)N(C)CCN(C)C)NC(=O)COC3=CC=C(C=C3)C(F)(F)F
DMLIOV2	IK	ZALRLWFCZSVMRA-UHFFFAOYSA-N
DMLIOV2	IU	N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methylquinazolin-6-yl]-2-[4-(trifluoromethyl)phenoxy]acetamide
DMLIOV2	DE	Discovery agent

DMBN6IE	ID	DMBN6IE
DMBN6IE	DN	ADS-103274
DMBN6IE	HS	Investigative
DMBN6IE	SN	ADS-103274; CHEMBL276393; BDBM50241099
DMBN6IE	DT	Small molecular drug
DMBN6IE	PC	16665072
DMBN6IE	MW	449.5
DMBN6IE	FM	C22H26F3N5O2
DMBN6IE	IC	InChI=1S/C22H26F3N5O2/c1-28(2)11-12-29(3)21-27-18-10-7-16(13-19(18)30(21)4)26-20(31)14-32-17-8-5-15(6-9-17)22(23,24)25/h5-10,13H,11-12,14H2,1-4H3,(H,26,31)
DMBN6IE	CS	CN1C2=C(C=CC(=C2)NC(=O)COC3=CC=C(C=C3)C(F)(F)F)N=C1N(C)CCN(C)C
DMBN6IE	IK	KMPCTCXLXOJTGD-UHFFFAOYSA-N
DMBN6IE	IU	N-[2-[2-(dimethylamino)ethyl-methylamino]-3-methylbenzimidazol-5-yl]-2-[4-(trifluoromethyl)phenoxy]acetamide
DMBN6IE	DE	Discovery agent

DM0C4QD	ID	DM0C4QD
DM0C4QD	DN	ADS-103293
DM0C4QD	HS	Investigative
DM0C4QD	SN	ADS-103293; CHEMBL217626; SCHEMBL6507646; BDBM50200786
DM0C4QD	DT	Small molecular drug
DM0C4QD	PC	11440885
DM0C4QD	MW	396.9
DM0C4QD	FM	C21H21ClN4O2
DM0C4QD	IC	InChI=1S/C21H21ClN4O2/c1-14-16-12-15(24-20(27)13-28-19-7-3-2-6-17(19)22)8-9-18(16)25-21(23-14)26-10-4-5-11-26/h2-3,6-9,12H,4-5,10-11,13H2,1H3,(H,24,27)
DM0C4QD	CS	CC1=C2C=C(C=CC2=NC(=N1)N3CCCC3)NC(=O)COC4=CC=CC=C4Cl
DM0C4QD	IK	XIYWAMFWFFFEQL-UHFFFAOYSA-N
DM0C4QD	IU	2-(2-chlorophenoxy)-N-(4-methyl-2-pyrrolidin-1-ylquinazolin-6-yl)acetamide
DM0C4QD	DE	Discovery agent

DMM2Q9L	ID	DMM2Q9L
DMM2Q9L	DN	ADS-103294
DMM2Q9L	HS	Investigative
DMM2Q9L	SN	ADS-103294; CHEMBL214678; SCHEMBL6533940; BDBM50200791
DMM2Q9L	DT	Small molecular drug
DMM2Q9L	PC	11188955
DMM2Q9L	MW	406.4
DMM2Q9L	FM	C20H21F3N4O2
DMM2Q9L	IC	InChI=1S/C20H21F3N4O2/c1-12(2)24-19-26-16-9-6-14(10-17(16)27(19)3)25-18(28)11-29-15-7-4-13(5-8-15)20(21,22)23/h4-10,12H,11H2,1-3H3,(H,24,26)(H,25,28)
DMM2Q9L	CS	CC(C)NC1=NC2=C(N1C)C=C(C=C2)NC(=O)COC3=CC=C(C=C3)C(F)(F)F
DMM2Q9L	IK	YFLYQHULFMRTHA-UHFFFAOYSA-N
DMM2Q9L	IU	N-[3-methyl-2-(propan-2-ylamino)benzimidazol-5-yl]-2-[4-(trifluoromethyl)phenoxy]acetamide
DMM2Q9L	DE	Discovery agent

DMKCOYE	ID	DMKCOYE
DMKCOYE	DN	ADS-103316
DMKCOYE	HS	Investigative
DMKCOYE	SN	ADS-103316; CHEMBL216754; SCHEMBL6507269; BDBM50200790
DMKCOYE	DT	Small molecular drug
DMKCOYE	PC	11440762
DMKCOYE	MW	392.5
DMKCOYE	FM	C22H24N4O3
DMKCOYE	IC	InChI=1S/C22H24N4O3/c1-15-19-13-16(5-10-20(19)25-22(23-15)26-11-3-4-12-26)24-21(27)14-29-18-8-6-17(28-2)7-9-18/h5-10,13H,3-4,11-12,14H2,1-2H3,(H,24,27)
DMKCOYE	CS	CC1=C2C=C(C=CC2=NC(=N1)N3CCCC3)NC(=O)COC4=CC=C(C=C4)OC
DMKCOYE	IK	YXNSFDJSYOVION-UHFFFAOYSA-N
DMKCOYE	IU	2-(4-methoxyphenoxy)-N-(4-methyl-2-pyrrolidin-1-ylquinazolin-6-yl)acetamide
DMKCOYE	DE	Discovery agent

DMA74PO	ID	DMA74PO
DMA74PO	DN	ADX-63365
DMA74PO	HS	Investigative
DMA74PO	SN	MGluR5 PAM; ADX-4; ADX-47273; ADX-50938; MGluR5 positive modulators, Addex; ADX-4 program, Addex
DMA74PO	CP	Addex Pharmaceuticals SA
DMA74PO	DT	Small molecular drug
DMA74PO	PC	11383075
DMA74PO	MW	369.4
DMA74PO	FM	C20H17F2N3O2
DMA74PO	IC	InChI=1S/C20H17F2N3O2/c21-16-7-3-13(4-8-16)18-23-19(27-24-18)15-2-1-11-25(12-15)20(26)14-5-9-17(22)10-6-14/h3-10,15H,1-2,11-12H2/t15-/m0/s1
DMA74PO	CS	C1C[C@@H](CN(C1)C(=O)C2=CC=C(C=C2)F)C3=NC(=NO3)C4=CC=C(C=C4)F
DMA74PO	IK	VXQCCZHCFBHTTD-HNNXBMFYSA-N
DMA74PO	IU	(4-fluorophenyl)-[(3S)-3-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone
DMA74PO	CA	CAS 851881-60-2
DMA74PO	DE	Central nervous system disease

DM3WAG6	ID	DM3WAG6
DM3WAG6	DN	ADX71743
DM3WAG6	HS	Investigative
DM3WAG6	SN	ADX 71743; ADX-71743
DM3WAG6	DT	Small molecular drug
DM3WAG6	PC	53391766
DM3WAG6	MW	269.34
DM3WAG6	FM	C17H19NO2
DM3WAG6	IC	InChI=1S/C17H19NO2/c1-4-16-18-17-14(19)8-12(9-15(17)20-16)13-6-5-10(2)7-11(13)3/h5-7,12H,4,8-9H2,1-3H3
DM3WAG6	CS	CCC1=NC2=C(O1)CC(CC2=O)C3=C(C=C(C=C3)C)C
DM3WAG6	IK	CPKZCQHJDFSOJT-UHFFFAOYSA-N
DM3WAG6	IU	6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydro-5H-1,3-benzoxazol-4-one
DM3WAG6	DE	Discovery agent

DM70H6P	ID	DM70H6P
DM70H6P	DN	ADX-88178
DM70H6P	HS	Investigative
DM70H6P	SN	MGluR4 positive modulators, Addex/Merck; MGluR4 PAM modulators (oral, Parkinson's disease/anxiety); MGluR4 PAM modulators (oral, Parkinson's disease/anxiety), Addex/Merck & Co
DM70H6P	CP	Addex Pharmaceuticals SA
DM70H6P	DT	Small molecular drug
DM70H6P	PC	46836872
DM70H6P	MW	272.33
DM70H6P	FM	C12H12N6S
DM70H6P	IC	InChI=1S/C12H12N6S/c1-7-3-4-13-11(16-7)18-12-17-10(8(2)19-12)9-5-14-15-6-9/h3-6H,1-2H3,(H,14,15)(H,13,16,17,18)
DM70H6P	CS	CC1=NC(=NC=C1)NC2=NC(=C(S2)C)C3=CNN=C3
DM70H6P	IK	MIQNXKWDQRNHAU-UHFFFAOYSA-N
DM70H6P	IU	5-methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)-1,3-thiazol-2-amine
DM70H6P	DE	Anxiety disorder

DMANEH2	ID	DMANEH2
DMANEH2	DN	AE-9C90CB
DMANEH2	HS	Investigative
DMANEH2	SN	Muscarinic M3 antagonists (urinary incontinence); RBx-7643; RBx-8444; RBx-9611; Muscarinic M3 antagonists (urinary incontinence), Daiichi Sankyo; Muscarinic M3 antagonists (urinary incontinence), Ranbaxy
DMANEH2	CP	Ranbaxy Laboratories Ltd
DMANEH2	DE	Overactive bladder

DMZ8SV3	ID	DMZ8SV3
DMZ8SV3	DN	AEKKDEGPYRMEHFRWGSPPKD
DMZ8SV3	HS	Investigative
DMZ8SV3	PC	16135998
DMZ8SV3	MW	2660.9
DMZ8SV3	FM	C118H174N34O35S
DMZ8SV3	IC	InChI=1S/C118H174N34O35S/c1-63(122)97(167)135-77(36-39-93(159)160)105(175)137-71(23-8-11-42-119)100(170)136-72(24-9-12-43-120)102(172)147-84(55-95(163)164)111(181)140-76(35-38-92(157)158)98(168)132-60-91(156)150-47-16-28-87(150)112(182)148-81(52-65-31-33-68(154)34-32-65)109(179)138-74(26-14-45-128-117(123)124)101(171)142-79(41-50-188-2)107(177)141-78(37-40-94(161)162)106(176)146-83(54-67-58-127-62-133-67)110(180)144-80(51-64-19-4-3-5-20-64)108(178)139-75(27-15-46-129-118(125)126)103(173)145-82(53-66-57-130-70-22-7-6-21-69(66)70)99(169)131-59-90(155)134-86(61-153)114(184)152-49-18-30-89(152)115(185)151-48-17-29-88(151)113(183)143-73(25-10-13-44-121)104(174)149-85(116(186)187)56-96(165)166/h3-7,19-22,31-34,57-58,62-63,71-89,130,153-154H,8-18,23-30,35-56,59-61,119-122H2,1-2H3,(H,127,133)(H,131,169)(H,132,168)(H,134,155)(H,135,167)(H,136,170)(H,137,175)(H,138,179)(H,139,178)(H,140,181)(H,141,177)(H,142,171)(H,143,183)(H,144,180)(H,145,173)(H,146,176)(H,147,172)(H,148,182)(H,149,174)(H,157,158)(H,159,160)(H,161,162)(H,163,164)(H,165,166)(H,186,187)(H4,123,124,128)(H4,125,126,129)/t63-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-/m0/s1
DMZ8SV3	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)NCC(=O)N[C@@H](CO)C(=O)N7CCC[C@H]7C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N
DMZ8SV3	IK	XLLJFSCSXTYVTN-UPWOUFKKSA-N
DMZ8SV3	IU	(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]butanedioic acid
DMZ8SV3	CA	CAS 9034-42-8
DMZ8SV3	DE	Discovery agent

DME0I6U	ID	DME0I6U
DME0I6U	DN	Aerophobin-1
DME0I6U	HS	Investigative
DME0I6U	SN	aerophobin-1; CHEMBL479515
DME0I6U	DT	Small molecular drug
DME0I6U	PC	14484008
DME0I6U	MW	476.12
DME0I6U	FM	C15H16Br2N4O4
DME0I6U	IC	InChI=1S/C15H16Br2N4O4/c1-24-12-9(16)4-15(13(22)11(12)17)5-10(21-25-15)14(23)19-3-2-8-6-18-7-20-8/h4,6-7,13,22H,2-3,5H2,1H3,(H,18,20)(H,19,23)
DME0I6U	CS	COC1=C(C(C2(CC(=NO2)C(=O)NCCC3=CN=CN3)C=C1Br)O)Br
DME0I6U	IK	MDUQIEXQKMPARD-UHFFFAOYSA-N
DME0I6U	IU	7,9-dibromo-6-hydroxy-N-[2-(1H-imidazol-5-yl)ethyl]-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,7,9-triene-3-carboxamide
DME0I6U	DE	Discovery agent

DMULWOG	ID	DMULWOG
DMULWOG	DN	AEZS-115
DMULWOG	HS	Investigative
DMULWOG	SN	D-85108; LHRH antagonist, Solvay; LHRH antagonist, Zentaris; ZEN-019; LHRH antagonists, Solvay/AEterna Zentaris
DMULWOG	CP	AEterna Zentaris Inc
DMULWOG	DE	Solid tumour/cancer

DMM52FD	ID	DMM52FD
DMM52FD	DN	AEZS-126
DMM52FD	HS	Investigative
DMM52FD	SN	AEZS-129; AEZS-132; D-106669; D-87503; Dual PI3K/ERK kinase inhibitors, AEterna Zentaris
DMM52FD	CP	AEterna Zentaris Inc
DMM52FD	PC	25151705
DMM52FD	MW	414.5
DMM52FD	FM	C19H22N6O3S
DMM52FD	IC	InChI=1S/C19H22N6O3S/c1-5-20-19(29)25-15-7-6-12-18(23-15)24-16(10-21-12)22-11-8-13(26-2)17(28-4)14(9-11)27-3/h6-10H,5H2,1-4H3,(H3,20,22,23,24,25,29)
DMM52FD	CS	CCNC(=S)NC1=NC2=NC(=CN=C2C=C1)NC3=CC(=C(C(=C3)OC)OC)OC
DMM52FD	IK	YJGOOHUUMIONLF-UHFFFAOYSA-N
DMM52FD	IU	1-ethyl-3-[3-(3,4,5-trimethoxyanilino)pyrido[2,3-b]pyrazin-6-yl]thiourea
DMM52FD	DE	Solid tumour/cancer

DMN9RE5	ID	DMN9RE5
DMN9RE5	DN	AEZS-131
DMN9RE5	HS	Investigative
DMN9RE5	SN	ERK inhibitor (cancer), AEterna
DMN9RE5	CP	AEterna Zentaris Inc
DMN9RE5	DE	Solid tumour/cancer

DMOYADT	ID	DMOYADT
DMOYADT	DN	AF150(S)
DMOYADT	HS	Investigative
DMOYADT	SN	AF150(S); SCHEMBL1328277; AF-150S; VGGGBQVTSUMURJ-UHFFFAOYSA-N; AF 150(S); AF-150(S); L007073; 1-methylpiperidine-4-spiro-(2'-methylthiazoline); 2,8-dimethyl-1-thia-3,8-diaza-spiro[4.5]dec-2-ene; 1-Thia-3,8-diazaspiro(4.5)dec-2-ene, 2,8-dimethyl-
DMOYADT	DT	Small molecular drug
DMOYADT	PC	10176415
DMOYADT	MW	184.3
DMOYADT	FM	C9H16N2S
DMOYADT	IC	InChI=1S/C9H16N2S/c1-8-10-7-9(12-8)3-5-11(2)6-4-9/h3-7H2,1-2H3
DMOYADT	CS	CC1=NCC2(S1)CCN(CC2)C
DMOYADT	IK	VGGGBQVTSUMURJ-UHFFFAOYSA-N
DMOYADT	IU	2,8-dimethyl-1-thia-3,8-diazaspiro[4.5]dec-2-ene
DMOYADT	CA	CAS 138300-72-8
DMOYADT	DE	Discovery agent

DM6B9CK	ID	DM6B9CK
DM6B9CK	DN	AF-3473
DM6B9CK	HS	Investigative
DM6B9CK	SN	5-HT4 antagonist (neuropathic pain), Angelini Pharmaceuticals
DM6B9CK	CP	Angelini Pharmaceuticals SpA
DM6B9CK	DE	Neuropathic pain

DMXQ3MO	ID	DMXQ3MO
DMXQ3MO	DN	AF353
DMXQ3MO	HS	Investigative
DMXQ3MO	SN	AF-353; AF 353
DMXQ3MO	DT	Small molecular drug
DMXQ3MO	PC	15953802
DMXQ3MO	MW	400.21
DMXQ3MO	FM	C14H17IN4O2
DMXQ3MO	IC	InChI=1S/C14H17IN4O2/c1-7(2)8-4-11(20-3)9(15)5-10(8)21-12-6-18-14(17)19-13(12)16/h4-7H,1-3H3,(H4,16,17,18,19)
DMXQ3MO	CS	CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)I)OC
DMXQ3MO	IK	AATPYXMXFBBKFO-UHFFFAOYSA-N
DMXQ3MO	IU	5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidine-2,4-diamine
DMXQ3MO	CA	CAS 865305-30-2
DMXQ3MO	DE	Discovery agent

DM65TUP	ID	DM65TUP
DM65TUP	DN	AFC-5128
DM65TUP	HS	Investigative
DM65TUP	SN	AFC-5261; P2X7 purinoreceptor antagonists (neuropathic pain/ multiple sclerosis); P2X7 purinoreceptor antagonist (inflammatory disease/neurodegenerative disorder), Affectis; P2X7 purinoreceptor antagonists (neuropathic pain/ multiple sclerosis), Affectis
DM65TUP	CP	Affectis Pharmaceuticals AG
DM65TUP	DE	Autoimmune diabetes

DME9Y8Q	ID	DME9Y8Q
DME9Y8Q	DN	AFD(R)
DME9Y8Q	HS	Investigative
DME9Y8Q	SN	AFD(R); GTPL2937; CHEMBL382739; SCHEMBL12084862; Phosphoric acid (R)-2-methyl-2-amino-4-(4-heptyloxyphenyl)butyl ester; [(2R)-2-amino-4-(4-heptoxyphenyl)-2-methylbutyl] dihydrogen phosphate
DME9Y8Q	DT	Small molecular drug
DME9Y8Q	PC	10904818
DME9Y8Q	MW	373.4
DME9Y8Q	FM	C18H32NO5P
DME9Y8Q	IC	InChI=1S/C18H32NO5P/c1-3-4-5-6-7-14-23-17-10-8-16(9-11-17)12-13-18(2,19)15-24-25(20,21)22/h8-11H,3-7,12-15,19H2,1-2H3,(H2,20,21,22)/t18-/m1/s1
DME9Y8Q	CS	CCCCCCCOC1=CC=C(C=C1)CC[C@](C)(COP(=O)(O)O)N
DME9Y8Q	IK	NMRLBSIYIBOLLJ-GOSISDBHSA-N
DME9Y8Q	IU	[(2R)-2-amino-4-(4-heptoxyphenyl)-2-methylbutyl] dihydrogen phosphate
DME9Y8Q	DE	Discovery agent

DMNY8H7	ID	DMNY8H7
DMNY8H7	DN	AF-DX-384
DMNY8H7	HS	Investigative
DMNY8H7	SN	MZDYABXXPZNUCT-UHFFFAOYSA-N; AF-DX 384; AFDX384; 118290-27-0; CHEMBL279453; N-(2-(2-((Dipropylamino)methyl)piperidin-1-yl)ethyl)-6-oxo-5H-benzo[e]pyrido[3,2-b][1,4]diazepine-11(6H)-carboxamide; N-[2-[2-[(Dipropylamino)methyl]-1-piperidinyl]ethyl]-5,6-dihydro-6-oxo-11H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide; AFDX-384; N-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide; [3H]AF-DX 384; [3H]AF DX-384; AC1L3ONW; GTPL368; 118290-26-9; SCHEMBL9824222;  AF-DX-384
DMNY8H7	DT	Small molecular drug
DMNY8H7	PC	119357
DMNY8H7	MW	478.6
DMNY8H7	FM	C27H38N6O2
DMNY8H7	IC	InChI=1S/C27H38N6O2/c1-3-16-31(17-4-2)20-21-10-7-8-18-32(21)19-15-29-27(35)33-24-13-6-5-11-22(24)26(34)30-23-12-9-14-28-25(23)33/h5-6,9,11-14,21H,3-4,7-8,10,15-20H2,1-2H3,(H,29,35)(H,30,34)
DMNY8H7	CS	CCCN(CCC)CC1CCCCN1CCNC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMNY8H7	IK	MZDYABXXPZNUCT-UHFFFAOYSA-N
DMNY8H7	IU	N-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide
DMNY8H7	CB	CHEBI:110176
DMNY8H7	DE	Discovery agent

DM6D3NQ	ID	DM6D3NQ
DM6D3NQ	DN	Affinitak + Cisplatin
DM6D3NQ	HS	Investigative
DM6D3NQ	TC	Antisense
DM6D3NQ	DT	Combination drug (Antisense drug)
DM6D3NQ	PC	71587700; 84093
DM6D3NQ	DE	Non-small-cell lung cancer

DMU98ES	ID	DMU98ES
DMU98ES	DN	Affinitak + Gemcitabine
DMU98ES	HS	Investigative
DMU98ES	TC	Antisense
DMU98ES	DT	Combination drug (Antisense drug)
DMU98ES	PC	71587700; 60750
DMU98ES	DE	Non-small-cell lung cancer

DM2R5F9	ID	DM2R5F9
DM2R5F9	DN	AFLATREME
DM2R5F9	HS	Investigative
DM2R5F9	SN	Aflatrem; UNII-ZEL123Y65D; 70553-75-2; ZEL123Y65D; CHEMBL327558; AFLATREME; C20555; 4H-3,15a-Epoxy-1-benzoxepino(6',7':6,7)indeno(1,2-b)indol-4-one, 9-(1,1-dimethyl-2-propenyl)-2,3,5b,6,7,7a,8,13,13b,13c,14,15-dodecahydro-5b-hydroxy-2,2,13b,13c-tetramethyl-, (3R-(3alpha,5balpha,7abeta,13balpha,13cbeta,15aalpha))-; 4H-3,15a-Epoxy-1-benzoxepino(6',7':6,7)indeno(1,2-b)indol-4-one, 9-(1,1-dimethyl-2-propenyl)-2,3,5b,6,7,7a,8,13,13b,13c,14,15-dodecahydro-5b-hydroxy-2,2,13b,13c-tetramethyl-, (3R,5bS,7aS,13bS,13cR,15aS)-
DM2R5F9	DT	Small molecular drug
DM2R5F9	PC	21118293
DM2R5F9	MW	501.7
DM2R5F9	FM	C32H39NO4
DM2R5F9	IC	InChI=1S/C32H39NO4/c1-8-27(2,3)20-10-9-11-21-24(20)19-16-18-12-13-31(35)23-17-22(34)26-28(4,5)37-32(23,36-26)15-14-29(31,6)30(18,7)25(19)33-21/h8-11,17-18,26,33,35H,1,12-16H2,2-7H3/t18-,26-,29+,30+,31+,32-/m0/s1
DM2R5F9	CS	C[C@]12CC[C@]34C(=CC(=O)[C@H](O3)C(O4)(C)C)[C@@]1(CC[C@@H]5[C@@]2(C6=C(C5)C7=C(C=CC=C7N6)C(C)(C)C=C)C)O
DM2R5F9	IK	YVDJBQQJIDPRKP-SLUQHKSNSA-N
DM2R5F9	IU	(1S,4R,5S,16S,19S,23R)-19-hydroxy-4,5,24,24-tetramethyl-12-(2-methylbut-3-en-2-yl)-25,26-dioxa-7-azaheptacyclo[21.2.1.01,20.04,19.05,16.06,14.08,13]hexacosa-6(14),8,10,12,20-pentaen-22-one
DM2R5F9	CA	CAS 70553-75-2
DM2R5F9	DE	Discovery agent

DM8U1IW	ID	DM8U1IW
DM8U1IW	DN	AFM-21
DM8U1IW	HS	Investigative
DM8U1IW	SN	Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed
DM8U1IW	CP	Affimed Therapeutics AG
DM8U1IW	DT	Antibody
DM8U1IW	DE	Solid tumour/cancer

DM4WVMU	ID	DM4WVMU
DM4WVMU	DN	AFP-07
DM4WVMU	HS	Investigative
DM4WVMU	SN	AFP07; AFP 07
DM4WVMU	DT	Small molecular drug
DM4WVMU	PC	5311226
DM4WVMU	MW	388.4
DM4WVMU	FM	C20H30F2O5
DM4WVMU	IC	InChI=1S/C20H30F2O5/c1-2-3-4-7-13(23)10-11-14-15(24)12-16-19(14)20(21,22)17(27-16)8-5-6-9-18(25)26/h8,10-11,13-16,19,23-24H,2-7,9,12H2,1H3,(H,25,26)/b11-10+,17-8-/t13-,14-,15+,16-,19+/m0/s1
DM4WVMU	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C(/C(=C/CCCC(=O)O)/O2)(F)F)O)O
DM4WVMU	IK	ILUYAOVLMOPQAI-BFOOZVJSSA-N
DM4WVMU	IU	(5Z)-5-[(3aR,4R,5R,6aS)-3,3-difluoro-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]furan-2-ylidene]pentanoic acid
DM4WVMU	DE	Discovery agent

DMF0SPB	ID	DMF0SPB
DMF0SPB	DN	AG 1024
DMF0SPB	HS	Investigative
DMF0SPB	SN	tyrphostin AG 1024; AG-1024; AG1024
DMF0SPB	DT	Small molecular drug
DMF0SPB	PC	2044
DMF0SPB	MW	305.17
DMF0SPB	FM	C14H13BrN2O
DMF0SPB	IC	InChI=1S/C14H13BrN2O/c1-14(2,3)11-5-9(4-10(7-16)8-17)6-12(15)13(11)18/h4-6,18H,1-3H3
DMF0SPB	CS	CC(C)(C)C1=C(C(=CC(=C1)C=C(C#N)C#N)Br)O
DMF0SPB	IK	ABBADGFSRBWENF-UHFFFAOYSA-N
DMF0SPB	IU	2-[(3-bromo-5-tert-butyl-4-hydroxyphenyl)methylidene]propanedinitrile
DMF0SPB	CA	CAS 65678-07-1
DMF0SPB	CB	CHEBI:93757
DMF0SPB	DE	Discovery agent

DMDYS0L	ID	DMDYS0L
DMDYS0L	DN	AG 112
DMDYS0L	HS	Investigative
DMDYS0L	SN	tyrphostin A48; tyrphostin AG 112; AG-112; AG112
DMDYS0L	DT	Small molecular drug
DMDYS0L	PC	5328804
DMDYS0L	MW	236.23
DMDYS0L	FM	C13H8N4O
DMDYS0L	IC	InChI=1S/C13H8N4O/c14-6-10(13(17)11(7-15)8-16)5-9-1-3-12(18)4-2-9/h1-5,18H,17H2/b10-5+
DMDYS0L	CS	C1=CC(=CC=C1/C=C(\\C#N)/C(=C(C#N)C#N)N)O
DMDYS0L	IK	DXVJRTIPBNBLLB-BJMVGYQFSA-N
DMDYS0L	IU	(3Z)-2-amino-4-(4-hydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile
DMDYS0L	CA	CAS 122520-87-0
DMDYS0L	CB	CHEBI:93930
DMDYS0L	DE	Discovery agent

DMSOUI0	ID	DMSOUI0
DMSOUI0	DN	AG 9
DMSOUI0	HS	Investigative
DMSOUI0	SN	tyrphostin 1; tyrphostin A1; AG9; AG-9
DMSOUI0	DT	Small molecular drug
DMSOUI0	PC	2063
DMSOUI0	MW	184.19
DMSOUI0	FM	C11H8N2O
DMSOUI0	IC	InChI=1S/C11H8N2O/c1-14-11-4-2-9(3-5-11)6-10(7-12)8-13/h2-6H,1H3
DMSOUI0	CS	COC1=CC=C(C=C1)C=C(C#N)C#N
DMSOUI0	IK	UOHFCPXBKJPCAD-UHFFFAOYSA-N
DMSOUI0	IU	2-[(4-methoxyphenyl)methylidene]propanedinitrile
DMSOUI0	CA	CAS 2826-26-8
DMSOUI0	CB	CHEBI:92740
DMSOUI0	DE	Discovery agent

DMHFYNE	ID	DMHFYNE
DMHFYNE	DN	AG-014376
DMHFYNE	HS	Investigative
DMHFYNE	SN	AG-014376; CHEMBL361489; SCHEMBL7159231; BDBM50154730; 6-(4-Dimethylaminomethyl-phenyl)-3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-one
DMHFYNE	DT	Small molecular drug
DMHFYNE	PC	9797108
DMHFYNE	MW	319.4
DMHFYNE	FM	C20H21N3O
DMHFYNE	IC	InChI=1S/C20H21N3O/c1-22(2)13-14-6-8-15(9-7-14)18-12-16-4-3-5-17-19(16)23(18)11-10-21-20(17)24/h3-9,12H,10-11,13H2,1-2H3,(H,21,24)
DMHFYNE	CS	CN(C)CC1=CC=C(C=C1)C2=CC3=C4N2CCNC(=O)C4=CC=C3
DMHFYNE	IK	PISBNXWDAGANOP-UHFFFAOYSA-N
DMHFYNE	IU	2-[4-[(dimethylamino)methyl]phenyl]-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7-tetraen-9-one
DMHFYNE	DE	Discovery agent

DMW7H28	ID	DMW7H28
DMW7H28	DN	AG-09/1
DMW7H28	HS	Investigative
DMW7H28	SN	AG-09/1 [benzimidazole derivative]; ST024252
DMW7H28	DT	Small molecular drug
DMW7H28	PC	3901842
DMW7H28	MW	358.4
DMW7H28	FM	C16H14N4O4S
DMW7H28	IC	InChI=1S/C16H14N4O4S/c1-24-12-6-7-13-14(8-12)19-16(18-13)25-9-15(21)17-10-2-4-11(5-3-10)20(22)23/h2-8H,9H2,1H3,(H,17,21)(H,18,19)
DMW7H28	CS	COC1=CC2=C(C=C1)N=C(N2)SCC(=O)NC3=CC=C(C=C3)[N+](=O)[O-]
DMW7H28	IK	LYQDSNOFTIZWAX-UHFFFAOYSA-N
DMW7H28	IU	2-[(6-methoxy-1H-benzimidazol-2-yl)sulfanyl]-N-(4-nitrophenyl)acetamide
DMW7H28	CA	CAS 356776-32-4
DMW7H28	DE	Discovery agent

DMZINUY	ID	DMZINUY
DMZINUY	DN	AG-11/03
DMZINUY	HS	Investigative
DMZINUY	SN	AG-11/03 [benzimidazole derivative]; STK220090
DMZINUY	DT	Small molecular drug
DMZINUY	PC	7342912
DMZINUY	MW	359.5
DMZINUY	FM	C17H17N3O2S2
DMZINUY	IC	InChI=1S/C17H17N3O2S2/c1-22-12-5-8-14-15(9-12)20-17(19-14)24-10-16(21)18-11-3-6-13(23-2)7-4-11/h3-9H,10H2,1-2H3,(H,18,21)(H,19,20)
DMZINUY	CS	COC1=CC2=C(C=C1)N=C(N2)SCC(=O)NC3=CC=C(C=C3)SC
DMZINUY	IK	FKTAXVGJKVSANI-UHFFFAOYSA-N
DMZINUY	IU	2-[(6-methoxy-1H-benzimidazol-2-yl)sulfanyl]-N-(4-methylsulfanylphenyl)acetamide
DMZINUY	DE	Discovery agent

DMVR9G0	ID	DMVR9G0
DMVR9G0	DN	AG-14
DMVR9G0	HS	Investigative
DMVR9G0	SN	AG14; AG 14
DMVR9G0	DT	Small molecular drug
DMVR9G0	PC	5503194
DMVR9G0	MW	404.4
DMVR9G0	FM	C23H20N2O5
DMVR9G0	IC	InChI=1S/C23H20N2O5/c1-27-21-11-17(7-9-19(21)28-14-16-5-3-2-4-6-16)13-24-25-23(26)18-8-10-20-22(12-18)30-15-29-20/h2-13H,14-15H2,1H3,(H,25,26)/b24-13-
DMVR9G0	CS	COC1=C(C=CC(=C1)/C=N\\NC(=O)C2=CC3=C(C=C2)OCO3)OCC4=CC=CC=C4
DMVR9G0	IK	ULOKADSYVZOTTL-CFRMEGHHSA-N
DMVR9G0	IU	N-[(Z)-(3-methoxy-4-phenylmethoxyphenyl)methylideneamino]-1,3-benzodioxole-5-carboxamide
DMVR9G0	DE	Discovery agent

DMT3ML6	ID	DMT3ML6
DMT3ML6	DN	AG-213
DMT3ML6	HS	Investigative
DMT3ML6	DT	Small molecular drug
DMT3ML6	PC	667601
DMT3ML6	MW	220.25
DMT3ML6	FM	C10H8N2O2S
DMT3ML6	IC	InChI=1S/C10H8N2O2S/c11-5-7(10(12)15)3-6-1-2-8(13)9(14)4-6/h1-4,13-14H,(H2,12,15)/b7-3+
DMT3ML6	CS	C1=CC(=C(C=C1/C=C(\\C#N)/C(=S)N)O)O
DMT3ML6	IK	ZGHQGWOETPXKLY-XVNBXDOJSA-N
DMT3ML6	IU	(E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enethioamide
DMT3ML6	CA	CAS 122520-86-9
DMT3ML6	CB	CHEBI:93703
DMT3ML6	DE	Discovery agent

DMMFQR2	ID	DMMFQR2
DMMFQR2	DN	AG-26
DMMFQR2	HS	Investigative
DMMFQR2	SN	AG26; AG 26
DMMFQR2	DT	Small molecular drug
DMMFQR2	PC	727787
DMMFQR2	MW	304.77
DMMFQR2	FM	C16H17ClN2O2
DMMFQR2	IC	InChI=1S/C16H17ClN2O2/c1-21-15-8-2-12(3-9-15)10-11-18-16(20)19-14-6-4-13(17)5-7-14/h2-9H,10-11H2,1H3,(H2,18,19,20)
DMMFQR2	CS	COC1=CC=C(C=C1)CCNC(=O)NC2=CC=C(C=C2)Cl
DMMFQR2	IK	OVFMMJNKICPJJH-UHFFFAOYSA-N
DMMFQR2	IU	1-(4-chlorophenyl)-3-[2-(4-methoxyphenyl)ethyl]urea
DMMFQR2	DE	Discovery agent

DM9KIS8	ID	DM9KIS8
DM9KIS8	DN	AG-538
DM9KIS8	HS	Investigative
DM9KIS8	SN	Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02
DM9KIS8	DT	Small molecular drug
DM9KIS8	PC	5328760
DM9KIS8	MW	297.26
DM9KIS8	FM	C16H11NO5
DM9KIS8	IC	InChI=1S/C16H11NO5/c17-8-11(5-9-1-3-12(18)14(20)6-9)16(22)10-2-4-13(19)15(21)7-10/h1-7,18-21H/b11-5+
DM9KIS8	CS	C1=CC(=C(C=C1/C=C(\\C#N)/C(=O)C2=CC(=C(C=C2)O)O)O)O
DM9KIS8	IK	CANOJKGQDCJDOX-VZUCSPMQSA-N
DM9KIS8	IU	(E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
DM9KIS8	CB	CHEBI:92138
DM9KIS8	DE	Discovery agent

DMAUJOM	ID	DMAUJOM
DMAUJOM	DN	agatoxin 489
DMAUJOM	HS	Investigative
DMAUJOM	SN	AG 489
DMAUJOM	DT	Small molecular drug
DMAUJOM	PC	131007
DMAUJOM	MW	489.7
DMAUJOM	FM	C26H47N7O2
DMAUJOM	IC	InChI=1S/C26H47N7O2/c27-11-5-14-28-12-3-4-13-29-15-6-16-30-17-7-19-33(35)20-8-18-31-26(34)21-23-22-32-25-10-2-1-9-24(23)25/h1-2,9-10,22,28-30,32,35H,3-8,11-21,27H2,(H,31,34)
DMAUJOM	CS	C1=CC=C2C(=C1)C(=CN2)CC(=O)NCCCN(CCCNCCCNCCCCNCCCN)O
DMAUJOM	IK	LIURIBSBVUMOJS-UHFFFAOYSA-N
DMAUJOM	IU	N-[3-[3-[3-[4-(3-aminopropylamino)butylamino]propylamino]propyl-hydroxyamino]propyl]-2-(1H-indol-3-yl)acetamide
DMAUJOM	CA	CAS 128549-96-2
DMAUJOM	DE	Discovery agent

DM83951	ID	DM83951
DM83951	DN	AG-E-85378
DM83951	HS	Investigative
DM83951	SN	N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide; 269390-69-4; VEGFR Tyrosine Kinase Inhibitor II; VEGF Receptor Tyrosine Kinase Inhibitor II; CHEMBL101683; 3hng; AG-E-85378; ZINC8732; SCHEMBL3005186; GTPL6056; N-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide; CTK4F8762; DTXSID60430900; MolPort-044-561-457; HMS3229O07; IN1017; BDBM50132151; AKOS030580576; DB07288; CCG-206804; NCGC00387770-01; ACM269390694; RT-016223; KB-299355; J-016613; N-(4-Chlorophenyl)-2-(4-pyridinylmethylamino)benzamide
DM83951	DT	Small molecular drug
DM83951	PC	9797919
DM83951	MW	337.8
DM83951	FM	C19H16ClN3O
DM83951	IC	InChI=1S/C19H16ClN3O/c20-15-5-7-16(8-6-15)23-19(24)17-3-1-2-4-18(17)22-13-14-9-11-21-12-10-14/h1-12,22H,13H2,(H,23,24)
DM83951	CS	C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)Cl)NCC3=CC=NC=C3
DM83951	IK	GGPZCOONYBPZEW-UHFFFAOYSA-N
DM83951	IU	N-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide
DM83951	CA	CAS 269390-69-4
DM83951	DE	Discovery agent

DMOJ3CW	ID	DMOJ3CW
DMOJ3CW	DN	AGELADINE A
DMOJ3CW	HS	Investigative
DMOJ3CW	SN	AGELADINE A; CHEMBL230806; CHEBI:65373; 4-(4,5-dibromo-1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-amine; Ageladine A, TFA; SCHEMBL12563004; BDBM50215926
DMOJ3CW	DT	Small molecular drug
DMOJ3CW	PC	10089677
DMOJ3CW	MW	357
DMOJ3CW	FM	C10H7Br2N5
DMOJ3CW	IC	InChI=1S/C10H7Br2N5/c11-4-3-6(15-9(4)12)7-8-5(1-2-14-7)16-10(13)17-8/h1-3,15H,(H3,13,16,17)
DMOJ3CW	CS	C1=CN=C(C2=C1NC(=N2)N)C3=CC(=C(N3)Br)Br
DMOJ3CW	IK	QAKGJAQGTQLMFN-UHFFFAOYSA-N
DMOJ3CW	IU	4-(4,5-dibromo-1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-amine
DMOJ3CW	CB	CHEBI:65373
DMOJ3CW	DE	Discovery agent

DM26AMU	ID	DM26AMU
DM26AMU	DN	AGK2
DM26AMU	HS	Investigative
DM26AMU	SN	AGK-2; AGK 2
DM26AMU	DT	Small molecular drug
DM26AMU	PC	2130404
DM26AMU	MW	434.3
DM26AMU	FM	C23H13Cl2N3O2
DM26AMU	IC	InChI=1S/C23H13Cl2N3O2/c24-15-6-8-19(25)18(12-15)22-9-7-16(30-22)11-14(13-26)23(29)28-21-5-1-4-20-17(21)3-2-10-27-20/h1-12H,(H,28,29)/b14-11+
DM26AMU	CS	C1=CC2=C(C=CC=N2)C(=C1)NC(=O)/C(=C/C3=CC=C(O3)C4=C(C=CC(=C4)Cl)Cl)/C#N
DM26AMU	IK	SVENPFFEMUOOGK-SDNWHVSQSA-N
DM26AMU	IU	(E)-2-cyano-3-[5-(2,5-dichlorophenyl)furan-2-yl]-N-quinolin-5-ylprop-2-enamide
DM26AMU	CA	CAS 304896-28-4
DM26AMU	CB	CHEBI:94578
DM26AMU	DE	Discovery agent

DMM9A5N	ID	DMM9A5N
DMM9A5N	DN	AGL 2043
DMM9A5N	HS	Investigative
DMM9A5N	SN	AGL-2043; HMS3229A05; AGL2043
DMM9A5N	DT	Small molecular drug
DMM9A5N	PC	9817165
DMM9A5N	MW	280.3
DMM9A5N	FM	C15H12N4S
DMM9A5N	IC	InChI=1S/C15H12N4S/c1-9-17-12-6-11-10(7-14(12)19(9)2)16-8-13(18-11)15-4-3-5-20-15/h3-8H,1-2H3
DMM9A5N	CS	CC1=NC2=C(N1C)C=C3C(=C2)N=C(C=N3)C4=CC=CS4
DMM9A5N	IK	ZGDACLBJJXLKJY-UHFFFAOYSA-N
DMM9A5N	IU	1,2-dimethyl-6-thiophen-2-ylimidazo[4,5-g]quinoxaline
DMM9A5N	CA	CAS 226717-28-8
DMM9A5N	DE	Discovery agent

DMSBZ29	ID	DMSBZ29
DMSBZ29	DN	Agmatine
DMSBZ29	HS	Investigative
DMSBZ29	SN	agmatine; 1-(4-Aminobutyl)guanidine; (4-Aminobutyl)guanidine; Argmatine; 306-60-5; 1-Amino-4-guanidobutane; N-4-Aminobutylguanidine; guanidine, (4-aminobutyl)-; N-(4-aminobutyl)guanidine; (4-Aminobutyl) guanidine; 1,4-Butanediamine, N-(aminoiminomethyl)-; 2-(4-aminobutyl)guanidine; UNII-70J407ZL5Q; EINECS 206-187-7; NSC 56332; 4-Guanidino-1-butanamine; CHEMBL58343; CHEBI:17431; QYPPJABKJHAVHS-UHFFFAOYSA-N; 70J407ZL5Q; agmatinium; Guanidine, (4-aminobutyl)- (8CI)(9CI); AGMATINE SULFATE ENDOGENOUS AGONIST AT; AG2
DMSBZ29	DT	Small molecular drug
DMSBZ29	PC	199
DMSBZ29	MW	130.19
DMSBZ29	FM	C5H14N4
DMSBZ29	IC	InChI=1S/C5H14N4/c6-3-1-2-4-9-5(7)8/h1-4,6H2,(H4,7,8,9)
DMSBZ29	CS	C(CCN=C(N)N)CN
DMSBZ29	IK	QYPPJABKJHAVHS-UHFFFAOYSA-N
DMSBZ29	IU	2-(4-aminobutyl)guanidine
DMSBZ29	CA	CAS 306-60-5
DMSBZ29	CB	CHEBI:17431
DMSBZ29	DE	Discovery agent

DMTPV4Y	ID	DMTPV4Y
DMTPV4Y	DN	AGN 191976
DMTPV4Y	HS	Investigative
DMTPV4Y	SN	AGN-191976; AGN191976
DMTPV4Y	DT	Small molecular drug
DMTPV4Y	PC	73755173
DMTPV4Y	MW	382.5
DMTPV4Y	FM	C21H34O6
DMTPV4Y	IC	InChI=1S/C21H34O6/c1-2-3-6-9-15(22)12-13-17-16(10-7-4-5-8-11-20(23)24)18-14-19(17)27-21(25)26-18/h4,7,15-19,22H,2-3,5-6,8-14H2,1H3,(H,23,24)/b7-4-/t15-,16+,17+,18-,19+/m0/s1
DMTPV4Y	CS	CCCCC[C@@H](CC[C@H]1[C@H]2C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)OC(=O)O2)O
DMTPV4Y	IK	CVQLYMOSZQTFDP-NFUXFLSFSA-N
DMTPV4Y	IU	(Z)-7-[(1R,5S,6R,7R)-7-[(3S)-3-hydroxyoctyl]-3-oxo-2,4-dioxabicyclo[3.2.1]octan-6-yl]hept-5-enoic acid
DMTPV4Y	DE	Discovery agent

DM53R94	ID	DM53R94
DM53R94	DN	AGN-190383
DM53R94	HS	Investigative
DM53R94	SN	120755-15-9
DM53R94	DT	Small molecular drug
DM53R94	PC	149069
DM53R94	MW	340.5
DM53R94	FM	C19H32O5
DM53R94	IC	InChI=1S/C19H32O5/c1-3-4-5-6-7-8-9-10-11-12-13-17(23-15(2)20)16-14-18(21)24-19(16)22/h14,17,19,22H,3-13H2,1-2H3
DM53R94	CS	CCCCCCCCCCCCC(C1=CC(=O)OC1O)OC(=O)C
DM53R94	IK	QDXHMXIOLIYZHD-UHFFFAOYSA-N
DM53R94	IU	1-(2-hydroxy-5-oxo-2H-furan-3-yl)tridecyl acetate
DM53R94	CA	CAS 120755-15-9
DM53R94	DE	Discovery agent

DMIKDAR	ID	DMIKDAR
DMIKDAR	DN	AGN-190744
DMIKDAR	HS	Investigative
DMIKDAR	SN	130162-96-8
DMIKDAR	DE	Discovery agent

DMISJXB	ID	DMISJXB
DMISJXB	DN	AGN192093
DMISJXB	HS	Investigative
DMISJXB	SN	AGN-192093; AGN 192093
DMISJXB	DT	Small molecular drug
DMISJXB	PC	11968293
DMISJXB	MW	366.5
DMISJXB	FM	C21H34O5
DMISJXB	IC	InChI=1S/C21H34O5/c1-2-3-7-10-16(23)12-13-18-17(11-8-5-4-6-9-14-22)19-15-20(18)26-21(24)25-19/h5,8,12-13,16-20,22-23H,2-4,6-7,9-11,14-15H2,1H3/b8-5-,13-12+/t16-,17+,18+,19-,20-/m0/s1
DMISJXB	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H]2C[C@@H]([C@@H]1C/C=C\\CCCCO)OC(=O)O2)O
DMISJXB	IK	PTIUXNGGNGQHQK-KTEVXADTSA-N
DMISJXB	IU	(1S,5S,6R,7R)-6-[(Z)-7-hydroxyhept-2-enyl]-7-[(E,3S)-3-hydroxyoct-1-enyl]-2,4-dioxabicyclo[3.2.1]octan-3-one
DMISJXB	DE	Discovery agent

DM946RA	ID	DM946RA
DM946RA	DN	AGN-192172
DM946RA	HS	Investigative
DM946RA	SN	AGN-192172; CHEMBL49284; BDBM50052881
DM946RA	DT	Small molecular drug
DM946RA	PC	9816048
DM946RA	MW	231.3
DM946RA	FM	C12H17N5
DM946RA	IC	InChI=1S/C12H17N5/c1-8-9(17-12-15-6-7-16-12)2-3-10-11(8)14-5-4-13-10/h2-3,13-14H,4-7H2,1H3,(H2,15,16,17)
DM946RA	CS	CC1=C(C=CC2=C1NCCN2)NC3=NCCN3
DM946RA	IK	PGOVKWAJCVAZNG-UHFFFAOYSA-N
DM946RA	IU	N-(4,5-dihydro-1H-imidazol-2-yl)-5-methyl-1,2,3,4-tetrahydroquinoxalin-6-amine
DM946RA	DE	Discovery agent

DMC0YOE	ID	DMC0YOE
DMC0YOE	DN	AGN193109
DMC0YOE	HS	Investigative
DMC0YOE	SN	AGN 193109; AGN-93109
DMC0YOE	DT	Small molecular drug
DMC0YOE	PC	177238
DMC0YOE	MW	392.5
DMC0YOE	FM	C28H24O2
DMC0YOE	IC	InChI=1S/C28H24O2/c1-19-4-11-22(12-5-19)24-16-17-28(2,3)26-15-10-21(18-25(24)26)7-6-20-8-13-23(14-9-20)27(29)30/h4-5,8-16,18H,17H2,1-3H3,(H,29,30)
DMC0YOE	CS	CC1=CC=C(C=C1)C2=CCC(C3=C2C=C(C=C3)C#CC4=CC=C(C=C4)C(=O)O)(C)C
DMC0YOE	IK	NCEQLLNVRRTCKJ-UHFFFAOYSA-N
DMC0YOE	IU	4-[2-[5,5-dimethyl-8-(4-methylphenyl)-6H-naphthalen-2-yl]ethynyl]benzoic acid
DMC0YOE	CA	CAS 171746-21-7
DMC0YOE	DE	Discovery agent

DMEB93D	ID	DMEB93D
DMEB93D	DN	AGN193836
DMEB93D	HS	Investigative
DMEB93D	SN	AGN-193836; AGN 193836
DMEB93D	DT	Small molecular drug
DMEB93D	PC	23001780
DMEB93D	MW	482.3
DMEB93D	FM	C22H22BrF2NO4
DMEB93D	IC	InChI=1S/C22H22BrF2NO4/c1-21(2)5-6-22(3,4)16-11(21)9-14(18(27)17(16)23)26-19(28)10-7-12(24)15(20(29)30)13(25)8-10/h7-9,27H,5-6H2,1-4H3,(H,26,28)(H,29,30)
DMEB93D	CS	CC1(CCC(C2=C(C(=C(C=C21)NC(=O)C3=CC(=C(C(=C3)F)C(=O)O)F)O)Br)(C)C)C
DMEB93D	IK	FADQHUSDAKOWFT-UHFFFAOYSA-N
DMEB93D	IU	4-[(4-bromo-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]-2,6-difluorobenzoic acid
DMEB93D	DE	Discovery agent

DM5ECDM	ID	DM5ECDM
DM5ECDM	DN	AGN-34
DM5ECDM	HS	Investigative
DM5ECDM	SN	AGN-34; CHEMBL190635; SCHEMBL1984049; 7-[2-(Hexyloxy)-3,5-diisopropylphenyl]-3-methyl-2,4,6-octatrienoic acid
DM5ECDM	DT	Small molecular drug
DM5ECDM	PC	9887925
DM5ECDM	MW	412.6
DM5ECDM	FM	C27H40O3
DM5ECDM	IC	InChI=1S/C27H40O3/c1-8-9-10-11-15-30-27-24(20(4)5)17-23(19(2)3)18-25(27)22(7)14-12-13-21(6)16-26(28)29/h12-14,16-20H,8-11,15H2,1-7H3,(H,28,29)/b13-12+,21-16+,22-14-
DM5ECDM	CS	CCCCCCOC1=C(C=C(C=C1/C(=C\\C=C\\C(=C\\C(=O)O)\\C)/C)C(C)C)C(C)C
DM5ECDM	IK	VTUYATVOWGSQFU-AQIGWABESA-N
DM5ECDM	IU	(2E,4E,6Z)-7-[2-hexoxy-3,5-di(propan-2-yl)phenyl]-3-methylocta-2,4,6-trienoic acid
DM5ECDM	DE	Discovery agent

DMT9FJZ	ID	DMT9FJZ
DMT9FJZ	DN	AGROCLAVINE
DMT9FJZ	HS	Investigative
DMT9FJZ	SN	Agroclavine; 8,9-Didehydro-6,8-dimethylergoline; 548-42-5; UNII-A8SW57GO7T; (-)-agroclavine; CCRIS 2099; Ergoline, 8,9-didehydro-6,8-dimethyl-; EINECS 208-947-3; (5R,10R)-agroclavine; NSC 93132; 6,8-Dimethyl-8,9-didehydroergoline; AGROCLAVIN; BRN 0024966; A8SW57GO7T; CHEMBL449081; CHEBI:2519; Indolo(4,3-fg)quinoline, 4,6,6a,7,8,10a-hexahydro-7,9-dimethyl-; NSC93132; (6aR,10aR)-7,9-dimethyl-4,6,6a,7,8,10a-hexahydroindolo[4,3-fg]quinoline; agroclavine-1; Lopac-A-206; AC1L2JXJ; Biomol-NT_000066; Lopac0_000128; MLS001216424; cid_73484
DMT9FJZ	DT	Small molecular drug
DMT9FJZ	PC	73484
DMT9FJZ	MW	238.33
DMT9FJZ	FM	C16H18N2
DMT9FJZ	IC	InChI=1S/C16H18N2/c1-10-6-13-12-4-3-5-14-16(12)11(8-17-14)7-15(13)18(2)9-10/h3-6,8,13,15,17H,7,9H2,1-2H3/t13-,15-/m1/s1
DMT9FJZ	CS	CC1=C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
DMT9FJZ	IK	XJOOMMHNYOJWCZ-UKRRQHHQSA-N
DMT9FJZ	IU	(6aR,10aR)-7,9-dimethyl-6,6a,8,10a-tetrahydro-4H-indolo[4,3-fg]quinoline
DMT9FJZ	CA	CAS 548-42-5
DMT9FJZ	CB	CHEBI:2519
DMT9FJZ	DE	Discovery agent

DMP9QW0	ID	DMP9QW0
DMP9QW0	DN	AGT-2000
DMP9QW0	HS	Investigative
DMP9QW0	SN	Gene therapy (intravenous, brain cancer), ArmaGen
DMP9QW0	CP	ArmaGen Technologies Inc
DMP9QW0	DE	Brain cancer

DMMO9YR	ID	DMMO9YR
DMMO9YR	DN	AGTAD[CFWKYC]V
DMMO9YR	HS	Investigative
DMMO9YR	SN	CHEMBL1163463; AGTAD[CFWKYC]V; 9047-55-6; Urotensin II mouse; BDBM50320454
DMMO9YR	PC	16150418
DMMO9YR	MW	1361.5
DMMO9YR	FM	C62H84N14O17S2
DMMO9YR	IC	InChI=1S/C62H84N14O17S2/c1-31(2)50(62(92)93)76-60(90)47-30-95-94-29-46(73-58(88)45(26-49(80)81)69-53(83)33(4)67-61(91)51(34(5)77)75-48(79)28-66-52(82)32(3)64)59(89)71-42(23-35-13-7-6-8-14-35)55(85)72-44(25-37-27-65-40-16-10-9-15-39(37)40)57(87)68-41(17-11-12-22-63)54(84)70-43(56(86)74-47)24-36-18-20-38(78)21-19-36/h6-10,13-16,18-21,27,31-34,41-47,50-51,65,77-78H,11-12,17,22-26,28-30,63-64H2,1-5H3,(H,66,82)(H,67,91)(H,68,87)(H,69,83)(H,70,84)(H,71,89)(H,72,85)(H,73,88)(H,74,86)(H,75,79)(H,76,90)(H,80,81)(H,92,93)/t32-,33-,34+,41-,42-,43-,44-,45-,46-,47-,50-,51-/m0/s1
DMMO9YR	CS	C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC=CC=C2)CC3=CNC4=CC=CC=C43)CCCCN)CC5=CC=C(C=C5)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)CNC(=O)[C@H](C)N)O
DMMO9YR	IK	YNQKMDDGZLLKHF-SYGGZGJOSA-N
DMMO9YR	IU	(2S)-2-[[(4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-19-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]-16-benzyl-7-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-methylbutanoic acid
DMMO9YR	DE	Discovery agent

DMF7ZYQ	ID	DMF7ZYQ
DMF7ZYQ	DN	AH 11110
DMF7ZYQ	HS	Investigative
DMF7ZYQ	SN	AH11110; AH-11110
DMF7ZYQ	DT	Small molecular drug
DMF7ZYQ	PC	9907616
DMF7ZYQ	MW	374.9
DMF7ZYQ	FM	C21H27ClN2O2
DMF7ZYQ	IC	InChI=1S/C21H26N2O2.ClH/c22-21(23-13-7-2-8-14-23)15-18(24)16-25-20-12-6-5-11-19(20)17-9-3-1-4-10-17;/h1,3-6,9-12,18,22,24H,2,7-8,13-16H2;1H
DMF7ZYQ	CS	C1CCN(CC1)C(=N)CC(COC2=CC=CC=C2C3=CC=CC=C3)O.Cl
DMF7ZYQ	IK	WWHGFIXWBLHHQB-UHFFFAOYSA-N
DMF7ZYQ	IU	4-imino-1-(2-phenylphenoxy)-4-piperidin-1-ylbutan-2-ol;hydrochloride
DMF7ZYQ	CA	CAS 179388-65-9
DMF7ZYQ	DE	Discovery agent

DM2VEHG	ID	DM2VEHG
DM2VEHG	DN	AH13205
DM2VEHG	HS	Investigative
DM2VEHG	SN	AH 13205; AH-13205
DM2VEHG	DT	Small molecular drug
DM2VEHG	PC	5310998
DM2VEHG	MW	388.5
DM2VEHG	FM	C24H36O4
DM2VEHG	IC	InChI=1S/C24H36O4/c1-2-3-6-10-22(25)19-14-12-18(13-15-19)20-16-17-23(26)21(20)9-7-4-5-8-11-24(27)28/h12-15,20-22,25H,2-11,16-17H2,1H3,(H,27,28)
DM2VEHG	CS	CCCCCC(C1=CC=C(C=C1)C2CCC(=O)C2CCCCCCC(=O)O)O
DM2VEHG	IK	XMQKDOCUWFCMEJ-UHFFFAOYSA-N
DM2VEHG	IU	7-[2-[4-(1-hydroxyhexyl)phenyl]-5-oxocyclopentyl]heptanoic acid
DM2VEHG	DE	Discovery agent

DM4S1Y6	ID	DM4S1Y6
DM4S1Y6	DN	AH23848
DM4S1Y6	HS	Investigative
DM4S1Y6	SN	(-)AH23848; (-)-AH23848; AH 23848; AH-23848
DM4S1Y6	DT	Small molecular drug
DM4S1Y6	PC	5310999
DM4S1Y6	MW	477.6
DM4S1Y6	FM	C29H35NO5
DM4S1Y6	IC	InChI=1S/C29H35NO5/c31-26-20-27(35-21-22-12-14-24(15-13-22)23-8-4-3-5-9-23)25(10-6-1-2-7-11-28(32)33)29(26)30-16-18-34-19-17-30/h1-5,8-9,12-15,25,27,29H,6-7,10-11,16-21H2,(H,32,33)/b2-1-/t25-,27-,29+/m0/s1
DM4S1Y6	CS	C1COCCN1[C@@H]2[C@H]([C@H](CC2=O)OCC3=CC=C(C=C3)C4=CC=CC=C4)CC/C=C\\CCC(=O)O
DM4S1Y6	IK	IOFUFYLETVNNRF-OSAZKUMMSA-N
DM4S1Y6	IU	(Z)-7-[(1R,2R,5S)-2-morpholin-4-yl-3-oxo-5-[(4-phenylphenyl)methoxy]cyclopentyl]hept-4-enoic acid
DM4S1Y6	CB	CHEBI:90389
DM4S1Y6	DE	Discovery agent

DMKN3R9	ID	DMKN3R9
DMKN3R9	DN	AH6809
DMKN3R9	HS	Investigative
DMKN3R9	SN	AH 6809; AH-6809
DMKN3R9	DT	Small molecular drug
DMKN3R9	PC	119461
DMKN3R9	MW	298.29
DMKN3R9	FM	C17H14O5
DMKN3R9	IC	InChI=1S/C17H14O5/c1-9(2)21-11-4-5-12-15(8-11)22-14-6-3-10(17(19)20)7-13(14)16(12)18/h3-9H,1-2H3,(H,19,20)
DMKN3R9	CS	CC(C)OC1=CC2=C(C=C1)C(=O)C3=C(O2)C=CC(=C3)C(=O)O
DMKN3R9	IK	AQFFXPQJLZFABJ-UHFFFAOYSA-N
DMKN3R9	IU	9-oxo-6-propan-2-yloxyxanthene-2-carboxylic acid
DMKN3R9	CA	CAS 33458-93-4
DMKN3R9	CB	CHEBI:95289
DMKN3R9	DE	Discovery agent

DMVZLIB	ID	DMVZLIB
DMVZLIB	DN	AHL
DMVZLIB	HS	Investigative
DMVZLIB	SN	AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark
DMVZLIB	CP	Quark Pharmaceuticals Inc
DMVZLIB	DT	siRNA drug
DMVZLIB	DE	Hearing disorder

DM8G6O4	ID	DM8G6O4
DM8G6O4	DN	AHPN
DM8G6O4	HS	Investigative
DM8G6O4	SN	Ro 47-2077; 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid; CD437; CD 437
DM8G6O4	DT	Small molecular drug
DM8G6O4	PC	135411
DM8G6O4	MW	398.5
DM8G6O4	FM	C27H26O3
DM8G6O4	IC	InChI=1S/C27H26O3/c28-25-6-5-22(20-1-2-21-11-23(26(29)30)4-3-19(21)10-20)12-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)
DM8G6O4	CS	C1C2CC3CC1CC(C2)(C3)C4=C(C=CC(=C4)C5=CC6=C(C=C5)C=C(C=C6)C(=O)O)O
DM8G6O4	IK	LDGIHZJOIQSHPB-UHFFFAOYSA-N
DM8G6O4	IU	6-[3-(1-adamantyl)-4-hydroxyphenyl]naphthalene-2-carboxylic acid
DM8G6O4	CA	CAS 125316-60-1
DM8G6O4	CB	CHEBI:88334
DM8G6O4	DE	Discovery agent

DM3LCDK	ID	DM3LCDK
DM3LCDK	DN	AIDA
DM3LCDK	HS	Investigative
DM3LCDK	SN	UPF 523; UPF523; GNF-Pf-1401
DM3LCDK	DT	Small molecular drug
DM3LCDK	PC	2071
DM3LCDK	MW	221.21
DM3LCDK	FM	C11H11NO4
DM3LCDK	IC	InChI=1S/C11H11NO4/c12-11(10(15)16)4-3-6-5-7(9(13)14)1-2-8(6)11/h1-2,5H,3-4,12H2,(H,13,14)(H,15,16)
DM3LCDK	CS	C1CC(C2=C1C=C(C=C2)C(=O)O)(C(=O)O)N
DM3LCDK	IK	LSTPKMWNRWCNLS-UHFFFAOYSA-N
DM3LCDK	IU	1-amino-2,3-dihydroindene-1,5-dicarboxylic acid
DM3LCDK	CA	CAS 168560-79-0
DM3LCDK	DE	Discovery agent

DMUQ6XH	ID	DMUQ6XH
DMUQ6XH	DN	AIKO-151
DMUQ6XH	HS	Investigative
DMUQ6XH	SN	Mu-opioid antagonist (oral, opiate dependence), Aiko Biotechnology
DMUQ6XH	CP	Aiko Biotechnology Inc
DMUQ6XH	DE	Opioid dependence

DML5Y1Q	ID	DML5Y1Q
DML5Y1Q	DN	AIKO-152
DML5Y1Q	HS	Investigative
DML5Y1Q	SN	AIKO-150 + opioid analgesic (pain/opiate dependence), Aiko Biotechnology
DML5Y1Q	CP	Aiko Biotechnology Inc
DML5Y1Q	DE	Opioid dependence

DMHMVOI	ID	DMHMVOI
DMHMVOI	DN	Ajinomoto 1
DMHMVOI	HS	Investigative
DMHMVOI	TC	Analgesics
DMHMVOI	DE	Pain

DMZE45V	ID	DMZE45V
DMZE45V	DN	Ajinomoto 2
DMZE45V	HS	Investigative
DMZE45V	TC	Analgesics
DMZE45V	DE	Pain

DMG12AE	ID	DMG12AE
DMG12AE	DN	Ajinomoto 3
DMG12AE	HS	Investigative
DMG12AE	TC	Analgesics
DMG12AE	DE	Pain

DMWKPJH	ID	DMWKPJH
DMWKPJH	DN	AK198
DMWKPJH	HS	Investigative
DMWKPJH	SN	{2-[(4-Amino-2-Fluorobenzyl)carbamoyl]-5-Chlorophenoxy}acetic Acid; AK198; GTPL8637; 2-[2-[(4-amino-2-fluorophenyl)methylcarbamoyl]-5-chlorophenoxy]acetic acid
DMWKPJH	DT	Small molecular drug
DMWKPJH	PC	91820714
DMWKPJH	MW	352.74
DMWKPJH	FM	C16H14ClFN2O4
DMWKPJH	IC	InChI=1S/C16H14ClFN2O4/c17-10-2-4-12(14(5-10)24-8-15(21)22)16(23)20-7-9-1-3-11(19)6-13(9)18/h1-6H,7-8,19H2,(H,20,23)(H,21,22)
DMWKPJH	CS	C1=CC(=C(C=C1N)F)CNC(=O)C2=C(C=C(C=C2)Cl)OCC(=O)O
DMWKPJH	IK	GFJYPJDGRCZNDI-UHFFFAOYSA-N
DMWKPJH	IU	2-[2-[(4-amino-2-fluorophenyl)methylcarbamoyl]-5-chlorophenoxy]acetic acid
DMWKPJH	DE	Discovery agent

DMQ90PJ	ID	DMQ90PJ
DMQ90PJ	DN	AK-41099
DMQ90PJ	HS	Investigative
DMQ90PJ	SN	Trans-3-hydroxy-l-proline; DL-trans-Hydroxyproline; L-Proline, 3-hydroxy-, (3S)-; SCHEMBL114870; trans-3-Hydroxyproline; trans-3-hydroxy-(L)-proline; trans-3-hydroxy-L-proline; trans-3-hydroxy-l -proline; trans-L-3-Hydroxyproline; (+)-cis-(2R,3S)-3-hydroxyproline; (2S,3S)-(-)-3-Hydroxy-L-proline; (2S,3S)-3-Hydroxypyrrolidine-2-carboxylic acid; (2S,3S)-3-hydroxyproline; (3S)-3-hydroxy-L-proline; 4298-06-0; 8ZWY97A2NG; AC1L99JX; AK-41099; CHEBI:16889; CHEMBL1233466; UNII-8ZWY97A2NG; trans-3-Hydroxypyrrolidine-2-carboxylic acid
DMQ90PJ	PC	440575
DMQ90PJ	MW	131.13
DMQ90PJ	FM	C5H9NO3
DMQ90PJ	IC	BJBUEDPLEOHJGE-IMJSIDKUSA-N
DMQ90PJ	CS	C1CNC(C1O)C(=O)O
DMQ90PJ	IK	1S/C5H9NO3/c7-3-1-2-6-4(3)5(8)9/h3-4,6-7H,1-2H2,(H,8,9)/t3-,4-/m0/s1
DMQ90PJ	IU	(2S,3S)-3-hydroxypyrrolidine-2-carboxylic acid
DMQ90PJ	CA	CAS 4298-08-2
DMQ90PJ	CB	CHEBI:16889
DMQ90PJ	DE	Discovery agent

DMANYU5	ID	DMANYU5
DMANYU5	DN	AKN-028
DMANYU5	HS	Investigative
DMANYU5	SN	Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska
DMANYU5	CP	Swedish Orphan Biovitrum AB
DMANYU5	DT	Small molecular drug
DMANYU5	PC	44177328
DMANYU5	MW	302.33
DMANYU5	FM	C17H14N6
DMANYU5	IC	InChI=1S/C17H14N6/c18-16-17(22-13-1-2-14-12(9-13)5-8-20-14)23-15(10-21-16)11-3-6-19-7-4-11/h1-10,20H,(H2,18,21)(H,22,23)
DMANYU5	CS	C1=CC2=C(C=CN2)C=C1NC3=NC(=CN=C3N)C4=CC=NC=C4
DMANYU5	IK	JLRIJKVMMZEKDF-UHFFFAOYSA-N
DMANYU5	IU	3-N-(1H-indol-5-yl)-5-pyridin-4-ylpyrazine-2,3-diamine
DMANYU5	CA	CAS 1175017-90-9
DMANYU5	DE	Acute myeloid leukaemia

DM4E6H1	ID	DM4E6H1
DM4E6H1	DN	AKNADILACTAM
DM4E6H1	HS	Investigative
DM4E6H1	SN	aknadilactam; CHEMBL1097185
DM4E6H1	DT	Small molecular drug
DM4E6H1	PC	15764659
DM4E6H1	MW	373.4
DM4E6H1	FM	C20H23NO6
DM4E6H1	IC	InChI=1S/C20H23NO6/c1-21-14(23)10-19-9-12(22)17(26-3)18(27-4)20(19,21)8-7-11-5-6-13(25-2)16(24)15(11)19/h5-6,24H,7-10H2,1-4H3/t19-,20-/m1/s1
DM4E6H1	CS	CN1C(=O)C[C@@]23[C@@]1(CCC4=C2C(=C(C=C4)OC)O)C(=C(C(=O)C3)OC)OC
DM4E6H1	IK	CLWJGNIITFMBQR-WOJBJXKFSA-N
DM4E6H1	IU	(1R,10S)-3-hydroxy-4,11,12-trimethoxy-17-methyl-17-azatetracyclo[8.4.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraene-13,16-dione
DM4E6H1	DE	Discovery agent

DMDVIT1	ID	DMDVIT1
DMDVIT1	DN	Akt inhibitor VIII
DMDVIT1	HS	Investigative
DMDVIT1	SN	isozyme-selective, Akti-1/2
DMDVIT1	DT	Small molecular drug
DMDVIT1	PC	135398501
DMDVIT1	MW	551.6
DMDVIT1	FM	C34H29N7O
DMDVIT1	IC	InChI=1S/C34H29N7O/c42-34-39-26-8-4-5-9-31(26)41(34)25-14-16-40(17-15-25)20-22-10-12-24(13-11-22)33-32(23-6-2-1-3-7-23)37-29-18-27-28(36-21-35-27)19-30(29)38-33/h1-13,18-19,21,25,38H,14-17,20H2,(H,39,42)
DMDVIT1	CS	C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=C(N=C6C=C7C(=NC=N7)C=C6N5)C8=CC=CC=C8
DMDVIT1	IK	IWCQHVUQEFDRIW-UHFFFAOYSA-N
DMDVIT1	IU	3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMDVIT1	CA	CAS 612847-09-3
DMDVIT1	CB	CHEBI:91346
DMDVIT1	DE	Discovery agent

DMJW4I5	ID	DMJW4I5
DMJW4I5	DN	AKUAMMIGINE
DMJW4I5	HS	Investigative
DMJW4I5	SN	akuammigine; 642-17-1; UNII-1E21YYE0UM; 1E21YYE0UM; CHEMBL122404; C21H24N2O3; AC1LOQX5; SCHEMBL563799; MolPort-039-052-713; CHEBI:141878; ZINC53174616; PDSP1_001665; BDBM50030622; 9078AF; AKOS032948886; Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (3beta,19alpha,20alpha)-; 4H-Indolo(2,3-a)pyrano(3,4-g)quinolizine-1-carboxylic acid, 4a,5,7,8,13,13b,14,14a-octahydro-4-methyl-, methyl ester, (4S,4aS,13bR,14aS)-; methyl (3beta,19alpha,20alpha)-19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylate
DMJW4I5	DT	Small molecular drug
DMJW4I5	PC	1268096
DMJW4I5	MW	352.4
DMJW4I5	FM	C21H24N2O3
DMJW4I5	IC	InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16-,19+/m0/s1
DMJW4I5	CS	C[C@H]1[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45
DMJW4I5	IK	GRTOGORTSDXSFK-BMYCAMMWSA-N
DMJW4I5	IU	methyl (1R,15S,16S,20S)-16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate
DMJW4I5	CA	CAS 642-17-1
DMJW4I5	CB	CHEBI:141878
DMJW4I5	DE	Discovery agent

DM8DYWN	ID	DM8DYWN
DM8DYWN	DN	AKUAMMINE
DM8DYWN	HS	Investigative
DM8DYWN	DT	Small molecular drug
DM8DYWN	PC	13491909
DM8DYWN	MW	382.5
DM8DYWN	FM	C22H26N2O4
DM8DYWN	IC	InChI=1S/C22H26N2O4/c1-4-13-11-24-8-7-21-16-9-14(25)5-6-17(16)23(2)22(21)18(24)10-15(13)20(21,12-28-22)19(26)27-3/h4-6,9,15,18,25H,7-8,10-12H2,1-3H3/b13-4-/t15-,18-,20-,21-,22+/m0/s1
DM8DYWN	CS	C/C=C\\1/CN2CC[C@@]34C5=C(C=CC(=C5)O)N([C@@]36[C@@H]2C[C@@H]1[C@@]4(CO6)C(=O)OC)C
DM8DYWN	IK	YILKZADAWNUTTB-QLWRWLBVSA-N
DM8DYWN	IU	methyl (1S,9S,14E,15S,16R,19S)-14-ethylidene-6-hydroxy-2-methyl-18-oxa-2,12-diazahexacyclo[13.3.2.01,9.03,8.09,16.012,19]icosa-3(8),4,6-triene-16-carboxylate
DM8DYWN	CA	CAS 3512-87-6
DM8DYWN	DE	Discovery agent

DM0JE4N	ID	DM0JE4N
DM0JE4N	DN	AL12180
DM0JE4N	HS	Investigative
DM0JE4N	SN	5,6-dihydro-4,5-didehydro-11-deoxy-11-oxa-16-(3-chlorophenoxy)-omega-tetranor-PGF2alpha; AL-12180
DM0JE4N	DT	Small molecular drug
DM0JE4N	PC	59107184
DM0JE4N	MW	410.9
DM0JE4N	FM	C21H27ClO6
DM0JE4N	IC	InChI=1S/C21H27ClO6/c22-15-6-5-7-17(12-15)27-13-16(23)10-11-20-18(19(24)14-28-20)8-3-1-2-4-9-21(25)26/h1-2,5-7,10-12,16,18-20,23-24H,3-4,8-9,13-14H2,(H,25,26)/b2-1-,11-10+/t16-,18+,19+,20-/m1/s1
DM0JE4N	CS	C1[C@@H]([C@@H]([C@H](O1)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)CC/C=C\\CCC(=O)O)O
DM0JE4N	IK	GLYAVTUPQOQHAD-MOBTWWNESA-N
DM0JE4N	IU	(Z)-7-[(2R,3S,4R)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-4-hydroxyoxolan-3-yl]hept-4-enoic acid
DM0JE4N	CA	CAS 748816-43-5
DM0JE4N	DE	Discovery agent

DM7XHDC	ID	DM7XHDC
DM7XHDC	DN	AL-209
DM7XHDC	HS	Investigative
DM7XHDC	SN	SAL; ADNF-9
DM7XHDC	CP	Allon Therapeutics Inc
DM7XHDC	DE	Central nervous system disease

DM69X2Z	ID	DM69X2Z
DM69X2Z	DN	AL-309
DM69X2Z	HS	Investigative
DM69X2Z	SN	D-SAL
DM69X2Z	CP	Allon Therapeutics Inc
DM69X2Z	DE	Central nervous system disease

DMRJ2GK	ID	DMRJ2GK
DMRJ2GK	DN	AL-37350A
DMRJ2GK	HS	Investigative
DMRJ2GK	SN	AL37350A; AL 37350A
DMRJ2GK	DT	Small molecular drug
DMRJ2GK	PC	10331436
DMRJ2GK	MW	230.31
DMRJ2GK	FM	C14H18N2O
DMRJ2GK	IC	InChI=1S/C14H18N2O/c1-9(15)7-10-8-16-12-4-5-13-11(14(10)12)3-2-6-17-13/h4-5,8-9,16H,2-3,6-7,15H2,1H3/t9-/m0/s1
DMRJ2GK	CS	C[C@@H](CC1=CNC2=C1C3=C(C=C2)OCCC3)N
DMRJ2GK	IK	VVHJUSGIUWQPIT-VIFPVBQESA-N
DMRJ2GK	IU	(2S)-1-(3,7,8,9-tetrahydropyrano[3,2-e]indol-1-yl)propan-2-amine
DMRJ2GK	CA	CAS 362603-40-5
DMRJ2GK	DE	Discovery agent

DM7K360	ID	DM7K360
DM7K360	DN	AL-408
DM7K360	HS	Investigative
DM7K360	SN	AL-108 analog (neurodegenerative diseases), Allon
DM7K360	CP	Allon Therapeutics Inc
DM7K360	DE	Central nervous system disease

DMLEDHR	ID	DMLEDHR
DMLEDHR	DN	AL-43
DMLEDHR	HS	Investigative
DMLEDHR	SN	AL-438; CHEMBL266282; A-240610.0; SCHEMBL4172433; BDBM50107347; A-224817.0; 5-Allyl-2,2,4-trimethyl-10-methoxy-2,5-dihydro-1H-1-aza-6-oxachrysene; 5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; 5-allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline; (+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; (+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene
DMLEDHR	DT	Small molecular drug
DMLEDHR	PC	9906282
DMLEDHR	MW	347.4
DMLEDHR	FM	C23H25NO2
DMLEDHR	IC	InChI=1S/C23H25NO2/c1-6-8-18-22-15(21-17(25-5)9-7-10-19(21)26-18)11-12-16-20(22)14(2)13-23(3,4)24-16/h6-7,9-13,18,24H,1,8H2,2-5H3
DMLEDHR	CS	CC1=CC(NC2=C1C3=C(C=C2)C4=C(C=CC=C4OC)OC3CC=C)(C)C
DMLEDHR	IK	CZSDJYXNNJQXBB-UHFFFAOYSA-N
DMLEDHR	IU	10-methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline
DMLEDHR	DE	Discovery agent

DMHG54F	ID	DMHG54F
DMHG54F	DN	AL4623
DMHG54F	HS	Investigative
DMHG54F	SN	AL4623; UNII-1M7AKN51DU; 1M7AKN51DU; (r)-4-ethylamino-3,4-dihydro-2-(2-methoylethyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; 1bnq; AC1N9ZNF; AL-4623A free base; SCHEMBL7508613; BDBM11934; AL-4623; DB03877; 138890-59-2; (4R)-4-(ethylamino)-2-(2-methoxyethyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 2H-Thieno(3,2-E)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(2-methoxyethyl)-, 1,1-dioxide, (4R)-
DMHG54F	DT	Small molecular drug
DMHG54F	PC	4369102
DMHG54F	MW	369.5
DMHG54F	FM	C11H19N3O5S3
DMHG54F	IC	InChI=1S/C11H19N3O5S3/c1-3-13-9-7-14(4-5-19-2)22(17,18)11-8(9)6-10(20-11)21(12,15)16/h6,9,13H,3-5,7H2,1-2H3,(H2,12,15,16)/t9-/m0/s1
DMHG54F	CS	CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCOC
DMHG54F	IK	XACIEZJJSXJZMD-VIFPVBQESA-N
DMHG54F	IU	(4R)-4-(ethylamino)-2-(2-methoxyethyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMHG54F	CA	CAS 138890-59-2
DMHG54F	DE	Discovery agent

DM1QJIV	ID	DM1QJIV
DM1QJIV	DN	AL5300
DM1QJIV	HS	Investigative
DM1QJIV	SN	AC1L1BUF; SCHEMBL5080690; BDBM11932; CTK8A0654; 4-hydroxy-2-(thiophen-2-ylmethyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 4-hydroxy-1,1-dioxo-2-(thiophen-2-ylmethyl)-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide
DM1QJIV	DT	Small molecular drug
DM1QJIV	PC	4369103
DM1QJIV	MW	380.5
DM1QJIV	FM	C11H12N2O5S4
DM1QJIV	IC	InChI=1S/C11H12N2O5S4/c12-21(15,16)10-4-8-9(14)6-13(5-7-2-1-3-19-7)22(17,18)11(8)20-10/h1-4,9,14H,5-6H2,(H2,12,15,16)/t9-/m0/s1
DM1QJIV	CS	C1[C@@H](C2=C(SC(=C2)S(=O)(=O)N)S(=O)(=O)N1CC3=CC=CS3)O
DM1QJIV	IK	HHPUQNGRNUOYCD-VIFPVBQESA-N
DM1QJIV	IU	(4R)-4-hydroxy-1,1-dioxo-2-(thiophen-2-ylmethyl)-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DM1QJIV	DE	Discovery agent

DMSD2U1	ID	DMSD2U1
DMSD2U1	DN	AL5424
DMSD2U1	HS	Investigative
DMSD2U1	SN	3,4-dihydro-4-hydroxy-2-(4-methoxyphenyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; AC1L1BUI; SCHEMBL678716; CTK7A4444; BDBM11933; 4-hydroxy-2-(4-methoxyphenyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMSD2U1	DT	Small molecular drug
DMSD2U1	PC	444612
DMSD2U1	MW	390.5
DMSD2U1	FM	C13H14N2O6S3
DMSD2U1	IC	InChI=1S/C13H14N2O6S3/c1-21-9-4-2-8(3-5-9)15-7-11(16)10-6-12(23(14,17)18)22-13(10)24(15,19)20/h2-6,11,16H,7H2,1H3,(H2,14,17,18)/t11-/m0/s1
DMSD2U1	CS	COC1=CC=C(C=C1)N2C[C@@H](C3=C(S2(=O)=O)SC(=C3)S(=O)(=O)N)O
DMSD2U1	IK	ZWTSOJQGEWPWGO-NSHDSACASA-N
DMSD2U1	IU	(4R)-4-hydroxy-2-(4-methoxyphenyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMSD2U1	DE	Discovery agent

DM624WO	ID	DM624WO
DM624WO	DN	AL5927
DM624WO	HS	Investigative
DM624WO	SN	AL5927; n-[(4-methoxyphenyl)methyl]2,5-thiophenedesulfonamide; 2-N-[(4-methoxyphenyl)methyl]thiophene-2,5-disulfonamide; N-(4-methoxybenzyl)thiophene-2,5-disulfonamide; AL9; 1bn4; AC1L1HW5; SCHEMBL680127; BDBM11930; 2,5-Thiophenedisulfonamide, N2-[(4-methoxyphenyl)methyl]-; DB03526
DM624WO	DT	Small molecular drug
DM624WO	PC	4316
DM624WO	MW	362.5
DM624WO	FM	C12H14N2O5S3
DM624WO	IC	InChI=1S/C12H14N2O5S3/c1-19-10-4-2-9(3-5-10)8-14-22(17,18)12-7-6-11(20-12)21(13,15)16/h2-7,14H,8H2,1H3,(H2,13,15,16)
DM624WO	CS	COC1=CC=C(C=C1)CNS(=O)(=O)C2=CC=C(S2)S(=O)(=O)N
DM624WO	IK	LRRAIRJIZOLGPR-UHFFFAOYSA-N
DM624WO	IU	2-N-[(4-methoxyphenyl)methyl]thiophene-2,5-disulfonamide
DM624WO	DE	Discovery agent

DMPHTX0	ID	DMPHTX0
DMPHTX0	DN	AL-59640
DMPHTX0	HS	Investigative
DMPHTX0	CP	Alcon Inc
DMPHTX0	DE	Xerophthalmia

DM1JIVR	ID	DM1JIVR
DM1JIVR	DN	AL6528
DM1JIVR	HS	Investigative
DM1JIVR	SN	AL6528; 2-(3-methoxyphenyl)-2h-thieno-[3,2-e]-1,2-thiazine-6-sulfinamide-1,1-dioxide; 2-(3-methoxyphenyl)-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 1bn3; AC1L1BMR; CTK7A9592; BDBM11938; DB04371; 2-(3-methoxyphenyl)-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide; 2-(3-methoxyphenyl)-1,1-dioxo-2H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide; 2-(3-Methoxyphenyl)-6-sulfamoyl-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
DM1JIVR	DT	Small molecular drug
DM1JIVR	PC	1514
DM1JIVR	MW	372.4
DM1JIVR	FM	C13H12N2O5S3
DM1JIVR	IC	InChI=1S/C13H12N2O5S3/c1-20-11-4-2-3-10(8-11)15-6-5-9-7-12(22(14,16)17)21-13(9)23(15,18)19/h2-8H,1H3,(H2,14,16,17)
DM1JIVR	CS	COC1=CC=CC(=C1)N2C=CC3=C(S2(=O)=O)SC(=C3)S(=O)(=O)N
DM1JIVR	IK	FBBLOSCXOZYUSS-UHFFFAOYSA-N
DM1JIVR	IU	2-(3-methoxyphenyl)-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide
DM1JIVR	DE	Discovery agent

DM3JNRC	ID	DM3JNRC
DM3JNRC	DN	AL-6802
DM3JNRC	HS	Investigative
DM3JNRC	SN	EGFR modulators (cancer), Advenchen/Simcere
DM3JNRC	CP	Advenchen Laboratories LLC
DM3JNRC	DE	Solid tumour/cancer

DMTXPJI	ID	DMTXPJI
DMTXPJI	DN	Al7089a
DMTXPJI	HS	Investigative
DMTXPJI	SN	AL7089A; 220402-83-5; (r)-3,4-dihydro-2-(3-methoxyphenyl)-4-methylamino-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; AL8; 1bnm; AC1MHYPX; SCHEMBL679736; BDBM11936; DTXSID20388458; AL7089; AL 7089; DB02220; (4R)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3H,4H-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide; (4R)-2-(3-methoxyphenyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 3,4-dihydro-2-(3-methoxyphenyl)-4-(m
DMTXPJI	DT	Small molecular drug
DMTXPJI	PC	3013848
DMTXPJI	MW	403.5
DMTXPJI	FM	C14H17N3O5S3
DMTXPJI	IC	InChI=1S/C14H17N3O5S3/c1-16-12-8-17(9-4-3-5-10(6-9)22-2)25(20,21)14-11(12)7-13(23-14)24(15,18)19/h3-7,12,16H,8H2,1-2H3,(H2,15,18,19)/t12-/m0/s1
DMTXPJI	CS	CN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C3=CC(=CC=C3)OC
DMTXPJI	IK	RMOXCYSVWCHXII-LBPRGKRZSA-N
DMTXPJI	IU	(4R)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMTXPJI	CA	CAS 220402-83-5
DMTXPJI	DE	Discovery agent

DMRI08C	ID	DMRI08C
DMRI08C	DN	AL7099A
DMRI08C	HS	Investigative
DMRI08C	SN	AL7099A; (s)-3,4-dihydro-2-(3-methoxyphenyl)-4-methylamino-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; 1bnv; AC1N9ZNC; SCHEMBL678443; BDBM11937; AL7099; DB03221; (4S)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4S)-2-(3-methoxyphenyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (4S)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide
DMRI08C	DT	Small molecular drug
DMRI08C	PC	4369101
DMRI08C	MW	403.5
DMRI08C	FM	C14H17N3O5S3
DMRI08C	IC	InChI=1S/C14H17N3O5S3/c1-16-12-8-17(9-4-3-5-10(6-9)22-2)25(20,21)14-11(12)7-13(23-14)24(15,18)19/h3-7,12,16H,8H2,1-2H3,(H2,15,18,19)/t12-/m1/s1
DMRI08C	CS	CN[C@@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C3=CC(=CC=C3)OC
DMRI08C	IK	RMOXCYSVWCHXII-GFCCVEGCSA-N
DMRI08C	IU	(4S)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMRI08C	DE	Discovery agent

DMG2D4S	ID	DMG2D4S
DMG2D4S	DN	AL7182
DMG2D4S	HS	Investigative
DMG2D4S	SN	AL7182; 3,,4-dihydro-2-(3-methoxyphenyl)-2h-thieno-[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; 1bnn; AC1L1BTX; SCHEMBL678649; CHEMBL331858; BDBM11935; DB02602; AL-7182; 2-(3-Methoxyphenyl)-6-sulfamoyl-3,4-dihydro-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide; 2-(3-methoxyphenyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 2-(3-methoxyphenyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; 2-(3-methoxyphenyl)-1,1-dioxo-3H,4H-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide
DMG2D4S	DT	Small molecular drug
DMG2D4S	PC	1604
DMG2D4S	MW	374.5
DMG2D4S	FM	C13H14N2O5S3
DMG2D4S	IC	InChI=1S/C13H14N2O5S3/c1-20-11-4-2-3-10(8-11)15-6-5-9-7-12(22(14,16)17)21-13(9)23(15,18)19/h2-4,7-8H,5-6H2,1H3,(H2,14,16,17)
DMG2D4S	CS	COC1=CC=CC(=C1)N2CCC3=C(S2(=O)=O)SC(=C3)S(=O)(=O)N
DMG2D4S	IK	ICIXQGGQPKFQRL-UHFFFAOYSA-N
DMG2D4S	IU	2-(3-methoxyphenyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMG2D4S	DE	Discovery agent

DMRWLQM	ID	DMRWLQM
DMRWLQM	DN	AL-8810
DMRWLQM	HS	Investigative
DMRWLQM	SN	AL8810; AL 8810
DMRWLQM	DT	Small molecular drug
DMRWLQM	PC	5311238
DMRWLQM	MW	402.5
DMRWLQM	FM	C24H31FO4
DMRWLQM	IC	InChI=1S/C24H31FO4/c25-21-15-23(27)20(9-3-1-2-4-10-24(28)29)19(21)11-12-22(26)18-13-16-7-5-6-8-17(16)14-18/h1,3,5-8,11-12,18-23,26-27H,2,4,9-10,13-15H2,(H,28,29)/b3-1-,12-11+/t19-,20-,21+,22+,23+/m1/s1
DMRWLQM	CS	C1[C@@H]([C@@H]([C@H]([C@H]1F)/C=C/[C@@H](C2CC3=CC=CC=C3C2)O)C/C=C\\CCCC(=O)O)O
DMRWLQM	IK	WTYSXBKKVNOOIX-JTGCGUAKSA-N
DMRWLQM	IU	(Z)-7-[(1R,2R,3S,5S)-2-[(E,3R)-3-(2,3-dihydro-1H-inden-2-yl)-3-hydroxyprop-1-enyl]-3-fluoro-5-hydroxycyclopentyl]hept-5-enoic acid
DMRWLQM	CA	CAS 246246-19-5
DMRWLQM	DE	Discovery agent

DMRWUQ5	ID	DMRWUQ5
DMRWUQ5	DN	Ala(1-naph)-Pro-CN
DMRWUQ5	HS	Investigative
DMRWUQ5	SN	Ala(1-naph)-Pro-CN; GTPL8607
DMRWUQ5	DT	Small molecular drug
DMRWUQ5	PC	74765859
DMRWUQ5	MW	293.4
DMRWUQ5	FM	C18H19N3O
DMRWUQ5	IC	InChI=1S/C18H19N3O/c19-12-15-8-4-10-21(15)18(22)17(20)11-14-7-3-6-13-5-1-2-9-16(13)14/h1-3,5-7,9,15,17H,4,8,10-11,20H2/t15-,17-/m0/s1
DMRWUQ5	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC3=CC=CC=C32)N)C#N
DMRWUQ5	IK	ZVRWNKCHASBEDZ-RDJZCZTQSA-N
DMRWUQ5	IU	(2S)-1-[(2S)-2-amino-3-naphthalen-1-ylpropanoyl]pyrrolidine-2-carbonitrile
DMRWUQ5	DE	Discovery agent

DMZH4NQ	ID	DMZH4NQ
DMZH4NQ	DN	Ala11-SRIF-14-amide
DMZH4NQ	HS	Investigative
DMZH4NQ	PC	44400605
DMZH4NQ	MW	1560.8
DMZH4NQ	FM	C70H101N19O18S2
DMZH4NQ	IC	InChI=1S/C70H101N19O18S2/c1-36(73)59(96)77-32-55(94)79-53-35-109-108-34-52(58(75)95)87-67(104)51(33-90)86-70(107)57(39(4)92)88-60(97)37(2)78-69(106)56(38(3)91)89-62(99)46(24-14-16-26-72)80-65(102)49(29-42-31-76-44-22-12-11-21-43(42)44)84-64(101)48(28-41-19-9-6-10-20-41)82-63(100)47(27-40-17-7-5-8-18-40)83-66(103)50(30-54(74)93)85-61(98)45(81-68(53)105)23-13-15-25-71/h5-12,17-22,31,36-39,45-53,56-57,76,90-92H,13-16,23-30,32-35,71-73H2,1-4H3,(H2,74,93)(H2,75,95)(H,77,96)(H,78,106)(H,79,94)(H,80,102)(H,81,105)(H,82,100)(H,83,103)(H,84,101)(H,85,98)(H,86,107)(H,87,104)(H,88,97)(H,89,99)/t36-,37-,38?,39?,45-,46+,47-,48+,49-,50+,51-,52-,53-,56+,57+/m0/s1
DMZH4NQ	CS	C[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)C(C)O)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)N)CO)C(C)O
DMZH4NQ	IK	DWTUVBZITHQYDR-CFWAKGAOSA-N
DMZH4NQ	IU	(4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-25,28-dibenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxamide
DMZH4NQ	DE	Discovery agent

DM9RQ7E	ID	DM9RQ7E
DM9RQ7E	DN	Ala6-SRIF-14-amide
DM9RQ7E	HS	Investigative
DM9RQ7E	PC	44400675
DM9RQ7E	MW	1560.8
DM9RQ7E	FM	C70H101N19O18S2
DM9RQ7E	IC	InChI=1S/C70H101N19O18S2/c1-36(73)59(96)77-32-55(94)79-53-35-109-108-34-52(58(75)95)87-67(104)51(33-90)86-70(107)57(39(4)92)89-66(103)48(28-41-19-9-6-10-20-41)85-69(106)56(38(3)91)88-62(99)46(24-14-16-26-72)80-65(102)49(29-42-31-76-44-22-12-11-21-43(42)44)83-64(101)47(27-40-17-7-5-8-18-40)82-60(97)37(2)78-63(100)50(30-54(74)93)84-61(98)45(81-68(53)105)23-13-15-25-71/h5-12,17-22,31,36-39,45-53,56-57,76,90-92H,13-16,23-30,32-35,71-73H2,1-4H3,(H2,74,93)(H2,75,95)(H,77,96)(H,78,100)(H,79,94)(H,80,102)(H,81,105)(H,82,97)(H,83,101)(H,84,98)(H,85,106)(H,86,107)(H,87,104)(H,88,99)(H,89,103)/t36-,37-,38?,39?,45-,46+,47+,48-,49-,50+,51-,52-,53-,56+,57+/m0/s1
DM9RQ7E	CS	C[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)N)CO)C(C)O)CC2=CC=CC=C2)C(C)O)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5
DM9RQ7E	IK	XOOYWFHODVEJSJ-XEOGGQMXSA-N
DM9RQ7E	IU	(4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25-dibenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-28-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxamide
DM9RQ7E	DE	Discovery agent

DMWF8GN	ID	DMWF8GN
DMWF8GN	DN	Ala7-SRIF-14-amide
DMWF8GN	HS	Investigative
DMWF8GN	PC	44400676
DMWF8GN	MW	1560.8
DMWF8GN	FM	C70H101N19O18S2
DMWF8GN	IC	InChI=1S/C70H101N19O18S2/c1-36(73)59(96)77-32-55(94)79-53-35-109-108-34-52(58(75)95)87-67(104)51(33-90)86-70(107)57(39(4)92)89-66(103)48(28-41-19-9-6-10-20-41)85-69(106)56(38(3)91)88-62(99)46(24-14-16-26-72)80-64(101)49(29-42-31-76-44-22-12-11-21-43(42)44)82-60(97)37(2)78-63(100)47(27-40-17-7-5-8-18-40)83-65(102)50(30-54(74)93)84-61(98)45(81-68(53)105)23-13-15-25-71/h5-12,17-22,31,36-39,45-53,56-57,76,90-92H,13-16,23-30,32-35,71-73H2,1-4H3,(H2,74,93)(H2,75,95)(H,77,96)(H,78,100)(H,79,94)(H,80,101)(H,81,105)(H,82,97)(H,83,102)(H,84,98)(H,85,106)(H,86,107)(H,87,104)(H,88,99)(H,89,103)/t36-,37+,38?,39?,45-,46+,47-,48-,49-,50+,51-,52-,53-,56+,57+/m0/s1
DMWF8GN	CS	C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)N)CO)C(C)O)CC3=CC=CC=C3)C(C)O)CCCCN)CC4=CNC5=CC=CC=C54
DMWF8GN	IK	IMPCJRRYNLCKNP-IORPGQRLSA-N
DMWF8GN	IU	(4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,28-dibenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-25-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxamide
DMWF8GN	DE	Discovery agent

DMTWB54	ID	DMTWB54
DMTWB54	DN	Ala-Pro-Glu
DMTWB54	HS	Investigative
DMTWB54	SN	Ala-Pro-Glu; 71190-92-6; CHEMBL381831; CTK2G2707; DTXSID10658778; L-Alanyl-L-prolyl-L-glutamic acid; L-Glutamic acid, L-alanyl-L-prolyl-
DMTWB54	DT	Small molecular drug
DMTWB54	PC	44408970
DMTWB54	MW	315.32
DMTWB54	FM	C13H21N3O6
DMTWB54	IC	InChI=1S/C13H21N3O6/c1-7(14)12(20)16-6-2-3-9(16)11(19)15-8(13(21)22)4-5-10(17)18/h7-9H,2-6,14H2,1H3,(H,15,19)(H,17,18)(H,21,22)/t7-,8-,9-/m0/s1
DMTWB54	CS	C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N
DMTWB54	IK	IORKCNUBHNIMKY-CIUDSAMLSA-N
DMTWB54	IU	(2S)-2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid
DMTWB54	CA	CAS 71190-92-6
DMTWB54	CB	CHEBI:158455
DMTWB54	DE	Discovery agent

DMO1ZC2	ID	DMO1ZC2
DMO1ZC2	DN	ALBAFURAN A
DMO1ZC2	HS	Investigative
DMO1ZC2	SN	Albafuran A; CHEMBL564896; CHEBI:2543; 84323-14-8; 4-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-(6-hydroxy-1-benzofuran-2-yl)benzene-1,3-diol; Albafuran; AC1NQYBF; C08732; BDBM50303002; 1,3-Benzenediol, 4-((2E)-3,7-dimethyl-2,6-octadienyl)-5-(6-hydroxy-2-benzofuranyl)-; 4-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-(6-hydroxy-1-benzofuran-2-yl)benzene-1,3-diol; 4-(3,7-Dimethyl-2,6-octadienyl)-5-(6-hydroxy-2-benzofuranyl)-1,3-benzenediol, 9CI; 4-(3,7-dimethylocta-2,6-dien-1-yl)-5-(6-hydroxy-1-benzofuran-2-yl)benzene-1,3-diol
DMO1ZC2	DT	Small molecular drug
DMO1ZC2	PC	5281297
DMO1ZC2	MW	378.5
DMO1ZC2	FM	C24H26O4
DMO1ZC2	IC	InChI=1S/C24H26O4/c1-15(2)5-4-6-16(3)7-10-20-21(12-19(26)13-22(20)27)24-11-17-8-9-18(25)14-23(17)28-24/h5,7-9,11-14,25-27H,4,6,10H2,1-3H3/b16-7+
DMO1ZC2	CS	CC(=CCC/C(=C/CC1=C(C=C(C=C1O)O)C2=CC3=C(O2)C=C(C=C3)O)/C)C
DMO1ZC2	IK	KGOOVUKZICPAIZ-FRKPEAEDSA-N
DMO1ZC2	IU	4-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-(6-hydroxy-1-benzofuran-2-yl)benzene-1,3-diol
DMO1ZC2	CA	CAS 84323-14-8
DMO1ZC2	CB	CHEBI:2543
DMO1ZC2	DE	Discovery agent

DMHIW2L	ID	DMHIW2L
DMHIW2L	DN	ALBANOL A
DMHIW2L	HS	Investigative
DMHIW2L	SN	Mulberrofuran G; Albanol A; 87085-00-5; NSC649229; iso-mulbel-rochromene; NSC 649229; AC1L51ZD; SCHEMBL4926236; AKOS032948258; 3aH-Benzo[3,4][2]benzopyrano[1,8-bc][1]-benzopyran-4,11-diol, 8a-(2,4-dihydroxphenyl)-1,8a,13b,13c-tetrahydro-6-(6-hydroxy-2-benzofuranyl)-2-methyl-, (3a,S,8aS,13bS,13cR)-
DMHIW2L	DT	Small molecular drug
DMHIW2L	PC	9959532
DMHIW2L	MW	562.6
DMHIW2L	FM	C34H26O8
DMHIW2L	IC	InChI=1S/C34H26O8/c1-16-8-23-22-6-4-21(37)15-30(22)41-34(25-7-5-19(35)13-26(25)38)33(23)24(9-16)32-27(39)10-18(12-31(32)42-34)28-11-17-2-3-20(36)14-29(17)40-28/h2-7,9-15,23-24,33,35-39H,8H2,1H3/t23-,24-,33-,34+/m0/s1
DMHIW2L	CS	CC1=C[C@@H]2[C@@H]3[C@@H](C1)C4=C(C=C(C=C4)O)O[C@@]3(OC5=CC(=CC(=C25)O)C6=CC7=C(O6)C=C(C=C7)O)C8=C(C=C(C=C8)O)O
DMHIW2L	IK	MJJWBJFYYRAYKU-OPKNDJPNSA-N
DMHIW2L	IU	(1S,9R,13R,21S)-1-(2,4-dihydroxyphenyl)-17-(6-hydroxy-1-benzofuran-2-yl)-11-methyl-2,20-dioxapentacyclo[11.7.1.03,8.09,21.014,19]henicosa-3(8),4,6,11,14,16,18-heptaene-5,15-diol
DMHIW2L	CB	CHEBI:2544
DMHIW2L	DE	Discovery agent

DMQXO5G	ID	DMQXO5G
DMQXO5G	DN	ALD-805
DMQXO5G	HS	Investigative
DMQXO5G	CP	Alder Biopharmaceuticals Inc
DMQXO5G	DT	Antibody
DMQXO5G	DE	Solid tumour/cancer

DMWBKH1	ID	DMWBKH1
DMWBKH1	DN	ALD-806
DMWBKH1	HS	Investigative
DMWBKH1	SN	Anti-HGF mAb (cancer), Alder Biopharmaceuticals
DMWBKH1	CP	Alder Biopharmaceuticals Inc
DMWBKH1	DT	Antibody
DMWBKH1	DE	Solid tumour/cancer

DMAYGK9	ID	DMAYGK9
DMAYGK9	DN	ALD-901
DMAYGK9	HS	Investigative
DMAYGK9	SN	ALD-916; Pain pathway antagonist mAb, Alder Biopharmaceuticals; Anti-NGF monoclonal antibody (pain), Alder Biopharmaceuticals
DMAYGK9	CP	Alder Biopharmaceuticals Inc
DMAYGK9	DT	Antibody
DMAYGK9	DE	Pain

DMS80DF	ID	DMS80DF
DMS80DF	DN	ALDISIN
DMS80DF	HS	Investigative
DMS80DF	SN	72908-87-3; Aldisin; Aldisine; 6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione; 6,7-Dihydro-1H,5H-pyrrolo[2,3-c]azepine-4,8-dione; CHEMBL357047; AK134979; Pyrrolo[2,3-c]azepine-4,8(1H,5H)-dione, 6,7-dihydro-; Pyrrolo(2,3-c)azepine-4,8(1H,5H)-dione, 6,7-dihydro-; AC1MJ57G; SCHEMBL7844916; 6,7-dihydro-Pyrrolo[2,3-c]azepine-4,8(1H,5H)-dione; CTK5D7039; KS-00000FCK; DTXSID40223211; Pyrrolo[2,3-c]azepine-4,8(1H,5H)-dione,6,7-dihydro-; AAPGLCCSVSGLFH-UHFFFAOYSA-N; MolPort-000-003-213; ZINC13310235; BDBM50108777; FCH858612
DMS80DF	DT	Small molecular drug
DMS80DF	PC	3085877
DMS80DF	MW	164.16
DMS80DF	FM	C8H8N2O2
DMS80DF	IC	InChI=1S/C8H8N2O2/c11-6-2-4-10-8(12)7-5(6)1-3-9-7/h1,3,9H,2,4H2,(H,10,12)
DMS80DF	CS	C1CNC(=O)C2=C(C1=O)C=CN2
DMS80DF	IK	AAPGLCCSVSGLFH-UHFFFAOYSA-N
DMS80DF	IU	1,5,6,7-tetrahydropyrrolo[2,3-c]azepine-4,8-dione
DMS80DF	CA	CAS 72908-87-3
DMS80DF	DE	Discovery agent

DM83CDK	ID	DM83CDK
DM83CDK	DN	Alexa-488-telenzepine
DM83CDK	HS	Investigative
DM83CDK	SN	Alexa-488-telenzepine
DM83CDK	DT	Small molecular drug
DM83CDK	PC	91827379
DM83CDK	MW	1026.2
DM83CDK	FM	C49H51N7O12S3-6
DM83CDK	IC	InChI=1S/C49H57N7O12S3/c1-29-42-35(28-69-29)48(59)53-38-12-8-9-13-39(38)56(42)40(57)27-55-24-22-54(23-25-55)21-11-7-5-3-2-4-6-10-20-52-47(58)30-14-15-31(34(26-30)49(60)61)41-32-16-18-36(50)45(70(62,63)64)43(32)68-44-33(41)17-19-37(51)46(44)71(65,66)67/h8-9,12-19,26,28,50,62-67H,2-7,10-11,20-25,27,51H2,1H3,(H,52,58)(H,53,59)(H,60,61)/p-6
DM83CDK	CS	CC1=C2C(=CS1)C(=O)NC3=CC=CC=C3N2C(=O)CN4CCN(CC4)CCCCCCCCCCNC(=O)C5=CC(=C(C=C5)C6=C7C=CC(=N)C(=C7OC8=C6C=CC(=C8S([O-])([O-])[O-])N)S([O-])([O-])[O-])C(=O)O
DM83CDK	IK	SRLBGILQMKQWSJ-UHFFFAOYSA-H
DM83CDK	IU	2-[3-amino-6-imino-4,5-bis(trioxido-lambda4-sulfanyl)xanthen-9-yl]-5-[10-[4-[2-(1-methyl-4-oxo-5H-thieno[3,4-b][1,5]benzodiazepin-10-yl)-2-oxoethyl]piperazin-1-yl]decylcarbamoyl]benzoic acid
DM83CDK	DE	Discovery agent

DM53KRA	ID	DM53KRA
DM53KRA	DN	ALF-421
DM53KRA	HS	Investigative
DM53KRA	SN	CORM-A1; Macromolecular carrier-linked carbon monoxide releasing molecules (inflammation); Carbon monoxide-releasing molecules (inflammatory diseases), Alfama; Macromolecular carrier-linked CORMs (inflammation), Alfama; Macromolecular carrier-linked carbon monoxide releasing molecules (inflammation), Alfama
DM53KRA	CP	Alfama
DM53KRA	DE	Acute liver failure

DMI4OTW	ID	DMI4OTW
DMI4OTW	DN	ALFAXALONE
DMI4OTW	HS	Investigative
DMI4OTW	SN	Alphaxalone; Alfaxalone; 23930-19-0; 5alpha-Pregnan-3alpha-ol-11,20-dione; GR 2/234; Alfaxalonum [INN-Latin]; Alfaxalona [INN-Spanish]; 3alpha-Hydroxy-5alpha-pregnane-11,20-dione; UNII-BD07M97B2A; BRN 3217240; MLS001076262; MLS000069684; 3alpha-Hydroxy-5alpha-pregnan-11,20-dion; BD07M97B2A; CHEMBL190279; CHEBI:34531; 3-alpha-Hydroxy-5-alpha-pregnane-11,20-dione; (3-alpha,5-alpha)-3-Hydroxypregnane-11,20-dione; alfaxolone; 3-Hydroxypregnane-11,20-dione; NCGC00023100-03; SMR000058494; (3a,5a)-3-Hydroxypregnane-11,20-dione
DMI4OTW	DT	Small molecular drug
DMI4OTW	PC	104845
DMI4OTW	MW	332.5
DMI4OTW	FM	C21H32O3
DMI4OTW	IC	InChI=1S/C21H32O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h13-17,19,23H,4-11H2,1-3H3/t13-,14+,15-,16+,17-,19+,20-,21+/m0/s1
DMI4OTW	CS	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C
DMI4OTW	IK	DUHUCHOQIDJXAT-OLVMNOGESA-N
DMI4OTW	IU	(3R,5S,8S,9S,10S,13S,14S,17S)-17-acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one
DMI4OTW	CA	CAS 23930-19-0
DMI4OTW	CB	CHEBI:34531
DMI4OTW	DE	Discovery agent

DMWMIRL	ID	DMWMIRL
DMWMIRL	DN	Alisporivir
DMWMIRL	HS	Investigative
DMWMIRL	SN	DEB-025; Debio-025; HCV infection therapy, Debiopharm/Novartis; HIV infection therapy, Debiopharm
DMWMIRL	CP	Novartis pharmaceuticals
DMWMIRL	TC	Antiviral Agents
DMWMIRL	DT	Protein/peptide drug
DMWMIRL	PC	11513676
DMWMIRL	MW	1216.6
DMWMIRL	FM	C63H113N11O12
DMWMIRL	IC	InChI=1S/C63H113N11O12/c1-26-29-30-40(16)52(75)51-56(79)66-44(27-2)59(82)68(20)43(19)58(81)74(28-3)49(38(12)13)55(78)67-48(37(10)11)62(85)69(21)45(31-34(4)5)54(77)64-41(17)53(76)65-42(18)57(80)70(22)46(32-35(6)7)60(83)71(23)47(33-36(8)9)61(84)72(24)50(39(14)15)63(86)73(51)25/h26,29,34-52,75H,27-28,30-33H2,1-25H3,(H,64,77)(H,65,76)(H,66,79)(H,67,78)/b29-26+/t40-,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-/m1/s1
DMWMIRL	CS	CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C
DMWMIRL	IK	OLROWHGDTNFZBH-XEMWPYQTSA-N
DMWMIRL	IU	(3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMWMIRL	CA	CAS 254435-95-5
DMWMIRL	DE	Duchenne muscular dystrophy; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM3DERI	ID	DM3DERI
DM3DERI	DN	alkyl glycerol phosphate 18:1
DM3DERI	HS	Investigative
DM3DERI	SN	AGP 18.1
DM3DERI	DT	Small molecular drug
DM3DERI	PC	10717228
DM3DERI	MW	424.6
DM3DERI	FM	C21H45O6P
DM3DERI	IC	InChI=1S/C21H45O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26-19-21(22)20-27-28(23,24)25/h21-22H,2-20H2,1H3,(H2,23,24,25)/t21-/m0/s1
DM3DERI	CS	CCCCCCCCCCCCCCCCCCOC[C@@H](COP(=O)(O)O)O
DM3DERI	IK	HUUYDUFSUADEJQ-NRFANRHFSA-N
DM3DERI	IU	[(2S)-2-hydroxy-3-octadecoxypropyl] dihydrogen phosphate
DM3DERI	DE	Discovery agent

DMM19AO	ID	DMM19AO
DMM19AO	DN	alkyl OMPT
DMM19AO	HS	Investigative
DMM19AO	SN	alkyl OMPT; GTPL2913; CHEMBL3621962; [(2S)-2-methoxy-3-[(9Z)-octadec-9-en-1-yloxy]propoxy](sulfanylidene)phosphonous acid
DMM19AO	DT	Small molecular drug
DMM19AO	PC	56947064
DMM19AO	MW	452.6
DMM19AO	FM	C22H45O5PS
DMM19AO	IC	InChI=1S/C22H45O5PS/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26-20-22(25-2)21-27-28(23,24)29/h10-11,22H,3-9,12-21H2,1-2H3,(H2,23,24,29)/b11-10-/t22-/m0/s1
DMM19AO	CS	CCCCCCCC/C=C\\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC
DMM19AO	IK	FEHMGBUAJYEJMW-YRBAHSOBSA-N
DMM19AO	IU	dihydroxy-[(2S)-2-methoxy-3-[(Z)-octadec-9-enoxy]propoxy]-sulfanylidene-lambda5-phosphane
DMM19AO	DE	Discovery agent

DMQH481	ID	DMQH481
DMQH481	DN	alkylbenzene sulfonate
DMQH481	HS	Investigative
DMQH481	SN	4-dodecan-6-ylbenzenesulfonic Acid; Alkylbenzene sulfonate; AC1Q6WLV; AC1L28EL; 6-(p-sulfophenyl) dodecane; SCHEMBL6128184; GTPL2362; DTXSID30860093; 4-(dodecan-6-yl)benzenesulfonic acid; 4-(1-Hexylhexyl)benzenesulfonic acid; 4-(Dodecan-6-yl)benzene-1-sulfonic acid
DMQH481	DT	Small molecular drug
DMQH481	PC	16652
DMQH481	MW	326.5
DMQH481	FM	C18H30O3S
DMQH481	IC	InChI=1S/C18H30O3S/c1-3-5-7-9-11-16(10-8-6-4-2)17-12-14-18(15-13-17)22(19,20)21/h12-16H,3-11H2,1-2H3,(H,19,20,21)
DMQH481	CS	CCCCCCC(CCCCC)C1=CC=C(C=C1)S(=O)(=O)O
DMQH481	IK	GHNRTXCRBJQVGN-UHFFFAOYSA-N
DMQH481	IU	4-dodecan-6-ylbenzenesulfonic acid
DMQH481	CA	CAS 23003-92-1
DMQH481	DE	Discovery agent

DMSOJ6H	ID	DMSOJ6H
DMSOJ6H	DN	ALLICIN
DMSOJ6H	HS	Investigative
DMSOJ6H	SN	Allicin; 539-86-6; Diallyl thiosulfinate; Diallyldisulfid-S-oxid; Thio-2-propene-1-sulfinic acid S-allyl ester; S-Allyl acrylo-1-sulphinothioate; Allylthiosulphinic acid allyl ester; DADSO; S-allyl prop-2-ene-1-sulfinothioate; diallyl disulfide-oxide; S-allyl 2-propene-1-sulfinothioate; C6H10OS2; CCRIS 9053; EINECS 208-727-7; 2-Propene-1-sulfinothioic acid, S-2-propenyl ester; BRN 1752823; 3-prop-2-enylsulfinylsulfanylprop-1-ene; CHEMBL359965; CHEBI:28411; 3-allylsulfinylsulfanylprop-1-ene; 2-Propene-1-sulfinic acid, thio-, S-
DMSOJ6H	DT	Small molecular drug
DMSOJ6H	PC	65036
DMSOJ6H	MW	162.3
DMSOJ6H	FM	C6H10OS2
DMSOJ6H	IC	InChI=1S/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2
DMSOJ6H	CS	C=CCSS(=O)CC=C
DMSOJ6H	IK	JDLKFOPOAOFWQN-UHFFFAOYSA-N
DMSOJ6H	IU	3-prop-2-enylsulfinylsulfanylprop-1-ene
DMSOJ6H	CA	CAS 539-86-6
DMSOJ6H	CB	CHEBI:28411
DMSOJ6H	DE	Discovery agent

DM05AYE	ID	DM05AYE
DM05AYE	DN	alloswitch-1
DM05AYE	HS	Investigative
DM05AYE	SN	trans-alloswitch-1
DM05AYE	DT	Small molecular drug
DM05AYE	PC	76853680
DM05AYE	MW	366.8
DM05AYE	FM	C19H15ClN4O2
DM05AYE	IC	InChI=1S/C19H15ClN4O2/c1-26-17-12-13(23-24-18-8-4-5-11-21-18)9-10-16(17)22-19(25)14-6-2-3-7-15(14)20/h2-12H,1H3,(H,22,25)
DM05AYE	CS	COC1=C(C=CC(=C1)N=NC2=CC=CC=N2)NC(=O)C3=CC=CC=C3Cl
DM05AYE	IK	JJRNGNCTPCWXGM-UHFFFAOYSA-N
DM05AYE	IU	2-chloro-N-[2-methoxy-4-(pyridin-2-yldiazenyl)phenyl]benzamide
DM05AYE	DE	Discovery agent

DM7U2BE	ID	DM7U2BE
DM7U2BE	DN	Alloxazine
DM7U2BE	HS	Investigative
DM7U2BE	SN	Alloxazine; Isoalloxazine; 490-59-5; Alloxazin; benzo[g]pteridine-2,4(1H,3H)-dione; 1H-Benzo[g]pteridine-2,4-dione; Benzo(g)pteridine-2,4(1H,3H)-dione; UNII-880W3VF9YW; benzo[g]pteridine-2,4(3H,10H)-dione; CHEMBL68500; 880W3VF9YW; CHEBI:37325; HAUGRYOERYOXHX-UHFFFAOYSA-N; Benzo[g]pteridine-2,4[1H,3H]-dione; 1H,2H,3H,4H-benzo[g]pteridine-2,4-dione; Benzo[g]pteridine-2,3H)-dione; WLN: T C666 BN DMVMV INJ; 1,3-dihydrobenzo[g]pteridine-2,4-dione; SR-01000075199; Alloxazine, 96%; EINECS 207-714-3; NSC 203056; AC1NSYUA; Lopac-A-242
DM7U2BE	DT	Small molecular drug
DM7U2BE	PC	5372720
DM7U2BE	MW	214.18
DM7U2BE	FM	C10H6N4O2
DM7U2BE	IC	InChI=1S/C10H6N4O2/c15-9-7-8(13-10(16)14-9)12-6-4-2-1-3-5(6)11-7/h1-4H,(H2,12,13,14,15,16)
DM7U2BE	CS	C1=CC=C2C(=C1)N=C3C(=N2)NC(=O)NC3=O
DM7U2BE	IK	HAUGRYOERYOXHX-UHFFFAOYSA-N
DM7U2BE	IU	1H-benzo[g]pteridine-2,4-dione
DM7U2BE	CA	CAS 490-59-5
DM7U2BE	CB	CHEBI:37325
DM7U2BE	DE	Discovery agent

DMM2R1N	ID	DMM2R1N
DMM2R1N	DN	all-trans-4-oxo-retinoic acid
DMM2R1N	HS	Investigative
DMM2R1N	SN	4-oxoretinoic acid; Ro 12-4824
DMM2R1N	DT	Small molecular drug
DMM2R1N	PC	6437063
DMM2R1N	MW	314.4
DMM2R1N	FM	C20H26O3
DMM2R1N	IC	InChI=1S/C20H26O3/c1-14(7-6-8-15(2)13-19(22)23)9-10-17-16(3)18(21)11-12-20(17,4)5/h6-10,13H,11-12H2,1-5H3,(H,22,23)/b8-6+,10-9+,14-7+,15-13+
DMM2R1N	CS	CC1=C(C(CCC1=O)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
DMM2R1N	IK	GGCUJPCCTQNTJF-FRCNGJHJSA-N
DMM2R1N	IU	(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DMM2R1N	CA	CAS 38030-57-8
DMM2R1N	CB	CHEBI:80656
DMM2R1N	DE	Discovery agent

DM6CEVB	ID	DM6CEVB
DM6CEVB	DN	All-trans-retinal
DM6CEVB	HS	Investigative
DM6CEVB	DT	Small molecular drug
DM6CEVB	PC	638015
DM6CEVB	MW	284.4
DM6CEVB	FM	C20H28O
DM6CEVB	IC	InChI=1S/C20H28O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,15H,7,10,14H2,1-5H3/b9-6+,12-11+,16-8+,17-13+
DM6CEVB	CS	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=O)/C)/C
DM6CEVB	IK	NCYCYZXNIZJOKI-OVSJKPMPSA-N
DM6CEVB	IU	(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenal
DM6CEVB	CA	CAS 116-31-4
DM6CEVB	CB	CHEBI:17898
DM6CEVB	DE	Discovery agent

DM8R5AS	ID	DM8R5AS
DM8R5AS	DN	Allyl 4-(2-oxohexadecanamido)butanoate
DM8R5AS	HS	Investigative
DM8R5AS	SN	CHEMBL520227
DM8R5AS	DT	Small molecular drug
DM8R5AS	PC	44563072
DM8R5AS	MW	395.6
DM8R5AS	FM	C23H41NO4
DM8R5AS	IC	InChI=1S/C23H41NO4/c1-3-5-6-7-8-9-10-11-12-13-14-15-17-21(25)23(27)24-19-16-18-22(26)28-20-4-2/h4H,2-3,5-20H2,1H3,(H,24,27)
DM8R5AS	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCCCC(=O)OCC=C
DM8R5AS	IK	NCGQJUXYFOTZRW-UHFFFAOYSA-N
DM8R5AS	IU	prop-2-enyl 4-(2-oxohexadecanoylamino)butanoate
DM8R5AS	DE	Discovery agent

DMYNKLR	ID	DMYNKLR
DMYNKLR	DN	Allyl 4-(aminosulfonyl)benzoate
DMYNKLR	HS	Investigative
DMYNKLR	SN	CHEMBL381455; 103204-31-5; Benzoic acid, 4-(aminosulfonyl)-, 2-propenyl ester; allyl 4-(aminosulfonyl)benzoate; ACMC-20m632; SCHEMBL6705334; CTK0G7183; DTXSID90468211; VWKMDRWBZTWKNM-UHFFFAOYSA-N; BDBM50175049; 4-Sulfamoyl-benzoic acid allyl ester
DMYNKLR	DT	Small molecular drug
DMYNKLR	PC	11536043
DMYNKLR	MW	241.27
DMYNKLR	FM	C10H11NO4S
DMYNKLR	IC	InChI=1S/C10H11NO4S/c1-2-7-15-10(12)8-3-5-9(6-4-8)16(11,13)14/h2-6H,1,7H2,(H2,11,13,14)
DMYNKLR	CS	C=CCOC(=O)C1=CC=C(C=C1)S(=O)(=O)N
DMYNKLR	IK	VWKMDRWBZTWKNM-UHFFFAOYSA-N
DMYNKLR	IU	prop-2-enyl 4-sulfamoylbenzoate
DMYNKLR	CA	CAS 103204-31-5
DMYNKLR	DE	Discovery agent

DMNFGRV	ID	DMNFGRV
DMNFGRV	DN	Allylamines
DMNFGRV	HS	Investigative
DMNFGRV	DE	Discovery agent

DMJWZB3	ID	DMJWZB3
DMJWZB3	DN	Allylcarbamic Acid Biphenyl-3-yl Ester
DMJWZB3	HS	Investigative
DMJWZB3	SN	Allylcarbamic Acid Biphenyl-3-yl Ester; CHEMBL451174; SCHEMBL4563341
DMJWZB3	DT	Small molecular drug
DMJWZB3	PC	24881608
DMJWZB3	MW	253.29
DMJWZB3	FM	C16H15NO2
DMJWZB3	IC	InChI=1S/C16H15NO2/c1-2-11-17-16(18)19-15-10-6-9-14(12-15)13-7-4-3-5-8-13/h2-10,12H,1,11H2,(H,17,18)
DMJWZB3	CS	C=CCNC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DMJWZB3	IK	IVZVLOUIEAWCIN-UHFFFAOYSA-N
DMJWZB3	IU	(3-phenylphenyl) N-prop-2-enylcarbamate
DMJWZB3	DE	Discovery agent

DM1VHCL	ID	DM1VHCL
DM1VHCL	DN	Allyl-trimethyl-ammonium
DM1VHCL	HS	Investigative
DM1VHCL	DT	Small molecular drug
DM1VHCL	PC	10425
DM1VHCL	MW	100.18
DM1VHCL	FM	C6H14N+
DM1VHCL	IC	InChI=1S/C6H14N/c1-5-6-7(2,3)4/h5H,1,6H2,2-4H3/q+1
DM1VHCL	CS	C[N+](C)(C)CC=C
DM1VHCL	IK	KGVWWFCEYXERAE-UHFFFAOYSA-N
DM1VHCL	IU	trimethyl(prop-2-enyl)azanium
DM1VHCL	DE	Discovery agent

DMY1OG7	ID	DMY1OG7
DMY1OG7	DN	ALM-301
DMY1OG7	HS	Investigative
DMY1OG7	SN	Akt inhibitors (cancer), Almac
DMY1OG7	CP	Almac Discovery Ltd
DMY1OG7	DE	Solid tumour/cancer

DMPTY8S	ID	DMPTY8S
DMPTY8S	DN	Aloe-emodin
DMPTY8S	HS	Investigative
DMPTY8S	SN	Aloe-emodin; Aloe emodin; 481-72-1; Aloeemodin; Aloe-emodine; Rhabarberone; EMODINE; 3-Hydroxymethylchrysazin; 1,8-dihydroxy-3-(hydroxymethyl)anthracene-9,10-dione; 3-Hydroxymethylchrysazine; 1,8-Dihydroxy-3-hydroxymethylanthraquinone; 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone; NSC 38628; 1,8-Dihydroxy-3-(hydroxymethyl)-9,10-anthracenedione; UNII-C8IYT9CR7C; 9,10-Anthracenedione, 1,8-dihydroxy-3-(hydroxymethyl)-; CCRIS 3526; EINECS 207-571-7; C8IYT9CR7C; 3-(Hydroxymethyl)chrysazin; BRN 2059062; CHEMBL40275; CHEBI:2607
DMPTY8S	DT	Small molecular drug
DMPTY8S	PC	10207
DMPTY8S	MW	270.24
DMPTY8S	FM	C15H10O5
DMPTY8S	IC	InChI=1S/C15H10O5/c16-6-7-4-9-13(11(18)5-7)15(20)12-8(14(9)19)2-1-3-10(12)17/h1-5,16-18H,6H2
DMPTY8S	CS	C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)CO
DMPTY8S	IK	YDQWDHRMZQUTBA-UHFFFAOYSA-N
DMPTY8S	IU	1,8-dihydroxy-3-(hydroxymethyl)anthracene-9,10-dione
DMPTY8S	CA	CAS 481-72-1
DMPTY8S	CB	CHEBI:2607
DMPTY8S	DE	Discovery agent

DM7HGX8	ID	DM7HGX8
DM7HGX8	DN	aloisine
DM7HGX8	HS	Investigative
DM7HGX8	SN	IN1538; RP106
DM7HGX8	DT	Small molecular drug
DM7HGX8	PC	3641059
DM7HGX8	MW	281.35
DM7HGX8	FM	C17H19N3O
DM7HGX8	IC	InChI=1S/C17H19N3O/c1-3-4-5-14-15(12-6-8-13(21-2)9-7-12)20-17-16(14)18-10-11-19-17/h6-11H,3-5H2,1-2H3,(H,19,20)
DM7HGX8	CS	CCCCC1=C(NC2=NC=CN=C12)C3=CC=C(C=C3)OC
DM7HGX8	IK	WVMANZPBOBRWCB-UHFFFAOYSA-N
DM7HGX8	IU	7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine
DM7HGX8	CA	CAS 496864-15-4
DM7HGX8	CB	CHEBI:92890
DM7HGX8	DE	Discovery agent

DM5U1LN	ID	DM5U1LN
DM5U1LN	DN	aloisine A
DM5U1LN	HS	Investigative
DM5U1LN	SN	ALOISINE A; 4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131
DM5U1LN	DT	Small molecular drug
DM5U1LN	PC	448912
DM5U1LN	MW	267.33
DM5U1LN	FM	C16H17N3O
DM5U1LN	IC	InChI=1S/C16H17N3O/c1-2-3-4-13-14(11-5-7-12(20)8-6-11)19-16-15(13)17-9-10-18-16/h5-10,20H,2-4H2,1H3,(H,18,19)
DM5U1LN	CS	CCCCC1=C(NC2=NC=CN=C12)C3=CC=C(C=C3)O
DM5U1LN	IK	PRIGRJPRGZCFAS-UHFFFAOYSA-N
DM5U1LN	IU	4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol
DM5U1LN	CA	CAS 496864-16-5
DM5U1LN	CB	CHEBI:93641
DM5U1LN	DE	Discovery agent

DMHRME4	ID	DMHRME4
DMHRME4	DN	Alpha,beta-methylene-dATP
DMHRME4	HS	Investigative
DMHRME4	SN	CHEMBL1162297; 2'-Deoxy-5'-O-[(S)-Hydroxy{[(S)-Hydroxy(Phosphonooxy)phosphoryl]methyl}phosphoryl]adenosine; alpha,beta-methylene-dATP; F2A
DMHRME4	DT	Small molecular drug
DMHRME4	PC	15667210
DMHRME4	MW	489.21
DMHRME4	FM	C11H18N5O11P3
DMHRME4	IC	InChI=1S/C11H18N5O11P3/c12-10-9-11(14-3-13-10)16(4-15-9)8-1-6(17)7(26-8)2-25-28(18,19)5-29(20,21)27-30(22,23)24/h3-4,6-8,17H,1-2,5H2,(H,18,19)(H,20,21)(H2,12,13,14)(H2,22,23,24)/t6-,7+,8+/m0/s1
DMHRME4	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O
DMHRME4	IK	XETARULVTCYJAN-XLPZGREQSA-N
DMHRME4	IU	[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-[[hydroxy(phosphonooxy)phosphoryl]methyl]phosphinic acid
DMHRME4	DE	Discovery agent

DMJI8TX	ID	DMJI8TX
DMJI8TX	DN	Alpha,beta-methylene-dCTP
DMJI8TX	HS	Investigative
DMJI8TX	SN	2'-Deoxy-5'-O-[(S)-Hydroxy{[(S)-Hydroxy(Phosphonooxy)phosphoryl]methyl}phosphoryl]cytidine; alpha,beta-methylene-dCTP; XC5
DMJI8TX	DT	Small molecular drug
DMJI8TX	PC	25128802
DMJI8TX	MW	465.18
DMJI8TX	FM	C10H18N3O12P3
DMJI8TX	IC	InChI=1S/C10H18N3O12P3/c11-8-1-2-13(10(15)12-8)9-3-6(14)7(24-9)4-23-26(16,17)5-27(18,19)25-28(20,21)22/h1-2,6-7,9,14H,3-5H2,(H,16,17)(H,18,19)(H2,11,12,15)(H2,20,21,22)/t6-,7+,9+/m0/s1
DMJI8TX	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O
DMJI8TX	IK	YSCOIIOUWFAHFY-LKEWCRSYSA-N
DMJI8TX	IU	[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-[[hydroxy(phosphonooxy)phosphoryl]methyl]phosphinic acid
DMJI8TX	DE	Discovery agent

DMPZS80	ID	DMPZS80
DMPZS80	DN	Alpha,beta-methylene-dGTP
DMPZS80	HS	Investigative
DMPZS80	DT	Small molecular drug
DMPZS80	PC	135566546
DMPZS80	MW	505.21
DMPZS80	FM	C11H18N5O12P3
DMPZS80	IC	InChI=1S/C11H18N5O12P3/c12-11-14-9-8(10(18)15-11)13-3-16(9)7-1-5(17)6(27-7)2-26-29(19,20)4-30(21,22)28-31(23,24)25/h3,5-7,17H,1-2,4H2,(H,19,20)(H,21,22)(H2,23,24,25)(H3,12,14,15,18)/t5-,6+,7+/m0/s1
DMPZS80	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O
DMPZS80	IK	JTBKCZGNQPBEJY-RRKCRQDMSA-N
DMPZS80	IU	[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-[[hydroxy(phosphonooxy)phosphoryl]methyl]phosphinic acid
DMPZS80	DE	Discovery agent

DMPAHJF	ID	DMPAHJF
DMPAHJF	DN	Alpha,beta-methylene-dTTP
DMPAHJF	HS	Investigative
DMPAHJF	SN	alpha,beta-CH2-DTTP; alpha,beta-methylene-dTTP; alpha,beta-Methylenedeoxythymidine 5'-triphosphate; CHEMBL1162299; 24716-71-0; Thymidine, 5'-O-(1,3,5,5-tetrahydroxy-4-oxa-1,3,5-triphosphapent-1-yl)-, P,P',P''-trioxide
DMPAHJF	DT	Small molecular drug
DMPAHJF	PC	15667207
DMPAHJF	MW	480.2
DMPAHJF	FM	C11H19N2O13P3
DMPAHJF	IC	InChI=1S/C11H19N2O13P3/c1-6-3-13(11(16)12-10(6)15)9-2-7(14)8(25-9)4-24-27(17,18)5-28(19,20)26-29(21,22)23/h3,7-9,14H,2,4-5H2,1H3,(H,17,18)(H,19,20)(H,12,15,16)(H2,21,22,23)/t7-,8+,9+/m0/s1
DMPAHJF	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O
DMPAHJF	IK	AFUOLHFRDGMFSB-DJLDLDEBSA-N
DMPAHJF	IU	[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]methyl-phosphonooxyphosphinic acid
DMPAHJF	CA	CAS 24716-71-0
DMPAHJF	DE	Discovery agent

DMLGMTQ	ID	DMLGMTQ
DMLGMTQ	DN	alpha.beta-methylene-2-thio-UDP
DMLGMTQ	HS	Investigative
DMLGMTQ	SN	alpha,beta-methylene-UDP
DMLGMTQ	DT	Small molecular drug
DMLGMTQ	PC	73755188
DMLGMTQ	MW	414.31
DMLGMTQ	FM	C12H20N2O8P2S
DMLGMTQ	IC	InChI=1S/C12H20N2O8P2S/c1-7-8(2)11(14-4-3-10(15)13-12(14)25)22-9(7)5-21-24(19,20)6-23(16,17)18/h3-4,7-9,11H,5-6H2,1-2H3,(H,19,20)(H,13,15,25)(H2,16,17,18)/t7-,8+,9+,11+/m0/s1
DMLGMTQ	CS	C[C@H]1[C@H]([C@@H](O[C@@H]1COP(=O)(CP(=O)(O)O)O)N2C=CC(=O)NC2=S)C
DMLGMTQ	IK	HGGLEWIKYOGGHB-YSSBGUOXSA-N
DMLGMTQ	IU	[[(2S,3S,4R,5R)-3,4-dimethyl-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
DMLGMTQ	DE	Discovery agent

DM257WX	ID	DM257WX
DM257WX	DN	alpha3IA
DM257WX	HS	Investigative
DM257WX	SN	CHEMBL413325; alpha3IA; GTPL4094; BDBM50112236; 3-(4-Methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-[2,4'']bipyridinyl-5-carboxylic acid methyl ester; methyl 5-(4-methoxyphenyl)-1-methyl-2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridine-3-carboxylate
DM257WX	DT	Small molecular drug
DM257WX	PC	11824289
DM257WX	MW	350.4
DM257WX	FM	C20H18N2O4
DM257WX	IC	InChI=1S/C20H18N2O4/c1-22-18(14-8-10-21-11-9-14)16(12-17(19(22)23)20(24)26-3)13-4-6-15(25-2)7-5-13/h4-12H,1-3H3
DM257WX	CS	CN1C(=C(C=C(C1=O)C(=O)OC)C2=CC=C(C=C2)OC)C3=CC=NC=C3
DM257WX	IK	LENMNEQXCQXJHV-UHFFFAOYSA-N
DM257WX	IU	methyl 5-(4-methoxyphenyl)-1-methyl-2-oxo-6-pyridin-4-ylpyridine-3-carboxylate
DM257WX	DE	Discovery agent

DMTU5QR	ID	DMTU5QR
DMTU5QR	DN	alpha5IA
DMTU5QR	HS	Investigative
DMTU5QR	SN	215874-86-5; 3-(5-Methylisoxazol-3-yl)-6-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy][1,2,4]triazolo[3,4-a]phthalazine; alpha5IA; UNII-1M7NI1A92L; 1M7NI1A92L; CHEMBL306422; L-822179; alpha-5IA; 3-(5-METHYLISOXAZOL-3-YL)-6-[(1-METHYL-1H-1,2,3-TRIAZOL-4-YL)METHOXY][1,2,4]TRIAZOLO[3,4-A]PHTHALAZI; 3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine; a5ia; alpha 5IA; 1,2,4-Triazolo[3,4-a]phthalazine, 3-(5-methyl-3-isoxazolyl)-6-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]-
DMTU5QR	DT	Small molecular drug
DMTU5QR	PC	6918451
DMTU5QR	MW	362.3
DMTU5QR	FM	C17H14N8O2
DMTU5QR	IC	InChI=1S/C17H14N8O2/c1-10-7-14(22-27-10)16-20-19-15-12-5-3-4-6-13(12)17(21-25(15)16)26-9-11-8-24(2)23-18-11/h3-8H,9H2,1-2H3
DMTU5QR	CS	CC1=CC(=NO1)C2=NN=C3N2N=C(C4=CC=CC=C43)OCC5=CN(N=N5)C
DMTU5QR	IK	NZMJFRXKGUCYNP-UHFFFAOYSA-N
DMTU5QR	IU	5-methyl-3-[6-[(1-methyltriazol-4-yl)methoxy]-[1,2,4]triazolo[3,4-a]phthalazin-3-yl]-1,2-oxazole
DMTU5QR	CA	CAS 215874-86-5
DMTU5QR	DE	Discovery agent

DMND5EU	ID	DMND5EU
DMND5EU	DN	Alpha-7-Deoxyhomonojirimycin
DMND5EU	HS	Investigative
DMND5EU	SN	CHEMBL503021; 7-Deoxyhomonojirimycin; alpha-1-C-Methyl-DNJ; SCHEMBL2438896; BDBM18359
DMND5EU	DT	Small molecular drug
DMND5EU	PC	10921056
DMND5EU	MW	177.2
DMND5EU	FM	C7H15NO4
DMND5EU	IC	InChI=1S/C7H15NO4/c1-3-5(10)7(12)6(11)4(2-9)8-3/h3-12H,2H2,1H3/t3-,4-,5+,6-,7-/m1/s1
DMND5EU	CS	C[C@@H]1[C@@H]([C@H]([C@@H]([C@H](N1)CO)O)O)O
DMND5EU	IK	ZEWFPWKROPWRKE-XUUWZHRGSA-N
DMND5EU	IU	(2R,3R,4R,5S,6R)-2-(hydroxymethyl)-6-methylpiperidine-3,4,5-triol
DMND5EU	DE	Discovery agent

DMHV14R	ID	DMHV14R
DMHV14R	DN	Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen
DMHV14R	HS	Investigative
DMHV14R	SN	156715-37-6
DMHV14R	DT	Small molecular drug
DMHV14R	PC	23724922
DMHV14R	MW	462.5
DMHV14R	FM	C25H31N2NaO5
DMHV14R	IC	InChI=1S/C25H32N2O5.Na/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29;/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29);/q;+1/p-1/t18-,20+,21+,23-;/m0./s1
DMHV14R	CS	CCCCCNC(=O)C1=COC(=N1)[C@@H]2[C@H]3CC[C@H]([C@@H]2CC4=CC=CC=C4CCC(=O)[O-])O3.[Na+]
DMHV14R	IK	WOHSQDNIXPEQAE-SLWCZEQYSA-M
DMHV14R	IU	sodium;3-[2-[[(1R,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate
DMHV14R	DE	Discovery agent

DM4IXUQ	ID	DM4IXUQ
DM4IXUQ	DN	Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen
DM4IXUQ	HS	Investigative
DM4IXUQ	DE	Discovery agent

DMW1LF0	ID	DMW1LF0
DMW1LF0	DN	Alpha-Aminobutyric Acid
DMW1LF0	HS	Investigative
DMW1LF0	SN	1492-24-6; L-2-Aminobutyric acid; h-abu-oh; (S)-2-Aminobutanoic acid; (2S)-2-aminobutanoic acid; (S)-(+)-2-Aminobutyric Acid; L-alpha-Aminobutyric acid; L-(+)-2-aminobutyric acid; (S)-2-Aminobutyric acid; (-)-2-Aminobutyric acid; (S)-2-Amino-butyric acid; L-Butyrine; L-alpha-Amino-n-butyric acid; h-2-abu-oh; L-alpha-Aminobutyrate; Butanoic acid, 2-amino-, (2S)-; (S)-2-Aminobutanoate; 2S-amino-butanoic acid; UNII-0QAJ5KN9IM; S-Butyrine; ALPHA-AMINOBUTYRIC ACID; (2S)-2-Aminobutyric acid; L-2-Aminobuttersaeure; l(+)-2-aminobutyric a
DMW1LF0	DT	Small molecular drug
DMW1LF0	PC	6657
DMW1LF0	MW	103.12
DMW1LF0	FM	C4H9NO2
DMW1LF0	IC	InChI=1S/C4H9NO2/c1-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)
DMW1LF0	CS	CCC(C(=O)O)N
DMW1LF0	IK	QWCKQJZIFLGMSD-UHFFFAOYSA-N
DMW1LF0	IU	2-aminobutanoic acid
DMW1LF0	CA	CAS 2835-81-6
DMW1LF0	CB	CHEBI:35621
DMW1LF0	DE	Discovery agent

DM9GXFJ	ID	DM9GXFJ
DM9GXFJ	DN	Alpha-Aminoisobutyric Acid
DM9GXFJ	HS	Investigative
DM9GXFJ	SN	2-Aminoisobutyric acid; 62-57-7; 2-Methylalanine; 2-Amino-2-methylpropanoic acid; H-Aib-OH; Alanine, 2-methyl-; ALPHA-AMINOISOBUTYRIC ACID; 2-Amino-2-methylpropionic acid; alpha-Methylalanine; alpha-Aminoisobutanoic acid; a-Aminoisobutyric acid; 2-amino isobutyric acid; NSC 16590; alpha,alpha-Dimethylglycine; AIB; Propionic acid, 2-amino-2-methyl-; 2-amino-isobutyric acid; 2-amino-2-methyl-propanoic acid; UNII-1E7ZW41IQU; a-Aminoisobutyrate; 2-Amino-2-methylpropanoate; .alpha.-Aminoisobutanoic acid; 2,2-dimethylglycine
DM9GXFJ	DT	Small molecular drug
DM9GXFJ	PC	6119
DM9GXFJ	MW	103.12
DM9GXFJ	FM	C4H9NO2
DM9GXFJ	IC	InChI=1S/C4H9NO2/c1-4(2,5)3(6)7/h5H2,1-2H3,(H,6,7)
DM9GXFJ	CS	CC(C)(C(=O)O)N
DM9GXFJ	IK	FUOOLUPWFVMBKG-UHFFFAOYSA-N
DM9GXFJ	IU	2-amino-2-methylpropanoic acid
DM9GXFJ	CA	CAS 62-57-7
DM9GXFJ	CB	CHEBI:27971
DM9GXFJ	DE	Discovery agent

DMRGFEM	ID	DMRGFEM
DMRGFEM	DN	alphabeta-methyleneADP
DMRGFEM	HS	Investigative
DMRGFEM	SN	Phosphomethylphosphonic acid adenosyl ester; Adenosine 5'-methylenediphosphate; phosphomethylphosphonic acid adenosyl ester; 3768-14-7; alpha,beta-methylene ADP; MethADP; AMP-CP; UNII-0T2A5439OE; Adenosine, 5'-(trihydrogen methylenebis(phosphonate)); EINECS 223-194-0; NSC 614641; ALPHA,BETA-METHYLENEADENOSINE 5'-DIPHOSPHATE; Adenosine 5'-(hydrogen (phosphonomethyl)phosphonate); CHEBI:40730; 0T2A5439OE; ALPHA,BETA-METHYLENEADENOSINE-5'-DIPHOSPHATE; AMPCP; 5'-O-[hydroxy(phosphonomethyl)phosphoryl]adenosine; Adenosine 5'-(alpha,beta-methylene)diphosphoric acid; alpha,beta-methyleneadenosine 5'-diphosphate (alphabetameADP); [alphabetaCH2]ADP; Phosphomethylphosphonic Acid Adenosyl Ester
DMRGFEM	DT	Small molecular drug
DMRGFEM	PC	92199
DMRGFEM	MW	425.23
DMRGFEM	FM	C11H17N5O9P2
DMRGFEM	IC	InChI=1S/C11H17N5O9P2/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(25-11)1-24-27(22,23)4-26(19,20)21/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H2,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1
DMRGFEM	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)N
DMRGFEM	IK	OLCWZBFDIYXLAA-IOSLPCCCSA-N
DMRGFEM	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
DMRGFEM	CA	CAS 3768-14-7
DMRGFEM	CB	CHEBI:40730
DMRGFEM	DE	Discovery agent

DM96EJ1	ID	DM96EJ1
DM96EJ1	DN	alpha-conotoxin AuIB
DM96EJ1	HS	Investigative
DM96EJ1	SN	GTPL3973
DM96EJ1	DT	Small molecular drug
DM96EJ1	PC	73755065
DM96EJ1	MW	1572.8
DM96EJ1	FM	C65H89N17O21S4
DM96EJ1	IC	InChI=1S/C65H89N17O21S4/c1-31-53(91)79-51(32(2)84)62(100)74-39(23-48(67)86)64(102)80-18-6-11-45(80)60(98)72-37(24-50(88)89)55(93)76-41(52(68)90)27-104-106-29-43-59(97)75-40(26-83)56(94)73-38(22-34-14-16-35(85)17-15-34)63(101)82-20-8-13-47(82)65(103)81-19-7-12-46(81)61(99)78-44(30-107-105-28-42(57(95)77-43)70-49(87)25-66)58(96)71-36(54(92)69-31)21-33-9-4-3-5-10-33/h3-5,9-10,14-17,31-32,36-47,51,83-85H,6-8,11-13,18-30,66H2,1-2H3,(H2,67,86)(H2,68,90)(H,69,92)(H,70,87)(H,71,96)(H,72,98)(H,73,94)(H,74,100)(H,75,97)(H,76,93)(H,77,95)(H,78,99)(H,79,91)(H,88,89)/t31-,32+,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,51-/m0/s1
DM96EJ1	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)NC(=O)CN)C(=O)N[C@H](C(=O)N1)CC6=CC=CC=C6)CC7=CC=C(C=C7)O)CO)C(=O)N)CC(=O)O)CC(=O)N)[C@@H](C)O
DM96EJ1	IK	SVNSCQIKKAACJG-SBLJLSJOSA-N
DM96EJ1	IU	2-[(1R,6R,9S,12S,18S,21S,24S,27S,30R,33S,39S,45S,48S,53R)-53-[(2-aminoacetyl)amino]-18-(2-amino-2-oxoethyl)-27-benzyl-6-carbamoyl-21-[(1R)-1-hydroxyethyl]-48-(hydroxymethyl)-45-[(4-hydroxyphenyl)methyl]-24-methyl-8,11,17,20,23,26,29,32,38,44,47,50,52-tridecaoxo-3,4,55,56-tetrathia-7,10,16,19,22,25,28,31,37,43,46,49,51-tridecazapentacyclo[28.20.7.012,16.033,37.039,43]heptapentacontan-9-yl]acetic acid
DM96EJ1	DE	Discovery agent

DMHO634	ID	DMHO634
DMHO634	DN	alpha-conotoxin GI
DMHO634	HS	Investigative
DMHO634	DT	Small molecular drug
DMHO634	PC	25084484
DMHO634	MW	1437.6
DMHO634	FM	C55H80N20O18S4
DMHO634	IC	InChI=1S/C55H80N20O18S4/c1-25-44(83)72-36-21-95-97-22-37(73-45(84)29(56)9-10-42(80)81)52(91)74-38(51(90)69-33(16-40(57)78)54(93)75-12-4-8-39(75)53(92)65-25)23-96-94-20-35(43(58)82)71-50(89)34(19-76)70-48(87)31(14-26-5-2-6-28(77)13-26)67-49(88)32(15-27-17-61-24-64-27)68-47(86)30(7-3-11-62-55(59)60)66-41(79)18-63-46(36)85/h2,5-6,13,17,24-25,29-39,76-77H,3-4,7-12,14-16,18-23,56H2,1H3,(H2,57,78)(H2,58,82)(H,61,64)(H,63,85)(H,65,92)(H,66,79)(H,67,88)(H,68,86)(H,69,90)(H,70,87)(H,71,89)(H,72,83)(H,73,84)(H,74,91)(H,80,81)(H4,59,60,62)/t25-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-/m0/s1
DMHO634	CS	C[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC2=O)CCCN=C(N)N)CC3=CN=CN3)CC4=CC(=CC=C4)O)CO)C(=O)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)NC(=O)[C@H](CCC(=O)O)N
DMHO634	IK	CSUQNJQRLCOOSR-NAKBKFBQSA-N
DMHO634	IU	(4S)-4-amino-5-[[(1R,7S,10S,13S,16S,19R,24R,27S,33S,36S,43R)-27-(2-amino-2-oxoethyl)-19-carbamoyl-7-[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-13-[(3-hydroxyphenyl)methyl]-10-(1H-imidazol-5-ylmethyl)-36-methyl-2,5,8,11,14,17,25,28,34,37,44-undecaoxo-21,22,40,41-tetrathia-3,6,9,12,15,18,26,29,35,38,45-undecazatricyclo[22.14.7.029,33]pentatetracontan-43-yl]amino]-5-oxopentanoic acid
DMHO634	CA	CAS 76862-65-2
DMHO634	DE	Discovery agent

DM1QOY0	ID	DM1QOY0
DM1QOY0	DN	alpha-conotoxin PnIA
DM1QOY0	HS	Investigative
DM1QOY0	SN	GTPL3982
DM1QOY0	DT	Small molecular drug
DM1QOY0	PC	73755066
DM1QOY0	MW	1622.8
DM1QOY0	FM	C65H95N19O22S4
DM1QOY0	IC	InChI=1S/C65H95N19O22S4/c1-29(2)18-37-63(104)84-17-7-10-46(84)65(106)83-16-6-9-45(83)62(103)81-42-27-110-108-26-41(72-49(89)23-66)59(100)80-43(60(101)78-39(24-85)57(98)76-37)28-109-107-25-40(51(69)92)79-54(95)34(19-32-11-13-33(86)14-12-32)74-56(97)36(22-50(90)91)75-61(102)44-8-5-15-82(44)64(105)38(21-48(68)88)77-55(96)35(20-47(67)87)73-53(94)31(4)70-52(93)30(3)71-58(42)99/h11-14,29-31,34-46,85-86H,5-10,15-28,66H2,1-4H3,(H2,67,87)(H2,68,88)(H2,69,92)(H,70,93)(H,71,99)(H,72,89)(H,73,94)(H,74,97)(H,75,102)(H,76,98)(H,77,96)(H,78,101)(H,79,95)(H,80,100)(H,81,103)(H,90,91)/t30-,31-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-/m0/s1
DM1QOY0	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)NC(=O)CN)C(=O)N[C@H](C(=O)N1)C)CC(C)C)CO)C(=O)N)CC6=CC=C(C=C6)O)CC(=O)O)CC(=O)N)CC(=O)N
DM1QOY0	IK	VUVGEYBNLLGGBG-MVPSLEAZSA-N
DM1QOY0	IU	2-[(1R,6R,9S,12S,15S,21S,24S,27S,30S,33R,36S,42S,48S,51S,56R)-56-[(2-aminoacetyl)amino]-21,24-bis(2-amino-2-oxoethyl)-6-carbamoyl-51-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-27,30-dimethyl-48-(2-methylpropyl)-8,11,14,20,23,26,29,32,35,41,47,50,53,55-tetradecaoxo-3,4,58,59-tetrathia-7,10,13,19,22,25,28,31,34,40,46,49,52,54-tetradecazapentacyclo[31.20.7.015,19.036,40.042,46]hexacontan-12-yl]acetic acid
DM1QOY0	DE	Discovery agent

DM6VH7A	ID	DM6VH7A
DM6VH7A	DN	Alpha-D-Fucose
DM6VH7A	HS	Investigative
DM6VH7A	SN	Alpha-D-Fucose; alpha-D-fucopyranose; alpha-D-Fucp; 6-deoxy-alpha-D-galactopyranose; alpha-D-Fuc; UNII-K15K52FOK4; CHEBI:42564; K15K52FOK4; (2S,3R,4S,5R,6R)-6-methyloxane-2,3,4,5-tetrol; 6-Deoxy-D-galactose; Fucopyranose, alpha-D-; 6-Deoxy-alpha-D-galactose; fucoside; 1abf; 7abp; alpha-D-Galactopyranose, 6-deoxy-; 6-dideoxy galactose; AC1L9FWD; Epitope ID:115015; SCHEMBL1399668; CHEMBL609880; ZINC1532815; AKOS006272406; RP22690; DB03485; 6189-71-5; CJ-24263; F-8000; A823144; 111719-EP2371811A2; 111719-EP2275420A1; 111719-EP2298757A2
DM6VH7A	DT	Small molecular drug
DM6VH7A	PC	444200
DM6VH7A	MW	164.16
DM6VH7A	FM	C6H12O5
DM6VH7A	IC	InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6+/m1/s1
DM6VH7A	CS	C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O)O)O)O
DM6VH7A	IK	SHZGCJCMOBCMKK-PHYPRBDBSA-N
DM6VH7A	IU	(2S,3R,4S,5R,6R)-6-methyloxane-2,3,4,5-tetrol
DM6VH7A	CA	CAS 6189-71-5
DM6VH7A	CB	CHEBI:42564
DM6VH7A	DE	Discovery agent

DMD2TPA	ID	DMD2TPA
DMD2TPA	DN	Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide
DMD2TPA	HS	Investigative
DMD2TPA	SN	ALPHA-D-GLUCOPYRANOSYL-2-CARBOXYLIC ACID AMIDE; CHEMBL135302; GLG; AC1L9IMU; SCHEMBL5961308; 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-carboxylic acid amide; (alpha-D-Glucopyranosyl)formamide; BDBM50306562; DB02720; (2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-carboxamide; (2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxamide; (2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxamide (non-preferred name)
DMD2TPA	DT	Small molecular drug
DMD2TPA	PC	445825
DMD2TPA	MW	207.18
DMD2TPA	FM	C7H13NO6
DMD2TPA	IC	InChI=1S/C7H13NO6/c8-7(13)6-5(12)4(11)3(10)2(1-9)14-6/h2-6,9-12H,1H2,(H2,8,13)/t2-,3-,4+,5-,6+/m1/s1
DMD2TPA	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)C(=O)N)O)O)O)O
DMD2TPA	IK	UKWLGCFJAVEFPE-DVKNGEFBSA-N
DMD2TPA	IU	(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-carboxamide
DMD2TPA	CA	CAS 58825-13-1
DMD2TPA	DE	Discovery agent

DM1X3VQ	ID	DM1X3VQ
DM1X3VQ	DN	Alpha-D-glucose
DM1X3VQ	HS	Investigative
DM1X3VQ	SN	D-gluco-hexose; D-gluose; Glucopyranose, alpha-D-; a-D-Glucopyranose; alpha-D-Glucopyranose; alpha-Dextrose; alpha-glucose; glucoses; (2S,3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; (2S,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; (2S,3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol; .alpha.-D-Glucose; 492-62-6; 5J5I9EB41E; CHEBI:17925; CHEMBL423707; UNII-5J5I9EB41E; alpha-D(+)-Glucose, 99+%, anhydrous; alpha-D-Glc; alpha-D-glucose
DM1X3VQ	PC	79025
DM1X3VQ	MW	180.16
DM1X3VQ	FM	C6H12O6
DM1X3VQ	IC	WQZGKKKJIJFFOK-DVKNGEFBSA-N
DM1X3VQ	CS	C(C1C(C(C(C(O1)O)O)O)O)O
DM1X3VQ	IK	1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6+/m1/s1
DM1X3VQ	IU	(2S,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM1X3VQ	CA	CAS 492-62-6
DM1X3VQ	CB	CHEBI:17925
DM1X3VQ	DE	Discovery agent

DMU36HT	ID	DMU36HT
DMU36HT	DN	Alpha-D-Glucose-1-Phosphate
DMU36HT	HS	Investigative
DMU36HT	SN	beta-D-Glucose 1-phosphate; 1-O-phosphono-beta-D-glucopyranose; 1-phospho-beta-D-glucopyranose; CHEBI:16218; beta-glucose-1-phosphate; UNII-X9QC3WD5G5; X9QC3WD5G5; beta-D-glucopyranose 1-(dihydrogen phosphate); 1-o-phosphono-; A-d-glucopyranose; Dol-P-glc; XGP; Glucosylphosphodolichol; Dolichylglucose phosphate; Epitope ID:145000; AC1L3U9A; AC1Q6S5M; NCIStruc2_000464; NCIStruc1_000461; SCHEMBL361623; CHEMBL67622; beta-d-glucopyranosyl phosphate; dolichol-D-glucosylmonophosphate; .alpha.-D-Glucose, 1-phosphate; ZINC3953999
DMU36HT	DT	Small molecular drug
DMU36HT	PC	65533
DMU36HT	MW	260.14
DMU36HT	FM	C6H13O9P
DMU36HT	IC	InChI=1S/C6H13O9P/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6-/m1/s1
DMU36HT	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)O)O)O)O)O
DMU36HT	IK	HXXFSFRBOHSIMQ-VFUOTHLCSA-N
DMU36HT	IU	[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate
DMU36HT	CA	CAS 59-56-3
DMU36HT	CB	CHEBI:29042
DMU36HT	DE	Discovery agent

DMR0EVN	ID	DMR0EVN
DMR0EVN	DN	Alpha-D-Glucose-6-Phosphate
DMR0EVN	HS	Investigative
DMR0EVN	SN	6-O-phosphono-alpha-D-glucopyranose; UNII-03JQ7I74CO; 03JQ7I74CO; CHEBI:17665; alpha-D-Glucopyranose, 6-(dihydrogen phosphate); alpha-D-glucopyranose 6-(dihydrogen phosphate); 15209-11-7; alpha-D-glucopyranose 6-phosphate; G6P; 1gpy; Epitope ID:144999; SCHEMBL6598; AC1L971Q; NBSCHQHZLSJFNQ-DVKNGEFBSA-N; CHEBI:136602; ZINC3875375; DB02007; C00668; WURCS=2.0/1,1,0/[a2122h-1a_1-5_6*OPO/3O/3=O]/1/
DMR0EVN	DT	Small molecular drug
DMR0EVN	PC	439284
DMR0EVN	MW	260.14
DMR0EVN	FM	C6H13O9P
DMR0EVN	IC	InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6+/m1/s1
DMR0EVN	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)O)OP(=O)(O)O
DMR0EVN	IK	NBSCHQHZLSJFNQ-DVKNGEFBSA-N
DMR0EVN	IU	[(2R,3S,4S,5R,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl dihydrogen phosphate
DMR0EVN	CA	CAS 15209-11-7
DMR0EVN	CB	CHEBI:17665
DMR0EVN	DE	Discovery agent

DM6ZTOW	ID	DM6ZTOW
DM6ZTOW	DN	Alpha-dihydroaldosterone
DM6ZTOW	HS	Investigative
DM6ZTOW	SN	5-Dihydroaldosterone; 5alpha-Dihydroaldosterone; 5Alpha-dihydroaldosterone; 6005-92-1; AC1MI1I2; 18,21-Dihydroxy-11,18-epoxypregnane-3,20-dione; DTXSID00975481
DM6ZTOW	PC	3036614
DM6ZTOW	MW	362.5
DM6ZTOW	FM	C21H30O5
DM6ZTOW	IC	WCYSTKTYJRHHAV-RXKCSFKASA-N
DM6ZTOW	CS	CC12CCC(=O)CC1CCC3C2C4CC5(C3CCC5C(=O)CO)C(O4)O
DM6ZTOW	IK	1S/C21H30O5/c1-20-7-6-12(23)8-11(20)2-3-13-14-4-5-15(16(24)10-22)21(14)9-17(18(13)20)26-19(21)25/h11,13-15,17-19,22,25H,2-10H2,1H3/t11-,13+,14+,15-,17-,18-,19?,20+,21?/m1/s1
DM6ZTOW	IU	(2S,5S,6S,9R,14S,15S,16R)-18-hydroxy-2-(2-hydroxyacetyl)-14-methyl-17-oxapentacyclo[14.2.1.01,5.06,15.09,14]nonadecan-11-one
DM6ZTOW	CA	CAS 6005-92-1
DM6ZTOW	DE	Discovery agent

DMF5DLW	ID	DMF5DLW
DMF5DLW	DN	Alpha-D-Mannose
DMF5DLW	HS	Investigative
DMF5DLW	SN	alpha-D-Mannose; alpha-D-Mannopyranose; alpha-Mannose; alpha-D-Man; UNII-W3F28J9G0W; CHEBI:28729; 7296-15-3; W3F28J9G0W; 3h-mannose; Manalpha1,; 1rdl; 1rin; 29696-75-1; Epitope ID:130701; AC1Q59RC; AC1L4HD7; SCHEMBL76882; CHEMBL365590; WQZGKKKJIJFFOK-PQMKYFCFSA-N; ZINC3860903; FT-0773891; C00936; WURCS=2.0/1,1,0/[a1122h-1a_1-5]/1/
DMF5DLW	DT	Small molecular drug
DMF5DLW	PC	185698
DMF5DLW	MW	180.16
DMF5DLW	FM	C6H12O6
DMF5DLW	IC	InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6+/m1/s1
DMF5DLW	CS	C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)O)O)O
DMF5DLW	IK	WQZGKKKJIJFFOK-PQMKYFCFSA-N
DMF5DLW	IU	(2S,3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMF5DLW	CA	CAS 7296-15-3
DMF5DLW	CB	CHEBI:28729
DMF5DLW	DE	Discovery agent

DM3NCM1	ID	DM3NCM1
DM3NCM1	DN	Alpha-D-Mannose-6-Phosphate
DM3NCM1	HS	Investigative
DM3NCM1	SN	alpha-D-mannose-6-phosphate; 6-H2PO3Manalpha; alpha-D-mannose 6-phosphate; (6P)Manalpha; Man6P; (6P)Mana; 6-O-phosphono-alpha-D-mannopyranose; UNII-C77UQ006XD; C77UQ006XD; CHEBI:43896; Mannose 6-phosphate; M6P; 1syo; 1m6p; 1sz0; AC1L9KGE; SCHEMBL742653; CHEMBL402001; NBSCHQHZLSJFNQ-PQMKYFCFSA-N; ZINC4096188; DB02900; alpha-D-Mannopyranose, 6-(dihydrogen phosphate); WURCS=2.0/1,1,0/[a1122h-1a_1-5_6*OPO/3O/3=O]/1/; [(2R,3S,4S,5S,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl dihydrogen phosphate
DM3NCM1	DT	Small molecular drug
DM3NCM1	PC	447096
DM3NCM1	MW	260.14
DM3NCM1	FM	C6H13O9P
DM3NCM1	IC	InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5+,6+/m1/s1
DM3NCM1	CS	C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)O)O)OP(=O)(O)O
DM3NCM1	IK	NBSCHQHZLSJFNQ-PQMKYFCFSA-N
DM3NCM1	IU	[(2R,3S,4S,5S,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl dihydrogen phosphate
DM3NCM1	CA	CAS 40436-60-0
DM3NCM1	CB	CHEBI:43896
DM3NCM1	DE	Discovery agent

DMULXO3	ID	DMULXO3
DMULXO3	DN	alpha-Emtbl
DMULXO3	HS	Investigative
DMULXO3	SN	alpha-Emtbl; 3-ethyl-3-methylthiolan-2-one; 103620-92-4; alpha-Ethyl-alpha-methyl-thiobutyrolactone; AC1L2TRI; CHEBI:35058; C13720; 2(3H)-Thiophenone, 3-ethyldihydro-3-methyl-; CHEMBL34197; GTPL2363
DMULXO3	DT	Small molecular drug
DMULXO3	PC	128423
DMULXO3	MW	144.24
DMULXO3	FM	C7H12OS
DMULXO3	IC	InChI=1S/C7H12OS/c1-3-7(2)4-5-9-6(7)8/h3-5H2,1-2H3
DMULXO3	CS	CCC1(CCSC1=O)C
DMULXO3	IK	PSYRIJIIQVMBLR-UHFFFAOYSA-N
DMULXO3	IU	3-ethyl-3-methylthiolan-2-one
DMULXO3	CA	CAS 103620-92-4
DMULXO3	CB	CHEBI:35058
DMULXO3	DE	Discovery agent

DMMPOEK	ID	DMMPOEK
DMMPOEK	DN	alpha-ergocryptine
DMMPOEK	HS	Investigative
DMMPOEK	SN	Ergocryptine; alpha-Ergocryptine; Ergocryptine-alpha; 511-09-1; UNII-6WFB60157B; alpha-Ergokryptine; NSC 169479; CHEMBL1403281; CHEBI:10276; YDOTUXAWKBPQJW-NSLWYYNWSA-N; 12'-Hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione; 6WFB60157B; EINECS 208-121-2; 12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)ergotaman-3',6',18-trione; 12'-hydroxy-5'alpha-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman; BRN 0078810; 12'-Hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotaman-3',6',18-trione
DMMPOEK	DT	Small molecular drug
DMMPOEK	PC	134551
DMMPOEK	MW	575.7
DMMPOEK	FM	C32H41N5O5
DMMPOEK	IC	InChI=1S/C32H41N5O5/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20/h6,8-9,13,15,17-18,20,24-26,33,41H,7,10-12,14,16H2,1-5H3,(H,34,38)/t20-,24-,25+,26+,31-,32+/m1/s1
DMMPOEK	CS	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O
DMMPOEK	IK	YDOTUXAWKBPQJW-NSLWYYNWSA-N
DMMPOEK	IU	(6aR,9R)-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMMPOEK	CA	CAS 511-09-1
DMMPOEK	CB	CHEBI:10276
DMMPOEK	DE	Discovery agent

DMYSCQU	ID	DMYSCQU
DMYSCQU	DN	Alpha-eudesmol
DMYSCQU	HS	Investigative
DMYSCQU	SN	.alpha.-Eudesmol; 2-Naphthalenemethanol, 1,2,3,4,4a,5,6,8a-octahydro-.alpha.,.alpha.,4a,8-tetramethyl-, [2R-(2.alpha.,4a.alpha.,8a.beta.)]-; AC1NSVC3; SCHEMBL17962962; FCSRUSQUAVXUKK-ILWWEHDPSA-N; 2-(4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydro-2-naphthalenyl)-2-propanol #
DMYSCQU	DT	Small molecular drug
DMYSCQU	PC	92762
DMYSCQU	MW	222.37
DMYSCQU	FM	C15H26O
DMYSCQU	IC	InChI=1S/C15H26O/c1-11-6-5-8-15(4)9-7-12(10-13(11)15)14(2,3)16/h6,12-13,16H,5,7-10H2,1-4H3/t12-,13+,15-/m1/s1
DMYSCQU	CS	CC1=CCC[C@]2([C@H]1C[C@@H](CC2)C(C)(C)O)C
DMYSCQU	IK	FCSRUSQUAVXUKK-VNHYZAJKSA-N
DMYSCQU	IU	2-[(2R,4aR,8aR)-4a,8-dimethyl-2,3,4,5,6,8a-hexahydro-1H-naphthalen-2-yl]propan-2-ol
DMYSCQU	CA	CAS 473-16-5
DMYSCQU	CB	CHEBI:10278
DMYSCQU	DE	Discovery agent

DM4GLZU	ID	DM4GLZU
DM4GLZU	DN	alpha-fluoromethylenephosphonate
DM4GLZU	HS	Investigative
DM4GLZU	SN	alpha-fluoromethylenephosphonate; GTPL2915; CHEMBL190717; [(3S)-1-fluoro-3-methoxy-4-[(9E)-octadec-9-enoyloxy]butyl]phosphonic acid
DM4GLZU	DT	Small molecular drug
DM4GLZU	PC	44400349
DM4GLZU	MW	466.6
DM4GLZU	FM	C23H44FO6P
DM4GLZU	IC	InChI=1S/C23H44FO6P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(25)30-20-21(29-2)19-22(24)31(26,27)28/h10-11,21-22H,3-9,12-20H2,1-2H3,(H2,26,27,28)/b11-10+/t21-,22?/m0/s1
DM4GLZU	CS	CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H](CC(F)P(=O)(O)O)OC
DM4GLZU	IK	KGVHPTQYUKZZPY-VXECIVMWSA-N
DM4GLZU	IU	[(3S)-1-fluoro-3-methoxy-4-[(E)-octadec-9-enoyl]oxybutyl]phosphonic acid
DM4GLZU	DE	Discovery agent

DMT17H0	ID	DMT17H0
DMT17H0	DN	Alpha-Homonojirimycin
DMT17H0	HS	Investigative
DMT17H0	SN	alpha-Homonojirimycin; Homonojirimycin; 119557-99-2; a-Homonojirimycin; alpha-Homoallonojirimycin; (2r,3r,5s,6r)-2,6-bis(hydroxymethyl)piperidine-3,4,5-triol; CHEMBL501355; CHEMBL2111688; Hnj cpd; .alpha.-Homonojirimycin; 2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol; AC1Q59RO; AC1L4LY0; 3,4,5-Piperidinetriol,2,6-bis(hydroxymethyl)-, (2R,3R,5S,6R)-; SCHEMBL2265531; SCHEMBL1469250; SCHEMBL2265529; BDBM18366; CTK4B1372; CLVUFWXGNIFGNC-OVHBTUCOSA-N; CLVUFWXGNIFGNC-QTSLKERKSA-N; alpha-homonojirimycin (alpha-HNJ); BDBM50259956
DMT17H0	DT	Small molecular drug
DMT17H0	PC	159496
DMT17H0	MW	193.2
DMT17H0	FM	C7H15NO5
DMT17H0	IC	InChI=1S/C7H15NO5/c9-1-3-5(11)7(13)6(12)4(2-10)8-3/h3-13H,1-2H2/t3-,4-,5-,6+,7?/m1/s1
DMT17H0	CS	C([C@@H]1[C@H](C([C@H]([C@H](N1)CO)O)O)O)O
DMT17H0	IK	CLVUFWXGNIFGNC-QTSLKERKSA-N
DMT17H0	IU	(2R,3S,5R,6R)-2,6-bis(hydroxymethyl)piperidine-3,4,5-triol
DMT17H0	CA	CAS 119557-99-2
DMT17H0	DE	Discovery agent

DMIH38V	ID	DMIH38V
DMIH38V	DN	ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID
DMIH38V	HS	Investigative
DMIH38V	SN	alpha-hydroxyfarnesylphosphonic acid; HFPA; MONZTFSZTWQCKH-IJFRVEDASA-N; 140633-12-1; 148796-53-6; alpha-Hydroxyfarnesylphosphonic aicd; alpha-hydroxy Farnesyl Phosphonic Acid; AC1NS45W; C15H27O4P; MolPort-003-941-743; HMS3649I13; 1609AH; .alpha.-hydroxy Farnesyl Phosphonic Acid; RT-011376; C-28812; SR-01000946574; J-008515; SR-01000946574-1; L-704272; 1-Hydroxy-3,7,11-trimethyl-2E,6E,10-dodecatriene-1-phosphonic acid; [1-Hydroxy-(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]phosphonic acid
DMIH38V	DT	Small molecular drug
DMIH38V	PC	5353399
DMIH38V	MW	302.35
DMIH38V	FM	C15H27O4P
DMIH38V	IC	InChI=1S/C15H27O4P/c1-12(2)7-5-8-13(3)9-6-10-14(4)11-15(16)20(17,18)19/h7,9,11,15-16H,5-6,8,10H2,1-4H3,(H2,17,18,19)/b13-9+,14-11+
DMIH38V	CS	CC(=CCC/C(=C/CC/C(=C/C(O)P(=O)(O)O)/C)/C)C
DMIH38V	IK	MONZTFSZTWQCKH-IJFRVEDASA-N
DMIH38V	IU	[(2E,6E)-1-hydroxy-3,7,11-trimethyldodeca-2,6,10-trienyl]phosphonic acid
DMIH38V	CA	CAS 148796-53-6
DMIH38V	DE	Discovery agent

DMAQBKX	ID	DMAQBKX
DMAQBKX	DN	Alpha-Hydroxy-Midazolam
DMAQBKX	HS	Investigative
DMAQBKX	SN	1'-hydroxymidazolam; 1-Hydroxymidazolam; alpha-Hydroxymidazolam; 1-Hydroxymethylmidazolam; 59468-90-5; UNII-E5142BN92Z; ALPHA-HYDROXY-MIDAZOLAM; CHEMBL1188; QHSMEGADRFZVNE-UHFFFAOYSA-N; E5142BN92Z; C18H13ClFN3O; 1-OH-Mdz; 8-Chloro-6-(2-fluorophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-1-methanol; [8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methanol; 8-Chloro-6-(2-fluorophenyl)-4H-imidazo(1,5-a)(1,4)benzodiazepine-1-methanol; 1'-Hydroxy Midazolam; AC1L32ZB; SCHEMBL7310758; DTXSID50208175
DMAQBKX	DT	Small molecular drug
DMAQBKX	PC	107917
DMAQBKX	MW	341.8
DMAQBKX	FM	C18H13ClFN3O
DMAQBKX	IC	InChI=1S/C18H13ClFN3O/c19-11-5-6-16-14(7-11)18(13-3-1-2-4-15(13)20)22-9-12-8-21-17(10-24)23(12)16/h1-8,24H,9-10H2
DMAQBKX	CS	C1C2=CN=C(N2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4F)CO
DMAQBKX	IK	QHSMEGADRFZVNE-UHFFFAOYSA-N
DMAQBKX	IU	[8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methanol
DMAQBKX	CA	CAS 59468-90-5
DMAQBKX	CB	CHEBI:145330
DMAQBKX	DE	Discovery agent

DM5LFYN	ID	DM5LFYN
DM5LFYN	DN	Alpha-ketoglutaric acid
DM5LFYN	HS	Investigative
DM5LFYN	SN	2-ketoglutarate; 2-oxoglutarate; alpha-ketoglutarate; 2-ketoglutaric acid; oxoglutarate
DM5LFYN	DT	Small molecular drug
DM5LFYN	PC	51
DM5LFYN	MW	146.1
DM5LFYN	FM	C5H6O5
DM5LFYN	IC	InChI=1S/C5H6O5/c6-3(5(9)10)1-2-4(7)8/h1-2H2,(H,7,8)(H,9,10)
DM5LFYN	CS	C(CC(=O)O)C(=O)C(=O)O
DM5LFYN	IK	KPGXRSRHYNQIFN-UHFFFAOYSA-N
DM5LFYN	IU	2-oxopentanedioic acid
DM5LFYN	CA	CAS 328-50-7
DM5LFYN	CB	CHEBI:30915
DM5LFYN	DE	Discovery agent

DMBZTS5	ID	DMBZTS5
DMBZTS5	DN	Alpha-ketoisovalerate
DMBZTS5	HS	Investigative
DMBZTS5	SN	3-Methyl-2-oxobutanoic acid; 759-05-7; 3-methyl-2-oxo-butanoic acid; alpha-Ketoisovalerate; alpha-Ketoisovaleric acid; 2-Ketoisovaleric acid; alpha-ketovaline; 2-oxoisovalerate; 3-Methyl-2-oxobutyric acid; Butanoic acid, 3-methyl-2-oxo-; 2-Oxoisovaleric acid; 2-ketovaline; 3-methyl-2-oxobutanoate; 2-keto-3-methylbutyric acid; 2-oxo-3-methylbutanoate; 2-oxoisopentanoate; alpha-oxoisovalerate; Dimethylpyruvic acid; a-ketoisovaleric acid; KETOVALINE; Isopropylglyoxylic acid; alpha-keto-isovaleric acid; 2-Oxo-3-methylbutanoic acid
DMBZTS5	DT	Small molecular drug
DMBZTS5	PC	49
DMBZTS5	MW	116.11
DMBZTS5	FM	C5H8O3
DMBZTS5	IC	InChI=1S/C5H8O3/c1-3(2)4(6)5(7)8/h3H,1-2H3,(H,7,8)
DMBZTS5	CS	CC(C)C(=O)C(=O)O
DMBZTS5	IK	QHKABHOOEWYVLI-UHFFFAOYSA-N
DMBZTS5	IU	3-methyl-2-oxobutanoic acid
DMBZTS5	CA	CAS 759-05-7
DMBZTS5	CB	CHEBI:16530
DMBZTS5	DE	Discovery agent

DM2I564	ID	DM2I564
DM2I564	DN	Alpha-l-arabinose
DM2I564	HS	Investigative
DM2I564	SN	Arabinopyranose, alpha-L-; Arabinose l-form; SCHEMBL112371; SRBFZHDQGSBBOR-QMKXCQHVSA-N; UO2PIV2K4C; ZINC1532575; alpha-L-Arabinose; alpha-L-arabinopyranose; 6abp; 7296-55-1; C02604; CHEBI:46987; CHEMBL505348; CTK5D7165; UNII-UO2PIV2K4C
DM2I564	PC	439731
DM2I564	MW	150.13
DM2I564	FM	C5H10O5
DM2I564	IC	SRBFZHDQGSBBOR-QMKXCQHVSA-N
DM2I564	CS	C1C(C(C(C(O1)O)O)O)O
DM2I564	IK	1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3-,4+,5+/m0/s1
DM2I564	IU	(2R,3R,4S,5S)-oxane-2,3,4,5-tetrol
DM2I564	CA	CAS 7296-55-1
DM2I564	CB	CHEBI:46987
DM2I564	DE	Discovery agent

DMY64HE	ID	DMY64HE
DMY64HE	DN	Alpha-linolenic acid
DMY64HE	HS	Investigative
DMY64HE	SN	Linolenic acid; linolenic acid; alpha-Linolenic acid; 463-40-1; linolenate; (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid; a-Linolenic acid; cis,cis,cis-9,12,15-Octadecatrienoic acid; all-cis-9,12,15-Octadecatrienoic acid; alpha-Linolenate; 9-cis,12-cis,15-cis-Octadecatrienoic acid; (Z,Z,Z)-9,12,15-Octadecatrienoic acid; Linolenic acid (8CI); 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-; (9,12,15)-linolenic acid; alpha-Lnn; 9Z,12Z,15Z-Octadecatrienoic acid; Industrene 120; CCRIS 656; UNII-0RBV727H71; (9Z,12Z,15Z)-Octadecatrienoic acid;  linolenate; alpha-LA; C18:3; LINOLENIC ACID
DMY64HE	DT	Small molecular drug
DMY64HE	PC	5280934
DMY64HE	MW	278.4
DMY64HE	FM	C18H30O2
DMY64HE	IC	InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-
DMY64HE	CS	CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O
DMY64HE	IK	DTOSIQBPPRVQHS-PDBXOOCHSA-N
DMY64HE	IU	(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid
DMY64HE	CA	CAS 463-40-1
DMY64HE	CB	CHEBI:27432
DMY64HE	DE	Discovery agent

DMCAYXF	ID	DMCAYXF
DMCAYXF	DN	alpha-methyl-5-HT
DMCAYXF	HS	Investigative
DMCAYXF	SN	alpha-Me-5-HT; alpha-methylserotonin
DMCAYXF	DT	Small molecular drug
DMCAYXF	PC	2107
DMCAYXF	MW	190.24
DMCAYXF	FM	C11H14N2O
DMCAYXF	IC	InChI=1S/C11H14N2O/c1-7(12)4-8-6-13-11-3-2-9(14)5-10(8)11/h2-3,5-7,13-14H,4,12H2,1H3
DMCAYXF	CS	CC(CC1=CNC2=C1C=C(C=C2)O)N
DMCAYXF	IK	LYPCGXKCQDYTFV-UHFFFAOYSA-N
DMCAYXF	IU	3-(2-aminopropyl)-1H-indol-5-ol
DMCAYXF	CA	CAS 304-52-9
DMCAYXF	CB	CHEBI:48295
DMCAYXF	DE	Discovery agent

DM7DBTZ	ID	DM7DBTZ
DM7DBTZ	DN	Alpha-methylalanyl-L-proline butylamide
DM7DBTZ	HS	Investigative
DM7DBTZ	SN	CHEMBL388062; alpha-methylalanyl-L-proline butylamide
DM7DBTZ	DT	Small molecular drug
DM7DBTZ	PC	11658913
DM7DBTZ	MW	255.36
DM7DBTZ	FM	C13H25N3O2
DM7DBTZ	IC	InChI=1S/C13H25N3O2/c1-4-5-8-15-11(17)10-7-6-9-16(10)12(18)13(2,3)14/h10H,4-9,14H2,1-3H3,(H,15,17)/t10-/m0/s1
DM7DBTZ	CS	CCCCNC(=O)[C@@H]1CCCN1C(=O)C(C)(C)N
DM7DBTZ	IK	XPMXVLRTYROPLL-JTQLQIEISA-N
DM7DBTZ	IU	(2S)-1-(2-amino-2-methylpropanoyl)-N-butylpyrrolidine-2-carboxamide
DM7DBTZ	DE	Discovery agent

DM892JF	ID	DM892JF
DM892JF	DN	Alpha-methyl-alpha-phenylsuccinimide (MPS)
DM892JF	HS	Investigative
DM892JF	SN	2-Methyl-2-phenylsuccinimide; 1497-17-2; 3-methyl-3-phenylpyrrolidine-2,5-dione; alpha-Methyl-alpha-phenylsuccinimide; N-Desmethylmethsuximide; Normesuximide; 2,5-Pyrrolidinedione, 3-methyl-3-phenyl-; a-methyl-a-phenylsuccinimide; N-Demethylmethsuximide; UDESUGJZUFALAM-UHFFFAOYSA-N; 3-Methyl-3-phenyl-2,5-pyrrolidinedione; .alpha.-Methyl-.alpha.-phenylsuccinimide; Normethsuximide; N-Normethsuximide; Desmethylmethsuximide; EINECS 216-091-7; Mesuximide, M(nor-); AC1Q6LV6; AC1L3NJ7; SCHEMBL1568276; UDESUGJZUFALAM-UHFFFAOYSA-
DM892JF	DT	Small molecular drug
DM892JF	PC	92154
DM892JF	MW	189.21
DM892JF	FM	C11H11NO2
DM892JF	IC	InChI=1S/C11H11NO2/c1-11(7-9(13)12-10(11)14)8-5-3-2-4-6-8/h2-6H,7H2,1H3,(H,12,13,14)
DM892JF	CS	CC1(CC(=O)NC1=O)C2=CC=CC=C2
DM892JF	IK	UDESUGJZUFALAM-UHFFFAOYSA-N
DM892JF	IU	3-methyl-3-phenylpyrrolidine-2,5-dione
DM892JF	CA	CAS 1497-17-2
DM892JF	DE	Discovery agent

DM0C4GP	ID	DM0C4GP
DM0C4GP	DN	Alpha-methylcubebin
DM0C4GP	HS	Investigative
DM0C4GP	SN	alpha-methylcubebin; CHEMBL520915
DM0C4GP	DT	Small molecular drug
DM0C4GP	PC	44575384
DM0C4GP	MW	370.4
DM0C4GP	FM	C21H22O6
DM0C4GP	IC	InChI=1S/C21H22O6/c1-22-21-16(7-14-3-5-18-20(9-14)27-12-25-18)15(10-23-21)6-13-2-4-17-19(8-13)26-11-24-17/h2-5,8-9,15-16,21H,6-7,10-12H2,1H3/t15-,16+,21+/m0/s1
DM0C4GP	CS	CO[C@H]1[C@@H]([C@H](CO1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5
DM0C4GP	IK	UUUXPUGZNDRYSV-GCKMJXCFSA-N
DM0C4GP	IU	5-[[(2R,3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-2-methoxyoxolan-3-yl]methyl]-1,3-benzodioxole
DM0C4GP	DE	Discovery agent

DM3YGWL	ID	DM3YGWL
DM3YGWL	DN	Alpha-Methylisocitric Acid
DM3YGWL	HS	Investigative
DM3YGWL	SN	alpha-methylisocitric acid; methylisocitrate; 71183-66-9; (2S,3R)-3-hydroxybutane-1,2,3-tricarboxylic acid; Methylisocitric acid; (2S,3R)-3-Hydroxybutane-1,2,3-tricarboxylate; AC1NUSCP; SCHEMBL1533821; CHEBI:15607; ZINC902108; LMFA01050444; AKOS030526883; DB04072; HY-16581; C04593; 3-carboxy-2,3-dideoxy-4-C-methyl-L-threo-pentaric acid; UNII-8518EC1Z2E component HHKPKXCSHMJWCF-WVBDSBKLSA-N; UNII-ZC5YS92LCE component HHKPKXCSHMJWCF-WVBDSBKLSA-N
DM3YGWL	DT	Small molecular drug
DM3YGWL	PC	5459784
DM3YGWL	MW	206.15
DM3YGWL	FM	C7H10O7
DM3YGWL	IC	InChI=1S/C7H10O7/c1-7(14,6(12)13)3(5(10)11)2-4(8)9/h3,14H,2H2,1H3,(H,8,9)(H,10,11)(H,12,13)/t3-,7-/m1/s1
DM3YGWL	CS	C[C@@]([C@H](CC(=O)O)C(=O)O)(C(=O)O)O
DM3YGWL	IK	HHKPKXCSHMJWCF-WVBDSBKLSA-N
DM3YGWL	IU	(2S,3R)-3-hydroxybutane-1,2,3-tricarboxylic acid
DM3YGWL	CA	CAS 71183-66-9
DM3YGWL	CB	CHEBI:15607
DM3YGWL	DE	Discovery agent

DMAUH96	ID	DMAUH96
DMAUH96	DN	alpha-methylphenylalanine
DMAUH96	HS	Investigative
DMAUH96	SN	alpha-Methyl-DL-phenylalanine; 1132-26-9; 2-amino-2-methyl-3-phenylpropanoic acid; 2-Amino-2-methyl-3-phenylpropionic acid; alpha-Methylphenylalanine; H--Me-DL-Phe-OH; HYOWVAAEQCNGLE-UHFFFAOYSA-N; alpha-Methyl-DL-phenylalanine, 98%; MFCD00010512; Phenylalanine, alpha-methyl-; 2-amino-2-methyl-3-phenyl-propanoic acid; 2-Methylphenylalanine #; D,L-Phe(alphaMe)-OH; a-methyl-dl-phenylalanine; alpha-me-dl-phenylalanine; Methylphenylalanine, alpha; H-DL-(ME)PHE-OH; dl-alpha-methylphenylalanine; ACMC-1AH59
DMAUH96	DT	Small molecular drug
DMAUH96	PC	108055
DMAUH96	MW	179.22
DMAUH96	FM	C10H13NO2
DMAUH96	IC	InChI=1S/C10H13NO2/c1-10(11,9(12)13)7-8-5-3-2-4-6-8/h2-6H,7,11H2,1H3,(H,12,13)
DMAUH96	CS	CC(CC1=CC=CC=C1)(C(=O)O)N
DMAUH96	IK	HYOWVAAEQCNGLE-UHFFFAOYSA-N
DMAUH96	IU	2-amino-2-methyl-3-phenylpropanoic acid
DMAUH96	CA	CAS 1132-26-9
DMAUH96	DE	Discovery agent

DMCIH1X	ID	DMCIH1X
DMCIH1X	DN	alpha-methylserine-O-phosphate
DMCIH1X	HS	Investigative
DMCIH1X	SN	alpha-MSOP
DMCIH1X	DT	Small molecular drug
DMCIH1X	PC	3964633
DMCIH1X	MW	199.1
DMCIH1X	FM	C4H10NO6P
DMCIH1X	IC	InChI=1S/C4H10NO6P/c1-4(5,3(6)7)2-11-12(8,9)10/h2,5H2,1H3,(H,6,7)(H2,8,9,10)
DMCIH1X	CS	CC(COP(=O)(O)O)(C(=O)O)N
DMCIH1X	IK	GSFCOAGADOGIGE-UHFFFAOYSA-N
DMCIH1X	IU	2-amino-2-methyl-3-phosphonooxypropanoic acid
DMCIH1X	CA	CAS 66515-29-5
DMCIH1X	DE	Discovery agent

DML7SU3	ID	DML7SU3
DML7SU3	DN	Alpha-monofluoromethyl-3,4-dehydroornithine
DML7SU3	HS	Investigative
DML7SU3	DE	Discovery agent

DMJTGZV	ID	DMJTGZV
DMJTGZV	DN	Alpha-monofluoromethyl-3,4-dehydroornithine ethyl ester
DMJTGZV	HS	Investigative
DMJTGZV	SN	Mdl-72430; 2-(Fluoromethyl)dehydroornithine ethyl ester; AC1O5Q9S; SCHEMBL10981099; 97501-15-0; ethyl (E)-2,5-diamino-2-(fluoromethyl)pent-3-enoate; 3-Pentenoic acid, 2,5-diamino-2-(fluoromethyl)-, ethyl ester
DMJTGZV	DT	Small molecular drug
DMJTGZV	PC	6438751
DMJTGZV	MW	190.22
DMJTGZV	FM	C8H15FN2O2
DMJTGZV	IC	InChI=1S/C8H15FN2O2/c1-2-13-7(12)8(11,6-9)4-3-5-10/h3-4H,2,5-6,10-11H2,1H3/b4-3+
DMJTGZV	CS	CCOC(=O)C(CF)(/C=C/CN)N
DMJTGZV	IK	RQVGWIPBGFYUQU-ONEGZZNKSA-N
DMJTGZV	IU	ethyl (E)-2,5-diamino-2-(fluoromethyl)pent-3-enoate
DMJTGZV	CA	CAS 97501-15-0
DMJTGZV	DE	Discovery agent

DMGI9SM	ID	DMGI9SM
DMGI9SM	DN	Alpha-monofluoromethyl-3,4-dehydroornithine methyl ester
DMGI9SM	HS	Investigative
DMGI9SM	SN	MFMOme; Methyl, 2-fluoromethyl-2,5-diamino-3-pentenoate; Mdl-72403; methyl (E)-2,5-diamino-2-(fluoromethyl)pent-3-enoate; 2-(Fluoromethyl)dehydroornithine methyl ester; 107742-04-1; AC1O5Q3S; SCHEMBL6361254; 2,5-Diamino-2-(fluoromethyl)-3-pentenoic acid methyl ester; 96681-91-3; .alpha.-monofluoromethyldehydroornithine methyl ester; 3-Pentenoic acid, 2,5-diamino-2-(fluoromethyl)-, methyl ester
DMGI9SM	DT	Small molecular drug
DMGI9SM	PC	6438668
DMGI9SM	MW	176.19
DMGI9SM	FM	C7H13FN2O2
DMGI9SM	IC	InChI=1S/C7H13FN2O2/c1-12-6(11)7(10,5-8)3-2-4-9/h2-3H,4-5,9-10H2,1H3/b3-2+
DMGI9SM	CS	COC(=O)C(CF)(/C=C/CN)N
DMGI9SM	IK	KIQXCFBLXGRXPY-NSCUHMNNSA-N
DMGI9SM	IU	methyl (E)-2,5-diamino-2-(fluoromethyl)pent-3-enoate
DMGI9SM	CA	CAS 96681-91-3
DMGI9SM	DE	Discovery agent

DMELOIQ	ID	DMELOIQ
DMELOIQ	DN	Alpha-naphthoflavone
DMELOIQ	HS	Investigative
DMELOIQ	SN	7,8-Benzoflavone; alpha-Naphthoflavone; 604-59-1; 2-Phenyl-4H-benzo[h]chromen-4-one; alpha-Naphthylflavone; 2-phenylbenzo[h]chromen-4-one; Benzo(h)flavone; 7,8-BF; 4H-Naphtho[1,2-b]pyran-4-one, 2-phenyl-; .alpha.-Naphthoflavone; 2-Phenyl-benzo[h]chromen-4-one; 2-Phenyl-4H-naphtho(1,2-b)pyran-4-one; CCRIS 3607; 2-Phenylbenzo(h)chromen-4-one; EINECS 210-071-1; UNII-FML65D8PY5; NSC 407011; BRN 0210862; FML65D8PY5; benzo[h]flavone; MLS003171601; CHEMBL283196; CHEBI:76995; VFMMPHCGEFXGIP-UHFFFAOYSA-N; 4H-NAPHTHO(1,2-b)PYRAN-4-ONE, 2-PH
DMELOIQ	DT	Small molecular drug
DMELOIQ	PC	11790
DMELOIQ	MW	272.3
DMELOIQ	FM	C19H12O2
DMELOIQ	IC	InChI=1S/C19H12O2/c20-17-12-18(14-7-2-1-3-8-14)21-19-15-9-5-4-6-13(15)10-11-16(17)19/h1-12H
DMELOIQ	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMELOIQ	IK	VFMMPHCGEFXGIP-UHFFFAOYSA-N
DMELOIQ	IU	2-phenylbenzo[h]chromen-4-one
DMELOIQ	CA	CAS 604-59-1
DMELOIQ	CB	CHEBI:76995
DMELOIQ	DE	Discovery agent

DM0KXN4	ID	DM0KXN4
DM0KXN4	DN	Alpha-oxoadipic acid
DM0KXN4	HS	Investigative
DM0KXN4	SN	alpha-ketoadipic acid; 2-ketoadipate; 2-oxoadipate
DM0KXN4	DT	Small molecular drug
DM0KXN4	PC	71
DM0KXN4	MW	160.12
DM0KXN4	FM	C6H8O5
DM0KXN4	IC	InChI=1S/C6H8O5/c7-4(6(10)11)2-1-3-5(8)9/h1-3H2,(H,8,9)(H,10,11)
DM0KXN4	CS	C(CC(=O)C(=O)O)CC(=O)O
DM0KXN4	IK	FGSBNBBHOZHUBO-UHFFFAOYSA-N
DM0KXN4	IU	2-oxohexanedioic acid
DM0KXN4	CA	CAS 3184-35-8
DM0KXN4	CB	CHEBI:15753
DM0KXN4	DE	Discovery agent

DMT6KI7	ID	DMT6KI7
DMT6KI7	DN	Alpha-Phosphoribosylpyrophosphoric Acid
DMT6KI7	HS	Investigative
DMT6KI7	SN	PRPP; PHOSPHORIBOSYL PYROPHOSPHATE; 5-Phospho-alpha-D-ribose 1-diphosphate; 5-Phosphoribosyl diphosphate; PRib-PP; 7540-64-9; phosphoribosylpyrophosphate; 5-Phosphoribosyl 1-pyrophosphate; Ribofuranose, 5-phosphate 1-pyrophosphate; PQGCEDQWHSBAJP-TXICZTDVSA-N; 5-Phosphorylribose 1-pyrophosphate; alpha-D-Ribofuranose 5-(dihydrogen phosphate) 1-(trihydrogen diphosphate); 13270-65-0; 5-PHOSPHORYLRIBOSE-1-PYROPHOSPHATE; 5-phosphoribosyl-1-pyrophosphate
DMT6KI7	DT	Small molecular drug
DMT6KI7	PC	7339
DMT6KI7	MW	390.07
DMT6KI7	FM	C5H13O14P3
DMT6KI7	IC	InChI=1S/C5H13O14P3/c6-3-2(1-16-20(8,9)10)17-5(4(3)7)18-22(14,15)19-21(11,12)13/h2-7H,1H2,(H,14,15)(H2,8,9,10)(H2,11,12,13)/t2-,3-,4-,5-/m1/s1
DMT6KI7	CS	C([C@@H]1[C@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)O)O)O)OP(=O)(O)O
DMT6KI7	IK	PQGCEDQWHSBAJP-TXICZTDVSA-N
DMT6KI7	IU	[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl] phosphono hydrogen phosphate
DMT6KI7	CA	CAS 7540-64-9
DMT6KI7	CB	CHEBI:17111
DMT6KI7	DE	Discovery agent

DMQKMX3	ID	DMQKMX3
DMQKMX3	DN	alpha-propyldopacetamide
DMQKMX3	HS	Investigative
DMQKMX3	SN	alpha-Propyldopacetamide; 2-(3,4-Dihydroxyphenyl)pentanamide; 154-62-1; a-propyldopacetamide; Dihydroxyphenylvaleramide; EINECS 205-830-9; Benzeneacetamide,3,4-dihydroxy-a-propyl-,(aR)-; Benzeneacetamide,3,4-dihydroxy-a-propyl-,(aS)-; .alpha.-Propyldopacetamide; ACMC-20mn67; ACMC-20mn66; AC1Q5IT3; AC1L2R8E; GTPL5095; CTK8G6411; GDXQWRJYXZXWMT-UHFFFAOYSA-N; MolPort-003-894-618; KUC106729N; 2-(3,4-Dihydroxyphenyl)valeramide; AKOS024285098; a-propyl-3,4-dihydroxyphenyl-acetamide; MCULE-1302132273
DMQKMX3	DT	Small molecular drug
DMQKMX3	PC	101635
DMQKMX3	MW	209.24
DMQKMX3	FM	C11H15NO3
DMQKMX3	IC	InChI=1S/C11H15NO3/c1-2-3-8(11(12)15)7-4-5-9(13)10(14)6-7/h4-6,8,13-14H,2-3H2,1H3,(H2,12,15)
DMQKMX3	CS	CCCC(C1=CC(=C(C=C1)O)O)C(=O)N
DMQKMX3	IK	GDXQWRJYXZXWMT-UHFFFAOYSA-N
DMQKMX3	IU	2-(3,4-dihydroxyphenyl)pentanamide
DMQKMX3	CA	CAS 154-62-1
DMQKMX3	DE	Discovery agent

DMWL172	ID	DMWL172
DMWL172	DN	Alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid
DMWL172	HS	Investigative
DMWL172	SN	alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid
DMWL172	DT	Small molecular drug
DMWL172	PC	46855771
DMWL172	MW	273.07
DMWL172	FM	C7H7Cl2O3PS
DMWL172	IC	InChI=1S/C7H7Cl2O3PS/c8-4-1-2-5(6(9)3-4)7(14)13(10,11)12/h1-3,7,14H,(H2,10,11,12)
DMWL172	CS	C1=CC(=C(C=C1Cl)Cl)C(P(=O)(O)O)S
DMWL172	IK	WJVBVZOYOCLGPI-UHFFFAOYSA-N
DMWL172	IU	[(2,4-dichlorophenyl)-sulfanylmethyl]phosphonic acid
DMWL172	DE	Discovery agent

DM42M6I	ID	DM42M6I
DM42M6I	DN	Alpha-Sulfanyl(2-methoxybenzyl)phosphonic acid
DM42M6I	HS	Investigative
DM42M6I	DT	Small molecular drug
DM42M6I	PC	46855772
DM42M6I	MW	234.21
DM42M6I	FM	C8H11O4PS
DM42M6I	IC	InChI=1S/C8H11O4PS/c1-12-7-5-3-2-4-6(7)8(14)13(9,10)11/h2-5,8,14H,1H3,(H2,9,10,11)
DM42M6I	CS	COC1=CC=CC=C1C(P(=O)(O)O)S
DM42M6I	IK	QXHIPTMANGQMPP-UHFFFAOYSA-N
DM42M6I	IU	[(2-methoxyphenyl)-sulfanylmethyl]phosphonic acid
DM42M6I	DE	Discovery agent

DMRIWDV	ID	DMRIWDV
DMRIWDV	DN	Alpha-Sulfanyl(4-bromobenzyl)phosphonic acid
DMRIWDV	HS	Investigative
DMRIWDV	DT	Small molecular drug
DMRIWDV	PC	46855773
DMRIWDV	MW	283.08
DMRIWDV	FM	C7H8BrO3PS
DMRIWDV	IC	InChI=1S/C7H8BrO3PS/c8-6-3-1-5(2-4-6)7(13)12(9,10)11/h1-4,7,13H,(H2,9,10,11)
DMRIWDV	CS	C1=CC(=CC=C1C(P(=O)(O)O)S)Br
DMRIWDV	IK	UIINFAMEMQXUIX-UHFFFAOYSA-N
DMRIWDV	IU	[(4-bromophenyl)-sulfanylmethyl]phosphonic acid
DMRIWDV	DE	Discovery agent

DMP6GXU	ID	DMP6GXU
DMP6GXU	DN	Alpha-Sulfanyl(4-chlorobenzyl)phosphonic acid
DMP6GXU	HS	Investigative
DMP6GXU	DT	Small molecular drug
DMP6GXU	PC	46855774
DMP6GXU	MW	238.63
DMP6GXU	FM	C7H8ClO3PS
DMP6GXU	IC	InChI=1S/C7H8ClO3PS/c8-6-3-1-5(2-4-6)7(13)12(9,10)11/h1-4,7,13H,(H2,9,10,11)
DMP6GXU	CS	C1=CC(=CC=C1C(P(=O)(O)O)S)Cl
DMP6GXU	IK	AVCBLMMQVNLVBY-UHFFFAOYSA-N
DMP6GXU	IU	[(4-chlorophenyl)-sulfanylmethyl]phosphonic acid
DMP6GXU	DE	Discovery agent

DMP9V42	ID	DMP9V42
DMP9V42	DN	Alpha-Sulfanyl(4-fluorobenzyl)phosphonic acid
DMP9V42	HS	Investigative
DMP9V42	DT	Small molecular drug
DMP9V42	PC	46855775
DMP9V42	MW	222.18
DMP9V42	FM	C7H8FO3PS
DMP9V42	IC	InChI=1S/C7H8FO3PS/c8-6-3-1-5(2-4-6)7(13)12(9,10)11/h1-4,7,13H,(H2,9,10,11)
DMP9V42	CS	C1=CC(=CC=C1C(P(=O)(O)O)S)F
DMP9V42	IK	SWPCIELITKHGKY-UHFFFAOYSA-N
DMP9V42	IU	[(4-fluorophenyl)-sulfanylmethyl]phosphonic acid
DMP9V42	DE	Discovery agent

DMWB07I	ID	DMWB07I
DMWB07I	DN	Alpha-Sulfanylbenzylphosphonic acid
DMWB07I	HS	Investigative
DMWB07I	DT	Small molecular drug
DMWB07I	PC	46855909
DMWB07I	MW	204.19
DMWB07I	FM	C7H9O3PS
DMWB07I	IC	InChI=1S/C7H9O3PS/c8-11(9,10)7(12)6-4-2-1-3-5-6/h1-5,7,12H,(H2,8,9,10)
DMWB07I	CS	C1=CC=C(C=C1)C(P(=O)(O)O)S
DMWB07I	IK	FSPBPXVXCWHRHO-UHFFFAOYSA-N
DMWB07I	IU	[phenyl(sulfanyl)methyl]phosphonic acid
DMWB07I	DE	Discovery agent

DM19NAI	ID	DM19NAI
DM19NAI	DN	Alpha-Sulfanylpropylphosphonic acid
DM19NAI	HS	Investigative
DM19NAI	SN	SCHEMBL2530501
DM19NAI	DT	Small molecular drug
DM19NAI	PC	46855908
DM19NAI	MW	156.14
DM19NAI	FM	C3H9O3PS
DM19NAI	IC	InChI=1S/C3H9O3PS/c1-2-3(8)7(4,5)6/h3,8H,2H2,1H3,(H2,4,5,6)
DM19NAI	CS	CCC(P(=O)(O)O)S
DM19NAI	IK	PMCCSSODVYHTNA-UHFFFAOYSA-N
DM19NAI	IU	1-sulfanylpropylphosphonic acid
DM19NAI	DE	Discovery agent

DMDI2KH	ID	DMDI2KH
DMDI2KH	DN	alsterpaullone 2-cyanoethyl
DMDI2KH	HS	Investigative
DMDI2KH	SN	alsterpaullone derivative7
DMDI2KH	DT	Small molecular drug
DMDI2KH	PC	16760286
DMDI2KH	MW	346.3
DMDI2KH	FM	C19H14N4O3
DMDI2KH	IC	InChI=1S/C19H14N4O3/c20-7-1-2-11-3-5-17-15(8-11)19-14(10-18(24)21-17)13-9-12(23(25)26)4-6-16(13)22-19/h3-6,8-9,22H,1-2,10H2,(H,21,24)
DMDI2KH	CS	C1C2=C(C3=C(C=CC(=C3)CCC#N)NC1=O)NC4=C2C=C(C=C4)[N+](=O)[O-]
DMDI2KH	IK	UBLFSMURWWWWMH-UHFFFAOYSA-N
DMDI2KH	IU	3-(9-nitro-6-oxo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-2-yl)propanenitrile
DMDI2KH	DE	Discovery agent

DM2FLDJ	ID	DM2FLDJ
DM2FLDJ	DN	Alstiphyllanine D
DM2FLDJ	HS	Investigative
DM2FLDJ	SN	Alstiphyllanine D; CHEMBL540945
DM2FLDJ	DT	Small molecular drug
DM2FLDJ	PC	45269680
DM2FLDJ	MW	606.7
DM2FLDJ	FM	C33H38N2O9
DM2FLDJ	IC	InChI=1S/C33H38N2O9/c1-8-18-16-35-26-14-21(18)31(30(37)42-7,17-43-29(36)19-11-24(39-4)28(41-6)25(12-19)40-5)32-15-27(35)44-33(26,32)34(2)23-10-9-20(38-3)13-22(23)32/h8-13,21,26-27H,14-17H2,1-7H3/b18-8-/t21-,26-,27-,31-,32-,33-/m0/s1
DM2FLDJ	CS	C/C=C\\1/CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(N(C6=C4C=C(C=C6)OC)C)O[C@H]2C5)(COC(=O)C7=CC(=C(C(=C7)OC)OC)OC)C(=O)OC
DM2FLDJ	IK	JIGZBLWURVFVNC-MPYFAWNJSA-N
DM2FLDJ	IU	methyl (1R,9S,11S,14E,15S,17S,19R)-14-ethylidene-6-methoxy-2-methyl-19-[(3,4,5-trimethoxybenzoyl)oxymethyl]-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3(8),4,6-triene-19-carboxylate
DM2FLDJ	DE	Discovery agent

DMTNQ5E	ID	DMTNQ5E
DMTNQ5E	DN	Alstiphyllanine E
DMTNQ5E	HS	Investigative
DMTNQ5E	SN	Alstiphyllanine E; CHEMBL592477
DMTNQ5E	DT	Small molecular drug
DMTNQ5E	PC	46229071
DMTNQ5E	MW	532.6
DMTNQ5E	FM	C30H32N2O7
DMTNQ5E	IC	InChI=1S/C30H32N2O7/c1-5-17-15-32-24-13-20(17)28(27(34)37-4,16-38-26(33)18-10-11-22(35-2)23(12-18)36-3)29-14-25(32)39-30(24,29)31-21-9-7-6-8-19(21)29/h5-12,20,24-25,31H,13-16H2,1-4H3/b17-5-/t20-,24-,25-,28-,29-,30-/m0/s1
DMTNQ5E	CS	C/C=C\\1/CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(NC6=CC=CC=C64)O[C@H]2C5)(COC(=O)C7=CC(=C(C=C7)OC)OC)C(=O)OC
DMTNQ5E	IK	NPAPHJSGCRCHBM-UMLFCLJTSA-N
DMTNQ5E	IU	methyl (1R,9S,11S,14E,15S,17S,19R)-19-[(3,4-dimethoxybenzoyl)oxymethyl]-14-ethylidene-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3,5,7-triene-19-carboxylate
DMTNQ5E	DE	Discovery agent

DMKRAEW	ID	DMKRAEW
DMKRAEW	DN	Alstiphyllanine F
DMKRAEW	HS	Investigative
DMKRAEW	SN	Alstiphyllanine F; CHEMBL592521
DMKRAEW	DT	Small molecular drug
DMKRAEW	PC	46229072
DMKRAEW	MW	592.6
DMKRAEW	FM	C32H36N2O9
DMKRAEW	IC	InChI=1S/C32H36N2O9/c1-7-17-15-34-25-13-20(17)30(29(36)41-6,16-42-28(35)18-10-23(38-3)27(40-5)24(11-18)39-4)31-14-26(34)43-32(25,31)33-22-9-8-19(37-2)12-21(22)31/h7-12,20,25-26,33H,13-16H2,1-6H3/b17-7-/t20-,25-,26-,30-,31-,32-/m0/s1
DMKRAEW	CS	C/C=C\\1/CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(NC6=C4C=C(C=C6)OC)O[C@H]2C5)(COC(=O)C7=CC(=C(C(=C7)OC)OC)OC)C(=O)OC
DMKRAEW	IK	JIBNKPQBEIZZCU-DYWXBFQLSA-N
DMKRAEW	IU	methyl (1R,9S,11S,14E,15S,17S,19R)-14-ethylidene-6-methoxy-19-[(3,4,5-trimethoxybenzoyl)oxymethyl]-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3(8),4,6-triene-19-carboxylate
DMKRAEW	DE	Discovery agent

DMBGAWI	ID	DMBGAWI
DMBGAWI	DN	ALTANSERIN
DMBGAWI	HS	Investigative
DMBGAWI	SN	ALTANSERIN TARTRATE; UNII-9P204CHE8J; 79449-96-0; Altanserin tartrate [USAN]; 9P204CHE8J; Altanserin tartrate (USAN); 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one; EINECS 279-159-5; AC1Q59OU; AC1MHW43; SCHEMBL124036; DTXSID20229675; 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2-thio-2,4(1H,3H)-quinazolinedione L-(+)-tartrate (1:1); D02836; R-53,200; 4(1H)-Quinazolinone, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-2,3-dihydro-2-thioxo-, (R-(R*,R
DMBGAWI	DT	Small molecular drug
DMBGAWI	PC	3033677
DMBGAWI	MW	411.5
DMBGAWI	FM	C22H22FN3O2S
DMBGAWI	IC	InChI=1S/C22H22FN3O2S/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
DMBGAWI	CS	C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=S
DMBGAWI	IK	SMYALUSCZJXWHG-UHFFFAOYSA-N
DMBGAWI	IU	3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one
DMBGAWI	CA	CAS 76330-71-7
DMBGAWI	CB	CHEBI:2613
DMBGAWI	DE	Discovery agent

DMYCS0B	ID	DMYCS0B
DMYCS0B	DN	ALTENUSIN
DMYCS0B	HS	Investigative
DMYCS0B	SN	AC1L4N6W; AC1Q68NU; SCHEMBL16971034; 4',5'-dihydroxy-5-methoxy-2'-methylbiphenyl-2-carboperoxoic acid; ACM31186126; J-018273; 2-(4,5-dihydroxy-2-methylphenyl)-4-methoxybenzenecarboperoxoic acid
DMYCS0B	DT	Small molecular drug
DMYCS0B	PC	6918469
DMYCS0B	MW	290.27
DMYCS0B	FM	C15H14O6
DMYCS0B	IC	InChI=1S/C15H14O6/c1-7-3-11(16)12(17)6-9(7)10-4-8(21-2)5-13(18)14(10)15(19)20/h3-6,16-18H,1-2H3,(H,19,20)
DMYCS0B	CS	CC1=CC(=C(C=C1C2=C(C(=CC(=C2)OC)O)C(=O)O)O)O
DMYCS0B	IK	ADPBTBPPIIKLEH-UHFFFAOYSA-N
DMYCS0B	IU	2-(4,5-dihydroxy-2-methylphenyl)-6-hydroxy-4-methoxybenzoic acid
DMYCS0B	CA	CAS 31186-12-6
DMYCS0B	CB	CHEBI:141340
DMYCS0B	DE	Discovery agent

DMDLN9S	ID	DMDLN9S
DMDLN9S	DN	ALTU-236
DMDLN9S	HS	Investigative
DMDLN9S	CP	Altus Pharmaceuticals Inc
DMDLN9S	DE	Genetic disease

DMP26K9	ID	DMP26K9
DMP26K9	DN	Alx 1393
DMP26K9	HS	Investigative
DMP26K9	SN	O-[2-benzyloxyphenyl-3-flurophenyl]methyl-L-serine; ALX-1393; ALX1393
DMP26K9	DT	Small molecular drug
DMP26K9	PC	16078939
DMP26K9	MW	395.4
DMP26K9	FM	C23H22FNO4
DMP26K9	IC	InChI=1S/C23H22FNO4/c24-18-10-6-9-17(13-18)22(29-15-20(25)23(26)27)19-11-4-5-12-21(19)28-14-16-7-2-1-3-8-16/h1-13,20,22H,14-15,25H2,(H,26,27)/t20-,22?/m0/s1
DMP26K9	CS	C1=CC=C(C=C1)COC2=CC=CC=C2C(C3=CC(=CC=C3)F)OC[C@@H](C(=O)O)N
DMP26K9	IK	ADUSZEGHFWRTQS-AIBWNMTMSA-N
DMP26K9	IU	(2S)-2-amino-3-[(3-fluorophenyl)-(2-phenylmethoxyphenyl)methoxy]propanoic acid
DMP26K9	DE	Discovery agent

DMFVGXW	ID	DMFVGXW
DMFVGXW	DN	AM-1241
DMFVGXW	HS	Investigative
DMFVGXW	SN	444912-48-5; AM1241; AM-1241; (2-iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)methanone; ZUHIXXCLLBMBDW-UHFFFAOYSA-N; AM 1241; GTPL3316; SCHEMBL2030690; CHEMBL408430; CTK8B9184; BDBM21283; MolPort-009-019-655; HMS3651A13; HMS3650F09; MFCD11045986; (R,S)-AM1241; (1-(Methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole); ANW-62168; s1544; AKOS016004972; SB19545; CCG-208738; NCGC00165726-04; NCGC00165726-01; HY-18640; TC-150913; LS-192021; KB-206133; AX8233934; SW219858-1; CS-0011638; ST24033932; Z-3231
DMFVGXW	DT	Small molecular drug
DMFVGXW	PC	10141893
DMFVGXW	MW	503.3
DMFVGXW	FM	C22H22IN3O3
DMFVGXW	IC	InChI=1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3
DMFVGXW	CS	CN1CCCCC1CN2C=C(C3=CC=CC=C32)C(=O)C4=C(C=CC(=C4)[N+](=O)[O-])I
DMFVGXW	IK	ZUHIXXCLLBMBDW-UHFFFAOYSA-N
DMFVGXW	IU	(2-iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone
DMFVGXW	CA	CAS 444912-48-5
DMFVGXW	DE	Discovery agent

DMGCOQF	ID	DMGCOQF
DMGCOQF	DN	AM-156
DMGCOQF	HS	Investigative
DMGCOQF	SN	AM-206; AM-432; CRTH2 receptor antagonists (oral, allergic rhinitis); CRTH2 receptor antagonists (oral, allergic rhinitis), Amira Pharmaceuticals; CRTH2 antagonists (COPD/asthma/allergic rhinitis), Amira; DP2 antagonists (COPD/asthma/allergic rhinitis), Amira; Prostaglandin D2 (PGD2) antagonists (COPD/asthma/allergic rhinitis), Amira
DMGCOQF	CP	Amira Pharmaceuticals Inc
DMGCOQF	DT	Small molecular drug
DMGCOQF	PC	46702966
DMGCOQF	MW	457.4
DMGCOQF	FM	C23H23F3NNaO4
DMGCOQF	IC	InChI=1S/C23H24F3NO4.Na/c1-3-27(22(30)15-5-6-15)13-16-12-17(23(24,25)26)7-8-18(16)19-10-14(11-21(28)29)4-9-20(19)31-2;/h4,7-10,12,15H,3,5-6,11,13H2,1-2H3,(H,28,29);/q;+1/p-1
DMGCOQF	CS	CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)[O-])OC)C(=O)C3CC3.[Na+]
DMGCOQF	IK	WFUYBZRTYBYLFG-UHFFFAOYSA-M
DMGCOQF	IU	sodium;2-[3-[2-[[cyclopropanecarbonyl(ethyl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxyphenyl]acetate
DMGCOQF	CA	CAS 1224977-85-8
DMGCOQF	DE	Allergic rhinitis

DMO7QUP	ID	DMO7QUP
DMO7QUP	DN	AM-1710
DMO7QUP	HS	Investigative
DMO7QUP	SN	AM-1710; UNII-R0GPP0WDF9; R0GPP0WDF9; CHEMBL266712; 3-(1,1-Dimethylheptyl)-1-hydroxy-9-methoxy-6H-dibenzo(b,d)pyran-6-one; 3-(1,1-Dimethylheptyl)-1-hydroxy-9-methoxy-6H-dibenzo[b,d]pyran-6-one; SCHEMBL3297145; GTPL10202; ZAIKPEWFCSQNQB-UHFFFAOYSA-N; BDBM50228073; AM1710; analog 4b [PMID: 18038967]; 1-hydroxy-9-methoxy-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one; 3-(1',1'-dimethylheptyl)-1-hydroxy-9-methoxy-6h-benzo[c]chromene-6-one; 6H-Dibenzo(b,d)pyran-6-one, 3-(1,1-dimethylheptyl)-1-hydroxy-9-methoxy-
DMO7QUP	DT	Small molecular drug
DMO7QUP	PC	11268660
DMO7QUP	MW	368.5
DMO7QUP	FM	C23H28O4
DMO7QUP	IC	InChI=1S/C23H28O4/c1-5-6-7-8-11-23(2,3)15-12-19(24)21-18-14-16(26-4)9-10-17(18)22(25)27-20(21)13-15/h9-10,12-14,24H,5-8,11H2,1-4H3
DMO7QUP	CS	CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(=O)C3=C2C=C(C=C3)OC)O
DMO7QUP	IK	ZAIKPEWFCSQNQB-UHFFFAOYSA-N
DMO7QUP	IU	1-hydroxy-9-methoxy-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one
DMO7QUP	CA	CAS 335371-36-3
DMO7QUP	DE	Discovery agent

DMW9ERM	ID	DMW9ERM
DMW9ERM	DN	AM-1714
DMW9ERM	HS	Investigative
DMW9ERM	SN	AM-1714; UNII-E3OY6PCU04; E3OY6PCU04; CHEMBL429797; BWKBVEVEQOCSCF-UHFFFAOYSA-N; 335371-37-4; SCHEMBL3298491; BDBM50228072; 6H-Dibenzo(b,d)pyran-6-one, 3-(1,1-dimethylheptyl)-1,9-dihydroxy-; 3-(1,1-Dimethylheptyl)-1,9-dihydroxy-6H-dibenzo[b,d]pyran-6-one; 1,9-dihydroxy-3-(2-methyloctan-2-yl)-6H-benzo[c]chromen-6-one
DMW9ERM	DT	Small molecular drug
DMW9ERM	PC	9950486
DMW9ERM	MW	354.4
DMW9ERM	FM	C22H26O4
DMW9ERM	IC	InChI=1S/C22H26O4/c1-4-5-6-7-10-22(2,3)14-11-18(24)20-17-13-15(23)8-9-16(17)21(25)26-19(20)12-14/h8-9,11-13,23-24H,4-7,10H2,1-3H3
DMW9ERM	CS	CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(=O)C3=C2C=C(C=C3)O)O
DMW9ERM	IK	BWKBVEVEQOCSCF-UHFFFAOYSA-N
DMW9ERM	IU	1,9-dihydroxy-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one
DMW9ERM	CA	CAS 335371-37-4
DMW9ERM	DE	Discovery agent

DMKJQZ4	ID	DMKJQZ4
DMKJQZ4	DN	AM-1715
DMKJQZ4	HS	Investigative
DMKJQZ4	SN	AM-1715; CHEMBL235585; BDBM50228074
DMKJQZ4	DT	Small molecular drug
DMKJQZ4	PC	24748863
DMKJQZ4	MW	382.5
DMKJQZ4	FM	C25H34O3
DMKJQZ4	IC	InChI=1S/C25H34O3/c1-7-8-9-10-13-24(2,3)17-14-21(26)23-19-16-18(27-6)11-12-20(19)25(4,5)28-22(23)15-17/h11-12,14-16,26H,7-10,13H2,1-6H3
DMKJQZ4	CS	CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)OC)(C)C)O
DMKJQZ4	IK	ZNHVPFVYQXICIO-UHFFFAOYSA-N
DMKJQZ4	IU	9-methoxy-6,6-dimethyl-3-(2-methyloctan-2-yl)benzo[c]chromen-1-ol
DMKJQZ4	DE	Discovery agent

DMTAWHL	ID	DMTAWHL
DMTAWHL	DN	AM251
DMTAWHL	HS	Investigative
DMTAWHL	SN	AM251; 183232-66-8; AM-251; AM 251; UNII-3I4FA44MAI; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; 3I4FA44MAI; CHEMBL285932; CHEBI:90724; MFCD01861181; CPD000466284; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
DMTAWHL	DT	Small molecular drug
DMTAWHL	PC	2125
DMTAWHL	MW	555.2
DMTAWHL	FM	C22H21Cl2IN4O
DMTAWHL	IC	InChI=1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMTAWHL	CS	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)I
DMTAWHL	IK	BUZAJRPLUGXRAB-UHFFFAOYSA-N
DMTAWHL	IU	1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMTAWHL	CA	CAS 183232-66-8
DMTAWHL	CB	CHEBI:90724
DMTAWHL	DE	Discovery agent

DMOKN27	ID	DMOKN27
DMOKN27	DN	AM-281
DMOKN27	HS	Investigative
DMOKN27	SN	AM 281; 202463-68-1; AM281; AM-281; UNII-SBP4A4DYH2; SBP4A4DYH2; 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide; CHEMBL476833; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholin-4-ylpyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholino-1H-pyrazole-3-carboxamide; Tocris-1115; AC1N7ICF; GTPL741; SCHEMBL1517458; CTK8E9266; CHEBI:93039; AJFFBPZYXRNAIC-UHFFFAOYSA-N; MolPort-003-940-033; HMS3267K18; EX-A1546; ZINC2575699; BCP07951; BN0064
DMOKN27	DT	Small molecular drug
DMOKN27	PC	4302962
DMOKN27	MW	557.2
DMOKN27	FM	C21H19Cl2IN4O2
DMOKN27	IC	InChI=1S/C21H19Cl2IN4O2/c1-13-19(21(29)26-27-8-10-30-11-9-27)25-28(18-7-4-15(22)12-17(18)23)20(13)14-2-5-16(24)6-3-14/h2-7,12H,8-11H2,1H3,(H,26,29)
DMOKN27	CS	CC1=C(N(N=C1C(=O)NN2CCOCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)I
DMOKN27	IK	AJFFBPZYXRNAIC-UHFFFAOYSA-N
DMOKN27	IU	1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholin-4-ylpyrazole-3-carboxamide
DMOKN27	CA	CAS 202463-68-1
DMOKN27	CB	CHEBI:93039
DMOKN27	DE	Discovery agent

DMZ46GI	ID	DMZ46GI
DMZ46GI	DN	AM-2S
DMZ46GI	HS	Investigative
DMZ46GI	SN	AM-2S; CHEMBL470194; SCHEMBL13208678; BDBM50278743
DMZ46GI	DT	Small molecular drug
DMZ46GI	PC	54726664
DMZ46GI	MW	351.4
DMZ46GI	FM	C20H17NO3S
DMZ46GI	IC	InChI=1S/C20H17NO3S/c1-13-11-17(25)18(22)19(24-13)20(23)21-12-14-7-9-16(10-8-14)15-5-3-2-4-6-15/h2-11,22H,12H2,1H3,(H,21,23)
DMZ46GI	CS	CC1=CC(=S)C(=C(O1)C(=O)NCC2=CC=C(C=C2)C3=CC=CC=C3)O
DMZ46GI	IK	ZOMMNLRHGAAUNM-UHFFFAOYSA-N
DMZ46GI	IU	3-hydroxy-6-methyl-N-[(4-phenylphenyl)methyl]-4-sulfanylidenepyran-2-carboxamide
DMZ46GI	DE	Discovery agent

DMZVLJH	ID	DMZVLJH
DMZVLJH	DN	AM-3701
DMZVLJH	HS	Investigative
DMZVLJH	SN	Cathepsin K inhibitors (oral, osteoporosis/bone metastasis), Amura
DMZVLJH	CP	Amura Therapeutics Ltd
DMZVLJH	DE	Bone metastases

DM2AOF8	ID	DM2AOF8
DM2AOF8	DN	AM-3840
DM2AOF8	HS	Investigative
DM2AOF8	SN	Cathepsin S inihibitors (oral, autoimmune disease/pain), Amura
DM2AOF8	CP	Amura Therapeutics Ltd
DM2AOF8	DE	Autoimmune diabetes

DMBK9PS	ID	DMBK9PS
DMBK9PS	DN	AM-404
DMBK9PS	HS	Investigative
DMBK9PS	SN	AM 404; AM-404; 183718-77-6; am404; UNII-XVJ94H0U21; 198022-70-7; CHEMBL39878; XVJ94H0U21; CPD000449274; (5Z,8Z,11Z,14Z)-N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide; N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide; SMR000449274; SR-01000597390; N-(4-Hydroxyphenyl)-arachidonylamide; N-(4-Hydroxyphenyl)arachidonylamide; N-(4-Hydroxyphenyl)arachidonoyl amide; NCGC00025010-01; Tocris-1116; AC1O7GXA; 5,8,11,14-Eicosatetraenamide, N-(4-hydroxyphenyl)-, (all-Z)-; N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide
DMBK9PS	DT	Small molecular drug
DMBK9PS	PC	6604822
DMBK9PS	MW	395.6
DMBK9PS	FM	C26H37NO2
DMBK9PS	IC	InChI=1S/C26H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26(29)27-24-20-22-25(28)23-21-24/h6-7,9-10,12-13,15-16,20-23,28H,2-5,8,11,14,17-19H2,1H3,(H,27,29)/b7-6-,10-9-,13-12-,16-15-
DMBK9PS	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NC1=CC=C(C=C1)O
DMBK9PS	IK	IJBZOOZRAXHERC-DOFZRALJSA-N
DMBK9PS	IU	(5Z,8Z,11Z,14Z)-N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide
DMBK9PS	CA	CAS 183718-77-6
DMBK9PS	DE	Discovery agent

DMU3Y4J	ID	DMU3Y4J
DMU3Y4J	DN	AM-411
DMU3Y4J	HS	Investigative
DMU3Y4J	SN	AM-411; CHEMBL434351; BDBM50169951; (6aR,10aR)-3-Adamantan-1-yl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol
DMU3Y4J	DT	Small molecular drug
DMU3Y4J	PC	9799945
DMU3Y4J	MW	378.5
DMU3Y4J	FM	C26H34O2
DMU3Y4J	IC	InChI=1S/C26H34O2/c1-15-4-5-21-20(6-15)24-22(27)10-19(11-23(24)28-25(21,2)3)26-12-16-7-17(13-26)9-18(8-16)14-26/h4,10-11,16-18,20-21,27H,5-9,12-14H2,1-3H3/t16?,17?,18?,20-,21-,26?/m1/s1
DMU3Y4J	CS	CC1=CC[C@@H]2[C@@H](C1)C3=C(C=C(C=C3OC2(C)C)C45CC6CC(C4)CC(C6)C5)O
DMU3Y4J	IK	RPBMPWGKZFLMFN-OKFSJJLXSA-N
DMU3Y4J	IU	(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DMU3Y4J	CA	CAS 212835-02-4
DMU3Y4J	DE	Discovery agent

DMETXA8	ID	DMETXA8
DMETXA8	DN	AM-4768
DMETXA8	HS	Investigative
DMETXA8	SN	AM-4768; CHEMBL238359; BDBM50228075
DMETXA8	DT	Small molecular drug
DMETXA8	PC	24748864
DMETXA8	MW	368.5
DMETXA8	FM	C24H32O3
DMETXA8	IC	InChI=1S/C24H32O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h10-11,13-15,25-26H,6-9,12H2,1-5H3
DMETXA8	CS	CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)O)(C)C)O
DMETXA8	IK	UNSSGNVPLKLAPB-UHFFFAOYSA-N
DMETXA8	IU	6,6-dimethyl-3-(2-methyloctan-2-yl)benzo[c]chromene-1,9-diol
DMETXA8	DE	Discovery agent

DM7R605	ID	DM7R605
DM7R605	DN	AM-630
DM7R605	HS	Investigative
DM7R605	SN	164178-33-0; AM630; AM-630; iodopravadoline; (6-iodo-2-methyl-1-(2-morpholinoethyl)-1H-indol-3-yl)(4-methoxyphenyl)methanone; AM 630; UNII-U1LNJ6NBKA; U1LNJ6NBKA; CHEMBL181633; [6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]-(4-methoxyphenyl)methanone; 6-iodopravadoline; 1-(2-(Morpholin-4-yl)ethyl)-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole; 1-[2-(morpholin-4-yl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole; Tocris-1120; AC1N7ICI; Iodopravadoline(AM-630); Iodopravadoline (AM630); GTPL750; MLS006010265
DM7R605	DT	Small molecular drug
DM7R605	PC	4302963
DM7R605	MW	504.4
DM7R605	FM	C23H25IN2O3
DM7R605	IC	InChI=1S/C23H25IN2O3/c1-16-22(23(27)17-3-6-19(28-2)7-4-17)20-8-5-18(24)15-21(20)26(16)10-9-25-11-13-29-14-12-25/h3-8,15H,9-14H2,1-2H3
DM7R605	CS	CC1=C(C2=C(N1CCN3CCOCC3)C=C(C=C2)I)C(=O)C4=CC=C(C=C4)OC
DM7R605	IK	JHOTYHDSLIUKCJ-UHFFFAOYSA-N
DM7R605	IU	[6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]-(4-methoxyphenyl)methanone
DM7R605	CA	CAS 164178-33-0
DM7R605	CB	CHEBI:93112
DM7R605	DE	Discovery agent

DMYVQFN	ID	DMYVQFN
DMYVQFN	DN	AM7
DMYVQFN	HS	Investigative
DMYVQFN	SN	pyrimidone, 22; AM 7; AM-7
DMYVQFN	DT	Small molecular drug
DMYVQFN	PC	11650194
DMYVQFN	MW	610.7
DMYVQFN	FM	C35H35FN4O5
DMYVQFN	IC	InChI=1S/C35H35FN4O5/c1-39-34(19-24-7-4-3-5-8-24)38-23-27(35(39)41)25-9-10-31(28(36)20-25)45-30-11-12-37-29-22-33(32(42-2)21-26(29)30)44-16-6-13-40-14-17-43-18-15-40/h3-5,7-12,20-23H,6,13-19H2,1-2H3
DMYVQFN	CS	CN1C(=NC=C(C1=O)C2=CC(=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OCCCN5CCOCC5)OC)F)CC6=CC=CC=C6
DMYVQFN	IK	PEGWVOKOYYAQEV-UHFFFAOYSA-N
DMYVQFN	IU	2-benzyl-5-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-3-methylpyrimidin-4-one
DMYVQFN	DE	Discovery agent

DM5JZUB	ID	DM5JZUB
DM5JZUB	DN	AMA
DM5JZUB	HS	Investigative
DM5JZUB	SN	S-(5'-deoxy-5'-adenosyl)-methylthioethyl-hydroxylamine
DM5JZUB	DT	Small molecular drug
DM5JZUB	PC	10428412
DM5JZUB	MW	357.41
DM5JZUB	FM	C13H21N6O4S+
DM5JZUB	IC	InChI=1S/C13H21N6O4S/c1-24(3-2-18-22)4-7-9(20)10(21)13(23-7)19-6-17-8-11(14)15-5-16-12(8)19/h5-7,9-10,13,18,20-22H,2-4H2,1H3,(H2,14,15,16)/q+1/t7-,9-,10-,13-,24?/m1/s1
DM5JZUB	CS	C[S+](CCNO)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DM5JZUB	IK	VJHFTTWXKUEKQP-VCZNENMGSA-N
DM5JZUB	IU	[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-[2-(hydroxyamino)ethyl]-methylsulfanium
DM5JZUB	DE	Discovery agent

DMW9TRD	ID	DMW9TRD
DMW9TRD	DN	AMA-237
DMW9TRD	HS	Investigative
DMW9TRD	SN	AMA-63; ROCK inhibitors (COPD); ROCK inhibitors (COPD), Amakem
DMW9TRD	CP	Amakem NV
DMW9TRD	DE	Chronic obstructive pulmonary disease

DMIZQOG	ID	DMIZQOG
DMIZQOG	DN	AMA37
DMIZQOG	HS	Investigative
DMIZQOG	SN	arylmorpholine analog 37
DMIZQOG	DT	Small molecular drug
DMIZQOG	PC	16760391
DMIZQOG	MW	283.32
DMIZQOG	FM	C17H17NO3
DMIZQOG	IC	InChI=1S/C17H17NO3/c19-16-12-14(18-8-10-21-11-9-18)6-7-15(16)17(20)13-4-2-1-3-5-13/h1-7,12,19H,8-11H2
DMIZQOG	CS	C1COCCN1C2=CC(=C(C=C2)C(=O)C3=CC=CC=C3)O
DMIZQOG	IK	FALILNHGILFDLC-UHFFFAOYSA-N
DMIZQOG	IU	(2-hydroxy-4-morpholin-4-ylphenyl)-phenylmethanone
DMIZQOG	CA	CAS 404009-46-7
DMIZQOG	CB	CHEBI:92885
DMIZQOG	DE	Discovery agent

DM59IT4	ID	DM59IT4
DM59IT4	DN	Amanitin
DM59IT4	HS	Investigative
DM59IT4	SN	alpha-amanitin
DM59IT4	DT	Small molecular drug
DM59IT4	PC	2100
DM59IT4	MW	919
DM59IT4	FM	C39H54N10O14S
DM59IT4	IC	InChI=1S/C39H54N10O14S/c1-4-16(2)31-36(60)42-11-29(55)43-25-15-64(63)38-21(20-6-5-18(51)7-22(20)46-38)9-23(33(57)41-12-30(56)47-31)44-37(61)32(17(3)27(53)14-50)48-35(59)26-8-19(52)13-49(26)39(62)24(10-28(40)54)45-34(25)58/h5-7,16-17,19,23-27,31-32,46,50-53H,4,8-15H2,1-3H3,(H2,40,54)(H,41,57)(H,42,60)(H,43,55)(H,44,61)(H,45,58)(H,47,56)(H,48,59)
DM59IT4	CS	CCC(C)C1C(=O)NCC(=O)NC2CS(=O)C3=C(CC(C(=O)NCC(=O)N1)NC(=O)C(NC(=O)C4CC(CN4C(=O)C(NC2=O)CC(=O)N)O)C(C)C(CO)O)C5=C(N3)C=C(C=C5)O
DM59IT4	IK	CIORWBWIBBPXCG-UHFFFAOYSA-N
DM59IT4	IU	2-[34-butan-2-yl-13-(3,4-dihydroxybutan-2-yl)-8,22-dihydroxy-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide
DM59IT4	CA	CAS 23109-05-9
DM59IT4	DE	Discovery agent

DML9W2V	ID	DML9W2V
DML9W2V	DN	Amarylline
DML9W2V	HS	Investigative
DML9W2V	SN	Lycorine; BSPBio_0; CHEBI:6601; CHEMBL400092; EINECS 207-503-6; GNF-PF-4974; Galanthidine; (-)-Lycorine; 2188-68-3; 3,2.beta.-diol; I9Q105R5BU; KBioGR_000022; KBioSS_000022; Licorine; Likorin; Lycorine hydrochloride; NSC 401360; NSC401360; NSC683873; Narcissine; UNII-I9Q105R5BU
DML9W2V	TC	Antiviral Agents
DML9W2V	DT	Small molecular drug
DML9W2V	PC	72378
DML9W2V	MW	287.31
DML9W2V	FM	C16H17NO4
DML9W2V	IC	InChI=1S/C16H17NO4/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19/h3-5,11,14-16,18-19H,1-2,6-7H2/t11-,14-,15+,16+/m0/s1
DML9W2V	CS	C1CN2CC3=CC4=C(C=C3[C@H]5[C@H]2C1=C[C@@H]([C@H]5O)O)OCO4
DML9W2V	IK	XGVJWXAYKUHDOO-DANNLKNASA-N
DML9W2V	IU	(1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraene-17,18-diol
DML9W2V	CA	CAS 476-28-8
DML9W2V	CB	CHEBI:6601
DML9W2V	DE	Middle East Respiratory Syndrome (MERS)

DMAVC9T	ID	DMAVC9T
DMAVC9T	DN	AMBAZONE
DMAVC9T	HS	Investigative
DMAVC9T	SN	Ambazone < Rec INNM; P-Benzoquinone amidinohydrazone thiosemicarbazone monohydrate; 1,4-Benzoquinoneguanylhydrazone thiosemicarbazone monohydrate
DMAVC9T	DT	Small molecular drug
DMAVC9T	PC	1549158
DMAVC9T	MW	237.29
DMAVC9T	FM	C8H11N7S
DMAVC9T	IC	InChI=1S/C8H11N7S/c9-7(10)14-12-5-1-3-6(4-2-5)13-15-8(11)16/h1-4,12H,(H2,11,16)(H4,9,10,14)
DMAVC9T	CS	C1=CC(=CC=C1NN=C(N)N)N=NC(=S)N
DMAVC9T	IK	ANZIOUQAFBXNHU-UHFFFAOYSA-N
DMAVC9T	IU	[4-[2-(diaminomethylidene)hydrazinyl]phenyl]iminothiourea
DMAVC9T	CA	CAS 539-21-9
DMAVC9T	CB	CHEBI:134962
DMAVC9T	DE	Solid tumour/cancer

DM75UK8	ID	DM75UK8
DM75UK8	DN	AMD3101
DM75UK8	HS	Investigative
DM75UK8	DT	Small molecular drug
DM75UK8	PC	23644377
DM75UK8	DE	Discovery agent

DMLRNV2	ID	DMLRNV2
DMLRNV2	DN	AMENTOFLAVONE
DMLRNV2	HS	Investigative
DMLRNV2	SN	Amentoflavone; 1617-53-4; 3',8''-Biapigenin; Didemethyl-ginkgetin; Amenthoflavone; UNII-9I1VC79L77; MLS000574827; CHEBI:2631; 9I1VC79L77; SMR000156235; Q-100192; 8-[5-(5,7-dihydroxy-4-oxo-chromen-2-yl)-2-hydroxy-phenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 8-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 8-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
DMLRNV2	DT	Small molecular drug
DMLRNV2	PC	5281600
DMLRNV2	MW	538.5
DMLRNV2	FM	C30H18O10
DMLRNV2	IC	InChI=1S/C30H18O10/c31-15-4-1-13(2-5-15)24-12-23(38)29-21(36)10-20(35)27(30(29)40-24)17-7-14(3-6-18(17)33)25-11-22(37)28-19(34)8-16(32)9-26(28)39-25/h1-12,31-36H
DMLRNV2	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)O)O
DMLRNV2	IK	YUSWMAULDXZHPY-UHFFFAOYSA-N
DMLRNV2	IU	8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
DMLRNV2	CA	CAS 1617-53-4
DMLRNV2	CB	CHEBI:2631
DMLRNV2	DE	Discovery agent

DMDRSFE	ID	DMDRSFE
DMDRSFE	DN	Ametantrone
DMDRSFE	HS	Investigative
DMDRSFE	SN	Ametantrone; 64862-96-0; Ametantrone [INN]; NSC-196473; NSC 196473; Ametantronum [INN-Latin]; Ametantrona [INN-Spanish]; UNII-PNT6041ST1; BRN 2791800; PNT6041ST1; C22H28N4O4; 1,4-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthraquinone; 1,4-Bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 9,10-Anthracenedione,1,4-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-; 1,4-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthracene-9,10-dione; 1,4-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9,10-anthracenedione; Ametantronum
DMDRSFE	DT	Small molecular drug
DMDRSFE	PC	2134
DMDRSFE	MW	412.5
DMDRSFE	FM	C22H28N4O4
DMDRSFE	IC	InChI=1S/C22H28N4O4/c27-13-11-23-7-9-25-17-5-6-18(26-10-8-24-12-14-28)20-19(17)21(29)15-3-1-2-4-16(15)22(20)30/h1-6,23-28H,7-14H2
DMDRSFE	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)NCCNCCO)NCCNCCO
DMDRSFE	IK	FFGSXKJJVBXWCY-UHFFFAOYSA-N
DMDRSFE	IU	1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
DMDRSFE	CA	CAS 64862-96-0
DMDRSFE	DE	Discovery agent

DM589XV	ID	DM589XV
DM589XV	DN	AMG 9810
DM589XV	HS	Investigative
DM589XV	SN	AMG-9810; AMG9810
DM589XV	DT	Small molecular drug
DM589XV	PC	680502
DM589XV	MW	337.4
DM589XV	FM	C21H23NO3
DM589XV	IC	InChI=1S/C21H23NO3/c1-21(2,3)16-7-4-15(5-8-16)6-11-20(23)22-17-9-10-18-19(14-17)25-13-12-24-18/h4-11,14H,12-13H2,1-3H3,(H,22,23)/b11-6+
DM589XV	CS	CC(C)(C)C1=CC=C(C=C1)/C=C/C(=O)NC2=CC3=C(C=C2)OCCO3
DM589XV	IK	GZTFUVZVLYUPRG-IZZDOVSWSA-N
DM589XV	IU	(E)-3-(4-tert-butylphenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)prop-2-enamide
DM589XV	CA	CAS 545395-94-6
DM589XV	CB	CHEBI:92757
DM589XV	DE	Discovery agent

DMUONK5	ID	DMUONK5
DMUONK5	DN	amg-1
DMUONK5	HS	Investigative
DMUONK5	SN	CHEMBL3342402; N-(1,3-benzodioxol-5-yl)-2-{[5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl}acetamide; BAS 06591295; AC1LLIU7; GTPL8227; SCHEMBL20313457; MolPort-000-220-791; ZINC801901; STL305655; BDBM50030791; AKOS000657540; MCULE-5294683561; ST50049773; Z56882059; N-(2H-1,3-benzodioxol-5-yl)-2-{[5-(4-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3]thiazol-3-yl]sulfanyl}acetamide; 496023-55-3; N-(2H-benzo[3,4-d]1,3-dioxolen-5-yl)-2-[5-(4-methylphenyl)(1,3-thiazolino[3,2- d]1,2,4-triazol-3-ylthio)]acetamide
DMUONK5	DT	Small molecular drug
DMUONK5	PC	1085108
DMUONK5	MW	424.5
DMUONK5	FM	C20H16N4O3S2
DMUONK5	IC	InChI=1S/C20H16N4O3S2/c1-12-2-4-13(5-3-12)15-9-28-19-22-23-20(24(15)19)29-10-18(25)21-14-6-7-16-17(8-14)27-11-26-16/h2-9H,10-11H2,1H3,(H,21,25)
DMUONK5	CS	CC1=CC=C(C=C1)C2=CSC3=NN=C(N23)SCC(=O)NC4=CC5=C(C=C4)OCO5
DMUONK5	IK	XYXNYQAJSYUYNZ-UHFFFAOYSA-N
DMUONK5	IU	N-(1,3-benzodioxol-5-yl)-2-[[5-(4-methylphenyl)-[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl]acetamide
DMUONK5	DE	Discovery agent

DM9H7AZ	ID	DM9H7AZ
DM9H7AZ	DN	AMG-126737
DM9H7AZ	HS	Investigative
DM9H7AZ	DT	Small molecular drug
DM9H7AZ	PC	10462207
DM9H7AZ	MW	678.8
DM9H7AZ	FM	C33H38N6O6S2
DM9H7AZ	IC	InChI=1S/C33H38N6O6S2/c34-32(35)26-6-4-8-30(20-26)46(40,41)38-22-24-10-14-28(15-11-24)44-18-2-1-3-19-45-29-16-12-25(13-17-29)23-39-47(42,43)31-9-5-7-27(21-31)33(36)37/h4-17,20-21,38-39H,1-3,18-19,22-23H2,(H3,34,35)(H3,36,37)
DM9H7AZ	CS	C1=CC(=CC(=C1)S(=O)(=O)NCC2=CC=C(C=C2)OCCCCCOC3=CC=C(C=C3)CNS(=O)(=O)C4=CC=CC(=C4)C(=N)N)C(=N)N
DM9H7AZ	IK	CTLMBCYIAXNYOG-UHFFFAOYSA-N
DM9H7AZ	IU	3-[[4-[5-[4-[[(3-carbamimidoylphenyl)sulfonylamino]methyl]phenoxy]pentoxy]phenyl]methylsulfamoyl]benzenecarboximidamide
DM9H7AZ	CA	CAS 224054-76-6
DM9H7AZ	DE	Discovery agent

DMU6WR9	ID	DMU6WR9
DMU6WR9	DN	AMG-247
DMU6WR9	HS	Investigative
DMU6WR9	SN	AMG-369; Multiple sclerosis therapeutics, Amgen; S1P1 receptor antagonists (multiple sclerosis/inflammation); S1P1 receptor antagonists (multiple sclerosis/inflammation), Amgen
DMU6WR9	CP	Amgen Inc
DMU6WR9	DE	Inflammation

DMRD83Q	ID	DMRD83Q
DMRD83Q	DN	AMG-2504
DMRD83Q	HS	Investigative
DMRD83Q	SN	AMG-2504; CHEMBL1086587; 4-nitro-N-{2,2,2-trichloro-1-[(4-chlorophenyl)sulfanyl]ethyl}benzamide; 4-nitro-n-(2,2,2-trichloro-1-((4-chlorophenyl)sulfanyl)ethyl)benzamide; AC1MD3F6; SCHEMBL19743227; MolPort-002-133-093; STK822395; BDBM50318457; AKOS016332516; AKOS003622338; MCULE-9954660789; AE-848/32004034; 4-nitro-N-(2,2,2-trichloro-1-(4-chlorophenylthio)ethyl)benzamide
DMRD83Q	DT	Small molecular drug
DMRD83Q	PC	2830271
DMRD83Q	MW	440.1
DMRD83Q	FM	C15H10Cl4N2O3S
DMRD83Q	IC	InChI=1S/C15H10Cl4N2O3S/c16-10-3-7-12(8-4-10)25-14(15(17,18)19)20-13(22)9-1-5-11(6-2-9)21(23)24/h1-8,14H,(H,20,22)
DMRD83Q	CS	C1=CC(=CC=C1C(=O)NC(C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl)[N+](=O)[O-]
DMRD83Q	IK	DNTIPHKVCXUYRM-UHFFFAOYSA-N
DMRD83Q	IU	4-nitro-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DMRD83Q	DE	Discovery agent

DME04BH	ID	DME04BH
DME04BH	DN	AMG-429
DME04BH	HS	Investigative
DME04BH	SN	KDR inhibitors (anticancer), Amgen; VEGFR-2 inhibitors (anticancer); VEGFR-2 inhibitors (anticancer), Amgen
DME04BH	CP	Amgen Inc
DME04BH	DE	Solid tumour/cancer

DMNEVXT	ID	DMNEVXT
DMNEVXT	DN	AMG-5445
DMNEVXT	HS	Investigative
DMNEVXT	SN	AMG-5445; CHEMBL1086586; 4-Methoxy-N-[2,2,2-trichloro-1-(4-chloro-phenylsulfanyl)-ethyl]-benzamide; BAS 00092441; AC1MD3F3; CBDivE_009656; SCHEMBL15159500; MolPort-001-914-251; BDBM50318456; AKOS016361849; AKOS000521797; MCULE-5981280288; ST50216415; 4-methoxy-N-(2,2,2-trichloro-1-(4-chlorophenylthio)ethyl)benzamide; 4-methoxy-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide; 4-methoxy-n-(2,2,2-trichloro-1-((4-chlorophenyl)sulfanyl)ethyl)benzamide
DMNEVXT	DT	Small molecular drug
DMNEVXT	PC	2830270
DMNEVXT	MW	425.2
DMNEVXT	FM	C16H13Cl4NO2S
DMNEVXT	IC	InChI=1S/C16H13Cl4NO2S/c1-23-12-6-2-10(3-7-12)14(22)21-15(16(18,19)20)24-13-8-4-11(17)5-9-13/h2-9,15H,1H3,(H,21,22)
DMNEVXT	CS	COC1=CC=C(C=C1)C(=O)NC(C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl
DMNEVXT	IK	MRIRDTYIRGDISF-UHFFFAOYSA-N
DMNEVXT	IU	4-methoxy-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DMNEVXT	DE	Discovery agent

DMI39YX	ID	DMI39YX
DMI39YX	DN	AMG-628
DMI39YX	HS	Investigative
DMI39YX	SN	AMG-628; UNII-G8JW58493W; G8JW58493W; N-{4-[(6-{4-[(1R)-1-(4-fluorophenyl)ethyl]piperazin-1-yl}pyrimidin-4-yl)oxy]-1,3-benzothiazol-2-yl}acetamide; 862269-93-0; AMG 628; AMG628; AMG-628, (R)-; SCHEMBL3841997; GTPL4130; CHEMBL226574; BDBM20581; QUHZTEMPQQZPNB-MRXNPFEDSA-N; MolPort-029-996-161; KS-00003MQ7; Piperazinylpyrimidine analogue, 16p; ZINC14974185; AKOS022193590; MB-0047; Acetamide, N-(4-((6-(4-((1R)-1-(4-fluorophenyl)ethyl)-1-piperazinyl)-4-pyrimidinyl)oxy)-2-benzothiazolyl)-; UNII-28J966TN3X component QUHZTEMPQQZPNB-M
DMI39YX	DT	Small molecular drug
DMI39YX	PC	11352366
DMI39YX	MW	492.6
DMI39YX	FM	C25H25FN6O2S
DMI39YX	IC	InChI=1S/C25H25FN6O2S/c1-16(18-6-8-19(26)9-7-18)31-10-12-32(13-11-31)22-14-23(28-15-27-22)34-20-4-3-5-21-24(20)30-25(35-21)29-17(2)33/h3-9,14-16H,10-13H2,1-2H3,(H,29,30,33)/t16-/m1/s1
DMI39YX	CS	C[C@H](C1=CC=C(C=C1)F)N2CCN(CC2)C3=CC(=NC=N3)OC4=C5C(=CC=C4)SC(=N5)NC(=O)C
DMI39YX	IK	QUHZTEMPQQZPNB-MRXNPFEDSA-N
DMI39YX	IU	N-[4-[6-[4-[(1R)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide
DMI39YX	CA	CAS 862269-93-0
DMI39YX	DE	Pain

DMEVNZI	ID	DMEVNZI
DMEVNZI	DN	AMG-7160
DMEVNZI	HS	Investigative
DMEVNZI	SN	AMG-7160; CHEMBL1086588; 4-Bromo-N-[2,2,2-trichloro-1-(4-chloro-phenylsulfanyl)-ethyl]-benzamide; 4-bromo-N-{2,2,2-trichloro-1-[(4-chlorophenyl)sulfanyl]ethyl}benzamide; 4-bromo-n-(2,2,2-trichloro-1-((4-chlorophenyl)sulfanyl)ethyl)benzamide; BAS 00084574; AC1MJD0X; SCHEMBL19743234; MolPort-001-818-003; BDBM50318458; AKOS016369423; AKOS000619708; MCULE-2387805859; ST082345; AG-690/32533021; 4-bromo-N-(2,2,2-trichloro-1-(4-chlorophenylthio)ethyl)benzamide; 4-bromo-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DMEVNZI	DT	Small molecular drug
DMEVNZI	PC	3089985
DMEVNZI	MW	474
DMEVNZI	FM	C15H10BrCl4NOS
DMEVNZI	IC	InChI=1S/C15H10BrCl4NOS/c16-10-3-1-9(2-4-10)13(22)21-14(15(18,19)20)23-12-7-5-11(17)6-8-12/h1-8,14H,(H,21,22)
DMEVNZI	CS	C1=CC(=CC=C1C(=O)NC(C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl)Br
DMEVNZI	IK	APLQHKFABMHWHP-UHFFFAOYSA-N
DMEVNZI	IU	4-bromo-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DMEVNZI	DE	Discovery agent

DMJ6L9U	ID	DMJ6L9U
DMJ6L9U	DN	AMG7703
DMJ6L9U	HS	Investigative
DMJ6L9U	SN	AMG 7703; AMG-7703
DMJ6L9U	DT	Small molecular drug
DMJ6L9U	PC	854189
DMJ6L9U	MW	294.8
DMJ6L9U	FM	C14H15ClN2OS
DMJ6L9U	IC	InChI=1S/C14H15ClN2OS/c1-9(2)12(10-3-5-11(15)6-4-10)13(18)17-14-16-7-8-19-14/h3-9,12H,1-2H3,(H,16,17,18)/t12-/m0/s1
DMJ6L9U	CS	CC(C)[C@@H](C1=CC=C(C=C1)Cl)C(=O)NC2=NC=CS2
DMJ6L9U	IK	AZYDQCGCBQYFSE-LBPRGKRZSA-N
DMJ6L9U	IU	(2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide
DMJ6L9U	DE	Discovery agent

DMNHM1B	ID	DMNHM1B
DMNHM1B	DN	AMG-837
DMNHM1B	HS	Investigative
DMNHM1B	SN	AMG 837; AMG837
DMNHM1B	DT	Small molecular drug
DMNHM1B	PC	46854655
DMNHM1B	MW	438.4
DMNHM1B	FM	C26H21F3O3
DMNHM1B	IC	InChI=1S/C26H21F3O3/c1-2-4-21(16-25(30)31)20-9-13-24(14-10-20)32-17-18-5-3-6-22(15-18)19-7-11-23(12-8-19)26(27,28)29/h3,5-15,21H,16-17H2,1H3,(H,30,31)/t21-/m0/s1
DMNHM1B	CS	CC#C[C@@H](CC(=O)O)C1=CC=C(C=C1)OCC2=CC(=CC=C2)C3=CC=C(C=C3)C(F)(F)F
DMNHM1B	IK	ZOPNBMMVVZRSGH-NRFANRHFSA-N
DMNHM1B	IU	(3S)-3-[4-[[3-[4-(trifluoromethyl)phenyl]phenyl]methoxy]phenyl]hex-4-ynoic acid
DMNHM1B	CA	CAS 865231-46-5
DMNHM1B	DE	Discovery agent

DMU8M0I	ID	DMU8M0I
DMU8M0I	DN	AMG-8563
DMU8M0I	HS	Investigative
DMU8M0I	SN	SCHEMBL15446081
DMU8M0I	CP	Amgen
DMU8M0I	TC	Analgesics
DMU8M0I	DT	Small molecular drug
DMU8M0I	PC	24863103
DMU8M0I	MW	430.5
DMU8M0I	FM	C24H25F3N2O2
DMU8M0I	IC	InChI=1S/C24H25F3N2O2/c25-24(26,27)18-9-7-16(22(14-18)29-11-2-1-3-12-29)8-10-23(31)28-21-6-4-5-17-13-19(30)15-20(17)21/h4-10,14,19,30H,1-3,11-13,15H2,(H,28,31)/b10-8+/t19-/m0/s1
DMU8M0I	CS	C1CCN(CC1)C2=C(C=CC(=C2)C(F)(F)F)/C=C/C(=O)NC3=CC=CC4=C3C[C@H](C4)O
DMU8M0I	IK	HAZYXDWNLMGLIS-RQMBKDMJSA-N
DMU8M0I	IU	(E)-N-[(2S)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]-3-[2-piperidin-1-yl-4-(trifluoromethyl)phenyl]prop-2-enamide
DMU8M0I	DE	Pain

DMKP8L9	ID	DMKP8L9
DMKP8L9	DN	AMG-889436
DMKP8L9	HS	Investigative
DMKP8L9	SN	Metabotropic glutamate receptor 4 agonist (Parkinson's disease), Amgen; Metabotropic glutamate receptor 4 positive allosteric modulator (Parkinson's disease), Amgen
DMKP8L9	CP	Amgen Inc
DMKP8L9	DE	Parkinson disease

DM1J46S	ID	DM1J46S
DM1J46S	DN	AMG-9090
DM1J46S	HS	Investigative
DM1J46S	SN	AMG-9090; 118215-82-0; CHEMBL1086371; N-{2,2,2-trichloro-1-[(4-chlorophenyl)sulfanyl]ethyl}benzamide; N-(2,2,2-trichloro-1-((4-chlorophenyl)sulfanyl)ethyl)benzamide; AC1MLXZ1; SCHEMBL15159501; MolPort-002-804-203; BDBM50318455; AKOS001602233; MCULE-4762847116; NCGC00322013-01; BC600809; A-300; ST50981355; AB01317363-02; AF-962/31929042; N-(2,2,2-trichloro-1-(4-chlorophenylthio)ethyl)benzamide; N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide; N-{2,2,2-trichloro-1-[(4-chlorophenyl)thio]ethyl}benzamide
DM1J46S	DT	Small molecular drug
DM1J46S	PC	3277297
DM1J46S	MW	395.1
DM1J46S	FM	C15H11Cl4NOS
DM1J46S	IC	InChI=1S/C15H11Cl4NOS/c16-11-6-8-12(9-7-11)22-14(15(17,18)19)20-13(21)10-4-2-1-3-5-10/h1-9,14H,(H,20,21)
DM1J46S	CS	C1=CC=C(C=C1)C(=O)NC(C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl
DM1J46S	IK	NOXDIPWNQOTUAB-UHFFFAOYSA-N
DM1J46S	IU	N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DM1J46S	DE	Discovery agent

DMSQ49N	ID	DMSQ49N
DMSQ49N	DN	AMG-JAK2-01
DMSQ49N	HS	Investigative
DMSQ49N	SN	JAK2 inhibitor (myeloproliferative disorder), Amgen
DMSQ49N	CP	Amgen Inc
DMSQ49N	DE	Myeloproliferative syndrome

DM4MXOB	ID	DM4MXOB
DM4MXOB	DN	AMI-1
DM4MXOB	HS	Investigative
DM4MXOB	SN	AMI1; AMI 1
DM4MXOB	DT	Small molecular drug
DM4MXOB	PC	88489
DM4MXOB	MW	548.5
DM4MXOB	FM	C21H14N2Na2O9S2
DM4MXOB	IC	InChI=1S/C21H16N2O9S2.2Na/c24-19-9-15(33(27,28)29)7-11-5-13(1-3-17(11)19)22-21(26)23-14-2-4-18-12(6-14)8-16(10-20(18)25)34(30,31)32;;/h1-10,24-25H,(H2,22,23,26)(H,27,28,29)(H,30,31,32);;/q;2*+1/p-2
DM4MXOB	CS	C1=CC2=C(C=C(C=C2C=C1NC(=O)NC3=CC4=CC(=CC(=C4C=C3)O)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+]
DM4MXOB	IK	MOUNHKKCIGVIDI-UHFFFAOYSA-L
DM4MXOB	IU	disodium;4-hydroxy-7-[(5-hydroxy-7-sulfonatonaphthalen-2-yl)carbamoylamino]naphthalene-2-sulfonate
DM4MXOB	CA	CAS 20324-87-2
DM4MXOB	DE	Discovery agent

DMST5VW	ID	DMST5VW
DMST5VW	DN	amidephrine
DMST5VW	HS	Investigative
DMST5VW	SN	amidephrine; Amidefrine; Amidefrine mesilate; UNII-U56LDN9FFT; 37571-84-9; UNII-NI24N176MY; U56LDN9FFT; NI24N176MY; 3354-67-4; Amidephrine, (+)-; N-(3-(1-Hydroxy-2-(methylamino)-ethyl)phenyl)methanesulfonamide; Amidephrine, (-)-; Amidefrine [INN:BAN]; Amidefrin; AC1L24YQ; GTPL514; SCHEMBL122479; CHEMBL146408; ZHOWHMXTJFZXRB-UHFFFAOYSA-N; CHEBI:134994; N-[3-[1-hydroxy-2-(methylamino)ethyl]phenyl]methanesulfonamide; BDBM50225291; Methanesulfonamide, N-(3-(1-hydroxy-2-(methylamino)ethyl)phenyl)-, (-)-; Methanesulfonamide, N-(3-(1-hy
DMST5VW	DT	Small molecular drug
DMST5VW	PC	15010
DMST5VW	MW	244.31
DMST5VW	FM	C10H16N2O3S
DMST5VW	IC	InChI=1S/C10H16N2O3S/c1-11-7-10(13)8-4-3-5-9(6-8)12-16(2,14)15/h3-6,10-13H,7H2,1-2H3
DMST5VW	CS	CNCC(C1=CC(=CC=C1)NS(=O)(=O)C)O
DMST5VW	IK	ZHOWHMXTJFZXRB-UHFFFAOYSA-N
DMST5VW	IU	N-[3-[1-hydroxy-2-(methylamino)ethyl]phenyl]methanesulfonamide
DMST5VW	CA	CAS 37571-84-9
DMST5VW	CB	CHEBI:134994
DMST5VW	DE	Discovery agent

DMJ0BEG	ID	DMJ0BEG
DMJ0BEG	DN	AMIFLAMINE
DMJ0BEG	HS	Investigative
DMJ0BEG	SN	Amiflamine; UNII-NE25WV9C8S; 77518-07-1; NE25WV9C8S; 4-[(2S)-2-aminopropyl]-N,N,3-trimethylaniline; Amiflaminum; Amiflamina; Amiflamine [INN]; Amiflaminum [Latin]; Amiflamina [Spanish]; Astra FLA 336; (+)-FLA 336; AC1Q4TOK; AC1L2FRS; AC1Q29JB; ZINC915; SCHEMBL198456; CHEMBL3989773; DTXSID00228222; AKOS006272872; (+)-4-(dimethylamino)-; A,2-dimethylphenethylamine; (+)-4-(Dimethylamino)-alpha-2-dimethylphenethylamine; Benzeneethanamine, 4-(dimethylamino)-alpha,2-dimethyl-, (S); Benzeneethanamine, 4-(dimethylamino)-alpha,2-dimethyl-,
DMJ0BEG	DT	Small molecular drug
DMJ0BEG	PC	71221
DMJ0BEG	MW	192.3
DMJ0BEG	FM	C12H20N2
DMJ0BEG	IC	InChI=1S/C12H20N2/c1-9-7-12(14(3)4)6-5-11(9)8-10(2)13/h5-7,10H,8,13H2,1-4H3/t10-/m0/s1
DMJ0BEG	CS	CC1=C(C=CC(=C1)N(C)C)C[C@H](C)N
DMJ0BEG	IK	HFQMYSHATTXRTC-JTQLQIEISA-N
DMJ0BEG	IU	4-[(2S)-2-aminopropyl]-N,N,3-trimethylaniline
DMJ0BEG	CA	CAS 77518-07-1
DMJ0BEG	DE	Discovery agent

DMNGW2M	ID	DMNGW2M
DMNGW2M	DN	Aminobenzoic acid
DMNGW2M	HS	Investigative
DMNGW2M	SN	AMINOBENZOIC ACID; Anti-chromotrichia factor; Anticanitic vitamin; Bacterial vitamin H1; Benzoic acid, 4-amino-; Benzoic acid, p-amino-; Chromotrichia factor; Hachemina; Pabacyd; Pabafilm; Pabamine; Papacidum; Paraminol; Paranate; Potaba; RVPaba Lipstick; Romavit; Rvpaba; Sunbrella; Super Shade by Coppertone; Trichochromogenic factor; Vitamin BX; Vitamin H'; p-Carboxyaniline; p-Carboxyphenylamine; p-aminobenzoic acid; para-aminobenzoic acid; 1-Amino-4-carboxybenzene; 150-13-0; 4-Carboxyaniline; 4-aminobenzoic acid; Amben; PABA
DMNGW2M	PC	978
DMNGW2M	MW	137.14
DMNGW2M	FM	C7H7NO2
DMNGW2M	IC	ALYNCZNDIQEVRV-UHFFFAOYSA-N
DMNGW2M	CS	C1=CC(=CC=C1C(=O)O)N
DMNGW2M	IK	1S/C7H7NO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,8H2,(H,9,10)
DMNGW2M	IU	4-aminobenzoic acid
DMNGW2M	CA	CAS 150-13-0
DMNGW2M	CB	CHEBI:30753
DMNGW2M	DE	Penile fibromatosis

DMWYS0Z	ID	DMWYS0Z
DMWYS0Z	DN	Aminobenzolamide derivative
DMWYS0Z	HS	Investigative
DMWYS0Z	SN	CHEMBL435094; Aminobenzolamide derivative
DMWYS0Z	DT	Small molecular drug
DMWYS0Z	PC	44395692
DMWYS0Z	MW	955.2
DMWYS0Z	FM	C28H38N14O8S8
DMWYS0Z	IC	InChI=1S/C28H38N14O8S8/c29-55(43,44)27-37-35-25(53-27)39-57(47,48)21-7-3-19(4-8-21)33-23(51)31-11-1-13-41-15-17-42(18-16-41)14-2-12-32-24(52)34-20-5-9-22(10-6-20)58(49,50)40-26-36-38-28(54-26)56(30,45)46/h3-10H,1-2,11-18H2,(H,35,39)(H,36,40)(H2,29,43,44)(H2,30,45,46)(H2,31,33,51)(H2,32,34,52)
DMWYS0Z	CS	C1CN(CCN1CCCNC(=S)NC2=CC=C(C=C2)S(=O)(=O)NC3=NN=C(S3)S(=O)(=O)N)CCCNC(=S)NC4=CC=C(C=C4)S(=O)(=O)NC5=NN=C(S5)S(=O)(=O)N
DMWYS0Z	IK	OCNLOXNOURUUDD-UHFFFAOYSA-N
DMWYS0Z	IU	1-[4-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)sulfamoyl]phenyl]-3-[3-[4-[3-[[4-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)sulfamoyl]phenyl]carbamothioylamino]propyl]piperazin-1-yl]propyl]thiourea
DMWYS0Z	DE	Discovery agent

DMCILV7	ID	DMCILV7
DMCILV7	DN	aminobenzovesamicol
DMCILV7	HS	Investigative
DMCILV7	SN	compound 11 [PMID: :7702637]; M-iodobenzyltrozamicol
DMCILV7	DT	Small molecular drug
DMCILV7	PC	10390222
DMCILV7	MW	476.4
DMCILV7	FM	C23H29IN2O
DMCILV7	IC	InChI=1S/C23H29IN2O/c24-21-8-4-5-18(15-21)16-25-12-11-23(27)22(17-25)26-13-9-20(10-14-26)19-6-2-1-3-7-19/h1-8,15,20,22-23,27H,9-14,16-17H2/t22-,23-/m1/s1
DMCILV7	CS	C1CN(C[C@H]([C@@H]1O)N2CCC(CC2)C3=CC=CC=C3)CC4=CC(=CC=C4)I
DMCILV7	IK	UBVKSFDICLMPLH-DHIUTWEWSA-N
DMCILV7	IU	(3R,4R)-1-[(3-iodophenyl)methyl]-3-(4-phenylpiperidin-1-yl)piperidin-4-ol
DMCILV7	DE	Discovery agent

DMT13EW	ID	DMT13EW
DMT13EW	DN	AMINOBENZTROPINE
DMT13EW	HS	Investigative
DMT13EW	SN	Aminobenztropine; CHEMBL330957; 88097-86-3; 3-(2'-Aminobenzhydryloxy)tropane; ABHT; Aminobenztropine, solid; Spectrum_000273; SpecPlus_000797; Spectrum5_001758; Spectrum4_001211; Spectrum3_000745; AC1L1D0L; AC1Q57ZN; Lopac0_000126; KBioGR_001642; BSPBio_002330; KBioSS_000753; MLS000859976; SPECTRUM2300334; DivK1c_006893; SCHEMBL1231000; 2-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)oxy-phenylmethyl]aniline; KBio3_001550; KBio2_003321; KBio1_001837; KBio2_005889; KBio2_000753; CTK5F9344; CHEBI:125384; HMS3260I14; HMS3374M03; HMS2232P19
DMT13EW	DT	Small molecular drug
DMT13EW	PC	2143
DMT13EW	MW	322.4
DMT13EW	FM	C21H26N2O
DMT13EW	IC	InChI=1S/C21H26N2O/c1-23-16-11-12-17(23)14-18(13-16)24-21(15-7-3-2-4-8-15)19-9-5-6-10-20(19)22/h2-10,16-18,21H,11-14,22H2,1H3
DMT13EW	CS	CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4N
DMT13EW	IK	KZFDKINRISJFCO-UHFFFAOYSA-N
DMT13EW	IU	2-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)oxy-phenylmethyl]aniline
DMT13EW	CA	CAS 88097-86-3
DMT13EW	CB	CHEBI:125384
DMT13EW	DE	Discovery agent

DMCLVOZ	ID	DMCLVOZ
DMCLVOZ	DN	Aminocarbonyl dihydrogen phosphate
DMCLVOZ	HS	Investigative
DMCLVOZ	SN	carbamoylphosphate; CARBAMYL PHOSPHATE; Carbamoyl phosphate; phosphono carbamate; 590-55-6; aminocarbonyl dihydrogen phosphate; monocarbamoyl phosphate; PHOSPHORIC ACID MONO(FORMAMIDE)ESTER; carbamoyl dihydrogen phosphate; CHEMBL369105; carbamic phosphoric monoanhydride; CHEBI:17672; carbamoyl-P; carbamyl-phosphate; carbamoyl-phosphate; carbamoyl phosphoric acid; AC1L18VP; SCHEMBL50374; Carbamic acid, monoanhydride with phosphoric acid; (carbamoyloxy)phosphonic acid; AC1Q68Q7; ZINC8383183; BDBM50162819; AKOS006341689; carbamic aci
DMCLVOZ	DT	Small molecular drug
DMCLVOZ	PC	278
DMCLVOZ	MW	141.02
DMCLVOZ	FM	CH4NO5P
DMCLVOZ	IC	InChI=1S/CH4NO5P/c2-1(3)7-8(4,5)6/h(H2,2,3)(H2,4,5,6)
DMCLVOZ	CS	C(=O)(N)OP(=O)(O)O
DMCLVOZ	IK	FFQKYPRQEYGKAF-UHFFFAOYSA-N
DMCLVOZ	IU	phosphono carbamate
DMCLVOZ	CA	CAS 590-55-6
DMCLVOZ	CB	CHEBI:17672
DMCLVOZ	DE	Discovery agent

DM79E2K	ID	DM79E2K
DM79E2K	DN	Aminodeoxykanamycin
DM79E2K	HS	Investigative
DM79E2K	SN	Aminodeoxykanamycin; bekanamycin; Kanamycin B; nebramycin factor 5; Bekanamycine; Bekanamycinum; Becanamicina; Bekanamycinum [INN-Latin]; Bekanamycine [INN-French]; Becanamicina [INN-Spanish]; EINECS 225-170-5; BRN 0061646; Aminodeoxykanamycin sulfate; 4696-76-8; Antibiotic derived from Streptomyces kanamyceticus; AC1L2FQA; AC1Q57UP; Antibiotic derived from Streptomyces kanamyceticus. Kanamycin B; (1r,2s,4r,6s)-4,6-diamino-3-[(3-amino-3-deoxy-; A-d-glucopyranosyl)oxy]-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-
DM79E2K	DT	Small molecular drug
DM79E2K	PC	439318
DM79E2K	MW	483.5
DM79E2K	FM	C18H37N5O10
DM79E2K	IC	InChI=1S/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1
DM79E2K	CS	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N
DM79E2K	IK	SKKLOUVUUNMCJE-FQSMHNGLSA-N
DM79E2K	IU	(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4-diol
DM79E2K	CA	CAS 4696-76-8
DM79E2K	CB	CHEBI:28098
DM79E2K	DE	Discovery agent

DM7Y6AL	ID	DM7Y6AL
DM7Y6AL	DN	AMINOFENTANYL
DM7Y6AL	HS	Investigative
DM7Y6AL	SN	CHEMBL385168; AMINOFENTANYL; BDBM50191054
DM7Y6AL	DT	Small molecular drug
DM7Y6AL	PC	44416393
DM7Y6AL	MW	351.5
DM7Y6AL	FM	C22H29N3O
DM7Y6AL	IC	InChI=1S/C22H29N3O/c23-15-11-22(26)25(20-9-5-2-6-10-20)21-13-17-24(18-14-21)16-12-19-7-3-1-4-8-19/h1-10,21H,11-18,23H2
DM7Y6AL	CS	C1CN(CCC1N(C2=CC=CC=C2)C(=O)CCN)CCC3=CC=CC=C3
DM7Y6AL	IK	WBHIZNRNVFOZMJ-UHFFFAOYSA-N
DM7Y6AL	IU	3-amino-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
DM7Y6AL	DE	Discovery agent

DMUN54G	ID	DMUN54G
DMUN54G	DN	Aminohippuric acid
DMUN54G	HS	Investigative
DMUN54G	SN	4-Aminohippuric acid; aminohippuric acid; 61-78-9; P-AMINOHIPPURIC ACID; Paha; Glycine, N-(4-aminobenzoyl)-; N-(4-Aminobenzoyl)glycine; para-Aminohippuric acid; Nefrotest; 2-(4-aminobenzamido)acetic acid; N-(p-Aminobenzoyl)glycine; p-Aminohippurate; Aminohippurate; PAH (amino acid); 4-Amino hippuric acid; N-(para-aminobenzoyl)glycine; Hippuric acid, p-amino-; N-(p-Aminobenzoyl)aminoacetic acid; para-Aminohippurate; paraaminohippuric acid; PAH; UNII-Y79XT83BJ9; NSC 13064; HSDB 2139; 4-Aminobenzoyl Glycine; EINECS 200-518-9
DMUN54G	DT	Small molecular drug
DMUN54G	PC	2148
DMUN54G	MW	194.19
DMUN54G	FM	C9H10N2O3
DMUN54G	IC	InChI=1S/C9H10N2O3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5,10H2,(H,11,14)(H,12,13)
DMUN54G	CS	C1=CC(=CC=C1C(=O)NCC(=O)O)N
DMUN54G	IK	HSMNQINEKMPTIC-UHFFFAOYSA-N
DMUN54G	IU	2-[(4-aminobenzoyl)amino]acetic acid
DMUN54G	CA	CAS 61-78-9
DMUN54G	CB	CHEBI:104011
DMUN54G	DE	Discovery agent

DMNX9FC	ID	DMNX9FC
DMNX9FC	DN	Aminomethylcyclohexane
DMNX9FC	HS	Investigative
DMNX9FC	SN	Cyclohexanemethylamine; Cyclohexylmethanamine; 3218-02-8; Aminomethylcyclohexane; (Aminomethyl)cyclohexane; Cyclohexanemethanamine; 1-Cyclohexylmethanamine; Hexahydrobenzylamine; 1-cyclohexylmethylamine; 4-aminomethylcyclohexane; C-Cyclohexyl-methylamine; CHEMBL1049; DECARBOXYLATED DERIVATIVE; AVKNGPAMCBSNSO-UHFFFAOYSA-N; EINECS 221-741-8; NSC 172991; BRN 0635751; 1tng; Cyclohexanemethyamine; cyclohexylmethyl amine; cyclohexanemethylamirie; CyclohexYl-Methanamine; cyclohexanemethyl amine; cyclohexane methylamine
DMNX9FC	DT	Small molecular drug
DMNX9FC	PC	76688
DMNX9FC	MW	113.2
DMNX9FC	FM	C7H15N
DMNX9FC	IC	InChI=1S/C7H15N/c8-6-7-4-2-1-3-5-7/h7H,1-6,8H2
DMNX9FC	CS	C1CCC(CC1)CN
DMNX9FC	IK	AVKNGPAMCBSNSO-UHFFFAOYSA-N
DMNX9FC	IU	cyclohexylmethanamine
DMNX9FC	CA	CAS 3218-02-8
DMNX9FC	DE	Discovery agent

DMHNDTW	ID	DMHNDTW
DMHNDTW	DN	aminooxyacetic acid
DMHNDTW	HS	Investigative
DMHNDTW	SN	Aminooxyacetic acid; (aminooxy)acetic acid; 2-(Aminooxy)acetic acid; AOAA; carboxymethoxylamine; 645-88-5; Carboxymethoxyamine; ACETIC ACID, (AMINOOXY)-; Aminooxyacetate; Aminooxy-acetic acid; (Carboxymethoxy)amine; (o-Carboxymethyl)hydroxylamine; aminoxyacetic acid; UNII-14I68GI3OQ; BRN 0878238; C2H5NO3; 14I68GI3OQ; U 7524; NQRKYASMKDDGHT-UHFFFAOYSA-N; u-7524; AOA; Aminooxyacetic acid hemihydrochloride; Carboxymethoxylamine hemihydrochloride; aminoxy-acetic acid; amino-oxyacetic acid; AOA hemihydrochloride; 2-aminooxyacetic acid;  AOAA
DMHNDTW	DT	Small molecular drug
DMHNDTW	PC	286
DMHNDTW	MW	91.07
DMHNDTW	FM	C2H5NO3
DMHNDTW	IC	InChI=1S/C2H5NO3/c3-6-1-2(4)5/h1,3H2,(H,4,5)
DMHNDTW	CS	C(C(=O)O)ON
DMHNDTW	IK	NQRKYASMKDDGHT-UHFFFAOYSA-N
DMHNDTW	IU	2-aminooxyacetic acid
DMHNDTW	CA	CAS 645-88-5
DMHNDTW	CB	CHEBI:40823
DMHNDTW	DE	Discovery agent

DMEMCQ9	ID	DMEMCQ9
DMEMCQ9	DN	Aminophenol
DMEMCQ9	HS	Investigative
DMEMCQ9	SN	Benzofur GG; Fouramine OP; Nako Yellow 3GA; Nako Yellow ga; O-AMINOPHENOL; ORTHO AMINO PHENOL; Paradone Olive Green B; Pelagol 3GA; Pelagol Grey GG; 2-Aminophenol; BASF ursol 3GA; Phenol, 2-amino-; Phenol, o-amino-; Questiomycin B; Zoba 3GA; o-Hydroxyaniline; o-Hydroxyphenylamine; ortho-aminophenol; 1-Amino-2-hydroxybenzene; 1-Hydroxy-2-aminobenzene; 2-Amino-1-hydroxybenzene; 2-Aminobenzenol; 2-Hydroxyanaline; 2-Hydroxyaniline; 2-amino-phenol; 95-55-6; C.I. 76520; C.I. Oxidation Base 17; CI Oxidation Base 17; NSC 1534
DMEMCQ9	PC	5801
DMEMCQ9	MW	109.13
DMEMCQ9	FM	C6H7NO
DMEMCQ9	IC	CDAWCLOXVUBKRW-UHFFFAOYSA-N
DMEMCQ9	CS	C1=CC=C(C(=C1)N)O
DMEMCQ9	IK	1S/C6H7NO/c7-5-3-1-2-4-6(5)8/h1-4,8H,7H2
DMEMCQ9	IU	2-aminophenol
DMEMCQ9	CA	CAS 95-55-6
DMEMCQ9	CB	CHEBI:18112
DMEMCQ9	DE	Discovery agent

DMT5HOA	ID	DMT5HOA
DMT5HOA	DN	amino-propylphosphinic acid
DMT5HOA	HS	Investigative
DMT5HOA	SN	Diadenosine diphosphate; AC1L4MLM; [({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4R,5S)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy})phosphinic acid; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
DMT5HOA	DT	Small molecular drug
DMT5HOA	PC	188326
DMT5HOA	MW	676.4
DMT5HOA	FM	C20H26N10O13P2
DMT5HOA	IC	InChI=1S/C20H26N10O13P2/c21-15-9-17(25-3-23-15)29(5-27-9)19-12(33)11(32)8(41-19)2-39-44(35,36)43-45(37,38)42-14-7(1-31)40-20(13(14)34)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20+/m1/s1
DMT5HOA	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O[C@@H]4[C@H](O[C@@H]([C@@H]4O)N5C=NC6=C(N=CN=C65)N)CO)O)O)N
DMT5HOA	IK	FHISWBUCBBVWGG-SNESVTBZSA-N
DMT5HOA	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
DMT5HOA	CA	CAS 14938-28-4
DMT5HOA	DE	Discovery agent

DMKLC3O	ID	DMKLC3O
DMKLC3O	DN	aminopurvalanol A
DMKLC3O	HS	Investigative
DMKLC3O	SN	NG-97
DMKLC3O	DT	Small molecular drug
DMKLC3O	PC	6604931
DMKLC3O	MW	403.9
DMKLC3O	FM	C19H26ClN7O
DMKLC3O	IC	InChI=1S/C19H26ClN7O/c1-10(2)15(8-28)24-19-25-17(23-14-6-12(20)5-13(21)7-14)16-18(26-19)27(9-22-16)11(3)4/h5-7,9-11,15,28H,8,21H2,1-4H3,(H2,23,24,25,26)/t15-/m0/s1
DMKLC3O	CS	CC(C)[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=CC(=C3)N)Cl
DMKLC3O	IK	RAMROQQYRRQPDL-HNNXBMFYSA-N
DMKLC3O	IU	(2R)-2-[[6-(3-amino-5-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol
DMKLC3O	CB	CHEBI:38937

DM94KQP	ID	DM94KQP
DM94KQP	DN	Aminopyridine deriv. 2
DM94KQP	HS	Investigative
DM94KQP	SN	JNK Inhibitor VIII; TCS JNK 6o; 894804-07-0; aminopyridine deriv. 2; N-(4-Amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)acetamide; Kinome_3020; SCHEMBL157014; GTPL5998; CHEMBL210618; BDBM15908; Aminopyridine-Based Inhibitor 6o; CTK8E8164; DTXSID20469650; MolPort-023-276-703; HMS3229K06; IN1283; ZINC14959960; AKOS024457488; CCG-206859; NCGC00387087-01; RT-013406; B7321
DM94KQP	DT	Small molecular drug
DM94KQP	PC	11624601
DM94KQP	MW	356.4
DM94KQP	FM	C18H20N4O4
DM94KQP	IC	InChI=1S/C18H20N4O4/c1-4-26-18-13(10-19)14(20)9-16(22-18)21-17(23)8-11-7-12(24-2)5-6-15(11)25-3/h5-7,9H,4,8H2,1-3H3,(H3,20,21,22,23)
DM94KQP	CS	CCOC1=C(C(=CC(=N1)NC(=O)CC2=C(C=CC(=C2)OC)OC)N)C#N
DM94KQP	IK	KQMPRSZTUSSXND-UHFFFAOYSA-N
DM94KQP	IU	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)acetamide
DM94KQP	CA	CAS 894804-07-0
DM94KQP	DE	Discovery agent

DMGEVBH	ID	DMGEVBH
DMGEVBH	DN	Aminothiazoline
DMGEVBH	HS	Investigative
DMGEVBH	SN	2-AMINOTHIAZOLE; aminothiazole; 96-50-4; thiazol-2-amine; 2-Thiazolamine; 1,3-Thiazol-2-amine; 2-Thiazolylamine; Abadole; Basedol; Abadol; 2-Thiazylamine; 4-Thiazolin-2-onimine; 2-Amino-1,3-thiazole; Aminothiazol; Aminotiazol; Aminothiazolum; Thiazole, 2-amino-; 2-Aminothiazol; 2-amino thiazole; USAF EK-P-5501; Aminothiazole [INN]; Aminotiazolo [DCIT]; Thiazolamine; RP 2921; Aminothiazol [INN-French]; Aminotiazol [INN-Spanish]; NSC 1900; Aminothiazolum [INN-Latin]; Thiazol-2-ylamine; UNII-5K8WKN668K; CCRIS 1279; 2-Aminothiazole, 97%
DMGEVBH	DT	Small molecular drug
DMGEVBH	PC	2155
DMGEVBH	MW	100.14
DMGEVBH	FM	C3H4N2S
DMGEVBH	IC	InChI=1S/C3H4N2S/c4-3-5-1-2-6-3/h1-2H,(H2,4,5)
DMGEVBH	CS	C1=CSC(=N1)N
DMGEVBH	IK	RAIPHJJURHTUIC-UHFFFAOYSA-N
DMGEVBH	IU	1,3-thiazol-2-amine
DMGEVBH	CA	CAS 96-50-4
DMGEVBH	CB	CHEBI:40782
DMGEVBH	DE	Discovery agent

DMXDUCP	ID	DMXDUCP
DMXDUCP	DN	AMN082
DMXDUCP	HS	Investigative
DMXDUCP	SN	AMN-082; AMN 082
DMXDUCP	DT	Small molecular drug
DMXDUCP	PC	11698390
DMXDUCP	MW	465.5
DMXDUCP	FM	C28H30Cl2N2
DMXDUCP	IC	InChI=1S/C28H28N2.2ClH/c1-5-13-23(14-6-1)27(24-15-7-2-8-16-24)29-21-22-30-28(25-17-9-3-10-18-25)26-19-11-4-12-20-26;;/h1-20,27-30H,21-22H2;2*1H
DMXDUCP	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)NCCNC(C3=CC=CC=C3)C4=CC=CC=C4.Cl.Cl
DMXDUCP	IK	YRQCDCNQANSUPB-UHFFFAOYSA-N
DMXDUCP	IU	N,N'-dibenzhydrylethane-1,2-diamine;dihydrochloride
DMXDUCP	DE	Discovery agent

DMC15DM	ID	DMC15DM
DMC15DM	DN	Amooranin
DMC15DM	HS	Investigative
DMC15DM	SN	MCH-100XC2; Caspase-8 stimulator/apoptosis stimulator/cell cycle inhibitor (cancer), Dharma Biomedical; P-glycoprotein modulator (small molecule therapeutic/natural product, cancer/autoimmune diseases/inflammatory diseases), Dharma BioMedical
DMC15DM	CP	Dharma Biomedical
DMC15DM	PC	11503749
DMC15DM	MW	470.7
DMC15DM	FM	C30H46O4
DMC15DM	IC	InChI=1S/C30H46O4/c1-25(2)13-15-29(24(33)34)16-14-27(5)19(20(29)17-25)7-8-22-28(27,6)11-9-21-26(3,4)23(32)10-12-30(21,22)18-31/h7,20-22,31H,8-18H2,1-6H3,(H,33,34)/t20-,21-,22-,27+,28+,29-,30+/m0/s1
DMC15DM	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(CCC(=O)C3(C)C)CO
DMC15DM	IK	SEOWASFHYNYGBU-RHXAIUOTSA-N
DMC15DM	IU	(4aS,6aS,6aS,6bR,8aR,12aS,14bS)-12a-(hydroxymethyl)-2,2,6a,6b,9,9-hexamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-4a-carboxylic acid
DMC15DM	DE	Autoimmune diabetes

DM64X25	ID	DM64X25
DM64X25	DN	AMPE4L
DM64X25	HS	Investigative
DM64X25	SN	Exendin4-Fc-Leptin; GLP1-Fc-Leptin; Exendin4-Fc-Leptin fusion protein (diabetes/obesity), Amprotein
DM64X25	CP	AmProtein Corp
DM64X25	DE	Diabetic complication

DMVHOQE	ID	DMVHOQE
DMVHOQE	DN	AMPPL
DMVHOQE	HS	Investigative
DMVHOQE	SN	PYY-Fc-Leptin; PYY-Fc-Leptin fusion protein (diabetes/obesity), Amprotein
DMVHOQE	CP	AmProtein Corp
DMVHOQE	DE	Diabetic complication

DMTOK1D	ID	DMTOK1D
DMTOK1D	DN	AMP-PNP
DMTOK1D	HS	Investigative
DMTOK1D	SN	Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; phosphoaminophosphonic acid-adenylate ester; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine; Phosphoaminophosphonic Acid-Adenylate Ester
DMTOK1D	DT	Small molecular drug
DMTOK1D	PC	33113
DMTOK1D	MW	506.2
DMTOK1D	FM	C10H17N6O12P3
DMTOK1D	IC	InChI=1S/C10H17N6O12P3/c11-8-5-9(13-2-12-8)16(3-14-5)10-7(18)6(17)4(27-10)1-26-31(24,25)28-30(22,23)15-29(19,20)21/h2-4,6-7,10,17-18H,1H2,(H,24,25)(H2,11,12,13)(H4,15,19,20,21,22,23)/t4-,6-,7-,10-/m1/s1
DMTOK1D	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N
DMTOK1D	IK	PVKSNHVPLWYQGJ-KQYNXXCUSA-N
DMTOK1D	IU	[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid
DMTOK1D	CA	CAS 25612-73-1
DMTOK1D	CB	CHEBI:47785
DMTOK1D	DE	Discovery agent

DMXRIUT	ID	DMXRIUT
DMXRIUT	DN	AMPSL
DMXRIUT	HS	Investigative
DMXRIUT	SN	Symlin-Fc-Leptin; Symlin-Fc-Leptin fusion protein (diabetes/obesity), Amprotein
DMXRIUT	CP	AmProtein Corp
DMXRIUT	DE	Diabetic complication

DM7WTKJ	ID	DM7WTKJ
DM7WTKJ	DN	AMR-SIX-1
DM7WTKJ	HS	Investigative
DM7WTKJ	SN	5-HT 6 modulators (obesity), Albany Molecular Research
DM7WTKJ	CP	Albany Molecular Research Inc
DM7WTKJ	DE	Obesity

DMO7EBX	ID	DMO7EBX
DMO7EBX	DN	AMSH
DMO7EBX	HS	Investigative
DMO7EBX	DE	Female sexual arousal dysfunction

DM4OCAH	ID	DM4OCAH
DM4OCAH	DN	AMTB
DM4OCAH	HS	Investigative
DM4OCAH	SN	AMTB; CHEMBL1289953; GTPL4132; SCHEMBL10039870; ZINC35076019; BDBM50331290; N-(3-aminopropyl)-2-(3-methylbenzyloxy)-N-(thiophen-2-ylmethyl)benzamide; N-(3-aminopropyl)-2-{[(3-methylphenyl)methyl]oxy}-N-(2-thienylmethyl)benzamide
DM4OCAH	DT	Small molecular drug
DM4OCAH	PC	16095384
DM4OCAH	MW	394.5
DM4OCAH	FM	C23H26N2O2S
DM4OCAH	IC	InChI=1S/C23H26N2O2S/c1-18-7-4-8-19(15-18)17-27-22-11-3-2-10-21(22)23(26)25(13-6-12-24)16-20-9-5-14-28-20/h2-5,7-11,14-15H,6,12-13,16-17,24H2,1H3
DM4OCAH	CS	CC1=CC(=CC=C1)COC2=CC=CC=C2C(=O)N(CCCN)CC3=CC=CS3
DM4OCAH	IK	LCQJRANJHOEQFG-UHFFFAOYSA-N
DM4OCAH	IU	N-(3-aminopropyl)-2-[(3-methylphenyl)methoxy]-N-(thiophen-2-ylmethyl)benzamide
DM4OCAH	DE	Discovery agent

DMBAX3P	ID	DMBAX3P
DMBAX3P	DN	amthamine
DMBAX3P	HS	Investigative
DMBAX3P	SN	Amthamine; 142437-67-0; 2-Amino-5-(2-aminoethyl)-4-methylthiazole; 5-(2-aminoethyl)-4-methyl-1,3-thiazol-2-amine; Tocris-0668; 5-(2-aminoethyl)-4-methylthiazol-2-amine; AC1L2QR3; SCHEMBL400272; ZINC5099; GTPL4025; CHEMBL293762; BDBM22881; CTK8E9579; CHEBI:92694; DTXSID80162039; AKOS006271424; RL01758; NCGC00024719-01; NCGC00024719-02; 5-Thiazoleethanamine, 2-amino-4-methyl-; KB-47389; RT-011284; FT-0694778; 2-AMINO-4-METHYLTHIAZOLE-5-ETHANAMINE; L000107; J-007652
DMBAX3P	DT	Small molecular drug
DMBAX3P	PC	126688
DMBAX3P	MW	157.24
DMBAX3P	FM	C6H11N3S
DMBAX3P	IC	InChI=1S/C6H11N3S/c1-4-5(2-3-7)10-6(8)9-4/h2-3,7H2,1H3,(H2,8,9)
DMBAX3P	CS	CC1=C(SC(=N1)N)CCN
DMBAX3P	IK	LHVRFUVVRXGZPV-UHFFFAOYSA-N
DMBAX3P	IU	5-(2-aminoethyl)-4-methyl-1,3-thiazol-2-amine
DMBAX3P	CA	CAS 142437-67-0
DMBAX3P	CB	CHEBI:92694
DMBAX3P	DE	Discovery agent

DMGHXQE	ID	DMGHXQE
DMGHXQE	DN	AMX-256
DMGHXQE	HS	Investigative
DMGHXQE	SN	GLP-2 (XTEN formulation, Crohns disease), Amunix; GLP-2 (XTEN formulation, Crohns disease/short bowel syndrome), Amunix
DMGHXQE	CP	Amunix Inc
DMGHXQE	DE	Short bowel syndrome

DMPSRZ0	ID	DMPSRZ0
DMPSRZ0	DN	AMXT-1501
DMPSRZ0	HS	Investigative
DMPSRZ0	SN	Difluoromethylornithine + polyamine transport inhibitors (head and neck cancer), Aminex Therapeutics; Polyamine transport inhibitors + polyamine biosynthesis inhibitor (head and neck cancer), Aminex Therapeutics/MediQuest Therapeutics; MQT-1426 + DFMO (head and neck cancer), Aminex Therapeutics/MediQuest Therapeutics; Polyamine-based therapy (head and neck-squamous cell carcinoma), Aminex Therapeutics/MediQuest Therapeutics
DMPSRZ0	CP	MediQuest Therapeutics Inc
DMPSRZ0	DE	Head and neck cancer

DM7SHQ1	ID	DM7SHQ1
DM7SHQ1	DN	Amythiamicin
DM7SHQ1	HS	Investigative
DM7SHQ1	DE	Discovery agent

DMRS0LA	ID	DMRS0LA
DMRS0LA	DN	AN-207
DMRS0LA	HS	Investigative
DMRS0LA	SN	D-26232; Doxorubicin-analog-[D-Lys(6)]LHRH conjugate, Tulane University/Zentaris
DMRS0LA	CP	Tulane University
DMRS0LA	PC	16134408
DMRS0LA	MW	1945.1
DMRS0LA	FM	C95H121N19O26
DMRS0LA	IC	InChI=1S/C95H121N19O26/c1-48(2)35-61(87(129)107-60(19-13-31-101-94(97)98)93(135)114-34-14-20-66(114)92(134)103-44-71(96)118)108-85(127)58(106-88(130)62(36-50-24-26-53(116)27-25-50)109-91(133)65(45-115)112-89(131)63(37-51-42-102-57-17-6-5-15-54(51)57)110-90(132)64(38-52-43-99-47-104-52)111-86(128)59-28-29-73(120)105-59)18-7-8-30-100-72(119)22-12-23-74(121)138-46-70(117)95(136)40-56-77(69(41-95)140-75-39-67(80(122)49(3)139-75)113-32-9-10-33-113)84(126)79-78(82(56)124)81(123)55-16-11-21-68(137-4)76(55)83(79)125/h5-6,9,11,15-17,21,24-27,32,42-43,47-49,58-67,69,75,80,102,115-116,122,124,126,136H,7-8,10,12-14,18-20,22-23,28-31,33-41,44-46H2,1-4H3,(H2,96,118)(H,99,104)(H,100,119)(H,103,134)(H,105,120)(H,106,130)(H,107,129)(H,108,127)(H,109,133)(H,110,132)(H,111,128)(H,112,131)(H4,97,98,101)/t49-,58+,59-,60-,61-,62-,63-,64-,65-,66-,67-,69-,75-,80+,95-/m0/s1
DMRS0LA	CS	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)NCC(=O)N)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)O)N1CCC=C1)O
DMRS0LA	IK	OIUSKDFJNIKIQX-OACKXKLTSA-N
DMRS0LA	IU	[2-[(2S,4S)-4-[(2R,4S,5S,6S)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 5-[[(5R)-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]amino]-5-oxopentanoate
DMRS0LA	DE	Solid tumour/cancer

DMIY134	ID	DMIY134
DMIY134	DN	ANA-04
DMIY134	HS	Investigative
DMIY134	SN	ANA-506; ANA-506); ANB-004; Human monoclonal antibody (inflammatory disease/autoimmune disease), AnaptysBio; Multi-specific antibody (autoimmune disease/inflammatory disease), AnaptysBio/VLST Corp
DMIY134	CP	AnaptysBio Inc
DMIY134	DT	Antibody
DMIY134	DE	Autoimmune diabetes

DM3DPSO	ID	DM3DPSO
DM3DPSO	DN	ANA-5
DM3DPSO	HS	Investigative
DM3DPSO	CP	Alzhyme Pty Ltd
DM3DPSO	DE	Alzheimer disease

DMAS5BI	ID	DMAS5BI
DMAS5BI	DN	anacardic acid
DMAS5BI	HS	Investigative
DMAS5BI	SN	Anacardic acid C15:3; CHEMBL464925; (8E,11E,14E)-Anacardic acid; NSC638512; 2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid; 18654-18-7; 2-hydroxy-6-[(8E,11E)-pentadeca-8,11,14-trienyl]benzoic acid; 2-hydroxy-6-[(8E,11E)-pentadeca-8,11,14-trien-1-yl]benzoic acid; 6-(8(Z),11(Z),14-Pentadecatrienyl)salicylic acid; 8,11,14-Anacardic acid; Anacardic acid IV; AC1NTUKB; 6-(8,11,14-Pentadecatrienyl)salicylic acid; Salicylic acid, 6-(8,11,14-pentadecatrienyl)-; SCHEMBL154720; GTPL6999; Benzoic acid, 2-hydroxy-6-(8,11,14-pentade
DMAS5BI	DT	Small molecular drug
DMAS5BI	PC	167551
DMAS5BI	MW	348.5
DMAS5BI	FM	C22H36O3
DMAS5BI	IC	InChI=1S/C22H36O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-17-15-18-20(23)21(19)22(24)25/h15,17-18,23H,2-14,16H2,1H3,(H,24,25)
DMAS5BI	CS	CCCCCCCCCCCCCCCC1=C(C(=CC=C1)O)C(=O)O
DMAS5BI	IK	ADFWQBGTDJIESE-UHFFFAOYSA-N
DMAS5BI	IU	2-hydroxy-6-pentadecylbenzoic acid
DMAS5BI	CA	CAS 16611-84-0
DMAS5BI	CB	CHEBI:2696
DMAS5BI	DE	Discovery agent

DMMKGT4	ID	DMMKGT4
DMMKGT4	DN	analog 3 (Vlattas et al., 1996)
DMMKGT4	HS	Investigative
DMMKGT4	SN	GTPL7994; CHEMBL1160330; analog 3 [Vlattas et al., 1996]; 2-[2-[hydroxy(phosphonooxy)phosphoryl]oxyethyl-methylamino]acetic acid
DMMKGT4	DT	Small molecular drug
DMMKGT4	PC	44306132
DMMKGT4	MW	293.11
DMMKGT4	FM	C5H13NO9P2
DMMKGT4	IC	InChI=1S/C5H13NO9P2/c1-6(4-5(7)8)2-3-14-17(12,13)15-16(9,10)11/h2-4H2,1H3,(H,7,8)(H,12,13)(H2,9,10,11)
DMMKGT4	CS	CN(CCOP(=O)(O)OP(=O)(O)O)CC(=O)O
DMMKGT4	IK	YERUUUBBRAPJND-UHFFFAOYSA-N
DMMKGT4	IU	2-[2-[hydroxy(phosphonooxy)phosphoryl]oxyethyl-methylamino]acetic acid
DMMKGT4	DE	Discovery agent

DMYW5JX	ID	DMYW5JX
DMYW5JX	DN	ANALOG OF DYNORPHIN A
DMYW5JX	HS	Investigative
DMYW5JX	SN	Dynorphin A (1-13); 72957-38-1; Analog of Dynorphin A; UNII-VFC23V742Z; Porcine dynorphin A(1-13); dynorphin (1-13); VFC23V742Z; CHEMBL405618; Dinorphin A (1-13); Dynorphin 1-13; dynorphin A(1-13); BDBM50241435; dynorphin A 1-13; 1-13-Dynorphin A (swine); Dynorphin A1-13; YGGFLRRIRPKLK; YGGFLRRXRPKLK; Dynorphin-(1-13); DYNORPHIN(1-13)-OH; BDBM224024; BDBM214798; L-Lysine, L-tyrosylglycylglycyl-L-phenylalanyl-L-leucyl-L-arginyl-L-arginyl-L-isoleucyl-L-arginyl-L-prolyl-L-lysyl-L-leucyl-; NCGC00163681-02; NCGC00163681-01; 957H381
DMYW5JX	PC	25075996
DMYW5JX	MW	1604
DMYW5JX	FM	C75H126N24O15
DMYW5JX	IC	InChI=1S/C75H126N24O15/c1-7-45(6)61(70(111)94-53(25-17-35-87-75(83)84)71(112)99-36-18-26-58(99)69(110)93-50(21-11-13-31-76)64(105)96-56(38-44(4)5)67(108)95-54(72(113)114)22-12-14-32-77)98-65(106)52(24-16-34-86-74(81)82)91-63(104)51(23-15-33-85-73(79)80)92-66(107)55(37-43(2)3)97-68(109)57(40-46-19-9-8-10-20-46)90-60(102)42-88-59(101)41-89-62(103)49(78)39-47-27-29-48(100)30-28-47/h8-10,19-20,27-30,43-45,49-58,61,100H,7,11-18,21-26,31-42,76-78H2,1-6H3,(H,88,101)(H,89,103)(H,90,102)(H,91,104)(H,92,107)(H,93,110)(H,94,111)(H,95,108)(H,96,105)(H,97,109)(H,98,106)(H,113,114)(H4,79,80,85)(H4,81,82,86)(H4,83,84,87)/t45-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,61-/m0/s1
DMYW5JX	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMYW5JX	IK	OVVIBUHLQIYUEU-IWIISZHXSA-N
DMYW5JX	IU	(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]hexanoic acid
DMYW5JX	CA	CAS 72957-38-1
DMYW5JX	DE	Discovery agent

DM5JN3P	ID	DM5JN3P
DM5JN3P	DN	ANALOGUE A
DM5JN3P	HS	Investigative
DM5JN3P	SN	ANALOGUE A; CHEMBL410852
DM5JN3P	DT	Small molecular drug
DM5JN3P	PC	44450788
DM5JN3P	MW	460.3
DM5JN3P	FM	C23H23Cl2N3O3
DM5JN3P	IC	InChI=1S/C23H23Cl2N3O3/c24-16-5-6-19-15(11-16)13-20(26-19)22(30)27-21(12-14-3-1-2-4-18(14)25)23(31)28-9-7-17(29)8-10-28/h1-6,11,13,17,21,26,29H,7-10,12H2,(H,27,30)/t21-/m0/s1
DM5JN3P	CS	C1CN(CCC1O)C(=O)[C@H](CC2=CC=CC=C2Cl)NC(=O)C3=CC4=C(N3)C=CC(=C4)Cl
DM5JN3P	IK	HJMXVPPJJMSWFO-NRFANRHFSA-N
DM5JN3P	IU	5-chloro-N-[(2S)-3-(2-chlorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboxamide
DM5JN3P	DE	Discovery agent

DMCKH3P	ID	DMCKH3P
DMCKH3P	DN	Anandamide
DMCKH3P	HS	Investigative
DMCKH3P	SN	Anandamide; Arachidonylethanolamide; Arachidonoyl ethanolamide; N-Arachidonoylethanolamine; Anandamide (20.4, n-6); N-Arachidonoyl-2-hydroxyethylamide; 94421-68-8; AEA; N-arachidonoyl ethanolamine; N-(2-Hydroxyethyl)anachidonamide; 5,8,11,14-Eicosatetraenoylethanolamide; arachidonoylethanolamide; (5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide; Arachidonoyl-EA; UNII-UR5G69TJKH; Arachidonic acid N-(hydroxyethyl)amide; Anandamide(20:4, n-6); Anandamide (20:4, n-6)
DMCKH3P	DT	Small molecular drug
DMCKH3P	PC	5281969
DMCKH3P	MW	347.5
DMCKH3P	FM	C22H37NO2
DMCKH3P	IC	InChI=1S/C22H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h6-7,9-10,12-13,15-16,24H,2-5,8,11,14,17-21H2,1H3,(H,23,25)/b7-6-,10-9-,13-12-,16-15-
DMCKH3P	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCO
DMCKH3P	IK	LGEQQWMQCRIYKG-DOFZRALJSA-N
DMCKH3P	IU	(5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide
DMCKH3P	CA	CAS 94421-68-8
DMCKH3P	CB	CHEBI:2700
DMCKH3P	DE	Discovery agent

DMX4P5A	ID	DMX4P5A
DMX4P5A	DN	andarine
DMX4P5A	HS	Investigative
DMX4P5A	SN	GTX007; GTX-007
DMX4P5A	DT	Small molecular drug
DMX4P5A	PC	9824562
DMX4P5A	MW	441.4
DMX4P5A	FM	C19H18F3N3O6
DMX4P5A	IC	InChI=1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14(7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30)15(9-13)19(20,21)22/h3-9,28H,10H2,1-2H3,(H,23,26)(H,24,27)/t18-/m0/s1
DMX4P5A	CS	CC(=O)NC1=CC=C(C=C1)OC[C@@](C)(C(=O)NC2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)O
DMX4P5A	IK	YVXVTLGIDOACBJ-SFHVURJKSA-N
DMX4P5A	IU	(2S)-3-(4-acetamidophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMX4P5A	CA	CAS 401900-40-1
DMX4P5A	CB	CHEBI:94760
DMX4P5A	DE	Discovery agent

DMHL0ID	ID	DMHL0ID
DMHL0ID	DN	Andromustine
DMHL0ID	HS	Investigative
DMHL0ID	SN	GTx-200; SARM (hormone refractory prostate cancer), GTx; Selective androgen receptor modulator (hormone refractory prostate cancer), GTx; Selective androgen receptor modulator (hormone refractory prostate cancer), Merck & Co
DMHL0ID	CP	GTx Inc
DMHL0ID	DE	Prostate cancer

DMPXF5I	ID	DMPXF5I
DMPXF5I	DN	androstanol
DMPXF5I	HS	Investigative
DMPXF5I	SN	5alpha-androstan-3alpha-ol
DMPXF5I	DT	Small molecular drug
DMPXF5I	PC	92877
DMPXF5I	MW	276.5
DMPXF5I	FM	C19H32O
DMPXF5I	IC	InChI=1S/C19H32O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h13-17,20H,3-12H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1
DMPXF5I	CS	C[C@@]12CCC[C@H]1[C@@H]3CC[C@H]4C[C@H](CC[C@@]4([C@H]3CC2)C)O
DMPXF5I	IK	DJTOLSNIKJIDFF-LOVVWNRFSA-N
DMPXF5I	IU	(3S,5S,8S,9S,10S,13S,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMPXF5I	CA	CAS 1224-92-6
DMPXF5I	DE	Discovery agent

DMPL0BA	ID	DMPL0BA
DMPL0BA	DN	ANDROSTENEDONE
DMPL0BA	HS	Investigative
DMPL0BA	SN	androsta-1,4-diene-3,17-dione; Boldione; 1,4-Androstadiene-3,17-dione; 897-06-3; Androstadienedione; 1-Dehydroandrostenedione; NSC 49080; UNII-2166Q8568W; EINECS 212-977-2; ANDROSTA-1,4-DIEN-3,17-DIONE; CHEBI:40799; LUJVUUWNAPIQQI-QAGGRKNESA-N; Androstra-1,4-diene-3,17-dione; 2166Q8568W; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; ANB
DMPL0BA	DT	Small molecular drug
DMPL0BA	PC	13472
DMPL0BA	MW	284.4
DMPL0BA	FM	C19H24O2
DMPL0BA	IC	InChI=1S/C19H24O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1
DMPL0BA	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=O)C=C[C@]34C
DMPL0BA	IK	LUJVUUWNAPIQQI-QAGGRKNESA-N
DMPL0BA	IU	(8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione
DMPL0BA	CA	CAS 897-06-3
DMPL0BA	CB	CHEBI:40799
DMPL0BA	DE	Discovery agent

DM7RXQ6	ID	DM7RXQ6
DM7RXQ6	DN	androstenol
DM7RXQ6	HS	Investigative
DM7RXQ6	SN	5alpha-Androst-16-en-3alpha-ol; Androstenol; 1153-51-1; Androst-16-en-3alpha-ol; 16,17-ANDROSTENE-3-OL; Androst-16-en-3-ol; 3alpha-Hydroxyandrost-16-ene; alpha-androstenol; UNII-48K9VAM062; (3alpha,5alpha)-Androst-16-en-3-ol; Androst-16-en-3-ol, (3alpha,5alpha)-; CHEMBL142348; CHEBI:40933; KRVXMNNRSSQZJP-PHFHYRSDSA-N; 48K9VAM062; Androst-16-en-3-ol, (3a,5a)-;  androst-16-en-3-ol; 16,17-Androstene-3-Ol
DM7RXQ6	DT	Small molecular drug
DM7RXQ6	PC	101989
DM7RXQ6	MW	274.4
DM7RXQ6	FM	C19H30O
DM7RXQ6	IC	InChI=1S/C19H30O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h3,9,13-17,20H,4-8,10-12H2,1-2H3/t13-,14+,15-,16-,17-,18-,19-/m0/s1
DM7RXQ6	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC=C2)CC[C@@H]4[C@@]3(CC[C@H](C4)O)C
DM7RXQ6	IK	KRVXMNNRSSQZJP-PHFHYRSDSA-N
DM7RXQ6	IU	(3R,5S,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM7RXQ6	CA	CAS 1153-51-1
DM7RXQ6	CB	CHEBI:40933
DM7RXQ6	DE	Discovery agent

DMK1IMC	ID	DMK1IMC
DMK1IMC	DN	ANG-2004
DMK1IMC	HS	Investigative
DMK1IMC	SN	ANG-Leptin; EPiC-peptide conjugated leptin (obesity), AngioChem
DMK1IMC	CP	AngioChem Inc
DMK1IMC	DE	Obesity

DMDLVH5	ID	DMDLVH5
DMDLVH5	DN	ANG-2684
DMDLVH5	HS	Investigative
DMDLVH5	SN	ANG-3038; PARP-1 inhibitors (acute pancreatitis/stroke); PARP-1 inhibitors (acute pancreatitis/stroke), Angion Biomedica
DMDLVH5	CP	Angion Biomedica Corp
DMDLVH5	DE	Cerebrovascular ischaemia

DMQ2TNL	ID	DMQ2TNL
DMQ2TNL	DN	ANG-2864
DMQ2TNL	HS	Investigative
DMQ2TNL	SN	PARP inhibitor (ischemia/cancer), Angion Biomedica
DMQ2TNL	CP	Angion Biomedica Corp
DMQ2TNL	DE	Solid tumour/cancer

DMVI93X	ID	DMVI93X
DMVI93X	DN	ANG-3407
DMVI93X	HS	Investigative
DMVI93X	SN	CYP17 inhibitor (prostate tumor), Angion
DMVI93X	CP	Angion Biomedica Corp
DMVI93X	DE	Prostate cancer

DM3KZ7P	ID	DM3KZ7P
DM3KZ7P	DN	Angiostatin/paclitaxel/carboplatin
DM3KZ7P	HS	Investigative
DM3KZ7P	CP	EntreMed
DM3KZ7P	DE	Lung cancer

DMYK0Z9	ID	DMYK0Z9
DMYK0Z9	DN	angiotensin III
DMYK0Z9	HS	Investigative
DMYK0Z9	SN	ang III
DMYK0Z9	DT	Small molecular drug
DMYK0Z9	PC	3082042
DMYK0Z9	MW	931.1
DMYK0Z9	FM	C46H66N12O9
DMYK0Z9	IC	InChI=1S/C46H66N12O9/c1-5-27(4)38(57-40(61)33(21-29-15-17-31(59)18-16-29)53-42(63)37(26(2)3)56-39(60)32(47)13-9-19-51-46(48)49)43(64)54-34(23-30-24-50-25-52-30)44(65)58-20-10-14-36(58)41(62)55-35(45(66)67)22-28-11-7-6-8-12-28/h6-8,11-12,15-18,24-27,32-38,59H,5,9-10,13-14,19-23,47H2,1-4H3,(H,50,52)(H,53,63)(H,54,64)(H,55,62)(H,56,60)(H,57,61)(H,66,67)(H4,48,49,51)/t27-,32-,33-,34-,35-,36-,37-,38-/m0/s1
DMYK0Z9	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)N
DMYK0Z9	IK	QMMRCKSBBNJCMR-KMZPNFOHSA-N
DMYK0Z9	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMYK0Z9	CA	CAS 13602-53-4
DMYK0Z9	CB	CHEBI:89666
DMYK0Z9	DE	Discovery agent

DMR9OD1	ID	DMR9OD1
DMR9OD1	DN	Angiotensin IV
DMR9OD1	HS	Investigative
DMR9OD1	SN	Nle-angiv; Human angiotensin IV; Ile3-angiotensin IV; Huamn angiotensin (3-8); Ang IV; VAL-TYR-ILE-HIS-PRO-PHE; Angiotensin II (3-8), human; 1-De-asp-2-de-arg-5-ile-angiotensin II; (Ile5)-angiotensin II (3-8); Human angiotensin hexapeptide (3-8); (3-8)-5-Isoleucine-angiotensin II; (Des(Asp1,Arg2)-Ile5)angiotensin II; (Isoleucine5)-angiotensin II hexapeptide; CHEMBL261120; 12676-15-2; 5-Isoleucine-angiotensin II 3-8-hexapeptide; 23025-68-5; ANGIOTENSIN I/II (3-8); Angiotensin II (3-8); MLS000069773
DMR9OD1	DT	Small molecular drug
DMR9OD1	PC	123814
DMR9OD1	MW	774.9
DMR9OD1	FM	C40H54N8O8
DMR9OD1	IC	InChI=1S/C40H54N8O8/c1-5-24(4)34(47-35(50)29(44-37(52)33(41)23(2)3)18-26-13-15-28(49)16-14-26)38(53)45-30(20-27-21-42-22-43-27)39(54)48-17-9-12-32(48)36(51)46-31(40(55)56)19-25-10-7-6-8-11-25/h6-8,10-11,13-16,21-24,29-34,49H,5,9,12,17-20,41H2,1-4H3,(H,42,43)(H,44,52)(H,45,53)(H,46,51)(H,47,50)(H,55,56)/t24-,29-,30-,31-,32-,33-,34-/m0/s1
DMR9OD1	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)N
DMR9OD1	IK	QSBGWDDCOJYQGY-KOQODJNWSA-N
DMR9OD1	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMR9OD1	CA	CAS 23025-68-5
DMR9OD1	CB	CHEBI:80127
DMR9OD1	DE	Discovery agent

DMGRWA3	ID	DMGRWA3
DMGRWA3	DN	ANHYDRORYANIDINE
DMGRWA3	HS	Investigative
DMGRWA3	SN	anhydroryanidine; CHEMBL283783; BDBM50044991; 2,6,9,11,13,14-hexahydroxy-11-isopropyl-7,10-dimethyl-3-methylene-(2R,7S,12R)-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadec-12-yl 1H-2-pyrrolecarboxylate(Dehydroryanodine); 2,6,9,11,13,14-hexahydroxy-11-isopropyl-7,10-dimethyl-3-methylene-(1R,7S,9S,12R)-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadec-12-yl 1H-2-pyrrolecarboxylate
DMGRWA3	DT	Small molecular drug
DMGRWA3	PC	44275813
DMGRWA3	MW	491.5
DMGRWA3	FM	C25H33NO9
DMGRWA3	IC	InChI=1S/C25H33NO9/c1-12(2)22(31)17(34-16(28)14-7-6-10-26-14)23(32)18(4)11-21(30)19(22,5)25(23,33)24(35-21)15(27)13(3)8-9-20(18,24)29/h6-7,10,12,15,17,26-27,29-33H,3,8-9,11H2,1-2,4-5H3/t15-,17-,18+,19?,20?,21?,22?,23?,24?,25?/m1/s1
DMGRWA3	CS	CC(C)C1([C@H](C2([C@]3(CC4(C1(C2(C5(C3(CCC(=C)[C@H]5O)O)O4)O)C)O)C)O)OC(=O)C6=CC=CN6)O
DMGRWA3	IK	BPFNBBLVUYSFRK-MKKQGFNNSA-N
DMGRWA3	IU	[(2R,7S,12R)-2,6,9,11,13,14-hexahydroxy-7,10-dimethyl-3-methylidene-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMGRWA3	DE	Discovery agent

DMJX1G9	ID	DMJX1G9
DMJX1G9	DN	ANIBAMINE
DMJX1G9	HS	Investigative
DMJX1G9	SN	anibamine TFA
DMJX1G9	DT	Small molecular drug
DMJX1G9	PC	6479877
DMJX1G9	MW	424.7
DMJX1G9	FM	C30H50N+
DMJX1G9	IC	InChI=1S/C30H50N/c1-5-7-9-11-13-15-17-19-22-28-26(3)29(30-24-21-25-31(30)27(28)4)23-20-18-16-14-12-10-8-6-2/h19-20,22-23H,5-18,21,24-25H2,1-4H3/q+1/b22-19-,23-20-
DMJX1G9	CS	CCCCCCCC/C=C\\C1=C(C(=C2CCC[N+]2=C1C)/C=C\\CCCCCCCC)C
DMJX1G9	IK	LOTZSYKJMYSNJV-IKJQKJQYSA-N
DMJX1G9	IU	6,8-bis[(Z)-dec-1-enyl]-5,7-dimethyl-2,3-dihydro-1H-indolizin-4-ium
DMJX1G9	DE	Discovery agent

DMJCWXK	ID	DMJCWXK
DMJCWXK	DN	Anidulafungin
DMJCWXK	HS	Investigative
DMJCWXK	SN	Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002
DMJCWXK	CP	Pfizer Pharmaceuticals
DMJCWXK	TC	Antiviral Agents
DMJCWXK	DT	Small molecular drug
DMJCWXK	PC	166548
DMJCWXK	MW	1140.2
DMJCWXK	FM	C58H73N7O17
DMJCWXK	IC	InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1
DMJCWXK	CS	CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O
DMJCWXK	IK	JHVAMHSQVVQIOT-MFAJLEFUSA-N
DMJCWXK	IU	N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
DMJCWXK	CA	CAS 166663-25-8
DMJCWXK	CB	CHEBI:55346
DMJCWXK	DE	Convulsion; Coronavirus Disease 2019 (COVID-19)

DMLCAR9	ID	DMLCAR9
DMLCAR9	DN	Aniline
DMLCAR9	HS	Investigative
DMLCAR9	SN	ANILINE; Aminobenzene; Aminophen; Anilin; Anilin [Czech]; Anilina; Anilina [Italian, Polish]; Aniline (and salts); Aniline and homologs; Aniline and homologues; Aniline oil; Aniline reagent; Anyvim; Arylamine; Benzenamine; Benzene, amino; Benzeneamine; Benzidam; Blue Oil; Cyanol; Krystallin; Kyanol; Phenylamine; RCRA waste no. U012; Rcra waste number U012; UN 1547; 62-53-3; C.I. 76000; C.I. Oxidation Base 1; CCRIS 44; CI Oxidation Base 1; Caswell No. 051C; HSDB 43; Huile D'aniline; Huile d'aniline [French]; NCI-C03736; UNII-SIR7XX2F1K
DMLCAR9	PC	6115
DMLCAR9	MW	93.13
DMLCAR9	FM	C6H7N
DMLCAR9	IC	PAYRUJLWNCNPSJ-UHFFFAOYSA-N
DMLCAR9	CS	C1=CC=C(C=C1)N
DMLCAR9	IK	1S/C6H7N/c7-6-4-2-1-3-5-6/h1-5H,7H2
DMLCAR9	IU	aniline
DMLCAR9	CA	CAS 62-53-3
DMLCAR9	CB	CHEBI:17296
DMLCAR9	DE	Discovery agent

DMHA9S3	ID	DMHA9S3
DMHA9S3	DN	ANISOCOUMARIN H
DMHA9S3	HS	Investigative
DMHA9S3	SN	ANISOCOUMARIN H; 123237-86-5; 5'-hydroxyauraptene; MLS000863598; MEGxp0_000088; CHEMBL408980; ACon1_000064; MolPort-001-740-267; HMS2270P13; BDBM50375220; MCULE-1296401261; NCGC00168829-01; SMR000440765; BRD-A19484421-001-01-1
DMHA9S3	DT	Small molecular drug
DMHA9S3	PC	14376449
DMHA9S3	MW	314.4
DMHA9S3	FM	C19H22O4
DMHA9S3	IC	InChI=1S/C19H22O4/c1-13(2)10-16(20)11-14(3)8-9-22-17-6-4-15-5-7-19(21)23-18(15)12-17/h4-8,10,12,16,20H,9,11H2,1-3H3/b14-8+
DMHA9S3	CS	CC(=CC(C/C(=C/COC1=CC2=C(C=C1)C=CC(=O)O2)/C)O)C
DMHA9S3	IK	VNADFOGBKXRWGC-RIYZIHGNSA-N
DMHA9S3	IU	7-[(2E)-5-hydroxy-3,7-dimethylocta-2,6-dienoxy]chromen-2-one
DMHA9S3	DE	Discovery agent

DMZKC7S	ID	DMZKC7S
DMZKC7S	DN	Ankinara
DMZKC7S	HS	Investigative
DMZKC7S	DE	Rheumatoid arthritis; Psoriasis vulgaris; Inflammatory bowel disease

DM0RUQ8	ID	DM0RUQ8
DM0RUQ8	DN	ANNULIN A
DM0RUQ8	HS	Investigative
DM0RUQ8	SN	annulin A; CHEMBL465019; SCHEMBL10013625
DM0RUQ8	DT	Small molecular drug
DM0RUQ8	PC	16059787
DM0RUQ8	MW	360.4
DM0RUQ8	FM	C19H20O7
DM0RUQ8	IC	InChI=1S/C19H20O7/c1-6-9-8(2)7-10-11(14(9)20)16(22)13-12(15(10)21)18(3,4)26-19(13,24)17(23)25-5/h7,20,24H,6H2,1-5H3
DM0RUQ8	CS	CCC1=C(C2=C(C=C1C)C(=O)C3=C(C2=O)C(OC3(C)C)(C(=O)OC)O)O
DM0RUQ8	IK	YRVWWGFREKZPIN-UHFFFAOYSA-N
DM0RUQ8	IU	methyl 6-ethyl-3,5-dihydroxy-1,1,7-trimethyl-4,9-dioxobenzo[f][2]benzofuran-3-carboxylate
DM0RUQ8	DE	Discovery agent

DMDQXJ2	ID	DMDQXJ2
DMDQXJ2	DN	ANNULIN B
DMDQXJ2	HS	Investigative
DMDQXJ2	SN	SCHEMBL10013624
DMDQXJ2	DT	Small molecular drug
DMDQXJ2	PC	44559102
DMDQXJ2	MW	388.4
DMDQXJ2	FM	C21H24O7
DMDQXJ2	IC	InChI=1S/C21H24O7/c1-7-10-9(2)8-11-12(14(10)22)16(24)17-13(15(11)23)20(3,4)18(25)21(5,28-17)19(26)27-6/h8,13,17,22H,7H2,1-6H3
DMDQXJ2	CS	CCC1=C(C2=C(C=C1C)C(=O)C3C(C2=O)OC(C(=O)C3(C)C)(C)C(=O)OC)O
DMDQXJ2	IK	OHWPXNCKGWEEQM-UHFFFAOYSA-N
DMDQXJ2	IU	methyl 8-ethyl-9-hydroxy-2,4,4,7-tetramethyl-3,5,10-trioxo-4a,10a-dihydrobenzo[g]chromene-2-carboxylate
DMDQXJ2	DE	Discovery agent

DMTYQDO	ID	DMTYQDO
DMTYQDO	DN	ANNULIN C
DMTYQDO	HS	Investigative
DMTYQDO	SN	annulin C; CHEMBL518688; SCHEMBL10013628; BDBM50241707; methyl 7-ethyl-8-hydroxy-1-methoxy-3,3,6-trimethyl-4,9-dioxo-1,3,4,9-tetrahydronaphtho[2,3-c]furan-1-carboxylate
DMTYQDO	DT	Small molecular drug
DMTYQDO	PC	16091658
DMTYQDO	MW	374.4
DMTYQDO	FM	C20H22O7
DMTYQDO	IC	InChI=1S/C20H22O7/c1-7-10-9(2)8-11-12(15(10)21)17(23)14-13(16(11)22)19(3,4)27-20(14,26-6)18(24)25-5/h8,21H,7H2,1-6H3
DMTYQDO	CS	CCC1=C(C2=C(C=C1C)C(=O)C3=C(C2=O)C(OC3(C)C)(C(=O)OC)OC)O
DMTYQDO	IK	DSYKJFFQHNSURC-UHFFFAOYSA-N
DMTYQDO	IU	methyl 6-ethyl-5-hydroxy-3-methoxy-1,1,7-trimethyl-4,9-dioxobenzo[f][2]benzofuran-3-carboxylate
DMTYQDO	DE	Discovery agent

DM6DYZ0	ID	DM6DYZ0
DM6DYZ0	DN	ANOLOBINE
DM6DYZ0	HS	Investigative
DM6DYZ0	SN	Anolobine; Anolobin; Annolobine; AC1Q6ZQY; 641-17-8; (R)-6,7,7a,8-Tetrahydro-5H-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinolin-10-ol; CHEBI:2742; CHEMBL257746; Analobine; AC1L4VB7; CTK5C0739; DTXSID60214303; BDBM50202287; 5H-Benzo(g)-1,3-benzodioxolo(6,5,4-de)quinolin-10-ol, 6,7,7a,8-tetrahydro-, (R)-; C09338; 5H-Benzo[g]-1,3-benzodioxolo[6,5,4-de]quinolin-10-ol,6,7,7a,8-tetrahydro-, (7aR)-
DM6DYZ0	DT	Small molecular drug
DM6DYZ0	PC	164710
DM6DYZ0	MW	281.3
DM6DYZ0	FM	C17H15NO3
DM6DYZ0	IC	InChI=1S/C17H15NO3/c19-11-1-2-12-10(5-11)6-13-15-9(3-4-18-13)7-14-17(16(12)15)21-8-20-14/h1-2,5,7,13,18-19H,3-4,6,8H2/t13-/m1/s1
DM6DYZ0	CS	C1CN[C@@H]2CC3=C(C=CC(=C3)O)C4=C2C1=CC5=C4OCO5
DM6DYZ0	IK	LTSPCGWFQLHECP-CYBMUJFWSA-N
DM6DYZ0	IU	(12R)-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14(19),15,17-hexaen-16-ol
DM6DYZ0	CA	CAS 641-17-8
DM6DYZ0	CB	CHEBI:2742
DM6DYZ0	DE	Discovery agent

DMM5PEV	ID	DMM5PEV
DMM5PEV	DN	ANONAINE
DMM5PEV	HS	Investigative
DMM5PEV	SN	Anonaine; (-)-Anonaine; Anonain; (-)-Annonaine; 1862-41-5; CHEBI:76; (7ar)-6,7,7a,8-tetrahydro-5h-[1,3]benzodioxolo[6,5,4-de]benzo[g]quinoline; CHEMBL401798; AC1L4NWO; AC1Q6ZR1; SCHEMBL15800856; CTK4D9192; DTXSID00171865; BDBM50202322; C09339; A15375; 5H-Benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline,6,7,7a,8-tetrahydro-, (7aR)-; (R)-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4'',5'':4,5]benzo[1,2,3-de]quinoline; 5H-Benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7,7a,8-tetrahydro-, (R)-
DMM5PEV	DT	Small molecular drug
DMM5PEV	PC	160597
DMM5PEV	MW	265.31
DMM5PEV	FM	C17H15NO2
DMM5PEV	IC	InChI=1S/C17H15NO2/c1-2-4-12-10(3-1)7-13-15-11(5-6-18-13)8-14-17(16(12)15)20-9-19-14/h1-4,8,13,18H,5-7,9H2/t13-/m1/s1
DMM5PEV	CS	C1CN[C@@H]2CC3=CC=CC=C3C4=C2C1=CC5=C4OCO5
DMM5PEV	IK	VZTUKBKUWSHDFM-CYBMUJFWSA-N
DMM5PEV	IU	(12R)-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14,16,18-hexaene
DMM5PEV	CA	CAS 1862-41-5
DMM5PEV	CB	CHEBI:76
DMM5PEV	DE	Discovery agent

DMGDZ6Q	ID	DMGDZ6Q
DMGDZ6Q	DN	Antanal 1
DMGDZ6Q	HS	Investigative
DMGDZ6Q	SN	antanal 1; CHEMBL507442
DMGDZ6Q	DT	Small molecular drug
DMGDZ6Q	PC	44568843
DMGDZ6Q	MW	688.8
DMGDZ6Q	FM	C40H44N6O5
DMGDZ6Q	IC	InChI=1S/C40H44N6O5/c1-23-16-29(47)17-24(2)31(23)21-32(41)40(51)46-15-7-12-36(46)39(50)45-35(20-28-22-43-33-11-6-5-10-30(28)33)38(49)44-34(37(42)48)19-25-13-14-26-8-3-4-9-27(26)18-25/h3-6,8-11,13-14,16-18,22,32,34-36,43,47H,7,12,15,19-21,41H2,1-2H3,(H2,42,48)(H,44,49)(H,45,50)/t32-,34+,35-,36+/m0/s1
DMGDZ6Q	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC6=CC=CC=C6C=C5)C(=O)N)N)C)O
DMGDZ6Q	IK	RVBUBWGVXJZPJO-GIFUDOJISA-N
DMGDZ6Q	IU	(2R)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMGDZ6Q	DE	Discovery agent

DMZSUHY	ID	DMZSUHY
DMZSUHY	DN	Antanal 2
DMZSUHY	HS	Investigative
DMZSUHY	SN	antanal 2; CHEMBL454035
DMZSUHY	DT	Small molecular drug
DMZSUHY	PC	44568844
DMZSUHY	MW	649.8
DMZSUHY	FM	C38H43N5O5
DMZSUHY	IC	InChI=1S/C38H43N5O5/c1-23-17-29(44)18-24(2)30(23)22-31(39)38(48)43-16-8-13-34(43)37(47)42-33(20-25-9-4-3-5-10-25)36(46)41-32(35(40)45)21-26-14-15-27-11-6-7-12-28(27)19-26/h3-7,9-12,14-15,17-19,31-34,44H,8,13,16,20-22,39H2,1-2H3,(H2,40,45)(H,41,46)(H,42,47)/t31-,32+,33-,34+/m0/s1
DMZSUHY	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CC5=CC=CC=C5C=C4)C(=O)N)N)C)O
DMZSUHY	IK	XQWLHPWPDQSALN-GJZXTFMBSA-N
DMZSUHY	IU	(2R)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMZSUHY	DE	Discovery agent

DMA7LUR	ID	DMA7LUR
DMA7LUR	DN	ANTAQ
DMA7LUR	HS	Investigative
DMA7LUR	DT	Small molecular drug
DMA7LUR	PC	44381715
DMA7LUR	MW	338.4
DMA7LUR	FM	C22H14N2O2
DMA7LUR	IC	InChI=1S/C22H14N2O2/c25-21-18-11-5-6-12-19(18)23-22(26)24(21)20-16-9-3-1-7-14(16)13-15-8-2-4-10-17(15)20/h1-13H,(H,23,26)
DMA7LUR	CS	C1=CC=C2C(=C1)C=C3C=CC=CC3=C2N4C(=O)C5=CC=CC=C5NC4=O
DMA7LUR	IK	SISSLRJYACXIQF-UHFFFAOYSA-N
DMA7LUR	IU	3-anthracen-9-yl-1H-quinazoline-2,4-dione
DMA7LUR	DE	Discovery agent

DM7TOGW	ID	DM7TOGW
DM7TOGW	DN	antarelix
DM7TOGW	HS	Investigative
DM7TOGW	SN	EP 24332; D-23234
DM7TOGW	DT	Small molecular drug
DM7TOGW	PC	16132443
DM7TOGW	MW	1459.1
DM7TOGW	FM	C74H100ClN15O14
DM7TOGW	IC	InChI=1S/C74H100ClN15O14/c1-43(2)35-57(66(96)84-56(19-10-11-32-79-44(3)4)73(103)90-34-14-20-63(90)72(102)81-45(5)64(76)94)85-65(95)55(18-9-12-33-80-74(77)104)83-68(98)59(38-48-24-29-54(93)30-25-48)88-71(101)62(42-91)89-70(100)61(40-50-15-13-31-78-41-50)87-69(99)60(37-47-22-27-53(75)28-23-47)86-67(97)58(82-46(6)92)39-49-21-26-51-16-7-8-17-52(51)36-49/h7-8,13,15-17,21-31,36,41,43-45,55-63,79,91,93H,9-12,14,18-20,32-35,37-40,42H2,1-6H3,(H2,76,94)(H,81,102)(H,82,92)(H,83,98)(H,84,96)(H,85,95)(H,86,97)(H,87,99)(H,88,101)(H,89,100)(H3,77,80,104)/t45?,55-,56+,57+,58-,59+,60+,61-,62+,63-/m1/s1
DM7TOGW	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@@H]1C(=O)NC(C)C(=O)N)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM7TOGW	IK	NOENHWMKHNSHGX-FAZSUBJTSA-N
DM7TOGW	IU	(2R)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(carbamoylamino)hexanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-(1-amino-1-oxopropan-2-yl)pyrrolidine-2-carboxamide
DM7TOGW	CA	CAS 151272-78-5
DM7TOGW	DE	Discovery agent

DMRQVW9	ID	DMRQVW9
DMRQVW9	DN	Anthoptilide C
DMRQVW9	HS	Investigative
DMRQVW9	SN	Anthoptilide C; CHEMBL496433
DMRQVW9	DT	Small molecular drug
DMRQVW9	PC	21775681
DMRQVW9	MW	444.5
DMRQVW9	FM	C25H32O7
DMRQVW9	IC	InChI=1S/C25H32O7/c1-7-22(28)32-21-9-8-13(2)10-20-17(15(4)24(29)31-20)12-18-14(3)11-19(27)23(25(18,21)6)30-16(5)26/h10-11,18,20-21,23H,7-9,12H2,1-6H3/b13-10-/t18-,20-,21+,23-,25-/m0/s1
DMRQVW9	CS	CCC(=O)O[C@@H]1CC/C(=C\\[C@H]2C(=C(C(=O)O2)C)C[C@@H]3[C@@]1([C@H](C(=O)C=C3C)OC(=O)C)C)/C
DMRQVW9	IK	SOZYLLOAOCBQFQ-GUNDZKFLSA-N
DMRQVW9	IU	[(1S,7S,8Z,12R,13S,14R)-14-acetyloxy-4,9,13,17-tetramethyl-5,15-dioxo-6-oxatricyclo[11.4.0.03,7]heptadeca-3,8,16-trien-12-yl] propanoate
DMRQVW9	DE	Discovery agent

DMGEMQX	ID	DMGEMQX
DMGEMQX	DN	Anthracen-10-yl(10H-phenothiazin-10-yl)methanone
DMGEMQX	HS	Investigative
DMGEMQX	SN	CHEMBL392577; anthracen-10-yl(10H-phenothiazin-10-yl)methanone; BDBM50219206; 10-(9-Anthrylcarbonyl)Phenothiazine; Anthracen-9-yl (10H-phenothiazine-10yl) methanone, 5
DMGEMQX	DT	Small molecular drug
DMGEMQX	PC	44435223
DMGEMQX	MW	403.5
DMGEMQX	FM	C27H17NOS
DMGEMQX	IC	InChI=1S/C27H17NOS/c29-27(26-20-11-3-1-9-18(20)17-19-10-2-4-12-21(19)26)28-22-13-5-7-15-24(22)30-25-16-8-6-14-23(25)28/h1-17H
DMGEMQX	CS	C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C(=O)N4C5=CC=CC=C5SC6=CC=CC=C64
DMGEMQX	IK	GEDDVJWUHICGPI-UHFFFAOYSA-N
DMGEMQX	IU	anthracen-9-yl(phenothiazin-10-yl)methanone
DMGEMQX	DE	Discovery agent

DMRC3OU	ID	DMRC3OU
DMRC3OU	DN	Anthracene-2-carboxylic acid hydroxyamide
DMRC3OU	HS	Investigative
DMRC3OU	SN	Anthracene-2-carboxylic acid hydroxyamide; CHEMBL175319; SCHEMBL10362855; Anthracene-2-carbohydroximic acid; BDBM50015189
DMRC3OU	DT	Small molecular drug
DMRC3OU	PC	20227315
DMRC3OU	MW	237.25
DMRC3OU	FM	C15H11NO2
DMRC3OU	IC	InChI=1S/C15H11NO2/c17-15(16-18)13-6-5-12-7-10-3-1-2-4-11(10)8-14(12)9-13/h1-9,18H,(H,16,17)
DMRC3OU	CS	C1=CC=C2C=C3C=C(C=CC3=CC2=C1)C(=O)NO
DMRC3OU	IK	YGGCUZPPJKJWPE-UHFFFAOYSA-N
DMRC3OU	IU	N-hydroxyanthracene-2-carboxamide
DMRC3OU	DE	Discovery agent

DMN1YFU	ID	DMN1YFU
DMN1YFU	DN	Anthraflavic acid
DMN1YFU	HS	Investigative
DMN1YFU	SN	APAJFZPFBHMFQR-UHFFFAOYSA-N; Anthraflavic acid; Anthraflavin; Anthrafravic acid; Anthraquinone, 2,6-dihydroxy-; W83883330W; 2,6-DIHYDROXY-ANTHRAQUINONE; 2,6-Dihydroxyanthra-9,10-quinone; 2,6-Dihydroxyanthraquinone; 2,6-dihydroxy-9,10-anthracenedione; 2,6-dihydroxy-9,10-anthraquinone; 2,6-dihydroxyanthracene-9,10-dione; 84-60-6; 9,10-Anthracenedione, 2,6-dihydroxy-; AK-86236; Az-F; BRN 2054127; CCRIS 5593; CHEBI:34250; CHEMBL298398; EINECS 201-544-3; MFCD00001228; NSC-33531; UNII-W83883330W
DMN1YFU	PC	6776
DMN1YFU	MW	240.21
DMN1YFU	FM	C14H8O4
DMN1YFU	IC	APAJFZPFBHMFQR-UHFFFAOYSA-N
DMN1YFU	CS	C1=CC2=C(C=C1O)C(=O)C3=C(C2=O)C=C(C=C3)O
DMN1YFU	IK	1S/C14H8O4/c15-7-1-3-9-11(5-7)14(18)10-4-2-8(16)6-12(10)13(9)17/h1-6,15-16H
DMN1YFU	IU	2,6-dihydroxyanthracene-9,10-dione
DMN1YFU	CA	CAS 84-60-6
DMN1YFU	CB	CHEBI:34250
DMN1YFU	DE	Discovery agent

DMNEGHJ	ID	DMNEGHJ
DMNEGHJ	DN	Anthramycin
DMNEGHJ	HS	Investigative
DMNEGHJ	SN	Antramycin; ANTHRAMYCIN; Anthramycin [USAN]; C16H17N3O4; Anthramycin (USAN); Antramycinum [INN-Latin]; Antramycine [INN-French]; Antramicina [INN-Spanish]; Antramycin (INN); Ro 5-9000; 4803-27-4; Antibiotic PBA; (E)-5,10,11,11a-Tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-1H-pyrrolo(2,1-c)(1,4)-benzodiazepine-2-acrylamide; AC1NSJTB; AC1Q5IYM; SCHEMBL4513; CHEMBL39373; 1H-Pyrrolo(2,1-c)(1,4)benzodiazepine-2-acrylamide, 5,10,11,11a-tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-, (E)-; 2-Propenamide, 3-(5,10,11,11a-tetrahydro-9,11-dihyd
DMNEGHJ	PC	5311005
DMNEGHJ	MW	315.32
DMNEGHJ	FM	C16H17N3O4
DMNEGHJ	IC	InChI=1S/C16H17N3O4/c1-8-2-4-10-13(14(8)21)18-15(22)11-6-9(3-5-12(17)20)7-19(11)16(10)23/h2-5,7,11,15,18,21-22H,6H2,1H3,(H2,17,20)/b5-3+
DMNEGHJ	CS	CC1=C(C2=C(C=C1)C(=O)N3C=C(CC3C(N2)O)/C=C/C(=O)N)O
DMNEGHJ	IK	VGQOVCHZGQWAOI-HWKANZROSA-N
DMNEGHJ	IU	(E)-3-(4,6-dihydroxy-3-methyl-11-oxo-5,6,6a,7-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl)prop-2-enamide
DMNEGHJ	DE	Discovery agent

DM29I0Y	ID	DM29I0Y
DM29I0Y	DN	ANTHRAQUINONE
DM29I0Y	HS	Investigative
DM29I0Y	SN	84-65-1; 9,10-Anthraquinone; anthracene-9,10-dione; 9,10-Anthracenedione; Anthradione; Hoelite; 9,10-Dioxoanthracene; Corbit; Morkit; 9,10-Anthrachinon; Anthra-9,10-quinone; Anthrapel; 9,10-quinone; Anthrachinon; Caswell No. 052A; Anthraquinone [BSI:ISO]; UNII-030MS0JBDO; NSC 7957; Bis-alkylamino anthraquinone; 9,10-Anthrachinon [Czech]; CCRIS 649; 9,10-Anthracendion; Anthracene, 9,10-dihydro-9,10-dioxo-; CHEBI:40448; HSDB 2074; EINECS 201-549-0; Anthracene-9,10-quinone; EPA Pesticide Chemical Code 122701
DM29I0Y	DT	Small molecular drug
DM29I0Y	PC	6780
DM29I0Y	MW	208.21
DM29I0Y	FM	C14H8O2
DM29I0Y	IC	InChI=1S/C14H8O2/c15-13-9-5-1-2-6-10(9)14(16)12-8-4-3-7-11(12)13/h1-8H
DM29I0Y	CS	C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2=O
DM29I0Y	IK	RZVHIXYEVGDQDX-UHFFFAOYSA-N
DM29I0Y	IU	anthracene-9,10-dione
DM29I0Y	CA	CAS 84-65-1
DM29I0Y	CB	CHEBI:40448
DM29I0Y	DE	Discovery agent

DMWZ093	ID	DMWZ093
DMWZ093	DN	ANTHRONE
DMWZ093	HS	Investigative
DMWZ093	SN	ANTHRONE; 90-44-8; 9(10H)-Anthracenone; Carbothrone; Anthranone; 9-Oxoanthracene; 9,10-Dihydro-9-oxoanthracene; 10H-anthracen-9-one; anthracen-9(10H)-one; Az-O; Anthracene, 9,10-dihydro-9-oxo-; UNII-FP0FJ7K744; CCRIS 3175; CHEBI:33835; HSDB 2158; NSC 1965; EINECS 201-994-0; AI3-11256; FP0FJ7K744; CHEMBL124440; 9-10-dihydro-9-oxoanthracene; 9,10-Dihydro-9-ketoanthracene; RJGDLRCDCYRQOQ-UHFFFAOYSA-N; MFCD00001187; Anthrone, ACS reagent; Anthrone, 95%, pure; 10-hydroanthracen-9-one; A-8100; 9-anthrone; Anthrone, 96%; AC1L1NTG
DMWZ093	DT	Small molecular drug
DMWZ093	PC	7018
DMWZ093	MW	194.23
DMWZ093	FM	C14H10O
DMWZ093	IC	InChI=1S/C14H10O/c15-14-12-7-3-1-5-10(12)9-11-6-2-4-8-13(11)14/h1-8H,9H2
DMWZ093	CS	C1C2=CC=CC=C2C(=O)C3=CC=CC=C31
DMWZ093	IK	RJGDLRCDCYRQOQ-UHFFFAOYSA-N
DMWZ093	IU	10H-anthracen-9-one
DMWZ093	CA	CAS 90-44-8
DMWZ093	CB	CHEBI:33835
DMWZ093	DE	Discovery agent

DM3IOR0	ID	DM3IOR0
DM3IOR0	DN	anti-BrP-LPA
DM3IOR0	HS	Investigative
DM3IOR0	SN	CHEMBL3621356; anti-BrP-LPA; GTPL6987; BDBM50187696; [(1S,3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]phosphonic acid; Hexadecanoic acid (2S,4S)-2-hydroxy-4-bromo-4-(dihydroxyphosphinyl)butyl ester
DM3IOR0	DT	Small molecular drug
DM3IOR0	PC	24771260
DM3IOR0	MW	487.4
DM3IOR0	FM	C20H40BrO6P
DM3IOR0	IC	InChI=1S/C20H40BrO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20(23)27-17-18(22)16-19(21)28(24,25)26/h18-19,22H,2-17H2,1H3,(H2,24,25,26)/t18-,19+/m0/s1
DM3IOR0	CS	CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@@H](P(=O)(O)O)Br)O
DM3IOR0	IK	HLVKVWDSLLFMSX-RBUKOAKNSA-N
DM3IOR0	IU	[(1S,3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]phosphonic acid
DM3IOR0	DE	Discovery agent

DMQJ3ZL	ID	DMQJ3ZL
DMQJ3ZL	DN	Anticalin
DMQJ3ZL	HS	Investigative
DMQJ3ZL	SN	Anticalin (Alzheimer's disease)
DMQJ3ZL	CP	Pieris AG
DMQJ3ZL	DE	Alzheimer disease

DMEHRKA	ID	DMEHRKA
DMEHRKA	DN	Anti-CD20 engineered toxin bodies
DMEHRKA	HS	Investigative
DMEHRKA	SN	Anti-CD20 engineered toxin bodies (lymphoma); Anti-CD20 ETBs (lymphoma), Molecular Templates; Anti-CD20 engineered toxin bodies (lymphoma), Molecular Templates
DMEHRKA	CP	Molecular Templates Inc
DMEHRKA	DE	Lymphoma

DMCYOPR	ID	DMCYOPR
DMCYOPR	DN	Anti-CD-20 mab
DMCYOPR	HS	Investigative
DMCYOPR	SN	Anti-CD-20 mAb (undisclosed indication); Anti-CD-20 mAb (undisclosed indication), PharmAbcine; CD-20 inhibitor (mAb, undisclosed indication), PharmAbcine
DMCYOPR	CP	PharmAbcine
DMCYOPR	DT	Monoclonal antibody
DMCYOPR	DE	Discovery agent

DM8QIB2	ID	DM8QIB2
DM8QIB2	DN	Anti-CD22/CD19 mab-toxin conjugate
DM8QIB2	HS	Investigative
DM8QIB2	CP	Abiogen Pharma
DM8QIB2	DT	Monoclonal antibody
DM8QIB2	DE	Acute lymphoblastic leukaemia

DM5BH7J	ID	DM5BH7J
DM5BH7J	DN	Anti-CD28
DM5BH7J	HS	Investigative
DM5BH7J	SN	Anti-CD28 (immune disease); Anti-CD28 antibody (immune disorder), BMS; Anti-CD28 (immune disease), Bristol-Myers Squibb
DM5BH7J	CP	Bristol-Myers Squibb Co
DM5BH7J	DT	Antibody
DM5BH7J	DE	Immune System disease

DMGZM6V	ID	DMGZM6V
DMGZM6V	DN	Anti-CD40-XTEN
DMGZM6V	HS	Investigative
DMGZM6V	SN	CD40 ligand receptor antagonist (XTEN, rheumatoid arthritis/transplant rejection), Amunix
DMGZM6V	CP	Amunix Inc
DMGZM6V	DE	Rheumatoid arthritis

DM2X1SG	ID	DM2X1SG
DM2X1SG	DN	Anti-cMET mab
DM2X1SG	HS	Investigative
DM2X1SG	SN	Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine
DM2X1SG	CP	PharmAbcine
DM2X1SG	DT	Monoclonal antibody
DM2X1SG	DE	Discovery agent

DMG7PC0	ID	DMG7PC0
DMG7PC0	DN	Anti-D
DMG7PC0	HS	Investigative
DMG7PC0	SN	(2-Amino-D-glucose Hydrochloride); glu-cosamine hydrochloride; 3h-glucosamine hydrochloride; SCHEMBL21212; SPECTRUM1500316; MolPort-003-666-196; Pharmakon1600-01500316; HMS1920B13; NSC757051; CCG-39600
DMG7PC0	DT	Small molecular drug
DMG7PC0	PC	9859210
DMG7PC0	MW	215.63
DMG7PC0	FM	C6H14ClNO5
DMG7PC0	IC	InChI=1S/C6H13NO5.ClH/c7-3-5(10)4(9)2(1-8)12-6(3)11;/h2-6,8-11H,1,7H2;1H/t2-,3-,4-,5-,6-;/m1./s1
DMG7PC0	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)N)O)O)O.Cl
DMG7PC0	IK	QKPLRMLTKYXDST-OCOFDJSDSA-N
DMG7PC0	IU	(2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride
DMG7PC0	CA	CAS 66-84-2
DMG7PC0	DE	Idiopathic thrombocytopenic purpura

DMWLMV2	ID	DMWLMV2
DMWLMV2	DN	Anti-EGFR humanized mabs
DMWLMV2	HS	Investigative
DMWLMV2	SN	Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor
DMWLMV2	CP	Xencor Inc
DMWLMV2	DT	Antibody
DMWLMV2	DE	Solid tumour/cancer

DMW85FP	ID	DMW85FP
DMW85FP	DN	Anti-EGFR mab
DMW85FP	HS	Investigative
DMW85FP	CP	GTC Biotherapeutics Inc
DMW85FP	DT	Antibody
DMW85FP	DE	Discovery agent

DMXWHDC	ID	DMXWHDC
DMXWHDC	DN	Anti-Fas mabs
DMXWHDC	HS	Investigative
DMXWHDC	SN	Anti-Fas mAbs (misfolded proteins, cancer); Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Apexigen; Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Epitomics; Anti-Fas mAbs (misfolded proteins, cancer), Amorfix/Apexigen
DMXWHDC	CP	Amorfix Life Sciences Ltd
DMXWHDC	DT	Antibody
DMXWHDC	DE	Solid tumour/cancer

DMP5VZQ	ID	DMP5VZQ
DMP5VZQ	DN	Anti-FGFR1 mab program
DMP5VZQ	HS	Investigative
DMP5VZQ	SN	Anti-FGFR1 mAb program (cancer); Anti-FGFR1 mAb program (cancer), AVEO Pharmaceuticals; Anti-fibroblast growth factor receptor-1 monoclonal antibody program (cancer), AVEO Pharmaceuticals
DMP5VZQ	CP	Cardiovascular biotherapeutics
DMP5VZQ	DT	Antibody
DMP5VZQ	DE	Solid tumour/cancer

DMMQ3WX	ID	DMMQ3WX
DMMQ3WX	DN	Anti-FGFR2 humanized mab
DMMQ3WX	HS	Investigative
DMMQ3WX	SN	HuGAL-FR21; HuGAL-FR22; Anti-FGFR2 humanized mAb (cancer); Anti-FGFR2 humanized mAb (cancer), Galaxy
DMMQ3WX	CP	Galaxy Biotech LLC
DMMQ3WX	DT	Antibody
DMMQ3WX	DE	Solid tumour/cancer

DM4HKC8	ID	DM4HKC8
DM4HKC8	DN	Anti-GnRH Spiegelmer
DM4HKC8	HS	Investigative
DM4HKC8	DE	Discovery agent

DMVF2YH	ID	DMVF2YH
DMVF2YH	DN	Antileukoprotease (ALP)
DMVF2YH	HS	Investigative
DMVF2YH	DE	Discovery agent

DMO41UZ	ID	DMO41UZ
DMO41UZ	DN	Anti-miR-191 modified oligonucleotide
DMO41UZ	HS	Investigative
DMO41UZ	DT	Antisense drug
DMO41UZ	DE	Hepatocellular carcinoma

DM2EMCW	ID	DM2EMCW
DM2EMCW	DN	Antimycin A
DM2EMCW	HS	Investigative
DM2EMCW	SN	Antimycin A; Antipiricullin; Fintrol; Virosin; Antimycin A1b; antimycin A1; Caswell No. 052B; Antimycin-A; CCRIS 924; HSDB 6417; UNII-75G3NMU1TS; EPA Pesticide Chemical Code 006314; 75G3NMU1TS; CHEMBL211501; CHEBI:22584; 1397-94-0; (2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl 3-methylbutanoate; 642-15-9; 116095-18-2; [(2r,3s,6s,7r,8r)-3-[(3-Formamido-2-Oxidanyl-Phenyl)carbonylamino]-8-Hexyl-2,6-Dimethyl-4,9-Bis(Oxidanylidene)-1,5-Dioxonan-7-Yl] 3-Methylbutanoate
DM2EMCW	DT	Small molecular drug
DM2EMCW	PC	14957
DM2EMCW	MW	548.6
DM2EMCW	FM	C28H40N2O9
DM2EMCW	IC	InChI=1S/C28H40N2O9/c1-6-7-8-9-11-20-25(39-22(32)14-16(2)3)18(5)38-28(36)23(17(4)37-27(20)35)30-26(34)19-12-10-13-21(24(19)33)29-15-31/h10,12-13,15-18,20,23,25,33H,6-9,11,14H2,1-5H3,(H,29,31)(H,30,34)/t17-,18+,20-,23+,25+/m1/s1
DM2EMCW	CS	CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C
DM2EMCW	IK	UIFFUZWRFRDZJC-SBOOETFBSA-N
DM2EMCW	IU	[(2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] 3-methylbutanoate
DM2EMCW	CA	CAS 1397-94-0
DM2EMCW	CB	CHEBI:22584
DM2EMCW	DE	Discovery agent

DMUESP8	ID	DMUESP8
DMUESP8	DN	ANTIOQUINE
DMUESP8	HS	Investigative
DMUESP8	SN	CHEMBL452904; Antioquine (S,R); SCHEMBL6044740
DMUESP8	DT	Small molecular drug
DMUESP8	PC	10393931
DMUESP8	MW	608.7
DMUESP8	FM	C37H40N2O6
DMUESP8	IC	InChI=1S/C37H40N2O6/c1-38-12-10-23-18-32(43-4)33-20-25(23)28(38)16-21-6-8-30(40)26(14-21)27-15-22(7-9-31(27)42-3)17-29-35-24(11-13-39(29)2)19-34(44-5)36(41)37(35)45-33/h6-9,14-15,18-20,28-29,40-41H,10-13,16-17H2,1-5H3/t28-,29+/m1/s1
DMUESP8	CS	CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC(=C(C=C4)O)C5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)O)OC)OC
DMUESP8	IK	MNNXIEANPHEHSB-WDYNHAJCSA-N
DMUESP8	IU	(1R,14S)-9,20,25-trimethoxy-15,30-dimethyl-23-oxa-15,30-diazaheptacyclo[22.6.2.13,7.18,12.114,18.027,31.022,33]pentatriaconta-3(35),4,6,8,10,12(34),18,20,22(33),24,26,31-dodecaene-6,21-diol
DMUESP8	CA	CAS 93767-27-2
DMUESP8	DE	Discovery agent

DM9THZE	ID	DM9THZE
DM9THZE	DN	Antiproliferative Agent A771726
DM9THZE	HS	Investigative
DM9THZE	SN	AC1L1BPO; 2-cyano-3-hydroxy-n-(4-trifluoromethyl-phenyl)-butyramide
DM9THZE	DT	Small molecular drug
DM9THZE	PC	17753809
DM9THZE	MW	272.22
DM9THZE	FM	C12H11F3N2O2
DM9THZE	IC	InChI=1S/C12H11F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,7,10,18H,1H3,(H,17,19)/t7-,10-/m1/s1
DM9THZE	CS	C[C@H]([C@@H](C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O
DM9THZE	IK	YODXEQNROKSLLQ-GMSGAONNSA-N
DM9THZE	IU	(2R,3R)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]butanamide
DM9THZE	DE	Discovery agent

DMO21T7	ID	DMO21T7
DMO21T7	DN	Anti-PSA mabs
DMO21T7	HS	Investigative
DMO21T7	SN	Anti-PSA IgG1; Anti-PSA IgG3; Anti-PSA mAbs (prostate cancer); Anti-PSA mAbs (prostate cancer), University of California/AIT; Anti-PSA monoclonal antibodies (prostate cancer), University of California/Advanced Immune Therapeutics
DMO21T7	CP	Advanced Immune Therapeutics Inc
DMO21T7	DT	Antibody
DMO21T7	DE	Prostate cancer

DMXACM2	ID	DMXACM2
DMXACM2	DN	Anti-RON receptor mabs
DMXACM2	HS	Investigative
DMXACM2	SN	AV-368 series; Hu-07F01; Hu-29B06; Anti-RON receptor mAbs (cancer); Anti-RON receptor mAbs (cancer), AVEO Pharmaceuticals; Anti-RON receptor mAbs (cancer), Centocor Ortho Biotech
DMXACM2	CP	AVEO Pharmaceuticals Inc
DMXACM2	DT	Antibody
DMXACM2	DE	Solid tumour/cancer

DMN76A4	ID	DMN76A4
DMN76A4	DN	Anti-TLR3 mabs
DMN76A4	HS	Investigative
DMN76A4	SN	Anti-TLR3 mAbs (autoimmune and inflammatory disorders)
DMN76A4	CP	Innate Pharma SA
DMN76A4	DT	Monoclonal antibody
DMN76A4	DE	Autoimmune diabetes

DMYKTF6	ID	DMYKTF6
DMYKTF6	DN	Anti-TNF human mabs
DMYKTF6	HS	Investigative
DMYKTF6	SN	Anti-TNF human mAbs (autoimmune disease); Anti-TNF human mAbs (autoimmune disease), Xencor; Anti-TNF human monoclonal antibodies (autoimmune disease), Xencor
DMYKTF6	CP	Xencor Inc
DMYKTF6	DT	Antibody
DMYKTF6	DE	Autoimmune diabetes

DMAJ6TC	ID	DMAJ6TC
DMAJ6TC	DN	Anti-VEGFR 3 mab
DMAJ6TC	HS	Investigative
DMAJ6TC	SN	Anti-VEGFR 3 mAb (undisclosed indication); Anti-VEGFR 3 mAb (undisclosed indication), PharmAbcine; Vascular endothelial growth factor receptor 3 inhibitor (mAb, undisclosed indication), PharmAbcine
DMAJ6TC	CP	PharmAbcine
DMAJ6TC	DT	Monoclonal antibody
DMAJ6TC	DE	Discovery agent

DML1PV3	ID	DML1PV3
DML1PV3	DN	Aom-0763
DML1PV3	HS	Investigative
DML1PV3	SN	Aim-0763; Xanthine oxidase inhibitor (oral/tablet, gout), Hangzhou Adamerck Pharmlabs
DML1PV3	CP	Hangzhou Adamerck Pharmlabs Inc
DML1PV3	DE	Gout

DMT4I2W	ID	DMT4I2W
DMT4I2W	DN	Aom-0890
DMT4I2W	HS	Investigative
DMT4I2W	SN	Aom-0891; PDE5 inhibitors (oral/tablet, erectile dysfunction); PDE5 inhibitors (oral/tablet, erectile dysfunction), Hangzhou Adamerck
DMT4I2W	CP	Hangzhou Adamerck Pharmlabs Inc
DMT4I2W	DE	Erectile dysfunction

DMHR3ZG	ID	DMHR3ZG
DMHR3ZG	DN	AP-101
DMHR3ZG	HS	Investigative
DMHR3ZG	CP	Aprogen Inc
DMHR3ZG	DE	Ischemia

DMRZMKT	ID	DMRZMKT
DMRZMKT	DN	AP-1189
DMRZMKT	HS	Investigative
DMRZMKT	SN	AP-1089; Melanocortin receptor-1 modulator (oral, inflammation), Action Pharma
DMRZMKT	CP	Action Pharma A/S
DMRZMKT	DE	Atopic dermatitis

DMCNG74	ID	DMCNG74
DMCNG74	DN	AP-21967
DMCNG74	HS	Investigative
DMCNG74	SN	CHEMBL525042; AP-21967; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin
DMCNG74	PC	44576241
DMCNG74	MW	1017.3
DMCNG74	FM	C59H88N2O12
DMCNG74	IC	InChI=1S/C59H88N2O12/c1-34-17-12-11-13-18-35(2)45(46-33-60-52-36(3)19-16-20-44(46)52)31-43-24-22-41(8)59(69,73-43)56(66)57(67)61-26-15-14-21-47(61)58(68)72-50(38(5)29-42-23-25-48(62)51(30-42)70-9)32-49(63)37(4)28-40(7)54(65)55(71-10)53(64)39(6)27-34/h11-13,16-20,28,33-34,37-39,41-43,45,47-51,53-55,60,62-65,69H,14-15,21-27,29-32H2,1-10H3/b13-11+,17-12+,35-18+,40-28+/t34-,37-,38-,39-,41-,42+,43+,45+,47+,48-,49+,50+,51-,53+,54-,55+,59-/m1/s1
DMCNG74	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H]([C@@H]([C@@H]([C@@H](/C(=C/[C@H]([C@H](C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)O)C)/C)O)OC)O)C)C)/C)C5=CNC6=C(C=CC=C56)C
DMCNG74	IK	PSLNMAUXUJLNBW-OUPLBGLBSA-N
DMCNG74	IU	(1R,9S,12S,14S,15R,16E,18R,19S,20S,21R,23S,24E,26E,28E,30S,32S,35R)-1,14,18,20-tetrahydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-30-(7-methyl-1H-indol-3-yl)-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10-trione
DMCNG74	DE	Discovery agent

DMQWIEL	ID	DMQWIEL
DMQWIEL	DN	AP-2238
DMQWIEL	HS	Investigative
DMQWIEL	SN	AP-2238; UNII-545225E0BC; CHEMBL75121; 545225E0BC; 3-(4-{[Benzyl(methyl)amino]methyl}-phenyl)-6,7-dimethoxy-2H-2-chromenone; AP2238; 553681-56-4; BDBM10949; 2H-1-Benzopyran-2-one, 6,7-dimethoxy-3-(4-((methyl(phenylmethyl)amino)methyl)phenyl)-
DMQWIEL	DT	Small molecular drug
DMQWIEL	PC	9844749
DMQWIEL	MW	415.5
DMQWIEL	FM	C26H25NO4
DMQWIEL	IC	InChI=1S/C26H25NO4/c1-27(16-18-7-5-4-6-8-18)17-19-9-11-20(12-10-19)22-13-21-14-24(29-2)25(30-3)15-23(21)31-26(22)28/h4-15H,16-17H2,1-3H3
DMQWIEL	CS	CN(CC1=CC=CC=C1)CC2=CC=C(C=C2)C3=CC4=CC(=C(C=C4OC3=O)OC)OC
DMQWIEL	IK	KXMCSAUVAHKCOR-UHFFFAOYSA-N
DMQWIEL	IU	3-[4-[[benzyl(methyl)amino]methyl]phenyl]-6,7-dimethoxychromen-2-one
DMQWIEL	CA	CAS 553681-56-4
DMQWIEL	DE	Discovery agent

DMRYL9X	ID	DMRYL9X
DMRYL9X	DN	AP-2243
DMRYL9X	HS	Investigative
DMRYL9X	SN	AP-2243; CHEMBL244416; BDBM50218528; 3-{4-[(benzylethylamino)methyl]phenyl}-6,7-dimethoxychromen-2-one
DMRYL9X	DT	Small molecular drug
DMRYL9X	PC	23643351
DMRYL9X	MW	429.5
DMRYL9X	FM	C27H27NO4
DMRYL9X	IC	InChI=1S/C27H27NO4/c1-4-28(17-19-8-6-5-7-9-19)18-20-10-12-21(13-11-20)23-14-22-15-25(30-2)26(31-3)16-24(22)32-27(23)29/h5-16H,4,17-18H2,1-3H3
DMRYL9X	CS	CCN(CC1=CC=CC=C1)CC2=CC=C(C=C2)C3=CC4=CC(=C(C=C4OC3=O)OC)OC
DMRYL9X	IK	PNZIOQNBQOTGPK-UHFFFAOYSA-N
DMRYL9X	IU	3-[4-[[benzyl(ethyl)amino]methyl]phenyl]-6,7-dimethoxychromen-2-one
DMRYL9X	DE	Discovery agent

DMVT6Y3	ID	DMVT6Y3
DMVT6Y3	DN	AP-24163
DMVT6Y3	HS	Investigative
DMVT6Y3	SN	AP-24163; CHEMBL539433; 926922-16-9; 3-{(E)-2-[6-(Cyclopropylamino)-9h-Purin-9-Yl]ethenyl}-4-Methyl-N-[3-(4-Methyl-1h-Imidazol-1-Yl)-5-(Trifluoromethyl)phenyl]benzamide; Benzamide,3-[(1E)-2-[6-(cyclopropylamino)-9H-purin-9-yl]ethenyl]-4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-; 3kfa; SCHEMBL4129401; SCHEMBL4129397; ZINC42919869; BDBM50294011; AP24163; KB-74929; 3-(2-(6-(cyclopropylamino)-9H-purin-9-yl)vinyl)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide
DMVT6Y3	DT	Small molecular drug
DMVT6Y3	PC	44517649
DMVT6Y3	MW	558.6
DMVT6Y3	FM	C29H25F3N8O
DMVT6Y3	IC	InChI=1S/C29H25F3N8O/c1-17-3-4-20(9-19(17)7-8-39-16-36-25-26(37-22-5-6-22)33-14-34-27(25)39)28(41)38-23-10-21(29(30,31)32)11-24(12-23)40-13-18(2)35-15-40/h3-4,7-16,22H,5-6H2,1-2H3,(H,38,41)(H,33,34,37)/b8-7+
DMVT6Y3	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)/C=C/N4C=NC5=C(N=CN=C54)NC6CC6
DMVT6Y3	IK	XQBYDVRVYRYLCH-BQYQJAHWSA-N
DMVT6Y3	IU	3-[(E)-2-[6-(cyclopropylamino)purin-9-yl]ethenyl]-4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]benzamide
DMVT6Y3	DE	Discovery agent

DMGTEXD	ID	DMGTEXD
DMGTEXD	DN	AP-24226
DMGTEXD	HS	Investigative
DMGTEXD	SN	AP-24226; UNII-53D46B0TIH; AP24226; 926922-22-7; 53D46B0TIH; CHEMBL556874; SCHEMBL4135035; SCHEMBL4135027; ZINC43058954; BDBM50294010; KB-74711; Benzamide, 3-((1E)-2-(6-(cyclopropylamino)-9H-purin-9-yl)ethenyl)-4-methyl-N-(4-(trifluoromethyl)-2-pyridinyl)-; 3-(2-(6-(cyclopropylamino)-9H-purin-9-yl)vinyl)-4-methyl-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide
DMGTEXD	DT	Small molecular drug
DMGTEXD	PC	25210550
DMGTEXD	MW	479.5
DMGTEXD	FM	C24H20F3N7O
DMGTEXD	IC	InChI=1S/C24H20F3N7O/c1-14-2-3-16(23(35)33-19-11-17(6-8-28-19)24(25,26)27)10-15(14)7-9-34-13-31-20-21(32-18-4-5-18)29-12-30-22(20)34/h2-3,6-13,18H,4-5H2,1H3,(H,28,33,35)(H,29,30,32)/b9-7+
DMGTEXD	CS	CC1=C(C=C(C=C1)C(=O)NC2=NC=CC(=C2)C(F)(F)F)/C=C/N3C=NC4=C(N=CN=C43)NC5CC5
DMGTEXD	IK	PPHMKXKASWTCSZ-VQHVLOKHSA-N
DMGTEXD	IU	3-[(E)-2-[6-(cyclopropylamino)purin-9-yl]ethenyl]-4-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide
DMGTEXD	CA	CAS 926922-22-7
DMGTEXD	DE	Discovery agent

DMBU942	ID	DMBU942
DMBU942	DN	AP-7
DMBU942	HS	Investigative
DMBU942	SN	2-Amino-7-phosphonoheptanoic acid; DL-AP7; 78966-69-5; DL-2-Amino-7-phosphonoheptanoic acid; NSC672105; 85797-13-3; BRN 3544152; CHEMBL274440; Heptanoic acid, 2-amino-7-phosphono-, (+-)-; 2-Amino-7-phosphono-heptanoic acid; Heptanoic acid, 2-amino-7-phosphono-; (+/-)-2-Amino-7-phosphonoheptanoic acid; C7H16NO5P; AP-7 compound; L(+)-2-Amino-7-phosphonoheptanoic acid; AP-7 (drug); AC1L1F7W; Lopac0_000008; SCHEMBL154303; CTK7D4156; ( inverted question mark)-AP-7; MYDMWESTDPJANS-UHFFFAOYSA-N; MolPort-002-514-441
DMBU942	DT	Small molecular drug
DMBU942	PC	3122
DMBU942	MW	225.18
DMBU942	FM	C7H16NO5P
DMBU942	IC	InChI=1S/C7H16NO5P/c8-6(7(9)10)4-2-1-3-5-14(11,12)13/h6H,1-5,8H2,(H,9,10)(H2,11,12,13)
DMBU942	CS	C(CCC(C(=O)O)N)CCP(=O)(O)O
DMBU942	IK	MYDMWESTDPJANS-UHFFFAOYSA-N
DMBU942	IU	2-amino-7-phosphonoheptanoic acid
DMBU942	CA	CAS 85797-13-3
DMBU942	DE	Discovery agent

DMILA4P	ID	DMILA4P
DMILA4P	DN	AP811
DMILA4P	HS	Investigative
DMILA4P	SN	AP-811; AP 811
DMILA4P	DT	Small molecular drug
DMILA4P	PC	73755108
DMILA4P	MW	914.1
DMILA4P	FM	C47H67N11O8
DMILA4P	IC	InChI=1S/C47H67N11O8/c1-6-28(3)27-53-43(63)36(14-11-23-52-47(49)50)56-45(65)38(26-40(60)61)57-46(66)41(29(4)7-2)58-44(64)37(15-10-22-51-30(5)48)55-39(59)24-31-16-20-35(21-17-31)54-42(62)34-19-18-32-12-8-9-13-33(32)25-34/h8-9,12-13,16-21,25,28-29,36-38,41H,6-7,10-11,14-15,22-24,26-27H2,1-5H3,(H2,48,51)(H,53,63)(H,54,62)(H,55,59)(H,56,65)(H,57,66)(H,58,64)(H,60,61)(H4,49,50,52)/t28-,29-,36-,37-,38-,41-/m0/s1
DMILA4P	CS	CC[C@H](C)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCN=C(C)N)NC(=O)CC1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3C=C2
DMILA4P	IK	SSSOLDGLOKWDSV-VLDRZRDYSA-N
DMILA4P	IU	(3S)-3-[[(2S,3S)-2-[[(2S)-5-(1-aminoethylideneamino)-2-[[2-[4-(naphthalene-2-carbonylamino)phenyl]acetyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-2-methylbutyl]amino]-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMILA4P	DE	Discovery agent

DMVG3K1	ID	DMVG3K1
DMVG3K1	DN	APA
DMVG3K1	HS	Investigative
DMVG3K1	SN	1-Aminooxy-3-aminopropane; 3-aminooxy-1-aminopropane; O-(3-aminopropyl)hydroxylamine; 98532-00-4; CHEMBL281021; 1-Propanamine, 3-(aminooxy)-; 3-Aminooxy-1-propanamine; XAP; 3-Aminooxypropylamine; 3-(aminooxy)propan-1-amine; GTPL5139; AC1L22F5; CTK3I7322; DTXSID20243634; BDBM50005719; AKOS006348478; (APA)O-(3-Amino-propyl)-hydroxylamine; O-(3-Aminopropyl)hydroxylamine,;  1-aminooxy-3-aminopropane
DMVG3K1	DT	Small molecular drug
DMVG3K1	PC	65020
DMVG3K1	MW	90.12
DMVG3K1	FM	C3H10N2O
DMVG3K1	IC	InChI=1S/C3H10N2O/c4-2-1-3-6-5/h1-5H2
DMVG3K1	CS	C(CN)CON
DMVG3K1	IK	VSZFWDPIWSPZON-UHFFFAOYSA-N
DMVG3K1	IU	O-(3-aminopropyl)hydroxylamine
DMVG3K1	CA	CAS 98532-00-4
DMVG3K1	DE	Discovery agent

DMYNBK5	ID	DMYNBK5
DMYNBK5	DN	Apamin
DMYNBK5	HS	Investigative
DMYNBK5	SN	08APA001_SMARTOX; GTPL2311; 08APA001; Apamin, synthetic, &gt; Apamin, from bee venom, &gt
DMYNBK5	DT	Small molecular drug
DMYNBK5	PC	16218850
DMYNBK5	MW	2027.4
DMYNBK5	FM	C79H131N31O24S4
DMYNBK5	IC	InChI=1S/C79H131N31O24S4/c1-35(2)26-49-70(127)107-51-31-136-135-30-41(81)63(120)105-50(28-57(84)114)71(128)108-53(73(130)99-42(12-7-8-22-80)64(121)96-38(5)77(134)110-25-11-15-54(110)75(132)102-47(18-21-58(115)116)69(126)109-59(39(6)111)76(133)95-37(4)62(119)104-49)33-138-137-32-52(106-66(123)44(14-10-24-92-79(88)89)98-65(122)43(13-9-23-91-78(86)87)97-61(118)36(3)94-72(51)129)74(131)101-45(16-19-55(82)112)67(124)100-46(17-20-56(83)113)68(125)103-48(60(85)117)27-40-29-90-34-93-40/h29,34-39,41-54,59,111H,7-28,30-33,80-81H2,1-6H3,(H2,82,112)(H2,83,113)(H2,84,114)(H2,85,117)(H,90,93)(H,94,129)(H,95,133)(H,96,121)(H,97,118)(H,98,122)(H,99,130)(H,100,124)(H,101,131)(H,102,132)(H,103,125)(H,104,119)(H,105,120)(H,106,123)(H,107,127)(H,108,128)(H,109,126)(H,115,116)(H4,86,87,91)(H4,88,89,92)/t36-,37-,38-,39+,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,59-/m0/s1
DMYNBK5	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)N)C(=O)N1)CC(C)C)C)[C@@H](C)O)CCC(=O)O)C)CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC4=CN=CN4)C(=O)N)CCCNC(=N)N)CCCNC(=N)N
DMYNBK5	IK	YVIIHEKJCKCXOB-STYWVVQQSA-N
DMYNBK5	IU	3-[(1R,4S,7S,13S,16S,19S,22S,25S,28R,31S,34S,37S,40R,47S,50R)-50-amino-40-[[(2S)-5-amino-1-[[(2S)-5-amino-1-[[(2S)-1-amino-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]-4-(4-aminobutyl)-47-(2-amino-2-oxoethyl)-34,37-bis(3-carbamimidamidopropyl)-19-[(1R)-1-hydroxyethyl]-7,22,31-trimethyl-25-(2-methylpropyl)-2,5,8,14,17,20,23,26,29,32,35,38,46,49-tetradecaoxo-42,43,52,53-tetrathia-3,6,9,15,18,21,24,27,30,33,36,39,45,48-tetradecazatricyclo[26.16.10.09,13]tetrapentacontan-16-yl]propanoic acid
DMYNBK5	DE	Discovery agent

DMNIEHV	ID	DMNIEHV
DMNIEHV	DN	APC-300
DMNIEHV	HS	Investigative
DMNIEHV	SN	CPC-300
DMNIEHV	CP	Colby Pharmaceuticals
DMNIEHV	DE	Prostate cancer

DMT9Z5A	ID	DMT9Z5A
DMT9Z5A	DN	AP-Cav
DMT9Z5A	HS	Investigative
DMT9Z5A	SN	AP-Cav
DMT9Z5A	DT	Small molecular drug
DMT9Z5A	PC	24779772
DMT9Z5A	MW	607.2
DMT9Z5A	FM	C33H51ClN2O6
DMT9Z5A	IC	InChI=1S/C20H30NO3.C13H21NO3.ClH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;4-6,12,14-17H,7-8H2,1-3H3;1H/q+1;;/p-1/t16-,17+,18?,19?,21?;12-;/m.0./s1
DMT9Z5A	CS	CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)[O-])CO)O.Cl
DMT9Z5A	IK	ABSQYTODNZGQMD-ORLLXICISA-M
DMT9Z5A	IU	4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenolate;[(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;hydrochloride
DMT9Z5A	DE	Discovery agent

DMNQ9M1	ID	DMNQ9M1
DMNQ9M1	DN	APCK-110
DMNQ9M1	HS	Investigative
DMNQ9M1	SN	APcK-110MD; C-Kit inhibitors (cancer); C-Kit inhibitors (cancer), MD Anderson
DMNQ9M1	CP	MD Anderson Cancer Center
DMNQ9M1	DE	Solid tumour/cancer

DM2CKUZ	ID	DM2CKUZ
DM2CKUZ	DN	apelin-13
DM2CKUZ	HS	Investigative
DM2CKUZ	SN	[Pyr1]-Apelin-13
DM2CKUZ	DT	Small molecular drug
DM2CKUZ	PC	25078060
DM2CKUZ	MW	1550.8
DM2CKUZ	FM	C69H111N23O16S
DM2CKUZ	IC	InChI=1S/C69H111N23O16S/c1-39(2)32-47(86-58(98)44(17-9-26-78-68(73)74)83-63(103)52-20-12-29-91(52)65(105)45(18-10-27-79-69(75)76)84-56(96)42(71)22-23-54(72)94)59(99)89-50(37-93)61(101)87-48(34-41-35-77-38-81-41)60(100)82-43(16-7-8-25-70)57(97)80-36-55(95)90-28-11-19-51(90)62(102)85-46(24-31-109-3)66(106)92-30-13-21-53(92)64(104)88-49(67(107)108)33-40-14-5-4-6-15-40/h4-6,14-15,35,38-39,42-53,93H,7-13,16-34,36-37,70-71H2,1-3H3,(H2,72,94)(H,77,81)(H,80,97)(H,82,100)(H,83,103)(H,84,96)(H,85,102)(H,86,98)(H,87,101)(H,88,104)(H,89,99)(H,107,108)(H4,73,74,78)(H4,75,76,79)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-/m0/s1
DM2CKUZ	CS	CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N
DM2CKUZ	IK	XXCCRHIAIBQDPX-PEWBXTNBSA-N
DM2CKUZ	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DM2CKUZ	CB	CHEBI:80131
DM2CKUZ	DE	Discovery agent

DM0JW2V	ID	DM0JW2V
DM0JW2V	DN	APETX2
DM0JW2V	HS	Investigative
DM0JW2V	TC	Analgesics
DM0JW2V	PC	90488973
DM0JW2V	MW	4561
DM0JW2V	FM	C196H280N54O61S6
DM0JW2V	IC	InChI=1S/C196H280N54O61S6/c1-12-94(4)152-186(303)230-125(71-107-48-56-112(263)57-49-107)169(286)229-126(72-108-77-209-114-34-20-19-33-113(108)114)170(287)228-122(67-103-31-17-14-18-32-103)167(284)227-123(69-105-44-52-110(261)53-45-105)165(282)223-118(38-25-61-208-196(204)205)190(307)248-62-26-40-141(248)183(300)235-133(86-254)177(294)241-139-92-317-316-91-138(181(298)247-157(101(11)259)192(309)250-64-28-39-140(250)182(299)215-95(5)158(275)232-129(193(310)311)75-151(273)274)239-180(297)137-90-315-313-88-135(236-159(276)96(6)216-187(304)154(98(8)256)242-144(265)76-198)179(296)234-132(85-253)176(293)237-134(163(280)213-79-146(267)218-127(73-143(199)264)171(288)233-131(84-252)175(292)221-115(35-21-22-58-197)160(277)211-81-148(269)243-152)87-312-314-89-136(178(295)222-117(37-24-60-207-195(202)203)164(281)225-124(70-106-46-54-111(262)55-47-106)168(285)226-121(66-102-29-15-13-16-30-102)166(283)224-119(65-93(2)3)162(279)212-82-149(270)244-155(99(9)257)188(305)240-137)238-174(291)130(83-251)219-147(268)80-214-185(302)153(97(7)255)245-173(290)120(68-104-42-50-109(260)51-43-104)217-145(266)78-210-161(278)116(36-23-59-206-194(200)201)220-172(289)128(74-150(271)272)231-189(306)156(100(10)258)246-184(301)142-41-27-63-249(142)191(139)308/h13-20,29-34,42-57,77,93-101,115-142,152-157,209,251-263H,12,21-28,35-41,58-76,78-92,197-198H2,1-11H3,(H2,199,264)(H,210,278)(H,211,277)(H,212,279)(H,213,280)(H,214,302)(H,215,299)(H,216,304)(H,217,266)(H,218,267)(H,219,268)(H,220,289)(H,221,292)(H,222,295)(H,223,282)(H,224,283)(H,225,281)(H,226,285)(H,227,284)(H,228,287)(H,229,286)(H,230,303)(H,231,306)(H,232,275)(H,233,288)(H,234,296)(H,235,300)(H,236,276)(H,237,293)(H,238,291)(H,239,297)(H,240,305)(H,241,294)(H,242,265)(H,243,269)(H,244,270)(H,245,290)(H,246,301)(H,247,298)(H,271,272)(H,273,274)(H,310,311)(H4,200,201,206)(H4,202,203,207)(H4,204,205,208)
DM0JW2V	CS	CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)NC3CSSCC(NC(=O)C4CSSCC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)N4)C(C)O)CC(C)C)CC5=CC=CC=C5)CC6=CC=C(C=C6)O)CCCNC(=N)N)NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C7CCCN7C3=O)C(C)O)CC(=O)O)CCCNC(=N)N)CC8=CC=C(C=C8)O)C(C)O)CO)C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N1)CCCCN)CO)CC(=O)N)CO)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)CN)C(=O)NC(C(C)O)C(=O)N9CCCC9C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)O)CO)CCCNC(=N)N)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CC1=CC=C(C=C1)O
DM0JW2V	IK	HEHYILNFEUDIQC-UHFFFAOYSA-N
DM0JW2V	IU	2-[2-[[1-[2-[[52-[2-[[2-[(2-aminoacetyl)amino]-3-hydroxybutanoyl]amino]propanoylamino]-34-(4-aminobutyl)-40-(2-amino-2-oxoethyl)-19,69-dibenzyl-28-butan-2-yl-13,75,96-tris(3-carbamimidamidopropyl)-99-(carboxymethyl)-2a,60,87-tris(1-hydroxyethyl)-4,37,49,81-tetrakis(hydroxymethyl)-16,25,72,90-tetrakis[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-66-(2-methylpropyl)-1a,3,4a,6,10a,12,15,17a,18,21,24,27,30,33,36,39,42,45,48,51,59,62,65,68,71,74,77,80,83,86,89,92,95,98-tetratriacontaoxo-12a,13a,19a,20a,54,55-hexathia-a,2,3a,5,9a,11,14,16a,17,20,23,26,29,32,35,38,41,44,47,50,58,61,64,67,70,73,76,79,82,85,88,91,94,97-tetratriacontazapentacyclo[55.53.7.446,78.07,11.0105,109]henicosahectane-15a-carbonyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]propanoylamino]butanedioic acid
DM0JW2V	DE	Pain

DMR93WE	ID	DMR93WE
DMR93WE	DN	APG-103
DMR93WE	HS	Investigative
DMR93WE	SN	CD95 receptor inhibitor (inflammatory disease), Apogenix
DMR93WE	CP	Apogenix GmbH
DMR93WE	DE	Inflammation

DM0BVJN	ID	DM0BVJN
DM0BVJN	DN	APG-201
DM0BVJN	HS	Investigative
DM0BVJN	SN	Protein-based apoptosis sensitizer (cancer), Apogenix
DM0BVJN	CP	Apogenix Biotechnology AG
DM0BVJN	DE	Solid tumour/cancer

DMBSDTR	ID	DMBSDTR
DMBSDTR	DN	APG-2305
DMBSDTR	HS	Investigative
DMBSDTR	SN	APG-2303; APG-2307; APG-2309; IL-23 receptor inhibitor (oral, autoimmune disease), Allostera
DMBSDTR	CP	Allostera Pharma Inc
DMBSDTR	DE	Autoimmune diabetes

DMYGKW7	ID	DMYGKW7
DMYGKW7	DN	APH-0911
DMYGKW7	HS	Investigative
DMYGKW7	SN	Docetaxel prodrug (oral nanoparticle formulation), Aphios; Paclitaxel prodrug (oral formulation), Aphios; Docetaxel prodrug (water-soluble), Aphios; Paclitaxel prodrug (water-soluble), Aphios; 10alpha-GAG-docetaxel
DMYGKW7	CP	Aphios Corp
DMYGKW7	DE	Solid tumour/cancer

DM83WVF	ID	DM83WVF
DM83WVF	DN	Apicidin
DM83WVF	HS	Investigative
DM83WVF	SN	CHEMBL430060; OSI-2040; (3S,6S,9S,12R)-3-[(2S)-butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone; Acipidin; AC1OCFAM; Apicidin _120249; SCHEMBL147997; ChEMBL_275631; GTPL7495; DTXSID40274182; MolPort-005-944-562; BDBM50238632; ZINC17654900; AKOS030622920; MCULE-8969470747; NCGC00165733-01
DM83WVF	DT	Small molecular drug
DM83WVF	PC	6918328
DM83WVF	MW	623.8
DM83WVF	FM	C34H49N5O6
DM83WVF	IC	InChI=1S/C34H49N5O6/c1-5-22(3)30-34(44)38-19-13-12-18-29(38)33(43)35-26(16-9-7-8-14-24(40)6-2)31(41)36-27(32(42)37-30)20-23-21-39(45-4)28-17-11-10-15-25(23)28/h10-11,15,17,21-22,26-27,29-30H,5-9,12-14,16,18-20H2,1-4H3,(H,35,43)(H,36,41)(H,37,42)/t22-,26-,27-,29+,30-/m0/s1
DM83WVF	CS	CC[C@H](C)[C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC3=CN(C4=CC=CC=C43)OC)CCCCCC(=O)CC
DM83WVF	IK	JWOGUUIOCYMBPV-GMFLJSBRSA-N
DM83WVF	IU	(3S,6S,9S,12R)-3-[(2S)-butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone
DM83WVF	DE	Solid tumour/cancer

DMI3491	ID	DMI3491
DMI3491	DN	Apigenin
DMI3491	HS	Investigative
DMI3491	SN	apigenin; 520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di
DMI3491	DT	Small molecular drug
DMI3491	PC	5280443
DMI3491	MW	270.24
DMI3491	FM	C15H10O5
DMI3491	IC	InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H
DMI3491	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
DMI3491	IK	KZNIFHPLKGYRTM-UHFFFAOYSA-N
DMI3491	IU	5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
DMI3491	CA	CAS 520-36-5
DMI3491	CB	CHEBI:18388
DMI3491	DE	Discovery agent

DMIQOXH	ID	DMIQOXH
DMIQOXH	DN	Apigenin-7-O-beta-D-glucuronide
DMIQOXH	HS	Investigative
DMIQOXH	SN	29741-09-1; Apigenin-7-glucuronide; Apigenin 7-O-b-glucuronide; Apigenin 7-glucuronide; apigenin-7-o-glucuronide; UNII-2CQ5KB3CH0; 2CQ5KB3CH0; CHEMBL254213; Scutellarin A; Apigenin 7-O-glucuronide; Apigenin 7-beta-glucuronide; apigenin-7-O-beta-D-glucuronide; Apigenin 7-O-beta-D-glucuronide; Apigenin-7-O-beta-D-glucuronoside; Apigenin 7-O-beta-D-glucuronopyranoside; AC1NSY61; MEGxp0_000795; SCHEMBL2400851; ACon1_001025; DTXSID10183893; MolPort-001-740-947; apigenin-7-O-betaD-glucuronic acid; HY-N1454; Apigenin 7-O-.beta.-D-glucur
DMIQOXH	DT	Small molecular drug
DMIQOXH	PC	5319484
DMIQOXH	MW	446.4
DMIQOXH	FM	C21H18O11
DMIQOXH	IC	InChI=1S/C21H18O11/c22-9-3-1-8(2-4-9)13-7-12(24)15-11(23)5-10(6-14(15)31-13)30-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21-23,25-27H,(H,28,29)/t16-,17-,18+,19-,21+/m0/s1
DMIQOXH	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O
DMIQOXH	IK	JBFOLLJCGUCDQP-ZFORQUDYSA-N
DMIQOXH	IU	(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylic acid
DMIQOXH	CA	CAS 29741-09-1
DMIQOXH	DE	Discovery agent

DMP7J0I	ID	DMP7J0I
DMP7J0I	DN	Apigenin-7-O-beta-D-glucuronide methyl ester
DMP7J0I	HS	Investigative
DMP7J0I	SN	53538-13-9; (2S,3S,4S,5R,6S)-Methyl 3,4,5-trihydroxy-6-((5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylate; CHEMBL464868; Apigenin 7-O-methylglucuronide; apigenin-7-O-beta-D-glucuronide methyl ester; MolPort-035-684-098; Apigenin 7-(6-O-methylglucuronide); ZINC40874044; BDBM50251270; AKOS024258585; AJ-103820; ST24034139
DMP7J0I	DT	Small molecular drug
DMP7J0I	PC	13844658
DMP7J0I	MW	460.4
DMP7J0I	FM	C22H20O11
DMP7J0I	IC	InChI=1S/C22H20O11/c1-30-21(29)20-18(27)17(26)19(28)22(33-20)31-11-6-12(24)16-13(25)8-14(32-15(16)7-11)9-2-4-10(23)5-3-9/h2-8,17-20,22-24,26-28H,1H3/t17-,18-,19+,20-,22+/m0/s1
DMP7J0I	CS	COC(=O)[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=CC(=C3C(=C2)OC(=CC3=O)C4=CC=C(C=C4)O)O)O)O)O
DMP7J0I	IK	XXKIWCKZQFBXIR-SXFAUFNYSA-N
DMP7J0I	IU	methyl (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylate
DMP7J0I	DE	Discovery agent

DM6NM8V	ID	DM6NM8V
DM6NM8V	DN	APLYSAMINE
DM6NM8V	HS	Investigative
DM6NM8V	SN	Aplysamine-1; APLYSAMINE; NSC625525; CHEMBL380697; 3-(2,6-Dibromo-4-(2-(dimethylamino)ethyl)phenoxy)-N,N-dimethyl-1-propanamine; AC1L7JVE; AC1Q25RU; BDBM50177729; NSC-625525; 3-[2,6-dibromo-4-(2-dimethylaminoethyl)phenoxy]-N,N-dimethyl-propan-1-amine; 3-(2,6-dibromo-4-(2-(dimethylamino)ethyl)phenoxy)-N,N-dimethylpropan-1-amine; N-(3-(2,6-Dibromo-4-(2-(dimethylamino)ethyl)phenoxy)propyl)-N,N-dimethylamine; 3-[2,6-dibromo-4-(2-dimethylaminoethyl)phenoxy]-N,N-dimethylpropan-1-amine
DM6NM8V	DT	Small molecular drug
DM6NM8V	PC	362025
DM6NM8V	MW	408.17
DM6NM8V	FM	C15H24Br2N2O
DM6NM8V	IC	InChI=1S/C15H24Br2N2O/c1-18(2)7-5-9-20-15-13(16)10-12(11-14(15)17)6-8-19(3)4/h10-11H,5-9H2,1-4H3
DM6NM8V	CS	CN(C)CCCOC1=C(C=C(C=C1Br)CCN(C)C)Br
DM6NM8V	IK	LWENJEAGCYZOBC-UHFFFAOYSA-N
DM6NM8V	IU	3-[2,6-dibromo-4-[2-(dimethylamino)ethyl]phenoxy]-N,N-dimethylpropan-1-amine
DM6NM8V	DE	Discovery agent

DMUPL3J	ID	DMUPL3J
DMUPL3J	DN	Aplysinopsin
DMUPL3J	HS	Investigative
DMUPL3J	DT	Small molecular drug
DMUPL3J	PC	135476741
DMUPL3J	MW	254.29
DMUPL3J	FM	C14H14N4O
DMUPL3J	IC	InChI=1S/C14H14N4O/c1-17-12(13(19)18(2)14(17)15)7-9-8-16-11-6-4-3-5-10(9)11/h3-8,15,19H,1-2H3/b9-7+,15-14?
DMUPL3J	CS	CN1C(=C(N(C1=N)C)O)/C=C/2\\C=NC3=CC=CC=C32
DMUPL3J	IK	CYKDGQFRORUDQP-YHUDWFPJSA-N
DMUPL3J	IU	2-imino-5-[(Z)-indol-3-ylidenemethyl]-1,3-dimethylimidazol-4-ol
DMUPL3J	CA	CAS 63153-56-0
DMUPL3J	DE	Discovery agent

DMW45GK	ID	DMW45GK
DMW45GK	DN	APNEA
DMW45GK	HS	Investigative
DMW45GK	SN	89705-21-5; CHEMBL1256714; N-[2-(4-Aminophenyl)ethyl]-adenosine; SMR000326823; MLS000859964; MLS002153195; SCHEMBL1230660; DTXSID40433272; XTPOZVLRZZIEBW-SCFUHWHPSA-N; HMS2233B08; ZINC8660412; BDBM50453442; AKOS030526973; CS-4923; Adenosine, N6-2-(4-aminophenyl)ethyl; HY-18687; LS-15099; N6-2-(4-Aminophenyl)ethyladenosine, &gt
DMW45GK	DT	Small molecular drug
DMW45GK	PC	9952135
DMW45GK	MW	386.4
DMW45GK	FM	C18H22N6O4
DMW45GK	IC	InChI=1S/C18H22N6O4/c19-11-3-1-10(2-4-11)5-6-20-16-13-17(22-8-21-16)24(9-23-13)18-15(27)14(26)12(7-25)28-18/h1-4,8-9,12,14-15,18,25-27H,5-7,19H2,(H,20,21,22)/t12-,14-,15-,18-/m1/s1
DMW45GK	CS	C1=CC(=CC=C1CCNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DMW45GK	IK	XTPOZVLRZZIEBW-SCFUHWHPSA-N
DMW45GK	IU	(2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMW45GK	CA	CAS 89705-21-5
DMW45GK	DE	Discovery agent

DM7OPCH	ID	DM7OPCH
DM7OPCH	DN	Apogossypol
DM7OPCH	HS	Investigative
DM7OPCH	SN	BI-79D10; BI-97C1; CNDO-103; CNDO-133
DM7OPCH	CP	Sanford-Burnham Medical Research Institute
DM7OPCH	DT	Small molecular drug
DM7OPCH	PC	454878
DM7OPCH	MW	462.5
DM7OPCH	FM	C28H30O6
DM7OPCH	IC	InChI=1S/C28H30O6/c1-11(2)21-15-7-13(5)23(25(31)17(15)9-19(29)27(21)33)24-14(6)8-16-18(26(24)32)10-20(30)28(34)22(16)12(3)4/h7-12,29-34H,1-6H3
DM7OPCH	CS	CC1=CC2=C(C(=C(C=C2C(=C1C3=C(C4=CC(=C(C(=C4C=C3C)C(C)C)O)O)O)O)O)O)C(C)C
DM7OPCH	IK	PBJKWGWHZVXBGU-UHFFFAOYSA-N
DM7OPCH	IU	3-methyl-5-propan-2-yl-2-(1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,6,7-triol
DM7OPCH	CA	CAS 475-56-9
DM7OPCH	DE	Solid tumour/cancer

DMPH7EO	ID	DMPH7EO
DMPH7EO	DN	Apomorphine SL
DMPH7EO	HS	Investigative
DMPH7EO	SN	Apomorphine HCl; Apomorphine chloride; (R)-(-)-Apomorphine hydrochloride; Apomorphinium chloride; Apomorphin hydrochlorid; 314-19-2; pomorphini hydrochloridum; Apomorphinum hydrochloricum; N-Methylnorapomorphine hydrochloride; UNII-9K13MD7A0D; (-)-Apomorphinium hydrochloride; Apomorphine hydrochloride anhydrous; EINECS 206-243-0; NSC 11442; 9K13MD7A0D; 6a-beta-Aporphine-10,11-diol, hydrochloride; 6abeta-Noraporphine-10,11-diol, 6-methyl-, hyd
DMPH7EO	DT	Small molecular drug
DMPH7EO	PC	9410
DMPH7EO	MW	303.8
DMPH7EO	FM	C17H18ClNO2
DMPH7EO	IC	InChI=1S/C17H17NO2.ClH/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12;/h2-6,13,19-20H,7-9H2,1H3;1H/t13-;/m1./s1
DMPH7EO	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.Cl
DMPH7EO	IK	SKYZYDSNJIOXRL-BTQNPOSSSA-N
DMPH7EO	IU	(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride
DMPH7EO	CA	CAS 314-19-2
DMPH7EO	DE	Discovery agent

DM0VBUL	ID	DM0VBUL
DM0VBUL	DN	Aprophen
DM0VBUL	HS	Investigative
DM0VBUL	SN	Aprofene; Aprophen; Aprofen; Aprophenum; Aprofene [INN]; 3563-01-7; 2-Diethylaminoethyl 2,2-diphenylpropionate; Aprofenum [INN-Latin]; Aprofeno [INN-Spanish]; UNII-PL791XXJ7B; PL791XXJ7B; CHEMBL26505; 2-(Diethylamino)ethyl 2,2-diphenylpropanoate; 2,2-Diphenylpropionic acid 2-diethylaminoethyl ester; BRN 2509326; NCGC00160676-01; Propionic acid, 2,2-diphenyl-, 2-(diethylamino)ethyl ester; DSSTox_CID_26294; DSSTox_RID_81519; DSSTox_GSID_46294; alpha,alpha-Diphenylpropionic acid beta-diethylaminoethyl ester
DM0VBUL	DT	Small molecular drug
DM0VBUL	PC	71128
DM0VBUL	MW	325.4
DM0VBUL	FM	C21H27NO2
DM0VBUL	IC	InChI=1S/C21H27NO2/c1-4-22(5-2)16-17-24-20(23)21(3,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15H,4-5,16-17H2,1-3H3
DM0VBUL	CS	CCN(CC)CCOC(=O)C(C)(C1=CC=CC=C1)C2=CC=CC=C2
DM0VBUL	IK	DIDYGLSKVUKRRP-UHFFFAOYSA-N
DM0VBUL	IU	2-(diethylamino)ethyl 2,2-diphenylpropanoate
DM0VBUL	CA	CAS 3563-01-7
DM0VBUL	DE	Discovery agent

DM8DOBG	ID	DM8DOBG
DM8DOBG	DN	APS-3010
DM8DOBG	HS	Investigative
DM8DOBG	SN	Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals
DM8DOBG	CP	Atlas Pharmaceuticals Inc
DM8DOBG	DE	Solid tumour/cancer

DMF1264	ID	DMF1264
DMF1264	DN	Aptiganel HCl
DMF1264	HS	Investigative
DMF1264	SN	Cerestat; CNS-1102; Aptiganel HCl; APTIGANEL HYDROCHLORIDE; UNII-40PWH14OXW; Cns 1102; 137160-11-3; 40PWH14OXW; NCGC00093759-01; DSSTox_CID_25762; DSSTox_RID_81104; DSSTox_GSID_45762; CHEMBL554054; N-(1-Naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine hcl; SMR000326976; CAS-137160-11-3; AC1Q3CFJ; MLS001056791; MLS000862213; SCHEMBL871689; AC1L1U12; DTXSID9045762; MolPort-003-940-636; CKAKVKWRMCAYJD-UHFFFAOYSA-N; Tox21_500312; Tox21_111220; Tox21_111220_1; AKOS025293480; CCG-221616; LP00312; NCGC00015236-04; NCGC00260997-01; CNS-1102, &gt;9
DMF1264	DT	Small molecular drug
DMF1264	PC	60839
DMF1264	MW	339.9
DMF1264	FM	C20H22ClN3
DMF1264	IC	InChI=1S/C20H21N3.ClH/c1-3-15-8-6-11-17(14-15)23(2)20(21)22-19-13-7-10-16-9-4-5-12-18(16)19;/h4-14H,3H2,1-2H3,(H2,21,22);1H
DMF1264	CS	CCC1=CC(=CC=C1)N(C)C(=NC2=CC=CC3=CC=CC=C32)N.Cl
DMF1264	IK	CKAKVKWRMCAYJD-UHFFFAOYSA-N
DMF1264	IU	1-(3-ethylphenyl)-1-methyl-2-naphthalen-1-ylguanidine;hydrochloride
DMF1264	CA	CAS 137160-11-3
DMF1264	DE	Ischemic stroke

DMCOMLS	ID	DMCOMLS
DMCOMLS	DN	APY29
DMCOMLS	HS	Investigative
DMCOMLS	SN	1216665-49-4; APY 29; APY-29; N~2~-1h-Benzimidazol-5-Yl-N~4~-(3-Cyclopropyl-1h-Pyrazol-5-Yl)pyrimidine-2,4-Diamine; N2-1H-Benzimidazol-6-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine; N2-(1H-benzo[d]imidazol-6-yl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; (E)-N-(6-((5-cyclopropyl-1H-pyrazol-3-yl)imino)-1,6-dihydropyrimidin-2-yl)-1H-benzo[d]imidazol-6-amine; APY 29;APY-29; CHEMBL1231018; SCHEMBL12045464; SCHEMBL20438003; SCHEMBL21067744; EX-A305; BCP09071; MFCD28023582; s6623; ZINC40163635; AKOS024458384; DB07382; 2-N-(3H-benzimidazol-5-yl)-4-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; NCGC00379217-02; NCGC00379217-03; AK547105; BS-14553; DA-47145; HY-17537; QC-11386; AB0098417; FT-0700119; J3.589.967G; Q27096602; 2,4-Pyrimidinediamine, N2-1H-benzimidazol-6-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-
DMCOMLS	DT	Small molecular drug
DMCOMLS	PC	42627755
DMCOMLS	MW	332.4
DMCOMLS	FM	C17H16N8
DMCOMLS	IC	InChI=1S/C17H16N8/c1-2-10(1)13-8-16(25-24-13)22-15-5-6-18-17(23-15)21-11-3-4-12-14(7-11)20-9-19-12/h3-10H,1-2H2,(H,19,20)(H3,18,21,22,23,24,25)
DMCOMLS	CS	C1CC1C2=CC(=NN2)NC3=NC(=NC=C3)NC4=CC5=C(C=C4)N=CN5
DMCOMLS	IK	WJNBSTLIALIIEW-UHFFFAOYSA-N
DMCOMLS	IU	2-N-(3H-benzimidazol-5-yl)-4-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
DMCOMLS	DE	Solid tumour/cancer

DMK2XB7	ID	DMK2XB7
DMK2XB7	DN	AR-00341677
DMK2XB7	HS	Investigative
DMK2XB7	SN	GDC-0879; Anticancer program, Array/Genentech; B-Raf kinase inhibitors (cancer), Array/Genentech
DMK2XB7	CP	Array BioPharma Inc
DMK2XB7	DT	Small molecular drug
DMK2XB7	PC	25093303
DMK2XB7	MW	334.4
DMK2XB7	FM	C19H18N4O2
DMK2XB7	IC	InChI=1S/C19H18N4O2/c24-10-9-23-12-17(19(21-23)13-5-7-20-8-6-13)15-1-3-16-14(11-15)2-4-18(16)22-25/h1,3,5-8,11-12,24-25H,2,4,9-10H2/b22-18-
DMK2XB7	CS	C1C/C(=N/O)/C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO
DMK2XB7	IK	DEZZLWQELQORIU-PYCFMQQDSA-N
DMK2XB7	IU	2-[4-[(1Z)-1-hydroxyimino-2,3-dihydroinden-5-yl]-3-pyridin-4-ylpyrazol-1-yl]ethanol
DMK2XB7	CA	CAS 905281-76-7
DMK2XB7	CB	CHEBI:91434
DMK2XB7	DE	Solid tumour/cancer

DMUSYKG	ID	DMUSYKG
DMUSYKG	DN	AR-129330
DMUSYKG	HS	Investigative
DMUSYKG	SN	CHEMBL193438; CHEMBL537846; SCHEMBL3938380; SCHEMBL3941081; SCHEMBL3938377; CHEMBL1188966; NWUCPBLQECHRFK-QAQDUYKDSA-N; BDBM50170189; BDBM50166555; trans-4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide; 4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide
DMUSYKG	DT	Small molecular drug
DMUSYKG	PC	9895867
DMUSYKG	MW	653
DMUSYKG	FM	C25H30BrClF3N5O3S
DMUSYKG	IC	InChI=1S/C25H29BrF3N5O3S.ClH/c1-34(2)23-19-5-3-4-6-20(19)32-24(33-23)30-14-16-7-9-17(10-8-16)15-31-38(35,36)22-12-11-18(26)13-21(22)37-25(27,28)29;/h3-6,11-13,16-17,31H,7-10,14-15H2,1-2H3,(H,30,32,33);1H
DMUSYKG	CS	CN(C)C1=NC(=NC2=CC=CC=C21)NCC3CCC(CC3)CNS(=O)(=O)C4=C(C=C(C=C4)Br)OC(F)(F)F.Cl
DMUSYKG	IK	SMEDDEAAKQVMQD-UHFFFAOYSA-N
DMUSYKG	IU	4-bromo-N-[[4-[[[4-(dimethylamino)quinazolin-2-yl]amino]methyl]cyclohexyl]methyl]-2-(trifluoromethoxy)benzenesulfonamide;hydrochloride
DMUSYKG	DE	Discovery agent

DMN8W46	ID	DMN8W46
DMN8W46	DN	AR231453
DMN8W46	HS	Investigative
DMN8W46	SN	AR-231,453; AR 231453; AR-231453
DMN8W46	DT	Small molecular drug
DMN8W46	PC	24939268
DMN8W46	MW	505.5
DMN8W46	FM	C21H24FN7O5S
DMN8W46	IC	InChI=1S/C21H24FN7O5S/c1-12(2)18-26-21(34-27-18)13-6-8-28(9-7-13)20-17(29(30)31)19(23-11-24-20)25-16-5-4-14(10-15(16)22)35(3,32)33/h4-5,10-13H,6-9H2,1-3H3,(H,23,24,25)
DMN8W46	CS	CC(C)C1=NOC(=N1)C2CCN(CC2)C3=NC=NC(=C3[N+](=O)[O-])NC4=C(C=C(C=C4)S(=O)(=O)C)F
DMN8W46	IK	DGBKNTVAKIFYNU-UHFFFAOYSA-N
DMN8W46	IU	N-(2-fluoro-4-methylsulfonylphenyl)-5-nitro-6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidin-4-amine
DMN8W46	CA	CAS 733750-99-7
DMN8W46	DE	Discovery agent

DMTN10D	ID	DMTN10D
DMTN10D	DN	AR234960
DMTN10D	HS	Investigative
DMTN10D	SN	AR 234960; AR-234960
DMTN10D	DT	Small molecular drug
DMTN10D	PC	89560738
DMTN10D	MW	555.6
DMTN10D	FM	C27H30FN5O5S
DMTN10D	IC	InChI=1S/C27H30FN5O5S/c1-38-25-16-23(33(34)35)8-9-26(25)39(36,37)32-18-21(24(19-32)20-5-4-6-22(28)15-20)17-30-11-13-31(14-12-30)27-7-2-3-10-29-27/h2-10,15-16,21,24H,11-14,17-19H2,1H3
DMTN10D	CS	COC1=C(C=CC(=C1)[N+](=O)[O-])S(=O)(=O)N2CC(C(C2)C3=CC(=CC=C3)F)CN4CCN(CC4)C5=CC=CC=N5
DMTN10D	IK	TUSCHIFEASZBBF-UHFFFAOYSA-N
DMTN10D	IU	1-[[4-(3-fluorophenyl)-1-(2-methoxy-4-nitrophenyl)sulfonylpyrrolidin-3-yl]methyl]-4-pyridin-2-ylpiperazine
DMTN10D	DE	Discovery agent

DM68QY0	ID	DM68QY0
DM68QY0	DN	AR244555
DM68QY0	HS	Investigative
DM68QY0	SN	AR 244555; AR-244555
DM68QY0	DT	Small molecular drug
DM68QY0	PC	59004159
DM68QY0	MW	416.9
DM68QY0	FM	C23H23ClF2N2O
DM68QY0	IC	InChI=1S/C23H23ClF2N2O/c1-2-3-11-27-12-9-23(10-13-27)15-28(20-8-7-16(24)14-17(20)23)22(29)21-18(25)5-4-6-19(21)26/h2,4-8,14H,1,3,9-13,15H2
DM68QY0	CS	C=CCCN1CCC2(CC1)CN(C3=C2C=C(C=C3)Cl)C(=O)C4=C(C=CC=C4F)F
DM68QY0	IK	QKPSTNGNDWHYCH-UHFFFAOYSA-N
DM68QY0	IU	(1'-but-3-enyl-5-chlorospiro[2H-indole-3,4'-piperidine]-1-yl)-(2,6-difluorophenyl)methanone
DM68QY0	DE	Discovery agent

DMNJ632	ID	DMNJ632
DMNJ632	DN	AR-534
DMNJ632	HS	Investigative
DMNJ632	SN	CHEMBL2177159
DMNJ632	DT	Small molecular drug
DMNJ632	PC	56603751
DMNJ632	MW	428.5
DMNJ632	FM	C19H20N6O4S
DMNJ632	IC	InChI=1S/C19H20N6O4S/c1-29-10-9-23-30(27,28)15-6-4-13(5-7-15)16-12-22-18(20)17(25-16)19(26)24-14-3-2-8-21-11-14/h2-8,11-12,23H,9-10H2,1H3,(H2,20,22)(H,24,26)
DMNJ632	CS	COCCNS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CN=CC=C3)N
DMNJ632	IK	OMGQIHJJEYTELG-UHFFFAOYSA-N
DMNJ632	IU	3-amino-6-[4-(2-methoxyethylsulfamoyl)phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide
DMNJ632	DE	Discovery agent

DM34P90	ID	DM34P90
DM34P90	DN	AR-7947
DM34P90	HS	Investigative
DM34P90	CP	Array BioPharma Inc
DM34P90	DE	Non-insulin dependent diabetes

DMAM619	ID	DMAM619
DMAM619	DN	Arabinose-5-Phosphate
DMAM619	HS	Investigative
DMAM619	SN	D-arabinose 5-phosphate; arabinose 5-phosphate; 13137-52-5; 5-O-phosphono-D-arabinose; D-A-5-P; D-arabinose, 5-(dihydrogen phosphate); CHEBI:16241; aldehydo-D-arabinose 5-phosphate; arabinose-5P; arabinose-5-P; 1uj6; AC1L4MLG; (2,3,4-trihydroxy-5-oxopentyl) dihydrogen phosphate; AC1Q6RV6; SCHEMBL939515; D-Arabinose 5-phosphoric acid; CHEMBL1162524; ZINC3606137; D-arabinose 5-(dihydrogen phosphate); AKOS027382411; C01112; (2,3,4-trihydroxy-5-oxo-pentyl) dihydrogen phosphate
DMAM619	DT	Small molecular drug
DMAM619	PC	5287584
DMAM619	MW	232.13
DMAM619	FM	C5H13O8P
DMAM619	IC	InChI=1S/C5H13O8P/c6-1-3(7)5(9)4(8)2-13-14(10,11)12/h3-9H,1-2H2,(H2,10,11,12)/t3-,4-,5+/m1/s1
DMAM619	CS	C([C@H]([C@@H]([C@@H](COP(=O)(O)O)O)O)O)O
DMAM619	IK	VJDOAZKNBQCAGE-WDCZJNDASA-N
DMAM619	IU	[(2R,3S,4R)-2,3,4,5-tetrahydroxypentyl] dihydrogen phosphate
DMAM619	DE	Discovery agent

DMUOQZD	ID	DMUOQZD
DMUOQZD	DN	Arachidonic acid
DMUOQZD	HS	Investigative
DMUOQZD	SN	arachidonic acid; 506-32-1; arachidonate; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid; Immunocytophyte; (all-Z)-5,8,11,14-Eicosatetraenoic acid; cis-5,8,11,14-Eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid, (all-Z)-; 5Z,8Z,11Z,14Z-eicosatetraenoic acid; UNII-27YG812J1I; all-cis-5,8,11,14-eicosatetraenoic acid; Arachidonic Acid, 99%; CHEMBL15594; CHEBI:15843; YZXBAPSDXZZRGB-DOFZRALJSA-N; 27YG812J1I; cis,cis,cis,cis-5,8,11,14-Eicosatetraenoic acid; (5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic Acid
DMUOQZD	DT	Small molecular drug
DMUOQZD	PC	444899
DMUOQZD	MW	304.5
DMUOQZD	FM	C20H32O2
DMUOQZD	IC	InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-
DMUOQZD	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O
DMUOQZD	IK	YZXBAPSDXZZRGB-DOFZRALJSA-N
DMUOQZD	IU	(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid
DMUOQZD	CA	CAS 506-32-1
DMUOQZD	CB	CHEBI:15843
DMUOQZD	DE	Discovery agent

DMHL48F	ID	DMHL48F
DMHL48F	DN	ARACHIDONYL TRIFLUOROMETHYLKETONE
DMHL48F	HS	Investigative
DMHL48F	SN	Arachidonyl trifluoromethyl ketone; Aacocf3; arachidonyl trifluoromethyl ketone; Arachidonyltrifluoromethane; 149301-79-1; Arachidonic acid trifluoromethyl ketone; Arachidonyltrifluoromethyl Ketone; ATFMK; UNII-00XIW1CR0F; C21H31F3O; (6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one; 00XIW1CR0F; CHEBI:2341; CHEMBL281211; 1,1,1-Trifluoro-6Z,9Z,12Z,15Z-heneicosatetraen-2-one; 6,9,12,15-Heneicosatetraen-2-one, 1,1,1-trifluoro-, (6Z,9Z,12Z,15Z)-; 6,9,12,15-Heneicosatetraen-2-one, 1,1,1-trifluoro-, (all-Z)-; Arachidonyl trifluoromethylketone; Arachidonyltrifluoromethyl ketone
DMHL48F	DT	Small molecular drug
DMHL48F	PC	5280436
DMHL48F	MW	356.5
DMHL48F	FM	C21H31F3O
DMHL48F	IC	InChI=1S/C21H31F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(25)21(22,23)24/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3/b7-6-,10-9-,13-12-,16-15-
DMHL48F	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)C(F)(F)F
DMHL48F	IK	PLWROONZUDKYKG-DOFZRALJSA-N
DMHL48F	IU	(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
DMHL48F	CA	CAS 149301-79-1
DMHL48F	CB	CHEBI:2341
DMHL48F	DE	Discovery agent

DMZM5KE	ID	DMZM5KE
DMZM5KE	DN	arachidonylcyclopropylamide
DMZM5KE	HS	Investigative
DMZM5KE	SN	arachidonyl cyclopropylamide
DMZM5KE	DT	Small molecular drug
DMZM5KE	PC	5311007
DMZM5KE	MW	343.5
DMZM5KE	FM	C23H37NO
DMZM5KE	IC	InChI=1S/C23H37NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(25)24-22-20-21-22/h6-7,9-10,12-13,15-16,22H,2-5,8,11,14,17-21H2,1H3,(H,24,25)/b7-6-,10-9-,13-12-,16-15-
DMZM5KE	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NC1CC1
DMZM5KE	IK	GLGAUBPACOBAMV-DOFZRALJSA-N
DMZM5KE	IU	(5Z,8Z,11Z,14Z)-N-cyclopropylicosa-5,8,11,14-tetraenamide
DMZM5KE	CA	CAS 229021-64-1
DMZM5KE	DE	Discovery agent

DMSM1PV	ID	DMSM1PV
DMSM1PV	DN	ARC-069
DMSM1PV	HS	Investigative
DMSM1PV	SN	Gamma secretase inhibitors (Alzheimer's disease), Archer Pharmaceuticals
DMSM1PV	CP	Archer Pharmaceuticals
DMSM1PV	DE	Alzheimer disease

DMWVULN	ID	DMWVULN
DMWVULN	DN	AR-C102222
DMWVULN	HS	Investigative
DMWVULN	SN	AR-C102222; CHEMBL447183; 5-(4-Amino-5,8-difluorospiro[1H-quinazoline-2,4'-piperidine]-1'-carbonyl)pyridine-2-carbonitrile; 1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE; SCHEMBL7806912; ZINC1489460; BDBM50124535; DB07405; NCGC00371031-01; 5-[(4'-amino-5',8'-difluoro-1H,1'H-spiro[piperidine-4,2'-quinazolin]-1-yl)carbonyl]pyridine-2-carbonitrile; 5-(4-Amino-5,8-difluorospiro[1H-quinazoline-2,4'-piperidine]-1'-carbonyl)pyridine-2-carbonitrile, 3
DMWVULN	DT	Small molecular drug
DMWVULN	PC	9886249
DMWVULN	MW	382.4
DMWVULN	FM	C19H16F2N6O
DMWVULN	IC	InChI=1S/C19H16F2N6O/c20-13-3-4-14(21)16-15(13)17(23)26-19(25-16)5-7-27(8-6-19)18(28)11-1-2-12(9-22)24-10-11/h1-4,10,25H,5-8H2,(H2,23,26)
DMWVULN	CS	C1CN(CCC12NC3=C(C=CC(=C3C(=N2)N)F)F)C(=O)C4=CN=C(C=C4)C#N
DMWVULN	IK	GIZYIOOBBUHOBS-UHFFFAOYSA-N
DMWVULN	IU	5-(4-amino-5,8-difluorospiro[1H-quinazoline-2,4'-piperidine]-1'-carbonyl)pyridine-2-carbonitrile
DMWVULN	DE	Discovery agent

DM0KDTG	ID	DM0KDTG
DM0KDTG	DN	ARC-1028
DM0KDTG	HS	Investigative
DM0KDTG	SN	ARC-1028; CHEMBL525385; BDBM27227; ARC-1028, 22
DM0KDTG	PC	25190769
DM0KDTG	MW	1571.8
DM0KDTG	FM	C64H118N34O13
DM0KDTG	IC	InChI=1S/C64H118N34O13/c65-24-6-5-15-36(91-42(99)22-4-2-8-26-81-57(110)47-45(101)46(102)58(111-47)98-34-90-44-48(66)88-33-89-50(44)98)51(104)80-25-7-1-3-23-43(100)92-37(17-10-28-83-60(70)71)52(105)94-39(19-12-30-85-62(74)75)54(107)96-41(21-14-32-87-64(78)79)56(109)97-40(20-13-31-86-63(76)77)55(108)95-38(18-11-29-84-61(72)73)53(106)93-35(49(67)103)16-9-27-82-59(68)69/h33-41,45-47,58,101-102H,1-32,65H2,(H2,67,103)(H,80,104)(H,81,110)(H,91,99)(H,92,100)(H,93,106)(H,94,105)(H,95,108)(H,96,107)(H,97,109)(H2,66,88,89)(H4,68,69,82)(H4,70,71,83)(H4,72,73,84)(H4,74,75,85)(H4,76,77,86)(H4,78,79,87)/t35-,36-,37-,38-,39-,40-,41-,45+,46-,47+,58-/m1/s1
DM0KDTG	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCC(=O)N[C@H](CCCCN)C(=O)NCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N)O)O)N
DM0KDTG	IK	FBAPHDWTBAGCKW-LJDCWIOTSA-N
DM0KDTG	IU	(2S,3S,4R,5R)-N-[6-[[(2R)-6-amino-1-[[6-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-6-oxohexyl]amino]-1-oxohexan-2-yl]amino]-6-oxohexyl]-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carboxamide
DM0KDTG	DE	Discovery agent

DMQCPXL	ID	DMQCPXL
DMQCPXL	DN	AR-C118925XX
DMQCPXL	HS	Investigative
DMQCPXL	SN	AR-C118925
DMQCPXL	DT	Small molecular drug
DMQCPXL	PC	54210200
DMQCPXL	MW	537.6
DMQCPXL	FM	C28H23N7O3S
DMQCPXL	IC	InChI=1S/C28H23N7O3S/c1-15-3-8-20-17(11-15)5-6-18-12-16(2)4-9-21(18)24(20)22-14-35(28(37)30-26(22)39)13-19-7-10-23(38-19)25(36)29-27-31-33-34-32-27/h3-12,14,24H,13H2,1-2H3,(H,30,37,39)(H2,29,31,32,33,34,36)
DMQCPXL	CS	CC1=CC2=C(C=C1)C(C3=C(C=C2)C=C(C=C3)C)C4=CN(C(=O)NC4=S)CC5=CC=C(O5)C(=O)NC6=NNN=N6
DMQCPXL	IK	PVKNPGQAFNALOI-UHFFFAOYSA-N
DMQCPXL	IU	5-[[5-(6,13-dimethyl-2-tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaenyl)-2-oxo-4-sulfanylidenepyrimidin-1-yl]methyl]-N-(2H-tetrazol-5-yl)furan-2-carboxamide
DMQCPXL	DE	Discovery agent

DMP1EWV	ID	DMP1EWV
DMP1EWV	DN	AR-C126313
DMP1EWV	HS	Investigative
DMP1EWV	SN	compound 71a [PMID: 15078212]; compound 52 [PMID: 18600475]
DMP1EWV	DT	Small molecular drug
DMP1EWV	PC	22003577
DMP1EWV	MW	373.9
DMP1EWV	FM	C17H12ClN3OS2
DMP1EWV	IC	InChI=1S/C17H12ClN3OS2/c1-21-7-12(16(23)20-17(21)22)14-11-4-3-10(18)6-9(11)2-5-13-15(14)19-8-24-13/h2-8,14H,1H3,(H,20,22,23)
DMP1EWV	CS	CN1C=C(C(=S)NC1=O)C2C3=C(C=CC4=C2N=CS4)C=C(C=C3)Cl
DMP1EWV	IK	ZDHQVQVNOIWLNX-UHFFFAOYSA-N
DMP1EWV	IU	5-(12-chloro-6-thia-4-azatricyclo[8.4.0.03,7]tetradeca-1(10),3(7),4,8,11,13-hexaen-2-yl)-1-methyl-4-sulfanylidenepyrimidin-2-one
DMP1EWV	DE	Discovery agent

DM71WQT	ID	DM71WQT
DM71WQT	DN	AR-C133057XX
DM71WQT	HS	Investigative
DM71WQT	SN	CHEMBL114500; 4-({4-[(4-Methoxypyridin-2-Yl)amino]piperidin-1-Yl}carbonyl)benzonitrile; 4-[4-[(4-Methoxypyridin-2-yl)amino]piperidine-1-carbonyl]benzonitrile; 4-{4-[(4-methoxypyridin-2-yl)amino]piperidine-1-carbonyl}benzonitrile; AR-C133057XX; SCHEMBL7824352; CHEBI:95013; BDBM50148167; DB07002; BRD-K40892394-001-01-9; 4-(4-(4-methoxypyridin-2-ylamino)piperidine-1-carbonyl)benzonitrile; 4-[4-(4-Methoxy-pyridin-2-ylamino)-piperidine-1-carbonyl]-benzonitrile
DM71WQT	DT	Small molecular drug
DM71WQT	PC	9797857
DM71WQT	MW	336.4
DM71WQT	FM	C19H20N4O2
DM71WQT	IC	InChI=1S/C19H20N4O2/c1-25-17-6-9-21-18(12-17)22-16-7-10-23(11-8-16)19(24)15-4-2-14(13-20)3-5-15/h2-6,9,12,16H,7-8,10-11H2,1H3,(H,21,22)
DM71WQT	CS	COC1=CC(=NC=C1)NC2CCN(CC2)C(=O)C3=CC=C(C=C3)C#N
DM71WQT	IK	SZUVGMCKKLJAFX-UHFFFAOYSA-N
DM71WQT	IU	4-[4-[(4-methoxypyridin-2-yl)amino]piperidine-1-carbonyl]benzonitrile
DM71WQT	CA	CAS 268730-08-1
DM71WQT	CB	CHEBI:95013
DM71WQT	DE	Discovery agent

DMAZV5D	ID	DMAZV5D
DMAZV5D	DN	ARC-200
DMAZV5D	HS	Investigative
DMAZV5D	CP	Archer Biosciences Inc
DMAZV5D	DE	Solid tumour/cancer

DMU3A57	ID	DMU3A57
DMU3A57	DN	AR-C70484XX
DMU3A57	HS	Investigative
DMU3A57	SN	CHEMBL30108; AR-C70484XX; SCHEMBL3688521; BDBM50110846; 4-[3-[4-(Decyloxy)phenoxy]acetonyloxy]benzoic acid; 4-[3-(4-Decyloxy-phenoxy)-2-oxo-propoxy]-benzoic acid; 4-(3-(4-(decyloxy)phenoxy)-2-oxopropoxy)benzoic acid; 4-[3-(4-Decyloxy-phenoxy)-2-oxo-propoxy]-benzoic acid(AR-C70484XX)
DMU3A57	DT	Small molecular drug
DMU3A57	PC	9846199
DMU3A57	MW	442.5
DMU3A57	FM	C26H34O6
DMU3A57	IC	InChI=1S/C26H34O6/c1-2-3-4-5-6-7-8-9-18-30-23-14-16-25(17-15-23)32-20-22(27)19-31-24-12-10-21(11-13-24)26(28)29/h10-17H,2-9,18-20H2,1H3,(H,28,29)
DMU3A57	CS	CCCCCCCCCCOC1=CC=C(C=C1)OCC(=O)COC2=CC=C(C=C2)C(=O)O
DMU3A57	IK	BBWMRBSEGFTSQC-UHFFFAOYSA-N
DMU3A57	IU	4-[3-(4-decoxyphenoxy)-2-oxopropoxy]benzoic acid
DMU3A57	DE	Discovery agent

DMXOYK0	ID	DMXOYK0
DMXOYK0	DN	Arcaine
DMXOYK0	HS	Investigative
DMXOYK0	SN	arcaine; Tetramethylenediguanide; 1,4-Diguanidinobutane; N,N'''-1,4-Butanediylbisguanidine; Arcain; 544-05-8; 1-(4-guanidinobutyl)guanidine; CHEMBL102740; CHEBI:16652; 1,1'-(butane-1,4-diyl)diguanidine; Guanidine, N,N'''-1,4-butanediylbis-; A-8340; 1-(4-carbamimidamidobutyl)guanidine; 58585-47-0; 2,2'-butane-1,4-diyldiguanidine; Tocris-0389; Spectrum_001819; Prestwick2_000876; Spectrum5_001638; Prestwick1_000876; Prestwick0_000876; Spectrum3_001100; Spectrum2_000601; Prestwick3_000876; Spectrum4_001929; Lopac-A-0384
DMXOYK0	DT	Small molecular drug
DMXOYK0	PC	2227
DMXOYK0	MW	172.23
DMXOYK0	FM	C6H16N6
DMXOYK0	IC	InChI=1S/C6H16N6/c7-5(8)11-3-1-2-4-12-6(9)10/h1-4H2,(H4,7,8,11)(H4,9,10,12)
DMXOYK0	CS	C(CCN=C(N)N)CN=C(N)N
DMXOYK0	IK	HGMDNMBBCKDWTQ-UHFFFAOYSA-N
DMXOYK0	IU	2-[4-(diaminomethylideneamino)butyl]guanidine
DMXOYK0	CA	CAS 544-05-8
DMXOYK0	CB	CHEBI:16652
DMXOYK0	DE	Discovery agent

DM03E28	ID	DM03E28
DM03E28	DN	ARD-412
DM03E28	HS	Investigative
DM03E28	SN	Oral delta opioid agonists (premature ejaculation); Oral delta opioid agonists (premature ejaculation), Enhance
DM03E28	CP	Ardent Pharmaceuticals Inc
DM03E28	DE	Premature ejaculation

DMSA6IY	ID	DMSA6IY
DMSA6IY	DN	arecaidine propargyl ester
DMSA6IY	HS	Investigative
DMSA6IY	SN	Arecaidine propargyl ester; 35516-99-5; NCGC00015006-01; Lopac-A-140; AC1L1D7L; AC1Q62JO; Lopac0_000136; GTPL295; CHEMBL128365; SCHEMBL13184690; CTK1B6885; CHEBI:92418; DTXSID30274358; SPHRJZBOFYIKMC-UHFFFAOYSA-N; prop-2-ynyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate; 2-Propynyl 1-methyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate; ZINC25720839; AKOS030566155; CCG-204231; NCGC00015006-03; NCGC00162072-01; NCGC00015006-04; NCGC00162072-02; NCGC00015006-02; L000114; BRD-K23922020-075-01-1; prop-2-ynyl 1-methyl-5,6-dihydro-2H-pyridin
DMSA6IY	DT	Small molecular drug
DMSA6IY	PC	2229
DMSA6IY	MW	179.22
DMSA6IY	FM	C10H13NO2
DMSA6IY	IC	InChI=1S/C10H13NO2/c1-3-7-13-10(12)9-5-4-6-11(2)8-9/h1,5H,4,6-8H2,2H3
DMSA6IY	CS	CN1CCC=C(C1)C(=O)OCC#C
DMSA6IY	IK	SPHRJZBOFYIKMC-UHFFFAOYSA-N
DMSA6IY	IU	prop-2-ynyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate
DMSA6IY	CA	CAS 35516-99-5
DMSA6IY	CB	CHEBI:92418
DMSA6IY	DE	Discovery agent

DM8KN0Q	ID	DM8KN0Q
DM8KN0Q	DN	ARGENINE VASOPRESSIN
DM8KN0Q	HS	Investigative
DM8KN0Q	SN	8-arginine vasopressin; Arginine-vasopressin (AVP); AVP (Arginine-vasopressin ); CHEMBL264048; BDBM50291330; cyclo[Cys-Tyr-Phe-Gln-Asn-Cys]-Pro-Arg-Gly-NH2; 1-[19-Amino-13-benzyl-10-(2-carbamoyl-ethyl)-7-carbamoylmethyl-16-(4-hydroxy-benzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carbonyl]-pyrrolidine-2-carboxylic acid [1-(carbamoylmethyl-carbamoyl)-4-guanidino-butyl]-amide
DM8KN0Q	PC	44285245
DM8KN0Q	MW	1084.2
DM8KN0Q	FM	C46H65N15O12S2
DM8KN0Q	IC	InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28+,29-,30-,31+,32+,33+,34-/m1/s1
DM8KN0Q	CS	C1C[C@@H](N(C1)C(=O)[C@@H]2CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DM8KN0Q	IK	KBZOIRJILGZLEJ-BOXDWKHASA-N
DM8KN0Q	IU	(2R)-1-[(4R,7S,10R,13S,16R,19S)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DM8KN0Q	DE	Discovery agent

DMQ1DWU	ID	DMQ1DWU
DMQ1DWU	DN	Argiotoxin-636
DMQ1DWU	HS	Investigative
DMQ1DWU	SN	argiotoxin 636; Argiotoxin-636; Argiopine; Argiopin; CHEMBL1098240; CHEBI:34541; 105029-41-2; 108687-79-2; Butanediamide, N1-(16,21-diamino-21-imino-15-oxo-6,10,14,20-tetraazaheneicos-1-yl)-2-(((2,4-dihydroxyphenyl)acetyl)amino)-, (S-(R*,R*))-; AR 636; AC1L3UBP; GTPL4138; SCHEMBL17014644; BDBM50316373; (S-(R*,R*))-N1-(16,21-Diamino-21-imino-15-oxo-6,10,14,20-tetraazaheneicos-1-yl)-2-(((2,4-dihydroxyphenyl)acetyl)amino)butanediamide; C13927
DMQ1DWU	DT	Small molecular drug
DMQ1DWU	PC	122294
DMQ1DWU	MW	636.8
DMQ1DWU	FM	C29H52N10O6
DMQ1DWU	IC	InChI=1S/C29H52N10O6/c30-22(7-4-15-38-29(32)33)27(44)36-16-6-13-35-12-5-11-34-10-2-1-3-14-37-28(45)23(19-25(31)42)39-26(43)17-20-8-9-21(40)18-24(20)41/h8-9,18,22-23,34-35,40-41H,1-7,10-17,19,30H2,(H2,31,42)(H,36,44)(H,37,45)(H,39,43)(H4,32,33,38)/t22-,23-/m0/s1
DMQ1DWU	CS	C1=CC(=C(C=C1O)O)CC(=O)N[C@@H](CC(=O)N)C(=O)NCCCCCNCCCNCCCNC(=O)[C@H](CCCN=C(N)N)N
DMQ1DWU	IK	FTNICLJXPYLDAH-GOTSBHOMSA-N
DMQ1DWU	IU	(2S)-N-[5-[3-[3-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propylamino]propylamino]pentyl]-2-[[2-(2,4-dihydroxyphenyl)acetyl]amino]butanediamide
DMQ1DWU	CA	CAS 105029-41-2
DMQ1DWU	CB	CHEBI:34541
DMQ1DWU	DE	Discovery agent

DM6PA1S	ID	DM6PA1S
DM6PA1S	DN	Arg-Pro-Lys-Pro-Ala-Gln-Phe-Phe-Gly-Leu-Met-NH2
DM6PA1S	HS	Investigative
DM6PA1S	SN	CHEMBL396426; Arg-Pro-Lys-Pro-Ala-Gln-Phe-Phe-Gly-Leu-Met-NH2
DM6PA1S	PC	44434485
DM6PA1S	MW	1290.6
DM6PA1S	FM	C61H95N17O12S
DM6PA1S	IC	InChI=1S/C61H95N17O12S/c1-36(2)32-44(55(85)72-41(51(65)81)26-31-91-4)71-50(80)35-69-53(83)45(33-38-16-7-5-8-17-38)75-56(86)46(34-39-18-9-6-10-19-39)76-54(84)42(24-25-49(64)79)73-52(82)37(3)70-57(87)47-22-15-30-78(47)60(90)43(21-11-12-27-62)74-58(88)48-23-14-29-77(48)59(89)40(63)20-13-28-68-61(66)67/h5-10,16-19,36-37,40-48H,11-15,20-35,62-63H2,1-4H3,(H2,64,79)(H2,65,81)(H,69,83)(H,70,87)(H,71,80)(H,72,85)(H,73,82)(H,74,88)(H,75,86)(H,76,84)(H4,66,67,68)/t37-,40-,41-,42-,43-,44-,45-,46-,47-,48-/m0/s1
DM6PA1S	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DM6PA1S	IK	VWZGDJIFNOBMMB-DYIQZKFVSA-N
DM6PA1S	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pentanediamide
DM6PA1S	DE	Discovery agent

DMYM91S	ID	DMYM91S
DMYM91S	DN	Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMYM91S	HS	Investigative
DMYM91S	SN	CHEMBL413827; Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMYM91S	PC	44434487
DMYM91S	MW	1249.5
DMYM91S	FM	C59H92N16O12S
DMYM91S	IC	InChI=1S/C59H92N16O12S/c1-35(2)30-42(52(81)69-40(49(62)78)24-29-88-4)68-48(77)33-66-51(80)43(31-37-16-7-5-8-17-37)71-53(82)44(32-38-18-9-6-10-19-38)72-54(83)45(34-76)73-50(79)36(3)67-55(84)46-22-15-28-75(46)58(87)41(21-11-12-25-60)70-56(85)47-23-14-27-74(47)57(86)39(61)20-13-26-65-59(63)64/h5-10,16-19,35-36,39-47,76H,11-15,20-34,60-61H2,1-4H3,(H2,62,78)(H,66,80)(H,67,84)(H,68,77)(H,69,81)(H,70,85)(H,71,82)(H,72,83)(H,73,79)(H4,63,64,65)/t36-,39-,40-,41-,42-,43-,44-,45-,46-,47-/m0/s1
DMYM91S	CS	C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DMYM91S	IK	HMZBUUAKDIVOFX-KWWDQKRUSA-N
DMYM91S	IU	(2S)-N-[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxamide
DMYM91S	DE	Discovery agent

DMA318X	ID	DMA318X
DMA318X	DN	Arg-Pro-Lys-Pro-Gln-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMA318X	HS	Investigative
DMA318X	SN	CHEMBL394671; Arg-Pro-Lys-Pro-Gln-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMA318X	PC	44434486
DMA318X	MW	1306.6
DMA318X	FM	C61H95N17O13S
DMA318X	IC	InChI=1S/C61H95N17O13S/c1-36(2)31-43(54(85)71-40(51(65)82)25-30-92-3)70-50(81)34-69-52(83)44(32-37-15-6-4-7-16-37)74-55(86)45(33-38-17-8-5-9-18-38)75-56(87)46(35-79)76-53(84)41(23-24-49(64)80)72-57(88)48-22-14-29-78(48)60(91)42(20-10-11-26-62)73-58(89)47-21-13-28-77(47)59(90)39(63)19-12-27-68-61(66)67/h4-9,15-18,36,39-48,79H,10-14,19-35,62-63H2,1-3H3,(H2,64,80)(H2,65,82)(H,69,83)(H,70,81)(H,71,85)(H,72,88)(H,73,89)(H,74,86)(H,75,87)(H,76,84)(H4,66,67,68)/t39-,40-,41-,42-,43-,44-,45-,46-,47-,48-/m0/s1
DMA318X	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DMA318X	IK	MXTQBPBXNQHASJ-BHEJXMHWSA-N
DMA318X	IU	(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMA318X	DE	Discovery agent

DM8NETP	ID	DM8NETP
DM8NETP	DN	ARH-1029
DM8NETP	HS	Investigative
DM8NETP	SN	AR-HP; Dual-acting H. pylori therapeutic (peptic ulcer disease), CJ Corp; Dual-acting H. pylori therapeutic, (peptic ulcer disease), Taiho Pharmaceutical
DM8NETP	CP	ARigen Pharmaceuticals Inc
DM8NETP	DE	Helicobacter infection

DM2PRHX	ID	DM2PRHX
DM2PRHX	DN	AR-HO29953XX
DM2PRHX	HS	Investigative
DM2PRHX	SN	CHEMBL117520; AR-HO29953XX; AR-H-029953XX; BDBM50149274; 2-[4-(3,4-Dichloro-phenylcarbamoyl)-benzylamino]-4-nitro-benzoic acid
DM2PRHX	DT	Small molecular drug
DM2PRHX	PC	10479348
DM2PRHX	MW	460.3
DM2PRHX	FM	C21H15Cl2N3O5
DM2PRHX	IC	InChI=1S/C21H15Cl2N3O5/c22-17-8-5-14(9-18(17)23)25-20(27)13-3-1-12(2-4-13)11-24-19-10-15(26(30)31)6-7-16(19)21(28)29/h1-10,24H,11H2,(H,25,27)(H,28,29)
DM2PRHX	CS	C1=CC(=CC=C1CNC2=C(C=CC(=C2)[N+](=O)[O-])C(=O)O)C(=O)NC3=CC(=C(C=C3)Cl)Cl
DM2PRHX	IK	HMZYRLHWICHTKH-UHFFFAOYSA-N
DM2PRHX	IU	2-[[4-[(3,4-dichlorophenyl)carbamoyl]phenyl]methylamino]-4-nitrobenzoic acid
DM2PRHX	DE	Discovery agent

DMIMD0T	ID	DMIMD0T
DMIMD0T	DN	ARI-3099
DMIMD0T	HS	Investigative
DMIMD0T	SN	compound 6 [PMID: 23594271]; compound 226 [PMID: 24997602]; Py(D)AlaboroPro
DMIMD0T	DT	Small molecular drug
DMIMD0T	PC	71655266
DMIMD0T	MW	291.11
DMIMD0T	FM	C13H18BN3O4
DMIMD0T	IC	InChI=1S/C13H18BN3O4/c1-9(16-12(18)10-4-6-15-7-5-10)13(19)17-8-2-3-11(17)14(20)21/h4-7,9,11,20-21H,2-3,8H2,1H3,(H,16,18)/t9-,11+/m1/s1
DMIMD0T	CS	B([C@@H]1CCCN1C(=O)[C@@H](C)NC(=O)C2=CC=NC=C2)(O)O
DMIMD0T	IK	DRBWRJPFNOBNIO-KOLCDFICSA-N
DMIMD0T	IU	[(2R)-1-[(2R)-2-(pyridine-4-carbonylamino)propanoyl]pyrrolidin-2-yl]boronic acid
DMIMD0T	DE	Discovery agent

DMEO82V	ID	DMEO82V
DMEO82V	DN	ARI-3531
DMEO82V	HS	Investigative
DMEO82V	SN	compound 22 [PMID: 23594271]
DMEO82V	DT	Small molecular drug
DMEO82V	PC	91827371
DMEO82V	MW	319.17
DMEO82V	FM	C15H22BN3O4
DMEO82V	IC	InChI=1S/C15H22BN3O4/c1-10(2)13(18-14(20)11-5-7-17-8-6-11)15(21)19-9-3-4-12(19)16(22)23/h5-8,10,12-13,22-23H,3-4,9H2,1-2H3,(H,18,20)/t12-,13-/m1/s1
DMEO82V	CS	B([C@H]1CCCN1C(=O)[C@@H](C(C)C)NC(=O)C2=CC=NC=C2)(O)O
DMEO82V	IK	MXZNUGFCDVAXLG-CHWSQXEVSA-N
DMEO82V	IU	[(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid
DMEO82V	DE	Discovery agent

DMNPEM4	ID	DMNPEM4
DMNPEM4	DN	ARL66096
DMNPEM4	HS	Investigative
DMNPEM4	SN	2-propylthio-betagamma-difluoromethylene ATP; FPL66096; ARL 66096
DMNPEM4	DT	Small molecular drug
DMNPEM4	PC	5311009
DMNPEM4	MW	615.3
DMNPEM4	FM	C14H22F2N5O12P3S
DMNPEM4	IC	InChI=1S/C14H22F2N5O12P3S/c1-2-3-37-13-19-10(17)7-11(20-13)21(5-18-7)12-9(23)8(22)6(32-12)4-31-36(29,30)33-35(27,28)14(15,16)34(24,25)26/h5-6,8-9,12,22-23H,2-4H2,1H3,(H,27,28)(H,29,30)(H2,17,19,20)(H2,24,25,26)/t6-,8-,9-,12-/m1/s1
DMNPEM4	CS	CCCSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(F)(F)P(=O)(O)O)O)O)O)N
DMNPEM4	IK	ZQXUQOHLHUWLSA-WOUKDFQISA-N
DMNPEM4	IU	[[[[(2R,3S,4R,5R)-5-(6-amino-2-propylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-difluoromethyl]phosphonic acid
DMNPEM4	DE	Discovery agent

DM24MKI	ID	DM24MKI
DM24MKI	DN	AR-mTOR-26
DM24MKI	HS	Investigative
DM24MKI	SN	AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma
DM24MKI	CP	Array BioPharma Inc
DM24MKI	DE	Solid tumour/cancer

DMBE0H8	ID	DMBE0H8
DMBE0H8	DN	ARN-2966
DMBE0H8	HS	Investigative
DMBE0H8	SN	ARN-4261; Abeta aggregation inhibitors (Alzheimer's disease); Abeta aggregation inhibitors (Alzheimer's disease), New York University/Aria Neurosciences
DMBE0H8	CP	New York University
DMBE0H8	DT	Small molecular drug
DMBE0H8	PC	14936865
DMBE0H8	MW	200.24
DMBE0H8	FM	C12H12N2O
DMBE0H8	IC	InChI=1S/C12H12N2O/c15-12-7-2-1-6-11(12)14-9-10-5-3-4-8-13-10/h1-8,14-15H,9H2
DMBE0H8	CS	C1=CC=C(C(=C1)NCC2=CC=CC=N2)O
DMBE0H8	IK	GXJRVWZNMZGWAQ-UHFFFAOYSA-N
DMBE0H8	IU	2-(pyridin-2-ylmethylamino)phenol
DMBE0H8	DE	Alzheimer disease

DMMCFEX	ID	DMMCFEX
DMMCFEX	DN	ARN34
DMMCFEX	HS	Investigative
DMMCFEX	DE	Discovery agent

DMNAJQY	ID	DMNAJQY
DMNAJQY	DN	ARO 087
DMNAJQY	HS	Investigative
DMNAJQY	CP	Aroule
DMNAJQY	DE	Solid tumour/cancer

DM6KQXF	ID	DM6KQXF
DM6KQXF	DN	ARP100
DM6KQXF	HS	Investigative
DM6KQXF	SN	ARP 100; ARP-100
DM6KQXF	DT	Small molecular drug
DM6KQXF	PC	10044321
DM6KQXF	MW	364.4
DM6KQXF	FM	C17H20N2O5S
DM6KQXF	IC	InChI=1S/C17H20N2O5S/c1-13(2)24-19(12-17(20)18-21)25(22,23)16-10-8-15(9-11-16)14-6-4-3-5-7-14/h3-11,13,21H,12H2,1-2H3,(H,18,20)
DM6KQXF	CS	CC(C)ON(CC(=O)NO)S(=O)(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DM6KQXF	IK	PHGLPDURIUEELR-UHFFFAOYSA-N
DM6KQXF	IU	N-hydroxy-2-[(4-phenylphenyl)sulfonyl-propan-2-yloxyamino]acetamide
DM6KQXF	CA	CAS 704888-90-4
DM6KQXF	DE	Discovery agent

DMU70YP	ID	DMU70YP
DMU70YP	DN	ARPFAQK-FAM
DMU70YP	HS	Investigative
DMU70YP	SN	CHEMBL441156
DMU70YP	PC	44460581
DMU70YP	MW	1272.3
DMU70YP	FM	C62H73N13O17
DMU70YP	IC	InChI=1S/C62H73N13O17/c1-32(63)53(81)71-42(16-9-27-68-62(65)66)59(87)74-28-10-17-45(74)57(85)73-44(29-34-11-4-3-5-12-34)56(84)69-33(2)54(82)70-41(22-23-48(64)78)55(83)72-43(60(88)89)15-6-7-26-67-58(86)52-39(13-8-14-40(52)61(90)92-75-49(79)24-25-50(75)80)51-37-20-18-35(76)30-46(37)91-47-31-36(77)19-21-38(47)51/h3-5,8,11-14,18-21,30-33,41-45,76H,6-7,9-10,15-17,22-29,63H2,1-2H3,(H2,64,78)(H,67,86)(H,69,84)(H,70,82)(H,71,81)(H,72,83)(H,73,85)(H,88,89)(H4,65,66,68)/t32-,33-,41-,42-,43-,44-,45-/m0/s1
DMU70YP	CS	C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)C3=C(C=CC=C3C(=O)ON4C(=O)CCC4=O)C5=C6C=CC(=O)C=C6OC7=C5C=CC(=C7)O)C(=O)O)N
DMU70YP	IK	IVWCINIISIMQBR-IPQUOSPJSA-N
DMU70YP	IU	(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-6-[[2-(2,5-dioxopyrrolidin-1-yl)oxycarbonyl-6-(3-hydroxy-6-oxoxanthen-9-yl)benzoyl]amino]hexanoic acid
DMU70YP	DE	Discovery agent

DMB9PDA	ID	DMB9PDA
DMB9PDA	DN	arpromidine
DMB9PDA	HS	Investigative
DMB9PDA	SN	Arpromidine; 106669-71-0; Arpromidinum; Arpromidina; Arpromidine [INN]; Arpromidinum [INN-Latin]; Arpromidina [INN-Spanish]; AC1Q4NMJ; SCHEMBL138015; CHEMBL293802; SCHEMBL9710060; GTPL1221; BDBM86171; AC1L2472; PDSP2_001296; PDSP1_001312; NSC_65895; CAS_65895; L000115; Guanidine, N-(3-(4-fluorophenyl)-3-(2-pyridinyl)propyl)-N'-(3-(1H-imidazol-4-yl)propyl)-; 1-[3-(4-fluorophenyl)-3-(2-pyridyl)propyl]-n2-[3-(1h-imidazol-4-yl)propyl]guanidine; (+-)-1-(3-(p-Fluorophenyl)-3-(2-pyridyl)propyl)-3-(3-imidazol-4-ylpropyl)guanidine
DMB9PDA	DT	Small molecular drug
DMB9PDA	PC	65895
DMB9PDA	MW	380.5
DMB9PDA	FM	C21H25FN6
DMB9PDA	IC	InChI=1S/C21H25FN6/c22-17-8-6-16(7-9-17)19(20-5-1-2-11-25-20)10-13-27-21(23)26-12-3-4-18-14-24-15-28-18/h1-2,5-9,11,14-15,19H,3-4,10,12-13H2,(H,24,28)(H3,23,26,27)
DMB9PDA	CS	C1=CC=NC(=C1)C(CCNC(=NCCCC2=CN=CN2)N)C3=CC=C(C=C3)F
DMB9PDA	IK	KZZIVOLMJPSDEP-UHFFFAOYSA-N
DMB9PDA	IU	1-[3-(4-fluorophenyl)-3-pyridin-2-ylpropyl]-2-[3-(1H-imidazol-5-yl)propyl]guanidine
DMB9PDA	CA	CAS 106669-71-0
DMB9PDA	DE	Discovery agent

DMIRTF5	ID	DMIRTF5
DMIRTF5	DN	ARRY-575
DMIRTF5	HS	Investigative
DMIRTF5	CP	Array BioPharma Inc
DMIRTF5	DE	Solid tumour/cancer

DMBCO4Q	ID	DMBCO4Q
DMBCO4Q	DN	Arsenite
DMBCO4Q	HS	Investigative
DMBCO4Q	SN	Arsenenous acid; 13768-07-5; Arsenite (ion); AC1L2NJ5
DMBCO4Q	DT	Small molecular drug
DMBCO4Q	PC	24577
DMBCO4Q	MW	107.928
DMBCO4Q	FM	AsHO2
DMBCO4Q	IC	InChI=1S/AsHO2/c2-1-3/h(H,2,3)
DMBCO4Q	CS	O[As]=O
DMBCO4Q	IK	XHTRYVMKFMUJLU-UHFFFAOYSA-N
DMBCO4Q	IU	arsenous acid
DMBCO4Q	CA	CAS 13768-07-5
DMBCO4Q	DE	Discovery agent

DMEVT4I	ID	DMEVT4I
DMEVT4I	DN	ART-144
DMEVT4I	HS	Investigative
DMEVT4I	SN	Anti-inflammatory agent (intra-articular/injectable, sustained release, osteoarthritis), Artyx pharmaceuticals
DMEVT4I	CP	ARTYX Pharmaceuticals Inc
DMEVT4I	DE	Osteoarthritis

DM8SP4X	ID	DM8SP4X
DM8SP4X	DN	Arteminolide
DM8SP4X	HS	Investigative
DM8SP4X	DT	Small molecular drug
DM8SP4X	PC	10627242
DM8SP4X	MW	590.7
DM8SP4X	FM	C35H42O8
DM8SP4X	IC	InChI=1S/C35H42O8/c1-16(2)12-23(37)41-22-14-18(4)24-21(36)13-17(3)25(24)28-26(22)35(31(39)43-28)15-34-11-10-32(35,6)29(34)27-20(8-9-33(34,7)40)19(5)30(38)42-27/h10-11,13,16,20,22,25-29,40H,5,8-9,12,14-15H2,1-4,6-7H3/t20-,22-,25-,26+,27-,28+,29-,32+,33+,34-,35+/m0/s1
DM8SP4X	CS	CC1=C2[C@@H]([C@@H]3[C@@H]([C@H](C1)OC(=O)CC(C)C)[C@]4(C[C@@]56C=C[C@@]4([C@@H]5[C@@H]7[C@@H](CC[C@@]6(C)O)C(=C)C(=O)O7)C)C(=O)O3)C(=CC2=O)C
DM8SP4X	IK	RAKYLPJLLBOHHN-CFTUDFFSSA-N
DM8SP4X	IU	[(1'R,2'R,3S,3aR,4S,5'S,9'S,9aS,9bR,10'S,11'R)-2'-hydroxy-2',6,9,11'-tetramethyl-6'-methylidene-2,7,7'-trioxospiro[4,5,9a,9b-tetrahydro-3aH-azuleno[4,5-b]furan-3,15'-8-oxatetracyclo[9.2.2.01,10.05,9]pentadec-12-ene]-4-yl] 3-methylbutanoate
DM8SP4X	DE	Discovery agent

DMWCDM8	ID	DMWCDM8
DMWCDM8	DN	artepillin C
DMWCDM8	HS	Investigative
DMWCDM8	SN	Artepillin C; artepillin; 72944-19-5; (E)-3-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]prop-2-enoic acid; CCRIS 8746; AC1NV86P; SCHEMBL1229229; CHEMBL456309; GTPL6302; NSC718732; 3-(4-Hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl)-2-propenoic acid; BDBM50362836; NSC-718732; 3,5-Bis(3-methyl-2-butenyl)-4-hydroxybenzenepropenoic acid; 2-Propenoic acid, 3-(4-hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl)-, (E)-
DMWCDM8	DT	Small molecular drug
DMWCDM8	PC	5472440
DMWCDM8	MW	300.4
DMWCDM8	FM	C19H24O3
DMWCDM8	IC	InChI=1S/C19H24O3/c1-13(2)5-8-16-11-15(7-10-18(20)21)12-17(19(16)22)9-6-14(3)4/h5-7,10-12,22H,8-9H2,1-4H3,(H,20,21)/b10-7+
DMWCDM8	CS	CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)/C=C/C(=O)O)C
DMWCDM8	IK	KABCFARPAMSXCC-JXMROGBWSA-N
DMWCDM8	IU	(E)-3-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]prop-2-enoic acid
DMWCDM8	CA	CAS 72944-19-5
DMWCDM8	DE	Discovery agent

DMB9AR7	ID	DMB9AR7
DMB9AR7	DN	ARTOBILOXANTHONE
DMB9AR7	HS	Investigative
DMB9AR7	SN	artobiloxanthone; CHEMBL1099162
DMB9AR7	DT	Small molecular drug
DMB9AR7	PC	46887866
DMB9AR7	MW	434.4
DMB9AR7	FM	C25H22O7
DMB9AR7	IC	InChI=1S/C25H22O7/c1-10(2)12-7-13-21(29)20-15(27)9-17-11(5-6-25(3,4)32-17)23(20)31-24(13)19-14(26)8-16(28)22(30)18(12)19/h5-6,8-9,12,26-28,30H,1,7H2,2-4H3/t12-/m1/s1
DMB9AR7	CS	CC(=C)[C@H]1CC2=C(C3=C1C(=C(C=C3O)O)O)OC4=C(C2=O)C(=CC5=C4C=CC(O5)(C)C)O
DMB9AR7	IK	ZIYAGIMFLYOZDS-GFCCVEGCSA-N
DMB9AR7	IU	(16R)-11,18,19,21-tetrahydroxy-7,7-dimethyl-16-prop-1-en-2-yl-2,8-dioxapentacyclo[12.8.0.03,12.04,9.017,22]docosa-1(14),3(12),4(9),5,10,17(22),18,20-octaen-13-one
DMB9AR7	CA	CAS 121748-25-2
DMB9AR7	DE	Discovery agent

DMHUXRP	ID	DMHUXRP
DMHUXRP	DN	ARTORIGIDIN A
DMHUXRP	HS	Investigative
DMHUXRP	SN	Artorigidin A; CHEMBL1094756
DMHUXRP	DT	Small molecular drug
DMHUXRP	PC	46834285
DMHUXRP	MW	504.6
DMHUXRP	FM	C30H32O7
DMHUXRP	IC	InChI=1S/C30H32O7/c1-13(2)7-9-16-25(33)17(10-8-14(3)4)29-24(26(16)34)27(35)19-11-18(15(5)6)22-23(30(19)37-29)20(31)12-21(32)28(22)36/h7-8,12,18,31-34,36H,5,9-11H2,1-4,6H3/t18-/m1/s1
DMHUXRP	CS	CC(=CCC1=C(C(=C2C(=C1O)C(=O)C3=C(O2)C4=C([C@H](C3)C(=C)C)C(=C(C=C4O)O)O)CC=C(C)C)O)C
DMHUXRP	IK	LAAYVNVIRVOBNR-GOSISDBHSA-N
DMHUXRP	IU	(5R)-1,3,4,8,10-pentahydroxy-9,11-bis(3-methylbut-2-enyl)-5-prop-1-en-2-yl-5,6-dihydrobenzo[c]xanthen-7-one
DMHUXRP	DE	Discovery agent

DMO5LUF	ID	DMO5LUF
DMO5LUF	DN	arvanil
DMO5LUF	HS	Investigative
DMO5LUF	SN	N-vanillylarachidonamide
DMO5LUF	DT	Small molecular drug
DMO5LUF	PC	6449767
DMO5LUF	MW	439.6
DMO5LUF	FM	C28H41NO3
DMO5LUF	IC	InChI=1S/C28H41NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-28(31)29-24-25-21-22-26(30)27(23-25)32-2/h7-8,10-11,13-14,16-17,21-23,30H,3-6,9,12,15,18-20,24H2,1-2H3,(H,29,31)/b8-7-,11-10-,14-13-,17-16-
DMO5LUF	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCC1=CC(=C(C=C1)O)OC
DMO5LUF	IK	QVLMCRFQGHWOPM-ZKWNWVNESA-N
DMO5LUF	IU	(5Z,8Z,11Z,14Z)-N-[(4-hydroxy-3-methoxyphenyl)methyl]icosa-5,8,11,14-tetraenamide
DMO5LUF	CA	CAS 128007-31-8
DMO5LUF	DE	Discovery agent

DM15KLR	ID	DM15KLR
DM15KLR	DN	ARX-AHD
DM15KLR	HS	Investigative
DM15KLR	SN	Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx
DM15KLR	CP	Ambrx Inc
DM15KLR	DT	Antibody
DM15KLR	DE	Breast cancer

DMWHUKZ	ID	DMWHUKZ
DMWHUKZ	DN	AR-XYZ
DMWHUKZ	HS	Investigative
DMWHUKZ	SN	CB2 agonists (pain/inflammation); CB2 agonists (pain/inflammation), Arena Pharmaceuticals
DMWHUKZ	CP	Arena Pharmaceuticals Inc
DMWHUKZ	DE	Inflammation

DMAWJPE	ID	DMAWJPE
DMAWJPE	DN	AS04
DMAWJPE	HS	Investigative
DMAWJPE	CP	GlaxoSmithKline plc
DMAWJPE	DE	Discovery agent

DMXZ8S9	ID	DMXZ8S9
DMXZ8S9	DN	AS100
DMXZ8S9	HS	Investigative
DMXZ8S9	SN	AS 100; AS-100
DMXZ8S9	DT	Small molecular drug
DMXZ8S9	PC	135489238
DMXZ8S9	MW	534.4
DMXZ8S9	FM	C23H25Cl2N7O4
DMXZ8S9	IC	InChI=1S/C23H25Cl2N7O4/c1-4-8-31-21-19(22(34)32(9-5-2)23(31)35)27-20(28-21)16-11-18(29-30(16)3)36-12-17(33)26-13-6-7-14(24)15(25)10-13/h6-7,10-11H,4-5,8-9,12H2,1-3H3,(H,26,33)(H,27,28)
DMXZ8S9	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC(=C(C=C4)Cl)Cl
DMXZ8S9	IK	OESRCCUPNGDTIR-UHFFFAOYSA-N
DMXZ8S9	IU	N-(3,4-dichlorophenyl)-2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetamide
DMXZ8S9	DE	Discovery agent

DM170G5	ID	DM170G5
DM170G5	DN	AS1269574
DM170G5	HS	Investigative
DM170G5	SN	AS 1269574; AS-1269574
DM170G5	DT	Small molecular drug
DM170G5	PC	5332859
DM170G5	MW	308.17
DM170G5	FM	C13H14BrN3O
DM170G5	IC	InChI=1S/C13H14BrN3O/c1-9-8-12(15-6-7-18)17-13(16-9)10-2-4-11(14)5-3-10/h2-5,8,18H,6-7H2,1H3,(H,15,16,17)
DM170G5	CS	CC1=CC(=NC(=N1)C2=CC=C(C=C2)Br)NCCO
DM170G5	IK	DUKPGOOUJNUIOI-UHFFFAOYSA-N
DM170G5	IU	2-[[2-(4-bromophenyl)-6-methylpyrimidin-4-yl]amino]ethanol
DM170G5	CA	CAS 330981-72-1
DM170G5	DE	Discovery agent

DMPX5SJ	ID	DMPX5SJ
DMPX5SJ	DN	AS-1397
DMPX5SJ	HS	Investigative
DMPX5SJ	SN	AS-1397; 10-(2-(Diethylamino)propionyl)phenothiazine; Methyldifazine; 10-(alpha-Diethylaminopropionyl)-phenothiazine hydrochloride; AC1L1BEE; AC1Q5K0B; Lopac0_000351; SCHEMBL1320997; CHEMBL376514; NIOSH/SO4600000; BDBM13551; CTK5B9958; 2-(diethylamino)-1-(10H-phenothiazin-10-yl)propan-1-one; CCG-204446; LS-105449; 10-(a-diethyl-aminopropionyl)-phenothiazine; SO46000000; Phenothiazine, 10-(2-(diethylamino)propionyl)-; 2-(diethylamino)-1-phenothiazin-10-ylpropan-1-one
DMPX5SJ	DT	Small molecular drug
DMPX5SJ	PC	1403
DMPX5SJ	MW	326.5
DMPX5SJ	FM	C19H22N2OS
DMPX5SJ	IC	InChI=1S/C19H22N2OS/c1-4-20(5-2)14(3)19(22)21-15-10-6-8-12-17(15)23-18-13-9-7-11-16(18)21/h6-14H,4-5H2,1-3H3
DMPX5SJ	CS	CCN(CC)C(C)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMPX5SJ	IK	QCEWCMMSOWEHFC-UHFFFAOYSA-N
DMPX5SJ	IU	2-(diethylamino)-1-phenothiazin-10-ylpropan-1-one
DMPX5SJ	DE	Discovery agent

DM7A8PX	ID	DM7A8PX
DM7A8PX	DN	AS-1522489-00
DM7A8PX	HS	Investigative
DM7A8PX	SN	GlyT-1 inhibitors (schizophrenia, dementia); GlyT-1 inhibitors (schizophrenia, dementia), Astellas
DM7A8PX	CP	Astellas Pharma Inc
DM7A8PX	DE	Dementia

DMP0A17	ID	DMP0A17
DMP0A17	DN	AS16
DMP0A17	HS	Investigative
DMP0A17	SN	AS 16; AS-16
DMP0A17	DT	Small molecular drug
DMP0A17	PC	135529391
DMP0A17	MW	555.6
DMP0A17	FM	C30H33N7O4
DMP0A17	IC	InChI=1S/C30H33N7O4/c1-4-15-36-28-26(29(39)37(16-5-2)30(36)40)32-27(33-28)23-18-24(34-35(23)3)31-25(38)17-20-11-13-22(14-12-20)41-19-21-9-7-6-8-10-21/h6-14,18H,4-5,15-17,19H2,1-3H3,(H,32,33)(H,31,34,38)
DMP0A17	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)NC(=O)CC4=CC=C(C=C4)OCC5=CC=CC=C5
DMP0A17	IK	YJWWRRYUAYGZCB-UHFFFAOYSA-N
DMP0A17	IU	N-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]-2-(4-phenylmethoxyphenyl)acetamide
DMP0A17	DE	Discovery agent

DM6MWDH	ID	DM6MWDH
DM6MWDH	DN	AS-1708727
DM6MWDH	HS	Investigative
DM6MWDH	CP	Astellas Pharma Inc
DM6MWDH	DE	Hypertriglyceridemia

DMS86PI	ID	DMS86PI
DMS86PI	DN	AS-1892802
DMS86PI	HS	Investigative
DMS86PI	SN	ROCK inhibitor (osteoarthritis pain), Astellas; Rho kinase inhibitor (osteoarthritis pain), Astellas
DMS86PI	CP	Astellas Pharma Inc
DMS86PI	PC	46911016
DMS86PI	MW	333.4
DMS86PI	FM	C20H19N3O2
DMS86PI	IC	InChI=1S/C20H19N3O2/c24-14-19(17-4-2-1-3-5-17)23-20(25)22-18-8-6-15(7-9-18)16-10-12-21-13-11-16/h1-13,19,24H,14H2,(H2,22,23,25)/t19-/m1/s1
DMS86PI	CS	C1=CC=C(C=C1)[C@@H](CO)NC(=O)NC2=CC=C(C=C2)C3=CC=NC=C3
DMS86PI	IK	WDTFYYZHMRBVHK-LJQANCHMSA-N
DMS86PI	IU	1-[(1S)-2-hydroxy-1-phenylethyl]-3-(4-pyridin-4-ylphenyl)urea
DMS86PI	DE	Pain

DMASE5O	ID	DMASE5O
DMASE5O	DN	AS-19
DMASE5O	HS	Investigative
DMASE5O	SN	AS 19; AS19
DMASE5O	DT	Small molecular drug
DMASE5O	PC	23642275
DMASE5O	MW	283.4
DMASE5O	FM	C18H25N3
DMASE5O	IC	InChI=1S/C18H25N3/c1-12-18(13(2)21(5)19-12)17-8-6-7-14-11-15(20(3)4)9-10-16(14)17/h6-8,15H,9-11H2,1-5H3/t15-/m0/s1
DMASE5O	CS	CC1=C(C(=NN1C)C)C2=CC=CC3=C2CC[C@@H](C3)N(C)C
DMASE5O	IK	BTTOYOKCLDAHHO-HNNXBMFYSA-N
DMASE5O	IU	(2S)-N,N-dimethyl-5-(1,3,5-trimethylpyrazol-4-yl)-1,2,3,4-tetrahydronaphthalen-2-amine
DMASE5O	CA	CAS 1000578-26-6
DMASE5O	DE	Discovery agent

DM0MAIW	ID	DM0MAIW
DM0MAIW	DN	AS-1907417
DM0MAIW	HS	Investigative
DM0MAIW	SN	AS-1535907; AS-1669058; AS-179009; GPR119 agonists (type 2 diabetes), Astellas Pharma
DM0MAIW	CP	Astellas Pharma Inc
DM0MAIW	DT	Small molecular drug
DM0MAIW	PC	11567371
DM0MAIW	MW	393.5
DM0MAIW	FM	C19H27N3O4S
DM0MAIW	IC	InChI=1S/C19H27N3O4S/c23-17(24)6-1-3-13-7-9-22(10-8-13)19-15-11-27(25,26)12-16(15)20-18(21-19)14-4-2-5-14/h13-14H,1-12H2,(H,23,24)
DM0MAIW	CS	C1CC(C1)C2=NC3=C(CS(=O)(=O)C3)C(=N2)N4CCC(CC4)CCCC(=O)O
DM0MAIW	IK	NFFANIJTECFGGM-UHFFFAOYSA-N
DM0MAIW	IU	4-[1-(2-cyclobutyl-6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperidin-4-yl]butanoic acid
DM0MAIW	DE	Non-insulin dependent diabetes

DMQ95EB	ID	DMQ95EB
DMQ95EB	DN	AS-601245
DMQ95EB	HS	Investigative
DMQ95EB	SN	JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673
DMQ95EB	DT	Small molecular drug
DMQ95EB	PC	10109823
DMQ95EB	MW	372.4
DMQ95EB	FM	C20H16N6S
DMQ95EB	IC	InChI=1S/C20H16N6S/c21-12-15(19-25-17-5-1-2-6-18(17)27-19)16-8-11-24-20(26-16)23-10-7-14-4-3-9-22-13-14/h1-6,8-9,11,13,15H,7,10H2,(H,23,24,26)
DMQ95EB	CS	C1=CC=C2C(=C1)N=C(S2)C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4
DMQ95EB	IK	RCYPVQCPYKNSTG-UHFFFAOYSA-N
DMQ95EB	IU	2-(1,3-benzothiazol-2-yl)-2-[2-(2-pyridin-3-ylethylamino)pyrimidin-4-yl]acetonitrile
DMQ95EB	CA	CAS 345987-15-7
DMQ95EB	CB	CHEBI:91345
DMQ95EB	DE	Discovery agent

DMANU3W	ID	DMANU3W
DMANU3W	DN	AS-602704
DMANU3W	HS	Investigative
DMANU3W	SN	339990-02-2; AIPs (Alzheimers), Axonyx/Serono; Ac-LPFFD-NH2; amyloid-inhibiting peptides, Serono/Axonyx; beta-amyloid inhibitors, Serono/Axonyx; beta-sheet breaker peptides (Alzheimers), Serono/Axonyx
DMANU3W	DE	Discovery agent

DM9IUSM	ID	DM9IUSM
DM9IUSM	DN	AS-604850
DM9IUSM	HS	Investigative
DM9IUSM	SN	AS 604850; PI 3-Kgamma inhibitor II
DM9IUSM	DT	Small molecular drug
DM9IUSM	PC	5287855
DM9IUSM	MW	285.23
DM9IUSM	FM	C11H5F2NO4S
DM9IUSM	IC	InChI=1S/C11H5F2NO4S/c12-11(13)17-6-2-1-5(3-7(6)18-11)4-8-9(15)14-10(16)19-8/h1-4H,(H,14,15,16)/b8-4-
DM9IUSM	CS	C1=CC2=C(C=C1/C=C\\3/C(=O)NC(=O)S3)OC(O2)(F)F
DM9IUSM	IK	SRLVNYDXMUGOFI-YWEYNIOJSA-N
DM9IUSM	IU	(5Z)-5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylidene]-1,3-thiazolidine-2,4-dione
DM9IUSM	CB	CHEBI:94690
DM9IUSM	DE	Discovery agent

DM9V5GS	ID	DM9V5GS
DM9V5GS	DN	AS604872
DM9V5GS	HS	Investigative
DM9V5GS	SN	AS 604872; AS-604872
DM9V5GS	DT	Small molecular drug
DM9V5GS	PC	10152528
DM9V5GS	MW	515.6
DM9V5GS	FM	C28H25N3O3S2
DM9V5GS	IC	InChI=1S/C28H25N3O3S2/c32-27(30-26(23-11-5-2-6-12-23)25-13-7-8-18-29-25)28-31(19-20-35-28)36(33,34)24-16-14-22(15-17-24)21-9-3-1-4-10-21/h1-18,26,28H,19-20H2,(H,30,32)/t26-,28+/m1/s1
DM9V5GS	CS	C1CS[C@H](N1S(=O)(=O)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)N[C@H](C4=CC=CC=C4)C5=CC=CC=N5
DM9V5GS	IK	LSSZZFZFFKZTCL-IAPPQJPRSA-N
DM9V5GS	IU	(2S)-3-(4-phenylphenyl)sulfonyl-N-[(R)-phenyl(pyridin-2-yl)methyl]-1,3-thiazolidine-2-carboxamide
DM9V5GS	DE	Discovery agent

DM9CIJP	ID	DM9CIJP
DM9CIJP	DN	AS70
DM9CIJP	HS	Investigative
DM9CIJP	SN	AS-70; AS 70
DM9CIJP	DT	Small molecular drug
DM9CIJP	PC	135443367
DM9CIJP	MW	534.6
DM9CIJP	FM	C27H34N8O4
DM9CIJP	IC	InChI=1S/C27H34N8O4/c1-4-11-34-25-23(26(37)35(12-5-2)27(34)38)28-24(29-25)20-17-21(30-31(20)3)39-18-22(36)33-15-13-32(14-16-33)19-9-7-6-8-10-19/h6-10,17H,4-5,11-16,18H2,1-3H3,(H,28,29)
DM9CIJP	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)N4CCN(CC4)C5=CC=CC=C5
DM9CIJP	IK	BVHLYIIHYJFKSI-UHFFFAOYSA-N
DM9CIJP	IU	8-[2-methyl-5-[2-oxo-2-(4-phenylpiperazin-1-yl)ethoxy]pyrazol-3-yl]-1,3-dipropyl-7H-purine-2,6-dione
DM9CIJP	DE	Discovery agent

DMZPHKG	ID	DMZPHKG
DMZPHKG	DN	AS74
DMZPHKG	HS	Investigative
DMZPHKG	SN	AS 74; AS-74
DMZPHKG	DT	Small molecular drug
DMZPHKG	PC	135465785
DMZPHKG	MW	496.5
DMZPHKG	FM	C23H24N6O7
DMZPHKG	IC	InChI=1S/C23H24N6O7/c1-3-7-28-21-19(22(31)29(8-4-2)23(28)32)25-20(26-21)16-10-18(27-36-16)33-11-17(30)24-13-5-6-14-15(9-13)35-12-34-14/h5-6,9-10H,3-4,7-8,11-12H2,1-2H3,(H,24,30)(H,25,26)
DMZPHKG	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NO3)OCC(=O)NC4=CC5=C(C=C4)OCO5
DMZPHKG	IK	ZPOGAROKPIBRMR-UHFFFAOYSA-N
DMZPHKG	IU	N-(1,3-benzodioxol-5-yl)-2-[[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1,2-oxazol-3-yl]oxy]acetamide
DMZPHKG	DE	Discovery agent

DM7WJ6F	ID	DM7WJ6F
DM7WJ6F	DN	AS94
DM7WJ6F	HS	Investigative
DM7WJ6F	SN	AS 94; AS-94
DM7WJ6F	DT	Small molecular drug
DM7WJ6F	PC	135529386
DM7WJ6F	MW	537.6
DM7WJ6F	FM	C26H31N7O6
DM7WJ6F	IC	InChI=1S/C26H31N7O6/c1-5-12-32-23-21(24(35)33(13-6-2)26(32)37)28-22(29-23)18-14-20(30-31(18)4)39-15-19(34)27-17-10-8-16(9-11-17)25(36)38-7-3/h8-11,14H,5-7,12-13,15H2,1-4H3,(H,27,34)(H,28,29)
DM7WJ6F	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC=C(C=C4)C(=O)OCC
DM7WJ6F	IK	BVABUBJIQWDRNZ-UHFFFAOYSA-N
DM7WJ6F	IU	ethyl 4-[[2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetyl]amino]benzoate
DM7WJ6F	DE	Discovery agent

DMN3E9Q	ID	DMN3E9Q
DMN3E9Q	DN	AS95
DMN3E9Q	HS	Investigative
DMN3E9Q	SN	AS 95; AS-95
DMN3E9Q	DT	Small molecular drug
DMN3E9Q	PC	135443359
DMN3E9Q	MW	509.5
DMN3E9Q	FM	C24H27N7O6
DMN3E9Q	IC	InChI=1S/C24H27N7O6/c1-4-10-30-21-19(22(33)31(11-5-2)24(30)36)26-20(27-21)16-12-18(28-29(16)3)37-13-17(32)25-15-8-6-14(7-9-15)23(34)35/h6-9,12H,4-5,10-11,13H2,1-3H3,(H,25,32)(H,26,27)(H,34,35)
DMN3E9Q	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC=C(C=C4)C(=O)O
DMN3E9Q	IK	JTHIYDNBNYRAEL-UHFFFAOYSA-N
DMN3E9Q	IU	4-[[2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetyl]amino]benzoic acid
DMN3E9Q	DE	Discovery agent

DML6I8J	ID	DML6I8J
DML6I8J	DN	AS96
DML6I8J	HS	Investigative
DML6I8J	SN	AS 96; AS-96
DML6I8J	DT	Small molecular drug
DML6I8J	PC	135416058
DML6I8J	MW	530.6
DML6I8J	FM	C27H30N8O4
DML6I8J	IC	InChI=1S/C27H30N8O4/c1-4-11-34-25-23(26(37)35(12-5-2)27(34)38)28-24(29-25)20-17-21(30-31(20)3)39-18-22(36)33-15-13-32(14-16-33)19-9-7-6-8-10-19/h4-10,17H,1-2,11-16,18H2,3H3,(H,28,29)
DML6I8J	CS	CN1C(=CC(=N1)OCC(=O)N2CCN(CC2)C3=CC=CC=C3)C4=NC5=C(N4)C(=O)N(C(=O)N5CC=C)CC=C
DML6I8J	IK	HCIZQLZOFGBZIE-UHFFFAOYSA-N
DML6I8J	IU	8-[2-methyl-5-[2-oxo-2-(4-phenylpiperazin-1-yl)ethoxy]pyrazol-3-yl]-1,3-bis(prop-2-enyl)-7H-purine-2,6-dione
DML6I8J	DE	Discovery agent

DMR01O4	ID	DMR01O4
DMR01O4	DN	AS-9705
DMR01O4	HS	Investigative
DMR01O4	CP	Dainippon Pharmaceuticals
DMR01O4	DT	Small molecular drug
DMR01O4	PC	2779822
DMR01O4	MW	249.3
DMR01O4	FM	C14H19NO3
DMR01O4	IC	InChI=1S/C14H19NO3/c1-5-18-14(17)13-9(3)15(11-6-7-11)8(2)12(13)10(4)16/h11H,5-7H2,1-4H3
DMR01O4	CS	CCOC(=O)C1=C(N(C(=C1C(=O)C)C)C2CC2)C
DMR01O4	IK	KUMRNXGGFLRUIV-UHFFFAOYSA-N
DMR01O4	IU	ethyl 4-acetyl-1-cyclopropyl-2,5-dimethylpyrrole-3-carboxylate
DMR01O4	CA	CAS 423768-51-8
DMR01O4	DE	Gastric motility disorder; Vomiting

DMZ7FJN	ID	DMZ7FJN
DMZ7FJN	DN	AS99
DMZ7FJN	HS	Investigative
DMZ7FJN	SN	AS 99; AS-99
DMZ7FJN	DT	Small molecular drug
DMZ7FJN	PC	135522368
DMZ7FJN	MW	493.6
DMZ7FJN	FM	C25H31N7O4
DMZ7FJN	IC	InChI=1S/C25H31N7O4/c1-6-10-31-23-21(24(34)32(11-7-2)25(31)35)27-22(28-23)18-13-20(29-30(18)5)36-14-19(33)26-17-9-8-15(3)16(4)12-17/h8-9,12-13H,6-7,10-11,14H2,1-5H3,(H,26,33)(H,27,28)
DMZ7FJN	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC(=C(C=C4)C)C
DMZ7FJN	IK	FCMUQGWJTIVYIU-UHFFFAOYSA-N
DMZ7FJN	IU	N-(3,4-dimethylphenyl)-2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetamide
DMZ7FJN	DE	Discovery agent

DM3WVPJ	ID	DM3WVPJ
DM3WVPJ	DN	Asacolitin
DM3WVPJ	HS	Investigative
DM3WVPJ	SN	Apriso; Asacol; Asacol HD; 5-Aminosalicylic acid; Benzoic acid, 5-amino-2-hydroxy-; Canasa; Claversal; Fisalamine; Lialda; Lixacol; Mesalamine [USAN]; Mesalazina; Mesalazina [Spanish]; Mesalazine; Mesalazinum; Mesalazinum [Latin]; Mesasal; Pentasa; Rowasa; Salofalk; m-Aminosalicylic acid; mesalamine; p-Aminosalicylsaeure; p-Aminosalicylsaeure [German]; sfRowasa; 2-Hydroxy-5-aminobenzoic acid; 5-ASA; 5-Amino Salicylic Acid; 5-Amino-2-hydroxybenzoic acid; 5-amino-2-hydroxy-benzoic acid; 89-57-6
DM3WVPJ	PC	4075
DM3WVPJ	MW	153.14
DM3WVPJ	FM	C7H7NO3
DM3WVPJ	IC	KBOPZPXVLCULAV-UHFFFAOYSA-N
DM3WVPJ	CS	C1=CC(=C(C=C1N)C(=O)O)O
DM3WVPJ	IK	1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
DM3WVPJ	IU	5-amino-2-hydroxybenzoic acid
DM3WVPJ	CA	CAS 89-57-6
DM3WVPJ	CB	CHEBI:6775
DM3WVPJ	DE	Inflammatory bowel disease

DM5WR0L	ID	DM5WR0L
DM5WR0L	DN	ASC-201
DM5WR0L	HS	Investigative
DM5WR0L	SN	Dipeptidyl peptidase-4 inhibitor (bone marrow transplantation), America Stem Cell
DM5WR0L	CP	America Stem Cell Inc
DM5WR0L	DE	Bone marrow transplantation

DMYJ87C	ID	DMYJ87C
DMYJ87C	DN	ASC-JMX2
DMYJ87C	HS	Investigative
DMYJ87C	SN	ASCJ-M12; ASCJ-M5; Q-103; Q-49; Androgen antagonist (prostate tumor/benign prostatic hyperplasia), AndroScience; ARD enhancers (oral, prostate tumor/benign prostatic hyperplasia), AndroScience
DMYJ87C	CP	AndroScience Corp
DMYJ87C	DE	Prostate hyperplasia

DMT5LJN	ID	DMT5LJN
DMT5LJN	DN	ASC-JMZ1
DMT5LJN	HS	Investigative
DMT5LJN	CP	AndroScience Corp
DMT5LJN	DE	Bladder cancer

DMT8Y65	ID	DMT8Y65
DMT8Y65	DN	ASIATIC ACID
DMT8Y65	HS	Investigative
DMT8Y65	SN	Asiatic acid; 464-92-6; Dammarolic acid; UNII-9PA5A687X5; NSC 166063; CHEBI:2873; CHEMBL404313; JXSVIVRDWWRQRT-UYDOISQJSA-N; 9PA5A687X5; Asiantic acid; (1S,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid; Asiatic-acid; MFCD00238541; HSDB 7662; NSC-166063; 2,3,23-trihydroxyurs-12-en-28-oic acid; A)-2,3,23-trihydroxyurs-12-en-28-oic acid; Asiatic acid, 97%; AC1Q5QHS; AC1L3O2W
DMT8Y65	DT	Small molecular drug
DMT8Y65	PC	119034
DMT8Y65	MW	488.7
DMT8Y65	FM	C30H48O5
DMT8Y65	IC	InChI=1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1
DMT8Y65	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H]([C@@]5(C)CO)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMT8Y65	IK	JXSVIVRDWWRQRT-UYDOISQJSA-N
DMT8Y65	IU	(1S,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMT8Y65	CA	CAS 464-92-6
DMT8Y65	CB	CHEBI:2873
DMT8Y65	DE	Discovery agent

DMTBZUC	ID	DMTBZUC
DMTBZUC	DN	ASKENDOSIDE B
DMTBZUC	HS	Investigative
DMTBZUC	SN	askendoside B; CHEMBL411981
DMTBZUC	DT	Small molecular drug
DMTBZUC	PC	44406305
DMTBZUC	MW	929.1
DMTBZUC	FM	C47H76O18
DMTBZUC	IC	InChI=1S/C47H76O18/c1-21(48)61-34-25(52)19-60-40(35(34)64-39-33(56)31(54)24(51)18-59-39)63-28-10-12-47-20-46(47)14-13-43(6)36(45(8)11-9-29(65-45)42(4,5)57)22(49)16-44(43,7)27(46)15-26(37(47)41(28,2)3)62-38-32(55)30(53)23(50)17-58-38/h22-40,49-57H,9-20H2,1-8H3/t22-,23+,24-,25+,26-,27-,28-,29+,30-,31-,32+,33+,34-,35+,36-,37-,38-,39-,40-,43+,44-,45+,46-,47+/m0/s1
DMTBZUC	CS	CC(=O)O[C@H]1[C@@H](CO[C@H]([C@@H]1O[C@H]2[C@@H]([C@H]([C@H](CO2)O)O)O)O[C@H]3CC[C@]45C[C@]46CC[C@@]7([C@H]([C@H](C[C@]7([C@@H]6C[C@@H]([C@H]5C3(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)C)O)[C@]9(CC[C@@H](O9)C(C)(C)O)C)C)O
DMTBZUC	IK	BTTRQTJYXLOSMR-WEWBRACISA-N
DMTBZUC	IU	[(2S,3R,4S,5R)-5-hydroxy-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-9-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-3-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-4-yl] acetate
DMTBZUC	DE	Discovery agent

DM2DPYQ	ID	DM2DPYQ
DM2DPYQ	DN	ASKH95
DM2DPYQ	HS	Investigative
DM2DPYQ	DE	Discovery agent

DMEO3Y4	ID	DMEO3Y4
DMEO3Y4	DN	ASN02563583
DMEO3Y4	HS	Investigative
DMEO3Y4	SN	ASN 02563583; ASN-02563583
DMEO3Y4	DT	Small molecular drug
DMEO3Y4	PC	3167869
DMEO3Y4	MW	460.5
DMEO3Y4	FM	C25H24N4O3S
DMEO3Y4	IC	InChI=1S/C25H24N4O3S/c1-17(24(30)26-18-9-5-4-6-10-18)33-25-28-27-23(21-11-7-8-12-22(21)32-3)29(25)19-13-15-20(31-2)16-14-19/h4-17H,1-3H3,(H,26,30)
DMEO3Y4	CS	CC(C(=O)NC1=CC=CC=C1)SC2=NN=C(N2C3=CC=C(C=C3)OC)C4=CC=CC=C4OC
DMEO3Y4	IK	KGGHSILNBGUJEN-UHFFFAOYSA-N
DMEO3Y4	IU	2-[[5-(2-methoxyphenyl)-4-(4-methoxyphenyl)-1,2,4-triazol-3-yl]sulfanyl]-N-phenylpropanamide
DMEO3Y4	DE	Discovery agent

DMC82XN	ID	DMC82XN
DMC82XN	DN	ASN04421891
DMC82XN	HS	Investigative
DMC82XN	SN	ASN 04421891; ASN-04421891
DMC82XN	DT	Small molecular drug
DMC82XN	PC	3187704
DMC82XN	MW	524.6
DMC82XN	FM	C30H32N6O3
DMC82XN	IC	InChI=1S/C30H32N6O3/c1-38-18-17-36-29(32-33-34-36)28(26-20-24-19-25(39-2)13-14-27(24)31-30(26)37)35(21-23-11-7-4-8-12-23)16-15-22-9-5-3-6-10-22/h3-14,19-20,28H,15-18,21H2,1-2H3,(H,31,37)
DMC82XN	CS	COCCN1C(=NN=N1)C(C2=CC3=C(C=CC(=C3)OC)NC2=O)N(CCC4=CC=CC=C4)CC5=CC=CC=C5
DMC82XN	IK	JKKKHIBCTKIWFJ-UHFFFAOYSA-N
DMC82XN	IU	3-[[benzyl(2-phenylethyl)amino]-[1-(2-methoxyethyl)tetrazol-5-yl]methyl]-6-methoxy-1H-quinolin-2-one
DMC82XN	DE	Discovery agent

DMKR69T	ID	DMKR69T
DMKR69T	DN	ASN04450772
DMKR69T	HS	Investigative
DMKR69T	SN	ASN 04450772; ASN-04450772
DMKR69T	DT	Small molecular drug
DMKR69T	PC	3188786
DMKR69T	MW	535.6
DMKR69T	FM	C26H25N5O6S
DMKR69T	IC	InChI=1S/C26H25N5O6S/c1-36-18-10-4-15(5-11-18)13-29-25(34)22(16-6-8-17(32)9-7-16)31(14-19-3-2-12-37-19)26(35)23-20(27)21(24(28)33)30-38-23/h2-12,22,32H,13-14,27H2,1H3,(H2,28,33)(H,29,34)
DMKR69T	CS	COC1=CC=C(C=C1)CNC(=O)C(C2=CC=C(C=C2)O)N(CC3=CC=CO3)C(=O)C4=C(C(=NS4)C(=O)N)N
DMKR69T	IK	TVONKIFIPYRNRD-UHFFFAOYSA-N
DMKR69T	IU	4-amino-5-N-(furan-2-ylmethyl)-5-N-[1-(4-hydroxyphenyl)-2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-1,2-thiazole-3,5-dicarboxamide
DMKR69T	DE	Discovery agent

DMQ0VZ8	ID	DMQ0VZ8
DMQ0VZ8	DN	ASN04885796
DMQ0VZ8	HS	Investigative
DMQ0VZ8	SN	ASN 04885796; ASN-04885796
DMQ0VZ8	DT	Small molecular drug
DMQ0VZ8	PC	3191600
DMQ0VZ8	MW	517.6
DMQ0VZ8	FM	C28H28FN5O4
DMQ0VZ8	IC	InChI=1S/C28H28FN5O4/c1-37-22-14-12-21(13-15-22)34(26(35)18-33-25-7-3-2-6-24(25)31-32-33)27(19-8-10-20(29)11-9-19)28(36)30-17-23-5-4-16-38-23/h2-3,6-15,23,27H,4-5,16-18H2,1H3,(H,30,36)
DMQ0VZ8	CS	COC1=CC=C(C=C1)N(C(C2=CC=C(C=C2)F)C(=O)NCC3CCCO3)C(=O)CN4C5=CC=CC=C5N=N4
DMQ0VZ8	IK	HIWKGPKZDUQDKF-UHFFFAOYSA-N
DMQ0VZ8	IU	2-(N-[2-(benzotriazol-1-yl)acetyl]-4-methoxyanilino)-2-(4-fluorophenyl)-N-(oxolan-2-ylmethyl)acetamide
DMQ0VZ8	DE	Discovery agent

DMA20JP	ID	DMA20JP
DMA20JP	DN	ASN06917370
DMA20JP	HS	Investigative
DMA20JP	SN	ASN 06917370; ASN-06917370
DMA20JP	DT	Small molecular drug
DMA20JP	PC	135439060
DMA20JP	MW	531.9
DMA20JP	FM	C24H21ClF3N7O2
DMA20JP	IC	InChI=1S/C24H21ClF3N7O2/c25-18-4-2-1-3-15(18)13-35-21-19(32-33-35)22(36)31-20(30-21)14-9-11-34(12-10-14)23(37)29-17-7-5-16(6-8-17)24(26,27)28/h1-8,14H,9-13H2,(H,29,37)(H,30,31,36)
DMA20JP	CS	C1CN(CCC1C2=NC3=C(C(=O)N2)N=NN3CC4=CC=CC=C4Cl)C(=O)NC5=CC=C(C=C5)C(F)(F)F
DMA20JP	IK	SKWHAHNDWJREJG-UHFFFAOYSA-N
DMA20JP	IU	4-[3-[(2-chlorophenyl)methyl]-7-oxo-6H-triazolo[4,5-d]pyrimidin-5-yl]-N-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide
DMA20JP	DE	Discovery agent

DMFNZOI	ID	DMFNZOI
DMFNZOI	DN	ASN-11124542
DMFNZOI	HS	Investigative
DMFNZOI	SN	AC1O5VPR; ASN 11124542
DMFNZOI	DT	Small molecular drug
DMFNZOI	PC	6490494
DMFNZOI	MW	268.3
DMFNZOI	FM	C13H8N4OS
DMFNZOI	IC	InChI=1S/C13H8N4OS/c18-13-8(3-7-4-14-5-15-7)11-9(17-13)1-2-10-12(11)19-6-16-10/h1-6H,(H,14,15)(H,17,18)/b8-3-
DMFNZOI	CS	C1=CC2=C(C\\3=C1NC(=O)/C3=C\\C4=CN=CN4)SC=N2
DMFNZOI	IK	VFBGXTUGODTSPK-BAQGIRSFSA-N
DMFNZOI	IU	(8Z)-8-(1H-imidazol-5-ylmethylidene)-6H-pyrrolo[2,3-g][1,3]benzothiazol-7-one
DMFNZOI	DE	Discovery agent

DM8XT1Y	ID	DM8XT1Y
DM8XT1Y	DN	ASOBAMAST
DM8XT1Y	HS	Investigative
DM8XT1Y	SN	Asobamast < Rec INN; Z-1819; N-[4-(3-Methylisoxazol-5-yl)thiazol-2-yl]oxamic acid 2-ethoxyethyl ester
DM8XT1Y	DT	Small molecular drug
DM8XT1Y	PC	72033
DM8XT1Y	MW	325.34
DM8XT1Y	FM	C13H15N3O5S
DM8XT1Y	IC	InChI=1S/C13H15N3O5S/c1-3-19-4-5-20-12(18)11(17)15-13-14-9(7-22-13)10-6-8(2)16-21-10/h6-7H,3-5H2,1-2H3,(H,14,15,17)
DM8XT1Y	CS	CCOCCOC(=O)C(=O)NC1=NC(=CS1)C2=CC(=NO2)C
DM8XT1Y	IK	IKYTUOHXXXPNOG-UHFFFAOYSA-N
DM8XT1Y	IU	2-ethoxyethyl 2-[[4-(3-methyl-1,2-oxazol-5-yl)-1,3-thiazol-2-yl]amino]-2-oxoacetate
DM8XT1Y	CA	CAS 104777-03-9
DM8XT1Y	DE	Asthma

DM3XCM1	ID	DM3XCM1
DM3XCM1	DN	ASP-2002
DM3XCM1	HS	Investigative
DM3XCM1	SN	Integrin antagonist (ulcerative colitis), Asphelia
DM3XCM1	CP	Asphelia Pharmaceuticals Inc
DM3XCM1	DE	Ulcerative colitis

DMZ9GQR	ID	DMZ9GQR
DMZ9GQR	DN	ASP-3258
DMZ9GQR	HS	Investigative
DMZ9GQR	SN	PDE 4 inhibitor (airway inflammation), Astellas; Phosphodiesterase 4 inhibitor (airway inflammation), Astellas
DMZ9GQR	CP	Astellas Pharma Inc
DMZ9GQR	PC	10156040
DMZ9GQR	MW	370.8
DMZ9GQR	FM	C20H19ClN2O3
DMZ9GQR	IC	InChI=1S/C20H19ClN2O3/c1-3-23-19-15(8-7-12(2)22-19)18(13-5-4-6-14(21)11-13)16(20(23)26)9-10-17(24)25/h4-8,11H,3,9-10H2,1-2H3,(H,24,25)
DMZ9GQR	CS	CCN1C2=C(C=CC(=N2)C)C(=C(C1=O)CCC(=O)O)C3=CC(=CC=C3)Cl
DMZ9GQR	IK	XYFVLSWIYKWKTC-UHFFFAOYSA-N
DMZ9GQR	IU	3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,8-naphthyridin-3-yl]propanoic acid
DMZ9GQR	DE	Respiratory tract inflammation

DMFWTOP	ID	DMFWTOP
DMFWTOP	DN	ASP-8370
DMFWTOP	HS	Investigative
DMFWTOP	SN	AS-1725195; AS-1928370; TRPV1 antagonists (neuropathic pain); TRPV1 antagonists (neuropathic pain), Astellas
DMFWTOP	CP	Astellas Pharma Inc
DMFWTOP	DE	Neuropathic pain

DMGB90V	ID	DMGB90V
DMGB90V	DN	Aspartate Semialdehyde
DMGB90V	HS	Investigative
DMGB90V	SN	Aspartate semialdehyde; (2S)-2-ammonio-4-oxobutanoate; L-Aspartate 4-semialdehyde; aspartate semi-aldehyde; L-aspartate beta-semialdehyde; 15106-57-7; AC1NRA59; L-2-ammonio-4-oxobutanoate; HOSWPDPVFBCLSY-VKHMYHEASA-N; CHEBI:537519; (2S)-2-azaniumyl-4-oxobutanoate; L-aspartic acid 4-semialdehyde betaine; (2S)-2-azaniumyl-4-oxidanylidene-butanoate
DMGB90V	DT	Small molecular drug
DMGB90V	PC	5287708
DMGB90V	MW	117.1
DMGB90V	FM	C4H7NO3
DMGB90V	IC	InChI=1S/C4H7NO3/c5-3(1-2-6)4(7)8/h2-3H,1,5H2,(H,7,8)/t3-/m0/s1
DMGB90V	CS	C(C=O)[C@@H](C(=O)[O-])[NH3+]
DMGB90V	IK	HOSWPDPVFBCLSY-VKHMYHEASA-N
DMGB90V	IU	(2S)-2-azaniumyl-4-oxobutanoate
DMGB90V	CA	CAS 2338-03-6
DMGB90V	CB	CHEBI:537519
DMGB90V	DE	Discovery agent

DMK7EYA	ID	DMK7EYA
DMK7EYA	DN	Aspartic acid
DMK7EYA	HS	Investigative
DMK7EYA	SN	(2S)-2-aminobutanedioic acid; (2S)-Aspartic acid; (S)-2-Aminosuccinic acid; (S)-Aminobutanedioic acid; (S)-Aspartic acid; Acidum asparticum; Aminosuccinic acid; Asparagic acid; Asparaginic acid; Asparaginsaeure [German]; Aspartate, L-; Aspartic acid, L-; Aspatofort; Butanedioic acid, amino-, (S); H-Asp-OH; L-(+)-Aspartic acid; L-2-Aminobutanedioic acid; L-Aminosuccinic acid; L-Asp; L-Asparagic acid; L-Asparaginic acid; L-Asparaginsaeure; L-Asparaginsyra; L-Aspartinsaeure; L-aspartate; L-aspartic acid; aspartate; aspartic acid
DMK7EYA	DT	Small molecular drug
DMK7EYA	PC	5960
DMK7EYA	MW	133.103
DMK7EYA	FM	C4H7NO4
DMK7EYA	IC	InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1
DMK7EYA	CS	C(C(C(=O)O)N)C(=O)O
DMK7EYA	IK	CKLJMWTZIZZHCS-REOHCLBHSA-N
DMK7EYA	IU	(2S)-2-aminobutanedioic acid
DMK7EYA	CA	CAS 56-84-8
DMK7EYA	CB	ChEBI:17053

DMJEZ62	ID	DMJEZ62
DMJEZ62	DN	Asp-BrPmp-Leu
DMJEZ62	HS	Investigative
DMJEZ62	SN	Asp-BrPmp-Leu; CHEMBL1289231; BDBM50331945
DMJEZ62	DT	Small molecular drug
DMJEZ62	PC	52949968
DMJEZ62	MW	566.3
DMJEZ62	FM	C20H29BrN3O9P
DMJEZ62	IC	InChI=1S/C20H29BrN3O9P/c1-10(2)7-15(20(29)30)24-19(28)14(23-18(27)13(22)9-16(25)26)8-11-3-5-12(6-4-11)17(21)34(31,32)33/h3-6,10,13-15,17H,7-9,22H2,1-2H3,(H,23,27)(H,24,28)(H,25,26)(H,29,30)(H2,31,32,33)/t13-,14-,15-,17?/m0/s1
DMJEZ62	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)C(P(=O)(O)O)Br)NC(=O)[C@H](CC(=O)O)N
DMJEZ62	IK	VZSILTSENHCLNI-CKSGOKGCSA-N
DMJEZ62	IU	(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-[4-[bromo(phosphono)methyl]phenyl]propanoyl]amino]-4-methylpentanoic acid
DMJEZ62	DE	Discovery agent

DMEW37R	ID	DMEW37R
DMEW37R	DN	Asp-D-Glu-Leu-Glu-Cha-Cys
DMEW37R	HS	Investigative
DMEW37R	SN	CHEMBL303541; Asp-D-Glu-Leu-Glu-Cha-Cys; AC1LAAJ7; BDBM50096402; Asp-D-Glu-Leu-Glu-Cha(beta-cyclohexylanine)-Cys; L-Asp-D-Glu-L-Leu-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (R)-2-[(S)-2-((S)-2-{(S)-2-[(R)-2-((S)-2-Amino-3-carboxy-propanoylamino)-4-carboxy-butanoylamino]-4-methyl-pentanoylamino}-4-carboxy-butanoylamino)-3-cyclohexyl-propanoylamino]-3-mercapto-propionic acid
DMEW37R	DT	Small molecular drug
DMEW37R	PC	484574
DMEW37R	MW	760.9
DMEW37R	FM	C32H52N6O13S
DMEW37R	IC	InChI=1S/C32H52N6O13S/c1-16(2)12-21(36-28(46)19(8-10-24(39)40)34-27(45)18(33)14-26(43)44)30(48)35-20(9-11-25(41)42)29(47)37-22(13-17-6-4-3-5-7-17)31(49)38-23(15-52)32(50)51/h16-23,52H,3-15,33H2,1-2H3,(H,34,45)(H,35,48)(H,36,46)(H,37,47)(H,38,49)(H,39,40)(H,41,42)(H,43,44)(H,50,51)/t18-,19+,20-,21-,22-,23-/m0/s1
DMEW37R	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N
DMEW37R	IK	ZFRKNLVWQDBGEY-ZKPZVSKHSA-N
DMEW37R	IU	(4S)-4-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMEW37R	DE	Discovery agent

DMAY2N3	ID	DMAY2N3
DMAY2N3	DN	Asperlicin
DMAY2N3	HS	Investigative
DMAY2N3	SN	asperlicin; UNII-U0MJE9LRXV; 93413-04-8; U0MJE9LRXV; CHEMBL283117; (S-(2alpha,9beta,9(R*),9alpha,beta))-6,7-Dihydro-7-((2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo(1,2-a)indol-9-yl)methyl)quinazolino(3,2-a)(1,4)benzodiazepine-5,13-dione; Quinazolino(3,2-a)(1,4)benzodiazepine-5,13-dione, 6,7-dihydro-7-((2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo(1,2-a)indol-9-yl)methyl)-, (2S-(2alpha,9beta,9(R*),9abeta))-; C31H29N5O4; AC1MHZCP; SCHEMBL1004269; BDBM50019777; LS-178211
DMAY2N3	DT	Small molecular drug
DMAY2N3	PC	3035433
DMAY2N3	MW	535.6
DMAY2N3	FM	C31H29N5O4
DMAY2N3	IC	InChI=1S/C31H29N5O4/c1-17(2)15-22-29(39)36-25-14-8-5-11-20(25)31(40,30(36)34-22)16-23-26-32-21-12-6-3-9-18(21)28(38)35(26)24-13-7-4-10-19(24)27(37)33-23/h3-14,17,22-23,30,34,40H,15-16H2,1-2H3,(H,33,37)/t22-,23-,30-,31-/m0/s1
DMAY2N3	CS	CC(C)C[C@H]1C(=O)N2[C@H](N1)[C@@](C3=CC=CC=C32)(C[C@H]4C5=NC6=CC=CC=C6C(=O)N5C7=CC=CC=C7C(=O)N4)O
DMAY2N3	IK	MGMRIOLWEROPJY-FPACPZPDSA-N
DMAY2N3	IU	(7S)-7-[[(2S,3aS,4S)-4-hydroxy-2-(2-methylpropyl)-1-oxo-3,3a-dihydro-2H-imidazo[1,2-a]indol-4-yl]methyl]-6,7-dihydroquinazolino[3,2-a][1,4]benzodiazepine-5,13-dione
DMAY2N3	CA	CAS 93413-04-8
DMAY2N3	DE	Gastrointestinal disease

DMLBSNP	ID	DMLBSNP
DMLBSNP	DN	aspirin triggered lipoxin A4
DMLBSNP	HS	Investigative
DMLBSNP	SN	aspirin-triggered lipoxin A4; ATL; aspirin triggered 15-epi lipoxin A4
DMLBSNP	DT	Small molecular drug
DMLBSNP	PC	9841438
DMLBSNP	MW	352.5
DMLBSNP	FM	C20H32O5
DMLBSNP	IC	InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18-,19+/m1/s1
DMLBSNP	CS	CCCCC[C@H](/C=C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)O)O
DMLBSNP	IK	IXAQOQZEOGMIQS-JEWNPAEBSA-N
DMLBSNP	IU	(5S,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid
DMLBSNP	CB	CHEBI:72789
DMLBSNP	DE	Discovery agent

DMOP941	ID	DMOP941
DMOP941	DN	aspirin-triggered resolvin D1
DMOP941	HS	Investigative
DMOP941	SN	AT-Resolvin D1; AT-RvD1
DMOP941	DT	Small molecular drug
DMOP941	PC	16126783
DMOP941	MW	376.5
DMOP941	FM	C22H32O5
DMOP941	IC	InChI=1S/C22H32O5/c1-2-3-9-14-19(23)15-10-6-4-5-7-11-16-20(24)21(25)17-12-8-13-18-22(26)27/h3-12,15-16,19-21,23-25H,2,13-14,17-18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,12-8-,15-10+,16-11+/t19-,20-,21+/m1/s1
DMOP941	CS	CC/C=C\\C[C@H](/C=C/C=C\\C=C\\C=C\\[C@H]([C@H](C/C=C\\CCC(=O)O)O)O)O
DMOP941	IK	OIWTWACQMDFHJG-BJEBZIPWSA-N
DMOP941	IU	(4Z,7S,8R,9E,11E,13Z,15E,17R,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid
DMOP941	CA	CAS 528583-91-7
DMOP941	CB	CHEBI:138179
DMOP941	DE	Discovery agent

DMKAHYQ	ID	DMKAHYQ
DMKAHYQ	DN	Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe
DMKAHYQ	HS	Investigative
DMKAHYQ	SN	Asp-Tyr(SO3Na)-Met-Gly-Trp-Met-Asp-Phe-NH2
DMKAHYQ	DE	Discovery agent

DME76KU	ID	DME76KU
DME76KU	DN	AST-487
DME76KU	HS	Investigative
DME76KU	SN	AST 487; NVP-AST 487; NVP-AST487
DME76KU	DT	Small molecular drug
DME76KU	PC	11409972
DME76KU	MW	529.6
DME76KU	FM	C26H30F3N7O2
DME76KU	IC	InChI=1S/C26H30F3N7O2/c1-3-35-10-12-36(13-11-35)16-18-4-5-20(14-22(18)26(27,28)29)34-25(37)33-19-6-8-21(9-7-19)38-24-15-23(30-2)31-17-32-24/h4-9,14-15,17H,3,10-13,16H2,1-2H3,(H,30,31,32)(H2,33,34,37)
DME76KU	CS	CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)NC3=CC=C(C=C3)OC4=NC=NC(=C4)NC)C(F)(F)F
DME76KU	IK	ODPGGGTTYSGTGO-UHFFFAOYSA-N
DME76KU	IU	1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea
DME76KU	CA	CAS 630124-46-8
DME76KU	DE	Discovery agent

DMJAPFH	ID	DMJAPFH
DMJAPFH	DN	Asterric acid
DMJAPFH	HS	Investigative
DMJAPFH	SN	577-64-0; MLS000863583; CHEMBL469424; SMR000440714; 2-hydroxy-6-(4-hydroxy-2-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoic acid; AC1MIV9I; Asterric acid_120092; MEGxm0_000244; ZINC7778; SCHEMBL6046569; XOKVHFNTYHPEHN-UHFFFAOYSA-; cid_3080568; ACon1_001529; ACon0_000930; CTK8F7847; BDBM50711; DTXSID60206405; MolPort-001-739-484; HMS2270H17; MFCD00216131; MCULE-7550426133; NCGC00180411-01; Asterric acid, &gt; L007432; BRD-K20637966-001-01-0
DMJAPFH	DT	Small molecular drug
DMJAPFH	PC	3080568
DMJAPFH	MW	348.3
DMJAPFH	FM	C17H16O8
DMJAPFH	IC	InChI=1S/C17H16O8/c1-8-4-11(19)14(16(20)21)12(5-8)25-15-10(17(22)24-3)6-9(18)7-13(15)23-2/h4-7,18-19H,1-3H3,(H,20,21)
DMJAPFH	CS	CC1=CC(=C(C(=C1)OC2=C(C=C(C=C2OC)O)C(=O)OC)C(=O)O)O
DMJAPFH	IK	XOKVHFNTYHPEHN-UHFFFAOYSA-N
DMJAPFH	IU	2-hydroxy-6-(4-hydroxy-2-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoic acid
DMJAPFH	CA	CAS 577-64-0
DMJAPFH	DE	Discovery agent

DMZHWPG	ID	DMZHWPG
DMZHWPG	DN	ASTRAGALIN
DMZHWPG	HS	Investigative
DMZHWPG	SN	Astragalin; 480-10-4; Astragaline; kaempferol-3-glucoside; Kaempferol 3-O-glucoside; Kaempferol 3-glucoside; Kaempferol-3-O-glucoside; asragalin; Kaempferol-3-beta-monoglucoside; Kaempferol-3-D-glucoside; Kaempferol-3-beta-glucopyranoside; UNII-APM8UQ3Z9O; 3,4',5,7-Tetrahydroxyflavone-3-glucoside; Kaempferol 3-O-beta-D-glucopyranoside; 3-Glucosylkaempferol; Kaempferol 3-O-beta-D-glucoside; APM8UQ3Z9O; 4H-1-Benzopyran-4-one, 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-; CHEMBL233930; CHEBI:30200
DMZHWPG	DT	Small molecular drug
DMZHWPG	PC	5282102
DMZHWPG	MW	448.4
DMZHWPG	FM	C21H20O11
DMZHWPG	IC	InChI=1S/C21H20O11/c22-7-13-15(26)17(28)18(29)21(31-13)32-20-16(27)14-11(25)5-10(24)6-12(14)30-19(20)8-1-3-9(23)4-2-8/h1-6,13,15,17-18,21-26,28-29H,7H2/t13-,15-,17+,18-,21+/m1/s1
DMZHWPG	CS	C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
DMZHWPG	IK	JPUKWEQWGBDDQB-QSOFNFLRSA-N
DMZHWPG	IU	5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMZHWPG	CA	CAS 480-10-4
DMZHWPG	CB	CHEBI:30200
DMZHWPG	DE	Discovery agent

DMSFLTK	ID	DMSFLTK
DMSFLTK	DN	astressin
DMSFLTK	HS	Investigative
DMSFLTK	SN	Astressin; 170809-51-5; GTPL925; CHEBI:76649; MFCD00798715; AKOS024456701; fHLLREVLE-Nle-ARAEQLAQ-cyclo-(EAHK)NRKL-Nle-EII-NH2; [D-Phe(12), Nle(21,38), Glu(30), Lys(33)]-CRF (12-41); [D-Phe12, Nle21,38, Glu30, Lys33]-Corticotropin Releasing Factor fragment 12-41; D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cyclo-(Glu-Ala-His-Lys)-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2; [D-Phe(12), Nle(21,38), Glu(30), Lys(33)]-corticotropin releasing factor fragment 12-41
DMSFLTK	DT	Small molecular drug
DMSFLTK	PC	16133798
DMSFLTK	MW	3563.2
DMSFLTK	FM	C161H269N49O42
DMSFLTK	IC	InChI=1S/C161H269N49O42/c1-23-27-41-96(189-145(239)107(52-59-123(217)218)199-152(246)114(71-84(13)14)207-157(251)126(85(15)16)208-147(241)108(53-60-124(219)220)197-140(234)102(47-38-66-179-161(172)173)193-151(245)112(69-82(9)10)204-153(247)113(70-83(11)12)205-155(249)116(74-94-77-175-79-181-94)201-134(228)95(163)72-92-39-30-29-31-40-92)135(229)182-88(19)130(224)186-100(45-36-64-177-159(168)169)136(230)183-89(20)131(225)188-106(51-58-122(215)216)144(238)195-104(49-56-119(165)212)146(240)202-110(67-80(5)6)149(243)185-90(21)132(226)187-103(48-55-118(164)211)143(237)196-105-50-57-121(214)176-63-35-33-44-99(192-154(248)115(73-93-76-174-78-180-93)200-133(227)91(22)184-137(105)231)142(236)206-117(75-120(166)213)156(250)194-101(46-37-65-178-160(170)171)139(233)190-98(43-32-34-62-162)141(235)203-111(68-81(7)8)150(244)191-97(42-28-24-2)138(232)198-109(54-61-125(221)222)148(242)210-128(87(18)26-4)158(252)209-127(129(167)223)86(17)25-3/h29-31,39-40,76-91,95-117,126-128H,23-28,32-38,41-75,162-163H2,1-22H3,(H2,164,211)(H2,165,212)(H2,166,213)(H2,167,223)(H,174,180)(H,175,181)(H,176,214)(H,182,229)(H,183,230)(H,184,231)(H,185,243)(H,186,224)(H,187,226)(H,188,225)(H,189,239)(H,190,233)(H,191,244)(H,192,248)(H,193,245)(H,194,250)(H,195,238)(H,196,237)(H,197,234)(H,198,232)(H,199,246)(H,200,227)(H,201,228)(H,202,240)(H,203,235)(H,204,247)(H,205,249)(H,206,236)(H,207,251)(H,208,241)(H,209,252)(H,210,242)(H,215,216)(H,217,218)(H,219,220)(H,221,222)(H4,168,169,177)(H4,170,171,178)(H4,172,173,179)/t86-,87-,88-,89-,90-,91-,95+,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,126-,127-,128-/m0/s1
DMSFLTK	CS	CCCC[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H]1CCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C)CC2=CNC=N2)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@@H](CC4=CC=CC=C4)N
DMSFLTK	IK	HPYIIXJJVYSMCV-MGDXKYBTSA-N
DMSFLTK	IU	(4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(3S,6S,9S,18S)-18-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamoyl]-3-(1H-imidazol-4-ylmethyl)-6-methyl-2,5,8,12-tetraoxo-1,4,7,13-tetrazacyclooctadec-9-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMSFLTK	CB	CHEBI:76649
DMSFLTK	DE	Discovery agent

DMODLPS	ID	DMODLPS
DMODLPS	DN	AT-008
DMODLPS	HS	Investigative
DMODLPS	CP	Affitech A/S
DMODLPS	DE	Autoimmune diabetes

DMCO2S4	ID	DMCO2S4
DMCO2S4	DN	AT-009
DMCO2S4	HS	Investigative
DMCO2S4	CP	Affitech A/S
DMCO2S4	DE	Solid tumour/cancer

DMJNQ5G	ID	DMJNQ5G
DMJNQ5G	DN	ATC0065
DMJNQ5G	HS	Investigative
DMJNQ5G	SN	ATC-0065; ATC 0065
DMJNQ5G	DT	Small molecular drug
DMJNQ5G	PC	11238212
DMJNQ5G	MW	552.4
DMJNQ5G	FM	C25H29BrF3N5O
DMJNQ5G	IC	InChI=1S/C25H29BrF3N5O/c1-34(2)23-20-5-3-4-6-21(20)32-24(33-23)31-19-11-9-18(10-12-19)30-14-13-16-7-8-17(26)15-22(16)35-25(27,28)29/h3-8,15,18-19,30H,9-14H2,1-2H3,(H,31,32,33)
DMJNQ5G	CS	CN(C)C1=NC(=NC2=CC=CC=C21)NC3CCC(CC3)NCCC4=C(C=C(C=C4)Br)OC(F)(F)F
DMJNQ5G	IK	FWKVXHBRMCTKHZ-UHFFFAOYSA-N
DMJNQ5G	IU	2-N-[4-[2-[4-bromo-2-(trifluoromethoxy)phenyl]ethylamino]cyclohexyl]-4-N,4-N-dimethylquinazoline-2,4-diamine
DMJNQ5G	CA	CAS 509145-82-8
DMJNQ5G	DE	Discovery agent

DMIA2F1	ID	DMIA2F1
DMIA2F1	DN	ATC-120
DMIA2F1	HS	Investigative
DMIA2F1	SN	CHEMBL412885; ATC-120; thiourea analogue, 14; SCHEMBL5947715; BDBM20317; ZINC14973328; BDBM50142759; N-(4-tert-butylbenzyl)-N''-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea; (R)-N-(4-(1-(3-(4-tert-butylbenzyl)thioureido)ethyl)phenyl)methanesulfonamide; N-(4-{(R)-1-[3-(4-tert-Butyl-benzyl)-thioureido]-ethyl}-phenyl)-methanesulfonamide
DMIA2F1	DT	Small molecular drug
DMIA2F1	PC	10093552
DMIA2F1	MW	419.6
DMIA2F1	FM	C21H29N3O2S2
DMIA2F1	IC	InChI=1S/C21H29N3O2S2/c1-15(17-8-12-19(13-9-17)24-28(5,25)26)23-20(27)22-14-16-6-10-18(11-7-16)21(2,3)4/h6-13,15,24H,14H2,1-5H3,(H2,22,23,27)/t15-/m1/s1
DMIA2F1	CS	C[C@H](C1=CC=C(C=C1)NS(=O)(=O)C)NC(=S)NCC2=CC=C(C=C2)C(C)(C)C
DMIA2F1	IK	MRGDOZGZFFCDRJ-OAHLLOKOSA-N
DMIA2F1	IU	1-[(4-tert-butylphenyl)methyl]-3-[(1R)-1-[4-(methanesulfonamido)phenyl]ethyl]thiourea
DMIA2F1	DE	Discovery agent

DMPJRHX	ID	DMPJRHX
DMPJRHX	DN	ATF-HI-8
DMPJRHX	HS	Investigative
DMPJRHX	SN	urokinase/urinary trypsin inhibitor chimera, Nissin/Hamamatsu University
DMPJRHX	DE	Discovery agent

DMSNBMQ	ID	DMSNBMQ
DMSNBMQ	DN	ATH-90879
DMSNBMQ	HS	Investigative
DMSNBMQ	SN	Histamine H3 antagonists (cognitive disorders/obesity); Histamine H3 antagonists (cognitive disorders/obesity), Athersys
DMSNBMQ	CP	Athersys Inc
DMSNBMQ	DE	Obesity

DMN5VDB	ID	DMN5VDB
DMN5VDB	DN	ATI-1150
DMN5VDB	HS	Investigative
DMN5VDB	SN	SN-38 (Protein Stabilized Nanoparticle, cancer), Azaya; SN-38 (injectable liposomal, Protein Stabilized Nanoparticle), Azaya
DMN5VDB	CP	Azaya Therapeutics
DMN5VDB	DE	Solid tumour/cancer

DMLDWHP	ID	DMLDWHP
DMLDWHP	DN	ATI-2341
DMLDWHP	HS	Investigative
DMLDWHP	SN	ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent
DMLDWHP	CP	Anchor Therapeutics Inc
DMLDWHP	PC	121513892
DMLDWHP	MW	2256.8
DMLDWHP	FM	C104H178N26O25S2
DMLDWHP	IC	InChI=1S/C104H178N26O25S2/c1-9-10-11-12-13-14-15-16-17-18-19-20-21-35-84(136)116-75(46-53-156-7)88(140)115-60-85(137)117-78(57-65-36-40-67(133)41-37-65)97(149)123-74(44-45-83(108)135)94(146)119-69(30-22-25-48-105)89(141)118-70(31-23-26-49-106)90(142)125-77(55-62(2)3)96(148)121-73(34-29-52-114-104(111)112)93(145)129-82(61-131)100(152)124-76(47-54-157-8)95(147)130-87(64(6)132)101(153)127-80(59-86(138)139)99(151)120-71(32-24-27-50-107)91(143)126-79(58-66-38-42-68(134)43-39-66)98(150)122-72(33-28-51-113-103(109)110)92(144)128-81(102(154)155)56-63(4)5/h36-43,62-64,69-82,87,131-134H,9-35,44-61,105-107H2,1-8H3,(H2,108,135)(H,115,140)(H,116,136)(H,117,137)(H,118,141)(H,119,146)(H,120,151)(H,121,148)(H,122,150)(H,123,149)(H,124,152)(H,125,142)(H,126,143)(H,127,153)(H,128,144)(H,129,145)(H,130,147)(H,138,139)(H,154,155)(H4,109,110,113)(H4,111,112,114)/t64-,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,87+/m1/s1
DMLDWHP	CS	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)O
DMLDWHP	IK	YMLOFEANRZSEGQ-QNHYGVTPSA-N
DMLDWHP	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-[[(2S)-2-(hexadecanoylamino)-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoic acid
DMLDWHP	DE	Bone marrow transplantation

DMAZ0EQ	ID	DMAZ0EQ
DMAZ0EQ	DN	ATL-801
DMAZ0EQ	HS	Investigative
DMAZ0EQ	SN	BWA-1433; Adenosine A2b receptor antagonists (coronary artery occlusion), Pennsylvania State University;Adenosine A2b receptor antagonists (diabetes), Pennsylvania State University
DMAZ0EQ	CP	Pennsylvania State University
DMAZ0EQ	DT	Small molecular drug
DMAZ0EQ	PC	24780665
DMAZ0EQ	MW	459.5
DMAZ0EQ	FM	C24H25N7O3
DMAZ0EQ	IC	InChI=1S/C24H25N7O3/c1-3-12-30-21-19(23(33)31(24(30)34)17-8-9-17)27-20(28-21)15-7-10-18(26-14-15)29(4-2)22(32)16-6-5-11-25-13-16/h5-7,10-11,13-14,17H,3-4,8-9,12H2,1-2H3,(H,27,28)
DMAZ0EQ	CS	CCCN1C2=C(C(=O)N(C1=O)C3CC3)NC(=N2)C4=CN=C(C=C4)N(CC)C(=O)C5=CN=CC=C5
DMAZ0EQ	IK	WULKGVCEOREGQF-UHFFFAOYSA-N
DMAZ0EQ	IU	N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7H-purin-8-yl)pyridin-2-yl]-N-ethylpyridine-3-carboxamide
DMAZ0EQ	CA	CAS 1000005-71-9
DMAZ0EQ	DE	Non-insulin dependent diabetes

DMYMCQA	ID	DMYMCQA
DMYMCQA	DN	ATL802
DMYMCQA	HS	Investigative
DMYMCQA	SN	ATL802; SCHEMBL1243258; GTPL5616
DMYMCQA	DT	Small molecular drug
DMYMCQA	PC	24780383
DMYMCQA	MW	513.5
DMYMCQA	FM	C24H22F3N7O3
DMYMCQA	IC	InChI=1S/C24H22F3N7O3/c1-3-10-33-20-18(22(36)34(23(33)37)15-6-7-15)30-19(31-20)13-5-9-17(29-11-13)32(2)21(35)14-4-8-16(28-12-14)24(25,26)27/h4-5,8-9,11-12,15H,3,6-7,10H2,1-2H3,(H,30,31)
DMYMCQA	CS	CCCN1C2=C(C(=O)N(C1=O)C3CC3)NC(=N2)C4=CN=C(C=C4)N(C)C(=O)C5=CN=C(C=C5)C(F)(F)F
DMYMCQA	IK	IKIXRBGOWUFFBN-UHFFFAOYSA-N
DMYMCQA	IU	N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7H-purin-8-yl)pyridin-2-yl]-N-methyl-6-(trifluoromethyl)pyridine-3-carboxamide
DMYMCQA	DE	Discovery agent

DM6V9SC	ID	DM6V9SC
DM6V9SC	DN	ATL-844
DM6V9SC	HS	Investigative
DM6V9SC	SN	N-(4-Cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; MRS 1754; 264622-58-4; MRS-1754; MRS1754; CHEMBL273807; N-(4-cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide; [3H]MRS1754; [3H]-MRS1754; NCGC00015689-01; Lopac-M-6316; Lopac0_000729; GTPL453; GTPL449; MLS002153324; SCHEMBL1222380; AC1O7G54; CTK8E7916; CHEBI:93269; AOB5542; DTXSID80424967; MolPort-023-276-567; HMS3373J21; HMS3268F13; HMS2230A06; ZINC4475274; BDBM50086170; AKOS027427086; AKOS024457276; EX-3306;  ATL-618; ATL-GW-22; ATL-GW-8; A2B adenosine receptor antagonists, Adenosine/Ortho-McNeil; A2B adenosine receptor antagonists (oral, asthma/diabetes), Adenosine Therapeutics; A2B adenosine receptor antagonists (oral, asthma/diabetes), Clinical Data
DM6V9SC	CP	University of Virginia
DM6V9SC	DT	Small molecular drug
DM6V9SC	PC	6603931
DM6V9SC	MW	486.5
DM6V9SC	FM	C26H26N6O4
DM6V9SC	IC	InChI=1S/C26H26N6O4/c1-3-13-31-24-22(25(34)32(14-4-2)26(31)35)29-23(30-24)18-7-11-20(12-8-18)36-16-21(33)28-19-9-5-17(15-27)6-10-19/h5-12H,3-4,13-14,16H2,1-2H3,(H,28,33)(H,29,30)
DM6V9SC	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)NC4=CC=C(C=C4)C#N
DM6V9SC	IK	AJBBEYXFRYFVNM-UHFFFAOYSA-N
DM6V9SC	IU	N-(4-cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide
DM6V9SC	CA	CAS 264622-58-4
DM6V9SC	CB	CHEBI:93269
DM6V9SC	DE	Asthma

DMA632U	ID	DMA632U
DMA632U	DN	ATLa2
DMA632U	HS	Investigative
DMA632U	SN	ATL analog [15-epi-16-(para-fluoro)-phenoxy-LXA4]
DMA632U	DT	Small molecular drug
DMA632U	PC	73755048
DMA632U	MW	404.5
DMA632U	FM	C23H29FO5
DMA632U	IC	InChI=1S/C23H29FO5/c1-18(17-29-20-15-13-19(24)14-16-20)9-6-4-2-3-5-7-10-21(25)22(26)11-8-12-23(27)28/h2-7,9-10,13-16,18,21-22,25-26H,8,11-12,17H2,1H3,(H,27,28)/b4-2-,5-3+,9-6+,10-7+/t18-,21+,22-/m0/s1
DMA632U	CS	C[C@H](COC1=CC=C(C=C1)F)/C=C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)O
DMA632U	IK	SGFIFYSIHRWSCE-LLXPRBAESA-N
DMA632U	IU	(5S,6R,7E,9E,11Z,13E,15S)-16-(4-fluorophenoxy)-5,6-dihydroxy-15-methylhexadeca-7,9,11,13-tetraenoic acid
DMA632U	DE	Discovery agent

DMR2M7L	ID	DMR2M7L
DMR2M7L	DN	ATN-658
DMR2M7L	HS	Investigative
DMR2M7L	SN	ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin
DMR2M7L	CP	Attenuon LLC
DMR2M7L	DE	Solid tumour/cancer

DM2DAFS	ID	DM2DAFS
DM2DAFS	DN	ATPA
DM2DAFS	HS	Investigative
DM2DAFS	SN	ATPA; AC1Q6BQV; AC1L1D9I; 3-(5-tert-butyl-3-hydroxy-1,2-oxazol-4-yl)alanine; GTPL4140; HMS3260K20; Tox21_500139; LP00139; CCG-204234; NCGC00093629-02; NCGC00093629-01; NCGC00015027-03; NCGC00015027-02; NCGC00260824-01; NCGC00015027-04; EU-0100139; 2-azaniumyl-3-(5-tert-butyl-3-oxo-1,2-oxazol-4-yl)propanoate
DM2DAFS	DT	Small molecular drug
DM2DAFS	PC	2253
DM2DAFS	MW	228.24
DM2DAFS	FM	C10H16N2O4
DM2DAFS	IC	InChI=1S/C10H16N2O4/c1-10(2,3)7-5(8(13)12-16-7)4-6(11)9(14)15/h6H,4,11H2,1-3H3,(H,12,13)(H,14,15)
DM2DAFS	CS	CC(C)(C)C1=C(C(=O)NO1)CC(C(=O)O)N
DM2DAFS	IK	PIXJURSCCVBKRF-UHFFFAOYSA-N
DM2DAFS	IU	2-amino-3-(5-tert-butyl-3-oxo-1,2-oxazol-4-yl)propanoic acid
DM2DAFS	CA	CAS 140158-50-5
DM2DAFS	CB	CHEBI:91806
DM2DAFS	DE	Discovery agent

DMXHQIN	ID	DMXHQIN
DMXHQIN	DN	ATPgammaS
DMXHQIN	HS	Investigative
DMXHQIN	SN	adenosine 5'-(3-thio)triphosphate
DMXHQIN	DT	Small molecular drug
DMXHQIN	PC	44123300
DMXHQIN	MW	519.22
DMXHQIN	FM	C10H12N5O12P3S-4
DMXHQIN	IC	InChI=1S/C10H16N5O12P3S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(25-10)1-24-28(18,19)26-29(20,21)27-30(22,23)31/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H,20,21)(H2,11,12,13)(H2,22,23,31)/p-4/t4-,6-,7-,10-/m1/s1
DMXHQIN	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)([O-])OP(=S)([O-])[O-])O)O)N
DMXHQIN	IK	NLTUCYMLOPLUHL-KQYNXXCUSA-J
DMXHQIN	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] dioxidophosphinothioyl phosphate
DMXHQIN	DE	Discovery agent

DMXLS78	ID	DMXLS78
DMXLS78	DN	ATPO
DMXLS78	HS	Investigative
DMXLS78	SN	ATPO; 252930-37-3; (R,S)-2-Amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid; 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid; ATPO, solid; AC1NECDZ; Lopac0_000092; SCHEMBL4318475; CHEMBL265301; GTPL4141; DTXSID70404915; MolPort-003-940-289; HMS3261F20; HMS3260C06; Tox21_500589; Tox21_500092; MFCD03452828; LP00092; LP00589; CCG-204187; NCGC00261274-01; NCGC00260777-01; NCGC00015093-05; NCGC00015093-02; NCGC00093594-01; NCGC00015093-04; NCGC00093594-02; NCGC00015093-03; EU-0100092; A 7845
DMXLS78	DT	Small molecular drug
DMXLS78	PC	4615193
DMXLS78	MW	322.25
DMXLS78	FM	C11H19N2O7P
DMXLS78	IC	InChI=1S/C11H19N2O7P/c1-11(2,3)8-6(4-7(12)10(14)15)9(13-20-8)19-5-21(16,17)18/h7H,4-5,12H2,1-3H3,(H,14,15)(H2,16,17,18)
DMXLS78	CS	CC(C)(C)C1=C(C(=NO1)OCP(=O)(O)O)CC(C(=O)O)N
DMXLS78	IK	AGSOOCUNMTYPSE-UHFFFAOYSA-N
DMXLS78	IU	2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid
DMXLS78	CA	CAS 252930-37-3
DMXLS78	DE	Discovery agent

DML2MAI	ID	DML2MAI
DML2MAI	DN	ATRIPLICIOLIDTIGLATE
DML2MAI	HS	Investigative
DML2MAI	SN	atripliciolidtiglate; Atripliciolide tiglate
DML2MAI	DT	Small molecular drug
DML2MAI	PC	14314512
DML2MAI	MW	358.4
DML2MAI	FM	C20H22O6
DML2MAI	IC	InChI=1S/C20H22O6/c1-6-10(2)18(22)25-15-9-20(5)16(21)8-13(26-20)11(3)7-14-17(15)12(4)19(23)24-14/h6-8,14-15,17H,4,9H2,1-3,5H3/b10-6+,11-7-/t14-,15-,17+,20-/m1/s1
DML2MAI	CS	C/C=C(\\C)/C(=O)O[C@@H]1C[C@@]2(C(=O)C=C(O2)/C(=C\\[C@@H]3[C@@H]1C(=C)C(=O)O3)/C)C
DML2MAI	IK	QATUWZPYBIHFFR-GAZZCERVSA-N
DML2MAI	IU	[(2Z,4R,8R,9R,11R)-2,11-dimethyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (E)-2-methylbut-2-enoate
DML2MAI	DE	Discovery agent

DML3R5Z	ID	DML3R5Z
DML3R5Z	DN	Atropisomer 1
DML3R5Z	HS	Investigative
DML3R5Z	SN	CHEMBL584052; atropisomer 1; Atropisomer 2; SCHEMBL2601123; BDBM50300196
DML3R5Z	DT	Small molecular drug
DML3R5Z	PC	44605611
DML3R5Z	MW	341.4
DML3R5Z	FM	C21H15N3O2
DML3R5Z	IC	InChI=1S/C21H15N3O2/c25-13-7-5-12(6-8-13)18-16-11-23-20-19(16)15(9-10-22-20)14-3-1-2-4-17(14)24-21(18)26/h1-11,18,25H,(H,22,23)(H,24,26)
DML3R5Z	CS	C1=CC=C2C(=C1)C3=C4C(=CNC4=NC=C3)C(C(=O)N2)C5=CC=C(C=C5)O
DML3R5Z	IK	LGIBDQRYOFBMTC-UHFFFAOYSA-N
DML3R5Z	IU	10-(4-hydroxyphenyl)-8,13,15-triazatetracyclo[9.6.1.02,7.014,18]octadeca-1(18),2,4,6,11,14,16-heptaen-9-one
DML3R5Z	DE	Discovery agent

DMHEK4U	ID	DMHEK4U
DMHEK4U	DN	ATS-907
DMHEK4U	HS	Investigative
DMHEK4U	SN	AK-138 series; ATS-907M1; Rho kinase inhibitor (ophthalmic liquid, glaucoma/ocular hypertension), Altheos
DMHEK4U	CP	Asahi Kasei Pharma Corp
DMHEK4U	DE	Glaucoma/ocular hypertension

DMKVDAN	ID	DMKVDAN
DMKVDAN	DN	Augustic acid
DMKVDAN	HS	Investigative
DMKVDAN	SN	augustic acid; CHEMBL482673; 2-hydroxyoleanolic acid; SCHEMBL829270; BDBM50299747; ZINC14980269; 26707-60-8; 2beta,3beta-Dihydroxyolean-12-en-28-oic Acid
DMKVDAN	DT	Small molecular drug
DMKVDAN	PC	15560128
DMKVDAN	MW	472.7
DMKVDAN	FM	C30H48O4
DMKVDAN	IC	InChI=1S/C30H48O4/c1-25(2)12-14-30(24(33)34)15-13-28(6)18(19(30)16-25)8-9-22-27(5)17-20(31)23(32)26(3,4)21(27)10-11-29(22,28)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20-,21-,22+,23-,27-,28+,29+,30-/m0/s1
DMKVDAN	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H]([C@@H](C3(C)C)O)O)C
DMKVDAN	IK	MDZKJHQSJHYOHJ-KRGADYIYSA-N
DMKVDAN	IU	(4aS,6aR,6aS,6bR,8aR,10R,11S,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMKVDAN	CA	CAS 26707-60-8
DMKVDAN	DE	Discovery agent

DMZNUDT	ID	DMZNUDT
DMZNUDT	DN	Aurachin
DMZNUDT	HS	Investigative
DMZNUDT	SN	Aurachin E; aurachin
DMZNUDT	PC	13746957
DMZNUDT	MW	404.5
DMZNUDT	FM	C26H32N2O2
DMZNUDT	IC	CQZZUPSXBXLXRM-CFBAGHHKSA-N
DMZNUDT	CS	CC1=C(C(=O)C2=C3N1C(=O)NC3=CC=C2)CC=C(C)CCC=C(C)CCC=C(C)C
DMZNUDT	IK	1S/C26H32N2O2/c1-17(2)9-6-10-18(3)11-7-12-19(4)15-16-21-20(5)28-24-22(25(21)29)13-8-14-23(24)27-26(28)30/h8-9,11,13-15H,6-7,10,12,16H2,1-5H3,(H,27,30)/b18-11+,19-15+
DMZNUDT	IU	11-methyl-10-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]-1,3-diazatricyclo[6.3.1.04,12]dodeca-4,6,8(12),10-tetraene-2,9-dione
DMZNUDT	CA	CAS 113366-10-2 
DMZNUDT	DE	Malaria

DMDKH8N	ID	DMDKH8N
DMDKH8N	DN	AURASPERONE A
DMDKH8N	HS	Investigative
DMDKH8N	SN	Aurasperone A; Aurasperone; UNII-B9PTQ8Z021; B9PTQ8Z021; 15085-74-2; (7,10'-Bi-4H-naphtho(2,3-b)pyran)-4,4'-dione, 5,5'-dihydroxy-6,6',8,8'-tetramethoxy-2,2'-dimethyl-; AC1MJ24O; CHEMBL450763; DTXSID30164629; CHEBI:133760; 5-HYDROXY-10-{5-HYDROXY-6,8-DIMETHOXY-2-METHYL-4-OXO-4H-BENZO[G]CHROMEN-7-YL}-6,8-DIMETHOXY-2-METHYL-4H-BENZO[G]CHROMEN-4-ONE; 5,5'-Dihydroxy-6,6',8,8'-tetramethoxy-2,2'-dimethyl-7,10'-bi-4H-naphtho[2,3-b]pyran-4,4'-dione, 9CI
DMDKH8N	DT	Small molecular drug
DMDKH8N	PC	3084216
DMDKH8N	MW	570.5
DMDKH8N	FM	C32H26O10
DMDKH8N	IC	InChI=1S/C32H26O10/c1-13-7-18(33)26-22(41-13)10-15-9-20(38-4)28(31(40-6)23(15)29(26)35)25-17-11-16(37-3)12-21(39-5)24(17)30(36)27-19(34)8-14(2)42-32(25)27/h7-12,35-36H,1-6H3
DMDKH8N	CS	CC1=CC(=O)C2=C(O1)C=C3C=C(C(=C(C3=C2O)OC)C4=C5C(=C(C6=C4C=C(C=C6OC)OC)O)C(=O)C=C(O5)C)OC
DMDKH8N	IK	QAHRSPAZSGMZMT-UHFFFAOYSA-N
DMDKH8N	IU	5-hydroxy-7-(5-hydroxy-6,8-dimethoxy-2-methyl-4-oxobenzo[g]chromen-10-yl)-6,8-dimethoxy-2-methylbenzo[g]chromen-4-one
DMDKH8N	CA	CAS 15085-74-2
DMDKH8N	CB	CHEBI:133760
DMDKH8N	DE	Discovery agent

DMOIQ4K	ID	DMOIQ4K
DMOIQ4K	DN	Auryntricarboxylic acid (ATA)
DMOIQ4K	HS	Investigative
DMOIQ4K	SN	244218-51-7; UNII-7I21WLZ2FP; TCMDC-125882; JTC-801 HCl; 7I21WLZ2FP; N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide hydrochloride; N-(4-Amino-2-methyl-6-quinolinyl)-2-[(4-ethylphenoxy)methyl]benzamide hydrochloride; C26H26ClN3O2; N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride; N-(4-amino-2-methylquinolin-6-yl)-2-[(4-ethylphenoxy)methyl]benzamide hydrochloride; AC1NSKGE; MLS006011235; SCHEMBL2240337; CHEMBL531742; CTK8E7568; DTXSID10415525
DMOIQ4K	DT	Small molecular drug
DMOIQ4K	DE	Discovery agent

DMFS4RD	ID	DMFS4RD
DMFS4RD	DN	Autoantibody LKM-3
DMFS4RD	HS	Investigative
DMFS4RD	DE	Discovery agent

DMVGIO5	ID	DMVGIO5
DMVGIO5	DN	AUY954
DMVGIO5	HS	Investigative
DMVGIO5	SN	AUY 954
DMVGIO5	DT	Small molecular drug
DMVGIO5	PC	11259583
DMVGIO5	MW	455.5
DMVGIO5	FM	C25H20F3NO2S
DMVGIO5	IC	InChI=1S/C25H20F3NO2S/c26-25(27,28)21-13-18(7-8-20(21)17-4-2-1-3-5-17)23-14-19-12-16(6-9-22(19)32-23)15-29-11-10-24(30)31/h1-9,12-14,29H,10-11,15H2,(H,30,31)
DMVGIO5	CS	C1=CC=C(C=C1)C2=C(C=C(C=C2)C3=CC4=C(S3)C=CC(=C4)CNCCC(=O)O)C(F)(F)F
DMVGIO5	IK	SKYYWSWIUKISCX-UHFFFAOYSA-N
DMVGIO5	IU	3-[[2-[4-phenyl-3-(trifluoromethyl)phenyl]-1-benzothiophen-5-yl]methylamino]propanoic acid
DMVGIO5	DE	Discovery agent

DMF1VS9	ID	DMF1VS9
DMF1VS9	DN	AV-370
DMF1VS9	HS	Investigative
DMF1VS9	SN	Anti-FGF3 receptor antibody (cancer), AVEO Pharmaceuticals
DMF1VS9	CP	AVEO Pharmaceuticals Inc
DMF1VS9	DT	Antibody
DMF1VS9	DE	Solid tumour/cancer

DM9R3WT	ID	DM9R3WT
DM9R3WT	DN	AVE 0991
DM9R3WT	HS	Investigative
DM9R3WT	SN	AVE 0991; 304462-19-9; AVE-0991; AVE0991; UNII-68JR6NCI7I; 68JR6NCI7I; GTPL5579; SCHEMBL15045765; KS-00000LDU; DTXSID50184526; C29H32N4O5S2; MolPort-019-995-543; BCP11067; ZINC3927311; 3460AH; FD5038; AKOS027338221; CS-1752; HY-15778; AK340230; 4CA-0212; 2-Thiophenesulfonamide, N-((ethylamino)carbonyl)-3-(4-((5-formyl-4-methoxy-2-phenyl-1H-imidazol-1-yl)methyl)phenyl)-5-(2-methylpropyl)-; AB0087841; B1007; A820377
DM9R3WT	DT	Small molecular drug
DM9R3WT	PC	9851724
DM9R3WT	MW	580.7
DM9R3WT	FM	C29H32N4O5S2
DM9R3WT	IC	InChI=1S/C29H32N4O5S2/c1-5-30-29(35)32-40(36,37)28-24(16-23(39-28)15-19(2)3)21-13-11-20(12-14-21)17-33-25(18-34)27(38-4)31-26(33)22-9-7-6-8-10-22/h6-14,16,18-19H,5,15,17H2,1-4H3,(H2,30,32,35)
DM9R3WT	CS	CCNC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C(=C(N=C3C4=CC=CC=C4)OC)C=O
DM9R3WT	IK	QTOZBSNPDCWHPV-UHFFFAOYSA-N
DM9R3WT	IU	1-ethyl-3-[3-[4-[(5-formyl-4-methoxy-2-phenylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylurea
DM9R3WT	CA	CAS 304462-19-9
DM9R3WT	DE	Discovery agent

DMC0PY5	ID	DMC0PY5
DMC0PY5	DN	AVE-1876
DMC0PY5	HS	Investigative
DMC0PY5	SN	AVE-1876A; GABA-B antagonists (depression/anxiety), sanofi-aventis
DMC0PY5	DE	Discovery agent

DMDTONZ	ID	DMDTONZ
DMDTONZ	DN	AVP-13546
DMDTONZ	HS	Investigative
DMDTONZ	DE	Autoimmune disease

DMBNDYK	ID	DMBNDYK
DMBNDYK	DN	AVP-13748
DMBNDYK	HS	Investigative
DMBNDYK	DE	Autoimmune disease

DMNQ9R4	ID	DMNQ9R4
DMNQ9R4	DN	AVPIAQKSEK-FAM
DMNQ9R4	HS	Investigative
DMNQ9R4	SN	CHEMBL404788; AVPIAQKSEK-FAM
DMNQ9R4	PC	44460469
DMNQ9R4	MW	1525.6
DMNQ9R4	FM	C72H96N14O23
DMNQ9R4	IC	InChI=1S/C72H96N14O23/c1-7-36(4)60(84-67(101)50-18-13-31-85(50)70(104)59(35(2)3)83-61(95)37(5)74)69(103)77-38(6)62(96)78-46(23-25-53(75)90)64(98)79-45(16-8-10-29-73)63(97)82-49(34-87)66(100)80-47(24-28-56(93)94)65(99)81-48(71(105)106)17-9-11-30-76-68(102)58-43(14-12-15-44(58)72(107)109-86-54(91)26-27-55(86)92)57-41-21-19-39(88)32-51(41)108-52-33-40(89)20-22-42(52)57/h12,14-15,19-22,32-33,35-38,45-50,59-60,87-88H,7-11,13,16-18,23-31,34,73-74H2,1-6H3,(H2,75,90)(H,76,102)(H,77,103)(H,78,96)(H,79,98)(H,80,100)(H,81,99)(H,82,97)(H,83,95)(H,84,101)(H,93,94)(H,105,106)/t36-,37-,38-,45-,46-,47-,48-,49-,50-,59-,60-/m0/s1
DMNQ9R4	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCNC(=O)C1=C(C=CC=C1C(=O)ON2C(=O)CCC2=O)C3=C4C=CC(=O)C=C4OC5=C3C=CC(=C5)O)C(=O)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
DMNQ9R4	IK	UIHIJARXXMWKOD-UVBGQCGDSA-N
DMNQ9R4	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-6-[[2-(2,5-dioxopyrrolidin-1-yl)oxycarbonyl-6-(3-hydroxy-6-oxoxanthen-9-yl)benzoyl]amino]hexanoic acid
DMNQ9R4	DE	Discovery agent

DMK9BMQ	ID	DMK9BMQ
DMK9BMQ	DN	AVVYPWT
DMK9BMQ	HS	Investigative
DMK9BMQ	SN	CHEMBL238310; AVVYPWT
DMK9BMQ	DT	Small molecular drug
DMK9BMQ	PC	25054398
DMK9BMQ	MW	835
DMK9BMQ	FM	C42H58N8O10
DMK9BMQ	IC	InChI=1S/C42H58N8O10/c1-21(2)33(48-40(57)34(22(3)4)47-36(53)23(5)43)39(56)46-31(18-25-13-15-27(52)16-14-25)41(58)50-17-9-12-32(50)38(55)45-30(37(54)49-35(24(6)51)42(59)60)19-26-20-44-29-11-8-7-10-28(26)29/h7-8,10-11,13-16,20-24,30-35,44,51-52H,9,12,17-19,43H2,1-6H3,(H,45,55)(H,46,56)(H,47,53)(H,48,57)(H,49,54)(H,59,60)/t23-,24+,30-,31-,32-,33-,34-,35-/m0/s1
DMK9BMQ	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N)O
DMK9BMQ	IK	JZZWLFSCHMSJQR-XXWLAZNXSA-N
DMK9BMQ	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DMK9BMQ	DE	Discovery agent

DMG6LJ8	ID	DMG6LJ8
DMG6LJ8	DN	AW-00430
DMG6LJ8	HS	Investigative
DMG6LJ8	SN	MLS000849730; SMR000455748; N-(4-bromo-2-chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)thiophene-2-sulfonamide; N2-(4-bromo-2-chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)thiophene-2-sulfonamide; Bio1C2; AW-00430; AC1Q2OSF; AC1MDU2J; Oprea1_610998; CHEMBL212314; cid_2795741; BDBM58217; MolPort-001-805-761; HMS2792P22; ZINC1023475; MCULE-6709059808; N-(4-bromo-2-chlorophenyl)-5-(2-methyl-4-thiazolyl)-2-thiophenesulfonamide; N-(4-bromo-2-chloro-phenyl)-5-(2-methylthiazol-4-yl)thiophene-2-sulfonamide
DMG6LJ8	DT	Small molecular drug
DMG6LJ8	PC	2795741
DMG6LJ8	MW	449.8
DMG6LJ8	FM	C14H10BrClN2O2S3
DMG6LJ8	IC	InChI=1S/C14H10BrClN2O2S3/c1-8-17-12(7-21-8)13-4-5-14(22-13)23(19,20)18-11-3-2-9(15)6-10(11)16/h2-7,18H,1H3
DMG6LJ8	CS	CC1=NC(=CS1)C2=CC=C(S2)S(=O)(=O)NC3=C(C=C(C=C3)Br)Cl
DMG6LJ8	IK	AMNKYHFERGWVCB-UHFFFAOYSA-N
DMG6LJ8	IU	N-(4-bromo-2-chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)thiophene-2-sulfonamide
DMG6LJ8	DE	Discovery agent

DMIWMJP	ID	DMIWMJP
DMIWMJP	DN	AwFwLL-NH2
DMIWMJP	HS	Investigative
DMIWMJP	SN	CHEMBL509976; AwFwLL-NH2
DMIWMJP	DT	Small molecular drug
DMIWMJP	PC	44576252
DMIWMJP	MW	834
DMIWMJP	FM	C46H59N9O6
DMIWMJP	IC	InChI=1S/C46H59N9O6/c1-26(2)19-36(41(48)56)51-43(58)37(20-27(3)4)53-46(61)40(23-31-25-50-35-18-12-10-16-33(31)35)55-44(59)38(21-29-13-7-6-8-14-29)54-45(60)39(52-42(57)28(5)47)22-30-24-49-34-17-11-9-15-32(30)34/h6-18,24-28,36-40,49-50H,19-23,47H2,1-5H3,(H2,48,56)(H,51,58)(H,52,57)(H,53,61)(H,54,60)(H,55,59)/t28-,36-,37-,38-,39+,40+/m0/s1
DMIWMJP	CS	C[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N)N
DMIWMJP	IK	SHJLXMWODYAZLK-JKHVPLMQSA-N
DMIWMJP	IU	(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-aminopropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanamide
DMIWMJP	DE	Discovery agent

DMDWCY7	ID	DMDWCY7
DMDWCY7	DN	AX-006
DMDWCY7	HS	Investigative
DMDWCY7	SN	AX-006
DMDWCY7	DT	Small molecular drug
DMDWCY7	PC	45482341
DMDWCY7	MW	369.5
DMDWCY7	FM	C21H39NO4
DMDWCY7	IC	InChI=1S/C21H39NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-20(25)21(26)22-17-14-15-19(24)18-23/h23H,2-18H2,1H3,(H,22,26)
DMDWCY7	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCCCC(=O)CO
DMDWCY7	IK	JVJFDPHNZMYFII-UHFFFAOYSA-N
DMDWCY7	IU	N-(5-hydroxy-4-oxopentyl)-2-oxohexadecanamide
DMDWCY7	DE	Discovery agent

DMIDXSN	ID	DMIDXSN
DMIDXSN	DN	AX-048
DMIDXSN	HS	Investigative
DMIDXSN	SN	CHEMBL573332
DMIDXSN	DT	Small molecular drug
DMIDXSN	PC	15950454
DMIDXSN	MW	383.6
DMIDXSN	FM	C22H41NO4
DMIDXSN	IC	InChI=1S/C22H41NO4/c1-3-5-6-7-8-9-10-11-12-13-14-15-17-20(24)22(26)23-19-16-18-21(25)27-4-2/h3-19H2,1-2H3,(H,23,26)
DMIDXSN	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCCCC(=O)OCC
DMIDXSN	IK	FMFKQXKYWWJNJS-UHFFFAOYSA-N
DMIDXSN	IU	ethyl 4-(2-oxohexadecanoylamino)butanoate
DMIDXSN	CA	CAS 873079-69-7
DMIDXSN	DE	Discovery agent

DMKCT0M	ID	DMKCT0M
DMKCT0M	DN	AX-9657
DMKCT0M	HS	Investigative
DMKCT0M	SN	Neutrophil elastase inhibitors (lung disease); HNE inhibitors (lung disease), Kyorin; Neutrophil elastase inhibitors (lung disease), Kyorin
DMKCT0M	CP	Kyorin Pharmaceutical Co Ltd
DMKCT0M	DT	Small molecular drug
DMKCT0M	PC	25205741
DMKCT0M	MW	394.5
DMKCT0M	FM	C22H26N4O3
DMKCT0M	IC	InChI=1S/C22H26N4O3/c1-5-14-11-16(28-4)12-18-19(14)22(27)29-21(24-18)17-7-6-9-23-20(17)26-10-8-15(13-26)25(2)3/h6-7,9,11-12,15H,5,8,10,13H2,1-4H3/t15-/m0/s1
DMKCT0M	CS	CCC1=C2C(=CC(=C1)OC)N=C(OC2=O)C3=C(N=CC=C3)N4CC[C@@H](C4)N(C)C
DMKCT0M	IK	RCPIMTCZGQJSGZ-HNNXBMFYSA-N
DMKCT0M	IU	2-[2-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]pyridin-3-yl]-5-ethyl-7-methoxy-3,1-benzoxazin-4-one
DMKCT0M	CA	CAS 1015439-77-6
DMKCT0M	DE	Pulmonary disease

DMT5P8O	ID	DMT5P8O
DMT5P8O	DN	Axogenesis Factor-1
DMT5P8O	HS	Investigative
DMT5P8O	SN	Oncomodulin; CNS nerve growth factors, Alseres; CNS nerve growth factors, Boston Life Sciences; AF-1, Alseres; AF-1, Boston Life Sciences; Axogenesis Factor-1, Alseres; Axogenesis Factor-1, Boston Life Sciences
DMT5P8O	CP	Children's Hospital Boston
DMT5P8O	DE	Cerebrovascular ischaemia

DMNO6PL	ID	DMNO6PL
DMNO6PL	DN	AZ10417808
DMNO6PL	HS	Investigative
DMNO6PL	SN	AZ-10417808; AZ 10417808
DMNO6PL	DT	Small molecular drug
DMNO6PL	PC	135665263
DMNO6PL	MW	434.2
DMNO6PL	FM	C18H13Cl2N5O4
DMNO6PL	IC	InChI=1S/C18H13Cl2N5O4/c1-2-5-21-16(26)11-7-10(25(28)29)8-12-15(11)23-18(24-17(12)27)22-9-3-4-13(19)14(20)6-9/h2-4,6-8H,1,5H2,(H,21,26)(H2,22,23,24,27)
DMNO6PL	CS	C=CCNC(=O)C1=CC(=CC2=C1N=C(NC2=O)NC3=CC(=C(C=C3)Cl)Cl)[N+](=O)[O-]
DMNO6PL	IK	VUBILPOZTRGZJK-UHFFFAOYSA-N
DMNO6PL	IU	2-(3,4-dichloroanilino)-6-nitro-4-oxo-N-prop-2-enyl-3H-quinazoline-8-carboxamide
DMNO6PL	CA	CAS 331645-84-2
DMNO6PL	CB	CHEBI:92637
DMNO6PL	DE	Discovery agent

DMDRXCP	ID	DMDRXCP
DMDRXCP	DN	AZ11645373
DMDRXCP	HS	Investigative
DMDRXCP	SN	AZ 11645373; AZ-11645373
DMDRXCP	DT	Small molecular drug
DMDRXCP	PC	9804433
DMDRXCP	MW	463.5
DMDRXCP	FM	C24H21N3O5S
DMDRXCP	IC	InChI=1S/C24H21N3O5S/c28-23-16-33-24(29)26(23)21(7-4-17-10-12-25-13-11-17)15-32-22-8-5-18(6-9-22)19-2-1-3-20(14-19)27(30)31/h1-3,5-6,8-14,21H,4,7,15-16H2
DMDRXCP	CS	C1C(=O)N(C(=O)S1)C(CCC2=CC=NC=C2)COC3=CC=C(C=C3)C4=CC(=CC=C4)[N+](=O)[O-]
DMDRXCP	IK	VQEHBLGYANQWEA-UHFFFAOYSA-N
DMDRXCP	IU	3-[1-[4-(3-nitrophenyl)phenoxy]-4-pyridin-4-ylbutan-2-yl]-1,3-thiazolidine-2,4-dione
DMDRXCP	CA	CAS 227088-94-0
DMDRXCP	DE	Discovery agent

DMRUA0Y	ID	DMRUA0Y
DMRUA0Y	DN	AZ-11657312
DMRUA0Y	HS	Investigative
DMRUA0Y	SN	P2X7 purinoceptor antagonists (inflammation); P2X7 purinoceptor antagonists (inflammation), AstraZeneca
DMRUA0Y	CP	AstraZeneca plc
DMRUA0Y	DE	Inflammation

DMVX8LO	ID	DMVX8LO
DMVX8LO	DN	AZ11657312 (salt free)
DMVX8LO	HS	Investigative
DMVX8LO	SN	AZ11657312 (salt free); SCHEMBL5079735; GTPL7722; CHEMBL550637
DMVX8LO	DT	Small molecular drug
DMVX8LO	PC	11193842
DMVX8LO	MW	437.6
DMVX8LO	FM	C26H35N3O3
DMVX8LO	IC	InChI=1S/C26H35N3O3/c1-16-2-3-20(25(31)29-14-21-12-27-13-22(15-29)32-21)7-23(16)28-24(30)11-26-8-17-4-18(9-26)6-19(5-17)10-26/h2-3,7,17-19,21-22,27H,4-6,8-15H2,1H3,(H,28,30)
DMVX8LO	CS	CC1=C(C=C(C=C1)C(=O)N2CC3CNCC(C2)O3)NC(=O)CC45CC6CC(C4)CC(C6)C5
DMVX8LO	IK	XYNNEMHCLNODBL-UHFFFAOYSA-N
DMVX8LO	IU	2-(1-adamantyl)-N-[2-methyl-5-(9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carbonyl)phenyl]acetamide
DMVX8LO	DE	Discovery agent

DM1IN35	ID	DM1IN35
DM1IN35	DN	AZ12216052
DM1IN35	HS	Investigative
DM1IN35	SN	AZ 12216052; AZ-12216052
DM1IN35	DT	Small molecular drug
DM1IN35	PC	73755190
DM1IN35	MW	392.4
DM1IN35	FM	C19H22BrNOS
DM1IN35	IC	InChI=1S/C19H22BrNOS/c1-3-14(2)16-6-10-18(11-7-16)21-19(22)13-23-12-15-4-8-17(20)9-5-15/h4-11,14H,3,12-13H2,1-2H3,(H,21,22)
DM1IN35	CS	CCC(C)C1=CC=C(C=C1)NC(=O)CSCC2=CC=C(C=C2)Br
DM1IN35	IK	QKUYZJOTWYRWNF-UHFFFAOYSA-N
DM1IN35	IU	2-[(4-bromophenyl)methylsulfanyl]-N-(4-butan-2-ylphenyl)acetamide
DM1IN35	DE	Discovery agent

DMQ5H2V	ID	DMQ5H2V
DMQ5H2V	DN	AZ12260493
DMQ5H2V	HS	Investigative
DMQ5H2V	SN	AZ 12260493; AZ-12260493
DMQ5H2V	DT	Small molecular drug
DMQ5H2V	PC	11655079
DMQ5H2V	MW	439.6
DMQ5H2V	FM	C24H29N3O3S
DMQ5H2V	IC	InChI=1S/C24H29N3O3S/c1-24(2,3)27-23(28)21(22(31(27,29)30)18-10-6-4-7-11-18)25-19-12-14-20(15-13-19)26-16-8-5-9-17-26/h4,6-7,10-15,25H,5,8-9,16-17H2,1-3H3
DMQ5H2V	CS	CC(C)(C)N1C(=O)C(=C(S1(=O)=O)C2=CC=CC=C2)NC3=CC=C(C=C3)N4CCCCC4
DMQ5H2V	IK	IVANYIPLGFVBGR-UHFFFAOYSA-N
DMQ5H2V	IU	2-tert-butyl-1,1-dioxo-5-phenyl-4-(4-piperidin-1-ylanilino)-1,2-thiazol-3-one
DMQ5H2V	DE	Discovery agent

DMYDWH1	ID	DMYDWH1
DMYDWH1	DN	AZ13483342
DMYDWH1	HS	Investigative
DMYDWH1	SN	AZ 13483342; AZ-13483342
DMYDWH1	DT	Small molecular drug
DMYDWH1	PC	9927967
DMYDWH1	MW	341.5
DMYDWH1	FM	C19H23N3OS
DMYDWH1	IC	InChI=1S/C19H23N3OS/c1-14-10-19(22-18-5-4-16(23-2)11-17(14)18)21-8-3-7-20-12-15-6-9-24-13-15/h4-6,9-11,13,20H,3,7-8,12H2,1-2H3,(H,21,22)
DMYDWH1	CS	CC1=CC(=NC2=C1C=C(C=C2)OC)NCCCNCC3=CSC=C3
DMYDWH1	IK	ZDKZIFSAJUTJSK-UHFFFAOYSA-N
DMYDWH1	IU	N'-(6-methoxy-4-methylquinolin-2-yl)-N-(thiophen-3-ylmethyl)propane-1,3-diamine
DMYDWH1	DE	Discovery agent

DMNQ3HV	ID	DMNQ3HV
DMNQ3HV	DN	AZ20
DMNQ3HV	HS	Investigative
DMNQ3HV	SN	AZ-20; AZ 20; compound 6 [PMID: 46244454]
DMNQ3HV	DT	Small molecular drug
DMNQ3HV	PC	46244454
DMNQ3HV	MW	412.5
DMNQ3HV	FM	C21H24N4O3S
DMNQ3HV	IC	InChI=1S/C21H24N4O3S/c1-14-13-28-11-10-25(14)19-12-18(21(7-8-21)29(2,26)27)23-20(24-19)16-4-3-5-17-15(16)6-9-22-17/h3-6,9,12,14,22H,7-8,10-11,13H2,1-2H3/t14-/m1/s1
DMNQ3HV	CS	C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)S(=O)(=O)C)C4=C5C=CNC5=CC=C4
DMNQ3HV	IK	SCGCBAAYLFTIJU-CQSZACIVSA-N
DMNQ3HV	IU	(3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)pyrimidin-4-yl]-3-methylmorpholine
DMNQ3HV	CB	CHEBI:124915
DMNQ3HV	DE	Discovery agent

DMVMW9S	ID	DMVMW9S
DMVMW9S	DN	AZ3971
DMVMW9S	HS	Investigative
DMVMW9S	SN	AZ 3971; AZ-3971
DMVMW9S	DT	Small molecular drug
DMVMW9S	PC	49858172
DMVMW9S	MW	422.5
DMVMW9S	FM	C25H22N6O
DMVMW9S	IC	InChI=1S/C25H22N6O/c1-15-9-20(10-16(2)22(15)32-3)25(23-21(24(26)31-25)29-7-8-30-23)19-6-4-5-17(11-19)18-12-27-14-28-13-18/h4-14H,1-3H3,(H2,26,31)/t25-/m0/s1
DMVMW9S	CS	CC1=CC(=CC(=C1OC)C)[C@]2(C3=NC=CN=C3C(=N2)N)C4=CC=CC(=C4)C5=CN=CN=C5
DMVMW9S	IK	BICGYFRWDDPYEI-VWLOTQADSA-N
DMVMW9S	IU	(5S)-5-(4-methoxy-3,5-dimethylphenyl)-5-(3-pyrimidin-5-ylphenyl)pyrrolo[3,4-b]pyrazin-7-amine
DMVMW9S	DE	Discovery agent

DMATC5P	ID	DMATC5P
DMATC5P	DN	AZ4800
DMATC5P	HS	Investigative
DMATC5P	SN	AZ 4800; AZ-4800
DMATC5P	DT	Small molecular drug
DMATC5P	PC	50996844
DMATC5P	MW	435.5
DMATC5P	FM	C24H29N5O3
DMATC5P	IC	InChI=1S/C24H29N5O3/c1-16-12-29(15-25-16)22-8-7-17(11-23(22)30-2)26-24-27-20-9-10-31-13-19(20)21(28-24)14-32-18-5-3-4-6-18/h7-8,11-12,15,18H,3-6,9-10,13-14H2,1-2H3,(H,26,27,28)
DMATC5P	CS	CC1=CN(C=N1)C2=C(C=C(C=C2)NC3=NC4=C(COCC4)C(=N3)COC5CCCC5)OC
DMATC5P	IK	RMRFSIAFQBYBSN-UHFFFAOYSA-N
DMATC5P	IU	4-(cyclopentyloxymethyl)-N-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amine
DMATC5P	DE	Discovery agent

DM1XE4F	ID	DM1XE4F
DM1XE4F	DN	AZ-599
DM1XE4F	HS	Investigative
DM1XE4F	SN	CB1 agonist (pain), AstraZeneca
DM1XE4F	CP	AstraZeneca plc
DM1XE4F	DE	Pain

DMEWQHP	ID	DMEWQHP
DMEWQHP	DN	AZ-628
DMEWQHP	HS	Investigative
DMEWQHP	SN	Mutant B-Raf Kinase inhibitors, AstraZeneca; Mutant B-Raf (V600E) kinase inhibitors (cancer), AstraZeneca
DMEWQHP	CP	AstraZeneca plc
DMEWQHP	DT	Small molecular drug
DMEWQHP	PC	11676786
DMEWQHP	MW	451.5
DMEWQHP	FM	C27H25N5O2
DMEWQHP	IC	InChI=1S/C27H25N5O2/c1-17-8-9-21(31-25(33)18-6-5-7-19(12-18)27(2,3)15-28)14-24(17)30-20-10-11-23-22(13-20)26(34)32(4)16-29-23/h5-14,16,30H,1-4H3,(H,31,33)
DMEWQHP	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(C)(C)C#N)NC3=CC4=C(C=C3)N=CN(C4=O)C
DMEWQHP	IK	ZGBGPEDJXCYQPH-UHFFFAOYSA-N
DMEWQHP	IU	3-(2-cyanopropan-2-yl)-N-[4-methyl-3-[(3-methyl-4-oxoquinazolin-6-yl)amino]phenyl]benzamide
DMEWQHP	CA	CAS 878739-06-1
DMEWQHP	CB	CHEBI:91354
DMEWQHP	DE	Solid tumour/cancer

DM95Y82	ID	DM95Y82
DM95Y82	DN	AZ960
DM95Y82	HS	Investigative
DM95Y82	SN	AZ 960; AZ-960
DM95Y82	DT	Small molecular drug
DM95Y82	PC	25099184
DM95Y82	MW	354.4
DM95Y82	FM	C18H16F2N6
DM95Y82	IC	InChI=1S/C18H16F2N6/c1-10-7-16(26-25-10)23-18-15(20)8-13(9-21)17(24-18)22-11(2)12-3-5-14(19)6-4-12/h3-8,11H,1-2H3,(H3,22,23,24,25,26)/t11-/m0/s1
DM95Y82	CS	CC1=CC(=NN1)NC2=C(C=C(C(=N2)N[C@@H](C)C3=CC=C(C=C3)F)C#N)F
DM95Y82	IK	SUNXHXDJOIXABJ-NSHDSACASA-N
DM95Y82	IU	5-fluoro-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile
DM95Y82	CA	CAS 905586-69-8
DM95Y82	DE	Discovery agent

DMOSI4U	ID	DMOSI4U
DMOSI4U	DN	Aza-C-nucleosides
DMOSI4U	HS	Investigative
DMOSI4U	DT	Small molecular drug
DMOSI4U	PC	1336
DMOSI4U	DE	Discovery agent

DM61H07	ID	DM61H07
DM61H07	DN	AZAKENPAULLONE
DM61H07	HS	Investigative
DM61H07	SN	1-Azakenpaullone; 676596-65-9; azakenpaullone; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866
DM61H07	DT	Small molecular drug
DM61H07	PC	6538897
DM61H07	MW	328.16
DM61H07	FM	C15H10BrN3O
DM61H07	IC	InChI=1S/C15H10BrN3O/c16-8-3-4-11-9(6-8)10-7-13(20)18-12-2-1-5-17-15(12)14(10)19-11/h1-6,19H,7H2,(H,18,20)
DM61H07	CS	C1C2=C(C3=C(C=CC=N3)NC1=O)NC4=C2C=C(C=C4)Br
DM61H07	IK	NTSBZVCEIVPKBJ-UHFFFAOYSA-N
DM61H07	IU	14-bromo-3,8,18-triazatetracyclo[9.7.0.02,7.012,17]octadeca-1(11),2(7),3,5,12(17),13,15-heptaen-9-one
DM61H07	CB	CHEBI:131490
DM61H07	DE	Discovery agent

DMN861Q	ID	DMN861Q
DMN861Q	DN	AZALINE B
DMN861Q	HS	Investigative
DMN861Q	PC	44422930
DMN861Q	MW	1613.3
DMN861Q	FM	C80H102ClN23O12
DMN861Q	IC	InChI=1S/C80H102ClN23O12/c1-44(2)35-59(68(108)91-58(16-9-10-33-86-45(3)4)76(116)104-34-12-17-66(104)75(115)87-46(5)67(82)107)92-70(110)62(38-49-21-28-56(29-22-49)89-79-98-77(83)100-102-79)94-72(112)63(39-50-23-30-57(31-24-50)90-80-99-78(84)101-103-80)96-74(114)65(43-105)97-73(113)64(41-52-13-11-32-85-42-52)95-71(111)61(37-48-19-26-55(81)27-20-48)93-69(109)60(88-47(6)106)40-51-18-25-53-14-7-8-15-54(53)36-51/h7-8,11,13-15,18-32,36,42,44-46,58-66,86,105H,9-10,12,16-17,33-35,37-41,43H2,1-6H3,(H2,82,107)(H,87,115)(H,88,106)(H,91,108)(H,92,110)(H,93,109)(H,94,112)(H,95,111)(H,96,114)(H,97,113)(H4,83,89,98,100,102)(H4,84,90,99,101,103)/t46-,58-,59-,60-,61-,62+,63-,64+,65-,66-/m0/s1
DMN861Q	CS	C[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC3=NC(=NN3)N)NC(=O)[C@H](CC4=CC=C(C=C4)NC5=NC(=NN5)N)NC(=O)[C@H](CO)NC(=O)[C@@H](CC6=CN=CC=C6)NC(=O)[C@H](CC7=CC=C(C=C7)Cl)NC(=O)[C@H](CC8=CC9=CC=CC=C9C=C8)NC(=O)C
DMN861Q	IK	VLGKQBGBPIVGBX-SIHJNPAHSA-N
DMN861Q	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]phenyl]propanoyl]amino]-3-[4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2S)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMN861Q	DE	Discovery agent

DM3BXUJ	ID	DM3BXUJ
DM3BXUJ	DN	Azapeptide
DM3BXUJ	HS	Investigative
DM3BXUJ	DE	Discovery agent

DMKI2GJ	ID	DMKI2GJ
DMKI2GJ	DN	Azaperone
DMKI2GJ	HS	Investigative
DMKI2GJ	SN	Azaperone; 1649-18-9; Azaperon; Stresnil; Fluoperidol; Suicalm; Eucalmyl; Azeperone; Sedaperone vet; Azaperona; Azaperonum; R-1929; NSC 170976; Azaperonum [INN-Latin]; Azaperona [INN-Spanish]; 1-Butanone, 1-(4-fluorophenyl)-4-[4-(2-pyridinyl)-1-piperazinyl]-; UNII-19BV78AK7W; 1-(3-(4-Fluorobenzoyl)propyl)-4-(2-pyridyl)piperazine; CCRIS 1586; C19H22FN3O; 1-(4-Fluorophenyl)-4-[4-(2-pyridinyl)-1-piperazinyl]-1-butanone; 4'-Fluoro-4-(4-(2-pyridyl)-1-piperazinyl)butyrophenone; EINECS 216-715-8; R 1929; BRN 0565491; MLS003106751
DMKI2GJ	DT	Small molecular drug
DMKI2GJ	PC	15443
DMKI2GJ	MW	327.4
DMKI2GJ	FM	C19H22FN3O
DMKI2GJ	IC	InChI=1S/C19H22FN3O/c20-17-8-6-16(7-9-17)18(24)4-3-11-22-12-14-23(15-13-22)19-5-1-2-10-21-19/h1-2,5-10H,3-4,11-15H2
DMKI2GJ	CS	C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=CC=CC=N3
DMKI2GJ	IK	XTKDAFGWCDAMPY-UHFFFAOYSA-N
DMKI2GJ	IU	1-(4-fluorophenyl)-4-(4-pyridin-2-ylpiperazin-1-yl)butan-1-one
DMKI2GJ	CA	CAS 1649-18-9
DMKI2GJ	CB	CHEBI:88301
DMKI2GJ	DE	Discovery agent

DML70NC	ID	DML70NC
DML70NC	DN	aza-THIP
DML70NC	HS	Investigative
DML70NC	SN	654666-65-6; 1,2,4,5,6,7-Hexahydro-3H-pyrazolo[3,4-c]pyridin-3-one; 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-ol; 3H-Pyrazolo[3,4-c]pyridin-3-one, 1,2,4,5,6,7-hexahydro-; 1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-3-ol; 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-ol; aza-THIP; THIP, Aza-; 4,5,6,7-tetrahydropyrazolo[5,4-c]pyridin-3-ol; SCHEMBL2946381; GTPL4143; SCHEMBL16057201; CTK1J6712; BDBM86256; DTXSID20717441; UPMMUUFLHUEUKP-UHFFFAOYSA-N; MolPort-022-468-866; ZINC13859300; AKOS022182337; AKOS022718659; AKOS006351664
DML70NC	DT	Small molecular drug
DML70NC	PC	55285412
DML70NC	MW	139.16
DML70NC	FM	C6H9N3O
DML70NC	IC	InChI=1S/C6H9N3O/c10-6-4-1-2-7-3-5(4)8-9-6/h7H,1-3H2,(H2,8,9,10)
DML70NC	CS	C1CNCC2=C1C(=O)NN2
DML70NC	IK	UPMMUUFLHUEUKP-UHFFFAOYSA-N
DML70NC	IU	1,2,4,5,6,7-hexahydropyrazolo[3,4-c]pyridin-3-one
DML70NC	CA	CAS 654666-65-6
DML70NC	DE	Discovery agent

DM0PVD9	ID	DM0PVD9
DM0PVD9	DN	AZD1332
DM0PVD9	HS	Investigative
DM0PVD9	SN	AZD 1332; AZD-1332
DM0PVD9	DT	Small molecular drug
DM0PVD9	PC	49831044
DM0PVD9	MW	391.8
DM0PVD9	FM	C17H19ClFN7O
DM0PVD9	IC	InChI=1S/C17H19ClFN7O/c1-9(2)27-15-6-14(25-26-15)23-16-12(18)8-21-17(24-16)22-10(3)13-5-4-11(19)7-20-13/h4-10H,1-3H3,(H3,21,22,23,24,25,26)
DM0PVD9	CS	CC(C)OC1=NNC(=C1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=C3)F
DM0PVD9	IK	LBVKEEFIPBQIMD-UHFFFAOYSA-N
DM0PVD9	IU	5-chloro-2-N-[1-(5-fluoropyridin-2-yl)ethyl]-4-N-(3-propan-2-yloxy-1H-pyrazol-5-yl)pyrimidine-2,4-diamine
DM0PVD9	DE	Discovery agent

DMAX9C3	ID	DMAX9C3
DMAX9C3	DN	AZD3463
DMAX9C3	HS	Investigative
DMAX9C3	SN	AZD-3463; CS-1382; HY-15609; KB-154896
DMAX9C3	DT	Small molecular drug
DMAX9C3	PC	56599293
DMAX9C3	MW	448.9
DMAX9C3	FM	C24H25ClN6O
DMAX9C3	IC	InChI=1S/C24H25ClN6O/c1-32-22-12-16(31-10-8-15(26)9-11-31)6-7-21(22)29-24-28-14-19(25)23(30-24)18-13-27-20-5-3-2-4-17(18)20/h2-7,12-15,27H,8-11,26H2,1H3,(H,28,29,30)
DMAX9C3	CS	COC1=C(C=CC(=C1)N2CCC(CC2)N)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl
DMAX9C3	IK	GCYIGMXOIWJGBU-UHFFFAOYSA-N
DMAX9C3	IU	N-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine
DMAX9C3	CA	CAS 1356962-20-3
DMAX9C3	DE	Discovery agent

DMPIHN6	ID	DMPIHN6
DMPIHN6	DN	AZD5582
DMPIHN6	HS	Investigative
DMPIHN6	SN	AZD 5582; AZD-5582
DMPIHN6	DT	Small molecular drug
DMPIHN6	PC	49847690
DMPIHN6	MW	1015.3
DMPIHN6	FM	C58H78N8O8
DMPIHN6	IC	InChI=1S/C58H78N8O8/c1-37(59-3)53(67)61-49(39-21-9-7-10-22-39)57(71)65-31-19-29-45(65)55(69)63-51-43-27-15-13-25-41(43)35-47(51)73-33-17-5-6-18-34-74-48-36-42-26-14-16-28-44(42)52(48)64-56(70)46-30-20-32-66(46)58(72)50(40-23-11-8-12-24-40)62-54(68)38(2)60-4/h13-16,25-28,37-40,45-52,59-60H,7-12,19-24,29-36H2,1-4H3,(H,61,67)(H,62,68)(H,63,69)(H,64,70)/t37-,38-,45-,46-,47+,48+,49-,50-,51-,52-/m0/s1
DMPIHN6	CS	C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)OCC#CC#CCO[C@@H]5CC6=CC=CC=C6[C@@H]5NC(=O)[C@@H]7CCCN7C(=O)[C@H](C8CCCCC8)NC(=O)[C@H](C)NC)NC
DMPIHN6	IK	WLMCRYCCYXHPQF-ZVMUOSSASA-N
DMPIHN6	IU	(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(1S,2R)-2-[6-[[(1S,2R)-1-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]oxy]hexa-2,4-diynoxy]-2,3-dihydro-1H-inden-1-yl]pyrrolidine-2-carboxamide
DMPIHN6	DE	Discovery agent

DMD4YO9	ID	DMD4YO9
DMD4YO9	DN	AZD-6319
DMD4YO9	HS	Investigative
DMD4YO9	SN	Alpha 7 neuronal nicotinic receptor agonist (Alzheimer's disease), AstraZeneca
DMD4YO9	CP	AstraZeneca plc
DMD4YO9	DE	Alzheimer disease

DMLJPDW	ID	DMLJPDW
DMLJPDW	DN	AZD-7507
DMLJPDW	HS	Investigative
DMLJPDW	SN	CSF-1R inhibitors (cancer); CSF-1R inhibitors (cancer), AstraZeneca; Colony stimulating factor-1 receptor inhibitors (cancer), AstraZeneca
DMLJPDW	CP	AstraZeneca plc
DMLJPDW	DE	Solid tumour/cancer

DM34W56	ID	DM34W56
DM34W56	DN	AZD-7806
DM34W56	HS	Investigative
DM34W56	SN	AZD 7806; AZD7806
DM34W56	DT	Small molecular drug
DM34W56	PC	9939892
DM34W56	MW	695.9
DM34W56	FM	C36H45N3O7S2
DM34W56	IC	InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1
DM34W56	CS	CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)C1)OCC(=O)N[C@H](C3=CC=CC=C3)C(=O)NCC(=O)O)SC)C4=CC=CC=C4)CCCC
DM34W56	IK	XFLQIRAKKLNXRQ-UUWRZZSWSA-N
DM34W56	IU	2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic acid
DM34W56	CA	CAS 439087-18-0
DM34W56	DE	Discovery agent

DM0HTXO	ID	DM0HTXO
DM0HTXO	DN	AZD8542
DM0HTXO	HS	Investigative
DM0HTXO	SN	AZD 8542; AZD-8542
DM0HTXO	DT	Small molecular drug
DM0HTXO	PC	53344810
DM0HTXO	MW	412.5
DM0HTXO	FM	C25H24N4O2
DM0HTXO	IC	InChI=1S/C25H24N4O2/c1-17-12-18(2)23(13-22(17)24-14-29(3)16-27-24)28-25(30)19-7-9-21(10-8-19)31-15-20-6-4-5-11-26-20/h4-14,16H,15H2,1-3H3,(H,28,30)
DM0HTXO	CS	CC1=CC(=C(C=C1C2=CN(C=N2)C)NC(=O)C3=CC=C(C=C3)OCC4=CC=CC=N4)C
DM0HTXO	IK	SMQVBAGSZVHCJP-UHFFFAOYSA-N
DM0HTXO	IU	N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(pyridin-2-ylmethoxy)benzamide
DM0HTXO	DE	Discovery agent

DMKSQY1	ID	DMKSQY1
DMKSQY1	DN	Azelaic bishydroxamic acid
DMKSQY1	HS	Investigative
DMKSQY1	SN	Azelaic bishydroxamic acid; 18992-11-5; Azelaic bis(hydroxamic acid); Nonanedihydroximic acid; N,N'-dihydroxynonanediamide; Azelaic bis hydroxamic acid; AC1L22XV; SCHEMBL4741072; CHEMBL495390; Nonanediamide, N,N'-dihydroxy-; DTXSID30172421; ZINC5178518; NSC611775
DMKSQY1	DT	Small molecular drug
DMKSQY1	PC	65268
DMKSQY1	MW	218.25
DMKSQY1	FM	C9H18N2O4
DMKSQY1	IC	InChI=1S/C9H18N2O4/c12-8(10-14)6-4-2-1-3-5-7-9(13)11-15/h14-15H,1-7H2,(H,10,12)(H,11,13)
DMKSQY1	CS	C(CCCC(=O)NO)CCCC(=O)NO
DMKSQY1	IK	VBJZDMOTYJEHEP-UHFFFAOYSA-N
DMKSQY1	IU	N,N'-dihydroxynonanediamide
DMKSQY1	CA	CAS 18992-11-5
DMKSQY1	DE	Discovery agent

DMZHV39	ID	DMZHV39
DMZHV39	DN	Azepan-(2Z)-ylideneamine
DMZHV39	HS	Investigative
DMZHV39	SN	Azepan-(2Z)-ylideneamine; 3,4,5,6-tetrahydro-2H-azepin-7-amine; CHEMBL315857; 2214-67-7; iminohomopiperidine; 2-Iminohexahydro-1H-azepine; SCHEMBL1575752; MolPort-007-996-393; GTLJSJNKRLFVSJ-UHFFFAOYSA-N; STL163828; ZINC13746433; BBL012958; BDBM50049257; AKOS002684184; AKOS006375172; MCULE-7781415779
DMZHV39	DT	Small molecular drug
DMZHV39	PC	9793728
DMZHV39	MW	112.17
DMZHV39	FM	C6H12N2
DMZHV39	IC	InChI=1S/C6H12N2/c7-6-4-2-1-3-5-8-6/h1-5H2,(H2,7,8)
DMZHV39	CS	C1CCC(=NCC1)N
DMZHV39	IK	GTLJSJNKRLFVSJ-UHFFFAOYSA-N
DMZHV39	IU	3,4,5,6-tetrahydro-2H-azepin-7-amine
DMZHV39	DE	Discovery agent

DM5XZYB	ID	DM5XZYB
DM5XZYB	DN	Azide
DM5XZYB	HS	Investigative
DM5XZYB	DT	Small molecular drug
DM5XZYB	PC	33558
DM5XZYB	MW	42.021
DM5XZYB	FM	N3-
DM5XZYB	IC	InChI=1S/N3/c1-3-2/q-1
DM5XZYB	CS	[N-]=[N+]=[N-]
DM5XZYB	IK	IVRMZWNICZWHMI-UHFFFAOYSA-N
DM5XZYB	IU	azide
DM5XZYB	CA	CAS 14343-69-2
DM5XZYB	CB	CHEBI:40910
DM5XZYB	DE	Discovery agent

DMD0LCA	ID	DMD0LCA
DMD0LCA	DN	Azidopine
DMD0LCA	HS	Investigative
DMD0LCA	SN	Azidopine; 90523-31-2; AC1LCUW1; NSC617999; CHEBI:2952; CHEMBL1993397; NSC-617999; O5-[2-[(4-azidobenzoyl)amino]ethyl] O3-ethyl 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate; GTPL6980; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-(trifluoromethyl)phenyl)-, 2-((4-azidobenzoyl)amino)ethyl ethyl ester; NCI60_005410; C11282; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-2-[(4-azidobenzoyl)amino]ethyl ethyl ester (9CI)
DMD0LCA	DT	Small molecular drug
DMD0LCA	PC	656406
DMD0LCA	MW	557.5
DMD0LCA	FM	C27H26F3N5O5
DMD0LCA	IC	InChI=1S/C27H26F3N5O5/c1-4-39-25(37)21-15(2)33-16(3)22(23(21)19-7-5-6-8-20(19)27(28,29)30)26(38)40-14-13-32-24(36)17-9-11-18(12-10-17)34-35-31/h5-12,23,33H,4,13-14H2,1-3H3,(H,32,36)
DMD0LCA	CS	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C(F)(F)F)C(=O)OCCNC(=O)C3=CC=C(C=C3)N=[N+]=[N-])C)C
DMD0LCA	IK	SWMHKFTXBOJETC-UHFFFAOYSA-N
DMD0LCA	IU	5-O-[2-[(4-azidobenzoyl)amino]ethyl] 3-O-ethyl 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMD0LCA	CA	CAS 90523-31-2
DMD0LCA	CB	CHEBI:2952
DMD0LCA	DE	Discovery agent

DM8ZQG3	ID	DM8ZQG3
DM8ZQG3	DN	Azithromycinarylalkylhydroxamic Acid
DM8ZQG3	HS	Investigative
DM8ZQG3	SN	Azithromycinarylalkylhydroxamic Acid; CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8
DM8ZQG3	PC	25151109
DM8ZQG3	MW	1011.3
DM8ZQG3	FM	C52H90N4O15
DM8ZQG3	IC	InChI=1S/C52H90N4O15/c1-14-39-52(10,64)45(60)34(6)55(11)28-30(2)26-50(8,63)47(32(4)44(33(5)48(62)69-39)70-42-27-51(9,66-13)46(61)35(7)68-42)71-49-43(59)38(25-31(3)67-49)56(12)29-36-21-23-37(24-22-36)53-40(57)19-17-15-16-18-20-41(58)54-65/h21-24,30-35,38-39,42-47,49,59-61,63-65H,14-20,25-29H2,1-13H3,(H,53,57)(H,54,58)/t30-,31-,32+,33-,34-,35+,38+,39-,42+,43-,44+,45-,46+,47-,49+,50-,51-,52-/m1/s1
DM8ZQG3	CS	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)NC(=O)CCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DM8ZQG3	IK	FRRIWMVHMJBTRB-CSAKRERUSA-N
DM8ZQG3	IU	N-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]-N'-hydroxyoctanediamide
DM8ZQG3	DE	Discovery agent

DMDQ2VN	ID	DMDQ2VN
DMDQ2VN	DN	Azithromycin-N-benzyltriazolyldecahydroxamic Acid
DMDQ2VN	HS	Investigative
DMDQ2VN	SN	Azithromycin-N-benzyltriazolyldecahydroxamic Acid; CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h
DMDQ2VN	PC	25190759
DMDQ2VN	MW	1077.4
DMDQ2VN	FM	C56H96N6O14
DMDQ2VN	IC	InChI=1S/C56H96N6O14/c1-14-44-56(10,69)49(65)38(6)60(11)31-34(2)29-54(8,68)51(36(4)48(37(5)52(67)74-44)75-46-30-55(9,71-13)50(66)39(7)73-46)76-53-47(64)43(28-35(3)72-53)61(12)32-40-23-25-41(26-24-40)42-33-62(59-57-42)27-21-19-17-15-16-18-20-22-45(63)58-70/h23-26,33-39,43-44,46-51,53,64-66,68-70H,14-22,27-32H2,1-13H3,(H,58,63)/t34-,35-,36+,37-,38-,39+,43+,44-,46+,47-,48+,49-,50+,51-,53+,54-,55-,56-/m1/s1
DMDQ2VN	CS	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)C5=CN(N=N5)CCCCCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DMDQ2VN	IK	PVDBHHHRLSRBII-GJUNKSMQSA-N
DMDQ2VN	IU	10-[4-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]triazol-1-yl]-N-hydroxydecanamide
DMDQ2VN	DE	Discovery agent

DM7KD5Y	ID	DM7KD5Y
DM7KD5Y	DN	Azithromycin-N-benzyltriazolylhexahydroxamic Acid
DM7KD5Y	HS	Investigative
DM7KD5Y	SN	Azithromycin-N-benzyltriazolylhexahydroxamic Acid; CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a
DM7KD5Y	PC	25152062
DM7KD5Y	MW	1021.3
DM7KD5Y	FM	C52H88N6O14
DM7KD5Y	IC	InChI=1S/C52H88N6O14/c1-14-40-52(10,65)45(61)34(6)56(11)27-30(2)25-50(8,64)47(32(4)44(33(5)48(63)70-40)71-42-26-51(9,67-13)46(62)35(7)69-42)72-49-43(60)39(24-31(3)68-49)57(12)28-36-19-21-37(22-20-36)38-29-58(55-53-38)23-17-15-16-18-41(59)54-66/h19-22,29-35,39-40,42-47,49,60-62,64-66H,14-18,23-28H2,1-13H3,(H,54,59)/t30-,31-,32+,33-,34-,35+,39+,40-,42+,43-,44+,45-,46+,47-,49+,50-,51-,52-/m1/s1
DM7KD5Y	CS	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)C5=CN(N=N5)CCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DM7KD5Y	IK	BCHUJJCIGPEYFV-RAYHFQHHSA-N
DM7KD5Y	IU	6-[4-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]triazol-1-yl]-N-hydroxyhexanamide
DM7KD5Y	DE	Discovery agent

DMW0HXO	ID	DMW0HXO
DMW0HXO	DN	Azithromycin-N-benzyltriazolylnonahydroxamic Acid
DMW0HXO	HS	Investigative
DMW0HXO	SN	Azithromycin-N-benzyltriazolylnonahydroxamic Acid; CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g
DMW0HXO	PC	25190758
DMW0HXO	MW	1063.4
DMW0HXO	FM	C55H94N6O14
DMW0HXO	IC	InChI=1S/C55H94N6O14/c1-14-43-55(10,68)48(64)37(6)59(11)30-33(2)28-53(8,67)50(35(4)47(36(5)51(66)73-43)74-45-29-54(9,70-13)49(65)38(7)72-45)75-52-46(63)42(27-34(3)71-52)60(12)31-39-22-24-40(25-23-39)41-32-61(58-56-41)26-20-18-16-15-17-19-21-44(62)57-69/h22-25,32-38,42-43,45-50,52,63-65,67-69H,14-21,26-31H2,1-13H3,(H,57,62)/t33-,34-,35+,36-,37-,38+,42+,43-,45+,46-,47+,48-,49+,50-,52+,53-,54-,55-/m1/s1
DMW0HXO	CS	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)C5=CN(N=N5)CCCCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DMW0HXO	IK	ZZONRCLYCNUZKQ-IEOJUODTSA-N
DMW0HXO	IU	9-[4-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]triazol-1-yl]-N-hydroxynonanamide
DMW0HXO	DE	Discovery agent

DMAJ4LI	ID	DMAJ4LI
DMAJ4LI	DN	Azithromycin-N-benzyltriazolyloctahydroxamic Acid
DMAJ4LI	HS	Investigative
DMAJ4LI	SN	Azithromycin-N-benzyltriazolyloctahydroxamic Acid; SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e
DMAJ4LI	PC	25151675
DMAJ4LI	MW	1049.3
DMAJ4LI	FM	C54H92N6O14
DMAJ4LI	IC	InChI=1S/C54H92N6O14/c1-14-42-54(10,67)47(63)36(6)58(11)29-32(2)27-52(8,66)49(34(4)46(35(5)50(65)72-42)73-44-28-53(9,69-13)48(64)37(7)71-44)74-51-45(62)41(26-33(3)70-51)59(12)30-38-21-23-39(24-22-38)40-31-60(57-55-40)25-19-17-15-16-18-20-43(61)56-68/h21-24,31-37,41-42,44-49,51,62-64,66-68H,14-20,25-30H2,1-13H3,(H,56,61)/t32-,33-,34+,35-,36-,37+,41+,42-,44+,45-,46+,47-,48+,49-,51+,52-,53-,54-/m1/s1
DMAJ4LI	CS	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)C5=CN(N=N5)CCCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DMAJ4LI	IK	YOTANXLDCGWPPQ-QASXAQIXSA-N
DMAJ4LI	IU	8-[4-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]triazol-1-yl]-N-hydroxyoctanamide
DMAJ4LI	DE	Discovery agent

DMQ13PZ	ID	DMQ13PZ
DMQ13PZ	DN	Azocan-(2Z)-ylideneamine
DMQ13PZ	HS	Investigative
DMQ13PZ	SN	Azocan-(2Z)-ylideneamine; CHEMBL329431; 2-Iminooctahydroazocine; SCHEMBL3928259; BDBM50049249
DMQ13PZ	DT	Small molecular drug
DMQ13PZ	PC	10749191
DMQ13PZ	MW	126.2
DMQ13PZ	FM	C7H14N2
DMQ13PZ	IC	InChI=1S/C7H14N2/c8-7-5-3-1-2-4-6-9-7/h1-6H2,(H2,8,9)
DMQ13PZ	CS	C1CCCN=C(CC1)N
DMQ13PZ	IK	AZNNPSMXKKWOPY-UHFFFAOYSA-N
DMQ13PZ	IU	2,3,4,5,6,7-hexahydroazocin-8-amine
DMQ13PZ	DE	Discovery agent

DMTQSNK	ID	DMTQSNK
DMTQSNK	DN	Azonan-(2Z)-ylideneamine
DMTQSNK	HS	Investigative
DMTQSNK	SN	Azonan-(2Z)-ylideneamine; CHEMBL158641; SCHEMBL8466372; SCHEMBL2661739; BDBM50049256; AKOS006356817
DMTQSNK	DT	Small molecular drug
DMTQSNK	PC	10606829
DMTQSNK	MW	140.23
DMTQSNK	FM	C8H16N2
DMTQSNK	IC	InChI=1S/C8H16N2/c9-8-6-4-2-1-3-5-7-10-8/h1-7H2,(H2,9,10)
DMTQSNK	CS	C1CCCC(=NCCC1)N
DMTQSNK	IK	NHHGJWDDKUEZBV-UHFFFAOYSA-N
DMTQSNK	IU	3,4,5,6,7,8-hexahydro-2H-azonin-9-amine
DMTQSNK	DE	Discovery agent

DMD4LGN	ID	DMD4LGN
DMD4LGN	DN	AZ-TAK1
DMD4LGN	HS	Investigative
DMD4LGN	SN	TAK1 inhibitor (mantle cell lymphoma), AstraZeneca; TGF-beta-activated kinase 1 inhibitor (mantle cell lymphoma), AstraZeneca
DMD4LGN	CP	AstraZeneca plc
DMD4LGN	DE	Mantle cell lymphoma

DMXOGE8	ID	DMXOGE8
DMXOGE8	DN	AZUMAMIDE B
DMXOGE8	HS	Investigative
DMXOGE8	SN	AZUMAMIDE B; CHEMBL402727
DMXOGE8	DT	Small molecular drug
DMXOGE8	PC	16095112
DMXOGE8	MW	529.6
DMXOGE8	FM	C27H39N5O6
DMXOGE8	IC	InChI=1S/C27H39N5O6/c1-15(2)23-27(38)29-17(4)25(36)31-21(14-18-10-12-19(33)13-11-18)26(37)30-20(16(3)24(35)32-23)8-6-5-7-9-22(28)34/h5-6,10-13,15-17,20-21,23,33H,7-9,14H2,1-4H3,(H2,28,34)(H,29,38)(H,30,37)(H,31,36)(H,32,35)/b6-5-/t16-,17+,20+,21+,23+/m0/s1
DMXOGE8	CS	C[C@H]1[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)C(C)C)C)CC2=CC=C(C=C2)O)C/C=C\\CCC(=O)N
DMXOGE8	IK	RFGAANHNJBCQAS-LFUPQXEOSA-N
DMXOGE8	IU	(Z)-6-[(2R,5R,8R,11R,12S)-8-[(4-hydroxyphenyl)methyl]-5,12-dimethyl-3,6,9,13-tetraoxo-2-propan-2-yl-1,4,7,10-tetrazacyclotridec-11-yl]hex-4-enamide
DMXOGE8	DE	Discovery agent

DMEBA61	ID	DMEBA61
DMEBA61	DN	AZUMAMIDE C
DMEBA61	HS	Investigative
DMEBA61	SN	AZUMAMIDE C; CHEMBL257972
DMEBA61	DT	Small molecular drug
DMEBA61	PC	16095114
DMEBA61	MW	530.6
DMEBA61	FM	C27H38N4O7
DMEBA61	IC	InChI=1S/C27H38N4O7/c1-15(2)23-27(38)28-17(4)25(36)30-21(14-18-10-12-19(32)13-11-18)26(37)29-20(16(3)24(35)31-23)8-6-5-7-9-22(33)34/h5-6,10-13,15-17,20-21,23,32H,7-9,14H2,1-4H3,(H,28,38)(H,29,37)(H,30,36)(H,31,35)(H,33,34)/b6-5-/t16-,17+,20+,21+,23+/m0/s1
DMEBA61	CS	C[C@H]1[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)C(C)C)C)CC2=CC=C(C=C2)O)C/C=C\\CCC(=O)O
DMEBA61	IK	QKNOLJBQLJGNKI-LFUPQXEOSA-N
DMEBA61	IU	(Z)-6-[(2R,5R,8R,11R,12S)-8-[(4-hydroxyphenyl)methyl]-5,12-dimethyl-3,6,9,13-tetraoxo-2-propan-2-yl-1,4,7,10-tetrazacyclotridec-11-yl]hex-4-enoic acid
DMEBA61	DE	Discovery agent

DMAX06G	ID	DMAX06G
DMAX06G	DN	AZUMAMIDE E
DMAX06G	HS	Investigative
DMAX06G	SN	azumamide E; CHEMBL402363
DMAX06G	DT	Small molecular drug
DMAX06G	PC	16095101
DMAX06G	MW	514.6
DMAX06G	FM	C27H38N4O6
DMAX06G	IC	InChI=1S/C27H38N4O6/c1-16(2)23-27(37)28-18(4)25(35)30-21(15-19-11-7-5-8-12-19)26(36)29-20(17(3)24(34)31-23)13-9-6-10-14-22(32)33/h5-9,11-12,16-18,20-21,23H,10,13-15H2,1-4H3,(H,28,37)(H,29,36)(H,30,35)(H,31,34)(H,32,33)/b9-6-/t17-,18+,20+,21+,23+/m0/s1
DMAX06G	CS	C[C@H]1[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)C(C)C)C)CC2=CC=CC=C2)C/C=C\\CCC(=O)O
DMAX06G	IK	DMXROUYLQHFRCS-GIORXHJXSA-N
DMAX06G	IU	(Z)-6-[(2R,5R,8R,11R,12S)-8-benzyl-5,12-dimethyl-3,6,9,13-tetraoxo-2-propan-2-yl-1,4,7,10-tetrazacyclotridec-11-yl]hex-4-enoic acid
DMAX06G	DE	Discovery agent

DMN2XTQ	ID	DMN2XTQ
DMN2XTQ	DN	B173
DMN2XTQ	HS	Investigative
DMN2XTQ	SN	BRL 54443 maleate; BRL 54443 maleate salt; 1197333-54-2; EU-0100207; 3-(1-Methylpiperidin-4-yl)-1H-indol-5-ol maleate; SCHEMBL4799792; CHEMBL1256797; MolPort-003-940-420; BRL 54443 maleate salt, solid; HMS3260J15; Tox21_500207; BN0117; LP00207; CCG-221511; NCGC00093680-01; NCGC00260892-01; B-173; SR-01000075573-1; J-004192; 3-(1-Methylpiperidin-4-yl)-1H-indol-5-ol maleate salt
DMN2XTQ	DT	Small molecular drug
DMN2XTQ	PC	11957480
DMN2XTQ	MW	346.4
DMN2XTQ	FM	C18H22N2O5
DMN2XTQ	IC	InChI=1S/C14H18N2O.C4H4O4/c1-16-6-4-10(5-7-16)13-9-15-14-3-2-11(17)8-12(13)14;5-3(6)1-2-4(7)8/h2-3,8-10,15,17H,4-7H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMN2XTQ	CS	CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)O.C(=C\\C(=O)O)\\C(=O)O
DMN2XTQ	IK	INGCLXPSKXSYND-BTJKTKAUSA-N
DMN2XTQ	IU	(Z)-but-2-enedioic acid;3-(1-methylpiperidin-4-yl)-1H-indol-5-ol
DMN2XTQ	DE	Discovery agent

DMEGX8H	ID	DMEGX8H
DMEGX8H	DN	B-2-Octylglucoside
DMEGX8H	HS	Investigative
DMEGX8H	SN	B-2-OCTYLGLUCOSIDE; BGL; AC1L9I1F; SCHEMBL61561; 2-O-octyl-beta-D-glucopyranose; DB03152; (2R,3R,4S,5S,6R)-6-(hydroxymethyl)-3-octoxyoxane-2,4,5-triol
DMEGX8H	DT	Small molecular drug
DMEGX8H	PC	445463
DMEGX8H	MW	292.37
DMEGX8H	FM	C14H28O6
DMEGX8H	IC	InChI=1S/C14H28O6/c1-2-3-4-5-6-7-8-19-13-12(17)11(16)10(9-15)20-14(13)18/h10-18H,2-9H2,1H3/t10-,11-,12+,13-,14-/m1/s1
DMEGX8H	CS	CCCCCCCCO[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O
DMEGX8H	IK	BVHPDIWLWHHJPD-RKQHYHRCSA-N
DMEGX8H	IU	(2R,3R,4S,5S,6R)-6-(hydroxymethyl)-3-octoxyoxane-2,4,5-triol
DMEGX8H	DE	Discovery agent

DMV3H0C	ID	DMV3H0C
DMV3H0C	DN	B3C
DMV3H0C	HS	Investigative
DMV3H0C	SN	compound 23 [PMID: 18752942]
DMV3H0C	DT	Small molecular drug
DMV3H0C	PC	24892831
DMV3H0C	MW	777.9
DMV3H0C	FM	C44H51N5O8
DMV3H0C	IC	InChI=1S/C44H51N5O8/c1-30-19-21-33(22-20-30)28-55-34-26-37(40(50)48-39(18-10-11-25-45)44(53,54)42-46-35-16-8-9-17-38(35)57-42)49(27-34)41(51)36(24-23-31-12-4-2-5-13-31)47-43(52)56-29-32-14-6-3-7-15-32/h2-9,12-17,19-22,34,36-37,39,53-54H,10-11,18,23-29,45H2,1H3,(H,47,52)(H,48,50)/t34-,36-,37+,39+/m1/s1
DMV3H0C	CS	CC1=CC=C(C=C1)CO[C@@H]2C[C@H](N(C2)C(=O)[C@@H](CCC3=CC=CC=C3)NC(=O)OCC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(C5=NC6=CC=CC=C6O5)(O)O
DMV3H0C	IK	KGNDCEVUMONOKF-UGPLYTSKSA-N
DMV3H0C	IU	benzyl N-[(2R)-1-[(2S,4R)-2-[[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate
DMV3H0C	DE	Discovery agent

DMIUD0L	ID	DMIUD0L
DMIUD0L	DN	B-623
DMIUD0L	HS	Investigative
DMIUD0L	SN	149732-37-6
DMIUD0L	PC	9820186
DMIUD0L	MW	322.4
DMIUD0L	FM	C18H14N2O2S
DMIUD0L	IC	InChI=1S/C18H14N2O2S/c19-18(20)17-9-13-12(2-1-3-16(13)23-17)6-4-11-5-7-14-15(8-11)22-10-21-14/h1-9H,10H2,(H3,19,20)/b6-4+
DMIUD0L	CS	C1OC2=C(O1)C=C(C=C2)/C=C/C3=C4C=C(SC4=CC=C3)C(=N)N
DMIUD0L	IK	BGFUKOBHJOFLNH-GQCTYLIASA-N
DMIUD0L	IU	4-[(E)-2-(1,3-benzodioxol-5-yl)ethenyl]-1-benzothiophene-2-carboximidamide
DMIUD0L	DE	Discovery agent

DMCK5DG	ID	DMCK5DG
DMCK5DG	DN	BADGE
DMCK5DG	HS	Investigative
DMCK5DG	SN	SCHEMBL7915436; GTPL2708; 2,2-Bis[4-(oxiranyloxy)phenyl]propane
DMCK5DG	DT	Small molecular drug
DMCK5DG	PC	2286
DMCK5DG	MW	340.4
DMCK5DG	FM	C21H24O4
DMCK5DG	IC	InChI=1S/C21H24O4/c1-21(2,15-3-7-17(8-4-15)22-11-19-13-24-19)16-5-9-18(10-6-16)23-12-20-14-25-20/h3-10,19-20H,11-14H2,1-2H3
DMCK5DG	CS	CC(C)(C1=CC=C(C=C1)OCC2CO2)C3=CC=C(C=C3)OCC4CO4
DMCK5DG	IK	LCFVJGUPQDGYKZ-UHFFFAOYSA-N
DMCK5DG	IU	2-[[4-[2-[4-(oxiran-2-ylmethoxy)phenyl]propan-2-yl]phenoxy]methyl]oxirane
DMCK5DG	CA	CAS 1675-54-3
DMCK5DG	CB	CHEBI:34578
DMCK5DG	DE	Discovery agent

DMUNK59	ID	DMUNK59
DMUNK59	DN	Bafilomycin A1
DMUNK59	HS	Investigative
DMUNK59	SN	bafilomycin A1; 88899-55-2; MFCD06795130; CHEMBL290814; CHEBI:22689; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-{(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-6-isopropyl-5-methyltetrahydro-2H-pyran-2-yl]-3-hydroxypentan-2-yl}-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyloxacyclohexadeca-3,5,11,13-tetraen-2-one; Bafilomycin; NSC381866; Bafilomycin A1/; Hygrolidin, 21-O-de(3-carboxy-1-oxo-2-propenyl)-2-demethyl-2-methoxy-24-methyl-; Bafilomycin A1 from Streptomyces griseus; BSPBio_001470; MEGxm0_000385; SCHEMBL13775181; ACon0_000813; HMS3402J12; Bafilomycin A1 Ready Made Solution; ABP000610; BDBM50064186; AKOS030213158; ZINC169647947; DB06733; MCULE-2359469972; NCGC00163426-02; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one; Q4841341; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-2,4-dihydroxy-6-isopropyl-5-methyl-tetrahydropyran-2-yl]-2-hydroxy-1-methyl-butyl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one
DMUNK59	DT	Small molecular drug
DMUNK59	PC	6436223
DMUNK59	MW	622.8
DMUNK59	FM	C35H58O9
DMUNK59	IC	InChI=1S/C35H58O9/c1-19(2)32-24(7)27(36)18-35(40,44-32)26(9)31(38)25(8)33-28(41-10)14-12-13-20(3)15-22(5)30(37)23(6)16-21(4)17-29(42-11)34(39)43-33/h12-14,16-17,19,22-28,30-33,36-38,40H,15,18H2,1-11H3/b14-12+,20-13+,21-16+,29-17-/t22-,23+,24-,25-,26-,27+,28-,30-,31+,32+,33+,35+/m0/s1
DMUNK59	CS	C[C@H]1C/C(=C/C=C/[C@@H]([C@H](OC(=O)/C(=C/C(=C/[C@H]([C@H]1O)C)/C)/OC)[C@@H](C)[C@H]([C@H](C)[C@]2(C[C@H]([C@@H]([C@H](O2)C(C)C)C)O)O)O)OC)/C
DMUNK59	IK	XDHNQDDQEHDUTM-JQWOJBOSSA-N
DMUNK59	IU	(3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one
DMUNK59	CA	CAS 88899-55-2
DMUNK59	CB	CHEBI:22689
DMUNK59	DE	B-cell acute lymphoblastic leukaemia

DMSWQED	ID	DMSWQED
DMSWQED	DN	bag-1
DMSWQED	HS	Investigative
DMSWQED	SN	AK120413
DMSWQED	DT	Small molecular drug
DMSWQED	PC	25025860
DMSWQED	MW	333.5
DMSWQED	FM	C22H27N3
DMSWQED	IC	InChI=1S/C22H27N3/c1-4-22(2,3)15-19-16-24-21(25-19)13-10-17-8-11-18(12-9-17)20-7-5-6-14-23-20/h5-9,11-12,14,16H,4,10,13,15H2,1-3H3,(H,24,25)
DMSWQED	CS	CCC(C)(C)CC1=CN=C(N1)CCC2=CC=C(C=C2)C3=CC=CC=N3
DMSWQED	IK	WVAKRQOMAINQPU-UHFFFAOYSA-N
DMSWQED	IU	2-[4-[2-[5-(2,2-dimethylbutyl)-1H-imidazol-2-yl]ethyl]phenyl]pyridine
DMSWQED	CA	CAS 1021937-07-4
DMSWQED	DE	Discovery agent

DMWC34B	ID	DMWC34B
DMWC34B	DN	BAG956
DMWC34B	HS	Investigative
DMWC34B	SN	NVP-BAG956; 853910-02-8; BAG 956; NVP-BAG956(BAG 956); BAG-956; UNII-4UFC2K6E50; 4UFC2K6E50; 2-Methyl-2-(4-(2-methyl-8-((pyridin-3-yl)ethynyl)imidazo(4,5-C)quinolin-1-yl)phenyl)propionitrile; 2-methyl-2-(4-(2-methyl-8-(pyridin-3-ylethynyl)-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile; BAG956; 2-Methyl-2-{4-[2-methyl-8-(pyridin-3-ylethynyl)-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile; 2-Methyl-2-[4-[2-methyl-8-[(pyridin-3-yl)ethynyl]imidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile; NVP-BAG-956
DMWC34B	TC	Anticancer Agents
DMWC34B	DT	Small molecular drug
DMWC34B	PC	24882589
DMWC34B	MW	427.5
DMWC34B	FM	C28H21N5
DMWC34B	IC	InChI=1S/C28H21N5/c1-19-32-26-17-31-25-13-8-20(6-7-21-5-4-14-30-16-21)15-24(25)27(26)33(19)23-11-9-22(10-12-23)28(2,3)18-29/h4-5,8-17H,1-3H3
DMWC34B	CS	CC1=NC2=CN=C3C=CC(=CC3=C2N1C4=CC=C(C=C4)C(C)(C)C#N)C#CC5=CN=CC=C5
DMWC34B	IK	GVPAGJWVBUZHNQ-UHFFFAOYSA-N
DMWC34B	IU	2-methyl-2-[4-[2-methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile
DMWC34B	CA	CAS 853910-02-8
DMWC34B	DE	Haematological malignancy

DMX6KTO	ID	DMX6KTO
DMX6KTO	DN	BAN-2203
DMX6KTO	HS	Investigative
DMX6KTO	SN	Beta amyloid modulator (Alzheimer's disease), BioArctic
DMX6KTO	CP	Bioarctic Neuroscience AB
DMX6KTO	DE	Alzheimer disease

DM4OT8M	ID	DM4OT8M
DM4OT8M	DN	bantag-1
DM4OT8M	HS	Investigative
DM4OT8M	SN	bantag-1; GTPL6176
DM4OT8M	DT	Small molecular drug
DM4OT8M	PC	73755180
DM4OT8M	MW	895.2
DM4OT8M	FM	C49H82N8O7+2
DM4OT8M	IC	InChI=1S/C49H80N8O7/c1-33(2)23-40(45(60)51-29-36-21-16-22-37(24-36)31-57(7,8)9)53-44(59)28-43(58)39(25-34-17-12-10-13-18-34)54-46(61)42(27-38-30-50-32-52-38)56(6)47(62)41(26-35-19-14-11-15-20-35)55-48(63)64-49(3,4)5/h11,14,19,21,24,30,32-34,39-43,46,54,58,61H,10,12-13,15-18,20,22-23,25-29,31H2,1-9H3,(H3-,50,51,52,53,55,59,60,63)/p+2/t39-,40-,41-,42-,43-,46?/m0/s1
DM4OT8M	CS	CC(C)C[C@@H](C(=O)NCC1=CCCC(=C1)C[N+](C)(C)C)NC(=O)C[C@@H]([C@H](CC2CCCCC2)NC([C@H](CC3=C[NH+]=CN3)N(C)C(=O)[C@H](CC4=CC=CCC4)NC(=O)OC(C)(C)C)O)O
DM4OT8M	IK	DAWSYEXBFLQUER-SLMIJXFKSA-P
DM4OT8M	IU	[3-[[[(2S)-2-[[(3S,4S)-4-[[(2S)-2-[[(2S)-3-cyclohexa-1,3-dien-1-yl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]-methylamino]-1-hydroxy-3-(1H-imidazol-3-ium-5-yl)propyl]amino]-5-cyclohexyl-3-hydroxypentanoyl]amino]-4-methylpentanoyl]amino]methyl]cyclohexa-1,3-dien-1-yl]methyl-trimethylazanium
DM4OT8M	DE	Discovery agent

DM9JXIZ	ID	DM9JXIZ
DM9JXIZ	DN	banyu (I)
DM9JXIZ	HS	Investigative
DM9JXIZ	SN	2-(6-Amino-benzothiazol-2-ylsulfanyl)-N-[1-(3,4-dichloro-benzyl)-piperidin-4-yl]-acetamide; CHEMBL20921; Banyu Compound 1b; [3H]banyu (I); GTPL795; GTPL796; SCHEMBL5489840; BDBM50099482; N-[1-(3,4-Dichlorobenzyl)-4-piperidinyl](6-amino-2-benzothiazolylthio)acetamide; 2-[(6-amino-1,3-benzothiazol-2-yl)sulfanyl]-N-[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]acetamid; 290363-23-4;  Banyu Compound 1b
DM9JXIZ	DT	Small molecular drug
DM9JXIZ	PC	9913085
DM9JXIZ	MW	481.5
DM9JXIZ	FM	C21H22Cl2N4OS2
DM9JXIZ	IC	InChI=1S/C21H22Cl2N4OS2/c22-16-3-1-13(9-17(16)23)11-27-7-5-15(6-8-27)25-20(28)12-29-21-26-18-4-2-14(24)10-19(18)30-21/h1-4,9-10,15H,5-8,11-12,24H2,(H,25,28)
DM9JXIZ	CS	C1CN(CCC1NC(=O)CSC2=NC3=C(S2)C=C(C=C3)N)CC4=CC(=C(C=C4)Cl)Cl
DM9JXIZ	IK	QOHFBKIKGAINLL-UHFFFAOYSA-N
DM9JXIZ	IU	2-[(6-amino-1,3-benzothiazol-2-yl)sulfanyl]-N-[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]acetamide
DM9JXIZ	DE	Discovery agent

DMD26XN	ID	DMD26XN
DMD26XN	DN	Banyu Compound-24
DMD26XN	HS	Investigative
DMD26XN	SN	C-24
DMD26XN	DT	Small molecular drug
DMD26XN	PC	10296561
DMD26XN	MW	433.6
DMD26XN	FM	C27H35N3O2
DMD26XN	IC	InChI=1S/C27H35N3O2/c31-26(25-12-6-17-30(25)20-22-8-2-1-3-9-22)28-15-7-16-29-18-13-27(14-19-29)24-11-5-4-10-23(24)21-32-27/h1-5,8-11,25H,6-7,12-21H2,(H,28,31)/t25-/m1/s1
DMD26XN	CS	C1C[C@@H](N(C1)CC2=CC=CC=C2)C(=O)NCCCN3CCC4(CC3)C5=CC=CC=C5CO4
DMD26XN	IK	MAKMQGKJURAJEN-RUZDIDTESA-N
DMD26XN	IU	(2R)-1-benzyl-N-(3-spiro[1H-2-benzofuran-3,4'-piperidine]-1'-ylpropyl)pyrrolidine-2-carboxamide
DMD26XN	DE	Discovery agent

DM2I19P	ID	DM2I19P
DM2I19P	DN	Barbituric acid derivative
DM2I19P	HS	Investigative
DM2I19P	SN	Barbituric acid derivative; UNII-R1JI58032B; R1JI58032B; AC1MHEP3; DB01496; 2-thioxo-5-[[5-[2-(trifluoromethyl)phenyl]-2-furyl]methyl]hexahydropyrimidine-4,6-dione; 2-sulfanylidene-5-[[5-[2-(trifluoromethyl)phenyl]furan-2-yl]methyl]-1,3-diazinane-4,6-dione; 959343-20-5; 4,6(1H,5H)-Pyrimidinedione, dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-
DM2I19P	DT	Small molecular drug
DM2I19P	PC	3003157
DM2I19P	MW	368.3
DM2I19P	FM	C16H11F3N2O3S
DM2I19P	IC	InChI=1S/C16H11F3N2O3S/c17-16(18,19)11-4-2-1-3-9(11)12-6-5-8(24-12)7-10-13(22)20-15(25)21-14(10)23/h1-6,10H,7H2,(H2,20,21,22,23,25)
DM2I19P	CS	C1=CC=C(C(=C1)C2=CC=C(O2)CC3C(=O)NC(=S)NC3=O)C(F)(F)F
DM2I19P	IK	DNZPLHRZXUJATK-UHFFFAOYSA-N
DM2I19P	IU	2-sulfanylidene-5-[[5-[2-(trifluoromethyl)phenyl]furan-2-yl]methyl]-1,3-diazinane-4,6-dione
DM2I19P	CA	CAS 959343-20-5
DM2I19P	DE	Discovery agent

DMU3D2O	ID	DMU3D2O
DMU3D2O	DN	BARETTIN
DMU3D2O	HS	Investigative
DMU3D2O	SN	(-)-Barettine; GBB 1-Z; 104311-70-8; AC1O5Z3U; 606933-69-1
DMU3D2O	DT	Small molecular drug
DMU3D2O	PC	11177588
DMU3D2O	MW	419.3
DMU3D2O	FM	C17H19BrN6O2
DMU3D2O	IC	InChI=1S/C17H19BrN6O2/c18-10-3-4-11-9(8-22-13(11)7-10)6-14-16(26)23-12(15(25)24-14)2-1-5-21-17(19)20/h3-4,6-8,12,22H,1-2,5H2,(H,23,26)(H,24,25)(H4,19,20,21)/b14-6-/t12-/m0/s1
DMU3D2O	CS	C1=CC2=C(C=C1Br)NC=C2/C=C\\3/C(=O)N[C@H](C(=O)N3)CCCN=C(N)N
DMU3D2O	IK	YYFNNPXWRXQUPR-JVXNRYDGSA-N
DMU3D2O	IU	2-[3-[(2S,5Z)-5-[(6-bromo-1H-indol-3-yl)methylidene]-3,6-dioxopiperazin-2-yl]propyl]guanidine
DMU3D2O	CA	CAS 104311-70-8
DMU3D2O	DE	Discovery agent

DMZPKGS	ID	DMZPKGS
DMZPKGS	DN	BAS-00387275
DMZPKGS	HS	Investigative
DMZPKGS	SN	BAS-00387275; CHEMBL379308; (4Z)-4-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]-1-(4-iodophenyl)pyrazolidine-3,5-dione; AC1M44RA; MolPort-001-928-844; ZINC37858290; STL508972; STL430984; BDBM50187579; AKOS000437993; BAS 00387275; 4-((6-bromobenzo[d][1,3]dioxol-5-yl)methylene)-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMZPKGS	DT	Small molecular drug
DMZPKGS	PC	2250919
DMZPKGS	MW	513.1
DMZPKGS	FM	C17H10BrIN2O4
DMZPKGS	IC	InChI=1S/C17H10BrIN2O4/c18-13-7-15-14(24-8-25-15)6-9(13)5-12-16(22)20-21(17(12)23)11-3-1-10(19)2-4-11/h1-7H,8H2,(H,20,22)/b12-5-
DMZPKGS	CS	C1OC2=C(O1)C=C(C(=C2)/C=C\\3/C(=O)NN(C3=O)C4=CC=C(C=C4)I)Br
DMZPKGS	IK	WMFFHUYJLJSDEU-XGICHPGQSA-N
DMZPKGS	IU	(4Z)-4-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMZPKGS	DE	Discovery agent

DM4OSFD	ID	DM4OSFD
DM4OSFD	DN	BAS-00387328
DM4OSFD	HS	Investigative
DM4OSFD	SN	CHEMBL210766; BAS-00387328; SCHEMBL5737024; BDBM50187569
DM4OSFD	DT	Small molecular drug
DM4OSFD	PC	10301426
DM4OSFD	MW	516.07
DM4OSFD	FM	C16H10I2N2O2
DM4OSFD	IC	InChI=1S/C16H10I2N2O2/c17-11-3-1-10(2-4-11)9-14-15(21)19-20(16(14)22)13-7-5-12(18)6-8-13/h1-9H,(H,19,21)/b14-9-
DM4OSFD	CS	C1=CC(=CC=C1/C=C\\2/C(=O)NN(C2=O)C3=CC=C(C=C3)I)I
DM4OSFD	IK	HOZMXIPMJIGFMB-ZROIWOOFSA-N
DM4OSFD	IU	(4Z)-1-(4-iodophenyl)-4-[(4-iodophenyl)methylidene]pyrazolidine-3,5-dione
DM4OSFD	DE	Discovery agent

DMUF28Q	ID	DMUF28Q
DMUF28Q	DN	BAS-00387347
DMUF28Q	HS	Investigative
DMUF28Q	SN	BAS-00387347; CHEMBL209617; AC1LKSRL; 4-benzylidene-1-(4-iodophenyl)pyrazolidine-3,5-dione; SCHEMBL5735322; ZINC726017; BDBM50187575; AKOS000438122; AG-690/10031054; 4-benzylidene-1-(4-iodophenyl)-3,5-pyrazolidinedione
DMUF28Q	DT	Small molecular drug
DMUF28Q	PC	1049055
DMUF28Q	MW	390.17
DMUF28Q	FM	C16H11IN2O2
DMUF28Q	IC	InChI=1S/C16H11IN2O2/c17-12-6-8-13(9-7-12)19-16(21)14(15(20)18-19)10-11-4-2-1-3-5-11/h1-10H,(H,18,20)/b14-10-
DMUF28Q	CS	C1=CC=C(C=C1)/C=C\\2/C(=O)NN(C2=O)C3=CC=C(C=C3)I
DMUF28Q	IK	KAGAMCCGZCDKMX-UVTDQMKNSA-N
DMUF28Q	IU	(4Z)-4-benzylidene-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMUF28Q	DE	Discovery agent

DM6R4X8	ID	DM6R4X8
DM6R4X8	DN	BAS-00672722
DM6R4X8	HS	Investigative
DM6R4X8	SN	BAS-00672722; CHEMBL207360; AC1LKX7K; BDBM50187572; 4-(3-(benzyloxy)benzylidene)-1-(3,4-dichlorophenyl)pyrazolidine-3,5-dione
DM6R4X8	DT	Small molecular drug
DM6R4X8	PC	1075248
DM6R4X8	MW	439.3
DM6R4X8	FM	C23H16Cl2N2O3
DM6R4X8	IC	InChI=1S/C23H16Cl2N2O3/c24-20-10-9-17(13-21(20)25)27-23(29)19(22(28)26-27)12-16-7-4-8-18(11-16)30-14-15-5-2-1-3-6-15/h1-13H,14H2,(H,26,28)/b19-12-
DM6R4X8	CS	C1=CC=C(C=C1)COC2=CC=CC(=C2)/C=C\\3/C(=O)NN(C3=O)C4=CC(=C(C=C4)Cl)Cl
DM6R4X8	IK	OSJPWEILZQFNPI-UNOMPAQXSA-N
DM6R4X8	IU	(4Z)-1-(3,4-dichlorophenyl)-4-[(3-phenylmethoxyphenyl)methylidene]pyrazolidine-3,5-dione
DM6R4X8	DE	Discovery agent

DMNB7CW	ID	DMNB7CW
DMNB7CW	DN	BAS-01047341
DMNB7CW	HS	Investigative
DMNB7CW	SN	BAS-01047341; CHEMBL208828; AC1LLNNX; MolPort-001-953-454; BDBM50187577; CCG-12153; ZINC13633981; AKOS000446912; BAS 01047341; BIM-0025124.P001; 4-(4-(diethylamino)-2-hydroxybenzylidene)-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMNB7CW	DT	Small molecular drug
DMNB7CW	PC	1113004
DMNB7CW	MW	477.3
DMNB7CW	FM	C20H20IN3O3
DMNB7CW	IC	InChI=1S/C20H20IN3O3/c1-3-23(4-2)16-8-5-13(18(25)12-16)11-17-19(26)22-24(20(17)27)15-9-6-14(21)7-10-15/h5-12,25H,3-4H2,1-2H3,(H,22,26)/b17-11-
DMNB7CW	CS	CCN(CC)C1=CC(=C(C=C1)/C=C\\2/C(=O)NN(C2=O)C3=CC=C(C=C3)I)O
DMNB7CW	IK	QOVNZWROVBIKQY-BOPFTXTBSA-N
DMNB7CW	IU	(4Z)-4-[[4-(diethylamino)-2-hydroxyphenyl]methylidene]-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMNB7CW	DE	Discovery agent

DMC0FLB	ID	DMC0FLB
DMC0FLB	DN	BAS-01047655
DMC0FLB	HS	Investigative
DMC0FLB	SN	BAS-01047655; CHEMBL380706; AC1LKNKS; MolPort-001-663-455; MolPort-019-782-693; ZINC12376560; STK392633; BDBM50187570; AKOS000548089; MCULE-2522435117; ST033733; BAS 01047655; AK-968/37005047; A2180/0091610; 4-[2-(benzyloxy)benzylidene]-1-phenyl-3,5-pyrazolidinedione; 4-(2-Benzyloxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione; 4-(2-(benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione; (4Z)-4-[2-(benzyloxy)benzylidene]-1-phenylpyrazolidine-3,5-dione
DMC0FLB	DT	Small molecular drug
DMC0FLB	PC	1021453
DMC0FLB	MW	370.4
DMC0FLB	FM	C23H18N2O3
DMC0FLB	IC	InChI=1S/C23H18N2O3/c26-22-20(23(27)25(24-22)19-12-5-2-6-13-19)15-18-11-7-8-14-21(18)28-16-17-9-3-1-4-10-17/h1-15H,16H2,(H,24,26)/b20-15-
DMC0FLB	CS	C1=CC=C(C=C1)COC2=CC=CC=C2/C=C\\3/C(=O)NN(C3=O)C4=CC=CC=C4
DMC0FLB	IK	NDWMSBYUWXNXGT-HKWRFOASSA-N
DMC0FLB	IU	(4Z)-1-phenyl-4-[(2-phenylmethoxyphenyl)methylidene]pyrazolidine-3,5-dione
DMC0FLB	DE	Discovery agent

DMZBIC3	ID	DMZBIC3
DMZBIC3	DN	BAS-01373578
DMZBIC3	HS	Investigative
DMZBIC3	SN	BAS-01373578; CHEMBL206575; (4Z)-4-[[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene]-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione; (4Z)-4-{[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene}-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione; AC1LWF8S; MolPort-030-043-249; MolPort-001-963-180; ZINC4471294; STL387426; STL383260; BDBM50187574; AKOS025249675; AKOS000447221; BAS 01373578; 4-((5-(3-chloro-4-methylphenyl)furan-2-yl)methylene)-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione
DMZBIC3	DT	Small molecular drug
DMZBIC3	PC	1728080
DMZBIC3	MW	406.9
DMZBIC3	FM	C23H19ClN2O3
DMZBIC3	IC	InChI=1S/C23H19ClN2O3/c1-13-5-7-17(10-15(13)3)26-23(28)19(22(27)25-26)12-18-8-9-21(29-18)16-6-4-14(2)20(24)11-16/h4-12H,1-3H3,(H,25,27)/b19-12-
DMZBIC3	CS	CC1=C(C=C(C=C1)N2C(=O)/C(=C\\C3=CC=C(O3)C4=CC(=C(C=C4)C)Cl)/C(=O)N2)C
DMZBIC3	IK	GCEFTTIUEIKKPW-UNOMPAQXSA-N
DMZBIC3	IU	(4Z)-4-[[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene]-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione
DMZBIC3	DE	Discovery agent

DMZGLHJ	ID	DMZGLHJ
DMZGLHJ	DN	BAS-0338868
DMZGLHJ	HS	Investigative
DMZGLHJ	SN	BAS-0338868; CHEMBL378903; N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; N-(5-Phenethyl-[1,3,4]thiadiazol-2-yl)-benzamide; AC1LGHJD; BAS 00338868; Oprea1_674367; Oprea1_387539; MLS001208166; cid_821478; MolPort-001-925-654; ZINC338374; HMS2838C05; BDBM50187578; AKOS000542350; MCULE-7705926672; SMR000513539
DMZGLHJ	DT	Small molecular drug
DMZGLHJ	PC	821478
DMZGLHJ	MW	309.4
DMZGLHJ	FM	C17H15N3OS
DMZGLHJ	IC	InChI=1S/C17H15N3OS/c21-16(14-9-5-2-6-10-14)18-17-20-19-15(22-17)12-11-13-7-3-1-4-8-13/h1-10H,11-12H2,(H,18,20,21)
DMZGLHJ	CS	C1=CC=C(C=C1)CCC2=NN=C(S2)NC(=O)C3=CC=CC=C3
DMZGLHJ	IK	LZMYTXMTFJGQJA-UHFFFAOYSA-N
DMZGLHJ	IU	N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMZGLHJ	DE	Discovery agent

DMZK0SC	ID	DMZK0SC
DMZK0SC	DN	BAS-0338872
DMZK0SC	HS	Investigative
DMZK0SC	SN	BAS-0338872; CHEMBL207986; 2-iodo-N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; BAS 00338872; AC1LM5IX; Oprea1_394225; Oprea1_118842; ZINC820816; BDBM50187565; AKOS000542403; MCULE-8600906341; ST50224059; 2-Iodo-N-(5-phenethyl-[1,3,4]thiadiazol-2-yl)-benzamide
DMZK0SC	DT	Small molecular drug
DMZK0SC	PC	1097674
DMZK0SC	MW	435.3
DMZK0SC	FM	C17H14IN3OS
DMZK0SC	IC	InChI=1S/C17H14IN3OS/c18-14-9-5-4-8-13(14)16(22)19-17-21-20-15(23-17)11-10-12-6-2-1-3-7-12/h1-9H,10-11H2,(H,19,21,22)
DMZK0SC	CS	C1=CC=C(C=C1)CCC2=NN=C(S2)NC(=O)C3=CC=CC=C3I
DMZK0SC	IK	SLBMNZPBYUAWPO-UHFFFAOYSA-N
DMZK0SC	IU	2-iodo-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMZK0SC	DE	Discovery agent

DMBS8N9	ID	DMBS8N9
DMBS8N9	DN	BAS-0338876
DMBS8N9	HS	Investigative
DMBS8N9	SN	BAS-0338876; CHEMBL206046; BDBM50187566
DMBS8N9	DT	Small molecular drug
DMBS8N9	PC	44412060
DMBS8N9	MW	435.3
DMBS8N9	FM	C17H14IN3OS
DMBS8N9	IC	InChI=1S/C17H14IN3OS/c18-14-9-7-13(8-10-14)16(22)19-17-21-20-15(23-17)11-6-12-4-2-1-3-5-12/h1-5,7-10H,6,11H2,(H,19,21,22)
DMBS8N9	CS	C1=CC=C(C=C1)CCC2=NN=C(S2)NC(=O)C3=CC=C(C=C3)I
DMBS8N9	IK	ISVOIGTWCBLSQY-UHFFFAOYSA-N
DMBS8N9	IU	4-iodo-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMBS8N9	DE	Discovery agent

DMFMBZ9	ID	DMFMBZ9
DMFMBZ9	DN	BAS-09534324
DMFMBZ9	HS	Investigative
DMFMBZ9	SN	BAS 09534324; BAS-09534324; CHEMBL376993; AC1LM0SZ; MolPort-002-015-109; ZINC815475; BDBM50187571; STK175770; AKOS000654857; MCULE-5021008908; 2-methoxy-4-methylsulfanyl-N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; 2-methoxy-4-(methylthio)-N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; 2-methoxy-4-(methylsulfanyl)-N~1~-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; 2-Methoxy-4-methylsulfanyl-N-(5-phenethyl-[1,3,4]thiadiazol-2-yl)-benzamide; 2-methoxy-4-(methylthio)-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMFMBZ9	DT	Small molecular drug
DMFMBZ9	PC	1094114
DMFMBZ9	MW	385.5
DMFMBZ9	FM	C19H19N3O2S2
DMFMBZ9	IC	InChI=1S/C19H19N3O2S2/c1-24-16-12-14(25-2)9-10-15(16)18(23)20-19-22-21-17(26-19)11-8-13-6-4-3-5-7-13/h3-7,9-10,12H,8,11H2,1-2H3,(H,20,22,23)
DMFMBZ9	CS	COC1=C(C=CC(=C1)SC)C(=O)NC2=NN=C(S2)CCC3=CC=CC=C3
DMFMBZ9	IK	JYHRBJVBNRDAJX-UHFFFAOYSA-N
DMFMBZ9	IU	2-methoxy-4-methylsulfanyl-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMFMBZ9	DE	Discovery agent

DMTH1JQ	ID	DMTH1JQ
DMTH1JQ	DN	BAS-450225
DMTH1JQ	HS	Investigative
DMTH1JQ	SN	BAS-450225; CHEMBL210036; 2,4-dichloro-N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; AC1LL38T; Oprea1_759762; Oprea1_195875
DMTH1JQ	DT	Small molecular drug
DMTH1JQ	PC	1103113
DMTH1JQ	MW	378.3
DMTH1JQ	FM	C17H13Cl2N3OS
DMTH1JQ	IC	InChI=1S/C17H13Cl2N3OS/c18-12-7-8-13(14(19)10-12)16(23)20-17-22-21-15(24-17)9-6-11-4-2-1-3-5-11/h1-5,7-8,10H,6,9H2,(H,20,22,23)
DMTH1JQ	CS	C1=CC=C(C=C1)CCC2=NN=C(S2)NC(=O)C3=C(C=C(C=C3)Cl)Cl
DMTH1JQ	IK	BVZCHEPRCHHCRQ-UHFFFAOYSA-N
DMTH1JQ	IU	2,4-dichloro-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMTH1JQ	DE	Discovery agent

DMFNAKU	ID	DMFNAKU
DMFNAKU	DN	BAS-4844343
DMFNAKU	HS	Investigative
DMFNAKU	SN	BAS-4844343; CHEMBL207672; N-[5-(1H-indol-3-ylmethyl)-1,3,4-thiadiazol-2-yl]-4-methoxybenzamide; AC1LK4AS; Oprea1_740559; MolPort-000-746-934; MolPort-001-911-292; ZINC17747698; STK758751; STK846597; BDBM50187576; AKOS005626974; AKOS000597970; MCULE-8653633709; BAS 04844343; SR-01000521375; SR-01000521375-1; A1870/0078659; N-[5-(1H-Indol-3-ylmethyl)-[1,3,4]thiadiazol-2-yl]-4-methoxy-benzamide; N~1~-[5-(1H-indol-3-ylmethyl)-1,3,4-thiadiazol-2-yl]-4-methoxybenzamide
DMFNAKU	DT	Small molecular drug
DMFNAKU	PC	1036901
DMFNAKU	MW	364.4
DMFNAKU	FM	C19H16N4O2S
DMFNAKU	IC	InChI=1S/C19H16N4O2S/c1-25-14-8-6-12(7-9-14)18(24)21-19-23-22-17(26-19)10-13-11-20-16-5-3-2-4-15(13)16/h2-9,11,20H,10H2,1H3,(H,21,23,24)
DMFNAKU	CS	COC1=CC=C(C=C1)C(=O)NC2=NN=C(S2)CC3=CNC4=CC=CC=C43
DMFNAKU	IK	AXHAJBIEOINPDH-UHFFFAOYSA-N
DMFNAKU	IU	N-[5-(1H-indol-3-ylmethyl)-1,3,4-thiadiazol-2-yl]-4-methoxybenzamide
DMFNAKU	DE	Discovery agent

DMTQX1G	ID	DMTQX1G
DMTQX1G	DN	Batimistat
DMTQX1G	HS	Investigative
DMTQX1G	DE	Discovery agent

DMYH9SU	ID	DMYH9SU
DMYH9SU	DN	Batrachotoxin
DMYH9SU	HS	Investigative
DMYH9SU	SN	BATRACHOTOXIN; UNII-TSG6XHX09R; TSG6XHX09R; Batrachotoxinin A, 20-(2,4-dimethyl-1H-pyrrole-3-carboxylate); Betrachotoxinin A, 20-alpha-(2,4-dimethyl-1H-pyrrole-3-carboxylate); 23509-16-2; GTPL2619; LS-24727; Betrachotoxinin A, 20-alpha-(2,4-dimethyl-1H-pyrrole-3-carboxylate) (9CI)
DMYH9SU	DT	Small molecular drug
DMYH9SU	PC	6324647
DMYH9SU	MW	538.7
DMYH9SU	FM	C31H42N2O6
DMYH9SU	IC	InChI=1S/C31H42N2O6/c1-18-16-32-19(2)25(18)26(35)38-20(3)22-8-9-30-23-7-6-21-14-29(36)11-10-27(21,4)31(23,39-29)24(34)15-28(22,30)17-33(5)12-13-37-30/h7-8,16,20-21,24,32,34,36H,6,9-15,17H2,1-5H3/t20-,21+,24+,27-,28-,29+,30-,31-/m0/s1
DMYH9SU	CS	CC1=CNC(=C1C(=O)O[C@@H](C)C2=CC[C@@]34[C@@]2(C[C@H]([C@@]56C3=CC[C@H]7[C@@]5(CC[C@](C7)(O6)O)C)O)CN(CCO4)C)C
DMYH9SU	IK	ISNYUQWBWALXEY-OMIQOYQYSA-N
DMYH9SU	IU	[(1S)-1-[(1R,5R,6S,9R,11S,12R,14R)-9,12-dihydroxy-6,16-dimethyl-10,19-dioxa-16-azahexacyclo[12.5.3.15,9.01,14.02,11.06,11]tricosa-2,21-dien-22-yl]ethyl] 2,4-dimethyl-1H-pyrrole-3-carboxylate
DMYH9SU	CA	CAS 23509-16-2
DMYH9SU	DE	Discovery agent

DMVP74I	ID	DMVP74I
DMVP74I	DN	BAY 367620
DMVP74I	HS	Investigative
DMVP74I	SN	BAY 36-7620; BAY36-7620; BAY-367620
DMVP74I	DT	Small molecular drug
DMVP74I	PC	9903757
DMVP74I	MW	278.3
DMVP74I	FM	C19H18O2
DMVP74I	IC	InChI=1S/C19H18O2/c1-13-8-17-12-21-18(20)19(17,10-13)11-14-6-7-15-4-2-3-5-16(15)9-14/h2-7,9,17H,1,8,10-12H2/t17-,19+/m1/s1
DMVP74I	CS	C=C1C[C@@H]2COC(=O)[C@@]2(C1)CC3=CC4=CC=CC=C4C=C3
DMVP74I	IK	CVIRWLJKDBYYOG-MJGOQNOKSA-N
DMVP74I	IU	(3aS,6aS)-5-methylidene-3a-(naphthalen-2-ylmethyl)-1,4,6,6a-tetrahydrocyclopenta[c]furan-3-one
DMVP74I	CA	CAS 232605-26-4
DMVP74I	DE	Discovery agent

DM743XB	ID	DM743XB
DM743XB	DN	BAY 50-7952
DM743XB	HS	Investigative
DM743XB	SN	CHEMBL157769; BAY-507952
DM743XB	DT	Small molecular drug
DM743XB	PC	9895647
DM743XB	MW	639.5
DM743XB	FM	C24H23BrN4O8S2
DM743XB	IC	InChI=1S/C24H23BrN4O8S2/c1-34-19-9-18(30)15(20(21(19)25)23(31)35-2)10-38-11-17(22-28-37-8-7-36-22)27-24-26-16(12-39-24)13-3-5-14(6-4-13)29(32)33/h3-6,9,12,17,30H,7-8,10-11H2,1-2H3,(H,26,27)/t17-/m0/s1
DM743XB	CS	COC1=C(C(=C(C(=C1)O)CSC[C@@H](C2=NOCCO2)NC3=NC(=CS3)C4=CC=C(C=C4)[N+](=O)[O-])C(=O)OC)Br
DM743XB	IK	MRGBDARDZKENAD-KRWDZBQOSA-N
DM743XB	IU	methyl 2-bromo-6-[[(2R)-2-(5,6-dihydro-1,4,2-dioxazin-3-yl)-2-[[4-(4-nitrophenyl)-1,3-thiazol-2-yl]amino]ethyl]sulfanylmethyl]-5-hydroxy-3-methoxybenzoate
DM743XB	DE	Discovery agent

DMRWSGO	ID	DMRWSGO
DMRWSGO	DN	Bay K 8644
DMRWSGO	HS	Investigative
DMRWSGO	SN	71145-03-4; methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate; MLS000028858; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, methyl ester; C16H15F3N2O4; R(+)-BAY K 8644; SMR000058424; Methyl 2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3-carboxylate
DMRWSGO	DT	Small molecular drug
DMRWSGO	PC	2303
DMRWSGO	MW	356.3
DMRWSGO	FM	C16H15F3N2O4
DMRWSGO	IC	InChI=1S/C16H15F3N2O4/c1-8-12(15(22)25-3)13(14(21(23)24)9(2)20-8)10-6-4-5-7-11(10)16(17,18)19/h4-7,13,20H,1-3H3
DMRWSGO	CS	CC1=C(C(C(=C(N1)C)[N+](=O)[O-])C2=CC=CC=C2C(F)(F)F)C(=O)OC
DMRWSGO	IK	ZFLWDHHVRRZMEI-UHFFFAOYSA-N
DMRWSGO	IU	methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate
DMRWSGO	CA	CAS 71145-03-4
DMRWSGO	CB	CHEBI:34555
DMRWSGO	DE	Discovery agent

DMQNOFA	ID	DMQNOFA
DMQNOFA	DN	BAY11-7082
DMQNOFA	HS	Investigative
DMQNOFA	SN	bay 11-7082; 19542-67-7; (E)-3-Tosylacrylonitrile; Bay 11-7821; (E)-3-(p-Toluenesulfonyl)acrylonitrile; BAY-11-7082; BAY11-7082; UNII-4Y5G2A4F6O; BAY-11-7821; (E)-3-(4-Methylphenyl)sulfonylprop-2-enenitrile; BAY-117082; BAY-117821; CHEMBL403183; 4Y5G2A4F6O; 3-(4-methylphenylsulfonyl)-2-propenenitrile; CHEBI:85928; 3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile; AK129348; (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile; (E)3-[(4-Methylphenyl)sulfonyl]-2-propenenitrile; J-501956; (2E)-3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile
DMQNOFA	CP	Biomol
DMQNOFA	DT	Small molecular drug
DMQNOFA	PC	5353431
DMQNOFA	MW	207.25
DMQNOFA	FM	C10H9NO2S
DMQNOFA	IC	InChI=1S/C10H9NO2S/c1-9-3-5-10(6-4-9)14(12,13)8-2-7-11/h2-6,8H,1H3/b8-2+
DMQNOFA	CS	CC1=CC=C(C=C1)S(=O)(=O)/C=C/C#N
DMQNOFA	IK	DOEWDSDBFRHVAP-KRXBUXKQSA-N
DMQNOFA	IU	(E)-3-(4-methylphenyl)sulfonylprop-2-enenitrile
DMQNOFA	CA	CAS 19542-67-7
DMQNOFA	CB	CHEBI:85928
DMQNOFA	DE	Multiple myeloma

DM0M59T	ID	DM0M59T
DM0M59T	DN	BAY412272
DM0M59T	HS	Investigative
DM0M59T	SN	BAY 41-2272; BAY-412272
DM0M59T	DT	Small molecular drug
DM0M59T	PC	9798973
DM0M59T	MW	360.4
DM0M59T	FM	C20H17FN6
DM0M59T	IC	InChI=1S/C20H17FN6/c21-16-6-2-1-4-13(16)11-27-20-14(5-3-9-23-20)17(26-27)19-24-10-15(12-7-8-12)18(22)25-19/h1-6,9-10,12H,7-8,11H2,(H2,22,24,25)
DM0M59T	CS	C1CC1C2=CN=C(N=C2N)C3=NN(C4=C3C=CC=N4)CC5=CC=CC=C5F
DM0M59T	IK	ATOAHNRJAXSBOR-UHFFFAOYSA-N
DM0M59T	IU	5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine
DM0M59T	CA	CAS 256376-24-6
DM0M59T	CB	CHEBI:142435
DM0M59T	DE	Discovery agent

DMQZ7JD	ID	DMQZ7JD
DMQZ7JD	DN	BAY-60-7550
DMQZ7JD	HS	Investigative
DMQZ7JD	DT	Small molecular drug
DMQZ7JD	PC	135564787
DMQZ7JD	MW	476.6
DMQZ7JD	FM	C27H32N4O4
DMQZ7JD	IC	InChI=1S/C27H32N4O4/c1-17-25-27(33)29-24(16-20-13-14-22(34-3)23(15-20)35-4)30-31(25)26(28-17)21(18(2)32)12-8-11-19-9-6-5-7-10-19/h5-7,9-10,13-15,18,21,32H,8,11-12,16H2,1-4H3,(H,29,30,33)/t18-,21+/m1/s1
DMQZ7JD	CS	CC1=C2C(=O)NC(=NN2C(=N1)[C@@H](CCCC3=CC=CC=C3)[C@@H](C)O)CC4=CC(=C(C=C4)OC)OC
DMQZ7JD	IK	MYTWFJKBZGMYCS-NQIIRXRSSA-N
DMQZ7JD	IU	2-[(3,4-dimethoxyphenyl)methyl]-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
DMQZ7JD	CA	CAS 439083-90-6
DMQZ7JD	DE	Discovery agent

DM5CPJ2	ID	DM5CPJ2
DM5CPJ2	DN	BAY-73-1449
DM5CPJ2	HS	Investigative
DM5CPJ2	SN	BAY-73-1449; SCHEMBL5906729; GTPL5851; (2S)-3-phenyl-2-[[6-[4-(phenylmethoxy)phenyl]pyrimidin-4-yl]amino]propanoic acid
DM5CPJ2	DT	Small molecular drug
DM5CPJ2	PC	11743147
DM5CPJ2	MW	425.5
DM5CPJ2	FM	C26H23N3O3
DM5CPJ2	IC	InChI=1S/C26H23N3O3/c30-26(31)24(15-19-7-3-1-4-8-19)29-25-16-23(27-18-28-25)21-11-13-22(14-12-21)32-17-20-9-5-2-6-10-20/h1-14,16,18,24H,15,17H2,(H,30,31)(H,27,28,29)/t24-/m0/s1
DM5CPJ2	CS	C1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=NC=NC(=C2)C3=CC=C(C=C3)OCC4=CC=CC=C4
DM5CPJ2	IK	RRYFPNITZGCUPZ-DEOSSOPVSA-N
DM5CPJ2	IU	(2S)-3-phenyl-2-[[6-(4-phenylmethoxyphenyl)pyrimidin-4-yl]amino]propanoic acid
DM5CPJ2	DE	Discovery agent

DMW625B	ID	DMW625B
DMW625B	DN	BAY-85-3474
DMW625B	HS	Investigative
DMW625B	SN	Met inhibitor (cancer), Bayer Schering
DMW625B	CP	Bayer Schering Pharma AG
DMW625B	DE	Solid tumour/cancer

DMKFTZA	ID	DMKFTZA
DMKFTZA	DN	BayCysLT2
DMKFTZA	HS	Investigative
DMKFTZA	SN	CysLT2cpd
DMKFTZA	DT	Small molecular drug
DMKFTZA	PC	53394034
DMKFTZA	MW	589.7
DMKFTZA	FM	C34H39NO8
DMKFTZA	IC	InChI=1S/C34H39NO8/c36-32(35-27-10-6-9-25(22-27)33(37)38)30-23-26(34(39)40)15-18-31(30)43-21-7-8-24-13-16-29(17-14-24)42-20-5-4-19-41-28-11-2-1-3-12-28/h1-3,11-18,23,25,27H,4-10,19-22H2,(H,35,36)(H,37,38)(H,39,40)
DMKFTZA	CS	C1CC(CC(C1)NC(=O)C2=C(C=CC(=C2)C(=O)O)OCCCC3=CC=C(C=C3)OCCCCOC4=CC=CC=C4)C(=O)O
DMKFTZA	IK	GKPAULTWHHPIHX-UHFFFAOYSA-N
DMKFTZA	IU	3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-phenoxybutoxy)phenyl]propoxy]benzoic acid
DMKFTZA	CA	CAS 712313-33-2
DMKFTZA	DE	Discovery agent

DMXQ14V	ID	DMXQ14V
DMXQ14V	DN	BAYu9773
DMXQ14V	HS	Investigative
DMXQ14V	SN	BAY u9773
DMXQ14V	DT	Small molecular drug
DMXQ14V	PC	5311015
DMXQ14V	MW	472.6
DMXQ14V	FM	C27H36O5S
DMXQ14V	IC	InChI=1S/C27H36O5S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-25(24(28)15-14-17-26(29)30)33-23-20-18-22(19-21-23)27(31)32/h6-7,9-13,16,18-21,24-25,28H,2-5,8,14-15,17H2,1H3,(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t24-,25+/m0/s1
DMXQ14V	CS	CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SC1=CC=C(C=C1)C(=O)O
DMXQ14V	IK	PKJINWOACFYDQN-RBVMPENBSA-N
DMXQ14V	IU	4-[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]sulfanylbenzoic acid
DMXQ14V	DE	Discovery agent

DMKDZLG	ID	DMKDZLG
DMKDZLG	DN	BAZ2-ICR
DMKDZLG	HS	Investigative
DMKDZLG	SN	inhibitor 13 [PMID: 25719566]
DMKDZLG	DT	Small molecular drug
DMKDZLG	PC	91654625
DMKDZLG	MW	357.4
DMKDZLG	FM	C20H19N7
DMKDZLG	IC	InChI=1S/C20H19N7/c1-25-12-16(10-23-25)7-8-27-14-22-19(18-11-24-26(2)13-18)20(27)17-5-3-15(9-21)4-6-17/h3-6,10-14H,7-8H2,1-2H3
DMKDZLG	CS	CN1C=C(C=N1)CCN2C=NC(=C2C3=CC=C(C=C3)C#N)C4=CN(N=C4)C
DMKDZLG	IK	RRZVGDGTWNQAPW-UHFFFAOYSA-N
DMKDZLG	IU	4-[5-(1-methylpyrazol-4-yl)-3-[2-(1-methylpyrazol-4-yl)ethyl]imidazol-4-yl]benzonitrile
DMKDZLG	DE	Discovery agent

DM5SDV9	ID	DM5SDV9
DM5SDV9	DN	Bb-3497
DM5SDV9	HS	Investigative
DM5SDV9	SN	BB-3497; CHEMBL431210; BB 3497; 235784-88-0; 2-[(FORMYL-HYDROXY-AMINO)-METHYL]-HEXANOIC ACID (1-DIMETHYLCARBAMOYL-2,2-DIMETHYL-PROPYL)-AMIDE; (2r)-n-[(2s)-1-(dimethylamino)-3,3-dimethyl-1-oxobutan-2-yl]-2-{[formyl(hydroxy)amino]methyl}hexanamide; BB1; 1g27; (2R)-N-[(2S)-1-(dimethylamino)-3,3-dimethyl-1-oxobutan-2-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide; AC1L4M3L; AC1Q5HZ8; SCHEMBL13754309; DTXSID80178216; BDBM50104501; BB3497; DB04368; (R)-2-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid ((S)-1-dimethylcarbamoyl-2,2-
DM5SDV9	DT	Small molecular drug
DM5SDV9	PC	159596
DM5SDV9	MW	329.43
DM5SDV9	FM	C16H31N3O4
DM5SDV9	IC	InChI=1S/C16H31N3O4/c1-7-8-9-12(10-19(23)11-20)14(21)17-13(16(2,3)4)15(22)18(5)6/h11-13,23H,7-10H2,1-6H3,(H,17,21)/t12-,13-/m1/s1
DM5SDV9	CS	CCCC[C@H](CN(C=O)O)C(=O)N[C@H](C(=O)N(C)C)C(C)(C)C
DM5SDV9	IK	AVDLWYHBABSSHC-CHWSQXEVSA-N
DM5SDV9	IU	(2R)-N-[(2S)-1-(dimethylamino)-3,3-dimethyl-1-oxobutan-2-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
DM5SDV9	CA	CAS 235784-88-0
DM5SDV9	DE	Discovery agent

DMFBN9O	ID	DMFBN9O
DMFBN9O	DN	BB-78484
DMFBN9O	HS	Investigative
DMFBN9O	SN	SCHEMBL5482389
DMFBN9O	DT	Small molecular drug
DMFBN9O	PC	9846531
DMFBN9O	MW	449.3
DMFBN9O	FM	C19H17BrN2O4S
DMFBN9O	IC	InChI=1S/C19H17BrN2O4S/c20-16-7-9-17(10-8-16)27(25,26)22-18(19(23)21-24)12-13-5-6-14-3-1-2-4-15(14)11-13/h1-11,18,22,24H,12H2,(H,21,23)/t18-/m1/s1
DMFBN9O	CS	C1=CC=C2C=C(C=CC2=C1)C[C@H](C(=O)NO)NS(=O)(=O)C3=CC=C(C=C3)Br
DMFBN9O	IK	WJFADFOFCRGJHM-GOSISDBHSA-N
DMFBN9O	IU	(2R)-2-[(4-bromophenyl)sulfonylamino]-N-hydroxy-3-naphthalen-2-ylpropanamide
DMFBN9O	DE	Discovery agent

DMJKA3F	ID	DMJKA3F
DMJKA3F	DN	BB-78485
DMJKA3F	HS	Investigative
DMJKA3F	SN	(2r)-N-Hydroxy-3-Naphthalen-2-Yl-2-[(Naphthalen-2-Ylsulfonyl)amino]propanamide; 2ves; BB-78485; SCHEMBL5485583; CHEMBL261713; DB07861; (2R)-N-hydroxy-3-(naphthalen-2-yl)-2-(naphthalene-2-sulfonamido)propanamide; (2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide (non-preferred name)
DMJKA3F	DT	Small molecular drug
DMJKA3F	PC	9823454
DMJKA3F	MW	420.5
DMJKA3F	FM	C23H20N2O4S
DMJKA3F	IC	InChI=1S/C23H20N2O4S/c26-23(24-27)22(14-16-9-10-17-5-1-3-7-19(17)13-16)25-30(28,29)21-12-11-18-6-2-4-8-20(18)15-21/h1-13,15,22,25,27H,14H2,(H,24,26)/t22-/m1/s1
DMJKA3F	CS	C1=CC=C2C=C(C=CC2=C1)C[C@H](C(=O)NO)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3
DMJKA3F	IK	MMOUXLMPQFMDRD-JOCHJYFZSA-N
DMJKA3F	IU	(2R)-N-hydroxy-3-naphthalen-2-yl-2-(naphthalen-2-ylsulfonylamino)propanamide
DMJKA3F	DE	Discovery agent

DMZPL63	ID	DMZPL63
DMZPL63	DN	BB-823
DMZPL63	HS	Investigative
DMZPL63	SN	139133-28-1
DMZPL63	DT	Small molecular drug
DMZPL63	PC	9954410
DMZPL63	MW	430.6
DMZPL63	FM	C22H30N4O3S
DMZPL63	IC	InChI=1S/C22H30N4O3S/c1-5-29-15-19(12-16(2)3)25-30(27,28)20-8-6-18(7-9-20)14-26-17(4)24-21-13-23-11-10-22(21)26/h6-11,13,16,19,25H,5,12,14-15H2,1-4H3/t19-/m0/s1
DMZPL63	CS	CCOC[C@H](CC(C)C)NS(=O)(=O)C1=CC=C(C=C1)CN2C(=NC3=C2C=CN=C3)C
DMZPL63	IK	BCRDOIMCNBBVGM-IBGZPJMESA-N
DMZPL63	IU	N-[(2S)-1-ethoxy-4-methylpentan-2-yl]-4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]benzenesulfonamide
DMZPL63	DE	Discovery agent

DMMUIQ6	ID	DMMUIQ6
DMMUIQ6	DN	BBI-11008
DMMUIQ6	HS	Investigative
DMMUIQ6	SN	DOR agonists (oral, chronic inflammatory pain), Biousian Biosystems; Delta opioid receptor agonists (oral, chronic inflammatory pain), Biousian Biosystems
DMMUIQ6	CP	Biousian Biosystems Inc
DMMUIQ6	DE	Pain

DM85AJ4	ID	DM85AJ4
DM85AJ4	DN	BB-PTH 1-84
DM85AJ4	HS	Investigative
DM85AJ4	SN	Aursos BB; BB-PTH 1-34; Black bear parathyroid hormone (osteoporosis), Aursos
DM85AJ4	CP	Michigan Technological University
DM85AJ4	DE	Osteoporosis

DMMJ4I5	ID	DMMJ4I5
DMMJ4I5	DN	Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir
DMMJ4I5	HS	Investigative
DMMJ4I5	SN	CHEMBL414125; Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir
DMMJ4I5	PC	44405684
DMMJ4I5	MW	3188.5
DMMJ4I5	FM	C142H215N31O50S
DMMJ4I5	IC	InChI=1S/C142H215N31O50S/c1-14-75(9)64-96(165-129(209)95(63-74(7)8)163-119(199)82(27-19-21-57-143)153-121(201)84(39-48-104(144)176)154-120(200)83(41-50-108(180)181)151-106(178)70-150-136(216)102-29-20-22-59-172(102)138(218)91(28-23-58-148-141(146)147)171-224(222,223)81-37-33-79(34-38-81)142(11,12)13)130(210)169-101(71-174)135(215)159-86(43-52-110(184)185)123(203)155-88(45-54-112(188)189)126(206)168-100(68-116(196)197)134(214)162-93(61-72(3)4)118(198)149-69-107(179)152-99(67-115(194)195)133(213)167-97(65-77-25-17-16-18-26-77)131(211)158-85(42-51-109(182)183)122(202)157-90(47-56-114(192)193)127(207)170-117(76(10)15-2)139(219)173-60-24-30-103(173)137(217)160-89(46-55-113(190)191)124(204)156-87(44-53-111(186)187)125(205)166-98(66-78-31-35-80(175)36-32-78)132(212)164-94(62-73(5)6)128(208)161-92(140(220)221)40-49-105(145)177/h16-18,25-26,31-38,72-76,82-103,117,171,174-175H,14-15,19-24,27-30,39-71,143H2,1-13H3,(H2,144,176)(H2,145,177)(H,149,198)(H,150,216)(H,151,178)(H,152,179)(H,153,201)(H,154,200)(H,155,203)(H,156,204)(H,157,202)(H,158,211)(H,159,215)(H,160,217)(H,161,208)(H,162,214)(H,163,199)(H,164,212)(H,165,209)(H,166,205)(H,167,213)(H,168,206)(H,169,210)(H,170,207)(H,180,181)(H,182,183)(H,184,185)(H,186,187)(H,188,189)(H,190,191)(H,192,193)(H,194,195)(H,196,197)(H,220,221)(H4,146,147,148)/t75-,76-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102+,103-,117-/m0/s1
DMMJ4I5	CS	CC[C@H](C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H]4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMMJ4I5	IK	GEUGFPVPSWNWIJ-JOTHITJKSA-N
DMMJ4I5	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,4S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylhexanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMMJ4I5	DE	Discovery agent

DM8TH4B	ID	DM8TH4B
DM8TH4B	DN	Bbs-Arg-(D-Pip)-Gly-(SPH(pY)EKVS)-Gly-Hir
DM8TH4B	HS	Investigative
DM8TH4B	PC	91936664
DM8TH4B	MW	2997.1
DM8TH4B	FM	C132H191N30O46PS
DM8TH4B	IC	InChI=1S/C132H191N30O46PS/c1-10-71(6)109(129(200)162-56-20-27-98(162)124(195)149-84(44-50-105(175)176)113(184)145-83(43-49-104(173)174)114(185)152-91(59-73-28-34-77(165)35-29-73)120(191)151-88(57-69(2)3)117(188)150-87(130(201)202)40-46-99(134)166)158-116(187)85(45-51-106(177)178)146-112(183)82(42-48-103(171)172)148-118(189)89(58-72-21-12-11-13-22-72)154-122(193)93(62-107(179)180)142-100(167)64-139-110(181)94(66-163)156-126(197)108(70(4)5)157-115(186)80(23-14-16-52-133)144-111(182)81(41-47-102(169)170)147-119(190)90(60-74-30-36-78(37-31-74)208-209(203,204)205)153-121(192)92(61-76-63-137-68-141-76)155-125(196)97-26-19-55-161(97)128(199)95(67-164)143-101(168)65-140-123(194)96-25-15-17-54-160(96)127(198)86(24-18-53-138-131(135)136)159-210(206,207)79-38-32-75(33-39-79)132(7,8)9/h11-13,21-22,28-39,63,68-71,80-98,108-109,159,163-165H,10,14-20,23-27,40-62,64-67,133H2,1-9H3,(H2,134,166)(H,137,141)(H,139,181)(H,140,194)(H,142,167)(H,143,168)(H,144,182)(H,145,184)(H,146,183)(H,147,190)(H,148,189)(H,149,195)(H,150,188)(H,151,191)(H,152,185)(H,153,192)(H,154,193)(H,155,196)(H,156,197)(H,157,186)(H,158,187)(H,169,170)(H,171,172)(H,173,174)(H,175,176)(H,177,178)(H,179,180)(H,201,202)(H4,135,136,138)(H2,203,204,205)/t71-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96+,97-,98-,108-,109-/m0/s1
DM8TH4B	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)OP(=O)(O)O)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]7CCCCN7C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C8=CC=C(C=C8)C(C)(C)C
DM8TH4B	IK	RUWSMOQBPSRIJB-OZHMLDCXSA-N
DM8TH4B	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-phosphonooxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DM8TH4B	DE	Discovery agent

DMQVRHG	ID	DMQVRHG
DMQVRHG	DN	Bbs-Arg-(D-Pip)-Gly-(SPHYEKVS)-Gly-Hir
DMQVRHG	HS	Investigative
DMQVRHG	PC	91936665
DMQVRHG	MW	2917.2
DMQVRHG	FM	C132H190N30O43S
DMQVRHG	IC	InChI=1S/C132H190N30O43S/c1-10-71(6)109(129(201)162-56-20-27-98(162)124(196)149-84(44-50-105(176)177)113(185)145-83(43-49-104(174)175)114(186)152-91(60-74-30-36-78(166)37-31-74)120(192)151-88(57-69(2)3)117(189)150-87(130(202)203)40-46-99(134)167)158-116(188)85(45-51-106(178)179)146-112(184)82(42-48-103(172)173)148-118(190)89(58-72-21-12-11-13-22-72)154-122(194)93(62-107(180)181)142-100(168)64-139-110(182)94(66-163)156-126(198)108(70(4)5)157-115(187)80(23-14-16-52-133)144-111(183)81(41-47-102(170)171)147-119(191)90(59-73-28-34-77(165)35-29-73)153-121(193)92(61-76-63-137-68-141-76)155-125(197)97-26-19-55-161(97)128(200)95(67-164)143-101(169)65-140-123(195)96-25-15-17-54-160(96)127(199)86(24-18-53-138-131(135)136)159-206(204,205)79-38-32-75(33-39-79)132(7,8)9/h11-13,21-22,28-39,63,68-71,80-98,108-109,159,163-166H,10,14-20,23-27,40-62,64-67,133H2,1-9H3,(H2,134,167)(H,137,141)(H,139,182)(H,140,195)(H,142,168)(H,143,169)(H,144,183)(H,145,185)(H,146,184)(H,147,191)(H,148,190)(H,149,196)(H,150,189)(H,151,192)(H,152,186)(H,153,193)(H,154,194)(H,155,197)(H,156,198)(H,157,187)(H,158,188)(H,170,171)(H,172,173)(H,174,175)(H,176,177)(H,178,179)(H,180,181)(H,202,203)(H4,135,136,138)/t71-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96+,97-,98-,108-,109-/m0/s1
DMQVRHG	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]7CCCCN7C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C8=CC=C(C=C8)C(C)(C)C
DMQVRHG	IK	GRDGGKZCNFVXJO-OZHMLDCXSA-N
DMQVRHG	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMQVRHG	DE	Discovery agent

DMXECFJ	ID	DMXECFJ
DMXECFJ	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir
DMXECFJ	HS	Investigative
DMXECFJ	SN	Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir; CHEMBL438400
DMXECFJ	PC	44405788
DMXECFJ	MW	3661.7
DMXECFJ	FM	C148H222N42O65S
DMXECFJ	IC	InChI=1S/C148H222N42O65S/c1-8-72(4)121(145(251)190-41-15-20-101(190)143(249)182-80(32-37-118(222)223)135(241)179-79(31-36-117(220)221)136(242)185-86(44-74-21-25-76(203)26-22-74)140(246)184-84(42-71(2)3)138(244)183-83(146(252)253)29-34-102(149)204)187-137(243)81(33-38-119(224)225)180-134(240)78(30-35-116(218)219)181-139(245)85(43-73-16-10-9-11-17-73)186-141(247)87(45-120(226)227)166-103(205)46-153-122(228)88(59-191)167-104(206)47-154-123(229)89(60-192)168-105(207)48-155-124(230)90(61-193)169-106(208)49-156-125(231)91(62-194)170-107(209)50-157-126(232)92(63-195)171-108(210)51-158-127(233)93(64-196)172-109(211)52-159-128(234)94(65-197)173-110(212)53-160-129(235)95(66-198)174-111(213)54-161-130(236)96(67-199)175-112(214)55-162-131(237)97(68-200)176-113(215)56-163-132(238)98(69-201)177-114(216)57-164-133(239)99(70-202)178-115(217)58-165-142(248)100-19-12-13-40-189(100)144(250)82(18-14-39-152-147(150)151)188-256(254,255)77-27-23-75(24-28-77)148(5,6)7/h9-11,16-17,21-28,71-72,78-101,121,188,191-203H,8,12-15,18-20,29-70H2,1-7H3,(H2,149,204)(H,153,228)(H,154,229)(H,155,230)(H,156,231)(H,157,232)(H,158,233)(H,159,234)(H,160,235)(H,161,236)(H,162,237)(H,163,238)(H,164,239)(H,165,248)(H,166,205)(H,167,206)(H,168,207)(H,169,208)(H,170,209)(H,171,210)(H,172,211)(H,173,212)(H,174,213)(H,175,214)(H,176,215)(H,177,216)(H,178,217)(H,179,241)(H,180,240)(H,181,245)(H,182,249)(H,183,244)(H,184,246)(H,185,242)(H,186,247)(H,187,243)(H,218,219)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,252,253)(H4,150,151,152)/t72-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100?,101-,121-/m0/s1
DMXECFJ	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMXECFJ	IK	CZTBIQRSYJGOBZ-NBINKJFGSA-N
DMXECFJ	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMXECFJ	DE	Discovery agent

DM5N6YE	ID	DM5N6YE
DM5N6YE	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir
DM5N6YE	HS	Investigative
DM5N6YE	SN	Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir; CHEMBL415370
DM5N6YE	PC	44405789
DM5N6YE	MW	3949.9
DM5N6YE	FM	C158H238N46O71S
DM5N6YE	IC	InChI=1S/C158H238N46O71S/c1-8-76(4)129(155(271)204-41-15-20-107(204)153(269)196-84(32-37-126(240)241)145(261)193-83(31-36-125(238)239)146(262)199-90(44-78-21-25-80(219)26-22-78)150(266)198-88(42-75(2)3)148(264)197-87(156(272)273)29-34-108(159)220)201-147(263)85(33-38-127(242)243)194-144(260)82(30-35-124(236)237)195-149(265)89(43-77-16-10-9-11-17-77)200-151(267)91(45-128(244)245)178-109(221)46-163-130(246)92(61-205)179-110(222)47-164-131(247)93(62-206)180-111(223)48-165-132(248)94(63-207)181-112(224)49-166-133(249)95(64-208)182-113(225)50-167-134(250)96(65-209)183-114(226)51-168-135(251)97(66-210)184-115(227)52-169-136(252)98(67-211)185-116(228)53-170-137(253)99(68-212)186-117(229)54-171-138(254)100(69-213)187-118(230)55-172-139(255)101(70-214)188-119(231)56-173-140(256)102(71-215)189-120(232)57-174-141(257)103(72-216)190-121(233)58-175-142(258)104(73-217)191-122(234)59-176-143(259)105(74-218)192-123(235)60-177-152(268)106-19-12-13-40-203(106)154(270)86(18-14-39-162-157(160)161)202-276(274,275)81-27-23-79(24-28-81)158(5,6)7/h9-11,16-17,21-28,75-76,82-107,129,202,205-219H,8,12-15,18-20,29-74H2,1-7H3,(H2,159,220)(H,163,246)(H,164,247)(H,165,248)(H,166,249)(H,167,250)(H,168,251)(H,169,252)(H,170,253)(H,171,254)(H,172,255)(H,173,256)(H,174,257)(H,175,258)(H,176,259)(H,177,268)(H,178,221)(H,179,222)(H,180,223)(H,181,224)(H,182,225)(H,183,226)(H,184,227)(H,185,228)(H,186,229)(H,187,230)(H,188,231)(H,189,232)(H,190,233)(H,191,234)(H,192,235)(H,193,261)(H,194,260)(H,195,265)(H,196,269)(H,197,264)(H,198,266)(H,199,262)(H,200,267)(H,201,263)(H,236,237)(H,238,239)(H,240,241)(H,242,243)(H,244,245)(H,272,273)(H4,160,161,162)/t76-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106?,107-,129-/m0/s1
DM5N6YE	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DM5N6YE	IK	UZMGIFBITDOUBH-GDGQYZPBSA-N
DM5N6YE	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DM5N6YE	DE	Discovery agent

DMTU0HR	ID	DMTU0HR
DMTU0HR	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir
DMTU0HR	HS	Investigative
DMTU0HR	SN	CHEMBL439881; Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir
DMTU0HR	PC	44405859
DMTU0HR	MW	2220.4
DMTU0HR	FM	C98H142N22O35S
DMTU0HR	IC	InChI=1S/C98H142N22O35S/c1-8-52(4)81(95(151)120-41-15-20-71(120)93(149)112-60(32-37-78(132)133)85(141)109-59(31-36-77(130)131)86(142)115-66(44-54-21-25-56(123)26-22-54)90(146)114-64(42-51(2)3)88(144)113-63(96(152)153)29-34-72(99)124)117-87(143)61(33-38-79(134)135)110-84(140)58(30-35-76(128)129)111-89(145)65(43-53-16-10-9-11-17-53)116-91(147)67(45-80(136)137)106-73(125)46-103-82(138)68(49-121)107-74(126)47-104-83(139)69(50-122)108-75(127)48-105-92(148)70-19-12-13-40-119(70)94(150)62(18-14-39-102-97(100)101)118-156(154,155)57-27-23-55(24-28-57)98(5,6)7/h9-11,16-17,21-28,51-52,58-71,81,118,121-123H,8,12-15,18-20,29-50H2,1-7H3,(H2,99,124)(H,103,138)(H,104,139)(H,105,148)(H,106,125)(H,107,126)(H,108,127)(H,109,141)(H,110,140)(H,111,145)(H,112,149)(H,113,144)(H,114,146)(H,115,142)(H,116,147)(H,117,143)(H,128,129)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,152,153)(H4,100,101,102)/t52-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70+,71-,81-/m0/s1
DMTU0HR	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMTU0HR	IK	UHXXZAFTLUMNIB-KZKSJJABSA-N
DMTU0HR	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMTU0HR	DE	Discovery agent

DMEL2GK	ID	DMEL2GK
DMEL2GK	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir
DMEL2GK	HS	Investigative
DMEL2GK	SN	CHEMBL414341; Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir
DMEL2GK	PC	44405865
DMEL2GK	MW	2508.6
DMEL2GK	FM	C108H158N26O41S
DMEL2GK	IC	InChI=1S/C108H158N26O41S/c1-8-56(4)89(105(171)134-41-15-20-77(134)103(169)126-64(32-37-86(150)151)95(161)123-63(31-36-85(148)149)96(162)129-70(44-58-21-25-60(139)26-22-58)100(166)128-68(42-55(2)3)98(164)127-67(106(172)173)29-34-78(109)140)131-97(163)65(33-38-87(152)153)124-94(160)62(30-35-84(146)147)125-99(165)69(43-57-16-10-9-11-17-57)130-101(167)71(45-88(154)155)118-79(141)46-113-90(156)72(51-135)119-80(142)47-114-91(157)73(52-136)120-81(143)48-115-92(158)74(53-137)121-82(144)49-116-93(159)75(54-138)122-83(145)50-117-102(168)76-19-12-13-40-133(76)104(170)66(18-14-39-112-107(110)111)132-176(174,175)61-27-23-59(24-28-61)108(5,6)7/h9-11,16-17,21-28,55-56,62-77,89,132,135-139H,8,12-15,18-20,29-54H2,1-7H3,(H2,109,140)(H,113,156)(H,114,157)(H,115,158)(H,116,159)(H,117,168)(H,118,141)(H,119,142)(H,120,143)(H,121,144)(H,122,145)(H,123,161)(H,124,160)(H,125,165)(H,126,169)(H,127,164)(H,128,166)(H,129,162)(H,130,167)(H,131,163)(H,146,147)(H,148,149)(H,150,151)(H,152,153)(H,154,155)(H,172,173)(H4,110,111,112)/t56-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76+,77-,89-/m0/s1
DMEL2GK	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMEL2GK	IK	QVAVWYLBNALTPM-TVNHPFTQSA-N
DMEL2GK	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMEL2GK	DE	Discovery agent

DMCN48J	ID	DMCN48J
DMCN48J	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir
DMCN48J	HS	Investigative
DMCN48J	SN	Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir; CHEMBL265596
DMCN48J	PC	44405866
DMCN48J	MW	2796.9
DMCN48J	FM	C118H174N30O47S
DMCN48J	IC	InChI=1S/C118H174N30O47S/c1-8-60(4)97(115(191)148-41-15-20-83(148)113(189)140-68(32-37-94(168)169)105(181)137-67(31-36-93(166)167)106(182)143-74(44-62-21-25-64(155)26-22-62)110(186)142-72(42-59(2)3)108(184)141-71(116(192)193)29-34-84(119)156)145-107(183)69(33-38-95(170)171)138-104(180)66(30-35-92(164)165)139-109(185)73(43-61-16-10-9-11-17-61)144-111(187)75(45-96(172)173)130-85(157)46-123-98(174)76(53-149)131-86(158)47-124-99(175)77(54-150)132-87(159)48-125-100(176)78(55-151)133-88(160)49-126-101(177)79(56-152)134-89(161)50-127-102(178)80(57-153)135-90(162)51-128-103(179)81(58-154)136-91(163)52-129-112(188)82-19-12-13-40-147(82)114(190)70(18-14-39-122-117(120)121)146-196(194,195)65-27-23-63(24-28-65)118(5,6)7/h9-11,16-17,21-28,59-60,66-83,97,146,149-155H,8,12-15,18-20,29-58H2,1-7H3,(H2,119,156)(H,123,174)(H,124,175)(H,125,176)(H,126,177)(H,127,178)(H,128,179)(H,129,188)(H,130,157)(H,131,158)(H,132,159)(H,133,160)(H,134,161)(H,135,162)(H,136,163)(H,137,181)(H,138,180)(H,139,185)(H,140,189)(H,141,184)(H,142,186)(H,143,182)(H,144,187)(H,145,183)(H,164,165)(H,166,167)(H,168,169)(H,170,171)(H,172,173)(H,192,193)(H4,120,121,122)/t60-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82?,83-,97-/m0/s1
DMCN48J	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMCN48J	IK	PUATYUGHSGBOAZ-BSPCXEMDSA-N
DMCN48J	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMCN48J	DE	Discovery agent

DMLK5I0	ID	DMLK5I0
DMLK5I0	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir
DMLK5I0	HS	Investigative
DMLK5I0	SN	Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir; CHEMBL427951
DMLK5I0	PC	44405786
DMLK5I0	MW	3085.1
DMLK5I0	FM	C128H190N34O53S
DMLK5I0	IC	InChI=1S/C128H190N34O53S/c1-8-64(4)105(125(211)162-41-15-20-89(162)123(209)154-72(32-37-102(186)187)115(201)151-71(31-36-101(184)185)116(202)157-78(44-66-21-25-68(171)26-22-66)120(206)156-76(42-63(2)3)118(204)155-75(126(212)213)29-34-90(129)172)159-117(203)73(33-38-103(188)189)152-114(200)70(30-35-100(182)183)153-119(205)77(43-65-16-10-9-11-17-65)158-121(207)79(45-104(190)191)142-91(173)46-133-106(192)80(55-163)143-92(174)47-134-107(193)81(56-164)144-93(175)48-135-108(194)82(57-165)145-94(176)49-136-109(195)83(58-166)146-95(177)50-137-110(196)84(59-167)147-96(178)51-138-111(197)85(60-168)148-97(179)52-139-112(198)86(61-169)149-98(180)53-140-113(199)87(62-170)150-99(181)54-141-122(208)88-19-12-13-40-161(88)124(210)74(18-14-39-132-127(130)131)160-216(214,215)69-27-23-67(24-28-69)128(5,6)7/h9-11,16-17,21-28,63-64,70-89,105,160,163-171H,8,12-15,18-20,29-62H2,1-7H3,(H2,129,172)(H,133,192)(H,134,193)(H,135,194)(H,136,195)(H,137,196)(H,138,197)(H,139,198)(H,140,199)(H,141,208)(H,142,173)(H,143,174)(H,144,175)(H,145,176)(H,146,177)(H,147,178)(H,148,179)(H,149,180)(H,150,181)(H,151,201)(H,152,200)(H,153,205)(H,154,209)(H,155,204)(H,156,206)(H,157,202)(H,158,207)(H,159,203)(H,182,183)(H,184,185)(H,186,187)(H,188,189)(H,190,191)(H,212,213)(H4,130,131,132)/t64-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88?,89-,105-/m0/s1
DMLK5I0	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMLK5I0	IK	WEYFLOFTQVOIIG-JSWHDTCYSA-N
DMLK5I0	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMLK5I0	DE	Discovery agent

DMLZ5R6	ID	DMLZ5R6
DMLZ5R6	DN	Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir
DMLZ5R6	HS	Investigative
DMLZ5R6	SN	Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir; CHEMBL441004
DMLZ5R6	PC	44405787
DMLZ5R6	MW	3373.4
DMLZ5R6	FM	C138H206N38O59S
DMLZ5R6	IC	InChI=1S/C138H206N38O59S/c1-8-68(4)113(135(231)176-41-15-20-95(176)133(229)168-76(32-37-110(204)205)125(221)165-75(31-36-109(202)203)126(222)171-82(44-70-21-25-72(187)26-22-70)130(226)170-80(42-67(2)3)128(224)169-79(136(232)233)29-34-96(139)188)173-127(223)77(33-38-111(206)207)166-124(220)74(30-35-108(200)201)167-129(225)81(43-69-16-10-9-11-17-69)172-131(227)83(45-112(208)209)154-97(189)46-143-114(210)84(57-177)155-98(190)47-144-115(211)85(58-178)156-99(191)48-145-116(212)86(59-179)157-100(192)49-146-117(213)87(60-180)158-101(193)50-147-118(214)88(61-181)159-102(194)51-148-119(215)89(62-182)160-103(195)52-149-120(216)90(63-183)161-104(196)53-150-121(217)91(64-184)162-105(197)54-151-122(218)92(65-185)163-106(198)55-152-123(219)93(66-186)164-107(199)56-153-132(228)94-19-12-13-40-175(94)134(230)78(18-14-39-142-137(140)141)174-236(234,235)73-27-23-71(24-28-73)138(5,6)7/h9-11,16-17,21-28,67-68,74-95,113,174,177-187H,8,12-15,18-20,29-66H2,1-7H3,(H2,139,188)(H,143,210)(H,144,211)(H,145,212)(H,146,213)(H,147,214)(H,148,215)(H,149,216)(H,150,217)(H,151,218)(H,152,219)(H,153,228)(H,154,189)(H,155,190)(H,156,191)(H,157,192)(H,158,193)(H,159,194)(H,160,195)(H,161,196)(H,162,197)(H,163,198)(H,164,199)(H,165,221)(H,166,220)(H,167,225)(H,168,229)(H,169,224)(H,170,226)(H,171,222)(H,172,227)(H,173,223)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,232,233)(H4,140,141,142)/t68-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94?,95-,113-/m0/s1
DMLZ5R6	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMLZ5R6	IK	UFWRMLMUWLGVGM-PIMIKREUSA-N
DMLZ5R6	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMLZ5R6	DE	Discovery agent

DMT0X6Q	ID	DMT0X6Q
DMT0X6Q	DN	BBT-007
DMT0X6Q	HS	Investigative
DMT0X6Q	SN	Long-acting GM-CSF (PEGylated, neutropenia), Bolder BioTechnology
DMT0X6Q	CP	Bolder BioTechnology Inc
DMT0X6Q	DE	Neutropenia

DM2YTXL	ID	DM2YTXL
DM2YTXL	DN	BBT-009
DM2YTXL	HS	Investigative
DM2YTXL	SN	BBT-004; Long-acting erythropoietin (PEGylated, anemia), Bolder BioTechnology Inc
DM2YTXL	CP	Bolder BioTechnology Inc
DM2YTXL	DE	Anemia

DMLIT84	ID	DMLIT84
DMLIT84	DN	BBT-021
DMLIT84	HS	Investigative
DMLIT84	SN	BBT-003; Erythropoietin IgG-Fc fusion proteins (anemia), Bolder BioTechnology Inc
DMLIT84	CP	Bolder BioTechnology Inc
DMLIT84	DE	Anemia

DMQNA7V	ID	DMQNA7V
DMQNA7V	DN	BC11-38
DMQNA7V	HS	Investigative
DMQNA7V	SN	686770-80-9; BC11-38; BC 11-38; C15H16N2OS2; AC1M0MXE; GTPL6559; CHEMBL3928332; SCHEMBL16200740; BDBM86642; AOB1847; SYN5070; MolPort-003-028-365; HMS1650C11; ZINC2459456; CCG-26916; AKOS024458190; MCULE-6438827024; AS-16436; KB-270820; B7673; EU-0088935; SR-01000093012; SR-01000093012-1; F0579-0060; 3-phenyl-2-propylsulfanyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one; 3-phenyl-2-(propylthio)-6,7-dihydrothieno[3,2-d]pyrimidin-4(3H)-one; 6,7-Dihydro-3-phenyl-2-(propylthio)thieno[3,2-d]pyrimidin-4(3H)one
DMQNA7V	DT	Small molecular drug
DMQNA7V	PC	2052828
DMQNA7V	MW	304.4
DMQNA7V	FM	C15H16N2OS2
DMQNA7V	IC	InChI=1S/C15H16N2OS2/c1-2-9-20-15-16-12-8-10-19-13(12)14(18)17(15)11-6-4-3-5-7-11/h3-7H,2,8-10H2,1H3
DMQNA7V	CS	CCCSC1=NC2=C(C(=O)N1C3=CC=CC=C3)SCC2
DMQNA7V	IK	YHNDCCKFNWDQGW-UHFFFAOYSA-N
DMQNA7V	IU	3-phenyl-2-propylsulfanyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one
DMQNA7V	DE	Discovery agent

DMQWOZ5	ID	DMQWOZ5
DMQWOZ5	DN	BC-264
DMQWOZ5	HS	Investigative
DMQWOZ5	SN	BC264; BC 264
DMQWOZ5	DT	Small molecular drug
DMQWOZ5	PC	5311016
DMQWOZ5	MW	1106.2
DMQWOZ5	FM	C53H71N9O15S
DMQWOZ5	IC	InChI=1S/C53H71N9O15S/c1-7-9-20-42(62(6)51(71)41(56-45(64)30-43(54)63)28-34-31-55-37-19-15-14-18-36(34)37)50(70)58-40(29-46(65)66)47(67)57-38(26-32-16-12-11-13-17-32)48(68)60-44(21-10-8-2)61-49(69)39(59-52(72)76-53(3,4)5)27-33-22-24-35(25-23-33)77-78(73,74)75/h11-19,22-25,31,38-42,44,55H,7-10,20-21,26-30H2,1-6H3,(H2,54,63)(H,56,64)(H,57,67)(H,58,70)(H,59,72)(H,60,68)(H,61,69)(H,65,66)(H,73,74,75)/t38-,39-,40-,41-,42-,44-/m0/s1
DMQWOZ5	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](CCCC)NC(=O)[C@H](CC2=CC=C(C=C2)OS(=O)(=O)O)NC(=O)OC(C)(C)C)N(C)C(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CC(=O)N
DMQWOZ5	IK	LEXXPLMUWFLNAN-OZUMUDGSSA-N
DMQWOZ5	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[(3-amino-3-oxopropanoyl)amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]pentyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMQWOZ5	DE	Discovery agent

DM047DQ	ID	DM047DQ
DM047DQ	DN	BCEAB
DM047DQ	HS	Investigative
DM047DQ	SN	CHEBI:6426; Ac-Leu-Leu-Arg-H; Ac-Leu-Leu-Argininal; Acetyl-L-leucyl-L-leucylargininal; N-Acetyl-L-leucyl-L-leucyl-L-argininal; 55123-66-5; UNII-J97339NR3V; J97339NR3V; 103476-89-7; Acetyl-Leu-Leu-Arg-al; Leupeptin hemisulfate; L-Leucinamide, N-acetyl-L-leucyl-N-(4-((aminoiminomethyl)amino)-1-formylbutyl)-; N-acetyl-L-leucyl-N-[(1S)-4-{[amino(imino)methyl]amino}-1-formylbutyl]-L-leucinamide
DM047DQ	DT	Small molecular drug
DM047DQ	PC	101210881
DM047DQ	MW	578.7
DM047DQ	FM	C35H34N2O6
DM047DQ	IC	InChI=1S/C35H34N2O6/c1-4-42-30-8-6-5-7-27(30)21-29-32(38)37(33(29)43-28-19-17-26(18-20-28)34(39)40)35(41)36-31(24-13-9-22(2)10-14-24)25-15-11-23(3)12-16-25/h5-20,29,31,33H,4,21H2,1-3H3,(H,36,41)(H,39,40)/t29-,33+/m1/s1
DM047DQ	CS	CCOC1=CC=CC=C1C[C@H]2[C@@H](N(C2=O)C(=O)NC(C3=CC=C(C=C3)C)C4=CC=C(C=C4)C)OC5=CC=C(C=C5)C(=O)O
DM047DQ	IK	IGIOAZWNIRIBNB-CPBHLAHYSA-N
DM047DQ	IU	4-[(2S,3S)-1-[bis(4-methylphenyl)methylcarbamoyl]-3-[(2-ethoxyphenyl)methyl]-4-oxoazetidin-2-yl]oxybenzoic acid
DM047DQ	DE	Discovery agent

DMPG1LJ	ID	DMPG1LJ
DMPG1LJ	DN	Bcecf-Am
DMPG1LJ	HS	Investigative
DMPG1LJ	SN	117464-70-7; 2',7'-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester; 2',7'-bis(2-Carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester Mixed isomers; AKOS015916474; BCECF-AM solution; BCECF-AM solution (5 mM in DMSO), 1 mg in 0.25 ml DMSO; BCECF-acetoxymethyl; FT-0622598; I14-51975; J-100048; MFCD00036969; SCHEMBL15570087; Spiro(isobenzofuran-1(3H),9'-(9H)xanthene)-2',7'-dipropanoic acid; ZINC169730836
DMPG1LJ	PC	53229972
DMPG1LJ	MW	880.761
DMPG1LJ	FM	C42H40O21
DMPG1LJ	IC	InChI=1S/C42H40O21/c1-22(43)52-17-57-34-15-36-32(13-27(34)7-10-38(48)59-19-54-24(3)45)42(31-9-6-29(12-30(31)41(51)63-42)40(50)61-21-56-26(5)47)33-14-28(8-11-39(49)60-20-55-25(4)46)35(16-37(33)62-36)58-18-53-23(2)44/h6,9,12-16H,7-8,10-11,17-21H2,1-5H3
DMPG1LJ	CS	CC(=O)OCOC1=C(C=C2C(=C1)OC3=CC(=C(C=C3C24C5=C(C=C(C=C5)C(=O)OCOC(=O)C)C(=O)O4)CCC(=O)OCOC(=O)C)OCOC(=O)C)CCC(=O)OCOC(=O)C
DMPG1LJ	IK	NTECHUXHORNEGZ-UHFFFAOYSA-N
DMPG1LJ	IU	acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate
DMPG1LJ	CA	CAS 117464-70-7

DM9IN0U	ID	DM9IN0U
DM9IN0U	DN	BCH
DM9IN0U	HS	Investigative
DM9IN0U	SN	20448-79-7; 2-Amino-2-norbornanecarboxylic acid; 2-Aminobicyclo[2.2.1]heptane-2-carboxylic acid; 2-Aminonorbornane-2-carboxylic acid; MPUVBVXDFRDIPT-UHFFFAOYSA-N; Bicyclo[2.2.1]heptane-2-carboxylicacid, 2-amino-; b-BCH; 2-Amino-2-carboxy-bicyclo-2,2,1-heptane; AC1L3GVN; AC1Q5TB7; 2-Aminobicyclo(2,2,1)heptane-2-carboxylic acid; SCHEMBL202772; GTPL4700; CHEMBL2074957; CTK1A1593; MolPort-003-928-121; 2-amino-2-norbornane carboxylic acid; AKOS016044739; AKOS002666381; VZ23542; MCULE-9216762478; Norbornane-2-carboxylic acid, 2-amino
DM9IN0U	DT	Small molecular drug
DM9IN0U	PC	115288
DM9IN0U	MW	155.19
DM9IN0U	FM	C8H13NO2
DM9IN0U	IC	InChI=1S/C8H13NO2/c9-8(7(10)11)4-5-1-2-6(8)3-5/h5-6H,1-4,9H2,(H,10,11)
DM9IN0U	CS	C1CC2CC1CC2(C(=O)O)N
DM9IN0U	IK	MPUVBVXDFRDIPT-UHFFFAOYSA-N
DM9IN0U	IU	2-aminobicyclo[2.2.1]heptane-2-carboxylic acid
DM9IN0U	CA	CAS 20448-79-7
DM9IN0U	CB	CHEBI:167508
DM9IN0U	DE	Discovery agent

DMT5AGJ	ID	DMT5AGJ
DMT5AGJ	DN	BCTC
DMT5AGJ	HS	Investigative
DMT5AGJ	SN	393514-24-4; N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide; CHEMBL441472; 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide, BCTC; SCHEMBL1269620; GTPL2460; KS-00001DIH; CTK8F0011; DTXSID90432997; MolPort-003-983-482; BCP19629; BCTC, &gt; BDBM50133817; ZINC27109670; MFCD08690556; BN0674; AKOS024457842; TRA0012037; MCULE-6176078265; CS-5476; NCGC00370959-01; HY-19960; DA-42544; RT-011429; B-110; FT-0696667; B7520; AZ0001-0587
DMT5AGJ	CP	Purdue Pharma
DMT5AGJ	TC	Analgesics
DMT5AGJ	DT	Small molecular drug
DMT5AGJ	PC	9929425
DMT5AGJ	MW	372.9
DMT5AGJ	FM	C20H25ClN4O
DMT5AGJ	IC	InChI=1S/C20H25ClN4O/c1-20(2,3)15-6-8-16(9-7-15)23-19(26)25-13-11-24(12-14-25)18-17(21)5-4-10-22-18/h4-10H,11-14H2,1-3H3,(H,23,26)
DMT5AGJ	CS	CC(C)(C)C1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=C(C=CC=N3)Cl
DMT5AGJ	IK	ROGUAPYLUCHQGK-UHFFFAOYSA-N
DMT5AGJ	IU	N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
DMT5AGJ	CA	CAS 393514-24-4
DMT5AGJ	DE	Pain

DMVOS2C	ID	DMVOS2C
DMVOS2C	DN	BCX-1827
DMVOS2C	HS	Investigative
DMVOS2C	SN	BCX-1827; (-)-(1R,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-[[amino(imino)methyl]amino]cyclopentanecarboxylic acid; (-)-(1R,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}cyclopentanecarboxylic Acid; AC1LAL6X; Cyclopentane Derivative 50; BDBM5023; CHEMBL136111; SCHEMBL14834652; CTK6C6205; (1R,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-guanidino-cyclopentanecarboxylic acid; (1R,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DMVOS2C	DT	Small molecular drug
DMVOS2C	PC	490519
DMVOS2C	MW	312.41
DMVOS2C	FM	C15H28N4O3
DMVOS2C	IC	InChI=1S/C15H28N4O3/c1-4-9(5-2)13(18-8(3)20)11-6-10(14(21)22)7-12(11)19-15(16)17/h9-13H,4-7H2,1-3H3,(H,18,20)(H,21,22)(H4,16,17,19)/t10-,11-,12-,13+/m1/s1
DMVOS2C	CS	CCC(CC)[C@@H]([C@@H]1C[C@H](C[C@H]1N=C(N)N)C(=O)O)NC(=O)C
DMVOS2C	IK	FOCBRFMNUQOMCY-LPWJVIDDSA-N
DMVOS2C	IU	(1R,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DMVOS2C	DE	Discovery agent

DM6JB32	ID	DM6JB32
DM6JB32	DN	BCX-1898
DM6JB32	HS	Investigative
DM6JB32	SN	BCX-1898
DM6JB32	DT	Small molecular drug
DM6JB32	PC	89337704
DM6JB32	MW	356.5
DM6JB32	FM	C17H32N4O4
DM6JB32	IC	InChI=1S/C17H32N4O4/c1-4-6-10(7-5-2)14(20-9(3)22)13-12(21-17(18)19)8-11(15(13)23)16(24)25/h10-15,23H,4-8H2,1-3H3,(H,20,22)(H,24,25)(H4,18,19,21)/t11-,12+,13+,14-,15+/m0/s1
DM6JB32	CS	CCCC(CCC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)N=C(N)N)NC(=O)C
DM6JB32	IK	IIZTWIZWLKRAMW-VYDRJRHOSA-N
DM6JB32	IU	(1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-propylpentyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
DM6JB32	DE	Discovery agent

DM8G4HS	ID	DM8G4HS
DM8G4HS	DN	BCX-1923
DM8G4HS	HS	Investigative
DM8G4HS	PC	500459
DM8G4HS	MW	340.5
DM8G4HS	FM	C17H32N4O3
DM8G4HS	IC	InChI=1S/C17H32N4O3/c1-4-6-11(7-5-2)15(20-10(3)22)13-8-12(16(23)24)9-14(13)21-17(18)19/h11-15H,4-9H2,1-3H3,(H,20,22)(H,23,24)(H4,18,19,21)
DM8G4HS	CS	CCCC(CCC)C(C1CC(CC1N=C(N)N)C(=O)O)NC(=O)C
DM8G4HS	IK	VUROMZOEXLKRSQ-UHFFFAOYSA-N
DM8G4HS	IU	3-(1-acetamido-2-propylpentyl)-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DM8G4HS	DE	Discovery agent

DMFIDA0	ID	DMFIDA0
DMFIDA0	DN	BD-1047
DMFIDA0	HS	Investigative
DMFIDA0	SN	BD1047; BD 1047
DMFIDA0	DT	Small molecular drug
DMFIDA0	PC	188914
DMFIDA0	MW	275.21
DMFIDA0	FM	C13H20Cl2N2
DMFIDA0	IC	InChI=1S/C13H20Cl2N2/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11/h4-5,10H,6-9H2,1-3H3
DMFIDA0	CS	CN(C)CCN(C)CCC1=CC(=C(C=C1)Cl)Cl
DMFIDA0	IK	MGVRNMUKTZOQOW-UHFFFAOYSA-N
DMFIDA0	IU	N'-[2-(3,4-dichlorophenyl)ethyl]-N,N,N'-trimethylethane-1,2-diamine
DMFIDA0	CA	CAS 138356-20-4
DMFIDA0	CB	CHEBI:92648
DMFIDA0	DE	Discovery agent

DMT0S7M	ID	DMT0S7M
DMT0S7M	DN	BD-NP
DMT0S7M	HS	Investigative
DMT0S7M	SN	ASBNP2.1
DMT0S7M	CP	Mayo Foundation
DMT0S7M	DE	Hypertension

DMZX57Y	ID	DMZX57Y
DMZX57Y	DN	befetupitant
DMZX57Y	HS	Investigative
DMZX57Y	SN	Ro 67-5930; Ro-675930
DMZX57Y	DT	Small molecular drug
DMZX57Y	PC	6450815
DMZX57Y	MW	565.5
DMZX57Y	FM	C29H29F6N3O2
DMZX57Y	IC	InChI=1S/C29H29F6N3O2/c1-18-7-5-6-8-22(18)23-16-25(38-9-11-40-12-10-38)36-17-24(23)37(4)26(39)27(2,3)19-13-20(28(30,31)32)15-21(14-19)29(33,34)35/h5-8,13-17H,9-12H2,1-4H3
DMZX57Y	CS	CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCOCC4
DMZX57Y	IK	ZGNPLCMMVKCTHM-UHFFFAOYSA-N
DMZX57Y	IU	2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-morpholin-4-ylpyridin-3-yl]propanamide
DMZX57Y	CA	CAS 290296-68-3
DMZX57Y	DE	Discovery agent

DMV15JC	ID	DMV15JC
DMV15JC	DN	Befunolol
DMV15JC	HS	Investigative
DMV15JC	SN	Befunolol; Befunolol (INN); Befunolol HCl; Befunolol [INN]; Befunololum; Befunololum [INN-Latin]; 1-(7-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)ethanone; 1-(7-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)ethanone hydrochloride; 2-Acetyl-7-(2-hyroxy-3-isopropylaminopropoxy)benzofuran; 39552-01-7; 7-(2-Hydroxy-3-(isopropylamino)propoxy)-2-benzofuranyl methyl ketone; AC1L1DE0; BRN 3620832; C16H21NO4; KETONE, 7-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)-2-BENZOFURANYL METHYL; SCHEMBL78720
DMV15JC	PC	2309
DMV15JC	MW	291.34
DMV15JC	FM	C16H21NO4
DMV15JC	IC	ZPQPDBIHYCBNIG-UHFFFAOYSA-N
DMV15JC	CS	CC(C)NCC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O
DMV15JC	IK	1S/C16H21NO4/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14/h4-7,10,13,17,19H,8-9H2,1-3H3
DMV15JC	IU	1-[7-[2-hydroxy-3-(propan-2-ylamino)propoxy]-1-benzofuran-2-yl]ethanone
DMV15JC	CA	CAS 39552-01-7
DMV15JC	CB	CHEBI:135212
DMV15JC	DE	Glaucoma

DM0WOS6	ID	DM0WOS6
DM0WOS6	DN	BELFOSDIL
DM0WOS6	HS	Investigative
DM0WOS6	SN	103486-79-9; 2-(2-Phenoxyethyl)-1,3-propylenediphosphonic acid tetrabutyl ester; BMY-21891; Belfosdil < Rec INN; SR-7037
DM0WOS6	DT	Small molecular drug
DM0WOS6	PC	72122
DM0WOS6	MW	548.6
DM0WOS6	FM	C27H50O7P2
DM0WOS6	IC	InChI=1S/C27H50O7P2/c1-5-9-19-31-35(28,32-20-10-6-2)24-26(18-23-30-27-16-14-13-15-17-27)25-36(29,33-21-11-7-3)34-22-12-8-4/h13-17,26H,5-12,18-25H2,1-4H3
DM0WOS6	CS	CCCCOP(=O)(CC(CCOC1=CC=CC=C1)CP(=O)(OCCCC)OCCCC)OCCCC
DM0WOS6	IK	QTBMDDQRDDABNC-UHFFFAOYSA-N
DM0WOS6	IU	[4-dibutoxyphosphoryl-3-(dibutoxyphosphorylmethyl)butoxy]benzene
DM0WOS6	CA	CAS 103486-79-9
DM0WOS6	DE	Discovery agent

DM7H3VY	ID	DM7H3VY
DM7H3VY	DN	Bencyclane
DM7H3VY	HS	Investigative
DM7H3VY	SN	BENCYCLANE; Benciclano; Benciclano [INN-Spanish]; Bencyclan; Bencyclane (INN); Bencyclane [INN]; Bencyclanum; Bencyclanum [INN-Latin]; Benzcyclan; benzcyclane; 1-Propanamine, N,N-dimethyl-3-((1-(phenylmethyl)cycloheptyl)oxy)-; 1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)cycloheptyl]oxy]-; 2179-37-5; 3-((1-Benzylcycloheptyl)oxy)-N,N-dimethylpropylamin; 6I97Z6S135; AC1L1DE9; AC1Q58XJ; C19H31NO; CHEMBL2110767; DSSTox_CID_2646; DSSTox_GSID_22646; DSSTox_RID_97536; DTXSID0022646; EINECS 218-547-0; SCHEMBL64881; UNII-6I97Z6S135
DM7H3VY	PC	2312
DM7H3VY	MW	289.5
DM7H3VY	FM	C19H31NO
DM7H3VY	IC	FYJJXENSONZJRG-UHFFFAOYSA-N
DM7H3VY	CS	CC(C)NCC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O
DM7H3VY	IK	1S/C19H31NO/c1-20(2)15-10-16-21-19(13-8-3-4-9-14-19)17-18-11-6-5-7-12-18/h5-7,11-12H,3-4,8-10,13-17H2,1-2H3
DM7H3VY	IU	3-(1-benzylcycloheptyl)oxy-N,N-dimethylpropan-1-amine
DM7H3VY	CA	CAS 2179-37-5
DM7H3VY	CB	CHEBI:135205
DM7H3VY	DE	Cerebral vasospasm

DMFPSOQ	ID	DMFPSOQ
DMFPSOQ	DN	Benzaldehyde O-4-(decyloxy)phenylcarbamoyl oxime
DMFPSOQ	HS	Investigative
DMFPSOQ	SN	CHEMBL597431; benzaldehyde O-4-(decyloxy)phenylcarbamoyl oxime
DMFPSOQ	DT	Small molecular drug
DMFPSOQ	PC	20872793
DMFPSOQ	MW	396.5
DMFPSOQ	FM	C24H32N2O3
DMFPSOQ	IC	InChI=1S/C24H32N2O3/c1-2-3-4-5-6-7-8-12-19-28-23-17-15-22(16-18-23)26-24(27)29-25-20-21-13-10-9-11-14-21/h9-11,13-18,20H,2-8,12,19H2,1H3,(H,26,27)/b25-20+
DMFPSOQ	CS	CCCCCCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMFPSOQ	IK	LFWYEOAFEYYRNZ-LKUDQCMESA-N
DMFPSOQ	IU	[(E)-benzylideneamino] N-(4-decoxyphenyl)carbamate
DMFPSOQ	DE	Discovery agent

DMU7INH	ID	DMU7INH
DMU7INH	DN	Benzaldehyde O-4-(heptyloxy)phenylcarbamoyl oxime
DMU7INH	HS	Investigative
DMU7INH	SN	CHEMBL597228; benzaldehyde O-4-(heptyloxy)phenylcarbamoyl oxime
DMU7INH	DT	Small molecular drug
DMU7INH	PC	20872796
DMU7INH	MW	354.4
DMU7INH	FM	C21H26N2O3
DMU7INH	IC	InChI=1S/C21H26N2O3/c1-2-3-4-5-9-16-25-20-14-12-19(13-15-20)23-21(24)26-22-17-18-10-7-6-8-11-18/h6-8,10-15,17H,2-5,9,16H2,1H3,(H,23,24)/b22-17+
DMU7INH	CS	CCCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMU7INH	IK	QGTJCMKYCHZBTK-OQKWZONESA-N
DMU7INH	IU	[(E)-benzylideneamino] N-(4-heptoxyphenyl)carbamate
DMU7INH	DE	Discovery agent

DMOK0U8	ID	DMOK0U8
DMOK0U8	DN	Benzaldehyde O-4-(hexyloxy)phenylcarbamoyl oxime
DMOK0U8	HS	Investigative
DMOK0U8	SN	CHEMBL598245; benzaldehyde O-4-(hexyloxy)phenylcarbamoyl oxime
DMOK0U8	DT	Small molecular drug
DMOK0U8	PC	20872797
DMOK0U8	MW	340.4
DMOK0U8	FM	C20H24N2O3
DMOK0U8	IC	InChI=1S/C20H24N2O3/c1-2-3-4-8-15-24-19-13-11-18(12-14-19)22-20(23)25-21-16-17-9-6-5-7-10-17/h5-7,9-14,16H,2-4,8,15H2,1H3,(H,22,23)/b21-16+
DMOK0U8	CS	CCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMOK0U8	IK	HNESYIHKTKWBMV-LTGZKZEYSA-N
DMOK0U8	IU	[(E)-benzylideneamino] N-(4-hexoxyphenyl)carbamate
DMOK0U8	DE	Discovery agent

DMIV3S8	ID	DMIV3S8
DMIV3S8	DN	Benzaldehyde O-4-(nonyloxy)phenylcarbamoyl oxime
DMIV3S8	HS	Investigative
DMIV3S8	SN	CHEMBL597430; benzaldehyde O-4-(nonyloxy)phenylcarbamoyl oxime
DMIV3S8	DT	Small molecular drug
DMIV3S8	PC	20872799
DMIV3S8	MW	382.5
DMIV3S8	FM	C23H30N2O3
DMIV3S8	IC	InChI=1S/C23H30N2O3/c1-2-3-4-5-6-7-11-18-27-22-16-14-21(15-17-22)25-23(26)28-24-19-20-12-9-8-10-13-20/h8-10,12-17,19H,2-7,11,18H2,1H3,(H,25,26)/b24-19+
DMIV3S8	CS	CCCCCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMIV3S8	IK	GOOXRXVIMOMQCL-LYBHJNIJSA-N
DMIV3S8	IU	[(E)-benzylideneamino] N-(4-nonoxyphenyl)carbamate
DMIV3S8	DE	Discovery agent

DMBW7PX	ID	DMBW7PX
DMBW7PX	DN	Benzaldehyde O-4-(octyloxy)phenylcarbamoyl oxime
DMBW7PX	HS	Investigative
DMBW7PX	SN	CHEMBL597229; benzaldehyde O-4-(octyloxy)phenylcarbamoyl oxime
DMBW7PX	DT	Small molecular drug
DMBW7PX	PC	20872800
DMBW7PX	MW	368.5
DMBW7PX	FM	C22H28N2O3
DMBW7PX	IC	InChI=1S/C22H28N2O3/c1-2-3-4-5-6-10-17-26-21-15-13-20(14-16-21)24-22(25)27-23-18-19-11-8-7-9-12-19/h7-9,11-16,18H,2-6,10,17H2,1H3,(H,24,25)/b23-18+
DMBW7PX	CS	CCCCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMBW7PX	IK	BALHAPBNIAUXLM-PTGBLXJZSA-N
DMBW7PX	IU	[(E)-benzylideneamino] N-(4-octoxyphenyl)carbamate
DMBW7PX	DE	Discovery agent

DMWEXOY	ID	DMWEXOY
DMWEXOY	DN	Benzaldehyde O-4-(pentyloxy)phenylcarbamoyl oxime
DMWEXOY	HS	Investigative
DMWEXOY	SN	CHEMBL598244; benzaldehyde O-4-(pentyloxy)phenylcarbamoyl oxime
DMWEXOY	DT	Small molecular drug
DMWEXOY	PC	20872801
DMWEXOY	MW	326.4
DMWEXOY	FM	C19H22N2O3
DMWEXOY	IC	InChI=1S/C19H22N2O3/c1-2-3-7-14-23-18-12-10-17(11-13-18)21-19(22)24-20-15-16-8-5-4-6-9-16/h4-6,8-13,15H,2-3,7,14H2,1H3,(H,21,22)/b20-15+
DMWEXOY	CS	CCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMWEXOY	IK	RMGKIVHTNJBERM-HMMYKYKNSA-N
DMWEXOY	IU	[(E)-benzylideneamino] N-(4-pentoxyphenyl)carbamate
DMWEXOY	DE	Discovery agent

DMHUQWN	ID	DMHUQWN
DMHUQWN	DN	Benzaldehyde O-4-butoxyphenylcarbamoyl oxime
DMHUQWN	HS	Investigative
DMHUQWN	SN	CHEMBL598243; benzaldehyde O-4-butoxyphenylcarbamoyl oxime
DMHUQWN	DT	Small molecular drug
DMHUQWN	PC	20872791
DMHUQWN	MW	312.4
DMHUQWN	FM	C18H20N2O3
DMHUQWN	IC	InChI=1S/C18H20N2O3/c1-2-3-13-22-17-11-9-16(10-12-17)20-18(21)23-19-14-15-7-5-4-6-8-15/h4-12,14H,2-3,13H2,1H3,(H,20,21)/b19-14+
DMHUQWN	CS	CCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMHUQWN	IK	BRPRTDQSLVFYMR-XMHGGMMESA-N
DMHUQWN	IU	[(E)-benzylideneamino] N-(4-butoxyphenyl)carbamate
DMHUQWN	DE	Discovery agent

DMD98YP	ID	DMD98YP
DMD98YP	DN	Benzaldehyde O-4-ethoxyphenylcarbamoyl oxime
DMD98YP	HS	Investigative
DMD98YP	SN	CHEMBL599470; benzaldehyde O-4-ethoxyphenylcarbamoyl oxime
DMD98YP	DT	Small molecular drug
DMD98YP	PC	20872795
DMD98YP	MW	284.31
DMD98YP	FM	C16H16N2O3
DMD98YP	IC	InChI=1S/C16H16N2O3/c1-2-20-15-10-8-14(9-11-15)18-16(19)21-17-12-13-6-4-3-5-7-13/h3-12H,2H2,1H3,(H,18,19)/b17-12+
DMD98YP	CS	CCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMD98YP	IK	QJZVEQAWKFWLAR-SFQUDFHCSA-N
DMD98YP	IU	[(E)-benzylideneamino] N-(4-ethoxyphenyl)carbamate
DMD98YP	DE	Discovery agent

DMLHKQS	ID	DMLHKQS
DMLHKQS	DN	Benzaldehyde O-4-methoxyphenylcarbamoyl oxime
DMLHKQS	HS	Investigative
DMLHKQS	SN	CHEMBL599469; benzaldehyde O-4-methoxyphenylcarbamoyl oxime; AC1NSB21; MLS001207590; MolPort-001-926-439; BDBM50309693; AKOS000588577; BAS 00346640; SMR000513623; ST50224746; AB00076721-01; [(E)-benzylideneamino] N-(4-methoxyphenyl)carbamate
DMLHKQS	DT	Small molecular drug
DMLHKQS	PC	5331416
DMLHKQS	MW	270.28
DMLHKQS	FM	C15H14N2O3
DMLHKQS	IC	InChI=1S/C15H14N2O3/c1-19-14-9-7-13(8-10-14)17-15(18)20-16-11-12-5-3-2-4-6-12/h2-11H,1H3,(H,17,18)/b16-11+
DMLHKQS	CS	COC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMLHKQS	IK	TZKNCCSAQUKSHR-LFIBNONCSA-N
DMLHKQS	IU	[(E)-benzylideneamino] N-(4-methoxyphenyl)carbamate
DMLHKQS	DE	Discovery agent

DMARBF9	ID	DMARBF9
DMARBF9	DN	Benzaldehyde O-4-propoxyphenylcarbamoyl oxime
DMARBF9	HS	Investigative
DMARBF9	SN	CHEMBL592635; benzaldehyde O-4-propoxyphenylcarbamoyl oxime
DMARBF9	DT	Small molecular drug
DMARBF9	PC	20872805
DMARBF9	MW	298.34
DMARBF9	FM	C17H18N2O3
DMARBF9	IC	InChI=1S/C17H18N2O3/c1-2-12-21-16-10-8-15(9-11-16)19-17(20)22-18-13-14-6-4-3-5-7-14/h3-11,13H,2,12H2,1H3,(H,19,20)/b18-13+
DMARBF9	CS	CCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMARBF9	IK	AIEVCSUZILYYSA-QGOAFFKASA-N
DMARBF9	IU	[(E)-benzylideneamino] N-(4-propoxyphenyl)carbamate
DMARBF9	DE	Discovery agent

DMB7DFT	ID	DMB7DFT
DMB7DFT	DN	Benzaldehyde O-benzoyloxime
DMB7DFT	HS	Investigative
DMB7DFT	SN	benzaldehyde O-benzoyloxime; CHEMBL178391; SCHEMBL3222745; SCHEMBL3222751; (Z)-Benzaldehyde O-benzoyloxime
DMB7DFT	DT	Small molecular drug
DMB7DFT	PC	11206881
DMB7DFT	MW	225.24
DMB7DFT	FM	C14H11NO2
DMB7DFT	IC	InChI=1S/C14H11NO2/c16-14(13-9-5-2-6-10-13)17-15-11-12-7-3-1-4-8-12/h1-11H/b15-11+
DMB7DFT	CS	C1=CC=C(C=C1)/C=N/OC(=O)C2=CC=CC=C2
DMB7DFT	IK	OILVJUHCCAKJGC-RVDMUPIBSA-N
DMB7DFT	IU	[(E)-benzylideneamino] benzoate
DMB7DFT	DE	Discovery agent

DM37GWL	ID	DM37GWL
DM37GWL	DN	Benzamidine
DM37GWL	HS	Investigative
DM37GWL	SN	benzamidine; Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395
DM37GWL	DT	Small molecular drug
DM37GWL	PC	2332
DM37GWL	MW	120.15
DM37GWL	FM	C7H8N2
DM37GWL	IC	InChI=1S/C7H8N2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H3,8,9)
DM37GWL	CS	C1=CC=C(C=C1)C(=N)N
DM37GWL	IK	PXXJHWLDUBFPOL-UHFFFAOYSA-N
DM37GWL	IU	benzenecarboximidamide
DM37GWL	CA	CAS 618-39-3
DM37GWL	CB	CHEBI:41033
DM37GWL	DE	Discovery agent

DM57SVW	ID	DM57SVW
DM57SVW	DN	Benzamil
DM57SVW	HS	Investigative
DM57SVW	SN	Benzamil; 2898-76-2; UNII-04659UUJ94; N-(N-Benzylamidino)-3,5-diamino-6-chloropyrazine carboxamide; GNF-Pf-192; CHEMBL212579; CHEBI:34558; 04659UUJ94; 3,5-Diamino-6-chloro-N-(imino((phenylmethyl)amino)methyl)pyrazinecarboxamide; 3,5-diamino-N-(N'-benzylcarbamimidoyl)-6-chloropyrazine-2-carboxamide; Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-(imino((phenylmethyl)amino)methyl)-; Spectrum3_001823; Prestwick1_000657; Prestwick3_000657; Prestwick2_000657; Prestwick0_000657; Lopac-B-2417; AC1L33CQ; Lopac0_000211; KBioGR_000300
DM57SVW	DT	Small molecular drug
DM57SVW	PC	108107
DM57SVW	MW	319.75
DM57SVW	FM	C13H14ClN7O
DM57SVW	IC	InChI=1S/C13H14ClN7O/c14-9-11(16)20-10(15)8(19-9)12(22)21-13(17)18-6-7-4-2-1-3-5-7/h1-5H,6H2,(H4,15,16,20)(H3,17,18,21,22)
DM57SVW	CS	C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N
DM57SVW	IK	KXDROGADUISDGY-UHFFFAOYSA-N
DM57SVW	IU	3,5-diamino-N-(N'-benzylcarbamimidoyl)-6-chloropyrazine-2-carboxamide
DM57SVW	CA	CAS 2898-76-2
DM57SVW	CB	CHEBI:34558
DM57SVW	DE	Discovery agent

DMK5QYW	ID	DMK5QYW
DMK5QYW	DN	BENZENEMETHANETHIOL
DMK5QYW	HS	Investigative
DMK5QYW	SN	BENZYL MERCAPTAN; Benzenemethanethiol; Phenylmethanethiol; 100-53-8; Benzylthiol; Thiobenzyl alcohol; alpha-Toluenethiol; Benzyl hydrosulfide; (Mercaptomethyl)benzene; alpha-Mercaptotoluene; Benzylhydrosulfide; alpha-Toluolthiol; Phenylmethyl mercaptan; Benzylmercaptan; Toluene-alpha-thiol; benzyl thiol; Methanethiol, phenyl-; alpha-Tolyl mercaptan; phenyl-methanethiol; USAF ex-1509; .alpha.-Toluenethiol; Toluene, alpha-mercapto-; UNII-OS34A21OBZ; NSC 41897; benzyl-MERCAPTAN; .alpha.-Toluolthiol; FEMA No. 2147; CCRIS 9
DMK5QYW	DT	Small molecular drug
DMK5QYW	PC	7509
DMK5QYW	MW	124.21
DMK5QYW	FM	C7H8S
DMK5QYW	IC	InChI=1S/C7H8S/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2
DMK5QYW	CS	C1=CC=C(C=C1)CS
DMK5QYW	IK	UENWRTRMUIOCKN-UHFFFAOYSA-N
DMK5QYW	IU	phenylmethanethiol
DMK5QYW	CA	CAS 100-53-8
DMK5QYW	CB	CHEBI:137674
DMK5QYW	DE	Discovery agent

DM3I8A1	ID	DM3I8A1
DM3I8A1	DN	BENZENESULFONAMIDE
DM3I8A1	HS	Investigative
DM3I8A1	SN	1998/10/2; Benzenesulphonamide; Benzosulfonamide; Benzolsulfonamide; phenyl sulfonamide; phenylsulfonamide; C6H7NO2S; M and B 7973; NSC 5341; EINECS 202-637-1; BRN 1100566; CHEMBL27601; AI3-04492; KHBQMWCZKVMBLN-UHFFFAOYSA-N; MFCD00007930; Benzenesulfonamide, 98+%; benzolsulfonamid; benzensulfonamide; phenylsulphonamide; 4jsa; 4jsz; 2wej; benzene sulphonamide; 1-benzenesulfonamide; Benzenesulfonyl amine; WLN: ZSWR; AC1Q6VDE; AC1L1OLV; benzenesulfonic acid amide; SCHEMBL729; EC 202
DM3I8A1	DT	Small molecular drug
DM3I8A1	PC	7370
DM3I8A1	MW	157.19
DM3I8A1	FM	C6H7NO2S
DM3I8A1	IC	InChI=1S/C6H7NO2S/c7-10(8,9)6-4-2-1-3-5-6/h1-5H,(H2,7,8,9)
DM3I8A1	CS	C1=CC=C(C=C1)S(=O)(=O)N
DM3I8A1	IK	KHBQMWCZKVMBLN-UHFFFAOYSA-N
DM3I8A1	IU	benzenesulfonamide
DM3I8A1	CA	CAS 98-10-2
DM3I8A1	DE	Discovery agent

DMMBYGE	ID	DMMBYGE
DMMBYGE	DN	Benzenesulfonyl
DMMBYGE	HS	Investigative
DMMBYGE	SN	benzenesulfinate; 16722-50-2; BENZENESULFONYL; phenylsulfinate; phenyl sulfinate; Phenylsulfinsaure; (Phenylsulfonyl)radical; AC1MYJCD; Benzenethiol S,S-dioxide; C6H5O2S; SCHEMBL13707414; CHEBI:38100; MolPort-019-857-533; JEHKKBHWRAXMCH-UHFFFAOYSA-M; STL483233; HTS027703; ZINC150345494; AKOS015890258; AB00990983-01
DMMBYGE	DT	Small molecular drug
DMMBYGE	PC	3857574
DMMBYGE	MW	141.17
DMMBYGE	FM	C6H5O2S-
DMMBYGE	IC	InChI=1S/C6H6O2S/c7-9(8)6-4-2-1-3-5-6/h1-5H,(H,7,8)/p-1
DMMBYGE	CS	C1=CC=C(C=C1)S(=O)[O-]
DMMBYGE	IK	JEHKKBHWRAXMCH-UHFFFAOYSA-M
DMMBYGE	IU	benzenesulfinate
DMMBYGE	CB	CHEBI:38100
DMMBYGE	DE	Discovery agent

DM5Y2M8	ID	DM5Y2M8
DM5Y2M8	DN	BENZIL
DM5Y2M8	HS	Investigative
DM5Y2M8	SN	BENZIL; 134-81-6; Diphenylethanedione; Dibenzoyl; Diphenylglyoxal; 1,2-Diphenylethane-1,2-dione; Bibenzoyl; Ethanedione, diphenyl-; 1,2-Diphenylethanedione; diphenylethane-1,2-dione; Glyoxal, diphenyl-; Diphenyldiketon; 1,2-ethanedione, 1,2-diphenyl-; Diphenyl-alpha,beta-diketone; NSC 220315; CCRIS 6179; UNII-S85X61172J; EINECS 205-157-0; WY-20910; AI3-00898; CHEMBL189886; CHEBI:51507; 1,2-diphenyl-ethane-1,2-dione; Diphenyl-.alpha.,.beta.-diketone; WURBFLDFSFBTLW-UHFFFAOYSA-N; C14H10O2; MFCD00003080; S85X61172J; 1,2-dione; Benzil, 99+
DM5Y2M8	DT	Small molecular drug
DM5Y2M8	PC	8651
DM5Y2M8	MW	210.23
DM5Y2M8	FM	C14H10O2
DM5Y2M8	IC	InChI=1S/C14H10O2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10H
DM5Y2M8	CS	C1=CC=C(C=C1)C(=O)C(=O)C2=CC=CC=C2
DM5Y2M8	IK	WURBFLDFSFBTLW-UHFFFAOYSA-N
DM5Y2M8	IU	1,2-diphenylethane-1,2-dione
DM5Y2M8	CA	CAS 134-81-6
DM5Y2M8	CB	CHEBI:51507
DM5Y2M8	DE	Discovery agent

DM75U9X	ID	DM75U9X
DM75U9X	DN	Benzimidazole 5-carboxamide
DM75U9X	HS	Investigative
DM75U9X	SN	116568-17-3; 1H-Benzo[d]imidazole-6-carboxamide; 1H-benzimidazole-5-carboxamide; 1H-Benzoimidazole-5-carboxylic acid amide; 1H-Benzimidazole-6-carboxamide; 1H-Benzo[d]imidazole-5-carboxamide; 1H-1,3-benzodiazole-5-carboxamide; benzimidazole-5-carboxamide; FNLQDVXHDNFXIY-UHFFFAOYSA-N; ACMC-20mmnb; benzoimidazole-5-carboxamide; SCHEMBL476587; 1H-Benzoimidazole-5-carboxamide; CTK8E3251; CTK0H3052; DTXSID30572624; MolPort-000-353-183; BCP27970; 2711AA; ZINC27986912; STL200279; AKOS002314950; AKOS022171450; FS-2220; MCULE-9328613043
DM75U9X	DT	Small molecular drug
DM75U9X	PC	15421642
DM75U9X	MW	161.16
DM75U9X	FM	C8H7N3O
DM75U9X	IC	InChI=1S/C8H7N3O/c9-8(12)5-1-2-6-7(3-5)11-4-10-6/h1-4H,(H2,9,12)(H,10,11)
DM75U9X	CS	C1=CC2=C(C=C1C(=O)N)NC=N2
DM75U9X	IK	FNLQDVXHDNFXIY-UHFFFAOYSA-N
DM75U9X	IU	3H-benzimidazole-5-carboxamide
DM75U9X	CA	CAS 116568-17-3
DM75U9X	DE	Hepatovirus infection

DM067NL	ID	DM067NL
DM067NL	DN	Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine
DM067NL	HS	Investigative
DM067NL	SN	CHEMBL66732; Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine; SCHEMBL5137740; MolPort-007-049-029; ZINC12360740; BDBM50038983; AKOS002366252; MCULE-7168990543
DM067NL	DT	Small molecular drug
DM067NL	PC	10356247
DM067NL	MW	279.29
DM067NL	FM	C16H13N3O2
DM067NL	IC	InChI=1S/C16H13N3O2/c1-2-4-13-12(3-1)16(19-9-18-13)17-8-11-5-6-14-15(7-11)21-10-20-14/h1-7,9H,8,10H2,(H,17,18,19)
DM067NL	CS	C1OC2=C(O1)C=C(C=C2)CNC3=NC=NC4=CC=CC=C43
DM067NL	IK	MLVNLAHRZDXSAM-UHFFFAOYSA-N
DM067NL	IU	N-(1,3-benzodioxol-5-ylmethyl)quinazolin-4-amine
DM067NL	DE	Discovery agent

DMJQSLW	ID	DMJQSLW
DMJQSLW	DN	Benzo[b]thiophen-2-ylboronic acid
DMJQSLW	HS	Investigative
DMJQSLW	SN	Benzo[B]thiophene-2-boronic acid; 98437-23-1; benzo[b]thiophen-2-ylboronic acid; 2-benzothienylboronic acid; BENZO[B]THIOPHENE-2-BORONIC ACID; 1-Benzothiophen-2-ylboronic acid; 1-benzothien-2-ylboronic acid; benzo(b)thiophene-2-boronic acid; Benzothiophene-2-boronic acid; Thianaphthene-2-boronic acid; Benzo[b]thiophene-2-ylboronic Acid; C8H7BO2S; 2-benzothiopheneboronic acid; CHEMBL34964; Benzothiophen-2-ylboronic acid; benzo[b]thiophen-2-boronic acid; 1-Benzothiophen-2-Yl-Boranediol; Boronic acid, benzo[b]thien-2-yl-; (1-benzothiophen-2-yl)boronic acid; Benzo[B]Thiophene-2-Boronic Acid
DMJQSLW	DT	Small molecular drug
DMJQSLW	PC	2359
DMJQSLW	MW	178.02
DMJQSLW	FM	C8H7BO2S
DMJQSLW	IC	InChI=1S/C8H7BO2S/c10-9(11)8-5-6-3-1-2-4-7(6)12-8/h1-5,10-11H
DMJQSLW	CS	B(C1=CC2=CC=CC=C2S1)(O)O
DMJQSLW	IK	YNCYPMUJDDXIRH-UHFFFAOYSA-N
DMJQSLW	IU	1-benzothiophen-2-ylboronic acid
DMJQSLW	CA	CAS 98437-23-1
DMJQSLW	DE	Discovery agent

DMZR02J	ID	DMZR02J
DMZR02J	DN	Benzo[c][1,2]oxaborol-1(3H)-ol
DMZR02J	HS	Investigative
DMZR02J	SN	5735-41-1; 1-Hydroxy-2,1-benzoxaborolane; benzo[c][1,2]oxaborol-1(3H)-ol; 2,1-benzoxaborol-1(3h)-ol; monoester; 1,3-dihydro-1-hydroxy-2,1-benzoxaborole; 1,3-DIHYDRO-2,1-BENZOXABOROL-1-OL; 2,1-Benzoxaborole, 1,3-dihydro-1-hydroxy-; CHEBI:78238; 1-hydroxy-3H-2,1-benzoxaborole; 2-(Hydroxymethyl)phenylboronic Acid Cyclic Monoester; 2-(HYDROXYMETHYL)PHENYLBORONIC ACID, DEHYDRATE; KSC-6-288; NSC719278; PubChem5079; 2,1-benzoxaborol-1-ol; 2-Oxa-1-boraindan-1-ol; AMTB152; C7H7BO2; 3H-2,1-benzoxaborol-1-ol; 1-hydroxy-2,1-benzoxaborole
DMZR02J	DT	Small molecular drug
DMZR02J	PC	403788
DMZR02J	MW	133.94
DMZR02J	FM	C7H7BO2
DMZR02J	IC	InChI=1S/C7H7BO2/c9-8-7-4-2-1-3-6(7)5-10-8/h1-4,9H,5H2
DMZR02J	CS	B1(C2=CC=CC=C2CO1)O
DMZR02J	IK	XOQABDOICLHPIS-UHFFFAOYSA-N
DMZR02J	IU	1-hydroxy-3H-2,1-benzoxaborole
DMZR02J	CA	CAS 5735-41-1
DMZR02J	CB	CHEBI:78238
DMZR02J	DE	Discovery agent

DMMYGB9	ID	DMMYGB9
DMMYGB9	DN	Benzo[c][1,5]naphthyridin-6(5H)-one
DMMYGB9	HS	Investigative
DMMYGB9	SN	benzo[c][1,5]naphthyridin-6(5H)-one; CHEMBL320031; Benzo[c]-1,5-naphthyridin-6(5H)-one; SCHEMBL12750384; BDBM50130585; 5H-Benzo[c][1,5]naphthyridin-6-one; Benzo[c][1,5]naphthyridine-6(5H)-one
DMMYGB9	DT	Small molecular drug
DMMYGB9	PC	10535869
DMMYGB9	MW	196.2
DMMYGB9	FM	C12H8N2O
DMMYGB9	IC	InChI=1S/C12H8N2O/c15-12-9-5-2-1-4-8(9)11-10(14-12)6-3-7-13-11/h1-7H,(H,14,15)
DMMYGB9	CS	C1=CC=C2C(=C1)C3=C(C=CC=N3)NC2=O
DMMYGB9	IK	NGHUYPCHBUPCNK-UHFFFAOYSA-N
DMMYGB9	IU	5H-benzo[c][1,5]naphthyridin-6-one
DMMYGB9	DE	Discovery agent

DMISHTB	ID	DMISHTB
DMISHTB	DN	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine
DMISHTB	HS	Investigative
DMISHTB	SN	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine
DMISHTB	DT	Small molecular drug
DMISHTB	PC	5328245
DMISHTB	MW	350.2
DMISHTB	FM	C18H12BrN3
DMISHTB	IC	InChI=1S/C18H12BrN3/c19-14-6-3-7-15(10-14)22-18-16-8-12-4-1-2-5-13(12)9-17(16)20-11-21-18/h1-11H,(H,20,21,22)
DMISHTB	CS	C1=CC=C2C=C3C(=CC2=C1)C(=NC=N3)NC4=CC(=CC=C4)Br
DMISHTB	IK	BUVKJPOCMOXSSQ-UHFFFAOYSA-N
DMISHTB	IU	N-(3-bromophenyl)benzo[g]quinazolin-4-amine
DMISHTB	DE	Discovery agent

DM9H34M	ID	DM9H34M
DM9H34M	DN	Benzodiazepine
DM9H34M	HS	Investigative
DM9H34M	SN	Benzodiazepine (Aversion, anxiety)
DM9H34M	CP	Acura Pharmaceuticals Inc
DM9H34M	DT	Small molecular drug
DM9H34M	PC	134664
DM9H34M	MW	144.17
DM9H34M	FM	C9H8N2
DM9H34M	IC	InChI=1S/C9H8N2/c1-2-6-9-8(4-1)5-3-7-10-11-9/h1-7,11H
DM9H34M	CS	C1=CC=C2C(=C1)C=CC=NN2
DM9H34M	IK	SVUOLADPCWQTTE-UHFFFAOYSA-N
DM9H34M	IU	1H-1,2-benzodiazepine
DM9H34M	CA	CAS 12794-10-4
DM9H34M	DE	Anxiety disorder

DMF1ZE6	ID	DMF1ZE6
DMF1ZE6	DN	Benzofuran-2-yl(indolin-1-yl)methanone
DMF1ZE6	HS	Investigative
DMF1ZE6	SN	CHEMBL496155; benzofuran-2-yl(indolin-1-yl)methanone; AC1LFLO9; Oprea1_781741; SCHEMBL2757847; MolPort-002-146-725; ZINC272979; BDBM50265522; ZINC 00272979; AKOS001474069; MCULE-1146733513; SR-01000206937; 1-benzofuran-2-yl(2,3-dihydroindol-1-yl)methanone
DMF1ZE6	DT	Small molecular drug
DMF1ZE6	PC	780029
DMF1ZE6	MW	263.29
DMF1ZE6	FM	C17H13NO2
DMF1ZE6	IC	InChI=1S/C17H13NO2/c19-17(16-11-13-6-2-4-8-15(13)20-16)18-10-9-12-5-1-3-7-14(12)18/h1-8,11H,9-10H2
DMF1ZE6	CS	C1CN(C2=CC=CC=C21)C(=O)C3=CC4=CC=CC=C4O3
DMF1ZE6	IK	NWLAYUVGWMPNSG-UHFFFAOYSA-N
DMF1ZE6	IU	1-benzofuran-2-yl(2,3-dihydroindol-1-yl)methanone
DMF1ZE6	DE	Discovery agent

DMQ7I06	ID	DMQ7I06
DMQ7I06	DN	Benzofuran-2-ylboronic acid
DMQ7I06	HS	Investigative
DMQ7I06	SN	Benzofuran-2-boronic acid; 98437-24-2; Benzo[b]furan-2-boronic acid; Benzofuran-2-ylboronic acid; 1-benzofuran-2-ylboronic acid; 2-Benzofuranboronic acid; 2-BENZOFURANYLBORONIC ACID; Benzo(b)furan-2-boronic acid; (1-benzofuran-2-yl)boronic acid; 2,3-Benzo[b]furan-2-boronic acid; Boronic acid, 2-benzofuranyl-; CHEMBL143399; MFCD00236019; Benzo[b]furan-2-boronic acid, 97%; Benzofuran-2-boronicacid; benzofurylboronic acid; PubChem1724; bezofuran boronic acid; PubChem1754; Benzofuran boronic acid; 2-Boronobenzo[b]furan
DMQ7I06	DT	Small molecular drug
DMQ7I06	PC	2776266
DMQ7I06	MW	161.95
DMQ7I06	FM	C8H7BO3
DMQ7I06	IC	InChI=1S/C8H7BO3/c10-9(11)8-5-6-3-1-2-4-7(6)12-8/h1-5,10-11H
DMQ7I06	CS	B(C1=CC2=CC=CC=C2O1)(O)O
DMQ7I06	IK	PKRRNTJIHGOMRC-UHFFFAOYSA-N
DMQ7I06	IU	1-benzofuran-2-ylboronic acid
DMQ7I06	CA	CAS 98437-24-2
DMQ7I06	DE	Discovery agent

DMNVG1M	ID	DMNVG1M
DMNVG1M	DN	Benzofuran-3-yl-(indol-3-yl)maleimides
DMNVG1M	HS	Investigative
DMNVG1M	DT	Small molecular drug
DMNVG1M	PC	9831814
DMNVG1M	MW	731.9
DMNVG1M	FM	C38H41N3O8S2
DMNVG1M	IC	InChI=1S/C22H23NO5S2.C16H18N2O3/c1-15(14-30(28)22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17;1-16(2)15(20)14(18-7-3-4-13(18)19)11-8-10(9-17)5-6-12(11)21-16/h2-11,15,18-19H,12-14H2,1H3,(H,25,26);5-6,8,14-15,20H,3-4,7H2,1-2H3/t15-,18-,19-,30?;14-,15+/m01/s1
DMNVG1M	CS	C[C@@H](CS(=O)C(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(=O)O)SC3=CC=CC=C3.CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N3CCCC3=O)O)C
DMNVG1M	IK	CPIFLUAOCGEKJE-QTQBKYSQSA-N
DMNVG1M	IU	(2S,4S)-1-[(2R)-3-benzoylsulfinyl-2-methylpropanoyl]-4-phenylsulfanylpyrrolidine-2-carboxylic acid;(3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydrochromene-6-carbonitrile
DMNVG1M	DE	Discovery agent

DMAQK0G	ID	DMAQK0G
DMAQK0G	DN	Benzoic acid 2,6-diisopropyl-phenyl ester
DMAQK0G	HS	Investigative
DMAQK0G	SN	Benzoic acid 2,6-diisopropyl-phenyl ester; CHEMBL55916; SCHEMBL8380667; ZINC13779585; Benzoic acid 2,6-diisopropylphenyl ester
DMAQK0G	DT	Small molecular drug
DMAQK0G	PC	10779272
DMAQK0G	MW	282.4
DMAQK0G	FM	C19H22O2
DMAQK0G	IC	InChI=1S/C19H22O2/c1-13(2)16-11-8-12-17(14(3)4)18(16)21-19(20)15-9-6-5-7-10-15/h5-14H,1-4H3
DMAQK0G	CS	CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)C2=CC=CC=C2
DMAQK0G	IK	FWWZVJVOMUKVKV-UHFFFAOYSA-N
DMAQK0G	IU	[2,6-di(propan-2-yl)phenyl] benzoate
DMAQK0G	CA	CAS 2005-09-6
DMAQK0G	DE	Discovery agent

DM6T8YM	ID	DM6T8YM
DM6T8YM	DN	Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DM6T8YM	HS	Investigative
DM6T8YM	SN	CHEMBL84113; Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DM6T8YM	DT	Small molecular drug
DM6T8YM	PC	10105296
DM6T8YM	MW	231.29
DM6T8YM	FM	C14H17NO2
DM6T8YM	IC	InChI=1S/C14H17NO2/c16-14(10-5-2-1-3-6-10)17-13-9-11-7-4-8-12(13)15-11/h1-3,5-6,11-13,15H,4,7-9H2
DM6T8YM	CS	C1CC2CC(C(C1)N2)OC(=O)C3=CC=CC=C3
DM6T8YM	IK	AKLGENRCHBXEKW-UHFFFAOYSA-N
DM6T8YM	IU	8-azabicyclo[3.2.1]octan-6-yl benzoate
DM6T8YM	DE	Discovery agent

DM50QMB	ID	DM50QMB
DM50QMB	DN	Benzoin
DM50QMB	HS	Investigative
DM50QMB	SN	BENZOIN; 119-53-9; 2-Hydroxy-1,2-diphenylethanone; 2-Hydroxy-2-phenylacetophenone; Benzoylphenylcarbinol; Benzoin tincture; Ethanone, 2-hydroxy-1,2-diphenyl-; Bitter almond oil camphor; Phenylbenzoyl carbinol; 2-hydroxy-1,2-diphenylethan-1-one; (+-)-Benzoin; DL-BENZOIN; alpha-Hydroxybenzyl phenyl ketone; 579-44-2; alpha-Hydroxy-alpha-phenylacetophenone; Benzoin resin; Phenyl-alpha-hydroxybenzyl ketone; NCI-C50011; Acetophenone, 2-hydroxy-2-phenyl-; Benzoin gum; Bitter-almond-oil camphor; Benzoin Siam; Benzoin extract (resinoid)
DM50QMB	DT	Small molecular drug
DM50QMB	PC	8400
DM50QMB	MW	212.24
DM50QMB	FM	C14H12O2
DM50QMB	IC	InChI=1S/C14H12O2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13,15H
DM50QMB	CS	C1=CC=C(C=C1)C(C(=O)C2=CC=CC=C2)O
DM50QMB	IK	ISAOCJYIOMOJEB-UHFFFAOYSA-N
DM50QMB	IU	2-hydroxy-1,2-diphenylethanone
DM50QMB	CA	CAS 119-53-9
DM50QMB	CB	CHEBI:17682
DM50QMB	DE	Discovery agent

DME5QPX	ID	DME5QPX
DME5QPX	DN	BENZOLAMIDE
DME5QPX	HS	Investigative
DME5QPX	SN	BENZOLAMIDE; 3368-13-6; UNII-FC5AAH89R5; CL 11366; FC5AAH89R5; 2-benzenesulfonamido-1,3,4-thiadiazole-5-sulfonamide; CHEMBL73962; 1,3,4-Thiadiazole-2-sulfonamide, 5-[(phenylsulfonyl)amino]-; W 1803; 5-(phenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide; 2-(Phenylsulfonylamino)-1,3,4-thiadiazole-5-sulfonamide; 5-[(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide; 1,3,4-Thiadiazole-2-sulfonamide, 5-((phenylsulfonyl)amino)-; 5-benzenesulfonamido-1,3,4-thiadiazol-2-sulfonamide; 3dbu; D8W; Benzolamide (BZA); 3d8w; AC1L2CTC
DME5QPX	DT	Small molecular drug
DME5QPX	PC	18794
DME5QPX	MW	320.4
DME5QPX	FM	C8H8N4O4S3
DME5QPX	IC	InChI=1S/C8H8N4O4S3/c9-18(13,14)8-11-10-7(17-8)12-19(15,16)6-4-2-1-3-5-6/h1-5H,(H,10,12)(H2,9,13,14)
DME5QPX	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=NN=C(S2)S(=O)(=O)N
DME5QPX	IK	PWDGTQXZLNDOKS-UHFFFAOYSA-N
DME5QPX	IU	5-(benzenesulfonamido)-1,3,4-thiadiazole-2-sulfonamide
DME5QPX	CA	CAS 3368-13-6
DME5QPX	DE	Discovery agent

DMRE96F	ID	DMRE96F
DMRE96F	DN	Benzomate
DMRE96F	HS	Investigative
DMRE96F	SN	Benzoxamate; Acarmate; Artaban; Citrazon; Azomate; Benzoximate [BSI:ISO]; UNII-32TAI9ZK5N; 32TAI9ZK5N; NA-53M; NA-53; EINECS 249-439-1; BRN 2783319; BENZOHYDROXAMIC ACID, O-BENZOYL-3-CHLORO-2,6-DIMETHOXY-N-ETHYL-; Benzoic acid, anhydride with 3-chloro-N-ethoxy-2,6-dimethoxybenzimidic acid; AC1L1RMU; 67011-39-6; SCHEMBL9806359; HOERQTQCTISLFR-UHFFFAOYSA-N; LS-35432; C19021; N-(Benzoyloxy)-3-chloro-N-ethyl-2,6-dimethoxybenzamide; Benzoic acid anhydride with 3-chloro-N-ethoxy-2,6-dimethoxybenzenecarboximidic acid (9CI); Benzoic aci
DMRE96F	DT	Small molecular drug
DMRE96F	PC	6035168
DMRE96F	MW	363.8
DMRE96F	FM	C18H18ClNO5
DMRE96F	IC	InChI=1S/C18H18ClNO5/c1-4-24-20-17(25-18(21)12-8-6-5-7-9-12)15-14(22-2)11-10-13(19)16(15)23-3/h5-11H,4H2,1-3H3/b20-17-
DMRE96F	CS	CCO/N=C(/C1=C(C=CC(=C1OC)Cl)OC)\\OC(=O)C2=CC=CC=C2
DMRE96F	IK	BZMIHNKNQJJVRO-JZJYNLBNSA-N
DMRE96F	IU	[(Z)-C-(3-chloro-2,6-dimethoxyphenyl)-N-ethoxycarbonimidoyl] benzoate
DMRE96F	CA	CAS 29104-30-1
DMRE96F	DE	Discovery agent

DMMKBFN	ID	DMMKBFN
DMMKBFN	DN	benzoquinazolinone 12
DMMKBFN	HS	Investigative
DMMKBFN	SN	benzoquinazolinone 12; SCHEMBL2404136; GTPL8549; 3-[(1S,2S)-2-hydroxycyclohexyl]-6-{[6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl]methyl}-3H,4H-benzo[h]quinazolin-4-one
DMMKBFN	DT	Small molecular drug
DMMKBFN	PC	46196414
DMMKBFN	MW	465.5
DMMKBFN	FM	C28H27N5O2
DMMKBFN	IC	InChI=1S/C28H27N5O2/c1-32-16-20(15-31-32)24-11-10-18(14-29-24)12-19-13-23-27(22-7-3-2-6-21(19)22)30-17-33(28(23)35)25-8-4-5-9-26(25)34/h2-3,6-7,10-11,13-17,25-26,34H,4-5,8-9,12H2,1H3/t25-,26-/m0/s1
DMMKBFN	CS	CN1C=C(C=N1)C2=NC=C(C=C2)CC3=CC4=C(C5=CC=CC=C53)N=CN(C4=O)[C@H]6CCCC[C@@H]6O
DMMKBFN	IK	SXJQBWJPNSOKQV-UIOOFZCWSA-N
DMMKBFN	IU	3-[(1S,2S)-2-hydroxycyclohexyl]-6-[[6-(1-methylpyrazol-4-yl)pyridin-3-yl]methyl]benzo[h]quinazolin-4-one
DMMKBFN	DE	Discovery agent

DMNBA0G	ID	DMNBA0G
DMNBA0G	DN	Benzoquinone
DMNBA0G	HS	Investigative
DMNBA0G	SN	p-benzoquinone; Benzoquinone; 1,4-BENZOQUINONE; Quinone; 106-51-4; p-Quinone; Chinone; 2,5-Cyclohexadiene-1,4-dione; para-Benzoquinone; cyclohexa-2,5-diene-1,4-dione; Cyclohexadienedione; para-Quinone; 1,4-Benzoquine; Steara pbq; 1,4-Dioxybenzene; p-Chinon; 1,4-Cyclohexadienedione; Benzo-chinon; Benzo-1,4-quinone; 1,4-Diossibenzene; Chinon; 1,4-Dioxy-benzol; 1,4-Cyclohexadiene dioxide; Semiquinone anion; semiquinone radicals; RCRA waste number U197; p-Chinon [German]; NCI-C55845; Caswell No. 719C; Benzo-chinon [German]; USAF P-220
DMNBA0G	DT	Small molecular drug
DMNBA0G	PC	4650
DMNBA0G	MW	108.09
DMNBA0G	FM	C6H4O2
DMNBA0G	IC	InChI=1S/C6H4O2/c7-5-1-2-6(8)4-3-5/h1-4H
DMNBA0G	CS	C1=CC(=O)C=CC1=O
DMNBA0G	IK	AZQWKYJCGOJGHM-UHFFFAOYSA-N
DMNBA0G	IU	cyclohexa-2,5-diene-1,4-dione
DMNBA0G	CA	CAS 106-51-4
DMNBA0G	CB	CHEBI:16509
DMNBA0G	DE	Discovery agent

DM4OKXI	ID	DM4OKXI
DM4OKXI	DN	Benzotetronic acid
DM4OKXI	HS	Investigative
DM4OKXI	SN	Coumarin, 4-hydroxy-; X954ZLL2RD; 1076-38-6; 2-Hydroxychromone; 2-hydroxychromen-4-one; 2H-1-BENZOPYRAN-2-ONE, 4-HYDROXY-; 4-Coumarinol; 4-Hydroxycoumarin; 4-HYDROXY-1-BENZOPYRAN-2-ONE; 4-Hydroxy-2H-1-benzopyran-2-one; 4-Hydroxy-2H-chromen-2-one; 4-Hydroxy-chromen-2-one; 4-Hydroxycoumarin, 98%; 4-Hydroxycoumarine; 4-hydroxy-2-chromenone; 4-hydroxy-coumarin; 4-hydroxychromen-2-one; 4H-1-Benzopyran-4-one, 2-hydroxy-; AI3-52393; BRN 0129768; CHEMBL301141; EINECS 214-060-2; MFCD00006856; NSC 11889; UNII-X954ZLL2RD
DM4OKXI	PC	54682930
DM4OKXI	MW	162.14
DM4OKXI	FM	C9H6O3
DM4OKXI	IC	VXIXUWQIVKSKSA-UHFFFAOYSA-N
DM4OKXI	CS	C1=CC=C2C(=C1)C(=CC(=O)O2)O
DM4OKXI	IK	1S/C9H6O3/c10-7-5-9(11)12-8-4-2-1-3-6(7)8/h1-5,10H
DM4OKXI	IU	4-hydroxychromen-2-one
DM4OKXI	CA	CAS 1076-38-6
DM4OKXI	CB	CHEBI:40070
DM4OKXI	DE	Discovery agent

DMV7MPL	ID	DMV7MPL
DMV7MPL	DN	BENZOTHIAZOLE
DMV7MPL	HS	Investigative
DMV7MPL	SN	BENZOTHIAZOLE; 95-16-9; BENZO[D]THIAZOLE; 1,3-Benzothiazole; Benzosulfonazole; 1-Thia-3-azaindene; Vangard BT; benzothiazol; USAF EK-4812; benzthiazole; CHEBI:45993; FEMA Number 3256; UNII-G5BW2593EP; O-2857; FEMA No. 3256; CCRIS 7893; HSDB 2796; NSC 8040; EINECS 202-396-2; BRN 0109468; AI3-05742; G5BW2593EP; IOJUPLGTWVMSFF-UHFFFAOYSA-N; MFCD00005775; Benzothiazole, 97%; DSSTox_CID_4586; DSSTox_RID_77458; DSSTox_GSID_24586; CAS-95-16-9; BOT; Benzothiazole, 96%; 1,3-Benzothiazole #; ACMC-209rv5; Epitope ID:138946; EC 202-396-2; SCHEMBL8430
DMV7MPL	DT	Small molecular drug
DMV7MPL	PC	7222
DMV7MPL	MW	135.19
DMV7MPL	FM	C7H5NS
DMV7MPL	IC	InChI=1S/C7H5NS/c1-2-4-7-6(3-1)8-5-9-7/h1-5H
DMV7MPL	CS	C1=CC=C2C(=C1)N=CS2
DMV7MPL	IK	IOJUPLGTWVMSFF-UHFFFAOYSA-N
DMV7MPL	IU	1,3-benzothiazole
DMV7MPL	CA	CAS 95-16-9
DMV7MPL	CB	CHEBI:45993
DMV7MPL	DE	Discovery agent

DMROP5Q	ID	DMROP5Q
DMROP5Q	DN	Benzothiazole-2-sulfonic acid amide
DMROP5Q	HS	Investigative
DMROP5Q	SN	2-Benzothiazolesulfonamide; 433-17-0; Benzo[d]thiazole-2-sulfonamide; 1,3-benzothiazole-2-sulfonamide; BENZOTHIAZOLE-2-SULFONAMIDE; Benzothiazole-2-sulfonic acid amide; CHEMBL168552; CHEBI:34262; 2-BTS; 6-Hydrogen-2-benzothiazolesulfonamide; AC1Q1HM9; AC1L28OQ; SCHEMBL81178; AC1Q55G4; CTK1D5756; DTXSID30195812; MolPort-006-728-089; SDYMYAFSQACTQP-UHFFFAOYSA-N; 3s73; ZINC1847418; ANW-70718; 5987AB; BDBM50160671; AKOS010998801; MCULE-9059575102; EN001332; AM100818; TC-159463; KB-142553; EN300-60766; C14181
DMROP5Q	DT	Small molecular drug
DMROP5Q	PC	67944
DMROP5Q	MW	214.3
DMROP5Q	FM	C7H6N2O2S2
DMROP5Q	IC	InChI=1S/C7H6N2O2S2/c8-13(10,11)7-9-5-3-1-2-4-6(5)12-7/h1-4H,(H2,8,10,11)
DMROP5Q	CS	C1=CC=C2C(=C1)N=C(S2)S(=O)(=O)N
DMROP5Q	IK	SDYMYAFSQACTQP-UHFFFAOYSA-N
DMROP5Q	IU	1,3-benzothiazole-2-sulfonamide
DMROP5Q	CA	CAS 433-17-0
DMROP5Q	CB	CHEBI:34262
DMROP5Q	DE	Discovery agent

DMC7TNF	ID	DMC7TNF
DMC7TNF	DN	Benzoyl-Arginine-Alanine-Methyl Ketone
DMC7TNF	HS	Investigative
DMC7TNF	SN	AC1NRDMD; benzyl N-[(2S)-5-(diaminomethylamino)-1-oxo-1-(3-oxobutan-2-ylamino)pentan-2-yl]carbamate; molecular hydrogen
DMC7TNF	DT	Small molecular drug
DMC7TNF	PC	6398520
DMC7TNF	MW	379.5
DMC7TNF	FM	C18H29N5O4
DMC7TNF	IC	InChI=1S/C18H29N5O4/c1-12(13(2)24)22-16(25)15(9-6-10-21-17(19)20)23-18(26)27-11-14-7-4-3-5-8-14/h3-5,7-8,12,15,17,21H,6,9-11,19-20H2,1-2H3,(H,22,25)(H,23,26)/t12-,15-/m0/s1
DMC7TNF	CS	C[C@@H](C(=O)C)NC(=O)[C@H](CCCNC(N)N)NC(=O)OCC1=CC=CC=C1
DMC7TNF	IK	SLLMMFWUJVANSC-WFASDCNBSA-N
DMC7TNF	IU	benzyl N-[(2S)-5-(diaminomethylamino)-1-oxo-1-[[(2S)-3-oxobutan-2-yl]amino]pentan-2-yl]carbamate
DMC7TNF	CA	CAS 1033745-37-7
DMC7TNF	DE	Discovery agent

DMY5O1U	ID	DMY5O1U
DMY5O1U	DN	BENZOYLENUREA
DMY5O1U	HS	Investigative
DMY5O1U	SN	Benzoyleneurea; 86-96-4; quinazoline-2,4(1H,3H)-dione; 2,4(1H,3H)-Quinazolinedione; 2,4-Dihydroxyquinazoline; Quinazolinedione; Benzouracil; Quinazoline-2,4-diol; Quinazoline-2,4-dione; 1H-Quinazoline-2,4-dione; Urea, benzoylene-; 1,2,3,4-Tetrahydroquinazoline-2,4-dione; 2-Keto-4-quinazolinone; 2,4-Dioxotetrahydroquinazoline; NSC 2108; (1H,3H)Quinazoline dione-2,4; (1H,3H)-Quinazoline-2,4-dione; EINECS 201-712-6; (1H,3H)Quinazoline dione-2,4 [French]; AI3-28016; CHEMBL421646; 1H,3H-quinazoline-2,4-dione; UNII-18K00A531C
DMY5O1U	DT	Small molecular drug
DMY5O1U	PC	64048
DMY5O1U	MW	162.15
DMY5O1U	FM	C8H6N2O2
DMY5O1U	IC	InChI=1S/C8H6N2O2/c11-7-5-3-1-2-4-6(5)9-8(12)10-7/h1-4H,(H2,9,10,11,12)
DMY5O1U	CS	C1=CC=C2C(=C1)C(=O)NC(=O)N2
DMY5O1U	IK	SDQJTWBNWQABLE-UHFFFAOYSA-N
DMY5O1U	IU	1H-quinazoline-2,4-dione
DMY5O1U	CA	CAS 86-96-4
DMY5O1U	DE	Discovery agent

DMIRD8S	ID	DMIRD8S
DMIRD8S	DN	BENZOYL-TYROSINE-ALANINE-METHYL KETONE
DMIRD8S	HS	Investigative
DMIRD8S	SN	benzoyl-tyrosine-alanine-methyl ketone
DMIRD8S	DT	Small molecular drug
DMIRD8S	PC	46937178
DMIRD8S	MW	384.4
DMIRD8S	FM	C21H24N2O5
DMIRD8S	IC	InChI=1S/C21H24N2O5/c1-14(15(2)24)22-20(26)19(12-16-8-10-18(25)11-9-16)23-21(27)28-13-17-6-4-3-5-7-17/h3-11,14,19,25H,12-13H2,1-2H3,(H,22,26)(H,23,27)/t14-,19-/m0/s1
DMIRD8S	CS	C[C@@H](C(=O)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)OCC2=CC=CC=C2
DMIRD8S	IK	CLDDOKCDXBMMKZ-LIRRHRJNSA-N
DMIRD8S	IU	benzyl N-[(2S)-3-(4-hydroxyphenyl)-1-oxo-1-[[(2S)-3-oxobutan-2-yl]amino]propan-2-yl]carbamate
DMIRD8S	DE	Discovery agent

DMT3JYE	ID	DMT3JYE
DMT3JYE	DN	Benzyl 2-hydroxyiminoolean-12-en-28-oate
DMT3JYE	HS	Investigative
DMT3JYE	SN	2-(Hydroxyimino)oleana-12-ene-28-oic acid benzyl ester
DMT3JYE	DT	Small molecular drug
DMT3JYE	PC	91937013
DMT3JYE	MW	559.8
DMT3JYE	FM	C37H53NO3
DMT3JYE	IC	InChI=1S/C37H53NO3/c1-32(2)17-19-37(31(39)41-24-25-11-9-8-10-12-25)20-18-35(6)27(28(37)23-32)13-14-30-34(5)22-26(38-40)21-33(3,4)29(34)15-16-36(30,35)7/h8-13,26,28-30H,14-24H2,1-7H3/t26?,28-,29-,30+,34-,35+,36+,37-/m0/s1
DMT3JYE	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OCC6=CC=CC=C6)C)(CC(CC3(C)C)N=O)C
DMT3JYE	IK	UQAJJIWPUXUAMF-NUBQHGELSA-N
DMT3JYE	IU	benzyl (4aS,6aR,6aS,6bR,8aS,12aS,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-11-nitroso-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMT3JYE	DE	Discovery agent

DMOKVAT	ID	DMOKVAT
DMOKVAT	DN	Benzyl 4-aminobutyl(3-aminopropyl)carbamate
DMOKVAT	HS	Investigative
DMOKVAT	SN	Benzyl 4-aminobutyl(3-aminopropyl)carbamate; CHEMBL418644; NSC685957; benzyl N-(4-aminobutyl)-N-(3-aminopropyl)carbamate; AC1L8YAY; SCHEMBL7535687; CTK8D1272; ZINC1650370; BDBM50184788; NSC-685957; NCI60_030939; benzyl(4-aminobutyl)(3-aminopropyl)carbamate; 3-Aminopropyl(4-aminobutyl)carbamic acid benzyl ester; (4-Amino-butyl)-(3-amino-propyl)-carbamic acid benzyl ester
DMOKVAT	DT	Small molecular drug
DMOKVAT	PC	389610
DMOKVAT	MW	279.38
DMOKVAT	FM	C15H25N3O2
DMOKVAT	IC	InChI=1S/C15H25N3O2/c16-9-4-5-11-18(12-6-10-17)15(19)20-13-14-7-2-1-3-8-14/h1-3,7-8H,4-6,9-13,16-17H2
DMOKVAT	CS	C1=CC=C(C=C1)COC(=O)N(CCCCN)CCCN
DMOKVAT	IK	ADDDUQKJZAGBIG-UHFFFAOYSA-N
DMOKVAT	IU	benzyl N-(4-aminobutyl)-N-(3-aminopropyl)carbamate
DMOKVAT	DE	Discovery agent

DM857X2	ID	DM857X2
DM857X2	DN	benzyl bromide
DM857X2	HS	Investigative
DM857X2	SN	BENZYL BROMIDE; 100-39-0; (Bromomethyl)benzene; alpha-Bromotoluene; Bromophenylmethane; Benzene, (bromomethyl)-; Benzene, bromomethyl-; Phenylmethyl bromide; 1-Bromotoluene; benzylbromide; Cyclite; bromomethylbenzene; A-BROMOTOLUENE; Toluene, alpha-bromo-; BnBr; NSC 8041; UNII-XR75BS721D; HSDB 369; .alpha.-Bromotoluene; .omega.-Bromotoluene; CCRIS 5980; EINECS 249-248-3; EINECS 202-847-3; UN1737; Toluene, .alpha.-bromo-; ALPHA-BROMOPHENYLMETHANE; AI3-15300; XR75BS721D; CHEMBL1085946; CHEBI:59858; AGEZXYOZHKGVCM-UHFFFAOYSA-N
DM857X2	DT	Small molecular drug
DM857X2	PC	7498
DM857X2	MW	171.03
DM857X2	FM	C7H7Br
DM857X2	IC	InChI=1S/C7H7Br/c8-6-7-4-2-1-3-5-7/h1-5H,6H2
DM857X2	CS	C1=CC=C(C=C1)CBr
DM857X2	IK	AGEZXYOZHKGVCM-UHFFFAOYSA-N
DM857X2	IU	bromomethylbenzene
DM857X2	CA	CAS 100-39-0
DM857X2	CB	CHEBI:59858
DM857X2	DE	Discovery agent

DMX8W4G	ID	DMX8W4G
DMX8W4G	DN	Benzyl derivative of M6G
DMX8W4G	HS	Investigative
DMX8W4G	SN	CHEMBL366917; Benzyl derivative of M6G
DMX8W4G	DT	Small molecular drug
DMX8W4G	PC	44390359
DMX8W4G	MW	865.1
DMX8W4G	FM	C54H60N2O8
DMX8W4G	IC	InChI=1S/C54H60N2O8/c1-56-28-27-54-43(46(56)29-41-23-24-42(57)30-44(41)54)25-26-45(53(54)59-2)55-49(58)31-47-50(61-33-38-17-9-4-10-18-38)52(63-35-40-21-13-6-14-22-40)51(62-34-39-19-11-5-12-20-39)48(64-47)36-60-32-37-15-7-3-8-16-37/h3-26,30,43,45-48,50-53,57H,27-29,31-36H2,1-2H3,(H,55,58)/t43-,45+,46+,47?,48?,50?,51?,52?,53?,54-/m0/s1
DMX8W4G	CS	CN1CC[C@]23[C@H]([C@H]1CC4=C2C=C(C=C4)O)C=C[C@H](C3OC)NC(=O)CC5C(C(C(C(O5)COCC6=CC=CC=C6)OCC7=CC=CC=C7)OCC8=CC=CC=C8)OCC9=CC=CC=C9
DMX8W4G	IK	AKEFSYMTVVZMKO-GZNILVGYSA-N
DMX8W4G	IU	N-[(1S,9R,10R,13R)-4-hydroxy-14-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-yl]-2-[3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]acetamide
DMX8W4G	DE	Discovery agent

DM6I5MU	ID	DM6I5MU
DM6I5MU	DN	Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine
DM6I5MU	HS	Investigative
DM6I5MU	SN	CHEMBL118944; Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine; SCHEMBL7280806; FNTPEBIGZTYDQK-UHFFFAOYSA-N; BDBM50033290; 4-Phenylmethylamino-2-(1-Imidazolyl)Quinazoline
DM6I5MU	DT	Small molecular drug
DM6I5MU	PC	10266864
DM6I5MU	MW	301.3
DM6I5MU	FM	C18H15N5
DM6I5MU	IC	InChI=1S/C18H15N5/c1-2-6-14(7-3-1)12-20-17-15-8-4-5-9-16(15)21-18(22-17)23-11-10-19-13-23/h1-11,13H,12H2,(H,20,21,22)
DM6I5MU	CS	C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)N4C=CN=C4
DM6I5MU	IK	FNTPEBIGZTYDQK-UHFFFAOYSA-N
DM6I5MU	IU	N-benzyl-2-imidazol-1-ylquinazolin-4-amine
DM6I5MU	DE	Discovery agent

DM3X50C	ID	DM3X50C
DM3X50C	DN	Benzyl-(2-phenyl-quinazolin-4-yl)-amine
DM3X50C	HS	Investigative
DM3X50C	SN	Benzyl-(2-phenyl-quinazolin-4-yl)-amine; N-Benzyl-2-phenyl-4-quinazolinamine; CHEMBL72650; N-benzyl-2-phenylquinazolin-4-amine; AC1LFMYC; BAS 01023367; Oprea1_781281; Oprea1_710967; MLS001210388; SCHEMBL1083763; MolPort-001-952-692; HMS2816J14; KUC104420N; ZINC274067; STL227888; BDBM50033296; KSC-1-145; benzyl(2-phenylquinazolin-4-yl)amine; AKOS000533392; MCULE-1161339740; SMR000515839
DM3X50C	DT	Small molecular drug
DM3X50C	PC	780643
DM3X50C	MW	311.4
DM3X50C	FM	C21H17N3
DM3X50C	IC	InChI=1S/C21H17N3/c1-3-9-16(10-4-1)15-22-21-18-13-7-8-14-19(18)23-20(24-21)17-11-5-2-6-12-17/h1-14H,15H2,(H,22,23,24)
DM3X50C	CS	C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)C4=CC=CC=C4
DM3X50C	IK	WXCHSHPXEPXKFN-UHFFFAOYSA-N
DM3X50C	IU	N-benzyl-2-phenylquinazolin-4-amine
DM3X50C	DE	Discovery agent

DMYDGCI	ID	DMYDGCI
DMYDGCI	DN	Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine
DMYDGCI	HS	Investigative
DMYDGCI	SN	CHEMBL119841; AC1LDIC6; Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine; Oprea1_641196; MLS001163907; cid_667555; ZINC5903; SCHEMBL7286130; MolPort-002-565-372; HMS2878H17; PCOP-956263; BDBM50033284; STK536221; NCGC00012858; AKOS001104531; MCULE-1376892352; NCGC00012858-02; SMR000539306; benzyl(2-(3-pyridyl)quinazolin-4-yl)amine; N-benzyl-2-pyridin-3-ylquinazolin-4-amine; N-Benzyl-2-(3-pyridinyl)quinazolin-4-amine; ST50015136; N-benzyl-2-(pyridin-3-yl)quinazolin-4-amine
DMYDGCI	DT	Small molecular drug
DMYDGCI	PC	667555
DMYDGCI	MW	312.4
DMYDGCI	FM	C20H16N4
DMYDGCI	IC	InChI=1S/C20H16N4/c1-2-7-15(8-3-1)13-22-20-17-10-4-5-11-18(17)23-19(24-20)16-9-6-12-21-14-16/h1-12,14H,13H2,(H,22,23,24)
DMYDGCI	CS	C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)C4=CN=CC=C4
DMYDGCI	IK	AELMNLIYFALJIR-UHFFFAOYSA-N
DMYDGCI	IU	N-benzyl-2-pyridin-3-ylquinazolin-4-amine
DMYDGCI	DE	Discovery agent

DMESVWC	ID	DMESVWC
DMESVWC	DN	Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine
DMESVWC	HS	Investigative
DMESVWC	SN	CHEMBL118462; AC1LJDWH; N-benzyl-2-pyridin-4-ylquinazolin-4-amine; Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine; SCHEMBL7277479; MolPort-000-723-072; ZINC509842; BDBM50033302; AKOS030512862
DMESVWC	DT	Small molecular drug
DMESVWC	PC	921562
DMESVWC	MW	312.4
DMESVWC	FM	C20H16N4
DMESVWC	IC	InChI=1S/C20H16N4/c1-2-6-15(7-3-1)14-22-20-17-8-4-5-9-18(17)23-19(24-20)16-10-12-21-13-11-16/h1-13H,14H2,(H,22,23,24)
DMESVWC	CS	C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)C4=CC=NC=C4
DMESVWC	IK	NZWWYUMFUATSTK-UHFFFAOYSA-N
DMESVWC	IU	N-benzyl-2-pyridin-4-ylquinazolin-4-amine
DMESVWC	DE	Discovery agent

DMH318X	ID	DMH318X
DMH318X	DN	Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine
DMH318X	HS	Investigative
DMH318X	SN	CHEMBL117108; Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine; MLS000334673; SCHEMBL7287132; AC1MA981; HMS3383C08; HMS2596E12; BDBM50033291; MCULE-3637836664; NCGC00184968-01; SMR000249431
DMH318X	DT	Small molecular drug
DMH318X	PC	2573787
DMH318X	MW	317.4
DMH318X	FM	C19H15N3S
DMH318X	IC	InChI=1S/C19H15N3S/c1-2-7-14(8-3-1)13-20-18-15-9-4-5-10-16(15)21-19(22-18)17-11-6-12-23-17/h1-12H,13H2,(H,20,21,22)
DMH318X	CS	C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)C4=CC=CS4
DMH318X	IK	XITKIGBKTNSGCP-UHFFFAOYSA-N
DMH318X	IU	N-benzyl-2-thiophen-2-ylquinazolin-4-amine
DMH318X	DE	Discovery agent

DMFTIMS	ID	DMFTIMS
DMFTIMS	DN	Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine
DMFTIMS	HS	Investigative
DMFTIMS	SN	CHEMBL65850; Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine; ZINC3834030
DMFTIMS	DT	Small molecular drug
DMFTIMS	PC	10424517
DMFTIMS	MW	294.3
DMFTIMS	FM	C18H18N2O2
DMFTIMS	IC	InChI=1S/C18H18N2O2/c1-21-17-9-14-8-15(12-20-16(14)10-18(17)22-2)19-11-13-6-4-3-5-7-13/h3-10,12,19H,11H2,1-2H3
DMFTIMS	CS	COC1=CC2=CC(=CN=C2C=C1OC)NCC3=CC=CC=C3
DMFTIMS	IK	JDKRDQWKIJSKHE-UHFFFAOYSA-N
DMFTIMS	IU	N-benzyl-6,7-dimethoxyquinolin-3-amine
DMFTIMS	DE	Discovery agent

DMW167A	ID	DMW167A
DMW167A	DN	Benzyl-(9H-beta-carbolin-6-yl)-amine
DMW167A	HS	Investigative
DMW167A	SN	N-benzyl-9H-pyrido[3,4-b]indol-6-amine; NSC629813; AC1Q4YVW; AC1L7O8V; CHEMBL54968; ZINC13223121; Benzyl-(9H-; A-carbolin-6-yl)-amine; NCI60_009694; N-Benzyl-9H-beta-carbolin-6-amine hydrochloride
DMW167A	DT	Small molecular drug
DMW167A	PC	364142
DMW167A	MW	273.3
DMW167A	FM	C18H15N3
DMW167A	IC	InChI=1S/C18H15N3/c1-2-4-13(5-3-1)11-20-14-6-7-17-16(10-14)15-8-9-19-12-18(15)21-17/h1-10,12,20-21H,11H2
DMW167A	CS	C1=CC=C(C=C1)CNC2=CC3=C(C=C2)NC4=C3C=CN=C4
DMW167A	IK	QLFFRGDGVGTTAT-UHFFFAOYSA-N
DMW167A	IU	N-benzyl-9H-pyrido[3,4-b]indol-6-amine
DMW167A	DE	Discovery agent

DMNE1M3	ID	DMNE1M3
DMNE1M3	DN	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine
DMNE1M3	HS	Investigative
DMNE1M3	SN	CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine
DMNE1M3	DT	Small molecular drug
DMNE1M3	PC	10730551
DMNE1M3	MW	267.33
DMNE1M3	FM	C15H17N5
DMNE1M3	IC	InChI=1S/C15H17N5/c1-11(2)20-10-19-13-14(17-9-18-15(13)20)16-8-12-6-4-3-5-7-12/h3-7,9-11H,8H2,1-2H3,(H,16,17,18)
DMNE1M3	CS	CC(C)N1C=NC2=C(N=CN=C21)NCC3=CC=CC=C3
DMNE1M3	IK	JBLZWJCKPDQCNX-UHFFFAOYSA-N
DMNE1M3	IU	N-benzyl-9-propan-2-ylpurin-6-amine
DMNE1M3	CA	CAS 111853-20-4
DMNE1M3	DE	Discovery agent

DMTC4G0	ID	DMTC4G0
DMTC4G0	DN	Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine
DMTC4G0	HS	Investigative
DMTC4G0	SN	CHEMBL87137; Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine; SCHEMBL8612003; BDBM50081109
DMTC4G0	DT	Small molecular drug
DMTC4G0	PC	9816808
DMTC4G0	MW	267.33
DMTC4G0	FM	C16H17N3O
DMTC4G0	IC	InChI=1S/C16H17N3O/c1-2-5-13(6-3-1)11-17-9-10-20-16-8-4-7-15-14(16)12-18-19-15/h1-8,12,17H,9-11H2,(H,18,19)
DMTC4G0	CS	C1=CC=C(C=C1)CNCCOC2=CC=CC3=C2C=NN3
DMTC4G0	IK	WYGBVOBBNUHWLX-UHFFFAOYSA-N
DMTC4G0	IU	N-benzyl-2-(1H-indazol-4-yloxy)ethanamine
DMTC4G0	DE	Discovery agent

DMV6DY7	ID	DMV6DY7
DMV6DY7	DN	Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine
DMV6DY7	HS	Investigative
DMV6DY7	SN	CHEMBL64283; Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine; SCHEMBL7206828; ZINC1903142; BDBM50077576
DMV6DY7	DT	Small molecular drug
DMV6DY7	PC	9838216
DMV6DY7	MW	266.34
DMV6DY7	FM	C17H18N2O
DMV6DY7	IC	InChI=1S/C17H18N2O/c1-2-5-14(6-3-1)13-18-11-12-20-17-8-4-7-16-15(17)9-10-19-16/h1-10,18-19H,11-13H2
DMV6DY7	CS	C1=CC=C(C=C1)CNCCOC2=CC=CC3=C2C=CN3
DMV6DY7	IK	ZEHDEZWEFBOGNZ-UHFFFAOYSA-N
DMV6DY7	IU	N-benzyl-2-(1H-indol-4-yloxy)ethanamine
DMV6DY7	DE	Discovery agent

DMRM6ES	ID	DMRM6ES
DMRM6ES	DN	Benzylamine
DMRM6ES	HS	Investigative
DMRM6ES	SN	Aminotoluene; BENZYLAMINE; Benzenemethanamine; Monobenzylamine; Moringine; N-Benzylamine; Phenylmethylamine; Sumine 2005; Sumine 2006; TOLUENE,ALPHA-AMINO; benzyl amine; benzyl-amine; omega-Aminotoluene; phenylmethanamine; (Aminomethyl)benzene; (Phenylmethyl)amine; .alpha.-Aminotoluene; .omega.-Aminotoluene; 1-phenylmethanamine; 100-46-9; 1utj; 1utn; 2bza; A1O31ROR09; AI3-15299; BRN 0741984; CHEBI:40538; CHEMBL522; EINECS 202-854-1; HSDB 2795; MFCD00008106; NSC 8046; UNII-A1O31ROR09; a-Aminotoluene; alpha-Aminotoluene
DMRM6ES	PC	7504
DMRM6ES	MW	107.15
DMRM6ES	FM	C7H9N
DMRM6ES	IC	WGQKYBSKWIADBV-UHFFFAOYSA-N
DMRM6ES	CS	C1=CC=C(C=C1)CN
DMRM6ES	IK	1S/C7H9N/c8-6-7-4-2-1-3-5-7/h1-5H,6,8H2
DMRM6ES	IU	phenylmethanamine
DMRM6ES	CA	CAS 100-46-9
DMRM6ES	CB	CHEBI:40538
DMRM6ES	DE	Functional nausea/vomiting

DMFB4M5	ID	DMFB4M5
DMFB4M5	DN	Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine
DMFB4M5	HS	Investigative
DMFB4M5	SN	CHEMBL490794; N-benzyl-N-[(4-phenylphenyl)methyl]imidazol-1-amine; Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine; AC1LA79Y; BDBM50263717; 1H-Imidazol-1-amine, N-([1,1'-biphenyl]-4-ylmethyl)-N-(phenylmethyl)-
DMFB4M5	DT	Small molecular drug
DMFB4M5	PC	508445
DMFB4M5	MW	339.4
DMFB4M5	FM	C23H21N3
DMFB4M5	IC	InChI=1S/C23H21N3/c1-3-7-20(8-4-1)17-26(25-16-15-24-19-25)18-21-11-13-23(14-12-21)22-9-5-2-6-10-22/h1-16,19H,17-18H2
DMFB4M5	CS	C1=CC=C(C=C1)CN(CC2=CC=C(C=C2)C3=CC=CC=C3)N4C=CN=C4
DMFB4M5	IK	PHOWNTQCWGWFEX-UHFFFAOYSA-N
DMFB4M5	IU	N-benzyl-N-[(4-phenylphenyl)methyl]imidazol-1-amine
DMFB4M5	DE	Discovery agent

DM7M9O2	ID	DM7M9O2
DM7M9O2	DN	Benzylcarbamic Acid Biphenyl-3-yl Ester
DM7M9O2	HS	Investigative
DM7M9O2	SN	CHEMBL485689; Benzylcarbamic Acid Biphenyl-3-yl Ester
DM7M9O2	DT	Small molecular drug
DM7M9O2	PC	24881737
DM7M9O2	MW	303.4
DM7M9O2	FM	C20H17NO2
DM7M9O2	IC	InChI=1S/C20H17NO2/c22-20(21-15-16-8-3-1-4-9-16)23-19-13-7-12-18(14-19)17-10-5-2-6-11-17/h1-14H,15H2,(H,21,22)
DM7M9O2	CS	C1=CC=C(C=C1)CNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DM7M9O2	IK	OSVRGOZPWLNARR-UHFFFAOYSA-N
DM7M9O2	IU	(3-phenylphenyl) N-benzylcarbamate
DM7M9O2	DE	Discovery agent

DMTCYHM	ID	DMTCYHM
DMTCYHM	DN	Benzylcysteine
DMTCYHM	HS	Investigative
DMTCYHM	SN	S-Benzyl-L-cysteine; 3054/1/1; H-Cys(Bzl)-OH; Poly-S-benzylcysteine; (R)-S-Benzylcysteine; (R)-2-amino-3-(benzylthio)propanoic acid; (S)-Benzyl-L-Cys; cysteine, s-(phenylmethyl)-; CHEMBL63130; UNII-9VRE13M548; GHBAYRBVXCRIHT-VIFPVBQESA-N; 9VRE13M548; MFCD00002613; NSC 523123; 25988-62-9; (2R)-2-amino-3-benzylsulfanyl-propanoic acid; B-1025; J-300089; D-S-butylcysteine; BCS; (2R)-2-amino-3-(phenylmethylthio)propanoic acid
DMTCYHM	DT	Small molecular drug
DMTCYHM	PC	193613
DMTCYHM	MW	211.28
DMTCYHM	FM	C10H13NO2S
DMTCYHM	IC	InChI=1S/C10H13NO2S/c11-9(10(12)13)7-14-6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)/t9-/m0/s1
DMTCYHM	CS	C1=CC=C(C=C1)CSC[C@@H](C(=O)O)N
DMTCYHM	IK	GHBAYRBVXCRIHT-VIFPVBQESA-N
DMTCYHM	IU	(2R)-2-amino-3-benzylsulfanylpropanoic acid
DMTCYHM	CA	CAS 3054-01-1
DMTCYHM	DE	Discovery agent

DMNRHSO	ID	DMNRHSO
DMNRHSO	DN	BENZYLIMIDAZOLE
DMNRHSO	HS	Investigative
DMNRHSO	SN	1-Benzylimidazole; 1-Benzyl-1H-imidazole; 4238-71-5; N-Benzylimidazole; Imidazole, 1-benzyl-; BENZYLIMIDAZOLE; 1H-Imidazole, 1-(phenylmethyl)-; 1-BENZYL IMIDAZOLE; CCRIS 5821; EINECS 224-200-4; 1-Benzylimidazole, 99%; NSC 217337; NSC 126828; CHEMBL14192; AI3-52572; MLS000069473; KKKDZZRICRFGSD-UHFFFAOYSA-N; MFCD00005296; SMR000059044; 1BN; 1-benzylimdazole; 2afx; 1-benzyl-imidazole; 3pb9; 1-Benzylimidazole (BI); Maybridge3_003880; Opera_ID_1637; SCHEMBL414; ACMC-209jp9; AC1Q28WR; AC1L2U3N; AC1Q4X5Z; AC1Q28WS; KSC492M7H; MLS001424205
DMNRHSO	DT	Small molecular drug
DMNRHSO	PC	77918
DMNRHSO	MW	158.2
DMNRHSO	FM	C10H10N2
DMNRHSO	IC	InChI=1S/C10H10N2/c1-2-4-10(5-3-1)8-12-7-6-11-9-12/h1-7,9H,8H2
DMNRHSO	CS	C1=CC=C(C=C1)CN2C=CN=C2
DMNRHSO	IK	KKKDZZRICRFGSD-UHFFFAOYSA-N
DMNRHSO	IU	1-benzylimidazole
DMNRHSO	CA	CAS 4238-71-5
DMNRHSO	DE	Discovery agent

DMQAEOL	ID	DMQAEOL
DMQAEOL	DN	Benzyl-methyl-[1-(1H-pyrrol-2-yl)-vinyl]-amine
DMQAEOL	HS	Investigative
DMQAEOL	SN	CHEMBL171809; Benzyl-methyl-[1-(1H-pyrrol-2-yl)-vinyl]-amine
DMQAEOL	DT	Small molecular drug
DMQAEOL	PC	44384137
DMQAEOL	MW	212.29
DMQAEOL	FM	C14H16N2
DMQAEOL	IC	InChI=1S/C14H16N2/c1-12(14-9-6-10-15-14)16(2)11-13-7-4-3-5-8-13/h3-10,15H,1,11H2,2H3
DMQAEOL	CS	CN(CC1=CC=CC=C1)C(=C)C2=CC=CN2
DMQAEOL	IK	UBPBOEOYYZRWQS-UHFFFAOYSA-N
DMQAEOL	IU	N-benzyl-N-methyl-1-(1H-pyrrol-2-yl)ethenamine
DMQAEOL	DE	Discovery agent

DMLJMOD	ID	DMLJMOD
DMLJMOD	DN	Benzyloxycarbonyl-glycylryanodine
DMLJMOD	HS	Investigative
DMLJMOD	SN	Benzyloxycarbonyl-glycylryanodine; CHEMBL28383
DMLJMOD	DT	Small molecular drug
DMLJMOD	PC	44275860
DMLJMOD	MW	684.7
DMLJMOD	FM	C35H44N2O12
DMLJMOD	IC	InChI=1S/C35H44N2O12/c1-19(2)32(43)26(48-25(39)22-12-9-15-36-22)33(44)28(4)18-31(42)29(32,5)35(33,45)34(49-31)24(20(3)13-14-30(28,34)41)47-23(38)16-37-27(40)46-17-21-10-7-6-8-11-21/h6-12,15,19-20,24,26,36,41-45H,13-14,16-18H2,1-5H3,(H,37,40)/t20?,24-,26-,28+,29?,30?,31?,32?,33?,34?,35?/m1/s1
DMLJMOD	CS	CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CNC(=O)OCC6=CC=CC=C6)O4)O)O)OC(=O)C7=CC=CN7)(C(C)C)O)C)O)C)O
DMLJMOD	IK	ZJAWJJNLZWLOIL-JIVHGXQSSA-N
DMLJMOD	IU	[(2R,7S,12R)-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-2-[2-(phenylmethoxycarbonylamino)acetyl]oxy-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMLJMOD	DE	Discovery agent

DM26SR7	ID	DM26SR7
DM26SR7	DN	Benzyloxyresorufin
DM26SR7	HS	Investigative
DM26SR7	SN	Benzyloxyresorfin; 7-Benzyloxyresorufin; J-100240; MCULE-6922850124; O7-Benzylresorufin; Resorufin benzyl ether; SCHEMBL563335; STK299141; ZINC4534147; 3H-Phenoxazin-3-one, 7-(phenylmethoxy)-; 7-(Phenylmethoxy)-3H-phenoxazin-3-one; 7-(benzyloxy)-3H-phenoxazin-3-one; 7-Benzoxyresorufin; 7-Benzyloxy-3H-phenoxazin-3-one; 87687-02-3; AKOS005429005; CTK8D9518; DTXSID90236553; FT-0642066; MFCD00171613; Resorufin benzyl ether CYP450 substrate; Resorufin benzyl ether, CYP450 substrate
DM26SR7	PC	114982
DM26SR7	MW	303.3
DM26SR7	FM	C19H13NO3
DM26SR7	IC	XNZRYTITWLGTJS-UHFFFAOYSA-N
DM26SR7	CS	C1=CC=C(C=C1)COC2=CC3=C(C=C2)N=C4C=CC(=O)C=C4O3
DM26SR7	IK	1S/C19H13NO3/c21-14-6-8-16-18(10-14)23-19-11-15(7-9-17(19)20-16)22-12-13-4-2-1-3-5-13/h1-11H,12H2
DM26SR7	IU	7-phenylmethoxyphenoxazin-3-one
DM26SR7	CA	CAS 87687-02-3
DM26SR7	DE	Discovery agent

DMRW5J4	ID	DMRW5J4
DMRW5J4	DN	Benzyl-quinazolin-4-yl-amine
DMRW5J4	HS	Investigative
DMRW5J4	SN	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; Benzyl-quinazolin-4-yl-amine; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine
DMRW5J4	DT	Small molecular drug
DMRW5J4	PC	6603129
DMRW5J4	MW	271.74
DMRW5J4	FM	C15H14ClN3
DMRW5J4	IC	InChI=1S/C15H13N3.ClH/c1-2-6-12(7-3-1)10-16-15-13-8-4-5-9-14(13)17-11-18-15;/h1-9,11H,10H2,(H,16,17,18);1H
DMRW5J4	CS	C1=CC=C(C=C1)CNC2=NC=NC3=CC=CC=C32.Cl
DMRW5J4	IK	DIKWZEPKULLMFX-UHFFFAOYSA-N
DMRW5J4	IU	N-benzylquinazolin-4-amine;hydrochloride
DMRW5J4	DE	Discovery agent

DMHIGDM	ID	DMHIGDM
DMHIGDM	DN	Benzylserine
DMHIGDM	HS	Investigative
DMHIGDM	SN	O-benzyl-L-serine
DMHIGDM	DT	Small molecular drug
DMHIGDM	PC	78457
DMHIGDM	MW	195.21
DMHIGDM	FM	C10H13NO3
DMHIGDM	IC	InChI=1S/C10H13NO3/c11-9(10(12)13)7-14-6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)/t9-/m0/s1
DMHIGDM	CS	C1=CC=C(C=C1)COC[C@@H](C(=O)O)N
DMHIGDM	IK	IDGQXGPQOGUGIX-VIFPVBQESA-N
DMHIGDM	IU	(2S)-2-amino-3-phenylmethoxypropanoic acid
DMHIGDM	CA	CAS 4726-96-9
DMHIGDM	DE	Discovery agent

DM7XK28	ID	DM7XK28
DM7XK28	DN	Benzylsulfinic Acid
DM7XK28	HS	Investigative
DM7XK28	SN	phenylmethanesulfinic acid; 4403-73-0; Benzenemethanesulfinic acid; Benzylfulfinic acid; AC1MNXPH; SCHEMBL50116; SCHEMBL14899852; MolPort-006-168-965; ZINC12503424
DM7XK28	DT	Small molecular drug
DM7XK28	PC	3311411
DM7XK28	MW	156.2
DM7XK28	FM	C7H8O2S
DM7XK28	IC	InChI=1S/C7H8O2S/c8-10(9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,8,9)
DM7XK28	CS	C1=CC=C(C=C1)CS(=O)O
DM7XK28	IK	NVSONFIVLCXXDH-UHFFFAOYSA-N
DM7XK28	IU	phenylmethanesulfinic acid
DM7XK28	DE	Discovery agent

DMDITNB	ID	DMDITNB
DMDITNB	DN	BERGAPTOL
DMDITNB	HS	Investigative
DMDITNB	SN	Bergaptol; 486-60-2; 5-Hydroxypsoralen; 4-Hydroxy-7H-furo[3,2-g]chromen-7-one; 5-Hydroxyfuranocoumarin; Psoralin, 5-hydroxy-; UNII-KTC8ANI30F; 4-Hydroxybergapten; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-hydroxy-; NSC341958; KTC8ANI30F; 4-oxidanylfuro[3,2-g]chromen-7-one; NSC 341958; 5-Hydroxy-6,7-furanocoumarin; CHEMBL242711; CHEBI:17377; GIJHDGJRTUSBJR-UHFFFAOYSA-N; 4-hydroxyfuro[3,2-g]chromen-7-one; AK158894; Bergaptols; 5-Hydroxy-Psoralen; 5-Hydroxyfurocoumarin; AC1NQWYH; 5-HYDROXY-PSORALIN; 7H-Furo[3, 4-hydroxy-; BSPBio_002390
DMDITNB	DT	Small molecular drug
DMDITNB	PC	5280371
DMDITNB	MW	202.16
DMDITNB	FM	C11H6O4
DMDITNB	IC	InChI=1S/C11H6O4/c12-10-2-1-6-9(15-10)5-8-7(11(6)13)3-4-14-8/h1-5,13H
DMDITNB	CS	C1=CC(=O)OC2=CC3=C(C=CO3)C(=C21)O
DMDITNB	IK	GIJHDGJRTUSBJR-UHFFFAOYSA-N
DMDITNB	IU	4-hydroxyfuro[3,2-g]chromen-7-one
DMDITNB	CA	CAS 486-60-2
DMDITNB	CB	CHEBI:17377
DMDITNB	DE	Discovery agent

DMP21ZO	ID	DMP21ZO
DMP21ZO	DN	Beta-(2-Naphthyl)-Alanine
DMP21ZO	HS	Investigative
DMP21ZO	SN	58438-03-2; 3-(2-Naphthyl)-L-alanine; H-2-Nal-OH; (S)-2-Amino-3-(naphthalen-2-yl)propanoic acid; l-2-naphthylalanine; BETA-(2-NAPHTHYL)-ALANINE; UNII-W425Q6KV9R; L-3-(2-Naphthyl)-alanine; (2S)-2-amino-3-(2-naphthyl)propanoic acid; (s)-2-amino-3-naphthalen-2-yl-propionic acid; W425Q6KV9R; NAL; (2S)-2-amino-3-naphthalen-2-ylpropanoic acid; (2S)-2-amino-3-(naphthalen-2-yl)propanoic acid; 3-(2-Naphthyl)-L-alanine, 98%; 3-(2-Naphthyl)alanine; beta-2-naphthyl-l-alanine; L-beta-(2-Naphthyl)alanine; L-3-(2-NAPHTHYL)ALANINE
DMP21ZO	DT	Small molecular drug
DMP21ZO	PC	185915
DMP21ZO	MW	215.25
DMP21ZO	FM	C13H13NO2
DMP21ZO	IC	InChI=1S/C13H13NO2/c14-12(13(15)16)8-9-5-6-10-3-1-2-4-11(10)7-9/h1-7,12H,8,14H2,(H,15,16)/t12-/m0/s1
DMP21ZO	CS	C1=CC=C2C=C(C=CC2=C1)C[C@@H](C(=O)O)N
DMP21ZO	IK	JPZXHKDZASGCLU-LBPRGKRZSA-N
DMP21ZO	IU	(2S)-2-amino-3-naphthalen-2-ylpropanoic acid
DMP21ZO	CA	CAS 58438-03-2
DMP21ZO	DE	Discovery agent

DM6FHQD	ID	DM6FHQD
DM6FHQD	DN	Beta,beta-dimethylmelatonin
DM6FHQD	HS	Investigative
DM6FHQD	SN	CHEMBL206472; beta,beta-dimethylmelatonin; BDBM50188423
DM6FHQD	DT	Small molecular drug
DM6FHQD	PC	11536239
DM6FHQD	MW	260.329
DM6FHQD	FM	C15H20N2O2
DM6FHQD	IC	InChI=1S/C15H20N2O2/c1-10(18)17-9-15(2,3)13-8-16-14-6-5-11(19-4)7-12(13)14/h5-8,16H,9H2,1-4H3,(H,17,18)
DM6FHQD	CS	CC(=O)NCC(C)(C)C1=CNC2=C1C=C(C=C2)OC
DM6FHQD	IK	OMYMGFDKAPBSGB-UHFFFAOYSA-N
DM6FHQD	IU	N-[2-(5-methoxy-1H-indol-3-yl)-2-methylpropyl]acetamide
DM6FHQD	DE	Discovery agent

DM6GTBC	ID	DM6GTBC
DM6GTBC	DN	Beta-1-C-butenyl-1-deoxygalactonojirimycin
DM6GTBC	HS	Investigative
DM6GTBC	SN	CHEMBL1163562; beta-1-C-butenyl-1-deoxygalactonojirimycin
DM6GTBC	DT	Small molecular drug
DM6GTBC	PC	46906931
DM6GTBC	MW	215.29
DM6GTBC	FM	C11H21NO3
DM6GTBC	IC	InChI=1S/C11H21NO3/c1-3-4-5-8-7(2)10(14)11(15)9(6-13)12-8/h3,7-15H,1,4-6H2,2H3/t7-,8-,9+,10+,11-/m0/s1
DM6GTBC	CS	C[C@H]1[C@@H](N[C@@H]([C@@H]([C@@H]1O)O)CO)CCC=C
DM6GTBC	IK	DJRPURFURDDUBK-DAWVFNFOSA-N
DM6GTBC	IU	(2R,3S,4R,5S,6S)-6-but-3-enyl-2-(hydroxymethyl)-5-methylpiperidine-3,4-diol
DM6GTBC	DE	Discovery agent

DMMKDEZ	ID	DMMKDEZ
DMMKDEZ	DN	Beta-1-C-Butyl-1-deoxygalactonojirimycin
DMMKDEZ	HS	Investigative
DMMKDEZ	SN	CHEMBL1163255; beta-1-C-Butyl-1-deoxygalactonojirimycin
DMMKDEZ	DT	Small molecular drug
DMMKDEZ	PC	46906930
DMMKDEZ	MW	217.31
DMMKDEZ	FM	C11H23NO3
DMMKDEZ	IC	InChI=1S/C11H23NO3/c1-3-4-5-8-7(2)10(14)11(15)9(6-13)12-8/h7-15H,3-6H2,1-2H3/t7-,8-,9+,10+,11-/m0/s1
DMMKDEZ	CS	CCCC[C@H]1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)C
DMMKDEZ	IK	CAVTXTZKYKUABF-DAWVFNFOSA-N
DMMKDEZ	IU	(2R,3S,4R,5S,6S)-6-butyl-2-(hydroxymethyl)-5-methylpiperidine-3,4-diol
DMMKDEZ	DE	Discovery agent

DMBAN5P	ID	DMBAN5P
DMBAN5P	DN	beta3-tetrapeptide
DMBAN5P	HS	Investigative
DMBAN5P	SN	beta3-tetrapeptide
DMBAN5P	DT	Small molecular drug
DMBAN5P	PC	73755026
DMBAN5P	MW	662.8
DMBAN5P	FM	C35H46N6O7
DMBAN5P	IC	InChI=1S/C35H46N6O7/c1-21-30(19-34(46)48-21)40-32(44)17-25(9-5-6-13-36)39-35(47)31(16-24-20-37-29-12-4-3-11-28(24)29)41-33(45)18-26(38-22(2)42)14-23-8-7-10-27(43)15-23/h3-4,7-8,10-12,15,20-21,25-26,30-31,37,43H,5-6,9,13-14,16-19,36H2,1-2H3,(H,38,42)(H,39,47)(H,40,44)(H,41,45)/t21-,25+,26+,30-,31?/m1/s1
DMBAN5P	CS	C[C@@H]1[C@@H](CC(=O)O1)NC(=O)C[C@H](CCCCN)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C[C@H](CC4=CC(=CC=C4)O)NC(=O)C
DMBAN5P	IK	GQYXVIIYXPRQJK-JZYDGZRSSA-N
DMBAN5P	IU	(3S)-3-[[2-[[(3S)-3-acetamido-4-(3-hydroxyphenyl)butanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-7-amino-N-[(2R,3R)-2-methyl-5-oxooxolan-3-yl]heptanamide
DMBAN5P	DE	Discovery agent

DMC64EI	ID	DMC64EI
DMC64EI	DN	Beta-alanine
DMC64EI	HS	Investigative
DMC64EI	SN	beta-alanine; 107-95-9; 3-Aminopropanoic acid; 3-Aminopropionic acid; Beta Alanine; Abufene; H-beta-Ala-OH; beta-Aminopropionic acid; 2-Carboxyethylamine; .beta.-Alanine; Propanoic acid, 3-amino-; Alanine, beta-; 3-Aminopropionsaeure; beta-Ala; beta-Aminopropionsaeure; 3-Aminopropanoate; omega-Aminopropionic acid; B-ALANINE; FEMA No. 3252; 3-amino-propionic acid; beta-Alaine; AI3-18470; .beta.-Aminopropionic acid; NSC 7603; UNII-11P2JDE17B; beta-Alanine, 99%; EINECS 203-536-5; MFCD00008200; 11P2JDE17B; CHEMBL297569; CHEBI:16958; NSC7603
DMC64EI	DT	Small molecular drug
DMC64EI	PC	239
DMC64EI	MW	89.09
DMC64EI	FM	C3H7NO2
DMC64EI	IC	InChI=1S/C3H7NO2/c4-2-1-3(5)6/h1-2,4H2,(H,5,6)
DMC64EI	CS	C(CN)C(=O)O
DMC64EI	IK	UCMIRNVEIXFBKS-UHFFFAOYSA-N
DMC64EI	IU	3-aminopropanoic acid
DMC64EI	CA	CAS 107-95-9
DMC64EI	CB	CHEBI:16958
DMC64EI	DE	Discovery agent

DMN7DJ5	ID	DMN7DJ5
DMN7DJ5	DN	BetaARKct
DMN7DJ5	HS	Investigative
DMN7DJ5	DE	Discovery agent

DM9LT60	ID	DM9LT60
DM9LT60	DN	Beta-Carboline-3-carboxylic acid t-butyl ester
DM9LT60	HS	Investigative
DM9LT60	DT	Small molecular drug
DM9LT60	PC	124514
DM9LT60	MW	268.31
DM9LT60	FM	C16H16N2O2
DM9LT60	IC	InChI=1S/C16H16N2O2/c1-16(2,3)20-15(19)13-8-11-10-6-4-5-7-12(10)18-14(11)9-17-13/h4-9,18H,1-3H3
DM9LT60	CS	CC(C)(C)OC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DM9LT60	IK	FVFFDKKTXYVCCW-UHFFFAOYSA-N
DM9LT60	IU	tert-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9LT60	CA	CAS 93835-05-3

DM1MFTZ	ID	DM1MFTZ
DM1MFTZ	DN	BETA-CCM
DM1MFTZ	HS	Investigative
DM1MFTZ	SN	beta-CCM; Methyl beta-carboline-3-carboxylate; beta-Carboline-3-carboxylic acid methyl ester; 69954-48-9; 3-Carbomethoxy-beta-carboline; UNII-I2A008F6YL; methyl 9H-pyrido[3,4-b]indole-3-carboxylate; CHEMBL453066; CHEMBL268191; I2A008F6YL; Methyl 9H-Pyrido(3,4-b)indole-3-carboxylate; methyl 9H-beta-carboline-3-carboxylate; 9H-beta-Carboline-3-carboxylic acid methyl ester; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, methyl ester; C13H10N2O2; Beta CCM; Lopac-E-002; Biomol-NT_000273; AC1L32LA; Lopac0_000523; SCHEMBL1066725
DM1MFTZ	DT	Small molecular drug
DM1MFTZ	PC	107704
DM1MFTZ	MW	226.23
DM1MFTZ	FM	C13H10N2O2
DM1MFTZ	IC	InChI=1S/C13H10N2O2/c1-17-13(16)11-6-9-8-4-2-3-5-10(8)15-12(9)7-14-11/h2-7,15H,1H3
DM1MFTZ	CS	COC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DM1MFTZ	IK	UKHFPVCOXBJPIN-UHFFFAOYSA-N
DM1MFTZ	IU	methyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM1MFTZ	CA	CAS 69954-48-9
DM1MFTZ	CB	CHEBI:92505
DM1MFTZ	DE	Discovery agent

DMZ2BR9	ID	DMZ2BR9
DMZ2BR9	DN	Beta-D-Glucopyranose Spirohydantoin
DMZ2BR9	HS	Investigative
DMZ2BR9	SN	BETA-D-GLUCOPYRANOSE SPIROHYDANTOIN; CHEMBL510975; GLS; (5S,7R,8S,9S,10R)-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione; 1a8i; AC1L9FVJ; BDBM50263768; 1beta,1-(Iminocarbonyliminocarbonyl)-1-deoxy-D-glucopyranose; (5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione
DMZ2BR9	DT	Small molecular drug
DMZ2BR9	PC	444185
DMZ2BR9	MW	248.19
DMZ2BR9	FM	C8H12N2O7
DMZ2BR9	IC	InChI=1S/C8H12N2O7/c11-1-2-3(12)4(13)5(14)8(17-2)6(15)9-7(16)10-8/h2-5,11-14H,1H2,(H2,9,10,15,16)/t2-,3-,4+,5-,8+/m1/s1
DMZ2BR9	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@]2(O1)C(=O)NC(=O)N2)O)O)O)O
DMZ2BR9	IK	QRXBDPYWCAAAAI-WWHASAIZSA-N
DMZ2BR9	IU	(5S,7R,8S,9S,10R)-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione
DMZ2BR9	DE	Discovery agent

DM5IHYP	ID	DM5IHYP
DM5IHYP	DN	Beta-D-Glucose
DM5IHYP	HS	Investigative
DM5IHYP	SN	beta-D-glucose; beta-D-glucopyranose; 492-61-5; glucoside; b-D-Glucopyranose; beta-glucose; beta-Dextrose; b-Glucose; b-d-glucose; UNII-J4R00M814D; 28905-12-6; .beta.-D-Glucopyranose; 9001-37-0; (2R,3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; CHEMBL1614854; CHEBI:15903; WQZGKKKJIJFFOK-VFUOTHLCSA-N; J4R00M814D; Curdlan; (2R,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; .beta.-D-Glucose; BGC; ZYMOSAN; Glucose, (beta-D)-Isomer; Callose; b-Dextrose; beta-D-Glucopyranose, anhydrous
DM5IHYP	DT	Small molecular drug
DM5IHYP	PC	64689
DM5IHYP	MW	180.16
DM5IHYP	FM	C6H12O6
DM5IHYP	IC	InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6-/m1/s1
DM5IHYP	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)O)O)O)O
DM5IHYP	IK	WQZGKKKJIJFFOK-VFUOTHLCSA-N
DM5IHYP	IU	(2R,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM5IHYP	CA	CAS 492-61-5
DM5IHYP	CB	CHEBI:15903
DM5IHYP	DE	Discovery agent

DMNE4C6	ID	DMNE4C6
DMNE4C6	DN	beta-D-hydroxybutyric acid
DMNE4C6	HS	Investigative
DMNE4C6	SN	3-hydroxybutyrate; (R)-3-hydroxybutanoate
DMNE4C6	DT	Small molecular drug
DMNE4C6	PC	92135
DMNE4C6	MW	104.1
DMNE4C6	FM	C4H8O3
DMNE4C6	IC	InChI=1S/C4H8O3/c1-3(5)2-4(6)7/h3,5H,2H2,1H3,(H,6,7)/t3-/m1/s1
DMNE4C6	CS	C[C@H](CC(=O)O)O
DMNE4C6	IK	WHBMMWSBFZVSSR-GSVOUGTGSA-N
DMNE4C6	IU	(3R)-3-hydroxybutanoic acid
DMNE4C6	CA	CAS 625-72-9
DMNE4C6	CB	CHEBI:17066
DMNE4C6	DE	Discovery agent

DMHIG9K	ID	DMHIG9K
DMHIG9K	DN	Beta-D-Mannose
DMHIG9K	HS	Investigative
DMHIG9K	SN	beta-D-Mannopyranose; beta-D-Mannose; beta-Mannose; 7322-31-8; UNII-CUO87O37MT; (2R,3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; CUO87O37MT; CHEBI:28563; beta-1,4-Mannan; Epitope ID:137485; (1-&gt; 2)-beta-D-mannan; 4)-beta-D-mannan; AC1L97TQ; SCHEMBL396651; 2)-beta-D-mannopyranan; CHEBI:80962; CHEBI:59573; CHEBI:27857; [2)-beta-D-Manp-(1-&gt; WQZGKKKJIJFFOK-RWOPYEJCSA-N; ZINC3830679; GUP; NE16895; C02209; WURCS=2.0/1,1,0/[a1122h-1b_1-5]/1/; (2RS,3S,4S,5S,6R)-6-(Hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol
DMHIG9K	DT	Small molecular drug
DMHIG9K	PC	439680
DMHIG9K	MW	180.16
DMHIG9K	FM	C6H12O6
DMHIG9K	IC	InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6-/m1/s1
DMHIG9K	CS	C([C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O)O)O)O)O
DMHIG9K	IK	WQZGKKKJIJFFOK-RWOPYEJCSA-N
DMHIG9K	IU	(2R,3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMHIG9K	CA	CAS 7322-31-8
DMHIG9K	CB	CHEBI:28563
DMHIG9K	DE	Discovery agent

DM7XC6B	ID	DM7XC6B
DM7XC6B	DN	Beta-endorphin
DM7XC6B	HS	Investigative
DM7XC6B	SN	UNII-3S51P4W3XQ; 3S51P4W3XQ; 61214-51-5; LPH (61-91); beta-Endorphin, human; SCHEMBL6238339; CHEMBL1866903; EINECS 262-330-3; beta-Endorphin human, &gt; NCGC00163196-01; NCGC00163196-02; 27-L-Tyrosine-31-L-glutamic acid-beta-endorphin (sheep); beta-Endorphin (sheep), 27-L-tyrosine-31-L-glutamic acid-
DM7XC6B	DT	Small molecular drug
DM7XC6B	PC	16132316
DM7XC6B	MW	3465
DM7XC6B	FM	C158H251N39O46S
DM7XC6B	IC	InChI=1S/C158H251N39O46S/c1-17-84(9)126(153(237)182-102(44-29-34-65-163)137(221)186-112(74-118(166)206)142(226)171-86(11)131(215)183-110(73-94-48-52-96(204)53-49-94)146(230)177-99(41-26-31-62-160)135(219)175-98(40-25-30-61-159)134(218)170-78-122(210)173-106(158(242)243)56-59-124(213)214)193-154(238)127(85(10)18-2)192-132(216)87(12)172-143(227)113(75-119(167)207)185-136(220)100(42-27-32-63-161)178-147(231)111(72-92-38-23-20-24-39-92)184-144(228)107(68-81(3)4)188-155(239)129(89(14)201)195-152(236)125(83(7)8)191-148(232)108(69-82(5)6)187-151(235)116-45-35-66-197(116)157(241)130(90(15)202)196-140(224)103(54-57-117(165)205)179-149(233)114(79-198)189-138(222)101(43-28-33-64-162)176-139(223)104(55-58-123(211)212)180-150(234)115(80-199)190-156(240)128(88(13)200)194-141(225)105(60-67-244-16)181-145(229)109(71-91-36-21-19-22-37-91)174-121(209)77-168-120(208)76-169-133(217)97(164)70-93-46-50-95(203)51-47-93/h19-24,36-39,46-53,81-90,97-116,125-130,198-204H,17-18,25-35,40-45,54-80,159-164H2,1-16H3,(H2,165,205)(H2,166,206)(H2,167,207)(H,168,208)(H,169,217)(H,170,218)(H,171,226)(H,172,227)(H,173,210)(H,174,209)(H,175,219)(H,176,223)(H,177,230)(H,178,231)(H,179,233)(H,180,234)(H,181,229)(H,182,237)(H,183,215)(H,184,228)(H,185,220)(H,186,221)(H,187,235)(H,188,239)(H,189,222)(H,190,240)(H,191,232)(H,192,216)(H,193,238)(H,194,225)(H,195,236)(H,196,224)(H,211,212)(H,213,214)(H,242,243)/t84-,85-,86-,87-,88+,89+,90+,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,125-,126-,127-,128-,129-,130-/m0/s1
DM7XC6B	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)CNC(=O)[C@H](CC5=CC=C(C=C5)O)N
DM7XC6B	IK	JMHFFDIMOUKDCZ-NTXHZHDSSA-N
DM7XC6B	IU	(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]hexanoyl]amino]acetyl]amino]pentanedioic acid
DM7XC6B	CA	CAS 60617-12-1
DM7XC6B	DE	Discovery agent

DMU3YXR	ID	DMU3YXR
DMU3YXR	DN	beta-ergocriptine
DMU3YXR	HS	Investigative
DMU3YXR	SN	beta-Ergocryptine; beta-Ergokryptine; EINECS 243-728-6; beta-ergocriptine; 5'alpha(S)-sec-Butyl-12'-hydroxy-2'-isopropylergotaman-3',6',18-trione; AC1L4P6P; GTPL988; YYWXOXLDOMRDHW-SGVWFJRMSA-N; PDSP2_001492; AKOS027307800; LS-64294
DMU3YXR	DT	Small molecular drug
DMU3YXR	PC	161309
DMU3YXR	MW	575.7
DMU3YXR	FM	C32H41N5O5
DMU3YXR	IC	InChI=1S/C32H41N5O5/c1-6-18(4)27-29(39)36-12-8-11-25(36)32(41)37(27)30(40)31(42-32,17(2)3)34-28(38)20-13-22-21-9-7-10-23-26(21)19(15-33-23)14-24(22)35(5)16-20/h7,9-10,13,15,17-18,20,24-25,27,33,41H,6,8,11-12,14,16H2,1-5H3,(H,34,38)/t18-,20+,24+,25-,27+,31+,32-/m0/s1
DMU3YXR	CS	CC[C@H](C)[C@@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O
DMU3YXR	IK	YYWXOXLDOMRDHW-SGVWFJRMSA-N
DMU3YXR	IU	(6aR,9R)-N-[(1S,2S,4R,7R)-7-[(2S)-butan-2-yl]-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMU3YXR	DE	Discovery agent

DM25QXM	ID	DM25QXM
DM25QXM	DN	Beta-fructose phosphate
DM25QXM	HS	Investigative
DM25QXM	SN	Beta-D-Fructose 6-phosphate; SCHEMBL8056; ZINC4096690; 1mto; 6-O-phosphono-beta-D-fructofuranose; AC1L99OC; C05345; CHEBI:16084; CHEMBL604196; DTXSID90889361; F6P; WURCS=2.0/1,1,0/[ha122h-2b_2-5_6*OPO/3O/3=O]/1/; beta-D-Fructofuranose 6-phosphoric acid; beta-D-fructofuranose 6-(dihydrogen phosphate); {[(2R,3S,4S,5R)-3,4,5-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methoxy}phosphonic acid
DM25QXM	PC	440641
DM25QXM	MW	260.14
DM25QXM	FM	C6H13O9P
DM25QXM	IC	BGWGXPAPYGQALX-ARQDHWQXSA-N
DM25QXM	CS	C(C1C(C(C(O1)(CO)O)O)O)OP(=O)(O)O
DM25QXM	IK	1S/C6H13O9P/c7-2-6(10)5(9)4(8)3(15-6)1-14-16(11,12)13/h3-5,7-10H,1-2H2,(H2,11,12,13)/t3-,4-,5+,6-/m1/s1
DM25QXM	IU	[(2R,3S,4S,5R)-3,4,5-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl dihydrogen phosphate
DM25QXM	CB	CHEBI:16084
DM25QXM	DE	Discovery agent

DMJORFK	ID	DMJORFK
DMJORFK	DN	Beta-funaltrexamine
DMJORFK	HS	Investigative
DMJORFK	SN	beta-Funaltrexamine; beta-Fna; Naltrexone fumarate methyl ester; 72782-05-9; CHEMBL473136; CHEBI:81527; 2-Butenoic acid, 4-(((5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl)amino)-4-oxo-, methyl ester, (E)-; Beta Funaltrexamine; Beta-Funeltrexamine; SCHEMBL1240811; GTPL1631; ZINC3995756; PDSP2_001549; PDSP2_000394; BDBM50247803; NCGC00163180-01; LS-47116; C18127; methyl 3-[4-cyclopropylmethyl-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-ylcarbamoyl]-
DMJORFK	DT	Small molecular drug
DMJORFK	PC	5311018
DMJORFK	MW	454.5
DMJORFK	FM	C25H30N2O6
DMJORFK	IC	InChI=1S/C25H30N2O6/c1-32-20(30)7-6-19(29)26-16-8-9-25(31)18-12-15-4-5-17(28)22-21(15)24(25,23(16)33-22)10-11-27(18)13-14-2-3-14/h4-7,14,16,18,23,28,31H,2-3,8-13H2,1H3,(H,26,29)/b7-6+/t16-,18-,23+,24+,25-/m1/s1
DMJORFK	CS	COC(=O)/C=C/C(=O)N[C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O
DMJORFK	IK	PQKHESYTSKMWFP-WZJCLRDWSA-N
DMJORFK	IU	methyl (E)-4-[[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]amino]-4-oxobut-2-enoate
DMJORFK	CA	CAS 72782-05-9
DMJORFK	CB	CHEBI:81527
DMJORFK	DE	Discovery agent

DMO8LPZ	ID	DMO8LPZ
DMO8LPZ	DN	Beta-Hydroxy Aspartic Acid
DMO8LPZ	HS	Investigative
DMO8LPZ	SN	71653-06-0; 2-Amino-3-hydroxysuccinic Acid; Malic acid, 3-amino-; 2-amino-3-hydroxybutanedioic acid; d,l-threo-3-HYDROXYASPARTIC ACID; NSC618260; 1860-87-3; CHEBI:83981; 2-amino-3-hydroxy-butanedioic acid; 3-Hydroxy-DL-aspartic acid; Aspartic acid, 3-hydroxy-; D,L-Threo-b-hydroxyaspartic acid; DL-threo-3-Hydroxyaspartic acid; 3-aminomalic acid; EINECS 275-771-1
DMO8LPZ	DT	Small molecular drug
DMO8LPZ	PC	5425
DMO8LPZ	MW	149.1
DMO8LPZ	FM	C4H7NO5
DMO8LPZ	IC	InChI=1S/C4H7NO5/c5-1(3(7)8)2(6)4(9)10/h1-2,6H,5H2,(H,7,8)(H,9,10)
DMO8LPZ	CS	C(C(C(=O)O)O)(C(=O)O)N
DMO8LPZ	IK	YYLQUHNPNCGKJQ-UHFFFAOYSA-N
DMO8LPZ	IU	2-amino-3-hydroxybutanedioic acid
DMO8LPZ	CA	CAS 71653-06-0
DMO8LPZ	CB	CHEBI:83981
DMO8LPZ	DE	Discovery agent

DMGP9MN	ID	DMGP9MN
DMGP9MN	DN	BETA-HYDROXYETHYL THEOPHYLLINE
DMGP9MN	HS	Investigative
DMGP9MN	SN	Etofylline
DMGP9MN	DT	Small molecular drug
DMGP9MN	PC	1892
DMGP9MN	MW	224.22
DMGP9MN	FM	C9H12N4O3
DMGP9MN	IC	InChI=1S/C9H12N4O3/c1-11-7-6(8(15)12(2)9(11)16)13(3-4-14)5-10-7/h5,14H,3-4H2,1-2H3
DMGP9MN	CS	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCO
DMGP9MN	IK	NWPRCRWQMGIBOT-UHFFFAOYSA-N
DMGP9MN	IU	7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione
DMGP9MN	CA	CAS 519-37-9
DMGP9MN	CB	CHEBI:94764
DMGP9MN	DE	Discovery agent

DM6QV8A	ID	DM6QV8A
DM6QV8A	DN	Beta-ionone
DM6QV8A	HS	Investigative
DM6QV8A	SN	BETA-IONONE; beta-Cyclocitrylideneacetone; beta-E-Ionone; trans-beta-Ionone; (3E)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)but-3-en-2-one; (E)-4-(2,6,6-Trimethylcyclohex-1-en-1-yl)but-3-en-2-one; (E)-beta-Ionone; .beta.-Ionone; 14901-07-6; 3-Buten-2-one, 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (3E)-; 4-(2,6,6-Trimethyl-1-cyclohexen-1-yl)-3-buten-2-one; 4-(2,6,6-Trimethyl-1-cyclohexenyl)-3-buten-2-one; 4-(2,6,6-Trimethylcyclohex-1-en-1-yl)but-3-en-2-one; 79-77-6; NSC 402758; UNII-A7NRR1HLH6
DM6QV8A	PC	638014
DM6QV8A	MW	192.3
DM6QV8A	FM	C13H20O
DM6QV8A	IC	PSQYTAPXSHCGMF-BQYQJAHWSA-N
DM6QV8A	CS	CC1=C(C(CCC1)(C)C)C=CC(=O)C
DM6QV8A	IK	1S/C13H20O/c1-10-6-5-9-13(3,4)12(10)8-7-11(2)14/h7-8H,5-6,9H2,1-4H3/b8-7+
DM6QV8A	IU	(E)-4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one
DM6QV8A	CA	CAS 79-77-6
DM6QV8A	CB	CHEBI:32325
DM6QV8A	DE	Breast cancer

DM3BOQA	ID	DM3BOQA
DM3BOQA	DN	Beta-L-fucose
DM3BOQA	HS	Investigative
DM3BOQA	SN	BETA-L-FUCOSE; beta-L-fucopyranose; 6-deoxy-beta-L-galactopyranose; beta-L-Fuc; 6-DEOXY-BETA-L-GALACTOSE; UNII-3MLV1G4S4M; 3MLV1G4S4M; 13224-93-6; (2S,3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol; FUL; MFB; 1rdj; 1ofz; AC1L9H0R; SCHEMBL1259620; CHEBI:42589; beta-L-Galactopyranose, 6-deoxy-; ZINC1532813; AKOS024286278; DB03283; CJ-24261; ST092737; AJ-26816; C20836; A817260; WURCS=2.0/1,1,0/[a1221m-1b_1-5]/1/
DM3BOQA	DT	Small molecular drug
DM3BOQA	PC	444863
DM3BOQA	MW	164.16
DM3BOQA	FM	C6H12O5
DM3BOQA	IC	InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6-/m0/s1
DM3BOQA	CS	C[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)O)O)O)O
DM3BOQA	IK	SHZGCJCMOBCMKK-KGJVWPDLSA-N
DM3BOQA	IU	(2S,3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol
DM3BOQA	CA	CAS 13224-93-6
DM3BOQA	CB	CHEBI:42589
DM3BOQA	DE	Discovery agent

DMA9CSG	ID	DMA9CSG
DMA9CSG	DN	Beta-methoxyamphetamine
DMA9CSG	HS	Investigative
DMA9CSG	SN	4-Methoxyamphetamine; p-Methoxyamphetamine; para-methoxyamphetamine; 1-(4-methoxyphenyl)propan-2-amine; 64-13-1; 1-p-Methoxyphenyl-2-propylamine; 1-p-Methoxyphenyl-2-aminopropane; paramethoxyamphetamine; beta-methoxyamphetamine; 1-(4-Methoxybenzyl)ethylamine; 2-Amino-1-(4'-methoxyphenyl)propane; p-Methoxy-alpha-methylphenethylamine; (+-)-p-Methoxyamphetamine; DEA No 7411; NSC 32757; 50505-80-1; 23239-32-9; DL-p-Methoxy-alpha-methylphenethylamine; (+-)-p-Methoxy-alpha-methylphenethylamine;  Para-Methoxyamphetamine
DMA9CSG	DT	Small molecular drug
DMA9CSG	PC	31721
DMA9CSG	MW	165.23
DMA9CSG	FM	C10H15NO
DMA9CSG	IC	InChI=1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3
DMA9CSG	CS	CC(CC1=CC=C(C=C1)OC)N
DMA9CSG	IK	NEGYEDYHPHMHGK-UHFFFAOYSA-N
DMA9CSG	IU	1-(4-methoxyphenyl)propan-2-amine
DMA9CSG	CA	CAS 64-13-1
DMA9CSG	DE	Discovery agent

DMKH32S	ID	DMKH32S
DMKH32S	DN	Beta-methylmelatonin
DMKH32S	HS	Investigative
DMKH32S	SN	beta-methylmelatonin; CHEMBL210147; SCHEMBL7055939
DMKH32S	DT	Small molecular drug
DMKH32S	PC	11630146
DMKH32S	MW	246.3
DMKH32S	FM	C14H18N2O2
DMKH32S	IC	InChI=1S/C14H18N2O2/c1-9(7-15-10(2)17)13-8-16-14-5-4-11(18-3)6-12(13)14/h4-6,8-9,16H,7H2,1-3H3,(H,15,17)
DMKH32S	CS	CC(CNC(=O)C)C1=CNC2=C1C=C(C=C2)OC
DMKH32S	IK	CKJPQNIMWAHOBV-UHFFFAOYSA-N
DMKH32S	IU	N-[2-(5-methoxy-1H-indol-3-yl)propyl]acetamide
DMKH32S	DE	Discovery agent

DMZ8Y67	ID	DMZ8Y67
DMZ8Y67	DN	Beta-naphthylboronic acid
DMZ8Y67	HS	Investigative
DMZ8Y67	SN	2-Naphthaleneboronic acid; 32316-92-0; Naphthalen-2-ylboronic Acid; 2-Naphthylboronic acid; Naphthalene-2-boronic acid; 2-naphthalene boronic acid; 2-naphthaleneylboronic acid; Naphthalenyl-2-boronic acid; 2-Naphtahaleneboronic acid; beta-naphthylboronic acid; Naphthalen-2-boronic acid; Naphthalen-2-Yl-Boranediol; 2-NAPHTHYLBORONIC CAID; Boronic acid, 2-naphthalenyl-; (naphthalen-2-yl)boronic acid; CHEMBL141079; MFCD00236051; NAPHTHALEN-2-YL-2-BORONIC ACID; 2-Naphthaleneboronic acid, 97+%; Naphthalene-2-boronicacid
DMZ8Y67	DT	Small molecular drug
DMZ8Y67	PC	2734375
DMZ8Y67	MW	171.99
DMZ8Y67	FM	C10H9BO2
DMZ8Y67	IC	InChI=1S/C10H9BO2/c12-11(13)10-6-5-8-3-1-2-4-9(8)7-10/h1-7,12-13H
DMZ8Y67	CS	B(C1=CC2=CC=CC=C2C=C1)(O)O
DMZ8Y67	IK	KPTRDYONBVUWPD-UHFFFAOYSA-N
DMZ8Y67	IU	naphthalen-2-ylboronic acid
DMZ8Y67	CA	CAS 32316-92-0
DMZ8Y67	DE	Discovery agent

DMQXMKB	ID	DMQXMKB
DMQXMKB	DN	Beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide
DMQXMKB	HS	Investigative
DMQXMKB	SN	beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide; proline scaffold, 26; CHEMBL490730; BDBM29377; DB07083; (2S)-1-[(2R)-2-amino-3,3-diphenylpropanoyl]-N-propylpyrrolidine-2-carboxamide
DMQXMKB	DT	Small molecular drug
DMQXMKB	PC	25271577
DMQXMKB	MW	379.5
DMQXMKB	FM	C23H29N3O2
DMQXMKB	IC	InChI=1S/C23H29N3O2/c1-2-15-25-22(27)19-14-9-16-26(19)23(28)21(24)20(17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19-21H,2,9,14-16,24H2,1H3,(H,25,27)/t19-,21+/m0/s1
DMQXMKB	CS	CCCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](C(C2=CC=CC=C2)C3=CC=CC=C3)N
DMQXMKB	IK	HZKKJPDVZGOOPU-PZJWPPBQSA-N
DMQXMKB	IU	(2S)-1-[(2R)-2-amino-3,3-diphenylpropanoyl]-N-propylpyrrolidine-2-carboxamide
DMQXMKB	DE	Discovery agent

DM4MZQW	ID	DM4MZQW
DM4MZQW	DN	BETP
DM4MZQW	HS	Investigative
DM4MZQW	SN	1371569-69-5; (4-(3-Benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine; GTPL7585; SCHEMBL20657432; MolPort-035-765-832; BETP, &gt; BCP19312; AKOS024458341; NCGC00379201-03; KB-271527; HY-103546; CS-0028074; 4-(3-Benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP); 2-ethylsulfinyl-4-(3-phenylmethoxyphenyl)-6-(trifluoromethyl)pyrimidine; 2-(Ethylsulfinyl)-4-[3-(phenylmethoxy)phenyl]-6-(trifluoromethyl)pyrimidine
DM4MZQW	DT	Small molecular drug
DM4MZQW	PC	49868481
DM4MZQW	MW	406.4
DM4MZQW	FM	C20H17F3N2O2S
DM4MZQW	IC	InChI=1S/C20H17F3N2O2S/c1-2-28(26)19-24-17(12-18(25-19)20(21,22)23)15-9-6-10-16(11-15)27-13-14-7-4-3-5-8-14/h3-12H,2,13H2,1H3
DM4MZQW	CS	CCS(=O)C1=NC(=CC(=N1)C(F)(F)F)C2=CC(=CC=C2)OCC3=CC=CC=C3
DM4MZQW	IK	NTDFYGSSDDMNHI-UHFFFAOYSA-N
DM4MZQW	IU	2-ethylsulfinyl-4-(3-phenylmethoxyphenyl)-6-(trifluoromethyl)pyrimidine
DM4MZQW	DE	Discovery agent

DMGQRON	ID	DMGQRON
DMGQRON	DN	BETULIN
DMGQRON	HS	Investigative
DMGQRON	SN	Betulin; 473-98-3; Betulinol; Betuline; Trochol; Lup-20(29)-ene-3b,28-diol; Betulol; Lup-20(29)-ene-3beta,28-diol; UNII-6W70HN7X7O; NSC 4644; C30H50O2; EINECS 207-475-5; Lup-20(30)-ene-3beta,28-diol; AI3-62999; CHEBI:3086; 6W70HN7X7O; Lup-20(29)-ene-3,28-diol, (3beta)-; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(Hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; Betulinic alcohol; lup-20(29)-ene-3 beta,28-diol
DMGQRON	DT	Small molecular drug
DMGQRON	PC	72326
DMGQRON	MW	442.7
DMGQRON	FM	C30H50O2
DMGQRON	IC	InChI=1S/C30H50O2/c1-19(2)20-10-15-30(18-31)17-16-28(6)21(25(20)30)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h20-25,31-32H,1,8-18H2,2-7H3/t20-,21+,22-,23+,24-,25+,27-,28+,29+,30+/m0/s1
DMGQRON	CS	CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)CO
DMGQRON	IK	FVWJYYTZTCVBKE-ROUWMTJPSA-N
DMGQRON	IU	(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol
DMGQRON	CA	CAS 473-98-3
DMGQRON	CB	CHEBI:3086
DMGQRON	DE	Discovery agent

DMOQEZK	ID	DMOQEZK
DMOQEZK	DN	BF/PC-18
DMOQEZK	HS	Investigative
DMOQEZK	SN	PC18-BF; Cathepsin S inhibitor (inflammation), Biofrontera
DMOQEZK	CP	Biofrontera Bioscience GmbH
DMOQEZK	DE	Inflammation

DMCWB1V	ID	DMCWB1V
DMCWB1V	DN	BF/PC-21
DMCWB1V	HS	Investigative
DMCWB1V	SN	Cathepsin X inhibitors (inflammation), Biofrontera
DMCWB1V	CP	Biofrontera Bioscience GmbH
DMCWB1V	DE	Inflammation

DM4XMZW	ID	DM4XMZW
DM4XMZW	DN	BH4
DM4XMZW	HS	Investigative
DM4XMZW	DT	Small molecular drug
DM4XMZW	PC	135398654
DM4XMZW	MW	241.25
DM4XMZW	FM	C9H15N5O3
DM4XMZW	IC	InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4+,6-/m0/s1
DM4XMZW	CS	C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DM4XMZW	IK	FNKQXYHWGSIFBK-RPDRRWSUSA-N
DM4XMZW	IU	(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one
DM4XMZW	CA	CAS 62989-33-7
DM4XMZW	CB	CHEBI:59560
DM4XMZW	DE	Discovery agent

DMP21ST	ID	DMP21ST
DMP21ST	DN	BHF-177
DMP21ST	HS	Investigative
DMP21ST	SN	Allosteric GABA B receptor modulators, Novartis; CGP-13501; CGP-7930; CPG-37656; GS-39783
DMP21ST	CP	Novartis AG
DMP21ST	DT	Small molecular drug
DMP21ST	PC	56940925
DMP21ST	MW	347.4
DMP21ST	FM	C19H20F3N3
DMP21ST	IC	InChI=1S/C19H20F3N3/c1-11-23-10-16(13-4-6-15(7-5-13)19(20,21)22)18(24-11)25-17-9-12-2-3-14(17)8-12/h4-7,10,12,14,17H,2-3,8-9H2,1H3,(H,23,24,25)/t12-,14+,17+/m0/s1
DMP21ST	CS	CC1=NC=C(C(=N1)N[C@@H]2C[C@H]3CC[C@@H]2C3)C4=CC=C(C=C4)C(F)(F)F
DMP21ST	IK	ADHZHPOKTRHZGT-DXCKQFNASA-N
DMP21ST	IU	N-[(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]-2-methyl-5-[4-(trifluoromethyl)phenyl]pyrimidin-4-amine
DMP21ST	CA	CAS 917896-43-6
DMP21ST	DE	Anxiety disorder

DMVH4LK	ID	DMVH4LK
DMVH4LK	DN	Bhg-F-N-Y-Y-W
DMVH4LK	HS	Investigative
DMVH4LK	SN	CHEMBL414917; bhg-F-N-Y-Y-W
DMVH4LK	PC	44371614
DMVH4LK	MW	1041.2
DMVH4LK	FM	C59H60N8O10
DMVH4LK	IC	InChI=1S/C59H60N8O10/c60-51(70)32-49(65-55(72)48(28-34-10-2-1-3-11-34)66-58(75)53(61)52-43-15-6-4-12-37(43)22-23-38-13-5-7-16-44(38)52)57(74)64-46(29-35-18-24-40(68)25-19-35)54(71)63-47(30-36-20-26-41(69)27-21-36)56(73)67-50(59(76)77)31-39-33-62-45-17-9-8-14-42(39)45/h1-21,24-27,33,46-50,52-53,62,68-69H,22-23,28-32,61H2,(H2,60,70)(H,63,71)(H,64,74)(H,65,72)(H,66,75)(H,67,73)(H,76,77)/t46-,47-,48-,49-,50-,53-/m0/s1
DMVH4LK	CS	C1CC2=CC=CC=C2C(C3=CC=CC=C31)[C@@H](C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)O)N
DMVH4LK	IK	ODHKJPGCAWIPPT-ZQJLCUDRSA-N
DMVH4LK	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)acetyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMVH4LK	DE	Discovery agent

DMZRS7A	ID	DMZRS7A
DMZRS7A	DN	BHT-3034
DMZRS7A	HS	Investigative
DMZRS7A	SN	RBHT-3034; Immunomodulator (myasthenia gravis), Bayhill
DMZRS7A	CP	Bayhill Therapeutics Inc
DMZRS7A	DE	Myasthenia gravis

DMI3ANC	ID	DMI3ANC
DMI3ANC	DN	BI 7273
DMI3ANC	HS	Investigative
DMI3ANC	SN	BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221
DMI3ANC	DT	Small molecular drug
DMI3ANC	PC	118796358
DMI3ANC	MW	353.4
DMI3ANC	FM	C20H23N3O3
DMI3ANC	IC	InChI=1S/C20H23N3O3/c1-22(2)11-17-18(25-4)8-13(9-19(17)26-5)16-12-23(3)20(24)15-10-21-7-6-14(15)16/h6-10,12H,11H2,1-5H3
DMI3ANC	CS	CN1C=C(C2=C(C1=O)C=NC=C2)C3=CC(=C(C(=C3)OC)CN(C)C)OC
DMI3ANC	IK	RBUYFHLQNPJMQM-UHFFFAOYSA-N
DMI3ANC	IU	4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one
DMI3ANC	DE	Acute myeloid leukaemia

DMN052T	ID	DMN052T
DMN052T	DN	BI-32169
DMN052T	HS	Investigative
DMN052T	SN	BI-32169; CHEMBL526383
DMN052T	PC	44584360
DMN052T	MW	2037.3
DMN052T	FM	C95H125N23O24S2
DMN052T	IC	InChI=1S/C95H125N23O24S2/c1-7-48(4)78-93(139)117-30-14-24-69(117)87(133)102-43-75(123)104-61(34-52-39-98-58-22-12-9-19-55(52)58)84(130)107-63(36-73(96)121)85(131)114-79(50(6)120)94(140)118-31-17-27-72(118)89(135)110-62(35-53-40-99-59-23-13-10-20-56(53)59)83(129)103-49(5)80(126)112-68(95(141)142)46-144-143-45-67-92(138)116-29-16-26-71(116)90(136)111-66(44-119)86(132)108-64(37-74(122)113-78)82(128)101-41-76(124)105-65(32-47(2)3)91(137)115-28-15-25-70(115)88(134)109-60(81(127)100-42-77(125)106-67)33-51-38-97-57-21-11-8-18-54(51)57/h8-13,18-23,38-40,47-50,60-72,78-79,97-99,119-120H,7,14-17,24-37,41-46H2,1-6H3,(H2,96,121)(H,100,127)(H,101,128)(H,102,133)(H,103,129)(H,104,123)(H,105,124)(H,106,125)(H,107,130)(H,108,132)(H,109,134)(H,110,135)(H,111,136)(H,112,126)(H,113,122)(H,114,131)(H,141,142)/t48-,49-,50+,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,78-,79-/m0/s1
DMN052T	CS	CC[C@H](C)[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N[C@@H](CC(=O)N1)C(=O)NCC(=O)N[C@H](C(=O)N6CCC[C@H]6C(=O)N[C@H](C(=O)NCC(=O)N4)CC7=CNC8=CC=CC=C87)CC(C)C)CO)C(=O)O)C)CC9=CNC1=CC=CC=C19)[C@@H](C)O)CC(=O)N)CC1=CNC2=CC=CC=C21
DMN052T	IK	VXOKYTDMQDFAQT-VJFZWUEESA-N
DMN052T	IU	(1S,5S,11S,17S,20S,23S,29S,32S,35S,38R,43R,49S,52S,58S,66S,69S)-20-(2-amino-2-oxoethyl)-5-[(2S)-butan-2-yl]-23-[(1R)-1-hydroxyethyl]-66-(hydroxymethyl)-17,32,49-tris(1H-indol-3-ylmethyl)-35-methyl-58-(2-methylpropyl)-3,6,12,15,18,21,24,30,33,36,45,48,51,57,60,63,65,68,74-nonadecaoxo-40,41-dithia-4,7,13,16,19,22,25,31,34,37,44,47,50,56,59,62,64,67,73-nonadecazahexacyclo[41.20.11.07,11.025,29.052,56.069,73]tetraheptacontane-38-carboxylic acid
DMN052T	DE	Discovery agent

DMRXK5G	ID	DMRXK5G
DMRXK5G	DN	BI6015
DMRXK5G	HS	Investigative
DMRXK5G	SN	BI 6015; BI-6015
DMRXK5G	DT	Small molecular drug
DMRXK5G	PC	3269393
DMRXK5G	MW	331.3
DMRXK5G	FM	C15H13N3O4S
DMRXK5G	IC	InChI=1S/C15H13N3O4S/c1-10-7-8-12(18(19)20)9-15(10)23(21,22)17-11(2)16-13-5-3-4-6-14(13)17/h3-9H,1-2H3
DMRXK5G	CS	CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N2C(=NC3=CC=CC=C32)C
DMRXK5G	IK	ILVCPQPMRPHZSG-UHFFFAOYSA-N
DMRXK5G	IU	2-methyl-1-(2-methyl-5-nitrophenyl)sulfonylbenzimidazole
DMRXK5G	DE	Discovery agent

DM4RZ9A	ID	DM4RZ9A
DM4RZ9A	DN	BIA
DM4RZ9A	HS	Investigative
DM4RZ9A	SN	UNII-X6H65DT067; X6H65DT067; 1-(3,4,DIHYDROXY-5-NITROPHENYL)-3-{4-[3-(TRIFLUOROMETHYL) PHENYL] PIPERAZIN-1-YL}PROPAN-1-ONE; BIA-3-335; BIA-3-335 free base; 1-(3,4-dihydroxy-5-nitrophenyl)-3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propan-1-one; 1-(3,4-dihydroxy-5-nitrophenyl)-3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propan-1-one; 1h1d; AC1N9ZVE; CHEMBL387347; DB03336; 747401-28-1; 1-Propanone, 1-(3,4-dihydroxy-5-nitrophenyl)-3-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)-
DM4RZ9A	DT	Small molecular drug
DM4RZ9A	PC	4369285
DM4RZ9A	MW	439.4
DM4RZ9A	FM	C20H20F3N3O5
DM4RZ9A	IC	InChI=1S/C20H20F3N3O5/c21-20(22,23)14-2-1-3-15(12-14)25-8-6-24(7-9-25)5-4-17(27)13-10-16(26(30)31)19(29)18(28)11-13/h1-3,10-12,28-29H,4-9H2
DM4RZ9A	CS	C1CN(CCN1CCC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-])C3=CC=CC(=C3)C(F)(F)F
DM4RZ9A	IK	KVIVJQWOYSWCCZ-UHFFFAOYSA-N
DM4RZ9A	IU	1-(3,4-dihydroxy-5-nitrophenyl)-3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propan-1-one
DM4RZ9A	CA	CAS 747401-28-1
DM4RZ9A	DE	Non-insulin dependent diabetes

DMUWO6D	ID	DMUWO6D
DMUWO6D	DN	BIBF100
DMUWO6D	HS	Investigative
DMUWO6D	CP	Boehringer Ingelheim
DMUWO6D	DE	Multiple myeloma

DMDTLSP	ID	DMDTLSP
DMDTLSP	DN	BIBF-1202
DMDTLSP	HS	Investigative
DMDTLSP	SN	BIBF 1202
DMDTLSP	DT	Small molecular drug
DMDTLSP	PC	135461425
DMDTLSP	MW	525.6
DMDTLSP	FM	C30H31N5O4
DMDTLSP	IC	InChI=1S/C30H31N5O4/c1-33-14-16-35(17-15-33)19-26(36)34(2)23-11-9-22(10-12-23)31-28(20-6-4-3-5-7-20)27-24-13-8-21(30(38)39)18-25(24)32-29(27)37/h3-13,18,32,37H,14-17,19H2,1-2H3,(H,38,39)
DMDTLSP	CS	CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)O)O
DMDTLSP	IK	SDJMWYVJAVLZEG-UHFFFAOYSA-N
DMDTLSP	IU	2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylic acid
DMDTLSP	DE	Discovery agent

DML7HFP	ID	DML7HFP
DML7HFP	DN	BIBO3304
DML7HFP	HS	Investigative
DML7HFP	SN	UNII-QKC82E736Q; BIBO3304; QKC82E736Q; CHEMBL1774204; 191868-14-1; BIBO-3304; BIBO 3304 TRIFLUOROACETATE; BIBO-3304 free base; AC1NSJUH; 191868-13-0; GTPL1528; SCHEMBL6899864; CTK8E9767; ZINC3952359; BDBM50343731; AKOS024457083; Benzeneacetamide, N-(1-((((4-(((aminocarbonyl)amino)methyl)phenyl)methyl)amino)carbonyl)-4-((aminoiminomethyl)amino)butyl)-alpha-phenyl-, (R)-; Benzeneacetamide, N-((1R)-1-((((4-(((aminocarbonyl)amino)methyl)phenyl)methyl)amino)carbonyl)-4-((aminoiminomethyl)amino)butyl)-alpha-phenyl-; RT-011503
DML7HFP	DT	Small molecular drug
DML7HFP	PC	5311022
DML7HFP	MW	529.6
DML7HFP	FM	C29H35N7O3
DML7HFP	IC	InChI=1S/C29H35N7O3/c30-28(31)33-17-7-12-24(26(37)34-18-20-13-15-21(16-14-20)19-35-29(32)39)36-27(38)25(22-8-3-1-4-9-22)23-10-5-2-6-11-23/h1-6,8-11,13-16,24-25H,7,12,17-19H2,(H,34,37)(H,36,38)(H4,30,31,33)(H3,32,35,39)/t24-/m1/s1
DML7HFP	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)CNC(=O)N
DML7HFP	IK	TVMJSGGZULFVCZ-XMMPIXPASA-N
DML7HFP	IU	(2R)-N-[[4-[(carbamoylamino)methyl]phenyl]methyl]-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]pentanamide
DML7HFP	CA	CAS 191868-13-0
DML7HFP	DE	Discovery agent

DMFS2V9	ID	DMFS2V9
DMFS2V9	DN	BIC1
DMFS2V9	HS	Investigative
DMFS2V9	SN	CHEMBL1738777; 1-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]-3-methyl-1,3-dihydro-2H-benzimidazole-2-thione; 1-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]-3-methylbenzimidazole-2-thione; BIC1; AC1LDQIR; TimTec1_003670; Oprea1_027553; 433249-32-2; GTPL7510; SCHEMBL8248939; ZINC34355; MolPort-000-901-027; HMS1544G18; BDBM50365462; STK767484; AKOS003573654; MCULE-4889087096; 1-[2-(1h-benzimidazol-2-ylthio)ethyl]-1,3-dihydro-3-methyl-2h-benzimidazole-2-thione; ST049583; KB-258991; SR-01000537551; SR-01000537551-1; BRD-K75297647-001-01-4
DMFS2V9	DT	Small molecular drug
DMFS2V9	PC	672548
DMFS2V9	MW	340.5
DMFS2V9	FM	C17H16N4S2
DMFS2V9	IC	InChI=1S/C17H16N4S2/c1-20-14-8-4-5-9-15(14)21(17(20)22)10-11-23-16-18-12-6-2-3-7-13(12)19-16/h2-9H,10-11H2,1H3,(H,18,19)
DMFS2V9	CS	CN1C2=CC=CC=C2N(C1=S)CCSC3=NC4=CC=CC=C4N3
DMFS2V9	IK	KDPSGIFCBZTBEZ-UHFFFAOYSA-N
DMFS2V9	IU	1-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]-3-methylbenzimidazole-2-thione
DMFS2V9	DE	Discovery agent

DMT5E36	ID	DMT5E36
DMT5E36	DN	Bicarbonate
DMT5E36	HS	Investigative
DMT5E36	SN	bicarbonate; Hydrogen carbonate; Bicarbonate ion; Carbonate, hydrogen; Hydrogencarbonate; Bicarbonate ions; 71-52-3; UNII-HN1ZRA3Q20; HCO3-; HN1ZRA3Q20; Bicarbonate anion; Hydrocarbonate(1-); Monohydrogen carbonate; Hydrogen carbonate ion; Hydrogen carbonate anion; Carbonate (HCO31-); Bicarbonates; Carbonate ion (HCO31-); Carboxyolate; Acid carbonate; hydrogen-carbonate; HYDROXYFORMATE; hydrogencarbonate(1-); HCO3; Carbonic acid, ion(1-); hydrogentrioxocarbonate(IV); hydrogentrioxocarbonate(1-); AC1L19ZH
DMT5E36	DT	Small molecular drug
DMT5E36	PC	769
DMT5E36	MW	61.017
DMT5E36	FM	CHO3-
DMT5E36	IC	InChI=1S/CH2O3/c2-1(3)4/h(H2,2,3,4)/p-1
DMT5E36	CS	C(=O)(O)[O-]
DMT5E36	IK	BVKZGUZCCUSVTD-UHFFFAOYSA-M
DMT5E36	IU	hydrogen carbonate
DMT5E36	CA	CAS 71-52-3
DMT5E36	CB	CHEBI:17544
DMT5E36	DE	Discovery agent

DMTRDPI	ID	DMTRDPI
DMTRDPI	DN	Bicine
DMTRDPI	HS	Investigative
DMTRDPI	SN	Bicine; 150-25-4; N,N-Bis(2-hydroxyethyl)glycine; Diethylolglycine; Dihydroxyethylglycine; 2-(bis(2-hydroxyethyl)amino)acetic acid; Diethanol glycine; N,N-Di(2-hydroxyethyl)glycine; Bicene; N,N-Dihydroxyethylglycine; N,N-Dihydroxyethyl glycine; Fe-3-Specific; DHEG; Glycine, N,N-bis(2-hydroxyethyl)-; Bis(2-Hydroxyethyl)glycine; N,N-(2-Hydroxyethyl)glycine; 2-[bis(2-hydroxyethyl)amino]acetic acid; N,N-Bis(2-hydroxyethyl)aminoacetic acid; N,N-Bis(beta-hydroxyethyl)glycine; NSC 7342; GLYCINE, N,N-DIHYDROXYETHYL-; UNII-1J484QFI1O
DMTRDPI	DT	Small molecular drug
DMTRDPI	PC	8761
DMTRDPI	MW	163.17
DMTRDPI	FM	C6H13NO4
DMTRDPI	IC	InChI=1S/C6H13NO4/c8-3-1-7(2-4-9)5-6(10)11/h8-9H,1-5H2,(H,10,11)
DMTRDPI	CS	C(CO)N(CCO)CC(=O)O
DMTRDPI	IK	FSVCELGFZIQNCK-UHFFFAOYSA-N
DMTRDPI	IU	2-[bis(2-hydroxyethyl)amino]acetic acid
DMTRDPI	CA	CAS 150-25-4
DMTRDPI	CB	CHEBI:40957
DMTRDPI	DE	Discovery agent

DMA6VQW	ID	DMA6VQW
DMA6VQW	DN	Bicuculline
DMA6VQW	HS	Investigative
DMA6VQW	SN	(+)-Bicuculline; bicuculline; d-Bicuculline; 485-49-4; Bicculine; Bicucullin; Bicuculline (+); UNII-Y37615DVKC; NSC 32192; C20H17NO6; EINECS 207-619-7; BRN 0098786; CHEMBL417990; CHEBI:3092; Y37615DVKC; (6R)-6-[(5S)-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]furo[3,4-e][1,3]benzodioxol-8(6H)-one; NSC32192; Furo(3,4-e)-1,3-benzodioxol-8(6H)-one, 6-(5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (R-(R*,S*))-
DMA6VQW	DT	Small molecular drug
DMA6VQW	PC	10237
DMA6VQW	MW	367.4
DMA6VQW	FM	C20H17NO6
DMA6VQW	IC	InChI=1S/C20H17NO6/c1-21-5-4-10-6-14-15(25-8-24-14)7-12(10)17(21)18-11-2-3-13-19(26-9-23-13)16(11)20(22)27-18/h2-3,6-7,17-18H,4-5,8-9H2,1H3/t17-,18+/m0/s1
DMA6VQW	CS	CN1CCC2=CC3=C(C=C2[C@H]1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3
DMA6VQW	IK	IYGYMKDQCDOMRE-ZWKOTPCHSA-N
DMA6VQW	IU	(6R)-6-[(5S)-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6H-furo[3,4-g][1,3]benzodioxol-8-one
DMA6VQW	CA	CAS 485-49-4
DMA6VQW	CB	CHEBI:3092
DMA6VQW	DE	Discovery agent

DM4MUXT	ID	DM4MUXT
DM4MUXT	DN	BIFENOX
DM4MUXT	HS	Investigative
DM4MUXT	SN	BIFENOX; 42576-02-3; Methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate; Modown; Caswell No. 561AA; MC-4379; 5-(2,4-Dichlorophenoxy)-2-nitrobenzoic acid methyl ester; UNII-KSB85XT26Y; Bifenox [ANSI:BSI:ISO]; CCRIS 7158; Benzoic acid, 5-(2,4-dichlorophenoxy)-2-nitro-, methyl ester; HSDB 6567; EINECS 255-894-7; EPA Pesticide Chemical Code 104301; BRN 2170169; KSB85XT26Y; CHEMBL449928; CHEBI:6613; SUSRORUBZHMPCO-UHFFFAOYSA-N; W-110976; Modown 4 flowable; MODOWN(R); AC1L21BG; DSSTox_RID_79477; DSSTox_CID_20320; DSSTox_GSID_40320
DM4MUXT	DT	Small molecular drug
DM4MUXT	PC	39230
DM4MUXT	MW	342.1
DM4MUXT	FM	C14H9Cl2NO5
DM4MUXT	IC	InChI=1S/C14H9Cl2NO5/c1-21-14(18)10-7-9(3-4-12(10)17(19)20)22-13-5-2-8(15)6-11(13)16/h2-7H,1H3
DM4MUXT	CS	COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-]
DM4MUXT	IK	SUSRORUBZHMPCO-UHFFFAOYSA-N
DM4MUXT	IU	methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate
DM4MUXT	CA	CAS 42576-02-3
DM4MUXT	CB	CHEBI:6613
DM4MUXT	DE	Discovery agent

DML4DQ3	ID	DML4DQ3
DML4DQ3	DN	BIIB-513
DML4DQ3	HS	Investigative
DML4DQ3	SN	NHE-1 inhibitors (myocardial infarction/reperfusion injury); NHE-1 inhibitors (myocardial infarction/reperfusion injury), Boehringer Ingelheim
DML4DQ3	CP	Boehringer Ingelheim Corp
DML4DQ3	DT	Small molecular drug
DML4DQ3	PC	6918374
DML4DQ3	MW	515.6
DML4DQ3	FM	C19H25N5O8S2
DML4DQ3	IC	InChI=1S/C18H21N5O5S.CH4O3S/c1-29(26,27)15-11-12(16(24)21-18(19)20)4-5-13(15)22-6-8-23(9-7-22)17(25)14-3-2-10-28-14;1-5(2,3)4/h2-5,10-11H,6-9H2,1H3,(H4,19,20,21,24);1H3,(H,2,3,4)
DML4DQ3	CS	CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)N2CCN(CC2)C(=O)C3=CC=CO3.CS(=O)(=O)O
DML4DQ3	IK	CIZHNWRBNREPCL-UHFFFAOYSA-N
DML4DQ3	IU	N-(diaminomethylidene)-4-[4-(furan-2-carbonyl)piperazin-1-yl]-3-methylsulfonylbenzamide;methanesulfonic acid
DML4DQ3	CA	CAS 265986-98-9
DML4DQ3	DE	Myocardial infarction

DMR2SEB	ID	DMR2SEB
DMR2SEB	DN	BIIE0246
DMR2SEB	HS	Investigative
DMR2SEB	SN	BIIE 0246; BIIE-0246
DMR2SEB	DT	Small molecular drug
DMR2SEB	PC	5311024
DMR2SEB	MW	896
DMR2SEB	FM	C49H57N11O6
DMR2SEB	IC	InChI=1S/C49H57N11O6/c50-46(51)53-25-13-22-40(45(64)52-26-27-58-47(65)59(34-14-3-1-4-15-34)60(48(58)66)35-16-5-2-6-17-35)54-41(61)32-49(23-11-12-24-49)33-42(62)56-28-30-57(31-29-56)43-36-18-7-8-19-37(36)44(63)55-39-21-10-9-20-38(39)43/h1-10,14-21,40,43H,11-13,22-33H2,(H,52,64)(H,54,61)(H,55,63)(H4,50,51,53)
DMR2SEB	CS	C1CCC(C1)(CC(=O)NC(CCCN=C(N)N)C(=O)NCCN2C(=O)N(N(C2=O)C3=CC=CC=C3)C4=CC=CC=C4)CC(=O)N5CCN(CC5)C6C7=CC=CC=C7C(=O)NC8=CC=CC=C68
DMR2SEB	IK	RSJAXPUYVJKAAA-UHFFFAOYSA-N
DMR2SEB	IU	5-(diaminomethylideneamino)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-2-[[2-[1-[2-oxo-2-[4-(6-oxo-5,11-dihydrobenzo[c][1]benzazepin-11-yl)piperazin-1-yl]ethyl]cyclopentyl]acetyl]amino]pentanamide
DMR2SEB	CA	CAS 246146-55-4
DMR2SEB	DE	Discovery agent

DMU09E4	ID	DMU09E4
DMU09E4	DN	BIIL 260
DMU09E4	HS	Investigative
DMU09E4	SN	BIIL-260; BIIL260
DMU09E4	DT	Small molecular drug
DMU09E4	PC	9956189
DMU09E4	MW	466.6
DMU09E4	FM	C30H30N2O3
DMU09E4	IC	InChI=1S/C30H30N2O3/c1-30(2,24-8-12-26(33)13-9-24)25-10-16-28(17-11-25)35-20-22-5-3-4-21(18-22)19-34-27-14-6-23(7-15-27)29(31)32/h3-18,33H,19-20H2,1-2H3,(H3,31,32)
DMU09E4	CS	CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCC3=CC=CC(=C3)COC4=CC=C(C=C4)C(=N)N
DMU09E4	IK	MBLJFKQACMILLC-UHFFFAOYSA-N
DMU09E4	IU	4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]benzenecarboximidamide
DMU09E4	CA	CAS 204974-93-6
DMU09E4	DE	Discovery agent

DMIY2HW	ID	DMIY2HW
DMIY2HW	DN	Bile acid
DMIY2HW	HS	Investigative
DMIY2HW	SN	SCHEMBL18394606; CHEMBL1258080; BDBM21679; 23(S)-methyl-BA derivative, 7c; (2S,4R)-4-[(1S,2S,5R,7S,8R,9R,10S,11S,14R,15R)-8-ethyl-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-2-methylpentanoic acid
DMIY2HW	DT	Small molecular drug
DMIY2HW	PC	439520
DMIY2HW	MW	408.6
DMIY2HW	FM	C24H40O5
DMIY2HW	IC	InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13?,14-,15+,16?,17?,18?,19+,20-,22?,23?,24?/m0/s1
DMIY2HW	CS	CC(CCC(=O)O)C1CCC2C1([C@H](CC3C2[C@@H](C[C@H]4C3(CC[C@H](C4)O)C)O)O)C
DMIY2HW	IK	BHQCQFFYRZLCQQ-UMZBRFQRSA-N
DMIY2HW	IU	4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMIY2HW	CB	CHEBI:22868
DMIY2HW	DE	Discovery agent

DMI0V4O	ID	DMI0V4O
DMI0V4O	DN	Bilirubin
DMI0V4O	HS	Investigative
DMI0V4O	SN	bilirubin; 635-65-4; Hematoidin; Hemetoidin; Principal bile pigment; UNII-RFM9X3LJ49; Bilirubin IXalpha; Bilirubin IX-alpha; EINECS 211-239-7; NSC 26685; BRN 0074376; RFM9X3LJ49; AI3-23078; 21H-Biline-8,12-dipropanoic acid, 2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-; CHEBI:16990; BPYKTIZUTYGOLE-IFADSCNNSA-N; PHEOPHYTIN; MFCD00005499; Bilirubin, 99%; Biline-8,12-dipropionic acid, 1,10,19,22,23,24-hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-
DMI0V4O	DT	Small molecular drug
DMI0V4O	PC	5280352
DMI0V4O	MW	584.7
DMI0V4O	FM	C33H36N4O6
DMI0V4O	IC	InChI=1S/C33H36N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h7-8,13-14,34-35H,1-2,9-12,15H2,3-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/b26-13-,27-14-
DMI0V4O	CS	CC1=C(NC(=C1CCC(=O)O)CC2=C(C(=C(N2)/C=C\\3/C(=C(C(=O)N3)C)C=C)C)CCC(=O)O)/C=C\\4/C(=C(C(=O)N4)C=C)C
DMI0V4O	IK	BPYKTIZUTYGOLE-IFADSCNNSA-N
DMI0V4O	IU	3-[2-[[3-(2-carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
DMI0V4O	CA	CAS 635-65-4
DMI0V4O	CB	CHEBI:16990
DMI0V4O	DE	Discovery agent

DMCA0WJ	ID	DMCA0WJ
DMCA0WJ	DN	Biliverdine Ix Alpha
DMCA0WJ	HS	Investigative
DMCA0WJ	SN	biliverdine; UNII-O9MIA842K9; NSC 62793; O9MIA842K9; CHEBI:17033; Biliverdin IX; 8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbilin-1(19)(21H,24H)-dione; Biliverdine dihydrochloride; QBUVFDKTZJNUPP-BBROENKCSA-N; Protobiliverdin IX; EINECS 204-042-2
DMCA0WJ	DT	Small molecular drug
DMCA0WJ	PC	5280353
DMCA0WJ	MW	582.6
DMCA0WJ	FM	C33H34N4O6
DMCA0WJ	IC	InChI=1S/C33H34N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h7-8,13-15,34-35H,1-2,9-12H2,3-6H3,(H,37,42)(H,38,39)(H,40,41)/b24-13-,27-14-,28-15-
DMCA0WJ	CS	CC\\1=C(/C(=C/C2=C(C(=C(N2)/C=C\\3/C(=C(C(=O)N3)C)C=C)C)CCC(=O)O)/N/C1=C\\C4=NC(=O)C(=C4C)C=C)CCC(=O)O
DMCA0WJ	IK	RCNSAJSGRJSBKK-NSQVQWHSSA-N
DMCA0WJ	IU	3-[(2Z,5Z)-2-[[3-(2-carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methylidene]-5-[(4-ethenyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid
DMCA0WJ	CA	CAS 114-25-0
DMCA0WJ	CB	CHEBI:17033

DM09Z35	ID	DM09Z35
DM09Z35	DN	bilobalide
DM09Z35	HS	Investigative
DM09Z35	SN	Bilobalide; 33570-04-6; Bilobalid; (-)-Bilobalide; UNII-M81D2O8H7U; CHEBI:3103; M81D2O8H7U; Bilobalide A; 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS*,5aalpha,8beta,8aS*,9alpha,10aalpha))-; (3aS,8R,8aS,9R,10aS)-9-tert-butyl-8,9-dihydroxydihydro-9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione; tert-butyl(dihydroxy)[ ]trione; C15H18O8; Bilobalide;; Bilobalide A;; ( )-Bilobalide; AC1L2K4G; MLS000563448
DM09Z35	DT	Small molecular drug
DM09Z35	PC	73581
DM09Z35	MW	326.3
DM09Z35	FM	C15H18O8
DM09Z35	IC	InChI=1S/C15H18O8/c1-12(2,3)14(20)4-6-13(5-7(16)21-6)10(19)23-11-15(13,14)8(17)9(18)22-11/h6,8,11,17,20H,4-5H2,1-3H3/t6-,8-,11-,13-,14+,15+/m0/s1
DM09Z35	CS	CC(C)(C)[C@@]1(C[C@H]2[C@@]3([C@]14[C@H](C(=O)O[C@H]4OC3=O)O)CC(=O)O2)O
DM09Z35	IK	MOLPUWBMSBJXER-YDGSQGCISA-N
DM09Z35	IU	(1S,4R,7R,8S,9R,11S)-9-tert-butyl-7,9-dihydroxy-3,5,12-trioxatetracyclo[6.6.0.01,11.04,8]tetradecane-2,6,13-trione
DM09Z35	CA	CAS 33570-04-6
DM09Z35	CB	CHEBI:3103
DM09Z35	DE	Discovery agent

DMPR14J	ID	DMPR14J
DMPR14J	DN	Bimetopyrole
DMPR14J	HS	Investigative
DMPR14J	TC	Analgesics
DMPR14J	DE	Pain

DM0HPWY	ID	DM0HPWY
DM0HPWY	DN	biochanin A
DM0HPWY	HS	Investigative
DM0HPWY	SN	Biochanin A; 491-80-5; Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Genistein 4-methyl ether; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanine A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; olmelin; Pratensol; NSC 123538; Biochanin-A; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; C16H12O5; UNII-U13J6U390T; CCRIS 5449; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; EINECS 207-744-7; NSC123538; Genistein 4'-methyl ether;  4'-methylgenistein; BIOCHANIN
DM0HPWY	DT	Small molecular drug
DM0HPWY	PC	5280373
DM0HPWY	MW	284.26
DM0HPWY	FM	C16H12O5
DM0HPWY	IC	InChI=1S/C16H12O5/c1-20-11-4-2-9(3-5-11)12-8-21-14-7-10(17)6-13(18)15(14)16(12)19/h2-8,17-18H,1H3
DM0HPWY	CS	COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O
DM0HPWY	IK	WUADCCWRTIWANL-UHFFFAOYSA-N
DM0HPWY	IU	5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one
DM0HPWY	CA	CAS 491-80-5
DM0HPWY	CB	CHEBI:17574
DM0HPWY	DE	Discovery agent

DMLNQ2F	ID	DMLNQ2F
DMLNQ2F	DN	Biopterin
DMLNQ2F	HS	Investigative
DMLNQ2F	DT	Small molecular drug
DMLNQ2F	PC	135449517
DMLNQ2F	MW	237.22
DMLNQ2F	FM	C9H11N5O3
DMLNQ2F	IC	InChI=1S/C9H11N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h2-3,6,15-16H,1H3,(H3,10,11,13,14,17)/t3-,6-/m1/s1
DMLNQ2F	CS	C[C@H]([C@H](C1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O
DMLNQ2F	IK	LHQIJBMDNUYRAM-AWFVSMACSA-N
DMLNQ2F	IU	2-amino-6-[(1S,2R)-1,2-dihydroxypropyl]-3H-pteridin-4-one
DMLNQ2F	CA	CAS 36183-24-1
DMLNQ2F	CB	CHEBI:41183
DMLNQ2F	DE	Discovery agent

DMKMCE1	ID	DMKMCE1
DMKMCE1	DN	Biotin
DMKMCE1	HS	Investigative
DMKMCE1	SN	Biodermatin; Bioepiderm; Bios II; Biotin Forte; Factor S; Lutavit H2; Meribin; Rovimix H2
DMKMCE1	DT	Small molecular drug
DMKMCE1	PC	171548
DMKMCE1	MW	244.31
DMKMCE1	FM	C10H16N2O3S
DMKMCE1	IC	InChI=1S/C10H16N2O3S/c13-8(14)4-2-1-3-7-9-6(5-16-7)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)/t6-,7-,9-/m0/s1
DMKMCE1	CS	C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2
DMKMCE1	IK	YBJHBAHKTGYVGT-ZKWXMUAHSA-N
DMKMCE1	IU	5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid
DMKMCE1	CA	CAS 58-85-5
DMKMCE1	CB	CHEBI:15956
DMKMCE1	DE	Discovery agent

DMVOJ0X	ID	DMVOJ0X
DMVOJ0X	DN	BioVant
DMVOJ0X	HS	Investigative
DMVOJ0X	SN	CAP vaccine adjuvant, BioSante; Calcium phosphate nanoparticles, BioSante; Nanoparticle adjuvant technology, BioSante
DMVOJ0X	CP	University of California
DMVOJ0X	DT	Vaccine
DMVOJ0X	DE	Vaccination

DM4D7V6	ID	DM4D7V6
DM4D7V6	DN	Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine
DM4D7V6	HS	Investigative
DM4D7V6	SN	CHEMBL478836; Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine; BDBM50262725
DM4D7V6	DT	Small molecular drug
DM4D7V6	PC	44578367
DM4D7V6	MW	252.35
DM4D7V6	FM	C17H20N2
DM4D7V6	IC	InChI=1S/C17H20N2/c1-2-6-14(7-3-1)17-9-5-4-8-15(17)12-19-16-10-11-18-13-16/h1-9,16,18-19H,10-13H2/t16-/m0/s1
DM4D7V6	CS	C1CNC[C@H]1NCC2=CC=CC=C2C3=CC=CC=C3
DM4D7V6	IK	DGKNIGATLZIOSX-INIZCTEOSA-N
DM4D7V6	IU	(3S)-N-[(2-phenylphenyl)methyl]pyrrolidin-3-amine
DM4D7V6	DE	Discovery agent

DMROG71	ID	DMROG71
DMROG71	DN	Biphenyl-3-carboxylic acid hydroxyamide
DMROG71	HS	Investigative
DMROG71	SN	CHEMBL154517; Biphenyl-3-carboxylic acid hydroxyamide; 3-biphenyl hydroxamic acid; 3-Phenylbenzohydroximic acid; SCHEMBL10363097; SEPGPMDDTZHYJV-UHFFFAOYSA-N; ZINC27646665
DMROG71	DT	Small molecular drug
DMROG71	PC	44369352
DMROG71	MW	213.23
DMROG71	FM	C13H11NO2
DMROG71	IC	InChI=1S/C13H11NO2/c15-13(14-16)12-8-4-7-11(9-12)10-5-2-1-3-6-10/h1-9,16H,(H,14,15)
DMROG71	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)C(=O)NO
DMROG71	IK	SEPGPMDDTZHYJV-UHFFFAOYSA-N
DMROG71	IU	N-hydroxy-3-phenylbenzamide
DMROG71	DE	Discovery agent

DMIAUB1	ID	DMIAUB1
DMIAUB1	DN	Biphenyl-3-ylboronic acid
DMIAUB1	HS	Investigative
DMIAUB1	SN	3-Biphenylboronic acid; 5122-95-2; Biphenyl-3-boronic acid; [1,1'-Biphenyl]-3-ylboronic acid; biphenyl-3-ylboronic acid; (3-phenylphenyl)boronic Acid; 3-biphenyl boronic acid; (3-phenylphenyl)boranediol; 3-PHENYLBENZENEBORONIC ACID; (1,1'-biphenyl-3-yl)boronic acid; [1,1'-Diphenyl]-3-ylboronic acid; MFCD01318102; Boronic acid, [1,1'-biphenyl]-3-yl-; AK-35405; Biphenyl-3-boronicacid; PubChem6404; Phenylboronic Acid, 5; Biphenyl-3-bronic acid; 3-biphenyl-boronic acid; ACMC-1AKSL; AC1MC0UE; Biphenyl-3-ylbronic acid
DMIAUB1	DT	Small molecular drug
DMIAUB1	PC	2734315
DMIAUB1	MW	198.03
DMIAUB1	FM	C12H11BO2
DMIAUB1	IC	InChI=1S/C12H11BO2/c14-13(15)12-8-4-7-11(9-12)10-5-2-1-3-6-10/h1-9,14-15H
DMIAUB1	CS	B(C1=CC(=CC=C1)C2=CC=CC=C2)(O)O
DMIAUB1	IK	GOXICVKOZJFRMB-UHFFFAOYSA-N
DMIAUB1	IU	(3-phenylphenyl)boronic acid
DMIAUB1	CA	CAS 5122-95-2
DMIAUB1	DE	Discovery agent

DMYCKGH	ID	DMYCKGH
DMYCKGH	DN	Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester
DMYCKGH	HS	Investigative
DMYCKGH	SN	CHEMBL451443; Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester; URB602, 3j
DMYCKGH	DT	Small molecular drug
DMYCKGH	PC	44585895
DMYCKGH	MW	365.4
DMYCKGH	FM	C25H19NO2
DMYCKGH	IC	InChI=1S/C25H19NO2/c27-25(26-23-15-7-13-21(17-23)19-9-3-1-4-10-19)28-24-16-8-14-22(18-24)20-11-5-2-6-12-20/h1-18H,(H,26,27)
DMYCKGH	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)OC3=CC=CC(=C3)C4=CC=CC=C4
DMYCKGH	IK	GJGNAZXEUGJLTC-UHFFFAOYSA-N
DMYCKGH	IU	(3-phenylphenyl) N-(3-phenylphenyl)carbamate
DMYCKGH	DE	Discovery agent

DM10AUP	ID	DM10AUP
DM10AUP	DN	Biphenyl-3-ylcarbamic acid cyclohexyl ester
DM10AUP	HS	Investigative
DM10AUP	SN	565460-15-3; URB602; cyclohexyl biphenyl-3-ylcarbamate; Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate; URB-602; UNII-B8371SFA9K; CHEMBL77767; Monoacylglycerol Lipase Inhibitor, URB602; biphenyl-3-ylcarbamic acid cyclohexyl ester; B8371SFA9K; URB 602; N-Biphenyl-3-ylcarbamic acid, cyclohexyl ester; N-[1,1'-Biphenyl]-3-yl-carbamic Acid Cyclohexyl Ester; SCHEMBL4274165; Cyclohexylbiphenyl-3-ylcarbamate; CTK8C4433; DTXSID90450611; HHVUFQYJOSFTEH-UHFFFAOYSA-N; MolPort-003-850-812; EX-A1228; BCP19101; BDBM50128581; ANW-71925; ZINC13520725
DM10AUP	DT	Small molecular drug
DM10AUP	PC	10979337
DM10AUP	MW	295.4
DM10AUP	FM	C19H21NO2
DM10AUP	IC	InChI=1S/C19H21NO2/c21-19(22-18-12-5-2-6-13-18)20-17-11-7-10-16(14-17)15-8-3-1-4-9-15/h1,3-4,7-11,14,18H,2,5-6,12-13H2,(H,20,21)
DM10AUP	CS	C1CCC(CC1)OC(=O)NC2=CC=CC(=C2)C3=CC=CC=C3
DM10AUP	IK	HHVUFQYJOSFTEH-UHFFFAOYSA-N
DM10AUP	IU	cyclohexyl N-(3-phenylphenyl)carbamate
DM10AUP	CA	CAS 565460-15-3
DM10AUP	DE	Discovery agent

DMK5VYG	ID	DMK5VYG
DMK5VYG	DN	Biphenyl-4-carboxylic acid hydroxyamide
DMK5VYG	HS	Investigative
DMK5VYG	SN	Biphenylhydroxamic acid; UNII-R3GRG20IPQ; R3GRG20IPQ; CHEMBL154585; 106359-54-0; Biphenyl-4-carboxylic acid hydroxyamide; 4-biphenyl hydroxamic acid; (1,1'-Biphenyl)-4-carboxamide, N-hydroxy-; 4-Phenylbenzohydroximic acid; SCHEMBL2143958; DTXSID00147585; JWLKPHOMARIZAB-UHFFFAOYSA-N; BDBM50015086
DMK5VYG	DT	Small molecular drug
DMK5VYG	PC	44369716
DMK5VYG	MW	213.23
DMK5VYG	FM	C13H11NO2
DMK5VYG	IC	InChI=1S/C13H11NO2/c15-13(14-16)12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9,16H,(H,14,15)
DMK5VYG	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NO
DMK5VYG	IK	JWLKPHOMARIZAB-UHFFFAOYSA-N
DMK5VYG	IU	N-hydroxy-4-phenylbenzamide
DMK5VYG	CA	CAS 106359-54-0
DMK5VYG	DE	Discovery agent

DM5DPHO	ID	DM5DPHO
DM5DPHO	DN	BIPHENYL-4-YL-ACETALDEHYDE
DM5DPHO	HS	Investigative
DM5DPHO	SN	2-([1,1'-biphenyl]-4-yl)acetaldehyde; 61502-90-7; 2-(4-phenylphenyl)acetaldehyde; 4-biphenylacetaldehyde; 2-{[1,1'-biphenyl]-4-yl}acetaldehyde; AC1MRDQD; (biphenyl-4-yl)ethanone; SCHEMBL850634; 2-(biphenyl-4-yl)acetaldehyde; CTK2D8632; DTXSID30392980; OIDMZCMVYZLDLI-UHFFFAOYSA-N; MolPort-020-915-677; [1,1'-Biphenyl]-4-acetaldehyde; ZINC2581188; AKOS006278290; AS-49992; BP4
DM5DPHO	DT	Small molecular drug
DM5DPHO	PC	3491292
DM5DPHO	MW	196.24
DM5DPHO	FM	C14H12O
DM5DPHO	IC	InChI=1S/C14H12O/c15-11-10-12-6-8-14(9-7-12)13-4-2-1-3-5-13/h1-9,11H,10H2
DM5DPHO	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CC=O
DM5DPHO	IK	OIDMZCMVYZLDLI-UHFFFAOYSA-N
DM5DPHO	IU	2-(4-phenylphenyl)acetaldehyde
DM5DPHO	CA	CAS 61502-90-7
DM5DPHO	DE	Discovery agent

DMIHMP5	ID	DMIHMP5
DMIHMP5	DN	Biphenyl-4-ylboronic acid
DMIHMP5	HS	Investigative
DMIHMP5	SN	Biphenylboronic acid
DMIHMP5	DT	Small molecular drug
DMIHMP5	PC	151253
DMIHMP5	MW	198.03
DMIHMP5	FM	C12H11BO2
DMIHMP5	IC	InChI=1S/C12H11BO2/c14-13(15)12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9,14-15H
DMIHMP5	CS	B(C1=CC=C(C=C1)C2=CC=CC=C2)(O)O
DMIHMP5	IK	XPEIJWZLPWNNOK-UHFFFAOYSA-N
DMIHMP5	IU	(4-phenylphenyl)boronic acid
DMIHMP5	CA	CAS 5122-94-1
DMIHMP5	DE	Discovery agent

DM2MYKC	ID	DM2MYKC
DM2MYKC	DN	biphenylindanone A
DM2MYKC	HS	Investigative
DM2MYKC	SN	LS-193,571
DM2MYKC	DT	Small molecular drug
DM2MYKC	PC	9868580
DM2MYKC	MW	454.6
DM2MYKC	FM	C30H30O4
DM2MYKC	IC	InChI=1S/C30H30O4/c1-18-19(2)28-25(15-26(29(28)31)22-7-3-4-8-22)16-27(18)34-17-20-6-5-9-24(14-20)21-10-12-23(13-11-21)30(32)33/h5-6,9-14,16,22,26H,3-4,7-8,15,17H2,1-2H3,(H,32,33)
DM2MYKC	CS	CC1=C(C=C2CC(C(=O)C2=C1C)C3CCCC3)OCC4=CC(=CC=C4)C5=CC=C(C=C5)C(=O)O
DM2MYKC	IK	KMKBEESNZAPKMP-UHFFFAOYSA-N
DM2MYKC	IU	4-[3-[(2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydroinden-5-yl)oxymethyl]phenyl]benzoic acid
DM2MYKC	CA	CAS 866823-73-6
DM2MYKC	DE	Discovery agent

DM4FSXK	ID	DM4FSXK
DM4FSXK	DN	Bip-tyr(3bzl)-thr-pro-lys-thr
DM4FSXK	HS	Investigative
DM4FSXK	SN	CHEMBL385983; bip-tyr(3bzl)-thr-pro-lys-thr
DM4FSXK	PC	44413638
DM4FSXK	MW	1009.2
DM4FSXK	FM	C53H68N8O12
DM4FSXK	IC	InChI=1S/C53H68N8O12/c1-30(62)45(51(69)61-24-8-12-43(61)50(68)57-41(11-6-7-23-54)48(66)60-46(31(2)63)53(72)73)59-49(67)42(29-35-17-22-44(64)38(26-35)25-32-9-4-3-5-10-32)58-47(65)39(55)27-33-13-18-36(19-14-33)37-20-15-34(16-21-37)28-40(56)52(70)71/h3-5,9-10,13-22,26,30-31,39-43,45-46,62-64H,6-8,11-12,23-25,27-29,54-56H2,1-2H3,(H,57,68)(H,58,65)(H,59,67)(H,60,66)(H,70,71)(H,72,73)/t30-,31-,39+,40+,41+,42+,43+,45+,46+/m1/s1
DM4FSXK	CS	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC(=C(C=C2)O)CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DM4FSXK	IK	VGTTXQUWJIRLOZ-PMDNFMOISA-N
DM4FSXK	IU	(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-amino-3-[4-[4-[(2S)-2-amino-2-carboxyethyl]phenyl]phenyl]propanoyl]amino]-3-(3-benzyl-4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-hydroxybutanoic acid
DM4FSXK	DE	Discovery agent

DM0VKA2	ID	DM0VKA2
DM0VKA2	DN	Bip-tyr-ala-pro-lys-thr(obzl)-gly
DM0VKA2	HS	Investigative
DM0VKA2	SN	CHEMBL277108; bip-tyr-ala-pro-lys-thr(obzl)-gly
DM0VKA2	PC	44413593
DM0VKA2	MW	1036.2
DM0VKA2	FM	C54H69N9O12
DM0VKA2	IC	InChI=1S/C54H69N9O12/c1-32(53(72)63-26-8-12-45(63)51(70)60-43(11-6-7-25-55)49(68)62-47(52(71)58-30-46(65)66)33(2)75-31-37-9-4-3-5-10-37)59-50(69)44(29-36-17-23-40(64)24-18-36)61-48(67)41(56)27-34-13-19-38(20-14-34)39-21-15-35(16-22-39)28-42(57)54(73)74/h3-5,9-10,13-24,32-33,41-45,47,64H,6-8,11-12,25-31,55-57H2,1-2H3,(H,58,71)(H,59,69)(H,60,70)(H,61,67)(H,62,68)(H,65,66)(H,73,74)/t32-,33+,41-,42-,43-,44-,45-,47-/m0/s1
DM0VKA2	CS	C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)C4=CC=C(C=C4)C[C@@H](C(=O)O)N)N)OCC5=CC=CC=C5
DM0VKA2	IK	WWXCYGORDIEWIZ-YAXCISKESA-N
DM0VKA2	IU	(2S)-2-amino-3-[4-[4-[(2S)-2-amino-3-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-(carboxymethylamino)-1-oxo-3-phenylmethoxybutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]phenyl]propanoic acid
DM0VKA2	DE	Discovery agent

DMUWE81	ID	DMUWE81
DMUWE81	DN	Bip-tyr-thr-ala-pro-phe
DMUWE81	HS	Investigative
DMUWE81	SN	bip-tyr-thr-ala-pro-phe; CHEMBL439332
DMUWE81	DT	Small molecular drug
DMUWE81	PC	44413270
DMUWE81	MW	836.9
DMUWE81	FM	C45H52N6O10
DMUWE81	IC	InChI=1S/C45H52N6O10/c1-26(52)39(43(57)51-21-5-8-38(51)42(56)49-37(45(60)61)25-27-6-3-2-4-7-27)50-41(55)36(24-30-13-19-33(53)20-14-30)48-40(54)34(46)22-28-9-15-31(16-10-28)32-17-11-29(12-18-32)23-35(47)44(58)59/h2-4,6-7,9-20,26,34-39,52-53H,5,8,21-25,46-47H2,1H3,(H,48,54)(H,49,56)(H,50,55)(H,58,59)(H,60,61)/t26-,34+,35+,36+,37+,38?,39+/m1/s1
DMUWE81	CS	C[C@H]([C@@H](C(=O)N1CCCC1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DMUWE81	IK	WOXOMROGQFUOGC-DWIRJLQSSA-N
DMUWE81	IU	(2S)-2-amino-3-[4-[4-[(2S)-2-amino-3-[[(2S)-1-[[(2S,3R)-1-[2-[[(1S)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]phenyl]propanoic acid
DMUWE81	DE	Discovery agent

DMN38JC	ID	DMN38JC
DMN38JC	DN	Bip-tyr-thr-pro-ala-thr(obzl)-gly
DMN38JC	HS	Investigative
DMN38JC	SN	bip-tyr-thr-pro-ala-thr(obzl)-gly; CHEMBL219358
DMN38JC	PC	44413374
DMN38JC	MW	1066.2
DMN38JC	FM	C55H71N9O13
DMN38JC	IC	InChI=1S/C55H71N9O13/c1-32(65)47(54(74)64-26-8-12-45(64)52(72)60-43(11-6-7-25-56)50(70)63-48(53(73)59-30-46(67)68)33(2)77-31-37-9-4-3-5-10-37)62-51(71)44(29-36-17-23-40(66)24-18-36)61-49(69)41(57)27-34-13-19-38(20-14-34)39-21-15-35(16-22-39)28-42(58)55(75)76/h3-5,9-10,13-24,32-33,41-45,47-48,65-66H,6-8,11-12,25-31,56-58H2,1-2H3,(H,59,73)(H,60,72)(H,61,69)(H,62,71)(H,63,70)(H,67,68)(H,75,76)/t32-,33?,41+,42+,43+,44+,45+,47+,48+/m1/s1
DMN38JC	CS	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)OCC2=CC=CC=C2)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DMN38JC	IK	WVGBZWZFWUOODF-AWANZDLNSA-N
DMN38JC	IU	(2S)-2-amino-3-[4-[4-[(2S)-2-amino-3-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-1-(carboxymethylamino)-1-oxo-3-phenylmethoxybutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]phenyl]propanoic acid
DMN38JC	DE	Discovery agent

DM7EKH3	ID	DM7EKH3
DM7EKH3	DN	Bip-tyr-thr-pro-lys-thr
DM7EKH3	HS	Investigative
DM7EKH3	SN	CHEMBL379496; bip-tyr-thr-pro-lys-thr
DM7EKH3	DT	Small molecular drug
DM7EKH3	PC	44413628
DM7EKH3	MW	919
DM7EKH3	FM	C46H62N8O12
DM7EKH3	IC	InChI=1S/C46H62N8O12/c1-25(55)38(44(62)54-21-5-7-37(54)43(61)50-35(6-3-4-20-47)41(59)53-39(26(2)56)46(65)66)52-42(60)36(24-29-12-18-32(57)19-13-29)51-40(58)33(48)22-27-8-14-30(15-9-27)31-16-10-28(11-17-31)23-34(49)45(63)64/h8-19,25-26,33-39,55-57H,3-7,20-24,47-49H2,1-2H3,(H,50,61)(H,51,58)(H,52,60)(H,53,59)(H,63,64)(H,65,66)/t25-,26-,33+,34+,35+,36+,37+,38+,39+/m1/s1
DM7EKH3	CS	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)C4=CC=C(C=C4)C[C@@H](C(=O)O)N)N)O
DM7EKH3	IK	IBJQKBDBQJHDOQ-KOXSSGOCSA-N
DM7EKH3	IU	(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-amino-3-[4-[4-[(2S)-2-amino-2-carboxyethyl]phenyl]phenyl]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-hydroxybutanoic acid
DM7EKH3	DE	Discovery agent

DMAPX9G	ID	DMAPX9G
DMAPX9G	DN	Bip-tyr-thr-pro-lys-thr(obzl)-gly
DMAPX9G	HS	Investigative
DMAPX9G	SN	CHEMBL428483; bip-tyr-thr-pro-lys-thr(obzl)-gly
DMAPX9G	PC	44413501
DMAPX9G	MW	1066.2
DMAPX9G	FM	C55H71N9O13
DMAPX9G	IC	InChI=1S/C55H71N9O13/c1-32(65)47(54(74)64-26-8-12-45(64)52(72)60-43(11-6-7-25-56)50(70)63-48(53(73)59-30-46(67)68)33(2)77-31-37-9-4-3-5-10-37)62-51(71)44(29-36-17-23-40(66)24-18-36)61-49(69)41(57)27-34-13-19-38(20-14-34)39-21-15-35(16-22-39)28-42(58)55(75)76/h3-5,9-10,13-24,32-33,41-45,47-48,65-66H,6-8,11-12,25-31,56-58H2,1-2H3,(H,59,73)(H,60,72)(H,61,69)(H,62,71)(H,63,70)(H,67,68)(H,75,76)/t32-,33-,41+,42+,43+,44+,45+,47+,48+/m1/s1
DMAPX9G	CS	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)OCC2=CC=CC=C2)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DMAPX9G	IK	WVGBZWZFWUOODF-QHLFIVFVSA-N
DMAPX9G	IU	(2S)-2-amino-3-[4-[4-[(2S)-2-amino-3-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-(carboxymethylamino)-1-oxo-3-phenylmethoxybutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]phenyl]propanoic acid
DMAPX9G	DE	Discovery agent

DM4CZ5B	ID	DM4CZ5B
DM4CZ5B	DN	Bip-tyr-thr-pro-thr(obzl)-gly
DM4CZ5B	HS	Investigative
DM4CZ5B	SN	CHEMBL374492; bip-tyr-thr-pro-thr(obzl)-gly
DM4CZ5B	DT	Small molecular drug
DM4CZ5B	PC	44413375
DM4CZ5B	MW	952.1
DM4CZ5B	FM	C50H61N7O12
DM4CZ5B	IC	InChI=1S/C50H61N7O12/c1-28(34-17-19-36(20-18-34)35-15-11-31(12-16-35)24-38(51)50(67)68)42(52)47(64)54-39(25-32-13-21-37(59)22-14-32)45(62)55-43(29(2)58)49(66)57-23-7-10-40(57)46(63)56-44(48(65)53-26-41(60)61)30(3)69-27-33-8-5-4-6-9-33/h4-6,8-9,11-22,28-30,38-40,42-44,58-59H,7,10,23-27,51-52H2,1-3H3,(H,53,65)(H,54,64)(H,55,62)(H,56,63)(H,60,61)(H,67,68)/t28?,29-,30-,38+,39+,40+,42+,43+,44+/m1/s1
DM4CZ5B	CS	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)OCC2=CC=CC=C2)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DM4CZ5B	IK	MGKWXTIOHURCAH-LZDYDXGASA-N
DM4CZ5B	IU	(2S)-2-amino-3-[4-[4-[(3S)-3-amino-4-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S,3R)-1-(carboxymethylamino)-1-oxo-3-phenylmethoxybutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutan-2-yl]phenyl]phenyl]propanoic acid
DM4CZ5B	DE	Discovery agent

DM0WKNI	ID	DM0WKNI
DM0WKNI	DN	Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate
DM0WKNI	HS	Investigative
DM0WKNI	SN	CHEMBL372823; bis-((-)-N-propargylmorphinan-3-yl) sebacoylate
DM0WKNI	DT	Small molecular drug
DM0WKNI	PC	44406704
DM0WKNI	MW	729
DM0WKNI	FM	C48H60N2O4
DM0WKNI	IC	InChI=1S/C48H60N2O4/c1-3-27-49-29-25-47-23-13-11-15-39(47)43(49)31-35-19-21-37(33-41(35)47)53-45(51)17-9-7-5-6-8-10-18-46(52)54-38-22-20-36-32-44-40-16-12-14-24-48(40,42(36)34-38)26-30-50(44)28-4-2/h1-2,19-22,33-34,39-40,43-44H,5-18,23-32H2/t39?,40?,43-,44-,47-,48-/m1/s1
DM0WKNI	CS	C#CCN1CC[C@]23CCCCC2[C@H]1CC4=C3C=C(C=C4)OC(=O)CCCCCCCCC(=O)OC5=CC6=C(C[C@@H]7C8[C@@]6(CCCC8)CCN7CC#C)C=C5
DM0WKNI	IK	CMJNSGDVJLNRPB-TXEWOLIYSA-N
DM0WKNI	IU	bis[(1R,9R)-17-prop-2-ynyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] decanedioate
DM0WKNI	DE	Discovery agent

DMWAS4Q	ID	DMWAS4Q
DMWAS4Q	DN	BIS(12)-HUPERZINE B
DMWAS4Q	HS	Investigative
DMWAS4Q	SN	Bis(12)-Huperzine B; Bis-huperzine B 5c; bis(12)-HupB; CHEMBL175975; BDBM10943
DMWAS4Q	DT	Small molecular drug
DMWAS4Q	PC	23645104
DMWAS4Q	MW	737
DMWAS4Q	FM	C44H60N6O4
DMWAS4Q	IC	InChI=1S/C44H60N6O4/c1-29-21-31-23-37-35(13-15-39(51)45-37)43(25-29)33(31)11-9-19-49(43)41(53)27-47(3)17-7-5-6-8-18-48(4)28-42(54)50-20-10-12-34-32-22-30(2)26-44(34,50)36-14-16-40(52)46-38(36)24-32/h13-16,21-22,31-34H,5-12,17-20,23-28H2,1-4H3,(H,45,51)(H,46,52)/t31?,32?,33-,34-,43-,44-/m1/s1
DMWAS4Q	CS	CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CN(C)CCCCCCN(C)CC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DMWAS4Q	IK	OSYUHORWAUGEMC-ZTZPCQEHSA-N
DMWAS4Q	IU	(1R,10R)-16-methyl-14-[2-[methyl-[6-[methyl-[2-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-2-oxoethyl]amino]hexyl]amino]acetyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMWAS4Q	DE	Discovery agent

DM58YDV	ID	DM58YDV
DM58YDV	DN	Bis(14)-Huperzine B
DM58YDV	HS	Investigative
DM58YDV	DE	Discovery agent

DMYQM3B	ID	DMYQM3B
DMYQM3B	DN	BIS(16)-HUPERZINE B
DMYQM3B	HS	Investigative
DMYQM3B	SN	Bis(16)-Huperzine B; Bis-huperzine B 5f; bis(16)-HupB; CHEMBL434898; BDBM10946
DMYQM3B	DT	Small molecular drug
DMYQM3B	PC	23645107
DMYQM3B	MW	793.1
DMYQM3B	FM	C48H68N6O4
DMYQM3B	IC	InChI=1S/C48H68N6O4/c1-33-27-35-29-41-39(15-17-43(55)49-41)47(31-33)37(35)13-11-23-53(47)45(57)19-25-51(3)21-9-7-5-6-8-10-22-52(4)26-20-46(58)54-24-12-14-38-36-28-34(2)32-48(38,54)40-16-18-44(56)50-42(40)30-36/h15-18,27-28,35-38H,5-14,19-26,29-32H2,1-4H3,(H,49,55)(H,50,56)/t35?,36?,37-,38-,47-,48-/m1/s1
DMYQM3B	CS	CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CCN(C)CCCCCCCCN(C)CCC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DMYQM3B	IK	XCDQISLHKSKFLH-AZGNAIHRSA-N
DMYQM3B	IU	(1R,10R)-16-methyl-14-[3-[methyl-[8-[methyl-[3-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-3-oxopropyl]amino]octyl]amino]propanoyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMYQM3B	DE	Discovery agent

DM3W1T4	ID	DM3W1T4
DM3W1T4	DN	BIS(18)-HUPERZINE B
DM3W1T4	HS	Investigative
DM3W1T4	SN	Bis(18)-Huperzine B; Bis-huperzine B 5g; bis(18)-HupB; CHEMBL176132; BDBM10947
DM3W1T4	DT	Small molecular drug
DM3W1T4	PC	23645108
DM3W1T4	MW	821.1
DM3W1T4	FM	C50H72N6O4
DM3W1T4	IC	InChI=1S/C50H72N6O4/c1-35-29-37-31-43-41(17-19-45(57)51-43)49(33-35)39(37)15-13-25-55(49)47(59)21-27-53(3)23-11-9-7-5-6-8-10-12-24-54(4)28-22-48(60)56-26-14-16-40-38-30-36(2)34-50(40,56)42-18-20-46(58)52-44(42)32-38/h17-20,29-30,37-40H,5-16,21-28,31-34H2,1-4H3,(H,51,57)(H,52,58)/t37?,38?,39-,40-,49-,50-/m1/s1
DM3W1T4	CS	CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CCN(C)CCCCCCCCCCN(C)CCC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DM3W1T4	IK	AATUHPZQANSFHE-NKUZXIPXSA-N
DM3W1T4	IU	(1R,10R)-16-methyl-14-[3-[methyl-[10-[methyl-[3-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-3-oxopropyl]amino]decyl]amino]propanoyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DM3W1T4	DE	Discovery agent

DMQ7KR1	ID	DMQ7KR1
DMQ7KR1	DN	Bis(2,3-dibromo-4,5-dihydroxyphenyl)ether
DMQ7KR1	HS	Investigative
DMQ7KR1	SN	CHEMBL1269935; Bis(2,3-dibromo-4,5-dihydroxyphenyl)ether; SCHEMBL15511613; BDBM50329693
DMQ7KR1	DT	Small molecular drug
DMQ7KR1	PC	52944683
DMQ7KR1	MW	549.79
DMQ7KR1	FM	C12H6Br4O5
DMQ7KR1	IC	InChI=1S/C12H6Br4O5/c13-7-5(1-3(17)11(19)9(7)15)21-6-2-4(18)12(20)10(16)8(6)14/h1-2,17-20H
DMQ7KR1	CS	C1=C(C(=C(C(=C1OC2=C(C(=C(C(=C2)O)O)Br)Br)Br)Br)O)O
DMQ7KR1	IK	USVLQGJGFKJBRW-UHFFFAOYSA-N
DMQ7KR1	IU	3,4-dibromo-5-(2,3-dibromo-4,5-dihydroxyphenoxy)benzene-1,2-diol
DMQ7KR1	DE	Discovery agent

DMEW49T	ID	DMEW49T
DMEW49T	DN	Bis(2,4-dinitrophenyl)sulfane
DMEW49T	HS	Investigative
DMEW49T	SN	Sulfide, bis(2,4-dinitrophenyl); 2,4-dinitrophenyl sulfide; CHEMBL204688; NSC633009; 2253-67-0; Benzene, 1,1'-thiobis(2,4-dinitro-; BRN 2067338; AI3-16371; 1-[(2,4-Dinitrophenyl)sulfanyl]-2,4-dinitrobenzene; Benzene, 1,1'-thiobis[2,4-dinitro-; 1-(2,4-dinitrophenyl)sulfanyl-2,4-dinitro-benzene; bis(2,4-dinitrophenyl)sulfane; NSC44806; AC1L3VGX; 1-[(2,4-dinitrophenyl)thio]-2,4-dinitrobenzene; SCHEMBL1032814; CTK5I2738; DTXSID00177044; MolPort-001-016-796; DMIUPZAMXYQKBR-UHFFFAOYSA-N; ZINC1846448; ZX-AT024794; NSC-44806
DMEW49T	DT	Small molecular drug
DMEW49T	PC	95960
DMEW49T	MW	366.27
DMEW49T	FM	C12H6N4O8S
DMEW49T	IC	InChI=1S/C12H6N4O8S/c17-13(18)7-1-3-11(9(5-7)15(21)22)25-12-4-2-8(14(19)20)6-10(12)16(23)24/h1-6H
DMEW49T	CS	C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])SC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-]
DMEW49T	IK	DMIUPZAMXYQKBR-UHFFFAOYSA-N
DMEW49T	IU	1-(2,4-dinitrophenyl)sulfanyl-2,4-dinitrobenzene
DMEW49T	CA	CAS 2253-67-0
DMEW49T	DE	Discovery agent

DMHQKCJ	ID	DMHQKCJ
DMHQKCJ	DN	BIS(20)-HUPERZINE B
DMHQKCJ	HS	Investigative
DMHQKCJ	SN	Bis(20)-Huperzine B; Bis-huperzine B 5h; bis(20)-HupB; CHEMBL368897; BDBM10948
DMHQKCJ	DT	Small molecular drug
DMHQKCJ	PC	23645348
DMHQKCJ	MW	849.2
DMHQKCJ	FM	C52H76N6O4
DMHQKCJ	IC	InChI=1S/C52H76N6O4/c1-37-31-39-33-45-43(19-21-47(59)53-45)51(35-37)41(39)17-15-27-57(51)49(61)23-29-55(3)25-13-11-9-7-5-6-8-10-12-14-26-56(4)30-24-50(62)58-28-16-18-42-40-32-38(2)36-52(42,58)44-20-22-48(60)54-46(44)34-40/h19-22,31-32,39-42H,5-18,23-30,33-36H2,1-4H3,(H,53,59)(H,54,60)/t39?,40?,41-,42-,51-,52-/m1/s1
DMHQKCJ	CS	CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CCN(C)CCCCCCCCCCCCN(C)CCC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DMHQKCJ	IK	TUYZMCKAYFZSRO-JDUDQBENSA-N
DMHQKCJ	IU	(1R,10R)-16-methyl-14-[3-[methyl-[12-[methyl-[3-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-3-oxopropyl]amino]dodecyl]amino]propanoyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMHQKCJ	DE	Discovery agent

DMKANOH	ID	DMKANOH
DMKANOH	DN	Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]
DMKANOH	HS	Investigative
DMKANOH	SN	Loxiglumide; LOXIGLUMIDE; 107097-80-3; Loxiglumide [INN]; Loxiglumidum [Latin]; Loxiglumida [Spanish]; CR 1505; CR-1505; CHEMBL206025; (+-)-4-(3,4-Dichlorobenzamido)-N-(3-methoxypropyl)-N-pentylglutaramic acid; 4-(3,4-dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; (+-)-4-((3,4-Dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino)-5-oxopentanoic acid; D,L-4-(3,4-Dichlorobenzoylamino)-5-(N-3-methoxypropylpentylamino)-5-oxo-pentanoic acid; Loxiglumidum; Loxiglumida; Pentanoic
DMKANOH	DT	Small molecular drug
DMKANOH	PC	60182
DMKANOH	MW	461.4
DMKANOH	FM	C21H30Cl2N2O5
DMKANOH	IC	InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)
DMKANOH	CS	CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
DMKANOH	IK	QNQZBKQEIFTHFZ-UHFFFAOYSA-N
DMKANOH	IU	4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid
DMKANOH	CA	CAS 107097-80-3
DMKANOH	CB	CHEBI:31785
DMKANOH	DE	Discovery agent

DMUN50H	ID	DMUN50H
DMUN50H	DN	Bis(3-bromo-4,5-dihydroxyphenyl)methanone
DMUN50H	HS	Investigative
DMUN50H	SN	CHEMBL1269421; Bis(3-bromo-4,5-dihydroxyphenyl)methanone; SCHEMBL15511901; BDBM50329695
DMUN50H	DT	Small molecular drug
DMUN50H	PC	52948935
DMUN50H	MW	404.01
DMUN50H	FM	C13H8Br2O5
DMUN50H	IC	InChI=1S/C13H8Br2O5/c14-7-1-5(3-9(16)12(7)19)11(18)6-2-8(15)13(20)10(17)4-6/h1-4,16-17,19-20H
DMUN50H	CS	C1=C(C=C(C(=C1O)O)Br)C(=O)C2=CC(=C(C(=C2)Br)O)O
DMUN50H	IK	QWGGKBRLOGNRAY-UHFFFAOYSA-N
DMUN50H	IU	bis(3-bromo-4,5-dihydroxyphenyl)methanone
DMUN50H	DE	Discovery agent

DM784AU	ID	DM784AU
DM784AU	DN	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone
DM784AU	HS	Investigative
DM784AU	DT	Small molecular drug
DM784AU	PC	136002679
DM784AU	MW	429.1
DM784AU	FM	C14H11Br2N3OS
DM784AU	IC	InChI=1S/C14H11Br2N3OS/c15-10-3-1-2-8(6-10)13(18-19-14(17)21)9-4-5-12(20)11(16)7-9/h1-7,20H,(H3,17,19,21)/b18-13-
DM784AU	CS	C1=CC(=CC(=C1)Br)/C(=N/NC(=S)N)/C2=CC(=C(C=C2)O)Br
DM784AU	IK	UIMSYLGHIQKPJZ-AQTBWJFISA-N
DM784AU	IU	[(Z)-[(3-bromo-4-hydroxyphenyl)-(3-bromophenyl)methylidene]amino]thiourea
DM784AU	DE	Discovery agent

DMASNGX	ID	DMASNGX
DMASNGX	DN	Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone
DMASNGX	HS	Investigative
DMASNGX	SN	CHEMBL1271493; Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone
DMASNGX	DT	Small molecular drug
DMASNGX	PC	52942034
DMASNGX	MW	429.1
DMASNGX	FM	C14H11Br2N3OS
DMASNGX	IC	InChI=1S/C14H11Br2N3OS/c15-10-3-1-2-8(4-10)13(18-19-14(17)21)9-5-11(16)7-12(20)6-9/h1-7,20H,(H3,17,19,21)/b18-13-
DMASNGX	CS	C1=CC(=CC(=C1)Br)/C(=N/NC(=S)N)/C2=CC(=CC(=C2)Br)O
DMASNGX	IK	PWIIBRZZZZNLFE-AQTBWJFISA-N
DMASNGX	IU	[(Z)-[(3-bromo-5-hydroxyphenyl)-(3-bromophenyl)methylidene]amino]thiourea
DMASNGX	DE	Discovery agent

DMMJ635	ID	DMMJ635
DMMJ635	DN	Bis(3-Fluorophenyl)-ketone]thiosemicarbazone
DMMJ635	HS	Investigative
DMMJ635	SN	CHEMBL602732; Bis(3-Fluorophenyl)-ketone]thiosemicarbazone
DMMJ635	DT	Small molecular drug
DMMJ635	PC	46232386
DMMJ635	MW	291.32
DMMJ635	FM	C14H11F2N3S
DMMJ635	IC	InChI=1S/C14H11F2N3S/c15-11-5-1-3-9(7-11)13(18-19-14(17)20)10-4-2-6-12(16)8-10/h1-8H,(H3,17,19,20)
DMMJ635	CS	C1=CC(=CC(=C1)F)C(=NNC(=S)N)C2=CC(=CC=C2)F
DMMJ635	IK	OBIMSARJMGBMKZ-UHFFFAOYSA-N
DMMJ635	IU	[bis(3-fluorophenyl)methylideneamino]thiourea
DMMJ635	DE	Discovery agent

DMO6HWJ	ID	DMO6HWJ
DMO6HWJ	DN	Bis(4-fluorophenyl)-2-fluorophenylacetamide
DMO6HWJ	HS	Investigative
DMO6HWJ	SN	CHEMBL272039; bis(4-fluorophenyl)-2-fluorophenylacetamide; SCHEMBL1443968; VDPKWHHLYDETTO-UHFFFAOYSA-N
DMO6HWJ	DT	Small molecular drug
DMO6HWJ	PC	9798060
DMO6HWJ	MW	341.3
DMO6HWJ	FM	C20H14F3NO
DMO6HWJ	IC	InChI=1S/C20H14F3NO/c21-15-9-5-13(6-10-15)20(19(24)25,14-7-11-16(22)12-8-14)17-3-1-2-4-18(17)23/h1-12H,(H2,24,25)
DMO6HWJ	CS	C1=CC=C(C(=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N)F
DMO6HWJ	IK	VDPKWHHLYDETTO-UHFFFAOYSA-N
DMO6HWJ	IU	2-(2-fluorophenyl)-2,2-bis(4-fluorophenyl)acetamide
DMO6HWJ	DE	Discovery agent

DM36VKH	ID	DM36VKH
DM36VKH	DN	Bis(5-acetoxybenzo[b]furan-2-yl)methanone
DM36VKH	HS	Investigative
DM36VKH	SN	CHEMBL226182; bis(5-acetoxybenzo[b]furan-2-yl)methanone
DM36VKH	DT	Small molecular drug
DM36VKH	PC	13471348
DM36VKH	MW	378.3
DM36VKH	FM	C21H14O7
DM36VKH	IC	InChI=1S/C21H14O7/c1-11(22)25-15-3-5-17-13(7-15)9-19(27-17)21(24)20-10-14-8-16(26-12(2)23)4-6-18(14)28-20/h3-10H,1-2H3
DM36VKH	CS	CC(=O)OC1=CC2=C(C=C1)OC(=C2)C(=O)C3=CC4=C(O3)C=CC(=C4)OC(=O)C
DM36VKH	IK	UACDZFCKAGJOFV-UHFFFAOYSA-N
DM36VKH	IU	[2-(5-acetyloxy-1-benzofuran-2-carbonyl)-1-benzofuran-5-yl] acetate
DM36VKH	DE	Discovery agent

DMHRGTY	ID	DMHRGTY
DMHRGTY	DN	Bis(5-aminobenzo[b]furan-2-yl)methanone
DMHRGTY	HS	Investigative
DMHRGTY	SN	CHEMBL376787; bis(5-aminobenzo[b]furan-2-yl)methanone
DMHRGTY	DT	Small molecular drug
DMHRGTY	PC	11098310
DMHRGTY	MW	292.29
DMHRGTY	FM	C17H12N2O3
DMHRGTY	IC	InChI=1S/C17H12N2O3/c18-11-1-3-13-9(5-11)7-15(21-13)17(20)16-8-10-6-12(19)2-4-14(10)22-16/h1-8H,18-19H2
DMHRGTY	CS	C1=CC2=C(C=C1N)C=C(O2)C(=O)C3=CC4=C(O3)C=CC(=C4)N
DMHRGTY	IK	UMBJVNBINWLZLH-UHFFFAOYSA-N
DMHRGTY	IU	bis(5-amino-1-benzofuran-2-yl)methanone
DMHRGTY	DE	Discovery agent

DMTSEXB	ID	DMTSEXB
DMTSEXB	DN	Bis-(5-hydroxy-1H-indol-2-yl)-methanone
DMTSEXB	HS	Investigative
DMTSEXB	SN	Flt-3 Inhibitor II; 896138-40-2; CHEMBL377193; Bis-(5-hydroxy-1H-indol-2-yl)methanone; Bis(5-hydroxy-1H-indol-2-yl)methanone; SCHEMBL2230377; GTPL5971; CTK8F1061; DTXSID40469293; HMS3229E09; IN1480; BDBM50187351; AKOS028113701; CCG-206752; RT-012728; Flt-3 inhibitor II
DMTSEXB	DT	Small molecular drug
DMTSEXB	PC	11601743
DMTSEXB	MW	292.29
DMTSEXB	FM	C17H12N2O3
DMTSEXB	IC	InChI=1S/C17H12N2O3/c20-11-1-3-13-9(5-11)7-15(18-13)17(22)16-8-10-6-12(21)2-4-14(10)19-16/h1-8,18-21H
DMTSEXB	CS	C1=CC2=C(C=C1O)C=C(N2)C(=O)C3=CC4=C(N3)C=CC(=C4)O
DMTSEXB	IK	NIMIWWQLOGNYHD-UHFFFAOYSA-N
DMTSEXB	IU	bis(5-hydroxy-1H-indol-2-yl)methanone
DMTSEXB	CA	CAS 896138-40-2
DMTSEXB	DE	Discovery agent

DMGRKDP	ID	DMGRKDP
DMGRKDP	DN	Bis(5-hydroxybenzo[b]furan-2-yl)methanone
DMGRKDP	HS	Investigative
DMGRKDP	SN	CHEMBL225826; bis(5-hydroxybenzo[b]furan-2-yl)methanone
DMGRKDP	DT	Small molecular drug
DMGRKDP	PC	13454380
DMGRKDP	MW	294.26
DMGRKDP	FM	C17H10O5
DMGRKDP	IC	InChI=1S/C17H10O5/c18-11-1-3-13-9(5-11)7-15(21-13)17(20)16-8-10-6-12(19)2-4-14(10)22-16/h1-8,18-19H
DMGRKDP	CS	C1=CC2=C(C=C1O)C=C(O2)C(=O)C3=CC4=C(O3)C=CC(=C4)O
DMGRKDP	IK	TYHFGEDRLCAJMH-UHFFFAOYSA-N
DMGRKDP	IU	bis(5-hydroxy-1-benzofuran-2-yl)methanone
DMGRKDP	DE	Discovery agent

DM9XC6A	ID	DM9XC6A
DM9XC6A	DN	Bis(5-methoxybenzo[b]furan-2-yl)methanone
DM9XC6A	HS	Investigative
DM9XC6A	SN	CHEMBL225772; bis(5-methoxybenzo[b]furan-2-yl)methanone
DM9XC6A	DT	Small molecular drug
DM9XC6A	PC	13454368
DM9XC6A	MW	322.3
DM9XC6A	FM	C19H14O5
DM9XC6A	IC	InChI=1S/C19H14O5/c1-21-13-3-5-15-11(7-13)9-17(23-15)19(20)18-10-12-8-14(22-2)4-6-16(12)24-18/h3-10H,1-2H3
DM9XC6A	CS	COC1=CC2=C(C=C1)OC(=C2)C(=O)C3=CC4=C(O3)C=CC(=C4)OC
DM9XC6A	IK	HEAUVWMQZFRPLK-UHFFFAOYSA-N
DM9XC6A	IU	bis(5-methoxy-1-benzofuran-2-yl)methanone
DM9XC6A	DE	Discovery agent

DMQ98H5	ID	DMQ98H5
DMQ98H5	DN	Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine
DMQ98H5	HS	Investigative
DMQ98H5	SN	CHEMBL178711; Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine; SCHEMBL3615338
DMQ98H5	DT	Small molecular drug
DMQ98H5	PC	11210706
DMQ98H5	MW	363.5
DMQ98H5	FM	C20H17N3S2
DMQ98H5	IC	InChI=1S/C20H17N3S2/c1-3-15(11-21-9-1)19-7-5-17(24-19)13-23-14-18-6-8-20(25-18)16-4-2-10-22-12-16/h1-12,23H,13-14H2
DMQ98H5	CS	C1=CC(=CN=C1)C2=CC=C(S2)CNCC3=CC=C(S3)C4=CN=CC=C4
DMQ98H5	IK	CKCZUAVVHJHNJY-UHFFFAOYSA-N
DMQ98H5	IU	1-(5-pyridin-3-ylthiophen-2-yl)-N-[(5-pyridin-3-ylthiophen-2-yl)methyl]methanamine
DMQ98H5	DE	Discovery agent

DMRGNSQ	ID	DMRGNSQ
DMRGNSQ	DN	Bis(6-hydroxybenzo[b]furan-2-yl)methanone
DMRGNSQ	HS	Investigative
DMRGNSQ	SN	CHEMBL225827; bis(6-hydroxybenzo[b]furan-2-yl)methanone
DMRGNSQ	DT	Small molecular drug
DMRGNSQ	PC	13393486
DMRGNSQ	MW	294.26
DMRGNSQ	FM	C17H10O5
DMRGNSQ	IC	InChI=1S/C17H10O5/c18-11-3-1-9-5-15(21-13(9)7-11)17(20)16-6-10-2-4-12(19)8-14(10)22-16/h1-8,18-19H
DMRGNSQ	CS	C1=CC2=C(C=C1O)OC(=C2)C(=O)C3=CC4=C(O3)C=C(C=C4)O
DMRGNSQ	IK	RMZPEAFTFQMIEY-UHFFFAOYSA-N
DMRGNSQ	IU	bis(6-hydroxy-1-benzofuran-2-yl)methanone
DMRGNSQ	DE	Discovery agent

DMER5GT	ID	DMER5GT
DMER5GT	DN	BIS(8)-HUPERZINE B
DMER5GT	HS	Investigative
DMER5GT	SN	Bis(8)-Huperzine B; Bis-huperzine B 5a; bis(8)-Hup B; CHEMBL360092; BDBM10941
DMER5GT	DT	Small molecular drug
DMER5GT	PC	23645102
DMER5GT	MW	680.9
DMER5GT	FM	C40H52N6O4
DMER5GT	IC	InChI=1S/C40H52N6O4/c1-25-17-27-19-33-31(9-11-35(47)41-33)39(21-25)29(27)7-5-13-45(39)37(49)23-43(3)15-16-44(4)24-38(50)46-14-6-8-30-28-18-26(2)22-40(30,46)32-10-12-36(48)42-34(32)20-28/h9-12,17-18,27-30H,5-8,13-16,19-24H2,1-4H3,(H,41,47)(H,42,48)/t27?,28?,29-,30-,39-,40-/m1/s1
DMER5GT	CS	CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CN(C)CCN(C)CC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DMER5GT	IK	CTEOPWRYKGOSFE-KUNPEOQISA-N
DMER5GT	IU	(1R,10R)-16-methyl-14-[2-[methyl-[2-[methyl-[2-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-2-oxoethyl]amino]ethyl]amino]acetyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMER5GT	DE	Discovery agent

DM5WFQM	ID	DM5WFQM
DM5WFQM	DN	BIS(9)-HUPERZINE B
DM5WFQM	HS	Investigative
DM5WFQM	SN	Bis(9)-Huperzine B; Bis-huperzine B 5b; bis(9)-Hup B; CHEMBL367977; BDBM10942
DM5WFQM	DT	Small molecular drug
DM5WFQM	PC	23645103
DM5WFQM	MW	694.9
DM5WFQM	FM	C41H54N6O4
DM5WFQM	IC	InChI=1S/C41H54N6O4/c1-26-18-28-20-34-32(10-12-36(48)42-34)40(22-26)30(28)8-5-16-46(40)38(50)24-44(3)14-7-15-45(4)25-39(51)47-17-6-9-31-29-19-27(2)23-41(31,47)33-11-13-37(49)43-35(33)21-29/h10-13,18-19,28-31H,5-9,14-17,20-25H2,1-4H3,(H,42,48)(H,43,49)/t28?,29?,30-,31-,40-,41-/m1/s1
DM5WFQM	CS	CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CN(C)CCCN(C)CC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DM5WFQM	IK	KTFGBMXGPUIYSS-LMMAWDAISA-N
DM5WFQM	IU	(1R,10R)-16-methyl-14-[2-[methyl-[3-[methyl-[2-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-2-oxoethyl]amino]propyl]amino]acetyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DM5WFQM	DE	Discovery agent

DMK2ZG4	ID	DMK2ZG4
DMK2ZG4	DN	Bis(benzo[b]furan-2-yl)methanone
DMK2ZG4	HS	Investigative
DMK2ZG4	SN	CHEMBL226417; bis(benzo[b]furan-2-yl)methanone; bis-benzofuranyl ketone; AC1PLNEG; SCHEMBL244107; bis(1-benzofuran-2-yl)methanone; MolPort-000-640-603; ZINC8048290; BDBM50202218; AKOS002385499; MCULE-1633046929; 2-(1-benzofuran-2-carbonyl)-1-benzofuran; Z232333564
DMK2ZG4	DT	Small molecular drug
DMK2ZG4	PC	9179241
DMK2ZG4	MW	262.26
DMK2ZG4	FM	C17H10O3
DMK2ZG4	IC	InChI=1S/C17H10O3/c18-17(15-9-11-5-1-3-7-13(11)19-15)16-10-12-6-2-4-8-14(12)20-16/h1-10H
DMK2ZG4	CS	C1=CC=C2C(=C1)C=C(O2)C(=O)C3=CC4=CC=CC=C4O3
DMK2ZG4	IK	ZLYFWIZGRHGKMM-UHFFFAOYSA-N
DMK2ZG4	IU	bis(1-benzofuran-2-yl)methanone
DMK2ZG4	DE	Discovery agent

DMYSQ2B	ID	DMYSQ2B
DMYSQ2B	DN	Bis-{[R-(-)-apomorphine-2-oxy]ethyl} ether
DMYSQ2B	HS	Investigative
DMYSQ2B	SN	CHEMBL444149; Bis-{[R-(-)-apomorphine-2-oxy]ethyl} ether
DMYSQ2B	DT	Small molecular drug
DMYSQ2B	PC	44567598
DMYSQ2B	MW	636.7
DMYSQ2B	FM	C38H40N2O7
DMYSQ2B	IC	InChI=1S/C38H40N2O7/c1-39-9-7-23-15-25(19-27-33(23)29(39)17-21-3-5-31(41)37(43)35(21)27)46-13-11-45-12-14-47-26-16-24-8-10-40(2)30-18-22-4-6-32(42)38(44)36(22)28(20-26)34(24)30/h3-6,15-16,19-20,29-30,41-44H,7-14,17-18H2,1-2H3/t29-,30-/m1/s1
DMYSQ2B	CS	CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OCCOCCOC5=CC6=C7[C@@H](CC8=C(C7=C5)C(=C(C=C8)O)O)N(CC6)C)C(=C(C=C4)O)O
DMYSQ2B	IK	GJLNFWNMAQBYPC-LOYHVIPDSA-N
DMYSQ2B	IU	(6aR)-2-[2-[2-[[(6aR)-10,11-dihydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-2-yl]oxy]ethoxy]ethoxy]-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMYSQ2B	DE	Discovery agent

DMVNC1R	ID	DMVNC1R
DMVNC1R	DN	Bis-7-tacrine
DMVNC1R	HS	Investigative
DMVNC1R	SN	Bis(7)-tacrine
DMVNC1R	DT	Small molecular drug
DMVNC1R	PC	9549196
DMVNC1R	MW	492.7
DMVNC1R	FM	C33H40N4
DMVNC1R	IC	InChI=1S/C33H40N4/c1(2-12-22-34-32-24-14-4-8-18-28(24)36-29-19-9-5-15-25(29)32)3-13-23-35-33-26-16-6-10-20-30(26)37-31-21-11-7-17-27(31)33/h4,6,8,10,14,16,18,20H,1-3,5,7,9,11-13,15,17,19,21-23H2,(H,34,36)(H,35,37)
DMVNC1R	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCNC4=C5CCCCC5=NC6=CC=CC=C64
DMVNC1R	IK	ITZOKHKOFJOBFS-UHFFFAOYSA-N
DMVNC1R	IU	N,N'-bis(1,2,3,4-tetrahydroacridin-9-yl)heptane-1,7-diamine
DMVNC1R	CA	CAS 181865-13-4
DMVNC1R	CB	CHEBI:138435
DMVNC1R	DE	Discovery agent

DMRSKGC	ID	DMRSKGC
DMRSKGC	DN	bisandrographolide
DMRSKGC	HS	Investigative
DMRSKGC	SN	bisandrographolide; Bisandrographolide A; Bisandrographolide C; 160498-00-0; 160498-02-2; C40H56O8; GTPL2502; MolPort-039-338-289; 9116AF; 9115AF; AKOS032948243
DMRSKGC	DT	Small molecular drug
DMRSKGC	PC	12000062
DMRSKGC	MW	664.9
DMRSKGC	FM	C40H56O8
DMRSKGC	IC	InChI=1S/C40H56O8/c1-23-7-11-31-37(3,16-13-33(43)39(31,5)21-41)28(23)10-9-25-19-30(48-35(25)45)27(26-15-18-47-36(26)46)20-29-24(2)8-12-32-38(29,4)17-14-34(44)40(32,6)22-42/h9-10,15,19,27-34,41-44H,1-2,7-8,11-14,16-18,20-22H2,3-6H3/b10-9+/t27?,28-,29-,30?,31+,32+,33-,34-,37+,38+,39+,40+/m1/s1
DMRSKGC	CS	C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2CC(C3C=C(C(=O)O3)/C=C/[C@@H]4C(=C)CC[C@H]5[C@]4(CC[C@H]([C@@]5(C)CO)O)C)C6=CCOC6=O)(C)CO)O
DMRSKGC	IK	WQHWOZANSOUSAY-LZBAHHAZSA-N
DMRSKGC	IU	4-[(E)-2-[(1R,4aS,5R,6R,8aR)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethenyl]-2-[2-[(1R,4aS,5R,6R,8aR)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-1-(5-oxo-2H-furan-4-yl)ethyl]-2H-furan-5-one
DMRSKGC	DE	Discovery agent

DMF4AHD	ID	DMF4AHD
DMF4AHD	DN	Bis-cyclosal-d4TMP
DMF4AHD	HS	Investigative
DMF4AHD	SN	bis-cyclosal-d4TMP; CHEMBL376095; 5-methyl-1-[(2R,5S)-5-[[8-[2-[[(2S,5R)-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methoxy]-2-oxo-4H-1,3,2$l^{5}-benzodioxaphosphinin-8-yl]-2-oxo-4H-1,3,2$l^{5}-benzodioxaphosphinin-2-yl]oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione; 2,4(1H,3H)-Pyrimidinedione, 1,1'-[(2,2'-dioxido[8,8'-bi-4H-1,3,2-benzodioxaphosphorin]-2,2'-diyl)bis[oxymethylene[(2R,5S)-2,5-dihydro-5,2-furandiyl]]]bis[5-methyl-
DMF4AHD	DT	Small molecular drug
DMF4AHD	PC	16115140
DMF4AHD	MW	782.6
DMF4AHD	FM	C34H32N4O14P2
DMF4AHD	IC	InChI=1S/C34H32N4O14P2/c1-19-13-37(33(41)35-31(19)39)27-11-9-23(49-27)17-47-53(43)45-15-21-5-3-7-25(29(21)51-53)26-8-4-6-22-16-46-54(44,52-30(22)26)48-18-24-10-12-28(50-24)38-14-20(2)32(40)36-34(38)42/h3-14,23-24,27-28H,15-18H2,1-2H3,(H,35,39,41)(H,36,40,42)/t23-,24-,27+,28+,53?,54?/m0/s1
DMF4AHD	CS	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=C(O3)C(=CC=C4)C5=CC=CC6=C5OP(=O)(OC6)OC[C@@H]7C=C[C@@H](O7)N8C=C(C(=O)NC8=O)C
DMF4AHD	IK	KHOMSKKMHVGQFN-QIKIAYFISA-N
DMF4AHD	IU	5-methyl-1-[(2R,5S)-5-[[8-[2-[[(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methoxy]-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-8-yl]-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl]oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione
DMF4AHD	DE	Discovery agent

DMVRXH3	ID	DMVRXH3
DMVRXH3	DN	Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]
DMVRXH3	HS	Investigative
DMVRXH3	SN	BISHYDROXY[2H-1-BENZOPYRAN-2-ONE,1,2-BENZOPYRONE]; DB04392
DMVRXH3	DT	Small molecular drug
DMVRXH3	PC	17753965
DMVRXH3	MW	336.3
DMVRXH3	FM	C19H12O6
DMVRXH3	IC	InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,12-13H,9H2/t12-,13+
DMVRXH3	CS	C1=CC=C2C(=C1)C(=O)[C@H](C(=O)O2)C[C@H]3C(=O)C4=CC=CC=C4OC3=O
DMVRXH3	IK	HIZKPJUTKKJDGA-BETUJISGSA-N
DMVRXH3	IU	(3S)-3-[[(3R)-2,4-dioxochromen-3-yl]methyl]chromene-2,4-dione
DMVRXH3	DE	Discovery agent

DM0MK6D	ID	DM0MK6D
DM0MK6D	DN	BIS-IMIDE A
DM0MK6D	HS	Investigative
DM0MK6D	SN	CHEMBL388648; BIS-IMIDE A; SCHEMBL5879127; BDBM50220067; 9H-Carbazole-1,2:3,4-bisdicarbimide
DM0MK6D	DT	Small molecular drug
DM0MK6D	PC	10086414
DM0MK6D	MW	305.24
DM0MK6D	FM	C16H7N3O4
DM0MK6D	IC	InChI=1S/C16H7N3O4/c20-13-8-7-5-3-1-2-4-6(5)17-12(7)11-10(9(8)14(21)18-13)15(22)19-16(11)23/h1-4,17H,(H,18,20,21)(H,19,22,23)
DM0MK6D	CS	C1=CC=C2C(=C1)C3=C4C(=C5C(=C3N2)C(=O)NC5=O)C(=O)NC4=O
DM0MK6D	IK	IZHSJTMCSHXFHX-UHFFFAOYSA-N
DM0MK6D	IU	4,9,19-triazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1,6,11,13,15,17-hexaene-3,5,8,10-tetrone
DM0MK6D	DE	Discovery agent

DMOQJZC	ID	DMOQJZC
DMOQJZC	DN	Bisindolylmaleimide-I
DMOQJZC	HS	Investigative
DMOQJZC	SN	Bisindolylmaleimide i; bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; 6850; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850
DMOQJZC	DT	Small molecular drug
DMOQJZC	PC	2396
DMOQJZC	MW	412.5
DMOQJZC	FM	C25H24N4O2
DMOQJZC	IC	InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)
DMOQJZC	CS	CN(C)CCCN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54
DMOQJZC	IK	QMGUOJYZJKLOLH-UHFFFAOYSA-N
DMOQJZC	IU	3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1H-indol-3-yl)pyrrole-2,5-dione
DMOQJZC	CA	CAS 133052-90-1
DMOQJZC	DE	Discovery agent

DM0K6QH	ID	DM0K6QH
DM0K6QH	DN	Bis-Napthyl Beta-Ketophosphonic Acid
DM0K6QH	HS	Investigative
DM0K6QH	SN	BIS-NAPTHYL BETA-KETOPHOSPHONIC ACID; [(1R)-1-naphthalen-1-yl-2-naphthalen-2-yl-2-oxoethyl]phosphonic acid; (2-NAPHTHALEN-2-YL-1-NAPHTHALEN-1-YL-2-OXO-ETHYL)-PHOSPHONIC ACID; KTP; 1kyn; AC1L9K5C; DB02360; (1R)-1-(naphthalen-1-yl)-2-(naphthalen-2-yl)-2-oxoethylphosphonic acid
DM0K6QH	DT	Small molecular drug
DM0K6QH	PC	446833
DM0K6QH	MW	376.3
DM0K6QH	FM	C22H17O4P
DM0K6QH	IC	InChI=1S/C22H17O4P/c23-21(18-13-12-15-6-1-2-8-17(15)14-18)22(27(24,25)26)20-11-5-9-16-7-3-4-10-19(16)20/h1-14,22H,(H2,24,25,26)/t22-/m1/s1
DM0K6QH	CS	C1=CC=C2C=C(C=CC2=C1)C(=O)[C@@H](C3=CC=CC4=CC=CC=C43)P(=O)(O)O
DM0K6QH	IK	OFHMUASCSJJNNA-JOCHJYFZSA-N
DM0K6QH	IU	[(1R)-1-naphthalen-1-yl-2-naphthalen-2-yl-2-oxoethyl]phosphonic acid
DM0K6QH	DE	Discovery agent

DM2ZLD7	ID	DM2ZLD7
DM2ZLD7	DN	Bisphenol A
DM2ZLD7	HS	Investigative
DM2ZLD7	SN	BPA
DM2ZLD7	DT	Small molecular drug
DM2ZLD7	PC	6623
DM2ZLD7	MW	228.29
DM2ZLD7	FM	C15H16O2
DM2ZLD7	IC	InChI=1S/C15H16O2/c1-15(2,11-3-7-13(16)8-4-11)12-5-9-14(17)10-6-12/h3-10,16-17H,1-2H3
DM2ZLD7	CS	CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O
DM2ZLD7	IK	IISBACLAFKSPIT-UHFFFAOYSA-N
DM2ZLD7	IU	4-[2-(4-hydroxyphenyl)propan-2-yl]phenol
DM2ZLD7	CA	CAS 80-05-7
DM2ZLD7	CB	CHEBI:33216
DM2ZLD7	DE	Discovery agent

DMFHY04	ID	DMFHY04
DMFHY04	DN	BIX 02188
DMFHY04	HS	Investigative
DMFHY04	SN	BIX02188; BIX-02188
DMFHY04	DT	Small molecular drug
DMFHY04	PC	135398492
DMFHY04	MW	412.5
DMFHY04	FM	C25H24N4O2
DMFHY04	IC	InChI=1S/C25H24N4O2/c1-29(2)15-16-7-6-10-19(13-16)27-23(17-8-4-3-5-9-17)22-20-12-11-18(24(26)30)14-21(20)28-25(22)31/h3-14,28,31H,15H2,1-2H3,(H2,26,30)
DMFHY04	CS	CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N)O
DMFHY04	IK	WGPXKFOFEXJMBD-UHFFFAOYSA-N
DMFHY04	IU	3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indole-6-carboxamide
DMFHY04	CA	CAS 1094614-84-2
DMFHY04	DE	Discovery agent

DMNAX1Q	ID	DMNAX1Q
DMNAX1Q	DN	BIX 02565
DMNAX1Q	HS	Investigative
DMNAX1Q	SN	BIX02565; BIX-02565
DMNAX1Q	DT	Small molecular drug
DMNAX1Q	PC	53246941
DMNAX1Q	MW	458.6
DMNAX1Q	FM	C26H30N6O2
DMNAX1Q	IC	InChI=1S/C26H30N6O2/c1-17-11-12-27-25(34)23-15-18-9-10-19(16-22(18)32(17)23)24(33)29-26-28-20-7-4-5-8-21(20)31(26)14-6-13-30(2)3/h4-5,7-10,15-17H,6,11-14H2,1-3H3,(H,27,34)(H,28,29,33)/t17-/m1/s1
DMNAX1Q	CS	C[C@@H]1CCNC(=O)C2=CC3=C(N12)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5N4CCCN(C)C
DMNAX1Q	IK	ZHMXXVNQAFCXKK-QGZVFWFLSA-N
DMNAX1Q	IU	(5R)-N-[1-[3-(dimethylamino)propyl]benzimidazol-2-yl]-5-methyl-1-oxo-2,3,4,5-tetrahydro-[1,4]diazepino[1,2-a]indole-8-carboxamide
DMNAX1Q	DE	Discovery agent

DMGULNZ	ID	DMGULNZ
DMGULNZ	DN	BL-5040
DMGULNZ	HS	Investigative
DMGULNZ	SN	Leptin antagonist (anorexia), BioLineRx; Leptin antagonist (cachexia), BioLineRx; Leptin antagonist (inflammatory bowel disease), BioLineRx
DMGULNZ	CP	Hebrew University of Jerusalem
DMGULNZ	DE	Cachexia

DMQLJMC	ID	DMQLJMC
DMQLJMC	DN	BL-6020
DMQLJMC	HS	Investigative
DMQLJMC	SN	SNT-207707; SNT-207858; SNT-209858; MC4-R antagonists (anorexia), Santhera; MC4-R antagonists (cachexia), Santhera; Melanocortin 4 receptor antagonists (cachexia/anorexia), Santhera; MC4-R antagonists (cachexia/anorexia), Santhera; MC4-R antagonists (cachexia/anorexia), Santhera/ BioLineRx
DMQLJMC	CP	MyoContract Pharmaceutical Research Ltd
DMQLJMC	DE	Cachexia

DMBRZ4P	ID	DMBRZ4P
DMBRZ4P	DN	BLV-0703
DMBRZ4P	HS	Investigative
DMBRZ4P	SN	BLV-200703; KTP-NH2; TAU-targeting compound (CNS disorders), Bioalvo
DMBRZ4P	CP	Bioalvo SA
DMBRZ4P	DE	Central nervous system disease

DMGB9PN	ID	DMGB9PN
DMGB9PN	DN	BLV-0801
DMGB9PN	HS	Investigative
DMGB9PN	SN	SBLK-200801; IDO inhibitor (CNS disorders), Bioalvo; Indoleamine dioxygenase inhibitor (CNS disorders), Bioalvo
DMGB9PN	CP	Bioalvo SA
DMGB9PN	DE	Solid tumour/cancer

DM728RW	ID	DM728RW
DM728RW	DN	BLX-301
DM728RW	HS	Investigative
DM728RW	SN	Glyco-optimized rituximab; Anti-CD20 antibody (LEX, non-Hodgkin lymphoma); Anti-CD20 antibody (non-Hodgkin lymphoma), EPIcyte; Anti-CD20 antibody (LEX, non-Hodgkin lymphoma), Biolex
DM728RW	CP	EPIcyte Pharmaceutical Inc
DM728RW	DT	Antibody
DM728RW	DE	Non-hodgkin lymphoma

DMDNPML	ID	DMDNPML
DMDNPML	DN	BM-162115
DMDNPML	HS	Investigative
DMDNPML	SN	115077-66-2; 1,6-Dioxadispiro[4.1.5.1]trideca-8,11-diene-2,10-dione; 1,6-Dioxadispiro(4.1.5.1)trideca-8,11-diene-2,10-dione; BM 162115; ACMC-20ml0u; BM-162115; BM 16.2115; SCHEMBL8797307; AC1L526V; CTK0I0331
DMDNPML	CP	Boehringer Mannheim GmbH
DMDNPML	DT	Small molecular drug
DMDNPML	PC	196711
DMDNPML	MW	206.19
DMDNPML	FM	C11H10O4
DMDNPML	IC	InChI=1S/C11H10O4/c12-8-1-4-10(5-2-8)7-11(15-10)6-3-9(13)14-11/h1-2,4-5H,3,6-7H2
DMDNPML	CS	C1CC2(CC3(O2)C=CC(=O)C=C3)OC1=O
DMDNPML	IK	CAZSBBDSSNQJGI-UHFFFAOYSA-N
DMDNPML	IU	4,13-dioxadispiro[4.1.57.15]trideca-8,11-diene-3,10-dione
DMDNPML	CA	CAS 115077-66-2
DMDNPML	DE	Inflammation

DMD2H7L	ID	DMD2H7L
DMD2H7L	DN	BM-573
DMD2H7L	HS	Investigative
DMD2H7L	SN	BM-573; UNII-8E9L957C3G; CHEMBL210602; 8E9L957C3G; AC1NSM3C; SCHEMBL3393325; BM 573; BDBM50188619; NSC732094; NSC-732094; 284464-83-1; Benzenesulfonamide, N-(((1,1-dimethylethyl)amino)carbonyl)-2-((4-methylphenyl)amino)-5-nitro-; LS-191119; 1-(2-(p-toluidino)-5-nitrophenylsulfonyl)-3-tert-butylurea; 1-tert-butyl-3-[2-(4-methylanilino)-5-nitrophenyl]sulfonylurea; N-tert-butyl-N''-[2-(4-methylphenylamino)-5-nitrobenzenesulfonyl]urea; N-tertbutyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfo nyl]urea
DMD2H7L	DT	Small molecular drug
DMD2H7L	PC	5312142
DMD2H7L	MW	406.5
DMD2H7L	FM	C18H22N4O5S
DMD2H7L	IC	InChI=1S/C18H22N4O5S/c1-12-5-7-13(8-6-12)19-15-10-9-14(22(24)25)11-16(15)28(26,27)21-17(23)20-18(2,3)4/h5-11,19H,1-4H3,(H2,20,21,23)
DMD2H7L	CS	CC1=CC=C(C=C1)NC2=C(C=C(C=C2)[N+](=O)[O-])S(=O)(=O)NC(=O)NC(C)(C)C
DMD2H7L	IK	SILRUCMXYIKULW-UHFFFAOYSA-N
DMD2H7L	IU	1-tert-butyl-3-[2-(4-methylanilino)-5-nitrophenyl]sulfonylurea
DMD2H7L	CA	CAS 284464-83-1
DMD2H7L	DE	Discovery agent

DM8AEQX	ID	DM8AEQX
DM8AEQX	DN	Bmab-200
DM8AEQX	HS	Investigative
DM8AEQX	SN	Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon
DM8AEQX	CP	Biocon Ltd
DM8AEQX	DT	Antibody
DM8AEQX	DE	Solid tumour/cancer

DMER2WS	ID	DMER2WS
DMER2WS	DN	BML3-C01
DMER2WS	HS	Investigative
DMER2WS	SN	Adrenic acid; TWSWSIQAPQLDBP-DOFZRALJSA-N; (7Z,10Z,13Z,16Z)-Docosa-7,10,13,16-tetraenoic acid; 28874-58-0; 7,10,13,16-Docosatetraenoate; 7,10,13,16-Docosatetraenoic acid; 7,10,13,16-Docosatetraenoic acid, (all-Z)-; 7,10,13,16-docosatetraenoic acid, (7Z,10Z,13Z,16Z)-; 7Z,10Z,13Z,16Z-Docosatetraenoic acid; AC1NUZMR; Cis-7,10,13,16-docosatetraenoic acid; BSPBio_001499; CHEBI:53487; CHEMBL1491103; HMS1791K21; HMS1989K21; SCHEMBL19452; all-cis-7,10,13,16-Docosatetraenoic acid; all-cis-docosa-7,10,13,16-tetraenoic acid; cis-7,10,13,16-Docosatetraenoic acid
DMER2WS	PC	5497181
DMER2WS	MW	332.5
DMER2WS	FM	C22H36O2
DMER2WS	IC	TWSWSIQAPQLDBP-DOFZRALJSA-N
DMER2WS	CS	CCCCCC=CCC=CCC=CCC=CCCCCCC(=O)O
DMER2WS	IK	1S/C22H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,23,24)/b7-6-,10-9-,13-12-,16-15-
DMER2WS	IU	(7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoic acid
DMER2WS	CA	CAS 28874-58-0
DMER2WS	CB	CHEBI:53487
DMER2WS	DE	Discovery agent

DMYWEO6	ID	DMYWEO6
DMYWEO6	DN	BMN-103
DMYWEO6	HS	Investigative
DMYWEO6	SN	Alpha-glucosidase (Pompe disease), BioMarin
DMYWEO6	CP	BioMarin Pharmaceutical Inc
DMYWEO6	DE	Pompe disease

DM0VMZ4	ID	DM0VMZ4
DM0VMZ4	DN	BMN-168
DM0VMZ4	HS	Investigative
DM0VMZ4	SN	Sapropterin prodrug, BioMarin; 6R-BH4 prodrug, BioMarin
DM0VMZ4	CP	BioMarin Pharmaceutical Inc
DM0VMZ4	DE	Phenylketonuria

DMR82WI	ID	DMR82WI
DMR82WI	DN	BMS compound 4c
DMR82WI	HS	Investigative
DMR82WI	DT	Small molecular drug
DMR82WI	PC	71655433
DMR82WI	MW	470.5
DMR82WI	FM	C24H21F3N4OS
DMR82WI	IC	InChI=1S/C24H21F3N4OS/c1-23(2,3)17-7-4-5-9-19(17)32-20-18(8-6-14-28-20)29-22-31-30-21(33-22)15-10-12-16(13-11-15)24(25,26)27/h4-14H,1-3H3,(H,29,31)
DMR82WI	CS	CC(C)(C)C1=CC=CC=C1OC2=C(C=CC=N2)NC3=NN=C(S3)C4=CC=C(C=C4)C(F)(F)F
DMR82WI	IK	ROIKEXLVELZTIZ-UHFFFAOYSA-N
DMR82WI	IU	N-[2-(2-tert-butylphenoxy)pyridin-3-yl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-amine
DMR82WI	DE	Discovery agent

DMJM8OQ	ID	DMJM8OQ
DMJM8OQ	DN	BMS pyrazole inhibitor 7f
DMJM8OQ	HS	Investigative
DMJM8OQ	SN	CHEMBL468927; BMS pyrazole inhibitor 7f; ASIS-P021; GTPL7030; SCHEMBL14565559; ZINC40891759; BDBM50258790; (2S)-2-amino-N-[(3-{5-[5-(1,3-benzothiazol-7-yl)-1,3,4-oxadiazol-2-yl]-3-(trifluoromethyl)-1H-pyrazol-1-yl}phenyl)methyl]propanamide; (S)-2-amino-N-(3-(5-(5-(benzo[d]thiazol-7-yl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide
DMJM8OQ	DT	Small molecular drug
DMJM8OQ	PC	44219611
DMJM8OQ	MW	513.5
DMJM8OQ	FM	C23H18F3N7O2S
DMJM8OQ	IC	InChI=1S/C23H18F3N7O2S/c1-12(27)20(34)28-10-13-4-2-5-14(8-13)33-17(9-18(32-33)23(24,25)26)22-31-30-21(35-22)15-6-3-7-16-19(15)36-11-29-16/h2-9,11-12H,10,27H2,1H3,(H,28,34)/t12-/m0/s1
DMJM8OQ	CS	C[C@@H](C(=O)NCC1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)C3=NN=C(O3)C4=C5C(=CC=C4)N=CS5)N
DMJM8OQ	IK	KODBDIFHMBDFOH-LBPRGKRZSA-N
DMJM8OQ	IU	(2S)-2-amino-N-[[3-[5-[5-(1,3-benzothiazol-7-yl)-1,3,4-oxadiazol-2-yl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]methyl]propanamide
DMJM8OQ	DE	Discovery agent

DM4D6ZB	ID	DM4D6ZB
DM4D6ZB	DN	BMS-1
DM4D6ZB	HS	Investigative
DM4D6ZB	SN	474429-87-3; Carbamic acid,N-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]-,2-fluorophenyl ester; SCHEMBL1709522; CHEMBL232782; bisarylimidazole derivative, 17; BDBM26758; ZINC1912275; KB-75932; 2-fluorophenyl N-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]carbamate
DM4D6ZB	DT	Small molecular drug
DM4D6ZB	PC	91663303
DM4D6ZB	MW	475.6
DM4D6ZB	FM	C29H33NO5
DM4D6ZB	IC	InChI=1S/C29H33NO5/c1-20-22(12-9-13-24(20)21-10-5-4-6-11-21)19-35-23-16-27(33-2)25(28(17-23)34-3)18-30-15-8-7-14-26(30)29(31)32/h4-6,9-13,16-17,26H,7-8,14-15,18-19H2,1-3H3,(H,31,32)/t26-/m0/s1
DM4D6ZB	CS	CC1=C(C=CC=C1C2=CC=CC=C2)COC3=CC(=C(C(=C3)OC)CN4CCCC[C@H]4C(=O)O)OC
DM4D6ZB	IK	ZBOYJODMIAUJHH-SANMLTNESA-N
DM4D6ZB	IU	(2S)-1-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid
DM4D6ZB	DE	Discovery agent

DMGE82R	ID	DMGE82R
DMGE82R	DN	BMS184394
DMGE82R	HS	Investigative
DMGE82R	SN	CHEMBL82089; AC1NBJP6; SCHEMBL6372648; BDBM31885; 6-[hydroxy-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)methyl]naphthalene-2-carboxylic Acid
DMGE82R	DT	Small molecular drug
DMGE82R	PC	445575
DMGE82R	MW	388.5
DMGE82R	FM	C26H28O3
DMGE82R	IC	InChI=1S/C26H28O3/c1-25(2)11-12-26(3,4)22-15-19(9-10-21(22)25)23(27)18-7-5-17-14-20(24(28)29)8-6-16(17)13-18/h5-10,13-15,23,27H,11-12H2,1-4H3,(H,28,29)/t23-/m0/s1
DMGE82R	CS	CC1(CCC(C2=C1C=CC(=C2)[C@H](C3=CC4=C(C=C3)C=C(C=C4)C(=O)O)O)(C)C)C
DMGE82R	IK	AYAJZQYENGWICE-QHCPKHFHSA-N
DMGE82R	IU	6-[(S)-hydroxy-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)methyl]naphthalene-2-carboxylic acid
DMGE82R	DE	Discovery agent

DMJ218E	ID	DMJ218E
DMJ218E	DN	BMS-187308
DMJ218E	HS	Investigative
DMJ218E	SN	153624-15-8
DMJ218E	DT	Small molecular drug
DMJ218E	PC	9908909
DMJ218E	MW	399.5
DMJ218E	FM	C21H25N3O3S
DMJ218E	IC	InChI=1S/C21H25N3O3S/c1-13(2)11-16-9-10-17(19(22)12-16)18-7-5-6-8-20(18)28(25,26)24-21-14(3)15(4)23-27-21/h5-10,12-13,24H,11,22H2,1-4H3
DMJ218E	CS	CC1=C(ON=C1C)NS(=O)(=O)C2=CC=CC=C2C3=C(C=C(C=C3)CC(C)C)N
DMJ218E	IK	OZDIAVKCLFSBME-UHFFFAOYSA-N
DMJ218E	IU	2-[2-amino-4-(2-methylpropyl)phenyl]-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide
DMJ218E	CA	CAS 153624-15-8
DMJ218E	DE	Discovery agent

DM7GUDC	ID	DM7GUDC
DM7GUDC	DN	BMS-189323
DM7GUDC	HS	Investigative
DM7GUDC	SN	SCHEMBL8353870; 2,6-Dimethyl-4-[3-[3-[3-[4-(2-methoxyphenyl)piperazino]propyl]ureido]phenyl]-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester
DM7GUDC	DT	Small molecular drug
DM7GUDC	PC	11548842
DM7GUDC	MW	591.7
DM7GUDC	FM	C32H41N5O6
DM7GUDC	IC	InChI=1S/C32H41N5O6/c1-21-27(30(38)42-4)29(28(22(2)34-21)31(39)43-5)23-10-8-11-24(20-23)35-32(40)33-14-9-15-36-16-18-37(19-17-36)25-12-6-7-13-26(25)41-3/h6-8,10-13,20,29,34H,9,14-19H2,1-5H3,(H2,33,35,40)
DM7GUDC	CS	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)NC(=O)NCCCN3CCN(CC3)C4=CC=CC=C4OC)C(=O)OC
DM7GUDC	IK	HSUYTMPXLKOBTD-UHFFFAOYSA-N
DM7GUDC	IU	dimethyl 4-[3-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylcarbamoylamino]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM7GUDC	DE	Discovery agent

DM1ZBU3	ID	DM1ZBU3
DM1ZBU3	DN	BMS-193885
DM1ZBU3	HS	Investigative
DM1ZBU3	SN	BMS-193885; UNII-819SRG2Y6N; 819SRG2Y6N; 186185-03-5; 1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-dimethyl ester-3,5-pyridinedicarboxylic acid; HMS3263K13; Tox21_501016; ZINC27088632; CCG-222320; NCGC00261701-01; NCGC00485144-01; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(3-((((3-(4-(3-methoxyphenyl)-1-piperidinyl)propyl)amino)carbonyl)amino)phenyl)-2,6-dimethyl-, dimethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(3-((((3-(4-(3-methoxyphen
DM1ZBU3	DT	Small molecular drug
DM1ZBU3	PC	9960164
DM1ZBU3	MW	590.7
DM1ZBU3	FM	C33H42N4O6
DM1ZBU3	IC	InChI=1S/C33H42N4O6/c1-21-28(31(38)42-4)30(29(22(2)35-21)32(39)43-5)25-10-6-11-26(19-25)36-33(40)34-15-8-16-37-17-13-23(14-18-37)24-9-7-12-27(20-24)41-3/h6-7,9-12,19-20,23,30,35H,8,13-18H2,1-5H3,(H2,34,36,40)
DM1ZBU3	CS	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)NC(=O)NCCCN3CCC(CC3)C4=CC(=CC=C4)OC)C(=O)OC
DM1ZBU3	IK	WMYSXJSJXZFODY-UHFFFAOYSA-N
DM1ZBU3	IU	dimethyl 4-[3-[3-[4-(3-methoxyphenyl)piperidin-1-yl]propylcarbamoylamino]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM1ZBU3	CA	CAS 186185-03-5
DM1ZBU3	DE	Discovery agent

DM5SNMQ	ID	DM5SNMQ
DM5SNMQ	DN	BMS-245782
DM5SNMQ	HS	Investigative
DM5SNMQ	DT	Small molecular drug
DM5SNMQ	PC	11505425
DM5SNMQ	MW	615.7
DM5SNMQ	FM	C33H41N7O5
DM5SNMQ	IC	InChI=1S/C33H41N7O5/c1-22-28(31(41)44-4)30(29(23(2)37-22)32(42)45-5)24-9-6-10-25(19-24)38-33(36-21-34)35-13-8-14-39-15-17-40(18-16-39)26-11-7-12-27(20-26)43-3/h6-7,9-12,19-20,30,37H,8,13-18H2,1-5H3,(H2,35,36,38)
DM5SNMQ	CS	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)NC(=NCCCN3CCN(CC3)C4=CC(=CC=C4)OC)NC#N)C(=O)OC
DM5SNMQ	IK	HDRYBCLMRKGHSG-UHFFFAOYSA-N
DM5SNMQ	IU	dimethyl 4-[3-[[N-cyano-N'-[3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl]carbamimidoyl]amino]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM5SNMQ	DE	Discovery agent

DMETNA3	ID	DMETNA3
DMETNA3	DN	BMS-262084
DMETNA3	HS	Investigative
DMETNA3	SN	BMS-262084; UNII-I0IR71971G; CHEMBL71037; I0IR71971G; 253174-92-4; (-)-BMS-262084; BDBM50120368; BDBM50220841; SB18716; 2-Azetidinecarboxylic acid, 3-(3-((aminoiminomethyl)amino)propyl)-1-((4-(((1,1-dimethylethyl)amino)carbonyl)-1-piperazinyl)carbonyl)-4-oxo-, (2S,3R)-; (R)-1-(4-tert-Butylcarbamoyl-piperazine-1-carbonyl)-3-(3-guanidino-propyl)-4-oxo-azetidine-2-carboxylic acid; (3S,4R)-1-(4-tert-Butylcarbamoyl-piperazine-1-carbonyl)-3-(3-guanidino-propyl)-4-oxo-azetidine-2-carboxylic acid
DMETNA3	DT	Small molecular drug
DMETNA3	PC	9802488
DMETNA3	MW	425.5
DMETNA3	FM	C18H31N7O5
DMETNA3	IC	InChI=1S/C18H31N7O5/c1-18(2,3)22-16(29)23-7-9-24(10-8-23)17(30)25-12(14(27)28)11(13(25)26)5-4-6-21-15(19)20/h11-12H,4-10H2,1-3H3,(H,22,29)(H,27,28)(H4,19,20,21)/t11-,12+/m1/s1
DMETNA3	CS	CC(C)(C)NC(=O)N1CCN(CC1)C(=O)N2[C@@H]([C@H](C2=O)CCCN=C(N)N)C(=O)O
DMETNA3	IK	MFTQITSPGQORDA-NEPJUHHUSA-N
DMETNA3	IU	(2S,3R)-1-[4-(tert-butylcarbamoyl)piperazine-1-carbonyl]-3-[3-(diaminomethylideneamino)propyl]-4-oxoazetidine-2-carboxylic acid
DMETNA3	CA	CAS 253174-92-4
DMETNA3	DE	Discovery agent

DM6LPIG	ID	DM6LPIG
DM6LPIG	DN	BMS-265246
DM6LPIG	HS	Investigative
DM6LPIG	SN	BMS 265246; BMS265246
DM6LPIG	DT	Small molecular drug
DM6LPIG	PC	135402864
DM6LPIG	MW	345.3
DM6LPIG	FM	C18H17F2N3O2
DM6LPIG	IC	InChI=1S/C18H17F2N3O2/c1-3-4-5-25-17-11(8-21-18-12(17)9-22-23-18)16(24)15-13(19)6-10(2)7-14(15)20/h6-9H,3-5H2,1-2H3,(H,21,22,23)
DM6LPIG	CS	CCCCOC1=C(C=NC2=NNC=C12)C(=O)C3=C(C=C(C=C3F)C)F
DM6LPIG	IK	SCFMWQIQBVZOQR-UHFFFAOYSA-N
DM6LPIG	IU	(4-butoxy-2H-pyrazolo[3,4-b]pyridin-5-yl)-(2,6-difluoro-4-methylphenyl)methanone
DM6LPIG	CA	CAS 582315-72-8
DM6LPIG	DE	Discovery agent

DMZLE0U	ID	DMZLE0U
DMZLE0U	DN	BMS-269223
DMZLE0U	HS	Investigative
DMZLE0U	SN	CHEMBL551991; cyanoguanidine, 3; BMS-269223
DMZLE0U	DT	Small molecular drug
DMZLE0U	PC	44249821
DMZLE0U	MW	436.5
DMZLE0U	FM	C23H28N6O3
DMZLE0U	IC	InChI=1S/C23H28N6O3/c1-16-12-17-13-18(7-8-20(17)32-16)26-23(25-15-24)27-19-6-2-3-11-29(22(19)31)14-21(30)28-9-4-5-10-28/h7-8,12-13,19H,2-6,9-11,14H2,1H3,(H2,25,26,27)/t19-/m0/s1
DMZLE0U	CS	CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC#N
DMZLE0U	IK	BQUXAJWDRCSKFN-IBGZPJMESA-N
DMZLE0U	IU	1-cyano-3-(2-methyl-1-benzofuran-5-yl)-2-[(3S)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]guanidine
DMZLE0U	DE	Discovery agent

DM82SJP	ID	DM82SJP
DM82SJP	DN	BMS270394
DM82SJP	HS	Investigative
DM82SJP	SN	BMS 961; BMS-270394; BMS 270394
DM82SJP	DT	Small molecular drug
DM82SJP	PC	445455
DM82SJP	MW	399.5
DM82SJP	FM	C23H26FNO4
DM82SJP	IC	InChI=1S/C23H26FNO4/c1-22(2)9-10-23(3,4)16-11-13(5-7-15(16)22)19(26)20(27)25-18-8-6-14(21(28)29)12-17(18)24/h5-8,11-12,19,26H,9-10H2,1-4H3,(H,25,27)(H,28,29)/t19-/m1/s1
DM82SJP	CS	CC1(CCC(C2=C1C=CC(=C2)[C@H](C(=O)NC3=C(C=C(C=C3)C(=O)O)F)O)(C)C)C
DM82SJP	IK	AANFHDFOMFRLLR-LJQANCHMSA-N
DM82SJP	IU	3-fluoro-4-[[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid
DM82SJP	DE	Discovery agent

DMOLCFQ	ID	DMOLCFQ
DMOLCFQ	DN	BMS-279700
DMOLCFQ	HS	Investigative
DMOLCFQ	SN	BMS-279700; UNII-8FX9DP2Y1W; 8FX9DP2Y1W; CHEMBL189338; 240814-54-4; SCHEMBL4036209; BDBM50151366; Imidazo(1,5-a)pyrido(3,2-E)pyrazin-6-amine, N-(2-chloro-6-methylphenyl)-2-((3S)-3-methyl-1-piperazinyl)-
DMOLCFQ	DT	Small molecular drug
DMOLCFQ	PC	9844320
DMOLCFQ	MW	407.9
DMOLCFQ	FM	C21H22ClN7
DMOLCFQ	IC	InChI=1S/C21H22ClN7/c1-13-4-3-5-15(22)19(13)27-20-17-10-23-12-29(17)21-16(25-20)6-7-18(26-21)28-9-8-24-14(2)11-28/h3-7,10,12,14,24H,8-9,11H2,1-2H3,(H,25,27)/t14-/m0/s1
DMOLCFQ	CS	C[C@H]1CN(CCN1)C2=NC3=C(C=C2)N=C(C4=CN=CN43)NC5=C(C=CC=C5Cl)C
DMOLCFQ	IK	PUNYTBZWCMNSRO-AWEZNQCLSA-N
DMOLCFQ	IU	N-(2-chloro-6-methylphenyl)-12-[(3S)-3-methylpiperazin-1-yl]-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-7-amine
DMOLCFQ	CA	CAS 240814-54-4
DMOLCFQ	DE	Discovery agent

DM21CYI	ID	DM21CYI
DM21CYI	DN	BMS-316810
DM21CYI	HS	Investigative
DM21CYI	SN	BMS-316810; CHEMBL360330; SCHEMBL12961958; BDBM50164025; Pyridine-2-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-thiophen-3-ylmethyl-amide
DM21CYI	DT	Small molecular drug
DM21CYI	PC	9806149
DM21CYI	MW	504.6
DM21CYI	FM	C25H24N6O2S2
DM21CYI	IC	InChI=1S/C25H24N6O2S2/c1-29-18-27-13-23(29)16-30-15-22(11-21-10-19(12-26)5-6-24(21)30)31(14-20-7-9-34-17-20)35(32,33)25-4-2-3-8-28-25/h2-10,13,17-18,22H,11,14-16H2,1H3
DM21CYI	CS	CN1C=NC=C1CN2CC(CC3=C2C=CC(=C3)C#N)N(CC4=CSC=C4)S(=O)(=O)C5=CC=CC=N5
DM21CYI	IK	FPEPZFNRGIPRRN-UHFFFAOYSA-N
DM21CYI	IU	N-[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2H-quinolin-3-yl]-N-(thiophen-3-ylmethyl)pyridine-2-sulfonamide
DM21CYI	DE	Discovery agent

DM9WRUG	ID	DM9WRUG
DM9WRUG	DN	BMS-344577
DM9WRUG	HS	Investigative
DM9WRUG	SN	BMS-344577; UNII-U259PQB19A; U259PQB19A; CHEMBL570867; 288079-93-6; BDBM35316; BDBM50328724; 2,5-Pyridinedicarboxamide, N5-((((3S)-hexahydro-2-oxo-1-(2-oxo-2-(1-pyrrolidinyl)ethyl)-1H-azepin-3-yl)imino)((2-methyl-5-benzofuranyl)amino)methyl)-N2,N2-dimethyl-; 2,5-Pyridinedicarboxamide, N5-((((3S)-hexahydro-2-oxo-1-(2-oxo-2-(1-pyrrolidinyl)ethyl)-1H-azepin-3-yl)amino)((2-methyl-5-benzofuranyl)amino)methylene)-N2,N2-dimethyl-
DM9WRUG	DT	Small molecular drug
DM9WRUG	PC	44473100
DM9WRUG	MW	587.7
DM9WRUG	FM	C31H37N7O5
DM9WRUG	IC	InChI=1S/C31H37N7O5/c1-20-16-22-17-23(10-12-26(22)43-20)33-31(35-28(40)21-9-11-24(32-18-21)29(41)36(2)3)34-25-8-4-5-15-38(30(25)42)19-27(39)37-13-6-7-14-37/h9-12,16-18,25H,4-8,13-15,19H2,1-3H3,(H2,33,34,35,40)/t25-/m0/s1
DM9WRUG	CS	CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N(C)C
DM9WRUG	IK	YLSKCQOVDOZHTQ-VWLOTQADSA-N
DM9WRUG	IU	2-N,2-N-dimethyl-5-N-[N-(2-methyl-1-benzofuran-5-yl)-N'-[(3S)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]carbamimidoyl]pyridine-2,5-dicarboxamide
DM9WRUG	CA	CAS 288079-93-6
DM9WRUG	DE	Discovery agent

DM7D519	ID	DM7D519
DM7D519	DN	BMS-345541
DM7D519	HS	Investigative
DM7D519	SN	445430-58-0; BMS345541; BMS-345541 free base; BMS-345541 (free base); UNII-26SU0NEF5F; N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine; 26SU0NEF5F; IKK Inhibitor III, BMS-345541; C14H17N5; 4-(2&amp; -Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline; BMS-345541(free base); IKK Inhibitor III; Kinome_3215; SCHEMBL118886; GTPL5669; CHEMBL249697; CTK8E9618; KS-00001CRN; CHEBI:91340; BDBM25919; DTXSID60196216; PSPFQEBFYXJZEV-UHFFFAOYSA-N; MolPort-035-395-836; HMS3653F06; HMS2043P05
DM7D519	DT	Small molecular drug
DM7D519	PC	9926054
DM7D519	MW	291.78
DM7D519	FM	C14H18ClN5
DM7D519	IC	InChI=1S/C14H17N5.ClH/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15;/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18);1H
DM7D519	CS	CC1=CC2=C(C=C1)N=C(C3=NC=C(N23)C)NCCN.Cl
DM7D519	IK	MIDKPVLYXNLFGZ-UHFFFAOYSA-N
DM7D519	IU	N'-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine;hydrochloride
DM7D519	CA	CAS 445430-59-1
DM7D519	DE	Arthritis

DM1ZDFG	ID	DM1ZDFG
DM1ZDFG	DN	BMS-404683
DM1ZDFG	HS	Investigative
DM1ZDFG	SN	BMS-404683
DM1ZDFG	DT	Small molecular drug
DM1ZDFG	PC	11409845
DM1ZDFG	MW	521.6
DM1ZDFG	FM	C26H31N7O3S
DM1ZDFG	IC	InChI=1S/C26H31N7O3S/c1-26(2,3)30-24(34)17-33(37(35,36)25-7-5-6-10-29-25)21-12-20-11-19(13-27)8-9-23(20)32(15-21)16-22-14-28-18-31(22)4/h5-11,14,18,21H,12,15-17H2,1-4H3,(H,30,34)
DM1ZDFG	CS	CC(C)(C)NC(=O)CN(C1CC2=C(C=CC(=C2)C#N)N(C1)CC3=CN=CN3C)S(=O)(=O)C4=CC=CC=N4
DM1ZDFG	IK	BRCRPMJRHQPZEZ-UHFFFAOYSA-N
DM1ZDFG	IU	N-tert-butyl-2-[[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2H-quinolin-3-yl]-pyridin-2-ylsulfonylamino]acetamide
DM1ZDFG	DE	Discovery agent

DMTPNI4	ID	DMTPNI4
DMTPNI4	DN	BMS-480404
DMTPNI4	HS	Investigative
DMTPNI4	SN	UNII-T78485CEYD; BMS-480404; T78485CEYD; CHEMBL378857; 533889-36-0; BDBM50192462; Benzeneacetic acid, 2,3-bis((2-chlorophenyl)methoxy)-alpha-hydroxy-, (alphaS)-; (S)-2-(2,3-bis(2-chlorobenzyloxy)phenyl)-2-hydroxyacetic acid
DMTPNI4	DT	Small molecular drug
DMTPNI4	PC	16046219
DMTPNI4	MW	433.3
DMTPNI4	FM	C22H18Cl2O5
DMTPNI4	IC	InChI=1S/C22H18Cl2O5/c23-17-9-3-1-6-14(17)12-28-19-11-5-8-16(20(25)22(26)27)21(19)29-13-15-7-2-4-10-18(15)24/h1-11,20,25H,12-13H2,(H,26,27)/t20-/m0/s1
DMTPNI4	CS	C1=CC=C(C(=C1)COC2=CC=CC(=C2OCC3=CC=CC=C3Cl)[C@@H](C(=O)O)O)Cl
DMTPNI4	IK	NCWQPARYSYJFNI-FQEVSTJZSA-N
DMTPNI4	IU	(2S)-2-[2,3-bis[(2-chlorophenyl)methoxy]phenyl]-2-hydroxyacetic acid
DMTPNI4	CA	CAS 533889-36-0
DMTPNI4	DE	Discovery agent

DM6Y1QF	ID	DM6Y1QF
DM6Y1QF	DN	BMS-488516
DM6Y1QF	HS	Investigative
DM6Y1QF	CP	Bristol-Myers Squibb
DM6Y1QF	PC	11527400
DM6Y1QF	MW	621.9
DM6Y1QF	FM	C33H43N5O3S2
DM6Y1QF	IC	InChI=1S/C33H43N5O3S2/c1-21-16-26(17-28(22(21)2)31(41)38-14-12-37(13-15-38)24(4)39)20-42-29-19-35-32(43-29)36-30(40)27-10-8-25(9-11-27)18-34-23(3)33(5,6)7/h8-11,16-17,19,23,34H,12-15,18,20H2,1-7H3,(H,35,36,40)
DM6Y1QF	CS	CC1=CC(=CC(=C1C)C(=O)N2CCN(CC2)C(=O)C)CSC3=CN=C(S3)NC(=O)C4=CC=C(C=C4)CNC(C)C(C)(C)C
DM6Y1QF	IK	DQPJVNQWPBLBAB-UHFFFAOYSA-N
DM6Y1QF	IU	N-[5-[[3-(4-acetylpiperazine-1-carbonyl)-4,5-dimethylphenyl]methylsulfanyl]-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide
DM6Y1QF	DE	Inflammation

DMGH1LX	ID	DMGH1LX
DMGH1LX	DN	BMS-509744
DMGH1LX	HS	Investigative
DMGH1LX	SN	BMS-509744; 439575-02-7; BMS 509744; CHEMBL209148; N-(5-((5-(4-Acetylpiperazine-1-carbonyl)-4-methoxy-2-methylphenyl)thio)thiazol-2-yl)-4-(((3,3-dimethylbutan-2-yl)amino)methyl)benzamide; N-[5-[5-(4-acetylpiperazine-1-carbonyl)-4-methoxy-2-methylphenyl]sulfanyl-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide; GTPL9994; SCHEMBL14460651; KS-00001CVA; CHEBI:91404; MolPort-039-101-283; C32H41N5O4S2; BMS509744; BDBM50186460; 3499AH; compound 3 [PMID:16682193]; AKOS025142036; NCGC00229512-02; NCGC00229512-01
DMGH1LX	CP	Bristol-Myers Squibb
DMGH1LX	DT	Small molecular drug
DMGH1LX	PC	11467730
DMGH1LX	MW	623.8
DMGH1LX	FM	C32H41N5O4S2
DMGH1LX	IC	InChI=1S/C32H41N5O4S2/c1-20-16-26(41-7)25(30(40)37-14-12-36(13-15-37)22(3)38)17-27(20)42-28-19-34-31(43-28)35-29(39)24-10-8-23(9-11-24)18-33-21(2)32(4,5)6/h8-11,16-17,19,21,33H,12-15,18H2,1-7H3,(H,34,35,39)
DMGH1LX	CS	CC1=CC(=C(C=C1SC2=CN=C(S2)NC(=O)C3=CC=C(C=C3)CNC(C)C(C)(C)C)C(=O)N4CCN(CC4)C(=O)C)OC
DMGH1LX	IK	ZHXNIYGJAOPMSO-UHFFFAOYSA-N
DMGH1LX	IU	N-[5-[5-(4-acetylpiperazine-1-carbonyl)-4-methoxy-2-methylphenyl]sulfanyl-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide
DMGH1LX	CA	CAS 439575-02-7
DMGH1LX	CB	CHEBI:91404
DMGH1LX	DE	Inflammation

DMAY9TM	ID	DMAY9TM
DMAY9TM	DN	BMS-520
DMAY9TM	HS	Investigative
DMAY9TM	SN	S1P1 agonists (immunology); S1P1 agonists (immunology), Bristol-Myers Squibb
DMAY9TM	CP	Bristol-Myers Squibb Co
DMAY9TM	DE	Immune System disease

DMXJB4N	ID	DMXJB4N
DMXJB4N	DN	BMS-536924
DMXJB4N	HS	Investigative
DMXJB4N	DT	Small molecular drug
DMXJB4N	PC	135440466
DMXJB4N	MW	480
DMXJB4N	FM	C25H26ClN5O3
DMXJB4N	IC	InChI=1S/C25H26ClN5O3/c1-15-11-18(31-7-9-34-10-8-31)13-20-23(15)30-24(29-20)22-19(5-6-27-25(22)33)28-14-21(32)16-3-2-4-17(26)12-16/h2-6,11-13,21,32H,7-10,14H2,1H3,(H,29,30)(H2,27,28,33)/t21-/m1/s1
DMXJB4N	CS	CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5
DMXJB4N	IK	ZWVZORIKUNOTCS-OAQYLSRUSA-N
DMXJB4N	IU	4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one
DMXJB4N	CA	CAS 468740-43-4
DMXJB4N	CB	CHEBI:91454
DMXJB4N	DE	Discovery agent

DM3WBKN	ID	DM3WBKN
DM3WBKN	DN	BMS-561388
DM3WBKN	HS	Investigative
DM3WBKN	SN	UNII-NQ8L686GDJ; NQ8L686GDJ; BMS-561388 besylate; SCHEMBL5104174; CHEMBL474287; BMS-561388 monobenzenesulfonate; 383368-51-2; Pyrazolo(1,5-a)-1,3,5-triazin-4-amine, N,N-bis(2-methoxyethyl)-8-(4-methoxy-2-methylphenyl)-2,7-dimethyl-, monobenzenesulfonate; Pyrazolo(1,5-a)-1,3,5-triazin-4-amine, N,N-bis(2-methoxyethyl)-8-(4-methoxy-2-methylphenyl)-2,7-dimethyl-, benzenesulfonate (1:1)
DM3WBKN	DT	Small molecular drug
DM3WBKN	PC	11249907
DM3WBKN	MW	557.7
DM3WBKN	FM	C27H35N5O6S
DM3WBKN	IC	InChI=1S/C21H29N5O3.C6H6O3S/c1-14-13-17(29-6)7-8-18(14)19-15(2)24-26-20(19)22-16(3)23-21(26)25(9-11-27-4)10-12-28-5;7-10(8,9)6-4-2-1-3-5-6/h7-8,13H,9-12H2,1-6H3;1-5H,(H,7,8,9)
DM3WBKN	CS	CC1=C(C=CC(=C1)OC)C2=C3N=C(N=C(N3N=C2C)N(CCOC)CCOC)C.C1=CC=C(C=C1)S(=O)(=O)O
DM3WBKN	IK	ZQUBMILBXQLTDU-UHFFFAOYSA-N
DM3WBKN	IU	benzenesulfonic acid;N,N-bis(2-methoxyethyl)-8-(4-methoxy-2-methylphenyl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DM3WBKN	CA	CAS 383368-51-2
DM3WBKN	DE	Anxiety disorder

DMILMHZ	ID	DMILMHZ
DMILMHZ	DN	BMS-564929
DMILMHZ	HS	Investigative
DMILMHZ	SN	BMS-564929; 627530-84-1; UNII-9BLW27W4X7; BMS 564929; 9BLW27W4X7; C14H12ClN3O3; 2-Chloro-4-[(7r,7as)-7-Hydroxy-1,3-Dioxotetrahydro-1h-Pyrrolo[1,2-C]imidazol-2(3h)-Yl]-3-Methylbenzonitrile; 2-Chloro-3-methyl-4-[(7R,7AS)-tetrahydro-7-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]benzonitrile; KEJORAMIZFOODM-PWSUYJOCSA-N; 2nw4; SCHEMBL2967577; DTXSID50432357; ZINC3938678; 3500AH; AKOS027288930; CS-1381; DB07286; BMS-564,929; NCGC00378909-01; HY-12111; 8NH; KB-75607; BMS 564929;BMS564929; W-5594; S900006120
DMILMHZ	DT	Small molecular drug
DMILMHZ	PC	9882972
DMILMHZ	MW	305.71
DMILMHZ	FM	C14H12ClN3O3
DMILMHZ	IC	InChI=1S/C14H12ClN3O3/c1-7-9(3-2-8(6-16)11(7)15)18-13(20)12-10(19)4-5-17(12)14(18)21/h2-3,10,12,19H,4-5H2,1H3/t10-,12+/m1/s1
DMILMHZ	CS	CC1=C(C=CC(=C1Cl)C#N)N2C(=O)[C@@H]3[C@@H](CCN3C2=O)O
DMILMHZ	IK	KEJORAMIZFOODM-PWSUYJOCSA-N
DMILMHZ	IU	4-[(7R,7aS)-7-hydroxy-1,3-dioxo-5,6,7,7a-tetrahydropyrrolo[1,2-c]imidazol-2-yl]-2-chloro-3-methylbenzonitrile
DMILMHZ	CA	CAS 627530-84-1
DMILMHZ	DE	Discovery agent

DMZWNO9	ID	DMZWNO9
DMZWNO9	DN	BMS614
DMZWNO9	HS	Investigative
DMZWNO9	SN	BMS 614; BMS-614
DMZWNO9	DT	Small molecular drug
DMZWNO9	PC	445091
DMZWNO9	MW	448.5
DMZWNO9	FM	C29H24N2O3
DMZWNO9	IC	InChI=1S/C29H24N2O3/c1-29(2)14-13-23(21-15-19-5-3-4-6-26(19)30-17-21)24-16-20(9-12-25(24)29)27(32)31-22-10-7-18(8-11-22)28(33)34/h3-13,15-17H,14H2,1-2H3,(H,31,32)(H,33,34)
DMZWNO9	CS	CC1(CC=C(C2=C1C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)C4=CC5=CC=CC=C5N=C4)C
DMZWNO9	IK	WGLMBRZXZDAQHP-UHFFFAOYSA-N
DMZWNO9	IU	4-[(5,5-dimethyl-8-quinolin-3-yl-6H-naphthalene-2-carbonyl)amino]benzoic acid
DMZWNO9	CA	CAS 182135-66-6
DMZWNO9	CB	CHEBI:132571
DMZWNO9	DE	Discovery agent

DMRT7G3	ID	DMRT7G3
DMRT7G3	DN	BMS641
DMRT7G3	HS	Investigative
DMRT7G3	SN	BMS-641; BMS 641
DMRT7G3	DT	Small molecular drug
DMRT7G3	PC	22737393
DMRT7G3	MW	414.9
DMRT7G3	FM	C27H23ClO2
DMRT7G3	IC	InChI=1S/C27H23ClO2/c1-27(2)15-14-22(19-6-4-3-5-7-19)23-16-18(9-13-24(23)27)8-10-20-11-12-21(26(29)30)17-25(20)28/h3-14,16-17H,15H2,1-2H3,(H,29,30)/b10-8+
DMRT7G3	CS	CC1(CC=C(C2=C1C=CC(=C2)/C=C/C3=C(C=C(C=C3)C(=O)O)Cl)C4=CC=CC=C4)C
DMRT7G3	IK	FRTYVAKGTFXRNY-CSKARUKUSA-N
DMRT7G3	IU	3-chloro-4-[(E)-2-(5,5-dimethyl-8-phenyl-6H-naphthalen-2-yl)ethenyl]benzoic acid
DMRT7G3	DE	Discovery agent

DMBTMO9	ID	DMBTMO9
DMBTMO9	DN	BMS-645737
DMBTMO9	HS	Investigative
DMBTMO9	SN	651744-16-0; BMS-645737; BMS645737; 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; UNII-86H6HFH34L; 86H6HFH34L; CHEMBL261592; 6-(5-methyl-1,3,4-oxadiazol-2-yl)-n-{2-methyl-1h-pyrrolo[2,3-b]pyridin-5-yl}-5-(propan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; 5-Isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo-[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; C20H20N8O
DMBTMO9	DT	Small molecular drug
DMBTMO9	PC	22273644
DMBTMO9	MW	388.4
DMBTMO9	FM	C20H20N8O
DMBTMO9	IC	InChI=1S/C20H20N8O/c1-10(2)16-15(20-27-26-12(4)29-20)8-28-17(16)19(22-9-23-28)25-14-6-13-5-11(3)24-18(13)21-7-14/h5-10H,1-4H3,(H,21,24)(H,22,23,25)
DMBTMO9	CS	CC1=CC2=CC(=CN=C2N1)NC3=NC=NN4C3=C(C(=C4)C5=NN=C(O5)C)C(C)C
DMBTMO9	IK	OOQXPATWSOGSAV-UHFFFAOYSA-N
DMBTMO9	IU	6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine
DMBTMO9	CA	CAS 651744-16-0
DMBTMO9	DE	Discovery agent

DMYAPG5	ID	DMYAPG5
DMYAPG5	DN	BMS-687453
DMYAPG5	HS	Investigative
DMYAPG5	SN	BMS-687453; 1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine
DMYAPG5	DT	Small molecular drug
DMYAPG5	PC	16725047
DMYAPG5	MW	444.9
DMYAPG5	FM	C22H21ClN2O6
DMYAPG5	IC	InChI=1S/C22H21ClN2O6/c1-14-19(24-21(31-14)16-6-8-17(23)9-7-16)13-30-18-5-3-4-15(10-18)11-25(12-20(26)27)22(28)29-2/h3-10H,11-13H2,1-2H3,(H,26,27)
DMYAPG5	CS	CC1=C(N=C(O1)C2=CC=C(C=C2)Cl)COC3=CC=CC(=C3)CN(CC(=O)O)C(=O)OC
DMYAPG5	IK	UJIBXDMNCMEJAY-UHFFFAOYSA-N
DMYAPG5	IU	2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid
DMYAPG5	CA	CAS 1000998-59-3
DMYAPG5	DE	Discovery agent

DM8PA3U	ID	DM8PA3U
DM8PA3U	DN	BMS-694153
DM8PA3U	HS	Investigative
DM8PA3U	SN	BMS-694153; UNII-69MB5VHL5J; 69MB5VHL5J; CHEMBL450668; (R)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide; BMS 694153; 1050381-35-5; BDBM50268484; 1-Piperidinecarboxamide, N-((1R)-2-(1,4'-bipiperidin)-1'-yl-1-((7-methyl-1H-indazol-5-yl)methyl)-2-oxoethyl)-4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-
DM8PA3U	DT	Small molecular drug
DM8PA3U	PC	44593666
DM8PA3U	MW	644.8
DM8PA3U	FM	C35H45FN8O3
DM8PA3U	IC	InChI=1S/C35H45FN8O3/c1-23-18-24(19-26-21-37-40-31(23)26)20-30(33(45)42-14-8-27(9-15-42)41-12-3-2-4-13-41)38-34(46)43-16-10-28(11-17-43)44-22-25-6-5-7-29(36)32(25)39-35(44)47/h5-7,18-19,21,27-28,30H,2-4,8-17,20,22H2,1H3,(H,37,40)(H,38,46)(H,39,47)/t30-/m1/s1
DM8PA3U	CS	CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O
DM8PA3U	IK	HBOINTMVWRSZQS-SSEXGKCCSA-N
DM8PA3U	IU	4-(8-fluoro-2-oxo-1,4-dihydroquinazolin-3-yl)-N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-piperidin-1-ylpiperidin-1-yl)propan-2-yl]piperidine-1-carboxamide
DM8PA3U	CA	CAS 1050381-35-5
DM8PA3U	DE	Migraine

DMFODQV	ID	DMFODQV
DMFODQV	DN	BMS-739562
DMFODQV	HS	Investigative
DMFODQV	SN	Pyrrolo triazine-based aurora kinase inhibitors (cancer); Pyrrolo triazine-based aurora kinase inhibitors (cancer), Bristol-Myers Squibb
DMFODQV	CP	Bristol-Myers Squibb Co
DMFODQV	DE	Solid tumour/cancer

DMQ24TI	ID	DMQ24TI
DMQ24TI	DN	BMS-740808
DMQ24TI	HS	Investigative
DMQ24TI	SN	BMS-740808; 280118-23-2; BMS 740808; UNII-LDD74E663F; BMS740808; LDD74E663F; 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2'-{[(3R)-3-HYDROXYPYRROLIDIN-1-YL]METHYL}BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE; 2fzz; 1-(3-amino-1,2-benzoxazol-5-yl)-6-[4-[2-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]phenyl]phenyl]-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-7-one; 5QC; AC1OCAC6; SCHEMBL8360280; CHEMBL378093; BDBM12693; DTXSID40182293; C31H27F3N6O3; BCPP000326; BCP23400; ZINC14210470
DMQ24TI	DT	Small molecular drug
DMQ24TI	PC	6914623
DMQ24TI	MW	588.6
DMQ24TI	FM	C31H27F3N6O3
DMQ24TI	IC	InChI=1S/C31H27F3N6O3/c32-31(33,34)28-24-12-14-39(30(42)27(24)40(36-28)21-9-10-26-25(15-21)29(35)37-43-26)20-7-5-18(6-8-20)23-4-2-1-3-19(23)16-38-13-11-22(41)17-38/h1-10,15,22,41H,11-14,16-17H2,(H2,35,37)/t22-/m1/s1
DMQ24TI	CS	C1CN(C[C@@H]1O)CC2=CC=CC=C2C3=CC=C(C=C3)N4CCC5=C(C4=O)N(N=C5C(F)(F)F)C6=CC7=C(C=C6)ON=C7N
DMQ24TI	IK	DFRIQJHMGZBFOM-JOCHJYFZSA-N
DMQ24TI	IU	1-(3-amino-1,2-benzoxazol-5-yl)-6-[4-[2-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]phenyl]phenyl]-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-7-one
DMQ24TI	CA	CAS 280118-23-2
DMQ24TI	DE	Discovery agent

DMSX1NF	ID	DMSX1NF
DMSX1NF	DN	BMS753
DMSX1NF	HS	Investigative
DMSX1NF	SN	BMS-753; BMS 753
DMSX1NF	DT	Small molecular drug
DMSX1NF	PC	9884820
DMSX1NF	MW	351.4
DMSX1NF	FM	C21H21NO4
DMSX1NF	IC	InChI=1S/C21H21NO4/c1-20(2)15-10-7-13(11-16(15)21(3,4)19(20)26)17(23)22-14-8-5-12(6-9-14)18(24)25/h5-11H,1-4H3,(H,22,23)(H,24,25)
DMSX1NF	CS	CC1(C2=C(C=C(C=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)C(C1=O)(C)C)C
DMSX1NF	IK	KFBPBWUZXBYJDG-UHFFFAOYSA-N
DMSX1NF	IU	4-[(1,1,3,3-tetramethyl-2-oxoindene-5-carbonyl)amino]benzoic acid
DMSX1NF	DE	Discovery agent

DM1HBF5	ID	DM1HBF5
DM1HBF5	DN	BMS-812204
DM1HBF5	HS	Investigative
DM1HBF5	SN	CB1 antagonists (obesity), BMS; CB1 antagonists (obesity), Bristol-Myers Squibb
DM1HBF5	CP	Bristol-Myers Squibb Co
DM1HBF5	DE	Obesity

DMI796T	ID	DMI796T
DMI796T	DN	BMS-A
DMI796T	HS	Investigative
DMI796T	SN	CCR2 antagonists (inflammatory/metabolic diseases); CCR2 antagonists (inflammatory/metabolic diseases), Bristol-Myers Squibb
DMI796T	CP	Bristol-Myers Squibb Co
DMI796T	DT	Small molecular drug
DMI796T	PC	10474339
DMI796T	MW	370.71
DMI796T	FM	C16H10ClF3N2O3
DMI796T	IC	InChI=1S/C16H10ClF3N2O3/c17-12-5-6-13(23)10(7-12)8-22-15(24)25-14(21-22)9-1-3-11(4-2-9)16(18,19)20/h1-7,23H,8H2
DMI796T	CS	C1=CC(=CC=C1C2=NN(C(=O)O2)CC3=C(C=CC(=C3)Cl)O)C(F)(F)F
DMI796T	IK	QKOWACXSXTXRKA-UHFFFAOYSA-N
DMI796T	IU	3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-one
DMI796T	CA	CAS 202821-81-6
DMI796T	CB	CHEBI:93672
DMI796T	DE	Inflammation

DMT02B8	ID	DMT02B8
DMT02B8	DN	BMY 45778
DMT02B8	HS	Investigative
DMT02B8	SN	BMY45778; BMY-45778
DMT02B8	DT	Small molecular drug
DMT02B8	PC	127861
DMT02B8	MW	438.4
DMT02B8	FM	C26H18N2O5
DMT02B8	IC	InChI=1S/C26H18N2O5/c29-21(30)15-31-20-13-7-12-19(14-20)24-23(27-16-32-24)26-28-22(17-8-3-1-4-9-17)25(33-26)18-10-5-2-6-11-18/h1-14,16H,15H2,(H,29,30)
DMT02B8	CS	C1=CC=C(C=C1)C2=C(OC(=N2)C3=C(OC=N3)C4=CC(=CC=C4)OCC(=O)O)C5=CC=CC=C5
DMT02B8	IK	DSRSEEYZGWTODH-UHFFFAOYSA-N
DMT02B8	IU	2-[3-[4-(4,5-diphenyl-1,3-oxazol-2-yl)-1,3-oxazol-5-yl]phenoxy]acetic acid
DMT02B8	CA	CAS 152575-66-1
DMT02B8	CB	CHEBI:51544
DMT02B8	DE	Discovery agent

DMAMYWL	ID	DMAMYWL
DMAMYWL	DN	BMY-27709
DMAMYWL	HS	Investigative
DMAMYWL	SN	BMY-27709; AC1L2RSV; AC1Q3LRY; 99390-76-8; CHEMBL68649; Brl 20627; SCHEMBL15532024; 4-amino-5-chloro-2-hydroxy-n-[(2s,6r,9ar)-6-methyloctahydro-2h-quinolizin-2-yl]benzamide; 4-Amino-5-chloro-2-hydroxy-N-(octahydro-6-methyl-2H-quinolizin-2yl)benzamide; N-[(2S,6R,9aR)-6-methyl-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-2-yl]-4-amino-5-chloro-2-hydroxy-benzamide; Benzamide, 4-amino-N-[(2S,6R,9aR)-octahydro-6-methyl-2H-quinolizin-2-yl]-5-chloro-2-hydroxy-
DMAMYWL	DT	Small molecular drug
DMAMYWL	PC	127317
DMAMYWL	MW	337.8
DMAMYWL	FM	C17H24ClN3O2
DMAMYWL	IC	InChI=1S/C17H24ClN3O2/c1-10-3-2-4-12-7-11(5-6-21(10)12)20-17(23)13-8-14(18)15(19)9-16(13)22/h8-12,22H,2-7,19H2,1H3,(H,20,23)/t10-,11+,12-/m1/s1
DMAMYWL	CS	C[C@@H]1CCC[C@H]2N1CC[C@@H](C2)NC(=O)C3=CC(=C(C=C3O)N)Cl
DMAMYWL	IK	SQQXDSFKORQHET-GRYCIOLGSA-N
DMAMYWL	IU	N-[(2S,6R,9aR)-6-methyl-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-2-yl]-4-amino-5-chloro-2-hydroxybenzamide
DMAMYWL	CA	CAS 99390-76-8
DMAMYWL	DE	Discovery agent

DM1CNU5	ID	DM1CNU5
DM1CNU5	DN	BN-81,644
DM1CNU5	HS	Investigative
DM1CNU5	SN	BN 81,644; BN81,644; BN-81644; BN81644; BN 81644
DM1CNU5	DT	Small molecular drug
DM1CNU5	PC	9802572
DM1CNU5	MW	426.6
DM1CNU5	FM	C28H34N4
DM1CNU5	IC	InChI=1S/C28H34N4/c1-3-5-16-28(17-6-4-2)26-22(21-14-10-11-15-23(21)30-26)18-24(32-28)27-29-19-25(31-27)20-12-8-7-9-13-20/h7-15,19,24,30,32H,3-6,16-18H2,1-2H3,(H,29,31)/t24-/m1/s1
DM1CNU5	CS	CCCCC1(C2=C(C[C@@H](N1)C3=NC=C(N3)C4=CC=CC=C4)C5=CC=CC=C5N2)CCCC
DM1CNU5	IK	FOBFICSYUINKAA-XMMPIXPASA-N
DM1CNU5	IU	(3R)-1,1-dibutyl-3-(5-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydropyrido[3,4-b]indole
DM1CNU5	DE	Discovery agent

DM7RPQ4	ID	DM7RPQ4
DM7RPQ4	DN	BN-81,674
DM7RPQ4	HS	Investigative
DM7RPQ4	SN	BN 81,674; BN81,674; BN-81674; BN81674; BN 81674
DM7RPQ4	DT	Small molecular drug
DM7RPQ4	PC	5311378
DM7RPQ4	MW	454.6
DM7RPQ4	FM	C30H38N4
DM7RPQ4	IC	InChI=1S/C30H38N4/c1-3-5-12-18-30(19-13-6-4-2)28-24(23-16-10-11-17-25(23)32-28)20-26(34-30)29-31-21-27(33-29)22-14-8-7-9-15-22/h7-11,14-17,21,26,32,34H,3-6,12-13,18-20H2,1-2H3,(H,31,33)/t26-/m1/s1
DM7RPQ4	CS	CCCCCC1(C2=C(C[C@@H](N1)C3=NC=C(N3)C4=CC=CC=C4)C5=CC=CC=C5N2)CCCCC
DM7RPQ4	IK	DGSMSHNIDMODOQ-AREMUKBSSA-N
DM7RPQ4	IU	(3R)-1,1-dipentyl-3-(5-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydropyrido[3,4-b]indole
DM7RPQ4	CA	CAS 252278-73-2
DM7RPQ4	DE	Discovery agent

DMXY574	ID	DMXY574
DMXY574	DN	BN-82002
DMXY574	HS	Investigative
DMXY574	DE	Solid tumour/cancer

DMZME4N	ID	DMZME4N
DMZME4N	DN	BN-82685
DMZME4N	HS	Investigative
DMZME4N	SN	UNII-YLE5P531SS; BN-82685; YLE5P531SS; IRC-083065; SCHEMBL1917819; 4,7-Benzothiazoledione, 5-((2-(dimethylamino)ethyl)amino)-2-methyl-; 5-((2-(Dimethylamino)ethyl)amino)-2-methyl-1,3-benzothiazole-4,7-dione; 477603-18-2
DMZME4N	DT	Small molecular drug
DMZME4N	PC	10286059
DMZME4N	MW	265.33
DMZME4N	FM	C12H15N3O2S
DMZME4N	IC	InChI=1S/C12H15N3O2S/c1-7-14-10-11(17)8(13-4-5-15(2)3)6-9(16)12(10)18-7/h6,13H,4-5H2,1-3H3
DMZME4N	CS	CC1=NC2=C(S1)C(=O)C=C(C2=O)NCCN(C)C
DMZME4N	IK	MTUYOFGUEXWKLC-UHFFFAOYSA-N
DMZME4N	IU	5-[2-(dimethylamino)ethylamino]-2-methyl-1,3-benzothiazole-4,7-dione
DMZME4N	CA	CAS 477603-18-2
DMZME4N	DE	Discovery agent

DMJI1EA	ID	DMJI1EA
DMJI1EA	DN	BND-001
DMJI1EA	HS	Investigative
DMJI1EA	SN	NiK-001; NiK-10001; NiK-10034; NiK-18862; Nik-21273; ORL-1 antagonists (CNS disorders); ORL-1 antagonists (CNS disorders), Brane; Opioid receptor like-1 antagonists (CNS disorders), NiKem Research
DMJI1EA	CP	NiKem Research Srl
DMJI1EA	DE	Central nervous system disease

DM48VJR	ID	DM48VJR
DM48VJR	DN	B-Nonylglucoside
DM48VJR	HS	Investigative
DM48VJR	SN	69984-73-2; B-Nonylglucoside; Nonyl beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(nonyloxy)tetrahydro-2H-pyran-3,4,5-triol; Nonyl b-D-glucopyranoside; n-nonyl -d-glucopyranoside; NONYL-beta-D-GLUCOPYRANOSIDE; n-Nonyl -D-glucoside-(1,5);NGP; b-D-Glucopyranoside, nonyl; N-NONYL-BETA-D-GLUCOPYRANOSIDE; BNG; beta-D-Glucopyranoside, nonyl; 4gby; 4gbz; Nonyl -D-glucopyranoside; Nonyl  -D-glucopyranoside; AC1L4EB7; SCHEMBL136394; Nonyl-I(2)-D-glucopyranoside; CHEMBL490225; MolPort-002-893-587; C15H30O6; GC1498
DM48VJR	DT	Small molecular drug
DM48VJR	PC	155448
DM48VJR	MW	306.39
DM48VJR	FM	C15H30O6
DM48VJR	IC	InChI=1S/C15H30O6/c1-2-3-4-5-6-7-8-9-20-15-14(19)13(18)12(17)11(10-16)21-15/h11-19H,2-10H2,1H3/t11-,12-,13+,14-,15-/m1/s1
DM48VJR	CS	CCCCCCCCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DM48VJR	IK	QFAPUKLCALRPLH-UXXRCYHCSA-N
DM48VJR	IU	(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-nonoxyoxane-3,4,5-triol
DM48VJR	CA	CAS 69984-73-2
DM48VJR	DE	Discovery agent

DMJY1KR	ID	DMJY1KR
DMJY1KR	DN	BNP-FIX
DMJY1KR	HS	Investigative
DMJY1KR	SN	Gene therapy (BNP, hemophilia B); Biological Nano Particles-Factor IX (hemophilia B), Asklepios; Gene therapy (BNP, hemophilia B), Asklepios; Gene therapy (hemophilia B), Asklepios/Bayer
DMJY1KR	CP	Asklepios Biopharmaceutical Inc
DMJY1KR	DE	Factor IX deficiency

DMIOHMZ	ID	DMIOHMZ
DMIOHMZ	DN	BNV-222
DMIOHMZ	HS	Investigative
DMIOHMZ	CP	Bionevia Pharmaceuticals Inc
DMIOHMZ	DE	Diabetic neuropathy

DMCUJH5	ID	DMCUJH5
DMCUJH5	DN	Bo(15)PZ
DMCUJH5	HS	Investigative
DMCUJH5	SN	CHEMBL198982; Bo(15)PZ
DMCUJH5	DT	Small molecular drug
DMCUJH5	PC	44405301
DMCUJH5	MW	849.8
DMCUJH5	FM	C44H50BF2N9O4S
DMCUJH5	IC	InChI=1S/C44H50BF2N9O4S/c46-45(47)55-32(15-16-33(55)30-34-17-19-38(56(34)45)39-13-9-29-61-39)18-20-41(58)49-21-5-1-2-14-40(57)48-22-6-7-24-52-25-27-53(28-26-52)31-42(59)54-37-12-4-3-10-35(37)44(60)51-36-11-8-23-50-43(36)54/h3-4,8-13,15-17,19,23,29-30H,1-2,5-7,14,18,20-22,24-28,31H2,(H,48,57)(H,49,58)(H,51,60)
DMCUJH5	CS	[B-]1(N2C(=CC=C2CCC(=O)NCCCCCC(=O)NCCCCN3CCN(CC3)CC(=O)N4C5=CC=CC=C5C(=O)NC6=C4N=CC=C6)C=C7[N+]1=C(C=C7)C8=CC=CS8)(F)F
DMCUJH5	IK	AZMSBCBXXBLHQP-UHFFFAOYSA-N
DMCUJH5	IU	6-[3-(2,2-difluoro-12-thiophen-2-yl-3-aza-1-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-1(12),4,6,8,10-pentaen-4-yl)propanoylamino]-N-[4-[4-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]piperazin-1-yl]butyl]hexanamide
DMCUJH5	DE	Discovery agent

DMDX8M3	ID	DMDX8M3
DMDX8M3	DN	Boc-Agly-Val-Agly-OEt
DMDX8M3	HS	Investigative
DMDX8M3	SN	Boc-Agly-Val-Agly-OEt; CHEMBL135413
DMDX8M3	DT	Small molecular drug
DMDX8M3	PC	44355107
DMDX8M3	MW	416.5
DMDX8M3	FM	C19H36N4O6
DMDX8M3	IC	InChI=1S/C19H36N4O6/c1-9-28-18(27)23-22-16(25)14(12(4)5)21-15(24)13(10-11(2)3)20-17(26)29-19(6,7)8/h11-14H,9-10H2,1-8H3,(H,20,26)(H,21,24)(H,22,25)(H,23,27)
DMDX8M3	CS	CCOC(=O)NNC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)OC(C)(C)C
DMDX8M3	IK	CCIRNXXUWFWJAR-UHFFFAOYSA-N
DMDX8M3	IU	tert-butyl N-[1-[[1-(2-ethoxycarbonylhydrazinyl)-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate
DMDX8M3	DE	Discovery agent

DMPJR98	ID	DMPJR98
DMPJR98	DN	Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2
DMPJR98	HS	Investigative
DMPJR98	SN	CHEMBL1159915
DMPJR98	PC	44278569
DMPJR98	MW	1193.3
DMPJR98	FM	C55H72N10O18S
DMPJR98	IC	InChI=1S/C55H72N10O18S/c1-6-8-18-37(47(71)62-42(28-44(66)67)51(75)60-39(46(56)70)25-31-15-11-10-12-16-31)58-50(74)41(27-33-30-57-36-20-14-13-17-35(33)36)63-53(77)65-48(72)38(19-9-7-2)59-49(73)40(26-32-21-23-34(24-22-32)83-84(79,80)81)61-52(76)43(29-45(68)69)64-54(78)82-55(3,4)5/h10-17,20-24,30,37-43,57H,6-9,18-19,25-29H2,1-5H3,(H2,56,70)(H,58,74)(H,59,73)(H,60,75)(H,61,76)(H,62,71)(H,64,78)(H,66,67)(H,68,69)(H,79,80,81)(H2,63,65,72,77)/t37-,38-,39-,40-,41-,42-,43-/m0/s1
DMPJR98	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)NC(=O)[C@H](CCCC)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)OC(C)(C)C
DMPJR98	IK	LWZREZWAQQSATC-NKUVHBIJSA-N
DMPJR98	IU	(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoyl]carbamoylamino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid
DMPJR98	DE	Discovery agent

DMRQVME	ID	DMRQVME
DMRQVME	DN	Boc-cyclo-(Glu-Tyr-Nle-D-Lys)-Trp-Nle-Asp-Phe-NH2
DMRQVME	HS	Investigative
DMRQVME	SN	CHEMBL273880; Boc-cyclo-(Glu-Tyr-Nle-D-Lys)-Trp-Nle-Asp-Phe-NH2
DMRQVME	PC	44272056
DMRQVME	MW	1194.4
DMRQVME	FM	C61H83N11O14
DMRQVME	IC	InChI=1S/C61H83N11O14/c1-6-8-20-42-53(78)65-44(23-15-16-30-63-50(74)29-28-45(72-60(85)86-61(3,4)5)56(81)69-47(57(82)66-42)32-37-24-26-39(73)27-25-37)55(80)70-48(33-38-35-64-41-22-14-13-19-40(38)41)58(83)67-43(21-9-7-2)54(79)71-49(34-51(75)76)59(84)68-46(52(62)77)31-36-17-11-10-12-18-36/h10-14,17-19,22,24-27,35,42-49,64,73H,6-9,15-16,20-21,23,28-34H2,1-5H3,(H2,62,77)(H,63,74)(H,65,78)(H,66,82)(H,67,83)(H,68,84)(H,69,81)(H,70,80)(H,71,79)(H,72,85)(H,75,76)/t42-,43-,44-,45+,46-,47+,48-,49-/m0/s1
DMRQVME	CS	CCCC[C@H]1C(=O)N[C@@H](CCCCNC(=O)CC[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)NC(=O)OC(C)(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N
DMRQVME	IK	RJGYFDISIBJKFO-UZLGZYMTSA-N
DMRQVME	IU	(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-[[(2R,5S,8S,17R)-5-butyl-2-[(4-hydroxyphenyl)methyl]-17-[(2-methylpropan-2-yl)oxycarbonylamino]-3,6,14,18-tetraoxo-1,4,7,13-tetrazacyclooctadecane-8-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid
DMRQVME	DE	Discovery agent

DMBCPKF	ID	DMBCPKF
DMBCPKF	DN	Boc-D-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMBCPKF	HS	Investigative
DMBCPKF	SN	CHEMBL440259; Boc-D-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMBCPKF	PC	44272077
DMBCPKF	MW	1292.5
DMBCPKF	FM	C61H85N11O18S
DMBCPKF	IC	InChI=1S/C61H85N11O18S/c1-6-8-20-42(66-57(82)47(32-37-24-26-39(27-25-37)90-91(86,87)88)69-56(81)45(28-29-50(73)74)72-60(85)89-61(3,4)5)53(78)65-44(23-15-16-30-62)55(80)70-48(33-38-35-64-41-22-14-13-19-40(38)41)58(83)67-43(21-9-7-2)54(79)71-49(34-51(75)76)59(84)68-46(52(63)77)31-36-17-11-10-12-18-36/h10-14,17-19,22,24-27,35,42-49,64H,6-9,15-16,20-21,23,28-34,62H2,1-5H3,(H2,63,77)(H,65,78)(H,66,82)(H,67,83)(H,68,84)(H,69,81)(H,70,80)(H,71,79)(H,72,85)(H,73,74)(H,75,76)(H,86,87,88)/t42-,43-,44-,45+,46-,47-,48-,49-/m0/s1
DMBCPKF	CS	CCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)OC(C)(C)C
DMBCPKF	IK	NLVKBXFAISROGJ-LMZFJFGWSA-N
DMBCPKF	IU	(4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid
DMBCPKF	DE	Discovery agent

DM1IXOG	ID	DM1IXOG
DM1IXOG	DN	Boc-D-Glu-Tyr(SO3H)-Nle-D-Nle-Trp-Nle-Asp-Phe-NH2
DM1IXOG	HS	Investigative
DM1IXOG	SN	CHEMBL216831; Boc-D-Glu-Tyr(SO3H)-Nle-D-Nle-Trp-Nle-Asp-Phe-NH2
DM1IXOG	PC	44272095
DM1IXOG	MW	1277.4
DM1IXOG	FM	C61H84N10O18S
DM1IXOG	IC	InChI=1S/C61H84N10O18S/c1-7-10-21-42(65-57(81)47(32-37-25-27-39(28-26-37)89-90(85,86)87)68-56(80)45(29-30-50(72)73)71-60(84)88-61(4,5)6)53(77)64-43(22-11-8-2)54(78)69-48(33-38-35-63-41-24-17-16-20-40(38)41)58(82)66-44(23-12-9-3)55(79)70-49(34-51(74)75)59(83)67-46(52(62)76)31-36-18-14-13-15-19-36/h13-20,24-28,35,42-49,63H,7-12,21-23,29-34H2,1-6H3,(H2,62,76)(H,64,77)(H,65,81)(H,66,82)(H,67,83)(H,68,80)(H,69,78)(H,70,79)(H,71,84)(H,72,73)(H,74,75)(H,85,86,87)/t42-,43-,44-,45+,46-,47-,48-,49-/m0/s1
DM1IXOG	CS	CCCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CCCC)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)OC(C)(C)C
DM1IXOG	IK	JFEDUJOXWDESON-LMZFJFGWSA-N
DM1IXOG	IU	(4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid
DM1IXOG	DE	Discovery agent

DMFWJC2	ID	DMFWJC2
DMFWJC2	DN	Boceprevir
DMFWJC2	HS	Investigative
DMFWJC2	SN	Victrelis; EBP 520; Sch 503034
DMFWJC2	TC	Antiviral Agents
DMFWJC2	DT	Small molecular drug
DMFWJC2	PC	10324367
DMFWJC2	MW	519.7
DMFWJC2	FM	C27H45N5O5
DMFWJC2	IC	InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
DMFWJC2	CS	CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
DMFWJC2	IK	LHHCSNFAOIFYRV-DOVBMPENSA-N
DMFWJC2	IU	(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
DMFWJC2	CA	CAS 394730-60-0
DMFWJC2	CB	CHEBI:68621
DMFWJC2	DE	Coronavirus Disease 2019 (COVID-19)

DMN3EU9	ID	DMN3EU9
DMN3EU9	DN	Boc-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMN3EU9	HS	Investigative
DMN3EU9	SN	CHEMBL386304; Boc-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMN3EU9	PC	44272078
DMN3EU9	MW	1292.5
DMN3EU9	FM	C61H85N11O18S
DMN3EU9	IC	InChI=1S/C61H85N11O18S/c1-6-8-20-42(66-57(82)47(32-37-24-26-39(27-25-37)90-91(86,87)88)69-56(81)45(28-29-50(73)74)72-60(85)89-61(3,4)5)53(78)65-44(23-15-16-30-62)55(80)70-48(33-38-35-64-41-22-14-13-19-40(38)41)58(83)67-43(21-9-7-2)54(79)71-49(34-51(75)76)59(84)68-46(52(63)77)31-36-17-11-10-12-18-36/h10-14,17-19,22,24-27,35,42-49,64H,6-9,15-16,20-21,23,28-34,62H2,1-5H3,(H2,63,77)(H,65,78)(H,66,82)(H,67,83)(H,68,84)(H,69,81)(H,70,80)(H,71,79)(H,72,85)(H,73,74)(H,75,76)(H,86,87,88)/t42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
DMN3EU9	CS	CCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)OC(C)(C)C
DMN3EU9	IK	NLVKBXFAISROGJ-XJIZABAQSA-N
DMN3EU9	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid
DMN3EU9	DE	Discovery agent

DMG35MJ	ID	DMG35MJ
DMG35MJ	DN	Boc-Ile-Leu-L-(difluoro)aminobutyric aid
DMG35MJ	HS	Investigative
DMG35MJ	SN	Boc-Ile-Leu-L-(difluoro)aminobutyric aid; CHEMBL175479
DMG35MJ	DT	Small molecular drug
DMG35MJ	PC	44388200
DMG35MJ	MW	493.5
DMG35MJ	FM	C22H37F2N3O7
DMG35MJ	IC	InChI=1S/C22H37F2N3O7/c1-8-12(4)16(27-21(33)34-22(5,6)7)19(30)26-14(9-11(2)3)18(29)25-13(10-15(23)24)17(28)20(31)32/h11-16H,8-10H2,1-7H3,(H,25,29)(H,26,30)(H,27,33)(H,31,32)/t12?,13?,14-,16-/m0/s1
DMG35MJ	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NC(CC(F)F)C(=O)C(=O)O)NC(=O)OC(C)(C)C
DMG35MJ	IK	JOMMVUMCDVMUOS-UJJWPFCGSA-N
DMG35MJ	IU	5,5-difluoro-3-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]pentanoyl]amino]-2-oxopentanoic acid
DMG35MJ	DE	Discovery agent

DMMO75G	ID	DMMO75G
DMMO75G	DN	B-Octylglucoside
DMMO75G	HS	Investigative
DMMO75G	SN	29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL
DMMO75G	DT	Small molecular drug
DMMO75G	PC	62852
DMMO75G	MW	292.37
DMMO75G	FM	C14H28O6
DMMO75G	IC	InChI=1S/C14H28O6/c1-2-3-4-5-6-7-8-19-14-13(18)12(17)11(16)10(9-15)20-14/h10-18H,2-9H2,1H3/t10-,11-,12+,13-,14-/m1/s1
DMMO75G	CS	CCCCCCCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMMO75G	IK	HEGSGKPQLMEBJL-RKQHYHRCSA-N
DMMO75G	IU	(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol
DMMO75G	CA	CAS 29836-26-8
DMMO75G	CB	CHEBI:41128
DMMO75G	DE	Discovery agent

DMAYWTI	ID	DMAYWTI
DMAYWTI	DN	Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2
DMAYWTI	HS	Investigative
DMAYWTI	SN	CHEMBL384035; Cholecystokinin (27-33), tert-butyloxycarbonyl-nle(28,31)-; Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2; 98640-66-5; Boc-28,31-nle-cck-7; BDNL; Boc-tyr(SO3H)nle-gly-trp-nle-asp-phenh2; t-Boc(nle(28,31))-cck (27-33); AC1MJ67S; DTXSID90243747; tert-Butyloxycarbonyl-28,31-nle-cholecystokinin (27-33); Cholecystokinin (27-33), tert-butyloxycarbonylnorleucyl(28,31)-; BDBM50016425; tert-Butoxycarbonyltyrosyl(sulfo)-norleucyl-glycyl-tryptophyl-norleucyl-aspartyl-phenylalaninamide
DMAYWTI	PC	3086453
DMAYWTI	MW	1092.2
DMAYWTI	FM	C52H69N9O15S
DMAYWTI	IC	InChI=1S/C52H69N9O15S/c1-6-8-18-37(57-48(68)40(61-51(71)75-52(3,4)5)26-32-21-23-34(24-22-32)76-77(72,73)74)46(66)55-30-43(62)56-41(27-33-29-54-36-20-14-13-17-35(33)36)49(69)58-38(19-9-7-2)47(67)60-42(28-44(63)64)50(70)59-39(45(53)65)25-31-15-11-10-12-16-31/h10-17,20-24,29,37-42,54H,6-9,18-19,25-28,30H2,1-5H3,(H2,53,65)(H,55,66)(H,56,62)(H,57,68)(H,58,69)(H,59,70)(H,60,67)(H,61,71)(H,63,64)(H,72,73,74)/t37-,38-,39-,40-,41-,42-/m0/s1
DMAYWTI	CS	CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)OC(C)(C)C
DMAYWTI	IK	CSXIDZJPJYRGSK-UJKKYYSESA-N
DMAYWTI	IU	(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid
DMAYWTI	CA	CAS 98640-66-5
DMAYWTI	DE	Discovery agent

DMY7CN3	ID	DMY7CN3
DMY7CN3	DN	BODIPY-pirenzepine
DMY7CN3	HS	Investigative
DMY7CN3	SN	BoPz
DMY7CN3	DT	Small molecular drug
DMY7CN3	PC	101244456
DMY7CN3	MW	764.7
DMY7CN3	FM	C40H43BF2N8O3S
DMY7CN3	IC	InChI=1S/C40H43BF2N8O3S/c42-41(43)51-30(14-15-31(51)27-29-13-17-33(46-29)36-12-8-26-55-36)16-18-37(52)44-19-5-1-2-6-21-48-22-24-49(25-23-48)28-38(53)50-35-11-4-3-9-32(35)40(54)47-34-10-7-20-45-39(34)50/h3-4,7-15,17,20,26-27H,1-2,5-6,16,18-19,21-25,28H2,(H,44,52)(H,47,54)/b29-27+
DMY7CN3	CS	B(N1C(=CC=C1/C=C/2\\C=CC(=N2)C3=CC=CS3)CCC(=O)NCCCCCCN4CCN(CC4)CC(=O)N5C6=CC=CC=C6C(=O)NC7=C5N=CC=C7)(F)F
DMY7CN3	IK	QGXCAYBSIKPOHP-ORIPQNMZSA-N
DMY7CN3	IU	3-[1-difluoroboranyl-5-[(E)-(5-thiophen-2-ylpyrrol-2-ylidene)methyl]pyrrol-2-yl]-N-[6-[4-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]piperazin-1-yl]hexyl]propanamide
DMY7CN3	DE	Discovery agent

DMLCMA3	ID	DMLCMA3
DMLCMA3	DN	BOHEMINE
DMLCMA3	HS	Investigative
DMLCMA3	SN	bohemine; 189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931
DMLCMA3	DT	Small molecular drug
DMLCMA3	PC	2422
DMLCMA3	MW	340.4
DMLCMA3	FM	C18H24N6O
DMLCMA3	IC	InChI=1S/C18H24N6O/c1-13(2)24-12-21-15-16(20-11-14-7-4-3-5-8-14)22-18(23-17(15)24)19-9-6-10-25/h3-5,7-8,12-13,25H,6,9-11H2,1-2H3,(H2,19,20,22,23)
DMLCMA3	CS	CC(C)N1C=NC2=C(N=C(N=C21)NCCCO)NCC3=CC=CC=C3
DMLCMA3	IK	OPQGFIAVPSXOBO-UHFFFAOYSA-N
DMLCMA3	IU	3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]propan-1-ol
DMLCMA3	CA	CAS 189232-42-6
DMLCMA3	CB	CHEBI:86007
DMLCMA3	DE	Discovery agent

DM0EKO5	ID	DM0EKO5
DM0EKO5	DN	Boldenone
DM0EKO5	HS	Investigative
DM0EKO5	SN	Boldenone; Dehydrotestosterone; 846-48-0; 1,2-Dehydrotestosterone; 1-Dehydrotestosterone; 1,2-Didehydrotestosterone; 17beta-Boldenone; delta1-Testosterone; Boldenonum; Boldenona; 17beta-Hydroxyandrosta-1,4-dien-3-one; 1,4-Androstadien-17beta-ol-3-one; Boldenonum [INN-Latin]; Boldenona [INN-Spanish]; Boldenone [INN:BAN]; UNII-5H7I2IP58X; 17beta-Hydroxyandrosta-1,4-diene-3-one; 17-beta-Hydroxyandrosta-1,4-dien-3-one; EINECS 212-686-0; NSC 79102; 17-beta-Hydroxy-17-alpha-1,4-androstadien-3-one; 5H7I2IP58X; CHEBI:34584
DM0EKO5	DT	Small molecular drug
DM0EKO5	PC	13308
DM0EKO5	MW	286.4
DM0EKO5	FM	C19H26O2
DM0EKO5	IC	InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-17,21H,3-6,8,10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
DM0EKO5	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)C=C[C@]34C
DM0EKO5	IK	RSIHSRDYCUFFLA-DYKIIFRCSA-N
DM0EKO5	IU	(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DM0EKO5	CA	CAS 846-48-0
DM0EKO5	CB	CHEBI:34584
DM0EKO5	DE	Discovery agent

DMMVB5P	ID	DMMVB5P
DMMVB5P	DN	BOLDINE
DMMVB5P	HS	Investigative
DMMVB5P	SN	Boldine; 476-70-0; Uniboldina; Boldin; (S)-Boldine; Boldine chloroform; (+)-Boldine; NSC 65689; UNII-8I91GE2769; (S)-(+)-Boldine; EINECS 207-509-9; BRN 0094036; 1,10-Dimethoxy-2,9-dihydroxyaporphine; CHEMBL388342; CHEBI:3148; 1,10-Dimethoxy-6a-alpha-aporphine-2,9-diol; LZJRNLRASBVRRX-ZDUSSCGKSA-N; 8I91GE2769; 4H-Dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (S)-; 4H-Dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6aS)-
DMMVB5P	DT	Small molecular drug
DMMVB5P	PC	10154
DMMVB5P	MW	327.4
DMMVB5P	FM	C19H21NO4
DMMVB5P	IC	InChI=1S/C19H21NO4/c1-20-5-4-10-7-15(22)19(24-3)18-12-9-16(23-2)14(21)8-11(12)6-13(20)17(10)18/h7-9,13,21-22H,4-6H2,1-3H3/t13-/m0/s1
DMMVB5P	CS	CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)O)OC)O
DMMVB5P	IK	LZJRNLRASBVRRX-ZDUSSCGKSA-N
DMMVB5P	IU	(6aS)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DMMVB5P	CA	CAS 476-70-0
DMMVB5P	CB	CHEBI:3148
DMMVB5P	DE	Discovery agent

DMVB6UG	ID	DMVB6UG
DMVB6UG	DN	BOLINAQUINONE
DMVB6UG	HS	Investigative
DMVB6UG	SN	bolinaquinone; SCHEMBL1231059
DMVB6UG	DT	Small molecular drug
DMVB6UG	PC	10066979
DMVB6UG	MW	358.5
DMVB6UG	FM	C22H30O4
DMVB6UG	IC	InChI=1S/C22H30O4/c1-13-7-6-8-16-14(2)21(3,9-10-22(13,16)4)12-15-19(24)17(23)11-18(26-5)20(15)25/h7,11,14,16,24H,6,8-10,12H2,1-5H3/t14-,16+,21-,22-/m1/s1
DMVB6UG	CS	C[C@@H]1[C@@H]2CCC=C([C@]2(CC[C@]1(C)CC3=C(C(=O)C=C(C3=O)OC)O)C)C
DMVB6UG	IK	PYUXUMSQSVWNDS-NSAJDELNSA-N
DMVB6UG	IU	3-[[(1R,2R,4aS,8aS)-1,2,4a,5-tetramethyl-1,3,4,7,8,8a-hexahydronaphthalen-2-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
DMVB6UG	DE	Discovery agent

DMAW40Y	ID	DMAW40Y
DMAW40Y	DN	BOMA
DMAW40Y	HS	Investigative
DMAW40Y	SN	BOMA; SCHEMBL660569; GTPL1421; LWSOZPNJUFEDJU-UHFFFAOYSA-N; [4-(1,3-benzoxazol-2-yl)-2-methoxyphenyl]acetonitrile
DMAW40Y	DT	Small molecular drug
DMAW40Y	PC	10192854
DMAW40Y	MW	264.28
DMAW40Y	FM	C16H12N2O2
DMAW40Y	IC	InChI=1S/C16H12N2O2/c1-19-15-10-12(7-6-11(15)8-9-17)16-18-13-4-2-3-5-14(13)20-16/h2-7,10H,8H2,1H3
DMAW40Y	CS	COC1=C(C=CC(=C1)C2=NC3=CC=CC=C3O2)CC#N
DMAW40Y	IK	LWSOZPNJUFEDJU-UHFFFAOYSA-N
DMAW40Y	IU	2-[4-(1,3-benzoxazol-2-yl)-2-methoxyphenyl]acetonitrile
DMAW40Y	DE	Discovery agent

DMDFQ0Y	ID	DMDFQ0Y
DMDFQ0Y	DN	bombesin
DMDFQ0Y	HS	Investigative
DMDFQ0Y	SN	GTPL616; AKOS024456418; FT-0688038
DMDFQ0Y	DT	Small molecular drug
DMDFQ0Y	PC	16133800
DMDFQ0Y	MW	1619.9
DMDFQ0Y	FM	C71H110N24O18S
DMDFQ0Y	IC	InChI=1S/C71H110N24O18S/c1-34(2)24-47(92-62(105)43(14-11-22-79-71(76)77)89-64(107)45(15-18-52(72)96)90-63(106)44-17-20-55(99)85-44)61(104)81-31-56(100)87-51(28-54(74)98)69(112)91-46(16-19-53(73)97)65(108)94-49(26-38-29-80-41-13-10-9-12-40(38)41)66(109)84-37(7)60(103)95-58(36(5)6)70(113)82-32-57(101)86-50(27-39-30-78-33-83-39)68(111)93-48(25-35(3)4)67(110)88-42(59(75)102)21-23-114-8/h9-10,12-13,29-30,33-37,42-51,58,80H,11,14-28,31-32H2,1-8H3,(H2,72,96)(H2,73,97)(H2,74,98)(H2,75,102)(H,78,83)(H,81,104)(H,82,113)(H,84,109)(H,85,99)(H,86,101)(H,87,100)(H,88,110)(H,89,107)(H,90,106)(H,91,112)(H,92,105)(H,93,111)(H,94,108)(H,95,103)(H4,76,77,79)/t37-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,58-/m0/s1
DMDFQ0Y	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]4CCC(=O)N4
DMDFQ0Y	IK	QXZBMSIDSOZZHK-DOPDSADYSA-N
DMDFQ0Y	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanediamide
DMDFQ0Y	CA	CAS 31362-50-2
DMDFQ0Y	DE	Discovery agent

DMI75A3	ID	DMI75A3
DMI75A3	DN	BOMPPA
DMI75A3	HS	Investigative
DMI75A3	SN	benzyloxy-methoxyphenyl-propylamide; compound 10 [PMID: 23228808]
DMI75A3	DT	Small molecular drug
DMI75A3	PC	71508234
DMI75A3	MW	341.4
DMI75A3	FM	C21H27NO3
DMI75A3	IC	InChI=1S/C21H27NO3/c1-4-21(23)22-12-6-8-17-15-20(25-3)11-10-18(17)13-16-7-5-9-19(14-16)24-2/h5,7,9-11,14-15H,4,6,8,12-13H2,1-3H3,(H,22,23)
DMI75A3	CS	CCC(=O)NCCCC1=C(C=CC(=C1)OC)CC2=CC(=CC=C2)OC
DMI75A3	IK	GJRIGACGWLYZAO-UHFFFAOYSA-N
DMI75A3	IU	N-[3-[5-methoxy-2-[(3-methoxyphenyl)methyl]phenyl]propyl]propanamide
DMI75A3	DE	Discovery agent

DMWALXQ	ID	DMWALXQ
DMWALXQ	DN	bongkrek acid
DMWALXQ	HS	Investigative
DMWALXQ	SN	bongkrekic acid; flavotoxin A
DMWALXQ	DT	Small molecular drug
DMWALXQ	PC	6433556
DMWALXQ	MW	486.6
DMWALXQ	FM	C28H38O7
DMWALXQ	IC	InChI=1S/C28H38O7/c1-21(15-18-24(19-26(29)30)20-27(31)32)13-11-9-7-5-6-8-10-12-14-25(35-4)22(2)16-17-23(3)28(33)34/h6,8-12,15-19,21,25H,5,7,13-14,20H2,1-4H3,(H,29,30)(H,31,32)(H,33,34)/b8-6+,11-9+,12-10-,18-15+,22-16-,23-17+,24-19+/t21-,25+/m0/s1
DMWALXQ	CS	C[C@@H](C/C=C/CC/C=C/C=C\\C[C@H](/C(=C\\C=C(/C)\\C(=O)O)/C)OC)/C=C/C(=C\\C(=O)O)/CC(=O)O
DMWALXQ	IK	SHCXABJSXUACKU-WUTQZGRKSA-N
DMWALXQ	IU	(2E,4Z,6R,8Z,10E,14E,17S,18E,20Z)-20-(carboxymethyl)-6-methoxy-2,5,17-trimethyldocosa-2,4,8,10,14,18,20-heptaenedioic acid
DMWALXQ	CA	CAS 11076-19-0
DMWALXQ	CB	CHEBI:77742
DMWALXQ	DE	Discovery agent

DMWBV1P	ID	DMWBV1P
DMWBV1P	DN	borneol
DMWBV1P	HS	Investigative
DMWBV1P	SN	isoborneol; (+)-borneol
DMWBV1P	DT	Small molecular drug
DMWBV1P	PC	64685
DMWBV1P	MW	154.25
DMWBV1P	FM	C10H18O
DMWBV1P	IC	InChI=1S/C10H18O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7-8,11H,4-6H2,1-3H3
DMWBV1P	CS	CC1(C2CCC1(C(C2)O)C)C
DMWBV1P	IK	DTGKSKDOIYIVQL-UHFFFAOYSA-N
DMWBV1P	IU	1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol
DMWBV1P	CA	CAS 507-70-0
DMWBV1P	CB	CHEBI:28093
DMWBV1P	DE	Discovery agent

DMR70ZO	ID	DMR70ZO
DMR70ZO	DN	Bornyl (3,4,5-trihydroxy)-cinnamate
DMR70ZO	HS	Investigative
DMR70ZO	SN	CHEMBL408621; bornyl (3,4,5-trihydroxy)-cinnamate
DMR70ZO	DT	Small molecular drug
DMR70ZO	PC	24882417
DMR70ZO	MW	332.4
DMR70ZO	FM	C19H24O5
DMR70ZO	IC	InChI=1S/C19H24O5/c1-18(2)12-6-7-19(18,3)15(10-12)24-16(22)5-4-11-8-13(20)17(23)14(21)9-11/h4-5,8-9,12,15,20-21,23H,6-7,10H2,1-3H3/b5-4+/t12?,15?,19-/m1/s1
DMR70ZO	CS	C[C@]12CCC(C1(C)C)CC2OC(=O)/C=C/C3=CC(=C(C(=C3)O)O)O
DMR70ZO	IK	IMMWANKYSKQCQN-UOAQAXRFSA-N
DMR70ZO	IU	[(1S)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl] (E)-3-(3,4,5-trihydroxyphenyl)prop-2-enoate
DMR70ZO	DE	Discovery agent

DMBSQTR	ID	DMBSQTR
DMBSQTR	DN	Borrelidin
DMBSQTR	HS	Investigative
DMBSQTR	SN	Borrelidin; 7184-60-3; 2-(7-Cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxooxacyclooctadeca-4,6-dien-2-yl)cyclopentanecarboxylic acid; Quinquangulin K 182; Quinquangulin K 031; AC1O53K5; Cyclopentanecarboxylic acid, 2-(7-cyano-8, 16-dihydroxy-9,11,13,15-tetramethyl-18-oxooxacyclooctadeca-4, 6-dien-2-yl)-; 2-[(4Z,6Z)-7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid
DMBSQTR	DT	Small molecular drug
DMBSQTR	PC	6436801
DMBSQTR	MW	489.6
DMBSQTR	FM	C28H43NO6
DMBSQTR	IC	InChI=1S/C28H43NO6/c1-17-12-18(2)14-20(4)27(32)21(16-29)8-5-6-11-25(22-9-7-10-23(22)28(33)34)35-26(31)15-24(30)19(3)13-17/h5-6,8,17-20,22-25,27,30,32H,7,9-15H2,1-4H3,(H,33,34)/b6-5+,21-8-/t17-,18+,19-,20-,22+,23+,24-,25-,27+/m0/s1
DMBSQTR	CS	C[C@H]1C[C@H](C[C@@H]([C@H](/C(=C\\C=C\\C[C@H](OC(=O)C[C@@H]([C@H](C1)C)O)[C@@H]2CCC[C@H]2C(=O)O)/C#N)O)C)C
DMBSQTR	IK	OJCKRNPLOZHAOU-UGKRXNSESA-N
DMBSQTR	IU	(1R,2R)-2-[(2S,4E,6Z,8R,9S,11R,13S,15S,16S)-7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid
DMBSQTR	CA	CAS 7184-60-3
DMBSQTR	DE	Discovery agent

DMRELJ0	ID	DMRELJ0
DMRELJ0	DN	Bovinic acid
DMRELJ0	HS	Investigative
DMRELJ0	SN	Trans-11 conjugated linoleic acid; Conjugated linoleic acid; Ricinenic acid; Rumenic acid; (9Z,11E)-9,11-octadecadienoic acid; (9Z,11E)-Octadecadienoic acid; (9Z,11E)-octadeca-9,11-dienoic acid; 2540-56-9; 46JZW3MR59; 9(Z),11(E)-octadecadienoic acid; 9,11-Octadecadienoic acid, (9Z,11E)-; 9-cis,11-trans-Octadecadienoic acid solution; 9-cis,11-trans-octadecadienoic acid; 9Z, 11E-Linoleic acid; 9Z,11E-octadecadienoic acid; UNII-46JZW3MR59; c9t11CLA; cis-9, trans-11-octadecadienoic acid; cis-9,trans-11 conjugated linoleic acid
DMRELJ0	PC	5280644
DMRELJ0	MW	280.4
DMRELJ0	FM	C18H32O2
DMRELJ0	IC	JBYXPOFIGCOSSB-GOJKSUSPSA-N
DMRELJ0	CS	CCCCCCC=CC=CCCCCCCCC(=O)O
DMRELJ0	IK	1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h7-10H,2-6,11-17H2,1H3,(H,19,20)/b8-7+,10-9-
DMRELJ0	IU	(9Z,11E)-octadeca-9,11-dienoic acid
DMRELJ0	CA	CAS 2540-56-9
DMRELJ0	CB	CHEBI:32798
DMRELJ0	DE	Discovery agent

DMGEYFB	ID	DMGEYFB
DMGEYFB	DN	BP-100-1.02
DMGEYFB	HS	Investigative
DMGEYFB	SN	Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path
DMGEYFB	CP	Bio-Path Holdings Inc
DMGEYFB	DT	Antisense drug
DMGEYFB	DE	Lymphoma

DMUOS3G	ID	DMUOS3G
DMUOS3G	DN	BPH-252
DMUOS3G	HS	Investigative
DMUOS3G	SN	BPH 252; BPH252
DMUOS3G	DT	Small molecular drug
DMUOS3G	PC	5276503
DMUOS3G	MW	318.24
DMUOS3G	FM	C10H24O7P2
DMUOS3G	IC	InChI=1S/C10H24O7P2/c1-2-3-4-5-6-7-8-9-10(11,18(12,13)14)19(15,16)17/h11H,2-9H2,1H3,(H2,12,13,14)(H2,15,16,17)
DMUOS3G	CS	CCCCCCCCCC(O)(P(=O)(O)O)P(=O)(O)O
DMUOS3G	IK	NSCPCMXKWUFFNL-UHFFFAOYSA-N
DMUOS3G	IU	(1-hydroxy-1-phosphonodecyl)phosphonic acid
DMUOS3G	DE	Discovery agent

DM0NQLI	ID	DM0NQLI
DM0NQLI	DN	BPH-608
DM0NQLI	HS	Investigative
DM0NQLI	SN	BPH608; BPH 608
DM0NQLI	DT	Small molecular drug
DM0NQLI	PC	16086422
DM0NQLI	MW	434.3
DM0NQLI	FM	C20H20O7P2
DM0NQLI	IC	InChI=1S/C20H20O7P2/c21-20(28(22,23)24,29(25,26)27)14-15-6-4-9-17(12-15)19-11-5-10-18(13-19)16-7-2-1-3-8-16/h1-13,21H,14H2,(H2,22,23,24)(H2,25,26,27)
DM0NQLI	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)C3=CC=CC(=C3)CC(O)(P(=O)(O)O)P(=O)(O)O
DM0NQLI	IK	YXQQNSYZOQHKHD-UHFFFAOYSA-N
DM0NQLI	IU	[1-hydroxy-2-[3-(3-phenylphenyl)phenyl]-1-phosphonoethyl]phosphonic acid
DM0NQLI	DE	Discovery agent

DM0TJ6R	ID	DM0TJ6R
DM0TJ6R	DN	BPH-628
DM0TJ6R	HS	Investigative
DM0TJ6R	SN	BPH 628; B28; BPH628
DM0TJ6R	DT	Small molecular drug
DM0TJ6R	PC	16122554
DM0TJ6R	MW	434.3
DM0TJ6R	FM	C20H20O7P2
DM0TJ6R	IC	InChI=1S/C20H20O7P2/c21-20(28(22,23)24,29(25,26)27)14-15-5-4-8-19(13-15)18-11-9-17(10-12-18)16-6-2-1-3-7-16/h1-13,21H,14H2,(H2,22,23,24)(H2,25,26,27)
DM0TJ6R	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=CC(=C3)CC(O)(P(=O)(O)O)P(=O)(O)O
DM0TJ6R	IK	MPBUFKZCEBTBSK-UHFFFAOYSA-N
DM0TJ6R	IU	[1-hydroxy-2-[3-(4-phenylphenyl)phenyl]-1-phosphonoethyl]phosphonic acid
DM0TJ6R	DE	Discovery agent

DM49BFM	ID	DM49BFM
DM49BFM	DN	BPH-629
DM49BFM	HS	Investigative
DM49BFM	SN	BPH 629; BPH629
DM49BFM	DT	Small molecular drug
DM49BFM	PC	16122553
DM49BFM	MW	448.3
DM49BFM	FM	C20H18O8P2
DM49BFM	IC	InChI=1S/C20H18O8P2/c21-20(29(22,23)24,30(25,26)27)12-13-5-3-6-14(11-13)15-8-4-9-17-16-7-1-2-10-18(16)28-19(15)17/h1-11,21H,12H2,(H2,22,23,24)(H2,25,26,27)
DM49BFM	CS	C1=CC=C2C(=C1)C3=C(O2)C(=CC=C3)C4=CC=CC(=C4)CC(O)(P(=O)(O)O)P(=O)(O)O
DM49BFM	IK	BYVXAUZOTGITQZ-UHFFFAOYSA-N
DM49BFM	IU	[2-(3-dibenzofuran-4-ylphenyl)-1-hydroxy-1-phosphonoethyl]phosphonic acid
DM49BFM	DE	Discovery agent

DMX4WI7	ID	DMX4WI7
DMX4WI7	DN	BPH-652
DMX4WI7	HS	Investigative
DMX4WI7	SN	FX24B-04652; Dehydrosqualene synthase inhibitor (MRSA), AuricX
DMX4WI7	CP	AuricX Pharmaceuticals Inc
DMX4WI7	DT	Small molecular drug
DMX4WI7	PC	16730264
DMX4WI7	MW	500.6
DMX4WI7	FM	C16H16K3O7PS
DMX4WI7	IC	InChI=1S/C16H19O7PS.3K/c17-24(18,19)16(25(20,21)22)11-5-7-13-6-4-10-15(12-13)23-14-8-2-1-3-9-14;;;/h1-4,6,8-10,12,16H,5,7,11H2,(H2,17,18,19)(H,20,21,22);;;/q;3*+1/p-3
DMX4WI7	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)CCCC(P(=O)([O-])[O-])S(=O)(=O)[O-].[K+].[K+].[K+]
DMX4WI7	IK	DRADVLDMPYYQDB-UHFFFAOYSA-K
DMX4WI7	IU	tripotassium;4-(3-phenoxyphenyl)-1-phosphonatobutane-1-sulfonate
DMX4WI7	DE	Hypercholesterolaemia

DM3IPYV	ID	DM3IPYV
DM3IPYV	DN	BPH-675
DM3IPYV	HS	Investigative
DM3IPYV	SN	BPH675; BPH 675
DM3IPYV	DT	Small molecular drug
DM3IPYV	PC	16122555
DM3IPYV	MW	563.5
DM3IPYV	FM	C24H23NO9P2S
DM3IPYV	IC	InChI=1S/C24H23NO9P2S/c26-24(35(27,28)29,36(30,31)32)16-17-5-3-8-19(13-17)20-9-4-10-22(14-20)25-37(33,34)23-12-11-18-6-1-2-7-21(18)15-23/h1-15,25-26H,16H2,(H2,27,28,29)(H2,30,31,32)
DM3IPYV	CS	C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)NC3=CC=CC(=C3)C4=CC=CC(=C4)CC(O)(P(=O)(O)O)P(=O)(O)O
DM3IPYV	IK	MZVWVRVNMXTDAK-UHFFFAOYSA-N
DM3IPYV	IU	[1-hydroxy-2-[3-[3-(naphthalen-2-ylsulfonylamino)phenyl]phenyl]-1-phosphonoethyl]phosphonic acid
DM3IPYV	DE	Discovery agent

DMPKAEW	ID	DMPKAEW
DMPKAEW	DN	BPH-676
DMPKAEW	HS	Investigative
DMPKAEW	SN	BPH676; BPH 676
DMPKAEW	DT	Small molecular drug
DMPKAEW	PC	16122556
DMPKAEW	MW	450.3
DMPKAEW	FM	C20H20O8P2
DMPKAEW	IC	InChI=1S/C20H20O8P2/c21-20(29(22,23)24,30(25,26)27)14-28-19-11-5-10-18(13-19)17-9-4-8-16(12-17)15-6-2-1-3-7-15/h1-13,21H,14H2,(H2,22,23,24)(H2,25,26,27)
DMPKAEW	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)C3=CC(=CC=C3)OCC(O)(P(=O)(O)O)P(=O)(O)O
DMPKAEW	IK	NWIARQRYIRVYCM-UHFFFAOYSA-N
DMPKAEW	IU	[1-hydroxy-2-[3-(3-phenylphenyl)phenoxy]-1-phosphonoethyl]phosphonic acid
DMPKAEW	DE	Discovery agent

DMTHW3F	ID	DMTHW3F
DMTHW3F	DN	BPH-715
DMTHW3F	HS	Investigative
DMTHW3F	SN	BPH 715; BPH715
DMTHW3F	DT	Small molecular drug
DMTHW3F	PC	25014899
DMTHW3F	MW	423.4
DMTHW3F	FM	C17H31NO7P2
DMTHW3F	IC	InChI=1S/C17H31NO7P2/c1-2-3-4-5-6-7-8-9-13-25-16-11-10-12-18(14-16)15-17(26(19,20)21)27(22,23)24/h10-12,14,17H,2-9,13,15H2,1H3,(H3-,19,20,21,22,23,24)
DMTHW3F	CS	CCCCCCCCCCOC1=C[N+](=CC=C1)CC(P(=O)(O)O)P(=O)(O)[O-]
DMTHW3F	IK	QYJHUOZDBUEKQC-UHFFFAOYSA-N
DMTHW3F	IU	[2-(3-decoxypyridin-1-ium-1-yl)-1-phosphonoethyl]-hydroxyphosphinate
DMTHW3F	CA	CAS 1059677-23-4
DMTHW3F	DE	Discovery agent

DMD0XEO	ID	DMD0XEO
DMD0XEO	DN	BPH-742
DMD0XEO	HS	Investigative
DMD0XEO	SN	bisphosphonate, 9; BPH742; BPH 742
DMD0XEO	DT	Small molecular drug
DMD0XEO	PC	25023860
DMD0XEO	MW	418.38
DMD0XEO	FM	C16H37O6P3
DMD0XEO	IC	InChI=1S/C16H37O6P3/c1-4-5-6-7-8-9-10-11-12-13-14-23(2,3)15-16(24(17,18)19)25(20,21)22/h16H,4-15H2,1-3H3,(H3-,17,18,19,20,21,22)
DMD0XEO	CS	CCCCCCCCCCCC[P+](C)(C)CC(P(=O)(O)O)P(=O)(O)[O-]
DMD0XEO	IK	QCMHKGWUOSRYCF-UHFFFAOYSA-N
DMD0XEO	IU	[2-[dodecyl(dimethyl)phosphaniumyl]-1-phosphonoethyl]-hydroxyphosphinate
DMD0XEO	DE	Discovery agent

DM15L2J	ID	DM15L2J
DM15L2J	DN	BPH-830
DM15L2J	HS	Investigative
DM15L2J	SN	BPH830; BPH 830
DM15L2J	DT	Small molecular drug
DM15L2J	PC	44182294
DM15L2J	MW	349.32
DM15L2J	FM	C17H20NO5P
DM15L2J	IC	InChI=1S/C17H20NO5P/c19-17(13-24(20,21)22)18-11-5-7-14-6-4-10-16(12-14)23-15-8-2-1-3-9-15/h1-4,6,8-10,12H,5,7,11,13H2,(H,18,19)(H2,20,21,22)
DM15L2J	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)CCCNC(=O)CP(=O)(O)O
DM15L2J	IK	GNETVUVZFYJATO-UHFFFAOYSA-N
DM15L2J	IU	[2-oxo-2-[3-(3-phenoxyphenyl)propylamino]ethyl]phosphonic acid
DM15L2J	DE	Discovery agent

DMGQXTR	ID	DMGQXTR
DMGQXTR	DN	BPI-704001
DMGQXTR	HS	Investigative
DMGQXTR	SN	BPI-705001; BPI-715001; PARP-1 inhibitors (cancer); PARP-1 inhibitors (cancer), Beta Pharma
DMGQXTR	CP	Beta Pharma Inc
DMGQXTR	DE	Solid tumour/cancer

DMOSG0Q	ID	DMOSG0Q
DMOSG0Q	DN	BPI-711001
DMOSG0Q	HS	Investigative
DMOSG0Q	SN	BPI-712001; DPP-4 inhibitors (oral, diabetes); DPP-4 inhibitors (oral, diabetes), Beta Pharma
DMOSG0Q	CP	Beta Pharma Inc
DMOSG0Q	DE	Hypoglycemia

DMNHEUT	ID	DMNHEUT
DMNHEUT	DN	BPIQ-I
DMNHEUT	HS	Investigative
DMNHEUT	SN	bpiq-i; 174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1
DMNHEUT	DT	Small molecular drug
DMNHEUT	PC	2427
DMNHEUT	MW	354.2
DMNHEUT	FM	C16H12BrN5
DMNHEUT	IC	InChI=1S/C16H12BrN5/c1-22-9-20-14-6-12-13(7-15(14)22)18-8-19-16(12)21-11-4-2-3-10(17)5-11/h2-9H,1H3,(H,18,19,21)
DMNHEUT	CS	CN1C=NC2=C1C=C3C(=C2)C(=NC=N3)NC4=CC(=CC=C4)Br
DMNHEUT	IK	YAMAGACQNDAKFB-UHFFFAOYSA-N
DMNHEUT	IU	N-(3-bromophenyl)-3-methylimidazo[4,5-g]quinazolin-8-amine
DMNHEUT	CA	CAS 174709-30-9
DMNHEUT	DE	Discovery agent

DM5OHIY	ID	DM5OHIY
DM5OHIY	DN	BPKDi
DM5OHIY	HS	Investigative
DM5OHIY	PC	46901383
DM5OHIY	MW	380.5
DM5OHIY	FM	C21H28N6O
DM5OHIY	IC	InChI=1S/C21H28N6O/c22-21(28)16-12-18(26-20(14-16)27-10-8-23-9-11-27)15-6-7-24-19(13-15)25-17-4-2-1-3-5-17/h6-7,12-14,17,23H,1-5,8-11H2,(H2,22,28)(H,24,25)
DM5OHIY	CS	C1CCC(CC1)NC2=NC=CC(=C2)C3=NC(=CC(=C3)C(=O)N)N4CCNCC4
DM5OHIY	IK	XNWDRALEEPGBHB-UHFFFAOYSA-N
DM5OHIY	IU	2-[2-(cyclohexylamino)pyridin-4-yl]-6-piperazin-1-ylpyridine-4-carboxamide
DM5OHIY	DE	Solid tumour/cancer

DMKX6LY	ID	DMKX6LY
DMKX6LY	DN	BPL-001
DMKX6LY	HS	Investigative
DMKX6LY	SN	HMG CoA reductase inhibitors (cardiovascular disease), Bradford Pharma; HMG CoA reductase inhibitors (cardiovascular disease), Redx Pharma; BPL-001 series (cardiovascular disease), Bradford Pharma; BPL-001 series (cardiovascular disease), Redx Pharma
DMKX6LY	CP	Bradford Pharma Ltd
DMKX6LY	DE	Cardiovascular disease

DMJPN8Z	ID	DMJPN8Z
DMJPN8Z	DN	BPR1K-0224
DMJPN8Z	HS	Investigative
DMJPN8Z	SN	Aurora kinase inhibitors (cancer); BPR1K-0025; BPR1K-0432; BPR1K-0648; BPR1K-0724; Aurora kinase inhibitors (cancer), National Health Research Institutes
DMJPN8Z	CP	National Health Research Institutes
DMJPN8Z	DE	Solid tumour/cancer

DMQBRSM	ID	DMQBRSM
DMQBRSM	DN	BQ 3020
DMQBRSM	HS	Investigative
DMQBRSM	SN	BQ3020; BQ-3020
DMQBRSM	DT	Small molecular drug
DMQBRSM	PC	16133801
DMQBRSM	MW	1992.3
DMQBRSM	FM	C95H138N20O25S
DMQBRSM	IC	InChI=1S/C95H138N20O25S/c1-15-52(10)79(94(138)114-78(51(8)9)93(137)112-73(95(139)140)41-58-45-98-62-26-20-19-25-61(58)62)115-91(135)72(44-76(122)123)110-87(131)67(38-49(4)5)107-89(133)70(42-59-46-97-47-99-59)106-80(124)53(11)101-85(129)68(39-56-23-17-16-18-24-56)108-88(132)69(40-57-28-30-60(117)31-29-57)111-92(136)77(50(6)7)113-81(125)54(12)100-82(126)64(32-33-74(118)119)104-83(127)63(27-21-22-35-96)103-90(134)71(43-75(120)121)109-84(128)65(34-36-141-14)105-86(130)66(37-48(2)3)102-55(13)116/h16-20,23-26,28-31,45-54,63-73,77-79,98,117H,15,21-22,27,32-44,96H2,1-14H3,(H,97,99)(H,100,126)(H,101,129)(H,102,116)(H,103,134)(H,104,127)(H,105,130)(H,106,124)(H,107,133)(H,108,132)(H,109,128)(H,110,131)(H,111,136)(H,112,137)(H,113,125)(H,114,138)(H,115,135)(H,118,119)(H,120,121)(H,122,123)(H,139,140)/t52-,53-,54-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,77-,78-,79-/m0/s1
DMQBRSM	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)C
DMQBRSM	IK	KBQLINQFUQUHIY-SGOWJZKMSA-N
DMQBRSM	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S,3S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMQBRSM	DE	Discovery agent

DMSGIXK	ID	DMSGIXK
DMSGIXK	DN	BQCA
DMSGIXK	HS	Investigative
DMSGIXK	SN	TBPB; Benzyl quinolone carboxylic acid; M1 muscarinic acetylcholine receptor agonist (Alzherimer's disease); M1mAChRs (neurological disorder), Merck & Co; M1 muscarinic acetylcholine receptor agonist (Alzherimer's disease), Merck & Co
DMSGIXK	CP	Merck & Co Inc
DMSGIXK	DT	Small molecular drug
DMSGIXK	PC	1476756
DMSGIXK	MW	309.3
DMSGIXK	FM	C18H15NO4
DMSGIXK	IC	InChI=1S/C18H15NO4/c1-23-13-8-6-12(7-9-13)10-19-11-15(18(21)22)17(20)14-4-2-3-5-16(14)19/h2-9,11H,10H2,1H3,(H,21,22)
DMSGIXK	CS	COC1=CC=C(C=C1)CN2C=C(C(=O)C3=CC=CC=C32)C(=O)O
DMSGIXK	IK	BZBBTGCKPRSPGF-UHFFFAOYSA-N
DMSGIXK	IU	1-[(4-methoxyphenyl)methyl]-4-oxoquinoline-3-carboxylic acid
DMSGIXK	CA	CAS 338747-41-4
DMSGIXK	DE	Neurological disorder

DMBTC23	ID	DMBTC23
DMBTC23	DN	Br-5MPEPy
DMBTC23	HS	Investigative
DMBTC23	SN	Br-5MPEPy; SCHEMBL3963310; GTPL6397; CHEMBL475270
DMBTC23	DT	Small molecular drug
DMBTC23	PC	16067787
DMBTC23	MW	273.13
DMBTC23	FM	C13H9BrN2
DMBTC23	IC	InChI=1S/C13H9BrN2/c1-10-2-4-13(16-7-10)5-3-11-6-12(14)9-15-8-11/h2,4,6-9H,1H3
DMBTC23	CS	CC1=CN=C(C=C1)C#CC2=CC(=CN=C2)Br
DMBTC23	IK	IHHBVGZPZBDKRA-UHFFFAOYSA-N
DMBTC23	IU	2-[2-(5-bromopyridin-3-yl)ethynyl]-5-methylpyridine
DMBTC23	CA	CAS 872428-51-8
DMBTC23	DE	Discovery agent

DM0DWSR	ID	DM0DWSR
DM0DWSR	DN	bradyzide
DM0DWSR	HS	Investigative
DM0DWSR	SN	Bradyzide; CHEMBL308468; AC1NSM1I; GTPL680; SCHEMBL8488232; LS-137389; 263011-13-8; (2S)-N-[2-(2-dimethylaminoethyl-methylamino)ethyl]-1-[4-[2-[di(phenyl)methylcarbamothioyl]hydrazinyl]-3-nitrophenyl]sulfonylpyrrolidine-2-carboxamide
DM0DWSR	DT	Small molecular drug
DM0DWSR	PC	5312119
DM0DWSR	MW	682.9
DM0DWSR	FM	C32H42N8O5S2
DM0DWSR	IC	InChI=1S/C32H42N8O5S2/c1-37(2)21-22-38(3)20-18-33-31(41)28-15-10-19-39(28)47(44,45)26-16-17-27(29(23-26)40(42)43)35-36-32(46)34-30(24-11-6-4-7-12-24)25-13-8-5-9-14-25/h4-9,11-14,16-17,23,28,30,35H,10,15,18-22H2,1-3H3,(H,33,41)(H2,34,36,46)/t28-/m0/s1
DM0DWSR	CS	CN(C)CCN(C)CCNC(=O)[C@@H]1CCCN1S(=O)(=O)C2=CC(=C(C=C2)NNC(=S)NC(C3=CC=CC=C3)C4=CC=CC=C4)[N+](=O)[O-]
DM0DWSR	IK	ZIBIVIRBYMBEHZ-NDEPHWFRSA-N
DM0DWSR	IU	(2S)-1-[4-[2-(benzhydrylcarbamothioyl)hydrazinyl]-3-nitrophenyl]sulfonyl-N-[2-[2-(dimethylamino)ethyl-methylamino]ethyl]pyrrolidine-2-carboxamide
DM0DWSR	DE	Discovery agent

DMIZ9ON	ID	DMIZ9ON
DMIZ9ON	DN	BRD1240
DMIZ9ON	HS	Investigative
DMIZ9ON	SN	BRD-1240; 3-(1,3-benzodioxol-5-yl)-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea; CHEMBL2355724; CHEBI:96315; BRD-K63431240-001-01-4; BRD-K63431240-001-02-2; Q27168409
DMIZ9ON	CP	Harvard University
DMIZ9ON	DT	Small molecular drug
DMIZ9ON	PC	54618771
DMIZ9ON	MW	592.7
DMIZ9ON	FM	C30H32N4O7S
DMIZ9ON	IC	InChI=1S/C30H32N4O7S/c1-20-16-34(21(2)18-35)42(37,38)29-9-6-23(5-4-22-10-12-31-13-11-22)14-27(29)41-28(20)17-33(3)30(36)32-24-7-8-25-26(15-24)40-19-39-25/h6-15,20-21,28,35H,16-19H2,1-3H3,(H,32,36)/t20-,21-,28+/m0/s1
DMIZ9ON	CS	C[C@H]1CN(S(=O)(=O)C2=C(C=C(C=C2)C#CC3=CC=NC=C3)O[C@@H]1CN(C)C(=O)NC4=CC5=C(C=C4)OCO5)[C@@H](C)CO
DMIZ9ON	IK	OYKBHWDUAQJSNT-YHGPEZAFSA-N
DMIZ9ON	IU	3-(1,3-benzodioxol-5-yl)-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
DMIZ9ON	CB	CHEBI:96315
DMIZ9ON	DE	Solid tumour/cancer

DMFAVB5	ID	DMFAVB5
DMFAVB5	DN	BRD9539
DMFAVB5	HS	Investigative
DMFAVB5	SN	BRD-9539; BRD 9539
DMFAVB5	DT	Small molecular drug
DMFAVB5	PC	73755260
DMFAVB5	MW	399.4
DMFAVB5	FM	C24H21N3O3
DMFAVB5	IC	InChI=1S/C24H21N3O3/c28-22(18-11-5-2-6-12-18)26-24-25-20-16-19(23(29)30)13-14-21(20)27(24)15-7-10-17-8-3-1-4-9-17/h1-6,8-9,11-14,16H,7,10,15H2,(H,29,30)(H,25,26,28)
DMFAVB5	CS	C1=CC=C(C=C1)CCCN2C3=C(C=C(C=C3)C(=O)O)N=C2NC(=O)C4=CC=CC=C4
DMFAVB5	IK	WPXMEOBILYVKBC-UHFFFAOYSA-N
DMFAVB5	IU	2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylic acid
DMFAVB5	CA	CAS 1374601-41-8
DMFAVB5	DE	Discovery agent

DM21ZBU	ID	DM21ZBU
DM21ZBU	DN	Breceptin
DM21ZBU	HS	Investigative
DM21ZBU	SN	B-10206; B-10396; B-10410; B-10458; B-199; B-201 acetate; B-202; B-9340; B-9430; B-9698; B-9870; CU-202; CU-201, Apoplogic
DM21ZBU	CP	University of Colorado System
DM21ZBU	DE	Solid tumour/cancer

DM3EIBU	ID	DM3EIBU
DM3EIBU	DN	BREMAZOCINE
DM3EIBU	HS	Investigative
DM3EIBU	SN	Bremazocine; (-)-Bremazocine; Bremazocine, (-)-; 75684-07-0; 2-(1-Hydroxy-cyclopropylmethyl)-5-ethyl-9,9-dimethyl-2'-hydroxy-6,7-benzomorphan; 2,6-Methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl-, (2R)-; SureCN157210; AC1Q2C6X; SCHEMBL157210; CHEBI:3171; GTPL1603; ZINC3870315; PDSP2_001570; PDSP1_001586; C11791; UNII-ISF76M2DBE component ZDXGFIXMPOUDFF-XLIONFOSSA-N
DM3EIBU	DT	Small molecular drug
DM3EIBU	PC	443406
DM3EIBU	MW	315.4
DM3EIBU	FM	C20H29NO2
DM3EIBU	IC	InChI=1S/C20H29NO2/c1-4-20-9-10-21(13-19(23)7-8-19)17(18(20,2)3)11-14-5-6-15(22)12-16(14)20/h5-6,12,17,22-23H,4,7-11,13H2,1-3H3/t17-,20+/m1/s1
DM3EIBU	CS	CC[C@@]12CCN([C@@H](C1(C)C)CC3=C2C=C(C=C3)O)CC4(CC4)O
DM3EIBU	IK	ZDXGFIXMPOUDFF-XLIONFOSSA-N
DM3EIBU	IU	(1S,9R)-1-ethyl-10-[(1-hydroxycyclopropyl)methyl]-13,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DM3EIBU	CA	CAS 75684-07-0
DM3EIBU	CB	CHEBI:3171
DM3EIBU	DE	Discovery agent

DM2JPX7	ID	DM2JPX7
DM2JPX7	DN	BRIFENTANIL
DM2JPX7	HS	Investigative
DM2JPX7	SN	Brifentanil < Rec INN; A-3331 (monohydrochloride); Rac-cis-1-[2-(4-Ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-3-methyl-4-[N-(2-fluorophenyl)methoxyacetamido]piperidine; Rac-cis-N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-3-methyl-4-piperidyl]-2'-fluoro-2-methoxyacetanilide
DM2JPX7	DT	Small molecular drug
DM2JPX7	PC	60672
DM2JPX7	MW	420.5
DM2JPX7	FM	C20H29FN6O3
DM2JPX7	IC	InChI=1S/C20H29FN6O3/c1-4-25-20(29)26(23-22-25)12-11-24-10-9-17(15(2)13-24)27(19(28)14-30-3)18-8-6-5-7-16(18)21/h5-8,15,17H,4,9-14H2,1-3H3/t15-,17+/m1/s1
DM2JPX7	CS	CCN1C(=O)N(N=N1)CCN2CC[C@@H]([C@@H](C2)C)N(C3=CC=CC=C3F)C(=O)COC
DM2JPX7	IK	KKMGCTVJCQYQPV-WBVHZDCISA-N
DM2JPX7	IU	N-[(3R,4S)-1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-3-methylpiperidin-4-yl]-N-(2-fluorophenyl)-2-methoxyacetamide
DM2JPX7	CA	CAS 101345-71-5
DM2JPX7	DE	Pain

DMTM7W0	ID	DMTM7W0
DMTM7W0	DN	BRL 43694A
DMTM7W0	HS	Investigative
DMTM7W0	SN	Granisetron HCl; Granisetron hydrochloride; 107007-99-8; Kytril; Granisetron (Hydrochloride); Kytril Injection; BRL 43694A; 1-Methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H-indazole-3-carboxamide hydrochloride; 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide hydrochloride; 1044956-47-9; BRL-43694A; Granisetron hydrochloride [USAN]; endo-1-Methyl-N-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide hydrochloride
DMTM7W0	DT	Small molecular drug
DMTM7W0	PC	65264
DMTM7W0	MW	348.9
DMTM7W0	FM	C18H25ClN4O
DMTM7W0	IC	InChI=1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H
DMTM7W0	CS	CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C.Cl
DMTM7W0	IK	QYZRTBKYBJRGJB-UHFFFAOYSA-N
DMTM7W0	IU	1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;hydrochloride
DMTM7W0	CA	CAS 107007-99-8
DMTM7W0	DE	Discovery agent

DM3WPO4	ID	DM3WPO4
DM3WPO4	DN	BRL 44408
DM3WPO4	HS	Investigative
DM3WPO4	SN	Brl-44408; BRL 44408; 118343-19-4; BRL44408; 2-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2,3-dihydro-1-methyl-1H-isoindole; 1H-Isoindole, 2-((4,5-dihydro-1H-imidazol-2-yl)methyl)-2,3-dihydro-1-methyl-; Brl 48553; C13H17N3; 2-(4,5-dihydro-1H-imidazol-2-ylmethyl)-1-methyl-1,3-dihydroisoindole; Brl 48962; 2-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole; BRL-48553; BRL-48962; AC1L3TIM; GTPL525; SCHEMBL7596949; CHEMBL216097; CTK8E7463; BDBM82520; PDSP2_001727; PDSP1_001744; NSC_121850; CAS_121850
DM3WPO4	DT	Small molecular drug
DM3WPO4	PC	121850
DM3WPO4	MW	215.29
DM3WPO4	FM	C13H17N3
DM3WPO4	IC	InChI=1S/C13H17N3/c1-10-12-5-3-2-4-11(12)8-16(10)9-13-14-6-7-15-13/h2-5,10H,6-9H2,1H3,(H,14,15)
DM3WPO4	CS	CC1C2=CC=CC=C2CN1CC3=NCCN3
DM3WPO4	IK	SGOFAUSEYBZKDQ-UHFFFAOYSA-N
DM3WPO4	IU	2-(4,5-dihydro-1H-imidazol-2-ylmethyl)-1-methyl-1,3-dihydroisoindole
DM3WPO4	CA	CAS 118343-19-4
DM3WPO4	DE	Discovery agent

DM16GUV	ID	DM16GUV
DM16GUV	DN	BRL 52537 hydrochloride
DM16GUV	HS	Investigative
DM16GUV	SN	2-(3,4-Dichlorophenyl)-1-(2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethanone hydrochloride; 130497-33-5; 112282-24-3; BRL 52537; AK-57392; (+/-)-1-(3,4-Dichlorophenyl)acetyl-2-(1-pyrrolidinyl)methylpiperidine hydrochloride; 2-(3,4-DICHLOROPHENYL)-1-(2-(PYRROLIDIN-1-YLMETHYL)PIPERIDIN-1-YL)ETHANONE HCL; SR-01000076141; EU-0101141; BRL-52537 hydrochloride; Brl 52537 HCl; MLS002153457; SCHEMBL8435659; CHEMBL1256835; KS-00000FTT; CTK8C4721; DTXSID00462129; MolPort-003-940-484; BCP21081; EBD29079
DM16GUV	DT	Small molecular drug
DM16GUV	PC	11315337
DM16GUV	MW	391.8
DM16GUV	FM	C18H25Cl3N2O
DM16GUV	IC	InChI=1S/C18H24Cl2N2O.ClH/c19-16-7-6-14(11-17(16)20)12-18(23)22-10-2-1-5-15(22)13-21-8-3-4-9-21;/h6-7,11,15H,1-5,8-10,12-13H2;1H
DM16GUV	CS	C1CCN(C(C1)CN2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl.Cl
DM16GUV	IK	NGVLSOWJSUUYDE-UHFFFAOYSA-N
DM16GUV	IU	2-(3,4-dichlorophenyl)-1-[2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]ethanone;hydrochloride
DM16GUV	CA	CAS 130497-33-5
DM16GUV	DE	Discovery agent

DM6XO72	ID	DM6XO72
DM6XO72	DN	BRL 52974
DM6XO72	HS	Investigative
DM6XO72	SN	145544-79-2; Ethanone,2-(3,4-dichlorophenyl)-1-[3,4,6,7-tetrahydro-4-(1-pyrrolidinylmethyl)-5H-imidazo[4,5-c]pyridin-5-yl]-; Brl-52974; Brl 52974; ACMC-20n4kx; SCHEMBL7641688; CTK4C4597; CJLJXCDVYJKDTR-UHFFFAOYSA-N; AKOS030599156; 5-((3,4-Dichlorophenyl)acetyl)-4-(1-pyrrolidinylmethyl)-4,5,6,7-tetrahydro-1H-imidazo(4,5-c)pyridine; 1H-Imidazo(4,5-c)pyridine, 5-((3,4-dichlorophenyl)acetyl)-4,5,6,7-tetrahydro-4-(1-pyrrolidinylmethyl)-
DM6XO72	DT	Small molecular drug
DM6XO72	PC	10000638
DM6XO72	MW	393.3
DM6XO72	FM	C19H22Cl2N4O
DM6XO72	IC	InChI=1S/C19H22Cl2N4O/c20-14-4-3-13(9-15(14)21)10-18(26)25-8-5-16-19(23-12-22-16)17(25)11-24-6-1-2-7-24/h3-4,9,12,17H,1-2,5-8,10-11H2,(H,22,23)
DM6XO72	CS	C1CCN(C1)CC2C3=C(CCN2C(=O)CC4=CC(=C(C=C4)Cl)Cl)NC=N3
DM6XO72	IK	CJLJXCDVYJKDTR-UHFFFAOYSA-N
DM6XO72	IU	2-(3,4-dichlorophenyl)-1-[4-(pyrrolidin-1-ylmethyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]ethanone
DM6XO72	CA	CAS 145544-79-2
DM6XO72	DE	Discovery agent

DMM61Y2	ID	DMM61Y2
DMM61Y2	DN	BRL-15572
DMM61Y2	HS	Investigative
DMM61Y2	SN	BRL15572; BRL-15,572; BRL 15572
DMM61Y2	DT	Small molecular drug
DMM61Y2	PC	3654103
DMM61Y2	MW	406.9
DMM61Y2	FM	C25H27ClN2O
DMM61Y2	IC	InChI=1S/C25H27ClN2O/c26-22-12-7-13-23(18-22)28-16-14-27(15-17-28)19-24(29)25(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-13,18,24-25,29H,14-17,19H2
DMM61Y2	CS	C1CN(CCN1CC(C(C2=CC=CC=C2)C3=CC=CC=C3)O)C4=CC(=CC=C4)Cl
DMM61Y2	IK	QJHCTHPYUOXOGM-UHFFFAOYSA-N
DMM61Y2	IU	3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol
DMM61Y2	CA	CAS 734517-40-9
DMM61Y2	CB	CHEBI:64060
DMM61Y2	DE	Discovery agent

DMSB4EW	ID	DMSB4EW
DMSB4EW	DN	BRL-24682
DMSB4EW	HS	Investigative
DMSB4EW	SN	Brl-24682; Brl 24682; SCHEMBL7292676; CHEMBL301039; BDBM82519; PDSP2_001249; PDSP1_001265; 76272-78-1; CAS_76272-78-1; 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide; Benzamide, 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-
DMSB4EW	DT	Small molecular drug
DMSB4EW	PC	9797313
DMSB4EW	MW	323.82
DMSB4EW	FM	C16H22ClN3O2
DMSB4EW	IC	InChI=1S/C16H22ClN3O2/c1-20-10-3-4-11(20)6-9(5-10)19-16(21)12-7-13(17)14(18)8-15(12)22-2/h7-11H,3-6,18H2,1-2H3,(H,19,21)
DMSB4EW	CS	CN1C2CCC1CC(C2)NC(=O)C3=CC(=C(C=C3OC)N)Cl
DMSB4EW	IK	HTMNINCXKXABOI-UHFFFAOYSA-N
DMSB4EW	IU	4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide
DMSB4EW	CA	CAS 76272-78-1
DMSB4EW	DE	Discovery agent

DMD0YL1	ID	DMD0YL1
DMD0YL1	DN	BRL-25594
DMD0YL1	HS	Investigative
DMD0YL1	PC	10069545
DMD0YL1	MW	399.9
DMD0YL1	FM	C22H26ClN3O2
DMD0YL1	IC	InChI=1S/C22H26ClN3O2/c1-28-21-12-20(24)19(23)11-18(21)22(27)25-15-9-16-7-8-17(10-15)26(16)13-14-5-3-2-4-6-14/h2-6,11-12,15-17H,7-10,13,24H2,1H3,(H,25,27)
DMD0YL1	CS	COC1=CC(=C(C=C1C(=O)NC2CC3CCC(C2)N3CC4=CC=CC=C4)Cl)N
DMD0YL1	IK	BQHYHGXYIOWFJL-UHFFFAOYSA-N
DMD0YL1	IU	4-amino-N-(8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)-5-chloro-2-methoxybenzamide
DMD0YL1	DE	Discovery agent

DMQ4MFY	ID	DMQ4MFY
DMQ4MFY	DN	BRL-26175
DMQ4MFY	HS	Investigative
DMQ4MFY	SN	BRL-26175; CHEMBL122533; BDBM50042732
DMQ4MFY	DT	Small molecular drug
DMQ4MFY	PC	44348012
DMQ4MFY	MW	413.9
DMQ4MFY	FM	C23H28ClN3O2
DMQ4MFY	IC	InChI=1S/C23H28ClN3O2/c1-29-22-13-21(25)20(24)12-19(22)23(28)26-16-10-17-8-5-9-18(11-16)27(17)14-15-6-3-2-4-7-15/h2-4,6-7,12-13,16-18H,5,8-11,14,25H2,1H3,(H,26,28)
DMQ4MFY	CS	COC1=CC(=C(C=C1C(=O)NC2CC3CCCC(C2)N3CC4=CC=CC=C4)Cl)N
DMQ4MFY	IK	BUPWFKLTAPZHIE-UHFFFAOYSA-N
DMQ4MFY	IU	4-amino-N-(9-benzyl-9-azabicyclo[3.3.1]nonan-3-yl)-5-chloro-2-methoxybenzamide
DMQ4MFY	DE	Discovery agent

DMRI49D	ID	DMRI49D
DMRI49D	DN	BRL-36378
DMRI49D	HS	Investigative
DMRI49D	SN	N-[4-(2,3-Dihydrobenzofuran-2-yl)-1-(ethoxycarbonyl)butyl]-L-alanyl-L-proline
DMRI49D	DT	Small molecular drug
DMRI49D	PC	134835
DMRI49D	MW	432.5
DMRI49D	FM	C23H32N2O6
DMRI49D	IC	InChI=1S/C23H32N2O6/c1-3-30-23(29)18(10-6-9-17-14-16-8-4-5-12-20(16)31-17)24-15(2)21(26)25-13-7-11-19(25)22(27)28/h4-5,8,12,15,17-19,24H,3,6-7,9-11,13-14H2,1-2H3,(H,27,28)/t15-,17?,18?,19-/m0/s1
DMRI49D	CS	CCOC(=O)C(CCCC1CC2=CC=CC=C2O1)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)O
DMRI49D	IK	HTBXOXWJOIKINE-RXQRSOPUSA-N
DMRI49D	IU	(2S)-1-[(2S)-2-[[5-(2,3-dihydro-1-benzofuran-2-yl)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMRI49D	CA	CAS 84768-09-2
DMRI49D	DE	Discovery agent

DMT4NM5	ID	DMT4NM5
DMT4NM5	DN	BRL-48482
DMT4NM5	HS	Investigative
DMT4NM5	SN	BRL-48482; SCHEMBL1850299; ZYKPNHFCNSVFNF-UHFFFAOYSA-N; 5-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(benzoxazol-2-yl-methylamino)ethoxy] benzyl]thiazolidine-2,4-dione
DMT4NM5	DT	Small molecular drug
DMT4NM5	PC	9822139
DMT4NM5	MW	397.4
DMT4NM5	FM	C20H19N3O4S
DMT4NM5	IC	InChI=1S/C20H19N3O4S/c1-23(19-21-15-4-2-3-5-16(15)27-19)10-11-26-14-8-6-13(7-9-14)12-17-18(24)22-20(25)28-17/h2-9,17H,10-12H2,1H3,(H,22,24,25)
DMT4NM5	CS	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=NC4=CC=CC=C4O3
DMT4NM5	IK	ZYKPNHFCNSVFNF-UHFFFAOYSA-N
DMT4NM5	IU	5-[[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMT4NM5	DE	Discovery agent

DMV2XUM	ID	DMV2XUM
DMV2XUM	DN	BRL50481
DMV2XUM	HS	Investigative
DMV2XUM	SN	BRL-50481; BRL 50481
DMV2XUM	DT	Small molecular drug
DMV2XUM	PC	2921148
DMV2XUM	MW	244.27
DMV2XUM	FM	C9H12N2O4S
DMV2XUM	IC	InChI=1S/C9H12N2O4S/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6H,1-3H3
DMV2XUM	CS	CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N(C)C
DMV2XUM	IK	IFIUFCJFLGCQPH-UHFFFAOYSA-N
DMV2XUM	IU	N,N,2-trimethyl-5-nitrobenzenesulfonamide
DMV2XUM	CA	CAS 433695-36-4
DMV2XUM	CB	CHEBI:93472
DMV2XUM	DE	Discovery agent

DM3TWBU	ID	DM3TWBU
DM3TWBU	DN	BRL54443
DM3TWBU	HS	Investigative
DM3TWBU	SN	57477-39-1; BRL 54443; BRL-54443; 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol; BRL54443; UNII-Q2DH1CHI0Y; Q2DH1CHI0Y; 1H-Indol-5-ol, 3-(1-methyl-4-piperidinyl)-; 5-Hydroxy-3-(1-methylpiperidin-4-yl)-1H-indole; 3-(1-METHYL-4-PIPERIDINYL)-1H-INDOL-5-OL; AK163730; NCGC00015134-01; Tocris-1129; Lopac-B-173; AC1L1DOE; Biomol-NT_000107; Lopac0_000207; ZINC7339; BPBio1_001401; SCHEMBL3546728; GTPL3927; CHEMBL1371156; CTK6I2277; CHEBI:92321; KS-00000SOT; QCR-209; DTXSID40206089; WKNFADCGOAHBPG-UHFFFAOYSA-N; MolPort-021-804-935; BCPP000316
DM3TWBU	DT	Small molecular drug
DM3TWBU	PC	2438
DM3TWBU	MW	230.31
DM3TWBU	FM	C14H18N2O
DM3TWBU	IC	InChI=1S/C14H18N2O/c1-16-6-4-10(5-7-16)13-9-15-14-3-2-11(17)8-12(13)14/h2-3,8-10,15,17H,4-7H2,1H3
DM3TWBU	CS	CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)O
DM3TWBU	IK	WKNFADCGOAHBPG-UHFFFAOYSA-N
DM3TWBU	IU	3-(1-methylpiperidin-4-yl)-1H-indol-5-ol
DM3TWBU	CA	CAS 57477-39-1
DM3TWBU	CB	CHEBI:92321
DM3TWBU	DE	Discovery agent

DM2J1FA	ID	DM2J1FA
DM2J1FA	DN	BRL-54504AX
DM2J1FA	HS	Investigative
DM2J1FA	SN	CHEMBL87114; BRL-54504AX
DM2J1FA	DT	Small molecular drug
DM2J1FA	PC	9903796
DM2J1FA	MW	279.34
DM2J1FA	FM	C17H17N3O
DM2J1FA	IC	InChI=1S/C17H17N3O/c1-9-7-8-11-14(16(9)21)15(18)13-10-5-3-4-6-12(10)20(2)17(13)19-11/h3-6,9H,7-8H2,1-2H3,(H2,18,19)
DM2J1FA	CS	CC1CCC2=C(C1=O)C(=C3C4=CC=CC=C4N(C3=N2)C)N
DM2J1FA	IK	NWCDOCLEZPSZBM-UHFFFAOYSA-N
DM2J1FA	IU	11-amino-2,6-dimethyl-3,4-dihydro-2H-indolo[2,3-b]quinolin-1-one
DM2J1FA	DE	Discovery agent

DMEMZ6Q	ID	DMEMZ6Q
DMEMZ6Q	DN	BRL-55473
DMEMZ6Q	HS	Investigative
DMEMZ6Q	SN	CHEMBL336590; SCHEMBL3133982; SCHEMBL3133975; SCHEMBL12390534; BRL-57269A; BDBM50212570
DMEMZ6Q	DT	Small molecular drug
DMEMZ6Q	PC	9816018
DMEMZ6Q	MW	193.25
DMEMZ6Q	FM	C10H15N3O
DMEMZ6Q	IC	InChI=1S/C10H15N3O/c1-14-12-10(6-11)9-7-13-4-2-8(9)3-5-13/h8-9H,2-5,7H2,1H3/b12-10+
DMEMZ6Q	CS	CO/N=C(\\C#N)/C1CN2CCC1CC2
DMEMZ6Q	IK	IQWCBYSUUOFOMF-ZRDIBKRKSA-N
DMEMZ6Q	IU	(3Z)-N-methoxy-1-azabicyclo[2.2.2]octane-3-carboximidoyl cyanide
DMEMZ6Q	DE	Discovery agent

DMZMWVX	ID	DMZMWVX
DMZMWVX	DN	BRN-0471734
DMZMWVX	HS	Investigative
DMZMWVX	SN	Benzaldehyde-4-carboxylic acid; Benzoic acid, 4-formyl-; GOUHYARYYWKXHS-UHFFFAOYSA-N; PubChem8075; Terephthalaldehydic acid; Terephthaldehydic acid; UES4QRK36E; p-Carboxybenzaldehyde; p-Formylbenzoic acid; 4-Carboxybenzaladehyde; 4-Carboxybenzaldehyde; 4-Carboxybenzaldehyde, 96%; 4-FORMYLBENZOIC ACID; 4-Formyl-benzoic acid; 4-FormylbenzoicAcid; 4-carboxybenzaldehyd; 4-formyl benzoic acid; 4carboxybenzaldehyde; 4formyl-benzoic acid; 619-66-9; EINECS 210-607-4; HSDB 5719; MFCD00006951; NSC 15797; UNII-UES4QRK36E
DMZMWVX	PC	12088
DMZMWVX	MW	150.13
DMZMWVX	FM	C8H6O3
DMZMWVX	IC	GOUHYARYYWKXHS-UHFFFAOYSA-N
DMZMWVX	CS	C1=CC(=CC=C1C=O)C(=O)O
DMZMWVX	IK	1S/C8H6O3/c9-5-6-1-3-7(4-2-6)8(10)11/h1-5H,(H,10,11)
DMZMWVX	IU	4-formylbenzoic acid
DMZMWVX	CA	CAS 619-66-9
DMZMWVX	DE	Discovery agent

DMOTU4P	ID	DMOTU4P
DMOTU4P	DN	BRN-1980310
DMOTU4P	HS	Investigative
DMOTU4P	SN	Benzo(a)pyrene, 9-hydroxy-; 9-Hydroxybenzo(a)Pyrene; Benzo[def]chrysen-9-ol; LS-40103; SCHEMBL3348130; ZINC4655178; benzo[a]pyren-9-ol; 17573-21-6; 9-Hydroxy Benzopyrene; 9-Hydroxy benzo[a]pyrene; 9-Hydroxybenzo[a]pyrene; 9-hydroxybenzo(a)pyrene, 3H-labeled; AC1L1FO7; ACM17573216; AKOS027321432; BIDD:ER0395; BRN 1980310; CCRIS 1073; CHEBI:34512; BENZO(a)PYREN-9-OL; CHEMBL351406; CTK0H8447; DTXSID20170012; FT-0669411
DMOTU4P	PC	28598
DMOTU4P	MW	268.3
DMOTU4P	FM	C20H12O
DMOTU4P	IC	OBBBXCAFTKLFGZ-UHFFFAOYSA-N
DMOTU4P	CS	C1=CC2=C3C(=C1)C=CC4=C5C=C(C=CC5=CC(=C43)C=C2)O
DMOTU4P	IK	1S/C20H12O/c21-16-8-6-14-10-15-5-4-12-2-1-3-13-7-9-17(18(14)11-16)20(15)19(12)13/h1-11,21H
DMOTU4P	IU	benzo[a]pyren-9-ol
DMOTU4P	CA	CAS 17573-21-6
DMOTU4P	CB	CHEBI:34512
DMOTU4P	DE	Discovery agent

DMC9Q4D	ID	DMC9Q4D
DMC9Q4D	DN	BRN-1999480
DMC9Q4D	HS	Investigative
DMC9Q4D	SN	4-Hydroxyestrone; SCHEMBL223170; (8R,9S,13S,14S)-3,4-Dihydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; 1,3,5(10)-Estratriene-3,4-diol-17-one; 3,4-Dihydroxyestra-1,3,5(10)-trien-17-one; 3,4-dihydroxy-1,3,5(10)-estratrien-17-one; 3,4-dihydroxy-estra-1,3,5(10)-trien-17-one; 3131-23-5; 3MN57C55S2; 4-Hydroxy Estrone; 4-Hydroxy-Estrone; BIDD:ER0089; BRN 1999480; CCRIS 9275; CHEBI:87602; ESTRA-1,3,5(10)-TRIEN-17-ONE, 3,4-DIHYDROXY-; UNII-3MN57C55S2; estra-1,3,5(10)-triene-3,4-diol-17-one
DMC9Q4D	PC	9971251
DMC9Q4D	MW	286.4
DMC9Q4D	FM	C18H22O3
DMC9Q4D	IC	XQZVQQZZOVBNLU-QDTBLXIISA-N
DMC9Q4D	CS	CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4O)O
DMC9Q4D	IK	1S/C18H22O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,19,21H,2-3,5,7-9H2,1H3/t11-,12-,14+,18+/m1/s1
DMC9Q4D	IU	(8R,9S,13S,14S)-3,4-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
DMC9Q4D	CA	CAS 3131-23-5
DMC9Q4D	CB	CHEBI:87602
DMC9Q4D	DE	Discovery agent

DM87VP6	ID	DM87VP6
DM87VP6	DN	BRN-2330710
DM87VP6	HS	Investigative
DM87VP6	SN	Pyren-2-ylmethanol; 2-(Hydroxymethyl)pyrene; 2-Hydroxymethylpyrene; 2-Pyrenemethanol; SCHEMBL9609744; 24471-48-5; 4-06-00-05008 (Beilstein Handbook Reference); AC1L3U62; CCRIS 7295; CTK1A3560; DTXSID90179234
DM87VP6	PC	146932
DM87VP6	MW	232.28
DM87VP6	FM	C17H12O
DM87VP6	IC	XIKICBSLAFJTDZ-UHFFFAOYSA-N
DM87VP6	CS	C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)CO)C=C2
DM87VP6	IK	1S/C17H12O/c18-10-11-8-14-6-4-12-2-1-3-13-5-7-15(9-11)17(14)16(12)13/h1-9,18H,10H2
DM87VP6	IU	pyren-2-ylmethanol
DM87VP6	CA	CAS 24471-48-5
DM87VP6	DE	Discovery agent

DM4KXT0	ID	DM4KXT0
DM4KXT0	DN	BRN-3548355
DM4KXT0	HS	Investigative
DM4KXT0	SN	NNK (carcinogen); 1-Butanone, 4-(methylnitrosoamino)-1-(3-pyridinyl)-; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; 4-(Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 4-(N-Nitroso-N-methylamino)-1-(3-pyridyl)-1-butanone; 4-Methylnitrosoamino-1-(3-pyridinyl)-1-butanone; 4-[methyl(nitroso)amino]-1-(pyridin-3-yl)butan-1-one; 64091-91-4; 7S395EDO61; CCRIS 1150; CHEBI:32692; MFCD00274580; N-Methyl-N-nitroso-4-oxo-4-(3-pyridyl)butyl amine; NNK; UNII-7S395EDO61
DM4KXT0	PC	47289
DM4KXT0	MW	207.23
DM4KXT0	FM	C10H13N3O2
DM4KXT0	IC	FLAQQSHRLBFIEZ-UHFFFAOYSA-N
DM4KXT0	CS	CN(CCCC(=O)C1=CN=CC=C1)N=O
DM4KXT0	IK	1S/C10H13N3O2/c1-13(12-15)7-3-5-10(14)9-4-2-6-11-8-9/h2,4,6,8H,3,5,7H2,1H3
DM4KXT0	IU	N-methyl-N-(4-oxo-4-pyridin-3-ylbutyl)nitrous amide
DM4KXT0	CA	CAS 64091-50-5
DM4KXT0	CB	CHEBI:32692
DM4KXT0	DE	Discovery agent

DM9UF02	ID	DM9UF02
DM9UF02	DN	Brocresine
DM9UF02	HS	Investigative
DM9UF02	SN	Brocresine; Brocresin; 555-65-7; 3-(Aminooxymethyl)-6-bromphenol; Brocresinum [INN-Latin]; Brocresina [INN-Spanish]; NSD 1055; Brocresine [USAN:INN:BAN]; UNII-11F6O06WN0; CL 54998; NSD-1055; alpha-(Aminooxy)-6-bromo-m-cresol; C7H8BrNO2; 5-((Aminooxy)methyl)-2-bromophenol; O-)4-Brom-3-hydroxybenzyl)hydroxylamin; BRN 1945736; Phenol, 5-((aminooxy)methyl)-2-bromo-; 4-Bromo-3-hydroxybenzyloxyamine; QNWOSJAGFSUDFE-UHFFFAOYSA-N; 11F6O06WN0; 5-[(Aminooxy)methyl]-2-bromophenol; m-CRESOL, alpha-(AMINOOXY)-6-BROMO-; Brocresina
DM9UF02	DT	Small molecular drug
DM9UF02	PC	11151
DM9UF02	MW	218.05
DM9UF02	FM	C7H8BrNO2
DM9UF02	IC	InChI=1S/C7H8BrNO2/c8-6-2-1-5(4-11-9)3-7(6)10/h1-3,10H,4,9H2
DM9UF02	CS	C1=CC(=C(C=C1CON)O)Br
DM9UF02	IK	QNWOSJAGFSUDFE-UHFFFAOYSA-N
DM9UF02	IU	5-(aminooxymethyl)-2-bromophenol
DM9UF02	CA	CAS 555-65-7
DM9UF02	DE	Discovery agent

DM7OF6N	ID	DM7OF6N
DM7OF6N	DN	Brodimoprim-4,6-Dicarboxylate
DM7OF6N	HS	Investigative
DM7OF6N	SN	brodimoprim-4,6-dicarboxylate; (2S)-2-[3-[2-bromo-5-[(2,4-diaminopyrimidin-1-ium-5-yl)methyl]-3-methoxyphenoxy]propyl]pentanedioate; (2S)-2-(3-{2-bromo-5-[(2,4-diaminopyrimidin-1-ium-5-yl)methyl]-3-methoxyphenoxy}propyl)pentanedioate; AC1NRA8B
DM7OF6N	DT	Small molecular drug
DM7OF6N	PC	5287754
DM7OF6N	MW	496.3
DM7OF6N	FM	C20H24BrN4O6-
DM7OF6N	IC	InChI=1S/C20H25BrN4O6/c1-30-14-8-11(7-13-10-24-20(23)25-18(13)22)9-15(17(14)21)31-6-2-3-12(19(28)29)4-5-16(26)27/h8-10,12H,2-7H2,1H3,(H,26,27)(H,28,29)(H4,22,23,24,25)/p-1/t12-/m0/s1
DM7OF6N	CS	COC1=C(C(=CC(=C1)CC2=C[NH+]=C(N=C2N)N)OCCC[C@@H](CCC(=O)[O-])C(=O)[O-])Br
DM7OF6N	IK	SZAVCZNFKJSWRN-LBPRGKRZSA-M
DM7OF6N	IU	(2S)-2-[3-[2-bromo-5-[(2,4-diaminopyrimidin-1-ium-5-yl)methyl]-3-methoxyphenoxy]propyl]pentanedioate
DM7OF6N	DE	Discovery agent

DMC4PF0	ID	DMC4PF0
DMC4PF0	DN	Brolamfetamine
DMC4PF0	HS	Investigative
DMC4PF0	SN	Brolamfetamine; 2,5-Dimethoxy-4-bromoamphetamine; 4-Bromo-2,5-dimethoxyamphetamine; DOB-4; 4-Bromo-2,5-dimethoxyphenylisopropylamine; 4-Bromo-DMA; 32156-26-6; 2,5-Dimethoxy-(4-bromo)phenylisopropylamine; 64638-07-9; 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine; 1-(2,5-Dimethoxyphenyl-4-bromo)-2-aminopropane; 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane; 4-Bromo-2,5-dimethoxy-alpha-methylbenzeneethanamine; CHEMBL6607; DOB; DEA No. 7391; Benzeneethanamine, 4-bromo-2,5-dimethoxy-alpha-methyl-; Brolamfetaminum
DMC4PF0	DT	Small molecular drug
DMC4PF0	PC	62065
DMC4PF0	MW	274.15
DMC4PF0	FM	C11H16BrNO2
DMC4PF0	IC	InChI=1S/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
DMC4PF0	CS	CC(CC1=CC(=C(C=C1OC)Br)OC)N
DMC4PF0	IK	FXMWUTGUCAKGQL-UHFFFAOYSA-N
DMC4PF0	IU	1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
DMC4PF0	CA	CAS 64638-07-9
DMC4PF0	DE	Discovery agent

DMMC4BY	ID	DMMC4BY
DMMC4BY	DN	Brominide tartrate
DMMC4BY	HS	Investigative
DMMC4BY	SN	BRIMONIDINE TARTRATE; 70359-46-5; Brimonidine tartarate; Alphagan; Brimonidine D-tartrate; UNII-4S9CL2DY2H; Brimonidinne tartrate; C11H10BrN5.C4H6O6; Brimonidine L-Tartrate; Brimonidine (tartrate); Brimonidine D-tartarate; 79570-19-7; 4S9CL2DY2H; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate; UK-14304-18; Qoliana; brimonidine Purite; Brimonidine tartrate [USAN]
DMMC4BY	DT	Small molecular drug
DMMC4BY	PC	54405
DMMC4BY	MW	442.22
DMMC4BY	FM	C15H16BrN5O6
DMMC4BY	IC	InChI=1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
DMMC4BY	CS	C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMMC4BY	IK	QZHBYNSSDLTCRG-LREBCSMRSA-N
DMMC4BY	IU	5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acid
DMMC4BY	CA	CAS 70359-46-5
DMMC4BY	DE	Discovery agent

DMTBO7F	ID	DMTBO7F
DMTBO7F	DN	bromoacetone
DMTBO7F	HS	Investigative
DMTBO7F	SN	martonite; monobromoacetone; acetonyl bromide
DMTBO7F	DT	Small molecular drug
DMTBO7F	PC	11715
DMTBO7F	MW	136.98
DMTBO7F	FM	C3H5BrO
DMTBO7F	IC	InChI=1S/C3H5BrO/c1-3(5)2-4/h2H2,1H3
DMTBO7F	CS	CC(=O)CBr
DMTBO7F	IK	VQFAIAKCILWQPZ-UHFFFAOYSA-N
DMTBO7F	IU	1-bromopropan-2-one
DMTBO7F	CA	CAS 598-31-2
DMTBO7F	CB	CHEBI:51845
DMTBO7F	DE	Discovery agent

DMXTVZ8	ID	DMXTVZ8
DMXTVZ8	DN	bromocresol green
DMXTVZ8	HS	Investigative
DMXTVZ8	SN	Bromocresol green; 76-60-8; BROMCRESOL GREEN; bromo cresol green; 3,3-Bis(3,5-dibromo-4-hydroxy-2-methylphenyl)-3H-benzo[c][1,2]oxathiole 1,1-dioxide; Tetrabromo-m-cresolphthalein sulfone; 3',3'',5',5''-Tetrabromo-m-cresolsulfonephthalein; Bromocresol blue; NSC 7817; UNII-8YGN0Y942M; EINECS 200-972-8; BRN 0372527; CHEMBL145704; 8YGN0Y942M; Bromocresol Green, ACS reagent; NSC7817; FRPHFZCDPYBUAU-UHFFFAOYSA-N; MFCD00005874; o-Toluenesulfonic acid, alpha-hydroxy-, gamma-sultone; BROMOCRESOL GREEN, ACS; Phenol, 4,4'-(3H-2,1-benzox
DMXTVZ8	DT	Small molecular drug
DMXTVZ8	PC	6451
DMXTVZ8	MW	698
DMXTVZ8	FM	C21H14Br4O5S
DMXTVZ8	IC	InChI=1S/C21H14Br4O5S/c1-9-12(7-14(22)19(26)17(9)24)21(13-8-15(23)20(27)18(25)10(13)2)11-5-3-4-6-16(11)31(28,29)30-21/h3-8,26-27H,1-2H3
DMXTVZ8	CS	CC1=C(C(=C(C=C1C2(C3=CC=CC=C3S(=O)(=O)O2)C4=CC(=C(C(=C4C)Br)O)Br)Br)O)Br
DMXTVZ8	IK	FRPHFZCDPYBUAU-UHFFFAOYSA-N
DMXTVZ8	IU	2,6-dibromo-4-[3-(3,5-dibromo-4-hydroxy-2-methylphenyl)-1,1-dioxo-2,1lambda6-benzoxathiol-3-yl]-3-methylphenol
DMXTVZ8	CA	CAS 76-60-8
DMXTVZ8	DE	Discovery agent

DMX2U7G	ID	DMX2U7G
DMX2U7G	DN	bromo-deaza-SAH
DMX2U7G	HS	Investigative
DMX2U7G	SN	CHEMBL2349526; bromo-deaza-SAH; (2s)-2-Amino-4-({[(2s,3s,4r,5r)-5-(4-Amino-5-Bromo-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl)-3,4-Dihydroxytetrahydrofuran-2-Yl]methyl}sulfanyl)butanoic Acid (Non-Preferred Name); GTPL7018; BDBM50431676; (S)-2-Amino-4-[[(2S)-3beta,4beta-dihydroxy-5alpha-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidine-7-yl)tetrahydrofuran-2alpha-yl]methylthio]butanoic acid; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid
DMX2U7G	DT	Small molecular drug
DMX2U7G	PC	53339032
DMX2U7G	MW	462.3
DMX2U7G	FM	C15H20BrN5O5S
DMX2U7G	IC	InChI=1S/C15H20BrN5O5S/c16-6-3-21(13-9(6)12(18)19-5-20-13)14-11(23)10(22)8(26-14)4-27-2-1-7(17)15(24)25/h3,5,7-8,10-11,14,22-23H,1-2,4,17H2,(H,24,25)(H2,18,19,20)/t7-,8+,10+,11+,14+/m0/s1
DMX2U7G	CS	C1=C(C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CSCC[C@@H](C(=O)O)N)O)O)N)Br
DMX2U7G	IK	DIULHULFPSIBAK-TWBCTODHSA-N
DMX2U7G	IU	(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid
DMX2U7G	DE	Discovery agent

DM0D7LA	ID	DM0D7LA
DM0D7LA	DN	BROMODEOXYURIDINE
DM0D7LA	HS	Investigative
DM0D7LA	SN	5-BROMO-2'-DEOXYURIDINE; 59-14-3; Broxuridine; Bromodeoxyuridine; 5-Bromodeoxyuridine; BRDU; 5-BrdU; BUDR; 5-Bromouracil deoxyriboside; Bromouracil deoxyriboside; 5-Bromodesoxyuridine; 5-Bdu; Broxuridinum; Broxuridina; 5-Bromouracil-2-deoxyriboside; 5-Bromo-2-deoxyuridine; bromodeoxyuridine (brdu); Broxuridinum [INN-Latin]; Uridine, 5-bromo-2'-deoxy-; Broxuridina [INN-Spanish]; C9H11BrN2O5; NSC-38297; Bromoouridine; Radibud; CCRIS 818; Brudr; UNII-G34N38R2N1; HSDB 7477; CHEBI:472552; EINECS 200-415-9; 5-Budr; 5-bromo-2'-deoxy uridine
DM0D7LA	DT	Small molecular drug
DM0D7LA	PC	6035
DM0D7LA	MW	307.1
DM0D7LA	FM	C9H11BrN2O5
DM0D7LA	IC	InChI=1S/C9H11BrN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DM0D7LA	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Br)CO)O
DM0D7LA	IK	WOVKYSAHUYNSMH-RRKCRQDMSA-N
DM0D7LA	IU	5-bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DM0D7LA	CA	CAS 59-14-3
DM0D7LA	CB	CHEBI:472552
DM0D7LA	DE	Discovery agent

DMKQ0CA	ID	DMKQ0CA
DMKQ0CA	DN	bromoenol lactone
DMKQ0CA	HS	Investigative
DMKQ0CA	SN	Bromoenol lactone; HELSS; 88070-98-8; 6-Btnpo; BTNP; C16H13BrO2; CHEMBL6206; BEL; 6-(Bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; Haloenol lactone suicide substrate; BYUCSFWXCMTYOI-ZRDIBKRKSA-N; (E)-6-(Bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-Pyran-2-one; (E)-6-(Bromomethylene)-3-(1-naphthalenyl)tetrahydro-2H-pyran-2-one; bromoenolactone; E-6-(Bromoethylene)tetrahydro-3-(1-naphthyl)-2H-pyran-2-one; 2H-Pyran-2-one, 6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-, (E)-; SR-01000075707;  bromoenolactone
DMKQ0CA	DT	Small molecular drug
DMKQ0CA	PC	5940264
DMKQ0CA	MW	317.18
DMKQ0CA	FM	C16H13BrO2
DMKQ0CA	IC	InChI=1S/C16H13BrO2/c17-10-12-8-9-15(16(18)19-12)14-7-3-5-11-4-1-2-6-13(11)14/h1-7,10,15H,8-9H2/b12-10+
DMKQ0CA	CS	C1C/C(=C\\Br)/OC(=O)C1C2=CC=CC3=CC=CC=C32
DMKQ0CA	IK	BYUCSFWXCMTYOI-ZRDIBKRKSA-N
DMKQ0CA	IU	(6E)-6-(bromomethylidene)-3-naphthalen-1-yloxan-2-one
DMKQ0CA	CA	CAS 88070-98-8
DMKQ0CA	DE	Discovery agent

DMKFTW8	ID	DMKFTW8
DMKFTW8	DN	Bromo-WR99210
DMKFTW8	HS	Investigative
DMKFTW8	SN	BROMO-WR99210; 1-[3-(4-BROMO-PHENOXY)-PROPOXY]-6,6-DIMETHYL-1.6-DIHYDRO-[1,3,5]TRIAZINE-2,4-DIAMINE; WRB; 1-[3-(4-bromophenoxy)propoxy]-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine; AC1L1DNN; SCHEMBL8934292; CHEMBL126726; CTK7D5371; DB04007
DMKFTW8	DT	Small molecular drug
DMKFTW8	PC	2429
DMKFTW8	MW	370.24
DMKFTW8	FM	C14H20BrN5O2
DMKFTW8	IC	InChI=1S/C14H20BrN5O2/c1-14(2)19-12(16)18-13(17)20(14)22-9-3-8-21-11-6-4-10(15)5-7-11/h4-7H,3,8-9H2,1-2H3,(H4,16,17,18,19)
DMKFTW8	CS	CC1(N=C(N=C(N1OCCCOC2=CC=C(C=C2)Br)N)N)C
DMKFTW8	IK	MPXYCOHVHSXSDC-UHFFFAOYSA-N
DMKFTW8	IU	1-[3-(4-bromophenoxy)propoxy]-6,6-dimethyl-1,3,5-triazine-2,4-diamine
DMKFTW8	DE	Discovery agent

DM9W2ZV	ID	DM9W2ZV
DM9W2ZV	DN	Bromsulphthalein
DM9W2ZV	HS	Investigative
DM9W2ZV	SN	sulfobromophthalein; BSP
DM9W2ZV	DT	Small molecular drug
DM9W2ZV	PC	6282
DM9W2ZV	MW	838
DM9W2ZV	FM	C20H8Br4Na2O10S2
DM9W2ZV	IC	InChI=1S/C20H10Br4O10S2.2Na/c21-15-13-14(16(22)18(24)17(15)23)20(34-19(13)27,7-1-3-9(25)11(5-7)35(28,29)30)8-2-4-10(26)12(6-8)36(31,32)33;;/h1-6,25-26H,(H,28,29,30)(H,31,32,33);;/q;2*+1/p-2
DM9W2ZV	CS	C1=CC(=C(C=C1C2(C3=C(C(=C(C(=C3Br)Br)Br)Br)C(=O)O2)C4=CC(=C(C=C4)O)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+]
DM9W2ZV	IK	GHAFORRTMVIXHS-UHFFFAOYSA-L
DM9W2ZV	IU	disodium;2-hydroxy-5-[4,5,6,7-tetrabromo-1-(4-hydroxy-3-sulfonatophenyl)-3-oxo-2-benzofuran-1-yl]benzenesulfonate
DM9W2ZV	CA	CAS 71-67-0
DM9W2ZV	CB	CHEBI:63827

DMB9SEI	ID	DMB9SEI
DMB9SEI	DN	Broussoflavonol F
DMB9SEI	HS	Investigative
DMB9SEI	SN	Broussoflavonol F; CHEMBL464007; 162558-94-3; Biooussoflavonol F; SCHEMBL6822778; MolPort-039-338-587; ZINC14727564; LMPK12111986
DMB9SEI	DT	Small molecular drug
DMB9SEI	PC	9866908
DMB9SEI	MW	422.5
DMB9SEI	FM	C25H26O6
DMB9SEI	IC	InChI=1S/C25H26O6/c1-13(2)5-7-15-11-16(8-10-18(15)26)24-23(30)22(29)21-20(28)12-19(27)17(25(21)31-24)9-6-14(3)4/h5-6,8,10-12,26-28,30H,7,9H2,1-4H3
DMB9SEI	CS	CC(=CCC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C(=C3O2)CC=C(C)C)O)O)O)O)C
DMB9SEI	IK	KNMMNUQOUANAJS-UHFFFAOYSA-N
DMB9SEI	IU	3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-8-(3-methylbut-2-enyl)chromen-4-one
DMB9SEI	DE	Discovery agent

DMXFN6H	ID	DMXFN6H
DMXFN6H	DN	BROUSSONIN A
DMXFN6H	HS	Investigative
DMXFN6H	SN	Broussonin A; 73731-87-0; CHEMBL465879; Biooussonin A; AC1NST4K; 2-[3-(4-hydroxyphenyl)propyl]-5-methoxyphenol; SCHEMBL774802; MSNVBURPCQDLEP-UHFFFAOYSA-N; MolPort-019-937-120; BDBM50251012; ZINC13341109; MCULE-7164788732
DMXFN6H	DT	Small molecular drug
DMXFN6H	PC	5315502
DMXFN6H	MW	258.31
DMXFN6H	FM	C16H18O3
DMXFN6H	IC	InChI=1S/C16H18O3/c1-19-15-10-7-13(16(18)11-15)4-2-3-12-5-8-14(17)9-6-12/h5-11,17-18H,2-4H2,1H3
DMXFN6H	CS	COC1=CC(=C(C=C1)CCCC2=CC=C(C=C2)O)O
DMXFN6H	IK	MSNVBURPCQDLEP-UHFFFAOYSA-N
DMXFN6H	IU	2-[3-(4-hydroxyphenyl)propyl]-5-methoxyphenol
DMXFN6H	CA	CAS 73731-87-0
DMXFN6H	DE	Discovery agent

DMKM9F0	ID	DMKM9F0
DMKM9F0	DN	Broussonin C
DMKM9F0	HS	Investigative
DMKM9F0	SN	Broussonin C; 76045-49-3; CHEBI:3186; CHEMBL468906; AC1L9CJQ; MolPort-039-052-705; ZINC898642; BDBM50254430; 9122AF; 1,3-Benzenediol,4-[3-[4-hydroxy-3-(3- methyl-2-butenyl)phenyl]propyl]-
DMKM9F0	DT	Small molecular drug
DMKM9F0	PC	442289
DMKM9F0	MW	312.4
DMKM9F0	FM	C20H24O3
DMKM9F0	IC	InChI=1S/C20H24O3/c1-14(2)6-8-17-12-15(7-11-19(17)22)4-3-5-16-9-10-18(21)13-20(16)23/h6-7,9-13,21-23H,3-5,8H2,1-2H3
DMKM9F0	CS	CC(=CCC1=C(C=CC(=C1)CCCC2=C(C=C(C=C2)O)O)O)C
DMKM9F0	IK	CMOZGCJOTGLPKO-UHFFFAOYSA-N
DMKM9F0	IU	4-[3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]propyl]benzene-1,3-diol
DMKM9F0	CA	CAS 76045-49-3
DMKM9F0	CB	CHEBI:3186
DMKM9F0	DE	Discovery agent

DMPGEO1	ID	DMPGEO1
DMPGEO1	DN	BrP-LPA
DMPGEO1	HS	Investigative
DMPGEO1	SN	alpha-bromomethylene phosphonate
DMPGEO1	DT	Small molecular drug
DMPGEO1	PC	16725999
DMPGEO1	MW	487.4
DMPGEO1	FM	C20H40BrO6P
DMPGEO1	IC	InChI=1S/C20H40BrO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20(23)27-17-18(22)16-19(21)28(24,25)26/h18-19,22H,2-17H2,1H3,(H2,24,25,26)/t18-,19?/m0/s1
DMPGEO1	CS	CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O
DMPGEO1	IK	HLVKVWDSLLFMSX-OYKVQYDMSA-N
DMPGEO1	IU	[(3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]phosphonic acid
DMPGEO1	DE	Discovery agent

DM50RUD	ID	DM50RUD
DM50RUD	DN	brucine
DM50RUD	HS	Investigative
DM50RUD	SN	10,11-dimethoxy strychnine
DM50RUD	DT	Small molecular drug
DM50RUD	PC	442021
DM50RUD	MW	394.5
DM50RUD	FM	C23H26N2O4
DM50RUD	IC	InChI=1S/C23H26N2O4/c1-27-16-8-14-15(9-17(16)28-2)25-20(26)10-18-21-13-7-19-23(14,22(21)25)4-5-24(19)11-12(13)3-6-29-18/h3,8-9,13,18-19,21-22H,4-7,10-11H2,1-2H3/t13-,18-,19-,21-,22-,23+/m0/s1
DM50RUD	CS	COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7[C@@H]4N2C(=O)C[C@@H]7OCC=C6C5)OC
DM50RUD	IK	RRKTZKIUPZVBMF-IBTVXLQLSA-N
DM50RUD	IU	(4aR,5aS,8aR,13aS,15aS,15bR)-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one
DM50RUD	CA	CAS 357-57-3
DM50RUD	CB	CHEBI:3193
DM50RUD	DE	Discovery agent

DMKZM1L	ID	DMKZM1L
DMKZM1L	DN	Brutieridin
DMKZM1L	HS	Investigative
DMKZM1L	SN	Melitidin; Bergamot juice flavonoids (hypercholesterolemia), Biopharm technologies; Brutieridin/melitidin (hypercholesterolemia), Biopharm technologies
DMKZM1L	CP	Biopharm Technology Corp
DMKZM1L	PC	101485561
DMKZM1L	MW	738.7
DMKZM1L	FM	C34H42O18
DMKZM1L	IC	InChI=1S/C34H42O18/c1-13-26(41)28(43)30(45)33(49-13)52-32-29(44)27(42)22(12-48-24(40)11-34(2,46)10-23(38)39)51-31(32)15-7-17(36)25-18(37)9-20(50-21(25)8-15)14-4-5-19(47-3)16(35)6-14/h4-8,13,20,22,26-33,35-36,41-46H,9-12H2,1-3H3,(H,38,39)/t13-,20?,22+,26-,27+,28+,29-,30+,31-,32+,33-,34?/m0/s1
DMKZM1L	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2C3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)COC(=O)CC(C)(CC(=O)O)O)O)O)O)O)O
DMKZM1L	IK	YZURXYIFQZWQHI-RODJDRFJSA-N
DMKZM1L	IU	5-[[(2R,3S,4S,5R,6S)-3,4-dihydroxy-6-[5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-2,3-dihydrochromen-7-yl]-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]methoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid
DMKZM1L	DE	Hypercholesterolaemia

DM1VF6H	ID	DM1VF6H
DM1VF6H	DN	BS 7581
DM1VF6H	HS	Investigative
DM1VF6H	SN	BS 7581; CHEMBL444541; CHEMBL1790046
DM1VF6H	DT	Small molecular drug
DM1VF6H	PC	56661208
DM1VF6H	MW	353.5
DM1VF6H	FM	C26H27N
DM1VF6H	IC	InChI=1S/C26H27N/c1-18(16-19-8-3-2-4-9-19)27-25-17-24-22-12-6-5-10-20(22)14-15-21-11-7-13-23(25)26(21)24/h2-13,18,24-25,27H,14-17H2,1H3
DM1VF6H	CS	CC(CC1=CC=CC=C1)NC2CC3C4=CC=CC=C4CCC5=C3C2=CC=C5
DM1VF6H	IK	DNSDIYWJKBRJKP-UHFFFAOYSA-N
DM1VF6H	IU	N-(1-phenylpropan-2-yl)tetracyclo[8.6.1.02,7.014,17]heptadeca-2,4,6,10(17),11,13-hexaen-15-amine
DM1VF6H	DE	Discovery agent

DMDYNBT	ID	DMDYNBT
DMDYNBT	DN	BS 7840
DMDYNBT	HS	Investigative
DMDYNBT	SN	BS 7840; CHEMBL380748
DMDYNBT	DT	Small molecular drug
DMDYNBT	PC	11964445
DMDYNBT	MW	331.4
DMDYNBT	FM	C23H25NO
DMDYNBT	IC	InChI=1S/C23H25NO/c1-24(2)16-15-23(25)21-10-6-4-8-18(21)12-14-19-13-11-17-7-3-5-9-20(17)22(19)23/h3-11,13,25H,12,14-16H2,1-2H3
DMDYNBT	CS	CN(C)CCC1(C2=CC=CC=C2CCC3=C1C4=CC=CC=C4C=C3)O
DMDYNBT	IK	IUXDSDVOBHKNSE-UHFFFAOYSA-N
DMDYNBT	IU	2-[2-(dimethylamino)ethyl]tetracyclo[9.8.0.03,8.014,19]nonadeca-1(11),3,5,7,12,14,16,18-octaen-2-ol
DMDYNBT	DE	Discovery agent

DMQ2FDA	ID	DMQ2FDA
DMQ2FDA	DN	BS 9106
DMQ2FDA	HS	Investigative
DMQ2FDA	SN	BS 9106; CHEMBL206647; CHEMBL1790047
DMQ2FDA	DT	Small molecular drug
DMQ2FDA	PC	56678302
DMQ2FDA	MW	345.5
DMQ2FDA	FM	C23H23NS
DMQ2FDA	IC	InChI=1S/C23H23NS/c1-2-8-18(9-3-1)14-16-24-17-15-19-20-10-4-6-12-22(20)25-23-13-7-5-11-21(19)23/h1-13,19,24H,14-17H2
DMQ2FDA	CS	C1=CC=C(C=C1)CCNCCC2C3=CC=CC=C3SC4=CC=CC=C24
DMQ2FDA	IK	BTFWDABQNDILAN-UHFFFAOYSA-N
DMQ2FDA	IU	N-(2-phenylethyl)-2-(9H-thioxanthen-9-yl)ethanamine
DMQ2FDA	DE	Discovery agent

DMLXFHD	ID	DMLXFHD
DMLXFHD	DN	BS-194
DMLXFHD	HS	Investigative
DMLXFHD	SN	CDK inhibitors (cancer), Imperial College London/Emory University
DMLXFHD	CP	Imperial College London
DMLXFHD	DT	Small molecular drug
DMLXFHD	PC	25125014
DMLXFHD	MW	385.5
DMLXFHD	FM	C20H27N5O3
DMLXFHD	IC	InChI=1S/C20H27N5O3/c1-13(2)15-10-22-25-19(21-9-14-6-4-3-5-7-14)8-18(24-20(15)25)23-16(11-26)17(28)12-27/h3-8,10,13,16-17,21,26-28H,9,11-12H2,1-2H3,(H,23,24)/t16-,17+/m0/s1
DMLXFHD	CS	CC(C)C1=C2N=C(C=C(N2N=C1)NCC3=CC=CC=C3)N[C@@H](CO)[C@@H](CO)O
DMLXFHD	IK	KRIWIRSMQRQYJG-DLBZAZTESA-N
DMLXFHD	IU	(2S,3S)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol
DMLXFHD	CA	CAS 1092443-55-4
DMLXFHD	DE	Solid tumour/cancer

DMJIKHQ	ID	DMJIKHQ
DMJIKHQ	DN	BsAb cG7-MICA
DMJIKHQ	HS	Investigative

DMNM63G	ID	DMNM63G
DMNM63G	DN	BTP2
DMNM63G	HS	Investigative
DMNM63G	SN	YM-58483
DMNM63G	DT	Small molecular drug
DMNM63G	PC	2455
DMNM63G	MW	421.3
DMNM63G	FM	C15H9F6N5OS
DMNM63G	IC	InChI=1S/C15H9F6N5OS/c1-7-12(28-25-23-7)13(27)22-8-2-4-9(5-3-8)26-11(15(19,20)21)6-10(24-26)14(16,17)18/h2-6H,1H3,(H,22,27)
DMNM63G	CS	CC1=C(SN=N1)C(=O)NC2=CC=C(C=C2)N3C(=CC(=N3)C(F)(F)F)C(F)(F)F
DMNM63G	IK	XPRZIORDEVHURQ-UHFFFAOYSA-N
DMNM63G	IU	N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-4-methylthiadiazole-5-carboxamide
DMNM63G	CA	CAS 223499-30-7
DMNM63G	DE	Discovery agent

DMGFY4X	ID	DMGFY4X
DMGFY4X	DN	BUDDLEDIN A
DMGFY4X	HS	Investigative
DMGFY4X	SN	BUDDLEDIN A; CHEBI:3206; CHEMBL485981; AC1NQYK4; 62346-20-7; CHEBI:542717; BDBM50241571; C09623; [(1S,5E,8R,9R)-6,10,10-trimethyl-2-methylidene-7-oxo-8-bicyclo[7.2.0]undec-5-enyl] acetate; [(1S,5E,8R,9R)-6,10,10-trimethyl-2-methylene-7-oxo-8-bicyclo[7.2.0]undec-5-enyl] acetate; (1R,2R,4E,9S)-4,11,11-trimethyl-8-methylidene-3-oxobicyclo[7.2.0]undec-4-en-2-yl acetate
DMGFY4X	DT	Small molecular drug
DMGFY4X	PC	5281514
DMGFY4X	MW	276.4
DMGFY4X	FM	C17H24O3
DMGFY4X	IC	InChI=1S/C17H24O3/c1-10-7-6-8-11(2)15(19)16(20-12(3)18)14-13(10)9-17(14,4)5/h8,13-14,16H,1,6-7,9H2,2-5H3/b11-8+/t13-,14+,16-/m1/s1
DMGFY4X	CS	C/C/1=C\\CCC(=C)[C@H]2CC([C@@H]2[C@H](C1=O)OC(=O)C)(C)C
DMGFY4X	IK	SXWKLEULMBLXJM-PCRFWOPQSA-N
DMGFY4X	IU	[(1R,2R,4E,9S)-4,11,11-trimethyl-8-methylidene-3-oxo-2-bicyclo[7.2.0]undec-4-enyl] acetate
DMGFY4X	CA	CAS 62346-20-7
DMGFY4X	CB	CHEBI:3206
DMGFY4X	DE	Discovery agent

DMQVL2U	ID	DMQVL2U
DMQVL2U	DN	BUDLEIN A
DMQVL2U	HS	Investigative
DMQVL2U	SN	Budlein A tiglate; CHEMBL189707; BDBM50433422; (E)-2-Methyl-2-butenoic acid [(3aR,4R,6R,10Z,11aR)-2,3,3a,4,5,6,7,11a-octahydro-10-hydroxymethyl-6-methyl-3-methylene-2,7-dioxo-6,9-epoxycyclodeca[b]furan]-4-yl ester
DMQVL2U	DT	Small molecular drug
DMQVL2U	PC	5281430
DMQVL2U	MW	374.4
DMQVL2U	FM	C20H22O7
DMQVL2U	IC	InChI=1S/C20H22O7/c1-5-10(2)18(23)26-15-8-20(4)16(22)7-13(27-20)12(9-21)6-14-17(15)11(3)19(24)25-14/h5-7,14-15,17,21H,3,8-9H2,1-2,4H3/b10-5-,12-6-/t14-,15-,17+,20-/m1/s1
DMQVL2U	CS	C/C=C(/C)\\C(=O)O[C@@H]1C[C@@]2(C(=O)C=C(O2)/C(=C\\[C@@H]3[C@@H]1C(=C)C(=O)O3)/CO)C
DMQVL2U	IK	BMVJFNLJSZHNNS-ZXRHVTAXSA-N
DMQVL2U	IU	[(2Z,4R,8R,9R,11R)-2-(hydroxymethyl)-11-methyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (Z)-2-methylbut-2-enoate
DMQVL2U	CA	CAS 59481-48-0
DMQVL2U	CB	CHEBI:3208
DMQVL2U	DE	Discovery agent

DM1D47I	ID	DM1D47I
DM1D47I	DN	BU-E 47
DM1D47I	HS	Investigative
DM1D47I	SN	CHEMBL304239; GTPL1219; SCHEMBL9710041; BU-E-47; BDBM50406050; PDSP1_001313; PDSP2_001297
DM1D47I	DT	Small molecular drug
DM1D47I	PC	14660352
DM1D47I	MW	396.9
DM1D47I	FM	C21H25ClN6
DM1D47I	IC	InChI=1S/C21H25ClN6/c22-17-8-6-16(7-9-17)19(20-5-1-2-11-25-20)10-13-27-21(23)26-12-3-4-18-14-24-15-28-18/h1-2,5-9,11,14-15,19H,3-4,10,12-13H2,(H,24,28)(H3,23,26,27)
DM1D47I	CS	C1=CC=NC(=C1)C(CCNC(=NCCCC2=CN=CN2)N)C3=CC=C(C=C3)Cl
DM1D47I	IK	ZOROCGHIPADEFK-UHFFFAOYSA-N
DM1D47I	IU	1-[3-(4-chlorophenyl)-3-pyridin-2-ylpropyl]-2-[3-(1H-imidazol-5-yl)propyl]guanidine
DM1D47I	DE	Discovery agent

DMD1SY9	ID	DMD1SY9
DMD1SY9	DN	bufotenine
DMD1SY9	HS	Investigative
DMD1SY9	SN	DM5-HT; dimethylserotonin; N,N-dimethyl-5-HT; N,N-dimethylserotonin; 5-OH-DMT
DMD1SY9	DT	Small molecular drug
DMD1SY9	PC	10257
DMD1SY9	MW	204.27
DMD1SY9	FM	C12H16N2O
DMD1SY9	IC	InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3
DMD1SY9	CS	CN(C)CCC1=CNC2=C1C=C(C=C2)O
DMD1SY9	IK	VTTONGPRPXSUTJ-UHFFFAOYSA-N
DMD1SY9	IU	3-[2-(dimethylamino)ethyl]-1H-indol-5-ol
DMD1SY9	CA	CAS 487-93-4
DMD1SY9	CB	CHEBI:3210
DMD1SY9	DE	Discovery agent

DM61F5W	ID	DM61F5W
DM61F5W	DN	BUFROLIN
DM61F5W	HS	Investigative
DM61F5W	SN	Bufrolin; 54867-56-0; UNII-46C1PX266N; ICI-74917; CHEMBL150764; 46C1PX266N; Bufrolinum; Bufroline; Bufrolino; Bufrolin [INN:BAN]; Bufrolinum [INN-Latin]; Bufroline [INN-French]; Bufrolino [INN-Spanish]; AC1Q5RDE; AC1L2HFD; SCHEMBL2109492; CTK1H2392; DTXSID60203353; ZINC4215124; 6-butyl-4,10-dihydroxy-1,7-phenanthroline-2,8-dicarboxylic acid; BDBM50020876; 6-Butyl-1,4,7,10-tetrahydro-4,10-dioxo-1,7-phenanthroline-2,8-dicarbonsaeure; 6-butyl-4,10-dioxo-1,7-dihydro-1,7-phenanthroline-2,8-dicarboxylic acid
DM61F5W	DT	Small molecular drug
DM61F5W	PC	72103
DM61F5W	MW	356.3
DM61F5W	FM	C18H16N2O6
DM61F5W	IC	InChI=1S/C18H16N2O6/c1-2-3-4-8-5-9-12(21)6-10(17(23)24)20-16(9)14-13(22)7-11(18(25)26)19-15(8)14/h5-7H,2-4H2,1H3,(H,19,22)(H,20,21)(H,23,24)(H,25,26)
DM61F5W	CS	CCCCC1=CC2=C(C3=C1NC(=CC3=O)C(=O)O)NC(=CC2=O)C(=O)O
DM61F5W	IK	BQVIONBNDNFCCP-UHFFFAOYSA-N
DM61F5W	IU	6-butyl-4,10-dioxo-1,7-dihydro-1,7-phenanthroline-2,8-dicarboxylic acid
DM61F5W	CA	CAS 54867-56-0
DM61F5W	DE	Discovery agent

DMWQ3RH	ID	DMWQ3RH
DMWQ3RH	DN	bufrudin
DMWQ3RH	HS	Investigative
DMWQ3RH	SN	137879-02-8; bufrudin
DMWQ3RH	DE	Discovery agent

DMJSC07	ID	DMJSC07
DMJSC07	DN	Bufuralol
DMJSC07	HS	Investigative
DMJSC07	SN	Bufuralol; Bufuralol [BAN:INN]; Bufuralol [INN:BAN]; Bufuralolum; Bufuralolum [INN-Latin]; Ro 3-4787; dl-Bufuralol; (RS)-alpha-(tert-Butylamino)methyl)-7-ethyl-12-benzofuranmethanol; 1-(7-Ethylbenzofuran-2-yl)-2-tert-butylamino-1-hydroxyethane; 2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol; 2-(tert-butylamino)-1-(7-ethylbenzofuran-2-yl)ethanol; 54340-62-4; AC1L2GPJ; AC1Q777C; CHEBI:34593; CHEMBL296035; EINECS 259-112-5; GTPL9834; SCHEMBL78552; alpha-((tert-Butylamino)methyl)-7-ethyl-2-benzofuranmethanol
DMJSC07	PC	71733
DMJSC07	MW	261.36
DMJSC07	FM	C16H23NO2
DMJSC07	IC	SSEBTPPFLLCUMN-UHFFFAOYSA-N
DMJSC07	CS	CCC1=CC=CC2=C1OC(=C2)C(CNC(C)(C)C)O
DMJSC07	IK	1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3
DMJSC07	IU	2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol
DMJSC07	CA	CAS 54340-62-4
DMJSC07	CB	CHEBI:34593
DMJSC07	DE	Cardiac arrhythmia

DMUT9IQ	ID	DMUT9IQ
DMUT9IQ	DN	Bupranolol
DMUT9IQ	HS	Investigative
DMUT9IQ	SN	BUPRANOLOL; Betadrenol; Bupranol; Bupranolol [INN:DCF]; Bupranololum; Bupranololum [INN-Latin]; HQIRNZOQPUAHHV-UHFFFAOYSA-N; KL 255; KL-255 [AS HYDROCHLORIDE]; Ophtorenin; SK&amp;F 16805-A; 1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol; 14556-46-8; 2-Propanol, 1-(2-chloro-5-methylphenoxy)-3-((1,1-dimethylethyl)amino)-; 2-Propanol, 1-(tert-butylamino)-3-(6-chloro-m-tolyloxy)-; 3-(tert-Butylamino)-1-(6-chloro-m-tolyloxy)-2-propanol; B 1312; BRN 2272923; C14H22ClNO2
DMUT9IQ	PC	2475
DMUT9IQ	MW	271.78
DMUT9IQ	FM	C14H22ClNO2
DMUT9IQ	IC	HQIRNZOQPUAHHV-UHFFFAOYSA-N
DMUT9IQ	CS	CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O
DMUT9IQ	IK	1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3
DMUT9IQ	IU	1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
DMUT9IQ	CA	CAS 14556-46-8
DMUT9IQ	CB	CHEBI:135123
DMUT9IQ	DE	Ventricular tachyarrhythmia

DMZ2VYG	ID	DMZ2VYG
DMZ2VYG	DN	burimamide
DMZ2VYG	HS	Investigative
DMZ2VYG	SN	1-[4-(1H-indazol-4-yl)butyl]-3-methylthiourea; AC1NSKDK; GTPL1229
DMZ2VYG	DT	Small molecular drug
DMZ2VYG	PC	3032915
DMZ2VYG	MW	212.32
DMZ2VYG	FM	C9H16N4S
DMZ2VYG	IC	InChI=1S/C9H16N4S/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7H,2-5H2,1H3,(H,11,13)(H2,10,12,14)
DMZ2VYG	CS	CNC(=S)NCCCCC1=CN=CN1
DMZ2VYG	IK	HXRBAVXGYZUSED-UHFFFAOYSA-N
DMZ2VYG	IU	1-[4-(1H-imidazol-5-yl)butyl]-3-methylthiourea
DMZ2VYG	CA	CAS 34970-69-9
DMZ2VYG	CB	CHEBI:3221
DMZ2VYG	DE	Discovery agent

DMBO0WI	ID	DMBO0WI
DMBO0WI	DN	Burnamine-17-O-3',4',5'-trimethoxybenzoate
DMBO0WI	HS	Investigative
DMBO0WI	SN	CHEMBL592589; BDBM50308526
DMBO0WI	DT	Small molecular drug
DMBO0WI	PC	15837283
DMBO0WI	MW	562.6
DMBO0WI	FM	C31H34N2O8
DMBO0WI	IC	InChI=1S/C31H34N2O8/c1-6-17-15-33-24-13-20(17)29(28(35)39-5,16-40-27(34)18-11-22(36-2)26(38-4)23(12-18)37-3)30-14-25(33)41-31(24,30)32-21-10-8-7-9-19(21)30/h6-12,20,24-25,32H,13-16H2,1-5H3/b17-6+/t20-,24-,25-,29-,30-,31-/m0/s1
DMBO0WI	CS	C/C=C/1\\CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(NC6=CC=CC=C64)O[C@H]2C5)(COC(=O)C7=CC(=C(C(=C7)OC)OC)OC)C(=O)OC
DMBO0WI	IK	CLCDMQIWPVOTMQ-RKJOYVLNSA-N
DMBO0WI	IU	methyl (1R,9S,11S,14Z,15S,17S,19R)-14-ethylidene-19-[(3,4,5-trimethoxybenzoyl)oxymethyl]-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3,5,7-triene-19-carboxylate
DMBO0WI	DE	Discovery agent

DMJP0QT	ID	DMJP0QT
DMJP0QT	DN	BURTTINONE
DMJP0QT	HS	Investigative
DMJP0QT	SN	burttinone; CHEMBL515837; 5,7-Dihydroxy-4'-methoxy-3'-prenyl-5'-[(3-methyl-2-butenyl)phenyl]flavanone; LMPK12140350
DMJP0QT	DT	Small molecular drug
DMJP0QT	PC	42607959
DMJP0QT	MW	438.5
DMJP0QT	FM	C26H30O6
DMJP0QT	IC	InChI=1S/C26H30O6/c1-15(2)6-7-16-10-18(11-17(25(16)31-5)8-9-26(3,4)30)22-14-21(29)24-20(28)12-19(27)13-23(24)32-22/h6,8-13,22,27-28,30H,7,14H2,1-5H3/b9-8+/t22-/m0/s1
DMJP0QT	CS	CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)/C=C/C(C)(C)O)OC)C
DMJP0QT	IK	BOBWTYODGOYWRC-UVIRAJKCSA-N
DMJP0QT	IU	(2S)-5,7-dihydroxy-2-[3-[(E)-3-hydroxy-3-methylbut-1-enyl]-4-methoxy-5-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DMJP0QT	DE	Discovery agent

DMDC7MT	ID	DMDC7MT
DMDC7MT	DN	Bu-RYYRIK-NH2
DMDC7MT	HS	Investigative
DMDC7MT	SN	CHEMBL428076
DMDC7MT	DT	Small molecular drug
DMDC7MT	PC	44456185
DMDC7MT	MW	951.2
DMDC7MT	FM	C46H74N14O8
DMDC7MT	IC	InChI=1S/C46H74N14O8/c1-4-13-37(62)55-33(17-11-24-53-45(49)50)40(64)58-35(26-29-14-7-6-8-15-29)43(67)59-36(27-30-19-21-31(61)22-20-30)42(66)57-34(18-12-25-54-46(51)52)41(65)60-38(28(3)5-2)44(68)56-32(39(48)63)16-9-10-23-47/h6-8,14-15,19-22,28,32-36,38,61H,4-5,9-13,16-18,23-27,47H2,1-3H3,(H2,48,63)(H,55,62)(H,56,68)(H,57,66)(H,58,64)(H,59,67)(H,60,65)(H4,49,50,53)(H4,51,52,54)/t28-,32-,33-,34-,35-,36-,38-/m0/s1
DMDC7MT	CS	CCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N
DMDC7MT	IK	DPJOADTYQPSSOH-LWFLANIVSA-N
DMDC7MT	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(butanoylamino)-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMDC7MT	DE	Discovery agent

DMMHGIN	ID	DMMHGIN
DMMHGIN	DN	But-3-enyl-trimethyl-ammonium bromide
DMMHGIN	HS	Investigative
DMMHGIN	DE	Discovery agent

DMTAJP7	ID	DMTAJP7
DMTAJP7	DN	Butanoic acid
DMTAJP7	HS	Investigative
DMTAJP7	SN	butyric acid; butanoic acid; n-Butyric acid; 107-92-6; n-Butanoic acid; propylformic acid; ethylacetic acid; 1-propanecarboxylic acid; Butanic acid; butyrate; 1-Butyric acid; Buttersaeure; butanoate; Kyselina maselna; Butyric acid (natural); Propanecarboxylic acid; Buttersaeure [German]; 1-butanoic acid; FEMA Number 2221; Kyselina maselna [Czech]; FEMA No. 2221; CCRIS 6552; HSDB 940; butoic acid; Ethyacetic Acid; 2-butanoate; NSC 8415; UNII-40UIR9Q29H; UN2820; AI3-15306; EINECS 203-532-3; BRN 0906770; CH3-[CH2]2-COOH; 40UIR9Q29H
DMTAJP7	DT	Small molecular drug
DMTAJP7	PC	264
DMTAJP7	MW	88.11
DMTAJP7	FM	C4H8O2
DMTAJP7	IC	InChI=1S/C4H8O2/c1-2-3-4(5)6/h2-3H2,1H3,(H,5,6)
DMTAJP7	CS	CCCC(=O)O
DMTAJP7	IK	FERIUCNNQQJTOY-UHFFFAOYSA-N
DMTAJP7	IU	butanoic acid
DMTAJP7	CA	CAS 107-92-6
DMTAJP7	CB	CHEBI:30772
DMTAJP7	DE	Discovery agent

DM5MZHP	ID	DM5MZHP
DM5MZHP	DN	butaprost (free acid form)
DM5MZHP	HS	Investigative
DM5MZHP	SN	butaprost acid
DM5MZHP	DT	Small molecular drug
DM5MZHP	PC	25886893
DM5MZHP	MW	394.5
DM5MZHP	FM	C23H38O5
DM5MZHP	IC	InChI=1S/C23H38O5/c1-2-13-23(14-8-15-23)21(26)11-7-10-18-17(19(24)16-20(18)25)9-5-3-4-6-12-22(27)28/h7,10,17-18,20-21,25-26H,2-6,8-9,11-16H2,1H3,(H,27,28)/b10-7+/t17-,18-,20-,21+/m1/s1
DM5MZHP	CS	CCCC1(CCC1)[C@H](C/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O)O
DM5MZHP	IK	PAYNQYXOKJDXAV-ZHIWTBQHSA-N
DM5MZHP	IU	7-[(1R,2R,3R)-3-hydroxy-2-[(E,4S)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoic acid
DM5MZHP	DE	Discovery agent

DM8E54P	ID	DM8E54P
DM8E54P	DN	BUTEIN
DM8E54P	HS	Investigative
DM8E54P	SN	butein; 487-52-5; 2',3,4,4'-Tetrahydroxychalcone; 3,4,2',4'-Tetrahydroxychalcone; 2',4',3,4-Tetrahydroxychalcone; UNII-4WVS5M0LGF; EINECS 207-659-5; 4WVS5M0LGF; (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; CHEMBL128000; CHEBI:3237; (2E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one; ,3,4-Tetrahydroxychalcone; Chalcone, 2',3,4,4'-tetrahydroxy- (7CI,8CI); Acrylophenone, 2',4'-dihydroxy-3-(3,4-dihy
DM8E54P	DT	Small molecular drug
DM8E54P	PC	5281222
DM8E54P	MW	272.25
DM8E54P	FM	C15H12O5
DM8E54P	IC	InChI=1S/C15H12O5/c16-10-3-4-11(14(19)8-10)12(17)5-1-9-2-6-13(18)15(20)7-9/h1-8,16,18-20H/b5-1+
DM8E54P	CS	C1=CC(=C(C=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O)O
DM8E54P	IK	AYMYWHCQALZEGT-ORCRQEGFSA-N
DM8E54P	IU	(E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
DM8E54P	CA	CAS 487-52-5
DM8E54P	CB	CHEBI:3237
DM8E54P	DE	Discovery agent

DMJ46CB	ID	DMJ46CB
DMJ46CB	DN	Buthionine sulfoximine
DMJ46CB	HS	Investigative
DMJ46CB	SN	AC1MS6SH
DMJ46CB	DT	Small molecular drug
DMJ46CB	PC	21157
DMJ46CB	MW	222.31
DMJ46CB	FM	C8H18N2O3S
DMJ46CB	IC	InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)
DMJ46CB	CS	CCCCS(=N)(=O)CCC(C(=O)O)N
DMJ46CB	IK	KJQFBVYMGADDTQ-UHFFFAOYSA-N
DMJ46CB	IU	2-amino-4-(butylsulfonimidoyl)butanoic acid
DMJ46CB	CA	CAS 5072-26-4
DMJ46CB	CB	CHEBI:28714
DMJ46CB	DE	Malaria; Solid tumour/cancer

DMR6GJK	ID	DMR6GJK
DMR6GJK	DN	Butirosin B
DMR6GJK	HS	Investigative
DMR6GJK	SN	Ambuyrosin A; AC1Q5OCU; AC1L1DSB; SCHEMBL19944113; C21H41N5O12; D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(beta-D-xylofuranosyl-(1-5))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-; Butirosin A from Bacillus vitellinus; LS-16557; 4-amino-n-{5-amino-4-[(2,6-diamino-2,6-dideoxyhexopyranosyl)oxy]-2-hydroxy-3-(pentofuranosyloxy)cyclohexyl}-2-hydroxybutanamide; LS-147025
DMR6GJK	DT	Small molecular drug
DMR6GJK	PC	12302172
DMR6GJK	MW	555.6
DMR6GJK	FM	C21H41N5O12
DMR6GJK	IC	InChI=1S/C21H41N5O12/c22-2-1-8(28)19(34)26-7-3-6(24)17(37-20-11(25)15(32)13(30)9(4-23)35-20)18(12(7)29)38-21-16(33)14(31)10(5-27)36-21/h6-18,20-21,27-33H,1-5,22-25H2,(H,26,34)/t6-,7+,8-,9+,10+,11+,12-,13+,14+,15+,16+,17+,18+,20+,21-/m0/s1
DMR6GJK	CS	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O)O[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N
DMR6GJK	IK	XEQLFNPSYWZPOW-HBYCGHPUSA-N
DMR6GJK	IU	(2S)-4-amino-N-[(1R,2S,3R,4R,5S)-5-amino-4-[(2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-hydroxycyclohexyl]-2-hydroxybutanamide
DMR6GJK	CA	CAS 34291-03-7
DMR6GJK	CB	CHEBI:65110
DMR6GJK	DE	Discovery agent

DM82KPQ	ID	DM82KPQ
DM82KPQ	DN	BUTORPHAN
DM82KPQ	HS	Investigative
DM82KPQ	SN	CHEMBL301160; butorphan; MCL-101; SCHEMBL11805323; ZINC3982790; 3-Hydroxy-N-cyclobutylmethylmorphinan; BDBM50135808; 3-hydroxy-n-cyclobutylmethyl morphinan
DM82KPQ	DT	Small molecular drug
DM82KPQ	PC	9804450
DM82KPQ	MW	311.5
DM82KPQ	FM	C21H29NO
DM82KPQ	IC	InChI=1S/C21H29NO/c23-17-8-7-16-12-20-18-6-1-2-9-21(18,19(16)13-17)10-11-22(20)14-15-4-3-5-15/h7-8,13,15,18,20,23H,1-6,9-12,14H2/t18-,20+,21+/m0/s1
DM82KPQ	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)O)CC5CCC5
DM82KPQ	IK	YSTAPDGDOHWKQR-CEWLAPEOSA-N
DM82KPQ	IU	(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DM82KPQ	DE	Discovery agent

DM7XN2J	ID	DM7XN2J
DM7XN2J	DN	Butoxamine
DM7XN2J	HS	Investigative
DM7XN2J	SN	AC1LELZ5; ZINC57209
DM7XN2J	DT	Small molecular drug
DM7XN2J	PC	134495
DM7XN2J	MW	267.36
DM7XN2J	FM	C15H25NO3
DM7XN2J	IC	InChI=1S/C15H25NO3/c1-10(16-15(2,3)4)14(17)12-9-11(18-5)7-8-13(12)19-6/h7-10,14,16-17H,1-6H3/t10-,14-/m0/s1
DM7XN2J	CS	C[C@@H]([C@@H](C1=C(C=CC(=C1)OC)OC)O)NC(C)(C)C
DM7XN2J	IK	TWUSDDMONZULSC-HZMBPMFUSA-N
DM7XN2J	IU	(1R,2S)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol
DM7XN2J	CA	CAS 2922-20-5
DM7XN2J	DE	Discovery agent

DMGHEQV	ID	DMGHEQV
DMGHEQV	DN	Butyl 10H-phenothiazine-10-carboxylate
DMGHEQV	HS	Investigative
DMGHEQV	SN	CHEMBL481142; butyl 10H-phenothiazine-10-carboxylate
DMGHEQV	DT	Small molecular drug
DMGHEQV	PC	24905534
DMGHEQV	MW	299.4
DMGHEQV	FM	C17H17NO2S
DMGHEQV	IC	InChI=1S/C17H17NO2S/c1-2-3-12-20-17(19)18-13-8-4-6-10-15(13)21-16-11-7-5-9-14(16)18/h4-11H,2-3,12H2,1H3
DMGHEQV	CS	CCCCOC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMGHEQV	IK	YNOVMVUUQJTZIS-UHFFFAOYSA-N
DMGHEQV	IU	butyl phenothiazine-10-carboxylate
DMGHEQV	DE	Discovery agent

DM1CX9Y	ID	DM1CX9Y
DM1CX9Y	DN	Butyl-indol-1-yl-pyridin-4-yl-amine
DM1CX9Y	HS	Investigative
DM1CX9Y	SN	CHEMBL155109; Butyl-indol-1-yl-pyridin-4-yl-amine; SCHEMBL7616007; BDBM50048576
DM1CX9Y	DT	Small molecular drug
DM1CX9Y	PC	10801657
DM1CX9Y	MW	265.35
DM1CX9Y	FM	C17H19N3
DM1CX9Y	IC	InChI=1S/C17H19N3/c1-2-3-13-19(16-8-11-18-12-9-16)20-14-10-15-6-4-5-7-17(15)20/h4-12,14H,2-3,13H2,1H3
DM1CX9Y	CS	CCCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DM1CX9Y	IK	OSRPQIAWURAKDF-UHFFFAOYSA-N
DM1CX9Y	IU	N-butyl-N-pyridin-4-ylindol-1-amine
DM1CX9Y	DE	Discovery agent

DMJUTWG	ID	DMJUTWG
DMJUTWG	DN	Butyl-methyl-prop-2-ynyl-amine hydrochloride
DMJUTWG	HS	Investigative
DMJUTWG	DE	Discovery agent

DMF5D1N	ID	DMF5D1N
DMF5D1N	DN	Butylphosphonate
DMF5D1N	HS	Investigative
DMF5D1N	SN	Dibutyl phosphite; Dibutyl phosphonate; Phosphonic acid, dibutyl ester; Dibutoxyphosphine oxide; Mobil DBHP; Dibutyl hydrogen phosphonate; Di-n-butyl hydrogen phosphite; Dibutylfosfit; Phosphorous acid, dibutyl ester; Butyl phosphonate ((BuO)2HPO); Butyl alcohol, hydrogen phosphite; di-n-Butylphosphite; Dibutylfosfit [Czech]; NSC 2668; Dibutyl phosphite (VAN); Phosphonic Acid Dibutyl Ester; UNII-R149712Z1F; HSDB 2597; Dibutyl hydrogen phosphite (VAN); EINECS 217-316-1; R149712Z1F; Phosphorous acid, dibutyl ester (VAN); BRN 10997
DMF5D1N	DT	Small molecular drug
DMF5D1N	PC	76839
DMF5D1N	MW	138.1
DMF5D1N	FM	C4H11O3P
DMF5D1N	IC	InChI=1S/C4H11O3P/c1-2-3-4-8(5,6)7/h2-4H2,1H3,(H2,5,6,7)
DMF5D1N	CS	CCCCP(=O)(O)O
DMF5D1N	IK	UOKRBSXOBUKDGE-UHFFFAOYSA-N
DMF5D1N	IU	butylphosphonic acid
DMF5D1N	CA	CAS 3321-64-0
DMF5D1N	CB	CHEBI:41384
DMF5D1N	DE	Discovery agent

DM9X2FV	ID	DM9X2FV
DM9X2FV	DN	Butyrfentanyl
DM9X2FV	HS	Investigative
DM9X2FV	SN	Butyr-fentanyl; Butyrfentanyl; Butyrfentanyl (Butyrylfentanyl); Butyryl fentanyl; Methyl-3-fentanyl; QQOMYEQLWQJRKK-UHFFFAOYSA-N; TRA0094848; ZINC32266443; 07V1H7R6ZN; 1169-70-6; AC1LDM56; AKOS025243418; AS-48590; Butanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-; CS-D0505; CTK0G0348; DB09173; DEA No. 9822; DTXSID30347410; MFCD22054430; N-(1-Phenethylpiperidin-4-yl)-N-phenylbutyramide; N-PHENYL-N-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL]BUTANAMIDE; N-Phenyl-N-(1-phenethyl-4-piperidinyl)butanamide; SCHEMBL18623773; UNII-07V1H7R6ZN
DM9X2FV	PC	621174
DM9X2FV	MW	350.5
DM9X2FV	FM	C23H30N2O
DM9X2FV	IC	QQOMYEQLWQJRKK-UHFFFAOYSA-N
DM9X2FV	CS	CCCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
DM9X2FV	IK	1S/C23H30N2O/c1-2-9-23(26)25(21-12-7-4-8-13-21)22-15-18-24(19-16-22)17-14-20-10-5-3-6-11-20/h3-8,10-13,22H,2,9,14-19H2,1H3
DM9X2FV	IU	N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide
DM9X2FV	CA	CAS 1169-70-6
DM9X2FV	DE	Anaesthesia

DMOBYVL	ID	DMOBYVL
DMOBYVL	DN	Butyrylthiocholine
DMOBYVL	HS	Investigative
DMOBYVL	SN	BUTYRYLTHIOCHOLINE; 4555-00-4; CHEMBL139908; CHEBI:41055; 2-(BUTYRYLSULFANYL)-N,N,N-TRIMETHYLETHANAMINIUM; CHEMBL148530; (Propylcarbonylthioethyl)trimethylammonium iodide; butanoylthiocholine; s-butyrylthiocholine; S-butanoylthiocholine; 2ha7; AC1L2GSR; SCHEMBL570209; Ethanaminium, N,N,N-trimethyl-2-((1-oxobutyl)thio)-; BDBM8978; CTK4I8879; AWBGQVBMGBZGLS-UHFFFAOYSA-; DTXSID00196553; ZINC1592591; MCULE-2436087085; DB04250; 2-butanoylsulfanylethyl(trimethyl)azanium; AN-22197; AJ-27734; CJ-25507
DMOBYVL	DT	Small molecular drug
DMOBYVL	PC	20689
DMOBYVL	MW	190.33
DMOBYVL	FM	C9H20NOS+
DMOBYVL	IC	InChI=1S/C9H20NOS/c1-5-6-9(11)12-8-7-10(2,3)4/h5-8H2,1-4H3/q+1
DMOBYVL	CS	CCCC(=O)SCC[N+](C)(C)C
DMOBYVL	IK	AWBGQVBMGBZGLS-UHFFFAOYSA-N
DMOBYVL	IU	2-butanoylsulfanylethyl(trimethyl)azanium
DMOBYVL	CA	CAS 4555-00-4
DMOBYVL	CB	CHEBI:41055
DMOBYVL	DE	Discovery agent

DMDTV7A	ID	DMDTV7A
DMDTV7A	DN	BV-6
DMDTV7A	HS	Investigative
DMDTV7A	SN	BV6
DMDTV7A	DT	Small molecular drug
DMDTV7A	PC	23657864
DMDTV7A	MW	1205.6
DMDTV7A	FM	C70H96N10O8
DMDTV7A	IC	InChI=1S/C70H96N10O8/c1-47(71-3)63(81)75-59(53-37-21-11-22-38-53)69(87)79-45-27-41-55(79)65(83)77-61(57(49-29-13-7-14-30-49)50-31-15-8-16-32-50)67(85)73-43-25-5-6-26-44-74-68(86)62(58(51-33-17-9-18-34-51)52-35-19-10-20-36-52)78-66(84)56-42-28-46-80(56)70(88)60(54-39-23-12-24-40-54)76-64(82)48(2)72-4/h7-10,13-20,29-36,47-48,53-62,71-72H,5-6,11-12,21-28,37-46H2,1-4H3,(H,73,85)(H,74,86)(H,75,81)(H,76,82)(H,77,83)(H,78,84)/t47-,48-,55-,56-,59-,60-,61-,62-/m0/s1
DMDTV7A	CS	C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)NCCCCCCNC(=O)[C@H](C(C5=CC=CC=C5)C6=CC=CC=C6)NC(=O)[C@@H]7CCCN7C(=O)[C@H](C8CCCCC8)NC(=O)[C@H](C)NC)NC
DMDTV7A	IK	DPXJXGNXKOVBJV-YLOPQIBLSA-N
DMDTV7A	IU	(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(2S)-1-[6-[[(2S)-2-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3,3-diphenylpropanoyl]amino]hexylamino]-1-oxo-3,3-diphenylpropan-2-yl]pyrrolidine-2-carboxamide
DMDTV7A	CB	CHEBI:47924
DMDTV7A	DE	Discovery agent

DM10UHA	ID	DM10UHA
DM10UHA	DN	BVB-808
DM10UHA	HS	Investigative
DM10UHA	SN	JAK2 tyrosine kinase inhibitors (cancer), Novartis; NVP-BSK-805
DM10UHA	CP	Novartis AG
DM10UHA	PC	90480481
DM10UHA	MW	533.6
DM10UHA	FM	C29H33F2N7O
DM10UHA	IC	InChI=1S/C29H33F2N7O/c1-19-16-37(17-20(2)33-19)23-5-3-22(4-6-23)34-29-32-15-21-7-8-38(28(21)35-29)24-13-26(30)25(27(31)14-24)18-36-9-11-39-12-10-36/h3-8,13-15,19-20,33H,9-12,16-18H2,1-2H3,(H,32,34,35)/t19-,20+
DM10UHA	CS	C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)NC3=NC=C4C=CN(C4=N3)C5=CC(=C(C(=C5)F)CN6CCOCC6)F
DM10UHA	IK	VIIPVCPPCBLRRL-BGYRXZFFSA-N
DM10UHA	IU	7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]phenyl]pyrrolo[2,3-d]pyrimidin-2-amine
DM10UHA	CA	CAS 1414587-22-6
DM10UHA	DE	Solid tumour/cancer

DMI1H3Y	ID	DMI1H3Y
DMI1H3Y	DN	BVDU-MP
DMI1H3Y	HS	Investigative
DMI1H3Y	SN	SCHEMBL4287705
DMI1H3Y	DT	Small molecular drug
DMI1H3Y	PC	46936977
DMI1H3Y	MW	413.11
DMI1H3Y	FM	C11H14BrN2O8P
DMI1H3Y	IC	InChI=1S/C11H14BrN2O8P/c12-2-1-6-4-14(11(17)13-10(6)16)9-3-7(15)8(22-9)5-21-23(18,19)20/h1-2,4,7-9,15H,3,5H2,(H,13,16,17)(H2,18,19,20)/b2-1+/t7-,8+,9-/m1/s1
DMI1H3Y	CS	C1[C@H]([C@@H](O[C@H]1N2C=C(C(=O)NC2=O)/C=C/Br)COP(=O)(O)O)O
DMI1H3Y	IK	LKWCVKAHHUJPQO-UDGIAEMFSA-N
DMI1H3Y	IU	[(2S,3R,5R)-5-[5-[(E)-2-bromoethenyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMI1H3Y	DE	Discovery agent

DM8N7BA	ID	DM8N7BA
DM8N7BA	DN	BVT 933
DM8N7BA	HS	Investigative
DM8N7BA	DE	Obesity

DMULZOP	ID	DMULZOP
DMULZOP	DN	BVT173187
DMULZOP	HS	Investigative
DMULZOP	SN	BVT 173187
DMULZOP	DT	Small molecular drug
DMULZOP	PC	73755160
DMULZOP	MW	330.6
DMULZOP	FM	C14H10Cl3NO2
DMULZOP	IC	InChI=1S/C14H10Cl3NO2/c1-7-2-3-10(16)12(4-7)18-14(20)9-5-8(15)6-11(17)13(9)19/h2-6,19H,1H3,(H,18,20)
DMULZOP	CS	CC1=CC(=C(C=C1)Cl)NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O
DMULZOP	IK	UCOQCHLODZCXRH-UHFFFAOYSA-N
DMULZOP	IU	3,5-dichloro-N-(2-chloro-5-methylphenyl)-2-hydroxybenzamide
DMULZOP	DE	Discovery agent

DMAVDNU	ID	DMAVDNU
DMAVDNU	DN	BVX-20-CD20
DMAVDNU	HS	Investigative
DMAVDNU	SN	BVX-20; Anti-CD20 mAb (NHL), Biocon; Anti-CD20 monoclonal antibody (non-Hodgkin's lymphoma), Biocon
DMAVDNU	CP	Vaccinex Inc
DMAVDNU	DT	Antibody
DMAVDNU	DE	Non-hodgkin lymphoma

DMA0FO5	ID	DMA0FO5
DMA0FO5	DN	BW 245C
DMA0FO5	HS	Investigative
DMA0FO5	SN	BW245C; BW-245C
DMA0FO5	DT	Small molecular drug
DMA0FO5	PC	119304
DMA0FO5	MW	368.5
DMA0FO5	FM	C19H32N2O5
DMA0FO5	IC	InChI=1S/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)
DMA0FO5	CS	C1CCC(CC1)C(CCN2C(C(=O)NC2=O)CCCCCCC(=O)O)O
DMA0FO5	IK	ZIDQIOZJEJFMOH-UHFFFAOYSA-N
DMA0FO5	IU	7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid
DMA0FO5	CA	CAS 75693-75-3
DMA0FO5	CB	CHEBI:131502
DMA0FO5	DE	Discovery agent

DMNSLGC	ID	DMNSLGC
DMNSLGC	DN	BW A360C
DMNSLGC	HS	Investigative
DMNSLGC	SN	139290-69-0; MDL 100151; C22H28FNO3; HXTGXYRHXAGCFP-UHFFFAOYSA-N; AC1Q4NRW; AC1L1U2G; SCHEMBL340674; CHEMBL257283; SCHEMBL13701277; 4-Piperidinemethanol, alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (+)-; MolPort-039-331-873; MDL100105; BDBM50232153; PDSP2_001480; PDSP1_001496; AKOS027338720; MDL 100105; AN-5556; LS-115604
DMNSLGC	DT	Small molecular drug
DMNSLGC	PC	60858
DMNSLGC	MW	373.5
DMNSLGC	FM	C22H28FNO3
DMNSLGC	IC	InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3
DMNSLGC	CS	COC1=CC=CC(=C1OC)C(C2CCN(CC2)CCC3=CC=C(C=C3)F)O
DMNSLGC	IK	HXTGXYRHXAGCFP-UHFFFAOYSA-N
DMNSLGC	IU	(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol
DMNSLGC	CA	CAS 139290-69-0
DMNSLGC	DE	Discovery agent

DMHQP84	ID	DMHQP84
DMHQP84	DN	BW B218C
DMHQP84	HS	Investigative
DMHQP84	SN	BW B218C; BW-B218C; ZLIVOFMPDUIULQ-VAWYXSNFSA-N; 134470-36-3; AC1O5RJN; SCHEMBL6008832; N-(1-Methyl-3-(3-phenoxyphenyl)prop-2-enyl)acetohydroxamic acid; N-hydroxy-N-[(E)-4-(3-phenoxyphenyl)but-3-en-2-yl]acetamide; Acetamide, N-hydroxy-N-(1-methyl-3-(3-phenoxyphenyl)-2-propenyl)-; (+)-(E)-N-[1-methyl-3-(3-phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; N-[(E)-3-(3-Phenoxyphenyl)-1-methyl-2-propenyl]acetohydroxamic acid
DMHQP84	DT	Small molecular drug
DMHQP84	PC	6439376
DMHQP84	MW	297.3
DMHQP84	FM	C18H19NO3
DMHQP84	IC	InChI=1S/C18H19NO3/c1-14(19(21)15(2)20)11-12-16-7-6-10-18(13-16)22-17-8-4-3-5-9-17/h3-14,21H,1-2H3/b12-11+
DMHQP84	CS	CC(/C=C/C1=CC(=CC=C1)OC2=CC=CC=C2)N(C(=O)C)O
DMHQP84	IK	ZLIVOFMPDUIULQ-VAWYXSNFSA-N
DMHQP84	IU	N-hydroxy-N-[(E)-4-(3-phenoxyphenyl)but-3-en-2-yl]acetamide
DMHQP84	CA	CAS 134470-36-3
DMHQP84	DE	Discovery agent

DMFKXMT	ID	DMFKXMT
DMFKXMT	DN	BW-202W92
DMFKXMT	HS	Investigative
DMFKXMT	SN	BW-202W92; SCHEMBL136398; CHEMBL448556; QEDNOUAODRFJQN-UHFFFAOYSA-N; BW202W92; 2.4-Diamino-5-(2,3,5-trichlorophenyl)-6-fluoromethylpyrimidine; 2,4-diamino-5-(2,3,5-trichlorophenyl)-6-fluoromethylpyrimidine
DMFKXMT	DT	Small molecular drug
DMFKXMT	PC	9883607
DMFKXMT	MW	321.6
DMFKXMT	FM	C11H8Cl3FN4
DMFKXMT	IC	InChI=1S/C11H8Cl3FN4/c12-4-1-5(9(14)6(13)2-4)8-7(3-15)18-11(17)19-10(8)16/h1-2H,3H2,(H4,16,17,18,19)
DMFKXMT	CS	C1=C(C=C(C(=C1C2=C(N=C(N=C2N)N)CF)Cl)Cl)Cl
DMFKXMT	IK	QEDNOUAODRFJQN-UHFFFAOYSA-N
DMFKXMT	IU	6-(fluoromethyl)-5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine
DMFKXMT	DE	Discovery agent

DMQ3AC0	ID	DMQ3AC0
DMQ3AC0	DN	BW284C51
DMQ3AC0	HS	Investigative
DMQ3AC0	SN	4-(5-{4-[Dimethyl(prop-2-enyl)ammonio]phenyl}-3-oxopentyl)-N,N-dimethyl-N-prop-2-enylbenzenaminium; BW284c51; CHEMBL140020; BW-28C51; EBW; 4-(5-{4-[DIMETHYL(PROP-2-ENYL)AMMONIO]PHENYL}-3-OXOPENTYL)-N,N-DIMETHYL-N-PROP-2-ENYLBENZENAMINIUM; CHEMBL464538; SCHEMBL7449688; GTPL6600; AC1L1B98; BDBM10624; ZAEXMNKDGJNLTA-UHFFFAOYSA-N; ZINC3814201; NCGC00247016-01; 1,5-Bis[4-(allyldimethylaminio)phenyl]pentane-3-one; 1,5-bis(4-allyldimethylammoniumphenyl)-pentan-3-one dibromide; 4,4'-(3-oxopentane-1,5-diyl)bis(N,N-dimethyl-N-prop-2-en-1-ylanilinium)
DMQ3AC0	DT	Small molecular drug
DMQ3AC0	PC	1338
DMQ3AC0	MW	406.6
DMQ3AC0	FM	C27H38N2O+2
DMQ3AC0	IC	InChI=1S/C27H38N2O/c1-7-21-28(3,4)25-15-9-23(10-16-25)13-19-27(30)20-14-24-11-17-26(18-12-24)29(5,6)22-8-2/h7-12,15-18H,1-2,13-14,19-22H2,3-6H3/q+2
DMQ3AC0	CS	C[N+](C)(CC=C)C1=CC=C(C=C1)CCC(=O)CCC2=CC=C(C=C2)[N+](C)(C)CC=C
DMQ3AC0	IK	ZAEXMNKDGJNLTA-UHFFFAOYSA-N
DMQ3AC0	IU	[4-[5-[4-[dimethyl(prop-2-enyl)azaniumyl]phenyl]-3-oxopentyl]phenyl]-dimethyl-prop-2-enylazanium
DMQ3AC0	DE	Discovery agent

DME15JU	ID	DME15JU
DME15JU	DN	BW723C86
DME15JU	HS	Investigative
DME15JU	SN	BW-72386
DME15JU	DT	Small molecular drug
DME15JU	PC	5311036
DME15JU	MW	322.9
DME15JU	FM	C16H19ClN2OS
DME15JU	IC	InChI=1S/C16H18N2OS.ClH/c1-11(17)7-12-9-18-16-5-4-13(8-15(12)16)19-10-14-3-2-6-20-14;/h2-6,8-9,11,18H,7,10,17H2,1H3;1H
DME15JU	CS	CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N.Cl
DME15JU	IK	PYJBJMIBANAOFJ-UHFFFAOYSA-N
DME15JU	IU	1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine;hydrochloride
DME15JU	CA	CAS 160521-72-2
DME15JU	DE	Discovery agent

DMM2WPH	ID	DMM2WPH
DMM2WPH	DN	BW-858C
DMM2WPH	HS	Investigative
DMM2WPH	CP	Burroughs Wellcome Inc
DMM2WPH	DE	Asthma

DM7SNU0	ID	DM7SNU0
DM7SNU0	DN	BW-A137C
DM7SNU0	HS	Investigative
DM7SNU0	SN	106328-28-3
DM7SNU0	DT	Small molecular drug
DM7SNU0	PC	129265
DM7SNU0	MW	271.31
DM7SNU0	FM	C16H17NO3
DM7SNU0	IC	InChI=1S/C16H17NO3/c1-13(18)17(19)11-14-7-9-16(10-8-14)20-12-15-5-3-2-4-6-15/h2-10,19H,11-12H2,1H3
DM7SNU0	CS	CC(=O)N(CC1=CC=C(C=C1)OCC2=CC=CC=C2)O
DM7SNU0	IK	LWIAYVCOMRXMSJ-UHFFFAOYSA-N
DM7SNU0	IU	N-hydroxy-N-[(4-phenylmethoxyphenyl)methyl]acetamide
DM7SNU0	CA	CAS 106328-28-3
DM7SNU0	DE	Discovery agent

DMU9LQW	ID	DMU9LQW
DMU9LQW	DN	BWA868C
DMU9LQW	HS	Investigative
DMU9LQW	SN	3-Benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin; BW A868C; 118675-50-6; BW-A868C; BW A 868C; BW-A-868C; C25H37N3O5; (+/-)-3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin; 4-Imidazolidineheptanoic acid, 3-((2-cyclohexyl-2-hydroxyethyl)amino)-2,5-dioxo-1-(phenylmethyl)-; 4-Imidazolidineheptanoicacid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-; 3-[(2-Cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- 4-imidazolidineheptanoic;  BWA-868C; BWA 868C; [3H]BWA868C
DMU9LQW	DT	Small molecular drug
DMU9LQW	PC	122021
DMU9LQW	MW	459.6
DMU9LQW	FM	C25H37N3O5
DMU9LQW	IC	InChI=1S/C25H37N3O5/c29-22(20-13-7-4-8-14-20)17-26-28-21(15-9-1-2-10-16-23(30)31)24(32)27(25(28)33)18-19-11-5-3-6-12-19/h3,5-6,11-12,20-22,26,29H,1-2,4,7-10,13-18H2,(H,30,31)
DMU9LQW	CS	C1CCC(CC1)C(CNN2C(C(=O)N(C2=O)CC3=CC=CC=C3)CCCCCCC(=O)O)O
DMU9LQW	IK	YZJVWSKJHGEIBL-UHFFFAOYSA-N
DMU9LQW	IU	7-[1-benzyl-3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxoimidazolidin-4-yl]heptanoic acid
DMU9LQW	CA	CAS 118675-50-6
DMU9LQW	DE	Discovery agent

DMA2B1C	ID	DMA2B1C
DMA2B1C	DN	BX 048
DMA2B1C	HS	Investigative
DMA2B1C	SN	BX-048; BX048
DMA2B1C	DT	Small molecular drug
DMA2B1C	PC	16741348
DMA2B1C	MW	558.6
DMA2B1C	FM	C27H34N4O9
DMA2B1C	IC	InChI=1S/C27H34N4O9/c1-5-39-26(38)31-12-10-30(11-13-31)24(35)18(8-9-22(32)33)29-23(34)20-15-21(40-27(3,4)25(36)37)17-7-6-16(2)14-19(17)28-20/h6-7,14-15,18H,5,8-13H2,1-4H3,(H,29,34)(H,32,33)(H,36,37)
DMA2B1C	CS	CCOC(=O)N1CCN(CC1)C(=O)C(CCC(=O)O)NC(=O)C2=NC3=C(C=CC(=C3)C)C(=C2)OC(C)(C)C(=O)O
DMA2B1C	IK	MCBLPJPMVOVJCO-UHFFFAOYSA-N
DMA2B1C	IU	4-[[4-(2-carboxypropan-2-yloxy)-7-methylquinoline-2-carbonyl]amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid
DMA2B1C	DE	Discovery agent

DM5CGXB	ID	DM5CGXB
DM5CGXB	DN	BX 471
DM5CGXB	HS	Investigative
DM5CGXB	SN	217645-70-0; BX471; BX-471; BX 471; BX-471 free base; BX-741; UNII-76K17ZG4ZN; ZK-811752; CHEMBL232656; 76K17ZG4ZN; CHEMBL535607; (R)-1-(5-chloro-2-(2-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)-2-oxoethoxy)phenyl)urea; Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]phenyl]-; N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]phenyl]-Urea; [5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]urea; Urea, N-
DM5CGXB	DT	Small molecular drug
DM5CGXB	PC	512282
DM5CGXB	MW	434.9
DM5CGXB	FM	C21H24ClFN4O3
DM5CGXB	IC	InChI=1S/C21H24ClFN4O3/c1-14-11-26(12-15-2-5-17(23)6-3-15)8-9-27(14)20(28)13-30-19-7-4-16(22)10-18(19)25-21(24)29/h2-7,10,14H,8-9,11-13H2,1H3,(H3,24,25,29)/t14-/m1/s1
DM5CGXB	CS	C[C@@H]1CN(CCN1C(=O)COC2=C(C=C(C=C2)Cl)NC(=O)N)CC3=CC=C(C=C3)F
DM5CGXB	IK	XQYASZNUFDVMFH-CQSZACIVSA-N
DM5CGXB	IU	[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]urea
DM5CGXB	CA	CAS 217645-70-0
DM5CGXB	DE	Discovery agent

DMBKVN9	ID	DMBKVN9
DMBKVN9	DN	BX 667
DMBKVN9	HS	Investigative
DMBKVN9	SN	BX-667; BX667
DMBKVN9	DT	Small molecular drug
DMBKVN9	PC	16681707
DMBKVN9	MW	586.6
DMBKVN9	FM	C29H38N4O9
DMBKVN9	IC	InChI=1S/C29H38N4O9/c1-6-40-27(38)29(4,5)42-23-17-22(30-21-16-18(3)8-9-19(21)23)25(36)31-20(10-11-24(34)35)26(37)32-12-14-33(15-13-32)28(39)41-7-2/h8-9,16-17,20H,6-7,10-15H2,1-5H3,(H,31,36)(H,34,35)/t20-/m0/s1
DMBKVN9	CS	CCOC(=O)C(C)(C)OC1=CC(=NC2=C1C=CC(=C2)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N3CCN(CC3)C(=O)OCC
DMBKVN9	IK	PHDMSNZRDFPYNQ-FQEVSTJZSA-N
DMBKVN9	IU	(4S)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(1-ethoxy-2-methyl-1-oxopropan-2-yl)oxy-7-methylquinoline-2-carbonyl]amino]-5-oxopentanoic acid
DMBKVN9	DE	Discovery agent

DMGK7U5	ID	DMGK7U5
DMGK7U5	DN	BX-201
DMGK7U5	HS	Investigative
DMGK7U5	SN	BX-201; indolinone based inhibitor, 3l; CHEMBL442229; SCHEMBL5728132; BDBM16981
DMGK7U5	DT	Small molecular drug
DMGK7U5	PC	11311693
DMGK7U5	MW	268.27
DMGK7U5	FM	C14H12N4O2
DMGK7U5	IC	InChI=1S/C14H12N4O2/c15-14(20)17-9-3-4-12-10(7-9)11(13(19)18-12)6-8-2-1-5-16-8/h1-7,16H,(H,18,19)(H3,15,17,20)/b11-6-
DMGK7U5	CS	C1=CNC(=C1)/C=C\\2/C3=C(C=CC(=C3)NC(=O)N)NC2=O
DMGK7U5	IK	SOVOJYOIAXOTIM-WDZFZDKYSA-N
DMGK7U5	IU	[(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-5-yl]urea
DMGK7U5	DE	Discovery agent

DMBQIEF	ID	DMBQIEF
DMBQIEF	DN	BX-517
DMBQIEF	HS	Investigative
DMBQIEF	SN	BX517; BX-517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-
DMBQIEF	DT	Small molecular drug
DMBQIEF	PC	11161844
DMBQIEF	MW	282.3
DMBQIEF	FM	C15H14N4O2
DMBQIEF	IC	InChI=1S/C15H14N4O2/c1-8(11-3-2-6-17-11)13-10-7-9(18-15(16)21)4-5-12(10)19-14(13)20/h2-7,17H,1H3,(H,19,20)(H3,16,18,21)/b13-8-
DMBQIEF	CS	C/C(=C/1\\C2=C(C=CC(=C2)NC(=O)N)NC1=O)/C3=CC=CN3
DMBQIEF	IK	DFURSNCTQGJRRX-JYRVWZFOSA-N
DMBQIEF	IU	[(3Z)-2-oxo-3-[1-(1H-pyrrol-2-yl)ethylidene]-1H-indol-5-yl]urea
DMBQIEF	CA	CAS 946843-63-6
DMBQIEF	DE	Discovery agent

DMRIMLJ	ID	DMRIMLJ
DMRIMLJ	DN	BX-795
DMRIMLJ	HS	Investigative
DMRIMLJ	SN	BX795; BX 795
DMRIMLJ	DT	Small molecular drug
DMRIMLJ	PC	10077147
DMRIMLJ	MW	591.5
DMRIMLJ	FM	C23H26IN7O2S
DMRIMLJ	IC	InChI=1S/C23H26IN7O2S/c24-18-15-27-22(30-20(18)25-9-5-10-26-21(32)19-8-4-13-34-19)28-16-6-3-7-17(14-16)29-23(33)31-11-1-2-12-31/h3-4,6-8,13-15H,1-2,5,9-12H2,(H,26,32)(H,29,33)(H2,25,27,28,30)
DMRIMLJ	CS	C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCCNC(=O)C4=CC=CS4)I
DMRIMLJ	IK	VAVXGGRQQJZYBL-UHFFFAOYSA-N
DMRIMLJ	IU	N-[3-[[5-iodo-4-[3-(thiophene-2-carbonylamino)propylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide
DMRIMLJ	CA	CAS 702675-74-9
DMRIMLJ	CB	CHEBI:91439
DMRIMLJ	DE	Discovery agent

DMZA45C	ID	DMZA45C
DMZA45C	DN	BX-912
DMZA45C	HS	Investigative
DMZA45C	SN	BX 912; BX912
DMZA45C	DT	Small molecular drug
DMZA45C	PC	11754511
DMZA45C	MW	471.4
DMZA45C	FM	C20H23BrN8O
DMZA45C	IC	InChI=1S/C20H23BrN8O/c21-17-12-24-19(28-18(17)23-7-6-16-11-22-13-25-16)26-14-4-3-5-15(10-14)27-20(30)29-8-1-2-9-29/h3-5,10-13H,1-2,6-9H2,(H,22,25)(H,27,30)(H2,23,24,26,28)
DMZA45C	CS	C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br
DMZA45C	IK	DMMILYKXNCVKOJ-UHFFFAOYSA-N
DMZA45C	IU	N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide
DMZA45C	CA	CAS 702674-56-4
DMZA45C	CB	CHEBI:91357
DMZA45C	DE	Discovery agent

DMAWMDN	ID	DMAWMDN
DMAWMDN	DN	BYK-191023
DMAWMDN	HS	Investigative
DMAWMDN	SN	INOS inhibitors (inflammatory diseases); INOS inhibitors (inflammatory diseases), Altana; INOS inhibitors (inflammatory diseases), Nycomed
DMAWMDN	CP	Nycomed
DMAWMDN	DT	Small molecular drug
DMAWMDN	PC	10308091
DMAWMDN	MW	254.29
DMAWMDN	FM	C14H14N4O
DMAWMDN	IC	InChI=1S/C14H14N4O/c1-19-11-6-8-15-10(9-11)4-5-13-17-12-3-2-7-16-14(12)18-13/h2-3,6-9H,4-5H2,1H3,(H,16,17,18)
DMAWMDN	CS	COC1=CC(=NC=C1)CCC2=NC3=C(N2)C=CC=N3
DMAWMDN	IK	YBOCDKFRGBOOFO-UHFFFAOYSA-N
DMAWMDN	IU	2-[2-(4-methoxypyridin-2-yl)ethyl]-1H-imidazo[4,5-b]pyridine
DMAWMDN	CA	CAS 608880-48-4
DMAWMDN	DE	Inflammation

DMN5X17	ID	DMN5X17
DMN5X17	DN	BZ3
DMN5X17	HS	Investigative
DMN5X17	SN	5-METHOXYINDOLE; 1006-94-6; 5-Methoxy-1H-indole; 1H-Indole, 5-methoxy-; Femedol; 5-Methoxy indole; Indole, 5-methoxy-; Methoxy-5 indole; Indol-5-yl methyl ether; UNII-DQM3AS43PQ; Methoxy-5 indole [French]; 5-Methoxyindole, 99%; EINECS 213-745-3; DQM3AS43PQ; NSC 521752; CHEMBL280311; DWAQDRSOVMLGRQ-UHFFFAOYSA-N; MFCD00005674; 916979-77-6; BZ3; 5Methoxyindole; 5-methoxyindol; 5-methoxy-indole; 3img; 3imc; PubChem7432; 1,3-dihydro-5-methyl-2H-Indol-2-one; ACMC-1BMAQ; 5-(methyloxy)-1H-indole; AC1Q4F1F; AC1L22NW; SCHEMBL74720; KSC177G3N; WLN: T
DMN5X17	DT	Small molecular drug
DMN5X17	PC	13872
DMN5X17	MW	147.17
DMN5X17	FM	C9H9NO
DMN5X17	IC	InChI=1S/C9H9NO/c1-11-8-2-3-9-7(6-8)4-5-10-9/h2-6,10H,1H3
DMN5X17	CS	COC1=CC2=C(C=C1)NC=C2
DMN5X17	IK	DWAQDRSOVMLGRQ-UHFFFAOYSA-N
DMN5X17	IU	5-methoxy-1H-indole
DMN5X17	CA	CAS 1006-94-6
DMN5X17	DE	Discovery agent

DMRXPFM	ID	DMRXPFM
DMRXPFM	DN	BZ5
DMRXPFM	HS	Investigative
DMRXPFM	PC	46241905
DMRXPFM	MW	336.4
DMRXPFM	FM	C16H16O6S
DMRXPFM	IC	InChI=1S/C16H16O6S/c17-11-7-16(22,15(20)21)10(13(18)14(11)19)6-8-1-2-12-9(5-8)3-4-23-12/h1-5,10-11,14,17,19,22H,6-7H2,(H,20,21)/t10-,11+,14-,16+/m0/s1
DMRXPFM	CS	C1[C@H]([C@@H](C(=O)[C@@H]([C@]1(C(=O)O)O)CC2=CC3=C(C=C2)SC=C3)O)O
DMRXPFM	IK	WFQJMZIPFQUOBR-FJXFWJLJSA-N
DMRXPFM	IU	(1R,2R,4S,5R)-2-(1-benzothiophen-5-ylmethyl)-1,4,5-trihydroxy-3-oxocyclohexane-1-carboxylic acid
DMRXPFM	DE	Discovery agent

DMF8UWE	ID	DMF8UWE
DMF8UWE	DN	BZ6
DMF8UWE	HS	Investigative
DMF8UWE	DT	Small molecular drug
DMF8UWE	PC	41673734
DMF8UWE	MW	330.4
DMF8UWE	FM	C20H18N4O
DMF8UWE	IC	InChI=1S/C20H18N4O/c1-25-19-9-7-16(8-10-19)20-17(13-23-12-11-21-15-23)14-24(22-20)18-5-3-2-4-6-18/h2-12,14-15H,13H2,1H3
DMF8UWE	CS	COC1=CC=C(C=C1)C2=NN(C=C2CN3C=CN=C3)C4=CC=CC=C4
DMF8UWE	IK	CZOCKHTYPCJURT-UHFFFAOYSA-N
DMF8UWE	IU	4-(imidazol-1-ylmethyl)-3-(4-methoxyphenyl)-1-phenylpyrazole
DMF8UWE	DE	Ataxia-telangiectasia

DM37GYA	ID	DM37GYA
DM37GYA	DN	BzATP
DM37GYA	HS	Investigative
DM37GYA	SN	BzATP; 3'-O-(4-Benzoyl)benzoyl ATP; 3'-O-(4-Benzoylbenzoyl)ATP; 3'-O-(4-Benzoyl)benzoyladenosine 5'-triphosphate; UNII-4P5DXU1F8Q; 81790-82-1; 4P5DXU1F8Q; CHEBI:34316; Adenosine 5'-(tetrahydrogen triphosphate), 3'-(4-benzoylbenzoate); C24H24N5O15P3; ATP, Bz; AC1L3GPW; AC1Q6S3N; SCHEMBL3682844; GTPL1757; CHEMBL2407634; BDBM86488; ZINC8295154; 3'-o-(4-benzoylbenzoyl)adenosine 5'-(tetrahydrogen triphosphate); LS-177651; CAS_81790-82-1; C13744; 3'-O-(4-benzoylbenzoyl)adenosine 5'-triphosphate
DM37GYA	DT	Small molecular drug
DM37GYA	PC	115205
DM37GYA	MW	715.4
DM37GYA	FM	C24H24N5O15P3
DM37GYA	IC	InChI=1S/C24H24N5O15P3/c25-21-17-22(27-11-26-21)29(12-28-17)23-19(31)20(16(41-23)10-40-46(36,37)44-47(38,39)43-45(33,34)35)42-24(32)15-8-6-14(7-9-15)18(30)13-4-2-1-3-5-13/h1-9,11-12,16,19-20,23,31H,10H2,(H,36,37)(H,38,39)(H2,25,26,27)(H2,33,34,35)/t16-,19-,20-,23-/m1/s1
DM37GYA	CS	C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C(=O)O[C@@H]3[C@H](O[C@H]([C@@H]3O)N4C=NC5=C(N=CN=C54)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
DM37GYA	IK	AWJJLYZBWRIBCZ-UGTJMOTHSA-N
DM37GYA	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]oxymethyl]oxolan-3-yl] 4-benzoylbenzoate
DM37GYA	CA	CAS 81790-82-1
DM37GYA	CB	CHEBI:34316
DM37GYA	DE	Discovery agent

DMUW87A	ID	DMUW87A
DMUW87A	DN	Bz--RYYRIK-NH2
DMUW87A	HS	Investigative
DMUW87A	SN	CHEMBL257921
DMUW87A	DT	Small molecular drug
DMUW87A	PC	44456187
DMUW87A	MW	985.2
DMUW87A	FM	C49H72N14O8
DMUW87A	IC	InChI=1S/C49H72N14O8/c1-3-30(2)40(47(71)58-35(41(51)65)18-10-11-25-50)63-44(68)37(20-13-27-57-49(54)55)60-45(69)39(29-32-21-23-34(64)24-22-32)62-46(70)38(28-31-14-6-4-7-15-31)61-43(67)36(19-12-26-56-48(52)53)59-42(66)33-16-8-5-9-17-33/h4-9,14-17,21-24,30,35-40,64H,3,10-13,18-20,25-29,50H2,1-2H3,(H2,51,65)(H,58,71)(H,59,66)(H,60,69)(H,61,67)(H,62,70)(H,63,68)(H4,52,53,56)(H4,54,55,57)/t30-,35-,36-,37-,38-,39-,40-/m0/s1
DMUW87A	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C3=CC=CC=C3
DMUW87A	IK	OBDOGETZOBOLDY-GCFINZEGSA-N
DMUW87A	IU	N-[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S,3S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]benzamide
DMUW87A	DE	Discovery agent

DMU13BY	ID	DMU13BY
DMU13BY	DN	BzT-7
DMU13BY	HS	Investigative
DMU13BY	SN	CHEMBL1958337; 8-Chloro-1,4-Dimethyl-6-Phenyl-4h-[1,2,4]triazolo[4,3-A][1,3,4]benzotriazepine; BzT-7; 3u5l; GTPL7515; SCHEMBL11468349; UYIVCPRWMLOCSB-UHFFFAOYSA-N; BDBM50365263; 8-chloro-1,4-dimethyl-6-phenyl-[1,2,4]triazolo[4,3-a][1,3,4]benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4)benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4 )benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a) (1,3,4)benzotriazepine
DMU13BY	DT	Small molecular drug
DMU13BY	PC	20350618
DMU13BY	MW	323.8
DMU13BY	FM	C17H14ClN5
DMU13BY	IC	InChI=1S/C17H14ClN5/c1-11-19-20-17-22(2)21-16(12-6-4-3-5-7-12)14-10-13(18)8-9-15(14)23(11)17/h3-10H,1-2H3
DMU13BY	CS	CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NN2C)C4=CC=CC=C4
DMU13BY	IK	UYIVCPRWMLOCSB-UHFFFAOYSA-N
DMU13BY	IU	8-chloro-1,4-dimethyl-6-phenyl-[1,2,4]triazolo[4,3-a][1,3,4]benzotriazepine
DMU13BY	DE	Discovery agent

DMA0GSY	ID	DMA0GSY
DMA0GSY	DN	BZYX
DMA0GSY	HS	Investigative
DMA0GSY	SN	Acetylcholinesterase inhibitors (neurodegenerative disease), Zhejiang University
DMA0GSY	CP	Zhejiang University
DMA0GSY	DE	Neurodegenerative disorder

DMMPXHQ	ID	DMMPXHQ
DMMPXHQ	DN	C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide
DMMPXHQ	HS	Investigative
DMMPXHQ	DE	Discovery agent

DMDLK9G	ID	DMDLK9G
DMDLK9G	DN	C-(1H-Indol-3-yl)-methylamine
DMDLK9G	HS	Investigative
DMDLK9G	SN	(1H-Indol-3-yl)methanamine; 22259-53-6; 1H-Indole-3-methanamine; 3-(aminomethyl)indole; 1H-indol-3-ylmethanamine; Indol-3-ylmethylamine; 1H-Indol-3-ylmethylamine; 3-aminomethylindole; CHEBI:65009; CHEMBL6509; C-(1H-Indol-3-yl)-methylamine; 3-Indolylmethylamine; Indole-3-methanamine; 3-Aminomethyl indole; AC1LAOER; 3-(aminomethyl) indole; 1H-indol-3-ylmethyl amine; Indole, 3-(aminomethyl)-; 1H-indol-3-yl-methyl-amine; SCHEMBL701395; AC1Q548H; C-(1H-indol-3-yl)methylamine; 1-(1H-indol-3-yl)methanamine; JXYGLMATGAAIBU-UHFFFAOYSA-
DMDLK9G	DT	Small molecular drug
DMDLK9G	PC	472107
DMDLK9G	MW	146.19
DMDLK9G	FM	C9H10N2
DMDLK9G	IC	InChI=1S/C9H10N2/c10-5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5,10H2
DMDLK9G	CS	C1=CC=C2C(=C1)C(=CN2)CN
DMDLK9G	IK	JXYGLMATGAAIBU-UHFFFAOYSA-N
DMDLK9G	IU	1H-indol-3-ylmethanamine
DMDLK9G	CA	CAS 22259-53-6
DMDLK9G	CB	CHEBI:65009
DMDLK9G	DE	Discovery agent

DM3VF9M	ID	DM3VF9M
DM3VF9M	DN	C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide
DM3VF9M	HS	Investigative
DM3VF9M	SN	C-(1-HYDROGYL-BETA-D-GLUCOPYRANOSYL) FORMAMIDE; CBF; alpha-D-gluco-2-Heptulopyranosonamide; AC1L9L7Q; DB02719; 361440-32-6; (1-Hydroxy-beta-D-glucopyranosyl)formamide; (2R,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxane-2-carboxamide; (2R,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxamide (non-preferred name)
DM3VF9M	DT	Small molecular drug
DM3VF9M	PC	447771
DM3VF9M	MW	223.18
DM3VF9M	FM	C7H13NO7
DM3VF9M	IC	InChI=1S/C7H13NO7/c8-6(13)7(14)5(12)4(11)3(10)2(1-9)15-7/h2-5,9-12,14H,1H2,(H2,8,13)/t2-,3-,4+,5-,7-/m1/s1
DM3VF9M	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@@](O1)(C(=O)N)O)O)O)O)O
DM3VF9M	IK	DTZYCNDAJQDPQC-UHKLXPPTSA-N
DM3VF9M	IU	(2R,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxane-2-carboxamide
DM3VF9M	CA	CAS 361440-32-6
DM3VF9M	DE	Discovery agent

DMNMYWI	ID	DMNMYWI
DMNMYWI	DN	C-(2'-Chloro-biphenyl-2-yl)-methylamine
DMNMYWI	HS	Investigative
DMNMYWI	SN	CHEMBL206496; 2'-Chlorobiphenyl-2-methylamine; [2-(2-chlorophenyl)phenyl]methanamine; AC1LRCRY; SCHEMBL6862516; BDBM50178431; AKOS010258410; 876170-46-6
DMNMYWI	DT	Small molecular drug
DMNMYWI	PC	1393052
DMNMYWI	MW	217.69
DMNMYWI	FM	C13H12ClN
DMNMYWI	IC	InChI=1S/C13H12ClN/c14-13-8-4-3-7-12(13)11-6-2-1-5-10(11)9-15/h1-8H,9,15H2
DMNMYWI	CS	C1=CC=C(C(=C1)CN)C2=CC=CC=C2Cl
DMNMYWI	IK	CQHFRBPHEMVDPT-UHFFFAOYSA-N
DMNMYWI	IU	[2-(2-chlorophenyl)phenyl]methanamine
DMNMYWI	DE	Discovery agent

DM0VKFO	ID	DM0VKFO
DM0VKFO	DN	C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine
DM0VKFO	HS	Investigative
DM0VKFO	SN	2CB-Ind; CHEMBL424890; 912342-23-5; C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine; DTXSID70582080; BDBM50194751; 1H-Indene-1-methanamine, 5-bromo-2,3-dihydro-4,7-dimethoxy-
DM0VKFO	DT	Small molecular drug
DM0VKFO	PC	16086368
DM0VKFO	MW	286.16
DM0VKFO	FM	C12H16BrNO2
DM0VKFO	IC	InChI=1S/C12H16BrNO2/c1-15-10-5-9(13)12(16-2)8-4-3-7(6-14)11(8)10/h5,7H,3-4,6,14H2,1-2H3
DM0VKFO	CS	COC1=CC(=C(C2=C1C(CC2)CN)OC)Br
DM0VKFO	IK	HCLPGYNQMVSQIM-UHFFFAOYSA-N
DM0VKFO	IU	(5-bromo-4,7-dimethoxy-2,3-dihydro-1H-inden-1-yl)methanamine
DM0VKFO	CA	CAS 912342-23-5
DM0VKFO	DE	Discovery agent

DMDHVY0	ID	DMDHVY0
DMDHVY0	DN	C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine
DMDHVY0	HS	Investigative
DMDHVY0	SN	CHEMBL46619; AC1L4MLR; C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine; SCHEMBL11335219; CTK7E4003; BKZVRYQHIBSITO-UHFFFAOYSA-N; ZINC3622666; BDBM50097217; 5-aminomethyl-5H-dibenzo[a,d]cycloheptene; 5H-Dibenzo[a,d]cycloheptene-5-methanamine
DMDHVY0	DT	Small molecular drug
DMDHVY0	PC	209436
DMDHVY0	MW	221.3
DMDHVY0	FM	C16H15N
DMDHVY0	IC	InChI=1S/C16H15N/c17-11-16-14-7-3-1-5-12(14)9-10-13-6-2-4-8-15(13)16/h1-10,16H,11,17H2
DMDHVY0	CS	C1=CC=C2C(C3=CC=CC=C3C=CC2=C1)CN
DMDHVY0	IK	BKZVRYQHIBSITO-UHFFFAOYSA-N
DMDHVY0	IU	2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylmethanamine
DMDHVY0	DE	Discovery agent

DMJ6SYI	ID	DMJ6SYI
DMJ6SYI	DN	C-(6-Methoxy-naphthalen-1-yl)-methylamine
DMJ6SYI	HS	Investigative
DMJ6SYI	SN	CHEMBL131412; 57382-44-2; 6-methoxy-1-naphthalenemethanamine; C-(6-Methoxy-naphthalen-1-yl)-methylamine; SCHEMBL15345391; BDBM50061312; 1-(Aminomethyl)-6-methoxynaphthalene; 6-Methoxynaphthalene-1-(methanamine)
DMJ6SYI	DT	Small molecular drug
DMJ6SYI	PC	44352202
DMJ6SYI	MW	187.24
DMJ6SYI	FM	C12H13NO
DMJ6SYI	IC	InChI=1S/C12H13NO/c1-14-11-5-6-12-9(7-11)3-2-4-10(12)8-13/h2-7H,8,13H2,1H3
DMJ6SYI	CS	COC1=CC2=C(C=C1)C(=CC=C2)CN
DMJ6SYI	IK	HOVVWANIDLIBGI-UHFFFAOYSA-N
DMJ6SYI	IU	(6-methoxynaphthalen-1-yl)methanamine
DMJ6SYI	DE	Discovery agent

DMDMA4Z	ID	DMDMA4Z
DMDMA4Z	DN	C-(9H-Thioxanthen-9-yl)-methylamine
DMDMA4Z	HS	Investigative
DMDMA4Z	SN	CHEMBL152509; (9H-thioxanthen-9-ylmethyl)amine; C-(9H-Thioxanthen-9-yl)-methylamine; 9H-Thioxanthene-9-methanamine; SCHEMBL7001557; ZINC6928031; BDBM50097225
DMDMA4Z	DT	Small molecular drug
DMDMA4Z	PC	13167699
DMDMA4Z	MW	227.33
DMDMA4Z	FM	C14H13NS
DMDMA4Z	IC	InChI=1S/C14H13NS/c15-9-12-10-5-1-3-7-13(10)16-14-8-4-2-6-11(12)14/h1-8,12H,9,15H2
DMDMA4Z	CS	C1=CC=C2C(=C1)C(C3=CC=CC=C3S2)CN
DMDMA4Z	IK	MYNBESFWFGVQQB-UHFFFAOYSA-N
DMDMA4Z	IU	9H-thioxanthen-9-ylmethanamine
DMDMA4Z	DE	Discovery agent

DMN5YOR	ID	DMN5YOR
DMN5YOR	DN	C-(9H-Xanthen-9-yl)-methylamine
DMN5YOR	HS	Investigative
DMN5YOR	SN	100866-28-2; XANTHENE-9-METHYLAMINE; 9H-Xanthene-9-methanamine; CHEMBL155276; 1-(9H-Xanthen-9-yl)methanamine; C-(9H-Xanthen-9-yl)-methylamine; 9-aminomethylxanthene; ACMC-20m3ww; 9-AMINOMETHYL XANTHENE; SCHEMBL4667689; CTK0H2362; DTXSID20576237; VYDDHEPARBFMGU-UHFFFAOYSA-N; ZINC21984468; BDBM50097214; AKOS015152152; (9H-XANTHEN-9-YL)METHANAMINE; AB24946
DMN5YOR	DT	Small molecular drug
DMN5YOR	PC	15645577
DMN5YOR	MW	211.26
DMN5YOR	FM	C14H13NO
DMN5YOR	IC	InChI=1S/C14H13NO/c15-9-12-10-5-1-3-7-13(10)16-14-8-4-2-6-11(12)14/h1-8,12H,9,15H2
DMN5YOR	CS	C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)CN
DMN5YOR	IK	VYDDHEPARBFMGU-UHFFFAOYSA-N
DMN5YOR	IU	9H-xanthen-9-ylmethanamine
DMN5YOR	CA	CAS 100866-28-2
DMN5YOR	DE	Discovery agent

DMHNZGP	ID	DMHNZGP
DMHNZGP	DN	C(Arg-Gly-Asp-D-Phe-Val)
DMHNZGP	HS	Investigative
DMHNZGP	SN	CHEMBL383412
DMHNZGP	DT	Small molecular drug
DMHNZGP	PC	44411994
DMHNZGP	MW	574.6
DMHNZGP	FM	C26H38N8O7
DMHNZGP	IC	InChI=1S/C26H38N8O7/c1-14(2)21-25(41)32-16(9-6-10-29-26(27)28)22(38)30-13-19(35)31-18(12-20(36)37)23(39)33-17(24(40)34-21)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18,21H,6,9-13H2,1-2H3,(H,30,38)(H,31,35)(H,32,41)(H,33,39)(H,34,40)(H,36,37)(H4,27,28,29)/t16-,17+,18-,21?/m0/s1
DMHNZGP	CS	CC(C)C1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DMHNZGP	IK	YYQUWEHEBOMRPH-YQMJFVBQSA-N
DMHNZGP	IU	2-[(2S,5R,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMHNZGP	DE	Discovery agent

DMTMJAI	ID	DMTMJAI
DMTMJAI	DN	C(-GRGDfL-)
DMTMJAI	HS	Investigative
DMTMJAI	SN	CHEMBL235999
DMTMJAI	DT	Small molecular drug
DMTMJAI	PC	15409414
DMTMJAI	MW	645.7
DMTMJAI	FM	C29H43N9O8
DMTMJAI	IC	InChI=1S/C29H43N9O8/c1-16(2)11-19-26(44)34-14-22(39)35-18(9-6-10-32-29(30)31)25(43)33-15-23(40)36-21(13-24(41)42)28(46)38-20(27(45)37-19)12-17-7-4-3-5-8-17/h3-5,7-8,16,18-21H,6,9-15H2,1-2H3,(H,33,43)(H,34,44)(H,35,39)(H,36,40)(H,37,45)(H,38,46)(H,41,42)(H4,30,31,32)/t18-,19-,20+,21-/m0/s1
DMTMJAI	CS	CC(C)C[C@H]1C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DMTMJAI	IK	VRTNUMBPIBDYLD-BURNTYAHSA-N
DMTMJAI	IU	2-[(2S,5R,8S,14S)-5-benzyl-14-[3-(diaminomethylideneamino)propyl]-8-(2-methylpropyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadec-2-yl]acetic acid
DMTMJAI	DE	Discovery agent

DMSLYHQ	ID	DMSLYHQ
DMSLYHQ	DN	C(his-D-phe-arg-trp-Abu)
DMSLYHQ	HS	Investigative
DMSLYHQ	SN	CHEMBL379531
DMSLYHQ	DT	Small molecular drug
DMSLYHQ	PC	44413577
DMSLYHQ	MW	711.8
DMSLYHQ	FM	C36H45N11O5
DMSLYHQ	IC	InChI=1S/C36H45N11O5/c37-36(38)41-15-6-12-27-33(50)47-29(17-23-19-42-26-11-5-4-10-25(23)26)32(49)40-14-7-13-31(48)44-30(18-24-20-39-21-43-24)35(52)46-28(34(51)45-27)16-22-8-2-1-3-9-22/h1-5,8-11,19-21,27-30,42H,6-7,12-18H2,(H,39,43)(H,40,49)(H,44,48)(H,45,51)(H,46,52)(H,47,50)(H4,37,38,41)/t27-,28+,29-,30+/m0/s1
DMSLYHQ	CS	C1CC(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NC1)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DMSLYHQ	IK	IYMUEULNOLBKRK-RRGQHJHPSA-N
DMSLYHQ	IU	2-[3-[(3S,6S,9R,12R)-9-benzyl-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacycloheptadec-6-yl]propyl]guanidine
DMSLYHQ	DE	Discovery agent

DM0IJFZ	ID	DM0IJFZ
DM0IJFZ	DN	C(his-D-phe-arg-trp-Ahp)
DM0IJFZ	HS	Investigative
DM0IJFZ	SN	CHEMBL379959
DM0IJFZ	DT	Small molecular drug
DM0IJFZ	PC	44413536
DM0IJFZ	MW	753.9
DM0IJFZ	FM	C39H51N11O5
DM0IJFZ	IC	InChI=1S/C39H51N11O5/c40-39(41)44-18-10-15-30-36(53)50-32(20-26-22-45-29-14-8-7-13-28(26)29)35(52)43-17-9-2-1-6-16-34(51)47-33(21-27-23-42-24-46-27)38(55)49-31(37(54)48-30)19-25-11-4-3-5-12-25/h3-5,7-8,11-14,22-24,30-33,45H,1-2,6,9-10,15-21H2,(H,42,46)(H,43,52)(H,47,51)(H,48,54)(H,49,55)(H,50,53)(H4,40,41,44)/t30-,31+,32+,33+/m0/s1
DM0IJFZ	CS	C1CCCNC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)CC1)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54
DM0IJFZ	IK	YQBUXOUSHPXETO-LDLFXXLYSA-N
DM0IJFZ	IU	2-[3-[(3R,6S,9R,12R)-9-benzyl-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacycloicos-6-yl]propyl]guanidine
DM0IJFZ	DE	Discovery agent

DMJKHAB	ID	DMJKHAB
DMJKHAB	DN	C(his-D-phe-arg-trp-Ahx)
DMJKHAB	HS	Investigative
DMJKHAB	SN	CHEMBL379627; c(his-D-phe-arg-trp-Ahx)
DMJKHAB	DT	Small molecular drug
DMJKHAB	PC	44413537
DMJKHAB	MW	739.9
DMJKHAB	FM	C38H49N11O5
DMJKHAB	IC	InChI=1S/C38H49N11O5/c39-38(40)43-17-9-14-29-35(52)49-31(19-25-21-44-28-13-7-6-12-27(25)28)34(51)42-16-8-2-5-15-33(50)46-32(20-26-22-41-23-45-26)37(54)48-30(36(53)47-29)18-24-10-3-1-4-11-24/h1,3-4,6-7,10-13,21-23,29-32,44H,2,5,8-9,14-20H2,(H,41,45)(H,42,51)(H,46,50)(H,47,53)(H,48,54)(H,49,52)(H4,39,40,43)/t29-,30+,31-,32+/m0/s1
DMJKHAB	CS	C1CCC(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC1)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DMJKHAB	IK	NKDXCOMNRCSRHU-MLMSKLGMSA-N
DMJKHAB	IU	2-[3-[(3S,6S,9R,12R)-9-benzyl-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclononadec-6-yl]propyl]guanidine
DMJKHAB	DE	Discovery agent

DM5NQUA	ID	DM5NQUA
DM5NQUA	DN	C(his-D-phe-arg-trp-Aoc)
DM5NQUA	HS	Investigative
DM5NQUA	SN	CHEMBL264120
DM5NQUA	DT	Small molecular drug
DM5NQUA	PC	44413535
DM5NQUA	MW	738.9
DM5NQUA	FM	C40H54N10O4
DM5NQUA	IC	InChI=1S/C40H54N10O4/c41-40(42)44-19-11-16-33-38(53)50-34(21-28-23-45-32-15-10-9-14-31(28)32)36(51)17-7-2-1-3-8-18-37(52)48-30(22-29-24-43-26-47-29)25-46-35(39(54)49-33)20-27-12-5-4-6-13-27/h4-6,9-10,12-15,23-24,26,30,33-35,45-46H,1-3,7-8,11,16-22,25H2,(H,43,47)(H,48,52)(H,49,54)(H,50,53)(H4,41,42,44)/t30-,33-,34-,35-/m0/s1
DM5NQUA	CS	C1CCCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC[C@@H](NC(=O)CCC1)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54
DM5NQUA	IK	VFJZBZLGBBBPQI-RONNFESSSA-N
DM5NQUA	IU	2-[3-[(3S,6S,9S,20S)-6-benzyl-9-(1H-imidazol-5-ylmethyl)-20-(1H-indol-3-ylmethyl)-2,5,11,19-tetraoxo-1,4,7,10-tetrazacycloicos-3-yl]propyl]guanidine
DM5NQUA	DE	Discovery agent

DMEC2PH	ID	DMEC2PH
DMEC2PH	DN	C(his-L-phe-arg-trp-Aoc)
DMEC2PH	HS	Investigative
DMEC2PH	SN	CHEMBL211131
DMEC2PH	DT	Small molecular drug
DMEC2PH	PC	44413592
DMEC2PH	MW	767.9
DMEC2PH	FM	C40H53N11O5
DMEC2PH	IC	InChI=1S/C40H53N11O5/c41-40(42)45-19-11-16-31-37(54)51-33(21-27-23-46-30-15-9-8-14-29(27)30)36(53)44-18-10-3-1-2-7-17-35(52)48-34(22-28-24-43-25-47-28)39(56)50-32(38(55)49-31)20-26-12-5-4-6-13-26/h4-6,8-9,12-15,23-25,31-34,46H,1-3,7,10-11,16-22H2,(H,43,47)(H,44,53)(H,48,52)(H,49,55)(H,50,56)(H,51,54)(H4,41,42,45)/t31-,32-,33-,34+/m0/s1
DMEC2PH	CS	C1CCCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCCC1)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DMEC2PH	IK	KYHILABVVZODQF-GZXHTMMISA-N
DMEC2PH	IU	2-[3-[(3S,6S,9S,12R)-9-benzyl-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohenicos-6-yl]propyl]guanidine
DMEC2PH	DE	Discovery agent

DMMBESU	ID	DMMBESU
DMMBESU	DN	C(RGDfF)
DMMBESU	HS	Investigative
DMMBESU	SN	CHEMBL380434
DMMBESU	DT	Small molecular drug
DMMBESU	PC	10699123
DMMBESU	MW	622.7
DMMBESU	FM	C30H38N8O7
DMMBESU	IC	InChI=1S/C30H38N8O7/c31-30(32)33-13-7-12-20-26(42)34-17-24(39)35-23(16-25(40)41)29(45)38-22(15-19-10-5-2-6-11-19)28(44)37-21(27(43)36-20)14-18-8-3-1-4-9-18/h1-6,8-11,20-23H,7,12-17H2,(H,34,42)(H,35,39)(H,36,43)(H,37,44)(H,38,45)(H,40,41)(H4,31,32,33)/t20-,21-,22+,23-/m0/s1
DMMBESU	CS	C1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CC=CC=C2)CC3=CC=CC=C3)CC(=O)O
DMMBESU	IK	VYLBOUQMYNRGBR-GPJHCHHRSA-N
DMMBESU	IU	2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMMBESU	DE	Discovery agent

DM8DU42	ID	DM8DU42
DM8DU42	DN	C(RGDfMeF)
DM8DU42	HS	Investigative
DM8DU42	SN	CHEMBL383747
DM8DU42	DT	Small molecular drug
DM8DU42	PC	44408450
DM8DU42	MW	636.7
DM8DU42	FM	C31H40N8O7
DM8DU42	IC	InChI=1S/C31H40N8O7/c1-39-24(16-20-11-6-3-7-12-20)29(45)37-21(13-8-14-34-31(32)33)27(43)35-18-25(40)36-22(17-26(41)42)28(44)38-23(30(39)46)15-19-9-4-2-5-10-19/h2-7,9-12,21-24H,8,13-18H2,1H3,(H,35,43)(H,36,40)(H,37,45)(H,38,44)(H,41,42)(H4,32,33,34)/t21-,22-,23+,24-/m0/s1
DM8DU42	CS	CN1[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C1=O)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N)CC3=CC=CC=C3
DM8DU42	IK	ZILGGGDRKNJYPR-XQUALCHDSA-N
DM8DU42	IU	2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM8DU42	DE	Discovery agent

DMY2NU8	ID	DMY2NU8
DMY2NU8	DN	C-[2-(1H-Imidazol-4-yl)-cyclopropyl]-methylamine
DMY2NU8	HS	Investigative
DMY2NU8	SN	CHEMBL292558; C-[2-(1H-Imidazol-4-yl)-cyclopropyl]-methylamine; BDBM50127603
DMY2NU8	DT	Small molecular drug
DMY2NU8	PC	10942498
DMY2NU8	MW	137.18
DMY2NU8	FM	C7H11N3
DMY2NU8	IC	InChI=1S/C7H11N3/c8-2-5-1-6(5)7-3-9-4-10-7/h3-6H,1-2,8H2,(H,9,10)/t5-,6+/m1/s1
DMY2NU8	CS	C1[C@@H]([C@H]1C2=CN=CN2)CN
DMY2NU8	IK	LMFNLINKCDGRTE-RITPCOANSA-N
DMY2NU8	IU	[(1S,2S)-2-(1H-imidazol-5-yl)cyclopropyl]methanamine
DMY2NU8	DE	Discovery agent

DMPOIDK	ID	DMPOIDK
DMPOIDK	DN	C[-Arg-Gly-Asp-Acpca19-]
DMPOIDK	HS	Investigative
DMPOIDK	SN	CHEMBL539338
DMPOIDK	DT	Small molecular drug
DMPOIDK	PC	11569720
DMPOIDK	MW	471.5
DMPOIDK	FM	C18H29N7O8
DMPOIDK	IC	InChI=1S/C18H29N7O8/c19-18(20)21-3-1-2-8-16(32)22-6-11(26)23-10(5-12(27)28)17(33)25-9-4-7(15(31)24-8)13(29)14(9)30/h7-10,13-14,29-30H,1-6H2,(H,22,32)(H,23,26)(H,24,31)(H,25,33)(H,27,28)(H4,19,20,21)/t7-,8-,9+,10-,13-,14-/m0/s1
DMPOIDK	CS	C1[C@H]2[C@@H]([C@H]([C@@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O)O
DMPOIDK	IK	VNLGSUKLIVHSOW-NDCHHBOESA-N
DMPOIDK	IU	2-[(1R,4S,10S,13S,14S,15S)-10-[3-(diaminomethylideneamino)propyl]-14,15-dihydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMPOIDK	DE	Discovery agent

DMJVW1N	ID	DMJVW1N
DMJVW1N	DN	C[-Arg-Gly-Asp-Acpca20-]
DMJVW1N	HS	Investigative
DMJVW1N	SN	CHEMBL540618
DMJVW1N	DT	Small molecular drug
DMJVW1N	PC	11656381
DMJVW1N	MW	471.5
DMJVW1N	FM	C18H29N7O8
DMJVW1N	IC	InChI=1S/C18H29N7O8/c19-18(20)21-3-1-2-8-16(32)22-6-11(26)23-10(5-12(27)28)17(33)25-9-4-7(15(31)24-8)13(29)14(9)30/h7-10,13-14,29-30H,1-6H2,(H,22,32)(H,23,26)(H,24,31)(H,25,33)(H,27,28)(H4,19,20,21)/t7-,8-,9+,10-,13+,14-/m0/s1
DMJVW1N	CS	C1[C@H]2[C@H]([C@H]([C@@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O)O
DMJVW1N	IK	VNLGSUKLIVHSOW-RNSQFEBMSA-N
DMJVW1N	IU	2-[(1R,4S,10S,13S,14R,15S)-10-[3-(diaminomethylideneamino)propyl]-14,15-dihydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMJVW1N	DE	Discovery agent

DMXCUDV	ID	DMXCUDV
DMXCUDV	DN	C[-Arg-Gly-Asp-Acpca21-]
DMXCUDV	HS	Investigative
DMXCUDV	SN	CHEMBL534711
DMXCUDV	DT	Small molecular drug
DMXCUDV	PC	11613122
DMXCUDV	MW	471.5
DMXCUDV	FM	C18H29N7O8
DMXCUDV	IC	InChI=1S/C18H29N7O8/c19-18(20)21-3-1-2-8-16(32)22-6-11(26)23-10(5-12(27)28)17(33)25-9-4-7(15(31)24-8)13(29)14(9)30/h7-10,13-14,29-30H,1-6H2,(H,22,32)(H,23,26)(H,24,31)(H,25,33)(H,27,28)(H4,19,20,21)/t7-,8+,9+,10+,13-,14-/m1/s1
DMXCUDV	CS	C1[C@@H]2[C@H]([C@@H]([C@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O)O
DMXCUDV	IK	VNLGSUKLIVHSOW-KOWOESDJSA-N
DMXCUDV	IU	2-[(1S,4S,10S,13R,14R,15R)-10-[3-(diaminomethylideneamino)propyl]-14,15-dihydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMXCUDV	DE	Discovery agent

DM6DV90	ID	DM6DV90
DM6DV90	DN	C[-Arg-Gly-Asp-Acpca22-]
DM6DV90	HS	Investigative
DM6DV90	SN	CHEMBL539850
DM6DV90	DT	Small molecular drug
DM6DV90	PC	11540715
DM6DV90	MW	471.5
DM6DV90	FM	C18H29N7O8
DM6DV90	IC	InChI=1S/C18H29N7O8/c19-18(20)21-3-1-2-8-16(32)22-6-11(26)23-10(5-12(27)28)17(33)25-9-4-7(15(31)24-8)13(29)14(9)30/h7-10,13-14,29-30H,1-6H2,(H,22,32)(H,23,26)(H,24,31)(H,25,33)(H,27,28)(H4,19,20,21)/t7-,8+,9+,10+,13+,14-/m1/s1
DM6DV90	CS	C1[C@@H]2[C@@H]([C@@H]([C@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O)O
DM6DV90	IK	VNLGSUKLIVHSOW-BDDFMHDSSA-N
DM6DV90	IU	2-[(1S,4S,10S,13R,14S,15R)-10-[3-(diaminomethylideneamino)propyl]-14,15-dihydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DM6DV90	DE	Discovery agent

DML0U8B	ID	DML0U8B
DML0U8B	DN	C-[-Arg-Gly-Asp-Acpca30-]
DML0U8B	HS	Investigative
DML0U8B	SN	CHEMBL540622
DML0U8B	DT	Small molecular drug
DML0U8B	PC	11712622
DML0U8B	MW	439.5
DML0U8B	FM	C18H29N7O6
DML0U8B	IC	InChI=1S/C18H29N7O6/c19-18(20)21-5-1-2-11-16(30)22-8-13(26)24-12(7-14(27)28)17(31)23-10-4-3-9(6-10)15(29)25-11/h9-12H,1-8H2,(H,22,30)(H,23,31)(H,24,26)(H,25,29)(H,27,28)(H4,19,20,21)/t9-,10+,11+,12+/m1/s1
DML0U8B	CS	C1C[C@H]2C[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DML0U8B	IK	SLTMEZLQPRTTBL-RHYQMDGZSA-N
DML0U8B	IU	2-[(1S,4S,10S,13R)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DML0U8B	DE	Discovery agent

DMKENFU	ID	DMKENFU
DMKENFU	DN	C-[-Arg-Gly-Asp-Acpca31-]
DMKENFU	HS	Investigative
DMKENFU	SN	CHEMBL534934
DMKENFU	DT	Small molecular drug
DMKENFU	PC	11533023
DMKENFU	MW	439.5
DMKENFU	FM	C18H29N7O6
DMKENFU	IC	InChI=1S/C18H29N7O6/c19-18(20)21-5-1-2-11-16(30)22-8-13(26)24-12(7-14(27)28)17(31)23-10-4-3-9(6-10)15(29)25-11/h9-12H,1-8H2,(H,22,30)(H,23,31)(H,24,26)(H,25,29)(H,27,28)(H4,19,20,21)/t9-,10+,11-,12-/m0/s1
DMKENFU	CS	C1C[C@@H]2C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMKENFU	IK	SLTMEZLQPRTTBL-USZNOCQGSA-N
DMKENFU	IU	2-[(1R,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMKENFU	DE	Discovery agent

DMVM7B2	ID	DMVM7B2
DMVM7B2	DN	C-[-Arg-Gly-Asp-Acpca32-]
DMVM7B2	HS	Investigative
DMVM7B2	SN	CHEMBL556402
DMVM7B2	DT	Small molecular drug
DMVM7B2	PC	11583738
DMVM7B2	MW	439.5
DMVM7B2	FM	C18H29N7O6
DMVM7B2	IC	InChI=1S/C18H29N7O6/c19-18(20)21-5-1-2-11-16(30)22-8-13(26)24-12(7-14(27)28)17(31)23-10-4-3-9(6-10)15(29)25-11/h9-12H,1-8H2,(H,22,30)(H,23,31)(H,24,26)(H,25,29)(H,27,28)(H4,19,20,21)/t9-,10-,11+,12+/m1/s1
DMVM7B2	CS	C1C[C@@H]2C[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMVM7B2	IK	SLTMEZLQPRTTBL-WYUUTHIRSA-N
DMVM7B2	IU	2-[(1R,4S,10S,13R)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMVM7B2	DE	Discovery agent

DMIBGWO	ID	DMIBGWO
DMIBGWO	DN	C-[-Arg-Gly-Asp-Acpca33-]
DMIBGWO	HS	Investigative
DMIBGWO	SN	CHEMBL534712
DMIBGWO	DT	Small molecular drug
DMIBGWO	PC	11670104
DMIBGWO	MW	439.5
DMIBGWO	FM	C18H29N7O6
DMIBGWO	IC	InChI=1S/C18H29N7O6/c19-18(20)21-5-1-2-11-16(30)22-8-13(26)24-12(7-14(27)28)17(31)23-10-4-3-9(6-10)15(29)25-11/h9-12H,1-8H2,(H,22,30)(H,23,31)(H,24,26)(H,25,29)(H,27,28)(H4,19,20,21)/t9-,10-,11-,12-/m0/s1
DMIBGWO	CS	C1C[C@H]2C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMIBGWO	IK	SLTMEZLQPRTTBL-BJDJZHNGSA-N
DMIBGWO	IU	2-[(1S,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMIBGWO	DE	Discovery agent

DMKHSAV	ID	DMKHSAV
DMKHSAV	DN	C[-Arg-Gly-Asp-Acpca34-]
DMKHSAV	HS	Investigative
DMKHSAV	SN	CHEMBL534933
DMKHSAV	DT	Small molecular drug
DMKHSAV	PC	11584047
DMKHSAV	MW	455.5
DMKHSAV	FM	C18H29N7O7
DMKHSAV	IC	InChI=1S/C18H29N7O7/c19-18(20)21-3-1-2-9-16(31)22-7-13(27)23-11(6-14(28)29)17(32)25-10-4-8(5-12(10)26)15(30)24-9/h8-12,26H,1-7H2,(H,22,31)(H,23,27)(H,24,30)(H,25,32)(H,28,29)(H4,19,20,21)/t8-,9-,10-,11-,12-/m0/s1
DMKHSAV	CS	C1[C@H]2C[C@@H]([C@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O
DMKHSAV	IK	CFCPTSHVAOVLJR-HTFCKZLJSA-N
DMKHSAV	IU	2-[(1S,4S,10S,13S,15S)-10-[3-(diaminomethylideneamino)propyl]-15-hydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMKHSAV	DE	Discovery agent

DMQOY3J	ID	DMQOY3J
DMQOY3J	DN	C[-Arg-Gly-Asp-Acpca35-]
DMQOY3J	HS	Investigative
DMQOY3J	SN	CHEMBL534713
DMQOY3J	DT	Small molecular drug
DMQOY3J	PC	11540460
DMQOY3J	MW	455.5
DMQOY3J	FM	C18H29N7O7
DMQOY3J	IC	InChI=1S/C18H29N7O7/c19-18(20)21-3-1-2-9-16(31)22-7-13(27)23-11(6-14(28)29)17(32)25-10-4-8(5-12(10)26)15(30)24-9/h8-12,26H,1-7H2,(H,22,31)(H,23,27)(H,24,30)(H,25,32)(H,28,29)(H4,19,20,21)/t8-,9-,10+,11-,12+/m0/s1
DMQOY3J	CS	C1[C@H]2C[C@H]([C@@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O
DMQOY3J	IK	CFCPTSHVAOVLJR-HHHUOAJASA-N
DMQOY3J	IU	2-[(1R,4S,10S,13S,15R)-10-[3-(diaminomethylideneamino)propyl]-15-hydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMQOY3J	DE	Discovery agent

DM7LCPW	ID	DM7LCPW
DM7LCPW	DN	C[-Arg-Gly-Asp-Acpca36-]
DM7LCPW	HS	Investigative
DM7LCPW	SN	CHEMBL557157
DM7LCPW	DT	Small molecular drug
DM7LCPW	PC	11518823
DM7LCPW	MW	455.5
DM7LCPW	FM	C18H29N7O7
DM7LCPW	IC	InChI=1S/C18H29N7O7/c19-18(20)21-3-1-2-9-16(31)22-7-13(27)23-11(6-14(28)29)17(32)25-10-4-8(5-12(10)26)15(30)24-9/h8-12,26H,1-7H2,(H,22,31)(H,23,27)(H,24,30)(H,25,32)(H,28,29)(H4,19,20,21)/t8-,9+,10+,11+,12+/m1/s1
DM7LCPW	CS	C1[C@@H]2C[C@@H]([C@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O
DM7LCPW	IK	CFCPTSHVAOVLJR-DGORSVRFSA-N
DM7LCPW	IU	2-[(1S,4S,10S,13R,15S)-10-[3-(diaminomethylideneamino)propyl]-15-hydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DM7LCPW	DE	Discovery agent

DMISP20	ID	DMISP20
DMISP20	DN	C[Asp22-Lys26][Gly8]GLP-1(7-37)-NH2
DMISP20	HS	Investigative
DMISP20	PC	91935394
DMISP20	MW	3380.7
DMISP20	FM	C152H227N41O47
DMISP20	IC	InChI=1S/C152H227N41O47/c1-16-77(10)122(149(238)170-80(13)127(216)178-104(59-86-63-162-91-35-24-23-34-89(86)91)138(227)180-100(55-74(4)5)140(229)190-120(75(6)7)147(236)177-93(36-25-27-51-153)130(219)165-67-114(204)171-92(38-29-53-161-152(157)158)129(218)163-65-111(156)201)192-141(230)102(56-83-30-19-17-20-31-83)181-134(223)97(45-49-117(208)209)174-133(222)94-37-26-28-52-160-112(202)61-105(139(228)175-96(43-47-110(155)200)132(221)169-78(11)125(214)168-79(12)126(215)173-94)183-135(224)98(46-50-118(210)211)176-136(225)99(54-73(2)3)179-137(226)101(58-85-39-41-88(199)42-40-85)182-144(233)107(69-194)186-146(235)109(71-196)187-148(237)121(76(8)9)191-143(232)106(62-119(212)213)184-145(234)108(70-195)188-151(240)124(82(15)198)193-142(231)103(57-84-32-21-18-22-33-84)185-150(239)123(81(14)197)189-115(205)68-166-131(220)95(44-48-116(206)207)172-113(203)66-164-128(217)90(154)60-87-64-159-72-167-87/h17-24,30-35,39-42,63-64,72-82,90,92-109,120-124,162,194-199H,16,25-29,36-38,43-62,65-71,153-154H2,1-15H3,(H2,155,200)(H2,156,201)(H,159,167)(H,160,202)(H,163,218)(H,164,217)(H,165,219)(H,166,220)(H,168,214)(H,169,221)(H,170,238)(H,171,204)(H,172,203)(H,173,215)(H,174,222)(H,175,228)(H,176,225)(H,177,236)(H,178,216)(H,179,226)(H,180,227)(H,181,223)(H,182,233)(H,183,224)(H,184,234)(H,185,239)(H,186,235)(H,187,237)(H,188,240)(H,189,205)(H,190,229)(H,191,232)(H,192,230)(H,193,231)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H4,157,158,161)/t77-,78-,79-,80-,81-,82-,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,120-,121-,122-,123-,124-/m0/s1
DMISP20	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCCNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMISP20	IK	XYYFVCKJZJFHBW-NINLSKNRSA-N
DMISP20	IU	(4S)-5-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,9S,12S,20S)-20-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-9-(3-amino-3-oxopropyl)-3,6-dimethyl-2,5,8,11,14-pentaoxo-1,4,7,10,15-pentazacycloicos-12-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMISP20	DE	Discovery agent

DMHARQX	ID	DMHARQX
DMHARQX	DN	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2
DMHARQX	HS	Investigative
DMHARQX	SN	CHEMBL267265; c[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2
DMHARQX	DT	Small molecular drug
DMHARQX	PC	44445085
DMHARQX	MW	880
DMHARQX	FM	C46H61N11O7
DMHARQX	IC	InChI=1S/C46H61N11O7/c47-34-14-5-3-12-32(58)20-21-40(59)51-22-8-7-16-36(41(48)60)54-45(64)39(26-31-27-53-35-15-6-4-13-33(31)35)57-43(62)37(17-9-23-52-46(49)50)55-44(63)38(56-42(34)61)25-28-18-19-29-10-1-2-11-30(29)24-28/h1-2,4,6,10-11,13,15,18-19,24,27,34,36-39,53H,3,5,7-9,12,14,16-17,20-23,25-26,47H2,(H2,48,60)(H,51,59)(H,54,64)(H,55,63)(H,56,61)(H,57,62)(H4,49,50,52)/t34-,36-,37-,38+,39-/m0/s1
DMHARQX	CS	C1CCC(=O)CCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](C1)N)CC2=CC3=CC=CC=C3C=C2)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N
DMHARQX	IK	KDTZLQMUHBEBMZ-OUBWENQOSA-N
DMHARQX	IU	(2R,5S,8S,11S,25S)-25-amino-5-[3-(diaminomethylideneamino)propyl]-8-(1H-indol-3-ylmethyl)-2-(naphthalen-2-ylmethyl)-3,6,9,17,20,26-hexaoxo-1,4,7,10,16-pentazacyclohexacosane-11-carboxamide
DMHARQX	DE	Discovery agent

DMI3CSJ	ID	DMI3CSJ
DMI3CSJ	DN	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2
DMI3CSJ	HS	Investigative
DMI3CSJ	SN	CHEMBL411391; c[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2
DMI3CSJ	DT	Small molecular drug
DMI3CSJ	PC	44445084
DMI3CSJ	MW	830
DMI3CSJ	FM	C42H59N11O7
DMI3CSJ	IC	InChI=1S/C42H59N11O7/c43-30-15-6-4-13-28(54)19-20-36(55)47-21-9-8-17-32(37(44)56)50-41(60)35(24-27-25-49-31-16-7-5-14-29(27)31)53-39(58)33(18-10-22-48-42(45)46)51-40(59)34(52-38(30)57)23-26-11-2-1-3-12-26/h1-3,5,7,11-12,14,16,25,30,32-35,49H,4,6,8-10,13,15,17-24,43H2,(H2,44,56)(H,47,55)(H,50,60)(H,51,59)(H,52,57)(H,53,58)(H4,45,46,48)/t30-,32-,33-,34+,35-/m0/s1
DMI3CSJ	CS	C1CCC(=O)CCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](C1)N)CC2=CC=CC=C2)CCCN=C(N)N)CC3=CNC4=CC=CC=C43)C(=O)N
DMI3CSJ	IK	HWDXGLQUFJWIAC-DIWSUELLSA-N
DMI3CSJ	IU	(2R,5S,8S,11S,25S)-25-amino-2-benzyl-5-[3-(diaminomethylideneamino)propyl]-8-(1H-indol-3-ylmethyl)-3,6,9,17,20,26-hexaoxo-1,4,7,10,16-pentazacyclohexacosane-11-carboxamide
DMI3CSJ	DE	Discovery agent

DMYPHVC	ID	DMYPHVC
DMYPHVC	DN	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMYPHVC	HS	Investigative
DMYPHVC	SN	CHEMBL398665; c[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMYPHVC	DT	Small molecular drug
DMYPHVC	PC	44445083
DMYPHVC	MW	954.1
DMYPHVC	FM	C52H63N11O7
DMYPHVC	IC	InChI=1S/C52H63N11O7/c53-46(65)40-18-7-8-24-56-25-10-21-45(64)37-15-3-4-16-38(37)51(70)63-27-11-20-44(63)50(69)62-42(29-32-22-23-33-12-1-2-13-34(33)28-32)48(67)60-41(19-9-26-57-52(54)55)47(66)61-43(49(68)59-40)30-35-31-58-39-17-6-5-14-36(35)39/h1-6,12-17,22-23,28,31,40-44,56,58H,7-11,18-21,24-27,29-30H2,(H2,53,65)(H,59,68)(H,60,67)(H,61,66)(H,62,69)(H4,54,55,57)/t40-,41-,42+,43-,44-/m0/s1
DMYPHVC	CS	C1CCNCCCC(=O)C2=CC=CC=C2C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC4=CNC5=CC=CC=C54)CCCN=C(N)N)CC6=CC7=CC=CC=C7C=C6
DMYPHVC	IK	YUUZCRILYWDWPO-PURVKFDZSA-N
DMYPHVC	IU	(7S,10R,13S,16S,19S)-13-[3-(diaminomethylideneamino)propyl]-16-(1H-indol-3-ylmethyl)-10-(naphthalen-2-ylmethyl)-2,8,11,14,17,28-hexaoxo-3,9,12,15,18,24-hexazatricyclo[27.4.0.03,7]tritriaconta-1(33),29,31-triene-19-carboxamide
DMYPHVC	DE	Discovery agent

DM0VP79	ID	DM0VP79
DM0VP79	DN	C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DM0VP79	HS	Investigative
DM0VP79	SN	CHEMBL398664; c[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DM0VP79	DT	Small molecular drug
DM0VP79	PC	44445082
DM0VP79	MW	800
DM0VP79	FM	C41H57N11O6
DM0VP79	IC	InChI=1S/C41H57N11O6/c42-36(54)30-15-6-7-19-45-20-9-18-35(53)52-22-10-17-34(52)40(58)51-32(23-26-11-2-1-3-12-26)38(56)49-31(16-8-21-46-41(43)44)37(55)50-33(39(57)48-30)24-27-25-47-29-14-5-4-13-28(27)29/h1-5,11-14,25,30-34,45,47H,6-10,15-24H2,(H2,42,54)(H,48,57)(H,49,56)(H,50,55)(H,51,58)(H4,43,44,46)/t30-,31-,32+,33-,34-/m0/s1
DM0VP79	CS	C1CCNCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5
DM0VP79	IK	VFHJQMPJMWPJBF-UBLLTGQXSA-N
DM0VP79	IU	(11S,14S,17S,20R,23S)-20-benzyl-17-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-2,13,16,19,22-pentaoxo-1,6,12,15,18,21-hexazabicyclo[21.3.0]hexacosane-11-carboxamide
DM0VP79	DE	Discovery agent

DM1VCJP	ID	DM1VCJP
DM1VCJP	DN	C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2
DM1VCJP	HS	Investigative
DM1VCJP	SN	CHEMBL253789; c[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2
DM1VCJP	DT	Small molecular drug
DM1VCJP	PC	24774438
DM1VCJP	MW	816.9
DM1VCJP	FM	C42H48N12O6
DM1VCJP	IC	InChI=1S/C42H48N12O6/c43-36(55)30-12-5-6-16-48-40(59)34-35(47-19-18-46-34)41(60)54-32(21-24-14-15-25-8-1-2-9-26(25)20-24)38(57)52-31(13-7-17-49-42(44)45)37(56)53-33(39(58)51-30)22-27-23-50-29-11-4-3-10-28(27)29/h1-4,8-11,14-15,18-20,23,30-33,50H,5-7,12-13,16-17,21-22H2,(H2,43,55)(H,48,59)(H,51,58)(H,52,57)(H,53,56)(H,54,60)(H4,44,45,49)/t30-,31-,32+,33-/m0/s1
DM1VCJP	CS	C1CCNC(=O)C2=NC=CN=C2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC6=CC=CC=C6C=C5
DM1VCJP	IK	YIHQUVPRWHIYHB-SSNHPIBPSA-N
DM1VCJP	IU	(4R,7S,10S,13S)-7-[3-(diaminomethylideneamino)propyl]-10-(1H-indol-3-ylmethyl)-4-(naphthalen-2-ylmethyl)-2,5,8,11,19-pentaoxo-3,6,9,12,18,21,24-heptazabicyclo[18.4.0]tetracosa-1(24),20,22-triene-13-carboxamide
DM1VCJP	DE	Discovery agent

DM8AMGF	ID	DM8AMGF
DM8AMGF	DN	C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2
DM8AMGF	HS	Investigative
DM8AMGF	SN	CHEMBL438744; c[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2
DM8AMGF	DT	Small molecular drug
DM8AMGF	PC	24774602
DM8AMGF	MW	766.8
DM8AMGF	FM	C38H46N12O6
DM8AMGF	IC	InChI=1S/C38H46N12O6/c39-32(51)26-13-6-7-15-44-36(55)30-31(43-18-17-42-30)37(56)50-28(19-22-9-2-1-3-10-22)34(53)48-27(14-8-16-45-38(40)41)33(52)49-29(35(54)47-26)20-23-21-46-25-12-5-4-11-24(23)25/h1-5,9-12,17-18,21,26-29,46H,6-8,13-16,19-20H2,(H2,39,51)(H,44,55)(H,47,54)(H,48,53)(H,49,52)(H,50,56)(H4,40,41,45)/t26-,27-,28+,29-/m0/s1
DM8AMGF	CS	C1CCNC(=O)C2=NC=CN=C2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5
DM8AMGF	IK	JJPMYGFCLXEQSM-FKWFRFQNSA-N
DM8AMGF	IU	(4R,7S,10S,13S)-4-benzyl-7-[3-(diaminomethylideneamino)propyl]-10-(1H-indol-3-ylmethyl)-2,5,8,11,19-pentaoxo-3,6,9,12,18,21,24-heptazabicyclo[18.4.0]tetracosa-1(24),20,22-triene-13-carboxamide
DM8AMGF	DE	Discovery agent

DMD6OW4	ID	DMD6OW4
DMD6OW4	DN	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMD6OW4	HS	Investigative
DMD6OW4	SN	CHEMBL253788; c[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMD6OW4	DT	Small molecular drug
DMD6OW4	PC	24774519
DMD6OW4	MW	912
DMD6OW4	FM	C49H57N11O7
DMD6OW4	IC	InChI=1S/C49H57N11O7/c50-42(61)37-17-7-8-22-53-43(62)34-14-3-4-15-35(34)48(67)60-24-10-19-41(60)47(66)59-39(26-29-20-21-30-11-1-2-12-31(30)25-29)45(64)57-38(18-9-23-54-49(51)52)44(63)58-40(46(65)56-37)27-32-28-55-36-16-6-5-13-33(32)36/h1-6,11-16,20-21,25,28,37-41,55H,7-10,17-19,22-24,26-27H2,(H2,50,61)(H,53,62)(H,56,65)(H,57,64)(H,58,63)(H,59,66)(H4,51,52,54)/t37-,38-,39+,40-,41-/m0/s1
DMD6OW4	CS	C1CCNC(=O)C2=CC=CC=C2C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC4=CNC5=CC=CC=C54)CCCN=C(N)N)CC6=CC7=CC=CC=C7C=C6
DMD6OW4	IK	VWRQHODLDKRSNP-LIZQXKDQSA-N
DMD6OW4	IU	(7S,10R,13S,16S,19S)-13-[3-(diaminomethylideneamino)propyl]-16-(1H-indol-3-ylmethyl)-10-(naphthalen-2-ylmethyl)-2,8,11,14,17,25-hexaoxo-3,9,12,15,18,24-hexazatricyclo[24.4.0.03,7]triaconta-1(30),26,28-triene-19-carboxamide
DMD6OW4	DE	Discovery agent

DMNKT8J	ID	DMNKT8J
DMNKT8J	DN	C[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DMNKT8J	HS	Investigative
DMNKT8J	SN	CHEMBL253574; c[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DMNKT8J	DT	Small molecular drug
DMNKT8J	PC	24774356
DMNKT8J	MW	862
DMNKT8J	FM	C45H55N11O7
DMNKT8J	IC	InChI=1S/C45H55N11O7/c46-38(57)33-18-8-9-21-49-39(58)30-15-4-5-16-31(30)44(63)56-23-11-20-37(56)43(62)55-35(24-27-12-2-1-3-13-27)41(60)53-34(19-10-22-50-45(47)48)40(59)54-36(42(61)52-33)25-28-26-51-32-17-7-6-14-29(28)32/h1-7,12-17,26,33-37,51H,8-11,18-25H2,(H2,46,57)(H,49,58)(H,52,61)(H,53,60)(H,54,59)(H,55,62)(H4,47,48,50)/t33-,34-,35+,36-,37-/m0/s1
DMNKT8J	CS	C1CCNC(=O)C2=CC=CC=C2C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC4=CNC5=CC=CC=C54)CCCN=C(N)N)CC6=CC=CC=C6
DMNKT8J	IK	CLUDKTYPSAGGGT-GJOOVXBSSA-N
DMNKT8J	IU	(7S,10R,13S,16S,19S)-10-benzyl-13-[3-(diaminomethylideneamino)propyl]-16-(1H-indol-3-ylmethyl)-2,8,11,14,17,25-hexaoxo-3,9,12,15,18,24-hexazatricyclo[24.4.0.03,7]triaconta-1(30),26,28-triene-19-carboxamide
DMNKT8J	DE	Discovery agent

DMYIJT1	ID	DMYIJT1
DMYIJT1	DN	C[Cpa19-Lys26][Gly8]GLP-1(7-37)-NH2
DMYIJT1	HS	Investigative
DMYIJT1	PC	91935398
DMYIJT1	MW	3350.6
DMYIJT1	FM	C151H225N41O46
DMYIJT1	IC	InChI=1S/C151H225N41O46/c1-16-77(10)121(148(236)170-80(13)126(214)178-104(59-87-62-161-91-35-24-23-34-89(87)91)138(226)180-100(55-74(4)5)139(227)189-119(75(6)7)146(234)177-93(36-25-27-51-152)130(218)164-66-112(201)171-92(38-29-53-160-151(156)157)129(217)162-64-110(155)199)191-140(228)102(56-83-30-19-17-20-31-83)181-135(223)98(46-50-117(208)209)176-134(222)94-37-26-28-52-159-127(215)86-41-39-85(40-42-86)58-101(137(225)179-99(54-73(2)3)136(224)175-96(45-49-116(206)207)132(220)165-67-113(202)173-97(43-47-109(154)198)133(221)169-78(11)124(212)168-79(12)125(213)174-94)182-143(231)106(69-193)185-145(233)108(71-195)186-147(235)120(76(8)9)190-142(230)105(61-118(210)211)183-144(232)107(70-194)187-150(238)123(82(15)197)192-141(229)103(57-84-32-21-18-22-33-84)184-149(237)122(81(14)196)188-114(203)68-166-131(219)95(44-48-115(204)205)172-111(200)65-163-128(216)90(153)60-88-63-158-72-167-88/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,161,193-197H,16,25-29,36-38,43-61,64-71,152-153H2,1-15H3,(H2,154,198)(H2,155,199)(H,158,167)(H,159,215)(H,162,217)(H,163,216)(H,164,218)(H,165,220)(H,166,219)(H,168,212)(H,169,221)(H,170,236)(H,171,201)(H,172,200)(H,173,202)(H,174,213)(H,175,224)(H,176,222)(H,177,234)(H,178,214)(H,179,225)(H,180,226)(H,181,223)(H,182,231)(H,183,232)(H,184,237)(H,185,233)(H,186,235)(H,187,238)(H,188,203)(H,189,227)(H,190,230)(H,191,228)(H,192,229)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,156,157,160)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
DMYIJT1	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCCNC(=O)C5=CC=C(C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)CCC(=O)O)CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N)C=C5
DMYIJT1	IK	NBZJWICSDFBTTN-RHBBJNDVSA-N
DMYIJT1	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(8S,11S,14S,17S,23S,26S,29S)-8-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-17-(3-amino-3-oxopropyl)-23-(2-carboxyethyl)-11,14-dimethyl-26-(2-methylpropyl)-2,10,13,16,19,22,25,28-octaoxo-3,9,12,15,18,21,24,27-octazabicyclo[29.2.2]pentatriaconta-1(33),31,34-trien-29-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMYIJT1	DE	Discovery agent

DMJR5UD	ID	DMJR5UD
DMJR5UD	DN	C[Glu18-Lys22][Gly8]GLP-1(7-37)-NH2
DMJR5UD	HS	Investigative
DMJR5UD	PC	91935383
DMJR5UD	MW	3435.8
DMJR5UD	FM	C156H236N42O46
DMJR5UD	IC	InChI=1S/C156H236N42O46/c1-16-81(10)126(153(242)175-84(13)131(220)185-110(65-90-68-167-95-37-24-23-36-93(90)95)144(233)187-106(61-78(4)5)145(234)195-124(79(6)7)151(240)184-97(38-25-28-56-157)134(223)170-72-118(208)176-96(41-31-59-166-156(162)163)133(222)168-70-115(161)205)197-146(235)108(62-87-32-19-17-20-33-87)189-141(230)104(50-55-122(214)215)181-137(226)98(39-26-29-57-158)178-130(219)83(12)173-129(218)82(11)174-136(225)101(46-51-114(160)204)180-138(227)99-40-27-30-58-165-116(206)52-47-102(140(229)188-107(64-89-42-44-92(203)45-43-89)143(232)186-105(60-77(2)3)142(231)182-103(139(228)179-99)49-54-121(212)213)183-149(238)112(74-199)192-152(241)125(80(8)9)196-148(237)111(67-123(216)217)190-150(239)113(75-200)193-155(244)128(86(15)202)198-147(236)109(63-88-34-21-18-22-35-88)191-154(243)127(85(14)201)194-119(209)73-171-135(224)100(48-53-120(210)211)177-117(207)71-169-132(221)94(159)66-91-69-164-76-172-91/h17-24,32-37,42-45,68-69,76-86,94,96-113,124-128,167,199-203H,16,25-31,38-41,46-67,70-75,157-159H2,1-15H3,(H2,160,204)(H2,161,205)(H,164,172)(H,165,206)(H,168,222)(H,169,221)(H,170,223)(H,171,224)(H,173,218)(H,174,225)(H,175,242)(H,176,208)(H,177,207)(H,178,219)(H,179,228)(H,180,227)(H,181,226)(H,182,231)(H,183,238)(H,184,240)(H,185,220)(H,186,232)(H,187,233)(H,188,229)(H,189,230)(H,190,239)(H,191,243)(H,192,241)(H,193,244)(H,194,209)(H,195,234)(H,196,237)(H,197,235)(H,198,236)(H,210,211)(H,212,213)(H,214,215)(H,216,217)(H4,162,163,166)/t81-,82-,83-,84-,85+,86+,94-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,124-,125-,126-,127-,128-/m0/s1
DMJR5UD	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCC(=O)O)CC(C)C)CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMJR5UD	IK	GOARADSSYIPKJH-IJFSHCFJSA-N
DMJR5UD	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,9S,12S,21S)-21-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]-3-(2-carboxyethyl)-9-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMJR5UD	DE	Discovery agent

DM6O4EZ	ID	DM6O4EZ
DM6O4EZ	DN	C[Glu19-Lys23][Gly8]GLP-1(7-37)-NH2
DM6O4EZ	HS	Investigative
DM6O4EZ	PC	91935384
DM6O4EZ	MW	3288.6
DM6O4EZ	FM	C147H227N41O45
DM6O4EZ	IC	InChI=1S/C147H227N41O45/c1-16-76(10)118(144(231)166-79(13)123(210)175-101(58-84-61-157-88-37-24-23-36-86(84)88)134(221)177-98(55-73(4)5)135(222)185-116(74(6)7)142(229)174-90(38-25-28-50-148)126(213)160-65-109(197)167-89(41-31-53-156-147(152)153)125(212)158-63-106(151)194)187-136(223)99(56-82-32-19-17-20-33-82)178-132(219)96(45-49-114(204)205)172-130(217)92(39-26-29-51-149)170-122(209)78(12)164-121(208)77(11)165-129(216)91-40-27-30-52-155-107(195)46-42-95(131(218)176-97(54-72(2)3)133(220)171-94(44-48-113(202)203)128(215)161-66-110(198)168-91)173-139(226)103(68-189)181-141(228)105(70-191)182-143(230)117(75(8)9)186-138(225)102(60-115(206)207)179-140(227)104(69-190)183-146(233)120(81(15)193)188-137(224)100(57-83-34-21-18-22-35-83)180-145(232)119(80(14)192)184-111(199)67-162-127(214)93(43-47-112(200)201)169-108(196)64-159-124(211)87(150)59-85-62-154-71-163-85/h17-24,32-37,61-62,71-81,87,89-105,116-120,157,189-193H,16,25-31,38-60,63-70,148-150H2,1-15H3,(H2,151,194)(H,154,163)(H,155,195)(H,158,212)(H,159,211)(H,160,213)(H,161,215)(H,162,214)(H,164,208)(H,165,216)(H,166,231)(H,167,197)(H,168,198)(H,169,196)(H,170,209)(H,171,220)(H,172,217)(H,173,226)(H,174,229)(H,175,210)(H,176,218)(H,177,221)(H,178,219)(H,179,227)(H,180,232)(H,181,228)(H,182,230)(H,183,233)(H,184,199)(H,185,222)(H,186,225)(H,187,223)(H,188,224)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,152,153,156)/t76-,77-,78-,79-,80+,81+,87-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,116-,117-,118-,119-,120-/m0/s1
DM6O4EZ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N4)CCC(=O)O)CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DM6O4EZ	IK	OCOAZSDHBCONHT-VHWHDJENSA-N
DM6O4EZ	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(6S,9S,12S,21S)-21-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-6-(2-carboxyethyl)-9-(2-methylpropyl)-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM6O4EZ	DE	Discovery agent

DMA3ZRJ	ID	DMA3ZRJ
DMA3ZRJ	DN	C[Glu21-Lys25][Gly8]GLP-1(7-37)-NH2
DMA3ZRJ	HS	Investigative
DMA3ZRJ	PC	91935386
DMA3ZRJ	MW	3379.7
DMA3ZRJ	FM	C153H232N42O45
DMA3ZRJ	IC	InChI=1S/C153H232N42O45/c1-15-80(10)124(150(238)172-82(12)128(216)181-107(62-88-65-164-93-36-23-22-35-91(88)93)140(228)183-103(58-77(4)5)141(229)192-122(78(6)7)148(236)180-95(37-24-27-53-154)131(219)167-69-116(206)173-94(40-30-56-163-153(159)160)130(218)165-67-113(158)203)194-142(230)105(59-85-31-18-16-19-32-85)184-137(225)101(48-52-120(211)212)179-136(224)97(38-25-28-54-155)177-135(223)96-39-26-29-55-162-114(204)50-46-99(133(221)168-70-117(207)175-100(45-49-112(157)202)134(222)171-81(11)127(215)176-96)178-138(226)102(57-76(2)3)182-139(227)104(61-87-41-43-90(201)44-42-87)185-145(233)109(72-196)188-147(235)111(74-198)189-149(237)123(79(8)9)193-144(232)108(64-121(213)214)186-146(234)110(73-197)190-152(240)126(84(14)200)195-143(231)106(60-86-33-20-17-21-34-86)187-151(239)125(83(13)199)191-118(208)71-169-132(220)98(47-51-119(209)210)174-115(205)68-166-129(217)92(156)63-89-66-161-75-170-89/h16-23,31-36,41-44,65-66,75-84,92,94-111,122-126,164,196-201H,15,24-30,37-40,45-64,67-74,154-156H2,1-14H3,(H2,157,202)(H2,158,203)(H,161,170)(H,162,204)(H,165,218)(H,166,217)(H,167,219)(H,168,221)(H,169,220)(H,171,222)(H,172,238)(H,173,206)(H,174,205)(H,175,207)(H,176,215)(H,177,223)(H,178,226)(H,179,224)(H,180,236)(H,181,216)(H,182,227)(H,183,228)(H,184,225)(H,185,233)(H,186,234)(H,187,239)(H,188,235)(H,189,237)(H,190,240)(H,191,208)(H,192,229)(H,193,232)(H,194,230)(H,195,231)(H,209,210)(H,211,212)(H,213,214)(H4,159,160,163)/t80-,81-,82-,83+,84+,92-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,122-,123-,124-,125-,126-/m0/s1
DMA3ZRJ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMA3ZRJ	IK	QOGYXVBERDYIBU-ZKFPJBBCSA-N
DMA3ZRJ	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,12S,21S)-21-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-6-(3-amino-3-oxopropyl)-3-methyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMA3ZRJ	DE	Discovery agent

DMPK74W	ID	DMPK74W
DMPK74W	DN	C[Glu21-Lys26][Gly8]GLP-1(7-37)-NH2
DMPK74W	HS	Investigative
DMPK74W	PC	91935397
DMPK74W	MW	3322.6
DMPK74W	FM	C150H225N41O45
DMPK74W	IC	InChI=1S/C150H225N41O45/c1-16-77(10)121(147(234)169-80(13)126(213)177-104(59-86-62-160-91-35-24-23-34-89(86)91)137(224)179-100(55-74(4)5)138(225)188-119(75(6)7)145(232)176-93(36-25-27-51-151)129(216)163-66-113(202)170-92(38-29-53-159-150(155)156)128(215)161-64-110(154)199)190-139(226)102(56-83-30-19-17-20-31-83)180-134(221)98(46-50-117(207)208)175-133(220)94-37-26-28-52-158-111(200)48-44-96(131(218)164-67-114(203)172-97(43-47-109(153)198)132(219)168-78(11)124(211)167-79(12)125(212)173-94)174-135(222)99(54-73(2)3)178-136(223)101(58-85-39-41-88(197)42-40-85)181-142(229)106(69-192)184-144(231)108(71-194)185-146(233)120(76(8)9)189-141(228)105(61-118(209)210)182-143(230)107(70-193)186-149(236)123(82(15)196)191-140(227)103(57-84-32-21-18-22-33-84)183-148(235)122(81(14)195)187-115(204)68-165-130(217)95(45-49-116(205)206)171-112(201)65-162-127(214)90(152)60-87-63-157-72-166-87/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,160,192-197H,16,25-29,36-38,43-61,64-71,151-152H2,1-15H3,(H2,153,198)(H2,154,199)(H,157,166)(H,158,200)(H,161,215)(H,162,214)(H,163,216)(H,164,218)(H,165,217)(H,167,211)(H,168,219)(H,169,234)(H,170,202)(H,171,201)(H,172,203)(H,173,212)(H,174,222)(H,175,220)(H,176,232)(H,177,213)(H,178,223)(H,179,224)(H,180,221)(H,181,229)(H,182,230)(H,183,235)(H,184,231)(H,185,233)(H,186,236)(H,187,204)(H,188,225)(H,189,228)(H,190,226)(H,191,227)(H,205,206)(H,207,208)(H,209,210)(H4,155,156,159)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
DMPK74W	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMPK74W	IK	YLHNVPBGRUSXJQ-RHBBJNDVSA-N
DMPK74W	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,9S,15S,24S)-24-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-9-(3-amino-3-oxopropyl)-3,6-dimethyl-2,5,8,11,14,18-hexaoxo-1,4,7,10,13,19-hexazacyclotetracos-15-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMPK74W	DE	Discovery agent

DM8I0CZ	ID	DM8I0CZ
DM8I0CZ	DN	C[Glu22-Lys26][Gly8]GLP-1(7-37)-NH2
DM8I0CZ	HS	Investigative
DM8I0CZ	DE	Discovery agent

DMMA9GE	ID	DMMA9GE
DMMA9GE	DN	C[Glu22-Orn26][Gly8]GLP-1(7-37)-NH2
DMMA9GE	HS	Investigative
DMMA9GE	PC	91935393
DMMA9GE	MW	3380.7
DMMA9GE	FM	C152H227N41O47
DMMA9GE	IC	InChI=1S/C152H227N41O47/c1-16-77(10)122(149(238)170-80(13)127(216)179-105(60-86-63-162-91-34-24-23-33-89(86)91)139(228)181-101(56-74(4)5)140(229)190-120(75(6)7)147(236)178-93(35-25-26-52-153)130(219)165-67-114(204)171-92(36-28-54-161-152(157)158)129(218)163-65-111(156)201)192-141(230)103(57-83-29-19-17-20-30-83)182-136(225)99(46-51-118(210)211)176-133(222)94-37-27-53-160-112(202)48-43-97(134(223)174-96(42-47-110(155)200)132(221)169-78(11)125(214)168-79(12)126(215)173-94)175-135(224)98(45-50-117(208)209)177-137(226)100(55-73(2)3)180-138(227)102(59-85-38-40-88(199)41-39-85)183-144(233)107(69-194)186-146(235)109(71-196)187-148(237)121(76(8)9)191-143(232)106(62-119(212)213)184-145(234)108(70-195)188-151(240)124(82(15)198)193-142(231)104(58-84-31-21-18-22-32-84)185-150(239)123(81(14)197)189-115(205)68-166-131(220)95(44-49-116(206)207)172-113(203)66-164-128(217)90(154)61-87-64-159-72-167-87/h17-24,29-34,38-41,63-64,72-82,90,92-109,120-124,162,194-199H,16,25-28,35-37,42-62,65-71,153-154H2,1-15H3,(H2,155,200)(H2,156,201)(H,159,167)(H,160,202)(H,163,218)(H,164,217)(H,165,219)(H,166,220)(H,168,214)(H,169,221)(H,170,238)(H,171,204)(H,172,203)(H,173,215)(H,174,223)(H,175,224)(H,176,222)(H,177,226)(H,178,236)(H,179,216)(H,180,227)(H,181,228)(H,182,225)(H,183,233)(H,184,234)(H,185,239)(H,186,235)(H,187,237)(H,188,240)(H,189,205)(H,190,229)(H,191,232)(H,192,230)(H,193,231)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H4,157,158,161)/t77-,78-,79-,80-,81-,82-,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,120-,121-,122-,123-,124-/m0/s1
DMMA9GE	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMMA9GE	IK	KMMGHNYLBGRIJN-NINLSKNRSA-N
DMMA9GE	IU	(4S)-5-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,5S,8S,11S,19S)-11-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-2-(3-amino-3-oxopropyl)-5,8-dimethyl-3,6,9,16,20-pentaoxo-1,4,7,10,15-pentazacycloicos-19-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMMA9GE	DE	Discovery agent

DMWYN87	ID	DMWYN87
DMWYN87	DN	C[Glu23-Lys27][Gly8]GLP-1(7-37)-NH2
DMWYN87	HS	Investigative
DMWYN87	PC	91935389
DMWYN87	MW	3322.7
DMWYN87	FM	C151H229N41O44
DMWYN87	IC	InChI=1S/C151H229N41O44/c1-16-79(10)122(148(234)170-82(13)127(213)178-106(61-88-64-161-93-37-24-23-36-91(88)93)138(224)180-102(57-76(4)5)139(225)189-120(77(6)7)146(232)177-95(38-25-28-52-152)130(216)164-68-114(202)171-94(41-31-55-160-151(156)157)129(215)162-66-111(155)199)191-140(226)104(58-85-32-19-17-20-33-85)181-135(221)97-40-27-30-54-159-112(200)49-46-100(133(219)169-80(11)125(211)168-81(12)126(212)174-96(134(220)175-97)39-26-29-53-153)173-115(203)69-165-132(218)99(48-51-118(207)208)176-136(222)101(56-75(2)3)179-137(223)103(60-87-42-44-90(198)45-43-87)182-143(229)108(71-193)185-145(231)110(73-195)186-147(233)121(78(8)9)190-142(228)107(63-119(209)210)183-144(230)109(72-194)187-150(236)124(84(15)197)192-141(227)105(59-86-34-21-18-22-35-86)184-149(235)123(83(14)196)188-116(204)70-166-131(217)98(47-50-117(205)206)172-113(201)67-163-128(214)92(154)62-89-65-158-74-167-89/h17-24,32-37,42-45,64-65,74-84,92,94-110,120-124,161,193-198H,16,25-31,38-41,46-63,66-73,152-154H2,1-15H3,(H2,155,199)(H,158,167)(H,159,200)(H,162,215)(H,163,214)(H,164,216)(H,165,218)(H,166,217)(H,168,211)(H,169,219)(H,170,234)(H,171,202)(H,172,201)(H,173,203)(H,174,212)(H,175,220)(H,176,222)(H,177,232)(H,178,213)(H,179,223)(H,180,224)(H,181,221)(H,182,229)(H,183,230)(H,184,235)(H,185,231)(H,186,233)(H,187,236)(H,188,204)(H,189,225)(H,190,228)(H,191,226)(H,192,227)(H,205,206)(H,207,208)(H,209,210)(H4,156,157,160)/t79-,80-,81-,82-,83+,84+,92-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,120-,121-,122-,123-,124-/m0/s1
DMWYN87	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCCCN)C)C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMWYN87	IK	WPXDPFYLELBEJH-MAGRMNHLSA-N
DMWYN87	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(3S,6S,9S,12S,21S)-21-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]-3-(4-aminobutyl)-6,9-dimethyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMWYN87	DE	Discovery agent

DMKZXV3	ID	DMKZXV3
DMKZXV3	DN	C[Glu24-Lys28][Gly8]GLP-1(7-37)-NH2
DMKZXV3	HS	Investigative
DMKZXV3	PC	91935387
DMKZXV3	MW	3361.7
DMKZXV3	FM	C149H230N42O47
DMKZXV3	IC	InChI=1S/C149H230N42O47/c1-15-76(10)120(146(236)168-78(12)124(214)178-102(58-83-61-160-88-31-20-19-30-86(83)88)137(227)180-99(55-73(4)5)138(228)188-118(74(6)7)144(234)177-90(32-21-24-50-150)127(217)163-65-111(202)169-89(35-27-53-159-149(155)156)126(216)161-63-108(154)199)190-134(224)92-34-23-26-52-158-109(200)46-41-96(130(220)167-77(11)123(213)172-91(33-22-25-51-151)131(221)176-97(133(223)173-92)44-49-116(209)210)175-132(222)95(40-45-107(153)198)171-112(203)66-164-129(219)94(43-48-115(207)208)174-135(225)98(54-72(2)3)179-136(226)100(57-82-36-38-85(197)39-37-82)181-141(231)104(68-192)184-143(233)106(70-194)185-145(235)119(75(8)9)189-140(230)103(60-117(211)212)182-142(232)105(69-193)186-148(238)122(80(14)196)191-139(229)101(56-81-28-17-16-18-29-81)183-147(237)121(79(13)195)187-113(204)67-165-128(218)93(42-47-114(205)206)170-110(201)64-162-125(215)87(152)59-84-62-157-71-166-84/h16-20,28-31,36-39,61-62,71-80,87,89-106,118-122,160,192-197H,15,21-27,32-35,40-60,63-70,150-152H2,1-14H3,(H2,153,198)(H2,154,199)(H,157,166)(H,158,200)(H,161,216)(H,162,215)(H,163,217)(H,164,219)(H,165,218)(H,167,220)(H,168,236)(H,169,202)(H,170,201)(H,171,203)(H,172,213)(H,173,223)(H,174,225)(H,175,222)(H,176,221)(H,177,234)(H,178,214)(H,179,226)(H,180,227)(H,181,231)(H,182,232)(H,183,237)(H,184,233)(H,185,235)(H,186,238)(H,187,204)(H,188,228)(H,189,230)(H,190,224)(H,191,229)(H,205,206)(H,207,208)(H,209,210)(H,211,212)(H4,155,156,159)/t76-,77-,78-,79+,80-,87-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,118-,119-,120-,121-,122-/m0/s1
DMKZXV3	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@@H]3CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCC(=O)O)CCCCN)C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DMKZXV3	IK	KPGVUBCFEGSCNW-NNIIIAALSA-N
DMKZXV3	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(3S,6S,9S,12S,21S)-21-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]-6-(4-aminobutyl)-3-(2-carboxyethyl)-9-methyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMKZXV3	DE	Discovery agent

DMX2WCZ	ID	DMX2WCZ
DMX2WCZ	DN	C[Glu26-Lys30][Gly8]GLP-1(7-37)-NH2
DMX2WCZ	HS	Investigative
DMX2WCZ	PC	91935391
DMX2WCZ	MW	3380.7
DMX2WCZ	FM	C152H227N41O47
DMX2WCZ	IC	InChI=1S/C152H227N41O47/c1-15-78(10)123-149(238)178-94(134(223)183-105(60-86-63-162-91-34-23-22-33-89(86)91)139(228)180-101(56-75(4)5)140(229)190-121(76(6)7)147(236)177-93(35-24-26-52-153)130(219)165-67-114(204)171-92(37-28-54-161-152(157)158)129(218)163-65-111(156)201)36-25-27-53-160-112(202)48-43-98(135(224)176-99(46-51-119(211)212)136(225)181-103(141(230)192-123)57-83-29-18-16-19-30-83)174-127(216)80(12)169-126(215)79(11)170-133(222)97(42-47-110(155)200)173-115(205)68-166-132(221)96(45-50-118(209)210)175-137(226)100(55-74(2)3)179-138(227)102(59-85-38-40-88(199)41-39-85)182-144(233)107(70-194)186-146(235)109(72-196)187-148(237)122(77(8)9)191-143(232)106(62-120(213)214)184-145(234)108(71-195)188-151(240)125(82(14)198)193-142(231)104(58-84-31-20-17-21-32-84)185-150(239)124(81(13)197)189-116(206)69-167-131(220)95(44-49-117(207)208)172-113(203)66-164-128(217)90(154)61-87-64-159-73-168-87/h16-23,29-34,38-41,63-64,73-82,90,92-109,121-125,162,194-199H,15,24-28,35-37,42-62,65-72,153-154H2,1-14H3,(H2,155,200)(H2,156,201)(H,159,168)(H,160,202)(H,163,218)(H,164,217)(H,165,219)(H,166,221)(H,167,220)(H,169,215)(H,170,222)(H,171,204)(H,172,203)(H,173,205)(H,174,216)(H,175,226)(H,176,224)(H,177,236)(H,178,238)(H,179,227)(H,180,228)(H,181,225)(H,182,233)(H,183,223)(H,184,234)(H,185,239)(H,186,235)(H,187,237)(H,188,240)(H,189,206)(H,190,229)(H,191,232)(H,192,230)(H,193,231)(H,207,208)(H,209,210)(H,211,212)(H,213,214)(H4,157,158,161)/t78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,121-,122-,123-,124-,125-/m0/s1
DMX2WCZ	CS	CC[C@H](C)[C@H]1C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CN=CN5)N)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMX2WCZ	IK	JGAQRLVKKDZZTH-KXYXCEFHSA-N
DMX2WCZ	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,9S,12S,21S)-21-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]-6-benzyl-3-[(2S)-butan-2-yl]-9-(2-carboxyethyl)-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMX2WCZ	DE	Discovery agent

DMTP5YZ	ID	DMTP5YZ
DMTP5YZ	DN	C[hGlu22-Lys26][Gly8]GLP-1(7-37)-NH2
DMTP5YZ	HS	Investigative
DMTP5YZ	PC	91935395
DMTP5YZ	MW	3408.7
DMTP5YZ	FM	C154H231N41O47
DMTP5YZ	IC	InChI=1S/C154H231N41O47/c1-16-79(10)124(151(240)172-82(13)129(218)181-107(62-88-65-164-93-36-24-23-35-91(88)93)141(230)183-103(58-76(4)5)142(231)192-122(77(6)7)149(238)180-95(37-25-27-54-155)132(221)167-69-116(206)173-94(40-30-56-163-154(159)160)131(220)165-67-113(158)203)194-143(232)105(59-85-31-19-17-20-32-85)184-138(227)101(49-53-120(212)213)178-135(224)96-38-26-28-55-162-114(204)41-29-39-97(136(225)177-99(46-50-112(157)202)134(223)171-80(11)127(216)170-81(12)128(217)175-96)176-137(226)100(48-52-119(210)211)179-139(228)102(57-75(2)3)182-140(229)104(61-87-42-44-90(201)45-43-87)185-146(235)109(71-196)188-148(237)111(73-198)189-150(239)123(78(8)9)193-145(234)108(64-121(214)215)186-147(236)110(72-197)190-153(242)126(84(15)200)195-144(233)106(60-86-33-21-18-22-34-86)187-152(241)125(83(14)199)191-117(207)70-168-133(222)98(47-51-118(208)209)174-115(205)68-166-130(219)92(156)63-89-66-161-74-169-89/h17-24,31-36,42-45,65-66,74-84,92,94-111,122-126,164,196-201H,16,25-30,37-41,46-64,67-73,155-156H2,1-15H3,(H2,157,202)(H2,158,203)(H,161,169)(H,162,204)(H,165,220)(H,166,219)(H,167,221)(H,168,222)(H,170,216)(H,171,223)(H,172,240)(H,173,206)(H,174,205)(H,175,217)(H,176,226)(H,177,225)(H,178,224)(H,179,228)(H,180,238)(H,181,218)(H,182,229)(H,183,230)(H,184,227)(H,185,235)(H,186,236)(H,187,241)(H,188,237)(H,189,239)(H,190,242)(H,191,207)(H,192,231)(H,193,234)(H,194,232)(H,195,233)(H,208,209)(H,210,211)(H,212,213)(H,214,215)(H4,159,160,163)/t79-,80-,81-,82-,83-,84-,92-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,122-,123-,124-,125-,126-/m0/s1
DMTP5YZ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCCNC(=O)CCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMTP5YZ	IK	FZOFJRYZQZCXIG-XPPJIRRWSA-N
DMTP5YZ	IU	(4S)-5-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,5S,8S,11S,21S)-11-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-2-(3-amino-3-oxopropyl)-5,8-dimethyl-3,6,9,17,22-pentaoxo-1,4,7,10,16-pentazacyclodocos-21-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMTP5YZ	DE	Discovery agent

DM8HK0J	ID	DM8HK0J
DM8HK0J	DN	C[homoPhe-Hca-Glu-Gly-Leu-Glu-Glu]-NH2
DM8HK0J	HS	Investigative
DM8HK0J	SN	CHEMBL410408; c[homoPhe-Hca-Glu-Gly-Leu-Glu-Glu]-NH2
DM8HK0J	DT	Small molecular drug
DM8HK0J	PC	44428818
DM8HK0J	MW	963
DM8HK0J	FM	C46H58N8O15
DM8HK0J	IC	InChI=1S/C46H58N8O15/c1-24(2)18-33-45(67)53-32(14-17-40(61)62)43(65)49-27(21-36(47)56)9-15-37(57)50-31(12-8-25-6-4-3-5-7-25)44(66)54-34(19-26-20-41(63)69-35-22-28(55)10-11-29(26)35)46(68)52-30(13-16-39(59)60)42(64)48-23-38(58)51-33/h3-7,10-11,20,22,24,27,30-34,55H,8-9,12-19,21,23H2,1-2H3,(H2,47,56)(H,48,64)(H,49,65)(H,50,57)(H,51,58)(H,52,68)(H,53,67)(H,54,66)(H,59,60)(H,61,62)/t27-,30-,31-,32-,33-,34-/m0/s1
DM8HK0J	CS	CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CCC(=O)O)CC2=CC(=O)OC3=C2C=CC(=C3)O)CCC4=CC=CC=C4)CC(=O)N)CCC(=O)O
DM8HK0J	IK	TZBPOQODYKOULE-HDARCNCQSA-N
DM8HK0J	IU	3-[(2S,5S,8S,14S,17S,20S)-20-(2-amino-2-oxoethyl)-17-(2-carboxyethyl)-5-[(7-hydroxy-2-oxochromen-4-yl)methyl]-14-(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-2-(2-phenylethyl)-1,4,7,10,13,16,19-heptazacyclotricos-8-yl]propanoic acid
DM8HK0J	DE	Discovery agent

DMHXTWK	ID	DMHXTWK
DMHXTWK	DN	C[L-Ala-D-pro-L-Phe-D-trp]
DMHXTWK	HS	Investigative
DMHXTWK	SN	CHEMBL499595; c[L-Ala-D-pro-L-Phe-D-trp]; SCHEMBL7991248
DMHXTWK	DT	Small molecular drug
DMHXTWK	PC	44583393
DMHXTWK	MW	501.6
DMHXTWK	FM	C28H31N5O4
DMHXTWK	IC	InChI=1S/C28H31N5O4/c1-17-28(37)33-13-7-12-24(33)27(36)32-22(14-18-8-3-2-4-9-18)26(35)31-23(25(34)30-17)15-19-16-29-21-11-6-5-10-20(19)21/h2-6,8-11,16-17,22-24,29H,7,12-15H2,1H3,(H,30,34)(H,31,35)(H,32,36)/t17-,22-,23+,24+/m0/s1
DMHXTWK	CS	C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5
DMHXTWK	IK	OTUDCPUMJPNZRR-UYGLSEIWSA-N
DMHXTWK	IU	(3S,6R,9S,12R)-9-benzyl-6-(1H-indol-3-ylmethyl)-3-methyl-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMHXTWK	DE	Discovery agent

DMNHSR0	ID	DMNHSR0
DMNHSR0	DN	C[L-mTyr-D-pro-L-Phe-D-trp]
DMNHSR0	HS	Investigative
DMNHSR0	SN	CHEMBL510506; c[L-mTyr-D-pro-L-Phe-D-trp]
DMNHSR0	DT	Small molecular drug
DMNHSR0	PC	44583376
DMNHSR0	MW	593.7
DMNHSR0	FM	C34H35N5O5
DMNHSR0	IC	InChI=1S/C34H35N5O5/c40-24-11-6-10-22(16-24)18-29-34(44)39-15-7-14-30(39)33(43)37-27(17-21-8-2-1-3-9-21)31(41)36-28(32(42)38-29)19-23-20-35-26-13-5-4-12-25(23)26/h1-6,8-13,16,20,27-30,35,40H,7,14-15,17-19H2,(H,36,41)(H,37,43)(H,38,42)/t27-,28+,29-,30+/m0/s1
DMNHSR0	CS	C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC(=CC=C3)O)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DMNHSR0	IK	NMGCCCXRAFVYBR-RRGQHJHPSA-N
DMNHSR0	IU	(3S,6R,9S,12R)-9-benzyl-3-[(3-hydroxyphenyl)methyl]-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMNHSR0	DE	Discovery agent

DM82ZOM	ID	DM82ZOM
DM82ZOM	DN	C[L-Phe-D-pro-L-mTyr-D-trp]
DM82ZOM	HS	Investigative
DM82ZOM	SN	CHEMBL509201; c[L-Phe-D-pro-L-mTyr-D-trp]
DM82ZOM	DT	Small molecular drug
DM82ZOM	PC	44583386
DM82ZOM	MW	593.7
DM82ZOM	FM	C34H35N5O5
DM82ZOM	IC	InChI=1S/C34H35N5O5/c40-24-11-6-10-22(16-24)18-27-31(41)36-28(19-23-20-35-26-13-5-4-12-25(23)26)32(42)38-29(17-21-8-2-1-3-9-21)34(44)39-15-7-14-30(39)33(43)37-27/h1-6,8-13,16,20,27-30,35,40H,7,14-15,17-19H2,(H,36,41)(H,37,43)(H,38,42)/t27-,28+,29-,30+/m0/s1
DM82ZOM	CS	C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CC6=CC(=CC=C6)O
DM82ZOM	IK	NXAWTNITTPJQAL-RRGQHJHPSA-N
DM82ZOM	IU	(3S,6R,9S,12R)-3-benzyl-9-[(3-hydroxyphenyl)methyl]-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM82ZOM	DE	Discovery agent

DM0NTU5	ID	DM0NTU5
DM0NTU5	DN	C[L-Phe-D-pro-L-Phe-D-trp]
DM0NTU5	HS	Investigative
DM0NTU5	SN	CHEMBL502411; c[L-Phe-D-pro-L-Phe-D-trp]; SCHEMBL7980647
DM0NTU5	DT	Small molecular drug
DM0NTU5	PC	44583373
DM0NTU5	MW	577.7
DM0NTU5	FM	C34H35N5O4
DM0NTU5	IC	InChI=1S/C34H35N5O4/c40-31-27(18-22-10-3-1-4-11-22)37-33(42)30-16-9-17-39(30)34(43)29(19-23-12-5-2-6-13-23)38-32(41)28(36-31)20-24-21-35-26-15-8-7-14-25(24)26/h1-8,10-15,21,27-30,35H,9,16-20H2,(H,36,40)(H,37,42)(H,38,41)/t27-,28+,29-,30+/m0/s1
DM0NTU5	CS	C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DM0NTU5	IK	GIZJWWQFOGQPRY-RRGQHJHPSA-N
DM0NTU5	IU	(3S,6R,9S,12R)-3,9-dibenzyl-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM0NTU5	DE	Discovery agent

DMCY4L0	ID	DMCY4L0
DMCY4L0	DN	C[L-Phe-D-pro-L-Phe-L-trp]
DMCY4L0	HS	Investigative
DMCY4L0	SN	CHEMBL506616; CJ-15208; c[L-Phe-D-pro-L-Phe-L-trp]; SCHEMBL12368055
DMCY4L0	DT	Small molecular drug
DMCY4L0	PC	44583372
DMCY4L0	MW	577.7
DMCY4L0	FM	C34H35N5O4
DMCY4L0	IC	InChI=1S/C34H35N5O4/c40-31-27(18-22-10-3-1-4-11-22)37-33(42)30-16-9-17-39(30)34(43)29(19-23-12-5-2-6-13-23)38-32(41)28(36-31)20-24-21-35-26-15-8-7-14-25(24)26/h1-8,10-15,21,27-30,35H,9,16-20H2,(H,36,40)(H,37,42)(H,38,41)/t27-,28-,29-,30+/m0/s1
DMCY4L0	CS	C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DMCY4L0	IK	GIZJWWQFOGQPRY-GCXHJFECSA-N
DMCY4L0	IU	(3S,6S,9S,12R)-3,9-dibenzyl-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMCY4L0	DE	Discovery agent

DM4M3OP	ID	DM4M3OP
DM4M3OP	DN	C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]
DM4M3OP	HS	Investigative
DM4M3OP	SN	CHEMBL506211; c[L-Phe-D-pro-L-Tyr(OMe)-D-trp]
DM4M3OP	DT	Small molecular drug
DM4M3OP	PC	44583388
DM4M3OP	MW	607.7
DM4M3OP	FM	C35H37N5O5
DM4M3OP	IC	InChI=1S/C35H37N5O5/c1-45-25-15-13-23(14-16-25)18-28-32(41)37-29(20-24-21-36-27-11-6-5-10-26(24)27)33(42)39-30(19-22-8-3-2-4-9-22)35(44)40-17-7-12-31(40)34(43)38-28/h2-6,8-11,13-16,21,28-31,36H,7,12,17-20H2,1H3,(H,37,41)(H,38,43)(H,39,42)/t28-,29+,30-,31+/m0/s1
DM4M3OP	CS	COC1=CC=C(C=C1)C[C@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N3CCC[C@@H]3C(=O)N2)CC4=CC=CC=C4)CC5=CNC6=CC=CC=C65
DM4M3OP	IK	UWYXKSHDABLYGG-XFBWMNOSSA-N
DM4M3OP	IU	(3S,6R,9S,12R)-3-benzyl-6-(1H-indol-3-ylmethyl)-9-[(4-methoxyphenyl)methyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM4M3OP	DE	Discovery agent

DMADSBT	ID	DMADSBT
DMADSBT	DN	C[L-Phe-D-pro-L-Tyr-D-trp]
DMADSBT	HS	Investigative
DMADSBT	SN	CHEMBL486388; c[L-Phe-D-pro-L-Tyr-D-trp]
DMADSBT	DT	Small molecular drug
DMADSBT	PC	44583375
DMADSBT	MW	593.7
DMADSBT	FM	C34H35N5O5
DMADSBT	IC	InChI=1S/C34H35N5O5/c40-24-14-12-22(13-15-24)17-27-31(41)36-28(19-23-20-35-26-10-5-4-9-25(23)26)32(42)38-29(18-21-7-2-1-3-8-21)34(44)39-16-6-11-30(39)33(43)37-27/h1-5,7-10,12-15,20,27-30,35,40H,6,11,16-19H2,(H,36,41)(H,37,43)(H,38,42)/t27-,28+,29-,30+/m0/s1
DMADSBT	CS	C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CC6=CC=C(C=C6)O
DMADSBT	IK	YMZQUJVCPUZHJG-RRGQHJHPSA-N
DMADSBT	IU	(3S,6R,9S,12R)-3-benzyl-9-[(4-hydroxyphenyl)methyl]-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMADSBT	DE	Discovery agent

DMLB6UA	ID	DMLB6UA
DMLB6UA	DN	C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]
DMLB6UA	HS	Investigative
DMLB6UA	SN	CHEMBL507127; c[L-Tyr(OMe)-D-pro-L-Phe-D-trp]
DMLB6UA	DT	Small molecular drug
DMLB6UA	PC	44583387
DMLB6UA	MW	607.7
DMLB6UA	FM	C35H37N5O5
DMLB6UA	IC	InChI=1S/C35H37N5O5/c1-45-25-15-13-23(14-16-25)19-30-35(44)40-17-7-12-31(40)34(43)38-28(18-22-8-3-2-4-9-22)32(41)37-29(33(42)39-30)20-24-21-36-27-11-6-5-10-26(24)27/h2-6,8-11,13-16,21,28-31,36H,7,12,17-20H2,1H3,(H,37,41)(H,38,43)(H,39,42)/t28-,29+,30-,31+/m0/s1
DMLB6UA	CS	COC1=CC=C(C=C1)C[C@H]2C(=O)N3CCC[C@@H]3C(=O)N[C@H](C(=O)N[C@@H](C(=O)N2)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DMLB6UA	IK	OGVYQAXJPKYKOQ-XFBWMNOSSA-N
DMLB6UA	IU	(3S,6R,9S,12R)-9-benzyl-6-(1H-indol-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMLB6UA	DE	Discovery agent

DM7OIY8	ID	DM7OIY8
DM7OIY8	DN	C[L-Tyr-D-pro-L-Phe-D-trp]
DM7OIY8	HS	Investigative
DM7OIY8	SN	CHEMBL506217; c[L-Tyr-D-pro-L-Phe-D-trp]
DM7OIY8	DT	Small molecular drug
DM7OIY8	PC	44583374
DM7OIY8	MW	593.7
DM7OIY8	FM	C34H35N5O5
DM7OIY8	IC	InChI=1S/C34H35N5O5/c40-24-14-12-22(13-15-24)18-29-34(44)39-16-6-11-30(39)33(43)37-27(17-21-7-2-1-3-8-21)31(41)36-28(32(42)38-29)19-23-20-35-26-10-5-4-9-25(23)26/h1-5,7-10,12-15,20,27-30,35,40H,6,11,16-19H2,(H,36,41)(H,37,43)(H,38,42)/t27-,28+,29-,30+/m0/s1
DM7OIY8	CS	C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=C(C=C3)O)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DM7OIY8	IK	YTXYSUHLDDXFGK-RRGQHJHPSA-N
DM7OIY8	IU	(3S,6R,9S,12R)-9-benzyl-3-[(4-hydroxyphenyl)methyl]-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM7OIY8	DE	Discovery agent

DMX7IVO	ID	DMX7IVO
DMX7IVO	DN	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2
DMX7IVO	HS	Investigative
DMX7IVO	SN	CHEMBL204263; BDBM50184365
DMX7IVO	DT	Small molecular drug
DMX7IVO	PC	44408515
DMX7IVO	MW	937.1
DMX7IVO	FM	C47H64N14O7
DMX7IVO	IC	InChI=1S/C47H64N14O7/c1-2-3-13-34-41(64)58-35(15-8-21-53-46(49)50)42(65)60-37(24-27-17-18-28-10-4-5-11-29(28)23-27)44(67)59-36(16-9-22-54-47(51)52)43(66)61-38(25-30-26-55-32-14-7-6-12-31(30)32)45(68)57-33(40(48)63)19-20-39(62)56-34/h4-7,10-12,14,17-18,23,26,33-38,55H,2-3,8-9,13,15-16,19-22,24-25H2,1H3,(H2,48,63)(H,56,62)(H,57,68)(H,58,64)(H,59,67)(H,60,65)(H,61,66)(H4,49,50,53)(H4,51,52,54)/t33-,34-,35+,36-,37+,38-/m0/s1
DMX7IVO	CS	CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CCCN=C(N)N
DMX7IVO	IK	UHCXNXMBPAFWDS-VRHOQGROSA-N
DMX7IVO	IU	(2S,5R,8R,11S,14S,17S)-2-butyl-5,11-bis[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMX7IVO	DE	Discovery agent

DMUESCH	ID	DMUESCH
DMUESCH	DN	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2
DMUESCH	HS	Investigative
DMUESCH	SN	CHEMBL263822; c[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2
DMUESCH	DT	Small molecular drug
DMUESCH	PC	44408443
DMUESCH	MW	887
DMUESCH	FM	C43H62N14O7
DMUESCH	IC	InChI=1S/C43H62N14O7/c1-2-3-14-30-37(60)54-31(16-9-20-49-42(45)46)38(61)56-33(22-25-11-5-4-6-12-25)40(63)55-32(17-10-21-50-43(47)48)39(62)57-34(23-26-24-51-28-15-8-7-13-27(26)28)41(64)53-29(36(44)59)18-19-35(58)52-30/h4-8,11-13,15,24,29-34,51H,2-3,9-10,14,16-23H2,1H3,(H2,44,59)(H,52,58)(H,53,64)(H,54,60)(H,55,63)(H,56,61)(H,57,62)(H4,45,46,49)(H4,47,48,50)/t29-,30-,31+,32-,33+,34-/m0/s1
DMUESCH	CS	CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CCCN=C(N)N
DMUESCH	IK	OVCXMKITXFVUSL-AIQTWYNVSA-N
DMUESCH	IU	(2S,5R,8R,11S,14S,17S)-8-benzyl-2-butyl-5,11-bis[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMUESCH	DE	Discovery agent

DM8SXLR	ID	DM8SXLR
DM8SXLR	DN	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2
DM8SXLR	HS	Investigative
DM8SXLR	SN	CHEMBL409144; BDBM50184350
DM8SXLR	DT	Small molecular drug
DM8SXLR	PC	44408400
DM8SXLR	MW	896
DM8SXLR	FM	C45H57N11O9
DM8SXLR	IC	InChI=1S/C45H57N11O9/c1-2-3-12-32-40(61)56-36(23-38(58)59)44(65)54-34(21-25-15-16-26-9-4-5-10-27(26)20-25)42(63)53-33(14-8-19-49-45(47)48)41(62)55-35(22-28-24-50-30-13-7-6-11-29(28)30)43(64)52-31(39(46)60)17-18-37(57)51-32/h4-7,9-11,13,15-16,20,24,31-36,50H,2-3,8,12,14,17-19,21-23H2,1H3,(H2,46,60)(H,51,57)(H,52,64)(H,53,63)(H,54,65)(H,55,62)(H,56,61)(H,58,59)(H4,47,48,49)/t31-,32-,33-,34+,35-,36+/m0/s1
DM8SXLR	CS	CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CC(=O)O
DM8SXLR	IK	VKDMHINLWUJYEZ-XBWXEZBPSA-N
DM8SXLR	IU	2-[(2S,5R,8R,11S,14S,17S)-2-butyl-17-carbamoyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicos-5-yl]acetic acid
DM8SXLR	DE	Discovery agent

DMXJAOI	ID	DMXJAOI
DMXJAOI	DN	C[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2
DMXJAOI	HS	Investigative
DMXJAOI	SN	CHEMBL203170; c[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2
DMXJAOI	DT	Small molecular drug
DMXJAOI	PC	11629290
DMXJAOI	MW	845.9
DMXJAOI	FM	C41H55N11O9
DMXJAOI	IC	InChI=1S/C41H55N11O9/c1-2-3-13-28-36(57)52-32(21-34(54)55)40(61)50-30(19-23-10-5-4-6-11-23)38(59)49-29(15-9-18-45-41(43)44)37(58)51-31(20-24-22-46-26-14-8-7-12-25(24)26)39(60)48-27(35(42)56)16-17-33(53)47-28/h4-8,10-12,14,22,27-32,46H,2-3,9,13,15-21H2,1H3,(H2,42,56)(H,47,53)(H,48,60)(H,49,59)(H,50,61)(H,51,58)(H,52,57)(H,54,55)(H4,43,44,45)/t27-,28-,29-,30+,31-,32-/m0/s1
DMXJAOI	CS	CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC(=O)O
DMXJAOI	IK	HUAMIBCEKZFYST-BCLKUREPSA-N
DMXJAOI	IU	2-[(2S,5S,8R,11S,14S,17S)-8-benzyl-2-butyl-17-carbamoyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicos-5-yl]acetic acid
DMXJAOI	DE	Discovery agent

DMM19SJ	ID	DMM19SJ
DMM19SJ	DN	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2
DMM19SJ	HS	Investigative
DMM19SJ	SN	CHEMBL204310; BDBM50184355
DMM19SJ	DT	Small molecular drug
DMM19SJ	PC	11498895
DMM19SJ	MW	909
DMM19SJ	FM	C46H60N12O8
DMM19SJ	IC	InChI=1S/C46H60N12O8/c1-2-3-12-33-41(62)56-35(17-19-38(47)59)43(64)57-36(23-26-15-16-27-9-4-5-10-28(27)22-26)44(65)55-34(14-8-21-51-46(49)50)42(63)58-37(24-29-25-52-31-13-7-6-11-30(29)31)45(66)54-32(40(48)61)18-20-39(60)53-33/h4-7,9-11,13,15-16,22,25,32-37,52H,2-3,8,12,14,17-21,23-24H2,1H3,(H2,47,59)(H2,48,61)(H,53,60)(H,54,66)(H,55,65)(H,56,62)(H,57,64)(H,58,63)(H4,49,50,51)/t32-,33-,34-,35-,36+,37-/m0/s1
DMM19SJ	CS	CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CCC(=O)N
DMM19SJ	IK	TUOOEJAUOYDGGA-BWBQVKFQSA-N
DMM19SJ	IU	(2S,5S,8R,11S,14S,17S)-5-(3-amino-3-oxopropyl)-2-butyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMM19SJ	DE	Discovery agent

DMSGWZE	ID	DMSGWZE
DMSGWZE	DN	C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2
DMSGWZE	HS	Investigative
DMSGWZE	SN	CHEMBL203602; c[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2
DMSGWZE	DT	Small molecular drug
DMSGWZE	PC	44408413
DMSGWZE	MW	859
DMSGWZE	FM	C42H58N12O8
DMSGWZE	IC	InChI=1S/C42H58N12O8/c1-2-3-13-29-37(58)52-31(16-18-34(43)55)39(60)53-32(21-24-10-5-4-6-11-24)40(61)51-30(15-9-20-47-42(45)46)38(59)54-33(22-25-23-48-27-14-8-7-12-26(25)27)41(62)50-28(36(44)57)17-19-35(56)49-29/h4-8,10-12,14,23,28-33,48H,2-3,9,13,15-22H2,1H3,(H2,43,55)(H2,44,57)(H,49,56)(H,50,62)(H,51,61)(H,52,58)(H,53,60)(H,54,59)(H4,45,46,47)/t28-,29-,30-,31+,32+,33-/m0/s1
DMSGWZE	CS	CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CCC(=O)N
DMSGWZE	IK	RNMRQCPIALKVBK-HSPZZYPGSA-N
DMSGWZE	IU	(2S,5R,8R,11S,14S,17S)-5-(3-amino-3-oxopropyl)-8-benzyl-2-butyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMSGWZE	DE	Discovery agent

DMHNCAG	ID	DMHNCAG
DMHNCAG	DN	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2
DMHNCAG	HS	Investigative
DMHNCAG	SN	CHEMBL383250; BDBM50184354
DMHNCAG	DT	Small molecular drug
DMHNCAG	PC	11520823
DMHNCAG	MW	910
DMHNCAG	FM	C46H59N11O9
DMHNCAG	IC	InChI=1S/C46H59N11O9/c1-2-3-12-33-41(62)55-35(18-20-39(59)60)43(64)56-36(23-26-15-16-27-9-4-5-10-28(27)22-26)44(65)54-34(14-8-21-50-46(48)49)42(63)57-37(24-29-25-51-31-13-7-6-11-30(29)31)45(66)53-32(40(47)61)17-19-38(58)52-33/h4-7,9-11,13,15-16,22,25,32-37,51H,2-3,8,12,14,17-21,23-24H2,1H3,(H2,47,61)(H,52,58)(H,53,66)(H,54,65)(H,55,62)(H,56,64)(H,57,63)(H,59,60)(H4,48,49,50)/t32-,33-,34-,35-,36+,37-/m0/s1
DMHNCAG	CS	CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CCC(=O)O
DMHNCAG	IK	PAILFUNFWZLMMN-BWBQVKFQSA-N
DMHNCAG	IU	3-[(2S,5S,8R,11S,14S,17S)-2-butyl-17-carbamoyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicos-5-yl]propanoic acid
DMHNCAG	DE	Discovery agent

DMVWOPG	ID	DMVWOPG
DMVWOPG	DN	C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2
DMVWOPG	HS	Investigative
DMVWOPG	SN	CHEMBL382369; c[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2
DMVWOPG	DT	Small molecular drug
DMVWOPG	PC	44408399
DMVWOPG	MW	860
DMVWOPG	FM	C42H57N11O9
DMVWOPG	IC	InChI=1S/C42H57N11O9/c1-2-3-13-29-37(58)51-31(17-19-35(55)56)39(60)52-32(21-24-10-5-4-6-11-24)40(61)50-30(15-9-20-46-42(44)45)38(59)53-33(22-25-23-47-27-14-8-7-12-26(25)27)41(62)49-28(36(43)57)16-18-34(54)48-29/h4-8,10-12,14,23,28-33,47H,2-3,9,13,15-22H2,1H3,(H2,43,57)(H,48,54)(H,49,62)(H,50,61)(H,51,58)(H,52,60)(H,53,59)(H,55,56)(H4,44,45,46)/t28-,29-,30-,31+,32+,33-/m0/s1
DMVWOPG	CS	CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CCC(=O)O
DMVWOPG	IK	ZIKRFHYQHLHVCP-HSPZZYPGSA-N
DMVWOPG	IU	3-[(2S,5R,8R,11S,14S,17S)-8-benzyl-2-butyl-17-carbamoyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicos-5-yl]propanoic acid
DMVWOPG	DE	Discovery agent

DM36HBK	ID	DM36HBK
DM36HBK	DN	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2
DM36HBK	HS	Investigative
DM36HBK	SN	CHEMBL425591; BDBM50184356
DM36HBK	DT	Small molecular drug
DM36HBK	PC	11672424
DM36HBK	MW	918.1
DM36HBK	FM	C47H59N13O7
DM36HBK	IC	InChI=1S/C47H59N13O7/c1-2-3-12-35-42(63)60-39(23-31-25-51-26-54-31)46(67)58-37(21-27-15-16-28-9-4-5-10-29(28)20-27)44(65)57-36(14-8-19-52-47(49)50)43(64)59-38(22-30-24-53-33-13-7-6-11-32(30)33)45(66)56-34(41(48)62)17-18-40(61)55-35/h4-7,9-11,13,15-16,20,24-26,34-39,53H,2-3,8,12,14,17-19,21-23H2,1H3,(H2,48,62)(H,51,54)(H,55,61)(H,56,66)(H,57,65)(H,58,67)(H,59,64)(H,60,63)(H4,49,50,52)/t34-,35-,36-,37+,38-,39-/m0/s1
DM36HBK	CS	CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CC6=CN=CN6
DM36HBK	IK	AYKQERUAGGPJLP-WYLITWLFSA-N
DM36HBK	IU	(2S,5S,8R,11S,14S,17S)-2-butyl-11-[3-(diaminomethylideneamino)propyl]-5-(1H-imidazol-5-ylmethyl)-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DM36HBK	DE	Discovery agent

DM5HRNM	ID	DM5HRNM
DM5HRNM	DN	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2
DM5HRNM	HS	Investigative
DM5HRNM	SN	CHEMBL446185; c[Nle-His-D-Phe-Arg-Trp-Glu]-NH2
DM5HRNM	DT	Small molecular drug
DM5HRNM	PC	11535237
DM5HRNM	MW	868
DM5HRNM	FM	C43H57N13O7
DM5HRNM	IC	InChI=1S/C43H57N13O7/c1-2-3-13-31-38(59)56-35(21-27-23-47-24-50-27)42(63)54-33(19-25-10-5-4-6-11-25)40(61)53-32(15-9-18-48-43(45)46)39(60)55-34(20-26-22-49-29-14-8-7-12-28(26)29)41(62)52-30(37(44)58)16-17-36(57)51-31/h4-8,10-12,14,22-24,30-35,49H,2-3,9,13,15-21H2,1H3,(H2,44,58)(H,47,50)(H,51,57)(H,52,62)(H,53,61)(H,54,63)(H,55,60)(H,56,59)(H4,45,46,48)/t30-,31-,32-,33+,34-,35-/m0/s1
DM5HRNM	CS	CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DM5HRNM	IK	JWVUTJWCWBNVDW-CXJNCMCBSA-N
DM5HRNM	IU	(2S,5S,8R,11S,14S,17S)-8-benzyl-2-butyl-11-[3-(diaminomethylideneamino)propyl]-5-(1H-imidazol-5-ylmethyl)-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DM5HRNM	DE	Discovery agent

DM73ZMG	ID	DM73ZMG
DM73ZMG	DN	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2
DM73ZMG	HS	Investigative
DM73ZMG	SN	CHEMBL204864; BDBM50184360
DM73ZMG	DT	Small molecular drug
DM73ZMG	PC	11700739
DM73ZMG	MW	894.1
DM73ZMG	FM	C47H63N11O7
DM73ZMG	IC	InChI=1S/C47H63N11O7/c1-3-5-15-35-42(61)55-36(16-6-4-2)43(62)57-38(25-28-19-20-29-12-7-8-13-30(29)24-28)45(64)56-37(18-11-23-51-47(49)50)44(63)58-39(26-31-27-52-33-17-10-9-14-32(31)33)46(65)54-34(41(48)60)21-22-40(59)53-35/h7-10,12-14,17,19-20,24,27,34-39,52H,3-6,11,15-16,18,21-23,25-26H2,1-2H3,(H2,48,60)(H,53,59)(H,54,65)(H,55,61)(H,56,64)(H,57,62)(H,58,63)(H4,49,50,51)/t34-,35-,36-,37-,38+,39-/m0/s1
DM73ZMG	CS	CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CCCC
DM73ZMG	IK	TYFFXNLNRYRUAU-LFSOJSGESA-N
DM73ZMG	IU	(2S,5S,8R,11S,14S,17S)-2,5-dibutyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DM73ZMG	DE	Discovery agent

DMDPBVS	ID	DMDPBVS
DMDPBVS	DN	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2
DMDPBVS	HS	Investigative
DMDPBVS	SN	CHEMBL380638; c[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2
DMDPBVS	DT	Small molecular drug
DMDPBVS	PC	11707715
DMDPBVS	MW	844
DMDPBVS	FM	C43H61N11O7
DMDPBVS	IC	InChI=1S/C43H61N11O7/c1-3-5-16-31-38(57)51-32(17-6-4-2)39(58)53-34(23-26-13-8-7-9-14-26)41(60)52-33(19-12-22-47-43(45)46)40(59)54-35(24-27-25-48-29-18-11-10-15-28(27)29)42(61)50-30(37(44)56)20-21-36(55)49-31/h7-11,13-15,18,25,30-35,48H,3-6,12,16-17,19-24H2,1-2H3,(H2,44,56)(H,49,55)(H,50,61)(H,51,57)(H,52,60)(H,53,58)(H,54,59)(H4,45,46,47)/t30-,31-,32-,33-,34+,35-/m0/s1
DMDPBVS	CS	CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CCCC
DMDPBVS	IK	WGLOHHGRWPHJBM-MAVCTHMOSA-N
DMDPBVS	IU	(2S,5S,8R,11S,14S,17S)-8-benzyl-2,5-dibutyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMDPBVS	DE	Discovery agent

DMPZ4VB	ID	DMPZ4VB
DMPZ4VB	DN	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2
DMPZ4VB	HS	Investigative
DMPZ4VB	SN	CHEMBL203760; BDBM50184366
DMPZ4VB	DT	Small molecular drug
DMPZ4VB	PC	11629326
DMPZ4VB	MW	878
DMPZ4VB	FM	C46H59N11O7
DMPZ4VB	IC	InChI=1S/C46H59N11O7/c1-2-3-13-35-45(64)57-22-9-16-38(57)44(63)56-36(24-27-17-18-28-10-4-5-11-29(28)23-27)42(61)54-34(15-8-21-50-46(48)49)41(60)55-37(25-30-26-51-32-14-7-6-12-31(30)32)43(62)53-33(40(47)59)19-20-39(58)52-35/h4-7,10-12,14,17-18,23,26,33-38,51H,2-3,8-9,13,15-16,19-22,24-25H2,1H3,(H2,47,59)(H,52,58)(H,53,62)(H,54,61)(H,55,60)(H,56,63)(H4,48,49,50)/t33-,34-,35-,36+,37-,38-/m0/s1
DMPZ4VB	CS	CCCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC6=CC=CC=C6C=C5
DMPZ4VB	IK	QQCJWXXVYXUARZ-ZPRVLUMXSA-N
DMPZ4VB	IU	(3S,8S,11S,14S,17R,20S)-3-butyl-14-[3-(diaminomethylideneamino)propyl]-11-(1H-indol-3-ylmethyl)-17-(naphthalen-2-ylmethyl)-2,5,10,13,16,19-hexaoxo-1,4,9,12,15,18-hexazabicyclo[18.3.0]tricosane-8-carboxamide
DMPZ4VB	DE	Discovery agent

DMZWMV0	ID	DMZWMV0
DMZWMV0	DN	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2
DMZWMV0	HS	Investigative
DMZWMV0	SN	CHEMBL381739; c[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2
DMZWMV0	DT	Small molecular drug
DMZWMV0	PC	44408408
DMZWMV0	MW	828
DMZWMV0	FM	C42H57N11O7
DMZWMV0	IC	InChI=1S/C42H57N11O7/c1-2-3-14-31-41(60)53-21-10-17-34(53)40(59)52-32(22-25-11-5-4-6-12-25)38(57)50-30(16-9-20-46-42(44)45)37(56)51-33(23-26-24-47-28-15-8-7-13-27(26)28)39(58)49-29(36(43)55)18-19-35(54)48-31/h4-8,11-13,15,24,29-34,47H,2-3,9-10,14,16-23H2,1H3,(H2,43,55)(H,48,54)(H,49,58)(H,50,57)(H,51,56)(H,52,59)(H4,44,45,46)/t29-,30-,31-,32+,33-,34+/m0/s1
DMZWMV0	CS	CCCC[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5
DMZWMV0	IK	AKNCBPIMUGVGES-IPLXUGDNSA-N
DMZWMV0	IU	(3S,8S,11S,14S,17R,20R)-17-benzyl-3-butyl-14-[3-(diaminomethylideneamino)propyl]-11-(1H-indol-3-ylmethyl)-2,5,10,13,16,19-hexaoxo-1,4,9,12,15,18-hexazabicyclo[18.3.0]tricosane-8-carboxamide
DMZWMV0	DE	Discovery agent

DMSIGJW	ID	DMSIGJW
DMSIGJW	DN	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2
DMSIGJW	HS	Investigative
DMSIGJW	SN	CHEMBL413573; BDBM50184361
DMSIGJW	DT	Small molecular drug
DMSIGJW	PC	11700730
DMSIGJW	MW	880
DMSIGJW	FM	C46H61N11O7
DMSIGJW	IC	InChI=1S/C46H61N11O7/c1-4-5-14-34-42(61)57-39(26(2)3)45(64)56-36(23-27-17-18-28-11-6-7-12-29(28)22-27)43(62)54-35(16-10-21-50-46(48)49)41(60)55-37(24-30-25-51-32-15-9-8-13-31(30)32)44(63)53-33(40(47)59)19-20-38(58)52-34/h6-9,11-13,15,17-18,22,25-26,33-37,39,51H,4-5,10,14,16,19-21,23-24H2,1-3H3,(H2,47,59)(H,52,58)(H,53,63)(H,54,62)(H,55,60)(H,56,64)(H,57,61)(H4,48,49,50)/t33-,34-,35-,36+,37-,39-/m0/s1
DMSIGJW	CS	CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)C(C)C
DMSIGJW	IK	GVZTZLFKKLVBJF-JDABYTJISA-N
DMSIGJW	IU	(2S,5S,8R,11S,14S,17S)-2-butyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-5-propan-2-yl-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMSIGJW	DE	Discovery agent

DM45ZLW	ID	DM45ZLW
DM45ZLW	DN	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2
DM45ZLW	HS	Investigative
DM45ZLW	SN	CHEMBL427205; c[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2
DM45ZLW	DT	Small molecular drug
DM45ZLW	PC	11593084
DM45ZLW	MW	830
DM45ZLW	FM	C42H59N11O7
DM45ZLW	IC	InChI=1S/C42H59N11O7/c1-4-5-15-30-38(57)53-35(24(2)3)41(60)52-32(21-25-12-7-6-8-13-25)39(58)50-31(17-11-20-46-42(44)45)37(56)51-33(22-26-23-47-28-16-10-9-14-27(26)28)40(59)49-29(36(43)55)18-19-34(54)48-30/h6-10,12-14,16,23-24,29-33,35,47H,4-5,11,15,17-22H2,1-3H3,(H2,43,55)(H,48,54)(H,49,59)(H,50,58)(H,51,56)(H,52,60)(H,53,57)(H4,44,45,46)/t29-,30-,31-,32+,33-,35-/m0/s1
DM45ZLW	CS	CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)C(C)C
DM45ZLW	IK	STHTUYXXUBUJIE-NMIKHESWSA-N
DM45ZLW	IU	(2S,5S,8R,11S,14S,17S)-8-benzyl-2-butyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-5-propan-2-yl-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DM45ZLW	DE	Discovery agent

DMF091Y	ID	DMF091Y
DMF091Y	DN	C[RGD-(R)-alpha-TfmfV]
DMF091Y	HS	Investigative
DMF091Y	SN	CHEMBL377066; c[RGD-(R)-alpha-TfmfV]
DMF091Y	DT	Small molecular drug
DMF091Y	PC	44408397
DMF091Y	MW	690.7
DMF091Y	FM	C31H37F3N8O7
DMF091Y	IC	InChI=1S/C31H37F3N8O7/c32-31(33,34)30(16-19-10-5-2-6-11-19)28(49)41-21(14-18-8-3-1-4-9-18)26(47)40-20(12-7-13-37-29(35)36)25(46)38-17-23(43)39-22(15-24(44)45)27(48)42-30/h1-6,8-11,20-22H,7,12-17H2,(H,38,46)(H,39,43)(H,40,47)(H,41,49)(H,42,48)(H,44,45)(H4,35,36,37)/t20-,21-,22-,30+/m0/s1
DMF091Y	CS	C1C(=O)N[C@H](C(=O)N[C@@](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CC=CC=C2)(CC3=CC=CC=C3)C(F)(F)F)CC(=O)O
DMF091Y	IK	UVOUWFPJSKSTMI-YNJMIAMQSA-N
DMF091Y	IU	2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-5-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMF091Y	DE	Discovery agent

DMC9G2Y	ID	DMC9G2Y
DMC9G2Y	DN	C[RGD-(S)-alpha-TfmfV]
DMC9G2Y	HS	Investigative
DMC9G2Y	SN	CHEMBL379056; c[RGD-(S)-alpha-TfmfV]
DMC9G2Y	DT	Small molecular drug
DMC9G2Y	PC	9986643
DMC9G2Y	MW	642.6
DMC9G2Y	FM	C27H37F3N8O7
DMC9G2Y	IC	InChI=1S/C27H37F3N8O7/c1-14(2)20-23(44)36-16(9-6-10-33-25(31)32)21(42)34-13-18(39)35-17(11-19(40)41)22(43)38-26(24(45)37-20,27(28,29)30)12-15-7-4-3-5-8-15/h3-5,7-8,14,16-17,20H,6,9-13H2,1-2H3,(H,34,42)(H,35,39)(H,36,44)(H,37,45)(H,38,43)(H,40,41)(H4,31,32,33)/t16-,17-,20-,26-/m0/s1
DMC9G2Y	CS	CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@](C(=O)N1)(CC2=CC=CC=C2)C(F)(F)F)CC(=O)O)CCCN=C(N)N
DMC9G2Y	IK	IIJWLNNXJHIKND-CVJKZBOTSA-N
DMC9G2Y	IU	2-[(2S,5S,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-5-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMC9G2Y	DE	Discovery agent

DM1DMR2	ID	DM1DMR2
DM1DMR2	DN	C[RGDf-(3R)-Carboxymorpholine]
DM1DMR2	HS	Investigative
DM1DMR2	SN	CHEMBL443362; c[RGDf-(3R)-Carboxymorpholine]
DM1DMR2	DT	Small molecular drug
DM1DMR2	PC	44123805
DM1DMR2	MW	588.6
DM1DMR2	FM	C26H36N8O8
DM1DMR2	IC	InChI=1S/C26H36N8O8/c27-26(28)29-8-4-7-16-22(38)30-13-20(35)31-17(12-21(36)37)23(39)33-18(11-15-5-2-1-3-6-15)25(41)34-9-10-42-14-19(34)24(40)32-16/h1-3,5-6,16-19H,4,7-14H2,(H,30,38)(H,31,35)(H,32,40)(H,33,39)(H,36,37)(H4,27,28,29)/t16-,17-,18+,19+/m0/s1
DM1DMR2	CS	C1COC[C@H]2N1C(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)CC3=CC=CC=C3
DM1DMR2	IK	HKLGBIAIHDSNGD-INDMIFKZSA-N
DM1DMR2	IU	2-[(3R,6S,12S,15R)-3-benzyl-12-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14-pentaoxo-17-oxa-1,4,7,10,13-pentazabicyclo[13.4.0]nonadecan-6-yl]acetic acid
DM1DMR2	DE	Discovery agent

DM0ULZM	ID	DM0ULZM
DM0ULZM	DN	C[RGDf-(3S)-Carboxymorpholine]
DM0ULZM	HS	Investigative
DM0ULZM	SN	CHEMBL452724; c[RGDf-(3S)-Carboxymorpholine]
DM0ULZM	DT	Small molecular drug
DM0ULZM	PC	44123804
DM0ULZM	MW	588.6
DM0ULZM	FM	C26H36N8O8
DM0ULZM	IC	InChI=1S/C26H36N8O8/c27-26(28)29-8-4-7-16-22(38)30-13-20(35)31-17(12-21(36)37)23(39)33-18(11-15-5-2-1-3-6-15)25(41)34-9-10-42-14-19(34)24(40)32-16/h1-3,5-6,16-19H,4,7-14H2,(H,30,38)(H,31,35)(H,32,40)(H,33,39)(H,36,37)(H4,27,28,29)/t16-,17-,18+,19-/m0/s1
DM0ULZM	CS	C1COC[C@@H]2N1C(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)CC3=CC=CC=C3
DM0ULZM	IK	HKLGBIAIHDSNGD-OKYOBFRVSA-N
DM0ULZM	IU	2-[(3R,6S,12S,15S)-3-benzyl-12-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14-pentaoxo-17-oxa-1,4,7,10,13-pentazabicyclo[13.4.0]nonadecan-6-yl]acetic acid
DM0ULZM	DE	Discovery agent

DMXA0JB	ID	DMXA0JB
DMXA0JB	DN	C[RGDf-(R)-alpha-TfmF]
DMXA0JB	HS	Investigative
DMXA0JB	SN	CHEMBL381589; c[RGDf-(R)-alpha-TfmF]
DMXA0JB	DT	Small molecular drug
DMXA0JB	PC	11636164
DMXA0JB	MW	690.7
DMXA0JB	FM	C31H37F3N8O7
DMXA0JB	IC	InChI=1S/C31H37F3N8O7/c32-31(33,34)30(16-19-10-5-2-6-11-19)28(49)41-20(12-7-13-37-29(35)36)25(46)38-17-23(43)39-22(15-24(44)45)26(47)40-21(27(48)42-30)14-18-8-3-1-4-9-18/h1-6,8-11,20-22H,7,12-17H2,(H,38,46)(H,39,43)(H,40,47)(H,41,49)(H,42,48)(H,44,45)(H4,35,36,37)/t20-,21+,22-,30+/m0/s1
DMXA0JB	CS	C1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)(CC2=CC=CC=C2)C(F)(F)F)CC3=CC=CC=C3)CC(=O)O
DMXA0JB	IK	QAYABLFYSHKUBR-ULBBTDGDSA-N
DMXA0JB	IU	2-[(2S,5R,8R,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMXA0JB	DE	Discovery agent

DM8FGMA	ID	DM8FGMA
DM8FGMA	DN	C[RGDf-(R)-alpha-TfmV]
DM8FGMA	HS	Investigative
DM8FGMA	SN	CHEMBL203077; c[RGDf-(R)-alpha-TfmV]
DM8FGMA	DT	Small molecular drug
DM8FGMA	PC	11505585
DM8FGMA	MW	642.6
DM8FGMA	FM	C27H37F3N8O7
DM8FGMA	IC	InChI=1S/C27H37F3N8O7/c1-14(2)26(27(28,29)30)24(45)37-16(9-6-10-33-25(31)32)21(42)34-13-19(39)35-18(12-20(40)41)22(43)36-17(23(44)38-26)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18H,6,9-13H2,1-2H3,(H,34,42)(H,35,39)(H,36,43)(H,37,45)(H,38,44)(H,40,41)(H4,31,32,33)/t16-,17+,18-,26+/m0/s1
DM8FGMA	CS	CC(C)[C@@]1(C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N)C(F)(F)F
DM8FGMA	IK	VYIBTYZRYKIMKX-ORVYPBFBSA-N
DM8FGMA	IU	2-[(2S,5R,8R,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM8FGMA	DE	Discovery agent

DM4ZWOD	ID	DM4ZWOD
DM4ZWOD	DN	C[RGDf-(R)-N-Me-alpha-TfmF]
DM4ZWOD	HS	Investigative
DM4ZWOD	SN	CHEMBL381590; c[RGDf-(R)-N-Me-alpha-TfmF]
DM4ZWOD	DT	Small molecular drug
DM4ZWOD	PC	11643340
DM4ZWOD	MW	704.7
DM4ZWOD	FM	C32H39F3N8O7
DM4ZWOD	IC	InChI=1S/C32H39F3N8O7/c1-43-28(49)23(15-19-9-4-2-5-10-19)41-27(48)22(16-25(45)46)40-24(44)18-39-26(47)21(13-8-14-38-30(36)37)42-29(50)31(43,32(33,34)35)17-20-11-6-3-7-12-20/h2-7,9-12,21-23H,8,13-18H2,1H3,(H,39,47)(H,40,44)(H,41,48)(H,42,50)(H,45,46)(H4,36,37,38)/t21-,22-,23+,31+/m0/s1
DM4ZWOD	CS	CN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@]1(CC2=CC=CC=C2)C(F)(F)F)CCCN=C(N)N)CC(=O)O)CC3=CC=CC=C3
DM4ZWOD	IK	IKBMFRHCMUKOBA-ZAUAPEEVSA-N
DM4ZWOD	IU	2-[(2S,5R,8R,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM4ZWOD	DE	Discovery agent

DMCXJOL	ID	DMCXJOL
DMCXJOL	DN	C[RGDf-(S)-alpha-TfmF]
DMCXJOL	HS	Investigative
DMCXJOL	SN	CHEMBL204309; c[RGDf-(S)-alpha-TfmF]
DMCXJOL	DT	Small molecular drug
DMCXJOL	PC	9831456
DMCXJOL	MW	690.7
DMCXJOL	FM	C31H37F3N8O7
DMCXJOL	IC	InChI=1S/C31H37F3N8O7/c32-31(33,34)30(16-19-10-5-2-6-11-19)28(49)41-20(12-7-13-37-29(35)36)25(46)38-17-23(43)39-22(15-24(44)45)26(47)40-21(27(48)42-30)14-18-8-3-1-4-9-18/h1-6,8-11,20-22H,7,12-17H2,(H,38,46)(H,39,43)(H,40,47)(H,41,49)(H,42,48)(H,44,45)(H4,35,36,37)/t20-,21+,22-,30-/m0/s1
DMCXJOL	CS	C1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)(CC2=CC=CC=C2)C(F)(F)F)CC3=CC=CC=C3)CC(=O)O
DMCXJOL	IK	QAYABLFYSHKUBR-QKFZZCAYSA-N
DMCXJOL	IU	2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMCXJOL	DE	Discovery agent

DMLRYXK	ID	DMLRYXK
DMLRYXK	DN	C[RGDf-(S)-alpha-TfmV]
DMLRYXK	HS	Investigative
DMLRYXK	SN	CHEMBL203693; c[RGDf-(S)-alpha-TfmV]
DMLRYXK	DT	Small molecular drug
DMLRYXK	PC	10416726
DMLRYXK	MW	642.6
DMLRYXK	FM	C27H37F3N8O7
DMLRYXK	IC	InChI=1S/C27H37F3N8O7/c1-14(2)26(27(28,29)30)24(45)37-16(9-6-10-33-25(31)32)21(42)34-13-19(39)35-18(12-20(40)41)22(43)36-17(23(44)38-26)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18H,6,9-13H2,1-2H3,(H,34,42)(H,35,39)(H,36,43)(H,37,45)(H,38,44)(H,40,41)(H4,31,32,33)/t16-,17+,18-,26-/m0/s1
DMLRYXK	CS	CC(C)[C@]1(C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N)C(F)(F)F
DMLRYXK	IK	VYIBTYZRYKIMKX-KTJGCZTMSA-N
DMLRYXK	IU	2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMLRYXK	DE	Discovery agent

DMNS3HC	ID	DMNS3HC
DMNS3HC	DN	C[RGDf-(S)-N-Me-alpha-TfmF]
DMNS3HC	HS	Investigative
DMNS3HC	SN	CHEMBL413574; c[RGDf-(S)-N-Me-alpha-TfmF]
DMNS3HC	DT	Small molecular drug
DMNS3HC	PC	10372586
DMNS3HC	MW	704.7
DMNS3HC	FM	C32H39F3N8O7
DMNS3HC	IC	InChI=1S/C32H39F3N8O7/c1-43-28(49)23(15-19-9-4-2-5-10-19)41-27(48)22(16-25(45)46)40-24(44)18-39-26(47)21(13-8-14-38-30(36)37)42-29(50)31(43,32(33,34)35)17-20-11-6-3-7-12-20/h2-7,9-12,21-23H,8,13-18H2,1H3,(H,39,47)(H,40,44)(H,41,48)(H,42,50)(H,45,46)(H4,36,37,38)/t21-,22-,23+,31-/m0/s1
DMNS3HC	CS	CN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@]1(CC2=CC=CC=C2)C(F)(F)F)CCCN=C(N)N)CC(=O)O)CC3=CC=CC=C3
DMNS3HC	IK	IKBMFRHCMUKOBA-KAFAUTGVSA-N
DMNS3HC	IU	2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMNS3HC	DE	Discovery agent

DMAILK8	ID	DMAILK8
DMAILK8	DN	C[RGDf-(S,R)-alpha-Dfm-F]
DMAILK8	HS	Investigative
DMAILK8	SN	c[RGDf-(S,R)-alpha-Dfm-F]; CHEMBL379911
DMAILK8	DT	Small molecular drug
DMAILK8	PC	11614485
DMAILK8	MW	672.7
DMAILK8	FM	C31H38F2N8O7
DMAILK8	IC	InChI=1S/C31H38F2N8O7/c32-28(33)31(16-19-10-5-2-6-11-19)29(48)40-20(12-7-13-36-30(34)35)25(45)37-17-23(42)38-22(15-24(43)44)26(46)39-21(27(47)41-31)14-18-8-3-1-4-9-18/h1-6,8-11,20-22,28H,7,12-17H2,(H,37,45)(H,38,42)(H,39,46)(H,40,48)(H,41,47)(H,43,44)(H4,34,35,36)/t20-,21+,22-,31?/m0/s1
DMAILK8	CS	C1C(=O)N[C@H](C(=O)N[C@@H](C(=O)NC(C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)(CC2=CC=CC=C2)C(F)F)CC3=CC=CC=C3)CC(=O)O
DMAILK8	IK	DZUCEYPUEFNCRE-ZONASRJLSA-N
DMAILK8	IU	2-[(2S,5R,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-8-(difluoromethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMAILK8	DE	Discovery agent

DMO7BMZ	ID	DMO7BMZ
DMO7BMZ	DN	C[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]
DMO7BMZ	HS	Investigative
DMO7BMZ	SN	CHEMBL438596; c[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]
DMO7BMZ	PC	44406905
DMO7BMZ	MW	1289.4
DMO7BMZ	FM	C63H84N16O14
DMO7BMZ	IC	InChI=1S/C63H84N16O14/c1-5-33(2)50-62(93)79-24-12-18-49(79)59(90)75-48(31-80)58(89)72-45(26-37-19-21-40(83)22-20-37)56(87)77-51(34(3)81)60(91)74-47(28-39-30-66-32-69-39)55(86)71-44(25-36-13-7-6-8-14-36)54(85)70-43(17-11-23-67-63(64)65)53(84)73-46(57(88)78-52(35(4)82)61(92)76-50)27-38-29-68-42-16-10-9-15-41(38)42/h6-10,13-16,19-22,29-30,32-35,43-52,68,80-83H,5,11-12,17-18,23-28,31H2,1-4H3,(H,66,69)(H,70,85)(H,71,86)(H,72,89)(H,73,84)(H,74,91)(H,75,90)(H,76,92)(H,77,87)(H,78,88)(H4,64,65,67)/t33-,34-,35-,43+,44-,45+,46-,47+,48+,49+,50-,51+,52-/m1/s1
DMO7BMZ	CS	CC[C@@H](C)[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)[C@@H](C)O)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5)CC6=CN=CN6)[C@@H](C)O)CC7=CC=C(C=C7)O)CO
DMO7BMZ	IK	FTGJNWCPPLBYMR-VTQDGRDPSA-N
DMO7BMZ	IU	2-[3-[(3R,6R,9R,12S,15R,18S,21S,24S,27S,30S)-15-benzyl-3-[(2R)-butan-2-yl]-6,21-bis[(1R)-1-hydroxyethyl]-27-(hydroxymethyl)-24-[(4-hydroxyphenyl)methyl]-18-(1H-imidazol-5-ylmethyl)-9-(1H-indol-3-ylmethyl)-2,5,8,11,14,17,20,23,26,29-decaoxo-1,4,7,10,13,16,19,22,25,28-decazabicyclo[28.3.0]tritriacontan-12-yl]propyl]guanidine
DMO7BMZ	DE	Discovery agent

DMRY95I	ID	DMRY95I
DMRY95I	DN	C[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]
DMRY95I	HS	Investigative
DMRY95I	SN	CHEMBL267492; c[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]
DMRY95I	PC	44406884
DMRY95I	MW	1353.5
DMRY95I	FM	C68H88N16O14
DMRY95I	IC	InChI=1S/C68H88N16O14/c1-6-35(2)54-67(98)84-27-13-21-53(84)63(94)83-56(37(4)86)65(96)78-49(28-39-22-24-44(88)25-23-39)61(92)81-55(36(3)85)64(95)79-52(31-43-33-71-34-74-43)60(91)77-50(29-41-16-11-15-40-14-7-8-17-45(40)41)59(90)75-48(20-12-26-72-68(69)70)58(89)76-51(62(93)82-57(38(5)87)66(97)80-54)30-42-32-73-47-19-10-9-18-46(42)47/h7-11,14-19,22-25,32-38,48-57,73,85-88H,6,12-13,20-21,26-31H2,1-5H3,(H,71,74)(H,75,90)(H,76,89)(H,77,91)(H,78,96)(H,79,95)(H,80,97)(H,81,92)(H,82,93)(H,83,94)(H4,69,70,72)/t35-,36-,37-,38-,48+,49+,50-,51-,52+,53-,54-,55+,56+,57-/m1/s1
DMRY95I	CS	CC[C@@H](C)[C@@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)[C@@H](C)O)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC6=CC=CC=C65)CC7=CN=CN7)[C@@H](C)O)CC8=CC=C(C=C8)O)[C@@H](C)O
DMRY95I	IK	JUOTYAXVJMXIJJ-RTWQMTKCSA-N
DMRY95I	IU	2-[3-[(3R,6R,9R,12S,15R,18S,21S,24S,27S,30R)-3-[(2R)-butan-2-yl]-6,21,27-tris[(1R)-1-hydroxyethyl]-24-[(4-hydroxyphenyl)methyl]-18-(1H-imidazol-5-ylmethyl)-9-(1H-indol-3-ylmethyl)-15-(naphthalen-1-ylmethyl)-2,5,8,11,14,17,20,23,26,29-decaoxo-1,4,7,10,13,16,19,22,25,28-decazabicyclo[28.3.0]tritriacontan-12-yl]propyl]guanidine
DMRY95I	DE	Discovery agent

DM0YLPV	ID	DM0YLPV
DM0YLPV	DN	C[YYAEGLEE]-NH2
DM0YLPV	HS	Investigative
DM0YLPV	SN	CHEMBL1082940; c[YYAEGLEE]-NH2
DM0YLPV	DT	Small molecular drug
DM0YLPV	PC	46831062
DM0YLPV	MW	954
DM0YLPV	FM	C44H59N9O15
DM0YLPV	IC	InChI=1S/C44H59N9O15/c1-22(2)18-31-43(67)52-30(14-17-37(60)61)41(65)50-28(38(45)62)12-15-34(56)48-32(19-24-4-8-26(54)9-5-24)44(68)53-33(20-25-6-10-27(55)11-7-25)42(66)47-23(3)39(63)51-29(13-16-36(58)59)40(64)46-21-35(57)49-31/h4-11,22-23,28-33,54-55H,12-21H2,1-3H3,(H2,45,62)(H,46,64)(H,47,66)(H,48,56)(H,49,57)(H,50,65)(H,51,63)(H,52,67)(H,53,68)(H,58,59)(H,60,61)/t23-,28-,29-,30-,31-,32-,33-/m0/s1
DM0YLPV	CS	C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)CC3=CC=C(C=C3)O)C(=O)N)CCC(=O)O)CC(C)C)CCC(=O)O
DM0YLPV	IK	WSKHBZRJCGPPOH-RKNQSKIKSA-N
DM0YLPV	IU	3-[(2S,5S,8S,11S,17S,20S,23S)-23-carbamoyl-20-(2-carboxyethyl)-2,5-bis[(4-hydroxyphenyl)methyl]-8-methyl-17-(2-methylpropyl)-3,6,9,12,15,18,21,26-octaoxo-1,4,7,10,13,16,19,22-octazacyclohexacos-11-yl]propanoic acid
DM0YLPV	DE	Discovery agent

DMSKW8H	ID	DMSKW8H
DMSKW8H	DN	C[YYDEGLEE]-NH2
DMSKW8H	HS	Investigative
DMSKW8H	SN	CHEMBL389147; c[YYDEGLEE]-NH2; BDBM50223446
DMSKW8H	DT	Small molecular drug
DMSKW8H	PC	23630507
DMSKW8H	MW	998
DMSKW8H	FM	C45H59N9O17
DMSKW8H	IC	InChI=1S/C45H59N9O17/c1-22(2)17-30-42(68)52-29(13-16-37(61)62)41(67)50-27(39(46)65)11-14-34(57)48-31(18-23-3-7-25(55)8-4-23)43(69)53-32(19-24-5-9-26(56)10-6-24)44(70)54-33(20-38(63)64)45(71)51-28(12-15-36(59)60)40(66)47-21-35(58)49-30/h3-10,22,27-33,55-56H,11-21H2,1-2H3,(H2,46,65)(H,47,66)(H,48,57)(H,49,58)(H,50,67)(H,51,71)(H,52,68)(H,53,69)(H,54,70)(H,59,60)(H,61,62)(H,63,64)/t27-,28-,29-,30-,31-,32-,33-/m0/s1
DMSKW8H	CS	CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CCC(=O)O)CC(=O)O)CC2=CC=C(C=C2)O)CC3=CC=C(C=C3)O)C(=O)N)CCC(=O)O
DMSKW8H	IK	FRCBDVBWQMWQOW-MRNVWEPHSA-N
DMSKW8H	IU	3-[(3S,6S,12S,15S,18S,21S,26S)-26-carbamoyl-12-(2-carboxyethyl)-15-(carboxymethyl)-18,21-bis[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,17,20,23-octaoxo-1,4,7,10,13,16,19,22-octazacyclohexacos-3-yl]propanoic acid
DMSKW8H	DE	Discovery agent

DMTHGMR	ID	DMTHGMR
DMTHGMR	DN	C[YYDEKLEE]-NH2
DMTHGMR	HS	Investigative
DMTHGMR	SN	CHEMBL1082946
DMTHGMR	PC	46831676
DMTHGMR	MW	1069.1
DMTHGMR	FM	C49H68N10O17
DMTHGMR	IC	InChI=1S/C49H68N10O17/c1-25(2)21-34-46(73)55-32(15-18-39(63)64)44(71)53-30(42(51)69)14-17-38(62)52-35(22-26-6-10-28(60)11-7-26)47(74)58-36(23-27-8-12-29(61)13-9-27)48(75)59-37(24-41(67)68)49(76)56-33(16-19-40(65)66)45(72)54-31(43(70)57-34)5-3-4-20-50/h6-13,25,30-37,60-61H,3-5,14-24,50H2,1-2H3,(H2,51,69)(H,52,62)(H,53,71)(H,54,72)(H,55,73)(H,56,76)(H,57,70)(H,58,74)(H,59,75)(H,63,64)(H,65,66)(H,67,68)/t30-,31-,32-,33-,34-,35-,36-,37-/m0/s1
DMTHGMR	CS	CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CCC(=O)O)CC(=O)O)CC2=CC=C(C=C2)O)CC3=CC=C(C=C3)O)C(=O)N)CCC(=O)O
DMTHGMR	IK	UHCDRMNHCPWMSL-MDKUUQCZSA-N
DMTHGMR	IU	3-[(3S,6S,9S,12S,15S,18S,21S,26S)-9-(4-aminobutyl)-26-carbamoyl-12-(2-carboxyethyl)-15-(carboxymethyl)-18,21-bis[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,17,20,23-octaoxo-1,4,7,10,13,16,19,22-octazacyclohexacos-3-yl]propanoic acid
DMTHGMR	DE	Discovery agent

DMD7OQA	ID	DMD7OQA
DMD7OQA	DN	C-014C
DMD7OQA	HS	Investigative
DMD7OQA	SN	C-014C; CHEMBL509396; BDBM50244050
DMD7OQA	DT	Small molecular drug
DMD7OQA	PC	44561260
DMD7OQA	MW	384.5
DMD7OQA	FM	C22H32N4O2
DMD7OQA	IC	InChI=1S/C22H32N4O2/c1-27-19-13-17-18(14-20(19)28-2)25-22(24-16-11-7-8-12-16)26-21(17)23-15-9-5-3-4-6-10-15/h13-16H,3-12H2,1-2H3,(H2,23,24,25,26)
DMD7OQA	CS	COC1=C(C=C2C(=C1)C(=NC(=N2)NC3CCCC3)NC4CCCCCC4)OC
DMD7OQA	IK	HZBKRPBMAVNOCZ-UHFFFAOYSA-N
DMD7OQA	IU	4-N-cycloheptyl-2-N-cyclopentyl-6,7-dimethoxyquinazoline-2,4-diamine
DMD7OQA	DE	Discovery agent

DMNV1ST	ID	DMNV1ST
DMNV1ST	DN	C-10068
DMNV1ST	HS	Investigative
DMNV1ST	SN	Deuterated sigma-1 agonists (epilepsy/brain injury/neuropathic pain); Deuterated sigma-1 agonists (epilepsy/brain injury/neuropathic pain), CoNCERT/Walter Reed Army Institute
DMNV1ST	CP	CoNCERT Pharmaceuticals Inc
DMNV1ST	DE	Brain injury

DMZXE6O	ID	DMZXE6O
DMZXE6O	DN	C-16-(S)-3-methylindolerapamycin
DMZXE6O	HS	Investigative
DMZXE6O	SN	CHEMBL503885; C-16-(S)-3-methylindolerapamycin
DMZXE6O	PC	44576240
DMZXE6O	MW	1013.3
DMZXE6O	FM	C59H84N2O12
DMZXE6O	IC	InChI=1S/C59H84N2O12/c1-34-17-12-11-13-18-35(2)46(45-20-16-19-44-40(7)33-60-52(44)45)31-43-24-22-41(8)59(69,73-43)56(66)57(67)61-26-15-14-21-47(61)58(68)72-50(37(4)29-42-23-25-48(62)51(30-42)70-9)32-49(63)36(3)28-39(6)54(65)55(71-10)53(64)38(5)27-34/h11-13,16-20,28,33-34,36-38,41-43,46-48,50-51,54-55,60,62,65,69H,14-15,21-27,29-32H2,1-10H3/b13-11+,17-12+,35-18+,39-28+/t34-,36-,37-,38-,41-,42+,43+,46+,47+,48-,50+,51-,54-,55+,59-/m1/s1
DMZXE6O	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)C5=CC=CC6=C5NC=C6C
DMZXE6O	IK	MYMSKXFGXABEON-OYYFJIJNSA-N
DMZXE6O	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-30-(3-methyl-1H-indol-7-yl)-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMZXE6O	DE	Discovery agent

DM23KNC	ID	DM23KNC
DM23KNC	DN	C16-Fatty-Acyl-Substrate-Mimic
DM23KNC	HS	Investigative
DM23KNC	SN	C16-FATTY-ACYL-SUBSTRATE-MIMIC; TRANS-2-HEXADECENOYL-(N-ACETYL-CYSTEAMINE)-THIOESTER; AC1MP1RZ; S-Palmitoyl-N-acetylcysteamine; SCHEMBL5088794; DB02990; S-(2-acetamidoethyl) hexadecanethioate; S-[2-(acetylamino)ethyl] hexadecanethioate
DM23KNC	DT	Small molecular drug
DM23KNC	PC	3378216
DM23KNC	MW	357.6
DM23KNC	FM	C20H39NO2S
DM23KNC	IC	InChI=1S/C20H39NO2S/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(23)24-18-17-21-19(2)22/h3-18H2,1-2H3,(H,21,22)
DM23KNC	CS	CCCCCCCCCCCCCCCC(=O)SCCNC(=O)C
DM23KNC	IK	GDVZALUOXPTSHD-UHFFFAOYSA-N
DM23KNC	IU	S-(2-acetamidoethyl) hexadecanethioate
DM23KNC	DE	Discovery agent

DMKGSRZ	ID	DMKGSRZ
DMKGSRZ	DN	C-176
DMKGSRZ	HS	Investigative
DMKGSRZ	SN	314054-00-7; N-(4-iodophenyl)-5-nitrofuran-2-carboxamide; C-176 STING inhibitor; STING inhibitor C-176; STING Inhibitor 1; Cambridge id 5344639; Oprea1_000586; Oprea1_014551; 5-Nitro-furan-2-carboxylic acid (4-iodo-phenyl)-amide; CHEMBL3593839; SCHEMBL13219564; ZINC830011; BCP30174; EX-A2974; s6575; STK016322; AKOS000670518; MCULE-4963641555; BS-16912; HY-112906; AK00792625; CS-0067918; ST50232559; STING inhibitor C-176; C176; C 176; AB00081654-01; N-(4-iodophenyl)(5-nitro(2-furyl))carboxamide; SR-01000406953; SR-01000406953-1
DMKGSRZ	DT	Small molecular drug
DMKGSRZ	PC	1103958
DMKGSRZ	MW	358.09
DMKGSRZ	FM	C11H7IN2O4
DMKGSRZ	IC	InChI=1S/C11H7IN2O4/c12-7-1-3-8(4-2-7)13-11(15)9-5-6-10(18-9)14(16)17/h1-6H,(H,13,15)
DMKGSRZ	CS	C1=CC(=CC=C1NC(=O)C2=CC=C(O2)[N+](=O)[O-])I
DMKGSRZ	IK	JBIKQXOZLBLMKI-UHFFFAOYSA-N
DMKGSRZ	IU	N-(4-iodophenyl)-5-nitrofuran-2-carboxamide
DMKGSRZ	DE	Aicardi-Goutieres syndrome

DM4FEU8	ID	DM4FEU8
DM4FEU8	DN	C-178
DM4FEU8	HS	Investigative
DM4FEU8	SN	329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide
DM4FEU8	DT	Small molecular drug
DM4FEU8	PC	2866412
DM4FEU8	MW	322.27
DM4FEU8	FM	C17H10N2O5
DM4FEU8	IC	InChI=1S/C17H10N2O5/c20-17(14-7-8-16(24-14)19(21)22)18-10-5-6-12-11-3-1-2-4-13(11)23-15(12)9-10/h1-9H,(H,18,20)
DM4FEU8	CS	C1=CC=C2C(=C1)C3=C(O2)C=C(C=C3)NC(=O)C4=CC=C(O4)[N+](=O)[O-]
DM4FEU8	IK	URUVDCCYSJEGQQ-UHFFFAOYSA-N
DM4FEU8	IU	N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide
DM4FEU8	DE	Aicardi-Goutieres syndrome

DMCAO3V	ID	DMCAO3V
DMCAO3V	DN	C-21191
DMCAO3V	HS	Investigative
DMCAO3V	SN	Deuterium-modified GABA-A modulator (spasticity/neuropathic pain/anxiety), CoNCERT Pharmaceuticals
DMCAO3V	CP	CoNCERT Pharmaceuticals Inc
DMCAO3V	DE	Anxiety disorder

DMS87IF	ID	DMS87IF
DMS87IF	DN	C2-MAD
DMS87IF	HS	Investigative
DMS87IF	SN	C2-MYCOPHENOLIC ADENINE DINUCLEOTIDE; CHEMBL410744; {[5-(6-AMINO-PURIN-7-YL)-3,4-DIHYDROXY-TETRAHYDRO-FURAN-2-YLMETHOXY]-HYDROXY-PHOSPHORYLMETHYL}-PHOSPHONIC ACID MONO-[2-(4-HYDROXY-6-METHOXY-7-METHYL-3-OXO-1,3-DIHYDRO-ISOBENZOFURAN-5-YL)-ETHYL] ESTER; C2-MAD; AC1L9X62; BDBM19265; C2-Mycophenolic Adenine Dinucleotide (C2-MDA); MYD; 4-Methyl-5-methoxy-6-[2-(5'-adenylylmethylphosphonyloxy)ethyl]-7-hydroxyisobenzofuran-1(3H)-one
DMS87IF	DT	Small molecular drug
DMS87IF	PC	477579
DMS87IF	MW	645.4
DMS87IF	FM	C23H29N5O13P2
DMS87IF	IC	InChI=1S/C23H29N5O13P2/c1-10-12-5-38-23(32)14(12)16(29)11(19(10)37-2)3-4-39-42(33,34)9-43(35,36)40-6-13-17(30)18(31)22(41-13)28-8-27-15-20(24)25-7-26-21(15)28/h7-8,13,17-18,22,29-31H,3-6,9H2,1-2H3,(H,33,34)(H,35,36)(H2,24,25,26)/t13-,17-,18-,22-/m1/s1
DMS87IF	CS	CC1=C2COC(=O)C2=C(C(=C1OC)CCOP(=O)(CP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O
DMS87IF	IK	AMYUZLUBFKOUEX-JKWAKEATSA-N
DMS87IF	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[hydroxy-[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)ethoxy]phosphoryl]methyl]phosphinic acid
DMS87IF	DE	Discovery agent

DMTCOY9	ID	DMTCOY9
DMTCOY9	DN	C3
DMTCOY9	HS	Investigative
DMTCOY9	SN	4-[2-[2-[3-acetamido-2-[[[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoylamino]-5-[[6-amino-1-[[1-[(1-hydroxy-1-oxopropan-2-yl)amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid; AC1L18UY
DMTCOY9	DT	Small molecular drug
DMTCOY9	PC	268
DMTCOY9	MW	1149.9
DMTCOY9	FM	C40H65N9O26P2
DMTCOY9	IC	InChI=1S/C40H65N9O26P2/c1-16(32(58)44-18(3)38(63)64)43-35(61)21(8-6-7-12-41)47-36(62)22(9-10-26(53)54)46-33(59)17(2)42-34(60)19(4)71-31-27(45-20(5)51)39(73-23(14-50)29(31)56)74-77(68,69)75-76(66,67)70-15-24-28(55)30(57)37(72-24)49-13-11-25(52)48-40(49)65/h11,13,16-19,21-24,27-31,37,39,50,55-57H,6-10,12,14-15,41H2,1-5H3,(H,42,60)(H,43,61)(H,44,58)(H,45,51)(H,46,59)(H,47,62)(H,53,54)(H,63,64)(H,66,67)(H,68,69)(H,48,52,65)
DMTCOY9	CS	CC(C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(C)C(=O)O)NC(=O)C(C)OC1C(C(OC(C1O)CO)OP(=O)(O)OP(=O)(O)OCC2C(C(C(O2)N3C=CC(=O)NC3=O)O)O)NC(=O)C
DMTCOY9	IK	QAXSYKNMKWGHOF-UHFFFAOYSA-N
DMTCOY9	IU	4-[2-[2-[3-acetamido-2-[[[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoylamino]-5-[[6-amino-1-[[1-(1-carboxyethylamino)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DMTCOY9	DE	Discovery agent

DMGA9U7	ID	DMGA9U7
DMGA9U7	DN	C4-MAD
DMGA9U7	HS	Investigative
DMGA9U7	SN	C4-MAD; AC1O51QQ; CHEMBL1170847; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-[[hydroxy-[(E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-2-methyl-but-2-enoxy]phosphoryl]methyl]phosphinic acid; 9H-Purin-6-amine, 9-[5-O-[[[[[(2E)-4-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-2-methyl-2-butenyl]oxy]hydroxyphosphinyl]methyl]hydroxyphosphinyl]pentofuranosyl]-
DMGA9U7	DT	Small molecular drug
DMGA9U7	PC	6475540
DMGA9U7	MW	685.5
DMGA9U7	FM	C26H33N5O13P2
DMGA9U7	IC	InChI=1S/C26H33N5O13P2/c1-12(4-5-14-19(32)17-15(7-41-26(17)35)13(2)22(14)40-3)6-42-45(36,37)11-46(38,39)43-8-16-20(33)21(34)25(44-16)31-10-30-18-23(27)28-9-29-24(18)31/h4,9-10,16,20-21,25,32-34H,5-8,11H2,1-3H3,(H,36,37)(H,38,39)(H2,27,28,29)/b12-4+/t16-,20-,21-,25-/m1/s1
DMGA9U7	CS	CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/COP(=O)(CP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O
DMGA9U7	IK	MCYWJNDIVYMDSF-AWOYCZEKSA-N
DMGA9U7	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[hydroxy-[(E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-2-methylbut-2-enoxy]phosphoryl]methyl]phosphinic acid
DMGA9U7	DE	Discovery agent

DM5971G	ID	DM5971G
DM5971G	DN	C4X-101
DM5971G	HS	Investigative
DM5971G	SN	TRH inhibitors (anxiety disorder/nutritional disorder/endocrine disease), Conformetrix
DM5971G	CP	Conformetrix
DM5971G	DE	Endocrine disease

DMEK4HZ	ID	DMEK4HZ
DMEK4HZ	DN	C5aR pepducins
DMEK4HZ	HS	Investigative
DMEK4HZ	SN	C5aR pepducins ((lipopeptide, inflammatory diseases); Component 5a receptor modulators (lipopeptide, inflammatory diseases), Anchor Therapeutics; C5aR pepducins ((lipopeptide, inflammatory diseases), Anchor Therapeutics
DMEK4HZ	CP	Anchor Therapeutics Inc
DMEK4HZ	DE	Inflammation

DMCOQKH	ID	DMCOQKH
DMCOQKH	DN	C646
DMCOQKH	HS	Investigative
DMCOQKH	SN	328968-36-1; CHEMBL1797936; 4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid; C24H19N3O6; 4-[4-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]benzoic acid; C 646; AC1LPE4V; GTPL7004; SCHEMBL12092858; QCR-235; DTXSID30361651; MolPort-002-171-380; CHEBI:132974; ZINC8780879; s7152; 2295AH; AKOS000113052; SB19338; ST020490; C646, &gt; J-018925; BRD-K73383190-001-03-1
DMCOQKH	DT	Small molecular drug
DMCOQKH	PC	1285940
DMCOQKH	MW	445.4
DMCOQKH	FM	C24H19N3O6
DMCOQKH	IC	InChI=1S/C24H19N3O6/c1-13-10-20(21(27(31)32)11-14(13)2)22-9-8-18(33-22)12-19-15(3)25-26(23(19)28)17-6-4-16(5-7-17)24(29)30/h4-12H,1-3H3,(H,29,30)/b19-12+
DMCOQKH	CS	CC1=CC(=C(C=C1C)[N+](=O)[O-])C2=CC=C(O2)/C=C/3\\C(=NN(C3=O)C4=CC=C(C=C4)C(=O)O)C
DMCOQKH	IK	HEKJYZZSCQBJGB-XDHOZWIPSA-N
DMCOQKH	IU	4-[(4E)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid
DMCOQKH	CA	CAS 328968-36-1
DMCOQKH	DE	Discovery agent

DM4LIHQ	ID	DM4LIHQ
DM4LIHQ	DN	C6S
DM4LIHQ	HS	Investigative
DM4LIHQ	SN	CHEMBL1417
DM4LIHQ	DT	Small molecular drug
DM4LIHQ	PC	44414814
DM4LIHQ	MW	379.4
DM4LIHQ	FM	C18H21NO6S
DM4LIHQ	IC	InChI=1S/C18H21NO6S/c1-19-8-7-18-11-4-6-14(25-26(20,21)22)17(18)24-16-13(23-2)5-3-10(15(16)18)9-12(11)19/h3-6,11-12,14,17H,7-9H2,1-2H3,(H,20,21,22)/t11-,12+,14-,17-,18-/m0/s1
DM4LIHQ	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)OS(=O)(=O)O
DM4LIHQ	IK	JIYGLXDCNSTUSY-XSSYPUMDSA-N
DM4LIHQ	IU	[(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] hydrogen sulfate
DM4LIHQ	DE	Discovery agent

DM7MNOX	ID	DM7MNOX
DM7MNOX	DN	C7/3-phth
DM7MNOX	HS	Investigative
DM7MNOX	SN	heptane-1,7-bis(dimethyl-3'-phthalimidopropylammonium)
DM7MNOX	DT	Small molecular drug
DM7MNOX	PC	168057
DM7MNOX	MW	562.7
DM7MNOX	FM	C33H46N4O4+2
DM7MNOX	IC	InChI=1S/C33H46N4O4/c1-36(2,24-14-20-34-30(38)26-16-8-9-17-27(26)31(34)39)22-12-6-5-7-13-23-37(3,4)25-15-21-35-32(40)28-18-10-11-19-29(28)33(35)41/h8-11,16-19H,5-7,12-15,20-25H2,1-4H3/q+2
DM7MNOX	CS	C[N+](C)(CCCCCCC[N+](C)(C)CCCN1C(=O)C2=CC=CC=C2C1=O)CCCN3C(=O)C4=CC=CC=C4C3=O
DM7MNOX	IK	OSALRKZRWVYPFR-UHFFFAOYSA-N
DM7MNOX	IU	3-(1,3-dioxoisoindol-2-yl)propyl-[7-[3-(1,3-dioxoisoindol-2-yl)propyl-dimethylazaniumyl]heptyl]-dimethylazanium
DM7MNOX	CA	CAS 22664-47-7
DM7MNOX	DE	Discovery agent

DMHGX1N	ID	DMHGX1N
DMHGX1N	DN	C75
DMHGX1N	HS	Investigative
DMHGX1N	SN	C75 trans; C75 (trans); 191282-48-1; 3-Carboxy-4-octyl-2-methylenebutyrolactone; CHEMBL449993; trans-4-Carboxy-5-octyl-3-methylenebutyrolactone; Fatty Acid Synthase Inhibitor, C75; (+)-trans-C75; C75 (racemic); SCHEMBL3007085; CTK8E7727; MolPort-005-933-439; HMS3649D16; ZINC2009913; BCP11074; HY-12364A; BDBM50256128; trans-Tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid; AKOS015960616; VC30664; CS-3561; AC-11808; RT-011885; SR-01000946704; SR-01000946704-1; J-012362; UNII-8E9A8CTX2H component VCWLZDVWHQVAJU-NEPJUHHUSA-
DMHGX1N	DT	Small molecular drug
DMHGX1N	PC	4248455
DMHGX1N	MW	254.32
DMHGX1N	FM	C14H22O4
DMHGX1N	IC	InChI=1S/C14H22O4/c1-3-4-5-6-7-8-9-11-12(13(15)16)10(2)14(17)18-11/h11-12H,2-9H2,1H3,(H,15,16)
DMHGX1N	CS	CCCCCCCCC1C(C(=C)C(=O)O1)C(=O)O
DMHGX1N	IK	VCWLZDVWHQVAJU-UHFFFAOYSA-N
DMHGX1N	IU	4-methylidene-2-octyl-5-oxooxolane-3-carboxylic acid
DMHGX1N	CA	CAS 218137-86-1
DMHGX1N	CB	CHEBI:95108
DMHGX1N	DE	Obesity

DMX85E7	ID	DMX85E7
DMX85E7	DN	Ca(2+) chelator
DMX85E7	HS	Investigative
DMX85E7	DE	Discovery agent

DMP5OSK	ID	DMP5OSK
DMP5OSK	DN	CA-327
DMP5OSK	HS	Investigative
DMP5OSK	DT	Small molecule immunotherapy 

DMCLN6M	ID	DMCLN6M
DMCLN6M	DN	CA-50040
DMCLN6M	HS	Investigative
DMCLN6M	CP	POZEN Inc
DMCLN6M	DE	Colorectal cancer

DMQATPN	ID	DMQATPN
DMQATPN	DN	CAA0225
DMQATPN	HS	Investigative
DMQATPN	SN	CAA0225; CAA-0225; GTPL6532; (2S,3S)-2-N-[(1S)-1-(benzylcarbamoyl)-2-phenylethyl]-3-N-[2-(4-hydroxyphenyl)ethyl]oxirane-2,3-dicarboxamide
DMQATPN	DT	Small molecular drug
DMQATPN	PC	50909779
DMQATPN	MW	487.5
DMQATPN	FM	C28H29N3O5
DMQATPN	IC	InChI=1S/C28H29N3O5/c32-22-13-11-19(12-14-22)15-16-29-27(34)24-25(36-24)28(35)31-23(17-20-7-3-1-4-8-20)26(33)30-18-21-9-5-2-6-10-21/h1-14,23-25,32H,15-18H2,(H,29,34)(H,30,33)(H,31,35)/t23-,24-,25-/m0/s1
DMQATPN	CS	C1=CC=C(C=C1)C[C@@H](C(=O)NCC2=CC=CC=C2)NC(=O)[C@@H]3[C@H](O3)C(=O)NCCC4=CC=C(C=C4)O
DMQATPN	IK	ZMZQYVMNDRBKLO-SDHOMARFSA-N
DMQATPN	IU	(2S,3S)-2-N-[(2S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-yl]-3-N-[2-(4-hydroxyphenyl)ethyl]oxirane-2,3-dicarboxamide
DMQATPN	DE	Discovery agent

DMPKFYZ	ID	DMPKFYZ
DMPKFYZ	DN	CACA
DMPKFYZ	HS	Investigative
DMPKFYZ	SN	cis-aminocrotonic acid; 4-aminocrotonic acid
DMPKFYZ	DT	Small molecular drug
DMPKFYZ	PC	6603697
DMPKFYZ	MW	101.1
DMPKFYZ	FM	C4H7NO2
DMPKFYZ	IC	InChI=1S/C4H7NO2/c5-3-1-2-4(6)7/h1-2H,3,5H2,(H,6,7)/b2-1-
DMPKFYZ	CS	C(/C=C\\C(=O)O)N
DMPKFYZ	IK	FMKJUUQOYOHLTF-UPHRSURJSA-N
DMPKFYZ	IU	(Z)-4-aminobut-2-enoic acid
DMPKFYZ	CA	CAS 55199-25-2
DMPKFYZ	DE	Discovery agent

DMK4XLD	ID	DMK4XLD
DMK4XLD	DN	Cacodylate Ion
DMK4XLD	HS	Investigative
DMK4XLD	SN	Dimethylarsinate; Arsinic acid, dimethyl-, ion(1-); Bolate; Bolls; 15132-04-4; Dimethylarsonic Acid; rad-e-cat 25; Cacodylate ions; Cacodylic acid, free acid; Kakodylat; DMAV; Dimethylarsinic acidanion; AC1L4ZLM; CAC; Me2AsO2(-); AC1Q1WC3; CHEBI:16223; CTK4C7002; BDBM92451; DTXSID60164758; OGGXGZAMXPVRFZ-UHFFFAOYSA-M; Scotts Stop Weeds After They Start; Scotts Spot Grass and Weed Control; [As(CH3)2O2](-); AKOS032954710; Arsinic acid,dimethyl-, ion(1-) (9CI)
DMK4XLD	DT	Small molecular drug
DMK4XLD	PC	167250
DMK4XLD	MW	136.99
DMK4XLD	FM	C2H6AsO2-
DMK4XLD	IC	InChI=1S/C2H7AsO2/c1-3(2,4)5/h1-2H3,(H,4,5)/p-1
DMK4XLD	CS	C[As](=O)(C)[O-]
DMK4XLD	IK	OGGXGZAMXPVRFZ-UHFFFAOYSA-M
DMK4XLD	IU	dimethylarsinate
DMK4XLD	CA	CAS 15132-04-4
DMK4XLD	CB	CHEBI:16223
DMK4XLD	DE	Discovery agent

DMIPJUS	ID	DMIPJUS
DMIPJUS	DN	CACOSPONGIONOLIDE
DMIPJUS	HS	Investigative
DMIPJUS	SN	cacospongionolide; CHEMBL480681
DMIPJUS	DT	Small molecular drug
DMIPJUS	PC	21774960
DMIPJUS	MW	400.5
DMIPJUS	FM	C25H36O4
DMIPJUS	IC	InChI=1S/C25H36O4/c1-16-8-12-25-15-23(25,2)10-4-5-20(25)24(16,3)11-9-17-6-7-19(28-14-17)18-13-21(26)29-22(18)27/h6,13,16,19-20,22,27H,4-5,7-12,14-15H2,1-3H3/t16-,19+,20+,22+,23-,24-,25-/m0/s1
DMIPJUS	CS	C[C@H]1CC[C@@]23C[C@@]2(CCC[C@@H]3[C@@]1(C)CCC4=CC[C@@H](OC4)C5=CC(=O)O[C@H]5O)C
DMIPJUS	IK	FPUWYDSKOKLTDH-FRMRWZTPSA-N
DMIPJUS	IU	(2R)-3-[(2R)-5-[2-[(1aS,4aR,5S,6S,8aS)-1a,5,6-trimethyl-1,2,3,4,4a,6,7,8-octahydrocyclopropa[e]naphthalen-5-yl]ethyl]-3,6-dihydro-2H-pyran-2-yl]-2-hydroxy-2H-furan-5-one
DMIPJUS	DE	Discovery agent

DMCSXNW	ID	DMCSXNW
DMCSXNW	DN	CACOSPONGIONOLIDE B
DMCSXNW	HS	Investigative
DMCSXNW	SN	cacospongionolide B; CHEMBL111739
DMCSXNW	DT	Small molecular drug
DMCSXNW	PC	10386285
DMCSXNW	MW	400.5
DMCSXNW	FM	C25H36O4
DMCSXNW	IC	InChI=1S/C25H36O4/c1-16-6-5-7-21-24(16,3)12-10-17(2)25(21,4)13-11-18-8-9-20(28-15-18)19-14-22(26)29-23(19)27/h8,14,17,20-21,23,27H,1,5-7,9-13,15H2,2-4H3/t17-,20?,21-,23?,24-,25-/m1/s1
DMCSXNW	CS	C[C@@H]1CC[C@]2([C@H]([C@]1(C)CCC3=CCC(OC3)C4=CC(=O)OC4O)CCCC2=C)C
DMCSXNW	IK	CVAZWHZRZNYCOV-ILKJNQADSA-N
DMCSXNW	IU	3-[5-[2-[(1R,2R,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]ethyl]-3,6-dihydro-2H-pyran-2-yl]-2-hydroxy-2H-furan-5-one
DMCSXNW	DE	Discovery agent

DM2DYAV	ID	DM2DYAV
DM2DYAV	DN	Cacospongionolide E
DM2DYAV	HS	Investigative
DM2DYAV	SN	cacospongionolide E; CHEMBL480874; BDBM50259952
DM2DYAV	DT	Small molecular drug
DM2DYAV	PC	23243376
DM2DYAV	MW	400.5
DM2DYAV	FM	C25H36O4
DM2DYAV	IC	InChI=1S/C25H36O4/c1-16-6-5-7-21-24(16,3)12-10-17(2)25(21,4)13-11-18-8-9-20(28-15-18)19-14-22(26)29-23(19)27/h6,8,14,17,20-21,23,27H,5,7,9-13,15H2,1-4H3/t17-,20+,21-,23+,24-,25-/m0/s1
DM2DYAV	CS	C[C@H]1CC[C@@]2([C@@H]([C@@]1(C)CCC3=CC[C@@H](OC3)C4=CC(=O)O[C@H]4O)CCC=C2C)C
DM2DYAV	IK	WBDQPITVPUAHAN-DRCQBYJMSA-N
DM2DYAV	IU	(2R)-3-[(2R)-5-[2-[(1S,2S,4aR,8aR)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]ethyl]-3,6-dihydro-2H-pyran-2-yl]-2-hydroxy-2H-furan-5-one
DM2DYAV	DE	Discovery agent

DMLKZQH	ID	DMLKZQH
DMLKZQH	DN	cADPR
DMLKZQH	HS	Investigative
DMLKZQH	SN	cyclic ADP ribose
DMLKZQH	DT	Small molecular drug
DMLKZQH	PC	123847
DMLKZQH	MW	541.3
DMLKZQH	FM	C15H21N5O13P2
DMLKZQH	IC	InChI=1S/C15H21N5O13P2/c16-12-7-13-18-4-19(12)14-10(23)8(21)5(31-14)1-29-34(25,26)33-35(27,28)30-2-6-9(22)11(24)15(32-6)20(13)3-17-7/h3-6,8-11,14-16,21-24H,1-2H2,(H,25,26)(H,27,28)/t5-,6-,8-,9-,10-,11-,14-,15-/m1/s1
DMLKZQH	CS	C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=CN(C4=N)[C@H]5[C@@H]([C@@H]([C@H](O5)COP(=O)(OP(=O)(O1)O)O)O)O)O)O
DMLKZQH	IK	BQOHYSXSASDCEA-KEOHHSTQSA-N
DMLKZQH	IU	(2R,3R,4S,5R,13R,14S,15R,16R)-8,10-dihydroxy-24-imino-8,10-dioxo-7,9,11,25,26-pentaoxa-1,17,19,22-tetraza-8lambda5,10lambda5-diphosphapentacyclo[18.3.1.12,5.113,16.017,21]hexacosa-18,20,22-triene-3,4,14,15-tetrol
DMLKZQH	CA	CAS 119340-53-3
DMLKZQH	CB	CHEBI:31445
DMLKZQH	DE	Discovery agent

DMRJKIV	ID	DMRJKIV
DMRJKIV	DN	Caffeic acid phenethyl ester
DMRJKIV	HS	Investigative
DMRJKIV	SN	Caffeic acid phenethyl ester; Phenethyl caffeate; 104594-70-9; CAPE; phenethyl 3-(3,4-dihydroxyphenyl)acrylate; Capeee; Phenylethyl caffeate; 115610-29-2; caffeic acid phenylethyl ester; UNII-G960R9S5SK; 2-phenylethyl caffeate; PHENETHYL CAFFEATE (CAPE); Caffeic acid-phenethyl ester; CHEBI:8062; G960R9S5SK; CHEMBL319244; 100981-80-4; Caffeic acid 2-phenylethyl ester; SWUARLUWKZWEBQ-VQHVLOKHSA-N; 2-phenylethyl 3-(3,4-dihydroxyphenyl)-2-propenoate; Caffeic Acid Phenethyl Ester, Synthetic; 2-Phenylethyl (2e)-3-(3,4-Dihydroxyphenyl
DMRJKIV	DT	Small molecular drug
DMRJKIV	PC	5281787
DMRJKIV	MW	284.31
DMRJKIV	FM	C17H16O4
DMRJKIV	IC	InChI=1S/C17H16O4/c18-15-8-6-14(12-16(15)19)7-9-17(20)21-11-10-13-4-2-1-3-5-13/h1-9,12,18-19H,10-11H2/b9-7+
DMRJKIV	CS	C1=CC=C(C=C1)CCOC(=O)/C=C/C2=CC(=C(C=C2)O)O
DMRJKIV	IK	SWUARLUWKZWEBQ-VQHVLOKHSA-N
DMRJKIV	IU	2-phenylethyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DMRJKIV	CA	CAS 115610-29-2
DMRJKIV	CB	CHEBI:8062
DMRJKIV	DE	Discovery agent

DM6NPUM	ID	DM6NPUM
DM6NPUM	DN	CALCEOLARIOSIDE A
DM6NPUM	HS	Investigative
DM6NPUM	SN	Calceolarioside A; CHEMBL481635; 84744-28-5; AC1NRV65; MEGxp0_000507; ACon1_000369; MolPort-001-740-672; ZINC31156700; BDBM50259819; MCULE-7153533238; NCGC00169142-01; Calceolarioside A, &gt; [(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-(hydroxymethyl)tetrahydropyran-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; beta-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate), (E)-; beta-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 4-O-[(2E)-3-(3
DM6NPUM	DT	Small molecular drug
DM6NPUM	PC	5273566
DM6NPUM	MW	478.4
DM6NPUM	FM	C23H26O11
DM6NPUM	IC	InChI=1S/C23H26O11/c24-11-18-22(34-19(29)6-3-12-1-4-14(25)16(27)9-12)20(30)21(31)23(33-18)32-8-7-13-2-5-15(26)17(28)10-13/h1-6,9-10,18,20-28,30-31H,7-8,11H2/b6-3+/t18-,20-,21-,22-,23-/m1/s1
DM6NPUM	CS	C1=CC(=C(C=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O)O)O
DM6NPUM	IK	UHIGZYLCYRQESL-VJWFJHQPSA-N
DM6NPUM	IU	[(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DM6NPUM	CA	CAS 84744-28-5
DM6NPUM	DE	Discovery agent

DMEAUK5	ID	DMEAUK5
DMEAUK5	DN	CALCEOLARIOSIDE B
DMEAUK5	HS	Investigative
DMEAUK5	SN	Calceolarioside B; 105471-98-5; Calceorioside B; CHEMBL518414; CHEBI:68345; Nuomioside A; Calceolarioside-B; AC1NRV68; MEGxp0_000508; ACon1_000407; DTXSID70414938; MolPort-001-740-673; ZINC14512219; BDBM50269516; AKOS016010662; MCULE-4912944466; NCGC00169106-01; AJ-64948; KB-279900; ST24046273; Y0045; 3,4-Dihydroxyphenethyl 6-O-[3-(3,4-dihydroxyphenyl)propenoyl]-beta-D-glucopyranoside; NCGC00169106-02![(2R,3S,4S,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,4,5-trihydroxyoxan-2-yl]methyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DMEAUK5	DT	Small molecular drug
DMEAUK5	PC	5273567
DMEAUK5	MW	478.4
DMEAUK5	FM	C23H26O11
DMEAUK5	IC	InChI=1S/C23H26O11/c24-14-4-1-12(9-16(14)26)3-6-19(28)33-11-18-20(29)21(30)22(31)23(34-18)32-8-7-13-2-5-15(25)17(27)10-13/h1-6,9-10,18,20-27,29-31H,7-8,11H2/b6-3+/t18-,20-,21+,22-,23-/m1/s1
DMEAUK5	CS	C1=CC(=C(C=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O)O)O)O
DMEAUK5	IK	LFKQVVDFNHDYNK-FOXCETOMSA-N
DMEAUK5	IU	[(2R,3S,4S,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,4,5-trihydroxyoxan-2-yl]methyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DMEAUK5	CA	CAS 105471-98-5
DMEAUK5	CB	CHEBI:68345
DMEAUK5	DE	Discovery agent

DML562D	ID	DML562D
DML562D	DN	Calcineurin
DML562D	HS	Investigative
DML562D	DE	T-cell mediated immune dysfunction

DMZ45M6	ID	DMZ45M6
DMZ45M6	DN	calcitriol-26,23-lactone
DMZ45M6	HS	Investigative
DMZ45M6	SN	(23S,25R)-1alpha,25-(OH)2D3-26,23-lactone; 1,25-dihydroxyvitamin D3-26,23-lactone; 1,25-lactone
DMZ45M6	DT	Small molecular drug
DMZ45M6	PC	6438368
DMZ45M6	MW	444.6
DMZ45M6	FM	C27H40O5
DMZ45M6	IC	InChI=1S/C27H40O5/c1-16(12-21-15-27(4,31)25(30)32-21)22-9-10-23-18(6-5-11-26(22,23)3)7-8-19-13-20(28)14-24(29)17(19)2/h7-8,16,20-24,28-29,31H,2,5-6,9-15H2,1,3-4H3/b18-7+,19-8-/t16-,20-,21+,22-,23+,24+,26-,27-/m1/s1
DMZ45M6	CS	C[C@H](C[C@H]1C[C@@](C(=O)O1)(C)O)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DMZ45M6	IK	WMYIVSWWSRCZFA-RWVJFQLJSA-N
DMZ45M6	IU	(3R,5S)-5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]propyl]-3-hydroxy-3-methyloxolan-2-one
DMZ45M6	CA	CAS 81203-50-1
DMZ45M6	CB	CHEBI:156153
DMZ45M6	DE	Discovery agent

DMJXZD5	ID	DMJXZD5
DMJXZD5	DN	calhex 231
DMJXZD5	HS	Investigative
DMJXZD5	SN	calhex-231
DMJXZD5	DT	Small molecular drug
DMJXZD5	PC	11849514
DMJXZD5	MW	406.9
DMJXZD5	FM	C25H27ClN2O
DMJXZD5	IC	InChI=1S/C25H27ClN2O/c1-17(21-10-6-8-18-7-2-3-9-22(18)21)27-23-11-4-5-12-24(23)28-25(29)19-13-15-20(26)16-14-19/h2-3,6-10,13-17,23-24,27H,4-5,11-12H2,1H3,(H,28,29)/t17-,23+,24+/m1/s1
DMJXZD5	CS	C[C@H](C1=CC=CC2=CC=CC=C21)N[C@H]3CCCC[C@@H]3NC(=O)C4=CC=C(C=C4)Cl
DMJXZD5	IK	YTFUQWWKTIWYEY-CQLNOVPUSA-N
DMJXZD5	IU	4-chloro-N-[(1S,2S)-2-[[(1R)-1-naphthalen-1-ylethyl]amino]cyclohexyl]benzamide
DMJXZD5	DE	Discovery agent

DMY9P6E	ID	DMY9P6E
DMY9P6E	DN	calindol
DMY9P6E	HS	Investigative
DMY9P6E	SN	calindol; CHEMBL2092942; Clindol; GTPL719; SCHEMBL4103949; CHEMBL1801356; ZINC1494434; BDBM50404271; NCGC00344505-01
DMY9P6E	DT	Small molecular drug
DMY9P6E	PC	9882793
DMY9P6E	MW	300.4
DMY9P6E	FM	C21H20N2
DMY9P6E	IC	InChI=1S/C21H20N2/c1-15(19-11-6-9-16-7-2-4-10-20(16)19)22-14-18-13-17-8-3-5-12-21(17)23-18/h2-13,15,22-23H,14H2,1H3/t15-/m1/s1
DMY9P6E	CS	C[C@H](C1=CC=CC2=CC=CC=C21)NCC3=CC4=CC=CC=C4N3
DMY9P6E	IK	JLPWXRZETODYFC-OAHLLOKOSA-N
DMY9P6E	IU	(1R)-N-(1H-indol-2-ylmethyl)-1-naphthalen-1-ylethanamine
DMY9P6E	CA	CAS 374933-30-9
DMY9P6E	DE	Discovery agent

DM5ZTJL	ID	DM5ZTJL
DM5ZTJL	DN	Calmidazolium
DM5ZTJL	HS	Investigative
DM5ZTJL	SN	Calmidazolium ion; 95013-41-5; CHEBI:75400; R24571; MLS002172477; CHEMBL1208858; SMR001254103; SR-01000075486; Probes1_000251; Probes2_000292; Lopac0_000272; methoxy]ethyl]-1H-imidazolium; cid_644274; SCHEMBL8224791; CHEMBL1229168; BDBM76238; DTXSID30915173; BDBM50323389; HSCI1_000319; CCG-204367; NCGC00015233-02; NCGC00015233-03; NCGC00015233-04; NCGC00015233-08; NCGC00162113-01; NCGC00167775-01; 1-(Bis(4-chlorophenyl)methyl)-3-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-1H-imidazolium; 1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazol-3-ium; 1-[bis(4-chlorophenyl)methyl]-3-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazol-3-ium; 1H-Imidazolium, 1-(bis(4-chlorophenyl)methyl)-3-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-; SR-01000075486-7; SR-01000075486-8; BRD-A26199074-003-01-2; Q27145276; 3-[bis(4-chlorophenyl)methyl]-1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl); 1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorobenzyl)oxy-2-(2,4-dichlorophenyl)ethyl]imidazol-3-ium;chloride; 1-[Bis(4-chlorophenyl)methyl]-3-{2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl}-1H-imidazol-3-ium
DM5ZTJL	DT	Small molecular drug
DM5ZTJL	PC	2531
DM5ZTJL	MW	652.2
DM5ZTJL	FM	C31H23Cl6N2O+
DM5ZTJL	IC	InChI=1S/C31H23Cl6N2O/c32-23-6-1-20(2-7-23)31(21-3-8-24(33)9-4-21)39-14-13-38(19-39)17-30(27-12-11-26(35)16-29(27)37)40-18-22-5-10-25(34)15-28(22)36/h1-16,19,30-31H,17-18H2/q+1
DM5ZTJL	CS	C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)N3C=C[N+](=C3)CC(C4=C(C=C(C=C4)Cl)Cl)OCC5=C(C=C(C=C5)Cl)Cl)Cl
DM5ZTJL	IK	CTKNMSVWMRRCPW-UHFFFAOYSA-N
DM5ZTJL	IU	1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazol-3-ium
DM5ZTJL	CA	CAS 95013-41-5
DM5ZTJL	CB	CHEBI:75400
DM5ZTJL	DE	Huntington disease

DMVXKLF	ID	DMVXKLF
DMVXKLF	DN	CALOPOCARPIN
DMVXKLF	HS	Investigative
DMVXKLF	SN	calopocarpin; CHEMBL1096407; MolPort-005-945-433; ZINC15115178; BDBM50317436; MCULE-1067987266; NCGC00347827-02; NCGC00347827-02_C20H20O4_6H-Benzofuro[3,2-c][1]benzopyran-3,9-diol, 6a,11a-dihydro-2-(3-methyl-2-buten-1-yl)-, (6aR,11aR)-
DMVXKLF	DT	Small molecular drug
DMVXKLF	PC	11709595
DMVXKLF	MW	324.4
DMVXKLF	FM	C20H20O4
DMVXKLF	IC	InChI=1S/C20H20O4/c1-11(2)3-4-12-7-15-18(9-17(12)22)23-10-16-14-6-5-13(21)8-19(14)24-20(15)16/h3,5-9,16,20-22H,4,10H2,1-2H3/t16-,20-/m0/s1
DMVXKLF	CS	CC(=CCC1=CC2=C(C=C1O)OC[C@@H]3[C@H]2OC4=C3C=CC(=C4)O)C
DMVXKLF	IK	CYXCYFYWIZXENQ-JXFKEZNVSA-N
DMVXKLF	IU	(6aR,11aR)-2-(3-methylbut-2-enyl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMVXKLF	DE	Discovery agent

DMR0CNQ	ID	DMR0CNQ
DMR0CNQ	DN	Calpastatin
DMR0CNQ	HS	Investigative
DMR0CNQ	SN	Acacetin-7-O-glucuronide methyl ester; AC1NUQS7; 79076-87-2; beta-D-Glucopyranosiduronic acid, 5-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-7-yl, methyl ester; methyl (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-methoxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylate
DMR0CNQ	DT	Small molecular drug
DMR0CNQ	PC	90488788
DMR0CNQ	MW	3177.6
DMR0CNQ	FM	C142H230N36O44S
DMR0CNQ	IC	InChI=1S/C142H230N36O44S/c1-18-74(11)111(172-129(211)97(65-81-38-42-83(185)43-39-81)168-136(218)113(77(14)181)174-131(213)100(69-180)170-130(212)99(68-179)169-124(206)92(52-60-223-17)162-132(214)101-33-26-57-176(101)138(220)98(66-109(195)196)154-79(16)183)135(217)163-90(46-50-107(191)192)121(203)159-88(44-48-105(187)188)122(204)164-93(61-70(3)4)116(198)152-67-104(186)155-84(29-20-22-53-143)117(199)156-86(31-24-55-150-141(146)147)118(200)160-91(47-51-108(193)194)125(207)171-110(73(9)10)134(216)175-114(78(15)182)137(219)173-112(75(12)19-2)140(222)178-59-28-35-103(178)139(221)177-58-27-34-102(177)133(215)161-85(30-21-23-54-144)120(202)167-96(64-80-36-40-82(184)41-37-80)128(210)157-87(32-25-56-151-142(148)149)119(201)158-89(45-49-106(189)190)123(205)165-95(63-72(7)8)127(209)166-94(62-71(5)6)126(208)153-76(13)115(145)197/h36-43,70-78,84-103,110-114,179-182,184-185H,18-35,44-69,143-144H2,1-17H3,(H2,145,197)(H,152,198)(H,153,208)(H,154,183)(H,155,186)(H,156,199)(H,157,210)(H,158,201)(H,159,203)(H,160,200)(H,161,215)(H,162,214)(H,163,217)(H,164,204)(H,165,205)(H,166,209)(H,167,202)(H,168,218)(H,169,206)(H,170,212)(H,171,207)(H,172,211)(H,173,219)(H,174,213)(H,175,216)(H,187,188)(H,189,190)(H,191,192)(H,193,194)(H,195,196)(H4,146,147,150)(H4,148,149,151)/t74-,75-,76-,77+,78+,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,110-,111-,112-,113-,114-/m0/s1
DMR0CNQ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC(=O)O)NC(=O)C
DMR0CNQ	IK	ZXJCOYBPXOBJMU-HSQGJUDPSA-N
DMR0CNQ	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-6-aminohexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-6-aminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMR0CNQ	CA	CAS 79079-11-1
DMR0CNQ	CB	CHEBI:131884
DMR0CNQ	DE	Discovery agent

DMBK2S8	ID	DMBK2S8
DMBK2S8	DN	Calusterone
DMBK2S8	HS	Investigative
DMBK2S8	SN	CALUSTERONE; Methosarb; Dimethyltestosterone; Calusteronum; Calusterona; 7-beta,17-Dimethyltestosterone; Calusteronum [INN-Latin]; Calusterona [INN-Spanish]; 7beta,17alpha-Dimethyltestosterone; 17021-26-0; 7beta,17-Dimethyltestosterone; Calusteron; 7-beta,17-alpha-Dimethyl testosterone; Calusterone [USAN:INN]; NSC-88536; UNII-0678G6Q58A; HSDB 3210; 17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-one; U 22550; U-22,550; BRN 3212336; 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one
DMBK2S8	DT	Small molecular drug
DMBK2S8	PC	28204
DMBK2S8	MW	316.5
DMBK2S8	FM	C21H32O2
DMBK2S8	IC	InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16-,17-,18+,19-,20-,21-/m0/s1
DMBK2S8	CS	C[C@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C)O)C
DMBK2S8	IK	IVFYLRMMHVYGJH-PVPPCFLZSA-N
DMBK2S8	IU	(7S,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,10,13,17-tetramethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMBK2S8	CA	CAS 17021-26-0
DMBK2S8	CB	CHEBI:135356
DMBK2S8	DE	Discovery agent

DMY29Q8	ID	DMY29Q8
DMY29Q8	DN	Calyculin-A
DMY29Q8	HS	Investigative
DMY29Q8	SN	calyculin A; C05370; 101932-71-2; [(3R,5R,7R,8S,9S)-2-[(1S,3S,4S,5R,6R,7E,9E,11E,13Z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyl-tetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[(1S)-3-[[(2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxy-pentanoyl]amino]-1-methyl-propyl]oxazol-4-yl]allyl]-7-hydroxy-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate
DMY29Q8	DT	Small molecular drug
DMY29Q8	PC	5311365
DMY29Q8	MW	1009.2
DMY29Q8	FM	C50H81N4O15P
DMY29Q8	IC	InChI=1S/C50H81N4O15P/c1-29(20-22-51)16-14-17-30(2)32(4)24-33(5)42(57)35(7)38(55)25-41(65-13)45-46(69-70(61,62)63)49(8,9)50(68-45)26-39(56)34(6)40(67-50)19-15-18-36-27-66-48(53-36)31(3)21-23-52-47(60)44(59)43(58)37(28-64-12)54(10)11/h14-18,20,24,27,31,33-35,37-46,55-59H,19,21,23,25-26,28H2,1-13H3,(H,52,60)(H2,61,62,63)/b16-14+,18-15+,29-20-,30-17+,32-24+/t31-,33+,34-,35-,37-,38-,39+,40-,41-,42+,43-,44-,45+,46-,50+/m0/s1
DMY29Q8	CS	C[C@H]1[C@@H](C[C@@]2(C([C@H]([C@H](O2)[C@H](C[C@@H]([C@H](C)[C@@H]([C@H](C)/C=C(\\C)/C(=C/C=C/C(=C\\C#N)/C)/C)O)O)OC)OP(=O)(O)O)(C)C)O[C@H]1C/C=C/C3=COC(=N3)[C@@H](C)CCNC(=O)[C@H]([C@H]([C@H](COC)N(C)C)O)O)O
DMY29Q8	IK	FKAWLXNLHHIHLA-YCBIHMBMSA-N
DMY29Q8	IU	[(2R,3R,5R,7R,8S,9S)-2-[(1S,3S,4S,5R,6R,7E,9E,11E,13Z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[(2S)-4-[[(2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4-yl]prop-2-enyl]-7-hydroxy-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate
DMY29Q8	CA	CAS 101932-71-2
DMY29Q8	DE	Discovery agent

DMMBA70	ID	DMMBA70
DMMBA70	DN	CALYSTEGINE B2
DMMBA70	HS	Investigative
DMMBA70	SN	Calystegine B2; (1S,2R,3S,4R,5S)-8-AZABICYCLO[3.2.1]OCTANE-1,2,3,4-TETROL; 8-Aza-bicyclo[3.2.1]octane-1,2,3,4-tetraol; (1R,2S,3R,4S,5R)-8-azabicyclo[3.2.1]octane-1,2,3,4-tetrol; 127414-85-1; CGB; Calystegine B(2); 2cbv; 1,2,3,4-Tetrahydroxy-nor-tropane; CID124434; SCHEMBL2435745; CHEMBL526330; BDBM36389; MolPort-006-169-861; ZINC12504453; (2-endo,3-exo,4-endo)-8-Azabicyclo(3.2.1)octane-1,2,3,4-tetrol; AKOS030531595; DB04658; LS-190985; W-200999; 8-Aza-bicyclo[3.2.1]octane-1,2,3,4-tetraol, 14
DMMBA70	DT	Small molecular drug
DMMBA70	PC	124434
DMMBA70	MW	175.18
DMMBA70	FM	C7H13NO4
DMMBA70	IC	InChI=1S/C7H13NO4/c9-4-3-1-2-7(12,8-3)6(11)5(4)10/h3-6,8-12H,1-2H2/t3-,4+,5-,6+,7-/m1/s1
DMMBA70	CS	C1C[C@]2([C@H]([C@@H]([C@H]([C@@H]1N2)O)O)O)O
DMMBA70	IK	FXFBVZOJVHCEDO-IBISWUOJSA-N
DMMBA70	IU	(1R,2S,3R,4S,5R)-8-azabicyclo[3.2.1]octane-1,2,3,4-tetrol
DMMBA70	CA	CAS 127414-85-1
DMMBA70	DE	Discovery agent

DM4FVDS	ID	DM4FVDS
DM4FVDS	DN	CAM-2036
DM4FVDS	HS	Investigative
DM4FVDS	SN	Glucagon-like peptide 1 agonist (sustained release subcutaneous injection, type 2 diabetes), Camurus
DM4FVDS	CP	Camurus AB
DM4FVDS	DE	Non-insulin dependent diabetes

DMVAP4T	ID	DMVAP4T
DMVAP4T	DN	Camrelizumab
DMVAP4T	HS	Investigative
DMVAP4T	SN	GTPL9758; SHR-1210
DMVAP4T	TC	Antiviral Agents
DMVAP4T	DT	Monoclonal antibody
DMVAP4T	DE	Coronavirus Disease 2019 (COVID-19)

DMNLTGF	ID	DMNLTGF
DMNLTGF	DN	Canaline
DMNLTGF	HS	Investigative
DMNLTGF	SN	L-Canaline; 496-93-5; (S)-2-Amino-4-(aminooxy)butanoic acid; O-Amino-L-homoserine; L-Homoserine, O-amino-; UNII-T7H2XP1ZNS; T7H2XP1ZNS; (2S)-2-amino-4-(aminooxy)butanoic acid; L-2-amino-4-(aminooxy)butyrate; L-2-amino-4-(aminooxy)butyric acid; L-a-amino-g-(aminooxy)-n-butyric acid; 2-Amino-4-(aminooxy)butyric acid; L-Canaline base; 1-Amino-3-amino-oxybutyric acid; AC1L9B6J; SCHEMBL440859; CHEMBL1231652; CTK1D6980; DTXSID60197925; MolPort-019-904-731; FQPGMQABJNQLLF-VKHMYHEASA-N; ZINC1531042; ANW-63284; AKOS006274866; L-canaline
DMNLTGF	DT	Small molecular drug
DMNLTGF	PC	441443
DMNLTGF	MW	134.13
DMNLTGF	FM	C4H10N2O3
DMNLTGF	IC	InChI=1S/C4H10N2O3/c5-3(4(7)8)1-2-9-6/h3H,1-2,5-6H2,(H,7,8)/t3-/m0/s1
DMNLTGF	CS	C(CON)[C@@H](C(=O)O)N
DMNLTGF	IK	FQPGMQABJNQLLF-VKHMYHEASA-N
DMNLTGF	IU	(2S)-2-amino-4-aminooxybutanoic acid
DMNLTGF	CA	CAS 496-93-5
DMNLTGF	CB	CHEBI:41401
DMNLTGF	DE	Discovery agent

DMM6A7P	ID	DMM6A7P
DMM6A7P	DN	cannabinol
DMM6A7P	HS	Investigative
DMM6A7P	SN	cannabinol; 521-35-7; Cannabinolo [DCIT]; Cannabinolum [INN-Latin]; Cannabinol [INN:BAN]; UNII-7UYP6MC9GH; 6H-Dibenzo(b,d)pyran-1-ol, 6,6,9-trimethyl-3-pentyl-; NSC 134455; 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo(b,d)pyran; 7UYP6MC9GH; BRN 0237145; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; CHEMBL74415; CHEBI:3360; VBGLYOIFKLUMQG-UHFFFAOYSA-N; 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl-
DMM6A7P	DT	Small molecular drug
DMM6A7P	PC	2543
DMM6A7P	MW	310.4
DMM6A7P	FM	C21H26O2
DMM6A7P	IC	InChI=1S/C21H26O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h9-13,22H,5-8H2,1-4H3
DMM6A7P	CS	CCCCCC1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)C)(C)C)O
DMM6A7P	IK	VBGLYOIFKLUMQG-UHFFFAOYSA-N
DMM6A7P	IU	6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol
DMM6A7P	CA	CAS 521-35-7
DMM6A7P	CB	CHEBI:3360
DMM6A7P	DE	Discovery agent

DME32XU	ID	DME32XU
DME32XU	DN	CANTHARIDIC_ACID
DME32XU	HS	Investigative
DME32XU	SN	cantharidic acid; 2,3-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid; exo-1,6-Dicarboxy-endo-1,6-dimethyl-7-oxabicylco[2,2,1]heptane; 2,3-Dicarboxy-2,3-dimethyl-1,4-epoxycyclohexane; NSC115503; AC1L1DX2; Lopac0_000318; SCHEMBL943636; BMK1-G11; CHEMBL275516; CTK7I5696; HMS3260P18; Tox21_500318; HSCI1_000263; CCG-204413; NSC-115503; LP00318; NCGC00093763-02; NCGC00015272-04; NCGC00015272-03; NCGC00015272-02; NCGC00261003-01; NCGC00093763-01; EU-0100318; C 8088; SR-01000075783; SR-01000075783-1
DME32XU	DT	Small molecular drug
DME32XU	PC	2544
DME32XU	MW	214.21
DME32XU	FM	C10H14O5
DME32XU	IC	InChI=1S/C10H14O5/c1-9(7(11)12)5-3-4-6(15-5)10(9,2)8(13)14/h5-6H,3-4H2,1-2H3,(H,11,12)(H,13,14)
DME32XU	CS	CC1(C2CCC(C1(C)C(=O)O)O2)C(=O)O
DME32XU	IK	NMTNUQBORQILRK-UHFFFAOYSA-N
DME32XU	IU	2,3-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid
DME32XU	DE	Discovery agent

DM9IG2P	ID	DM9IG2P
DM9IG2P	DN	Cantide + Cisplatin
DM9IG2P	HS	Investigative
DM9IG2P	SN	cis-Diaminedichloroplatinum; CPDC; cis-Diamminedichlorplatine; cis-Dichlorodiamine platinum; Diamminedichloroplatinum; Platinum diamine dichloride; Platinum, diamminedichloro-; trans-Diaminedichloroplatinum; NCGC00090759-01; DSSTox_CID_4983; DSSTox_RID_77611; DSSTox_GSID_24983; CAS-15663-27-1; Platiblastin; cisplatin complex; DDPt; cis-Platinum(II); Pt(II) Complex; cis Pt II; CPDD; dichloroplatinumdiamine; Platinum(IV) Complex; Platinum (II) complex; Neuro_000055; cis-Platinum diamminedichloride; DTXSID4024983; MolPort-003-983-464
DM9IG2P	TC	Antisense
DM9IG2P	DT	Combination drug (Antisense drug)
DM9IG2P	PC	2767
DM9IG2P	MW	298.03
DM9IG2P	FM	Cl2H4N2Pt
DM9IG2P	IC	InChI=1S/2ClH.2H2N.Pt/h2*1H;2*1H2;/q;;2*-1;+4/p-2
DM9IG2P	CS	[NH2-].[NH2-].Cl[Pt+2]Cl
DM9IG2P	IK	DQLATGHUWYMOKM-UHFFFAOYSA-L
DM9IG2P	IU	azanide;dichloroplatinum(2+)
DM9IG2P	CA	CAS 26035-31-4
DM9IG2P	DE	Tumour

DMDZE8N	ID	DMDZE8N
DMDZE8N	DN	CAPROCTAMINE
DMDZE8N	HS	Investigative
DMDZE8N	SN	CAPROCTAMINE; CHEMBL11805; SCHEMBL18398791; BDBM50067482; N,N''''-(octane-1,8-diyl)bis(6-((2-methoxybenzyl)(methyl)amino)-N-methylhexanamide); 6-[(2-Methoxy-benzyl)-methyl-amino]-hexanoic acid [8-({6-[(2-methoxy-benzyl)-methyl-amino]-hexanoyl}-methyl-amino)-octyl]-methyl-amide
DMDZE8N	DT	Small molecular drug
DMDZE8N	PC	10055202
DMDZE8N	MW	667
DMDZE8N	FM	C40H66N4O4
DMDZE8N	IC	InChI=1S/C40H66N4O4/c1-41(33-35-23-15-17-25-37(35)47-5)29-19-11-13-27-39(45)43(3)31-21-9-7-8-10-22-32-44(4)40(46)28-14-12-20-30-42(2)34-36-24-16-18-26-38(36)48-6/h15-18,23-26H,7-14,19-22,27-34H2,1-6H3
DMDZE8N	CS	CN(CCCCCC(=O)N(C)CCCCCCCCN(C)C(=O)CCCCCN(C)CC1=CC=CC=C1OC)CC2=CC=CC=C2OC
DMDZE8N	IK	HDAQKLAKMZNBQB-UHFFFAOYSA-N
DMDZE8N	IU	6-[(2-methoxyphenyl)methyl-methylamino]-N-[8-[6-[(2-methoxyphenyl)methyl-methylamino]hexanoyl-methylamino]octyl]-N-methylhexanamide
DMDZE8N	DE	Discovery agent

DMLGS82	ID	DMLGS82
DMLGS82	DN	Caprylic acid
DMLGS82	HS	Investigative
DMLGS82	SN	octanoic acid; caprylic acid; 124-07-2; n-octanoic acid; n-caprylic acid; Octylic acid; octoic acid; n-octylic acid; n-Octoic acid; neo-fat 8; 1-heptanecarboxylic acid; Enantic acid; Octic acid; C-8 acid; Caprylsaeure; capryloate; Kaprylsaeure; Hexacid 898; Acido octanoico; Acide octanoique; 0ctanoic acid; Acidum octanocium; Caprylic acid (natural); Kyselina kaprylova; Fatty acids, C6-10; octylate; Octansaeure; Acide octanoique [French]; 1-octanoic acid; Acidum octanocium [Latin]; Acido octanoico [Spanish]; NSC 5024; Kyselina kaprylova [C
DMLGS82	DT	Small molecular drug
DMLGS82	PC	379
DMLGS82	MW	144.21
DMLGS82	FM	C8H16O2
DMLGS82	IC	InChI=1S/C8H16O2/c1-2-3-4-5-6-7-8(9)10/h2-7H2,1H3,(H,9,10)
DMLGS82	CS	CCCCCCCC(=O)O
DMLGS82	IK	WWZKQHOCKIZLMA-UHFFFAOYSA-N
DMLGS82	IU	octanoic acid
DMLGS82	CA	CAS 124-07-2
DMLGS82	CB	CHEBI:28837
DMLGS82	DE	Discovery agent

DM4ATCI	ID	DM4ATCI
DM4ATCI	DN	CAPSAZEPINE
DM4ATCI	HS	Investigative
DM4ATCI	SN	capsazepine; 138977-28-3; capsazepin; N-[2-(4-Chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-benzazepine-2-carbothioamide; UNII-LFW48MY844; N-[2-(4-chlorophenyl)ethyl]-7,8-dihydroxy-1,3,4,5-tetrahydro-2-benzazepine-2-carbothioamide; CHEMBL391997; LFW48MY844; ST50826300; CHEBI:70773; N-[2-(4-chlorophenyl)ethyl]-7,8-dihydroxy-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carbothioamide; N-(2-[4-chlorophenyl]ethyl)-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-benzazepine-2-carbothioamide
DM4ATCI	DT	Small molecular drug
DM4ATCI	PC	2733484
DM4ATCI	MW	376.9
DM4ATCI	FM	C19H21ClN2O2S
DM4ATCI	IC	InChI=1S/C19H21ClN2O2S/c20-16-5-3-13(4-6-16)7-8-21-19(25)22-9-1-2-14-10-17(23)18(24)11-15(14)12-22/h3-6,10-11,23-24H,1-2,7-9,12H2,(H,21,25)
DM4ATCI	CS	C1CC2=CC(=C(C=C2CN(C1)C(=S)NCCC3=CC=C(C=C3)Cl)O)O
DM4ATCI	IK	DRCMAZOSEIMCHM-UHFFFAOYSA-N
DM4ATCI	IU	N-[2-(4-chlorophenyl)ethyl]-7,8-dihydroxy-1,3,4,5-tetrahydro-2-benzazepine-2-carbothioamide
DM4ATCI	CA	CAS 138977-28-3
DM4ATCI	CB	CHEBI:70773
DM4ATCI	DE	Discovery agent

DMJFPA9	ID	DMJFPA9
DMJFPA9	DN	CARAMIPEN
DMJFPA9	HS	Investigative
DMJFPA9	SN	Caramiphen; Parpanil; 77-22-5; Pentaphen (pharmaceutical); Caramiphen [INN:BAN]; Caramiphenum [INN-Latin]; Caramiphene [INN-French]; UNII-97J7NP0XJY; Caramifenio [INN-Spanish]; EINECS 201-013-6; BRN 2144901; 97J7NP0XJY; CYCLOPENTANECARBOXYLIC ACID, 1-PHENYL-, 2-(DIETHYLAMINO)ETHYL ESTER; CHEMBL61946; 1-Phenylcyclopentanecarboxylic acid 2-(diethylamino)ethyl ester; 2-Diethylaminoethyl 1-phenylcyclopentancarboxylat; 2-(Diethylamino)ethyl 1-phenylcyclopentanecarboxylate; 2-Diethylaminoethyl 1-phenylcyclopentane-1-carboxylate
DMJFPA9	DT	Small molecular drug
DMJFPA9	PC	6472
DMJFPA9	MW	289.4
DMJFPA9	FM	C18H27NO2
DMJFPA9	IC	InChI=1S/C18H27NO2/c1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16/h5-7,10-11H,3-4,8-9,12-15H2,1-2H3
DMJFPA9	CS	CCN(CC)CCOC(=O)C1(CCCC1)C2=CC=CC=C2
DMJFPA9	IK	OFAIGZWCDGNZGT-UHFFFAOYSA-N
DMJFPA9	IU	2-(diethylamino)ethyl 1-phenylcyclopentane-1-carboxylate
DMJFPA9	CA	CAS 77-22-5
DMJFPA9	CB	CHEBI:135204
DMJFPA9	DE	Discovery agent

DMEKI1J	ID	DMEKI1J
DMEKI1J	DN	Carazolol
DMEKI1J	HS	Investigative
DMEKI1J	SN	Carazolol; 57775-29-8; Conducton; Suacron; corazolol; Carazolol [INN:BAN]; 1-((9H-Carbazol-4-yl)oxy)-3-(isopropylamino)propan-2-ol; Carazololum [INN-Latin]; CCRIS 1047; Conducton hydrochloride; 1-(Carbazol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(9H-carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol; EINECS 260-945-1; BRN 3620576; BM-51052; BM 51052; CHEMBL324665; 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(4-Carbazolyloxy)-3-isopropylamino-2-propanol
DMEKI1J	DT	Small molecular drug
DMEKI1J	PC	71739
DMEKI1J	MW	298.4
DMEKI1J	FM	C18H22N2O2
DMEKI1J	IC	InChI=1S/C18H22N2O2/c1-12(2)19-10-13(21)11-22-17-9-5-8-16-18(17)14-6-3-4-7-15(14)20-16/h3-9,12-13,19-21H,10-11H2,1-2H3
DMEKI1J	CS	CC(C)NCC(COC1=CC=CC2=C1C3=CC=CC=C3N2)O
DMEKI1J	IK	BQXQGZPYHWWCEB-UHFFFAOYSA-N
DMEKI1J	IU	1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
DMEKI1J	CA	CAS 57775-29-8
DMEKI1J	CB	CHEBI:135261
DMEKI1J	DE	Discovery agent

DMMBQYE	ID	DMMBQYE
DMMBQYE	DN	carbacyclin
DMMBQYE	HS	Investigative
DMMBQYE	SN	carboprostacyclin
DMMBQYE	DT	Small molecular drug
DMMBQYE	PC	5311242
DMMBQYE	MW	350.5
DMMBQYE	FM	C21H34O4
DMMBQYE	IC	InChI=1S/C21H34O4/c1-2-3-4-8-17(22)10-11-18-19-13-15(7-5-6-9-21(24)25)12-16(19)14-20(18)23/h7,10-11,16-20,22-23H,2-6,8-9,12-14H2,1H3,(H,24,25)/b11-10+,15-7-/t16-,17-,18+,19-,20+/m0/s1
DMMBQYE	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C\\CCCC(=O)O)/C2)O)O
DMMBQYE	IK	XZFRIPGNUQRGPI-WLPVIMDJSA-N
DMMBQYE	IU	(5Z)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
DMMBQYE	DE	Discovery agent

DMJQ3LN	ID	DMJQ3LN
DMJQ3LN	DN	Carbamic Acid
DMJQ3LN	HS	Investigative
DMJQ3LN	SN	Aminoformic acid; 463-77-4; UNII-O0UC6XOS4H; O0UC6XOS4H; CHEBI:28616; OUT; Carbamidsaeure; Aminoformate; ammoniocarboxylate; Aminoameisensaeure; imidocarbonic acid; Aminomethanoic Acid; aminocarboxylic acid; AC1L18VM; CHEMBL125278; DTXSID5048009; CTK1D6698; 1111-78-0 (ammonium salt); KXDHJXZQYSOELW-UHFFFAOYSA-N; 4366-93-2 (potassium salt); ZINC8383199; BDBM50369454; ABP000336; Carbamic acid(6CI,7CI,8CI,9CI); ACM463774; AKOS006223007; DB04261; NCGC00166327-01; LS-69662; KB-75881; DB-011502; FT-0689176
DMJQ3LN	DT	Small molecular drug
DMJQ3LN	PC	277
DMJQ3LN	MW	61.04
DMJQ3LN	FM	CH3NO2
DMJQ3LN	IC	InChI=1S/CH3NO2/c2-1(3)4/h2H2,(H,3,4)
DMJQ3LN	CS	C(=O)(N)O
DMJQ3LN	IK	KXDHJXZQYSOELW-UHFFFAOYSA-N
DMJQ3LN	IU	carbamic acid
DMJQ3LN	CA	CAS 463-77-4
DMJQ3LN	CB	CHEBI:28616
DMJQ3LN	DE	Discovery agent

DMZYK1W	ID	DMZYK1W
DMZYK1W	DN	Carbamoyl phosphate disodium
DMZYK1W	HS	Investigative
DMZYK1W	DE	Discovery agent

DMGP4M3	ID	DMGP4M3
DMGP4M3	DN	Carba-Nicotinamide-Adenine-Dinucleotide
DMGP4M3	HS	Investigative
DMGP4M3	SN	Carba-NAD; Carbanicotinamide adenine dinucleotide; 112345-60-5; AC1L4TS7; AC1Q5J0L; SCHEMBL16445201; 5'-o-{[({[(1r,2r,3s,4r)-4-(3-carbamoylpyridinium-1-yl)-2,3-dihydroxycyclopentyl]methoxy}phosphinato)oxy](hydroxy)phosphoryl}adenosine; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1R,2R,3S,4R)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate; Adenosine 5'-(trihydrogen diphosphate), 5'-((4-(3-(aminocarbonyl)pyridinio)-2,3-dihydroxycyclopentyl)m
DMGP4M3	DT	Small molecular drug
DMGP4M3	PC	163884
DMGP4M3	MW	662.5
DMGP4M3	FM	C22H30N7O13P2+
DMGP4M3	IC	InChI=1S/C22H29N7O13P2/c23-19-14-21(26-8-25-19)29(9-27-14)22-18(33)17(32)13(41-22)7-40-44(37,38)42-43(35,36)39-6-11-4-12(16(31)15(11)30)28-3-1-2-10(5-28)20(24)34/h1-3,5,8-9,11-13,15-18,22,30-33H,4,6-7H2,(H5-,23,24,25,26,34,35,36,37,38)/p+1/t11-,12-,13-,15-,16+,17-,18-,22-/m1/s1
DMGP4M3	CS	C1[C@@H]([C@H]([C@H]([C@@H]1[N+]2=CC=CC(=C2)C(=O)N)O)O)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O
DMGP4M3	IK	DGPLSUKWXXSBCU-VGXGLJSLSA-O
DMGP4M3	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1R,2R,3S,4R)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl hydrogen phosphate
DMGP4M3	DE	Discovery agent

DMGFLI7	ID	DMGFLI7
DMGFLI7	DN	Carbaphosphonate
DMGFLI7	HS	Investigative
DMGFLI7	SN	carbaphosphonate; CRB; [1R-(1ALPHA,3BETA,4ALPHA,5BETA)]-5-(PHOSPHONOMETHYL)-1,3,4-TRIHYDROXYCYCLOHEXANE-1-CARBOXYLIC ACID; AC1L9HHC; DB02592; (1S,3R,4R,5S)-1,3,4-trihydroxy-5-(phosphonomethyl)cyclohexanecarboxylic acid; 1,3beta,4alpha-Trihydroxy-5beta-(phosphonomethyl)cyclohexane-1beta-carboxylic acid; (1S,3R,4R,5S)-1,3,4-trihydroxy-5-(phosphonomethyl)cyclohexane-1-carboxylic acid
DMGFLI7	DT	Small molecular drug
DMGFLI7	PC	445131
DMGFLI7	MW	270.17
DMGFLI7	FM	C8H15O8P
DMGFLI7	IC	InChI=1S/C8H15O8P/c9-5-2-8(13,7(11)12)1-4(6(5)10)3-17(14,15)16/h4-6,9-10,13H,1-3H2,(H,11,12)(H2,14,15,16)/t4-,5-,6-,8+/m1/s1
DMGFLI7	CS	C1[C@@H]([C@H]([C@@H](C[C@@]1(C(=O)O)O)O)O)CP(=O)(O)O
DMGFLI7	IK	BKLICLLAHMTUPK-UNGCPHIMSA-N
DMGFLI7	IU	(1S,3R,4R,5S)-1,3,4-trihydroxy-5-(phosphonomethyl)cyclohexane-1-carboxylic acid
DMGFLI7	DE	Discovery agent

DMO648T	ID	DMO648T
DMO648T	DN	Carbenoxolone
DMO648T	HS	Investigative
DMO648T	SN	carbenoxolone; 5697-56-3; UNII-MM6384NG73; OBZHEBDUNPOCJG-WBXJDKIVSA-N; MM6384NG73; Carbenoxolone [INN:BAN]; Carbenoxolonum [INN-Latin]; Carbenoxolona [INN-Spanish]; Carbenoxolona; Carbenoxolonum; EINECS 227-174-2; CBO; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-(4-hydroxy-4-oxobutanoyl)oxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; 3beta-Hydroxy-11-oxoolean-12-en-30-saeure hydogensuccinat; 3beta-(3-Carboxypropionyloxy)-11-oxo-olean-12-en-30-saeure
DMO648T	DT	Small molecular drug
DMO648T	PC	636403
DMO648T	MW	570.8
DMO648T	FM	C34H50O7
DMO648T	IC	InChI=1S/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h18,21,23-24,27H,8-17,19H2,1-7H3,(H,36,37)(H,39,40)/t21-,23-,24-,27+,30+,31-,32-,33+,34+/m0/s1
DMO648T	CS	C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)O)C)(C)C(=O)O
DMO648T	IK	OBZHEBDUNPOCJG-WBXJDKIVSA-N
DMO648T	IU	(2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-(3-carboxypropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid
DMO648T	CA	CAS 5697-56-3
DMO648T	DE	Discovery agent

DM87SOX	ID	DM87SOX
DM87SOX	DN	Carbocyclic Peptidomimetic
DM87SOX	HS	Investigative
DM87SOX	SN	Carbocyclic Peptidomimetic; CHEMBL434943; OM99-2 cyclopentano analog 3; BDBM16049; N-{[(1R,2R)-2-{(1S,2S)-2-[(L-alpha-glutamyl-L-valyl-L-asparaginyl)amino]-1-hydroxy-4-methylpentyl}cyclopentyl]carbonyl}-L-alanyl-L-alpha-glutamyl-L-phenylalanine; (4S)-4-[(2S)-2-{[(1R,2R)-2-[(1S,2S)-2-[(2S)-2-[(2S)-2-[(4S)-4-amino-4-formamidobutanoic acid]-3-methylbutanamido]butanediamido]-1-hydroxy-4-methylpentyl]cyclopentyl]formamido}propanamido]-4-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}butanoic acid
DM87SOX	DT	Small molecular drug
DM87SOX	PC	11205295
DM87SOX	MW	919
DM87SOX	FM	C43H66N8O14
DM87SOX	IC	InChI=1S/C43H66N8O14/c1-21(2)18-29(48-41(62)30(20-32(45)52)49-42(63)35(22(3)4)51-39(60)27(44)14-16-33(53)54)36(57)25-12-9-13-26(25)38(59)46-23(5)37(58)47-28(15-17-34(55)56)40(61)50-31(43(64)65)19-24-10-7-6-8-11-24/h6-8,10-11,21-23,25-31,35-36,57H,9,12-20,44H2,1-5H3,(H2,45,52)(H,46,59)(H,47,58)(H,48,62)(H,49,63)(H,50,61)(H,51,60)(H,53,54)(H,55,56)(H,64,65)/t23-,25+,26+,27-,28-,29-,30-,31-,35-,36-/m0/s1
DM87SOX	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@@H]2CCC[C@H]2[C@@H]([C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)N)O
DM87SOX	IK	SEJYUEISOCTKKB-SABPYFDQSA-N
DM87SOX	IU	(4S)-4-amino-5-[[(2S)-1-[[(2S)-4-amino-1-[[(1S,2S)-1-[(1R,2R)-2-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]cyclopentyl]-1-hydroxy-4-methylpentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM87SOX	DE	Discovery agent

DMGKSVF	ID	DMGKSVF
DMGKSVF	DN	carbocyclic thromboxane A2
DMGKSVF	HS	Investigative
DMGKSVF	SN	9alpha,11alpha,11a-dicarba-TXA2; CTA-2
DMGKSVF	DT	Small molecular drug
DMGKSVF	PC	5311387
DMGKSVF	MW	348.5
DMGKSVF	FM	C22H36O3
DMGKSVF	IC	InChI=1S/C22H36O3/c1-2-3-6-9-20(23)13-12-18-14-17-15-19(16-17)21(18)10-7-4-5-8-11-22(24)25/h4,7,12-13,17-21,23H,2-3,5-6,8-11,14-16H2,1H3,(H,24,25)/b7-4-,13-12+/t17?,18-,19?,20-,21+/m0/s1
DMGKSVF	CS	CCCCC[C@@H](/C=C/[C@H]1CC2CC(C2)[C@@H]1C/C=C\\CCCC(=O)O)O
DMGKSVF	IK	ZIWNJZLXPXFNGN-GXTQQWMXSA-N
DMGKSVF	IU	(Z)-7-[(2S,3R)-3-[(E,3S)-3-hydroxyoct-1-enyl]-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DMGKSVF	CA	CAS 74034-56-3
DMGKSVF	DE	Discovery agent

DMA3FZR	ID	DMA3FZR
DMA3FZR	DN	Carbodine
DMA3FZR	HS	Investigative
DMA3FZR	SN	Carbocyclic cytidine; 4-amino-1-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]pyrimidin-2-one; 71184-20-8; (-)-Carbodine; (+/-)-Carbodine; AC1LA1FO; C-ARC-C; SCHEMBL3333453; CHEMBL1089302; 2(1H)-Pyrimidinone, 4-amino-1-[2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]-, (2:1),(1alpha,2beta,3beta, 4alpha)-(+/-)-
DMA3FZR	DT	Small molecular drug
DMA3FZR	PC	459903
DMA3FZR	MW	241.24
DMA3FZR	FM	C10H15N3O4
DMA3FZR	IC	InChI=1S/C10H15N3O4/c11-7-1-2-13(10(17)12-7)6-3-5(4-14)8(15)9(6)16/h1-2,5-6,8-9,14-16H,3-4H2,(H2,11,12,17)/t5-,6-,8-,9+/m1/s1
DMA3FZR	CS	C1[C@@H]([C@H]([C@H]([C@@H]1N2C=CC(=NC2=O)N)O)O)CO
DMA3FZR	IK	UAZJPMMKWBPACD-GCXDCGAKSA-N
DMA3FZR	IU	4-amino-1-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]pyrimidin-2-one
DMA3FZR	DE	Discovery agent

DMCNV68	ID	DMCNV68
DMCNV68	DN	Carboron Cluster with phenol
DMCNV68	HS	Investigative
DMCNV68	DE	Discovery agent

DMEORTQ	ID	DMEORTQ
DMEORTQ	DN	Carboxyatractyloside
DMEORTQ	HS	Investigative
DMEORTQ	SN	Carboxyatractyloside; CATR; SCHEMBL1612956; GTPL4572; AQFATIOBERWBDY-LNQSNDDKSA-N; (2alpha,8alpha,10alpha,13alpha,15beta)-15-hydroxy-2-{[2-O-(3-methylbutanoyl)-3,4-di-O-sulfo-beta-D-glucopyranosyl]oxy}kaur-16-ene-18,19-dioic acid; (1R,4S,7S,9S,10S,13R,15S)-15-hydroxy-7-{[(2R,3R,4R,5R,6R)-6-(hydroxymethyl)-3-[(3-methylbutanoyl)oxy]-4,5-bis(sulfooxy)oxan-2-yl]oxy}-9-methyl-14-methylidenetetracyclo[11.2.1.0^{1,10}.0^{4,9}]hexadecane-5,5-dicarboxylic acid
DMEORTQ	DT	Small molecular drug
DMEORTQ	PC	20055804
DMEORTQ	MW	770.8
DMEORTQ	FM	C31H46O18S2
DMEORTQ	IC	InChI=1S/C31H46O18S2/c1-14(2)9-21(33)47-24-23(49-51(42,43)44)22(48-50(39,40)41)18(13-32)46-26(24)45-17-11-29(4)19-6-5-16-10-30(19,25(34)15(16)3)8-7-20(29)31(12-17,27(35)36)28(37)38/h14,16-20,22-26,32,34H,3,5-13H2,1-2,4H3,(H,35,36)(H,37,38)(H,39,40,41)(H,42,43,44)/t16-,17+,18-,19+,20+,22-,23+,24-,25+,26-,29+,30-/m1/s1
DMEORTQ	CS	CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@H]2C[C@]3([C@@H]4CC[C@@H]5C[C@@]4(CC[C@@H]3C(C2)(C(=O)O)C(=O)O)[C@H](C5=C)O)C)CO)OS(=O)(=O)O)OS(=O)(=O)O
DMEORTQ	IK	AQFATIOBERWBDY-LNQSNDDKSA-N
DMEORTQ	IU	(1R,4S,7S,9S,10S,13R,15S)-15-hydroxy-7-[(2R,3R,4R,5R,6R)-6-(hydroxymethyl)-3-(3-methylbutanoyloxy)-4,5-disulfooxyoxan-2-yl]oxy-9-methyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5,5-dicarboxylic acid
DMEORTQ	DE	Discovery agent

DMTAYMR	ID	DMTAYMR
DMTAYMR	DN	Carboxydichlorofluorescein
DMTAYMR	HS	Investigative
DMTAYMR	SN	5,6-carboxydichlorofluorescein
DMTAYMR	PC	129670681
DMTAYMR	MW	445.204
DMTAYMR	FM	C21H10Cl2O7
DMTAYMR	IC	InChI=1S/C21H10Cl2O7/c22-16-12(25)7-13-15(17(16)23)21(9-4-2-1-3-8(9)20(28)30-21)10-5-6-11(24)14(19(26)27)18(10)29-13/h1-7,24-25H,(H,26,27)
DMTAYMR	CS	C1=CC=C2C(=C1)C(=O)OC23C4=C(C(=C(C=C4)O)C(=O)O)OC5=CC(=C(C(=C35)Cl)Cl)O
DMTAYMR	IK	SQVCXKJBMHVPIO-UHFFFAOYSA-N
DMTAYMR	IU	7',8'-dichloro-3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-carboxylic acid

DMI7Q61	ID	DMI7Q61
DMI7Q61	DN	CARBOXYFENTANYL
DMI7Q61	HS	Investigative
DMI7Q61	SN	CARBOXYFENTANYL; CHEBI:61106; CHEMBL216239; 4-oxo-4-{phenyl[1-(2-phenylethyl)piperidin-4-yl]amino}butanoic acid; 4-anilidopiperidine, 8; Epitope ID:153518; SCHEMBL5163413; BDBM21114; ZINC14975441; 4-Oxo-4-[N-(1-phenethylpiperidine-4-yl)anilino]butyric acid; 3-{phenyl[1-(2-phenylethyl)piperidin-4-yl]carbamoyl}propanoic acid
DMI7Q61	DT	Small molecular drug
DMI7Q61	PC	23635044
DMI7Q61	MW	380.5
DMI7Q61	FM	C23H28N2O3
DMI7Q61	IC	InChI=1S/C23H28N2O3/c26-22(11-12-23(27)28)25(20-9-5-2-6-10-20)21-14-17-24(18-15-21)16-13-19-7-3-1-4-8-19/h1-10,21H,11-18H2,(H,27,28)
DMI7Q61	CS	C1CN(CCC1N(C2=CC=CC=C2)C(=O)CCC(=O)O)CCC3=CC=CC=C3
DMI7Q61	IK	MEVFKTVEGJUHHI-UHFFFAOYSA-N
DMI7Q61	IU	4-oxo-4-(N-[1-(2-phenylethyl)piperidin-4-yl]anilino)butanoic acid
DMI7Q61	CB	CHEBI:61106
DMI7Q61	DE	Discovery agent

DM105YR	ID	DM105YR
DM105YR	DN	Carboxylated glucosamine
DM105YR	HS	Investigative
DM105YR	SN	carboxylated glucosamine
DM105YR	DT	Small molecular drug
DM105YR	PC	44411803
DM105YR	MW	305.32
DM105YR	FM	C13H23NO7
DM105YR	IC	InChI=1S/C13H23NO7/c1-2-7-8(5-15)21-9(6-16)12(13(7)20)14-10(17)3-4-11(18)19/h7-9,12-13,15-16,20H,2-6H2,1H3,(H,14,17)(H,18,19)/t7-,8-,9+,12+,13+/m1/s1
DM105YR	CS	CC[C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)NC(=O)CCC(=O)O)CO)CO
DM105YR	IK	PTKIBGLZJSEXPT-KOOJSXSQSA-N
DM105YR	IU	4-[[(2R,3R,4S,5S,6S)-5-ethyl-4-hydroxy-2,6-bis(hydroxymethyl)oxan-3-yl]amino]-4-oxobutanoic acid
DM105YR	DE	Discovery agent

DMCTUR1	ID	DMCTUR1
DMCTUR1	DN	Carboxylic PRPP
DMCTUR1	HS	Investigative
DMCTUR1	SN	CARBOXYLIC PRPP; CPRPP; 1-ALPHA-PYROPHOSPHORYL-2-ALPHA,3-ALPHA-DIHYDROXY-4-BETA-CYCLOPENTANE-METHANOL-5-PHOSPHATE; AC1L9FVP; CARBOXYLIC PRPP; CPRPP; DB03942; (1S,2R,3R,4R)-2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl trihydrogen diphosphate; [(1S,2R,3R,4R)-2,3-dihydroxy-4-(phosphonooxymethyl)cyclopentyl] phosphono hydrogen phosphate
DMCTUR1	DT	Small molecular drug
DMCTUR1	PC	444189
DMCTUR1	MW	388.1
DMCTUR1	FM	C6H15O13P3
DMCTUR1	IC	InChI=1S/C6H15O13P3/c7-5-3(2-17-20(9,10)11)1-4(6(5)8)18-22(15,16)19-21(12,13)14/h3-8H,1-2H2,(H,15,16)(H2,9,10,11)(H2,12,13,14)/t3-,4+,5-,6+/m1/s1
DMCTUR1	CS	C1[C@@H]([C@H]([C@H]([C@H]1OP(=O)(O)OP(=O)(O)O)O)O)COP(=O)(O)O
DMCTUR1	IK	OICBXEWBKALHHB-MOJAZDJTSA-N
DMCTUR1	IU	[(1S,2R,3R,4R)-2,3-dihydroxy-4-(phosphonooxymethyl)cyclopentyl] phosphono hydrogen phosphate
DMCTUR1	DE	Discovery agent

DMQUKBG	ID	DMQUKBG
DMQUKBG	DN	CARCININE
DMQUKBG	HS	Investigative
DMQUKBG	SN	Carcinine; 56897-53-1; N-(2-(1H-Imidazol-5-yl)ethyl)-3-aminopropanamide; beta-Alanylhistamine; UNII-WIV0W167TC; WIV0W167TC; N-[2-(1H-imidazol-5-yl)ethyl]-beta-alaninamide; SPBio_002343; beta-alaninylhistamine; N-beta-alanylhistamine; AC1L1DZE; Prestwick2_000422; Prestwick1_000422; Prestwick0_000422; Prestwick3_000422; Lopac-C-2321; AC1Q5P6Q; n-[2-(1h-imidazol-5-yl)ethyl]-; A-alaninamide; Lopac0_000210; BSPBio_000404; KSC921E6R; MLS002153803; SCHEMBL2819350; CHEMBL461024; BPBio1_000446; SCHEMBL19051459; CHEBI:95262; CTK8C1268
DMQUKBG	DT	Small molecular drug
DMQUKBG	PC	2574
DMQUKBG	MW	182.22
DMQUKBG	FM	C8H14N4O
DMQUKBG	IC	InChI=1S/C8H14N4O/c9-3-1-8(13)11-4-2-7-5-10-6-12-7/h5-6H,1-4,9H2,(H,10,12)(H,11,13)
DMQUKBG	CS	C1=C(NC=N1)CCNC(=O)CCN
DMQUKBG	IK	ANRUJJLGVODXIK-UHFFFAOYSA-N
DMQUKBG	IU	3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide
DMQUKBG	CA	CAS 56897-53-1
DMQUKBG	CB	CHEBI:95262
DMQUKBG	DE	Discovery agent

DMCSMX4	ID	DMCSMX4
DMCSMX4	DN	Cardiolipin
DMCSMX4	HS	Investigative
DMCSMX4	SN	Cardiolipins(20:4w3/20:4w6/18:2w6/18:2w6); Cardiolipins(20:4n3/20:4n6/18:2n6/18:2n6); Cardiolipin(20:4w3/20:4w6/18:2w6/18:2w6); Cardiolipin(20:4n3/20:4n6/18:2n6/18:2n6); CL(20:4w3/20:4w6/18:2w6/18:2w6); CL(20:4n3/20:4n6/18:2n6/18:2n6); CL(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/16:0); CL(1'-[20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)],3'-[18:2(9Z,12Z)/18:2(9Z,12Z)])
DMCSMX4	DT	Small molecular drug
DMCSMX4	PC	75228679
DMCSMX4	MW	1493.9
DMCSMX4	FM	C81H140Na2O17P2
DMCSMX4	IC	InChI=1S/C81H142O17P2.2Na/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-61-65-78(83)91-71-76(97-80(85)67-63-59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)73-95-99(87,88)93-69-75(82)70-94-100(89,90)96-74-77(98-81(86)68-64-60-56-52-48-44-40-36-32-28-24-20-16-12-8-4)72-92-79(84)66-62-58-54-50-46-42-38-34-30-26-22-18-14-10-6-2;;/h21-28,33-40,75-77,82H,5-20,29-32,41-74H2,1-4H3,(H,87,88)(H,89,90);;/q;2*+1/p-2
DMCSMX4	CS	CCCCCC=CCC=CCCCCCCCC(=O)OCC(COP(=O)([O-])OCC(COP(=O)([O-])OCC(COC(=O)CCCCCCCC=CCC=CCCCCC)OC(=O)CCCCCCCC=CCC=CCCCCC)O)OC(=O)CCCCCCCC=CCC=CCCCCC.[Na+].[Na+]
DMCSMX4	IK	ZGSPNIOCEDOHGS-UHFFFAOYSA-L
DMCSMX4	IU	disodium;[3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate
DMCSMX4	DE	Discovery agent

DMUSGYQ	ID	DMUSGYQ
DMUSGYQ	DN	Carinatumins B (2)
DMUSGYQ	HS	Investigative
DMUSGYQ	SN	carinatumins B (2); CHEMBL241838
DMUSGYQ	DT	Small molecular drug
DMUSGYQ	PC	44428320
DMUSGYQ	MW	272.34
DMUSGYQ	FM	C16H20N2O2
DMUSGYQ	IC	InChI=1S/C16H20N2O2/c1-9-6-10-7-12-11(2-3-14(20)18-12)16(8-9)15(10)13(19)4-5-17-16/h2-3,6,10,13,15,17,19H,4-5,7-8H2,1H3,(H,18,20)/t10-,13+,15-,16-/m0/s1
DMUSGYQ	CS	CC1=C[C@H]2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2[C@@H](CCN4)O
DMUSGYQ	IK	RGJUWLMFRYLAOJ-UXVLEFJLSA-N
DMUSGYQ	IU	(1R,9R,10R,11R)-11-hydroxy-16-methyl-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMUSGYQ	DE	Discovery agent

DMFYCB4	ID	DMFYCB4
DMFYCB4	DN	Carnosine
DMFYCB4	HS	Investigative
DMFYCB4	SN	beta-alanyl-L-histidine; L-carnosine
DMFYCB4	DT	Small molecular drug
DMFYCB4	PC	439224
DMFYCB4	MW	226.23
DMFYCB4	FM	C9H14N4O3
DMFYCB4	IC	InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)/t7-/m0/s1
DMFYCB4	CS	C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CCN
DMFYCB4	IK	CQOVPNPJLQNMDC-ZETCQYMHSA-N
DMFYCB4	IU	(2S)-2-(3-aminopropanoylamino)-3-(1H-imidazol-5-yl)propanoic acid
DMFYCB4	CA	CAS 305-84-0
DMFYCB4	CB	CHEBI:15727
DMFYCB4	DE	Discovery agent

DMBKQ03	ID	DMBKQ03
DMBKQ03	DN	Carpropamid
DMBKQ03	HS	Investigative
DMBKQ03	SN	Carpropamid; 104030-54-8; 2,2-Dichloro-N-[1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide; 2,2-dichloro-N-[1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropane-1-carboxamide; Carpropamid [ISO]; AC1L4B6R; SCHEMBL22262; CHEBI:3434; DTXSID4057922; RXDMAYSSBPYBFW-UHFFFAOYSA-N; KTU-3616; AKOS015888200; Cyclopropanecarboxamide, 2,2-dichloro-N-(1-(4-chlorophenyl)ethyl)-1-ethyl-3-methyl-; AN-34090; TR-000928; Carpropamid, PESTANAL(R), analytical standard; C10932; SR-01000883725; SR-01000883725-1; I01-10136
DMBKQ03	DT	Small molecular drug
DMBKQ03	PC	153847
DMBKQ03	MW	334.7
DMBKQ03	FM	C15H18Cl3NO
DMBKQ03	IC	InChI=1S/C15H18Cl3NO/c1-4-14(10(3)15(14,17)18)13(20)19-9(2)11-5-7-12(16)8-6-11/h5-10H,4H2,1-3H3,(H,19,20)
DMBKQ03	CS	CCC1(C(C1(Cl)Cl)C)C(=O)NC(C)C2=CC=C(C=C2)Cl
DMBKQ03	IK	RXDMAYSSBPYBFW-UHFFFAOYSA-N
DMBKQ03	IU	2,2-dichloro-N-[1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropane-1-carboxamide
DMBKQ03	CA	CAS 104030-54-8
DMBKQ03	CB	CHEBI:3434
DMBKQ03	DE	Discovery agent

DMSKT8G	ID	DMSKT8G
DMSKT8G	DN	Cartazolate
DMSKT8G	HS	Investigative
DMSKT8G	SN	CARTAZOLATE; 34966-41-1; UNII-8K93Z46WPY; CHEMBL8184; SQ 65396; 8K93Z46WPY; SQ-65396; Cartazolato; Cartazolatum; Ethyl 4-(butylamino)-1-ethyl-1H-pyrazolo(3,4-b)-pyridine-5-carboxylate; 4-Butylamino-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester; Cartazolatum [INN-Latin]; Cartazolate [USAN:INN]; Cartazolato [INN-Spanish]; Ethyl 4-(butylamino)-1-ethyl-1H-pyrazolo[3,4-b]-pyridine-5-carboxylate; NSC 166873; AC1L1WUF; Cartazolate (USAN/INN); SCHEMBL123839; DTXSID20188511; IQNQAOGGWGCROX-UHFFFAOYSA-N; BDBM50098221
DMSKT8G	DT	Small molecular drug
DMSKT8G	PC	37015
DMSKT8G	MW	290.36
DMSKT8G	FM	C15H22N4O2
DMSKT8G	IC	InChI=1S/C15H22N4O2/c1-4-7-8-16-13-11-10-18-19(5-2)14(11)17-9-12(13)15(20)21-6-3/h9-10H,4-8H2,1-3H3,(H,16,17)
DMSKT8G	CS	CCCCNC1=C2C=NN(C2=NC=C1C(=O)OCC)CC
DMSKT8G	IK	IQNQAOGGWGCROX-UHFFFAOYSA-N
DMSKT8G	IU	ethyl 4-(butylamino)-1-ethylpyrazolo[3,4-b]pyridine-5-carboxylate
DMSKT8G	CA	CAS 34966-41-1
DMSKT8G	DE	Discovery agent

DMINM2D	ID	DMINM2D
DMINM2D	DN	carvacrol
DMINM2D	HS	Investigative
DMINM2D	SN	CARVACROL; 5-Isopropyl-2-methylphenol; 499-75-2; Isopropyl-o-cresol; Karvakrol; o-Thymol; Antioxine; 5-Isopropyl-o-cresol; 2-p-Cymenol; 2-Hydroxy-p-cymene; Isothymol; Phenol, 2-methyl-5-(1-methylethyl)-; p-Cymen-2-ol; 2-Methyl-5-isopropylphenol; 3-Isopropyl-6-methylphenol; p-Cymene, 2-hydroxy-; 5-Isopropyl-2-methyl-phenol; 2-Methyl-5-(Propan-2-Yl)Phenol; 2-Methyl-5-(1-methylethyl)phenol; o-Cresol, 5-isopropyl-; 1-Hydroxy-2-methyl-5-isopropylbenzene; 6-Methyl-3-isopropylphenol; Phenol, 5-isopropyl-2-methyl-; Cymene-2-ol, p-
DMINM2D	DT	Small molecular drug
DMINM2D	PC	10364
DMINM2D	MW	150.22
DMINM2D	FM	C10H14O
DMINM2D	IC	InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H3
DMINM2D	CS	CC1=C(C=C(C=C1)C(C)C)O
DMINM2D	IK	RECUKUPTGUEGMW-UHFFFAOYSA-N
DMINM2D	IU	2-methyl-5-propan-2-ylphenol
DMINM2D	CA	CAS 499-75-2
DMINM2D	CB	CHEBI:3440
DMINM2D	DE	Discovery agent

DMXTCE7	ID	DMXTCE7
DMXTCE7	DN	Carvedilol
DMXTCE7	HS	Investigative
DMXTCE7	SN	Coreg; Dilatrend; Eucardic; Carvedilolum [Latin]; BM 14190; Carvedilolum; SKF 105517; BM-14190; Coreg CR; DQ 2466; HSDB 7044; DQ-2466
DMXTCE7	TC	Antiviral Agents
DMXTCE7	DT	Small molecular drug
DMXTCE7	PC	2585
DMXTCE7	MW	406.5
DMXTCE7	FM	C24H26N2O4
DMXTCE7	IC	InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
DMXTCE7	CS	COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
DMXTCE7	IK	OGHNVEJMJSYVRP-UHFFFAOYSA-N
DMXTCE7	IU	1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
DMXTCE7	CA	CAS 72956-09-3
DMXTCE7	CB	CHEBI:3441
DMXTCE7	DE	Coronavirus Disease 2019 (COVID-19)

DMGIZ5U	ID	DMGIZ5U
DMGIZ5U	DN	carveol
DMGIZ5U	HS	Investigative
DMGIZ5U	SN	L-carveol
DMGIZ5U	DT	Small molecular drug
DMGIZ5U	PC	7438
DMGIZ5U	MW	152.23
DMGIZ5U	FM	C10H16O
DMGIZ5U	IC	InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h4,9-11H,1,5-6H2,2-3H3
DMGIZ5U	CS	CC1=CCC(CC1O)C(=C)C
DMGIZ5U	IK	BAVONGHXFVOKBV-UHFFFAOYSA-N
DMGIZ5U	IU	2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-ol
DMGIZ5U	CA	CAS 99-48-9
DMGIZ5U	CB	CHEBI:23046
DMGIZ5U	DE	Discovery agent

DMVD481	ID	DMVD481
DMVD481	DN	Carzenide
DMVD481	HS	Investigative
DMVD481	SN	Para-Carboxybenzenesulfonamide (Weak Carbonic Anhydrase Inhibitor)
DMVD481	DT	Small molecular drug
DMVD481	PC	8739
DMVD481	MW	201.2
DMVD481	FM	C7H7NO4S
DMVD481	IC	InChI=1S/C7H7NO4S/c8-13(11,12)6-3-1-5(2-4-6)7(9)10/h1-4H,(H,9,10)(H2,8,11,12)
DMVD481	CS	C1=CC(=CC=C1C(=O)O)S(=O)(=O)N
DMVD481	IK	UCAGLBKTLXCODC-UHFFFAOYSA-N
DMVD481	IU	4-sulfamoylbenzoic acid
DMVD481	CA	CAS 138-41-0
DMVD481	DE	Discovery agent

DMW6P4A	ID	DMW6P4A
DMW6P4A	DN	casp 4 inhib
DMW6P4A	HS	Investigative
DMW6P4A	SN	5-nitro-isatin 1 [PMID: 11384246]
DMW6P4A	DT	Small molecular drug
DMW6P4A	PC	515950
DMW6P4A	MW	206.15
DMW6P4A	FM	C9H6N2O4
DMW6P4A	IC	InChI=1S/C9H6N2O4/c1-10-7-3-2-5(11(14)15)4-6(7)8(12)9(10)13/h2-4H,1H3
DMW6P4A	CS	CN1C2=C(C=C(C=C2)[N+](=O)[O-])C(=O)C1=O
DMW6P4A	IK	JPTDPTOWOMFBRY-UHFFFAOYSA-N
DMW6P4A	IU	1-methyl-5-nitroindole-2,3-dione
DMW6P4A	CA	CAS 3484-32-0
DMW6P4A	DE	Discovery agent

DM5E21C	ID	DM5E21C
DM5E21C	DN	CASUARIIN
DM5E21C	HS	Investigative
DM5E21C	SN	Casuariin; CHEMBL509562; SCHEMBL1883046
DM5E21C	DT	Small molecular drug
DM5E21C	PC	14035442
DM5E21C	MW	784.5
DM5E21C	FM	C34H24O22
DM5E21C	IC	InChI=1S/C34H24O22/c35-8-1-5-12(21(42)18(8)39)13-6(2-9(36)19(40)22(13)43)32(50)54-28(11(38)4-53-31(5)49)30-29-26(47)17-16(34(52)55-29)15(24(45)27(48)25(17)46)14-7(33(51)56-30)3-10(37)20(41)23(14)44/h1-3,11,26,28-30,35-48H,4H2/t11-,26-,28-,29+,30+/m1/s1
DM5E21C	CS	C1[C@H]([C@@H](OC(=O)C2=CC(=C(C(=C2C3=C(C(=C(C=C3C(=O)O1)O)O)O)O)O)O)[C@H]4[C@@H]5[C@@H](C6=C(C(=C(C(=C6C(=O)O5)C7=C(C(=C(C=C7C(=O)O4)O)O)O)O)O)O)O)O
DM5E21C	IK	CHBITXAMNKHJCR-JNUHSSLSSA-N
DM5E21C	IU	(14R,15S,19R)-14-[(10R,11R)-3,4,5,11,17,18,19-heptahydroxy-8,14-dioxo-9,13-dioxatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]-2,3,4,7,8,9,19-heptahydroxy-13,16-dioxatetracyclo[13.3.1.05,18.06,11]nonadeca-1,3,5(18),6,8,10-hexaene-12,17-dione
DM5E21C	DE	Discovery agent

DMWHP52	ID	DMWHP52
DMWHP52	DN	CAT-2200
DMWHP52	HS	Investigative
DMWHP52	SN	MEDI-571; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), MedImmune; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), Cambridge Antibody Technology (CAT)
DMWHP52	CP	Cambridge Antibody Technology Group plc
DMWHP52	DT	Antibody
DMWHP52	DE	Rheumatoid arthritis

DMY38SB	ID	DMY38SB
DMY38SB	DN	CATECHIN
DMY38SB	HS	Investigative
DMY38SB	SN	Cianidanol; (+)-catechin; 154-23-4; Catechuic acid; Cyanidanol; Catechinic acid; D-Catechin; Catergen; Cianidol; (+)-Cyanidanol; (+)-Cyanidan-3-ol; Biocatechin; (+)-Catechin Hydrate; D-(+)-Catechin; Dexcyanidanol; Catechin (flavan); Catechol (flavan); D-Catechol; (2R,3S)-Catechin; (2R,3S)-2-(3,4-Dihydroxyphenyl)chroman-3,5,7-triol; Gambier; 3-Cyanidanol, (+)-; Cianidanolum; Catechu; Transepar; Katha; (2R,3S)-(+)-Catechin; Cutch (dye); (+)-Cianidanol; 3,3',4',5,7-Flavanpentol; KB-53; (+)-Cyanidanol-3; CCRIS 6855
DMY38SB	DT	Small molecular drug
DMY38SB	PC	9064
DMY38SB	MW	290.27
DMY38SB	FM	C15H14O6
DMY38SB	IC	InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15+/m0/s1
DMY38SB	CS	C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O
DMY38SB	IK	PFTAWBLQPZVEMU-DZGCQCFKSA-N
DMY38SB	IU	(2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
DMY38SB	CA	CAS 7295-85-4
DMY38SB	CB	CHEBI:15600
DMY38SB	DE	Discovery agent

DML0YEK	ID	DML0YEK
DML0YEK	DN	Catechol
DML0YEK	HS	Investigative
DML0YEK	SN	pyrocatechol; 1,2-dihydroxybenzene; 120-80-9; 1,2-benzenediol; benzene-1,2-diol; pyrocatechin; 2-hydroxyphenol; o-Benzenediol; Pyrocatechine; o-Dihydroxybenzene; Oxyphenic acid; o-Hydroxyphenol; o-Hydroquinone; o-Dioxybenzene; o-Phenylenediol; Phthalhydroquinone; Fouramine PCH; Durafur developer C; Pelagol Grey C; benzenediol; Catechin (phenol); Fourrine 68; Benzene, o-dihydroxy-; Catechol (phenol); o-Diphenol; ortho-Hydroxyphenol; Pyrokatechol; Pyrokatechin; Katechol; ortho-Dihydroxybenzene; C.I. Oxidation Base 26
DML0YEK	DT	Small molecular drug
DML0YEK	PC	289
DML0YEK	MW	110.11
DML0YEK	FM	C6H6O2
DML0YEK	IC	InChI=1S/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8H
DML0YEK	CS	C1=CC=C(C(=C1)O)O
DML0YEK	IK	YCIMNLLNPGFGHC-UHFFFAOYSA-N
DML0YEK	IU	benzene-1,2-diol
DML0YEK	CA	CAS 120-80-9
DML0YEK	CB	CHEBI:18135
DML0YEK	DE	Discovery agent

DMLEJHF	ID	DMLEJHF
DMLEJHF	DN	Cation chloride
DMLEJHF	HS	Investigative

DMF7TBW	ID	DMF7TBW
DMF7TBW	DN	CATPB
DMF7TBW	HS	Investigative
DMF7TBW	SN	(s)-3-(2-(3-chlorophenyl)acetamido)-4-(4-(trifluoromethyl)phenyl)butanoic acid; GTPL6487; SCHEMBL2312533; CATPB, &gt; ZINC118616157; AKOS030210965; 1322598-09-3; (3S)-3-[2-(3-chlorophenyl)acetamido]-4-[4-(trifluoromethyl)phenyl]butanoic acid
DMF7TBW	DT	Small molecular drug
DMF7TBW	PC	53308747
DMF7TBW	MW	399.8
DMF7TBW	FM	C19H17ClF3NO3
DMF7TBW	IC	InChI=1S/C19H17ClF3NO3/c20-15-3-1-2-13(8-15)10-17(25)24-16(11-18(26)27)9-12-4-6-14(7-5-12)19(21,22)23/h1-8,16H,9-11H2,(H,24,25)(H,26,27)/t16-/m0/s1
DMF7TBW	CS	C1=CC(=CC(=C1)Cl)CC(=O)N[C@@H](CC2=CC=C(C=C2)C(F)(F)F)CC(=O)O
DMF7TBW	IK	QOSIJVVNNGXEKE-INIZCTEOSA-N
DMF7TBW	IU	(3S)-3-[[2-(3-chlorophenyl)acetyl]amino]-4-[4-(trifluoromethyl)phenyl]butanoic acid
DMF7TBW	DE	Discovery agent

DM4QKVN	ID	DM4QKVN
DM4QKVN	DN	CAULERPIN
DM4QKVN	HS	Investigative
DM4QKVN	SN	Caulerpin; 26612-48-6; CHEMBL377236; CHEBI:80923; Cycloocta(1,2-b:5,6-b')diindole-6,13-dicarboxylic acid, 5,12-dihydro-, dimethyl ester; Cycloocta[1,2-b:5,6-b']diindole-6,13-dicarboxylic acid, 5,12-dihydro-, dimethyl ester; SCHEMBL13808752; NSC719624; BDBM50184688; NSC-719624
DM4QKVN	DT	Small molecular drug
DM4QKVN	PC	5326018
DM4QKVN	MW	398.4
DM4QKVN	FM	C24H18N2O4
DM4QKVN	IC	InChI=1S/C24H18N2O4/c1-29-23(27)17-11-15-13-7-3-6-10-20(13)26-22(15)18(24(28)30-2)12-16-14-8-4-5-9-19(14)25-21(16)17/h3-12,25-26H,1-2H3/b15-11?,16-12?,17-11+,18-12+,21-17?,22-18?
DM4QKVN	CS	COC(=O)/C/1=C/C2=C(NC3=CC=CC=C23)/C(=C\\C4=C1NC5=CC=CC=C45)/C(=O)OC
DM4QKVN	IK	PVWALMHWUOWPPA-RPLHEXBESA-N
DM4QKVN	IU	dimethyl (2E,13E)-11,22-diazapentacyclo[13.7.0.04,12.05,10.016,21]docosa-1(15),2,4(12),5,7,9,13,16,18,20-decaene-2,13-dicarboxylate
DM4QKVN	CB	CHEBI:80923
DM4QKVN	DE	Discovery agent

DM4O69H	ID	DM4O69H
DM4O69H	DN	CAY 10471
DM4O69H	HS	Investigative
DM4O69H	SN	CAY10471; CAY-10471
DM4O69H	CP	7TM Pharma A/S
DM4O69H	DT	Small molecular drug
DM4O69H	PC	11384493
DM4O69H	MW	416.5
DM4O69H	FM	C21H21FN2O4S
DM4O69H	IC	InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-15)17-4-2-3-5-19(17)24(20)13-21(25)26/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)
DM4O69H	CS	CN(C1CCC2=C(C1)C3=CC=CC=C3N2CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F
DM4O69H	IK	CANCTKXGRVNXFP-UHFFFAOYSA-N
DM4O69H	IU	2-[3-[(4-fluorophenyl)sulfonyl-methylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]acetic acid
DM4O69H	DE	Allergy

DMT3MBD	ID	DMT3MBD
DMT3MBD	DN	CAY10583
DMT3MBD	HS	Investigative
DMT3MBD	SN	compound A [PMID:15866883]; CAY 10583; CAY-10583
DMT3MBD	DT	Small molecular drug
DMT3MBD	PC	51529932
DMT3MBD	MW	387.5
DMT3MBD	FM	C25H25NO3
DMT3MBD	IC	InChI=1S/C25H25NO3/c1-2-3-13-24(27)26(21-9-5-4-6-10-21)18-19-14-16-20(17-15-19)22-11-7-8-12-23(22)25(28)29/h4-12,14-17H,2-3,13,18H2,1H3,(H,28,29)
DMT3MBD	CS	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C(=O)O)C3=CC=CC=C3
DMT3MBD	IK	IUJTVDNJFPZYBL-UHFFFAOYSA-N
DMT3MBD	IU	2-[4-[(N-pentanoylanilino)methyl]phenyl]benzoic acid
DMT3MBD	CA	CAS 862891-27-8
DMT3MBD	DE	Discovery agent

DMSFXZU	ID	DMSFXZU
DMSFXZU	DN	CB-1922
DMSFXZU	HS	Investigative
DMSFXZU	SN	HIV replication inhibitor (synthetic steroid), Canopus
DMSFXZU	CP	Canopus BioPharma Inc
DMSFXZU	DE	Human immunodeficiency virus infection

DMXON4L	ID	DMXON4L
DMXON4L	DN	CB-676475
DMXON4L	HS	Investigative
DMXON4L	SN	690206-97-4; ZM 306416; ZM306416; ZM-306416; N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine; ZM-306416(CB 676475); CB-676475; CHEMBL150315; AK174923; CB 676475; Anilinoquinazoline deriv. 4; AC1NS5UJ; SCHEMBL3012896; BDBM4621; GTPL8245; CTK8E8823; CHEBI:92732; DTXSID90416176; AOB6790; MolPort-035-395-727; HMS3651N06; BCP06445; ZINC2583789; HSCI1_000042; s2897; 2820AH; AKOS025404926; SB16593; CS-1349; KS-00000T57; NCGC00167747-01; SC-95590; DA-41680; CB676475; HY-13785; AB0165814; RT-016341; KB-299318; SW219943-1; FT-0706412; S-7773
DMXON4L	DT	Small molecular drug
DMXON4L	PC	5329006
DMXON4L	MW	333.74
DMXON4L	FM	C16H13ClFN3O2
DMXON4L	IC	InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-12-4-3-9(17)5-11(12)18/h3-8H,1-2H3,(H,19,20,21)
DMXON4L	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=C(C=C(C=C3)Cl)F)OC
DMXON4L	IK	YHUIUSRCUKUUQA-UHFFFAOYSA-N
DMXON4L	IU	N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine
DMXON4L	CA	CAS 690206-97-4
DMXON4L	CB	CHEBI:92732
DMXON4L	DE	Discovery agent

DMALVY7	ID	DMALVY7
DMALVY7	DN	CBiPES
DMALVY7	HS	Investigative
DMALVY7	SN	CBiPES; LY-566332; 856702-40-4; GTPL3372; DTXSID70432071; ZINC43201133; NCGC00370754-01; LY566332
DMALVY7	DT	Small molecular drug
DMALVY7	PC	9864510
DMALVY7	MW	377.5
DMALVY7	FM	C21H19N3O2S
DMALVY7	IC	InChI=1S/C21H19N3O2S/c1-2-27(25,26)24(16-18-5-4-12-23-15-18)21-7-3-6-20(13-21)19-10-8-17(14-22)9-11-19/h3-13,15H,2,16H2,1H3
DMALVY7	CS	CCS(=O)(=O)N(CC1=CN=CC=C1)C2=CC=CC(=C2)C3=CC=C(C=C3)C#N
DMALVY7	IK	HDVYXILCBYGKGU-UHFFFAOYSA-N
DMALVY7	IU	N-[3-(4-cyanophenyl)phenyl]-N-(pyridin-3-ylmethyl)ethanesulfonamide
DMALVY7	CA	CAS 353235-01-5
DMALVY7	DE	Discovery agent

DMDIW1M	ID	DMDIW1M
DMDIW1M	DN	CBIQ
DMDIW1M	HS	Investigative
DMDIW1M	SN	4-Chlorobenzo[f]isoquinoline; 32081-28-0; SCHEMBL610880; GTPL4152; CHEMBL1372588; CTK8F8501; DTXSID30464737; HMS3260E20; ZINC2577904; Tox21_500109; CBIQ, &gt; MFCD02179769; AKOS017550392; CCG-221413; LP00109; NCGC00093606-01; NCGC00093606-05; NCGC00260794-01; NCGC00093606-03; NCGC00093606-04; NCGC00093606-02; KB-38182; UX00000203; FT-0618182
DMDIW1M	DT	Small molecular drug
DMDIW1M	PC	11401613
DMDIW1M	MW	213.66
DMDIW1M	FM	C13H8ClN
DMDIW1M	IC	InChI=1S/C13H8ClN/c14-13-12-6-5-9-3-1-2-4-10(9)11(12)7-8-15-13/h1-8H
DMDIW1M	CS	C1=CC=C2C(=C1)C=CC3=C2C=CN=C3Cl
DMDIW1M	IK	SHQLTRRYZVBEMR-UHFFFAOYSA-N
DMDIW1M	IU	4-chlorobenzo[f]isoquinoline
DMDIW1M	CA	CAS 32081-28-0
DMDIW1M	DE	Discovery agent

DMCFR8U	ID	DMCFR8U
DMCFR8U	DN	CBLB-612
DMCFR8U	HS	Investigative
DMCFR8U	SN	Recombinant flagellin proteins (injectable, radiation induced bone marrow deficiency), Cleveland BioLabs; CBLB-600 series (injectable, radiation sickness), Cleveland BioLabs
DMCFR8U	CP	Cleveland BioLabs Inc
DMCFR8U	DE	Radiation syndrome

DMITY0H	ID	DMITY0H
DMITY0H	DN	CBOBNEA
DMITY0H	HS	Investigative
DMITY0H	SN	carboxybiphenyloxy-butoxy-naphthalen-ethylacetamide
DMITY0H	DT	Small molecular drug
DMITY0H	PC	9957516
DMITY0H	MW	497.6
DMITY0H	FM	C31H31NO5
DMITY0H	IC	InChI=1S/C31H31NO5/c1-22(33)32-18-17-26-6-4-5-25-13-16-29(21-30(25)26)37-20-3-2-19-36-28-14-11-24(12-15-28)23-7-9-27(10-8-23)31(34)35/h4-16,21H,2-3,17-20H2,1H3,(H,32,33)(H,34,35)
DMITY0H	CS	CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OCCCCOC3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)O
DMITY0H	IK	VTMXSWVEWDJSKG-UHFFFAOYSA-N
DMITY0H	IU	4-[4-[4-[8-(2-acetamidoethyl)naphthalen-2-yl]oxybutoxy]phenyl]benzoic acid
DMITY0H	DE	Discovery agent

DM21JVF	ID	DM21JVF
DM21JVF	DN	Cbz-Glu(OtBu)-Ala-LeuVSMe
DM21JVF	HS	Investigative
DM21JVF	SN	CHEMBL208015; Cbz-Glu(OtBu)-Ala-LeuVSMe
DM21JVF	DT	Small molecular drug
DM21JVF	PC	11621207
DM21JVF	MW	581.7
DM21JVF	FM	C28H43N3O8S
DM21JVF	IC	InChI=1S/C28H43N3O8S/c1-19(2)17-22(15-16-40(7,36)37)30-25(33)20(3)29-26(34)23(13-14-24(32)39-28(4,5)6)31-27(35)38-18-21-11-9-8-10-12-21/h8-12,15-16,19-20,22-23H,13-14,17-18H2,1-7H3,(H,29,34)(H,30,33)(H,31,35)/b16-15+/t20-,22+,23-/m0/s1
DM21JVF	CS	C[C@@H](C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1
DM21JVF	IK	LRSBIKVQDTUNIU-DSNMTOQLSA-N
DM21JVF	IU	tert-butyl (4S)-5-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-5-oxo-4-(phenylmethoxycarbonylamino)pentanoate
DM21JVF	DE	Discovery agent

DMV8CJK	ID	DMV8CJK
DMV8CJK	DN	Cbz-Ile-hPhe-Ala-LeuVSMe
DMV8CJK	HS	Investigative
DMV8CJK	SN	CHEMBL446443; Cbz-Ile-hPhe-Ala-LeuVSMe
DMV8CJK	DT	Small molecular drug
DMV8CJK	PC	11714476
DMV8CJK	MW	670.9
DMV8CJK	FM	C35H50N4O7S
DMV8CJK	IC	InChI=1S/C35H50N4O7S/c1-7-25(4)31(39-35(43)46-23-28-16-12-9-13-17-28)34(42)38-30(19-18-27-14-10-8-11-15-27)33(41)36-26(5)32(40)37-29(22-24(2)3)20-21-47(6,44)45/h8-17,20-21,24-26,29-31H,7,18-19,22-23H2,1-6H3,(H,36,41)(H,37,40)(H,38,42)(H,39,43)/b21-20+/t25-,26-,29+,30-,31-/m0/s1
DMV8CJK	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC2=CC=CC=C2
DMV8CJK	IK	BZKLWACICJITOJ-QBZCPKQRSA-N
DMV8CJK	IU	benzyl N-[(2S,3S)-3-methyl-1-[[(2S)-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DMV8CJK	DE	Discovery agent

DMBFLHD	ID	DMBFLHD
DMBFLHD	DN	Cbz-Ile-Leu-Ala-LeuVSMe
DMBFLHD	HS	Investigative
DMBFLHD	SN	CHEMBL207403; Cbz-Ile-Leu-Ala-LeuVSMe
DMBFLHD	DT	Small molecular drug
DMBFLHD	PC	11534625
DMBFLHD	MW	622.8
DMBFLHD	FM	C31H50N4O7S
DMBFLHD	IC	InChI=1S/C31H50N4O7S/c1-9-22(6)27(35-31(39)42-19-24-13-11-10-12-14-24)30(38)34-26(18-21(4)5)29(37)32-23(7)28(36)33-25(17-20(2)3)15-16-43(8,40)41/h10-16,20-23,25-27H,9,17-19H2,1-8H3,(H,32,37)(H,33,36)(H,34,38)(H,35,39)/b16-15+/t22-,23-,25+,26-,27-/m0/s1
DMBFLHD	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
DMBFLHD	IK	PXJWGKDQRNBYKI-HUHPYHTRSA-N
DMBFLHD	IU	benzyl N-[(2S,3S)-3-methyl-1-[[(2S)-4-methyl-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DMBFLHD	DE	Discovery agent

DMI53WR	ID	DMI53WR
DMI53WR	DN	Cbz-Ile-Leu-L-(difluoro)aminobutyric acid
DMI53WR	HS	Investigative
DMI53WR	SN	CHEMBL175623; Cbz-Ile-Leu-L-(difluoro)aminobutyric acid
DMI53WR	DT	Small molecular drug
DMI53WR	PC	44388151
DMI53WR	MW	527.6
DMI53WR	FM	C25H35F2N3O7
DMI53WR	IC	InChI=1S/C25H35F2N3O7/c1-5-15(4)20(30-25(36)37-13-16-9-7-6-8-10-16)23(33)29-18(11-14(2)3)22(32)28-17(12-19(26)27)21(31)24(34)35/h6-10,14-15,17-20H,5,11-13H2,1-4H3,(H,28,32)(H,29,33)(H,30,36)(H,34,35)/t15?,17?,18-,20-/m0/s1
DMI53WR	CS	CCC(C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NC(CC(F)F)C(=O)C(=O)O)NC(=O)OCC1=CC=CC=C1
DMI53WR	IK	IXLOEMUNKMDCDV-IVJQXSGXSA-N
DMI53WR	IU	5,5-difluoro-3-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]amino]-2-oxopentanoic acid
DMI53WR	DE	Discovery agent

DMY4M3J	ID	DMY4M3J
DMY4M3J	DN	Cbz-Ile-MetO2-Ala-LeuVSMe
DMY4M3J	HS	Investigative
DMY4M3J	SN	CHEMBL383730; Cbz-Ile-MetO2-Ala-LeuVSMe
DMY4M3J	DT	Small molecular drug
DMY4M3J	PC	11585523
DMY4M3J	MW	658.8
DMY4M3J	FM	C29H46N4O9S2
DMY4M3J	IC	InChI=1S/C29H46N4O9S2/c1-8-20(4)25(33-29(37)42-17-22-12-10-9-11-13-22)28(36)32-24(18-44(7,40)41)27(35)30-21(5)26(34)31-23(16-19(2)3)14-15-43(6,38)39/h9-15,19-21,23-25H,8,16-18H2,1-7H3,(H,30,35)(H,31,34)(H,32,36)(H,33,37)/b15-14+/t20-,21-,23+,24-,25-/m0/s1
DMY4M3J	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CS(=O)(=O)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
DMY4M3J	IK	HIMUOMBMABFMIW-VHISICEBSA-N
DMY4M3J	IU	benzyl N-[(2S,3S)-3-methyl-1-[[(2R)-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-3-methylsulfonyl-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DMY4M3J	DE	Discovery agent

DM1OAW3	ID	DM1OAW3
DM1OAW3	DN	Cbz-Ile-Phe-Ala-LeuVSMe
DM1OAW3	HS	Investigative
DM1OAW3	SN	CHEMBL207284; Cbz-Ile-Phe-Ala-LeuVSMe
DM1OAW3	DT	Small molecular drug
DM1OAW3	PC	11534772
DM1OAW3	MW	656.8
DM1OAW3	FM	C34H48N4O7S
DM1OAW3	IC	InChI=1S/C34H48N4O7S/c1-7-24(4)30(38-34(42)45-22-27-16-12-9-13-17-27)33(41)37-29(21-26-14-10-8-11-15-26)32(40)35-25(5)31(39)36-28(20-23(2)3)18-19-46(6,43)44/h8-19,23-25,28-30H,7,20-22H2,1-6H3,(H,35,40)(H,36,39)(H,37,41)(H,38,42)/b19-18+/t24-,25-,28+,29-,30-/m0/s1
DM1OAW3	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC2=CC=CC=C2
DM1OAW3	IK	NDQAQUAWHJQVGE-HZPWIFGKSA-N
DM1OAW3	IU	benzyl N-[(2S,3S)-3-methyl-1-[[(2S)-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DM1OAW3	DE	Discovery agent

DM1KDWE	ID	DM1KDWE
DM1KDWE	DN	Cbz-Ile-Pro-Ala-LeuVSMe
DM1KDWE	HS	Investigative
DM1KDWE	SN	CHEMBL207670; Cbz-Ile-Pro-Ala-LeuVSMe
DM1KDWE	DT	Small molecular drug
DM1KDWE	PC	11505372
DM1KDWE	MW	606.8
DM1KDWE	FM	C30H46N4O7S
DM1KDWE	IC	InChI=1S/C30H46N4O7S/c1-7-21(4)26(33-30(38)41-19-23-12-9-8-10-13-23)29(37)34-16-11-14-25(34)28(36)31-22(5)27(35)32-24(18-20(2)3)15-17-42(6,39)40/h8-10,12-13,15,17,20-22,24-26H,7,11,14,16,18-19H2,1-6H3,(H,31,36)(H,32,35)(H,33,38)/b17-15+/t21-,22-,24+,25-,26-/m0/s1
DM1KDWE	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC2=CC=CC=C2
DM1KDWE	IK	QUUKVNWZLKQWBG-DHJGLREUSA-N
DM1KDWE	IU	benzyl N-[(2S,3S)-3-methyl-1-[(2S)-2-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]carbamate
DM1KDWE	DE	Discovery agent

DMGTFON	ID	DMGTFON
DMGTFON	DN	Cbz-Ile-t-ButylGln-Ala-LeuVSMe
DMGTFON	HS	Investigative
DMGTFON	SN	CHEMBL438612; Cbz-Ile-t-ButylGln-Ala-LeuVSMe
DMGTFON	DT	Small molecular drug
DMGTFON	PC	11621748
DMGTFON	MW	693.9
DMGTFON	FM	C34H55N5O8S
DMGTFON	IC	InChI=1S/C34H55N5O8S/c1-10-23(4)29(38-33(44)47-21-25-14-12-11-13-15-25)32(43)37-27(16-17-28(40)39-34(6,7)8)31(42)35-24(5)30(41)36-26(20-22(2)3)18-19-48(9,45)46/h11-15,18-19,22-24,26-27,29H,10,16-17,20-21H2,1-9H3,(H,35,42)(H,36,41)(H,37,43)(H,38,44)(H,39,40)/b19-18+/t23-,24-,26+,27-,29-/m0/s1
DMGTFON	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)NC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
DMGTFON	IK	YIFPZVMURBGBNU-NHVLHDLVSA-N
DMGTFON	IU	benzyl N-[(2S,3S)-1-[[(2S)-5-(tert-butylamino)-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamate
DMGTFON	DE	Discovery agent

DMNKC9J	ID	DMNKC9J
DMNKC9J	DN	Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe
DMNKC9J	HS	Investigative
DMNKC9J	SN	CHEMBL207196; Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe
DMNKC9J	DT	Small molecular drug
DMNKC9J	PC	11513217
DMNKC9J	MW	708.9
DMNKC9J	FM	C35H56N4O9S
DMNKC9J	IC	InChI=1S/C35H56N4O9S/c1-10-24(4)30(39-34(44)47-22-26-15-12-11-13-16-26)33(43)38-28(17-14-18-29(40)48-35(6,7)8)32(42)36-25(5)31(41)37-27(21-23(2)3)19-20-49(9,45)46/h11-13,15-16,19-20,23-25,27-28,30H,10,14,17-18,21-22H2,1-9H3,(H,36,42)(H,37,41)(H,38,43)(H,39,44)/b20-19+/t24-,25-,27+,28-,30-/m0/s1
DMNKC9J	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
DMNKC9J	IK	JWIOGOVPAFUFAB-OKNAZKIESA-N
DMNKC9J	IU	tert-butyl (5S)-6-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-5-[[(2S,3S)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-6-oxohexanoate
DMNKC9J	DE	Discovery agent

DM6TYRA	ID	DM6TYRA
DM6TYRA	DN	Cbz-Val-Pro-Val-(2-benzoxazole)
DM6TYRA	HS	Investigative
DM6TYRA	SN	CHEMBL108783; Cbz-Val-Pro-Val-(2-benzoxazole); BDBM50031199; ((S)-1-{(S)-2-[(S)-1-(Benzooxazole-2-carbonyl)-2-methyl-propylcarbamoyl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid benzyl ester
DM6TYRA	DT	Small molecular drug
DM6TYRA	PC	10053241
DM6TYRA	MW	548.6
DM6TYRA	FM	C30H36N4O6
DM6TYRA	IC	InChI=1S/C30H36N4O6/c1-18(2)24(26(35)28-31-21-13-8-9-15-23(21)40-28)32-27(36)22-14-10-16-34(22)29(37)25(19(3)4)33-30(38)39-17-20-11-6-5-7-12-20/h5-9,11-13,15,18-19,22,24-25H,10,14,16-17H2,1-4H3,(H,32,36)(H,33,38)/t22-,24-,25-/m0/s1
DM6TYRA	CS	CC(C)[C@@H](C(=O)C1=NC2=CC=CC=C2O1)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)OCC4=CC=CC=C4
DM6TYRA	IK	MRIBOSDZTNAJSS-HVCNVCAESA-N
DM6TYRA	IU	benzyl N-[(2S)-1-[(2S)-2-[[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DM6TYRA	DE	Discovery agent

DMSE20Y	ID	DMSE20Y
DMSE20Y	DN	CCACSSKWCRDHSRCC
DMSE20Y	HS	Investigative
DMSE20Y	SN	CHEMBL508113
DMSE20Y	PC	44560054
DMSE20Y	MW	1841.1
DMSE20Y	FM	C69H105N27O21S6
DMSE20Y	IC	InChI=1S/C69H105N27O21S6/c1-31-53(103)93-48-27-121-119-25-46(52(72)102)92-67(117)50-29-123-122-26-47(64(114)82-31)94-54(104)35(71)24-118-120-28-49(96-58(108)40(16-32-19-80-36-9-3-2-8-34(32)36)86-55(105)37(10-4-5-13-70)83-62(112)44(22-98)90-63(113)45(23-99)91-66(48)116)65(115)85-38(11-6-14-78-68(73)74)56(106)88-42(18-51(100)101)60(110)87-41(17-33-20-77-30-81-33)59(109)89-43(21-97)61(111)84-39(57(107)95-50)12-7-15-79-69(75)76/h2-3,8-9,19-20,30-31,35,37-50,80,97-99H,4-7,10-18,21-29,70-71H2,1H3,(H2,72,102)(H,77,81)(H,82,114)(H,83,112)(H,84,111)(H,85,115)(H,86,105)(H,87,110)(H,88,106)(H,89,109)(H,90,113)(H,91,116)(H,92,117)(H,93,103)(H,94,104)(H,95,107)(H,96,108)(H,100,101)(H4,73,74,78)(H4,75,76,79)/t31-,35+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+/m1/s1
DMSE20Y	CS	C[C@@H]1C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@@H]3CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCNC(=N)N)CO)CC4=CN=CN4)CC(=O)O)CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CO)CCCCN)CC5=CNC6=CC=CC=C65)N)C(=O)N
DMSE20Y	IK	DSVGHPDROAIMFA-YDQMBMOMSA-N
DMSE20Y	IU	2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-12,33,36-tris(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-42-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMSE20Y	DE	Discovery agent

DMUQJ6X	ID	DMUQJ6X
DMUQJ6X	DN	CCG-50014
DMUQJ6X	HS	Investigative
DMUQJ6X	SN	CCG 50014; compound 1a; CCG50014
DMUQJ6X	DT	Small molecular drug
DMUQJ6X	PC	2733079
DMUQJ6X	MW	316.4
DMUQJ6X	FM	C16H13FN2O2S
DMUQJ6X	IC	InChI=1S/C16H13FN2O2S/c1-11-2-8-14(9-3-11)19-15(20)18(16(21)22-19)10-12-4-6-13(17)7-5-12/h2-9H,10H2,1H3
DMUQJ6X	CS	CC1=CC=C(C=C1)N2C(=O)N(C(=O)S2)CC3=CC=C(C=C3)F
DMUQJ6X	IK	QUIIIYITNGOFEI-UHFFFAOYSA-N
DMUQJ6X	IU	4-[(4-fluorophenyl)methyl]-2-(4-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione
DMUQJ6X	CA	CAS 883050-24-6
DMUQJ6X	DE	Discovery agent

DM1N0ED	ID	DM1N0ED
DM1N0ED	DN	CCK-33
DM1N0ED	HS	Investigative
DM1N0ED	SN	CCRIS 3307; cholecystokinin 33
DM1N0ED	DT	Small molecular drug
DM1N0ED	PC	16129670
DM1N0ED	MW	3931
DM1N0ED	FM	C166H261N51O52S4
DM1N0ED	IC	InChI=1S/C166H261N51O52S4/c1-15-84(9)130(159(261)211-116(78-220)154(256)206-110(68-125(227)228)150(252)191-97(38-27-54-182-165(176)177)139(241)205-112(70-127(231)232)152(254)215-132(88-42-44-91(45-43-88)269-273(266,267)268)161(263)197-100(48-58-270-12)135(237)185-75-124(226)190-106(64-89-72-184-94-35-21-20-33-92(89)94)146(248)195-101(49-59-271-13)141(243)204-111(69-126(229)230)151(253)198-103(133(173)235)63-87-31-18-17-19-32-87)213-143(245)98(39-28-55-183-166(178)179)192-147(249)107(65-90-73-180-80-187-90)201-153(255)115(77-219)210-157(259)119-41-30-57-217(119)163(265)113(71-128(233)234)207-145(247)105(62-82(5)6)200-149(251)109(67-122(172)224)203-140(242)99(46-47-120(170)222)193-144(246)104(61-81(3)4)199-148(250)108(66-121(171)223)202-138(240)96(36-23-25-52-168)196-158(260)129(83(7)8)212-160(262)131(85(10)16-2)214-155(257)117(79-221)208-142(244)102(50-60-272-14)194-137(239)95(37-26-53-181-164(174)175)189-123(225)74-186-136(238)114(76-218)209-156(258)118-40-29-56-216(118)162(264)86(11)188-134(236)93(169)34-22-24-51-167/h17-21,31-33,35,42-45,72-73,80-86,93,95-119,129-132,184,218-221H,15-16,22-30,34,36-41,46-71,74-79,167-169H2,1-14H3,(H2,170,222)(H2,171,223)(H2,172,224)(H2,173,235)(H,180,187)(H,185,237)(H,186,238)(H,188,236)(H,189,225)(H,190,226)(H,191,252)(H,192,249)(H,193,246)(H,194,239)(H,195,248)(H,196,260)(H,197,263)(H,198,253)(H,199,250)(H,200,251)(H,201,255)(H,202,240)(H,203,242)(H,204,243)(H,205,241)(H,206,256)(H,207,247)(H,208,244)(H,209,258)(H,210,259)(H,211,261)(H,212,262)(H,213,245)(H,214,257)(H,215,254)(H,227,228)(H,229,230)(H,231,232)(H,233,234)(H4,174,175,181)(H4,176,177,182)(H4,178,179,183)(H,266,267,268)
DM1N0ED	CS	CCC(C)C(C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(C1=CC=C(C=C1)OS(=O)(=O)O)C(=O)NC(CCSC)C(=O)NCC(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC4=CC=CC=C4)C(=O)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC5=CNC=N5)NC(=O)C(CO)NC(=O)C6CCCN6C(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(CO)NC(=O)C7CCCN7C(=O)C(C)NC(=O)C(CCCCN)N
DM1N0ED	IK	QFLBZJPOIZFFJQ-UHFFFAOYSA-N
DM1N0ED	IU	3-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[1-[2-[[2-[[4-amino-2-[[5-amino-2-[[2-[[4-amino-2-[[6-amino-2-[[2-[[2-[[2-[[2-[[5-carbamimidamido-2-[[2-[[2-[[1-[2-(2,6-diaminohexanoylamino)propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]pentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-2-(4-sulfooxyphenyl)acetyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-oxobutanoic acid
DM1N0ED	CA	CAS 9011-97-6
DM1N0ED	DE	Discovery agent

DMN0J4W	ID	DMN0J4W
DMN0J4W	DN	CCK-8
DMN0J4W	HS	Investigative
DMN0J4W	SN	cholecystokinin 8; cholecystokinin fragment 26-33 amide (sulphated); CCK-8 (sulphated)
DMN0J4W	DT	Small molecular drug
DMN0J4W	PC	9833444
DMN0J4W	MW	1143.3
DMN0J4W	FM	C49H62N10O16S3
DMN0J4W	IC	InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
DMN0J4W	CS	CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
DMN0J4W	IK	IZTQOLKUZKXIRV-YRVFCXMDSA-N
DMN0J4W	IU	(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
DMN0J4W	CA	CAS 25126-32-3
DMN0J4W	CB	CHEBI:135946

DMRFA5O	ID	DMRFA5O
DMRFA5O	DN	CCNCASKWCRDHSRCC
DMRFA5O	HS	Investigative
DMRFA5O	SN	CHEMBL524481
DMRFA5O	PC	44560055
DMRFA5O	MW	1868.2
DMRFA5O	FM	C70H106N28O21S6
DMRFA5O	IC	InChI=1S/C70H106N28O21S6/c1-31-54(105)92-44(22-99)63(114)85-37(10-4-5-13-71)56(107)88-40(16-32-20-82-36-9-3-2-8-34(32)36)59(110)98-49-28-122-120-24-35(72)55(106)95-48-27-124-125-29-50(68(119)94-46(53(74)104)25-121-123-26-47(65(116)84-31)97-61(112)42(18-51(73)101)90-67(48)118)96-58(109)39(12-7-15-81-70(77)78)86-64(115)45(23-100)93-60(111)41(17-33-21-79-30-83-33)89-62(113)43(19-52(102)103)91-57(108)38(87-66(49)117)11-6-14-80-69(75)76/h2-3,8-9,20-21,30-31,35,37-50,82,99-100H,4-7,10-19,22-29,71-72H2,1H3,(H2,73,101)(H2,74,104)(H,79,83)(H,84,116)(H,85,114)(H,86,115)(H,87,117)(H,88,107)(H,89,113)(H,90,118)(H,91,108)(H,92,105)(H,93,111)(H,94,119)(H,95,106)(H,96,109)(H,97,112)(H,98,110)(H,102,103)(H4,75,76,80)(H4,77,78,81)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMRFA5O	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H]3CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](NC3=O)CC(=O)N)C(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CCCNC(=N)N)CC(=O)O)CC4=CN=CN4)CO)CCCNC(=N)N)N)CC5=CNC6=CC=CC=C65)CCCCN)CO
DMRFA5O	IK	SAPIXEQVQIRZOT-CPQFHPGLSA-N
DMRFA5O	IU	2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-12,33-bis(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-36-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMRFA5O	DE	Discovery agent

DMZKJ37	ID	DMZKJ37
DMZKJ37	DN	CCNCSAKWCRDHSRCC
DMZKJ37	HS	Investigative
DMZKJ37	SN	CHEMBL503290
DMZKJ37	PC	44560056
DMZKJ37	MW	1868.2
DMZKJ37	FM	C70H106N28O21S6
DMZKJ37	IC	InChI=1S/C70H106N28O21S6/c1-31-54(105)85-37(10-4-5-13-71)56(107)88-40(16-32-20-82-36-9-3-2-8-34(32)36)59(110)97-48-27-122-120-24-35(72)55(106)95-47-26-124-125-29-50(68(119)94-46(53(74)104)25-121-123-28-49(67(118)93-44(22-99)63(114)84-31)98-61(112)42(18-51(73)101)90-66(47)117)96-58(109)39(12-7-15-81-70(77)78)86-64(115)45(23-100)92-60(111)41(17-33-21-79-30-83-33)89-62(113)43(19-52(102)103)91-57(108)38(87-65(48)116)11-6-14-80-69(75)76/h2-3,8-9,20-21,30-31,35,37-50,82,99-100H,4-7,10-19,22-29,71-72H2,1H3,(H2,73,101)(H2,74,104)(H,79,83)(H,84,114)(H,85,105)(H,86,115)(H,87,116)(H,88,107)(H,89,113)(H,90,117)(H,91,108)(H,92,111)(H,93,118)(H,94,119)(H,95,106)(H,96,109)(H,97,110)(H,98,112)(H,102,103)(H4,75,76,80)(H4,77,78,81)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMZKJ37	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H]3CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CO)NC(=O)[C@H](NC3=O)CC(=O)N)C(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CCCNC(=N)N)CC(=O)O)CC4=CN=CN4)CO)CCCNC(=N)N)N)CC5=CNC6=CC=CC=C65)CCCCN
DMZKJ37	IK	AOAFXQNJFCOYGE-CPQFHPGLSA-N
DMZKJ37	IU	2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-12,36-bis(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-33-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMZKJ37	DE	Discovery agent

DM96YR2	ID	DM96YR2
DM96YR2	DN	CCNCSSKWCRAHSRCC
DM96YR2	HS	Investigative
DM96YR2	SN	CHEMBL524475
DM96YR2	PC	44560061
DM96YR2	MW	1840.2
DM96YR2	FM	C69H106N28O20S6
DM96YR2	IC	InChI=1S/C69H106N28O20S6/c1-31-53(103)87-41(17-33-20-78-30-82-33)59(109)90-43(21-98)61(111)85-39(12-7-15-80-69(76)77)57(107)95-50-29-123-122-26-47-65(115)89-42(18-51(72)101)60(110)97-49(28-121-119-25-46(52(73)102)93-67(50)117)66(116)92-45(23-100)63(113)91-44(22-99)62(112)84-37(10-4-5-13-70)56(106)88-40(16-32-19-81-36-9-3-2-8-34(32)36)58(108)96-48(27-120-118-24-35(71)54(104)94-47)64(114)86-38(55(105)83-31)11-6-14-79-68(74)75/h2-3,8-9,19-20,30-31,35,37-50,81,98-100H,4-7,10-18,21-29,70-71H2,1H3,(H2,72,101)(H2,73,102)(H,78,82)(H,83,105)(H,84,112)(H,85,111)(H,86,114)(H,87,103)(H,88,106)(H,89,115)(H,90,109)(H,91,113)(H,92,116)(H,93,117)(H,94,104)(H,95,107)(H,96,108)(H,97,110)(H4,74,75,79)(H4,76,77,80)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DM96YR2	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](NC2=O)C(=O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC4=CNC5=CC=CC=C54)CCCCN)CO)CO)CC(=O)N)CCCNC(=N)N)CO)CC6=CN=CN6
DM96YR2	IK	RFBOHZPDDZVGLQ-CPQFHPGLSA-N
DM96YR2	IU	(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-9,21-bis(3-carbamimidamidopropyl)-12,33,36-tris(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-18-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontane-56-carboxamide
DM96YR2	DE	Discovery agent

DMP0C7B	ID	DMP0C7B
DMP0C7B	DN	CCNCSSKWCRDHARCC
DMP0C7B	HS	Investigative
DMP0C7B	SN	CHEMBL525208
DMP0C7B	PC	44560063
DMP0C7B	MW	1868.2
DMP0C7B	FM	C70H106N28O21S6
DMP0C7B	IC	InChI=1S/C70H106N28O21S6/c1-31-54(105)85-38(11-6-14-80-69(75)76)58(109)96-50-29-125-124-26-47-66(117)90-42(18-51(73)101)61(112)98-49(28-123-121-25-46(53(74)104)94-68(50)119)67(118)93-45(23-100)64(115)92-44(22-99)63(114)86-37(10-4-5-13-71)56(107)88-40(16-32-20-82-36-9-3-2-8-34(32)36)60(111)97-48(27-122-120-24-35(72)55(106)95-47)65(116)87-39(12-7-15-81-70(77)78)57(108)91-43(19-52(102)103)62(113)89-41(59(110)84-31)17-33-21-79-30-83-33/h2-3,8-9,20-21,30-31,35,37-50,82,99-100H,4-7,10-19,22-29,71-72H2,1H3,(H2,73,101)(H2,74,104)(H,79,83)(H,84,110)(H,85,105)(H,86,114)(H,87,116)(H,88,107)(H,89,113)(H,90,117)(H,91,108)(H,92,115)(H,93,118)(H,94,119)(H,95,106)(H,96,109)(H,97,111)(H,98,112)(H,102,103)(H4,75,76,80)(H4,77,78,81)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMP0C7B	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](NC2=O)C(=O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CN=CN4)CC(=O)O)CCCNC(=N)N)CC5=CNC6=CC=CC=C65)CCCCN)CO)CO)CC(=O)N)CCCNC(=N)N
DMP0C7B	IK	ILMKBHRRAVBBMV-CPQFHPGLSA-N
DMP0C7B	IU	2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-33,36-bis(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-12-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMP0C7B	DE	Discovery agent

DMBGHTW	ID	DMBGHTW
DMBGHTW	DN	CCNCSSKWCRDHSRCC
DMBGHTW	HS	Investigative
DMBGHTW	PC	91935560
DMBGHTW	MW	1884.2
DMBGHTW	FM	C70H106N28O22S6
DMBGHTW	IC	InChI=1S/C70H106N28O22S6/c71-12-4-3-9-36-55(107)87-39(15-31-19-82-35-8-2-1-7-33(31)35)58(110)97-48-27-123-121-24-34(72)54(106)95-47-26-125-126-29-50(68(120)94-46(53(74)105)25-122-124-28-49(98-60(112)41(17-51(73)102)89-66(47)118)67(119)93-45(23-101)64(116)92-44(22-100)63(115)84-36)96-57(109)38(11-6-14-81-70(77)78)85-62(114)43(21-99)91-59(111)40(16-32-20-79-30-83-32)88-61(113)42(18-52(103)104)90-56(108)37(86-65(48)117)10-5-13-80-69(75)76/h1-2,7-8,19-20,30,34,36-50,82,99-101H,3-6,9-18,21-29,71-72H2,(H2,73,102)(H2,74,105)(H,79,83)(H,84,115)(H,85,114)(H,86,117)(H,87,107)(H,88,113)(H,89,118)(H,90,108)(H,91,111)(H,92,116)(H,93,119)(H,94,120)(H,95,106)(H,96,109)(H,97,110)(H,98,112)(H,103,104)(H4,75,76,80)(H4,77,78,81)/t34-,36-,37-,38-,39-,40-,41+,42-,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMBGHTW	CS	C1[C@@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCN=C(N)N)CO)CC4=CN=CN4)CC(=O)O)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)CCCCN)CO)CO)NC(=O)[C@H](NC2=O)CC(=O)N)C(=O)N)N
DMBGHTW	IK	PRXVBAUMWHTDJW-HEDOAMBMSA-N
DMBGHTW	IU	2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-56-carbamoyl-9,21-bis[3-(diaminomethylideneamino)propyl]-12,33,36-tris(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMBGHTW	DE	Discovery agent

DM2UJM8	ID	DM2UJM8
DM2UJM8	DN	CCP
DM2UJM8	HS	Investigative
DM2UJM8	SN	N-Pentadecylcyclohexanecarboxamide; CHEMBL190662; Cyclohexanecarboxylic acid pentadecylamide; GTPL5161; MolPort-009-019-076; VMFXYTSKMWPHQH-UHFFFAOYSA-N; N-Pentadecyl-cyclohexanecarboxamide; HMS3650I19; BDBM50171299; 1921AH; ZINC38140992; AKOS027276373; RT-014383; SR-01000946796
DM2UJM8	DT	Small molecular drug
DM2UJM8	PC	44398718
DM2UJM8	MW	337.6
DM2UJM8	FM	C22H43NO
DM2UJM8	IC	InChI=1S/C22H43NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-20-23-22(24)21-18-15-14-16-19-21/h21H,2-20H2,1H3,(H,23,24)
DM2UJM8	CS	CCCCCCCCCCCCCCCNC(=O)C1CCCCC1
DM2UJM8	IK	VMFXYTSKMWPHQH-UHFFFAOYSA-N
DM2UJM8	IU	N-pentadecylcyclohexanecarboxamide
DM2UJM8	DE	Discovery agent

DMZXFT9	ID	DMZXFT9
DMZXFT9	DN	CCT-241533
DMZXFT9	HS	Investigative
DMZXFT9	SN	Chk2 inhibitors (cancer); Chk2 inhibitors (cancer), Cancer Research Technology
DMZXFT9	CP	Cancer Research Technology Ltd
DMZXFT9	DT	Small molecular drug
DMZXFT9	PC	135564841
DMZXFT9	MW	442.5
DMZXFT9	FM	C23H27FN4O4
DMZXFT9	IC	InChI=1S/C23H27FN4O4/c1-23(2,30)15-10-25-11-17(15)27-21-13-8-19(31-3)20(32-4)9-16(13)26-22(28-21)14-7-12(24)5-6-18(14)29/h5-9,15,17,25,29-30H,10-11H2,1-4H3,(H,26,27,28)/t15-,17-/m1/s1
DMZXFT9	CS	CC(C)([C@@H]1CNC[C@H]1NC2=NC(=NC3=CC(=C(C=C32)OC)OC)C4=C(C=CC(=C4)F)O)O
DMZXFT9	IK	HZASIAXCPXTISQ-NVXWUHKLSA-N
DMZXFT9	IU	4-fluoro-2-[4-[[(3S,4R)-4-(2-hydroxypropan-2-yl)pyrrolidin-3-yl]amino]-6,7-dimethoxyquinazolin-2-yl]phenol
DMZXFT9	CA	CAS 1262849-73-9
DMZXFT9	DE	Solid tumour/cancer

DMSDH3A	ID	DMSDH3A
DMSDH3A	DN	CCT244747
DMSDH3A	HS	Investigative
DMSDH3A	SN	compound 26 [PMID 23082860]
DMSDH3A	DT	Small molecular drug
DMSDH3A	PC	54758482
DMSDH3A	MW	408.5
DMSDH3A	FM	C20H24N8O2
DMSDH3A	IC	InChI=1S/C20H24N8O2/c1-13(11-27(2)3)30-20-16(7-21)22-10-19(26-20)25-18-6-17(29-5)15(9-23-18)14-8-24-28(4)12-14/h6,8-10,12-13H,11H2,1-5H3,(H,23,25,26)/t13-/m1/s1
DMSDH3A	CS	C[C@H](CN(C)C)OC1=NC(=CN=C1C#N)NC2=NC=C(C(=C2)OC)C3=CN(N=C3)C
DMSDH3A	IK	IENLGMOXAQMNEH-CYBMUJFWSA-N
DMSDH3A	IU	3-[(2R)-1-(dimethylamino)propan-2-yl]oxy-5-[[4-methoxy-5-(1-methylpyrazol-4-yl)pyridin-2-yl]amino]pyrazine-2-carbonitrile
DMSDH3A	DE	Discovery agent

DM6WX1A	ID	DM6WX1A
DM6WX1A	DN	CCX-662
DM6WX1A	HS	Investigative
DM6WX1A	SN	CCX-733; CCX-754; CXCR7 antagonists, ChemoCentryx
DM6WX1A	CP	ChemoCentryx Inc
DM6WX1A	DE	Solid tumour/cancer

DM9BMDO	ID	DM9BMDO
DM9BMDO	DN	CD154
DM9BMDO	HS	Investigative
DM9BMDO	DE	Discovery agent

DMT6M5E	ID	DMT6M5E
DMT6M5E	DN	CD-160130
DMT6M5E	HS	Investigative
DMT6M5E	SN	PDE-4 inhibitor (oral, B-CLL), Curacyte Discovery; PDE-4 inhibitor (oral, B-cell chronic lymphocytic leukemia), Curacyte Discovery
DMT6M5E	CP	Curacyte AG
DMT6M5E	PC	24990553
DMT6M5E	MW	374.4
DMT6M5E	FM	C21H22N6O
DMT6M5E	IC	InChI=1S/C21H22N6O/c1-2-28-20-19-18(25-21(26-20)27-11-9-23-10-12-27)16-4-3-15(13-17(16)24-19)14-5-7-22-8-6-14/h3-8,13,23-24H,2,9-12H2,1H3
DMT6M5E	CS	CCOC1=NC(=NC2=C1NC3=C2C=CC(=C3)C4=CC=NC=C4)N5CCNCC5
DMT6M5E	IK	HFGHRUCCKVYFKL-UHFFFAOYSA-N
DMT6M5E	IU	4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole
DMT6M5E	DE	Chronic lymphocytic leukaemia

DM05M9X	ID	DM05M9X
DM05M9X	DN	CD2665
DM05M9X	HS	Investigative
DM05M9X	SN	CD 2665; CD-2665
DM05M9X	DT	Small molecular drug
DM05M9X	PC	216241
DM05M9X	MW	486.6
DM05M9X	FM	C31H34O5
DM05M9X	IC	InChI=1S/C31H34O5/c1-34-8-9-35-19-36-29-15-26-7-6-25(23-2-4-24(5-3-23)30(32)33)13-27(26)14-28(29)31-16-20-10-21(17-31)12-22(11-20)18-31/h2-7,13-15,20-22H,8-12,16-19H2,1H3,(H,32,33)
DM05M9X	CS	COCCOCOC1=C(C=C2C=C(C=CC2=C1)C3=CC=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5
DM05M9X	IK	JBALRFFXKQPVLT-UHFFFAOYSA-N
DM05M9X	IU	4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic acid
DM05M9X	CA	CAS 170355-78-9
DM05M9X	DE	Discovery agent

DM38MU1	ID	DM38MU1
DM38MU1	DN	CD3254
DM38MU1	HS	Investigative
DM38MU1	SN	CD 3254; CD-3254
DM38MU1	DT	Small molecular drug
DM38MU1	PC	44566110
DM38MU1	MW	364.5
DM38MU1	FM	C24H28O3
DM38MU1	IC	InChI=1S/C24H28O3/c1-15-12-19-20(24(4,5)11-10-23(19,2)3)14-17(15)18-13-16(6-8-21(18)25)7-9-22(26)27/h6-9,12-14,25H,10-11H2,1-5H3,(H,26,27)/b9-7+
DM38MU1	CS	CC1=CC2=C(C=C1C3=C(C=CC(=C3)/C=C/C(=O)O)O)C(CCC2(C)C)(C)C
DM38MU1	IK	DYLLZSVPAUUSSB-VQHVLOKHSA-N
DM38MU1	IU	(E)-3-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid
DM38MU1	CA	CAS 196961-43-0
DM38MU1	DE	Discovery agent

DMIV82T	ID	DMIV82T
DMIV82T	DN	CD4 red blood cell electroinsertion
DMIV82T	HS	Investigative
DMIV82T	SN	RBC-CD4, Sheffield
DMIV82T	DE	Discovery agent

DMFQVLW	ID	DMFQVLW
DMFQVLW	DN	CD45RB
DMFQVLW	HS	Investigative
DMFQVLW	SN	Abeta amyloid agonist (peptide, glioma); Abeta amyloid agonist (peptide, glioma), Lee Moffitt Cancer Center
DMFQVLW	CP	H Lee Moffitt Cancer Center and Research Institute
DMFQVLW	DE	Glioma

DMZ2LPO	ID	DMZ2LPO
DMZ2LPO	DN	CD564
DMZ2LPO	HS	Investigative
DMZ2LPO	SN	cd564; CHEMBL309282; 110952-26-6; 6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)naphthalene-2-carboxylic acid; 2-Naphthalenecarboxylicacid, 6-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]-; 1fcy; ACMC-20mdu5; AC1L1E1W; SCHEMBL2391376; CTK0I1187; BDBM31886; DTXSID60274381; DB02741; 6-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoyl)-2-naphthoic acid; 6-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]naphthalene-2-carboxylic acid
DMZ2LPO	DT	Small molecular drug
DMZ2LPO	PC	2605
DMZ2LPO	MW	386.5
DMZ2LPO	FM	C26H26O3
DMZ2LPO	IC	InChI=1S/C26H26O3/c1-25(2)11-12-26(3,4)22-15-19(9-10-21(22)25)23(27)18-7-5-17-14-20(24(28)29)8-6-16(17)13-18/h5-10,13-15H,11-12H2,1-4H3,(H,28,29)
DMZ2LPO	CS	CC1(CCC(C2=C1C=CC(=C2)C(=O)C3=CC4=C(C=C3)C=C(C=C4)C(=O)O)(C)C)C
DMZ2LPO	IK	RWYREGSYPCNZTL-UHFFFAOYSA-N
DMZ2LPO	IU	6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)naphthalene-2-carboxylic acid
DMZ2LPO	CA	CAS 110952-26-6
DMZ2LPO	DE	Discovery agent

DMC8X9Y	ID	DMC8X9Y
DMC8X9Y	DN	CD666
DMC8X9Y	HS	Investigative
DMC8X9Y	SN	CD-666; CD 666
DMC8X9Y	DT	Small molecular drug
DMC8X9Y	PC	10090192
DMC8X9Y	MW	364.5
DMC8X9Y	FM	C24H28O3
DMC8X9Y	IC	InChI=1S/C24H28O3/c1-23(2)13-14-24(3,4)20-15-18(10-11-19(20)23)21(25)12-7-16-5-8-17(9-6-16)22(26)27/h5-12,15,21,25H,13-14H2,1-4H3,(H,26,27)/b12-7+
DMC8X9Y	CS	CC1(CCC(C2=C1C=CC(=C2)C(/C=C/C3=CC=C(C=C3)C(=O)O)O)(C)C)C
DMC8X9Y	IK	QCSYBKHFYYISTQ-KPKJPENVSA-N
DMC8X9Y	IU	4-[(E)-3-hydroxy-3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid
DMC8X9Y	DE	Discovery agent

DMWP63C	ID	DMWP63C
DMWP63C	DN	CD79-targeted immunotoxins
DMWP63C	HS	Investigative
DMWP63C	SN	Anti-CD79b-MC-MMAF; Anti-CD79b-MCC-DM1; Anti-CD79b-vc-MMAE; Anti-CD79b-vc-vedotin; CD79-targeted immunotoxins (non-Hodgkin's lymphoma); CD79-targeted immunotoxins (non-Hodgkin's lymphoma), Genentech; Anti-CD79 antibody-drug conjugates (non-Hodgkin's lymphoma), Genentech
DMWP63C	CP	Genentech Inc
DMWP63C	DT	Antibody
DMWP63C	DE	Non-hodgkin lymphoma

DMFYWE3	ID	DMFYWE3
DMFYWE3	DN	CD-832.HCL
DMFYWE3	HS	Investigative
DMFYWE3	SN	129904-55-8; 2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 5-(3-nitrooxypropyl) 3-[2-(3-pyridylcarbonylamino)ethyl] diester monohydrochloride; CD-832.HCl
DMFYWE3	DT	Small molecular drug
DMFYWE3	PC	179844
DMFYWE3	MW	606
DMFYWE3	FM	C26H28ClN5O10
DMFYWE3	IC	InChI=1S/C26H27N5O10.ClH/c1-16-21(25(33)39-11-5-12-41-31(37)38)23(18-6-3-8-20(14-18)30(35)36)22(17(2)29-16)26(34)40-13-10-28-24(32)19-7-4-9-27-15-19;/h3-4,6-9,14-15,23,29H,5,10-13H2,1-2H3,(H,28,32);1H
DMFYWE3	CS	CC1=C(C(C(=C(N1)C)C(=O)OCCNC(=O)C2=CN=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCCO[N+](=O)[O-].Cl
DMFYWE3	IK	MWVXLKFCDZXILL-UHFFFAOYSA-N
DMFYWE3	IU	3-O-(3-nitrooxypropyl) 5-O-[2-(pyridine-3-carbonylamino)ethyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride
DMFYWE3	CA	CAS 129904-55-8
DMFYWE3	DE	Discovery agent

DM03NUV	ID	DM03NUV
DM03NUV	DN	CDDO
DM03NUV	HS	Investigative
DM03NUV	SN	Bardoxolone; CDDO; 218600-44-3; RTA-401; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid; UNII-7HT68L8941; RTA 401; 7HT68L8941; (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid; C31H41NO4; 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid; RTA 402; CCDO;(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid; NSC711193; bardoxolone RTA 401
DM03NUV	DT	Small molecular drug
DM03NUV	PC	400010
DM03NUV	MW	491.7
DM03NUV	FM	C31H41NO4
DM03NUV	IC	InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1
DM03NUV	CS	C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)O
DM03NUV	IK	TXGZJQLMVSIZEI-UQMAOPSPSA-N
DM03NUV	IU	(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid
DM03NUV	CA	CAS 218600-44-3
DM03NUV	DE	Discovery agent

DMNW12R	ID	DMNW12R
DMNW12R	DN	Cdk1 inhibitor
DMNW12R	HS	Investigative
DMNW12R	SN	cdk1 inhibitor; 3-(2-Chloro-3-indolylmethylene)-1,3-dihydroindol-2-one; CHEMBL261425; 220749-41-7; K00028; AC1NV88J; SCHEMBL1394886; GTPL5944; CHEBI:113538; HMS3229C12; NSC720148; BDBM50375670; HSCI1_000249; CCG-206822; NSC-720148; RT-011955; J-014469; BRD-K81836716-001-01-7; 3-[(2-Chloro-1H-indole-3-yl)methylene]-1H-indole-2(3H)-one; (3E)-3-[(2-chloro-1H-indol-3-yl)methylidene]-1H-indol-2-one
DMNW12R	DT	Small molecular drug
DMNW12R	PC	5472558
DMNW12R	MW	294.7
DMNW12R	FM	C17H11ClN2O
DMNW12R	IC	InChI=1S/C17H11ClN2O/c18-16-12(10-5-1-3-7-14(10)19-16)9-13-11-6-2-4-8-15(11)20-17(13)21/h1-9,19H,(H,20,21)/b13-9+
DMNW12R	CS	C1=CC=C2C(=C1)/C(=C\\C3=C(NC4=CC=CC=C43)Cl)/C(=O)N2
DMNW12R	IK	QJKBRWSJWQVKLY-UKTHLTGXSA-N
DMNW12R	IU	(3E)-3-[(2-chloro-1H-indol-3-yl)methylidene]-1H-indol-2-one
DMNW12R	CB	CHEBI:113538
DMNW12R	DE	Discovery agent

DMS62T0	ID	DMS62T0
DMS62T0	DN	Cdk1/2 inhibitor III
DMS62T0	HS	Investigative
DMS62T0	SN	Cdk1/2 Inhibitor III; 443798-55-8; CDK 1/2 INHIBITOR; UNII-LFR1253W75; LFR1253W75; 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE; 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide; 5-Amino-3-((4-(aminosulfonyl)phenyl)amino)-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide; 2wu6; AC1NS9OB; CHEMBL261720; GTPL5946; BDBM6878; SCHEMBL1394721; CTK8E9250; DTXSID60416209; MolPort-044-561-528; HMS3229C16; ZINC12355112; DB07664
DMS62T0	DT	Small molecular drug
DMS62T0	PC	5330812
DMS62T0	MW	425.4
DMS62T0	FM	C15H13F2N7O2S2
DMS62T0	IC	InChI=1S/C15H13F2N7O2S2/c16-10-2-1-3-11(17)12(10)21-15(27)24-13(18)22-14(23-24)20-8-4-6-9(7-5-8)28(19,25)26/h1-7H,(H,21,27)(H2,19,25,26)(H3,18,20,22,23)
DMS62T0	CS	C1=CC(=C(C(=C1)F)NC(=S)N2C(=NC(=N2)NC3=CC=C(C=C3)S(=O)(=O)N)N)F
DMS62T0	IK	ARIOBGGRZJITQX-UHFFFAOYSA-N
DMS62T0	IU	5-amino-N-(2,6-difluorophenyl)-3-(4-sulfamoylanilino)-1,2,4-triazole-1-carbothioamide
DMS62T0	CA	CAS 443798-47-8
DMS62T0	DE	Discovery agent

DMNZJAX	ID	DMNZJAX
DMNZJAX	DN	Cdk4 inhibitor III
DMNZJAX	HS	Investigative
DMNZJAX	SN	Ryuvidine; Cdk4 Inhibitor III; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830
DMNZJAX	DT	Small molecular drug
DMNZJAX	PC	481747
DMNZJAX	MW	284.3
DMNZJAX	FM	C15H12N2O2S
DMNZJAX	IC	InChI=1S/C15H12N2O2S/c1-8-3-5-10(6-4-8)17-11-7-12(18)15-13(14(11)19)16-9(2)20-15/h3-7,17H,1-2H3
DMNZJAX	CS	CC1=CC=C(C=C1)NC2=CC(=O)C3=C(C2=O)N=C(S3)C
DMNZJAX	IK	HFPLHASLIOXVGS-UHFFFAOYSA-N
DMNZJAX	IU	2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione
DMNZJAX	CB	CHEBI:92119
DMNZJAX	DE	Discovery agent

DMQDA5W	ID	DMQDA5W
DMQDA5W	DN	CDRI-85/92
DMQDA5W	HS	Investigative
DMQDA5W	SN	Proton pump inhibitor (gastric ulcer), CDRI
DMQDA5W	CP	Central Drug Research Institute
DMQDA5W	DE	Stomach ulcer

DMUKGEA	ID	DMUKGEA
DMUKGEA	DN	Cebutolol
DMUKGEA	HS	Investigative
DMUKGEA	DE	Discovery agent

DMRYX1P	ID	DMRYX1P
DMRYX1P	DN	CEL-1000
DMRYX1P	HS	Investigative
DMRYX1P	SN	CEL-1000C; DerG, CEL-SCI; Immunostimulant peptide, CEL-SCI; Peptide vaccine (Vaxcine, oral, herpes simplex virus infection); Peptide vaccine (Vaxcine, oral, herpes simplex virus infection), Infexion
DMRYX1P	CP	CEL-SCI Corp; Infexion
DMRYX1P	DT	Vaccine
DMRYX1P	DE	Solid tumour/cancer

DMQ0HCT	ID	DMQ0HCT
DMQ0HCT	DN	CEM-301
DMQ0HCT	HS	Investigative
DMQ0HCT	SN	Macrolide motilin agonists, Optimer/Cempra
DMQ0HCT	CP	Cempra Pharmaceuticals Inc
DMQ0HCT	DE	Gastric motility disorder

DMCLXO0	ID	DMCLXO0
DMCLXO0	DN	CENTAUREIDIN
DMCLXO0	HS	Investigative
DMCLXO0	SN	Centaureidin; Desmethoxycentaureidine; 17313-52-9; 5,7,3'-Trihydroxy-3,6,4'-trimethoxyflavone; NSC-106969; UNII-548R7290J9; CHEMBL77552; MLS002701956; CHEBI:69356; 548R7290J9; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,6-dimethoxy-4H-chromen-4-one; centaureidine; NSC106969; NSC 106969; AC1NSTGP; SCHEMBL9953; cid_5315773; DTXSID50169530; MolPort-023-274-268; ZINC3871987; ZINC03871987; LMPK12113000; BDBM50064891; quercetagetin 3,6,4'-trimethyl ether; AKOS027326559; MCULE-7507998415; SMR001565538; 6-hydroxyquercetin 3,6,4''-trimethyl
DMCLXO0	DT	Small molecular drug
DMCLXO0	PC	5315773
DMCLXO0	MW	360.3
DMCLXO0	FM	C18H16O8
DMCLXO0	IC	InChI=1S/C18H16O8/c1-23-11-5-4-8(6-9(11)19)16-18(25-3)15(22)13-12(26-16)7-10(20)17(24-2)14(13)21/h4-7,19-21H,1-3H3
DMCLXO0	CS	COC1=C(C=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C(=C3O)OC)O)OC)O
DMCLXO0	IK	BZXULYMZYPRZOG-UHFFFAOYSA-N
DMCLXO0	IU	5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,6-dimethoxychromen-4-one
DMCLXO0	CA	CAS 17313-52-9
DMCLXO0	CB	CHEBI:69356
DMCLXO0	DE	Discovery agent

DMOHELX	ID	DMOHELX
DMOHELX	DN	Centratherin
DMOHELX	HS	Investigative
DMOHELX	SN	centratherin; CHEMBL382151
DMOHELX	DT	Small molecular drug
DMOHELX	PC	44409502
DMOHELX	MW	374.4
DMOHELX	FM	C20H22O7
DMOHELX	IC	InChI=1S/C20H22O7/c1-5-10(2)18(23)26-15-8-20(4)16(22)7-13(27-20)12(9-21)6-14-17(15)11(3)19(24)25-14/h5-7,14-15,17,21H,3,8-9H2,1-2,4H3/b10-5-,12-6-/t14-,15+,17+,20-/m1/s1
DMOHELX	CS	C/C=C(/C)\\C(=O)O[C@H]1C[C@@]2(C(=O)C=C(O2)/C(=C\\[C@@H]3[C@@H]1C(=C)C(=O)O3)/CO)C
DMOHELX	IK	BMVJFNLJSZHNNS-YUDFMKBLSA-N
DMOHELX	IU	[(2Z,4R,8R,9S,11R)-2-(hydroxymethyl)-11-methyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (Z)-2-methylbut-2-enoate
DMOHELX	CA	CAS 71939-83-8
DMOHELX	DE	Discovery agent

DMA7JO4	ID	DMA7JO4
DMA7JO4	DN	CEP1348
DMA7JO4	HS	Investigative
DMA7JO4	DE	Discovery agent

DMOAZX5	ID	DMOAZX5
DMOAZX5	DN	CEP1349
DMOAZX5	HS	Investigative
DMOAZX5	DE	Discovery agent

DMCIOSM	ID	DMCIOSM
DMCIOSM	DN	CEP-18050
DMCIOSM	HS	Investigative
DMCIOSM	SN	ALK inhibitors (anaplastic large cell lymphoma); ALK inhibitors (anaplastic large cell lymphoma), Cephalon; Alk inhibitors (cancer), Cephalon
DMCIOSM	CP	Cephalon Inc
DMCIOSM	DE	Lymphoma

DMAY04M	ID	DMAY04M
DMAY04M	DN	CEP-28122
DMAY04M	HS	Investigative
DMAY04M	SN	ALK inhibitor (cancer), Cephalon
DMAY04M	CP	Cephalon Inc
DMAY04M	DT	Small molecular drug
DMAY04M	PC	57325421
DMAY04M	MW	539.1
DMAY04M	FM	C28H35ClN6O3
DMAY04M	IC	InChI=1S/C28H35ClN6O3/c1-37-25-20-8-7-19(35-10-12-38-13-11-35)6-4-16(20)5-9-22(25)32-28-31-15-21(29)27(34-28)33-24-18-3-2-17(14-18)23(24)26(30)36/h2-3,5,9,15,17-19,23-24H,4,6-8,10-14H2,1H3,(H2,30,36)(H2,31,32,33,34)/t17-,18+,19+,23+,24-/m1/s1
DMAY04M	CS	COC1=C(C=CC2=C1CC[C@H](CC2)N3CCOCC3)NC4=NC=C(C(=N4)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl
DMAY04M	IK	LAJAFFLJAJMYLK-CVOKMOJFSA-N
DMAY04M	IU	(1S,2S,3R,4R)-3-[[5-chloro-2-[[(7S)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide
DMAY04M	CA	CAS 1431697-87-8
DMAY04M	DE	Solid tumour/cancer

DMV43GY	ID	DMV43GY
DMV43GY	DN	CEP-5104
DMV43GY	HS	Investigative
DMV43GY	SN	C25H22N2O3; 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-5104; CHEMBL460989; SCHEMBL3264941; BDBM24947; ZINC40861910; 5-oxo dihydronaphthylcarbazole analogue, 14; X7364
DMV43GY	DT	Small molecular drug
DMV43GY	PC	23378546
DMV43GY	MW	398.5
DMV43GY	FM	C25H22N2O3
DMV43GY	IC	InChI=1S/C25H22N2O3/c1-30-15-7-9-16-14(12-15)6-8-18-21(16)23-19(13-26-25(23)29)22-17-4-2-3-5-20(17)27(10-11-28)24(18)22/h2-5,7,9,12,28H,6,8,10-11,13H2,1H3,(H,26,29)
DMV43GY	CS	COC1=CC2=C(C=C1)C3=C(CC2)C4=C(C5=C3C(=O)NC5)C6=CC=CC=C6N4CCO
DMV43GY	IK	QMLALHXGVBGFIC-UHFFFAOYSA-N
DMV43GY	IU	3-(2-hydroxyethyl)-20-methoxy-3,13-diazahexacyclo[14.8.0.02,10.04,9.011,15.017,22]tetracosa-1(16),2(10),4,6,8,11(15),17(22),18,20-nonaen-14-one
DMV43GY	DE	Discovery agent

DMNXBTD	ID	DMNXBTD
DMNXBTD	DN	CEP-6331
DMNXBTD	HS	Investigative
DMNXBTD	SN	2-Isopropoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-6331; CHEMBL460990; BDBM24949; MolPort-027-637-287; ZINC33970297; 5-oxo dihydronaphthylcarbazole analogue, 16; X7365
DMNXBTD	DT	Small molecular drug
DMNXBTD	PC	9823787
DMNXBTD	MW	426.5
DMNXBTD	FM	C27H26N2O3
DMNXBTD	IC	InChI=1S/C27H26N2O3/c1-15(2)32-17-8-10-18-16(13-17)7-9-20-23(18)25-21(14-28-27(25)31)24-19-5-3-4-6-22(19)29(11-12-30)26(20)24/h3-6,8,10,13,15,30H,7,9,11-12,14H2,1-2H3,(H,28,31)
DMNXBTD	CS	CC(C)OC1=CC2=C(C=C1)C3=C(CC2)C4=C(C5=C3C(=O)NC5)C6=CC=CC=C6N4CCO
DMNXBTD	IK	HSWWFIPPMAFLPH-UHFFFAOYSA-N
DMNXBTD	IU	3-(2-hydroxyethyl)-20-propan-2-yloxy-3,13-diazahexacyclo[14.8.0.02,10.04,9.011,15.017,22]tetracosa-1(16),2(10),4,6,8,11(15),17(22),18,20-nonaen-14-one
DMNXBTD	DE	Discovery agent

DMS16BD	ID	DMS16BD
DMS16BD	DN	CEP-6800
DMS16BD	HS	Investigative
DMS16BD	SN	CEP-6800; UNII-0X7U7SRK9H; 0X7U7SRK9H; CHEMBL247374; 609848-02-4; SCHEMBL12256417; BDBM50197585; 1H-Cyclopenta(a)pyrrolo(3,4-C)carbazole-1,3(2H)-dione, 10-(aminomethyl)-4,5,6,7-tetrahydro-; 8-aminomethyl-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione
DMS16BD	DT	Small molecular drug
DMS16BD	PC	9948440
DMS16BD	MW	305.3
DMS16BD	FM	C18H15N3O2
DMS16BD	IC	InChI=1S/C18H15N3O2/c19-7-8-4-5-12-11(6-8)13-15-14(17(22)21-18(15)23)9-2-1-3-10(9)16(13)20-12/h4-6,20H,1-3,7,19H2,(H,21,22,23)
DMS16BD	CS	C1CC2=C(C1)C3=C(C4=C(N3)C=CC(=C4)CN)C5=C2C(=O)NC5=O
DMS16BD	IK	SDXBGOVSVBZDFL-UHFFFAOYSA-N
DMS16BD	IU	15-(aminomethyl)-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione
DMS16BD	CA	CAS 609848-02-4
DMS16BD	DE	Discovery agent

DMYW3ZG	ID	DMYW3ZG
DMYW3ZG	DN	Cephalosporin C
DMYW3ZG	HS	Investigative
DMYW3ZG	SN	cephalosporin C; 7-(5-Amino-5-carboxyvaleramido)cephalosporanic acid; 61-24-5; UNII-3XIY7HJT5L; CHEBI:15776; EINECS 200-501-6; 3XIY7HJT5L; BRN 0065348; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((5-amino-5-carboxy-1-oxopentyl)amino)-8-oxo-, (6R-(6alpha,7beta(R*)))-; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(5R)-5-amino-5-carboxypentanoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(5-amino-5-carboxyvaleramid
DMYW3ZG	DT	Small molecular drug
DMYW3ZG	PC	65536
DMYW3ZG	MW	415.4
DMYW3ZG	FM	C16H21N3O8S
DMYW3ZG	IC	InChI=1S/C16H21N3O8S/c1-7(20)27-5-8-6-28-14-11(13(22)19(14)12(8)16(25)26)18-10(21)4-2-3-9(17)15(23)24/h9,11,14H,2-6,17H2,1H3,(H,18,21)(H,23,24)(H,25,26)/t9-,11-,14-/m1/s1
DMYW3ZG	CS	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O
DMYW3ZG	IK	HOKIDJSKDBPKTQ-GLXFQSAKSA-N
DMYW3ZG	IU	(6R,7R)-3-(acetyloxymethyl)-7-[[(5R)-5-amino-5-carboxypentanoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYW3ZG	CA	CAS 61-24-5
DMYW3ZG	CB	CHEBI:15776
DMYW3ZG	DE	Discovery agent

DMCE3NA	ID	DMCE3NA
DMCE3NA	DN	CEPHARANTINE
DMCE3NA	HS	Investigative
DMCE3NA	SN	cepharantine; CHEMBL500862; BDBM50242977
DMCE3NA	DT	Small molecular drug
DMCE3NA	PC	7098680
DMCE3NA	MW	606.7
DMCE3NA	FM	C37H38N2O6
DMCE3NA	IC	InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29-/m0/s1
DMCE3NA	CS	CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)C[C@H]7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3
DMCE3NA	IK	YVPXVXANRNDGTA-VMPREFPWSA-N
DMCE3NA	IU	(14S,27S)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.216,19.13,10.121,25.04,8.031,35.014,39]nonatriaconta-1(33),3(39),4(8),9,16(38),17,19(37),21,23,25(36),31,34-dodecaene
DMCE3NA	DE	Discovery agent

DMY8LBO	ID	DMY8LBO
DMY8LBO	DN	Ceplene/Peg-Intron/Rebetol
DMY8LBO	HS	Investigative
DMY8LBO	SN	Histamine dihydrochloride/peg-interferon alfa-2b/ribavirin
DMY8LBO	CP	Maxim Pharmaceuticals
DMY8LBO	DE	Hepatitis C virus infection

DMSL4FQ	ID	DMSL4FQ
DMSL4FQ	DN	CFGGFTCARKSARK
DMSL4FQ	HS	Investigative
DMSL4FQ	DE	Discovery agent

DM2B0RX	ID	DM2B0RX
DM2B0RX	DN	CFGGFTGARKCARK
DM2B0RX	HS	Investigative
DM2B0RX	DE	Discovery agent

DMN8B1S	ID	DMN8B1S
DMN8B1S	DN	CFMMC
DMN8B1S	HS	Investigative
DMN8B1S	SN	CFMMC; 1190598-60-7; 3-cyclohexyl-5-fluoro-6-methyl-7-[2-(morpholin-4-yl)ethoxy]-4H-chromen-4-one; GTPL6340; AKOS028114903; ZINC207688804
DMN8B1S	DT	Small molecular drug
DMN8B1S	PC	73755208
DMN8B1S	MW	389.5
DMN8B1S	FM	C22H28FNO4
DMN8B1S	IC	InChI=1S/C22H28FNO4/c1-15-18(27-12-9-24-7-10-26-11-8-24)13-19-20(21(15)23)22(25)17(14-28-19)16-5-3-2-4-6-16/h13-14,16H,2-12H2,1H3
DMN8B1S	CS	CC1=C(C=C2C(=C1F)C(=O)C(=CO2)C3CCCCC3)OCCN4CCOCC4
DMN8B1S	IK	PHQKNLJAPYWXQQ-UHFFFAOYSA-N
DMN8B1S	IU	3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)chromen-4-one
DMN8B1S	DE	Discovery agent

DM9HMP4	ID	DM9HMP4
DM9HMP4	DN	CFMTI
DM9HMP4	HS	Investigative
DM9HMP4	SN	CFMTI; 864864-17-5; CHEMBL578995; SCHEMBL1499981; GTPL6341; KS-00001CMY; XZBFQWRAIYRPPZ-UHFFFAOYSA-N; MolPort-044-567-623; BCP18264; ZINC13983188; BDBM50301824; AKOS028114902; CS-5757; 2-cyclopropyl-5-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one; HY-100402; C-365; L023899; 2-cyclopropyl-5-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-3H-isoindol-1-one.; 2-cyclopropyl-5-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-
DM9HMP4	DT	Small molecular drug
DM9HMP4	PC	11175501
DM9HMP4	MW	349.4
DM9HMP4	FM	C19H16FN5O
DM9HMP4	IC	InChI=1S/C19H16FN5O/c1-11-17(22-23-25(11)16-3-2-8-21-18(16)20)12-4-7-15-13(9-12)10-24(19(15)26)14-5-6-14/h2-4,7-9,14H,5-6,10H2,1H3
DM9HMP4	CS	CC1=C(N=NN1C2=C(N=CC=C2)F)C3=CC4=C(C=C3)C(=O)N(C4)C5CC5
DM9HMP4	IK	XZBFQWRAIYRPPZ-UHFFFAOYSA-N
DM9HMP4	IU	2-cyclopropyl-5-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-3H-isoindol-1-one
DM9HMP4	DE	Discovery agent

DM8TJW3	ID	DM8TJW3
DM8TJW3	DN	CFTRinh-172
DM8TJW3	HS	Investigative
DM8TJW3	SN	CFTRinh-172; 307510-92-5; 4-({4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene}methyl)benzoic acid; 4-[4-oxo-2-thioxo-3-(3-trifluoromethyl-phenyl)-thiazolidin-(5z)-ylidenemethyl]-benzoic acid; 4-[[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid; AC1L9ZJU; CBMicro_044684; (inh)-172; SCHEMBL919042; GTPL4153; KS-00000NFK; CTK8F1370; CHEBI:131686; 5-[(4-carboxyphenyl)methylene]-2-thioxo-3-[(3-trifluoromethyl)phenyl]-4-thiazolidinone; HMS3653A11
DM8TJW3	DT	Small molecular drug
DM8TJW3	PC	504670
DM8TJW3	MW	409.4
DM8TJW3	FM	C18H10F3NO3S2
DM8TJW3	IC	InChI=1S/C18H10F3NO3S2/c19-18(20,21)12-2-1-3-13(9-12)22-15(23)14(27-17(22)26)8-10-4-6-11(7-5-10)16(24)25/h1-9H,(H,24,25)
DM8TJW3	CS	C1=CC(=CC(=C1)N2C(=O)C(=CC3=CC=C(C=C3)C(=O)O)SC2=S)C(F)(F)F
DM8TJW3	IK	JIMHYXZZCWVCMI-UHFFFAOYSA-N
DM8TJW3	IU	4-[[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid
DM8TJW3	CA	CAS 307510-92-5
DM8TJW3	CB	CHEBI:131686
DM8TJW3	DE	Discovery agent

DMGW9QL	ID	DMGW9QL
DMGW9QL	DN	CG-103065
DMGW9QL	HS	Investigative
DMGW9QL	SN	Syk inhibitor (inflammation/cancer); Syk inhibitor (inflammation/cancer), CG Pharmaceuticals; Syk inhibitors (inflammation/cancer), CG Pharmaceuticals; Syk inhibitors (inflammation/cancer), CrystalGenomics
DMGW9QL	CP	CG Pharmaceuticals Inc
DMGW9QL	DT	Small molecular drug
DMGW9QL	PC	6419747
DMGW9QL	MW	353.4
DMGW9QL	FM	C18H15N3O3S
DMGW9QL	IC	InChI=1S/C18H15N3O3S/c1-21-10-11(13-4-2-3-5-17(13)21)8-15-14-9-12(25(19,23)24)6-7-16(14)20-18(15)22/h2-10H,1H3,(H,20,22)(H2,19,23,24)/b15-8-
DMGW9QL	CS	CN1C=C(C2=CC=CC=C21)/C=C\\3/C4=C(C=CC(=C4)S(=O)(=O)N)NC3=O
DMGW9QL	IK	MLKHXLFEYOOYEY-NVNXTCNLSA-N
DMGW9QL	IU	(3Z)-3-[(1-methylindol-3-yl)methylidene]-2-oxo-1H-indole-5-sulfonamide
DMGW9QL	CA	CAS 622387-85-3
DMGW9QL	CB	CHEBI:92522
DMGW9QL	DE	Solid tumour/cancer

DMN3YEQ	ID	DMN3YEQ
DMN3YEQ	DN	CG-1521
DMN3YEQ	HS	Investigative
DMN3YEQ	SN	CG-1521; UNII-028K52V859; 028K52V859; 2,4,6-Heptatrienamide, N-hydroxy-7-phenyl-, (2E,4E,6E)-; 674767-29-4; CHEMBL159249; SCHEMBL10323570; DBBYYRWVNDQECM-CDWOPPGASA-N; N-hydroxy-7-phenylhepta-2,4,6-trienamide
DMN3YEQ	DT	Small molecular drug
DMN3YEQ	PC	10220017
DMN3YEQ	MW	215.25
DMN3YEQ	FM	C13H13NO2
DMN3YEQ	IC	InChI=1S/C13H13NO2/c15-13(14-16)11-7-2-1-4-8-12-9-5-3-6-10-12/h1-11,16H,(H,14,15)/b2-1+,8-4+,11-7+
DMN3YEQ	CS	C1=CC=C(C=C1)/C=C/C=C/C=C/C(=O)NO
DMN3YEQ	IK	DBBYYRWVNDQECM-CDWOPPGASA-N
DMN3YEQ	IU	(2E,4E,6E)-N-hydroxy-7-phenylhepta-2,4,6-trienamide
DMN3YEQ	CA	CAS 674767-29-4
DMN3YEQ	CB	CHEBI:156510
DMN3YEQ	DE	Solid tumour/cancer

DM4FMPJ	ID	DM4FMPJ
DM4FMPJ	DN	CGEN-855
DM4FMPJ	HS	Investigative
DM4FMPJ	SN	CGEN-855A; CGEN-855B; FPRL1 G-protein-coupled receptor agonists (peptide, inflammation/cardiac disorder); FPRL1 G-protein-coupled receptor agonists (peptide, inflammation/cardiac disorder), Compugen
DM4FMPJ	CP	Compugen Ltd
DM4FMPJ	DE	Inflammation

DMTPRBX	ID	DMTPRBX
DMTPRBX	DN	CGI-1316
DMTPRBX	HS	Investigative
DMTPRBX	SN	CGI-1746; CGI-2233; CGI-2815; CGI-3130; CGI-560; CGI-676; Btk inhibitors (autoimmune disease/inflammatory disease); Btk inhibitors (autoimmune disease/inflammatory disease), CGI Pharmaceuticals; Btk inhibitors (autoimmune disease/inflammatory disease), Cellular Genomics; Btk inhibitors (autoimmune disease/inflammatory disease), Gilead
DMTPRBX	CP	CGI Pharmaceuticals Inc
DMTPRBX	DT	Small molecular drug
DMTPRBX	PC	24857323
DMTPRBX	MW	579.7
DMTPRBX	FM	C34H37N5O4
DMTPRBX	IC	InChI=1S/C34H37N5O4/c1-22-27(7-6-8-28(22)37-31(40)23-9-13-25(14-10-23)34(2,3)4)29-21-38(5)33(42)30(36-29)35-26-15-11-24(12-16-26)32(41)39-17-19-43-20-18-39/h6-16,21H,17-20H2,1-5H3,(H,35,36)(H,37,40)
DMTPRBX	CS	CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C(C)(C)C)C3=CN(C(=O)C(=N3)NC4=CC=C(C=C4)C(=O)N5CCOCC5)C
DMTPRBX	IK	JIFCFQDXHMUPGP-UHFFFAOYSA-N
DMTPRBX	IU	4-tert-butyl-N-[2-methyl-3-[4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxopyrazin-2-yl]phenyl]benzamide
DMTPRBX	CA	CAS 910232-84-7
DMTPRBX	DE	Autoimmune diabetes

DM8OAN9	ID	DM8OAN9
DM8OAN9	DN	CGK733
DM8OAN9	HS	Investigative
DM8OAN9	SN	CGK733; 905973-89-9; CGK 733; CGK-733; 2,2-Diphenyl-N-(2,2,2-trichloro-1-(3-(4-fluoro-3-nitrophenyl)thioureido)ethyl)acetamide; CHEMBL1221601; 2,2-Diphenyl-n-(2,2,2-trichloro-1-[3-(4-fluoro-3-nitrophenyl)thioureido]ethyl)acetamide; UNII-L3DGZ99QYM; 2,2-diphenyl-N-(2,2,2-trichloro-1-{[(4-fluoro-3-nitrophenyl)carbamothioyl]amino}ethyl)acetamide; 2,2-diphenyl-N-[2,2,2-trichloro-1-[(4-fluoro-3-nitrophenyl)carbamothioylamino]ethyl]acetamide; L3DGZ99QYM
DM8OAN9	DT	Small molecular drug
DM8OAN9	PC	6605258
DM8OAN9	MW	555.8
DM8OAN9	FM	C23H18Cl3FN4O3S
DM8OAN9	IC	InChI=1S/C23H18Cl3FN4O3S/c24-23(25,26)21(30-22(35)28-16-11-12-17(27)18(13-16)31(33)34)29-20(32)19(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-13,19,21H,(H,29,32)(H2,28,30,35)
DM8OAN9	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC3=CC(=C(C=C3)F)[N+](=O)[O-]
DM8OAN9	IK	HLCDNLNLQNYZTK-UHFFFAOYSA-N
DM8OAN9	IU	2,2-diphenyl-N-[2,2,2-trichloro-1-[(4-fluoro-3-nitrophenyl)carbamothioylamino]ethyl]acetamide
DM8OAN9	CA	CAS 905973-89-9
DM8OAN9	CB	CHEBI:91739
DM8OAN9	DE	Discovery agent

DMQ3SAY	ID	DMQ3SAY
DMQ3SAY	DN	CGNLSTCBLGTYTQDF[DKFHO]YPQTAIGVGAP-amide
DMQ3SAY	HS	Investigative
DMQ3SAY	PC	73352989
DMQ3SAY	MW	3431.9
DMQ3SAY	FM	C146H244N44O47S2
DMQ3SAY	IC	InChI=1S/C146H244N44O47S2/c1-18-19-27-82(123(215)179-96(51-77-33-35-79(199)36-34-77)144(236)190-45-26-32-103(190)139(231)169-84(30-24-43-158-146(155)156)126(218)187-114(74(15)196)142(234)178-95(55-107(153)203)134(226)186-113(73(14)195)140(232)161-58-109(205)164-97(60-191)120(212)160-59-110(206)184-116(76(17)198)145(237)189-44-25-31-102(189)117(154)209)165-131(223)92(52-78-56-157-66-162-78)174-127(219)88(47-68(4)5)171-122(214)83(29-21-23-42-148)166-132(224)93(53-105(151)201)175-128(220)89(48-69(6)7)172-125(217)86(38-40-111(207)208)167-124(216)85(37-39-104(150)200)168-135(227)99(62-193)181-129(221)90(49-70(8)9)170-121(213)81(28-20-22-41-147)163-108(204)57-159-119(211)87(46-67(2)3)177-141(233)112(72(12)13)185-138(230)101(65-239)183-143(235)115(75(16)197)188-137(229)100(63-194)182-130(222)91(50-71(10)11)173-133(225)94(54-106(152)202)176-136(228)98(61-192)180-118(210)80(149)64-238/h33-36,56,66-76,80-103,112-116,191-199,238-239H,18-32,37-55,57-65,147-149H2,1-17H3,(H2,150,200)(H2,151,201)(H2,152,202)(H2,153,203)(H2,154,209)(H,157,162)(H,159,211)(H,160,212)(H,161,232)(H,163,204)(H,164,205)(H,165,223)(H,166,224)(H,167,216)(H,168,227)(H,169,231)(H,170,213)(H,171,214)(H,172,217)(H,173,225)(H,174,219)(H,175,220)(H,176,228)(H,177,233)(H,178,234)(H,179,215)(H,180,210)(H,181,221)(H,182,222)(H,183,235)(H,184,206)(H,185,230)(H,186,226)(H,187,218)(H,188,229)(H,207,208)(H4,155,156,158)/t73-,74-,75-,76-,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102-,103-,112+,113+,114+,115+,116+/m1/s1
DMQ3SAY	CS	CCCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@@H]3C(=O)N)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N
DMQ3SAY	IK	YNPHTODKUNFPBE-PQRPONEFSA-N
DMQ3SAY	IU	(4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMQ3SAY	DE	Discovery agent

DMLA384	ID	DMLA384
DMLA384	DN	CGNLSTCBLGTYTQDFNKFHZYPQTAIGVGAP-amide
DMLA384	HS	Investigative
DMLA384	PC	73350025
DMLA384	MW	3372.8
DMLA384	FM	C152H231N39O44S2
DMLA384	IC	InChI=1S/C152H231N39O44S2/c1-17-20-36-94(171-143(226)108(72-237)183-150(233)125(83(16)196)189-142(225)107(70-192)182-135(218)99(56-75(6)7)176-138(221)103(62-113(157)201)169-116(204)67-161-129(212)91(154)71-236)132(215)175-98(55-74(4)5)130(213)162-68-118(206)185-122(80(13)193)148(231)180-101(59-86-40-44-89(197)45-41-86)141(224)188-124(82(15)195)149(232)173-95(48-50-111(155)199)133(216)179-105(64-119(207)208)140(223)177-100(58-85-34-25-22-26-35-85)136(219)178-104(63-114(158)202)139(222)170-92(37-27-28-52-153)126(209)97(57-84-32-23-21-24-33-84)174-137(220)102(61-88-65-160-73-165-88)168-93(31-18-2)131(214)181-106(60-87-42-46-90(198)47-43-87)152(235)191-54-30-39-110(191)144(227)172-96(49-51-112(156)200)134(217)187-123(81(14)194)147(230)167-78(11)128(211)186-121(77(10)19-3)146(229)164-69-117(205)184-120(76(8)9)145(228)163-66-115(203)166-79(12)151(234)190-53-29-38-109(190)127(159)210/h21-26,32-35,40-47,65,73-83,91-110,120-125,168,192-198,236-237H,17-20,27-31,36-39,48-64,66-72,153-154H2,1-16H3,(H2,155,199)(H2,156,200)(H2,157,201)(H2,158,202)(H2,159,210)(H,160,165)(H,161,212)(H,162,213)(H,163,228)(H,164,229)(H,166,203)(H,167,230)(H,169,204)(H,170,222)(H,171,226)(H,172,227)(H,173,232)(H,174,220)(H,175,215)(H,176,221)(H,177,223)(H,178,219)(H,179,216)(H,180,231)(H,181,214)(H,182,218)(H,183,233)(H,184,205)(H,185,206)(H,186,211)(H,187,217)(H,188,224)(H,189,225)(H,207,208)/t77-,78-,79-,80+,81+,82+,83+,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102?,103-,104-,105-,106-,107-,108-,109+,110+,120-,121-,122-,123-,124-,125-/m0/s1
DMLA384	CS	CCCC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)[C@H](CC3=CC=CC=C3)NC(=O)C(CC4=CNC=N4)N[C@@H](CCC)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N6CCC[C@@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N7CCC[C@@H]7C(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMLA384	IK	NUIBIJAKPBPKQM-RQTBQGNLSA-N
DMLA384	IU	(3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,4S)-8-amino-2-[[2-[[(2S)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-oxo-1-phenyloctan-4-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DMLA384	DE	Discovery agent

DMUGAYT	ID	DMUGAYT
DMUGAYT	DN	CGNLSTCMLGTYTQDFc[DKFHK]FPQTAIGVGAP-amide
DMUGAYT	HS	Investigative
DMUGAYT	PC	73356077
DMUGAYT	MW	3354.8
DMUGAYT	FM	C152H229N39O43S2
DMUGAYT	IC	InChI=1S/C152H229N39O43S2/c1-16-18-39-94(171-143(225)108(73-236)183-150(232)125(84(15)196)189-142(224)107(71-192)182-135(217)99(57-76(5)6)176-138(220)103(63-113(157)200)169-116(203)68-161-129(211)91(154)72-235)132(214)175-98(56-75(3)4)130(212)162-69-118(205)185-122(81(12)193)148(230)180-101(60-87-37-26-21-27-38-87)141(223)188-124(83(14)195)149(231)173-95(48-50-111(155)198)133(215)179-105(65-119(206)207)140(222)177-100(59-86-35-24-20-25-36-86)136(218)178-104-64-114(201)160-53-30-41-93(168-102(62-89-66-159-74-165-89)137(219)174-97(58-85-33-22-19-23-34-85)126(208)92(170-139(104)221)40-28-29-52-153)131(213)181-106(61-88-44-46-90(197)47-45-88)152(234)191-55-32-43-110(191)144(226)172-96(49-51-112(156)199)134(216)187-123(82(13)194)147(229)167-79(10)128(210)186-121(78(9)17-2)146(228)164-70-117(204)184-120(77(7)8)145(227)163-67-115(202)166-80(11)151(233)190-54-31-42-109(190)127(158)209/h19-27,33-38,44-47,66,74-84,91-110,120-125,168,192-197,235-236H,16-18,28-32,39-43,48-65,67-73,153-154H2,1-15H3,(H2,155,198)(H2,156,199)(H2,157,200)(H2,158,209)(H,159,165)(H,160,201)(H,161,211)(H,162,212)(H,163,227)(H,164,228)(H,166,202)(H,167,229)(H,169,203)(H,170,221)(H,171,225)(H,172,226)(H,173,231)(H,174,219)(H,175,214)(H,176,220)(H,177,222)(H,178,218)(H,179,215)(H,180,230)(H,181,213)(H,182,217)(H,183,232)(H,184,204)(H,185,205)(H,186,210)(H,187,216)(H,188,223)(H,189,224)(H,206,207)/t78-,79-,80-,81+,82+,83+,84+,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102?,103-,104-,105-,106-,107-,108-,109+,110+,120-,121-,122-,123-,124-,125-/m0/s1
DMUGAYT	CS	CCCC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H]3CC(=O)NCCC[C@H](NC(C(=O)N[C@H](C(=O)[C@@H](NC3=O)CCCCN)CC4=CC=CC=C4)CC5=CNC=N5)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N7CCC[C@@H]7C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N8CCC[C@@H]8C(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMUGAYT	IK	NRTVMMGXEUIAJK-VZBVTIHGSA-N
DMUGAYT	IU	(3S)-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(5S,7S,10S,17S)-7-(4-aminobutyl)-17-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-5-benzyl-2-(1H-imidazol-4-ylmethyl)-3,6,9,12-tetraoxo-1,4,8,13-tetrazacycloheptadec-10-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMUGAYT	DE	Discovery agent

DM3FP47	ID	DM3FP47
DM3FP47	DN	CGNLSTCMLGTYTQDFc[DKFHO]FPQTAIGVGAP-amide
DM3FP47	HS	Investigative
DM3FP47	PC	73350028
DM3FP47	MW	3372.9
DM3FP47	FM	C151H227N39O43S3
DM3FP47	IC	InChI=1S/C151H227N39O43S3/c1-16-77(8)120(145(227)163-69-116(203)183-119(76(6)7)144(226)162-66-114(201)165-79(10)150(232)189-52-29-39-108(189)126(157)208)185-127(209)78(9)166-146(228)122(81(12)193)186-133(215)94(46-48-111(155)198)171-143(225)109-40-30-53-190(109)151(233)105(60-86-35-24-19-25-36-86)180-130(212)92-38-28-51-159-113(200)63-103(138(220)169-91(37-26-27-50-152)125(207)96(57-84-31-20-17-21-32-84)173-136(218)101(167-92)61-88-65-158-73-164-88)177-135(217)99(58-85-33-22-18-23-34-85)176-139(221)104(64-118(205)206)178-131(213)93(45-47-110(154)197)172-148(230)123(82(13)194)187-140(222)100(59-87-41-43-89(196)44-42-87)179-147(229)121(80(11)192)184-117(204)68-161-129(211)97(55-74(2)3)174-132(214)95(49-54-236-15)170-142(224)107(72-235)182-149(231)124(83(14)195)188-141(223)106(70-191)181-134(216)98(56-75(4)5)175-137(219)102(62-112(156)199)168-115(202)67-160-128(210)90(153)71-234/h17-25,31-36,41-44,65,73-83,90-109,119-124,167,191-196,234-235H,16,26-30,37-40,45-64,66-72,152-153H2,1-15H3,(H2,154,197)(H2,155,198)(H2,156,199)(H2,157,208)(H,158,164)(H,159,200)(H,160,210)(H,161,211)(H,162,226)(H,163,227)(H,165,201)(H,166,228)(H,168,202)(H,169,220)(H,170,224)(H,171,225)(H,172,230)(H,173,218)(H,174,214)(H,175,219)(H,176,221)(H,177,217)(H,178,213)(H,179,229)(H,180,212)(H,181,216)(H,182,231)(H,183,203)(H,184,204)(H,185,209)(H,186,215)(H,187,222)(H,188,223)(H,205,206)/t77-,78-,79-,80+,81+,82+,83+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108+,109+,119-,120-,121-,122-,123-,124-/m0/s1
DM3FP47	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCNC(=O)C[C@@H](C(=O)N[C@H](C(=O)[C@@H](NC(=O)[C@@H](N4)CC5=CNC=N5)CC6=CC=CC=C6)CCCCN)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DM3FP47	IK	QYDBESOJOBAYMS-KPTDGZOOSA-N
DM3FP47	IU	(3S)-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S,5S,7S,10S,17S)-7-(4-aminobutyl)-17-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamoyl]-5-benzyl-2-(1H-imidazol-4-ylmethyl)-3,6,9,12-tetraoxo-1,4,8,13-tetrazacycloheptadec-10-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DM3FP47	DE	Discovery agent

DMJ9Z31	ID	DMJ9Z31
DMJ9Z31	DN	CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-amide
DMJ9Z31	HS	Investigative
DMJ9Z31	PC	73351527
DMJ9Z31	MW	3376.8
DMJ9Z31	FM	C150H227N39O44S3
DMJ9Z31	IC	InChI=1S/C150H227N39O44S3/c1-17-75(8)118(143(226)162-67-114(203)182-117(74(6)7)142(225)161-64-112(201)164-77(10)149(232)188-50-29-38-106(188)125(157)208)184-126(209)76(9)165-144(227)121(80(13)193)185-131(214)92(45-47-109(154)198)170-141(224)107-39-30-51-189(107)150(233)103(58-85-35-25-20-26-36-85)179-145(228)119(78(11)191)167-99(59-87-63-158-71-163-87)134(217)172-94(55-83-31-21-18-22-32-83)124(207)90(37-27-28-49-151)168-136(219)101(61-111(156)200)176-133(216)97(56-84-33-23-19-24-34-84)175-137(220)102(62-116(205)206)177-129(212)91(44-46-108(153)197)171-147(230)122(81(14)194)186-138(221)98(57-86-40-42-88(196)43-41-86)178-146(229)120(79(12)192)183-115(204)66-160-128(211)95(53-72(2)3)173-130(213)93(48-52-236-16)169-140(223)105(70-235)181-148(231)123(82(15)195)187-139(222)104(68-190)180-132(215)96(54-73(4)5)174-135(218)100(60-110(155)199)166-113(202)65-159-127(210)89(152)69-234/h18-26,31-36,40-43,63,71-82,89-107,117-123,167,190-196,234-235H,17,27-30,37-39,44-62,64-70,151-152H2,1-16H3,(H2,153,197)(H2,154,198)(H2,155,199)(H2,156,200)(H2,157,208)(H,158,163)(H,159,210)(H,160,211)(H,161,225)(H,162,226)(H,164,201)(H,165,227)(H,166,202)(H,168,219)(H,169,223)(H,170,224)(H,171,230)(H,172,217)(H,173,213)(H,174,218)(H,175,220)(H,176,216)(H,177,212)(H,178,229)(H,179,228)(H,180,215)(H,181,231)(H,182,203)(H,183,204)(H,184,209)(H,185,214)(H,186,221)(H,187,222)(H,205,206)/t75-,76-,77-,78+,79+,80+,81+,82+,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99?,100-,101-,102-,103-,104-,105-,106+,107+,117-,118-,119-,120-,121-,122-,123-/m0/s1
DMJ9Z31	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(CC4=CNC=N4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMJ9Z31	IK	LHKCIEAVJUMENU-LTFZDLSNSA-N
DMJ9Z31	IU	(3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,4S)-8-amino-2-[[2-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-oxo-1-phenyloctan-4-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DMJ9Z31	DE	Discovery agent

DME84PN	ID	DME84PN
DME84PN	DN	CGNLSTCMLGTYTQDFNKPHTFPQTAIGVGAP-amide
DME84PN	HS	Investigative
DME84PN	PC	73348438
DME84PN	MW	3326.8
DME84PN	FM	C146H225N39O44S3
DME84PN	IC	InChI=1S/C146H225N39O44S3/c1-17-72(8)114(138(221)158-64-110(199)177-113(71(6)7)137(220)157-61-108(197)160-74(10)144(227)184-48-27-35-102(184)121(153)204)179-122(205)73(9)161-139(222)117(77(13)189)180-127(210)88(42-44-105(150)194)166-136(219)103-36-28-49-185(103)145(228)97(55-81-31-22-19-23-32-81)174-140(223)115(75(11)187)163-98(56-83-60-154-68-159-83)146(229)183-47-26-34-101(183)120(203)86(33-24-25-46-147)164-131(214)95(58-107(152)196)171-129(212)92(53-80-29-20-18-21-30-80)170-132(215)96(59-112(201)202)172-125(208)87(41-43-104(149)193)167-142(225)118(78(14)190)181-133(216)93(54-82-37-39-84(192)40-38-82)173-141(224)116(76(12)188)178-111(200)63-156-124(207)90(51-69(2)3)168-126(209)89(45-50-232-16)165-135(218)100(67-231)176-143(226)119(79(15)191)182-134(217)99(65-186)175-128(211)91(52-70(4)5)169-130(213)94(57-106(151)195)162-109(198)62-155-123(206)85(148)66-230/h18-23,29-32,37-40,60,68-79,85-103,113-119,163,186-192,230-231H,17,24-28,33-36,41-59,61-67,147-148H2,1-16H3,(H2,149,193)(H2,150,194)(H2,151,195)(H2,152,196)(H2,153,204)(H,154,159)(H,155,206)(H,156,207)(H,157,220)(H,158,221)(H,160,197)(H,161,222)(H,162,198)(H,164,214)(H,165,218)(H,166,219)(H,167,225)(H,168,209)(H,169,213)(H,170,215)(H,171,212)(H,172,208)(H,173,224)(H,174,223)(H,175,211)(H,176,226)(H,177,199)(H,178,200)(H,179,205)(H,180,210)(H,181,216)(H,182,217)(H,201,202)/t72-,73-,74-,75+,76+,77+,78+,79+,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102+,103+,113-,114-,115-,116-,117-,118-,119-/m0/s1
DME84PN	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)N[C@@H](CC4=CNC=N4)C(=O)N5CCC[C@H]5C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DME84PN	IK	NKZSJXPCNXUROW-ZRSYVJPOSA-N
DME84PN	IU	(3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[(2S)-1-[(2S)-2-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]pyrrolidin-2-yl]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DME84PN	DE	Discovery agent

DMV7TE4	ID	DMV7TE4
DMV7TE4	DN	CGNLSTCMLGTYTQDFNPFHTFPQTAIGVGAP-amide
DMV7TE4	HS	Investigative
DMV7TE4	PC	44269042
DMV7TE4	MW	3345.8
DMV7TE4	FM	C149H222N38O44S3
DMV7TE4	IC	InChI=1S/C149H222N38O44S3/c1-17-74(8)117(141(223)160-66-113(201)179-116(73(6)7)140(222)159-63-111(199)162-76(10)147(229)186-49-28-37-105(186)124(155)206)181-125(207)75(9)163-142(224)120(79(13)191)182-130(212)90(44-46-108(152)196)167-139(221)106-38-29-50-187(106)148(230)100(57-84-34-25-20-26-35-84)176-143(225)118(77(11)189)165-97(58-86-62-156-70-161-86)133(215)169-92(54-82-30-21-18-22-31-82)123(205)104-36-27-48-185(104)149(231)101(60-110(154)198)175-132(214)95(55-83-32-23-19-24-33-83)172-135(217)99(61-115(203)204)173-128(210)89(43-45-107(151)195)168-145(227)121(80(14)192)183-136(218)96(56-85-39-41-87(194)42-40-85)174-144(226)119(78(12)190)180-114(202)65-158-127(209)93(52-71(2)3)170-129(211)91(47-51-234-16)166-138(220)103(69-233)178-146(228)122(81(15)193)184-137(219)102(67-188)177-131(213)94(53-72(4)5)171-134(216)98(59-109(153)197)164-112(200)64-157-126(208)88(150)68-232/h18-26,30-35,39-42,62,70-81,88-106,116-122,165,188-194,232-233H,17,27-29,36-38,43-61,63-69,150H2,1-16H3,(H2,151,195)(H2,152,196)(H2,153,197)(H2,154,198)(H2,155,206)(H,156,161)(H,157,208)(H,158,209)(H,159,222)(H,160,223)(H,162,199)(H,163,224)(H,164,200)(H,166,220)(H,167,221)(H,168,227)(H,169,215)(H,170,211)(H,171,216)(H,172,217)(H,173,210)(H,174,226)(H,175,214)(H,176,225)(H,177,213)(H,178,228)(H,179,201)(H,180,202)(H,181,207)(H,182,212)(H,183,218)(H,184,219)(H,203,204)/t74-,75-,76-,77+,78+,79-,80+,81+,88-,89-,90-,91-,92?,93-,94-,95-,96-,97?,98-,99-,100-,101-,102-,103-,104?,105+,106+,116-,117-,118-,119-,120-,121-,122-/m0/s1
DMV7TE4	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(CC4=CNC=N4)C(=O)NC(CC5=CC=CC=C5)C(=O)C6CCCN6C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMV7TE4	IK	HFYXIJPNTYGTQI-ZAGQHXPESA-N
DMV7TE4	IU	(3S)-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-4-amino-1-[2-[2-[[2-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMV7TE4	DE	Discovery agent

DMMO8A2	ID	DMMO8A2
DMMO8A2	DN	CGNLSTCMLGTYTQDFNPKHTFPQTAIGVGAP-amide
DMMO8A2	HS	Investigative
DMMO8A2	PC	73354513
DMMO8A2	MW	3255.7
DMMO8A2	FM	C142H216N38O44S3
DMMO8A2	IC	InChI=1S/C142H216N38O44S3/c1-17-69(8)111(134(216)154-61-107(195)172-110(68(6)7)133(215)153-58-105(193)156-71(10)140(222)179-44-25-32-98(179)117(148)199)174-118(200)70(9)157-135(217)114(74(13)184)175-124(206)84(39-41-102(145)190)161-132(214)99-33-26-45-180(99)141(223)93(51-78-29-22-19-23-30-78)169-136(218)112(72(11)182)159-90(52-80-56-149-65-155-80)121(203)150-57-100(188)97-31-24-43-178(97)142(224)94(54-104(147)192)168-126(208)88(49-77-27-20-18-21-28-77)165-128(210)92(55-109(197)198)166-122(204)83(38-40-101(144)189)162-138(220)115(75(14)185)176-129(211)89(50-79-34-36-81(187)37-35-79)167-137(219)113(73(12)183)173-108(196)60-152-120(202)86(47-66(2)3)163-123(205)85(42-46-227-16)160-131(213)96(64-226)171-139(221)116(76(15)186)177-130(212)95(62-181)170-125(207)87(48-67(4)5)164-127(209)91(53-103(146)191)158-106(194)59-151-119(201)82(143)63-225/h18-23,27-30,34-37,56,65-76,82-99,110-116,159,181-187,225-226H,17,24-26,31-33,38-55,57-64,143H2,1-16H3,(H2,144,189)(H2,145,190)(H2,146,191)(H2,147,192)(H2,148,199)(H,149,155)(H,150,203)(H,151,201)(H,152,202)(H,153,215)(H,154,216)(H,156,193)(H,157,217)(H,158,194)(H,160,213)(H,161,214)(H,162,220)(H,163,205)(H,164,209)(H,165,210)(H,166,204)(H,167,219)(H,168,208)(H,169,218)(H,170,207)(H,171,221)(H,172,195)(H,173,196)(H,174,200)(H,175,206)(H,176,211)(H,177,212)(H,197,198)/t69-,70-,71-,72+,73+,74+,75+,76+,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98+,99+,110-,111-,112-,113-,114-,115-,116-/m0/s1
DMMO8A2	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)N[C@@H](CC4=CNC=N4)C(=O)NCC(=O)[C@@H]5CCCN5C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMMO8A2	IK	YYIDQLADSCSELD-ILODDJEPSA-N
DMMO8A2	IU	(3S)-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-4-amino-1-[(2S)-2-[2-[[(2S)-2-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMMO8A2	DE	Discovery agent

DML79NU	ID	DML79NU
DML79NU	DN	CGP 20712A
DML79NU	HS	Investigative
DML79NU	SN	GKJZEKSHCJELPL-UHFFFAOYSA-N; Cgp 20712; CGP-20712A; CGP-20712; 137888-49-4; CGP20712A; C23H25F3N4O5; 81015-67-0; 2-hydroxy-5-{2-[(2-hydroxy-3-{4-[1-methyl-4-(trifluoromethyl)-1h-imidazol-2-yl]phenoxy}propyl)amino]ethoxy}benzamide; Cgp 26505; CGP 20712-A; 2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide; Cgp-20712-A; SR-01000076208; 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide; CGP 26505
DML79NU	DT	Small molecular drug
DML79NU	PC	10008573
DML79NU	MW	590.6
DML79NU	FM	C24H29F3N4O8S
DML79NU	IC	InChI=1S/C23H25F3N4O5.CH4O3S/c1-30-12-20(23(24,25)26)29-22(30)14-2-4-16(5-3-14)35-13-15(31)11-28-8-9-34-17-6-7-19(32)18(10-17)21(27)33;1-5(2,3)4/h2-7,10,12,15,28,31-32H,8-9,11,13H2,1H3,(H2,27,33);1H3,(H,2,3,4)
DML79NU	CS	CN1C=C(N=C1C2=CC=C(C=C2)OCC(CNCCOC3=CC(=C(C=C3)O)C(=O)N)O)C(F)(F)F.CS(=O)(=O)O
DML79NU	IK	VFPOVCXWKBYDNF-UHFFFAOYSA-N
DML79NU	IU	2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide;methanesulfonic acid
DML79NU	CA	CAS 105737-62-0
DML79NU	DE	Discovery agent

DMTECXA	ID	DMTECXA
DMTECXA	DN	CGP 23996
DMTECXA	HS	Investigative
DMTECXA	SN	CGP23996; CGP-23996
DMTECXA	DT	Small molecular drug
DMTECXA	PC	16130961
DMTECXA	MW	1474.7
DMTECXA	FM	C73H99N15O18
DMTECXA	IC	InChI=1S/C73H99N15O18/c1-41(90)61-71(103)85-55(36-45-28-30-47(92)31-29-45)69(101)88-62(42(2)91)72(104)86-58(40-89)70(102)80-52(73(105)106)26-10-5-11-27-60(94)78-50(24-14-16-32-74)63(95)84-57(38-59(76)93)68(100)82-53(34-43-18-6-3-7-19-43)65(97)81-54(35-44-20-8-4-9-21-44)66(98)83-56(37-46-39-77-49-23-13-12-22-48(46)49)67(99)79-51(64(96)87-61)25-15-17-33-75/h3-4,6-9,12-13,18-23,28-31,39,41-42,50-58,61-62,77,89-92H,5,10-11,14-17,24-27,32-38,40,74-75H2,1-2H3,(H2,76,93)(H,78,94)(H,79,99)(H,80,102)(H,81,97)(H,82,100)(H,83,98)(H,84,95)(H,85,103)(H,86,104)(H,87,96)(H,88,101)(H,105,106)/t41-,42-,50+,51+,52+,53+,54+,55+,56+,57?,58+,61?,62?/m1/s1
DMTECXA	CS	C[C@H](C1C(=O)N[C@H](C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CCCCCC(=O)N[C@H](C(=O)NC(C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)C(=O)O)CO)[C@@H](C)O)CC6=CC=C(C=C6)O)O
DMTECXA	IK	HTEPNQQGQXAYEW-YQENAMKYSA-N
DMTECXA	IU	(2S,8S,11S,14S,17S,23S,29S,32S)-2,17-bis(4-aminobutyl)-5-(2-amino-2-oxoethyl)-8,11-dibenzyl-20,26-bis[(1R)-1-hydroxyethyl]-29-(hydroxymethyl)-23-[(4-hydroxyphenyl)methyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,18,21,24,27,30,38-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecazacyclooctatriacontane-32-carboxylic acid
DMTECXA	CA	CAS 86170-12-9
DMTECXA	DE	Discovery agent

DMEA5BZ	ID	DMEA5BZ
DMEA5BZ	DN	CGP 40336A
DMEA5BZ	HS	Investigative
DMEA5BZ	SN	GNF-Pf-5020; CGP40336; AC1LALV6; CHEMBL97338; SCHEMBL8891798; CGP40336A; CGP-40336A; N'-(3-aminopropyl)-N'-[3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl]butane-1,4-diamine; (4-Aminobutyl)(3-aminopropyl){3-[(6-chloro-2-methyloxyacridin-9-yl)amino]propyl}amine
DMEA5BZ	DT	Small molecular drug
DMEA5BZ	PC	470828
DMEA5BZ	MW	444
DMEA5BZ	FM	C24H34ClN5O
DMEA5BZ	IC	InChI=1S/C24H34ClN5O/c1-31-19-7-9-22-21(17-19)24(20-8-6-18(25)16-23(20)29-22)28-12-5-15-30(14-4-11-27)13-3-2-10-26/h6-9,16-17H,2-5,10-15,26-27H2,1H3,(H,28,29)
DMEA5BZ	CS	COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCCN(CCCCN)CCCN
DMEA5BZ	IK	BIGAHIIWPDZJMX-UHFFFAOYSA-N
DMEA5BZ	IU	N'-(3-aminopropyl)-N'-[3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl]butane-1,4-diamine
DMEA5BZ	DE	Discovery agent

DMXV6RD	ID	DMXV6RD
DMXV6RD	DN	CGP 46381
DMXV6RD	HS	Investigative
DMXV6RD	SN	CGP-46381; CGP46381
DMXV6RD	DT	Small molecular drug
DMXV6RD	PC	130022
DMXV6RD	MW	219.26
DMXV6RD	FM	C10H22NO2P
DMXV6RD	IC	InChI=1S/C10H22NO2P/c11-7-4-8-14(12,13)9-10-5-2-1-3-6-10/h10H,1-9,11H2,(H,12,13)
DMXV6RD	CS	C1CCC(CC1)CP(=O)(CCCN)O
DMXV6RD	IK	XOESDNIUAWGCLU-UHFFFAOYSA-N
DMXV6RD	IU	3-aminopropyl(cyclohexylmethyl)phosphinic acid
DMXV6RD	CA	CAS 123691-14-5
DMXV6RD	DE	Discovery agent

DME39UQ	ID	DME39UQ
DME39UQ	DN	CGP 47656
DME39UQ	HS	Investigative
DME39UQ	SN	(3-Amino-propyl)-difluoromethyl-phosphinic acid; CGP-47656; CHEMBL113553; 3-aminopropyl-(difluoromethyl)phosphinic Acid; CGP47656; SCHEMBL342825; GTPL1066; TXAHGWWWANKBDA-UHFFFAOYSA-N; BDBM50032968; P-(3-aminopropyl)-P-difluoromethyl-phosphinic;  CGP-47656
DME39UQ	DT	Small molecular drug
DME39UQ	PC	10154248
DME39UQ	MW	173.1
DME39UQ	FM	C4H10F2NO2P
DME39UQ	IC	InChI=1S/C4H10F2NO2P/c5-4(6)10(8,9)3-1-2-7/h4H,1-3,7H2,(H,8,9)
DME39UQ	CS	C(CN)CP(=O)(C(F)F)O
DME39UQ	IK	TXAHGWWWANKBDA-UHFFFAOYSA-N
DME39UQ	IU	3-aminopropyl(difluoromethyl)phosphinic acid
DME39UQ	DE	Discovery agent

DMEHYVS	ID	DMEHYVS
DMEHYVS	DN	CGP 54626A
DMEHYVS	HS	Investigative
DMEHYVS	SN	Cyclohexylmethyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid; Cgp-54626; Cgp 54626; cyclohexylmethyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid; CGP54626; [3H]CGP54626; [3H]CGP 54626; Tocris-1088; NCGC00024989-01; Biomol-NT_000240; AC1L53OP; GTPL1070; SCHEMBL2957659; GTPL1090; BPBio1_000640; CHEMBL1213187; CGP-54626A; ZINC31544793; NCGC00024989-02;  CGP-54626
DMEHYVS	DT	Small molecular drug
DMEHYVS	PC	197584
DMEHYVS	MW	408.3
DMEHYVS	FM	C18H28Cl2NO3P
DMEHYVS	IC	InChI=1S/C18H28Cl2NO3P/c1-13(15-7-8-17(19)18(20)9-15)21-10-16(22)12-25(23,24)11-14-5-3-2-4-6-14/h7-9,13-14,16,21-22H,2-6,10-12H2,1H3,(H,23,24)/t13-,16-/m0/s1
DMEHYVS	CS	C[C@@H](C1=CC(=C(C=C1)Cl)Cl)NC[C@@H](CP(=O)(CC2CCCCC2)O)O
DMEHYVS	IK	JGGVBBYJRQOPPA-BBRMVZONSA-N
DMEHYVS	IU	cyclohexylmethyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid
DMEHYVS	DE	Discovery agent

DMNMG0I	ID	DMNMG0I
DMNMG0I	DN	CGP 55845
DMNMG0I	HS	Investigative
DMNMG0I	SN	CGP55845; CGP-55845A; CGP-55845
DMNMG0I	DT	Small molecular drug
DMNMG0I	PC	5311042
DMNMG0I	MW	402.2
DMNMG0I	FM	C18H22Cl2NO3P
DMNMG0I	IC	InChI=1S/C18H22Cl2NO3P/c1-13(15-7-8-17(19)18(20)9-15)21-10-16(22)12-25(23,24)11-14-5-3-2-4-6-14/h2-9,13,16,21-22H,10-12H2,1H3,(H,23,24)/t13-,16-/m0/s1
DMNMG0I	CS	C[C@@H](C1=CC(=C(C=C1)Cl)Cl)NC[C@@H](CP(=O)(CC2=CC=CC=C2)O)O
DMNMG0I	IK	ZODSPDOOCZZEIM-BBRMVZONSA-N
DMNMG0I	IU	benzyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid
DMNMG0I	CA	CAS 150175-54-5
DMNMG0I	CB	CHEBI:91949
DMNMG0I	DE	Discovery agent

DMR708D	ID	DMR708D
DMR708D	DN	CGP 56999A
DMR708D	HS	Investigative
DMR708D	SN	CGP56999A; CGP-56999A
DMR708D	DT	Small molecular drug
DMR708D	PC	9800175
DMR708D	MW	383.4
DMR708D	FM	C19H30NO5P
DMR708D	IC	InChI=1S/C19H30NO5P/c1-14(16-8-5-9-17(10-16)19(22)23)20-11-18(21)13-26(24,25)12-15-6-3-2-4-7-15/h5,8-10,14-15,18,20-21H,2-4,6-7,11-13H2,1H3,(H,22,23)(H,24,25)/t14-,18+/m1/s1
DMR708D	CS	C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CC2CCCCC2)O)O
DMR708D	IK	JCFULPDIJOVUHP-KDOFPFPSSA-N
DMR708D	IU	3-[(1R)-1-[[(2S)-3-[cyclohexylmethyl(hydroxy)phosphoryl]-2-hydroxypropyl]amino]ethyl]benzoic acid
DMR708D	DE	Discovery agent

DMYXE39	ID	DMYXE39
DMYXE39	DN	CGP 62349
DMYXE39	HS	Investigative
DMYXE39	SN	AKUSEWDIEMJQBM-BEFAXECRSA-N; 3-[(1R)-1-[[(2S)-2-hydroxy-3-[hydroxy-[(4-methoxyphenyl)methyl]phosphoryl]propyl]-methylamino]ethyl]benzoic acid; 10-31-1; CGP62349; [3H]CGP62349; [3H]CGP 62349; [3H]-CGP 62349; AC1NSJP8; GTPL1072; GTPL3429; SCHEMBL12477448;  CGP62349; CGP-62349
DMYXE39	DT	Small molecular drug
DMYXE39	PC	5310936
DMYXE39	MW	421.4
DMYXE39	FM	C21H28NO6P
DMYXE39	IC	InChI=1S/C21H28NO6P/c1-15(17-5-4-6-18(11-17)21(24)25)22(2)12-19(23)14-29(26,27)13-16-7-9-20(28-3)10-8-16/h4-11,15,19,23H,12-14H2,1-3H3,(H,24,25)(H,26,27)/t15-,19+/m1/s1
DMYXE39	CS	C[C@H](C1=CC(=CC=C1)C(=O)O)N(C)C[C@@H](CP(=O)(CC2=CC=C(C=C2)OC)O)O
DMYXE39	IK	AKUSEWDIEMJQBM-BEFAXECRSA-N
DMYXE39	IU	3-[(1R)-1-[[(2S)-2-hydroxy-3-[hydroxy-[(4-methoxyphenyl)methyl]phosphoryl]propyl]-methylamino]ethyl]benzoic acid
DMYXE39	CA	CAS 10-31-1
DMYXE39	DE	Discovery agent

DMR8U1M	ID	DMR8U1M
DMR8U1M	DN	CGP 64213
DMR8U1M	HS	Investigative
DMR8U1M	SN	CGP64213; CGP-64213
DMR8U1M	DT	Small molecular drug
DMR8U1M	PC	5311043
DMR8U1M	MW	646.5
DMR8U1M	FM	C26H36IN2O7P
DMR8U1M	IC	InChI=1S/C26H36IN2O7P/c1-18(20-6-5-7-21(15-20)26(33)34)29-16-22(30)17-37(35,36)13-4-2-3-12-28-25(32)11-9-19-8-10-24(31)23(27)14-19/h5-8,10,14-15,18,22,29-31H,2-4,9,11-13,16-17H2,1H3,(H,28,32)(H,33,34)(H,35,36)/t18-,22+/m1/s1
DMR8U1M	CS	C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CCCCCNC(=O)CCC2=CC(=C(C=C2)O)I)O)O
DMR8U1M	IK	RLYLJDJFHZHCTR-GCJKJVERSA-N
DMR8U1M	IU	3-[(1R)-1-[[(2S)-2-hydroxy-3-[hydroxy-[5-[3-(4-hydroxy-3-iodophenyl)propanoylamino]pentyl]phosphoryl]propyl]amino]ethyl]benzoic acid
DMR8U1M	DE	Discovery agent

DMJWED7	ID	DMJWED7
DMJWED7	DN	CGP 71872
DMJWED7	HS	Investigative
DMJWED7	SN	CGP71872; CGP-71872
DMJWED7	DT	Small molecular drug
DMJWED7	PC	6324595
DMJWED7	MW	659.4
DMJWED7	FM	C24H31IN5O7P
DMJWED7	IC	InChI=1S/C24H31IN5O7P/c1-15(16-6-5-7-17(10-16)24(34)35)28-13-18(31)14-38(36,37)9-4-2-3-8-27-23(33)19-11-20(25)21(29-30-26)12-22(19)32/h5-7,10-12,15,18,28,31-32H,2-4,8-9,13-14H2,1H3,(H,27,33)(H,34,35)(H,36,37)/t15-,18+/m1/s1
DMJWED7	CS	C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CCCCCNC(=O)C2=CC(=C(C=C2O)N=[N+]=[N-])I)O)O
DMJWED7	IK	IHFUJPDKHJTHGQ-QAPCUYQASA-N
DMJWED7	IU	3-[(1R)-1-[[(2S)-3-[5-[(4-azido-2-hydroxy-5-iodobenzoyl)amino]pentyl-hydroxyphosphoryl]-2-hydroxypropyl]amino]ethyl]benzoic acid
DMJWED7	DE	Discovery agent

DMXH2R3	ID	DMXH2R3
DMXH2R3	DN	CGP 77675
DMXH2R3	HS	Investigative
DMXH2R3	SN	234772-64-6; CGP-77675; UNII-EQH27E0WRV; 1-(4-(4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenethyl)piperidin-4-ol; CGP77675; EQH27E0WRV; CHEMBL475584; 1-[2-[4-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]ethyl]piperidin-4-ol; 4-Piperidinol, 1-(2-(4-(4-amino-5-(3-methoxyphenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)phenyl)ethyl)-; 4-piperidinol, 1-[2-[4-[4-amino-5-(3-methoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]ethyl]-; AC1NSKIU; SCHEMBL6250604; CTK8E3165; DTXSID20178033
DMXH2R3	DT	Small molecular drug
DMXH2R3	PC	5311381
DMXH2R3	MW	443.5
DMXH2R3	FM	C26H29N5O2
DMXH2R3	IC	InChI=1S/C26H29N5O2/c1-33-22-4-2-3-19(15-22)23-16-31(26-24(23)25(27)28-17-29-26)20-7-5-18(6-8-20)9-12-30-13-10-21(32)11-14-30/h2-8,15-17,21,32H,9-14H2,1H3,(H2,27,28,29)
DMXH2R3	CS	COC1=CC=CC(=C1)C2=CN(C3=NC=NC(=C23)N)C4=CC=C(C=C4)CCN5CCC(CC5)O
DMXH2R3	IK	WUPXZZWTHIZICK-UHFFFAOYSA-N
DMXH2R3	IU	1-[2-[4-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]ethyl]piperidin-4-ol
DMXH2R3	CA	CAS 234772-64-6
DMXH2R3	DE	Discovery agent

DMNUQAG	ID	DMNUQAG
DMNUQAG	DN	CGP-029482
DMNUQAG	HS	Investigative
DMNUQAG	SN	CGP-029482; CHEMBL92361; (5-OXO-5,6-DIHYDRO-INDOLO[1,2-A]QUINAZOLIN-7-YL)-ACETIC ACID; (5-oxo-5,6-dihydroindolo[1,2-a]quinazolin-7-yl)acetic acid; IQA; 1om1; AC1L9L3Y; SCHEMBL263731; BDBM11319; MolPort-006-167-937; HMS3229D05; ZINC2047511; CGP029482; AKOS005266257; DB01765; {5-oxo-6H-indolo[1,2-a]quinazolin-7-yl}acetic acid; 2-(5-oxo-6H-indolo[1,2-a]quinazolin-7-yl)acetic acid; [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid
DMNUQAG	DT	Small molecular drug
DMNUQAG	PC	447682
DMNUQAG	MW	292.29
DMNUQAG	FM	C17H12N2O3
DMNUQAG	IC	InChI=1S/C17H12N2O3/c20-15(21)9-12-10-5-1-3-7-13(10)19-14-8-4-2-6-11(14)17(22)18-16(12)19/h1-8H,9H2,(H,18,22)(H,20,21)
DMNUQAG	CS	C1=CC=C2C(=C1)C(=C3N2C4=CC=CC=C4C(=O)N3)CC(=O)O
DMNUQAG	IK	INSBKYCYLCEBOD-UHFFFAOYSA-N
DMNUQAG	IU	2-(5-oxo-6H-indolo[1,2-a]quinazolin-7-yl)acetic acid
DMNUQAG	CA	CAS 391670-48-7
DMNUQAG	DE	Discovery agent

DMCE6WJ	ID	DMCE6WJ
DMCE6WJ	DN	CGP-191
DMCE6WJ	HS	Investigative
DMCE6WJ	SN	CHEMBL122243; 1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine; pyrazolopyrimidine deriv. 1; CGP-191; AC1NS35Q; SCHEMBL2360645; BDBM3003; AKOS028111796; 129852-40-0; 1,3-diphenylpyrazolo[3,4-d]pyrimidin-4-amine; 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1,3-diphenyl-; 1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (11)
DMCE6WJ	DT	Small molecular drug
DMCE6WJ	PC	5327820
DMCE6WJ	MW	287.32
DMCE6WJ	FM	C17H13N5
DMCE6WJ	IC	InChI=1S/C17H13N5/c18-16-14-15(12-7-3-1-4-8-12)21-22(17(14)20-11-19-16)13-9-5-2-6-10-13/h1-11H,(H2,18,19,20)
DMCE6WJ	CS	C1=CC=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C4=CC=CC=C4
DMCE6WJ	IK	CGWOMXNQGSNOHL-UHFFFAOYSA-N
DMCE6WJ	IU	1,3-diphenylpyrazolo[3,4-d]pyrimidin-4-amine
DMCE6WJ	DE	Discovery agent

DMS61KA	ID	DMS61KA
DMS61KA	DN	CGP-29030A
DMS61KA	HS	Investigative
DMS61KA	SN	1-[2-(4-Chlorophenyl)ethyl]-4-(3,5-dimethoxybenzoyl)piperazine hydrochloride
DMS61KA	DT	Small molecular drug
DMS61KA	PC	3082655
DMS61KA	MW	425.3
DMS61KA	FM	C21H26Cl2N2O3
DMS61KA	IC	InChI=1S/C21H25ClN2O3.ClH/c1-26-19-13-17(14-20(15-19)27-2)21(25)24-11-9-23(10-12-24)8-7-16-3-5-18(22)6-4-16;/h3-6,13-15H,7-12H2,1-2H3;1H
DMS61KA	CS	COC1=CC(=CC(=C1)C(=O)N2CCN(CC2)CCC3=CC=C(C=C3)Cl)OC.Cl
DMS61KA	IK	OGLXGFIBROXFPU-UHFFFAOYSA-N
DMS61KA	IU	[4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-(3,5-dimethoxyphenyl)methanone;hydrochloride
DMS61KA	CA	CAS 113240-27-0
DMS61KA	DE	Pain

DM84TSH	ID	DM84TSH
DM84TSH	DN	CGP-34938
DM84TSH	HS	Investigative
DM84TSH	SN	CHEMBL113304; CGP-34938; AC1NOZJY; SCHEMBL185737; MolPort-003-824-912; AKOS006286757; (3-amino-2-hydroxypropyl)-methylphosphinic acid; L013629; (3-amino-2-hydroxypropyl)(methyl)phosphinic acid
DM84TSH	DT	Small molecular drug
DM84TSH	PC	5097016
DM84TSH	MW	153.12
DM84TSH	FM	C4H12NO3P
DM84TSH	IC	InChI=1S/C4H12NO3P/c1-9(7,8)3-4(6)2-5/h4,6H,2-3,5H2,1H3,(H,7,8)
DM84TSH	CS	CP(=O)(CC(CN)O)O
DM84TSH	IK	FUUPFUIGNBPCAY-UHFFFAOYSA-N
DM84TSH	IU	(3-amino-2-hydroxypropyl)-methylphosphinic acid
DM84TSH	DE	Discovery agent

DMHKETG	ID	DMHKETG
DMHKETG	DN	CGP-35024
DMHKETG	HS	Investigative
DMHKETG	SN	3-Aminopropyl(methyl)phosphinic Acid; 3-Apmpa; 3-aminopropyl(methyl)phosphinic Acid; skf-97541; 127729-35-5; F 97541; CGP 35024; SKF 97541; (3-(Aminopropyl)methyl)phosphinic acid; CHEMBL112710; SKF 97541 hydrochloride; CGP35024; SKF-97,541; (3-aminopropyl)(methyl)phosphinic acid; Phosphinic acid, (3-(aminopropyl)methyl)-; (3-ammoniopropyl)methylphosphinate; SR-01000076225; (3-aminopropyl)methylphosphinic acid; Tocris-0379; Phosphinic acid, (3-aminopropyl)methyl-; Lopac-A-196; AC1L1JVX; Biomol-NT_000257; AC1Q6RJ4; Lopac0_000098; C4H12NO2P; SKF-97541
DMHKETG	DT	Small molecular drug
DMHKETG	PC	5230
DMHKETG	MW	137.12
DMHKETG	FM	C4H12NO2P
DMHKETG	IC	InChI=1S/C4H12NO2P/c1-8(6,7)4-2-3-5/h2-5H2,1H3,(H,6,7)
DMHKETG	CS	CP(=O)(CCCN)O
DMHKETG	IK	NHVRIDDXGZPJTJ-UHFFFAOYSA-N
DMHKETG	IU	3-aminopropyl(methyl)phosphinic acid
DMHKETG	CA	CAS 127729-35-5
DMHKETG	DE	Discovery agent

DM3J6HM	ID	DM3J6HM
DM3J6HM	DN	CGP-35582
DM3J6HM	HS	Investigative
DM3J6HM	SN	CGP-35582; CHEMBL113396; SCHEMBL341418; Phosphinic acid, P-(3-amino-1-methylpropyl)-P-methyl-; CCFBFTKQKRGULP-UHFFFAOYSA-N; BDBM50032971; 133345-75-2; P-(4-aminobut-2-yl)-P-methyl-phosphinic acid; (3-Amino-1-methyl-propyl)-methyl-phosphinic acid
DM3J6HM	DT	Small molecular drug
DM3J6HM	PC	10219532
DM3J6HM	MW	151.14
DM3J6HM	FM	C5H14NO2P
DM3J6HM	IC	InChI=1S/C5H14NO2P/c1-5(3-4-6)9(2,7)8/h5H,3-4,6H2,1-2H3,(H,7,8)
DM3J6HM	CS	CC(CCN)P(=O)(C)O
DM3J6HM	IK	CCFBFTKQKRGULP-UHFFFAOYSA-N
DM3J6HM	IU	4-aminobutan-2-yl(methyl)phosphinic acid
DM3J6HM	DE	Discovery agent

DM9U8TO	ID	DM9U8TO
DM9U8TO	DN	CGP-36216
DM9U8TO	HS	Investigative
DM9U8TO	SN	CGP-36216; CHEMBL325921; 123691-29-2; SCHEMBL2348729; RWCIPYZWXPUGRM-UHFFFAOYSA-N; ethyl(3-aminopropyl)phosphinic acid; 3-aminopropyl(ethyl)phosphinic acid; (3-aminopropyl)ethylphosphinic acid; ZINC13742894; PDSP1_000409; PDSP2_000407; ethyl-(3-aminopropyl)phosphinic acid; BDBM50032972; (3-Amino-propyl)-ethyl-phosphinic acid; Phosphinic acid, P-(3-aminopropyl)-P-ethyl-
DM9U8TO	DT	Small molecular drug
DM9U8TO	PC	9898878
DM9U8TO	MW	151.14
DM9U8TO	FM	C5H14NO2P
DM9U8TO	IC	InChI=1S/C5H14NO2P/c1-2-9(7,8)5-3-4-6/h2-6H2,1H3,(H,7,8)
DM9U8TO	CS	CCP(=O)(CCCN)O
DM9U8TO	IK	RWCIPYZWXPUGRM-UHFFFAOYSA-N
DM9U8TO	IU	3-aminopropyl(ethyl)phosphinic acid
DM9U8TO	DE	Discovery agent

DMKF0GH	ID	DMKF0GH
DMKF0GH	DN	CGP-44532
DMKF0GH	HS	Investigative
DMKF0GH	SN	CGP-44532; CGP 44532; [(2R)-3-amino-2-hydroxypropyl]-methylphosphinic acid; FUUPFUIGNBPCAY-SCSAIBSYSA-N; AC1NSJP2; 133345-68-3; SCHEMBL185739; GTPL1082; CHEMBL113348; Phosphinic acid, P-[(2R)-3-amino-2-hydroxypropyl]-P-methyl-; CGP 44533; ZINC13742955; LS-106096; P-[3-amino-2(R)-hydroxy-propyl]-P-methyl-phosphinic acid
DMKF0GH	DT	Small molecular drug
DMKF0GH	PC	5310934
DMKF0GH	MW	153.12
DMKF0GH	FM	C4H12NO3P
DMKF0GH	IC	InChI=1S/C4H12NO3P/c1-9(7,8)3-4(6)2-5/h4,6H,2-3,5H2,1H3,(H,7,8)/t4-/m1/s1
DMKF0GH	CS	CP(=O)(C[C@@H](CN)O)O
DMKF0GH	IK	FUUPFUIGNBPCAY-SCSAIBSYSA-N
DMKF0GH	IU	[(2R)-3-amino-2-hydroxypropyl]-methylphosphinic acid
DMKF0GH	CA	CAS 133345-68-3
DMKF0GH	DE	Drug abuse

DM5SATN	ID	DM5SATN
DM5SATN	DN	CGP-49870
DM5SATN	HS	Investigative
DM5SATN	SN	186615-82-7; AT1 angiotensin II antagonist, Novartis
DM5SATN	DE	Discovery agent

DMFPOUC	ID	DMFPOUC
DMFPOUC	DN	CGP-57380
DMFPOUC	HS	Investigative
DMFPOUC	SN	CGP 57380; 522629-08-9; CGP-57380; MNK1 Inhibitor; N3-(4-fluorophenyl)-1h-pyrazolo[3,4-d]pyrimidine-3,4-diamine; CGP57380; CHEMBL1240885; C11H9FN6; 4-Amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine; SCHEMBL987991; GTPL6010; CHEMBL576817; SCHEMBL16714452; CHEBI:92749; DTXSID50469941; MolPort-006-725-822; HMS3653G22; HMS3269P13; HMS3263L14; HMS3229K20; HMS3648M14; Tox21_501256; BDBM50130693; 2314AH; NSC741567; MFCD03861062; ZINC13816313; s7421; IN1236; BDBM50298223; AKOS024457265; CCG-206868; NSC-741567; LP01256; NCGC00162380-06
DMFPOUC	DT	Small molecular drug
DMFPOUC	PC	11644425
DMFPOUC	MW	244.23
DMFPOUC	FM	C11H9FN6
DMFPOUC	IC	InChI=1S/C11H9FN6/c12-6-1-3-7(4-2-6)16-11-8-9(13)14-5-15-10(8)17-18-11/h1-5H,(H4,13,14,15,16,17,18)
DMFPOUC	CS	C1=CC(=CC=C1NC2=C3C(=NC=NC3=NN2)N)F
DMFPOUC	IK	UQPMANVRZYYQMD-UHFFFAOYSA-N
DMFPOUC	IU	3-N-(4-fluorophenyl)-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine
DMFPOUC	CA	CAS 522629-08-9
DMFPOUC	CB	CHEBI:92749
DMFPOUC	DE	Discovery agent

DMYZ72J	ID	DMYZ72J
DMYZ72J	DN	CGP-57698
DMYZ72J	HS	Investigative
DMYZ72J	SN	168082-74-4
DMYZ72J	DT	Small molecular drug
DMYZ72J	PC	9888588
DMYZ72J	MW	424.5
DMYZ72J	FM	C24H25FN2O4
DMYZ72J	IC	InChI=1S/C24H25FN2O4/c1-3-24(4-2,23(29)30)14-22(28)27-18-6-5-7-20(13-18)31-15-19-11-9-16-8-10-17(25)12-21(16)26-19/h5-13H,3-4,14-15H2,1-2H3,(H,27,28)(H,29,30)
DMYZ72J	CS	CCC(CC)(CC(=O)NC1=CC(=CC=C1)OCC2=NC3=C(C=CC(=C3)F)C=C2)C(=O)O
DMYZ72J	IK	BFNAFTJCDGWFMQ-UHFFFAOYSA-N
DMYZ72J	IU	2,2-diethyl-4-[3-[(7-fluoroquinolin-2-yl)methoxy]anilino]-4-oxobutanoic acid
DMYZ72J	CA	CAS 168082-74-4
DMYZ72J	DE	Discovery agent

DM8KFZH	ID	DM8KFZH
DM8KFZH	DN	CGP61594
DM8KFZH	HS	Investigative
DM8KFZH	SN	4-[2-(4-Azidophenyl)acetamido]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; 4-[2-(4-azidophenyl)acetamido]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; CGP 61594; [3H]CGP61594; CGP-61594; [3H]CGP 61594; GTPL5474;  CGP-61594
DM8KFZH	DT	Small molecular drug
DM8KFZH	PC	10025114
DM8KFZH	MW	420.2
DM8KFZH	FM	C18H15Cl2N5O3
DM8KFZH	IC	InChI=1S/C18H15Cl2N5O3/c19-10-6-12(20)17-13(7-10)22-15(18(27)28)8-14(17)23-16(26)5-9-1-3-11(4-2-9)24-25-21/h1-4,6-7,14-15,22H,5,8H2,(H,23,26)(H,27,28)
DM8KFZH	CS	C1C(C2=C(C=C(C=C2Cl)Cl)NC1C(=O)O)NC(=O)CC3=CC=C(C=C3)N=[N+]=[N-]
DM8KFZH	IK	OVAIIHUWSLJJPO-UHFFFAOYSA-N
DM8KFZH	IU	4-[[2-(4-azidophenyl)acetyl]amino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid
DM8KFZH	DE	Discovery agent

DMZ34P1	ID	DMZ34P1
DMZ34P1	DN	CGP-62464
DMZ34P1	HS	Investigative
DMZ34P1	SN	CGP-62464; CHEMBL169757; 5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine; NSC606429; AC1Q4VCQ; 5,7-diphenyl-4-aminopyrrolo[2,3-d]pyrimidine; AC1L74EC; SCHEMBL5936176; ZINC1609260; BDBM50088900; NSC-606429; 121405-24-1; FT-0761196; 5,7-diphenylpyrrolo[2,3-d]pyrimidin-4-amine; 5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine
DMZ34P1	DT	Small molecular drug
DMZ34P1	PC	354471
DMZ34P1	MW	286.3
DMZ34P1	FM	C18H14N4
DMZ34P1	IC	InChI=1S/C18H14N4/c19-17-16-15(13-7-3-1-4-8-13)11-22(18(16)21-12-20-17)14-9-5-2-6-10-14/h1-12H,(H2,19,20,21)
DMZ34P1	CS	C1=CC=C(C=C1)C2=CN(C3=NC=NC(=C23)N)C4=CC=CC=C4
DMZ34P1	IK	AFVGAHBUCVDPPI-UHFFFAOYSA-N
DMZ34P1	IU	5,7-diphenylpyrrolo[2,3-d]pyrimidin-4-amine
DMZ34P1	DE	Discovery agent

DMU5984	ID	DMU5984
DMU5984	DN	CGP74514A
DMU5984	HS	Investigative
DMU5984	SN	CGP-74514A; CGP 74514A
DMU5984	DT	Small molecular drug
DMU5984	PC	2794188
DMU5984	MW	385.9
DMU5984	FM	C19H24ClN7
DMU5984	IC	InChI=1S/C19H24ClN7/c1-2-27-11-22-16-17(23-13-7-5-6-12(20)10-13)25-19(26-18(16)27)24-15-9-4-3-8-14(15)21/h5-7,10-11,14-15H,2-4,8-9,21H2,1H3,(H2,23,24,25,26)/t14-,15+/m0/s1
DMU5984	CS	CCN1C=NC2=C(N=C(N=C21)N[C@@H]3CCCC[C@@H]3N)NC4=CC(=CC=C4)Cl
DMU5984	IK	UTBSBSOBZHXMHI-LSDHHAIUSA-N
DMU5984	IU	2-N-[(1R,2S)-2-aminocyclohexyl]-6-N-(3-chlorophenyl)-9-ethylpurine-2,6-diamine
DMU5984	CA	CAS 190653-73-7
DMU5984	DE	Discovery agent

DMZ0TGY	ID	DMZ0TGY
DMZ0TGY	DN	CGS 21680
DMZ0TGY	HS	Investigative
DMZ0TGY	SN	2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; Cgs 21680; CGS-21680; 120225-54-9; UNII-T5HB1E831H; T5HB1E831H; CHEMBL331372; CGS21680; 4-(2-((6-Amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl)amino)ethyl)benzenepropanoic acid; CHEBI:73283; CGS 21680 hydrochloride; Benzenepropanoic acid, 4-(2-((6-amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl)amino)ethyl)-; 2-[p-(2-Carboxyethyl)phenylethyl-Amino]-5'-N-Ethylcarboxamido Adenosine; [3H]CGS 21680
DMZ0TGY	DT	Small molecular drug
DMZ0TGY	PC	3086599
DMZ0TGY	MW	499.5
DMZ0TGY	FM	C23H29N7O6
DMZ0TGY	IC	InChI=1S/C23H29N7O6/c1-2-25-21(35)18-16(33)17(34)22(36-18)30-11-27-15-19(24)28-23(29-20(15)30)26-10-9-13-5-3-12(4-6-13)7-8-14(31)32/h3-6,11,16-18,22,33-34H,2,7-10H2,1H3,(H,25,35)(H,31,32)(H3,24,26,28,29)/t16-,17+,18-,22+/m0/s1
DMZ0TGY	CS	CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)NCCC4=CC=C(C=C4)CCC(=O)O)N)O)O
DMZ0TGY	IK	PAOANWZGLPPROA-RQXXJAGISA-N
DMZ0TGY	IU	3-[4-[2-[[6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid
DMZ0TGY	CA	CAS 120225-54-9
DMZ0TGY	CB	CHEBI:73283
DMZ0TGY	DE	Discovery agent

DMRU8G7	ID	DMRU8G7
DMRU8G7	DN	CGS 24012
DMRU8G7	HS	Investigative
DMRU8G7	SN	DPMA; CGS-24012; CGS24012
DMRU8G7	DT	Small molecular drug
DMRU8G7	PC	10391971
DMRU8G7	MW	521.6
DMRU8G7	FM	C27H31N5O6
DMRU8G7	IC	InChI=1S/C27H31N5O6/c1-15-6-4-5-7-19(15)20(16-8-17(36-2)10-18(9-16)37-3)11-28-25-22-26(30-13-29-25)32(14-31-22)27-24(35)23(34)21(12-33)38-27/h4-10,13-14,20-21,23-24,27,33-35H,11-12H2,1-3H3,(H,28,29,30)/t20?,21-,23-,24-,27-/m1/s1
DMRU8G7	CS	CC1=CC=CC=C1C(CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)C5=CC(=CC(=C5)OC)OC
DMRU8G7	IK	BUHVIAUBTBOHAG-FOYDDCNASA-N
DMRU8G7	IU	(2R,3R,4S,5R)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMRU8G7	DE	Discovery agent

DMCHT27	ID	DMCHT27
DMCHT27	DN	CGS 35066
DMCHT27	HS	Investigative
DMCHT27	SN	CGS-35066; CHEMBL34668; SCHEMBL4558321
DMCHT27	DT	Small molecular drug
DMCHT27	PC	24868306
DMCHT27	MW	349.27
DMCHT27	FM	C16H16NO6P
DMCHT27	IC	InChI=1S/C16H16NO6P/c18-16(19)13(17-9-24(20,21)22)7-10-5-6-12-11-3-1-2-4-14(11)23-15(12)8-10/h1-6,8,13,17H,7,9H2,(H,18,19)(H2,20,21,22)
DMCHT27	CS	C1=CC=C2C(=C1)C3=C(O2)C=C(C=C3)CC(C(=O)O)NCP(=O)(O)O
DMCHT27	IK	CRUVAUSVWLATAE-UHFFFAOYSA-N
DMCHT27	IU	3-dibenzofuran-3-yl-2-(phosphonomethylamino)propanoic acid
DMCHT27	DE	Discovery agent

DM4DSE7	ID	DM4DSE7
DM4DSE7	DN	CGS-13767
DM4DSE7	HS	Investigative
DM4DSE7	DT	Small molecular drug
DM4DSE7	PC	135465884
DM4DSE7	MW	262.27
DM4DSE7	FM	C15H10N4O
DM4DSE7	IC	InChI=1S/C15H10N4O/c20-15-16-12-9-5-4-8-11(12)14-17-13(18-19(14)15)10-6-2-1-3-7-10/h1-9H,(H,16,20)
DM4DSE7	CS	C1=CC=C(C=C1)C2=NN3C(=N2)C4=CC=CC=C4NC3=O
DM4DSE7	IK	AXPGZURVLRWNBR-UHFFFAOYSA-N
DM4DSE7	IU	2-phenyl-6H-[1,2,4]triazolo[1,5-c]quinazolin-5-one
DM4DSE7	DE	Discovery agent

DM2CS5A	ID	DM2CS5A
DM2CS5A	DN	CGS-18320B
DM2CS5A	HS	Investigative
DM2CS5A	SN	Cgs-18320B; CHEMBL29482; AC1L33QO; SCHEMBL1507825; ZINC3775824; CGS-18320; BDBM50047260; 4,4''-((1H-imidazol-1-yl)methylene)dibenzonitrile; 4-[4-cyanophenyl(1H-1-imidazolyl)methyl]benzonitrile; 4-[(4-cyanophenyl)-imidazol-1-ylmethyl]benzonitrile
DM2CS5A	DT	Small molecular drug
DM2CS5A	PC	133966
DM2CS5A	MW	284.3
DM2CS5A	FM	C18H12N4
DM2CS5A	IC	InChI=1S/C18H12N4/c19-11-14-1-5-16(6-2-14)18(22-10-9-21-13-22)17-7-3-15(12-20)4-8-17/h1-10,13,18H
DM2CS5A	CS	C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=CN=C3
DM2CS5A	IK	NRXVWQIGPASRKU-UHFFFAOYSA-N
DM2CS5A	IU	4-[(4-cyanophenyl)-imidazol-1-ylmethyl]benzonitrile
DM2CS5A	DE	Discovery agent

DMDB2KJ	ID	DMDB2KJ
DMDB2KJ	DN	CGS-19281A
DMDB2KJ	HS	Investigative
DMDB2KJ	SN	Cgs-19281A; CHEMBL6409; 31652-37-6; 4,9-Dihydro-7-methoxy-3H-pyrido(3,4b)indole; 3H-Pyrido(3,4-b)indole, 4,9-dihydro-7-methoxy-; AC1L53KC; AC1Q56KK; 7-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole; SCHEMBL2930783; CTK4G7530; DTXSID90185537; BDBM50079903; 7-Methoxy-4,9-dihydro-3H-beta-carboline
DMDB2KJ	DT	Small molecular drug
DMDB2KJ	PC	169339
DMDB2KJ	MW	200.24
DMDB2KJ	FM	C12H12N2O
DMDB2KJ	IC	InChI=1S/C12H12N2O/c1-15-8-2-3-9-10-4-5-13-7-12(10)14-11(9)6-8/h2-3,6-7,14H,4-5H2,1H3
DMDB2KJ	CS	COC1=CC2=C(C=C1)C3=C(N2)C=NCC3
DMDB2KJ	IK	VTEZDUSEJVSZGQ-UHFFFAOYSA-N
DMDB2KJ	IU	7-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole
DMDB2KJ	CA	CAS 31652-37-6
DMDB2KJ	DE	Discovery agent

DMC41UH	ID	DMC41UH
DMC41UH	DN	CGS-19480A
DMC41UH	HS	Investigative
DMC41UH	SN	3-(Dipropylamino)-5-ethoxy-3,4-dihydro-2H-[1]-benzothiopyran hydrochloride
DMC41UH	DE	Anxiety disorder

DM5P7TR	ID	DM5P7TR
DM5P7TR	DN	CGS-23885
DM5P7TR	HS	Investigative
DM5P7TR	SN	134822-78-9
DM5P7TR	DT	Small molecular drug
DM5P7TR	PC	131820
DM5P7TR	MW	312.32
DM5P7TR	FM	C17H16N2O4
DM5P7TR	IC	InChI=1S/C17H16N2O4/c18-17(20)19(21)10-12-8-13-9-15(6-7-16(13)22-11-12)23-14-4-2-1-3-5-14/h1-9,21H,10-11H2,(H2,18,20)
DM5P7TR	CS	C1C(=CC2=C(O1)C=CC(=C2)OC3=CC=CC=C3)CN(C(=O)N)O
DM5P7TR	IK	FPOBKZCHKXONBB-UHFFFAOYSA-N
DM5P7TR	IU	1-hydroxy-1-[(6-phenoxy-2H-chromen-3-yl)methyl]urea
DM5P7TR	CA	CAS 134822-78-9
DM5P7TR	DE	Discovery agent

DM514L0	ID	DM514L0
DM514L0	DN	CGS-314447
DM514L0	HS	Investigative
DM514L0	SN	CHEMBL415967; CGS-314447; BDBM50159369; CGS-31,4447; {1-[(S)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)-ethylamino]-2-naphthalen-2-yl-ethyl}-phosphonic acid
DM514L0	DT	Small molecular drug
DM514L0	PC	9913857
DM514L0	MW	499.5
DM514L0	FM	C27H26N5O3P
DM514L0	IC	InChI=1S/C27H26N5O3P/c33-36(34,35)26(18-20-12-15-22-8-4-5-9-24(22)16-20)28-25(27-29-31-32-30-27)17-19-10-13-23(14-11-19)21-6-2-1-3-7-21/h1-16,25-26,28H,17-18H2,(H2,33,34,35)(H,29,30,31,32)/t25-,26?/m0/s1
DM514L0	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C[C@@H](C3=NNN=N3)NC(CC4=CC5=CC=CC=C5C=C4)P(=O)(O)O
DM514L0	IK	PIBUIEXHVFJHNQ-PMCHYTPCSA-N
DM514L0	IU	[2-naphthalen-2-yl-1-[[(1S)-2-(4-phenylphenyl)-1-(2H-tetrazol-5-yl)ethyl]amino]ethyl]phosphonic acid
DM514L0	DE	Discovery agent

DMZKS6Q	ID	DMZKS6Q
DMZKS6Q	DN	CGS-7181
DMZKS6Q	HS	Investigative
DMZKS6Q	SN	200345-93-3; CGS-7184; CGS-7590; CGS-7725
DMZKS6Q	DT	Small molecular drug
DMZKS6Q	PC	656759
DMZKS6Q	MW	406.4
DMZKS6Q	FM	C20H17F3N2O4
DMZKS6Q	IC	InChI=1S/C20H17F3N2O4/c1-3-29-18(27)16-14-9-6-12(20(21,22)23)10-15(14)25(17(16)26)19(28)24-13-7-4-11(2)5-8-13/h4-10,26H,3H2,1-2H3,(H,24,28)
DMZKS6Q	CS	CCOC(=O)C1=C(N(C2=C1C=CC(=C2)C(F)(F)F)C(=O)NC3=CC=C(C=C3)C)O
DMZKS6Q	IK	YMEXYIFTFLKKQK-UHFFFAOYSA-N
DMZKS6Q	IU	ethyl 2-hydroxy-1-[(4-methylphenyl)carbamoyl]-6-(trifluoromethyl)indole-3-carboxylate
DMZKS6Q	CA	CAS 200345-93-3
DMZKS6Q	CB	CHEBI:34601
DMZKS6Q	DE	Discovery agent

DMKY6CU	ID	DMKY6CU
DMKY6CU	DN	CGS-9895
DMKY6CU	HS	Investigative
DMKY6CU	SN	Cgs-9895; 77779-50-1; Cgs 9895; MLS003171322; NSC373970; 2-(4-methoxy-phenyl)-1,2-dihydro-pyrazolo[4,3-c]quinolin-3-one; CHEMBL296335; 2-(4-Methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one; FTHGIXILGYJOBQ-UHFFFAOYSA-N; NSC 373970; AC1L2PJC; AC1Q4BZG; SCHEMBL3646887; SCHEMBL1466285; CHEMBL3144739; CTK5E4891; BDBM84956; AOB4750; MolPort-010-675-457; KSKRJZMRHSNRBX-UHFFFAOYSA-N; HMS3436H11; PDSP2_001747; PDSP1_001764; 2,5-Dihydro-2-(4-methoxyphenyl)-3H-pyrazolo(4,3-c)quinolin-3-one; AKOS021660772; ZINC101168346; NSC-373970
DMKY6CU	DT	Small molecular drug
DMKY6CU	PC	100812
DMKY6CU	MW	291.3
DMKY6CU	FM	C17H13N3O2
DMKY6CU	IC	InChI=1S/C17H13N3O2/c1-22-12-8-6-11(7-9-12)20-17(21)14-10-18-15-5-3-2-4-13(15)16(14)19-20/h2-10,19H,1H3
DMKY6CU	CS	COC1=CC=C(C=C1)N2C(=O)C3=C(N2)C4=CC=CC=C4N=C3
DMKY6CU	IK	FTHGIXILGYJOBQ-UHFFFAOYSA-N
DMKY6CU	IU	2-(4-methoxyphenyl)-1H-pyrazolo[4,3-c]quinolin-3-one
DMKY6CU	CA	CAS 77779-50-1
DMKY6CU	DE	Discovery agent

DMMJZYC	ID	DMMJZYC
DMMJZYC	DN	CH-223191
DMMJZYC	HS	Investigative
DMMJZYC	SN	301326-22-7; CH 223191; CH223191; UNII-HYE7315Z4C; HYE7315Z4C; CHEMBL1743245; AhR Antagonist; 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide; 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide; 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide; (E)-1-methyl-N-(2-methyl-4-(o-tolyldiazenyl)phenyl)-1H-pyrazole-5-carboxamide; 1-methyl-N-{2-methyl-4-[(E)-(2-methylphenyl)diazenyl]phenyl}-1H-pyrazole-5-carboxamide; 2-Methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide; CBDivE_007629; SCHEMBL363547; DTXSID5058698; AOB1977; EX-A771; SYN5007; CHEBI:125508; HMS3412G22; HMS3676G22; HMS3750E07; BCP12814; ZINC4762981; BDBM50525572; MFCD00377884; s7711; SBB081907; STK837883; 2-Methyl-2H-pyrazole-3-carboxylic acid-(2-methyl-4-o-tolyl-azophenyl)-amide; AKOS000629906; AKOS026750492; ZINC100550218; ZINC254429865; CCG-267843; CS-3905; MCULE-3225752823; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-((2-methylphenyl)azo)phenyl)-; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-(2-(2-methylphenyl)diazenyl)phenyl)-; AC-32878; AS-16374; HY-12684; QC-11824; FT-0696668; X3558; J-017795; BRD-K22314899-001-01-6; Q27216129; Q27280162; 1-methyl-N-{2-methyl-4-[2-(2-methylphenyl)diazen-1-yl]phenyl}-1H-pyrazole-5-carboxamide; N-{2-methyl-4-[(2-methylphenyl)diazenyl]phenyl}(1-methylpyrazol-5-yl)carboxami de
DMMJZYC	DT	Small molecular drug
DMMJZYC	PC	3091786
DMMJZYC	MW	333.4
DMMJZYC	FM	C19H19N5O
DMMJZYC	IC	InChI=1S/C19H19N5O/c1-13-6-4-5-7-17(13)23-22-15-8-9-16(14(2)12-15)21-19(25)18-10-11-20-24(18)3/h4-12H,1-3H3,(H,21,25)
DMMJZYC	CS	CC1=CC=CC=C1N=NC2=CC(=C(C=C2)NC(=O)C3=CC=NN3C)C
DMMJZYC	IK	LKTNEXPODAWWFM-UHFFFAOYSA-N
DMMJZYC	IU	2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide
DMMJZYC	CA	CAS 301326-22-7
DMMJZYC	CB	CHEBI:125508
DMMJZYC	DE	Solid tumour/cancer

DM0RFTJ	ID	DM0RFTJ
DM0RFTJ	DN	CH-3697
DM0RFTJ	HS	Investigative
DM0RFTJ	CP	Chiroscience R&D Ltd
DM0RFTJ	DE	Asthma

DMP9UHT	ID	DMP9UHT
DMP9UHT	DN	CH4474
DMP9UHT	HS	Investigative
DMP9UHT	SN	Methotrexate hydrate; Methotrexate hydrate(1:x); 133073-73-1; L-Amethopterin hydrate; Methotrexate monohydrate; UNII-84DMZ3IHO0; 84DMZ3IHO0; Antifolan hydrate; MTX hydrate; L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- [CAS]; 6745-93-3; Methylaminopterin hydrate; MLS001401431; 4-Amino-10-methylfolic acid hydrate; SMR000449324; Methotrexate trihydrate; Abitrexate(Methotrexate)/; AC1Q5QR4; AC1L4WT9; MLS000758248; L-Amethopterin hydrate, 98%; C20H22N8O5.xH2O; SCHEMBL1230252
DMP9UHT	DT	Small molecular drug
DMP9UHT	PC	165528
DMP9UHT	MW	472.5
DMP9UHT	FM	C20H24N8O6
DMP9UHT	IC	InChI=1S/C20H22N8O5.H2O/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);1H2/t13-;/m0./s1
DMP9UHT	CS	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O.O
DMP9UHT	IK	FPJYMUQSRFJSEW-ZOWNYOTGSA-N
DMP9UHT	IU	(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;hydrate
DMP9UHT	CA	CAS 6745-93-3
DMP9UHT	DE	Discovery agent

DM1ZF3Y	ID	DM1ZF3Y
DM1ZF3Y	DN	CH-4933468
DM1ZF3Y	HS	Investigative
DM1ZF3Y	SN	CH-5137291; Androgen receptor antagonists (oral, prostate tumor); Androgen receptor antagonists (oral, prostate tumor), Chugai
DM1ZF3Y	CP	Chugai Pharmaceutical Co Ltd
DM1ZF3Y	DT	Small molecular drug
DM1ZF3Y	PC	11632731
DM1ZF3Y	MW	400.9
DM1ZF3Y	FM	C15H17ClN4O3S2
DM1ZF3Y	IC	InChI=1S/C15H17ClN4O3S2/c1-15(2)13(21)20(11-5-4-10(9-17)12(16)8-11)14(24)19(15)6-3-7-25(18,22)23/h4-5,8H,3,6-7H2,1-2H3,(H2,18,22,23)
DM1ZF3Y	CS	CC1(C(=O)N(C(=S)N1CCCS(=O)(=O)N)C2=CC(=C(C=C2)C#N)Cl)C
DM1ZF3Y	IK	DSIHXMZSDDJEHM-UHFFFAOYSA-N
DM1ZF3Y	IU	3-[3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]propane-1-sulfonamide
DM1ZF3Y	CA	CAS 875055-92-8
DM1ZF3Y	DE	Prostate cancer

DMBK86L	ID	DMBK86L
DMBK86L	DN	chaetocin
DMBK86L	HS	Investigative
DMBK86L	SN	Chaetocin; Chetocin; 28097-03-2; Chaetocin from Chaetomium minutum; BRN 5722505; AC1L4PPK; GTPL8388; SCHEMBL13662584; CHEBI:94977; MolPort-003-983-881; NSC745363; NSC-745363; LS-52961; Chaetocin from Chaetomium minutum, &gt; J-016970; BRD-A85860691-001-01-4; BRD-A85860691-001-03-0; hydroxymethyl-(hydroxymethyl-methyl-dioxo-[ ]yl)-methyl-[ ]dione; [10b,10'b(11H,11'H)-Bi-3,11a-epidithio-11aH-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole]-1,1',4,4'-tetrone, 2,2',3,3',5a,5'a,6,6'-octahydro-3,3'-bis(hydroxymethyl)-2,2'-dime
DMBK86L	DT	Small molecular drug
DMBK86L	PC	11657687
DMBK86L	MW	696.8
DMBK86L	FM	C30H28N6O6S4
DMBK86L	IC	InChI=1S/C30H28N6O6S4/c1-33-21(39)27-11-25(15-7-3-5-9-17(15)31-19(25)35(27)23(41)29(33,13-37)45-43-27)26-12-28-22(40)34(2)30(14-38,46-44-28)24(42)36(28)20(26)32-18-10-6-4-8-16(18)26/h3-10,19-20,31-32,37-38H,11-14H2,1-2H3/t19-,20-,25+,26+,27+,28+,29+,30+/m1/s1
DMBK86L	CS	CN1C(=O)[C@@]23C[C@]4([C@@H](N2C(=O)[C@@]1(SS3)CO)NC5=CC=CC=C54)[C@]67C[C@]89C(=O)N([C@](C(=O)N8[C@H]6NC1=CC=CC=C71)(SS9)CO)C
DMBK86L	IK	PZPPOCZWRGNKIR-PNVYSBBASA-N
DMBK86L	IU	(1S,3R,11R,14S)-14-(hydroxymethyl)-3-[(1S,3R,11R,14S)-14-(hydroxymethyl)-18-methyl-13,17-dioxo-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-trien-3-yl]-18-methyl-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-triene-13,17-dione
DMBK86L	CA	CAS 28097-03-2
DMBK86L	DE	Discovery agent

DM16QTM	ID	DM16QTM
DM16QTM	DN	CHALCONE
DM16QTM	HS	Investigative
DM16QTM	SN	Chalcone; (E)-Chalcone; trans-Chalcone; Benzalacetophenone; 614-47-1; 94-41-7; Benzylideneacetophenone; Chalkone; Phenyl styryl ketone; Cinnamophenone; 2-Benzalacetophenone; 2-Benzylideneacetophenone; 1,3-DIPHENYL-2-PROPEN-1-ONE; 1,3-Diphenylpropenone; (2E)-1,3-diphenylprop-2-en-1-one; Styryl phenyl ketone; 3-Phenylacrylophenone; 1-Benzoyl-2-phenylethene; trans-Benzalacetophenone; beta-Benzoylstyrene; Benzylidenecetophenone; Phenyl trans-styryl ketone; 2-Propen-1-one, 1,3-diphenyl-; 1-Benzoyl-1-phenylethene
DM16QTM	DT	Small molecular drug
DM16QTM	PC	637760
DM16QTM	MW	208.25
DM16QTM	FM	C15H12O
DM16QTM	IC	InChI=1S/C15H12O/c16-15(14-9-5-2-6-10-14)12-11-13-7-3-1-4-8-13/h1-12H/b12-11+
DM16QTM	CS	C1=CC=C(C=C1)/C=C/C(=O)C2=CC=CC=C2
DM16QTM	IK	DQFBYFPFKXHELB-VAWYXSNFSA-N
DM16QTM	IU	(E)-1,3-diphenylprop-2-en-1-one
DM16QTM	CA	CAS 614-47-1
DM16QTM	CB	CHEBI:48965
DM16QTM	DE	Discovery agent

DMBZ0QY	ID	DMBZ0QY
DMBZ0QY	DN	CHAP1
DMBZ0QY	HS	Investigative
DMBZ0QY	SN	CHEMBL99392; chap-1; CHAP1; AC1OCEVW; BDBM50082325
DMBZ0QY	DT	Small molecular drug
DMBZ0QY	PC	6917986
DMBZ0QY	MW	577.7
DMBZ0QY	FM	C31H39N5O6
DMBZ0QY	IC	InChI=1S/C31H39N5O6/c37-27(35-42)17-9-3-8-15-23-28(38)33-24(19-21-11-4-1-5-12-21)29(39)34-25(20-22-13-6-2-7-14-22)31(41)36-18-10-16-26(36)30(40)32-23/h1-2,4-7,11-14,23-26,42H,3,8-10,15-20H2,(H,32,40)(H,33,38)(H,34,39)(H,35,37)/t23-,24-,25-,26+/m0/s1
DMBZ0QY	CS	C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CC=CC=C4)CCCCCC(=O)NO
DMBZ0QY	IK	FQWUNUXAOHTLLG-ASDGIDEWSA-N
DMBZ0QY	IU	6-[(3S,6S,9S,12R)-3,6-dibenzyl-2,5,8,11-tetraoxo-1,4,7,10-tetrazabicyclo[10.3.0]pentadecan-9-yl]-N-hydroxyhexanamide
DMBZ0QY	DE	Solid tumour/cancer

DMOXRID	ID	DMOXRID
DMOXRID	DN	CHAP31
DMOXRID	HS	Investigative
DMOXRID	SN	SCHEMBL16585076
DMOXRID	DT	Small molecular drug
DMOXRID	PC	56603758
DMOXRID	MW	575.7
DMOXRID	FM	C29H45N5O7
DMOXRID	IC	InChI=1S/C29H45N5O7/c1-4-19(2)25(18-35)33-29(39)24(17-20-12-14-21(41-3)15-13-20)32-28(38)23(9-6-5-7-11-26(36)34-40)31-27(37)22-10-8-16-30-22/h12-15,18-19,22-25,30,40H,4-11,16-17H2,1-3H3,(H,31,37)(H,32,38)(H,33,39)(H,34,36)/t19-,22?,23+,24-,25-/m1/s1
DMOXRID	CS	CC[C@@H](C)[C@@H](C=O)NC(=O)[C@@H](CC1=CC=C(C=C1)OC)NC(=O)[C@H](CCCCCC(=O)NO)NC(=O)C2CCCN2
DMOXRID	IK	NTGGUMOPMBIWTJ-UIKXIZPHSA-N
DMOXRID	IU	(2S)-N'-hydroxy-N-[(2R)-3-(4-methoxyphenyl)-1-[[(2S,3R)-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-2-(pyrrolidine-2-carbonylamino)octanediamide
DMOXRID	DE	Solid tumour/cancer

DM0H7AV	ID	DM0H7AV
DM0H7AV	DN	Chebulagic acid
DM0H7AV	HS	Investigative
DM0H7AV	SN	Chebulagic acid; 23094-71-5; NSC 342674; AC1L2HS4; beta-D-Glucopyranose, cyclic 3,6-(4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1-(3,4,5-trihydroxybenzoate), cyclic 2-5:4-1-ester with (5-carboxy-3,4-dihydro-3,7,8-trihydroxy-2-oxo-2H-1-benzopyran-4-yl)butanedioic acid, stereoisomer
DM0H7AV	DT	Small molecular drug
DM0H7AV	PC	442674
DM0H7AV	MW	954.7
DM0H7AV	FM	C41H30O27
DM0H7AV	IC	InChI=1S/C41H30O27/c42-13-1-8(2-14(43)24(13)49)35(56)68-41-34-33-31(64-39(60)12(6-19(47)48)22-23-11(38(59)67-34)5-17(46)27(52)32(23)65-40(61)30(22)55)18(63-41)7-62-36(57)9-3-15(44)25(50)28(53)20(9)21-10(37(58)66-33)4-16(45)26(51)29(21)54/h1-5,12,18,22,30-31,33-34,41-46,49-55H,6-7H2,(H,47,48)/t12-,18+,22-,30-,31+,33-,34+,41-/m0/s1
DM0H7AV	CS	C1[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@H]([C@@H](C(=O)O3)CC(=O)O)[C@@H](C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O
DM0H7AV	IK	HGJXAVROWQLCTP-YABCKIEDSA-N
DM0H7AV	IU	2-[(4R,5S,7R,25S,26R,29S,30S,31S)-13,14,15,18,19,20,31,35,36-nonahydroxy-2,10,23,28,32-pentaoxo-5-(3,4,5-trihydroxybenzoyl)oxy-3,6,9,24,27,33-hexaoxaheptacyclo[28.7.1.04,25.07,26.011,16.017,22.034,38]octatriaconta-1(37),11,13,15,17,19,21,34(38),35-nonaen-29-yl]acetic acid
DM0H7AV	CB	CHEBI:3583
DM0H7AV	DE	Discovery agent

DMR8HKC	ID	DMR8HKC
DMR8HKC	DN	Chebulinic acid
DMR8HKC	HS	Investigative
DMR8HKC	SN	Chebulinic acid; 18942-26-2; UNII-HVC8VQJ6EK; HVC8VQJ6EK; AC1L2HS1; CHEMBL501154; NSC69862; NSC 69862; CHEBI:3584; ZINC195763592; FT-0697896; C10215; Q-100932; beta-D-Glucopyranose, cyclic 2,4-ester with 3-(6-carboxy-2,3,4-trihydroxyphenyl)-4-hydroxy-1,2,4-butanetricarboxylic acid, 1,3,6-tris(3,4,5-trihydroxybenzoate)
DMR8HKC	DT	Small molecular drug
DMR8HKC	PC	72284
DMR8HKC	MW	956.7
DMR8HKC	FM	C41H32O27
DMR8HKC	IC	InChI=1S/C41H32O27/c42-15-1-10(2-16(43)26(15)51)35(56)62-9-22-31-33(66-36(57)11-3-17(44)27(52)18(45)4-11)34(41(63-22)68-37(58)12-5-19(46)28(53)20(47)6-12)67-38(59)13-7-21(48)29(54)32-25(13)24(30(55)40(61)65-32)14(8-23(49)50)39(60)64-31/h1-7,14,22,24,30-31,33-34,41-48,51-55H,8-9H2,(H,49,50)/t14-,22+,24-,30-,31+,33-,34+,41-/m0/s1
DMR8HKC	CS	C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@H]([C@@H](C(=O)O3)CC(=O)O)[C@@H](C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O
DMR8HKC	IK	YGVHOSGNOYKRIH-FJPMMHPYSA-N
DMR8HKC	IU	2-[(4R,5S,7R,8R,11S,12S,13S,21S)-13,17,18-trihydroxy-2,10,14-trioxo-5,21-bis[(3,4,5-trihydroxybenzoyl)oxy]-7-[(3,4,5-trihydroxybenzoyl)oxymethyl]-3,6,9,15-tetraoxatetracyclo[10.7.1.14,8.016,20]henicosa-1(19),16(20),17-trien-11-yl]acetic acid
DMR8HKC	CB	CHEBI:3584
DMR8HKC	DE	Discovery agent

DMCP1G9	ID	DMCP1G9
DMCP1G9	DN	Chelerythrine
DMCP1G9	HS	Investigative
DMCP1G9	SN	broussonpapyrine; cheleritrine; chelerythrine hydroxide; toddalin
DMCP1G9	DT	Small molecular drug
DMCP1G9	PC	2703
DMCP1G9	MW	348.4
DMCP1G9	FM	C21H18NO4+
DMCP1G9	IC	InChI=1S/C21H18NO4/c1-22-10-16-13(6-7-17(23-2)21(16)24-3)14-5-4-12-8-18-19(26-11-25-18)9-15(12)20(14)22/h4-10H,11H2,1-3H3/q+1
DMCP1G9	CS	C[N+]1=C2C(=C3C=CC(=C(C3=C1)OC)OC)C=CC4=CC5=C(C=C42)OCO5
DMCP1G9	IK	LLEJIEBFSOEYIV-UHFFFAOYSA-N
DMCP1G9	IU	1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium
DMCP1G9	CA	CAS 34316-15-9
DMCP1G9	CB	CHEBI:78373
DMCP1G9	DE	Discovery agent

DMYSG9J	ID	DMYSG9J
DMYSG9J	DN	Chemosensitizers
DMYSG9J	HS	Investigative
DMYSG9J	DT	Small molecular drug
DMYSG9J	PC	24783227
DMYSG9J	MW	385.2
DMYSG9J	FM	C16H18ClN3SZn+2
DMYSG9J	IC	InChI=1S/C16H18N3S.ClH.Zn/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;/h5-10H,1-4H3;1H;/q+1;;+2/p-1
DMYSG9J	CS	CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-].[Zn+2]
DMYSG9J	IK	LXXWTKZXINWUFR-UHFFFAOYSA-M
DMYSG9J	IU	zinc;[7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride
DMYSG9J	DE	Discovery agent

DMLJGVX	ID	DMLJGVX
DMLJGVX	DN	CHF-2819
DMLJGVX	HS	Investigative
DMLJGVX	SN	CHEMBL539624
DMLJGVX	DT	Small molecular drug
DMLJGVX	PC	23645738
DMLJGVX	MW	417.9
DMLJGVX	FM	C22H28ClN3O3
DMLJGVX	IC	InChI=1S/C22H27N3O3.ClH/c1-5-15-8-6-7-9-18(15)23-21(26)28-16-10-11-19-17(14-16)22(2)12-13-25(4,27)20(22)24(19)3;/h6-11,14,20H,5,12-13H2,1-4H3,(H,23,26);1H/t20-,22-,25?;/m0./s1
DMLJGVX	CS	CCC1=CC=CC=C1NC(=O)OC2=CC3=C(C=C2)N([C@@H]4[C@]3(CC[N+]4(C)[O-])C)C.Cl
DMLJGVX	IK	GPQRGFUTRVNTHA-QFPJJMDASA-N
DMLJGVX	IU	[(3aS,8bS)-3,4,8b-trimethyl-3-oxido-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-3-ium-7-yl] N-(2-ethylphenyl)carbamate;hydrochloride
DMLJGVX	DE	Discovery agent

DM5T64L	ID	DM5T64L
DM5T64L	DN	CHF-5480
DM5T64L	HS	Investigative
DM5T64L	SN	PDE 4 inhibitors (COPD/asthma); PDE 4 inhibitors (COPD/asthma), Chiesi
DM5T64L	CP	Chiesi Farmaceutici SpA
DM5T64L	DE	Chronic obstructive pulmonary disease

DMJATBL	ID	DMJATBL
DMJATBL	DN	Chimeric small nucleolar RNA-TAR decoy
DMJATBL	HS	Investigative
DMJATBL	DT	Small molecular drug
DMJATBL	PC	6426938
DMJATBL	MW	682.8
DMJATBL	FM	C37H50N2O10
DMJATBL	IC	InChI=1S/C37H50N2O10/c1-7-38-17-34(18-49-32(42)20-10-8-9-11-23(20)39-26(40)14-19(2)31(39)41)13-12-25(46-4)36-22-15-21-24(45-3)16-35(43,27(22)28(21)47-5)37(44,33(36)38)30(48-6)29(34)36/h8-11,19,21-22,24-25,27-30,33,43-44H,7,12-18H2,1-6H3/t19?,21?,22?,24?,25?,27?,28?,29?,30-,33?,34?,35+,36?,37-/m0/s1
DMJATBL	CS	CCN1CC2(CCC(C34C2[C@@H]([C@](C31)([C@]5(CC(C6CC4C5C6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N8C(=O)CC(C8=O)C
DMJATBL	IK	XLTANAWLDBYGFU-SCAXRLHISA-N
DMJATBL	IU	[(8R,9R,18S)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-13-yl]methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate
DMJATBL	CA	CAS 1356-60-1
DMJATBL	DE	Discovery agent

DMVEBT6	ID	DMVEBT6
DMVEBT6	DN	CHIR-98014
DMVEBT6	HS	Investigative
DMVEBT6	SN	CHIR98014; CHIR 98014
DMVEBT6	DT	Small molecular drug
DMVEBT6	PC	53396311
DMVEBT6	MW	486.3
DMVEBT6	FM	C20H17Cl2N9O2
DMVEBT6	IC	InChI=1S/C20H17Cl2N9O2/c21-12-1-2-13(14(22)9-12)18-16(30-8-7-24-11-30)10-27-20(29-18)26-6-5-25-17-4-3-15(31(32)33)19(23)28-17/h1-4,7-11H,5-6H2,(H3,23,25,28)(H,26,27,29)
DMVEBT6	CS	C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC=C2N3C=CN=C3)NCCNC4=NC(=C(C=C4)[N+](=O)[O-])N
DMVEBT6	IK	MDZCSIDIPDZWKL-UHFFFAOYSA-N
DMVEBT6	IU	6-N-[2-[[4-(2,4-dichlorophenyl)-5-imidazol-1-ylpyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine
DMVEBT6	CA	CAS 252935-94-7
DMVEBT6	DE	Discovery agent

DMFBW1H	ID	DMFBW1H
DMFBW1H	DN	CHIR-98023
DMFBW1H	HS	Investigative
DMFBW1H	SN	CT-98014
DMFBW1H	DT	Small molecular drug
DMFBW1H	PC	9847557
DMFBW1H	MW	471.3
DMFBW1H	FM	C20H16Cl2N8O2
DMFBW1H	IC	InChI=1S/C20H16Cl2N8O2/c21-12-1-3-14(16(22)9-12)18-15(19-24-6-7-25-19)11-28-20(29-18)26-8-5-23-17-4-2-13(10-27-17)30(31)32/h1-4,6-7,9-11H,5,8H2,(H,23,27)(H,24,25)(H,26,28,29)
DMFBW1H	CS	C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC=C2C3=NC=CN3)NCCNC4=NC=C(C=C4)[N+](=O)[O-]
DMFBW1H	IK	GUMBZKISKUIHJB-UHFFFAOYSA-N
DMFBW1H	IU	N'-[4-(2,4-dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl]-N-(5-nitropyridin-2-yl)ethane-1,2-diamine
DMFBW1H	CA	CAS 252916-76-0
DMFBW1H	DE	Discovery agent

DMLCZ3D	ID	DMLCZ3D
DMLCZ3D	DN	Chk1-A
DMLCZ3D	HS	Investigative
DMLCZ3D	SN	Chk1-B; Chk1-C; Chk 1 inhibitor (oral, cancer); Chk 1 inhibitor (oral, cancer), Array
DMLCZ3D	CP	Array BioPharma Inc
DMLCZ3D	DE	Solid tumour/cancer

DMNSPFG	ID	DMNSPFG
DMNSPFG	DN	Chk2 inhibitor II
DMNSPFG	HS	Investigative
DMNSPFG	SN	BML-277; 516480-79-8; Chk2 Inhibitor II; Chk2 Inhibitor II hydrate; CHEMBL179583; 2-(4-(4-chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide; C20H14ClN3O2; 2-[4-(4-Chlorophenoxy)phenyl]-1h-Benzimidazole-6-Carboxamide; 2-[4-(4-chlorophenoxy)phenyl]-1H-1,3-benzodiazole-6-carboxamide; 2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide hydrate; 2-arylbenzimidazole; 4a9r; MLS006010751; GTPL5954; BML277; SCHEMBL1723139; CTK8E8283; BDBM34064; DTXSID40433479; MolPort-039-139-575; HMS3229E12; ZINC3815901; EX-A1077; BCP09077
DMNSPFG	DT	Small molecular drug
DMNSPFG	PC	9969021
DMNSPFG	MW	363.8
DMNSPFG	FM	C20H14ClN3O2
DMNSPFG	IC	InChI=1S/C20H14ClN3O2/c21-14-4-8-16(9-5-14)26-15-6-1-12(2-7-15)20-23-17-10-3-13(19(22)25)11-18(17)24-20/h1-11H,(H2,22,25)(H,23,24)
DMNSPFG	CS	C1=CC(=CC=C1C2=NC3=C(N2)C=C(C=C3)C(=O)N)OC4=CC=C(C=C4)Cl
DMNSPFG	IK	UXGJAOIJSROTTN-UHFFFAOYSA-N
DMNSPFG	IU	2-[4-(4-chlorophenoxy)phenyl]-3H-benzimidazole-5-carboxamide
DMNSPFG	CA	CAS 516480-79-8
DMNSPFG	DE	Discovery agent

DMCHGF1	ID	DMCHGF1
DMCHGF1	DN	CHLORANIL
DMCHGF1	HS	Investigative
DMCHGF1	SN	Chloranil; 118-75-2; p-Chloranil; Tetrachloro-p-benzoquinone; Tetrachloro-1,4-benzoquinone; Tetrachlorobenzoquinone; 2,3,5,6-tetrachlorocyclohexa-2,5-diene-1,4-dione; Spergon; Coversan; Vulklor; Reranil; 2,3,5,6-TETRACHLORO-1,4-BENZOQUINONE; Psorisan; Khloranil; Tetrachloroparabenzoquinone; Spergon technical; Spergon I; Tetrachloroquinone; Chloranile; Quinone tetrachloride; Tetrachloro-p-quinone; Geigy-444E; 2,3,5,6-Tetrachlorobenzo-1,4-quinone; 2,3,5,6-Tetrachloro-p-benzoquinone; Dow Seed Disinfectant No. 5
DMCHGF1	DT	Small molecular drug
DMCHGF1	PC	8371
DMCHGF1	MW	245.9
DMCHGF1	FM	C6Cl4O2
DMCHGF1	IC	InChI=1S/C6Cl4O2/c7-1-2(8)6(12)4(10)3(9)5(1)11
DMCHGF1	CS	C1(=C(C(=O)C(=C(C1=O)Cl)Cl)Cl)Cl
DMCHGF1	IK	UGNWTBMOAKPKBL-UHFFFAOYSA-N
DMCHGF1	IU	2,3,5,6-tetrachlorocyclohexa-2,5-diene-1,4-dione
DMCHGF1	CA	CAS 118-75-2
DMCHGF1	CB	CHEBI:36703
DMCHGF1	DE	Discovery agent

DMMHU8G	ID	DMMHU8G
DMMHU8G	DN	chlordane
DMMHU8G	HS	Investigative
DMMHU8G	SN	Chlorindan; chlordan
DMMHU8G	DT	Small molecular drug
DMMHU8G	PC	5993
DMMHU8G	MW	409.8
DMMHU8G	FM	C10H6Cl8
DMMHU8G	IC	InChI=1S/C10H6Cl8/c11-3-1-2-4(5(3)12)9(16)7(14)6(13)8(2,15)10(9,17)18/h2-5H,1H2
DMMHU8G	CS	C1C2C(C(C1Cl)Cl)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl
DMMHU8G	IK	BIWJNBZANLAXMG-UHFFFAOYSA-N
DMMHU8G	IU	1,3,4,7,8,9,10,10-octachlorotricyclo[5.2.1.02,6]dec-8-ene
DMMHU8G	CA	CAS 57-74-9
DMMHU8G	CB	CHEBI:34623
DMMHU8G	DE	Discovery agent

DM64K0A	ID	DM64K0A
DM64K0A	DN	Chlormadinone
DM64K0A	HS	Investigative
DM64K0A	SN	Chlormadinon; Chlormadinone; Chlormadinone (INN); Chlormadinone [INN:BAN]; Chlormadinonum; Chlormadinonum [INN-Latin]; Clormadinona; Clormadinona [INN-Spanish]; Clormadinone; Clormadinone [DCIT]; SDS4N642GG; Tox21_112988; 1961-77-9; 6-Chloro-17-hydroxypregna-4,6-diene-3,20-dione; AC1NR4MV; BCP16136; C21H27ClO3; CHEMBL1697830; CTK8F8596; DSSTox_CID_2796; DSSTox_GSID_22796; DSSTox_RID_76731; DTXSID3022796; EINECS 217-802-3; MLS006010797; NCGC00181768-01; Pregna-4,6-diene-3,20-dione, 6-chloro-17-hydroxy-; SCHEMBL37291; UNII-SDS4N642GG
DM64K0A	PC	5284533
DM64K0A	MW	362.9
DM64K0A	FM	C21H27ClO3
DM64K0A	IC	VUHJZBBCZGVNDZ-TTYLFXKOSA-N
DM64K0A	CS	CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)CCC34C)Cl)C)O
DM64K0A	IK	1S/C21H27ClO3/c1-12(23)21(25)9-6-16-14-11-18(22)17-10-13(24)4-7-19(17,2)15(14)5-8-20(16,21)3/h10-11,14-16,25H,4-9H2,1-3H3/t14-,15+,16+,19-,20+,21+/m1/s1
DM64K0A	IU	(8R,9S,10R,13S,14S,17R)-17-acetyl-6-chloro-17-hydroxy-10,13-dimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
DM64K0A	CA	CAS 1961-77-9
DM64K0A	DE	Discovery agent

DMY40UB	ID	DMY40UB
DMY40UB	DN	Chloroben
DMY40UB	HS	Investigative
DMY40UB	SN	Chloroden; Cloroben; Benzene, 1,2-dichloro-; Benzene, dichloro-; Benzene, o-dichloro-; Dichlorobenzene, o-; Dichlorobenzene, ortho, liquid; 2-Dichlorobenzene; Dilantin DB; Dilatin DB; Dizene; Dowtherm E; Orthodichlorobenzene; Orthodichlorobenzol; Special termite fluid; Termitkil; o-Dichlor benzol; o-Dichlorbenzene; o-Dichlorbenzol; o-Dichlorobenzene; o-Dichlorobenzol; ortho-Dichlorobenzene; 1,2-DICHLOROBENZENE; 1,2-Dichlorbenzene; 95-50-1; CCRIS 1360; Caswell No. 301; NCI-C54944; NSC 60644; ODCB; UNII-6PJ93I88XL; o-DCB
DMY40UB	PC	7239
DMY40UB	MW	147
DMY40UB	FM	C6H4Cl2
DMY40UB	IC	RFFLAFLAYFXFSW-UHFFFAOYSA-N
DMY40UB	CS	C1=CC=C(C(=C1)Cl)Cl
DMY40UB	IK	1S/C6H4Cl2/c7-5-3-1-2-4-6(5)8/h1-4H
DMY40UB	IU	1,2-dichlorobenzene
DMY40UB	CA	CAS 95-50-1
DMY40UB	CB	CHEBI:35290
DMY40UB	DE	Discovery agent

DMLF7MK	ID	DMLF7MK
DMLF7MK	DN	chlorobenzylidene malononitrile
DMLF7MK	HS	Investigative
DMLF7MK	SN	2-chlorobenzylidene malononitrile; alonitrile; CS gas (lacrimator)
DMLF7MK	DT	Small molecular drug
DMLF7MK	PC	17604
DMLF7MK	MW	188.61
DMLF7MK	FM	C10H5ClN2
DMLF7MK	IC	InChI=1S/C10H5ClN2/c11-10-4-2-1-3-9(10)5-8(6-12)7-13/h1-5H
DMLF7MK	CS	C1=CC=C(C(=C1)C=C(C#N)C#N)Cl
DMLF7MK	IK	JJNZXLAFIPKXIG-UHFFFAOYSA-N
DMLF7MK	IU	2-[(2-chlorophenyl)methylidene]propanedinitrile
DMLF7MK	CA	CAS 2698-41-1
DMLF7MK	DE	Discovery agent

DMZA394	ID	DMZA394
DMZA394	DN	CHLOROCYCLINONE A
DMZA394	HS	Investigative
DMZA394	SN	CHLOROCYCLINONE A; CHEMBL253120; BDBM50228358; methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate
DMZA394	DT	Small molecular drug
DMZA394	PC	24762579
DMZA394	MW	454.9
DMZA394	FM	C24H19ClO7
DMZA394	IC	InChI=1S/C24H19ClO7/c1-5-11-12(24(30)32-4)8-13-16(20(11)27)22(29)17-14(26)7-10-6-9(2)19(25)23(31-3)15(10)18(17)21(13)28/h6-8,26-27H,5H2,1-4H3
DMZA394	CS	CCC1=C(C=C2C(=C1O)C(=O)C3=C(C=C4C=C(C(=C(C4=C3C2=O)OC)Cl)C)O)C(=O)OC
DMZA394	IK	NFJVYTZFJNVKBA-UHFFFAOYSA-N
DMZA394	IU	methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxobenzo[a]anthracene-10-carboxylate
DMZA394	DE	Discovery agent

DMO78QB	ID	DMO78QB
DMO78QB	DN	CHLOROCYCLINONE B
DMO78QB	HS	Investigative
DMO78QB	SN	CHLOROCYCLINONE B; CHEMBL254814; BDBM50228360; methyl 9-[1-(acetyloxyethyl)]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate
DMO78QB	DT	Small molecular drug
DMO78QB	PC	24762580
DMO78QB	MW	512.9
DMO78QB	FM	C26H21ClO9
DMO78QB	IC	InChI=1S/C26H21ClO9/c1-9-6-12-7-15(29)19-20(17(12)25(34-4)21(9)27)22(30)13-8-14(26(33)35-5)16(10(2)36-11(3)28)23(31)18(13)24(19)32/h6-8,10,29,31H,1-5H3
DMO78QB	CS	CC1=CC2=CC(=C3C(=C2C(=C1Cl)OC)C(=O)C4=CC(=C(C(=C4C3=O)O)C(C)OC(=O)C)C(=O)OC)O
DMO78QB	IK	MFLXCCWOEBQIHW-UHFFFAOYSA-N
DMO78QB	IU	methyl 9-(1-acetyloxyethyl)-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxobenzo[a]anthracene-10-carboxylate
DMO78QB	DE	Discovery agent

DMX2DQ5	ID	DMX2DQ5
DMX2DQ5	DN	CHLOROCYCLINONE C
DMX2DQ5	HS	Investigative
DMX2DQ5	SN	CHLOROCYCLINONE C; CHEMBL254815; BDBM50228359; methyl 2-chloro-6,8-dihydroxy-9-{1-[(hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate
DMX2DQ5	DT	Small molecular drug
DMX2DQ5	PC	24180661
DMX2DQ5	MW	528.9
DMX2DQ5	FM	C26H21ClO10
DMX2DQ5	IC	InChI=1S/C26H21ClO10/c1-9-5-11-6-14(29)19-20(17(11)25(35-3)21(9)27)22(31)12-7-13(26(34)36-4)16(10(2)37-15(30)8-28)23(32)18(12)24(19)33/h5-7,10,28-29,32H,8H2,1-4H3
DMX2DQ5	CS	CC1=CC2=CC(=C3C(=C2C(=C1Cl)OC)C(=O)C4=CC(=C(C(=C4C3=O)O)C(C)OC(=O)CO)C(=O)OC)O
DMX2DQ5	IK	LMNHPKWXMIGBEL-UHFFFAOYSA-N
DMX2DQ5	IU	methyl 2-chloro-6,8-dihydroxy-9-[1-(2-hydroxyacetyl)oxyethyl]-1-methoxy-3-methyl-7,12-dioxobenzo[a]anthracene-10-carboxylate
DMX2DQ5	DE	Discovery agent

DMK7VS1	ID	DMK7VS1
DMK7VS1	DN	CHLOROCYCLINONE D
DMK7VS1	HS	Investigative
DMK7VS1	SN	CHLOROCYCLINONE D; CHEMBL400132; BDBM50228361
DMK7VS1	DT	Small molecular drug
DMK7VS1	PC	24762578
DMK7VS1	MW	438.8
DMK7VS1	FM	C23H15ClO7
DMK7VS1	IC	InChI=1S/C23H15ClO7/c1-7-4-9-5-12(25)16-17(14(9)22(30-3)18(7)24)19(26)10-6-11-13(8(2)31-23(11)29)20(27)15(10)21(16)28/h4-6,8,25,27H,1-3H3
DMK7VS1	CS	CC1C2=C(C3=C(C=C2C(=O)O1)C(=O)C4=C5C(=CC(=C4C3=O)O)C=C(C(=C5OC)Cl)C)O
DMK7VS1	IK	RSSUHOCYQSARQQ-UHFFFAOYSA-N
DMK7VS1	IU	16-chloro-4,21-dihydroxy-15-methoxy-6,17-dimethyl-7-oxapentacyclo[11.8.0.03,11.05,9.014,19]henicosa-1(21),3(11),4,9,13,15,17,19-octaene-2,8,12-trione
DMK7VS1	DE	Discovery agent

DMQT3WJ	ID	DMQT3WJ
DMQT3WJ	DN	CHLORODEOXYURIDINE
DMQT3WJ	HS	Investigative
DMQT3WJ	SN	Chlorodeoxyuridine; 5-Chlorodeoxyuridine; 5-Chloro-2'-deoxyuridine; CldU; 50-90-8; BRN 0546807; CHEMBL505732; Uridine, 5-chloro-2'-deoxy-; Uridine,5-chloro-2'-deoxy-; 5-chloro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; 5-Chloro-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2'-Deoxy-5-chlorouridine; 5-Chloro-dUrd; 5-Chloro-2 -deoxyuridine; AC1L23DV; AC1Q77TD; SCHEMBL1469771; CTK4J3337; NJCXGFKPQSFZIB-RRKCRQDMSA-N; MolPort-001-814-149
DMQT3WJ	DT	Small molecular drug
DMQT3WJ	PC	65510
DMQT3WJ	MW	262.65
DMQT3WJ	FM	C9H11ClN2O5
DMQT3WJ	IC	InChI=1S/C9H11ClN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DMQT3WJ	CS	C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Cl)CO)O
DMQT3WJ	IK	NJCXGFKPQSFZIB-RRKCRQDMSA-N
DMQT3WJ	IU	5-chloro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMQT3WJ	CA	CAS 50-90-8
DMQT3WJ	DE	Discovery agent

DMGS3FI	ID	DMGS3FI
DMGS3FI	DN	CHLORODYSINOSIN A
DMGS3FI	HS	Investigative
DMGS3FI	SN	Chlorodysinosin A; CHEMBL568990
DMGS3FI	DT	Small molecular drug
DMGS3FI	PC	16079152
DMGS3FI	MW	667.2
DMGS3FI	FM	C26H43ClN6O10S
DMGS3FI	IC	InChI=1S/C26H43ClN6O10S/c1-13(2)21(27)22(31-24(37)20(42-3)12-43-44(39,40)41)25(38)33-16-10-19(35)18(34)9-15(16)8-17(33)23(36)30-6-4-14-5-7-32(11-14)26(28)29/h5,13,15-22,34-35H,4,6-12H2,1-3H3,(H6,28,29,30,31,36,37,39,40,41)/t15-,16+,17+,18+,19+,20-,21-,22-/m1/s1
DMGS3FI	CS	CC(C)[C@H]([C@H](C(=O)N1[C@H]2C[C@@H]([C@H](C[C@H]2C[C@H]1C(=O)NCCC3=CC[N+](=C(N)N)C3)O)O)NC(=O)[C@@H](COS(=O)(=O)[O-])OC)Cl
DMGS3FI	IK	DLWZHBAKINZMIF-WNZJUFNWSA-N
DMGS3FI	IU	[(2R)-3-[[(2S,3R)-1-[(2S,3aR,5S,6S,7aS)-2-[2-[1-(diaminomethylidene)-2,5-dihydropyrrol-1-ium-3-yl]ethylcarbamoyl]-5,6-dihydroxy-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-3-chloro-4-methyl-1-oxopentan-2-yl]amino]-2-methoxy-3-oxopropyl] sulfate
DMGS3FI	DE	Discovery agent

DMKZIES	ID	DMKZIES
DMKZIES	DN	Chloroethylclonidine
DMKZIES	HS	Investigative
DMKZIES	SN	Chloroethylclonidine; Chlorethylclonidine; UNII-3X825O680H; N-(2,6-Dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-1H-imidazol-2-amine; 3X825O680H; 98086-36-3; 1h-imidazol-2-amine, n-[2,6-dichloro-4-[[(2-chloroethyl)methylamino]methyl]phenyl]-4,5-dihydro-; 1H-Imidazol-2-amine, N-(2,6-dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-; Lopac-B-003; AC1Q3UQS; AC1L2XTB; Lopac0_000195; C11H12Cl3N3; SCHEMBL4107963; CHEMBL326967; SCHEMBL18154646; CTK3I7576; PDSP2_000070; ZINC27089957
DMKZIES	DT	Small molecular drug
DMKZIES	PC	104973
DMKZIES	MW	335.7
DMKZIES	FM	C13H17Cl3N4
DMKZIES	IC	InChI=1S/C13H17Cl3N4/c1-20(5-2-14)8-9-6-10(15)12(11(16)7-9)19-13-17-3-4-18-13/h6-7H,2-5,8H2,1H3,(H2,17,18,19)
DMKZIES	CS	CN(CCCl)CC1=CC(=C(C(=C1)Cl)NC2=NCCN2)Cl
DMKZIES	IK	XFDVJGKSQRUEEM-UHFFFAOYSA-N
DMKZIES	IU	N-[2,6-dichloro-4-[[2-chloroethyl(methyl)amino]methyl]phenyl]-4,5-dihydro-1H-imidazol-2-amine
DMKZIES	CA	CAS 77472-95-8
DMKZIES	DE	Discovery agent

DM2Y3P4	ID	DM2Y3P4
DM2Y3P4	DN	Chlorogenic acid
DM2Y3P4	HS	Investigative
DM2Y3P4	SN	CHLOROGENIC ACID; 327-97-9; 3-Caffeoylquinic acid; 3-O-Caffeoylquinic acid; 3-(3,4-Dihydroxycinnamoyl)quinic acid; Chlorogenate; Heriguard; Hlorogenic acid; Caffeoyl quinic acid; NSC-407296; 3-Caffeoylquinate; UNII-318ADP12RI; 5-O-(3,4-Dihydroxycinnamoyl)-L-quinic acid; CCRIS 1400; Chlorogenic acid (8CI); EINECS 206-325-6; NSC 70861; NSC 407296; 3-trans-Caffeoylquinic acid; CHEMBL284616; 318ADP12RI; CHEBI:16112; 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate); 3-(3,4-Dihydroxycinnamoyl)quinate
DM2Y3P4	DT	Small molecular drug
DM2Y3P4	PC	1794427
DM2Y3P4	MW	354.31
DM2Y3P4	FM	C16H18O9
DM2Y3P4	IC	InChI=1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24,15(22)23)6-11(19)14(12)21/h1-5,11-12,14,17-19,21,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14-,16+/m1/s1
DM2Y3P4	CS	C1[C@H]([C@H]([C@@H](C[C@@]1(C(=O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O
DM2Y3P4	IK	CWVRJTMFETXNAD-JUHZACGLSA-N
DM2Y3P4	IU	(1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid
DM2Y3P4	CA	CAS 202650-88-2
DM2Y3P4	CB	CHEBI:16112
DM2Y3P4	DE	Discovery agent

DMOA8L2	ID	DMOA8L2
DMOA8L2	DN	Chlorophenylpiperazine
DMOA8L2	HS	Investigative
DMOA8L2	PC	22015046
DMOA8L2	MW	196.67
DMOA8L2	FM	C10H13ClN2
DMOA8L2	IC	InChI=1S/C10H13ClN2/c11-10-8-12-6-7-13(10)9-4-2-1-3-5-9/h1-5,10,12H,6-8H2
DMOA8L2	CS	C1CN(C(CN1)Cl)C2=CC=CC=C2
DMOA8L2	IK	JQQKTEXFNXKDIQ-UHFFFAOYSA-N
DMOA8L2	IU	2-chloro-1-phenylpiperazine
DMOA8L2	DE	Discovery agent

DMSGBQA	ID	DMSGBQA
DMSGBQA	DN	chloropicrin
DMSGBQA	HS	Investigative
DMSGBQA	SN	trichloronitromethane; nitrotrichloromethane
DMSGBQA	DT	Small molecular drug
DMSGBQA	PC	6423
DMSGBQA	MW	164.37
DMSGBQA	FM	CCl3NO2
DMSGBQA	IC	InChI=1S/CCl3NO2/c2-1(3,4)5(6)7
DMSGBQA	CS	C([N+](=O)[O-])(Cl)(Cl)Cl
DMSGBQA	IK	LFHISGNCFUNFFM-UHFFFAOYSA-N
DMSGBQA	IU	trichloro(nitro)methane
DMSGBQA	CA	CAS 76-06-2
DMSGBQA	CB	CHEBI:39285
DMSGBQA	DE	Discovery agent

DM8B0VZ	ID	DM8B0VZ
DM8B0VZ	DN	CHLOROPUUPEHENONE
DM8B0VZ	HS	Investigative
DM8B0VZ	SN	Chloropuupehenone; (+)-Chloropuupehenone
DM8B0VZ	DT	Small molecular drug
DM8B0VZ	PC	9998777
DM8B0VZ	MW	362.9
DM8B0VZ	FM	C21H27ClO3
DM8B0VZ	IC	InChI=1S/C21H27ClO3/c1-19(2)7-5-8-20(3)15(19)6-9-21(4)16(20)10-12-14(25-21)11-13(23)18(24)17(12)22/h10-11,15-16,24H,5-9H2,1-4H3/t15-,16+,20-,21-/m0/s1
DM8B0VZ	CS	C[C@]12CCCC([C@@H]1CC[C@]3([C@@H]2C=C4C(=CC(=O)C(=C4Cl)O)O3)C)(C)C
DM8B0VZ	IK	IVURSJNKOFPQMR-GQSCTRQFSA-N
DM8B0VZ	IU	(4aS,6aS,12aR,12bS)-11-chloro-10-hydroxy-4,4,6a,12b-tetramethyl-2,3,4a,5,6,12a-hexahydro-1H-benzo[a]xanthen-9-one
DM8B0VZ	DE	Discovery agent

DMM75WZ	ID	DMM75WZ
DMM75WZ	DN	Chloroxylenol
DMM75WZ	HS	Investigative
DMM75WZ	SN	Benzytol; Chloro-xylenol; Chloroxylenolum; Chlorxylenolum; Clorossilenolo; Cloroxilenol; Desson; Dettol; Dettol, liquid antiseptic; Espadol; Husept Extra; Nipacide MX; Ottasept; Ottasept Extra; Parametaxylenol; Phenol, 4-chloro-3,5-dimethyl-; RBA 777; Septiderm-Hydrochloride; Willenol V; chloroxylenol; p-Chloro-3,5-xylenol; p-Chloro-m-xylenol; parachlorometaxylenol; 2-Chloro-5-hydroxy-m-xylene; 2-Chloro-m-xylenol; 3,5-Dimethyl-4-chlorophenol; 4-Chloro-3,5-dimethylphenol; 4-Chloro-3,5-xylenol; 4-Chloro-m-xylenol; 88-04-0; PCMX
DMM75WZ	PC	2723
DMM75WZ	MW	156.61
DMM75WZ	FM	C8H9ClO
DMM75WZ	IC	OSDLLIBGSJNGJE-UHFFFAOYSA-N
DMM75WZ	CS	CC1=CC(=CC(=C1Cl)C)O
DMM75WZ	IK	1S/C8H9ClO/c1-5-3-7(10)4-6(2)8(5)9/h3-4,10H,1-2H3
DMM75WZ	IU	4-chloro-3,5-dimethylphenol
DMM75WZ	CA	CAS 88-04-0
DMM75WZ	CB	CHEBI:34393
DMM75WZ	DE	Pseudomonas infection

DMGBT68	ID	DMGBT68
DMGBT68	DN	Chlorphrifos oxon
DMGBT68	HS	Investigative
DMGBT68	SN	Diethyl 3,5,6-trichloropyridin-2-yl phosphate
DMGBT68	DT	Small molecular drug
DMGBT68	PC	21804
DMGBT68	MW	334.5
DMGBT68	FM	C9H11Cl3NO4P
DMGBT68	IC	InChI=1S/C9H11Cl3NO4P/c1-3-15-18(14,16-4-2)17-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3
DMGBT68	CS	CCOP(=O)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl
DMGBT68	IK	OTMOUPHCTWPNSL-UHFFFAOYSA-N
DMGBT68	IU	diethyl (3,5,6-trichloropyridin-2-yl) phosphate
DMGBT68	CA	CAS 5598-15-2
DMGBT68	DE	Discovery agent

DMKPUI6	ID	DMKPUI6
DMKPUI6	DN	Chlorpyrifos
DMKPUI6	HS	Investigative
DMKPUI6	SN	chlorpyrifos; 2921-88-2; Chlorpyriphos; Dursban; Trichlorpyrphos; Lorsban; Chlorpyrifos-ethyl; Pyrinex; Coroban; Brodan; Killmaster; Piridane; Danusban; Spannit; Lentrek; Geodinfos; Tafaban; Stipend; Bonidel; Zidil; Terial; Durmet; Equity; Suscon green; Suscon blue; suSCon; Dursban R; Dursban F; Lock-On; Dursban 4E; Dowco 179; Chlorpyriphos-ethyl; Ethyl chlorpyriphos; Dursban 10CR; Chlorpyrifos (Dursban); Detmol U.A.; Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl) ester; Chloropyrifos; Clorpyrifos; Dhanusban; Grofo; Detmol ua
DMKPUI6	DT	Small molecular drug
DMKPUI6	PC	2730
DMKPUI6	MW	350.6
DMKPUI6	FM	C9H11Cl3NO3PS
DMKPUI6	IC	InChI=1S/C9H11Cl3NO3PS/c1-3-14-17(18,15-4-2)16-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3
DMKPUI6	CS	CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl
DMKPUI6	IK	SBPBAQFWLVIOKP-UHFFFAOYSA-N
DMKPUI6	IU	diethoxy-sulfanylidene-(3,5,6-trichloropyridin-2-yl)oxy-lambda5-phosphane
DMKPUI6	CA	CAS 2921-88-2
DMKPUI6	CB	CHEBI:34631
DMKPUI6	DE	Discovery agent

DMZHO3S	ID	DMZHO3S
DMZHO3S	DN	CHO793076
DMZHO3S	HS	Investigative
DMZHO3S	SN	CHEMBL493342; CHO793076; SCHEMBL1455615; NPAAFPODGAKMTC-SANMLTNESA-N; BDBM50257522
DMZHO3S	DT	Small molecular drug
DMZHO3S	PC	9981577
DMZHO3S	MW	458.5
DMZHO3S	FM	C26H26N4O4
DMZHO3S	IC	InChI=1S/C26H26N4O4/c1-3-5-6-10-29-14-27-18-8-7-9-19-21(18)23(29)15-12-30-20(22(15)28-19)11-17-16(24(30)31)13-34-25(32)26(17,33)4-2/h7-9,11,14,33H,3-6,10,12-13H2,1-2H3/t26-/m0/s1
DMZHO3S	CS	CCCCCN1C=NC2=CC=CC3=C2C1=C4CN5C(=CC6=C(C5=O)COC(=O)[C@@]6(CC)O)C4=N3
DMZHO3S	IK	NPAAFPODGAKMTC-SANMLTNESA-N
DMZHO3S	IU	(10S)-10-ethyl-10-hydroxy-23-pentyl-8-oxa-4,15,21,23-tetrazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16(24),17,19,21-octaene-5,9-dione
DMZHO3S	DE	Discovery agent

DMVJMG8	ID	DMVJMG8
DMVJMG8	DN	Cholecystokinin-9
DMVJMG8	HS	Investigative
DMVJMG8	SN	Cholecystokinin-9; CHEMBL414345; Cholecystokinin 9; AC1L4TL1; CCK-9; BDBM50154437; 108050-84-6; Caerulein, 1-de(5-oxo-L-proline)-2-L-arginine-5-L-methionine-
DMVJMG8	PC	163781
DMVJMG8	MW	1299.5
DMVJMG8	FM	C55H74N14O17S3
DMVJMG8	IC	InChI=1S/C55H74N14O17S3/c1-87-21-18-37(64-51(79)40(24-31-14-16-33(17-15-31)86-89(83,84)85)68-54(82)42(26-45(71)72)67-48(76)35(56)12-8-20-60-55(58)59)49(77)62-29-44(70)63-41(25-32-28-61-36-13-7-6-11-34(32)36)52(80)65-38(19-22-88-2)50(78)69-43(27-46(73)74)53(81)66-39(47(57)75)23-30-9-4-3-5-10-30/h3-7,9-11,13-17,28,35,37-43,61H,8,12,18-27,29,56H2,1-2H3,(H2,57,75)(H,62,77)(H,63,70)(H,64,79)(H,65,80)(H,66,81)(H,67,76)(H,68,82)(H,69,78)(H,71,72)(H,73,74)(H4,58,59,60)(H,83,84,85)/t35-,37-,38-,39-,40-,41-,42-,43-/m0/s1
DMVJMG8	CS	CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N
DMVJMG8	IK	AOVFOMQIRNOPOR-LVHVEONVSA-N
DMVJMG8	IU	(3S)-3-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
DMVJMG8	CA	CAS 108050-84-6
DMVJMG8	DE	Discovery agent

DMKM3WJ	ID	DMKM3WJ
DMKM3WJ	DN	cholesten
DMKM3WJ	HS	Investigative
DMKM3WJ	SN	cholestane; cholestan; alpha-cholestane
DMKM3WJ	DT	Small molecular drug
DMKM3WJ	PC	6857534
DMKM3WJ	MW	372.7
DMKM3WJ	FM	C27H48
DMKM3WJ	IC	InChI=1S/C27H48/c1-19(2)9-8-10-20(3)23-14-15-24-22-13-12-21-11-6-7-17-26(21,4)25(22)16-18-27(23,24)5/h19-25H,6-18H2,1-5H3/t20-,21?,22+,23-,24+,25+,26+,27-/m1/s1
DMKM3WJ	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CCCC4)C)C
DMKM3WJ	IK	XIIAYQZJNBULGD-LDHZKLTISA-N
DMKM3WJ	IU	(8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene
DMKM3WJ	CA	CAS 14982-53-7
DMKM3WJ	CB	CHEBI:35516
DMKM3WJ	DE	Discovery agent

DMR3J6S	ID	DMR3J6S
DMR3J6S	DN	Cholesterol
DMR3J6S	HS	Investigative
DMR3J6S	SN	cholesterol; 57-88-5; Cholesterin; Cholest-5-en-3beta-ol; Cholesteryl alcohol; Cholestrin; Dusoran; Cordulan; Dusoline; Cholesterine; Hydrocerin; Cholestrol; Kathro; Dythol; Lanol; Super hartolan; Provitamin D; Cholesterol base H; Lidinite; Nimco cholesterol base H; Lidinit; Wool alcohols B. P.; (-)-Cholesterol; Tegolan (VAN); Cholest-5-en-3-beta-ol; 5:6-Cholesten-3beta-ol; Tegolan; 3beta-Hydroxycholest-5-ene; 5-Cholesten-3beta-ol; Cholest-5-en-3-ol (3beta)-; 3-beta-Hydroxycholest-5-ene; (3beta)-cholest-5-en-3-ol; CCRIS 2834; Dastar; HSDB 7
DMR3J6S	DT	Small molecular drug
DMR3J6S	PC	5997
DMR3J6S	MW	386.7
DMR3J6S	FM	C27H46O
DMR3J6S	IC	InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DMR3J6S	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DMR3J6S	IK	HVYWMOMLDIMFJA-DPAQBDIFSA-N
DMR3J6S	IU	(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMR3J6S	CA	CAS 57-88-5
DMR3J6S	CB	CHEBI:16113
DMR3J6S	DE	Discovery agent

DM5D9YK	ID	DM5D9YK
DM5D9YK	DN	Choline
DM5D9YK	HS	Investigative
DM5D9YK	SN	choline; Choline ion; Bilineurine; Choline cation; Cholinum; 2-Hydroxy-N,N,N-trimethylethanaminium; 62-49-7; (2-Hydroxyethyl)trimethylammonium; trimethylethanolamine; N-trimethylethanolamine; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-; CCRIS 5847; UNII-N91BDP6H0X; AI3-24208; BRN 1736748; N,N,N-trimethylethanol-ammonium; CHEBI:15354; (beta-hydroxyethyl)trimethylammonium; EINECS 200-535-1; CHEMBL920; N91BDP6H0X; 2-hydroxyethyl(trimethyl)ammonium
DM5D9YK	DT	Small molecular drug
DM5D9YK	PC	305
DM5D9YK	MW	104.17
DM5D9YK	FM	C5H14NO+
DM5D9YK	IC	InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1
DM5D9YK	CS	C[N+](C)(C)CCO
DM5D9YK	IK	OEYIOHPDSNJKLS-UHFFFAOYSA-N
DM5D9YK	IU	2-hydroxyethyl(trimethyl)azanium
DM5D9YK	CA	CAS 62-49-7
DM5D9YK	CB	CHEBI:15354
DM5D9YK	DE	Discovery agent

DMW6U7K	ID	DMW6U7K
DMW6U7K	DN	CHOLINE IODIDE
DMW6U7K	HS	Investigative
DMW6U7K	SN	Choline iodide; 17773-10-3; 2-Hydroxy-N,N,N-trimethylethanaminium iodide; Jodoetano; Dilatol zambon; UNII-39528O55VK; EINECS 241-754-2; (2-Hydroxyethyl)trimethylammonium Iodide; AI3-61505; CHEMBL293410; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, iodide; 39528O55VK; CholineIodide; AC1L3DCR; AC1Q1TNR; ACMC-209ed9; SCHEMBL315876; CTK4D6569; ANW-22891; MFCD00011900; AKOS027320917; 2-hydroxyethyl(trimethyl)azanium iodide; ACM17773103; KS-0000140P; LS-53247; KB-76072; TC-111636; FT-0623771; C-45721; Ethanaminium,2-hydroxy-N,N,N-trimethyl-, io
DMW6U7K	DT	Small molecular drug
DMW6U7K	PC	87300
DMW6U7K	MW	231.08
DMW6U7K	FM	C5H14INO
DMW6U7K	IC	InChI=1S/C5H14NO.HI/c1-6(2,3)4-5-7;/h7H,4-5H2,1-3H3;1H/q+1;/p-1
DMW6U7K	CS	C[N+](C)(C)CCO.[I-]
DMW6U7K	IK	FNPBHXSBDADRBT-UHFFFAOYSA-M
DMW6U7K	IU	2-hydroxyethyl(trimethyl)azanium;iodide
DMW6U7K	CA	CAS 17773-10-3
DMW6U7K	DE	Discovery agent

DMVBQ20	ID	DMVBQ20
DMVBQ20	DN	Cholini alfosceras
DMVBQ20	HS	Investigative
DMVBQ20	SN	Alfoscerate de choline; Alfoscerato de colina; Choline Alfoscerate; Choline Alphoscerate; Choline glycerophosphate; Glycerophosphorylcholine; Cholini glycerophosphas; Glicerofosfato de colina; Glycerol phosphorylcholine; Glycerophosphate de choline; Glycerophosphocholine; L-alpha-Glycerophosphocholine; L-alpha-Glycerophosphorylcholine; L-alpha-Glycerylphosphorylcholine; SN-glycero-3-phosphocholine; Sn-3-GPC; alpha-Glycerophosphorylcholine; glycerol-3-phosphocholine; 28319-77-9; GPCho; UNII-60M22SGW66
DMVBQ20	PC	657272
DMVBQ20	MW	257.22
DMVBQ20	FM	C8H20NO6P
DMVBQ20	IC	SUHOQUVVVLNYQR-MRVPVSSYSA-N
DMVBQ20	CS	C[N+](C)(C)CCOP(=O)([O-])OCC(CO)O
DMVBQ20	IK	1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1
DMVBQ20	IU	[(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMVBQ20	CA	CAS 28319-77-9
DMVBQ20	CB	CHEBI:16870
DMVBQ20	DE	Discovery agent

DMZ956E	ID	DMZ956E
DMZ956E	DN	CHPG
DMZ956E	HS	Investigative
DMZ956E	SN	2-chloro-5-hydroxyphenylglycine
DMZ956E	DT	Small molecular drug
DMZ956E	PC	3645780
DMZ956E	MW	201.61
DMZ956E	FM	C8H8ClNO3
DMZ956E	IC	InChI=1S/C8H8ClNO3/c9-6-2-1-4(11)3-5(6)7(10)8(12)13/h1-3,7,11H,10H2,(H,12,13)
DMZ956E	CS	C1=CC(=C(C=C1O)C(C(=O)O)N)Cl
DMZ956E	IK	UNIDAFCQFPGYJJ-UHFFFAOYSA-N
DMZ956E	IU	2-amino-2-(2-chloro-5-hydroxyphenyl)acetic acid
DMZ956E	CA	CAS 170846-74-9
DMZ956E	DE	Discovery agent

DMXKU73	ID	DMXKU73
DMXKU73	DN	CHR-4125
DMXKU73	HS	Investigative
DMXKU73	SN	CHR-4146; CHR-5010; PLK-1 inhibitors (cancer), Chroma Therapeutics; Polo-like kinase-1 inhibitors (cancer); Polo-likekinase-1 inhibitors (cancer), Chroma Therapeutics
DMXKU73	CP	Chroma Therapeutics Ltd
DMXKU73	DE	Solid tumour/cancer

DMVDB7S	ID	DMVDB7S
DMVDB7S	DN	chroman 28
DMVDB7S	HS	Investigative
DMVDB7S	SN	CHEMBL415848; chroman 28; GTPL664; SCHEMBL4136892; BDBM50203200; (R)-3-(naphthalene-7-sulfonamido)-3-phenyl-N-((R)-7-(piperidin-1-ylmethyl)-3,4-dihydro-2H-chromen-4-yl)propanamide; (3R)-3-(naphthalen-2-ylsulfonylamino)-3-phenyl-N-[(4R)-7-(piperidin-1-ylmethyl)chroman-4-yl]propanamide
DMVDB7S	DT	Small molecular drug
DMVDB7S	PC	16108961
DMVDB7S	MW	583.7
DMVDB7S	FM	C34H37N3O4S
DMVDB7S	IC	InChI=1S/C34H37N3O4S/c38-34(35-31-17-20-41-33-21-25(13-16-30(31)33)24-37-18-7-2-8-19-37)23-32(27-10-3-1-4-11-27)36-42(39,40)29-15-14-26-9-5-6-12-28(26)22-29/h1,3-6,9-16,21-22,31-32,36H,2,7-8,17-20,23-24H2,(H,35,38)/t31-,32-/m1/s1
DMVDB7S	CS	C1CCN(CC1)CC2=CC3=C(C=C2)[C@@H](CCO3)NC(=O)C[C@H](C4=CC=CC=C4)NS(=O)(=O)C5=CC6=CC=CC=C6C=C5
DMVDB7S	IK	IQPWKAIEQBOLPJ-ROJLCIKYSA-N
DMVDB7S	IU	(3R)-3-(naphthalen-2-ylsulfonylamino)-3-phenyl-N-[(4R)-7-(piperidin-1-ylmethyl)-3,4-dihydro-2H-chromen-4-yl]propanamide
DMVDB7S	DE	Discovery agent

DM5JHUN	ID	DM5JHUN
DM5JHUN	DN	CHROMOTROPATE
DM5JHUN	HS	Investigative
DM5JHUN	SN	129-96-4; Chromotropic acid disodium salt; Sodium chromotropate; 2,7-Naphthalenedisulfonic acid, 4,5-dihydroxy-, disodium salt; Disodium chromotropate; Sodium 4,5-dihydroxynaphthalene-2,7-disulfonate; disodium 4,5-dihydroxynaphthalene-2,7-disulfonate; Disodium 4,5-dihydroxynaphthalene-2,7-disulphonate; Mordant Brown 7; Chromotropic acid sodium salt; 3888-44-6; 2,7-Naphthalenedisulfonic acid, 4,5-dihydroxy-, sodium salt (1:2); CHEMBL425511; 148-25-4 (Parent); CHROMOTROPATE; mordantbrown; Chromogen C; NSC 4883; EINECS 204-972-
DM5JHUN	DT	Small molecular drug
DM5JHUN	PC	67220
DM5JHUN	MW	364.3
DM5JHUN	FM	C10H6Na2O8S2
DM5JHUN	IC	InChI=1S/C10H8O8S2.2Na/c11-8-3-6(19(13,14)15)1-5-2-7(20(16,17)18)4-9(12)10(5)8;;/h1-4,11-12H,(H,13,14,15)(H,16,17,18);;/q;2*+1/p-2
DM5JHUN	CS	C1=C2C=C(C=C(C2=C(C=C1S(=O)(=O)[O-])O)O)S(=O)(=O)[O-].[Na+].[Na+]
DM5JHUN	IK	AFGPCIMUGMJQPD-UHFFFAOYSA-L
DM5JHUN	IU	disodium;4,5-dihydroxynaphthalene-2,7-disulfonate
DM5JHUN	CA	CAS 129-96-4
DM5JHUN	DE	Discovery agent

DMLEXN0	ID	DMLEXN0
DMLEXN0	DN	Chrysamine -G
DMLEXN0	HS	Investigative
DMLEXN0	DT	Small molecular drug
DMLEXN0	PC	160843
DMLEXN0	MW	482.4
DMLEXN0	FM	C26H18N4O6
DMLEXN0	IC	InChI=1S/C26H18N4O6/c31-23-11-9-19(13-21(23)25(33)34)29-27-17-5-1-15(2-6-17)16-3-7-18(8-4-16)28-30-20-10-12-24(32)22(14-20)26(35)36/h1-14,31-32H,(H,33,34)(H,35,36)
DMLEXN0	CS	C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O)N=NC4=CC(=C(C=C4)O)C(=O)O
DMLEXN0	IK	XFFSCOOTVXBLCK-UHFFFAOYSA-N
DMLEXN0	IU	5-[[4-[4-[(3-carboxy-4-hydroxyphenyl)diazenyl]phenyl]phenyl]diazenyl]-2-hydroxybenzoic acid
DMLEXN0	DE	Discovery agent

DM7V2LG	ID	DM7V2LG
DM7V2LG	DN	Chrysin
DM7V2LG	HS	Investigative
DM7V2LG	SN	chrysin; 480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0
DM7V2LG	DT	Small molecular drug
DM7V2LG	PC	5281607
DM7V2LG	MW	254.24
DM7V2LG	FM	C15H10O4
DM7V2LG	IC	InChI=1S/C15H10O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-8,16-17H
DM7V2LG	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O
DM7V2LG	IK	RTIXKCRFFJGDFG-UHFFFAOYSA-N
DM7V2LG	IU	5,7-dihydroxy-2-phenylchromen-4-one
DM7V2LG	CA	CAS 480-40-0
DM7V2LG	CB	CHEBI:75095
DM7V2LG	DE	Discovery agent

DM96ECL	ID	DM96ECL
DM96ECL	DN	CHRYSOERIOL
DM96ECL	HS	Investigative
DM96ECL	SN	Chrysoeriol; 491-71-4; Chryseriol; Luteolin 3'-methyl ether; 3'-O-Methylluteolin; 3'-O-Methyluteolin; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; UNII-Q813145M20; EINECS 207-742-6; BRN 0295004; CHEMBL214321; CHEBI:16514
DM96ECL	DT	Small molecular drug
DM96ECL	PC	5280666
DM96ECL	MW	300.26
DM96ECL	FM	C16H12O6
DM96ECL	IC	InChI=1S/C16H12O6/c1-21-14-4-8(2-3-10(14)18)13-7-12(20)16-11(19)5-9(17)6-15(16)22-13/h2-7,17-19H,1H3
DM96ECL	CS	COC1=C(C=CC(=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
DM96ECL	IK	SCZVLDHREVKTSH-UHFFFAOYSA-N
DM96ECL	IU	5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one
DM96ECL	CA	CAS 491-71-4
DM96ECL	CB	CHEBI:16514
DM96ECL	DE	Discovery agent

DMT27QD	ID	DMT27QD
DMT27QD	DN	CHYMOSTATIN
DMT27QD	HS	Investigative
DMT27QD	SN	Chymostatin; CHEMBL247767; AC1L9E22; MRXDGVXSWIXTQL-HYHFHBMOSA-N; C11308; 9076-44-2; SCHEMBL8259564; BDBM87059; CHEBI:510447; C31H41N7O6; BDBM222139; LS-187745; X6871; FT-0623815; (2S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-1-benzyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]amino]-1-(2-iminohexahydropyrimidin-4-yl)-2-oxo-ethyl]carbamoylamino]-3-phenyl-propanoic acid
DMT27QD	DT	Small molecular drug
DMT27QD	PC	443119
DMT27QD	MW	607.7
DMT27QD	FM	C31H41N7O6
DMT27QD	IC	InChI=1S/C31H41N7O6/c1-19(2)15-24(27(40)34-22(18-39)16-20-9-5-3-6-10-20)35-28(41)26(23-13-14-33-30(32)36-23)38-31(44)37-25(29(42)43)17-21-11-7-4-8-12-21/h3-12,18-19,22-26H,13-17H2,1-2H3,(H,34,40)(H,35,41)(H,42,43)(H3,32,33,36)(H2,37,38,44)/t22-,23?,24-,25-,26-/m0/s1
DMT27QD	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)[C@H](C2CCN=C(N2)N)NC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O
DMT27QD	IK	MRXDGVXSWIXTQL-HYHFHBMOSA-N
DMT27QD	IU	(2S)-2-[[(1S)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid
DMT27QD	CA	CAS 9076-44-2
DMT27QD	CB	CHEBI:510447
DMT27QD	DE	Discovery agent

DMQ5CE1	ID	DMQ5CE1
DMQ5CE1	DN	CI-1015
DMQ5CE1	HS	Investigative
DMQ5CE1	SN	CI 1015; PD 144598; CI1015
DMQ5CE1	DT	Small molecular drug
DMQ5CE1	PC	3074331
DMQ5CE1	MW	493.6
DMQ5CE1	FM	C29H39N3O4
DMQ5CE1	IC	InChI=1S/C29H39N3O4/c1-28(26(34)31-24-8-4-5-9-25(24)33,16-21-17-30-23-7-3-2-6-22(21)23)32-27(35)36-29-13-18-10-19(14-29)12-20(11-18)15-29/h2-3,6-7,17-20,24-25,30,33H,4-5,8-16H2,1H3,(H,31,34)(H,32,35)/t18?,19?,20?,24-,25-,28+,29?/m0/s1
DMQ5CE1	CS	C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@H]3CCCC[C@@H]3O)NC(=O)OC45CC6CC(C4)CC(C6)C5
DMQ5CE1	IK	UOFRODPUIMDZTB-HDCXSGMISA-N
DMQ5CE1	IU	1-adamantyl N-[(2R)-1-[[(1S,2S)-2-hydroxycyclohexyl]amino]-3-(1H-indol-3-yl)-2-methyl-1-oxopropan-2-yl]carbamate
DMQ5CE1	DE	Discovery agent

DMTKVDZ	ID	DMTKVDZ
DMTKVDZ	DN	CI-1031
DMTKVDZ	HS	Investigative
DMTKVDZ	DT	Small molecular drug
DMTKVDZ	PC	4322
DMTKVDZ	MW	526.5
DMTKVDZ	FM	C25H24F2N6O5
DMTKVDZ	IC	InChI=1S/C25H24F2N6O5/c1-32-9-8-30-23(32)14-4-3-5-15(10-14)37-24-19(26)21(33(2)12-18(35)36)20(27)25(31-24)38-17-11-13(22(28)29)6-7-16(17)34/h3-7,10-11,34H,8-9,12H2,1-2H3,(H3,28,29)(H,35,36)
DMTKVDZ	CS	CN1CCN=C1C2=CC(=CC=C2)OC3=NC(=C(C(=C3F)N(C)CC(=O)O)F)OC4=C(C=CC(=C4)C(=N)N)O
DMTKVDZ	IK	NPNSVNGQJGRSNR-UHFFFAOYSA-N
DMTKVDZ	IU	2-[[2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyridin-4-yl]-methylamino]acetic acid
DMTKVDZ	CA	CAS 183305-24-0
DMTKVDZ	DE	Discovery agent

DMF3DZX	ID	DMF3DZX
DMF3DZX	DN	CI-1040
DMF3DZX	HS	Investigative
DMF3DZX	DT	Small molecular drug
DMF3DZX	PC	6918454
DMF3DZX	MW	478.7
DMF3DZX	FM	C17H14ClF2IN2O2
DMF3DZX	IC	InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)
DMF3DZX	CS	C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl
DMF3DZX	IK	GFMMXOIFOQCCGU-UHFFFAOYSA-N
DMF3DZX	IU	2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide
DMF3DZX	CA	CAS 212631-79-3
DMF3DZX	CB	CHEBI:91353
DMF3DZX	DE	Discovery agent

DMG5D6B	ID	DMG5D6B
DMG5D6B	DN	CI-1044
DMG5D6B	HS	Investigative
DMG5D6B	SN	CI-1044; UNII-O4T475XIIY; O4T475XIIY; 197894-84-1; DSSTox_CID_27291; DSSTox_RID_82245; DSSTox_GSID_47291; CAS-NOCAS_47291; SCHEMBL6441242; CHEMBL342285; DTXSID5047291; NOCAS_47291; Tox21_300455; NCGC00254387-01; NCGC00248057-01; PD-189659; HY-100246; CS-0018397; (+)-CI-1044; 3-Pyridinecarboxamide, N-((3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-; 3-Pyridinecarboxamide, N-(9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (R)-
DMG5D6B	DT	Small molecular drug
DMG5D6B	PC	9843744
DMG5D6B	MW	397.4
DMG5D6B	FM	C23H19N5O2
DMG5D6B	IC	InChI=1S/C23H19N5O2/c24-17-11-15-8-10-28-20(15)18(12-17)19(14-5-2-1-3-6-14)26-21(23(28)30)27-22(29)16-7-4-9-25-13-16/h1-7,9,11-13,21H,8,10,24H2,(H,27,29)/t21-/m0/s1
DMG5D6B	CS	C1CN2C(=O)[C@@H](N=C(C3=CC(=CC1=C32)N)C4=CC=CC=C4)NC(=O)C5=CN=CC=C5
DMG5D6B	IK	XGXOSJSGDNPEEF-NRFANRHFSA-N
DMG5D6B	IU	N-[(11R)-6-amino-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl]pyridine-3-carboxamide
DMG5D6B	CA	CAS 197894-84-1
DMG5D6B	DE	Discovery agent

DM0RH3S	ID	DM0RH3S
DM0RH3S	DN	CI-218872
DM0RH3S	HS	Investigative
DM0RH3S	SN	66548-69-4; CL 218872; CL 218,872; 3-methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; CHEMBL13662; CL-218872; CI-218872; 3-Methyl-6-(3-(trifluoromethyl)phenyl)-1,2,4-triazolo(4,2-b)pyridazine; 1,2,4-Triazolo(4,3-b)pyridazine, 3-methyl-6-(3-(trifluoromethyl)phenyl)-; 3-Methyl-6-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-b]pyridazine; 3-Methyl-6-[-3-(trifluoromethyl)phenyl]-1,2,4-triazolo[4,3-b]pyridazine; 3-Methyl-6-[3-(trifluoromethyl)phenyl]-1,2,4-triazolo-(4,3-b)pyridazine
DM0RH3S	DT	Small molecular drug
DM0RH3S	PC	107950
DM0RH3S	MW	278.23
DM0RH3S	FM	C13H9F3N4
DM0RH3S	IC	InChI=1S/C13H9F3N4/c1-8-17-18-12-6-5-11(19-20(8)12)9-3-2-4-10(7-9)13(14,15)16/h2-7H,1H3
DM0RH3S	CS	CC1=NN=C2N1N=C(C=C2)C3=CC(=CC=C3)C(F)(F)F
DM0RH3S	IK	GUOQUXNJZHGPQF-UHFFFAOYSA-N
DM0RH3S	IU	3-methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine
DM0RH3S	CA	CAS 66548-69-4
DM0RH3S	CB	CHEBI:92018
DM0RH3S	DE	Discovery agent

DMWE1N8	ID	DMWE1N8
DMWE1N8	DN	Cibacron blue
DMWE1N8	HS	Investigative
DMWE1N8	SN	Affi gel blue; Cibacron Blue F 3GA; Cibacron Blue 3G; Cibacronblau F3G-A; Procion Blue H-B; C.I. Reactive Blue 2; UNII-J0A052J6QF; Basilen Blue; CHEBI:34946; EINECS 235-465-0; NSC 328383; J0A052J6QF; C.I. 61211; 26763-68-8; 2-Anthracenesulfonic acid, 1-amino-4-((4-((4-chloro-6-((3(or 4)-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-; Affi-gel blue
DMWE1N8	DT	Small molecular drug
DMWE1N8	PC	172469
DMWE1N8	MW	774.2
DMWE1N8	FM	C29H20ClN7O11S3
DMWE1N8	IC	InChI=1S/C29H20ClN7O11S3/c30-27-35-28(33-16-7-3-4-8-19(16)49(40,41)42)37-29(36-27)34-17-10-9-13(11-20(17)50(43,44)45)32-18-12-21(51(46,47)48)24(31)23-22(18)25(38)14-5-1-2-6-15(14)26(23)39/h1-12,32H,31H2,(H,40,41,42)(H,43,44,45)(H,46,47,48)(H2,33,34,35,36,37)
DMWE1N8	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3NC4=CC(=C(C=C4)NC5=NC(=NC(=N5)NC6=CC=CC=C6S(=O)(=O)O)Cl)S(=O)(=O)O)S(=O)(=O)O)N
DMWE1N8	IK	YKCWQPZFAFZLBI-UHFFFAOYSA-N
DMWE1N8	IU	1-amino-4-[4-[[4-chloro-6-(2-sulfoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid
DMWE1N8	CA	CAS 84166-13-2
DMWE1N8	DE	Discovery agent

DM7ZJ4H	ID	DM7ZJ4H
DM7ZJ4H	DN	cicaprost
DM7ZJ4H	HS	Investigative
DM7ZJ4H	SN	ZK 96480; ZK-96480
DM7ZJ4H	DT	Small molecular drug
DM7ZJ4H	PC	5311044
DM7ZJ4H	MW	374.5
DM7ZJ4H	FM	C22H30O5
DM7ZJ4H	IC	InChI=1S/C22H30O5/c1-3-4-5-6-15(2)20(23)8-7-18-19-12-16(9-10-27-14-22(25)26)11-17(19)13-21(18)24/h9,15,17-21,23-24H,3,6,10-14H2,1-2H3,(H,25,26)/b16-9+/t15-,17-,18+,19-,20+,21+/m0/s1
DM7ZJ4H	CS	CCC#CC[C@H](C)[C@@H](C#C[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/COCC(=O)O)/C2)O)O
DM7ZJ4H	IK	ARUGKOZUKWAXDS-SEWALLKFSA-N
DM7ZJ4H	IU	2-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]acetic acid
DM7ZJ4H	CA	CAS 94079-80-8
DM7ZJ4H	CB	CHEBI:135578
DM7ZJ4H	DE	Discovery agent

DM27S6E	ID	DM27S6E
DM27S6E	DN	cicloprolol
DM27S6E	HS	Investigative
DM27S6E	SN	SL 75-177-10
DM27S6E	DT	Small molecular drug
DM27S6E	PC	146294
DM27S6E	MW	323.4
DM27S6E	FM	C18H29NO4
DM27S6E	IC	InChI=1S/C18H29NO4/c1-14(2)19-11-16(20)13-23-18-7-5-17(6-8-18)22-10-9-21-12-15-3-4-15/h5-8,14-16,19-20H,3-4,9-13H2,1-2H3
DM27S6E	CS	CC(C)NCC(COC1=CC=C(C=C1)OCCOCC2CC2)O
DM27S6E	IK	JNDJPKHYZWRRIS-UHFFFAOYSA-N
DM27S6E	IU	1-[4-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-(propan-2-ylamino)propan-2-ol
DM27S6E	CA	CAS 94651-09-9
DM27S6E	CB	CHEBI:135377
DM27S6E	DE	Discovery agent

DMP6BU3	ID	DMP6BU3
DMP6BU3	DN	Ciclosporin
DMP6BU3	HS	Investigative
DMP6BU3	SN	Cyclosporine A; CSA; CsA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin; Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine A; Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin
DMP6BU3	CP	Sandoz
DMP6BU3	TC	Antiviral Agents
DMP6BU3	DT	Protein/peptide drug
DMP6BU3	PC	24883466
DMP6BU3	MW	1202.6
DMP6BU3	FM	C62H111N11O12
DMP6BU3	IC	InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1
DMP6BU3	CS	CC[C@@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMP6BU3	IK	PMATZTZNYRCHOR-VJRYSDSKSA-N
DMP6BU3	IU	(3R,6S,9S,12S,15S,18R,21S,24S,30R,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMP6BU3	CA	CAS 59865-13-3
DMP6BU3	DE	Psoriasis vulgaris; Xerophthalmia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMK6YOP	ID	DMK6YOP
DMK6YOP	DN	CID1172084
DMK6YOP	HS	Investigative
DMK6YOP	SN	CID 1172084
DMK6YOP	DT	Small molecular drug
DMK6YOP	PC	1172084
DMK6YOP	MW	479.6
DMK6YOP	FM	C23H18FN5O2S2
DMK6YOP	IC	InChI=1S/C23H18FN5O2S2/c1-13-9-15-5-8-17(31-2)10-19(15)29-21(13)27-28-23(29)33-12-20(30)26-22-25-18(11-32-22)14-3-6-16(24)7-4-14/h3-11H,12H2,1-2H3,(H,25,26,30)
DMK6YOP	CS	CC1=CC2=C(C=C(C=C2)OC)N3C1=NN=C3SCC(=O)NC4=NC(=CS4)C5=CC=C(C=C5)F
DMK6YOP	IK	NQAXYXKWUOWLNN-UHFFFAOYSA-N
DMK6YOP	IU	N-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-2-[(8-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinolin-1-yl)sulfanyl]acetamide
DMK6YOP	DE	Discovery agent

DMLWZRT	ID	DMLWZRT
DMLWZRT	DN	CID16020046
DMLWZRT	HS	Investigative
DMLWZRT	SN	CID 16020046
DMLWZRT	DT	Small molecular drug
DMLWZRT	PC	16020046
DMLWZRT	MW	425.4
DMLWZRT	FM	C25H19N3O4
DMLWZRT	IC	InChI=1S/C25H19N3O4/c1-14-5-7-15(8-6-14)21-20-22(27-26-21)24(30)28(18-11-9-16(10-12-18)25(31)32)23(20)17-3-2-4-19(29)13-17/h2-13,23,29H,1H3,(H,26,27)(H,31,32)
DMLWZRT	CS	CC1=CC=C(C=C1)C2=NNC3=C2C(N(C3=O)C4=CC=C(C=C4)C(=O)O)C5=CC(=CC=C5)O
DMLWZRT	IK	VGUQVYZXABOXCX-UHFFFAOYSA-N
DMLWZRT	IU	4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-c]pyrazol-5-yl]benzoic acid
DMLWZRT	CA	CAS 834903-43-4
DMLWZRT	DE	Discovery agent

DMP6I98	ID	DMP6I98
DMP6I98	DN	CID16197121
DMP6I98	HS	Investigative
DMP6I98	SN	MLS000766570; SMR000441998; CID16197121; GTPL8579; CHEMBL1302410; cid_16197121; BDBM114082; HMS2226B08; (4R,5S,6S)-4-(1-benzothiophen-3-yl)-6-ethoxy-5-(3-hydroxypropyl)-N-phenyl-5,6-dihydro-4H-pyran-2-carboxamide; (2S,3S,4R)-4-(benzothiophen-3-yl)-2-ethoxy-3-(3-hydroxypropyl)-N-phenyl-3,4-dihydro-2H-pyran-6-carboxamide; (2S,3S,4R)-4-(1-benzothiophen-3-yl)-2-ethoxy-3-(3-oxidanylpropyl)-N-phenyl-3,4-dihydro-2H-pyran-6-carboxamide
DMP6I98	DT	Small molecular drug
DMP6I98	PC	16197121
DMP6I98	MW	437.6
DMP6I98	FM	C25H27NO4S
DMP6I98	IC	InChI=1S/C25H27NO4S/c1-2-29-25-19(12-8-14-27)20(21-16-31-23-13-7-6-11-18(21)23)15-22(30-25)24(28)26-17-9-4-3-5-10-17/h3-7,9-11,13,15-16,19-20,25,27H,2,8,12,14H2,1H3,(H,26,28)/t19-,20+,25-/m0/s1
DMP6I98	CS	CCO[C@@H]1[C@H]([C@@H](C=C(O1)C(=O)NC2=CC=CC=C2)C3=CSC4=CC=CC=C43)CCCO
DMP6I98	IK	DPIFUIZFNOZKRB-DFIYOIEZSA-N
DMP6I98	IU	(2S,3S,4R)-4-(1-benzothiophen-3-yl)-2-ethoxy-3-(3-hydroxypropyl)-N-phenyl-3,4-dihydro-2H-pyran-6-carboxamide
DMP6I98	DE	Discovery agent

DMEGZY7	ID	DMEGZY7
DMEGZY7	DN	CID1792197
DMEGZY7	HS	Investigative
DMEGZY7	SN	CID 1792197
DMEGZY7	DT	Small molecular drug
DMEGZY7	PC	1792197
DMEGZY7	MW	481.6
DMEGZY7	FM	C24H23N3O4S2
DMEGZY7	IC	InChI=1S/C24H23N3O4S2/c1-27(20-9-4-3-5-10-20)33(29,30)21-15-13-19(14-16-21)25-24(32)26-23(28)17-12-18-8-6-7-11-22(18)31-2/h3-17H,1-2H3,(H2,25,26,28,32)/b17-12+
DMEGZY7	CS	CN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)NC(=S)NC(=O)/C=C/C3=CC=CC=C3OC
DMEGZY7	IK	XOMQERYBMDFBAG-SFQUDFHCSA-N
DMEGZY7	IU	(E)-3-(2-methoxyphenyl)-N-[[4-[methyl(phenyl)sulfamoyl]phenyl]carbamothioyl]prop-2-enamide
DMEGZY7	DE	Discovery agent

DMA3F7S	ID	DMA3F7S
DMA3F7S	DN	CID2440433
DMA3F7S	HS	Investigative
DMA3F7S	SN	CID 2440433
DMA3F7S	DT	Small molecular drug
DMA3F7S	PC	2440433
DMA3F7S	MW	470.6
DMA3F7S	FM	C25H34N4O3S
DMA3F7S	IC	InChI=1S/C25H34N4O3S/c1-19-8-7-9-23(20(19)2)28-14-16-29(17-15-28)25(30)22-18-21(33(31,32)26(3)4)10-11-24(22)27-12-5-6-13-27/h7-11,18H,5-6,12-17H2,1-4H3
DMA3F7S	CS	CC1=C(C(=CC=C1)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)S(=O)(=O)N(C)C)N4CCCC4)C
DMA3F7S	IK	VRSJAHQGJHDACS-UHFFFAOYSA-N
DMA3F7S	IU	3-[4-(2,3-dimethylphenyl)piperazine-1-carbonyl]-N,N-dimethyl-4-pyrrolidin-1-ylbenzenesulfonamide
DMA3F7S	CB	CHEBI:93272
DMA3F7S	DE	Discovery agent

DMSHIQA	ID	DMSHIQA
DMSHIQA	DN	CID755673
DMSHIQA	HS	Investigative
DMSHIQA	SN	CID755673; 521937-07-5; CID 755673; cid-755673; MLS000043346; 7-Hydroxy-2,3,4,5-tetrahydro-1H-benzofuro[2,3-c]azepin-1-one; 7-hydroxy-2,3,4,5-tetrahydro-1H-[1]benzofuro[2,3-c]azepin-1-one; SMR000019965; 7-hydroxy-2,3,4,5-tetrahydro-[1]benzofuro[2,3-c]azepin-1-one; 2,3,4,5-Tetrahydro-7-hydroxy-1H-benzofuro[2,3-c]azepin-1-one; 3-Hydroxy-5,6,7,8-tetrahydro-10-oxa-8-aza-benzo[a]azulen-9-one; AC1LFLHI; SCHEMBL9904268; cid_755673; REGID_for_CID_755673; CHEMBL1450770; BDBM32334; CTK4J5567; CHEBI:92059; KS-00001CWT; EX-A393
DMSHIQA	DT	Small molecular drug
DMSHIQA	PC	755673
DMSHIQA	MW	217.22
DMSHIQA	FM	C12H11NO3
DMSHIQA	IC	InChI=1S/C12H11NO3/c14-7-3-4-10-9(6-7)8-2-1-5-13-12(15)11(8)16-10/h3-4,6,14H,1-2,5H2,(H,13,15)
DMSHIQA	CS	C1CC2=C(C(=O)NC1)OC3=C2C=C(C=C3)O
DMSHIQA	IK	AACFPJSJOWQNBN-UHFFFAOYSA-N
DMSHIQA	IU	7-hydroxy-2,3,4,5-tetrahydro-[1]benzofuro[2,3-c]azepin-1-one
DMSHIQA	CA	CAS 521937-07-5
DMSHIQA	CB	CHEBI:92059
DMSHIQA	DE	Solid tumour/cancer

DMP35OM	ID	DMP35OM
DMP35OM	DN	CIFEA
DMP35OM	HS	Investigative
DMP35OM	SN	cyclohexylmethyl-indenofurane-ethylacetamide
DMP35OM	DT	Small molecular drug
DMP35OM	PC	53238181
DMP35OM	MW	339.5
DMP35OM	FM	C22H29NO2
DMP35OM	IC	InChI=1S/C22H29NO2/c1-15(24)23-11-9-19-18(13-16-5-3-2-4-6-16)14-17-7-8-21-20(22(17)19)10-12-25-21/h7-8,16H,2-6,9-14H2,1H3,(H,23,24)
DMP35OM	CS	CC(=O)NCCC1=C(CC2=C1C3=C(C=C2)OCC3)CC4CCCCC4
DMP35OM	IK	MMMAALHYEKMNHU-UHFFFAOYSA-N
DMP35OM	IU	N-[2-[7-(cyclohexylmethyl)-2,6-dihydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]acetamide
DMP35OM	DE	Discovery agent

DMBVIKY	ID	DMBVIKY
DMBVIKY	DN	Cilostamide
DMBVIKY	HS	Investigative
DMBVIKY	SN	cilostamide; 68550-75-4; ciloalamide; OPC 3689; Cilostamide [INN]; N-Cyclohexyl-N-methyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide; Cilostamidum [INN-Latin]; Cilostamida [INN-Spanish]; UNII-45S5605Q18; OPC 3869; CHEMBL34431; NCGC00015269-03; N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide; 45S5605Q18; Butanamide, N-cyclohexyl-4-((1,2-dihydro-2-oxo-6-quinolinyl)oxy)-N-methyl-; N-Cyclohexyl-N-methyl-4-((2-oxo-1,2-dihydroquinolin-6-yl)oxy)butanamide; DSSTox_RID_80698; DSSTox_CID_25140; DSSTox_GSID_45140
DMBVIKY	DT	Small molecular drug
DMBVIKY	PC	2753
DMBVIKY	MW	342.4
DMBVIKY	FM	C20H26N2O3
DMBVIKY	IC	InChI=1S/C20H26N2O3/c1-22(16-6-3-2-4-7-16)20(24)8-5-13-25-17-10-11-18-15(14-17)9-12-19(23)21-18/h9-12,14,16H,2-8,13H2,1H3,(H,21,23)
DMBVIKY	CS	CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC(=O)C=C3
DMBVIKY	IK	UIAYVIIHMORPSJ-UHFFFAOYSA-N
DMBVIKY	IU	N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide
DMBVIKY	CA	CAS 68550-75-4
DMBVIKY	CB	CHEBI:92503
DMBVIKY	DE	Discovery agent

DM6TJFU	ID	DM6TJFU
DM6TJFU	DN	CINANSERIN
DM6TJFU	HS	Investigative
DM6TJFU	SN	CINANSERIN; Cinanserin [INN]; 1166-34-3; Cinanserine [INN-French]; Cinanserinum [INN-Latin]; UNII-KI6J9OY7A3; Cinanserina [INN-Spanish]; KI6J9OY7A3; CHEMBL18786; NCGC00024599-02; 2-Propenamide, N-(2-((3-(dimethylamino)propyl)thio)phenyl)-3-phenyl-; DSSTox_RID_81031; DSSTox_CID_25653; DSSTox_GSID_45653; Cinanserinum; Cinanserina; Cinanserine; CAS-1166-34-3; Cinanserin Monohydrochloride; Cinaserin; SQ 16167; SQ-16,167; SQ-10,643; AC1NUDS4; Biomol-NT_000092; 2'-((3-Dimethylaminopropyl)thio)cinnamanilide; SCHEMBL571561; BPBio1_001097
DM6TJFU	DT	Small molecular drug
DM6TJFU	PC	5475158
DM6TJFU	MW	340.5
DM6TJFU	FM	C20H24N2OS
DM6TJFU	IC	InChI=1S/C20H24N2OS/c1-22(2)15-8-16-24-19-12-7-6-11-18(19)21-20(23)14-13-17-9-4-3-5-10-17/h3-7,9-14H,8,15-16H2,1-2H3,(H,21,23)/b14-13+
DM6TJFU	CS	CN(C)CCCSC1=CC=CC=C1NC(=O)/C=C/C2=CC=CC=C2
DM6TJFU	IK	RSUVYMGADVXGOU-BUHFOSPRSA-N
DM6TJFU	IU	(E)-N-[2-[3-(dimethylamino)propylsulfanyl]phenyl]-3-phenylprop-2-enamide
DM6TJFU	CA	CAS 1166-34-3
DM6TJFU	CB	CHEBI:92281
DM6TJFU	DE	Discovery agent

DMOJ917	ID	DMOJ917
DMOJ917	DN	Cinchoninic acid
DMOJ917	HS	Investigative
DMOJ917	SN	Quinoline-4-carboxylic acid; 486-74-8; 4-Quinolinecarboxylic acid; CINCHONINIC ACID; 4-Carboxyquinoline; Cinchonic acid; USAF D-2; NSC 13138; EINECS 207-640-1; MFCD00006782; Quinoline-4-Carboxylicacid; BRN 0005224; 4-QuinolinecarboxylicAcid; Cinchoninsaure; PubChem5843; Chinolin-4-carbonsaeure; AC1L1USE; Maybridge1_002367; quinoline4-carboxylic acid; 4-quinoline carboxylic acid; ACMC-1AM77; WLN: T66 BNJ EVQ; Oprea1_466681; KSC171Q1F; 5-22-03-00204 (Beilstein Handbook Reference); SCHEMBL228713; DivK1c_001119; AC1Q72O9; CHEBI:18311
DMOJ917	DT	Small molecular drug
DMOJ917	PC	10243
DMOJ917	MW	173.17
DMOJ917	FM	C10H7NO2
DMOJ917	IC	InChI=1S/C10H7NO2/c12-10(13)8-5-6-11-9-4-2-1-3-7(8)9/h1-6H,(H,12,13)
DMOJ917	CS	C1=CC=C2C(=C1)C(=CC=N2)C(=O)O
DMOJ917	IK	VQMSRUREDGBWKT-UHFFFAOYSA-N
DMOJ917	IU	quinoline-4-carboxylic acid
DMOJ917	CA	CAS 486-74-8
DMOJ917	CB	CHEBI:18311
DMOJ917	DE	Discovery agent

DMZDUXG	ID	DMZDUXG
DMZDUXG	DN	cinnamaldehyde
DMZDUXG	HS	Investigative
DMZDUXG	SN	cinnamic aldehyde
DMZDUXG	DT	Small molecular drug
DMZDUXG	PC	637511
DMZDUXG	MW	132.16
DMZDUXG	FM	C9H8O
DMZDUXG	IC	InChI=1S/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4+
DMZDUXG	CS	C1=CC=C(C=C1)/C=C/C=O
DMZDUXG	IK	KJPRLNWUNMBNBZ-QPJJXVBHSA-N
DMZDUXG	IU	(E)-3-phenylprop-2-enal
DMZDUXG	CA	CAS 104-55-2
DMZDUXG	CB	CHEBI:16731
DMZDUXG	DE	Discovery agent

DM340FH	ID	DM340FH
DM340FH	DN	Cinnamic acid
DM340FH	HS	Investigative
DM340FH	SN	CINNAMIC ACID; TRANS-CINNAMIC ACID; 140-10-3; 621-82-9; (E)-Cinnamic acid; trans-3-Phenylacrylic acid; 3-Phenylacrylic acid; Phenylacrylic acid; Zimtsaeure; (2E)-3-phenylprop-2-enoic acid; 3-phenylprop-2-enoic acid; E-Cinnamic Acid; 3-Phenylpropenoic acid; (E)-3-phenylprop-2-enoic acid; trans-beta-Carboxystyrene; Benzenepropenoic acid; trans-Cinnamate; (E)-3-Phenyl-2-propenoic acid; (E)-cinnamate; Benzeneacrylic acid; trans-3-Phenyl-2-propenoic acid; Cinnamylic acid; Cinnamic acid, (E)-; t-Cinnamic acid; (2E)-3-Phenyl-2-propenoic 
DM340FH	DT	Small molecular drug
DM340FH	PC	444539
DM340FH	MW	148.16
DM340FH	FM	C9H8O2
DM340FH	IC	InChI=1S/C9H8O2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-7H,(H,10,11)/b7-6+
DM340FH	CS	C1=CC=C(C=C1)/C=C/C(=O)O
DM340FH	IK	WBYWAXJHAXSJNI-VOTSOKGWSA-N
DM340FH	IU	(E)-3-phenylprop-2-enoic acid
DM340FH	CA	CAS 140-10-3
DM340FH	CB	CHEBI:35697
DM340FH	DE	Discovery agent

DMZ2WS9	ID	DMZ2WS9
DMZ2WS9	DN	CIP-137401
DMZ2WS9	HS	Investigative
DMZ2WS9	SN	CIP-1374; MEK inhibitors, Cheminpharma; MEK inhibitors (cancer), AlloStem
DMZ2WS9	CP	Cheminpharma LLC
DMZ2WS9	DE	Solid tumour/cancer

DM9N8WM	ID	DM9N8WM
DM9N8WM	DN	Ciproxifan
DM9N8WM	HS	Investigative
DM9N8WM	SN	ciproxifan; 184025-18-1; FUB-359; FUB 359; FUB359; UNII-5EVQ7IRG99; 5EVQ7IRG99; CHEMBL14638; ACQBHJXEAYTHCY-UHFFFAOYSA-N; cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone; (4-(3-(1H-imidazol-4-yl)propoxy)phenyl)(cyclopropyl)methanone; Ciproxifan; FUB 359; Methanone, cyclopropyl(4-(3-(1H-imidazol-5-yl)propoxy)phenyl)-; Ciproxifan (FUB-359); AC1O4Y0P; GTPL1265; SCHEMBL3335184; BDBM27213; EX-A077; DTXSID50171532; cyclopropyl-(4-(3-1H-imidazol-4-yl)propyloxyphenyl)ketone; CHEBI:125467; MolPort-027-720-958; ZINC1892860
DM9N8WM	DT	Small molecular drug
DM9N8WM	PC	6422124
DM9N8WM	MW	270.33
DM9N8WM	FM	C16H18N2O2
DM9N8WM	IC	InChI=1S/C16H18N2O2/c19-16(12-3-4-12)13-5-7-15(8-6-13)20-9-1-2-14-10-17-11-18-14/h5-8,10-12H,1-4,9H2,(H,17,18)
DM9N8WM	CS	C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3
DM9N8WM	IK	ACQBHJXEAYTHCY-UHFFFAOYSA-N
DM9N8WM	IU	cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone
DM9N8WM	CA	CAS 184025-18-1
DM9N8WM	CB	CHEBI:125467
DM9N8WM	DE	Obesity; Dementia

DMU6JOK	ID	DMU6JOK
DMU6JOK	DN	cirazoline
DMU6JOK	HS	Investigative
DMU6JOK	SN	cirazoline; Cirazoline [INN]; Cirazolinum [INN-Latin]; Cirazolina [INN-Spanish]; UNII-QK318GVY3Y; 59939-16-1; LD-3098; QK318GVY3Y; CHEMBL13852; NCGC00015196-04; 2-((o-Cyclopropylphenoxy)methyl)-2-imidazoline; DSSTox_CID_25131; DSSTox_RID_80692; DSSTox_GSID_45131; Cirazolina; Cirazolinum; 1H-Imidazole, 2-((2-cyclopropylphenoxy)methyl)-4,5-dihydro-; 2-[(2-cyclopropylphenoxy)methyl]-4,5-dihydro-1H-imidazole; CAS-59939-16-1; LD 3098; Tocris-0888; Lopac-C-223; AC1L1EEZ; Lopac0_000354; KBioGR_000306; BSPBio_001586; KBioSS_000306; GTPL515
DMU6JOK	DT	Small molecular drug
DMU6JOK	PC	2765
DMU6JOK	MW	216.28
DMU6JOK	FM	C13H16N2O
DMU6JOK	IC	InChI=1S/C13H16N2O/c1-2-4-12(11(3-1)10-5-6-10)16-9-13-14-7-8-15-13/h1-4,10H,5-9H2,(H,14,15)
DMU6JOK	CS	C1CC1C2=CC=CC=C2OCC3=NCCN3
DMU6JOK	IK	YAORIDZYZDUZCM-UHFFFAOYSA-N
DMU6JOK	IU	2-[(2-cyclopropylphenoxy)methyl]-4,5-dihydro-1H-imidazole
DMU6JOK	CA	CAS 59939-16-1
DMU6JOK	CB	CHEBI:92950
DMU6JOK	DE	Discovery agent

DMM10TG	ID	DMM10TG
DMM10TG	DN	Cirsimarin
DMM10TG	HS	Investigative
DMM10TG	SN	Cirsimarin; Cirsitakaoside; 13020-19-4; CHEMBL517637; 2-(4-(beta-D-Glucopyranosyloxy)phenyl)-5-hydroxy-6,7-dimethoxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(4-(beta-D-glucopyranosyloxy)phenyl)-5-hydroxy-6,7-dimethoxy-; AC1L4LVL; AC1Q6CLV; SCHEMBL2016369; MolPort-019-937-034; BDBM50250467; ZINC31459932; MCULE-1339456605; 4-(5-hydroxy-6,7-dimethoxy-4-oxo-4h-chromen-2-yl)phenyl; LS-39681
DMM10TG	DT	Small molecular drug
DMM10TG	PC	159460
DMM10TG	MW	476.4
DMM10TG	FM	C23H24O11
DMM10TG	IC	InChI=1S/C23H24O11/c1-30-15-8-14-17(19(27)22(15)31-2)12(25)7-13(33-14)10-3-5-11(6-4-10)32-23-21(29)20(28)18(26)16(9-24)34-23/h3-8,16,18,20-21,23-24,26-29H,9H2,1-2H3/t16-,18-,20+,21-,23-/m1/s1
DMM10TG	CS	COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)OC
DMM10TG	IK	RETJLKUBHXTIGH-FZFRBNDOSA-N
DMM10TG	IU	5-hydroxy-6,7-dimethoxy-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
DMM10TG	CA	CAS 13020-19-4
DMM10TG	DE	Discovery agent

DMA3N9R	ID	DMA3N9R
DMA3N9R	DN	CIRSIMARITIN
DMA3N9R	HS	Investigative
DMA3N9R	SN	Cirsimaritin; 6601-62-3; Scrophulein; Skrofulein; 4',5-Dihydroxy-6,7-dimethoxyflavone; 7-Methylcapillarisin; cirsimartin; 6,7-Dimethoxyscutellarein; CHEMBL348436; 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-chromen-4-one; CHEBI:81337; 4H-1-Benzopyran-4-one, 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-; 6-Methoxygenkwanin; Flavone, 4',5-dihydroxy-6,7-dimethoxy-; AC1Q6AIG; AC1L4MLD; MLS000876998; cid_188323; MEGxp0_000498; SCHEMBL1663486; CTK2F4258; ACon1_000850; DTXSID00216220; PubChem SID: 26725076; MolPort-000-779-119
DMA3N9R	DT	Small molecular drug
DMA3N9R	PC	188323
DMA3N9R	MW	314.29
DMA3N9R	FM	C17H14O6
DMA3N9R	IC	InChI=1S/C17H14O6/c1-21-14-8-13-15(16(20)17(14)22-2)11(19)7-12(23-13)9-3-5-10(18)6-4-9/h3-8,18,20H,1-2H3
DMA3N9R	CS	COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC=C(C=C3)O)O)OC
DMA3N9R	IK	ZIIAJIWLQUVGHB-UHFFFAOYSA-N
DMA3N9R	IU	5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxychromen-4-one
DMA3N9R	CA	CAS 6601-62-3
DMA3N9R	CB	CHEBI:81337
DMA3N9R	DE	Discovery agent

DMWX6J0	ID	DMWX6J0
DMWX6J0	DN	Cis-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine
DMWX6J0	HS	Investigative
DMWX6J0	SN	CHEMBL469024; cis-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine; SCHEMBL16019175; ZINC13559955
DMWX6J0	DT	Small molecular drug
DMWX6J0	PC	11423691
DMWX6J0	MW	151.18
DMWX6J0	FM	C9H10FN
DMWX6J0	IC	InChI=1S/C9H10FN/c10-9(6-8(9)11)7-4-2-1-3-5-7/h1-5,8H,6,11H2/t8-,9+/m0/s1
DMWX6J0	CS	C1[C@@H]([C@@]1(C2=CC=CC=C2)F)N
DMWX6J0	IK	UJTQURLMCYMANH-DTWKUNHWSA-N
DMWX6J0	IU	(1S,2R)-2-fluoro-2-phenylcyclopropan-1-amine
DMWX6J0	DE	Discovery agent

DMV3RYK	ID	DMV3RYK
DMV3RYK	DN	Cis-[PtCl(NH3)2(N7-acyclovir)]+
DMV3RYK	HS	Investigative
DMV3RYK	DT	Small molecular drug
DMV3RYK	PC	56603759
DMV3RYK	DE	Discovery agent

DMP3F0D	ID	DMP3F0D
DMP3F0D	DN	Cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea
DMP3F0D	HS	Investigative
DMP3F0D	SN	CHEMBL242257; CHEMBL395714; cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea; SCHEMBL3260841; SCHEMBL1066689; SCHEMBL1065034; SCHEMBL1065036; YHZXOUHNBSOYQD-QVTUNDJTSA-N; YHZXOUHNBSOYQD-PIYFJZFMSA-N; BDBM50217474; BDBM50217447; AKOS031057010; AKOS009538033; trans-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea; cis-1-(4-Hydroxy-cyclohexyl)-3-tricyclo[3.3.1.13,7]decan-1-yl-urea
DMP3F0D	DT	Small molecular drug
DMP3F0D	PC	11529433
DMP3F0D	MW	292.4
DMP3F0D	FM	C17H28N2O2
DMP3F0D	IC	InChI=1S/C17H28N2O2/c20-15-3-1-14(2-4-15)18-16(21)19-17-8-11-5-12(9-17)7-13(6-11)10-17/h11-15,20H,1-10H2,(H2,18,19,21)
DMP3F0D	CS	C1CC(CCC1NC(=O)NC23CC4CC(C2)CC(C4)C3)O
DMP3F0D	IK	YHZXOUHNBSOYQD-UHFFFAOYSA-N
DMP3F0D	IU	1-(1-adamantyl)-3-(4-hydroxycyclohexyl)urea
DMP3F0D	DE	Discovery agent

DM8NX3Q	ID	DM8NX3Q
DM8NX3Q	DN	Cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea
DM8NX3Q	HS	Investigative
DM8NX3Q	SN	CHEMBL397669; CHEMBL395987; cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea; SCHEMBL3262525; SCHEMBL3262523; BDBM50217464; BDBM50217445
DM8NX3Q	DT	Small molecular drug
DM8NX3Q	PC	16756626
DM8NX3Q	MW	388.6
DM8NX3Q	FM	C24H40N2O2
DM8NX3Q	IC	InChI=1S/C24H40N2O2/c27-23(26-24-13-18-10-19(14-24)12-20(11-18)15-24)25-21-6-8-22(9-7-21)28-16-17-4-2-1-3-5-17/h17-22H,1-16H2,(H2,25,26,27)
DM8NX3Q	CS	C1CCC(CC1)COC2CCC(CC2)NC(=O)NC34CC5CC(C3)CC(C5)C4
DM8NX3Q	IK	IWFDYFIMYQSEQD-UHFFFAOYSA-N
DM8NX3Q	IU	1-(1-adamantyl)-3-[4-(cyclohexylmethoxy)cyclohexyl]urea
DM8NX3Q	DE	Discovery agent

DMVRF9H	ID	DMVRF9H
DMVRF9H	DN	Cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine
DMVRF9H	HS	Investigative
DMVRF9H	SN	CHEMBL460269; cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine
DMVRF9H	DT	Small molecular drug
DMVRF9H	PC	11390419
DMVRF9H	MW	185.62
DMVRF9H	FM	C9H9ClFN
DMVRF9H	IC	InChI=1S/C9H9ClFN/c10-7-3-1-6(2-4-7)9(11)5-8(9)12/h1-4,8H,5,12H2/t8-,9+/m1/s1
DMVRF9H	CS	C1[C@H]([C@]1(C2=CC=C(C=C2)Cl)F)N
DMVRF9H	IK	UTADHPUNQUNGFZ-BDAKNGLRSA-N
DMVRF9H	IU	(1R,2S)-2-(4-chlorophenyl)-2-fluorocyclopropan-1-amine
DMVRF9H	DE	Discovery agent

DMPZ1LY	ID	DMPZ1LY
DMPZ1LY	DN	Cis-2-(para-fluorophenyl)cyclopropylamine
DMPZ1LY	HS	Investigative
DMPZ1LY	SN	CHEMBL446771; cis-2-(para-fluorophenyl)cyclopropylamine
DMPZ1LY	DT	Small molecular drug
DMPZ1LY	PC	11401479
DMPZ1LY	MW	169.17
DMPZ1LY	FM	C9H9F2N
DMPZ1LY	IC	InChI=1S/C9H9F2N/c10-7-3-1-6(2-4-7)9(11)5-8(9)12/h1-4,8H,5,12H2/t8-,9+/m1/s1
DMPZ1LY	CS	C1[C@H]([C@]1(C2=CC=C(C=C2)F)F)N
DMPZ1LY	IK	JCUGJWBVZNWAIJ-BDAKNGLRSA-N
DMPZ1LY	IU	(1R,2S)-2-fluoro-2-(4-fluorophenyl)cyclopropan-1-amine
DMPZ1LY	DE	Discovery agent

DMJ3HG9	ID	DMJ3HG9
DMJ3HG9	DN	Cis-2,6-dimethyl-1-methyl sulfonyl piperidine
DMJ3HG9	HS	Investigative
DMJ3HG9	SN	CHEMBL576005; cis-2,6-dimethyl-1-methyl sulfonyl piperidine
DMJ3HG9	DT	Small molecular drug
DMJ3HG9	PC	44245252
DMJ3HG9	MW	191.29
DMJ3HG9	FM	C8H17NO2S
DMJ3HG9	IC	InChI=1S/C8H17NO2S/c1-7-5-4-6-8(2)9(7)12(3,10)11/h7-8H,4-6H2,1-3H3/t7-,8+
DMJ3HG9	CS	C[C@@H]1CCC[C@@H](N1S(=O)(=O)C)C
DMJ3HG9	IK	NDRNIFSBRLCSCZ-OCAPTIKFSA-N
DMJ3HG9	IU	(2R,6S)-2,6-dimethyl-1-methylsulfonylpiperidine
DMJ3HG9	DE	Discovery agent

DMF10WT	ID	DMF10WT
DMF10WT	DN	Cis-2-aminocyclohexylcarbamoylphosphonic acid
DMF10WT	HS	Investigative
DMF10WT	SN	cis-ACCP; cis-2-aminocyclohexylcarbamoylphosphonic acid; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634
DMF10WT	DT	Small molecular drug
DMF10WT	PC	44457233
DMF10WT	MW	222.18
DMF10WT	FM	C7H15N2O4P
DMF10WT	IC	InChI=1S/C7H15N2O4P/c8-5-3-1-2-4-6(5)9-7(10)14(11,12)13/h5-6H,1-4,8H2,(H,9,10)(H2,11,12,13)/t5-,6+/m0/s1
DMF10WT	CS	C1CC[C@H]([C@H](C1)N)NC(=O)P(=O)(O)O
DMF10WT	IK	XHCXISPZIHYKQD-NTSWFWBYSA-N
DMF10WT	IU	[(1R,2S)-2-aminocyclohexyl]carbamoylphosphonic acid
DMF10WT	DE	Discovery agent

DMNG9B2	ID	DMNG9B2
DMNG9B2	DN	Cis-2-Fluoro-2-(4-methoxyphenyl)cyclopropylamine
DMNG9B2	HS	Investigative
DMNG9B2	SN	CHEMBL468854; cis-2-Fluoro-2-(4-methoxyphenyl)cyclopropylamine
DMNG9B2	DT	Small molecular drug
DMNG9B2	PC	44577747
DMNG9B2	MW	181.21
DMNG9B2	FM	C10H12FNO
DMNG9B2	IC	InChI=1S/C10H12FNO/c1-13-8-4-2-7(3-5-8)10(11)6-9(10)12/h2-5,9H,6,12H2,1H3/t9-,10+/m1/s1
DMNG9B2	CS	COC1=CC=C(C=C1)[C@]2(C[C@H]2N)F
DMNG9B2	IK	IFVJHRWUMHINNO-ZJUUUORDSA-N
DMNG9B2	IU	(1R,2S)-2-fluoro-2-(4-methoxyphenyl)cyclopropan-1-amine
DMNG9B2	DE	Discovery agent

DMFSPHE	ID	DMFSPHE
DMFSPHE	DN	Cis-2-fluoro-2-phenylcyclopropanamine
DMFSPHE	HS	Investigative
DMFSPHE	SN	CHEMBL466769; cis-2-fluoro-2-phenylcyclopropanamine; SCHEMBL16010002; ZINC13584960; BDBM50261916; AKOS027415699; 784133-88-6; KB-276212
DMFSPHE	DT	Small molecular drug
DMFSPHE	PC	12098585
DMFSPHE	MW	151.18
DMFSPHE	FM	C9H10FN
DMFSPHE	IC	InChI=1S/C9H10FN/c10-9(6-8(9)11)7-4-2-1-3-5-7/h1-5,8H,6,11H2/t8-,9+/m1/s1
DMFSPHE	CS	C1[C@H]([C@]1(C2=CC=CC=C2)F)N
DMFSPHE	IK	UJTQURLMCYMANH-BDAKNGLRSA-N
DMFSPHE	IU	(1R,2S)-2-fluoro-2-phenylcyclopropan-1-amine
DMFSPHE	DE	Discovery agent

DMKZ32J	ID	DMKZ32J
DMKZ32J	DN	Cis-2-phenylcyclopropylamine
DMKZ32J	HS	Investigative
DMKZ32J	SN	cis-2-phenylcyclopropylamine; Tranylcypromine, cis-; CHEMBL467794; 13531-35-6; cis-Cypromine; CIS-1-AMINO-2-PHENYLCYCLOPROPANE; DL-cis-2-Phenylcyclopropylamine; Cyclopropanamine, 2-phenyl-, cis-; (+/-)-cis-2-Phenylcyclopropylamine; AC1ODZ9B; Tranylcypromine related compound A free base; Cyclopropanamine, 2-phenyl-, (1R,2R)-rel-; cis-2-Phenylcyclopropanamine; SCHEMBL1720497; CTK0F4162; DTXSID80159308; (-) cis-2-phenylcyclopropylamine; AELCINSCMGFISI-RKDXNWHRSA-N; (1R,2R)-2-Phenylcyclopropanamine; ZINC1639567; BDBM50261814
DMKZ32J	DT	Small molecular drug
DMKZ32J	PC	6971118
DMKZ32J	MW	133.19
DMKZ32J	FM	C9H11N
DMKZ32J	IC	InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9-/m1/s1
DMKZ32J	CS	C1[C@@H]([C@@H]1N)C2=CC=CC=C2
DMKZ32J	IK	AELCINSCMGFISI-RKDXNWHRSA-N
DMKZ32J	IU	(1R,2R)-2-phenylcyclopropan-1-amine
DMKZ32J	CA	CAS 13531-35-6
DMKZ32J	DE	Discovery agent

DMQ0EA7	ID	DMQ0EA7
DMQ0EA7	DN	cis-3-ACPBPA
DMQ0EA7	HS	Investigative
DMQ0EA7	SN	3-amino-cyclopentenylbutylphosphonic acid
DMQ0EA7	DT	Small molecular drug
DMQ0EA7	PC	23399992
DMQ0EA7	MW	205.23
DMQ0EA7	FM	C9H20NO2P
DMQ0EA7	IC	InChI=1S/C9H20NO2P/c1-2-3-6-13(11,12)9-5-4-8(10)7-9/h8-9H,2-7,10H2,1H3,(H,11,12)/t8-,9+/m0/s1
DMQ0EA7	CS	CCCCP(=O)([C@@H]1CC[C@@H](C1)N)O
DMQ0EA7	IK	UQGQAMARAMOEID-DTWKUNHWSA-N
DMQ0EA7	IU	[(1R,3S)-3-aminocyclopentyl]-butylphosphinic acid
DMQ0EA7	DE	Discovery agent

DMTH4BG	ID	DMTH4BG
DMTH4BG	DN	Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine
DMTH4BG	HS	Investigative
DMTH4BG	SN	CHEMBL530334; cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine
DMTH4BG	DT	Small molecular drug
DMTH4BG	PC	44560576
DMTH4BG	MW	225.28
DMTH4BG	FM	C15H15NO
DMTH4BG	IC	InChI=1S/C15H15NO/c16-14-10-15(13-9-5-4-8-12(13)14)17-11-6-2-1-3-7-11/h1-9,14-15H,10,16H2/t14-,15+/m1/s1
DMTH4BG	CS	C1[C@H](C2=CC=CC=C2[C@H]1OC3=CC=CC=C3)N
DMTH4BG	IK	AFPFOKAYUJMERG-CABCVRRESA-N
DMTH4BG	IU	(1R,3S)-3-phenoxy-2,3-dihydro-1H-inden-1-amine
DMTH4BG	DE	Discovery agent

DMX07BG	ID	DMX07BG
DMX07BG	DN	Cis-4-hydroxynipecotic acid
DMX07BG	HS	Investigative
DMX07BG	PC	172852
DMX07BG	MW	145.16
DMX07BG	FM	C6H11NO3
DMX07BG	IC	InChI=1S/C6H11NO3/c8-5-1-2-7-3-4(5)6(9)10/h4-5,7-8H,1-3H2,(H,9,10)/t4-,5+/m1/s1
DMX07BG	CS	C1CNC[C@H]([C@H]1O)C(=O)O
DMX07BG	IK	DAMFVOCECLPLSI-UHNVWZDZSA-N
DMX07BG	IU	(3R,4S)-4-hydroxypiperidine-3-carboxylic acid
DMX07BG	CA	CAS 71609-37-5
DMX07BG	DE	Discovery agent

DMRFTB5	ID	DMRFTB5
DMRFTB5	DN	Cis-4-hydroxytamoxifen
DMRFTB5	HS	Investigative
DMRFTB5	SN	Afimoxifene, E-isomer; E-4-Hydroxytamoxifen; AKE3PH0IML; SCHEMBL2132301; SCHEMBL640496; ZINC1530090; cis-4-Hydroxytamoxifen; cis/trans-4-Hydroxytamoxifen; (E)-4-Hydroxytamoxifen; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)-phenyl)-2-phenylbut-1-en-1-yl)phenol; 174592-47-3; 4-((1E)-1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; AC1NS1S8; ACM174592473; AKOS015894466; API0000886; BCP9000165; BCP9000243; CHEBI:92076; CHEMBL279301; CP-0071; DTXSID10169854; HY-16950B; UNII-AKE3PH0IML
DMRFTB5	PC	5352135
DMRFTB5	MW	387.5
DMRFTB5	FM	C26H29NO2
DMRFTB5	IC	TXUZVZSFRXZGTL-OCEACIFDSA-N
DMRFTB5	CS	CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
DMRFTB5	IK	1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25+
DMRFTB5	IU	4-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMRFTB5	CA	CAS 174592-47-3
DMRFTB5	CB	CHEBI:92076
DMRFTB5	DE	Discovery agent

DMQUB19	ID	DMQUB19
DMQUB19	DN	Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH
DMQUB19	HS	Investigative
DMQUB19	SN	cDADAE(8); cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH; CHEMBL375025; BDBM21125; (5S,8R,10Z,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid
DMQUB19	DT	Small molecular drug
DMQUB19	PC	16733485
DMQUB19	MW	551.6
DMQUB19	FM	C28H33N5O7
DMQUB19	IC	InChI=1S/C28H33N5O7/c29-20(14-18-10-12-19(34)13-11-18)25(36)32-21-8-4-5-9-22(28(39)40)33-27(38)23(15-17-6-2-1-3-7-17)31-24(35)16-30-26(21)37/h1-7,10-13,20-23,34H,8-9,14-16,29H2,(H,30,37)(H,31,35)(H,32,36)(H,33,38)(H,39,40)/b5-4-/t20-,21+,22+,23-/m0/s1
DMQUB19	CS	C1/C=C\\C[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]1NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CC=CC=C3)C(=O)O
DMQUB19	IK	VNZCTJLIVONUDE-HOJIFOFPSA-N
DMQUB19	IU	(5S,8R,10Z,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid
DMQUB19	DE	Discovery agent

DM75SO4	ID	DM75SO4
DM75SO4	DN	Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
DM75SO4	HS	Investigative
DM75SO4	SN	CHEMBL215688; cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
DM75SO4	DT	Small molecular drug
DM75SO4	PC	44417210
DM75SO4	MW	324.4
DM75SO4	FM	C19H20N2O3
DM75SO4	IC	InChI=1S/C19H20N2O3/c22-18(20-12-15-9-5-2-6-10-15)17-13-24-19(23)16(21-17)11-14-7-3-1-4-8-14/h1-10,16-17,21H,11-13H2,(H,20,22)/t16-,17-/m0/s1
DM75SO4	CS	C1[C@H](N[C@H](C(=O)O1)CC2=CC=CC=C2)C(=O)NCC3=CC=CC=C3
DM75SO4	IK	ORMAGLLOPOBCBO-IRXDYDNUSA-N
DM75SO4	IU	(3S,5S)-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
DM75SO4	DE	Discovery agent

DM7TU1I	ID	DM7TU1I
DM7TU1I	DN	Cis-N-oleoylcyclopropanolamide
DM7TU1I	HS	Investigative
DM7TU1I	SN	cyclopropanolamide, 13b; cis-N-oleoylcyclopropanolamide; cyclopropanolamide, rac-10b; CHEMBL472661; BDBM29081
DM7TU1I	DT	Small molecular drug
DM7TU1I	PC	42617985
DM7TU1I	MW	337.5
DM7TU1I	FM	C21H39NO2
DM7TU1I	IC	InChI=1S/C21H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)22-19-18-20(19)23/h9-10,19-20,23H,2-8,11-18H2,1H3,(H,22,24)/b10-9-/t19-,20+/m1/s1
DM7TU1I	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)N[C@@H]1C[C@@H]1O
DM7TU1I	IK	VCMSNKIQHBVCSW-VSEBXTFHSA-N
DM7TU1I	IU	(Z)-N-[(1R,2S)-2-hydroxycyclopropyl]octadec-9-enamide

DM0N634	ID	DM0N634
DM0N634	DN	CITCO
DM0N634	HS	Investigative
DM0N634	SN	CITCO; 338404-52-7; UNII-D77H8321PB; 6-(4-CHLOROPHENYL)IMIDAZO[2,1-B][1,3]THIAZOLE-5-CARBALDEHYDE O-(3,4-DICHLOROBENZYL)OXIME; CHEMBL458603; D77H8321PB; 6-(4-Chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime; CITCO cpd; Spectrum5_001974; BSPBio_001028; SCHEMBL241281; DTXSID4040761; CHEBI:92928; BCBcMAP01_000217; 6-[4-Chlorophenyl]imidazo[2,1-b][1,3]thiazole-5-carbaldehydeo-[3,4-dichlorobenzyl]oxime
DM0N634	DT	Small molecular drug
DM0N634	PC	9600409
DM0N634	MW	436.7
DM0N634	FM	C19H12Cl3N3OS
DM0N634	IC	InChI=1S/C19H12Cl3N3OS/c20-14-4-2-13(3-5-14)18-17(25-7-8-27-19(25)24-18)10-23-26-11-12-1-6-15(21)16(22)9-12/h1-10H,11H2/b23-10+
DM0N634	CS	C1=CC(=CC=C1C2=C(N3C=CSC3=N2)/C=N/OCC4=CC(=C(C=C4)Cl)Cl)Cl
DM0N634	IK	ZQWBOKJVVYNKTL-AUEPDCJTSA-N
DM0N634	IU	(E)-1-[6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]-N-[(3,4-dichlorophenyl)methoxy]methanimine
DM0N634	CA	CAS 338404-52-7
DM0N634	CB	CHEBI:92928
DM0N634	DE	Discovery agent

DMCIM9A	ID	DMCIM9A
DMCIM9A	DN	Citraconic acid
DMCIM9A	HS	Investigative
DMCIM9A	SN	Citraconic acid; 2-methylmaleic acid; METHYLMALEIC ACID; 498-23-7; 2-Methyl-2-butenedioic acid; cis-Methylbutenedioic acid; Citraconate; (Z)-2-Methyl-2-butenedioic acid; Maleic acid, methyl-; Citraconsaeure; Methyl-maleinsaeure; Kyselina citrakonova; Kyselina citrakonova [Czech]; citraconsaure; UNII-0RQ6CXO9KD; (2Z)-2-methylbut-2-enedioic acid; BRN 1722679; 2-Butenedioic acid, 2-methyl-, (Z)-; 2-Methylmaleate; alpha-methylmaleic acid; EINECS 207-858-7; NSC 32949; 0RQ6CXO9KD; cis-2-methylbutenedioic acid; 2-methyl-2Z-butenedioic ac
DMCIM9A	DT	Small molecular drug
DMCIM9A	PC	643798
DMCIM9A	MW	130.1
DMCIM9A	FM	C5H6O4
DMCIM9A	IC	InChI=1S/C5H6O4/c1-3(5(8)9)2-4(6)7/h2H,1H3,(H,6,7)(H,8,9)/b3-2-
DMCIM9A	CS	C/C(=C/C(=O)O)/C(=O)O
DMCIM9A	IK	HNEGQIOMVPPMNR-IHWYPQMZSA-N
DMCIM9A	IU	(Z)-2-methylbut-2-enedioic acid
DMCIM9A	CA	CAS 498-23-7
DMCIM9A	CB	CHEBI:17626
DMCIM9A	DE	Discovery agent

DM53ZGY	ID	DM53ZGY
DM53ZGY	DN	citral
DM53ZGY	HS	Investigative
DM53ZGY	SN	geranial; geranialdehyde; citral a; trans-citral
DM53ZGY	DT	Small molecular drug
DM53ZGY	PC	638011
DM53ZGY	MW	152.23
DM53ZGY	FM	C10H16O
DM53ZGY	IC	InChI=1S/C10H16O/c1-9(2)5-4-6-10(3)7-8-11/h5,7-8H,4,6H2,1-3H3/b10-7+
DM53ZGY	CS	CC(=CCC/C(=C/C=O)/C)C
DM53ZGY	IK	WTEVQBCEXWBHNA-JXMROGBWSA-N
DM53ZGY	IU	(2E)-3,7-dimethylocta-2,6-dienal
DM53ZGY	CA	CAS 5392-40-5
DM53ZGY	CB	CHEBI:16980
DM53ZGY	DE	Discovery agent

DM80YI7	ID	DM80YI7
DM80YI7	DN	citric acid
DM80YI7	HS	Investigative
DM80YI7	SN	Citric acid; 77-92-9; Citric acid, anhydrous; citrate; Citro; Anhydrous citric acid; Aciletten; Citretten; Chemfill; Hydrocerol A; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Kyselina citronova; 2-hydroxy-1,2,3-propanetricarboxylic acid; 2-Hydroxytricarballylic acid; Citric acid anhydrous; Caswell No 221C; F 0001 (polycarboxylic acid); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; 2-Hydroxypropanetricarboxylic acid; beta-Hydroxytricarballylic acid; FEMA Number 2306; K-Lyte
DM80YI7	DT	Small molecular drug
DM80YI7	PC	311
DM80YI7	MW	192.12
DM80YI7	FM	C6H8O7
DM80YI7	IC	InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DM80YI7	CS	C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DM80YI7	IK	KRKNYBCHXYNGOX-UHFFFAOYSA-N
DM80YI7	IU	2-hydroxypropane-1,2,3-tricarboxylic acid
DM80YI7	CA	CAS 77-92-9
DM80YI7	CB	CHEBI:30769
DM80YI7	DE	Discovery agent

DMH204Y	ID	DMH204Y
DMH204Y	DN	CKD-533
DMH204Y	HS	Investigative
DMH204Y	SN	PDE 5 inhibitor (oral, erectile dysfunction), Chong Kun Dang
DMH204Y	CP	Chong Kun Dang Pharmaceutical Corp
DMH204Y	DE	Erectile dysfunction

DML8MSC	ID	DML8MSC
DML8MSC	DN	CL 385319
DML8MSC	HS	Investigative
DML8MSC	SN	CHEMBL2088468; cl-385319
DML8MSC	DT	Small molecular drug
DML8MSC	PC	46176195
DML8MSC	MW	354.77
DML8MSC	FM	C15H19ClF4N2O
DML8MSC	IC	InChI=1S/C15H18F4N2O.ClH/c16-13-9-11(8-12(10-13)15(17,18)19)14(22)20-4-7-21-5-2-1-3-6-21;/h8-10H,1-7H2,(H,20,22);1H
DML8MSC	CS	C1CCN(CC1)CCNC(=O)C2=CC(=CC(=C2)F)C(F)(F)F.Cl
DML8MSC	IK	FEMIHMMAZDXYBI-UHFFFAOYSA-N
DML8MSC	IU	3-fluoro-N-(2-piperidin-1-ylethyl)-5-(trifluoromethyl)benzamide;hydrochloride
DML8MSC	DE	Discovery agent

DMB6XUY	ID	DMB6XUY
DMB6XUY	DN	CL-205086
DMB6XUY	HS	Investigative
DMB6XUY	SN	Imidazole, 4-nitro-; PubChem7615; VYDWQPKRHOGLPA-UHFFFAOYSA-N; Y8U32AZ5O7; 100214-79-7; 1H-4-Nitroimidazole; 1H-5-Nitroimidazole; 1H-Imidazole, 4-nitro-; 1H-Imidazole, 5-nitro-; 3034-38-6; 4(5)-Nitroimidazole; 4-NITRO-1H-IMIDAZOLE; 4-Nitroimidazole; 4-Nitroimidazole, 97%; 4-Nitroimidazole, 98%; 4-nitro-3H-imidazole; 4-nitro-imidazole; 5(4)-nitroimidazole; 5-Nitro-1H-imidazole; 5-Nitroimidazole; 88054-21-1; ACMC-1AIMC; AI3-60154; CHEBI:64635; EC 221-224-7; EINECS 221-224-7; MFCD00005196; NSC 50359; UNII-Y8U32AZ5O7
DMB6XUY	PC	18208
DMB6XUY	MW	113.08
DMB6XUY	FM	C3H3N3O2
DMB6XUY	IC	VYDWQPKRHOGLPA-UHFFFAOYSA-N
DMB6XUY	CS	C1=C(NC=N1)[N+](=O)[O-]
DMB6XUY	IK	1S/C3H3N3O2/c7-6(8)3-1-4-2-5-3/h1-2H,(H,4,5)
DMB6XUY	IU	5-nitro-1H-imidazole
DMB6XUY	CA	CAS 3034-38-6
DMB6XUY	CB	CHEBI:64635
DMB6XUY	DE	Amebiasis

DMW3RLB	ID	DMW3RLB
DMW3RLB	DN	CL-301
DMW3RLB	HS	Investigative
DMW3RLB	SN	CLP-301; CL-301 series, Chlorion
DMW3RLB	CP	Chlorion Pharma Inc
DMW3RLB	DE	Neurological disorder

DMLQZGJ	ID	DMLQZGJ
DMLQZGJ	DN	CL-385004
DMLQZGJ	HS	Investigative
DMLQZGJ	SN	CL-385004; UNII-YS11IQJ45S; YS11IQJ45S; CHEMBL300946; SCHEMBL5738957; BDBM50078663; Benzamide, 5-fluoro-2-methyl-N-(5-(5H-pyrrolo(2,1-C)(1,4)benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl)-; 180416-31-3; L015160
DMLQZGJ	DT	Small molecular drug
DMLQZGJ	PC	9954905
DMLQZGJ	MW	440.5
DMLQZGJ	FM	C26H21FN4O2
DMLQZGJ	IC	InChI=1S/C26H21FN4O2/c1-17-8-10-20(27)13-22(17)25(32)29-24-11-9-18(14-28-24)26(33)31-16-21-6-4-12-30(21)15-19-5-2-3-7-23(19)31/h2-14H,15-16H2,1H3,(H,28,29,32)
DMLQZGJ	CS	CC1=C(C=C(C=C1)F)C(=O)NC2=NC=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53
DMLQZGJ	IK	XJZRYHGTQLKUDO-UHFFFAOYSA-N
DMLQZGJ	IU	N-[5-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)pyridin-2-yl]-5-fluoro-2-methylbenzamide
DMLQZGJ	CA	CAS 180416-31-3
DMLQZGJ	DE	Discovery agent

DMLKFZC	ID	DMLKFZC
DMLKFZC	DN	CL-387785
DMLKFZC	HS	Investigative
DMLKFZC	SN	cl-387785; 194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide
DMLKFZC	DT	Small molecular drug
DMLKFZC	PC	2776
DMLKFZC	MW	381.2
DMLKFZC	FM	C18H13BrN4O
DMLKFZC	IC	InChI=1S/C18H13BrN4O/c1-2-4-17(24)22-14-7-8-16-15(10-14)18(21-11-20-16)23-13-6-3-5-12(19)9-13/h3,5-11H,1H3,(H,22,24)(H,20,21,23)
DMLKFZC	CS	CC#CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Br
DMLKFZC	IK	BTYYWOYVBXILOJ-UHFFFAOYSA-N
DMLKFZC	IU	N-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide
DMLKFZC	CA	CAS 194423-06-8
DMLKFZC	CB	CHEBI:90180
DMLKFZC	DE	Discovery agent

DM9AFZ3	ID	DM9AFZ3
DM9AFZ3	DN	CL-5343
DM9AFZ3	HS	Investigative
DM9AFZ3	SN	5-Amino-1,3,4-thiadiazole-2-sulfonamide; 14949-00-9; Tio-urasin; CL 5343; UNII-F687N81LIZ; NSC 22979; 2-Amino-1,3,4-thiadiazole-5-sulfonamide; CHEMBL265674; F687N81LIZ; 1,3,4-Thiadiazole-2-sulfonamide, 5-amino-; 5-Amino-TDSNH2; PubChem15758; Acetazolamide Impurity D; AC1Q6UUX; 1,3,4-Thiadiazole-5-sulfonamide, 2-amino-; SCHEMBL282413; AC1L382D; CTK4C6227; BDBM10868; DTXSID10164324; MolPort-022-374-081; VGMVBPQOACUDRU-UHFFFAOYSA-N; NSC22979; ZINC16969869; NSC-22979; 1,3,4-thiadiazole-2-sulfonamide 15; aromatic/heteroaromatic;  CL-5343; Carbonic anhydrase inhibitors, Universita degli Studi di Firenze; Sulfonamide CA inhibitors, Universita degli Studi di Firenze; Sulfonamide CA inhibitors, University of Florence; Carbonic anhydrase inhibitors (cancer/epilepsy/glaucoma/obesity); Carbonic anhydrase inhibitors (cancer/epilepsy/glaucoma/obesity), University of Florence/ULS; 5-amino-1,3,4-thiadiazole-2-sulfonamide
DM9AFZ3	CP	Universita degli Studi di Firenze
DM9AFZ3	DT	Small molecular drug
DM9AFZ3	PC	84724
DM9AFZ3	MW	180.21
DM9AFZ3	FM	C2H4N4O2S2
DM9AFZ3	IC	InChI=1S/C2H4N4O2S2/c3-1-5-6-2(9-1)10(4,7)8/h(H2,3,5)(H2,4,7,8)
DM9AFZ3	CS	C1(=NN=C(S1)S(=O)(=O)N)N
DM9AFZ3	IK	VGMVBPQOACUDRU-UHFFFAOYSA-N
DM9AFZ3	IU	5-amino-1,3,4-thiadiazole-2-sulfonamide
DM9AFZ3	CA	CAS 14949-00-9
DM9AFZ3	DE	Solid tumour/cancer

DMP3MDS	ID	DMP3MDS
DMP3MDS	DN	CL82198
DMP3MDS	HS	Investigative
DMP3MDS	SN	CL-82198; CL 82198
DMP3MDS	DT	Small molecular drug
DMP3MDS	PC	2777
DMP3MDS	MW	302.37
DMP3MDS	FM	C17H22N2O3
DMP3MDS	IC	InChI=1S/C17H22N2O3/c20-17(16-13-14-5-1-2-6-15(14)22-16)18-7-3-4-8-19-9-11-21-12-10-19/h1-2,5-6,13H,3-4,7-12H2,(H,18,20)
DMP3MDS	CS	C1COCCN1CCCCNC(=O)C2=CC3=CC=CC=C3O2
DMP3MDS	IK	KUJQEQAVMNFFAO-UHFFFAOYSA-N
DMP3MDS	IU	N-(4-morpholin-4-ylbutyl)-1-benzofuran-2-carboxamide
DMP3MDS	CA	CAS 307002-71-7
DMP3MDS	CB	CHEBI:92019
DMP3MDS	DE	Discovery agent

DMRV89X	ID	DMRV89X
DMRV89X	DN	Cl-amidine
DMRV89X	HS	Investigative
DMRV89X	SN	Cl-amidine; CHEMBL1962361; N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide; 913723-61-2; CHEMBL1910972; GTPL8685; US8969333, CI-amidine; SCHEMBL1979577; BDBM144279; ZINC71746281; BDBM50355657; 4373AJ; NE62957; HY-100574; CS-0019714; FT-0700077; (2S)-5-(2-chloroethanimidamido)-2-(phenylformamido)pentanamide
DMRV89X	DT	Small molecular drug
DMRV89X	PC	24970878
DMRV89X	MW	310.78
DMRV89X	FM	C14H19ClN4O2
DMRV89X	IC	InChI=1S/C14H19ClN4O2/c15-9-12(16)18-8-4-7-11(13(17)20)19-14(21)10-5-2-1-3-6-10/h1-3,5-6,11H,4,7-9H2,(H2,16,18)(H2,17,20)(H,19,21)/t11-/m0/s1
DMRV89X	CS	C1=CC=C(C=C1)C(=O)N[C@@H](CCCN=C(CCl)N)C(=O)N
DMRV89X	IK	BPWATVWOHQZVRP-NSHDSACASA-N
DMRV89X	IU	N-[(2S)-1-amino-5-[(1-amino-2-chloroethylidene)amino]-1-oxopentan-2-yl]benzamide
DMRV89X	DE	Discovery agent

DMIX347	ID	DMIX347
DMIX347	DN	CLAVARINONE
DMIX347	HS	Investigative
DMIX347	SN	SCHEMBL606234
DMIX347	DT	Small molecular drug
DMIX347	PC	10005132
DMIX347	MW	474.7
DMIX347	FM	C30H50O4
DMIX347	IC	InChI=1S/C30H50O4/c1-18(9-12-24(32)27(4,5)34)19-13-15-30(8)21-10-11-23-26(2,3)25(33)22(31)17-28(23,6)20(21)14-16-29(19,30)7/h18-19,22-24,31-32,34H,9-17H2,1-8H3/t18-,19-,22-,23+,24?,28-,29-,30+/m1/s1
DMIX347	CS	C[C@H](CCC(C(C)(C)O)O)[C@H]1CC[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(C[C@H](C(=O)C4(C)C)O)C)C)C
DMIX347	IK	TZXHHXSEUPQHDR-ITLZUSRVSA-N
DMIX347	IU	(2R,5R,10S,13R,14R,17R)-17-[(2R)-5,6-dihydroxy-6-methylheptan-2-yl]-2-hydroxy-4,4,10,13,14-pentamethyl-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMIX347	DE	Discovery agent

DMAJNYM	ID	DMAJNYM
DMAJNYM	DN	Clavulanate+Amoxicillin
DMAJNYM	HS	Investigative
DMAJNYM	SN	Potassium clavulanate; 61177-45-5; CLAVULANATE POTASSIUM; Amonate; BRL 14151K; UNII-Q42OMW3AT8; EINECS 262-640-9; Q42OMW3AT8; CHEBI:85264; potassium (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate; Potassium (Z)-(2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylate; Potassium clavulanate with microcrystalline cellulose; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, monopotassium salt, (2R-(2alpha,3Z,5alpha))-
DMAJNYM	CP	GlaxoSmithKline
DMAJNYM	DT	Small molecular drug
DMAJNYM	PC	23665591
DMAJNYM	MW	237.25
DMAJNYM	FM	C8H8KNO5
DMAJNYM	IC	InChI=1S/C8H9NO5.K/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h1,6-7,10H,2-3H2,(H,12,13);/q;+1/p-1/b4-1-;/t6-,7-;/m1./s1
DMAJNYM	CS	C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)[O-].[K+]
DMAJNYM	IK	ABVRVIZBZKUTMK-JSYANWSFSA-M
DMAJNYM	IU	potassium;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMAJNYM	CA	CAS 61177-45-5
DMAJNYM	CB	CHEBI:85264
DMAJNYM	DE	Infectious disease

DMTLOU6	ID	DMTLOU6
DMTLOU6	DN	CLEBOPRIDE
DMTLOU6	HS	Investigative
DMTLOU6	SN	Clebopride; 55905-53-8; Cleboril; Clebopridum [INN-Latin]; Cleboprida [INN-Spanish]; 4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide; UNII-I0A84520Y9; LAS 9273; EINECS 259-885-9; C20H24ClN3O2; BRN 0493934; CHEMBL325109; I0A84520Y9; 4-Amino-N-(1-benzyl-4-piperidyl)-5-chloro-o-anisamide; clebopride malate; 4-Amino-5-chloro-2-methoxy-N-(1-benzyl-4-piperidyl)benzamide; Clebopridum; Cleboprida; N-(1'-Benzyl-4'-piperidyl)-2-methoxy-4-amino-5-chlorobenzamide; BENZAMIDE, 4-AMINO-5-CHLORO-2-METHOXY-N-(1-(PHENYLMETHYL)-4
DMTLOU6	DT	Small molecular drug
DMTLOU6	PC	2780
DMTLOU6	MW	373.9
DMTLOU6	FM	C20H24ClN3O2
DMTLOU6	IC	InChI=1S/C20H24ClN3O2/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25)
DMTLOU6	CS	COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3)Cl)N
DMTLOU6	IK	BVPWJMCABCPUQY-UHFFFAOYSA-N
DMTLOU6	IU	4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide
DMTLOU6	CA	CAS 55905-53-8
DMTLOU6	CB	CHEBI:92309
DMTLOU6	DE	Discovery agent

DM4SKYA	ID	DM4SKYA
DM4SKYA	DN	CLEMATOMANDSHURICA SAPONIN A
DM4SKYA	HS	Investigative
DM4SKYA	SN	CHEMBL526701; BDBM50241847; 6)-[(3-O-isoferuloyl)-beta-D-glucopyranosyl]-(1-&gt; 3)-alph-L-rhamnopyranosyl-(1-&gt; 2)-alpha-L-arabinopyranosyloleanolicacid 28-O-alph-L-rhamnopyranosyl-(1-&gt
DM4SKYA	PC	44559170
DM4SKYA	MW	1984.1
DM4SKYA	FM	C92H142O46
DM4SKYA	IC	InChI=1S/C92H142O46/c1-34-52(98)60(106)65(111)77(124-34)121-33-47-59(105)74(133-51(97)17-13-37-12-15-42(119-11)40(95)26-37)70(116)84(131-47)136-75-58(104)43(28-93)127-83(71(75)117)130-46-32-123-79(64(110)57(46)103)135-73-54(100)36(3)126-82(69(73)115)137-76-55(101)41(96)30-120-85(76)132-50-19-20-89(8)48(88(50,6)7)18-21-91(10)49(89)16-14-38-39-27-87(4,5)22-24-92(39,25-23-90(38,91)9)86(118)138-81-67(113)62(108)56(102)45(129-81)31-122-78-68(114)63(109)72(44(29-94)128-78)134-80-66(112)61(107)53(99)35(2)125-80/h12-15,17,26,34-36,39,41,43-50,52-85,93-96,98-117H,16,18-25,27-33H2,1-11H3/b17-13+/t34-,35-,36-,39-,41-,43+,44+,45+,46+,47+,48-,49+,50-,52-,53-,54-,55-,56+,57+,58+,59+,60+,61+,62-,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74-,75-,76+,77+,78+,79-,80-,81-,82-,83-,84-,85-,89-,90+,91+,92-/m0/s1
DM4SKYA	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@H]3[C@@H]([C@H](O[C@H]([C@@H]3O)O[C@@H]4CO[C@H]([C@@H]([C@@H]4O)O)O[C@@H]5[C@H]([C@@H](O[C@H]([C@@H]5O)O[C@@H]6[C@H]([C@H](CO[C@H]6O[C@H]7CC[C@]8([C@H](C7(C)C)CC[C@@]9([C@@H]8CC=C1[C@]9(CC[C@@]2([C@H]1CC(CC2)(C)C)C(=O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O)O)O)O)O)O)C)C)C)O)O)C)O)CO)O)O)OC(=O)/C=C/C1=CC(=C(C=C1)OC)O)O)O)O)O
DM4SKYA	IK	NPRWMYIWVVAUEC-KQFZDZHOSA-N
DM4SKYA	IU	[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-4-[(2S,3R,4S,5R)-5-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[(E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]oxy-3,5-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DM4SKYA	DE	Discovery agent

DMNWXOC	ID	DMNWXOC
DMNWXOC	DN	CLEMATOMANDSHURICA SAPONIN B
DMNWXOC	HS	Investigative
DMNWXOC	SN	CHEMBL525269; BDBM50241848; 6)-[(2-O-isoferuloyl)-beta-D-glucopyranosyl]-(1-&gt; 3)-alpha-L-rhamnopyranosyl-(1-&gt; 2)-alpha-L-arabinopyranosyloleanolic acid-28-O-alpha-L-rhamnopyranosyl-(1-&gt
DMNWXOC	PC	11994182
DMNWXOC	MW	1984.1
DMNWXOC	FM	C92H142O46
DMNWXOC	IC	InChI=1S/C92H142O46/c1-34-52(98)59(105)66(112)77(124-34)121-32-46-57(103)62(108)76(133-51(97)17-13-37-12-15-42(119-11)40(95)26-37)85(131-46)135-73-44(29-94)128-81(70(116)64(73)110)129-47-33-123-79(65(111)58(47)104)136-74-54(100)36(3)126-83(71(74)117)137-75-55(101)41(96)30-120-84(75)132-50-19-20-89(8)48(88(50,6)7)18-21-91(10)49(89)16-14-38-39-27-87(4,5)22-24-92(39,25-23-90(38,91)9)86(118)138-82-68(114)61(107)56(102)45(130-82)31-122-78-69(115)63(109)72(43(28-93)127-78)134-80-67(113)60(106)53(99)35(2)125-80/h12-15,17,26,34-36,39,41,43-50,52-85,93-96,98-117H,16,18-25,27-33H2,1-11H3/b17-13+/t34-,35-,36-,39-,41-,43+,44+,45+,46+,47+,48-,49+,50-,52-,53-,54-,55-,56+,57+,58+,59+,60+,61-,62-,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79-,80-,81-,82-,83-,84-,85-,89-,90+,91+,92-/m0/s1
DMNWXOC	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O[C@@H]4CO[C@H]([C@@H]([C@@H]4O)O)O[C@@H]5[C@H]([C@@H](O[C@H]([C@@H]5O)O[C@@H]6[C@H]([C@H](CO[C@H]6O[C@H]7CC[C@]8([C@H](C7(C)C)CC[C@@]9([C@@H]8CC=C1[C@]9(CC[C@@]2([C@H]1CC(CC2)(C)C)C(=O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O)O)O)O)O)O)C)C)C)O)O)C)O)CO)OC(=O)/C=C/C1=CC(=C(C=C1)OC)O)O)O)O)O)O
DMNWXOC	IK	NMYXWQYOXWOLSB-ZSBIDDPTSA-N
DMNWXOC	IU	[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-4-[(2S,3R,4S,5R)-5-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]oxy-3,5-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMNWXOC	DE	Discovery agent

DM9WUHD	ID	DM9WUHD
DM9WUHD	DN	Clik60
DM9WUHD	HS	Investigative
DM9WUHD	DE	Discovery agent

DMS58P1	ID	DMS58P1
DMS58P1	DN	Clinopodic acid C
DMS58P1	HS	Investigative
DMS58P1	SN	Clinopodic acid C; CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid
DMS58P1	DT	Small molecular drug
DMS58P1	PC	44254596
DMS58P1	MW	538.5
DMS58P1	FM	C27H22O12
DMS58P1	IC	InChI=1S/C27H22O12/c28-16-5-1-14(9-18(16)30)11-22(26(33)34)37-23(32)8-3-13-2-7-20-21(10-13)39-25(27(35)36)24(38-20)15-4-6-17(29)19(31)12-15/h1-10,12,22,24-25,28-31H,11H2,(H,33,34)(H,35,36)/b8-3+/t22-,24+,25+/m1/s1
DMS58P1	CS	C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=CC3=C(C=C2)O[C@H]([C@H](O3)C(=O)O)C4=CC(=C(C=C4)O)O)O)O
DMS58P1	IK	KPKHMGUZUPELJC-RXYMDKBQSA-N
DMS58P1	IU	(2S,3S)-6-[(E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-1,4-benzodioxine-3-carboxylic acid
DMS58P1	DE	Discovery agent

DM537OH	ID	DM537OH
DM537OH	DN	Clobenpropit
DM537OH	HS	Investigative
DM537OH	SN	clobenpropit; 145231-45-4; Vuf-9153; Vuf 9153; UNII-RKU631JF4H; S-(3-(4(5)-Imidazolyl))propyl-N-(4-chlorobenzyl)isothiourea; CHEBI:64177; RKU631JF4H; 3-(1h-imidazol-5-yl)propyl n'-(4-chlorobenzyl)carbamimidothioate; 3-(1H-imidazol-4-yl)propyl ((4-chlorophenyl)methyl)carbamimidothioate; Carbamimidothioic acid, ((4-chlorophenyl)methyl)-, 3-(1H-imidazol-4-yl)propyl ester; 3-(1H-imidazol-4-yl)propyl N-(4-chlorobenzyl)carbamimidothioate; Carbamimidothioic acid,N-[(4-chlorophenyl)methyl]-, 3-(1H-imidazol-5-yl)propyl ester
DM537OH	DT	Small molecular drug
DM537OH	PC	2790
DM537OH	MW	308.8
DM537OH	FM	C14H17ClN4S
DM537OH	IC	InChI=1S/C14H17ClN4S/c15-12-5-3-11(4-6-12)8-18-14(16)20-7-1-2-13-9-17-10-19-13/h3-6,9-10H,1-2,7-8H2,(H2,16,18)(H,17,19)
DM537OH	CS	C1=CC(=CC=C1CN=C(N)SCCCC2=CN=CN2)Cl
DM537OH	IK	UCAIEVHKDLMIFL-UHFFFAOYSA-N
DM537OH	IU	3-(1H-imidazol-5-yl)propyl N'-[(4-chlorophenyl)methyl]carbamimidothioate
DM537OH	CA	CAS 145231-45-4
DM537OH	CB	CHEBI:64177
DM537OH	DE	Discovery agent

DMZLMJH	ID	DMZLMJH
DMZLMJH	DN	Clocinnamox
DMZLMJH	HS	Investigative
DMZLMJH	SN	clocinnamox; Methoclocinnamox; C-CAM; 14-beta-(4-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnorpmorphine mesylate; Clocinnamox mesylate; 117332-69-1; 2-Propenamide, 3-(4-chlorophenyl)-N-((5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-oxomorphinan-14-yl)-, monomethanesulfonate; NIH 10443 mesylate; NIH 10989; SCHEMBL4404383; AKOS024259103
DMZLMJH	DT	Small molecular drug
DMZLMJH	PC	6540640
DMZLMJH	MW	505
DMZLMJH	FM	C29H29ClN2O4
DMZLMJH	IC	InChI=1S/C29H29ClN2O4/c30-20-7-3-17(4-8-20)5-10-24(35)31-29-12-11-22(34)27-28(29)13-14-32(16-18-1-2-18)23(29)15-19-6-9-21(33)26(36-27)25(19)28/h3-10,18,23,27,33H,1-2,11-16H2,(H,31,35)/b10-5+/t23-,27+,28+,29-/m1/s1
DMZLMJH	CS	C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)NC(=O)/C=C/C7=CC=C(C=C7)Cl
DMZLMJH	IK	RAURUSFBVQLAPW-DNIKMYEQSA-N
DMZLMJH	IU	(E)-N-[(4R,4aS,7aR,12bR)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-chlorophenyl)prop-2-enamide
DMZLMJH	DE	Discovery agent

DMALRU9	ID	DMALRU9
DMALRU9	DN	Clodinafop
DMALRU9	HS	Investigative
DMALRU9	SN	Propanoic acid, 2-[4-[(5-chloro-3-fluoro-2-pyridinyl)oxy]phenoxy]-; 87135-08-8; AC1L3BBN; SCHEMBL1535846; CTK3C5537; DTXSID60275833; YUIKUTLBPMDDNQ-UHFFFAOYSA-N; 2-[4-(5-chloro-3-fluoropyridin-2-yl)oxyphenoxy]propanoic acid; 2-[4-(5-chloro-3-fluoropyridin-2-yloxy)phenoxy]propionic acid; 2-[4-(5-chloro-3-fluoropyrdin-2-yloxy)phenoxy]propionic acid; 2-[4-[(5-chloro-3-fluoro-2-pyridyl)oxy]phenoxy]propanoic acid; (+)-[4-(5-chloro-3-fluoropyridin-2-yloxy)-phenoxy]-propionic acid
DMALRU9	DT	Small molecular drug
DMALRU9	PC	5483847
DMALRU9	MW	311.69
DMALRU9	FM	C14H11ClFNO4
DMALRU9	IC	InChI=1S/C14H11ClFNO4/c1-8(14(18)19)20-10-2-4-11(5-3-10)21-13-12(16)6-9(15)7-17-13/h2-8H,1H3,(H,18,19)/t8-/m1/s1
DMALRU9	CS	C[C@H](C(=O)O)OC1=CC=C(C=C1)OC2=C(C=C(C=N2)Cl)F
DMALRU9	IK	YUIKUTLBPMDDNQ-MRVPVSSYSA-N
DMALRU9	IU	(2R)-2-[4-(5-chloro-3-fluoropyridin-2-yl)oxyphenoxy]propanoic acid
DMALRU9	CA	CAS 114420-56-3
DMALRU9	CB	CHEBI:132841
DMALRU9	DE	Discovery agent

DMQ37OP	ID	DMQ37OP
DMQ37OP	DN	clofilium
DMQ37OP	HS	Investigative
DMQ37OP	SN	Clofilium; 68379-02-2; 4-(4-chlorophenyl)butyl-diethyl-heptylazanium; UNII-847G178BMC; 4-Chloro-N,N-diethyl-N-heptylbenzenebutanaminium; AC1L1EHQ; CHEMBL9484; Benzenebutanaminium, 4-chloro-N,N-diethyl-N-heptyl-; CHEBI:34649; 847G178BMC; MLS002154263; GNF-Pf-3889; SMR001233522; Prestwick2_000319; Prestwick3_000319; Prestwick1_000319; BSPBio_000318; SCHEMBL157537; SPBio_002537; cid_175533; GTPL2507; BPBio1_000350; DTXSID9048568; CTK2F6670; BDBM89440; ZINC8035458; NCGC00168464-02; NCGC00168464-01; 68379-03-3 (phosphate[1:1]); LS-186732
DMQ37OP	DT	Small molecular drug
DMQ37OP	PC	2798
DMQ37OP	MW	339
DMQ37OP	FM	C21H37ClN+
DMQ37OP	IC	InChI=1S/C21H37ClN/c1-4-7-8-9-11-18-23(5-2,6-3)19-12-10-13-20-14-16-21(22)17-15-20/h14-17H,4-13,18-19H2,1-3H3/q+1
DMQ37OP	CS	CCCCCCC[N+](CC)(CC)CCCCC1=CC=C(C=C1)Cl
DMQ37OP	IK	WPSYTTKBGAZSCX-UHFFFAOYSA-N
DMQ37OP	IU	4-(4-chlorophenyl)butyl-diethyl-heptylazanium
DMQ37OP	CA	CAS 68379-02-2
DMQ37OP	CB	CHEBI:34649
DMQ37OP	DE	Discovery agent

DMH01JV	ID	DMH01JV
DMH01JV	DN	cloprostenol
DMH01JV	HS	Investigative
DMH01JV	SN	ICI 80996
DMH01JV	DT	Small molecular drug
DMH01JV	PC	5311053
DMH01JV	MW	424.9
DMH01JV	FM	C22H29ClO6
DMH01JV	IC	InChI=1S/C22H29ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28)/b3-1-,11-10+/t16-,18-,19-,20+,21-/m1/s1
DMH01JV	CS	C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)C/C=C\\CCCC(=O)O)O
DMH01JV	IK	VJGGHXVGBSZVMZ-QIZQQNKQSA-N
DMH01JV	IU	(Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid
DMH01JV	CA	CAS 54276-21-0
DMH01JV	DE	Discovery agent

DMH7GKB	ID	DMH7GKB
DMH7GKB	DN	Cloranolol
DMH7GKB	HS	Investigative
DMH7GKB	SN	Chloranolol-d9; Cloranolol; Cloranolol (INN); Cloranolol [INN]; Cloranolol-d9; Cloranololum; Cloranololum [INN-Latin]; Tobanum-d9; chloranolol; chlorpropanol; 1-(2,5-dichlorophenoxy)-3-tertiary-butylamino-2-propanol; 1-(tert-Butylamino)-3-(2,5-dichlorophenoxy)-2-propanol; 1-(tert-butylamino)-3-(2,5-dichlorophenoxy)propan-2-ol; 2-Propanol, 1-(2,5-dichlorophenoxy)-3-((1,1-dimethylethyl)amino)-; 39563-28-5; AC1L240Q; C13H19Cl2NO2; CHEBI:135217; CHEMBL156791; Gyki 41099; SCHEMBL80493; tobanum, hydrochloride, (+-)-isomer
DMH7GKB	PC	65814
DMH7GKB	MW	292.2
DMH7GKB	FM	C13H19Cl2NO2
DMH7GKB	IC	XYCMOTOFHFTUIU-UHFFFAOYSA-N
DMH7GKB	CS	CC(C)(C)NCC(COC1=C(C=CC(=C1)Cl)Cl)O
DMH7GKB	IK	1S/C13H19Cl2NO2/c1-13(2,3)16-7-10(17)8-18-12-6-9(14)4-5-11(12)15/h4-6,10,16-17H,7-8H2,1-3H3
DMH7GKB	IU	1-(tert-butylamino)-3-(2,5-dichlorophenoxy)propan-2-ol
DMH7GKB	CA	CAS 39563-28-5
DMH7GKB	CB	CHEBI:135217
DMH7GKB	DE	Discovery agent

DMLPXNC	ID	DMLPXNC
DMLPXNC	DN	Clorindione
DMLPXNC	HS	Investigative
DMLPXNC	SN	Chlophenadione; Chlor-athrombon; Chlorindione; Chlorindionum; Clorindiona [INN-Spanish]; Clorindione; Clorindione [INN:BAN]; Clorindionum [INN-Latin]; Indaliton; M.G. 2552; 1,3-Indandione, 2-(p-chlorophenyl)-; 1146-99-2; 2-(4-CHLOROPHENYL)INDANE-1,3-DIONE; 2-(4-Chlorophenyl)-1H-indene-1,3(2H)-dione; 2-(4-Chlorophenyl)indan-1,3-dione; 2-(4-chlorophenyl)indene-1,3-dione; 2-(p-Chlorophenyl)-1,3-indandione; 2-(p-Chlorophenyl)indan-1,3-dione; BRN 2052412; CHEMBL278519; EINECS 214-553-2; G 25766; G-25766; UNII-541C7WS64R
DMLPXNC	PC	70846
DMLPXNC	MW	256.68
DMLPXNC	FM	C15H9ClO2
DMLPXNC	IC	NJDUWAXIURWWLN-UHFFFAOYSA-N
DMLPXNC	CS	C1=CC=C2C(=C1)C(=O)C(C2=O)C3=CC=C(C=C3)Cl
DMLPXNC	IK	1S/C15H9ClO2/c16-10-7-5-9(6-8-10)13-14(17)11-3-1-2-4-12(11)15(13)18/h1-8,13H
DMLPXNC	IU	2-(4-chlorophenyl)indene-1,3-dione
DMLPXNC	CA	CAS 1146-99-2
DMLPXNC	CB	CHEBI:135057
DMLPXNC	DE	Hypertriglyceridaemia

DMD5FIU	ID	DMD5FIU
DMD5FIU	DN	Clorobiocin
DMD5FIU	HS	Investigative
DMD5FIU	SN	Clorobiocin; Chlorobiocin; Antibiotic RP 18,631; NSC 227186; RP 18631; 18631 RP; 39868-96-7; CHEMBL303984; 1H-Pyrrole-2-carboxylic acid, 5-methyl-, 3'-ester with N-(8-chloro-7-((6-deoxy-5-C-methyl-4-O-methyl-alpha-L-lyxo-hexopyranosyl)oxy)-4-hydroxy-2-oxo-2H-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-butenyl)benzamide; [(3R,4S,5R,6S)-6-[8-chloro-4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-2-oxo-chromen-7-yl]oxy-5-hydroxy-3-methoxy-2,2-dimethyl-tetrahydropyran-4-yl] 5-methyl-1H-pyrrole-2-carboxylate
DMD5FIU	DT	Small molecular drug
DMD5FIU	PC	54706138
DMD5FIU	MW	697.1
DMD5FIU	FM	C35H37ClN2O11
DMD5FIU	IC	InChI=1S/C35H37ClN2O11/c1-16(2)7-9-18-15-19(10-13-22(18)39)31(42)38-25-26(40)20-11-14-23(24(36)28(20)47-33(25)44)46-34-27(41)29(30(45-6)35(4,5)49-34)48-32(43)21-12-8-17(3)37-21/h7-8,10-15,27,29-30,34,37,39-41H,9H2,1-6H3,(H,38,42)/t27-,29+,30-,34-/m1/s1
DMD5FIU	CS	CC1=CC=C(N1)C(=O)O[C@H]2[C@H]([C@@H](OC([C@@H]2OC)(C)C)OC3=C(C4=C(C=C3)C(=C(C(=O)O4)NC(=O)C5=CC(=C(C=C5)O)CC=C(C)C)O)Cl)O
DMD5FIU	IK	FJAQNRBDVKIIKK-LFLQOBSNSA-N
DMD5FIU	IU	[(3R,4S,5R,6S)-6-[8-chloro-4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-2-oxochromen-7-yl]oxy-5-hydroxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1H-pyrrole-2-carboxylate
DMD5FIU	CA	CAS 39868-96-7
DMD5FIU	DE	Discovery agent

DMU6FOG	ID	DMU6FOG
DMU6FOG	DN	Clorsulon
DMU6FOG	HS	Investigative
DMU6FOG	SN	CLORSULON; 60200-06-8; Curatrem; Clorsulonum [Latin]; Clorsulone [French]; Clorsulon [Spanish]; UNII-EG1ZDO6LRD; EG1ZDO6LRD; EINECS 262-100-2; MK 401; MK-401; BRN 2821757; 4-amino-6-(1,2,2-trichloroethenyl)benzene-1,3-disulfonamide; 4-Amino-6-(trichlorovinyl)-m-benzenedisulfonamide; L 631529; L-631,529; 4-Amino-6-(trichlorovinyl)-1,3-benzenedisulfonamide; 4-Amino-6-(trichloroethenyl)-1,3-benzenedisulfonamide; 1,3-Benzenedisulfonamide, 4-amino-6-(trichloroethenyl)-; NCGC00016893-01; NCGC00182084-01
DMU6FOG	DT	Small molecular drug
DMU6FOG	PC	43231
DMU6FOG	MW	380.7
DMU6FOG	FM	C8H8Cl3N3O4S2
DMU6FOG	IC	InChI=1S/C8H8Cl3N3O4S2/c9-7(8(10)11)3-1-4(12)6(20(14,17)18)2-5(3)19(13,15)16/h1-2H,12H2,(H2,13,15,16)(H2,14,17,18)
DMU6FOG	CS	C1=C(C(=CC(=C1N)S(=O)(=O)N)S(=O)(=O)N)C(=C(Cl)Cl)Cl
DMU6FOG	IK	QOVTVIYTBRHADL-UHFFFAOYSA-N
DMU6FOG	IU	4-amino-6-(1,2,2-trichloroethenyl)benzene-1,3-disulfonamide
DMU6FOG	CA	CAS 60200-06-8
DMU6FOG	CB	CHEBI:94811
DMU6FOG	DE	Discovery agent

DMWTBG8	ID	DMWTBG8
DMWTBG8	DN	Clostridial collagenase
DMWTBG8	HS	Investigative
DMWTBG8	DE	Discovery agent

DM1B0PY	ID	DM1B0PY
DM1B0PY	DN	CLP-635
DM1B0PY	HS	Investigative
DM1B0PY	SN	CLP-656
DM1B0PY	CP	Chlorion Pharma Inc
DM1B0PY	DE	Epilepsy

DM9LSOW	ID	DM9LSOW
DM9LSOW	DN	CLR-151
DM9LSOW	HS	Investigative
DM9LSOW	SN	CLR-100 series; CLR-136; CLR-155; CLR-161
DM9LSOW	CP	Clera Inc
DM9LSOW	DE	Psychotic disorder

DM7TX3D	ID	DM7TX3D
DM7TX3D	DN	CM-156
DM7TX3D	HS	Investigative
DM7TX3D	SN	Sigma opioid antagonists (addiction); Sigma opioid antagonists (addiction), University of Mississippi; 2(3H)-benzoxalones and 2(3H)-benzothiazolones (addiction), University of Mississippi
DM7TX3D	CP	University of Mississippi
DM7TX3D	DE	Drug abuse

DMXA8K1	ID	DMXA8K1
DMXA8K1	DN	CM-352
DMXA8K1	HS	Investigative
DMXA8K1	SN	compound 2 [PMID 25686022]
DMXA8K1	DT	Small molecular drug
DMXA8K1	PC	91623362
DMXA8K1	MW	487.6
DMXA8K1	FM	C24H29N3O6S
DMXA8K1	IC	InChI=1S/C24H29N3O6S/c1-25-21(28)17-2-4-18(5-3-17)33-19-6-8-20(9-7-19)34(31,32)24(22(29)27-30)11-10-23(16-24)12-14-26-15-13-23/h2-9,26,30H,10-16H2,1H3,(H,25,28)(H,27,29)/t24-/m1/s1
DMXA8K1	CS	CNC(=O)C1=CC=C(C=C1)OC2=CC=C(C=C2)S(=O)(=O)[C@@]3(CCC4(C3)CCNCC4)C(=O)NO
DMXA8K1	IK	ZUZGJCNWNOCKEB-XMMPIXPASA-N
DMXA8K1	IU	(3R)-N-hydroxy-3-[4-[4-(methylcarbamoyl)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carboxamide
DMXA8K1	DE	Discovery agent

DM6PFG0	ID	DM6PFG0
DM6PFG0	DN	CMET Avimer polypeptides
DM6PFG0	HS	Investigative
DM6PFG0	SN	CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune
DM6PFG0	CP	Medlmmune LLC
DM6PFG0	DE	Solid tumour/cancer

DMYPG01	ID	DMYPG01
DMYPG01	DN	CMI-1145
DMYPG01	HS	Investigative
DMYPG01	SN	AKOS014861624
DMYPG01	DT	Small molecular drug
DMYPG01	PC	100962651
DMYPG01	MW	180.21
DMYPG01	FM	C8H12N4O
DMYPG01	IC	InChI=1S/C8H12N4O/c9-8-11-7(13-12-8)5-3-4-1-2-6(5)10-4/h4-6,10H,1-3H2,(H2,9,12)/t4-,5-,6+/m1/s1
DMYPG01	CS	C1C[C@H]2[C@@H](C[C@@H]1N2)C3=NC(=NO3)N
DMYPG01	IK	XODBGPCGVOHHEP-PBXRRBTRSA-N
DMYPG01	IU	5-[(1S,2R,4R)-7-azabicyclo[2.2.1]heptan-2-yl]-1,2,4-oxadiazol-3-amine
DMYPG01	DE	Discovery agent

DM4PWDJ	ID	DM4PWDJ
DM4PWDJ	DN	CMI-489
DM4PWDJ	HS	Investigative
DM4PWDJ	SN	CMI-489; CHEMBL291498; HLNPMOXPJPCMLY-UHFFFAOYSA-N; N-methylepibatidine; N-methyl Epibatidine; SCHEMBL10105083; 222/224 N-Methyl-Epibatidine; BDBM50079453; 7-Methyl-2-(6-chloro-3-pyridyl)-7-azabicyclo[2.2.1]heptane; 2-(6-Chloro-pyridin-3-yl)-7-methyl-7-aza-bicyclo[2.2.1]heptane
DM4PWDJ	DT	Small molecular drug
DM4PWDJ	PC	11601009
DM4PWDJ	MW	222.71
DM4PWDJ	FM	C12H15ClN2
DM4PWDJ	IC	InChI=1S/C12H15ClN2/c1-15-9-3-4-11(15)10(6-9)8-2-5-12(13)14-7-8/h2,5,7,9-11H,3-4,6H2,1H3
DM4PWDJ	CS	CN1C2CCC1C(C2)C3=CN=C(C=C3)Cl
DM4PWDJ	IK	HLNPMOXPJPCMLY-UHFFFAOYSA-N
DM4PWDJ	IU	2-(6-chloropyridin-3-yl)-7-methyl-7-azabicyclo[2.2.1]heptane
DM4PWDJ	DE	Discovery agent

DMT9YKG	ID	DMT9YKG
DMT9YKG	DN	CMI-936
DMT9YKG	HS	Investigative
DMT9YKG	SN	AKOS014858886
DMT9YKG	DT	Small molecular drug
DMT9YKG	PC	100962650
DMT9YKG	MW	179.22
DMT9YKG	FM	C9H13N3O
DMT9YKG	IC	InChI=1S/C9H13N3O/c1-5-10-9(13-12-5)7-4-6-2-3-8(7)11-6/h6-8,11H,2-4H2,1H3/t6-,7-,8+/m1/s1
DMT9YKG	CS	CC1=NOC(=N1)[C@@H]2C[C@H]3CC[C@@H]2N3
DMT9YKG	IK	DCXSASGOFIVZCG-PRJMDXOYSA-N
DMT9YKG	IU	5-[(1S,2R,4R)-7-azabicyclo[2.2.1]heptan-2-yl]-3-methyl-1,2,4-oxadiazole
DMT9YKG	DE	Discovery agent

DMM9K5S	ID	DMM9K5S
DMM9K5S	DN	Cmp-2-Keto-3-Deoxy-Octulosonic Acid
DMM9K5S	HS	Investigative
DMM9K5S	SN	CMP-KDO; CMP-2-KETO-3-DEOXY-OCTULOSONIC ACID; AC1L9IPX; CMP-3-deoxy-D-manno-octulosonate; CMP-beta-KDO; cytidine 5'-monophosphate 3-deoxy-beta-d-gulo-oct-2-ulo-pyranosonic acid; C04121; CHEBI:86284; DB04482; CMP-3-deoxy-beta-D-manno-octulosonic acid; cytidine 5'-[(3-deoxy-beta-D-manno-oct-2-ulopyranosonyl) hydrogen phosphate]
DMM9K5S	DT	Small molecular drug
DMM9K5S	PC	445888
DMM9K5S	MW	543.4
DMM9K5S	FM	C17H26N3O15P
DMM9K5S	IC	InChI=1S/C17H26N3O15P/c18-9-1-2-20(16(29)19-9)14-12(26)11(25)8(33-14)5-32-36(30,31)35-17(15(27)28)3-6(22)10(24)13(34-17)7(23)4-21/h1-2,6-8,10-14,21-26H,3-5H2,(H,27,28)(H,30,31)(H2,18,19,29)/t6-,7-,8-,10-,11-,12-,13-,14-,17-/m1/s1
DMM9K5S	CS	C1[C@H]([C@H]([C@H](O[C@@]1(C(=O)O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)O)[C@@H](CO)O)O)O
DMM9K5S	IK	YWWJKULNWGRYAS-UOVSKDHASA-N
DMM9K5S	IU	(2R,4R,5R,6R)-2-[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-6-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxyoxane-2-carboxylic acid
DMM9K5S	CB	CHEBI:86284
DMM9K5S	DE	Discovery agent

DMBT2ZW	ID	DMBT2ZW
DMBT2ZW	DN	cmp5
DMBT2ZW	HS	Investigative
DMBT2ZW	SN	ChemBridge ID 9033823
DMBT2ZW	DT	Small molecular drug
DMBT2ZW	PC	6462334
DMBT2ZW	MW	351.9
DMBT2ZW	FM	C21H22ClN3
DMBT2ZW	IC	InChI=1S/C21H21N3.ClH/c1-2-24-20-9-4-3-8-18(20)19-13-16(10-11-21(19)24)14-22-15-17-7-5-6-12-23-17;/h3-13,22H,2,14-15H2,1H3;1H
DMBT2ZW	CS	CCN1C2=C(C=C(C=C2)CNCC3=CC=CC=N3)C4=CC=CC=C41.Cl
DMBT2ZW	IK	LTMOFUKBECEABM-UHFFFAOYSA-N
DMBT2ZW	IU	1-(9-ethylcarbazol-3-yl)-N-(pyridin-2-ylmethyl)methanamine;hydrochloride
DMBT2ZW	DE	Discovery agent

DM241YW	ID	DM241YW
DM241YW	DN	CMP-6
DM241YW	HS	Investigative
DM241YW	SN	Pyridone 6; 457081-03-7; JAK Inhibitor I; Merck-5; Merck 5; CMP 6; 2-tert-butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]isoquinolin-7(6H)-one; CHEMBL21156; 2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one; CHEBI:87103; Compound # 2; 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE; 2-TERT-BUTYL-9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLINE-7-ONE; IZA; C18H16FN3O; MERk-5
DM241YW	DT	Small molecular drug
DM241YW	PC	5494425
DM241YW	MW	309.3
DM241YW	FM	C18H16FN3O
DM241YW	IC	InChI=1S/C18H16FN3O/c1-18(2,3)17-21-14-10-5-4-9(19)8-12(10)13-11(15(14)22-17)6-7-20-16(13)23/h4-8H,1-3H3,(H,20,23)(H,21,22)
DM241YW	CS	CC(C)(C)C1=NC2=C(N1)C3=C(C=C(C=C3)F)C4=C2C=CNC4=O
DM241YW	IK	VNDWQCSOSCCWIP-UHFFFAOYSA-N
DM241YW	IU	4-tert-butyl-15-fluoro-3,5,10-triazatetracyclo[11.4.0.02,6.07,12]heptadeca-1(13),2(6),4,7(12),8,14,16-heptaen-11-one
DM241YW	CA	CAS 457081-03-7
DM241YW	CB	CHEBI:87103
DM241YW	DE	Discovery agent

DMKNUYF	ID	DMKNUYF
DMKNUYF	DN	CMPD1
DMKNUYF	HS	Investigative
DMKNUYF	SN	MAPKAPK2a inhibitor
DMKNUYF	DT	Small molecular drug
DMKNUYF	PC	11382492
DMKNUYF	MW	349.4
DMKNUYF	FM	C22H20FNO2
DMKNUYF	IC	InChI=1S/C22H20FNO2/c23-21-6-2-1-5-20(21)17-10-8-16(9-11-17)4-3-7-22(26)24-18-12-14-19(25)15-13-18/h1-2,5-6,8-15,25H,3-4,7H2,(H,24,26)
DMKNUYF	CS	C1=CC=C(C(=C1)C2=CC=C(C=C2)CCCC(=O)NC3=CC=C(C=C3)O)F
DMKNUYF	IK	ODYAQBDIXCVKAE-UHFFFAOYSA-N
DMKNUYF	IU	4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide
DMKNUYF	CA	CAS 41179-33-3
DMKNUYF	CB	CHEBI:92949
DMKNUYF	DE	Discovery agent

DM9IPH4	ID	DM9IPH4
DM9IPH4	DN	CMPD-167
DM9IPH4	HS	Investigative
DM9IPH4	SN	L-167; MRK-167; CCR5 inhibitor (HIV infection), IPM; CCR5 inhibitor (vaginal formulation), IPM; CMPD-167 (HIV infection); CMPD-167 (HIV infection), IPM; CMPD-167 (HIV infection), International Partnership for Microbiocides
DM9IPH4	CP	Merck & Co Inc
DM9IPH4	DT	Small molecular drug
DM9IPH4	PC	5481119
DM9IPH4	MW	574.8
DM9IPH4	FM	C35H47FN4O2
DM9IPH4	IC	InChI=1S/C35H47FN4O2/c1-5-40-33(21-30(37-40)18-25-10-7-6-8-11-25)26-14-16-39(17-15-26)23-28-20-31(38(4)34(24(2)3)35(41)42)22-32(28)27-12-9-13-29(36)19-27/h6-13,19,21,24,26,28,31-32,34H,5,14-18,20,22-23H2,1-4H3,(H,41,42)/t28-,31+,32-,34-/m1/s1
DM9IPH4	CS	CCN1C(=CC(=N1)CC2=CC=CC=C2)C3CCN(CC3)C[C@H]4C[C@@H](C[C@@H]4C5=CC(=CC=C5)F)N(C)[C@H](C(C)C)C(=O)O
DM9IPH4	IK	ZTENZJJCFACIAK-ADWVOTLJSA-N
DM9IPH4	IU	(2R)-2-[[(1R,3S,4S)-3-[[4-(5-benzyl-2-ethylpyrazol-3-yl)piperidin-1-yl]methyl]-4-(3-fluorophenyl)cyclopentyl]-methylamino]-3-methylbutanoic acid
DM9IPH4	CA	CAS 313994-79-5
DM9IPH4	DE	Human immunodeficiency virus-1 infection

DMH48YE	ID	DMH48YE
DMH48YE	DN	CMP-sialic acid
DMH48YE	HS	Investigative
DMH48YE	SN	CMP-Sialic acid; CMP-N-acetylneuraminate; cytidine monophosphate N-acetylneuraminic acid; CMP-NeuNAc; CYTIDINE-5'-MONOPHOSPHATE-5-N-ACETYLNEURAMINIC ACID; Cmp-D-N-acetylneuraminic acid; CHEBI:16556; Cmp-nana; CMP acetylneuraminic acid; 3063-71-6; CMP-N-acetyl-beta-neuraminate; NCC; (2R,4S,5R,6R)-2-[({[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]-5-acetamido-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMH48YE	DT	Small molecular drug
DMH48YE	PC	448209
DMH48YE	MW	614.5
DMH48YE	FM	C20H31N4O16P
DMH48YE	IC	InChI=1S/C20H31N4O16P/c1-7(26)22-12-8(27)4-20(18(32)33,39-16(12)13(29)9(28)5-25)40-41(35,36)37-6-10-14(30)15(31)17(38-10)24-3-2-11(21)23-19(24)34/h2-3,8-10,12-17,25,27-31H,4-6H2,1H3,(H,22,26)(H,32,33)(H,35,36)(H2,21,23,34)/t8-,9+,10+,12+,13+,14+,15+,16+,17+,20+/m0/s1
DMH48YE	CS	CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)O)O
DMH48YE	IK	TXCIAUNLDRJGJZ-BILDWYJOSA-N
DMH48YE	IU	(2R,4S,5R,6R)-5-acetamido-2-[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMH48YE	CA	CAS 3063-71-6
DMH48YE	CB	CHEBI:16556
DMH48YE	DE	Discovery agent

DMA5Z2G	ID	DMA5Z2G
DMA5Z2G	DN	C-myb
DMA5Z2G	HS	Investigative
DMA5Z2G	TC	Analgesics
DMA5Z2G	DE	Pain

DMJA8I4	ID	DMJA8I4
DMJA8I4	DN	CN-2097
DMJA8I4	HS	Investigative
DMJA8I4	SN	NMDA receptor 2B modulator (neurological diseases), Ardane Therapeutics; PDZ binding domain-targeting peptidomimetic (neurological diseases), Ardane Therapeutics
DMJA8I4	CP	Ardane Therapeutics Inc
DMJA8I4	PC	132608720
DMJA8I4	MW	2376.8
DMJA8I4	FM	C96H174N44O23S2
DMJA8I4	IC	InChI=1S/C96H174N44O23S2/c1-49(2)71(89(162)163)139-85(158)65-31-32-69(144)118-44-33-70(145)117-36-9-6-19-58(84(157)140-72(50(3)141)88(161)136-65)129-77(150)57(18-5-8-35-98)135-86(159)66(45-51-27-29-52(142)30-28-51)137-87(160)67(46-68(101)143)138-83(156)56(17-4-7-34-97)127-74(147)53(99)47-164-165-48-54(100)75(148)128-59(21-11-38-120-91(105)106)78(151)131-61(23-13-40-122-93(109)110)80(153)133-63(25-15-42-124-95(113)114)82(155)134-64(26-16-43-125-96(115)116)81(154)132-62(24-14-41-123-94(111)112)79(152)130-60(22-12-39-121-92(107)108)76(149)126-55(73(102)146)20-10-37-119-90(103)104/h27-30,49-50,53-67,71-72,141-142H,4-26,31-48,97-100H2,1-3H3,(H2,101,143)(H2,102,146)(H,117,145)(H,118,144)(H,126,149)(H,127,147)(H,128,148)(H,129,150)(H,130,152)(H,131,151)(H,132,154)(H,133,153)(H,134,155)(H,135,159)(H,136,161)(H,137,160)(H,138,156)(H,139,158)(H,140,157)(H,162,163)(H4,103,104,119)(H4,105,106,120)(H4,107,108,121)(H4,109,110,122)(H4,111,112,123)(H4,113,114,124)(H4,115,116,125)/t50-,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,71+,72+/m1/s1
DMJA8I4	CS	C[C@H]([C@H]1C(=N[C@@H](CCC(=NCCC(=NCCCC[C@@H](C(=N1)O)N=C([C@H](CCCCN)N=C([C@H](CC2=CC=C(C=C2)O)N=C([C@H](CC(=N)O)N=C([C@H](CCCCN)N=C([C@H](CSSC[C@@H](C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N)O)O)O)O)O)O)O)O)N)N)O)O)O)O)O)O)O)C(=N[C@@H](C(C)C)C(=O)O)O)O)O
DMJA8I4	IK	YVHNLJSCOYUIPK-YPBSVZMPSA-N
DMJA8I4	IU	(2S)-2-[[[(2S,5S,18S)-18-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2R)-2-amino-3-[[(2R)-2-amino-3-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-hydroxy-1-iminopentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-3-hydroxypropyl]disulfanyl]-1-hydroxypropylidene]amino]-1-hydroxyhexylidene]amino]-1,4-dihydroxy-4-iminobutylidene]amino]-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino]-1-hydroxyhexylidene]amino]-3,8,12,19-tetrahydroxy-2-[(1R)-1-hydroxyethyl]-1,4,9,13-tetrazacyclononadeca-3,8,12,19-tetraen-5-yl]-hydroxymethylidene]amino]-3-methylbutanoic acid
DMJA8I4	DE	Neurological disorder

DMFW1JC	ID	DMFW1JC
DMFW1JC	DN	C-Naphthalen-1-yl-methylamine
DMFW1JC	HS	Investigative
DMFW1JC	SN	1-Naphthalenemethylamine; 118-31-0; naphthalen-1-ylmethanamine; 1-Naphthylmethylamine; 1-NAPHTHALENEMETHANAMINE; 1-(Aminomethyl)naphthalene; 1-Naphthalenemethyl amine; C-Naphthalen-1-yl-methylamine; 1-Naphthylmethanamine; (1-naphthylmethyl)amine hydrochloride; CHEMBL128633; 1-AMINOMETHYLNAPHTHALENE; naphthylmethylamine; NVSYANRBXPURRQ-UHFFFAOYSA-N; MFCD00004048; 1-Naphthalenemethylamine, 97%; Naphthalene-1-methylamine; naphtalenemethylamine; EINECS 204-244-0; naphth-1-ylmethylamine; 1-naphthylmethyl-amine
DMFW1JC	DT	Small molecular drug
DMFW1JC	PC	8355
DMFW1JC	MW	157.21
DMFW1JC	FM	C11H11N
DMFW1JC	IC	InChI=1S/C11H11N/c12-8-10-6-3-5-9-4-1-2-7-11(9)10/h1-7H,8,12H2
DMFW1JC	CS	C1=CC=C2C(=C1)C=CC=C2CN
DMFW1JC	IK	NVSYANRBXPURRQ-UHFFFAOYSA-N
DMFW1JC	IU	naphthalen-1-ylmethanamine
DMFW1JC	CA	CAS 118-31-0
DMFW1JC	DE	Discovery agent

DMEVM0J	ID	DMEVM0J
DMEVM0J	DN	CNICIN
DMEVM0J	HS	Investigative
DMEVM0J	SN	Cnicin; 24394-09-0; CTK8F8750
DMEVM0J	DT	Small molecular drug
DMEVM0J	PC	5281435
DMEVM0J	MW	378.4
DMEVM0J	FM	C20H26O7
DMEVM0J	IC	InChI=1S/C20H26O7/c1-11-5-4-6-14(9-21)8-17-18(13(3)20(25)27-17)16(7-11)26-19(24)12(2)15(23)10-22/h5,8,15-18,21-23H,2-4,6-7,9-10H2,1H3/b11-5+,14-8-/t15-,16-,17+,18+/m0/s1
DMEVM0J	CS	C/C/1=C\\CC/C(=C/[C@@H]2[C@@H]([C@H](C1)OC(=O)C(=C)[C@H](CO)O)C(=C)C(=O)O2)/CO
DMEVM0J	IK	ZTDFZLVUIVPZDU-QGNHJMHWSA-N
DMEVM0J	IU	[(3aR,4S,6E,10Z,11aR)-10-(hydroxymethyl)-6-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (3R)-3,4-dihydroxy-2-methylidenebutanoate
DMEVM0J	CA	CAS 24394-09-0
DMEVM0J	DE	Discovery agent

DMTEGNB	ID	DMTEGNB
DMTEGNB	DN	CNS-1169
DMTEGNB	HS	Investigative
DMTEGNB	CP	CeNeS Pharmaceuticals Inc
DMTEGNB	DE	Schizophrenia

DMZ57O1	ID	DMZ57O1
DMZ57O1	DN	CNTO-736
DMZ57O1	HS	Investigative
DMZ57O1	SN	GLP-1 mimetibody (type 2 diabetes), Centocor
DMZ57O1	CP	Centocor Ortho Biotech Inc
DMZ57O1	DE	Non-insulin dependent diabetes

DMDK5BL	ID	DMDK5BL
DMDK5BL	DN	CNX-010
DMDK5BL	HS	Investigative
DMDK5BL	SN	11-beta hydroxysteroid dehydrogenase 1 inhibitors (type 2 diabetes), Connexios Life Sciences
DMDK5BL	CP	Connexios Life Sciences Pvt Ltd
DMDK5BL	DE	Non-insulin dependent diabetes

DM5T401	ID	DM5T401
DM5T401	DN	CNX-011
DM5T401	HS	Investigative
DM5T401	SN	GPR 40 agonists (type 2 diabetes); CNX-011-67; GPR 40 agonists (type 2 diabetes), Connexios LifeSciences; G-protein coupled receptor 40 agonists (type 2 diabetes), Connexios Life Sciences
DM5T401	CP	Connexios Life Sciences Pvt Ltd
DM5T401	DE	Non-insulin dependent diabetes

DMTB965	ID	DMTB965
DMTB965	DN	Cobalt Hexammine Ion
DMTB965	HS	Investigative
DMTB965	SN	Cobalt Hexammine Ion; Cobalt Hexammine(Iii); Hexaamminecobalt(3+); Cobalt III hexamine; hexaamminecobalt(III); Co(NH3)6; hexakis(azaniumyl)cobalt(3+); CHEBI:30027; [Co(NH3)6](3+)
DMTB965	DT	Small molecular drug
DMTB965	PC	453369
DMTB965	MW	161.12
DMTB965	FM	CoH18N6+3
DMTB965	IC	InChI=1S/Co.6H3N/h;6*1H3/q+3;;;;;;
DMTB965	CS	N.N.N.N.N.N.[Co+3]
DMTB965	IK	DYLMFCCYOUSRTK-UHFFFAOYSA-N
DMTB965	IU	azane;cobalt(3+)
DMTB965	CB	CHEBI:30027
DMTB965	DE	Discovery agent

DMJRSIF	ID	DMJRSIF
DMJRSIF	DN	COCAINE.HCL
DMJRSIF	HS	Investigative
DMJRSIF	SN	Cocaine muriate; Cocaine chloride; Sal de merck; l-Cocaine hydrochloride; Cocain-chlorhydrat [German]; EINECS 200-167-1; Cocaine hydrochloride [JAN]; 1alpha-H,5alpha-H-Tropane-2beta-carboxylic acid, 3beta-hydroxy-,; Methyl 3beta-hydroxy-1alphaH,5alphaH-tropan-2beta-carboxylate, benzoate (ester) hydrochloride; Methyl 3-beta-hydroxy-1-alpha-H,5-alpha-H-tropan-2-beta-carboxylate, benzoate (ester) HCl; 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, hydrochloride, (1R-(exo,exo))-
DMJRSIF	DT	Small molecular drug
DMJRSIF	PC	5871
DMJRSIF	MW	339.8
DMJRSIF	FM	C17H22ClNO4
DMJRSIF	IC	InChI=1S/C17H21NO4.ClH/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11;/h3-7,12-15H,8-10H2,1-2H3;1H/t12-,13-,14+,15-;/m1./s1
DMJRSIF	CS	CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC.Cl
DMJRSIF	IK	PIQVDUKEQYOJNR-RWXTUVLLSA-N
DMJRSIF	IU	methyl (1R,2R,3S,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate;hydrochloride
DMJRSIF	DE	Discovery agent

DMCSAIJ	ID	DMCSAIJ
DMCSAIJ	DN	COCHINCHINENENE B
DMCSAIJ	HS	Investigative
DMCSAIJ	SN	COCHINCHINENENE B; CHEMBL399481; BDBM50222765
DMCSAIJ	DT	Small molecular drug
DMCSAIJ	PC	23655936
DMCSAIJ	MW	512.6
DMCSAIJ	FM	C32H32O6
DMCSAIJ	IC	InChI=1S/C32H32O6/c1-36-27-15-9-22(10-16-27)29(17-11-23-8-14-26(34)19-31(23)38-3)32-24(18-28(37-2)20-30(32)35)7-4-21-5-12-25(33)13-6-21/h4-10,12-16,18-20,29,33-35H,11,17H2,1-3H3/b7-4+
DMCSAIJ	CS	COC1=CC=C(C=C1)C(CCC2=C(C=C(C=C2)O)OC)C3=C(C=C(C=C3O)OC)/C=C/C4=CC=C(C=C4)O
DMCSAIJ	IK	XZVDYCHPJWUZFS-QPJJXVBHSA-N
DMCSAIJ	IU	2-[3-(4-hydroxy-2-methoxyphenyl)-1-(4-methoxyphenyl)propyl]-3-[(E)-2-(4-hydroxyphenyl)ethenyl]-5-methoxyphenol
DMCSAIJ	DE	Discovery agent

DMIGB7N	ID	DMIGB7N
DMIGB7N	DN	COCHINCHINENIN B
DMIGB7N	HS	Investigative
DMIGB7N	SN	COCHINCHINENIN B; CHEMBL254648; BDBM50222763
DMIGB7N	DT	Small molecular drug
DMIGB7N	PC	23634523
DMIGB7N	MW	542.6
DMIGB7N	FM	C33H34O7
DMIGB7N	IC	InChI=1S/C33H34O7/c1-38-31-19-27(36)15-8-23(31)9-16-28(21-4-11-25(34)12-5-21)29-18-24(32(39-2)20-33(29)40-3)10-17-30(37)22-6-13-26(35)14-7-22/h4-8,11-15,18-20,28,34-36H,9-10,16-17H2,1-3H3
DMIGB7N	CS	COC1=CC(=C(C=C1CCC(=O)C2=CC=C(C=C2)O)C(CCC3=C(C=C(C=C3)O)OC)C4=CC=C(C=C4)O)OC
DMIGB7N	IK	QFWXEYRQNKRQDH-UHFFFAOYSA-N
DMIGB7N	IU	3-[5-[3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)propyl]-2,4-dimethoxyphenyl]-1-(4-hydroxyphenyl)propan-1-one
DMIGB7N	DE	Discovery agent

DMOUSWN	ID	DMOUSWN
DMOUSWN	DN	Cochliobolic acid
DMOUSWN	HS	Investigative
DMOUSWN	SN	Cochliobolic acid; CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid
DMOUSWN	DT	Small molecular drug
DMOUSWN	PC	6450172
DMOUSWN	MW	426.5
DMOUSWN	FM	C25H30O6
DMOUSWN	IC	InChI=1S/C25H30O6/c1-3-19(2)16-17-22(27)21(26)15-13-11-9-7-5-4-6-8-10-12-14-20-18-23(28)24(31-20)25(29)30/h4-17,19-20,23-24,28H,3,18H2,1-2H3,(H,29,30)/b6-4+,7-5+,10-8+,11-9+,14-12+,15-13+,17-16+/t19?,20-,23-,24-/m1/s1
DMOUSWN	CS	CCC(C)/C=C/C(=O)C(=O)/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H]1C[C@H]([C@@H](O1)C(=O)O)O
DMOUSWN	IK	UWFRQOWLUPERFN-WUSQRGMKSA-N
DMOUSWN	IU	(2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid
DMOUSWN	CA	CAS 185846-15-5
DMOUSWN	DE	Discovery agent

DMZ1VSI	ID	DMZ1VSI
DMZ1VSI	DN	COCLAURINE
DMZ1VSI	HS	Investigative
DMZ1VSI	SN	(S)-Coclaurine; 486-39-5; UNII-CW1576313Y; (1S)-1-(4-hydroxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol; CHEMBL446211; CHEBI:15950; CW1576313Y; 1-(p-Hydroxybenzyl)-6-methoxy-7-hydroxy-1,2,3,4-tetrahydroisoquinoline; Coclaurin; (S)-1,2,3,4-Tetrahydro-1-[(4-hydroxyphenyl)methyl]-6-methoxy-7-isoquinolinol; 7-Isoquinolinol,1,2,3,4-tetrahydro-1-[(4-hydroxyphenyl)methyl]-6-methoxy-, (1S)-; AC1L4NPG; AC1Q7A6I; SCHEMBL20683184; CTK4J0916; DTXSID60197561; MolPort-019-904-720; ZINC896120
DMZ1VSI	DT	Small molecular drug
DMZ1VSI	PC	160487
DMZ1VSI	MW	285.34
DMZ1VSI	FM	C17H19NO3
DMZ1VSI	IC	InChI=1S/C17H19NO3/c1-21-17-9-12-6-7-18-15(14(12)10-16(17)20)8-11-2-4-13(19)5-3-11/h2-5,9-10,15,18-20H,6-8H2,1H3/t15-/m0/s1
DMZ1VSI	CS	COC1=C(C=C2[C@@H](NCCC2=C1)CC3=CC=C(C=C3)O)O
DMZ1VSI	IK	LVVKXRQZSRUVPY-HNNXBMFYSA-N
DMZ1VSI	IU	(1S)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol
DMZ1VSI	CA	CAS 486-39-5
DMZ1VSI	CB	CHEBI:15950
DMZ1VSI	DE	Discovery agent

DM08WPL	ID	DM08WPL
DM08WPL	DN	CODEINONE
DM08WPL	HS	Investigative
DM08WPL	SN	Codeinone; 6-Codeinone; 467-13-0; UNII-22B5AW0ANN; (5alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-one; EINECS 207-386-1; BRN 0094188; 22B5AW0ANN; CHEBI:18399; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6-one; Morphinan-6-one, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; 6-Oxocodeine; (-)-Codeinone; SCHEMBL100655; CHEMBL257627; DTXSID70196909; XYYVYLMBEZUESM-CMKMFDCUSA-N; ZINC4097036; API0000487; LS-92114; C06171; 7,8-Didehydro-4,5; A-epoxy-3-methoxy-17-methyl-morphinan-6-one
DM08WPL	DT	Small molecular drug
DM08WPL	PC	5459910
DM08WPL	MW	297.3
DM08WPL	FM	C18H19NO3
DM08WPL	IC	InChI=1S/C18H19NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-12,17H,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
DM08WPL	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)C=C4
DM08WPL	IK	XYYVYLMBEZUESM-CMKMFDCUSA-N
DM08WPL	IU	(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM08WPL	CA	CAS 467-13-0
DM08WPL	CB	CHEBI:18399
DM08WPL	DE	Discovery agent

DM1I8LU	ID	DM1I8LU
DM1I8LU	DN	Coenzyme A
DM1I8LU	HS	Investigative
DM1I8LU	SN	coenzyme A; CoASH; CoA-SH; Zeel; 85-61-0; Depot-Zeel; CoA; HSCoA; Coenzym A; Coenzyme ASH; co-enzyme-A; UNII-SAA04E81UX; HS-CoA; SAA04E81UX; CHEBI:15346; 3'-phosphoadenosine-(5')diphospho(4')pantatheine; Coenzyme A hydrate; co-A; Co-A-SH; Reduced CoA; 3'-phosphoadenosine 5'-{3-[(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl] dihydrogen diphosphate}
DM1I8LU	DT	Small molecular drug
DM1I8LU	PC	87642
DM1I8LU	MW	767.5
DM1I8LU	FM	C21H36N7O16P3S
DM1I8LU	IC	InChI=1S/C21H36N7O16P3S/c1-21(2,16(31)19(32)24-4-3-12(29)23-5-6-48)8-41-47(38,39)44-46(36,37)40-7-11-15(43-45(33,34)35)14(30)20(42-11)28-10-27-13-17(22)25-9-26-18(13)28/h9-11,14-16,20,30-31,48H,3-8H2,1-2H3,(H,23,29)(H,24,32)(H,36,37)(H,38,39)(H2,22,25,26)(H2,33,34,35)/t11-,14-,15-,16+,20-/m1/s1
DM1I8LU	CS	CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCS)O
DM1I8LU	IK	RGJOEKWQDUBAIZ-IBOSZNHHSA-N
DM1I8LU	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] hydrogen phosphate
DM1I8LU	CA	CAS 85-61-0
DM1I8LU	CB	CHEBI:15346
DM1I8LU	DE	Discovery agent

DM0ACL9	ID	DM0ACL9
DM0ACL9	DN	Coformycin
DM0ACL9	HS	Investigative
DM0ACL9	SN	coformycin; 11033-22-0; UNII-E49510ZL0H; NSC 277817; (R)-3,4,7,8-Tetrahydro-3-beta-D-ribofuranosylimidazo(4,5-d)(1,3)diazepin-8-ol; CHEBI:16213; E49510ZL0H; (8R)-3-beta-D-ribofuranosyl-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; Imidazo(4,5-d)(1,3)diazepin-8-ol, 3,4,7,8-tetrahydro-3-beta-D-ribofuranosyl-, (R)-; CHEMBL284483; NSC277817; SCHEMBL442534; YOOVTUPUBVHMPG-LODYRLCVSA-N; AC1L1956; BDBM50367032; LS-77849; C01677; Imidazo[4,5-d][1,3]diazepin-8-ol, 3,4,7,8-tetrahydro-3-.beta.-D-ribofuranosyl-, (8R)
DM0ACL9	DT	Small molecular drug
DM0ACL9	PC	25447
DM0ACL9	MW	284.27
DM0ACL9	FM	C11H16N4O5
DM0ACL9	IC	InChI=1S/C11H16N4O5/c16-2-6-8(18)9(19)11(20-6)15-4-14-7-5(17)1-12-3-13-10(7)15/h3-6,8-9,11,16-19H,1-2H2,(H,12,13)/t5-,6-,8-,9-,11-/m1/s1
DM0ACL9	CS	C1[C@H](C2=C(NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O
DM0ACL9	IK	YOOVTUPUBVHMPG-LODYRLCVSA-N
DM0ACL9	IU	(2R,3R,4S,5R)-2-[(8R)-8-hydroxy-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-3-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM0ACL9	CA	CAS 11033-22-0
DM0ACL9	CB	CHEBI:16213
DM0ACL9	DE	Discovery agent

DM326VN	ID	DM326VN
DM326VN	DN	COLCHINOL
DM326VN	HS	Investigative
DM326VN	SN	Colchinol; (S)-5-Amino-6,7-dihydro-9,10,11-trimethoxy-5H-dibenzo(a,c)cyclohepten-3-ol; 477-31-6; CHEMBL198808; AC1Q7B91; AC1L4V44; CTK4J0211; 5H-Dibenzo(a,c)cyclohepten-3-ol, 5-amino-6,7-dihydro-9,10,11-trimethoxy-, (S)-
DM326VN	DT	Small molecular drug
DM326VN	PC	164612
DM326VN	MW	315.4
DM326VN	FM	C18H21NO4
DM326VN	IC	InChI=1S/C18H21NO4/c1-21-15-8-10-4-7-14(19)13-9-11(20)5-6-12(13)16(10)18(23-3)17(15)22-2/h5-6,8-9,14,20H,4,7,19H2,1-3H3/t14-/m0/s1
DM326VN	CS	COC1=C(C(=C2C(=C1)CC[C@@H](C3=C2C=CC(=C3)O)N)OC)OC
DM326VN	IK	HSDSUBIABLFGDX-AWEZNQCLSA-N
DM326VN	IU	(8S)-8-amino-13,14,15-trimethoxytricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,5,11,13-hexaen-5-ol
DM326VN	CA	CAS 477-31-6
DM326VN	DE	Discovery agent

DMIKD8X	ID	DMIKD8X
DMIKD8X	DN	COMBETASTATIN
DMIKD8X	HS	Investigative
DMIKD8X	DT	Small molecular drug
DMIKD8X	PC	44303123
DMIKD8X	MW	318.4
DMIKD8X	FM	C18H22O5
DMIKD8X	IC	InChI=1S/C18H22O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-10,13,19H,11H2,1-4H3/b6-5-
DMIKD8X	CS	COC1=C(C(=CC(C1)/C=C\\C2=CC(=C(C=C2)OC)O)OC)OC
DMIKD8X	IK	YHCKDJOSGUSXBN-WAYWQWQTSA-N
DMIKD8X	IU	2-methoxy-5-[(Z)-2-(3,4,5-trimethoxycyclohexa-2,4-dien-1-yl)ethenyl]phenol
DMIKD8X	DE	Discovery agent

DMC2IYH	ID	DMC2IYH
DMC2IYH	DN	Conantokin-G
DMC2IYH	HS	Investigative
DMC2IYH	SN	Conantokin-G; Conantokin G; UNII-32CFR9L3TD; 93438-65-4; 32CFR9L3TD; Con-G; GTPL4161; Conantokin G, &gt;=75% (HPLC)
DMC2IYH	DT	Small molecular drug
DMC2IYH	PC	16181638
DMC2IYH	MW	2264.2
DMC2IYH	FM	C88H138N26O44
DMC2IYH	IC	InChI=1S/C88H138N26O44/c1-7-34(6)61(77(138)103-41(12-10-20-98-88(96)97)63(124)107-48(23-35(78(139)140)79(141)142)69(130)100-40(11-8-9-19-89)64(125)113-54(31-115)76(137)104-45(62(95)123)28-57(93)118)114-75(136)47(22-33(4)5)106-70(131)49(24-36(80(143)144)81(145)146)109-67(128)44(14-17-56(92)117)102-74(135)53(29-58(94)119)112-73(134)51(26-38(84(151)152)85(153)154)110-66(127)43(13-16-55(91)116)101-68(129)46(21-32(2)3)105-71(132)52(27-39(86(155)156)87(157)158)111-72(133)50(25-37(82(147)148)83(149)150)108-65(126)42(15-18-60(121)122)99-59(120)30-90/h32-54,61,115H,7-31,89-90H2,1-6H3,(H2,91,116)(H2,92,117)(H2,93,118)(H2,94,119)(H2,95,123)(H,99,120)(H,100,130)(H,101,129)(H,102,135)(H,103,138)(H,104,137)(H,105,132)(H,106,131)(H,107,124)(H,108,126)(H,109,128)(H,110,127)(H,111,133)(H,112,134)(H,113,125)(H,114,136)(H,121,122)(H,139,140)(H,141,142)(H,143,144)(H,145,146)(H,147,148)(H,149,150)(H,151,152)(H,153,154)(H,155,156)(H,157,158)(H4,96,97,98)/t34-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,61-/m0/s1
DMC2IYH	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C(=O)O)C(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN
DMC2IYH	IK	HTBKFGWATIYCSF-QGXIKSNHSA-N
DMC2IYH	IU	2-[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-4-carboxybutanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-oxopropyl]propanedioic acid
DMC2IYH	DE	Discovery agent

DMN4KJI	ID	DMN4KJI
DMN4KJI	DN	Conantokin-R
DMN4KJI	HS	Investigative
DMN4KJI	PC	44560113
DMN4KJI	MW	3057.4
DMN4KJI	FM	C126H202N34O48S3
DMN4KJI	IC	InChI=1S/C126H202N34O48S3/c1-15-57(8)93(115(189)141-62(13)96(170)145-71(24-16-19-36-127)100(174)136-51-89(165)143-83(52-209)111(185)147-73(26-18-21-38-129)104(178)157-92(56(6)7)114(188)154-80(48-86(131)162)108(182)156-84(53-210)112(186)155-82(43-63-29-31-64(161)32-30-63)116(190)160-40-23-28-85(160)125(207)208)159-110(184)81(49-87(132)163)150-99(173)65(44-66(117(191)192)118(193)194)70(27-22-39-135-126(133)134)144-95(169)60(11)139-105(179)76(42-54(2)3)151-106(180)77(45-67(119(195)196)120(197)198)149-98(172)59(10)137-94(168)58(9)138-101(175)75(35-41-211-14)148-102(176)72(25-17-20-37-128)146-97(171)61(12)140-113(187)91(55(4)5)158-109(183)79(47-69(123(203)204)124(205)206)153-107(181)78(46-68(121(199)200)122(201)202)152-103(177)74(33-34-90(166)167)142-88(164)50-130/h29-32,54-62,65-85,91-93,161,209-210H,15-28,33-53,127-130H2,1-14H3,(H2,131,162)(H2,132,163)(H,136,174)(H,137,168)(H,138,175)(H,139,179)(H,140,187)(H,141,189)(H,142,164)(H,143,165)(H,144,169)(H,145,170)(H,146,171)(H,147,185)(H,148,176)(H,149,172)(H,150,173)(H,151,180)(H,152,177)(H,153,181)(H,154,188)(H,155,186)(H,156,182)(H,157,178)(H,158,183)(H,159,184)(H,166,167)(H,191,192)(H,193,194)(H,195,196)(H,197,198)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,207,208)(H4,133,134,135)/t57-,58-,59-,60-,61-,62-,65?,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,91-,92-,93-/m0/s1
DMN4KJI	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)C(CC(C(=O)O)C(=O)O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN
DMN4KJI	IK	XIRRXDGMZVHVEG-AZOPZXLDSA-N
DMN4KJI	IU	2-[(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-4-carboxybutanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4,4-dicarboxybutanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]propanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-2-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2R)-1-[[(2S)-1-[(2S)-2-carboxypyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamoyl]-6-carbamimidamidohexyl]propanedioic acid
DMN4KJI	DE	Discovery agent

DMLHF3E	ID	DMLHF3E
DMLHF3E	DN	Conantokins G
DMLHF3E	HS	Investigative
DMLHF3E	DE	Discovery agent

DMV6H5S	ID	DMV6H5S
DMV6H5S	DN	Conantokins T
DMV6H5S	HS	Investigative
DMV6H5S	DE	Discovery agent

DMC5RKY	ID	DMC5RKY
DMC5RKY	DN	Concatameric CTLA4Ig
DMC5RKY	HS	Investigative
DMC5RKY	SN	Concatameric CTLA4Ig (Immunoadhesin); Concatameric CD152Ig (Immunoadhesin), Medexgen; Concatameric CTLA4Ig (Immunoadhesin), Medexgen
DMC5RKY	CP	Medexgen Co Ltd
DMC5RKY	DE	Discovery agent

DMRPV0A	ID	DMRPV0A
DMRPV0A	DN	Concatameric LAG3Ig
DMRPV0A	HS	Investigative
DMRPV0A	SN	Concatameric LAG3Ig (immunoadhesin); CD223Ig (immunoadhesin), Medexgen; Concatameric LAG3Ig (immunoadhesin),Medexgen
DMRPV0A	CP	Medexgen Co Ltd
DMRPV0A	DE	Discovery agent

DM4VYP0	ID	DM4VYP0
DM4VYP0	DN	CONESSINE
DM4VYP0	HS	Investigative
DM4VYP0	SN	conessine; Roquessine; Neriine; 546-06-5; Conessinum; Wrightine; Conessin; UNII-EZ38J9BBDF; NSC 119994; EZ38J9BBDF; Konessin; CHEBI:27965; GPLGAQQQNWMVMM-MYAJQUOBSA-N; Conessine [INN]; N,N-dimethylcon-5-enin-3beta-amine; ST066907; Conesina [INN-Spanish]; Conessinum [INN-Latin]; DSSTox_CID_26000; DSSTox_RID_81281; DSSTox_GSID_46000; 3beta-(Dimethylamino)con-5-ene; Conesina; EINECS 208-897-2; BRN 4702160; Con-5-enine, 3.beta.-(dimethylamino)-; ((2S,5S,12S,16S,1R,9R,13R)-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0&lt; 2,9&gt; 5, 9&gt
DM4VYP0	DT	Small molecular drug
DM4VYP0	PC	441082
DM4VYP0	MW	356.6
DM4VYP0	FM	C24H40N2
DM4VYP0	IC	InChI=1S/C24H40N2/c1-16-20-8-9-22-19-7-6-17-14-18(25(3)4)10-12-23(17,2)21(19)11-13-24(20,22)15-26(16)5/h6,16,18-22H,7-15H2,1-5H3/t16-,18-,19+,20+,21-,22-,23-,24-/m0/s1
DM4VYP0	CS	C[C@H]1[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)N(C)C)C)CN1C
DM4VYP0	IK	GPLGAQQQNWMVMM-MYAJQUOBSA-N
DM4VYP0	IU	(1R,2S,5S,6S,9R,12S,13R,16S)-N,N,6,7,13-pentamethyl-7-azapentacyclo[10.8.0.02,9.05,9.013,18]icos-18-en-16-amine
DM4VYP0	CA	CAS 546-06-5
DM4VYP0	CB	CHEBI:27965
DM4VYP0	DE	Discovery agent

DMQG2MC	ID	DMQG2MC
DMQG2MC	DN	Conotoxin
DMQG2MC	HS	Investigative
DMQG2MC	DE	Discovery agent

DM5DTZR	ID	DM5DTZR
DM5DTZR	DN	COOH
DM5DTZR	HS	Investigative
DM5DTZR	SN	LS-191838
DM5DTZR	DT	Small molecular drug
DM5DTZR	PC	10025649
DM5DTZR	MW	429.5
DM5DTZR	FM	C27H27NO4
DM5DTZR	IC	InChI=1S/C27H27NO4/c1-2-6-20-18-24(32-23-7-4-3-5-8-23)10-12-26(20)31-14-13-22-17-21-15-19(16-27(29)30)9-11-25(21)28-22/h3-5,7-12,15,17-18,28H,2,6,13-14,16H2,1H3,(H,29,30)
DM5DTZR	CS	CCCC1=C(C=CC(=C1)OC2=CC=CC=C2)OCCC3=CC4=C(N3)C=CC(=C4)CC(=O)O
DM5DTZR	IK	DFFOSEJNFZUOSK-UHFFFAOYSA-N
DM5DTZR	IU	2-[2-[2-(4-phenoxy-2-propylphenoxy)ethyl]-1H-indol-5-yl]acetic acid
DM5DTZR	CA	CAS 209808-51-5
DM5DTZR	DE	Discovery agent

DMFH5J9	ID	DMFH5J9
DMFH5J9	DN	cooling agent 10
DMFH5J9	HS	Investigative
DMFH5J9	SN	(-)-menthoxypropane-1,2-diol
DMFH5J9	DT	Small molecular drug
DMFH5J9	PC	5362595
DMFH5J9	MW	230.34
DMFH5J9	FM	C13H26O3
DMFH5J9	IC	InChI=1S/C13H26O3/c1-9(2)12-5-4-10(3)6-13(12)16-8-11(15)7-14/h9-15H,4-8H2,1-3H3
DMFH5J9	CS	CC1CCC(C(C1)OCC(CO)O)C(C)C
DMFH5J9	IK	MDVYIGJINBYKOM-UHFFFAOYSA-N
DMFH5J9	IU	3-(5-methyl-2-propan-2-ylcyclohexyl)oxypropane-1,2-diol
DMFH5J9	CA	CAS 87061-04-9
DMFH5J9	DE	Discovery agent

DMT5SED	ID	DMT5SED
DMT5SED	DN	CORDOIN
DMT5SED	HS	Investigative
DMT5SED	SN	Cordoin; Derricidin; trans-1-(2-Hydroxy-4-((3-methyl-2-butenyl)oxy)phenyl)-3-phenyl-2-propen-1-one; 2-Propen-1-one, 1-(2-hydroxy-4-((3-methyl-2-butenyl)oxy)phenyl)-3-phenyl-, (E)-; 38965-74-1; substituted chalcone, 5a; AC1NZGI9; AC1Q5EJC; CHEMBL450771; SCHEMBL18265486; BDBM29137; 51619-65-9; 2'-Hydroxy-4'-(prenyloxy)chalcone; NSC270894; LMPK12120040; NSC-270894; 1-{2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}-3-phenylprop-2-en-1-one; LS-123926; J3.608.736F
DMT5SED	DT	Small molecular drug
DMT5SED	PC	5961410
DMT5SED	MW	308.4
DMT5SED	FM	C20H20O3
DMT5SED	IC	InChI=1S/C20H20O3/c1-15(2)12-13-23-17-9-10-18(20(22)14-17)19(21)11-8-16-6-4-3-5-7-16/h3-12,14,22H,13H2,1-2H3/b11-8+
DMT5SED	CS	CC(=CCOC1=CC(=C(C=C1)C(=O)/C=C/C2=CC=CC=C2)O)C
DMT5SED	IK	DGUGLZYULGVSIZ-DHZHZOJOSA-N
DMT5SED	IU	(E)-1-[2-hydroxy-4-(3-methylbut-2-enoxy)phenyl]-3-phenylprop-2-en-1-one
DMT5SED	CA	CAS 38965-74-1
DMT5SED	DE	Discovery agent

DM72Y01	ID	DM72Y01
DM72Y01	DN	Cordycepin
DM72Y01	HS	Investigative
DM72Y01	SN	3'-deoxyadenosine
DM72Y01	DT	Small molecular drug
DM72Y01	PC	6303
DM72Y01	MW	251.24
DM72Y01	FM	C10H13N5O3
DM72Y01	IC	InChI=1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,10+/m0/s1
DM72Y01	CS	C1[C@H](O[C@H]([C@@H]1O)N2C=NC3=C(N=CN=C32)N)CO
DM72Y01	IK	OFEZSBMBBKLLBJ-BAJZRUMYSA-N
DM72Y01	IU	(2R,3R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
DM72Y01	CA	CAS 73-03-0
DM72Y01	CB	CHEBI:29014
DM72Y01	DE	Discovery agent

DMAC698	ID	DMAC698
DMAC698	DN	CORILAGIN
DMAC698	HS	Investigative
DMAC698	SN	Corilagin; 23094-69-1; CHEMBL449392; CHEBI:3884; TUSDEZXZIZRFGC-XIGLUPEJSA-N; Corillagin; Corilagin,(S); AC1Q6PBU; AC1L2K3M; (1s,19r,21s,22r,23r)-6,7,8,11,12,13,22,23-octahydroxy-3,16-dioxo-2,17,20-trioxatetracyclo[17.3.1.04,9.010,15]tricosa-4,6,8,10,12,14-hexaen-21-yl 3,4,5-trihydroxybenzoate; SCHEMBL329080; Corilagin, analytical standard; CTK4F0871; MolPort-020-005-758; b-D-Glucopyranose, cyclic3,6-[(1R)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate]1-(3,4,5-trihydroxybenzoate); ZINC4098612; BDBM50242279
DMAC698	DT	Small molecular drug
DMAC698	PC	73568
DMAC698	MW	634.5
DMAC698	FM	C27H22O18
DMAC698	IC	InChI=1S/C27H22O18/c28-9-1-6(2-10(29)16(9)32)24(39)45-27-22(38)23-19(35)13(43-27)5-42-25(40)7-3-11(30)17(33)20(36)14(7)15-8(26(41)44-23)4-12(31)18(34)21(15)37/h1-4,13,19,22-23,27-38H,5H2/t13-,19-,22-,23+,27+/m1/s1
DMAC698	CS	C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O1)O)O)O)O)O)O)O
DMAC698	IK	TUSDEZXZIZRFGC-XIGLUPEJSA-N
DMAC698	IU	[(1S,19R,21S,22R,23R)-6,7,8,11,12,13,22,23-octahydroxy-3,16-dioxo-2,17,20-trioxatetracyclo[17.3.1.04,9.010,15]tricosa-4,6,8,10,12,14-hexaen-21-yl] 3,4,5-trihydroxybenzoate
DMAC698	CA	CAS 2088321-44-0
DMAC698	CB	CHEBI:3884
DMAC698	DE	Discovery agent

DMZBUE7	ID	DMZBUE7
DMZBUE7	DN	CORONARIDINE
DMZBUE7	HS	Investigative
DMZBUE7	SN	CORONARIDINE; Coronardine; CHEMBL364613; CHEBI:3887; (-)-Coronaridine; NSC127490; Ibogamine-18-carboxylic acid, methyl ester; Methyl ibogamine-18-carboxylate; 467-77-6; AC1L2JXS; NVVDQMVGALBDGE-KSWFMABOSA-N; BDBM50329102
DMZBUE7	DT	Small molecular drug
DMZBUE7	PC	73489
DMZBUE7	MW	338.4
DMZBUE7	FM	C21H26N2O2
DMZBUE7	IC	InChI=1S/C21H26N2O2/c1-3-14-10-13-11-21(20(24)25-2)18-16(8-9-23(12-13)19(14)21)15-6-4-5-7-17(15)22-18/h4-7,13-14,19,22H,3,8-12H2,1-2H3/t13-,14-,19-,21+/m0/s1
DMZBUE7	CS	CC[C@H]1C[C@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC
DMZBUE7	IK	NVVDQMVGALBDGE-KSWFMABOSA-N
DMZBUE7	IU	methyl (1S,15S,17S,18S)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMZBUE7	CA	CAS 467-77-6
DMZBUE7	CB	CHEBI:3887
DMZBUE7	DE	Discovery agent

DM563PZ	ID	DM563PZ
DM563PZ	DN	Corosolic acid
DM563PZ	HS	Investigative
DM563PZ	SN	A,5xi,18; A)-2,3-dihydroxyurs-12-en-28-oic acid; AC1Q5QHO; AC1L4WCO; SCHEMBL1157257; KB-333790; LS-193275; (2a,3b)-2,3-dihydroxy-urs-12-en-28-oic acid; (1S,2R,4aS,6aR,6aS,6bR,10R,11R,12aR,14bR)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DM563PZ	DT	Small molecular drug
DM563PZ	PC	6918774
DM563PZ	MW	472.7
DM563PZ	FM	C30H48O4
DM563PZ	IC	InChI=1S/C30H48O4/c1-17-10-13-30(25(33)34)15-14-28(6)19(23(30)18(17)2)8-9-22-27(5)16-20(31)24(32)26(3,4)21(27)11-12-29(22,28)7/h8,17-18,20-24,31-32H,9-16H2,1-7H3,(H,33,34)/t17-,18+,20-,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1
DM563PZ	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H](C5(C)C)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DM563PZ	IK	HFGSQOYIOKBQOW-ZSDYHTTISA-N
DM563PZ	IU	(1S,2R,4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DM563PZ	CA	CAS 4547-24-4
DM563PZ	CB	CHEBI:67895
DM563PZ	DE	Discovery agent

DM5ISQK	ID	DM5ISQK
DM5ISQK	DN	Correloid
DM5ISQK	HS	Investigative
DM5ISQK	SN	Correloid; CHEMBL362198
DM5ISQK	DT	Small molecular drug
DM5ISQK	PC	44389018
DM5ISQK	MW	788.8
DM5ISQK	FM	C40H52O16
DM5ISQK	IC	InChI=1S/C40H52O16/c1-18-16-39(48)26-14-15-35(8)25-12-13-27(46)50-17-38(25,19(2)51-20(3)41)31(53-22(5)43)28(52-21(4)42)29(35)36(26,9)32(54-23(6)44)33(55-24(7)45)37(39,10)40(30(18)56-40)34(47)49-11/h12-13,19,25-26,28-33,48H,1,14-17H2,2-11H3/t19-,25?,26?,28+,29?,30-,31+,32-,33+,35+,36+,37-,38-,39-,40?/m1/s1
DM5ISQK	CS	C[C@H]([C@]12COC(=O)C=CC1[C@@]3(CCC4[C@@](C3[C@@H]([C@@H]2OC(=O)C)OC(=O)C)([C@@H]([C@@H]([C@@]5([C@]4(CC(=C)[C@@H]6C5(O6)C(=O)OC)O)C)OC(=O)C)OC(=O)C)C)C)OC(=O)C
DM5ISQK	IK	VKDXHXWBOARFPD-MDAQDJAWSA-N
DM5ISQK	IU	methyl (2R,3S,4R,5R,8R,11R,15S,22R,23R,24S)-3,4,23,24-tetraacetyloxy-22-[(1R)-1-acetyloxyethyl]-11-hydroxy-2,5,15-trimethyl-9-methylidene-19-oxo-7,20-dioxahexacyclo[13.9.0.02,12.05,11.06,8.016,22]tetracos-17-ene-6-carboxylate
DM5ISQK	DE	Discovery agent

DMACH7K	ID	DMACH7K
DMACH7K	DN	correolide
DMACH7K	HS	Investigative
DMACH7K	SN	Correolide; C13849; GTPL2555
DMACH7K	DT	Small molecular drug
DMACH7K	PC	11643509
DMACH7K	MW	788.8
DMACH7K	FM	C40H52O16
DMACH7K	IC	InChI=1S/C40H52O16/c1-18-16-39(48)26-14-15-35(8)25-12-13-27(46)50-17-38(25,19(2)51-20(3)41)31(53-22(5)43)28(52-21(4)42)29(35)36(26,9)32(54-23(6)44)33(55-24(7)45)37(39,10)40(30(18)56-40)34(47)49-11/h12-13,19,25-26,28-33,48H,1,14-17H2,2-11H3/t19?,25-,26+,28-,29-,30+,31-,32+,33-,35-,36-,37+,38+,39+,40-/m0/s1
DMACH7K	CS	CC([C@]12COC(=O)C=C[C@H]1[C@@]3(CC[C@@H]4[C@@]([C@H]3[C@@H]([C@@H]2OC(=O)C)OC(=O)C)([C@@H]([C@@H]([C@@]5([C@]4(CC(=C)[C@@H]6[C@]5(O6)C(=O)OC)O)C)OC(=O)C)OC(=O)C)C)C)OC(=O)C
DMACH7K	IK	VKDXHXWBOARFPD-IHWRNOMOSA-N
DMACH7K	IU	methyl (1S,2R,3S,4R,5R,6S,8R,11R,12R,15S,16S,22R,23R,24S)-3,4,23,24-tetraacetyloxy-22-(1-acetyloxyethyl)-11-hydroxy-2,5,15-trimethyl-9-methylidene-19-oxo-7,20-dioxahexacyclo[13.9.0.02,12.05,11.06,8.016,22]tetracos-17-ene-6-carboxylate
DMACH7K	CB	CHEBI:34654
DMACH7K	DE	Discovery agent

DM463S2	ID	DM463S2
DM463S2	DN	CORYMBONE B
DM463S2	HS	Investigative
DM463S2	SN	corymbone B
DM463S2	DT	Small molecular drug
DM463S2	PC	24878741
DM463S2	MW	522.6
DM463S2	FM	C31H38O7
DM463S2	IC	InChI=1S/C31H38O7/c1-16(2)15-19(22-27(36)30(4,5)29(38)31(6,7)28(22)37)21-24(33)17(3)25(34)23(26(21)35)20(32)14-13-18-11-9-8-10-12-18/h8-12,16,19,33-36H,13-15H2,1-7H3
DM463S2	CS	CC1=C(C(=C(C(=C1O)C(=O)CCC2=CC=CC=C2)O)C(CC(C)C)C3=C(C(C(=O)C(C3=O)(C)C)(C)C)O)O
DM463S2	IK	LCFIVEWYLOYPOX-UHFFFAOYSA-N
DM463S2	IU	5-hydroxy-2,2,6,6-tetramethyl-4-[3-methyl-1-[2,4,6-trihydroxy-3-methyl-5-(3-phenylpropanoyl)phenyl]butyl]cyclohex-4-ene-1,3-dione
DM463S2	DE	Discovery agent

DM18CUZ	ID	DM18CUZ
DM18CUZ	DN	CORYNANTHEINE
DM18CUZ	HS	Investigative
DM18CUZ	SN	Corynantheine; Hirsuteine; BRN 0096586; 18904-54-6; 17,18-Secoyohimban-16-carboxylic acid, 16,17,18,19-tetradehydro-17-methoxy-, methyl ester, (E)-; AC1MHD3Z; SCHEMBL3084853; MolPort-039-338-502; ZINC85909641; LS-144745; (16E)-16,17,18,19-Tetradehydro-17-methoxycorynan-16-carboxylic acid methyl ester; methyl (Z)-2-[(2S,3R,12bS)-3-vinyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxy-prop-2-enoate; methyl (Z)-2-[(2S,3R,12bS)-3-ethenyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methox
DM18CUZ	DT	Small molecular drug
DM18CUZ	PC	3037997
DM18CUZ	MW	366.5
DM18CUZ	FM	C22H26N2O3
DM18CUZ	IC	InChI=1S/C22H26N2O3/c1-4-14-12-24-10-9-16-15-7-5-6-8-19(15)23-21(16)20(24)11-17(14)18(13-26-2)22(25)27-3/h4-8,13-14,17,20,23H,1,9-12H2,2-3H3/b18-13+/t14-,17-,20-/m0/s1
DM18CUZ	CS	CO/C=C(\\[C@H]1C[C@H]2C3=C(CCN2C[C@@H]1C=C)C4=CC=CC=C4N3)/C(=O)OC
DM18CUZ	IK	TZUGIFAYWNNSAO-XPOGPMDLSA-N
DM18CUZ	IU	methyl (E)-2-[(2S,3R,12bS)-3-ethenyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
DM18CUZ	CA	CAS 18904-54-6
DM18CUZ	CB	CHEBI:141891
DM18CUZ	DE	Discovery agent

DMSFXJ8	ID	DMSFXJ8
DMSFXJ8	DN	Cosalane derivative
DMSFXJ8	HS	Investigative
DMSFXJ8	PC	44371300
DMSFXJ8	MW	1123.7
DMSFXJ8	FM	C59H70B2Cl2Na4O10
DMSFXJ8	IC	InChI=1S/C59H72B2Cl2O10.4Na/c1-35(2)10-6-11-36(3)49-20-21-50-46-19-18-42-26-37(22-24-58(42,4)51(46)23-25-59(49,50)5)12-9-17-45(40-29-47(56(64)65)54(52(62)31-40)72-33-38-13-7-15-43(27-38)60(68)69)41-30-48(57(66)67)55(53(63)32-41)73-34-39-14-8-16-44(28-39)61(70)71;;;;/h7-8,13-17,27-32,35-37,42,46,49-51,68,70H,6,9-12,18-26,33-34H2,1-5H3,(H,64,65)(H,66,67);;;;/q-2;4*+1/p-2/t36?,37-,42?,46?,49+,50?,51?,58-,59+;;;;/m0..../s1
DMSFXJ8	CS	B(C1=CC(=CC=C1)COC2=C(C=C(C=C2Cl)C(=CCC[C@H]3CC[C@]4(C(C3)CCC5C4CC[C@]6(C5CC[C@@H]6C(C)CCCC(C)C)C)C)C7=CC(=C(C(=C7)Cl)OCC8=CC=CC(=C8)B(O)[O-])C(=O)[O-])C(=O)[O-])(O)[O-].[Na+].[Na+].[Na+].[Na+]
DMSFXJ8	IK	ABZNJZXRGKGMJC-MCUHGXDSSA-L
DMSFXJ8	IU	tetrasodium;5-[1-[3-carboxylato-5-chloro-4-[[3-[hydroxy(oxido)boranyl]phenyl]methoxy]phenyl]-4-[(3S,10S,13R,17R)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]but-1-enyl]-3-chloro-2-[[3-[hydroxy(oxido)boranyl]phenyl]methoxy]benzoate
DMSFXJ8	DE	Discovery agent

DMU6OB4	ID	DMU6OB4
DMU6OB4	DN	Costunolide
DMU6OB4	HS	Investigative
DMU6OB4	SN	Costunolide; Costunolid; Costus lactone; Costunlide; AC1NSPGS; HRYLQFBHBWLLLL-GYIATTAWSA-N; Cyclodeca[b]furan-2(3H)-one, 3a,4,5,8,9,11a-hexahydro-6,10-dimethyl-3-methylene-, [3aS-(3aR*,6E,10E,11aS*)]-; BRD-A49888826-001-01-8; (6E,10E)-3a,4,5,8,9,11a-Hexahydro-6,10-dimethyl-3-methylenecyclodeca[b]furan-2(3H)-one; (E,E)-6-.alpha.-Hydroxygermacra-1(10),4,11(13)-trien-12-oic acid .gamma.-lactone; Germacra-1(10),4,11(13)-trien-12-oic acid, 6.alpha.-hydroxy-, .gamma.-lactone, (E,E)-
DMU6OB4	DT	Small molecular drug
DMU6OB4	PC	5281437
DMU6OB4	MW	232.32
DMU6OB4	FM	C15H20O2
DMU6OB4	IC	InChI=1S/C15H20O2/c1-10-5-4-6-11(2)9-14-13(8-7-10)12(3)15(16)17-14/h5,9,13-14H,3-4,6-8H2,1-2H3/b10-5+,11-9+/t13-,14+/m0/s1
DMU6OB4	CS	C/C/1=C\\CC/C(=C/[C@@H]2[C@@H](CC1)C(=C)C(=O)O2)/C
DMU6OB4	IK	HRYLQFBHBWLLLL-AHNJNIBGSA-N
DMU6OB4	IU	(3aS,6E,10E,11aR)-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one
DMU6OB4	CA	CAS 553-21-9
DMU6OB4	CB	CHEBI:3900
DMU6OB4	DE	Discovery agent

DM7TCPG	ID	DM7TCPG
DM7TCPG	DN	Coumaranone
DM7TCPG	HS	Investigative
DM7TCPG	SN	Benzofuran-3(2H)-one; Benzofuran-3-one; Coumaran-3-one; Coumaranone; MGKPCLNUSDGXGT-UHFFFAOYSA-N; PubChem7023; benzofuran-3 (2h)-one; benzofuran-3-(2H)-one; 1-Benzofuran-3(2H)-one; 1-benzofuran-3-one; 2,3-Dihydrobenzo[b]furan-3-one; 2,3-dihydro-1-benzofuran-3-one; 2-hydrobenzo[b]furan-3-one; 2H-3-Benzofuranone; 2H-BENZOFURAN-3-ONE; 2H-BEZOFURAN-3-ONE; 3(2H)-BENZOFURANONE; 3-(2H)-benzo[b]furanone; 3-BENZOFURANONE; 3-Coumaranone; 7169-34-8; 71699-34-8; AC1L2MLQ; CCRIS 3596; MFCD00051810; NCIOpen2_003700; SCHEMBL69412
DM7TCPG	PC	23556
DM7TCPG	MW	134.13
DM7TCPG	FM	C8H6O2
DM7TCPG	IC	MGKPCLNUSDGXGT-UHFFFAOYSA-N
DM7TCPG	CS	C1C(=O)C2=CC=CC=C2O1
DM7TCPG	IK	1S/C8H6O2/c9-7-5-10-8-4-2-1-3-6(7)8/h1-4H,5H2
DM7TCPG	IU	1-benzofuran-3-one
DM7TCPG	CA	CAS 7169-34-8
DM7TCPG	DE	Discovery agent

DM0N8ZM	ID	DM0N8ZM
DM0N8ZM	DN	Coumarin
DM0N8ZM	HS	Investigative
DM0N8ZM	SN	coumarin; 2H-Chromen-2-one; 91-64-5; 2H-1-Benzopyran-2-one; cumarin; 1,2-Benzopyrone; Rattex; Tonka bean camphor; Coumarinic anhydride; chromen-2-one; Coumarine; Benzo-alpha-pyrone; cis-o-Coumarinic acid lactone; o-Hydroxycinnamic acid lactone; o-Hydroxycinnamic lactone; 2-Oxo-1,2-benzopyran; Coumarinic lactone; Kumarin; Benzo-a-pyrone; Kumarin [Czech]; 5,6-Benzo-2-pyrone; 2H-1-Benzopyran, 2-oxo-; 5,6-Benzo-alpha-pyrone; 2H-Benzo(b)pyran-2-one; 2H-Benzo[b]pyran-2-one; Caswell No. 259C; o-Coumaric acid lactone
DM0N8ZM	DT	Small molecular drug
DM0N8ZM	PC	323
DM0N8ZM	MW	146.14
DM0N8ZM	FM	C9H6O2
DM0N8ZM	IC	InChI=1S/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H
DM0N8ZM	CS	C1=CC=C2C(=C1)C=CC(=O)O2
DM0N8ZM	IK	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N
DM0N8ZM	IU	chromen-2-one
DM0N8ZM	CA	CAS 91-64-5
DM0N8ZM	CB	CHEBI:28794
DM0N8ZM	DE	Discovery agent

DMAJNPS	ID	DMAJNPS
DMAJNPS	DN	Coumermycin
DMAJNPS	HS	Investigative
DMAJNPS	DT	Small molecular drug
DMAJNPS	PC	54675768
DMAJNPS	MW	1110.1
DMAJNPS	FM	C55H59N5O20
DMAJNPS	IC	InChI=1S/C55H59N5O20/c1-21-12-16-29(57-21)48(67)77-42-38(63)52(79-54(6,7)44(42)71-10)73-31-18-14-26-36(61)34(50(69)75-40(26)24(31)4)59-46(65)28-20-56-33(23(28)3)47(66)60-35-37(62)27-15-19-32(25(5)41(27)76-51(35)70)74-53-39(64)43(45(72-11)55(8,9)80-53)78-49(68)30-17-13-22(2)58-30/h12-20,38-39,42-45,52-53,56-58,61-64H,1-11H3,(H,59,65)(H,60,66)/t38-,39-,42+,43+,44-,45-,52-,53-/m1/s1
DMAJNPS	CS	CC1=CC=C(N1)C(=O)O[C@H]2[C@H]([C@@H](OC([C@@H]2OC)(C)C)OC3=C(C4=C(C=C3)C(=C(C(=O)O4)NC(=O)C5=CNC(=C5C)C(=O)NC6=C(C7=C(C(=C(C=C7)O[C@H]8[C@@H]([C@@H]([C@H](C(O8)(C)C)OC)OC(=O)C9=CC=C(N9)C)O)C)OC6=O)O)O)C)O
DMAJNPS	IK	WTIJXIZOODAMJT-DHFGXMAYSA-N
DMAJNPS	IU	[(3R,4S,5R,6R)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2R,3R,4S,5R)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1H-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1H-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1H-pyrrole-2-carboxylate
DMAJNPS	CA	CAS 4434-05-3
DMAJNPS	CB	CHEBI:3907
DMAJNPS	DE	Discovery agent

DM40TBU	ID	DM40TBU
DM40TBU	DN	Coumestrol
DM40TBU	HS	Investigative
DM40TBU	SN	COUMESTROL; 479-13-0; Cumoestrol; Cumoesterol; Cumostrol; Coumesterol; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; 7,12-Dihydroxycoumestan; 3,9-Dihydroxycoumestan; UNII-V7NW98OB34; NSC 22842; CCRIS 7311; NSC22842; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; EINECS 207-525-6; BRN 0266702; CHEMBL30707; MLS000738006; V7NW98OB34; CHEBI:3908; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-
DM40TBU	DT	Small molecular drug
DM40TBU	PC	5281707
DM40TBU	MW	268.22
DM40TBU	FM	C15H8O5
DM40TBU	IC	InChI=1S/C15H8O5/c16-7-1-3-9-11(5-7)19-14-10-4-2-8(17)6-12(10)20-15(18)13(9)14/h1-6,16-17H
DM40TBU	CS	C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O
DM40TBU	IK	ZZIALNLLNHEQPJ-UHFFFAOYSA-N
DM40TBU	IU	3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one
DM40TBU	CA	CAS 479-13-0
DM40TBU	CB	CHEBI:3908
DM40TBU	DE	Discovery agent

DM2LWNF	ID	DM2LWNF
DM2LWNF	DN	COV08-0064
DM2LWNF	HS	Investigative
DM2LWNF	CP	Mallinckrodt Pharma
DM2LWNF	DT	Small molecular drug
DM2LWNF	DE	Parkinson disease

DMT2RHV	ID	DMT2RHV
DMT2RHV	DN	CP 4010
DMT2RHV	HS	Investigative
DMT2RHV	SN	CP-4010
DMT2RHV	DE	Discovery agent

DMSNVKP	ID	DMSNVKP
DMSNVKP	DN	CP 93129
DMSNVKP	HS	Investigative
DMSNVKP	SN	CP-93129; CP93129; CP-93,129
DMSNVKP	DT	Small molecular drug
DMSNVKP	PC	124007
DMSNVKP	MW	215.25
DMSNVKP	FM	C12H13N3O
DMSNVKP	IC	InChI=1S/C12H13N3O/c16-11-2-1-10-12(15-11)9(7-14-10)8-3-5-13-6-4-8/h1-3,7,13-14H,4-6H2,(H,15,16)
DMSNVKP	CS	C1CNCC=C1C2=CNC3=C2NC(=O)C=C3
DMSNVKP	IK	PJYVGMRFPFNZCT-UHFFFAOYSA-N
DMSNVKP	IU	3-(1,2,3,6-tetrahydropyridin-4-yl)-1,4-dihydropyrrolo[3,2-b]pyridin-5-one
DMSNVKP	CA	CAS 127792-75-0
DMSNVKP	CB	CHEBI:93436
DMSNVKP	DE	Discovery agent

DMLFNTH	ID	DMLFNTH
DMLFNTH	DN	CP-100263
DMLFNTH	HS	Investigative
DMLFNTH	SN	3-Piperidinamine,N-[(2-methoxyphenyl)methyl]-2-phenyl-, (2S,3S)-; ACMC-1CCIL; SCHEMBL3951618; CTK4C0571; L007874
DMLFNTH	CP	Pfizer
DMLFNTH	DT	Small molecular drug
DMLFNTH	PC	9796216
DMLFNTH	MW	296.4
DMLFNTH	FM	C19H24N2O
DMLFNTH	IC	InChI=1S/C19H24N2O/c1-22-18-12-6-5-10-16(18)14-21-17-11-7-13-20-19(17)15-8-3-2-4-9-15/h2-6,8-10,12,17,19-21H,7,11,13-14H2,1H3/t17-,19-/m1/s1
DMLFNTH	CS	COC1=CC=CC=C1CN[C@@H]2CCCN[C@@H]2C3=CC=CC=C3
DMLFNTH	IK	DTQNEFOKTXXQKV-IEBWSBKVSA-N
DMLFNTH	IU	(2R,3R)-N-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine
DMLFNTH	CA	CAS 872726-33-5
DMLFNTH	DE	Vomiting

DM3ZIDT	ID	DM3ZIDT
DM3ZIDT	DN	CP-126998
DM3ZIDT	HS	Investigative
DM3ZIDT	SN	3-[2-(1-Benzylpiperidin-4-yl)ethyl]-7-methyl-6,7-dihydro-5H-pyrrolo[3,2-f][1,2-]benzisoxazol-6-one
DM3ZIDT	PC	10318177
DM3ZIDT	MW	389.5
DM3ZIDT	FM	C24H27N3O2
DM3ZIDT	IC	InChI=1S/C24H27N3O2/c1-26-22-15-23-20(13-19(22)14-24(26)28)21(25-29-23)8-7-17-9-11-27(12-10-17)16-18-5-3-2-4-6-18/h2-6,13,15,17H,7-12,14,16H2,1H3
DM3ZIDT	CS	CN1C(=O)CC2=CC3=C(C=C21)ON=C3CCC4CCN(CC4)CC5=CC=CC=C5
DM3ZIDT	IK	GBRYDMXCJVBJHH-UHFFFAOYSA-N
DM3ZIDT	IU	3-[2-(1-benzylpiperidin-4-yl)ethyl]-7-methyl-5H-pyrrolo[3,2-f][1,2]benzoxazol-6-one
DM3ZIDT	DE	Discovery agent

DMYHR74	ID	DMYHR74
DMYHR74	DN	CP154,526
DMYHR74	HS	Investigative
DMYHR74	SN	CP-154526; 157286-86-7; CP 154,526; CHEMBL9946; CP154526; UNII-9A549FB00R; 9A549FB00R; CHEMBL475903; CP-154526-1; CP-154,526; N-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine; N-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)pyrrolo(2,3-d)pyrimidin-4-amine; PDSP1_001299; AC1NSJWW; CP154,526; butyl-(2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)ethylamine; SCHEMBL5707848; GTPL3495; FHQYJZCJRZHINA-UHFFFAOYSA-N; ZINC1539133; BCP26372; BDBM50058163; BDBM50369802
DMYHR74	DT	Small molecular drug
DMYHR74	PC	5311055
DMYHR74	MW	364.5
DMYHR74	FM	C23H32N4
DMYHR74	IC	InChI=1S/C23H32N4/c1-8-10-11-26(9-2)22-20-18(6)14-27(23(20)25-19(7)24-22)21-16(4)12-15(3)13-17(21)5/h12-14H,8-11H2,1-7H3
DMYHR74	CS	CCCCN(CC)C1=NC(=NC2=C1C(=CN2C3=C(C=C(C=C3C)C)C)C)C
DMYHR74	IK	FHQYJZCJRZHINA-UHFFFAOYSA-N
DMYHR74	IU	N-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine
DMYHR74	CA	CAS 157286-86-7
DMYHR74	DE	Depression

DMGLO2X	ID	DMGLO2X
DMGLO2X	DN	CP-226269
DMGLO2X	HS	Investigative
DMGLO2X	SN	CP-226,269; CP 226269; CP226269
DMGLO2X	DT	Small molecular drug
DMGLO2X	PC	9796720
DMGLO2X	MW	310.4
DMGLO2X	FM	C18H19FN4
DMGLO2X	IC	InChI=1S/C18H19FN4/c19-15-4-5-17-14(11-15)12-16(21-17)13-22-7-9-23(10-8-22)18-3-1-2-6-20-18/h1-6,11-12,21H,7-10,13H2
DMGLO2X	CS	C1CN(CCN1CC2=CC3=C(N2)C=CC(=C3)F)C4=CC=CC=N4
DMGLO2X	IK	PQOIDBZLMJMYCD-UHFFFAOYSA-N
DMGLO2X	IU	5-fluoro-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-indole
DMGLO2X	CA	CAS 220941-93-5
DMGLO2X	DE	Discovery agent

DMGN38F	ID	DMGN38F
DMGN38F	DN	CP-271485
DMGN38F	HS	Investigative
DMGN38F	SN	CP-271485; 2-(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL) ETHYL-4-(4'-ETHOXY [1,1'-BIPHENYL]-4-YL)-4-OXOBUTANOIC ACID; CP8; (6R)-4-BENZYL-6-(1-METHYL-2,2-DIOXIDO-1,3-DIHYDRO-2,1-BENZISOTHIAZOL-5-YL)MORPHOLIN-3-ONE; 1utt; AC1L9MIT; DB02118; CP 271485; (6S)-4-benzyl-6-(1-methyl-2,2-dioxo-3H-2,1-benzothiazol-5-yl)morpholin-3-one; 3-Morpholinone, 6-(1,3-dihydro-1-methyl-2,1-benzisothiazol-5-yl)-4-(phenylmethyl)-, S,S-dioxid; 35580-46-2; (6S)-4-benzyl-6-(1-methyl-2,2-dioxido-1,3-dihydro-2,1-benzisothiazol-5-yl)morpholin-3-one
DMGN38F	DT	Small molecular drug
DMGN38F	PC	448940
DMGN38F	MW	372.4
DMGN38F	FM	C19H20N2O4S
DMGN38F	IC	InChI=1S/C19H20N2O4S/c1-20-17-8-7-15(9-16(17)13-26(20,23)24)18-11-21(19(22)12-25-18)10-14-5-3-2-4-6-14/h2-9,18H,10-13H2,1H3/t18-/m1/s1
DMGN38F	CS	CN1C2=C(CS1(=O)=O)C=C(C=C2)[C@H]3CN(C(=O)CO3)CC4=CC=CC=C4
DMGN38F	IK	CIUMOGWIMXNXSQ-GOSISDBHSA-N
DMGN38F	IU	(6S)-4-benzyl-6-(1-methyl-2,2-dioxo-3H-2,1-benzothiazol-5-yl)morpholin-3-one
DMGN38F	CA	CAS 35580-46-2
DMGN38F	DE	Discovery agent

DM6BRLA	ID	DM6BRLA
DM6BRLA	DN	CP-294838
DM6BRLA	HS	Investigative
DM6BRLA	SN	CP 294838; CP294838
DM6BRLA	DT	Small molecular drug
DM6BRLA	PC	9889227
DM6BRLA	MW	436.3
DM6BRLA	FM	C22H23Cl2NO4
DM6BRLA	IC	InChI=1S/C22H23Cl2NO4/c1-22(2,3)12-25-17-9-8-13(23)10-15(17)20(14-6-4-5-7-16(14)24)29-18(21(25)28)11-19(26)27/h4-10,18,20H,11-12H2,1-3H3,(H,26,27)
DM6BRLA	CS	CC(C)(C)CN1C2=C(C=C(C=C2)Cl)C(OC(C1=O)CC(=O)O)C3=CC=CC=C3Cl
DM6BRLA	IK	BHDQOMHFEOHAQK-UHFFFAOYSA-N
DM6BRLA	IU	2-[7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetic acid
DM6BRLA	DE	Discovery agent

DMME6K2	ID	DMME6K2
DMME6K2	DN	CP-305202
DMME6K2	HS	Investigative
DMME6K2	SN	CP-305202; CHEMBL1276497; BDBM50330342
DMME6K2	DT	Small molecular drug
DMME6K2	PC	52948369
DMME6K2	MW	512.7
DMME6K2	FM	C30H44N2O5
DMME6K2	IC	InChI=1S/C30H44N2O5/c1-21(2)18-25(33)29(34)24(19-22-10-5-4-6-11-22)32-30(35)28-26(36-3)14-7-15-27(28)37-17-9-13-23-12-8-16-31-20-23/h7-8,12,14-16,20-22,24-25,29,33-34H,4-6,9-11,13,17-19H2,1-3H3,(H,32,35)/t24-,25-,29+/m0/s1
DMME6K2	CS	CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)C2=C(C=CC=C2OCCCC3=CN=CC=C3)OC)O)O
DMME6K2	IK	PJZBKGNAKHKHSH-IALVYGIMSA-N
DMME6K2	IU	N-[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]-2-methoxy-6-(3-pyridin-3-ylpropoxy)benzamide
DMME6K2	DE	Discovery agent

DMY8O0B	ID	DMY8O0B
DMY8O0B	DN	CP-320626
DMY8O0B	HS	Investigative
DMY8O0B	SN	CP-320626; UNII-FKX709RK3Q; FKX709RK3Q; CHEMBL99889; 5-CHLORO-1H-INDOLE-2-CARBOXYLIC ACID [1-(4-FLUOROBENZYL)-2-(4-HYDROXYPIPERIDIN-1YL)-2-OXOETHYL]AMIDE; 5-chloro-N-[(2S)-3-(4-fluorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboxamide; YDCGVASFVACWKF-NRFANRHFSA-N; AC1L9GTI; 1H-Indole-2-carboxamide, 5-chloro-N-((1S)-1-((4-fluorophenyl)methyl)-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl)-; 186430-23-9; SCHEMBL7234251; BDBM35346; DB03383; 1H-Indole-2-carboxamide, 5-chloro-N-(1-((4-fluorophenyl)methyl)-
DMY8O0B	DT	Small molecular drug
DMY8O0B	PC	444746
DMY8O0B	MW	443.9
DMY8O0B	FM	C23H23ClFN3O3
DMY8O0B	IC	InChI=1S/C23H23ClFN3O3/c24-16-3-6-19-15(12-16)13-20(26-19)22(30)27-21(11-14-1-4-17(25)5-2-14)23(31)28-9-7-18(29)8-10-28/h1-6,12-13,18,21,26,29H,7-11H2,(H,27,30)/t21-/m0/s1
DMY8O0B	CS	C1CN(CCC1O)C(=O)[C@H](CC2=CC=C(C=C2)F)NC(=O)C3=CC4=C(N3)C=CC(=C4)Cl
DMY8O0B	IK	YDCGVASFVACWKF-NRFANRHFSA-N
DMY8O0B	IU	5-chloro-N-[(2S)-3-(4-fluorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboxamide
DMY8O0B	CA	CAS 186430-23-9
DMY8O0B	DE	Discovery agent

DMTJOWH	ID	DMTJOWH
DMTJOWH	DN	CP-339818
DMTJOWH	HS	Investigative
DMTJOWH	SN	CHEMBL281622; AC1LCVJB; CP 339818; Tocris-1399; C13847; (1-Benzyl-1H-quinolin-4-ylidene)-pentyl-amine; SureCN12648579; GTPL2558; SCHEMBL12648579; CHEBI:34602; 1-benzyl-N-pentylquinolin-4-imine; 1-benzyl-N-pentyl-quinolin-4-imine; ZINC17919916; BDBM50083523; ZINC100002080; ZINC253533285; NCGC00025144-01; AJ-70179; CP339818; AJ-70180; N-pentyl-1-(phenylmethyl)quinolin-4-imine
DMTJOWH	DT	Small molecular drug
DMTJOWH	PC	656767
DMTJOWH	MW	304.4
DMTJOWH	FM	C21H24N2
DMTJOWH	IC	InChI=1S/C21H24N2/c1-2-3-9-15-22-20-14-16-23(17-18-10-5-4-6-11-18)21-13-8-7-12-19(20)21/h4-8,10-14,16H,2-3,9,15,17H2,1H3
DMTJOWH	CS	CCCCCN=C1C=CN(C2=CC=CC=C12)CC3=CC=CC=C3
DMTJOWH	IK	MMGAVKCAGQCFHS-UHFFFAOYSA-N
DMTJOWH	IU	1-benzyl-N-pentylquinolin-4-imine
DMTJOWH	CA	CAS 185855-91-8
DMTJOWH	CB	CHEBI:34602
DMTJOWH	DE	Discovery agent

DM93CA4	ID	DM93CA4
DM93CA4	DN	CP-376395
DM93CA4	HS	Investigative
DM93CA4	SN	CP-376395; CP 376395; 175140-00-8; UNII-5113G7FP34; 3,6-Dimethyl-N-(Pentan-3-Yl)-2-(2,4,6-Trimethylphenoxy)pyridin-4-Amine; 5113G7FP34; VIZBSVDBNLAVAW-UHFFFAOYSA-N; 1Q5; CP376395; 4k5y; SCHEMBL123421; GTPL3496; CHEMBL270948; DTXSID0047298; BDBM20966; MolPort-009-194-134; KS-00002WT7; 2-Aryloxy-4-alkylaminopyridine, 3a; ZINC14975027; AKOS015994585; 4-Pyridinamine, N-(1-ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-; GD-0065; CS-7833; API0007847; compound 3a [PMID: 18288792]; HY-14130; KB-76174; CP-376,395; CP 376,395
DM93CA4	DT	Small molecular drug
DM93CA4	PC	9862166
DM93CA4	MW	326.5
DM93CA4	FM	C21H30N2O
DM93CA4	IC	InChI=1S/C21H30N2O/c1-8-18(9-2)23-19-12-16(6)22-21(17(19)7)24-20-14(4)10-13(3)11-15(20)5/h10-12,18H,8-9H2,1-7H3,(H,22,23)
DM93CA4	CS	CCC(CC)NC1=C(C(=NC(=C1)C)OC2=C(C=C(C=C2C)C)C)C
DM93CA4	IK	VIZBSVDBNLAVAW-UHFFFAOYSA-N
DM93CA4	IU	3,6-dimethyl-N-pentan-3-yl-2-(2,4,6-trimethylphenoxy)pyridin-4-amine
DM93CA4	CA	CAS 175140-00-8
DM93CA4	DE	Discovery agent

DMDPH3W	ID	DMDPH3W
DMDPH3W	DN	CP-394531
DMDPH3W	HS	Investigative
DMDPH3W	SN	CP-394531; UNII-227D9ED2SI; CHEMBL77779; 227D9ED2SI; 305822-63-3; SCHEMBL3111189; BDBM50113783; 2,7-Phenanthrenediol, 2-(chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 2,7-Phenanthrenediol, 2-(2-chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 4a-Benzyl-2-chloroethynyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-2,7-diol(CP-394531)
DMDPH3W	DT	Small molecular drug
DMDPH3W	PC	9820558
DMDPH3W	MW	366.9
DMDPH3W	FM	C23H23ClO2
DMDPH3W	IC	InChI=1S/C23H23ClO2/c24-13-12-22(26)10-11-23(15-17-4-2-1-3-5-17)19(16-22)7-6-18-14-20(25)8-9-21(18)23/h1-5,8-9,14,19,25-26H,6-7,10-11,15-16H2/t19-,22+,23+/m1/s1
DMDPH3W	CS	C1CC2=C(C=CC(=C2)O)[C@]3([C@H]1C[C@](CC3)(C#CCl)O)CC4=CC=CC=C4
DMDPH3W	IK	CNOAOQSZNOTZLQ-OIBXWCBGSA-N
DMDPH3W	IU	(2R,4aS,10aR)-4a-benzyl-2-(2-chloroethynyl)-1,3,4,9,10,10a-hexahydrophenanthrene-2,7-diol
DMDPH3W	CA	CAS 305822-63-3
DMDPH3W	DE	Discovery agent

DM1U6P7	ID	DM1U6P7
DM1U6P7	DN	CP-409069
DM1U6P7	HS	Investigative
DM1U6P7	SN	CHEMBL78625; CP-409069; SCHEMBL3114566; BDBM50113780; (2R,4aS,10aR)-4a-benzyl-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,7-diol
DM1U6P7	DT	Small molecular drug
DM1U6P7	PC	9819614
DM1U6P7	MW	346.5
DM1U6P7	FM	C24H26O2
DM1U6P7	IC	InChI=1S/C24H26O2/c1-2-12-23(26)13-14-24(16-18-6-4-3-5-7-18)20(17-23)9-8-19-15-21(25)10-11-22(19)24/h3-7,10-11,15,20,25-26H,8-9,13-14,16-17H2,1H3/t20-,23-,24+/m1/s1
DM1U6P7	CS	CC#C[C@]1(CC[C@@]2([C@@H](C1)CCC3=C2C=CC(=C3)O)CC4=CC=CC=C4)O
DM1U6P7	IK	WDSPVCXWXOIFRA-HUVFLSCGSA-N
DM1U6P7	IU	(2R,4aS,10aR)-4a-benzyl-2-prop-1-ynyl-1,3,4,9,10,10a-hexahydrophenanthrene-2,7-diol
DM1U6P7	DE	Discovery agent

DMROYD7	ID	DMROYD7
DMROYD7	DN	CP-409092
DMROYD7	HS	Investigative
DMROYD7	SN	GABA(A) partial agonists (anxiety), Pfizer
DMROYD7	PC	9839190
DMROYD7	MW	297.35
DMROYD7	FM	C17H19N3O2
DMROYD7	IC	InChI=1S/C17H19N3O2/c1-18-9-11-5-7-12(8-6-11)20-17(22)13-10-19-14-3-2-4-15(21)16(13)14/h5-8,10,18-19H,2-4,9H2,1H3,(H,20,22)
DMROYD7	CS	CNCC1=CC=C(C=C1)NC(=O)C2=CNC3=C2C(=O)CCC3
DMROYD7	IK	XFJIYNUISLDNLP-UHFFFAOYSA-N
DMROYD7	IU	N-[4-(methylaminomethyl)phenyl]-4-oxo-1,5,6,7-tetrahydroindole-3-carboxamide
DMROYD7	CA	CAS 194098-25-4
DMROYD7	DE	Discovery agent

DMZMKAQ	ID	DMZMKAQ
DMZMKAQ	DN	CP-4200
DMZMKAQ	HS	Investigative
DMZMKAQ	SN	Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate
DMZMKAQ	CP	Clavis Pharma AS
DMZMKAQ	DE	Solid tumour/cancer

DMTHVCA	ID	DMTHVCA
DMTHVCA	DN	CP-4497
DMTHVCA	HS	Investigative
DMTHVCA	SN	CP-47497
DMTHVCA	PC	15942731
DMTHVCA	MW	318.5
DMTHVCA	FM	C21H34O2
DMTHVCA	IC	InChI=1S/C21H34O2/c1-4-5-6-7-13-21(2,3)17-11-12-19(20(23)15-17)16-9-8-10-18(22)14-16/h11-12,15-16,18,22-23H,4-10,13-14H2,1-3H3/t16-,18+/m0/s1
DMTHVCA	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@H]2CCC[C@H](C2)O)O
DMTHVCA	IK	ZWWRREXSUJTKNN-FUHWJXTLSA-N
DMTHVCA	IU	2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol
DMTHVCA	CA	CAS 114753-51-4
DMTHVCA	DE	Discovery agent

DMS2RHE	ID	DMS2RHE
DMS2RHE	DN	CP-470,711
DMS2RHE	HS	Investigative
DMS2RHE	SN	CP-470711; CHEMBL36514; SCHEMBL6294633; BDBM50113494; LS-135453
DMS2RHE	DT	Small molecular drug
DMS2RHE	PC	9841731
DMS2RHE	MW	358.4
DMS2RHE	FM	C18H26N6O2
DMS2RHE	IC	InChI=1S/C18H26N6O2/c1-11-9-23(15-5-7-19-17(21-15)13(3)25)10-12(2)24(11)16-6-8-20-18(22-16)14(4)26/h5-8,11-14,25-26H,9-10H2,1-4H3/t11-,12+,13-,14-/m1/s1
DMS2RHE	CS	C[C@@H]1CN(C[C@@H](N1C2=NC(=NC=C2)[C@@H](C)O)C)C3=NC(=NC=C3)[C@@H](C)O
DMS2RHE	IK	ATNZXIACLONSSN-XJFOESAGSA-N
DMS2RHE	IU	(1R)-1-[4-[(3S,5R)-4-[2-[(1R)-1-hydroxyethyl]pyrimidin-4-yl]-3,5-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol
DMS2RHE	DE	Discovery agent

DMZT7C1	ID	DMZT7C1
DMZT7C1	DN	CP-481,715
DMZT7C1	HS	Investigative
DMZT7C1	SN	CP481715; CP 481715; CP-481715
DMZT7C1	DT	Small molecular drug
DMZT7C1	PC	5311123
DMZT7C1	MW	482.5
DMZT7C1	FM	C26H31FN4O4
DMZT7C1	IC	InChI=1S/C26H31FN4O4/c1-26(2,35)11-10-17(24(28)33)14-23(32)21(13-16-6-5-7-18(27)12-16)31-25(34)22-15-29-19-8-3-4-9-20(19)30-22/h3-9,12,15,17,21,23,32,35H,10-11,13-14H2,1-2H3,(H2,28,33)(H,31,34)/t17-,21+,23+/m1/s1
DMZT7C1	CS	CC(C)(CC[C@H](C[C@@H]([C@H](CC1=CC(=CC=C1)F)NC(=O)C2=NC3=CC=CC=C3N=C2)O)C(=O)N)O
DMZT7C1	IK	YEQJVHQCUDMXFG-FHZYATBESA-N
DMZT7C1	IU	N-[(2S,3S,5R)-5-carbamoyl-1-(3-fluorophenyl)-3,8-dihydroxy-8-methylnonan-2-yl]quinoxaline-2-carboxamide
DMZT7C1	CA	CAS 212790-31-3
DMZT7C1	DE	Discovery agent

DMKWB31	ID	DMKWB31
DMKWB31	DN	CP55,244
DMKWB31	HS	Investigative
DMKWB31	SN	CP 55244; CP-55,244; CP 55,244; CP55244; CP-55244
DMKWB31	DT	Small molecular drug
DMKWB31	PC	9844074
DMKWB31	MW	402.6
DMKWB31	FM	C26H42O3
DMKWB31	IC	InChI=1S/C26H42O3/c1-4-5-6-7-12-26(2,3)20-10-11-22(25(29)15-20)24-16-21(28)14-19-9-8-18(17-27)13-23(19)24/h10-11,15,18-19,21,23-24,27-29H,4-9,12-14,16-17H2,1-3H3/t18-,19-,21+,23+,24-/m0/s1
DMKWB31	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@@H]2C[C@@H](C[C@H]3[C@H]2C[C@H](CC3)CO)O)O
DMKWB31	IK	ZAELPWSCABXXAB-NWXGMGMZSA-N
DMKWB31	IU	(2R,4R,4aR,6S,8aS)-6-(hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl]-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol
DMKWB31	CA	CAS 79678-32-3
DMKWB31	DE	Discovery agent

DMNLD6E	ID	DMNLD6E
DMNLD6E	DN	CP55,667
DMNLD6E	HS	Investigative
DMNLD6E	SN	CP 55,667; CP-55,667
DMNLD6E	DT	Small molecular drug
DMNLD6E	PC	4412255
DMNLD6E	MW	376.6
DMNLD6E	FM	C24H40O3
DMNLD6E	IC	InChI=1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3
DMNLD6E	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)C2CC(CCC2CCCO)O)O
DMNLD6E	IK	YNZFFALZMRAPHQ-UHFFFAOYSA-N
DMNLD6E	IU	2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol
DMNLD6E	CB	CHEBI:91490
DMNLD6E	DE	Discovery agent

DMTKO7P	ID	DMTKO7P
DMTKO7P	DN	CP608,039
DMTKO7P	HS	Investigative
DMTKO7P	SN	CP-608,039
DMTKO7P	DT	Small molecular drug
DMTKO7P	PC	73977920
DMTKO7P	MW	528.9
DMTKO7P	FM	C23H25ClN8O5
DMTKO7P	IC	InChI=1S/C23H25ClN8O5/c1-11-5-15(37-31-11)35-8-12-3-4-14(24)6-13(12)7-27-20-17-21(29-9-28-20)32(10-30-17)23-18(33)16(25)19(36-23)22(34)26-2/h3-6,9-10,16,18-19,23,33H,7-8,25H2,1-2H3,(H,26,34)(H,27,28,29)/t16-,18+,19-,23+/m0/s1
DMTKO7P	CS	CC1=NOC(=C1)OCC2=C(C=C(C=C2)Cl)CNC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)C(=O)NC)N)O
DMTKO7P	IK	KXDJDMIUJGBFAV-QYUDBREXSA-N
DMTKO7P	IU	(2S,3S,4R,5R)-3-amino-5-[6-[[5-chloro-2-[(3-methyl-1,2-oxazol-5-yl)oxymethyl]phenyl]methylamino]purin-9-yl]-4-hydroxy-N-methyloxolane-2-carboxamide
DMTKO7P	DE	Discovery agent

DMO0PS9	ID	DMO0PS9
DMO0PS9	DN	CP-640186
DMO0PS9	HS	Investigative
DMO0PS9	SN	CP-640186; 591778-68-6; UNII-04L1E4J3ZT; CP640186; (R)-anthracen-9-yl(3-(morpholine-4-carbonyl)-[1,4'-bipiperidin]-1'-yl)methanone; CHEMBL208943; 04L1E4J3ZT; CHEBI:45293; (3R)-1'-(9-anthrylcarbonyl)-3-(morpholin-4-ylcarbonyl)-1,4'-bipiperidine; (3R)-1'-(anthracen-9-ylcarbonyl)-3-(morpholin-4-ylcarbonyl)-1,4'-bipiperidine; RCP; CP 640186; {(3R)-1'-(anthracen-9-ylcarbonyl)[1,4'-bipiperidin]-3-yl}(morpholin-4-yl)methanone; [(3R)-1-[1-(anthracene-9-carbonyl)piperidin-4-yl]piperidin-3-yl]-morpholin-4-ylmethanone; 591778-70-0
DMO0PS9	DT	Small molecular drug
DMO0PS9	PC	449097
DMO0PS9	MW	485.6
DMO0PS9	FM	C30H35N3O3
DMO0PS9	IC	InChI=1S/C30H35N3O3/c34-29(32-16-18-36-19-17-32)24-8-5-13-33(21-24)25-11-14-31(15-12-25)30(35)28-26-9-3-1-6-22(26)20-23-7-2-4-10-27(23)28/h1-4,6-7,9-10,20,24-25H,5,8,11-19,21H2/t24-/m1/s1
DMO0PS9	CS	C1C[C@H](CN(C1)C2CCN(CC2)C(=O)C3=C4C=CC=CC4=CC5=CC=CC=C53)C(=O)N6CCOCC6
DMO0PS9	IK	LDQKDRLEMKIYMC-XMMPIXPASA-N
DMO0PS9	IU	[(3R)-1-[1-(anthracene-9-carbonyl)piperidin-4-yl]piperidin-3-yl]-morpholin-4-ylmethanone
DMO0PS9	CA	CAS 591778-68-6
DMO0PS9	CB	CHEBI:45293
DMO0PS9	DE	Discovery agent

DMVBPRO	ID	DMVBPRO
DMVBPRO	DN	CP-673451
DMVBPRO	HS	Investigative
DMVBPRO	SN	CP-673,451
DMVBPRO	DT	Small molecular drug
DMVBPRO	PC	10158940
DMVBPRO	MW	417.5
DMVBPRO	FM	C24H27N5O2
DMVBPRO	IC	InChI=1S/C24H27N5O2/c1-30-13-14-31-19-6-7-21-20(15-19)26-16-29(21)23-8-5-17-3-2-4-22(24(17)27-23)28-11-9-18(25)10-12-28/h2-8,15-16,18H,9-14,25H2,1H3
DMVBPRO	CS	COCCOC1=CC2=C(C=C1)N(C=N2)C3=NC4=C(C=CC=C4N5CCC(CC5)N)C=C3
DMVBPRO	IK	DEEOXSOLTLIWMG-UHFFFAOYSA-N
DMVBPRO	IU	1-[2-[5-(2-methoxyethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DMVBPRO	CA	CAS 343787-29-1
DMVBPRO	CB	CHEBI:131173
DMVBPRO	DE	Discovery agent

DMBQTZG	ID	DMBQTZG
DMBQTZG	DN	CP-70949
DMBQTZG	HS	Investigative
DMBQTZG	SN	PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer
DMBQTZG	CP	Pfizer Inc
DMBQTZG	DE	Diabetic complication

DM9LYJT	ID	DM9LYJT
DM9LYJT	DN	CP734432
DM9LYJT	HS	Investigative
DM9LYJT	SN	CP 734432; CP-734432
DM9LYJT	DT	Small molecular drug
DM9LYJT	PC	73755071
DM9LYJT	MW	468.5
DM9LYJT	FM	C23H25F3NO4S-
DM9LYJT	IC	InChI=1S/C23H26F3NO4S/c24-23(25,26)16-4-1-3-15(13-16)14-18(28)8-6-17-7-11-21(29)27(17)12-2-5-19-9-10-20(32-19)22(30)31/h1,3-4,9-10,13,17-18,28H,2,5-8,11-12,14H2,(H,30,31)/p-1/t17-,18+/m0/s1
DM9LYJT	CS	C1CC(=O)N([C@H]1CC[C@H](CC2=CC(=CC=C2)C(F)(F)F)O)CCCC3=CC=C(S3)C(=O)[O-]
DM9LYJT	IK	JYZXGURJKNAFPT-ZWKOTPCHSA-M
DM9LYJT	IU	5-[3-[(2S)-2-[(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate
DM9LYJT	DE	Discovery agent

DMANV7R	ID	DMANV7R
DMANV7R	DN	CP-775146
DMANV7R	HS	Investigative
DMANV7R	SN	CP775146
DMANV7R	DT	Small molecular drug
DMANV7R	PC	10410059
DMANV7R	MW	423.5
DMANV7R	FM	C26H33NO4
DMANV7R	IC	InChI=1S/C26H33NO4/c1-18(2)20-12-10-19(11-13-20)15-24(28)27-14-6-8-22(17-27)21-7-5-9-23(16-21)31-26(3,4)25(29)30/h5,7,9-13,16,18,22H,6,8,14-15,17H2,1-4H3,(H,29,30)/t22-/m1/s1
DMANV7R	CS	CC(C)C1=CC=C(C=C1)CC(=O)N2CCC[C@H](C2)C3=CC(=CC=C3)OC(C)(C)C(=O)O
DMANV7R	IK	OISHBINQIFNIPV-JOCHJYFZSA-N
DMANV7R	IU	2-methyl-2-[3-[(3S)-1-[2-(4-propan-2-ylphenyl)acetyl]piperidin-3-yl]phenoxy]propanoic acid
DMANV7R	CA	CAS 702680-17-9
DMANV7R	DE	Discovery agent

DM3M1LA	ID	DM3M1LA
DM3M1LA	DN	CP-809101
DM3M1LA	HS	Investigative
DM3M1LA	SN	PF-3246799; PHA-181731A; PHA-57378; PHA-670080; PNU-181731A; PNU-57378; PNU-57378E; 5-HT 2 agonists, Pharmacia
DM3M1LA	CP	Pharmacia Corp
DM3M1LA	DT	Small molecular drug
DM3M1LA	PC	9901086
DM3M1LA	MW	304.77
DM3M1LA	FM	C15H17ClN4O
DM3M1LA	IC	InChI=1S/C15H17ClN4O/c16-13-3-1-2-12(8-13)11-21-15-10-18-9-14(19-15)20-6-4-17-5-7-20/h1-3,8-10,17H,4-7,11H2
DM3M1LA	CS	C1CN(CCN1)C2=CN=CC(=N2)OCC3=CC(=CC=C3)Cl
DM3M1LA	IK	PCWGGOVOEWHPMG-UHFFFAOYSA-N
DM3M1LA	IU	2-[(3-chlorophenyl)methoxy]-6-piperazin-1-ylpyrazine
DM3M1LA	CA	CAS 479683-64-2
DM3M1LA	DE	Neurological disorder

DMXDG13	ID	DMXDG13
DMXDG13	DN	CP-810123
DMXDG13	HS	Investigative
DMXDG13	SN	CP-810123; UNII-E6G4550EC4; CHEMBL604798; E6G4550EC4; BSNKYWSMUAGMDO-UHFFFAOYSA-N; 439608-12-5; SCHEMBL1459339; BDBM50309861; 1,4-Diazabicyclo(3.2.2)nonane, 4-(5-methyloxazolo(4,5-b)pyridin-2-yl)-; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane; 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
DMXDG13	DT	Small molecular drug
DMXDG13	PC	11184481
DMXDG13	MW	258.32
DMXDG13	FM	C14H18N4O
DMXDG13	IC	InChI=1S/C14H18N4O/c1-10-2-3-12-13(15-10)16-14(19-12)18-9-8-17-6-4-11(18)5-7-17/h2-3,11H,4-9H2,1H3
DMXDG13	CS	CC1=NC2=C(C=C1)OC(=N2)N3CCN4CCC3CC4
DMXDG13	IK	BSNKYWSMUAGMDO-UHFFFAOYSA-N
DMXDG13	IU	2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-5-methyl-[1,3]oxazolo[4,5-b]pyridine
DMXDG13	CA	CAS 439608-12-5
DMXDG13	DE	Discovery agent

DMHN2LT	ID	DMHN2LT
DMHN2LT	DN	CP-94,253
DMHN2LT	HS	Investigative
DMHN2LT	SN	CP-94253; CP-94,253; Tocris-1317; NCGC00025108-01; AC1N1FU8; SCHEMBL9695044; GTPL3221; CHEMBL1570196; CHEBI:92591; ZINC1894220; BCP28082; AKOS022184337; CP94253; CP94253NIEaNI/CP94253NIEaNI; AJ-32224; LS-139500; L003950; BRD-K33860217-003-01-6; 4-{5-propoxypyrrolo[3,2-b]pyridin-3-yl}-1,2,3,6-tetrahydropyridine
DMHN2LT	DT	Small molecular drug
DMHN2LT	PC	4029677
DMHN2LT	MW	257.329
DMHN2LT	FM	C15H19N3O
DMHN2LT	IC	InChI=1S/C15H19N3O/c1-2-9-19-14-4-3-13-15(18-14)12(10-17-13)11-5-7-16-8-6-11/h3-5,10,16-17H,2,6-9H2,1H3
DMHN2LT	CS	CCCOC1=NC2=C(C=C1)NC=C2C3=CCNCC3
DMHN2LT	IK	KWQWBZIGHIOKIO-UHFFFAOYSA-N
DMHN2LT	IU	5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine
DMHN2LT	CA	CAS 131084-35-0
DMHN2LT	CB	CHEBI:92591
DMHN2LT	DE	Discovery agent

DMVJX21	ID	DMVJX21
DMVJX21	DN	CP-99,994
DMVJX21	HS	Investigative
DMVJX21	SN	CP-99994; CHEMBL441225; CP99994; CP 99994; (2S,3S)-N-(2-methoxybenzyl)-2-phenylpiperidin-3-amine; (2S,3S)-N-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine; (2~{S},3~{S})-~{N}-[(2-methoxyphenyl)methyl]-2-phenyl-piperidin-3-amine; UNII-5KM4QA7RZC; 5KM4QA7RZC; AC1NSJX2; (2-Methoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine; SCHEMBL1282327; GTPL2102; DTQNEFOKTXXQKV-HKUYNNGSSA-N; ZINC22441784; BDBM50000041; AKOS027453648; NCGC00370844-01; Cis-3-(2-methoxybenzylamino)-2-phenylpiperidine
DMVJX21	DT	Small molecular drug
DMVJX21	PC	5311057
DMVJX21	MW	296.4
DMVJX21	FM	C19H24N2O
DMVJX21	IC	InChI=1S/C19H24N2O/c1-22-18-12-6-5-10-16(18)14-21-17-11-7-13-20-19(17)15-8-3-2-4-9-15/h2-6,8-10,12,17,19-21H,7,11,13-14H2,1H3/t17-,19-/m0/s1
DMVJX21	CS	COC1=CC=CC=C1CN[C@H]2CCCN[C@H]2C3=CC=CC=C3
DMVJX21	IK	DTQNEFOKTXXQKV-HKUYNNGSSA-N
DMVJX21	IU	(2S,3S)-N-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine
DMVJX21	CA	CAS 136982-36-0
DMVJX21	DE	Discovery agent

DMI4WVE	ID	DMI4WVE
DMI4WVE	DN	CPCCOEt
DMI4WVE	HS	Investigative
DMI4WVE	SN	CHEMBL327783; 179067-99-3; AC1O3E8H; 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester; SCHEMBL12648369; MolPort-003-940-874; CPCCOEt, &gt; AKOS024456339; LP00300; NCGC00024948-02; KB-49121; AS-16761; L000202; SR-01000597466; SR-01000597466-1; BRD-A05729358-001-01-2; ethyl (7E)-7-hydroxyimino-1,7a-dihydrocyclopropa[b]chromene-1a-carboxylate
DMI4WVE	DT	Small molecular drug
DMI4WVE	PC	6278000
DMI4WVE	MW	247.25
DMI4WVE	FM	C13H13NO4
DMI4WVE	IC	InChI=1S/C13H13NO4/c1-2-17-12(15)13-7-9(13)11(14-16)8-5-3-4-6-10(8)18-13/h3-6,9,16H,2,7H2,1H3/b14-11-
DMI4WVE	CS	CCOC(=O)C12CC1/C(=N\\O)/C3=CC=CC=C3O2
DMI4WVE	IK	FXCTZFMSAHZQTR-KAMYIIQDSA-N
DMI4WVE	IU	ethyl (7E)-7-hydroxyimino-1,7a-dihydrocyclopropa[b]chromene-1a-carboxylate
DMI4WVE	DE	Discovery agent

DMFE5GX	ID	DMFE5GX
DMFE5GX	DN	CPFPX
DMFE5GX	HS	Investigative
DMFE5GX	SN	CHEMBL2311146; 8-cyclopentyl-3-(3-fluoranylpropyl)-1-propyl-7H-purine-2,6-dione; CPFPX; [18F]CPFPX; AC1NUVWE; GTPL5603
DMFE5GX	DT	Small molecular drug
DMFE5GX	PC	5461879
DMFE5GX	MW	321.38
DMFE5GX	FM	C16H23FN4O2
DMFE5GX	IC	InChI=1S/C16H23FN4O2/c1-2-9-21-15(22)12-14(20(16(21)23)10-5-8-17)19-13(18-12)11-6-3-4-7-11/h11H,2-10H2,1H3,(H,18,19)/i17-1
DMFE5GX	CS	CCCN1C(=O)C2=C(N=C(N2)C3CCCC3)N(C1=O)CCC[18F]
DMFE5GX	IK	GGGMDKJPUXTDAW-SJPDSGJFSA-N
DMFE5GX	IU	8-cyclopentyl-3-(3-(18F)fluoranylpropyl)-1-propyl-7H-purine-2,6-dione
DMFE5GX	DE	Discovery agent

DMXSYTA	ID	DMXSYTA
DMXSYTA	DN	CPI-203
DMXSYTA	HS	Investigative
DMXSYTA	SN	CPI203; CPI 203
DMXSYTA	DT	Small molecular drug
DMXSYTA	PC	71291068
DMXSYTA	MW	399.9
DMXSYTA	FM	C19H18ClN5OS
DMXSYTA	IC	InChI=1S/C19H18ClN5OS/c1-9-10(2)27-19-16(9)17(12-4-6-13(20)7-5-12)22-14(8-15(21)26)18-24-23-11(3)25(18)19/h4-7,14H,8H2,1-3H3,(H2,21,26)/t14-/m0/s1
DMXSYTA	CS	CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)N)C4=CC=C(C=C4)Cl)C
DMXSYTA	IK	QECMENZMDBOLDR-AWEZNQCLSA-N
DMXSYTA	IU	2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamide
DMXSYTA	DE	Discovery agent

DMVHX5T	ID	DMVHX5T
DMVHX5T	DN	CPPG
DMVHX5T	HS	Investigative
DMVHX5T	SN	cyclopropyl-4-phosphonophenylglycine
DMVHX5T	DT	Small molecular drug
DMVHX5T	PC	2878
DMVHX5T	MW	271.21
DMVHX5T	FM	C11H14NO5P
DMVHX5T	IC	InChI=1S/C11H14NO5P/c12-11(10(13)14,7-1-2-7)8-3-5-9(6-4-8)18(15,16)17/h3-7H,1-2,12H2,(H,13,14)(H2,15,16,17)
DMVHX5T	CS	C1CC1C(C2=CC=C(C=C2)P(=O)(O)O)(C(=O)O)N
DMVHX5T	IK	IGODGTDUQSMDQU-UHFFFAOYSA-N
DMVHX5T	IU	2-amino-2-cyclopropyl-2-(4-phosphonophenyl)acetic acid
DMVHX5T	CB	CHEBI:125380
DMVHX5T	DE	Discovery agent

DMDG2Y9	ID	DMDG2Y9
DMDG2Y9	DN	CPPHA
DMDG2Y9	HS	Investigative
DMDG2Y9	SN	693288-97-0; CHEMBL366217; C22H15ClN2O4; N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide; N-(4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide; N-[4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide; N-[4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl]-2-hydroxybenzamide; SCHEMBL1821580; GTPL1423; AOB4169; DTXSID80433014; UFOUABRZSDGGAZ-UHFFFAOYSA-N; MolPort-028-748-388; CPPHA, &gt
DMDG2Y9	DT	Small molecular drug
DMDG2Y9	PC	9931205
DMDG2Y9	MW	406.8
DMDG2Y9	FM	C22H15ClN2O4
DMDG2Y9	IC	InChI=1S/C22H15ClN2O4/c23-14-9-10-18(24-20(27)17-7-3-4-8-19(17)26)13(11-14)12-25-21(28)15-5-1-2-6-16(15)22(25)29/h1-11,26H,12H2,(H,24,27)
DMDG2Y9	CS	C1=CC=C2C(=C1)C(=O)N(C2=O)CC3=C(C=CC(=C3)Cl)NC(=O)C4=CC=CC=C4O
DMDG2Y9	IK	UFOUABRZSDGGAZ-UHFFFAOYSA-N
DMDG2Y9	IU	N-[4-chloro-2-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-2-hydroxybenzamide
DMDG2Y9	CA	CAS 693288-97-0
DMDG2Y9	DE	Discovery agent

DM9OWG5	ID	DM9OWG5
DM9OWG5	DN	CPPZ
DM9OWG5	HS	Investigative
DM9OWG5	SN	CHEMBL1289113; 1-(4-(2-chloro-4-fluorophenyl)piperazin-1-yl)-2-(pyridin-4-ylmethoxy)ethanone; CPPZ; 1-[4-(2-chloro-4-fluorophenyl)piperazin-1-yl]-2-(pyridin-4-ylmethoxy)ethanone; SCHEMBL1904664; GTPL6416; BDBM50331975
DM9OWG5	DT	Small molecular drug
DM9OWG5	PC	24763119
DM9OWG5	MW	363.8
DM9OWG5	FM	C18H19ClFN3O2
DM9OWG5	IC	InChI=1S/C18H19ClFN3O2/c19-16-11-15(20)1-2-17(16)22-7-9-23(10-8-22)18(24)13-25-12-14-3-5-21-6-4-14/h1-6,11H,7-10,12-13H2
DM9OWG5	CS	C1CN(CCN1C2=C(C=C(C=C2)F)Cl)C(=O)COCC3=CC=NC=C3
DM9OWG5	IK	XNOMHUDLVRWWLV-UHFFFAOYSA-N
DM9OWG5	IU	1-[4-(2-chloro-4-fluorophenyl)piperazin-1-yl]-2-(pyridin-4-ylmethoxy)ethanone
DM9OWG5	DE	Discovery agent

DMG2NI9	ID	DMG2NI9
DMG2NI9	DN	CPS125
DMG2NI9	HS	Investigative
DMG2NI9	SN	CPS125; GTPL6369; SCHEMBL15257793
DMG2NI9	DT	Small molecular drug
DMG2NI9	PC	56929387
DMG2NI9	MW	416.5
DMG2NI9	FM	C21H28N4O3S
DMG2NI9	IC	InChI=1S/C21H28N4O3S/c1-14(2)18-10-5-15(3)13-19(18)20(26)24-16-6-8-17(9-7-16)29(27,28)25-21-22-11-4-12-23-21/h4,6-9,11-12,14-15,18-19H,5,10,13H2,1-3H3,(H,24,26)(H,22,23,25)/t15-,18+,19-/m1/s1
DMG2NI9	CS	C[C@@H]1CC[C@H]([C@@H](C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC3=NC=CC=N3)C(C)C
DMG2NI9	IK	IIVDSKOVPRNBND-AYOQOUSVSA-N
DMG2NI9	IU	(1R,2S,5R)-5-methyl-2-propan-2-yl-N-[4-(pyrimidin-2-ylsulfamoyl)phenyl]cyclohexane-1-carboxamide
DMG2NI9	DE	Discovery agent

DMM8FUT	ID	DMM8FUT
DMM8FUT	DN	CPU-228
DMM8FUT	HS	Investigative
DMM8FUT	SN	Dofetilide analog (cardiac failure), China Pharmaceutical University
DMM8FUT	CP	China Pharmaceutical University
DMM8FUT	DT	Small molecular drug
DMM8FUT	PC	10025495
DMM8FUT	MW	426.5
DMM8FUT	FM	C23H26N2O4S
DMM8FUT	IC	InChI=1S/C23H26N2O4S/c1-18(26)25(15-14-19-10-12-21(13-11-19)24-30(2,27)28)16-17-29-23-9-5-7-20-6-3-4-8-22(20)23/h3-13,24H,14-17H2,1-2H3
DMM8FUT	CS	CC(=O)N(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=CC3=CC=CC=C32
DMM8FUT	IK	NSXHCQYUSBIMAJ-UHFFFAOYSA-N
DMM8FUT	IU	N-[2-[4-(methanesulfonamido)phenyl]ethyl]-N-(2-naphthalen-1-yloxyethyl)acetamide
DMM8FUT	CA	CAS 446877-42-5
DMM8FUT	DE	Cardiac failure

DMFG0XS	ID	DMFG0XS
DMFG0XS	DN	CR-2345
DMFG0XS	HS	Investigative
DMFG0XS	SN	CHEMBL558614
DMFG0XS	DT	Small molecular drug
DMFG0XS	PC	45265542
DMFG0XS	MW	560
DMFG0XS	FM	C26H37Cl3N4O3
DMFG0XS	IC	InChI=1S/C26H36Cl2N4O3.ClH/c1-30-12-14-31(15-13-30)23(33)5-4-22(29-24(34)19-16-20(27)18-21(28)17-19)25(35)32-10-8-26(9-11-32)6-2-3-7-26;/h16-18,22H,2-15H2,1H3,(H,29,34);1H
DMFG0XS	CS	CN1CCN(CC1)C(=O)CCC(C(=O)N2CCC3(CCCC3)CC2)NC(=O)C4=CC(=CC(=C4)Cl)Cl.Cl
DMFG0XS	IK	FXORBQJCRPUVDJ-UHFFFAOYSA-N
DMFG0XS	IU	N-[1-(8-azaspiro[4.5]decan-8-yl)-5-(4-methylpiperazin-1-yl)-1,5-dioxopentan-2-yl]-3,5-dichlorobenzamide;hydrochloride
DMFG0XS	DE	Discovery agent

DM3M5AW	ID	DM3M5AW
DM3M5AW	DN	CR-4174
DM3M5AW	HS	Investigative
DM3M5AW	SN	NO-COX-2 inhibitors (osteoarthritis/inflammatory disease), Rottapharm Madaus
DM3M5AW	CP	Rottapharm Madaus
DM3M5AW	DE	Inflammation

DMXHIFZ	ID	DMXHIFZ
DMXHIFZ	DN	CR-4892
DMXHIFZ	HS	Investigative
DMXHIFZ	SN	Nav 1.8 blockers (pain), Rottapharm Madaus
DMXHIFZ	CP	Rottapharm Madaus
DMXHIFZ	DE	Pain

DME5IJQ	ID	DME5IJQ
DME5IJQ	DN	CR-5259
DME5IJQ	HS	Investigative
DME5IJQ	SN	CR-4144 series; CR-4152 series; CR-4153 series; CR-4167 series; Aggrecanase (ADAMTS-4 and 5) inhibitors (osteoarthritis),Rottapharm Madaus
DME5IJQ	CP	Rottapharm Madaus
DME5IJQ	DE	Osteoarthritis

DMY2P5C	ID	DMY2P5C
DMY2P5C	DN	CR-5790
DMY2P5C	HS	Investigative
DMY2P5C	SN	EP4 receptor antagonist (osteoarthritis), Rottapharm Madaus
DMY2P5C	CP	Rottapharm Madaus
DMY2P5C	DE	Osteoarthritis

DM70YRT	ID	DM70YRT
DM70YRT	DN	CRA_10655
DM70YRT	HS	Investigative
DM70YRT	SN	AC1O4QGF
DM70YRT	DT	Small molecular drug
DM70YRT	PC	447480
DM70YRT	MW	336.4
DM70YRT	FM	C19H20N4O2
DM70YRT	IC	InChI=1S/C19H20N4O2/c20-18(21)11-8-9-14-15(10-11)23-19(22-14)13-6-3-7-16(17(13)24)25-12-4-1-2-5-12/h3,6-10,12,24H,1-2,4-5H2,(H3,20,21)(H,22,23)
DM70YRT	CS	C1CCC(C1)OC2=CC=CC(=C2O)C3=NC4=C(N3)C=C(C=C4)C(=N)N
DM70YRT	IK	WCFWDBPDMBXMTQ-UHFFFAOYSA-N
DM70YRT	IU	2-(3-cyclopentyloxy-2-hydroxyphenyl)-3H-benzimidazole-5-carboximidamide
DM70YRT	DE	Discovery agent

DMK54RM	ID	DMK54RM
DMK54RM	DN	CRA_1144
DMK54RM	HS	Investigative
DMK54RM	SN	AC1O4QI2
DMK54RM	DT	Small molecular drug
DMK54RM	PC	1506
DMK54RM	MW	252.27
DMK54RM	FM	C14H12N4O
DMK54RM	IC	InChI=1S/C14H12N4O/c15-13(16)8-5-6-10-11(7-8)18-14(17-10)9-3-1-2-4-12(9)19/h1-7,19H,(H3,15,16)(H,17,18)
DMK54RM	CS	C1=CC=C(C(=C1)C2=NC3=C(N2)C=C(C=C3)C(=N)N)O
DMK54RM	IK	URJKRCBBKTXOHS-UHFFFAOYSA-N
DMK54RM	IU	2-(2-hydroxyphenyl)-3H-benzimidazole-5-carboximidamide
DMK54RM	CA	CAS 220955-03-3
DMK54RM	DE	Discovery agent

DM3IZOP	ID	DM3IZOP
DM3IZOP	DN	CRA_8696
DM3IZOP	HS	Investigative
DM3IZOP	SN	AC1O4QGN
DM3IZOP	DT	Small molecular drug
DM3IZOP	PC	447476
DM3IZOP	MW	327.4
DM3IZOP	FM	C21H17N3O
DM3IZOP	IC	InChI=1S/C21H17N3O/c22-21(23)14-9-10-18-15(11-14)12-19(24-18)17-8-4-7-16(20(17)25)13-5-2-1-3-6-13/h1-12,24-25H,(H3,22,23)
DM3IZOP	CS	C1=CC=C(C=C1)C2=C(C(=CC=C2)C3=CC4=C(N3)C=CC(=C4)C(=N)N)O
DM3IZOP	IK	GAVRMVQHHVMXFD-UHFFFAOYSA-N
DM3IZOP	IU	2-(2-hydroxy-3-phenylphenyl)-1H-indole-5-carboximidamide
DM3IZOP	DE	Discovery agent

DMPWZOK	ID	DMPWZOK
DMPWZOK	DN	CRB-0022
DMPWZOK	HS	Investigative
DMPWZOK	SN	Anti-NGF monoclonal antibody (osteoarthritis pain/chronic pain), Rottapharm Madaus; Anti-nerve growth factor monoclonal antibody (osteoarthritis pain/chronic pain), Rottapharm Madaus
DMPWZOK	CP	Rottapharm Madaus
DMPWZOK	DT	Antibody
DMPWZOK	DE	Pain

DMLJOGK	ID	DMLJOGK
DMLJOGK	DN	Cremastrine
DMLJOGK	HS	Investigative
DMLJOGK	SN	cremastrine; CHEMBL480464; AC1LCUUY; BDBM50259847; pentanoic acid, 2-hydroxy-3-methyl-, [(1S,7aS)-hexahydro-1H-pyrrolizin-1-yl]methyl ester, (2R,3R)-; [(1S,8S)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl (2R,3R)-2-hydroxy-3-methylpentanoate
DMLJOGK	DT	Small molecular drug
DMLJOGK	PC	656392
DMLJOGK	MW	255.35
DMLJOGK	FM	C14H25NO3
DMLJOGK	IC	InChI=1S/C14H25NO3/c1-3-10(2)13(16)14(17)18-9-11-6-8-15-7-4-5-12(11)15/h10-13,16H,3-9H2,1-2H3/t10-,11-,12+,13-/m1/s1
DMLJOGK	CS	CC[C@@H](C)[C@H](C(=O)OC[C@H]1CCN2[C@H]1CCC2)O
DMLJOGK	IK	AVBKRVFZNFJQBK-FVCCEPFGSA-N
DMLJOGK	IU	[(1S,8S)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl (2R,3R)-2-hydroxy-3-methylpentanoate
DMLJOGK	DE	Discovery agent

DMY0GXM	ID	DMY0GXM
DMY0GXM	DN	CRISNATOL MESILATE
DMY0GXM	HS	Investigative
DMY0GXM	SN	2-[(6-Chrysenylmethyl)amino]-2-methyl-1,3-propanediol methanesulfonate; 770U82 mesylate; 96389-69-4; BW-A770U mesylate; Crisnatol mesilate < Rec INNM
DMY0GXM	DT	Small molecular drug
DMY0GXM	PC	57061
DMY0GXM	MW	441.5
DMY0GXM	FM	C24H27NO5S
DMY0GXM	IC	InChI=1S/C23H23NO2.CH4O3S/c1-23(14-25,15-26)24-13-17-12-22-18-7-3-2-6-16(18)10-11-21(22)20-9-5-4-8-19(17)20;1-5(2,3)4/h2-12,24-26H,13-15H2,1H3;1H3,(H,2,3,4)
DMY0GXM	CS	CC(CO)(CO)NCC1=CC2=C(C=CC3=CC=CC=C32)C4=CC=CC=C41.CS(=O)(=O)O
DMY0GXM	IK	NJWBUDCAWGTQAS-UHFFFAOYSA-N
DMY0GXM	IU	2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid
DMY0GXM	CA	CAS 96389-69-4
DMY0GXM	DE	Discovery agent

DMYPLZ8	ID	DMYPLZ8
DMYPLZ8	DN	Cristacarpin
DMYPLZ8	HS	Investigative
DMYPLZ8	SN	Cristacarpin; Erythrabyssin I; 74515-47-2; Crystacarpin; CHEMBL454849; CHEBI:3917; AC1L2QIR; AC1Q70TT; SCHEMBL4740053; MolPort-005-945-627; ZINC4098607; LMPK12070114; BDBM50317430; 9166AF; 6h-benzofuro(3,2-c)(1)benzopyran-3,6a(11ah)-diol, 9-methoxy-10-(3-methyl-2-butenyl)-,(6as-cis)-; C10206; 6H-Benzofuro(3,2-c)(1)benzopyran-3,6a(11aH)-diol, 9-methoxy-10-(3-methyl-2-butenyl)-, (6aS-cis)-; 6H-Benzofuro[3,2-c][1]benzopyran-3,6a(11aH)-diol,9-methoxy-10-(3-methyl-2-buten-1-yl)-, (6aS,11aS)-
DMYPLZ8	DT	Small molecular drug
DMYPLZ8	PC	126540
DMYPLZ8	MW	354.4
DMYPLZ8	FM	C21H22O5
DMYPLZ8	IC	InChI=1S/C21H22O5/c1-12(2)4-6-14-17(24-3)9-8-16-19(14)26-20-15-7-5-13(22)10-18(15)25-11-21(16,20)23/h4-5,7-10,20,22-23H,6,11H2,1-3H3/t20-,21+/m0/s1
DMYPLZ8	CS	CC(=CCC1=C(C=CC2=C1O[C@@H]3[C@]2(COC4=C3C=CC(=C4)O)O)OC)C
DMYPLZ8	IK	ZHPYEBFYLDGZKF-LEWJYISDSA-N
DMYPLZ8	IU	(6aS,11aS)-9-methoxy-10-(3-methylbut-2-enyl)-6,11a-dihydro-[1]benzofuro[3,2-c]chromene-3,6a-diol
DMYPLZ8	CA	CAS 74515-47-2
DMYPLZ8	CB	CHEBI:3917
DMYPLZ8	DE	Discovery agent

DMERKU2	ID	DMERKU2
DMERKU2	DN	CRL-37212
DMERKU2	HS	Investigative
DMERKU2	SN	Anaplastic lymphoma kinase inhibitors (cancer); CRL-43425; CRL-82007; ALK inihibitors (cancer), ChemBridge Research; Anaplastic lymphoma kinase inhibitors (cancer), ChemBridge Research
DMERKU2	CP	ChemBridge Research Laboratories LLC
DMERKU2	DE	Solid tumour/cancer

DMELUG5	ID	DMELUG5
DMELUG5	DN	Crocusatin-K
DMELUG5	HS	Investigative
DMELUG5	SN	Crocusatin K; CHEMBL446756; Crocusatin-K; AC1LD3L5; BDBM50250531
DMELUG5	DT	Small molecular drug
DMELUG5	PC	641786
DMELUG5	MW	184.23
DMELUG5	FM	C10H16O3
DMELUG5	IC	InChI=1S/C10H16O3/c1-6-4-8(12)9(13)10(2,3)7(6)5-11/h5,8-9,12-13H,4H2,1-3H3/t8-,9+/m1/s1
DMELUG5	CS	CC1=C(C([C@H]([C@@H](C1)O)O)(C)C)C=O
DMELUG5	IK	YDOIHIWSLMXTHV-BDAKNGLRSA-N
DMELUG5	IU	(4R,5R)-4,5-dihydroxy-2,6,6-trimethylcyclohexene-1-carbaldehyde
DMELUG5	DE	Discovery agent

DMTWRQI	ID	DMTWRQI
DMTWRQI	DN	crotylaldehyde
DMTWRQI	HS	Investigative
DMTWRQI	SN	Crotonaldehyde; CROTONALDEHYDE; 2-Butenal; Crotylaldehyde; Crotonal; (2E)-but-2-enal; trans-Crotonaldehyde; 123-73-9; Crotonic aldehyde; (E)-Crotonaldehyde; (E)-but-2-enal; trans-2-Butenal; Methylpropenal; Propylene aldehyde; 1-Formylpropene; beta-Methylacrolein; 4170-30-3; 2-Butenal, (2E)-; Aldehyde crotonique; 2-Butenaldehyde; but-2-enal; Topanel; trans- Crotonal; 2-Butenal, (E)-; Topanel CA; trans-but-2-enal; RCRA waste number U053; E-2-Butenal; beta-Methyl acrolein; trans-2-butenaldehyde; Krotonaldehyd [Czech]; (E)-2-Butenal; CROTONALDEHYDE, (E)-;  2-butenal; crotonal; trans-crotonaldehyde
DMTWRQI	DT	Small molecular drug
DMTWRQI	PC	447466
DMTWRQI	MW	70.09
DMTWRQI	FM	C4H6O
DMTWRQI	IC	InChI=1S/C4H6O/c1-2-3-4-5/h2-4H,1H3/b3-2+
DMTWRQI	CS	C/C=C/C=O
DMTWRQI	IK	MLUCVPSAIODCQM-NSCUHMNNSA-N
DMTWRQI	IU	(E)-but-2-enal
DMTWRQI	CA	CAS 4170-30-3
DMTWRQI	CB	CHEBI:41607
DMTWRQI	DE	Discovery agent

DMVYSAZ	ID	DMVYSAZ
DMVYSAZ	DN	CRT-0004592
DMVYSAZ	HS	Investigative
DMVYSAZ	SN	CRT-0066854; CRT-0099431; Protein kinase C iota inhibitors (cancer); PKCi inhibitors (cancer), CRT; Protein kinase C iota inhibitors (cancer), Cancer Research Technology
DMVYSAZ	CP	Cancer Research Technology Ltd
DMVYSAZ	DE	Solid tumour/cancer

DMX09KI	ID	DMX09KI
DMX09KI	DN	CRT0066101
DMX09KI	HS	Investigative
DMX09KI	DT	Small molecular drug
DMX09KI	PC	136664697
DMX09KI	MW	411.3
DMX09KI	FM	C18H24Cl2N6O
DMX09KI	IC	InChI=1S/C18H22N6O.2ClH/c1-3-14(19)10-21-17-6-7-20-18(23-17)15-8-12(4-5-16(15)25)13-9-22-24(2)11-13;;/h4-9,11,14,25H,3,10,19H2,1-2H3,(H,20,21,23);2*1H/t14-;;/m1../s1
DMX09KI	CS	CC[C@H](CNC1=NC(=NC=C1)C2=C(C=CC(=C2)C3=CN(N=C3)C)O)N.Cl.Cl
DMX09KI	IK	CXYCRYGNFKDPRH-FMOMHUKBSA-N
DMX09KI	IU	2-[4-[[(2R)-2-aminobutyl]amino]pyrimidin-2-yl]-4-(1-methylpyrazol-4-yl)phenol;dihydrochloride
DMX09KI	DE	Solid tumour/cancer

DMBV79R	ID	DMBV79R
DMBV79R	DN	CRTX-070
DMBV79R	HS	Investigative
DMBV79R	CP	Cornerstone Therapeutics Inc
DMBV79R	DE	Allergic rhinitis

DMW61UK	ID	DMW61UK
DMW61UK	DN	CRX-526
DMW61UK	HS	Investigative
DMW61UK	SN	CRX-526; UNII-8NLO017HHA; 8NLO017HHA; CHEMBL505526; BDBM50275658; 245515-64-4; Hexanoic acid, (1R)-1-(2-(((1S)-1-carboxy-2-((2-deoxy-3-O-((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)-2-(((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)amino)-4-O-phosphono-beta-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester; N-[(3R)-3-(Hexanoyloxy)myristoyl]-O-[2-[[(3R)-3-(hexanoyloxy)myristoyl]amino]-3-O-[(3R)-3-(hexanoyloxy)myristoyl]-4-O-phosphono-2-deoxy-beta-D-glucopyranosyl]-L-serine
DMW61UK	PC	24849153
DMW61UK	MW	1319.7
DMW61UK	FM	C69H127N2O19P
DMW61UK	IC	InChI=1S/C69H127N2O19P/c1-7-13-19-22-25-28-31-34-40-43-54(85-61(75)46-37-16-10-4)49-59(73)70-57(68(79)80)53-84-69-65(71-60(74)50-55(86-62(76)47-38-17-11-5)44-41-35-32-29-26-23-20-14-8-2)67(66(58(52-72)88-69)90-91(81,82)83)89-64(78)51-56(87-63(77)48-39-18-12-6)45-42-36-33-30-27-24-21-15-9-3/h54-58,65-67,69,72H,7-53H2,1-6H3,(H,70,73)(H,71,74)(H,79,80)(H2,81,82,83)/t54-,55-,56-,57+,58-,65-,66-,67-,69-/m1/s1
DMW61UK	CS	CCCCCCCCCCC[C@H](CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC[C@@H](C(=O)O)NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCC)CO)OP(=O)(O)O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCC)OC(=O)CCCCC
DMW61UK	IK	PRIXXGNJDNLMBH-DPGPRPECSA-N
DMW61UK	IU	(2S)-2-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-3-[(2R,3R,4R,5S,6R)-3-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-4-[(3R)-3-hexanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid
DMW61UK	CA	CAS 245515-64-4
DMW61UK	DE	Discovery agent

DM92IK8	ID	DM92IK8
DM92IK8	DN	CRYPTADINE B
DM92IK8	HS	Investigative
DM92IK8	SN	cryptadine B; CHEMBL240094
DM92IK8	DT	Small molecular drug
DM92IK8	PC	24809844
DM92IK8	MW	467.7
DM92IK8	FM	C30H49N3O
DM92IK8	IC	InChI=1S/C30H49N3O/c1-20-14-23(27-10-6-12-32(4)29(27)16-20)18-25-8-5-9-26(31-25)19-24-15-21(2)17-30-28(24)11-7-13-33(30)22(3)34/h20-21,25-26,29-31H,5-19H2,1-4H3/t20-,21+,25-,26-,29+,30+/m1/s1
DM92IK8	CS	C[C@H]1C[C@H]2C(=C(C1)C[C@H]3CCC[C@@H](N3)CC4=C5CCCN([C@H]5C[C@H](C4)C)C(=O)C)CCCN2C
DM92IK8	IK	GNBIIUGCLQZEQB-QERBKSRWSA-N
DM92IK8	IU	1-[(7S,8aS)-5-[[(2R,6R)-6-[[(7R,8aS)-1,7-dimethyl-3,4,6,7,8,8a-hexahydro-2H-quinolin-5-yl]methyl]piperidin-2-yl]methyl]-7-methyl-3,4,6,7,8,8a-hexahydro-2H-quinolin-1-yl]ethanone
DM92IK8	DE	Discovery agent

DM8W7VL	ID	DM8W7VL
DM8W7VL	DN	CS-6969
DM8W7VL	HS	Investigative
DM8W7VL	SN	Hydroxycholesterol; 24-hydroxycholesterol; IOWMKBFJCNLRTC-GHMQSXNDSA-N; SCHEMBL200705; cholest-5-ene-3beta,24-diol; 30271-38-6; 474-73-7; CHEBI:50515; CS-6969; CTK4J0024; HY-N2370
DM8W7VL	PC	12302757
DM8W7VL	MW	402.7
DM8W7VL	FM	C27H46O2
DM8W7VL	IC	IOWMKBFJCNLRTC-GHMQSXNDSA-N
DM8W7VL	CS	CC(C)C(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)O
DM8W7VL	IK	1S/C27H46O2/c1-17(2)25(29)11-6-18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20+,21+,22-,23+,24+,25?,26+,27-/m1/s1
DM8W7VL	IU	(3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-5-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM8W7VL	CA	CAS 474-73-7
DM8W7VL	CB	CHEBI:50515
DM8W7VL	DE	Alzheimer disease

DM6K123	ID	DM6K123
DM6K123	DN	CSC-500297
DM6K123	HS	Investigative
DM6K123	SN	CSC-500204; CSC-500 series, Cascade; 5-HT2c receptor agonists (obesity/obsessive compulsive disorder), Cascade
DM6K123	CP	Cascade Therapeutics Inc
DM6K123	DE	Obesity

DMTN1P2	ID	DMTN1P2
DMTN1P2	DN	CSL-324
DMTN1P2	HS	Investigative
DMTN1P2	SN	Anti-GCSF human mAb (inflammation), CSL; Anti-GCSF human monoclonal antibody (inflammation), CSL; Soluble human GCSFR extracellular domain-Fc (inflammation), CSL; Soluble human GCSFR extracellular domain-Fc (arthritis), MuriGen/CSL LTd; Soluble human granulocyte-colony stimulating factor receptor extracellular domain-Fc (arthritis), MuriGen/CSL LTd; Soluble human granulocyte-colony stimulating factor receptor extracellular domain-Fc (arthritis), MuriGen/Zenyth
DMTN1P2	CP	MuriGen Therapeutics
DMTN1P2	DT	Antibody
DMTN1P2	DE	Inflammation

DMYDTO8	ID	DMYDTO8
DMYDTO8	DN	CSNLSTCVLGKLSQELc[DKLHK]YPRTNTGSGTP-amide
DMYDTO8	HS	Investigative
DMYDTO8	PC	73346944
DMYDTO8	MW	3433.9
DMYDTO8	FM	C145H242N44O48S2
DMYDTO8	IC	InChI=1S/C145H242N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99(63-239)181-142(235)114(74(16)197)187-135(228)98(61-193)180-129(222)90(49-69(9)10)172-131(224)92(52-104(151)202)174-134(227)96(59-191)178-117(210)79(148)62-238)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199,238-239H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)/t71-,72-,73-,74-,75-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100-,101-,110+,111+,112+,113+,114+,115+/m1/s1
DMYDTO8	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@@H]3C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O
DMYDTO8	IK	AZCMZZXDDMAXIT-KOYPLZMPSA-N
DMYDTO8	IU	(4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMYDTO8	DE	Discovery agent

DMQXEHJ	ID	DMQXEHJ
DMQXEHJ	DN	CSNLSTCVLGKLSQELc[DKLHO]YPRTNTGSGTP-amide
DMQXEHJ	HS	Investigative
DMQXEHJ	PC	73346940
DMQXEHJ	MW	3430.9
DMQXEHJ	FM	C145H241N45O47S2
DMQXEHJ	IC	InChI=1S/C145H241N45O47S2/c1-66(2)45-86(176-140(233)111(71(11)12)184-137(230)100(64-239)182-142(235)114(74(15)197)187-136(229)99(62-194)181-129(222)90(49-70(9)10)172-131(224)92(52-104(150)201)174-135(228)97(60-192)179-117(210)79(148)63-238)118(211)158-55-107(204)162-80(25-17-19-39-146)120(213)169-89(48-69(7)8)128(221)180-98(61-193)134(227)167-84(35-37-103(149)200)123(216)166-85(36-38-110(207)208)124(217)171-88(47-68(5)6)127(220)175-94-54-106(203)156-41-21-27-82(165-130(223)91(51-77-58-188(155)65-161-77)173-126(219)87(46-67(3)4)170-121(214)81(164-132(94)225)26-18-20-40-147)122(215)178-95(50-76-31-33-78(199)34-32-76)143(236)190-44-24-30-102(190)138(231)168-83(28-22-42-157-145(153)154)125(218)186-113(73(14)196)141(234)177-93(53-105(151)202)133(226)185-112(72(13)195)139(232)160-56-108(205)163-96(59-191)119(212)159-57-109(206)183-115(75(16)198)144(237)189-43-23-29-101(189)116(152)209/h31-34,58,65-75,79-102,111-115,191-199,238-239H,17-30,35-57,59-64,146-148,155H2,1-16H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,209)(H,156,203)(H,158,211)(H,159,212)(H,160,232)(H,162,204)(H,163,205)(H,164,225)(H,165,223)(H,166,216)(H,167,227)(H,168,231)(H,169,213)(H,170,214)(H,171,217)(H,172,224)(H,173,219)(H,174,228)(H,175,220)(H,176,233)(H,177,234)(H,178,215)(H,179,210)(H,180,221)(H,181,222)(H,182,235)(H,183,206)(H,184,230)(H,185,226)(H,186,218)(H,187,229)(H,207,208)(H4,153,154,157)/t72-,73-,74-,75-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101-,102-,111+,112+,113+,114+,115+/m1/s1
DMQXEHJ	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@@H]4CCCNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC5=CN(C=N5)N)CC(C)C)CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O
DMQXEHJ	IK	YQLRYCAIJODBIC-AIKTXAPFSA-N
DMQXEHJ	IU	(4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(3S,6S,9S,12S,19S)-9-(4-aminobutyl)-19-[[(2S)-1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-3-[(1-aminoimidazol-4-yl)methyl]-6-(2-methylpropyl)-2,5,8,11,14-pentaoxo-1,4,7,10,15-pentazacyclononadec-12-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMQXEHJ	DE	Discovery agent

DMMZK89	ID	DMMZK89
DMMZK89	DN	CSNLSTCVLGKLSQELc[DKLQK]YPRTNTGSGTP-amide
DMMZK89	HS	Investigative
DMMZK89	PC	73351528
DMMZK89	MW	3406.8
DMMZK89	FM	C144H241N43O48S2
DMMZK89	IC	InChI=1S/C144H241N43O48S2/c1-65(2)47-85(174-139(231)110(70(11)12)182-136(228)98(64-237)180-141(233)113(73(15)194)185-135(227)97(62-191)179-129(221)89(51-69(9)10)171-130(222)90(53-103(150)199)172-134(226)95(60-189)177-116(208)77(147)63-236)117(209)157-56-106(202)160-78(25-17-19-41-145)119(211)168-88(50-68(7)8)128(220)178-96(61-190)133(225)166-83(36-39-102(149)198)123(215)164-84(37-40-109(205)206)124(216)170-87(49-67(5)6)127(219)173-92-55-105(201)155-43-21-27-80(162-122(214)82(35-38-101(148)197)165-126(218)86(48-66(3)4)169-120(212)79(163-131(92)223)26-18-20-42-146)121(213)176-93(52-75-31-33-76(196)34-32-75)142(234)187-46-24-30-100(187)137(229)167-81(28-22-44-156-144(153)154)125(217)184-112(72(14)193)140(232)175-91(54-104(151)200)132(224)183-111(71(13)192)138(230)159-57-107(203)161-94(59-188)118(210)158-58-108(204)181-114(74(16)195)143(235)186-45-23-29-99(186)115(152)207/h31-34,65-74,77-100,110-114,188-196,236-237H,17-30,35-64,145-147H2,1-16H3,(H2,148,197)(H2,149,198)(H2,150,199)(H2,151,200)(H2,152,207)(H,155,201)(H,157,209)(H,158,210)(H,159,230)(H,160,202)(H,161,203)(H,162,214)(H,163,223)(H,164,215)(H,165,218)(H,166,225)(H,167,229)(H,168,211)(H,169,212)(H,170,216)(H,171,222)(H,172,226)(H,173,219)(H,174,231)(H,175,232)(H,176,213)(H,177,208)(H,178,220)(H,179,221)(H,180,233)(H,181,204)(H,182,228)(H,183,224)(H,184,217)(H,185,227)(H,205,206)(H4,153,154,156)/t71-,72-,73-,74-,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99-,100-,110+,111+,112+,113+,114+/m1/s1
DMMZK89	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@@H]4CCCNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCC(=O)N)CC(C)C)CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O
DMMZK89	IK	PPKRHPCXCVMULC-IFCDPWAYSA-N
DMMZK89	IU	(4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(3S,6S,9S,12S,19S)-9-(4-aminobutyl)-19-[[(2S)-1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-3-(3-amino-3-oxopropyl)-6-(2-methylpropyl)-2,5,8,11,14-pentaoxo-1,4,7,10,15-pentazacyclononadec-12-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMMZK89	DE	Discovery agent

DMTL2BA	ID	DMTL2BA
DMTL2BA	DN	CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-amide
DMTL2BA	HS	Investigative
DMTL2BA	PC	44269048
DMTL2BA	MW	3433.9
DMTL2BA	FM	C145H242N44O48S2
DMTL2BA	IC	InChI=1S/C145H242N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99(63-239)181-142(235)114(74(16)197)187-135(228)98(61-193)180-129(222)90(49-69(9)10)172-131(224)92(52-104(151)202)174-134(227)96(59-191)178-117(210)79(148)62-238)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199,238-239H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)/t71-,72-,73-,74-,75-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94?,95+,96+,97+,98+,99+,100-,101-,110+,111+,112+,113+,114+,115+/m1/s1
DMTL2BA	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]2CCCN2C(=O)C(CC3=CC=C(C=C3)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O
DMTL2BA	IK	AZCMZZXDDMAXIT-SLFAFRAOSA-N
DMTL2BA	IU	(4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMTL2BA	DE	Discovery agent

DM61V5W	ID	DM61V5W
DM61V5W	DN	CSNLSTCVLGKLSQELNKLHBYPRTNTGSGTP-amide
DM61V5W	HS	Investigative
DM61V5W	PC	44269080
DM61V5W	MW	3431.9
DM61V5W	FM	C146H244N44O47S2
DM61V5W	IC	InChI=1S/C146H244N44O47S2/c1-18-19-27-82(123(215)179-96(51-77-33-35-79(199)36-34-77)144(236)190-45-26-32-103(190)139(231)169-84(30-24-43-158-146(155)156)126(218)187-114(74(15)196)142(234)178-95(55-107(153)203)134(226)186-113(73(14)195)140(232)161-58-109(205)164-97(60-191)120(212)160-59-110(206)184-116(76(17)198)145(237)189-44-25-31-102(189)117(154)209)165-131(223)92(52-78-56-157-66-162-78)174-127(219)88(47-68(4)5)171-122(214)83(29-21-23-42-148)166-132(224)93(53-105(151)201)175-128(220)89(48-69(6)7)172-125(217)86(38-40-111(207)208)167-124(216)85(37-39-104(150)200)168-135(227)99(62-193)181-129(221)90(49-70(8)9)170-121(213)81(28-20-22-41-147)163-108(204)57-159-119(211)87(46-67(2)3)177-141(233)112(72(12)13)185-138(230)101(65-239)183-143(235)115(75(16)197)188-137(229)100(63-194)182-130(222)91(50-71(10)11)173-133(225)94(54-106(152)202)176-136(228)98(61-192)180-118(210)80(149)64-238/h33-36,56,66-76,80-103,112-116,191-199,238-239H,18-32,37-55,57-65,147-149H2,1-17H3,(H2,150,200)(H2,151,201)(H2,152,202)(H2,153,203)(H2,154,209)(H,157,162)(H,159,211)(H,160,212)(H,161,232)(H,163,204)(H,164,205)(H,165,223)(H,166,224)(H,167,216)(H,168,227)(H,169,231)(H,170,213)(H,171,214)(H,172,217)(H,173,225)(H,174,219)(H,175,220)(H,176,228)(H,177,233)(H,178,234)(H,179,215)(H,180,210)(H,181,221)(H,182,222)(H,183,235)(H,184,206)(H,185,230)(H,186,226)(H,187,218)(H,188,229)(H,207,208)(H4,155,156,158)/t73-,74-,75-,76-,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96?,97+,98+,99+,100+,101+,102-,103-,112+,113+,114+,115+,116+/m1/s1
DM61V5W	CS	CCCC[C@@H](C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@@H]3C(=O)N)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N
DM61V5W	IK	YNPHTODKUNFPBE-HJMCUHAQSA-N
DM61V5W	IU	(4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM61V5W	DE	Discovery agent

DM3W6PQ	ID	DM3W6PQ
DM3W6PQ	DN	CT-003230
DM3W6PQ	HS	Investigative
DM3W6PQ	SN	CT-0011; CT-007640; CT-007650; CT-007660; CT-007670; CT-007680; CT-008650; CT-0093; CT-0107; CT-0109; Amyloid beta 1-42 inhibitors (Alzheimers/mild cognitive impairment/Downs' syndrome); Amyloid beta 1-42 inhibitors (Alzheimers/mild cognitive impairment/Downs' syndrome), Cognition
DM3W6PQ	CP	Cognition Therapeutics Inc
DM3W6PQ	DE	Cognitive impairment

DMIVNMJ	ID	DMIVNMJ
DMIVNMJ	DN	CT-10
DMIVNMJ	HS	Investigative
DMIVNMJ	SN	GGTase inhibitors (cancer); GGTase inhibitors (cancer), Cellona Therapeutics/Duke University; Geranylgeranyl transferase inhibitors (cancer), Cellona Therapeutics/Duke University
DMIVNMJ	CP	Duke University
DMIVNMJ	DE	Solid tumour/cancer

DMUVQFW	ID	DMUVQFW
DMUVQFW	DN	CT301
DMUVQFW	HS	Investigative
DMUVQFW	DE	Discovery agent

DM6W9LA	ID	DM6W9LA
DM6W9LA	DN	CT-5357
DM6W9LA	HS	Investigative
DM6W9LA	DE	Discovery agent

DM6F8DM	ID	DM6F8DM
DM6F8DM	DN	CT-98024
DM6F8DM	HS	Investigative
DM6F8DM	SN	556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284
DM6F8DM	DT	Small molecular drug
DM6F8DM	PC	9957049
DM6F8DM	MW	486.3
DM6F8DM	FM	C20H17Cl2N9O2
DM6F8DM	IC	InChI=1S/C20H17Cl2N9O2/c21-11-1-2-12(14(22)9-11)17-13(19-25-6-7-26-19)10-28-20(30-17)27-8-5-24-16-4-3-15(31(32)33)18(23)29-16/h1-4,6-7,9-10H,5,8H2,(H,25,26)(H3,23,24,29)(H,27,28,30)
DM6F8DM	CS	C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC=C2C3=NC=CN3)NCCNC4=NC(=C(C=C4)[N+](=O)[O-])N
DM6F8DM	IK	NDFXSHIIGXVOKT-UHFFFAOYSA-N
DM6F8DM	IU	6-N-[2-[[4-(2,4-dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine
DM6F8DM	CA	CAS 556813-39-9
DM6F8DM	DE	Discovery agent

DMLON9K	ID	DMLON9K
DMLON9K	DN	CTAP
DMLON9K	HS	Investigative
DMLON9K	SN	CTAP
DMLON9K	DT	Small molecular drug
DMLON9K	PC	44309215
DMLON9K	MW	1104.3
DMLON9K	FM	C51H69N13O11S2
DMLON9K	IC	InChI=1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33+,35+,36+,37+,38+,39+,40+,41-/m1/s1
DMLON9K	CS	C[C@H]([C@H]1C(=O)N[C@@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMLON9K	IK	OFMQLVRLOGHAJI-RWMSPKCPSA-N
DMLON9K	IU	(4R,7S,10S,13S,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2S)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMLON9K	DE	Discovery agent

DMEGZHF	ID	DMEGZHF
DMEGZHF	DN	CTCE-0324
DMEGZHF	HS	Investigative
DMEGZHF	SN	Vascular disease therapeutic, Chemokine Therapeutics
DMEGZHF	CP	Chemokine Therapeutics Corp
DMEGZHF	DE	Peripheral vascular disease

DMYRVZ8	ID	DMYRVZ8
DMYRVZ8	DN	CTEP
DMYRVZ8	HS	Investigative
DMYRVZ8	SN	2-Chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine; 871362-31-1; CTEP (RO4956371); 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine; CHEMBL3410223; 2-chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]ethynyl]pyridine; [3H]CTEP; mGluR5 inhibitor; C19H13ClF3N3O; SCHEMBL608379; GTPL6409; GTPL6408; DTXSID50469986; EX-A095; MolPort-035-395-697; HMS3651N19; BCP06140; AOB87758; ZINC35996961; BDBM50071375; s2861; 2340AH; AKOS027301517; compound 3 [PMID: 25565255]; CS-0974; KS-000006G1; NCGC00386156-06; KB-76209; HY-15445;  MGluR5 antagonist (oral), Roche; Metabotropic glutamate receptor 5 antagonist (oral), Roche
DMYRVZ8	CP	F Hoffmann-La Roche Ltd
DMYRVZ8	DT	Small molecular drug
DMYRVZ8	PC	11646823
DMYRVZ8	MW	391.8
DMYRVZ8	FM	C19H13ClF3N3O
DMYRVZ8	IC	InChI=1S/C19H13ClF3N3O/c1-12-17(8-3-14-9-10-24-18(20)11-14)25-13(2)26(12)15-4-6-16(7-5-15)27-19(21,22)23/h4-7,9-11H,1-2H3
DMYRVZ8	CS	CC1=C(N=C(N1C2=CC=C(C=C2)OC(F)(F)F)C)C#CC3=CC(=NC=C3)Cl
DMYRVZ8	IK	GOHCTCOGYKAJLZ-UHFFFAOYSA-N
DMYRVZ8	IU	2-chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]ethynyl]pyridine
DMYRVZ8	CA	CAS 871362-31-1
DMYRVZ8	DE	Fragile X syndrome

DMI3J0F	ID	DMI3J0F
DMI3J0F	DN	CTK1G9578
DMI3J0F	HS	Investigative
DMI3J0F	SN	Delta(5)-androstene-3,17-dione; HEE11L5C3G; SCHEMBL1419434; SQGZFRITSMYKRH-QAGGRKNESA-N; ZINC100041759; delta5-ADD; delta5-Androstene-3,17-dione; .DELTA.5-Androsten-3,17-dione; .DELTA.5-Androstene-3,17-dione; 5-Androsten-3,17-dione; 5-Androstene-3,17-dione; 5-Androstenedione; 571-36-8; AC1L4NSA; AC1Q6OKV; Androst-5-en-3,17-dione; Androst-5-ene-3,17-dione; Androst-5-ene-3,17-dione (8CI)(9CI); C20252; CHEBI:83865; CHEMBL1743203; DB01456; NSC 12873; NSC-12873; NSC12873; UNII-HEE11L5C3G
DMI3J0F	PC	160531
DMI3J0F	MW	286.4
DMI3J0F	FM	C19H26O2
DMI3J0F	IC	SQGZFRITSMYKRH-QAGGRKNESA-N
DMI3J0F	CS	CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(=O)C4)C
DMI3J0F	IK	1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,14-16H,4-11H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1
DMI3J0F	IU	(8R,9S,10R,13S,14S)-10,13-dimethyl-2,4,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMI3J0F	CA	CAS 571-36-8
DMI3J0F	CB	CHEBI:83865
DMI3J0F	DE	Discovery agent

DMKEIAS	ID	DMKEIAS
DMKEIAS	DN	CTLA-4-XTEN
DMKEIAS	HS	Investigative
DMKEIAS	SN	Cytotoxic T-lymphocyte protein 4 modulator (XTEN, rheumatoid arthritis/transplant rejection), Amunix
DMKEIAS	CP	Amunix Inc
DMKEIAS	DE	Rheumatoid arthritis

DM7VAJX	ID	DM7VAJX
DM7VAJX	DN	CTOP
DM7VAJX	HS	Investigative
DM7VAJX	SN	Ctop-NH2; CTOPA; CHEMBL507214; 103429-31-8; AC1NSJX5; H-D-Phe-c[Cys-Tyr-DTrp-Orn-Thr-Pen]-Thr-NH2; GTPL1674; CTOP, &gt; BDBM50252861; (4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM7VAJX	DT	Small molecular drug
DM7VAJX	PC	2884
DM7VAJX	MW	1062.3
DM7VAJX	FM	C50H67N11O11S2
DM7VAJX	IC	InChI=1S/C50H67N11O11S2/c1-26(62)39(42(53)65)59-49(72)41-50(3,4)74-73-25-38(58-43(66)33(52)21-28-11-6-5-7-12-28)47(70)56-36(22-29-16-18-31(64)19-17-29)45(68)57-37(23-30-24-54-34-14-9-8-13-32(30)34)46(69)55-35(15-10-20-51)44(67)60-40(27(2)63)48(71)61-41/h5-9,11-14,16-19,24,26-27,33,35-41,54,62-64H,10,15,20-23,25,51-52H2,1-4H3,(H2,53,65)(H,55,69)(H,56,70)(H,57,68)(H,58,66)(H,59,72)(H,60,67)(H,61,71)
DM7VAJX	CS	CC(C1C(=O)NC(C(SSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)(C)C)C(=O)NC(C(C)O)C(=O)N)O
DM7VAJX	IK	PZWWYAHWHHNCHO-UHFFFAOYSA-N
DM7VAJX	IU	N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-phenylpropanoyl)amino]-10-(3-aminopropyl)-7-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM7VAJX	CA	CAS 103429-31-8
DM7VAJX	DE	Discovery agent

DM4T62U	ID	DM4T62U
DM4T62U	DN	CTP
DM4T62U	HS	Investigative
DM4T62U	SN	cytidine triphosphate
DM4T62U	DT	Small molecular drug
DM4T62U	PC	6176
DM4T62U	MW	483.16
DM4T62U	FM	C9H16N3O14P3
DM4T62U	IC	InChI=1S/C9H16N3O14P3/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DM4T62U	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DM4T62U	IK	PCDQPRRSZKQHHS-XVFCMESISA-N
DM4T62U	IU	[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM4T62U	CA	CAS 65-47-4
DM4T62U	CB	CHEBI:17677
DM4T62U	DE	Discovery agent

DMQ5JX8	ID	DMQ5JX8
DMQ5JX8	DN	CTT-54
DMQ5JX8	HS	Investigative
DMQ5JX8	CP	Cancer Targeted Technology Llc
DMQ5JX8	DE	Solid tumour/cancer

DMDPJWF	ID	DMDPJWF
DMDPJWF	DN	CU201 (B9870)
DMDPJWF	HS	Investigative
DMDPJWF	DE	Discovery agent

DMY1WEM	ID	DMY1WEM
DMY1WEM	DN	CU-906
DMY1WEM	HS	Investigative
DMY1WEM	CP	Curis Inc
DMY1WEM	DE	Solid tumour/cancer

DMBL46A	ID	DMBL46A
DMBL46A	DN	CUDRATRICUSXANTHONE
DMBL46A	HS	Investigative
DMBL46A	DT	Small molecular drug
DMBL46A	PC	44592062
DMBL46A	MW	398.4
DMBL46A	FM	C23H26O6
DMBL46A	IC	InChI=1S/C23H26O6/c1-6-23(4,5)19-14(25)9-13(24)18-21(28)17-12(8-7-11(2)3)20(27)15(26)10-16(17)29-22(18)19/h6-7,9-10,18,22,24-27H,1,8H2,2-5H3
DMBL46A	CS	CC(=CCC1=C(C(=CC2=C1C(=O)C3C(O2)C(=C(C=C3O)O)C(C)(C)C=C)O)O)C
DMBL46A	IK	RAIAMYMZPGRUDU-UHFFFAOYSA-N
DMBL46A	IU	1,3,6,7-tetrahydroxy-4-(2-methylbut-3-en-2-yl)-8-(3-methylbut-2-enyl)-4a,9a-dihydroxanthen-9-one
DMBL46A	DE	Discovery agent

DM10BOC	ID	DM10BOC
DM10BOC	DN	Cudratricusxanthone F
DM10BOC	HS	Investigative
DM10BOC	DT	Small molecular drug
DM10BOC	PC	44592092
DM10BOC	MW	412.5
DM10BOC	FM	C24H28O6
DM10BOC	IC	InChI=1S/C24H28O6/c1-7-24(4,5)20-17(29-6)10-14(25)19-22(28)18-13(9-8-12(2)3)21(27)15(26)11-16(18)30-23(19)20/h7-8,10-11,19,23,25-27H,1,9H2,2-6H3
DM10BOC	CS	CC(=CCC1=C(C(=CC2=C1C(=O)C3C(O2)C(=C(C=C3O)OC)C(C)(C)C=C)O)O)C
DM10BOC	IK	WIZSEOVKPIAUIS-UHFFFAOYSA-N
DM10BOC	IU	1,6,7-trihydroxy-3-methoxy-4-(2-methylbut-3-en-2-yl)-8-(3-methylbut-2-enyl)-4a,9a-dihydroxanthen-9-one
DM10BOC	DE	Discovery agent

DMBQ1VO	ID	DMBQ1VO
DMBQ1VO	DN	Cudraxanthone D
DMBQ1VO	HS	Investigative
DMBQ1VO	SN	cudraxanthone D; 96552-41-9; CHEMBL425926; MolPort-035-706-470; ZINC13411981; BDBM50175019; AKOS032948528; 4CN-1670; W2633; 2,3,8-trihydroxy-6-methoxy-5-(2-methyl-3-buten-2-yl)-1-(3-methyl- 2-buten-1-yl)-9h-xanthen-9-one
DMBQ1VO	DT	Small molecular drug
DMBQ1VO	PC	11611248
DMBQ1VO	MW	410.5
DMBQ1VO	FM	C24H26O6
DMBQ1VO	IC	InChI=1S/C24H26O6/c1-7-24(4,5)20-17(29-6)10-14(25)19-22(28)18-13(9-8-12(2)3)21(27)15(26)11-16(18)30-23(19)20/h7-8,10-11,25-27H,1,9H2,2-6H3
DMBQ1VO	CS	CC(=CCC1=C(C(=CC2=C1C(=O)C3=C(O2)C(=C(C=C3O)OC)C(C)(C)C=C)O)O)C
DMBQ1VO	IK	UIIGEZZURHDEDK-UHFFFAOYSA-N
DMBQ1VO	IU	2,3,8-trihydroxy-6-methoxy-5-(2-methylbut-3-en-2-yl)-1-(3-methylbut-2-enyl)xanthen-9-one
DMBQ1VO	DE	Discovery agent

DMP1D5Q	ID	DMP1D5Q
DMP1D5Q	DN	Cudraxanthone L
DMP1D5Q	HS	Investigative
DMP1D5Q	SN	cudraxanthone L; 135541-40-1; CHEMBL197916; MolPort-035-706-469; BDBM50175013; ZINC13412042; AKOS032948133; W2632; 1,3,6,7-tetrahydroxy-5-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-9H-xanthen-9-one
DMP1D5Q	DT	Small molecular drug
DMP1D5Q	PC	11486277
DMP1D5Q	MW	396.4
DMP1D5Q	FM	C23H24O6
DMP1D5Q	IC	InChI=1S/C23H24O6/c1-6-23(4,5)18-14(24)10-16-17(21(18)28)20(27)13-9-15(25)19(26)12(22(13)29-16)8-7-11(2)3/h6-7,9-10,24-26,28H,1,8H2,2-5H3
DMP1D5Q	CS	CC(=CCC1=C2C(=CC(=C1O)O)C(=O)C3=C(O2)C=C(C(=C3O)C(C)(C)C=C)O)C
DMP1D5Q	IK	LVKPSBFBKBJJOB-UHFFFAOYSA-N
DMP1D5Q	IU	1,3,6,7-tetrahydroxy-2-(2-methylbut-3-en-2-yl)-5-(3-methylbut-2-enyl)xanthen-9-one
DMP1D5Q	DE	Discovery agent

DMIQFAU	ID	DMIQFAU
DMIQFAU	DN	Cudraxanthone M
DMIQFAU	HS	Investigative
DMIQFAU	SN	cudraxanthone M; CHEMBL371024; BDBM50175018
DMIQFAU	DT	Small molecular drug
DMIQFAU	PC	11689770
DMIQFAU	MW	396.4
DMIQFAU	FM	C23H24O6
DMIQFAU	IC	InChI=1S/C23H24O6/c1-10(2)6-7-12-19(25)14(24)8-13-20(26)17-15(29-22(12)13)9-16-18(21(17)27)23(4,5)11(3)28-16/h6,8-9,11,24-25,27H,7H2,1-5H3
DMIQFAU	CS	CC1C(C2=C(O1)C=C3C(=C2O)C(=O)C4=CC(=C(C(=C4O3)CC=C(C)C)O)O)(C)C
DMIQFAU	IK	ZYJVDWWKUSJAQY-UHFFFAOYSA-N
DMIQFAU	IU	4,7,8-trihydroxy-2,3,3-trimethyl-9-(3-methylbut-2-enyl)-2H-furo[3,2-b]xanthen-5-one
DMIQFAU	DE	Discovery agent

DMEB0FX	ID	DMEB0FX
DMEB0FX	DN	CV-11194
DMEB0FX	HS	Investigative
DMEB0FX	SN	CV-11194; CV 11194; 136284-47-4; CHEMBL48242; 1H-Benzimidazole-7-carboxylicacid, 2-butyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; FLOKGHWIQFCIJW-UHFFFAOYSA-N; AC1MHFWM; ACMC-1CI8P; SCHEMBL905714; SCHEMBL12787593; CTK0H7043; DTXSID70159756; BDBM50044402; 2-Butyl-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylic acid; 2-Butyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1H-benzimidazole-7-carboxylic acid; L005054
DMEB0FX	DT	Small molecular drug
DMEB0FX	PC	3025727
DMEB0FX	MW	452.5
DMEB0FX	FM	C26H24N6O2
DMEB0FX	IC	InChI=1S/C26H24N6O2/c1-2-3-11-23-27-22-10-6-9-21(26(33)34)24(22)32(23)16-17-12-14-18(15-13-17)19-7-4-5-8-20(19)25-28-30-31-29-25/h4-10,12-15H,2-3,11,16H2,1H3,(H,33,34)(H,28,29,30,31)
DMEB0FX	CS	CCCCC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
DMEB0FX	IK	FLOKGHWIQFCIJW-UHFFFAOYSA-N
DMEB0FX	IU	2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMEB0FX	CA	CAS 136284-47-4
DMEB0FX	DE	Discovery agent

DM9AL7W	ID	DM9AL7W
DM9AL7W	DN	CV-1674
DM9AL7W	HS	Investigative
DM9AL7W	SN	2-(4-methoxyphenyl)adenosine; CV 1674; NSC 310669; CV1674
DM9AL7W	DT	Small molecular drug
DM9AL7W	PC	10067935
DM9AL7W	MW	373.4
DM9AL7W	FM	C17H19N5O5
DM9AL7W	IC	InChI=1S/C17H19N5O5/c1-26-9-4-2-8(3-5-9)15-20-14(18)11-16(21-15)22(7-19-11)17-13(25)12(24)10(6-23)27-17/h2-5,7,10,12-13,17,23-25H,6H2,1H3,(H2,18,20,21)/t10-,12-,13-,17-/m1/s1
DM9AL7W	CS	COC1=CC=C(C=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DM9AL7W	IK	VKSRAKNPXOTFAX-CNEMSGBDSA-N
DM9AL7W	IU	(2R,3R,4S,5R)-2-[6-amino-2-(4-methoxyphenyl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM9AL7W	CA	CAS 37151-17-0
DM9AL7W	DE	Discovery agent

DM07VRS	ID	DM07VRS
DM07VRS	DN	CV-1808
DM07VRS	HS	Investigative
DM07VRS	SN	2-phenylaminoadenosine; CV1808; CV 1808
DM07VRS	DT	Small molecular drug
DM07VRS	PC	6917803
DM07VRS	MW	358.35
DM07VRS	FM	C16H18N6O4
DM07VRS	IC	InChI=1S/C16H18N6O4/c17-13-10-14(21-16(20-13)19-8-4-2-1-3-5-8)22(7-18-10)15-12(25)11(24)9(6-23)26-15/h1-5,7,9,11-12,15,23-25H,6H2,(H3,17,19,20,21)/t9-,11-,12-,15-/m1/s1
DM07VRS	CS	C1=CC=C(C=C1)NC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DM07VRS	IK	SCNILGOVBBRMBK-SDBHATRESA-N
DM07VRS	IU	(2R,3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM07VRS	CA	CAS 53296-10-9
DM07VRS	DE	Discovery agent

DMM7RAD	ID	DMM7RAD
DMM7RAD	DN	CV-3988
DMM7RAD	HS	Investigative
DMM7RAD	SN	CV 3988; CV3988
DMM7RAD	DT	Small molecular drug
DMM7RAD	PC	107681
DMM7RAD	MW	592.8
DMM7RAD	FM	C28H53N2O7PS
DMM7RAD	IC	InChI=1S/C28H53N2O7PS/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-29-28(31)35-24-27(34-2)25-37-38(32,33)36-22-20-30-21-23-39-26-30/h21,23,26-27H,3-20,22,24-25H2,1-2H3,(H-,29,31,32,33)
DMM7RAD	CS	CCCCCCCCCCCCCCCCCCNC(=O)OCC(COP(=O)([O-])OCC[N+]1=CSC=C1)OC
DMM7RAD	IK	NMHKTASGTFXJPL-UHFFFAOYSA-N
DMM7RAD	IU	[2-methoxy-3-(octadecylcarbamoyloxy)propyl] 2-(1,3-thiazol-3-ium-3-yl)ethyl phosphate
DMM7RAD	CA	CAS 85703-73-7
DMM7RAD	DE	Discovery agent

DM983QP	ID	DM983QP
DM983QP	DN	CV-4093
DM983QP	HS	Investigative
DM983QP	SN	Manidipine dihydrochloride; 89226-75-5; Manidipine 2HCl; manidipine hydrochloride; Calslot; Franidipine hydrochloride; Manidipine.2HCl; Manidipine (dihydrochloride); (+-)-Manidipine hydrochloride; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride; DSSTox_CID_796; DSSTox_RID_75794; DSSTox_GSID_20796; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-
DM983QP	DT	Small molecular drug
DM983QP	PC	150762
DM983QP	MW	683.6
DM983QP	FM	C35H40Cl2N4O6
DM983QP	IC	InChI=1S/C35H38N4O6.2ClH/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27;;/h4-16,23,32-33,36H,17-22H2,1-3H3;2*1H
DM983QP	CS	CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC.Cl.Cl
DM983QP	IK	JINNGBXKBDUGQT-UHFFFAOYSA-N
DM983QP	IU	5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;dihydrochloride
DM983QP	CA	CAS 89226-75-5
DM983QP	CB	CHEBI:31800
DM983QP	DE	Discovery agent

DMO9WZN	ID	DMO9WZN
DMO9WZN	DN	CV-6504.HCL
DMO9WZN	HS	Investigative
DMO9WZN	SN	117585-83-8; 2,3,5-Trimethyl-6-(3-pyridylmethyl)-2,5-cyclohexane-1,4-dione hydrochloride; 3,5,6-Trimethyl-2-(3-pyridylmethyl)-1,4-benzoquinone hydrochloride; CV-6504.HCl
DMO9WZN	DT	Small molecular drug
DMO9WZN	PC	9817080
DMO9WZN	MW	277.74
DMO9WZN	FM	C15H16ClNO2
DMO9WZN	IC	InChI=1S/C15H15NO2.ClH/c1-9-10(2)15(18)13(11(3)14(9)17)7-12-5-4-6-16-8-12;/h4-6,8H,7H2,1-3H3;1H
DMO9WZN	CS	CC1=C(C(=O)C(=C(C1=O)C)CC2=CN=CC=C2)C.Cl
DMO9WZN	IK	FBOCJGYMOAAFSO-UHFFFAOYSA-N
DMO9WZN	IU	2,3,5-trimethyl-6-(pyridin-3-ylmethyl)cyclohexa-2,5-diene-1,4-dione;hydrochloride
DMO9WZN	DE	Discovery agent

DMO9UMK	ID	DMO9UMK
DMO9UMK	DN	CVS-1578
DMO9UMK	HS	Investigative
DMO9UMK	SN	174960-52-2; 186318-81-0; CV-1778; CVS-1778; CVS-1832; CVS-1897; CVS-2097
DMO9UMK	DT	Small molecular drug
DMO9UMK	PC	9869156
DMO9UMK	MW	466.6
DMO9UMK	FM	C20H30N6O5S
DMO9UMK	IC	InChI=1S/C20H30N6O5S/c21-20(22)26-11-5-8-15(19(26)29)23-17(27)12-25-10-4-9-16(18(25)28)24-32(30,31)13-14-6-2-1-3-7-14/h1-3,6-7,15-16,19,24,29H,4-5,8-13H2,(H3,21,22)(H,23,27)/t15-,16-,19?/m0/s1
DMO9UMK	CS	C1C[C@@H](C(N(C1)C(=N)N)O)NC(=O)CN2CCC[C@@H](C2=O)NS(=O)(=O)CC3=CC=CC=C3
DMO9UMK	IK	SPUAEQJRVQHWKF-NRAVZPKASA-N
DMO9UMK	IU	2-[(3S)-3-(benzylsulfonylamino)-2-oxopiperidin-1-yl]-N-[(3S)-1-carbamimidoyl-2-hydroxypiperidin-3-yl]acetamide
DMO9UMK	DE	Discovery agent

DMT5R1Q	ID	DMT5R1Q
DMT5R1Q	DN	CVS-2139
DMT5R1Q	HS	Investigative
DMT5R1Q	SN	CVS-2139; CHEMBL19599; BDBM50111717
DMT5R1Q	DT	Small molecular drug
DMT5R1Q	PC	44272797
DMT5R1Q	MW	496.5
DMT5R1Q	FM	C20H25FN6O6S
DMT5R1Q	IC	InChI=1S/C20H25FN6O6S/c21-14-6-2-1-5-13(14)12-34(32,33)26-15-8-4-10-27(18(15)29)11-17(28)25-16(19(30)31)7-3-9-24-20(22)23/h1-2,4-6,8,10,16,26H,3,7,9,11-12H2,(H,25,28)(H,30,31)(H4,22,23,24)/t16-/m1/s1
DMT5R1Q	CS	C1=CC=C(C(=C1)CS(=O)(=O)NC2=CC=CN(C2=O)CC(=O)N[C@H](CCCN=C(N)N)C(=O)O)F
DMT5R1Q	IK	OFDAQIKHAJYTBV-MRXNPFEDSA-N
DMT5R1Q	IU	(2R)-5-(diaminomethylideneamino)-2-[[2-[3-[(2-fluorophenyl)methylsulfonylamino]-2-oxopyridin-1-yl]acetyl]amino]pentanoic acid
DMT5R1Q	DE	Discovery agent

DM3KB4H	ID	DM3KB4H
DM3KB4H	DN	CVS-2359
DM3KB4H	HS	Investigative
DM3KB4H	SN	CVS-2359; CHEMBL431292; BDBM50111730
DM3KB4H	DT	Small molecular drug
DM3KB4H	PC	44272875
DM3KB4H	MW	510.5
DM3KB4H	FM	C21H27FN6O6S
DM3KB4H	IC	InChI=1S/C21H27FN6O6S/c1-13-8-9-16(27-35(33,34)12-14-5-2-3-6-15(14)22)19(30)28(13)11-18(29)26-17(20(31)32)7-4-10-25-21(23)24/h2-3,5-6,8-9,17,27H,4,7,10-12H2,1H3,(H,26,29)(H,31,32)(H4,23,24,25)/t17-/m1/s1
DM3KB4H	CS	CC1=CC=C(C(=O)N1CC(=O)N[C@H](CCCN=C(N)N)C(=O)O)NS(=O)(=O)CC2=CC=CC=C2F
DM3KB4H	IK	QTGRXIGBXXVLEH-QGZVFWFLSA-N
DM3KB4H	IU	(2R)-5-(diaminomethylideneamino)-2-[[2-[3-[(2-fluorophenyl)methylsulfonylamino]-6-methyl-2-oxopyridin-1-yl]acetyl]amino]pentanoic acid
DM3KB4H	DE	Discovery agent

DMDH6PJ	ID	DMDH6PJ
DMDH6PJ	DN	CVT-10216
DMDH6PJ	HS	Investigative
DMDH6PJ	SN	CVT-10083; CVT-10200; CVT-10992; ALDH2 antagonists (alcoholism), CV Therapeutics; ALDH2 antagonists (alcoholism), Gilead Palo Alto; Aldehyde dehydrogenase-2 antagonists (alcoholism), CV Therapeutics
DMDH6PJ	CP	Gilead Palo Alto Inc
DMDH6PJ	DT	Small molecular drug
DMDH6PJ	PC	23661666
DMDH6PJ	MW	465.5
DMDH6PJ	FM	C24H19NO7S
DMDH6PJ	IC	InChI=1S/C24H19NO7S/c1-33(29,30)25-18-7-5-16(6-8-18)21-14-32-22-12-19(9-10-20(22)23(21)26)31-13-15-3-2-4-17(11-15)24(27)28/h2-12,14,25H,13H2,1H3,(H,27,28)
DMDH6PJ	CS	CS(=O)(=O)NC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)OCC4=CC(=CC=C4)C(=O)O
DMDH6PJ	IK	YYOOFJZTRCPVFD-UHFFFAOYSA-N
DMDH6PJ	IU	3-[[3-[4-(methanesulfonamido)phenyl]-4-oxochromen-7-yl]oxymethyl]benzoic acid
DMDH6PJ	CA	CAS 1005334-57-5
DMDH6PJ	DE	Alcohol dependence

DMOCKMZ	ID	DMOCKMZ
DMOCKMZ	DN	CVT-12012
DMOCKMZ	HS	Investigative
DMOCKMZ	SN	CVT-12012; UNII-OH3J29Q653; 1018675-35-8; CHEMBL573829; OH3J29Q653; SCHEMBL906403; EX-A2767; BDBM50298898; HY-11034; 2-Hydroxy-N-(2-(3-methyl-2-oxo-7-(((3-(trifluoromethyl)phenyl)methyl)amino)-1,2-dihydroquinoxalin-1-yl)ethyl)acetamide; Acetamide, 2-hydroxy-N-(2-(3-methyl-2-oxo-7-(((3-(trifluoromethyl)phenyl)methyl)amino)-1(2H)-quinoxalinyl)ethyl)-; CS-0003005; 2-hydroxy-N-(2-(3-methyl-2-oxo-7-(3-(trifluoromethyl)benzylamino)quinoxalin-1(2H)-yl)ethyl)acetamide
DMOCKMZ	DT	Small molecular drug
DMOCKMZ	PC	25195516
DMOCKMZ	MW	434.4
DMOCKMZ	FM	C21H21F3N4O3
DMOCKMZ	IC	InChI=1S/C21H21F3N4O3/c1-13-20(31)28(8-7-25-19(30)12-29)18-10-16(5-6-17(18)27-13)26-11-14-3-2-4-15(9-14)21(22,23)24/h2-6,9-10,26,29H,7-8,11-12H2,1H3,(H,25,30)
DMOCKMZ	CS	CC1=NC2=C(C=C(C=C2)NCC3=CC(=CC=C3)C(F)(F)F)N(C1=O)CCNC(=O)CO
DMOCKMZ	IK	HRAQDVZJYIAWOV-UHFFFAOYSA-N
DMOCKMZ	IU	2-hydroxy-N-[2-[3-methyl-2-oxo-7-[[3-(trifluoromethyl)phenyl]methylamino]quinoxalin-1-yl]ethyl]acetamide
DMOCKMZ	CA	CAS 1018675-35-8
DMOCKMZ	DE	Diabetic complication

DMSEK5W	ID	DMSEK5W
DMSEK5W	DN	CVT-313
DMSEK5W	HS	Investigative
DMSEK5W	SN	AC1OCFD4; NG 26
DMSEK5W	DT	Small molecular drug
DMSEK5W	PC	6918386
DMSEK5W	MW	400.5
DMSEK5W	FM	C20H28N6O3
DMSEK5W	IC	InChI=1S/C20H28N6O3/c1-14(2)26-13-22-17-18(21-12-15-4-6-16(29-3)7-5-15)23-20(24-19(17)26)25(8-10-27)9-11-28/h4-7,13-14,27-28H,8-12H2,1-3H3,(H,21,23,24)
DMSEK5W	CS	CC(C)N1C=NC2=C(N=C(N=C21)N(CCO)CCO)NCC3=CC=C(C=C3)OC
DMSEK5W	IK	NQVIIUBWMBHLOZ-UHFFFAOYSA-N
DMSEK5W	IU	2-[2-hydroxyethyl-[6-[(4-methoxyphenyl)methylamino]-9-propan-2-ylpurin-2-yl]amino]ethanol
DMSEK5W	CA	CAS 199986-75-9
DMSEK5W	DE	Discovery agent

DMYC1DW	ID	DMYC1DW
DMYC1DW	DN	CVT-6694
DMYC1DW	HS	Investigative
DMYC1DW	SN	CVT-6694; CHEMBL252048; SCHEMBL242234; BDBM50233086
DMYC1DW	DT	Small molecular drug
DMYC1DW	PC	10226014
DMYC1DW	MW	452.9
DMYC1DW	FM	C20H17ClN8O3
DMYC1DW	IC	InChI=1S/C20H17ClN8O3/c1-2-7-29-19(30)15-17(26-20(29)31)25-16(24-15)12-8-22-28(9-12)10-14-23-18(32-27-14)11-3-5-13(21)6-4-11/h3-6,8-9H,2,7,10H2,1H3,(H,24,25)(H,26,31)
DMYC1DW	CS	CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CN(N=C3)CC4=NOC(=N4)C5=CC=C(C=C5)Cl
DMYC1DW	IK	HWHLLTUJISZFDN-UHFFFAOYSA-N
DMYC1DW	IU	8-[1-[[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]pyrazol-4-yl]-1-propyl-3,7-dihydropurine-2,6-dione
DMYC1DW	DE	Discovery agent

DM53VA8	ID	DM53VA8
DM53VA8	DN	CVT-7124
DM53VA8	HS	Investigative
DM53VA8	SN	CVT-7124; CHEMBL251876; SCHEMBL1945825; BDBM50233088; 1-ethyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione
DM53VA8	DT	Small molecular drug
DM53VA8	PC	11774068
DM53VA8	MW	404.3
DM53VA8	FM	C18H15F3N6O2
DM53VA8	IC	InChI=1S/C18H15F3N6O2/c1-2-27-16(28)13-15(25-17(27)29)24-14(23-13)11-7-22-26(9-11)8-10-4-3-5-12(6-10)18(19,20)21/h3-7,9H,2,8H2,1H3,(H,23,24)(H,25,29)
DM53VA8	CS	CCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CN(N=C3)CC4=CC(=CC=C4)C(F)(F)F
DM53VA8	IK	OFXKKKKJJGJUBD-UHFFFAOYSA-N
DM53VA8	IU	1-ethyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione
DM53VA8	DE	Discovery agent

DMXMIT4	ID	DMXMIT4
DMXMIT4	DN	CX-02
DMXMIT4	HS	Investigative
DMXMIT4	SN	CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics
DMXMIT4	CP	Northwest Biotherapeutics Inc
DMXMIT4	DT	Antibody
DMXMIT4	DE	Solid tumour/cancer

DM7293Q	ID	DM7293Q
DM7293Q	DN	CX-1001
DM7293Q	HS	Investigative
DM7293Q	SN	SERT ligand (cancer), Celentyx; Reprofiled marketed drug (B-cell cancers), Celentyx
DM7293Q	CP	Celentyx Ltd
DM7293Q	DE	Solid tumour/cancer

DMCNEXF	ID	DMCNEXF
DMCNEXF	DN	CX4
DMCNEXF	HS	Investigative
DMCNEXF	SN	AC1MBGFP; Maybridge4_002933; CX-4; GTPL7663; CCG-196; MolPort-002-912-245; HMS1529F07; MCULE-4373871510; NCGC00176395-01; BRD-A62325689-001-01-9; 1-(2-chloro-6-methylphenyl)-3-(1,2-diphenylethyl)thiourea
DMCNEXF	DT	Small molecular drug
DMCNEXF	PC	2725220
DMCNEXF	MW	380.9
DMCNEXF	FM	C22H21ClN2S
DMCNEXF	IC	InChI=1S/C22H21ClN2S/c1-16-9-8-14-19(23)21(16)25-22(26)24-20(18-12-6-3-7-13-18)15-17-10-4-2-5-11-17/h2-14,20H,15H2,1H3,(H2,24,25,26)
DMCNEXF	CS	CC1=C(C(=CC=C1)Cl)NC(=S)NC(CC2=CC=CC=C2)C3=CC=CC=C3
DMCNEXF	IK	LHTLPGOZLLOCIS-UHFFFAOYSA-N
DMCNEXF	IU	1-(2-chloro-6-methylphenyl)-3-(1,2-diphenylethyl)thiourea
DMCNEXF	DE	Discovery agent

DMXD1IN	ID	DMXD1IN
DMXD1IN	DN	CX-5011
DMXD1IN	HS	Investigative
DMXD1IN	SN	1333382-30-1; UNII-2F5JG09KS6; CX-5011; 2F5JG09KS6; sodium 5-(3-ethynylphenylamino)pyrimido[4,5-c]quinoline-8-carboxylate; AOB1816; AKOS027422619; Pyrimido(4,5-C)quinoline-8-carboxylic acid, 5-((3-ethynylphenyl)amino)-, sodium salt (1:1)
DMXD1IN	CP	Cylene Pharmaceuticals Inc
DMXD1IN	DT	Small molecular drug
DMXD1IN	PC	70702100
DMXD1IN	MW	362.3
DMXD1IN	FM	C20H11N4NaO2
DMXD1IN	IC	InChI=1S/C20H12N4O2.Na/c1-2-12-4-3-5-14(8-12)23-19-18-16(10-21-11-22-18)15-7-6-13(20(25)26)9-17(15)24-19;/h1,3-11H,(H,23,24)(H,25,26);/q;+1/p-1
DMXD1IN	CS	C#CC1=CC(=CC=C1)NC2=NC3=C(C=CC(=C3)C(=O)[O-])C4=CN=CN=C42.[Na+]
DMXD1IN	IK	FSIFELDKZUCPMJ-UHFFFAOYSA-M
DMXD1IN	IU	sodium;5-(3-ethynylanilino)pyrimido[4,5-c]quinoline-8-carboxylate
DMXD1IN	CA	CAS 1333382-30-1
DMXD1IN	DE	Solid tumour/cancer

DMNTAV8	ID	DMNTAV8
DMNTAV8	DN	CX-7000
DMNTAV8	HS	Investigative
DMNTAV8	SN	Second generation CK2 inhibitors (cancer), Cylene
DMNTAV8	CP	Cylene Pharmaceuticals Inc
DMNTAV8	DE	Solid tumour/cancer

DM526C9	ID	DM526C9
DM526C9	DN	CX-9051
DM526C9	HS	Investigative
DM526C9	SN	J-13016; COX-2 inhibitors (cancer); COX-2 inhibitors (cancer), National Taiwan University
DM526C9	CP	National Taiwan University
DM526C9	DE	Solid tumour/cancer

DMAPRDE	ID	DMAPRDE
DMAPRDE	DN	CXB-029
DMAPRDE	HS	Investigative
DMAPRDE	SN	CB1 antagonist (pain/obesity/glaucoma/CNS-related disease), CeNeRx
DMAPRDE	CP	PharmaNess Neurosciences
DMAPRDE	DE	Central nervous system disease

DMG1SXD	ID	DMG1SXD
DMG1SXD	DN	CXCL8
DMG1SXD	HS	Investigative
DMG1SXD	SN	Interleukin-8; CHEMBL411250;  interleukin-8; IL-8
DMG1SXD	DT	Small molecular drug
DMG1SXD	PC	74974005
DMG1SXD	MW	2504.7
DMG1SXD	FM	C112H150N24O38S2
DMG1SXD	IC	InChI=1S/C112H150N24O38S2/c1-55(2)41-69(122-103(165)77(49-89(149)150)131-106(168)79(51-91(153)154)129-98(160)70(42-59-19-10-8-11-20-59)123-105(167)78(50-90(151)152)130-100(162)73(45-62-52-115-65-24-15-14-23-64(62)65)126-96(158)67(34-39-175-6)118-58(5)139)97(159)127-74(46-84(113)141)101(163)125-72(43-60-21-12-9-13-22-60)107(169)133-92(57(4)138)109(171)116-53-85(142)119-68(35-40-176-7)110(172)136-38-18-27-83(136)112(174)135-37-17-26-82(135)108(170)117-56(3)94(156)121-75(47-87(145)146)102(164)120-66(32-33-86(143)144)95(157)128-76(48-88(147)148)104(166)124-71(44-61-28-30-63(140)31-29-61)99(161)132-80(54-137)111(173)134-36-16-25-81(134)93(114)155/h8-15,19-24,28-31,52,55-57,66-83,92,115,137-138,140H,16-18,25-27,32-51,53-54H2,1-7H3,(H2,113,141)(H2,114,155)(H,116,171)(H,117,170)(H,118,139)(H,119,142)(H,120,164)(H,121,156)(H,122,165)(H,123,167)(H,124,166)(H,125,163)(H,126,158)(H,127,159)(H,128,157)(H,129,160)(H,130,162)(H,131,168)(H,132,161)(H,133,169)(H,143,144)(H,145,146)(H,147,148)(H,149,150)(H,151,152)(H,153,154)
DMG1SXD	CS	CC(C)CC(C(=O)NC(CC(=O)N)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CCSC)C(=O)N2CCCC2C(=O)N3CCCC3C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)NC(CO)C(=O)N5CCCC5C(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(=O)O)NC(=O)C(CC7=CNC8=CC=CC=C87)NC(=O)C(CCSC)NC(=O)C
DMG1SXD	IK	XKTZWUACRZHVAN-UHFFFAOYSA-N
DMG1SXD	IU	4-[[2-[2-[[1-[1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[(2-acetamido-4-methylsulfanylbutanoyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-5-[[1-[[1-[[1-(2-carbamoylpyrrolidin-1-yl)-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMG1SXD	DE	Psoriasis vulgaris

DMNSUD9	ID	DMNSUD9
DMNSUD9	DN	CXCR4 gene disrupted T cells
DMNSUD9	HS	Investigative
DMNSUD9	SN	CXCR4 gene disrupted T cells (HIV infection)
DMNSUD9	CP	Scripps Research Institute
DMNSUD9	DE	Human immunodeficiency virus infection

DMBKTHI	ID	DMBKTHI
DMBKTHI	DN	Cy3B-telenzepine
DMBKTHI	HS	Investigative
DMBKTHI	SN	Cy3B-telenzepine
DMBKTHI	DT	Small molecular drug
DMBKTHI	PC	91827377
DMBKTHI	MW	1054.4
DMBKTHI	FM	C59H71N7O7S2-2
DMBKTHI	IC	InChI=1S/C59H73N7O7S2/c1-38-54-43(37-74-38)57(69)61-46-16-12-13-17-49(46)66(54)53(68)36-63-30-28-62(29-31-63)25-15-11-9-7-6-8-10-14-24-60-52(67)33-39-18-20-47-44(32-39)58(2,3)55-41-35-42-51(73-50(41)22-26-64(47)55)23-27-65-48-21-19-40(75(70,71)72)34-45(48)59(4,5)56(42)65/h12-13,16-21,32,34-35,37,50-51H,6-11,14-15,22-31,33,36H2,1-5H3,(H4-,60,61,67,69,70,71,72)/p-2
DMBKTHI	CS	CC1=C2C(=CS1)C(=O)NC3=CC=CC=C3N2C(=O)CN4CCN(CC4)CCCCCCCCCCNC(=O)CC5=CC6=C(C=C5)N7CCC8C(=C7C6(C)C)C=C9C(O8)CC[N+]1=C9C(C2=C1C=CC(=C2)S([O-])([O-])[O-])(C)C
DMBKTHI	IK	DGPHRPUJPHDIPO-UHFFFAOYSA-L
DMBKTHI	IU	N-[10-[4-[2-(1-methyl-4-oxo-5H-thieno[3,4-b][1,5]benzodiazepin-10-yl)-2-oxoethyl]piperazin-1-yl]decyl]-2-[5,5,27,27-tetramethyl-24-(trioxido-lambda4-sulfanyl)-16-oxa-12-aza-20-azoniaheptacyclo[15.11.0.03,15.04,12.06,11.020,28.021,26]octacosa-1,3,6(11),7,9,20(28),21(26),22,24-nonaen-8-yl]acetamide
DMBKTHI	DE	Discovery agent

DMZ6YPV	ID	DMZ6YPV
DMZ6YPV	DN	Cyamemazine
DMZ6YPV	HS	Investigative
DMZ6YPV	SN	cyamepromazine; RP-7204
DMZ6YPV	DT	Small molecular drug
DMZ6YPV	PC	62865
DMZ6YPV	MW	323.5
DMZ6YPV	FM	C19H21N3S
DMZ6YPV	IC	InChI=1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3
DMZ6YPV	CS	CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C#N)CN(C)C
DMZ6YPV	IK	SLFGIOIONGJGRT-UHFFFAOYSA-N
DMZ6YPV	IU	10-[3-(dimethylamino)-2-methylpropyl]phenothiazine-2-carbonitrile
DMZ6YPV	CA	CAS 3546-03-0
DMZ6YPV	CB	CHEBI:135379
DMZ6YPV	DE	Discovery agent

DM6HQDL	ID	DM6HQDL
DM6HQDL	DN	CYANATE
DM6HQDL	HS	Investigative
DM6HQDL	SN	cyanate; ISOCYANATE; UNII-YML51WA0FW; YML51WA0FW; 661-20-1; 71000-82-3; UN2206; Cyanate ion(1-); Isocyanate ion(1-); Isocyanate ion (1-); Isocyanic acid, ion(1-); isocynate; Zyanat; Cyanat; carbonyl amide; hydrogen cyanate; UN3080; nitridooxidocarbonate(1-); AC1L2XX2; OCN(-); CHEBI:29195; CTK5I4582; CTK2H4173; BDBM26982; CNO(-1); IQPQWNKOIGAROB-UHFFFAOYSA-N; XLJMAIOERFSOGZ-UHFFFAOYSA-M; AC1Q2283; BDBM50098562; [C(N)O](-); Isocyanates, toxic, n.o.s. or isocyanate solutions, toxic, n.o.s., Fp 61 C and Bp 300 C; Isocyanates, toxic, n.o.s. o
DM6HQDL	DT	Small molecular drug
DM6HQDL	PC	105034
DM6HQDL	MW	42.017
DM6HQDL	FM	CNO-
DM6HQDL	IC	InChI=1S/CNO/c2-1-3/q-1
DM6HQDL	CS	C(=[N-])=O
DM6HQDL	IK	IQPQWNKOIGAROB-UHFFFAOYSA-N
DM6HQDL	IU	isocyanate
DM6HQDL	CA	CAS 71000-82-3
DM6HQDL	CB	CHEBI:29195
DM6HQDL	DE	Discovery agent

DMJE4HK	ID	DMJE4HK
DMJE4HK	DN	Cyanide
DMJE4HK	HS	Investigative
DMJE4HK	SN	cyanide; CYANIDE ION; Isocyanide; Cyanide anion; Nitrile anion; Cyanide ions; 57-12-5; Cyanure [French]; Cyanide(1-) ion; Cyanide(1-); Cyanide (anion); UNII-OXN4E7L11K; RCRA waste number P030; Cyanide (CN(sup 1-)); Carbon nitride ion (CN1-); Hydrocyanic acid, ion(1-)-; Carbon nitride ion (CN(sup 1-)); UN1935; RCRA waste no. P030; BRN 1900509; OXN4E7L11K; CN-; Cyanides (soluble salts and complexes) not otherwise specified; Cyanure; Cyanide, free; iminomethanide; isonitrile; Prussiate; Zyanid; Cyano; nitridocarbonate(1-); Cyanide with pota
DMJE4HK	DT	Small molecular drug
DMJE4HK	PC	5975
DMJE4HK	MW	26.017
DMJE4HK	FM	CN-
DMJE4HK	IC	InChI=1S/CN/c1-2/q-1
DMJE4HK	CS	[C-]#N
DMJE4HK	IK	XFXPMWWXUTWYJX-UHFFFAOYSA-N
DMJE4HK	IU	cyanide
DMJE4HK	CA	CAS 57-12-5
DMJE4HK	CB	CHEBI:17514
DMJE4HK	DE	Discovery agent

DMZBDO1	ID	DMZBDO1
DMZBDO1	DN	CYANIDIN
DMZBDO1	HS	Investigative
DMZBDO1	SN	Cyanidin; 13306-05-3; UNII-7732ZHU564; 3,5,7,3',4'-Pentahydroxyflavylium; 2-(3,4-dihydroxyphenyl)chromenylium-3,5,7-triol; CHEMBL404515; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-1-Benzopyrylium; CHEBI:27843; 3,3',4',5,7-pentahydroxyflavylium; 7732ZHU564; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromenylium; cyanidin cation; 3,3',4,5,7-Pentahydroxyflavylium chloride; cyanidin(1+); Flavylium, 3,3',4',5,7-pentahydroxy-; AC1L2UL2; SCHEMBL20799; 528-58-5 (chloride); DTXSID10157933; MolPort-044-559-814
DMZBDO1	DT	Small molecular drug
DMZBDO1	PC	128861
DMZBDO1	MW	287.24
DMZBDO1	FM	C15H11O6+
DMZBDO1	IC	InChI=1S/C15H10O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-6H,(H4-,16,17,18,19,20)/p+1
DMZBDO1	CS	C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2O)O)O)O)O
DMZBDO1	IK	VEVZSMAEJFVWIL-UHFFFAOYSA-O
DMZBDO1	IU	2-(3,4-dihydroxyphenyl)chromenylium-3,5,7-triol
DMZBDO1	CA	CAS 13306-05-3
DMZBDO1	CB	CHEBI:27843
DMZBDO1	DE	Discovery agent

DMIBLGH	ID	DMIBLGH
DMIBLGH	DN	Cyanopindolol
DMIBLGH	HS	Investigative
DMIBLGH	SN	Cyanopindolol; 69906-85-0; CYANOPINDOLOL HEMIFUMARATE; 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile; (+-)-Cyanopindolol; (-)-Cyanopindolol; AC1L4E3D; CYANOPINDOLOL(+/-); GTPL132; SCHEMBL353756; CHEMBL378501; CTK8E9328; BDBM81499; CHEBI:125406; PDSP1_001601; PDSP2_001585; PDSP1_001094; PDSP2_001078; NSC707473; CAS_155346; NSC_155346; NSC-707473; 1H-Indole-2-carbonitrile, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-; NCI60_038172; RT-012114; SR-01000597973; L000210; SR-01000597973-1; BRD-A47884604-001-01-7
DMIBLGH	DT	Small molecular drug
DMIBLGH	PC	155346
DMIBLGH	MW	287.36
DMIBLGH	FM	C16H21N3O2
DMIBLGH	IC	InChI=1S/C16H21N3O2/c1-16(2,3)18-9-12(20)10-21-15-6-4-5-14-13(15)7-11(8-17)19-14/h4-7,12,18-20H,9-10H2,1-3H3
DMIBLGH	CS	CC(C)(C)NCC(COC1=CC=CC2=C1C=C(N2)C#N)O
DMIBLGH	IK	QXIUMMLTJVHILT-UHFFFAOYSA-N
DMIBLGH	IU	4-[3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile
DMIBLGH	CA	CAS 69906-85-0
DMIBLGH	CB	CHEBI:125406
DMIBLGH	DE	Discovery agent

DMC6DAZ	ID	DMC6DAZ
DMC6DAZ	DN	CYCLAZOCINE
DMC6DAZ	HS	Investigative
DMC6DAZ	SN	(-)-cyclazocine; 7313-86-2; l-Cyclazocine; (-)-cis-Cyclazocine; A-Cyclazocine; AC1L55DZ; GTPL1604; CTK8F1400; DTXSID20617937; MCV 4512; (2R,6R,11R)-3-(Cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; NIH 10450; AKOS030242899; FT-0665329
DMC6DAZ	DT	Small molecular drug
DMC6DAZ	PC	19143
DMC6DAZ	MW	271.4
DMC6DAZ	FM	C18H25NO
DMC6DAZ	IC	InChI=1S/C18H25NO/c1-12-17-9-14-5-6-15(20)10-16(14)18(12,2)7-8-19(17)11-13-3-4-13/h5-6,10,12-13,17,20H,3-4,7-9,11H2,1-2H3
DMC6DAZ	CS	CC1C2CC3=C(C1(CCN2CC4CC4)C)C=C(C=C3)O
DMC6DAZ	IK	YQYVFVRQLZMJKJ-UHFFFAOYSA-N
DMC6DAZ	IU	10-(cyclopropylmethyl)-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMC6DAZ	CA	CAS 3572-80-3
DMC6DAZ	DE	Discovery agent

DMPXHO8	ID	DMPXHO8
DMPXHO8	DN	Cyclazosin
DMPXHO8	HS	Investigative
DMPXHO8	SN	Cyclazosin; (+)-cyclazosin; 139953-73-4; CHEBI:63937; cis-1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)decahydroquinoxaline; [(4aR,8aS)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)octahydroquinoxalin-1(2H)-yl](2-furyl)methanone; AC1L30OJ; GTPL486; (4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)octahydroquinoxalin-1-yl)furan-2-ylmethanone hydrochloride; CHEMBL423294; ZINC2385764; BDBM50403649; [(4aR,8aS)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2,3,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-(furan-2-yl)methanone
DMPXHO8	DT	Small molecular drug
DMPXHO8	PC	132266
DMPXHO8	MW	437.5
DMPXHO8	FM	C23H27N5O4
DMPXHO8	IC	InChI=1S/C23H27N5O4/c1-30-19-12-14-15(13-20(19)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)18-8-5-11-32-18/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26)/t16-,17+/m0/s1
DMPXHO8	CS	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN([C@@H]4[C@H]3CCCC4)C(=O)C5=CC=CO5)N)OC
DMPXHO8	IK	XBRXTUGRUXGBPX-DLBZAZTESA-N
DMPXHO8	IU	[(4aR,8aS)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2,3,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-(furan-2-yl)methanone
DMPXHO8	CA	CAS 139953-73-4
DMPXHO8	CB	CHEBI:63937
DMPXHO8	DE	Discovery agent

DMVJL8H	ID	DMVJL8H
DMVJL8H	DN	cyclic CMP
DMVJL8H	HS	Investigative
DMVJL8H	SN	cytidine, cyclic 3',5'-(hydrogen phosphate)
DMVJL8H	DT	Small molecular drug
DMVJL8H	PC	19236
DMVJL8H	MW	305.18
DMVJL8H	FM	C9H12N3O7P
DMVJL8H	IC	InChI=1S/C9H12N3O7P/c10-5-1-2-12(9(14)11-5)8-6(13)7-4(18-8)3-17-20(15,16)19-7/h1-2,4,6-8,13H,3H2,(H,15,16)(H2,10,11,14)/t4-,6-,7-,8-/m1/s1
DMVJL8H	CS	C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)OP(=O)(O1)O
DMVJL8H	IK	WCPTXJJVVDAEMW-XVFCMESISA-N
DMVJL8H	IU	1-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-4-aminopyrimidin-2-one
DMVJL8H	CA	CAS 3616-08-8
DMVJL8H	CB	CHEBI:17065
DMVJL8H	DE	Discovery agent

DMOU93V	ID	DMOU93V
DMOU93V	DN	Cyclic guanosine monophosphate
DMOU93V	HS	Investigative
DMOU93V	DT	Small molecular drug
DMOU93V	PC	135398570
DMOU93V	MW	345.21
DMOU93V	FM	C10H12N5O7P
DMOU93V	IC	InChI=1S/C10H12N5O7P/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6-3(21-9)1-20-23(18,19)22-6/h2-3,5-6,9,16H,1H2,(H,18,19)(H3,11,13,14,17)/t3-,5-,6-,9-/m1/s1
DMOU93V	CS	C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=C(NC4=O)N)O)OP(=O)(O1)O
DMOU93V	IK	ZOOGRGPOEVQQDX-UUOKFMHZSA-N
DMOU93V	IU	9-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-2-amino-1H-purin-6-one
DMOU93V	CA	CAS 7665-99-8
DMOU93V	CB	CHEBI:16356
DMOU93V	DE	Discovery agent

DM2JE5F	ID	DM2JE5F
DM2JE5F	DN	Cyclic LVVYPWT
DM2JE5F	HS	Investigative
DM2JE5F	SN	CHEMBL397926; cyclic LVVYPWT
DM2JE5F	DT	Small molecular drug
DM2JE5F	PC	17756317
DM2JE5F	MW	859
DM2JE5F	FM	C45H62N8O9
DM2JE5F	IC	InChI=1S/C45H62N8O9/c1-23(2)19-32-39(56)50-37(25(5)6)43(60)51-36(24(3)4)42(59)49-34(20-27-14-16-29(55)17-15-27)45(62)53-18-10-13-35(53)41(58)47-33(40(57)52-38(26(7)54)44(61)48-32)21-28-22-46-31-12-9-8-11-30(28)31/h8-9,11-12,14-17,22-26,32-38,46,54-55H,10,13,18-21H2,1-7H3,(H,47,58)(H,48,61)(H,49,59)(H,50,56)(H,51,60)(H,52,57)/t26-,32+,33+,34+,35+,36+,37+,38+/m1/s1
DM2JE5F	CS	C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N1)CC3=CNC4=CC=CC=C43)CC5=CC=C(C=C5)O)C(C)C)C(C)C)CC(C)C)O
DM2JE5F	IK	COEPOBZXGUREGL-BYZYSQTKSA-N
DM2JE5F	IU	(3S,6S,9S,12S,15S,18S,21S)-15-[(1R)-1-hydroxyethyl]-3-[(4-hydroxyphenyl)methyl]-18-(1H-indol-3-ylmethyl)-12-(2-methylpropyl)-6,9-di(propan-2-yl)-1,4,7,10,13,16,19-heptazabicyclo[19.3.0]tetracosane-2,5,8,11,14,17,20-heptone
DM2JE5F	DE	Discovery agent

DMFUG05	ID	DMFUG05
DMFUG05	DN	Cyclo(1,10)EIYDPGDDIK
DMFUG05	HS	Investigative
DMFUG05	SN	CHEMBL499996
DMFUG05	PC	44571079
DMFUG05	MW	1146.2
DMFUG05	FM	C51H75N11O19
DMFUG05	IC	InChI=1S/C51H75N11O19/c1-5-25(3)41-49(79)56-29(10-7-8-18-52)43(73)55-30(16-17-37(65)66)44(74)60-42(26(4)6-2)50(80)58-31(20-27-12-14-28(63)15-13-27)45(75)59-34(23-40(71)72)51(81)62-19-9-11-35(62)48(78)53-24-36(64)54-32(21-38(67)68)46(76)57-33(22-39(69)70)47(77)61-41/h12-15,25-26,29-35,41-42,63H,5-11,16-24,52H2,1-4H3,(H,53,78)(H,54,64)(H,55,73)(H,56,79)(H,57,76)(H,58,80)(H,59,75)(H,60,74)(H,61,77)(H,65,66)(H,67,68)(H,69,70)(H,71,72)/t25-,26-,29-,30-,31-,32+,33-,34-,35-,41-,42-/m0/s1
DMFUG05	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCC(=O)O)CCCCN)[C@@H](C)CC)CC(=O)O)CC(=O)O)CC(=O)O)CC3=CC=C(C=C3)O
DMFUG05	IK	JDTPYTFDRAQKHK-ZHDLRRBESA-N
DMFUG05	IU	3-[(3S,6S,9S,12S,15S,18S,21S,24R,30S)-15-(4-aminobutyl)-9,18-bis[(2S)-butan-2-yl]-3,21,24-tris(carboxymethyl)-6-[(4-hydroxyphenyl)methyl]-2,5,8,11,14,17,20,23,26,29-decaoxo-1,4,7,10,13,16,19,22,25,28-decazabicyclo[28.3.0]tritriacontan-12-yl]propanoic acid
DMFUG05	DE	Discovery agent

DM5CBQ9	ID	DM5CBQ9
DM5CBQ9	DN	Cyclo(1,10)H-EIYDPGDDIK-OH
DM5CBQ9	HS	Investigative
DM5CBQ9	SN	CHEMBL506798
DM5CBQ9	PC	44571080
DM5CBQ9	MW	1146.2
DM5CBQ9	FM	C51H75N11O19
DM5CBQ9	IC	InChI=1S/C51H75N11O19/c1-5-25(3)41-49(78)58-31(20-27-12-14-28(63)15-13-27)44(73)59-34(23-40(70)71)50(79)62-19-9-11-35(62)47(76)54-24-37(65)55-32(21-38(66)67)45(74)57-33(22-39(68)69)46(75)61-42(26(4)6-2)48(77)56-30(51(80)81)10-7-8-18-53-36(64)17-16-29(52)43(72)60-41/h12-15,25-26,29-35,41-42,63H,5-11,16-24,52H2,1-4H3,(H,53,64)(H,54,76)(H,55,65)(H,56,77)(H,57,74)(H,58,78)(H,59,73)(H,60,72)(H,61,75)(H,66,67)(H,68,69)(H,70,71)(H,80,81)/t25-,26-,29-,30-,31-,32-,33-,34-,35-,41-,42-/m0/s1
DM5CBQ9	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N1)N)C(=O)O)[C@@H](C)CC)CC(=O)O)CC(=O)O)CC(=O)O)CC3=CC=C(C=C3)O
DM5CBQ9	IK	NYVKKYBROIXDPN-ZGHCNQEKSA-N
DM5CBQ9	IU	(3S,6S,9S,12S,21S,24S,27S,30S,36S)-12-amino-9,24-bis[(2S)-butan-2-yl]-3,27,30-tris(carboxymethyl)-6-[(4-hydroxyphenyl)methyl]-2,5,8,11,15,23,26,29,32,35-decaoxo-1,4,7,10,16,22,25,28,31,34-decazabicyclo[34.3.0]nonatriacontane-21-carboxylic acid
DM5CBQ9	DE	Discovery agent

DM4A1TF	ID	DM4A1TF
DM4A1TF	DN	Cyclo(1,11)H-ESIYDPGDDIK-OH
DM4A1TF	HS	Investigative
DM4A1TF	SN	CHEMBL525597
DM4A1TF	PC	44571078
DM4A1TF	MW	1233.3
DM4A1TF	FM	C54H80N12O21
DM4A1TF	IC	InChI=1S/C54H80N12O21/c1-5-26(3)43-51(83)59-31(54(86)87)10-7-8-18-56-38(69)17-16-30(55)45(77)63-36(25-67)49(81)65-44(27(4)6-2)52(84)61-32(20-28-12-14-29(68)15-13-28)46(78)62-35(23-42(75)76)53(85)66-19-9-11-37(66)50(82)57-24-39(70)58-33(21-40(71)72)47(79)60-34(22-41(73)74)48(80)64-43/h12-15,26-27,30-37,43-44,67-68H,5-11,16-25,55H2,1-4H3,(H,56,69)(H,57,82)(H,58,70)(H,59,83)(H,60,79)(H,61,84)(H,62,78)(H,63,77)(H,64,80)(H,65,81)(H,71,72)(H,73,74)(H,75,76)(H,86,87)/t26-,27-,30-,31-,32-,33-,34-,35-,36-,37-,43-,44-/m0/s1
DM4A1TF	CS	CC[C@H](C)[C@H]1C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)O)CC(=O)O)CC(=O)O)CC3=CC=C(C=C3)O)[C@@H](C)CC)CO)N)C(=O)O
DM4A1TF	IK	QVRGILAZQGYCSV-ZGJOQXBESA-N
DM4A1TF	IU	(3S,6S,9S,12S,15S,24S,27S,30S,33S,39S)-15-amino-9,27-bis[(2S)-butan-2-yl]-3,30,33-tris(carboxymethyl)-12-(hydroxymethyl)-6-[(4-hydroxyphenyl)methyl]-2,5,8,11,14,18,26,29,32,35,38-undecaoxo-1,4,7,10,13,19,25,28,31,34,37-undecazabicyclo[37.3.0]dotetracontane-24-carboxylic acid
DM4A1TF	DE	Discovery agent

DMVDS8B	ID	DMVDS8B
DMVDS8B	DN	Cyclo(1,12)PenIYDTKGKNVLC-OH
DMVDS8B	HS	Investigative
DMVDS8B	PC	44403758
DMVDS8B	MW	1382.7
DMVDS8B	FM	C60H99N15O18S2
DMVDS8B	IC	InChI=1S/C60H99N15O18S2/c1-10-31(6)46-56(89)71-38(24-33-17-19-34(77)20-18-33)52(85)69-40(26-44(80)81)54(87)75-47(32(7)76)57(90)67-35(15-11-13-21-61)49(82)65-27-43(79)66-36(16-12-14-22-62)50(83)68-39(25-42(63)78)53(86)73-45(30(4)5)55(88)70-37(23-29(2)3)51(84)72-41(59(92)93)28-94-95-60(8,9)48(64)58(91)74-46/h17-20,29-32,35-41,45-48,76-77H,10-16,21-28,61-62,64H2,1-9H3,(H2,63,78)(H,65,82)(H,66,79)(H,67,90)(H,68,83)(H,69,85)(H,70,88)(H,71,89)(H,72,84)(H,73,86)(H,74,91)(H,75,87)(H,80,81)(H,92,93)/t31-,32+,35-,36-,37+,38+,39+,40-,41+,45-,46-,47+,48?/m0/s1
DMVDS8B	CS	CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC(C(C(=O)N1)N)(C)C)C(=O)O)CC(C)C)C(C)C)CC(=O)N)CCCCN)CCCCN)[C@@H](C)O)CC(=O)O)CC2=CC=C(C=C2)O
DMVDS8B	IK	PADTZYYZHQSVHY-JPKRNNDPSA-N
DMVDS8B	IU	(4S,7R,10S,13R,16S,22S,25R,28S,31R,34S)-37-amino-16,22-bis(4-aminobutyl)-13-(2-amino-2-oxoethyl)-34-[(2S)-butan-2-yl]-28-(carboxymethyl)-25-[(1R)-1-hydroxyethyl]-31-[(4-hydroxyphenyl)methyl]-38,38-dimethyl-7-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DMVDS8B	DE	Discovery agent

DMLY8CU	ID	DMLY8CU
DMLY8CU	DN	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)
DMLY8CU	HS	Investigative
DMLY8CU	SN	CHEMBL373440; cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)
DMLY8CU	DT	Small molecular drug
DMLY8CU	PC	44418868
DMLY8CU	MW	637.7
DMLY8CU	FM	C30H43N11O5
DMLY8CU	IC	InChI=1S/C30H43N11O5/c1-17-25(43)37-16-24(42)39-23(15-18-10-11-19-6-2-3-7-20(19)14-18)28(46)41-22(9-5-13-36-30(33)34)27(45)40-21(26(44)38-17)8-4-12-35-29(31)32/h2-3,6-7,10-11,14,17,21-23H,4-5,8-9,12-13,15-16H2,1H3,(H,37,43)(H,38,44)(H,39,42)(H,40,45)(H,41,46)(H4,31,32,35)(H4,33,34,36)/t17-,21-,22+,23+/m1/s1
DMLY8CU	CS	C[C@@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CCCN=C(N)N)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2
DMLY8CU	IK	SSVKJORMBVSSPN-DZWOVHDNSA-N
DMLY8CU	IU	2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMLY8CU	DE	Discovery agent

DMBKRQ9	ID	DMBKRQ9
DMBKRQ9	DN	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)
DMBKRQ9	HS	Investigative
DMBKRQ9	SN	CHEMBL375993; cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)
DMBKRQ9	DT	Small molecular drug
DMBKRQ9	PC	44418891
DMBKRQ9	MW	743.9
DMBKRQ9	FM	C37H49N11O6
DMBKRQ9	IC	InChI=1S/C37H49N11O6/c1-48-30(20-22-11-14-26(49)15-12-22)34(53)44-21-31(50)45-29(19-23-10-13-24-6-2-3-7-25(24)18-23)33(52)46-27(8-4-16-42-36(38)39)32(51)47-28(35(48)54)9-5-17-43-37(40)41/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,53)(H,45,50)(H,46,52)(H,47,51)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30+/m0/s1
DMBKRQ9	CS	CN1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1=O)CCCN=C(N)N)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O
DMBKRQ9	IK	KKHZUKILPGNUFR-RRGQHJHPSA-N
DMBKRQ9	IU	2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-7-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMBKRQ9	DE	Discovery agent

DMHI0UL	ID	DMHI0UL
DMHI0UL	DN	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)
DMHI0UL	HS	Investigative
DMHI0UL	SN	CHEMBL219096; cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)
DMHI0UL	DT	Small molecular drug
DMHI0UL	PC	44418886
DMHI0UL	MW	743.9
DMHI0UL	FM	C37H49N11O6
DMHI0UL	IC	InChI=1S/C37H49N11O6/c1-48-30(20-22-11-14-26(49)15-12-22)34(53)44-21-31(50)45-29(19-23-10-13-24-6-2-3-7-25(24)18-23)33(52)46-27(8-4-16-42-36(38)39)32(51)47-28(35(48)54)9-5-17-43-37(40)41/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,53)(H,45,50)(H,46,52)(H,47,51)(H4,38,39,42)(H4,40,41,43)/t27-,28-,29-,30+/m0/s1
DMHI0UL	CS	CN1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C1=O)CCCN=C(N)N)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O
DMHI0UL	IK	KKHZUKILPGNUFR-GCXHJFECSA-N
DMHI0UL	IU	2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-7-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMHI0UL	DE	Discovery agent

DM82C6Q	ID	DM82C6Q
DM82C6Q	DN	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)
DM82C6Q	HS	Investigative
DM82C6Q	SN	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-); Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine
DM82C6Q	DT	Small molecular drug
DM82C6Q	PC	5275843
DM82C6Q	MW	729.8
DM82C6Q	FM	C36H47N11O6
DM82C6Q	IC	InChI=1S/C36H47N11O6/c37-35(38)41-15-3-7-26-32(51)45-27(8-4-16-42-36(39)40)33(52)47-28(19-22-9-12-23-5-1-2-6-24(23)17-22)31(50)43-20-30(49)44-29(34(53)46-26)18-21-10-13-25(48)14-11-21/h1-2,5-6,9-14,17,26-29,48H,3-4,7-8,15-16,18-20H2,(H,43,50)(H,44,49)(H,45,51)(H,46,53)(H,47,52)(H4,37,38,41)(H4,39,40,42)/t26-,27-,28-,29+/m0/s1
DM82C6Q	CS	C1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC3=CC=CC=C3C=C2)CCCN=C(N)N)CCCN=C(N)N)CC4=CC=C(C=C4)O
DM82C6Q	IK	MBXBICVKLVYNKD-XFTNXAEASA-N
DM82C6Q	IU	2-[3-[(2S,5S,8S,14R)-5-[3-(diaminomethylideneamino)propyl]-14-[(4-hydroxyphenyl)methyl]-8-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM82C6Q	DE	Discovery agent

DM8RKT1	ID	DM8RKT1
DM8RKT1	DN	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)
DM8RKT1	HS	Investigative
DM8RKT1	SN	CHEMBL384429; cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)
DM8RKT1	DT	Small molecular drug
DM8RKT1	PC	44418869
DM8RKT1	MW	644.7
DM8RKT1	FM	C33H40N8O6
DM8RKT1	IC	InChI=1S/C33H40N8O6/c1-19-29(44)41-26(16-20-9-12-24(42)13-10-20)30(45)37-18-28(43)39-27(17-21-8-11-22-5-2-3-6-23(22)15-21)32(47)40-25(31(46)38-19)7-4-14-36-33(34)35/h2-3,5-6,8-13,15,19,25-27,42H,4,7,14,16-18H2,1H3,(H,37,45)(H,38,46)(H,39,43)(H,40,47)(H,41,44)(H4,34,35,36)/t19-,25+,26-,27+/m1/s1
DM8RKT1	CS	C[C@@H]1C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O
DM8RKT1	IK	KSQLRHSLMODJAS-ABXDHCHGSA-N
DM8RKT1	IU	2-[3-[(2S,5R,8R,14S)-8-[(4-hydroxyphenyl)methyl]-5-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM8RKT1	DE	Discovery agent

DM8XVAW	ID	DM8XVAW
DM8XVAW	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)
DM8XVAW	HS	Investigative
DM8XVAW	SN	CHEMBL426169; cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)
DM8XVAW	DT	Small molecular drug
DM8XVAW	PC	44418894
DM8XVAW	MW	743.9
DM8XVAW	FM	C37H49N11O6
DM8XVAW	IC	InChI=1S/C37H49N11O6/c1-48-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-28(9-5-17-43-37(40)41)33(52)45-27(8-4-16-42-36(38)39)34(53)47-29(32(51)44-21-31(48)50)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,52)(H,46,54)(H,47,53)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30+/m1/s1
DM8XVAW	CS	CN1[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)NCC1=O)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DM8XVAW	IK	XUKFERKCRCTLBJ-ATIZSFMBSA-N
DM8XVAW	IU	2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-13-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM8XVAW	DE	Discovery agent

DMWFITM	ID	DMWFITM
DMWFITM	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)
DMWFITM	HS	Investigative
DMWFITM	SN	CHEMBL219135; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)
DMWFITM	DT	Small molecular drug
DMWFITM	PC	44418885
DMWFITM	MW	743.9
DMWFITM	FM	C37H49N11O6
DMWFITM	IC	InChI=1S/C37H49N11O6/c38-36(39)43-16-3-7-27-33(52)46-28(8-4-17-44-37(40)41)34(53)48-29(20-22-10-13-26(49)14-11-22)32(51)42-18-15-31(50)45-30(35(54)47-27)21-23-9-12-24-5-1-2-6-25(24)19-23/h1-2,5-6,9-14,19,27-30,49H,3-4,7-8,15-18,20-21H2,(H,42,51)(H,45,50)(H,46,52)(H,47,54)(H,48,53)(H4,38,39,43)(H4,40,41,44)/t27-,28+,29+,30-/m0/s1
DMWFITM	CS	C1CNC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC3=CC=CC=C3C=C2)CCCN=C(N)N)CCCN=C(N)N)CC4=CC=C(C=C4)O
DMWFITM	IK	LMVXXKJNXQKPHR-KJHMZRPRSA-N
DMWFITM	IU	2-[3-[(2S,5S,8R,11R)-8-[3-(diaminomethylideneamino)propyl]-11-[(4-hydroxyphenyl)methyl]-2-(naphthalen-2-ylmethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]propyl]guanidine
DMWFITM	DE	Discovery agent

DMSA0IW	ID	DMSA0IW
DMSA0IW	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)
DMSA0IW	HS	Investigative
DMSA0IW	SN	CHEMBL373636; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)
DMSA0IW	DT	Small molecular drug
DMSA0IW	PC	44418880
DMSA0IW	MW	743.9
DMSA0IW	FM	C37H49N11O6
DMSA0IW	IC	InChI=1S/C37H49N11O6/c1-21-31(50)47-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)48-29(34(53)44-21)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,21,27-30,49H,4-5,8-9,16-17,19-20H2,1H3,(H,44,53)(H,45,51)(H,46,54)(H,47,50)(H,48,52)(H4,38,39,42)(H4,40,41,43)/t21-,27+,28-,29-,30+/m1/s1
DMSA0IW	CS	C[C@@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMSA0IW	IK	VWZBFEAQYFTPKH-UIMYGGOYSA-N
DMSA0IW	IU	2-[3-[(2S,5R,8R,11R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-11-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMSA0IW	DE	Discovery agent

DMGOW1E	ID	DMGOW1E
DMGOW1E	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)
DMGOW1E	HS	Investigative
DMGOW1E	SN	CHEMBL219339; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)
DMGOW1E	DT	Small molecular drug
DMGOW1E	PC	11331592
DMGOW1E	MW	729.8
DMGOW1E	FM	C36H47N11O6
DMGOW1E	IC	InChI=1S/C36H47N11O6/c37-35(38)41-15-3-7-26-32(51)45-27(8-4-16-42-36(39)40)33(52)47-28(18-21-10-13-25(48)14-11-21)31(50)43-20-30(49)44-29(34(53)46-26)19-22-9-12-23-5-1-2-6-24(23)17-22/h1-2,5-6,9-14,17,26-29,48H,3-4,7-8,15-16,18-20H2,(H,43,50)(H,44,49)(H,45,51)(H,46,53)(H,47,52)(H4,37,38,41)(H4,39,40,42)/t26-,27+,28+,29-/m0/s1
DMGOW1E	CS	C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMGOW1E	IK	YASYVKCWJGCXLS-AUAHOFGGSA-N
DMGOW1E	IU	2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMGOW1E	DE	Discovery agent

DM3PRHF	ID	DM3PRHF
DM3PRHF	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)
DM3PRHF	HS	Investigative
DM3PRHF	SN	CHEMBL376811; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)
DM3PRHF	DT	Small molecular drug
DM3PRHF	PC	44418879
DM3PRHF	MW	743.9
DM3PRHF	FM	C37H49N11O6
DM3PRHF	IC	InChI=1S/C37H49N11O6/c1-21-31(50)47-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)48-29(34(53)44-21)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,21,27-30,49H,4-5,8-9,16-17,19-20H2,1H3,(H,44,53)(H,45,51)(H,46,54)(H,47,50)(H,48,52)(H4,38,39,42)(H4,40,41,43)/t21-,27-,28+,29+,30-/m0/s1
DM3PRHF	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DM3PRHF	IK	VWZBFEAQYFTPKH-DXQNDIIUSA-N
DM3PRHF	IU	2-[3-[(2S,5R,8R,11S,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-11-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM3PRHF	DE	Discovery agent

DMS9QHI	ID	DMS9QHI
DMS9QHI	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)
DMS9QHI	HS	Investigative
DMS9QHI	SN	CHEMBL373637; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)
DMS9QHI	DT	Small molecular drug
DMS9QHI	PC	44418883
DMS9QHI	MW	783.9
DMS9QHI	FM	C40H53N11O6
DMS9QHI	IC	InChI=1S/C40H53N11O6/c41-39(42)45-18-5-9-29-34(53)47-30(10-6-19-46-40(43)44)35(54)50-32(22-24-13-16-28(52)17-14-24)38(57)51-20-4-3-11-33(51)37(56)49-31(36(55)48-29)23-25-12-15-26-7-1-2-8-27(26)21-25/h1-2,7-8,12-17,21,29-33,52H,3-6,9-11,18-20,22-23H2,(H,47,53)(H,48,55)(H,49,56)(H,50,54)(H4,41,42,45)(H4,43,44,46)/t29-,30+,31-,32+,33-/m0/s1
DMS9QHI	CS	C1CCN2[C@@H](C1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C2=O)CC3=CC=C(C=C3)O)CCCN=C(N)N)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4
DMS9QHI	IK	OGLLNRFCXLYAMK-AUURQCAXSA-N
DMS9QHI	IU	2-[3-[(3R,6R,9S,12S,15S)-6-[3-(diaminomethylideneamino)propyl]-3-[(4-hydroxyphenyl)methyl]-12-(naphthalen-2-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazabicyclo[13.4.0]nonadecan-9-yl]propyl]guanidine
DMS9QHI	DE	Discovery agent

DM3Y1TZ	ID	DM3Y1TZ
DM3Y1TZ	DN	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)
DM3Y1TZ	HS	Investigative
DM3Y1TZ	SN	CHEMBL374862; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)
DM3Y1TZ	DT	Small molecular drug
DM3Y1TZ	PC	44418895
DM3Y1TZ	MW	743.9
DM3Y1TZ	FM	C37H49N11O6
DM3Y1TZ	IC	InChI=1S/C37H49N11O6/c1-48-21-31(50)44-29(20-23-10-13-24-6-2-3-7-25(24)18-23)34(53)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)47-30(35(48)54)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,50)(H,45,51)(H,46,53)(H,47,52)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30+/m0/s1
DM3Y1TZ	CS	CN1CC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C1=O)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DM3Y1TZ	IK	RVFLZIGZHRQETC-RRGQHJHPSA-N
DM3Y1TZ	IU	2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-10-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM3Y1TZ	DE	Discovery agent

DMUWC5O	ID	DMUWC5O
DMUWC5O	DN	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)
DMUWC5O	HS	Investigative
DMUWC5O	SN	CHEMBL376219; cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)
DMUWC5O	DT	Small molecular drug
DMUWC5O	PC	44418893
DMUWC5O	MW	743.9
DMUWC5O	FM	C37H49N11O6
DMUWC5O	IC	InChI=1S/C37H49N11O6/c1-48-30(9-5-17-43-37(40)41)34(53)46-27(8-4-16-42-36(38)39)33(52)47-28(19-22-11-14-26(49)15-12-22)32(51)44-21-31(50)45-29(35(48)54)20-23-10-13-24-6-2-3-7-25(24)18-23/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,50)(H,46,53)(H,47,52)(H4,38,39,42)(H4,40,41,43)/t27-,28-,29+,30+/m1/s1
DMUWC5O	CS	CN1[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C1=O)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O)CCCN=C(N)N)CCCN=C(N)N
DMUWC5O	IK	UYLRGPNGYHIOPK-XAZDILKDSA-N
DMUWC5O	IU	2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-1-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMUWC5O	DE	Discovery agent

DM8F5DY	ID	DM8F5DY
DM8F5DY	DN	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)
DM8F5DY	HS	Investigative
DM8F5DY	SN	CHEMBL218806; cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)
DM8F5DY	DT	Small molecular drug
DM8F5DY	PC	44418892
DM8F5DY	MW	743.9
DM8F5DY	FM	C37H49N11O6
DM8F5DY	IC	InChI=1S/C37H49N11O6/c1-48-30(9-5-17-43-37(40)41)34(53)47-28(19-22-11-14-26(49)15-12-22)32(51)44-21-31(50)45-29(20-23-10-13-24-6-2-3-7-25(24)18-23)33(52)46-27(35(48)54)8-4-16-42-36(38)39/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,50)(H,46,52)(H,47,53)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30+/m0/s1
DM8F5DY	CS	CN1[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C1=O)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O)CCCN=C(N)N
DM8F5DY	IK	ACYXHFQQOQRMGX-RRGQHJHPSA-N
DM8F5DY	IU	2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-4-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM8F5DY	DE	Discovery agent

DMPW9SD	ID	DMPW9SD
DMPW9SD	DN	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)
DMPW9SD	HS	Investigative
DMPW9SD	SN	CHEMBL374108; cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)
DMPW9SD	DT	Small molecular drug
DMPW9SD	PC	44418865
DMPW9SD	MW	644.7
DMPW9SD	FM	C33H40N8O6
DMPW9SD	IC	InChI=1S/C33H40N8O6/c1-19-29(44)41-26(16-20-9-12-24(42)13-10-20)30(45)37-18-28(43)39-27(17-21-8-11-22-5-2-3-6-23(22)15-21)32(47)40-25(31(46)38-19)7-4-14-36-33(34)35/h2-3,5-6,8-13,15,19,25-27,42H,4,7,14,16-18H2,1H3,(H,37,45)(H,38,46)(H,39,43)(H,40,47)(H,41,44)(H4,34,35,36)/t19-,25-,26+,27-/m0/s1
DMPW9SD	CS	C[C@H]1C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O
DMPW9SD	IK	KSQLRHSLMODJAS-OQVMAISDSA-N
DMPW9SD	IU	2-[3-[(2S,5S,8R,14S)-8-[(4-hydroxyphenyl)methyl]-5-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMPW9SD	DE	Discovery agent

DMOWT4H	ID	DMOWT4H
DMOWT4H	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)
DMOWT4H	HS	Investigative
DMOWT4H	SN	CHEMBL219075; cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)
DMOWT4H	DT	Small molecular drug
DMOWT4H	PC	44418890
DMOWT4H	MW	617.7
DMOWT4H	FM	C27H43N11O6
DMOWT4H	IC	InChI=1S/C27H43N11O6/c1-15-22(41)35-18(5-3-11-32-26(28)29)23(42)36-19(6-4-12-33-27(30)31)24(43)37-20(13-16-7-9-17(39)10-8-16)25(44)38(2)14-21(40)34-15/h7-10,15,18-20,39H,3-6,11-14H2,1-2H3,(H,34,40)(H,35,41)(H,36,42)(H,37,43)(H4,28,29,32)(H4,30,31,33)/t15-,18-,19-,20+/m0/s1
DMOWT4H	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N1)C)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N
DMOWT4H	IK	DUPFTLXKUNVZDO-MVJPYGJCSA-N
DMOWT4H	IU	2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-10,14-dimethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMOWT4H	DE	Discovery agent

DMPZ316	ID	DMPZ316
DMPZ316	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)
DMPZ316	HS	Investigative
DMPZ316	SN	CHEMBL375850; cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)
DMPZ316	DT	Small molecular drug
DMPZ316	PC	44418889
DMPZ316	MW	743.9
DMPZ316	FM	C37H49N11O6
DMPZ316	IC	InChI=1S/C37H49N11O6/c1-48-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-28(9-5-17-43-37(40)41)33(52)45-27(8-4-16-42-36(38)39)34(53)47-29(32(51)44-21-31(48)50)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,52)(H,46,54)(H,47,53)(H4,38,39,42)(H4,40,41,43)/t27-,28-,29+,30-/m0/s1
DMPZ316	CS	CN1[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC1=O)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMPZ316	IK	XUKFERKCRCTLBJ-ZXYZSCNASA-N
DMPZ316	IU	2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-13-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMPZ316	DE	Discovery agent

DMNQWBS	ID	DMNQWBS
DMNQWBS	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)
DMNQWBS	HS	Investigative
DMNQWBS	SN	CHEMBL375991; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)
DMNQWBS	DT	Small molecular drug
DMNQWBS	PC	44418878
DMNQWBS	MW	743.9
DMNQWBS	FM	C37H49N11O6
DMNQWBS	IC	InChI=1S/C37H49N11O6/c38-36(39)43-16-3-7-27-33(52)46-28(8-4-17-44-37(40)41)34(53)48-29(20-22-10-13-26(49)14-11-22)32(51)42-18-15-31(50)45-30(35(54)47-27)21-23-9-12-24-5-1-2-6-25(24)19-23/h1-2,5-6,9-14,19,27-30,49H,3-4,7-8,15-18,20-21H2,(H,42,51)(H,45,50)(H,46,52)(H,47,54)(H,48,53)(H4,38,39,43)(H4,40,41,44)/t27-,28-,29+,30-/m0/s1
DMNQWBS	CS	C1CNC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC3=CC=CC=C3C=C2)CCCN=C(N)N)CCCN=C(N)N)CC4=CC=C(C=C4)O
DMNQWBS	IK	LMVXXKJNXQKPHR-ZXYZSCNASA-N
DMNQWBS	IU	2-[3-[(2S,5S,8S,11R)-8-[3-(diaminomethylideneamino)propyl]-11-[(4-hydroxyphenyl)methyl]-2-(naphthalen-2-ylmethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]propyl]guanidine
DMNQWBS	DE	Discovery agent

DMV6C9N	ID	DMV6C9N
DMV6C9N	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)
DMV6C9N	HS	Investigative
DMV6C9N	SN	CHEMBL375990; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)
DMV6C9N	DT	Small molecular drug
DMV6C9N	PC	44418873
DMV6C9N	MW	743.9
DMV6C9N	FM	C37H49N11O6
DMV6C9N	IC	InChI=1S/C37H49N11O6/c1-21-31(50)47-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)48-29(34(53)44-21)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,21,27-30,49H,4-5,8-9,16-17,19-20H2,1H3,(H,44,53)(H,45,51)(H,46,54)(H,47,50)(H,48,52)(H4,38,39,42)(H4,40,41,43)/t21-,27+,28+,29-,30+/m1/s1
DMV6C9N	CS	C[C@@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMV6C9N	IK	VWZBFEAQYFTPKH-CSHHCLTFSA-N
DMV6C9N	IU	2-[3-[(2S,5S,8R,11R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-11-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMV6C9N	DE	Discovery agent

DMH9VMO	ID	DMH9VMO
DMH9VMO	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)
DMH9VMO	HS	Investigative
DMH9VMO	SN	CHEMBL219474; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)
DMH9VMO	DT	Small molecular drug
DMH9VMO	PC	11158428
DMH9VMO	MW	729.8
DMH9VMO	FM	C36H47N11O6
DMH9VMO	IC	InChI=1S/C36H47N11O6/c37-35(38)41-15-3-7-26-32(51)45-27(8-4-16-42-36(39)40)33(52)47-28(18-21-10-13-25(48)14-11-21)31(50)43-20-30(49)44-29(34(53)46-26)19-22-9-12-23-5-1-2-6-24(23)17-22/h1-2,5-6,9-14,17,26-29,48H,3-4,7-8,15-16,18-20H2,(H,43,50)(H,44,49)(H,45,51)(H,46,53)(H,47,52)(H4,37,38,41)(H4,39,40,42)/t26-,27-,28+,29-/m0/s1
DMH9VMO	CS	C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMH9VMO	IK	YASYVKCWJGCXLS-FKWFRFQNSA-N
DMH9VMO	IU	2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMH9VMO	DE	Discovery agent

DM72HW3	ID	DM72HW3
DM72HW3	DN	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)
DM72HW3	HS	Investigative
DM72HW3	SN	CHEMBL387120; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)
DM72HW3	DT	Small molecular drug
DM72HW3	PC	44418872
DM72HW3	MW	743.9
DM72HW3	FM	C37H49N11O6
DM72HW3	IC	InChI=1S/C37H49N11O6/c1-21-31(50)47-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)48-29(34(53)44-21)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,21,27-30,49H,4-5,8-9,16-17,19-20H2,1H3,(H,44,53)(H,45,51)(H,46,54)(H,47,50)(H,48,52)(H4,38,39,42)(H4,40,41,43)/t21-,27-,28-,29+,30-/m0/s1
DM72HW3	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DM72HW3	IK	VWZBFEAQYFTPKH-JTIXJMNMSA-N
DM72HW3	IU	2-[3-[(2S,5S,8R,11S,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-11-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM72HW3	DE	Discovery agent

DMSPKWD	ID	DMSPKWD
DMSPKWD	DN	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)
DMSPKWD	HS	Investigative
DMSPKWD	SN	CHEMBL436536; cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)
DMSPKWD	DT	Small molecular drug
DMSPKWD	PC	44418888
DMSPKWD	MW	743.9
DMSPKWD	FM	C37H49N11O6
DMSPKWD	IC	InChI=1S/C37H49N11O6/c1-48-30(9-5-17-43-37(40)41)34(53)46-27(8-4-16-42-36(38)39)33(52)47-28(19-22-11-14-26(49)15-12-22)32(51)44-21-31(50)45-29(35(48)54)20-23-10-13-24-6-2-3-7-25(24)18-23/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,50)(H,46,53)(H,47,52)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30-/m0/s1
DMSPKWD	CS	CN1[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C1=O)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O)CCCN=C(N)N)CCCN=C(N)N
DMSPKWD	IK	UYLRGPNGYHIOPK-XJYHXZFBSA-N
DMSPKWD	IU	2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-1-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMSPKWD	DE	Discovery agent

DMIUVQ6	ID	DMIUVQ6
DMIUVQ6	DN	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)
DMIUVQ6	HS	Investigative
DMIUVQ6	SN	CHEMBL374421; cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)
DMIUVQ6	DT	Small molecular drug
DMIUVQ6	PC	44418887
DMIUVQ6	MW	743.9
DMIUVQ6	FM	C37H49N11O6
DMIUVQ6	IC	InChI=1S/C37H49N11O6/c1-48-30(9-5-17-43-37(40)41)34(53)47-28(19-22-11-14-26(49)15-12-22)32(51)44-21-31(50)45-29(20-23-10-13-24-6-2-3-7-25(24)18-23)33(52)46-27(35(48)54)8-4-16-42-36(38)39/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,50)(H,46,52)(H,47,53)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30-/m0/s1
DMIUVQ6	CS	CN1[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C1=O)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O)CCCN=C(N)N
DMIUVQ6	IK	ACYXHFQQOQRMGX-XJYHXZFBSA-N
DMIUVQ6	IU	2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-4-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMIUVQ6	DE	Discovery agent

DMZF35W	ID	DMZF35W
DMZF35W	DN	Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)
DMZF35W	HS	Investigative
DMZF35W	SN	CHEMBL394261; cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)
DMZF35W	DT	Small molecular drug
DMZF35W	PC	44437869
DMZF35W	MW	595.8
DMZF35W	FM	C30H37N5O4S2
DMZF35W	IC	InChI=1S/C30H37N5O4S2/c1-20-28(38)35-16-9-13-24(35)27(37)33-23(12-3-2-8-17-40-41-25-14-6-7-15-31-25)26(36)34-30(29(39)32-20)18-21-10-4-5-11-22(21)19-30/h4-7,10-11,14-15,20,23-24H,2-3,8-9,12-13,16-19H2,1H3,(H,32,39)(H,33,37)(H,34,36)/t20-,23-,24+/m0/s1
DMZF35W	CS	C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)NC3(CC4=CC=CC=C4C3)C(=O)N1)CCCCCSSC5=CC=CC=N5
DMZF35W	IK	RKZORBYVFSJNHI-NKKJXINNSA-N
DMZF35W	IU	(3'S,9'S,12'R)-3'-methyl-9'-[5-(pyridin-2-yldisulfanyl)pentyl]spiro[1,3-dihydroindene-2,6'-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane]-2',5',8',11'-tetrone
DMZF35W	DE	Discovery agent

DMIVREK	ID	DMIVREK
DMIVREK	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)
DMIVREK	HS	Investigative
DMIVREK	SN	CHEMBL238596; cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-); BDBM50222727
DMIVREK	DT	Small molecular drug
DMIVREK	PC	44437883
DMIVREK	MW	521.7
DMIVREK	FM	C24H35N5O4S2
DMIVREK	IC	InChI=1S/C24H35N5O4S2/c1-16-22(32)29-14-9-11-18(29)21(31)27-17(20(30)28-24(2,3)23(33)26-16)10-5-4-8-15-34-35-19-12-6-7-13-25-19/h6-7,12-13,16-18H,4-5,8-11,14-15H2,1-3H3,(H,26,33)(H,27,31)(H,28,30)/t16-,17-,18+/m0/s1
DMIVREK	CS	C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)NC(C(=O)N1)(C)C)CCCCCSSC3=CC=CC=N3
DMIVREK	IK	SNOZDSAKXKVXTD-OKZBNKHCSA-N
DMIVREK	IU	(3S,9S,12R)-3,6,6-trimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMIVREK	DE	Discovery agent

DMLBECR	ID	DMLBECR
DMLBECR	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)
DMLBECR	HS	Investigative
DMLBECR	SN	CHEMBL238587; cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)
DMLBECR	DT	Small molecular drug
DMLBECR	PC	44437875
DMLBECR	MW	569.8
DMLBECR	FM	C29H39N5O3S2
DMLBECR	IC	InChI=1S/C29H39N5O3S2/c1-20-18-34-19-22-12-7-6-11-21(22)17-24(34)27(36)32-23(26(35)33-29(2,3)28(37)31-20)13-5-4-10-16-38-39-25-14-8-9-15-30-25/h6-9,11-12,14-15,20,23-24H,4-5,10,13,16-19H2,1-3H3,(H,31,37)(H,32,36)(H,33,35)/t20-,23-,24+/m0/s1
DMLBECR	CS	C[C@H]1CN2CC3=CC=CC=C3C[C@@H]2C(=O)N[C@H](C(=O)NC(C(=O)N1)(C)C)CCCCCSSC4=CC=CC=N4
DMLBECR	IK	ALYDIERJMKHYLO-NKKJXINNSA-N
DMLBECR	IU	(3S,9S,12R)-3,6,6-trimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazatricyclo[10.8.0.014,19]icosa-14,16,18-triene-5,8,11-trione
DMLBECR	DE	Discovery agent

DMA76KW	ID	DMA76KW
DMA76KW	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)
DMA76KW	HS	Investigative
DMA76KW	SN	CHEMBL391383; cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)
DMA76KW	DT	Small molecular drug
DMA76KW	PC	44437877
DMA76KW	MW	611.8
DMA76KW	FM	C31H41N5O4S2
DMA76KW	IC	InChI=1S/C31H41N5O4S2/c1-31(2)30(40)34-24(18-17-22-12-5-3-6-13-22)29(39)36-20-11-15-25(36)28(38)33-23(27(37)35-31)14-7-4-10-21-41-42-26-16-8-9-19-32-26/h3,5-6,8-9,12-13,16,19,23-25H,4,7,10-11,14-15,17-18,20-21H2,1-2H3,(H,33,38)(H,34,40)(H,35,37)/t23-,24-,25+/m0/s1
DMA76KW	CS	CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)CCC4=CC=CC=C4)C
DMA76KW	IK	VOORCQROXYSHCG-CCDWMCETSA-N
DMA76KW	IU	(3S,9S,12R)-6,6-dimethyl-3-(2-phenylethyl)-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMA76KW	DE	Discovery agent

DMLNJ0O	ID	DMLNJ0O
DMLNJ0O	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)
DMLNJ0O	HS	Investigative
DMLNJ0O	SN	CHEMBL391384; cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)
DMLNJ0O	DT	Small molecular drug
DMLNJ0O	PC	44437878
DMLNJ0O	MW	625.8
DMLNJ0O	FM	C32H43N5O4S2
DMLNJ0O	IC	InChI=1S/C32H43N5O4S2/c1-32(2)31(41)35-25(17-11-15-23-13-5-3-6-14-23)30(40)37-21-12-18-26(37)29(39)34-24(28(38)36-32)16-7-4-10-22-42-43-27-19-8-9-20-33-27/h3,5-6,8-9,13-14,19-20,24-26H,4,7,10-12,15-18,21-22H2,1-2H3,(H,34,39)(H,35,41)(H,36,38)/t24-,25-,26+/m0/s1
DMLNJ0O	CS	CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)CCCC4=CC=CC=C4)C
DMLNJ0O	IK	DIIWIWBDXZTFQP-KKUQBAQOSA-N
DMLNJ0O	IU	(3S,9S,12R)-6,6-dimethyl-3-(3-phenylpropyl)-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMLNJ0O	DE	Discovery agent

DMTVMWA	ID	DMTVMWA
DMTVMWA	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)
DMTVMWA	HS	Investigative
DMTVMWA	SN	CHEMBL238829; cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-); BDBM50222732
DMTVMWA	DT	Small molecular drug
DMTVMWA	PC	44437868
DMTVMWA	MW	597.8
DMTVMWA	FM	C30H39N5O4S2
DMTVMWA	IC	InChI=1S/C30H39N5O4S2/c1-30(2)29(39)33-23(20-21-12-5-3-6-13-21)28(38)35-18-11-15-24(35)27(37)32-22(26(36)34-30)14-7-4-10-19-40-41-25-16-8-9-17-31-25/h3,5-6,8-9,12-13,16-17,22-24H,4,7,10-11,14-15,18-20H2,1-2H3,(H,32,37)(H,33,39)(H,34,36)/t22-,23-,24+/m0/s1
DMTVMWA	CS	CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)CC4=CC=CC=C4)C
DMTVMWA	IK	GNIYZHFLRFNYMZ-KMDXXIMOSA-N
DMTVMWA	IU	(3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMTVMWA	DE	Discovery agent

DMUSEDF	ID	DMUSEDF
DMUSEDF	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)
DMUSEDF	HS	Investigative
DMUSEDF	SN	CHEMBL428737; cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)
DMUSEDF	DT	Small molecular drug
DMUSEDF	PC	44437876
DMUSEDF	MW	583.8
DMUSEDF	FM	C29H37N5O4S2
DMUSEDF	IC	InChI=1S/C29H37N5O4S2/c1-29(2)28(38)32-24(20-12-5-3-6-13-20)27(37)34-18-11-15-22(34)26(36)31-21(25(35)33-29)14-7-4-10-19-39-40-23-16-8-9-17-30-23/h3,5-6,8-9,12-13,16-17,21-22,24H,4,7,10-11,14-15,18-19H2,1-2H3,(H,31,36)(H,32,38)(H,33,35)/t21-,22+,24-/m0/s1
DMUSEDF	CS	CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)C4=CC=CC=C4)C
DMUSEDF	IK	MAESVPGWPSVAHM-ZDXQCDESSA-N
DMUSEDF	IU	(3S,9S,12R)-6,6-dimethyl-3-phenyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMUSEDF	DE	Discovery agent

DMSEQ0W	ID	DMSEQ0W
DMSEQ0W	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)
DMSEQ0W	HS	Investigative
DMSEQ0W	SN	CHEMBL241555; cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)
DMSEQ0W	DT	Small molecular drug
DMSEQ0W	PC	44437879
DMSEQ0W	MW	627.8
DMSEQ0W	FM	C31H41N5O5S2
DMSEQ0W	IC	InChI=1S/C31H41N5O5S2/c1-31(2)30(40)34-24(21-41-20-22-12-5-3-6-13-22)29(39)36-18-11-15-25(36)28(38)33-23(27(37)35-31)14-7-4-10-19-42-43-26-16-8-9-17-32-26/h3,5-6,8-9,12-13,16-17,23-25H,4,7,10-11,14-15,18-21H2,1-2H3,(H,33,38)(H,34,40)(H,35,37)/t23-,24-,25+/m0/s1
DMSEQ0W	CS	CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)COCC4=CC=CC=C4)C
DMSEQ0W	IK	UAUCMCUCWAXYRK-CCDWMCETSA-N
DMSEQ0W	IU	(3S,9S,12R)-6,6-dimethyl-3-(phenylmethoxymethyl)-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMSEQ0W	DE	Discovery agent

DMBKP48	ID	DMBKP48
DMBKP48	DN	Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)
DMBKP48	HS	Investigative
DMBKP48	SN	CHEMBL393961; cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)
DMBKP48	DT	Small molecular drug
DMBKP48	PC	44437880
DMBKP48	MW	537.7
DMBKP48	FM	C24H35N5O5S2
DMBKP48	IC	InChI=1S/C24H35N5O5S2/c1-24(2)23(34)27-17(15-30)22(33)29-13-8-10-18(29)21(32)26-16(20(31)28-24)9-4-3-7-14-35-36-19-11-5-6-12-25-19/h5-6,11-12,16-18,30H,3-4,7-10,13-15H2,1-2H3,(H,26,32)(H,27,34)(H,28,31)/t16-,17-,18+/m0/s1
DMBKP48	CS	CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)CO)C
DMBKP48	IK	HNLHPMBNXUOXHG-OKZBNKHCSA-N
DMBKP48	IU	(3S,9S,12R)-3-(hydroxymethyl)-6,6-dimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMBKP48	DE	Discovery agent

DMVY89X	ID	DMVY89X
DMVY89X	DN	Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
DMVY89X	HS	Investigative
DMVY89X	SN	CHEMBL393261; cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
DMVY89X	DT	Small molecular drug
DMVY89X	PC	44437873
DMVY89X	MW	597.8
DMVY89X	FM	C30H39N5O4S2
DMVY89X	IC	InChI=1S/C30H39N5O4S2/c1-21-28(38)35-18-11-15-24(35)27(37)33-23(14-7-4-10-19-40-41-25-16-8-9-17-31-25)26(36)34-30(2,29(39)32-21)20-22-12-5-3-6-13-22/h3,5-6,8-9,12-13,16-17,21,23-24H,4,7,10-11,14-15,18-20H2,1-2H3,(H,32,39)(H,33,37)(H,34,36)/t21-,23-,24+,30+/m0/s1
DMVY89X	CS	C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@](C(=O)N1)(C)CC3=CC=CC=C3)CCCCCSSC4=CC=CC=N4
DMVY89X	IK	ITTWBEZYTYPCGB-HVGAQBFTSA-N
DMVY89X	IU	(3S,6R,9S,12R)-6-benzyl-3,6-dimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMVY89X	DE	Discovery agent

DMTDIM9	ID	DMTDIM9
DMTDIM9	DN	Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)
DMTDIM9	HS	Investigative
DMTDIM9	SN	CHEMBL390991; cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)
DMTDIM9	DT	Small molecular drug
DMTDIM9	PC	44437870
DMTDIM9	MW	595.8
DMTDIM9	FM	C30H37N5O4S2
DMTDIM9	IC	InChI=1S/C30H37N5O4S2/c1-20-28(38)35-18-9-13-24(35)27(37)33-23(12-3-2-8-19-40-41-25-14-6-7-17-31-25)26(36)34-30(29(39)32-20)16-15-21-10-4-5-11-22(21)30/h4-7,10-11,14,17,20,23-24H,2-3,8-9,12-13,15-16,18-19H2,1H3,(H,32,39)(H,33,37)(H,34,36)/t20-,23-,24+,30-/m0/s1
DMTDIM9	CS	C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@]3(CCC4=CC=CC=C43)C(=O)N1)CCCCCSSC5=CC=CC=N5
DMTDIM9	IK	ZGCIQVPLYZBUHQ-KGPFVPCYSA-N
DMTDIM9	IU	(3S,3'S,9'S,12'R)-3'-methyl-9'-[5-(pyridin-2-yldisulfanyl)pentyl]spiro[1,2-dihydroindene-3,6'-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane]-2',5',8',11'-tetrone
DMTDIM9	DE	Discovery agent

DMV23XD	ID	DMV23XD
DMV23XD	DN	Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)
DMV23XD	HS	Investigative
DMV23XD	SN	CHEMBL393464; cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)
DMV23XD	DT	Small molecular drug
DMV23XD	PC	44437874
DMV23XD	MW	597.8
DMV23XD	FM	C30H39N5O4S2
DMV23XD	IC	InChI=1S/C30H39N5O4S2/c1-21-28(38)35-18-11-15-24(35)27(37)33-23(14-7-4-10-19-40-41-25-16-8-9-17-31-25)26(36)34-30(2,29(39)32-21)20-22-12-5-3-6-13-22/h3,5-6,8-9,12-13,16-17,21,23-24H,4,7,10-11,14-15,18-20H2,1-2H3,(H,32,39)(H,33,37)(H,34,36)/t21-,23-,24+,30-/m0/s1
DMV23XD	CS	C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@@](C(=O)N1)(C)CC3=CC=CC=C3)CCCCCSSC4=CC=CC=N4
DMV23XD	IK	ITTWBEZYTYPCGB-GAOIQBMKSA-N
DMV23XD	IU	(3S,6S,9S,12R)-6-benzyl-3,6-dimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMV23XD	DE	Discovery agent

DM0VIH4	ID	DM0VIH4
DM0VIH4	DN	Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
DM0VIH4	HS	Investigative
DM0VIH4	SN	CHEMBL393260; cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
DM0VIH4	DT	Small molecular drug
DM0VIH4	PC	44437872
DM0VIH4	MW	595.8
DM0VIH4	FM	C30H37N5O4S2
DM0VIH4	IC	InChI=1S/C30H37N5O4S2/c1-20-28(38)35-18-9-13-24(35)27(37)33-23(12-3-2-8-19-40-41-25-14-6-7-17-31-25)26(36)34-30(29(39)32-20)16-15-21-10-4-5-11-22(21)30/h4-7,10-11,14,17,20,23-24H,2-3,8-9,12-13,15-16,18-19H2,1H3,(H,32,39)(H,33,37)(H,34,36)/t20-,23-,24+,30+/m0/s1
DM0VIH4	CS	C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@@]3(CCC4=CC=CC=C43)C(=O)N1)CCCCCSSC5=CC=CC=N5
DM0VIH4	IK	ZGCIQVPLYZBUHQ-AEPSZFNXSA-N
DM0VIH4	IU	(3R,3'S,9'S,12'R)-3'-methyl-9'-[5-(pyridin-2-yldisulfanyl)pentyl]spiro[1,2-dihydroindene-3,6'-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane]-2',5',8',11'-tetrone
DM0VIH4	DE	Discovery agent

DM3QVOB	ID	DM3QVOB
DM3QVOB	DN	Cyclo(RGDfV) (control)
DM3QVOB	HS	Investigative
DM3QVOB	SN	CHEMBL206344; cyclo(RGDfV) (control)
DM3QVOB	DT	Small molecular drug
DM3QVOB	PC	44409460
DM3QVOB	MW	574.6
DM3QVOB	FM	C26H38N8O7
DM3QVOB	IC	InChI=1S/C26H38N8O7/c1-14(2)21-25(41)32-16(9-6-10-29-26(27)28)23(39)33-18(12-20(36)37)22(38)30-13-19(35)31-17(24(40)34-21)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18,21H,6,9-13H2,1-2H3,(H,30,38)(H,31,35)(H,32,41)(H,33,39)(H,34,40)(H,36,37)(H4,27,28,29)/t16-,17+,18+,21+/m1/s1
DM3QVOB	CS	CC(C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DM3QVOB	IK	PWWDFRZRXPLJAN-WKRCXCSHSA-N
DM3QVOB	IU	2-[(2S,8S,11S,14R)-8-benzyl-14-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-11-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM3QVOB	DE	Discovery agent

DM9ZCWV	ID	DM9ZCWV
DM9ZCWV	DN	Cyclo[(6-bromotryptophan)arginine]
DM9ZCWV	HS	Investigative
DM9ZCWV	SN	CHEMBL511609; cyclo[(6-bromotryptophan)arginine]
DM9ZCWV	DT	Small molecular drug
DM9ZCWV	PC	44559159
DM9ZCWV	MW	421.3
DM9ZCWV	FM	C17H21BrN6O2
DM9ZCWV	IC	InChI=1S/C17H21BrN6O2/c18-10-3-4-11-9(8-22-13(11)7-10)6-14-16(26)23-12(15(25)24-14)2-1-5-21-17(19)20/h3-4,7-8,12,14,22H,1-2,5-6H2,(H,23,26)(H,24,25)(H4,19,20,21)/t12-,14-/m0/s1
DM9ZCWV	CS	C1=CC2=C(C=C1Br)NC=C2C[C@H]3C(=O)N[C@H](C(=O)N3)CCCN=C(N)N
DM9ZCWV	IK	HVWYYWIRLPBRTO-JSGCOSHPSA-N
DM9ZCWV	IU	2-[3-[(2S,5S)-5-[(6-bromo-1H-indol-3-yl)methyl]-3,6-dioxopiperazin-2-yl]propyl]guanidine
DM9ZCWV	DE	Discovery agent

DM67CAY	ID	DM67CAY
DM67CAY	DN	Cyclo[Ac-Cys-Ile-Phe]-Lys-Tyr-Tyr
DM67CAY	HS	Investigative
DM67CAY	DT	Small molecular drug
DM67CAY	PC	44412126
DM67CAY	MW	919.1
DM67CAY	FM	C45H58N8O11S
DM67CAY	IC	InChI=1S/C45H58N8O11S/c1-3-25(2)38-43(61)53-39(28-11-13-29(14-12-28)47-36(56)19-20-37(57)48-35(24-65)42(60)52-38)44(62)49-32(6-4-5-21-46)40(58)50-33(22-26-7-15-30(54)16-8-26)41(59)51-34(45(63)64)23-27-9-17-31(55)18-10-27/h7-18,25,32-35,38-39,54-55,65H,3-6,19-24,46H2,1-2H3,(H,47,56)(H,48,57)(H,49,62)(H,50,58)(H,51,59)(H,52,60)(H,53,61)(H,63,64)/t25?,32-,33-,34-,35+,38-,39-/m0/s1
DM67CAY	CS	CCC(C)[C@H]1C(=O)N[C@@H](C2=CC=C(C=C2)NC(=O)CCC(=O)N[C@@H](C(=O)N1)CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O
DM67CAY	IK	HFHVOHKEMBUZCY-GKLJNLTASA-N
DM67CAY	IU	(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(8S,11S,14S)-11-butan-2-yl-3,6,9,12-tetraoxo-8-(sulfanylmethyl)-2,7,10,13-tetrazabicyclo[13.2.2]nonadeca-1(17),15,18-triene-14-carbonyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM67CAY	DE	Discovery agent

DMB2DV1	ID	DMB2DV1
DMB2DV1	DN	Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe]
DMB2DV1	HS	Investigative
DMB2DV1	SN	Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe]; CHEMBL380288
DMB2DV1	DT	Small molecular drug
DMB2DV1	PC	44412084
DMB2DV1	MW	933.1
DMB2DV1	FM	C46H60N8O11S
DMB2DV1	IC	InChI=1S/C46H60N8O11S/c1-3-26(2)40-45(63)52-35(23-29-11-17-32(56)18-12-29)42(60)50-33(6-4-5-21-47)41(59)51-34(22-28-9-15-31(55)16-10-28)43(61)53-36(46(64)65)24-27-7-13-30(14-8-27)48-38(57)19-20-39(58)49-37(25-66)44(62)54-40/h7-18,26,33-37,40,55-56,66H,3-6,19-25,47H2,1-2H3,(H,48,57)(H,49,58)(H,50,60)(H,51,59)(H,52,63)(H,53,61)(H,54,62)(H,64,65)/t26-,33-,34-,35-,36-,37-,40?/m0/s1
DMB2DV1	CS	CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC2=CC=C(C=C2)NC(=O)CCC(=O)N[C@H](C(=O)N1)CS)C(=O)O)CC3=CC=C(C=C3)O)CCCCN)CC4=CC=C(C=C4)O
DMB2DV1	IK	QMRXULYAQQEMJC-FYDLKOHDSA-N
DMB2DV1	IU	(8R,14S,17S,20S,23S)-17-(4-aminobutyl)-11-[(2S)-butan-2-yl]-14,20-bis[(4-hydroxyphenyl)methyl]-3,6,9,12,15,18,21-heptaoxo-8-(sulfanylmethyl)-2,7,10,13,16,19,22-heptazabicyclo[23.2.2]nonacosa-1(27),25,28-triene-23-carboxylic acid
DMB2DV1	DE	Discovery agent

DMO5V9M	ID	DMO5V9M
DMO5V9M	DN	Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr]
DMO5V9M	HS	Investigative
DMO5V9M	SN	CHEMBL429525; Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr]
DMO5V9M	DT	Small molecular drug
DMO5V9M	PC	11643573
DMO5V9M	MW	834
DMO5V9M	FM	C42H55N7O9S
DMO5V9M	IC	InChI=1S/C42H55N7O9S/c1-3-24(2)36-42(58)47-34(22-27-11-17-30(52)18-12-27)38(54)44-31(6-4-5-19-43)37(53)45-32(20-25-7-13-28(50)14-8-25)39(55)46-33(21-26-9-15-29(51)16-10-26)40(56)48-35(23-59)41(57)49-36/h7-18,24,31-36,50-52,59H,3-6,19-23,43H2,1-2H3,(H,44,54)(H,45,53)(H,46,55)(H,47,58)(H,48,56)(H,49,57)/t24-,31-,32-,33-,34-,35-,36-/m0/s1
DMO5V9M	CS	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CS)CC2=CC=C(C=C2)O)CC3=CC=C(C=C3)O)CCCCN)CC4=CC=C(C=C4)O
DMO5V9M	IK	FFQZQESXYOBYDZ-AAWCNGQVSA-N
DMO5V9M	IU	(3S,6S,9S,12R,15S,18S)-3-(4-aminobutyl)-9-[(2S)-butan-2-yl]-6,15,18-tris[(4-hydroxyphenyl)methyl]-12-(sulfanylmethyl)-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone
DMO5V9M	DE	Discovery agent

DMVXPUB	ID	DMVXPUB
DMVXPUB	DN	Cyclo-[-Arg-Gly-Asp-Amp21-]
DMVXPUB	HS	Investigative
DMVXPUB	SN	CHEMBL411863; BDBM50372589
DMVXPUB	DT	Small molecular drug
DMVXPUB	PC	24822953
DMVXPUB	MW	440.5
DMVXPUB	FM	C17H28N8O6
DMVXPUB	IC	InChI=1S/C17H28N8O6/c18-17(19)20-3-1-2-9-14(29)22-7-12(26)24-11(5-13(27)28)16(31)23-8-4-10(21-6-8)15(30)25-9/h8-11,21H,1-7H2,(H,22,29)(H,23,31)(H,24,26)(H,25,30)(H,27,28)(H4,18,19,20)/t8-,9-,10-,11-/m0/s1
DMVXPUB	CS	C1[C@H]2CN[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMVXPUB	IK	RLABYQGJZRFBJA-NAKRPEOUSA-N
DMVXPUB	IU	2-[(1S,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMVXPUB	DE	Discovery agent

DMBELJK	ID	DMBELJK
DMBELJK	DN	Cyclo-[-Arg-Gly-Asp-Amp22-]
DMBELJK	HS	Investigative
DMBELJK	SN	CHEMBL406912
DMBELJK	DT	Small molecular drug
DMBELJK	PC	24822283
DMBELJK	MW	544.6
DMBELJK	FM	C24H32N8O7
DMBELJK	IC	InChI=1S/C24H32N8O7/c25-24(26)27-8-4-7-15-20(36)28-11-18(33)30-16(10-19(34)35)21(37)29-14-9-17(22(38)31-15)32(12-14)23(39)13-5-2-1-3-6-13/h1-3,5-6,14-17H,4,7-12H2,(H,28,36)(H,29,37)(H,30,33)(H,31,38)(H,34,35)(H4,25,26,27)/t14-,15-,16-,17-/m0/s1
DMBELJK	CS	C1[C@H]2CN([C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N)C(=O)C3=CC=CC=C3
DMBELJK	IK	UIBGFNHGJUQMPO-QAETUUGQSA-N
DMBELJK	IU	2-[(1S,4S,10S,13S)-14-benzoyl-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMBELJK	DE	Discovery agent

DMT29VJ	ID	DMT29VJ
DMT29VJ	DN	Cyclo-[-Arg-Gly-Asp-Amp23-]
DMT29VJ	HS	Investigative
DMT29VJ	SN	CHEMBL410050
DMT29VJ	DT	Small molecular drug
DMT29VJ	PC	24822282
DMT29VJ	MW	496.5
DMT29VJ	FM	C20H32N8O7
DMT29VJ	IC	InChI=1S/C20H32N8O7/c1-2-15(30)28-9-10-6-13(28)19(35)27-11(4-3-5-23-20(21)22)17(33)24-8-14(29)26-12(7-16(31)32)18(34)25-10/h10-13H,2-9H2,1H3,(H,24,33)(H,25,34)(H,26,29)(H,27,35)(H,31,32)(H4,21,22,23)/t10-,11-,12-,13-/m0/s1
DMT29VJ	CS	CCC(=O)N1C[C@@H]2C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMT29VJ	IK	BGIHRGIMRVRYKO-CYDGBPFRSA-N
DMT29VJ	IU	2-[(1S,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-14-propanoyl-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMT29VJ	DE	Discovery agent

DM35ZLK	ID	DM35ZLK
DM35ZLK	DN	Cyclo-[-Arg-Gly-Asp-Amp24-]
DM35ZLK	HS	Investigative
DM35ZLK	SN	CHEMBL437072
DM35ZLK	DT	Small molecular drug
DM35ZLK	PC	24823110
DM35ZLK	MW	538.6
DM35ZLK	FM	C24H42N8O6
DM35ZLK	IC	InChI=1S/C24H42N8O6/c1-2-3-4-5-6-10-32-14-15-11-18(32)23(38)31-16(8-7-9-27-24(25)26)21(36)28-13-19(33)30-17(12-20(34)35)22(37)29-15/h15-18H,2-14H2,1H3,(H,28,36)(H,29,37)(H,30,33)(H,31,38)(H,34,35)(H4,25,26,27)/t15-,16-,17-,18-/m0/s1
DM35ZLK	CS	CCCCCCCN1C[C@@H]2C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DM35ZLK	IK	JNEZPOFKGHMQAC-XSLAGTTESA-N
DM35ZLK	IU	2-[(1S,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-14-heptyl-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DM35ZLK	DE	Discovery agent

DMEIXUQ	ID	DMEIXUQ
DMEIXUQ	DN	Cyclo-[-Arg-Gly-Asp-Amp25-]
DMEIXUQ	HS	Investigative
DMEIXUQ	SN	CHEMBL270690
DMEIXUQ	DT	Small molecular drug
DMEIXUQ	PC	24822784
DMEIXUQ	MW	440.5
DMEIXUQ	FM	C17H28N8O6
DMEIXUQ	IC	InChI=1S/C17H28N8O6/c18-17(19)20-3-1-2-9-14(29)22-7-12(26)24-11(5-13(27)28)16(31)23-8-4-10(21-6-8)15(30)25-9/h8-11,21H,1-7H2,(H,22,29)(H,23,31)(H,24,26)(H,25,30)(H,27,28)(H4,18,19,20)/t8-,9+,10+,11+/m1/s1
DMEIXUQ	CS	C1[C@@H]2CN[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMEIXUQ	IK	RLABYQGJZRFBJA-RCWTZXSCSA-N
DMEIXUQ	IU	2-[(1R,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMEIXUQ	DE	Discovery agent

DME5HRW	ID	DME5HRW
DME5HRW	DN	Cyclo-[-Arg-Gly-Asp-Amp26-]
DME5HRW	HS	Investigative
DME5HRW	SN	CHEMBL406680
DME5HRW	DT	Small molecular drug
DME5HRW	PC	24822444
DME5HRW	MW	544.6
DME5HRW	FM	C24H32N8O7
DME5HRW	IC	InChI=1S/C24H32N8O7/c25-24(26)27-8-4-7-15-20(36)28-11-18(33)30-16(10-19(34)35)21(37)29-14-9-17(22(38)31-15)32(12-14)23(39)13-5-2-1-3-6-13/h1-3,5-6,14-17H,4,7-12H2,(H,28,36)(H,29,37)(H,30,33)(H,31,38)(H,34,35)(H4,25,26,27)/t14-,15+,16+,17+/m1/s1
DME5HRW	CS	C1[C@@H]2CN([C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N)C(=O)C3=CC=CC=C3
DME5HRW	IK	UIBGFNHGJUQMPO-QZWWFDLISA-N
DME5HRW	IU	2-[(1R,4S,10S,13S)-14-benzoyl-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DME5HRW	DE	Discovery agent

DMBNJZ0	ID	DMBNJZ0
DMBNJZ0	DN	Cyclo-[-Arg-Gly-Asp-Amp27-]
DMBNJZ0	HS	Investigative
DMBNJZ0	SN	CHEMBL272436
DMBNJZ0	DT	Small molecular drug
DMBNJZ0	PC	44456982
DMBNJZ0	MW	440.5
DMBNJZ0	FM	C17H28N8O6
DMBNJZ0	IC	InChI=1S/C17H28N8O6/c18-9-5-12(26)23-8-4-11(21-6-8)15(29)25-17(19)20-3-1-2-10(16(30)31)24-13(27)7-22-14(9)28/h8-11,21H,1-7,18H2,(H,22,28)(H,23,26)(H,24,27)(H,30,31)(H3,19,20,25,29)/t8-,9?,10-,11+/m0/s1
DMBNJZ0	CS	C1C[C@H](NC(=O)CNC(=O)C(CC(=O)N[C@H]2C[C@H](C(=O)NC(=NC1)N)NC2)N)C(=O)O
DMBNJZ0	IK	HWQCIVMCAIEOPT-OFLUOSHYSA-N
DMBNJZ0	IU	(1S,11S,19R)-5,16-diamino-3,6,9,18-tetraoxo-2,7,10,15,17,20-hexazabicyclo[17.2.1]docos-15-ene-11-carboxylic acid
DMBNJZ0	DE	Discovery agent

DMJMHAV	ID	DMJMHAV
DMJMHAV	DN	Cyclo-[-Arg-Gly-Asp-Amp28-]
DMJMHAV	HS	Investigative
DMJMHAV	SN	CHEMBL270683
DMJMHAV	DT	Small molecular drug
DMJMHAV	PC	24824620
DMJMHAV	MW	440.5
DMJMHAV	FM	C17H28N8O6
DMJMHAV	IC	InChI=1S/C17H28N8O6/c18-17(19)20-3-1-2-9-14(29)22-7-12(26)24-11(5-13(27)28)16(31)23-8-4-10(21-6-8)15(30)25-9/h8-11,21H,1-7H2,(H,22,29)(H,23,31)(H,24,26)(H,25,30)(H,27,28)(H4,18,19,20)/t8-,9+,10-,11+/m1/s1
DMJMHAV	CS	C1[C@@H]2CN[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMJMHAV	IK	RLABYQGJZRFBJA-YTWAJWBKSA-N
DMJMHAV	IU	2-[(1R,4S,10S,13R)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMJMHAV	DE	Discovery agent

DMWD5RK	ID	DMWD5RK
DMWD5RK	DN	Cyclo-[Asp6,Lys10]N/OFQ(1-13)NH2
DMWD5RK	HS	Investigative
DMWD5RK	SN	CHEMBL1162357
DMWD5RK	PC	25084507
DMWD5RK	MW	1462.7
DMWD5RK	FM	C66H107N23O15
DMWD5RK	IC	InChI=1S/C66H107N23O15/c1-37(55(95)84-46(25-16-30-76-65(71)72)59(99)83-43(54(70)94)22-10-13-27-67)80-58(98)44-24-12-15-29-75-50(91)34-49(62(102)81-38(2)56(96)85-47(26-17-31-77-66(73)74)61(101)87-45(60(100)86-44)23-11-14-28-68)88-64(104)53(39(3)90)89-63(103)48(33-41-20-8-5-9-21-41)82-52(93)36-78-51(92)35-79-57(97)42(69)32-40-18-6-4-7-19-40/h4-9,18-21,37-39,42-49,53,90H,10-17,22-36,67-69H2,1-3H3,(H2,70,94)(H,75,91)(H,78,92)(H,79,97)(H,80,98)(H,81,102)(H,82,93)(H,83,99)(H,84,95)(H,85,96)(H,86,100)(H,87,101)(H,88,104)(H,89,103)(H4,71,72,76)(H4,73,74,77)/t37-,38-,39+,42-,43-,44-,45-,46-,47-,48-,49-,53-/m0/s1
DMWD5RK	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(=O)N1)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)CCCCN)CCCN=C(N)N
DMWD5RK	IK	QRTPPIOAYQKBJN-WYNMOEERSA-N
DMWD5RK	IU	(3S,6S,9S,12S,20S)-3-(4-aminobutyl)-12-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-6-[3-(diaminomethylideneamino)propyl]-9-methyl-2,5,8,11,14-pentaoxo-1,4,7,10,15-pentazacycloicosane-20-carboxamide
DMWD5RK	DE	Discovery agent

DMSMH6T	ID	DMSMH6T
DMSMH6T	DN	Cyclo[Cys6,Cys10]N/OFQ(1-13)NH2
DMSMH6T	HS	Investigative
DMSMH6T	SN	CHEMBL269029; cyclo[Cys6,Cys10]N/OFQ(1-13)NH2
DMSMH6T	PC	25088989
DMSMH6T	MW	1441.7
DMSMH6T	FM	C62H100N22O14S2
DMSMH6T	IC	InChI=1S/C62H100N22O14S2/c1-34(51(89)79-42(22-14-26-71-61(67)68)54(92)78-40(50(66)88)20-10-12-24-63)75-58(96)45-32-99-100-33-46(59(97)76-35(2)52(90)80-43(23-15-27-72-62(69)70)55(93)81-41(56(94)82-45)21-11-13-25-64)83-60(98)49(36(3)85)84-57(95)44(29-38-18-8-5-9-19-38)77-48(87)31-73-47(86)30-74-53(91)39(65)28-37-16-6-4-7-17-37/h4-9,16-19,34-36,39-46,49,85H,10-15,20-33,63-65H2,1-3H3,(H2,66,88)(H,73,86)(H,74,91)(H,75,96)(H,76,97)(H,77,87)(H,78,92)(H,79,89)(H,80,90)(H,81,93)(H,82,94)(H,83,98)(H,84,95)(H4,67,68,71)(H4,69,70,72)/t34-,35-,36+,39-,40-,41-,42-,43-,44-,45-,46-,49-/m0/s1
DMSMH6T	CS	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)CCCCN)CCCN=C(N)N
DMSMH6T	IK	YCXQOGDEHMJXPM-JOEKKRFNSA-N
DMSMH6T	IU	(4R,7S,10S,13S,16R)-7-(4-aminobutyl)-16-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-10-[3-(diaminomethylideneamino)propyl]-13-methyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide
DMSMH6T	DE	Discovery agent

DMI9C57	ID	DMI9C57
DMI9C57	DN	Cyclo[Cys7,Cys10]N/OFQ(1-13)NH2
DMI9C57	HS	Investigative
DMI9C57	SN	CHEMBL1162359
DMI9C57	PC	25080768
DMI9C57	MW	1427.7
DMI9C57	FM	C61H98N22O14S2
DMI9C57	IC	InChI=1S/C61H98N22O14S2/c1-34(51(89)79-41(21-13-25-70-60(66)67)53(91)78-39(50(65)88)19-9-11-23-62)75-57(95)45-33-99-98-32-44(58(96)81-42(22-14-26-71-61(68)69)54(92)80-40(55(93)82-45)20-10-12-24-63)77-48(87)31-74-59(97)49(35(2)84)83-56(94)43(28-37-17-7-4-8-18-37)76-47(86)30-72-46(85)29-73-52(90)38(64)27-36-15-5-3-6-16-36/h3-8,15-18,34-35,38-45,49,84H,9-14,19-33,62-64H2,1-2H3,(H2,65,88)(H,72,85)(H,73,90)(H,74,97)(H,75,95)(H,76,86)(H,77,87)(H,78,91)(H,79,89)(H,80,92)(H,81,96)(H,82,93)(H,83,94)(H4,66,67,70)(H4,68,69,71)/t34-,35+,38-,39-,40-,41-,42-,43-,44-,45-,49-/m0/s1
DMI9C57	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCN=C(N)N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DMI9C57	IK	ZCRGDVZWIYXXNX-QAOCYNJESA-N
DMI9C57	IU	(4R,7S,10S,13R)-7-(4-aminobutyl)-13-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-10-[3-(diaminomethylideneamino)propyl]-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMI9C57	DE	Discovery agent

DM39UMT	ID	DM39UMT
DM39UMT	DN	Cyclo[DAsp7,Lys10]N/OFQ(1-13)NH2
DM39UMT	HS	Investigative
DM39UMT	SN	CHEMBL1162358
DM39UMT	PC	44578000
DM39UMT	MW	1448.7
DM39UMT	FM	C65H105N23O15
DM39UMT	IC	InChI=1S/C65H105N23O15/c1-37(55(95)84-45(24-15-29-75-64(70)71)58(98)83-42(54(69)94)21-9-12-26-66)80-57(97)43-23-11-14-28-74-49(90)33-48(61(101)87-46(25-16-30-76-65(72)73)60(100)86-44(59(99)85-43)22-10-13-27-67)82-52(93)36-79-63(103)53(38(2)89)88-62(102)47(32-40-19-7-4-8-20-40)81-51(92)35-77-50(91)34-78-56(96)41(68)31-39-17-5-3-6-18-39/h3-8,17-20,37-38,41-48,53,89H,9-16,21-36,66-68H2,1-2H3,(H2,69,94)(H,74,90)(H,77,91)(H,78,96)(H,79,103)(H,80,97)(H,81,92)(H,82,93)(H,83,98)(H,84,95)(H,85,99)(H,86,100)(H,87,101)(H,88,102)(H4,70,71,75)(H4,72,73,76)/t37-,38+,41-,42-,43-,44-,45-,46-,47-,48-,53-/m0/s1
DM39UMT	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCN=C(N)N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DM39UMT	IK	MUJYKGBDMXOPCE-CFUMCULZSA-N
DM39UMT	IU	(3S,6S,9S,17S)-3-(4-aminobutyl)-9-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-6-[3-(diaminomethylideneamino)propyl]-2,5,8,11-tetraoxo-1,4,7,12-tetrazacycloheptadecane-17-carboxamide
DM39UMT	DE	Discovery agent

DMWYFLD	ID	DMWYFLD
DMWYFLD	DN	Cyclo[RGDfK(cypate)]
DMWYFLD	HS	Investigative
DMWYFLD	SN	CHEMBL407126; cyclo[RGDfK(cypate)]
DMWYFLD	PC	44409643
DMWYFLD	MW	1181.4
DMWYFLD	FM	C67H78N11O9+
DMWYFLD	IC	InChI=1S/C67H77N11O9/c1-66(2)54-28-11-6-5-7-12-29-55-67(3,4)60-46-25-16-14-23-44(46)31-33-52(60)78(55)41-57(81)73-48(27-19-36-71-65(69)70)62(85)72-40-56(80)74-50(39-58(82)83)64(87)76-49(38-42-20-9-8-10-21-42)63(86)75-47(26-17-18-35-68)61(84)53(79)34-37-77(54)51-32-30-43-22-13-15-24-45(43)59(51)66/h5-16,20-25,28-33,47-50H,17-19,26-27,34-41,68H2,1-4H3,(H9-,69,70,71,72,73,74,75,76,80,81,82,83,85,86,87)/p+1/t47-,48+,49+,50-/m1/s1
DMWYFLD	CS	CC1(C/2=[N+](CC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)C(=O)CCN\\3C4=C(C5=CC=CC=C5C=C4)C(/C3=C\\C=C\\C=C\\C=C2)(C)C)CCCCN)CC6=CC=CC=C6)CC(=O)O)CCCN=C(N)N)C7=C1C8=CC=CC=C8C=C7)C
DMWYFLD	IK	GCUFPHJXORLRLN-CZFAESEUSA-O
DMWYFLD	IU	2-[(1E,3E,5E,7E,25S,31R,34S,37R)-37-(4-aminobutyl)-34-benzyl-25-[3-(diaminomethylideneamino)propyl]-10,10,53,53-tetramethyl-23,26,29,32,35,38,39-heptaoxo-24,27,30,33,36,42-hexaza-21-azoniaheptacyclo[40.11.0.09,21.011,20.012,17.043,52.046,51]tripentaconta-1,3,5,7,9(21),11(20),12,14,16,18,43(52),44,46,48,50-pentadecaen-31-yl]acetic acid
DMWYFLD	DE	Discovery agent

DM35PIJ	ID	DM35PIJ
DM35PIJ	DN	Cyclobutyl
DM35PIJ	HS	Investigative
DM35PIJ	SN	Cyclobutyl radical; cyclobutanyl; cyclobutan-1-yl; 4548-06-5; Cyclobutylradical; AC1L3CHP; DTXSID90196522; 16188-EP2281563A1; 16097-EP2316459A1; 16097-EP2275401A1; 16188-EP2316459A1; 16188-EP2308873A1; 16097-EP2308848A1
DM35PIJ	DT	Small molecular drug
DM35PIJ	PC	138291
DM35PIJ	MW	55.1
DM35PIJ	FM	C4H7
DM35PIJ	IC	InChI=1S/C4H7/c1-2-4-3-1/h1H,2-4H2
DM35PIJ	CS	C1C[CH]C1
DM35PIJ	IK	ZAEBLFKQMDEPDM-UHFFFAOYSA-N
DM35PIJ	CA	CAS 4548-06-5
DM35PIJ	DE	Discovery agent

DMYLA7F	ID	DMYLA7F
DMYLA7F	DN	Cyclobutylcarbamic Acid Biphenyl-3-yl Ester
DMYLA7F	HS	Investigative
DMYLA7F	SN	CHEMBL451441; Cyclobutylcarbamic Acid Biphenyl-3-yl Ester
DMYLA7F	DT	Small molecular drug
DMYLA7F	PC	24881673
DMYLA7F	MW	267.32
DMYLA7F	FM	C17H17NO2
DMYLA7F	IC	InChI=1S/C17H17NO2/c19-17(18-15-9-5-10-15)20-16-11-4-8-14(12-16)13-6-2-1-3-7-13/h1-4,6-8,11-12,15H,5,9-10H2,(H,18,19)
DMYLA7F	CS	C1CC(C1)NC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMYLA7F	IK	CACLVJBQOQELCV-UHFFFAOYSA-N
DMYLA7F	IU	(3-phenylphenyl) N-cyclobutylcarbamate
DMYLA7F	DE	Discovery agent

DMC520D	ID	DMC520D
DMC520D	DN	Cycloguanil
DMC520D	HS	Investigative
DMC520D	SN	Cycloguanil; Cycloguanyl; Cycloguanilum; 516-21-2; Chlorcycloguanil; Chlorguanide triazine; UNII-26RM326WVN; BN2410; WR 5473; BN-24-10; CHEMBL747; BRN 0229760; 1-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine; 26RM326WVN; QMNFFXRFOJIOKZ-UHFFFAOYSA-N; 1-(p-Chlorophenyl)-4,6-diamino-2,2-dimethyl-1,2-dihydro-s-triazine; 1-(4-chlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine; 1-p-Chlorophenyl-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine
DMC520D	DT	Small molecular drug
DMC520D	PC	9049
DMC520D	MW	251.71
DMC520D	FM	C11H14ClN5
DMC520D	IC	InChI=1S/C11H14ClN5/c1-11(2)16-9(13)15-10(14)17(11)8-5-3-7(12)4-6-8/h3-6H,1-2H3,(H4,13,14,15,16)
DMC520D	CS	CC1(N=C(N=C(N1C2=CC=C(C=C2)Cl)N)N)C
DMC520D	IK	QMNFFXRFOJIOKZ-UHFFFAOYSA-N
DMC520D	IU	1-(4-chlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine
DMC520D	CA	CAS 516-21-2
DMC520D	CB	CHEBI:135029
DMC520D	DE	Malaria

DMGDA3C	ID	DMGDA3C
DMGDA3C	DN	Cycloheximide
DMGDA3C	HS	Investigative
DMGDA3C	SN	naramycin A; NSC 185; FT 3422-2; NM-MCD 80
DMGDA3C	DT	Small molecular drug
DMGDA3C	PC	6197
DMGDA3C	MW	281.35
DMGDA3C	FM	C15H23NO4
DMGDA3C	IC	InChI=1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11-,12+/m0/s1
DMGDA3C	CS	C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C
DMGDA3C	IK	YPHMISFOHDHNIV-FSZOTQKASA-N
DMGDA3C	IU	4-[(2R)-2-[(1S,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione
DMGDA3C	CA	CAS 66-81-9
DMGDA3C	CB	CHEBI:27641
DMGDA3C	DE	Discovery agent

DMZKH4R	ID	DMZKH4R
DMZKH4R	DN	Cyclohexyl biphenyl-4-ylcarbamate
DMZKH4R	HS	Investigative
DMZKH4R	SN	cyclohexyl biphenyl-4-ylcarbamate; CHEMBL541244; SCHEMBL12166742; URB602, 3k
DMZKH4R	DT	Small molecular drug
DMZKH4R	PC	45272494
DMZKH4R	MW	295.4
DMZKH4R	FM	C19H21NO2
DMZKH4R	IC	InChI=1S/C19H21NO2/c21-19(22-18-9-5-2-6-10-18)20-17-13-11-16(12-14-17)15-7-3-1-4-8-15/h1,3-4,7-8,11-14,18H,2,5-6,9-10H2,(H,20,21)
DMZKH4R	CS	C1CCC(CC1)OC(=O)NC2=CC=C(C=C2)C3=CC=CC=C3
DMZKH4R	IK	SSVRRVRYQFRADL-UHFFFAOYSA-N
DMZKH4R	IU	cyclohexyl N-(4-phenylphenyl)carbamate
DMZKH4R	DE	Discovery agent

DM84ZX5	ID	DM84ZX5
DM84ZX5	DN	Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine
DM84ZX5	HS	Investigative
DM84ZX5	SN	CHEMBL363419; Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine; SCHEMBL935805; ZINC13648479; BDBM50170816
DM84ZX5	DT	Small molecular drug
DM84ZX5	PC	11771279
DM84ZX5	MW	309.4
DM84ZX5	FM	C17H19N5O
DM84ZX5	IC	InChI=1S/C17H19N5O/c1-3-7-12(8-4-1)20-16-14-15(19-11-18-14)21-17(22-16)23-13-9-5-2-6-10-13/h2,5-6,9-12H,1,3-4,7-8H2,(H2,18,19,20,21,22)
DM84ZX5	CS	C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)OC4=CC=CC=C4
DM84ZX5	IK	OGCQBCHLFMBCCE-UHFFFAOYSA-N
DM84ZX5	IU	N-cyclohexyl-2-phenoxy-7H-purin-6-amine
DM84ZX5	DE	Discovery agent

DMLREDJ	ID	DMLREDJ
DMLREDJ	DN	Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine
DMLREDJ	HS	Investigative
DMLREDJ	SN	CHEMBL191270; Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine
DMLREDJ	DT	Small molecular drug
DMLREDJ	PC	11450197
DMLREDJ	MW	325.4
DMLREDJ	FM	C17H19N5S
DMLREDJ	IC	InChI=1S/C17H19N5S/c1-3-7-12(8-4-1)20-16-14-15(19-11-18-14)21-17(22-16)23-13-9-5-2-6-10-13/h2,5-6,9-12H,1,3-4,7-8H2,(H2,18,19,20,21,22)
DMLREDJ	CS	C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)SC4=CC=CC=C4
DMLREDJ	IK	NFXCEGOWTIZWIH-UHFFFAOYSA-N
DMLREDJ	IU	N-cyclohexyl-2-phenylsulfanyl-7H-purin-6-amine
DMLREDJ	DE	Discovery agent

DMJEN45	ID	DMJEN45
DMJEN45	DN	Cyclohexyl-(3,4-dichloro-phenyl)-acetonitrile
DMJEN45	HS	Investigative
DMJEN45	SN	CHEMBL432482; Cyclohexyl-(3,4-dichloro-phenyl)-acetonitrile; SCHEMBL5903164; BDBM50126935
DMJEN45	DT	Small molecular drug
DMJEN45	PC	10084369
DMJEN45	MW	268.2
DMJEN45	FM	C14H15Cl2N
DMJEN45	IC	InChI=1S/C14H15Cl2N/c15-13-7-6-11(8-14(13)16)12(9-17)10-4-2-1-3-5-10/h6-8,10,12H,1-5H2
DMJEN45	CS	C1CCC(CC1)C(C#N)C2=CC(=C(C=C2)Cl)Cl
DMJEN45	IK	HAXWFRNRCIQCDM-UHFFFAOYSA-N
DMJEN45	IU	2-cyclohexyl-2-(3,4-dichlorophenyl)acetonitrile
DMJEN45	DE	Discovery agent

DM1F7I5	ID	DM1F7I5
DM1F7I5	DN	Cyclohexyl-(9-ethyl-9H-purin-6-yl)-amine
DM1F7I5	HS	Investigative
DM1F7I5	SN	CHEMBL321753; Cyclohexyl-(9-ethyl-9H-purin-6-yl)-amine; BDBM50009690
DM1F7I5	DT	Small molecular drug
DM1F7I5	PC	15693949
DM1F7I5	MW	245.32
DM1F7I5	FM	C13H19N5
DM1F7I5	IC	InChI=1S/C13H19N5/c1-2-18-9-16-11-12(14-8-15-13(11)18)17-10-6-4-3-5-7-10/h8-10H,2-7H2,1H3,(H,14,15,17)
DM1F7I5	CS	CCN1C=NC2=C(N=CN=C21)NC3CCCCC3
DM1F7I5	IK	ZKBBSCAFNVXZSZ-UHFFFAOYSA-N
DM1F7I5	IU	N-cyclohexyl-9-ethylpurin-6-amine
DM1F7I5	DE	Discovery agent

DMIUCSW	ID	DMIUCSW
DMIUCSW	DN	Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine
DMIUCSW	HS	Investigative
DMIUCSW	SN	CHEMBL95332; 109292-93-5; 9H-Purin-6-amine, N-cyclohexyl-9-methyl-; N6-Cyclohexyl-9-methyladenine; Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine; ACMC-20mc61; SCHEMBL14564552; CTK0D5868; DTXSID10576963; BDBM50009683; 6-Cyclohexylamino-9-methyl-9H-purine; AKOS030562210
DMIUCSW	DT	Small molecular drug
DMIUCSW	PC	15693939
DMIUCSW	MW	231.3
DMIUCSW	FM	C12H17N5
DMIUCSW	IC	InChI=1S/C12H17N5/c1-17-8-15-10-11(13-7-14-12(10)17)16-9-5-3-2-4-6-9/h7-9H,2-6H2,1H3,(H,13,14,16)
DMIUCSW	CS	CN1C=NC2=C(N=CN=C21)NC3CCCCC3
DMIUCSW	IK	YWCWGJZQICOVCA-UHFFFAOYSA-N
DMIUCSW	IU	N-cyclohexyl-9-methylpurin-6-amine
DMIUCSW	CA	CAS 109292-93-5
DMIUCSW	DE	Discovery agent

DMYQH2N	ID	DMYQH2N
DMYQH2N	DN	Cyclohexylammonium Ion
DMYQH2N	HS	Investigative
DMYQH2N	SN	CYCLOHEXYLAMMONIUM ION; cyclohexylammonium; cyclohexylazanium; cyclohexanaminium; Cyclohexaniminium; cyclohexyl-ammonium; cyclohexyl ammonium; AC1LU7QN; SAMPL4, C7; CHEBI:42939; PAFZNILMFXTMIY-UHFFFAOYSA-O; BDBM197294; DB02995; NCGC00249017-01; CJ-13833; A801941
DMYQH2N	DT	Small molecular drug
DMYQH2N	PC	1549093
DMYQH2N	MW	100.18
DMYQH2N	FM	C6H14N+
DMYQH2N	IC	InChI=1S/C6H13N/c7-6-4-2-1-3-5-6/h6H,1-5,7H2/p+1
DMYQH2N	CS	C1CCC(CC1)[NH3+]
DMYQH2N	IK	PAFZNILMFXTMIY-UHFFFAOYSA-O
DMYQH2N	IU	cyclohexylazanium
DMYQH2N	CB	CHEBI:42939
DMYQH2N	DE	Discovery agent

DM06OLY	ID	DM06OLY
DM06OLY	DN	Cyclohexylcarbamic acidbiphenyl-3-yl ester
DM06OLY	HS	Investigative
DM06OLY	SN	CHEMBL431202; biphenyl-N-cyclopentyl-carbamate; 546141-07-5; URB524; URB-524; cyclohexylcarbamic acidbiphenyl-3-yl ester; SCHEMBL530169; 3-Biphenylyl cyclohexylcarbamate; biphenyl-3-yl-cyclohexylcarbamate; biphenyl-3-yl cyclohexylcarbamate; ZINC3816417; BDBM50128585; AKOS015909861; KB-48012; Cyclohexyl-carbamic acid biphenyl-3-yl ester
DM06OLY	DT	Small molecular drug
DM06OLY	PC	10108554
DM06OLY	MW	295.4
DM06OLY	FM	C19H21NO2
DM06OLY	IC	InChI=1S/C19H21NO2/c21-19(20-17-11-5-2-6-12-17)22-18-13-7-10-16(14-18)15-8-3-1-4-9-15/h1,3-4,7-10,13-14,17H,2,5-6,11-12H2,(H,20,21)
DM06OLY	CS	C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DM06OLY	IK	KGKDDSYRBQOMLE-UHFFFAOYSA-N
DM06OLY	IU	(3-phenylphenyl) N-cyclohexylcarbamate
DM06OLY	DE	Discovery agent

DMNG4B1	ID	DMNG4B1
DMNG4B1	DN	Cyclohexylglycine-(2S)-cyanopyrrolidine
DMNG4B1	HS	Investigative
DMNG4B1	SN	Chg-Pro-CN; CHEMBL307636; cyclohexylglycine-(2S)-cyanopyrrolidine; BMCL15687 Compound 3; SCHEMBL14392566; BDBM11694; Cyclohexylglycine-(2S)-cyanopyrolidine 3; Cyclohexylglycine-(2S)-cyanopyrrolidine 2
DMNG4B1	DT	Small molecular drug
DMNG4B1	PC	11075394
DMNG4B1	MW	235.33
DMNG4B1	FM	C13H21N3O
DMNG4B1	IC	InChI=1S/C13H21N3O/c14-9-11-7-4-8-16(11)13(17)12(15)10-5-2-1-3-6-10/h10-12H,1-8,15H2/t11-,12-/m0/s1
DMNG4B1	CS	C1CCC(CC1)[C@@H](C(=O)N2CCC[C@H]2C#N)N
DMNG4B1	IK	SXNUNNAPZNTPQV-RYUDHWBXSA-N
DMNG4B1	IU	(2S)-1-[(2S)-2-amino-2-cyclohexylacetyl]pyrrolidine-2-carbonitrile
DMNG4B1	DE	Discovery agent

DMEW7AY	ID	DMEW7AY
DMEW7AY	DN	Cyclohexylmethylcarbamic Acid Biphenyl-3-yl Ester
DMEW7AY	HS	Investigative
DMEW7AY	SN	CHEMBL485685; Cyclohexylmethylcarbamic Acid Biphenyl-3-yl Ester
DMEW7AY	DT	Small molecular drug
DMEW7AY	PC	24881675
DMEW7AY	MW	309.4
DMEW7AY	FM	C20H23NO2
DMEW7AY	IC	InChI=1S/C20H23NO2/c22-20(21-15-16-8-3-1-4-9-16)23-19-13-7-12-18(14-19)17-10-5-2-6-11-17/h2,5-7,10-14,16H,1,3-4,8-9,15H2,(H,21,22)
DMEW7AY	CS	C1CCC(CC1)CNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMEW7AY	IK	AARHPAICPBZNBZ-UHFFFAOYSA-N
DMEW7AY	IU	(3-phenylphenyl) N-(cyclohexylmethyl)carbamate
DMEW7AY	DE	Discovery agent

DM0L6E1	ID	DM0L6E1
DM0L6E1	DN	Cycloleucine
DM0L6E1	HS	Investigative
DM0L6E1	SN	cycloleucine; 1-Aminocyclopentanecarboxylic acid; 52-52-8; 1-Aminocyclopentane-1-carboxylic acid; Cycloleucin; 1-Amino-1-cyclopentanecarboxylic acid; 1-Amino-1-carboxycyclopentane; 1-Amino-cyclopentanecarboxylic acid; CYCLO-LEUCINE; Cyclopentanecarboxylic acid, 1-amino-; NSC 1026; CB 1639; X 201; UNII-0TQU7668EI; 1-Aminocyclopentanecarboxylate; HSDB 5195; WR 14,997; NSC1026; 1-amino cyclopentane carboxylic acid; EINECS 200-144-6; BRN 0636626; aminocyclopentanecarboxylic acid; Cyclopentanecarboxylic acid, 1-amino-, L-; AI3-26442
DM0L6E1	DT	Small molecular drug
DM0L6E1	PC	2901
DM0L6E1	MW	129.16
DM0L6E1	FM	C6H11NO2
DM0L6E1	IC	InChI=1S/C6H11NO2/c7-6(5(8)9)3-1-2-4-6/h1-4,7H2,(H,8,9)
DM0L6E1	CS	C1CCC(C1)(C(=O)O)N
DM0L6E1	IK	NILQLFBWTXNUOE-UHFFFAOYSA-N
DM0L6E1	IU	1-aminocyclopentane-1-carboxylic acid
DM0L6E1	CA	CAS 52-52-8
DM0L6E1	CB	CHEBI:40547
DM0L6E1	DE	Discovery agent

DMEM2SW	ID	DMEM2SW
DMEM2SW	DN	CYCLOPAMINE
DMEM2SW	HS	Investigative
DMEM2SW	SN	CYCLOPAMINE; 11-Deoxojervine; 4449-51-8; UNII-ZH658AJ192; CHEMBL254129; CHEBI:4021; 11-Deoxyjervine; ZH658AJ192; HSDB 3505; Jervine, 11-deoxo-; Spiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol, 1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-octadecahydro-3',6',10,11b-tetramethyl-, (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)- (9CI); (3beta,22S,23R)-17,23-epoxyveratraman-3-ol; Veratraman-3-ol, 17,23-epoxy-, (3beta,23beta)-; CY8; [3H]-Cyclopamine; AC1L9DRQ; DSSTox_CID_23709; DSSTox_RID_80067; SCHEMBL29153
DMEM2SW	DT	Small molecular drug
DMEM2SW	PC	442972
DMEM2SW	MW	411.6
DMEM2SW	FM	C27H41NO2
DMEM2SW	IC	InChI=1S/C27H41NO2/c1-15-11-24-25(28-14-15)17(3)27(30-24)10-8-20-21-6-5-18-12-19(29)7-9-26(18,4)23(21)13-22(20)16(27)2/h5,15,17,19-21,23-25,28-29H,6-14H2,1-4H3/t15-,17+,19-,20-,21-,23-,24+,25-,26-,27-/m0/s1
DMEM2SW	CS	C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@]6([C@H]5CC4=C3C)C)O)C)NC1
DMEM2SW	IK	QASFUMOKHFSJGL-LAFRSMQTSA-N
DMEM2SW	IU	(3S,3'R,3'aS,6'S,6aS,6bS,7'aR,9R,11aS,11bR)-3',6',10,11b-tetramethylspiro[2,3,4,6,6a,6b,7,8,11,11a-decahydro-1H-benzo[a]fluorene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-ol
DMEM2SW	CA	CAS 4449-51-8
DMEM2SW	CB	CHEBI:4021
DMEM2SW	DE	Discovery agent

DM78PR5	ID	DM78PR5
DM78PR5	DN	Cyclopentane amide derivatives 1
DM78PR5	HS	Investigative
DM78PR5	DT	Small molecular drug
DM78PR5	PC	56603762
DM78PR5	MW	328.41
DM78PR5	FM	C15H28N4O4
DM78PR5	IC	InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9?,10-,11-,12?,13?/m1/s1
DM78PR5	CS	CCC(CC)C([C@H]1[C@@H](CC(C1O)C(=O)O)N=C(N)N)NC(=O)C
DM78PR5	IK	XRQDFNLINLXZLB-WFNKCNOUSA-N
DM78PR5	IU	(3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
DM78PR5	DE	Discovery agent

DMGU97P	ID	DMGU97P
DMGU97P	DN	Cyclopentane amide derivatives 2
DMGU97P	HS	Investigative
DMGU97P	DT	Small molecular drug
DMGU97P	PC	56603763
DMGU97P	MW	312.41
DMGU97P	FM	C15H28N4O3
DMGU97P	IC	InChI=1S/C15H28N4O3/c1-4-9(5-2)13(18-8(3)20)11-6-10(14(21)22)7-12(11)19-15(16)17/h9-13H,4-7H2,1-3H3,(H,18,20)(H,21,22)(H4,16,17,19)/t10?,11-,12-,13?/m1/s1
DMGU97P	CS	CCC(CC)C([C@@H]1CC(C[C@H]1N=C(N)N)C(=O)O)NC(=O)C
DMGU97P	IK	FOCBRFMNUQOMCY-QZQSVVMZSA-N
DMGU97P	IU	(3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DMGU97P	DE	Discovery agent

DMHTVRL	ID	DMHTVRL
DMHTVRL	DN	Cyclopentane amide derivatives 3
DMHTVRL	HS	Investigative
DMHTVRL	DT	Small molecular drug
DMHTVRL	PC	56603764
DMHTVRL	MW	340.5
DMHTVRL	FM	C17H32N4O3
DMHTVRL	IC	InChI=1S/C17H32N4O3/c1-4-6-11(7-5-2)15(20-10(3)22)13-8-12(16(23)24)9-14(13)21-17(18)19/h11-15H,4-9H2,1-3H3,(H,20,22)(H,23,24)(H4,18,19,21)/t12?,13-,14-,15?/m1/s1
DMHTVRL	CS	CCCC(CCC)C([C@@H]1CC(C[C@H]1N=C(N)N)C(=O)O)NC(=O)C
DMHTVRL	IK	VUROMZOEXLKRSQ-PIOWNMBXSA-N
DMHTVRL	IU	(3S,4R)-3-(1-acetamido-2-propylpentyl)-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DMHTVRL	DE	Discovery agent

DMOA7EP	ID	DMOA7EP
DMOA7EP	DN	Cyclopentane amide derivatives 4
DMOA7EP	HS	Investigative
DMOA7EP	DT	Small molecular drug
DMOA7EP	PC	56603765
DMOA7EP	MW	356.5
DMOA7EP	FM	C17H32N4O4
DMOA7EP	IC	InChI=1S/C17H32N4O4/c1-4-6-10(7-5-2)14(20-9(3)22)13-12(21-17(18)19)8-11(15(13)23)16(24)25/h10-15,23H,4-8H2,1-3H3,(H,20,22)(H,24,25)(H4,18,19,21)/t11?,12-,13-,14?,15?/m1/s1
DMOA7EP	CS	CCCC(CCC)C([C@H]1[C@@H](CC(C1O)C(=O)O)N=C(N)N)NC(=O)C
DMOA7EP	IK	IIZTWIZWLKRAMW-YATPQJKZSA-N
DMOA7EP	IU	(3S,4R)-3-(1-acetamido-2-propylpentyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
DMOA7EP	DE	Discovery agent

DMMV2LN	ID	DMMV2LN
DMMV2LN	DN	Cyclopentyl 10H-phenothiazine-10-carboxylate
DMMV2LN	HS	Investigative
DMMV2LN	SN	CHEMBL520588; cyclopentyl 10H-phenothiazine-10-carboxylate
DMMV2LN	DT	Small molecular drug
DMMV2LN	PC	24905535
DMMV2LN	MW	311.4
DMMV2LN	FM	C18H17NO2S
DMMV2LN	IC	InChI=1S/C18H17NO2S/c20-18(21-13-7-1-2-8-13)19-14-9-3-5-11-16(14)22-17-12-6-4-10-15(17)19/h3-6,9-13H,1-2,7-8H2
DMMV2LN	CS	C1CCC(C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMMV2LN	IK	NFZAMIJBLBLKQJ-UHFFFAOYSA-N
DMMV2LN	IU	cyclopentyl phenothiazine-10-carboxylate
DMMV2LN	DE	Discovery agent

DMAKT65	ID	DMAKT65
DMAKT65	DN	Cyclopentyl-(3,4-dichloro-phenyl)-acetonitrile
DMAKT65	HS	Investigative
DMAKT65	SN	CHEMBL39241; Cyclopentyl-(3,4-dichloro-phenyl)-acetonitrile; SCHEMBL5903239; BDBM50126930
DMAKT65	DT	Small molecular drug
DMAKT65	PC	10244015
DMAKT65	MW	254.15
DMAKT65	FM	C13H13Cl2N
DMAKT65	IC	InChI=1S/C13H13Cl2N/c14-12-6-5-10(7-13(12)15)11(8-16)9-3-1-2-4-9/h5-7,9,11H,1-4H2
DMAKT65	CS	C1CCC(C1)C(C#N)C2=CC(=C(C=C2)Cl)Cl
DMAKT65	IK	MWISMDNUXLOMTQ-UHFFFAOYSA-N
DMAKT65	IU	2-cyclopentyl-2-(3,4-dichlorophenyl)acetonitrile
DMAKT65	DE	Discovery agent

DM0J9I5	ID	DM0J9I5
DM0J9I5	DN	Cyclopentyl(5-(pyridin-2-yl)oxazol-2-yl)methanone
DM0J9I5	HS	Investigative
DM0J9I5	SN	alpha-ketooxazole, 14e; cyclopentyl(5-(pyridin-2-yl)oxazol-2-yl)methanone; SCHEMBL711639; CHEMBL376397; BDBM23134; CZXHLRXAHDZQJF-UHFFFAOYSA-N
DM0J9I5	DT	Small molecular drug
DM0J9I5	PC	16737623
DM0J9I5	MW	242.27
DM0J9I5	FM	C14H14N2O2
DM0J9I5	IC	InChI=1S/C14H14N2O2/c17-13(10-5-1-2-6-10)14-16-9-12(18-14)11-7-3-4-8-15-11/h3-4,7-10H,1-2,5-6H2
DM0J9I5	CS	C1CCC(C1)C(=O)C2=NC=C(O2)C3=CC=CC=N3
DM0J9I5	IK	CZXHLRXAHDZQJF-UHFFFAOYSA-N
DM0J9I5	IU	cyclopentyl-(5-pyridin-2-yl-1,3-oxazol-2-yl)methanone
DM0J9I5	DE	Discovery agent

DMBDTFQ	ID	DMBDTFQ
DMBDTFQ	DN	Cyclopentyl-(9-cyclopentyl-9H-purin-6-yl)-amine
DMBDTFQ	HS	Investigative
DMBDTFQ	SN	CHEMBL95617; Cyclopentyl-(9-cyclopentyl-9H-purin-6-yl)-amine; BDBM50009696
DMBDTFQ	DT	Small molecular drug
DMBDTFQ	PC	15693951
DMBDTFQ	MW	271.36
DMBDTFQ	FM	C15H21N5
DMBDTFQ	IC	InChI=1S/C15H21N5/c1-2-6-11(5-1)19-14-13-15(17-9-16-14)20(10-18-13)12-7-3-4-8-12/h9-12H,1-8H2,(H,16,17,19)
DMBDTFQ	CS	C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)C4CCCC4
DMBDTFQ	IK	TYMGLHAHNFQONV-UHFFFAOYSA-N
DMBDTFQ	IU	N,9-dicyclopentylpurin-6-amine
DMBDTFQ	DE	Discovery agent

DMQ6BS2	ID	DMQ6BS2
DMQ6BS2	DN	Cyclopentyl-(9-ethyl-9H-purin-6-yl)-amine
DMQ6BS2	HS	Investigative
DMQ6BS2	SN	CHEMBL301574; Cyclopentyl-(9-ethyl-9H-purin-6-yl)-amine; BDBM50009684; 6-Cyclopentylamino-9-ethyl-9H-purine
DMQ6BS2	DT	Small molecular drug
DMQ6BS2	PC	15693948
DMQ6BS2	MW	231.3
DMQ6BS2	FM	C12H17N5
DMQ6BS2	IC	InChI=1S/C12H17N5/c1-2-17-8-15-10-11(13-7-14-12(10)17)16-9-5-3-4-6-9/h7-9H,2-6H2,1H3,(H,13,14,16)
DMQ6BS2	CS	CCN1C=NC2=C(N=CN=C21)NC3CCCC3
DMQ6BS2	IK	CDVHQRUOORNLKE-UHFFFAOYSA-N
DMQ6BS2	IU	N-cyclopentyl-9-ethylpurin-6-amine
DMQ6BS2	DE	Discovery agent

DM9DHNZ	ID	DM9DHNZ
DM9DHNZ	DN	Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine
DM9DHNZ	HS	Investigative
DM9DHNZ	SN	N6-Cyclopentyl-9-methyladenine; N(6)-Cyclopentyl-9-methyladenine; N-0840; n-cyclopentyl-9-methyl-9h-purin-6-amine; CHEMBL48278; 109292-91-3; Lopac-N-154; 9H-Purin-6-amine,N-cyclopentyl-9-methyl-; AC1Q4XZM; Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine; Lopac0_000921; ZINC5203; SCHEMBL1322040; AC1L1I31; DTXSID60148871; LZMRVYPPUVMKOI-UHFFFAOYSA-N; N6 -Cyclopentyl-9-Methyl Adenine; N-cyclopentyl-9-methylpurin-6-amine; n0840; BDBM50009698; CCG-205003; NCGC00094232-01; NCGC00015717-03; NCGC00094232-03; NCGC00015717-02; NCGC00015717-01
DM9DHNZ	DT	Small molecular drug
DM9DHNZ	PC	4401
DM9DHNZ	MW	217.27
DM9DHNZ	FM	C11H15N5
DM9DHNZ	IC	InChI=1S/C11H15N5/c1-16-7-14-9-10(12-6-13-11(9)16)15-8-4-2-3-5-8/h6-8H,2-5H2,1H3,(H,12,13,15)
DM9DHNZ	CS	CN1C=NC2=C(N=CN=C21)NC3CCCC3
DM9DHNZ	IK	LZMRVYPPUVMKOI-UHFFFAOYSA-N
DM9DHNZ	IU	N-cyclopentyl-9-methylpurin-6-amine
DM9DHNZ	CA	CAS 109292-91-3
DM9DHNZ	DE	Discovery agent

DMBJV90	ID	DMBJV90
DMBJV90	DN	Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine
DMBJV90	HS	Investigative
DMBJV90	SN	CHEMBL319010; Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine; BDBM50009699
DMBJV90	DT	Small molecular drug
DMBJV90	PC	15693952
DMBJV90	MW	279.34
DMBJV90	FM	C16H17N5
DMBJV90	IC	InChI=1S/C16H17N5/c1-2-8-13(9-3-1)21-11-19-14-15(17-10-18-16(14)21)20-12-6-4-5-7-12/h1-3,8-12H,4-7H2,(H,17,18,20)
DMBJV90	CS	C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)C4=CC=CC=C4
DMBJV90	IK	HMTXZOPPYXBLIU-UHFFFAOYSA-N
DMBJV90	IU	N-cyclopentyl-9-phenylpurin-6-amine
DMBJV90	DE	Discovery agent

DMQLGFH	ID	DMQLGFH
DMQLGFH	DN	Cyclopentylcarbamic Acid Biphenyl-3-yl Ester
DMQLGFH	HS	Investigative
DMQLGFH	SN	CHEMBL448753; Cyclopentylcarbamic Acid Biphenyl-3-yl Ester; BDBM50256913; Cyclopentyl-carbamic acid biphenyl-3-yl ester
DMQLGFH	DT	Small molecular drug
DMQLGFH	PC	24881674
DMQLGFH	MW	281.3
DMQLGFH	FM	C18H19NO2
DMQLGFH	IC	InChI=1S/C18H19NO2/c20-18(19-16-10-4-5-11-16)21-17-12-6-9-15(13-17)14-7-2-1-3-8-14/h1-3,6-9,12-13,16H,4-5,10-11H2,(H,19,20)
DMQLGFH	CS	C1CCC(C1)NC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMQLGFH	IK	ASBRBCNHGJSXLE-UHFFFAOYSA-N
DMQLGFH	IU	(3-phenylphenyl) N-cyclopentylcarbamate
DMQLGFH	DE	Discovery agent

DM4KZ1W	ID	DM4KZ1W
DM4KZ1W	DN	Cyclopentylcytosine
DM4KZ1W	HS	Investigative
DM4KZ1W	SN	cyclopentylcytosine
DM4KZ1W	DT	Small molecular drug
DM4KZ1W	PC	129775084
DM4KZ1W	MW	455.06
DM4KZ1W	FM	C9H4N3O13P3
DM4KZ1W	IC	InChI=1S/C9H4N3O13P3/c13-6-10-4-3-5-11(6)7-1-2-8-9(7,22-27(15,20-8)21-8)23-28(16,19-7)25-12(5)24-26(14,17-3)18-4/h1-2H2
DM4KZ1W	CS	C1CC23C4(C15N6C7=C8C(=NC6=O)OP(=O)(O8)ON7OP(=O)(O5)O4)OP(=O)(O2)O3
DM4KZ1W	IK	VLAUHALXFDMKAB-UHFFFAOYSA-N
DM4KZ1W	IU	7,13,17-trioxo-6,8,12,14,16,18,22,23,24-nonaoxa-2,4,11-triaza-7lambda5,13lambda5,17lambda5-triphosphaoctacyclo[11.8.1.17,11.117,19.01,15.02,10.05,9.015,19]tetracosa-4,9-dien-3-one
DM4KZ1W	DE	Discovery agent

DMPJ08G	ID	DMPJ08G
DMPJ08G	DN	Cyclopiazonic acid
DMPJ08G	HS	Investigative
DMPJ08G	SN	2o9j; 2oa0; BSPBio_001303; GTPL5350; SCHEMBL1471247; MolPort-003-983-745; BS0055; ZINC100061481; ZINC100067111; ZINC110970687; FT-0624278; J-011619; (2R,3S,9R)-5-acetyl-4-hydroxy-8,8-dimethyl-7,16-diazapentacyclo[9.6.1.0^{2,9}.0^{3,7}.0^{15,18}]octadeca-1(17),4,11(18),12,14-pentaen-6-one
DMPJ08G	DT	Small molecular drug
DMPJ08G	PC	54682463
DMPJ08G	MW	336.4
DMPJ08G	FM	C20H20N2O3
DMPJ08G	IC	InChI=1S/C20H20N2O3/c1-9(23)14-18(24)17-16-11-8-21-13-6-4-5-10(15(11)13)7-12(16)20(2,3)22(17)19(14)25/h4-6,8,12,16-17,21,24H,7H2,1-3H3/t12-,16+,17+/m1/s1
DMPJ08G	CS	CC(=O)C1=C([C@@H]2[C@@H]3[C@@H](CC4=C5C3=CNC5=CC=C4)C(N2C1=O)(C)C)O
DMPJ08G	IK	SZINUGQCTHLQAZ-DQYPLSBCSA-N
DMPJ08G	IU	(2R,3S,9R)-5-acetyl-4-hydroxy-8,8-dimethyl-7,16-diazapentacyclo[9.6.1.02,9.03,7.015,18]octadeca-1(17),4,11(18),12,14-pentaen-6-one
DMPJ08G	CA	CAS 18172-33-3
DMPJ08G	DE	Discovery agent

DMGFEPJ	ID	DMGFEPJ
DMGFEPJ	DN	Cyclopropyl
DMGFEPJ	HS	Investigative
DMGFEPJ	SN	Cyclopropyl; Cyclopropyl radical; cyclopropan-1-yl; 2417-82-5; AC1L3VZL; AC1Q1GU5; DTXSID30178882; 16084-EP2281563A1; 16084-EP2275401A1; 16084-EP2316459A1
DMGFEPJ	DT	Small molecular drug
DMGFEPJ	PC	123162
DMGFEPJ	MW	41.07
DMGFEPJ	FM	C3H5
DMGFEPJ	IC	InChI=1S/C3H5/c1-2-3-1/h1H,2-3H2
DMGFEPJ	CS	C1C[CH]1
DMGFEPJ	IK	XIPUIGPNIDKXJU-UHFFFAOYSA-N
DMGFEPJ	CA	CAS 2417-82-5
DMGFEPJ	DE	Discovery agent

DMGZ0KM	ID	DMGZ0KM
DMGZ0KM	DN	Cyclorgdfv
DMGZ0KM	HS	Investigative
DMGZ0KM	SN	CYCLORGDFV; cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid
DMGZ0KM	DT	Small molecular drug
DMGZ0KM	PC	9851104
DMGZ0KM	MW	574.6
DMGZ0KM	FM	C26H38N8O7
DMGZ0KM	IC	InChI=1S/C26H38N8O7/c1-14(2)21-25(41)32-16(9-6-10-29-26(27)28)22(38)30-13-19(35)31-18(12-20(36)37)23(39)33-17(24(40)34-21)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18,21H,6,9-13H2,1-2H3,(H,30,38)(H,31,35)(H,32,41)(H,33,39)(H,34,40)(H,36,37)(H4,27,28,29)/t16-,17+,18-,21-/m0/s1
DMGZ0KM	CS	CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DMGZ0KM	IK	YYQUWEHEBOMRPH-NYUBLWNDSA-N
DMGZ0KM	IU	2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid

DMB1U8V	ID	DMB1U8V
DMB1U8V	DN	CYCLORPHAN
DMB1U8V	HS	Investigative
DMB1U8V	SN	17-(Cyclopropylmethyl)morphinan-3-ol; 4163-15-9; UNII-U6Z73N36V0; EINECS 224-007-5; CHEMBL49269; (-)-3-Hydroxy-N-cyclopropylmethylmorphinan; U6Z73N36V0; Morphinan, (-)-3-hydroxy-N-cyclopropylmethyl-; Morphinan-3-ol, 17-(cyclopropylmethyl)- (8CI,9CI); SCHEMBL159134; CTK4I5050; ZINC4215487; PDSP2_000668; BDBM50135800; N-cyclopropylmethyl 3-hydroxymorphinan; 3-Hydroxy-N-cyclopropylmethylmorphinan; LS-91818; (-)-17-(Cyclopropylmethyl)morphinan-3-ol; (-)-3-Hydroxy-N-cycloproypylmethylmorphinan Mandelate
DMB1U8V	DT	Small molecular drug
DMB1U8V	PC	5359966
DMB1U8V	MW	297.4
DMB1U8V	FM	C20H27NO
DMB1U8V	IC	InChI=1S/C20H27NO/c22-16-7-6-15-11-19-17-3-1-2-8-20(17,18(15)12-16)9-10-21(19)13-14-4-5-14/h6-7,12,14,17,19,22H,1-5,8-11,13H2/t17-,19+,20+/m0/s1
DMB1U8V	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)O)CC5CC5
DMB1U8V	IK	NLBUEDSBXVNAPB-DFQSSKMNSA-N
DMB1U8V	IU	(1R,9R,10R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMB1U8V	CA	CAS 4163-15-9
DMB1U8V	DE	Discovery agent

DMLC041	ID	DMLC041
DMLC041	DN	Cyclosal-d4TMP
DMLC041	HS	Investigative
DMLC041	SN	CycloSal-d4TMP; cycosal-d4TMP; CHEMBL375767; AC1LABYX; BDBM50206637; 5-methyl-1-[(2R,5S)-5-[(2-oxo-4H-1,3,2; 5-Methyl-1-{5-[(2-oxo(4H-benzo[e]1,3,2-dioxaphosphan-2-yloxy))methyl](2-2,5-dihydrofuryl)}-1,3-dihydropyrimidine-2,4-dione; 5-methyl-1-[(2R,5S)-5-[(2-oxo-4H-1,3,2$l^{5}-benzodioxaphosphinin-2-yl)oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione; 5-methyl-1-[(2R,5R)-5-(2-oxo-4H-2lambda5-benzo[1,3,2]dioxaphosphinin-2-yloxy)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione
DMLC041	DT	Small molecular drug
DMLC041	PC	465614
DMLC041	MW	392.3
DMLC041	FM	C17H17N2O7P
DMLC041	IC	InChI=1S/C17H17N2O7P/c1-11-8-19(17(21)18-16(11)20)15-7-6-13(25-15)10-24-27(22)23-9-12-4-2-3-5-14(12)26-27/h2-8,13,15H,9-10H2,1H3,(H,18,20,21)/t13-,15+,27?/m0/s1
DMLC041	CS	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=CC=CC=C4O3
DMLC041	IK	NEUXRWCLDPVEMR-OHDXJBIGSA-N
DMLC041	IU	5-methyl-1-[(2R,5S)-5-[(2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl)oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione
DMLC041	DE	Discovery agent

DMFTDPQ	ID	DMFTDPQ
DMFTDPQ	DN	Cyclostellettamine derivative
DMFTDPQ	HS	Investigative
DMFTDPQ	SN	CHEMBL88332
DMFTDPQ	DT	Small molecular drug
DMFTDPQ	PC	23327627
DMFTDPQ	MW	744.9
DMFTDPQ	FM	C40H58F6N2O4
DMFTDPQ	IC	InChI=1S/C36H58N2.2C2HF3O2/c1-2-5-9-13-17-21-29-37-31-24-28-36(34-37)26-20-16-12-8-4-6-10-14-18-22-30-38-32-23-27-35(33-38)25-19-15-11-7-3-1;2*3-2(4,5)1(6)7/h1-2,23-24,27-28,31-34H,3-22,25-26,29-30H2;2*(H,6,7)/q+2;;/p-2/b2-1+;;
DMFTDPQ	CS	C1CCCCCC[N+]2=CC=CC(=C2)CCCCCC/C=C/CCCCCC[N+]3=CC=CC(=C3)CCCCC1.C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-]
DMFTDPQ	IK	LUAUOMZCZVKFMM-SEPHDYHBSA-L
DMFTDPQ	IU	(25E)-1,18-diazoniatricyclo[31.3.1.114,18]octatriaconta-1(36),14(38),15,17,25,33(37),34-heptaene;2,2,2-trifluoroacetate
DMFTDPQ	DE	Discovery agent

DM8HG0K	ID	DM8HG0K
DM8HG0K	DN	Cyclotheonamide E
DM8HG0K	HS	Investigative
DM8HG0K	SN	Cyclotheonamide E; CHEMBL507449
DM8HG0K	DT	Small molecular drug
DM8HG0K	PC	44584171
DM8HG0K	MW	859
DM8HG0K	FM	C43H58N10O9
DM8HG0K	IC	InChI=1S/C43H58N10O9/c1-4-25(2)36-40(60)49-29(22-28-14-17-30(54)18-15-28)16-19-34(55)47-24-32(51-38(58)26(3)48-35(56)23-27-10-6-5-7-11-27)42(62)53-21-9-13-33(53)39(59)50-31(37(57)41(61)52-36)12-8-20-46-43(44)45/h5-7,10-11,14-19,25-26,29,31-33,36,54H,4,8-9,12-13,20-24H2,1-3H3,(H,47,55)(H,48,56)(H,49,60)(H,50,59)(H,51,58)(H,52,61)(H4,44,45,46)/b19-16+/t25-,26+,29-,31+,32+,33+,36+/m1/s1
DM8HG0K	CS	CC[C@@H](C)[C@H]1C(=O)N[C@H](/C=C/C(=O)NC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)C(=O)N1)CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)O
DM8HG0K	IK	JAVOTTCUBDNFEA-YFQACERUSA-N
DM8HG0K	IU	(2S)-N-[(3S,7E,9S,12S,16S,19S)-12-[(2R)-butan-2-yl]-16-[3-(diaminomethylideneamino)propyl]-9-[(4-hydroxyphenyl)methyl]-2,6,11,14,15,18-hexaoxo-1,5,10,13,17-pentazabicyclo[17.3.0]docos-7-en-3-yl]-2-[(2-phenylacetyl)amino]propanamide
DM8HG0K	DE	Discovery agent

DM2E5VZ	ID	DM2E5VZ
DM2E5VZ	DN	Cyclotheonamide E4
DM2E5VZ	HS	Investigative
DM2E5VZ	SN	cyclotheonamide E4; CHEMBL448961
DM2E5VZ	DT	Small molecular drug
DM2E5VZ	PC	44584172
DM2E5VZ	MW	839
DM2E5VZ	FM	C41H62N10O9
DM2E5VZ	IC	InChI=1S/C41H62N10O9/c1-6-23(3)20-33(54)46-25(5)36(56)49-30-22-45-32(53)17-14-27(21-26-12-15-28(52)16-13-26)47-38(58)34(24(4)7-2)50-39(59)35(55)29(10-8-18-44-41(42)43)48-37(57)31-11-9-19-51(31)40(30)60/h12-17,23-25,27,29-31,34,52H,6-11,18-22H2,1-5H3,(H,45,53)(H,46,54)(H,47,58)(H,48,57)(H,49,56)(H,50,59)(H4,42,43,44)/b17-14+/t23?,24-,25+,27-,29+,30+,31+,34+/m1/s1
DM2E5VZ	CS	CC[C@@H](C)[C@H]1C(=O)N[C@H](/C=C/C(=O)NC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)C(=O)N1)CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)CC(C)CC)CC3=CC=C(C=C3)O
DM2E5VZ	IK	SJGLOQSIMVYUEK-BJQFAPFESA-N
DM2E5VZ	IU	N-[(2S)-1-[[(3S,7E,9S,12S,16S,19S)-12-[(2R)-butan-2-yl]-16-[3-(diaminomethylideneamino)propyl]-9-[(4-hydroxyphenyl)methyl]-2,6,11,14,15,18-hexaoxo-1,5,10,13,17-pentazabicyclo[17.3.0]docos-7-en-3-yl]amino]-1-oxopropan-2-yl]-3-methylpentanamide
DM2E5VZ	DE	Discovery agent

DMCA76M	ID	DMCA76M
DMCA76M	DN	Cyclotheonamide E5
DMCA76M	HS	Investigative
DMCA76M	SN	Cyclotheonamide E5; CHEMBL502059
DMCA76M	DT	Small molecular drug
DMCA76M	PC	44584173
DMCA76M	MW	855
DMCA76M	FM	C41H62N10O10
DMCA76M	IC	InChI=1S/C41H62N10O10/c1-6-22(3)18-33(55)46-24(5)36(57)49-28-21-45-32(54)15-13-26(19-25-12-14-30(52)31(53)20-25)47-38(59)34(23(4)7-2)50-39(60)35(56)27(10-8-16-44-41(42)43)48-37(58)29-11-9-17-51(29)40(28)61/h12-15,20,22-24,26-29,34,52-53H,6-11,16-19,21H2,1-5H3,(H,45,54)(H,46,55)(H,47,59)(H,48,58)(H,49,57)(H,50,60)(H4,42,43,44)/b15-13+/t22?,23-,24+,26-,27+,28+,29+,34+/m1/s1
DMCA76M	CS	CC[C@@H](C)[C@H]1C(=O)N[C@H](/C=C/C(=O)NC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)C(=O)N1)CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)CC(C)CC)CC3=CC(=C(C=C3)O)O
DMCA76M	IK	GPMPQICWVQKULK-TUTRKGMZSA-N
DMCA76M	IU	N-[(2S)-1-[[(3S,7E,9S,12S,16S,19S)-12-[(2R)-butan-2-yl]-16-[3-(diaminomethylideneamino)propyl]-9-[(3,4-dihydroxyphenyl)methyl]-2,6,11,14,15,18-hexaoxo-1,5,10,13,17-pentazabicyclo[17.3.0]docos-7-en-3-yl]amino]-1-oxopropan-2-yl]-3-methylpentanamide
DMCA76M	DE	Discovery agent

DMTS8D5	ID	DMTS8D5
DMTS8D5	DN	CYLINDOL A
DMTS8D5	HS	Investigative
DMTS8D5	SN	cylindol A; CHEBI:65709; dimethyl 3,3'-oxybis(4-hydroxybenzoate); methyl 4-hydroxy-3-(2-hydroxy-5-methoxycarbonylphenoxy)benzoate
DMTS8D5	DT	Small molecular drug
DMTS8D5	PC	10425993
DMTS8D5	MW	318.28
DMTS8D5	FM	C16H14O7
DMTS8D5	IC	InChI=1S/C16H14O7/c1-21-15(19)9-3-5-11(17)13(7-9)23-14-8-10(16(20)22-2)4-6-12(14)18/h3-8,17-18H,1-2H3
DMTS8D5	CS	COC(=O)C1=CC(=C(C=C1)O)OC2=C(C=CC(=C2)C(=O)OC)O
DMTS8D5	IK	OEYSNLOOZVNLRA-UHFFFAOYSA-N
DMTS8D5	IU	methyl 4-hydroxy-3-(2-hydroxy-5-methoxycarbonylphenoxy)benzoate
DMTS8D5	CB	CHEBI:65709
DMTS8D5	DE	Discovery agent

DMCRU4H	ID	DMCRU4H
DMCRU4H	DN	CYLINDROL A
DMCRU4H	HS	Investigative
DMCRU4H	SN	CYLINDROL A; CHEMBL318783; BDBM50059845; Propionic acid (E)-(R)-4-(3-formyl-2,6-dihydroxy-4-methyl-phenyl)-2-methyl-1-((1S,2R,6R)-1,2,6-trimethyl-3-oxo-cyclohexylmethyl)-but-2-enyl ester
DMCRU4H	DT	Small molecular drug
DMCRU4H	PC	10456134
DMCRU4H	MW	444.6
DMCRU4H	FM	C26H36O6
DMCRU4H	IC	InChI=1S/C26H36O6/c1-7-24(30)32-23(13-26(6)17(4)9-11-21(28)18(26)5)15(2)8-10-19-22(29)12-16(3)20(14-27)25(19)31/h8,12,14,17-18,23,29,31H,7,9-11,13H2,1-6H3/b15-8+/t17-,18+,23-,26+/m1/s1
DMCRU4H	CS	CCC(=O)O[C@H](C[C@]1([C@@H](CCC(=O)[C@@H]1C)C)C)/C(=C/CC2=C(C=C(C(=C2O)C=O)C)O)/C
DMCRU4H	IK	VLFRJRBSRCFKPU-AXNCTASFSA-N
DMCRU4H	IU	[(E,2R)-5-(3-formyl-2,6-dihydroxy-4-methylphenyl)-3-methyl-1-[(1S,2R,6R)-1,2,6-trimethyl-3-oxocyclohexyl]pent-3-en-2-yl] propanoate
DMCRU4H	DE	Discovery agent

DMQWLIC	ID	DMQWLIC
DMQWLIC	DN	Cylopentenyl cytosine
DMQWLIC	HS	Investigative
DMQWLIC	DE	Discovery agent

DM5NFEA	ID	DM5NFEA
DM5NFEA	DN	CYM2503
DM5NFEA	HS	Investigative
DM5NFEA	SN	CYM-2503
DM5NFEA	DT	Small molecular drug
DM5NFEA	PC	91827369
DM5NFEA	MW	765.9
DM5NFEA	FM	C44H55N5O7
DM5NFEA	IC	InChI=1S/C44H55N5O7/c1-27-23-39(50)47-37-25-29(20-21-30(27)37)46-40(51)36(19-12-22-45-42(53)56-44(2,3)4)48-41(52)38(24-28-13-6-5-7-14-28)49-43(54)55-26-35-33-17-10-8-15-31(33)32-16-9-11-18-34(32)35/h8-11,15-18,20-21,23,25,28,31,33,35-36,38H,5-7,12-14,19,22,24,26H2,1-4H3,(H,45,53)(H,46,51)(H,47,50)(H,48,52)(H,49,54)/t31?,33?,35?,36-,38-/m0/s1
DM5NFEA	CS	CC1=CC(=O)NC2=C1C=CC(=C2)NC(=O)[C@H](CCCNC(=O)OC(C)(C)C)NC(=O)[C@H](CC3CCCCC3)NC(=O)OCC4C5C=CC=CC5C6=CC=CC=C46
DM5NFEA	IK	DSRPDMJWEFCXMI-GHKFOJCISA-N
DM5NFEA	IU	tert-butyl N-[(4S)-4-[[(2S)-2-(9,9a-dihydro-4aH-fluoren-9-ylmethoxycarbonylamino)-3-cyclohexylpropanoyl]amino]-5-[(4-methyl-2-oxo-1H-quinolin-7-yl)amino]-5-oxopentyl]carbamate
DM5NFEA	DE	Discovery agent

DMGTZ9Q	ID	DMGTZ9Q
DMGTZ9Q	DN	CYM5181
DMGTZ9Q	HS	Investigative
DMGTZ9Q	SN	CYM-5181
DMGTZ9Q	DT	Small molecular drug
DMGTZ9Q	PC	976135
DMGTZ9Q	MW	311.33
DMGTZ9Q	FM	C17H17N3O3
DMGTZ9Q	IC	InChI=1S/C17H17N3O3/c1-3-21-14-6-5-13(11-15(14)22-4-2)17-19-16(20-23-17)12-7-9-18-10-8-12/h5-11H,3-4H2,1-2H3
DMGTZ9Q	CS	CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC=NC=C3)OCC
DMGTZ9Q	IK	MMKXHTDCKLZHIM-UHFFFAOYSA-N
DMGTZ9Q	IU	5-(3,4-diethoxyphenyl)-3-pyridin-4-yl-1,2,4-oxadiazole
DMGTZ9Q	CB	CHEBI:92489
DMGTZ9Q	DE	Discovery agent

DMURD2E	ID	DMURD2E
DMURD2E	DN	CYM5442
DMURD2E	HS	Investigative
DMURD2E	SN	CYM-5442
DMURD2E	DT	Small molecular drug
DMURD2E	PC	25110406
DMURD2E	MW	409.5
DMURD2E	FM	C23H27N3O4
DMURD2E	IC	InChI=1S/C23H27N3O4/c1-3-28-20-11-8-15(14-21(20)29-4-2)23-25-22(26-30-23)18-7-5-6-17-16(18)9-10-19(17)24-12-13-27/h5-8,11,14,19,24,27H,3-4,9-10,12-13H2,1-2H3
DMURD2E	CS	CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)OCC
DMURD2E	IK	NUIKTBLZSPQGCP-UHFFFAOYSA-N
DMURD2E	IU	2-[[4-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl]amino]ethanol
DMURD2E	CA	CAS 1094042-01-9
DMURD2E	DE	Discovery agent

DMG0PHU	ID	DMG0PHU
DMG0PHU	DN	CYNAROPICRIN
DMG0PHU	HS	Investigative
DMG0PHU	SN	Cynaropicrin; aguerin; 35730-78-0; CHEMBL374146; CHEBI:4038; UNII-M9233789I9; M9233789I9; [(3aR,4S,6aR,8S,9aR,9bR)-8-hydroxy-3,6,9-trimethylidene-2-oxo-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-4-yl] 2-(hydroxymethyl)prop-2-enoate; AC1Q69JD; AC1L3O6W; SCHEMBL1711811; MEGxp0_001095; ACon1_000045; MolPort-001-741-258; ZINC4098049; HY-N2350; BDBM50194430; AKOS032971358; MCULE-5051144608; CS-8041; NCGC00168845-01; NCGC00168845-02; 2-Propenoic acid, 2-(hydroxymethyl)-, (3aR,4S,6aR,8S,9aR,9bR)-dodecahydro-8-hydroxy-3,6,9-tris(m
DMG0PHU	DT	Small molecular drug
DMG0PHU	PC	119093
DMG0PHU	MW	346.4
DMG0PHU	FM	C19H22O6
DMG0PHU	IC	InChI=1S/C19H22O6/c1-8-5-14(24-18(22)9(2)7-20)16-11(4)19(23)25-17(16)15-10(3)13(21)6-12(8)15/h12-17,20-21H,1-7H2/t12-,13-,14-,15-,16+,17+/m0/s1
DMG0PHU	CS	C=C1C[C@@H]([C@@H]2[C@@H]([C@@H]3[C@H]1C[C@@H](C3=C)O)OC(=O)C2=C)OC(=O)C(=C)CO
DMG0PHU	IK	KHSCYOFDKADJDJ-NQLMQOPMSA-N
DMG0PHU	IU	[(3aR,4S,6aR,8S,9aR,9bR)-8-hydroxy-3,6,9-trimethylidene-2-oxo-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-4-yl] 2-(hydroxymethyl)prop-2-enoate
DMG0PHU	CA	CAS 35730-78-0
DMG0PHU	CB	CHEBI:4038
DMG0PHU	DE	Discovery agent

DMZCA15	ID	DMZCA15
DMZCA15	DN	Cynooxide anion
DMZCA15	HS	Investigative
DMZCA15	SN	Fulminic acid; formonitrile oxide; Knallsaeure; HCNO; Hydrogen cyanide N-oxide; H-C#NO; formonitrile-N-oxide; [C(H)NO]; [CH(NO)]; (methylidyneammoniumyl)oxidanide; methylidyne(oxo)-lambda(5)-azane; hydrido(oxidonitrato-N)carbon; hydrido(nitrosyl-kappaN)carbon; CHEMBL185198; CHEBI:29813; 51060-05-0; Cynooxide anion; Formnitrile oxide; AC1LAVEA; CTK1G9581; DTXSID30334603; BDBM50152965; formonitrile oxideformonitrile-N-oxidehydrido(nitrosyl-kappaN)carbonhydrido(oxidonitrato-N)carbon
DMZCA15	DT	Small molecular drug
DMZCA15	PC	521293
DMZCA15	MW	43.025
DMZCA15	FM	CHNO
DMZCA15	IC	InChI=1S/CHNO/c1-2-3/h1H
DMZCA15	CS	C#[N+][O-]
DMZCA15	IK	UXKUODQYLDZXDL-UHFFFAOYSA-N
DMZCA15	IU	formonitrile oxide
DMZCA15	CA	CAS 506-85-4
DMZCA15	CB	CHEBI:29813
DMZCA15	DE	Discovery agent

DMBTU7G	ID	DMBTU7G
DMBTU7G	DN	Cypate-[(RGD)2-NH2]1
DMBTU7G	HS	Investigative
DMBTU7G	SN	CHEMBL438186; cypate-[(RGD)2-NH2]1
DMBTU7G	PC	44409497
DMBTU7G	MW	1267.4
DMBTU7G	FM	C64H80N15O13+
DMBTU7G	IC	InChI=1S/C64H79N15O13/c1-63(2)47(78(31-28-52(83)84)45-26-24-37-16-10-12-18-39(37)55(45)63)22-8-6-5-7-9-23-48-64(3,4)56-40-19-13-11-17-38(40)25-27-46(56)79(48)36-51(82)74-41(20-14-29-70-61(66)67)58(90)72-35-50(81)76-44(33-54(87)88)60(92)77-42(21-15-30-71-62(68)69)59(91)73-34-49(80)75-43(57(65)89)32-53(85)86/h5-13,16-19,22-27,41-44H,14-15,20-21,28-36H2,1-4H3,(H18-,65,66,67,68,69,70,71,72,73,74,75,76,77,80,81,82,83,84,85,86,87,88,89,90,91,92)/p+1/t41-,42-,43+,44+/m0/s1
DMBTU7G	CS	CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)O)C=CC6=CC=CC=C65)(C)C)C
DMBTU7G	IK	LXIIZUXXHZFFKQ-IYTFMMMVSA-O
DMBTU7G	IU	(3R)-4-amino-3-[[2-[[(2S)-2-[[(2R)-3-carboxy-2-[[2-[[(2S)-2-[[2-[2-[(1E,3E,5E,7E)-7-[3-(2-carboxyethyl)-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMBTU7G	DE	Discovery agent

DMJNW9P	ID	DMJNW9P
DMJNW9P	DN	Cypate-[(RGD)2-NH2]2
DMJNW9P	HS	Investigative
DMJNW9P	PC	91936295
DMJNW9P	MW	1923.1
DMJNW9P	FM	C88H121N28O22+
DMJNW9P	IC	InChI=1S/C88H120N28O22/c1-87(2)61(115(59-30-28-47-18-10-12-20-49(47)73(59)87)37-32-63(117)107-51(22-14-33-99-83(91)92)77(133)103-44-66(120)111-57(40-71(127)128)81(137)113-53(24-16-35-101-85(95)96)79(135)105-42-64(118)109-55(75(89)131)38-69(123)124)26-8-6-5-7-9-27-62-88(3,4)74-50-21-13-11-19-48(50)29-31-60(74)116(62)46-68(122)108-52(23-15-34-100-84(93)94)78(134)104-45-67(121)112-58(41-72(129)130)82(138)114-54(25-17-36-102-86(97)98)80(136)106-43-65(119)110-56(76(90)132)39-70(125)126/h5-13,18-21,26-31,51-58H,14-17,22-25,32-46H2,1-4H3,(H35-,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138)/p+1/t51-,52-,53-,54-,55+,56+,57+,58+/m0/s1
DMJNW9P	CS	CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)C=CC6=CC=CC=C65)(C)C)C
DMJNW9P	IK	UFEFOGNPPROIQU-SESQYOPQSA-O
DMJNW9P	IU	(3R)-4-amino-3-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[3-[(2E)-2-[(2E,4E,6E)-7-[3-[2-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(2R)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-1,1-dimethylbenzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]propanoylamino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMJNW9P	DE	Discovery agent

DMWINK5	ID	DMWINK5
DMWINK5	DN	Cypate-[(RGD)3-NH2]1
DMWINK5	HS	Investigative
DMWINK5	PC	91936298
DMWINK5	MW	1595.7
DMWINK5	FM	C76H100N21O18+
DMWINK5	IC	InChI=1S/C76H99N21O18/c1-75(2)54(96(34-30-61(103)104)52-28-26-42-17-10-12-19-44(42)64(52)75)24-8-6-5-7-9-25-55-76(3,4)65-45-20-13-11-18-43(45)27-29-53(65)97(55)41-60(102)90-46(21-14-31-84-72(78)79)66(109)87-38-57(99)91-49(36-62(105)106)69(112)94-47(22-15-32-85-73(80)81)67(110)88-39-58(100)92-50(37-63(107)108)70(113)95-48(23-16-33-86-74(82)83)68(111)89-40-59(101)93-51(71(114)115)35-56(77)98/h5-13,17-20,24-29,46-51H,14-16,21-23,30-41H2,1-4H3,(H26-,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115)/p+1/t46-,47-,48-,49+,50+,51+/m0/s1
DMWINK5	CS	CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)N)C(=O)O)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)O)C=CC6=CC=CC=C65)(C)C)C
DMWINK5	IK	JDBLOSLZCJNMOD-QCWHUYCXSA-O
DMWINK5	IU	(2R)-4-amino-2-[[2-[[(2S)-5-carbamimidamido-2-[[(2R)-2-[[2-[[(2S)-5-carbamimidamido-2-[[(2R)-2-[[2-[[(2S)-5-carbamimidamido-2-[[2-[2-[(1E,3E,5E,7E)-7-[3-(2-carboxyethyl)-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]acetyl]amino]pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMWINK5	DE	Discovery agent

DM1SAIX	ID	DM1SAIX
DM1SAIX	DN	Cypate-[(RGD)3-NH2]2
DM1SAIX	HS	Investigative
DM1SAIX	PC	91936296
DM1SAIX	MW	2579.7
DM1SAIX	FM	C112H161N40O32+
DM1SAIX	IC	InChI=1S/C112H160N40O32/c1-111(2)75(151(73-34-32-57-20-10-12-22-59(57)91(73)111)43-36-79(155)139-61(24-14-37-127-105(115)116)93(171)133-50-80(156)141-67(46-87(163)164)99(177)147-63(26-16-39-129-107(119)120)95(173)135-52-82(158)143-69(48-89(167)168)101(179)149-65(28-18-41-131-109(123)124)97(175)137-54-84(160)145-71(103(181)182)44-77(113)153)30-8-6-5-7-9-31-76-112(3,4)92-60-23-13-11-21-58(60)33-35-74(92)152(76)56-86(162)140-62(25-15-38-128-106(117)118)94(172)134-51-81(157)142-68(47-88(165)166)100(178)148-64(27-17-40-130-108(121)122)96(174)136-53-83(159)144-70(49-90(169)170)102(180)150-66(29-19-42-132-110(125)126)98(176)138-55-85(161)146-72(104(183)184)45-78(114)154/h5-13,20-23,30-35,61-72H,14-19,24-29,36-56H2,1-4H3,(H51-,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184)/p+1/t61-,62-,63-,64-,65-,66-,67+,68+,69+,70+,71+,72+/m0/s1
DM1SAIX	CS	CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)N)C(=O)O)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)N)C(=O)O)C=CC6=CC=CC=C65)(C)C)C
DM1SAIX	IK	RXCTZKKSKSPTFA-PRPZEPFNSA-O
DM1SAIX	IU	(2R)-4-amino-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[3-[(2E)-2-[(2E,4E,6E)-7-[3-[2-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(1R)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-1,1-dimethylbenzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]propanoylamino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DM1SAIX	DE	Discovery agent

DM3GLMP	ID	DM3GLMP
DM3GLMP	DN	Cypate-[(RGD)4-NH2]1
DM3GLMP	HS	Investigative
DM3GLMP	PC	91936299
DM3GLMP	MW	1924.1
DM3GLMP	FM	C88H120N27O23+
DM3GLMP	IC	InChI=1S/C88H119N27O23/c1-87(2)61(26-8-6-5-7-9-27-62-88(3,4)74-50-21-13-11-19-48(50)29-31-60(74)115(62)46-72(128)129)114(59-30-28-47-18-10-12-20-49(47)73(59)87)37-32-63(116)106-51(22-14-33-98-83(90)91)76(131)103-43-66(119)109-56(40-70(124)125)80(135)112-53(24-16-35-100-85(94)95)78(133)104-44-67(120)110-57(41-71(126)127)81(136)113-54(25-17-36-101-86(96)97)79(134)105-45-68(121)111-58(82(137)138)38-64(117)107-52(23-15-34-99-84(92)93)77(132)102-42-65(118)108-55(75(89)130)39-69(122)123/h5-13,18-21,26-31,51-58H,14-17,22-25,32-46H2,1-4H3,(H34-,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138)/p+1/t51-,52-,53-,54-,55+,56+,57+,58+/m0/s1
DM3GLMP	CS	CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)C(=O)O)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CC(=O)O)C=CC6=CC=CC=C65)(C)C)C
DM3GLMP	IK	GOWQHAYGNUHKIR-SESQYOPQSA-O
DM3GLMP	IU	(2R)-4-[[(2S)-1-[[2-[[(2R)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-[[2-[[(2S)-5-carbamimidamido-2-[[(2R)-2-[[2-[[(2S)-5-carbamimidamido-2-[[(2R)-2-[[2-[[(2S)-5-carbamimidamido-2-[3-[2-[(1E,3E,5E,7E)-7-[3-(carboxymethyl)-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]propanoylamino]pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DM3GLMP	DE	Discovery agent

DMR74OM	ID	DMR74OM
DMR74OM	DN	Cypate-[(RGD)4-NH2]2
DMR74OM	HS	Investigative
DMR74OM	PC	91936297
DMR74OM	MW	3236.4
DMR74OM	FM	C136H201N52O42+
DMR74OM	IC	InChI=1S/C136H200N52O42/c1-135(2)89(187(87-38-36-67-22-10-12-24-69(67)109(87)135)49-40-91(189)171-71(26-14-41-155-127(139)140)113(215)165-60-96(194)177-81(54-105(205)206)121(223)183-75(30-18-45-159-131(147)148)117(219)167-62-98(196)179-83(56-107(209)210)123(225)185-77(32-20-47-161-133(151)152)119(221)169-64-100(198)181-85(125(227)228)50-92(190)172-72(27-15-42-156-128(141)142)114(216)163-58-94(192)175-79(111(137)213)52-103(201)202)34-8-6-5-7-9-35-90-136(3,4)110-70-25-13-11-23-68(70)37-39-88(110)188(90)66-102(200)174-74(29-17-44-158-130(145)146)116(218)166-61-97(195)178-82(55-106(207)208)122(224)184-76(31-19-46-160-132(149)150)118(220)168-63-99(197)180-84(57-108(211)212)124(226)186-78(33-21-48-162-134(153)154)120(222)170-65-101(199)182-86(126(229)230)51-93(191)173-73(28-16-43-157-129(143)144)115(217)164-59-95(193)176-80(112(138)214)53-104(203)204/h5-13,22-25,34-39,71-86H,14-21,26-33,40-66H2,1-4H3,(H67-,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230)/p+1/t71-,72-,73-,74-,75-,76-,77-,78-,79+,80+,81+,82+,83+,84+,85+,86+/m0/s1
DMR74OM	CS	CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)C(=O)O)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)C(=O)O)C=CC6=CC=CC=C65)(C)C)C
DMR74OM	IK	ZQQKMIYGRGPTIR-LKERAZDISA-O
DMR74OM	IU	(2R)-4-[[(2S)-1-[[2-[[(2R)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[3-[(2E)-2-[(2E,4E,6E)-7-[3-[2-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(1R)-3-[[(2S)-1-[[2-[[(2R)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-1,1-dimethylbenzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]propanoylamino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMR74OM	DE	Discovery agent

DM64L9I	ID	DM64L9I
DM64L9I	DN	CyPPA
DM64L9I	HS	Investigative
DM64L9I	SN	73029-73-9; N-cyclohexyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidin-4-amine; CHEMBL453730; cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine; C16H23N5; N-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine; AC1LIR5Q; SCHEMBL3233745; GTPL2323; CTK8F8875; DTXSID20358676; USEMRPYUFJNFQN-UHFFFAOYSA-N; MolPort-000-762-862; ZINC492516; HMS3262M15; Tox21_500707; STK052676; MFCD01550586; BDBM50275157; CyPPA, &gt
DM64L9I	DT	Small molecular drug
DM64L9I	PC	909822
DM64L9I	MW	285.39
DM64L9I	FM	C16H23N5
DM64L9I	IC	InChI=1S/C16H23N5/c1-11-10-15(18-14-7-5-4-6-8-14)19-16(17-11)21-13(3)9-12(2)20-21/h9-10,14H,4-8H2,1-3H3,(H,17,18,19)
DM64L9I	CS	CC1=CC(=NC(=N1)N2C(=CC(=N2)C)C)NC3CCCCC3
DM64L9I	IK	USEMRPYUFJNFQN-UHFFFAOYSA-N
DM64L9I	IU	N-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine
DM64L9I	CA	CAS 73029-73-9
DM64L9I	DE	Discovery agent

DME9LPO	ID	DME9LPO
DME9LPO	DN	cyPPTS
DME9LPO	HS	Investigative
DME9LPO	SN	CHEMBL321968; cyPPTS; SCHEMBL6733000; GTPL6257; BDBM50147156; 2,2,2-Trifluoro-ethanesulfonic acid (3-cyclopentyloxy-phenyl)-pyridin-3-ylmethyl-amide; N-[3-(cyclopentyloxy)phenyl]-2,2,2-trifluoro-N-(pyridin-3-ylmethyl)ethane-1-sulfonamide
DME9LPO	DT	Small molecular drug
DME9LPO	PC	44335556
DME9LPO	MW	414.4
DME9LPO	FM	C19H21F3N2O3S
DME9LPO	IC	InChI=1S/C19H21F3N2O3S/c20-19(21,22)14-28(25,26)24(13-15-5-4-10-23-12-15)16-6-3-9-18(11-16)27-17-7-1-2-8-17/h3-6,9-12,17H,1-2,7-8,13-14H2
DME9LPO	CS	C1CCC(C1)OC2=CC=CC(=C2)N(CC3=CN=CC=C3)S(=O)(=O)CC(F)(F)F
DME9LPO	IK	WCYYNLFGFUQJMF-UHFFFAOYSA-N
DME9LPO	IU	N-(3-cyclopentyloxyphenyl)-2,2,2-trifluoro-N-(pyridin-3-ylmethyl)ethanesulfonamide
DME9LPO	DE	Discovery agent

DMJXCVA	ID	DMJXCVA
DMJXCVA	DN	CYPRODIME
DMJXCVA	HS	Investigative
DMJXCVA	SN	Cyprodime; CHEMBL322796; N-(Cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one; SCHEMBL3619261; BDBM50148071; ZINC13580323; NCGC00344512-01; Morphinan-6-one, 17-(cyclopropylmethyl)-4,14-dimethoxy-; (-)-N-(Cycloproylmethyl)-4,14-dimethoxymorphinan-6-one(Cyprodime); 17-cyclopropylmethyl-3,10-dimethoxy-(1R,9R,10S)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one; 17-cyclopropylmethyl-10-hydroxy-4,14-dimethoxy-(1S,9R,10S)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3-dien-6-one(cyprodime)
DMJXCVA	DT	Small molecular drug
DMJXCVA	PC	5748293
DMJXCVA	MW	355.5
DMJXCVA	FM	C22H29NO3
DMJXCVA	IC	InChI=1S/C22H29NO3/c1-25-18-5-3-4-16-12-19-22(26-2)9-8-17(24)13-21(22,20(16)18)10-11-23(19)14-15-6-7-15/h3-5,15,19H,6-14H2,1-2H3/t19-,21-,22-/m1/s1
DMJXCVA	CS	COC1=CC=CC2=C1[C@]34CCN([C@H](C2)[C@@]3(CCC(=O)C4)OC)CC5CC5
DMJXCVA	IK	INUCRGMCKDQKNA-CEMLEFRQSA-N
DMJXCVA	IU	(1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dimethoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one
DMJXCVA	CA	CAS 118111-54-9
DMJXCVA	DE	Discovery agent

DM7T96M	ID	DM7T96M
DM7T96M	DN	Cyprodine
DM7T96M	HS	Investigative
DM7T96M	DT	Small molecular drug
DM7T96M	PC	24758534
DM7T96M	MW	1492.5
DM7T96M	FM	C67H97CoN14O17PS
DM7T96M	IC	InChI=1S/C62H90N13O14P.C5H9NO3S.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-3(7)6-4(2-10)5(8)9;/h20-21,23,28,31,34-37,41,52-53,56-57,71,76,84H,12-19,22,24-27H2,1-11H3,(H2,63,77)(H2,64,78)(H2,65,79)(H2,66,80)(H2,67,81)(H2,68,82)(H,69,83)(H,85,86);4,10H,2H2,1H3,(H,6,7)(H,8,9);/q;;+2/p-2/b38-23-,50-32-,55-33-;;/t31-,34+,35+,36+,37-,41+,52+,53+,56+,57-,59+,60-,61-,62-;4-;/m00./s1
DM7T96M	CS	CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)([O-])O[C@@H](C)CNC(=O)CC[C@@]4([C@H]([C@@H]5[C@]6([C@@]([C@@H](C(=N6)/C(=C\\7/[C@@]([C@@H](/C(=C/C8=N/C(=C(\\C4=N5)/C)/[C@H](C8(C)C)CCC(=O)N)/N7)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.CC(=O)N[C@@H](CS)C(=O)[O-].[Co+2]
DM7T96M	IK	BZLYFDSDKLBOFC-SFSIFEIQSA-L
DM7T96M	IU	(2R)-2-acetamido-3-sulfanylpropanoate;cobalt(2+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2S)-1-[3-[(1R,2R,3R,5Z,7S,10Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-1,2,7,12,17,23-hexahydrocorrin-3-yl]propanoylamino]propan-2-yl] phosphate
DM7T96M	DE	Parkinson disease

DMS5DHY	ID	DMS5DHY
DMS5DHY	DN	Cystamine
DMS5DHY	HS	Investigative
DMS5DHY	SN	Cystamine dihydrochloride; 56-17-7; 2,2'-Disulfanediyldiethanamine dihydrochloride; Ethanamine, 2,2'-dithiobis-, dihydrochloride; Cystamin dihydrochloride; Bis(2-aminoethyl) disulfide dihydrochloride; USAF CB-34; 2-Aminoethyl disulfide dihydrochloride; Cystamine 2HCL; UNII-I90T518457; EINECS 200-260-7; NSC 39322; 2,2'-Dithiodi(ethylammonium) dichloride; Decarboxycystine dihydrochloride; 2,2'-Dithio-bis-(ethylamine) dihydrochloride; Usafcb-34; MFCD00012905; 2-Aminoethyl Dislufide Dihydrochloride
DMS5DHY	DT	Small molecular drug
DMS5DHY	PC	2915
DMS5DHY	MW	152.3
DMS5DHY	FM	C4H12N2S2
DMS5DHY	IC	InChI=1S/C4H12N2S2/c5-1-3-7-8-4-2-6/h1-6H2
DMS5DHY	CS	C(CSSCCN)N
DMS5DHY	IK	APQPRKLAWCIJEK-UHFFFAOYSA-N
DMS5DHY	IU	2-(2-aminoethyldisulfanyl)ethanamine
DMS5DHY	CA	CAS 51-85-4
DMS5DHY	CB	CHEBI:78757
DMS5DHY	DE	Discovery agent

DM4GZUJ	ID	DM4GZUJ
DM4GZUJ	DN	Cysteine Sulfenic Acid
DM4GZUJ	HS	Investigative
DM4GZUJ	SN	S-Hydroxycysteine; s-hydroxy-l-cysteine; Cysteinesulfenic acid; Cys-sulfenic acid; L-cysteinesulfenic acid; UNII-FB8KIA847T; L-Cysteinsulfensaeure; Alanine, 3-sulfeno-; Cys(OH); FB8KIA847T; L-2-amino-3-sulfeno-propionic acid; 5722-80-5; 2-amino-3-hydroxysulfanylpropionic acid; Cysteine-sulfenic acid; L-Alanine, 3-sulfeno-; S-(Propylcarbamoyl)cysteine; AC1Q5QNT; AC1L4WIO; SCHEMBL333356; CHEBI:41710; CTK1H0247; AKOS006339917; DB01915; L-Cysteine, S-[(propylamino)carbonyl]-; 73243-12-6
DM4GZUJ	DT	Small molecular drug
DM4GZUJ	PC	165339
DM4GZUJ	MW	137.16
DM4GZUJ	FM	C3H7NO3S
DM4GZUJ	IC	InChI=1S/C3H7NO3S/c4-2(1-8-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1
DM4GZUJ	CS	C([C@@H](C(=O)O)N)SO
DM4GZUJ	IK	FXIRVRPOOYSARH-REOHCLBHSA-N
DM4GZUJ	IU	(2R)-2-amino-3-hydroxysulfanylpropanoic acid
DM4GZUJ	CA	CAS 5722-80-5
DM4GZUJ	CB	CHEBI:41710

DMXI8FP	ID	DMXI8FP
DMXI8FP	DN	Cysteinesulfonic Acid
DMXI8FP	HS	Investigative
DMXI8FP	SN	Cysteic Acid; 3-Sulfoalanine; 2-amino-3-sulfopropanoic acid; DL-CYSTEIC ACID; 13100-82-8; beta-Sulfoalanine; Alanine, 3-sulfo-; Cysteinic acid; Cysteric acid; Cipteic acid; Cepteic acid; 3024-83-7; CHEBI:21260; C-9550; 2-amino-3-sulfopropanoate; cysteinsaure; Cepteate; Cysterate; Cipteate; Cysteinesulfonate; NSC 254030; (2R)-2-amino-3-sulfo-propanoic acid; L-Cysteic acid, 8; ACMC-209kii; 3-Sulfoalanine, (L)-; 2-Amino-3-sulfopropionate; AC1L19KC; SCHEMBL44030; CHEMBL1171434; 2-amino-3-sulfopro-panoic acid; BDBM85473; CTK8G7889
DMXI8FP	DT	Small molecular drug
DMXI8FP	PC	72886
DMXI8FP	MW	169.16
DMXI8FP	FM	C3H7NO5S
DMXI8FP	IC	InChI=1S/C3H7NO5S/c4-2(3(5)6)1-10(7,8)9/h2H,1,4H2,(H,5,6)(H,7,8,9)/t2-/m0/s1
DMXI8FP	CS	C([C@@H](C(=O)O)N)S(=O)(=O)O
DMXI8FP	IK	XVOYSCVBGLVSOL-REOHCLBHSA-N
DMXI8FP	IU	(2R)-2-amino-3-sulfopropanoic acid
DMXI8FP	CA	CAS 498-40-8
DMXI8FP	CB	CHEBI:17285
DMXI8FP	DE	Discovery agent

DMK0W8E	ID	DMK0W8E
DMK0W8E	DN	Cytidine
DMK0W8E	HS	Investigative
DMK0W8E	SN	cytidine; 65-46-3; Cytosine riboside; 1-beta-D-Ribofuranosylcytosine; 4-Amino-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone; 1beta-Ribofuranosylcytosine; beta-D-Ribofuranoside, cytosine-1; 1-beta-Ribofuranosylcytosine; Zytidin; Cytidin; 4-Amino-1beta-D-ribofuranosyl-2(1H)-pyrimidinone; Cytosine, 1-beta-D-ribofuranosyl-; 1beta-2'-Ribofuranosylcytosine, d-; UNII-5CSZ8459RP; NSC 20258; Cyd; CHEBI:17562; 2(1H)-Pyrimidinone, 4-amino-1-beta-D-ribofuranosyl-; EINECS 200-610-9; 2(1H)-Pyrimidinone, 4-amino-1beta-D-ribofuranosyl-
DMK0W8E	DT	Small molecular drug
DMK0W8E	PC	6175
DMK0W8E	MW	243.22
DMK0W8E	FM	C9H13N3O5
DMK0W8E	IC	InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8-/m1/s1
DMK0W8E	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
DMK0W8E	IK	UHDGCWIWMRVCDJ-XVFCMESISA-N
DMK0W8E	IU	4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMK0W8E	CA	CAS 65-46-3
DMK0W8E	CB	CHEBI:17562
DMK0W8E	DE	Discovery agent

DMA5FGS	ID	DMA5FGS
DMA5FGS	DN	Cytidine-5'-Diphosphate
DMA5FGS	HS	Investigative
DMA5FGS	SN	CDP trianion; cytidine 5'-diphosphate(2-); cytidine 5'-pyrophosphate(2-); CHEBI:58069; CDP(3-); 5'-O-[(phosphonatooxy)phosphinato]cytidine; A834354; [[(2R,3S,4R,5R)-5-(4-azanyl-2-oxidanylidene-pyrimidin-1-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanidyl-phosphoryl] phosphate; [[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1-pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]methoxy-oxidophosphoryl] phosphate
DMA5FGS	DT	Small molecular drug
DMA5FGS	PC	6132
DMA5FGS	MW	403.18
DMA5FGS	FM	C9H15N3O11P2
DMA5FGS	IC	InChI=1S/C9H15N3O11P2/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(22-8)3-21-25(19,20)23-24(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DMA5FGS	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)O)O
DMA5FGS	IK	ZWIADYZPOWUWEW-XVFCMESISA-N
DMA5FGS	IU	[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMA5FGS	CA	CAS 63-38-7
DMA5FGS	CB	CHEBI:17239
DMA5FGS	DE	Discovery agent

DM6PAXD	ID	DM6PAXD
DM6PAXD	DN	Cytidine-5'-Monophosphate
DM6PAXD	HS	Investigative
DM6PAXD	SN	cytidine-monophosphate; CMP dianion; AC1OEJZP; CMP; 5'-O-phosphonatocytidine; cytidine 5'-monophosphate(2-); Cytidine-5-monophosphate dianion; CHEBI:60377; CMP(2-); CJ-10966; LS-190174; A834351; [(2R,3S,4R,5R)-5-(4-amino-2-oxo-1-pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]methyl phosphate; [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate; [(2R,3S,4R,5R)-5-(4-azanyl-2-oxidanylidene-pyrimidin-1-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl phosphate
DM6PAXD	DT	Small molecular drug
DM6PAXD	PC	6131
DM6PAXD	MW	323.2
DM6PAXD	FM	C9H14N3O8P
DM6PAXD	IC	InChI=1S/C9H14N3O8P/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DM6PAXD	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O
DM6PAXD	IK	IERHLVCPSMICTF-XVFCMESISA-N
DM6PAXD	IU	[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM6PAXD	CA	CAS 63-37-6
DM6PAXD	CB	CHEBI:17361
DM6PAXD	DE	Discovery agent

DMPT4WM	ID	DMPT4WM
DMPT4WM	DN	Cytosine Arabinose-5'-Phosphate
DMPT4WM	HS	Investigative
DMPT4WM	SN	7075-11-8; Ara-5'-CMP; Ara-CMP; Cytarabine 5'-monophosphate; ((2R,3S,4S,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate; CYTOSINE ARABINOSE-5'-PHOSPHATE; AraCMP; Cytosine arabinoside monophosphate; Aracytidine 5'-phosphate; Cytosine arabinoside 5'MP; Aracytidine 5'-monophosphate; UNII-Y73692GHI4; Y73692GHI4; NSC 99445; 1-beta-D-Arabinofuranosylcytosine 5'-phosphate; Cytosine-beta-D-arabinofuranoside-5'-monophosphate; Cytosine beta-D-arabinofuranoside 5'-monophosphate
DMPT4WM	DT	Small molecular drug
DMPT4WM	PC	65177
DMPT4WM	MW	323.2
DMPT4WM	FM	C9H14N3O8P
DMPT4WM	IC	InChI=1S/C9H14N3O8P/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18)/t4-,6-,7+,8-/m1/s1
DMPT4WM	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O
DMPT4WM	IK	IERHLVCPSMICTF-CCXZUQQUSA-N
DMPT4WM	IU	[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMPT4WM	CA	CAS 7075-11-8
DMPT4WM	DE	Discovery agent

DM7SVLZ	ID	DM7SVLZ
DM7SVLZ	DN	Cytotoxin Peptide Conjugate
DM7SVLZ	HS	Investigative
DM7SVLZ	DE	Discovery agent

DMLBYFG	ID	DMLBYFG
DMLBYFG	DN	CZC 24832
DMLBYFG	HS	Investigative
DMLBYFG	SN	CZC24832; CZC-24832
DMLBYFG	DT	Small molecular drug
DMLBYFG	PC	42623951
DMLBYFG	MW	364.4
DMLBYFG	FM	C15H17FN6O2S
DMLBYFG	IC	InChI=1S/C15H17FN6O2S/c1-15(2,3)21-25(23,24)11-4-9(6-18-7-11)10-5-12(16)13-19-14(17)20-22(13)8-10/h4-8,21H,1-3H3,(H2,17,20)
DMLBYFG	CS	CC(C)(C)NS(=O)(=O)C1=CN=CC(=C1)C2=CN3C(=NC(=N3)N)C(=C2)F
DMLBYFG	IK	RXRZPHQBTHQXSV-UHFFFAOYSA-N
DMLBYFG	IU	5-(2-amino-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-tert-butylpyridine-3-sulfonamide
DMLBYFG	CA	CAS 1159824-67-5
DMLBYFG	DE	Discovery agent

DMYBL5G	ID	DMYBL5G
DMYBL5G	DN	CZC-19091
DMYBL5G	HS	Investigative
DMYBL5G	SN	PI3K gamma inhibitors (inflammation); PI3K gamma inhibitors (inflammation), Cellzome
DMYBL5G	CP	Cellzome
DMYBL5G	DE	Inflammation

DM1E5C4	ID	DM1E5C4
DM1E5C4	DN	D 2343
DM1E5C4	HS	Investigative
DM1E5C4	SN	D-2343; AC1OCEM5; SCHEMBL11327703; 4-[1-hydroxy-2-[[4-(2-methoxyphenyl)-2-methylbutan-2-yl]amino]ethyl]phenol hydrochloride
DM1E5C4	DT	Small molecular drug
DM1E5C4	PC	166295
DM1E5C4	MW	329.4
DM1E5C4	FM	C20H27NO3
DM1E5C4	IC	InChI=1S/C20H27NO3/c1-20(2,13-12-16-6-4-5-7-19(16)24-3)21-14-18(23)15-8-10-17(22)11-9-15/h4-11,18,21-23H,12-14H2,1-3H3
DM1E5C4	CS	CC(C)(CCC1=CC=CC=C1OC)NCC(C2=CC=C(C=C2)O)O
DM1E5C4	IK	QQNHGKXYJUREIZ-UHFFFAOYSA-N
DM1E5C4	IU	4-[1-hydroxy-2-[[4-(2-methoxyphenyl)-2-methylbutan-2-yl]amino]ethyl]phenol
DM1E5C4	CA	CAS 72734-63-5
DM1E5C4	DE	Discovery agent

DMAX7LW	ID	DMAX7LW
DMAX7LW	DN	d(CH2)5[D-Ile2,Ile4]AVP
DMAX7LW	HS	Investigative
DMAX7LW	SN	beta-mercapto-beta,beta,cyclopentamethylenepropionyl[D-Ile2,Ile4]AVP; d(CH2)5[D-Ile2,Ile4]VP
DMAX7LW	DT	Small molecular drug
DMAX7LW	PC	3080966
DMAX7LW	MW	1072.4
DMAX7LW	FM	C49H77N13O10S2
DMAX7LW	IC	InChI=1S/C49H77N13O10S2/c1-5-27(3)40(60-39(65)23-30-16-10-11-19-36(30)74)46(70)57-32(22-29-14-8-7-9-15-29)44(68)61-41(28(4)6-2)47(71)58-33(24-37(50)63)43(67)59-34(26-73)48(72)62-21-13-18-35(62)45(69)56-31(17-12-20-54-49(52)53)42(66)55-25-38(51)64/h7-9,14-15,27-28,30-35,40-41,73H,5-6,10-13,16-26H2,1-4H3,(H2,50,63)(H2,51,64)(H,55,66)(H,56,69)(H,57,70)(H,58,71)(H,59,67)(H,60,65)(H,61,68)(H4,52,53,54)/t27-,28+,30?,31-,32-,33-,34-,35-,40-,41+/m0/s1
DMAX7LW	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)CC3CCCCC3=S
DMAX7LW	IK	CNWFVLCMGVAHSD-HAEBMLOOSA-N
DMAX7LW	IU	(2S)-N-[(2R)-1-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-sulfanylpropan-2-yl]-2-[[(2R,3R)-3-methyl-2-[[(2S)-2-[[(2S,3S)-3-methyl-2-[[2-(2-sulfanylidenecyclohexyl)acetyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]amino]butanediamide
DMAX7LW	CA	CAS 103529-95-9
DMAX7LW	DE	Discovery agent

DMVHMGA	ID	DMVHMGA
DMVHMGA	DN	D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT
DMVHMGA	HS	Investigative
DMVHMGA	PC	44320911
DMVHMGA	MW	1484.7
DMVHMGA	FM	C73H85N11O19S2
DMVHMGA	IC	InChI=1S/C73H85N11O19S2/c1-5-37(2)58-66(97)80-59(38(3)85)67(98)78-51(34-56(74)90)64(95)79-52(36-104-105-72(27-7-6-8-28-72)35-57(91)83-71(4,70(101)82-58)41-16-20-43(87)21-17-41)68(99)84-30-10-12-53(84)65(96)77-50(63(94)81-60(61(75)92)39-13-18-42(86)19-14-39)11-9-29-76-62(93)40-15-24-46-49(31-40)73(103-69(46)100)47-25-22-44(88)32-54(47)102-55-33-45(89)23-26-48(55)73/h13-26,31-33,37-38,50-53,58-60,85-89H,5-12,27-30,34-36H2,1-4H3,(H2,74,90)(H2,75,92)(H,76,93)(H,77,96)(H,78,98)(H,79,95)(H,80,97)(H,81,94)(H,82,101)(H,83,91)/t37?,38?,50-,51+,52+,53+,58+,59+,60-,71+/m0/s1
DMVHMGA	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC2(CCCCC2)CC(=O)N[C@](C(=O)N1)(C)C3=CC=C(C=C3)O)C(=O)N4CCC[C@@H]4C(=O)N[C@@H](CCCNC(=O)C5=CC6=C(C=C5)C(=O)OC67C8=C(C=C(C=C8)O)OC9=C7C=CC(=C9)O)C(=O)N[C@@H](C1=CC=C(C=C1)O)C(=O)N)CC(=O)N)C(C)O
DMVHMGA	IK	BBABDJYQAOTGDM-JEIVZFIASA-N
DMVHMGA	IU	(2R)-N-[(2S)-1-[[(1S)-2-amino-1-(4-hydroxyphenyl)-2-oxoethyl]amino]-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(10S,13R,16R,19R,22R)-13-(2-amino-2-oxoethyl)-19-butan-2-yl-16-(1-hydroxyethyl)-22-(4-hydroxyphenyl)-22-methyl-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
DMVHMGA	DE	Discovery agent

DM1BMT7	ID	DM1BMT7
DM1BMT7	DN	D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT
DM1BMT7	HS	Investigative
DM1BMT7	PC	44320910
DM1BMT7	MW	1126.4
DM1BMT7	FM	C52H75N11O13S2
DM1BMT7	IC	InChI=1S/C52H75N11O13S2/c1-5-28(2)40-47(73)59-41(29(3)64)48(74)57-35(25-38(54)67)45(71)58-36(27-77-78-52(21-7-6-8-22-52)26-39(68)62-51(4,50(76)61-40)31-15-19-33(66)20-16-31)49(75)63-24-10-12-37(63)46(72)56-34(11-9-23-53)44(70)60-42(43(55)69)30-13-17-32(65)18-14-30/h13-20,28-29,34-37,40-42,64-66H,5-12,21-27,53H2,1-4H3,(H2,54,67)(H2,55,69)(H,56,72)(H,57,74)(H,58,71)(H,59,73)(H,60,70)(H,61,76)(H,62,68)/t28?,29?,34-,35+,36+,37+,40+,41+,42-,51+/m0/s1
DM1BMT7	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC2(CCCCC2)CC(=O)N[C@](C(=O)N1)(C)C3=CC=C(C=C3)O)C(=O)N4CCC[C@@H]4C(=O)N[C@@H](CCCN)C(=O)N[C@@H](C5=CC=C(C=C5)O)C(=O)N)CC(=O)N)C(C)O
DM1BMT7	IK	MRGPBAZYRUEDDT-YHXQAOAKSA-N
DM1BMT7	IU	(2R)-N-[(2S)-5-amino-1-[[(1S)-2-amino-1-(4-hydroxyphenyl)-2-oxoethyl]amino]-1-oxopentan-2-yl]-1-[(10S,13R,16R,19R,22R)-13-(2-amino-2-oxoethyl)-19-butan-2-yl-16-(1-hydroxyethyl)-22-(4-hydroxyphenyl)-22-methyl-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
DM1BMT7	DE	Discovery agent

DMHTSAX	ID	DMHTSAX
DMHTSAX	DN	d(CH2)5[Tyr(Me)2]AVP
DMHTSAX	HS	Investigative
DMHTSAX	SN	Pmp[Tyr(Me)2]AVP; SKF-100273; d(CH2)5[O-methyl-Tyr2]AVP
DMHTSAX	DT	Small molecular drug
DMHTSAX	PC	6917952
DMHTSAX	MW	1151.4
DMHTSAX	FM	C52H74N14O12S2
DMHTSAX	IC	InChI=1S/C52H74N14O12S2/c1-78-32-16-14-31(15-17-32)25-35-46(73)63-36(24-30-10-4-2-5-11-30)47(74)61-34(18-19-40(53)67)45(72)64-37(26-41(54)68)48(75)65-38(29-79-80-52(27-43(70)60-35)20-6-3-7-21-52)50(77)66-23-9-13-39(66)49(76)62-33(12-8-22-58-51(56)57)44(71)59-28-42(55)69/h2,4-5,10-11,14-17,33-39H,3,6-9,12-13,18-29H2,1H3,(H2,53,67)(H2,54,68)(H2,55,69)(H,59,71)(H,60,70)(H,61,74)(H,62,76)(H,63,73)(H,64,72)(H,65,75)(H4,56,57,58)/t33-,34-,35+,36-,37-,38-,39+/m0/s1
DMHTSAX	CS	COC1=CC=C(C=C1)C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC3(CCCCC3)CC(=O)N2)C(=O)N4CCC[C@@H]4C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)CC5=CC=CC=C5
DMHTSAX	IK	QVQOGNOOAMQKCE-OVSZNHMYSA-N
DMHTSAX	IU	(2R)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(10R,13S,16S,19S,22R)-13-(2-amino-2-oxoethyl)-16-(3-amino-3-oxopropyl)-19-benzyl-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
DMHTSAX	DE	Discovery agent

DMCU8HK	ID	DMCU8HK
DMCU8HK	DN	D[Arg4,Dab8]VP
DMCU8HK	HS	Investigative
DMCU8HK	SN	CHEMBL385739; d[Arg4,Dab8]VP
DMCU8HK	PC	16109443
DMCU8HK	MW	1041.2
DMCU8HK	FM	C45H64N14O11S2
DMCU8HK	IC	InChI=1S/C45H64N14O11S2/c46-16-14-29(38(64)52-23-36(48)62)55-43(69)34-9-5-18-59(34)44(70)33-24-72-71-19-15-37(63)53-30(21-26-10-12-27(60)13-11-26)40(66)56-31(20-25-6-2-1-3-7-25)41(67)54-28(8-4-17-51-45(49)50)39(65)57-32(22-35(47)61)42(68)58-33/h1-3,6-7,10-13,28-34,60H,4-5,8-9,14-24,46H2,(H2,47,61)(H2,48,62)(H,52,64)(H,53,63)(H,54,67)(H,55,69)(H,56,66)(H,57,65)(H,58,68)(H4,49,50,51)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
DMCU8HK	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN=C(N)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCN)C(=O)NCC(=O)N
DMCU8HK	IK	JTUSVVYBCYZYRH-NXBWRCJVSA-N
DMCU8HK	IU	(2S)-N-[(2S)-4-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxobutan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMCU8HK	DE	Discovery agent

DM69OVM	ID	DM69OVM
DM69OVM	DN	D[Arg4,Lys8]VP
DM69OVM	HS	Investigative
DM69OVM	SN	CHEMBL375325; d[Arg4,Lys8]VP
DM69OVM	PC	16109442
DM69OVM	MW	1069.3
DM69OVM	FM	C47H68N14O11S2
DM69OVM	IC	InChI=1S/C47H68N14O11S2/c48-18-5-4-10-30(40(66)54-25-38(50)64)57-45(71)36-12-7-20-61(36)46(72)35-26-74-73-21-17-39(65)55-32(23-28-13-15-29(62)16-14-28)42(68)58-33(22-27-8-2-1-3-9-27)43(69)56-31(11-6-19-53-47(51)52)41(67)59-34(24-37(49)63)44(70)60-35/h1-3,8-9,13-16,30-36,62H,4-7,10-12,17-26,48H2,(H2,49,63)(H2,50,64)(H,54,66)(H,55,65)(H,56,69)(H,57,71)(H,58,68)(H,59,67)(H,60,70)(H4,51,52,53)/t30-,31-,32-,33-,34-,35-,36-/m0/s1
DM69OVM	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN=C(N)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DM69OVM	IK	KYQCNVIVUUQTRA-QJCLFNHPSA-N
DM69OVM	IU	(2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM69OVM	DE	Discovery agent

DM8D4QT	ID	DM8D4QT
DM8D4QT	DN	D[Arg4,Orn8]VP
DM8D4QT	HS	Investigative
DM8D4QT	SN	CHEMBL385068; d[Arg4,Orn8]VP
DM8D4QT	PC	16109448
DM8D4QT	MW	1055.2
DM8D4QT	FM	C46H66N14O11S2
DM8D4QT	IC	InChI=1S/C46H66N14O11S2/c47-17-4-9-29(39(65)53-24-37(49)63)56-44(70)35-11-6-19-60(35)45(71)34-25-73-72-20-16-38(64)54-31(22-27-12-14-28(61)15-13-27)41(67)57-32(21-26-7-2-1-3-8-26)42(68)55-30(10-5-18-52-46(50)51)40(66)58-33(23-36(48)62)43(69)59-34/h1-3,7-8,12-15,29-35,61H,4-6,9-11,16-25,47H2,(H2,48,62)(H2,49,63)(H,53,65)(H,54,64)(H,55,68)(H,56,70)(H,57,67)(H,58,66)(H,59,69)(H4,50,51,52)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DM8D4QT	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN=C(N)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N
DM8D4QT	IK	FEMJEHRQGCUGEY-POFDKVPJSA-N
DM8D4QT	IU	(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM8D4QT	DE	Discovery agent

DM76Q2B	ID	DM76Q2B
DM76Q2B	DN	D[Arg4]AVP
DM76Q2B	HS	Investigative
DM76Q2B	SN	CHEMBL375324; d[Arg4]AVP
DM76Q2B	PC	44419039
DM76Q2B	MW	1097.3
DM76Q2B	FM	C47H68N16O11S2
DM76Q2B	IC	InChI=1S/C47H68N16O11S2/c48-36(65)23-33-43(72)62-34(45(74)63-19-6-11-35(63)44(73)59-29(9-4-17-54-46(50)51)39(68)56-24-37(49)66)25-76-75-20-16-38(67)57-31(22-27-12-14-28(64)15-13-27)41(70)60-32(21-26-7-2-1-3-8-26)42(71)58-30(40(69)61-33)10-5-18-55-47(52)53/h1-3,7-8,12-15,29-35,64H,4-6,9-11,16-25H2,(H2,48,65)(H2,49,66)(H,56,68)(H,57,67)(H,58,71)(H,59,73)(H,60,70)(H,61,69)(H,62,72)(H4,50,51,54)(H4,52,53,55)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DM76Q2B	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN=C(N)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DM76Q2B	IK	NZPQDNABVFGPNI-POFDKVPJSA-N
DM76Q2B	IU	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM76Q2B	DE	Discovery agent

DMCLUXI	ID	DMCLUXI
DMCLUXI	DN	D[Cha4,Dab8]VP
DMCLUXI	HS	Investigative
DMCLUXI	SN	CHEMBL412742; d[Cha4,Dab8]VP
DMCLUXI	PC	16109444
DMCLUXI	MW	1038.2
DMCLUXI	FM	C48H67N11O11S2
DMCLUXI	IC	InChI=1S/C48H67N11O11S2/c49-19-17-32(42(64)52-26-40(51)62)54-47(69)38-12-7-20-59(38)48(70)37-27-72-71-21-18-41(63)53-33(24-30-13-15-31(60)16-14-30)43(65)55-34(22-28-8-3-1-4-9-28)44(66)56-35(23-29-10-5-2-6-11-29)45(67)57-36(25-39(50)61)46(68)58-37/h1,3-4,8-9,13-16,29,32-38,60H,2,5-7,10-12,17-27,49H2,(H2,50,61)(H2,51,62)(H,52,64)(H,53,63)(H,54,69)(H,55,65)(H,56,66)(H,57,67)(H,58,68)/t32-,33-,34-,35-,36-,37-,38-/m0/s1
DMCLUXI	CS	C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCN)C(=O)NCC(=O)N)CC(=O)N
DMCLUXI	IK	DPVYQFBOSXXNLG-CXWHUAPYSA-N
DMCLUXI	IU	(2S)-N-[(2S)-4-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxobutan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMCLUXI	DE	Discovery agent

DMAPZKB	ID	DMAPZKB
DMAPZKB	DN	D[Cha4,Dap8]VP
DMAPZKB	HS	Investigative
DMAPZKB	SN	CHEMBL375187; d[Cha4,Dap8]VP
DMAPZKB	PC	16109439
DMAPZKB	MW	1024.2
DMAPZKB	FM	C47H65N11O11S2
DMAPZKB	IC	InChI=1S/C47H65N11O11S2/c48-24-35(41(63)51-25-39(50)61)56-46(68)37-12-7-18-58(37)47(69)36-26-71-70-19-17-40(62)52-31(22-29-13-15-30(59)16-14-29)42(64)53-32(20-27-8-3-1-4-9-27)43(65)54-33(21-28-10-5-2-6-11-28)44(66)55-34(23-38(49)60)45(67)57-36/h1,3-4,8-9,13-16,28,31-37,59H,2,5-7,10-12,17-26,48H2,(H2,49,60)(H2,50,61)(H,51,63)(H,52,62)(H,53,64)(H,54,65)(H,55,66)(H,56,68)(H,57,67)/t31-,32-,33-,34-,35-,36-,37-/m0/s1
DMAPZKB	CS	C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CN)C(=O)NCC(=O)N)CC(=O)N
DMAPZKB	IK	XABCPBOFMBSCDK-PEAOEFARSA-N
DMAPZKB	IU	(2S)-N-[(2S)-3-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopropan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMAPZKB	DE	Discovery agent

DM0GO7U	ID	DM0GO7U
DM0GO7U	DN	D[Cha4,Lys8]VP
DM0GO7U	HS	Investigative
DM0GO7U	SN	CHEMBL221485; d[Cha4,Lys8]VP
DM0GO7U	PC	16109437
DM0GO7U	MW	1066.3
DM0GO7U	FM	C50H71N11O11S2
DM0GO7U	IC	InChI=1S/C50H71N11O11S2/c51-21-8-7-14-34(44(66)54-28-42(53)64)56-49(71)40-15-9-22-61(40)50(72)39-29-74-73-23-20-43(65)55-35(26-32-16-18-33(62)19-17-32)45(67)57-36(24-30-10-3-1-4-11-30)46(68)58-37(25-31-12-5-2-6-13-31)47(69)59-38(27-41(52)63)48(70)60-39/h1,3-4,10-11,16-19,31,34-40,62H,2,5-9,12-15,20-29,51H2,(H2,52,63)(H2,53,64)(H,54,66)(H,55,65)(H,56,71)(H,57,67)(H,58,68)(H,59,69)(H,60,70)/t34-,35-,36-,37-,38-,39-,40-/m0/s1
DM0GO7U	CS	C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N)CC(=O)N
DM0GO7U	IK	RJWLIPGRNZUUNS-OAKHNGAUSA-N
DM0GO7U	IU	(2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM0GO7U	DE	Discovery agent

DMZWTJK	ID	DMZWTJK
DMZWTJK	DN	D[Cha4,Orn8]VP
DMZWTJK	HS	Investigative
DMZWTJK	SN	CHEMBL263090; d[Cha4,Orn8]VP
DMZWTJK	PC	16109438
DMZWTJK	MW	1052.3
DMZWTJK	FM	C49H69N11O11S2
DMZWTJK	IC	InChI=1S/C49H69N11O11S2/c50-20-7-13-33(43(65)53-27-41(52)63)55-48(70)39-14-8-21-60(39)49(71)38-28-73-72-22-19-42(64)54-34(25-31-15-17-32(61)18-16-31)44(66)56-35(23-29-9-3-1-4-10-29)45(67)57-36(24-30-11-5-2-6-12-30)46(68)58-37(26-40(51)62)47(69)59-38/h1,3-4,9-10,15-18,30,33-39,61H,2,5-8,11-14,19-28,50H2,(H2,51,62)(H2,52,63)(H,53,65)(H,54,64)(H,55,70)(H,56,66)(H,57,67)(H,58,68)(H,59,69)/t33-,34-,35-,36-,37-,38-,39-/m0/s1
DMZWTJK	CS	C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N
DMZWTJK	IK	CADGMGWLZUBCQD-ZTYVOHGWSA-N
DMZWTJK	IU	(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMZWTJK	DE	Discovery agent

DM8FCX5	ID	DM8FCX5
DM8FCX5	DN	D[Cha4]AVP
DM8FCX5	HS	Investigative
DM8FCX5	SN	d[Cha4]AVP; CHEMBL265858; BDBM50205312
DM8FCX5	PC	44419028
DM8FCX5	MW	1094.3
DM8FCX5	FM	C50H71N13O11S2
DM8FCX5	IC	InChI=1S/C50H71N13O11S2/c51-40(65)26-37-47(72)62-38(49(74)63-21-8-14-39(63)48(73)58-33(13-7-20-55-50(53)54)43(68)56-27-41(52)66)28-76-75-22-19-42(67)57-34(25-31-15-17-32(64)18-16-31)44(69)59-35(23-29-9-3-1-4-10-29)45(70)60-36(46(71)61-37)24-30-11-5-2-6-12-30/h1,3-4,9-10,15-18,30,33-39,64H,2,5-8,11-14,19-28H2,(H2,51,65)(H2,52,66)(H,56,68)(H,57,67)(H,58,73)(H,59,69)(H,60,70)(H,61,71)(H,62,72)(H4,53,54,55)/t33-,34-,35-,36-,37-,38-,39-/m0/s1
DM8FCX5	CS	C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DM8FCX5	IK	ZKYCVZNKBXGNEK-ZTYVOHGWSA-N
DM8FCX5	IU	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM8FCX5	DE	Discovery agent

DMD4V6U	ID	DMD4V6U
DMD4V6U	DN	D[D-3-Pal2]AVP
DMD4V6U	HS	Investigative
DMD4V6U	SN	CHEMBL414074; 136105-89-0; D3PVP; d[D-3-Pal2]AVP; [deamino-Cys1, D-3-Pyridyl-Ala2, Arg8]-Vasopressin; (Deamino-Cys1,b-(3-pyridyl)-D-Ala2,Arg8)-Vasopressin; MFCD00214667
DMD4V6U	PC	44419027
DMD4V6U	MW	1054.2
DMD4V6U	FM	C45H63N15O11S2
DMD4V6U	IC	InChI=1S/C45H63N15O11S2/c46-34(61)13-12-28-39(66)58-31(21-35(47)62)42(69)59-32(44(71)60-17-6-11-33(60)43(70)56-27(10-5-16-52-45(49)50)38(65)53-23-36(48)63)24-73-72-18-14-37(64)54-29(20-26-9-4-15-51-22-26)40(67)57-30(41(68)55-28)19-25-7-2-1-3-8-25/h1-4,7-9,15,22,27-33H,5-6,10-14,16-21,23-24H2,(H2,46,61)(H2,47,62)(H2,48,63)(H,53,65)(H,54,64)(H,55,68)(H,56,70)(H,57,67)(H,58,66)(H,59,69)(H4,49,50,52)/t27-,28-,29+,30-,31-,32-,33-/m0/s1
DMD4V6U	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CN=CC=C4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMD4V6U	IK	KEAHYTRPVNOHKL-ZHFJCBJKSA-N
DMD4V6U	IU	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-6,9,12,15,18-pentaoxo-16-(pyridin-3-ylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMD4V6U	DE	Discovery agent

DMNSXG9	ID	DMNSXG9
DMNSXG9	DN	D[Leu4,Dab8]VP
DMNSXG9	HS	Investigative
DMNSXG9	SN	CHEMBL412973; d[Leu4,Dab8]VP
DMNSXG9	DT	Small molecular drug
DMNSXG9	PC	16109440
DMNSXG9	MW	998.2
DMNSXG9	FM	C45H63N11O11S2
DMNSXG9	IC	InChI=1S/C45H63N11O11S2/c1-25(2)19-30-40(62)54-33(22-36(47)58)43(65)55-34(45(67)56-17-6-9-35(56)44(66)51-29(14-16-46)39(61)49-23-37(48)59)24-69-68-18-15-38(60)50-31(21-27-10-12-28(57)13-11-27)41(63)53-32(42(64)52-30)20-26-7-4-3-5-8-26/h3-5,7-8,10-13,25,29-35,57H,6,9,14-24,46H2,1-2H3,(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,64)(H,53,63)(H,54,62)(H,55,65)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DMNSXG9	CS	CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCN)C(=O)NCC(=O)N)CC(=O)N
DMNSXG9	IK	VIYXBPSZIAMFAA-POFDKVPJSA-N
DMNSXG9	IU	(2S)-N-[(2S)-4-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxobutan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMNSXG9	DE	Discovery agent

DME3HK8	ID	DME3HK8
DME3HK8	DN	D[Leu4,Dap8]VP
DME3HK8	HS	Investigative
DME3HK8	SN	CHEMBL373968; d[Leu4,Dap8]VP
DME3HK8	DT	Small molecular drug
DME3HK8	PC	16109446
DME3HK8	MW	984.2
DME3HK8	FM	C44H61N11O11S2
DME3HK8	IC	InChI=1S/C44H61N11O11S2/c1-24(2)17-28-39(61)52-31(20-35(46)57)42(64)54-33(44(66)55-15-6-9-34(55)43(65)53-32(21-45)38(60)48-22-36(47)58)23-68-67-16-14-37(59)49-29(19-26-10-12-27(56)13-11-26)40(62)51-30(41(63)50-28)18-25-7-4-3-5-8-25/h3-5,7-8,10-13,24,28-34,56H,6,9,14-23,45H2,1-2H3,(H2,46,57)(H2,47,58)(H,48,60)(H,49,59)(H,50,63)(H,51,62)(H,52,61)(H,53,65)(H,54,64)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
DME3HK8	CS	CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CN)C(=O)NCC(=O)N)CC(=O)N
DME3HK8	IK	ZAOGZAMKKBQERK-NXBWRCJVSA-N
DME3HK8	IU	(2S)-N-[(2S)-3-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopropan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DME3HK8	DE	Discovery agent

DMDBU7Q	ID	DMDBU7Q
DMDBU7Q	DN	D[Leu4,Lys8]VP
DMDBU7Q	HS	Investigative
DMDBU7Q	SN	42061-33-6; CHEMBL412972; d[Leu4,Lys8]-VP; d[Leu4,Lys8]VP; 1-Deamino-4-leu-8-lys-vasopressin; Vasopressin, 1-deamino-leu(4)-lys(8)-; Vasopressin, 1-deamino-leucyl(4)-lysine(8)-; BDBM50205309; AKOS024457446; (Deamino-Cys1,Leu4,Lys8)-Vasopressin; Vasopressin, 1-(3-mercaptopropanoic acid)-4-L-leucine-8-L-lysine-
DMDBU7Q	PC	44419030
DMDBU7Q	MW	1026.2
DMDBU7Q	FM	C47H67N11O11S2
DMDBU7Q	IC	InChI=1S/C47H67N11O11S2/c1-27(2)21-32-42(64)56-35(24-38(49)60)45(67)57-36(47(69)58-19-8-12-37(58)46(68)53-31(11-6-7-18-48)41(63)51-25-39(50)61)26-71-70-20-17-40(62)52-33(23-29-13-15-30(59)16-14-29)43(65)55-34(44(66)54-32)22-28-9-4-3-5-10-28/h3-5,9-10,13-16,27,31-37,59H,6-8,11-12,17-26,48H2,1-2H3,(H2,49,60)(H2,50,61)(H,51,63)(H,52,62)(H,53,68)(H,54,66)(H,55,65)(H,56,64)(H,57,67)/t31-,32-,33-,34-,35-,36-,37-/m0/s1
DMDBU7Q	CS	CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N)CC(=O)N
DMDBU7Q	IK	QGZMLGLFLYCDQT-PEAOEFARSA-N
DMDBU7Q	IU	(2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMDBU7Q	CA	CAS 42061-33-6
DMDBU7Q	DE	Discovery agent

DMJCW8Y	ID	DMJCW8Y
DMJCW8Y	DN	D[Leu4,Orn8]VP
DMJCW8Y	HS	Investigative
DMJCW8Y	SN	CHEMBL375188; d[Leu4,Orn8]VP
DMJCW8Y	PC	16109445
DMJCW8Y	MW	1012.2
DMJCW8Y	FM	C46H65N11O11S2
DMJCW8Y	IC	InChI=1S/C46H65N11O11S2/c1-26(2)20-31-41(63)55-34(23-37(48)59)44(66)56-35(46(68)57-18-7-11-36(57)45(67)52-30(10-6-17-47)40(62)50-24-38(49)60)25-70-69-19-16-39(61)51-32(22-28-12-14-29(58)15-13-28)42(64)54-33(43(65)53-31)21-27-8-4-3-5-9-27/h3-5,8-9,12-15,26,30-36,58H,6-7,10-11,16-25,47H2,1-2H3,(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,67)(H,53,65)(H,54,64)(H,55,63)(H,56,66)/t30-,31-,32-,33-,34-,35-,36-/m0/s1
DMJCW8Y	CS	CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N
DMJCW8Y	IK	FVVIZMMVAAKOOP-QJCLFNHPSA-N
DMJCW8Y	IU	(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMJCW8Y	DE	Discovery agent

DMREZT7	ID	DMREZT7
DMREZT7	DN	D[Leu4]AVP
DMREZT7	HS	Investigative
DMREZT7	SN	CHEMBL265859; d[Leu4]AVP
DMREZT7	PC	44419029
DMREZT7	MW	1054.3
DMREZT7	FM	C47H67N13O11S2
DMREZT7	IC	InChI=1S/C47H67N13O11S2/c1-26(2)20-31-41(66)58-34(23-37(48)62)44(69)59-35(46(71)60-18-7-11-36(60)45(70)55-30(10-6-17-52-47(50)51)40(65)53-24-38(49)63)25-73-72-19-16-39(64)54-32(22-28-12-14-29(61)15-13-28)42(67)57-33(43(68)56-31)21-27-8-4-3-5-9-27/h3-5,8-9,12-15,26,30-36,61H,6-7,10-11,16-25H2,1-2H3,(H2,48,62)(H2,49,63)(H,53,65)(H,54,64)(H,55,70)(H,56,68)(H,57,67)(H,58,66)(H,59,69)(H4,50,51,52)/t30-,31-,32-,33-,34-,35-,36-/m0/s1
DMREZT7	CS	CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DMREZT7	IK	CYOLRNSRVHAZDY-QJCLFNHPSA-N
DMREZT7	IU	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMREZT7	DE	Discovery agent

DME2PKB	ID	DME2PKB
DME2PKB	DN	D[Lys8(5/6-Flu)]VT
DME2PKB	HS	Investigative
DME2PKB	PC	44320997
DME2PKB	MW	1323.5
DME2PKB	FM	C62H74N12O17S2
DME2PKB	IC	InChI=1S/C62H74N12O17S2/c1-3-31(2)51-58(86)69-42(19-20-48(64)78)55(83)70-43(28-49(65)79)56(84)71-44(29-93-92-24-21-50(80)72-52(59(87)73-51)32-9-12-34(75)13-10-32)60(88)74-23-6-8-45(74)57(85)68-41(54(82)67-30-63)7-4-5-22-66-53(81)33-11-16-37-40(25-33)62(91-61(37)89)38-17-14-35(76)26-46(38)90-47-27-36(77)15-18-39(47)62/h9-18,25-27,31,41-45,51-52,75-77H,3-8,19-24,28-30,63H2,1-2H3,(H2,64,78)(H2,65,79)(H,66,81)(H,67,82)(H,68,85)(H,69,86)(H,70,83)(H,71,84)(H,72,80)(H,73,87)/t31?,41-,42+,43+,44+,45+,51+,52-/m0/s1
DME2PKB	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCCC(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DME2PKB	IK	OXFDSXJSRLFTMF-NRQFMKBZSA-N
DME2PKB	IU	(2R)-N-[(2S)-1-(aminomethylamino)-6-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxohexan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DME2PKB	DE	Discovery agent

DMNQTBU	ID	DMNQTBU
DMNQTBU	DN	D[Orn4,Lys8]VP
DMNQTBU	HS	Investigative
DMNQTBU	SN	CHEMBL375323; d[Orn4,Lys8]VP
DMNQTBU	PC	16109441
DMNQTBU	MW	1027.2
DMNQTBU	FM	C46H66N12O11S2
DMNQTBU	IC	InChI=1S/C46H66N12O11S2/c47-18-5-4-10-30(40(63)51-25-38(50)61)54-45(68)36-12-7-20-58(36)46(69)35-26-71-70-21-17-39(62)52-32(23-28-13-15-29(59)16-14-28)42(65)55-33(22-27-8-2-1-3-9-27)43(66)53-31(11-6-19-48)41(64)56-34(24-37(49)60)44(67)57-35/h1-3,8-9,13-16,30-36,59H,4-7,10-12,17-26,47-48H2,(H2,49,60)(H2,50,61)(H,51,63)(H,52,62)(H,53,66)(H,54,68)(H,55,65)(H,56,64)(H,57,67)/t30-,31-,32-,33-,34-,35-,36-/m0/s1
DMNQTBU	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DMNQTBU	IK	MYTIGVSAVZNLKG-QJCLFNHPSA-N
DMNQTBU	IU	(2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-aminopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMNQTBU	DE	Discovery agent

DMONV0M	ID	DMONV0M
DMONV0M	DN	D[Orn4,Orn8]VP
DMONV0M	HS	Investigative
DMONV0M	SN	CHEMBL219272; d[Orn4,Orn8]VP
DMONV0M	PC	16109447
DMONV0M	MW	1013.2
DMONV0M	FM	C45H64N12O11S2
DMONV0M	IC	InChI=1S/C45H64N12O11S2/c46-17-4-9-29(39(62)50-24-37(49)60)53-44(67)35-11-6-19-57(35)45(68)34-25-70-69-20-16-38(61)51-31(22-27-12-14-28(58)15-13-27)41(64)54-32(21-26-7-2-1-3-8-26)42(65)52-30(10-5-18-47)40(63)55-33(23-36(48)59)43(66)56-34/h1-3,7-8,12-15,29-35,58H,4-6,9-11,16-25,46-47H2,(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,65)(H,53,67)(H,54,64)(H,55,63)(H,56,66)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DMONV0M	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N
DMONV0M	IK	NLYHQDXERCUYHP-POFDKVPJSA-N
DMONV0M	IU	(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-aminopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMONV0M	DE	Discovery agent

DMJNT95	ID	DMJNT95
DMJNT95	DN	D[Orn4]AVP
DMJNT95	HS	Investigative
DMJNT95	SN	CHEMBL375096; d[Orn4]AVP
DMJNT95	PC	11366713
DMJNT95	MW	1055.2
DMJNT95	FM	C46H66N14O11S2
DMJNT95	IC	InChI=1S/C46H66N14O11S2/c47-17-4-9-30-40(66)58-33(23-36(48)62)43(69)59-34(45(71)60-19-6-11-35(60)44(70)56-29(10-5-18-52-46(50)51)39(65)53-24-37(49)63)25-73-72-20-16-38(64)54-31(22-27-12-14-28(61)15-13-27)41(67)57-32(42(68)55-30)21-26-7-2-1-3-8-26/h1-3,7-8,12-15,29-35,61H,4-6,9-11,16-25,47H2,(H2,48,62)(H2,49,63)(H,53,65)(H,54,64)(H,55,68)(H,56,70)(H,57,67)(H,58,66)(H,59,69)(H4,50,51,52)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DMJNT95	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMJNT95	IK	HBVZQPKQFUSYKR-POFDKVPJSA-N
DMJNT95	IU	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-aminopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMJNT95	DE	Discovery agent

DMH791N	ID	DMH791N
DMH791N	DN	D[Orn8(5/6C-Flu)]VT
DMH791N	HS	Investigative
DMH791N	PC	44321042
DMH791N	MW	1309.4
DMH791N	FM	C61H72N12O17S2
DMH791N	IC	InChI=1S/C61H72N12O17S2/c1-3-30(2)50-57(85)68-41(18-19-47(63)77)54(82)69-42(27-48(64)78)55(83)70-43(28-92-91-23-20-49(79)71-51(58(86)72-50)31-8-11-33(74)12-9-31)59(87)73-22-5-7-44(73)56(84)67-40(53(81)66-29-62)6-4-21-65-52(80)32-10-15-36-39(24-32)61(90-60(36)88)37-16-13-34(75)25-45(37)89-46-26-35(76)14-17-38(46)61/h8-17,24-26,30,40-44,50-51,74-76H,3-7,18-23,27-29,62H2,1-2H3,(H2,63,77)(H2,64,78)(H,65,80)(H,66,81)(H,67,84)(H,68,85)(H,69,82)(H,70,83)(H,71,79)(H,72,86)/t30?,40-,41+,42+,43+,44+,50+,51-/m0/s1
DMH791N	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCCC(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DMH791N	IK	JOVDCZXVGAWIKQ-VUINKVIFSA-N
DMH791N	IU	(2R)-N-[(2S)-1-(aminomethylamino)-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMH791N	DE	Discovery agent

DMT8KI6	ID	DMT8KI6
DMT8KI6	DN	d[Pen1,Tyr(Me)2]AVP
DMT8KI6	HS	Investigative
DMT8KI6	SN	1-deaminopenicillamine-2-(O-methyl-tyr)-argipressin; dPTyr(Me)AVP
DMT8KI6	DT	Small molecular drug
DMT8KI6	PC	119517
DMT8KI6	MW	1111.3
DMT8KI6	FM	C49H70N14O12S2
DMT8KI6	IC	InChI=1S/C49H70N14O12S2/c1-49(2)24-40(67)57-32(22-28-13-15-29(75-3)16-14-28)43(70)60-33(21-27-9-5-4-6-10-27)44(71)58-31(17-18-37(50)64)42(69)61-34(23-38(51)65)45(72)62-35(26-76-77-49)47(74)63-20-8-12-36(63)46(73)59-30(11-7-19-55-48(53)54)41(68)56-25-39(52)66/h4-6,9-10,13-16,30-36H,7-8,11-12,17-26H2,1-3H3,(H2,50,64)(H2,51,65)(H2,52,66)(H,56,68)(H,57,67)(H,58,71)(H,59,73)(H,60,70)(H,61,69)(H,62,72)(H4,53,54,55)
DMT8KI6	CS	CC1(CC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSS1)C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)OC)C
DMT8KI6	IK	HNOGCDKPALYUIG-UHFFFAOYSA-N
DMT8KI6	IU	N-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-methoxyphenyl)methyl]-20,20-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMT8KI6	CA	CAS 67269-08-3
DMT8KI6	DE	Discovery agent

DMS4F8O	ID	DMS4F8O
DMS4F8O	DN	D[Thr4,Lys8(5/6C-Flu)]VT
DMS4F8O	HS	Investigative
DMS4F8O	PC	44321256
DMS4F8O	MW	1296.4
DMS4F8O	FM	C61H73N11O17S2
DMS4F8O	IC	InChI=1S/C61H73N11O17S2/c1-4-30(2)49-56(83)71-50(31(3)73)57(84)67-42(27-47(63)77)54(81)68-43(28-91-90-23-20-48(78)69-51(58(85)70-49)32-10-13-34(74)14-11-32)59(86)72-22-7-9-44(72)55(82)66-41(53(80)65-29-62)8-5-6-21-64-52(79)33-12-17-37-40(24-33)61(89-60(37)87)38-18-15-35(75)25-45(38)88-46-26-36(76)16-19-39(46)61/h10-19,24-26,30-31,41-44,49-51,73-76H,4-9,20-23,27-29,62H2,1-3H3,(H2,63,77)(H,64,79)(H,65,80)(H,66,82)(H,67,84)(H,68,81)(H,69,78)(H,70,85)(H,71,83)/t30?,31?,41-,42+,43+,44+,49+,50+,51-/m0/s1
DMS4F8O	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCCC(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)C(C)O
DMS4F8O	IK	NBPSKZJBUIXUIP-IAPRXICDSA-N
DMS4F8O	IU	(2R)-N-[(2S)-1-(aminomethylamino)-6-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxohexan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMS4F8O	DE	Discovery agent

DMBDZQA	ID	DMBDZQA
DMBDZQA	DN	D[Thr4,Orn8(5/6C-Flu)]VT
DMBDZQA	HS	Investigative
DMBDZQA	PC	44320890
DMBDZQA	MW	1282.4
DMBDZQA	FM	C60H71N11O17S2
DMBDZQA	IC	InChI=1S/C60H71N11O17S2/c1-4-29(2)48-55(82)70-49(30(3)72)56(83)66-41(26-46(62)76)53(80)67-42(27-90-89-22-19-47(77)68-50(57(84)69-48)31-9-12-33(73)13-10-31)58(85)71-21-6-8-43(71)54(81)65-40(52(79)64-28-61)7-5-20-63-51(78)32-11-16-36-39(23-32)60(88-59(36)86)37-17-14-34(74)24-44(37)87-45-25-35(75)15-18-38(45)60/h9-18,23-25,29-30,40-43,48-50,72-75H,4-8,19-22,26-28,61H2,1-3H3,(H2,62,76)(H,63,78)(H,64,79)(H,65,81)(H,66,83)(H,67,80)(H,68,77)(H,69,84)(H,70,82)/t29?,30?,40-,41+,42+,43+,48+,49+,50-/m0/s1
DMBDZQA	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCCC(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)C(C)O
DMBDZQA	IK	JFIITURTLJMTOM-OPCZXTJTSA-N
DMBDZQA	IU	(2R)-N-[(2S)-1-(aminomethylamino)-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMBDZQA	DE	Discovery agent

DM3GM8E	ID	DM3GM8E
DM3GM8E	DN	D[Val4]AVP
DM3GM8E	HS	Investigative
DM3GM8E	SN	CHEMBL221436; d[Val4]AVP
DM3GM8E	PC	44419025
DM3GM8E	MW	1040.2
DM3GM8E	FM	C46H65N13O11S2
DM3GM8E	IC	InChI=1S/C46H65N13O11S2/c1-25(2)38-44(69)56-32(22-35(47)61)41(66)57-33(45(70)59-18-7-11-34(59)43(68)54-29(10-6-17-51-46(49)50)39(64)52-23-36(48)62)24-72-71-19-16-37(63)53-30(21-27-12-14-28(60)15-13-27)40(65)55-31(42(67)58-38)20-26-8-4-3-5-9-26/h3-5,8-9,12-15,25,29-34,38,60H,6-7,10-11,16-24H2,1-2H3,(H2,47,61)(H2,48,62)(H,52,64)(H,53,63)(H,54,68)(H,55,65)(H,56,69)(H,57,66)(H,58,67)(H4,49,50,51)/t29-,30-,31-,32-,33-,34-,38-/m0/s1
DM3GM8E	CS	CC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DM3GM8E	IK	KEBRFHAVFOSSOX-CDKUOFBKSA-N
DM3GM8E	IU	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM3GM8E	DE	Discovery agent

DMQJD4P	ID	DMQJD4P
DMQJD4P	DN	D-166A
DMQJD4P	HS	Investigative
DMQJD4P	SN	D-166A; CHEMBL260151
DMQJD4P	DT	Small molecular drug
DMQJD4P	PC	44450666
DMQJD4P	MW	426.6
DMQJD4P	FM	C29H34N2O
DMQJD4P	IC	InChI=1S/C29H34N2O/c32-27(20-23-10-4-1-5-11-23)22-30-18-19-31-21-26(30)16-17-28(31)29(24-12-6-2-7-13-24)25-14-8-3-9-15-25/h1-15,26-29,32H,16-22H2/t26-,27+,28-/m0/s1
DMQJD4P	CS	C1C[C@H](N2CCN([C@@H]1C2)C[C@@H](CC3=CC=CC=C3)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DMQJD4P	IK	WRZZCPUVRXRVCC-IARZGTGTSA-N
DMQJD4P	IU	(2R)-1-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-3-phenylpropan-2-ol
DMQJD4P	DE	Discovery agent

DMSON1P	ID	DMSON1P
DMSON1P	DN	D17.4
DMSON1P	HS	Investigative
DMSON1P	SN	26482-53-1; 2-(1-adamantyl)ethanamine; 2-(adamantan-1-yl)ethanamine; 1-C-Ethylaminoadamantane; Tricyclo[3.3.1.13,7]decane-1-ethanamine; 1-Adamantanethylamine; 1-adamantaneethanamine; 2-Adamantan-1-yl-ethylamine; 2-adamantanylethylamine; Tricyclo(3.3.1.13,7)decane-1-ethanamine; PubChem21555; Enamine_005504; D-174; 2-(1-adamantyl)ethylamine; AC1L20RI; 2-(2-amino)ethyladamantane; Oprea1_362282; 2-(Adamant-1-yl)ethylamine; SCHEMBL973650; CHEMBL341013; Mrz-2/174; CTK1A4494; DTXSID50181075; MolPort-002-464-537
DMSON1P	DT	Aptamer
DMSON1P	DE	Myasthenia gravis

DMU8BJH	ID	DMU8BJH
DMU8BJH	DN	D-189
DMU8BJH	HS	Investigative
DMU8BJH	SN	CHEMBL468834; D-189; SCHEMBL7877095; BDBM50261304
DMU8BJH	DT	Small molecular drug
DMU8BJH	PC	24866288
DMU8BJH	MW	367.5
DMU8BJH	FM	C22H33N5
DMU8BJH	IC	InChI=1S/C22H33N5/c1-2-10-26(21-8-9-22-19(17-21)18-23-24-22)14-11-25-12-15-27(16-13-25)20-6-4-3-5-7-20/h3-7,18,21H,2,8-17H2,1H3,(H,23,24)
DMU8BJH	CS	CCCN(CCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=C(C3)C=NN4
DMU8BJH	IK	LHOJVHKKDRWEEV-UHFFFAOYSA-N
DMU8BJH	IU	N-[2-(4-phenylpiperazin-1-yl)ethyl]-N-propyl-4,5,6,7-tetrahydro-1H-indazol-5-amine
DMU8BJH	DE	Discovery agent

DMUMNSW	ID	DMUMNSW
DMUMNSW	DN	D-190
DMUMNSW	HS	Investigative
DMUMNSW	SN	CHEMBL467767; D-190; BDBM50261335
DMUMNSW	DT	Small molecular drug
DMUMNSW	PC	24866294
DMUMNSW	MW	432.5
DMUMNSW	FM	C21H31N5Se
DMUMNSW	IC	InChI=1S/C21H31N5Se/c1-2-10-25(19-8-9-20-21(17-19)27-23-22-20)14-11-24-12-15-26(16-13-24)18-6-4-3-5-7-18/h3-7,19H,2,8-17H2,1H3
DMUMNSW	CS	CCCN(CCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=C(C3)[Se]N=N4
DMUMNSW	IK	PFIKDGAKWFWZIM-UHFFFAOYSA-N
DMUMNSW	IU	N-[2-(4-phenylpiperazin-1-yl)ethyl]-N-propyl-4,5,6,7-tetrahydro-1,2,3-benzoselenadiazol-6-amine
DMUMNSW	DE	Discovery agent

DM8D26T	ID	DM8D26T
DM8D26T	DN	D-192
DM8D26T	HS	Investigative
DM8D26T	SN	CHEMBL469182; D-192; SCHEMBL7885003; BDBM50261306
DM8D26T	DT	Small molecular drug
DM8D26T	PC	24866118
DM8D26T	MW	368.5
DM8D26T	FM	C22H32N4O
DM8D26T	IC	InChI=1S/C22H32N4O/c1-2-10-25(21-8-9-22-19(17-21)18-27-23-22)14-11-24-12-15-26(16-13-24)20-6-4-3-5-7-20/h3-7,18,21H,2,8-17H2,1H3
DM8D26T	CS	CCCN(CCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=NOC=C4C3
DM8D26T	IK	FVLVETKUEQQGET-UHFFFAOYSA-N
DM8D26T	IU	N-[2-(4-phenylpiperazin-1-yl)ethyl]-N-propyl-4,5,6,7-tetrahydro-2,1-benzoxazol-5-amine
DM8D26T	DE	Discovery agent

DMU83T7	ID	DMU83T7
DMU83T7	DN	D-193
DMU83T7	HS	Investigative
DMU83T7	SN	CHEMBL469181; D-193; BDBM50261305
DMU83T7	DT	Small molecular drug
DMU83T7	PC	24866290
DMU83T7	MW	368.5
DMU83T7	FM	C22H32N4O
DMU83T7	IC	InChI=1S/C22H32N4O/c1-2-10-25(21-8-9-22-19(17-21)18-23-27-22)14-11-24-12-15-26(16-13-24)20-6-4-3-5-7-20/h3-7,18,21H,2,8-17H2,1H3
DMU83T7	CS	CCCN(CCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=C(C3)C=NO4
DMU83T7	IK	SYVXHALPVYBOLF-UHFFFAOYSA-N
DMU83T7	IU	N-[2-(4-phenylpiperazin-1-yl)ethyl]-N-propyl-4,5,6,7-tetrahydro-1,2-benzoxazol-5-amine
DMU83T7	DE	Discovery agent

DMKPIH0	ID	DMKPIH0
DMKPIH0	DN	D-203
DMKPIH0	HS	Investigative
DMKPIH0	SN	CHEMBL468022; BDBM50261280
DMKPIH0	DT	Small molecular drug
DMKPIH0	PC	24866616
DMKPIH0	MW	427.7
DMKPIH0	FM	C24H37N5S
DMKPIH0	IC	InChI=1S/C24H37N5S/c1-2-12-28(21-10-11-22-23(19-21)30-24(25)26-22)14-7-6-13-27-15-17-29(18-16-27)20-8-4-3-5-9-20/h3-5,8-9,21H,2,6-7,10-19H2,1H3,(H2,25,26)
DMKPIH0	CS	CCCN(CCCCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=C(C3)SC(=N4)N
DMKPIH0	IK	AHNMVVBJGPOWFW-UHFFFAOYSA-N
DMKPIH0	IU	6-N-[4-(4-phenylpiperazin-1-yl)butyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMKPIH0	DE	Discovery agent

DMNLE4S	ID	DMNLE4S
DMNLE4S	DN	D-210
DMNLE4S	HS	Investigative
DMNLE4S	SN	CHEMBL468016; D-210; BDBM50261278; N6-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiaxole-2,6-diamine; (+)-N6-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine
DMNLE4S	DT	Small molecular drug
DMNLE4S	PC	24866614
DMNLE4S	MW	429.6
DMNLE4S	FM	C23H35N5OS
DMNLE4S	IC	InChI=1S/C23H35N5OS/c1-3-10-27(18-8-9-19-22(17-18)30-23(24)25-19)14-11-26-12-15-28(16-13-26)20-6-4-5-7-21(20)29-2/h4-7,18H,3,8-17H2,1-2H3,(H2,24,25)
DMNLE4S	CS	CCCN(CCN1CCN(CC1)C2=CC=CC=C2OC)C3CCC4=C(C3)SC(=N4)N
DMNLE4S	IK	WIZIUHWXARABLD-UHFFFAOYSA-N
DMNLE4S	IU	6-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMNLE4S	DE	Discovery agent

DMIBOAK	ID	DMIBOAK
DMIBOAK	DN	D-211A
DMIBOAK	HS	Investigative
DMIBOAK	SN	D-211A; CHEMBL263636; SCHEMBL10291414
DMIBOAK	DT	Small molecular drug
DMIBOAK	PC	44450649
DMIBOAK	MW	444.6
DMIBOAK	FM	C29H33FN2O
DMIBOAK	IC	InChI=1S/C29H33FN2O/c30-25-13-11-22(12-14-25)28(33)17-18-31-19-20-32-21-26(31)15-16-27(32)29(23-7-3-1-4-8-23)24-9-5-2-6-10-24/h1-14,26-29,33H,15-21H2/t26-,27-,28+/m0/s1
DMIBOAK	CS	C1C[C@H](N2CCN([C@@H]1C2)CC[C@H](C3=CC=C(C=C3)F)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DMIBOAK	IK	GAKAYJNKCDLKCE-HZFUHODCSA-N
DMIBOAK	IU	(1R)-3-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-1-(4-fluorophenyl)propan-1-ol
DMIBOAK	DE	Discovery agent

DM54CKZ	ID	DM54CKZ
DM54CKZ	DN	D-211B
DM54CKZ	HS	Investigative
DM54CKZ	SN	D-211B; CHEMBL260682
DM54CKZ	DT	Small molecular drug
DM54CKZ	PC	44450635
DM54CKZ	MW	444.6
DM54CKZ	FM	C29H33FN2O
DM54CKZ	IC	InChI=1S/C29H33FN2O/c30-25-13-11-22(12-14-25)28(33)17-18-31-19-20-32-21-26(31)15-16-27(32)29(23-7-3-1-4-8-23)24-9-5-2-6-10-24/h1-14,26-29,33H,15-21H2/t26-,27-,28-/m0/s1
DM54CKZ	CS	C1C[C@H](N2CCN([C@@H]1C2)CC[C@@H](C3=CC=C(C=C3)F)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM54CKZ	IK	GAKAYJNKCDLKCE-KCHLEUMXSA-N
DM54CKZ	IU	(1S)-3-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-1-(4-fluorophenyl)propan-1-ol
DM54CKZ	DE	Discovery agent

DMQLT84	ID	DMQLT84
DMQLT84	DN	D-218
DMQLT84	HS	Investigative
DMQLT84	SN	CHEMBL513352; D-218; BDBM50261302
DMQLT84	DT	Small molecular drug
DMQLT84	PC	44577151
DMQLT84	MW	425.6
DMQLT84	FM	C23H31N5OS
DMQLT84	IC	InChI=1S/C23H31N5OS/c1-3-10-27(18-8-9-19-22(17-18)30-23(24)25-19)14-11-26-12-15-28(16-13-26)20-6-4-5-7-21(20)29-2/h1,4-7,18H,8-17H2,2H3,(H2,24,25)
DMQLT84	CS	COC1=CC=CC=C1N2CCN(CC2)CCN(CC#C)C3CCC4=C(C3)SC(=N4)N
DMQLT84	IK	GUCAXHFLECNGRL-UHFFFAOYSA-N
DMQLT84	IU	6-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-6-N-prop-2-ynyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMQLT84	DE	Discovery agent

DMQ2U4G	ID	DMQ2U4G
DMQ2U4G	DN	D-219
DMQ2U4G	HS	Investigative
DMQ2U4G	SN	CHEMBL468017; D-219; BDBM50261279; N6-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiaxole-2,6-diamine; (-)-N6-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine
DMQ2U4G	DT	Small molecular drug
DMQ2U4G	PC	24866114
DMQ2U4G	MW	468.5
DMQ2U4G	FM	C22H31Cl2N5S
DMQ2U4G	IC	InChI=1S/C22H31Cl2N5S/c1-2-8-28(16-6-7-18-20(15-16)30-22(25)26-18)12-9-27-10-13-29(14-11-27)19-5-3-4-17(23)21(19)24/h3-5,16H,2,6-15H2,1H3,(H2,25,26)
DMQ2U4G	CS	CCCN(CCN1CCN(CC1)C2=C(C(=CC=C2)Cl)Cl)C3CCC4=C(C3)SC(=N4)N
DMQ2U4G	IK	MTSRJJUOIYINNP-UHFFFAOYSA-N
DMQ2U4G	IU	6-N-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMQ2U4G	DE	Discovery agent

DMTUJWN	ID	DMTUJWN
DMTUJWN	DN	D-220
DMTUJWN	HS	Investigative
DMTUJWN	SN	CHEMBL468833; D-220; BDBM50261303
DMTUJWN	DT	Small molecular drug
DMTUJWN	PC	44577152
DMTUJWN	MW	464.5
DMTUJWN	FM	C22H27Cl2N5S
DMTUJWN	IC	InChI=1S/C22H27Cl2N5S/c1-2-8-28(16-6-7-18-20(15-16)30-22(25)26-18)12-9-27-10-13-29(14-11-27)19-5-3-4-17(23)21(19)24/h1,3-5,16H,6-15H2,(H2,25,26)
DMTUJWN	CS	C#CCN(CCN1CCN(CC1)C2=C(C(=CC=C2)Cl)Cl)C3CCC4=C(C3)SC(=N4)N
DMTUJWN	IK	AWFHSDHVMOYPMI-UHFFFAOYSA-N
DMTUJWN	IU	6-N-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]-6-N-prop-2-ynyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMTUJWN	DE	Discovery agent

DMGA48T	ID	DMGA48T
DMGA48T	DN	D-237
DMGA48T	HS	Investigative
DMGA48T	SN	CHEMBL457025; BDBM50273939; (R)-6-((2-(4-phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol
DMGA48T	DT	Small molecular drug
DMGA48T	PC	24754478
DMGA48T	MW	393.6
DMGA48T	FM	C25H35N3O
DMGA48T	IC	InChI=1S/C25H35N3O/c1-2-13-27(23-11-12-24-21(20-23)7-6-10-25(24)29)17-14-26-15-18-28(19-16-26)22-8-4-3-5-9-22/h3-10,23,29H,2,11-20H2,1H3/t23-/m1/s1
DMGA48T	CS	CCCN(CCN1CCN(CC1)C2=CC=CC=C2)[C@@H]3CCC4=C(C3)C=CC=C4O
DMGA48T	IK	ACDYFMOSSUKHJD-HSZRJFAPSA-N
DMGA48T	IU	(6R)-6-[2-(4-phenylpiperazin-1-yl)ethyl-propylamino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMGA48T	DE	Discovery agent

DM6KFCO	ID	DM6KFCO
DM6KFCO	DN	D-254C
DM6KFCO	HS	Investigative
DM6KFCO	SN	D-254C; CHEMBL258725; SCHEMBL4886148
DM6KFCO	DT	Small molecular drug
DM6KFCO	PC	16040321
DM6KFCO	MW	400.6
DM6KFCO	FM	C27H32N2O
DM6KFCO	IC	InChI=1S/C27H32N2O/c30-25(18-21-10-4-1-5-11-21)20-28-24-16-17-26(29-19-24)27(22-12-6-2-7-13-22)23-14-8-3-9-15-23/h1-15,24-30H,16-20H2/t24-,25+,26-/m0/s1
DM6KFCO	CS	C1C[C@H](NC[C@H]1NC[C@@H](CC2=CC=CC=C2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DM6KFCO	IK	YKFRXVGLZNKBAS-NXCFDTQHSA-N
DM6KFCO	IU	(2R)-1-[[(3S,6S)-6-benzhydrylpiperidin-3-yl]amino]-3-phenylpropan-2-ol
DM6KFCO	DE	Discovery agent

DMN7E6Y	ID	DMN7E6Y
DMN7E6Y	DN	D-257A
DMN7E6Y	HS	Investigative
DMN7E6Y	SN	D-257A; CHEMBL409881
DMN7E6Y	DT	Small molecular drug
DMN7E6Y	PC	44450664
DMN7E6Y	MW	412.6
DMN7E6Y	FM	C28H32N2O
DMN7E6Y	IC	InChI=1S/C28H32N2O/c31-27(22-10-4-1-5-11-22)21-29-18-19-30-20-25(29)16-17-26(30)28(23-12-6-2-7-13-23)24-14-8-3-9-15-24/h1-15,25-28,31H,16-21H2/t25-,26-,27-/m0/s1
DMN7E6Y	CS	C1C[C@H](N2CCN([C@@H]1C2)C[C@@H](C3=CC=CC=C3)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DMN7E6Y	IK	OWLHXXQEBCXCEF-QKDODKLFSA-N
DMN7E6Y	IU	(1R)-2-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-1-phenylethanol
DMN7E6Y	DE	Discovery agent

DM5GLJ2	ID	DM5GLJ2
DM5GLJ2	DN	D-257C
DM5GLJ2	HS	Investigative
DM5GLJ2	SN	D-257C; CHEMBL408950
DM5GLJ2	DT	Small molecular drug
DM5GLJ2	PC	44450651
DM5GLJ2	MW	430.6
DM5GLJ2	FM	C28H31FN2O
DM5GLJ2	IC	InChI=1S/C28H31FN2O/c29-24-13-11-21(12-14-24)27(32)20-30-17-18-31-19-25(30)15-16-26(31)28(22-7-3-1-4-8-22)23-9-5-2-6-10-23/h1-14,25-28,32H,15-20H2/t25-,26-,27-/m0/s1
DM5GLJ2	CS	C1C[C@H](N2CCN([C@@H]1C2)C[C@@H](C3=CC=C(C=C3)F)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM5GLJ2	IK	FESQDZTUIIZPPV-QKDODKLFSA-N
DM5GLJ2	IU	(1R)-2-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-1-(4-fluorophenyl)ethanol
DM5GLJ2	DE	Discovery agent

DMWLHBQ	ID	DMWLHBQ
DMWLHBQ	DN	D-264
DMWLHBQ	HS	Investigative
DMWLHBQ	SN	D-264; CHEMBL514885; SCHEMBL10075564; BDBM50273996; (S)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine
DMWLHBQ	DT	Small molecular drug
DMWLHBQ	PC	24866612
DMWLHBQ	MW	475.7
DMWLHBQ	FM	C28H37N5S
DMWLHBQ	IC	InChI=1S/C28H37N5S/c1-2-14-32(25-12-13-26-27(21-25)34-28(29)30-26)18-15-31-16-19-33(20-17-31)24-10-8-23(9-11-24)22-6-4-3-5-7-22/h3-11,25H,2,12-21H2,1H3,(H2,29,30)/t25-/m0/s1
DMWLHBQ	CS	CCCN(CCN1CCN(CC1)C2=CC=C(C=C2)C3=CC=CC=C3)[C@H]4CCC5=C(C4)SC(=N5)N
DMWLHBQ	IK	YDLWLYDTYNHXBM-VWLOTQADSA-N
DMWLHBQ	IU	(6S)-6-N-[2-[4-(4-phenylphenyl)piperazin-1-yl]ethyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMWLHBQ	DE	Discovery agent

DMG1CD5	ID	DMG1CD5
DMG1CD5	DN	D-315
DMG1CD5	HS	Investigative
DMG1CD5	SN	CHEMBL456825; D-315; SCHEMBL10075562; BDBM50273937; (R)-7-((2-(4-phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-2-ol
DMG1CD5	DT	Small molecular drug
DMG1CD5	PC	44588498
DMG1CD5	MW	393.6
DMG1CD5	FM	C25H35N3O
DMG1CD5	IC	InChI=1S/C25H35N3O/c1-2-12-27(24-10-8-21-9-11-25(29)20-22(21)19-24)16-13-26-14-17-28(18-15-26)23-6-4-3-5-7-23/h3-7,9,11,20,24,29H,2,8,10,12-19H2,1H3/t24-/m1/s1
DMG1CD5	CS	CCCN(CCN1CCN(CC1)C2=CC=CC=C2)[C@@H]3CCC4=C(C3)C=C(C=C4)O
DMG1CD5	IK	POVCSYONXDMZKL-XMMPIXPASA-N
DMG1CD5	IU	(7R)-7-[2-(4-phenylpiperazin-1-yl)ethyl-propylamino]-5,6,7,8-tetrahydronaphthalen-2-ol
DMG1CD5	DE	Discovery agent

DMZAM3G	ID	DMZAM3G
DMZAM3G	DN	D-366
DMZAM3G	HS	Investigative
DMZAM3G	SN	CHEMBL569746; D-366; BDBM50303793; (S)-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)(1H-indol-2-yl)methanone
DMZAM3G	DT	Small molecular drug
DMZAM3G	PC	45486362
DMZAM3G	MW	460.6
DMZAM3G	FM	C28H36N4O2
DMZAM3G	IC	InChI=1S/C28H36N4O2/c1-2-12-31(23-10-11-24-21(19-23)7-5-9-27(24)33)16-13-30-14-17-32(18-15-30)28(34)26-20-22-6-3-4-8-25(22)29-26/h3-9,20,23,29,33H,2,10-19H2,1H3/t23-/m0/s1
DMZAM3G	CS	CCCN(CCN1CCN(CC1)C(=O)C2=CC3=CC=CC=C3N2)[C@H]4CCC5=C(C4)C=CC=C5O
DMZAM3G	IK	DQMMOHPPKACCQN-QHCPKHFHSA-N
DMZAM3G	IU	[4-[2-[[(2S)-5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl]-propylamino]ethyl]piperazin-1-yl]-(1H-indol-2-yl)methanone
DMZAM3G	DE	Discovery agent

DM048OG	ID	DM048OG
DM048OG	DN	D-420720
DM048OG	HS	Investigative
DM048OG	SN	Dipeptidyl peptidase inhibitor (diabetes), Development Centre for Biotechnology
DM048OG	CP	Development Centre for Biotechnology
DM048OG	DE	Diabetic complication

DM0M81E	ID	DM0M81E
DM0M81E	DN	D609
DM0M81E	HS	Investigative
DM0M81E	SN	D609; O-(Octahydro-4,7-methano-1H-inden-5-yl) carbonopotassium dithioate; D609 potassium salt; Carbonodithioic acid, O-(octahydro-4,7-methano-1H-inden-5-yl) ester potassium; SCHEMBL15720168; tricyclodecan-9-yl xanthogenate k; Tricyclodecan-9-yl xanthogenate potassium salt; o-tricyclo[5.2.1.0(2,6)]dec-9-yl dithiocarbonate potassium salt
DM0M81E	DT	Small molecular drug
DM0M81E	PC	4234241
DM0M81E	MW	266.5
DM0M81E	FM	C11H15KOS2
DM0M81E	IC	InChI=1S/C11H16OS2.K/c13-11(14)12-10-5-6-4-9(10)8-3-1-2-7(6)8;/h6-10H,1-5H2,(H,13,14);/q;+1/p-1
DM0M81E	CS	C1CC2C(C1)C3CC2CC3OC(=S)[S-].[K+]
DM0M81E	IK	IGULCCCBGBDZKQ-UHFFFAOYSA-M
DM0M81E	IU	potassium;8-tricyclo[5.2.1.02,6]decanyloxymethanedithioate
DM0M81E	CA	CAS 83373-60-8
DM0M81E	DE	Discovery agent

DM0A54V	ID	DM0A54V
DM0A54V	DN	D-65476
DM0A54V	HS	Investigative
DM0A54V	SN	bis(1H-2-indolyl)methanone deriv. 52
DM0A54V	DT	Small molecular drug
DM0A54V	PC	5330548
DM0A54V	MW	346.4
DM0A54V	FM	C21H18N2O3
DM0A54V	IC	InChI=1S/C21H18N2O3/c1-2-5-20(24)26-15-8-9-17-14(10-15)12-19(23-17)21(25)18-11-13-6-3-4-7-16(13)22-18/h3-4,6-12,22-23H,2,5H2,1H3
DM0A54V	CS	CCCC(=O)OC1=CC2=C(C=C1)NC(=C2)C(=O)C3=CC4=CC=CC=C4N3
DM0A54V	IK	CZDUJGOCEPWCNA-UHFFFAOYSA-N
DM0A54V	IU	[2-(1H-indole-2-carbonyl)-1H-indol-5-yl] butanoate
DM0A54V	DE	Discovery agent

DM54T8J	ID	DM54T8J
DM54T8J	DN	DAB-486-IL-2
DM54T8J	HS	Investigative
DM54T8J	SN	153641-26-0
DM54T8J	DE	Discovery agent

DMHZKMG	ID	DMHZKMG
DMHZKMG	DN	DABCO
DMHZKMG	HS	Investigative
DMHZKMG	SN	1,4-Diazabicyclo[2.2.2]octane; Triethylenediamine; 280-57-9; Dabco; Dabco 33LV; 1,4-Ethylenepiperazine; 1,4-DIAZABICYCLO(2.2.2)OCTANE; Dabco crystal; TEDA; Texacat TD 100; N,N'-endo-Ethylenepiperazine; Dabco S-25; D 33LV; Dabco EG; 1,4-Diazabicyclo-octane; Dabco R-8020; 1,4-Diazobicyclo(2.2.2)octane; Thancat TD 33; Bicyclo(2,2,2)-1,4-diazaoctane; 1,4-diazabicyclooctane; 1,4-diazabicyclo[2,2,2]octane; 1,4-diaza-bicyclo[2.2.2]octane; UNII-X8M57R0JS5; NSC 56362; CCRIS 6692; TED; HSDB 5556; 1,4-Diaza[2.2.2]bicyclooctane; EINECS 205-999-9
DMHZKMG	DT	Small molecular drug
DMHZKMG	PC	9237
DMHZKMG	MW	112.17
DMHZKMG	FM	C6H12N2
DMHZKMG	IC	InChI=1S/C6H12N2/c1-2-8-5-3-7(1)4-6-8/h1-6H2
DMHZKMG	CS	C1CN2CCN1CC2
DMHZKMG	IK	IMNIMPAHZVJRPE-UHFFFAOYSA-N
DMHZKMG	IU	1,4-diazabicyclo[2.2.2]octane
DMHZKMG	CA	CAS 280-57-9
DMHZKMG	CB	CHEBI:151129
DMHZKMG	DE	Discovery agent

DMN3GTF	ID	DMN3GTF
DMN3GTF	DN	DABCO-C16
DMN3GTF	HS	Investigative
DMN3GTF	SN	TA279; C16-1,4-Diazabicyclo[2.2.2]octane
DMN3GTF	DT	Small molecular drug
DMN3GTF	PC	11611423
DMN3GTF	MW	337.6
DMN3GTF	FM	C22H45N2+
DMN3GTF	IC	InChI=1S/C22H45N2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-24-20-16-23(17-21-24)18-22-24/h2-22H2,1H3/q+1
DMN3GTF	CS	CCCCCCCCCCCCCCCC[N+]12CCN(CC1)CC2
DMN3GTF	IK	YPKLQHHICPWJRD-UHFFFAOYSA-N
DMN3GTF	IU	1-hexadecyl-4-aza-1-azoniabicyclo[2.2.2]octane
DMN3GTF	DE	Discovery agent

DMCNAME	ID	DMCNAME
DMCNAME	DN	DACTHF
DMCNAME	HS	Investigative
DMCNAME	SN	Deazaacyclotetrahydrofolate; 5-deazaacyclotetrahydrofolate; 5-DACTHF
DMCNAME	DE	Discovery agent

DMRM0OW	ID	DMRM0OW
DMRM0OW	DN	Dadle
DMRM0OW	HS	Investigative
DMRM0OW	SN	Dadle; 63631-40-3; H-TYR-D-ALA-GLY-PHE-D-LEU-OH; DADL; (D-Ala2,D-Leu5)-Enkephalin; [D-Ala2, D-Leu5]-enkephalin; CHEMBL340032; BW-180C; Tyr-D-Ala-Gly-Phe-D-Leu; (2R,5S,11R,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-isobutyl-11-methyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic acid; (2R)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid; UNII-HB4QD9GL6F; HB4QD9GL6F; DADLE-OH; AC1OCEJN; ZINC14952092; H-Tyr-D-Ala-Gly-Phe-D-Leu
DMRM0OW	DT	Small molecular drug
DMRM0OW	PC	6917707
DMRM0OW	MW	569.6
DMRM0OW	FM	C29H39N5O7
DMRM0OW	IC	InChI=1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1
DMRM0OW	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMRM0OW	IK	ZHUJMSMQIPIPTF-IBURTVSXSA-N
DMRM0OW	IU	(2R)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMRM0OW	CA	CAS 63631-40-3
DMRM0OW	DE	Discovery agent

DMJIFY3	ID	DMJIFY3
DMJIFY3	DN	DADMe-ImmG
DMJIFY3	HS	Investigative
DMJIFY3	PC	135415984
DMJIFY3	MW	279.3
DMJIFY3	FM	C12H17N5O3
DMJIFY3	IC	InChI=1S/C12H17N5O3/c13-12-15-9-6(1-14-10(9)11(20)16-12)2-17-3-7(5-18)8(19)4-17/h1,7-8,14,18-19H,2-5H2,(H3,13,15,16,20)/t7-,8+/m1/s1
DMJIFY3	CS	C1[C@@H]([C@H](CN1CC2=CNC3=C2N=C(NC3=O)N)O)CO
DMJIFY3	IK	GSPTUGDLYPMLCQ-SFYZADRCSA-N
DMJIFY3	IU	2-amino-7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMJIFY3	CA	CAS 548486-61-9
DMJIFY3	DE	Discovery agent

DMWR3XL	ID	DMWR3XL
DMWR3XL	DN	DAEDALIN A
DMWR3XL	HS	Investigative
DMWR3XL	SN	CHEMBL602533; CHEBI:65721; (2R)-2-(hydroxymethyl)-2-methyl-2H-chromen-6-ol
DMWR3XL	DT	Small molecular drug
DMWR3XL	PC	46216805
DMWR3XL	MW	192.21
DMWR3XL	FM	C11H12O3
DMWR3XL	IC	InChI=1S/C11H12O3/c1-11(7-12)5-4-8-6-9(13)2-3-10(8)14-11/h2-6,12-13H,7H2,1H3/t11-/m1/s1
DMWR3XL	CS	C[C@@]1(C=CC2=C(O1)C=CC(=C2)O)CO
DMWR3XL	IK	LTKJWSBGTNWRNP-LLVKDONJSA-N
DMWR3XL	IU	(2R)-2-(hydroxymethyl)-2-methylchromen-6-ol
DMWR3XL	CB	CHEBI:65721
DMWR3XL	DE	Discovery agent

DMRFTJX	ID	DMRFTJX
DMRFTJX	DN	Daidzein
DMRFTJX	HS	Investigative
DMRFTJX	SN	Daidzein; 486-66-8; 4',7-Dihydroxyisoflavone; Daidzeol; 7,4'-Dihydroxyisoflavone; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; UNII-6287WC5J2L; CCRIS 7600; K 251b; 4,7-Dihydroxyisoflavone; EINECS 207-635-4; BRN 0231523; CHEMBL8145; 4',7-Dihydroxy-iso-flavone; d-(+)-alpha-methylbenzylamine; ,7-Dihydroxyisoflavone; 7,4'-dihydroxyisoflavone; DIADZEIN
DMRFTJX	DT	Small molecular drug
DMRFTJX	PC	5281708
DMRFTJX	MW	254.24
DMRFTJX	FM	C15H10O4
DMRFTJX	IC	InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H
DMRFTJX	CS	C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O
DMRFTJX	IK	ZQSIJRDFPHDXIC-UHFFFAOYSA-N
DMRFTJX	IU	7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one
DMRFTJX	CA	CAS 486-66-8
DMRFTJX	CB	CHEBI:28197
DMRFTJX	DE	Discovery agent

DM3M652	ID	DM3M652
DM3M652	DN	Daio-Orengedokuto (DOT)
DM3M652	HS	Investigative
DM3M652	SN	26159-34-2; Miranax; Naproxen sodium salt; Synflex; Naprodol; Naprodil; Leniartril; Gibixen; Floxalin; Flogogin; Aprowell; Anapran; Primeral; Pactens; Naprovite; Gibinap; Floneks; Anaprotab; Monarit; Karoksen; Sodimax; Natrioxen; Floginex; Opraks; Kapnax; Tandax; Flogen; Nixal; Aprol; Naprux Gesic; Causalon Pro; Naproxen natrium; Axer Alfa; Dysmenalgit; Veradol; Naprium; Diocodal; Proxen; Prexan; Naprux; A-Nox; Xenar; Laser; Apo-Napro-NA; UNII-9TN87S3A3C; sodium na
DM3M652	DT	Small molecular drug
DM3M652	PC	23681059
DM3M652	MW	252.24
DM3M652	FM	C14H13NaO3
DM3M652	IC	InChI=1S/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/m0./s1
DM3M652	CS	C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-].[Na+]
DM3M652	IK	CDBRNDSHEYLDJV-FVGYRXGTSA-M
DM3M652	IU	sodium;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DM3M652	CA	CAS 26159-34-2
DM3M652	CB	CHEBI:7477
DM3M652	DE	Discovery agent

DMVIDQL	ID	DMVIDQL
DMVIDQL	DN	D-alanine
DMVIDQL	HS	Investigative
DMVIDQL	SN	D-alanine; 338-69-2; H-D-Ala-OH; (2R)-2-aminopropanoic acid; (R)-Alanine; (R)-2-aminopropanoic acid; D-2-Aminopropionic acid; D-alpha-Alanine; Alanine, D-; Alanine D-form; D-Alanin; (R)-2-Aminopropionic acid; D-alpha-Aminopropionsaeure; (R)-2-Aminopropionsaeure; Ba 2776; D-alpha-aminopropionic acid; UNII-E3UDS4613U; D-.alpha.-Alanine; D-(-)-Alanine; CHEMBL66693; E3UDS4613U; CHEBI:15570; QNAYBMKLOCPYGJ-UWTATZPHSA-N; MFCD00008077; DAL; NCGC00024493-02; D-Alanine, 99+%; DSSTox_RID_81027; DSSTox_CID_25649; DSSTox_GSID_45649
DMVIDQL	DT	Small molecular drug
DMVIDQL	PC	71080
DMVIDQL	MW	89.09
DMVIDQL	FM	C3H7NO2
DMVIDQL	IC	InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m1/s1
DMVIDQL	CS	C[C@H](C(=O)O)N
DMVIDQL	IK	QNAYBMKLOCPYGJ-UWTATZPHSA-N
DMVIDQL	IU	(2R)-2-aminopropanoic acid
DMVIDQL	CA	CAS 338-69-2
DMVIDQL	CB	CHEBI:15570
DMVIDQL	DE	Discovery agent

DMS1DVA	ID	DMS1DVA
DMS1DVA	DN	DAMGO
DMS1DVA	HS	Investigative
DMS1DVA	SN	DAMGO; DAGO; glyol; Dagol; DAMGE; 78123-71-4; 2-Ala-4-mephe-5-gly-enkephalin; Tyr-ala-gly-(nme)phe-gly-ol; Enkephalin, ala(2)-mephe(4)-gly(5)-; RX 783006; (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin; Ala(2)-mephe(4)-gly-ol(5) enkephalin; CHEBI:272; CHEMBL38874; Tyr-D-Ala-Gly-MePhe-Gly-ol; Enkephalin, Ala(2)-MePhe(4)-Gly-ol(5)-; H-Tyr-D-Ala-Gly-N-Me-Phe-Glycinol; Enkephalin, alanyl(2)-methylphenylalanyl(4)-glycine(5)-; [3H]DAMGO; L-Phenylalaninamide, L-tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nalpha-methyl-
DMS1DVA	DT	Small molecular drug
DMS1DVA	PC	5462471
DMS1DVA	MW	513.6
DMS1DVA	FM	C26H35N5O6
DMS1DVA	IC	InChI=1S/C26H35N5O6/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36)/t17-,21+,22+/m1/s1
DMS1DVA	CS	C[C@H](C(=O)NCC(=O)N(C)[C@@H](CC1=CC=CC=C1)C(=O)NCCO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMS1DVA	IK	HPZJMUBDEAMBFI-WTNAPCKOSA-N
DMS1DVA	IU	(2S)-2-amino-N-[(2R)-1-[[2-[[(2S)-1-(2-hydroxyethylamino)-1-oxo-3-phenylpropan-2-yl]-methylamino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
DMS1DVA	CA	CAS 78123-71-4
DMS1DVA	CB	CHEBI:272
DMS1DVA	DE	Discovery agent

DMXM7JR	ID	DMXM7JR
DMXM7JR	DN	daminozide
DMXM7JR	HS	Investigative
DMXM7JR	SN	DMASA; SADH; B 995; Alar; Kylar; B-NINE
DMXM7JR	DT	Small molecular drug
DMXM7JR	PC	15331
DMXM7JR	MW	160.17
DMXM7JR	FM	C6H12N2O3
DMXM7JR	IC	InChI=1S/C6H12N2O3/c1-8(2)7-5(9)3-4-6(10)11/h3-4H2,1-2H3,(H,7,9)(H,10,11)
DMXM7JR	CS	CN(C)NC(=O)CCC(=O)O
DMXM7JR	IK	NOQGZXFMHARMLW-UHFFFAOYSA-N
DMXM7JR	IU	4-(2,2-dimethylhydrazinyl)-4-oxobutanoic acid
DMXM7JR	CA	CAS 1596-84-5
DMXM7JR	CB	CHEBI:4312
DMXM7JR	DE	Discovery agent

DMQ4L1I	ID	DMQ4L1I
DMQ4L1I	DN	Dansylamide
DMQ4L1I	HS	Investigative
DMQ4L1I	SN	Dansylamide; 1431-39-6; 5-(dimethylamino)naphthalene-1-sulfonamide; 5-DIMETHYLAMINO-1-NAPHTHALENESULFONAMIDE; Dansyl amide; 5-Dimethylaminonaphthalene-1-sulfonamide; 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONAMIDE; TYNBFJJKZPTRKS-UHFFFAOYSA-N; 5-[Dimethylamino]-1-naphthalenesulfonamide; 1-Naphthalenesulfonamide, 5-(dimethylamino)-; 1okl; EINECS 215-854-1; AC1Q3WHH; 5-(Dimethylamino)naphthalene-1-sulphonamide; AC1L22JG; Oprea1_628153; SCHEMBL108421; CHEMBL119489; ZINC56543; BDBM11402; TYNBFJJKZPTRKS-UHFFFAOYSA-; DTXSID70162306
DMQ4L1I	DT	Small molecular drug
DMQ4L1I	PC	65077
DMQ4L1I	MW	250.32
DMQ4L1I	FM	C12H14N2O2S
DMQ4L1I	IC	InChI=1S/C12H14N2O2S/c1-14(2)11-7-3-6-10-9(11)5-4-8-12(10)17(13,15)16/h3-8H,1-2H3,(H2,13,15,16)
DMQ4L1I	CS	CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)N
DMQ4L1I	IK	TYNBFJJKZPTRKS-UHFFFAOYSA-N
DMQ4L1I	IU	5-(dimethylamino)naphthalene-1-sulfonamide
DMQ4L1I	CA	CAS 1431-39-6
DMQ4L1I	DE	Discovery agent

DM2WS8B	ID	DM2WS8B
DM2WS8B	DN	D-AP4
DM2WS8B	HS	Investigative
DM2WS8B	SN	D-AP4; 78739-01-2; (2R)-2-amino-4-phosphonobutanoic acid; (R)-2-Amino-4-phosphonobutanoic acid; d(-)-2-amino-4-phosphonobutyric acid; Tocris-0101; Tocris-0102; D-APB; AC1LT3KN; Lopac-A-1910; GTPL1443; SCHEMBL12648443; CHEMBL1319383; CTK2I0929; BDBM82006; MolPort-004-956-473; ZINC1656225; PDSP1_000361; PDSP2_000359; BN0083; (r)-2-amino-4-phosphonobutyric acid; AKOS024456336; FCH3604711; API0009835; NCGC00024467-01; D-(-)-2-Amino-4-phosphonobutyric acid; NCGC00024466-01; NCGC00015041-02; NCGC00015041-01; B6201; FT-0772107; Butanoic acid, 2
DM2WS8B	DT	Small molecular drug
DM2WS8B	PC	1550579
DM2WS8B	MW	183.1
DM2WS8B	FM	C4H10NO5P
DM2WS8B	IC	InChI=1S/C4H10NO5P/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H2,8,9,10)/t3-/m1/s1
DM2WS8B	CS	C(CP(=O)(O)O)[C@H](C(=O)O)N
DM2WS8B	IK	DDOQBQRIEWHWBT-GSVOUGTGSA-N
DM2WS8B	IU	(2R)-2-amino-4-phosphonobutanoic acid
DM2WS8B	DE	Discovery agent

DMY5OTN	ID	DMY5OTN
DMY5OTN	DN	d-AP5
DMY5OTN	HS	Investigative
DMY5OTN	SN	D-AP-5; D-aminophosphonovaleric acid
DMY5OTN	DT	Small molecular drug
DMY5OTN	PC	135342
DMY5OTN	MW	197.13
DMY5OTN	FM	C5H12NO5P
DMY5OTN	IC	InChI=1S/C5H12NO5P/c6-4(5(7)8)2-1-3-12(9,10)11/h4H,1-3,6H2,(H,7,8)(H2,9,10,11)/t4-/m1/s1
DMY5OTN	CS	C(C[C@H](C(=O)O)N)CP(=O)(O)O
DMY5OTN	IK	VOROEQBFPPIACJ-SCSAIBSYSA-N
DMY5OTN	IU	(2R)-2-amino-5-phosphonopentanoic acid
DMY5OTN	CA	CAS 79055-68-8
DMY5OTN	DE	Discovery agent

DMZ4Q0B	ID	DMZ4Q0B
DMZ4Q0B	DN	Dasatinib
DMZ4Q0B	HS	Investigative
DMZ4Q0B	SN	Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
DMZ4Q0B	CP	Bristol Myers Squibb
DMZ4Q0B	TC	Antiviral Agents
DMZ4Q0B	DT	Small molecular drug
DMZ4Q0B	PC	3062316
DMZ4Q0B	MW	488
DMZ4Q0B	FM	C22H26ClN7O2S
DMZ4Q0B	IC	InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
DMZ4Q0B	CS	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
DMZ4Q0B	IK	ZBNZXTGUTAYRHI-UHFFFAOYSA-N
DMZ4Q0B	IU	N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DMZ4Q0B	CA	CAS 302962-49-8
DMZ4Q0B	CB	CHEBI:49375
DMZ4Q0B	DE	Chronic myelogenous leukaemia; Multiple myeloma; Parkinson disease; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM7Z892	ID	DM7Z892
DM7Z892	DN	D-aspartic acid
DM7Z892	HS	Investigative
DM7Z892	SN	D-Aspartic acid; 1783-96-6; (R)-2-aminosuccinic acid; D-Aspartate; H-D-Asp-OH; (-)-Aspartic acid; (R)-Aspartic acid; Aspartic acid D-form; (2R)-2-aminobutanedioic acid; Aspartic acid, D-; D-(-)-Aspartic acid; (R)-(-)-Aminosuccinic acid; D-Asp; D-Aminosuccinic acid; NSC 97922; D-Asparaginsaeure; UNII-4SR0Q8YD1X; BRN 1723529; Tocris-0213; EINECS 217-234-6; 4SR0Q8YD1X; (R)-2-aminobutanedioic acid; CHEMBL29757; CHEBI:17364; CKLJMWTZIZZHCS-UWTATZPHSA-N; MFCD00063081; NCGC00024498-02; (R)-2-Aminobutanedioate; D(-)-Aspartic acid, 99+%;  D-aspartate; [3H]D-aspartic acid
DM7Z892	DT	Small molecular drug
DM7Z892	PC	83887
DM7Z892	MW	133.1
DM7Z892	FM	C4H7NO4
DM7Z892	IC	InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m1/s1
DM7Z892	CS	C([C@H](C(=O)O)N)C(=O)O
DM7Z892	IK	CKLJMWTZIZZHCS-UWTATZPHSA-N
DM7Z892	IU	(2R)-2-aminobutanedioic acid
DM7Z892	CA	CAS 1783-96-6
DM7Z892	CB	CHEBI:17364
DM7Z892	DE	Discovery agent

DMMXFBJ	ID	DMMXFBJ
DMMXFBJ	DN	dATP
DMMXFBJ	HS	Investigative
DMMXFBJ	SN	deoxyadenosine triphosphate
DMMXFBJ	DT	Small molecular drug
DMMXFBJ	PC	15993
DMMXFBJ	MW	491.18
DMMXFBJ	FM	C10H16N5O12P3
DMMXFBJ	IC	InChI=1S/C10H16N5O12P3/c11-9-8-10(13-3-12-9)15(4-14-8)7-1-5(16)6(25-7)2-24-29(20,21)27-30(22,23)26-28(17,18)19/h3-7,16H,1-2H2,(H,20,21)(H,22,23)(H2,11,12,13)(H2,17,18,19)/t5-,6+,7+/m0/s1
DMMXFBJ	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O
DMMXFBJ	IK	SUYVUBYJARFZHO-RRKCRQDMSA-N
DMMXFBJ	IU	[[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMMXFBJ	CA	CAS 1927-31-7
DMMXFBJ	CB	CHEBI:16284
DMMXFBJ	DE	Discovery agent

DMRDX8U	ID	DMRDX8U
DMRDX8U	DN	dATPalphaS
DMRDX8U	HS	Investigative
DMRDX8U	SN	Datpalphas; [[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate; 2'-Deoxyadenosine 5'-O-(1-thiotriphosphate); alpha-Thio-datp; Sp-Datp alpha S; Sp-dATP-.alpha.-S; AC1L51OG; SCHEMBL222923; GTPL1715; CHEMBL2390988; alpha-Thiodeoxyadenosine triphosphate; Deoxyadenosine 5'-(alpha-thio)triphosphate; 2'-deoxyadenosine-5'-O-(1-thiotriphosphate); (Sp-)2'- Deoxyadenosine- 5'- O- (.alpha.-thiotriphosphate); Adenosine, 2'-deoxy-, 5'-P''-ester with thiotriphosphoric ac
DMRDX8U	DT	Small molecular drug
DMRDX8U	PC	196416
DMRDX8U	MW	507.25
DMRDX8U	FM	C10H16N5O11P3S
DMRDX8U	IC	InChI=1S/C10H16N5O11P3S/c11-9-8-10(13-3-12-9)15(4-14-8)7-1-5(16)6(24-7)2-23-29(22,30)26-28(20,21)25-27(17,18)19/h3-7,16H,1-2H2,(H,20,21)(H,22,30)(H2,11,12,13)(H2,17,18,19)/t5-,6+,7+,29?/m0/s1
DMRDX8U	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)COP(=S)(O)OP(=O)(O)OP(=O)(O)O)O
DMRDX8U	IK	CCPIKNHZOWQALM-DLQJRSQOSA-N
DMRDX8U	IU	[[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate
DMRDX8U	CA	CAS 64145-28-4
DMRDX8U	DE	Discovery agent

DMT14A7	ID	DMT14A7
DMT14A7	DN	DAU-5750
DMT14A7	HS	Investigative
DMT14A7	SN	Dau-5750; Dau 5750; AC1Q6M3K; AC1L4RM2; (1r,5s)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl(3s)-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-3-carboxylate; 164575-86-4; [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (3S)-3-methyl-2-oxo-1,4-dihydroquinoline-3-carboxylate; 3-Quinolinecarboxylic acid, 1,2,3,4-tetrahydro-3-methyl-2-oxo-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (3(S)-endo)-
DMT14A7	DT	Small molecular drug
DMT14A7	PC	190973
DMT14A7	MW	328.4
DMT14A7	FM	C19H24N2O3
DMT14A7	IC	InChI=1S/C19H24N2O3/c1-19(11-12-5-3-4-6-16(12)20-17(19)22)18(23)24-15-9-13-7-8-14(10-15)21(13)2/h3-6,13-15H,7-11H2,1-2H3,(H,20,22)/t13-,14+,15?,19-/m0/s1
DMT14A7	CS	C[C@@]1(CC2=CC=CC=C2NC1=O)C(=O)OC3C[C@H]4CC[C@@H](C3)N4C
DMT14A7	IK	HQZQXIVKGOJOLP-FKGKKHCZSA-N
DMT14A7	IU	[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (3S)-3-methyl-2-oxo-1,4-dihydroquinoline-3-carboxylate
DMT14A7	CA	CAS 164575-86-4
DMT14A7	DE	Discovery agent

DMEZVGK	ID	DMEZVGK
DMEZVGK	DN	DAU-5884
DMEZVGK	HS	Investigative
DMEZVGK	SN	131780-47-7
DMEZVGK	PC	16759154
DMEZVGK	MW	351.8
DMEZVGK	FM	C17H22ClN3O3
DMEZVGK	IC	InChI=1S/C17H21N3O3.ClH/c1-19-12-6-7-13(19)9-14(8-12)23-17(22)20-10-11-4-2-3-5-15(11)18-16(20)21;/h2-5,12-14H,6-10H2,1H3,(H,18,21);1H/t12-,13+,14?;
DMEZVGK	CS	CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)N3CC4=CC=CC=C4NC3=O.Cl
DMEZVGK	IK	FDERDDSQHZRNGC-LIWIJTDLSA-N
DMEZVGK	IU	[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-oxo-1,4-dihydroquinazoline-3-carboxylate;hydrochloride
DMEZVGK	CA	CAS 131780-47-7
DMEZVGK	DE	Discovery agent

DMM5SI1	ID	DMM5SI1
DMM5SI1	DN	DAU-6202
DMM5SI1	HS	Investigative
DMM5SI1	SN	131780-83-1
DMM5SI1	PC	9905592
DMM5SI1	MW	331.4
DMM5SI1	FM	C17H21N3O4
DMM5SI1	IC	InChI=1S/C17H21N3O4/c1-19-10-6-7-11(19)9-12(8-10)24-17(23)20-15(21)13-4-2-3-5-14(13)18-16(20)22/h2-5,10-12,15,21H,6-9H2,1H3,(H,18,22)
DMM5SI1	CS	CN1C2CCC1CC(C2)OC(=O)N3C(C4=CC=CC=C4NC3=O)O
DMM5SI1	IK	DCNXOLLXJNMTQB-UHFFFAOYSA-N
DMM5SI1	IU	(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-hydroxy-2-oxo-1,4-dihydroquinazoline-3-carboxylate
DMM5SI1	DE	Discovery agent

DMEST0R	ID	DMEST0R
DMEST0R	DN	DB-160
DMEST0R	HS	Investigative
DMEST0R	SN	Dipeptidyl peptidase IV inhibitor (oral, type 2 diabetes), DARA BioSciences
DMEST0R	CP	DARA BioSciences
DMEST0R	DE	Non-insulin dependent diabetes

DMGRUN1	ID	DMGRUN1
DMGRUN1	DN	DB-900
DMGRUN1	HS	Investigative
DMGRUN1	CP	DARA BioSciences
DMGRUN1	DE	Type-2 diabetes

DMFYCQ1	ID	DMFYCQ1
DMFYCQ1	DN	DBT-066
DMFYCQ1	HS	Investigative
DMFYCQ1	SN	RAGE modulator (dementia), Digital Biotech
DMFYCQ1	CP	Seoul National University
DMFYCQ1	DE	Dementia

DM09YI7	ID	DM09YI7
DM09YI7	DN	DBT-1339
DM09YI7	HS	Investigative
DM09YI7	SN	DBTA-1339; DBTAI-1339; DWJ-501; DWK-1339; Beta-amyloid aggregation inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid deposition inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid aggregation/deposition inhibitors (Alzheimer's), Digital Biotech
DM09YI7	CP	Digital Biotech Co Ltd
DM09YI7	DE	Alzheimer disease

DMX9FOB	ID	DMX9FOB
DMX9FOB	DN	DC6S
DMX9FOB	HS	Investigative
DMX9FOB	SN	DC6S
DMX9FOB	DT	Small molecular drug
DMX9FOB	PC	44414725
DMX9FOB	MW	381.4
DMX9FOB	FM	C18H23NO6S
DMX9FOB	IC	InChI=1S/C18H23NO6S/c1-19-8-7-18-11-4-6-14(25-26(20,21)22)17(18)24-16-13(23-2)5-3-10(15(16)18)9-12(11)19/h3,5,11-12,14,17H,4,6-9H2,1-2H3,(H,20,21,22)/t11-,12+,14-,17-,18-/m0/s1
DMX9FOB	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)OS(=O)(=O)O
DMX9FOB	IK	UFGYWOICNCSHBB-XSSYPUMDSA-N
DMX9FOB	IU	[(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] hydrogen sulfate
DMX9FOB	DE	Discovery agent

DM62IBX	ID	DM62IBX
DM62IBX	DN	DC-9703
DM62IBX	HS	Investigative
DM62IBX	CP	Obio Pharmaceutical Holdings Ltd
DM62IBX	DE	Non-insulin dependent diabetes

DMHNAJ7	ID	DMHNAJ7
DMHNAJ7	DN	D-carnitine
DMHNAJ7	HS	Investigative
DMHNAJ7	SN	(+)-Carnitine; (3S)-3-hydroxy-4-(trimethylammonio)butanoate; (3S)-3-hydroxy-4-(trimethylazaniumyl)butanoate; (S)-3-Hydroxy-4-(trimethylammonio)butanoate; CHEBI:11060; Carnitine D-form; D-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; D-carnitine; U9VY0ZOK7A; UNII-U9VY0ZOK7A
DMHNAJ7	DT	Small molecular drug
DMHNAJ7	PC	2724480
DMHNAJ7	MW	161.201
DMHNAJ7	FM	C7H15NO3
DMHNAJ7	IC	InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m0/s1
DMHNAJ7	CS	C[N+](C)(C)CC(CC(=O)[O-])O
DMHNAJ7	IK	PHIQHXFUZVPYII-LURJTMIESA-N
DMHNAJ7	IU	(3S)-3-hydroxy-4-(trimethylazaniumyl)butanoate
DMHNAJ7	CA	CAS 541-14-0
DMHNAJ7	CB	ChEBI:11060

DMPRYTW	ID	DMPRYTW
DMPRYTW	DN	DCB-3503
DMPRYTW	HS	Investigative
DMPRYTW	SN	DCB-3503; UNII-TXF835U41K; NSC-716802; CHEMBL399454; TXF835U41K; NSC716802; AC1L8JU6; (13aS,14S)-Tylophorinine; 87302-58-7; SCHEMBL12389871; CTK7A0055; BDBM50213933; Dibenzo(f,H)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-2,3,6,7-tetramethoxy-, (13aS,14S)-; NCI60_040362; Dibenzo(f,H)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-2,3,6,7-tetramethoxy-, (13as-trans)-; (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol; Dibenzo[f,2-b]isoquinolin-14-ol, 9
DMPRYTW	DT	Small molecular drug
DMPRYTW	PC	402628
DMPRYTW	MW	409.5
DMPRYTW	FM	C24H27NO5
DMPRYTW	IC	InChI=1S/C24H27NO5/c1-27-19-8-13-14-9-20(28-2)22(30-4)11-16(14)23-17(15(13)10-21(19)29-3)12-25-7-5-6-18(25)24(23)26/h8-11,18,24,26H,5-7,12H2,1-4H3/t18-,24+/m0/s1
DMPRYTW	CS	COC1=C(C=C2C(=C1)C3=C([C@@H]([C@@H]4CCCN4C3)O)C5=CC(=C(C=C25)OC)OC)OC
DMPRYTW	IK	JWHWLMNMGLICQZ-MHECFPHRSA-N
DMPRYTW	IU	(13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol
DMPRYTW	CA	CAS 87302-58-7
DMPRYTW	DE	Discovery agent

DM36D0F	ID	DM36D0F
DM36D0F	DN	d-CCPene
DM36D0F	HS	Investigative
DM36D0F	SN	Cppene; 137424-80-7; 4-(3-Phosphonoprop-2-enyl)piperazine-2-carboxylic acid; 3-(2-Carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid; C8H15N2O5P; 2-Piperazinecarboxylic acid, 4-(3-phosphono-2-propenyl)-; Midafotee; SDZ EAA 494, (E)-isomer; AC1O5NJ1; SCHEMBL726553; GTPL4170; CHEMBL224678; RT-012176; LS-172991; LS-172816; J-003616; (e)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid; 4-[(E)-3-phosphonoprop-2-enyl]piperazine-2-carboxylic acid
DM36D0F	DT	Small molecular drug
DM36D0F	PC	6437356
DM36D0F	MW	250.19
DM36D0F	FM	C8H15N2O5P
DM36D0F	IC	InChI=1S/C8H15N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h1,5,7,9H,2-4,6H2,(H,11,12)(H2,13,14,15)/b5-1+
DM36D0F	CS	C1CN(CC(N1)C(=O)O)C/C=C/P(=O)(O)O
DM36D0F	IK	VZXMZMJSGLFKQI-ORCRQEGFSA-N
DM36D0F	IU	4-[(E)-3-phosphonoprop-2-enyl]piperazine-2-carboxylic acid
DM36D0F	CA	CAS 132014-88-1
DM36D0F	DE	Discovery agent

DMG9BFR	ID	DMG9BFR
DMG9BFR	DN	DCDPC
DMG9BFR	HS	Investigative
DMG9BFR	SN	dichloro-diphenylamine 2-carboxylic acid
DMG9BFR	DT	Small molecular drug
DMG9BFR	PC	87345
DMG9BFR	MW	282.12
DMG9BFR	FM	C13H9Cl2NO2
DMG9BFR	IC	InChI=1S/C13H9Cl2NO2/c14-8-2-1-3-10(6-8)16-12-7-9(15)4-5-11(12)13(17)18/h1-7,16H,(H,17,18)
DMG9BFR	CS	C1=CC(=CC(=C1)Cl)NC2=C(C=CC(=C2)Cl)C(=O)O
DMG9BFR	IK	GSDQYSSLIKJJOG-UHFFFAOYSA-N
DMG9BFR	IU	4-chloro-2-(3-chloroanilino)benzoic acid
DMG9BFR	CA	CAS 17870-85-8
DMG9BFR	DE	Discovery agent

DM2T5OV	ID	DM2T5OV
DM2T5OV	DN	DC-EBIO
DM2T5OV	HS	Investigative
DM2T5OV	SN	dichloro-EBIO
DM2T5OV	DT	Small molecular drug
DM2T5OV	PC	656765
DM2T5OV	MW	231.08
DM2T5OV	FM	C9H8Cl2N2O
DM2T5OV	IC	InChI=1S/C9H8Cl2N2O/c1-2-13-8-4-6(11)5(10)3-7(8)12-9(13)14/h3-4H,2H2,1H3,(H,12,14)
DM2T5OV	CS	CCN1C2=CC(=C(C=C2NC1=O)Cl)Cl
DM2T5OV	IK	LKHRMULASXZCLG-UHFFFAOYSA-N
DM2T5OV	IU	5,6-dichloro-3-ethyl-1H-benzimidazol-2-one
DM2T5OV	CA	CAS 60563-36-2
DM2T5OV	CB	CHEBI:34662
DM2T5OV	DE	Discovery agent

DM9HG1Y	ID	DM9HG1Y
DM9HG1Y	DN	DCG IV
DM9HG1Y	HS	Investigative
DM9HG1Y	SN	Dcg-IV; DCG IV; 147782-19-2; CHEMBL284193; (1r,2r)-3-[(S)-Amino(Carboxy)methyl]cyclopropane-1,2-Dicarboxylic Acid; (1R,2R)-3-[(1S)-1-amino-2-hydroxy-2-oxoethyl]cyclopropane-1,2-dicarboxylic acid; DCGIV; AC1NSJRH; (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine; SCHEMBL658075; GTPL1377; 1,2-Cyclopropanedicarboxylicacid, 3-[(S)-aminocarboxymethyl]-, (1R,2R)-; CTK0H7426; MATPZHBYOVDBLI-JJYYJPOSSA-N; ZINC3995770; BDBM50034503; AKOS030230932; API0015797; B5039; CS-0021174; (2S,2''R,3''R)-2-(2'',3'')-dicarboxycyclopropylglycine
DM9HG1Y	DT	Small molecular drug
DM9HG1Y	PC	5310979
DM9HG1Y	MW	203.15
DM9HG1Y	FM	C7H9NO6
DM9HG1Y	IC	InChI=1S/C7H9NO6/c8-4(7(13)14)1-2(5(9)10)3(1)6(11)12/h1-4H,8H2,(H,9,10)(H,11,12)(H,13,14)/t2-,3-,4+/m1/s1
DM9HG1Y	CS	[C@@H]1([C@@H](C1[C@@H](C(=O)O)N)C(=O)O)C(=O)O
DM9HG1Y	IK	MATPZHBYOVDBLI-JJYYJPOSSA-N
DM9HG1Y	IU	(1R,2R)-3-[(S)-amino(carboxy)methyl]cyclopropane-1,2-dicarboxylic acid
DM9HG1Y	CA	CAS 147782-19-2
DM9HG1Y	DE	Discovery agent

DMU287Q	ID	DMU287Q
DMU287Q	DN	Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMU287Q	HS	Investigative
DMU287Q	SN	CHEMBL373489; Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMU287Q	DT	Small molecular drug
DMU287Q	PC	44415255
DMU287Q	MW	673.8
DMU287Q	FM	C29H35N7O8S2
DMU287Q	IC	InChI=1S/C29H35N7O8S2/c1-15-9-18(26(30)39)10-16(2)20(15)7-8-24(37)34-23-14-46-45-13-22(27(31)40)35-29(42)21(33-25(38)12-32-28(23)41)11-17-3-5-19(6-4-17)36(43)44/h3-6,9-10,21-23H,7-8,11-14H2,1-2H3,(H2,30,39)(H2,31,40)(H,32,41)(H,33,38)(H,34,37)(H,35,42)/t21-,22-,23-/m0/s1
DMU287Q	CS	CC1=CC(=CC(=C1CCC(=O)N[C@H]2CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC2=O)CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)N)C)C(=O)N
DMU287Q	IK	IPRXWMYVCKZIQS-VABKMULXSA-N
DMU287Q	IU	(4R,7S,13R)-13-[3-(4-carbamoyl-2,6-dimethylphenyl)propanoylamino]-7-[(4-nitrophenyl)methyl]-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMU287Q	DE	Discovery agent

DM9NMIY	ID	DM9NMIY
DM9NMIY	DN	DCPIB
DM9NMIY	HS	Investigative
DM9NMIY	SN	4-(2-butyl-6,7-dichlor-2-cyclopentyl-indan-1-on-5-yl) oxybutyric acid
DM9NMIY	DT	Small molecular drug
DM9NMIY	PC	10071166
DM9NMIY	MW	427.4
DM9NMIY	FM	C22H28Cl2O4
DM9NMIY	IC	InChI=1S/C22H28Cl2O4/c1-2-3-10-22(15-7-4-5-8-15)13-14-12-16(28-11-6-9-17(25)26)19(23)20(24)18(14)21(22)27/h12,15H,2-11,13H2,1H3,(H,25,26)
DM9NMIY	CS	CCCCC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCCCC(=O)O)C3CCCC3
DM9NMIY	IK	KHKGTPJPBOQECW-UHFFFAOYSA-N
DM9NMIY	IU	4-[(2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3H-inden-5-yl)oxy]butanoic acid
DM9NMIY	CA	CAS 82749-70-0
DM9NMIY	CB	CHEBI:91677
DM9NMIY	DE	Discovery agent

DMV0JQG	ID	DMV0JQG
DMV0JQG	DN	DD7
DMV0JQG	HS	Investigative
DMV0JQG	DT	Aptamer
DMV0JQG	DE	Acute respiratory distress syndrome; Myocardial reperfusion injury; Sepsis

DM6GWAC	ID	DM6GWAC
DM6GWAC	DN	DDATHF
DM6GWAC	HS	Investigative
DM6GWAC	SN	DATHF; 95693-76-8; 5,10-dideazatetrahydrofolate; 5,10-Dideaza-5,6,7,8-tetrahydrofolic acid; 5,10-dideazatetrahydrofolic acid; L-Glutamic acid,N-[4-[2-(2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]-; L-Glutamic acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-; C21H25N5O6; AC1L2XXH; Pyrido(2,3-d)pyrimidine, L-glutamic acid deriv; CHEMBL142806; SCHEMBL9045915; ZUQBAQVRAURMCL-CVRLYYSRSA-N; 5,10-Dideazatetrahydrofolic Acid
DM6GWAC	DT	Small molecular drug
DM6GWAC	PC	135436405
DM6GWAC	MW	443.5
DM6GWAC	FM	C21H25N5O6
DM6GWAC	IC	InChI=1S/C21H25N5O6/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30)
DM6GWAC	CS	C1C(CNC2=C1C(=O)NC(=N2)N)CCC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DM6GWAC	IK	ZUQBAQVRAURMCL-UHFFFAOYSA-N
DM6GWAC	IU	2-[[4-[2-(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]amino]pentanedioic acid
DM6GWAC	DE	Discovery agent

DMHLNA2	ID	DMHLNA2
DMHLNA2	DN	DdCTP SODIUM
DMHLNA2	HS	Investigative
DMHLNA2	SN	ddCTP SODIUM; CHEMBL486991; 132619-66-0; 2',3'-Dideoxycytidine 5'-triphosphate sodium salt; DTXSID60635554; PUBCHEM_23679072; FT-0643179; J-006199; 2',3'-Dideoxycytidine 5'-triphosphate sodium salt, &gt; 2',3'-Dideoxycytidine 5'-triphosphate sodium salt solution, for MALDI MS, &gt; =98.0% (HPLC); 2 inverted exclamation marka,3 inverted exclamation marka-Dideoxycytidine 5 inverted exclamation marka-triphosphate sodium salt solution; 2 inverted exclamation marka,3 inverted exclamation marka-Dideoxycytidine 5
DMHLNA2	DT	Small molecular drug
DMHLNA2	PC	23679072
DMHLNA2	MW	473.14
DMHLNA2	FM	C9H15N3NaO12P3
DMHLNA2	IC	InChI=1S/C9H16N3O12P3.Na/c10-7-3-4-12(9(13)11-7)8-2-1-6(22-8)5-21-26(17,18)24-27(19,20)23-25(14,15)16;/h3-4,6,8H,1-2,5H2,(H,17,18)(H,19,20)(H2,10,11,13)(H2,14,15,16);/q;+1/p-1/t6-,8+;/m0./s1
DMHLNA2	CS	C1C[C@@H](O[C@@H]1COP(=O)([O-])OP(=O)(O)OP(=O)(O)O)N2C=CC(=NC2=O)N.[Na+]
DMHLNA2	IK	LOOMQRBEBYCFPP-QDOHZIMISA-M
DMHLNA2	IU	sodium;[(2S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [hydroxy(phosphonooxy)phosphoryl] phosphate
DMHLNA2	CA	CAS 132619-66-0
DMHLNA2	DE	Discovery agent

DMDFRTI	ID	DMDFRTI
DMDFRTI	DN	Deamido-NAD
DMDFRTI	HS	Investigative
DMDFRTI	SN	Nicotinic acid adenine dinucleotide sodium salt; 104809-30-5; Nicotinic acid adenine dinucleotide sodium salt, &gt
DMDFRTI	DT	Small molecular drug
DMDFRTI	PC	165491
DMDFRTI	MW	665.4
DMDFRTI	FM	C21H27N6O15P2+
DMDFRTI	IC	InChI=1S/C21H26N6O15P2/c22-17-12-18(24-7-23-17)27(8-25-12)20-16(31)14(29)11(41-20)6-39-44(36,37)42-43(34,35)38-5-10-13(28)15(30)19(40-10)26-3-1-2-9(4-26)21(32)33/h1-4,7-8,10-11,13-16,19-20,28-31H,5-6H2,(H4-,22,23,24,32,33,34,35,36,37)/p+1/t10-,11-,13-,14-,15-,16-,19-,20-/m1/s1
DMDFRTI	CS	C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)O
DMDFRTI	IK	SENPVEZBRZQVST-HISDBWNOSA-O
DMDFRTI	IU	1-[(2R,3R,4S,5R)-5-[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylic acid
DMDFRTI	CA	CAS 6450-77-7
DMDFRTI	CB	CHEBI:18304

DMFTNAP	ID	DMFTNAP
DMFTNAP	DN	Debio-0930
DMFTNAP	HS	Investigative
DMFTNAP	SN	MT-63-78; AMPK stimulator (oral, cancer), Mercury Therapeutics/Debiopharm SA; Adenosine monophosphate activated protein kinase stimulator (oral, cancer), Mercury Therapeutics/Debiopharm SA
DMFTNAP	CP	Mercury Therapeutics Inc
DMFTNAP	DE	Metabolic disorder

DMDLER8	ID	DMDLER8
DMDLER8	DN	DEBROMOHYMENIALDISINE
DMDLER8	HS	Investigative
DMDLER8	DT	Small molecular drug
DMDLER8	PC	135451156
DMDLER8	MW	245.24
DMDLER8	FM	C11H11N5O2
DMDLER8	IC	InChI=1S/C11H11N5O2/c12-11-15-8(10(18)16-11)6-2-4-14-9(17)7-5(6)1-3-13-7/h1,3,13H,2,4H2,(H,14,17)(H3,12,15,16,18)/b8-6-
DMDLER8	CS	C\\1CNC(=O)C2=C(/C1=C\\3/C(=O)NC(=N3)N)C=CN2
DMDLER8	IK	JYRJOQGKGMHTOO-VURMDHGXSA-N
DMDLER8	IU	(4Z)-4-(2-amino-5-oxo-1H-imidazol-4-ylidene)-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one
DMDLER8	CA	CAS 125118-55-0
DMDLER8	DE	Discovery agent

DMWZKLM	ID	DMWZKLM
DMWZKLM	DN	Decanal
DMWZKLM	HS	Investigative
DMWZKLM	SN	Aldehyde C-10; Aldehyde C10; Capraldehyde; Capric aldehyde; Caprinaldehyde; Caprinic aldehyde; DECALDEHYDE; Decanal; Decanal (natural); Decanaldehyde; Decyl aldehyde; Decyl aldehyde, 95%; Decylic aldehyde; KSMVZQYAVGTKIV-UHFFFAOYSA-N; decylaldehyde; n-DECYLALDEHYDE; n-Decaldehyde; n-Decanal; n-Decyl aldehyde; 1-Decanal; 1-Decanal(mixed isomers); 1-Decyl aldehyde; 112-31-2; 31Z90Q7KQJ; AC1L1QFM; AI3-04860; BRN 1362530; C-10 aldehyde; CHEBI:31457; EINECS 203-957-4; FEMA No. 2362; HSDB 288; MFCD00007031; NSC 6087; NSC6087; UNII-31Z90Q7KQJ
DMWZKLM	PC	8175
DMWZKLM	MW	156.26
DMWZKLM	FM	C10H20O
DMWZKLM	IC	KSMVZQYAVGTKIV-UHFFFAOYSA-N
DMWZKLM	CS	CCCCCCCCCC=O
DMWZKLM	IK	1S/C10H20O/c1-2-3-4-5-6-7-8-9-10-11/h10H,2-9H2,1H3
DMWZKLM	IU	decanal
DMWZKLM	CA	CAS 112-31-2
DMWZKLM	CB	CHEBI:31457
DMWZKLM	DE	Discovery agent

DM1ESVR	ID	DM1ESVR
DM1ESVR	DN	Decane-1,10-diyl disulfamate
DM1ESVR	HS	Investigative
DM1ESVR	SN	Sulfamic acid, decamethylene ester; Decane-1,10-Diyl Disulfamate; 1,10-Decanediol, bisulfamate (ester); BRN 2290905; CHEMBL171476; 60548-61-0; 10-sulfamoyloxydecyl sulfamate; 3ibn; bis-sulfamate, 4; 1,10-decanediol disulfamate; AC1L3Y02; SCHEMBL11592779; BDBM33282; DTXSID80209296; XPDWKENHTJHZSC-UHFFFAOYSA-N; Bis(sulfamic acid)1,10-decanediyl ester; 1,10-Bis-O-sulfamyl-1,10-decanediol; LS-147672
DM1ESVR	DT	Small molecular drug
DM1ESVR	PC	148885
DM1ESVR	MW	332.4
DM1ESVR	FM	C10H24N2O6S2
DM1ESVR	IC	InChI=1S/C10H24N2O6S2/c11-19(13,14)17-9-7-5-3-1-2-4-6-8-10-18-20(12,15)16/h1-10H2,(H2,11,13,14)(H2,12,15,16)
DM1ESVR	CS	C(CCCCCOS(=O)(=O)N)CCCCOS(=O)(=O)N
DM1ESVR	IK	XPDWKENHTJHZSC-UHFFFAOYSA-N
DM1ESVR	IU	10-sulfamoyloxydecyl sulfamate
DM1ESVR	CA	CAS 60548-61-0
DM1ESVR	DE	Discovery agent

DM8FMYL	ID	DM8FMYL
DM8FMYL	DN	Decanoic Acid
DM8FMYL	HS	Investigative
DM8FMYL	SN	Decanoic acid; CAPRIC ACID; 334-48-5; n-Decanoic acid; n-Capric acid; Decylic acid; Caprinic acid; Decoic acid; n-Decylic acid; n-Decoic acid; 1-Nonanecarboxylic acid; Caprynic acid; Neo-fat 10; Hexacid 1095; decanoate; tert-DECANOIC ACID; C10 fatty acid; Versatic 10 acid; Versatic 10; Fatty acid(C10); NSC 5025; Econosan Acid Sanitizer; Decanoic acid (natural); UNII-4G9EDB6V73; FEMA No. 2364; CCRIS 4610; HSDB 2751; Emery 659; C10:0; EINECS 206-376-4; EPA Pesticide Chemical Code 128955; BRN 1754556; AI3-04453; 4G9EDB6V73; CHEBI:30813
DM8FMYL	DT	Small molecular drug
DM8FMYL	PC	2969
DM8FMYL	MW	172.26
DM8FMYL	FM	C10H20O2
DM8FMYL	IC	InChI=1S/C10H20O2/c1-2-3-4-5-6-7-8-9-10(11)12/h2-9H2,1H3,(H,11,12)
DM8FMYL	CS	CCCCCCCCCC(=O)O
DM8FMYL	IK	GHVNFZFCNZKVNT-UHFFFAOYSA-N
DM8FMYL	IU	decanoic acid
DM8FMYL	CA	CAS 334-48-5
DM8FMYL	CB	CHEBI:30813
DM8FMYL	DE	Discovery agent

DMLT1N3	ID	DMLT1N3
DMLT1N3	DN	decavanadate
DMLT1N3	HS	Investigative
DMLT1N3	SN	Decavanidate
DMLT1N3	DT	Small molecular drug
DMLT1N3	PC	5311062
DMLT1N3	MW	957.4
DMLT1N3	FM	O28V10-6
DMLT1N3	IC	InChI=1S/28O.10V/q;;;;;;;;;;;;;;;;;;;;;;6*-1;;;;;;;;;;
DMLT1N3	CS	[O-][V](=O)([O-])O[V]1(=O)O[V]2(=O)O[V]3(=O)O[V](=O)(O[V](=O)(O3)O[V](=O)([O-])[O-])O[V](=O)(O[V](=O)(O2)O1)O[V](=O)([O-])[O-]
DMLT1N3	IK	OSBWBKHFRWKREF-UHFFFAOYSA-N
DMLT1N3	IU	[5,13-bis[(dioxido(oxo)vanadio)oxy]-1,3,5,7,9,11,13-heptaoxo-2,4,6,8,10,12,14,15,16-nonaoxa-1lambda5,3lambda5,5lambda5,7lambda5,9lambda5,11lambda5,13lambda5-heptavanadatricyclo[9.3.1.13,7]hexadecan-9-yl]oxy-dioxido-oxovanadium
DMLT1N3	DE	Discovery agent

DM4SWYX	ID	DM4SWYX
DM4SWYX	DN	DECIDIUM
DM4SWYX	HS	Investigative
DM4SWYX	SN	Decidium diiodide; AC1L2WE8; 123048-04-4; 3,8-Diamino-5,10'-(trimethylammonium)decyl-6-phenyl phenanthridium diiodide; 4-Phenanthrenedecanaminium, 1,6-diamino-N,N,N-trimethyl-3-phenyl-, iodide, monohydriodide; 10-(1,6-diamino-3-phenylphenanthren-4-yl)decyl-trimethylazanium iodide hydroiodide
DM4SWYX	DT	Small molecular drug
DM4SWYX	PC	129883
DM4SWYX	MW	737.5
DM4SWYX	FM	C33H45I2N3
DM4SWYX	IC	InChI=1S/C33H44N3.2HI/c1-36(2,3)22-14-9-7-5-4-6-8-13-17-28-30(25-15-11-10-12-16-25)24-32(35)29-21-19-26-18-20-27(34)23-31(26)33(28)29;;/h10-12,15-16,18-21,23-24H,4-9,13-14,17,22,34-35H2,1-3H3;2*1H/q+1;;/p-1
DM4SWYX	CS	C[N+](C)(C)CCCCCCCCCCC1=C2C(=C(C=C1C3=CC=CC=C3)N)C=CC4=C2C=C(C=C4)N.I.[I-]
DM4SWYX	IK	RJEYFBQMUHTEAX-UHFFFAOYSA-M
DM4SWYX	IU	10-(1,6-diamino-3-phenylphenanthren-4-yl)decyl-trimethylazanium;iodide;hydroiodide
DM4SWYX	CA	CAS 123048-04-4
DM4SWYX	DE	Discovery agent

DMHO3N1	ID	DMHO3N1
DMHO3N1	DN	Decoyinine
DMHO3N1	HS	Investigative
DMHO3N1	SN	AC1L1EVQ; UPCMLD-DP098; CBiol_001975; KBioSS_000329; KBioGR_000329; CHEMBL2360461; UPCMLD-DP098:002; UPCMLD-DP098:001; KBio3_000657; KBio2_002897; KBio3_000658; KBio2_005465; KBio2_000329; CTK8A2092; Bio2_000805; Bio2_000325; Bio1_000261; Bio1_001239; HMS1362A11; Bio1_000750; SMP2_000077; IDI1_002080; NCGC00161649-01; NCGC00161649-02
DMHO3N1	DT	Small molecular drug
DMHO3N1	PC	121578
DMHO3N1	MW	279.25
DMHO3N1	FM	C11H13N5O4
DMHO3N1	IC	InChI=1S/C11H13N5O4/c1-5-7(18)8(19)11(2-17,20-5)16-4-15-6-9(12)13-3-14-10(6)16/h3-4,7-8,17-19H,1-2H2,(H2,12,13,14)/t7-,8-,11-/m1/s1
DMHO3N1	CS	C=C1[C@H]([C@H]([C@](O1)(CO)N2C=NC3=C(N=CN=C32)N)O)O
DMHO3N1	IK	UZSSGAOAYPICBZ-SOCHQFKDSA-N
DMHO3N1	IU	(2R,3R,4S)-2-(6-aminopurin-9-yl)-2-(hydroxymethyl)-5-methylideneoxolane-3,4-diol
DMHO3N1	CA	CAS 2004-04-8
DMHO3N1	DE	Discovery agent

DMNKDT5	ID	DMNKDT5
DMNKDT5	DN	decyl dihydrogen phosphate
DMNKDT5	HS	Investigative
DMNKDT5	SN	FAP10; decanol phosphate; FAP-10; decyl phosphate; n-decyl phosphoric acid
DMNKDT5	DT	Small molecular drug
DMNKDT5	PC	62532
DMNKDT5	MW	238.26
DMNKDT5	FM	C10H23O4P
DMNKDT5	IC	InChI=1S/C10H23O4P/c1-2-3-4-5-6-7-8-9-10-14-15(11,12)13/h2-10H2,1H3,(H2,11,12,13)
DMNKDT5	CS	CCCCCCCCCCOP(=O)(O)O
DMNKDT5	IK	SCIGVHCNNXTQDB-UHFFFAOYSA-N
DMNKDT5	IU	decyl dihydrogen phosphate
DMNKDT5	CA	CAS 3921-30-0
DMNKDT5	DE	Discovery agent

DMIERWO	ID	DMIERWO
DMIERWO	DN	Decyl sulfamate
DMIERWO	HS	Investigative
DMIERWO	SN	Decyl Sulfamate; CHEMBL153094; Sulfamic acid, decyl ester; n-decyl sulfamate; 3ibu; aliphatic sulfamate, 2; BDBM33280; 475562-13-1
DMIERWO	DT	Small molecular drug
DMIERWO	PC	19772348
DMIERWO	MW	237.36
DMIERWO	FM	C10H23NO3S
DMIERWO	IC	InChI=1S/C10H23NO3S/c1-2-3-4-5-6-7-8-9-10-14-15(11,12)13/h2-10H2,1H3,(H2,11,12,13)
DMIERWO	CS	CCCCCCCCCCOS(=O)(=O)N
DMIERWO	IK	JBKMRMOTMJVNML-UHFFFAOYSA-N
DMIERWO	IU	decyl sulfamate
DMIERWO	DE	Discovery agent

DMQMR3P	ID	DMQMR3P
DMQMR3P	DN	DECYL(DIMETHYL)PHOSPHINE OXIDE
DMQMR3P	HS	Investigative
DMQMR3P	SN	Dimethyldecylphosphine oxide; APO-10; Decyl(Dimethyl)phosphine Oxide; Decyldimethylphosphine oxide; 2190-95-6; 1-(dimethylphosphoryl)decane; decyl(dimethyl)phosphane oxide; Phosphine oxide, decyldimethyl-; decyldimethylphosphino-1-one; DCX; AC1MRFCU; 1-dimethylphosphoryldecane; Dimethyldecyl phosphine oxide; Phosphine oxide,decyldimethyl-; SCHEMBL158223; CTK4E7952; DTXSID90176309; MolPort-000-474-112; ZINC3130911; STK954185; SBB039895; MFCD00226006; AKOS000271378; MCULE-7993897252; DB07641; ST50109137; Dimethyldecylphosphine oxide, 
DMQMR3P	DT	Small molecular drug
DMQMR3P	PC	3492020
DMQMR3P	MW	218.32
DMQMR3P	FM	C12H27OP
DMQMR3P	IC	InChI=1S/C12H27OP/c1-4-5-6-7-8-9-10-11-12-14(2,3)13/h4-12H2,1-3H3
DMQMR3P	CS	CCCCCCCCCCP(=O)(C)C
DMQMR3P	IK	GSVLCKASFMVUSW-UHFFFAOYSA-N
DMQMR3P	IU	1-dimethylphosphoryldecane
DMQMR3P	CA	CAS 2190-95-6
DMQMR3P	DE	Discovery agent

DM2WEB9	ID	DM2WEB9
DM2WEB9	DN	Decylamine-N,N-Dimethyl-N-Oxide
DM2WEB9	HS	Investigative
DM2WEB9	SN	2605-79-0; N,N-Dimethyldecylamine N-oxide; N,N-Dimethyldecylamine oxide; 1-Decanamine, N,N-dimethyl-, N-oxide; DECYLAMINE-N,N-DIMETHYL-N-OXIDE; decyl(dimethyl)amine oxide; UNII-G387VUT5EZ; Capric dimethyl amine oxide; N,N-Dimethyldecylamine-N-oxide; N,N-dimethyldecan-1-amine oxide; Decyl dimethyl amine oxide; N,N-dimethyldecanamine oxide; G387VUT5EZ; CHEBI:41899; N,N-Dimethyl-1-decanamine-N-oxide; 1-Decanamine,N,N-dimethyl-, N-oxide; Alkyldimethylamine oxides, commercial grade; 3nok; EINECS 220-020-5; decyldimethylamine oxide
DM2WEB9	DT	Small molecular drug
DM2WEB9	PC	62452
DM2WEB9	MW	201.35
DM2WEB9	FM	C12H27NO
DM2WEB9	IC	InChI=1S/C12H27NO/c1-4-5-6-7-8-9-10-11-12-13(2,3)14/h4-12H2,1-3H3
DM2WEB9	CS	CCCCCCCCCC[N+](C)(C)[O-]
DM2WEB9	IK	ZRKZFNZPJKEWPC-UHFFFAOYSA-N
DM2WEB9	IU	N,N-dimethyldecan-1-amine oxide
DM2WEB9	CA	CAS 2605-79-0
DM2WEB9	CB	CHEBI:41899
DM2WEB9	DE	Discovery agent

DMFT3J2	ID	DMFT3J2
DMFT3J2	DN	Decyl-phosphonic acid
DMFT3J2	HS	Investigative
DMFT3J2	SN	Decylphosphonic acid; 6874-60-8; Decanephosphonic acid; Phosphonic acid, decyl-; 1-Decanephosphonic acid; n-Decylphosphonic acid; 1-DECYLPHOSPHONIC ACID; Phosphonic acid, P-decyl-; EINECS 229-975-2; NSC 407850; BRN 1771572; AI3-23065; CHEMBL188083; DZQISOJKASMITI-UHFFFAOYSA-N; C10H23O3P; DecylphosphonicAcid; 1-decanephosphonicacid; n-Decanephosphonic acid; ACMC-1CUHV; Phosphonic acid,P-decyl-; Decylphosphonic acid, 97%; AC1Q6RQ2; 10; 4-04-00-03564 (Beilstein Handbook Reference); SCHEMBL110008
DMFT3J2	DT	Small molecular drug
DMFT3J2	PC	81309
DMFT3J2	MW	222.26
DMFT3J2	FM	C10H23O3P
DMFT3J2	IC	InChI=1S/C10H23O3P/c1-2-3-4-5-6-7-8-9-10-14(11,12)13/h2-10H2,1H3,(H2,11,12,13)
DMFT3J2	CS	CCCCCCCCCCP(=O)(O)O
DMFT3J2	IK	DZQISOJKASMITI-UHFFFAOYSA-N
DMFT3J2	IU	decylphosphonic acid
DMFT3J2	CA	CAS 6874-60-8
DMFT3J2	DE	Discovery agent

DM1ITJ5	ID	DM1ITJ5
DM1ITJ5	DN	Decyltrimethylammonium
DM1ITJ5	HS	Investigative
DM1ITJ5	SN	Decyltrimethylammonium; Trimethyldecylammonium; 15053-09-5; n-decyltrimethylammonium; CHEBI:55325; Ammonium, decyltrimethyl-; Decyltrimethylaminium; decyl(trimethyl)azanium; trimethyl-n-decylammonium; decyltrimethylammonium ion; AC1L27UL; SCHEMBL363068; N,N,N-trimethyldecan-1-aminium; N,N,N-trimethyl-1-decanaminium; CHEMBL1180301; 2082-84-0 (bromide); CTK4C6688; 10108-87-9 (chloride); DTXSID10164566; 1-Decanaminium,N,N,N-trimethyl-; 1-Decanaminium, N,N,N-trimethyl-; ZINC1700269; MCULE-3384760582; 65059-98-5 (methyl sulfate salt)
DM1ITJ5	DT	Small molecular drug
DM1ITJ5	PC	16389
DM1ITJ5	MW	200.38
DM1ITJ5	FM	C13H30N+
DM1ITJ5	IC	InChI=1S/C13H30N/c1-5-6-7-8-9-10-11-12-13-14(2,3)4/h5-13H2,1-4H3/q+1
DM1ITJ5	CS	CCCCCCCCCC[N+](C)(C)C
DM1ITJ5	IK	RKMJXTWHATWGNX-UHFFFAOYSA-N
DM1ITJ5	IU	decyl(trimethyl)azanium
DM1ITJ5	CA	CAS 15053-09-5
DM1ITJ5	CB	CHEBI:55325
DM1ITJ5	DE	Discovery agent

DMWCTZ7	ID	DMWCTZ7
DMWCTZ7	DN	Decynium 22
DMWCTZ7	HS	Investigative
DMWCTZ7	SN	Pseudoisocyanine; 1,1'-Diethyl-2,2'-cyanine; 1-Ethyl-2-((1-ethyl-2(1H)-quinolylidene)methyl)quinolinium; 20766-49-8; CHEMBL1197556; CHEBI:37994; Pseudocyanine; 1-ethyl-2-[(E)-(1-ethylquinolin-2(1H)-ylidene)methyl]quinolinium; Diethylpseudoisocyanine; MLS000532635; AC1NUNMU; AC1Q1IYW; SMR000137574; AC1L2OT9; CBDivE_000769; SCHEMBL737002; 977-96-8 (iodide); 2402-42-8 (chloride); SCHEMBL13619260; 1613-31-6 (bromide); BDBM39687; cid_5717105; CHEBI:38002; DTXSID40174835; MolPort-006-385-585; STK396423; (E)-1,1'-diethyl-2,2'-cyanine;  Dy22; 1,1'-diethyl-2,2'-cyanine; NSC-97374
DMWCTZ7	DT	Small molecular drug
DMWCTZ7	PC	5484462
DMWCTZ7	MW	454.3
DMWCTZ7	FM	C23H23IN2
DMWCTZ7	IC	InChI=1S/C23H23N2.HI/c1-3-24-20(15-13-18-9-5-7-11-22(18)24)17-21-16-14-19-10-6-8-12-23(19)25(21)4-2;/h5-17H,3-4H2,1-2H3;1H/q+1;/p-1
DMWCTZ7	CS	CCN1/C(=C/C2=[N+](C3=CC=CC=C3C=C2)CC)/C=CC4=CC=CC=C41.[I-]
DMWCTZ7	IK	GMYRVMSXMHEDTL-UHFFFAOYSA-M
DMWCTZ7	IU	(2E)-1-ethyl-2-[(1-ethylquinolin-1-ium-2-yl)methylidene]quinoline;iodide
DMWCTZ7	CA	CAS 977-96-8
DMWCTZ7	CB	CHEBI:37993
DMWCTZ7	DE	Discovery agent

DMKRT20	ID	DMKRT20
DMKRT20	DN	Degraded Cephaloridine
DMKRT20	HS	Investigative
DMKRT20	SN	DEGRADED CEPHALORIDINE; 5-METHYL-2-[2-OXO-1-(2-THIOPHEN-2-YL-ACETYLAMINO)-ETHYL]-3,6-DIHYDRO-2H-[1,3]THIAZINE-4-CARBOXYLIC ACID; 4ivk; AC1NRAIF; DB04133; FT-0771180; (2R)-5-methyl-2-[(1R)-2-oxo-1-[2-(thiophen-2-yl)acetamido]ethyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; (2R)-5-methyl-2-{(1R)-2-oxo-1-[(thiophen-2-ylacetyl)amino]ethyl}-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; (2R)-5-methyl-2-[(1R)-2-oxo-1-[(2-thiophen-2-ylacetyl)amino]ethyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMKRT20	DT	Small molecular drug
DMKRT20	PC	5287902
DMKRT20	MW	340.4
DMKRT20	FM	C14H16N2O4S2
DMKRT20	IC	InChI=1S/C14H16N2O4S2/c1-8-7-22-13(16-12(8)14(19)20)10(6-17)15-11(18)5-9-3-2-4-21-9/h2-4,6,10,13,16H,5,7H2,1H3,(H,15,18)(H,19,20)/t10-,13-/m1/s1
DMKRT20	CS	CC1=C(N[C@H](SC1)[C@@H](C=O)NC(=O)CC2=CC=CS2)C(=O)O
DMKRT20	IK	SFVACKBZMIZHCK-ZWNOBZJWSA-N
DMKRT20	IU	(2R)-5-methyl-2-[(1R)-2-oxo-1-[(2-thiophen-2-ylacetyl)amino]ethyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMKRT20	DE	Discovery agent

DMXT7WG	ID	DMXT7WG
DMXT7WG	DN	Deguelin
DMXT7WG	HS	Investigative
DMXT7WG	SN	522-17-8; (-)-Deguelin; (-)-cis-deguelin; DEGUELIN(-); UNII-K5Z93K66IE; CHEBI:4357; K5Z93K66IE; MFCD01740600; C23H22O6; (7as,13as)-13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-3h-bis[1]benzopyrano[3,4-b:6',5'-e]pyran-7(7ah)-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one; (7aS,13aS)-9,10-dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one.; SR-01000597503; CCRIS 8104; Deguelin/; (-)-Deguelin, Mundulea sericea; Spectrum_001044; Tocris-1770; Spectrum2_000298; Spectrum3_001122; Spectrum4_001965; Spectrum5_001852; SCHEMBL73183; BSPBio_002583; KBioGR_002434; KBioSS_001524; SPECTRUM201138; MLS006010295; SPBio_000236; CHEMBL393417; KBio2_001524; KBio2_004092; KBio2_006660; KBio3_002083; DTXSID10200231; HMS1923A05; HMS3268E12; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS-cis)-; EX-A4158; ZINC3978987; 1702AH; ABP000411; BDBM50505204; CCG-39856; LMPK12060019; s8132; AKOS024456769; ACN-053693; BCP9000596; CS-1802; SDCCGMLS-0066380.P001; NCGC00025288-01; NCGC00025288-02; NCGC00025288-03; (-)-Deguelin, >98% (HPLC), powder; AS-56004; HY-13425; SMR004701363; C10417; Q5251862; SR-01000597503-1; SR-01000597503-3; SR-01000597503-4; BRD-K61401890-001-02-0; BRD-K61401890-001-03-8; BRD-K61401890-001-04-6; (1S,14S)-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H,7aH-pyrano[2,3-c;6,5-f']dichromen-7-one; 13,13aS-Dihydro-9,10-dimethoxy-3,3-dimethyl-3H-[1]benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aS)-one; 3H-[1]Benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-
DMXT7WG	DT	Small molecular drug
DMXT7WG	PC	107935
DMXT7WG	MW	394.4
DMXT7WG	FM	C23H22O6
DMXT7WG	IC	InChI=1S/C23H22O6/c1-23(2)8-7-12-15(29-23)6-5-13-21(24)20-14-9-17(25-3)18(26-4)10-16(14)27-11-19(20)28-22(12)13/h5-10,19-20H,11H2,1-4H3/t19-,20+/m1/s1
DMXT7WG	CS	CC1(C=CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC)C
DMXT7WG	IK	ORDAZKGHSNRHTD-UXHICEINSA-N
DMXT7WG	IU	(1S,14S)-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one
DMXT7WG	CA	CAS 522-17-8
DMXT7WG	CB	CHEBI:4357
DMXT7WG	DE	Esophageal squamous cell carcinoma

DMKYQO4	ID	DMKYQO4
DMKYQO4	DN	Dehydroascorbic acid
DMKYQO4	HS	Investigative
DMKYQO4	SN	dehydroascorbate
DMKYQO4	DT	Small molecular drug
DMKYQO4	PC	440667
DMKYQO4	MW	174.11
DMKYQO4	FM	C6H6O6
DMKYQO4	IC	InChI=1S/C6H6O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-8H,1H2/t2-,5+/m0/s1
DMKYQO4	CS	C([C@@H]([C@@H]1C(=O)C(=O)C(=O)O1)O)O
DMKYQO4	IK	SBJKKFFYIZUCET-JLAZNSOCSA-N
DMKYQO4	IU	(5R)-5-[(1S)-1,2-dihydroxyethyl]oxolane-2,3,4-trione
DMKYQO4	CA	CAS 490-83-5
DMKYQO4	CB	CHEBI:27956
DMKYQO4	DE	Discovery agent

DMCDLH2	ID	DMCDLH2
DMCDLH2	DN	Dehydrocholic acid
DMCDLH2	HS	Investigative
DMCDLH2	SN	Acolen; Bilidren; Bilostat; Biochol; Cholagon; Cholan DH; Cholic acid, dehydro-; Cholimed; Chologon; Decholin; Dee-Co; Dehychol; Dehycol; Dehycon; Dehydrocholsaeure; Dehystolin; Deidrocolico Vita; Didocol; Didrocolo; Dilabil; Doxycholpotassium; Drenobyl; Erebile; Felacrinos; Hykolex; Ketochol; Ketocholanic acid; Khologon; Novocolin; Oxycholin; Procholon; Sanocholen; Triketocholanic acid; dehydrocholate; dehydrocholic acid; 3,7,12-Triketocholanic acid; 3,7,12-Trioxo-5beta-cholanic acid; 3,7,12-Trioxocholanic acid; 81-23-2
DMCDLH2	PC	6674
DMCDLH2	MW	402.5
DMCDLH2	FM	C24H34O5
DMCDLH2	IC	OHXPGWPVLFPUSM-KLRNGDHRSA-N
DMCDLH2	CS	CC(CCC(=O)O)C1CCC2C1(C(=O)CC3C2C(=O)CC4C3(CCC(=O)C4)C)C
DMCDLH2	IK	1S/C24H34O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29)/t13-,14+,16-,17+,18+,22+,23+,24-/m1/s1
DMCDLH2	IU	(4R)-4-[(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
DMCDLH2	CA	CAS 81-23-2
DMCDLH2	CB	CHEBI:31459
DMCDLH2	DE	Asthma

DM48KMB	ID	DM48KMB
DM48KMB	DN	Dehydrocorticosterone
DM48KMB	HS	Investigative
DM48KMB	SN	Corticosterone, 11-dehydro-; Corticosterone, dehydro-; Cortisone, 17-deoxy-; 11-Dehydrocorticosterone; Dehydrocortocicosterone; FO4V44A3G3; Kendall's compound A; SCHEMBL141610; 11-DEHYDROCORTICOSTERONE; 11-DHC; 11-Dehydrocorticosteron; 11-Oxo-11-deoxycorticosterone; 17-Deoxycortisone; 21-Hydroxypregn-4-ene-3,11,20-trione; 21-Hydroxypregn-4-ene-3,11-20-trione; 4-Pregnen-21-ol-3,11,20-trione; 4qf7; 72-23-1; AC1NSKHU; CHEBI:78600; EINECS 200-776-2; NSC 9702; NSC-9702; Pregn-4-ene-3,11,20-trione, 21-hydroxy-; UNII-FO4V44A3G3
DM48KMB	PC	5311364
DM48KMB	MW	344.4
DM48KMB	FM	C21H28O4
DM48KMB	IC	FUFLCEKSBBHCMO-KJQYFISQSA-N
DM48KMB	CS	CC12CCC(=O)C=C1CCC3C2C(=O)CC4(C3CCC4C(=O)CO)C
DM48KMB	IK	1S/C21H28O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-16,19,22H,3-8,10-11H2,1-2H3/t14-,15-,16+,19+,20-,21-/m0/s1
DM48KMB	IU	(8S,9S,10R,13S,14S,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,11-dione
DM48KMB	CA	CAS 72-23-1
DM48KMB	CB	CHEBI:78600
DM48KMB	DE	Discovery agent

DM0V1NH	ID	DM0V1NH
DM0V1NH	DN	DEHYDROLEUCODIN
DM0V1NH	HS	Investigative
DM0V1NH	SN	Dehydroleucodin; Dehydroleucodine; 36150-07-9; NSC 180034; CHEMBL441260; Azuleno(4,5-b)furan-2,7-dione, 3,3a,4,5,9a,9b-hexahydro-6,9-dimethyl-3-methylene-, (3aS-(3aalpha,9aalpha,9bbeta))-; Lidbeckialactone; Mesatlantin E; 11,13-Dehydroleucodin; AC1L2JV1; AC1Q69JZ; (3as,9as,9bs)-6,9-dimethyl-3-methylidene-3,3a,4,5,9a,9b-hexahydroazuleno[4,5-b]furan-2,7-dione; SCHEMBL4998391; CTK4H5993; ZINC5202250; Dehydroleucodine, &gt; BDBM50318392; NCGC00485131-01; LS-182153
DM0V1NH	DT	Small molecular drug
DM0V1NH	PC	73440
DM0V1NH	MW	244.28
DM0V1NH	FM	C15H16O3
DM0V1NH	IC	InChI=1S/C15H16O3/c1-7-4-5-10-9(3)15(17)18-14(10)13-8(2)6-11(16)12(7)13/h6,10,13-14H,3-5H2,1-2H3/t10-,13-,14-/m0/s1
DM0V1NH	CS	CC1=C2[C@@H]([C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C(=CC2=O)C
DM0V1NH	IK	SKNVIAFTENCNGB-BPNCWPANSA-N
DM0V1NH	IU	(3aS,9aS,9bS)-6,9-dimethyl-3-methylidene-4,5,9a,9b-tetrahydro-3aH-azuleno[4,5-b]furan-2,7-dione
DM0V1NH	CA	CAS 36150-07-9
DM0V1NH	DE	Discovery agent

DMIOA9M	ID	DMIOA9M
DMIOA9M	DN	Dehydropipernonaline
DMIOA9M	HS	Investigative
DMIOA9M	SN	Dehydropipernonaline; 107584-38-3; Dehydropipernoline; Piperidine, 1-[9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl]-, (E,E,E)-; Piperidine, 1-(9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl)-, (E,E,E)-; AC1O5SQM; CHEMBL483708; MolPort-039-101-180; KAYVDASZRFLFRZ-PQECNABGSA-N; N-(9-(3,4-Methylenedioxyphenyl)-2,4,8-nonatrienoyl)piperidine; ZINC14658239; 9-(3,4-Methylenedioxy)-2,4,8-nonatrienoic acid piperidide; (2E,4E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,4,8-trien-1-one; Piperidine, 1-[(2E,4E,8E)-9-(1
DMIOA9M	DT	Small molecular drug
DMIOA9M	PC	6439947
DMIOA9M	MW	339.4
DMIOA9M	FM	C21H25NO3
DMIOA9M	IC	InChI=1S/C21H25NO3/c23-21(22-14-8-5-9-15-22)11-7-4-2-1-3-6-10-18-12-13-19-20(16-18)25-17-24-19/h2,4,6-7,10-13,16H,1,3,5,8-9,14-15,17H2/b4-2+,10-6+,11-7+
DMIOA9M	CS	C1CCN(CC1)C(=O)/C=C/C=C/CC/C=C/C2=CC3=C(C=C2)OCO3
DMIOA9M	IK	KAYVDASZRFLFRZ-PQECNABGSA-N
DMIOA9M	IU	(2E,4E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,4,8-trien-1-one
DMIOA9M	CA	CAS 107584-38-3
DMIOA9M	DE	Discovery agent

DM9TWR7	ID	DM9TWR7
DM9TWR7	DN	DEHYDROZINGERONE
DM9TWR7	HS	Investigative
DM9TWR7	SN	Dehydrozingerone; 1080-12-2; Feruloylmethane; 4-(4-Hydroxy-3-methoxyphenyl)-3-buten-2-one; 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one; Vanillalacetone; Dehydro(O)-paradol; MHSK; Dehydrogingerone; Vanylidenacetone; 3-BUTEN-2-ONE, 4-(4-HYDROXY-3-METHOXYPHENYL)-; (O)-Paradol, dehydro-; Vanillidene acetone; 3-Methoxy-4-hydroxybenzalacetone; (O)-Dehydroparadol; (E)-4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one; 4-Hydroxy-3-methoxystyryl methyl ketone; NSC 5316; NSC 4019; Vanillylidene acetone; UNII-8CJX5I27B7; Vanillylideneacetone
DM9TWR7	DT	Small molecular drug
DM9TWR7	PC	5354238
DM9TWR7	MW	192.21
DM9TWR7	FM	C11H12O3
DM9TWR7	IC	InChI=1S/C11H12O3/c1-8(12)3-4-9-5-6-10(13)11(7-9)14-2/h3-7,13H,1-2H3/b4-3+
DM9TWR7	CS	CC(=O)/C=C/C1=CC(=C(C=C1)O)OC
DM9TWR7	IK	AFWKBSMFXWNGRE-ONEGZZNKSA-N
DM9TWR7	IU	(E)-4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one
DM9TWR7	CA	CAS 1080-12-2
DM9TWR7	CB	CHEBI:81361
DM9TWR7	DE	Discovery agent

DMGZ2H5	ID	DMGZ2H5
DMGZ2H5	DN	Del 60 tetramer
DMGZ2H5	HS	Investigative
DMGZ2H5	DT	Aptamer
DMGZ2H5	DE	Solid tumour/cancer

DM5ARHI	ID	DM5ARHI
DM5ARHI	DN	DELTA 8-TETRAHYDROCANNOBINOL
DM5ARHI	HS	Investigative
DM5ARHI	SN	5957-75-5; UNII-B49D0HH807; DELTA 8-TETRAHYDROCANNOBINOL; CHEMBL267227; B49D0HH807; delta8-THC; delta(sup 8)-Thc; delta(sup 6)-Thc; delta-(sup6)-THC; delta-(sup8)-THC; delta6-Tetrahydrocannabinol; delta-6-THC; (-)-delta8-Tetrahydrocannabinol; Cannabinol, delta1(6)-tetrahydro-; delta1(6)-trans-Tetrahydrocannabinol; BRN 0023921; 1-trans-delta-(sup8)-Tetrahydrocannabinol; 1-trans-delta(sup 8)-Tetrahydrocannabinol; (-)-delta(sup 8)-trans-Tetrahydrocannabinol; (-)-delta-(sup8)-trans-Tetrahydrocannabinol; Cannabinol, 1-trans-delta(s
DM5ARHI	DT	Small molecular drug
DM5ARHI	PC	638026
DM5ARHI	MW	314.5
DM5ARHI	FM	C21H30O2
DM5ARHI	IC	InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h9,12-13,16-17,22H,5-8,10-11H2,1-4H3/t16-,17-/m1/s1
DM5ARHI	CS	CCCCCC1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)C)O
DM5ARHI	IK	HCAWPGARWVBULJ-IAGOWNOFSA-N
DM5ARHI	IU	(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DM5ARHI	CA	CAS 5957-75-5
DM5ARHI	DE	Discovery agent

DMB6ADI	ID	DMB6ADI
DMB6ADI	DN	Delta12-PGJ2
DMB6ADI	HS	Investigative
DMB6ADI	SN	Dddd-PGD2; delta(12)-PGJ2; delta-12-prostaglandin D2
DMB6ADI	DT	Small molecular drug
DMB6ADI	PC	5280885
DMB6ADI	MW	334.4
DMB6ADI	FM	C20H30O4
DMB6ADI	IC	InChI=1S/C20H30O4/c1-2-3-6-10-17(21)13-14-18-16(12-15-19(18)22)9-7-4-5-8-11-20(23)24/h4,7,12,14-17,21H,2-3,5-6,8-11,13H2,1H3,(H,23,24)/b7-4-,18-14+/t16-,17-/m0/s1
DMB6ADI	CS	CCCCC[C@@H](C/C=C/1\\[C@H](C=CC1=O)C/C=C\\CCCC(=O)O)O
DMB6ADI	IK	TUXFWOHFPFBNEJ-GJGHEGAFSA-N
DMB6ADI	IU	(Z)-7-[(1S,5E)-5-[(3S)-3-hydroxyoctylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
DMB6ADI	CA	CAS 87893-54-7
DMB6ADI	CB	CHEBI:28130
DMB6ADI	DE	Discovery agent

DML6MVH	ID	DML6MVH
DML6MVH	DN	Delta1-dihydrotestosterone
DML6MVH	HS	Investigative
DML6MVH	SN	1-testosterone; Delta1-dihydrotestosterone; 1-Testo; 65-06-5; 17beta-Hydroxy-5alpha-androst-1-en-3-one; UNII-Y984BV1Q0G; Y984BV1Q0G; 5alpha-androst-1-en-17beta-ol-3-one; 1-T [Steroid]; 5.alpha.-Androst-1-en-3-one, 17.beta.-hydroxy-; AC1L5X4C; Delta(1)-dihydrotestosterone; SCHEMBL867595; CHEBI:59714; DTXSID80215312; OKJCFMUGMSVJBG-ABEVXSGRSA-N; NSC39366; ZINC4791927; NSC121140; NSC-39366; LMST02020110; NSC-121140; DB01481; LS-193302; (5alpha,17beta)-hydroxyandrost-1-en-3-one; C15377; 171T609; 1-T
DML6MVH	DT	Small molecular drug
DML6MVH	PC	236666
DML6MVH	MW	288.4
DML6MVH	FM	C19H28O2
DML6MVH	IC	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12,14-17,21H,3-6,8,10-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
DML6MVH	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(C=CC(=O)C4)C
DML6MVH	IK	OKJCFMUGMSVJBG-ABEVXSGRSA-N
DML6MVH	IU	(5S,8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DML6MVH	CA	CAS 65-06-5
DML6MVH	CB	CHEBI:59714
DML6MVH	DE	Discovery agent

DMV7IAK	ID	DMV7IAK
DMV7IAK	DN	Delta-Amino Valeric Acid
DMV7IAK	HS	Investigative
DMV7IAK	SN	DELTA-AMINO VALERIC ACID; 4-Carboxybutylammonium; AC1L9NAD; 4-carboxybutan-1-aminium; (5-hydroxy-5-oxopentyl)azanium; DB02068
DMV7IAK	DT	Small molecular drug
DMV7IAK	PC	449593
DMV7IAK	MW	118.15
DMV7IAK	FM	C5H12NO2+
DMV7IAK	IC	InChI=1S/C5H11NO2/c6-4-2-1-3-5(7)8/h1-4,6H2,(H,7,8)/p+1
DMV7IAK	CS	C(CC[NH3+])CC(=O)O
DMV7IAK	IK	JJMDCOVWQOJGCB-UHFFFAOYSA-O
DMV7IAK	IU	4-carboxybutylazanium
DMV7IAK	DE	Discovery agent

DMHOT9P	ID	DMHOT9P
DMHOT9P	DN	DELTORPHIN
DMHOT9P	HS	Investigative
DMHOT9P	SN	Deltorphin; Dermenkephalin; Deltorphin A; 119975-64-3; CHEMBL20775; CHEBI:81455; Tyr-met-phe-his-leu-met-asp-NH2; AC1MHYOS; DTXSID60152630; BDBM50000518; Tyrosyl-methionyl-phenylalanyl-histidyl-leucyl-methionyl-aspartamide; ZINC169301619
DMHOT9P	DT	Small molecular drug
DMHOT9P	PC	3035060
DMHOT9P	MW	955.2
DMHOT9P	FM	C44H62N10O10S2
DMHOT9P	IC	InChI=1S/C44H62N10O10S2/c1-25(2)18-34(42(62)50-32(15-17-66-4)40(60)51-33(38(46)58)22-37(56)57)52-44(64)36(21-28-23-47-24-48-28)54-43(63)35(20-26-8-6-5-7-9-26)53-41(61)31(14-16-65-3)49-39(59)30(45)19-27-10-12-29(55)13-11-27/h5-13,23-25,30-36,55H,14-22,45H2,1-4H3,(H2,46,58)(H,47,48)(H,49,59)(H,50,62)(H,51,60)(H,52,64)(H,53,61)(H,54,63)(H,56,57)/t30-,31+,32-,33-,34-,35-,36-/m0/s1
DMHOT9P	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCSC)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMHOT9P	IK	BHSURCCZOBVHJJ-NWOHMYAQSA-N
DMHOT9P	IU	(3S)-4-amino-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DMHOT9P	CA	CAS 119975-64-3
DMHOT9P	CB	CHEBI:81455
DMHOT9P	DE	Discovery agent

DM9ZWRK	ID	DM9ZWRK
DM9ZWRK	DN	DELTORPHIN-II
DM9ZWRK	HS	Investigative
DM9ZWRK	SN	Deltorphin-II; Delt II; Delt-II; (Ala(2))deltorphin II; deltorphin II, Ala(2)-; (Ala(2),glu(4))deltorphin; Deltorphin, ala(2)-glu(4)-; Tyr-ala-phe-glu-val-val-gly-NH2; Deltorphin, alanyl(2)-glutamyl(4)-; Glycinamide, L-tyrosyl-D-alanyl-L-phenylalanyl-L-alpha-glutamyl-L-valyl-L-valyl-; AC1L3XB1; LS-72217
DM9ZWRK	DT	Small molecular drug
DM9ZWRK	PC	123795
DM9ZWRK	MW	782.9
DM9ZWRK	FM	C38H54N8O10
DM9ZWRK	IC	InChI=1S/C38H54N8O10/c1-20(2)31(37(55)41-19-29(40)48)46-38(56)32(21(3)4)45-35(53)27(15-16-30(49)50)43-36(54)28(18-23-9-7-6-8-10-23)44-33(51)22(5)42-34(52)26(39)17-24-11-13-25(47)14-12-24/h6-14,20-22,26-28,31-32,47H,15-19,39H2,1-5H3,(H2,40,48)(H,41,55)(H,42,52)(H,43,54)(H,44,51)(H,45,53)(H,46,56)(H,49,50)/t22-,26+,27+,28+,31+,32?/m1/s1
DM9ZWRK	CS	C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)NC(C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DM9ZWRK	IK	NUNBRHVOPFWRRG-MPNDMYOWSA-N
DM9ZWRK	IU	(4S)-4-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-[[1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM9ZWRK	CA	CAS 122752-16-3
DM9ZWRK	DE	Discovery agent

DMO5UGV	ID	DMO5UGV
DMO5UGV	DN	DEMETHOXYCURCUMIN
DMO5UGV	HS	Investigative
DMO5UGV	SN	Demethoxycurcumin; monodemethoxycurcumin; 22608-11-3; BHCFM; 24939-17-1; 4-Hydroxycinnamoyl(feroyl)methane; desmethoxycurcumin; Feruloyl-P-hydroxycinnnamoylmethane; curcuminII; UNII-W2F8059T80; 33171-16-3; 4-hydroxycinnamoyl(feruloyl)methane; NSC687841; W2F8059T80; 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-; 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; demethoxy-curcumin
DMO5UGV	DT	Small molecular drug
DMO5UGV	PC	5469424
DMO5UGV	MW	338.4
DMO5UGV	FM	C20H18O5
DMO5UGV	IC	InChI=1S/C20H18O5/c1-25-20-12-15(6-11-19(20)24)5-10-18(23)13-17(22)9-4-14-2-7-16(21)8-3-14/h2-12,21,24H,13H2,1H3/b9-4+,10-5+
DMO5UGV	CS	COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC=C(C=C2)O)O
DMO5UGV	IK	HJTVQHVGMGKONQ-LUZURFALSA-N
DMO5UGV	IU	(1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione
DMO5UGV	CA	CAS 22608-11-3
DMO5UGV	CB	CHEBI:65737
DMO5UGV	DE	Discovery agent

DMJBAEP	ID	DMJBAEP
DMJBAEP	DN	DEMETHYLDEBROMOFLUSTRAMINE B
DMJBAEP	HS	Investigative
DMJBAEP	SN	demethyldebromoflustramine B; CHEMBL446242
DMJBAEP	DT	Small molecular drug
DMJBAEP	PC	11173982
DMJBAEP	MW	296.4
DMJBAEP	FM	C20H28N2
DMJBAEP	IC	InChI=1S/C20H28N2/c1-15(2)9-11-20-12-13-21-19(20)22(14-10-16(3)4)18-8-6-5-7-17(18)20/h5-10,19,21H,11-14H2,1-4H3
DMJBAEP	CS	CC(=CCC12CCNC1N(C3=CC=CC=C23)CC=C(C)C)C
DMJBAEP	IK	TWRZIFGLJFJQJK-UHFFFAOYSA-N
DMJBAEP	IU	4,8b-bis(3-methylbut-2-enyl)-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole
DMJBAEP	DE	Discovery agent

DMUVR5T	ID	DMUVR5T
DMUVR5T	DN	DEMETHYLMEDICARPIN
DMUVR5T	HS	Investigative
DMUVR5T	SN	3,9-Dihydroxypterocarpan; demethylmedicarpin; 61135-91-9; (6aR,11aR)-3,9-Dihydroxypterocarpan; CHEMBL1098413; CHEBI:15648; (6aR-cis)-6a,11a-Dihydro-6H-benzofuro(3,2-c)(1)benzopyran-3,9-diol; (6aR,11aR)-6a,11a-dihydro-6H-benzo[4,5]furo[3,2-c]chromene-3,9-diol; C04271; AC1Q70TU; AC1L4S7L; (-)-3,9-dihydroxypterocarpan; DTXSID80210024; ZINC902004; BDBM50317431; AKOS032948673; 6h-benzofuro(3,2-c)(1)benzopyran-3,9-diol, 6a,11a-dihydro-,(6ar-cis)-; W2072; (6aR,11aR)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMUVR5T	DT	Small molecular drug
DMUVR5T	PC	162933
DMUVR5T	MW	256.25
DMUVR5T	FM	C15H12O4
DMUVR5T	IC	InChI=1S/C15H12O4/c16-8-2-4-11-13(5-8)18-7-12-10-3-1-9(17)6-14(10)19-15(11)12/h1-6,12,15-17H,7H2/t12-,15-/m0/s1
DMUVR5T	CS	C1[C@@H]2[C@H](C3=C(O1)C=C(C=C3)O)OC4=C2C=CC(=C4)O
DMUVR5T	IK	ODMIEGVTNZNSLD-WFASDCNBSA-N
DMUVR5T	IU	(6aR,11aR)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMUVR5T	CA	CAS 61135-91-9
DMUVR5T	CB	CHEBI:15648
DMUVR5T	DE	Discovery agent

DMAMS7R	ID	DMAMS7R
DMAMS7R	DN	DEMETHYLZEYLASTERONE
DMAMS7R	HS	Investigative
DMAMS7R	SN	demethylzeylasterone; CHEMBL465251
DMAMS7R	DT	Small molecular drug
DMAMS7R	PC	10391130
DMAMS7R	MW	496.6
DMAMS7R	FM	C29H36O7
DMAMS7R	IC	InChI=1S/C29H36O7/c1-25-6-7-26(2,24(35)36)14-19(25)29(5)11-9-27(3)15-12-17(31)22(32)21(23(33)34)20(15)16(30)13-18(27)28(29,4)10-8-25/h12-13,19,31-32H,6-11,14H2,1-5H3,(H,33,34)(H,35,36)/t19-,25-,26-,27+,28-,29+/m1/s1
DMAMS7R	CS	C[C@]12CC[C@@](C[C@H]1[C@@]3(CC[C@]4(C5=CC(=C(C(=C5C(=O)C=C4[C@]3(CC2)C)C(=O)O)O)O)C)C)(C)C(=O)O
DMAMS7R	IK	IGEUWSSSLAVCIX-GPQUBRLFSA-N
DMAMS7R	IU	(2R,4aS,6aR,6aS,14aS,14bR)-10,11-dihydroxy-2,4a,6a,6a,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2,9-dicarboxylic acid
DMAMS7R	DE	Discovery agent

DMRICV6	ID	DMRICV6
DMRICV6	DN	Demotensin 1
DMRICV6	HS	Investigative
DMRICV6	PC	11847007
DMRICV6	MW	1060.3
DMRICV6	FM	C48H85N17O10
DMRICV6	IC	InChI=1S/C48H85N17O10/c1-5-29(4)39(44(72)63-36(46(74)75)23-28(2)3)64-42(70)35(24-30-12-14-32(66)15-13-30)62-43(71)37-11-8-22-65(37)45(73)34(10-7-19-58-48(53)54)61-41(69)33(9-6-18-57-47(51)52)60-38(67)27-59-40(68)31(25-55-20-16-49)26-56-21-17-50/h12-15,28-29,31,33-37,39,55-56,66H,5-11,16-27,49-50H2,1-4H3,(H,59,68)(H,60,67)(H,61,69)(H,62,71)(H,63,72)(H,64,70)(H,74,75)(H4,51,52,57)(H4,53,54,58)/t29-,33-,34-,35-,36-,37-,39-/m0/s1
DMRICV6	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)C(CNCCN)CNCCN
DMRICV6	IK	HMOSHXNVAPZVAT-INYUMPDKSA-N
DMRICV6	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DMRICV6	DE	Discovery agent

DMW2GA4	ID	DMW2GA4
DMW2GA4	DN	Demotensin 2
DMW2GA4	HS	Investigative
DMW2GA4	PC	56661177
DMW2GA4	MW	1018.3
DMW2GA4	FM	C48H87N15O9
DMW2GA4	IC	InChI=1S/C48H87N15O9/c1-5-31(4)41(45(69)61-38(47(71)72)24-30(2)3)62-43(67)37(25-32-13-15-35(64)16-14-32)60-44(68)39-12-9-23-63(39)46(70)36(11-8-20-56-48(52)53)57-28-34(10-6-7-17-49)59-40(65)29-58-42(66)33(26-54-21-18-50)27-55-22-19-51/h13-16,30-31,33-34,36-39,41,54-55,57,64H,5-12,17-29,49-51H2,1-4H3,(H,58,66)(H,59,65)(H,60,68)(H,61,69)(H,62,67)(H,71,72)(H4,52,53,56)/t31-,34?,36-,37-,38-,39-,41-/m0/s1
DMW2GA4	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NCC(CCCCN)NC(=O)CNC(=O)C(CNCCN)CNCCN
DMW2GA4	IK	DMDCNLGMRLTMHD-PLXGHWBHSA-N
DMW2GA4	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[6-amino-2-[[2-[[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]amino]acetyl]amino]hexyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DMW2GA4	DE	Discovery agent

DMS0V84	ID	DMS0V84
DMS0V84	DN	Demotensin 3
DMS0V84	HS	Investigative
DMS0V84	SN	Demotensin 3; CHEMBL219862
DMS0V84	PC	44413846
DMS0V84	MW	1018.3
DMS0V84	FM	C48H87N15O9
DMS0V84	IC	InChI=1S/C48H87N15O9/c1-30(2)24-37(46(71)72)61-44(69)40(48(3,4)5)62-42(67)36(25-31-13-15-34(64)16-14-31)60-43(68)38-12-9-23-63(38)45(70)35(11-8-20-56-47(52)53)57-28-33(10-6-7-17-49)59-39(65)29-58-41(66)32(26-54-21-18-50)27-55-22-19-51/h13-16,30,32-33,35-38,40,54-55,57,64H,6-12,17-29,49-51H2,1-5H3,(H,58,66)(H,59,65)(H,60,68)(H,61,69)(H,62,67)(H,71,72)(H4,52,53,56)/t33?,35-,36-,37-,38-,40+/m0/s1
DMS0V84	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NCC(CCCCN)NC(=O)CNC(=O)C(CNCCN)CNCCN
DMS0V84	IK	XXQNJIPZSZMHCW-FZJJICHOSA-N
DMS0V84	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[6-amino-2-[[2-[[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]amino]acetyl]amino]hexyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-methylpentanoic acid
DMS0V84	DE	Discovery agent

DMB2HXM	ID	DMB2HXM
DMB2HXM	DN	Demotensin 4
DMB2HXM	HS	Investigative
DMB2HXM	SN	Demotensin 4; CHEMBL375002
DMB2HXM	PC	44413847
DMB2HXM	MW	1046.3
DMB2HXM	FM	C48H87N17O9
DMB2HXM	IC	InChI=1S/C48H87N17O9/c1-29(2)23-36(45(73)74)63-43(71)39(48(3,4)5)64-41(69)35(24-30-12-14-33(66)15-13-30)62-42(70)37-11-8-22-65(37)44(72)34(10-7-19-58-47(53)54)59-27-32(9-6-18-57-46(51)52)61-38(67)28-60-40(68)31(25-55-20-16-49)26-56-21-17-50/h12-15,29,31-32,34-37,39,55-56,59,66H,6-11,16-28,49-50H2,1-5H3,(H,60,68)(H,61,67)(H,62,70)(H,63,71)(H,64,69)(H,73,74)(H4,51,52,57)(H4,53,54,58)/t32?,34-,35-,36-,37-,39+/m0/s1
DMB2HXM	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NCC(CCCN=C(N)N)NC(=O)CNC(=O)C(CNCCN)CNCCN
DMB2HXM	IK	GDXILVHURHRHQL-DTKPYEPFSA-N
DMB2HXM	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[2-[[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-methylpentanoic acid
DMB2HXM	DE	Discovery agent

DMNWRV9	ID	DMNWRV9
DMNWRV9	DN	De-O-sulfonated kotalanol
DMNWRV9	HS	Investigative
DMNWRV9	SN	De-O-Sulfonated Kotalanol
DMNWRV9	DT	Small molecular drug
DMNWRV9	PC	52942310
DMNWRV9	MW	380.84
DMNWRV9	FM	C12H25ClO9S
DMNWRV9	IC	InChI=1S/C12H25O9S.ClH/c13-1-5(15)10(19)12(21)11(20)7(17)4-22-3-6(16)9(18)8(22)2-14;/h5-21H,1-4H2;1H/q+1;/p-1/t5-,6+,7+,8+,9-,10+,11+,12+,22?;/m0./s1
DMNWRV9	CS	C1[C@H]([C@@H]([C@H]([S+]1C[C@H]([C@H]([C@@H]([C@@H]([C@H](CO)O)O)O)O)O)CO)O)O.[Cl-]
DMNWRV9	IK	RCIVZPJZNIFSOZ-RDZATYDKSA-M
DMNWRV9	IU	(2S,3R,4R,5S,6S)-7-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]heptane-1,2,3,4,5,6-hexol;chloride
DMNWRV9	DE	Discovery agent

DM5JFKX	ID	DM5JFKX
DM5JFKX	DN	DEOXY SALVINORIN A
DM5JFKX	HS	Investigative
DM5JFKX	SN	deoxy salvinorin A; CHEMBL378635; SCHEMBL13044189; BDBM50189165; (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-ethoxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-dodecahydro-1H-benzo[f]isochromene-7-carboxylate
DM5JFKX	DT	Small molecular drug
DM5JFKX	PC	44415858
DM5JFKX	MW	418.5
DM5JFKX	FM	C23H30O7
DM5JFKX	IC	InChI=1S/C23H30O7/c1-5-29-16-10-15(20(25)27-4)22(2)8-6-14-21(26)30-17(13-7-9-28-12-13)11-23(14,3)19(22)18(16)24/h7,9,12,14-17,19H,5-6,8,10-11H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1
DM5JFKX	CS	CCO[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DM5JFKX	IK	IYIKKRWPZJDFNB-AGQYDFLVSA-N
DM5JFKX	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-ethoxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM5JFKX	DE	Discovery agent

DMS6X1I	ID	DMS6X1I
DMS6X1I	DN	DEOXYADENOSINE
DMS6X1I	HS	Investigative
DMS6X1I	SN	CHEMBL416340; 9H-Purin-6-amine, 9-(2-deoxy-.beta.-D-ribofuranosyl)-; 9-(2-deoxypentofuranosyl)-9H-purin-6-amine; .beta.-D-erythro-Pentofuranoside, adenine-9 2-deoxy-; .beta.-D-Ribofuranose,2-dideoxy-; 9H-Purin-6-amine, 9-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-; SR-01000397552; 13276-53-4; dAdo
DMS6X1I	DT	Small molecular drug
DMS6X1I	PC	13730
DMS6X1I	MW	251.24
DMS6X1I	FM	C10H13N5O3
DMS6X1I	IC	InChI=1S/C10H13N5O3/c11-9-8-10(13-3-12-9)15(4-14-8)7-1-5(17)6(2-16)18-7/h3-7,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,7+/m0/s1
DMS6X1I	CS	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)CO)O
DMS6X1I	IK	OLXZPDWKRNYJJZ-RRKCRQDMSA-N
DMS6X1I	IU	(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
DMS6X1I	CA	CAS 958-09-8
DMS6X1I	CB	CHEBI:17256

DMYAJCG	ID	DMYAJCG
DMYAJCG	DN	Deoxy-Bigchap
DMYAJCG	HS	Investigative
DMYAJCG	SN	Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide
DMYAJCG	DT	Small molecular drug
DMYAJCG	PC	446320
DMYAJCG	MW	862.1
DMYAJCG	FM	C42H75N3O15
DMYAJCG	IC	InChI=1S/C42H75N3O15/c1-22(26-9-10-27-25-8-7-23-18-24(48)12-13-41(23,2)28(25)19-31(51)42(26,27)3)6-11-32(52)45(16-4-14-43-39(59)37(57)35(55)33(53)29(49)20-46)17-5-15-44-40(60)38(58)36(56)34(54)30(50)21-47/h22-31,33-38,46-51,53-58H,4-21H2,1-3H3,(H,43,59)(H,44,60)/t22-,23-,24-,25+,26-,27+,28+,29-,30-,31+,33-,34-,35+,36+,37-,38-,41+,42-/m1/s1
DMYAJCG	CS	C[C@H](CCC(=O)N(CCCNC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)CCCNC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMYAJCG	IK	OJSUWTDDXLCUFR-HGZMBBKESA-N
DMYAJCG	IU	(2R,3S,4R,5R)-N-[3-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]-[3-[[(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide
DMYAJCG	CA	CAS 86303-23-3
DMYAJCG	DE	Discovery agent

DMW6YLS	ID	DMW6YLS
DMW6YLS	DN	Deoxycorticosterone
DMW6YLS	HS	Investigative
DMW6YLS	SN	11-deoxycorticosterone; 21-hydroxyprogesterone
DMW6YLS	DT	Small molecular drug
DMW6YLS	PC	6166
DMW6YLS	MW	330.5
DMW6YLS	FM	C21H30O3
DMW6YLS	IC	InChI=1S/C21H30O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h11,15-18,22H,3-10,12H2,1-2H3/t15-,16-,17-,18+,20-,21-/m0/s1
DMW6YLS	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)CO)CCC4=CC(=O)CC[C@]34C
DMW6YLS	IK	ZESRJSPZRDMNHY-YFWFAHHUSA-N
DMW6YLS	IU	(8S,9S,10R,13S,14S,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMW6YLS	CA	CAS 64-85-7
DMW6YLS	CB	CHEBI:16973
DMW6YLS	DE	Discovery agent

DMKFMRY	ID	DMKFMRY
DMKFMRY	DN	Deoxyfluorothymidine
DMKFMRY	HS	Investigative
DMKFMRY	PC	66659296
DMKFMRY	MW	244.22
DMKFMRY	FM	C10H13FN2O4
DMKFMRY	IC	InChI=1S/C10H13FN2O4/c1-6-4-13(9(16)12-8(6)15)10(11)3-2-7(5-14)17-10/h4,7,14H,2-3,5H2,1H3,(H,12,15,16)/t7-,10-/m0/s1
DMKFMRY	CS	CC1=CN(C(=O)NC1=O)[C@]2(CC[C@H](O2)CO)F
DMKFMRY	IK	KKBCCKWJPCJQLO-XVKPBYJWSA-N
DMKFMRY	IU	1-[(2S,5S)-2-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMKFMRY	DE	Discovery agent

DMR90HY	ID	DMR90HY
DMR90HY	DN	Deoxythymidine
DMR90HY	HS	Investigative
DMR90HY	SN	Thymidine; thymidine; 50-89-5; deoxythymidine; 2'-Deoxythymidine; Beta-Thymidine; 5-Methyldeoxyuridine; Thymidin; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; 5-Methyldeoxyurindine; dThd; Uridine, 2'-deoxy-5-methyl-; Thymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; dT; UNII-VC2W18DGKR; Deoxyribothymidine; AI3-52267; 2'-thymidine; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748
DMR90HY	DT	Small molecular drug
DMR90HY	PC	5789
DMR90HY	MW	242.23
DMR90HY	FM	C10H14N2O5
DMR90HY	IC	InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m0/s1
DMR90HY	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O
DMR90HY	IK	IQFYYKKMVGJFEH-XLPZGREQSA-N
DMR90HY	IU	1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR90HY	CA	CAS 146183-25-7
DMR90HY	CB	CHEBI:17748
DMR90HY	DE	Discovery agent

DMIFMDC	ID	DMIFMDC
DMIFMDC	DN	Deoxyuridine-5'-Diphosphate
DMIFMDC	HS	Investigative
DMIFMDC	SN	dUDP; DEOXYURIDINE-5'-DIPHOSPHATE; 2'-Deoxyuridine 5'-diphosphate; 4208-67-7; deoxyuridine-diphosphate; Deoxyuridine diphosphate; Uridine 5'-(trihydrogen diphosphate), 2'-deoxy-; CHEMBL9519; CHEBI:28850; 2'-deoxyuridine-5'-diphosphate; 2'-deoxyuridine 5'-(trihydrogen diphosphate); DUD; 1dud; Deoxyuridine 5'-diphosphate; AC1L3RS9; SCHEMBL156694; Uridine, 2'-deoxy-, 5'-(trihydrogen pyrophosphate); DTXSID90194922; 2''-Deoxyuridine-5''-diphosphate; ZINC8217150; DEOXYURIDINE-5''-DIPHOSPHATE; BDBM50179185; DB03413
DMIFMDC	DT	Small molecular drug
DMIFMDC	PC	145729
DMIFMDC	MW	388.16
DMIFMDC	FM	C9H14N2O11P2
DMIFMDC	IC	InChI=1S/C9H14N2O11P2/c12-5-3-8(11-2-1-7(13)10-9(11)14)21-6(5)4-20-24(18,19)22-23(15,16)17/h1-2,5-6,8,12H,3-4H2,(H,18,19)(H,10,13,14)(H2,15,16,17)/t5-,6+,8+/m0/s1
DMIFMDC	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(O)OP(=O)(O)O)O
DMIFMDC	IK	QHWZTVCCBMIIKE-SHYZEUOFSA-N
DMIFMDC	IU	[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMIFMDC	CA	CAS 4208-67-7
DMIFMDC	CB	CHEBI:28850
DMIFMDC	DE	Discovery agent

DMCG5V2	ID	DMCG5V2
DMCG5V2	DN	Deoxyuridine-5'-Triphosphate
DMCG5V2	HS	Investigative
DMCG5V2	SN	dUTP; Deoxyuridine triphosphate; deoxy-UTP; DEOXYURIDINE-5'-TRIPHOSPHATE; 2'-Deoxyuridine 5'-triphosphate; Deoxyuridine 5'-triphosphate; 2'-deoxy-UTP; 2'-Deoxyuracil 5'-triphosphate; 1173-82-6; 102814-08-4; CHEMBL374361; CHEBI:17625; N(4)-Methoxydeoxycytidine triphosphate; 2'-deoxyuridine 5'-(tetrahydrogen triphosphate); Uridine 5'-(tetrahydrogen triphosphate), 2'-deoxy-; 2'-Deoxyuridine-5'-triphosphate trisodium salt; [[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosp
DMCG5V2	DT	Small molecular drug
DMCG5V2	PC	65070
DMCG5V2	MW	468.14
DMCG5V2	FM	C9H15N2O14P3
DMCG5V2	IC	InChI=1S/C9H15N2O14P3/c12-5-3-8(11-2-1-7(13)10-9(11)14)23-6(5)4-22-27(18,19)25-28(20,21)24-26(15,16)17/h1-2,5-6,8,12H,3-4H2,(H,18,19)(H,20,21)(H,10,13,14)(H2,15,16,17)/t5-,6+,8+/m0/s1
DMCG5V2	CS	C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O
DMCG5V2	IK	AHCYMLUZIRLXAA-SHYZEUOFSA-N
DMCG5V2	IU	[[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMCG5V2	CA	CAS 1173-82-6
DMCG5V2	CB	CHEBI:17625
DMCG5V2	DE	Discovery agent

DMGHM1L	ID	DMGHM1L
DMGHM1L	DN	Dephospho Coenzyme A
DMGHM1L	HS	Investigative
DMGHM1L	SN	3'-dephospho-CoA; 3-dephospho-CoA; 3633-59-8; 3'-dephospho-CoA(2-); CHEBI:57328; adenosine 5'-{3-[(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl] diphosphate}
DMGHM1L	DT	Small molecular drug
DMGHM1L	PC	444485
DMGHM1L	MW	687.6
DMGHM1L	FM	C21H35N7O13P2S
DMGHM1L	IC	InChI=1S/C21H35N7O13P2S/c1-21(2,16(32)19(33)24-4-3-12(29)23-5-6-44)8-39-43(36,37)41-42(34,35)38-7-11-14(30)15(31)20(40-11)28-10-27-13-17(22)25-9-26-18(13)28/h9-11,14-16,20,30-32,44H,3-8H2,1-2H3,(H,23,29)(H,24,33)(H,34,35)(H,36,37)(H2,22,25,26)/t11-,14-,15-,16+,20-/m1/s1
DMGHM1L	CS	CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)[C@H](C(=O)NCCC(=O)NCCS)O
DMGHM1L	IK	KDTSHFARGAKYJN-IBOSZNHHSA-N
DMGHM1L	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] hydrogen phosphate
DMGHM1L	CA	CAS 3633-59-8
DMGHM1L	CB	CHEBI:15468
DMGHM1L	DE	Discovery agent

DMRFBD0	ID	DMRFBD0
DMRFBD0	DN	Deprenyl
DMRFBD0	HS	Investigative
DMRFBD0	SN	2323-36-6; CHEBI:50217; N,alpha-Dimethyl-N-2-propynylphenethylamine; N,alpha-Dimethyl-N-2-propynylbenzeneethanamine; methyl(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine; PHENETHYLAMINE, N,alpha-DIMETHYL-N-2-PROPYNYL-; N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine; dl-Deprenyl; phenylisopropyl-n-methylpropinylamine; AC1L1JT6; CHEMBL8663; SCHEMBL74753; cid_92913; 4-fluorodeprenyl, (-)-isomer; BDBM39862; MEZLKOACVSPNER-UHFFFAOYSA-N; HMS2089B08; AC1Q2862; MCULE-3188554308; ACM2323366
DMRFBD0	DT	Small molecular drug
DMRFBD0	PC	5195
DMRFBD0	MW	187.28
DMRFBD0	FM	C13H17N
DMRFBD0	IC	InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3
DMRFBD0	CS	CC(CC1=CC=CC=C1)N(C)CC#C
DMRFBD0	IK	MEZLKOACVSPNER-UHFFFAOYSA-N
DMRFBD0	IU	N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
DMRFBD0	CA	CAS 2323-36-6
DMRFBD0	CB	CHEBI:50217
DMRFBD0	DE	Discovery agent

DMH340E	ID	DMH340E
DMH340E	DN	Deprotected cogener of M6G
DMH340E	HS	Investigative
DMH340E	SN	Deprotected cogener of M6G; CHEMBL362202
DMH340E	DT	Small molecular drug
DMH340E	PC	44390358
DMH340E	MW	504.6
DMH340E	FM	C26H36N2O8
DMH340E	IC	InChI=1S/C26H36N2O8/c1-28-8-7-26-15(18(28)9-13-3-4-14(30)10-16(13)26)5-6-17(25(26)35-2)27-21(31)11-19-22(32)24(34)23(33)20(12-29)36-19/h3-6,10,15,17-20,22-25,29-30,32-34H,7-9,11-12H2,1-2H3,(H,27,31)/t15-,17+,18+,19?,20?,22?,23?,24?,25?,26-/m0/s1
DMH340E	CS	CN1CC[C@]23[C@H]([C@H]1CC4=C2C=C(C=C4)O)C=C[C@H](C3OC)NC(=O)CC5C(C(C(C(O5)CO)O)O)O
DMH340E	IK	RSJUYYKJXWPIQQ-LEBYPUKTSA-N
DMH340E	IU	N-[(1S,9R,10R,13R)-4-hydroxy-14-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-yl]-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide
DMH340E	DE	Discovery agent

DM4JM50	ID	DM4JM50
DM4JM50	DN	DEPX
DM4JM50	HS	Investigative
DM4JM50	SN	1,3-Diethyl-8-phenylxanthine; 75922-48-4; UNII-2KCV39GKGL; 2KCV39GKGL; 1,3-Dithyl-8-phenylxanthine; CHEMBL11348; 1,3-diethyl-8-phenyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione,1,3-diethyl-3,9-dihydro-8-phenyl-; Lopac-A-003; AC1Q6LCB; AC1L1B8H; Lopac0_000125; GTPL445; 8-Phenyl-1,3-diethylxanthine; SCHEMBL1321894; AC1Q312F; 1,3-Diethyl-8-phenyl-3,7-dihydro-purine-2,6-dione; BDBM81971; CTK5E2202; CAS_1328; ZINC9229229; NSC_1328; PDSP2_000975; PDSP1_000991; PDSP2_000324; PDSP2_000321; PDSP1_000326; PDSP1_000323; AKOS027378654;  1,3-diethyl-8-phenylxanthine; DPX
DM4JM50	DT	Small molecular drug
DM4JM50	PC	1328
DM4JM50	MW	284.31
DM4JM50	FM	C15H16N4O2
DM4JM50	IC	InChI=1S/C15H16N4O2/c1-3-18-13-11(14(20)19(4-2)15(18)21)16-12(17-13)10-8-6-5-7-9-10/h5-9H,3-4H2,1-2H3,(H,16,17)
DM4JM50	CS	CCN1C2=C(C(=O)N(C1=O)CC)NC(=N2)C3=CC=CC=C3
DM4JM50	IK	LVSWNSHUTPWCNF-UHFFFAOYSA-N
DM4JM50	IU	1,3-diethyl-8-phenyl-7H-purine-2,6-dione
DM4JM50	CA	CAS 75922-48-4
DM4JM50	DE	Discovery agent

DM2XT7S	ID	DM2XT7S
DM2XT7S	DN	D-Eritadenine
DM2XT7S	HS	Investigative
DM2XT7S	SN	AC1O59J4; ZINC3872190; (2S,3R)-4-(6-aminopurin-9-yl)-2,3-dihydroxybutanoic acid; (2S,3R)-4-(6-aminopurin-9-yl)-2,3-dihydroxy-butanoic acid; 9H-Purine-9-propanoic acid, 6-amino-alpha-hydroxy-, (alphaR)-
DM2XT7S	DT	Small molecular drug
DM2XT7S	PC	159961
DM2XT7S	MW	253.22
DM2XT7S	FM	C9H11N5O4
DM2XT7S	IC	InChI=1S/C9H11N5O4/c10-7-5-8(12-2-11-7)14(3-13-5)1-4(15)6(16)9(17)18/h2-4,6,15-16H,1H2,(H,17,18)(H2,10,11,12)/t4-,6-/m1/s1
DM2XT7S	CS	C1=NC(=C2C(=N1)N(C=N2)C[C@H]([C@H](C(=O)O)O)O)N
DM2XT7S	IK	LIEMBEWXEZJEEZ-INEUFUBQSA-N
DM2XT7S	IU	(2R,3R)-4-(6-aminopurin-9-yl)-2,3-dihydroxybutanoic acid
DM2XT7S	CA	CAS 23918-98-1

DMCYQHO	ID	DMCYQHO
DMCYQHO	DN	DERMORPHIN
DMCYQHO	HS	Investigative
DMCYQHO	SN	Dermorphin; 77614-16-5; H-Tyr-D-ala-phe-gly-tyr-pro-ser-NH2; UNII-2SEC01B703; DERMORPHIN ACETATE; Tyrosyl-alanyl-phenylalanyl-glycyl-tyrosyl-prolyl-serinamide; CHEMBL278789; 2SEC01B703; Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2; AC1NUNYZ; YAFGYPS-NH2; SCHEMBL237169; Tyr-Ala-Phe-Gly-Tyr-Pro-Ser; DTXSID40228281; HY-P0244
DMCYQHO	DT	Small molecular drug
DMCYQHO	PC	5485199
DMCYQHO	MW	802.9
DMCYQHO	FM	C40H50N8O10
DMCYQHO	IC	InChI=1S/C40H50N8O10/c1-23(44-37(55)29(41)18-25-9-13-27(50)14-10-25)36(54)46-30(19-24-6-3-2-4-7-24)38(56)43-21-34(52)45-31(20-26-11-15-28(51)16-12-26)40(58)48-17-5-8-33(48)39(57)47-32(22-49)35(42)53/h2-4,6-7,9-16,23,29-33,49-51H,5,8,17-22,41H2,1H3,(H2,42,53)(H,43,56)(H,44,55)(H,45,52)(H,46,54)(H,47,57)/t23-,29+,30+,31+,32+,33+/m1/s1
DMCYQHO	CS	C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMCYQHO	IK	FHZPGIUBXYVUOY-VWGYHWLBSA-N
DMCYQHO	IU	(2S)-N-[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]-1-[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DMCYQHO	CA	CAS 77614-16-5
DMCYQHO	DE	Discovery agent

DMMWDC5	ID	DMMWDC5
DMMWDC5	DN	Des-AA1,2,4,12,13-[D-Trp8]SRIF
DMMWDC5	HS	Investigative
DMMWDC5	SN	CHEMBL263587; Des-AA1,2,4,12,13-[D-Trp8]SRIF
DMMWDC5	PC	44388046
DMMWDC5	MW	1193.4
DMMWDC5	FM	C58H72N12O12S2
DMMWDC5	IC	InChI=1S/C58H72N12O12S2/c1-33(71)49-57(80)68-44(27-36-19-9-4-10-20-36)54(77)69-47(58(81)82)32-84-83-31-39(60)50(73)64-46(29-48(61)72)56(79)66-42(25-34-15-5-2-6-16-34)52(75)65-43(26-35-17-7-3-8-18-35)53(76)67-45(28-37-30-62-40-22-12-11-21-38(37)40)55(78)63-41(51(74)70-49)23-13-14-24-59/h2-12,15-22,30,33,39,41-47,49,62,71H,13-14,23-29,31-32,59-60H2,1H3,(H2,61,72)(H,63,78)(H,64,73)(H,65,75)(H,66,79)(H,67,76)(H,68,80)(H,69,77)(H,70,74)(H,81,82)/t33-,39-,41+,42-,43+,44+,45+,46+,47+,49-/m1/s1
DMMWDC5	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)N)C(=O)O)CC6=CC=CC=C6)O
DMMWDC5	IK	LAZNVYHNZZBPSL-ZXQPUDBWSA-N
DMMWDC5	IU	(4R,7S,10R,13S,16S,19S,22R,25S,28S)-28-amino-13-(4-aminobutyl)-25-(2-amino-2-oxoethyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DMMWDC5	DE	Discovery agent

DMR6Z2N	ID	DMR6Z2N
DMR6Z2N	DN	Des-AA1,2,4,13-[D-Trp8]SRIF
DMR6Z2N	HS	Investigative
DMR6Z2N	SN	CHEMBL410047; Des-AA1,2,4,13-[D-Trp8]SRIF
DMR6Z2N	PC	44388125
DMR6Z2N	MW	1294.5
DMR6Z2N	FM	C62H79N13O14S2
DMR6Z2N	IC	InChI=1S/C62H79N13O14S2/c1-34(76)51-60(86)72-46(28-38-20-10-5-11-21-38)59(85)75-52(35(2)77)61(87)73-49(62(88)89)33-91-90-32-41(64)53(79)68-48(30-50(65)78)58(84)70-44(26-36-16-6-3-7-17-36)55(81)69-45(27-37-18-8-4-9-19-37)56(82)71-47(29-39-31-66-42-23-13-12-22-40(39)42)57(83)67-43(54(80)74-51)24-14-15-25-63/h3-13,16-23,31,34-35,41,43-49,51-52,66,76-77H,14-15,24-30,32-33,63-64H2,1-2H3,(H2,65,78)(H,67,83)(H,68,79)(H,69,81)(H,70,84)(H,71,82)(H,72,86)(H,73,87)(H,74,80)(H,75,85)(H,88,89)/t34-,35-,41-,43+,44-,45+,46+,47+,48+,49+,51-,52-/m1/s1
DMR6Z2N	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)N)C(=O)O)[C@@H](C)O)CC6=CC=CC=C6)O
DMR6Z2N	IK	AQDRYTXOCJPYQG-WJYXJFIFSA-N
DMR6Z2N	IU	(4R,7R,10S,13R,16S,19S,22S,25R,28S,31S)-31-amino-16-(4-aminobutyl)-28-(2-amino-2-oxoethyl)-10,22,25-tribenzyl-7,13-bis[(1R)-1-hydroxyethyl]-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carboxylic acid
DMR6Z2N	DE	Discovery agent

DMEVOD2	ID	DMEVOD2
DMEVOD2	DN	Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF
DMEVOD2	HS	Investigative
DMEVOD2	SN	CHEMBL438285; Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF
DMEVOD2	DT	Small molecular drug
DMEVOD2	PC	44388051
DMEVOD2	MW	978.2
DMEVOD2	FM	C50H59N9O8S2
DMEVOD2	IC	InChI=1S/C50H59N9O8S2/c51-23-13-12-22-38-45(61)56-41(26-33-18-8-3-9-19-33)48(64)59-43(50(66)67)30-69-68-29-36(52)44(60)55-39(24-31-14-4-1-5-15-31)46(62)57-40(25-32-16-6-2-7-17-32)47(63)58-42(49(65)54-38)27-34-28-53-37-21-11-10-20-35(34)37/h1-11,14-21,28,36,38-43,53H,12-13,22-27,29-30,51-52H2,(H,54,65)(H,55,60)(H,56,61)(H,57,62)(H,58,63)(H,59,64)(H,66,67)/t36-,38+,39-,40+,41+,42+,43+/m1/s1
DMEVOD2	CS	C1[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)O)CC2=CC=CC=C2)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)N
DMEVOD2	IK	NQJATBPHPBJDPZ-CEDQUOLKSA-N
DMEVOD2	IU	(4R,7S,10S,13S,16S,19R,22S)-22-amino-10-(4-aminobutyl)-7,16,19-tribenzyl-13-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxylic acid
DMEVOD2	DE	Discovery agent

DMJI6BK	ID	DMJI6BK
DMJI6BK	DN	Des-AA1,2,4,5,11,12,13-[D-Trp8]SRIF
DMJI6BK	HS	Investigative
DMJI6BK	SN	CHEMBL368304; Des-AA1,2,4,5,11,12,13-[D-Trp8]SRIF
DMJI6BK	DT	Small molecular drug
DMJI6BK	PC	44388050
DMJI6BK	MW	932.1
DMJI6BK	FM	C45H57N9O9S2
DMJI6BK	IC	InChI=1S/C45H57N9O9S2/c1-26(55)38-44(61)53-37(45(62)63)25-65-64-24-31(47)39(56)50-34(20-27-12-4-2-5-13-27)41(58)51-35(21-28-14-6-3-7-15-28)42(59)52-36(22-29-23-48-32-17-9-8-16-30(29)32)43(60)49-33(40(57)54-38)18-10-11-19-46/h2-9,12-17,23,26,31,33-38,48,55H,10-11,18-22,24-25,46-47H2,1H3,(H,49,60)(H,50,56)(H,51,58)(H,52,59)(H,53,61)(H,54,57)(H,62,63)/t26-,31-,33+,34-,35+,36+,37+,38-/m1/s1
DMJI6BK	CS	C[C@H]([C@@H]1C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)O
DMJI6BK	IK	SEXJHXQMYWDZHJ-CNNVYZKHSA-N
DMJI6BK	IU	(4R,7R,10S,13S,16S,19R,22S)-22-amino-10-(4-aminobutyl)-16,19-dibenzyl-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxylic acid
DMJI6BK	DE	Discovery agent

DMYZXEO	ID	DMYZXEO
DMYZXEO	DN	Des-AA1,2,4,5,13-[D-Trp8]-SRIF
DMYZXEO	HS	Investigative
DMYZXEO	SN	CHEMBL386784; Des-AA1,2,4,5,13-[D-Trp8]-SRIF
DMYZXEO	PC	44388023
DMYZXEO	MW	1180.4
DMYZXEO	FM	C58H73N11O12S2
DMYZXEO	IC	InChI=1S/C58H73N11O12S2/c1-33(70)48-56(78)66-45(28-37-20-10-5-11-21-37)55(77)69-49(34(2)71)57(79)67-47(58(80)81)32-83-82-31-40(60)50(72)63-43(26-35-16-6-3-7-17-35)52(74)64-44(27-36-18-8-4-9-19-36)53(75)65-46(29-38-30-61-41-23-13-12-22-39(38)41)54(76)62-42(51(73)68-48)24-14-15-25-59/h3-13,16-23,30,33-34,40,42-49,61,70-71H,14-15,24-29,31-32,59-60H2,1-2H3,(H,62,76)(H,63,72)(H,64,74)(H,65,75)(H,66,78)(H,67,79)(H,68,73)(H,69,77)(H,80,81)/t33-,34-,40-,42+,43-,44+,45+,46+,47+,48-,49-/m1/s1
DMYZXEO	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)[C@@H](C)O)CC6=CC=CC=C6)O
DMYZXEO	IK	IHKVTDBEFCOKGW-FNLAWZLKSA-N
DMYZXEO	IU	(4R,7R,10S,13R,16S,19S,22S,25R,28S)-28-amino-16-(4-aminobutyl)-10,22,25-tribenzyl-7,13-bis[(1R)-1-hydroxyethyl]-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DMYZXEO	DE	Discovery agent

DM6HZ8D	ID	DM6HZ8D
DM6HZ8D	DN	Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF
DM6HZ8D	HS	Investigative
DM6HZ8D	SN	CHEMBL367125; Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF
DM6HZ8D	DT	Small molecular drug
DM6HZ8D	PC	44388049
DM6HZ8D	MW	932.1
DM6HZ8D	FM	C45H57N9O9S2
DM6HZ8D	IC	InChI=1S/C45H57N9O9S2/c1-26(55)38-44(61)52-35(21-28-14-6-3-7-15-28)42(59)53-37(45(62)63)25-65-64-24-31(47)39(56)50-34(20-27-12-4-2-5-13-27)41(58)51-36(22-29-23-48-32-17-9-8-16-30(29)32)43(60)49-33(40(57)54-38)18-10-11-19-46/h2-9,12-17,23,26,31,33-38,48,55H,10-11,18-22,24-25,46-47H2,1H3,(H,49,60)(H,50,56)(H,51,58)(H,52,61)(H,53,59)(H,54,57)(H,62,63)/t26-,31-,33+,34+,35+,36+,37+,38-/m1/s1
DM6HZ8D	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)N)C(=O)O)CC5=CC=CC=C5)O
DM6HZ8D	IK	GGSHKARHPHVZOO-KLCDHWPJSA-N
DM6HZ8D	IU	(4R,7S,10R,13S,16S,19S,22S)-22-amino-13-(4-aminobutyl)-7,19-dibenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxylic acid
DM6HZ8D	DE	Discovery agent

DMEN4G8	ID	DMEN4G8
DMEN4G8	DN	Des-AA1,2,4,5-[D-Trp8]SRIF
DMEN4G8	HS	Investigative
DMEN4G8	SN	CHEMBL436962; Des-AA1,2,4,5-[D-Trp8]SRIF
DMEN4G8	PC	44388022
DMEN4G8	MW	1267.5
DMEN4G8	FM	C61H78N12O14S2
DMEN4G8	IC	InChI=1S/C61H78N12O14S2/c1-34(75)50-59(84)69-46(28-38-20-10-5-11-21-38)57(82)73-51(35(2)76)60(85)70-48(31-74)58(83)71-49(61(86)87)33-89-88-32-41(63)52(77)66-44(26-36-16-6-3-7-17-36)54(79)67-45(27-37-18-8-4-9-19-37)55(80)68-47(29-39-30-64-42-23-13-12-22-40(39)42)56(81)65-43(53(78)72-50)24-14-15-25-62/h3-13,16-23,30,34-35,41,43-51,64,74-76H,14-15,24-29,31-33,62-63H2,1-2H3,(H,65,81)(H,66,77)(H,67,79)(H,68,80)(H,69,84)(H,70,85)(H,71,83)(H,72,78)(H,73,82)(H,86,87)/t34-,35-,41-,43+,44-,45+,46+,47+,48+,49+,50-,51-/m1/s1
DMEN4G8	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)CO)[C@@H](C)O)CC6=CC=CC=C6)O
DMEN4G8	IK	CGHVCXMPDMMIFL-JFJBRMBESA-N
DMEN4G8	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31S)-31-amino-19-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carboxylic acid
DMEN4G8	DE	Discovery agent

DMZPXGY	ID	DMZPXGY
DMZPXGY	DN	Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF
DMZPXGY	HS	Investigative
DMZPXGY	SN	CHEMBL265836; Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF
DMZPXGY	PC	44388048
DMZPXGY	MW	1297.6
DMZPXGY	FM	C67H84N12O11S2
DMZPXGY	IC	InChI=1S/C67H84N12O11S2/c1-40(2)70-36-46-28-26-45(27-29-46)34-55-65(87)79-58(41(3)80)66(88)77-54(33-44-21-11-6-12-22-44)63(85)78-57(67(89)90)39-92-91-38-49(69)59(81)72-51(25-15-16-30-68)60(82)73-52(31-42-17-7-4-8-18-42)61(83)74-53(32-43-19-9-5-10-20-43)62(84)76-56(64(86)75-55)35-47-37-71-50-24-14-13-23-48(47)50/h4-14,17-24,26-29,37,40-41,49,51-58,70-71,80H,15-16,25,30-36,38-39,68-69H2,1-3H3,(H,72,81)(H,73,82)(H,74,83)(H,75,86)(H,76,84)(H,77,88)(H,78,85)(H,79,87)(H,89,90)/t41-,49-,51-,52-,53+,54+,55+,56+,57+,58-/m1/s1
DMZPXGY	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CC7=CC=CC=C7)O
DMZPXGY	IK	CRBKELXXBMEXSB-BHKHLLRWSA-N
DMZPXGY	IU	(4R,7S,10R,13S,16S,19S,22R,25R,28S)-28-amino-25-(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-13-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DMZPXGY	DE	Discovery agent

DM1KJAE	ID	DM1KJAE
DM1KJAE	DN	Des-AA1,2,5,12,13-[D-Trp8]SRIF
DM1KJAE	HS	Investigative
DM1KJAE	SN	CHEMBL216992; Des-AA1,2,5,12,13-[D-Trp8]SRIF
DM1KJAE	PC	44388047
DM1KJAE	MW	1207.5
DM1KJAE	FM	C60H78N12O11S2
DM1KJAE	IC	InChI=1S/C60H78N12O11S2/c1-36(73)51-59(81)70-48(31-39-21-9-4-10-22-39)57(79)71-50(60(82)83)35-85-84-34-42(63)52(74)65-44(25-13-15-27-61)53(75)67-46(29-37-17-5-2-6-18-37)55(77)68-47(30-38-19-7-3-8-20-38)56(78)69-49(32-40-33-64-43-24-12-11-23-41(40)43)58(80)66-45(54(76)72-51)26-14-16-28-62/h2-12,17-24,33,36,42,44-51,64,73H,13-16,25-32,34-35,61-63H2,1H3,(H,65,74)(H,66,80)(H,67,75)(H,68,77)(H,69,78)(H,70,81)(H,71,79)(H,72,76)(H,82,83)/t36-,42-,44-,45+,46-,47+,48+,49+,50+,51-/m1/s1
DM1KJAE	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CCCCN)N)C(=O)O)CC6=CC=CC=C6)O
DM1KJAE	IK	ANCUAJMQRRZZNC-JFMJRBFYSA-N
DM1KJAE	IU	(4R,7S,10R,13S,16S,19S,22R,25R,28S)-28-amino-13,25-bis(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DM1KJAE	DE	Discovery agent

DMVYHGI	ID	DMVYHGI
DMVYHGI	DN	Des-AA1,2,5-[(NalphaMe)Cys3,D-Nal8,IAmp9]SRIF
DMVYHGI	HS	Investigative
DMVYHGI	SN	CHEMBL408611; Des-AA1,2,5-[(NalphaMe)Cys3,D-Nal8,IAmp9]SRIF
DMVYHGI	PC	44388131
DMVYHGI	MW	1510.8
DMVYHGI	FM	C77H99N13O15S2
DMVYHGI	IC	InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)39-59-71(98)89-65(46(3)92)75(102)86-60(38-50-23-13-8-14-24-50)72(99)90-66(47(4)93)76(103)87-62(42-91)73(100)88-64(77(104)105)44-107-106-43-63(79-5)74(101)81-56(27-17-18-34-78)67(94)82-57(36-48-19-9-6-10-20-48)68(95)83-58(37-49-21-11-7-12-22-49)69(96)85-61(70(97)84-59)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,79-80,91-93H,17-18,27,34,36-44,78H2,1-5H3,(H,81,101)(H,82,94)(H,83,95)(H,84,97)(H,85,96)(H,86,102)(H,87,103)(H,88,100)(H,89,98)(H,90,99)(H,104,105)/t46-,47-,56-,57-,58+,59+,60+,61+,62+,63-,64+,65-,66-/m1/s1
DMVYHGI	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)NC)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMVYHGI	IK	ZXYYWYGCHOCUCC-TWURSWGVSA-N
DMVYHGI	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-34-(methylamino)-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMVYHGI	DE	Discovery agent

DMY6NID	ID	DMY6NID
DMY6NID	DN	Des-AA1,2,5-[(NalphaMe)Cys3,D-Trp8,IAmp9]SRIF
DMY6NID	HS	Investigative
DMY6NID	SN	CHEMBL265120; Des-AA1,2,5-[(NalphaMe)Cys3,D-Trp8,IAmp9]SRIF
DMY6NID	PC	44388071
DMY6NID	MW	1499.8
DMY6NID	FM	C75H98N14O15S2
DMY6NID	IC	InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)36-57-69(97)88-63(44(3)91)73(101)85-58(35-48-23-13-8-14-24-48)70(98)89-64(45(4)92)74(102)86-60(40-90)71(99)87-62(75(103)104)42-106-105-41-61(77-5)72(100)80-54(27-17-18-32-76)65(93)81-55(33-46-19-9-6-10-20-46)66(94)82-56(34-47-21-11-7-12-22-47)67(95)84-59(68(96)83-57)37-51-39-79-53-26-16-15-25-52(51)53/h6-16,19-26,28-31,39,43-45,54-64,77-79,90-92H,17-18,27,32-38,40-42,76H2,1-5H3,(H,80,100)(H,81,93)(H,82,94)(H,83,96)(H,84,95)(H,85,101)(H,86,102)(H,87,99)(H,88,97)(H,89,98)(H,103,104)/t44-,45-,54-,55-,56+,57+,58+,59+,60+,61-,62+,63-,64-/m1/s1
DMY6NID	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)NC)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMY6NID	IK	TUTDPAIJDZFFHJ-NLGCSLGGSA-N
DMY6NID	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-34-(methylamino)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMY6NID	DE	Discovery agent

DMQPVGO	ID	DMQPVGO
DMQPVGO	DN	Des-AA1,2,5-[(NalphaMe)D-Nal8,IAmp9]SRIF
DMQPVGO	HS	Investigative
DMQPVGO	SN	CHEMBL407125; Des-AA1,2,5-[(NalphaMe)D-Nal8,IAmp9]SRIF
DMQPVGO	PC	44388041
DMQPVGO	MW	1510.8
DMQPVGO	FM	C77H99N13O15S2
DMQPVGO	IC	InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)38-59-70(97)88-65(46(3)92)74(101)84-60(37-49-21-11-7-12-22-49)71(98)89-66(47(4)93)75(102)86-62(42-91)72(99)87-63(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)85-61(39-50-23-13-8-14-24-50)76(103)90(5)64(73(100)83-59)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,100)(H,84,101)(H,85,96)(H,86,102)(H,87,99)(H,88,97)(H,89,98)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMQPVGO	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)C)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMQPVGO	IK	QWPPERHSUFQZTH-PCKPOTSRSA-N
DMQPVGO	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-23-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMQPVGO	DE	Discovery agent

DM478XZ	ID	DM478XZ
DM478XZ	DN	Des-AA1,2,5-[(NalphaMe)Lys4,D-Nal8,IAmp9]SRIF
DM478XZ	HS	Investigative
DM478XZ	SN	CHEMBL406559; Des-AA1,2,5-[(NalphaMe)Lys4,D-Nal8,IAmp9]SRIF
DM478XZ	PC	44388034
DM478XZ	MW	1510.8
DM478XZ	FM	C77H99N13O15S2
DM478XZ	IC	InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)39-59-70(97)88-65(46(3)92)74(101)85-60(38-50-23-13-8-14-24-50)71(98)89-66(47(4)93)75(102)86-62(42-91)72(99)87-63(77(104)105)44-107-106-43-56(79)76(103)90(5)64(27-17-18-34-78)73(100)84-58(37-49-21-11-7-12-22-49)68(95)81-57(36-48-19-9-6-10-20-48)67(94)83-61(69(96)82-59)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,95)(H,82,96)(H,83,94)(H,84,100)(H,85,101)(H,86,102)(H,87,99)(H,88,97)(H,89,98)(H,104,105)/t46-,47-,56-,57+,58-,59+,60+,61+,62+,63+,64-,65-,66-/m1/s1
DM478XZ	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N([C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)C)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DM478XZ	IK	MQVPKOMHWCOKLK-DXVDGIIASA-N
DM478XZ	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-32-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM478XZ	DE	Discovery agent

DMQOL73	ID	DMQOL73
DMQOL73	DN	Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9,Tyr11]SRIF
DMQOL73	HS	Investigative
DMQOL73	SN	CHEMBL384195; Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9,Tyr11]SRIF
DMQOL73	PC	44388111
DMQOL73	MW	1526.8
DMQOL73	FM	C77H99N13O16S2
DMQOL73	IC	InChI=1S/C77H99N13O16S2/c1-44(2)80-40-51-25-23-50(24-26-51)39-64-73(101)89-66(46(4)93)74(102)84-60(37-49-28-31-55(94)32-29-49)71(99)88-65(45(3)92)75(103)86-62(41-91)72(100)87-63(77(105)106)43-108-107-42-56(79)67(95)81-57(22-14-15-33-78)68(96)82-58(35-47-16-8-6-9-17-47)69(97)83-59(36-48-18-10-7-11-19-48)70(98)85-61(76(104)90(64)5)38-52-27-30-53-20-12-13-21-54(53)34-52/h6-13,16-21,23-32,34,44-46,56-66,80,91-94H,14-15,22,33,35-43,78-79H2,1-5H3,(H,81,95)(H,82,96)(H,83,97)(H,84,102)(H,85,98)(H,86,103)(H,87,100)(H,88,99)(H,89,101)(H,105,106)/t45-,46-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMQOL73	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CC5=CC=CC=C5C=C4)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DMQOL73	IK	UJXURZZWDWWNQY-SKAXSEQXSA-N
DMQOL73	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-20-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMQOL73	DE	Discovery agent

DMN4ZYO	ID	DMN4ZYO
DMN4ZYO	DN	Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9]SRIF
DMN4ZYO	HS	Investigative
DMN4ZYO	SN	CHEMBL427658; Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9]SRIF
DMN4ZYO	PC	44388042
DMN4ZYO	MW	1510.8
DMN4ZYO	FM	C77H99N13O15S2
DMN4ZYO	IC	InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)40-64-73(100)89-66(47(4)93)74(101)84-60(38-50-23-13-8-14-24-50)71(98)88-65(46(3)92)75(102)86-62(42-91)72(99)87-63(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-61(76(103)90(64)5)39-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,101)(H,85,97)(H,86,102)(H,87,99)(H,88,98)(H,89,100)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMN4ZYO	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CC5=CC=CC=C5C=C4)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DMN4ZYO	IK	JNLTXZJTSBQWNR-PCKPOTSRSA-N
DMN4ZYO	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-20-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMN4ZYO	DE	Discovery agent

DMXD60K	ID	DMXD60K
DMXD60K	DN	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Cys14]SRIF
DMXD60K	HS	Investigative
DMXD60K	SN	CHEMBL438576; Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Cys14]SRIF
DMXD60K	PC	44388056
DMXD60K	MW	1510.8
DMXD60K	FM	C77H99N13O15S2
DMXD60K	IC	InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)39-60-72(99)88-65(46(3)92)74(101)86-61(38-50-23-13-8-14-24-50)73(100)89-66(47(4)93)75(102)87-63(42-91)76(103)90(5)64(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-62(71(98)84-60)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,98)(H,85,97)(H,86,101)(H,87,102)(H,88,99)(H,89,100)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMXD60K	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N([C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)C)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMXD60K	IK	OCBPOFXOMWHIND-PCKPOTSRSA-N
DMXD60K	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-5-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMXD60K	DE	Discovery agent

DM0574W	ID	DM0574W
DM0574W	DN	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Phe11]SRIF
DM0574W	HS	Investigative
DM0574W	SN	CHEMBL415143; Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Phe11]SRIF
DM0574W	PC	44388044
DM0574W	MW	1510.8
DM0574W	FM	C77H99N13O15S2
DM0574W	IC	InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)38-60-72(99)89-66(47(4)93)76(103)90(5)64(40-50-23-13-8-14-24-50)74(101)88-65(46(3)92)75(102)86-62(42-91)73(100)87-63(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-61(71(98)84-60)39-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,98)(H,85,97)(H,86,102)(H,87,100)(H,88,101)(H,89,99)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DM0574W	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N1)CC2=CC=CC=C2)C)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)CC4=CC5=CC=CC=C5C=C4)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DM0574W	IK	VSHSVJQIYKFIKJ-PCKPOTSRSA-N
DM0574W	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-14-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM0574W	DE	Discovery agent

DMOZ9WC	ID	DMOZ9WC
DMOZ9WC	DN	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Ser13]SRIF
DMOZ9WC	HS	Investigative
DMOZ9WC	SN	CHEMBL264839; Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Ser13]SRIF
DMOZ9WC	PC	44388055
DMOZ9WC	MW	1510.8
DMOZ9WC	FM	C77H99N13O15S2
DMOZ9WC	IC	InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)39-60-72(99)88-65(46(3)92)75(102)86-61(38-50-23-13-8-14-24-50)73(100)89-66(47(4)93)76(103)90(5)64(42-91)74(101)87-63(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-62(71(98)84-60)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,98)(H,85,97)(H,86,102)(H,87,101)(H,88,99)(H,89,100)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMOZ9WC	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)C)[C@@H](C)O)CC7=CC=CC=C7)O
DMOZ9WC	IK	XJZZHUHCSZMQGG-PCKPOTSRSA-N
DMOZ9WC	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-8-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMOZ9WC	DE	Discovery agent

DMYFCB0	ID	DMYFCB0
DMYFCB0	DN	Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF
DMYFCB0	HS	Investigative
DMYFCB0	SN	CHEMBL437905; Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF
DMYFCB0	PC	44388045
DMYFCB0	MW	1510.8
DMYFCB0	FM	C77H99N13O15S2
DMYFCB0	IC	InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)38-60-72(99)89-65(46(3)92)74(101)86-62(39-50-23-13-8-14-24-50)76(103)90(5)66(47(4)93)75(102)87-63(42-91)73(100)88-64(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-61(71(98)84-60)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,98)(H,85,97)(H,86,101)(H,87,102)(H,88,100)(H,89,99)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMYFCB0	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)C)CC7=CC=CC=C7)O
DMYFCB0	IK	NJKZOMFLMSOAAY-PCKPOTSRSA-N
DMYFCB0	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-11-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMYFCB0	DE	Discovery agent

DM6JAFM	ID	DM6JAFM
DM6JAFM	DN	Des-AA1,2,5-[D-Nal8,IAmp9]SRIF
DM6JAFM	HS	Investigative
DM6JAFM	SN	CHEMBL410428; Des-AA1,2,5-[D-Nal8,IAmp9]SRIF
DM6JAFM	PC	44388130
DM6JAFM	MW	1496.8
DM6JAFM	FM	C76H97N13O15S2
DM6JAFM	IC	InChI=1S/C76H97N13O15S2/c1-44(2)79-40-51-29-27-50(28-30-51)38-59-71(98)88-64(45(3)91)74(101)85-60(37-49-22-12-7-13-23-49)72(99)89-65(46(4)92)75(102)86-62(41-90)73(100)87-63(76(103)104)43-106-105-42-55(78)66(93)80-56(26-16-17-33-77)67(94)81-57(35-47-18-8-5-9-19-47)68(95)82-58(36-48-20-10-6-11-21-48)69(96)84-61(70(97)83-59)39-52-31-32-53-24-14-15-25-54(53)34-52/h5-15,18-25,27-32,34,44-46,55-65,79,90-92H,16-17,26,33,35-43,77-78H2,1-4H3,(H,80,93)(H,81,94)(H,82,95)(H,83,97)(H,84,96)(H,85,101)(H,86,102)(H,87,100)(H,88,98)(H,89,99)(H,103,104)/t45-,46-,55-,56-,57-,58+,59+,60+,61+,62+,63+,64-,65-/m1/s1
DM6JAFM	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DM6JAFM	IK	VQFBJGSUDSOXIC-MKQNODHSSA-N
DM6JAFM	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM6JAFM	DE	Discovery agent

DMLHUPY	ID	DMLHUPY
DMLHUPY	DN	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9,Tyr11]SRIF
DMLHUPY	HS	Investigative
DMLHUPY	SN	CHEMBL411860; Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9,Tyr11]SRIF
DMLHUPY	PC	44388074
DMLHUPY	MW	1515.8
DMLHUPY	FM	C75H98N14O16S2
DMLHUPY	IC	InChI=1S/C75H98N14O16S2/c1-42(2)78-37-49-25-23-48(24-26-49)35-62-71(100)88-64(44(4)92)72(101)83-58(34-47-27-29-51(93)30-28-47)69(98)87-63(43(3)91)73(102)85-60(39-90)70(99)86-61(75(104)105)41-107-106-40-53(77)65(94)80-55(22-14-15-31-76)66(95)81-56(32-45-16-8-6-9-17-45)67(96)82-57(33-46-18-10-7-11-19-46)68(97)84-59(74(103)89(62)5)36-50-38-79-54-21-13-12-20-52(50)54/h6-13,16-21,23-30,38,42-44,53,55-64,78-79,90-93H,14-15,22,31-37,39-41,76-77H2,1-5H3,(H,80,94)(H,81,95)(H,82,96)(H,83,101)(H,84,97)(H,85,102)(H,86,99)(H,87,98)(H,88,100)(H,104,105)/t43-,44-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DMLHUPY	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DMLHUPY	IK	HLFGUCDHVNBZCJ-SQPHWWHVSA-N
DMLHUPY	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-20-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMLHUPY	DE	Discovery agent

DMX2I4P	ID	DMX2I4P
DMX2I4P	DN	Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF
DMX2I4P	HS	Investigative
DMX2I4P	SN	CHEMBL425465; Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF
DMX2I4P	PC	44388072
DMX2I4P	MW	1499.8
DMX2I4P	FM	C75H98N14O15S2
DMX2I4P	IC	InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)36-62-71(99)88-64(45(4)92)72(100)83-58(35-48-23-13-8-14-24-48)69(97)87-63(44(3)91)73(101)85-60(40-90)70(98)86-61(75(103)104)42-106-105-41-53(77)65(93)80-55(27-17-18-32-76)66(94)81-56(33-46-19-9-6-10-20-46)67(95)82-57(34-47-21-11-7-12-22-47)68(96)84-59(74(102)89(62)5)37-51-39-79-54-26-16-15-25-52(51)54/h6-16,19-26,28-31,39,43-45,53,55-64,78-79,90-92H,17-18,27,32-38,40-42,76-77H2,1-5H3,(H,80,93)(H,81,94)(H,82,95)(H,83,100)(H,84,96)(H,85,101)(H,86,98)(H,87,97)(H,88,99)(H,103,104)/t44-,45-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DMX2I4P	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DMX2I4P	IK	SRQXVUQUEBDWHI-YNBIXHCXSA-N
DMX2I4P	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-20-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMX2I4P	DE	Discovery agent

DMFXKRO	ID	DMFXKRO
DMFXKRO	DN	Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Cys14]SRIF
DMFXKRO	HS	Investigative
DMFXKRO	SN	CHEMBL414716; Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Cys14]SRIF
DMFXKRO	PC	44388065
DMFXKRO	MW	1499.8
DMFXKRO	FM	C75H98N14O15S2
DMFXKRO	IC	InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)36-58-70(98)87-63(44(3)91)72(100)85-59(35-48-23-13-8-14-24-48)71(99)88-64(45(4)92)73(101)86-61(40-90)74(102)89(5)62(75(103)104)42-106-105-41-53(77)65(93)80-55(27-17-18-32-76)66(94)81-56(33-46-19-9-6-10-20-46)67(95)82-57(34-47-21-11-7-12-22-47)68(96)84-60(69(97)83-58)37-51-39-79-54-26-16-15-25-52(51)54/h6-16,19-26,28-31,39,43-45,53,55-64,78-79,90-92H,17-18,27,32-38,40-42,76-77H2,1-5H3,(H,80,93)(H,81,94)(H,82,95)(H,83,97)(H,84,96)(H,85,100)(H,86,101)(H,87,98)(H,88,99)(H,103,104)/t44-,45-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DMFXKRO	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N([C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)C)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMFXKRO	IK	ZLXHFZGOMNAVTA-YNBIXHCXSA-N
DMFXKRO	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-5-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMFXKRO	DE	Discovery agent

DM9EN01	ID	DM9EN01
DM9EN01	DN	Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Ser13]SRIF
DM9EN01	HS	Investigative
DM9EN01	SN	CHEMBL413442; Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Ser13]SRIF
DM9EN01	PC	44388064
DM9EN01	MW	1499.8
DM9EN01	FM	C75H98N14O15S2
DM9EN01	IC	InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)36-58-70(98)87-63(44(3)91)73(101)85-59(35-48-23-13-8-14-24-48)71(99)88-64(45(4)92)74(102)89(5)62(40-90)72(100)86-61(75(103)104)42-106-105-41-53(77)65(93)80-55(27-17-18-32-76)66(94)81-56(33-46-19-9-6-10-20-46)67(95)82-57(34-47-21-11-7-12-22-47)68(96)84-60(69(97)83-58)37-51-39-79-54-26-16-15-25-52(51)54/h6-16,19-26,28-31,39,43-45,53,55-64,78-79,90-92H,17-18,27,32-38,40-42,76-77H2,1-5H3,(H,80,93)(H,81,94)(H,82,95)(H,83,97)(H,84,96)(H,85,101)(H,86,100)(H,87,98)(H,88,99)(H,103,104)/t44-,45-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DM9EN01	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)C)[C@@H](C)O)CC7=CC=CC=C7)O
DM9EN01	IK	LSNMSNQCPXUTAH-YNBIXHCXSA-N
DM9EN01	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-8-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM9EN01	DE	Discovery agent

DMB10GV	ID	DMB10GV
DMB10GV	DN	Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Thr12]SRIF
DMB10GV	HS	Investigative
DMB10GV	SN	CHEMBL268448; Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Thr12]SRIF
DMB10GV	PC	44388073
DMB10GV	MW	1499.8
DMB10GV	FM	C75H98N14O15S2
DMB10GV	IC	InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)35-58-70(98)88-63(44(3)91)72(100)85-60(36-48-23-13-8-14-24-48)74(102)89(5)64(45(4)92)73(101)86-61(40-90)71(99)87-62(75(103)104)42-106-105-41-53(77)65(93)80-55(27-17-18-32-76)66(94)81-56(33-46-19-9-6-10-20-46)67(95)82-57(34-47-21-11-7-12-22-47)68(96)84-59(69(97)83-58)37-51-39-79-54-26-16-15-25-52(51)54/h6-16,19-26,28-31,39,43-45,53,55-64,78-79,90-92H,17-18,27,32-38,40-42,76-77H2,1-5H3,(H,80,93)(H,81,94)(H,82,95)(H,83,97)(H,84,96)(H,85,100)(H,86,101)(H,87,99)(H,88,98)(H,103,104)/t44-,45-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DMB10GV	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)C)CC7=CC=CC=C7)O
DMB10GV	IK	YZXQZTRDHNBZMS-YNBIXHCXSA-N
DMB10GV	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-11-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMB10GV	DE	Discovery agent

DMH0DLZ	ID	DMH0DLZ
DMH0DLZ	DN	Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF
DMH0DLZ	HS	Investigative
DMH0DLZ	SN	CHEMBL413419; Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF
DMH0DLZ	PC	44388094
DMH0DLZ	MW	1626.7
DMH0DLZ	FM	C74H96IN15O15S2
DMH0DLZ	IC	InChI=1S/C74H96IN15O15S2/c1-40(2)79-35-46-24-22-45(23-25-46)31-57-70(101)89-62(41(3)92)73(104)86-58(32-47-26-27-49(94)34-51(47)75)71(102)90-63(42(4)93)74(105)87-60(37-91)72(103)88-61(64(78)95)39-107-106-38-52(77)65(96)81-54(21-13-14-28-76)66(97)82-55(29-43-15-7-5-8-16-43)67(98)83-56(30-44-17-9-6-10-18-44)68(99)85-59(69(100)84-57)33-48-36-80-53-20-12-11-19-50(48)53/h5-12,15-20,22-27,34,36,40-42,52,54-63,79-80,91-94H,13-14,21,28-33,35,37-39,76-77H2,1-4H3,(H2,78,95)(H,81,96)(H,82,97)(H,83,98)(H,84,100)(H,85,99)(H,86,104)(H,87,105)(H,88,103)(H,89,101)(H,90,102)/t41-,42-,52-,54-,55-,56+,57+,58+,59+,60+,61+,62-,63-/m1/s1
DMH0DLZ	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)N)CO)[C@@H](C)O)CC7=C(C=C(C=C7)O)I)O
DMH0DLZ	IK	LLJHRJNXPMGDKL-JFAFYCKWSA-N
DMH0DLZ	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-13-[(4-hydroxy-2-iodophenyl)methyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxamide
DMH0DLZ	DE	Discovery agent

DMXWF2Z	ID	DMXWF2Z
DMXWF2Z	DN	Des-AA1,2,5-[D-Trp8,IAmp9,Tyr11]Cbm-SRIF
DMXWF2Z	HS	Investigative
DMXWF2Z	SN	CHEMBL414717; Des-AA1,2,5-[D-Trp8,IAmp9,Tyr11]Cbm-SRIF
DMXWF2Z	PC	44388092
DMXWF2Z	MW	1500.8
DMXWF2Z	FM	C74H97N15O15S2
DMXWF2Z	IC	InChI=1S/C74H97N15O15S2/c1-41(2)78-36-48-24-22-46(23-25-48)33-57-70(100)88-62(42(3)91)73(103)85-58(34-47-26-28-50(93)29-27-47)71(101)89-63(43(4)92)74(104)86-60(38-90)72(102)87-61(64(77)94)40-106-105-39-52(76)65(95)80-54(21-13-14-30-75)66(96)81-55(31-44-15-7-5-8-16-44)67(97)82-56(32-45-17-9-6-10-18-45)68(98)84-59(69(99)83-57)35-49-37-79-53-20-12-11-19-51(49)53/h5-12,15-20,22-29,37,41-43,52,54-63,78-79,90-93H,13-14,21,30-36,38-40,75-76H2,1-4H3,(H2,77,94)(H,80,95)(H,81,96)(H,82,97)(H,83,99)(H,84,98)(H,85,103)(H,86,104)(H,87,102)(H,88,100)(H,89,101)/t42-,43-,52-,54-,55-,56+,57+,58+,59+,60+,61+,62-,63-/m1/s1
DMXWF2Z	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)N)CO)[C@@H](C)O)CC7=CC=C(C=C7)O)O
DMXWF2Z	IK	CLYXKNIFFVWQGI-HXVVHKOFSA-N
DMXWF2Z	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxamide
DMXWF2Z	DE	Discovery agent

DMSXILZ	ID	DMSXILZ
DMSXILZ	DN	Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275
DMSXILZ	HS	Investigative
DMSXILZ	SN	CHEMBL386023; Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275
DMSXILZ	PC	44388129
DMSXILZ	MW	1485.8
DMSXILZ	FM	C74H96N14O15S2
DMSXILZ	IC	InChI=1S/C74H96N14O15S2/c1-42(2)77-37-49-29-27-48(28-30-49)35-57-69(97)87-62(43(3)90)72(100)84-58(34-47-22-12-7-13-23-47)70(98)88-63(44(4)91)73(101)85-60(39-89)71(99)86-61(74(102)103)41-105-104-40-52(76)64(92)79-54(26-16-17-31-75)65(93)80-55(32-45-18-8-5-9-19-45)66(94)81-56(33-46-20-10-6-11-21-46)67(95)83-59(68(96)82-57)36-50-38-78-53-25-15-14-24-51(50)53/h5-15,18-25,27-30,38,42-44,52,54-63,77-78,89-91H,16-17,26,31-37,39-41,75-76H2,1-4H3,(H,79,92)(H,80,93)(H,81,94)(H,82,96)(H,83,95)(H,84,100)(H,85,101)(H,86,99)(H,87,97)(H,88,98)(H,102,103)/t43-,44-,52-,54-,55-,56+,57+,58+,59+,60+,61+,62-,63-/m1/s1
DMSXILZ	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMSXILZ	IK	SYHQUPOPQRNSKD-ZDFJKKNGSA-N
DMSXILZ	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMSXILZ	DE	Discovery agent

DM7MZ2V	ID	DM7MZ2V
DM7MZ2V	DN	Des-AA1,2,5-[D-Trp8,Tyr11]SRIF
DM7MZ2V	HS	Investigative
DM7MZ2V	SN	CHEMBL262379; Des-AA1,2,5-[D-Trp8,Tyr11]SRIF
DM7MZ2V	PC	44388115
DM7MZ2V	MW	1411.6
DM7MZ2V	FM	C67H90N14O16S2
DM7MZ2V	IC	InChI=1S/C67H90N14O16S2/c1-37(83)55-65(94)77-51(31-41-23-25-43(85)26-24-41)63(92)81-56(38(2)84)66(95)78-53(34-82)64(93)79-54(67(96)97)36-99-98-35-45(70)57(86)72-47(21-11-13-27-68)58(87)74-49(29-39-15-5-3-6-16-39)60(89)75-50(30-40-17-7-4-8-18-40)61(90)76-52(32-42-33-71-46-20-10-9-19-44(42)46)62(91)73-48(59(88)80-55)22-12-14-28-69/h3-10,15-20,23-26,33,37-38,45,47-56,71,82-85H,11-14,21-22,27-32,34-36,68-70H2,1-2H3,(H,72,86)(H,73,91)(H,74,87)(H,75,89)(H,76,90)(H,77,94)(H,78,95)(H,79,93)(H,80,88)(H,81,92)(H,96,97)/t37-,38-,45-,47-,48+,49-,50+,51+,52+,53+,54+,55-,56-/m1/s1
DM7MZ2V	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC6=CC=C(C=C6)O)O
DM7MZ2V	IK	NIVBKEGMFSFLSD-KGVPGVLISA-N
DM7MZ2V	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-19,31-bis(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM7MZ2V	DE	Discovery agent

DMQRUF6	ID	DMQRUF6
DMQRUF6	DN	Des-AA1,2,5-[IAmp9,Tyr11]-SRIF
DMQRUF6	HS	Investigative
DMQRUF6	SN	CHEMBL436887; Des-AA1,2,5-[IAmp9,Tyr11]-SRIF; BDBM50100745
DMQRUF6	PC	44311674
DMQRUF6	MW	1501.8
DMQRUF6	FM	C74H96N14O16S2
DMQRUF6	IC	InChI=1S/C74H96N14O16S2/c1-41(2)77-36-48-24-22-46(23-25-48)33-57-69(98)87-62(42(3)90)72(101)84-58(34-47-26-28-50(92)29-27-47)70(99)88-63(43(4)91)73(102)85-60(38-89)71(100)86-61(74(103)104)40-106-105-39-52(76)64(93)79-54(21-13-14-30-75)65(94)80-55(31-44-15-7-5-8-16-44)66(95)81-56(32-45-17-9-6-10-18-45)67(96)83-59(68(97)82-57)35-49-37-78-53-20-12-11-19-51(49)53/h5-12,15-20,22-29,37,41-43,52,54-63,77-78,89-92H,13-14,21,30-36,38-40,75-76H2,1-4H3,(H,79,93)(H,80,94)(H,81,95)(H,82,97)(H,83,96)(H,84,101)(H,85,102)(H,86,100)(H,87,98)(H,88,99)(H,103,104)/t42-,43-,52-,54-,55-,56+,57+,58+,59-,60+,61+,62-,63-/m1/s1
DMQRUF6	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=C(C=C7)O)O
DMQRUF6	IK	FJRAPOZDHJLSPN-KVMFXWMESA-N
DMQRUF6	IU	(4R,7S,10R,13S,16R,19S,22R,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMQRUF6	DE	Discovery agent

DMPMAXI	ID	DMPMAXI
DMPMAXI	DN	Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF
DMPMAXI	HS	Investigative
DMPMAXI	SN	CHEMBL438630; Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF
DMPMAXI	PC	44388024
DMPMAXI	MW	1433.7
DMPMAXI	FM	C74H88N12O14S2
DMPMAXI	IC	InChI=1S/C74H88N12O14S2/c1-42(2)76-38-50-26-24-49(25-27-50)36-58-69(94)85-63(43(3)87)72(97)82-59(35-47-20-12-7-13-21-47)70(95)86-64(44(4)88)73(98)84-62(74(99)100)41-102-101-40-61(83-65(90)54(75)32-48-28-30-52(89)31-29-48)71(96)80-57(34-46-18-10-6-11-19-46)66(91)78-56(33-45-16-8-5-9-17-45)67(92)81-60(68(93)79-58)37-51-39-77-55-23-15-14-22-53(51)55/h5-31,39,42-44,54,56-64,76-77,87-89H,32-38,40-41,75H2,1-4H3,(H,78,91)(H,79,93)(H,80,96)(H,81,92)(H,82,97)(H,83,90)(H,84,98)(H,85,94)(H,86,95)(H,99,100)/t43-,44-,54+,56+,57-,58+,59+,60+,61-,62+,63-,64-/m1/s1
DMPMAXI	CS	C[C@H]([C@@H]1C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)NC(=O)[C@H](CC8=CC=C(C=C8)O)N)C(=O)O)O
DMPMAXI	IK	GYAXOXYXFASSKI-GAZSGENXSA-N
DMPMAXI	IU	(4R,7R,10S,13R,16S,19S,22S,25R,28S)-28-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-10,22,25-tribenzyl-7,13-bis[(1R)-1-hydroxyethyl]-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-16-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DMPMAXI	DE	Discovery agent

DMFCA05	ID	DMFCA05
DMFCA05	DN	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF
DMFCA05	HS	Investigative
DMFCA05	SN	CHEMBL262790; Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF
DMFCA05	PC	44388113
DMFCA05	MW	1662
DMFCA05	FM	C84H108N16O16S2
DMFCA05	IC	InChI=1S/C84H108N16O16S2/c1-48(2)88-43-56-30-28-55(29-31-56)41-70-81(113)99-72(50(4)103)82(114)93-65(40-53-23-13-8-14-24-53)78(110)98-71(49(3)102)83(115)95-67(45-101)79(111)96-68(73(87)105)46-117-118-47-69(97-74(106)60(86)37-54-32-34-58(104)35-33-54)80(112)90-62(27-17-18-36-85)75(107)91-63(38-51-19-9-6-10-20-51)76(108)92-64(39-52-21-11-7-12-22-52)77(109)94-66(84(116)100(70)5)42-57-44-89-61-26-16-15-25-59(57)61/h6-16,19-26,28-35,44,48-50,60,62-72,88-89,101-104H,17-18,27,36-43,45-47,85-86H2,1-5H3,(H2,87,105)(H,90,112)(H,91,107)(H,92,108)(H,93,114)(H,94,109)(H,95,115)(H,96,111)(H,97,106)(H,98,110)(H,99,113)/t49-,50-,60+,62-,63-,64+,65+,66+,67+,68+,69-,70+,71-,72-/m1/s1
DMFCA05	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)NC(=O)[C@H](CC8=CC=C(C=C8)O)N)C(=O)N)CO)O
DMFCA05	IK	UTASAEBFJXWNHX-PIBSBZCFSA-N
DMFCA05	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-34-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-20-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxamide
DMFCA05	DE	Discovery agent

DMW56NI	ID	DMW56NI
DMW56NI	DN	Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF
DMW56NI	HS	Investigative
DMW56NI	SN	CHEMBL414692; Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF
DMW56NI	PC	44388102
DMW56NI	MW	1663
DMW56NI	FM	C84H107N15O17S2
DMW56NI	IC	InChI=1S/C84H107N15O17S2/c1-48(2)87-43-56-30-28-55(29-31-56)41-70-80(111)98-72(50(4)102)81(112)92-65(40-53-23-13-8-14-24-53)77(108)97-71(49(3)101)82(113)94-67(45-100)78(109)96-69(84(115)116)47-118-117-46-68(95-73(104)60(86)37-54-32-34-58(103)35-33-54)79(110)89-62(27-17-18-36-85)74(105)90-63(38-51-19-9-6-10-20-51)75(106)91-64(39-52-21-11-7-12-22-52)76(107)93-66(83(114)99(70)5)42-57-44-88-61-26-16-15-25-59(57)61/h6-16,19-26,28-35,44,48-50,60,62-72,87-88,100-103H,17-18,27,36-43,45-47,85-86H2,1-5H3,(H,89,110)(H,90,105)(H,91,106)(H,92,112)(H,93,107)(H,94,113)(H,95,104)(H,96,109)(H,97,108)(H,98,111)(H,115,116)/t49-,50-,60+,62-,63-,64+,65+,66+,67+,68-,69+,70+,71-,72-/m1/s1
DMW56NI	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)NC(=O)[C@H](CC8=CC=C(C=C8)O)N)C(=O)O)CO)O
DMW56NI	IK	MGQOSJMBSMGOOM-DNKCOYOSSA-N
DMW56NI	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-34-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-20-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMW56NI	DE	Discovery agent

DMV8EWF	ID	DMV8EWF
DMV8EWF	DN	Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF
DMV8EWF	HS	Investigative
DMV8EWF	SN	CHEMBL385811; Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF
DMV8EWF	PC	44388103
DMV8EWF	MW	1648
DMV8EWF	FM	C83H106N16O16S2
DMV8EWF	IC	InChI=1S/C83H106N16O16S2/c1-47(2)87-42-55-29-27-54(28-30-55)40-64-78(110)98-70(48(3)101)82(114)94-65(39-52-22-12-7-13-23-52)79(111)99-71(49(4)102)83(115)95-67(44-100)80(112)96-68(72(86)104)45-116-117-46-69(97-73(105)59(85)36-53-31-33-57(103)34-32-53)81(113)89-61(26-16-17-35-84)74(106)90-62(37-50-18-8-5-9-19-50)75(107)91-63(38-51-20-10-6-11-21-51)76(108)93-66(77(109)92-64)41-56-43-88-60-25-15-14-24-58(56)60/h5-15,18-25,27-34,43,47-49,59,61-71,87-88,100-103H,16-17,26,35-42,44-46,84-85H2,1-4H3,(H2,86,104)(H,89,113)(H,90,106)(H,91,107)(H,92,109)(H,93,108)(H,94,114)(H,95,115)(H,96,112)(H,97,105)(H,98,110)(H,99,111)/t48-,49-,59+,61-,62-,63+,64+,65+,66+,67+,68+,69-,70-,71-/m1/s1
DMV8EWF	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)NC(=O)[C@H](CC7=CC=C(C=C7)O)N)C(=O)N)CO)[C@@H](C)O)CC8=CC=CC=C8)O
DMV8EWF	IK	GIGRDXKZXVSPEN-OFTQGXSVSA-N
DMV8EWF	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-34-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxamide
DMV8EWF	DE	Discovery agent

DMLY7DC	ID	DMLY7DC
DMLY7DC	DN	Des-AA1,5-[Tyr2,D-Trp8,IAmp9]SRIF CH-288
DMLY7DC	HS	Investigative
DMLY7DC	SN	CHEMBL411002; Des-AA1,5-[Tyr2,D-Trp8,IAmp9]SRIF CH-288
DMLY7DC	PC	44388059
DMLY7DC	MW	1648.9
DMLY7DC	FM	C83H105N15O17S2
DMLY7DC	IC	InChI=1S/C83H105N15O17S2/c1-47(2)86-42-55-29-27-54(28-30-55)40-64-77(108)97-70(48(3)100)81(112)93-65(39-52-22-12-7-13-23-52)78(109)98-71(49(4)101)82(113)94-67(44-99)79(110)96-69(83(114)115)46-117-116-45-68(95-72(103)59(85)36-53-31-33-57(102)34-32-53)80(111)88-61(26-16-17-35-84)73(104)89-62(37-50-18-8-5-9-19-50)74(105)90-63(38-51-20-10-6-11-21-51)75(106)92-66(76(107)91-64)41-56-43-87-60-25-15-14-24-58(56)60/h5-15,18-25,27-34,43,47-49,59,61-71,86-87,99-102H,16-17,26,35-42,44-46,84-85H2,1-4H3,(H,88,111)(H,89,104)(H,90,105)(H,91,107)(H,92,106)(H,93,112)(H,94,113)(H,95,103)(H,96,110)(H,97,108)(H,98,109)(H,114,115)/t48-,49-,59+,61-,62-,63+,64+,65+,66+,67+,68-,69+,70-,71-/m1/s1
DMLY7DC	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)NC(=O)[C@H](CC7=CC=C(C=C7)O)N)C(=O)O)CO)[C@@H](C)O)CC8=CC=CC=C8)O
DMLY7DC	IK	UKGIKHPFMXOGRF-UXDQVZPXSA-N
DMLY7DC	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-34-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMLY7DC	DE	Discovery agent

DMO3CFV	ID	DMO3CFV
DMO3CFV	DN	Des-AA5-[D-Trp8]SRIF
DMO3CFV	HS	Investigative
DMO3CFV	SN	CHEMBL408338; Des-AA5-[D-Trp8]SRIF
DMO3CFV	PC	44388128
DMO3CFV	MW	1523.8
DMO3CFV	FM	C72H98N16O17S2
DMO3CFV	IC	InChI=1S/C72H98N16O17S2/c1-40(75)61(93)77-36-58(92)78-56-38-106-107-39-57(72(104)105)86-68(100)55(37-89)85-71(103)60(42(3)91)88-67(99)53(33-45-23-11-6-12-24-45)84-70(102)59(41(2)90)87-63(95)50(28-16-18-30-74)79-66(98)54(34-46-35-76-48-26-14-13-25-47(46)48)83-65(97)52(32-44-21-9-5-10-22-44)82-64(96)51(31-43-19-7-4-8-20-43)81-62(94)49(80-69(56)101)27-15-17-29-73/h4-14,19-26,35,40-42,49-57,59-60,76,89-91H,15-18,27-34,36-39,73-75H2,1-3H3,(H,77,93)(H,78,92)(H,79,98)(H,80,101)(H,81,94)(H,82,96)(H,83,97)(H,84,102)(H,85,103)(H,86,100)(H,87,95)(H,88,99)(H,104,105)/t40-,41+,42+,49+,50-,51+,52-,53-,54-,55-,56+,57-,59+,60+/m0/s1
DMO3CFV	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)O)CO)[C@@H](C)O)CC6=CC=CC=C6)O
DMO3CFV	IK	ZIHRAPFYJSDXSV-BVGUNDCQSA-N
DMO3CFV	IU	(4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-19,31-bis(4-aminobutyl)-34-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMO3CFV	DE	Discovery agent

DMVX9I0	ID	DMVX9I0
DMVX9I0	DN	Des-Arg(9)-[Leu(8)]-BK
DMVX9I0	HS	Investigative
DMVX9I0	SN	5-Chloro-4-(N-(cyclopropyl)methyl-N-propylamino)-2-methyl-6-(2,4,6-trichlorophenyl)aminopyridine; NBI 27914; NBI27914; NBI-27914; CHEMBL45281; SR-01000075865; Tocris-1591; Lopac-N-3911; AC1L41YH; Lopac0_000493; MLS000860080; cid_176157; GTPL3512; SCHEMBL16606734; CHEBI:93069; DTXSID20171549; HMS3261D07; HMS3371C20; HMS2230I15; ZINC2511843; Tox21_500493; BDBM50054245; CCG-204584; API0008466; LP00493; 2-methyl-4-(N-propyl-N-cycloproanemethylamino)-5-chloro-6-(2,4,6-trichloranilino)pyrimidine; NCGC00261178-01; NCGC00015737-05
DMVX9I0	DT	Small molecular drug
DMVX9I0	PC	176157
DMVX9I0	MW	434.2
DMVX9I0	FM	C18H20Cl4N4
DMVX9I0	IC	InChI=1S/C18H20Cl4N4/c1-3-6-26(9-11-4-5-11)18-15(22)17(23-10(2)24-18)25-16-13(20)7-12(19)8-14(16)21/h7-8,11H,3-6,9H2,1-2H3,(H,23,24,25)
DMVX9I0	CS	CCCN(CC1CC1)C2=NC(=NC(=C2Cl)NC3=C(C=C(C=C3Cl)Cl)Cl)C
DMVX9I0	IK	KNADXBVKFAUMCR-UHFFFAOYSA-N
DMVX9I0	IU	5-chloro-4-N-(cyclopropylmethyl)-2-methyl-4-N-propyl-6-N-(2,4,6-trichlorophenyl)pyrimidine-4,6-diamine
DMVX9I0	CA	CAS 184241-44-9
DMVX9I0	CB	CHEBI:93069
DMVX9I0	DE	Depression

DMZ5Y94	ID	DMZ5Y94
DMZ5Y94	DN	Des-Arg10-Kallidin
DMZ5Y94	HS	Investigative
DMZ5Y94	SN	des-Arg10-Kallidin; 71800-36-7; kallidin, des-Arg(10)-; Lys-[Des-Arg9]Bradykinin; CHEMBL264100; [des-Arg10]kallidin; (Des-Arg10)kallidin; Lys-[des-Arg9]-bradykinin; Lys-(Des-Arg9)-Bradykinin; Bradykinin, lys-desarg(9); 10-De-arg-kallidin; Lys-des-arg(9)-BK; Des-arg(10)-kallidin
DMZ5Y94	DT	Small molecular drug
DMZ5Y94	PC	122227
DMZ5Y94	MW	1032.2
DMZ5Y94	FM	C50H73N13O11
DMZ5Y94	IC	InChI=1S/C50H73N13O11/c51-22-8-7-17-33(52)42(66)58-34(18-9-23-55-50(53)54)46(70)63-26-12-21-40(63)48(72)62-25-10-19-38(62)44(68)56-29-41(65)57-35(27-31-13-3-1-4-14-31)43(67)60-37(30-64)47(71)61-24-11-20-39(61)45(69)59-36(49(73)74)28-32-15-5-2-6-16-32/h1-6,13-16,33-40,64H,7-12,17-30,51-52H2,(H,56,68)(H,57,65)(H,58,66)(H,59,69)(H,60,67)(H,73,74)(H4,53,54,55)/t33-,34-,35-,36-,37-,38-,39-,40-/m0/s1
DMZ5Y94	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O
DMZ5Y94	IK	AILVBOHFGXNHCC-TZPCGENMSA-N
DMZ5Y94	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMZ5Y94	CA	CAS 71800-36-7
DMZ5Y94	DE	Discovery agent

DMWO4EI	ID	DMWO4EI
DMWO4EI	DN	Des-Arg10-Leu9-Kallidin
DMWO4EI	HS	Investigative
DMWO4EI	SN	71800-37-8; Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt; Lys-(Des-Arg9,Leu8)-Bradykinin; AC1NSJPW; Lys-[Leu...8...][des-Arg...9...]Bradykinin; des(Arg10, Leu9)-Kallidin; CHEMBL384721; ZINC169731077; CP-0298; [Leu8]des-Arg10-Kallidin (Lys-[Leu8]des-Arg9-Bradykinin); Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt, &gt
DMWO4EI	DT	Small molecular drug
DMWO4EI	PC	5310951
DMWO4EI	MW	998.2
DMWO4EI	FM	C47H75N13O11
DMWO4EI	IC	InChI=1S/C47H75N13O11/c1-28(2)24-33(46(70)71)56-42(66)36-17-10-21-58(36)44(68)34(27-61)57-40(64)32(25-29-12-4-3-5-13-29)54-38(62)26-53-41(65)35-16-9-22-59(35)45(69)37-18-11-23-60(37)43(67)31(15-8-20-52-47(50)51)55-39(63)30(49)14-6-7-19-48/h3-5,12-13,28,30-37,61H,6-11,14-27,48-49H2,1-2H3,(H,53,65)(H,54,62)(H,55,63)(H,56,66)(H,57,64)(H,70,71)(H4,50,51,52)/t30-,31-,32-,33-,34-,35-,36-,37-/m0/s1
DMWO4EI	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N
DMWO4EI	IK	AGTPZUQKOYEAOH-MDKUUQCZSA-N
DMWO4EI	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid
DMWO4EI	DE	Discovery agent

DMIKUBY	ID	DMIKUBY
DMIKUBY	DN	Des-bromoaplysamine-1
DMIKUBY	HS	Investigative
DMIKUBY	SN	des-bromoaplysamine-1; CHEMBL204377; BDBM50177732; SY246342; MFCD30297079 (95%); 3-[4-[2-(Dimethylamino)ethyl]phenoxy-2,6-D2]-N,N-dimethyl-1-propanamine
DMIKUBY	DT	Small molecular drug
DMIKUBY	PC	44407803
DMIKUBY	MW	250.38
DMIKUBY	FM	C15H26N2O
DMIKUBY	IC	InChI=1S/C15H26N2O/c1-16(2)11-5-13-18-15-8-6-14(7-9-15)10-12-17(3)4/h6-9H,5,10-13H2,1-4H3
DMIKUBY	CS	CN(C)CCCOC1=CC=C(C=C1)CCN(C)C
DMIKUBY	IK	DXZMBOOTLSIFGN-UHFFFAOYSA-N
DMIKUBY	IU	3-[4-[2-(dimethylamino)ethyl]phenoxy]-N,N-dimethylpropan-1-amine
DMIKUBY	DE	Discovery agent

DMQER8D	ID	DMQER8D
DMQER8D	DN	Deschloroflavopiridol
DMQER8D	HS	Investigative
DMQER8D	DT	Small molecular drug
DMQER8D	PC	102397231
DMQER8D	MW	368.4
DMQER8D	FM	C21H22NO5+
DMQER8D	IC	InChI=1S/C21H21NO5/c1-22-8-7-13(17(26)11-22)19-14(23)9-15(24)20-16(25)10-18(27-21(19)20)12-5-3-2-4-6-12/h2-6,9-10,13,17,23-24,26H,7-8,11H2,1H3/p+1
DMQER8D	CS	C[NH+]1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4)O)O
DMQER8D	IK	PGWURUYAKNYOPM-UHFFFAOYSA-O
DMQER8D	IU	5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-1-ium-4-yl)-2-phenylchromen-4-one
DMQER8D	DE	Discovery agent

DMAB9KG	ID	DMAB9KG
DMAB9KG	DN	Desclasinose Azithromycinarylalkyl Hydroxamate
DMAB9KG	HS	Investigative
DMAB9KG	SN	Desclasinose Azithromycinarylalkyl Hydroxamate; CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10
DMAB9KG	DT	Small molecular drug
DMAB9KG	PC	25151110
DMAB9KG	MW	853.1
DMAB9KG	FM	C44H76N4O12
DMAB9KG	IC	InChI=1S/C44H76N4O12/c1-11-34-44(8,56)39(53)30(6)47(9)24-26(2)23-43(7,55)40(28(4)37(51)29(5)41(54)59-34)60-42-38(52)33(22-27(3)58-42)48(10)25-31-18-20-32(21-19-31)45-35(49)16-14-12-13-15-17-36(50)46-57/h18-21,26-30,33-34,37-40,42,51-53,55-57H,11-17,22-25H2,1-10H3,(H,45,49)(H,46,50)/t26-,27-,28+,29-,30-,33+,34-,37+,38-,39-,40-,42+,43-,44-/m1/s1
DMAB9KG	CS	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O)C)O[C@H]2[C@@H]([C@H](C[C@H](O2)C)N(C)CC3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DMAB9KG	IK	DJGOCARXUHEYRZ-AYWHDHSOSA-N
DMAB9KG	IU	N-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]-N'-hydroxyoctanediamide
DMAB9KG	DE	Discovery agent

DM47JFS	ID	DM47JFS
DM47JFS	DN	Desethyl isoquine
DM47JFS	HS	Investigative
DM47JFS	SN	desethyl isoquine; CHEMBL146826; ZINC1912679; BDBM50134934
DM47JFS	DT	Small molecular drug
DM47JFS	PC	11450263
DM47JFS	MW	327.8
DM47JFS	FM	C18H18ClN3O
DM47JFS	IC	InChI=1S/C18H18ClN3O/c1-2-20-11-12-3-5-14(10-18(12)23)22-16-7-8-21-17-9-13(19)4-6-15(16)17/h3-10,20,23H,2,11H2,1H3,(H,21,22)
DM47JFS	CS	CCNCC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O
DM47JFS	IK	XWBLHPDICBKAEX-UHFFFAOYSA-N
DM47JFS	IU	5-[(7-chloroquinolin-4-yl)amino]-2-(ethylaminomethyl)phenol
DM47JFS	DE	Discovery agent

DMJK0H5	ID	DMJK0H5
DMJK0H5	DN	DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT
DMJK0H5	HS	Investigative
DMJK0H5	PC	44321093
DMJK0H5	MW	1322.5
DMJK0H5	FM	C64H75N9O18S2
DMJK0H5	IC	InChI=1S/C64H75N9O18S2/c1-4-32(2)51-57(83)72-52(33(3)74)58(84)68-44(29-49(65)78)55(81)69-45(31-92-93-63(22-6-5-7-23-63)30-50(79)70-53(59(85)71-51)34-12-15-36(75)16-13-34)60(86)73-25-9-11-46(73)56(82)67-43(61(87)88)10-8-24-66-54(80)35-14-19-39-42(26-35)64(91-62(39)89)40-20-17-37(76)27-47(40)90-48-28-38(77)18-21-41(48)64/h12-21,26-28,32-33,43-46,51-53,74-77H,4-11,22-25,29-31H2,1-3H3,(H2,65,78)(H,66,80)(H,67,82)(H,68,84)(H,69,81)(H,70,79)(H,71,85)(H,72,83)(H,87,88)/t32?,33?,43-,44+,45+,46+,51+,52+,53-/m0/s1
DMJK0H5	CS	CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC2(CCCCC2)CC(=O)N[C@H](C(=O)N1)C3=CC=C(C=C3)O)C(=O)N4CCC[C@@H]4C(=O)N[C@@H](CCCNC(=O)C5=CC6=C(C=C5)C(=O)OC67C8=C(C=C(C=C8)O)OC9=C7C=CC(=C9)O)C(=O)O)CC(=O)N)C(C)O
DMJK0H5	IK	YDQFMQKHNPCEQF-AMPJLWALSA-N
DMJK0H5	IU	(2S)-2-[[(2R)-1-[(10S,13R,16R,19R,22S)-13-(2-amino-2-oxoethyl)-19-butan-2-yl-16-(1-hydroxyethyl)-22-(4-hydroxyphenyl)-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carbonyl]amino]-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]pentanoic acid
DMJK0H5	DE	Discovery agent

DMGTAZ4	ID	DMGTAZ4
DMGTAZ4	DN	Des-His1[Glu9]glucagon-NH2
DMGTAZ4	HS	Investigative
DMGTAZ4	PC	44389629
DMGTAZ4	MW	3509.8
DMGTAZ4	FM	C155H230N44O48S
DMGTAZ4	IC	InChI=1S/C155H230N44O48S/c1-74(2)55-100(137(231)180-98(50-54-248-12)135(229)188-107(63-117(160)212)146(240)198-123(78(8)204)126(161)220)183-141(235)106(61-85-66-170-90-30-20-19-29-89(85)90)187-133(227)96(44-48-116(159)211)181-151(245)122(76(5)6)197-144(238)104(57-81-25-15-13-16-26-81)186-142(236)108(64-120(216)217)189-132(226)95(43-47-115(158)210)174-127(221)77(7)173-129(223)92(32-23-52-168-154(162)163)175-130(224)93(33-24-53-169-155(164)165)177-148(242)112(71-202)194-143(237)109(65-121(218)219)190-138(232)101(56-75(3)4)182-139(233)102(59-83-34-38-87(207)39-35-83)184-131(225)91(31-21-22-51-156)176-147(241)111(70-201)193-140(234)103(60-84-36-40-88(208)41-37-84)185-134(228)97(45-49-119(214)215)179-150(244)113(72-203)195-153(247)125(80(10)206)199-145(239)105(58-82-27-17-14-18-28-82)191-152(246)124(79(9)205)196-118(213)68-171-128(222)94(42-46-114(157)209)178-149(243)110(69-200)192-136(230)99(166-11)62-86-67-167-73-172-86/h13-20,25-30,34-41,66-67,73-80,91-113,122-125,166,170,200-208H,21-24,31-33,42-65,68-72,156H2,1-12H3,(H2,157,209)(H2,158,210)(H2,159,211)(H2,160,212)(H2,161,220)(H,167,172)(H,171,222)(H,173,223)(H,174,221)(H,175,224)(H,176,241)(H,177,242)(H,178,243)(H,179,244)(H,180,231)(H,181,245)(H,182,233)(H,183,235)(H,184,225)(H,185,228)(H,186,236)(H,187,227)(H,188,229)(H,189,226)(H,190,232)(H,191,246)(H,192,230)(H,193,234)(H,194,237)(H,195,247)(H,196,213)(H,197,238)(H,198,240)(H,199,239)(H,214,215)(H,216,217)(H,218,219)(H4,162,163,168)(H4,164,165,169)/t77-,78+,79+,80+,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-,125-/m0/s1
DMGTAZ4	CS	C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)NC)O
DMGTAZ4	IK	QAFHHWFRTULWIL-OQZBCNBHSA-N
DMGTAZ4	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-3-hydroxy-2-[[(2S)-3-(1H-imidazol-4-yl)-2-(methylamino)propanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DMGTAZ4	DE	Discovery agent

DMB07WE	ID	DMB07WE
DMB07WE	DN	Desirudine
DMB07WE	HS	Investigative
DMB07WE	DE	Discovery agent

DM58XJN	ID	DM58XJN
DM58XJN	DN	Desmethylastemizole
DM58XJN	HS	Investigative
DM58XJN	SN	O-Desmethyl Astemizole; 73736-50-2; UNII-L460QHM1YN; L460QHM1YN; CHEMBL60796; Demethylastemizole; 4-[2-[4-[[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]amino]piperidin-1-yl]ethyl]phenol; Desmethylasteizole; R-44-271; R 44 271; O-Demethylastemizole; O-Desmethylastemizole; AC1L4F06; SCHEMBL1152697; CTK8G2140; DTXSID10224058; LAGYWHSFHIMTPE-UHFFFAOYSA-N; ZINC13537287; BDBM50131433; AKOS030240026; Phenol, 4-(2-(4-((1-((4-fluorophenyl)methyl)-1H-benzimidazol-2-yl)amino)-1-piperidinyl)ethyl)-; FT-0666079; R 44271; DESMETHEYLASTEMIZOLE
DM58XJN	DT	Small molecular drug
DM58XJN	PC	155805
DM58XJN	MW	444.5
DM58XJN	FM	C27H29FN4O
DM58XJN	IC	InChI=1S/C27H29FN4O/c28-22-9-5-21(6-10-22)19-32-26-4-2-1-3-25(26)30-27(32)29-23-14-17-31(18-15-23)16-13-20-7-11-24(33)12-8-20/h1-12,23,33H,13-19H2,(H,29,30)
DM58XJN	CS	C1CN(CCC1NC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)CCC5=CC=C(C=C5)O
DM58XJN	IK	LAGYWHSFHIMTPE-UHFFFAOYSA-N
DM58XJN	IU	4-[2-[4-[[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]amino]piperidin-1-yl]ethyl]phenol
DM58XJN	CA	CAS 73736-50-2
DM58XJN	DE	Discovery agent

DMIESYM	ID	DMIESYM
DMIESYM	DN	Desmethylclomipramine
DMIESYM	HS	Investigative
DMIESYM	SN	Desmethylclomipramine; Norclomipramine; UNII-01DN47PPQG; 01DN47PPQG; N-Demethylclomipramine; Demethylchlorimipramine; Desmethylchlorimipramine; AC1LDNXR; SCHEMBL11384662; VPIXQGUBUKFLRF-UHFFFAOYSA-N; CHEBI:124969; ZINC2570877; API0007900; BRD-K52696183-003-01-0; 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N-methyl-; 3-Chloro-10,11-dihydro-N-methyl-5H-dibenz(b,f)azepine-5-propanamine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
DMIESYM	DT	Small molecular drug
DMIESYM	PC	622606
DMIESYM	MW	300.8
DMIESYM	FM	C18H21ClN2
DMIESYM	IC	InChI=1S/C18H21ClN2/c1-20-11-4-12-21-17-6-3-2-5-14(17)7-8-15-9-10-16(19)13-18(15)21/h2-3,5-6,9-10,13,20H,4,7-8,11-12H2,1H3
DMIESYM	CS	CNCCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
DMIESYM	IK	VPIXQGUBUKFLRF-UHFFFAOYSA-N
DMIESYM	IU	3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
DMIESYM	CA	CAS 303-48-0
DMIESYM	CB	CHEBI:124969
DMIESYM	DE	Discovery agent

DMLKBNR	ID	DMLKBNR
DMLKBNR	DN	DESMETHYLOLANZAPINE
DMLKBNR	HS	Investigative
DMLKBNR	DT	Small molecular drug
DMLKBNR	PC	135446209
DMLKBNR	MW	298.4
DMLKBNR	FM	C16H18N4S
DMLKBNR	IC	InChI=1S/C16H18N4S/c1-11-10-12-15(20-8-6-17-7-9-20)18-13-4-2-3-5-14(13)19-16(12)21-11/h2-5,10,17,19H,6-9H2,1H3
DMLKBNR	CS	CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCNCC4
DMLKBNR	IK	FHPIXVHJEIZKJW-UHFFFAOYSA-N
DMLKBNR	IU	2-methyl-4-piperazin-1-yl-10H-thieno[2,3-b][1,5]benzodiazepine
DMLKBNR	CA	CAS 161696-76-0
DMLKBNR	DE	Discovery agent

DMV8SUM	ID	DMV8SUM
DMV8SUM	DN	Desmosterol
DMV8SUM	HS	Investigative
DMV8SUM	SN	DESMOSTEROL; 24-Dehydrocholesterol; 313-04-2; UNII-ANP93865R8; cholest-5,24-dien-3beta-ol; Cholesta-5,24-dien-3beta-ol; NSC 226126; CHEBI:17737; 3beta-cholesta-5,24-dien-3-ol; ANP93865R8; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholesta-5,24-dien-3-ol; desmesterol; EINECS 206-236-2; 24-dehydro Cholesterol; 24,25-Dehydrocholesterol; AC1L97ME; Cholesta-5,24-dien-3b-ol; 5,24-Cholestadien-3beta-ol; 5,24-Cholestadien-3
DMV8SUM	DT	Small molecular drug
DMV8SUM	PC	439577
DMV8SUM	MW	384.6
DMV8SUM	FM	C27H44O
DMV8SUM	IC	InChI=1S/C27H44O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h7,9,19,21-25,28H,6,8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DMV8SUM	CS	C[C@H](CCC=C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DMV8SUM	IK	AVSXSVCZWQODGV-DPAQBDIFSA-N
DMV8SUM	IU	(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMV8SUM	CA	CAS 313-04-2
DMV8SUM	CB	CHEBI:17737
DMV8SUM	DE	Discovery agent

DMW740T	ID	DMW740T
DMW740T	DN	desulfated cholecystokinin-8
DMW740T	HS	Investigative
DMW740T	SN	des-CCK-8; desulfated sincalide
DMW740T	DT	Small molecular drug
DMW740T	PC	3084441
DMW740T	MW	1063.2
DMW740T	FM	C49H62N10O13S2
DMW740T	IC	InChI=1S/C49H62N10O13S2/c1-73-18-16-34(46(69)56-36(20-28-12-14-30(60)15-13-28)44(67)43(66)32(50)23-41(62)63)54-40(61)26-53-45(68)37(22-29-25-52-33-11-7-6-10-31(29)33)57-47(70)35(17-19-74-2)55-48(71)38(24-42(64)65)58-49(72)39(59-51)21-27-8-4-3-5-9-27/h3-15,25,32,34-39,52,59-60H,16-24,26,50-51H2,1-2H3,(H,53,68)(H,54,61)(H,55,71)(H,56,69)(H,57,70)(H,58,72)(H,62,63)(H,64,65)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
DMW740T	CS	CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)C(=O)[C@H](CC(=O)O)N)NC(=O)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC4=CC=CC=C4)NN
DMW740T	IK	ZBTPHEHKAHBSMT-YRVFCXMDSA-N
DMW740T	IU	(3S,6S)-3-amino-6-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-hydrazinyl-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]-4-methylsulfanylbutanoyl]amino]-7-(4-hydroxyphenyl)-4,5-dioxoheptanoic acid
DMW740T	CA	CAS 25679-24-7
DMW740T	DE	Discovery agent

DMFWDNJ	ID	DMFWDNJ
DMFWDNJ	DN	detirelix
DMFWDNJ	HS	Investigative
DMFWDNJ	SN	102583-46-0; 89662-30-6; RS-68439; detirelix acetate
DMFWDNJ	DT	Small molecular drug
DMFWDNJ	PC	16129698
DMFWDNJ	MW	1538.2
DMFWDNJ	FM	C78H105ClN18O13
DMFWDNJ	IC	InChI=1S/C78H105ClN18O13/c1-7-83-78(84-8-2)86-34-14-13-21-58(68(102)92-60(37-45(3)4)69(103)91-59(22-15-35-85-77(81)82)76(110)97-36-16-23-66(97)75(109)88-46(5)67(80)101)90-71(105)62(40-49-27-32-55(100)33-28-49)94-74(108)65(44-98)96-73(107)64(42-53-43-87-57-20-12-11-19-56(53)57)95-72(106)63(39-48-25-30-54(79)31-26-48)93-70(104)61(89-47(6)99)41-50-24-29-51-17-9-10-18-52(51)38-50/h9-12,17-20,24-33,38,43,45-46,58-66,87,98,100H,7-8,13-16,21-23,34-37,39-42,44H2,1-6H3,(H2,80,101)(H,88,109)(H,89,99)(H,90,105)(H,91,103)(H,92,102)(H,93,104)(H,94,108)(H,95,106)(H,96,107)(H4,81,82,85)(H2,83,84,86)/t46-,58-,59+,60+,61-,62+,63-,64-,65+,66+/m1/s1
DMFWDNJ	CS	CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)NCC
DMFWDNJ	IK	OFQNFLLLCMQNEP-MIPXGPCFSA-N
DMFWDNJ	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMFWDNJ	CA	CAS 89662-30-6
DMFWDNJ	DE	Discovery agent

DMPCRSY	ID	DMPCRSY
DMPCRSY	DN	Detrothyronine
DMPCRSY	HS	Investigative
DMPCRSY	SN	DT-3; 3,5,3'-Triiodo-D-thyronine; CHEMBL557; UNII-46XII7C16X; 46XII7C16X; Detrothyronin; dt 3; 5714/8/9; Dextro-3:5:3'-triiodothyronine; Detrothyroninum; Detrotironina; D-Trijodthyronin; DEXTROTHYRONINE; Triiodothyronine, D-; Detrothyronine [INN]; AC1L2FR4; SCHEMBL8301; AC1Q5R0T; DT 3 (hormone) (VAN); Detrotironina [INN-Spanish]; Detrothyroninum [INN-Latin]; DT3 (VAN); D-3,5,3'-Triiodothyronine; CTK4G9296; (2R)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; SKF D 2623
DMPCRSY	DT	Small molecular drug
DMPCRSY	PC	71212
DMPCRSY	MW	650.97
DMPCRSY	FM	C15H12I3NO4
DMPCRSY	IC	InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m1/s1
DMPCRSY	CS	C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@H](C(=O)O)N)I)I)O
DMPCRSY	IK	AUYYCJSJGJYCDS-GFCCVEGCSA-N
DMPCRSY	IU	(2R)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
DMPCRSY	CA	CAS 5714-08-9
DMPCRSY	DE	Discovery agent

DMD4N2F	ID	DMD4N2F
DMD4N2F	DN	Devazepide
DMD4N2F	HS	Investigative
DMD4N2F	SN	DEVAZEPIDE; 103420-77-5; MK-329; Devazepidum; Devazepida; MK 329; L-364,718; UNII-JE6P7QY7NH; L 364718; (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide; JE6P7QY7NH; CHEMBL9506; CHEBI:4460; L-364718; 3(S)-(-)-1,3-Dihydro-3-(2-indolecarbonylamino)-1-methyl-5-phenyl-2H-(1,4)benzodiazepin-2-one; NCGC00159551-01; DSSTox_RID_81331; DSSTox_CID_26092; DSSTox_GSID_46092; 1H-Indole-2-carboxamide,
DMD4N2F	DT	Small molecular drug
DMD4N2F	PC	443375
DMD4N2F	MW	408.5
DMD4N2F	FM	C25H20N4O2
DMD4N2F	IC	InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
DMD4N2F	CS	CN1C2=CC=CC=C2C(=N[C@@H](C1=O)NC(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=C5
DMD4N2F	IK	NFHRQQKPEBFUJK-HSZRJFAPSA-N
DMD4N2F	IU	N-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-1H-indole-2-carboxamide
DMD4N2F	CA	CAS 103420-77-5
DMD4N2F	CB	CHEBI:4460
DMD4N2F	DE	Gastrointestinal disease

DM9P4JW	ID	DM9P4JW
DM9P4JW	DN	Dexverapamil
DM9P4JW	HS	Investigative
DM9P4JW	SN	Dexverapamil; Dexverapamil [INN]; Dexverapamilo; Dexverapamilo [INN-Spanish]; Dexverapamilum; Dexverapamilum [INN-Latin]; QR5PYD126V; R(+)-VERAPAMIL; Verapramil; verapamil-r; (+)-(R)-5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; (+)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; (+)-verapamil; (R)-5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile; 38321-02-7; CHEBI:77734; UNII-QR5PYD126V
DM9P4JW	PC	65808
DM9P4JW	MW	454.6
DM9P4JW	FM	C27H38N2O4
DM9P4JW	IC	SGTNSNPWRIOYBX-HHHXNRCGSA-N
DM9P4JW	CS	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DM9P4JW	IK	1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3/t27-/m1/s1
DM9P4JW	IU	(2R)-2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DM9P4JW	CA	CAS 38321-02-7
DM9P4JW	CB	CHEBI:77734
DM9P4JW	DE	Discovery agent

DMR8M19	ID	DMR8M19
DMR8M19	DN	DFGYVAE
DMR8M19	HS	Investigative
DMR8M19	SN	DFGYVAE; CHEMBL1163804; GTPL3023; BDBM50321104; (2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-phenylpropanamido]acetamido}-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]pentanedioic acid
DMR8M19	DT	Small molecular drug
DMR8M19	PC	46906168
DMR8M19	MW	799.8
DMR8M19	FM	C37H49N7O13
DMR8M19	IC	InChI=1S/C37H49N7O13/c1-19(2)31(36(55)40-20(3)32(51)42-25(37(56)57)13-14-29(47)48)44-35(54)27(16-22-9-11-23(45)12-10-22)41-28(46)18-39-34(53)26(15-21-7-5-4-6-8-21)43-33(52)24(38)17-30(49)50/h4-12,19-20,24-27,31,45H,13-18,38H2,1-3H3,(H,39,53)(H,40,55)(H,41,46)(H,42,51)(H,43,52)(H,44,54)(H,47,48)(H,49,50)(H,56,57)/t20-,24-,25-,26-,27-,31-/m0/s1
DMR8M19	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)N
DMR8M19	IK	RRCWAJVJCDGGKS-UQPWSHDPSA-N
DMR8M19	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]pentanedioic acid
DMR8M19	DE	Discovery agent

DMNX5VI	ID	DMNX5VI
DMNX5VI	DN	D-fructose
DMNX5VI	HS	Investigative
DMNX5VI	SN	D-Arabino-Hex-2-ulo-Pyranose; D-Fructopyranose; D-Fructopyranoside; D-Fructose; D-arabino-Hex-2-ulopyranose; Fructopyranose; Fructopyranoside; Fructose; LKDRXBCSQODPBY-VRPWFDPXSA-N; Q27117234; SCHEMBL239448; AKOS004910390; C05003; CHEBI:37714; CHEMBL2325229; CTK2F9011; D-Fru; EB37038E-44A6-4AF7-B0D8-47A315AD2F74; F0317; Fru; [14C]-Fructose
DMNX5VI	PC	2723872
DMNX5VI	MW	180.16
DMNX5VI	FM	C6H12O6
DMNX5VI	IC	LKDRXBCSQODPBY-VRPWFDPXSA-N
DMNX5VI	CS	C1C(C(C(C(O1)(CO)O)O)O)O
DMNX5VI	IK	1S/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4-,5+,6?/m1/s1
DMNX5VI	IU	(3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMNX5VI	CA	CAS 7660-25-5
DMNX5VI	CB	CHEBI:37714
DMNX5VI	DE	Functional nausea/vomiting

DMUM84K	ID	DMUM84K
DMUM84K	DN	DFU
DMUM84K	HS	Investigative
DMUM84K	SN	Deoxyfuconojirimycin; 1,2,6-Trideoxy-2,6-imino-D-galactitol; (2S,3R,4S,5R)-2-methylpiperidine-3,4,5-triol; 99212-30-3; 1,5-Dideoxy-1,5-iminofucitol; CHEMBL314772; 1-Deoxyfuconojirimycin HCl; 1,5-Dideoxy-1,5-imino-L-fucitol; L-fuco-Deoxynojirimycin; Fucosidase Inhibitor, 3; AC1L3UXS; AC1Q59GC; SCHEMBL4378188; 3,4,5-Piperidinetriol, 2-methyl-, (2S,3R,4S,5R)-; CHEBI:132866; 1-Deoxyfuconojirimycin hydrochloride; ZINC2585424; BDBM50065258; AKOS006283710; D-Galactitol, 1,2,6-trideoxy-2,6-imino-; FT-0624513
DMUM84K	TC	Analgesics
DMUM84K	DT	Small molecular drug
DMUM84K	PC	9906892
DMUM84K	MW	360.4
DMUM84K	FM	C19H17FO4S
DMUM84K	IC	InChI=1S/C19H17FO4S/c1-19(2)17(12-7-9-15(10-8-12)25(3,22)23)16(18(21)24-19)13-5-4-6-14(20)11-13/h4-11H,1-3H3
DMUM84K	CS	CC1(C(=C(C(=O)O1)C2=CC(=CC=C2)F)C3=CC=C(C=C3)S(=O)(=O)C)C
DMUM84K	IK	NXERGIJHYVUXHM-UHFFFAOYSA-N
DMUM84K	IU	3-(3-fluorophenyl)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one
DMUM84K	CA	CAS 178402-36-3
DMUM84K	DE	Pain

DM527XP	ID	DM527XP
DM527XP	DN	D-Gluconhydroximo-1,5-Lactam
DM527XP	HS	Investigative
DM527XP	SN	D-GLUCONHYDROXIMO-1,5-LACTAM; CHEMBL1213470; (Z)-D-Gluconhydroximo-1,5-lactam; GOX; (2S,3S,4R,5R)-6-(HYDROXYAMINO)-2-(HYDROXYMETHYL)-2,3,4,5-TETRAHYDROPYRIDINE-3,4,5-TRIOL; CID445248; GHIL; 1e6s; AC1L9HO3; BDBM36390; 3d51; 2j78; BDBM50120840; DB02376; (Z)-D-Gluconhydroximo-1,5-lactam, 15; (2Z,3S,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-one oxime
DM527XP	DT	Small molecular drug
DM527XP	PC	445248
DM527XP	MW	192.17
DM527XP	FM	C6H12N2O5
DM527XP	IC	InChI=1S/C6H12N2O5/c9-1-2-3(10)4(11)5(12)6(7-2)8-13/h2-5,9-13H,1H2,(H,7,8)/t2-,3-,4+,5-/m1/s1
DM527XP	CS	C([C@@H]1[C@H]([C@@H]([C@H](C(=N1)NO)O)O)O)O
DM527XP	IK	VBXHGXTYZGYTQG-SQOUGZDYSA-N
DM527XP	IU	(2R,3R,4S,5S)-6-(hydroxyamino)-2-(hydroxymethyl)-2,3,4,5-tetrahydropyridine-3,4,5-triol
DM527XP	DE	Discovery agent

DMPMYTE	ID	DMPMYTE
DMPMYTE	DN	D-glucosamine-phosphate
DMPMYTE	HS	Investigative
DMPMYTE	SN	D-glucosamine 6-phosphate; D-glucosamine phosphate; EN300-258467; XHMJOUIAFHJHBW-IVMDWMLBSA-N; glucosamine-6-phosphate; 2-Amino-2-deoxy-D-glucopyranose 6-phosphoric acid; D-GLUCOSAMINE6-PHOSPHATE; 2-amino-2-deoxy-6-O-phosphono-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose 6-(dihydrogen phosphate); 2-amino-2-deoxy-D-glucopyranose 6-phosphate; 6590AH; AC1L9AD1; C00352; C6H14NO8P; CHEBI:47987; CHEMBL3426569; MFCD00067382; SCHEMBL13321929; WURCS=2.0/1,1,0/[a2122h-1x_1-5_2*N_6*OPO/3O/3=O]/1/
DMPMYTE	PC	440997
DMPMYTE	MW	259.149
DMPMYTE	FM	C6H14NO8P
DMPMYTE	IC	XHMJOUIAFHJHBW-IVMDWMLBSA-N
DMPMYTE	CS	C(C1C(C(C(C(O1)O)N)O)O)OP(=O)(O)O
DMPMYTE	IK	1S/C6H14NO8P/c7-3-5(9)4(8)2(15-6(3)10)1-14-16(11,12)13/h2-6,8-10H,1,7H2,(H2,11,12,13)/t2-,3-,4-,5-,6?/m1/s1
DMPMYTE	IU	[(2R,3S,4R,5R)-5-amino-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMPMYTE	CA	CAS 3616-42-0
DMPMYTE	CB	CHEBI:47987
DMPMYTE	DE	Discovery agent

DMMG2TO	ID	DMMG2TO
DMMG2TO	DN	D-glucose
DMMG2TO	HS	Investigative
DMMG2TO	SN	D-Glucopyranose; Glucopyranose; D-Glc; D-Glcp; Glucodin; Meritose; Clintose L; Roferose ST; CPC hydrate; Clearsweet 95; 2280-44-6; Staleydex 95M; CHEBI:4167; Glucopyranoside; D-Glucopyranoside; Glc; (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; Glucopyranose, D-; DSSTox_CID_2910; Glucose solution; D-Glucopyranose, anhydrous; glc-ring; D-glucose-ring; Cartose Cerelose; Staleydex 130; Glucose 40; EINECS 218-914-5; Meritose 200; Glc-OH
DMMG2TO	DT	Small molecular drug
DMMG2TO	PC	5793
DMMG2TO	MW	180.16
DMMG2TO	FM	C6H12O6
DMMG2TO	IC	InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6?/m1/s1
DMMG2TO	CS	C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)O
DMMG2TO	IK	WQZGKKKJIJFFOK-GASJEMHNSA-N
DMMG2TO	IU	(3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMMG2TO	CA	CAS 2280-44-6
DMMG2TO	CB	CHEBI:4167
DMMG2TO	DE	Discovery agent

DMPW46G	ID	DMPW46G
DMPW46G	DN	D-glucose 1-phosphate
DMPW46G	HS	Investigative
DMPW46G	SN	CIX3U01VAU; D-Glucose alpha-1-phosphate; Glucos P; Glucose 1-(dihydrogen phosphate); Glucose monophosphate; Glucose-1-phosphate; alpha-glucose-1-phosphate; .alpha.-D-Glucopyranose, 1-(dihydrogen phosphate); 1-O-phosphono-alpha-D-glucopyranose; 59-56-3; CHEBI:29042; G1P; HXXFSFRBOHSIMQ-VFUOTHLCSA-N; UNII-CIX3U01VAU; alpha-D-Glucopyranose, 1-(dihydrogen phosphate); alpha-D-Glucopyranosyl phosphate; alpha-D-Glucose 1-phosphate; alpha-D-glucose-1-phosphate
DMPW46G	PC	65533
DMPW46G	MW	260.14
DMPW46G	FM	C6H13O9P
DMPW46G	IC	HXXFSFRBOHSIMQ-VFUOTHLCSA-N
DMPW46G	CS	C(C1C(C(C(C(O1)OP(=O)(O)O)O)O)O)O
DMPW46G	IK	1S/C6H13O9P/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6-/m1/s1
DMPW46G	IU	[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate
DMPW46G	CA	CAS 59-56-3
DMPW46G	CB	CHEBI:29042
DMPW46G	DE	Discovery agent

DMNRW57	ID	DMNRW57
DMNRW57	DN	D-glucose 6-phosphate
DMNRW57	HS	Investigative
DMNRW57	SN	Aldohexose 6-phosphate; D(+)-Glucopyranose 6-phosphate; D-Glucose 6-phosphate; D-Glucose 6-phosphoric acid; D-glucose-6-phosphate; SCHEMBL6599; VFRROHXSMXFLSN-SLPGGIOYSA-N; ZINC19850142; glucose-6 phosphate; (2R,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl dihydrogen phosphate; 375AW34SQA; 56-73-5; 6-O-phosphono-D-glucose; AC1L98E0; CHEBI:15954; CTK3I9725; UNII-375AW34SQA; [(2R,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate; aldehydo-D-glucose 6-(dihydrogen phosphate); aldehydo-D-glucose 6-phosphate
DMNRW57	PC	439958
DMNRW57	MW	260.14
DMNRW57	FM	C6H13O9P
DMNRW57	IC	VFRROHXSMXFLSN-SLPGGIOYSA-N
DMNRW57	CS	C(C(C(C(C(C=O)O)O)O)O)OP(=O)(O)O
DMNRW57	IK	1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h1,3-6,8-11H,2H2,(H2,12,13,14)/t3-,4+,5+,6+/m0/s1
DMNRW57	IU	[(2R,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate
DMNRW57	CA	CAS 56-73-5
DMNRW57	CB	CHEBI:15954
DMNRW57	DE	Discovery agent

DM1YBTC	ID	DM1YBTC
DM1YBTC	DN	D-glucuronate
DM1YBTC	HS	Investigative
DM1YBTC	SN	AEMOLEFTQBMNLQ-AQKNRBDQSA-N; D-GlcA; D-Glucopyranuronate; D-Glucopyranuronic Acid; D-Glucuronate; D-Glucuronic Acid; Glucopyranuronate; Glucopyranuronic Acid; Glucosiduronic acid; Glucuronate; Glucuronic Acid; Maybridge1_004154; O_FULL_00000000001000_GS_791; SR-01000639202-1; AC1L3SRL; AC1Q5R59; AKOS015955920; C00191; CCG-49770; CHEBI:47952; CHEMBL496672; DTXSID50894097; EINECS 208-429-7; Epitope ID:115136; GlcA; HMS553E20; SCHEMBL30411; WURCS=2.0/1,1,0/[a2122A-1x_1-5]/1/; bmse000140
DM1YBTC	PC	94715
DM1YBTC	MW	194.14
DM1YBTC	FM	C6H10O7
DM1YBTC	IC	AEMOLEFTQBMNLQ-AQKNRBDQSA-N
DM1YBTC	CS	C1(C(C(OC(C1O)O)C(=O)O)O)O
DM1YBTC	IK	1S/C6H10O7/c7-1-2(8)4(5(10)11)13-6(12)3(1)9/h1-4,6-9,12H,(H,10,11)/t1-,2-,3+,4-,6?/m0/s1
DM1YBTC	IU	(2S,3S,4S,5R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid
DM1YBTC	CA	CAS 528-16-5
DM1YBTC	CB	CHEBI:47952
DM1YBTC	DE	Discovery agent

DMAYPLE	ID	DMAYPLE
DMAYPLE	DN	D-glyceraldehyde
DMAYPLE	HS	Investigative
DMAYPLE	SN	D(+)-Glyceraldehyde; D-(+)-Glyceraldehyde; D-2,3-dihydroxypropanal; D-2,3-dihydroxypropionaldehyde; D-aldotriose; D-glyceraldehyde; D-glycerose; Glyceraldehyde, D-; J-502403; Propanal, 2,3-dihydroxy-, (2R)-; Propanal, 2,3-dihydroxy-, (r)-; PubChem6338; Triose; (2R)-2,3-DIHYDROXYPROPANAL; (R)-2,3-Dihydroxypropanal; (R)-glyceraldehyde; (R);-2,3-Dihydroxypropanal; 41A680M0WB; 453-17-8; AC1L2WGP; AC1Q6A7Z; AK122382; EINECS 207-217-1; NSC 91534; Propanal, 2,3-dihydroxy-, (R)- (9CI); UNII-41A680M0WB; bmse000298
DMAYPLE	PC	79014
DMAYPLE	MW	90.08
DMAYPLE	FM	C3H6O3
DMAYPLE	IC	MNQZXJOMYWMBOU-VKHMYHEASA-N
DMAYPLE	CS	C(C(C=O)O)O
DMAYPLE	IK	1S/C3H6O3/c4-1-3(6)2-5/h1,3,5-6H,2H2/t3-/m0/s1
DMAYPLE	IU	(2R)-2,3-dihydroxypropanal
DMAYPLE	CA	CAS 497-09-6
DMAYPLE	CB	CHEBI:17378
DMAYPLE	DE	Discovery agent

DM7UVOD	ID	DM7UVOD
DM7UVOD	DN	DH97
DM7UVOD	HS	Investigative
DM7UVOD	SN	DH 97; DH97; 343263-95-6; N-[2-(2-benzyl-1H-indol-3-yl)ethyl]pentanamide; N-(2-(2-Benzyl-1H-indol-3-yl)ethyl)pentanamide; Luzindole,N-pentanoyl; Tocris-1218; AC1MRF3Z; 220339-00-4; N-pentanoyl 2-benzyltryptamine; N-Pentanoyl-2-benzyltryptamine; SCHEMBL1626901; GTPL3366; CHEMBL1327247; CHEBI:92107; CTK8E7620; BDBM85384; DTXSID90392749; MolPort-003-983-554; HMS3267D11; ZINC2581407; BN0182; AKOS024456472; NCGC00025049-01; NCGC00025049-02; ACM343263956; RT-012298; FT-0763744; SR-01000597373; SR-01000597373-1; J-019556
DM7UVOD	DT	Small molecular drug
DM7UVOD	PC	3467177
DM7UVOD	MW	334.5
DM7UVOD	FM	C22H26N2O
DM7UVOD	IC	InChI=1S/C22H26N2O/c1-2-3-13-22(25)23-15-14-19-18-11-7-8-12-20(18)24-21(19)16-17-9-5-4-6-10-17/h4-12,24H,2-3,13-16H2,1H3,(H,23,25)
DM7UVOD	CS	CCCCC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3
DM7UVOD	IK	HDOIPCLEKCEANF-UHFFFAOYSA-N
DM7UVOD	IU	N-[2-(2-benzyl-1H-indol-3-yl)ethyl]pentanamide
DM7UVOD	CB	CHEBI:92107
DM7UVOD	DE	Discovery agent

DMSN87T	ID	DMSN87T
DMSN87T	DN	Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMSN87T	HS	Investigative
DMSN87T	SN	CHEMBL386043; Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMSN87T	DT	Small molecular drug
DMSN87T	PC	44415281
DMSN87T	MW	646.7
DMSN87T	FM	C28H34N6O8S2
DMSN87T	IC	InChI=1S/C28H34N6O8S2/c1-15-9-19(35)10-16(2)20(15)7-8-24(36)32-23-14-44-43-13-22(26(29)38)33-28(40)21(31-25(37)12-30-27(23)39)11-17-3-5-18(6-4-17)34(41)42/h3-6,9-10,21-23,35H,7-8,11-14H2,1-2H3,(H2,29,38)(H,30,39)(H,31,37)(H,32,36)(H,33,40)/t21-,22-,23-/m0/s1
DMSN87T	CS	CC1=CC(=CC(=C1CCC(=O)N[C@H]2CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC2=O)CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)N)C)O
DMSN87T	IK	UHOUPDXHBXXBLE-VABKMULXSA-N
DMSN87T	IU	(4R,7S,13R)-13-[3-(4-hydroxy-2,6-dimethylphenyl)propanoylamino]-7-[(4-nitrophenyl)methyl]-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMSN87T	DE	Discovery agent

DM3DR6J	ID	DM3DR6J
DM3DR6J	DN	Di(1H-indol-2-yl)methanone
DM3DR6J	HS	Investigative
DM3DR6J	SN	CHEMBL207483; 200706-56-5; di(1H-indol-2-yl)methanone; indolyl ketone; Di(1H-indole-2-yl) ketone; SCHEMBL370573; Methanone, di-1H-indol-2-yl-; ZINC24262; CTK0J0872; DTXSID70436953
DM3DR6J	DT	Small molecular drug
DM3DR6J	PC	10220822
DM3DR6J	MW	260.29
DM3DR6J	FM	C17H12N2O
DM3DR6J	IC	InChI=1S/C17H12N2O/c20-17(15-9-11-5-1-3-7-13(11)18-15)16-10-12-6-2-4-8-14(12)19-16/h1-10,18-19H
DM3DR6J	CS	C1=CC=C2C(=C1)C=C(N2)C(=O)C3=CC4=CC=CC=C4N3
DM3DR6J	IK	GQJIQKLWZMQQGO-UHFFFAOYSA-N
DM3DR6J	IU	bis(1H-indol-2-yl)methanone
DM3DR6J	CA	CAS 200706-56-5
DM3DR6J	DE	Discovery agent

DMG21PZ	ID	DMG21PZ
DMG21PZ	DN	Di(2,6-diisopropylphenol)
DMG21PZ	HS	Investigative
DMG21PZ	SN	3,3',5,5'-Tetraisopropylbiphenyl-4,4'-diol; 2416-95-7; Dipropofo; UNII-H9GE6HX42A; di(2,6-diisopropylphenol); H9GE6HX42A; CHEMBL478518; 3,3',5,5'-Tetrakis(1-methylethyl)biphenyl-4,4'-diol; AK-51092; 3,3',5,5'-Tetraisopropyl-[1,1'-biphenyl]-4,4'-diol; Propofol related compound A; Dipropofol; Propofol related compound A [USP]; Propofol specified impurity E [EP]; Propofol Impurity E; Propofol related compound A RS [USP]; 3,3',5,5'-Tetraisopropyl-4,4'-dihydroxybiphenyl; SCHEMBL275427; CTK4F3066; DTXSID30178867
DMG21PZ	DT	Small molecular drug
DMG21PZ	PC	11602828
DMG21PZ	MW	354.5
DMG21PZ	FM	C24H34O2
DMG21PZ	IC	InChI=1S/C24H34O2/c1-13(2)19-9-17(10-20(14(3)4)23(19)25)18-11-21(15(5)6)24(26)22(12-18)16(7)8/h9-16,25-26H,1-8H3
DMG21PZ	CS	CC(C)C1=CC(=CC(=C1O)C(C)C)C2=CC(=C(C(=C2)C(C)C)O)C(C)C
DMG21PZ	IK	QAISRHCMPQROAX-UHFFFAOYSA-N
DMG21PZ	IU	4-[4-hydroxy-3,5-di(propan-2-yl)phenyl]-2,6-di(propan-2-yl)phenol
DMG21PZ	CA	CAS 2416-95-7
DMG21PZ	DE	Discovery agent

DMZ3EML	ID	DMZ3EML
DMZ3EML	DN	Di(2,6-dimethylphenol)
DMZ3EML	HS	Investigative
DMZ3EML	SN	2417-04-1; 2,2',6,6'-tetramethyl-4,4'-biphenol; 3,3',5,5'-tetramethylbiphenyl-4,4'-diol; di(2,6-dimethylphenol); 2,2',6,6'-Tetramethyl-p,p'-biphenol; CHEMBL449983; [1,1'-Biphenyl]-4,4'-diol, 3,3',5,5'-tetramethyl-; 3,3',5,5'-tetramethyl-4,4'-diallyloxybiphenyl; 3,3,5,5-Tetramehtyl [1,1'-biphenyl] 4,4'-diol; 4-(4-hydroxy-3,5-dimethylphenyl)-2,6-dimethylphenol; 3,3',5,5'-TETRAMETHYL-4,4'-DIHYDROXYBIPHENYL; 3,3,5,5-Tetramethylbiphenyl-4,4-diol; 4,4'-dihydroxy-3,3',5,5'-tetramethyl-biphenyl
DMZ3EML	DT	Small molecular drug
DMZ3EML	PC	75490
DMZ3EML	MW	242.31
DMZ3EML	FM	C16H18O2
DMZ3EML	IC	InChI=1S/C16H18O2/c1-9-5-13(6-10(2)15(9)17)14-7-11(3)16(18)12(4)8-14/h5-8,17-18H,1-4H3
DMZ3EML	CS	CC1=CC(=CC(=C1O)C)C2=CC(=C(C(=C2)C)O)C
DMZ3EML	IK	YGYPMFPGZQPETF-UHFFFAOYSA-N
DMZ3EML	IU	4-(4-hydroxy-3,5-dimethylphenyl)-2,6-dimethylphenol
DMZ3EML	CA	CAS 2417-04-1
DMZ3EML	DE	Discovery agent

DMO6Z02	ID	DMO6Z02
DMO6Z02	DN	Di(2,6-di-t-butylphenol)
DMO6Z02	HS	Investigative
DMO6Z02	SN	128-38-1; Ethyl 712; 3,3',5,5'-Tetra-tert-butylbiphenyl-4,4'-diol; UNII-D85N5VOL1N; 3,3',5,5'-tetra(tert-butyl)[1,1'-biphenyl]-4,4'-diol; D85N5VOL1N; CHEMBL1662; 4,4-Bis(2,6-di-tert-butylphenol); [1,1'-Biphenyl]-4,4'-diol, 3,3',5,5'-tetrakis(1,1-dimethylethyl)-; 3,3',5,5'-Tetra-tert-butyl-[1,1'-biphenyl]-4,4'-diol; Inter008513,3',5,5'-Tetra-tert-butyl-4,4'-dihydroxybiphenyl; 2,6-bis(tert-butyl)-4-[3,5-bis(tert-butyl)-4-hydroxyphenyl]phenol; 4, 3,3',5,5'-tetra-tert-butyl-; [1,4'-diol, 3,3',5,5'-tetrakis(1,1-dimethylethyl
DMO6Z02	DT	Small molecular drug
DMO6Z02	PC	67185
DMO6Z02	MW	410.6
DMO6Z02	FM	C28H42O2
DMO6Z02	IC	InChI=1S/C28H42O2/c1-25(2,3)19-13-17(14-20(23(19)29)26(4,5)6)18-15-21(27(7,8)9)24(30)22(16-18)28(10,11)12/h13-16,29-30H,1-12H3
DMO6Z02	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C
DMO6Z02	IK	GSOYMOAPJZYXTB-UHFFFAOYSA-N
DMO6Z02	IU	2,6-ditert-butyl-4-(3,5-ditert-butyl-4-hydroxyphenyl)phenol
DMO6Z02	CA	CAS 128-38-1
DMO6Z02	DE	Discovery agent

DMOCQ9J	ID	DMOCQ9J
DMOCQ9J	DN	Diamide
DMOCQ9J	HS	Investigative
DMOCQ9J	SN	N1,N1,N2,N2-Tetramethyldiazene-1,2-dicarboxamide; CHEBI:48958; VLSDXINSOMDCBK-BQYQJAHWSA-N; N,N',N'-Tetramethylazodicarboxamide; AC1L1HSY; ACMC-2098cn; Lopac0_000397; MLS002153343; DTXSID6040456; CHEMBL1338900; CTK8A9086; CTK8E8363; VLSDXINSOMDCBK-UHFFFAOYSA-N; HMS2234I06; 1,1-azobis(n,n-dimethylformamide); KS-00000EC9; ANW-15093; ZINC13552228; ZINC100005746; 1,1'-azobis(N,N'-dimethylformamide); ZINC253921216; AKOS028108436; n,n,n',n'-tetramethylazo-dicarboxamide; n,n,n',n'-tetramethyl azodicarboxamide
DMOCQ9J	DT	Small molecular drug
DMOCQ9J	PC	5353800
DMOCQ9J	MW	172.19
DMOCQ9J	FM	C6H12N4O2
DMOCQ9J	IC	InChI=1S/C6H12N4O2/c1-9(2)5(11)7-8-6(12)10(3)4/h1-4H3/b8-7+
DMOCQ9J	CS	CN(C)C(=O)/N=N/C(=O)N(C)C
DMOCQ9J	IK	VLSDXINSOMDCBK-BQYQJAHWSA-N
DMOCQ9J	IU	(3E)-3-(dimethylcarbamoylimino)-1,1-dimethylurea
DMOCQ9J	CA	CAS 10465-78-8
DMOCQ9J	CB	CHEBI:48963
DMOCQ9J	DE	Discovery agent

DM4EX8Y	ID	DM4EX8Y
DM4EX8Y	DN	diamide 7
DM4EX8Y	HS	Investigative
DM4EX8Y	SN	CHEMBL1770298; diamide 7; GTPL5830; BDBM50418334
DM4EX8Y	DT	Small molecular drug
DM4EX8Y	PC	53233899
DM4EX8Y	MW	394.5
DM4EX8Y	FM	C22H22N2O3S
DM4EX8Y	IC	InChI=1S/C22H22N2O3S/c1-13-7-6-8-14(2)19(13)23-22(27)20(18-12-11-15(3)28-18)24-21(26)16-9-4-5-10-17(16)25/h4-12,20,25H,1-3H3,(H,23,27)(H,24,26)
DM4EX8Y	CS	CC1=C(C(=CC=C1)C)NC(=O)C(C2=CC=C(S2)C)NC(=O)C3=CC=CC=C3O
DM4EX8Y	IK	AHTURLVFIJHCLS-UHFFFAOYSA-N
DM4EX8Y	IU	N-[2-(2,6-dimethylanilino)-1-(5-methylthiophen-2-yl)-2-oxoethyl]-2-hydroxybenzamide
DM4EX8Y	DE	Discovery agent

DMDGIT6	ID	DMDGIT6
DMDGIT6	DN	Diaminopropyl sulfate
DMDGIT6	HS	Investigative
DMDGIT6	DE	Discovery agent

DM14X29	ID	DM14X29
DM14X29	DN	diarylpropionitril
DM14X29	HS	Investigative
DM14X29	SN	1428-67-7; diarylpropionitrile; 2,3-bis(4-hydroxyphenyl)propionitrile; 2,3-bis(4-hydroxyphenyl)propanenitrile; 2,3-bis(4-hydroxyphenyl)-propionitrile; 2,3-Bis(p-hydroxyphenyl)propionitrile; CHEMBL334773; CHEBI:63949; DPN compound; Benzenepropanenitrile,4-hydroxy-a-(4-hydroxyphenyl)-; SR-01000597601; BRN 3337109; SC-4473; 2,3-Bis(p-hydroxyphenyl)-propionitrile; Propionitrile, 2,3-bis(p-hydroxyphenyl); Propionitrile, 2,3-bis(p-hydroxyphenyl)-; AC1L2T6L; GTPL2825; SCHEMBL1940848; DTXSID0040387; CTK8F9375; MolPort-003-983-761
DM14X29	DT	Small molecular drug
DM14X29	PC	102614
DM14X29	MW	239.27
DM14X29	FM	C15H13NO2
DM14X29	IC	InChI=1S/C15H13NO2/c16-10-13(12-3-7-15(18)8-4-12)9-11-1-5-14(17)6-2-11/h1-8,13,17-18H,9H2
DM14X29	CS	C1=CC(=CC=C1CC(C#N)C2=CC=C(C=C2)O)O
DM14X29	IK	GHZHWDWADLAOIQ-UHFFFAOYSA-N
DM14X29	IU	2,3-bis(4-hydroxyphenyl)propanenitrile
DM14X29	CA	CAS 1428-67-7
DM14X29	CB	CHEBI:63949
DM14X29	DE	Discovery agent

DM3CQV6	ID	DM3CQV6
DM3CQV6	DN	DIASTEREOMER 2
DM3CQV6	HS	Investigative
DM3CQV6	SN	571170-81-5; 2-(4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; DIASTEREOMER 2; CHEMBL221007; 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-Cyclopent[b]indole-3-acetic acid; MK-0524 Laropiprant; SCHEMBL1044552; CTK8C2002; DTXSID00436805; CS-M1273; KS-00001EH0; ANW-67605; BDBM50205278; AKOS016006816; KB-71920; CS-13849; AX8238513; TC-156350; 126596-EP2295409A1; 1-(4-Chlorobenzyl)-5-fluoro-7-mesyl-2,3-propano-1H-indole-10-ylacetic acid
DM3CQV6	DT	Small molecular drug
DM3CQV6	PC	10216733
DM3CQV6	MW	435.9
DM3CQV6	FM	C21H19ClFNO4S
DM3CQV6	IC	InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)
DM3CQV6	CS	CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CCC3CC(=O)O)CC4=CC=C(C=C4)Cl)F
DM3CQV6	IK	NXFFJDQHYLNEJK-UHFFFAOYSA-N
DM3CQV6	IU	2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid
DM3CQV6	CA	CAS 571170-81-5
DM3CQV6	DE	Discovery agent

DM5UFZX	ID	DM5UFZX
DM5UFZX	DN	Diazaborines
DM5UFZX	HS	Investigative
DM5UFZX	SN	KBPMSEXASFSGEI-WRBBICKQSA-N; Neomycin B-arginine conjugate; NeoR; AC1LAWYH; Hexaarginine-Neomycin B Conjugate; [D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1fwdarw4)-O-[O-2,6-diamino-2,6-dideoxy-beta-L-idopyranyl- (1fwdarw3)-beta-D-ribofuranosyl-(1fwdarw5)]-2-deoxy]-arginine
DM5UFZX	DT	Small molecular drug
DM5UFZX	PC	496913
DM5UFZX	MW	1551.8
DM5UFZX	FM	C59H118N30O19
DM5UFZX	IC	InChI=1S/C59H118N30O19/c60-23(7-1-13-78-54(66)67)45(97)84-20-31-37(92)39(94)34(88-49(101)27(64)11-5-17-82-58(74)75)51(103-31)106-42-30(87-48(100)26(63)10-4-16-81-57(72)73)19-29(86-47(99)25(62)9-3-15-80-56(70)71)36(91)44(42)108-53-41(96)43(33(22-90)105-53)107-52-35(89-50(102)28(65)12-6-18-83-59(76)77)40(95)38(93)32(104-52)21-85-46(98)24(61)8-2-14-79-55(68)69/h23-44,51-53,90-96H,1-22,60-65H2,(H,84,97)(H,85,98)(H,86,99)(H,87,100)(H,88,101)(H,89,102)(H4,66,67,78)(H4,68,69,79)(H4,70,71,80)(H4,72,73,81)(H4,74,75,82)(H4,76,77,83)/t23-,24-,25-,26-,27-,28-,29+,30-,31+,32-,33+,34+,35+,36-,37+,38+,39+,40+,41+,42+,43+,44+,51+,52?,53-/m0/s1
DM5UFZX	CS	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1NC(=O)[C@H](CCCN=C(N)N)N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CNC(=O)[C@H](CCCN=C(N)N)N)O)O)NC(=O)[C@H](CCCN=C(N)N)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)OC4[C@@H]([C@H]([C@@H]([C@@H](O4)CNC(=O)[C@H](CCCN=C(N)N)N)O)O)NC(=O)[C@H](CCCN=C(N)N)N)O)O)NC(=O)[C@H](CCCN=C(N)N)N
DM5UFZX	IK	KBPMSEXASFSGEI-WRBBICKQSA-N
DM5UFZX	IU	(2S)-2-amino-N-[[(2R,3S,4R,5R,6R)-5-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-6-[(1R,2R,3S,4R,6S)-4,6-bis[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-2-[(2S,3R,4S,5R)-4-[(3R,4R,5S,6S)-3-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-6-[[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]methyl]-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxy-3,4-dihydroxyoxan-2-yl]methyl]-5-(diaminomethylideneamino)pentanamide
DM5UFZX	DE	Discovery agent

DM5DPM4	ID	DM5DPM4
DM5DPM4	DN	Diazacholesterol
DM5DPM4	HS	Investigative
DM5DPM4	PC	129632053
DM5DPM4	MW	388.6
DM5DPM4	FM	C25H44N2O
DM5DPM4	IC	InChI=1S/C25H44N2O/c1-17(6-5-15-27(4)26)21-9-10-22-20-8-7-18-16-19(28)11-13-24(18,2)23(20)12-14-25(21,22)3/h7,17,19-23,28H,5-6,8-16,26H2,1-4H3/t17-,19+,20+,21-,22+,23+,24+,25-/m1/s1
DM5DPM4	CS	C[C@H](CCCN(C)N)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DM5DPM4	IK	CAVTXXDDLXAFFB-NMQWMWRVSA-N
DM5DPM4	IU	(3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-5-[amino(methyl)amino]pentan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM5DPM4	DE	Discovery agent

DM9KPHZ	ID	DM9KPHZ
DM9KPHZ	DN	diBA-(5)-C4
DM9KPHZ	HS	Investigative
DM9KPHZ	SN	bis-(1,3-dibutylbarbituric acid)pentamethine oxanol; oxalon dye
DM9KPHZ	DT	Small molecular drug
DM9KPHZ	PC	2733616
DM9KPHZ	MW	542.7
DM9KPHZ	FM	C29H42N4O6
DM9KPHZ	IC	InChI=1S/C29H42N4O6/c1-5-9-18-30-24(34)22(25(35)31(28(30)38)19-10-6-2)16-14-13-15-17-23-26(36)32(20-11-7-3)29(39)33(27(23)37)21-12-8-4/h13-17,34H,5-12,18-21H2,1-4H3
DM9KPHZ	CS	CCCCN1C(=C(C(=O)N(C1=O)CCCC)C=CC=CC=C2C(=O)N(C(=O)N(C2=O)CCCC)CCCC)O
DM9KPHZ	IK	CQAPPGVBCMJDML-UHFFFAOYSA-N
DM9KPHZ	IU	1,3-dibutyl-5-[5-(1,3-dibutyl-4-hydroxy-2,6-dioxopyrimidin-5-yl)penta-2,4-dienylidene]-1,3-diazinane-2,4,6-trione
DM9KPHZ	DE	Discovery agent

DMOKNXE	ID	DMOKNXE
DMOKNXE	DN	Dibenzo-p-dioxin-2-carboxylic acid
DMOKNXE	HS	Investigative
DMOKNXE	SN	Oxanthrene-2-carboxylic acid; 17054-75-0; SCHEMBL18288092; ZINC34729704; AKOS000276725
DMOKNXE	DT	Small molecular drug
DMOKNXE	PC	15728264
DMOKNXE	MW	228.2
DMOKNXE	FM	C13H8O4
DMOKNXE	IC	InChI=1S/C13H8O4/c14-13(15)8-5-6-11-12(7-8)17-10-4-2-1-3-9(10)16-11/h1-7H,(H,14,15)
DMOKNXE	CS	C1=CC=C2C(=C1)OC3=C(O2)C=C(C=C3)C(=O)O
DMOKNXE	IK	MCNODAPWJQPAIE-UHFFFAOYSA-N
DMOKNXE	IU	dibenzo-p-dioxin-2-carboxylic acid
DMOKNXE	DE	Discovery agent

DMEDKA3	ID	DMEDKA3
DMEDKA3	DN	Dibenzothiazepines
DMEDKA3	HS	Investigative
DMEDKA3	SN	Cannabinoid CB1 inverse agonists (CNS disorder); Cannabinoid CB1 inverse agonists (CNS disorder), ACADIA; CB1 inverse agonists (obesity, substance abuse), ACADIA
DMEDKA3	CP	ACADIA Pharmaceuticals Inc
DMEDKA3	DE	Drug abuse

DMD8TWC	ID	DMD8TWC
DMD8TWC	DN	dibenzoxazepine
DMD8TWC	HS	Investigative
DMD8TWC	SN	CR gas
DMD8TWC	DT	Small molecular drug
DMD8TWC	PC	66624158
DMD8TWC	MW	195.22
DMD8TWC	FM	C13H9NO
DMD8TWC	IC	InChI=1S/C13H9NO/c1-2-6-11-10(5-1)9-14-15-13-8-4-3-7-12(11)13/h1-9H
DMD8TWC	CS	C1=CC=C2C(=C1)C=NOC3=CC=CC=C23
DMD8TWC	IK	RVSGRNKUJJUAPV-UHFFFAOYSA-N
DMD8TWC	IU	benzo[d][1,2]benzoxazepine
DMD8TWC	DE	Discovery agent

DMAYSGI	ID	DMAYSGI
DMAYSGI	DN	Di-Benzyloxycarbonyl-guanidino acetylryanodine
DMAYSGI	HS	Investigative
DMAYSGI	SN	CHEMBL416926; Di-Benzyloxycarbonyl-guanidino acetylryanodine
DMAYSGI	DT	Small molecular drug
DMAYSGI	PC	44275895
DMAYSGI	MW	860.9
DMAYSGI	FM	C44H52N4O14
DMAYSGI	IC	InChI=1S/C44H52N4O14/c1-25(2)41(55)33(61-32(50)29-17-12-20-45-29)42(56)37(4)24-40(54)38(41,5)44(42,57)43(62-40)31(26(3)18-19-39(37,43)53)60-30(49)21-46-34(47-35(51)58-22-27-13-8-6-9-14-27)48-36(52)59-23-28-15-10-7-11-16-28/h6-17,20,25-26,31,33,45,53-57H,18-19,21-24H2,1-5H3,(H2,46,47,48,51,52)/t26?,31-,33-,37+,38?,39?,40?,41?,42?,43?,44?/m1/s1
DMAYSGI	CS	CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CN=C(NC(=O)OCC6=CC=CC=C6)NC(=O)OCC7=CC=CC=C7)O4)O)O)OC(=O)C8=CC=CN8)(C(C)C)O)C)O)C)O
DMAYSGI	IK	NQGUDUOLYOZNBB-UTTPSZOSSA-N
DMAYSGI	IU	[(2R,7S,12R)-2-[2-[bis(phenylmethoxycarbonylamino)methylideneamino]acetyl]oxy-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMAYSGI	DE	Discovery agent

DM2G8ON	ID	DM2G8ON
DM2G8ON	DN	Dibutyl 2,2,2-trifluoro-1-phenylethyl phosphate
DM2G8ON	HS	Investigative
DM2G8ON	SN	CHEMBL573979; Dibutyl 2,2,2-trifluoro-1-phenylethyl phosphate
DM2G8ON	DT	Small molecular drug
DM2G8ON	PC	14026658
DM2G8ON	MW	368.33
DM2G8ON	FM	C16H24F3O4P
DM2G8ON	IC	InChI=1S/C16H24F3O4P/c1-3-5-12-21-24(20,22-13-6-4-2)23-15(16(17,18)19)14-10-8-7-9-11-14/h7-11,15H,3-6,12-13H2,1-2H3
DM2G8ON	CS	CCCCOP(=O)(OCCCC)OC(C1=CC=CC=C1)C(F)(F)F
DM2G8ON	IK	BREZEIOVGIZIOU-UHFFFAOYSA-N
DM2G8ON	IU	dibutyl (2,2,2-trifluoro-1-phenylethyl) phosphate
DM2G8ON	DE	Discovery agent

DMEDGKO	ID	DMEDGKO
DMEDGKO	DN	Dibutyl phthalate
DMEDGKO	HS	Investigative
DMEDGKO	SN	di-n-butyl phthalate; n-butyl phthalate; nutyl phthalate
DMEDGKO	DT	Small molecular drug
DMEDGKO	PC	3026
DMEDGKO	MW	278.34
DMEDGKO	FM	C16H22O4
DMEDGKO	IC	InChI=1S/C16H22O4/c1-3-5-11-19-15(17)13-9-7-8-10-14(13)16(18)20-12-6-4-2/h7-10H,3-6,11-12H2,1-2H3
DMEDGKO	CS	CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC
DMEDGKO	IK	DOIRQSBPFJWKBE-UHFFFAOYSA-N
DMEDGKO	IU	dibutyl benzene-1,2-dicarboxylate
DMEDGKO	CA	CAS 84-74-2
DMEDGKO	CB	CHEBI:34687
DMEDGKO	DE	Discovery agent

DM4I5Z3	ID	DM4I5Z3
DM4I5Z3	DN	Dicaffeoylquinic acids
DM4I5Z3	HS	Investigative
DM4I5Z3	DE	Human immunodeficiency virus infection

DMAV0BX	ID	DMAV0BX
DMAV0BX	DN	Dicaffeoyltartaric acids
DMAV0BX	HS	Investigative
DMAV0BX	DE	Human immunodeficiency virus infection

DML3HEM	ID	DML3HEM
DML3HEM	DN	Dicarboxylate
DML3HEM	HS	Investigative
DML3HEM	SN	1,3-Propanedioic acid; 9KX7ZMG0MK; AI3-15375; BRN 1751370; CHEBI:30794; Carboxyacetic acid; DICARBOXYLIC ACID C3; Dicarboxylate; Dicarboxylic acid; Dicarboxymethane; EINECS 205-503-0; Kyselina malonova; Kyselina malonova [Czech]; METAHNEDICARBOXYLIC ACID; MFCD00002707; Malonic acid; Malonic acid, 99%; Methanedicarbonic acid; Methanedicarboxylic acid; NSC 8124; NSC8124; OFOBLEOULBTSOW-UHFFFAOYSA-N; PROPANEDIOLIC ACID; Thallium malonate; UNII-9KX7ZMG0MK; USAF EK-695; alpha,omega-Dicarboxylic acid; malonic acid; propanedioic acid
DML3HEM	DT	Small molecular drug
DML3HEM	PC	867
DML3HEM	MW	104.061
DML3HEM	FM	C3H4O4
DML3HEM	IC	InChI=1S/C3H4O4/c4-2(5)1-3(6)7/h1H2,(H,4,5)(H,6,7)
DML3HEM	CS	C(C(=O)O)C(=O)O
DML3HEM	IK	OFOBLEOULBTSOW-UHFFFAOYSA-N
DML3HEM	IU	propanedioic acid
DML3HEM	CA	CAS 141-82-2
DML3HEM	CB	CHEBI:30794

DMXGV63	ID	DMXGV63
DMXGV63	DN	Dichloroallyl lawsone
DMXGV63	HS	Investigative
DMXGV63	SN	Dichloroallyl lawsone; Dichlorolapachol; Dichlorolawsone; Dichloroallyllawsone; Lawsone, dichlorallyl-; 36417-16-0; NSC 126771; NSC-126771; 2-Hydroxy-3-(3,3-dichloroallyl)-1,4-naphthoquinone; UNII-ZE2BI297KA; BRN 1977648; ZE2BI297KA; 1,4-Naphthoquinone, 2-(3,3-dichloroallyl)-3-hydroxy-; MLS002701983; 1,4-NAPHTHALENEDIONE, 2-(3,3-DICHLORO-2-PROPENYL)-3-HYDROXY-; NSC126771; 3-(3,3-Dichloroallyl)-2-hydroxy-1,4-naphthoquinone; AC1L5MNX; AC1Q3FFX; NCIMech_000041; Dichloroallyl lawsone (DCL); C13H8Cl2O3
DMXGV63	DT	Small molecular drug
DMXGV63	PC	277767
DMXGV63	MW	283.1
DMXGV63	FM	C13H8Cl2O3
DMXGV63	IC	InChI=1S/C13H8Cl2O3/c14-10(15)6-5-9-11(16)7-3-1-2-4-8(7)12(17)13(9)18/h1-4,6,16H,5H2
DMXGV63	CS	C1=CC=C2C(=C1)C(=C(C(=O)C2=O)CC=C(Cl)Cl)O
DMXGV63	IK	LWQZLQISFLBSGW-UHFFFAOYSA-N
DMXGV63	IU	3-(3,3-dichloroprop-2-enyl)-4-hydroxynaphthalene-1,2-dione
DMXGV63	CA	CAS 36417-16-0
DMXGV63	DE	Discovery agent

DMAU5VM	ID	DMAU5VM
DMAU5VM	DN	Dichloroally-lawsone
DMAU5VM	HS	Investigative
DMAU5VM	DE	Discovery agent

DMAEI51	ID	DMAEI51
DMAEI51	DN	Dichloroindophenol
DMAEI51	HS	Investigative
DMAEI51	SN	Dichlorophenolindophenol; Indochlorophenol; Tillmans Reagent; 2,5-Cyclohexadien-1-one, 2,6-dichloro-4-((4-hydroxyphenyl)imino)-; 2,6-Dichlorophenolindophenol; 2,5-cyclohexadien-1-one, 2,6-dichloro-4-[(4-hydroxyphenyl)imino]-; 2,6-DICHLOROINDOPHENOL; 2,6-Dichloro-N-4-hydroxyphenyl-p-benzoquinone monoimine; 4-[(3,5-dichloro-4-hydroxyphenyl)imino]cyclohexa-2,5-dien-1-one; 956-48-9; C35QN2Z58B; CHEBI:27451; CHEBI:945; DCPIP; DPIP; N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine; UNII-C35QN2Z58B
DMAEI51	PC	13726
DMAEI51	MW	268.09
DMAEI51	FM	C12H7Cl2NO2
DMAEI51	IC	FBWADIKARMIWNM-UHFFFAOYSA-N
DMAEI51	CS	C1=CC(=O)C=CC1=NC2=CC(=C(C(=C2)Cl)O)Cl
DMAEI51	IK	1S/C12H7Cl2NO2/c13-10-5-8(6-11(14)12(10)17)15-7-1-3-9(16)4-2-7/h1-6,17H
DMAEI51	IU	4-(3,5-dichloro-4-hydroxyphenyl)iminocyclohexa-2,5-dien-1-one
DMAEI51	CA	CAS 956-48-9
DMAEI51	CB	CHEBI:945
DMAEI51	DE	Discovery agent

DMSZ7UE	ID	DMSZ7UE
DMSZ7UE	DN	Dichloroisoproterenol
DMSZ7UE	HS	Investigative
DMSZ7UE	SN	Dichloroisoproterenol; Dichlorisoproterenol; Dichloroisoprenaline; Dichlorisoprenaline [German]; 59-61-0; 3,4-Dichlor-isoproterenol [German]; 1-(3,4-Dichlorophenyl)-2-isopropylaminoethanol; BRN 2807251; CHEMBL30816; beta-Hydroxy-N-isopropyl-3,4-dichlorophenethylamine; 3,4-Dichloro-alpha-(isopropylaminomethyl)benzyl alcohol; N-(beta-(3,4-Dichlorophenyl)-beta-hydroxyethyl)isopropylamine; 3,4-Dichloro-alpha-(((1-methylethyl)amino)methyl)benzenemethanol; 1-(3,4-Dichlorophenyl)-2-(isopropylamino)ethanol; BENZYL ALCOHOL, 3,4-D
DMSZ7UE	DT	Small molecular drug
DMSZ7UE	PC	5806
DMSZ7UE	MW	248.15
DMSZ7UE	FM	C11H15Cl2NO
DMSZ7UE	IC	InChI=1S/C11H15Cl2NO/c1-7(2)14-6-11(15)8-3-4-9(12)10(13)5-8/h3-5,7,11,14-15H,6H2,1-2H3
DMSZ7UE	CS	CC(C)NCC(C1=CC(=C(C=C1)Cl)Cl)O
DMSZ7UE	IK	VKMGSWIFEHZQRS-UHFFFAOYSA-N
DMSZ7UE	IU	1-(3,4-dichlorophenyl)-2-(propan-2-ylamino)ethanol
DMSZ7UE	CA	CAS 59-61-0
DMSZ7UE	DE	Discovery agent

DMWADLM	ID	DMWADLM
DMWADLM	DN	Diclofenac glucuronide
DMWADLM	HS	Investigative
DMWADLM	SN	Diclofenac acyl glucuronide; Diclofenac glucuronide; CHEBI:59609; Diclofenac beta-D-glucosiduronic acid; UNII-C8BEZ13XEN; C8BEZ13XEN; CHEMBL3527338; 64118-81-6; 1-O-({2-[(2,6-dichlorophenyl)amino]phenyl}acetyl)-beta-D-glucopyranuronic acid; Diclofenac acyl-D-glucuronide; Diclofenac O-glucuronide; Epitope ID:131803; Diclofenac-beta-D-glucuronide; SCHEMBL4258872; Diclofenac-acyl-beta-D-glucuronide; BDBM50088512; ZINC35048352; Q27126801; 2-(2,6-Dichloroanilino)phenylacetic acid beta-D-glucopyranuronosyl ester
DMWADLM	PC	16084218
DMWADLM	MW	472.3
DMWADLM	FM	C20H19Cl2NO8
DMWADLM	IC	JXIKYYSIYCILNG-HBWRTXEVSA-N
DMWADLM	CS	C1=CC=C(C(=C1)CC(=O)OC2C(C(C(C(O2)C(=O)O)O)O)O)NC3=C(C=CC=C3Cl)Cl
DMWADLM	IK	1S/C20H19Cl2NO8/c21-10-5-3-6-11(22)14(10)23-12-7-2-1-4-9(12)8-13(24)30-20-17(27)15(25)16(26)18(31-20)19(28)29/h1-7,15-18,20,23,25-27H,8H2,(H,28,29)/t15-,16-,17+,18-,20+/m0/s1
DMWADLM	IU	(2S,3S,4S,5R,6S)-6-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMWADLM	CA	CAS 64118-81-6
DMWADLM	CB	CHEBI:59609
DMWADLM	DE	Discovery agent

DMO3KU5	ID	DMO3KU5
DMO3KU5	DN	Diclosan
DMO3KU5	HS	Investigative
DMO3KU5	SN	SONECLOSAN; DICLOSAN; 3380-30-1; 5-chloro-2-(4-chlorophenoxy)phenol; 5-Chloro-2-(p-chlorophenoxy)phenol; UNII-814H7B74XK; hydroxydichlorodiphenyl ether; Phenol, 5-chloro-2-(p-chlorophenoxy)-; 814H7B74XK; Snoclosan; Soneclosan [INN]; DCN; Tinosan HP-100; Phenol, 5-chloro-2-(4-chlorophenoxy)-; AC1L2CUC; AC1Q3QSN; EC 429-290-0; SCHEMBL465591; CHEMBL1232142; CTK1C4131; DTXSID80187464; ZINC2027016; ACT08242; AKOS027382858; DB04393; 4,4'-dichloro-2-hydroxydiphenyl ether
DMO3KU5	DT	Small molecular drug
DMO3KU5	PC	18807
DMO3KU5	MW	255.09
DMO3KU5	FM	C12H8Cl2O2
DMO3KU5	IC	InChI=1S/C12H8Cl2O2/c13-8-1-4-10(5-2-8)16-12-6-3-9(14)7-11(12)15/h1-7,15H
DMO3KU5	CS	C1=CC(=CC=C1OC2=C(C=C(C=C2)Cl)O)Cl
DMO3KU5	IK	BYNQFCJOHGOKSS-UHFFFAOYSA-N
DMO3KU5	IU	5-chloro-2-(4-chlorophenoxy)phenol
DMO3KU5	CA	CAS 3380-30-1
DMO3KU5	DE	Discovery agent

DM9WU3R	ID	DM9WU3R
DM9WU3R	DN	Dideazaacyclotetrahydrofolic acid
DM9WU3R	HS	Investigative
DM9WU3R	DT	Small molecular drug
DM9WU3R	PC	135884475
DM9WU3R	MW	431.4
DM9WU3R	FM	C20H25N5O6
DM9WU3R	IC	InChI=1S/C20H25N5O6/c21-16-13(18(29)25-20(22)24-16)4-2-1-3-11-5-7-12(8-6-11)17(28)23-14(19(30)31)9-10-15(26)27/h5-8,14H,1-4,9-10H2,(H,23,28)(H,26,27)(H,30,31)(H5,21,22,24,25,29)/t14-/m0/s1
DM9WU3R	CS	C1=CC(=CC=C1CCCCC2=C(N=C(NC2=O)N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM9WU3R	IK	LNUHUIPUTGDPDG-AWEZNQCLSA-N
DM9WU3R	IU	(2S)-2-[[4-[4-(2,4-diamino-6-oxo-1H-pyrimidin-5-yl)butyl]benzoyl]amino]pentanedioic acid
DM9WU3R	DE	Discovery agent

DMAIOC9	ID	DMAIOC9
DMAIOC9	DN	Dideazafolate
DMAIOC9	HS	Investigative
DMAIOC9	DT	Small molecular drug
DMAIOC9	PC	135517463
DMAIOC9	MW	439.4
DMAIOC9	FM	C21H21N5O6
DMAIOC9	IC	InChI=1S/C21H21N5O6/c22-21-25-15-6-1-11(9-14(15)19(30)26-21)10-23-13-4-2-12(3-5-13)18(29)24-16(20(31)32)7-8-17(27)28/h1-6,9,16,23H,7-8,10H2,(H,24,29)(H,27,28)(H,31,32)(H3,22,25,26,30)
DMAIOC9	CS	C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CC3=C(C=C2)N=C(NC3=O)N
DMAIOC9	IK	UQFCLENKCDVITL-UHFFFAOYSA-N
DMAIOC9	IU	2-[[4-[(2-amino-4-oxo-3H-quinazolin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMAIOC9	DE	Discovery agent

DM2FLRQ	ID	DM2FLRQ
DM2FLRQ	DN	DIDODECANOYLPHLOROGLUCINOL
DM2FLRQ	HS	Investigative
DM2FLRQ	SN	DIDODECANOYLPHLOROGLUCINOL; CHEMBL470757; SCHEMBL9188500; MolPort-044-550-959; BDBM50256011; ZINC44417494; 1,1''-(2,4,6-trihydroxy-1,3-phenylene)didodecan-1-one; 1,1'-(2,4,6-trihydroxy-1,3-phenylene)bis-1-dodecanone; 1,1'-(2,4,6-Trihydroxy-1,3-phenylene)bis(dodecan-1-one)
DM2FLRQ	DT	Small molecular drug
DM2FLRQ	PC	9957245
DM2FLRQ	MW	490.7
DM2FLRQ	FM	C30H50O5
DM2FLRQ	IC	InChI=1S/C30H50O5/c1-3-5-7-9-11-13-15-17-19-21-24(31)28-26(33)23-27(34)29(30(28)35)25(32)22-20-18-16-14-12-10-8-6-4-2/h23,33-35H,3-22H2,1-2H3
DM2FLRQ	CS	CCCCCCCCCCCC(=O)C1=C(C(=C(C=C1O)O)C(=O)CCCCCCCCCCC)O
DM2FLRQ	IK	AIKYCZDMJFKXLS-UHFFFAOYSA-N
DM2FLRQ	IU	1-(3-dodecanoyl-2,4,6-trihydroxyphenyl)dodecan-1-one
DM2FLRQ	DE	Discovery agent

DMKSQUB	ID	DMKSQUB
DMKSQUB	DN	DIDS
DMKSQUB	HS	Investigative
DMKSQUB	SN	4,4'-diisothiocyanostilbene-2,2'-disulphonic acid
DMKSQUB	DT	Small molecular drug
DMKSQUB	PC	5281951
DMKSQUB	MW	454.5
DMKSQUB	FM	C16H10N2O6S4
DMKSQUB	IC	InChI=1S/C16H10N2O6S4/c19-27(20,21)15-7-13(17-9-25)5-3-11(15)1-2-12-4-6-14(18-10-26)8-16(12)28(22,23)24/h1-8H,(H,19,20,21)(H,22,23,24)/b2-1+
DMKSQUB	CS	C1=CC(=C(C=C1N=C=S)S(=O)(=O)O)/C=C/C2=C(C=C(C=C2)N=C=S)S(=O)(=O)O
DMKSQUB	IK	YSCNMFDFYJUPEF-OWOJBTEDSA-N
DMKSQUB	IU	5-isothiocyanato-2-[(E)-2-(4-isothiocyanato-2-sulfophenyl)ethenyl]benzenesulfonic acid
DMKSQUB	CA	CAS 152216-76-7
DMKSQUB	CB	CHEBI:4286
DMKSQUB	DE	Discovery agent

DMBCK4G	ID	DMBCK4G
DMBCK4G	DN	DIECKOL
DMBCK4G	HS	Investigative
DMBCK4G	SN	Dieckol; UNII-ZU0ESU4399; CHEMBL508791; ZU0ESU4399; CHEBI:65769; 88095-77-6; 4-(4-{[6-(3,5-dihydroxyphenoxy)-4,7,9-trihydroxyoxanthren-2-yl]oxy}-3,5-dihydroxyphenoxy)oxanthrene-1,3,6,8-tetrol; 4-[4-[[6-(3,5-dihydroxyphenoxy)-4,7,9-trihydroxydibenzo[b,e][1,4]dioxin-2-yl]oxy]-3,5-dihydroxyphenoxy]-dibenzo[b,e][1,4]dioxin-1,3,6,8-tetrol; Dibenzo(b,E)(1,4)dioxin-1,3,6,8-tetrol, 4-(4-((6-(3,5-dihydroxyphenoxy)-4,7,9-trihydroxydibenzo(b,E)(1,4)dioxin-2-yl)oxy)-3,5-dihydroxyphenoxy)-
DMBCK4G	DT	Small molecular drug
DMBCK4G	PC	3008868
DMBCK4G	MW	742.5
DMBCK4G	FM	C36H22O18
DMBCK4G	IC	InChI=1S/C36H22O18/c37-12-1-13(38)3-15(2-12)49-31-22(44)10-25(47)34-35(31)54-30-21(43)8-17(9-27(30)52-34)48-28-19(41)6-16(7-20(28)42)50-32-23(45)11-24(46)33-36(32)53-29-18(40)4-14(39)5-26(29)51-33/h1-11,37-47H
DMBCK4G	CS	C1=C(C=C(C=C1O)OC2=C(C=C(C3=C2OC4=C(C=C(C=C4O3)OC5=C(C=C(C=C5O)OC6=C(C=C(C7=C6OC8=C(C=C(C=C8O7)O)O)O)O)O)O)O)O)O
DMBCK4G	IK	DRZQFGYIIYNNEC-UHFFFAOYSA-N
DMBCK4G	IU	4-[4-[6-(3,5-dihydroxyphenoxy)-4,7,9-trihydroxydibenzo-p-dioxin-2-yl]oxy-3,5-dihydroxyphenoxy]dibenzo-p-dioxin-1,3,6,8-tetrol
DMBCK4G	CA	CAS 88095-77-6
DMBCK4G	CB	CHEBI:65769
DMBCK4G	DE	Discovery agent

DMK7QXA	ID	DMK7QXA
DMK7QXA	DN	DIETHOXYFLOURESCEIN
DMK7QXA	HS	Investigative
DMK7QXA	SN	DIETHOXYFLOURESCEIN; CHEMBL1257567; Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 3',6'-diethoxy-; 21934-70-3; Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-diethoxy-; AC1Q6MMX; AC1L4PB7; 3',6'-Diethoxyfluorescein; SCHEMBL6404797; XAPFGEPPWZRGFN-UHFFFAOYSA-N; BDBM50328442; AKOS028111348
DMK7QXA	DT	Small molecular drug
DMK7QXA	PC	161373
DMK7QXA	MW	388.4
DMK7QXA	FM	C24H20O5
DMK7QXA	IC	InChI=1S/C24H20O5/c1-3-26-15-9-11-19-21(13-15)28-22-14-16(27-4-2)10-12-20(22)24(19)18-8-6-5-7-17(18)23(25)29-24/h5-14H,3-4H2,1-2H3
DMK7QXA	CS	CCOC1=CC2=C(C=C1)C3(C4=C(O2)C=C(C=C4)OCC)C5=CC=CC=C5C(=O)O3
DMK7QXA	IK	XAPFGEPPWZRGFN-UHFFFAOYSA-N
DMK7QXA	IU	3',6'-diethoxyspiro[2-benzofuran-3,9'-xanthene]-1-one
DMK7QXA	CA	CAS 21934-70-3
DMK7QXA	DE	Discovery agent

DM7YHBR	ID	DM7YHBR
DM7YHBR	DN	Diethyl 2-((biphenyl-3-ylamino)methylene)malonate
DM7YHBR	HS	Investigative
DM7YHBR	SN	CHEMBL217897; ZINC14956351; diethyl [(biphenyl-3-ylamino)methylidene]propanedioate
DM7YHBR	DT	Small molecular drug
DM7YHBR	PC	91895907
DM7YHBR	MW	339.4
DM7YHBR	FM	C20H21NO4
DM7YHBR	IC	InChI=1S/C20H21NO4/c1-3-24-19(22)18(20(23)25-4-2)14-21-17-12-8-11-16(13-17)15-9-6-5-7-10-15/h5-14,18H,3-4H2,1-2H3
DM7YHBR	CS	CCOC(=O)C(C=NC1=CC=CC(=C1)C2=CC=CC=C2)C(=O)OCC
DM7YHBR	IK	WHQSBENLMFJXRC-UHFFFAOYSA-N
DM7YHBR	IU	diethyl 2-[(3-phenylphenyl)iminomethyl]propanedioate
DM7YHBR	DE	Discovery agent

DMDJ9QA	ID	DMDJ9QA
DMDJ9QA	DN	Diethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMDJ9QA	HS	Investigative
DMDJ9QA	SN	CHEMBL575301; Diethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMDJ9QA	DT	Small molecular drug
DMDJ9QA	PC	14026656
DMDJ9QA	MW	312.22
DMDJ9QA	FM	C12H16F3O4P
DMDJ9QA	IC	InChI=1S/C12H16F3O4P/c1-3-17-20(16,18-4-2)19-11(12(13,14)15)10-8-6-5-7-9-10/h5-9,11H,3-4H2,1-2H3
DMDJ9QA	CS	CCOP(=O)(OCC)OC(C1=CC=CC=C1)C(F)(F)F
DMDJ9QA	IK	LLGREQYHEQMYRW-UHFFFAOYSA-N
DMDJ9QA	IU	diethyl (2,2,2-trifluoro-1-phenylethyl) phosphate
DMDJ9QA	CA	CAS 120245-10-5
DMDJ9QA	DE	Discovery agent

DMM4QFL	ID	DMM4QFL
DMM4QFL	DN	Diethylphosphono Group
DMM4QFL	HS	Investigative
DMM4QFL	SN	Diethyl phosphonate; 762-04-9; Phosphonic acid, diethyl ester; Phosphonic acid diethyl ester; Diethoxyphosphine oxide; Hydrogen diethyl phosphite; Diethyl acid phosphite; O,O-Diethyl phosphonate; Phosphorous acid, diethyl ester; Ethyl phosphonate ((EtO)2HPO); Diethylfosfit [Czech]; UNII-U9X9YBA22W; NSC 2665; DIETHYLPHOSPHONO GROUP; HSDB 2591; diethoxyphosphino-1-one; diethoxy(oxo)phosphonium; Diethyl phosphite, 98%; EINECS 212-091-6; BRN 0605759; U9X9YBA22W; MJUJXFBTEFXVKU-UHFFFAOYSA-N; Diethylfosfit; MFCD00044573
DMM4QFL	DT	Small molecular drug
DMM4QFL	PC	6327654
DMM4QFL	MW	137.09
DMM4QFL	FM	C4H10O3P+
DMM4QFL	IC	InChI=1S/C4H10O3P/c1-3-6-8(5)7-4-2/h3-4H2,1-2H3/q+1
DMM4QFL	CS	CCO[P+](=O)OCC
DMM4QFL	IK	LXCYSACZTOKNNS-UHFFFAOYSA-N
DMM4QFL	IU	diethoxy(oxo)phosphanium
DMM4QFL	CA	CAS 762-04-9
DMM4QFL	CB	CHEBI:41962
DMM4QFL	DE	Discovery agent

DM8AZQ3	ID	DM8AZQ3
DM8AZQ3	DN	difluoroagomelatine
DM8AZQ3	HS	Investigative
DM8AZQ3	SN	difluoroagomelatine; GTPL7776; CHEMBL1946221
DM8AZQ3	DT	Small molecular drug
DM8AZQ3	PC	57381112
DM8AZQ3	MW	279.28
DM8AZQ3	FM	C15H15F2NO2
DM8AZQ3	IC	InChI=1S/C15H15F2NO2/c1-20-12-6-5-10-3-2-4-11(13(10)9-12)7-8-18-15(19)14(16)17/h2-6,9,14H,7-8H2,1H3,(H,18,19)
DM8AZQ3	CS	COC1=CC2=C(C=CC=C2CCNC(=O)C(F)F)C=C1
DM8AZQ3	IK	UTLRQLQDJLNKNY-UHFFFAOYSA-N
DM8AZQ3	IU	2,2-difluoro-N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
DM8AZQ3	DE	Discovery agent

DM8ABD6	ID	DM8ABD6
DM8ABD6	DN	Difluorobenztropine
DM8ABD6	HS	Investigative
DM8ABD6	SN	CHEMBL317757; DIFLUOROBENZTROPINE; 4,4'-DifluoroBZT; AC1MZYZJ; Biomol-NT_000053; Lopac0_000439; SCHEMBL6478352; BPBio1_001309; SCHEMBL12648564; BDBM86701; CHEBI:110199; NCGC00024872-02; LS-190982; BRD-A85216385-003-01-6; 3-[bis(4-fluorophenyl)methoxy]-8-methyl-8-azabicyclo[3.2.1]octane; 3-[Bis-(4-fluoro-phenyl)-methoxy]-8-methyl-8-azonia-bicyclo[3.2.1]octane; 3-(bis(4-fluorophenyl)methoxy)-8-methyl-8-aza-bicyclo[3.2.1]octane
DM8ABD6	DT	Small molecular drug
DM8ABD6	PC	3929516
DM8ABD6	MW	343.4
DM8ABD6	FM	C21H23F2NO
DM8ABD6	IC	InChI=1S/C21H23F2NO/c1-24-18-10-11-19(24)13-20(12-18)25-21(14-2-6-16(22)7-3-14)15-4-8-17(23)9-5-15/h2-9,18-21H,10-13H2,1H3
DM8ABD6	CS	CN1C2CCC1CC(C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DM8ABD6	IK	MHNSOBBJZCWUGS-UHFFFAOYSA-N
DM8ABD6	IU	3-[bis(4-fluorophenyl)methoxy]-8-methyl-8-azabicyclo[3.2.1]octane
DM8ABD6	CB	CHEBI:110199
DM8ABD6	DE	Discovery agent

DM8TG41	ID	DM8TG41
DM8TG41	DN	Difluoromethionine
DM8TG41	HS	Investigative
DM8TG41	SN	DIFLUOROMETHIONINE; S-(Difluoromethyl)homocysteine; 2FM; difluoro-L-methionine; AC1L9LA0; S-difluoromethyl-l-homocysteine; SCHEMBL2977180; DB03816; (2S)-2-amino-4-(difluoromethylsulfanyl)butanoic acid
DM8TG41	DT	Small molecular drug
DM8TG41	PC	447827
DM8TG41	MW	185.19
DM8TG41	FM	C5H9F2NO2S
DM8TG41	IC	InChI=1S/C5H9F2NO2S/c6-5(7)11-2-1-3(8)4(9)10/h3,5H,1-2,8H2,(H,9,10)/t3-/m0/s1
DM8TG41	CS	C(CSC(F)F)[C@@H](C(=O)O)N
DM8TG41	IK	YHBNXKYHZMAFED-VKHMYHEASA-N
DM8TG41	IU	(2S)-2-amino-4-(difluoromethylsulfanyl)butanoic acid
DM8TG41	DE	Discovery agent

DMXK8BH	ID	DMXK8BH
DMXK8BH	DN	digeranyl bisphosphonate
DMXK8BH	HS	Investigative
DMXK8BH	SN	digeranyl bisphosphonate; [(6E,11E)-2,6,12,16-tetramethyl-9-phosphonoheptadeca-2,6,11,15-tetraen-9-yl]phosphonic acid; bisphosphonate, 5; CHEMBL258994; GTPL3187; SCHEMBL14408741
DMXK8BH	DT	Small molecular drug
DMXK8BH	PC	11606263
DMXK8BH	MW	448.5
DMXK8BH	FM	C21H38O6P2
DMXK8BH	IC	InChI=1S/C21H38O6P2/c1-17(2)9-7-11-19(5)13-15-21(28(22,23)24,29(25,26)27)16-14-20(6)12-8-10-18(3)4/h9-10,13-14H,7-8,11-12,15-16H2,1-6H3,(H2,22,23,24)(H2,25,26,27)/b19-13+,20-14+
DMXK8BH	CS	CC(=CCC/C(=C/CC(P(=O)(O)O)(P(=O)(O)O)C/C=C(/CCC=C(C)C)\\C)/C)C
DMXK8BH	IK	SQERRIVHBWCION-IWGRKNQJSA-N
DMXK8BH	IU	[(6E,11E)-2,6,12,16-tetramethyl-9-phosphonoheptadeca-2,6,11,15-tetraen-9-yl]phosphonic acid
DMXK8BH	DE	Discovery agent

DM5AOFW	ID	DM5AOFW
DM5AOFW	DN	Digitoxigenin
DM5AOFW	HS	Investigative
DM5AOFW	SN	Uzarigenin; 466-09-1; UNII-K9ZR7LI283; EINECS 207-373-0; NSC 119993; BRN 0095446; K9ZR7LI283; 3-beta-14-beta-5-Allo-cardenolid [German]; 3beta,14-Dihydroxy-5alpha-card-20(22)-enolide; 3-beta,14-Dihydroxy-5-alpha-card-20(22)-enolide; 4-18-00-01470 (Beilstein Handbook Reference); Urarigenin; Odorigeni; 3-beta-14-beta-5-Allo-cardenolid; AC1L3OS7; CHEMBL109863; SCHEMBL1152953; XZTUSOXSLKTKJQ-CIXPXFMPSA-N; MolPort-006-111-351; ZINC4073972; MCULE-2541512222; NCGC00384854-01; BC271971; 3,14-Dihydroxycard-20(22)-enolide #
DM5AOFW	DT	Small molecular drug
DM5AOFW	PC	4369270
DM5AOFW	MW	374.5
DM5AOFW	FM	C23H34O4
DM5AOFW	IC	InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,15-19,24,26H,3-10,12-13H2,1-2H3/t15-,16+,17-,18+,19-,21+,22-,23+/m1/s1
DM5AOFW	CS	C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O
DM5AOFW	IK	XZTUSOXSLKTKJQ-CESUGQOBSA-N
DM5AOFW	IU	3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DM5AOFW	CA	CAS 143-62-4
DM5AOFW	CB	CHEBI:42219
DM5AOFW	DE	Discovery agent

DMBAY7P	ID	DMBAY7P
DMBAY7P	DN	Diheptan-3-yl 5-(hydroxymethyl)isophthalate
DMBAY7P	HS	Investigative
DMBAY7P	SN	CHEMBL494361; diheptan-3-yl 5-(hydroxymethyl)isophthalate; SCHEMBL13625629
DMBAY7P	DT	Small molecular drug
DMBAY7P	PC	44186619
DMBAY7P	MW	392.5
DMBAY7P	FM	C23H36O5
DMBAY7P	IC	InChI=1S/C23H36O5/c1-5-9-11-20(7-3)27-22(25)18-13-17(16-24)14-19(15-18)23(26)28-21(8-4)12-10-6-2/h13-15,20-21,24H,5-12,16H2,1-4H3
DMBAY7P	CS	CCCCC(CC)OC(=O)C1=CC(=CC(=C1)CO)C(=O)OC(CC)CCCC
DMBAY7P	IK	ZBGSOGNHNSNOLN-UHFFFAOYSA-N
DMBAY7P	IU	diheptan-3-yl 5-(hydroxymethyl)benzene-1,3-dicarboxylate
DMBAY7P	DE	Discovery agent

DM8TBQ9	ID	DM8TBQ9
DM8TBQ9	DN	Dihexan-3-yl 5-(hydroxymethyl)isophthalate
DM8TBQ9	HS	Investigative
DM8TBQ9	SN	CHEMBL523053; dihexan-3-yl 5-(hydroxymethyl)isophthalate; SCHEMBL13625642
DM8TBQ9	DT	Small molecular drug
DM8TBQ9	PC	44186618
DM8TBQ9	MW	364.5
DM8TBQ9	FM	C21H32O5
DM8TBQ9	IC	InChI=1S/C21H32O5/c1-5-9-18(7-3)25-20(23)16-11-15(14-22)12-17(13-16)21(24)26-19(8-4)10-6-2/h11-13,18-19,22H,5-10,14H2,1-4H3
DM8TBQ9	CS	CCCC(CC)OC(=O)C1=CC(=CC(=C1)CO)C(=O)OC(CC)CCC
DM8TBQ9	IK	ONMFJTSDBZIFTK-UHFFFAOYSA-N
DM8TBQ9	IU	dihexan-3-yl 5-(hydroxymethyl)benzene-1,3-dicarboxylate
DM8TBQ9	DE	Discovery agent

DMW1ALX	ID	DMW1ALX
DMW1ALX	DN	DIHYDROAKUAMMINE
DMW1ALX	HS	Investigative
DMW1ALX	SN	Dihydroakuammine
DMW1ALX	DT	Small molecular drug
DMW1ALX	PC	44576039
DMW1ALX	MW	384.5
DMW1ALX	FM	C22H28N2O4
DMW1ALX	IC	InChI=1S/C22H28N2O4/c1-4-14-12-24-10-9-21-17-11-15(26)5-6-18(17)23(2)22(21,24)8-7-16(14)20(21,13-25)19(27)28-3/h4-6,11,16,25-26H,7-10,12-13H2,1-3H3/b14-4-/t16-,20+,21+,22+/m1/s1
DMW1ALX	CS	C/C=C\\1/CN2CC[C@@]34[C@@]2(CC[C@H]1[C@@]3(CO)C(=O)OC)N(C5=C4C=C(C=C5)O)C
DMW1ALX	IK	SJFXTBHAODZALL-PEZZAXBTSA-N
DMW1ALX	IU	methyl (1S,9R,12R,13E,18R)-13-ethylidene-4-hydroxy-18-(hydroxymethyl)-8-methyl-8,15-diazapentacyclo[10.5.1.01,9.02,7.09,15]octadeca-2(7),3,5-triene-18-carboxylate
DMW1ALX	DE	Discovery agent

DMS4U68	ID	DMS4U68
DMS4U68	DN	dihydrocarveol
DMS4U68	HS	Investigative
DMS4U68	SN	neodihydrocarveol
DMS4U68	DT	Small molecular drug
DMS4U68	PC	12072
DMS4U68	MW	154.25
DMS4U68	FM	C10H18O
DMS4U68	IC	InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-11H,1,4-6H2,2-3H3
DMS4U68	CS	CC1CCC(CC1O)C(=C)C
DMS4U68	IK	KRCZYMFUWVJCLI-UHFFFAOYSA-N
DMS4U68	IU	2-methyl-5-prop-1-en-2-ylcyclohexan-1-ol
DMS4U68	CA	CAS 619-01-2
DMS4U68	CB	CHEBI:50215
DMS4U68	DE	Discovery agent

DMGLX1R	ID	DMGLX1R
DMGLX1R	DN	Dihydrocoumarin
DMGLX1R	HS	Investigative
DMGLX1R	SN	Benzodihydropyrone; Benzopyranone, dihydro-; Chroman, 2-oxo-; Coumarin, 3,4-dihydro-; Dihydrobenzopyrone; Melilotic acid lactone; Melilotine; Meliotine; Oxochroman; Usaf do-12; chroman-2-one; dihydrocoumarin; hydrocoumarin; melilotic lactone; melilotin; melilotol; 1,2-benzodihydropyrone; 119-84-6; 2-Hydroxydihydrocinnamic acid lactone; 2-chromanone; 2H-1-Benzopyran-2-one, 3,4-dihydro-; 3,4-Dihydro-2H-1-benzopyran-2-one; 3,4-Dyhydrocoumarin; 3,4-dihydro-2H-chromen-2-one; 3,4-dihydrocoumarin; NCI-C55890
DMGLX1R	PC	660
DMGLX1R	MW	148.16
DMGLX1R	FM	C9H8O2
DMGLX1R	IC	VMUXSMXIQBNMGZ-UHFFFAOYSA-N
DMGLX1R	CS	C1CC(=O)OC2=CC=CC=C21
DMGLX1R	IK	1S/C9H8O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-4H,5-6H2
DMGLX1R	IU	3,4-dihydrochromen-2-one
DMGLX1R	CA	CAS 119-84-6
DMGLX1R	CB	CHEBI:16151
DMGLX1R	DE	Discovery agent

DMZL7R6	ID	DMZL7R6
DMZL7R6	DN	DIHYDROCUBEBIN
DMZL7R6	HS	Investigative
DMZL7R6	SN	Dihydrocubebin; (-)-Dihydrocubebin; 24563-03-9; (2R,3R)-2,3-bis(1,3-benzodioxol-5-ylmethyl)butane-1,4-diol; CHEMBL486597; CHEBI:543841; 1,4-Butanediol, 2,3-bis(1,3-benzodioxol-5-ylmethyl)-, (R-(R*,R*))-; 1,4-Butanediol, 2,3-bis(1,3-benzodioxol-5-ylmethyl)-, [R-(R*,R*)]-; Cubebin, dihydro-; AC1Q6ZWV; AC1L4VHK; SCHEMBL15775181; CTK4F3896; DTXSID00179301; JKCVMTYNARDGET-HOTGVXAUSA-N; ZINC899938; BDBM50241937; 1,4-Butanediol, 2,3-bis(1,3-benzodioxol-5-ylmethyl)-, (R*,R*)-(-)-; 1,4-Butanediol, 2,3-dipiperonyl-, (-)-; C10558
DMZL7R6	DT	Small molecular drug
DMZL7R6	PC	193042
DMZL7R6	MW	358.4
DMZL7R6	FM	C20H22O6
DMZL7R6	IC	InChI=1S/C20H22O6/c21-9-15(5-13-1-3-17-19(7-13)25-11-23-17)16(10-22)6-14-2-4-18-20(8-14)26-12-24-18/h1-4,7-8,15-16,21-22H,5-6,9-12H2/t15-,16-/m0/s1
DMZL7R6	CS	C1OC2=C(O1)C=C(C=C2)C[C@@H](CO)[C@@H](CC3=CC4=C(C=C3)OCO4)CO
DMZL7R6	IK	JKCVMTYNARDGET-HOTGVXAUSA-N
DMZL7R6	IU	(2R,3R)-2,3-bis(1,3-benzodioxol-5-ylmethyl)butane-1,4-diol
DMZL7R6	CA	CAS 24563-03-9
DMZL7R6	CB	CHEBI:543841
DMZL7R6	DE	Discovery agent

DMDW2NL	ID	DMDW2NL
DMDW2NL	DN	dihydroergocryptine
DMDW2NL	HS	Investigative
DMDW2NL	SN	dihydroergokryptine
DMDW2NL	DT	Small molecular drug
DMDW2NL	PC	114948
DMDW2NL	MW	577.7
DMDW2NL	FM	C32H43N5O5
DMDW2NL	IC	InChI=1S/C32H43N5O5/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38)/t20-,22-,24-,25+,26+,31-,32+/m1/s1
DMDW2NL	CS	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@@H]4C[C@H]5[C@@H](CC6=CNC7=CC=CC5=C67)N(C4)C)O
DMDW2NL	IK	PBUNVLRHZGSROC-VTIMJTGVSA-N
DMDW2NL	IU	(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMDW2NL	CA	CAS 25447-66-9
DMDW2NL	CB	CHEBI:59919
DMDW2NL	DE	Discovery agent

DM1BDM8	ID	DM1BDM8
DM1BDM8	DN	Dihydrofolic Acid
DM1BDM8	HS	Investigative
DM1BDM8	DT	Small molecular drug
DM1BDM8	PC	135398604
DM1BDM8	MW	443.4
DM1BDM8	FM	C19H21N7O6
DM1BDM8	IC	InChI=1S/C19H21N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,12,21H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t12-/m0/s1
DM1BDM8	CS	C1C(=NC2=C(N1)N=C(NC2=O)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM1BDM8	IK	OZRNSSUDZOLUSN-LBPRGKRZSA-N
DM1BDM8	IU	(2S)-2-[[4-[(2-amino-4-oxo-7,8-dihydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DM1BDM8	CA	CAS 4033-27-6
DM1BDM8	CB	CHEBI:15633
DM1BDM8	DE	Discovery agent

DM73OTF	ID	DM73OTF
DM73OTF	DN	DIHYDROKAEMPFEROL
DM73OTF	HS	Investigative
DM73OTF	SN	aromadendrin; 480-20-6; (+)-Dihydrokaempferol; dihydrokaempferol; katuranin; (+)-aromadendrin; Aromadendrol; (2R,3R)-3,5,7-Trihydroxy-2-(4-hydroxyphenyl)chroman-4-one; (+)-Aromadendrol; UNII-7YA4640575; (2R,3R)-3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; CHEMBL9323; CHEBI:15401; PADQINQHPQKXNL-LSDHHAIUSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-, (2R,3R)-; 7YA4640575; Arbo 14; AC1L3VDW; AC1Q6KIF; (2R,3R)-dihydrokaempferol; MLS000697722
DM73OTF	DT	Small molecular drug
DM73OTF	PC	122850
DM73OTF	MW	288.25
DM73OTF	FM	C15H12O6
DM73OTF	IC	InChI=1S/C15H12O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,14-18,20H/t14-,15+/m0/s1
DM73OTF	CS	C1=CC(=CC=C1[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O)O
DM73OTF	IK	PADQINQHPQKXNL-LSDHHAIUSA-N
DM73OTF	IU	(2R,3R)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DM73OTF	CA	CAS 480-20-6
DM73OTF	CB	CHEBI:15401
DM73OTF	DE	Discovery agent

DM9NO6F	ID	DM9NO6F
DM9NO6F	DN	DIHYDROKAINATE
DM9NO6F	HS	Investigative
DM9NO6F	SN	GTPL4571
DM9NO6F	DT	Small molecular drug
DM9NO6F	PC	107883
DM9NO6F	MW	215.25
DM9NO6F	FM	C10H17NO4
DM9NO6F	IC	InChI=1S/C10H17NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h5-7,9,11H,3-4H2,1-2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1
DM9NO6F	CS	CC(C)[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O
DM9NO6F	IK	JQPDCKOQOOQUSC-OOZYFLPDSA-N
DM9NO6F	IU	(2S,3S,4R)-3-(carboxymethyl)-4-propan-2-ylpyrrolidine-2-carboxylic acid
DM9NO6F	CA	CAS 52497-36-6
DM9NO6F	CB	CHEBI:43562
DM9NO6F	DE	Discovery agent

DMG0PXI	ID	DMG0PXI
DMG0PXI	DN	Dihydrolanosterol
DMG0PXI	HS	Investigative
DMG0PXI	SN	Dihydrolanosterin; Dihydrolanosterol; Lanost-8-en-3-ol; Lanost-8-en-3-ol #; Lanost-8-en-3-ol, (3.beta.)-; Lanost-8-en-3.beta.-ol; Lanost-8-en-3beta-ol; Lanostenol; Lanosterol, dihydro-; MBZYKEVPFYHDOH-BQNIITSRSA-N; SCHEMBL288306; (3beta)-Lanost-8-en-3-ol; 24,25-Dihydrolanosterol; 24-dihydrolanosterol; 3beta-Hydroxylanost-8-ene; 5alpha-Lanost-8-en-3 beta-ol; 5alpha-Lanost-8-en-3beta-ol; 79-62-9; 9H273A8B2X; CHEBI:28113; CHEMBL4213010; DTXSID101000181; UNII-9H273A8B2X
DMG0PXI	PC	440560
DMG0PXI	MW	428.7
DMG0PXI	FM	C30H52O
DMG0PXI	IC	MBZYKEVPFYHDOH-BQNIITSRSA-N
DMG0PXI	CS	CC(C)CCCC(C)C1CCC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)O)C)C)C
DMG0PXI	IK	1S/C30H52O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h20-22,25-26,31H,9-19H2,1-8H3/t21-,22-,25+,26+,28-,29-,30+/m1/s1
DMG0PXI	IU	(3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DMG0PXI	CA	CAS 79-62-9
DMG0PXI	CB	CHEBI:28113
DMG0PXI	DE	Discovery agent

DM4TR0D	ID	DM4TR0D
DM4TR0D	DN	Dihydromorphine
DM4TR0D	HS	Investigative
DM4TR0D	SN	Dihydromorphine; Paramorphan; 7,8-DIHYDROMORPHINE; 6-alpha-Hydromorphol; 509-60-4; Dihydromorfin [Czech]; UNII-C3S5FRP6JW; Hydromorphine; Paramorfan; Morphine, dihydro-; EINECS 208-100-8; C3S5FRP6JW; NSC 117865; Dihydromorfin; CHEBI:4575; DEA No. 9145; Morphinan-3,6alpha-diol, 4,5alpha-epoxy-17-methyl-; Morphinan-3,6-alpha-diol, 4,5-alpha-epoxy-17-methyl-; (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol; 7,8-Dihydromorphin; 1421-28-9; dihydromorphin
DM4TR0D	DT	Small molecular drug
DM4TR0D	PC	5359421
DM4TR0D	MW	287.35
DM4TR0D	FM	C17H21NO3
DM4TR0D	IC	InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
DM4TR0D	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](CC4)O
DM4TR0D	IK	IJVCSMSMFSCRME-KBQPJGBKSA-N
DM4TR0D	IU	(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
DM4TR0D	CA	CAS 509-60-4
DM4TR0D	CB	CHEBI:4575
DM4TR0D	DE	Discovery agent

DM76BGZ	ID	DM76BGZ
DM76BGZ	DN	Dihydroorotate
DM76BGZ	HS	Investigative
DM76BGZ	SN	Dihydroorotic acid; hydroorotic acid; 4,5-dihydroorotic acid; DL-Dihydroorotic acid; 155-54-4; 5,6-dihydroorotate; dihydroorotate; 2,6-dioxohexahydropyrimidine-4-carboxylic acid; 2,6-dioxo-1,3-diazinane-4-carboxylic acid; hexahydro-2,6-dioxo-4-Pyrimidinecarboxylic acid; 6202/10/4; CHEBI:30865; L-Hydroorotic acid; 4,5-dihydroorotate; 2,6-Dioxohexahydro-4-pyrimidinecarboxylic acid; Orotic acid, 4,5-dihydro-; L-hydroorotate; R,S-Hydroorotate; 2,6-dioxohexahydro-4-pyrimidincarbons; DL-dihydroortotic acid; AC1Q6GGT; Dihydroorotic Acid
DM76BGZ	DT	Small molecular drug
DM76BGZ	PC	5461056
DM76BGZ	MW	157.1
DM76BGZ	FM	C5H5N2O4-
DM76BGZ	IC	InChI=1S/C5H6N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h2H,1H2,(H,9,10)(H2,6,7,8,11)/p-1
DM76BGZ	CS	C1C(NC(=O)NC1=O)C(=O)[O-]
DM76BGZ	IK	UFIVEPVSAGBUSI-UHFFFAOYSA-M
DM76BGZ	IU	2,6-dioxo-1,3-diazinane-4-carboxylate
DM76BGZ	CB	CHEBI:30867
DM76BGZ	DE	Discovery agent

DM0W64U	ID	DM0W64U
DM0W64U	DN	Dihydropyridines
DM0W64U	HS	Investigative
DM0W64U	SN	1,2-dihydropyridine; UNII-YA306KG67U; 22694-45-7; YA306KG67U; Pyridine, 1,2-dihydro-; AC1L8RRH; CTK1A1117; MMWRGWQTAMNAFC-UHFFFAOYSA-N; AKOS006352484; 27183-EP2311806A2; 27183-EP2308562A2; 27183-EP2301911A1; 27183-EP2292593A2; 27183-EP2314575A1; 27183-EP2295427A1; 27183-EP2270010A1; 27183-EP2269990A1; 27617-EP2270006A1; 27183-EP2371811A2; 27183-EP2308510A1; 27183-EP2295426A1; 27183-EP2275404A1; 27617-EP2314587A1; 27183-EP2292611A1; 27183-EP2284149A1
DM0W64U	DT	Small molecular drug
DM0W64U	PC	407038
DM0W64U	MW	81.12
DM0W64U	FM	C5H7N
DM0W64U	IC	InChI=1S/C5H7N/c1-2-4-6-5-3-1/h1-4,6H,5H2
DM0W64U	CS	C1C=CC=CN1
DM0W64U	IK	MMWRGWQTAMNAFC-UHFFFAOYSA-N
DM0W64U	IU	1,2-dihydropyridine
DM0W64U	CA	CAS 22694-45-7
DM0W64U	DE	Discovery agent

DMYSPMH	ID	DMYSPMH
DMYSPMH	DN	Dihydropyrone
DMYSPMH	HS	Investigative
DMYSPMH	SN	Butopyronoxyl; INDALONE; 532-34-3; Dihydropyrone; BMOO; Indalon; Butyl mesityl oxide oxalate; ENT 9; n-Butylmesityloxid oxalate; Butyl mesityl oxide; n-Butyl mesityl oxide oxalate; Caswell No. 128; Butylmesityl oxide oxalate; UNII-4I5PG5VZ0V; NSC 404420; HSDB 1526; EINECS 208-535-3; Butyl 3,4-dihydro-2,2-dimethyl-4-oxo-2H-pyran-6-carboxylate; EPA Pesticide Chemical Code 046801; 2,2-Dimethyl-6-carbobutoxy-2,3-dihydro-4-pyrone; BRN 0160461; 4I5PG5VZ0V; Butyl dimethyl dihydro-pyrone carboxylate; 2H-Pyran-6-carboxylic acid, 3,4-dihyd
DMYSPMH	DT	Small molecular drug
DMYSPMH	PC	10760
DMYSPMH	MW	226.27
DMYSPMH	FM	C12H18O4
DMYSPMH	IC	InChI=1S/C12H18O4/c1-4-5-6-15-11(14)10-7-9(13)8-12(2,3)16-10/h7H,4-6,8H2,1-3H3
DMYSPMH	CS	CCCCOC(=O)C1=CC(=O)CC(O1)(C)C
DMYSPMH	IK	OKIJSNGRQAOIGZ-UHFFFAOYSA-N
DMYSPMH	IU	butyl 2,2-dimethyl-4-oxo-3H-pyran-6-carboxylate
DMYSPMH	CA	CAS 532-34-3
DMYSPMH	CB	CHEBI:82262
DMYSPMH	DE	Hepatovirus infection

DM9UK6D	ID	DM9UK6D
DM9UK6D	DN	Dihydro-quinolinone
DM9UK6D	HS	Investigative
DM9UK6D	SN	553-03-7; 3,4-Dihydro-2(1H)-quinolinone; 3,4-Dihydroquinolin-2(1H)-one; Hydrocarbostyril; 1,2,3,4-tetrahydroquinolin-2-one; 3,4-Dihydrocarbostyril; 3,4-dihydro-1H-quinolin-2-one; 2-Oxo-1,2,3,4-tetrahydroquinoline; Dihydro-quinolinone; 3,4-Dihydro-2-quinolinol; o-Aminohydrocinnamic acid lactam; UNII-2CKG6TX32F; 3,4-Dihydro-2(1H)quinolinone; 2(1H)-Quinolinone, 3,4-dihydro-; NSC 49170; 2CKG6TX32F; CHEMBL388582; TZOYXRMEFDYWDQ-UHFFFAOYSA-N; 3,4-DIHYDRO-2-QUINOLONE; MFCD00016722; 3,4-Dihydro-2(1H)-quinolinone, 98%
DM9UK6D	DT	Small molecular drug
DM9UK6D	PC	64796
DM9UK6D	MW	147.17
DM9UK6D	FM	C9H9NO
DM9UK6D	IC	InChI=1S/C9H9NO/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-4H,5-6H2,(H,10,11)
DM9UK6D	CS	C1CC(=O)NC2=CC=CC=C21
DM9UK6D	IK	TZOYXRMEFDYWDQ-UHFFFAOYSA-N
DM9UK6D	IU	3,4-dihydro-1H-quinolin-2-one
DM9UK6D	CA	CAS 553-03-7
DM9UK6D	DE	Discovery agent

DM70OIC	ID	DM70OIC
DM70OIC	DN	DIHYDRORALOXIFENE
DM70OIC	HS	Investigative
DM70OIC	SN	DIHYDRORALOXIFENE; CHEMBL14955; BDBM50217538; ZINC15919388
DM70OIC	DT	Small molecular drug
DM70OIC	PC	15788490
DM70OIC	MW	475.6
DM70OIC	FM	C28H29NO4S
DM70OIC	IC	InChI=1S/C28H29NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,26,28,30-31H,1-3,14-17H2/t26-,28-/m1/s1
DM70OIC	CS	C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)[C@@H]3[C@H](SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
DM70OIC	IK	IKZMTNSYXDOFJH-IXCJQBJRSA-N
DM70OIC	IU	[(2S,3R)-6-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
DM70OIC	DE	Discovery agent

DM58KHY	ID	DM58KHY
DM58KHY	DN	dihydrosphingosine-1-phosphate
DM58KHY	HS	Investigative
DM58KHY	SN	sphinganine-phosphate; dihydroS1P
DM58KHY	DT	Small molecular drug
DM58KHY	PC	644260
DM58KHY	MW	381.5
DM58KHY	FM	C18H40NO5P
DM58KHY	IC	InChI=1S/C18H40NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)17(19)16-24-25(21,22)23/h17-18,20H,2-16,19H2,1H3,(H2,21,22,23)/t17-,18+/m0/s1
DM58KHY	CS	CCCCCCCCCCCCCCC[C@H]([C@H](COP(=O)(O)O)N)O
DM58KHY	IK	YHEDRJPUIRMZMP-ZWKOTPCHSA-N
DM58KHY	IU	[(2S,3R)-2-amino-3-hydroxyoctadecyl] dihydrogen phosphate
DM58KHY	CA	CAS 19794-97-9
DM58KHY	CB	CHEBI:16893

DMPDQSV	ID	DMPDQSV
DMPDQSV	DN	Dihydrostreptomycin
DMPDQSV	HS	Investigative
DMPDQSV	SN	Dihidroestreptomicina; Dihydrostreptomycin [INN:BAN]; Dihydrostreptomycine; Dihydrostreptomycine [INN-French]; Dihydrostreptomycinum; Diidrostreptomicina; Diidrostreptomicina [DCIT]; P2I6R8W6UA; Streptomycin, dihydro-; Vibriomycin; dihydrostreptomycin; 128-46-1; Abiocine; CHEBI:38291; DHMS; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-(hydroxymethyl)-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; UNII-P2I6R8W6UA
DMPDQSV	PC	439369
DMPDQSV	MW	583.6
DMPDQSV	FM	C21H41N7O12
DMPDQSV	IC	ASXBYYWOLISCLQ-HZYVHMACSA-N
DMPDQSV	CS	CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(CO)O
DMPDQSV	IK	1S/C21H41N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h5-18,26,29-36H,3-4H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
DMPDQSV	IU	2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
DMPDQSV	CA	CAS 128-46-1
DMPDQSV	CB	CHEBI:38291
DMPDQSV	DE	Pulmonary tuberculosis

DMFKWRM	ID	DMFKWRM
DMFKWRM	DN	DIHYDROXANTHOHUMOL
DMFKWRM	HS	Investigative
DMFKWRM	SN	dihydroxanthohumol; alpha,beta-dihydroxanthohumol; MLS000863606; 4,2',4'-Trihydroxy-6'-methoxy-3'-prenyldihydrochalcone; CHEBI:66332; SMR000440746; a,b-Dihydroxanthohumol; MEGxp0_001797; CHEMBL510279; SCHEMBL15704299; BDBM76566; ACon1_000059; cid_10450920; HMS2267A19; LMPK12120536; 1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)propan-1-one; NCGC00168833-01; BRD-K15951006-001-01-4; 2',4,4'-Trihydroxy-6'-methoxy-3'-prenyldihydrochalcone
DMFKWRM	DT	Small molecular drug
DMFKWRM	PC	10450920
DMFKWRM	MW	356.4
DMFKWRM	FM	C21H24O5
DMFKWRM	IC	InChI=1S/C21H24O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-6,8-9,12,22,24-25H,7,10-11H2,1-3H3
DMFKWRM	CS	CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)CCC2=CC=C(C=C2)O)O)C
DMFKWRM	IK	SVTCZHIDEDUTBH-UHFFFAOYSA-N
DMFKWRM	IU	1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)propan-1-one
DMFKWRM	CA	CAS 102448-00-0
DMFKWRM	CB	CHEBI:66332
DMFKWRM	DE	Discovery agent

DME4NH1	ID	DME4NH1
DME4NH1	DN	Di-imidazole lexitropsin
DME4NH1	HS	Investigative
DME4NH1	SN	DIIMIDAZOLE LEXITROPSIN; AC1NDQQ9; [1-amino-3-[[4-[(4-formamido-1-methylimidazole-2-carbonyl)amino]-1-methylimidazole-2-carbonyl]amino]propylidene]azanium
DME4NH1	DT	Small molecular drug
DME4NH1	PC	449424
DME4NH1	MW	361.36
DME4NH1	FM	C14H19N9O3
DME4NH1	IC	InChI=1S/C14H19N9O3/c1-22-5-9(18-7-24)19-12(22)14(26)21-10-6-23(2)11(20-10)13(25)17-4-3-8(15)16/h5-7H,3-4H2,1-2H3,(H3,15,16)(H,17,25)(H,18,24)(H,21,26)
DME4NH1	CS	CN1C=C(N=C1C(=O)NC2=CN(C(=N2)C(=O)NCCC(=N)N)C)NC=O
DME4NH1	IK	WISSDOJERIUENW-UHFFFAOYSA-N
DME4NH1	IU	N-[2-[(3-amino-3-iminopropyl)carbamoyl]-1-methylimidazol-4-yl]-4-formamido-1-methylimidazole-2-carboxamide
DME4NH1	CA	CAS 114139-02-5
DME4NH1	DE	Discovery agent

DM917FE	ID	DM917FE
DM917FE	DN	Diiodo-l-thyronine
DM917FE	HS	Investigative
DM917FE	SN	L-3,3'-Diiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl]propanoic acid; (S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl)propanoic acid; 3,3'-DEIODO-THYROXINE; 3,3'-Diiodo-L-thyronine; 3,3'-Diiodothyronine; 3,3'-Diiodothyronine, L-; 3,3'-T2; 3,3'-Diiodo-l-thyronine; 3L9U2Z4602; 4604-41-5; AC1L32DA; CHEBI:45698; CHEMBL1236140; EINECS 225-005-7; MFCD01863378; O-(4-Hydroxy-3-iodophenyl)-3-iodo-L-tyrosine; Tyrosine, O-(4-hydroxy-3-iodophenyl)-3-iodo-; UNII-3L9U2Z4602
DM917FE	PC	107564
DM917FE	MW	525.08
DM917FE	FM	C15H13I2NO4
DM917FE	IC	CPCJBZABTUOGNM-LBPRGKRZSA-N
DM917FE	CS	C1=CC(=C(C=C1CC(C(=O)O)N)I)OC2=CC(=C(C=C2)O)I
DM917FE	IK	1S/C15H13I2NO4/c16-10-7-9(2-3-13(10)19)22-14-4-1-8(5-11(14)17)6-12(18)15(20)21/h1-5,7,12,19H,6,18H2,(H,20,21)/t12-/m0/s1
DM917FE	IU	(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl]propanoic acid
DM917FE	CA	CAS 4604-41-5
DM917FE	CB	CHEBI:45698
DM917FE	DE	Discovery agent

DMNR439	ID	DMNR439
DMNR439	DN	Diisopropyl 1-mercaptopropylphosphonate
DMNR439	HS	Investigative
DMNR439	SN	diisopropyl 1-mercaptopropylphosphonate; CHEMBL1173339
DMNR439	DT	Small molecular drug
DMNR439	PC	21576786
DMNR439	MW	240.3
DMNR439	FM	C9H21O3PS
DMNR439	IC	InChI=1S/C9H21O3PS/c1-6-9(14)13(10,11-7(2)3)12-8(4)5/h7-9,14H,6H2,1-5H3
DMNR439	CS	CCC(P(=O)(OC(C)C)OC(C)C)S
DMNR439	IK	SGAGKIQXGMCPPU-UHFFFAOYSA-N
DMNR439	IU	1-di(propan-2-yloxy)phosphorylpropane-1-thiol
DMNR439	DE	Discovery agent

DMVFJAH	ID	DMVFJAH
DMVFJAH	DN	Diisopropyl 2-(sulfanylmethyl)phenylphosphonate
DMVFJAH	HS	Investigative
DMVFJAH	SN	CHEMBL1173337; Diisopropyl 2-(sulfanylmethyl)phenylphosphonate; Bis(1-Methylethyl) [2-(Sulfanylmethyl)phenyl]phosphonate; 3iof; BDBM50322605; dipropan-2-yl [2-(sulfanylmethyl)phenyl]phosphonate
DMVFJAH	DT	Small molecular drug
DMVFJAH	PC	46173032
DMVFJAH	MW	288.34
DMVFJAH	FM	C13H21O3PS
DMVFJAH	IC	InChI=1S/C13H21O3PS/c1-10(2)15-17(14,16-11(3)4)13-8-6-5-7-12(13)9-18/h5-8,10-11,18H,9H2,1-4H3
DMVFJAH	CS	CC(C)OP(=O)(C1=CC=CC=C1CS)OC(C)C
DMVFJAH	IK	JFZVPWMZPZJUTE-UHFFFAOYSA-N
DMVFJAH	IU	[2-di(propan-2-yloxy)phosphorylphenyl]methanethiol
DMVFJAH	DE	Discovery agent

DMHKE3M	ID	DMHKE3M
DMHKE3M	DN	Diisopropyl mercapto(phenyl)methylphosphonate
DMHKE3M	HS	Investigative
DMHKE3M	SN	diisopropyl mercapto(phenyl)methylphosphonate; CHEMBL1170023
DMHKE3M	DT	Small molecular drug
DMHKE3M	PC	21576785
DMHKE3M	MW	288.34
DMHKE3M	FM	C13H21O3PS
DMHKE3M	IC	InChI=1S/C13H21O3PS/c1-10(2)15-17(14,16-11(3)4)13(18)12-8-6-5-7-9-12/h5-11,13,18H,1-4H3
DMHKE3M	CS	CC(C)OP(=O)(C(C1=CC=CC=C1)S)OC(C)C
DMHKE3M	IK	NOPVXMUUBWYONO-UHFFFAOYSA-N
DMHKE3M	IU	di(propan-2-yloxy)phosphoryl-phenylmethanethiol
DMHKE3M	DE	Discovery agent

DMND2AS	ID	DMND2AS
DMND2AS	DN	Diisopropylphosphono Group
DMND2AS	HS	Investigative
DMND2AS	SN	Diisopropyl phosphonate; Phosphonic acid, bis(1-methylethyl) ester; Diisopropylphosphine oxide; Phosphonic acid, diisopropyl ester; O,O-Diisopropyl phosphonate; Isopropyl phosphonate; Diisopropyl hydrogen phosphonate; Isopropyl phosphonate ((C3H7O)2HPO); Diisopropylphosphonate; DIISOPROPYLPHOSPHONO GROUP; NSC 82344; O,O-Diisopropyl phosphite; bis(propan-2-yl) phosphonate; BLKXLEPPVDUHBY-UHFFFAOYSA-N; EINECS 217-317-7; BRN 1703675; diisopropylphosponate; di-i-Propylphosphite; AC1O3FKK; diisopropoxy(oxo)phosphonium
DMND2AS	DT	Small molecular drug
DMND2AS	PC	6327350
DMND2AS	MW	165.15
DMND2AS	FM	C6H14O3P+
DMND2AS	IC	InChI=1S/C6H14O3P/c1-5(2)8-10(7)9-6(3)4/h5-6H,1-4H3/q+1
DMND2AS	CS	CC(C)O[P+](=O)OC(C)C
DMND2AS	IK	BJLZAAWLLPMZQR-UHFFFAOYSA-N
DMND2AS	IU	oxo-di(propan-2-yloxy)phosphanium
DMND2AS	CA	CAS 1809-20-7
DMND2AS	DE	Discovery agent

DMPKQER	ID	DMPKQER
DMPKQER	DN	Diketonitrile
DMPKQER	HS	Investigative
DMPKQER	PC	15461303
DMPKQER	MW	359.3
DMPKQER	FM	C15H12F3NO4S
DMPKQER	IC	InChI=1S/C15H12F3NO4S/c1-24(22,23)12-6-9(15(16,17)18)4-5-10(12)14(21)11(7-19)13(20)8-2-3-8/h4-6,8,11H,2-3H2,1H3
DMPKQER	CS	CS(=O)(=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C(C#N)C(=O)C2CC2
DMPKQER	IK	ZTTKDUXKVPEXCG-UHFFFAOYSA-N
DMPKQER	IU	2-(cyclopropanecarbonyl)-3-[2-methylsulfonyl-4-(trifluoromethyl)phenyl]-3-oxopropanenitrile
DMPKQER	CA	CAS 143701-75-1
DMPKQER	CB	CHEBI:141214
DMPKQER	DE	Discovery agent

DMOD5Y0	ID	DMOD5Y0
DMOD5Y0	DN	Dilazep
DMOD5Y0	HS	Investigative
DMOD5Y0	SN	Dilazep; 35898-87-4; Dilazep [INN]; Dilazepum [INN-Latin]; UNII-F8KLC2BD5Z; Dilazepam [INN-Spanish]; F8KLC2BD5Z; CHEMBL126075; Dilazep (INN); Benzoic acid, 3,4,5-trimethoxy-, (tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)di-3,1-propanediyl ester; NCGC00016747-03; AS 05; DSSTox_RID_80871; DSSTox_CID_25425; DSSTox_GSID_45425; Dilazepum; Dilazepam; Tetrahydro-1H-1,4-diazepine-1,4(5H)-dipropanol 3,4,5-trimethoxybenzoate (diester); 3-{4-[3-(3,4,5-trimethoxybenzoyloxy)propyl]-1,4-diazepan-1-yl}propyl 3,4,5-trimethoxybenzoate
DMOD5Y0	DT	Small molecular drug
DMOD5Y0	PC	3074
DMOD5Y0	MW	604.7
DMOD5Y0	FM	C31H44N2O10
DMOD5Y0	IC	InChI=1S/C31H44N2O10/c1-36-24-18-22(19-25(37-2)28(24)40-5)30(34)42-16-8-12-32-10-7-11-33(15-14-32)13-9-17-43-31(35)23-20-26(38-3)29(41-6)27(21-23)39-4/h18-21H,7-17H2,1-6H3
DMOD5Y0	CS	COC1=CC(=CC(=C1OC)OC)C(=O)OCCCN2CCCN(CC2)CCCOC(=O)C3=CC(=C(C(=C3)OC)OC)OC
DMOD5Y0	IK	QVZCXCJXTMIDME-UHFFFAOYSA-N
DMOD5Y0	IU	3-[4-[3-(3,4,5-trimethoxybenzoyl)oxypropyl]-1,4-diazepan-1-yl]propyl 3,4,5-trimethoxybenzoate
DMOD5Y0	CA	CAS 35898-87-4
DMOD5Y0	CB	CHEBI:92842
DMOD5Y0	DE	Discovery agent

DMA4NI2	ID	DMA4NI2
DMA4NI2	DN	Dimaprit
DMA4NI2	HS	Investigative
DMA4NI2	SN	Dimaprit; 65119-89-3; UNII-ZZQ699148P; BRN 2350552; CHEMBL12344; 3-(dimethylamino)propyl imidothiocarbamate; 3-(dimethylamino)propyl carbamimidothioate; CARBAMIMIDOTHIOIC ACID, 3-(DIMETHYLAMINO)PROPYL ESTER; CHEBI:81389; ZZQ699148P; Pseudourea, 2-(3-(dimethylamino)propyl)-2-thio-; [3-(carbamimidoylsulfanyl)propyl]dimethylamine; Carbamimidothioicacid, 3-(dimethylamino)propyl ester; C6H15N3S; AE-641/25069014; Tocris-0506; AC1Q1UAQ; Prestwick0_000983; Prestwick3_000983; Prestwick2_000983; Prestwick1_000983; AC1L1F4E; BSPBio_001045
DMA4NI2	DT	Small molecular drug
DMA4NI2	PC	3077
DMA4NI2	MW	161.27
DMA4NI2	FM	C6H15N3S
DMA4NI2	IC	InChI=1S/C6H15N3S/c1-9(2)4-3-5-10-6(7)8/h3-5H2,1-2H3,(H3,7,8)
DMA4NI2	CS	CN(C)CCCSC(=N)N
DMA4NI2	IK	OLHQOJYVQUNWPL-UHFFFAOYSA-N
DMA4NI2	IU	3-(dimethylamino)propyl carbamimidothioate
DMA4NI2	CA	CAS 65119-89-3
DMA4NI2	CB	CHEBI:81389
DMA4NI2	DE	Discovery agent

DMV8ZQG	ID	DMV8ZQG
DMV8ZQG	DN	DIMEBOLIN
DMV8ZQG	HS	Investigative
DMV8ZQG	SN	Dimebolin; Dimebon; 3613-73-8; Latrepirdine; Dimebone; Dimeboline; Preparation 84; UNII-OD9237K1Z6; C21H25N3; BRN 0622478; CHEMBL589390; JNODQFNWMXFMEV-UHFFFAOYSA-N; OD9237K1Z6; 2,8-Dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole; 2,3,4,5-Tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-1H-pyrido(4,3-b)indole; 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole
DMV8ZQG	DT	Small molecular drug
DMV8ZQG	PC	197033
DMV8ZQG	MW	319.4
DMV8ZQG	FM	C21H25N3
DMV8ZQG	IC	InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3
DMV8ZQG	CS	CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C
DMV8ZQG	IK	JNODQFNWMXFMEV-UHFFFAOYSA-N
DMV8ZQG	IU	2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole
DMV8ZQG	CA	CAS 3613-73-8
DMV8ZQG	CB	CHEBI:92976
DMV8ZQG	DE	Discovery agent

DM2Q3CL	ID	DM2Q3CL
DM2Q3CL	DN	Dimemorfan
DM2Q3CL	HS	Investigative
DM2Q3CL	SN	Dimemorfan (INN); 36309-01-0; SCHEMBL509122
DM2Q3CL	DT	Small molecular drug
DM2Q3CL	PC	3037918
DM2Q3CL	MW	255.4
DM2Q3CL	FM	C18H25N
DM2Q3CL	IC	InChI=1S/C18H25N/c1-13-6-7-14-12-17-15-5-3-4-8-18(15,16(14)11-13)9-10-19(17)2/h6-7,11,15,17H,3-5,8-10,12H2,1-2H3/t15-,17+,18+/m1/s1
DM2Q3CL	CS	CC1=CC2=C(C[C@H]3[C@@H]4[C@]2(CCCC4)CCN3C)C=C1
DM2Q3CL	IK	KBEZZLAAKIIPFK-NJAFHUGGSA-N
DM2Q3CL	IU	(1S,9S,10S)-4,17-dimethyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DM2Q3CL	CA	CAS 36309-01-0
DM2Q3CL	CB	CHEBI:135048
DM2Q3CL	DE	Discovery agent

DMRMHE8	ID	DMRMHE8
DMRMHE8	DN	Dimepheptanol
DMRMHE8	HS	Investigative
DMRMHE8	SN	Dimepheptanol; Methadol; Racemethadol; Pangerin; Bimethadol; 545-90-4; NIH 2933; Betamethadol; Betametadol; 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL; 3-HEPTANOL, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-; Dimepheptanolum; Dimefeptanol; Dimefeptanolo; Bimethadolum; (-)-beta-Methadol; Betametadolo [DCIT]; (3S,6R)-Methadol; beta-Methadol, (-)-; Betametadol [INN-Spanish]; Dimefeptanolo [DCIT]; Betamethadolum [INN-Latin]; 3-Heptanol,4-diphenyl-, hydrochloride; Betamethadol [INN:BAN:DCF]; DEA No. 9609; Dimefeptanol [INN-Spanish]; Dimepheptanolum [IN
DMRMHE8	DT	Small molecular drug
DMRMHE8	PC	28397
DMRMHE8	MW	311.5
DMRMHE8	FM	C21H29NO
DMRMHE8	IC	InChI=1S/C21H29NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20,23H,5,16H2,1-4H3
DMRMHE8	CS	CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)O
DMRMHE8	IK	QIRAYNIFEOXSPW-UHFFFAOYSA-N
DMRMHE8	IU	6-(dimethylamino)-4,4-diphenylheptan-3-ol
DMRMHE8	CA	CAS 545-90-4
DMRMHE8	CB	CHEBI:135332
DMRMHE8	DE	Discovery agent

DMTVA49	ID	DMTVA49
DMTVA49	DN	Dimethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMTVA49	HS	Investigative
DMTVA49	SN	CHEMBL575281; Dimethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMTVA49	DT	Small molecular drug
DMTVA49	PC	11666354
DMTVA49	MW	284.17
DMTVA49	FM	C10H12F3O4P
DMTVA49	IC	InChI=1S/C10H12F3O4P/c1-15-18(14,16-2)17-9(10(11,12)13)8-6-4-3-5-7-8/h3-7,9H,1-2H3
DMTVA49	CS	COP(=O)(OC)OC(C1=CC=CC=C1)C(F)(F)F
DMTVA49	IK	LEDQZLXLDMICCN-UHFFFAOYSA-N
DMTVA49	IU	dimethyl (2,2,2-trifluoro-1-phenylethyl) phosphate
DMTVA49	DE	Discovery agent

DMP5I47	ID	DMP5I47
DMP5I47	DN	Dimethylallyl Diphosphate
DMP5I47	HS	Investigative
DMP5I47	SN	di-CH3-allyl-PPi; dimethylallyl-PP; prenyl diphosphate trianion; delta-Prenyl diphosphate; prenyl-diphosphate; delta2-isopentenyl-diphosphate; prenyl diphosphate(3-); prenyl pyrophosphate trianion; polycis-polyprenyl diphosphate; GTPL3049; CHEBI:83374; CHEBI:57623; CTK4H5497; CHEBI:58914; CBIDRCWHNCKSTO-UHFFFAOYSA-K; Dimethylallyl pyrophosphate trianion; an all-trans-polyprenyl diphosphate; 3-methylbut-2-en-1-yl diphosphate; all-cis-polyprenyl diphosphate(3-); poly-cis-polyprenyl diphosphate(3-); all-trans-polyprenyl diphospha
DMP5I47	DT	Small molecular drug
DMP5I47	PC	647
DMP5I47	MW	246.09
DMP5I47	FM	C5H12O7P2
DMP5I47	IC	InChI=1S/C5H12O7P2/c1-5(2)3-4-11-14(9,10)12-13(6,7)8/h3H,4H2,1-2H3,(H,9,10)(H2,6,7,8)
DMP5I47	CS	CC(=CCOP(=O)(O)OP(=O)(O)O)C
DMP5I47	IK	CBIDRCWHNCKSTO-UHFFFAOYSA-N
DMP5I47	IU	3-methylbut-2-enyl phosphono hydrogen phosphate
DMP5I47	CA	CAS 358-72-5
DMP5I47	CB	CHEBI:16057
DMP5I47	DE	Discovery agent

DM2HYEN	ID	DM2HYEN
DM2HYEN	DN	dimethylethylamine
DM2HYEN	HS	Investigative
DM2HYEN	SN	N,N-DIMETHYLETHYLAMINE; 598-56-1; Dimethylethylamine; N,N-Dimethylethanamine; N-Ethyldimethylamine; Ethanamine, N,N-dimethyl-; Ethyldimethylamine; Ethylamine, N,N-dimethyl-; Methanamine, N-ethyl-N-methyl-; UNII-9N5384XVEM; HSDB 5712; EINECS 209-940-8; N,N-Dimethylethylamine, 99%; AI3-52225; 9N5384XVEM; DAZXVJBJRMWXJP-UHFFFAOYSA-N; C13-15-Alkyldimethylamines; Amines, C13-15-alkyldimethyl; dimethylaminoethane; dimethylethyl amine; EINECS 275-053-8; NEtMe2; NMe2Et; EtNMe2; n,n-dimethylaminoethane; PubChem10322; N,N-dimethyl-ethanamine
DM2HYEN	DT	Small molecular drug
DM2HYEN	PC	11723
DM2HYEN	MW	73.14
DM2HYEN	FM	C4H11N
DM2HYEN	IC	InChI=1S/C4H11N/c1-4-5(2)3/h4H2,1-3H3
DM2HYEN	CS	CCN(C)C
DM2HYEN	IK	DAZXVJBJRMWXJP-UHFFFAOYSA-N
DM2HYEN	IU	N,N-dimethylethanamine
DM2HYEN	CA	CAS 598-56-1
DM2HYEN	DE	Discovery agent

DML6O4N	ID	DML6O4N
DML6O4N	DN	Dimethylformamide
DML6O4N	HS	Investigative
DML6O4N	SN	N,N-DIMETHYLFORMAMIDE; Dimethylformamide; 68-12-2; N,N-Dimethylmethanamide; Dimethyl formamide; N-Formyldimethylamine; Formamide, N,N-dimethyl-; DMF; Dimethylformamid; Dimetilformamide; Dwumetyloformamid; DMFA; Formyldimethylamine; N,N-Dimethyl formamide; Dimethylforamide; Dimetylformamidu; DMF (amide); NCI-C60913; N,N-Dimethylformamid; n,n,dimethylformamide; Dimethylamid kyseliny mravenci; Caswell No. 366A; Dimetylformamidu [Czech]; Dimethylformamid [German]; Dimetilformamide [Italian]; Dwumetyloformamid [Polish]
DML6O4N	DT	Small molecular drug
DML6O4N	PC	6228
DML6O4N	MW	73.09
DML6O4N	FM	C3H7NO
DML6O4N	IC	InChI=1S/C3H7NO/c1-4(2)3-5/h3H,1-2H3
DML6O4N	CS	CN(C)C=O
DML6O4N	IK	ZMXDDKWLCZADIW-UHFFFAOYSA-N
DML6O4N	IU	N,N-dimethylformamide
DML6O4N	CA	CAS 68-12-2
DML6O4N	CB	CHEBI:17741
DML6O4N	DE	Discovery agent

DMW0MTV	ID	DMW0MTV
DMW0MTV	DN	DIMETHYLGRISABINE
DMW0MTV	HS	Investigative
DMW0MTV	SN	Dimethylgrisabine; CHEMBL450147; Grisabine dimethyl ether
DMW0MTV	DT	Small molecular drug
DMW0MTV	PC	14137099
DMW0MTV	MW	638.8
DMW0MTV	FM	C39H46N2O6
DMW0MTV	IC	InChI=1S/C39H46N2O6/c1-40-16-14-27-21-35(43-4)37(45-6)23-30(27)32(40)18-25-8-11-29(12-9-25)47-39-20-26(10-13-34(39)42-3)19-33-31-24-38(46-7)36(44-5)22-28(31)15-17-41(33)2/h8-13,20-24,32-33H,14-19H2,1-7H3/t32-,33+/m1/s1
DMW0MTV	CS	CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@H]5C6=CC(=C(C=C6CCN5C)OC)OC)OC)OC)OC
DMW0MTV	IK	UHYCXSGUNAWVBW-SAIUNTKASA-N
DMW0MTV	IU	(1R)-1-[[4-[5-[[(1S)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]phenyl]methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline
DMW0MTV	DE	Discovery agent

DMY0FVU	ID	DMY0FVU
DMY0FVU	DN	dimethylhistaprodifen
DMY0FVU	HS	Investigative
DMY0FVU	SN	dimethylhistaprodifen; CHEMBL11553; GTPL1203; BDBM86170; PDSP1_001311; PDSP2_001295; N,N-Dimethyl-2-(3,3-diphenylpropyl)-1H-imidazole-4-(ethanamine)
DMY0FVU	DT	Small molecular drug
DMY0FVU	PC	10042467
DMY0FVU	MW	333.5
DMY0FVU	FM	C22H27N3
DMY0FVU	IC	InChI=1S/C22H27N3/c1-25(2)16-15-20-17-23-22(24-20)14-13-21(18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3-12,17,21H,13-16H2,1-2H3,(H,23,24)
DMY0FVU	CS	CN(C)CCC1=CN=C(N1)CCC(C2=CC=CC=C2)C3=CC=CC=C3
DMY0FVU	IK	GNBOIGBQIBQOIA-UHFFFAOYSA-N
DMY0FVU	IU	2-[2-(3,3-diphenylpropyl)-1H-imidazol-5-yl]-N,N-dimethylethanamine
DMY0FVU	DE	Discovery agent

DMG3WTE	ID	DMG3WTE
DMG3WTE	DN	Dimethylnordihydroguarierate acid
DMG3WTE	HS	Investigative
DMG3WTE	SN	dimethylnordihydroguarierate acid; CHEMBL103600; AC1L9VQY; CTK7A7114; ZINC13780579; BDBM50065997; meso-1,4-Bis-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutane; 5,5'-[(2R,3S)-2,3-Dimethyl-1,4-butanediyl]bis(2-methoxyphenol); 5-[(2S,3R)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutyl]-2-methoxyphenol; 5-[(2r,3s)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutyl]-2-methoxyphenol; 5-[4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethyl-(2R,3S)-butyl]-2-methoxyphenol
DMG3WTE	DT	Small molecular drug
DMG3WTE	PC	476857
DMG3WTE	MW	330.4
DMG3WTE	FM	C20H26O4
DMG3WTE	IC	InChI=1S/C20H26O4/c1-13(9-15-5-7-19(23-3)17(21)11-15)14(2)10-16-6-8-20(24-4)18(22)12-16/h5-8,11-14,21-22H,9-10H2,1-4H3/t13-,14+
DMG3WTE	CS	C[C@H](CC1=CC(=C(C=C1)OC)O)[C@@H](C)CC2=CC(=C(C=C2)OC)O
DMG3WTE	IK	FHAGEYRSWPQEQJ-OKILXGFUSA-N
DMG3WTE	IU	5-[(2S,3R)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutyl]-2-methoxyphenol
DMG3WTE	DE	Discovery agent

DMO0UI8	ID	DMO0UI8
DMO0UI8	DN	Dimethyl-pent-4-enyl-ammonium bromide
DMO0UI8	HS	Investigative
DMO0UI8	DE	Discovery agent

DM1OKN0	ID	DM1OKN0
DM1OKN0	DN	DIMETHYLSPINGOSINE
DM1OKN0	HS	Investigative
DM1OKN0	SN	N,N-Dimethylsphing-4-enine; D-erythro-N,N-dimethylsphingosine; N,N-Dimethylspingosine; CHEMBL322333; CHEBI:78759; D-erythro-Sphingosine, N,N-Dimethyl-; N,N-Dimethylsphingenine; N,N-dimethyl-erythro-sphingosine; N,N-Dimethyl-D-erythrosphingenine; N-dimethylsphingosine; AC1NQZUP; C13914; N,N-Dimethyl-4-sphingenine; BSPBio_001420; N,N-Dimethylsphingosine, oil; SCHEMBL121927; SCHEMBL5493697; BML3-C12; Dimethyl Sphingosine (d18:1)
DM1OKN0	DT	Small molecular drug
DM1OKN0	PC	5282309
DM1OKN0	MW	327.5
DM1OKN0	FM	C20H41NO2
DM1OKN0	IC	InChI=1S/C20H41NO2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)19(18-22)21(2)3/h16-17,19-20,22-23H,4-15,18H2,1-3H3/b17-16+/t19-,20+/m0/s1
DM1OKN0	CS	CCCCCCCCCCCCC/C=C/[C@H]([C@H](CO)N(C)C)O
DM1OKN0	IK	YRXOQXUDKDCXME-YIVRLKKSSA-N
DM1OKN0	IU	(E,2S,3R)-2-(dimethylamino)octadec-4-ene-1,3-diol
DM1OKN0	CA	CAS 119567-63-4
DM1OKN0	CB	CHEBI:78759

DM7EKAF	ID	DM7EKAF
DM7EKAF	DN	Dimethylthiambutene
DM7EKAF	HS	Investigative
DM7EKAF	SN	Dimethylthiambutene; Dimethibutin; Ohton; Dimetiltiambuteno; Aminobutene; Dimethylthiambutenum; Kobaton; N,N,1-Trimethyl-3,3-di-2-thienylallylamine; 3-Dimethylamino-1,1-bis(2-thienyl)-1-butene; 524-84-5; 3-Dimethylamino-1,1-di-(2'-thienyl)-1-butene; Dimetiltiambutene [DCIT]; N,N,1-Trimethyl-3,3-di(2-thienyl)-2-propenylamine; Dimetiltiambuteno [INN-Spanish]; Dimethylthiambutenum [INN-Latin]; Dimethylthiambutene [INN:BAN:DCF]; 338C48; Allylamine, N,N,1-trimethyl-3,3-di-2-thienyl-; BRN 0084891; DEA No. 9619; CHEBI:59781; NIH4542
DM7EKAF	DT	Small molecular drug
DM7EKAF	PC	10668
DM7EKAF	MW	263.4
DM7EKAF	FM	C14H17NS2
DM7EKAF	IC	InChI=1S/C14H17NS2/c1-11(15(2)3)10-12(13-6-4-8-16-13)14-7-5-9-17-14/h4-11H,1-3H3
DM7EKAF	CS	CC(C=C(C1=CC=CS1)C2=CC=CS2)N(C)C
DM7EKAF	IK	CANBGVXYBPOLRR-UHFFFAOYSA-N
DM7EKAF	IU	N,N-dimethyl-4,4-dithiophen-2-ylbut-3-en-2-amine
DM7EKAF	CA	CAS 524-84-5
DM7EKAF	CB	CHEBI:59781
DM7EKAF	DE	Discovery agent

DM2Y0AI	ID	DM2Y0AI
DM2Y0AI	DN	Diminazene
DM2Y0AI	HS	Investigative
DM2Y0AI	SN	DIMINAZENE; 536-71-0; berenil; Diminazenum; Diminazeno; Diminazine; Azidin; Pirocide; Diminazene [INN:BAN]; Diminazenum [INN-Latin]; Diminazeno [INN-Spanish]; UNII-Y5G36EEA5Z; 4,4'-(Diazoamino)benzamidine; CHEBI:81724; 4,4'-(1-Triazene-1,3-diyl)bis-benzenecarboximidamide; Benzenecarboximidamide, 4,4'-(1-triazene-1,3-diyl)bis-; EINECS 208-644-6; Y5G36EEA5Z; C14H15N7; Bevenil; 1,3-TRIS-(4'AMIDINOPHENYL)TRIAZINE; 4,4'-(Triaz-1-ene-1,3-diyl)dibenzimidamide; 4,4'-(1-Triazene-1,3-diyl)bisbenzenecarboximidamide
DM2Y0AI	DT	Small molecular drug
DM2Y0AI	PC	2354
DM2Y0AI	MW	281.32
DM2Y0AI	FM	C14H15N7
DM2Y0AI	IC	InChI=1S/C14H15N7/c15-13(16)9-1-5-11(6-2-9)19-21-20-12-7-3-10(4-8-12)14(17)18/h1-8H,(H3,15,16)(H3,17,18)(H,19,20)
DM2Y0AI	CS	C1=CC(=CC=C1C(=N)N)NN=NC2=CC=C(C=C2)C(=N)N
DM2Y0AI	IK	XNYZHCFCZNMTFY-UHFFFAOYSA-N
DM2Y0AI	IU	4-[2-(4-carbamimidoylphenyl)iminohydrazinyl]benzenecarboximidamide
DM2Y0AI	CA	CAS 536-71-0
DM2Y0AI	CB	CHEBI:81724
DM2Y0AI	DE	Discovery agent

DMJGKND	ID	DMJGKND
DMJGKND	DN	DIMS-9054
DMJGKND	HS	Investigative
DMJGKND	SN	DNA-based immunomodulatory sequence (multiple sclerosis/infectious disease), InDex
DMJGKND	CP	InDex Pharmaceuticals AB
DMJGKND	DE	Infectious disease

DM8CSOJ	ID	DM8CSOJ
DM8CSOJ	DN	Dinoterb
DM8CSOJ	HS	Investigative
DM8CSOJ	SN	DINOTERB; Dinoterb [BSI:ISO]; Dinoterbe; Dinoterbe [ISO-French]; EPA Pesticide Chemical Code 228400; Herbogil; Phenol, 2-tert-butyl-4,6-dinitro-; Phenol, o-t-butyl-4,6-dinitro-; Phenol, o-tert-butyl-4,6-dinitro-; Stirpan forte; 1420-07-1; 2,4-Dinitro-6-tert-butylphenol; 2-(1,1-Dimethylethyl)-4,6-dinitrophenol; 2-tert-Butyl-4,6-dinitrophenol; 2-tert-Butyl-4,6-dinitrophenol [ISO]; 2O5H456CFI; BRN 1887173; Caswell No. 392F; Dntbp; EINECS 215-813-8; HSDB 1598; NSC 166496; Phenol, 2-(1,1-dimethylethyl)-4,6-dinitro-; UNII-2O5H456CFI
DM8CSOJ	PC	14994
DM8CSOJ	MW	240.21
DM8CSOJ	FM	C10H12N2O5
DM8CSOJ	IC	IIPZYDQGBIWLBU-UHFFFAOYSA-N
DM8CSOJ	CS	CC(C)(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])O
DM8CSOJ	IK	1S/C10H12N2O5/c1-10(2,3)7-4-6(11(14)15)5-8(9(7)13)12(16)17/h4-5,13H,1-3H3
DM8CSOJ	IU	2-tert-butyl-4,6-dinitrophenol
DM8CSOJ	CA	CAS 1420-07-1
DM8CSOJ	CB	CHEBI:81883
DM8CSOJ	DE	Discovery agent

DMBKJL8	ID	DMBKJL8
DMBKJL8	DN	DIOA
DMBKJL8	HS	Investigative
DMBKJL8	SN	dihydroindenyl-oxyalkanoic acid
DMBKJL8	DT	Small molecular drug
DMBKJL8	PC	5017
DMBKJL8	MW	399.3
DMBKJL8	FM	C20H24Cl2O4
DMBKJL8	IC	InChI=1S/C20H24Cl2O4/c1-2-3-8-20(13-6-4-5-7-13)10-12-9-14(26-11-15(23)24)17(21)18(22)16(12)19(20)25/h9,13H,2-8,10-11H2,1H3,(H,23,24)
DMBKJL8	CS	CCCCC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C3CCCC3
DMBKJL8	IK	YAWWQIFONIPBKT-UHFFFAOYSA-N
DMBKJL8	IU	2-[(2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3H-inden-5-yl)oxy]acetic acid
DMBKJL8	CA	CAS 106105-17-3
DMBKJL8	DE	Discovery agent

DM0QY1V	ID	DM0QY1V
DM0QY1V	DN	dioctanoylglycerol pyrophosphate
DM0QY1V	HS	Investigative
DM0QY1V	SN	DGPP 8:0
DM0QY1V	DT	Small molecular drug
DM0QY1V	PC	10051843
DM0QY1V	MW	504.4
DM0QY1V	FM	C19H38O11P2
DM0QY1V	IC	InChI=1S/C19H38O11P2/c1-3-5-7-9-11-13-18(20)27-15-17(16-28-32(25,26)30-31(22,23)24)29-19(21)14-12-10-8-6-4-2/h17H,3-16H2,1-2H3,(H,25,26)(H2,22,23,24)/t17-/m1/s1
DM0QY1V	CS	CCCCCCCC(=O)OC[C@H](COP(=O)(O)OP(=O)(O)O)OC(=O)CCCCCCC
DM0QY1V	IK	MBDSUZSCJLRKPC-QGZVFWFLSA-N
DM0QY1V	IU	[(2R)-3-[hydroxy(phosphonooxy)phosphoryl]oxy-2-octanoyloxypropyl] octanoate
DM0QY1V	CB	CHEBI:77961
DM0QY1V	DE	Discovery agent

DM7D6JV	ID	DM7D6JV
DM7D6JV	DN	dioleoylphosphatidic acid
DM7D6JV	HS	Investigative
DM7D6JV	SN	doPA; dioleoyl phosphatidic acid
DM7D6JV	DT	Small molecular drug
DM7D6JV	PC	9547172
DM7D6JV	MW	701
DM7D6JV	FM	C39H73O8P
DM7D6JV	IC	InChI=1S/C39H73O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,37H,3-16,21-36H2,1-2H3,(H2,42,43,44)/b19-17-,20-18-
DM7D6JV	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCCCC/C=C\\CCCCCCCC
DM7D6JV	IK	MHUWZNTUIIFHAS-CLFAGFIQSA-N
DM7D6JV	IU	[2-[(Z)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (Z)-octadec-9-enoate
DM7D6JV	CA	CAS 14268-17-8
DM7D6JV	CB	CHEBI:60427
DM7D6JV	DE	Discovery agent

DM5G4O7	ID	DM5G4O7
DM5G4O7	DN	DI-O-METHYLENDIANDRIN A
DM5G4O7	HS	Investigative
DM5G4O7	SN	di-O-methylendiandrin A; CHEMBL388363
DM5G4O7	DT	Small molecular drug
DM5G4O7	PC	16756782
DM5G4O7	MW	356.5
DM5G4O7	FM	C22H28O4
DM5G4O7	IC	InChI=1S/C22H28O4/c1-13-14(2)22(16-8-10-18(24-4)20(12-16)26-6)21(13)15-7-9-17(23-3)19(11-15)25-5/h7-14,21-22H,1-6H3/t13-,14-,21-,22-/m0/s1
DM5G4O7	CS	C[C@H]1[C@@H]([C@H]([C@@H]1C2=CC(=C(C=C2)OC)OC)C3=CC(=C(C=C3)OC)OC)C
DM5G4O7	IK	IOTXFXWARGNLEJ-WJWAULOUSA-N
DM5G4O7	IU	4-[(1R,2R,3S,4S)-2-(3,4-dimethoxyphenyl)-3,4-dimethylcyclobutyl]-1,2-dimethoxybenzene
DM5G4O7	DE	Discovery agent

DM4KXIM	ID	DM4KXIM
DM4KXIM	DN	DIOSMETIN
DM4KXIM	HS	Investigative
DM4KXIM	SN	Diosmetin; 520-34-3; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; Salinigricoflavonol; 4'-Methylluteolin; 5,7,3'-Trihydroxy-4'-methoxyflavone; UNII-TWZ37241OT; Luteolin 4-methyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3',5,7-trihydroxy-4'-methoxyflavone; CHEBI:4630; TWZ37241OT; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-; MFCD00017425; AK111246
DM4KXIM	DT	Small molecular drug
DM4KXIM	PC	5281612
DM4KXIM	MW	300.26
DM4KXIM	FM	C16H12O6
DM4KXIM	IC	InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3
DM4KXIM	CS	COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
DM4KXIM	IK	MBNGWHIJMBWFHU-UHFFFAOYSA-N
DM4KXIM	IU	5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one
DM4KXIM	CA	CAS 520-34-3
DM4KXIM	CB	CHEBI:4630
DM4KXIM	DE	Discovery agent

DML2B04	ID	DML2B04
DML2B04	DN	DIOXINODEHYDROECKOL
DML2B04	HS	Investigative
DML2B04	SN	DIOXINODEHYDROECKOL; Eckstolonol; UNII-N5P71K0GE3; CHEMBL559870; N5P71K0GE3; CHEBI:65820; 5,8,13,14-tetraoxa-pentaphene-1,3,6,9,11-pentol; [1,4]benzodioxino[2,3-a]oxanthrene-1,3,6,9,11-pentol; SCHEMBL14848420; BDBM50319629; 5,8,13,14-Tetraoxa-pentaphene-1,3,6,9,11-pentaol; Benzo(1,2-b:3,4-b')bis(1,4)benzodioxin-1,3,6,9,11-pentol
DML2B04	DT	Small molecular drug
DML2B04	PC	10429214
DML2B04	MW	370.3
DML2B04	FM	C18H10O9
DML2B04	IC	InChI=1S/C18H10O9/c19-6-1-8(21)14-11(3-6)26-17-13(24-14)5-10(23)16-18(17)27-15-9(22)2-7(20)4-12(15)25-16/h1-5,19-23H
DML2B04	CS	C1=C(C=C2C(=C1O)OC3=C(O2)C4=C(C(=C3)O)OC5=CC(=CC(=C5O4)O)O)O
DML2B04	IK	LBHQACSAGWCMAB-UHFFFAOYSA-N
DML2B04	IU	[1,4]benzodioxino[2,3-a]oxanthrene-1,3,6,9,11-pentol
DML2B04	CA	CAS 639514-05-9
DML2B04	CB	CHEBI:65820
DML2B04	DE	Discovery agent

DM93MAB	ID	DM93MAB
DM93MAB	DN	Dioxothiomolybdenum(VI) ion
DM93MAB	HS	Investigative
DM93MAB	SN	DIOXOTHIOMOLYBDENUM(VI) ION; dioxo(sulfanyl)molybdenum; CHEBI:47566
DM93MAB	DT	Small molecular drug
DM93MAB	PC	5162682
DM93MAB	MW	161.02
DM93MAB	FM	HMoO2S-
DM93MAB	IC	InChI=1S/Mo.2O.H2S/h;;;1H2/p-1
DM93MAB	CS	O=[Mo]=O.[SH-]
DM93MAB	IK	LMGKUBJWYNQHBP-UHFFFAOYSA-M
DM93MAB	IU	dioxomolybdenum;sulfanide
DM93MAB	CB	CHEBI:47566
DM93MAB	DE	Discovery agent

DMO4XUC	ID	DMO4XUC
DMO4XUC	DN	Diphenyl(piperidin-4-yl)methanol
DMO4XUC	HS	Investigative
DMO4XUC	SN	Azacyclonol; 115-46-8; diphenyl(piperidin-4-yl)methanol; alpha,alpha-diphenyl-4-piperidinomethanol; Frenquel; alpha,alpha-Diphenyl-4-piperidinemethanol; alpha-(4-Piperidyl)benzhydrol; gamma-Pipradol; Calmeran; Ataractan; Diphenyl-piperidin-4-yl-methanol; Diphenyl(4-piperidinyl)methanol; 4-Piperidinemethanol, alpha,alpha-diphenyl-; Azaciclonolo [DCIT]; Azacyklonol; Psychosan; MER 17; Frenoton; Azacyclonol [INN:BAN]; UNII-2MMR990PEM; Azacyclonolum [INN-Latin]; EINECS 204-092-5; Diphenyl-4-piperidylmethanol; BRN 0230221; 2MMR990PEM
DMO4XUC	DT	Small molecular drug
DMO4XUC	PC	15723
DMO4XUC	MW	267.4
DMO4XUC	FM	C18H21NO
DMO4XUC	IC	InChI=1S/C18H21NO/c20-18(15-7-3-1-4-8-15,16-9-5-2-6-10-16)17-11-13-19-14-12-17/h1-10,17,19-20H,11-14H2
DMO4XUC	CS	C1CNCCC1C(C2=CC=CC=C2)(C3=CC=CC=C3)O
DMO4XUC	IK	ZMISODWVFHHWNR-UHFFFAOYSA-N
DMO4XUC	IU	diphenyl(piperidin-4-yl)methanol
DMO4XUC	CA	CAS 115-46-8
DMO4XUC	CB	CHEBI:93706
DMO4XUC	DE	Discovery agent

DMP6IHR	ID	DMP6IHR
DMP6IHR	DN	Diphenylacetic Acid
DMP6IHR	HS	Investigative
DMP6IHR	SN	DIPHENYLACETIC ACID; 2,2-diphenylacetic acid; 117-34-0; Diphenylethanoic acid; Acetic acid, diphenyl-; Benzeneacetic acid, .alpha.-phenyl-; 1,1-Diphenylacetic acid; UNII-658NCZ0NKO; Diphenyl-acetic acid; alpha-Toluic acid, alpha-phenyl-; Benzeneacetic acid, alpha-phenyl-; EINECS 204-185-0; NSC 120417; BRN 1910978; 658NCZ0NKO; AI3-23777; CHEBI:41967; PYHXGXCGESYPCW-UHFFFAOYSA-N; .alpha.,.alpha.-Diphenylacetic acid; MFCD00004251; .alpha.-Toluic acid, .alpha.-phenyl-; A-Toluic Acid, A-Phenyl-; Diphenylacetic acid, 99+%
DMP6IHR	DT	Small molecular drug
DMP6IHR	PC	8333
DMP6IHR	MW	212.24
DMP6IHR	FM	C14H12O2
DMP6IHR	IC	InChI=1S/C14H12O2/c15-14(16)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13H,(H,15,16)
DMP6IHR	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)O
DMP6IHR	IK	PYHXGXCGESYPCW-UHFFFAOYSA-N
DMP6IHR	IU	2,2-diphenylacetic acid
DMP6IHR	CA	CAS 117-34-0
DMP6IHR	CB	CHEBI:41967
DMP6IHR	DE	Discovery agent

DMBV19T	ID	DMBV19T
DMBV19T	DN	diphenylamine-2-carboxylic acid
DMBV19T	HS	Investigative
DMBV19T	SN	N-phenylanthranilic acid; fenamic acid
DMBV19T	DT	Small molecular drug
DMBV19T	PC	4386
DMBV19T	MW	213.23
DMBV19T	FM	C13H11NO2
DMBV19T	IC	InChI=1S/C13H11NO2/c15-13(16)11-8-4-5-9-12(11)14-10-6-2-1-3-7-10/h1-9,14H,(H,15,16)
DMBV19T	CS	C1=CC=C(C=C1)NC2=CC=CC=C2C(=O)O
DMBV19T	IK	ZWJINEZUASEZBH-UHFFFAOYSA-N
DMBV19T	IU	2-anilinobenzoic acid
DMBV19T	CA	CAS 91-40-7
DMBV19T	CB	CHEBI:34756
DMBV19T	DE	Discovery agent

DMRQZTS	ID	DMRQZTS
DMRQZTS	DN	diphenylboronic anhydride
DMRQZTS	HS	Investigative
DMRQZTS	SN	diphenylborinic anhydride
DMRQZTS	DT	Small molecular drug
DMRQZTS	PC	596810
DMRQZTS	MW	346
DMRQZTS	FM	C24H20B2O
DMRQZTS	IC	InChI=1S/C24H20B2O/c1-5-13-21(14-6-1)25(22-15-7-2-8-16-22)27-26(23-17-9-3-10-18-23)24-19-11-4-12-20-24/h1-20H
DMRQZTS	CS	B(C1=CC=CC=C1)(C2=CC=CC=C2)OB(C3=CC=CC=C3)C4=CC=CC=C4
DMRQZTS	IK	SNQFEECGHGUHBK-UHFFFAOYSA-N
DMRQZTS	IU	diphenylboranyloxy(diphenyl)borane
DMRQZTS	CA	CAS 4426-21-5
DMRQZTS	DE	Discovery agent

DMB75PV	ID	DMB75PV
DMB75PV	DN	diphenyleneiodonium chloride
DMB75PV	HS	Investigative
DMB75PV	SN	Diphenyleneiodonium chloride; 4673-26-1; Dibenziodolium chloride; UNII-7M9D81YZ2N; DPI; 7M9D81YZ2N; CHEBI:77967; CHEMBL397686; SR-01000075494; Dibenziodolium, chloride; AC1MBZ20; C12H8I.Cl; dibenzo[b,d]iodolium chloride; SCHEMBL159318; GTPL7802; CTK8F9249; DTXSID00196932; MolPort-003-983-758; MolPort-023-275-892; HMS3266G10; HMS3261I15; 2,2'-biphenylyleneiodonium chloride; Diphenyleneiodonium chloride, 97+%; BCP08692; Tox21_500367; Diphenyleneiodonium chloride, &gt; MFCD00214165; 1726AH; AKOS015903219; LP00367; CCG-221671
DMB75PV	DT	Small molecular drug
DMB75PV	PC	2733504
DMB75PV	MW	314.55
DMB75PV	FM	C12H8ClI
DMB75PV	IC	InChI=1S/C12H8I.ClH/c1-3-7-11-9(5-1)10-6-2-4-8-12(10)13-11;/h1-8H;1H/q+1;/p-1
DMB75PV	CS	C1=CC=C2C(=C1)C3=CC=CC=C3[I+]2.[Cl-]
DMB75PV	IK	FCFZKAVCDNTYID-UHFFFAOYSA-M
DMB75PV	IU	8-iodoniatricyclo[7.4.0.02,7]trideca-1(13),2,4,6,9,11-hexaene;chloride
DMB75PV	CA	CAS 4673-26-1
DMB75PV	CB	CHEBI:77967
DMB75PV	DE	Discovery agent

DMK8T61	ID	DMK8T61
DMK8T61	DN	diphenyltetrahydrofuran
DMK8T61	HS	Investigative
DMK8T61	SN	2,2-Diphenyltetrahydrofuran; 887-15-0; 2,2-diphenyloxolane; diphenyltetrahydrofuran; NSC89761; EINECS 212-957-3; 2,2-di(phenyl)oxolane; AC1L2DIK; AC1Q1IAM; AC1Q70T2; GTPL2498; SCHEMBL1569110; Furan,tetrahydro-2,2-diphenyl-; CTK5G1253; DTXSID70237245; Furan, tetrahydro-2,2-diphenyl-; ZINC1575610; NSC-89761; AKOS024323254; MCULE-6052973560; X4640
DMK8T61	DT	Small molecular drug
DMK8T61	PC	70175
DMK8T61	MW	224.3
DMK8T61	FM	C16H16O
DMK8T61	IC	InChI=1S/C16H16O/c1-3-8-14(9-4-1)16(12-7-13-17-16)15-10-5-2-6-11-15/h1-6,8-11H,7,12-13H2
DMK8T61	CS	C1CC(OC1)(C2=CC=CC=C2)C3=CC=CC=C3
DMK8T61	IK	ONRSPOWNRLCCGF-UHFFFAOYSA-N
DMK8T61	IU	2,2-diphenyloxolane
DMK8T61	CA	CAS 887-15-0
DMK8T61	DE	Discovery agent

DMHY30B	ID	DMHY30B
DMHY30B	DN	Diphosphate
DMHY30B	HS	Investigative
DMHY30B	SN	Pyrophosphate ion; 14000-31-8; UNII-X3SSV2V6L3; Diphosphate(4-); X3SSV2V6L3; phosphonato phosphate; diphospate; Pyrophosphat; Diphosphat; Pyrophosphate(4-); 2o1c; mu-oxo-hexaoxodiphosphate; AC1LD8JZ; Phosphate (P2O74-); Diphosphate (P2O74-); Pyrophosphate (P2O74-); Diphosphoric acid tetraanion; diphosphoric acid, ion(4-); DTXSID4074514; CHEBI:18361; CTK0H7511; 3c14; XPPKVPWEQAFLFU-UHFFFAOYSA-J; [O3POPO3](4-); mu-oxido-bis(trioxidophosphate)(4-); BDBM50278316; P2O7(4-)
DMHY30B	DT	Small molecular drug
DMHY30B	PC	644102
DMHY30B	MW	173.94
DMHY30B	FM	O7P2-4
DMHY30B	IC	InChI=1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)/p-4
DMHY30B	CS	[O-]P(=O)([O-])OP(=O)([O-])[O-]
DMHY30B	IK	XPPKVPWEQAFLFU-UHFFFAOYSA-J
DMHY30B	IU	phosphonato phosphate
DMHY30B	CA	CAS 14000-31-8
DMHY30B	CB	CHEBI:18361
DMHY30B	DE	Discovery agent

DM28NIU	ID	DM28NIU
DM28NIU	DN	diphosphoglycolyl proline
DM28NIU	HS	Investigative
DM28NIU	SN	diphosphoglycolyproline; (R,S)-diphosphoglycolyl proline
DM28NIU	DT	Small molecular drug
DM28NIU	PC	73755030
DM28NIU	MW	335.14
DM28NIU	FM	C7H15NO10P2
DM28NIU	IC	InChI=1S/C7H15NO10P2/c9-5(10)4-2-1-3-8(4)6(11)7(12,19(13,14)15)20(16,17)18/h4,6,11-12H,1-3H2,(H,9,10)(H2,13,14,15)(H2,16,17,18)
DM28NIU	CS	C1CC(N(C1)C(C(O)(P(=O)(O)O)P(=O)(O)O)O)C(=O)O
DM28NIU	IK	CDFDGXYBANXCPC-UHFFFAOYSA-N
DM28NIU	IU	1-(1,2-dihydroxy-2,2-diphosphonoethyl)pyrrolidine-2-carboxylic acid
DM28NIU	DE	Discovery agent

DMYWL89	ID	DMYWL89
DMYWL89	DN	diphosphoric acid
DMYWL89	HS	Investigative
DMYWL89	SN	pyrophosphoric acid; phosphonooxyphosphonic acid
DMYWL89	DT	Small molecular drug
DMYWL89	PC	1023
DMYWL89	MW	177.98
DMYWL89	FM	H4O7P2
DMYWL89	IC	InChI=1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)
DMYWL89	CS	OP(=O)(O)OP(=O)(O)O
DMYWL89	IK	XPPKVPWEQAFLFU-UHFFFAOYSA-N
DMYWL89	IU	phosphono dihydrogen phosphate
DMYWL89	CA	CAS 2466-09-3
DMYWL89	CB	CHEBI:29888
DMYWL89	DE	Discovery agent

DMRWD9M	ID	DMRWD9M
DMRWD9M	DN	Diphthamide
DMRWD9M	HS	Investigative
DMRWD9M	SN	2-(3-Carboxyamido-3-(trimethylammonio)propyl)histidine
DMRWD9M	DT	Small molecular drug
DMRWD9M	PC	6438375
DMRWD9M	MW	297.35
DMRWD9M	FM	C13H23N5O3
DMRWD9M	IC	InChI=1S/C13H23N5O3/c1-18(2,3)10(12(15)19)4-5-11-16-7-8(17-11)6-9(14)13(20)21/h7,9-10H,4-6,14H2,1-3H3,(H3-,15,16,17,19,20,21)
DMRWD9M	CS	C[N+](C)(C)C(CCC1=NC=C(N1)CC(C(=O)[O-])N)C(=O)N
DMRWD9M	IK	FOOBQHKMWYGHCE-UHFFFAOYSA-N
DMRWD9M	IU	2-amino-3-[2-[4-amino-4-oxo-3-(trimethylazaniumyl)butyl]-1H-imidazol-5-yl]propanoate
DMRWD9M	CA	CAS 75645-22-6
DMRWD9M	DE	Discovery agent

DMIXPU6	ID	DMIXPU6
DMIXPU6	DN	Diprenorphine
DMIXPU6	HS	Investigative
DMIXPU6	SN	Diprenorphine; 14357-78-9; UNII-1F0L5N25ZZ; CHEMBL281786; CHEBI:4650; 1F0L5N25ZZ; DEA No. 9058; M50-50 Injection; Diprenorphine [INN:BAN]; Diprenorphinum [INN-Latin]; Diprenorfina [INN-Spanish]; Diprenorphinum; Diprenorfina; EINECS 238-325-7; 21-Cyclopropyl-6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylethyl)-6,14-endo-ethanooripavine; Diprenorfin; (5 ,7 )-17-(Cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- , -dimethyl-6,14-ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4
DMIXPU6	DT	Small molecular drug
DMIXPU6	PC	443408
DMIXPU6	MW	425.6
DMIXPU6	FM	C26H35NO4
DMIXPU6	IC	InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1
DMIXPU6	CS	CC(C)([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O
DMIXPU6	IK	OIJXLIIMXHRJJH-KNLIIKEYSA-N
DMIXPU6	IU	(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxypropan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMIXPU6	CA	CAS 14357-78-9
DMIXPU6	CB	CHEBI:4650
DMIXPU6	DE	Discovery agent

DM9VKXC	ID	DM9VKXC
DM9VKXC	DN	dipropyl-5-CT
DM9VKXC	HS	Investigative
DM9VKXC	SN	DP-5-CT; DP5CT; N,N-dipropylcarboxamidotryptamine
DM9VKXC	DT	Small molecular drug
DM9VKXC	PC	156314
DM9VKXC	MW	287.4
DM9VKXC	FM	C17H25N3O
DM9VKXC	IC	InChI=1S/C17H25N3O/c1-3-8-20(9-4-2)10-7-14-12-19-16-6-5-13(17(18)21)11-15(14)16/h5-6,11-12,19H,3-4,7-10H2,1-2H3,(H2,18,21)
DM9VKXC	CS	CCCN(CCC)CCC1=CNC2=C1C=C(C=C2)C(=O)N
DM9VKXC	IK	DPXOFRGRKPFZOD-UHFFFAOYSA-N
DM9VKXC	IU	3-[2-(dipropylamino)ethyl]-1H-indole-5-carboxamide
DM9VKXC	CA	CAS 74885-25-9
DM9VKXC	CB	CHEBI:92566
DM9VKXC	DE	Discovery agent

DMGBCP0	ID	DMGBCP0
DMGBCP0	DN	DIPROTIN A
DMGBCP0	HS	Investigative
DMGBCP0	SN	diprotin A; MLS002207185; NSC602337; HIV inhibitor; AC1Q5KXE; AC1L1F6Q; DivK1c_000899; CHEMBL158110; SCHEMBL17867000; KBio1_000899; HMS502M21; NINDS_000899; Ile-Pro-Ile, &gt; BDBM50085083; NSC-602337; IDI1_000899; AN-25068; SMR001306756; Bacillus cereus BMF673-RF1 culture filtrate; 2-[[1-(2-amino-3-methyl-pentanoyl)pyrrolidine-2-carbonyl]amino]-3-methyl-pentanoic acid; 2-{[1-(2-Amino-3-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoic acid
DMGBCP0	DT	Small molecular drug
DMGBCP0	PC	94701
DMGBCP0	MW	341.4
DMGBCP0	FM	C17H31N3O4
DMGBCP0	IC	InChI=1S/C17H31N3O4/c1-5-10(3)13(18)16(22)20-9-7-8-12(20)15(21)19-14(17(23)24)11(4)6-2/h10-14H,5-9,18H2,1-4H3,(H,19,21)(H,23,24)/t10-,11-,12-,13-,14-/m0/s1
DMGBCP0	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N
DMGBCP0	IK	JNTMAZFVYNDPLB-PEDHHIEDSA-N
DMGBCP0	IU	(2S,3S)-2-[[(2S)-1-[(2S,3S)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid
DMGBCP0	CA	CAS 90614-48-5
DMGBCP0	CB	CHEBI:93213
DMGBCP0	DE	Discovery agent

DM2MV9O	ID	DM2MV9O
DM2MV9O	DN	DIRLOTAPIDE
DM2MV9O	HS	Investigative
DM2MV9O	SN	Dirlotapide; Slentrol; UNII-578H0RMP25; 481658-94-0; CHEMBL410414; 578H0RMP25; Dirlotapide [USAN:INN]; CP 742033; Dirlotapide (USAN/INN); Slentrol [veterinary] (TN); SCHEMBL37781; TUOSYWCFRFNJBS-BHVANESWSA-N; HY-U00070; BDBM50204367; CS-6779; CP-742033; CP-742,033; D03867; N-((1S)-2-(Benzylmethylamino)-2-oxo-1-phenylethyl)-1-methyl-5-(((4'-(trifluoromethyl)biphenyl-2-yl)carbonyl)amino)-1H-indole-2-carboxamide; 1H-Indole-2-carboxamide, 1-methyl-N-((1S)-2-(methyl(phenylmethyl)amino)-2-oxo-1-phenylethyl)-5-(((4'-(trifluoromethyl
DM2MV9O	DT	Small molecular drug
DM2MV9O	PC	9917862
DM2MV9O	MW	674.7
DM2MV9O	FM	C40H33F3N4O3
DM2MV9O	IC	InChI=1S/C40H33F3N4O3/c1-46(25-26-11-5-3-6-12-26)39(50)36(28-13-7-4-8-14-28)45-38(49)35-24-29-23-31(21-22-34(29)47(35)2)44-37(48)33-16-10-9-15-32(33)27-17-19-30(20-18-27)40(41,42)43/h3-24,36H,25H2,1-2H3,(H,44,48)(H,45,49)/t36-/m0/s1
DM2MV9O	CS	CN1C2=C(C=C(C=C2)NC(=O)C3=CC=CC=C3C4=CC=C(C=C4)C(F)(F)F)C=C1C(=O)N[C@@H](C5=CC=CC=C5)C(=O)N(C)CC6=CC=CC=C6
DM2MV9O	IK	TUOSYWCFRFNJBS-BHVANESWSA-N
DM2MV9O	IU	N-[(1S)-2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]-1-methyl-5-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]indole-2-carboxamide
DM2MV9O	CA	CAS 481658-94-0
DM2MV9O	DE	Discovery agent

DMPVNDK	ID	DMPVNDK
DMPVNDK	DN	Distamycin A
DMPVNDK	HS	Investigative
DMPVNDK	SN	distamycin a; Stallimycin; Distamycin; Herperetin; 636-47-5; DST-A; UNII-80O63P88IS; NSC82150; FI 6426; CHEMBL11252; 80O63P88IS; NCGC00018292-04; NSC 150528; Stallimycinum; Stallimycine; Estalimicina; Stallimicina; Distamicina A; DISTAMYCIN HYDROCHLORIDE; NSC150528; Dst-3; AC1Q5M1Q; AC1L1F7B; DSSTox_RID_81018; DSSTox_CID_25637; DSSTox_GSID_45637; DISTAMYCIN; STALLIMYCIN; SCHEMBL108585; DTXSID9045637; cid_6602691; UPBAOYRENQEPJO-UHFFFAOYSA-N; ZINC3872327; Tox21_110857; 6576-51-8 (mono-hydrochloride); NSC-82150; CCG-36393; BDBM50055659
DMPVNDK	DT	Small molecular drug
DMPVNDK	PC	3115
DMPVNDK	MW	481.5
DMPVNDK	FM	C22H27N9O4
DMPVNDK	IC	InChI=1S/C22H27N9O4/c1-29-9-13(26-12-32)6-17(29)21(34)28-15-8-18(31(3)11-15)22(35)27-14-7-16(30(2)10-14)20(33)25-5-4-19(23)24/h6-12H,4-5H2,1-3H3,(H3,23,24)(H,25,33)(H,26,32)(H,27,35)(H,28,34)
DMPVNDK	CS	CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CN(C(=C3)C(=O)NCCC(=N)N)C)C)NC=O
DMPVNDK	IK	UPBAOYRENQEPJO-UHFFFAOYSA-N
DMPVNDK	IU	N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide
DMPVNDK	CA	CAS 636-47-5
DMPVNDK	DE	Discovery agent

DM0GQJ2	ID	DM0GQJ2
DM0GQJ2	DN	Di-Stearoyl-3-Sn-Phosphatidylcholine
DM0GQJ2	HS	Investigative
DM0GQJ2	SN	DI-STEAROYL-3-SN-PHOSPHATIDYLCHOLINE; DSPC;L-,-Distearoyl--lecithin; Distearoylphosphatidylcholine; AC1L3RPB; SCHEMBL10001505; ZINC85433138; DB04178; DB-027511; 816D944; O-(1-O,2-O-Distearoyl-L-glycero-3-phospho)choline
DM0GQJ2	DT	Small molecular drug
DM0GQJ2	PC	94191
DM0GQJ2	MW	791.2
DM0GQJ2	FM	C44H89NO8P+
DM0GQJ2	IC	InChI=1S/C44H88NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h42H,6-41H2,1-5H3/p+1/t42-/m1/s1
DM0GQJ2	CS	CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC
DM0GQJ2	IK	NRJAVPSFFCBXDT-HUESYALOSA-O
DM0GQJ2	IU	2-[[(2R)-2,3-di(octadecanoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
DM0GQJ2	DE	Discovery agent

DM6TVAX	ID	DM6TVAX
DM6TVAX	DN	Disulergine
DM6TVAX	HS	Investigative
DM6TVAX	SN	Disulergine; UNII-1Q3CYC1YR6; 1Q3CYC1YR6; CHEMBL95067; 59032-40-5; Disulergina; Disulerginum; Sulergin; disulergine[inn]; Disulergine [INN]; Disulerginum [INN-Latin]; Disulergina [INN-Spanish]; Compound 71; SULERGINE; CM 29717; CH 29-717; CH-29717; AC1Q6V4Q; AC1L2AG4; SCHEMBL1841646; BDBM50130260; CH 29717; N,N-Dimethyl-N'-(6-methylergolin-8alpha-yl)sulfamide; N,N-Dimethyl-N'-((8 alpha)-6-methylergolin-8-yl)sulfamide
DM6TVAX	DT	Small molecular drug
DM6TVAX	PC	68788
DM6TVAX	MW	348.5
DM6TVAX	FM	C17H24N4O2S
DM6TVAX	IC	InChI=1S/C17H24N4O2S/c1-20(2)24(22,23)19-12-8-14-13-5-4-6-15-17(13)11(9-18-15)7-16(14)21(3)10-12/h4-6,9,12,14,16,18-19H,7-8,10H2,1-3H3/t12-,14+,16+/m0/s1
DM6TVAX	CS	CN1C[C@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)NS(=O)(=O)N(C)C
DM6TVAX	IK	VUEGYUOUAAVYAS-JGGQBBKZSA-N
DM6TVAX	IU	(6aR,9S,10aR)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
DM6TVAX	CA	CAS 59032-40-5
DM6TVAX	DE	Discovery agent

DMVJYKG	ID	DMVJYKG
DMVJYKG	DN	Dithiazoline
DMVJYKG	HS	Investigative
DMVJYKG	SN	dithiazoline
DMVJYKG	PC	17990703
DMVJYKG	MW	105.19
DMVJYKG	FM	C2H3NS2
DMVJYKG	IC	WPEVFLXBCFUSFF-UHFFFAOYSA-N
DMVJYKG	CS	C1C=NSS1
DMVJYKG	IK	1S/C2H3NS2/c1-2-4-5-3-1/h1H,2H2
DMVJYKG	IU	5H-dithiazole
DMVJYKG	CA	CAS 504-79-0
DMVJYKG	DE	Gonococcal infection

DMK0VFS	ID	DMK0VFS
DMK0VFS	DN	dithiipin-1,1,4,4-tetroxide analogue 7
DMK0VFS	HS	Investigative
DMK0VFS	SN	dithiipin-1,1,4,4-tetroxide analogue 7; GTPL6124; CHEMBL3906195; 2-(4-methylphenyl)-6,7-dihydro-5H-1,4-dithiepine 1,1,4,4-tetraoxide; 2-(4-Methylphenyl)-6,7-dihydro-5H-1,4-dithiepin 1,1,4,4-tetraoxide
DMK0VFS	DT	Small molecular drug
DMK0VFS	PC	9947811
DMK0VFS	MW	286.4
DMK0VFS	FM	C12H14O4S2
DMK0VFS	IC	InChI=1S/C12H14O4S2/c1-10-3-5-11(6-4-10)12-9-17(13,14)7-2-8-18(12,15)16/h3-6,9H,2,7-8H2,1H3
DMK0VFS	CS	CC1=CC=C(C=C1)C2=CS(=O)(=O)CCCS2(=O)=O
DMK0VFS	IK	KZYCUCAZAITGMW-UHFFFAOYSA-N
DMK0VFS	IU	2-(4-methylphenyl)-6,7-dihydro-5H-1,4-dithiepine 1,1,4,4-tetraoxide
DMK0VFS	DE	Discovery agent

DM0QZ6I	ID	DM0QZ6I
DM0QZ6I	DN	D-kynurenine
DM0QZ6I	HS	Investigative
DM0QZ6I	SN	D-Kynurenine; 13441-51-5; (R)-2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid; UNII-DK8PQD0WC5; DK8PQD0WC5; CHEBI:86262; (2R)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid; K-8980; Kynurenine, D-; D-2-Amino-4-[2-aminophenyl]-4-oxobutanoic acid; D-2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid; D-KYN; D-Kynurenine, free base; AC1LMC0V; GTPL5799; SCHEMBL13969610; CHEMBL1233899; Benzenebutanoic acid, alpha,2-diamino-gamma-oxo-, (R)-; CTK8C4802; DTXSID50360767; Benzenebutanoic acid, alpha,2-diamino-gamma-oxo-, (alphaR)-; ZINC901103
DM0QZ6I	DT	Small molecular drug
DM0QZ6I	PC	1152206
DM0QZ6I	MW	208.21
DM0QZ6I	FM	C10H12N2O3
DM0QZ6I	IC	InChI=1S/C10H12N2O3/c11-7-4-2-1-3-6(7)9(13)5-8(12)10(14)15/h1-4,8H,5,11-12H2,(H,14,15)/t8-/m1/s1
DM0QZ6I	CS	C1=CC=C(C(=C1)C(=O)C[C@H](C(=O)O)N)N
DM0QZ6I	IK	YGPSJZOEDVAXAB-MRVPVSSYSA-N
DM0QZ6I	IU	(2R)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid
DM0QZ6I	CA	CAS 13441-51-5
DM0QZ6I	CB	CHEBI:86262
DM0QZ6I	DE	Discovery agent

DME9ODX	ID	DME9ODX
DME9ODX	DN	DL-3
DME9ODX	HS	Investigative
DME9ODX	CP	University of Cincinnati
DME9ODX	DE	Prostate cancer

DMBNFQ8	ID	DMBNFQ8
DMBNFQ8	DN	D-lactic acid
DMBNFQ8	HS	Investigative
DMBNFQ8	SN	R-lactic acid; D-lactate
DMBNFQ8	DT	Small molecular drug
DMBNFQ8	PC	61503
DMBNFQ8	MW	90.08
DMBNFQ8	FM	C3H6O3
DMBNFQ8	IC	InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m1/s1
DMBNFQ8	CS	C[C@H](C(=O)O)O
DMBNFQ8	IK	JVTAAEKCZFNVCJ-UWTATZPHSA-N
DMBNFQ8	IU	(2R)-2-hydroxypropanoic acid
DMBNFQ8	CA	CAS 10326-41-7
DMBNFQ8	CB	CHEBI:42111
DMBNFQ8	DE	Discovery agent

DMHI9ZJ	ID	DMHI9ZJ
DMHI9ZJ	DN	DL-benzylsuccinic acid
DMHI9ZJ	HS	Investigative
DMHI9ZJ	SN	2-Benzylsuccinic acid; 884-33-3; Benzylsuccinic acid; 2-benzylbutanedioic acid; DL-Benzylsuccinic acid; alpha-Benzylsuccinic acid; 36092-42-9; (phenylmethyl)butanedioic acid; beta-carboxybenzenebutanoic acid; D,L-Benzylsuccinic Acid; Butanedioic acid,2-(phenylmethyl)-; NSC20708; .alpha.-Benzylsuccinic acid; CHEMBL151284; CHEBI:16054; GTOFKXZQQDSVFH-UHFFFAOYSA-N; MFCD00055798; Benzenebutanoic acid, .beta.-carboxy-; 2-Benzyl-succinic acid; NSC-20708; NSC 20708; mono benzyl succinic acid; AC1L1GVE; 2-Benzylsuccinic acid #
DMHI9ZJ	DT	Small molecular drug
DMHI9ZJ	PC	3858
DMHI9ZJ	MW	208.21
DMHI9ZJ	FM	C11H12O4
DMHI9ZJ	IC	InChI=1S/C11H12O4/c12-10(13)7-9(11(14)15)6-8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,12,13)(H,14,15)
DMHI9ZJ	CS	C1=CC=C(C=C1)CC(CC(=O)O)C(=O)O
DMHI9ZJ	IK	GTOFKXZQQDSVFH-UHFFFAOYSA-N
DMHI9ZJ	IU	2-benzylbutanedioic acid
DMHI9ZJ	CA	CAS 884-33-3
DMHI9ZJ	CB	CHEBI:16054
DMHI9ZJ	DE	Discovery agent

DMVN93B	ID	DMVN93B
DMVN93B	DN	D-leucyl-N-(3-chlorobenzyl)-L-prolinamide
DMVN93B	HS	Investigative
DMVN93B	SN	D-Leucyl-N-(3-Chlorobenzyl)-L-Prolinamide; CHEMBL1229801; DB06911; N-(3-Chlorobenzyl)-1-[(2R)-2-amino-4-methylpentanoyl]-L-prolinamide; (2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide
DMVN93B	DT	Small molecular drug
DMVN93B	PC	25113127
DMVN93B	MW	351.9
DMVN93B	FM	C18H26ClN3O2
DMVN93B	IC	InChI=1S/C18H26ClN3O2/c1-12(2)9-15(20)18(24)22-8-4-7-16(22)17(23)21-11-13-5-3-6-14(19)10-13/h3,5-6,10,12,15-16H,4,7-9,11,20H2,1-2H3,(H,21,23)/t15-,16+/m1/s1
DMVN93B	CS	CC(C)C[C@H](C(=O)N1CCC[C@H]1C(=O)NCC2=CC(=CC=C2)Cl)N
DMVN93B	IK	FHVBVJXZKNCSLP-CVEARBPZSA-N
DMVN93B	IU	(2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide
DMVN93B	DE	Discovery agent

DMIFCHL	ID	DMIFCHL
DMIFCHL	DN	D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
DMIFCHL	HS	Investigative
DMIFCHL	SN	D-Leucyl-N-(4-Carbamimidoylbenzyl)-L-Prolinamide; CHEMBL1230016; DB06996; N-(4-Amidinobenzyl)-1-[(2R)-2-amino-4-methylpentanoyl]-L-prolinamide; 31U
DMIFCHL	DT	Small molecular drug
DMIFCHL	PC	25220914
DMIFCHL	MW	359.5
DMIFCHL	FM	C19H29N5O2
DMIFCHL	IC	InChI=1S/C19H29N5O2/c1-12(2)10-15(20)19(26)24-9-3-4-16(24)18(25)23-11-13-5-7-14(8-6-13)17(21)22/h5-8,12,15-16H,3-4,9-11,20H2,1-2H3,(H3,21,22)(H,23,25)/t15-,16+/m1/s1
DMIFCHL	CS	CC(C)C[C@H](C(=O)N1CCC[C@H]1C(=O)NCC2=CC=C(C=C2)C(=N)N)N
DMIFCHL	IK	XFNMDMGNNKIXBT-CVEARBPZSA-N
DMIFCHL	IU	(2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide
DMIFCHL	CA	CAS 1186647-77-7
DMIFCHL	DE	Discovery agent

DMM1GXI	ID	DMM1GXI
DMM1GXI	DN	DL-guanidinoethylmercaptosuccinic acid
DMM1GXI	HS	Investigative
DMM1GXI	SN	77482-44-1; gemsa; guanidinoethylmercaptosuccinic acid; DL-guanidinoethylmercaptosuccinic acid; CHEMBL560871; GUANIDINOETHYLMERCAPTO-SUCCINIC ACID; Butanedioic acid,2-[[2-[(aminoiminomethyl)amino]ethyl]thio]-; 2-[2-(diaminomethylideneamino)ethylsulfanyl]butanedioic acid; Guanidinoethyl-Mercaptosuccinic Acid; AC1L1FZW; AC1Q5SXD; 2-[(2-carbamimidamidoethyl)sulfanyl]succinic acid; AC1Q50E8; SCHEMBL1765999; CTK5E4534; 2-Guanidinoethylthiosuccinic acid; MolPort-004-964-125; (2-Guanidinoethylthio)succinic acid; BDBM50296412
DMM1GXI	DT	Small molecular drug
DMM1GXI	PC	3464
DMM1GXI	MW	235.26
DMM1GXI	FM	C7H13N3O4S
DMM1GXI	IC	InChI=1S/C7H13N3O4S/c8-7(9)10-1-2-15-4(6(13)14)3-5(11)12/h4H,1-3H2,(H,11,12)(H,13,14)(H4,8,9,10)
DMM1GXI	CS	C(CSC(CC(=O)O)C(=O)O)N=C(N)N
DMM1GXI	IK	VKVCLXDFOQQABP-UHFFFAOYSA-N
DMM1GXI	IU	2-[2-(diaminomethylideneamino)ethylsulfanyl]butanedioic acid
DMM1GXI	CA	CAS 77482-44-1
DMM1GXI	DE	Discovery agent

DM2HGNU	ID	DM2HGNU
DM2HGNU	DN	DL-TBOA
DM2HGNU	HS	Investigative
DM2HGNU	SN	dl-threo-beta-benzyloxyaspartate
DM2HGNU	DT	Small molecular drug
DM2HGNU	PC	5311218
DM2HGNU	MW	239.22
DM2HGNU	FM	C11H13NO5
DM2HGNU	IC	InChI=1S/C11H13NO5/c12-8(10(13)14)9(11(15)16)17-6-7-4-2-1-3-5-7/h1-5,8-9H,6,12H2,(H,13,14)(H,15,16)/t8-,9-/m0/s1
DM2HGNU	CS	C1=CC=C(C=C1)CO[C@@H]([C@@H](C(=O)O)N)C(=O)O
DM2HGNU	IK	BYOBCYXURWDEDS-IUCAKERBSA-N
DM2HGNU	IU	(2S,3S)-2-amino-3-phenylmethoxybutanedioic acid
DM2HGNU	CA	CAS 208706-75-6
DM2HGNU	DE	Discovery agent

DMPD2XF	ID	DMPD2XF
DMPD2XF	DN	DLX-521
DMPD2XF	HS	Investigative
DMPD2XF	SN	Anti-ALK antibody fragment, Delenex; Anti-CD246 antibody fragment, Delenex
DMPD2XF	CP	Delenex Therapeutics AG
DMPD2XF	DT	Antibody
DMPD2XF	DE	Discovery agent

DMRYQVJ	ID	DMRYQVJ
DMRYQVJ	DN	DM-107
DMRYQVJ	HS	Investigative
DMRYQVJ	SN	MDPK-67; MDPK-67b; Kallikrein 2 inhibitor (anticancer), Med Discovery; Kallikrein 2 inhibitor (dermatological disorders), Dermadis
DMRYQVJ	CP	Med Discovery SA
DMRYQVJ	DE	Atopic dermatitis

DMM0VDK	ID	DMM0VDK
DMM0VDK	DN	DM-1451
DMM0VDK	HS	Investigative
DMM0VDK	SN	DM 1451
DMM0VDK	DT	Small molecular drug
DMM0VDK	PC	9847259
DMM0VDK	MW	464.4
DMM0VDK	FM	C23H27Cl2N3O3
DMM0VDK	IC	InChI=1S/C23H27Cl2N3O3/c24-22-19(6-7-20(29)23(22)25)28-12-10-27(11-13-28)9-1-2-14-31-17-5-3-16-4-8-21(30)26-18(16)15-17/h3,5-7,15,29H,1-2,4,8-14H2,(H,26,30)
DMM0VDK	CS	C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=C(C=C4)O)Cl)Cl
DMM0VDK	IK	YZIVLADPQQPFLO-UHFFFAOYSA-N
DMM0VDK	IU	7-[4-[4-(2,3-dichloro-4-hydroxyphenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
DMM0VDK	CA	CAS 173456-49-0
DMM0VDK	DE	Discovery agent

DMSXI6W	ID	DMSXI6W
DMSXI6W	DN	DM-204
DMSXI6W	HS	Investigative
DMSXI6W	SN	Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune
DMSXI6W	CP	Sanomune Inc
DMSXI6W	DT	Antibody
DMSXI6W	DE	Solid tumour/cancer

DM7YXKL	ID	DM7YXKL
DM7YXKL	DN	DM3A6S
DM7YXKL	HS	Investigative
DM7YXKL	SN	CHEMBL437682
DM7YXKL	DT	Small molecular drug
DM7YXKL	PC	44414785
DM7YXKL	MW	409.5
DM7YXKL	FM	C19H23NO7S
DM7YXKL	IC	InChI=1S/C19H23NO7S/c1-10(21)25-14-5-3-11-9-13-12-4-6-15(27-28(22,23)24)18-19(12,7-8-20(13)2)16(11)17(14)26-18/h3,5,12-13,15,18H,4,6-9H2,1-2H3,(H,22,23,24)/t12-,13+,15-,18-,19-/m0/s1
DM7YXKL	CS	CC(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](CC5)OS(=O)(=O)[O-])C=C1
DM7YXKL	IK	YATYBWXTHXFYJT-SSTWWWIQSA-N
DM7YXKL	IU	[(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DM7YXKL	DE	Discovery agent

DML68UF	ID	DML68UF
DML68UF	DN	DM3B6S
DML68UF	HS	Investigative
DML68UF	SN	CHEMBL213737
DML68UF	DT	Small molecular drug
DML68UF	PC	44414801
DML68UF	MW	471.5
DML68UF	FM	C24H25NO7S
DML68UF	IC	InChI=1S/C24H25NO7S/c1-25-12-11-24-16-8-10-19(32-33(27,28)29)22(24)31-21-18(9-7-15(20(21)24)13-17(16)25)30-23(26)14-5-3-2-4-6-14/h2-7,9,16-17,19,22H,8,10-13H2,1H3,(H,27,28,29)/t16-,17+,19-,22-,24-/m0/s1
DML68UF	CS	C[NH+]1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC(=O)C6=CC=CC=C6)O[C@H]3[C@H](CC4)OS(=O)(=O)[O-]
DML68UF	IK	YEYZQNSVGVDYOU-MJFIPZRTSA-N
DML68UF	IU	[(4R,4aR,7S,7aR,12bS)-9-benzoyloxy-3-methyl-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DML68UF	DE	Discovery agent

DMAJ0Q8	ID	DMAJ0Q8
DMAJ0Q8	DN	DM6S
DMAJ0Q8	HS	Investigative
DMAJ0Q8	SN	CHEMBL385448
DMAJ0Q8	DT	Small molecular drug
DMAJ0Q8	PC	44414783
DMAJ0Q8	MW	367.4
DMAJ0Q8	FM	C17H21NO6S
DMAJ0Q8	IC	InChI=1S/C17H21NO6S/c1-18-7-6-17-10-3-5-13(24-25(20,21)22)16(17)23-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19H,3,5-8H2,1H3,(H,20,21,22)/t10-,11+,13-,16-,17-/m0/s1
DMAJ0Q8	CS	C[NH+]1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](CC4)OS(=O)(=O)[O-]
DMAJ0Q8	IK	QTALQTUQMLSRSG-KBQPJGBKSA-N
DMAJ0Q8	IU	[(4R,4aR,7S,7aR,12bS)-9-hydroxy-3-methyl-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMAJ0Q8	DE	Discovery agent

DMT6X03	ID	DMT6X03
DMT6X03	DN	D-mannose
DMT6X03	HS	Investigative
DMT6X03	SN	D-Mannose; Mannose; D-Mannopyranose; Seminose; Carubinose; Mannopyranose; Mannopyranoside; D-(+)-Mannose; 530-26-7; CHEBI:4208; DL-Mannose; D(+)-Mannose; (+-)-Mannose; (3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; D-Mannopyranoside; D-Man; WQZGKKKJIJFFOK-QTVWNMPRSA-N; Man; Mannopyranose, D-; SMR000857125; EINECS 208-474-2; D-Mannose,(S); alpha,beta-D-mannopyranose; bmse000018; bmse000882; Epitope ID:152206; bmse000874; AC1L2D5C; SCHEMBL38300; MLS001332528; MLS001332527; GTPL4650; CHEMBL469448; DTXSID5040463
DMT6X03	DT	Small molecular drug
DMT6X03	PC	18950
DMT6X03	MW	180.16
DMT6X03	FM	C6H12O6
DMT6X03	IC	InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6?/m1/s1
DMT6X03	CS	C([C@@H]1[C@H]([C@@H]([C@@H](C(O1)O)O)O)O)O
DMT6X03	IK	WQZGKKKJIJFFOK-QTVWNMPRSA-N
DMT6X03	IU	(3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMT6X03	CA	CAS 530-26-7
DMT6X03	CB	CHEBI:4208
DMT6X03	DE	Discovery agent

DM7O1IW	ID	DM7O1IW
DM7O1IW	DN	D-mannose 1-phosphate
DM7O1IW	HS	Investigative
DM7O1IW	SN	D-Mannose 1-phosphate; Mannose 1-phosphate; mannose-1-P; D-mannose-1-phosphate; D-mannose 1-phosphates; CHEBI:35374; 27251-84-9; AC1LD8PO; delta-mannose-1-phosphate; Mannose 1-phosphoric acid; delta-mannose 1-phosphates; Epitope ID:145013; D-Mannopyranose-1-phosphate; D-Mannopyranose, 1-phosphate; SCHEMBL284741; alpha-delta-Mannose 1-phosphate; Mannose 1-phosphate-Mannopyranose; D-Mannose, 1-(dihydrogen phosphate); DB02867; D-mannopyranose 1-(dihydrogen phosphate); 1-(dihydrogen phosphate)-D-Mannopyranose; D-Mannopyranose, 1-(d
DM7O1IW	DT	Small molecular drug
DM7O1IW	PC	644175
DM7O1IW	MW	260.14
DM7O1IW	FM	C6H13O9P
DM7O1IW	IC	InChI=1S/C6H13O9P/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5+,6?/m1/s1
DM7O1IW	CS	C([C@@H]1[C@H]([C@@H]([C@@H](C(O1)OP(=O)(O)O)O)O)O)O
DM7O1IW	IK	HXXFSFRBOHSIMQ-QTVWNMPRSA-N
DM7O1IW	IU	[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate
DM7O1IW	CA	CAS 27251-84-9
DM7O1IW	CB	CHEBI:35374
DM7O1IW	DE	Discovery agent

DMK3WY4	ID	DMK3WY4
DMK3WY4	DN	DMCM
DMK3WY4	HS	Investigative
DMK3WY4	SN	DMCM; Methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate; UNII-1309288N1J; 82499-00-1; CHEMBL17468; METHYL-6,7-DIMETHOXY-4-ETHYL-BETA-CARBOLINE-3-CARBOXYLATE; methyl 4-ethyl-6,7-dimethoxy-9H-pyrido[3,4-b]indole-3-carboxylate; 1309288N1J; Methyl 4-ethyl-6,7-dimethoxy-9H-pyrido(3,4-b)indole-3-carboxylate; 4-Ethyl-6,7-dimethoxy-9H-pyrido(3,4-b)indole-3-carboxylic acid, methyl ester; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-ethyl-6,7-dimethoxy-, methyl ester; C17H18N2O4; Lopac-E-007; Biomol-NT_000249; AC1Q5ZP9
DMK3WY4	DT	Small molecular drug
DMK3WY4	PC	104999
DMK3WY4	MW	314.34
DMK3WY4	FM	C17H18N2O4
DMK3WY4	IC	InChI=1S/C17H18N2O4/c1-5-9-15-10-6-13(21-2)14(22-3)7-11(10)19-12(15)8-18-16(9)17(20)23-4/h6-8,19H,5H2,1-4H3
DMK3WY4	CS	CCC1=C2C3=CC(=C(C=C3NC2=CN=C1C(=O)OC)OC)OC
DMK3WY4	IK	GADIKQPUNWAMEB-UHFFFAOYSA-N
DMK3WY4	IU	methyl 4-ethyl-6,7-dimethoxy-9H-pyrido[3,4-b]indole-3-carboxylate
DMK3WY4	CA	CAS 82499-00-1
DMK3WY4	CB	CHEBI:92263
DMK3WY4	DE	Discovery agent

DMOJ92D	ID	DMOJ92D
DMOJ92D	DN	DMI-bisphosphate
DMOJ92D	HS	Investigative
DMOJ92D	SN	D-myo-inositol 3,4-bisphosphate; Inositol 3,4-bisphosphate; SCHEMBL2044892; 1D-myo-Inositol 3,4-bisphosphate; 1D-myo-inositol 3,4-bis(dihydrogen phosphate); 1L-myo-inositol 1,6-bis(dihydrogen phosphate); 23410-61-9; 69256-53-7; AC1L98W7; C04063; CHEBI:28858; CTK2F6528; [(1S,2R,3S,4S,5S,6S)-2,3,4,5-tetrahydroxy-6-phosphonooxy-cyclohexyl]oxyphosphonic acid; [(1S,2S,3S,4S,5R,6S)-2,3,4,5-tetrahydroxy-6-phosphonooxycyclohexyl] dihydrogen phosphate
DMOJ92D	PC	440211
DMOJ92D	MW	340.12
DMOJ92D	FM	C6H14O12P2
DMOJ92D	IC	MCKAJXMRULSUKI-CNWJWELYSA-N
DMOJ92D	CS	C1(C(C(C(C(C1O)OP(=O)(O)O)OP(=O)(O)O)O)O)O
DMOJ92D	IK	1S/C6H14O12P2/c7-1-2(8)4(10)6(18-20(14,15)16)5(3(1)9)17-19(11,12)13/h1-10H,(H2,11,12,13)(H2,14,15,16)/t1-,2-,3-,4+,5-,6-/m0/s1
DMOJ92D	IU	[(1S,2R,3S,4S,5S,6S)-2,3,4,5-tetrahydroxy-6-phosphonooxycyclohexyl] dihydrogen phosphate
DMOJ92D	CA	CAS 69256-53-7
DMOJ92D	CB	CHEBI:28858
DMOJ92D	DE	Discovery agent

DM3GYFZ	ID	DM3GYFZ
DM3GYFZ	DN	DMI-trisphosphate
DM3GYFZ	HS	Investigative
DM3GYFZ	SN	D-myo-inositol 1,3,4-trisphosphate; D-myo-Inositol-1,3,4-triphosphate; Inositol 1,3,4-triphosphate; SCHEMBL9382320; ZINC4095596; inositol 1,3,4-trisphosphate; myo-inositol 1,3,4-trisphosphate; (1S,3S,4S)-1,3,4-TRIPHOSPHO-MYO-INOSITOL; 1,3,4-Itp; 1D-myo-Inositol 1,3,4-trisphosphate; 1D-myo-inositol 1,3,4-tris(dihydrogen phosphate); AC1L97DW; C01243; CHEBI:18228; CHEMBL329137; DB01729; I3S; MMWCIQZXVOZEGG-MLQGYMEPSA-N; d-myo-inositol-1,3,4-tris(dihydrogen phosphate)
DM3GYFZ	PC	439455
DM3GYFZ	MW	420.1
DM3GYFZ	FM	C6H15O15P3
DM3GYFZ	IC	MMWCIQZXVOZEGG-MLQGYMEPSA-N
DM3GYFZ	CS	C1(C(C(C(C(C1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O
DM3GYFZ	IK	1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2-,3+,4+,5+,6+/m1/s1
DM3GYFZ	IU	[(1S,2R,3R,4S,5S,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate
DM3GYFZ	CA	CAS 98102-63-7
DM3GYFZ	CB	CHEBI:18228
DM3GYFZ	DE	Discovery agent

DMNRLA7	ID	DMNRLA7
DMNRLA7	DN	DMP-695/696
DMNRLA7	HS	Investigative
DMNRLA7	DT	Small molecular drug
DMNRLA7	PC	56603766
DMNRLA7	MW	410.3
DMNRLA7	FM	C18H21Cl2N5O2
DMNRLA7	IC	InChI=1S/C18H21Cl2N5O2/c1-10-16(12-5-13(19)7-14(20)6-12)17-21-11(2)22-18(25(17)24-10)23-15(8-26-3)9-27-4/h5-7,15H,8-9H2,1-4H3,(H,21,22,23)
DMNRLA7	CS	CC1=NN2C(=C1C3=CC(=CC(=C3)Cl)Cl)N=C(N=C2NC(COC)COC)C
DMNRLA7	IK	RHSNHBGJLLYGNA-UHFFFAOYSA-N
DMNRLA7	IU	8-(3,5-dichlorophenyl)-N-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DMNRLA7	DE	Depression

DMUGPD1	ID	DMUGPD1
DMUGPD1	DN	DM-PPP
DMUGPD1	HS	Investigative
DMUGPD1	SN	CHEMBL232052; DM-PPP; GTPL1383; BDBM50204428; D-255; O4-(3,3-dimethylbutan-2-yl) O2-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate; (S)-4-(3,3-dimethylbutan-2-yl) 2-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate; 4-O-[(2S)-3,3-dimethylbutan-2-yl] 2-O-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate.
DMUGPD1	DT	Small molecular drug
DMUGPD1	PC	44431042
DMUGPD1	MW	309.4
DMUGPD1	FM	C17H27NO4
DMUGPD1	IC	InChI=1S/C17H27NO4/c1-8-9-21-16(20)14-10(2)13(11(3)18-14)15(19)22-12(4)17(5,6)7/h12,18H,8-9H2,1-7H3/t12-/m0/s1
DMUGPD1	CS	CCCOC(=O)C1=C(C(=C(N1)C)C(=O)O[C@@H](C)C(C)(C)C)C
DMUGPD1	IK	DOYZAIRDDZPMQZ-LBPRGKRZSA-N
DMUGPD1	IU	4-O-[(2S)-3,3-dimethylbutan-2-yl] 2-O-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate
DMUGPD1	DE	Discovery agent

DM5WEFK	ID	DM5WEFK
DM5WEFK	DN	Dmt-Pro-3,5Dmp-Phe-NH2
DM5WEFK	HS	Investigative
DM5WEFK	SN	CHEMBL389949; Dmt-Pro-3,5Dmp-Phe-NH2
DM5WEFK	DT	Small molecular drug
DM5WEFK	PC	16736676
DM5WEFK	MW	627.8
DM5WEFK	FM	C36H45N5O5
DM5WEFK	IC	InChI=1S/C36H45N5O5/c1-21-13-22(2)15-26(14-21)19-31(34(44)39-30(33(38)43)18-25-9-6-5-7-10-25)40-35(45)32-11-8-12-41(32)36(46)29(37)20-28-23(3)16-27(42)17-24(28)4/h5-7,9-10,13-17,29-32,42H,8,11-12,18-20,37H2,1-4H3,(H2,38,43)(H,39,44)(H,40,45)/t29-,30-,31-,32-/m0/s1
DM5WEFK	CS	CC1=CC(=CC(=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N)C
DM5WEFK	IK	GBRVPIBAPYVZMY-YDPTYEFTSA-N
DM5WEFK	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(3,5-dimethylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM5WEFK	DE	Discovery agent

DMGUIR1	ID	DMGUIR1
DMGUIR1	DN	Dmt-Pro-Dmp-Phe-NH2
DMGUIR1	HS	Investigative
DMGUIR1	SN	CHEMBL228409; Dmt-Pro-Dmp-Phe-NH2
DMGUIR1	DT	Small molecular drug
DMGUIR1	PC	16736727
DMGUIR1	MW	627.8
DMGUIR1	FM	C36H45N5O5
DMGUIR1	IC	InChI=1S/C36H45N5O5/c1-21-10-8-11-22(2)28(21)20-31(34(44)39-30(33(38)43)18-25-12-6-5-7-13-25)40-35(45)32-14-9-15-41(32)36(46)29(37)19-27-23(3)16-26(42)17-24(27)4/h5-8,10-13,16-17,29-32,42H,9,14-15,18-20,37H2,1-4H3,(H2,38,43)(H,39,44)(H,40,45)/t29-,30-,31-,32-/m0/s1
DMGUIR1	CS	CC1=C(C(=CC=C1)C)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N
DMGUIR1	IK	KIPQYPCUMMQKJB-YDPTYEFTSA-N
DMGUIR1	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2,6-dimethylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMGUIR1	DE	Discovery agent

DM4VEU2	ID	DM4VEU2
DM4VEU2	DN	Dmt-Pro-Dmt-Phe-NH2
DM4VEU2	HS	Investigative
DM4VEU2	SN	CHEMBL388800; Dmt-Pro-Dmt-Phe-NH2
DM4VEU2	DT	Small molecular drug
DM4VEU2	PC	44424810
DM4VEU2	MW	629.7
DM4VEU2	FM	C35H43N5O6
DM4VEU2	IC	InChI=1S/C35H43N5O6/c1-20-14-25(41)12-11-24(20)18-30(33(44)38-29(32(37)43)17-23-8-5-4-6-9-23)39-34(45)31-10-7-13-40(31)35(46)28(36)19-27-21(2)15-26(42)16-22(27)3/h4-6,8-9,11-12,14-16,28-31,41-42H,7,10,13,17-19,36H2,1-3H3,(H2,37,43)(H,38,44)(H,39,45)/t28-,29-,30-,31-/m0/s1
DM4VEU2	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=C(C=C(C=C3)O)C)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N)N)C)O
DM4VEU2	IK	VSPCTLNQMKBUFW-ORYMTKCHSA-N
DM4VEU2	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxy-2-methylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM4VEU2	DE	Discovery agent

DM06VGY	ID	DM06VGY
DM06VGY	DN	Dmt-Pro-Emp-Phe-NH2
DM06VGY	HS	Investigative
DM06VGY	SN	CHEMBL374818; Dmt-Pro-Emp-Phe-NH2
DM06VGY	DT	Small molecular drug
DM06VGY	PC	16736880
DM06VGY	MW	641.8
DM06VGY	FM	C37H47N5O5
DM06VGY	IC	InChI=1S/C37H47N5O5/c1-5-26-14-9-11-22(2)29(26)21-32(35(45)40-31(34(39)44)19-25-12-7-6-8-13-25)41-36(46)33-15-10-16-42(33)37(47)30(38)20-28-23(3)17-27(43)18-24(28)4/h6-9,11-14,17-18,30-33,43H,5,10,15-16,19-21,38H2,1-4H3,(H2,39,44)(H,40,45)(H,41,46)/t30-,31-,32-,33-/m0/s1
DM06VGY	CS	CCC1=CC=CC(=C1C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N)C
DM06VGY	IK	FZEQHIVEBCRYJC-YRCZKMHPSA-N
DM06VGY	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2-ethyl-6-methylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM06VGY	DE	Discovery agent

DMXUI1J	ID	DMXUI1J
DMXUI1J	DN	Dmt-Pro-Imp-Phe-NH2
DMXUI1J	HS	Investigative
DMXUI1J	SN	CHEMBL228516; Dmt-Pro-Imp-Phe-NH2
DMXUI1J	DT	Small molecular drug
DMXUI1J	PC	16737137
DMXUI1J	MW	655.8
DMXUI1J	FM	C38H49N5O5
DMXUI1J	IC	InChI=1S/C38H49N5O5/c1-22(2)28-14-9-11-23(3)30(28)21-33(36(46)41-32(35(40)45)19-26-12-7-6-8-13-26)42-37(47)34-15-10-16-43(34)38(48)31(39)20-29-24(4)17-27(44)18-25(29)5/h6-9,11-14,17-18,22,31-34,44H,10,15-16,19-21,39H2,1-5H3,(H2,40,45)(H,41,46)(H,42,47)/t31-,32-,33-,34-/m0/s1
DMXUI1J	CS	CC1=C(C(=CC=C1)C(C)C)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N
DMXUI1J	IK	PUIMPGYMFMJIOK-CUPIEXAXSA-N
DMXUI1J	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2-methyl-6-propan-2-ylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMXUI1J	DE	Discovery agent

DM78PFN	ID	DM78PFN
DM78PFN	DN	Dmt-Pro-Mmp-Phe-NH2
DM78PFN	HS	Investigative
DM78PFN	SN	CHEMBL389948; Dmt-Pro-Mmp-Phe-NH2
DM78PFN	DT	Small molecular drug
DM78PFN	PC	16737287
DM78PFN	MW	613.7
DM78PFN	FM	C35H43N5O5
DM78PFN	IC	InChI=1S/C35H43N5O5/c1-21-10-7-8-13-25(21)19-30(33(43)38-29(32(37)42)18-24-11-5-4-6-12-24)39-34(44)31-14-9-15-40(31)35(45)28(36)20-27-22(2)16-26(41)17-23(27)3/h4-8,10-13,16-17,28-31,41H,9,14-15,18-20,36H2,1-3H3,(H2,37,42)(H,38,43)(H,39,44)/t28-,29-,30-,31-/m0/s1
DM78PFN	CS	CC1=CC=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N
DM78PFN	IK	ILQNJTWDEDHFTC-ORYMTKCHSA-N
DM78PFN	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2-methylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM78PFN	DE	Discovery agent

DM0VCWA	ID	DM0VCWA
DM0VCWA	DN	Dmt-Pro-Phe-D-1-Nal-NH2
DM0VCWA	HS	Investigative
DM0VCWA	SN	CHEMBL385583; Dmt-Pro-Phe-D-1-Nal-NH2
DM0VCWA	DT	Small molecular drug
DM0VCWA	PC	16105560
DM0VCWA	MW	649.8
DM0VCWA	FM	C38H43N5O5
DM0VCWA	IC	InChI=1S/C38H43N5O5/c1-23-18-26(19-24(2)34(23)44)20-30(39)38(48)43-17-9-16-33(43)37(47)42-32(21-25-10-4-3-5-11-25)36(46)41-31(35(40)45)22-28-14-8-13-27-12-6-7-15-29(27)28/h3-8,10-15,18-19,30-33,44H,9,16-17,20-22,39H2,1-2H3,(H2,40,45)(H,41,46)(H,42,47)/t30-,31+,32-,33-/m0/s1
DM0VCWA	CS	CC1=CC(=CC(=C1O)C)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CC=CC5=CC=CC=C54)C(=O)N)N
DM0VCWA	IK	UOSWQKPDVGZIDQ-YGXYGYJOSA-N
DM0VCWA	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-3,5-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-amino-3-naphthalen-1-yl-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM0VCWA	DE	Discovery agent

DMRJVE8	ID	DMRJVE8
DMRJVE8	DN	Dmt-Pro-Phe-D-2-Nal-NH2
DMRJVE8	HS	Investigative
DMRJVE8	DE	Discovery agent

DMM8BIE	ID	DMM8BIE
DMM8BIE	DN	Dmt-Pro-Phe-Phe-NH2
DMM8BIE	HS	Investigative
DMM8BIE	SN	CHEMBL331325; 596792-36-8; Dmt-Pro-Phe-Phe-NH2; Dmt-endomorphin-2; CTK1E6813; DTXSID10435187; BDBM50149384; AKOS030610408; L-Phenylalaninamide, 2,6-dimethyl-L-tyrosyl-L-prolyl-L-phenylalanyl-; (S)-1-[(S)-2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-pyrrolidine-2-carboxylic acid [(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethyl]-amide
DMM8BIE	DT	Small molecular drug
DMM8BIE	PC	10077295
DMM8BIE	MW	599.7
DMM8BIE	FM	C34H41N5O5
DMM8BIE	IC	InChI=1S/C34H41N5O5/c1-21-16-25(40)17-22(2)26(21)20-27(35)34(44)39-15-9-14-30(39)33(43)38-29(19-24-12-7-4-8-13-24)32(42)37-28(31(36)41)18-23-10-5-3-6-11-23/h3-8,10-13,16-17,27-30,40H,9,14-15,18-20,35H2,1-2H3,(H2,36,41)(H,37,42)(H,38,43)/t27-,28-,29-,30-/m0/s1
DMM8BIE	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N)N)C)O
DMM8BIE	IK	PJAMNQXPYIKTPE-KRCBVYEFSA-N
DMM8BIE	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMM8BIE	CA	CAS 596792-36-8
DMM8BIE	DE	Discovery agent

DMEMQAK	ID	DMEMQAK
DMEMQAK	DN	Dmt-Pro-Tmp-Phe-NH2
DMEMQAK	HS	Investigative
DMEMQAK	SN	CHEMBL228503; Dmt-Pro-Tmp-Phe-NH2
DMEMQAK	DT	Small molecular drug
DMEMQAK	PC	16737135
DMEMQAK	MW	641.8
DMEMQAK	FM	C37H47N5O5
DMEMQAK	IC	InChI=1S/C37H47N5O5/c1-21-14-22(2)29(23(3)15-21)20-32(35(45)40-31(34(39)44)18-26-10-7-6-8-11-26)41-36(46)33-12-9-13-42(33)37(47)30(38)19-28-24(4)16-27(43)17-25(28)5/h6-8,10-11,14-17,30-33,43H,9,12-13,18-20,38H2,1-5H3,(H2,39,44)(H,40,45)(H,41,46)/t30-,31-,32-,33-/m0/s1
DMEMQAK	CS	CC1=CC(=C(C(=C1)C)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N)C
DMEMQAK	IK	NHSNBLRALWOIIA-YRCZKMHPSA-N
DMEMQAK	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-(2,4,6-trimethylphenyl)propan-2-yl]pyrrolidine-2-carboxamide
DMEMQAK	DE	Discovery agent

DMKEV5U	ID	DMKEV5U
DMKEV5U	DN	Dmt-Pro-Trp-D-2-Nal-NH2
DMKEV5U	HS	Investigative
DMKEV5U	SN	CHEMBL218433; Dmt-Pro-Trp-D-2-Nal-NH2
DMKEV5U	DT	Small molecular drug
DMKEV5U	PC	16105563
DMKEV5U	MW	688.8
DMKEV5U	FM	C40H44N6O5
DMKEV5U	IC	InChI=1S/C40H44N6O5/c1-23-16-26(17-24(2)36(23)47)19-31(41)40(51)46-15-7-12-35(46)39(50)45-34(21-29-22-43-32-11-6-5-10-30(29)32)38(49)44-33(37(42)48)20-25-13-14-27-8-3-4-9-28(27)18-25/h3-6,8-11,13-14,16-18,22,31,33-35,43,47H,7,12,15,19-21,41H2,1-2H3,(H2,42,48)(H,44,49)(H,45,50)/t31-,33+,34-,35-/m0/s1
DMKEV5U	CS	CC1=CC(=CC(=C1O)C)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC6=CC=CC=C6C=C5)C(=O)N)N
DMKEV5U	IK	DAHITVLHYSLLFU-ZFOKTMFVSA-N
DMKEV5U	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxy-3,5-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMKEV5U	DE	Discovery agent

DMHRT0F	ID	DMHRT0F
DMHRT0F	DN	Dmt-Sar-Phe-D-2-Nal-NH
DMHRT0F	HS	Investigative
DMHRT0F	SN	CHEMBL254927; Dmt-Sar-Phe-D-2-Nal-NH; BDBM50232770
DMHRT0F	DT	Small molecular drug
DMHRT0F	PC	44447368
DMHRT0F	MW	623.7
DMHRT0F	FM	C36H41N5O5
DMHRT0F	IC	InChI=1S/C36H41N5O5/c1-22-15-28(42)16-23(2)29(22)20-30(37)36(46)41(3)21-33(43)39-32(18-24-9-5-4-6-10-24)35(45)40-31(34(38)44)19-25-13-14-26-11-7-8-12-27(26)17-25/h4-17,30-32,42H,18-21,37H2,1-3H3,(H2,38,44)(H,39,43)(H,40,45)/t30-,31+,32-/m0/s1
DMHRT0F	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N(C)CC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC3=CC4=CC=CC=C4C=C3)C(=O)N)N)C)O
DMHRT0F	IK	LCSGBFCHAFMKLD-QAXCHELISA-N
DMHRT0F	IU	(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-methylamino]acetyl]amino]-N-[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]-3-phenylpropanamide
DMHRT0F	DE	Discovery agent

DMNUKIX	ID	DMNUKIX
DMNUKIX	DN	D-myo-inositol 1,4,5-trisphosphate
DMNUKIX	HS	Investigative
DMNUKIX	SN	d-Myo-inositol-1,4,5-triphosphate; inositol 1,4,5-trisphosphate; 1,4,5-Insp3; InsP3; d-myo-inositol-1,4,5-triphosphate; 1D-myo-Inositol 1,4,5-trisphosphate; D-myo-Inositol 1,4,5-trisphosphate; IP3; Ins(1,4,5)P3; 85166-31-0; CHEMBL279107; CHEBI:16595; Triphosphoinositol; I3P; 1D-myo-inositol 1,4,5-tris(dihydrogen phosphate); D-myo-Inositol, 1,4,5-tris(dihydrogen phosphate); {[(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-bis(phosphonooxy)cyclohexyl]oxy}phosphonic acid; D-myo-Inositol 1,4,5-triphosphate; 1btn; 1mai; Inositol trisphosphate; 1n4k; 1h0a; D-Myo-Inositol-1,4,5-Triphosphate
DMNUKIX	DT	Small molecular drug
DMNUKIX	PC	439456
DMNUKIX	MW	420.1
DMNUKIX	FM	C6H15O15P3
DMNUKIX	IC	InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2+,3+,4-,5-,6-/m1/s1
DMNUKIX	CS	[C@H]1([C@@H]([C@H]([C@@H]([C@H]([C@@H]1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O
DMNUKIX	IK	MMWCIQZXVOZEGG-XJTPDSDZSA-N
DMNUKIX	IU	[(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate
DMNUKIX	CA	CAS 85166-31-0
DMNUKIX	CB	CHEBI:16595
DMNUKIX	DE	Discovery agent

DMQXPA5	ID	DMQXPA5
DMQXPA5	DN	DNQX
DMQXPA5	HS	Investigative
DMQXPA5	SN	dnqx; 2379-57-9; 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione; FG-9041; FG 9041; UNII-62T278S1MX; 6,7-Dinitroquinoxaline-2,3-dione (DNQX); 2,3-Quinoxalinedione, 1,4-dihydro-6,7-dinitro-; 6,7-Dinitroquinoxaline-2,3(1H,4H)-dione; 62T278S1MX; 6,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione; SR-01000075442; 1ftl; Tocris-0189; AC1MZKE9; Lopac-D-0540; Biomol-NT_000182; Oprea1_127694; Lopac0_000345; MLS000705107; SCHEMBL594575; SCHEMBL8128055; BPBio1_001176; CHEMBL155265; C8H4N4O6; CHEBI:93492; CTK8F7031; DTXSID60178476; MolPort-003-846-931
DMQXPA5	DT	Small molecular drug
DMQXPA5	PC	3899541
DMQXPA5	MW	252.14
DMQXPA5	FM	C8H4N4O6
DMQXPA5	IC	InChI=1S/C8H4N4O6/c13-7-8(14)10-4-2-6(12(17)18)5(11(15)16)1-3(4)9-7/h1-2H,(H,9,13)(H,10,14)
DMQXPA5	CS	C1=C2C(=CC(=C1[N+](=O)[O-])[N+](=O)[O-])NC(=O)C(=O)N2
DMQXPA5	IK	RWVIMCIPOAXUDG-UHFFFAOYSA-N
DMQXPA5	IU	6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione
DMQXPA5	CA	CAS 2379-57-9
DMQXPA5	CB	CHEBI:93492
DMQXPA5	DE	Discovery agent

DMC5RL7	ID	DMC5RL7
DMC5RL7	DN	DNX-2000
DMC5RL7	HS	Investigative
DMC5RL7	SN	SYK kinase inhibitor (autoimmune disorders), Dynamix/Teva Pharmaceutical
DMC5RL7	CP	Dynamix Pharmaceuticals Ltd
DMC5RL7	DE	Autoimmune diabetes

DMVCP6X	ID	DMVCP6X
DMVCP6X	DN	Docosapentaenoic acid
DMVCP6X	HS	Investigative
DMVCP6X	SN	Docosa-4,7,10,13,16-pentaenoic acid; 2313-14-6; 25182-74-5; 4-7-10-13-16 Docsapentaenoic acid; CTK1A5509; CTK1A4905; AVKOENOBFIYBSA-UHFFFAOYSA-N; 4,7,10,13,16-Docosapentaenoicacid; 4,7,10,13,16-Docosapentaenoicacid, (4Z,7Z,10Z,13Z,16Z)-; CH3(CH2)4-CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)2COOH
DMVCP6X	DT	Small molecular drug
DMVCP6X	PC	5497182
DMVCP6X	MW	330.5
DMVCP6X	FM	C22H34O2
DMVCP6X	IC	InChI=1S/C22H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-
DMVCP6X	CS	CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCCC(=O)O
DMVCP6X	IK	YUFFSWGQGVEMMI-JLNKQSITSA-N
DMVCP6X	IU	(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoic acid
DMVCP6X	CA	CAS 24880-45-3
DMVCP6X	CB	CHEBI:53488
DMVCP6X	DE	Discovery agent

DMEKU71	ID	DMEKU71
DMEKU71	DN	Dodeca-2E,4E-dienoic acid isobutylamide
DMEKU71	HS	Investigative
DMEKU71	SN	UNII-5F4WO3BVS9; dodeca-2E,4E-dienoic acid isobutylamide; N-isobutyl-(2E,4E)-dodecadienamide; N-Isobutyldodeca-trans-2,4-dienamide; 5F4WO3BVS9; CHEMBL426912; CHEBI:70101; 2,4-Dodecadienamide, N-(2-methylpropyl)-, (2E,4E)-; Kalecide; Dodecatetraenoic acid isobutylamide, (2E,4E)-; AC1O5Y9Z; (2E,4E)-N-(2-methylpropyl)dodeca-2,4-dienamide; SCHEMBL2262688; MolPort-005-944-951; BBRMJCAPNGJKEM-AQASXUMVSA-N; BDBM50212599; ZINC36294914; 2,4-(E,E)-Dodecadienoylisobutylamide; MCULE-7934862818; (E,E)-N-Isobutyl-2,4-dodecadienamide
DMEKU71	DT	Small molecular drug
DMEKU71	PC	6443006
DMEKU71	MW	251.41
DMEKU71	FM	C16H29NO
DMEKU71	IC	InChI=1S/C16H29NO/c1-4-5-6-7-8-9-10-11-12-13-16(18)17-14-15(2)3/h10-13,15H,4-9,14H2,1-3H3,(H,17,18)/b11-10+,13-12+
DMEKU71	CS	CCCCCCC/C=C/C=C/C(=O)NCC(C)C
DMEKU71	IK	BBRMJCAPNGJKEM-AQASXUMVSA-N
DMEKU71	IU	(2E,4E)-N-(2-methylpropyl)dodeca-2,4-dienamide
DMEKU71	CA	CAS 24738-51-0
DMEKU71	CB	CHEBI:70101
DMEKU71	DE	Discovery agent

DME9CGK	ID	DME9CGK
DME9CGK	DN	Dodecane-1-sulfonyl fluoride
DME9CGK	HS	Investigative
DME9CGK	SN	dodecane-1-sulfonyl fluoride; Dodecanesulfonyl fluoride; CHEMBL97038; dodecyl sulfonyl fluoride; 1-(Fluorosulfonyl)dodecane; SCHEMBL1470419; BDBM50132715
DME9CGK	DT	Small molecular drug
DME9CGK	PC	18516661
DME9CGK	MW	252.39
DME9CGK	FM	C12H25FO2S
DME9CGK	IC	InChI=1S/C12H25FO2S/c1-2-3-4-5-6-7-8-9-10-11-12-16(13,14)15/h2-12H2,1H3
DME9CGK	CS	CCCCCCCCCCCCS(=O)(=O)F
DME9CGK	IK	UVLRFDMRDPQRSM-UHFFFAOYSA-N
DME9CGK	IU	dodecane-1-sulfonyl fluoride
DME9CGK	DE	Discovery agent

DMCNFEL	ID	DMCNFEL
DMCNFEL	DN	Dodecanesulfonate ion
DMCNFEL	HS	Investigative
DMCNFEL	SN	1-DODECANESULFONIC ACID; 1510-16-3; Dodecane-1-sulphonic acid; Dodecylsulfonic acid; dodecane-1-sulfonic acid; UNII-YGB5540EYF; YGB5540EYF; NSC238164; 38480-64-7; Dodecylsulfonate; Benzenemethanaminium, N-(C12-C16-alkyl)-N,N-dimethyl-, 1-dodecanesulfonate; 3300-34-3; dodecyl sulfonic acid; NSC29062; 1-Dodecanesulfonic acid, ion(1-); EINECS 216-146-5; NSC 29062; NSC 238164; dodecane sulfonic acid; AC1L25CW; SCHEMBL16659; CHEMBL1208337; DTXSID3073262; CTK0H6625; LDMOEFOXLIZJOW-UHFFFAOYSA-N; ZINC1651926; 2386-53-0 (hydrochloride salt)
DMCNFEL	DT	Small molecular drug
DMCNFEL	PC	3383616
DMCNFEL	MW	249.39
DMCNFEL	FM	C12H25O3S-
DMCNFEL	IC	InChI=1S/C12H26O3S/c1-2-3-4-5-6-7-8-9-10-11-12-16(13,14)15/h2-12H2,1H3,(H,13,14,15)/p-1
DMCNFEL	CS	CCCCCCCCCCCCS(=O)(=O)[O-]
DMCNFEL	IK	LDMOEFOXLIZJOW-UHFFFAOYSA-M
DMCNFEL	IU	dodecane-1-sulfonate
DMCNFEL	DE	Discovery agent

DMUPMCZ	ID	DMUPMCZ
DMUPMCZ	DN	Dodecane-Trimethylamine
DMUPMCZ	HS	Investigative
DMUPMCZ	SN	DODECANE-TRIMETHYLAMINE; n-Dodecyltrimethylammonium; Dotac compound; Dodecyltrimethylammonium; N,N,N-trimethyldodecan-1-aminium; UNII-GT3793XV5S; 10182-91-9; DODECYLTRIMETHYLAMMONIUM ION; N,N,N-Trimethyl-1-dodecanaminium; dodecyl(trimethyl)azanium; GT3793XV5S; CHEBI:41378; 1-Dodecanaminium, N,N,N-trimethyl-; CHEMBL109873; Lauryltrimethylaminium; dodecyl-trimethyl-azanium; AC1L1QDV; dodecyl(trimethyl)ammonium; AC1Q28RJ; SCHEMBL93498; 112-00-5 (chloride); DTXSID4045008; CHEMBL1180004; 1119-94-4 (bromide); CTK4A0283
DMUPMCZ	DT	Small molecular drug
DMUPMCZ	PC	8153
DMUPMCZ	MW	228.44
DMUPMCZ	FM	C15H34N+
DMUPMCZ	IC	InChI=1S/C15H34N/c1-5-6-7-8-9-10-11-12-13-14-15-16(2,3)4/h5-15H2,1-4H3/q+1
DMUPMCZ	CS	CCCCCCCCCCCC[N+](C)(C)C
DMUPMCZ	IK	VICYBMUVWHJEFT-UHFFFAOYSA-N
DMUPMCZ	IU	dodecyl(trimethyl)azanium
DMUPMCZ	CA	CAS 10182-91-9
DMUPMCZ	CB	CHEBI:41378
DMUPMCZ	DE	Discovery agent

DM6TIQX	ID	DM6TIQX
DM6TIQX	DN	Dodecanoic acid adamantan-1-ylamide
DM6TIQX	HS	Investigative
DM6TIQX	SN	N-(1-adamantyl)dodecanamide; Dodecanoic acid adamantan-1-ylamide; CHEMBL192273; AC1NNKRI; N-adamantyl n-dodecanamide; SCHEMBL12931877; ZINC36330560; BDBM50167054
DM6TIQX	DT	Small molecular drug
DM6TIQX	PC	5071820
DM6TIQX	MW	333.6
DM6TIQX	FM	C22H39NO
DM6TIQX	IC	InChI=1S/C22H39NO/c1-2-3-4-5-6-7-8-9-10-11-21(24)23-22-15-18-12-19(16-22)14-20(13-18)17-22/h18-20H,2-17H2,1H3,(H,23,24)
DM6TIQX	CS	CCCCCCCCCCCC(=O)NC12CC3CC(C1)CC(C3)C2
DM6TIQX	IK	FRFKXRWIBACCCN-UHFFFAOYSA-N
DM6TIQX	IU	N-(1-adamantyl)dodecanamide
DM6TIQX	DE	Discovery agent

DMMDG92	ID	DMMDG92
DMMDG92	DN	Dodecyl-Alpha-D-Maltoside
DMMDG92	HS	Investigative
DMMDG92	SN	DODECYL-ALPHA-D-MALTOSIDE; 116183-64-3; N-Dodecylmaltoside; Dodecyl a-D-maltopyranoside; n-Dodecyl alpha-D-maltoside; LMU; (2R,3R,4S,5S,6R)-2-(((2R,3S,4R,5R,6S)-6-(Dodecyloxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; AC1L9I0U; Dodecyl alpha-D-maltopyranoside; SCHEMBL17817178; Dodecyl-I+/--D-maltopyranoside; ZINC14253923; GC5636; AKOS030567697; DB03279; W0537; K-1145; 183D643; W-200893; dodecyl 4-O-alpha-D-glucopyranosyl-alpha-D-glucopyranoside
DMMDG92	DT	Small molecular drug
DMMDG92	PC	445456
DMMDG92	MW	510.6
DMMDG92	FM	C24H46O11
DMMDG92	IC	InChI=1S/C24H46O11/c1-2-3-4-5-6-7-8-9-10-11-12-32-23-21(31)19(29)22(16(14-26)34-23)35-24-20(30)18(28)17(27)15(13-25)33-24/h15-31H,2-14H2,1H3/t15-,16-,17-,18+,19-,20-,21-,22-,23+,24-/m1/s1
DMMDG92	CS	CCCCCCCCCCCCO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O
DMMDG92	IK	NLEBIOOXCVAHBD-YHBSTRCHSA-N
DMMDG92	IU	(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMMDG92	DE	Discovery agent

DMPCLTW	ID	DMPCLTW
DMPCLTW	DN	dodecylphosphate
DMPCLTW	HS	Investigative
DMPCLTW	SN	FAP12; dodecanol phosphate; FAP-12; lauryl phosphate
DMPCLTW	DT	Small molecular drug
DMPCLTW	PC	1550836
DMPCLTW	MW	264.3
DMPCLTW	FM	C12H25O4P-2
DMPCLTW	IC	InChI=1S/C12H27O4P/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h2-12H2,1H3,(H2,13,14,15)/p-2
DMPCLTW	CS	CCCCCCCCCCCCOP(=O)([O-])[O-]
DMPCLTW	IK	TVACALAUIQMRDF-UHFFFAOYSA-L
DMPCLTW	IU	dodecyl phosphate
DMPCLTW	DE	Discovery agent

DMLHKI9	ID	DMLHKI9
DMLHKI9	DN	Dodecyl-phosphonic acid
DMLHKI9	HS	Investigative
DMLHKI9	SN	Dodecylphosphonic acid; n-Dodecylphosphonic acid; 5137-70-2; Phosphonic acid, dodecyl-; n-Dodecanephosphonic acid; Dodecane phosphonic acid; 1-Dodecanephosphonic acid; n-Dodecyl phosphonic acid; Phosphonic acid, P-dodecyl-; 1-Dodecylphosphonic Acid; EINECS 225-897-8; NSC 407872; BRN 1778341; CHEMBL363067; N-DODECYLPHOSPHONICACID; AC1L2W0V; 12; SCHEMBL194178; DTXSID2063715; CTK3J3207; MolPort-004-285-423; KS-00000W0I; ZINC1600143; MFCD00015832; BDBM50170845; SBB057480; NSC407872; AKOS015899842
DMLHKI9	DT	Small molecular drug
DMLHKI9	PC	78816
DMLHKI9	MW	250.31
DMLHKI9	FM	C12H27O3P
DMLHKI9	IC	InChI=1S/C12H27O3P/c1-2-3-4-5-6-7-8-9-10-11-12-16(13,14)15/h2-12H2,1H3,(H2,13,14,15)
DMLHKI9	CS	CCCCCCCCCCCCP(=O)(O)O
DMLHKI9	IK	SVMUEEINWGBIPD-UHFFFAOYSA-N
DMLHKI9	IU	dodecylphosphonic acid
DMLHKI9	CA	CAS 5137-70-2
DMLHKI9	DE	Discovery agent

DMAJVPI	ID	DMAJVPI
DMAJVPI	DN	dodecyl-thiophosphate
DMAJVPI	HS	Investigative
DMAJVPI	SN	Dodecyl-thiophosphate; Thiophosphoric acid dodecyl ester; CHEMBL191365; Phosphorothioic acid, O-dodecyl ester; SCHEMBL40052; GTPL6990; thiophosphoric acid o-dodecyl ester; BDBM50170860
DMAJVPI	DT	Small molecular drug
DMAJVPI	PC	10468943
DMAJVPI	MW	282.38
DMAJVPI	FM	C12H27O3PS
DMAJVPI	IC	InChI=1S/C12H27O3PS/c1-2-3-4-5-6-7-8-9-10-11-12-15-16(13,14)17/h2-12H2,1H3,(H2,13,14,17)
DMAJVPI	CS	CCCCCCCCCCCCOP(=S)(O)O
DMAJVPI	IK	ISWBBUXCFWZBKC-UHFFFAOYSA-N
DMAJVPI	IU	dodecoxy-dihydroxy-sulfanylidene-lambda5-phosphane
DMAJVPI	CA	CAS 710277-85-3
DMAJVPI	DE	Discovery agent

DM1YCQF	ID	DM1YCQF
DM1YCQF	DN	dolichol phosphate
DM1YCQF	HS	Investigative
DM1YCQF	SN	Dolichol-P; dolichol-phosphate; dolichyl-phosphate; Dolychol phosphate; Dolichol-PO4; AC1NQWWQ; GTPL3214; [(6E)-3,7,11-trimethyldodeca-6,10-dienyl] dihydrogen phosphate; {[(6E)-3,7,11-trimethyldodeca-6,10-dien-1-yl]oxy}phosphonic acid
DM1YCQF	DT	Small molecular drug
DM1YCQF	PC	5280322
DM1YCQF	MW	304.36
DM1YCQF	FM	C15H29O4P
DM1YCQF	IC	InChI=1S/C15H29O4P/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-19-20(16,17)18/h7,9,15H,5-6,8,10-12H2,1-4H3,(H2,16,17,18)/b14-9+
DM1YCQF	CS	CC(CC/C=C(\\C)/CCC=C(C)C)CCOP(=O)(O)O
DM1YCQF	IK	DZHSRPJGCZHWOM-NTEUORMPSA-N
DM1YCQF	IU	[(6E)-3,7,11-trimethyldodeca-6,10-dienyl] dihydrogen phosphate
DM1YCQF	CA	CAS 34457-14-2
DM1YCQF	DE	Discovery agent

DM53KZX	ID	DM53KZX
DM53KZX	DN	DOM
DM53KZX	HS	Investigative
DM53KZX	SN	2,5-Dimethoxy-4-methylamphetamine; STP (hallucinogen); (RS)-DOM; DOM; 15588-95-1; dl-2,5-Dimethoxy-4-methylamphetamine; 2,5-Dimethoxymethylamphetamine; 4-Methyl-2,5-dimethoxyamphetamine; (+-)-DOM; dl-4-Methyl-2,5-dimethoxyamphetamine; 2',5'-Dimethoxy-4'-methylamphetamine; CHEMBL8600; (+-)-2,5-Dimethoxy-4-methylamphetamine; 2,5-Dimethoxy-4-methylphenylisopropylamine; 2,5-Dimethoxy-4,alpha-dimethylphenethylamin; DEA No. 7395; 2,5-Dimethoxy-alpha,4-dimethylphenylethylamine; 2-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane
DM53KZX	DT	Small molecular drug
DM53KZX	PC	85875
DM53KZX	MW	209.28
DM53KZX	FM	C12H19NO2
DM53KZX	IC	InChI=1S/C12H19NO2/c1-8-5-12(15-4)10(6-9(2)13)7-11(8)14-3/h5,7,9H,6,13H2,1-4H3
DM53KZX	CS	CC1=CC(=C(C=C1OC)CC(C)N)OC
DM53KZX	IK	NTJQREUGJKIARY-UHFFFAOYSA-N
DM53KZX	IU	1-(2,5-dimethoxy-4-methylphenyl)propan-2-amine
DM53KZX	CA	CAS 15588-95-1
DM53KZX	DE	Discovery agent

DMXJOYH	ID	DMXJOYH
DMXJOYH	DN	DOM-0215
DMXJOYH	HS	Investigative
DMXJOYH	SN	dual anti-TNFalpha/unspecified target human dAb (rheumatoid arthritis), Domantis; dual-targeting domain antibody therapy (rheumatoid arthritis), Domantis
DMXJOYH	DE	Discovery agent

DMYPVO0	ID	DMYPVO0
DMYPVO0	DN	domoic acid
DMYPVO0	HS	Investigative
DMYPVO0	SN	domoate; NSC 288031
DMYPVO0	DT	Small molecular drug
DMYPVO0	PC	5282253
DMYPVO0	MW	311.33
DMYPVO0	FM	C15H21NO6
DMYPVO0	IC	InChI=1S/C15H21NO6/c1-8(4-3-5-9(2)14(19)20)11-7-16-13(15(21)22)10(11)6-12(17)18/h3-5,9-11,13,16H,6-7H2,1-2H3,(H,17,18)(H,19,20)(H,21,22)/b5-3+,8-4-/t9-,10+,11-,13+/m1/s1
DMYPVO0	CS	C[C@H](/C=C/C=C(/C)\\[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O)C(=O)O
DMYPVO0	IK	VZFRNCSOCOPNDB-AOKDLOFSSA-N
DMYPVO0	IU	(2S,3S,4S)-4-[(2Z,4E,6R)-6-carboxyhepta-2,4-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
DMYPVO0	CA	CAS 14277-97-5
DMYPVO0	CB	CHEBI:34727
DMYPVO0	DE	Discovery agent

DMOJF6D	ID	DMOJF6D
DMOJF6D	DN	Domoric acid
DMOJF6D	HS	Investigative
DMOJF6D	SN	domoric acid; CHEMBL482097; E,E-Isodomoic acid; ISODOMOIC ACID E; ( )-Isodomoic acid E; (-)-Isodomoic acid E; SCHEMBL13319904; ZINC4521465; (2S,3S,4S)-2-CARBOXY-4-[(1Z,3E,5R)-5-CARBOXY-1-METHYL-1,3-HEXADIENYL]-3-PYRROLIDINEACETIC ACID; BDBM50252103
DMOJF6D	DT	Small molecular drug
DMOJF6D	PC	44568340
DMOJF6D	MW	311.33
DMOJF6D	FM	C15H21NO6
DMOJF6D	IC	InChI=1S/C15H21NO6/c1-8(4-3-5-9(2)14(19)20)11-7-16-13(15(21)22)10(11)6-12(17)18/h3-5,9-11,13,16H,6-7H2,1-2H3,(H,17,18)(H,19,20)(H,21,22)/b5-3+,8-4+/t9-,10+,11-,13+/m1/s1
DMOJF6D	CS	C[C@H](/C=C/C=C(\\C)/[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O)C(=O)O
DMOJF6D	IK	VZFRNCSOCOPNDB-JIUSADRUSA-N
DMOJF6D	IU	(2S,3S,4S)-4-[(2E,4E,6R)-6-carboxyhepta-2,4-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
DMOJF6D	CA	CAS 133005-85-3
DMOJF6D	DE	Discovery agent

DMKYXJW	ID	DMKYXJW
DMKYXJW	DN	Dorsomorphin
DMKYXJW	HS	Investigative
DMKYXJW	SN	dorsomorphin; 866405-64-3; 6-(4-(2-(Piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine; BML-275; Compound C; AMPK Inhibitor, Compound C; 6-[4-(2-Piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine; CHEMBL478629; CHEBI:78510; 4-(6-{4-[2-(piperidin-1-yl)ethoxy]phenyl}pyrazolo[1,5-a]pyrimidin-3-yl)pyridine; 6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine; AMPK Inhibitor
DMKYXJW	DT	Small molecular drug
DMKYXJW	PC	11524144
DMKYXJW	MW	399.5
DMKYXJW	FM	C24H25N5O
DMKYXJW	IC	InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2
DMKYXJW	CS	C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC=C5)N=C3
DMKYXJW	IK	XHBVYDAKJHETMP-UHFFFAOYSA-N
DMKYXJW	IU	6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine
DMKYXJW	CA	CAS 866405-64-3
DMKYXJW	CB	CHEBI:78510
DMKYXJW	DE	Discovery agent

DM6TU84	ID	DM6TU84
DM6TU84	DN	Double Oxidized Cysteine
DM6TU84	HS	Investigative
DM6TU84	DT	Small molecular drug
DM6TU84	PC	6398956
DM6TU84	MW	152.15
DM6TU84	FM	C3H6NO4S-
DM6TU84	IC	InChI=1S/C3H7NO4S/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)(H,7,8)/p-1/t2-/m0/s1
DM6TU84	CS	C([C@@H](C(=O)O)N)S(=O)[O-]
DM6TU84	IK	ADVPTQAUNPRNPO-REOHCLBHSA-M
DM6TU84	IU	(2R)-2-amino-3-hydroxy-3-oxopropane-1-sulfinate
DM6TU84	CB	CHEBI:41721
DM6TU84	DE	Discovery agent

DMQIK9S	ID	DMQIK9S
DMQIK9S	DN	DOV-51892
DMQIK9S	HS	Investigative
DMQIK9S	SN	DOV-22047; GABA-A modulators, DOV
DMQIK9S	CP	DOV Pharmaceutical Inc
DMQIK9S	DE	Panic disorder

DMJF6AQ	ID	DMJF6AQ
DMJF6AQ	DN	Doxorubicin-Formaldehyde Conjugate
DMJF6AQ	HS	Investigative
DMJF6AQ	PC	44397072
DMJF6AQ	MW	1140.1
DMJF6AQ	FM	C57H56F3N5O17
DMJF6AQ	IC	InChI=1S/C57H56F3N5O17/c1-6-10-41(68)81-37-16-13-29(26-79-18-8-7-17-64-54(76)65(53(75)55(64,3)4)31-15-14-30(24-61)35(20-31)57(58,59)60)19-33(37)52(74)63-27-62-36-21-42(80-28(2)47(36)69)82-39-23-56(77,40(67)25-66)22-34-44(39)51(73)46-45(49(34)71)48(70)32-11-9-12-38(78-5)43(32)50(46)72/h9,11-16,19-20,28,36,39,42,47,62,66,69,71,73,77H,6,10,17-18,21-23,25-27H2,1-5H3,(H,63,74)/t28-,36-,39?,42?,47+,56-/m0/s1
DMJF6AQ	CS	CCCC(=O)OC1=C(C=C(C=C1)COCC#CCN2C(=O)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F)C(=O)NCN[C@H]4CC(O[C@H]([C@H]4O)C)OC5C[C@@](CC6=C5C(=C7C(=C6O)C(=O)C8=C(C7=O)C(=CC=C8)OC)O)(C(=O)CO)O
DMJF6AQ	IK	WLZCINFVVNITPX-ZJLMMONESA-N
DMJF6AQ	IU	[4-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl]but-2-ynoxymethyl]-2-[[[(2S,3S,4S)-3-hydroxy-2-methyl-6-[[(3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]amino]methylcarbamoyl]phenyl] butanoate
DMJF6AQ	DE	Discovery agent

DMNJBF8	ID	DMNJBF8
DMNJBF8	DN	doxorubicin-LL2 conjugate
DMNJBF8	HS	Investigative
DMNJBF8	SN	DOX-LL2, Immunomedics
DMNJBF8	DE	Discovery agent

DM2OCZ8	ID	DM2OCZ8
DM2OCZ8	DN	doxorubicin-peptide-PEG conjugate
DM2OCZ8	HS	Investigative
DM2OCZ8	DE	Discovery agent

DMXEVA2	ID	DMXEVA2
DMXEVA2	DN	DP-3005
DMXEVA2	HS	Investigative
DMXEVA2	SN	TCCB (hypertension/angina), Diakron Pharmaceuticals; T-type calcium channel blocker (hypertension/angina), Diakron Pharmaceuticals
DMXEVA2	CP	Diakron Pharmaceuticals Inc
DMXEVA2	DE	Angina pectoris

DMFZML9	ID	DMFZML9
DMFZML9	DN	DP-3590
DMFZML9	HS	Investigative
DMFZML9	SN	DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera
DMFZML9	CP	Deciphera Pharmaceuticals Inc
DMFZML9	DE	Solid tumour/cancer

DMARTC2	ID	DMARTC2
DMARTC2	DN	DP-802
DMARTC2	HS	Investigative
DMARTC2	SN	P38-alpha inhibitors (inflammation); P38-alpha inhibitors (inflammation), Deciphera
DMARTC2	CP	Deciphera Pharmaceuticals Inc
DMARTC2	DE	Inflammation

DMIRSNA	ID	DMIRSNA
DMIRSNA	DN	DPDPE
DMIRSNA	HS	Investigative
DMIRSNA	SN	DPDPE; 2,5-Pen-enkephalin; (D-Pen2,D-Pen5)-Enkephalin; Enkephalin, D-penicillamine (2,5)-; (4s,7s,13s)-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-13-(l-tyrosylamino)-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid; DPLPE; c[D-Pen(2,5)]-enkephalin; CHEMBL31421; CHEBI:73356; Enkephalin, penicillamine(2,5)-; cyclo-[D-Pen(2,5)]-enkephalin; 88373-73-3; D-penicillamine-(2,5)-enkephalin; H-Tyr-c(D-Pen-Gly-Phe-D-Pen)-OH; [D-Pen(2)-D-Pen(5)]-enkephaline; H-Tyr-cyclo-(D-Pen-Gly-Phe-D-Pen)-OH; [3H]DPDPE; D-Valine, L-tyros
DMIRSNA	DT	Small molecular drug
DMIRSNA	PC	104787
DMIRSNA	MW	645.8
DMIRSNA	FM	C30H39N5O7S2
DMIRSNA	IC	InChI=1S/C30H39N5O7S2/c1-29(2)23(34-25(38)20(31)14-18-10-12-19(36)13-11-18)27(40)32-16-22(37)33-21(15-17-8-6-5-7-9-17)26(39)35-24(28(41)42)30(3,4)44-43-29/h5-13,20-21,23-24,36H,14-16,31H2,1-4H3,(H,32,40)(H,33,37)(H,34,38)(H,35,39)(H,41,42)/t20-,21-,23-,24-/m0/s1
DMIRSNA	CS	CC1([C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(SS1)(C)C)C(=O)O)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C
DMIRSNA	IK	MCMMCRYPQBNCPH-WMIMKTLMSA-N
DMIRSNA	IU	(4S,7S,13S)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid
DMIRSNA	CA	CAS 88373-73-3
DMIRSNA	CB	CHEBI:73356
DMIRSNA	DE	Discovery agent

DMLK428	ID	DMLK428
DMLK428	DN	D-Phe-Arg-2-Nal-NHCH3
DMLK428	HS	Investigative
DMLK428	DE	Discovery agent

DM0YQHM	ID	DM0YQHM
DM0YQHM	DN	D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2
DM0YQHM	HS	Investigative
DM0YQHM	SN	CHEMBL269532; D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2
DM0YQHM	PC	44403231
DM0YQHM	MW	1060.3
DM0YQHM	FM	C50H65N11O11S2
DM0YQHM	IC	InChI=1S/C50H65N11O11S2/c1-27(2)42-50(72)60-40(48(70)56-36(43(53)65)23-41(63)64)26-74-73-25-39(59-44(66)33(52)20-28-10-4-3-5-11-28)49(71)57-37(21-29-15-17-31(62)18-16-29)46(68)58-38(22-30-24-54-34-13-7-6-12-32(30)34)47(69)55-35(45(67)61-42)14-8-9-19-51/h3-7,10-13,15-18,24,27,33,35-40,42,54,62H,8-9,14,19-23,25-26,51-52H2,1-2H3,(H2,53,65)(H,55,69)(H,56,70)(H,57,71)(H,58,68)(H,59,66)(H,60,72)(H,61,67)(H,63,64)/t33-,35-,36-,37-,38+,39-,40+,42+/m0/s1
DM0YQHM	CS	CC(C)[C@@H]1C(=O)N[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CC(=O)O)C(=O)N
DM0YQHM	IK	HFLJXACCXCUGOQ-OZHBEKPPSA-N
DM0YQHM	IU	(3S)-4-amino-3-[[(4S,7R,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2S)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-4-oxobutanoic acid
DM0YQHM	DE	Discovery agent

DM2EFLA	ID	DM2EFLA
DM2EFLA	DN	D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)
DM2EFLA	HS	Investigative
DM2EFLA	SN	CHEMBL413950; D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)
DM2EFLA	PC	44316483
DM2EFLA	MW	1104.3
DM2EFLA	FM	C51H69N13O11S2
DM2EFLA	IC	InChI=1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33-,35+,36+,37-,38+,39+,40-,41+/m1/s1
DM2EFLA	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DM2EFLA	IK	OFMQLVRLOGHAJI-JGPYJKKXSA-N
DM2EFLA	IU	(4S,7R,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM2EFLA	DE	Discovery agent

DMPQHRC	ID	DMPQHRC
DMPQHRC	DN	D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)
DMPQHRC	HS	Investigative
DMPQHRC	SN	CHEMBL437283; D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)
DMPQHRC	PC	44316364
DMPQHRC	MW	1076.3
DMPQHRC	FM	C51H69N11O11S2
DMPQHRC	IC	InChI=1S/C51H69N11O11S2/c1-27(63)40(43(54)66)60-50(73)42-51(3,4)75-74-26-39(59-44(67)34(53)22-29-12-6-5-7-13-29)48(71)57-37(23-30-17-19-32(65)20-18-30)46(69)58-38(24-31-25-55-35-15-9-8-14-33(31)35)47(70)56-36(16-10-11-21-52)45(68)61-41(28(2)64)49(72)62-42/h5-9,12-15,17-20,25,27-28,34,36-42,55,63-65H,10-11,16,21-24,26,52-53H2,1-4H3,(H2,54,66)(H,56,70)(H,57,71)(H,58,69)(H,59,67)(H,60,73)(H,61,68)(H,62,72)/t27-,28-,34-,36+,37+,38-,39+,40+,41-,42+/m1/s1
DMPQHRC	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMPQHRC	IK	VSEYLDNPHYTJMJ-MHKBYQEDSA-N
DMPQHRC	IU	(4S,7R,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMPQHRC	DE	Discovery agent

DMX1IYO	ID	DMX1IYO
DMX1IYO	DN	D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2(CTOP)
DMX1IYO	HS	Investigative
DMX1IYO	SN	CHEMBL406014
DMX1IYO	PC	44316520
DMX1IYO	MW	1062.3
DMX1IYO	FM	C50H67N11O11S2
DMX1IYO	IC	InChI=1S/C50H67N11O11S2/c1-26(62)39(42(53)65)59-49(72)41-50(3,4)74-73-25-38(58-43(66)33(52)21-28-11-6-5-7-12-28)47(70)56-36(22-29-16-18-31(64)19-17-29)45(68)57-37(23-30-24-54-34-14-9-8-13-32(30)34)46(69)55-35(15-10-20-51)44(67)60-40(27(2)63)48(71)61-41/h5-9,11-14,16-19,24,26-27,33,35-41,54,62-64H,10,15,20-23,25,51-52H2,1-4H3,(H2,53,65)(H,55,69)(H,56,70)(H,57,68)(H,58,66)(H,59,72)(H,60,67)(H,61,71)/t26-,27-,33-,35+,36+,37-,38+,39+,40-,41+/m1/s1
DMX1IYO	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMX1IYO	IK	PZWWYAHWHHNCHO-JGPYJKKXSA-N
DMX1IYO	IU	(4S,7R,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMX1IYO	DE	Discovery agent

DMUJC97	ID	DMUJC97
DMUJC97	DN	D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2
DMUJC97	HS	Investigative
DMUJC97	SN	CHEMBL274400; D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2
DMUJC97	PC	44316657
DMUJC97	MW	1076.3
DMUJC97	FM	C51H69N11O11S2
DMUJC97	IC	InChI=1S/C51H69N11O11S2/c1-27(63)40(43(54)66)60-50(73)42-51(3,4)75-74-26-39(59-44(67)34(53)22-29-12-6-5-7-13-29)48(71)57-37(23-30-17-19-32(65)20-18-30)46(69)58-38(24-31-25-55-35-15-9-8-14-33(31)35)47(70)56-36(16-10-11-21-52)45(68)61-41(28(2)64)49(72)62-42/h5-9,12-15,17-20,25,27-28,34,36-42,55,63-65H,10-11,16,21-24,26,52-53H2,1-4H3,(H2,54,66)(H,56,70)(H,57,71)(H,58,69)(H,59,67)(H,60,73)(H,61,68)(H,62,72)/t27-,28-,34-,36+,37+,38+,39+,40+,41-,42+/m1/s1
DMUJC97	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMUJC97	IK	VSEYLDNPHYTJMJ-AVTOYXFISA-N
DMUJC97	IU	(4S,7R,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMUJC97	DE	Discovery agent

DMTUHFX	ID	DMTUHFX
DMTUHFX	DN	D-Phenylalanine
DMTUHFX	HS	Investigative
DMTUHFX	SN	D-phenylalanine; 673-06-3; H-D-Phe-OH; (2R)-2-amino-3-phenylpropanoic acid; Sabiden; Phenylalanine D-form; D-Phe; (R)-2-AMINO-3-PHENYLPROPANOIC ACID; Alanine, phenyl-, D-; NCI-C60195; UNII-032K16VRCU; (R)-2-Amino-3-phenylpropionic acid; D-alpha-Amino-beta-phenylpropionic acid; CCRIS 6267; EINECS 211-603-5; NSC 25005; 032K16VRCU; CHEBI:16998; COLNVLDHVKWLRT-MRVPVSSYSA-N; MFCD00004270; D-Phenylalanine, 99+%; d-phenylalanin; D-.beta.-Phenylalanine; Phenylalanine,d-; DPhe; l-3-phenylalanine; HDPheOH; (D)-Phenylalanine; Phenylalanine,(S)
DMTUHFX	DT	Small molecular drug
DMTUHFX	PC	71567
DMTUHFX	MW	165.19
DMTUHFX	FM	C9H11NO2
DMTUHFX	IC	InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m1/s1
DMTUHFX	CS	C1=CC=C(C=C1)C[C@H](C(=O)O)N
DMTUHFX	IK	COLNVLDHVKWLRT-MRVPVSSYSA-N
DMTUHFX	IU	(2R)-2-amino-3-phenylpropanoic acid
DMTUHFX	CA	CAS 673-06-3
DMTUHFX	CB	CHEBI:16998
DMTUHFX	DE	Discovery agent

DMGD7JM	ID	DMGD7JM
DMGD7JM	DN	D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide
DMGD7JM	HS	Investigative
DMGD7JM	SN	D-Phenylalanyl-N-(3-Chlorobenzyl)-L-Prolinamide; CHEMBL321130; CHEMBL599035; 628262-82-8; 22U; CTK1I8953; DTXSID70648418; BDBM50133531; BDBM50307858; DB06919; D-Phenylalanyl-N-[(3-chlorophenyl)methyl]-L-prolinamide; L-Prolinamide, D-phenylalanyl-N-[(3-chlorophenyl)methyl]-; N-(3-Chlorobenzyl)-1-[(2R)-2-amino-3-phenylpropionyl]-L-prolinamide; (S)-1-((R)-2-Amino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid 3-chloro-benzylamide; (S)-1-((R)-2-amino-3-phenylpropanoyl)-N-(3-chlorobenzyl)pyrrolidine-2-carboxamide hydrochlo
DMGD7JM	DT	Small molecular drug
DMGD7JM	PC	25011732
DMGD7JM	MW	385.9
DMGD7JM	FM	C21H24ClN3O2
DMGD7JM	IC	InChI=1S/C21H24ClN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h1-4,6-9,12,18-19H,5,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1
DMGD7JM	CS	C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)NCC3=CC(=CC=C3)Cl
DMGD7JM	IK	CJHLRGCXPGIPCB-MOPGFXCFSA-N
DMGD7JM	IU	(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide
DMGD7JM	CA	CAS 628262-82-8
DMGD7JM	DE	Discovery agent

DM5XHA6	ID	DM5XHA6
DM5XHA6	DN	D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide
DM5XHA6	HS	Investigative
DM5XHA6	SN	D-Phenylalanyl-N-(3-Fluorobenzyl)-L-Prolinamide; DB07027; 37U; (2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-fluorophenyl)methyl]pyrrolidine-2-carboxamide
DM5XHA6	DT	Small molecular drug
DM5XHA6	PC	25011733
DM5XHA6	MW	369.4
DM5XHA6	FM	C21H24FN3O2
DM5XHA6	IC	InChI=1S/C21H24FN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h1-4,6-9,12,18-19H,5,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1
DM5XHA6	CS	C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)NCC3=CC(=CC=C3)F
DM5XHA6	IK	JGZSVYZIJHGHMA-MOPGFXCFSA-N
DM5XHA6	IU	(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-fluorophenyl)methyl]pyrrolidine-2-carboxamide
DM5XHA6	DE	Discovery agent

DMV9RAN	ID	DMV9RAN
DMV9RAN	DN	D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide
DMV9RAN	HS	Investigative
DMV9RAN	SN	D-Phenylalanyl-N-(3-Methylbenzyl)-L-Prolinamide; DB07133; 51U
DMV9RAN	DT	Small molecular drug
DMV9RAN	PC	25021183
DMV9RAN	MW	365.5
DMV9RAN	FM	C22H27N3O2
DMV9RAN	IC	InChI=1S/C22H27N3O2/c1-16-7-5-10-18(13-16)15-24-21(26)20-11-6-12-25(20)22(27)19(23)14-17-8-3-2-4-9-17/h2-5,7-10,13,19-20H,6,11-12,14-15,23H2,1H3,(H,24,26)/t19-,20+/m1/s1
DMV9RAN	CS	CC1=CC(=CC=C1)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC3=CC=CC=C3)N
DMV9RAN	IK	CHKWABXWPATIIG-UXHICEINSA-N
DMV9RAN	IU	(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-methylphenyl)methyl]pyrrolidine-2-carboxamide
DMV9RAN	DE	Discovery agent

DMHNR63	ID	DMHNR63
DMHNR63	DN	D-phenylalanyl-N-benzyl-L-prolinamide
DMHNR63	HS	Investigative
DMHNR63	SN	D-Phenylalanyl-N-Benzyl-L-Prolinamide; CHEMBL116597; BDBM50133518; DB07143; (2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-benzylpyrrolidine-2-carboxamide; (S)-1-((R)-2-Amino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid benzylamide; (2S)-1-((2R)-2-amino-3-phenyl-propanoyl)-N-(phenylmethyl)pyrrolidine-2-carboxamide
DMHNR63	DT	Small molecular drug
DMHNR63	PC	25113125
DMHNR63	MW	351.4
DMHNR63	FM	C21H25N3O2
DMHNR63	IC	InChI=1S/C21H25N3O2/c22-18(14-16-8-3-1-4-9-16)21(26)24-13-7-12-19(24)20(25)23-15-17-10-5-2-6-11-17/h1-6,8-11,18-19H,7,12-15,22H2,(H,23,25)/t18-,19+/m1/s1
DMHNR63	CS	C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)NCC3=CC=CC=C3
DMHNR63	IK	MEPJWLFTTFHOQO-MOPGFXCFSA-N
DMHNR63	IU	(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-benzylpyrrolidine-2-carboxamide
DMHNR63	DE	Discovery agent

DMMXA5K	ID	DMMXA5K
DMMXA5K	DN	D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2
DMMXA5K	HS	Investigative
DMMXA5K	SN	CHEMBL384284; D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2
DMMXA5K	PC	44316656
DMMXA5K	MW	1062.3
DMMXA5K	FM	C50H67N11O11S2
DMMXA5K	IC	InChI=1S/C50H67N11O11S2/c1-26(62)39(42(53)65)59-49(72)41-50(3,4)74-73-25-37(58-47(70)38(52)29-12-6-5-7-13-29)46(69)56-35(22-28-17-19-31(64)20-18-28)44(67)57-36(23-30-24-54-33-15-9-8-14-32(30)33)45(68)55-34(16-10-11-21-51)43(66)60-40(27(2)63)48(71)61-41/h5-9,12-15,17-20,24,26-27,34-41,54,62-64H,10-11,16,21-23,25,51-52H2,1-4H3,(H2,53,65)(H,55,68)(H,56,69)(H,57,67)(H,58,70)(H,59,72)(H,60,66)(H,61,71)/t26-,27-,34+,35+,36-,37+,38-,39+,40-,41+/m1/s1
DMMXA5K	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](C5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMMXA5K	IK	MAYLVNQSAJCEEF-XGMLMNQMSA-N
DMMXA5K	IU	(4S,7R,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-2-phenylacetyl]amino]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMMXA5K	DE	Discovery agent

DME5S3C	ID	DME5S3C
DME5S3C	DN	DPI-221
DME5S3C	HS	Investigative
DME5S3C	CP	Ardent Pharmaceuticals Inc
DME5S3C	DE	Urinary incontinence

DMTHZ3B	ID	DMTHZ3B
DMTHZ3B	DN	DPI59
DMTHZ3B	HS	Investigative
DMTHZ3B	SN	DPI59; HYDROXY(1-NAPHTHYL)METHYLPHOSPHONIC ACID; [(S)-hydroxy(naphthalen-1-yl)methyl]phosphonic acid; I59; 1o4g; AC1L9KXU
DMTHZ3B	DT	Small molecular drug
DMTHZ3B	PC	447531
DMTHZ3B	MW	238.18
DMTHZ3B	FM	C11H11O4P
DMTHZ3B	IC	InChI=1S/C11H11O4P/c12-11(16(13,14)15)10-7-3-5-8-4-1-2-6-9(8)10/h1-7,11-12H,(H2,13,14,15)/t11-/m0/s1
DMTHZ3B	CS	C1=CC=C2C(=C1)C=CC=C2[C@@H](O)P(=O)(O)O
DMTHZ3B	IK	AXIBZLYWMBUYRV-NSHDSACASA-N
DMTHZ3B	IU	[(S)-hydroxy(naphthalen-1-yl)methyl]phosphonic acid
DMTHZ3B	DE	Discovery agent

DMSRUKQ	ID	DMSRUKQ
DMSRUKQ	DN	DPN-205-734
DMSRUKQ	HS	Investigative
DMSRUKQ	SN	5-(4-Cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
DMSRUKQ	DT	Small molecular drug
DMSRUKQ	PC	145915
DMSRUKQ	MW	235.24
DMSRUKQ	FM	C14H9N3O
DMSRUKQ	IC	InChI=1S/C14H9N3O/c1-9-13(6-12(8-16)14(18)17-9)11-4-2-10(7-15)3-5-11/h2-6H,1H3,(H,17,18)
DMSRUKQ	CS	CC1=C(C=C(C(=O)N1)C#N)C2=CC=C(C=C2)C#N
DMSRUKQ	IK	NMIRAZSAZYNODX-UHFFFAOYSA-N
DMSRUKQ	IU	5-(4-cyanophenyl)-6-methyl-2-oxo-1H-pyridine-3-carbonitrile
DMSRUKQ	CA	CAS 88594-78-9
DMSRUKQ	DE	Cardiac disease

DMHCZP0	ID	DMHCZP0
DMHCZP0	DN	DPO-1
DMHCZP0	HS	Investigative
DMHCZP0	SN	IKur blockers (atrial arrythmia), Merck & Co; Kv1.5 voltage-gated potassium channel antagonists (atrial arrythmia); Kv1.5 voltage-gated potassium channel antagonists (atrial arrythmia), Merck & Co
DMHCZP0	CP	Merck & Co Inc
DMHCZP0	DT	Small molecular drug
DMHCZP0	PC	21678144
DMHCZP0	MW	340.4
DMHCZP0	FM	C22H29OP
DMHCZP0	IC	InChI=1S/C22H29OP/c1-17(2)21-15-14-18(3)16-22(21)24(23,19-10-6-4-7-11-19)20-12-8-5-9-13-20/h4-13,17-18,21-22H,14-16H2,1-3H3/t18-,21+,22+/m1/s1
DMHCZP0	CS	C[C@@H]1CC[C@H]([C@H](C1)P(=O)(C2=CC=CC=C2)C3=CC=CC=C3)C(C)C
DMHCZP0	IK	BPCNGVCAHAIZEE-COPCDDAFSA-N
DMHCZP0	IU	[[(1S,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]-phenylphosphoryl]benzene
DMHCZP0	CA	CAS 43077-30-1
DMHCZP0	CB	CHEBI:93748
DMHCZP0	DE	Atrial fibrillation

DMRJQ8X	ID	DMRJQ8X
DMRJQ8X	DN	D-Pro-Phe-Arg chloromethyl ketone
DMRJQ8X	HS	Investigative
DMRJQ8X	SN	H-D-Pro-Phe-Arg-chloromethylketone; 88546-74-1; CHEMBL521527; BDBM23569; CTK8G0139; DTXSID90440219; ZINC13507825; D-Pro-Phe-Arg chloromethyl ketone (PCK); (R)-N-((S)-1-((S)-1-chloro-6-guanidino-2-oxohexan-3-ylamino)-1-oxo-3-phenylpropan-2-yl)pyrrolidine-2-carboxamide
DMRJQ8X	DT	Small molecular drug
DMRJQ8X	PC	10456438
DMRJQ8X	MW	451
DMRJQ8X	FM	C21H31ClN6O3
DMRJQ8X	IC	InChI=1S/C21H31ClN6O3/c22-13-18(29)15(8-4-11-26-21(23)24)27-20(31)17(12-14-6-2-1-3-7-14)28-19(30)16-9-5-10-25-16/h1-3,6-7,15-17,25H,4-5,8-13H2,(H,27,31)(H,28,30)(H4,23,24,26)/t15-,16+,17-/m0/s1
DMRJQ8X	CS	C1C[C@@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl
DMRJQ8X	IK	HCCRRLVJBLDSLL-BBWFWOEESA-N
DMRJQ8X	IU	(2R)-N-[(2S)-1-[[(3S)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMRJQ8X	CA	CAS 88546-74-1
DMRJQ8X	DE	Discovery agent

DM35CKE	ID	DM35CKE
DM35CKE	DN	DprwFwLL-NH2
DM35CKE	HS	Investigative
DM35CKE	SN	CHEMBL507636; DprwFwLL-NH2
DM35CKE	PC	44576250
DM35CKE	MW	1131.3
DM35CKE	FM	C58H78N14O10
DM35CKE	IC	InChI=1S/C58H78N14O10/c1-32(2)24-43(50(60)75)67-52(77)44(25-33(3)4)68-54(79)47(28-36-31-65-41-19-11-9-17-38(36)41)71-53(78)45(26-34-14-6-5-7-15-34)69-55(80)46(27-35-30-64-40-18-10-8-16-37(35)40)70-51(76)42(20-12-22-63-58(61)62)66-56(81)48-21-13-23-72(48)57(82)39(59)29-49(73)74/h5-11,14-19,30-33,39,42-48,64-65H,12-13,20-29,59H2,1-4H3,(H2,60,75)(H,66,81)(H,67,77)(H,68,79)(H,69,80)(H,70,76)(H,71,78)(H,73,74)(H4,61,62,63)/t39-,42+,43-,44-,45-,46+,47+,48+/m0/s1
DM35CKE	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H]6CCCN6C(=O)[C@H](CC(=O)O)N
DM35CKE	IK	CZJDWLOOIMAJCD-JXDKTPIUSA-N
DM35CKE	IU	(3S)-3-amino-4-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acid
DM35CKE	DE	Discovery agent

DMQLJ3Y	ID	DMQLJ3Y
DMQLJ3Y	DN	DQP-1105
DMQLJ3Y	HS	Investigative
DMQLJ3Y	SN	KB-272091
DMQLJ3Y	DT	Small molecular drug
DMQLJ3Y	PC	76849261
DMQLJ3Y	MW	558.4
DMQLJ3Y	FM	C29H24BrN3O4
DMQLJ3Y	IC	InChI=1S/C29H24BrN3O4/c1-17-7-12-22-21(15-17)27(19-5-3-2-4-6-19)28(29(37)31-22)23-16-24(18-8-10-20(30)11-9-18)33(32-23)25(34)13-14-26(35)36/h2-12,15,24,28H,13-14,16H2,1H3,(H,35,36)
DMQLJ3Y	CS	CC1=CC2=C(C(C(=O)N=C2C=C1)C3=NN(C(C3)C4=CC=C(C=C4)Br)C(=O)CCC(=O)O)C5=CC=CC=C5
DMQLJ3Y	IK	ACUGSRUCGXYFTL-UHFFFAOYSA-N
DMQLJ3Y	IU	4-[3-(4-bromophenyl)-5-(6-methyl-2-oxo-4-phenyl-3H-quinolin-3-yl)-3,4-dihydropyrazol-2-yl]-4-oxobutanoic acid
DMQLJ3Y	DE	Discovery agent

DM1AV5R	ID	DM1AV5R
DM1AV5R	DN	DR2313
DM1AV5R	HS	Investigative
DM1AV5R	DT	Small molecular drug
DM1AV5R	PC	135522417
DM1AV5R	MW	182.25
DM1AV5R	FM	C8H10N2OS
DM1AV5R	IC	InChI=1S/C8H10N2OS/c1-5-9-7-2-3-12-4-6(7)8(11)10-5/h2-4H2,1H3,(H,9,10,11)
DM1AV5R	CS	CC1=NC2=C(CSCC2)C(=O)N1
DM1AV5R	IK	HRYKZAKEAVZGJD-UHFFFAOYSA-N
DM1AV5R	IU	2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one
DM1AV5R	CA	CAS 284028-90-6
DM1AV5R	DE	Stroke

DMW8ORN	ID	DMW8ORN
DMW8ORN	DN	DR-4004
DMW8ORN	HS	Investigative
DMW8ORN	SN	compound 7 [PMID 10052959]
DMW8ORN	DT	Small molecular drug
DMW8ORN	PC	9843179
DMW8ORN	MW	386.5
DMW8ORN	FM	C26H30N2O
DMW8ORN	IC	InChI=1S/C26H30N2O/c29-25-26(16-7-11-22-10-6-12-23(27-25)24(22)26)15-4-5-17-28-18-13-21(14-19-28)20-8-2-1-3-9-20/h1-3,6,8-10,12-13H,4-5,7,11,14-19H2,(H,27,29)
DMW8ORN	CS	C1CC2=C3C(=CC=C2)NC(=O)C3(C1)CCCCN4CCC(=CC4)C5=CC=CC=C5
DMW8ORN	IK	JBQOYPLKTTXLSQ-UHFFFAOYSA-N
DMW8ORN	IU	2a-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1,3,4,5-tetrahydrobenzo[cd]indol-2-one
DMW8ORN	CA	CAS 201608-41-5
DMW8ORN	DE	Discovery agent

DMX2TZD	ID	DMX2TZD
DMX2TZD	DN	DR-5/DR-4 cross reactive mabs
DMX2TZD	HS	Investigative
DMX2TZD	SN	DR-5/DR-4 cross reactive mAbs (cancer); Death receptor-5/4 cross reactive mAbs (cancer), Crystal Bioscience; DR-5/DR-4 cross reactive mAbs (cancer), Crystal Bioscience
DMX2TZD	CP	Crystal Bioscience Inc
DMX2TZD	DT	Antibody
DMX2TZD	DE	Solid tumour/cancer

DMTFQG3	ID	DMTFQG3
DMTFQG3	DN	DRF 2519
DMTFQG3	HS	Investigative
DMTFQG3	SN	DRF 2519; 5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2
DMTFQG3	DT	Small molecular drug
DMTFQG3	PC	9908833
DMTFQG3	MW	398.4
DMTFQG3	FM	C20H18N2O5S
DMTFQG3	IC	InChI=1S/C20H18N2O5S/c23-18-17(28-20(25)21-18)11-13-5-7-14(8-6-13)26-10-9-22-12-27-16-4-2-1-3-15(16)19(22)24/h1-8,17H,9-12H2,(H,21,23,25)
DMTFQG3	CS	C1N(C(=O)C2=CC=CC=C2O1)CCOC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DMTFQG3	IK	RFMNEXVCPAPDRA-UHFFFAOYSA-N
DMTFQG3	IU	5-[[4-[2-(4-oxo-2H-1,3-benzoxazin-3-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMTFQG3	DE	Discovery agent

DMYOLEV	ID	DMYOLEV
DMYOLEV	DN	D-ribosylnicotinate
DMYOLEV	HS	Investigative
DMYOLEV	SN	D-ribosylnicotinate; Beta-D-ribosylnicotinate; Nicotinate ribonucleoside; Nicotinate ribose; Nicotinate riboside; Nicotinic Riboside; Nicotinic acid ribonucleoside; beta-D-Ribosylnicotinate; nicotinic acid ribose; nicotinic acid riboside; ribosylnicotinate; 1-(; 1-(beta-D-ribofuranosyl)pyridinium-3-carboxylate; 1-Pentofuranosylpyridin-1-ium-3-carboxylate; 17720-18-2; 3-Carboxy-1-; A-D-ribofuranosylpyridinium Inner Salt; A-d-ribofuranosyl)pyridinium-3-carboxylate; AC1L4P1J; AC1Q22CH; CHEBI:58527; DTXSID20938912; SCHEMBL20152239
DMYOLEV	PC	161233
DMYOLEV	MW	255.22
DMYOLEV	FM	C11H13NO6
DMYOLEV	IC	PUEDDPCUCPRQNY-ZYUZMQFOSA-N
DMYOLEV	CS	C1=CC(=C[N+](=C1)C2C(C(C(O2)CO)O)O)C(=O)[O-]
DMYOLEV	IK	1S/C11H13NO6/c13-5-7-8(14)9(15)10(18-7)12-3-1-2-6(4-12)11(16)17/h1-4,7-10,13-15H,5H2/t7-,8-,9-,10-/m1/s1
DMYOLEV	IU	1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylate
DMYOLEV	CA	CAS 17720-18-2
DMYOLEV	CB	CHEBI:58527
DMYOLEV	DE	Discovery agent

DM5IA9W	ID	DM5IA9W
DM5IA9W	DN	droxinostat
DM5IA9W	HS	Investigative
DM5IA9W	SN	NS-41080; NS41080
DM5IA9W	DT	Small molecular drug
DM5IA9W	PC	568416
DM5IA9W	MW	243.68
DM5IA9W	FM	C11H14ClNO3
DM5IA9W	IC	InChI=1S/C11H14ClNO3/c1-8-7-9(12)4-5-10(8)16-6-2-3-11(14)13-15/h4-5,7,15H,2-3,6H2,1H3,(H,13,14)
DM5IA9W	CS	CC1=C(C=CC(=C1)Cl)OCCCC(=O)NO
DM5IA9W	IK	JHSXDAWGLCZYSM-UHFFFAOYSA-N
DM5IA9W	IU	4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide
DM5IA9W	CA	CAS 99873-43-5
DM5IA9W	CB	CHEBI:94504
DM5IA9W	DE	Discovery agent

DMBUH02	ID	DMBUH02
DMBUH02	DN	DRP-049
DMBUH02	HS	Investigative
DMBUH02	SN	TGF-beta inhibitor (fibrosis), Sosei Group
DMBUH02	CP	Sosei Group Corp
DMBUH02	DE	Fibrosis

DM5QUJV	ID	DM5QUJV
DM5QUJV	DN	Drug 311383
DM5QUJV	HS	Investigative
DM5QUJV	SN	311383
DM5QUJV	DE	Discovery agent

DMOIFBK	ID	DMOIFBK
DMOIFBK	DN	Drug 311440
DMOIFBK	HS	Investigative
DMOIFBK	SN	311440
DMOIFBK	DE	Discovery agent

DMXTCJ1	ID	DMXTCJ1
DMXTCJ1	DN	Drug 311951
DMXTCJ1	HS	Investigative
DMXTCJ1	SN	311951
DMXTCJ1	DE	Discovery agent

DM27ILS	ID	DM27ILS
DM27ILS	DN	Drug 311952
DM27ILS	HS	Investigative
DM27ILS	SN	311952
DM27ILS	DE	Discovery agent

DML4V73	ID	DML4V73
DML4V73	DN	Drug 7684380
DML4V73	HS	Investigative
DML4V73	SN	7684380
DML4V73	DE	Discovery agent

DME3WBQ	ID	DME3WBQ
DME3WBQ	DN	DS-437
DME3WBQ	HS	Investigative
DME3WBQ	SN	DS437
DME3WBQ	DT	Small molecular drug
DME3WBQ	PC	91827358
DME3WBQ	MW	397.5
DME3WBQ	FM	C15H23N7O4S
DME3WBQ	IC	InChI=1S/C15H23N7O4S/c1-2-17-15(25)18-3-4-27-5-8-10(23)11(24)14(26-8)22-7-21-9-12(16)19-6-20-13(9)22/h6-8,10-11,14,23-24H,2-5H2,1H3,(H2,16,19,20)(H2,17,18,25)/t8-,10+,11-,14?/m1/s1
DME3WBQ	CS	CCNC(=O)NCCSC[C@@H]1[C@@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)O
DME3WBQ	IK	CACMCLIHCDTJHL-XLAISSFRSA-N
DME3WBQ	IU	1-[2-[[(2S,3R,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]ethyl]-3-ethylurea
DME3WBQ	DE	Discovery agent

DMZGWQA	ID	DMZGWQA
DMZGWQA	DN	DS-AH-14
DMZGWQA	HS	Investigative
DMZGWQA	CP	Boehringer Ingelheim Corp
DMZGWQA	PC	19801656
DMZGWQA	MW	363.4
DMZGWQA	FM	C20H21N5O2
DMZGWQA	IC	InChI=1S/C20H21N5O2/c1-23-11-8-17-16(23)9-12-24(17)20(27)25-15-7-3-2-5-13(15)19(26)22-14-6-4-10-21-18(14)25/h2-7,10,16-17H,8-9,11-12H2,1H3,(H,22,26)
DMZGWQA	CS	CN1CCC2C1CCN2C(=O)N3C4=CC=CC=C4C(=O)NC5=C3N=CC=C5
DMZGWQA	IK	QBUPWEMXZYDTRC-UHFFFAOYSA-N
DMZGWQA	IU	11-(1-methyl-2,3,3a,5,6,6a-hexahydropyrrolo[3,2-b]pyrrole-4-carbonyl)-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMZGWQA	DE	Asthma

DMSTOB0	ID	DMSTOB0
DMSTOB0	DN	DSLET
DMSTOB0	HS	Investigative
DMSTOB0	SN	DSTLE; Dislet; [D-Ser2, Leu5, Thr6]-enkephalin
DMSTOB0	DT	Small molecular drug
DMSTOB0	PC	107847
DMSTOB0	MW	686.8
DMSTOB0	FM	C33H46N6O10
DMSTOB0	IC	InChI=1S/C33H46N6O10/c1-18(2)13-24(32(47)39-28(19(3)41)33(48)49)37-31(46)25(15-20-7-5-4-6-8-20)36-27(43)16-35-30(45)26(17-40)38-29(44)23(34)14-21-9-11-22(42)12-10-21/h4-12,18-19,23-26,28,40-42H,13-17,34H2,1-3H3,(H,35,45)(H,36,43)(H,37,46)(H,38,44)(H,39,47)(H,48,49)/t19-,23+,24+,25+,26-,28+/m1/s1
DMSTOB0	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O
DMSTOB0	IK	PKSODCLCMBUCPW-LVNBQDLPSA-N
DMSTOB0	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DMSTOB0	CA	CAS 75644-90-5
DMSTOB0	DE	Discovery agent

DM1LK0C	ID	DM1LK0C
DM1LK0C	DN	DSM1
DM1LK0C	HS	Investigative
DM1LK0C	DE	Malaria

DMZYQOB	ID	DMZYQOB
DMZYQOB	DN	DSM2
DMZYQOB	HS	Investigative
DMZYQOB	DE	Malaria

DM4EKHR	ID	DM4EKHR
DM4EKHR	DN	DSR-17759
DM4EKHR	HS	Investigative
DM4EKHR	SN	Glucagon receptor antagonist (type 2 diabetes), Dainippon Sumitomo
DM4EKHR	CP	Dainippon Sumitomo Pharma Co Ltd
DM4EKHR	DE	Non-insulin dependent diabetes

DMSVP1K	ID	DMSVP1K
DMSVP1K	DN	DSTBULET
DMSVP1K	HS	Investigative
DMSVP1K	SN	Dstbulet; CHEMBL298972; Tyrosyl-seryl(O-tert-butyl)-glycyl-phenylalanyl-leucyl-threonine; 111035-56-4; (2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2-methylpropan-2-yl)oxy]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid; Tyr-ser(O-tert-Bu)-gly-phe-leu-thr; AC1L2XS7; (Ser(2)(O-t-butyl)-leu(5))enkephalyl-thr(6); Leu(5) enkephalin, ser(2)(O-tert-butyl)-thr(6); GTPL3873; DTXSID40149447
DMSVP1K	DT	Small molecular drug
DMSVP1K	PC	130662
DMSVP1K	MW	742.9
DMSVP1K	FM	C37H54N6O10
DMSVP1K	IC	InChI=1S/C37H54N6O10/c1-21(2)16-27(35(50)43-31(22(3)44)36(51)52)41-34(49)28(18-23-10-8-7-9-11-23)40-30(46)19-39-33(48)29(20-53-37(4,5)6)42-32(47)26(38)17-24-12-14-25(45)15-13-24/h7-15,21-22,26-29,31,44-45H,16-20,38H2,1-6H3,(H,39,48)(H,40,46)(H,41,49)(H,42,47)(H,43,50)(H,51,52)/t22-,26+,27+,28+,29-,31+/m1/s1
DMSVP1K	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O
DMSVP1K	IK	DOMQMNWQZKXZCU-GUVNKXFDSA-N
DMSVP1K	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2-methylpropan-2-yl)oxy]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DMSVP1K	CA	CAS 111035-56-4
DMSVP1K	DE	Discovery agent

DMCKQF7	ID	DMCKQF7
DMCKQF7	DN	DT-2228
DMCKQF7	HS	Investigative
DMCKQF7	SN	MGluR2 NAMs (Alzheimer's disease/depression), DomainTherapeutics; Metabotropic glutamate receptor 2 modulators (Alzheimer's disease/depression), DomainTherapeutics
DMCKQF7	CP	Domain Therapeutics SA
DMCKQF7	DE	Major depressive disorder

DM3TMUK	ID	DM3TMUK
DM3TMUK	DN	DT-831j
DM3TMUK	HS	Investigative
DM3TMUK	SN	Factor Xa antagonists, Daiichi Sankyo
DM3TMUK	CP	Daiichi Sankyo Co Ltd
DM3TMUK	DE	Thrombosis

DM376J2	ID	DM376J2
DM376J2	DN	D-tartaric acid
DM376J2	HS	Investigative
DM376J2	SN	d-Tartaric acid; 147-71-7; D-(-)-Tartaric acid; (2S,3S)-2,3-Dihydroxysuccinic acid; D(-)-TARTARIC ACID; (2S,3S)-2,3-dihydroxybutanedioic acid; D-threaric acid; (-)-D-Tartaric acid; (-)-Tartaric acid; (2S,3S)-(-)-Tartaric acid; (S,S)-Tartaric acid; (-)-(S,S)-Tartaric acid; (S,S)-(-)-Tartaric acid; UNII-RRX6A4PL3C; Butanedioic acid, 2,3-dihydroxy-, (2S,3S)-; D-(-)-tartaricacid; (2S,3S)-Tartaric acid; RRX6A4PL3C; CHEBI:15672; MFCD00004238; D-Tartrate; (S,S)-Tartrate; D(-)-Tartaric acid, 99%; levo-Tartaric acid
DM376J2	DT	Small molecular drug
DM376J2	PC	439655
DM376J2	MW	150.09
DM376J2	FM	C4H6O6
DM376J2	IC	InChI=1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)/t1-,2-/m0/s1
DM376J2	CS	[C@H]([C@@H](C(=O)O)O)(C(=O)O)O
DM376J2	IK	FEWJPZIEWOKRBE-LWMBPPNESA-N
DM376J2	IU	(2S,3S)-2,3-dihydroxybutanedioic acid
DM376J2	CA	CAS 133-37-9
DM376J2	CB	CHEBI:15672
DM376J2	DE	Discovery agent

DMPKTB4	ID	DMPKTB4
DMPKTB4	DN	DTD
DMPKTB4	HS	Investigative
DMPKTB4	SN	DITHIANE DIOL; trans-1,2-Dithiane-4,5-diol; Oxidized dithiothreitol; (4R,5R)-1,2-dithiane-4,5-diol; D-4,5-Dihydroxy-1,2-dithiane; 16096-98-3; NSC 667089; trans-4,5-Dihydroxy-1,2-dithiane; o-DITHIANE, 4,5-DIHYDROXY-, D-; 14193-38-5; 51621-02-4; DTD; 1qtn; 2izx; AC1L97AN; trans-O-Dithiane-4,5-diol; Threo-O-dithiane-4,5-diol; SCHEMBL1628862; (4R,5R)-dithiane-4,5-diol; YPGMOWHXEQDBBV-IMJSIDKUSA-; CHEBI:42147; 1,2-Dithiane-4alpha,5beta-diol; YPGMOWHXEQDBBV-IMJSIDKUSA-N; 1,2-Dithiane-4,5-diol, trans-; ZINC4095547; AKOS022180307; DB01822
DMPKTB4	DT	Small molecular drug
DMPKTB4	PC	439407
DMPKTB4	MW	152.2
DMPKTB4	FM	C4H8O2S2
DMPKTB4	IC	InChI=1S/C4H8O2S2/c5-3-1-7-8-2-4(3)6/h3-6H,1-2H2/t3-,4-/m0/s1
DMPKTB4	CS	C1[C@@H]([C@H](CSS1)O)O
DMPKTB4	IK	YPGMOWHXEQDBBV-IMJSIDKUSA-N
DMPKTB4	IU	(4R,5R)-dithiane-4,5-diol
DMPKTB4	CA	CAS 16096-98-3
DMPKTB4	CB	CHEBI:42147
DMPKTB4	DE	Discovery agent

DMNS265	ID	DMNS265
DMNS265	DN	DTPA Conjugate
DMNS265	HS	Investigative
DMNS265	SN	CHEMBL415548; DTPA Conjugate
DMNS265	PC	44403823
DMNS265	MW	3127.4
DMNS265	FM	C123H180N26O53S8
DMNS265	IC	InChI=1S/C123H180N26O53S8/c1-122(2,41-19-23-57-201-105-69-88(84-29-9-5-10-30-84)67-91(130-105)86-33-13-7-14-34-86)120-139-141-143-148(120)47-21-17-37-101(150)124-43-25-53-195-59-63-199-65-61-197-55-27-45-126-111(162)93(76-203(171,172)173)132-115(166)97(80-207(183,184)185)136-118(169)99(82-209(189,190)191)135-114(165)95(78-205(177,178)179)129-103(152)40-39-90(128-104(153)71-146(73-108(156)157)51-49-145(72-107(154)155)50-52-147(74-109(158)159)75-110(160)161)113(164)134-96(79-206(180,181)182)117(168)138-100(83-210(192,193)194)119(170)137-98(81-208(186,187)188)116(167)133-94(77-204(174,175)176)112(163)127-46-28-56-198-62-66-200-64-60-196-54-26-44-125-102(151)38-18-22-48-149-121(140-142-144-149)123(3,4)42-20-24-58-202-106-70-89(85-31-11-6-12-32-85)68-92(131-106)87-35-15-8-16-36-87/h5-16,29-36,67-70,90,93-100H,17-28,37-66,71-83H2,1-4H3,(H,124,150)(H,125,151)(H,126,162)(H,127,163)(H,128,153)(H,129,152)(H,132,166)(H,133,167)(H,134,164)(H,135,165)(H,136,169)(H,137,170)(H,138,168)(H,154,155)(H,156,157)(H,158,159)(H,160,161)(H,171,172,173)(H,174,175,176)(H,177,178,179)(H,180,181,182)(H,183,184,185)(H,186,187,188)(H,189,190,191)(H,192,193,194)/t90-,93-,94-,95-,96-,97-,98-,99-,100-/m0/s1
DMNS265	CS	CC(C)(CCCCOC1=CC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)C4=NN=NN4CCCCC(=O)NCCCOCCOCCOCCCNC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CC[C@@H](C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCCCOCCOCCOCCCNC(=O)CCCCN5C(=NN=N5)C(C)(C)CCCCOC6=CC(=CC(=N6)C7=CC=CC=C7)C8=CC=CC=C8)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O
DMNS265	IK	DIGMLMRBDDSXMD-MSOXLDFBSA-N
DMNS265	IU	2-[2-[bis(carboxymethyl)amino]ethyl-[2-[[2-[[(2S)-1,5-bis[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[3-[2-[2-[3-[5-[5-[6-(4,6-diphenylpyridin-2-yl)oxy-2-methylhexan-2-yl]tetrazol-1-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propylamino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]-(carboxymethyl)amino]ethyl]amino]acetic acid
DMNS265	DE	Discovery agent

DM1JL5W	ID	DM1JL5W
DM1JL5W	DN	D-Trp8-SRIF-14
DM1JL5W	HS	Investigative
DM1JL5W	PC	44400604
DM1JL5W	MW	1637.9
DM1JL5W	FM	C76H104N18O19S2
DM1JL5W	IC	InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t41-,42?,43?,50-,51+,52-,53+,54-,55-,56+,57-,58-,59-,62+,63+/m0/s1
DM1JL5W	CS	C[C@@H](C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCCCN)CC(=O)N)CC2=CC=CC=C2)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CCCCN)C(C)O)CC6=CC=CC=C6)C(C)O)CO)C(=O)O)N
DM1JL5W	IK	NHXLMOGPVYXJNR-VOWFNQDTSA-N
DM1JL5W	IU	(4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25,28-tribenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DM1JL5W	DE	Discovery agent

DMKIML1	ID	DMKIML1
DMKIML1	DN	D-tryptophan
DMKIML1	HS	Investigative
DMKIML1	SN	D-Tryptophan; 153-94-6; H-D-Trp-OH; D(+)-Tryptophan; (R)-Tryptophan; D-TRYPTOPHANE; (2R)-2-amino-3-(1H-indol-3-yl)propanoic acid; D-Trytophane; H-D-Typ-OH; Tryptophan, D-; D-Trp; UNII-7NS97N9H1G; D-(+)-Tryptophan; (R)-2-Amino-3-(3-indolyl)propionic acid; EINECS 205-819-9; NSC 97942; (R)-(+)-2-Amino-3-(3-indolyl)propionic Acid; 7NS97N9H1G; CHEMBL292303; DTR; CHEBI:16296; QIVBCDIJIAJPQS-SECBINFHSA-N; MFCD00005647; D-alpha-Amino-3-indolepropionic acid; NCGC00093372-02; DSSTox_RID_82038; DSSTox_CID_26989; D(+)-Tryptophan,
DMKIML1	DT	Small molecular drug
DMKIML1	PC	9060
DMKIML1	MW	204.22
DMKIML1	FM	C11H12N2O2
DMKIML1	IC	InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m1/s1
DMKIML1	CS	C1=CC=C2C(=C1)C(=CN2)C[C@H](C(=O)O)N
DMKIML1	IK	QIVBCDIJIAJPQS-SECBINFHSA-N
DMKIML1	IU	(2R)-2-amino-3-(1H-indol-3-yl)propanoic acid
DMKIML1	CA	CAS 153-94-6
DMKIML1	CB	CHEBI:16296
DMKIML1	DE	Discovery agent

DM7PNOK	ID	DM7PNOK
DM7PNOK	DN	DTS-108
DM7PNOK	HS	Investigative
DM7PNOK	SN	SN-38 prodrug (cancer), Diatos
DM7PNOK	CP	Diatos SA
DM7PNOK	DE	Solid tumour/cancer

DMUKPO3	ID	DMUKPO3
DMUKPO3	DN	Duo3
DMUKPO3	HS	Investigative
DMUKPO3	SN	DUO3
DMUKPO3	DT	Small molecular drug
DMUKPO3	PC	86277833
DMUKPO3	MW	604.3
DMUKPO3	FM	C29H26Cl4N4O2+2
DMUKPO3	IC	InChI=1S/C29H26Cl4N4O2/c30-26-4-1-5-27(31)24(26)20-38-34-18-22-8-14-36(15-9-22)12-3-13-37-16-10-23(11-17-37)19-35-39-21-25-28(32)6-2-7-29(25)33/h1-2,4-11,14-19H,3,12-13,20-21H2/q+2/b34-18-,35-19-
DMUKPO3	CS	C1=CC(=C(C(=C1)Cl)CO/N=C\\C2=CC=[N+](C=C2)CCC[N+]3=CC=C(C=C3)/C=N\\OCC4=C(C=CC=C4Cl)Cl)Cl
DMUKPO3	IK	RAHLDBGBLYIYDN-OQWDZDEYSA-N
DMUKPO3	IU	(Z)-N-[(2,6-dichlorophenyl)methoxy]-1-[1-[3-[4-[(Z)-(2,6-dichlorophenyl)methoxyiminomethyl]pyridin-1-ium-1-yl]propyl]pyridin-1-ium-4-yl]methanimine
DMUKPO3	DE	Discovery agent

DM0CQIP	ID	DM0CQIP
DM0CQIP	DN	Duocarmycin
DM0CQIP	HS	Investigative
DM0CQIP	SN	AC1L1FCB; CTK7A0066; methyl 4-hydroxy-2,8-dimethyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]-1,2,3,6,7,8-hexahydropyrrolo[3,2-e]indole-2-carboxylate; methyl 4-hydroxy-2,8-dimethyl-1-oxo-6-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-7,8-dihydro-3H-pyrrolo[3,2-e]indole-2-carboxylate
DM0CQIP	DT	Small molecular drug
DM0CQIP	PC	3175
DM0CQIP	MW	509.5
DM0CQIP	FM	C26H27N3O8
DM0CQIP	IC	InChI=1S/C26H27N3O8/c1-11-10-29(14-9-15(30)20-18(17(11)14)23(31)26(2,28-20)25(33)37-6)24(32)13-7-12-8-16(34-3)21(35-4)22(36-5)19(12)27-13/h7-9,11,27-28,30H,10H2,1-6H3
DM0CQIP	CS	CC1CN(C2=CC(=C3C(=C12)C(=O)C(N3)(C)C(=O)OC)O)C(=O)C4=CC5=CC(=C(C(=C5N4)OC)OC)OC
DM0CQIP	IK	WQAYQZWERWNDPV-UHFFFAOYSA-N
DM0CQIP	IU	methyl 4-hydroxy-2,8-dimethyl-1-oxo-6-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-7,8-dihydro-3H-pyrrolo[3,2-e]indole-2-carboxylate
DM0CQIP	DE	Discovery agent

DM29PTO	ID	DM29PTO
DM29PTO	DN	Durhamycin A
DM29PTO	HS	Investigative
DM29PTO	SN	AC1LCSNY
DM29PTO	DT	Small molecular drug
DM29PTO	PC	6478419
DM29PTO	MW	1285.4
DM29PTO	FM	C62H92O28
DM29PTO	IC	InChI=1S/C62H92O28/c1-12-22(2)47-36(85-43-18-37(53(70)26(6)80-43)86-41-16-34(65)51(68)24(4)78-41)15-32-13-31-14-33(61(77-11)59(76)50(67)23(3)63)62(58(75)49(31)57(74)48(32)56(47)73)90-46-20-39(55(72)28(8)82-46)88-45-21-40(60(29(9)83-45)84-30(10)64)89-44-19-38(54(71)27(7)81-44)87-42-17-35(66)52(69)25(5)79-42/h13,15,22-29,33-35,37-46,50-55,60-63,65-74H,12,14,16-21H2,1-11H3/t22?,23?,24-,25-,26-,27-,28-,29-,33?,34-,35-,37-,38-,39-,40-,41+,42+,43+,44+,45+,46+,50?,51-,52-,53-,54-,55-,60+,61?,62?/m1/s1
DM29PTO	CS	CCC(C)C1=C(C2=C(C3=C(CC(C(C3=O)O[C@H]4C[C@H]([C@@H]([C@H](O4)C)O)O[C@H]5C[C@H]([C@H]([C@H](O5)C)OC(=O)C)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7C[C@H]([C@@H]([C@H](O7)C)O)O)C(C(=O)C(C(C)O)O)OC)C=C2C=C1O[C@H]8C[C@H]([C@@H]([C@H](O8)C)O)O[C@H]9C[C@H]([C@@H]([C@H](O9)C)O)O)O)O
DM29PTO	IK	GKQPKEYSNFSHDQ-XQGPSDOPSA-N
DM29PTO	IU	[(2R,3S,4R,6S)-6-[(2R,3R,4R,6S)-6-[[7-butan-2-yl-3-(3,4-dihydroxy-1-methoxy-2-oxopentyl)-6-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-1-oxo-3,4-dihydro-2H-anthracen-2-yl]oxy]-3-hydroxy-2-methyloxan-4-yl]oxy-4-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate
DM29PTO	DE	Discovery agent

DML7YPS	ID	DML7YPS
DML7YPS	DN	Duroquinone
DML7YPS	HS	Investigative
DML7YPS	SN	Duroquinone; 527-17-3; Tetramethyl-1,4-benzoquinone; Tetramethyl-p-benzoquinone; Tetramethylquinone; 2,3,5,6-Tetramethyl-1,4-benzoquinone; 2,3,5,6-tetramethylcyclohexa-2,5-diene-1,4-dione; Tetramethyl-p-quinone; 2,3,5,6-Tetramethylbenzoquinone; p-Benzoquinone, tetramethyl-; p-Benzoquinone, 2,3,5,6-tetramethyl-; 2,3,5,6-Tetramethyl-p-benzoquinone; 2,5-Cyclohexadiene-1,4-dione, 2,3,5,6-tetramethyl-; NSC 2068; CCRIS 2989; p-Benzoquinone, tetramethyl-, semiquinone; UNII-X0Q8791R69; EINECS 208-409-8
DML7YPS	DT	Small molecular drug
DML7YPS	PC	68238
DML7YPS	MW	164.2
DML7YPS	FM	C10H12O2
DML7YPS	IC	InChI=1S/C10H12O2/c1-5-6(2)10(12)8(4)7(3)9(5)11/h1-4H3
DML7YPS	CS	CC1=C(C(=O)C(=C(C1=O)C)C)C
DML7YPS	IK	WAMKWBHYPYBEJY-UHFFFAOYSA-N
DML7YPS	IU	2,3,5,6-tetramethylcyclohexa-2,5-diene-1,4-dione
DML7YPS	CA	CAS 527-17-3
DML7YPS	CB	CHEBI:42023
DML7YPS	DE	Discovery agent

DML4G6K	ID	DML4G6K
DML4G6K	DN	D-Val-L-boroPro
DML4G6K	HS	Investigative
DML4G6K	DT	Small molecular drug
DML4G6K	PC	44422921
DML4G6K	MW	215.08
DML4G6K	FM	C9H20BN2O3+
DML4G6K	IC	InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/p+1/t7-,8+/m0/s1
DML4G6K	CS	B([C@@H]1CCCN1C(=O)[C@@H](C(C)C)[NH3+])(O)O
DML4G6K	IK	FKCMADOPPWWGNZ-JGVFFNPUSA-O
DML4G6K	IU	[(2R)-1-[(2R)-2-boronopyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]azanium
DML4G6K	DE	Discovery agent

DM53079	ID	DM53079
DM53079	DN	DVDAVP
DM53079	HS	Investigative
DM53079	SN	1-Deamino-4-val-8-arg-vasopressin; Vasopressin, 1-deamino-4-val-8-arg-; 1-Deamino-4-valyl-8-arginine vasopressin; Vasopressin, 1-deamino-4-valyl-8-arginine-; (1-Deamino,4-valine)-8-D-argininevasopressin; 51980-16-6; Vasopressin 1-(3-mercaptopropanoic acid)-4-L-valine-8-L-arginine-
DM53079	DT	Small molecular drug
DM53079	PC	44419026
DM53079	MW	1040.2
DM53079	FM	C46H65N13O11S2
DM53079	IC	InChI=1S/C46H65N13O11S2/c1-25(2)38-44(69)56-32(22-35(47)61)41(66)57-33(45(70)59-18-7-11-34(59)43(68)54-29(10-6-17-51-46(49)50)39(64)52-23-36(48)62)24-72-71-19-16-37(63)53-30(21-27-12-14-28(60)15-13-27)40(65)55-31(42(67)58-38)20-26-8-4-3-5-9-26/h3-5,8-9,12-15,25,29-34,38,60H,6-7,10-11,16-24H2,1-2H3,(H2,47,61)(H2,48,62)(H,52,64)(H,53,63)(H,54,68)(H,55,65)(H,56,69)(H,57,66)(H,58,67)(H4,49,50,51)/t29-,30+,31+,32+,33+,34+,38+/m1/s1
DM53079	CS	CC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DM53079	IK	KEBRFHAVFOSSOX-WSFLLCRESA-N
DM53079	IU	(2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM53079	CA	CAS 43157-23-9
DM53079	DE	Discovery agent

DMWF9GQ	ID	DMWF9GQ
DMWF9GQ	DN	DVD-Ig
DMWF9GQ	HS	Investigative
DMWF9GQ	SN	DVD-Ig (arthritis); DVD-Ig (arthritis), Abbott; Dual anti-CD20/CD3 immunoglobulin, Abbott; Dual anti-TNF/PGE2 innunoglobulin, Abbott; Dual anti-IL-1 alpha/beta immunoglobulin (arthritis), Abbott; Dual anti-IL-12/IL-18 immunoglobulin, Abbott; 1D4.1-2.5; 1D4.1-ABT325
DMWF9GQ	CP	Abbott Laboratories
DMWF9GQ	DE	Solid tumour/cancer

DMEUVIP	ID	DMEUVIP
DMEUVIP	DN	DwFwLL-NH2
DMEUVIP	HS	Investigative
DMEUVIP	SN	CHEMBL449590; DwFwLL-NH2
DMEUVIP	DT	Small molecular drug
DMEUVIP	PC	44576251
DMEUVIP	MW	878
DMEUVIP	FM	C47H59N9O8
DMEUVIP	IC	InChI=1S/C47H59N9O8/c1-26(2)18-36(42(49)59)52-44(61)37(19-27(3)4)54-47(64)40(22-30-25-51-35-17-11-9-15-32(30)35)56-45(62)38(20-28-12-6-5-7-13-28)55-46(63)39(53-43(60)33(48)23-41(57)58)21-29-24-50-34-16-10-8-14-31(29)34/h5-17,24-27,33,36-40,50-51H,18-23,48H2,1-4H3,(H2,49,59)(H,52,61)(H,53,60)(H,54,64)(H,55,63)(H,56,62)(H,57,58)/t33-,36-,37-,38-,39+,40+/m0/s1
DMEUVIP	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CC(=O)O)N
DMEUVIP	IK	AYYVHEGPWNZVTO-YAQHVWCZSA-N
DMEUVIP	IU	(3S)-3-amino-4-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMEUVIP	DE	Discovery agent

DMW9GT7	ID	DMW9GT7
DMW9GT7	DN	DwLIP-GCGRrx
DMW9GT7	HS	Investigative
DMW9GT7	SN	UNII-T450D0Q71D; 1-Nitro-9-(3-dimethylaminopropylamino)-acridine dihydrochloride; 6514-85-8; Nitracrine HCl; ACRIDINE, 9-((3-(DIMETHYLAMINO)PROPYL)AMINO)-1-NITRO-, DIHYDROCHLORIDE; T450D0Q71D; 1,3-Propanediamine, N,N-dimethyl-N'-(1-nitro-9-acridinyl)-, dihydrochloride; CCRIS 9297; AC1L2LHF; SCHEMBL1652148; LS-14357; 1-NITRO-9-(DIMETHYLAMINOPROPYLAMINO)ACRIDINE DIHYDROCHLORIDE; dimethyl-[3-[(1-nitroacridin-9-yl)azaniumyl]propyl]azanium dichloride
DMW9GT7	CP	ISIS
DMW9GT7	DT	Small molecular drug
DMW9GT7	PC	23015
DMW9GT7	MW	397.3
DMW9GT7	FM	C18H22Cl2N4O2
DMW9GT7	IC	InChI=1S/C18H20N4O2.2ClH/c1-21(2)12-6-11-19-18-13-7-3-4-8-14(13)20-15-9-5-10-16(17(15)18)22(23)24;;/h3-5,7-10H,6,11-12H2,1-2H3,(H,19,20);2*1H
DMW9GT7	CS	C[NH+](C)CCC[NH2+]C1=C2C(=NC3=CC=CC=C31)C=CC=C2[N+](=O)[O-].[Cl-].[Cl-]
DMW9GT7	IK	XBHIADYHFGJGSK-UHFFFAOYSA-N
DMW9GT7	IU	dimethyl-[3-[(1-nitroacridin-9-yl)azaniumyl]propyl]azanium;dichloride
DMW9GT7	CA	CAS 6514-85-8
DMW9GT7	DE	Diabetic complication

DMF9M06	ID	DMF9M06
DMF9M06	DN	DX-2400
DMF9M06	HS	Investigative
DMF9M06	SN	DX-2410; MMP inhibitors (fully human antibodies), Dyax
DMF9M06	CP	Dyax Corp
DMF9M06	DE	Solid tumour/cancer

DM3BWTM	ID	DM3BWTM
DM3BWTM	DN	DX-2500
DM3BWTM	HS	Investigative
DM3BWTM	SN	Anti-FcRn antibody (autoimmune disorder), Dyax Corp
DM3BWTM	CP	Dyax Corp
DM3BWTM	DT	Antibody
DM3BWTM	DE	Ischemic heart disease

DMZWAQ3	ID	DMZWAQ3
DMZWAQ3	DN	DXL-625
DMZWAQ3	HS	Investigative
DMZWAQ3	SN	DXLr-120; Anti-CD20 monoclonal antibodies (DXL, cancer), InNexus; Autophilic peptide conjuagted rituximab (rheumatoid arthritis/NHL/CLL), InNexus; Anti-CD20 monoclonal antibodies (DXL, non-Hodgkin's lymphoma/ rheumatoid arthritis), InNexus
DMZWAQ3	CP	InNexus Biotechnology Inc
DMZWAQ3	DE	Chronic lymphocytic leukaemia

DM1ROU7	ID	DM1ROU7
DM1ROU7	DN	D-xylulose
DM1ROU7	HS	Investigative
DM1ROU7	SN	D-threo-2-Pentulose; D-threo-pent-2-ulose; D-xylulose; HY-W010256; Lyxulose; Threo-2-pentulose (9CI); Threo-2-pentulose(9ci); Threo-2-pentulose, D-; Xylulose D-isomer [MI]; Xylulose, D-; YSC9WAF8X1; ZAQJHHRNXZUBTE-WUJLRWPWSA-N; ZINC100028356; threo-2-Pentulose; xylulose; (3S,4R)-1,3,4,5-tetrahydroxypentan-2-one; 551-84-8; 5962-29-8; AC1NRDJS; AKOS027320628; CHEBI:17140; CHEMBL195094; CS-W010972; CTK5A3156; D-Xul; DTXSID70415364; FCH4007851; FT-0625634; SCHEMBL37387; UNII-YSC9WAF8X1; XUL
DM1ROU7	PC	5289590
DM1ROU7	MW	150.13
DM1ROU7	FM	C5H10O5
DM1ROU7	IC	ZAQJHHRNXZUBTE-WUJLRWPWSA-N
DM1ROU7	CS	C(C(C(C(=O)CO)O)O)O
DM1ROU7	IK	1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h3,5-8,10H,1-2H2/t3-,5+/m1/s1
DM1ROU7	IU	(3S,4R)-1,3,4,5-tetrahydroxypentan-2-one
DM1ROU7	CA	CAS 551-84-8
DM1ROU7	CB	CHEBI:17140
DM1ROU7	DE	Discovery agent

DMFJ3VC	ID	DMFJ3VC
DMFJ3VC	DN	DY131
DMFJ3VC	HS	Investigative
DMFJ3VC	SN	DY-131; GSK9089
DMFJ3VC	DT	Small molecular drug
DMFJ3VC	PC	5497124
DMFJ3VC	MW	311.4
DMFJ3VC	FM	C18H21N3O2
DMFJ3VC	IC	InChI=1S/C18H21N3O2/c1-3-21(4-2)16-9-5-14(6-10-16)13-19-20-18(23)15-7-11-17(22)12-8-15/h5-13,22H,3-4H2,1-2H3,(H,20,23)/b19-13+
DMFJ3VC	CS	CCN(CC)C1=CC=C(C=C1)/C=N/NC(=O)C2=CC=C(C=C2)O
DMFJ3VC	IK	WLKOCYWYAWBGKY-CPNJWEJPSA-N
DMFJ3VC	IU	N-[(E)-[4-(diethylamino)phenyl]methylideneamino]-4-hydroxybenzamide
DMFJ3VC	CA	CAS 95167-41-2
DMFJ3VC	CB	CHEBI:93087
DMFJ3VC	DE	Discovery agent

DMSPVLM	ID	DMSPVLM
DMSPVLM	DN	dynorphin B
DMSPVLM	HS	Investigative
DMSPVLM	SN	rimorphin
DMSPVLM	DT	Small molecular drug
DMSPVLM	PC	25075991
DMSPVLM	MW	1570.8
DMSPVLM	FM	C74H115N21O17
DMSPVLM	IC	InChI=1S/C74H115N21O17/c1-40(2)34-53(91-68(107)54(36-44-18-10-8-11-19-44)86-58(100)39-84-57(99)38-85-62(101)48(76)35-46-25-27-47(97)28-26-46)67(106)89-51(24-17-33-83-74(80)81)63(102)87-50(23-16-32-82-73(78)79)64(103)90-52(29-30-56(77)98)65(104)92-55(37-45-20-12-9-13-21-45)69(108)88-49(22-14-15-31-75)66(105)93-59(41(3)4)70(109)94-60(42(5)6)71(110)95-61(43(7)96)72(111)112/h8-13,18-21,25-28,40-43,48-55,59-61,96-97H,14-17,22-24,29-39,75-76H2,1-7H3,(H2,77,98)(H,84,99)(H,85,101)(H,86,100)(H,87,102)(H,88,108)(H,89,106)(H,90,103)(H,91,107)(H,92,104)(H,93,105)(H,94,109)(H,95,110)(H,111,112)(H4,78,79,82)(H4,80,81,83)/t43-,48+,49+,50+,51+,52+,53+,54+,55+,59+,60+,61+/m1/s1
DMSPVLM	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N)O
DMSPVLM	IK	AGTSSZRZBSNTGQ-ITZCFHCWSA-N
DMSPVLM	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoic acid
DMSPVLM	CA	CAS 83335-41-5
DMSPVLM	DE	Discovery agent

DMM92LG	ID	DMM92LG
DMM92LG	DN	Dynorphin(1-8)
DMM92LG	HS	Investigative
DMM92LG	DT	Small molecular drug
DMM92LG	PC	44273338
DMM92LG	DE	Discovery agent

DMIZQTX	ID	DMIZQTX
DMIZQTX	DN	DYSIDENIN
DMIZQTX	HS	Investigative
DMIZQTX	SN	Isodysidenin; Dysidenine; Isodysidenine; (+)-Isodysidenin; 67528-34-1; 65647-65-6; AC1L2TGX; AC1Q5L6U; 5,5,5-trichloro-n2-methyl-n-[1-(1,3-thiazol-2-yl)ethyl]-n2-(4,4,4-trichloro-3-methylbutanoyl)leucinamide; A836069; 5,5,5-trichloro-4-methyl-2-[methyl-(4,4,4-trichloro-3-methylbutanoyl)amino]-N-[1-(1,3-thiazol-2-yl)ethyl]pentanamide; 5,5,5-trichloro-4-methyl-2-[methyl-(4,4,4-trichloro-3-methyl-1-oxobutyl)amino]-N-[1-(2-thiazolyl)ethyl]pentanamide; Pentanamide, 5,5,5-trichloro-4-methyl-2-(methyl(4,4,4-trichloro-3-methyl
DMIZQTX	DT	Small molecular drug
DMIZQTX	PC	10007601
DMIZQTX	MW	546.2
DMIZQTX	FM	C17H23Cl6N3O2S
DMIZQTX	IC	InChI=1S/C17H23Cl6N3O2S/c1-9(16(18,19)20)7-12(14(28)25-11(3)15-24-5-6-29-15)26(4)13(27)8-10(2)17(21,22)23/h5-6,9-12H,7-8H2,1-4H3,(H,25,28)/t9-,10-,11-,12-/m0/s1
DMIZQTX	CS	C[C@@H](C[C@@H](C(=O)N[C@@H](C)C1=NC=CS1)N(C)C(=O)C[C@H](C)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl
DMIZQTX	IK	BFVRAKVNXYQMID-BJDJZHNGSA-N
DMIZQTX	IU	(2S,4S)-5,5,5-trichloro-4-methyl-2-[methyl-[(3S)-4,4,4-trichloro-3-methylbutanoyl]amino]-N-[(1S)-1-(1,3-thiazol-2-yl)ethyl]pentanamide
DMIZQTX	DE	Discovery agent

DMNYQL9	ID	DMNYQL9
DMNYQL9	DN	DYSIDINE
DMNYQL9	HS	Investigative
DMNYQL9	SN	Dysidine; CHEBI:65816; 2-[(4-hydroxy-3,6-dioxo-5-{[(1R,2R,4aS,8aS)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-2-yl]methyl}cyclohexa-1,4-dien-1-yl)amino]ethanesulfonic acid; dicidin
DMNYQL9	DT	Small molecular drug
DMNYQL9	PC	10321583
DMNYQL9	MW	451.6
DMNYQL9	FM	C23H33NO6S
DMNYQL9	IC	InChI=1S/C23H33NO6S/c1-14-6-5-7-17-15(2)22(3,8-9-23(14,17)4)13-16-20(26)18(12-19(25)21(16)27)24-10-11-31(28,29)30/h6,12,15,17,24,26H,5,7-11,13H2,1-4H3,(H,28,29,30)/t15-,17+,22-,23-/m1/s1
DMNYQL9	CS	C[C@@H]1[C@@H]2CCC=C([C@]2(CC[C@]1(C)CC3=C(C(=CC(=O)C3=O)NCCS(=O)(=O)O)O)C)C
DMNYQL9	IK	JUZCKAMLAZUOHD-CIVZFWGOSA-N
DMNYQL9	IU	2-[[5-[[(1R,2R,4aS,8aS)-1,2,4a,5-tetramethyl-1,3,4,7,8,8a-hexahydronaphthalen-2-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]ethanesulfonic acid
DMNYQL9	CB	CHEBI:65816
DMNYQL9	DE	Discovery agent

DM0EBAF	ID	DM0EBAF
DM0EBAF	DN	dysiherbaine
DM0EBAF	HS	Investigative
DM0EBAF	SN	dysiherbaine; (2r,3ar,6s,7r,7ar)-2-[(2s)-2-Amino-2-Carboxyethyl]-6-Hydroxy-7-(Methylamino)hexahydro-2h-Furo[3,2-B]pyran-2-Carboxylic Acid; DYH; CHEMBL221142; GTPL4185; SCHEMBL12409079; BDBM85740; (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)hexahydro-2H-furo[3,2-b]pyran-2-carboxylic acid (non-preferred name); (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)-hexahydro-2H-furo[3,2-b]pyran-2-carboxylic acid
DM0EBAF	DT	Small molecular drug
DM0EBAF	PC	9839436
DM0EBAF	MW	304.3
DM0EBAF	FM	C12H20N2O7
DM0EBAF	IC	InChI=1S/C12H20N2O7/c1-14-8-6(15)4-20-7-3-12(11(18)19,21-9(7)8)2-5(13)10(16)17/h5-9,14-15H,2-4,13H2,1H3,(H,16,17)(H,18,19)/t5-,6+,7+,8+,9-,12+/m0/s1
DM0EBAF	CS	CN[C@@H]1[C@@H](CO[C@H]2[C@@H]1O[C@@](C2)(C[C@@H](C(=O)O)N)C(=O)O)O
DM0EBAF	IK	YUSZFKPLFIQTGF-FDNSHYBFSA-N
DM0EBAF	IU	(2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-carboxylic acid
DM0EBAF	DE	Discovery agent

DMU42C1	ID	DMU42C1
DMU42C1	DN	DYSINOSIN A
DMU42C1	HS	Investigative
DMU42C1	SN	dysinosin A; CHEMBL502639
DMU42C1	DT	Small molecular drug
DMU42C1	PC	10439038
DMU42C1	MW	632.7
DMU42C1	FM	C26H44N6O10S
DMU42C1	IC	InChI=1S/C26H44N6O10S/c1-14(2)8-17(30-24(36)22(41-3)13-42-43(38,39)40)25(37)32-18-11-21(34)20(33)10-16(18)9-19(32)23(35)29-6-4-15-5-7-31(12-15)26(27)28/h5,14,16-22,33-34H,4,6-13H2,1-3H3,(H6,27,28,29,30,35,36,38,39,40)/t16-,17-,18+,19+,20+,21+,22-/m1/s1
DMU42C1	CS	CC(C)C[C@H](C(=O)N1[C@H]2C[C@@H]([C@H](C[C@H]2C[C@H]1C(=O)NCCC3=CC[N+](=C(N)N)C3)O)O)NC(=O)[C@@H](COS(=O)(=O)[O-])OC
DMU42C1	IK	FJKGWCOVORXKMM-FAWMDMTCSA-N
DMU42C1	IU	[(2R)-3-[[(2R)-1-[(2S,3aR,5S,6S,7aS)-2-[2-[1-(diaminomethylidene)-2,5-dihydropyrrol-1-ium-3-yl]ethylcarbamoyl]-5,6-dihydroxy-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-2-methoxy-3-oxopropyl] sulfate
DMU42C1	DE	Discovery agent

DM0JXBK	ID	DM0JXBK
DM0JXBK	DN	DZNep
DM0JXBK	HS	Investigative
DM0JXBK	SN	3-deazaneplanocin A
DM0JXBK	DT	Small molecular drug
DM0JXBK	PC	73087
DM0JXBK	MW	262.26
DM0JXBK	FM	C12H14N4O3
DM0JXBK	IC	InChI=1S/C12H14N4O3/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14)/t8-,10-,11+/m1/s1
DM0JXBK	CS	C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N
DM0JXBK	IK	OMKHWTRUYNAGFG-IEBDPFPHSA-N
DM0JXBK	IU	(1S,2R,5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
DM0JXBK	CA	CAS 102052-95-9
DM0JXBK	DE	Discovery agent

DM76UJY	ID	DM76UJY
DM76UJY	DN	E[c(RGDyK)]2
DM76UJY	HS	Investigative
DM76UJY	SN	E[c(RGDyK)]2; CHEMBL414385
DM76UJY	PC	44388431
DM76UJY	MW	1422.5
DM76UJY	FM	C62H91N19O20
DM76UJY	IC	InChI=1S/C62H91N19O20/c63-61(64)69-24-5-9-37-53(94)71-31-48(87)74-44(29-50(89)90)59(100)80-42(27-33-11-15-35(83)16-12-33)57(98)78-39(55(96)76-37)7-1-3-22-67-46(85)20-19-41(73-47(86)21-26-82)52(93)68-23-4-2-8-40-56(97)77-38(10-6-25-70-62(65)66)54(95)72-32-49(88)75-45(30-51(91)92)60(101)81-43(58(99)79-40)28-34-13-17-36(84)18-14-34/h11-18,37-45,82-84H,1-10,19-32H2,(H,67,85)(H,68,93)(H,71,94)(H,72,95)(H,73,86)(H,74,87)(H,75,88)(H,76,96)(H,77,97)(H,78,98)(H,79,99)(H,80,100)(H,81,101)(H,89,90)(H,91,92)(H4,63,64,69)(H4,65,66,70)/t37-,38-,39-,40?,41?,42+,43+,44-,45-/m1/s1
DM76UJY	CS	C1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN=C(N)N)CCCCNC(=O)CCC(C(=O)NCCCCC2C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N2)CC3=CC=C(C=C3)O)CC(=O)O)CCCN=C(N)N)NC(=O)CCO)CC4=CC=C(C=C4)O)CC(=O)O
DM76UJY	IK	ACEBGKIPKRNNIW-JMIOTQLUSA-N
DM76UJY	IU	2-[(2R,5S,8R,11R)-8-[4-[[5-[4-[(5R,11R,14S)-11-(carboxymethyl)-5-[3-(diaminomethylideneamino)propyl]-14-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]butylamino]-4-(3-hydroxypropanoylamino)-5-oxopentanoyl]amino]butyl]-11-[3-(diaminomethylideneamino)propyl]-5-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM76UJY	DE	Discovery agent

DMS1LZI	ID	DMS1LZI
DMS1LZI	DN	E[c(RGDyK)]2-PTX conjugate
DMS1LZI	HS	Investigative
DMS1LZI	PC	91933274
DMS1LZI	MW	2258.4
DMS1LZI	FM	C109H140N20O33
DMS1LZI	IC	InChI=1S/C109H140N20O33/c1-57-76(53-109(156)91(161-102(154)64-26-14-9-15-27-64)89-107(6,77(134)52-78-108(89,56-158-78)162-59(3)131)90(143)87(159-58(2)130)85(57)106(109,4)5)160-103(155)88(86(62-22-10-7-11-23-62)129-92(144)63-24-12-8-13-25-63)157-47-42-80(136)120-71(93(145)115-44-19-17-29-70-97(149)124-68(31-21-46-117-105(112)113)95(147)119-55-82(138)122-75(51-84(141)142)101(153)128-73(99(151)126-70)49-61-34-38-66(133)39-35-61)40-41-79(135)114-43-18-16-28-69-96(148)123-67(30-20-45-116-104(110)111)94(146)118-54-81(137)121-74(50-83(139)140)100(152)127-72(98(150)125-69)48-60-32-36-65(132)37-33-60/h7-15,22-27,32-39,67-78,86-89,91,132-134,156H,16-21,28-31,40-56H2,1-6H3,(H,114,135)(H,115,145)(H,118,146)(H,119,147)(H,120,136)(H,121,137)(H,122,138)(H,123,148)(H,124,149)(H,125,150)(H,126,151)(H,127,152)(H,128,153)(H,129,144)(H,139,140)(H,141,142)(H4,110,111,116)(H4,112,113,117)/t67-,68-,69-,70?,71?,72+,73+,74-,75-,76?,77+,78?,86+,87-,88+,89?,91+,107-,108+,109-/m1/s1
DMS1LZI	CS	CC1=C2[C@H](C(=O)[C@@]3([C@H](CC4[C@](C3[C@@H]([C@@](C2(C)C)(CC1OC(=O)[C@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)OCCC(=O)NC(CCC(=O)NCCCC[C@@H]7C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N7)CC8=CC=C(C=C8)O)CC(=O)O)CCCNC(=N)N)C(=O)NCCCCC9C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N9)CC1=CC=C(C=C1)O)CC(=O)O)CCCNC(=N)N)O)OC(=O)C1=CC=CC=C1)(CO4)OC(=O)C)O)C)OC(=O)C
DMS1LZI	IK	YUHVDRZERRVMDC-XLKUZTQTSA-N
DMS1LZI	IU	2-[(2R,5S,8R,11R)-8-[4-[[4-[3-[(1S,2S)-1-benzamido-3-[[(1S,2S,4S,9S,10S,12R)-4,12-diacetyloxy-2-benzoyloxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-15-yl]oxy]-3-oxo-1-phenylpropan-2-yl]oxypropanoylamino]-5-[4-[(5R,11R,14S)-5-(3-carbamimidamidopropyl)-11-(carboxymethyl)-14-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]butylamino]-5-oxopentanoyl]amino]butyl]-11-(3-carbamimidamidopropyl)-5-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMS1LZI	DE	Discovery agent

DMA9CZV	ID	DMA9CZV
DMA9CZV	DN	E-003
DMA9CZV	HS	Investigative
DMA9CZV	SN	Bcl-xL modulators (oral, cancer); Ensemblin macrocycle (oral, cancer), Ensemble Therapeutics; Bcl-xL modulators (oral, cancer), Ensemble
DMA9CZV	CP	Ensemble Therapeutics Corp
DMA9CZV	DE	Solid tumour/cancer

DMHPFMV	ID	DMHPFMV
DMHPFMV	DN	E-1455
DMHPFMV	HS	Investigative
DMHPFMV	SN	E-1043; Clozapine prodrug (oral, ECLYPS), ProCor Pharmaceuticals
DMHPFMV	CP	ProCor Pharmaceuticals
DMHPFMV	PC	74890720
DMHPFMV	MW	277.2
DMHPFMV	FM	C14H20BNO2S
DMHPFMV	IC	InChI=1S/C14H20BNO2S/c1-13(2)14(3,4)18-15(17-13)9-8-11-6-7-12(19-5)16-10-11/h6-10H,1-5H3/b9-8+
DMHPFMV	CS	B1(OC(C(O1)(C)C)(C)C)/C=C/C2=CN=C(C=C2)SC
DMHPFMV	IK	MTGNTJQBNWXEMY-CMDGGOBGSA-N
DMHPFMV	IU	2-methylsulfanyl-5-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridine
DMHPFMV	DE	Schizophrenia

DME5JBH	ID	DME5JBH
DME5JBH	DN	E-3024
DME5JBH	HS	Investigative
DME5JBH	SN	DPP-IV inhibitors (type 2 diabetes), Eisai; ER-260891; IDDBCP150088; IDDBCP150131
DME5JBH	DE	Discovery agent

DMGPRT7	ID	DMGPRT7
DMGPRT7	DN	E339-3D6
DMGPRT7	HS	Investigative
DMGPRT7	SN	E339-3D6; GTPL6187; 4-{[(1-{[2-(1-benzyl-3-methyl-1H-imidazol-3-ium-4-yl)-1-[(1-methylpiperidin-1-ium-4-yl)carbamoyl]ethyl]carbamoyl}-5-({[12-({4-[6-(diethylamino)-3-(diethyliminiumyl)-3H-xanthen-9-yl]-3-sulfobenzene}sulfonamido)dodecyl]carbamoyl}amino)pentyl)carbamoyl]methyl}-2-imino-3-methyl-2,3-dihydro-1,3-thiazol-3-ium tritrifluoroacetate
DMGPRT7	DT	Small molecular drug
DMGPRT7	PC	73755182
DMGPRT7	MW	1747.9
DMGPRT7	FM	C78H105F9N13O16S3+
DMGPRT7	IC	InChI=1S/C72H101N13O10S3.3C2HF3O2/c1-8-84(9-2)54-30-33-59-64(44-54)95-65-45-55(85(10-3)11-4)31-34-60(65)68(59)61-35-32-58(47-66(61)98(92,93)94)97(90,91)76-40-25-19-17-15-13-12-14-16-18-24-38-74-72(89)75-39-26-23-29-62(78-67(86)46-57-50-96-71(73)82(57)7)69(87)79-63(70(88)77-53-36-41-80(5)42-37-53)43-56-49-83(51-81(56)6)48-52-27-21-20-22-28-52;3*3-2(4,5)1(6)7/h20-22,27-28,30-35,44-45,47,49-51,53,62-63,73,76H,8-19,23-26,29,36-43,46,48H2,1-7H3,(H4-2,74,75,77,78,79,86,87,88,89,92,93,94);3*(H,6,7)/p+1
DMGPRT7	CS	CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCCCCCCCCNC(=O)NCCCCC(C(=O)NC(CC5=C[N+](=CN5C)CC6=CC=CC=C6)C(=O)NC7CC[NH+](CC7)C)NC(=O)CC8=CSC(=N)[NH+]8C)S(=O)(=O)O.C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-]
DMGPRT7	IK	SEZVZMIKECAWEG-UHFFFAOYSA-O
DMGPRT7	IU	[9-[4-[12-[[6-[[3-(1-benzyl-3-methylimidazol-1-ium-4-yl)-1-[(1-methylpiperidin-1-ium-4-yl)amino]-1-oxopropan-2-yl]amino]-5-[[2-(2-imino-3-methyl-3H-1,3-thiazol-3-ium-4-yl)acetyl]amino]-6-oxohexyl]carbamoylamino]dodecylsulfamoyl]-2-sulfophenyl]-6-(diethylamino)xanthen-3-ylidene]-diethylazanium;2,2,2-trifluoroacetate
DMGPRT7	DE	Discovery agent

DMLZU09	ID	DMLZU09
DMLZU09	DN	E-52862
DMLZU09	HS	Investigative
DMLZU09	SN	S1RA; UNII-ZW18DSD1H4; ZW18DSD1H4; GTPL10431; MR309; BCP08990; AOB87704; sigma 1 receptor antagonist (S1RA); ZINC95000617; s6754; BDBM50396352; AKOS026750239; SB17181; MCULE-6623106441; CS-2187; compound 28 [PMID: 22784008]; NCGC00371119-04; DA-40938; HY-18099; FT-0700391; E52862; A12504; Q7388203
DMLZU09	TC	Antiviral Agents
DMLZU09	DT	Small molecular drug
DMLZU09	PC	44247568
DMLZU09	MW	337.4
DMLZU09	FM	C20H23N3O2
DMLZU09	IC	InChI=1S/C20H23N3O2/c1-16-14-20(25-13-10-22-8-11-24-12-9-22)21-23(16)19-7-6-17-4-2-3-5-18(17)15-19/h2-7,14-15H,8-13H2,1H3
DMLZU09	CS	CC1=CC(=NN1C2=CC3=CC=CC=C3C=C2)OCCN4CCOCC4
DMLZU09	IK	DGPGXHRHNRYVDH-UHFFFAOYSA-N
DMLZU09	IU	4-[2-(5-methyl-1-naphthalen-2-ylpyrazol-3-yl)oxyethyl]morpholine
DMLZU09	CA	CAS 878141-96-9
DMLZU09	DE	Coronavirus Disease 2019 (COVID-19)

DM0O8KR	ID	DM0O8KR
DM0O8KR	DN	E55888
DM0O8KR	HS	Investigative
DM0O8KR	SN	E-55888; E 55888
DM0O8KR	DT	Small molecular drug
DM0O8KR	PC	24825775
DM0O8KR	MW	257.37
DM0O8KR	FM	C16H23N3
DM0O8KR	IC	InChI=1S/C16H23N3/c1-12-16(13(2)19(5)17-12)15-8-6-7-14(11-15)9-10-18(3)4/h6-8,11H,9-10H2,1-5H3
DM0O8KR	CS	CC1=C(C(=NN1C)C)C2=CC=CC(=C2)CCN(C)C
DM0O8KR	IK	MFUWRMRKXKCSPL-UHFFFAOYSA-N
DM0O8KR	IU	N,N-dimethyl-2-[3-(1,3,5-trimethylpyrazol-4-yl)phenyl]ethanamine
DM0O8KR	CA	CAS 1034142-33-0
DM0O8KR	DE	Discovery agent

DM8LPBF	ID	DM8LPBF
DM8LPBF	DN	E5700
DM8LPBF	HS	Investigative
DM8LPBF	SN	E 5700; E-5700
DM8LPBF	DT	Small molecular drug
DM8LPBF	PC	56947067
DM8LPBF	MW	433.5
DM8LPBF	FM	C26H31N3O3
DM8LPBF	IC	InChI=1S/C26H31N3O3/c1-32-24-17-29(16-23(24)30)25-8-7-20(22(27-25)15-19-5-3-2-4-6-19)9-12-26(31)18-28-13-10-21(26)11-14-28/h2-8,21,23-24,30-31H,10-11,13-18H2,1H3/t23-,24+,26-/m0/s1
DM8LPBF	CS	CO[C@@H]1CN(C[C@@H]1O)C2=NC(=C(C=C2)C#C[C@@]3(CN4CCC3CC4)O)CC5=CC=CC=C5
DM8LPBF	IK	NDEOTZXSBKCQLS-GSLIJJQTSA-N
DM8LPBF	IU	(3S)-3-[2-[2-benzyl-6-[(3S,4R)-3-hydroxy-4-methoxypyrrolidin-1-yl]pyridin-3-yl]ethynyl]-1-azabicyclo[2.2.2]octan-3-ol
DM8LPBF	DE	Discovery agent

DMMOPAK	ID	DMMOPAK
DMMOPAK	DN	E-64
DMMOPAK	HS	Investigative
DMMOPAK	SN	e-64; 66701-25-5; CHEMBL189382; AC1NEEQI; SCHEMBL13283063; HMS3369L13; trans-Epoxysuccinyl-leucylamido-[4-guanidino]butane; [L-3-trans-carboxy-oxiran-2-carbonyl]-Leu-agmatin; trans-Epoxysuccinyl-leucylamido- [4-guanidino]butane; [L -3-trans-carboxy- oxiran-2-carbonyl]-Leu-agmatin; 3-({1-[(4-carbamimidamidobutyl)carbamoyl]-3-methylbutyl}carbamoyl)oxirane-2-carboxylic acid; 3-[[1-[4-(diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DMMOPAK	DT	Small molecular drug
DMMOPAK	PC	123985
DMMOPAK	MW	357.41
DMMOPAK	FM	C15H27N5O5
DMMOPAK	IC	InChI=1S/C15H27N5O5/c1-8(2)7-9(20-13(22)10-11(25-10)14(23)24)12(21)18-5-3-4-6-19-15(16)17/h8-11H,3-7H2,1-2H3,(H,18,21)(H,20,22)(H,23,24)(H4,16,17,19)/t9-,10-,11-/m0/s1
DMMOPAK	CS	CC(C)C[C@@H](C(=O)NCCCCN=C(N)N)NC(=O)[C@@H]1[C@H](O1)C(=O)O
DMMOPAK	IK	LTLYEAJONXGNFG-DCAQKATOSA-N
DMMOPAK	IU	(2S,3S)-3-[[(2S)-1-[4-(diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DMMOPAK	CA	CAS 66701-25-5
DMMOPAK	CB	CHEBI:30270
DMMOPAK	DE	Discovery agent

DM7LGAF	ID	DM7LGAF
DM7LGAF	DN	E6801
DM7LGAF	HS	Investigative
DM7LGAF	SN	E 6801; E-6801
DM7LGAF	DT	Small molecular drug
DM7LGAF	PC	10202564
DM7LGAF	MW	423.9
DM7LGAF	FM	C17H18ClN5O2S2
DM7LGAF	IC	InChI=1S/C17H18ClN5O2S2/c1-22(2)6-5-11-10-19-14-4-3-12(9-13(11)14)21-27(24,25)16-15(18)20-17-23(16)7-8-26-17/h3-4,7-10,19,21H,5-6H2,1-2H3
DM7LGAF	CS	CN(C)CCC1=CNC2=C1C=C(C=C2)NS(=O)(=O)C3=C(N=C4N3C=CS4)Cl
DM7LGAF	IK	RZAXUKVIIWUIOM-UHFFFAOYSA-N
DM7LGAF	IU	6-chloro-N-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide
DM7LGAF	CA	CAS 528859-04-3
DM7LGAF	DE	Discovery agent

DMJ2P0N	ID	DMJ2P0N
DMJ2P0N	DN	E-6837
DMJ2P0N	HS	Investigative
DMJ2P0N	SN	E-6837; E 6837; CHEMBL175835; 528859-61-2; AC1OCFY6; SCHEMBL1423485; BDBM34143; ZINC13611722; AKOS032954248; KB-76740
DMJ2P0N	DT	Small molecular drug
DMJ2P0N	PC	6918836
DMJ2P0N	MW	427.9
DMJ2P0N	FM	C22H22ClN3O2S
DMJ2P0N	IC	InChI=1S/C22H22ClN3O2S/c1-26(2)11-10-16-14-24-22-9-6-17(13-20(16)22)25-29(27,28)18-7-8-19-15(12-18)4-3-5-21(19)23/h3-9,12-14,24-25H,10-11H2,1-2H3
DMJ2P0N	CS	CN(C)CCC1=CNC2=C1C=C(C=C2)NS(=O)(=O)C3=CC4=C(C=C3)C(=CC=C4)Cl
DMJ2P0N	IK	OOIQBABUMXSCPC-UHFFFAOYSA-N
DMJ2P0N	IU	5-chloro-N-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]naphthalene-2-sulfonamide
DMJ2P0N	CA	CAS 528859-61-2
DMJ2P0N	DE	Discovery agent

DM7ROJI	ID	DM7ROJI
DM7ROJI	DN	E-6-O-p-methoxycinnamoyl scandoside methyl ester
DM7ROJI	HS	Investigative
DM7ROJI	SN	CHEMBL447012; E-6-O-p-methoxycinnamoyl scandoside methyl ester; BDBM50305815; 6-O-E-p-methoxycinnamoyl scandoside methyl ester; (1S)-1alpha-(beta-D-Glucopyranosyloxy)-1,4aalpha,5,7aalpha-tetrahydro-5alpha-[[(E)-4-methoxycinnamoyl]oxy]-7-hydroxymethylcyclopenta[c]pyran-4-carboxylic acid methyl ester
DM7ROJI	DT	Small molecular drug
DM7ROJI	PC	44584782
DM7ROJI	MW	564.5
DM7ROJI	FM	C27H32O13
DM7ROJI	IC	InChI=1S/C27H32O13/c1-35-15-6-3-13(4-7-15)5-8-19(30)38-17-9-14(10-28)20-21(17)16(25(34)36-2)12-37-26(20)40-27-24(33)23(32)22(31)18(11-29)39-27/h3-9,12,17-18,20-24,26-29,31-33H,10-11H2,1-2H3/b8-5+/t17-,18-,20-,21+,22-,23+,24-,26+,27+/m1/s1
DM7ROJI	CS	COC1=CC=C(C=C1)/C=C/C(=O)O[C@@H]2C=C([C@@H]3[C@H]2C(=CO[C@H]3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C(=O)OC)CO
DM7ROJI	IK	VBHBNHXZBKWQNO-BIIYMWGFSA-N
DM7ROJI	IU	methyl (1S,4aS,5R,7aS)-7-(hydroxymethyl)-5-[(E)-3-(4-methoxyphenyl)prop-2-enoyl]oxy-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate
DM7ROJI	DE	Discovery agent

DMY6DM5	ID	DMY6DM5
DMY6DM5	DN	E-758
DMY6DM5	HS	Investigative
DMY6DM5	SN	E-759; E-761; Lycobetaine analogs (cancer); Lycobetaine analogs (cancer), Oncotest; Topoisomerase inhibitors (cancer), Oncotest
DMY6DM5	CP	Oncotest GmbH
DMY6DM5	DE	Solid tumour/cancer

DMB7685	ID	DMB7685
DMB7685	DN	EAPB0203
DMB7685	HS	Investigative
DMB7685	SN	UNII-KXZ9LA2QV7; KXZ9LA2QV7; EAPB-0203; N-Methyl-1-(2-phenylethyl)imidazo(1,2-a)quinoxalin-4-amine; n-methyl-1-(2-phenylethyl)imidazo[1,2-a]quinoxalin-4-amine; CHEMBL488644; SCHEMBL2815787; EAPB 0203; Imidazo(1,2-a)quinoxalin-4-amine, N-methyl-1-(2-phenylethyl)-; 681284-86-6
DMB7685	DT	Small molecular drug
DMB7685	PC	24779760
DMB7685	MW	302.4
DMB7685	FM	C19H18N4
DMB7685	IC	InChI=1S/C19H18N4/c1-20-18-19-21-13-15(12-11-14-7-3-2-4-8-14)23(19)17-10-6-5-9-16(17)22-18/h2-10,13H,11-12H2,1H3,(H,20,22)
DMB7685	CS	CNC1=NC2=CC=CC=C2N3C1=NC=C3CCC4=CC=CC=C4
DMB7685	IK	HOACPUXUWCASLE-UHFFFAOYSA-N
DMB7685	IU	N-methyl-1-(2-phenylethyl)imidazo[1,2-a]quinoxalin-4-amine
DMB7685	CA	CAS 681284-86-6
DMB7685	DE	T-cell leukaemia

DM4UZ6V	ID	DM4UZ6V
DM4UZ6V	DN	EB-47
DM4UZ6V	HS	Investigative
DM4UZ6V	SN	EB 47; 366454-36-6; 5'-Deoxy-5'-[4-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5'-oxoadenosine Dihydrochloride; DTXSID40692822; ZINC98052573; NCGC00370771-01; KB-76747; FT-0667818; 4-[1-(6-Amino-9H-purin-9-yl)-1-deoxy-; A-D-ribofuranuronoyl]-N-(2,3-dihydro-1-oxo-1H-isoindol-4-yl)-1-piperazineacetamide Dihydrochloride; 2-{4-[(2R,3R,4S,5S)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]piperazin-1-yl}-N-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)acetamide (non-preferred name)
DM4UZ6V	DT	Small molecular drug
DM4UZ6V	PC	9871899
DM4UZ6V	MW	537.5
DM4UZ6V	FM	C24H27N9O6
DM4UZ6V	IC	InChI=1S/C24H27N9O6/c25-20-16-21(28-10-27-20)33(11-29-16)24-18(36)17(35)19(39-24)23(38)32-6-4-31(5-7-32)9-15(34)30-14-3-1-2-12-13(14)8-26-22(12)37/h1-3,10-11,17-19,24,35-36H,4-9H2,(H,26,37)(H,30,34)(H2,25,27,28)/t17-,18+,19-,24+/m0/s1
DM4UZ6V	CS	C1CN(CCN1CC(=O)NC2=CC=CC3=C2CNC3=O)C(=O)[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O
DM4UZ6V	IK	DDFLFKTXUWPNMV-UAKAABGRSA-N
DM4UZ6V	IU	2-[4-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]piperazin-1-yl]-N-(1-oxo-2,3-dihydroisoindol-4-yl)acetamide
DM4UZ6V	DE	Discovery agent

DMPKI0N	ID	DMPKI0N
DMPKI0N	DN	EBIO
DMPKI0N	HS	Investigative
DMPKI0N	SN	10045-45-1; 1-Ethyl-2-benzimidazolinone; 1-EBIO; 1-ethyl-1H-benzo[d]imidazol-2(3H)-one; 1-Ethylbenzimidazolinone; 1-Ethylbenzimidazolin-2-one; 1-ethyl-1,3-dihydro-2h-benzimidazol-2-one; 2H-Benzimidazol-2-one, 1-ethyl-1,3-dihydro-; 1-Ethyl-Benzimidazolinone; UNII-M82W79SS4W; 3-ethyl-1H-benzimidazol-2-one; EINECS 233-148-1; CHEMBL452887; M82W79SS4W; CHEBI:34076; CXUCKELNYMZTRT-UHFFFAOYSA-N; 1-ethyl-2,3-dihydro-1H-1,3-benzodiazol-2-one; 1-EB10; EBIO; 1-ethyl-1,3-dihydrobenzimidazol-2-one; Tocris-1041; AC1Q2ZX3; AC1Q2ZX4
DMPKI0N	DT	Small molecular drug
DMPKI0N	PC	82320
DMPKI0N	MW	162.19
DMPKI0N	FM	C9H10N2O
DMPKI0N	IC	InChI=1S/C9H10N2O/c1-2-11-8-6-4-3-5-7(8)10-9(11)12/h3-6H,2H2,1H3,(H,10,12)
DMPKI0N	CS	CCN1C2=CC=CC=C2NC1=O
DMPKI0N	IK	CXUCKELNYMZTRT-UHFFFAOYSA-N
DMPKI0N	IU	3-ethyl-1H-benzimidazol-2-one
DMPKI0N	CA	CAS 10045-45-1
DMPKI0N	CB	CHEBI:34076
DMPKI0N	DE	Discovery agent

DMIC372	ID	DMIC372
DMIC372	DN	EC-0565
DMIC372	HS	Investigative
DMIC372	SN	Folate-everolimus conjugate (inflammation), Endocyte
DMIC372	CP	Endocyte Inc
DMIC372	DE	Solid tumour/cancer

DMK6E10	ID	DMK6E10
DMK6E10	DN	EC-0845
DMK6E10	HS	Investigative
DMK6E10	SN	MTOR modulator (inflammatory disease), Endocyte
DMK6E10	CP	Endocyte Inc
DMK6E10	DE	Inflammation

DM61FB0	ID	DM61FB0
DM61FB0	DN	EC18
DM61FB0	HS	Investigative
DM61FB0	SN	EC18; SCHEMBL1028017; GTPL6262
DM61FB0	DT	Small molecular drug
DM61FB0	PC	50902958
DM61FB0	MW	496.6
DM61FB0	FM	C29H40N2O5
DM61FB0	IC	InChI=1S/C29H40N2O5/c1-30(13-11-20-9-10-25(33-2)26(15-20)34-3)23-7-6-8-24(19-23)31-14-12-21-16-27(35-4)28(36-5)17-22(21)18-29(31)32/h9-10,15-17,23-24H,6-8,11-14,18-19H2,1-5H3
DM61FB0	CS	CN(CCC1=CC(=C(C=C1)OC)OC)C2CCCC(C2)N3CCC4=CC(=C(C=C4CC3=O)OC)OC
DM61FB0	IK	IUAVZEYOWYFRAS-UHFFFAOYSA-N
DM61FB0	IU	3-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]cyclohexyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
DM61FB0	DE	Discovery agent

DM67549	ID	DM67549
DM67549	DN	EC33
DM67549	HS	Investigative
DM67549	DE	Discovery agent

DMIVY0Q	ID	DMIVY0Q
DMIVY0Q	DN	Eckol
DMIVY0Q	HS	Investigative
DMIVY0Q	SN	Eckol; 88798-74-7; 4-(3,5-dihydroxyphenoxy)dibenzo-p-dioxin-1,3,6,8-tetrol; 1-(3,5-Dihydroxyphenoxy)-2,4,7,9-tetrahydroxydibenzo-1,4-dioxin; UNII-4A5E8354UB; CHEMBL471187; CHEBI:65819; 4A5E8354UB; 4-(3,5-dihydroxyphenoxy)oxanthrene-1,3,6,8-tetrol; 4-(3,5-dihydroxyphenoxy)-dibenzo(b,e)(1,4)dioxin-1,3,6,8-tetrol; AC1L3S7Z; SCHEMBL2562621; DTXSID40237333; ZINC6091359; BDBM50259982; Dibenzo[b,e][1,4]dioxin-1,3,6,8-tetrol, 4-(3,5-dihydroxyphenoxy)-; Dibenzo(b,e)(1,4)-dioxin-1,3,6,8-tetrol, 4-(3,5-dihydroxyphenoxy)-
DMIVY0Q	DT	Small molecular drug
DMIVY0Q	PC	145937
DMIVY0Q	MW	372.3
DMIVY0Q	FM	C18H12O9
DMIVY0Q	IC	InChI=1S/C18H12O9/c19-7-1-8(20)3-10(2-7)25-16-12(23)6-13(24)17-18(16)27-15-11(22)4-9(21)5-14(15)26-17/h1-6,19-24H
DMIVY0Q	CS	C1=C(C=C(C=C1O)OC2=C(C=C(C3=C2OC4=C(C=C(C=C4O3)O)O)O)O)O
DMIVY0Q	IK	PCZZRBGISTUIOA-UHFFFAOYSA-N
DMIVY0Q	IU	4-(3,5-dihydroxyphenoxy)dibenzo-p-dioxin-1,3,6,8-tetrol
DMIVY0Q	CA	CAS 88798-74-7
DMIVY0Q	CB	CHEBI:65819
DMIVY0Q	DE	Discovery agent

DMWKS29	ID	DMWKS29
DMWKS29	DN	ECOPLADIB
DMWKS29	HS	Investigative
DMWKS29	SN	Ecopladib; UNII-48TI67E57Q; PLA-725; CHEMBL269787; 48TI67E57Q; 381683-92-7; Ecopladib [USAN:INN]; Ecopladib (USAN/INN); AC1L4BXD; SCHEMBL1500755; DTXSID70191555; BDBM50205515; HY-U00037; CS-6742; D03938; Benzoic acid, 4-(2-(5-chloro-2-(2-((((3,4-dichlorophenyl)methyl)sulfonyl)amino)ethyl)-1-(diphenylmethyl)-1H-indol-3-yl)ethoxy)-; 4-(2-(5-Chloro-2-(2-(((3,4-dichlorobenzyl)sulfonyl)amino)ethyl)-1-(diphenylmethyl)-1H-indol-3-yl)ethoxy)benzoic acid
DMWKS29	DT	Small molecular drug
DMWKS29	PC	204106
DMWKS29	MW	748.1
DMWKS29	FM	C39H33Cl3N2O5S
DMWKS29	IC	InChI=1S/C39H33Cl3N2O5S/c40-30-14-18-36-33(24-30)32(20-22-49-31-15-12-29(13-16-31)39(45)46)37(19-21-43-50(47,48)25-26-11-17-34(41)35(42)23-26)44(36)38(27-7-3-1-4-8-27)28-9-5-2-6-10-28/h1-18,23-24,38,43H,19-22,25H2,(H,45,46)
DMWKS29	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)N3C4=C(C=C(C=C4)Cl)C(=C3CCNS(=O)(=O)CC5=CC(=C(C=C5)Cl)Cl)CCOC6=CC=C(C=C6)C(=O)O
DMWKS29	IK	FMMCHWHNSUBYAV-UHFFFAOYSA-N
DMWKS29	IU	4-[2-[1-benzhydryl-5-chloro-2-[2-[(3,4-dichlorophenyl)methylsulfonylamino]ethyl]indol-3-yl]ethoxy]benzoic acid
DMWKS29	CA	CAS 381683-92-7
DMWKS29	DE	Discovery agent

DMYZVLN	ID	DMYZVLN
DMYZVLN	DN	EC-SOD
DMYZVLN	HS	Investigative
DMYZVLN	DE	Discovery agent

DM5QS17	ID	DM5QS17
DM5QS17	DN	ED1
DM5QS17	HS	Investigative
DM5QS17	SN	ethylenediamine scaffold, 10; BDBM31426; ED1; 3-{2'-[{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}(2-{(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino}ethyl)sulfamoyl]biphenyl-3-yl}propanoic acid
DM5QS17	DT	Aptamer
DM5QS17	PC	25181318
DM5QS17	MW	740.9
DM5QS17	FM	C40H48N6O6S
DM5QS17	IC	InChI=1S/C40H48N6O6S/c1-40(2,3)52-39(49)44-20-18-32(19-21-44)27-46(23-22-45(28-35-26-42-29-43(35)4)34-15-12-31(25-41)13-16-34)53(50,51)37-11-6-5-10-36(37)33-9-7-8-30(24-33)14-17-38(47)48/h5-13,15-16,24,26,29,32H,14,17-23,27-28H2,1-4H3,(H,47,48)
DM5QS17	CS	CC(C)(C)OC(=O)N1CCC(CC1)CN(CCN(CC2=CN=CN2C)C3=CC=C(C=C3)C#N)S(=O)(=O)C4=CC=CC=C4C5=CC=CC(=C5)CCC(=O)O
DM5QS17	IK	IQLSFMXNAXIRFW-UHFFFAOYSA-N
DM5QS17	IU	3-[3-[2-[2-[4-cyano-N-[(3-methylimidazol-4-yl)methyl]anilino]ethyl-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methyl]sulfamoyl]phenyl]phenyl]propanoic acid
DM5QS17	DE	Acute respiratory distress syndrome; Myocardial reperfusion injury; Sepsis

DMX32JY	ID	DMX32JY
DMX32JY	DN	ED45
DMX32JY	HS	Investigative
DMX32JY	DT	Aptamer
DMX32JY	DE	Acute respiratory distress syndrome; Myocardial reperfusion injury; Sepsis

DM32O0L	ID	DM32O0L
DM32O0L	DN	Edatrexate
DM32O0L	HS	Investigative
DM32O0L	SN	EDATREXATE; 80576-83-6; TCMDC-137768; GNF-Pf-63; CHEMBL296373; 10-Ethyl-10-deazaaminopterin; CGP-30694; Edatrexate [USAN:INN]; Edatrexatum [INN-Latin]; Edatrexato [INN-Spanish]; Edatrexatum; Edatrexato; CGP 30694; EDX; psylliumseed; N-(p-(1-((2,4-Diamino-6-pteridinyl)methyl)propyl)benzoyl)-L-glutamic acid; L-Glutamic acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)propyl)benzoyl)-; AC1OCESK; Edatrexate (USAN/INN); SCHEMBL4676; 10-ethyl-10-deazaaminopterine; CHEBI:135757
DM32O0L	DT	Small molecular drug
DM32O0L	PC	6917908
DM32O0L	MW	467.5
DM32O0L	FM	C22H25N7O5
DM32O0L	IC	InChI=1S/C22H25N7O5/c1-2-11(9-14-10-25-19-17(26-14)18(23)28-22(24)29-19)12-3-5-13(6-4-12)20(32)27-15(21(33)34)7-8-16(30)31/h3-6,10-11,15H,2,7-9H2,1H3,(H,27,32)(H,30,31)(H,33,34)(H4,23,24,25,28,29)/t11?,15-/m0/s1
DM32O0L	CS	CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM32O0L	IK	FSIRXIHZBIXHKT-MHTVFEQDSA-N
DM32O0L	IU	(2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid
DM32O0L	CA	CAS 80576-83-6
DM32O0L	CB	CHEBI:135757
DM32O0L	DE	Discovery agent

DM10D85	ID	DM10D85
DM10D85	DN	Edetic acid
DM10D85	HS	Investigative
DM10D85	SN	Ethylenediaminetetraacetic acid; EDTA; 60-00-4; Edathamil; Versene; Titriplex; Havidote; EDTA acid; Sequestrol; Cheelox; Sequestric acid; Warkeelate acid; Gluma cleanser; Sequestrene aa; Komplexon ii; Versene acid; Tetrine acid; Quastal Special; Metaquest A; Trilon bw; Complexon II; Titriplex II; Hamp-ene acid; Cheelox BF acid; Trilon BS; Celon A; Questex 4H; Chelest 3A; Celon ATH; Chemcolox 340; Versenate; Acidum edeticum; Universne acid; Acido edetico; Acide edetique; Vinkeil 100; Dissolvine E; Nullapon B acid; Perma
DM10D85	DT	Small molecular drug
DM10D85	PC	6049
DM10D85	MW	292.24
DM10D85	FM	C10H16N2O8
DM10D85	IC	InChI=1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)
DM10D85	CS	C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O
DM10D85	IK	KCXVZYZYPLLWCC-UHFFFAOYSA-N
DM10D85	IU	2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid
DM10D85	CA	CAS 60-00-4
DM10D85	CB	CHEBI:42191
DM10D85	DE	Discovery agent

DMS3AXK	ID	DMS3AXK
DMS3AXK	DN	EDMT
DMS3AXK	HS	Investigative
DMS3AXK	SN	2-Ethyl-5-methoxy-N,N-dimethyltryptamine; EMDT; 2-ethyl-5-methoxy-N,N-dimethyltryptamine; CHEMBL267615; 2-(2-ethyl-5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine; AC1OCFIZ; GTPL12; SCHEMBL2537573; BDBM34142; ZINC13805803; PDSP1_001417; PDSP2_001401; AKOS027422828; NCGC00387149-01; N,N-Dimethyl-2-ethyl-5-methoxy-1H-indole-3-ethanamine; [2-(2-ethyl-5-methoxy-1H-indol-3-yl)ethyl]dimethylamine,
DMS3AXK	DT	Small molecular drug
DMS3AXK	PC	6918513
DMS3AXK	MW	246.35
DMS3AXK	FM	C15H22N2O
DMS3AXK	IC	InChI=1S/C15H22N2O/c1-5-14-12(8-9-17(2)3)13-10-11(18-4)6-7-15(13)16-14/h6-7,10,16H,5,8-9H2,1-4H3
DMS3AXK	CS	CCC1=C(C2=C(N1)C=CC(=C2)OC)CCN(C)C
DMS3AXK	IK	ZEYRDXUWJDGTLD-UHFFFAOYSA-N
DMS3AXK	IU	2-(2-ethyl-5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine
DMS3AXK	DE	Discovery agent

DMHCGIS	ID	DMHCGIS
DMHCGIS	DN	EDN-OL1
DMHCGIS	HS	Investigative
DMHCGIS	SN	Amyloid beta oligonucleotide (Alzheimer's disease/Down syndrome), Edunn
DMHCGIS	CP	Edunn Biotechnology Inc
DMHCGIS	DE	Alzheimer disease

DMC7DYX	ID	DMC7DYX
DMC7DYX	DN	Edoxudine
DMC7DYX	HS	Investigative
DMC7DYX	SN	5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione; ORF-15817; RWJ-15817; Edurid (Salt/Mix); 1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione; AC1L1CAR; .beta.-5-Ethyldeoxyuridine; TimTec1_004024; SCHEMBL65580; MLS001360450; AC1Q69H9; 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; .beta.-5-Ethyl-2'-deoxyuridine; XACKNLSZYYIACO-UHFFFAOYSA-N; HMS3056J10; HMS3369L22; HMS1545G20; EDU; AKOS024282522; 5-Ethyl-2'-deoxyuridine ; Edoxudine; MCULE-3445830855; ST056929
DMC7DYX	DT	Small molecular drug
DMC7DYX	PC	66377
DMC7DYX	MW	256.25
DMC7DYX	FM	C11H16N2O5
DMC7DYX	IC	InChI=1S/C11H16N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h4,7-9,14-15H,2-3,5H2,1H3,(H,12,16,17)/t7-,8+,9+/m0/s1
DMC7DYX	CS	CCC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O
DMC7DYX	IK	XACKNLSZYYIACO-DJLDLDEBSA-N
DMC7DYX	IU	5-ethyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMC7DYX	CA	CAS 15176-29-1
DMC7DYX	CB	CHEBI:135051
DMC7DYX	DE	Discovery agent

DMLSMBI	ID	DMLSMBI
DMLSMBI	DN	EDP-13
DMLSMBI	HS	Investigative
DMLSMBI	SN	Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma
DMLSMBI	CP	BioLineRx Ltd
DMLSMBI	DE	Solid tumour/cancer

DMTVRKG	ID	DMTVRKG
DMTVRKG	DN	EDP-18
DMTVRKG	HS	Investigative
DMTVRKG	SN	TRPV3 agonist (depression), Biolinerx
DMTVRKG	CP	BioLineRx Ltd
DMTVRKG	DE	Major depressive disorder

DMMN0GO	ID	DMMN0GO
DMMN0GO	DN	EDP-21
DMMN0GO	HS	Investigative
DMMN0GO	SN	Recombinant leptin analogs (obesity), BioLineRx
DMMN0GO	CP	BioLineRx Ltd
DMMN0GO	DE	Obesity

DMN8JKX	ID	DMN8JKX
DMN8JKX	DN	E-EBU-dM
DMN8JKX	HS	Investigative
DMN8JKX	SN	132774-45-9; 136011-43-3; E-EPU; E-EPU-S
DMN8JKX	DT	Small molecular drug
DMN8JKX	PC	453151
DMN8JKX	MW	316.4
DMN8JKX	FM	C18H24N2O3
DMN8JKX	IC	InChI=1S/C18H24N2O3/c1-5-15-16(10-14-8-12(3)7-13(4)9-14)20(11-23-6-2)18(22)19-17(15)21/h7-9H,5-6,10-11H2,1-4H3,(H,19,21,22)
DMN8JKX	CS	CCC1=C(N(C(=O)NC1=O)COCC)CC2=CC(=CC(=C2)C)C
DMN8JKX	IK	LNEPZLRCYLNOIU-UHFFFAOYSA-N
DMN8JKX	IU	6-[(3,5-dimethylphenyl)methyl]-1-(ethoxymethyl)-5-ethylpyrimidine-2,4-dione
DMN8JKX	CA	CAS 136160-30-0
DMN8JKX	DE	Discovery agent

DMXZRND	ID	DMXZRND
DMXZRND	DN	EFFUSOL
DMXZRND	HS	Investigative
DMXZRND	SN	EFFUSOL; 73166-28-6; NSC 371300; 5-ethenyl-1-methyl-9,10-dihydrophenanthrene-2,7-diol; UNII-S436Y000RU; CHEMBL205119; S436Y000RU; 1-methyl-5-vinyl-9,10-dihydrophenanthrene-2,7-diol; NSC-371300; 2,7-Phenanthrenediol, 5-ethenyl-9,10-dihydro-1-methyl-; NSC371300; AC1L2PII; AC1Q7B8H; CTK8D4698; DTXSID00223419; MolPort-042-624-482; ZINC1588038; BDBM50180512; FT-0667825
DMXZRND	DT	Small molecular drug
DMXZRND	PC	100801
DMXZRND	MW	252.31
DMXZRND	FM	C17H16O2
DMXZRND	IC	InChI=1S/C17H16O2/c1-3-11-8-13(18)9-12-4-5-14-10(2)16(19)7-6-15(14)17(11)12/h3,6-9,18-19H,1,4-5H2,2H3
DMXZRND	CS	CC1=C(C=CC2=C1CCC3=C2C(=CC(=C3)O)C=C)O
DMXZRND	IK	GEXAPRXWKRZPCK-UHFFFAOYSA-N
DMXZRND	IU	5-ethenyl-1-methyl-9,10-dihydrophenanthrene-2,7-diol
DMXZRND	CA	CAS 73166-28-6
DMXZRND	DE	Discovery agent

DMOKX76	ID	DMOKX76
DMOKX76	DN	Efomycine M
DMOKX76	HS	Investigative
DMOKX76	DE	Discovery agent

DMZ2XOH	ID	DMZ2XOH
DMZ2XOH	DN	EFPPEA
DMZ2XOH	HS	Investigative
DMZ2XOH	SN	ethyl-furo-pyrazolo-pyridine-ethyl-acetamide; N-[2-(2-Ethyl-8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridin-1-yl)ethyl]acetamide
DMZ2XOH	DT	Small molecular drug
DMZ2XOH	PC	24954989
DMZ2XOH	MW	273.33
DMZ2XOH	FM	C15H19N3O2
DMZ2XOH	IC	InChI=1S/C15H19N3O2/c1-3-13-11(4-7-16-10(2)19)15-12-6-9-20-14(12)5-8-18(15)17-13/h5,8H,3-4,6-7,9H2,1-2H3,(H,16,19)
DMZ2XOH	CS	CCC1=NN2C=CC3=C(C2=C1CCNC(=O)C)CCO3
DMZ2XOH	IK	IZDHETWMKYCGAU-UHFFFAOYSA-N
DMZ2XOH	IU	N-[2-(4-ethyl-10-oxa-5,6-diazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7-tetraen-3-yl)ethyl]acetamide
DMZ2XOH	DE	Discovery agent

DMRP9K3	ID	DMRP9K3
DMRP9K3	DN	EG-10
DMRP9K3	HS	Investigative
DMRP9K3	SN	IL-10 human gene therapy (nanoparticle , inflammatory bowel disease), enGene
DMRP9K3	CP	EnGene Inc
DMRP9K3	DE	Inflammatory bowel disease

DM7AYH4	ID	DM7AYH4
DM7AYH4	DN	EGFR inhibitor
DM7AYH4	HS	Investigative
DM7AYH4	SN	EGFR Inhibitor; 879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01
DM7AYH4	DT	Small molecular drug
DM7AYH4	PC	9549299
DM7AYH4	MW	413.4
DM7AYH4	FM	C21H18F3N5O
DM7AYH4	IC	InChI=1S/C21H18F3N5O/c22-21(23,24)14-3-1-4-15(9-14)27-18-11-19(26-12-25-18)28-16-5-2-6-17(10-16)29-20(30)13-7-8-13/h1-6,9-13H,7-8H2,(H,29,30)(H2,25,26,27,28)
DM7AYH4	CS	C1CC1C(=O)NC2=CC=CC(=C2)NC3=NC=NC(=C3)NC4=CC=CC(=C4)C(F)(F)F
DM7AYH4	IK	YOHYSYJDKVYCJI-UHFFFAOYSA-N
DM7AYH4	IU	N-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide
DM7AYH4	CA	CAS 879127-07-8
DM7AYH4	DE	Discovery agent

DMLK4X5	ID	DMLK4X5
DMLK4X5	DN	EGIS-7625
DMLK4X5	HS	Investigative
DMLK4X5	SN	UNII-ZD6AG3N96D; ZD6AG3N96D; EGIS-7625; EGIS-7625 free base; GTPL176; SCHEMBL7430234; Benzenamine, 2-methyl-4-nitro-5-(4-(phenylmethyl)-1-piperazinyl)-; 751462-86-9; L017292
DMLK4X5	DT	Small molecular drug
DMLK4X5	PC	9930788
DMLK4X5	MW	399.3
DMLK4X5	FM	C18H24Cl2N4O2
DMLK4X5	IC	InChI=1S/C18H22N4O2.2ClH/c1-14-11-18(22(23)24)17(12-16(14)19)21-9-7-20(8-10-21)13-15-5-3-2-4-6-15;;/h2-6,11-12H,7-10,13,19H2,1H3;2*1H
DMLK4X5	CS	CC1=CC(=C(C=C1N)N2CCN(CC2)CC3=CC=CC=C3)[N+](=O)[O-].Cl.Cl
DMLK4X5	IK	AYRFPZMTRYDWGP-UHFFFAOYSA-N
DMLK4X5	IU	5-(4-benzylpiperazin-1-yl)-2-methyl-4-nitroaniline;dihydrochloride
DMLK4X5	CA	CAS 755040-97-2
DMLK4X5	DE	Discovery agent

DMKW0Q3	ID	DMKW0Q3
DMKW0Q3	DN	eGlu
DMKW0Q3	HS	Investigative
DMKW0Q3	SN	EGLU; (s)-alpha-ethylglutamate
DMKW0Q3	DT	Small molecular drug
DMKW0Q3	PC	5311079
DMKW0Q3	MW	175.18
DMKW0Q3	FM	C7H13NO4
DMKW0Q3	IC	InChI=1S/C7H13NO4/c1-2-7(8,6(11)12)4-3-5(9)10/h2-4,8H2,1H3,(H,9,10)(H,11,12)/t7-/m0/s1
DMKW0Q3	CS	CC[C@](CCC(=O)O)(C(=O)O)N
DMKW0Q3	IK	QFYBYZLHPIALCZ-ZETCQYMHSA-N
DMKW0Q3	IU	(2S)-2-amino-2-ethylpentanedioic acid
DMKW0Q3	CA	CAS 170984-72-2
DMKW0Q3	DE	Discovery agent

DMW9MRO	ID	DMW9MRO
DMW9MRO	DN	EGTA
DMW9MRO	HS	Investigative
DMW9MRO	SN	EGTA; 67-42-5; Egtazic acid; Ethylenebis(oxyethylenenitrilo)tetraacetic acid; Gedta; Ebonta; 6,9-Dioxa-3,12-diazatetradecanedioic acid, 3,12-bis(carboxymethyl)-; 1,2-Bis[2-[bis(carboxymethyl)amino]ethoxy]ethane; Ethylene Glycol Tetraacetic Acid; H4egta; Egtazic acid [USAN:INN]; Ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid; NSC 615010; Acide egtazique [INN-French]; Acido egtazico [INN-Spanish]; Acidum egtazicum [INN-Latin]; Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid; Ethylene glyc
DMW9MRO	DT	Small molecular drug
DMW9MRO	PC	6207
DMW9MRO	MW	380.35
DMW9MRO	FM	C14H24N2O10
DMW9MRO	IC	InChI=1S/C14H24N2O10/c17-11(18)7-15(8-12(19)20)1-3-25-5-6-26-4-2-16(9-13(21)22)10-14(23)24/h1-10H2,(H,17,18)(H,19,20)(H,21,22)(H,23,24)
DMW9MRO	CS	C(COCCOCCN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O
DMW9MRO	IK	DEFVIWRASFVYLL-UHFFFAOYSA-N
DMW9MRO	IU	2-[2-[2-[2-[bis(carboxymethyl)amino]ethoxy]ethoxy]ethyl-(carboxymethyl)amino]acetic acid
DMW9MRO	CA	CAS 67-42-5
DMW9MRO	CB	CHEBI:30740
DMW9MRO	DE	Discovery agent

DM014WS	ID	DM014WS
DM014WS	DN	EHNA
DM014WS	HS	Investigative
DM014WS	SN	erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride
DM014WS	DT	Small molecular drug
DM014WS	PC	3206
DM014WS	MW	277.37
DM014WS	FM	C14H23N5O
DM014WS	IC	InChI=1S/C14H23N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-7H2,1-2H3,(H2,15,16,17)
DM014WS	CS	CCCCCCC(C(C)O)N1C=NC2=C(N=CN=C21)N
DM014WS	IK	IOSAAWHGJUZBOG-UHFFFAOYSA-N
DM014WS	IU	3-(6-aminopurin-9-yl)nonan-2-ol
DM014WS	CA	CAS 59262-86-1
DM014WS	DE	Discovery agent

DMBQCMU	ID	DMBQCMU
DMBQCMU	DN	EI1
DMBQCMU	HS	Investigative
DMBQCMU	SN	KB-145943
DMBQCMU	DT	Small molecular drug
DMBQCMU	PC	72199293
DMBQCMU	MW	390.5
DMBQCMU	FM	C23H26N4O2
DMBQCMU	IC	InChI=1S/C23H26N4O2/c1-5-17(6-2)27-8-7-18-19(10-16(12-24)11-21(18)27)22(28)25-13-20-14(3)9-15(4)26-23(20)29/h7-11,17H,5-6,13H2,1-4H3,(H,25,28)(H,26,29)
DMBQCMU	CS	CCC(CC)N1C=CC2=C(C=C(C=C21)C#N)C(=O)NCC3=C(C=C(NC3=O)C)C
DMBQCMU	IK	PFHDWRIVDDIFRP-UHFFFAOYSA-N
DMBQCMU	IU	6-cyano-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-pentan-3-ylindole-4-carboxamide
DMBQCMU	CA	CAS 1418308-27-6
DMBQCMU	DE	Discovery agent

DMVJK9W	ID	DMVJK9W
DMVJK9W	DN	Eicosadienoic acid
DMVJK9W	HS	Investigative
DMVJK9W	SN	Eicosadienoic acid; HOMO-GAMMA-LINOLEICACID; Homo-gamma-linoleic acid; Icosadienoic acid; SCHEMBL416181; cis-11,14-Eicosadienoic acid; cis-11,14-eicosadienoicacid; (11Z,14Z)-Eicosa-11,14-dienoic acid; (11Z,14Z)-Icosa-11,14-dienoic acid; (11Z,14Z)-icosadienoic acid; 11, 14-icosadienoate; 11, 14-icosadienoic acid; 11,14-Eicosadienoate; 11,14-Eicosadienoic acid, (Z,Z)-; 11,14-Icosadienoic acid; 11C,14C-Eicosadienoic acid; 11Z,14Z-eicosadienoic acid; 2091-39-6; 5598-38-9; AC1O5SJA; BSPBio_001326; CHEBI:73731; CHEMBL464983; FA 20:2
DMVJK9W	PC	6439848
DMVJK9W	MW	308.5
DMVJK9W	FM	C20H36O2
DMVJK9W	IC	XSXIVVZCUAHUJO-HZJYTTRNSA-N
DMVJK9W	CS	CCCCCC=CCC=CCCCCCCCCCC(=O)O
DMVJK9W	IK	1S/C20H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10H,2-5,8,11-19H2,1H3,(H,21,22)/b7-6-,10-9-
DMVJK9W	IU	(11Z,14Z)-icosa-11,14-dienoic acid
DMVJK9W	CA	CAS 5598-38-9
DMVJK9W	CB	CHEBI:73731
DMVJK9W	DE	Discovery agent

DMAKP20	ID	DMAKP20
DMAKP20	DN	eicosatetranoic acid
DMAKP20	HS	Investigative
DMAKP20	SN	ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; eicosatetranoic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128
DMAKP20	DT	Small molecular drug
DMAKP20	PC	1780
DMAKP20	MW	296.4
DMAKP20	FM	C20H24O2
DMAKP20	IC	InChI=1S/C20H24O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h2-5,8,11,14,17-19H2,1H3,(H,21,22)
DMAKP20	CS	CCCCCC#CCC#CCC#CCC#CCCCC(=O)O
DMAKP20	IK	MGLDCXPLYOWQRP-UHFFFAOYSA-N
DMAKP20	IU	icosa-5,8,11,14-tetraynoic acid
DMAKP20	CA	CAS 1191-85-1
DMAKP20	CB	CHEBI:94483
DMAKP20	DE	Discovery agent

DM03X7D	ID	DM03X7D
DM03X7D	DN	EISAI-1
DM03X7D	HS	Investigative
DM03X7D	SN	Malptll; EISAI-1; NT-1; (Me)Arg-lys-pro-trp-tert-leu-leu-oet; H(CH3)-Arg-lys-pro-trp-tert-leu-leu-oet; AC1L2XGU; 125600-60-4; GTPL1566; Methylarginyl-lysyl-prolyl-tryptophyl-tert-leucyl-leucyl-ethyl ester; (Methyl)-arginyl-lysyl-prolyl-tryptophyl-tert-leucyl-leucine ethyl ester; ethyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-5-(diaminomethylideneamino)-2-(methylamino)pentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-methylpentanoate
DM03X7D	DT	Small molecular drug
DM03X7D	PC	130482
DM03X7D	MW	854.1
DM03X7D	FM	C43H71N11O7
DM03X7D	IC	InChI=1S/C43H71N11O7/c1-8-61-41(60)33(23-26(2)3)52-39(58)35(43(4,5)6)53-37(56)32(24-27-25-49-29-16-10-9-15-28(27)29)51-38(57)34-19-14-22-54(34)40(59)31(17-11-12-20-44)50-36(55)30(47-7)18-13-21-48-42(45)46/h9-10,15-16,25-26,30-35,47,49H,8,11-14,17-24,44H2,1-7H3,(H,50,55)(H,51,57)(H,52,58)(H,53,56)(H4,45,46,48)/t30-,31-,32-,33-,34-,35+/m0/s1
DM03X7D	CS	CCOC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC
DM03X7D	IK	BLWANJSERJECRU-ULWXFTFZSA-N
DM03X7D	IU	ethyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-5-(diaminomethylideneamino)-2-(methylamino)pentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-methylpentanoate
DM03X7D	CA	CAS 125600-60-4
DM03X7D	DE	Discovery agent

DMRHSCQ	ID	DMRHSCQ
DMRHSCQ	DN	ELAEOCARPENINE
DMRHSCQ	HS	Investigative
DMRHSCQ	SN	elaeocarpenine
DMRHSCQ	DT	Small molecular drug
DMRHSCQ	PC	16747727
DMRHSCQ	MW	257.329
DMRHSCQ	FM	C16H19NO2
DMRHSCQ	IC	InChI=1S/C16H19NO2/c1-11-5-2-8-14(18)15(11)16(19)12-6-3-9-17-10-4-7-13(12)17/h2,5-6,8,13,18H,3-4,7,9-10H2,1H3/t13-/m1/s1
DMRHSCQ	CS	CC1=C(C(=CC=C1)O)C(=O)C2=CCCN3[C@@H]2CCC3
DMRHSCQ	IK	KNSLYJICIDVPEX-CYBMUJFWSA-N
DMRHSCQ	IU	[(8aR)-1,2,3,5,6,8a-hexahydroindolizin-8-yl]-(2-hydroxy-6-methylphenyl)methanone
DMRHSCQ	DE	Discovery agent

DMP8VDT	ID	DMP8VDT
DMP8VDT	DN	Elaidoylamide
DMP8VDT	HS	Investigative
DMP8VDT	SN	Oleamide; Oleic acid amide; 301-02-0; Oleylamide; Oleyl amide; Adogen 73; Crodamide O; Slip-eze; Armoslip CP; Crodamide OR; cis-9,10-Octadecenoamide; (Z)-9-OCTADECENAMIDE; (9Z)-octadec-9-enamide; 9-Octadecenamide, (Z)-; (Z)-octadec-9-enamide; ELAIDOYLAMIDE; 9Z-octadecenamide; 9,10-octadecenamide; Unislip 1759; Kemamide O; Petrac Slip-Eze; UNII-7L25QK8BWO; Armid O; Amide O; trans-9,10-octadecenoamide; cis-9-Octadecenamide; 9-Octadecenamide, (9Z)-; 14C-labeled oleamide; Diamide O 200; HSDB 5560; (9E)-OCTADEC-9-ENAMIDE; oleamide
DMP8VDT	DT	Small molecular drug
DMP8VDT	PC	5283387
DMP8VDT	MW	281.5
DMP8VDT	FM	C18H35NO
DMP8VDT	IC	InChI=1S/C18H35NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H2,19,20)/b10-9-
DMP8VDT	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)N
DMP8VDT	IK	FATBGEAMYMYZAF-KTKRTIGZSA-N
DMP8VDT	IU	(Z)-octadec-9-enamide
DMP8VDT	CA	CAS 301-02-0
DMP8VDT	CB	CHEBI:116314
DMP8VDT	DE	Discovery agent

DMEOJ9W	ID	DMEOJ9W
DMEOJ9W	DN	eledoisin
DMEOJ9W	HS	Investigative
DMEOJ9W	SN	ELD 950; eledone peptide; ELD-950
DMEOJ9W	DT	Small molecular drug
DMEOJ9W	PC	10328936
DMEOJ9W	MW	1188.4
DMEOJ9W	FM	C54H85N13O15S
DMEOJ9W	IC	InChI=1S/C54H85N13O15S/c1-7-30(4)44(53(81)57-27-42(70)60-36(24-29(2)3)49(77)61-33(45(56)73)20-23-83-6)66-50(78)37(25-32-14-9-8-10-15-32)63-46(74)31(5)58-48(76)38(26-43(71)72)64-47(75)34(16-11-12-21-55)62-51(79)39(28-68)65-52(80)40-17-13-22-67(40)54(82)35-18-19-41(69)59-35/h8-10,14-15,29-31,33-40,44,68H,7,11-13,16-28,55H2,1-6H3,(H2,56,73)(H,57,81)(H,58,76)(H,59,69)(H,60,70)(H,61,77)(H,62,79)(H,63,74)(H,64,75)(H,65,80)(H,66,78)(H,71,72)/t30-,31-,33-,34-,35-,36-,37-,38-,39-,40-,44-/m0/s1
DMEOJ9W	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCC(=O)N3
DMEOJ9W	IK	AYLPVIWBPZMVSH-FCKMLYJASA-N
DMEOJ9W	IU	(3S)-3-[[(2S)-6-amino-2-[[(2S)-3-hydroxy-2-[[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMEOJ9W	CA	CAS 69-25-0
DMEOJ9W	CB	CHEBI:135903
DMEOJ9W	DE	Discovery agent

DMMVZU0	ID	DMMVZU0
DMMVZU0	DN	Eleutherobin
DMMVZU0	HS	Investigative
DMMVZU0	SN	Eleutherobin; 174545-76-7; CHEMBL504387; SCHEMBL12015046
DMMVZU0	DT	Small molecular drug
DMMVZU0	PC	6918335
DMMVZU0	MW	656.8
DMMVZU0	FM	C35H48N2O10
DMMVZU0	IC	InChI=1S/C35H48N2O10/c1-20(2)25-10-8-21(3)26-15-29(46-30(40)11-9-24-16-37(6)19-36-24)34(5)12-13-35(42-7,47-34)23(14-27(25)26)17-43-33-32(45-22(4)38)31(41)28(39)18-44-33/h8-9,11-14,16,19-20,25-29,31-33,39,41H,10,15,17-18H2,1-7H3/b11-9+,23-14-/t25-,26+,27-,28-,29+,31-,32+,33-,34+,35-/m1/s1
DMMVZU0	CS	CC1=CC[C@@H]([C@@H]/2[C@H]1C[C@@H]([C@@]3(C=C[C@@](O3)(/C(=C2)/CO[C@H]4[C@H]([C@@H]([C@@H](CO4)O)O)OC(=O)C)OC)C)OC(=O)/C=C/C5=CN(C=N5)C)C(C)C
DMMVZU0	IK	XOPYFXBZMVTEJF-PDACKIITSA-N
DMMVZU0	IU	[(1S,2S,4R,8R,9S,10Z,12R)-11-[[(2R,3S,4R,5R)-3-acetyloxy-4,5-dihydroxyoxan-2-yl]oxymethyl]-12-methoxy-1,5-dimethyl-8-propan-2-yl-15-oxatricyclo[10.2.1.04,9]pentadeca-5,10,13-trien-2-yl] (E)-3-(1-methylimidazol-4-yl)prop-2-enoate
DMMVZU0	CA	CAS 174545-76-7
DMMVZU0	DE	Discovery agent

DMX8BS5	ID	DMX8BS5
DMX8BS5	DN	ELLAGIC ACID
DMX8BS5	HS	Investigative
DMX8BS5	SN	ellagic acid; 476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728
DMX8BS5	DT	Small molecular drug
DMX8BS5	PC	5281855
DMX8BS5	MW	302.19
DMX8BS5	FM	C14H6O8
DMX8BS5	IC	InChI=1S/C14H6O8/c15-5-1-3-7-8-4(14(20)22-11(7)9(5)17)2-6(16)10(18)12(8)21-13(3)19/h1-2,15-18H
DMX8BS5	CS	C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O
DMX8BS5	IK	AFSDNFLWKVMVRB-UHFFFAOYSA-N
DMX8BS5	IU	6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione
DMX8BS5	CA	CAS 476-66-4
DMX8BS5	CB	CHEBI:4775
DMX8BS5	DE	Discovery agent

DMHPYSM	ID	DMHPYSM
DMHPYSM	DN	Ellipticine
DMHPYSM	HS	Investigative
DMHPYSM	SN	ellipticine; 519-23-3; Elliptisine; 5,11-Dimethyl-6H-pyrido[4,3-b]carbazole; NSC 71795; TCMDC-125546; NSC-71795; 5,11-Dimethyl-6H-pyrido(4,3-b)carbazole; ICIG 770; 5,11-Dimethylpyrido[4,3-b]carbazole; CCRIS 2003; CP 5; UNII-117VLW7484; NSC71795; EINECS 208-264-0; CHEMBL123; BRN 0221300; MLS000736786; MLS000028487; CHEBI:4776; 6H-Pyrido(4,3-b)carbazole, 5,11-dimethyl-; CCG-36483; 117VLW7484; SMR000058370; 6H-Pyrido[4,3-b]carbazole,5,11-dimethyl-; 6H-Pyrido[4,3-b]carbazole, 5,11-dimethyl-; SR-01000003083; elliptecine; Ellipticin
DMHPYSM	DT	Small molecular drug
DMHPYSM	PC	3213
DMHPYSM	MW	246.31
DMHPYSM	FM	C17H14N2
DMHPYSM	IC	InChI=1S/C17H14N2/c1-10-14-9-18-8-7-12(14)11(2)17-16(10)13-5-3-4-6-15(13)19-17/h3-9,19H,1-2H3
DMHPYSM	CS	CC1=C2C=CN=CC2=C(C3=C1NC4=CC=CC=C43)C
DMHPYSM	IK	CTSPAMFJBXKSOY-UHFFFAOYSA-N
DMHPYSM	IU	5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMHPYSM	CA	CAS 519-23-3
DMHPYSM	CB	CHEBI:4776
DMHPYSM	DE	Discovery agent

DM2DERW	ID	DM2DERW
DM2DERW	DN	ELN-864709
DM2DERW	HS	Investigative
DM2DERW	SN	ELN-330977; ELN-678033; JNK3 inhibitors (neuronal injury), Elan; JNK3 inhibitors (neuronalinjury/neurodegenerative disease); JNK3 inhibitors (neuronal injury/neurodegenerative disease), Elan
DM2DERW	CP	Elan Corp plc
DM2DERW	DE	Central nervous system injury

DM5G1SF	ID	DM5G1SF
DM5G1SF	DN	ELND-007
DM5G1SF	HS	Investigative
DM5G1SF	SN	ELN-318463; ELN-318611; ELN-44989; ELN-475513; ELN-475516; ELN-480271; ELN-481090; ELN-481970; ELND-006; Gamma secretase inhibitors (Alzheimer's disease), Elan
DM5G1SF	CP	Elan Pharmaceuticals Inc
DM5G1SF	DT	Small molecular drug
DM5G1SF	PC	53308121
DM5G1SF	MW	455.4
DM5G1SF	FM	C20H14F5N3O2S
DM5G1SF	IC	InChI=1S/C20H14F5N3O2S/c21-15-7-13-17(8-16(15)22)28(19(10-1-2-10)14-9-26-27-18(13)14)31(29,30)12-5-3-11(4-6-12)20(23,24)25/h3-10,19H,1-2H2,(H,26,27)/t19-/m1/s1
DM5G1SF	CS	C1CC1[C@@H]2C3=C(C4=CC(=C(C=C4N2S(=O)(=O)C5=CC=C(C=C5)C(F)(F)F)F)F)NN=C3
DM5G1SF	IK	XODSHWXKSMPDRP-LJQANCHMSA-N
DM5G1SF	IU	(4R)-4-cyclopropyl-7,8-difluoro-5-[4-(trifluoromethyl)phenyl]sulfonyl-1,4-dihydropyrazolo[4,3-c]quinoline
DM5G1SF	CA	CAS 959997-22-9
DM5G1SF	DE	Alzheimer disease

DMQ63J2	ID	DMQ63J2
DMQ63J2	DN	EM-101
DMQ63J2	HS	Investigative
DMQ63J2	SN	EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH
DMQ63J2	CP	National Institutes of Health
DMQ63J2	DT	Small molecular drug
DMQ63J2	PC	3971
DMQ63J2	MW	306.4
DMQ63J2	FM	C19H18N2O2
DMQ63J2	IC	InChI=1S/C19H18N2O2/c22-17-13-18(21-11-9-20-10-12-21)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13,20H,9-12H2
DMQ63J2	CS	C1CN(CCN1)C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DMQ63J2	IK	NGAGMBNBKCDCDJ-UHFFFAOYSA-N
DMQ63J2	IU	8-phenyl-2-piperazin-1-ylchromen-4-one
DMQ63J2	CA	CAS 154447-38-8
DMQ63J2	CB	CHEBI:92399
DMQ63J2	DE	Solid tumour/cancer

DMZ2EL1	ID	DMZ2EL1
DMZ2EL1	DN	EM1396
DMZ2EL1	HS	Investigative
DMZ2EL1	SN	EM-1396; CHEMBL490979
DMZ2EL1	DT	Small molecular drug
DMZ2EL1	PC	44576211
DMZ2EL1	MW	451.6
DMZ2EL1	FM	C28H37NO4
DMZ2EL1	IC	InChI=1S/C28H37NO4/c1-26(2)11-12-28(33-25(26)30)10-8-23-21-6-5-18-16-24(32-14-13-31-4)19(17-29)15-22(18)20(21)7-9-27(23,28)3/h15-16,20-21,23H,5-14H2,1-4H3/t20-,21+,23-,27-,28+/m0/s1
DMZ2EL1	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]24CCC(C(=O)O4)(C)C)CCC5=CC(=C(C=C35)C#N)OCCOC
DMZ2EL1	IK	DBERIEFIHOJVNL-NOPJHZOQSA-N
DMZ2EL1	IU	(8R,9S,13S,14S,17R)-3-(2-methoxyethoxy)-5',5',13-trimethyl-6'-oxospiro[7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17,2'-oxane]-2-carbonitrile
DMZ2EL1	DE	Discovery agent

DMSLHDN	ID	DMSLHDN
DMSLHDN	DN	EM-1424
DMSLHDN	HS	Investigative
DMSLHDN	SN	CHEMBL490978
DMSLHDN	DT	Small molecular drug
DMSLHDN	PC	23647683
DMSLHDN	MW	485.6
DMSLHDN	FM	C28H39NO6
DMSLHDN	IC	InChI=1S/C28H39NO6/c1-26(2)11-12-28(34-25(26)31)10-8-22-19-6-5-17-15-23(33-14-13-32-4)21(24(30)35-29)16-20(17)18(19)7-9-27(22,28)3/h15-16,18-19,22H,5-14,29H2,1-4H3/t18?,19?,22?,27-,28+/m0/s1
DMSLHDN	CS	C[C@]12CCC3C(C1CC[C@@]24CCC(C(=O)O4)(C)C)CCC5=CC(=C(C=C35)C(=O)ON)OCCOC
DMSLHDN	IK	CUTJLDJFYWQIRX-LFCNJKSUSA-N
DMSLHDN	IU	amino (13S,17R)-3-(2-methoxyethoxy)-5',5',13-trimethyl-6'-oxospiro[7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17,2'-oxane]-2-carboxylate
DMSLHDN	DE	Discovery agent

DM3RSYO	ID	DM3RSYO
DM3RSYO	DN	EM-1745
DM3RSYO	HS	Investigative
DM3RSYO	SN	BDBM17290; E2-adenosine hybrid compound, 8; EM1745; [5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl 9-[(1S,10R,11S,14S,15S)-5,14-dihydroxy-15-methyltetracyclo[8.7.0.0; {11,15}]heptadeca-2,4,6-trien-13-yl]nonanoate
DM3RSYO	DT	Small molecular drug
DM3RSYO	PC	446201
DM3RSYO	MW	677.8
DM3RSYO	FM	C37H51N5O7
DM3RSYO	IC	InChI=1S/C37H51N5O7/c1-37-15-14-25-24-13-11-23(43)16-21(24)10-12-26(25)27(37)17-22(33(37)47)8-6-4-2-3-5-7-9-29(44)48-18-28-31(45)32(46)36(49-28)42-20-41-30-34(38)39-19-40-35(30)42/h11,13,16,19-20,22,25-28,31-33,36,43,45-47H,2-10,12,14-15,17-18H2,1H3,(H2,38,39,40)/t22-,25+,26+,27-,28+,31+,32+,33-,36+,37-/m0/s1
DM3RSYO	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@@H]([C@@H]2O)CCCCCCCCC(=O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)CCC7=C3C=CC(=C7)O
DM3RSYO	IK	CKSDYJASHNGOOS-KTXOUVACSA-N
DM3RSYO	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl 9-[(8R,9S,13S,14S,16S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]nonanoate
DM3RSYO	DE	Discovery agent

DMC4XJ6	ID	DMC4XJ6
DMC4XJ6	DN	EM-523
DMC4XJ6	HS	Investigative
DMC4XJ6	SN	N-ethyl,N-methyl EM-A enolether; erythromycin analogue (523)
DMC4XJ6	DT	Small molecular drug
DMC4XJ6	PC	184178
DMC4XJ6	MW	729.9
DMC4XJ6	FM	C38H67NO12
DMC4XJ6	IC	InChI=1S/C38H67NO12/c1-14-26-38(11,44)31(41)21(5)29-19(3)17-37(10,51-29)33(50-35-28(40)25(39(12)15-2)16-20(4)46-35)22(6)30(23(7)34(43)48-26)49-27-18-36(9,45-13)32(42)24(8)47-27/h20-28,30-33,35,40-42,44H,14-18H2,1-13H3/t20-,21+,22+,23-,24+,25+,26-,27+,28-,30+,31-,32+,33-,35+,36-,37+,38-/m1/s1
DMC4XJ6	CS	CC[C@@H]1[C@@]([C@@H]([C@H](C2=C(C[C@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)CC)O)C)C)C)O)(C)O
DMC4XJ6	IK	UTTLXGDLSXWDJI-OTELOYJSSA-N
DMC4XJ6	IU	(2R,3R,4S,5R,8R,9S,10S,11R,12S)-5-ethyl-11-[(2S,3R,4S,6R)-4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-3,4-dihydroxy-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DMC4XJ6	DE	Discovery agent

DMFQX1U	ID	DMFQX1U
DMFQX1U	DN	EMATE
DMFQX1U	HS	Investigative
DMFQX1U	SN	Emate compound; Estrone 3-O-Sulfamate; EMATE; Estrone-3-O-sulfamate; Oestrone-3-O-sulphamate; 148672-09-7; Estra-1,3,5(10)-trien-17-one-3-sulfamate; CHEMBL122708; 3-((Aminosulfonyl)oxy)estra-1,3,5(10)-trien-17-one; C18H23NO4S; 3-[(Aminosulfonyl)oxy]estra-1,3,5(10)-trien-17-one; Estra-1,3,5(10)-trien-17-one, 3-((aminosulfonyl)oxy)-; Estrone Sulfamate; estrone3-O-sulfamate; NSC685426; Estrone O-Sulfamate; Estrone 3-Sulfamate; AC1L2SFZ; SCHEMBL305660; CTK8F0296; RVKFQAJIXCZXQY-CBZIJGRNSA-N; ZINC5832614; BDBM50134329; AKOS030241107
DMFQX1U	DT	Small molecular drug
DMFQX1U	PC	127676
DMFQX1U	MW	349.4
DMFQX1U	FM	C18H23NO4S
DMFQX1U	IC	InChI=1S/C18H23NO4S/c1-18-9-8-14-13-5-3-12(23-24(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16H,2,4,6-9H2,1H3,(H2,19,21,22)/t14-,15-,16+,18+/m1/s1
DMFQX1U	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)N
DMFQX1U	IK	RVKFQAJIXCZXQY-CBZIJGRNSA-N
DMFQX1U	IU	[(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfamate
DMFQX1U	CA	CAS 148672-09-7
DMFQX1U	DE	Discovery agent

DMUH1JX	ID	DMUH1JX
DMUH1JX	DN	EMC-0901
DMUH1JX	HS	Investigative
DMUH1JX	SN	EMC-0902; Dipeptidyl peptidase IV inhibitors (diabetes), EMC Microcollections; DPP-IV inhibitors (diabetes), EMC Microcollections
DMUH1JX	CP	EMC Microcollections GmbH
DMUH1JX	DE	Diabetic complication

DM4SEMA	ID	DM4SEMA
DM4SEMA	DN	EMD 56551
DM4SEMA	HS	Investigative
DM4SEMA	DE	Discovery agent

DM3AGUQ	ID	DM3AGUQ
DM3AGUQ	DN	EMD-386088
DM3AGUQ	HS	Investigative
DM3AGUQ	SN	compound 18 [PMID 16055331]; EMD 386088; EMD386088
DM3AGUQ	DT	Small molecular drug
DM3AGUQ	PC	10131112
DM3AGUQ	MW	246.73
DM3AGUQ	FM	C14H15ClN2
DM3AGUQ	IC	InChI=1S/C14H15ClN2/c1-9-14(10-4-6-16-7-5-10)12-8-11(15)2-3-13(12)17-9/h2-4,8,16-17H,5-7H2,1H3
DM3AGUQ	CS	CC1=C(C2=C(N1)C=CC(=C2)Cl)C3=CCNCC3
DM3AGUQ	IK	BPPGPYJBCVXILI-UHFFFAOYSA-N
DM3AGUQ	IU	5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
DM3AGUQ	CA	CAS 54635-62-0
DM3AGUQ	CB	CHEBI:92829
DM3AGUQ	DE	Discovery agent

DM6O2BR	ID	DM6O2BR
DM6O2BR	DN	EMPA
DM6O2BR	HS	Investigative
DM6O2BR	SN	EMPA; 680590-49-2; CHEMBL2385132; N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonyl-amino]-N-(pyridin-3-ylmethyl)ethanamide; 7MA; GTPL4037; SCHEMBL1040297; MolPort-035-765-760; KJPHTXTWFHVJIG-UHFFFAOYSA-N; BCP23952; ZINC95617557; BDBM50434481; AKOS024458223; API0017731; NCGC00386678-02; N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonylamino]-N-(pyridin-3-ylmethyl)acetamide; N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulphonyl)-amino]-N-pyridin-3-ylmethyl-acetamide
DM6O2BR	DT	Small molecular drug
DM6O2BR	PC	9981404
DM6O2BR	MW	454.5
DM6O2BR	FM	C23H26N4O4S
DM6O2BR	IC	InChI=1S/C23H26N4O4S/c1-4-26(16-19-9-7-13-24-14-19)23(28)17-27(20-11-12-22(31-3)25-15-20)32(29,30)21-10-6-5-8-18(21)2/h5-15H,4,16-17H2,1-3H3
DM6O2BR	CS	CCN(CC1=CN=CC=C1)C(=O)CN(C2=CN=C(C=C2)OC)S(=O)(=O)C3=CC=CC=C3C
DM6O2BR	IK	KJPHTXTWFHVJIG-UHFFFAOYSA-N
DM6O2BR	IU	N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonylamino]-N-(pyridin-3-ylmethyl)acetamide
DM6O2BR	CA	CAS 680590-49-2
DM6O2BR	DE	Discovery agent

DMQLNZC	ID	DMQLNZC
DMQLNZC	DN	Empagli ozin
DMQLNZC	HS	Investigative
DMQLNZC	CP	Boehringer ingelheim pharmaceuticals; eli lilly
DMQLNZC	DE	Type-2 diabetes

DMASQWV	ID	DMASQWV
DMASQWV	DN	enantio PAF C-16
DMASQWV	HS	Investigative
DMASQWV	SN	enantio platelet-activating factor C-16
DMASQWV	DT	Small molecular drug
DMASQWV	PC	2499
DMASQWV	MW	523.7
DMASQWV	FM	C26H54NO7P
DMASQWV	IC	InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3
DMASQWV	CS	CCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)C
DMASQWV	IK	HVAUUPRFYPCOCA-UHFFFAOYSA-N
DMASQWV	IU	(2-acetyloxy-3-hexadecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
DMASQWV	CA	CAS 77286-68-1
DMASQWV	DE	Discovery agent

DMUCZPJ	ID	DMUCZPJ
DMUCZPJ	DN	ENDG-4010
DMUCZPJ	HS	Investigative
DMUCZPJ	SN	ENDG-1620; Imaging agent (tumor), EndogenX
DMUCZPJ	CP	EndogenX Inc
DMUCZPJ	DE	Solid tumour/cancer

DM7RDGH	ID	DM7RDGH
DM7RDGH	DN	ENDIANDRIN A
DM7RDGH	HS	Investigative
DM7RDGH	SN	ENDIANDRIN A; CHEMBL228274; BDBM50216277; 4,4''-((1R,2R,3S,4S)-3,4-dimethylcyclobutane-1,2-diyl)bis(2-methoxyphenol)
DM7RDGH	DT	Small molecular drug
DM7RDGH	PC	16756780
DM7RDGH	MW	328.4
DM7RDGH	FM	C20H24O4
DM7RDGH	IC	InChI=1S/C20H24O4/c1-11-12(2)20(14-6-8-16(22)18(10-14)24-4)19(11)13-5-7-15(21)17(9-13)23-3/h5-12,19-22H,1-4H3/t11-,12-,19-,20-/m0/s1
DM7RDGH	CS	C[C@H]1[C@@H]([C@H]([C@@H]1C2=CC(=C(C=C2)O)OC)C3=CC(=C(C=C3)O)OC)C
DM7RDGH	IK	QDBUCXMBHJMGCN-HIGYNYDNSA-N
DM7RDGH	IU	4-[(1R,2R,3S,4S)-2-(4-hydroxy-3-methoxyphenyl)-3,4-dimethylcyclobutyl]-2-methoxyphenol
DM7RDGH	DE	Discovery agent

DM4AI91	ID	DM4AI91
DM4AI91	DN	Endo-CD
DM4AI91	HS	Investigative
DM4AI91	SN	Endostatin-cytosine deaminase fusion protein
DM4AI91	DE	Discovery agent

DMOQWBU	ID	DMOQWBU
DMOQWBU	DN	ENDOMORPHIN 2
DMOQWBU	HS	Investigative
DMOQWBU	SN	Endomorphin 2; Endomorphin-2; 141801-26-5; H-Tyr-Pro-Phe-Phe-NH2; UNII-3PH5M0466G; CHEMBL333357; 3PH5M0466G; L-Phenylalaninamide,L-tyrosyl-L-prolyl-L-phenylalanyl-; (S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide; (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMOQWBU	DT	Small molecular drug
DMOQWBU	PC	5311081
DMOQWBU	MW	571.7
DMOQWBU	FM	C32H37N5O5
DMOQWBU	IC	InChI=1S/C32H37N5O5/c33-25(18-23-13-15-24(38)16-14-23)32(42)37-17-7-12-28(37)31(41)36-27(20-22-10-5-2-6-11-22)30(40)35-26(29(34)39)19-21-8-3-1-4-9-21/h1-6,8-11,13-16,25-28,38H,7,12,17-20,33H2,(H2,34,39)(H,35,40)(H,36,41)/t25-,26-,27-,28-/m0/s1
DMOQWBU	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N
DMOQWBU	IK	XIJHWXXXIMEHKW-LJWNLINESA-N
DMOQWBU	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMOQWBU	CA	CAS 141801-26-5
DMOQWBU	DE	Discovery agent

DMBJUEM	ID	DMBJUEM
DMBJUEM	DN	ENDOMORPHIN-1
DMBJUEM	HS	Investigative
DMBJUEM	SN	Endomorphin 1; Endomorphin-1; 189388-22-5; Tyr-Pro-Trp-Phe-Nh2; H-Tyr-Pro-Trp-Phe-NH2; CHEMBL316446; L-Phenylalaninamide,L-tyrosyl-L-prolyl-L-tryptophyl-; (S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide; (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMBJUEM	DT	Small molecular drug
DMBJUEM	PC	5311080
DMBJUEM	MW	610.7
DMBJUEM	FM	C34H38N6O5
DMBJUEM	IC	InChI=1S/C34H38N6O5/c35-26(17-22-12-14-24(41)15-13-22)34(45)40-16-6-11-30(40)33(44)39-29(19-23-20-37-27-10-5-4-9-25(23)27)32(43)38-28(31(36)42)18-21-7-2-1-3-8-21/h1-5,7-10,12-15,20,26,28-30,37,41H,6,11,16-19,35H2,(H2,36,42)(H,38,43)(H,39,44)/t26-,28-,29-,30-/m0/s1
DMBJUEM	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N
DMBJUEM	IK	ZEXLJFNSKAHNFH-SYKYGTKKSA-N
DMBJUEM	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMBJUEM	CA	CAS 189388-22-5
DMBJUEM	DE	Discovery agent

DMI2RQS	ID	DMI2RQS
DMI2RQS	DN	Endomorphins
DMI2RQS	HS	Investigative
DMI2RQS	SN	EM-1; EM-2; Endomorphins (chronic inflammation); Endomorphin EM-1, University of Bristol; Endomorphin EM-2, University of Bristol; Endomorphins (chronic inflammation), University of Bristol
DMI2RQS	CP	University of Bristol
DMI2RQS	DE	Inflammation

DMOEIYQ	ID	DMOEIYQ
DMOEIYQ	DN	Endothelin-2
DMOEIYQ	HS	Investigative
DMOEIYQ	SN	Endothelin 2, human; ET-2; CHEMBL3774897; Endothelin-2; endothelin-2 human; Endothelin 2 human; GTPL990
DMOEIYQ	DT	Small molecular drug
DMOEIYQ	PC	16219332
DMOEIYQ	MW	2546.9
DMOEIYQ	FM	C115H160N26O32S4
DMOEIYQ	IC	InChI=1S/C115H160N26O32S4/c1-11-59(9)93(113(170)132-82(115(172)173)41-64-46-120-71-27-19-17-25-68(64)71)141-114(171)94(60(10)12-2)140-105(162)81(44-91(150)151)130-99(156)75(37-57(5)6)125-103(160)79(42-65-47-118-55-121-65)128-109(166)86-52-175-174-51-69(117)95(152)133-83(48-142)108(165)138-87-53-176-177-54-88(111(168)139-92(58(7)8)112(169)131-77(39-62-29-31-66(145)32-30-62)100(157)126-76(101(158)137-86)38-61-22-14-13-15-23-61)136-97(154)73(33-34-89(146)147)123-96(153)72(28-20-21-35-116)122-104(161)80(43-90(148)149)129-98(155)74(36-56(3)4)124-102(159)78(40-63-45-119-70-26-18-16-24-67(63)70)127-106(163)84(49-143)134-107(164)85(50-144)135-110(87)167/h13-19,22-27,29-32,45-47,55-60,69,72-88,92-94,119-120,142-145H,11-12,20-21,28,33-44,48-54,116-117H2,1-10H3,(H,118,121)(H,122,161)(H,123,153)(H,124,159)(H,125,160)(H,126,157)(H,127,163)(H,128,166)(H,129,155)(H,130,156)(H,131,169)(H,132,170)(H,133,152)(H,134,164)(H,135,167)(H,136,154)(H,137,158)(H,138,165)(H,139,168)(H,140,162)(H,141,171)(H,146,147)(H,148,149)(H,150,151)(H,172,173)/t59-,60-,69-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,92-,93-,94-/m0/s1
DMOEIYQ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC6=CC=CC=C6)CC7=CC=C(C=C7)O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC5=O)CO)CO)CC8=CNC9=CC=CC=C98)CC(C)C)CC(=O)O)CCCCN)CCC(=O)O)CO)N
DMOEIYQ	IK	MLFJHYIHIKEBTQ-IYRKOGFYSA-N
DMOEIYQ	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(1R,4S,7S,10S,13S,16S,19S,22S,25R,28S,31R,36R,39S,42S,45S)-31-amino-7-(4-aminobutyl)-39-benzyl-4-(2-carboxyethyl)-10-(carboxymethyl)-19,22,28-tris(hydroxymethyl)-42-[(4-hydroxyphenyl)methyl]-16-(1H-indol-3-ylmethyl)-13-(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-45-propan-2-yl-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecazabicyclo[23.22.4]henpentacontane-36-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMOEIYQ	DE	Discovery agent

DM0DM6X	ID	DM0DM6X
DM0DM6X	DN	Endothelin-3
DM0DM6X	HS	Investigative
DM0DM6X	SN	ET-3; Endothelin 3 human, rat; 117399-93-6; Endothelin 3 human, rat, &gt; =97% (HPLC), powder
DM0DM6X	DT	Small molecular drug
DM0DM6X	PC	16219334
DM0DM6X	MW	2643.1
DM0DM6X	FM	C121H168N26O33S4
DM0DM6X	IC	InChI=1S/C121H168N26O33S4/c1-11-62(7)97(117(175)139-89(121(179)180)49-70-53-126-77-25-17-16-24-75(70)77)145-118(176)98(63(8)12-2)144-112(170)88(52-95(157)158)136-105(163)81(44-60(3)4)131-109(167)86(50-71-54-125-59-127-71)134-113(171)90-56-182-181-55-76(124)101(159)146-99(64(9)148)120(178)142-91-57-183-184-58-92(115(173)143-96(61(5)6)116(174)137-84(48-69-32-38-74(152)39-33-69)107(165)132-82(108(166)141-90)46-67-28-34-72(150)35-29-67)140-104(162)80(40-41-93(153)154)130-102(160)78(26-18-20-42-122)129-110(168)87(51-94(155)156)135-103(161)79(27-19-21-43-123)128-106(164)83(47-68-30-36-73(151)37-31-68)138-119(177)100(65(10)149)147-111(169)85(133-114(91)172)45-66-22-14-13-15-23-66/h13-17,22-25,28-39,53-54,59-65,76,78-92,96-100,126,148-152H,11-12,18-21,26-27,40-52,55-58,122-124H2,1-10H3,(H,125,127)(H,128,164)(H,129,168)(H,130,160)(H,131,167)(H,132,165)(H,133,172)(H,134,171)(H,135,161)(H,136,163)(H,137,174)(H,138,177)(H,139,175)(H,140,162)(H,141,166)(H,142,178)(H,143,173)(H,144,170)(H,145,176)(H,146,159)(H,147,169)(H,153,154)(H,155,156)(H,157,158)(H,179,180)/t62-,63-,64?,65?,76-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,96-,97-,98-,99-,100-/m0/s1
DM0DM6X	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC6=CC=C(C=C6)O)CC7=CC=C(C=C7)O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC5=O)CC8=CC=CC=C8)C(C)O)CC9=CC=C(C=C9)O)CCCCN)CC(=O)O)CCCCN)CCC(=O)O)C(C)O)N
DM0DM6X	IK	OQGZWNZGVYLIFX-XKIQDWPYSA-N
DM0DM6X	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(1R,4S,7S,10S,13S,16S,19S,22S,25R,28S,31R,36R,39S,42S,45S)-31-amino-7,13-bis(4-aminobutyl)-22-benzyl-4-(2-carboxyethyl)-10-(carboxymethyl)-19,28-bis(1-hydroxyethyl)-16,39,42-tris[(4-hydroxyphenyl)methyl]-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-45-propan-2-yl-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecazabicyclo[23.22.4]henpentacontane-36-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DM0DM6X	CA	CAS 117399-93-6
DM0DM6X	DE	Discovery agent

DM0STFR	ID	DM0STFR
DM0STFR	DN	ENHYDRIN
DM0STFR	HS	Investigative
DM0STFR	SN	Enhydrin; enhydrine; CHEMBL206765
DM0STFR	DT	Small molecular drug
DM0STFR	PC	5281441
DM0STFR	MW	464.5
DM0STFR	FM	C23H28O10
DM0STFR	IC	InChI=1S/C23H28O10/c1-10-14-16(31-21(27)23(5)11(2)32-23)15(29-12(3)24)13(20(26)28-6)8-7-9-22(4)18(33-22)17(14)30-19(10)25/h8,11,14-18H,1,7,9H2,2-6H3/b13-8+/t11-,14-,15+,16+,17+,18-,22-,23-/m1/s1
DM0STFR	CS	C[C@@H]1[C@](O1)(C)C(=O)O[C@H]2[C@@H]3[C@@H]([C@@H]4[C@](O4)(CC/C=C(\\[C@@H]2OC(=O)C)/C(=O)OC)C)OC(=O)C3=C
DM0STFR	IK	VCBNPTWPJQLHQN-FQAPAZNFSA-N
DM0STFR	IU	methyl (1S,2R,4R,7E,9S,10S,11R)-9-acetyloxy-10-[(2R,3R)-2,3-dimethyloxirane-2-carbonyl]oxy-4-methyl-12-methylidene-13-oxo-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-ene-8-carboxylate
DM0STFR	CA	CAS 33880-85-2
DM0STFR	DE	Discovery agent

DMYJ8ZB	ID	DMYJ8ZB
DMYJ8ZB	DN	Enoxaprin
DMYJ8ZB	HS	Investigative
DMYJ8ZB	DE	Discovery agent

DMSPIF2	ID	DMSPIF2
DMSPIF2	DN	EP 157
DMSPIF2	HS	Investigative
DMSPIF2	SN	EP-157; EP157
DMSPIF2	DT	Small molecular drug
DMSPIF2	PC	73755162
DMSPIF2	MW	443.6
DMSPIF2	FM	C29H33NO3
DMSPIF2	IC	InChI=1S/C29H33NO3/c31-28(32)16-10-2-1-9-15-26-22-17-19-23(20-18-22)27(26)21-30-33-29(24-11-5-3-6-12-24)25-13-7-4-8-14-25/h1,3-9,11-14,17,19,21-23,26-27,29H,2,10,15-16,18,20H2,(H,31,32)/b9-1-,30-21-/t22-,23+,26+,27+/m0/s1
DMSPIF2	CS	C1C[C@H]2C=C[C@@H]1[C@H]([C@@H]2/C=N\\OC(C3=CC=CC=C3)C4=CC=CC=C4)C/C=C\\CCCC(=O)O
DMSPIF2	IK	NBBRUBRIVJNCKV-WXGDQWFLSA-N
DMSPIF2	IU	(Z)-7-[(1R,2R,3R,4S)-3-[(Z)-benzhydryloxyiminomethyl]-2-bicyclo[2.2.2]oct-5-enyl]hept-5-enoic acid
DMSPIF2	DE	Discovery agent

DM7YION	ID	DM7YION
DM7YION	DN	EP 171
DM7YION	HS	Investigative
DM7YION	SN	EP-171; EP171
DM7YION	DT	Small molecular drug
DM7YION	PC	5311384
DM7YION	MW	404.5
DM7YION	FM	C23H29FO5
DM7YION	IC	InChI=1S/C23H29FO5/c24-16-7-10-18(11-8-16)28-15-17(25)9-12-20-19(21-13-14-22(20)29-21)5-3-1-2-4-6-23(26)27/h1,3,7-12,17,19-22,25H,2,4-6,13-15H2,(H,26,27)/b3-1-,12-9+/t17-,19+,20+,21-,22+/m0/s1
DM7YION	CS	C1C[C@@H]2[C@@H]([C@H]([C@H]1O2)C/C=C\\CCCC(=O)O)/C=C/[C@@H](COC3=CC=C(C=C3)F)O
DM7YION	IK	JEUSDRLWFSRHSX-XUEDOEMRSA-N
DM7YION	IU	(Z)-7-[(1S,2R,3R,4R)-3-[(E,3S)-4-(4-fluorophenoxy)-3-hydroxybut-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DM7YION	DE	Discovery agent

DMAURX5	ID	DMAURX5
DMAURX5	DN	EP-200
DMAURX5	HS	Investigative
DMAURX5	SN	HCG targeted oncolytic peptide (iv, CLYP, multiple cancers), Esperance Pharmaceuticals; Luteinizing hormone receptor targeted oncolytic peptide (iv/CLYP, multiple cancers), Esperance Pharmaceuticals
DMAURX5	CP	Esperance Pharmaceuticals Inc
DMAURX5	DE	Solid tumour/cancer

DMHN82B	ID	DMHN82B
DMHN82B	DN	EP-37
DMHN82B	HS	Investigative
DMHN82B	SN	Factor Xa antagonist (oral, stroke prevention in atrial fibrillation), Endotis
DMHN82B	CP	Endotis Pharma
DMHN82B	DE	Cerebrovascular ischaemia

DM01MW7	ID	DM01MW7
DM01MW7	DN	EPALRESTATE
DM01MW7	HS	Investigative
DM01MW7	SN	CHEMBL449204; AC1Q1J87; [5-(2-Methyl-3-phenyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid; ZINC967120
DM01MW7	DT	Small molecular drug
DM01MW7	PC	1201332
DM01MW7	MW	319.4
DM01MW7	FM	C15H13NO3S2
DM01MW7	IC	InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7-,12-8+
DM01MW7	CS	C/C(=C/C1=CC=CC=C1)/C=C/2\\C(=O)N(C(=S)S2)CC(=O)O
DM01MW7	IK	CHNUOJQWGUIOLD-MITUOZDPSA-N
DM01MW7	IU	2-[(5E)-5-[(Z)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
DM01MW7	DE	Discovery agent

DMBLSX3	ID	DMBLSX3
DMBLSX3	DN	EPB-415
DMBLSX3	HS	Investigative
DMBLSX3	SN	Ribavirin prodrug (hepatitis C virus infection), Epiphany
DMBLSX3	CP	Epiphany Biosciences
DMBLSX3	DE	Hepatitis C virus infection

DMT7RXZ	ID	DMT7RXZ
DMT7RXZ	DN	E-pentenylbutanedioic acid 32
DMT7RXZ	HS	Investigative
DMT7RXZ	DT	Small molecular drug
DMT7RXZ	PC	56603767
DMT7RXZ	MW	210.1
DMT7RXZ	FM	C10H12Li2O4
DMT7RXZ	IC	InChI=1S/C10H14O4.2Li/c1-7(2)4-3-5-8(10(13)14)6-9(11)12;;/h6H,1,3-5H2,2H3,(H,11,12)(H,13,14);;/q;2*+1/p-2/b8-6+;;
DMT7RXZ	CS	[Li+].[Li+].CC(=C)CCC/C(=C\\C(=O)[O-])/C(=O)[O-]
DMT7RXZ	IK	GPRQQRASSGZCNY-OVGXCEQFSA-L
DMT7RXZ	IU	dilithium;(E)-2-(4-methylpent-4-enyl)but-2-enedioate
DMT7RXZ	DE	Discovery agent

DM3F427	ID	DM3F427
DM3F427	DN	EphB4-131
DM3F427	HS	Investigative
DM3F427	SN	EphB4 neutralizing antibody, Vasgene
DM3F427	CP	VasGene Therapeutics Inc
DM3F427	DT	Antibody
DM3F427	DE	Solid tumour/cancer

DMYWV81	ID	DMYWV81
DMYWV81	DN	EPI-001
DMYWV81	HS	Investigative
DMYWV81	SN	227947-06-0; BADGE-HCl-H2O; Bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether; 3-[4-[2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl]phenoxy]propane-1,2-diol; 3-(4-{2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl}phenoxy)propane-1,2-diol; EPI 001; AC1N56RN; SCHEMBL12267194; CTK8F8201; CHEBI:59642; DTXSID30400170; MolPort-003-939-733; BCP18361; EX-A2389; s7955; AKOS030573303; ACM227947060; AC-29035; RT-011557; EPI-001, &gt; J-014857
DMYWV81	CP	British Columbia Cancer Agency
DMYWV81	DT	Small molecular drug
DMYWV81	PC	4166922
DMYWV81	MW	394.9
DMYWV81	FM	C21H27ClO5
DMYWV81	IC	InChI=1S/C21H27ClO5/c1-21(2,15-3-7-19(8-4-15)26-13-17(24)11-22)16-5-9-20(10-6-16)27-14-18(25)12-23/h3-10,17-18,23-25H,11-14H2,1-2H3
DMYWV81	CS	CC(C)(C1=CC=C(C=C1)OCC(CO)O)C2=CC=C(C=C2)OCC(CCl)O
DMYWV81	IK	HDTYUHNZRYZEEB-UHFFFAOYSA-N
DMYWV81	IU	3-[4-[2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl]phenoxy]propane-1,2-diol
DMYWV81	CA	CAS 227947-06-0
DMYWV81	CB	CHEBI:59642
DMYWV81	DE	Prostate cancer

DM72DO1	ID	DM72DO1
DM72DO1	DN	EPI-0030
DM72DO1	HS	Investigative
DM72DO1	SN	APX-003; SIM-BD-0801; Humanized anti-VEGF mAbs (RabMab/MLG, cancer), Apexigen/Simcere; Humanized anti-VEGF mAbs (RabMab/MLG, cancer), Epitomics/Simcere
DM72DO1	CP	Epitomics Inc
DM72DO1	DE	Solid tumour/cancer

DMAGZD8	ID	DMAGZD8
DMAGZD8	DN	Epibatidine
DMAGZD8	HS	Investigative
DMAGZD8	SN	( inverted exclamation markA)-Epibatidine; CHEMBL298517; (1S,2S,4R)-Epibatidine; CMI 477; 152378-30-8; 148152-66-3; (1S-exo)-2-(6-Chloro-3-pyridinyl)-7-azabicyclo(2.2.1)heptane; 7-Azabicyclo(2.2.1)heptane, 2-(6-chloro-3-pyridinyl)-, (1S-exo)-; (-)-1-epidatidine; Tocris-0684; SCHEMBL316977; (1S,2S,4R)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane; GTPL5348; CMI 488; ZINC967913; BDBM50143320
DMAGZD8	DT	Small molecular drug
DMAGZD8	PC	854023
DMAGZD8	MW	208.69
DMAGZD8	FM	C11H13ClN2
DMAGZD8	IC	InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2/t8-,9+,10+/m0/s1
DMAGZD8	CS	C1C[C@@H]2[C@H](C[C@H]1N2)C3=CN=C(C=C3)Cl
DMAGZD8	IK	NLPRAJRHRHZCQQ-IVZWLZJFSA-N
DMAGZD8	IU	(1R,2R,4S)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane
DMAGZD8	CA	CAS 140111-52-0
DMAGZD8	DE	Discovery agent

DMFMWA7	ID	DMFMWA7
DMFMWA7	DN	EpiCept
DMFMWA7	HS	Investigative
DMFMWA7	TC	Analgesics
DMFMWA7	DE	Neuropathic pain

DMGKIYE	ID	DMGKIYE
DMGKIYE	DN	EPIDEPRIDE
DMGKIYE	HS	Investigative
DMGKIYE	SN	Epidepride; CHEMBL44237; 107188-87-4; N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-iodo-2,3-dimethoxybenzamide; AC1L3AWQ; SCHEMBL8961795; DTXSID00147929; CHEBI:125687; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-iodo-2,3-dimethoxybenzamide; BDBM50008782; PDSP2_001484; BRD-K99502674-001-01-5; (s)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxy-benzamide; N-(1-Ethyl-pyrrolidin-2-ylmethyl)-5-iodo-2,3-dimethoxy-benzamide (epidepride); Epidepride;N-(1-Ethyl-pyrrolidin-2-ylmethyl)-5-iodo-2,3-dimethoxy-benzamide; Benzamide, N-((1-
DMGKIYE	DT	Small molecular drug
DMGKIYE	PC	86101
DMGKIYE	MW	418.27
DMGKIYE	FM	C16H23IN2O3
DMGKIYE	IC	InChI=1S/C16H23IN2O3/c1-4-19-7-5-6-12(19)10-18-16(20)13-8-11(17)9-14(21-2)15(13)22-3/h8-9,12H,4-7,10H2,1-3H3,(H,18,20)/t12-/m0/s1
DMGKIYE	CS	CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2)I)OC)OC
DMGKIYE	IK	APNNSBJHVTUORL-LBPRGKRZSA-N
DMGKIYE	IU	N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-iodo-2,3-dimethoxybenzamide
DMGKIYE	CA	CAS 107188-87-4
DMGKIYE	CB	CHEBI:125687
DMGKIYE	DE	Discovery agent

DMVZW92	ID	DMVZW92
DMVZW92	DN	Epierenone
DMVZW92	HS	Investigative
DMVZW92	SN	epierenone; CHEMBL237122; SCHEMBL13806060
DMVZW92	DT	Small molecular drug
DMVZW92	PC	44433505
DMVZW92	MW	414.5
DMVZW92	FM	C24H30O6
DMVZW92	IC	InChI=1S/C24H30O6/c1-22-7-4-13(25)10-12(22)11-14(21(27)28-3)17-15-5-8-24(9-6-16(26)30-24)23(15,2)20-19(29-20)18(17)22/h10,14-15,17-20H,4-9,11H2,1-3H3/t14-,15?,17?,18?,19+,20+,22+,23-,24-/m1/s1
DMVZW92	CS	C[C@]12CCC(=O)C=C1C[C@H](C3C2[C@H]4[C@H](O4)[C@]5(C3CC[C@@]56CCC(=O)O6)C)C(=O)OC
DMVZW92	IK	QBIRIYASLUPKQB-CBHLJOAQSA-N
DMVZW92	IU	methyl (2S,4R,5R,6R,11R,18R)-5,18-dimethyl-5',15-dioxospiro[3-oxapentacyclo[8.8.0.02,4.05,9.013,18]octadec-13-ene-6,2'-oxolane]-11-carboxylate
DMVZW92	DE	Discovery agent

DMQAEU8	ID	DMQAEU8
DMQAEU8	DN	EPIMER A
DMQAEU8	HS	Investigative
DMQAEU8	SN	CHEMBL564088; EPIMER A; BDBM50296787; N-((S)-2''-oxo-1,1'',2'',3-tetrahydrospiro[indene-2,3''-pyrrolo[2,3-b]pyridine]-5-yl)-2-(4-oxo-2a,3,4,5-tetrahydropyrrolo[4,3,2-de]quinolin-1(2H)-yl)acetamide 2; N-((S)-2''-oxo-1,1'',2'',3-tetrahydrospiro[indene-2,3''-pyrrolo[2,3-b]pyridine]-5-yl)-2-(4-oxo-2a,3,4,5-tetrahydropyrrolo[4,3,2-de]quinolin-1(2H)-yl)acetamide 1
DMQAEU8	DT	Small molecular drug
DMQAEU8	PC	23582940
DMQAEU8	MW	465.5
DMQAEU8	FM	C27H23N5O3
DMQAEU8	IC	InChI=1S/C27H23N5O3/c33-22-10-17-13-32(21-5-1-4-20(30-22)24(17)21)14-23(34)29-18-7-6-15-11-27(12-16(15)9-18)19-3-2-8-28-25(19)31-26(27)35/h1-9,17H,10-14H2,(H,29,34)(H,30,33)(H,28,31,35)/t17?,27-/m0/s1
DMQAEU8	CS	C1C2CN(C3=CC=CC(=C23)NC1=O)CC(=O)NC4=CC5=C(C[C@]6(C5)C7=C(NC6=O)N=CC=C7)C=C4
DMQAEU8	IK	YMMTXWRRJUTBEI-LYTHVRBOSA-N
DMQAEU8	IU	2-(6-oxo-2,7-diazatricyclo[6.3.1.04,12]dodeca-1(11),8(12),9-trien-2-yl)-N-[(2S)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide
DMQAEU8	DE	Discovery agent

DMW271Q	ID	DMW271Q
DMW271Q	DN	epipregnanolone sulphate
DMW271Q	HS	Investigative
DMW271Q	SN	epipregnanolone sulfate
DMW271Q	DT	Small molecular drug
DMW271Q	PC	73755084
DMW271Q	MW	398.6
DMW271Q	FM	C21H34O5S
DMW271Q	IC	InChI=1S/C21H34O5S/c1-13(22)17-6-7-18-16-5-4-14-12-15(26-27(23,24)25)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19H,4-12H2,1-3H3,(H,23,24,25)/t14-,15+,16?,17?,18?,19?,20+,21-/m1/s1
DMW271Q	CS	CC(=O)C1CCC2[C@@]1(CCC3C2CC[C@H]4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C)C
DMW271Q	IK	MENQCIVHHONJLU-ACWDEBGSSA-N
DMW271Q	IU	[(3S,5R,10S,13S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMW271Q	DE	Discovery agent

DM1C8FW	ID	DM1C8FW
DM1C8FW	DN	Epitinib
DM1C8FW	HS	Investigative
DM1C8FW	SN	HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma
DM1C8FW	CP	Hutchison Medipharma Enterprises Ltd
DM1C8FW	DT	Small molecular drug
DM1C8FW	PC	59142777
DM1C8FW	MW	430.5
DM1C8FW	FM	C24H26N6O2
DM1C8FW	IC	InChI=1S/C24H26N6O2/c1-4-17-7-6-8-18(13-17)27-23-19-14-21(22(32-3)15-20(19)25-16-26-23)28-24(31)30-11-9-29(5-2)10-12-30/h1,6-8,13-16H,5,9-12H2,2-3H3,(H,28,31)(H,25,26,27)
DM1C8FW	CS	CCN1CCN(CC1)C(=O)NC2=C(C=C3C(=C2)C(=NC=N3)NC4=CC=CC(=C4)C#C)OC
DM1C8FW	IK	DQAZPZIYEOGZAF-UHFFFAOYSA-N
DM1C8FW	IU	4-ethyl-N-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide
DM1C8FW	CA	1203902-67-3
DM1C8FW	DE	Solid tumour/cancer

DMVOD03	ID	DMVOD03
DMVOD03	DN	Eplerenone
DMVOD03	HS	Investigative
DMVOD03	SN	Epoxymexrenone; Inspra; Selara; SC-66110; Epleremone; CGP-30083; UNII-6995V82D0B; Cgp 30083
DMVOD03	TC	Antiviral Agents
DMVOD03	DT	Small molecular drug
DMVOD03	PC	443872
DMVOD03	MW	414.5
DMVOD03	FM	C24H30O6
DMVOD03	IC	InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
DMVOD03	CS	C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC
DMVOD03	IK	JUKPWJGBANNWMW-VWBFHTRKSA-N
DMVOD03	IU	methyl (1R,2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate
DMVOD03	CA	CAS 107724-20-9
DMVOD03	CB	CHEBI:31547
DMVOD03	DE	Coronavirus Disease 2019 (COVID-19)

DMDOR0L	ID	DMDOR0L
DMDOR0L	DN	EPLIVANSERIN MESILATE
DMDOR0L	HS	Investigative
DMDOR0L	SN	1(Z)-[2-(Dimethylamino)ethoxyimino]-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2(E)-propene methanesulfonate; Eplivanserin mesilate; SR-46349C
DMDOR0L	DE	Discovery agent

DMP2QF0	ID	DMP2QF0
DMP2QF0	DN	EPO peptide mimetics
DMP2QF0	HS	Investigative
DMP2QF0	SN	HemoMer; SESTide; AGE-49C; AGE-53C; EPO peptide mimetics (anemia); AG-EM-0040; EPO peptide mimetics (anemia), AplaGen; Erythropoietin peptide mimetics (anemia), AplaGen
DMP2QF0	CP	AplaGen GmbH
DMP2QF0	DE	Anemia

DMHQDLX	ID	DMHQDLX
DMHQDLX	DN	EPO-derived peptide
DMHQDLX	HS	Investigative
DMHQDLX	SN	EPO-derived peptide (diabetic retinopathy); EPO helix-B domain peptide (diabetic retinopathy), Araim Pharmaceuticals; EPO-derived peptide (diabetic retinopathy), Araim Pharmaceuticals; Erythropoietin-derived peptide (diabetic retinopathy), Araim Pharmaceuticals
DMHQDLX	CP	Araim Pharmaceuticals Inc
DMHQDLX	DE	Diabetic retinopathy

DMV8PB4	ID	DMV8PB4
DMV8PB4	DN	Epostane
DMV8PB4	HS	Investigative
DMV8PB4	SN	Epostane; Epostanum [Latin]; Epostano [Spanish]; WIN 32729; AC1L1HB6; Epostane [USAN:BAN:INN]; 4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta); Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-; LS-19418; Androst-2-ene-2-carbonitrile, 3,17-dihydroxy-4,17-dimethyl-4,5-epoxy-, (4-alpha,5-alpha,17-beta)-
DMV8PB4	DT	Small molecular drug
DMV8PB4	PC	6917713
DMV8PB4	MW	357.5
DMV8PB4	FM	C22H31NO3
DMV8PB4	IC	InChI=1S/C22H31NO3/c1-18-8-6-16-14(15(18)7-9-20(18,3)25)5-10-22-19(16,2)11-13(12-23)17(24)21(22,4)26-22/h14-16,24-25H,5-11H2,1-4H3/t14-,15-,16-,18-,19+,20-,21+,22-/m0/s1
DMV8PB4	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@]45[C@@]3(CC(=C([C@]4(O5)C)O)C#N)C
DMV8PB4	IK	CETKWEWBSMKADK-GSXVSZIWSA-N
DMV8PB4	IU	(1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,6,15,16-tetramethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile
DMV8PB4	CA	CAS 80471-63-2
DMV8PB4	DE	Abortion

DMK3VID	ID	DMK3VID
DMK3VID	DN	EPPTB
DMK3VID	HS	Investigative
DMK3VID	SN	Ro 5212773; Ro5212773; Ro-5212773
DMK3VID	DT	Small molecular drug
DMK3VID	PC	25175634
DMK3VID	MW	378.4
DMK3VID	FM	C20H21F3N2O2
DMK3VID	IC	InChI=1S/C20H21F3N2O2/c1-2-27-16-7-5-6-15(13-16)24-19(26)14-8-9-18(25-10-3-4-11-25)17(12-14)20(21,22)23/h5-9,12-13H,2-4,10-11H2,1H3,(H,24,26)
DMK3VID	CS	CCOC1=CC=CC(=C1)NC(=O)C2=CC(=C(C=C2)N3CCCC3)C(F)(F)F
DMK3VID	IK	KLFVWQCQUXXLOU-UHFFFAOYSA-N
DMK3VID	IU	N-(3-ethoxyphenyl)-4-pyrrolidin-1-yl-3-(trifluoromethyl)benzamide
DMK3VID	DE	Discovery agent

DMLN4V5	ID	DMLN4V5
DMLN4V5	DN	EPZ-004777
DMLN4V5	HS	Investigative
DMLN4V5	SN	DOT1L inhibitors (mixed lineage leukemia); DOT1L inhibitors (leukemia), Epizyme/GSK; DOT1L inhibitors (mixed lineage leukemia), Epizyme/GlaxoSmithKline
DMLN4V5	CP	Epizyme Inc
DMLN4V5	DT	Small molecular drug
DMLN4V5	PC	56962336
DMLN4V5	MW	539.7
DMLN4V5	FM	C28H41N7O4
DMLN4V5	IC	InChI=1S/C28H41N7O4/c1-17(2)34(13-6-12-30-27(38)33-19-9-7-18(8-10-19)28(3,4)5)15-21-22(36)23(37)26(39-21)35-14-11-20-24(29)31-16-32-25(20)35/h7-11,14,16-17,21-23,26,36-37H,6,12-13,15H2,1-5H3,(H2,29,31,32)(H2,30,33,38)/t21-,22-,23-,26-/m1/s1
DMLN4V5	CS	CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)C[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC4=C(N=CN=C43)N)O)O
DMLN4V5	IK	WXRGFPHDRFQODR-ICLZECGLSA-N
DMLN4V5	IU	1-[3-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea
DMLN4V5	CA	CAS 1338466-77-5
DMLN4V5	CB	CHEBI:124920
DMLN4V5	DE	leukaemia

DMYISTE	ID	DMYISTE
DMYISTE	DN	EPZ005687
DMYISTE	HS	Investigative
DMYISTE	SN	EPZ-005687; EPZ 005687
DMYISTE	DT	Small molecular drug
DMYISTE	PC	60160561
DMYISTE	MW	539.7
DMYISTE	FM	C32H37N5O3
DMYISTE	IC	InChI=1S/C32H37N5O3/c1-21-15-22(2)35-32(39)28(21)18-33-31(38)27-16-25(17-30-29(27)19-34-37(30)26-5-3-4-6-26)24-9-7-23(8-10-24)20-36-11-13-40-14-12-36/h7-10,15-17,19,26H,3-6,11-14,18,20H2,1-2H3,(H,33,38)(H,35,39)
DMYISTE	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC=C(C=C4)CN5CCOCC5)C6CCCC6)C
DMYISTE	IK	ZOIBZSZLMJDVDQ-UHFFFAOYSA-N
DMYISTE	IU	1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(morpholin-4-ylmethyl)phenyl]indazole-4-carboxamide
DMYISTE	CA	CAS 1396772-26-1
DMYISTE	CB	CHEBI:124922
DMYISTE	DE	Discovery agent

DM3INX7	ID	DM3INX7
DM3INX7	DN	EPZ015666
DM3INX7	HS	Investigative
DM3INX7	SN	EPZ-015666; EPZ 015666
DM3INX7	DT	Small molecular drug
DM3INX7	PC	90241673
DM3INX7	MW	383.4
DM3INX7	FM	C20H25N5O3
DM3INX7	IC	InChI=1S/C20H25N5O3/c26-17(10-25-6-5-14-3-1-2-4-15(14)9-25)8-21-20(27)18-7-19(23-13-22-18)24-16-11-28-12-16/h1-4,7,13,16-17,26H,5-6,8-12H2,(H,21,27)(H,22,23,24)/t17-/m0/s1
DM3INX7	CS	C1CN(CC2=CC=CC=C21)C[C@H](CNC(=O)C3=CC(=NC=N3)NC4COC4)O
DM3INX7	IK	ZKXZLIFRWWKZRY-KRWDZBQOSA-N
DM3INX7	IU	N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide
DM3INX7	DE	Discovery agent

DM2KMNU	ID	DM2KMNU
DM2KMNU	DN	EQ-1280
DM2KMNU	HS	Investigative
DM2KMNU	SN	11-beta hydroxysteroid dehydrogenase 1 inhibitor (diabetes), Equispharm
DM2KMNU	CP	Equispharm Co Ltd
DM2KMNU	DE	Diabetic complication

DMHO56W	ID	DMHO56W
DMHO56W	DN	Equilenin
DMHO56W	HS	Investigative
DMHO56W	SN	EQUILENIN; 517-09-9; UNII-W8FTJ17C4J; 3-Hydroxyestra-1,3,5(10),6,8-pentaen-17-one; W8FTJ17C4J; Equilenina [Spanish]; 3-hydroxy-estra-1,3,5(10),6,8-pentaen-17-one; CCRIS 9075; Equilenin solution; EINECS 208-230-5; (13S,14S)-3-hydroxy-13-methyl-12,14,15,16-tetrahydro-11H-cyclopenta[a]phenanthren-17-one; BRN 2335367; EQU; 3-Hydroxyoestra-1,3,5(10),6,8-pentaen-17-one; 1ogz; 1ogx; 1w6y; AC1L9H0U; 4-08-00-01420 (Beilstein Handbook Reference); SCHEMBL120922; CHEMBL225546; DTXSID2052156; CTK8F9475; ZINC393154; LMST02010007; BDBM50423545
DMHO56W	DT	Small molecular drug
DMHO56W	PC	444865
DMHO56W	MW	266.3
DMHO56W	FM	C18H18O2
DMHO56W	IC	InChI=1S/C18H18O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2-5,10,16,19H,6-9H2,1H3/t16-,18-/m0/s1
DMHO56W	CS	C[C@]12CCC3=C([C@@H]1CCC2=O)C=CC4=C3C=CC(=C4)O
DMHO56W	IK	PDRGHUMCVRDZLQ-WMZOPIPTSA-N
DMHO56W	IU	(13S,14S)-3-hydroxy-13-methyl-12,14,15,16-tetrahydro-11H-cyclopenta[a]phenanthren-17-one
DMHO56W	CA	CAS 517-09-9
DMHO56W	CB	CHEBI:34739
DMHO56W	DE	Discovery agent

DM2Q19U	ID	DM2Q19U
DM2Q19U	DN	Equilin
DM2Q19U	HS	Investigative
DM2Q19U	SN	7-Dehydroestrone; Dihydroequilenin; Equilin [USP]; UNII-08O86EX0J4; CCRIS 9074; EINECS 207-488-6; NSC 10971; BRN 2624302
DM2Q19U	TC	Antiviral Agents
DM2Q19U	DT	Small molecular drug
DM2Q19U	PC	223368
DM2Q19U	MW	268.3
DM2Q19U	FM	C18H20O2
DM2Q19U	IC	InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1
DM2Q19U	CS	C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)O)[C@@H]1CCC2=O
DM2Q19U	IK	WKRLQDKEXYKHJB-HFTRVMKXSA-N
DM2Q19U	IU	(9S,13S,14S)-3-hydroxy-13-methyl-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one
DM2Q19U	CA	CAS 474-86-2
DM2Q19U	CB	CHEBI:42309
DM2Q19U	DE	Coronavirus Disease 2019 (COVID-19)

DM9PT03	ID	DM9PT03
DM9PT03	DN	Equilin
DM9PT03	HS	Investigative
DM9PT03	SN	equilin; 7-Dehydroestrone; 474-86-2; Dihydroequilenin; 3-HYDROXYESTRA-1,3,5(10),7-TETRAEN-17-ONE; 1,3,5,7-Estratetraen-3-ol-17-one; Equilin [USP]; UNII-08O86EX0J4; MLS000028624; CHEBI:42309; WKRLQDKEXYKHJB-HFTRVMKXSA-N; 08O86EX0J4; Equilin (USP); SMR000058656; 3-hydroxy-estra-1,3,5(10),7tetraen-17-one; Estra-1,3,5(10),7-tetraen-17-one,3-hydroxy-; CCRIS 9074; EINECS 207-488-6; NSC 10971; BRN 2624302; (9S,13S,14S)-3-hydroxy-13-methyl-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one
DM9PT03	DT	Small molecular drug
DM9PT03	PC	223368
DM9PT03	MW	268.3
DM9PT03	FM	C18H20O2
DM9PT03	IC	InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1
DM9PT03	CS	C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)O)[C@@H]1CCC2=O
DM9PT03	IK	WKRLQDKEXYKHJB-HFTRVMKXSA-N
DM9PT03	IU	(9S,13S,14S)-3-hydroxy-13-methyl-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one
DM9PT03	CA	CAS 474-86-2
DM9PT03	CB	CHEBI:42309
DM9PT03	DE	Discovery agent

DMIQ801	ID	DMIQ801
DMIQ801	DN	ER-119884
DMIQ801	HS	Investigative
DMIQ801	SN	ER-119884; CHEMBL258503; (3r)-3-{[2-Benzyl-6-(3-Methoxypropoxy)pyridin-3-Yl]ethynyl}-1-Azabicyclo[2.2.2]octan-3-Ol; ER4; SCHEMBL6377294; BDBM50208577; (R)-3-(2-(2-benzyl-6-(3-methoxypropoxy)pyridin-3-yl)ethynyl)quinuclidin-3-ol; (R)-3-((2-benzyl-6-(3-methoxypropoxy)pyridin-3-yl)ethynyl)quinuclidin-3-ol; (3r)-3-[[2-benzyl-6-(3-methoxypropyloxy)-pyridin-3-yl]ethynyl] quinuclidin-3-ol
DMIQ801	DT	Small molecular drug
DMIQ801	PC	9844255
DMIQ801	MW	406.5
DMIQ801	FM	C25H30N2O3
DMIQ801	IC	InChI=1S/C25H30N2O3/c1-29-16-5-17-30-24-9-8-21(23(26-24)18-20-6-3-2-4-7-20)10-13-25(28)19-27-14-11-22(25)12-15-27/h2-4,6-9,22,28H,5,11-12,14-19H2,1H3/t25-/m1/s1
DMIQ801	CS	COCCCOC1=NC(=C(C=C1)C#C[C@]2(CN3CCC2CC3)O)CC4=CC=CC=C4
DMIQ801	IK	HVIKCINYHLGLMN-RUZDIDTESA-N
DMIQ801	IU	(3R)-3-[2-[2-benzyl-6-(3-methoxypropoxy)pyridin-3-yl]ethynyl]-1-azabicyclo[2.2.2]octan-3-ol
DMIQ801	DE	Discovery agent

DMUNO4R	ID	DMUNO4R
DMUNO4R	DN	ER-21018
DMUNO4R	HS	Investigative
DMUNO4R	SN	5-HT 4 receptor agonist (sustained release/tablet, gastrointestinal disease), Eurapharm
DMUNO4R	CP	Eurapharm Inc
DMUNO4R	DE	Gastrointestinal disease

DMAO6JS	ID	DMAO6JS
DMAO6JS	DN	ER-23006
DMAO6JS	HS	Investigative
DMAO6JS	CP	Eurapharm Inc
DMAO6JS	DE	Asthma

DMSG91J	ID	DMSG91J
DMSG91J	DN	ER819762
DMSG91J	HS	Investigative
DMSG91J	SN	ER-819762; ER 819762
DMSG91J	DT	Small molecular drug
DMSG91J	PC	42596951
DMSG91J	MW	489.6
DMSG91J	FM	C30H39N3O3
DMSG91J	IC	InChI=1S/C30H39N3O3/c1-7-33-29(34)32-19-24-16-25(35-5)17-26(36-6)28(24)22(4)15-27(32)30(33)8-10-31(11-9-30)18-23-13-20(2)12-21(3)14-23/h12-17,22H,7-11,18-19H2,1-6H3/t22-/m0/s1
DMSG91J	CS	CCN1C(=O)N2CC3=C([C@H](C=C2C14CCN(CC4)CC5=CC(=CC(=C5)C)C)C)C(=CC(=C3)OC)OC
DMSG91J	IK	ANKFBAJRCGOKJJ-QFIPXVFZSA-N
DMSG91J	IU	(5S)-1'-[(3,5-dimethylphenyl)methyl]-2-ethyl-6,8-dimethoxy-5-methylspiro[5,10-dihydroimidazo[1,5-b][2]benzazepine-3,4'-piperidine]-1-one
DMSG91J	DE	Discovery agent

DMYRDBX	ID	DMYRDBX
DMYRDBX	DN	ERB-002
DMYRDBX	HS	Investigative
DMYRDBX	SN	ERB-131; ERb agonists, ACADIA; Estrogen receptor beta agonists, ACADIA
DMYRDBX	CP	ACADIA Pharmaceuticals Inc
DMYRDBX	DE	Inflammation

DMD3BEQ	ID	DMD3BEQ
DMD3BEQ	DN	ERIODICTYOL
DMD3BEQ	HS	Investigative
DMD3BEQ	SN	(+/-)-Eriodictyol; 4049-38-1; MLS000877024; 5,7,3',4'-Tetrahydroxyflavanone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one; SMR000440624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one; Eriodictyol, (+/-)-; Eriodicytol; ERIODYCTOL; Flavanone, 3',4',5,7-tetrahydroxy-; AC1L1WLT
DMD3BEQ	DT	Small molecular drug
DMD3BEQ	PC	440735
DMD3BEQ	MW	288.25
DMD3BEQ	FM	C15H12O6
DMD3BEQ	IC	InChI=1S/C15H12O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-5,13,16-19H,6H2/t13-/m0/s1
DMD3BEQ	CS	C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C=C3)O)O
DMD3BEQ	IK	SBHXYTNGIZCORC-ZDUSSCGKSA-N
DMD3BEQ	IU	(2S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one
DMD3BEQ	CA	CAS 552-58-9
DMD3BEQ	CB	CHEBI:28412
DMD3BEQ	DE	Discovery agent

DMB3ROZ	ID	DMB3ROZ
DMB3ROZ	DN	ERK inhibitor III
DMB3ROZ	HS	Investigative
DMB3ROZ	SN	AC1NSSSU; 1-nitro-2-[(Z)-[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine
DMB3ROZ	DT	Small molecular drug
DMB3ROZ	PC	5721470
DMB3ROZ	MW	318.25
DMB3ROZ	FM	C12H10N6O5
DMB3ROZ	IC	InChI=1S/C12H10N6O5/c13-12(16-18(21)22)15-14-7-10-4-5-11(23-10)8-2-1-3-9(6-8)17(19)20/h1-7H,(H3,13,15,16)/b14-7+
DMB3ROZ	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC=C(O2)/C=N/N=C(/N)\\N[N+](=O)[O-]
DMB3ROZ	IK	RODAAYVFYDKHGT-VGOFMYFVSA-N
DMB3ROZ	IU	1-nitro-2-[(E)-[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine
DMB3ROZ	DE	Discovery agent

DM27FRY	ID	DM27FRY
DM27FRY	DN	Erybreadin b
DM27FRY	HS	Investigative
DM27FRY	SN	ERYBREADIN B; CHEMBL561967
DM27FRY	DT	Small molecular drug
DM27FRY	PC	45268827
DM27FRY	MW	390.5
DM27FRY	FM	C25H26O4
DM27FRY	IC	InChI=1S/C25H26O4/c1-14(2)5-6-16-20(26)9-7-18-22(16)27-13-19-15-8-10-21-17(23(15)28-24(18)19)11-12-25(3,4)29-21/h5,7-12,19,24,26H,6,13H2,1-4H3/t19-,24-/m0/s1
DM27FRY	CS	CC(=CCC1=C(C=CC2=C1OC[C@@H]3[C@H]2OC4=C3C=CC5=C4C=CC(O5)(C)C)O)C
DM27FRY	IK	XDRMVDDOBVPELW-CYFREDJKSA-N
DM27FRY	IU	(2R,11R)-17,17-dimethyl-6-(3-methylbut-2-enyl)-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),15,20-heptaen-7-ol
DM27FRY	DE	Discovery agent

DMNS976	ID	DMNS976
DMNS976	DN	Erybreadin C
DMNS976	HS	Investigative
DMNS976	SN	Erybreadin C; CHEMBL1086765
DMNS976	DT	Small molecular drug
DMNS976	PC	21147013
DMNS976	MW	392.5
DMNS976	FM	C25H28O4
DMNS976	IC	InChI=1S/C25H28O4/c1-14(2)5-7-16-11-19-20-13-28-24-17(8-6-15(3)4)21(26)10-9-18(24)25(20)29-23(19)12-22(16)27/h5-6,9-12,20,25-27H,7-8,13H2,1-4H3/t20-,25-/m0/s1
DMNS976	CS	CC(=CCC1=CC2=C(C=C1O)O[C@@H]3[C@H]2COC4=C3C=CC(=C4CC=C(C)C)O)C
DMNS976	IK	SAXBNTXROWQAKX-CPJSRVTESA-N
DMNS976	IU	(6aR,11aR)-4,8-bis(3-methylbut-2-enyl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMNS976	DE	Discovery agent

DMYG7BM	ID	DMYG7BM
DMYG7BM	DN	Erybreadin D
DMYG7BM	HS	Investigative
DMYG7BM	SN	Erybreadin D; CHEMBL1087148
DMYG7BM	DT	Small molecular drug
DMYG7BM	PC	46880036
DMYG7BM	MW	390.5
DMYG7BM	FM	C25H26O4
DMYG7BM	IC	InChI=1S/C25H26O4/c1-14(2)5-7-17-20(26)10-9-18-22(17)27-13-19-16-8-6-15-11-12-25(3,4)29-21(15)24(16)28-23(18)19/h5-6,8-12,19,23,26H,7,13H2,1-4H3/t19-,23-/m0/s1
DMYG7BM	CS	CC(=CCC1=C(C=CC2=C1OC[C@@H]3[C@H]2OC4=C3C=CC5=C4OC(C=C5)(C)C)O)C
DMYG7BM	IK	YODBFZQPDZJGJG-CVDCTZTESA-N
DMYG7BM	IU	(2R,11R)-16,16-dimethyl-6-(3-methylbut-2-enyl)-4,12,15-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),17,20-heptaen-7-ol
DMYG7BM	DE	Discovery agent

DMCHVIG	ID	DMCHVIG
DMCHVIG	DN	ERYSTAGALLIN A
DMCHVIG	HS	Investigative
DMCHVIG	SN	Erystagallin A; CHEMBL1088462
DMCHVIG	DT	Small molecular drug
DMCHVIG	PC	10410005
DMCHVIG	MW	422.5
DMCHVIG	FM	C26H30O5
DMCHVIG	IC	InChI=1S/C26H30O5/c1-15(2)6-8-17-12-19-23(13-21(17)27)30-14-26(28)20-10-11-22(29-5)18(9-7-16(3)4)24(20)31-25(19)26/h6-7,10-13,25,27-28H,8-9,14H2,1-5H3/t25-,26+/m0/s1
DMCHVIG	CS	CC(=CCC1=CC2=C(C=C1O)OC[C@@]3([C@H]2OC4=C3C=CC(=C4CC=C(C)C)OC)O)C
DMCHVIG	IK	OOAXWUFECWLVEQ-IZZNHLLZSA-N
DMCHVIG	IU	(6aS,11aS)-9-methoxy-2,10-bis(3-methylbut-2-enyl)-6,11a-dihydro-[1]benzofuro[3,2-c]chromene-3,6a-diol
DMCHVIG	DE	Discovery agent

DMVA9F7	ID	DMVA9F7
DMVA9F7	DN	Erysubin D
DMVA9F7	HS	Investigative
DMVA9F7	SN	erysubin D; CHEMBL1095422
DMVA9F7	DT	Small molecular drug
DMVA9F7	PC	12051846
DMVA9F7	MW	408.5
DMVA9F7	FM	C25H28O5
DMVA9F7	IC	InChI=1S/C25H28O5/c1-13(2)5-6-14-9-16-21(11-19(14)26)28-12-18-15-7-8-20-17(23(15)29-24(16)18)10-22(27)25(3,4)30-20/h5,7-9,11,18,22,24,26-27H,6,10,12H2,1-4H3/t18-,22?,24-/m0/s1
DMVA9F7	CS	CC(=CCC1=CC2=C(C=C1O)OC[C@@H]3[C@H]2OC4=C3C=CC5=C4CC(C(O5)(C)C)O)C
DMVA9F7	IK	UNODSKHATHZQGW-HRKCMRQESA-N
DMVA9F7	IU	(2R,11R)-17,17-dimethyl-8-(3-methylbut-2-enyl)-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),20-hexaene-7,16-diol
DMVA9F7	DE	Discovery agent

DMXWK1A	ID	DMXWK1A
DMXWK1A	DN	Erysubin E
DMXWK1A	HS	Investigative
DMXWK1A	SN	Erysubin E; CHEMBL1086764; AC1LCTGM; BDBM50311581; InChI=1/C25H26O5/c1-14(2)5-6-15-11-17-21(12-19(15)26)28-13-25(27)18-7-8-20-16(22(18)29-23(17)25)9-10-24(3,4)30-20/h5,7-12,23,26-27H,6,13H2,1-4H3/t23-,25+/m0/s; 3H,7H-pyrano[2',3':6,7]benzofuro[3,2-c][1]benzopyran-6b,10(12bH)-diol, 3,3-dimethyl-11-(3-methyl-2-butenyl)-, (6bS,12bS)-; 3,3-Dimethyl-11-(3-methyl-but-2-enyl)-3H,12bH-4,8,13-trioxa-dibenzo[a,i]fluorene-6b,10-diol
DMXWK1A	DT	Small molecular drug
DMXWK1A	PC	637080
DMXWK1A	MW	406.5
DMXWK1A	FM	C25H26O5
DMXWK1A	IC	InChI=1S/C25H26O5/c1-14(2)5-6-15-11-17-21(12-19(15)26)28-13-25(27)18-7-8-20-16(22(18)29-23(17)25)9-10-24(3,4)30-20/h5,7-12,23,26-27H,6,13H2,1-4H3/t23-,25+/m0/s1
DMXWK1A	CS	CC(=CCC1=CC2=C(C=C1O)OC[C@@]3([C@H]2OC4=C3C=CC5=C4C=CC(O5)(C)C)O)C
DMXWK1A	IK	CMHGFGMNRHHGSN-UKILVPOCSA-N
DMXWK1A	IU	(2S,11S)-17,17-dimethyl-8-(3-methylbut-2-enyl)-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),15,20-heptaene-2,7-diol
DMXWK1A	DE	Discovery agent

DMLT7FQ	ID	DMLT7FQ
DMLT7FQ	DN	Erythose-4-Phosphate
DMLT7FQ	HS	Investigative
DMLT7FQ	SN	D-Erythrose 4-phosphate; erythrose 4-phosphate; threose 4-phosphate; ERYTHOSE-4-PHOSPHATE; D-erythrose-4-phosphate; 585-18-2; erythrose-4-phosphate; erythrose-4P; erythrose-4-P; D-erythrose-4-P; UNII-2156QF7O8M; CHEBI:48153; 2156QF7O8M; (2R,3R)-2,3-dihydroxy-4-oxobutyl dihydrogen phosphate; E4P; Butanal, 2,3-dihydroxy-4-(phosphonooxy)-, (R-(R*,R*))-; 4-D-erythrosephosphoric acid; Erythrose 4-PO4; D-Erythrose 4-PO4; AC1L3UFJ; 4-O-phosphono-D-erythrose; SCHEMBL50110; AC1Q6S62; butanal, 2,3-dihydroxy-4-(phosphonooxy)-,(2r,3r)-
DMLT7FQ	DT	Small molecular drug
DMLT7FQ	PC	122357
DMLT7FQ	MW	200.08
DMLT7FQ	FM	C4H9O7P
DMLT7FQ	IC	InChI=1S/C4H9O7P/c5-1-3(6)4(7)2-11-12(8,9)10/h1,3-4,6-7H,2H2,(H2,8,9,10)/t3-,4+/m0/s1
DMLT7FQ	CS	C([C@H]([C@H](C=O)O)O)OP(=O)(O)O
DMLT7FQ	IK	NGHMDNPXVRFFGS-IUYQGCFVSA-N
DMLT7FQ	IU	[(2R,3R)-2,3-dihydroxy-4-oxobutyl] dihydrogen phosphate
DMLT7FQ	CA	CAS 585-18-2
DMLT7FQ	CB	CHEBI:48153
DMLT7FQ	DE	Discovery agent

DM5GEUN	ID	DM5GEUN
DM5GEUN	DN	ERYTHRIBYSSIN A
DM5GEUN	HS	Investigative
DM5GEUN	SN	Erythribyssin A; CHEMBL1076430
DM5GEUN	DT	Small molecular drug
DM5GEUN	PC	46879996
DM5GEUN	MW	368.4
DM5GEUN	FM	C22H24O5
DM5GEUN	IC	InChI=1S/C22H24O5/c1-13(2)5-7-15-18(24-3)10-9-17-20(15)27-21-16-8-6-14(23)11-19(16)26-12-22(17,21)25-4/h5-6,8-11,21,23H,7,12H2,1-4H3/t21-,22+/m0/s1
DM5GEUN	CS	CC(=CCC1=C(C=CC2=C1O[C@@H]3[C@]2(COC4=C3C=CC(=C4)O)OC)OC)C
DM5GEUN	IK	IGSYALWDCAHJEF-FCHUYYIVSA-N
DM5GEUN	IU	(6aS,11aS)-6a,9-dimethoxy-10-(3-methylbut-2-enyl)-6,11a-dihydro-[1]benzofuro[3,2-c]chromen-3-ol
DM5GEUN	DE	Discovery agent

DMBVSKZ	ID	DMBVSKZ
DMBVSKZ	DN	Erythribyssin D
DMBVSKZ	HS	Investigative
DMBVSKZ	SN	Erythribyssin D; CHEMBL1099089
DMBVSKZ	DT	Small molecular drug
DMBVSKZ	PC	46887822
DMBVSKZ	MW	340.4
DMBVSKZ	FM	C20H20O5
DMBVSKZ	IC	InChI=1S/C20H20O5/c1-20(2)17(22)8-13-15(25-20)6-5-11-14-9-23-16-7-10(21)3-4-12(16)19(14)24-18(11)13/h3-7,14,17,19,21-22H,8-9H2,1-2H3/t14-,17?,19-/m0/s1
DMBVSKZ	CS	CC1(C(CC2=C(O1)C=CC3=C2O[C@@H]4[C@H]3COC5=C4C=CC(=C5)O)O)C
DMBVSKZ	IK	ZCLUCQDBFSBCJB-OZIHFDBSSA-N
DMBVSKZ	IU	(2R,11R)-17,17-dimethyl-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),20-hexaene-7,16-diol
DMBVSKZ	DE	Discovery agent

DMUL4AP	ID	DMUL4AP
DMUL4AP	DN	Erythribyssin L
DMUL4AP	HS	Investigative
DMUL4AP	SN	Erythribyssin L; CHEMBL1096408
DMUL4AP	DT	Small molecular drug
DMUL4AP	PC	46887764
DMUL4AP	MW	408.5
DMUL4AP	FM	C25H28O5
DMUL4AP	IC	InChI=1S/C25H28O5/c1-13(2)5-6-16-19(26)8-7-15-18-12-28-21-11-20-14(10-22(27)25(3,4)30-20)9-17(21)24(18)29-23(15)16/h5,7-9,11,18,22,24,26-27H,6,10,12H2,1-4H3/t18-,22?,24-/m0/s1
DMUL4AP	CS	CC(=CCC1=C(C=CC2=C1O[C@@H]3[C@H]2COC4=C3C=C5CC(C(OC5=C4)(C)C)O)O)C
DMUL4AP	IK	HAOOQCMPFMLAJM-HRKCMRQESA-N
DMUL4AP	IU	(2R,10R)-17,17-dimethyl-5-(3-methylbut-2-enyl)-3,12,16-trioxapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(13),4(9),5,7,14,20-hexaene-6,18-diol
DMUL4AP	DE	Discovery agent

DMWEK8I	ID	DMWEK8I
DMWEK8I	DN	Erythribyssin M
DMWEK8I	HS	Investigative
DMWEK8I	SN	Erythribyssin M; CHEMBL1099090
DMWEK8I	DT	Small molecular drug
DMWEK8I	PC	46887823
DMWEK8I	MW	340.4
DMWEK8I	FM	C20H20O5
DMWEK8I	IC	InChI=1S/C20H20O5/c1-20(2)17(22)8-13-15(25-20)6-5-11-14-9-23-16-7-10(21)3-4-12(16)19(14)24-18(11)13/h3-7,14,17,19,21-22H,8-9H2,1-2H3/t14-,17?,19-/m1/s1
DMWEK8I	CS	CC1(C(CC2=C(O1)C=CC3=C2O[C@H]4[C@@H]3COC5=C4C=CC(=C5)O)O)C
DMWEK8I	IK	ZCLUCQDBFSBCJB-LJMFKLJISA-N
DMWEK8I	IU	(2S,11S)-17,17-dimethyl-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),20-hexaene-7,16-diol
DMWEK8I	DE	Discovery agent

DM8LEJ4	ID	DM8LEJ4
DM8LEJ4	DN	Erythribyssin O
DM8LEJ4	HS	Investigative
DM8LEJ4	SN	Erythribyssin O; CHEMBL1096406
DM8LEJ4	DT	Small molecular drug
DM8LEJ4	PC	46861837
DM8LEJ4	MW	350.4
DM8LEJ4	FM	C21H18O5
DM8LEJ4	IC	InChI=1S/C21H18O5/c1-11(2)3-4-14-17(23)6-5-13-16-10-25-19-8-18(24)12(9-22)7-15(19)21(16)26-20(13)14/h3,5-9,23-24H,4,10H2,1-2H3
DM8LEJ4	CS	CC(=CCC1=C(C=CC2=C1OC3=C2COC4=C3C=C(C(=C4)O)C=O)O)C
DM8LEJ4	IK	AGFXXWXSPAYWMF-UHFFFAOYSA-N
DM8LEJ4	IU	3,9-dihydroxy-10-(3-methylbut-2-enyl)-6H-[1]benzofuro[3,2-c]chromene-2-carbaldehyde
DM8LEJ4	DE	Discovery agent

DM8UVI3	ID	DM8UVI3
DM8UVI3	DN	Erythro-3,4-dichloromethylphenidate hydrochloride
DM8UVI3	HS	Investigative
DM8UVI3	SN	CHEMBL537654; Erythro-3,4-Dichloromethylphenidate HCl
DM8UVI3	DT	Small molecular drug
DM8UVI3	PC	16719762
DM8UVI3	MW	302.2
DM8UVI3	FM	C14H17Cl2NO2
DM8UVI3	IC	InChI=1S/C14H17Cl2NO2/c1-19-14(18)13(12-4-2-3-7-17-12)9-5-6-10(15)11(16)8-9/h5-6,8,12-13,17H,2-4,7H2,1H3/t12-,13+/m1/s1
DM8UVI3	CS	COC(=O)[C@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)Cl)Cl
DM8UVI3	IK	JUKMAYKVHWKRKY-OLZOCXBDSA-N
DM8UVI3	IU	methyl (2S)-2-(3,4-dichlorophenyl)-2-[(2R)-piperidin-2-yl]acetate
DM8UVI3	DE	Discovery agent

DM0PHEW	ID	DM0PHEW
DM0PHEW	DN	Erythromycin salnacedin
DM0PHEW	HS	Investigative
DM0PHEW	SN	Actagen; G 101
DM0PHEW	DT	Small molecular drug
DM0PHEW	PC	9854689
DM0PHEW	MW	1017.2
DM0PHEW	FM	C49H80N2O18S
DM0PHEW	IC	InChI=1S/C37H67NO13.C12H13NO5S/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-7(14)13-9(11(16)17)6-19-12(18)8-4-2-3-5-10(8)15/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-5,9,15H,6H2,1H3,(H,13,14)(H,16,17)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;9-/m10/s1
DM0PHEW	CS	CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.CC(=O)N[C@@H](CSC(=O)C1=CC=CC=C1O)C(=O)O
DM0PHEW	IK	CEKAAZRHRXXWDX-CQWDQVLCSA-N
DM0PHEW	IU	(2R)-2-acetamido-3-(2-hydroxybenzoyl)sulfanylpropanoic acid;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DM0PHEW	CA	CAS 87573-04-4
DM0PHEW	DE	Discovery agent

DM3R8YL	ID	DM3R8YL
DM3R8YL	DN	Erythropoietin
DM3R8YL	HS	Investigative
DM3R8YL	SN	NuPIAO; Erythropoietin (second generation, anemia/blood cell mobilization); Erythropoietin (second generation, anemia/blood cell mobilization), 3SBio
DM3R8YL	CP	3SBio Inc
DM3R8YL	SQ	DB00016 (Erythropoietin) sequence: APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR
DM3R8YL	PC	11751549
DM3R8YL	MW	461
DM3R8YL	FM	C22H22ClKN6O
DM3R8YL	IC	InChI=1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1
DM3R8YL	CS	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+]
DM3R8YL	IK	OXCMYAYHXIHQOA-UHFFFAOYSA-N
DM3R8YL	IU	potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
DM3R8YL	CA	CAS 124750-99-8
DM3R8YL	DE	Anemia

DM8BS5C	ID	DM8BS5C
DM8BS5C	DN	Eryvarin D
DM8BS5C	HS	Investigative
DM8BS5C	SN	eryvarin D; CHEMBL1097045
DM8BS5C	DT	Small molecular drug
DM8BS5C	PC	15546808
DM8BS5C	MW	336.4
DM8BS5C	FM	C21H20O4
DM8BS5C	IC	InChI=1S/C21H20O4/c1-12(2)4-6-15-18(23-3)9-8-14-17-11-24-19-10-13(22)5-7-16(19)21(17)25-20(14)15/h4-5,7-10,22H,6,11H2,1-3H3
DM8BS5C	CS	CC(=CCC1=C(C=CC2=C1OC3=C2COC4=C3C=CC(=C4)O)OC)C
DM8BS5C	IK	BYZVMAQRPFEPSV-UHFFFAOYSA-N
DM8BS5C	IU	9-methoxy-10-(3-methylbut-2-enyl)-6H-[1]benzofuro[3,2-c]chromen-3-ol
DM8BS5C	DE	Discovery agent

DMSNM5O	ID	DMSNM5O
DMSNM5O	DN	ES-6864
DMSNM5O	HS	Investigative
DMSNM5O	SN	N-[N-[3-(Morpholinocarbonyl)-2(R)-(1-naphthylmethyl)propionyl]-3-(4-thiazolyl)-L-alanyl]cyclostatin-(2-morpholinoethyl)amide; 4(S)-[N-[3-(Morpholinocarbonyl)-2(R)-(1-naphthylmethyl)propionyl]-3-(4-thiazolyl)-L-alanylamino]-5-cyclohexyl-3(S)-hydroxypentanoic acid 2-morpholinoethylamide
DMSNM5O	DT	Small molecular drug
DMSNM5O	PC	6918071
DMSNM5O	MW	791
DMSNM5O	FM	C42H58N6O7S
DMSNM5O	IC	InChI=1S/C42H58N6O7S/c49-38(27-39(50)43-13-14-47-15-19-54-20-16-47)36(23-30-7-2-1-3-8-30)45-42(53)37(26-34-28-56-29-44-34)46-41(52)33(25-40(51)48-17-21-55-22-18-48)24-32-11-6-10-31-9-4-5-12-35(31)32/h4-6,9-12,28-30,33,36-38,49H,1-3,7-8,13-27H2,(H,43,50)(H,45,53)(H,46,52)/t33-,36+,37+,38+/m1/s1
DMSNM5O	CS	C1CCC(CC1)C[C@@H]([C@H](CC(=O)NCCN2CCOCC2)O)NC(=O)[C@H](CC3=CSC=N3)NC(=O)[C@H](CC4=CC=CC5=CC=CC=C54)CC(=O)N6CCOCC6
DMSNM5O	IK	UACWUNAXAAUHDZ-MVPOBJIPSA-N
DMSNM5O	IU	(3S,4S)-5-cyclohexyl-3-hydroxy-N-(2-morpholin-4-ylethyl)-4-[[(2S)-2-[[(2R)-4-morpholin-4-yl-2-(naphthalen-1-ylmethyl)-4-oxobutanoyl]amino]-3-(1,3-thiazol-4-yl)propanoyl]amino]pentanamide
DMSNM5O	DE	Hypertension

DMIVZ3W	ID	DMIVZ3W
DMIVZ3W	DN	ES-936
DMIVZ3W	HS	Investigative
DMIVZ3W	SN	192820-78-3; ES 936; UNII-1XI90I177M; 5-METHOXY-1,2-DIMETHYL-3-(4-NITROPHENOXYMETHYL)INDOLE-4,7-DIONE; 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione; 1XI90I177M; 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione; AC1NBNHW; CHEMBL357217; SCHEMBL3991028; CTK8E6509; DTXSID20172879; MolPort-006-168-362; ZINC587989; AKOS024457934; 1H-Indole-4,7-dione, 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)-; API0010300; DB02400; ES936, &gt; LS-191843; B5514; KS-00000189; J-012477
DMIVZ3W	DT	Small molecular drug
DMIVZ3W	PC	4470790
DMIVZ3W	MW	356.3
DMIVZ3W	FM	C18H16N2O6
DMIVZ3W	IC	InChI=1S/C18H16N2O6/c1-10-13(9-26-12-6-4-11(5-7-12)20(23)24)16-17(19(10)2)14(21)8-15(25-3)18(16)22/h4-8H,9H2,1-3H3
DMIVZ3W	CS	CC1=C(C2=C(N1C)C(=O)C=C(C2=O)OC)COC3=CC=C(C=C3)[N+](=O)[O-]
DMIVZ3W	IK	IBLWSLZYYZHSRG-UHFFFAOYSA-N
DMIVZ3W	IU	5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione
DMIVZ3W	CA	CAS 192820-78-3
DMIVZ3W	DE	Discovery agent

DMPTDHC	ID	DMPTDHC
DMPTDHC	DN	ESCHOLTZINE
DMPTDHC	HS	Investigative
DMPTDHC	SN	escholtzine; Escholzine; Crychine; 4040-75-9; CHEMBL481839; BDBM50259677; ZINC27865962
DMPTDHC	DT	Small molecular drug
DMPTDHC	PC	12304178
DMPTDHC	MW	323.3
DMPTDHC	FM	C19H17NO4
DMPTDHC	IC	InChI=1S/C19H17NO4/c1-20-14-2-10-4-16-18(23-8-21-16)6-12(10)15(20)3-11-5-17-19(7-13(11)14)24-9-22-17/h4-7,14-15H,2-3,8-9H2,1H3/t14-,15-/m0/s1
DMPTDHC	CS	CN1[C@H]2CC3=CC4=C(C=C3[C@@H]1CC5=CC6=C(C=C25)OCO6)OCO4
DMPTDHC	IK	PGINMPJZCWDQNT-GJZGRUSLSA-N
DMPTDHC	IU	(1S,12S)-23-methyl-5,7,16,18-tetraoxa-23-azahexacyclo[10.10.1.02,10.04,8.013,21.015,19]tricosa-2,4(8),9,13,15(19),20-hexaene
DMPTDHC	CA	CAS 4040-75-9
DMPTDHC	DE	Discovery agent

DMANEC9	ID	DMANEC9
DMANEC9	DN	Esculin
DMANEC9	HS	Investigative
DMANEC9	SN	Aesculetin glukosid; Aesculinum; Esculetin 6-O-glucoside; Esculetin 6-beta-D-glucoside; Esculin; Esculin hydrate; Esculin hydrate, 97%; Esculine; Esculoside; Polychrome; Venoplant; XHCADAYNFIFUHF-TVKJYDDYSA-N; aesculin; (-)-Esculin; 1Y1L18LQAF; 531-75-9; 6,7-Dihydroxycoumarin 6-glucoside; 6,7-Dihydroxycoumarin-6-O-glucoside; 6-(beta-D-Glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one; 6-(beta-D-Glucopyranosyloxy)-7-hydroxy-cumarin; 7-Hydroxy-6-cumarinyl-glucosid; 7-Hydroxy-6-glucosyloxy-2H-chromene; CHEBI:4853; UNII-1Y1L18LQAF
DMANEC9	PC	5281417
DMANEC9	MW	340.28
DMANEC9	FM	C15H16O9
DMANEC9	IC	XHCADAYNFIFUHF-TVKJYDDYSA-N
DMANEC9	CS	C1=CC(=O)OC2=CC(=C(C=C21)OC3C(C(C(C(O3)CO)O)O)O)O
DMANEC9	IK	1S/C15H16O9/c16-5-10-12(19)13(20)14(21)15(24-10)23-9-3-6-1-2-11(18)22-8(6)4-7(9)17/h1-4,10,12-17,19-21H,5H2/t10-,12-,13+,14-,15-/m1/s1
DMANEC9	IU	7-hydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
DMANEC9	CA	CAS 531-75-9
DMANEC9	CB	CHEBI:4853
DMANEC9	DE	Appendicitis

DMTJDXY	ID	DMTJDXY
DMTJDXY	DN	ESI-09
DMTJDXY	HS	Investigative
DMTJDXY	SN	ESI 09; ESI09
DMTJDXY	DT	Small molecular drug
DMTJDXY	PC	5704083
DMTJDXY	MW	330.77
DMTJDXY	FM	C16H15ClN4O2
DMTJDXY	IC	InChI=1S/C16H15ClN4O2/c1-16(2,3)14-8-12(21-23-14)15(22)13(9-18)20-19-11-6-4-5-10(17)7-11/h4-8,19H,1-3H3/b20-13-
DMTJDXY	CS	CC(C)(C)C1=CC(=NO1)C(=O)/C(=N\\NC2=CC(=CC=C2)Cl)/C#N
DMTJDXY	IK	DXEATJQGQHDURZ-MOSHPQCFSA-N
DMTJDXY	IU	(1Z)-2-(5-tert-butyl-1,2-oxazol-3-yl)-N-(3-chloroanilino)-2-oxoethanimidoyl cyanide
DMTJDXY	DE	Discovery agent

DM7K14V	ID	DM7K14V
DM7K14V	DN	Estradiol 17-O-sulfamate
DM7K14V	HS	Investigative
DM7K14V	SN	CHEMBL220493; estradiol 17-O-sulfamate; Estradiol-17-O-Sulfamate; SCHEMBL628173; BDBM50200938
DM7K14V	DT	Small molecular drug
DM7K14V	PC	20718630
DM7K14V	MW	351.5
DM7K14V	FM	C18H25NO4S
DM7K14V	IC	InChI=1S/C18H25NO4S/c1-18-9-8-14-13-5-3-12(20)10-11(13)2-4-15(14)16(18)6-7-17(18)23-24(19,21)22/h3,5,10,14-17,20H,2,4,6-9H2,1H3,(H2,19,21,22)/t14-,15-,16+,17+,18+/m1/s1
DM7K14V	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=C3C=CC(=C4)O
DM7K14V	IK	NALROBPVVYUESB-ZBRFXRBCSA-N
DM7K14V	IU	[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DM7K14V	DE	Discovery agent

DMPM8I5	ID	DMPM8I5
DMPM8I5	DN	Estradiol 3,17-O,O-bis-sulfamate
DMPM8I5	HS	Investigative
DMPM8I5	SN	CHEMBL221802; estradiol 3,17-O,O-bis-sulfamate; SCHEMBL5167329; ZINC3825541; BDBM50159804; Sulfamic acid (8R,9S,13S,14S,17S)-13-methyl-3-sulfamoyloxy-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl ester
DMPM8I5	DT	Small molecular drug
DMPM8I5	PC	9954405
DMPM8I5	MW	430.5
DMPM8I5	FM	C18H26N2O6S2
DMPM8I5	IC	InChI=1S/C18H26N2O6S2/c1-18-9-8-14-13-5-3-12(25-27(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)26-28(20,23)24/h3,5,10,14-17H,2,4,6-9H2,1H3,(H2,19,21,22)(H2,20,23,24)/t14-,15-,16+,17+,18+/m1/s1
DMPM8I5	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=C3C=CC(=C4)OS(=O)(=O)N
DMPM8I5	IK	ZVSCPWTWOPVEDW-ZBRFXRBCSA-N
DMPM8I5	IU	[(8R,9S,13S,14S,17S)-13-methyl-3-sulfamoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMPM8I5	DE	Discovery agent

DMNXO9C	ID	DMNXO9C
DMNXO9C	DN	Estriol E3
DMNXO9C	HS	Investigative
DMNXO9C	SN	Estriol E3 (oral formulation, multiple sclerosis)
DMNXO9C	CP	Effective Pharmaceuticals Inc
DMNXO9C	DE	Multiple sclerosis

DMH4MBW	ID	DMH4MBW
DMH4MBW	DN	ET bromodomain inhibitor
DMH4MBW	HS	Investigative
DMH4MBW	SN	Methyl (2r)-2-[(4s)-6-(4-Chlorophenyl)-8-Methoxy-1-Methyl-4h-[1,2,4]triazolo[4,3-A][1,4]benzodiazepin-4-Yl]butanoate; ET bromodomain inhibitor; GTPL7808; SCHEMBL16771873
DMH4MBW	DT	Small molecular drug
DMH4MBW	PC	86277843
DMH4MBW	MW	438.9
DMH4MBW	FM	C23H23ClN4O3
DMH4MBW	IC	InChI=1S/C23H23ClN4O3/c1-5-17(23(29)31-4)21-22-27-26-13(2)28(22)19-11-10-16(30-3)12-18(19)20(25-21)14-6-8-15(24)9-7-14/h6-12,17,21H,5H2,1-4H3/t17-,21+/m1/s1
DMH4MBW	CS	CC[C@H]([C@H]1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C)C(=O)OC
DMH4MBW	IK	WGMDCNPABCIZCD-UTKZUKDTSA-N
DMH4MBW	IU	methyl (2R)-2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]butanoate
DMH4MBW	DE	Discovery agent

DM0IYLS	ID	DM0IYLS
DM0IYLS	DN	EtBut-RYYRIK-NH2
DM0IYLS	HS	Investigative
DM0IYLS	SN	CHEMBL443765
DM0IYLS	DT	Small molecular drug
DM0IYLS	PC	44456217
DM0IYLS	MW	979.2
DM0IYLS	FM	C48H78N14O8
DM0IYLS	IC	InChI=1S/C48H78N14O8/c1-5-29(4)39(46(70)57-34(40(50)64)17-11-12-24-49)62-43(67)36(19-14-26-56-48(53)54)59-44(68)38(28-31-20-22-33(63)23-21-31)61-45(69)37(27-30-15-9-8-10-16-30)60-42(66)35(18-13-25-55-47(51)52)58-41(65)32(6-2)7-3/h8-10,15-16,20-23,29,32,34-39,63H,5-7,11-14,17-19,24-28,49H2,1-4H3,(H2,50,64)(H,57,70)(H,58,65)(H,59,68)(H,60,66)(H,61,69)(H,62,67)(H4,51,52,55)(H4,53,54,56)/t29-,34-,35-,36-,37-,38-,39-/m0/s1
DM0IYLS	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(CC)CC
DM0IYLS	IK	ZOGNSEAXOALIEC-ICJZXESVSA-N
DM0IYLS	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2-ethylbutanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DM0IYLS	DE	Discovery agent

DMMEQUR	ID	DMMEQUR
DMMEQUR	DN	Ethidium
DMMEQUR	HS	Investigative
DMMEQUR	SN	Ethidium; homidium; Ethidium cation; Novidium; 3546-21-2; UNII-EN464416SI; 3,8-Diamino-5-ethyl-6-phenylphenanthridinium; Phenanthridinium, 3,8-diamino-5-ethyl-6-phenyl-; BRN 3627183; CHEBI:42478; EN464416SI; AB00053825_07; CHEMBL284328; NSC84423; NSC522843; 5-ethyl-6-phenyl-phenanthridin-5-ium-3,8-diamine; 5-ethyl-6-phenylphenanthridin-5-ium-3,8-diamine; C21H20N3; Spectrum_001500; AC1L1GCK; Spectrum2_001587; Spectrum5_001263; Spectrum4_000198; UPCMLD-DP076; NCIMech_000529; cid_3624; Piperine &amp; Ethidium bromide; NCIOpen2_009324
DMMEQUR	DT	Small molecular drug
DMMEQUR	PC	3624
DMMEQUR	MW	314.4
DMMEQUR	FM	C21H20N3+
DMMEQUR	IC	InChI=1S/C21H19N3/c1-2-24-20-13-16(23)9-11-18(20)17-10-8-15(22)12-19(17)21(24)14-6-4-3-5-7-14/h3-13,23H,2,22H2,1H3/p+1
DMMEQUR	CS	CC[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N)N
DMMEQUR	IK	QTANTQQOYSUMLC-UHFFFAOYSA-O
DMMEQUR	IU	5-ethyl-6-phenylphenanthridin-5-ium-3,8-diamine
DMMEQUR	CA	CAS 3546-21-2
DMMEQUR	CB	CHEBI:42478
DMMEQUR	DE	Discovery agent

DMQTEDP	ID	DMQTEDP
DMQTEDP	DN	ETHIOFENCARB
DMQTEDP	HS	Investigative
DMQTEDP	SN	Ethiofencarb; 29973-13-5; CRONETON; Arylmate; Kronetone; Croneton 500; Ethiophencarbe; Ethiofencarb [BSI:ISO]; alpha-Ethylthio-o-tolyl methylcarbamate; Hox 1901; 2-((Ethylthio)methyl)phenol methylcarbamate; 2-((Ethylthio)methyl)phenyl methylcarbamate; BAY-HOX-1901; Caswell No. 263AA; CHOX 1901; alpha-(Ethylthio)-o-tolyl methylcarbamate; UNII-FY0YB813XV; Ethiophencarbe [ISO-French]; 2-Ethylthiomethylphenyl N-methylcarbamate; HSDB 7140; (2-Ethylthiomethyl-phenyl)-N-methylcarbamate; EINECS 249-981-9
DMQTEDP	DT	Small molecular drug
DMQTEDP	PC	34766
DMQTEDP	MW	225.31
DMQTEDP	FM	C11H15NO2S
DMQTEDP	IC	InChI=1S/C11H15NO2S/c1-3-15-8-9-6-4-5-7-10(9)14-11(13)12-2/h4-7H,3,8H2,1-2H3,(H,12,13)
DMQTEDP	CS	CCSCC1=CC=CC=C1OC(=O)NC
DMQTEDP	IK	HEZNVIYQEUHLNI-UHFFFAOYSA-N
DMQTEDP	IU	[2-(ethylsulfanylmethyl)phenyl] N-methylcarbamate
DMQTEDP	CA	CAS 29973-13-5
DMQTEDP	CB	CHEBI:38483
DMQTEDP	DE	Discovery agent

DMGESUH	ID	DMGESUH
DMGESUH	DN	ETHIONINE
DMGESUH	HS	Investigative
DMGESUH	SN	L-Ethionine; Ethionine; 13073-35-3; S-Ethyl-L-homocysteine; (S)-2-amino-4-(ethylthio)butanoic acid; L-S-Ethylhomocysteine; Homocysteine, S-ethyl-; L-Homocysteine, S-ethyl-; Ethionine (VAN); L-2-Amino-4-(ethylthio)butyric acid; UNII-WX1BN24WZT; (L)-Ethionine; (+)-ethionine; NSC 82393; CCRIS 289; C6H13NO2S; HSDB 5080; Butyric acid, 2-amino-4-(ethylthio)-, L-; EINECS 235-966-4; WX1BN24WZT; Butanoic acid, 2-amino-4-(ethylthio)-, (S)-; BRN 1722528; (+)-S-ethyl-L-homocysteine; CHEMBL203187; CHEBI:4886; Butyric acid, 2-amino-4-(ethylene)-
DMGESUH	DT	Small molecular drug
DMGESUH	PC	25674
DMGESUH	MW	163.24
DMGESUH	FM	C6H13NO2S
DMGESUH	IC	InChI=1S/C6H13NO2S/c1-2-10-4-3-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1
DMGESUH	CS	CCSCC[C@@H](C(=O)O)N
DMGESUH	IK	GGLZPLKKBSSKCX-YFKPBYRVSA-N
DMGESUH	IU	(2S)-2-amino-4-ethylsulfanylbutanoic acid
DMGESUH	CA	CAS 13073-35-3
DMGESUH	CB	CHEBI:4886
DMGESUH	DE	Discovery agent

DMDXRP1	ID	DMDXRP1
DMDXRP1	DN	ETHISTERONE
DMDXRP1	HS	Investigative
DMDXRP1	SN	17-Hydroxypregn-4-en-20-yn-3-one; Syngestrotabs; Aethisteron; Progestolets; Pregneninolone; Progestoral; Gestoral; Ethinone; Colutoid; Trosinone; Prolutol; Progestab; Produxan; Nalutoral; Prodroxan; Prodoxan; Nugestoral; Pregnin; Prone; Lucorteum Oral; Lutidon Oral; Progestin P; Proluton C; Primolut C; Ora-Lutin; Ethinyltestosterone; Anhydroxyprogesterone; 17.alpha.-Ethynyltestosterone; Anhydrohydroxyprogesterone; Ethynyltestosterone; Testosterone, 17-ethynyl-; NSC-9565; 17-Ethinyltestosterone; 17.alpha.-Pregn-4-en-20-yn-3-one, 17-hydroxy-
DMDXRP1	DT	Small molecular drug
DMDXRP1	PC	5284557
DMDXRP1	MW	312.4
DMDXRP1	FM	C21H28O2
DMDXRP1	IC	InChI=1S/C21H28O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,13,16-18,23H,5-12H2,2-3H3/t16-,17+,18+,19+,20+,21+/m1/s1
DMDXRP1	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C
DMDXRP1	IK	CHNXZKVNWQUJIB-CEGNMAFCSA-N
DMDXRP1	IU	(8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMDXRP1	CA	CAS 434-03-7
DMDXRP1	CB	CHEBI:34749
DMDXRP1	DE	Discovery agent

DM1MGTX	ID	DM1MGTX
DM1MGTX	DN	ETHOXYCLUSIN
DM1MGTX	HS	Investigative
DM1MGTX	SN	ethoxyclusin; CHEMBL480295
DM1MGTX	DT	Small molecular drug
DM1MGTX	PC	44575400
DM1MGTX	MW	446.5
DM1MGTX	FM	C24H30O8
DM1MGTX	IC	InChI=1S/C24H30O8/c1-5-29-20-10-14(11-21-23(20)32-13-31-21)6-16-12-30-24(25)17(16)7-15-8-18(26-2)22(28-4)19(9-15)27-3/h8-11,16-17,24-25H,5-7,12-13H2,1-4H3/t16-,17+,24?/m0/s1
DM1MGTX	CS	CCOC1=CC(=CC2=C1OCO2)C[C@H]3COC([C@@H]3CC4=CC(=C(C(=C4)OC)OC)OC)O
DM1MGTX	IK	PPKABVGOUVBEEX-HSQXHLSASA-N
DM1MGTX	IU	(3R,4R)-4-[(7-ethoxy-1,3-benzodioxol-5-yl)methyl]-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-ol
DM1MGTX	DE	Discovery agent

DMSKU4M	ID	DMSKU4M
DMSKU4M	DN	ETHOXYCOUMARIN
DMSKU4M	HS	Investigative
DMSKU4M	SN	7-ETHOXYCOUMARIN; 31005-02-4; 7-ethoxy-2H-chromen-2-one; Ethylumbelliferone; 2H-1-Benzopyran-2-one, 7-ethoxy-; 7-ethoxychromen-2-one; 7-ethoxy-2H-1-benzopyran-2-one; CHEMBL191528; CHEBI:28184; LIFAQMGORKPVDH-UHFFFAOYSA-N; 7-Ethoxycoumarine; EINECS 250-429-4; 7 - Ethoxycoumarin; PubChem8680; Coumarin, 7-ethoxy-; ACMC-209hjx; 7-Ethoxy-chromen-2-one; 7-Ethoxycoumarin, 99.5%; SCHEMBL119072; 7-Ethoxy-1-benzopyran-2-one; AC1L1U91; ZINC57719; CTK4G6277; DTXSID30184983; MolPort-001-759-189; HMS1722P19; KS-000014EB
DMSKU4M	DT	Small molecular drug
DMSKU4M	PC	182475
DMSKU4M	MW	190.19
DMSKU4M	FM	C11H10O3
DMSKU4M	IC	InChI=1S/C11H10O3/c1-2-13-10-7-8-5-3-4-6-9(8)14-11(10)12/h3-7H,2H2,1H3
DMSKU4M	CS	CCOC1=CC2=CC=CC=C2OC1=O
DMSKU4M	IK	PPGXDBJURPEKDZ-UHFFFAOYSA-N
DMSKU4M	IU	3-ethoxychromen-2-one
DMSKU4M	CA	CAS 65216-93-5
DMSKU4M	DE	Discovery agent

DMNOTH5	ID	DMNOTH5
DMNOTH5	DN	ETHOXY-IDAZOXAN
DMNOTH5	HS	Investigative
DMNOTH5	SN	RX-811059; 2-(2-Ethoxy-1,4-benzodioxan-2-yl)-1-imidazoline
DMNOTH5	DT	Small molecular drug
DMNOTH5	PC	125992
DMNOTH5	MW	248.28
DMNOTH5	FM	C13H16N2O3
DMNOTH5	IC	InChI=1S/C13H16N2O3/c1-2-17-13(12-14-7-8-15-12)9-16-10-5-3-4-6-11(10)18-13/h3-6H,2,7-9H2,1H3,(H,14,15)
DMNOTH5	CS	CCOC1(COC2=CC=CC=C2O1)C3=NCCN3
DMNOTH5	IK	PXTLRBYNGGDZBN-UHFFFAOYSA-N
DMNOTH5	IU	2-(3-ethoxy-2H-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole
DMNOTH5	CA	CAS 96576-24-8
DMNOTH5	DE	Poison intoxication

DM7390Y	ID	DM7390Y
DM7390Y	DN	ethyketazocine
DM7390Y	HS	Investigative
DM7390Y	SN	WIN-35,197-2
DM7390Y	DT	Small molecular drug
DM7390Y	PC	135018
DM7390Y	MW	299.4
DM7390Y	FM	C19H25NO2
DM7390Y	IC	InChI=1S/C19H25NO2/c1-3-19-8-9-20(11-13-4-5-13)17(12(19)2)18(22)15-7-6-14(21)10-16(15)19/h6-7,10,12-13,17,21H,3-5,8-9,11H2,1-2H3/t12-,17-,19-/m1/s1
DM7390Y	CS	CC[C@@]12CCN([C@H]([C@H]1C)C(=O)C3=C2C=C(C=C3)O)CC4CC4
DM7390Y	IK	SEJUQQOPVAUETF-QHLBDZCJSA-N
DM7390Y	IU	(1R,9R,13S)-10-(cyclopropylmethyl)-1-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one
DM7390Y	CA	CAS 6036-52-8
DM7390Y	DE	Discovery agent

DM0O4A2	ID	DM0O4A2
DM0O4A2	DN	ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE
DM0O4A2	HS	Investigative
DM0O4A2	SN	ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE; S-BENZYL PHENYLACETOTHIOHYDROXIMATE-O-SULFATE; DB04779; ethyl (1Z)-2-phenyl-N-(sulfooxy)ethanimidothioate; [(Z)-[1-(ethylsulfanyl)-2-phenylethylidene]amino]oxysulfonic acid
DM0O4A2	DT	Small molecular drug
DM0O4A2	PC	9600421
DM0O4A2	MW	275.3
DM0O4A2	FM	C10H13NO4S2
DM0O4A2	IC	InChI=1S/C10H13NO4S2/c1-2-16-10(11-15-17(12,13)14)8-9-6-4-3-5-7-9/h3-7H,2,8H2,1H3,(H,12,13,14)/b11-10-
DM0O4A2	CS	CCS/C(=N\\OS(=O)(=O)O)/CC1=CC=CC=C1
DM0O4A2	IK	VZFUNHITNWTQFU-KHPPLWFESA-N
DM0O4A2	IU	ethyl (1Z)-2-phenyl-N-sulfooxyethanimidothioate
DM0O4A2	DE	Discovery agent

DM3FH02	ID	DM3FH02
DM3FH02	DN	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM3FH02	HS	Investigative
DM3FH02	SN	2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893
DM3FH02	DT	Small molecular drug
DM3FH02	PC	9860529
DM3FH02	MW	281.3
DM3FH02	FM	C17H15NO3
DM3FH02	IC	InChI=1S/C17H15NO3/c19-15-11-16(18-7-9-20-10-8-18)21-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2
DM3FH02	CS	C1COCCN1C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DM3FH02	IK	KKTZALUTXUZPSN-UHFFFAOYSA-N
DM3FH02	IU	2-morpholin-4-ylbenzo[h]chromen-4-one
DM3FH02	CA	CAS 154447-35-5
DM3FH02	CB	CHEBI:92165
DM3FH02	DE	Discovery agent

DMQ0XYH	ID	DMQ0XYH
DMQ0XYH	DN	Ethyl 1-[(1H-benzimidazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DMQ0XYH	HS	Investigative
DMQ0XYH	SN	ethyl 1-(3H-benzimidazol-5-ylsulfonyl)pyrrole-2-carboxylate; AC1LA3ZP; CTK6F6830; ZINC5884309; 1h-pyrrole-2-carboxylic acid,1-(1h-benzimidazol-6-ylsulfonyl)-,ethyl ester; 306964-90-9; KB-266409; ethyl 1-(1h-benzimidazol-6-ylsulfonyl)-1h-pyrrole-2-carboxylate; 1-(3H-Benzoimidazole-5-sulfonyl)-1H-pyrrole-2-carboxylic acid ethyl ester; 1-[(1H-Benzimidazole-5-yl)sulfonyl]1H-pyrrole-2-carboxylic acid ethyl ester
DMQ0XYH	DT	Small molecular drug
DMQ0XYH	PC	481117
DMQ0XYH	MW	319.34
DMQ0XYH	FM	C14H13N3O4S
DMQ0XYH	IC	InChI=1S/C14H13N3O4S/c1-2-21-14(18)13-4-3-7-17(13)22(19,20)10-5-6-11-12(8-10)16-9-15-11/h3-9H,2H2,1H3,(H,15,16)
DMQ0XYH	CS	CCOC(=O)C1=CC=CN1S(=O)(=O)C2=CC3=C(C=C2)N=CN3
DMQ0XYH	IK	UVYMCWVOZHENRB-UHFFFAOYSA-N
DMQ0XYH	IU	ethyl 1-(3H-benzimidazol-5-ylsulfonyl)pyrrole-2-carboxylate
DMQ0XYH	DE	Discovery agent

DM82X3J	ID	DM82X3J
DM82X3J	DN	Ethyl 1-[(1H-benzotriazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM82X3J	HS	Investigative
DM82X3J	DE	Discovery agent

DM762HQ	ID	DM762HQ
DM762HQ	DN	Ethyl 2-(2-oxohexadecanamido)acetate
DM762HQ	HS	Investigative
DM762HQ	SN	Ethyl 2-(2-oxohexadecanamido)acetate
DM762HQ	DT	Small molecular drug
DM762HQ	PC	16118320
DM762HQ	MW	355.5
DM762HQ	FM	C20H37NO4
DM762HQ	IC	InChI=1S/C20H37NO4/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-18(22)20(24)21-17-19(23)25-4-2/h3-17H2,1-2H3,(H,21,24)
DM762HQ	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCC(=O)OCC
DM762HQ	IK	OUAFHJCWFYXWSR-UHFFFAOYSA-N
DM762HQ	IU	ethyl 2-(2-oxohexadecanoylamino)acetate
DM762HQ	DE	Discovery agent

DMPUCMV	ID	DMPUCMV
DMPUCMV	DN	Ethyl 2beta-hydroxyolean-12-en-28-oate
DMPUCMV	HS	Investigative
DMPUCMV	SN	CHEMBL1077973; Ethyl 2beta-hydroxyolean-12-en-28-oate
DMPUCMV	DT	Small molecular drug
DMPUCMV	PC	44254513
DMPUCMV	MW	484.8
DMPUCMV	FM	C32H52O3
DMPUCMV	IC	InChI=1S/C32H52O3/c1-9-35-26(34)32-16-14-27(2,3)20-23(32)22-10-11-25-29(6)19-21(33)18-28(4,5)24(29)12-13-31(25,8)30(22,7)15-17-32/h10,21,23-25,33H,9,11-20H2,1-8H3/t21-,23+,24+,25-,29+,30-,31-,32+/m1/s1
DMPUCMV	CS	CCOC(=O)[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H](CC5(C)C)O)C)C)[C@@H]1CC(CC2)(C)C)C
DMPUCMV	IK	ZGVDWCUGEWKVJU-UMIBNUPHSA-N
DMPUCMV	IU	ethyl (4aS,6aR,6aS,6bR,8aS,11R,12aS,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMPUCMV	DE	Discovery agent

DM06AQZ	ID	DM06AQZ
DM06AQZ	DN	Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate
DM06AQZ	HS	Investigative
DM06AQZ	SN	AC1NVSSE; MLS000104229; CHEMBL3197417; MolPort-002-136-693; MolPort-019-735-612; HMS2400I13; CCG-2361; ZINC18045921; STL321690; AKOS022107323; SMR000051278; SR-01000198931; SR-01000198931-1; ethyl (2Z)-cyano(quinoxalin-2(1H)-ylidene)ethanoate; ethyl (2Z)-2-cyano-2-(1H-quinoxalin-2-ylidene)acetate
DM06AQZ	DT	Small molecular drug
DM06AQZ	PC	607092
DM06AQZ	MW	241.24
DM06AQZ	FM	C13H11N3O2
DM06AQZ	IC	InChI=1S/C13H11N3O2/c1-2-18-13(17)9(7-14)12-8-15-10-5-3-4-6-11(10)16-12/h3-6,8-9H,2H2,1H3
DM06AQZ	CS	CCOC(=O)C(C#N)C1=NC2=CC=CC=C2N=C1
DM06AQZ	IK	KKQBQZXMEPUMLX-UHFFFAOYSA-N
DM06AQZ	IU	ethyl 2-cyano-2-quinoxalin-2-ylacetate
DM06AQZ	DE	Discovery agent

DM5XYFN	ID	DM5XYFN
DM5XYFN	DN	Ethyl 3-(biphenyl-3-ylamino)-2-cyanoacrylate
DM5XYFN	HS	Investigative
DM5XYFN	SN	CHEMBL387254; ethyl (2z)-3-(biphenyl-3-ylamino)-2-cyanoprop-2-enoate
DM5XYFN	DT	Small molecular drug
DM5XYFN	PC	91895906
DM5XYFN	MW	292.3
DM5XYFN	FM	C18H16N2O2
DM5XYFN	IC	InChI=1S/C18H16N2O2/c1-2-22-18(21)16(12-19)13-20-17-10-6-9-15(11-17)14-7-4-3-5-8-14/h3-11,13,16H,2H2,1H3
DM5XYFN	CS	CCOC(=O)C(C=NC1=CC=CC(=C1)C2=CC=CC=C2)C#N
DM5XYFN	IK	ADNKWYMTGWSRNK-UHFFFAOYSA-N
DM5XYFN	IU	ethyl 2-cyano-3-(3-phenylphenyl)iminopropanoate
DM5XYFN	DE	Discovery agent

DM4UWYF	ID	DM4UWYF
DM4UWYF	DN	Ethyl 3-(pyridin-4-yl)-1H-indole-6-carboxylate
DM4UWYF	HS	Investigative
DM4UWYF	SN	CHEMBL208261; ethyl 3-(pyridin-4-yl)-1H-indole-6-carboxylate
DM4UWYF	DT	Small molecular drug
DM4UWYF	PC	44410730
DM4UWYF	MW	266.29
DM4UWYF	FM	C16H14N2O2
DM4UWYF	IC	InChI=1S/C16H14N2O2/c1-2-20-16(19)12-3-4-13-14(10-18-15(13)9-12)11-5-7-17-8-6-11/h3-10,18H,2H2,1H3
DM4UWYF	CS	CCOC(=O)C1=CC2=C(C=C1)C(=CN2)C3=CC=NC=C3
DM4UWYF	IK	HFXZBVKGWWNQBD-UHFFFAOYSA-N
DM4UWYF	IU	ethyl 3-pyridin-4-yl-1H-indole-6-carboxylate
DM4UWYF	DE	Discovery agent

DMKJGLO	ID	DMKJGLO
DMKJGLO	DN	ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE
DMKJGLO	HS	Investigative
DMKJGLO	SN	Ethyl 3-[4-(Aminosulfonyl)phenyl]propanoate; ethyl 3-(4-sulfamoylphenyl)propanoate; 2nnv; M29; 2nn7; AKOS009166834; DB08157; 4-PROPYL BENZENESULFONAMIDE ETHYL ESTER
DMKJGLO	DT	Small molecular drug
DMKJGLO	PC	16122582
DMKJGLO	MW	257.31
DMKJGLO	FM	C11H15NO4S
DMKJGLO	IC	InChI=1S/C11H15NO4S/c1-2-16-11(13)8-5-9-3-6-10(7-4-9)17(12,14)15/h3-4,6-7H,2,5,8H2,1H3,(H2,12,14,15)
DMKJGLO	CS	CCOC(=O)CCC1=CC=C(C=C1)S(=O)(=O)N
DMKJGLO	IK	OJBJALUJMRMNIR-UHFFFAOYSA-N
DMKJGLO	IU	ethyl 3-(4-sulfamoylphenyl)propanoate
DMKJGLO	DE	Discovery agent

DM5GLP7	ID	DM5GLP7
DM5GLP7	DN	Ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate
DM5GLP7	HS	Investigative
DM5GLP7	SN	YD-3; CHEMBL125021; SCHEMBL363569; GTPL9458; LPROLPQTWKDPNU-UHFFFAOYSA-N; BDBM50024254; 1-benzyl-3-(4'-ethoxycarbonylphenyl)indazole; ethyl 4-(1-benzyl-1h-indazol-3-yl)-benzoate
DM5GLP7	DT	Small molecular drug
DM5GLP7	PC	10132921
DM5GLP7	MW	356.4
DM5GLP7	FM	C23H20N2O2
DM5GLP7	IC	InChI=1S/C23H20N2O2/c1-2-27-23(26)19-14-12-18(13-15-19)22-20-10-6-7-11-21(20)25(24-22)16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3
DM5GLP7	CS	CCOC(=O)C1=CC=C(C=C1)C2=NN(C3=CC=CC=C32)CC4=CC=CC=C4
DM5GLP7	IK	LPROLPQTWKDPNU-UHFFFAOYSA-N
DM5GLP7	IU	ethyl 4-(1-benzylindazol-3-yl)benzoate
DM5GLP7	DE	Discovery agent

DMQ3LMF	ID	DMQ3LMF
DMQ3LMF	DN	Ethyl 4-(2-oxo-2H-chromene-3-carboxamido)benzoate
DMQ3LMF	HS	Investigative
DMQ3LMF	SN	111947-24-1; ethyl 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoate; AC1LHTSN; CBMicro_028869; 3-carboxamido coumarin, 15; Oprea1_481544; ethyl 4-(2-oxo-2H-chromene-3-carboxamido)benzoate; CHEMBL470419; BDBM29165; MolPort-000-375-263; MISJYZJMFQOBPG-UHFFFAOYSA-N; ZINC434162; STK401564; AKOS001279407; MCULE-7936571021; LS-38062; BIM-0028988.P001; ST4083371; ethyl 4-(2-oxo-2H-chromene-3-amido)benzoate; ethyl 4-[(2-oxochromen-3-yl)carbonylamino]benzoate; ethyl 4-[(2-oxochromene-3-carbonyl)amino]benzoate; Z30248586; F1006-0090
DMQ3LMF	DT	Small molecular drug
DMQ3LMF	PC	869109
DMQ3LMF	MW	337.3
DMQ3LMF	FM	C19H15NO5
DMQ3LMF	IC	InChI=1S/C19H15NO5/c1-2-24-18(22)12-7-9-14(10-8-12)20-17(21)15-11-13-5-3-4-6-16(13)25-19(15)23/h3-11H,2H2,1H3,(H,20,21)
DMQ3LMF	CS	CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMQ3LMF	IK	MISJYZJMFQOBPG-UHFFFAOYSA-N
DMQ3LMF	IU	ethyl 4-[(2-oxochromene-3-carbonyl)amino]benzoate
DMQ3LMF	DE	Discovery agent

DMB12M7	ID	DMB12M7
DMB12M7	DN	Ethyl 4-(2-oxohexadecanamido)benzoate
DMB12M7	HS	Investigative
DMB12M7	SN	CHEMBL460083
DMB12M7	DT	Small molecular drug
DMB12M7	PC	44562728
DMB12M7	MW	417.6
DMB12M7	FM	C25H39NO4
DMB12M7	IC	InChI=1S/C25H39NO4/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-23(27)24(28)26-22-19-17-21(18-20-22)25(29)30-4-2/h17-20H,3-16H2,1-2H3,(H,26,28)
DMB12M7	CS	CCCCCCCCCCCCCCC(=O)C(=O)NC1=CC=C(C=C1)C(=O)OCC
DMB12M7	IK	HUIFVZXXYFVZMD-UHFFFAOYSA-N
DMB12M7	IU	ethyl 4-(2-oxohexadecanoylamino)benzoate
DMB12M7	DE	Discovery agent

DMK4T5Y	ID	DMK4T5Y
DMK4T5Y	DN	Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate
DMK4T5Y	HS	Investigative
DMK4T5Y	SN	CHEMBL603129; MLS000537589; Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate; AC1OJ6S4; cid_7315331; REGID_for_CID_7315331; HMS2189O04; BDBM50308501; SMR000161712; MLS-0103498.0001; ethyl 5-benzoyl-4-phenyl-1,3-thiazol-2-ylcarbamate; ethyl N-(5-benzoyl-4-phenyl-1,3-thiazol-2-yl)carbamate
DMK4T5Y	DT	Small molecular drug
DMK4T5Y	PC	7315331
DMK4T5Y	MW	352.4
DMK4T5Y	FM	C19H16N2O3S
DMK4T5Y	IC	InChI=1S/C19H16N2O3S/c1-2-24-19(23)21-18-20-15(13-9-5-3-6-10-13)17(25-18)16(22)14-11-7-4-8-12-14/h3-12H,2H2,1H3,(H,20,21,23)
DMK4T5Y	CS	CCOC(=O)NC1=NC(=C(S1)C(=O)C2=CC=CC=C2)C3=CC=CC=C3
DMK4T5Y	IK	VMTZCTQCFMWSEO-UHFFFAOYSA-N
DMK4T5Y	IU	ethyl N-(5-benzoyl-4-phenyl-1,3-thiazol-2-yl)carbamate
DMK4T5Y	DE	Discovery agent

DM5G91Z	ID	DM5G91Z
DM5G91Z	DN	Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z	HS	Investigative
DM5G91Z	SN	CHEMBL1269786; iodo-betaCCE; ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate; SCHEMBL7380021; LTYUPBZLKIUGQX-UHFFFAOYSA-N; BDBM50329629; 6-iodo-beta-carboline-3-carboxylic-acid-ethylester; 6-Iodo-beta-carbolin-3-carboxylic acid ethyl ester
DM5G91Z	DT	Small molecular drug
DM5G91Z	PC	13037317
DM5G91Z	MW	366.15
DM5G91Z	FM	C14H11IN2O2
DM5G91Z	IC	InChI=1S/C14H11IN2O2/c1-2-19-14(18)12-6-10-9-5-8(15)3-4-11(9)17-13(10)7-16-12/h3-7,17H,2H2,1H3
DM5G91Z	CS	CCOC(=O)C1=NC=C2C(=C1)C3=C(N2)C=CC(=C3)I
DM5G91Z	IK	LTYUPBZLKIUGQX-UHFFFAOYSA-N
DM5G91Z	IU	ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z	DE	Discovery agent

DM7FPX8	ID	DM7FPX8
DM7FPX8	DN	Ethyl 7-hydroxy-2-oxo-2H-chromene-3-carboxylate
DM7FPX8	HS	Investigative
DM7FPX8	SN	6093-71-6; ethyl 7-hydroxy-2-oxo-2H-chromene-3-carboxylate; 3-CARBETHOXYUMBELIFERONE; ethyl 7-hydroxy-2-oxochromene-3-carboxylate; 7-Hydroxycoumarin-3-carboxylic acid ethyl ester; 3-carbethoxy-7-hydroxycoumarin; YZ9; 2H-1-Benzopyran-3-carboxylic acid, 7-hydroxy-2-oxo-, ethyl ester; CHEMBL155103; 7-HYDROXY-2-OXO-CHROMENE-3-CARBOXYLIC ACID ETHYL ESTER; Ethyl umbelliferone-3-carboxylate; Ethyl 7-hydroxy-2-oxo-2H-1-benzopyran-3-carboxylate; AK146029; 7-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid ethyl ester; 1gcz; AC1NRDLP
DM7FPX8	DT	Small molecular drug
DM7FPX8	PC	5289613
DM7FPX8	MW	234.2
DM7FPX8	FM	C12H10O5
DM7FPX8	IC	InChI=1S/C12H10O5/c1-2-16-11(14)9-5-7-3-4-8(13)6-10(7)17-12(9)15/h3-6,13H,2H2,1H3
DM7FPX8	CS	CCOC(=O)C1=CC2=C(C=C(C=C2)O)OC1=O
DM7FPX8	IK	IETDBZQIWIJQJG-UHFFFAOYSA-N
DM7FPX8	IU	ethyl 7-hydroxy-2-oxochromene-3-carboxylate
DM7FPX8	CA	CAS 6093-71-6
DM7FPX8	DE	Discovery agent

DMWIB0V	ID	DMWIB0V
DMWIB0V	DN	Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate
DMWIB0V	HS	Investigative
DMWIB0V	SN	ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate; 6093-72-7; CHEMBL568385; ethyl 7-methoxy-2-oxochromene-3-carboxylate; 7-Methoxy-2-oxo-2H-chromene-3-carboxylic acid ethyl ester; MLS000554938; AC1LIZL3; Oprea1_386697; AC1Q645E; SCHEMBL1406462; CTK8D4125; CHEBI:108321; MolPort-000-258-049; ZINC499358; HMS2332G10; STK527622; BDBM50303495; AKOS002230558; MCULE-3724351908; AJ-23200; SMR000147055; TC-069558; KB-296861; AX8285479; ST50114633; 2-Oxo-7-methoxy-2H-1-benzopyran-3-carboxylic acid ethyl ester; 2H-1-Benzopyran-3-carboxylic acid, 
DMWIB0V	DT	Small molecular drug
DMWIB0V	PC	914298
DMWIB0V	MW	248.23
DMWIB0V	FM	C13H12O5
DMWIB0V	IC	InChI=1S/C13H12O5/c1-3-17-12(14)10-6-8-4-5-9(16-2)7-11(8)18-13(10)15/h4-7H,3H2,1-2H3
DMWIB0V	CS	CCOC(=O)C1=CC2=C(C=C(C=C2)OC)OC1=O
DMWIB0V	IK	FWFVXBZXJKTVGL-UHFFFAOYSA-N
DMWIB0V	IU	ethyl 7-methoxy-2-oxochromene-3-carboxylate
DMWIB0V	CA	CAS 6093-72-7
DMWIB0V	CB	CHEBI:108321
DMWIB0V	DE	Discovery agent

DMJQTIK	ID	DMJQTIK
DMJQTIK	DN	Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate
DMJQTIK	HS	Investigative
DMJQTIK	SN	CHEMBL571926
DMJQTIK	DT	Small molecular drug
DMJQTIK	PC	54736443
DMJQTIK	MW	394.3
DMJQTIK	FM	C21H14O8
DMJQTIK	IC	InChI=1S/C21H14O8/c1-27-19(24)14(15-17(22)10-6-2-4-8-12(10)28-20(15)25)16-18(23)11-7-3-5-9-13(11)29-21(16)26/h2-9,14,22-23H,1H3
DMJQTIK	CS	COC(=O)C(C1=C(C2=CC=CC=C2OC1=O)O)C3=C(C4=CC=CC=C4OC3=O)O
DMJQTIK	IK	XCIPOAZOZKLEOW-UHFFFAOYSA-N
DMJQTIK	IU	methyl 2,2-bis(4-hydroxy-2-oxochromen-3-yl)acetate
DMJQTIK	DE	Discovery agent

DMR5Z2A	ID	DMR5Z2A
DMR5Z2A	DN	Ethyl biscoumacetate
DMR5Z2A	HS	Investigative
DMR5Z2A	SN	Aethyli biscumacetas; Aethylis biscumacetas; Aethylum biscumaceticum; Dicumacyl; ETHYL BISCOUMACETATE; Ethyl biscumacetate; Ethyldicoumarol; Ethyldicoumarol acetate; Neodicoumarin; Neodicoumarol; Neodicumarinum; Neodicumarol; Neodikumarin; Pelentan; Trombarin; Trombil; Trombolysan; Tromexan; Tromexan ethyl acetate; 548-00-5; BOEA; Bis(4-hydroxy-2-oxo-2H-1-benzopyran-3-yl)acetic acid ethyl ester; Bis-(4-hydroxy-3-coumarinyl)ethyl acetate; Ethyl bis(4-hydroxy-3-coumarinyl)acetate; Ethyl bis(4-hydroxycoumarinyl)acetate; NSC 36366
DMR5Z2A	PC	54685524
DMR5Z2A	MW	408.4
DMR5Z2A	FM	C22H16O8
DMR5Z2A	IC	JCLHQFUTFHUXNN-UHFFFAOYSA-N
DMR5Z2A	CS	CCOC(=O)C(C1=C(C2=CC=CC=C2OC1=O)O)C3=C(C4=CC=CC=C4OC3=O)O
DMR5Z2A	IK	1S/C22H16O8/c1-2-28-20(25)15(16-18(23)11-7-3-5-9-13(11)29-21(16)26)17-19(24)12-8-4-6-10-14(12)30-22(17)27/h3-10,15,23-24H,2H2,1H3
DMR5Z2A	IU	ethyl 2,2-bis(4-hydroxy-2-oxochromen-3-yl)acetate
DMR5Z2A	CA	CAS 548-00-5
DMR5Z2A	CB	CHEBI:135659
DMR5Z2A	DE	Thrombosis

DMW0J3D	ID	DMW0J3D
DMW0J3D	DN	Ethyl Dihydrogen Phosphate
DMW0J3D	HS	Investigative
DMW0J3D	SN	Ethyl dihydrogen phosphate; Monoethyl phosphate; O-Ethyl dihydrogen phosphate; Monoethyl acid phosphate; 1623-14-9; ethylphosphate; Ethyl phosphate, mono-; PHOSPHORIC ACID, MONOETHYL ESTER; UNII-BMH1WT204A; Phosphoric acid monoethyl ester; EINECS 216-603-9; Phosphoric Acid Ethyl Ester; BRN 1702252; BMH1WT204A; AI3-15046; CHEBI:42383; EFS; ethanol-phosphate; mono-ethyl phosphate; ethoxyphosphonic acid; AC1L2LDP; ETHYLPHOSPHORIC ACID; Epitope ID:143619; AC1Q6S7W; SCHEMBL40792; CTK6G4379; Ethyl phosphate ((eto)(ho)2po)
DMW0J3D	DT	Small molecular drug
DMW0J3D	PC	74190
DMW0J3D	MW	126.05
DMW0J3D	FM	C2H7O4P
DMW0J3D	IC	InChI=1S/C2H7O4P/c1-2-6-7(3,4)5/h2H2,1H3,(H2,3,4,5)
DMW0J3D	CS	CCOP(=O)(O)O
DMW0J3D	IK	ZJXZSIYSNXKHEA-UHFFFAOYSA-N
DMW0J3D	IU	ethyl dihydrogen phosphate
DMW0J3D	CA	CAS 1623-14-9
DMW0J3D	CB	CHEBI:42383
DMW0J3D	DE	Discovery agent

DMXTLJE	ID	DMXTLJE
DMXTLJE	DN	Ethyl estrone-16-methylcarboxylate
DMXTLJE	HS	Investigative
DMXTLJE	SN	SCHEMBL12379501
DMXTLJE	DT	Small molecular drug
DMXTLJE	PC	53319855
DMXTLJE	MW	356.5
DMXTLJE	FM	C22H28O4
DMXTLJE	IC	InChI=1S/C22H28O4/c1-3-26-20(24)12-14-11-19-18-6-4-13-10-15(23)5-7-16(13)17(18)8-9-22(19,2)21(14)25/h5,7,10,14,17-19,23H,3-4,6,8-9,11-12H2,1-2H3/t14?,17-,18-,19+,22+/m1/s1
DMXTLJE	CS	CCOC(=O)CC1C[C@H]2[C@@H]3CCC4=C([C@H]3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMXTLJE	IK	SRWMNPAYNHYCEU-LRHWGCDKSA-N
DMXTLJE	IU	ethyl 2-[(8R,9S,13S,14S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]acetate
DMXTLJE	DE	Discovery agent

DMT4XJM	ID	DMT4XJM
DMT4XJM	DN	ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE
DMT4XJM	HS	Investigative
DMT4XJM	SN	Ethyl Hydrogen Diethylamidophosphate; SCHEMBL3141511; diethylamino(ethoxy)phosphinic acid; DB08658; N,N-Diethylamidophosphoric acid hydrogen ethyl ester
DMT4XJM	DT	Small molecular drug
DMT4XJM	PC	15083623
DMT4XJM	MW	181.17
DMT4XJM	FM	C6H16NO3P
DMT4XJM	IC	InChI=1S/C6H16NO3P/c1-4-7(5-2)11(8,9)10-6-3/h4-6H2,1-3H3,(H,8,9)
DMT4XJM	CS	CCN(CC)P(=O)(O)OCC
DMT4XJM	IK	DUNFIZRDIMDMIH-UHFFFAOYSA-N
DMT4XJM	IU	ethoxy-N,N-diethylphosphonamidic acid
DMT4XJM	DE	Discovery agent

DMXMRK7	ID	DMXMRK7
DMXMRK7	DN	Ethyl octylfluorophosphonate
DMXMRK7	HS	Investigative
DMXMRK7	SN	CHEMBL1222256
DMXMRK7	DT	Small molecular drug
DMXMRK7	PC	49864679
DMXMRK7	MW	238.28
DMXMRK7	FM	C11H24FO2P
DMXMRK7	IC	InChI=1S/C11H24FO2P/c1-4-5-6-7-8-9-10-15(12,13)14-11(2)3/h11H,4-10H2,1-3H3
DMXMRK7	CS	CCCCCCCCP(=O)(OC(C)C)F
DMXMRK7	IK	GLHLEAFTUHVDCD-UHFFFAOYSA-N
DMXMRK7	IU	1-[fluoro(propan-2-yloxy)phosphoryl]octane
DMXMRK7	DE	Discovery agent

DM9KF0H	ID	DM9KF0H
DM9KF0H	DN	Ethyl Oxo(Piperidin-1-Yl)Acetate
DM9KF0H	HS	Investigative
DM9KF0H	SN	53074-96-7; Ethyl 1-piperidineglyoxylate; Ethyl 1-piperidineoxoacetate; ETHYL OXO(PIPERIDIN-1-YL)ACETATE; ethyl 2-oxo-2-(piperidin-1-yl)acetate; ASBDXHCMVYVJQQ-UHFFFAOYSA-N; 1-Piperidineaceticacid, a-oxo-, ethyl ester; E1P; Ethyl1-piperidineglyoxylate; EINECS 258-343-9; N-ethoxalylpiperidine; 1w8m; AI3-26189; AC1L2WQF; ethyl 2-oxo-2-piperidylacetate; SCHEMBL1819086; CTK4J7020; DTXSID60201157; MolPort-001-510-784; Ethyl oxo(1-piperidinyl)acetate #; ZINC2149356; ALBB-030316; ethyl 2-oxo-2-piperidin-1-ylacetate; AKOS000444140
DM9KF0H	DT	Small molecular drug
DM9KF0H	PC	104406
DM9KF0H	MW	185.22
DM9KF0H	FM	C9H15NO3
DM9KF0H	IC	InChI=1S/C9H15NO3/c1-2-13-9(12)8(11)10-6-4-3-5-7-10/h2-7H2,1H3
DM9KF0H	CS	CCOC(=O)C(=O)N1CCCCC1
DM9KF0H	IK	ASBDXHCMVYVJQQ-UHFFFAOYSA-N
DM9KF0H	IU	ethyl 2-oxo-2-piperidin-1-ylacetate
DM9KF0H	CA	CAS 53074-96-7
DM9KF0H	DE	Discovery agent

DMYFK4L	ID	DMYFK4L
DMYFK4L	DN	Ethyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine
DMYFK4L	HS	Investigative
DMYFK4L	SN	CHEMBL77421; 2H-Indazol-5-amine, N-ethyl-4,5,6,7-tetrahydro-; 121867-55-8; Ethyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine
DMYFK4L	DT	Small molecular drug
DMYFK4L	PC	14539718
DMYFK4L	MW	165.24
DMYFK4L	FM	C9H15N3
DMYFK4L	IC	InChI=1S/C9H15N3/c1-2-10-8-3-4-9-7(5-8)6-11-12-9/h6,8,10H,2-5H2,1H3,(H,11,12)
DMYFK4L	CS	CCNC1CCC2=C(C1)C=NN2
DMYFK4L	IK	DDFOVLJCDZCIIF-UHFFFAOYSA-N
DMYFK4L	IU	N-ethyl-4,5,6,7-tetrahydro-1H-indazol-5-amine
DMYFK4L	DE	Discovery agent

DMBULX4	ID	DMBULX4
DMBULX4	DN	Ethylene diamine
DMBULX4	HS	Investigative
DMBULX4	SN	ethylenediamine; Ethane-1,2-diamine; 1,2-Ethanediamine; 107-15-3; 1,2-Diaminoethane; Ethylene diamine; Ethylendiamine; Dimethylenediamine; edamine; 1,2-Ethylenediamine; Aethaldiamin; Ethyleendiamine; Aethylenediamin; Ethylene-diamine; beta-Aminoethylamine; 1,2-Diaminoaethan; Amerstat 274; Algicode 106L; 1,2-Diamino-ethano; 1,2-Diamino-ethaan; Aethaldiamin [German]; Caswell No. 437; Ethylenediamine [JAN]; Ethyleendiamine [Dutch]; 1,2-Ethanediamine, homopolymer; Aethylenediamin [German]; Ethylene-diamine [French]; NCI-C60402
DMBULX4	DT	Small molecular drug
DMBULX4	PC	3301
DMBULX4	MW	60.1
DMBULX4	FM	C2H8N2
DMBULX4	IC	InChI=1S/C2H8N2/c3-1-2-4/h1-4H2
DMBULX4	CS	C(CN)N
DMBULX4	IK	PIICEJLVQHRZGT-UHFFFAOYSA-N
DMBULX4	IU	ethane-1,2-diamine
DMBULX4	CA	CAS 107-15-3
DMBULX4	CB	CHEBI:30347
DMBULX4	DE	Tuberculosis

DMJ6PB8	ID	DMJ6PB8
DMJ6PB8	DN	Ethylgallate
DMJ6PB8	HS	Investigative
DMJ6PB8	SN	ETHYL GALLATE; 831-61-8; Ethyl 3,4,5-trihydroxybenzoate; Gallic acid ethyl ester; Phyllemblin; Nipagallin A; Progallin A; Ethylgallate; Nipa No. 48; Gallic acid, ethyl ester; Benzoic acid, 3,4,5-trihydroxy-, ethyl ester; NIPA 48; 3,4,5-Trihydroxybenzoic acid ethyl ester; Ethyl-3,4,5-trihydroxybenzoate; Ethylester kyseliny gallove; UNII-235I6UDD3L; NSC 402626; Ethylester kyseliny gallove [Czech]; EINECS 212-608-5; BRN 2116014; CHEMBL453196; 235I6UDD3L; CHEBI:87247; VFPFQHQNJCMNBZ-UHFFFAOYSA-N; NSC402626; AK-94174; Q-100846; Gallic aci
DMJ6PB8	DT	Small molecular drug
DMJ6PB8	PC	13250
DMJ6PB8	MW	198.17
DMJ6PB8	FM	C9H10O5
DMJ6PB8	IC	InChI=1S/C9H10O5/c1-2-14-9(13)5-3-6(10)8(12)7(11)4-5/h3-4,10-12H,2H2,1H3
DMJ6PB8	CS	CCOC(=O)C1=CC(=C(C(=C1)O)O)O
DMJ6PB8	IK	VFPFQHQNJCMNBZ-UHFFFAOYSA-N
DMJ6PB8	IU	ethyl 3,4,5-trihydroxybenzoate
DMJ6PB8	CA	CAS 831-61-8
DMJ6PB8	CB	CHEBI:87247
DMJ6PB8	DE	Discovery agent

DM3CWFR	ID	DM3CWFR
DM3CWFR	DN	Ethyl-indol-1-yl-pyridin-4-yl-amine
DM3CWFR	HS	Investigative
DM3CWFR	SN	CHEMBL154541; Ethyl-indol-1-yl-pyridin-4-yl-amine; SCHEMBL7613957; BDBM50048600
DM3CWFR	DT	Small molecular drug
DM3CWFR	PC	10561859
DM3CWFR	MW	237.3
DM3CWFR	FM	C15H15N3
DM3CWFR	IC	InChI=1S/C15H15N3/c1-2-17(14-7-10-16-11-8-14)18-12-9-13-5-3-4-6-15(13)18/h3-12H,2H2,1H3
DM3CWFR	CS	CCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DM3CWFR	IK	RBKZPZVPVZNIMS-UHFFFAOYSA-N
DM3CWFR	IU	N-ethyl-N-pyridin-4-ylindol-1-amine
DM3CWFR	DE	Discovery agent

DMV9OCU	ID	DMV9OCU
DMV9OCU	DN	Ethylisothiourea
DMV9OCU	HS	Investigative
DMV9OCU	SN	etiron; 2-Ethyl-2-thiopseudourea; ethyron; ETHYLISOTHIOUREA; 2-Ethyl-isothiourea; 2986-20-1; Carbamimidothioic acid, ethyl ester; UNII-236P47H4VR; Pseudourea, 2-ethyl-2-thio-; CHEMBL321691; VFIZBHJTOHUOEK-UHFFFAOYSA-N; 236P47H4VR; S-ethyl-thioureum; Ethiron (Salt/Mix); Ethyl imidothiocarbamate; Tocris-0873; ethylsulfanyl-formamidine; AC1L1JOU; Lopac-E-3149; Ethyl imidothiocarbamate #; AC1Q1UA8; WR 539 (Salt/Mix); Lopac0_000491; SCHEMBL160501
DMV9OCU	DT	Small molecular drug
DMV9OCU	PC	5139
DMV9OCU	MW	104.18
DMV9OCU	FM	C3H8N2S
DMV9OCU	IC	InChI=1S/C3H8N2S/c1-2-6-3(4)5/h2H2,1H3,(H3,4,5)
DMV9OCU	CS	CCSC(=N)N
DMV9OCU	IK	VFIZBHJTOHUOEK-UHFFFAOYSA-N
DMV9OCU	IU	ethyl carbamimidothioate
DMV9OCU	CA	CAS 2986-20-1

DM9YRCU	ID	DM9YRCU
DM9YRCU	DN	ethylketocyclazocine
DM9YRCU	HS	Investigative
DM9YRCU	SN	CHEMBL71301; AC1L28LJ; GTPL1602; BDBM50017232; L024009
DM9YRCU	DT	Small molecular drug
DM9YRCU	PC	443409
DM9YRCU	MW	299.4
DM9YRCU	FM	C19H25NO2
DM9YRCU	IC	InChI=1S/C19H25NO2/c1-3-19-8-9-20(11-13-4-5-13)17(12(19)2)18(22)15-7-6-14(21)10-16(15)19/h6-7,10,12-13,17,21H,3-5,8-9,11H2,1-2H3/t12?,17-,19+/m0/s1
DM9YRCU	CS	CC[C@@]12CCN([C@@H](C1C)C(=O)C3=C2C=C(C=C3)O)CC4CC4
DM9YRCU	IK	SEJUQQOPVAUETF-SCTOPSOGSA-N
DM9YRCU	IU	(1R,9S)-10-(cyclopropylmethyl)-1-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one
DM9YRCU	CA	CAS 6036-52-8
DM9YRCU	CB	CHEBI:4901
DM9YRCU	DE	Discovery agent

DM0YROF	ID	DM0YROF
DM0YROF	DN	Ethylmorphine
DM0YROF	HS	Investigative
DM0YROF	SN	Ethylmorphine; Codethyline; DIONINE; 76-58-4; Morphine, ethyl-; Ethyl morphine; UNII-RWO67D87EU; Ethylmorphine [BAN]; 3-O-Ethylmorphine; EINECS 200-970-7; RWO67D87EU; CHEBI:4902; DEA No. 9190; Dionin; Ethylmorphine (BAN); NCGC00168251-01; Ethomorphine; Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-ethoxy-17-methyl-; (4R,4aR,7S,7aR,12bS)-9-ethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol; Morphine 3-ethyl ether; AC1Q37UW; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-ethoxy-17-methyl-
DM0YROF	DT	Small molecular drug
DM0YROF	PC	5359271
DM0YROF	MW	313.4
DM0YROF	FM	C19H23NO3
DM0YROF	IC	InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1
DM0YROF	CS	CCOC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CCN4C)[C@@H](O2)[C@H](C=C5)O)C=C1
DM0YROF	IK	OGDVEMNWJVYAJL-LEPYJNQMSA-N
DM0YROF	IU	(4R,4aR,7S,7aR,12bS)-9-ethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
DM0YROF	CA	CAS 76-58-4
DM0YROF	CB	CHEBI:4902
DM0YROF	DE	Discovery agent

DMT51QD	ID	DMT51QD
DMT51QD	DN	ETHYLPHENSERINE
DMT51QD	HS	Investigative
DMT51QD	SN	2-ethylphenserine.tartaric acid; ETHYLPHENSERINE; homotolserine; 2-ethylphenserine; eseroline 2-ethylphenylcarbamate; CHEMBL340391; BDBM10961; (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-(2-ethylphenyl)carbamate
DMT51QD	DT	Small molecular drug
DMT51QD	PC	9976105
DMT51QD	MW	365.5
DMT51QD	FM	C22H27N3O2
DMT51QD	IC	InChI=1S/C22H27N3O2/c1-5-15-8-6-7-9-18(15)23-21(26)27-16-10-11-19-17(14-16)22(2)12-13-24(3)20(22)25(19)4/h6-11,14,20H,5,12-13H2,1-4H3,(H,23,26)/t20-,22+/m1/s1
DMT51QD	CS	CCC1=CC=CC=C1NC(=O)OC2=CC3=C(C=C2)N([C@@H]4[C@]3(CCN4C)C)C
DMT51QD	IK	NRKKZJALIFDZIJ-IRLDBZIGSA-N
DMT51QD	IU	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(2-ethylphenyl)carbamate
DMT51QD	DE	Discovery agent

DM4FW3H	ID	DM4FW3H
DM4FW3H	DN	ETICLOPRIDE
DM4FW3H	HS	Investigative
DM4FW3H	SN	Eticlopride; Eticlopride [INN]; Eticlopridum [Latin]; Eticloprida [Spanish]; CHEMBL8946; UNII-J8M468HBH4; J8M468HBH4; FLB 131; FLB-131; 3-Chloro-5-Ethyl-N-{[(2s)-1-Ethylpyrrolidin-2-Yl]methyl}-6-Hydroxy-2-Methoxybenzamide; C17H25ClN2O3; 5-chloro-3-ethyl-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide; (-)-(S)-5-Chloro-3-ethyl-N-((1-ethyl-2-pyrrolidinyl)methyl)-6-methoxysalicylamide; NCGC00016963-01; NCGC00161393-01; CAS-97612-24-3; Eticlopridum; Eticloprida; Prestwick3_000932; ETICLOPRIDE,S(-); AC1L1MN4
DM4FW3H	DT	Small molecular drug
DM4FW3H	PC	57267
DM4FW3H	MW	340.8
DM4FW3H	FM	C17H25ClN2O3
DM4FW3H	IC	InChI=1S/C17H25ClN2O3/c1-4-11-9-13(18)16(23-3)14(15(11)21)17(22)19-10-12-7-6-8-20(12)5-2/h9,12,21H,4-8,10H2,1-3H3,(H,19,22)/t12-/m0/s1
DM4FW3H	CS	CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCCN2CC)OC)Cl
DM4FW3H	IK	AADCDMQTJNYOSS-LBPRGKRZSA-N
DM4FW3H	IU	5-chloro-3-ethyl-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide
DM4FW3H	CA	CAS 84226-12-0
DM4FW3H	CB	CHEBI:92874
DM4FW3H	DE	Discovery agent

DMR9YL6	ID	DMR9YL6
DMR9YL6	DN	Etilamfetamine
DMR9YL6	HS	Investigative
DMR9YL6	SN	Apetinil; Ethylamphetamine; Etilamfetamina [INN-Spanish]; Etilamfetamine; Etilamfetamine (INN); Etilamfetamine [INN]; Etilamfetaminum [INN-Latin]; Etilamfetaminum [Latin]; Etilanfetamina [Spanish]; N-Ethylamphetamine; N-ethyl-1-phenylpropan-2-amine; 1-Phenyl-2-aethylamino-propan; 1-Phenyl-2-aethylamino-propan [German]; 1-Phenyl-2-ethylaminopropane; 457-87-4; BRN 2357701; Benzeneethanamine, N-ethyl-.alpha.-methyl-; DEA No. 1475; N-Ethyl-alpha-methylphenethylamine; alpha-Phenyl-beta-ethylaminopropane
DMR9YL6	PC	9982
DMR9YL6	MW	163.26
DMR9YL6	FM	C11H17N
DMR9YL6	IC	YAGBSNMZQKEFCO-UHFFFAOYSA-N
DMR9YL6	CS	CCNC(C)CC1=CC=CC=C1
DMR9YL6	IK	1S/C11H17N/c1-3-12-10(2)9-11-7-5-4-6-8-11/h4-8,10,12H,3,9H2,1-2H3
DMR9YL6	IU	N-ethyl-1-phenylpropan-2-amine
DMR9YL6	CA	CAS 457-87-4
DMR9YL6	CB	CHEBI:134796
DMR9YL6	DE	Pulmonary hypertension

DMVI9DM	ID	DMVI9DM
DMVI9DM	DN	ETIOCHOLANOLONE
DMVI9DM	HS	Investigative
DMVI9DM	SN	etiocholanolone; 5-Isoandrosterone; 53-42-9; Etiocholan-3alpha-ol-17-one; Aetiocholanolone; 3alpha-Etiocholanolone; 5beta-Androsterone; 3alpha-Hydroxy-5beta-androstan-17-one; 5b-androsterone; Androsterone, (5beta)-; UNII-97CGB1M48I; alpha-Etiocholanolone; 5.beta.-Androsterone; 5beta-Androstan-3alpha-ol-17-one; 3.alpha.-Etiocholanolone; NSC 50908; Androsterone, (5.beta.)-; CHEMBL85799; 97CGB1M48I; 3alpha-Hydroxyetiocholan-17-one; CHEBI:28195; Etiocholan-3.alpha.-ol-17-one; 3a-Hydroxy-5b-androstan-17-one
DMVI9DM	DT	Small molecular drug
DMVI9DM	PC	5880
DMVI9DM	MW	290.4
DMVI9DM	FM	C19H30O2
DMVI9DM	IC	InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14+,15+,16+,18+,19+/m1/s1
DMVI9DM	CS	C[C@]12CC[C@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DMVI9DM	IK	QGXBDMJGAMFCBF-BNSUEQOYSA-N
DMVI9DM	IU	(3R,5R,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMVI9DM	CA	CAS 53-42-9
DMVI9DM	CB	CHEBI:28195
DMVI9DM	DE	Discovery agent

DMKH8TC	ID	DMKH8TC
DMKH8TC	DN	Etisulergine
DMKH8TC	HS	Investigative
DMKH8TC	SN	Etisulergine; UNII-28N73Q6O7Y; 64795-23-9; 28N73Q6O7Y; Etisulerginum; Etisulergina; etisulergine[inn]; Etisulergine [INN]; Etisulerginum [INN-Latin]; Etisulergina [INN-Spanish]; CQ 32-084; AC1L2AKJ; AC1Q6V8T; SCHEMBL219311; CHEMBL38992; BDBM50225361; 72782-54-8 (mono-hydrochloride)
DMKH8TC	DT	Small molecular drug
DMKH8TC	PC	68847
DMKH8TC	MW	376.5
DMKH8TC	FM	C19H28N4O2S
DMKH8TC	IC	InChI=1S/C19H28N4O2S/c1-4-23(5-2)26(24,25)21-14-10-16-15-7-6-8-17-19(15)13(11-20-17)9-18(16)22(3)12-14/h6-8,11,14,16,18,20-21H,4-5,9-10,12H2,1-3H3/t14-,16+,18+/m0/s1
DMKH8TC	CS	CCN(CC)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
DMKH8TC	IK	YHEIHLVIKSTGJE-YXJHDRRASA-N
DMKH8TC	IU	(6aR,9S,10aR)-9-(diethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
DMKH8TC	CA	CAS 64795-23-9
DMKH8TC	DE	Discovery agent

DMDOX1Z	ID	DMDOX1Z
DMDOX1Z	DN	Etoloxamine
DMDOX1Z	HS	Investigative
DMDOX1Z	SN	Etoloxamine; UNII-NEZ417265P; CHEMBL366265; 1157-87-5; NEZ417265P; Etoloxaminum; Etoloxamina; Aetholoxaminum; etoloxamine[inn]; Etoloxamine [INN]; Etoloxaminum [INN-Latin]; Etoloxamina [INN-Spanish]; 2-(2-benzylphenoxy)-N,N-diethylethanamine; AC1L2ASA; AC1Q57OP; SCHEMBL2110223; ZINC1407; BPXIOWINQPQVOY-UHFFFAOYSA-N; BDBM50151052; 2-((alpha-Phenyl-o-tolyl)oxy)triethylamine
DMDOX1Z	DT	Small molecular drug
DMDOX1Z	PC	68950
DMDOX1Z	MW	283.4
DMDOX1Z	FM	C19H25NO
DMDOX1Z	IC	InChI=1S/C19H25NO/c1-3-20(4-2)14-15-21-19-13-9-8-12-18(19)16-17-10-6-5-7-11-17/h5-13H,3-4,14-16H2,1-2H3
DMDOX1Z	CS	CCN(CC)CCOC1=CC=CC=C1CC2=CC=CC=C2
DMDOX1Z	IK	BPXIOWINQPQVOY-UHFFFAOYSA-N
DMDOX1Z	IU	2-(2-benzylphenoxy)-N,N-diethylethanamine
DMDOX1Z	CA	CAS 1157-87-5
DMDOX1Z	DE	Discovery agent

DMFR1SE	ID	DMFR1SE
DMFR1SE	DN	ETONITAZENE
DMFR1SE	HS	Investigative
DMFR1SE	SN	Etonitazene; Etonitazine; Etonitazinum; Ciba 20-684BA; ARC 1G2; Etobedolum; 911-65-9; Etonitazenum [INN-Latin]; NIH 7607; Etonitazeno [INN-Spanish]; Etonitazene [INN:BAN:DCF]; UNII-9U3GT3353T; EINECS 213-009-1; Ba-20684; Ba 20684; BRN 0363324; CHEMBL312040; DEA No. 9624; PXDBZSCGSQSKST-UHFFFAOYSA-N; C22H28N4O3; 9U3GT3353T; 1-(2-(Diethylamino)ethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole; 1-(2-Diethylaminoethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole; 1H-Benzimidazole-1-ethanamine, 2-((4-ethoxyphenyl)methyl)-N,N-diethyl-5-nitro-
DMFR1SE	DT	Small molecular drug
DMFR1SE	PC	13493
DMFR1SE	MW	396.5
DMFR1SE	FM	C22H28N4O3
DMFR1SE	IC	InChI=1S/C22H28N4O3/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3/h7-12,16H,4-6,13-15H2,1-3H3
DMFR1SE	CS	CCN(CC)CCN1C2=C(C=C(C=C2)[N+](=O)[O-])N=C1CC3=CC=C(C=C3)OCC
DMFR1SE	IK	PXDBZSCGSQSKST-UHFFFAOYSA-N
DMFR1SE	IU	2-[2-[(4-ethoxyphenyl)methyl]-5-nitrobenzimidazol-1-yl]-N,N-diethylethanamine
DMFR1SE	CA	CAS 911-65-9
DMFR1SE	DE	Discovery agent

DM79YZN	ID	DM79YZN
DM79YZN	DN	Etorphine
DM79YZN	HS	Investigative
DM79YZN	SN	Etorphine; 19-Propylorvinol; 6,14-Ethenomorphinan-7-methanol, 4,5-epoxy-3-hydroxy-6-methoxy-.alpha.,17-dimethyl-.alpha.-propyl-, [5.alpha.,7.alpha.(R)]-; 7.alpha.-Etorphine; AC1LARGT; ETORPHINE - HCI; GTPL1625; SCHEMBL10031275; Oripavine, 6,14-endo-ethylenetetrahydro-7-(1-hydroxy-1-methylbutyl)-; BDBM82425; CAHCBJPUTCKATP-UHFFFAOYSA-N; M99; CAS_61677; NSC_61677; FT-0668440; L024016; Tetrahydro-7-.alpha.-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine; 6,14-endo-Ethenotetrahydrooripavine, 7.alpha.-(1-hydroxy-1-methylbuty
DM79YZN	DT	Small molecular drug
DM79YZN	PC	644209
DM79YZN	MW	411.5
DM79YZN	FM	C25H33NO4
DM79YZN	IC	InChI=1S/C25H33NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,9-10,17-18,21,27-28H,5,8,11-14H2,1-4H3/t17-,18-,21-,22-,23-,24+,25-/m1/s1
DM79YZN	CS	CCC[C@](C)([C@H]1C[C@@]23C=C[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)C)OC)O
DM79YZN	IK	CAHCBJPUTCKATP-FAWZKKEFSA-N
DM79YZN	IU	(1R,2S,6R,14R,15R,19R)-19-[(2R)-2-hydroxypentan-2-yl]-15-methoxy-5-methyl-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,16-tetraen-11-ol
DM79YZN	CA	CAS 14521-96-1
DM79YZN	CB	CHEBI:4912
DM79YZN	DE	Discovery agent

DM79XSF	ID	DM79XSF
DM79XSF	DN	ETP-45658
DM79XSF	HS	Investigative
DM79XSF	SN	1198357-79-7; ETP 45658; 3-(1-methyl-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-6-yl)phenol; 3-(4-Morpholino-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)phenol; 3-[1-Methyl-4-(4-morpholinyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenol; CHEMBL4303351; SCHEMBL12684765; BDBM92585; ETP45658; ZINC59155589; AKOS025293482; ETP-45658, 13; 3-[1-Methyl-4-(4-morpholinyl)-1H-pyrazolo[3,4-d]pyrimidin-6-ylphenol
DM79XSF	DT	Small molecular drug
DM79XSF	PC	25229608
DM79XSF	MW	311.34
DM79XSF	FM	C16H17N5O2
DM79XSF	IC	InChI=1S/C16H17N5O2/c1-20-15-13(10-17-20)16(21-5-7-23-8-6-21)19-14(18-15)11-3-2-4-12(22)9-11/h2-4,9-10,22H,5-8H2,1H3
DM79XSF	CS	CN1C2=C(C=N1)C(=NC(=N2)C3=CC(=CC=C3)O)N4CCOCC4
DM79XSF	IK	BJVRNXSHJLDZJR-UHFFFAOYSA-N
DM79XSF	IU	3-(1-methyl-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-6-yl)phenol
DM79XSF	DE	Breast cancer

DMO2PY8	ID	DMO2PY8
DMO2PY8	DN	ETP-46321
DMO2PY8	HS	Investigative
DMO2PY8	SN	1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine
DMO2PY8	DT	Small molecular drug
DMO2PY8	PC	46927938
DMO2PY8	MW	473.6
DMO2PY8	FM	C20H27N9O3S
DMO2PY8	IC	InChI=1S/C20H27N9O3S/c1-33(30,31)29-4-2-26(3-5-29)12-16-13-28-14-17(15-10-22-20(21)23-11-15)25-19(18(28)24-16)27-6-8-32-9-7-27/h10-11,13-14H,2-9,12H2,1H3,(H2,21,22,23)
DMO2PY8	CS	CS(=O)(=O)N1CCN(CC1)CC2=CN3C=C(N=C(C3=N2)N4CCOCC4)C5=CN=C(N=C5)N
DMO2PY8	IK	OHKDVDMWRKFZRB-UHFFFAOYSA-N
DMO2PY8	IU	5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine
DMO2PY8	DE	Rheumatoid arthritis

DMZ1FCJ	ID	DMZ1FCJ
DMZ1FCJ	DN	EU-517
DMZ1FCJ	HS	Investigative
DMZ1FCJ	SN	Mcl-1 inhibitors (cancer), Eutropics; BH3 mimetics/Mcl-1 inhibitors (cancer), Eutropics
DMZ1FCJ	CP	Harvard Medical School
DMZ1FCJ	DE	Solid tumour/cancer

DMR3487	ID	DMR3487
DMR3487	DN	EU-C-001
DMR3487	HS	Investigative
DMR3487	CP	James Cook University of North Queensland
DMR3487	DE	Brain injury

DME5CK3	ID	DME5CK3
DME5CK3	DN	eucalyptol
DME5CK3	HS	Investigative
DME5CK3	SN	Eucalyptol; cineole; 1,8-Cineole; 1,8-Cineol; Cajeputol; 470-82-6; 1,8-Epoxy-p-menthane; Eucalyptole; Zineol; Eucapur; Terpan; p-Cineole; 1,8-Oxido-p-menthane; 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane; Eukalyptol; CINEOL; Cucalyptol; Soledum; Eukalyptol [Czech]; Zedoary oil; Eucalyptol (natural); EUCALYPTUS OIL; p-Menthane, 1,8-epoxy-; Cineole (VAN); 2-Oxabicyclo[2.2.2]octane, 1,3,3-trimethyl-; NCI-C56575; Eucalyptol [USAN]; UNII-RV6J6604TK; FEMA No. 2465; 2-Oxabicyclo(2.2.2)octane, 1,3,3-trimethyl-; NSC 6171
DME5CK3	DT	Small molecular drug
DME5CK3	PC	2758
DME5CK3	MW	154.25
DME5CK3	FM	C10H18O
DME5CK3	IC	InChI=1S/C10H18O/c1-9(2)8-4-6-10(3,11-9)7-5-8/h8H,4-7H2,1-3H3
DME5CK3	CS	CC1(C2CCC(O1)(CC2)C)C
DME5CK3	IK	WEEGYLXZBRQIMU-UHFFFAOYSA-N
DME5CK3	IU	1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane
DME5CK3	CA	CAS 470-82-6
DME5CK3	CB	CHEBI:27961
DME5CK3	DE	Discovery agent

DMUA485	ID	DMUA485
DMUA485	DN	EUGENIIN
DMUA485	HS	Investigative
DMUA485	SN	beta-D-Glucopyranose, cyclic 4,6-((1S)-4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1,2,3-tris(3,4,5-trihydroxybenzoate); 81571-72-4; 58970-75-5; SCHEMBL618555; AC1L46N3; LS-71467; 1,2,3-Tri-O-galloyl-4,6-(S)-hexahydroxydiphenoyl-b-D-glucopyranose; beta-D-Glucopyranose, cyclic 4,6-(4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1,2,3-tris(3,4,5-trihydroxybenzoate)
DMUA485	DT	Small molecular drug
DMUA485	PC	442679
DMUA485	MW	938.7
DMUA485	FM	C41H30O26
DMUA485	IC	InChI=1S/C41H30O26/c42-15-1-10(2-16(43)26(15)50)36(57)65-34-33-23(9-62-39(60)13-7-21(48)29(53)31(55)24(13)25-14(40(61)64-33)8-22(49)30(54)32(25)56)63-41(67-38(59)12-5-19(46)28(52)20(47)6-12)35(34)66-37(58)11-3-17(44)27(51)18(45)4-11/h1-8,23,33-35,41-56H,9H2/t23-,33-,34+,35-,41+/m1/s1
DMUA485	CS	C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)OC(=O)C6=CC(=C(C(=C6C7=C(C(=C(C=C7C(=O)O1)O)O)O)O)O)O
DMUA485	IK	JCGHAEBIBSEQAD-UUUCSUBKSA-N
DMUA485	IU	[(10R,11S,12R,13S,15R)-3,4,5,21,22,23-hexahydroxy-8,18-dioxo-12,13-bis[(3,4,5-trihydroxybenzoyl)oxy]-9,14,17-trioxatetracyclo[17.4.0.02,7.010,15]tricosa-1(23),2,4,6,19,21-hexaen-11-yl] 3,4,5-trihydroxybenzoate
DMUA485	CB	CHEBI:4916
DMUA485	DE	Discovery agent

DMLXKZH	ID	DMLXKZH
DMLXKZH	DN	EUPAFOLIN
DMLXKZH	HS	Investigative
DMLXKZH	SN	6-Methoxyluteolin; 520-11-6; Nepetin; EUPAFOLIN; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-4H-chromen-4-one; Eurafolin; UNII-I3O7LF3GED; I3O7LF3GED; CHEMBL172350; NSC122416; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one; SMR000440634; Pedaltin; NSC 122416; AC1NSVCV; MLS000728561; MLS000877025; SCHEMBL828390; MEGxp0_000458; cid_5317284; ACon1_000516; BDBM23412; DTXSID10199959; FHHSEFRSDKWJKJ-UHFFFAOYSA-N; REGID_for_CID_5317284
DMLXKZH	DT	Small molecular drug
DMLXKZH	PC	5317284
DMLXKZH	MW	316.26
DMLXKZH	FM	C16H12O7
DMLXKZH	IC	InChI=1S/C16H12O7/c1-22-16-11(20)6-13-14(15(16)21)10(19)5-12(23-13)7-2-3-8(17)9(18)4-7/h2-6,17-18,20-21H,1H3
DMLXKZH	CS	COC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O
DMLXKZH	IK	FHHSEFRSDKWJKJ-UHFFFAOYSA-N
DMLXKZH	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one
DMLXKZH	CA	CAS 520-11-6
DMLXKZH	DE	Discovery agent

DM068CY	ID	DM068CY
DM068CY	DN	EUPATORIOPICRIN
DM068CY	HS	Investigative
DM068CY	SN	Eupatoriopicrin; CHEMBL221283; 6856-01-5; Eupatoriopicrine; AC1NQYHY; CHEBI:4937; BDBM50194428; C09442; [(3aR,4R,6E,10E,11aR)-6,10-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (E)-4-hydroxy-2-(hydroxymethyl)but-2-enoate
DM068CY	DT	Small molecular drug
DM068CY	PC	5281461
DM068CY	MW	362.4
DM068CY	FM	C20H26O6
DM068CY	IC	InChI=1S/C20H26O6/c1-12-5-4-6-13(2)10-17(26-20(24)15(11-22)7-8-21)18-14(3)19(23)25-16(18)9-12/h6-7,9,16-18,21-22H,3-5,8,10-11H2,1-2H3/b12-9+,13-6+,15-7+/t16-,17-,18+/m1/s1
DM068CY	CS	C/C/1=C\\[C@@H]2[C@@H]([C@@H](C/C(=C/CC1)/C)OC(=O)/C(=C/CO)/CO)C(=C)C(=O)O2
DM068CY	IK	VWJYWGYJIDQUEG-DKDOXNMLSA-N
DM068CY	IU	[(3aR,4R,6E,10E,11aR)-6,10-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (E)-4-hydroxy-2-(hydroxymethyl)but-2-enoate
DM068CY	CA	CAS 6856-01-5
DM068CY	CB	CHEBI:4937
DM068CY	DE	Discovery agent

DMO3AZ6	ID	DMO3AZ6
DMO3AZ6	DN	Euro-Celtique 1
DMO3AZ6	HS	Investigative
DMO3AZ6	TC	Analgesics
DMO3AZ6	DE	Pain

DMJH4BF	ID	DMJH4BF
DMJH4BF	DN	Euro-Celtique 2
DMJH4BF	HS	Investigative
DMJH4BF	TC	Analgesics
DMJH4BF	DE	Pain

DM8VI3T	ID	DM8VI3T
DM8VI3T	DN	Euro-Celtique 3
DM8VI3T	HS	Investigative
DM8VI3T	TC	Analgesics
DM8VI3T	DE	Pain

DMO4CEL	ID	DMO4CEL
DMO4CEL	DN	Euro-Celtique 4
DMO4CEL	HS	Investigative
DMO4CEL	TC	Analgesics
DMO4CEL	DE	Pain

DMXBGSL	ID	DMXBGSL
DMXBGSL	DN	EUSYNSTYELAMIDE B
DMXBGSL	HS	Investigative
DMXBGSL	PC	70685496
DMXBGSL	MW	802.6
DMXBGSL	FM	C33H42Br2N10O4
DMXBGSL	IC	InChI=1S/C33H42Br2N10O4/c34-21-5-7-23-19(17-43-25(23)14-21)13-27-32(48,16-20-18-44-26-15-22(35)6-8-24(20)26)29(47)45(12-4-3-11-42-31(38)39)33(27,49)28(46)40-9-1-2-10-41-30(36)37/h5-8,14-15,17-18,27,43-44,48-49H,1-4,9-13,16H2,(H,40,46)(H4,36,37,41)(H4,38,39,42)/t27-,32+,33+/m1/s1
DMXBGSL	CS	C1=CC2=C(C=C1Br)NC=C2C[C@@H]3[C@](C(=O)N([C@]3(C(=O)NCCCCN=C(N)N)O)CCCCN=C(N)N)(CC4=CNC5=C4C=CC(=C5)Br)O
DMXBGSL	IK	FWIZAEZOEFOBCD-LGBXHZPNSA-N
DMXBGSL	IU	(2S,3R,4S)-3,4-bis[(6-bromo-1H-indol-3-yl)methyl]-N,1-bis[4-(diaminomethylideneamino)butyl]-2,4-dihydroxy-5-oxopyrrolidine-2-carboxamide
DMXBGSL	DE	Discovery agent

DM6ODAS	ID	DM6ODAS
DM6ODAS	DN	Eusynstyelamide C
DM6ODAS	HS	Investigative
DM6ODAS	DE	Discovery agent

DMNMEAW	ID	DMNMEAW
DMNMEAW	DN	Evatak
DMNMEAW	HS	Investigative
DMNMEAW	SN	Echovirus type 1 cancer therapy, Psiron; Echovirus type 1 cancer therapy, Viralytics
DMNMEAW	CP	University of Newcastle
DMNMEAW	DE	Solid tumour/cancer

DM17TYR	ID	DM17TYR
DM17TYR	DN	Everolimus
DM17TYR	HS	Investigative
DM17TYR	SN	Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
DM17TYR	CP	Novartis
DM17TYR	TC	Antiviral Agents
DM17TYR	DT	Small molecular drug
DM17TYR	PC	6442177
DM17TYR	MW	958.2
DM17TYR	FM	C53H83NO14
DM17TYR	IC	InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
DM17TYR	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC
DM17TYR	IK	HKVAMNSJSFKALM-GKUWKFKPSA-N
DM17TYR	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM17TYR	CA	CAS 159351-69-6
DM17TYR	CB	CHEBI:68478
DM17TYR	DE	Advanced kidney cancer; Diffuse large B-cell lymphoma; Renal cell carcinoma; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMHMFKE	ID	DMHMFKE
DMHMFKE	DN	EVP-4473
DMHMFKE	HS	Investigative
DMHMFKE	CP	Bayer AG
DMHMFKE	DE	Alzheimer disease

DM4Q2HZ	ID	DM4Q2HZ
DM4Q2HZ	DN	EVT-501
DM4Q2HZ	HS	Investigative
DM4Q2HZ	SN	H3 antagonists (cognitive/sleep disorders), Evotec
DM4Q2HZ	CP	Evotec AG
DM4Q2HZ	DE	Sleep-wake disorder

DMBKM30	ID	DMBKM30
DMBKM30	DN	EX-1311
DMBKM30	HS	Investigative
DMBKM30	SN	EX-1350; EX-1365; EX-1832; EX-51; Ghrelin antagonists (metabolic disease); Ghrelin antagonists (metabolic disease), Elixir; Ghrelin antagonists (metabolic disease), Elixir/Novartis
DMBKM30	CP	Elixir Pharmaceuticals Inc
DMBKM30	DE	Metabolic disorder

DMWF8U5	ID	DMWF8U5
DMWF8U5	DN	EX-1314
DMWF8U5	HS	Investigative
DMWF8U5	SN	BMS-317180; BMS-604992; BMS-606056; Ghrelin agonists, BMS; Ghrelin agonists, Elixir; Growth hormone secretagogues, BMS; Growthhormone secretagogues, Elixir
DMWF8U5	CP	Bristol-Myers Squibb Co
DMWF8U5	DT	Small molecular drug
DMWF8U5	PC	72941845
DMWF8U5	MW	534
DMWF8U5	FM	C24H32ClN7O5
DMWF8U5	IC	InChI=1S/C24H31N7O5.ClH/c1-24(2,26)22(33)27-18(15-35-13-16-8-5-4-6-9-16)21-29-28-20-11-7-10-17(31(20)21)14-36-23(34)30(3)12-19(25)32;/h4-11,18H,12-15,26H2,1-3H3,(H2,25,32)(H,27,33);1H/t18-;/m1./s1
DMWF8U5	CS	CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C2=NN=C3N2C(=CC=C3)COC(=O)N(C)CC(=O)N)N.Cl
DMWF8U5	IK	DFDPBEQMMOYQHK-GMUIIQOCSA-N
DMWF8U5	IU	[3-[(1S)-1-[(2-amino-2-methylpropanoyl)amino]-2-phenylmethoxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-5-yl]methyl N-(2-amino-2-oxoethyl)-N-methylcarbamate;hydrochloride
DMWF8U5	CA	CAS 674343-47-6
DMWF8U5	DE	Cachexia

DMNI6YU	ID	DMNI6YU
DMNI6YU	DN	EX5
DMNI6YU	HS	Investigative
DMNI6YU	TC	Antisense
DMNI6YU	DT	Antisense drug
DMNI6YU	DE	Discovery agent

DMSG8RI	ID	DMSG8RI
DMSG8RI	DN	example 131 [WO2009133348]
DMSG8RI	HS	Investigative
DMSG8RI	SN	example 131 [WO2009133348]; SCHEMBL1431769; GTPL8489
DMSG8RI	DT	Small molecular drug
DMSG8RI	PC	44468926
DMSG8RI	MW	431.5
DMSG8RI	FM	C22H27F2N5O2
DMSG8RI	IC	InChI=1S/C22H27F2N5O2/c1-2-29-9-3-4-19(29)22(31)28-18(11-14-5-7-16(23)17(24)10-14)21(30)27-13-15-6-8-20(25)26-12-15/h5-8,10,12,18-19H,2-4,9,11,13H2,1H3,(H2,25,26)(H,27,30)(H,28,31)/t18-,19+/m0/s1
DMSG8RI	CS	CCN1CCC[C@@H]1C(=O)N[C@@H](CC2=CC(=C(C=C2)F)F)C(=O)NCC3=CN=C(C=C3)N
DMSG8RI	IK	ALLYUHIQZKTLFG-RBUKOAKNSA-N
DMSG8RI	IU	(2R)-N-[(2S)-1-[(6-aminopyridin-3-yl)methylamino]-3-(3,4-difluorophenyl)-1-oxopropan-2-yl]-1-ethylpyrrolidine-2-carboxamide
DMSG8RI	DE	Discovery agent

DMY3CKG	ID	DMY3CKG
DMY3CKG	DN	example 166  (WO2014154727)
DMY3CKG	HS	Investigative
DMY3CKG	SN	GTPL7892; SCHEMBL18725165; example 166  [WO2014154727]; 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid
DMY3CKG	DT	Small molecular drug
DMY3CKG	PC	78426198
DMY3CKG	MW	414.9
DMY3CKG	FM	C21H19ClN2O3S
DMY3CKG	IC	InChI=1S/C21H19ClN2O3S/c1-12-11-24-21(28-12)18(10-20(26)27)16-7-15(8-17(22)9-16)14-4-2-3-13(5-14)6-19(23)25/h2-5,7-9,11,18H,6,10H2,1H3,(H2,23,25)(H,26,27)
DMY3CKG	CS	CC1=CN=C(S1)C(CC(=O)O)C2=CC(=CC(=C2)C3=CC=CC(=C3)CC(=O)N)Cl
DMY3CKG	IK	SRVXSISGYBMIHR-UHFFFAOYSA-N
DMY3CKG	IU	3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid
DMY3CKG	DE	Discovery agent

DMU25HZ	ID	DMU25HZ
DMU25HZ	DN	example 2 (WO2013004676)
DMU25HZ	HS	Investigative
DMU25HZ	SN	entry 2 [PMID: 24900681]
DMU25HZ	DT	Small molecular drug
DMU25HZ	PC	71202307
DMU25HZ	MW	390.9
DMU25HZ	FM	C18H16ClFN4OS
DMU25HZ	IC	InChI=1S/C18H16ClFN4OS/c19-11-1-4-15(22-9-11)16(25)23-12-2-3-14(20)13(7-12)18-8-10(18)5-6-26-17(21)24-18/h1-4,7,9-10H,5-6,8H2,(H2,21,24)(H,23,25)/t10-,18+/m1/s1
DMU25HZ	CS	C1CSC(=N[C@@]2([C@H]1C2)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)Cl)F)N
DMU25HZ	IK	COCAUCFPFHUGAA-MGNBDDOMSA-N
DMU25HZ	IU	N-[3-[(1S,7S)-3-amino-4-thia-2-azabicyclo[5.1.0]oct-2-en-1-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide
DMU25HZ	DE	Discovery agent

DMF9W41	ID	DMF9W41
DMF9W41	DN	example 20 (WO2010128058)
DMF9W41	HS	Investigative
DMF9W41	SN	SCHEMBL297687; GTPL7853; example 20 [WO2010128058]
DMF9W41	DT	Small molecular drug
DMF9W41	PC	46944265
DMF9W41	MW	372.8
DMF9W41	FM	C17H17ClN6O2
DMF9W41	IC	InChI=1S/C17H17ClN6O2/c1-17(7-13(25)24(2)16(19)23-17)10-4-3-5-12(6-10)22-15(26)14-20-8-11(18)9-21-14/h3-6,8-9H,7H2,1-2H3,(H2,19,23)(H,22,26)/t17-/m0/s1
DMF9W41	CS	C[C@]1(CC(=O)N(C(=N1)N)C)C2=CC(=CC=C2)NC(=O)C3=NC=C(C=N3)Cl
DMF9W41	IK	VZUGBLTVBZJZOE-KRWDZBQOSA-N
DMF9W41	IU	N-[3-[(4S)-2-amino-1,4-dimethyl-6-oxo-5H-pyrimidin-4-yl]phenyl]-5-chloropyrimidine-2-carboxamide
DMF9W41	DE	Discovery agent

DMP8A5R	ID	DMP8A5R
DMP8A5R	DN	example 373 [WO2012093101]
DMP8A5R	HS	Investigative
DMP8A5R	SN	CHEMBL2180765; example 373 [WO2012093101]; GTPL8296; SCHEMBL19210538; BDBM50400274
DMP8A5R	DT	Small molecular drug
DMP8A5R	PC	57412074
DMP8A5R	MW	524.9
DMP8A5R	FM	C25H22ClFN6O4
DMP8A5R	IC	InChI=1S/C25H22ClFN6O4/c26-17-3-1-2-13(22(17)27)11-30-23(34)21-9-14-8-20(14)33(21)25(36)31-18-12-32(24(29)35)19-5-4-15(10-16(18)19)37-7-6-28/h1-5,10,12,14,20-21H,7-9,11H2,(H2,29,35)(H,30,34)(H,31,36)/t14-,20-,21+/m1/s1
DMP8A5R	CS	C1[C@H]2[C@@H]1N([C@@H](C2)C(=O)NCC3=C(C(=CC=C3)Cl)F)C(=O)NC4=CN(C5=C4C=C(C=C5)OCC#N)C(=O)N
DMP8A5R	IK	SOCAXRLFGRNEPK-IFZYUDKTSA-N
DMP8A5R	IU	(1R,3S,5R)-2-N-[1-carbamoyl-5-(cyanomethoxy)indol-3-yl]-3-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxamide
DMP8A5R	DE	Discovery agent

DM2N9Y8	ID	DM2N9Y8
DM2N9Y8	DN	example 41 (WO2012028563)
DM2N9Y8	HS	Investigative
DM2N9Y8	SN	SCHEMBL719875; GTPL7855; example 41 [WO2012028563]
DM2N9Y8	DT	Small molecular drug
DM2N9Y8	PC	56846820
DM2N9Y8	MW	759.9
DM2N9Y8	FM	C36H40F3N5O6S2
DM2N9Y8	IC	InChI=1S/C36H40F3N5O6S2/c1-23-22-51-34(41-23)31-13-8-14-44(31)35(47)27-17-26(18-28(19-27)43(2)52(3,48)49)33(46)42-30(16-24-9-5-4-6-10-24)32(45)21-40-20-25-11-7-12-29(15-25)50-36(37,38)39/h4-7,9-12,15,17-19,22,30-32,40,45H,8,13-14,16,20-21H2,1-3H3,(H,42,46)/t30-,31+,32+/m0/s1
DM2N9Y8	CS	CC1=CSC(=N1)[C@H]2CCCN2C(=O)C3=CC(=CC(=C3)C(=O)N[C@@H](CC4=CC=CC=C4)[C@@H](CNCC5=CC(=CC=C5)OC(F)(F)F)O)N(C)S(=O)(=O)C
DM2N9Y8	IK	GUOONOJYWQOJJP-DCMFLLSESA-N
DM2N9Y8	IU	N-[(2S,3R)-3-hydroxy-1-phenyl-4-[[3-(trifluoromethoxy)phenyl]methylamino]butan-2-yl]-3-[methyl(methylsulfonyl)amino]-5-[(2R)-2-(4-methyl-1,3-thiazol-2-yl)pyrrolidine-1-carbonyl]benzamide
DM2N9Y8	DE	Discovery agent

DMFSHXW	ID	DMFSHXW
DMFSHXW	DN	example 8 [WO1999033801A1]
DMFSHXW	HS	Investigative
DMFSHXW	SN	example 8 [WO1999033801A1]; GTPL8581
DMFSHXW	DT	Small molecular drug
DMFSHXW	PC	57180216
DMFSHXW	MW	347.31
DMFSHXW	FM	C15H17F4N3O2
DMFSHXW	IC	InChI=1S/C15H17F4N3O2/c1-2-10(20)14(24)22-11-5-3-4-9(16)8(11)6-12(22)13(23)21-7-15(17,18)19/h3-5,10,12H,2,6-7,20H2,1H3,(H,21,23)/t10-,12+/m0/s1
DMFSHXW	CS	CC[C@@H](C(=O)N1[C@H](CC2=C1C=CC=C2F)C(=O)NCC(F)(F)F)N
DMFSHXW	IK	GNYDXSHWPPTVEX-CMPLNLGQSA-N
DMFSHXW	IU	(2R)-1-[(2S)-2-aminobutanoyl]-4-fluoro-N-(2,2,2-trifluoroethyl)-2,3-dihydroindole-2-carboxamide
DMFSHXW	DE	Discovery agent

DMU42CR	ID	DMU42CR
DMU42CR	DN	example 92 (WO2012095521)
DMU42CR	HS	Investigative
DMU42CR	SN	US8846658, 92; SCHEMBL363629; GTPL7856; CHEMBL3653509; BDBM18751; example 92 [WO2012095521]; US8846658, 93
DMU42CR	DT	Small molecular drug
DMU42CR	PC	50913216
DMU42CR	MW	394.8
DMU42CR	FM	C18H17ClF2N4O2
DMU42CR	IC	InChI=1S/C18H17ClF2N4O2/c1-10-4-11(19)6-23-16(10)17(26)24-12-2-3-14(21)13(5-12)18(8-20)9-27-7-15(22)25-18/h2-6H,7-9H2,1H3,(H2,22,25)(H,24,26)/t18-/m0/s1
DMU42CR	CS	CC1=CC(=CN=C1C(=O)NC2=CC(=C(C=C2)F)[C@@]3(COCC(=N3)N)CF)Cl
DMU42CR	IK	NQNLROFWOGGJGK-SFHVURJKSA-N
DMU42CR	IU	N-[3-[(3R)-5-amino-3-(fluoromethyl)-2,6-dihydro-1,4-oxazin-3-yl]-4-fluorophenyl]-5-chloro-3-methylpyridine-2-carboxamide
DMU42CR	DE	Discovery agent

DMMZH3Q	ID	DMMZH3Q
DMMZH3Q	DN	Exiguamine A
DMMZH3Q	HS	Investigative
DMMZH3Q	SN	CHEMBL468547; BDBM21975
DMMZH3Q	DT	Small molecular drug
DMMZH3Q	PC	16066751
DMMZH3Q	MW	492.5
DMMZH3Q	FM	C25H26N5O6+
DMMZH3Q	IC	InChI=1S/C25H25N5O6/c1-28-23(34)25(29(2)24(28)35)18-17(21(33)19-15(20(18)32)11(5-7-26)10-27-19)16-12-6-8-30(3,4)13(12)9-14(31)22(16)36-25/h9-10H,5-8,26H2,1-4H3,(H-,27,31,32,33)/p+1/t25-/m1/s1
DMMZH3Q	CS	CN1C(=O)[C@]2(C3=C(C4=C5CC[N+](C5=CC(=C4O2)O)(C)C)C(=O)C6=C(C3=O)C(=CN6)CCN)N(C1=O)C
DMMZH3Q	IK	UEKKREMMIOJMRO-RUZDIDTESA-O
DMMZH3Q	IU	(12R)-16-(2-aminoethyl)-9-hydroxy-1',3',6,6-tetramethylspiro[11-oxa-18-aza-6-azoniapentacyclo[11.7.0.02,10.03,7.015,19]icosa-1(13),2,7,9,15(19),16-hexaene-12,5'-imidazolidine]-2',4',14,20-tetrone
DMMZH3Q	CB	CHEBI:50655
DMMZH3Q	DE	Discovery agent

DME1TGM	ID	DME1TGM
DME1TGM	DN	EXIGUAMINE B
DME1TGM	HS	Investigative
DME1TGM	SN	CHEMBL1221412
DME1TGM	DT	Small molecular drug
DME1TGM	PC	24856337
DME1TGM	MW	508.5
DME1TGM	FM	C25H26N5O7+
DME1TGM	IC	InChI=1S/C25H25N5O7/c1-28-23(35)25(29(2)24(28)36)18-17(21(34)19-14(20(18)33)10(5-6-26)8-27-19)16-15-11(7-12(31)22(16)37-25)30(3,4)9-13(15)32/h7-8,13,32H,5-6,9,26H2,1-4H3,(H-,27,31,33,34)/p+1/t13-,25-/m1/s1
DME1TGM	CS	CN1C(=O)[C@]2(C3=C(C4=C5[C@@H](C[N+](C5=CC(=C4O2)O)(C)C)O)C(=O)C6=C(C3=O)C(=CN6)CCN)N(C1=O)C
DME1TGM	IK	YOXFPJITBOPKPN-YMXBGEKHSA-O
DME1TGM	IU	(4S,12R)-16-(2-aminoethyl)-4,9-dihydroxy-1',3',6,6-tetramethylspiro[11-oxa-18-aza-6-azoniapentacyclo[11.7.0.02,10.03,7.015,19]icosa-1(13),2,7,9,15(19),16-hexaene-12,5'-imidazolidine]-2',4',14,20-tetrone
DME1TGM	CB	CHEBI:50657
DME1TGM	DE	Discovery agent

DMWIBFM	ID	DMWIBFM
DMWIBFM	DN	EXP3174
DMWIBFM	HS	Investigative
DMWIBFM	SN	Losartan carboxylic acid; 124750-92-1; EXP-3174; Exp3174; EXP 3174; E-3174; UNII-GD76OCH73X; CHEBI:74125; CHEMBL907; GD76OCH73X; L-158641; 2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; 2-Butyl-4-chloro-1-[(2'-(1-H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-H-imidazole-5-carboxylic acid; 1H-Imidazole-5-carboxylicacid, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-;  EXP-3174; Carboxylic Acid Metabolite (E-3174)
DMWIBFM	DT	Small molecular drug
DMWIBFM	PC	108185
DMWIBFM	MW	436.9
DMWIBFM	FM	C22H21ClN6O2
DMWIBFM	IC	InChI=1S/C22H21ClN6O2/c1-2-3-8-18-24-20(23)19(22(30)31)29(18)13-14-9-11-15(12-10-14)16-6-4-5-7-17(16)21-25-27-28-26-21/h4-7,9-12H,2-3,8,13H2,1H3,(H,30,31)(H,25,26,27,28)
DMWIBFM	CS	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)Cl
DMWIBFM	IK	ZEUXAIYYDDCIRX-UHFFFAOYSA-N
DMWIBFM	IU	2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
DMWIBFM	CA	CAS 124750-92-1
DMWIBFM	CB	CHEBI:74125
DMWIBFM	DE	Discovery agent

DMY96KO	ID	DMY96KO
DMY96KO	DN	EXRD-4605
DMY96KO	HS	Investigative
DMY96KO	SN	DIRA-7471; Epoxide hydrolase inhibitors (hypertension); Epoxide hydrolase inhibitors (hypertension), Boehringer Ingelheim
DMY96KO	CP	Boehringer Ingelheim Corp
DMY96KO	DE	Hypertension

DM5V3S7	ID	DM5V3S7
DM5V3S7	DN	Ezetimibe-glucuronide
DM5V3S7	HS	Investigative
DM5V3S7	SN	ezetimibe-glucuronide; 190448-57-8; Ezetimibe b-D-glucuronide; CHEMBL321017; Ezetimibe beta-D-Glucuronide; Ezetimibe Phenoxy Glucuronide; EZM-G; Sch-58235 Glucuronide; Sch 58235 Glucuronide; A-D-Glucuronide; Ezetimibe Phenexy Glucuronide; Sch 60663; SCHEMBL10027374; CTK8F0579; DTXSID10432454; ZINC3975560; Ezetimibe Phenoxy; BDBM50240720; AKOS030241675; B-D-GLUCOPYRANOSIDURONIC ACID,4-[(2S,3R)-1-(4-FLUOROPHENYL)-3-[(3S)-3-(4-FLUOROPHENYL)-3-HYDROXYPROPYL]-4-OXO-2-AZETIDINYL]PHENYL; RT-012671
DM5V3S7	DT	Small molecular drug
DM5V3S7	PC	9894653
DM5V3S7	MW	585.5
DM5V3S7	FM	C30H29F2NO9
DM5V3S7	IC	InChI=1S/C30H29F2NO9/c31-17-5-1-15(2-6-17)22(34)14-13-21-23(33(28(21)38)19-9-7-18(32)8-10-19)16-3-11-20(12-4-16)41-30-26(37)24(35)25(36)27(42-30)29(39)40/h1-12,21-27,30,34-37H,13-14H2,(H,39,40)/t21-,22+,23-,24+,25+,26-,27+,30-/m1/s1
DM5V3S7	CS	C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O
DM5V3S7	IK	UOFYCFMTERCNEW-ADEYADIWSA-N
DM5V3S7	IU	(2S,3S,4S,5R,6S)-6-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DM5V3S7	CA	CAS 190448-57-8
DM5V3S7	DE	Discovery agent

DMXV5PM	ID	DMXV5PM
DMXV5PM	DN	EZN-3920
DMXV5PM	HS	Investigative
DMXV5PM	SN	SPC-3920; ERBB3 RNA inhibitor (cancer), Enzon/Santaris
DMXV5PM	CP	Santaris Pharma A/S
DMXV5PM	DE	Solid tumour/cancer

DMTW571	ID	DMTW571
DMTW571	DN	F(4-Fluoro)VAE
DMTW571	HS	Investigative
DMTW571	SN	CHEMBL258583; F(4-Fluoro)VAE; F(4-fluro)VAE
DMTW571	DT	Small molecular drug
DMTW571	PC	44452269
DMTW571	MW	482.5
DMTW571	FM	C22H31FN4O7
DMTW571	IC	InChI=1S/C22H31FN4O7/c1-11(2)18(27-20(31)15(24)10-13-4-6-14(23)7-5-13)21(32)25-12(3)19(30)26-16(22(33)34)8-9-17(28)29/h4-7,11-12,15-16,18H,8-10,24H2,1-3H3,(H,25,32)(H,26,30)(H,27,31)(H,28,29)(H,33,34)/t12-,15-,16-,18-/m0/s1
DMTW571	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)F)N
DMTW571	IK	HREKBPJJOGCVRC-RPZXMPESSA-N
DMTW571	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]pentanedioic acid
DMTW571	DE	Discovery agent

DMXHKE3	ID	DMXHKE3
DMXHKE3	DN	F-12458
DMXHKE3	HS	Investigative
DMXHKE3	SN	CAAX tetrapeptide analogs, Pierre Fabre; Farnesyl transferase inhibitors, Pierre Fabre; Ras inhibitor, Pierre Fabre
DMXHKE3	CP	Pierre Fabre SA
DMXHKE3	DE	Solid tumour/cancer

DMHETZN	ID	DMHETZN
DMHETZN	DN	F-18 exendin-4 derivative PET tracers
DMHETZN	HS	Investigative
DMHETZN	SN	[18F]FB12-Ex4; [18F]FB40-Ex4; F-18 exendin-4 derivative PET tracers (diabetes); F-18 exendin-4 derivative PET tracers (diabetes), Kyoto University/Arkray
DMHETZN	CP	Kyoto University
DMHETZN	DE	Diabetic complication

DM69MKU	ID	DM69MKU
DM69MKU	DN	F3
DM69MKU	HS	Investigative
DM69MKU	SN	1-Chloro-1,2,2-trifluorocyclobutane; 661-71-2; Cyclobutane, 1-chloro-1,2,2-trifluoro-; 1-Ctfcb; AC1Q4KXO; AC1L2WN1; GTPL2400; SCHEMBL3123282; CTK5C3598; MolPort-001-773-111; ZX-AP007208; 7606AE; PC2028; 7607AE; FCH917920; SBB086362; MFCD00042139; AKOS006230600; Cyclobutane,1-chloro-1,2,2-trifluoro-; TR-022419; FT-0607576; C-47497; I14-28177
DM69MKU	DT	Small molecular drug
DM69MKU	PC	79091
DM69MKU	MW	144.52
DM69MKU	FM	C4H4ClF3
DM69MKU	IC	InChI=1S/C4H4ClF3/c5-3(6)1-2-4(3,7)8/h1-2H2
DM69MKU	CS	C1CC(C1(F)F)(F)Cl
DM69MKU	IK	ZZQYDYODFHABLC-UHFFFAOYSA-N
DM69MKU	IU	1-chloro-1,2,2-trifluorocyclobutane
DM69MKU	CA	CAS 661-71-2
DM69MKU	DE	Discovery agent

DMD7HO8	ID	DMD7HO8
DMD7HO8	DN	F61F12
DMD7HO8	HS	Investigative
DMD7HO8	SN	Anti-Fas mAb (cancer), IMED
DMD7HO8	CP	IMED AB
DMD7HO8	DT	Antibody
DMD7HO8	DE	Solid tumour/cancer

DMYWERO	ID	DMYWERO
DMYWERO	DN	F-9TG
DMYWERO	HS	Investigative
DMYWERO	SN	Recombinant human coagulation factor IX (type B hemophilia), ProGenetics; Recombinant human coagulation factor IX (type B hemophilia), GTC/LFB
DMYWERO	CP	Progenetics LLC
DMYWERO	DE	Factor IX deficiency

DMDBO89	ID	DMDBO89
DMDBO89	DN	FA-70
DMDBO89	HS	Investigative
DMDBO89	CP	Universitat Autonoma de Barcelona
DMDBO89	PC	9816234
DMDBO89	MW	242.32
DMDBO89	FM	C15H18N2O
DMDBO89	IC	InChI=1S/C15H18N2O/c1-4-5-8-16(2)11-13-9-12-10-14(18)6-7-15(12)17(13)3/h6-7,9-10,18H,8,11H2,1-3H3
DMDBO89	CS	CC#CCN(C)CC1=CC2=C(N1C)C=CC(=C2)O
DMDBO89	IK	VJSXYTMXFSBYDX-UHFFFAOYSA-N
DMDBO89	IU	2-[[but-2-ynyl(methyl)amino]methyl]-1-methylindol-5-ol
DMDBO89	CA	CAS 133846-05-6
DMDBO89	DE	Major depressive disorder

DMSQ3I9	ID	DMSQ3I9
DMSQ3I9	DN	Factor IX-XTEN
DMSQ3I9	HS	Investigative
DMSQ3I9	SN	FIX-XTEN; Coagulation factor IX modulator (XTEN, hemophilia), Amunix/Biogen
DMSQ3I9	CP	Amunix Inc
DMSQ3I9	DE	Hemophilia

DM1AYVU	ID	DM1AYVU
DM1AYVU	DN	Factor VIII-XTEN
DM1AYVU	HS	Investigative
DM1AYVU	SN	FVIII-XTEN; Factor VIII modulator (XTEN, hemophilia), Amunix/Biogen
DM1AYVU	CP	Amunix Inc
DM1AYVU	DE	Hemophilia

DMDWSH1	ID	DMDWSH1
DMDWSH1	DN	Factor-VIIa-XTEN
DMDWSH1	HS	Investigative
DMDWSH1	SN	FVIIa-XTEN; Factor VIIa modulator (XTEN, hemophilia), Amunix/Biogen
DMDWSH1	CP	Amunix Inc
DMDWSH1	DE	Hemophilia

DMJFKSU	ID	DMJFKSU
DMJFKSU	DN	FAICAR
DMJFKSU	HS	Investigative
DMJFKSU	SN	Faicar; phosphoribosyl formamidocarboxamide; 5-Formamidoimidazole-4-carboxamide ribotide; 13018-54-7; CHEBI:18381; 5-Formamido-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide; 5'-Phosphoribosyl-5-formamido-4-imidazolecarboxamide; 5-Formamido-1-(5-phosphoribosyl)imidazole-4-carboxamide; 1-(5'-Phosphoribosyl)-5-formamido-4-imidazolecarboxamide; 5-(Formylamino)-1-(5-O-Phosphono-Beta-D-Ribofuranosyl)-1h-Imidazole-4-Carboxamide
DMJFKSU	DT	Small molecular drug
DMJFKSU	PC	166760
DMJFKSU	MW	366.22
DMJFKSU	FM	C10H15N4O9P
DMJFKSU	IC	InChI=1S/C10H15N4O9P/c11-8(18)5-9(13-3-15)14(2-12-5)10-7(17)6(16)4(23-10)1-22-24(19,20)21/h2-4,6-7,10,16-17H,1H2,(H2,11,18)(H,13,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1
DMJFKSU	CS	C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)NC=O)C(=O)N
DMJFKSU	IK	ABCOOORLYAOBOZ-KQYNXXCUSA-N
DMJFKSU	IU	[(2R,3S,4R,5R)-5-(4-carbamoyl-5-formamidoimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMJFKSU	CA	CAS 13018-54-7
DMJFKSU	CB	CHEBI:18381
DMJFKSU	DE	Discovery agent

DMLOV18	ID	DMLOV18
DMLOV18	DN	FALCARINDIOL
DMLOV18	HS	Investigative
DMLOV18	SN	Falcarindiol; 55297-87-5; 1,9-Heptadecadiene-4,6-diyne-3,8-diol; Heptadeca-1,9-diene-4,6-diyne-3,8-diol; AC1L1FO2; SCHEMBL16680213; CTK1C6414; 225110-25-8; AKOS030230026; AN-40378; 4CN-1774
DMLOV18	DT	Small molecular drug
DMLOV18	PC	5281148
DMLOV18	MW	260.399
DMLOV18	FM	C17H24O2
DMLOV18	IC	InChI=1S/C17H24O2/c1-3-5-6-7-8-9-10-14-17(19)15-12-11-13-16(18)4-2/h4,10,14,16-19H,2-3,5-9H2,1H3/b14-10-/t16-,17+/m1/s1
DMLOV18	CS	CCCCCCC/C=C\\[C@@H](C#CC#C[C@@H](C=C)O)O
DMLOV18	IK	QWCNQXNAFCBLLV-YWALDVPYSA-N
DMLOV18	IU	(3R,8S,9Z)-heptadeca-1,9-dien-4,6-diyne-3,8-diol
DMLOV18	DE	Discovery agent

DMJYNMC	ID	DMJYNMC
DMJYNMC	DN	FAMOXADONE
DMJYNMC	HS	Investigative
DMJYNMC	SN	(S)-famoxadone; (-)-famoxadone; (S)-(-)-famoxadone; CHEBI:106738; (5S)-5-methyl-5-(4-phenoxyphenyl)-3-(phenylamino)-1,3-oxazolidine-2,4-dione; (5S)-3-anilino-5-methyl-5-(4-phenoxyphenyl)-1,3-oxazolidine-2,4-dione; (S)-5-Methyl-5-(4-phenoxy-phenyl)-3-phenylamino-oxazolidine-2,4-dione; 5-METHYL-5-(4-PHENOXYPHENYL)-3-(PHENYLAMINO)-2,4-OXAZOLIDINEDIONE; FMX; AC1L9K5S; CHEMBL10118; SCHEMBL673443; PCCSBWNGDMYFCW-QFIPXVFZSA-N; ZINC6491064; DB07778; AJ-56253; UNII-V1C07OR6II component PCCSBWNGDMYFCW-QFIPXVFZSA-N
DMJYNMC	DT	Small molecular drug
DMJYNMC	PC	213032
DMJYNMC	MW	374.4
DMJYNMC	FM	C22H18N2O4
DMJYNMC	IC	InChI=1S/C22H18N2O4/c1-22(16-12-14-19(15-13-16)27-18-10-6-3-7-11-18)20(25)24(21(26)28-22)23-17-8-4-2-5-9-17/h2-15,23H,1H3
DMJYNMC	CS	CC1(C(=O)N(C(=O)O1)NC2=CC=CC=C2)C3=CC=C(C=C3)OC4=CC=CC=C4
DMJYNMC	IK	PCCSBWNGDMYFCW-UHFFFAOYSA-N
DMJYNMC	IU	3-anilino-5-methyl-5-(4-phenoxyphenyl)-1,3-oxazolidine-2,4-dione
DMJYNMC	CA	CAS 131807-57-3
DMJYNMC	CB	CHEBI:83250
DMJYNMC	DE	Discovery agent

DM45K8W	ID	DM45K8W
DM45K8W	DN	FANA
DM45K8W	HS	Investigative
DM45K8W	DT	Small molecular drug
DM45K8W	PC	56603768
DM45K8W	MW	345.23
DM45K8W	FM	C11H14F3NO8
DM45K8W	IC	InChI=1S/C11H14F3NO8/c12-11(13,14)10(22)15-6-3(17)1-5(9(20)21)23-8(6)7(19)4(18)2-16/h1,3-4,6-8,16-19H,2H2,(H,15,22)(H,20,21)/t3-,4-,6+,7+,8?/m0/s1
DM45K8W	CS	C1=C(OC([C@@H]([C@H]1O)NC(=O)C(F)(F)F)[C@@H]([C@H](CO)O)O)C(=O)O
DM45K8W	IK	GEGPMWUYMRCINJ-DELVFIHMSA-N
DM45K8W	IU	(3R,4S)-4-hydroxy-3-[(2,2,2-trifluoroacetyl)amino]-2-[(1R,2S)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DM45K8W	DE	Discovery agent

DMV2X1B	ID	DMV2X1B
DMV2X1B	DN	Farnesol
DMV2X1B	HS	Investigative
DMV2X1B	SN	farnesol; 4602-84-0; Farnesyl alcohol; 3,7,11-trimethyldodeca-2,6,10-trien-1-ol; Spectrum_001282; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, (2Z,6Z)-; ACMC-20aplp; ACMC-209ukw; SpecPlus_000549; AC1L1FOK; Spectrum3_001070; Spectrum2_001397; Spectrum4_001221; KBioSS_001762; KBioGR_001682; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, (2E,6Z)-; DivK1c_006645; SPBio_001414; GTPL3215; DTXSID3032389; KBio2_006898; KBio1_001589; KBio3_001880; KBio2_004330; CTK1B4647; CTK1D5922; KBio2_001762; CTK0H6624; CTK0E6577; MolPort-006-116-336
DMV2X1B	DT	Small molecular drug
DMV2X1B	PC	445070
DMV2X1B	MW	222.37
DMV2X1B	FM	C15H26O
DMV2X1B	IC	InChI=1S/C15H26O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16H,5-6,8,10,12H2,1-4H3/b14-9+,15-11+
DMV2X1B	CS	CC(=CCC/C(=C/CC/C(=C/CO)/C)/C)C
DMV2X1B	IK	CRDAMVZIKSXKFV-YFVJMOTDSA-N
DMV2X1B	IU	(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol
DMV2X1B	CA	CAS 4602-84-0
DMV2X1B	CB	CHEBI:16619
DMV2X1B	DE	Discovery agent

DMXYWD7	ID	DMXYWD7
DMXYWD7	DN	FARNESYL
DMXYWD7	HS	Investigative
DMXYWD7	SN	FARNESYL; (6E,10E)-2,6,10-trimethyldodeca-2,6,10-triene; 2,6E,10E-Trimethyl-2,6,10-dodecatriene; CHEBI:36534; 2,6,10-trimethyldodeca-2,6,10-triene; 2,6,10-Farnesatriene; AC1L9FQ4; CHEBI:42362; LMFA11000034; (2E)-3,7,11-Trimethyl-2,6,10-dodecatriene; (6E)-3,7,11-Trimethyl-2,6,10-dodecatriene; (2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatriene; (6E,10E)-2,6,10-trimethyl-dodeca-2,6,10-triene
DMXYWD7	DT	Small molecular drug
DMXYWD7	PC	444108
DMXYWD7	MW	206.37
DMXYWD7	FM	C15H26
DMXYWD7	IC	InChI=1S/C15H26/c1-6-14(4)10-8-12-15(5)11-7-9-13(2)3/h6,9,12H,7-8,10-11H2,1-5H3/b14-6+,15-12+
DMXYWD7	CS	C/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DMXYWD7	IK	JXBSHSBNOVLGHF-BUJBXKITSA-N
DMXYWD7	IU	(6E,10E)-2,6,10-trimethyldodeca-2,6,10-triene
DMXYWD7	CB	CHEBI:36534
DMXYWD7	DE	Discovery agent

DMRMI0V	ID	DMRMI0V
DMRMI0V	DN	FAS-031
DMRMI0V	HS	Investigative
DMRMI0V	SN	FASi; FAS inhibitors (cancer); FAS-093; FAS-31; FAS-93; FAS inhibitors (cancer), FASgen/Johns Hopkins; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins; FAS inhibitors (cancer), FASgen/Johns Hopkins/Johnson & Johnson; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins/ Johnson & Johnson
DMRMI0V	CP	Johns Hopkins University
DMRMI0V	DE	Solid tumour/cancer

DMG5OZP	ID	DMG5OZP
DMG5OZP	DN	Fascaplysin
DMG5OZP	HS	Investigative
DMG5OZP	SN	Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6
DMG5OZP	DT	Small molecular drug
DMG5OZP	PC	73292
DMG5OZP	MW	306.7
DMG5OZP	FM	C18H11ClN2O
DMG5OZP	IC	InChI=1S/C18H10N2O.ClH/c21-18-13-6-2-4-8-15(13)20-10-9-12-11-5-1-3-7-14(11)19-16(12)17(18)20;/h1-10H;1H
DMG5OZP	CS	C1=CC=C2C(=C1)C3=C(N2)C4=[N+](C=C3)C5=CC=CC=C5C4=O.[Cl-]
DMG5OZP	IK	PWUOOJVYZQILBG-UHFFFAOYSA-N
DMG5OZP	IU	3-aza-13-azoniapentacyclo[11.7.0.02,10.04,9.014,19]icosa-1(13),2(10),4,6,8,11,14,16,18-nonaen-20-one;chloride
DMG5OZP	CA	CAS 114719-57-2
DMG5OZP	DE	Discovery agent

DMC8G7X	ID	DMC8G7X
DMC8G7X	DN	fasidotrilat
DMC8G7X	HS	Investigative
DMC8G7X	SN	AC1O52DL; DTXSID20159221; (2R)-2-[[(2R)-2-(1,3-benzodioxol-5-ylmethyl)-3-sulfanylpropanoyl]amino]propanoic acid
DMC8G7X	DT	Small molecular drug
DMC8G7X	PC	9818189
DMC8G7X	MW	311.36
DMC8G7X	FM	C14H17NO5S
DMC8G7X	IC	InChI=1S/C14H17NO5S/c1-8(14(17)18)15-13(16)10(6-21)4-9-2-3-11-12(5-9)20-7-19-11/h2-3,5,8,10,21H,4,6-7H2,1H3,(H,15,16)(H,17,18)/t8-,10+/m0/s1
DMC8G7X	CS	C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC2=C(C=C1)OCO2)CS
DMC8G7X	IK	TXSINLUUGRGAJO-WCBMZHEXSA-N
DMC8G7X	IU	(2S)-2-[[(2S)-2-(1,3-benzodioxol-5-ylmethyl)-3-sulfanylpropanoyl]amino]propanoic acid
DMC8G7X	CA	CAS 135038-59-4
DMC8G7X	DE	Discovery agent

DMTCNOM	ID	DMTCNOM
DMTCNOM	DN	Fasudil
DMTCNOM	HS	Investigative
DMTCNOM	SN	103745-39-7; HA1077; ha-1077; HA 1077; Fasudil [INN]; AT 877; Fasudilum [INN-Latin]; 1-(5-Isoquinolinesulfonyl)homopiperazine; 1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)-; UNII-Q0CH43PGXS; 5-(1,4-diazepane-1-sulfonyl)isoquinoline; 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline; (5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE; AT-877; AT877; Q0CH43PGXS; 5-(1,4-DIAZEPAN-1-SULFONYL)ISOQUINOLINE; CHEMBL38380; Hexahydro-1-(5-isoquinolinylsulfonyl)-1H-1,4-diazepine; Fasudil (INN); Fasudilhydrochloride
DMTCNOM	DT	Small molecular drug
DMTCNOM	PC	3547
DMTCNOM	MW	291.37
DMTCNOM	FM	C14H17N3O2S
DMTCNOM	IC	InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2
DMTCNOM	CS	C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3
DMTCNOM	IK	NGOGFTYYXHNFQH-UHFFFAOYSA-N
DMTCNOM	IU	5-(1,4-diazepan-1-ylsulfonyl)isoquinoline
DMTCNOM	CA	CAS 103745-39-7
DMTCNOM	DE	Discovery agent

DMC6J3B	ID	DMC6J3B
DMC6J3B	DN	FAUC 113
DMC6J3B	HS	Investigative
DMC6J3B	SN	fauc-113; CHEMBL7927; FAUC 113; 221470-50-4; SCHEMBL1058707; CTK0I8746; DTXSID50439407; ZINC13438692; BDBM50073805; KB-272556; 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)H-pyrazolo[1,5-a]pyridine; 3-[4-(4-Chloro-phenyl)-piperazin-1-ylmethyl]-pyrazolo[1,5-a]pyridine; 4-(4-Chloro-phenyl)-1-pyrazolo[1,5-a]pyridin-3-ylmethyl-piperazin-1-ium; Pyrazolo[1,5-a]pyridine, 3-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-
DMC6J3B	DT	Small molecular drug
DMC6J3B	PC	10404144
DMC6J3B	MW	326.8
DMC6J3B	FM	C18H19ClN4
DMC6J3B	IC	InChI=1S/C18H19ClN4/c19-16-4-6-17(7-5-16)22-11-9-21(10-12-22)14-15-13-20-23-8-2-1-3-18(15)23/h1-8,13H,9-12,14H2
DMC6J3B	CS	C1CN(CCN1CC2=C3C=CC=CN3N=C2)C4=CC=C(C=C4)Cl
DMC6J3B	IK	XVPRVMIFXXOEFR-UHFFFAOYSA-N
DMC6J3B	IU	3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]pyrazolo[1,5-a]pyridine
DMC6J3B	CA	CAS 221470-50-4
DMC6J3B	DE	Discovery agent

DM1LMFG	ID	DM1LMFG
DM1LMFG	DN	FAUC213
DM1LMFG	HS	Investigative
DM1LMFG	SN	FAUC 213; 337972-47-1; FAUC-213; UNII-G8F040299R; CHEMBL310843; G8F040299R; 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine; GTPL974; CTK8E8281; DTXSID40187460; HMS3263F09; Tox21_501144; BDBM50102712; ZINC52541476; MFCD06798338; Pyrazolo(1,5-a)pyridine, 2-((4-(4-chlorophenyl)-1-piperazinyl)methyl)-; CCG-222448; LP01144; API0002679; NCGC00261829-01; NCGC00165795-01; NCGC00165795-02; RT-012699; FAUC 213, &gt; J-019326; 2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-pyrazolo[1,5-a]pyridine
DM1LMFG	DT	Small molecular drug
DM1LMFG	PC	10336538
DM1LMFG	MW	326.8
DM1LMFG	FM	C18H19ClN4
DM1LMFG	IC	InChI=1S/C18H19ClN4/c19-15-4-6-17(7-5-15)22-11-9-21(10-12-22)14-16-13-18-3-1-2-8-23(18)20-16/h1-8,13H,9-12,14H2
DM1LMFG	CS	C1CN(CCN1CC2=NN3C=CC=CC3=C2)C4=CC=C(C=C4)Cl
DM1LMFG	IK	DTRXURJDKOYCCD-UHFFFAOYSA-N
DM1LMFG	IU	2-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]pyrazolo[1,5-a]pyridine
DM1LMFG	CA	CAS 337972-47-1
DM1LMFG	DE	Discovery agent

DM7IEL2	ID	DM7IEL2
DM7IEL2	DN	FD-1
DM7IEL2	HS	Investigative
DM7IEL2	SN	GTPL1182
DM7IEL2	DT	Small molecular drug
DM7IEL2	PC	10279142
DM7IEL2	MW	509.6
DM7IEL2	FM	C28H35N3O6
DM7IEL2	IC	InChI=1S/C28H35N3O6/c1-15-12-18-17(27(3,4)14-16(2)28(18,5)6)13-20(15)37-21-11-10-19(36-21)23(32)29-22-24(33-7)30-26(35-9)31-25(22)34-8/h10-13,16H,14H2,1-9H3,(H,29,32)
DM7IEL2	CS	CC1CC(C2=C(C1(C)C)C=C(C(=C2)OC3=CC=C(O3)C(=O)NC4=C(N=C(N=C4OC)OC)OC)C)(C)C
DM7IEL2	IK	JTFNDUMPCFHPFC-UHFFFAOYSA-N
DM7IEL2	IU	5-[(3,5,5,6,8,8-hexamethyl-6,7-dihydronaphthalen-2-yl)oxy]-N-(2,4,6-trimethoxypyrimidin-5-yl)furan-2-carboxamide
DM7IEL2	DE	Discovery agent

DMYXA7E	ID	DMYXA7E
DMYXA7E	DN	FdG
DMYXA7E	HS	Investigative
DMYXA7E	DE	Discovery agent

DMKVA6Z	ID	DMKVA6Z
DMKVA6Z	DN	FE 999011
DMKVA6Z	HS	Investigative
DMKVA6Z	SN	Tle-Pro-CN; UNII-I17T1J33X6; CHEMBL363250; I17T1J33X6; FE-999011; 171092-64-1; SCHEMBL369343; fe999011; BDBM50151003; ZINC53122800; 2-Pyrrolidinecarbonitrile, 1-(2-amino-3,3-dimethyl-1-oxobutyl)-, (S-(R*,R*))-; 2-Pyrrolidinecarbonitrile, 1-((2S)-2-amino-3,3-dimethyl-1-oxobutyl)-, (2S)-
DMKVA6Z	DT	Small molecular drug
DMKVA6Z	PC	10130510
DMKVA6Z	MW	209.29
DMKVA6Z	FM	C11H19N3O
DMKVA6Z	IC	InChI=1S/C11H19N3O/c1-11(2,3)9(13)10(15)14-6-4-5-8(14)7-12/h8-9H,4-6,13H2,1-3H3/t8-,9+/m0/s1
DMKVA6Z	CS	CC(C)(C)[C@@H](C(=O)N1CCC[C@H]1C#N)N
DMKVA6Z	IK	XGNBIYXILDDDQR-DTWKUNHWSA-N
DMKVA6Z	IU	(2S)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]pyrrolidine-2-carbonitrile
DMKVA6Z	CA	CAS 171092-64-1
DMKVA6Z	DE	Discovery agent

DMBX81R	ID	DMBX81R
DMBX81R	DN	FE-203799
DMBX81R	HS	Investigative
DMBX81R	SN	GLP-2 analog (gastrointestinal disease), Ferring; Glucagon-like peptide 2 analog (gastrointestinal disease), Ferring
DMBX81R	CP	Ferring Pharmaceuticals Inc
DMBX81R	DE	Gastrointestinal disease

DM3UCWM	ID	DM3UCWM
DM3UCWM	DN	FE-999040
DM3UCWM	HS	Investigative
DM3UCWM	SN	FAP inhibitors, Vantia; Fibroblast activation protein inhibitors (sc/oral, cancer/pulmonary fibrosis/IBD), Vantia
DM3UCWM	CP	Vantia Therapeutics
DM3UCWM	DE	Solid tumour/cancer

DMN1579	ID	DMN1579
DMN1579	DN	Fedratinib
DMN1579	HS	Investigative
DMN1579	SN	Tg-101348; TG101348; TG 101348; SAR302503; UNII-6L1XP550I6; SAR-302503; Fedratinib (SAR302503, TG101348); TG101348 (SAR302503); SAR 302503; CHEMBL1287853; C27H36N6O3S; 6L1XP550I6
DMN1579	TC	Antiviral Agents
DMN1579	DT	Small molecular drug
DMN1579	PC	16722836
DMN1579	MW	524.7
DMN1579	FM	C27H36N6O3S
DMN1579	IC	InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)
DMN1579	CS	CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4
DMN1579	IK	JOOXLOJCABQBSG-UHFFFAOYSA-N
DMN1579	IU	N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
DMN1579	CA	CAS 936091-26-8
DMN1579	CB	CHEBI:91408
DMN1579	DE	Coronavirus Disease 2019 (COVID-19)

DMUBO3E	ID	DMUBO3E
DMUBO3E	DN	fenclonine
DMUBO3E	HS	Investigative
DMUBO3E	SN	4-chlorophenylalanine; para-chlorophenylalanine; PCPA
DMUBO3E	DT	Small molecular drug
DMUBO3E	PC	4652
DMUBO3E	MW	199.63
DMUBO3E	FM	C9H10ClNO2
DMUBO3E	IC	InChI=1S/C9H10ClNO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)
DMUBO3E	CS	C1=CC(=CC=C1CC(C(=O)O)N)Cl
DMUBO3E	IK	NIGWMJHCCYYCSF-UHFFFAOYSA-N
DMUBO3E	IU	2-amino-3-(4-chlorophenyl)propanoic acid
DMUBO3E	CA	CAS 7424-00-2
DMUBO3E	CB	CHEBI:110187
DMUBO3E	DE	Discovery agent

DM34V5W	ID	DM34V5W
DM34V5W	DN	Fenethylline
DM34V5W	HS	Investigative
DM34V5W	SN	Amfetyline; Amphetaminoethyltheophylline; Captagon; Ethylteophylline amphetamine; FENETHYLLINE; Fenetilina; Fenetilina [INN-Spanish]; Fenetillina; Fenetillina [DCIT]; Fenetylinum; Fenetyllin; Fenetylline; Fenetylline (INN); Fenetylline [INN:BAN]; Fenetyllinum; Fenetyllinum [INN-Latin]; Humburg 814; Phenethylline; Theophyllineethylamphetamine; 7-(2-((alpha-Methylphenethyl)amino)ethyl)theophylline; BRN 1169517; C18H23N5O2; D323; DEA No. 1503; NCGC00247730-01; Theophylline, 7-(2-((alpha-methylphenethyl)amino)ethyl)-
DM34V5W	PC	19527
DM34V5W	MW	341.4
DM34V5W	FM	C18H23N5O2
DM34V5W	IC	NMCHYWGKBADVMK-UHFFFAOYSA-N
DM34V5W	CS	CC(CC1=CC=CC=C1)NCCN2C=NC3=C2C(=O)N(C(=O)N3C)C
DM34V5W	IK	1S/C18H23N5O2/c1-13(11-14-7-5-4-6-8-14)19-9-10-23-12-20-16-15(23)17(24)22(3)18(25)21(16)2/h4-8,12-13,19H,9-11H2,1-3H3
DM34V5W	IU	1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino)ethyl]purine-2,6-dione
DM34V5W	CA	CAS 3736-08-1
DM34V5W	CB	CHEBI:135451
DM34V5W	DE	Narcolepsy

DMKEG49	ID	DMKEG49
DMKEG49	DN	Fenthion
DMKEG49	HS	Investigative
DMKEG49	SN	Baytex; ENT 25,540; Fenthion 4E; Fenthion [BAN]; Fenthion [BSI:ISO]; Fenthion-methyl; Fenthione; Figuron; Lebaycid; Lebayeid; MPP (pesticide); Mercaptophos; Mosquitocide 700; Phenthion; Pro-Spot; Queletox; S 1752; Spotton; Sulfidophos; Talodex; Tiguvon; fenthion; 4-Methylmercapto-3-methylphenyl dimethyl thiophosphate; 55-38-9; B 29493; BAY 29493; Bay-Bassa; Baycid; Bayer 29493; Bayer 9007; Bayer S-1752; BL0L45OVKT; C10H15O3PS2; CCRIS 310; Caswell No. 456F; EINECS 200-231-9; Entex; HSDB 1403; NCI-C08651; OMS 2; UNII-BL0L45OVKT
DMKEG49	PC	3346
DMKEG49	MW	278.3
DMKEG49	FM	C10H15O3PS2
DMKEG49	IC	PNVJTZOFSHSLTO-UHFFFAOYSA-N
DMKEG49	CS	CC1=C(C=CC(=C1)OP(=S)(OC)OC)SC
DMKEG49	IK	1S/C10H15O3PS2/c1-8-7-9(5-6-10(8)16-4)13-14(15,11-2)12-3/h5-7H,1-4H3
DMKEG49	IU	dimethoxy-(3-methyl-4-methylsulfanylphenoxy)-sulfanylidene-lambda5-phosphane
DMKEG49	CA	CAS 55-38-9
DMKEG49	CB	CHEBI:34761
DMKEG49	DE	Discovery agent

DM4OLRS	ID	DM4OLRS
DM4OLRS	DN	Fenthion sulfoxide
DM4OLRS	HS	Investigative
DM4OLRS	SN	FENTHION SULFOXIDE; FENTHION-SULFOXIDE; Fensulfoxide; Fenthionsulfoxide; Mesulfenfos; Mesulfenfos [ISO]; Mesulfenfos, (+)-; Mesulfenfos, (R)-; Mesulfenfos, (S)-; Mesulfenos; TM8HKU4HKN; 3761-41-9; BRN 2136026; O,O-Dimethyl O-((4-methylthio)-m-tolyl)phosphorothioate sulfoxide; O,O-Dimethyl O-(4-(methylsulfinyl)-m-tolyl) phosphorothioate; Phosphorothioic acid, O,O-dimethyl O-(3-methyl-4-(methylsulfinyl)phenyl) ester; Phosphorothioic acid, O,O-dimethyl O-(4-(methylsulfinyl)-m-tolyl) ester; UNII-J04Q566L5K; UNII-TM8HKU4HKN
DM4OLRS	PC	19577
DM4OLRS	MW	294.3
DM4OLRS	FM	C10H15O4PS2
DM4OLRS	IC	DLAPIMGBBDILHJ-UHFFFAOYSA-N
DM4OLRS	CS	CC1=C(C=CC(=C1)OP(=S)(OC)OC)S(=O)C
DM4OLRS	IK	1S/C10H15O4PS2/c1-8-7-9(5-6-10(8)17(4)11)14-15(16,12-2)13-3/h5-7H,1-4H3
DM4OLRS	IU	dimethoxy-(3-methyl-4-methylsulfinylphenoxy)-sulfanylidene-lambda5-phosphane
DM4OLRS	CA	CAS 3761-41-9
DM4OLRS	DE	Discovery agent

DM1TH08	ID	DM1TH08
DM1TH08	DN	Ferricyanide
DM1TH08	HS	Investigative
DM1TH08	SN	Ferric hexacyanide; Ferricyanide; Hexacyanoferrate(III); Hexazyanoferrat(III); hexacyanidoferrate(3-); hexacyanidoferrate(III); hexacyanoferrate III; hexacyanoferrate(3-); hexacyanoiron(3-); 13408-62-3; CHEBI:5020; CRWNKXHVYMVLCY-UHFFFAOYSA-N; [Fe(CN)6](3-)
DM1TH08	PC	439210
DM1TH08	MW	211.95
DM1TH08	FM	C6FeN6-3
DM1TH08	IC	YAGKRVSRTSUGEY-UHFFFAOYSA-N
DM1TH08	CS	[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+3]
DM1TH08	IK	1S/6CN.Fe/c6*1-2;/q6*-1;+3
DM1TH08	IU	iron(3+);hexacyanide
DM1TH08	CA	CAS 13408-62-3
DM1TH08	CB	CHEBI:5020
DM1TH08	DE	Discovery agent

DMO1N2T	ID	DMO1N2T
DMO1N2T	DN	FETAV
DMO1N2T	HS	Investigative
DMO1N2T	SN	FETAV; CHEMBL492642
DMO1N2T	DT	Small molecular drug
DMO1N2T	PC	44568793
DMO1N2T	MW	565.6
DMO1N2T	FM	C26H39N5O9
DMO1N2T	IC	InChI=1S/C26H39N5O9/c1-13(2)20(26(39)40)30-22(35)14(3)28-25(38)21(15(4)32)31-24(37)18(10-11-19(33)34)29-23(36)17(27)12-16-8-6-5-7-9-16/h5-9,13-15,17-18,20-21,32H,10-12,27H2,1-4H3,(H,28,38)(H,29,36)(H,30,35)(H,31,37)(H,33,34)(H,39,40)/t14-,15?,17-,18-,20-,21-/m0/s1
DMO1N2T	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N
DMO1N2T	IK	ILLATSRMKXLBOS-HWJJFRRQSA-N
DMO1N2T	IU	(4S)-4-[[(2S)-2-amino-3-phenylpropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMO1N2T	DE	Discovery agent

DMWCLQ5	ID	DMWCLQ5
DMWCLQ5	DN	Fexaramine
DMWCLQ5	HS	Investigative
DMWCLQ5	SN	574013-66-4; CHEMBL192966; CHEBI:80003; FEX; (E)-methyl 3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate; C32H36N2O3; AC1NS0YI; A1-01872; GTPL2744; Fexaramine, &gt; SCHEMBL17083218; AOB5017; MolPort-023-276-486; EX-A2246; BCP15784; ZINC13831232; 3671AH; BDBM50167161; AKOS024457169; DB02545; CS-3884; NCGC00167776-01; HY-10912; AS-35318; AK175872; BC600742; KB-69557; RT-012704; B7108; C15649; BRD-K34170797-001-01-1
DMWCLQ5	DT	Small molecular drug
DMWCLQ5	PC	5326713
DMWCLQ5	MW	496.6
DMWCLQ5	FM	C32H36N2O3
DMWCLQ5	IC	InChI=1S/C32H36N2O3/c1-33(2)29-19-17-27(18-20-29)26-15-12-25(13-16-26)23-34(32(36)28-9-5-4-6-10-28)30-11-7-8-24(22-30)14-21-31(35)37-3/h7-8,11-22,28H,4-6,9-10,23H2,1-3H3/b21-14+
DMWCLQ5	CS	CN(C)C1=CC=C(C=C1)C2=CC=C(C=C2)CN(C3=CC=CC(=C3)/C=C/C(=O)OC)C(=O)C4CCCCC4
DMWCLQ5	IK	VLQTUNDJHLEFEQ-KGENOOAVSA-N
DMWCLQ5	IU	methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-[4-(dimethylamino)phenyl]phenyl]methyl]amino]phenyl]prop-2-enoate
DMWCLQ5	CA	CAS 574013-66-4
DMWCLQ5	CB	CHEBI:80003
DMWCLQ5	DE	Discovery agent

DM1NL3Z	ID	DM1NL3Z
DM1NL3Z	DN	FG-5893
DM1NL3Z	HS	Investigative
DM1NL3Z	SN	FG5893; FG 5893
DM1NL3Z	DT	Small molecular drug
DM1NL3Z	PC	127728
DM1NL3Z	MW	465.5
DM1NL3Z	FM	C27H29F2N3O2
DM1NL3Z	IC	InChI=1S/C27H29F2N3O2/c1-34-27(33)25-4-2-14-30-26(25)32-18-16-31(17-19-32)15-3-5-24(20-6-10-22(28)11-7-20)21-8-12-23(29)13-9-21/h2,4,6-14,24H,3,5,15-19H2,1H3
DM1NL3Z	CS	COC(=O)C1=C(N=CC=C1)N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DM1NL3Z	IK	NDCPNKXUTJGQQC-UHFFFAOYSA-N
DM1NL3Z	IU	methyl 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]pyridine-3-carboxylate
DM1NL3Z	CA	CAS 150527-23-4
DM1NL3Z	DE	Discovery agent

DML9IGY	ID	DML9IGY
DML9IGY	DN	FGGFTCARKCARK
DML9IGY	HS	Investigative
DML9IGY	SN	CHEMBL442113
DML9IGY	PC	10986104
DML9IGY	MW	1443.7
DML9IGY	FM	C62H102N22O14S2
DML9IGY	IC	InChI=1S/C62H102N22O14S2/c1-34(51(89)79-42(22-14-26-71-61(67)68)54(92)78-40(50(66)88)20-10-12-24-63)75-58(96)45(32-99)82-56(94)41(21-11-13-25-64)81-55(93)43(23-15-27-72-62(69)70)80-52(90)35(2)76-59(97)46(33-100)83-60(98)49(36(3)85)84-57(95)44(29-38-18-8-5-9-19-38)77-48(87)31-73-47(86)30-74-53(91)39(65)28-37-16-6-4-7-17-37/h4-9,16-19,34-36,39-46,49,85,99-100H,10-15,20-33,63-65H2,1-3H3,(H2,66,88)(H,73,86)(H,74,91)(H,75,96)(H,76,97)(H,77,87)(H,78,92)(H,79,89)(H,80,90)(H,81,93)(H,82,94)(H,83,98)(H,84,95)(H4,67,68,71)(H4,69,70,72)/t34-,35-,36+,39-,40-,41-,42-,43-,44-,45-,46-,49-/m0/s1
DML9IGY	CS	C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DML9IGY	IK	APYUYQWYKXKSOW-JOEKKRFNSA-N
DML9IGY	IU	(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanamide
DML9IGY	DE	Discovery agent

DMMV061	ID	DMMV061
DMMV061	DN	F-G-G-F-T-G-Aib-R-K-S-Aib-R-K-L-A-N-Q-CONH2
DMMV061	HS	Investigative
DMMV061	PC	91932083
DMMV061	MW	1836.1
DMMV061	FM	C81H134N28O21
DMMV061	IC	InChI=1S/C81H134N28O21/c1-7-49(98-64(116)41-96-79(130)65(45(6)111)109-77(128)57(37-47-23-13-10-14-24-47)99-63(115)40-94-62(114)39-95-68(119)48(84)36-46-21-11-9-12-22-46)69(120)102-54(27-19-33-92-80(88)89)71(122)105-53(26-16-18-32-83)74(125)108-59(42-110)78(129)100-50(8-2)70(121)103-55(28-20-34-93-81(90)91)72(123)104-52(25-15-17-31-82)73(124)107-56(35-43(3)4)75(126)97-44(5)67(118)106-58(38-61(86)113)76(127)101-51(66(87)117)29-30-60(85)112/h9-14,21-24,43-45,48-59,65,110-111H,7-8,15-20,25-42,82-84H2,1-6H3,(H2,85,112)(H2,86,113)(H2,87,117)(H,94,114)(H,95,119)(H,96,130)(H,97,126)(H,98,116)(H,99,115)(H,100,129)(H,101,127)(H,102,120)(H,103,121)(H,104,123)(H,105,122)(H,106,118)(H,107,124)(H,108,125)(H,109,128)(H4,88,89,92)(H4,90,91,93)/t44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,65-/m0/s1
DMMV061	CS	CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMMV061	IK	JDXIHEXWMPKRIL-METNDEIASA-N
DMMV061	IU	(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMMV061	DE	Discovery agent

DMN7501	ID	DMN7501
DMN7501	DN	F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-CONH2
DMN7501	HS	Investigative
DMN7501	PC	91932085
DMN7501	MW	1822.1
DMN7501	FM	C80H132N28O21
DMN7501	IC	InChI=1S/C80H132N28O21/c1-7-49(98-63(115)40-95-78(129)64(45(6)110)108-76(127)56(36-47-22-12-9-13-23-47)99-62(114)39-93-61(113)38-94-68(119)48(83)35-46-20-10-8-11-21-46)69(120)102-54(27-19-33-92-80(89)90)71(122)104-52(25-15-17-31-82)73(124)107-58(41-109)77(128)97-43(4)66(117)101-53(26-18-32-91-79(87)88)70(121)103-51(24-14-16-30-81)72(123)106-55(34-42(2)3)74(125)96-44(5)67(118)105-57(37-60(85)112)75(126)100-50(65(86)116)28-29-59(84)111/h8-13,20-23,42-45,48-58,64,109-110H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,119)(H,95,129)(H,96,125)(H,97,128)(H,98,115)(H,99,114)(H,100,126)(H,101,117)(H,102,120)(H,103,121)(H,104,122)(H,105,118)(H,106,123)(H,107,124)(H,108,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMN7501	CS	CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMN7501	IK	UWYRKSVDCJMXNB-KMOVSZGYSA-N
DMN7501	IU	(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMN7501	DE	Discovery agent

DMU3IJL	ID	DMU3IJL
DMU3IJL	DN	F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-COOH
DMU3IJL	HS	Investigative
DMU3IJL	PC	91932082
DMU3IJL	MW	1823.1
DMU3IJL	FM	C80H131N27O22
DMU3IJL	IC	InChI=1S/C80H131N27O22/c1-7-49(97-63(114)40-94-77(127)64(45(6)109)107-75(125)56(36-47-22-12-9-13-23-47)98-62(113)39-92-61(112)38-93-67(117)48(83)35-46-20-10-8-11-21-46)68(118)100-53(27-19-33-91-80(88)89)70(120)102-51(25-15-17-31-82)72(122)106-58(41-108)76(126)96-43(4)65(115)99-52(26-18-32-90-79(86)87)69(119)101-50(24-14-16-30-81)71(121)105-55(34-42(2)3)73(123)95-44(5)66(116)104-57(37-60(85)111)74(124)103-54(78(128)129)28-29-59(84)110/h8-13,20-23,42-45,48-58,64,108-109H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,117)(H,94,127)(H,95,123)(H,96,126)(H,97,114)(H,98,113)(H,99,115)(H,100,118)(H,101,119)(H,102,120)(H,103,124)(H,104,116)(H,105,121)(H,106,122)(H,107,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMU3IJL	CS	CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMU3IJL	IK	XQBWITORWNZMQG-KMOVSZGYSA-N
DMU3IJL	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMU3IJL	DE	Discovery agent

DMTEO35	ID	DMTEO35
DMTEO35	DN	FGGFTGARKCARKC
DMTEO35	HS	Investigative
DMTEO35	DE	Discovery agent

DMIFKPE	ID	DMIFKPE
DMIFKPE	DN	FGGFTGARKRKRKLANQ
DMIFKPE	HS	Investigative
DMIFKPE	PC	91934902
DMIFKPE	MW	1935.2
DMIFKPE	FM	C85H143N31O21
DMIFKPE	IC	InChI=1S/C85H143N31O21/c1-46(2)39-60(78(132)105-48(4)70(124)114-62(42-64(91)119)79(133)113-59(82(136)137)31-32-63(90)118)115-77(131)55(27-14-17-35-88)110-76(130)58(30-20-38-100-85(96)97)112-73(127)54(26-13-16-34-87)109-75(129)57(29-19-37-99-84(94)95)111-72(126)53(25-12-15-33-86)108-74(128)56(28-18-36-98-83(92)93)107-69(123)47(3)104-66(121)45-103-81(135)68(49(5)117)116-80(134)61(41-51-23-10-7-11-24-51)106-67(122)44-101-65(120)43-102-71(125)52(89)40-50-21-8-6-9-22-50/h6-11,21-24,46-49,52-62,68,117H,12-20,25-45,86-89H2,1-5H3,(H2,90,118)(H2,91,119)(H,101,120)(H,102,125)(H,103,135)(H,104,121)(H,105,132)(H,106,122)(H,107,123)(H,108,128)(H,109,129)(H,110,130)(H,111,126)(H,112,127)(H,113,133)(H,114,124)(H,115,131)(H,116,134)(H,136,137)(H4,92,93,98)(H4,94,95,99)(H4,96,97,100)/t47-,48-,49+,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,68-/m0/s1
DMIFKPE	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMIFKPE	IK	OPYGIVVZZPRQCO-BANXXPNRSA-N
DMIFKPE	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMIFKPE	DE	Discovery agent

DM9H80P	ID	DM9H80P
DM9H80P	DN	F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-CONH2
DM9H80P	HS	Investigative
DM9H80P	PC	91932091
DM9H80P	MW	1822.1
DM9H80P	FM	C80H132N28O21
DM9H80P	IC	InChI=1S/C80H132N28O21/c1-7-49(69(120)102-54(27-19-33-92-80(89)90)71(122)103-51(24-14-16-30-81)72(123)106-55(34-42(2)3)74(125)97-44(5)67(118)105-57(37-60(85)112)75(126)100-50(65(86)116)28-29-59(84)111)99-77(128)58(41-109)107-73(124)52(25-15-17-31-82)104-70(121)53(26-18-32-91-79(87)88)101-66(117)43(4)96-62(114)40-95-78(129)64(45(6)110)108-76(127)56(36-47-22-12-9-13-23-47)98-63(115)39-93-61(113)38-94-68(119)48(83)35-46-20-10-8-11-21-46/h8-13,20-23,42-45,48-58,64,109-110H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,119)(H,95,129)(H,96,114)(H,97,125)(H,98,115)(H,99,128)(H,100,126)(H,101,117)(H,102,120)(H,103,122)(H,104,121)(H,105,118)(H,106,123)(H,107,124)(H,108,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DM9H80P	CS	CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DM9H80P	IK	BMXJNWVYNYOAHC-KMOVSZGYSA-N
DM9H80P	IU	(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DM9H80P	DE	Discovery agent

DMPRZ8N	ID	DMPRZ8N
DMPRZ8N	DN	F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-COOH
DMPRZ8N	HS	Investigative
DMPRZ8N	PC	91932088
DMPRZ8N	MW	1823.1
DMPRZ8N	FM	C80H131N27O22
DMPRZ8N	IC	InChI=1S/C80H131N27O22/c1-7-49(68(118)100-53(27-19-33-91-80(88)89)70(120)101-50(24-14-16-30-81)71(121)105-55(34-42(2)3)73(123)96-44(5)66(116)104-57(37-60(85)111)74(124)103-54(78(128)129)28-29-59(84)110)98-76(126)58(41-108)106-72(122)51(25-15-17-31-82)102-69(119)52(26-18-32-90-79(86)87)99-65(115)43(4)95-62(113)40-94-77(127)64(45(6)109)107-75(125)56(36-47-22-12-9-13-23-47)97-63(114)39-92-61(112)38-93-67(117)48(83)35-46-20-10-8-11-21-46/h8-13,20-23,42-45,48-58,64,108-109H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,117)(H,94,127)(H,95,113)(H,96,123)(H,97,114)(H,98,126)(H,99,115)(H,100,118)(H,101,120)(H,102,119)(H,103,124)(H,104,116)(H,105,121)(H,106,122)(H,107,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMPRZ8N	CS	CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMPRZ8N	IK	FBSIFFHLVXSJIC-KMOVSZGYSA-N
DMPRZ8N	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMPRZ8N	DE	Discovery agent

DM5W1VF	ID	DM5W1VF
DM5W1VF	DN	FGGFTGARKSARKAANQ
DM5W1VF	HS	Investigative
DM5W1VF	PC	91934910
DM5W1VF	MW	1767
DM5W1VF	FM	C76H123N27O22
DM5W1VF	IC	InChI=1S/C76H123N27O22/c1-39(91-58(109)37-90-73(123)60(43(5)105)103-71(121)52(33-45-20-10-7-11-21-45)95-59(110)36-88-57(108)35-89-65(115)46(79)32-44-18-8-6-9-19-44)62(112)96-49(24-16-30-86-75(82)83)68(118)99-48(23-13-15-29-78)69(119)102-54(38-104)72(122)94-42(4)63(113)97-50(25-17-31-87-76(84)85)67(117)98-47(22-12-14-28-77)66(116)93-40(2)61(111)92-41(3)64(114)101-53(34-56(81)107)70(120)100-51(74(124)125)26-27-55(80)106/h6-11,18-21,39-43,46-54,60,104-105H,12-17,22-38,77-79H2,1-5H3,(H2,80,106)(H2,81,107)(H,88,108)(H,89,115)(H,90,123)(H,91,109)(H,92,111)(H,93,116)(H,94,122)(H,95,110)(H,96,112)(H,97,113)(H,98,117)(H,99,118)(H,100,120)(H,101,114)(H,102,119)(H,103,121)(H,124,125)(H4,82,83,86)(H4,84,85,87)/t39-,40-,41-,42-,43+,46-,47-,48-,49-,50-,51-,52-,53-,54-,60-/m0/s1
DM5W1VF	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM5W1VF	IK	FMVUBOOWCUPBBL-OVWUADNCSA-N
DM5W1VF	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]propanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM5W1VF	DE	Discovery agent

DMYJTZ7	ID	DMYJTZ7
DMYJTZ7	DN	FGGFTGARKSARKFANQ
DMYJTZ7	HS	Investigative
DMYJTZ7	PC	91934912
DMYJTZ7	MW	1843.1
DMYJTZ7	FM	C82H127N27O22
DMYJTZ7	IC	InChI=1S/C82H127N27O22/c1-44(97-64(115)42-96-79(129)66(47(4)111)109-77(127)57(37-49-22-10-6-11-23-49)100-65(116)41-94-63(114)40-95-70(120)51(85)36-48-20-8-5-9-21-48)67(117)101-54(28-18-34-92-81(88)89)71(121)104-53(27-15-17-33-84)74(124)108-60(43-110)78(128)99-45(2)68(118)102-55(29-19-35-93-82(90)91)72(122)103-52(26-14-16-32-83)73(123)107-58(38-50-24-12-7-13-25-50)75(125)98-46(3)69(119)106-59(39-62(87)113)76(126)105-56(80(130)131)30-31-61(86)112/h5-13,20-25,44-47,51-60,66,110-111H,14-19,26-43,83-85H2,1-4H3,(H2,86,112)(H2,87,113)(H,94,114)(H,95,120)(H,96,129)(H,97,115)(H,98,125)(H,99,128)(H,100,116)(H,101,117)(H,102,118)(H,103,122)(H,104,121)(H,105,126)(H,106,119)(H,107,123)(H,108,124)(H,109,127)(H,130,131)(H4,88,89,92)(H4,90,91,93)/t44-,45-,46-,47+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DMYJTZ7	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DMYJTZ7	IK	XBCTWRVAMOVPCA-UUKLZGIWSA-N
DMYJTZ7	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMYJTZ7	DE	Discovery agent

DMHG2TB	ID	DMHG2TB
DMHG2TB	DN	FGGFTGARKSARKKANQ
DMHG2TB	HS	Investigative
DMHG2TB	PC	91934909
DMHG2TB	MW	1824.1
DMHG2TB	FM	C79H130N28O22
DMHG2TB	IC	InChI=1S/C79H130N28O22/c1-42(95-61(113)40-94-76(127)63(45(4)109)107-74(125)55(36-47-21-9-6-10-22-47)98-62(114)39-92-60(112)38-93-67(118)48(83)35-46-19-7-5-8-20-46)64(115)99-52(26-17-33-90-78(86)87)70(121)103-51(25-13-16-32-82)72(123)106-57(41-108)75(126)97-43(2)65(116)100-53(27-18-34-91-79(88)89)71(122)102-50(24-12-15-31-81)69(120)101-49(23-11-14-30-80)68(119)96-44(3)66(117)105-56(37-59(85)111)73(124)104-54(77(128)129)28-29-58(84)110/h5-10,19-22,42-45,48-57,63,108-109H,11-18,23-41,80-83H2,1-4H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,118)(H,94,127)(H,95,113)(H,96,119)(H,97,126)(H,98,114)(H,99,115)(H,100,116)(H,101,120)(H,102,122)(H,103,121)(H,104,124)(H,105,117)(H,106,123)(H,107,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t42-,43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,63-/m0/s1
DMHG2TB	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMHG2TB	IK	OYXJMSJHGINGKM-SMFNREODSA-N
DMHG2TB	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMHG2TB	DE	Discovery agent

DMY347Q	ID	DMY347Q
DMY347Q	DN	FGGFTGARKSARKKKNQ
DMY347Q	HS	Investigative
DMY347Q	PC	91934907
DMY347Q	MW	1881.1
DMY347Q	FM	C82H137N29O22
DMY347Q	IC	InChI=1S/C82H137N29O22/c1-45(99-64(117)43-98-79(131)66(47(3)113)111-77(129)58(39-49-22-8-5-9-23-49)101-65(118)42-96-63(116)41-97-69(121)50(87)38-48-20-6-4-7-21-48)67(119)102-55(28-18-36-94-81(90)91)72(124)107-54(27-13-17-35-86)75(127)110-60(44-112)78(130)100-46(2)68(120)103-56(29-19-37-95-82(92)93)73(125)105-52(25-11-15-33-84)70(122)104-51(24-10-14-32-83)71(123)106-53(26-12-16-34-85)74(126)109-59(40-62(89)115)76(128)108-57(80(132)133)30-31-61(88)114/h4-9,20-23,45-47,50-60,66,112-113H,10-19,24-44,83-87H2,1-3H3,(H2,88,114)(H2,89,115)(H,96,116)(H,97,121)(H,98,131)(H,99,117)(H,100,130)(H,101,118)(H,102,119)(H,103,120)(H,104,122)(H,105,125)(H,106,123)(H,107,124)(H,108,128)(H,109,126)(H,110,127)(H,111,129)(H,132,133)(H4,90,91,94)(H4,92,93,95)/t45-,46-,47+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DMY347Q	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMY347Q	IK	UDQRAMWZBFAZAV-WBMOPDPASA-N
DMY347Q	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMY347Q	DE	Discovery agent

DMPG8NC	ID	DMPG8NC
DMPG8NC	DN	FGGFTGARKSARKKRNQ
DMPG8NC	HS	Investigative
DMPG8NC	PC	91934905
DMPG8NC	MW	1909.2
DMPG8NC	FM	C82H137N31O22
DMPG8NC	IC	InChI=1S/C82H137N31O22/c1-44(101-63(119)42-100-78(133)65(46(3)115)113-76(131)57(38-48-21-8-5-9-22-48)103-64(120)41-98-62(118)40-99-68(123)49(86)37-47-19-6-4-7-20-47)66(121)104-53(26-16-34-95-80(89)90)71(126)108-52(25-12-15-33-85)74(129)112-59(43-114)77(132)102-45(2)67(122)105-54(27-17-35-96-81(91)92)72(127)107-50(23-10-13-31-83)69(124)106-51(24-11-14-32-84)70(125)109-55(28-18-36-97-82(93)94)73(128)111-58(39-61(88)117)75(130)110-56(79(134)135)29-30-60(87)116/h4-9,19-22,44-46,49-59,65,114-115H,10-18,23-43,83-86H2,1-3H3,(H2,87,116)(H2,88,117)(H,98,118)(H,99,123)(H,100,133)(H,101,119)(H,102,132)(H,103,120)(H,104,121)(H,105,122)(H,106,124)(H,107,127)(H,108,126)(H,109,125)(H,110,130)(H,111,128)(H,112,129)(H,113,131)(H,134,135)(H4,89,90,95)(H4,91,92,96)(H4,93,94,97)/t44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,65-/m0/s1
DMPG8NC	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMPG8NC	IK	LIKGHYIDQTYXFY-VUXBHJHDSA-N
DMPG8NC	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMPG8NC	DE	Discovery agent

DMHD6N7	ID	DMHD6N7
DMHD6N7	DN	FGGFTGARKSARKKWNQ
DMHD6N7	HS	Investigative
DMHD6N7	PC	91934382
DMHD6N7	MW	1939.2
DMHD6N7	FM	C87H135N29O22
DMHD6N7	IC	InChI=1S/C87H135N29O22/c1-47(104-69(122)45-103-84(136)71(49(3)118)116-82(134)62(39-51-22-8-5-9-23-51)106-70(123)44-101-68(121)43-102-74(126)54(91)38-50-20-6-4-7-21-50)72(124)107-59(29-18-36-98-86(94)95)76(128)111-58(28-14-17-35-90)79(131)115-65(46-117)83(135)105-48(2)73(125)108-60(30-19-37-99-87(96)97)77(129)109-56(26-12-15-33-88)75(127)110-57(27-13-16-34-89)78(130)113-63(40-52-42-100-55-25-11-10-24-53(52)55)80(132)114-64(41-67(93)120)81(133)112-61(85(137)138)31-32-66(92)119/h4-11,20-25,42,47-49,54,56-65,71,100,117-118H,12-19,26-41,43-46,88-91H2,1-3H3,(H2,92,119)(H2,93,120)(H,101,121)(H,102,126)(H,103,136)(H,104,122)(H,105,135)(H,106,123)(H,107,124)(H,108,125)(H,109,129)(H,110,127)(H,111,128)(H,112,133)(H,113,130)(H,114,132)(H,115,131)(H,116,134)(H,137,138)(H4,94,95,98)(H4,96,97,99)/t47-,48-,49+,54-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,71-/m0/s1
DMHD6N7	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMHD6N7	IK	URYINPOXJIHSDS-PBUARHPHSA-N
DMHD6N7	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMHD6N7	DE	Discovery agent

DM78I2W	ID	DM78I2W
DM78I2W	DN	FGGFTGARKSARKL
DM78I2W	HS	Investigative
DM78I2W	SN	CHEMBL437915; FGGFTGARKSARKL
DM78I2W	PC	44352919
DM78I2W	MW	1494.7
DM78I2W	FM	C67H111N23O16
DM78I2W	IC	InChI=1S/C67H111N23O16/c1-37(2)30-48(55(71)96)88-61(102)44(22-12-14-26-68)86-60(101)47(25-17-29-77-67(74)75)85-57(98)39(4)82-64(105)50(36-91)89-62(103)45(23-13-15-27-69)87-59(100)46(24-16-28-76-66(72)73)84-56(97)38(3)81-52(94)35-80-65(106)54(40(5)92)90-63(104)49(32-42-20-10-7-11-21-42)83-53(95)34-78-51(93)33-79-58(99)43(70)31-41-18-8-6-9-19-41/h6-11,18-21,37-40,43-50,54,91-92H,12-17,22-36,68-70H2,1-5H3,(H2,71,96)(H,78,93)(H,79,99)(H,80,106)(H,81,94)(H,82,105)(H,83,95)(H,84,97)(H,85,98)(H,86,101)(H,87,100)(H,88,102)(H,89,103)(H,90,104)(H4,72,73,76)(H4,74,75,77)/t38-,39-,40+,43-,44-,45-,46-,47-,48-,49-,50-,54-/m0/s1
DM78I2W	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM78I2W	IK	LZQNOYOFRMAEJW-SYMNRJDYSA-N
DM78I2W	IU	(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]hexanamide
DM78I2W	DE	Discovery agent

DMS5AH4	ID	DMS5AH4
DMS5AH4	DN	FGGFTGARKSARKLADE
DMS5AH4	HS	Investigative
DMS5AH4	PC	91931808
DMS5AH4	MW	1810
DMS5AH4	FM	C79H128N26O23
DMS5AH4	IC	InChI=1S/C79H128N26O23/c1-41(2)33-54(73(124)94-44(5)67(118)102-56(36-62(113)114)74(125)97-49(64(83)115)27-28-61(111)112)103-71(122)50(23-13-15-29-80)100-70(121)53(26-18-32-89-79(86)87)99-66(117)43(4)95-76(127)57(40-106)104-72(123)51(24-14-16-30-81)101-69(120)52(25-17-31-88-78(84)85)98-65(116)42(3)93-59(109)39-92-77(128)63(45(6)107)105-75(126)55(35-47-21-11-8-12-22-47)96-60(110)38-90-58(108)37-91-68(119)48(82)34-46-19-9-7-10-20-46/h7-12,19-22,41-45,48-57,63,106-107H,13-18,23-40,80-82H2,1-6H3,(H2,83,115)(H,90,108)(H,91,119)(H,92,128)(H,93,109)(H,94,124)(H,95,127)(H,96,110)(H,97,125)(H,98,116)(H,99,117)(H,100,121)(H,101,120)(H,102,118)(H,103,122)(H,104,123)(H,105,126)(H,111,112)(H,113,114)(H4,84,85,88)(H4,86,87,89)/t42-,43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,63-/m0/s1
DMS5AH4	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMS5AH4	IK	PUPSFQBPHILNGY-SMFNREODSA-N
DMS5AH4	IU	(4S)-5-amino-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoic acid
DMS5AH4	DE	Discovery agent

DMKLSBN	ID	DMKLSBN
DMKLSBN	DN	F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-CONH2
DMKLSBN	HS	Investigative
DMKLSBN	PC	91932087
DMKLSBN	MW	1822.1
DMKLSBN	FM	C80H132N28O21
DMKLSBN	IC	InChI=1S/C80H132N28O21/c1-7-49(69(120)106-57(37-60(85)112)75(126)100-50(65(86)116)28-29-59(84)111)99-74(125)55(34-42(2)3)105-72(123)51(24-14-16-30-81)103-71(122)54(27-19-33-92-80(89)90)102-67(118)44(5)97-77(128)58(41-109)107-73(124)52(25-15-17-31-82)104-70(121)53(26-18-32-91-79(87)88)101-66(117)43(4)96-62(114)40-95-78(129)64(45(6)110)108-76(127)56(36-47-22-12-9-13-23-47)98-63(115)39-93-61(113)38-94-68(119)48(83)35-46-20-10-8-11-21-46/h8-13,20-23,42-45,48-58,64,109-110H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,119)(H,95,129)(H,96,114)(H,97,128)(H,98,115)(H,99,125)(H,100,126)(H,101,117)(H,102,118)(H,103,122)(H,104,121)(H,105,123)(H,106,120)(H,107,124)(H,108,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMKLSBN	CS	CC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMKLSBN	IK	FNRHKDQQWGJCOM-KMOVSZGYSA-N
DMKLSBN	IU	(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMKLSBN	DE	Discovery agent

DMPDMFA	ID	DMPDMFA
DMPDMFA	DN	F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-COOH
DMPDMFA	HS	Investigative
DMPDMFA	PC	91932094
DMPDMFA	MW	1823.1
DMPDMFA	FM	C80H131N27O22
DMPDMFA	IC	InChI=1S/C80H131N27O22/c1-7-49(68(118)105-57(37-60(85)111)74(124)103-54(78(128)129)28-29-59(84)110)98-73(123)55(34-42(2)3)104-71(121)50(24-14-16-30-81)101-70(120)53(27-19-33-91-80(88)89)100-66(116)44(5)96-76(126)58(41-108)106-72(122)51(25-15-17-31-82)102-69(119)52(26-18-32-90-79(86)87)99-65(115)43(4)95-62(113)40-94-77(127)64(45(6)109)107-75(125)56(36-47-22-12-9-13-23-47)97-63(114)39-92-61(112)38-93-67(117)48(83)35-46-20-10-8-11-21-46/h8-13,20-23,42-45,48-58,64,108-109H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,117)(H,94,127)(H,95,113)(H,96,126)(H,97,114)(H,98,123)(H,99,115)(H,100,116)(H,101,120)(H,102,119)(H,103,124)(H,104,121)(H,105,118)(H,106,122)(H,107,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMPDMFA	CS	CC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMPDMFA	IK	CBBZIEAUVSBRPS-KMOVSZGYSA-N
DMPDMFA	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMPDMFA	DE	Discovery agent

DMSMK70	ID	DMSMK70
DMSMK70	DN	FGGFTGARKSARKLARK
DMSMK70	HS	Investigative
DMSMK70	SN	CHEMBL499157; FGGFTGARKSARKLARK
DMSMK70	PC	44588828
DMSMK70	MW	1704
DMSMK70	FM	C73H130N28O19
DMSMK70	IC	InChI=1S/C73H130N28O19/c1-39(2)33-52(67(116)91-41(4)59(108)95-50(26-18-32-86-73(82)83)64(113)98-51(70(119)120)23-12-15-29-76)99-65(114)46(21-10-13-27-74)96-63(112)49(25-17-31-85-72(80)81)94-60(109)42(5)92-68(117)53(38-102)100-66(115)47(22-11-14-28-75)97-62(111)48(24-16-30-84-71(78)79)93-58(107)40(3)90-55(105)37-89-69(118)57(43(6)103)101-56(106)36-87-54(104)35-88-61(110)45(77)34-44-19-8-7-9-20-44/h7-9,19-20,39-43,45-53,57,102-103H,10-18,21-38,74-77H2,1-6H3,(H,87,104)(H,88,110)(H,89,118)(H,90,105)(H,91,116)(H,92,117)(H,93,107)(H,94,109)(H,95,108)(H,96,112)(H,97,111)(H,98,113)(H,99,114)(H,100,115)(H,101,106)(H,119,120)(H4,78,79,84)(H4,80,81,85)(H4,82,83,86)/t40-,41-,42-,43+,45-,46-,47-,48-,49-,50-,51-,52-,53-,57-/m0/s1
DMSMK70	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CNC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)N)O
DMSMK70	IK	UNHQLKTVYYARAV-VKORATPISA-N
DMSMK70	IU	(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoic acid
DMSMK70	DE	Discovery agent

DMLDWFE	ID	DMLDWFE
DMLDWFE	DN	FGGFTGARKSARKLFNQ
DMLDWFE	HS	Investigative
DMLDWFE	PC	91934919
DMLDWFE	MW	1885.1
DMLDWFE	FM	C85H133N27O22
DMLDWFE	IC	InChI=1S/C85H133N27O22/c1-46(2)37-59(77(127)109-61(40-52-25-13-8-14-26-52)78(128)110-62(41-65(90)116)79(129)107-58(83(133)134)31-32-64(89)115)108-75(125)54(27-15-17-33-86)105-74(124)57(30-20-36-96-85(93)94)104-71(121)48(4)101-81(131)63(45-113)111-76(126)55(28-16-18-34-87)106-73(123)56(29-19-35-95-84(91)92)103-70(120)47(3)100-67(118)44-99-82(132)69(49(5)114)112-80(130)60(39-51-23-11-7-12-24-51)102-68(119)43-97-66(117)42-98-72(122)53(88)38-50-21-9-6-10-22-50/h6-14,21-26,46-49,53-63,69,113-114H,15-20,27-45,86-88H2,1-5H3,(H2,89,115)(H2,90,116)(H,97,117)(H,98,122)(H,99,132)(H,100,118)(H,101,131)(H,102,119)(H,103,120)(H,104,121)(H,105,124)(H,106,123)(H,107,129)(H,108,125)(H,109,127)(H,110,128)(H,111,126)(H,112,130)(H,133,134)(H4,91,92,95)(H4,93,94,96)/t47-,48-,49+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,69-/m0/s1
DMLDWFE	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DMLDWFE	IK	KCPGYTKGECMLMX-UAOIWBIESA-N
DMLDWFE	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMLDWFE	DE	Discovery agent

DMIA2XJ	ID	DMIA2XJ
DMIA2XJ	DN	FGGFTGARKSARKLKNQ
DMIA2XJ	HS	Investigative
DMIA2XJ	PC	91934916
DMIA2XJ	MW	1866.1
DMIA2XJ	FM	C82H136N28O22
DMIA2XJ	IC	InChI=1S/C82H136N28O22/c1-44(2)36-57(75(126)105-52(25-13-16-32-84)73(124)108-59(39-62(88)114)76(127)106-56(80(131)132)29-30-61(87)113)107-72(123)51(24-12-15-31-83)103-71(122)55(28-19-35-94-82(91)92)102-68(119)46(4)99-78(129)60(43-111)109-74(125)53(26-14-17-33-85)104-70(121)54(27-18-34-93-81(89)90)101-67(118)45(3)98-64(116)42-97-79(130)66(47(5)112)110-77(128)58(38-49-22-10-7-11-23-49)100-65(117)41-95-63(115)40-96-69(120)50(86)37-48-20-8-6-9-21-48/h6-11,20-23,44-47,50-60,66,111-112H,12-19,24-43,83-86H2,1-5H3,(H2,87,113)(H2,88,114)(H,95,115)(H,96,120)(H,97,130)(H,98,116)(H,99,129)(H,100,117)(H,101,118)(H,102,119)(H,103,122)(H,104,121)(H,105,126)(H,106,127)(H,107,123)(H,108,124)(H,109,125)(H,110,128)(H,131,132)(H4,89,90,93)(H4,91,92,94)/t45-,46-,47+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DMIA2XJ	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMIA2XJ	IK	PODXIWAAMNUDTK-WBMOPDPASA-N
DMIA2XJ	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMIA2XJ	DE	Discovery agent

DMRVSXG	ID	DMRVSXG
DMRVSXG	DN	FGGFTGARKSARKLLNQ
DMRVSXG	HS	Investigative
DMRVSXG	PC	91934917
DMRVSXG	MW	1851.1
DMRVSXG	FM	C82H135N27O22
DMRVSXG	IC	InChI=1S/C82H135N27O22/c1-43(2)34-56(74(124)106-57(35-44(3)4)75(125)107-59(38-62(87)113)76(126)104-55(80(130)131)28-29-61(86)112)105-72(122)51(24-14-16-30-83)102-71(121)54(27-19-33-93-82(90)91)101-68(118)46(6)98-78(128)60(42-110)108-73(123)52(25-15-17-31-84)103-70(120)53(26-18-32-92-81(88)89)100-67(117)45(5)97-64(115)41-96-79(129)66(47(7)111)109-77(127)58(37-49-22-12-9-13-23-49)99-65(116)40-94-63(114)39-95-69(119)50(85)36-48-20-10-8-11-21-48/h8-13,20-23,43-47,50-60,66,110-111H,14-19,24-42,83-85H2,1-7H3,(H2,86,112)(H2,87,113)(H,94,114)(H,95,119)(H,96,129)(H,97,115)(H,98,128)(H,99,116)(H,100,117)(H,101,118)(H,102,121)(H,103,120)(H,104,126)(H,105,122)(H,106,124)(H,107,125)(H,108,123)(H,109,127)(H,130,131)(H4,88,89,92)(H4,90,91,93)/t45-,46-,47+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DMRVSXG	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMRVSXG	IK	OQBMVKTZJNOYNF-WBMOPDPASA-N
DMRVSXG	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMRVSXG	DE	Discovery agent

DMD9SOF	ID	DMD9SOF
DMD9SOF	DN	F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-CONH2
DMD9SOF	HS	Investigative
DMD9SOF	PC	91932084
DMD9SOF	MW	1822.1
DMD9SOF	FM	C80H132N28O21
DMD9SOF	IC	InChI=1S/C80H132N28O21/c1-42(2)34-57(78(129)108(7)45(5)68(119)104-56(37-60(85)112)74(125)99-50(65(86)116)28-29-59(84)111)105-72(123)51(24-14-16-30-81)102-71(122)54(27-19-33-92-80(89)90)101-67(118)44(4)97-76(127)58(41-109)106-73(124)52(25-15-17-31-82)103-70(121)53(26-18-32-91-79(87)88)100-66(117)43(3)96-62(114)40-95-77(128)64(46(6)110)107-75(126)55(36-48-22-12-9-13-23-48)98-63(115)39-93-61(113)38-94-69(120)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,109-110H,14-19,24-41,81-83H2,1-7H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,120)(H,95,128)(H,96,114)(H,97,127)(H,98,115)(H,99,125)(H,100,117)(H,101,118)(H,102,122)(H,103,121)(H,104,119)(H,105,123)(H,106,124)(H,107,126)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMD9SOF	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMD9SOF	IK	DLMXQMKGBYRHOA-FKPOJLNCSA-N
DMD9SOF	IU	(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]-methylamino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMD9SOF	DE	Discovery agent

DMCSN9M	ID	DMCSN9M
DMCSN9M	DN	F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-COOH
DMCSN9M	HS	Investigative
DMCSN9M	PC	91932086
DMCSN9M	MW	1823.1
DMCSN9M	FM	C80H131N27O22
DMCSN9M	IC	InChI=1S/C80H131N27O22/c1-42(2)34-57(77(127)107(7)45(5)67(117)103-56(37-60(85)111)73(123)102-54(78(128)129)28-29-59(84)110)104-71(121)50(24-14-16-30-81)100-70(120)53(27-19-33-91-80(88)89)99-66(116)44(4)96-75(125)58(41-108)105-72(122)51(25-15-17-31-82)101-69(119)52(26-18-32-90-79(86)87)98-65(115)43(3)95-62(113)40-94-76(126)64(46(6)109)106-74(124)55(36-48-22-12-9-13-23-48)97-63(114)39-92-61(112)38-93-68(118)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,108-109H,14-19,24-41,81-83H2,1-7H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,118)(H,94,126)(H,95,113)(H,96,125)(H,97,114)(H,98,115)(H,99,116)(H,100,120)(H,101,119)(H,102,123)(H,103,117)(H,104,121)(H,105,122)(H,106,124)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMCSN9M	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMCSN9M	IK	NQIPFWOYZKKZKS-FKPOJLNCSA-N
DMCSN9M	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]-methylamino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMCSN9M	DE	Discovery agent

DMCSTP5	ID	DMCSTP5
DMCSTP5	DN	FGGFTGARKSARKLRNQ
DMCSTP5	HS	Investigative
DMCSTP5	PC	91934915
DMCSTP5	MW	1894.1
DMCSTP5	FM	C82H136N30O22
DMCSTP5	IC	InChI=1S/C82H136N30O22/c1-43(2)35-56(74(128)107-54(27-18-34-96-82(92)93)72(126)110-58(38-61(87)116)75(129)108-55(79(133)134)28-29-60(86)115)109-71(125)50(23-12-14-30-83)105-70(124)53(26-17-33-95-81(90)91)104-67(121)45(4)101-77(131)59(42-113)111-73(127)51(24-13-15-31-84)106-69(123)52(25-16-32-94-80(88)89)103-66(120)44(3)100-63(118)41-99-78(132)65(46(5)114)112-76(130)57(37-48-21-10-7-11-22-48)102-64(119)40-97-62(117)39-98-68(122)49(85)36-47-19-8-6-9-20-47/h6-11,19-22,43-46,49-59,65,113-114H,12-18,23-42,83-85H2,1-5H3,(H2,86,115)(H2,87,116)(H,97,117)(H,98,122)(H,99,132)(H,100,118)(H,101,131)(H,102,119)(H,103,120)(H,104,121)(H,105,124)(H,106,123)(H,107,128)(H,108,129)(H,109,125)(H,110,126)(H,111,127)(H,112,130)(H,133,134)(H4,88,89,94)(H4,90,91,95)(H4,92,93,96)/t44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,65-/m0/s1
DMCSTP5	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMCSTP5	IK	YWJIJXCRNQLPGY-VUXBHJHDSA-N
DMCSTP5	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMCSTP5	DE	Discovery agent

DMDEJS6	ID	DMDEJS6
DMDEJS6	DN	FGGFTGARKSARKLVNQ
DMDEJS6	HS	Investigative
DMDEJS6	PC	91934918
DMDEJS6	MW	1837.1
DMDEJS6	FM	C81H133N27O22
DMDEJS6	IC	InChI=1S/C81H133N27O22/c1-42(2)34-55(74(124)107-64(43(3)4)78(128)105-57(37-60(86)112)73(123)103-54(79(129)130)28-29-59(85)111)104-71(121)50(24-14-16-30-82)101-70(120)53(27-19-33-92-81(89)90)100-67(117)45(6)97-76(126)58(41-109)106-72(122)51(25-15-17-31-83)102-69(119)52(26-18-32-91-80(87)88)99-66(116)44(5)96-62(114)40-95-77(127)65(46(7)110)108-75(125)56(36-48-22-12-9-13-23-48)98-63(115)39-93-61(113)38-94-68(118)49(84)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64-65,109-110H,14-19,24-41,82-84H2,1-7H3,(H2,85,111)(H2,86,112)(H,93,113)(H,94,118)(H,95,127)(H,96,114)(H,97,126)(H,98,115)(H,99,116)(H,100,117)(H,101,120)(H,102,119)(H,103,123)(H,104,121)(H,105,128)(H,106,122)(H,107,124)(H,108,125)(H,129,130)(H4,87,88,91)(H4,89,90,92)/t44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-,65-/m0/s1
DMDEJS6	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMDEJS6	IK	ONIQWXAYTYHYLD-BEIYNOPZSA-N
DMDEJS6	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMDEJS6	DE	Discovery agent

DMV34KQ	ID	DMV34KQ
DMV34KQ	DN	FGGFTGARKSARKLWNQ
DMV34KQ	HS	Investigative
DMV34KQ	PC	91934921
DMV34KQ	MW	1924.2
DMV34KQ	FM	C87H134N28O22
DMV34KQ	IC	InChI=1S/C87H134N28O22/c1-46(2)36-61(79(130)112-63(39-52-41-99-55-25-13-12-24-53(52)55)80(131)113-64(40-67(92)119)81(132)110-60(85(136)137)30-31-66(91)118)111-77(128)56(26-14-16-32-88)108-76(127)59(29-19-35-98-87(95)96)107-73(124)48(4)104-83(134)65(45-116)114-78(129)57(27-15-17-33-89)109-75(126)58(28-18-34-97-86(93)94)106-72(123)47(3)103-69(121)44-102-84(135)71(49(5)117)115-82(133)62(38-51-22-10-7-11-23-51)105-70(122)43-100-68(120)42-101-74(125)54(90)37-50-20-8-6-9-21-50/h6-13,20-25,41,46-49,54,56-65,71,99,116-117H,14-19,26-40,42-45,88-90H2,1-5H3,(H2,91,118)(H2,92,119)(H,100,120)(H,101,125)(H,102,135)(H,103,121)(H,104,134)(H,105,122)(H,106,123)(H,107,124)(H,108,127)(H,109,126)(H,110,132)(H,111,128)(H,112,130)(H,113,131)(H,114,129)(H,115,133)(H,136,137)(H4,93,94,97)(H4,95,96,98)/t47-,48-,49+,54-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,71-/m0/s1
DMV34KQ	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMV34KQ	IK	IXCVHRQJQPARCV-PBUARHPHSA-N
DMV34KQ	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMV34KQ	DE	Discovery agent

DMG5LXT	ID	DMG5LXT
DMG5LXT	DN	FGGFTGARKSARKLYNQ
DMG5LXT	HS	Investigative
DMG5LXT	PC	91934920
DMG5LXT	MW	1901.1
DMG5LXT	FM	C85H133N27O23
DMG5LXT	IC	InChI=1S/C85H133N27O23/c1-45(2)36-59(77(128)109-61(39-51-26-28-52(115)29-27-51)78(129)110-62(40-65(90)117)79(130)107-58(83(134)135)30-31-64(89)116)108-75(126)54(22-12-14-32-86)105-74(125)57(25-17-35-96-85(93)94)104-71(122)47(4)101-81(132)63(44-113)111-76(127)55(23-13-15-33-87)106-73(124)56(24-16-34-95-84(91)92)103-70(121)46(3)100-67(119)43-99-82(133)69(48(5)114)112-80(131)60(38-50-20-10-7-11-21-50)102-68(120)42-97-66(118)41-98-72(123)53(88)37-49-18-8-6-9-19-49/h6-11,18-21,26-29,45-48,53-63,69,113-115H,12-17,22-25,30-44,86-88H2,1-5H3,(H2,89,116)(H2,90,117)(H,97,118)(H,98,123)(H,99,133)(H,100,119)(H,101,132)(H,102,120)(H,103,121)(H,104,122)(H,105,125)(H,106,124)(H,107,130)(H,108,126)(H,109,128)(H,110,129)(H,111,127)(H,112,131)(H,134,135)(H4,91,92,95)(H4,93,94,96)/t46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,69-/m0/s1
DMG5LXT	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DMG5LXT	IK	BDVDLXKNELSDGP-RLSGEJHXSA-N
DMG5LXT	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMG5LXT	DE	Discovery agent

DM21XBO	ID	DM21XBO
DM21XBO	DN	FGGFTGARKSARKRANQ
DM21XBO	HS	Investigative
DM21XBO	PC	91934908
DM21XBO	MW	1852.1
DM21XBO	FM	C79H130N30O22
DM21XBO	IC	InChI=1S/C79H130N30O22/c1-41(97-60(115)39-96-75(129)62(44(4)111)109-73(127)54(35-46-20-9-6-10-21-46)100-61(116)38-94-59(114)37-95-66(120)47(82)34-45-18-7-5-8-19-45)63(117)101-51(25-16-32-92-78(87)88)69(123)104-49(23-12-14-30-81)71(125)108-56(40-110)74(128)99-42(2)64(118)102-52(26-17-33-93-79(89)90)70(124)103-48(22-11-13-29-80)68(122)105-50(24-15-31-91-77(85)86)67(121)98-43(3)65(119)107-55(36-58(84)113)72(126)106-53(76(130)131)27-28-57(83)112/h5-10,18-21,41-44,47-56,62,110-111H,11-17,22-40,80-82H2,1-4H3,(H2,83,112)(H2,84,113)(H,94,114)(H,95,120)(H,96,129)(H,97,115)(H,98,121)(H,99,128)(H,100,116)(H,101,117)(H,102,118)(H,103,124)(H,104,123)(H,105,122)(H,106,126)(H,107,119)(H,108,125)(H,109,127)(H,130,131)(H4,85,86,91)(H4,87,88,92)(H4,89,90,93)/t41-,42-,43-,44+,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,62-/m0/s1
DM21XBO	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM21XBO	IK	YTLZMPJDUFYROB-YRFUXTPFSA-N
DM21XBO	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM21XBO	DE	Discovery agent

DM9RHXC	ID	DM9RHXC
DM9RHXC	DN	FGGFTGARKSARKRKNQ
DM9RHXC	HS	Investigative
DM9RHXC	SN	[Arg14,Lys15]Nociceptin; 236098-40-1
DM9RHXC	PC	91934903
DM9RHXC	MW	1909.2
DM9RHXC	FM	C82H137N31O22
DM9RHXC	IC	InChI=1S/C82H137N31O22/c1-44(101-63(119)42-100-78(133)65(46(3)115)113-76(131)57(38-48-21-8-5-9-22-48)103-64(120)41-98-62(118)40-99-68(123)49(86)37-47-19-6-4-7-20-47)66(121)104-53(26-16-34-95-80(89)90)70(125)108-52(25-12-15-33-85)74(129)112-59(43-114)77(132)102-45(2)67(122)105-54(27-17-35-96-81(91)92)71(126)106-50(23-10-13-31-83)69(124)109-55(28-18-36-97-82(93)94)72(127)107-51(24-11-14-32-84)73(128)111-58(39-61(88)117)75(130)110-56(79(134)135)29-30-60(87)116/h4-9,19-22,44-46,49-59,65,114-115H,10-18,23-43,83-86H2,1-3H3,(H2,87,116)(H2,88,117)(H,98,118)(H,99,123)(H,100,133)(H,101,119)(H,102,132)(H,103,120)(H,104,121)(H,105,122)(H,106,126)(H,107,127)(H,108,125)(H,109,124)(H,110,130)(H,111,128)(H,112,129)(H,113,131)(H,134,135)(H4,89,90,95)(H4,91,92,96)(H4,93,94,97)/t44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,65-/m0/s1
DM9RHXC	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM9RHXC	IK	VULLMZOQBGUKAT-VUXBHJHDSA-N
DM9RHXC	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM9RHXC	DE	Discovery agent

DMWK0Z6	ID	DMWK0Z6
DMWK0Z6	DN	FGGFTGARKSARKRKRK
DMWK0Z6	HS	Investigative
DMWK0Z6	PC	91934904
DMWK0Z6	MW	1951.3
DMWK0Z6	FM	C85H147N33O20
DMWK0Z6	IC	InChI=1S/C85H147N33O20/c1-48(106-65(122)46-105-80(136)67(50(3)120)118-78(134)62(43-52-24-8-5-9-25-52)108-66(123)45-103-64(121)44-104-70(126)53(90)42-51-22-6-4-7-23-51)68(124)109-57(30-18-38-99-82(91)92)73(129)113-56(28-12-16-36-88)77(133)117-63(47-119)79(135)107-49(2)69(125)110-58(31-19-39-100-83(93)94)74(130)111-54(26-10-14-34-86)71(127)114-59(32-20-40-101-84(95)96)75(131)112-55(27-11-15-35-87)72(128)115-60(33-21-41-102-85(97)98)76(132)116-61(81(137)138)29-13-17-37-89/h4-9,22-25,48-50,53-63,67,119-120H,10-21,26-47,86-90H2,1-3H3,(H,103,121)(H,104,126)(H,105,136)(H,106,122)(H,107,135)(H,108,123)(H,109,124)(H,110,125)(H,111,130)(H,112,131)(H,113,129)(H,114,127)(H,115,128)(H,116,132)(H,117,133)(H,118,134)(H,137,138)(H4,91,92,99)(H4,93,94,100)(H4,95,96,101)(H4,97,98,102)/t48-,49-,50+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,67-/m0/s1
DMWK0Z6	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMWK0Z6	IK	UJJPEJMTOWTFSE-VDORGCAASA-N
DMWK0Z6	IU	(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoic acid
DMWK0Z6	DE	Discovery agent

DMDMT5U	ID	DMDMT5U
DMDMT5U	DN	FGGFTGARKSARKRRNQ
DMDMT5U	HS	Investigative
DMDMT5U	PC	91934906
DMDMT5U	MW	1937.2
DMDMT5U	FM	C82H137N33O22
DMDMT5U	IC	InChI=1S/C82H137N33O22/c1-43(103-62(121)41-102-77(135)64(45(3)117)115-75(133)56(37-47-20-8-5-9-21-47)105-63(122)40-100-61(120)39-101-67(125)48(85)36-46-18-6-4-7-19-46)65(123)106-51(24-14-32-96-79(88)89)69(127)109-50(23-11-13-31-84)73(131)114-58(42-116)76(134)104-44(2)66(124)107-52(25-15-33-97-80(90)91)70(128)108-49(22-10-12-30-83)68(126)110-53(26-16-34-98-81(92)93)71(129)111-54(27-17-35-99-82(94)95)72(130)113-57(38-60(87)119)74(132)112-55(78(136)137)28-29-59(86)118/h4-9,18-21,43-45,48-58,64,116-117H,10-17,22-42,83-85H2,1-3H3,(H2,86,118)(H2,87,119)(H,100,120)(H,101,125)(H,102,135)(H,103,121)(H,104,134)(H,105,122)(H,106,123)(H,107,124)(H,108,128)(H,109,127)(H,110,126)(H,111,129)(H,112,132)(H,113,130)(H,114,131)(H,115,133)(H,136,137)(H4,88,89,96)(H4,90,91,97)(H4,92,93,98)(H4,94,95,99)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMDMT5U	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMDMT5U	IK	DJPBHOCLMOWQPP-KMOVSZGYSA-N
DMDMT5U	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMDMT5U	DE	Discovery agent

DMEGW7F	ID	DMEGW7F
DMEGW7F	DN	FGGFTGARKSARKRWNQ
DMEGW7F	HS	Investigative
DMEGW7F	PC	91934381
DMEGW7F	MW	1967.2
DMEGW7F	FM	C87H135N31O22
DMEGW7F	IC	InChI=1S/C87H135N31O22/c1-46(106-68(124)44-105-83(138)70(48(3)120)118-81(136)61(38-50-21-8-5-9-22-50)108-69(125)43-103-67(123)42-104-73(128)53(90)37-49-19-6-4-7-20-49)71(126)109-57(27-16-34-99-85(93)94)75(130)112-56(26-13-15-33-89)78(133)117-64(45-119)82(137)107-47(2)72(127)110-58(28-17-35-100-86(95)96)76(131)111-55(25-12-14-32-88)74(129)113-59(29-18-36-101-87(97)98)77(132)115-62(39-51-41-102-54-24-11-10-23-52(51)54)79(134)116-63(40-66(92)122)80(135)114-60(84(139)140)30-31-65(91)121/h4-11,19-24,41,46-48,53,55-64,70,102,119-120H,12-18,25-40,42-45,88-90H2,1-3H3,(H2,91,121)(H2,92,122)(H,103,123)(H,104,128)(H,105,138)(H,106,124)(H,107,137)(H,108,125)(H,109,126)(H,110,127)(H,111,131)(H,112,130)(H,113,129)(H,114,135)(H,115,132)(H,116,134)(H,117,133)(H,118,136)(H,139,140)(H4,93,94,99)(H4,95,96,100)(H4,97,98,101)/t46-,47-,48+,53-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,70-/m0/s1
DMEGW7F	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMEGW7F	IK	HCNFEYAQXGBVLO-UWALROLSSA-N
DMEGW7F	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMEGW7F	DE	Discovery agent

DM1QTN5	ID	DM1QTN5
DM1QTN5	DN	FGGFTGARKSARKVANQ
DM1QTN5	HS	Investigative
DM1QTN5	PC	91934911
DM1QTN5	MW	1795
DM1QTN5	FM	C78H127N27O22
DM1QTN5	IC	InChI=1S/C78H127N27O22/c1-40(2)61(75(125)95-43(5)65(115)102-54(35-57(83)109)71(121)101-52(76(126)127)27-28-56(82)108)104-70(120)49(24-14-16-30-80)100-68(118)51(26-18-32-89-78(86)87)98-64(114)42(4)94-73(123)55(39-106)103-69(119)48(23-13-15-29-79)99-67(117)50(25-17-31-88-77(84)85)97-63(113)41(3)93-59(111)38-92-74(124)62(44(6)107)105-72(122)53(34-46-21-11-8-12-22-46)96-60(112)37-90-58(110)36-91-66(116)47(81)33-45-19-9-7-10-20-45/h7-12,19-22,40-44,47-55,61-62,106-107H,13-18,23-39,79-81H2,1-6H3,(H2,82,108)(H2,83,109)(H,90,110)(H,91,116)(H,92,124)(H,93,111)(H,94,123)(H,95,125)(H,96,112)(H,97,113)(H,98,114)(H,99,117)(H,100,118)(H,101,121)(H,102,115)(H,103,119)(H,104,120)(H,105,122)(H,126,127)(H4,84,85,88)(H4,86,87,89)/t41-,42-,43-,44+,47-,48-,49-,50-,51-,52-,53-,54-,55-,61-,62-/m0/s1
DM1QTN5	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM1QTN5	IK	PLDGJAGJBNNRQP-OTYLYHRBSA-N
DM1QTN5	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM1QTN5	DE	Discovery agent

DMM17AO	ID	DMM17AO
DMM17AO	DN	FGGFTGARKSARKWANQ
DMM17AO	HS	Investigative
DMM17AO	PC	91934914
DMM17AO	MW	1882.1
DMM17AO	FM	C84H128N28O22
DMM17AO	IC	InChI=1S/C84H128N28O22/c1-44(100-66(118)42-99-81(132)68(47(4)114)112-79(130)59(36-49-21-9-6-10-22-49)103-67(119)41-97-65(117)40-98-72(123)52(87)35-48-19-7-5-8-20-48)69(120)104-56(27-17-33-94-83(90)91)73(124)107-55(26-14-16-32-86)76(127)111-62(43-113)80(131)102-45(2)70(121)105-57(28-18-34-95-84(92)93)74(125)106-54(25-13-15-31-85)75(126)110-60(37-50-39-96-53-24-12-11-23-51(50)53)77(128)101-46(3)71(122)109-61(38-64(89)116)78(129)108-58(82(133)134)29-30-63(88)115/h5-12,19-24,39,44-47,52,54-62,68,96,113-114H,13-18,25-38,40-43,85-87H2,1-4H3,(H2,88,115)(H2,89,116)(H,97,117)(H,98,123)(H,99,132)(H,100,118)(H,101,128)(H,102,131)(H,103,119)(H,104,120)(H,105,121)(H,106,125)(H,107,124)(H,108,129)(H,109,122)(H,110,126)(H,111,127)(H,112,130)(H,133,134)(H4,90,91,94)(H4,92,93,95)/t44-,45-,46-,47+,52-,54-,55-,56-,57-,58-,59-,60-,61-,62-,68-/m0/s1
DMM17AO	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMM17AO	IK	MRPJNGQFWWZSQY-FMCSKRGOSA-N
DMM17AO	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMM17AO	DE	Discovery agent

DM1YN0F	ID	DM1YN0F
DM1YN0F	DN	FGGFTGARKSARKWKNQ
DM1YN0F	HS	Investigative
DM1YN0F	PC	91934380
DM1YN0F	MW	1939.2
DM1YN0F	FM	C87H135N29O22
DM1YN0F	IC	InChI=1S/C87H135N29O22/c1-47(104-69(122)45-103-84(136)71(49(3)118)116-82(134)62(39-51-22-8-5-9-23-51)106-70(123)44-101-68(121)43-102-74(126)54(91)38-50-20-6-4-7-21-50)72(124)107-59(29-18-36-98-86(94)95)75(127)110-58(28-14-17-35-90)79(131)115-65(46-117)83(135)105-48(2)73(125)108-60(30-19-37-99-87(96)97)76(128)109-56(26-12-15-33-88)77(129)113-63(40-52-42-100-55-25-11-10-24-53(52)55)80(132)111-57(27-13-16-34-89)78(130)114-64(41-67(93)120)81(133)112-61(85(137)138)31-32-66(92)119/h4-11,20-25,42,47-49,54,56-65,71,100,117-118H,12-19,26-41,43-46,88-91H2,1-3H3,(H2,92,119)(H2,93,120)(H,101,121)(H,102,126)(H,103,136)(H,104,122)(H,105,135)(H,106,123)(H,107,124)(H,108,125)(H,109,128)(H,110,127)(H,111,132)(H,112,133)(H,113,129)(H,114,130)(H,115,131)(H,116,134)(H,137,138)(H4,94,95,98)(H4,96,97,99)/t47-,48-,49+,54-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,71-/m0/s1
DM1YN0F	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DM1YN0F	IK	ZXXWZZVFRTXDSC-PBUARHPHSA-N
DM1YN0F	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM1YN0F	DE	Discovery agent

DMRLZKJ	ID	DMRLZKJ
DMRLZKJ	DN	FGGFTGARKSARKWRNQ
DMRLZKJ	HS	Investigative
DMRLZKJ	PC	91934379
DMRLZKJ	MW	1967.2
DMRLZKJ	FM	C87H135N31O22
DMRLZKJ	IC	InChI=1S/C87H135N31O22/c1-46(106-68(124)44-105-83(138)70(48(3)120)118-81(136)61(38-50-21-8-5-9-22-50)108-69(125)43-103-67(123)42-104-73(128)53(90)37-49-19-6-4-7-20-49)71(126)109-57(27-16-34-99-85(93)94)74(129)112-56(26-13-15-33-89)78(133)117-64(45-119)82(137)107-47(2)72(127)110-58(28-17-35-100-86(95)96)75(130)111-55(25-12-14-32-88)76(131)115-62(39-51-41-102-54-24-11-10-23-52(51)54)79(134)113-59(29-18-36-101-87(97)98)77(132)116-63(40-66(92)122)80(135)114-60(84(139)140)30-31-65(91)121/h4-11,19-24,41,46-48,53,55-64,70,102,119-120H,12-18,25-40,42-45,88-90H2,1-3H3,(H2,91,121)(H2,92,122)(H,103,123)(H,104,128)(H,105,138)(H,106,124)(H,107,137)(H,108,125)(H,109,126)(H,110,127)(H,111,130)(H,112,129)(H,113,134)(H,114,135)(H,115,131)(H,116,132)(H,117,133)(H,118,136)(H,139,140)(H4,93,94,99)(H4,95,96,100)(H4,97,98,101)/t46-,47-,48+,53-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,70-/m0/s1
DMRLZKJ	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMRLZKJ	IK	KUDFNAMEWORXOZ-UWALROLSSA-N
DMRLZKJ	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMRLZKJ	DE	Discovery agent

DM5FRXN	ID	DM5FRXN
DM5FRXN	DN	FGGFTGARKSARKYANQ
DM5FRXN	HS	Investigative
DM5FRXN	PC	91934913
DM5FRXN	MW	1859.1
DM5FRXN	FM	C82H127N27O23
DM5FRXN	IC	InChI=1S/C82H127N27O23/c1-43(97-64(116)41-96-79(130)66(46(4)111)109-77(128)57(36-48-19-9-6-10-20-48)100-65(117)40-94-63(115)39-95-70(121)51(85)35-47-17-7-5-8-18-47)67(118)101-54(23-15-33-92-81(88)89)71(122)104-53(22-12-14-32-84)74(125)108-60(42-110)78(129)99-44(2)68(119)102-55(24-16-34-93-82(90)91)72(123)103-52(21-11-13-31-83)73(124)107-58(37-49-25-27-50(112)28-26-49)75(126)98-45(3)69(120)106-59(38-62(87)114)76(127)105-56(80(131)132)29-30-61(86)113/h5-10,17-20,25-28,43-46,51-60,66,110-112H,11-16,21-24,29-42,83-85H2,1-4H3,(H2,86,113)(H2,87,114)(H,94,115)(H,95,121)(H,96,130)(H,97,116)(H,98,126)(H,99,129)(H,100,117)(H,101,118)(H,102,119)(H,103,123)(H,104,122)(H,105,127)(H,106,120)(H,107,124)(H,108,125)(H,109,128)(H,131,132)(H4,88,89,92)(H4,90,91,93)/t43-,44-,45-,46+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DM5FRXN	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DM5FRXN	IK	NTZGMAAQXGNGFH-VDVVPONDSA-N
DM5FRXN	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM5FRXN	DE	Discovery agent

DMV3ZF1	ID	DMV3ZF1
DMV3ZF1	DN	F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-CONH2
DMV3ZF1	HS	Investigative
DMV3ZF1	PC	91932089
DMV3ZF1	MW	1822.1
DMV3ZF1	FM	C80H132N28O21
DMV3ZF1	IC	InChI=1S/C80H132N28O21/c1-42(2)34-55(74(125)97-44(4)67(118)104-57(37-60(85)112)75(126)99-50(65(86)116)28-29-59(84)111)105-72(123)51(24-14-16-30-81)102-71(122)54(27-19-33-92-80(89)90)101-68(119)45(5)108(7)78(129)58(41-109)106-73(124)52(25-15-17-31-82)103-70(121)53(26-18-32-91-79(87)88)100-66(117)43(3)96-62(114)40-95-77(128)64(46(6)110)107-76(127)56(36-48-22-12-9-13-23-48)98-63(115)39-93-61(113)38-94-69(120)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,109-110H,14-19,24-41,81-83H2,1-7H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,120)(H,95,128)(H,96,114)(H,97,125)(H,98,115)(H,99,126)(H,100,117)(H,101,119)(H,102,122)(H,103,121)(H,104,118)(H,105,123)(H,106,124)(H,107,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMV3ZF1	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMV3ZF1	IK	JRFVGOSSKZWBRX-FKPOJLNCSA-N
DMV3ZF1	IU	(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]-methylamino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMV3ZF1	DE	Discovery agent

DMZI6RD	ID	DMZI6RD
DMZI6RD	DN	F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-COOH
DMZI6RD	HS	Investigative
DMZI6RD	PC	91932092
DMZI6RD	MW	1823.1
DMZI6RD	FM	C80H131N27O22
DMZI6RD	IC	InChI=1S/C80H131N27O22/c1-42(2)34-55(73(123)96-44(4)66(116)103-57(37-60(85)111)74(124)102-54(78(128)129)28-29-59(84)110)104-71(121)50(24-14-16-30-81)100-70(120)53(27-19-33-91-80(88)89)99-67(117)45(5)107(7)77(127)58(41-108)105-72(122)51(25-15-17-31-82)101-69(119)52(26-18-32-90-79(86)87)98-65(115)43(3)95-62(113)40-94-76(126)64(46(6)109)106-75(125)56(36-48-22-12-9-13-23-48)97-63(114)39-92-61(112)38-93-68(118)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,108-109H,14-19,24-41,81-83H2,1-7H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,118)(H,94,126)(H,95,113)(H,96,123)(H,97,114)(H,98,115)(H,99,117)(H,100,120)(H,101,119)(H,102,124)(H,103,116)(H,104,121)(H,105,122)(H,106,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMZI6RD	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMZI6RD	IK	MJZVYHXPHQEPQQ-FKPOJLNCSA-N
DMZI6RD	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]-methylamino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMZI6RD	DE	Discovery agent

DM2PYE7	ID	DM2PYE7
DM2PYE7	DN	FGGFTGCRKSARKC
DM2PYE7	HS	Investigative
DM2PYE7	DE	Discovery agent

DMQX2GK	ID	DMQX2GK
DMQX2GK	DN	FGGFTGCRKSCRK
DMQX2GK	HS	Investigative
DMQX2GK	DE	Discovery agent

DMPHIBZ	ID	DMPHIBZ
DMPHIBZ	DN	F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-CONH2
DMPHIBZ	HS	Investigative
DMPHIBZ	PC	91932090
DMPHIBZ	MW	1822.1
DMPHIBZ	FM	C80H132N28O21
DMPHIBZ	IC	InChI=1S/C80H132N28O21/c1-42(2)34-55(74(125)96-44(4)67(118)104-57(37-60(85)112)75(126)99-50(65(86)116)28-29-59(84)111)105-72(123)51(24-14-16-30-81)102-70(121)53(26-18-32-91-79(87)88)100-66(117)43(3)97-77(128)58(41-109)106-73(124)52(25-15-17-31-82)103-71(122)54(27-19-33-92-80(89)90)101-68(119)45(5)108(7)63(115)40-95-78(129)64(46(6)110)107-76(127)56(36-48-22-12-9-13-23-48)98-62(114)39-93-61(113)38-94-69(120)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,109-110H,14-19,24-41,81-83H2,1-7H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,120)(H,95,129)(H,96,125)(H,97,128)(H,98,114)(H,99,126)(H,100,117)(H,101,119)(H,102,121)(H,103,122)(H,104,118)(H,105,123)(H,106,124)(H,107,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMPHIBZ	CS	C[C@H]([C@@H](C(=O)NCC(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMPHIBZ	IK	JKAMREUJRZWECK-FKPOJLNCSA-N
DMPHIBZ	IU	(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]-methylamino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMPHIBZ	DE	Discovery agent

DMXH2D8	ID	DMXH2D8
DMXH2D8	DN	F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-COOH
DMXH2D8	HS	Investigative
DMXH2D8	PC	91932093
DMXH2D8	MW	1823.1
DMXH2D8	FM	C80H131N27O22
DMXH2D8	IC	InChI=1S/C80H131N27O22/c1-42(2)34-55(73(123)95-44(4)66(116)103-57(37-60(85)111)74(124)102-54(78(128)129)28-29-59(84)110)104-71(121)50(24-14-16-30-81)100-69(119)52(26-18-32-90-79(86)87)98-65(115)43(3)96-76(126)58(41-108)105-72(122)51(25-15-17-31-82)101-70(120)53(27-19-33-91-80(88)89)99-67(117)45(5)107(7)63(114)40-94-77(127)64(46(6)109)106-75(125)56(36-48-22-12-9-13-23-48)97-62(113)39-92-61(112)38-93-68(118)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,108-109H,14-19,24-41,81-83H2,1-7H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,118)(H,94,127)(H,95,123)(H,96,126)(H,97,113)(H,98,115)(H,99,117)(H,100,119)(H,101,120)(H,102,124)(H,103,116)(H,104,121)(H,105,122)(H,106,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMXH2D8	CS	C[C@H]([C@@H](C(=O)NCC(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMXH2D8	IK	AZDMRQCLZWWKEK-FKPOJLNCSA-N
DMXH2D8	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]-methylamino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMXH2D8	DE	Discovery agent

DMD9UQN	ID	DMD9UQN
DMD9UQN	DN	FGGFTRKRKSARKLANQ
DMD9UQN	HS	Investigative
DMD9UQN	PC	91934901
DMD9UQN	MW	1965.3
DMD9UQN	FM	C86H145N31O22
DMD9UQN	IC	InChI=1S/C86H145N31O22/c1-46(2)39-60(78(133)104-48(4)70(125)114-62(42-65(92)121)79(134)113-59(83(138)139)31-32-64(91)120)115-76(131)54(26-13-16-34-88)109-73(128)56(28-18-36-99-84(93)94)107-69(124)47(3)105-81(136)63(45-118)116-77(132)55(27-14-17-35-89)110-74(129)57(29-19-37-100-85(95)96)111-72(127)53(25-12-15-33-87)108-75(130)58(30-20-38-101-86(97)98)112-82(137)68(49(5)119)117-80(135)61(41-51-23-10-7-11-24-51)106-67(123)44-102-66(122)43-103-71(126)52(90)40-50-21-8-6-9-22-50/h6-11,21-24,46-49,52-63,68,118-119H,12-20,25-45,87-90H2,1-5H3,(H2,91,120)(H2,92,121)(H,102,122)(H,103,126)(H,104,133)(H,105,136)(H,106,123)(H,107,124)(H,108,130)(H,109,128)(H,110,129)(H,111,127)(H,112,137)(H,113,134)(H,114,125)(H,115,131)(H,116,132)(H,117,135)(H,138,139)(H4,93,94,99)(H4,95,96,100)(H4,97,98,101)/t47-,48-,49+,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,68-/m0/s1
DMD9UQN	CS	C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMD9UQN	IK	SNTZLYOXEWYFBE-UTPVZXCMSA-N
DMD9UQN	IU	(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMD9UQN	DE	Discovery agent

DM4T5DY	ID	DM4T5DY
DM4T5DY	DN	FGIN-1-27
DM4T5DY	HS	Investigative
DM4T5DY	SN	FGIN-1-27; 142720-24-9; N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide; Fgin 1 27; Fgin 1-27; N,N-Di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide; CHEMBL63154; 1H-Indole-3-acetamide, 2-(4-fluorophenyl)-N,N-dihexyl-; 2-(2-(4-fluorophenyl)-1H-indol-3-yl)-N,N-dihexylacetamide; 2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide; SR-01000075838; Tocris-0658; Lopac-D-8555; Biomol-NT_000279; Lopac0_000453; MLS002153299; SCHEMBL1229718; BPBio1_001277; AC1L313J; FGIN1-27; CHEBI:92171; CTK8E7869; DTXSID90162141
DM4T5DY	DT	Small molecular drug
DM4T5DY	PC	132496
DM4T5DY	MW	436.6
DM4T5DY	FM	C28H37FN2O
DM4T5DY	IC	InChI=1S/C28H37FN2O/c1-3-5-7-11-19-31(20-12-8-6-4-2)27(32)21-25-24-13-9-10-14-26(24)30-28(25)22-15-17-23(29)18-16-22/h9-10,13-18,30H,3-8,11-12,19-21H2,1-2H3
DM4T5DY	CS	CCCCCCN(CCCCCC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)F
DM4T5DY	IK	VUWXAQFLTSBUDB-UHFFFAOYSA-N
DM4T5DY	IU	2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide
DM4T5DY	CA	CAS 142720-24-9
DM4T5DY	CB	CHEBI:92171
DM4T5DY	DE	Discovery agent

DMH7LDX	ID	DMH7LDX
DMH7LDX	DN	FHT-2107
DMH7LDX	HS	Investigative
DMH7LDX	SN	EGFR-targeting siRNA agent, ForHumanTech
DMH7LDX	CP	ForHumanTech Co Ltd
DMH7LDX	DT	siRNA drug
DMH7LDX	DE	Discovery agent

DMFNTMY	ID	DMFNTMY
DMFNTMY	DN	Fibrates
DMFNTMY	HS	Investigative
DMFNTMY	SN	clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c
DMFNTMY	DT	Small molecular drug
DMFNTMY	PC	2797
DMFNTMY	MW	214.64
DMFNTMY	FM	C10H11ClO3
DMFNTMY	IC	InChI=1S/C10H11ClO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)
DMFNTMY	CS	CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl
DMFNTMY	IK	TXCGAZHTZHNUAI-UHFFFAOYSA-N
DMFNTMY	IU	2-(4-chlorophenoxy)-2-methylpropanoic acid
DMFNTMY	CA	CAS 882-09-7
DMFNTMY	CB	CHEBI:34648
DMFNTMY	DE	Dyslipidemia

DMUX702	ID	DMUX702
DMUX702	DN	Fibronectin extra domain A
DMUX702	HS	Investigative
DMUX702	SN	Fibronectin extra domain A (vaccine adjuvant); Fibronectin extra domain A (vaccine adjuvant), Digna Biotech; TLR-4 antagonist (protein recombinant, vaccination), Digna Biotech/University of Navarra
DMUX702	CP	University of Navarra
DMUX702	DT	Vaccine
DMUX702	DE	Discovery agent

DMETVLB	ID	DMETVLB
DMETVLB	DN	Fidarestat(Stereoisomer)
DMETVLB	HS	Investigative
DMETVLB	SN	FIDARESTAT(STEREOISOMER); CHEMBL84060; (2R,4S)-2-AMINOFORMYL-6-FLUORO-SPIRO[CHROMAN-4,4'-IMIDAZOLIDINE]-2',5'-DIONE; Fir; AC1L9MSJ; (R,S)-FIDARESTAT; SCHEMBL48828; ZINC5704; BDBM50089423; (2R,4S)-6-Fluoro-2',5'-dioxospiro[2H-1-benzopyran-4(3H),4'-imidazolidine]-2-carboxamide; (2R,4S)-6-fluoro-2',5'-dioxo-2,3-dihydrospiro[chromene-4,4'-imidazolidine]-2-carboxamide; (2R,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMETVLB	DT	Small molecular drug
DMETVLB	PC	449157
DMETVLB	MW	279.22
DMETVLB	FM	C12H10FN3O4
DMETVLB	IC	InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12+/m0/s1
DMETVLB	CS	C1[C@H](OC2=C([C@@]13C(=O)NC(=O)N3)C=C(C=C2)F)C(=O)N
DMETVLB	IK	WAAPEIZFCHNLKK-QPUJVOFHSA-N
DMETVLB	IU	(2S,4R)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMETVLB	DE	Discovery agent

DM29TVC	ID	DM29TVC
DM29TVC	DN	FIG 1
DM29TVC	HS	Investigative
DM29TVC	SN	CHEMBL428429; FIG 1; SCHEMBL5095865; BDBM50239276
DM29TVC	DT	Small molecular drug
DM29TVC	PC	10193044
DM29TVC	MW	293.4
DM29TVC	FM	C19H23N3
DM29TVC	IC	InChI=1S/C19H23N3/c1-22-17(16-5-3-2-4-6-16)20-21-18(22)19-10-13-7-14(11-19)9-15(8-13)12-19/h2-6,13-15H,7-12H2,1H3
DM29TVC	CS	CN1C(=NN=C1C23CC4CC(C2)CC(C4)C3)C5=CC=CC=C5
DM29TVC	IK	SPLKSRDVCTUAGF-UHFFFAOYSA-N
DM29TVC	IU	3-(1-adamantyl)-4-methyl-5-phenyl-1,2,4-triazole
DM29TVC	DE	Discovery agent

DMP6GNY	ID	DMP6GNY
DMP6GNY	DN	Firocoxib
DMP6GNY	HS	Investigative
DMP6GNY	SN	Firocoxib; 189954-96-9; Equioxx; Previcox; Equixx; Librens; UNII-Y6V2W4S4WT; Y6V2W4S4WT; CHEMBL69998; CHEBI:76136; 3-(CYCLOPROPYLMETHOXY)-5,5-DIMETHYL-4-[4-(METHYLSULFONYL)PHENYL]-2(5H)-FURANONE; ML 1785713; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one; 3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one; Firocoxib [USAN:INN]; firocoxibum; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one; Firocoxib (USAN/INN); AC1L4LLA; ML-1,785,713
DMP6GNY	DT	Small molecular drug
DMP6GNY	PC	208910
DMP6GNY	MW	336.4
DMP6GNY	FM	C17H20O5S
DMP6GNY	IC	InChI=1S/C17H20O5S/c1-17(2)14(12-6-8-13(9-7-12)23(3,19)20)15(16(18)22-17)21-10-11-4-5-11/h6-9,11H,4-5,10H2,1-3H3
DMP6GNY	CS	CC1(C(=C(C(=O)O1)OCC2CC2)C3=CC=C(C=C3)S(=O)(=O)C)C
DMP6GNY	IK	FULAPETWGIGNMT-UHFFFAOYSA-N
DMP6GNY	IU	3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one
DMP6GNY	CA	CAS 189954-96-9
DMP6GNY	CB	CHEBI:76136
DMP6GNY	DE	Discovery agent

DMW2VOX	ID	DMW2VOX
DMW2VOX	DN	FITC-LMNNAEHINQFYMFI
DMW2VOX	HS	Investigative
DMW2VOX	PC	44577018
DMW2VOX	MW	2258.6
DMW2VOX	FM	C107H136N22O27S3
DMW2VOX	IC	InChI=1S/C107H136N22O27S3/c1-10-55(5)88(103(151)125-79(51-85(111)135)99(147)116-68(35-37-82(108)132)91(139)119-73(44-58-21-14-12-15-22-58)98(146)121-74(46-60-29-31-62(130)32-30-60)97(145)118-70(39-41-158-8)93(141)120-75(45-59-23-16-13-17-24-59)101(149)129-89(104(152)153)56(6)11-2)128-102(150)76(47-61-52-112-53-113-61)122-92(140)69(36-38-86(136)137)115-90(138)57(7)114-95(143)77(49-83(109)133)124-100(148)78(50-84(110)134)123-94(142)71(40-42-159-9)117-96(144)72(43-54(3)4)127-106(157)126-67-27-20-26-66-87(67)105(154)156-107(66)64-25-18-19-28-80(64)155-81-48-63(131)33-34-65(81)107/h12-34,48,52-57,68-79,88-89,130-131H,10-11,35-47,49-51H2,1-9H3,(H2,108,132)(H2,109,133)(H2,110,134)(H2,111,135)(H,112,113)(H,114,143)(H,115,138)(H,116,147)(H,117,144)(H,118,145)(H,119,139)(H,120,141)(H,121,146)(H,122,140)(H,123,142)(H,124,148)(H,125,151)(H,128,150)(H,129,149)(H,136,137)(H,152,153)(H2,126,127,157)/t55-,56-,57-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,88?,89?,107?/m0/s1
DMW2VOX	CS	CC[C@H](C)C(C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NC([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=S)NC5=CC=CC6=C5C(=O)OC67C8=C(C=C(C=C8)O)OC9=CC=CC=C79
DMW2VOX	IK	IHNJXISEZYRUDB-YDQBPDQJSA-N
DMW2VOX	IU	(3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[(3'-hydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-4-yl)carbamothioylamino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoic acid
DMW2VOX	DE	Discovery agent

DM9K834	ID	DM9K834
DM9K834	DN	FKB-001
DM9K834	HS	Investigative
DM9K834	SN	FKB-001; 1-[2,2-DIFLUORO-2-(3,4,5-TRIMETHOXY-PHENYL)-ACETYL]-PIPERIDINE-2-CARBOXYLIC ACID 4-PHENYL-1-(3-PYRIDIN-3-YL-PROPYL)-BUTYL ESTER; (S)-4-phenyl-1-[3-(3-pyridyl)propyl]butyl N-[difluoro(3,4,5-trimethoxy)acetyl]-L-pipecolate; (1S)-4-phenyl-1-(3-pyridin-3-ylpropyl)butyl (2S)-1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate; (4S)-1-phenyl-7-(pyridin-3-yl)heptan-4-yl (2S)-1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate; 1j4r; AC1L9JNT; CHEBI:39485; DB02888
DM9K834	DT	Small molecular drug
DM9K834	PC	446414
DM9K834	MW	624.7
DM9K834	FM	C35H42F2N2O6
DM9K834	IC	InChI=1S/C35H42F2N2O6/c1-42-30-22-27(23-31(43-2)32(30)44-3)35(36,37)34(41)39-21-8-7-19-29(39)33(40)45-28(17-9-14-25-12-5-4-6-13-25)18-10-15-26-16-11-20-38-24-26/h4-6,11-13,16,20,22-24,28-29H,7-10,14-15,17-19,21H2,1-3H3/t28-,29-/m0/s1
DM9K834	CS	COC1=CC(=CC(=C1OC)OC)C(C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CCCC3=CC=CC=C3)CCCC4=CN=CC=C4)(F)F
DM9K834	IK	NBYCDVVSYOMFMS-VMPREFPWSA-N
DM9K834	IU	[(4S)-1-phenyl-7-pyridin-3-ylheptan-4-yl] (2S)-1-[2,2-difluoro-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
DM9K834	CA	CAS 251909-04-3
DM9K834	CB	CHEBI:39485
DM9K834	DE	Discovery agent

DMO7U62	ID	DMO7U62
DMO7U62	DN	FL104
DMO7U62	HS	Investigative
DMO7U62	SN	885672-81-1; CHEMBL583981; [1,1'-Biphenyl]-4-carboxamide,N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-; FL104; CHEMBL204989; GTPL3501; SCHEMBL14204301; BDBM50414782; KB-63706
DMO7U62	DT	Small molecular drug
DMO7U62	PC	11663047
DMO7U62	MW	392.9
DMO7U62	FM	C24H25ClN2O
DMO7U62	IC	InChI=1S/C24H25ClN2O/c1-27(2)17-16-23(20-12-14-22(25)15-13-20)26-24(28)21-10-8-19(9-11-21)18-6-4-3-5-7-18/h3-15,23H,16-17H2,1-2H3,(H,26,28)
DMO7U62	CS	CN(C)CCC(C1=CC=C(C=C1)Cl)NC(=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMO7U62	IK	JXJCJZNVWYQHIF-UHFFFAOYSA-N
DMO7U62	IU	N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-4-phenylbenzamide
DMO7U62	DE	Discovery agent

DMNWIYM	ID	DMNWIYM
DMNWIYM	DN	Flavanone
DMNWIYM	HS	Investigative
DMNWIYM	SN	FLAVANONE; 487-26-3; 2-Phenylchroman-4-one; 2,3-Dihydroflavone; 2-Phenyl-4-chromanone; 4-Flavanone; 2,3-Dihydro-2-phenyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-phenyl-; 2-Phenyl-2,3-dihydro-4H-chromen-4-one; NSC-50393; 2,3-Dihydro-2-phenyl-4H-benzopyran-4-one; 2-Phenyl-chroman-4-one; 2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one; EINECS 207-654-8; NSC 50393; BRN 0183227; MLS002667384; CHEMBL274318; CHEBI:5070; ZONYXWQDUYMKFB-UHFFFAOYSA-N; NSC50393; 2-phenyl-2,3-dihydrochromen-4-one; MFCD00006841; (-)-Flavanone
DMNWIYM	DT	Small molecular drug
DMNWIYM	PC	10251
DMNWIYM	MW	224.25
DMNWIYM	FM	C15H12O2
DMNWIYM	IC	InChI=1S/C15H12O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-9,15H,10H2
DMNWIYM	CS	C1C(OC2=CC=CC=C2C1=O)C3=CC=CC=C3
DMNWIYM	IK	ZONYXWQDUYMKFB-UHFFFAOYSA-N
DMNWIYM	IU	2-phenyl-2,3-dihydrochromen-4-one
DMNWIYM	CA	CAS 487-26-3
DMNWIYM	CB	CHEBI:5070
DMNWIYM	DE	Discovery agent

DM5S4GK	ID	DM5S4GK
DM5S4GK	DN	Flavin-Adenine Dinucleotide
DM5S4GK	HS	Investigative
DM5S4GK	SN	flavin adenine dinucleotide; Flavin-adenine dinucleotide; 146-14-5; FAD; flavitan; Flavine-adenine dinucleotide; Flanin F; UNII-ZC44YTI8KK; Flamitajin B; Adenine-flavin dinucleotide; Adenine-flavine dinucleotide; ZC44YTI8KK; Flavine adenosine diphosphate; Riboflavin 5'-adenosine diphosphate; Flaziren (free acid); Riboflavin-adenine dinucleotide; Adenine-riboflavin dinucleotide; Adenine-riboflavine dinucleotide; Riboflavine-adenine dinucleotide; Isoalloxazine-adenine dinucleotide; Flavin adenin dinucleotide; CHEBI:16238; flavin a
DM5S4GK	DT	Small molecular drug
DM5S4GK	PC	643975
DM5S4GK	MW	785.5
DM5S4GK	FM	C27H33N9O15P2
DM5S4GK	IC	InChI=1S/C27H33N9O15P2/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H,34,42,43)/t14-,15+,16+,19-,20+,21+,26+/m0/s1
DM5S4GK	CS	CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O
DM5S4GK	IK	VWWQXMAJTJZDQX-UYBVJOGSSA-N
DM5S4GK	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate
DM5S4GK	CA	CAS 146-14-5
DM5S4GK	CB	CHEBI:16238
DM5S4GK	DE	Discovery agent

DMEQH6J	ID	DMEQH6J
DMEQH6J	DN	Flavone
DMEQH6J	HS	Investigative
DMEQH6J	SN	Flavone; FLAVONE; 525-82-6; 2-Phenylchromone; 2-Phenyl-4H-chromen-4-one; 2-Phenyl-4-chromone; Asmacoril; 2-Phenyl-4H-1-benzopyran-4-one; 2-Phenyl-4-benzopyron; 4H-1-Benzopyran-4-one, 2-phenyl-; Chromocor; Cromaril; 2-phenylchromen-4-one; Phenylchromone; 2-Phenyl-chromen-4-one; 2-Phenyl-gamma-benzopyrone; 2-Phenylbenzopyran-4-one; Cromarile; 2-Phenyl-4H-benzopyran-4-one; Flavon; 2-Phenylchrome; UNII-S2V45N7G3B; NSC 19028; 2-Phenyl-4H-chromen-4-on; CCRIS 4288; NSC19028; EINECS 208-383-8; NSC-19028; BRN 0157598
DMEQH6J	DT	Small molecular drug
DMEQH6J	PC	10680
DMEQH6J	MW	222.24
DMEQH6J	FM	C15H10O2
DMEQH6J	IC	InChI=1S/C15H10O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-10H
DMEQH6J	CS	C1=CC=C(C=C1)C2=CC(=O)C3=CC=CC=C3O2
DMEQH6J	IK	VHBFFQKBGNRLFZ-UHFFFAOYSA-N
DMEQH6J	IU	2-phenylchromen-4-one
DMEQH6J	CA	CAS 525-82-6
DMEQH6J	CB	CHEBI:42491
DMEQH6J	DE	Discovery agent

DMQSDM7	ID	DMQSDM7
DMQSDM7	DN	FLUANISONE
DMQSDM7	HS	Investigative
DMQSDM7	SN	Fluanisone; Haloanisone; Haloanison; Sedalande; Fluanison; 1480-19-9; Anti-Pica; Metorin; MD 2028; NSC 170977; R 2028; 2028 MD; R 2167; Fluanisonum [INN-Latin]; Fluanisona [INN-Spanish]; Fluanisone [INN:BAN:DCF]; UNII-1D0W98U1I4; EINECS 216-038-8; BRN 0707524; 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one; CHEMBL58792; 4-(4-(o-Methoxyphenyl)-1-piperazinyl)-p-fluorobutyrophenone; 4'-Fluoro-4-(4-(o-methoxyphenyl)-1-piperazinyl)butyrophenone; C21H25FN2O2; 1D0W98U1I4; Butyrophenone, 4'-fluoro-4-[4-(o-methoxyphenyl
DMQSDM7	DT	Small molecular drug
DMQSDM7	PC	15139
DMQSDM7	MW	356.4
DMQSDM7	FM	C21H25FN2O2
DMQSDM7	IC	InChI=1S/C21H25FN2O2/c1-26-21-7-3-2-5-19(21)24-15-13-23(14-16-24)12-4-6-20(25)17-8-10-18(22)11-9-17/h2-3,5,7-11H,4,6,12-16H2,1H3
DMQSDM7	CS	COC1=CC=CC=C1N2CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F
DMQSDM7	IK	IRYFCWPNDIUQOW-UHFFFAOYSA-N
DMQSDM7	IU	1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one
DMQSDM7	CA	CAS 1480-19-9
DMQSDM7	DE	Discovery agent

DMN8AP0	ID	DMN8AP0
DMN8AP0	DN	flufenamate
DMN8AP0	HS	Investigative
DMN8AP0	SN	Flufenamate; 2-[3-(trifluoromethyl)anilino]benzoate; 2-{[3-(trifluoromethyl)phenyl]amino}benzoate; 2-[[3-(trifluoromethyl)phenyl]amino]benzoate; 2pix; AC1MU9L1; GTPL4191; BDBM85514; CHEBI:520819; NSC_27881; ZB003097; CAS_530-78-9; CJ-00698; 2-(3-(trifluoromethyl)phenylamino)benzoate
DMN8AP0	DT	Small molecular drug
DMN8AP0	PC	3637398
DMN8AP0	MW	280.22
DMN8AP0	FM	C14H9F3NO2-
DMN8AP0	IC	InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)/p-1
DMN8AP0	CS	C1=CC=C(C(=C1)C(=O)[O-])NC2=CC=CC(=C2)C(F)(F)F
DMN8AP0	IK	LPEPZBJOKDYZAD-UHFFFAOYSA-M
DMN8AP0	IU	2-[3-(trifluoromethyl)anilino]benzoate
DMN8AP0	CB	CHEBI:520819
DMN8AP0	DE	Discovery agent

DMW0HOG	ID	DMW0HOG
DMW0HOG	DN	FLUMEZAPINE
DMW0HOG	HS	Investigative
DMW0HOG	DT	Small molecular drug
DMW0HOG	PC	135413528
DMW0HOG	MW	330.4
DMW0HOG	FM	C17H19FN4S
DMW0HOG	IC	InChI=1S/C17H19FN4S/c1-11-9-13-16(22-7-5-21(2)6-8-22)19-15-10-12(18)3-4-14(15)20-17(13)23-11/h3-4,9-10,20H,5-8H2,1-2H3
DMW0HOG	CS	CC1=CC2=C(S1)NC3=C(C=C(C=C3)F)N=C2N4CCN(CC4)C
DMW0HOG	IK	JBHUBOISLBWHAR-UHFFFAOYSA-N
DMW0HOG	IU	7-fluoro-2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
DMW0HOG	CA	CAS 61325-80-2
DMW0HOG	DE	Discovery agent

DMLO9FU	ID	DMLO9FU
DMLO9FU	DN	Fluo-3
DMLO9FU	HS	Investigative
DMLO9FU	SN	121714-13-4; 123632-39-3; 23D4W0B50Y; AC1L2XTQ; AKOS015894386; C11369; CHEBI:5107; CHEMBL509919; CTK8F0793; Fluo 3; Fluo-3; Fluo-3, suitable for fluorescence, ~70%; Fluo-3-AM; Glycine,N-[2-[2-[2-[bis(carboxymethyl)amino]-5-(2,7-dichloro-6-hydroxy-3-oxo-3H-xanthen-9-yl)phenoxy]ethoxy]-4-methylphenyl]-N-(carboxymethyl)-; OZLGRUXZXMRXGP-UHFFFAOYSA-N; SCHEMBL28109; UNII-23D4W0B50Y; ZINC8295051
DMLO9FU	DT	Small molecular drug
DMLO9FU	PC	104978
DMLO9FU	MW	769.537
DMLO9FU	FM	C36H30Cl2N2O13
DMLO9FU	IC	InChI=1S/C36H30Cl2N2O13/c1-18-2-4-24(39(14-32(43)44)15-33(45)46)30(8-18)51-6-7-52-31-9-19(3-5-25(31)40(16-34(47)48)17-35(49)50)36-20-10-22(37)26(41)12-28(20)53-29-13-27(42)23(38)11-21(29)36/h2-5,8-13,41H,6-7,14-17H2,1H3,(H,43,44)(H,45,46)(H,47,48)(H,49,50)
DMLO9FU	CS	CC1=CC(=C(C=C1)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=CC(=C2)C3=C4C=C(C(=O)C=C4OC5=CC(=C(C=C53)Cl)O)Cl)N(CC(=O)O)CC(=O)O
DMLO9FU	IK	OZLGRUXZXMRXGP-UHFFFAOYSA-N
DMLO9FU	IU	2-[2-[2-[2-[bis(carboxymethyl)amino]-5-(2,7-dichloro-3-hydroxy-6-oxoxanthen-9-yl)phenoxy]ethoxy]-N-(carboxymethyl)-4-methylanilino]acetic acid
DMLO9FU	CA	CAS 123632-39-3
DMLO9FU	CB	ChEBI:5107

DMJS62X	ID	DMJS62X
DMJS62X	DN	Fluoro loxoprofen
DMJS62X	HS	Investigative
DMJS62X	SN	fluoro loxoprofen
DMJS62X	DT	Small molecular drug
DMJS62X	PC	49837499
DMJS62X	MW	286.27
DMJS62X	FM	C15H16FNaO3
DMJS62X	IC	InChI=1S/C15H17FO3.Na/c1-9(15(18)19)12-6-5-10(8-13(12)16)7-11-3-2-4-14(11)17;/h5-6,8-9,11H,2-4,7H2,1H3,(H,18,19);/q;+1/p-1
DMJS62X	CS	CC(C1=C(C=C(C=C1)CC2CCCC2=O)F)C(=O)[O-].[Na+]
DMJS62X	IK	ISLFLEUBAXYHSW-UHFFFAOYSA-M
DMJS62X	IU	sodium;2-[2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl]propanoate
DMJS62X	DE	Discovery agent

DM0LR7G	ID	DM0LR7G
DM0LR7G	DN	FLUORO-NEPLANOCIN A
DM0LR7G	HS	Investigative
DM0LR7G	SN	CHEMBL64718; (1s,2r,5s)-5-(6-amino-9h-purin-9-yl)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; FLUORO-NEPLANOCIN A; AC1LAYBA; SCHEMBL9215628; ZINC3801483; BDBM50144206; KB-77273; 5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxymethyl-cyclopent-3-ene-1,2-diol; (1S,2R,5S)-5-(6-aminopurin-9-yl)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
DM0LR7G	DT	Small molecular drug
DM0LR7G	PC	498018
DM0LR7G	MW	281.24
DM0LR7G	FM	C11H12FN5O3
DM0LR7G	IC	InChI=1S/C11H12FN5O3/c12-5-4(1-18)8(19)9(20)7(5)17-3-16-6-10(13)14-2-15-11(6)17/h2-3,7-9,18-20H,1H2,(H2,13,14,15)/t7-,8-,9+/m1/s1
DM0LR7G	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H](C(=C3F)CO)O)O)N
DM0LR7G	IK	RWUXFWACUXDNKY-HLTSFMKQSA-N
DM0LR7G	IU	(1S,2R,5S)-5-(6-aminopurin-9-yl)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
DM0LR7G	DE	Discovery agent

DMIRBYE	ID	DMIRBYE
DMIRBYE	DN	Fluoro-Phosphite Ion
DMIRBYE	HS	Investigative
DMIRBYE	SN	Fluorophosphate; FLUORO-PHOSPHITE ION; Phosphorofluoridate; UNII-4964UZ79MI; 15181-43-8; 4964UZ79MI; Monofluorophosphate(2-); Fluorotrioxophosphate(2-); Fluorophosphate (FPO32-); Monofluorophostae (PO3F2-); fluoridophosphate; Fluorophosphate ion (PFO32-); fluoro-dioxido-oxo-; AC1L22VV; fluoridotrioxidophosphate(2-); Phosphorofluoridate(8CI,9CI); CHEBI:42699; CTK0H6578; DTXSID90164882; 7789-74-4 (calcium salt); 15600-53-0 (barium salt); DB02348; [PFO3](2-); 10163-15-2 (di-hydrochloride salt); 7631-97-2 (unspecified hydrochloride sa
DMIRBYE	DT	Small molecular drug
DMIRBYE	PC	65241
DMIRBYE	MW	97.97
DMIRBYE	FM	FO3P-2
DMIRBYE	IC	InChI=1S/FH2O3P/c1-5(2,3)4/h(H2,2,3,4)/p-2
DMIRBYE	CS	[O-]P(=O)([O-])F
DMIRBYE	IK	DWYMPOCYEZONEA-UHFFFAOYSA-L
DMIRBYE	IU	fluoro-dioxido-oxo-lambda5-phosphane
DMIRBYE	CA	CAS 15181-43-8
DMIRBYE	CB	CHEBI:42699
DMIRBYE	DE	Discovery agent

DMELB5S	ID	DMELB5S
DMELB5S	DN	Flupentixole
DMELB5S	HS	Investigative
DMELB5S	SN	(E)-Flupenthixol; beta-Flupenthixol; trans-flupenthixol; trans-(E)-Flupentixol; trans-Flupentixol; 53772-85-3; EINECS 258-759-0; UNII-895OJP78MJ; Flupentiol; 2709-56-0; 895OJP78MJ; Flupenthixol, Beta; FLUPENTHIXOL, Alpha; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (E)-; (E)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DMELB5S	DT	Small molecular drug
DMELB5S	PC	5281878
DMELB5S	MW	434.5
DMELB5S	FM	C23H25F3N2OS
DMELB5S	IC	InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5+
DMELB5S	CS	C1CN(CCN1CC/C=C/2\\C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DMELB5S	IK	NJMYODHXAKYRHW-BLLMUTORSA-N
DMELB5S	IU	2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DMELB5S	CA	CAS 53772-85-3
DMELB5S	CB	CHEBI:93235
DMELB5S	DE	Discovery agent

DMEGL84	ID	DMEGL84
DMEGL84	DN	FLUPERAMIDE
DMEGL84	HS	Investigative
DMEGL84	SN	Fluperamide; UNII-6H13T09362; 53179-10-5; CHEMBL421665; 6H13T09362; R-18910; Fluperamide [USAN:INN]; AC1L2ZCI; AC1Q4JI5; SCHEMBL120826; ZINC4216287; BDBM50017686; R 18,910; 4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; 4-(4-Chloro-alpha,alpha,alpha-trifluoro-m-tolyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-1-piperidinebutyramide; 4-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide; 1-Piperidinebutanamide, 4-(4-
DMEGL84	DT	Small molecular drug
DMEGL84	PC	131534
DMEGL84	MW	545
DMEGL84	FM	C30H32ClF3N2O2
DMEGL84	IC	InChI=1S/C30H32ClF3N2O2/c1-35(2)27(37)29(22-9-5-3-6-10-22,23-11-7-4-8-12-23)17-20-36-18-15-28(38,16-19-36)24-13-14-26(31)25(21-24)30(32,33)34/h3-14,21,38H,15-20H2,1-2H3
DMEGL84	CS	CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)(C3=CC=CC=C3)C4=CC=CC=C4
DMEGL84	IK	WPYGCZCMGMVGNO-UHFFFAOYSA-N
DMEGL84	IU	4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
DMEGL84	CA	CAS 53179-10-5
DMEGL84	DE	Discovery agent

DM9KIPU	ID	DM9KIPU
DM9KIPU	DN	fluperlapine
DM9KIPU	HS	Investigative
DM9KIPU	SN	C10967
DM9KIPU	DT	Small molecular drug
DM9KIPU	PC	49381
DM9KIPU	MW	309.4
DM9KIPU	FM	C19H20FN3
DM9KIPU	IC	InChI=1S/C19H20FN3/c1-22-8-10-23(11-9-22)19-17-5-3-2-4-14(17)12-15-6-7-16(20)13-18(15)21-19/h2-7,13H,8-12H2,1H3
DM9KIPU	CS	CN1CCN(CC1)C2=NC3=C(CC4=CC=CC=C42)C=CC(=C3)F
DM9KIPU	IK	OBWGMKKHCLHVIE-UHFFFAOYSA-N
DM9KIPU	IU	3-fluoro-6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine
DM9KIPU	CA	CAS 67121-76-0
DM9KIPU	CB	CHEBI:5122
DM9KIPU	DE	Discovery agent

DM496RP	ID	DM496RP
DM496RP	DN	Fluphenazine
DM496RP	HS	Investigative
DM496RP	SN	FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334;  Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)
DM496RP	CP	Bristol-Myers Squibb
DM496RP	TC	Antiviral Agents
DM496RP	DT	Small molecular drug
DM496RP	PC	3372
DM496RP	MW	437.5
DM496RP	FM	C22H26F3N3OS
DM496RP	IC	InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
DM496RP	CS	C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DM496RP	IK	PLDUPXSUYLZYBN-UHFFFAOYSA-N
DM496RP	IU	2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol
DM496RP	CA	CAS 69-23-8
DM496RP	CB	CHEBI:5123
DM496RP	DE	Psychotic disorders; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM9Q2PG	ID	DM9Q2PG
DM9Q2PG	DN	fluprostenol
DM9Q2PG	HS	Investigative
DM9Q2PG	SN	Fluprostenol; travoprost acid; (+)-fluprostenol; Fluprostenolum; travoprost free acid; ICI 81,008; UNII-MEH3MCE8X1; EINECS 255-029-3; 40666-16-8; CHEBI:60782; MEH3MCE8X1; 54276-17-4; NCGC00160386-01; Fluprostenol [INN:BAN]; ICI 81008; Fluprostenolum [INN-Latin]; AL-5848; rac-(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoic acid; (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoic;  ICI 81008; [3H](+)-fluprostenol
DM9Q2PG	DT	Small molecular drug
DM9Q2PG	PC	5311100
DM9Q2PG	MW	458.5
DM9Q2PG	FM	C23H29F3O6
DM9Q2PG	IC	InChI=1S/C23H29F3O6/c24-23(25,26)15-6-5-7-17(12-15)32-14-16(27)10-11-19-18(20(28)13-21(19)29)8-3-1-2-4-9-22(30)31/h1,3,5-7,10-12,16,18-21,27-29H,2,4,8-9,13-14H2,(H,30,31)/b3-1-,11-10+/t16-,18-,19-,20+,21-/m1/s1
DM9Q2PG	CS	C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)C/C=C\\CCCC(=O)O)O
DM9Q2PG	IK	WWSWYXNVCBLWNZ-QIZQQNKQSA-N
DM9Q2PG	IU	(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoic acid
DM9Q2PG	CA	CAS 40666-16-8
DM9Q2PG	CB	CHEBI:60782
DM9Q2PG	DE	Discovery agent

DMUOHVL	ID	DMUOHVL
DMUOHVL	DN	FLUTROLINE
DMUOHVL	HS	Investigative
DMUOHVL	SN	FLUTROLINE; 70801-02-4; CP-36,584; Flutrolinum; Flutrolino; 2H-Pyrido(4,3-b)indole-2-butanol, 8-fluoro-alpha,5-bis(4-fluorophenyl)-1,3,4,5-tetrahydro-, (+-)-; Flutroline [USAN:INN]; Flutrolinum [INN-Latin]; Flutrolino [INN-Spanish]; 62655-22-5; CP 36,584; AC1L1ALJ; Flutroline (USAN/INN); CHEMBL57241; SCHEMBL121860; OYGDOCFZQVGFIP-UHFFFAOYSA-N; (2-Parafluorophenyl-4-hydroxybutyl)-5-parafluorophenyl-8-fluoro-1,2,3,4-tetrahydro-gamma-carboline
DMUOHVL	DT	Small molecular drug
DMUOHVL	PC	51174
DMUOHVL	MW	450.5
DMUOHVL	FM	C27H25F3N2O
DMUOHVL	IC	InChI=1S/C27H25F3N2O/c28-19-5-3-18(4-6-19)27(33)2-1-14-31-15-13-26-24(17-31)23-16-21(30)9-12-25(23)32(26)22-10-7-20(29)8-11-22/h3-12,16,27,33H,1-2,13-15,17H2
DMUOHVL	CS	C1CN(CC2=C1N(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F)CCCC(C5=CC=C(C=C5)F)O
DMUOHVL	IK	OYGDOCFZQVGFIP-UHFFFAOYSA-N
DMUOHVL	IU	4-[8-fluoro-5-(4-fluorophenyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-2-yl]-1-(4-fluorophenyl)butan-1-ol
DMUOHVL	CA	CAS 70801-02-4
DMUOHVL	DE	Discovery agent

DMXK6EI	ID	DMXK6EI
DMXK6EI	DN	FM-101
DMXK6EI	HS	Investigative
DMXK6EI	CP	Femta Pharmaceuticals Inc
DMXK6EI	DE	Multiple myeloma

DM5782Z	ID	DM5782Z
DM5782Z	DN	FM1-10
DM5782Z	HS	Investigative
DM5782Z	SN	CHEMBL257643; 4-((E)-2-[4-(DIETHYLAMINO)PHENYL]ETHENYL)-1-[3-(TRIETHYLAMMONIO)PROPYL]PYRIDINIUM DIBROMIDE; AC1O6V5O; SCHEMBL1527145; AKOS000814322; ACM336185207; (E)-4-(4-(diethylamino)styryl)-1-(3-(triethylammonio)propyl)pyridinium bromide; 336185-20-7; 3-[4-[(E)-2-[4-(diethylamino)phenyl]ethenyl]pyridin-1-ium-1-yl]propyl-triethylazanium dibromide
DM5782Z	DT	Small molecular drug
DM5782Z	PC	6508730
DM5782Z	MW	555.4
DM5782Z	FM	C26H41Br2N3
DM5782Z	IC	InChI=1S/C26H41N3.2BrH/c1-6-28(7-2)26-16-14-24(15-17-26)12-13-25-18-21-27(22-19-25)20-11-23-29(8-3,9-4)10-5;;/h12-19,21-22H,6-11,20,23H2,1-5H3;2*1H/q+2;;/p-2
DM5782Z	CS	CCN(CC)C1=CC=C(C=C1)/C=C/C2=CC=[N+](C=C2)CCC[N+](CC)(CC)CC.[Br-].[Br-]
DM5782Z	IK	HLNKJDYNEWLULB-UHFFFAOYSA-L
DM5782Z	IU	3-[4-[(E)-2-[4-(diethylamino)phenyl]ethenyl]pyridin-1-ium-1-yl]propyl-triethylazanium;dibromide
DM5782Z	DE	Discovery agent

DMAP8VY	ID	DMAP8VY
DMAP8VY	DN	FM1-43
DMAP8VY	HS	Investigative
DMAP8VY	SN	149838-22-2; UNII-83IGZ86I9D; 83IGZ86I9D; CHEBI:52077; N-(3-(triethylammonium)propyl)-4-(4-(dibutylamino)styryl)pyridinium; Fm1 43; CHEMBL257431; FM 1-43; SynaptoGreen&amp; C4; FM 1-43 dye; AC1O6V5E; SCHEMBL1527120; N-(3-(triethylammonium)propyl)-4-(2-(4-dibutylaminophenyl)vinyl)pyridinium; AKOS000814323; SynaptoGreen(TM) C4, &gt; =95% (HPLC), solid; n-(3-triethylammoniumpropyl)-4-(4-(dibutylamino)styryl)pyridinium dibromide; 4-[2-[4-(dibutylamino)phenyl]ethenyl]-1-[3-(triethylammonio)propyl]-pyridiniumbromide
DMAP8VY	DT	Small molecular drug
DMAP8VY	PC	6508724
DMAP8VY	MW	611.5
DMAP8VY	FM	C30H49Br2N3
DMAP8VY	IC	InChI=1S/C30H49N3.2BrH/c1-6-11-23-32(24-12-7-2)30-18-16-28(17-19-30)14-15-29-20-25-31(26-21-29)22-13-27-33(8-3,9-4)10-5;;/h14-21,25-26H,6-13,22-24,27H2,1-5H3;2*1H/q+2;;/p-2
DMAP8VY	CS	CCCCN(CCCC)C1=CC=C(C=C1)/C=C/C2=CC=[N+](C=C2)CCC[N+](CC)(CC)CC.[Br-].[Br-]
DMAP8VY	IK	VZUVCAGXYLMFEC-UHFFFAOYSA-L
DMAP8VY	IU	3-[4-[(E)-2-[4-(dibutylamino)phenyl]ethenyl]pyridin-1-ium-1-yl]propyl-triethylazanium;dibromide
DMAP8VY	CA	CAS 149838-22-2
DMAP8VY	CB	CHEBI:52077
DMAP8VY	DE	Discovery agent

DMZRI6H	ID	DMZRI6H
DMZRI6H	DN	FM-303
DMZRI6H	HS	Investigative
DMZRI6H	SN	IL-23 antagonist (ATLAb antibody technology, IBD), Femta Pharmaceuticals
DMZRI6H	CP	Femta Pharmaceuticals Inc
DMZRI6H	DT	Antibody
DMZRI6H	DE	Inflammatory bowel disease

DMQ391A	ID	DMQ391A
DMQ391A	DN	Fmet-leu-phe
DMQ391A	HS	Investigative
DMQ391A	SN	fMetLeuPhe; formyl-Met-Leu-Phe
DMQ391A	DT	Small molecular drug
DMQ391A	PC	443295
DMQ391A	MW	437.6
DMQ391A	FM	C21H31N3O5S
DMQ391A	IC	InChI=1S/C21H31N3O5S/c1-14(2)11-17(23-19(26)16(22-13-25)9-10-30-3)20(27)24-18(21(28)29)12-15-7-5-4-6-8-15/h4-8,13-14,16-18H,9-12H2,1-3H3,(H,22,25)(H,23,26)(H,24,27)(H,28,29)/t16-,17-,18-/m0/s1
DMQ391A	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCSC)NC=O
DMQ391A	IK	PRQROPMIIGLWRP-BZSNNMDCSA-N
DMQ391A	IU	(2S)-2-[[(2S)-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoic acid
DMQ391A	CA	CAS 59880-97-6
DMQ391A	CB	CHEBI:53490

DMW5V9U	ID	DMW5V9U
DMW5V9U	DN	FMP-825
DMW5V9U	HS	Investigative
DMW5V9U	SN	Obesity therapeutics, MDI; Anti-obesity agent, MDI; Beta-3 adrenoceptor agonist, Molecular Design International; Beta-3 adrenoceptor agonists (obesity/diabetes); Beta-3 adrenoceptor agonists (obesity/diabetes), MDI
DMW5V9U	CP	Molecular Design International Inc
DMW5V9U	DE	Diabetic complication

DMQBTL3	ID	DMQBTL3
DMQBTL3	DN	FMS586
DMQBTL3	HS	Investigative
DMQBTL3	SN	FMS 586; FMS-586
DMQBTL3	DT	Small molecular drug
DMQBTL3	PC	11589975
DMQBTL3	MW	390.5
DMQBTL3	FM	C24H30N4O
DMQBTL3	IC	InChI=1S/C24H30N4O/c1-17(2)28-22-7-5-4-6-20(22)21-16-19(8-9-23(21)28)26-24(29)27(3)15-12-18-10-13-25-14-11-18/h8-11,13-14,16-17H,4-7,12,15H2,1-3H3,(H,26,29)
DMQBTL3	CS	CC(C)N1C2=C(CCCC2)C3=C1C=CC(=C3)NC(=O)N(C)CCC4=CC=NC=C4
DMQBTL3	IK	YLNOMVNCZMWDST-UHFFFAOYSA-N
DMQBTL3	IU	1-methyl-3-(9-propan-2-yl-5,6,7,8-tetrahydrocarbazol-3-yl)-1-(2-pyridin-4-ylethyl)urea
DMQBTL3	DE	Discovery agent

DMJ4F3Q	ID	DMJ4F3Q
DMJ4F3Q	DN	Folate gamma-hydroxamic acid
DMJ4F3Q	HS	Investigative
DMJ4F3Q	DT	Small molecular drug
DMJ4F3Q	PC	136177317
DMJ4F3Q	MW	456.4
DMJ4F3Q	FM	C19H20N8O6
DMJ4F3Q	IC	InChI=1S/C19H20N8O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(28)27-33/h1-4,8,12,21,33H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
DMJ4F3Q	CS	C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)NO)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
DMJ4F3Q	IK	TZBJIYPNYFAUQG-LBPRGKRZSA-N
DMJ4F3Q	IU	(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-(hydroxyamino)-5-oxopentanoic acid
DMJ4F3Q	DE	Discovery agent

DM76AUO	ID	DM76AUO
DM76AUO	DN	Folate gamma-L-phenylalaninehydroxamic acid
DM76AUO	HS	Investigative
DM76AUO	DT	Small molecular drug
DM76AUO	PC	136117931
DM76AUO	MW	603.6
DM76AUO	FM	C28H29N9O7
DM76AUO	IC	InChI=1S/C28H29N9O7/c29-28-35-23-22(26(41)36-28)32-18(14-31-23)13-30-17-8-6-16(7-9-17)24(39)34-19(27(42)43)10-11-21(38)33-20(25(40)37-44)12-15-4-2-1-3-5-15/h1-9,14,19-20,30,44H,10-13H2,(H,33,38)(H,34,39)(H,37,40)(H,42,43)(H3,29,31,35,36,41)/t19-,20-/m0/s1
DM76AUO	CS	C1=CC=C(C=C1)C[C@@H](C(=O)NO)NC(=O)CC[C@@H](C(=O)O)NC(=O)C2=CC=C(C=C2)NCC3=CN=C4C(=N3)C(=O)NC(=N4)N
DM76AUO	IK	WYBGJFMKGROIBY-PMACEKPBSA-N
DM76AUO	IU	(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-1-(hydroxyamino)-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid
DM76AUO	DE	Discovery agent

DMH5SQV	ID	DMH5SQV
DMH5SQV	DN	Folate gamma-L-proline-hydroxamic acid
DMH5SQV	HS	Investigative
DMH5SQV	SN	CHEMBL388878
DMH5SQV	DT	Small molecular drug
DMH5SQV	PC	44428663
DMH5SQV	MW	553.5
DMH5SQV	FM	C24H27N9O7
DMH5SQV	IC	InChI=1S/C24H27N9O7/c25-24-30-19-18(22(37)31-24)28-14(11-27-19)10-26-13-5-3-12(4-6-13)20(35)29-15(23(38)39)7-8-17(34)33-9-1-2-16(33)21(36)32-40/h3-6,11,15-16,18,26,40H,1-2,7-10H2,(H,29,35)(H,32,36)(H,38,39)(H2,25,31,37)/t15-,16-,18?/m0/s1
DMH5SQV	CS	C1C[C@H](N(C1)C(=O)CC[C@@H](C(=O)O)NC(=O)C2=CC=C(C=C2)NCC3=NC4C(=NC(=NC4=O)N)N=C3)C(=O)NO
DMH5SQV	IK	RDZUJKVCOZNTDE-MZQXSQAVSA-N
DMH5SQV	IU	(2S)-2-[[4-[(2-amino-4-oxo-4aH-pteridin-6-yl)methylamino]benzoyl]amino]-5-[(2S)-2-(hydroxycarbamoyl)pyrrolidin-1-yl]-5-oxopentanoic acid
DMH5SQV	DE	Discovery agent

DMEPZ2I	ID	DMEPZ2I
DMEPZ2I	DN	folipastatin
DMEPZ2I	HS	Investigative
DMEPZ2I	SN	139959-71-0
DMEPZ2I	DT	Small molecular drug
DMEPZ2I	PC	6439424
DMEPZ2I	MW	380.4
DMEPZ2I	FM	C23H24O5
DMEPZ2I	IC	InChI=1S/C23H24O5/c1-7-11(3)15-9-17(24)13(5)20-19(15)23(26)28-21-14(6)18(25)10-16(12(4)8-2)22(21)27-20/h7-10,24-25H,1-6H3/b11-7-,12-8-
DMEPZ2I	CS	C/C=C(/C)\\C1=CC(=C(C2=C1C(=O)OC3=C(O2)C(=CC(=C3C)O)/C(=C\\C)/C)C)O
DMEPZ2I	IK	JJMKBGPTPXPMBH-OXAWKVHCSA-N
DMEPZ2I	IU	1,7-bis[(Z)-but-2-en-2-yl]-3,9-dihydroxy-4,10-dimethylbenzo[b][1,4]benzodioxepin-6-one
DMEPZ2I	CA	CAS 139959-71-0
DMEPZ2I	DE	Discovery agent

DMSBQL0	ID	DMSBQL0
DMSBQL0	DN	FOLITENOL
DMSBQL0	HS	Investigative
DMSBQL0	SN	folitenol; CHEMBL551155; BDBM50311579
DMSBQL0	DT	Small molecular drug
DMSBQL0	PC	15840592
DMSBQL0	MW	390.5
DMSBQL0	FM	C25H26O4
DMSBQL0	IC	InChI=1S/C25H26O4/c1-14(2)5-6-15-11-18-22(12-20(15)26)27-13-19-16-7-8-21-17(23(16)28-24(18)19)9-10-25(3,4)29-21/h5,7-12,19,24,26H,6,13H2,1-4H3/t19-,24-/m0/s1
DMSBQL0	CS	CC(=CCC1=CC2=C(C=C1O)OC[C@@H]3[C@H]2OC4=C3C=CC5=C4C=CC(O5)(C)C)C
DMSBQL0	IK	XERSCIKBWOLVNC-CYFREDJKSA-N
DMSBQL0	IU	(2R,11R)-17,17-dimethyl-8-(3-methylbut-2-enyl)-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),15,20-heptaen-7-ol
DMSBQL0	DE	Discovery agent

DM7Q6M0	ID	DM7Q6M0
DM7Q6M0	DN	Formaldehyde
DM7Q6M0	HS	Investigative
DM7Q6M0	SN	formalin; methanal; formol; Paraformaldehyde; Methylene oxide; 50-00-0; Oxomethane; Paraform; Formic aldehyde; Oxymethylene; Methyl aldehyde; Formalith; Fannoform; Formaldehyde solution; Superlysoform; Methaldehyde; Morbicid; Formalina; Lysoform; Karsan; Formaline; Oxomethylene; Formaldehyd; Polyoxymethylene; Aldehyde formique; FYDE; Formaldehyde, gas; Formalin 40; Aldeide formica; 30525-89-4; Oplossingen; Dormol; Polyformaldehyde; Formalin-loesungen; Paraformic aldehyde; Rcra waste number U122; Aldacide; Paraformaldehydum
DM7Q6M0	DT	Small molecular drug
DM7Q6M0	PC	712
DM7Q6M0	MW	30.026
DM7Q6M0	FM	CH2O
DM7Q6M0	IC	InChI=1S/CH2O/c1-2/h1H2
DM7Q6M0	CS	C=O
DM7Q6M0	IK	WSFSSNUMVMOOMR-UHFFFAOYSA-N
DM7Q6M0	IU	formaldehyde
DM7Q6M0	CA	CAS 50-00-0
DM7Q6M0	CB	CHEBI:16842
DM7Q6M0	DE	Discovery agent

DMNFZC6	ID	DMNFZC6
DMNFZC6	DN	Formic Acid
DMNFZC6	HS	Investigative
DMNFZC6	SN	formate; Formic acid, ion(1-); HCO2 anion; 71-47-6; formylate; aminate; methanoate; hydrogen carboxylate; CHEMBL183491; formiate; Formate ion; a carboxyl group; Hydrogencarboxylic acid; HCOO-; AC1L18W4; GTPL4540; CTK5I5292; CHEBI:15740; DTXSID60221219; BDAGIHXWWSANSR-UHFFFAOYSA-M; BDBM50155538; STL483235
DMNFZC6	DT	Small molecular drug
DMNFZC6	PC	284
DMNFZC6	MW	46.025
DMNFZC6	FM	CH2O2
DMNFZC6	IC	InChI=1S/CH2O2/c2-1-3/h1H,(H,2,3)
DMNFZC6	CS	C(=O)O
DMNFZC6	IK	BDAGIHXWWSANSR-UHFFFAOYSA-N
DMNFZC6	IU	formic acid
DMNFZC6	CA	CAS 64-18-6
DMNFZC6	CB	CHEBI:30751
DMNFZC6	DE	Discovery agent

DM7WFZ8	ID	DM7WFZ8
DM7WFZ8	DN	Formononetin
DM7WFZ8	HS	Investigative
DM7WFZ8	SN	formononetin; 485-72-3; Biochanin B; Formononetol; 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; 7-Hydroxy-4'-methoxyisoflavone; 4'-O-methyldaidzein; 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-; UNII-295DQC67BJ; 7-Hydroxy-3-(4-methoxyphenyl)-4-benzopyrone; CHEBI:18088; Isoflavone, 7-hydroxy-4'-methoxy-; EINECS 207-623-9; NSC 93360; NSC-93360; 7-Hydroxy-3-(4-methoxyphenyl)chromone; 295DQC67BJ; HKQYGTCOTHHOMP-UHFFFAOYSA-N; NSC93360; AK106172
DM7WFZ8	DT	Small molecular drug
DM7WFZ8	PC	5280378
DM7WFZ8	MW	268.26
DM7WFZ8	FM	C16H12O4
DM7WFZ8	IC	InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3
DM7WFZ8	CS	COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O
DM7WFZ8	IK	HKQYGTCOTHHOMP-UHFFFAOYSA-N
DM7WFZ8	IU	7-hydroxy-3-(4-methoxyphenyl)chromen-4-one
DM7WFZ8	CA	CAS 485-72-3
DM7WFZ8	CB	CHEBI:18088
DM7WFZ8	DE	Discovery agent

DMWG0P3	ID	DMWG0P3
DMWG0P3	DN	Formycin
DMWG0P3	HS	Investigative
DMWG0P3	SN	Formycin; formycin A; CHEBI:42452; 6742-12-7; (1S)-1-(7-amino-1H-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-D-ribitol; FMC; 2qtt; NSC 102811; BRN 0624229; 1nc3; 8-Aza-9-deazaadenosine; AC1L9KKW; 7-Amino-3-beta-D-ribofuranosyl-1H-pyrazolo(4,3-d)pyrimidine; SCHEMBL980049; 1H-Pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-D-ribofuranosyl-; CHEMBL471524; KBHMEHLJSZMEMI-KSYZLYKTSA-N; ZINC18275505; API0010090; DB02281; D-Ribitol, 1-C-(7-amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-, (S)- (9CI); D-Ribitol, 1-C-(7-amino-1H-pyrazolo[4
DMWG0P3	DT	Small molecular drug
DMWG0P3	PC	447199
DMWG0P3	MW	267.24
DMWG0P3	FM	C10H13N5O4
DMWG0P3	IC	InChI=1S/C10H13N5O4/c11-10-6-4(12-2-13-10)5(14-15-6)9-8(18)7(17)3(1-16)19-9/h2-3,7-9,16-18H,1H2,(H,14,15)(H2,11,12,13)/t3-,7-,8-,9+/m1/s1
DMWG0P3	CS	C1=NC2=C(NN=C2C(=N1)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMWG0P3	IK	KBHMEHLJSZMEMI-KSYZLYKTSA-N
DMWG0P3	IU	(2S,3R,4S,5R)-2-(7-amino-2H-pyrazolo[4,3-d]pyrimidin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMWG0P3	CA	CAS 6742-12-7
DMWG0P3	CB	CHEBI:42452
DMWG0P3	DE	Discovery agent

DMHLYUM	ID	DMHLYUM
DMHLYUM	DN	Formycin B
DMHLYUM	HS	Investigative
DMHLYUM	DT	Small molecular drug
DMHLYUM	PC	135449281
DMHLYUM	MW	268.23
DMHLYUM	FM	C10H12N4O5
DMHLYUM	IC	InChI=1S/C10H12N4O5/c15-1-3-7(16)8(17)9(19-3)5-4-6(14-13-5)10(18)12-2-11-4/h2-3,7-9,15-17H,1H2,(H,13,14)(H,11,12,18)/t3-,7-,8-,9+/m1/s1
DMHLYUM	CS	C1=NC2=C(NN=C2C(=O)N1)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMHLYUM	IK	MTCJZZBQNCXKAP-KSYZLYKTSA-N
DMHLYUM	IU	3-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,6-dihydropyrazolo[4,3-d]pyrimidin-7-one
DMHLYUM	CA	CAS 13877-76-4
DMHLYUM	CB	CHEBI:42654
DMHLYUM	DE	Discovery agent

DMFOU92	ID	DMFOU92
DMFOU92	DN	FORMYLCHROMONE
DMFOU92	HS	Investigative
DMFOU92	SN	CHEMBL559311; BDBM50296368
DMFOU92	DT	Small molecular drug
DMFOU92	PC	45273571
DMFOU92	MW	326.3
DMFOU92	FM	C22H14O3
DMFOU92	IC	InChI=1S/C22H14O3/c23-13-19-14-25-21-12-18(10-11-20(21)22(19)24)17-8-6-16(7-9-17)15-4-2-1-3-5-15/h1-14H
DMFOU92	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)C(=CO4)C=O
DMFOU92	IK	LWZMEMOPULJQIN-UHFFFAOYSA-N
DMFOU92	IU	4-oxo-7-(4-phenylphenyl)chromene-3-carbaldehyde
DMFOU92	DE	Discovery agent

DMVBGAT	ID	DMVBGAT
DMVBGAT	DN	For-RYYRIK-NH2
DMVBGAT	HS	Investigative
DMVBGAT	SN	CHEMBL271478
DMVBGAT	DT	Small molecular drug
DMVBGAT	PC	44456296
DMVBGAT	MW	909.1
DMVBGAT	FM	C43H68N14O8
DMVBGAT	IC	InChI=1S/C43H68N14O8/c1-3-26(2)35(41(65)53-30(36(45)60)13-7-8-20-44)57-38(62)32(15-10-22-51-43(48)49)54-39(63)34(24-28-16-18-29(59)19-17-28)56-40(64)33(23-27-11-5-4-6-12-27)55-37(61)31(52-25-58)14-9-21-50-42(46)47/h4-6,11-12,16-19,25-26,30-35,59H,3,7-10,13-15,20-24,44H2,1-2H3,(H2,45,60)(H,52,58)(H,53,65)(H,54,63)(H,55,61)(H,56,64)(H,57,62)(H4,46,47,50)(H4,48,49,51)/t26-,30-,31-,32-,33-,34-,35-/m0/s1
DMVBGAT	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC=O
DMVBGAT	IK	ZABHXVCIKRRWGE-OLPQHFNPSA-N
DMVBGAT	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-formamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMVBGAT	DE	Discovery agent

DM6ITNG	ID	DM6ITNG
DM6ITNG	DN	Forskolin
DM6ITNG	HS	Investigative
DM6ITNG	SN	forskolin; Colforsin; 66575-29-9; Coleonol; colforsina; colforsinum; colforsine; Boforsin; Colforsinum [Latin]; Colforsine [French]; Colforsina [Spanish]; Coleonolk; Colforsin [USAN:INN]; UNII-1F7A44V6OU; 7beta-Acetoxy-8,13-epoxy-1alpha,6beta,9alpha-trihydroxylabd-14-en-11-one; EINECS 266-410-9; HL 362; (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxododecahydro-1H-benzo[f]chromen-5-yl acetate; NSC 357088; NSC 375489; Forskolin, Coleus forskohlii; CHEMBL52606; 1F7A44V6OU; L 75 1362B
DM6ITNG	DT	Small molecular drug
DM6ITNG	PC	47936
DM6ITNG	MW	410.5
DM6ITNG	FM	C22H34O7
DM6ITNG	IC	InChI=1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3/t13-,15-,16-,17-,19-,20-,21+,22-/m0/s1
DM6ITNG	CS	CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)O
DM6ITNG	IK	OHCQJHSOBUTRHG-KGGHGJDLSA-N
DM6ITNG	IU	[(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate
DM6ITNG	CA	CAS 66575-29-9
DM6ITNG	CB	CHEBI:42471
DM6ITNG	DE	Solid tumour/cancer

DMPC568	ID	DMPC568
DMPC568	DN	FORSYTHIASIDE
DMPC568	HS	Investigative
DMPC568	SN	Forsythoside A; Forsythiaside; 79916-77-1; UNII-OUH5BQ893P; CHEMBL504363; AC1NQZ1W; OUH5BQ893P; CHEBI:5160; MEGxp0_001187; [(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; Forsythoside A; Forsythoside-A; SureCN3318896; SCHEMBL3318896; ACon1_001402; EBD9590; MolPort-001-741-410; ZINC8234345; BDBM50269517; NSC729638; AKOS015897128; NSC-729638; MCULE-6865459907
DMPC568	DT	Small molecular drug
DMPC568	PC	5281773
DMPC568	MW	624.6
DMPC568	FM	C29H36O15
DMPC568	IC	InChI=1S/C29H36O15/c1-13-22(35)23(36)25(38)29(42-13)41-12-20-27(44-21(34)7-4-14-2-5-16(30)18(32)10-14)24(37)26(39)28(43-20)40-9-8-15-3-6-17(31)19(33)11-15/h2-7,10-11,13,20,22-33,35-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29+/m0/s1
DMPC568	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OCCC3=CC(=C(C=C3)O)O)O)O)OC(=O)/C=C/C4=CC(=C(C=C4)O)O)O)O)O
DMPC568	IK	DTOUWTJYUCZJQD-UJERWXFOSA-N
DMPC568	IU	[(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DMPC568	CA	CAS 79916-77-1
DMPC568	CB	CHEBI:5160
DMPC568	DE	Discovery agent

DMYBQN9	ID	DMYBQN9
DMYBQN9	DN	FP0429
DMYBQN9	HS	Investigative
DMYBQN9	SN	FP 0429; FP-0429
DMYBQN9	DT	Small molecular drug
DMYBQN9	PC	11565290
DMYBQN9	MW	272.21
DMYBQN9	FM	C10H12N2O7
DMYBQN9	IC	InChI=1S/C10H12N2O7/c11-10(9(18)19)3-5(8(16)17)12(4-10)6(13)1-2-7(14)15/h1-2,5H,3-4,11H2,(H,14,15)(H,16,17)(H,18,19)/b2-1+/t5-,10-/m0/s1
DMYBQN9	CS	C1[C@H](N(C[C@@]1(C(=O)O)N)C(=O)/C=C/C(=O)O)C(=O)O
DMYBQN9	IK	ZALHFQNLXQORTH-FGLATXDZSA-N
DMYBQN9	IU	(2S,4S)-4-amino-1-[(E)-3-carboxyprop-2-enoyl]pyrrolidine-2,4-dicarboxylic acid
DMYBQN9	DE	Discovery agent

DMGID4T	ID	DMGID4T
DMGID4T	DN	FP-1102
DMGID4T	HS	Investigative
DMGID4T	SN	Farbetics; FP-1101; AOC3 protein inhibitors (incipient vasculopathies), Faron Pharmaceuticals; Vascular adhesion protein 1 inhibitor (incipient vasculopathies), Faron Pharmaceuticals; Vitamin B1 analog (incipient vasculopathies), Faron Pharmaceuticals
DMGID4T	CP	Faron Pharmaceuticals Ltd
DMGID4T	DE	Vascular disease

DMB8U4F	ID	DMB8U4F
DMB8U4F	DN	FPL64176
DMB8U4F	HS	Investigative
DMB8U4F	SN	FPL-64176; FPL 64176
DMB8U4F	DT	Small molecular drug
DMB8U4F	PC	3423
DMB8U4F	MW	347.4
DMB8U4F	FM	C22H21NO3
DMB8U4F	IC	InChI=1S/C22H21NO3/c1-14-19(20(15(2)23-14)22(25)26-3)21(24)18-12-8-7-11-17(18)13-16-9-5-4-6-10-16/h4-12,23H,13H2,1-3H3
DMB8U4F	CS	CC1=C(C(=C(N1)C)C(=O)OC)C(=O)C2=CC=CC=C2CC3=CC=CC=C3
DMB8U4F	IK	MDMWHKZANMNXTF-UHFFFAOYSA-N
DMB8U4F	IU	methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate
DMB8U4F	CA	CAS 120934-96-5
DMB8U4F	CB	CHEBI:249982
DMB8U4F	DE	Discovery agent

DM0T2LQ	ID	DM0T2LQ
DM0T2LQ	DN	FPT-038
DM0T2LQ	HS	Investigative
DM0T2LQ	SN	Hypoglycemic recombinant secreted protein (type 2 diabetes), Five Prime Therapeutics
DM0T2LQ	CP	FivePrime Therapeutics Inc
DM0T2LQ	DE	Non-insulin dependent diabetes

DMR2NBK	ID	DMR2NBK
DMR2NBK	DN	FPTQ
DMR2NBK	HS	Investigative
DMR2NBK	SN	FPTQ; 864863-72-9; CHEMBL1645352; 6-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]quinoline; SCHEMBL1499977; GTPL6353; MolPort-044-724-493; KS-00001CM0; BDBM50333367; ZINC66251948; AKOS028114901; CS-5754; HY-100382; F-185; 6-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]quinolone.
DMR2NBK	DT	Small molecular drug
DMR2NBK	PC	11301185
DMR2NBK	MW	305.31
DMR2NBK	FM	C17H12FN5
DMR2NBK	IC	InChI=1S/C17H12FN5/c1-11-16(13-6-7-14-12(10-13)4-2-8-19-14)21-22-23(11)15-5-3-9-20-17(15)18/h2-10H,1H3
DMR2NBK	CS	CC1=C(N=NN1C2=C(N=CC=C2)F)C3=CC4=C(C=C3)N=CC=C4
DMR2NBK	IK	RTUBNVSZHGWRCV-UHFFFAOYSA-N
DMR2NBK	IU	6-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]quinoline
DMR2NBK	DE	Discovery agent

DMDUR4C	ID	DMDUR4C
DMDUR4C	DN	FPYVAE peptide
DMDUR4C	HS	Investigative
DMDUR4C	SN	CHEMBL1165259; FPYVAE; GTPL3024; BDBM50321107; FPYVAE peptide [PMID: 20494585]; (2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]pentanedioic acid
DMDUR4C	DT	Small molecular drug
DMDUR4C	PC	46906163
DMDUR4C	MW	724.8
DMDUR4C	FM	C36H48N6O10
DMDUR4C	IC	InChI=1S/C36H48N6O10/c1-20(2)30(34(49)38-21(3)31(46)39-26(36(51)52)15-16-29(44)45)41-32(47)27(19-23-11-13-24(43)14-12-23)40-33(48)28-10-7-17-42(28)35(50)25(37)18-22-8-5-4-6-9-22/h4-6,8-9,11-14,20-21,25-28,30,43H,7,10,15-19,37H2,1-3H3,(H,38,49)(H,39,46)(H,40,48)(H,41,47)(H,44,45)(H,51,52)/t21-,25-,26-,27-,28-,30-/m0/s1
DMDUR4C	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)N
DMDUR4C	IK	QKSOHTFYHNYHRK-YFVDCHTDSA-N
DMDUR4C	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]pentanedioic acid
DMDUR4C	DE	Discovery agent

DM7UP4E	ID	DM7UP4E
DM7UP4E	DN	FR-104
DM7UP4E	HS	Investigative
DM7UP4E	SN	Anti-CD28 (PEGylated formulation, transplant rejection/autoimmune disease), TcL Pharma
DM7UP4E	CP	TcL Pharma
DM7UP4E	DT	Antibody
DM7UP4E	DE	Autoimmune diabetes

DM6UWVB	ID	DM6UWVB
DM6UWVB	DN	FR117016
DM6UWVB	HS	Investigative
DM6UWVB	SN	FR117016; CHEMBL93647; 2-(4-{5-[(1H-1,3-benzodiazol-2-ylamino)methyl]thiophen-2-yl}-1,3-thiazol-2-yl)guanidine; N''-(4-(5-((1H-BENZIMIDAZOL-2-YLAMINO)METHYL)-2-THIENYL)-1,3-THIAZOL-2-YL)GUANIDINE; 1ndv; 2-(4-{5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl}-1,3-thiazol-2-yl)guanidine; 2-[4-[5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl]-1,3-thiazol-2-yl]guanidine; AC1L9KQW; BDBM22918; BDBM50170632; DB02616; FR0; N-(4-{5-[(1H-Benzoimidazol-2-ylamino)-methyl]-thiophen-2-yl}-thiazol-2-yl)-guanidine
DM6UWVB	DT	Small molecular drug
DM6UWVB	PC	447339
DM6UWVB	MW	369.5
DM6UWVB	FM	C16H15N7S2
DM6UWVB	IC	InChI=1S/C16H15N7S2/c17-14(18)23-16-22-12(8-24-16)13-6-5-9(25-13)7-19-15-20-10-3-1-2-4-11(10)21-15/h1-6,8H,7H2,(H2,19,20,21)(H4,17,18,22,23)
DM6UWVB	CS	C1=CC=C2C(=C1)NC(=N2)NCC3=CC=C(S3)C4=CSC(=N4)N=C(N)N
DM6UWVB	IK	CKJGKHXCUDWFDC-UHFFFAOYSA-N
DM6UWVB	IU	2-[4-[5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl]-1,3-thiazol-2-yl]guanidine
DM6UWVB	DE	Discovery agent

DMAYTWN	ID	DMAYTWN
DMAYTWN	DN	FR122047
DMAYTWN	HS	Investigative
DMAYTWN	SN	FR 122047; FR 122047 hydrochloride; FR-122047
DMAYTWN	DT	Small molecular drug
DMAYTWN	PC	196840
DMAYTWN	MW	460
DMAYTWN	FM	C23H26ClN3O3S
DMAYTWN	IC	InChI=1S/C23H25N3O3S.ClH/c1-25-12-14-26(15-13-25)23(27)22-24-20(16-4-8-18(28-2)9-5-16)21(30-22)17-6-10-19(29-3)11-7-17;/h4-11H,12-15H2,1-3H3;1H
DMAYTWN	CS	CN1CCN(CC1)C(=O)C2=NC(=C(S2)C3=CC=C(C=C3)OC)C4=CC=C(C=C4)OC.Cl
DMAYTWN	IK	YWMAVHIKOAOSFM-UHFFFAOYSA-N
DMAYTWN	IU	[4,5-bis(4-methoxyphenyl)-1,3-thiazol-2-yl]-(4-methylpiperazin-1-yl)methanone;hydrochloride
DMAYTWN	CA	CAS 130717-51-0
DMAYTWN	DE	Discovery agent

DMNMO83	ID	DMNMO83
DMNMO83	DN	FR-122788
DMNMO83	HS	Investigative
DMNMO83	DE	Discovery agent

DMZSFEP	ID	DMZSFEP
DMZSFEP	DN	FR161282
DMZSFEP	HS	Investigative
DMZSFEP	SN	SCHEMBL6701281; IOISKVCNGOOFMR-UHFFFAOYSA-N; L011765; 1-[2-Oxo-2-(4-methylpiperazino)ethyl]-5-[4-(4'-methyl-2-biphenylylcarbonylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-2-one; 5-{4-[2-(4-methylphenyl)benzoylamino]benzoyl}-1-[(4-methyl-1-piperazinyl)carbonylmethyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2(2H)-one
DMZSFEP	DT	Small molecular drug
DMZSFEP	PC	9873768
DMZSFEP	MW	615.7
DMZSFEP	FM	C37H37N5O4
DMZSFEP	IC	InChI=1S/C37H37N5O4/c1-26-11-13-27(14-12-26)30-7-3-4-8-31(30)36(45)38-29-17-15-28(16-18-29)37(46)41-20-19-34(43)42(33-10-6-5-9-32(33)41)25-35(44)40-23-21-39(2)22-24-40/h3-18H,19-25H2,1-2H3,(H,38,45)
DMZSFEP	CS	CC1=CC=C(C=C1)C2=CC=CC=C2C(=O)NC3=CC=C(C=C3)C(=O)N4CCC(=O)N(C5=CC=CC=C54)CC(=O)N6CCN(CC6)C
DMZSFEP	IK	IOISKVCNGOOFMR-UHFFFAOYSA-N
DMZSFEP	IU	2-(4-methylphenyl)-N-[4-[5-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-4-oxo-2,3-dihydro-1,5-benzodiazepine-1-carbonyl]phenyl]benzamide
DMZSFEP	DE	Discovery agent

DMPCBXT	ID	DMPCBXT
DMPCBXT	DN	FR-166124
DMPCBXT	HS	Investigative
DMPCBXT	SN	FR-166124; CHEMBL59673; SCHEMBL6050347; AHLONZJYCGNSFG-UHFFFAOYSA-N; BDBM50079650; L013227; {2-[6-Oxo-3-(2-phenyl-pyrazolo[1,5-a]pyridin-3-yl)-6H-pyridazin-1-yl]-cyclohex-1-enyl}-acetic acid
DMPCBXT	DT	Small molecular drug
DMPCBXT	PC	9910335
DMPCBXT	MW	426.5
DMPCBXT	FM	C25H22N4O3
DMPCBXT	IC	InChI=1S/C25H22N4O3/c30-22-14-13-19(26-29(22)20-11-5-4-10-18(20)16-23(31)32)24-21-12-6-7-15-28(21)27-25(24)17-8-2-1-3-9-17/h1-3,6-9,12-15H,4-5,10-11,16H2,(H,31,32)
DMPCBXT	CS	C1CCC(=C(C1)CC(=O)O)N2C(=O)C=CC(=N2)C3=C4C=CC=CN4N=C3C5=CC=CC=C5
DMPCBXT	IK	AHLONZJYCGNSFG-UHFFFAOYSA-N
DMPCBXT	IU	2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-1-yl]cyclohexen-1-yl]acetic acid
DMPCBXT	DE	Discovery agent

DM2W5VA	ID	DM2W5VA
DM2W5VA	DN	FR167344
DM2W5VA	HS	Investigative
DM2W5VA	SN	FR-167344; FR 167344
DM2W5VA	DT	Small molecular drug
DM2W5VA	PC	9810391
DM2W5VA	MW	673.4
DM2W5VA	FM	C30H28BrCl2N5O4
DM2W5VA	IC	InChI=1S/C30H28BrCl2N5O4/c1-18-28(31)38-15-5-6-24(29(38)35-18)42-17-21-22(32)12-13-23(27(21)33)37(4)26(40)16-34-25(39)14-9-19-7-10-20(11-8-19)30(41)36(2)3/h5-15H,16-17H2,1-4H3,(H,34,39)/b14-9+
DM2W5VA	CS	CC1=C(N2C=CC=C(C2=N1)OCC3=C(C=CC(=C3Cl)N(C)C(=O)CNC(=O)/C=C/C4=CC=C(C=C4)C(=O)N(C)C)Cl)Br
DM2W5VA	IK	NDOBHDUXUJNXHX-NTEUORMPSA-N
DM2W5VA	IU	4-[(E)-3-[[2-[3-[(3-bromo-2-methylimidazo[1,2-a]pyridin-8-yl)oxymethyl]-2,4-dichloro-N-methylanilino]-2-oxoethyl]amino]-3-oxoprop-1-enyl]-N,N-dimethylbenzamide
DM2W5VA	DE	Discovery agent

DMQDP23	ID	DMQDP23
DMQDP23	DN	FR-175985
DMQDP23	HS	Investigative
DMQDP23	SN	CHEMBL49085; FR-175985; BDBM50290398; L014760
DMQDP23	DT	Small molecular drug
DMQDP23	PC	9872735
DMQDP23	MW	567.7
DMQDP23	FM	C33H34FN5O3
DMQDP23	IC	InChI=1S/C33H34FN5O3/c1-21-7-6-8-24(17-21)35-33(42)37-31-32(41)39(20-29(40)38-18-22-13-14-23(19-38)16-15-22)28-12-5-3-10-26(28)30(36-31)25-9-2-4-11-27(25)34/h2-12,17,22-23,31H,13-16,18-20H2,1H3,(H2,35,37,42)
DMQDP23	CS	CC1=CC(=CC=C1)NC(=O)NC2C(=O)N(C3=CC=CC=C3C(=N2)C4=CC=CC=C4F)CC(=O)N5CC6CCC(C5)CC6
DMQDP23	IK	GWKWFUNKYXSZQP-UHFFFAOYSA-N
DMQDP23	IU	1-[1-[2-(3-azabicyclo[3.2.2]nonan-3-yl)-2-oxoethyl]-5-(2-fluorophenyl)-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DMQDP23	DE	Discovery agent

DM051PI	ID	DM051PI
DM051PI	DN	FR-180204
DM051PI	HS	Investigative
DM051PI	SN	865362-74-9; FR 180204; FR180204; FR-180204; ERK Inhibitor II, FR180204; 5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine; CHEMBL259551; 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE; C18H13N7; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-1H-pyrazolo[3,4-c]pyridazin-3-amine; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-2H-pyrazolo[3,4-c]pyridazin-3-amine; 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine; ERK inhibitor II; MLS002607685
DM051PI	DT	Small molecular drug
DM051PI	PC	11493598
DM051PI	MW	327.3
DM051PI	FM	C18H13N7
DM051PI	IC	InChI=1S/C18H13N7/c19-17-12-10-13(20-22-18(12)23-21-17)15-14-8-4-5-9-25(14)24-16(15)11-6-2-1-3-7-11/h1-10H,(H3,19,21,22,23)
DM051PI	CS	C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=CC5=C(NN=C5N=N4)N
DM051PI	IK	XVECMUKVOMUNLE-UHFFFAOYSA-N
DM051PI	IU	5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine
DM051PI	CA	CAS 865362-74-9
DM051PI	CB	CHEBI:91383
DM051PI	DE	Discovery agent

DM2V7U1	ID	DM2V7U1
DM2V7U1	DN	FR-181157
DM2V7U1	HS	Investigative
DM2V7U1	SN	SCHEMBL7960020; GTPL5854; FR181157; FR 181157; 2-[3-[[2-[4,5-di(phenyl)-1,3-oxazol-2-yl]-1-cyclohex-2-enyl]methyl]phenoxy]acetic acid
DM2V7U1	DT	Small molecular drug
DM2V7U1	PC	23685469
DM2V7U1	MW	487.5
DM2V7U1	FM	C30H26NNaO4
DM2V7U1	IC	InChI=1S/C30H27NO4.Na/c32-27(33)20-34-25-16-9-10-21(19-25)18-24-15-7-8-17-26(24)30-31-28(22-11-3-1-4-12-22)29(35-30)23-13-5-2-6-14-23;/h1-6,9-14,16-17,19,24H,7-8,15,18,20H2,(H,32,33);/q;+1/p-1/t24-;/m0./s1
DM2V7U1	CS	C1CC=C([C@@H](C1)CC2=CC(=CC=C2)OCC(=O)[O-])C3=NC(=C(O3)C4=CC=CC=C4)C5=CC=CC=C5.[Na+]
DM2V7U1	IK	DPECFBBZFTXROT-JIDHJSLPSA-M
DM2V7U1	IU	sodium;2-[3-[[(1S)-2-(4,5-diphenyl-1,3-oxazol-2-yl)cyclohex-2-en-1-yl]methyl]phenoxy]acetate
DM2V7U1	CA	CAS 171046-15-4
DM2V7U1	DE	Discovery agent

DM0G4HP	ID	DM0G4HP
DM0G4HP	DN	FR190997
DM0G4HP	HS	Investigative
DM0G4HP	SN	FR-190997; FR 190997
DM0G4HP	DT	Small molecular drug
DM0G4HP	PC	5311114
DM0G4HP	MW	698.6
DM0G4HP	FM	C37H33Cl2N5O5
DM0G4HP	IC	InChI=1S/C37H33Cl2N5O5/c1-23-19-32(48-21-26-7-4-5-18-41-26)27-8-6-9-31(36(27)43-23)49-22-28-29(38)15-16-30(35(28)39)44(3)34(46)20-42-33(45)17-12-24-10-13-25(14-11-24)37(47)40-2/h4-19H,20-22H2,1-3H3,(H,40,47)(H,42,45)/b17-12+
DM0G4HP	CS	CC1=CC(=C2C=CC=C(C2=N1)OCC3=C(C=CC(=C3Cl)N(C)C(=O)CNC(=O)/C=C/C4=CC=C(C=C4)C(=O)NC)Cl)OCC5=CC=CC=N5
DM0G4HP	IK	YFMDLMSUZMRKKH-SFQUDFHCSA-N
DM0G4HP	IU	4-[(E)-3-[[2-[2,4-dichloro-N-methyl-3-[[2-methyl-4-(pyridin-2-ylmethoxy)quinolin-8-yl]oxymethyl]anilino]-2-oxoethyl]amino]-3-oxoprop-1-enyl]-N-methylbenzamide
DM0G4HP	DE	Discovery agent

DM75VHN	ID	DM75VHN
DM75VHN	DN	FR191413
DM75VHN	HS	Investigative
DM75VHN	SN	FR-191413; FR 191413
DM75VHN	DT	Small molecular drug
DM75VHN	PC	10394861
DM75VHN	MW	688.6
DM75VHN	FM	C34H31Cl2N7O5
DM75VHN	IC	InChI=1S/C34H31Cl2N7O5/c1-21(44)40-29-14-10-22(17-38-29)11-15-30(45)39-18-31(46)42(2)26-13-12-25(35)24(32(26)36)20-48-28-9-6-8-27-33(28)41-34(47-3)43(27)19-23-7-4-5-16-37-23/h4-17H,18-20H2,1-3H3,(H,39,45)(H,38,40,44)/b15-11+
DM75VHN	CS	CC(=O)NC1=NC=C(C=C1)/C=C/C(=O)NCC(=O)N(C)C2=C(C(=C(C=C2)Cl)COC3=CC=CC4=C3N=C(N4CC5=CC=CC=N5)OC)Cl
DM75VHN	IK	KXMCFJQQOFOBKN-RVDMUPIBSA-N
DM75VHN	IU	(E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-3-[[2-methoxy-1-(pyridin-2-ylmethyl)benzimidazol-4-yl]oxymethyl]-N-methylanilino]-2-oxoethyl]prop-2-enamide
DM75VHN	DE	Discovery agent

DM9BS3W	ID	DM9BS3W
DM9BS3W	DN	FR-193262
DM9BS3W	HS	Investigative
DM9BS3W	SN	FR-193262; UNII-6799C86Z0K; 6799C86Z0K; CHEMBL190497; Acetic acid, (((5R)-5-((2R)-2-(4,5-diphenyl-2-oxazolyl)-1-pyrrolidinyl)-5,6,7,8-tetrahydro-1-naphthalenyl)oxy)-, sodium salt; Acetic acid, ((5-(2-(4,5-diphenyl-2-oxazolyl)-1-pyrrolidinyl)-5,6,7,8-tetrahydro-1-naphthalenyl)oxy)-, sodium salt, (R-(R*,R*))-; 187992-22-9; Acetic acid, 2-(((5R)-5-((2R)-2-(4,5-diphenyl-2-oxazolyl)-1-pyrrolidinyl)-5,6,7,8-tetrahydro-1-naphthalenyl)oxy)-, sodium salt (1:1)
DM9BS3W	DT	Small molecular drug
DM9BS3W	PC	23664784
DM9BS3W	MW	516.6
DM9BS3W	FM	C31H29N2NaO4
DM9BS3W	IC	InChI=1S/C31H30N2O4.Na/c34-28(35)20-36-27-18-8-14-23-24(27)15-7-16-25(23)33-19-9-17-26(33)31-32-29(21-10-3-1-4-11-21)30(37-31)22-12-5-2-6-13-22;/h1-6,8,10-14,18,25-26H,7,9,15-17,19-20H2,(H,34,35);/q;+1/p-1/t25-,26-;/m1./s1
DM9BS3W	CS	C1C[C@H](C2=C(C1)C(=CC=C2)OCC(=O)[O-])N3CCC[C@@H]3C4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6.[Na+]
DM9BS3W	IK	NRXVVCOCESTRSY-JUJAXGASSA-M
DM9BS3W	IU	sodium;2-[[(5R)-5-[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-1-yl]oxy]acetate
DM9BS3W	CA	CAS 187992-22-9
DM9BS3W	DE	Discovery agent

DMISP7G	ID	DMISP7G
DMISP7G	DN	FR194921
DMISP7G	HS	Investigative
DMISP7G	SN	FR-194921; FR 194921
DMISP7G	DT	Small molecular drug
DMISP7G	PC	9821511
DMISP7G	MW	385.5
DMISP7G	FM	C23H23N5O
DMISP7G	IC	InChI=1S/C23H23N5O/c1-26-15-12-18(13-16-26)28-21(29)11-10-19(24-28)22-20-9-5-6-14-27(20)25-23(22)17-7-3-2-4-8-17/h2-11,14,18H,12-13,15-16H2,1H3
DMISP7G	CS	CN1CCC(CC1)N2C(=O)C=CC(=N2)C3=C4C=CC=CN4N=C3C5=CC=CC=C5
DMISP7G	IK	YHDRUTMZCJZJAL-UHFFFAOYSA-N
DMISP7G	IU	2-(1-methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one
DMISP7G	CA	CAS 202646-80-8
DMISP7G	DE	Discovery agent

DM70UQR	ID	DM70UQR
DM70UQR	DN	FR221647
DM70UQR	HS	Investigative
DM70UQR	SN	FR-221647; CHEMBL13696; 256461-28-6; 1H-Imidazole-4-carboxamide, 1-[1-(hydroxymethyl)-3-phenylpropyl]-; 1H-Imidazole-4-carboxamide, 1-(1-(hydroxymethyl)-3-phenylpropyl)-; FR221647; ZUYUIKKHHBEVHL-UHFFFAOYSA-N; AC1MHQ05; SCHEMBL7659103; CTK0J3882; BDBM22917; imidazole-4-carboxamide derivative, 1; AKOS030619368; 1-(1-hydroxy-4-phenyl-2-butyl)imidazole-4-carboxamide; 1-(1-hydroxy-4-phenylbutan-2-yl)imidazole-4-carboxamide; 1-[1-(hydroxymethyl)-3-phenyl-propyl]imidazole-4-carboxamide
DM70UQR	DT	Small molecular drug
DM70UQR	PC	447340
DM70UQR	MW	259.3
DM70UQR	FM	C14H17N3O2
DM70UQR	IC	InChI=1S/C14H17N3O2/c15-14(19)13-8-17(10-16-13)12(9-18)7-6-11-4-2-1-3-5-11/h1-5,8,10,12,18H,6-7,9H2,(H2,15,19)/t12-/m1/s1
DM70UQR	CS	C1=CC=C(C=C1)CC[C@H](CO)N2C=C(N=C2)C(=O)N
DM70UQR	IK	ZUYUIKKHHBEVHL-GFCCVEGCSA-N
DM70UQR	IU	1-[(2R)-1-hydroxy-4-phenylbutan-2-yl]imidazole-4-carboxamide
DM70UQR	CA	CAS 256461-28-6
DM70UQR	DE	Discovery agent

DMBY3T5	ID	DMBY3T5
DMBY3T5	DN	FR-226928
DMBY3T5	HS	Investigative
DMBY3T5	SN	FR-226928; CHEMBL350620; FR-226928 free base; BDBM50110416; 1-Naphthalenesulfonamide, N-(2-(4-((((6,7,8,9-tetrahydro-3-methoxy-5H-benzocyclohepten-6-yl)methyl)amino)methyl)-1-piperidinyl)ethyl)-; 765261-46-9; Naphthalene-1-sulfonic acid [2-(4-{[(3-methoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylmethyl)-amino]-methyl}-piperidin-1-yl)-ethyl]-amide
DMBY3T5	DT	Small molecular drug
DMBY3T5	PC	10007341
DMBY3T5	MW	535.7
DMBY3T5	FM	C31H41N3O3S
DMBY3T5	IC	InChI=1S/C31H41N3O3S/c1-37-29-13-12-26-8-4-6-25(20-28(26)21-29)23-32-22-24-14-17-34(18-15-24)19-16-33-38(35,36)31-11-5-9-27-7-2-3-10-30(27)31/h2-3,5,7,9-13,21,24-25,32-33H,4,6,8,14-20,22-23H2,1H3
DMBY3T5	CS	COC1=CC2=C(CCCC(C2)CNCC3CCN(CC3)CCNS(=O)(=O)C4=CC=CC5=CC=CC=C54)C=C1
DMBY3T5	IK	ITJLZSOZZWEOJL-UHFFFAOYSA-N
DMBY3T5	IU	N-[2-[4-[[(3-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)methylamino]methyl]piperidin-1-yl]ethyl]naphthalene-1-sulfonamide
DMBY3T5	CA	CAS 765261-46-9
DMBY3T5	DE	Discovery agent

DMKJQWR	ID	DMKJQWR
DMKJQWR	DN	FR-230481
DMKJQWR	HS	Investigative
DMKJQWR	SN	FR-230481; CHEMBL167991; BDBM50110571; FR230481; Naphthalene-1-sulfonic acid [2-(4-{[(1-hydroxy-7-methoxy-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-amino]-methyl}-piperidin-1-yl)-ethyl]-amide
DMKJQWR	DT	Small molecular drug
DMKJQWR	PC	10030142
DMKJQWR	MW	537.7
DMKJQWR	FM	C30H39N3O4S
DMKJQWR	IC	InChI=1S/C30H39N3O4S/c1-37-26-12-11-25-8-5-15-30(34,28(25)20-26)22-31-21-23-13-17-33(18-14-23)19-16-32-38(35,36)29-10-4-7-24-6-2-3-9-27(24)29/h2-4,6-7,9-12,20,23,31-32,34H,5,8,13-19,21-22H2,1H3
DMKJQWR	CS	COC1=CC2=C(CCCC2(CNCC3CCN(CC3)CCNS(=O)(=O)C4=CC=CC5=CC=CC=C54)O)C=C1
DMKJQWR	IK	HROMPGSHGXAFBQ-UHFFFAOYSA-N
DMKJQWR	IU	N-[2-[4-[[(1-hydroxy-7-methoxy-3,4-dihydro-2H-naphthalen-1-yl)methylamino]methyl]piperidin-1-yl]ethyl]naphthalene-1-sulfonamide
DMKJQWR	DE	Discovery agent

DM3V0HA	ID	DM3V0HA
DM3V0HA	DN	FR230513
DM3V0HA	HS	Investigative
DM3V0HA	SN	FR230513; 1-((1R)-1-(HYDROXYMETHYL)-3-(1-NAPHTHYL)PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE; 1ndy; AC1L9KR0; DB03572; 1-[(2R)-1-hydroxy-4-naphthalen-1-ylbutan-2-yl]imidazole-4-carboxamide; 1-[(2R)-1-hydroxy-4-(naphthalen-1-yl)butan-2-yl]imidazole-4-carboxamide; 1-[(1R)-1-(hydroxymethyl)-3-(1-naphthyl)propyl]imidazole-4-carboxamide; 1-[(1R)-1-(hydroxymethyl)-3-naphthalen-1-ylpropyl]-1H-imidazole-4-carboxamide; 1H-Imidazole-4-carboxamide, 1-[1-(hydroxymethyl)-3-(1-naphthalenyl)propyl]-
DM3V0HA	DT	Small molecular drug
DM3V0HA	PC	447341
DM3V0HA	MW	309.4
DM3V0HA	FM	C18H19N3O2
DM3V0HA	IC	InChI=1S/C18H19N3O2/c19-18(23)17-10-21(12-20-17)15(11-22)9-8-14-6-3-5-13-4-1-2-7-16(13)14/h1-7,10,12,15,22H,8-9,11H2,(H2,19,23)/t15-/m1/s1
DM3V0HA	CS	C1=CC=C2C(=C1)C=CC=C2CC[C@H](CO)N3C=C(N=C3)C(=O)N
DM3V0HA	IK	URGFTPMACWKJKU-OAHLLOKOSA-N
DM3V0HA	IU	1-[(2R)-1-hydroxy-4-naphthalen-1-ylbutan-2-yl]imidazole-4-carboxamide
DM3V0HA	DE	Discovery agent

DMPD16N	ID	DMPD16N
DMPD16N	DN	FR-233118
DMPD16N	HS	Investigative
DMPD16N	SN	FR-233118; CHEMBL166606; BDBM50110562
DMPD16N	DT	Small molecular drug
DMPD16N	PC	10052173
DMPD16N	MW	514.1
DMPD16N	FM	C27H32ClN3O3S
DMPD16N	IC	InChI=1S/C27H32ClN3O3S/c1-34-23-7-5-19-3-2-4-22(13-20(19)14-23)29-16-18-9-11-30(12-10-18)26(32)17-31-24-15-21(28)6-8-25(24)35-27(31)33/h5-8,14-15,18,22,29H,2-4,9-13,16-17H2,1H3
DMPD16N	CS	COC1=CC2=C(CCCC(C2)NCC3CCN(CC3)C(=O)CN4C5=C(C=CC(=C5)Cl)SC4=O)C=C1
DMPD16N	IK	RYHPEQQPQCIMIB-UHFFFAOYSA-N
DMPD16N	IU	5-chloro-3-[2-[4-[[(3-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)amino]methyl]piperidin-1-yl]-2-oxoethyl]-1,3-benzothiazol-2-one
DMPD16N	DE	Discovery agent

DMR251H	ID	DMR251H
DMR251H	DN	FR233623
DMR251H	HS	Investigative
DMR251H	SN	UNII-10302WQ21V; FR233623; CHEMBL93560; 10302WQ21V; 1H-Imidazole-4-carboxamide, 1-((1R,2S)-2-hydroxy-1-(2-(1-naphthalenyl)ethyl)propyl)-; 1-{(1R,2S)-2-HYDROXY-1-[2-(1-NAPHTHYL)ETHYL]PROPYL}-1H-IMIDAZOLE-4-CARBOXAMIDE; 1-[(1R,2S)-2-hydroxy-1-(2-naphthalen-1-ylethyl)propyl]-1H-imidazole-4-carboxamide; 1H-Imidazole-4-carboxamide, 1-[(1R,2S)-2-hydroxy-1-[2-(1-naphthalenyl)ethyl]propyl]-; OODDZQQDDOVCFD-SCLBCKFNSA-N; 2e1w; FR-234938; AC1L9MM5; (+)-FR-234938; 256461-79-7; SCHEMBL6172027; BDBM22948; imidazole-4-carboxamide analog
DMR251H	DT	Small molecular drug
DMR251H	PC	449013
DMR251H	MW	323.4
DMR251H	FM	C19H21N3O2
DMR251H	IC	InChI=1S/C19H21N3O2/c1-13(23)18(22-11-17(19(20)24)21-12-22)10-9-15-7-4-6-14-5-2-3-8-16(14)15/h2-8,11-13,18,23H,9-10H2,1H3,(H2,20,24)/t13-,18+/m0/s1
DMR251H	CS	C[C@@H]([C@@H](CCC1=CC=CC2=CC=CC=C21)N3C=C(N=C3)C(=O)N)O
DMR251H	IK	OODDZQQDDOVCFD-SCLBCKFNSA-N
DMR251H	IU	1-[(3R,4S)-4-hydroxy-1-naphthalen-1-ylpentan-3-yl]imidazole-4-carboxamide
DMR251H	CA	CAS 256461-79-7
DMR251H	DE	Discovery agent

DMLH546	ID	DMLH546
DMLH546	DN	FR236913
DMLH546	HS	Investigative
DMLH546	DT	Small molecular drug
DMLH546	PC	447546
DMLH546	MW	446.5
DMLH546	FM	C24H26N6O3
DMLH546	IC	InChI=1S/C24H26N6O3/c25-23(32)21-14-30(16-27-21)20(15-31)9-11-29-10-8-18-6-7-19(12-22(18)29)28-24(33)26-13-17-4-2-1-3-5-17/h1-8,10,12,14,16,20,31H,9,11,13,15H2,(H2,25,32)(H2,26,28,33)/t20-/m1/s1
DMLH546	CS	C1=CC=C(C=C1)CNC(=O)NC2=CC3=C(C=C2)C=CN3CC[C@H](CO)N4C=C(N=C4)C(=O)N
DMLH546	IK	KCCUBLLGAMGDJL-HXUWFJFHSA-N
DMLH546	IU	1-[(2R)-4-[6-(benzylcarbamoylamino)indol-1-yl]-1-hydroxybutan-2-yl]imidazole-4-carboxamide
DMLH546	DE	Discovery agent

DMMJDXT	ID	DMMJDXT
DMMJDXT	DN	FR239087
DMMJDXT	HS	Investigative
DMMJDXT	SN	AC1NRB3Z
DMMJDXT	DT	Small molecular drug
DMMJDXT	PC	449014
DMMJDXT	MW	342.2
DMMJDXT	FM	C15H17Cl2N3O2
DMMJDXT	IC	InChI=1S/C15H17Cl2N3O2/c1-9(21)13(20-7-12(15(18)22)19-8-20)6-5-10-3-2-4-11(16)14(10)17/h2-4,7-9,13,21H,5-6H2,1H3,(H2,18,22)/t9-,13+/m0/s1
DMMJDXT	CS	C[C@@H]([C@@H](CCC1=C(C(=CC=C1)Cl)Cl)N2C=C(N=C2)C(=O)N)O
DMMJDXT	IK	HCJYSIGJDKNVRU-TVQRCGJNSA-N
DMMJDXT	IU	1-[(3R,4S)-1-(2,3-dichlorophenyl)-4-hydroxypentan-3-yl]imidazole-4-carboxamide
DMMJDXT	DE	Discovery agent

DMSQ6CV	ID	DMSQ6CV
DMSQ6CV	DN	FR260010
DMSQ6CV	HS	Investigative
DMSQ6CV	SN	FR-260010; FR 260010
DMSQ6CV	DT	Small molecular drug
DMSQ6CV	PC	9968450
DMSQ6CV	MW	353.4
DMSQ6CV	FM	C22H19N5
DMSQ6CV	IC	InChI=1S/C22H19N5/c1-15-12-27(14-25-15)18-7-4-6-17(11-18)26-22-20-10-9-16-5-2-3-8-19(16)21(20)23-13-24-22/h2-8,11-14H,9-10H2,1H3,(H,23,24,26)
DMSQ6CV	CS	CC1=CN(C=N1)C2=CC=CC(=C2)NC3=NC=NC4=C3CCC5=CC=CC=C54
DMSQ6CV	IK	LFKNMCJSJZOQJF-UHFFFAOYSA-N
DMSQ6CV	IU	N-[3-(4-methylimidazol-1-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine
DMSQ6CV	DE	Discovery agent

DMV0UM2	ID	DMV0UM2
DMV0UM2	DN	FR-73966
DMV0UM2	HS	Investigative
DMV0UM2	SN	FR-73966; CHEMBL279073; BDBM50110568; FR73966; 1-[2-(5-Chloro-2-oxo-benzothiazol-3-yl)-acetyl]-piperidine-4-carboxylic acid thiazol-2-ylamide
DMV0UM2	DT	Small molecular drug
DMV0UM2	PC	9889267
DMV0UM2	MW	436.9
DMV0UM2	FM	C18H17ClN4O3S2
DMV0UM2	IC	InChI=1S/C18H17ClN4O3S2/c19-12-1-2-14-13(9-12)23(18(26)28-14)10-15(24)22-6-3-11(4-7-22)16(25)21-17-20-5-8-27-17/h1-2,5,8-9,11H,3-4,6-7,10H2,(H,20,21,25)
DMV0UM2	CS	C1CN(CCC1C(=O)NC2=NC=CS2)C(=O)CN3C4=C(C=CC(=C4)Cl)SC3=O
DMV0UM2	IK	MYSZTUDXDIGAGW-UHFFFAOYSA-N
DMV0UM2	IU	1-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]-N-(1,3-thiazol-2-yl)piperidine-4-carboxamide
DMV0UM2	DE	Discovery agent

DMMGWXQ	ID	DMMGWXQ
DMMGWXQ	DN	FR-900452
DMMGWXQ	HS	Investigative
DMMGWXQ	SN	101706-33-6
DMMGWXQ	DT	Small molecular drug
DMMGWXQ	PC	3035856
DMMGWXQ	MW	411.5
DMMGWXQ	FM	C22H25N3O3S
DMMGWXQ	IC	InChI=1S/C22H25N3O3S/c1-12(18-13-7-4-5-9-16(13)25(2)22(18)28)19-20(14-8-6-10-17(14)26)23-15(11-29-3)21(27)24-19/h4-7,9-10,12,15,18-19,23H,8,11H2,1-3H3,(H,24,27)/b20-14+/t12-,15-,18-,19-/m0/s1
DMMGWXQ	CS	C[C@@H]([C@H]1C2=CC=CC=C2N(C1=O)C)[C@H]3/C(=C\\4/CC=CC4=O)/N[C@H](C(=O)N3)CSC
DMMGWXQ	IK	UAPDNDKYPBHNQT-WVPMBWLTSA-N
DMMGWXQ	IU	(3S)-1-methyl-3-[(1S)-1-[(2S,3E,5R)-5-(methylsulfanylmethyl)-6-oxo-3-(2-oxocyclopent-3-en-1-ylidene)piperazin-2-yl]ethyl]-3H-indol-2-one
DMMGWXQ	CA	CAS 101706-33-6
DMMGWXQ	DE	Discovery agent

DMEYNGP	ID	DMEYNGP
DMEYNGP	DN	frescolat MGA
DMEYNGP	HS	Investigative
DMEYNGP	SN	menthone 1,2-glycerol ketal
DMEYNGP	DT	Small molecular drug
DMEYNGP	PC	162184
DMEYNGP	MW	228.33
DMEYNGP	FM	C13H24O3
DMEYNGP	IC	InChI=1S/C13H24O3/c1-9(2)12-5-4-10(3)6-13(12)15-8-11(7-14)16-13/h9-12,14H,4-8H2,1-3H3
DMEYNGP	CS	CC1CCC(C2(C1)OCC(O2)CO)C(C)C
DMEYNGP	IK	ZBJCYZPANVLBRK-UHFFFAOYSA-N
DMEYNGP	IU	(9-methyl-6-propan-2-yl-1,4-dioxaspiro[4.5]decan-3-yl)methanol
DMEYNGP	CA	CAS 63187-91-7
DMEYNGP	DE	Discovery agent

DMIBCZJ	ID	DMIBCZJ
DMIBCZJ	DN	frescolat ML
DMIBCZJ	HS	Investigative
DMIBCZJ	SN	(-)-menthyl lactate
DMIBCZJ	DT	Small molecular drug
DMIBCZJ	PC	62151
DMIBCZJ	MW	228.33
DMIBCZJ	FM	C13H24O3
DMIBCZJ	IC	InChI=1S/C13H24O3/c1-8(2)11-6-5-9(3)7-12(11)16-13(15)10(4)14/h8-12,14H,5-7H2,1-4H3/t9-,10?,11+,12-/m1/s1
DMIBCZJ	CS	C[C@@H]1CC[C@H]([C@@H](C1)OC(=O)C(C)O)C(C)C
DMIBCZJ	IK	UJNOLBSYLSYIBM-SGUBAKSOSA-N
DMIBCZJ	IU	[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] 2-hydroxypropanoate
DMIBCZJ	CA	CAS 61597-98-6
DMIBCZJ	DE	Discovery agent

DMU5SAF	ID	DMU5SAF
DMU5SAF	DN	Fructose-6-phosphate
DMU5SAF	HS	Investigative
DMU5SAF	SN	Fructose 6-Phosphate; D-fructose-6-phosphate; fructose-6P; fructose-6-P; D-fructose-6-P; FRUCTOSE -6-PHOSPHATE; fru-6-P; UNII-2012QM764Y; 2012QM764Y; 6814-87-5; keto-D-fructose 6-phosphate; F6R; D-fructose-6P; D-Fructose 6-phosphorate; 6-O-phosphono-D-fructose; Fructose 6-phosphoric acid; SCHEMBL8230; AC1Q28E6; AC1L2C15; CTK5C7413; CHEBI:15946; GSXOAOHZAIYLCY-HSUXUTPPSA-N; Fructose 6-(dihydrogen phosphate); Fructose, 6-(dihydrogen phosphate); EINECS 211-395-6; d-fructose-6-phosphate (open form); ZINC85994845; DB04493; AJ-127870
DMU5SAF	DT	Small molecular drug
DMU5SAF	PC	69507
DMU5SAF	MW	260.14
DMU5SAF	FM	C6H13O9P
DMU5SAF	IC	InChI=1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h4-7,9-11H,1-2H2,(H2,12,13,14)/t4-,5-,6-/m1/s1
DMU5SAF	CS	C([C@H]([C@H]([C@@H](C(=O)CO)O)O)O)OP(=O)(O)O
DMU5SAF	IK	GSXOAOHZAIYLCY-HSUXUTPPSA-N
DMU5SAF	IU	[(2R,3R,4S)-2,3,4,6-tetrahydroxy-5-oxohexyl] dihydrogen phosphate
DMU5SAF	CA	CAS 643-13-0
DMU5SAF	CB	CHEBI:15946
DMU5SAF	DE	Discovery agent

DMPRMOD	ID	DMPRMOD
DMPRMOD	DN	FSHR NAM
DMPRMOD	HS	Investigative
DMPRMOD	SN	ADX-68692; ADX-68693
DMPRMOD	CP	Addex Pharmaceuticals SA
DMPRMOD	DE	Contraception

DM2KUEV	ID	DM2KUEV
DM2KUEV	DN	Fsn-0503
DM2KUEV	HS	Investigative
DM2KUEV	SN	Cathepsin S mAb (cancer), Fusion
DM2KUEV	CP	Fusion Antibodies Ltd
DM2KUEV	DT	Antibody
DM2KUEV	DE	Solid tumour/cancer

DMN2Q7Y	ID	DMN2Q7Y
DMN2Q7Y	DN	FTI 276
DMN2Q7Y	HS	Investigative
DMN2Q7Y	SN	FTI-276; FTI276
DMN2Q7Y	DT	Small molecular drug
DMN2Q7Y	PC	395754
DMN2Q7Y	MW	433.6
DMN2Q7Y	FM	C21H27N3O3S2
DMN2Q7Y	IC	InChI=1S/C21H27N3O3S2/c1-29-10-9-19(21(26)27)24-20(25)17-8-7-16(23-12-15(22)13-28)11-18(17)14-5-3-2-4-6-14/h2-8,11,15,19,23,28H,9-10,12-13,22H2,1H3,(H,24,25)(H,26,27)/t15-,19+/m1/s1
DMN2Q7Y	CS	CSCC[C@@H](C(=O)O)NC(=O)C1=C(C=C(C=C1)NC[C@H](CS)N)C2=CC=CC=C2
DMN2Q7Y	IK	ZIXDDEATQSBHHL-BEFAXECRSA-N
DMN2Q7Y	IU	(2S)-2-[[4-[[(2R)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
DMN2Q7Y	CA	CAS 170006-72-1
DMN2Q7Y	CB	CHEBI:94119
DMN2Q7Y	DE	Discovery agent

DM65VLB	ID	DM65VLB
DM65VLB	DN	FTIDC
DM65VLB	HS	Investigative
DM65VLB	SN	FTIDC; 873551-53-2; CHEMBL502882; 4-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-N-methyl-N-propan-2-yl-3,6-dihydro-2H-pyridine-1-carboxamide; SCHEMBL658737; GTPL6363; MolPort-035-941-181; BCP18262; BDBM50273942; ZINC40979996; AKOS025142035; NCGC00387221-01; F-190; 4-[1-(2-Fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-3,6-dihydro-N-methyl-N-(1-methylethyl)-1(2H)-pyridinecarboxamide; 4-(1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl)-N-isopropyl-N-methyl-5,6-dihydropyridine-1(2H)-carboxamide
DM65VLB	DT	Small molecular drug
DM65VLB	PC	11245287
DM65VLB	MW	358.4
DM65VLB	FM	C18H23FN6O
DM65VLB	IC	InChI=1S/C18H23FN6O/c1-12(2)23(4)18(26)24-10-7-14(8-11-24)16-13(3)25(22-21-16)15-6-5-9-20-17(15)19/h5-7,9,12H,8,10-11H2,1-4H3
DM65VLB	CS	CC1=C(N=NN1C2=C(N=CC=C2)F)C3=CCN(CC3)C(=O)N(C)C(C)C
DM65VLB	IK	CJTLKLBSIFQKNT-UHFFFAOYSA-N
DM65VLB	IU	4-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-N-methyl-N-propan-2-yl-3,6-dihydro-2H-pyridine-1-carboxamide
DM65VLB	DE	Discovery agent

DMDZBQH	ID	DMDZBQH
DMDZBQH	DN	FTY720-phosphate
DMDZBQH	HS	Investigative
DMDZBQH	SN	fingolimod phosphate
DMDZBQH	DT	Small molecular drug
DMDZBQH	PC	9908268
DMDZBQH	MW	387.5
DMDZBQH	FM	C19H34NO5P
DMDZBQH	IC	InChI=1S/C19H34NO5P/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-25-26(22,23)24/h9-12,21H,2-8,13-16,20H2,1H3,(H2,22,23,24)
DMDZBQH	CS	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(COP(=O)(O)O)N
DMDZBQH	IK	LRFKWQGGENFBFO-UHFFFAOYSA-N
DMDZBQH	IU	[2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl] dihydrogen phosphate
DMDZBQH	CA	CAS 402616-23-3
DMDZBQH	CB	CHEBI:73420
DMDZBQH	DE	Discovery agent

DMUAYWX	ID	DMUAYWX
DMUAYWX	DN	FUB 349
DMUAYWX	HS	Investigative
DMUAYWX	SN	4-(4-Phenyl-butyl)-1H-imidazole; FUB-349; CHEMBL296450; FUB349; 4-(4-phenylbutyl)-3H-imidazole; GTPL1259; BDBM50071197; ZINC29405823;  FUB-349
DMUAYWX	DT	Small molecular drug
DMUAYWX	PC	9990388
DMUAYWX	MW	200.28
DMUAYWX	FM	C13H16N2
DMUAYWX	IC	InChI=1S/C13H16N2/c1-2-6-12(7-3-1)8-4-5-9-13-10-14-11-15-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,14,15)
DMUAYWX	CS	C1=CC=C(C=C1)CCCCC2=CN=CN2
DMUAYWX	IK	BQTXNCXSCSNHGA-UHFFFAOYSA-N
DMUAYWX	IU	5-(4-phenylbutyl)-1H-imidazole
DMUAYWX	DE	Discovery agent

DMCLSE0	ID	DMCLSE0
DMCLSE0	DN	FUB-130
DMCLSE0	HS	Investigative
DMCLSE0	SN	FUB-132; FUB-250; FUB-465; FUB-86; UCL-1860; UCL-2065; UCL-2283; H3 antagonists, Bioprojet/Berlin Free University/INSERM/UCL
DMCLSE0	CP	BioProjet; Societe Civile de Recherche
DMCLSE0	DT	Small molecular drug
DMCLSE0	PC	9989449
DMCLSE0	MW	154.21
DMCLSE0	FM	C8H14N2O
DMCLSE0	IC	InChI=1S/C8H14N2O/c1-2-11-5-3-4-8-6-9-7-10-8/h6-7H,2-5H2,1H3,(H,9,10)
DMCLSE0	CS	CCOCCCC1=CN=CN1
DMCLSE0	IK	RSHKAUMLIJVWFJ-UHFFFAOYSA-N
DMCLSE0	IU	5-(3-ethoxypropyl)-1H-imidazole
DMCLSE0	DE	Neurological disorder

DMAHMSV	ID	DMAHMSV
DMAHMSV	DN	Fucose
DMAHMSV	HS	Investigative
DMAHMSV	SN	L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707
DMAHMSV	DT	Small molecular drug
DMAHMSV	PC	17106
DMAHMSV	MW	164.16
DMAHMSV	FM	C6H12O5
DMAHMSV	IC	InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6?/m0/s1
DMAHMSV	CS	C[C@H]1[C@H]([C@H]([C@@H](C(O1)O)O)O)O
DMAHMSV	IK	SHZGCJCMOBCMKK-DHVFOXMCSA-N
DMAHMSV	IU	(3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol
DMAHMSV	CA	CAS 87-96-7
DMAHMSV	CB	CHEBI:2181

DMWF82O	ID	DMWF82O
DMWF82O	DN	FUKUGETIN
DMWF82O	HS	Investigative
DMWF82O	SN	CHEMBL446790; BDBM50292533
DMWF82O	DT	Small molecular drug
DMWF82O	PC	12110448
DMWF82O	MW	556.5
DMWF82O	FM	C30H20O11
DMWF82O	IC	InChI=1S/C30H20O11/c31-14-4-1-12(2-5-14)29-27(28(39)25-18(35)8-15(32)9-23(25)41-29)26-20(37)10-19(36)24-21(38)11-22(40-30(24)26)13-3-6-16(33)17(34)7-13/h1-11,27,29,31-37H/t27-,29+/m1/s1
DMWF82O	CS	C1=CC(=CC=C1[C@H]2[C@@H](C(=O)C3=C(C=C(C=C3O2)O)O)C4=C(C=C(C5=C4OC(=CC5=O)C6=CC(=C(C=C6)O)O)O)O)O
DMWF82O	IK	GFWPWSNIXRDQJC-PXJZQJOASA-N
DMWF82O	IU	8-[(2R,3S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMWF82O	CA	CAS 16851-21-1
DMWF82O	CB	CHEBI:70331
DMWF82O	DE	Discovery agent

DM4M91Z	ID	DM4M91Z
DM4M91Z	DN	Full-length Factor VIII molecule
DM4M91Z	HS	Investigative
DM4M91Z	SN	Full-length Factor VIII molecule (hemophilia)
DM4M91Z	CP	Bayer Schering Pharma AG
DM4M91Z	DE	Hemophilia

DMA3Y8C	ID	DMA3Y8C
DMA3Y8C	DN	Fumagillin
DMA3Y8C	HS	Investigative
DMA3Y8C	SN	MLS002702991; SMR001566800; NCGC00163699-01; AC1NS4EN; SCHEMBL6953272; MEGxm0_000010; CHEMBL1396346; BDBM95462; ACon0_000963; MolPort-044-567-755; cid_45281154; MolPort-001-739-223; MCULE-6695017352; NCGC00163699-03; J-014992; Fumagillin from Aspergillus fumigatus, &gt; =90%, powder; NCGC00163699-03_C26H34O7_2,4,6,8-Decatetraenedioic acid, mono[5-methoxy-4-[2-methyl-3-(3-methyl-2-buten-1-yl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester, (2E,4E,6E,8E)-
DMA3Y8C	DT	Small molecular drug
DMA3Y8C	PC	6917655
DMA3Y8C	MW	458.5
DMA3Y8C	FM	C26H34O7
DMA3Y8C	IC	InChI=1S/C26H34O7/c1-18(2)13-14-20-25(3,33-20)24-23(30-4)19(15-16-26(24)17-31-26)32-22(29)12-10-8-6-5-7-9-11-21(27)28/h5-13,19-20,23-24H,14-17H2,1-4H3,(H,27,28)/b7-5+,8-6+,11-9+,12-10+/t19-,20-,23-,24-,25+,26+/m1/s1
DMA3Y8C	CS	CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)/C=C/C=C/C=C/C=C/C(=O)O)OC)C
DMA3Y8C	IK	NGGMYCMLYOUNGM-CSDLUJIJSA-N
DMA3Y8C	IU	(2E,4E,6E,8E)-10-[[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl]oxy]-10-oxodeca-2,4,6,8-tetraenoic acid
DMA3Y8C	CA	CAS 23110-15-8
DMA3Y8C	CB	CHEBI:48635
DMA3Y8C	DE	Discovery agent

DM9VLS2	ID	DM9VLS2
DM9VLS2	DN	Fumarate
DM9VLS2	HS	Investigative
DM9VLS2	SN	Fumarate(2-); (2E)-but-2-enedioate; 142-42-7; (E)-2-Butenedioate; (E)-Butenedioic acid; but-2-enedioate; Fumarate dianion; (E)-but-2-enedioate; butenedioate; Fumerate; 2-Butenedioic acid (E)-, ion(2-); AC1NUT2F; Fumaric acid, ion(2-); AC1Q22C1; DTXSID9037660; CHEBI:36180; CHEBI:29806; VZCYOOQTPOCHFL-OWOJBTEDSA-L; trans-1,2-Ethenedicarboxylic acid; (E)-1,2-Ethylenedicarboxylic acid; (E)-2-butenedioic acid, ion(2-); trans-1,2-Ethylenediccarboxylic acid; CJ-10837; 3861-EP2371811A2; 3861-EP2316829A1; 3861-EP2316450A1
DM9VLS2	DT	Small molecular drug
DM9VLS2	PC	5460307
DM9VLS2	MW	114.06
DM9VLS2	FM	C4H2O4-2
DM9VLS2	IC	InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/p-2/b2-1+
DM9VLS2	CS	C(=C/C(=O)[O-])\\C(=O)[O-]
DM9VLS2	IK	VZCYOOQTPOCHFL-OWOJBTEDSA-L
DM9VLS2	IU	(E)-but-2-enedioate
DM9VLS2	CA	CAS 142-42-7
DM9VLS2	CB	CHEBI:29806
DM9VLS2	DE	Discovery agent

DMCFEBW	ID	DMCFEBW
DMCFEBW	DN	furan-1
DMCFEBW	HS	Investigative
DMCFEBW	DT	Small molecular drug
DMCFEBW	PC	9957278
DMCFEBW	MW	491.6
DMCFEBW	FM	C30H37NO5
DMCFEBW	IC	InChI=1S/C30H37NO5/c1-18-13-22-23(30(4,5)12-11-29(22,2)3)15-19(18)14-20-9-10-24(36-20)28(32)31-27-25(34-7)16-21(33-6)17-26(27)35-8/h9-10,13,15-17H,11-12,14H2,1-8H3,(H,31,32)
DMCFEBW	CS	CC1=CC2=C(C=C1CC3=CC=C(O3)C(=O)NC4=C(C=C(C=C4OC)OC)OC)C(CCC2(C)C)(C)C
DMCFEBW	IK	IPEMCIBPDYCJLO-UHFFFAOYSA-N
DMCFEBW	IU	5-[(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)methyl]-N-(2,4,6-trimethoxyphenyl)furan-2-carboxamide
DMCFEBW	CA	CAS 263847-55-8
DMCFEBW	DE	Discovery agent

DM9XPUN	ID	DM9XPUN
DM9XPUN	DN	Furan-2-ylmethylcarbamic Acid Biphenyl-3-yl Ester
DM9XPUN	HS	Investigative
DM9XPUN	SN	CHEMBL449538; Furan-2-ylmethylcarbamic Acid Biphenyl-3-yl Ester
DM9XPUN	DT	Small molecular drug
DM9XPUN	PC	24881738
DM9XPUN	MW	293.3
DM9XPUN	FM	C18H15NO3
DM9XPUN	IC	InChI=1S/C18H15NO3/c20-18(19-13-17-10-5-11-21-17)22-16-9-4-8-15(12-16)14-6-2-1-3-7-14/h1-12H,13H2,(H,19,20)
DM9XPUN	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)OC(=O)NCC3=CC=CO3
DM9XPUN	IK	OLMUNVAXPITDSI-UHFFFAOYSA-N
DM9XPUN	IU	(3-phenylphenyl) N-(furan-2-ylmethyl)carbamate
DM9XPUN	DE	Discovery agent

DMPC6YL	ID	DMPC6YL
DMPC6YL	DN	Furan-3-yl(4-(methylsulfonyl)phenyl)methanone
DMPC6YL	HS	Investigative
DMPC6YL	SN	CHEMBL1240537; 3-(p-methylsulfonylbenzoyl)furan; 1244038-62-7; furan-3-yl(4-(methylsulfonyl)phenyl)methanone
DMPC6YL	DT	Small molecular drug
DMPC6YL	PC	46939837
DMPC6YL	MW	250.27
DMPC6YL	FM	C12H10O4S
DMPC6YL	IC	InChI=1S/C12H10O4S/c1-17(14,15)11-4-2-9(3-5-11)12(13)10-6-7-16-8-10/h2-8H,1H3
DMPC6YL	CS	CS(=O)(=O)C1=CC=C(C=C1)C(=O)C2=COC=C2
DMPC6YL	IK	ULFFSZMVURLRPK-UHFFFAOYSA-N
DMPC6YL	IU	furan-3-yl-(4-methylsulfonylphenyl)methanone
DMPC6YL	DE	Discovery agent

DM78NOM	ID	DM78NOM
DM78NOM	DN	furin inhibitor peptide
DM78NOM	HS	Investigative
DM78NOM	SN	CHEMBL502642; furin inhibitor peptide; GTPL8668
DM78NOM	DT	Small molecular drug
DM78NOM	PC	44584947
DM78NOM	MW	1424.7
DM78NOM	FM	C58H113N29O13
DM78NOM	IC	InChI=1S/C58H113N29O13/c1-30(78-45(92)35(16-8-24-73-54(63)64)85-52(99)40-21-13-29-87(40)53(100)41(61)31(2)88)44(91)79-36(17-9-25-74-55(65)66)48(95)82-38(19-11-27-76-57(69)70)50(97)83-37(18-10-26-75-56(67)68)49(96)81-33(14-4-6-22-59)46(93)80-34(15-5-7-23-60)47(94)84-39(20-12-28-77-58(71)72)51(98)86-42(32(3)89)43(62)90/h30-42,88-89H,4-29,59-61H2,1-3H3,(H2,62,90)(H,78,92)(H,79,91)(H,80,93)(H,81,96)(H,82,95)(H,83,97)(H,84,94)(H,85,99)(H,86,98)(H4,63,64,73)(H4,65,66,74)(H4,67,68,75)(H4,69,70,76)(H4,71,72,77)/t30-,31+,32+,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-/m0/s1
DM78NOM	CS	C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
DM78NOM	IK	XIHRZTWKTVFWSV-HQSWAJDZSA-N
DM78NOM	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carboxamide
DM78NOM	DE	Discovery agent

DMVYEZ1	ID	DMVYEZ1
DMVYEZ1	DN	Furo[2,3d]Pyrimidine Antifolate
DMVYEZ1	HS	Investigative
DMVYEZ1	SN	Dpmmabg; furo[2,3d]pyrimidine antifolate; CHEMBL104829; 156595-85-6; N-[4-[(2,4-DIAMINOFURO[2,3D]PYRIMIDIN-5-YL)METHYL]METHYLAMINO]-BENZOYL]-L-GLUTAMATE; MOT; MTXO; AC1L4JTH; CTK4C9124; DTXSID50166105; 2-{4-[(2,4-Diamino-furo[2,3-d]pyrimidin-5-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid; BDBM50091145; AKOS030607152; DB02026; N-(4-(((2,4-Diaminofuro(2,3-d)pyrimidin-5-yl)methyl)methylamino)benzoyl)-L-glutamic acid; N-(4-(N-((2,4-Diamino-furo(2,3-d)pyrimidin-5-yl)methyl)methylamino)benzoyl)glutamic acid
DMVYEZ1	DT	Small molecular drug
DMVYEZ1	PC	158376
DMVYEZ1	MW	442.4
DMVYEZ1	FM	C20H22N6O6
DMVYEZ1	IC	InChI=1S/C20H22N6O6/c1-26(8-11-9-32-18-15(11)16(21)24-20(22)25-18)12-4-2-10(3-5-12)17(29)23-13(19(30)31)6-7-14(27)28/h2-5,9,13H,6-8H2,1H3,(H,23,29)(H,27,28)(H,30,31)(H4,21,22,24,25)/t13-/m0/s1
DMVYEZ1	CS	CN(CC1=COC2=NC(=NC(=C12)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMVYEZ1	IK	WXINNGCGSCFUCR-ZDUSSCGKSA-N
DMVYEZ1	IU	(2S)-2-[[4-[(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
DMVYEZ1	CA	CAS 156595-85-6
DMVYEZ1	DE	Discovery agent

DMVT0JO	ID	DMVT0JO
DMVT0JO	DN	FUROSIN
DMVT0JO	HS	Investigative
DMVT0JO	SN	Furosin; CHEMBL447361
DMVT0JO	DT	Small molecular drug
DMVT0JO	PC	10416810
DMVT0JO	MW	650.5
DMVT0JO	FM	C27H22O19
DMVT0JO	IC	InChI=1S/C27H22O19/c28-5-12-19-18(35)21(25(42-12)45-22(36)6-1-9(29)16(33)10(30)2-6)44-23(37)7-3-11(31)17(34)20-14(7)15-8(24(38)43-19)4-13(32)26(39,40)27(15,41)46-20/h1-4,12,15,18-19,21,25,28-31,33-35,39-41H,5H2/t12-,15+,18+,19-,21-,25+,27?/m1/s1
DMVT0JO	CS	C1=C(C=C(C(=C1O)O)O)C(=O)O[C@H]2[C@H]3[C@H]([C@@H]([C@H](O2)CO)OC(=O)C4=CC(=O)C(C5([C@@H]4C6=C(O5)C(=C(C=C6C(=O)O3)O)O)O)(O)O)O
DMVT0JO	IK	CXTMLIMZRPKULL-YXYYPBJFSA-N
DMVT0JO	IU	[(1S,9R,18R,19S,21R,22S)-7,7,8,12,13,22-hexahydroxy-21-(hydroxymethyl)-3,6,16-trioxo-2,17,20,23-tetraoxapentacyclo[16.3.1.18,11.04,9.010,15]tricosa-4,10,12,14-tetraen-19-yl] 3,4,5-trihydroxybenzoate
DMVT0JO	DE	Discovery agent

DM4M3C8	ID	DM4M3C8
DM4M3C8	DN	furtrethonium
DM4M3C8	HS	Investigative
DM4M3C8	SN	furmethide
DM4M3C8	DT	Small molecular drug
DM4M3C8	PC	10938
DM4M3C8	MW	140.2
DM4M3C8	FM	C8H14NO+
DM4M3C8	IC	InChI=1S/C8H14NO/c1-9(2,3)7-8-5-4-6-10-8/h4-6H,7H2,1-3H3/q+1
DM4M3C8	CS	C[N+](C)(C)CC1=CC=CO1
DM4M3C8	IK	HEDXEAAVEOJUCR-UHFFFAOYSA-N
DM4M3C8	IU	furan-2-ylmethyl(trimethyl)azanium
DM4M3C8	CA	CAS 7618-86-2
DM4M3C8	CB	CHEBI:134764
DM4M3C8	DE	Discovery agent

DMP3BZH	ID	DMP3BZH
DMP3BZH	DN	Fusion peptide EK1
DMP3BZH	HS	Investigative
DMP3BZH	SN	EK1 peptide
DMP3BZH	TC	Antiviral Agents
DMP3BZH	DT	Protein/peptide drug
DMP3BZH	SQ	SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL
DMP3BZH	DE	Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMFBP7C	ID	DMFBP7C
DMFBP7C	DN	FUTOENONE
DMFBP7C	HS	Investigative
DMFBP7C	SN	Futoenone; 19913-01-0; (-)-Futoenone; SCHEMBL3468519; CHEMBL295191; SXHVHWXETMBKPP-KXXATPMCSA-N; CHEBI:132647; OAS 1136; BDBM50213210; ZINC29395822; AKOS032949051; (2S,4S,5R,5aS)-4-(2H-1,3-benzodioxol-5-yl)-7-methoxy-5-methyl-2,3,4,5-tetrahydro-8H-2,5a-methano-1-benzoxepin-8-one
DMFBP7C	DT	Small molecular drug
DMFBP7C	PC	9819306
DMFBP7C	MW	340.4
DMFBP7C	FM	C20H20O5
DMFBP7C	IC	InChI=1S/C20H20O5/c1-11-14(12-3-4-16-17(5-12)24-10-23-16)6-13-8-20(11)9-18(22-2)15(21)7-19(20)25-13/h3-5,7,9,11,13-14H,6,8,10H2,1-2H3/t11-,13+,14+,20-/m1/s1
DMFBP7C	CS	C[C@@H]1[C@H](C[C@H]2C[C@@]13C=C(C(=O)C=C3O2)OC)C4=CC5=C(C=C4)OCO5
DMFBP7C	IK	SXHVHWXETMBKPP-KXXATPMCSA-N
DMFBP7C	IU	(1S,8S,10S,11R)-10-(1,3-benzodioxol-5-yl)-3-methoxy-11-methyl-7-oxatricyclo[6.3.1.01,6]dodeca-2,5-dien-4-one
DMFBP7C	CA	CAS 19913-01-0
DMFBP7C	CB	CHEBI:132647
DMFBP7C	DE	Discovery agent

DMEI890	ID	DMEI890
DMEI890	DN	FV-Aib-TDVGPFAF
DMEI890	HS	Investigative
DMEI890	SN	[Aib29,Asp31,Pro34,Phe35]CGRP(27-37)
DMEI890	PC	44406785
DMEI890	MW	1184.3
DMEI890	FM	C59H81N11O15
DMEI890	IC	InChI=1S/C59H81N11O15/c1-32(2)46(67-52(78)41(30-45(73)74)64-55(81)48(35(6)71)68-58(85)59(7,8)69-56(82)47(33(3)4)66-50(76)39(60)27-36-19-12-9-13-20-36)54(80)61-31-44(72)70-26-18-25-43(70)53(79)63-40(28-37-21-14-10-15-22-37)51(77)62-34(5)49(75)65-42(57(83)84)29-38-23-16-11-17-24-38/h9-17,19-24,32-35,39-43,46-48,71H,18,25-31,60H2,1-8H3,(H,61,80)(H,62,77)(H,63,79)(H,64,81)(H,65,75)(H,66,76)(H,67,78)(H,68,85)(H,69,82)(H,73,74)(H,83,84)/t34-,35+,39-,40-,41-,42-,43-,46-,47-,48-/m0/s1
DMEI890	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N)O
DMEI890	IK	GUILBDPDYMIGBQ-GBWZQAKSSA-N
DMEI890	IU	(3S)-3-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-2-methylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMEI890	DE	Discovery agent

DMDG1ZX	ID	DMDG1ZX
DMDG1ZX	DN	FVATDVGPFAF
DMDG1ZX	HS	Investigative
DMDG1ZX	SN	CHEMBL385986; FVATDVGPFAF
DMDG1ZX	PC	44406786
DMDG1ZX	MW	1170.3
DMDG1ZX	FM	C58H79N11O15
DMDG1ZX	IC	InChI=1S/C58H79N11O15/c1-31(2)46(67-53(78)41(29-45(72)73)64-57(82)48(35(7)70)68-50(75)34(6)62-56(81)47(32(3)4)66-51(76)39(59)26-36-18-11-8-12-19-36)55(80)60-30-44(71)69-25-17-24-43(69)54(79)63-40(27-37-20-13-9-14-21-37)52(77)61-33(5)49(74)65-42(58(83)84)28-38-22-15-10-16-23-38/h8-16,18-23,31-35,39-43,46-48,70H,17,24-30,59H2,1-7H3,(H,60,80)(H,61,77)(H,62,81)(H,63,79)(H,64,82)(H,65,74)(H,66,76)(H,67,78)(H,68,75)(H,72,73)(H,83,84)/t33-,34-,35+,39-,40-,41-,42-,43-,46-,47-,48-/m0/s1
DMDG1ZX	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N)O
DMDG1ZX	IK	WMTZDAHGKCEIAT-ILJNECBNSA-N
DMDG1ZX	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMDG1ZX	DE	Discovery agent

DMXQC6H	ID	DMXQC6H
DMXQC6H	DN	FV-Hyp-TDVGPFAF
DMXQC6H	HS	Investigative
DMXQC6H	PC	73348632
DMXQC6H	MW	1212.3
DMXQC6H	FM	C60H81N11O16
DMXQC6H	IC	InChI=1S/C60H81N11O16/c1-32(2)48(57(83)62-30-46(74)70-24-16-23-44(70)55(81)64-41(26-37-19-12-8-13-20-37)53(79)63-34(5)51(77)66-43(60(86)87)27-38-21-14-9-15-22-38)67-54(80)42(29-47(75)76)65-58(84)50(35(6)72)69-56(82)45-28-39(73)31-71(45)59(85)49(33(3)4)68-52(78)40(61)25-36-17-10-7-11-18-36/h7-15,17-22,32-35,39-45,48-50,72-73H,16,23-31,61H2,1-6H3,(H,62,83)(H,63,79)(H,64,81)(H,65,84)(H,66,77)(H,67,80)(H,68,78)(H,69,82)(H,75,76)(H,86,87)/t34-,35+,39+,40-,41-,42-,43-,44-,45-,48-,49-,50-/m0/s1
DMXQC6H	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)N)O)O
DMXQC6H	IK	RYURPNQKLUHMSX-UVHAUATQSA-N
DMXQC6H	IU	(3S)-3-[[(2S,3R)-2-[[(2S,4R)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMXQC6H	DE	Discovery agent

DMSD7B1	ID	DMSD7B1
DMSD7B1	DN	FVPTDVGAFAF
DMSD7B1	HS	Investigative
DMSD7B1	SN	CHEMBL406459; FVPTDVGAFAF
DMSD7B1	PC	44274034
DMSD7B1	MW	1170.3
DMSD7B1	FM	C58H79N11O15
DMSD7B1	IC	InChI=1S/C58H79N11O15/c1-31(2)46(55(80)60-30-44(71)61-33(5)49(74)63-40(27-37-20-13-9-14-21-37)52(77)62-34(6)50(75)65-42(58(83)84)28-38-22-15-10-16-23-38)66-53(78)41(29-45(72)73)64-56(81)48(35(7)70)68-54(79)43-24-17-25-69(43)57(82)47(32(3)4)67-51(76)39(59)26-36-18-11-8-12-19-36/h8-16,18-23,31-35,39-43,46-48,70H,17,24-30,59H2,1-7H3,(H,60,80)(H,61,71)(H,62,77)(H,63,74)(H,64,81)(H,65,75)(H,66,78)(H,67,76)(H,68,79)(H,72,73)(H,83,84)/t33-,34-,35+,39-,40-,41-,42-,43-,46-,47-,48-/m0/s1
DMSD7B1	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N)O
DMSD7B1	IK	SQQZSWBNZZDEAJ-ILJNECBNSA-N
DMSD7B1	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMSD7B1	DE	Discovery agent

DMUVXZQ	ID	DMUVXZQ
DMUVXZQ	DN	FVPTDVGPFAF
DMUVXZQ	HS	Investigative
DMUVXZQ	SN	CHEMBL264010; FVPTDVGPFAF
DMUVXZQ	PC	44274033
DMUVXZQ	MW	1196.3
DMUVXZQ	FM	C60H81N11O15
DMUVXZQ	IC	InChI=1S/C60H81N11O15/c1-33(2)48(67-54(79)42(31-47(74)75)65-58(83)50(36(6)72)69-56(81)45-25-17-27-71(45)59(84)49(34(3)4)68-52(77)40(61)28-37-18-10-7-11-19-37)57(82)62-32-46(73)70-26-16-24-44(70)55(80)64-41(29-38-20-12-8-13-21-38)53(78)63-35(5)51(76)66-43(60(85)86)30-39-22-14-9-15-23-39/h7-15,18-23,33-36,40-45,48-50,72H,16-17,24-32,61H2,1-6H3,(H,62,82)(H,63,78)(H,64,80)(H,65,83)(H,66,76)(H,67,79)(H,68,77)(H,69,81)(H,74,75)(H,85,86)/t35-,36+,40-,41-,42-,43-,44-,45-,48-,49-,50-/m0/s1
DMUVXZQ	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)N)O
DMUVXZQ	IK	COFTYEBEOOYCDC-KTHKGSMISA-N
DMUVXZQ	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMUVXZQ	DE	Discovery agent

DM58JFR	ID	DM58JFR
DM58JFR	DN	FVPTDVG-Tic-FAF-Tic
DM58JFR	HS	Investigative
DM58JFR	PC	73353193
DM58JFR	MW	1417.6
DM58JFR	FM	C75H92N12O16
DM58JFR	IC	InChI=1S/C75H92N12O16/c1-42(2)62(82-68(95)55(38-61(90)91)80-72(99)64(45(6)88)84-69(96)57-31-20-32-85(57)74(101)63(43(3)4)83-66(93)53(76)33-46-21-10-7-11-22-46)71(98)77-39-60(89)86-40-51-29-18-16-27-49(51)36-58(86)70(97)79-54(34-47-23-12-8-13-24-47)67(94)78-44(5)65(92)81-56(35-48-25-14-9-15-26-48)73(100)87-41-52-30-19-17-28-50(52)37-59(87)75(102)103/h7-19,21-30,42-45,53-59,62-64,88H,20,31-41,76H2,1-6H3,(H,77,98)(H,78,94)(H,79,97)(H,80,99)(H,81,92)(H,82,95)(H,83,93)(H,84,96)(H,90,91)(H,102,103)/t44-,45+,53-,54-,55-,56-,57-,58-,59-,62-,63-,64-/m0/s1
DM58JFR	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N5CC6=CC=CC=C6C[C@H]5C(=O)O)NC(=O)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)[C@H](CC8=CC=CC=C8)N)O
DM58JFR	IK	LZESRBNZLWMEIJ-GKKQDZIBSA-N
DM58JFR	IU	(3S)-2-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(3S)-2-[2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]acetyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DM58JFR	DE	Discovery agent

DMBOE1U	ID	DMBOE1U
DMBOE1U	DN	FV-Tic-TDVGPFAF
DMBOE1U	HS	Investigative
DMBOE1U	PC	11956141
DMBOE1U	MW	1258.4
DMBOE1U	FM	C65H83N11O15
DMBOE1U	IC	InChI=1S/C65H83N11O15/c1-36(2)53(62(87)67-34-51(78)75-28-18-27-49(75)60(85)69-46(30-41-21-12-8-13-22-41)58(83)68-38(5)56(81)71-48(65(90)91)31-42-23-14-9-15-24-42)72-59(84)47(33-52(79)80)70-63(88)55(39(6)77)74-61(86)50-32-43-25-16-17-26-44(43)35-76(50)64(89)54(37(3)4)73-57(82)45(66)29-40-19-10-7-11-20-40/h7-17,19-26,36-39,45-50,53-55,77H,18,27-35,66H2,1-6H3,(H,67,87)(H,68,83)(H,69,85)(H,70,88)(H,71,81)(H,72,84)(H,73,82)(H,74,86)(H,79,80)(H,90,91)/t38-,39+,45-,46-,47-,48-,49-,50-,53-,54-,55-/m0/s1
DMBOE1U	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@@H]4CC5=CC=CC=C5CN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC6=CC=CC=C6)N)O
DMBOE1U	IK	RFOPIEIJLKLOPX-HGULNMISSA-N
DMBOE1U	IU	(3S)-3-[[(2S,3R)-2-[[(3S)-2-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMBOE1U	DE	Discovery agent

DMAZ1NW	ID	DMAZ1NW
DMAZ1NW	DN	FXI-AS1
DMAZ1NW	HS	Investigative
DMAZ1NW	SN	FXI antisense oligonucleotides (thrombosis); FXI-AS2; FXI-ASO; ISIS-404071; FXI antisense oligonucleotides (thrombosis), Isis Pharmaceuticals; Factor XI antisense oligonucleotides (thrombosis), Isis Pharmaceuticals
DMAZ1NW	CP	Isis Pharmaceuticals Inc
DMAZ1NW	DT	Antisense drug
DMAZ1NW	DE	Thrombosis

DMUC0F5	ID	DMUC0F5
DMUC0F5	DN	G(D-Pen)-G-H-R-G-D-L-R-C-A
DMUC0F5	HS	Investigative
DMUC0F5	SN	CHEMBL437813; G(D-Pen)-G-H-R-G-D-L-R-C-A
DMUC0F5	PC	44379110
DMUC0F5	MW	1170.3
DMUC0F5	FM	C45H75N19O14S2
DMUC0F5	IC	InChI=1S/C45H75N19O14S2/c1-21(2)12-26-37(72)62-25(9-7-11-53-44(49)50)36(71)64-29(40(75)58-22(3)42(77)78)19-79-80-45(4,5)34(46)41(76)56-16-30(65)54-17-31(66)59-27(13-23-15-51-20-57-23)38(73)61-24(8-6-10-52-43(47)48)35(70)55-18-32(67)60-28(14-33(68)69)39(74)63-26/h15,20-22,24-29,34H,6-14,16-19,46H2,1-5H3,(H,51,57)(H,54,65)(H,55,70)(H,56,76)(H,58,75)(H,59,66)(H,60,67)(H,61,73)(H,62,72)(H,63,74)(H,64,71)(H,68,69)(H,77,78)(H4,47,48,52)(H4,49,50,53)/t22-,24-,25-,26+,27+,28-,29-,34-/m0/s1
DMUC0F5	CS	C[C@@H](C(=O)O)NC(=O)[C@@H]1CSSC([C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC(C)C)CC(=O)O)CCCN=C(N)N)CC2=CN=CN2)N)(C)C
DMUC0F5	IK	RGCFJZZTHIGGDJ-UHZMXWKHSA-N
DMUC0F5	IU	(2S)-2-[[(4R,7S,10R,13S,19S,22R,31S)-31-amino-13-(carboxymethyl)-7,19-bis[3-(diaminomethylideneamino)propyl]-22-(1H-imidazol-5-ylmethyl)-32,32-dimethyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]propanoic acid
DMUC0F5	DE	Discovery agent

DMXZGKI	ID	DMXZGKI
DMXZGKI	DN	G009
DMXZGKI	HS	Investigative
DMXZGKI	SN	Beta-(1-3)-Glucan with beta-(1-6) side chain isolated from the Basidiomycetes Ganoderma lucidum
DMXZGKI	DE	Immune System disease

DMMEC9D	ID	DMMEC9D
DMMEC9D	DN	G15
DMMEC9D	HS	Investigative
DMMEC9D	SN	G-15
DMMEC9D	DT	Small molecular drug
DMMEC9D	PC	7433743
DMMEC9D	MW	370.2
DMMEC9D	FM	C19H16BrNO2
DMMEC9D	IC	InChI=1S/C19H16BrNO2/c20-15-9-18-17(22-10-23-18)8-14(15)19-13-6-3-5-11(13)12-4-1-2-7-16(12)21-19/h1-5,7-9,11,13,19,21H,6,10H2/t11-,13-,19+/m0/s1
DMMEC9D	CS	C1C=C[C@@H]2[C@H]1[C@@H](NC3=CC=CC=C23)C4=CC5=C(C=C4Br)OCO5
DMMEC9D	IK	YOLTZIVRJAPVPH-MJLGCCKJSA-N
DMMEC9D	IU	(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline
DMMEC9D	CA	CAS 1161002-05-6
DMMEC9D	DE	Discovery agent

DMADOK6	ID	DMADOK6
DMADOK6	DN	G-25
DMADOK6	HS	Investigative
DMADOK6	SN	SCHEMBL16529235; BDBM286896; US9567304, Compound G-25
DMADOK6	DT	Small molecular drug
DMADOK6	PC	117921588
DMADOK6	MW	687.5
DMADOK6	FM	C25H27Cl2F3N4O7S2
DMADOK6	IC	InChI=1S/C25H27Cl2F3N4O7S2/c1-3-43(39,40)20-7-6-15(26)9-14(20)12-34-23(35)17-10-19(41-25(28,29)30)18(21(27)22(17)32-24(34)36)13-33-8-4-5-16(33)11-31-42(2,37)38/h6-7,9-10,16,31H,3-5,8,11-13H2,1-2H3,(H,32,36)/t16-/m0/s1
DMADOK6	CS	CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CN2C(=O)C3=CC(=C(C(=C3NC2=O)Cl)CN4CCC[C@H]4CNS(=O)(=O)C)OC(F)(F)F
DMADOK6	IK	ADNJLXQZOZXZJU-INIZCTEOSA-N
DMADOK6	IU	N-[[(2S)-1-[[8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-2,4-dioxo-6-(trifluoromethoxy)-1H-quinazolin-7-yl]methyl]pyrrolidin-2-yl]methyl]methanesulfonamide
DMADOK6	DE	Discovery agent

DM3ZBGQ	ID	DM3ZBGQ
DM3ZBGQ	DN	G3139 + cytarabine (ARA-C)
DM3ZBGQ	HS	Investigative
DM3ZBGQ	TC	Antisense
DM3ZBGQ	DT	Combination drug (Antisense drug)
DM3ZBGQ	PC	91865905; 6253
DM3ZBGQ	DE	Acute leukaemia

DMFJ1EI	ID	DMFJ1EI
DMFJ1EI	DN	G3139 + Dacarbazine
DMFJ1EI	HS	Investigative
DMFJ1EI	TC	Antisense
DMFJ1EI	DT	Combination drug (Antisense drug)
DMFJ1EI	PC	91865905; 5353562
DMFJ1EI	DE	Melanoma

DMJ9DN3	ID	DMJ9DN3
DMJ9DN3	DN	G3139 + Dexamethasone
DMJ9DN3	HS	Investigative
DMJ9DN3	TC	Antisense
DMJ9DN3	DT	Combination drug (Antisense drug)
DMJ9DN3	PC	91865905; 5743
DMJ9DN3	DE	Multiple myeloma

DMRVLZ4	ID	DMRVLZ4
DMRVLZ4	DN	G3139 + Fludarabine
DMRVLZ4	HS	Investigative
DMRVLZ4	TC	Antisense
DMRVLZ4	DT	Combination drug (Antisense drug)
DMRVLZ4	PC	91865905; 657237
DMRVLZ4	DE	Acute leukaemia

DMH6UOL	ID	DMH6UOL
DMH6UOL	DN	G3139 + G-CSF
DMH6UOL	HS	Investigative
DMH6UOL	TC	Antisense
DMH6UOL	DT	Combination drug (Antisense drug)
DMH6UOL	PC	91865905; 
DMH6UOL	DE	Acute leukaemia

DMZLJ21	ID	DMZLJ21
DMZLJ21	DN	G3139 + Irinotecan
DMZLJ21	HS	Investigative
DMZLJ21	TC	Antisense
DMZLJ21	DT	Combination drug (Antisense drug)
DMZLJ21	PC	91865905; 60838
DMZLJ21	DE	Metastatic colorectal cancer

DM3MK9Z	ID	DM3MK9Z
DM3MK9Z	DN	G3139 + Paclitaxel
DM3MK9Z	HS	Investigative
DM3MK9Z	CP	Genta
DM3MK9Z	TC	Antisense
DM3MK9Z	DT	Combination drug (Antisense drug)
DM3MK9Z	PC	91865905; 36314
DM3MK9Z	DE	Small-cell lung cancer

DM5KO80	ID	DM5KO80
DM5KO80	DN	G3139 + Thalidomide
DM5KO80	HS	Investigative
DM5KO80	TC	Antisense
DM5KO80	DT	Combination drug (Antisense drug)
DM5KO80	PC	91865905; 5426
DM5KO80	DE	Multiple myeloma

DMDJCIP	ID	DMDJCIP
DMDJCIP	DN	G36
DMDJCIP	HS	Investigative
DMDJCIP	SN	G-36
DMDJCIP	DT	Small molecular drug
DMDJCIP	PC	73755224
DMDJCIP	MW	412.3
DMDJCIP	FM	C22H22BrNO2
DMDJCIP	IC	InChI=1S/C22H22BrNO2/c1-12(2)13-6-7-19-16(8-13)14-4-3-5-15(14)22(24-19)17-9-20-21(10-18(17)23)26-11-25-20/h3-4,6-10,12,14-15,22,24H,5,11H2,1-2H3/t14-,15+,22-/m1/s1
DMDJCIP	CS	CC(C)C1=CC2=C(C=C1)N[C@H]([C@@H]3[C@H]2C=CC3)C4=CC5=C(C=C4Br)OCO5
DMDJCIP	IK	QTOCPACSSHFGOY-ZCCHDVMBSA-N
DMDJCIP	IU	(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-8-propan-2-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline
DMDJCIP	DE	Discovery agent

DMKTJBU	ID	DMKTJBU
DMKTJBU	DN	G418
DMKTJBU	HS	Investigative
DMKTJBU	SN	Geneticin; geneticin; antibiotic G 418; antibiotic G-418; UNII-A08F5XTI6G; 49863-47-0; BRN 1669188; A08F5XTI6G; O-2-Amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-D-streptamine; G 418 sulfate; G 418; G-418; C20H40N4O10; GET; D-Streptamine, O-2-amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-; AC1L3XFV; SCHEMBL5006573; CHEMBL215226; DTXSID10198129
DMKTJBU	DT	Small molecular drug
DMKTJBU	PC	123865
DMKTJBU	MW	496.6
DMKTJBU	FM	C20H40N4O10
DMKTJBU	IC	InChI=1S/C20H40N4O10/c1-6(25)14-11(27)10(26)9(23)18(32-14)33-15-7(21)4-8(22)16(12(15)28)34-19-13(29)17(24-3)20(2,30)5-31-19/h6-19,24-30H,4-5,21-23H2,1-3H3/t6-,7+,8-,9-,10-,11+,12+,13-,14-,15-,16+,17-,18-,19-,20+/m1/s1
DMKTJBU	CS	C[C@H]([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)O)O)O
DMKTJBU	IK	BRZYSWJRSDMWLG-DJWUNRQOSA-N
DMKTJBU	IU	(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMKTJBU	CA	CAS 49863-47-0
DMKTJBU	DE	Discovery agent

DMC54UG	ID	DMC54UG
DMC54UG	DN	G-573
DMC54UG	HS	Investigative
DMC54UG	SN	G-573; CHEMBL2087078; CHEBI:83404; 1009333-44-1; 7-Fluoro-3-[(2-Fluoro-4-Iodophenyl)amino]-N-{[(2s)-2-Hydroxypropyl]oxy}furo[3,2-C]pyridine-2-Carboxamide; SCHEMBL12164599; ZINC43207624; BDBM50420694; KB-77496
DMC54UG	CP	Genentech Inc
DMC54UG	DT	Small molecular drug
DMC54UG	PC	46926364
DMC54UG	MW	489.21
DMC54UG	FM	C17H14F2IN3O4
DMC54UG	IC	InChI=1S/C17H14F2IN3O4/c1-8(24)7-26-23-17(25)16-14(10-5-21-6-12(19)15(10)27-16)22-13-3-2-9(20)4-11(13)18/h2-6,8,22,24H,7H2,1H3,(H,23,25)/t8-/m0/s1
DMC54UG	CS	C[C@@H](CONC(=O)C1=C(C2=CN=CC(=C2O1)F)NC3=C(C=C(C=C3)I)F)O
DMC54UG	IK	ZEZHPEIEEFTILY-QMMMGPOBSA-N
DMC54UG	IU	7-fluoro-3-(2-fluoro-4-iodoanilino)-N-[(2S)-2-hydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide
DMC54UG	CB	CHEBI:83404
DMC54UG	DE	Solid tumour/cancer

DMEZO4M	ID	DMEZO4M
DMEZO4M	DN	G6976
DMEZO4M	HS	Investigative
DMEZO4M	SN	12H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-; Go 6976; 136194-77-9; GO6976; Go-6976; Goe 6976; UNII-B9IQO7JZ16; 6976; Go 6976, Solution; B9IQO7JZ16; 5,6,7,13-Tetrahydro-13-Methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile; CHEMBL302449; CHEBI:51913; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole; Go6976
DMEZO4M	DT	Small molecular drug
DMEZO4M	PC	3501
DMEZO4M	MW	378.4
DMEZO4M	FM	C24H18N4O
DMEZO4M	IC	InChI=1S/C24H18N4O/c1-27-17-9-4-2-7-14(17)20-21-16(13-26-24(21)29)19-15-8-3-5-10-18(15)28(12-6-11-25)23(19)22(20)27/h2-5,7-10H,6,12-13H2,1H3,(H,26,29)
DMEZO4M	CS	CN1C2=CC=CC=C2C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CCC#N)CNC4=O
DMEZO4M	IK	VWVYILCFSYNJHF-UHFFFAOYSA-N
DMEZO4M	IU	3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile
DMEZO4M	CA	CAS 136194-77-9
DMEZO4M	CB	CHEBI:51913
DMEZO4M	DE	Solid tumour/cancer

DMC7HIS	ID	DMC7HIS
DMC7HIS	DN	G749
DMC7HIS	HS	Investigative
DMC7HIS	SN	G-749
DMC7HIS	DT	Small molecular drug
DMC7HIS	PC	78357765
DMC7HIS	MW	521.4
DMC7HIS	FM	C25H25BrN6O2
DMC7HIS	IC	InChI=1S/C25H25BrN6O2/c1-32-13-11-17(12-14-32)29-25-30-22-20(26)15-27-24(33)21(22)23(31-25)28-16-7-9-19(10-8-16)34-18-5-3-2-4-6-18/h2-10,15,17H,11-14H2,1H3,(H,27,33)(H2,28,29,30,31)
DMC7HIS	CS	CN1CCC(CC1)NC2=NC3=C(C(=O)NC=C3Br)C(=N2)NC4=CC=C(C=C4)OC5=CC=CC=C5
DMC7HIS	IK	SXWMIXPJPNCXQQ-UHFFFAOYSA-N
DMC7HIS	IU	8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6H-pyrido[4,3-d]pyrimidin-5-one
DMC7HIS	CA	CAS 1457983-28-6
DMC7HIS	DE	Discovery agent

DMOF7JL	ID	DMOF7JL
DMOF7JL	DN	GABA-B receptor PAM
DMOF7JL	HS	Investigative
DMOF7JL	SN	ADX-1; ADX-1a; ADX-1b; ADX-71441; ADX-1 program (GABA b positive allosteric modulators), Addex; GABA-B receptor PAM (pain/fragile X syndrome/urinary incontinence/GERD); GABA-B receptor PAM (pain/fragile X syndrome/urinary incontinence/GERD), Addex
DMOF7JL	CP	Addex Pharmaceuticals SA
DMOF7JL	DE	Anxiety disorder

DMDEAWS	ID	DMDEAWS
DMDEAWS	DN	Gababutin
DMDEAWS	HS	Investigative
DMDEAWS	SN	Gababutin; CHEMBL610734; 60142-99-6; Cyclopentaneacetic acid, 1-(aminomethyl)-; 2-[1-(aminomethyl)cyclopentyl]acetic Acid; SCHEMBL25615; CTK2F1329; DTXSID70432495; ZINC34016806; BDBM50304691
DMDEAWS	DT	Small molecular drug
DMDEAWS	PC	9898895
DMDEAWS	MW	157.21
DMDEAWS	FM	C8H15NO2
DMDEAWS	IC	InChI=1S/C8H15NO2/c9-6-8(5-7(10)11)3-1-2-4-8/h1-6,9H2,(H,10,11)
DMDEAWS	CS	C1CCC(C1)(CC(=O)O)CN
DMDEAWS	IK	MKGSCDBHUPQQMX-UHFFFAOYSA-N
DMDEAWS	IU	2-[1-(aminomethyl)cyclopentyl]acetic acid
DMDEAWS	CA	CAS 60142-99-6
DMDEAWS	DE	Discovery agent

DMH17MU	ID	DMH17MU
DMH17MU	DN	Gabaculine
DMH17MU	HS	Investigative
DMH17MU	SN	DL-Gabaculine; 3-Amino-2,3-dihydrobenzoic acid; GABACULINE, D.L-; Gabaculin; 59556-18-2; 5-Amino-1,3-cyclohexadienylcarboxylic acid; 5-aminocyclohexa-1,3-diene-1-carboxylic acid; NSC-329502; 87980-11-8; C7H9NO2; (+-)-Gabaculine; AC1L1FYB; AC1Q5RCE; Biomol-NT_000232; Lopac0_000006; SCHEMBL2024044; BPBio1_000639; CHEMBL1394922; CTK1H1588; DTXSID90274399; KFNRJXCQEJIBER-UHFFFAOYSA-N; CPD0-1467; NSC329502; Benzoic acid, 3-amino-2,3-dihydro-; NSC 329502; CCG-204102; NCGC00015051-04; NCGC00015051-03; NCGC00162040-01; NCGC00015051-02
DMH17MU	DT	Small molecular drug
DMH17MU	PC	3445
DMH17MU	MW	139.15
DMH17MU	FM	C7H9NO2
DMH17MU	IC	InChI=1S/C7H9NO2/c8-6-3-1-2-5(4-6)7(9)10/h1-3,6H,4,8H2,(H,9,10)
DMH17MU	CS	C1C(C=CC=C1C(=O)O)N
DMH17MU	IK	KFNRJXCQEJIBER-UHFFFAOYSA-N
DMH17MU	IU	5-aminocyclohexa-1,3-diene-1-carboxylic acid
DMH17MU	CA	CAS 59556-18-2
DMH17MU	CB	CHEBI:29585
DMH17MU	DE	Discovery agent

DM5TQ2O	ID	DM5TQ2O
DM5TQ2O	DN	Galangin
DM5TQ2O	HS	Investigative
DM5TQ2O	SN	Galangin; 548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one
DM5TQ2O	DT	Small molecular drug
DM5TQ2O	PC	5281616
DM5TQ2O	MW	270.24
DM5TQ2O	FM	C15H10O5
DM5TQ2O	IC	InChI=1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H
DM5TQ2O	CS	C1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
DM5TQ2O	IK	VCCRNZQBSJXYJD-UHFFFAOYSA-N
DM5TQ2O	IU	3,5,7-trihydroxy-2-phenylchromen-4-one
DM5TQ2O	CA	CAS 548-83-4
DM5TQ2O	CB	CHEBI:5262
DM5TQ2O	DE	Discovery agent

DMHPV8A	ID	DMHPV8A
DMHPV8A	DN	GALANIN
DMHPV8A	HS	Investigative
DMHPV8A	DE	Discovery agent

DMAFE24	ID	DMAFE24
DMAFE24	DN	Galanthamine derivative
DMAFE24	HS	Investigative
DMAFE24	SN	GALANTHAMINE DERIVATIVE; (4AR,6S,8AR)-11-[8-(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)OCTYL]-6-HYDROXY-3-METHOXY-5,6,9,10-TETRAHYDRO-4AH-[1]BENZOFURO[3A,3,2-EF][2]BENZAZEPIN-11-IUM; galanthamine deriv. 4d; 1w4l; Galanthamine derivative 3; CHEMBL490866; BDBM10406; DB02673; (4aS,8aS)-3-Methoxy-6beta-hydroxy-11-[8-(1,3-dioxo-1,3-dihydro-2H-isoindole-2-yl)octyl]-4aalpha,5,9,10-tetrahydro-6H-benzofuro[3a,3,2-ef][2]benzazepine-11-ium
DMAFE24	DT	Small molecular drug
DMAFE24	PC	5288394
DMAFE24	MW	529.6
DMAFE24	FM	C32H37N2O5+
DMAFE24	IC	InChI=1S/C32H37N2O5/c1-38-26-13-12-22-21-33(19-16-32-15-14-23(35)20-27(32)39-29(26)28(22)32)17-8-4-2-3-5-9-18-34-30(36)24-10-6-7-11-25(24)31(34)37/h6-7,10-15,21,23,27,35H,2-5,8-9,16-20H2,1H3/q+1/t23-,27-,32-/m0/s1
DMAFE24	CS	COC1=C2C3=C(C=C1)C=[N+](CC[C@]34C=C[C@@H](C[C@@H]4O2)O)CCCCCCCCN5C(=O)C6=CC=CC=C6C5=O
DMAFE24	IK	VLGAHTYYCHWLNI-BHRZLAGCSA-N
DMAFE24	IU	2-[8-[(1S,12S,14R)-14-hydroxy-9-methoxy-11-oxa-4-azoniatetracyclo[8.6.1.01,12.06,17]heptadeca-4,6(17),7,9,15-pentaen-4-yl]octyl]isoindole-1,3-dione
DMAFE24	DE	Discovery agent

DMDZHEO	ID	DMDZHEO
DMDZHEO	DN	GALANTIDE
DMDZHEO	HS	Investigative
DMDZHEO	SN	52364-71-3; 4'-Pentyloxy-[1,1'-Biphenyl]-4-carbonitrile; 4-Pentyloxy-4'-cyanobiphenyl; 4-Cyano-4'-pentyloxybiphenyl; 4-Amyloxycyanodiphenyl; 5OCB; 4'-(pentyloxy)biphenyl-4-carbonitrile; [1,1'-Biphenyl]-4-carbonitrile, 4'-(pentyloxy)-; 5COB; M 15 (liquid crystal); NZh K 1; 4-Cyano-4'-pentoxybiphenyl; D 105 (stationary phase); Ro CB 5315; m 15; 4-Pentyloxy-[1,1'-biphenyl]-4'-carbonitrile; EINECS 257-875-9; BRN 2215500; 4-(4-pentoxyphenyl)benzonitrile; D 105; 4'-(Pentyloxy)-(1,1'-biphenyl)-4-carbonitrile
DMDZHEO	DT	Small molecular drug
DMDZHEO	PC	16132126
DMDZHEO	MW	2199.5
DMDZHEO	FM	C104H151N25O26S
DMDZHEO	IC	InChI=1S/C104H151N25O26S/c1-54(2)39-70(91(142)113-52-87(139)129-37-20-27-80(129)103(154)120-69(33-35-82(107)134)93(144)119-68(32-34-81(106)133)94(145)124-76(44-61-23-16-13-17-24-61)99(150)123-74(43-60-21-14-12-15-22-60)92(143)112-51-86(138)116-71(40-55(3)4)95(146)118-67(89(109)140)36-38-156-11)121-96(147)72(41-56(5)6)122-98(149)75(45-62-28-30-64(132)31-29-62)117-85(137)50-111-90(141)58(9)114-102(153)79(53-130)127-100(151)78(47-83(108)135)125-97(148)73(42-57(7)8)126-104(155)88(59(10)131)128-101(152)77(115-84(136)48-105)46-63-49-110-66-26-19-18-25-65(63)66/h12-19,21-26,28-31,49,54-59,67-80,88,110,130-132H,20,27,32-48,50-53,105H2,1-11H3,(H2,106,133)(H2,107,134)(H2,108,135)(H2,109,140)(H,111,141)(H,112,143)(H,113,142)(H,114,153)(H,115,136)(H,116,138)(H,117,137)(H,118,146)(H,119,144)(H,120,154)(H,121,147)(H,122,149)(H,123,150)(H,124,145)(H,125,148)(H,126,155)(H,127,151)(H,128,152)/t58-,59+,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,88-/m0/s1
DMDZHEO	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)CN)O
DMDZHEO	IK	TZOJVPDIYKRJSM-GKPUQKAJSA-N
DMDZHEO	IU	(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DMDZHEO	CA	CAS 138579-66-5
DMDZHEO	DE	Discovery agent

DMGX6UH	ID	DMGX6UH
DMGX6UH	DN	GalB2
DMGX6UH	HS	Investigative
DMGX6UH	SN	GalB2; CHEMBL578514
DMGX6UH	PC	24760995
DMGX6UH	MW	2113.6
DMGX6UH	FM	C104H173N23O23
DMGX6UH	IC	InChI=1S/C104H173N23O23/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-86(132)110-50-33-29-39-74(95(140)120-76(104(149)150)40-28-32-49-107)118-93(138)73(37-26-30-47-105)117-94(139)75(38-27-31-48-106)119-102(147)84-41-34-51-127(84)89(135)61-113-92(137)77(52-63(2)3)121-96(141)78(53-64(4)5)122-98(143)80(55-68-43-45-70(130)46-44-68)115-88(134)60-112-91(136)66(8)114-101(146)83(62-128)125-99(144)82(57-85(108)131)123-97(142)79(54-65(6)7)124-103(148)90(67(9)129)126-100(145)81(116-87(133)59-109-10)56-69-58-111-72-36-25-24-35-71(69)72/h24-25,35-36,43-46,58,63-67,73-84,90,109,111,128-130H,11-23,26-34,37-42,47-57,59-62,105-107H2,1-10H3,(H2,108,131)(H,110,132)(H,112,136)(H,113,137)(H,114,146)(H,115,134)(H,116,133)(H,117,139)(H,118,138)(H,119,147)(H,120,140)(H,121,141)(H,122,143)(H,123,142)(H,124,148)(H,125,144)(H,126,145)(H,149,150)/t66-,67+,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,90-/m0/s1
DMGX6UH	CS	CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CNC
DMGX6UH	IK	DWLPZUABYQBJIQ-CMDPNKGGSA-N
DMGX6UH	IU	(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-3-hydroxy-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-(methylamino)acetyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]hexanoyl]amino]-6-(hexadecanoylamino)hexanoyl]amino]hexanoic acid
DMGX6UH	DE	Discovery agent

DM7PR5E	ID	DM7PR5E
DM7PR5E	DN	Gal-B5
DM7PR5E	HS	Investigative
DM7PR5E	SN	Gal-B5; CHEMBL506495
DM7PR5E	PC	25180495
DM7PR5E	MW	2041.6
DM7PR5E	FM	C101H169N23O21
DM7PR5E	IC	InChI=1S/C101H169N23O21/c1-10-11-12-13-14-15-16-17-18-19-20-21-22-41-84(129)108-49-32-28-39-74(92(136)114-72(88(107)132)36-25-29-46-102)116-93(137)73(37-26-30-47-103)115-94(138)75(38-27-31-48-104)117-100(144)82-40-33-50-124(82)86(131)59-111-91(135)76(51-61(2)3)118-95(139)77(52-62(4)5)119-97(141)79(54-66-42-44-68(127)45-43-66)113-85(130)58-110-89(133)64(8)112-99(143)81(60-125)122-98(142)80(56-83(106)128)120-96(140)78(53-63(6)7)121-101(145)87(65(9)126)123-90(134)70(105)55-67-57-109-71-35-24-23-34-69(67)71/h23-24,34-35,42-45,57,61-65,70,72-82,87,109,125-127H,10-22,25-33,36-41,46-56,58-60,102-105H2,1-9H3,(H2,106,128)(H2,107,132)(H,108,129)(H,110,133)(H,111,135)(H,112,143)(H,113,130)(H,114,136)(H,115,138)(H,116,137)(H,117,144)(H,118,139)(H,119,141)(H,120,140)(H,121,145)(H,122,142)(H,123,134)/t64-,65+,70-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,87-/m0/s1
DM7PR5E	CS	CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N
DM7PR5E	IK	CYRNKOJFIDMNMV-WCXAHCKYSA-N
DM7PR5E	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]butanediamide
DM7PR5E	DE	Discovery agent

DMNWU83	ID	DMNWU83
DMNWU83	DN	Gallic acid 5,6-dihydroxy-3-carboxyphenylester
DMNWU83	HS	Investigative
DMNWU83	SN	gallic acid 5,6-dihydroxy-3-carboxyphenylester; SCHEMBL2280107; CHEMBL498103
DMNWU83	DT	Small molecular drug
DMNWU83	PC	44592636
DMNWU83	MW	322.22
DMNWU83	FM	C14H10O9
DMNWU83	IC	InChI=1S/C14H10O9/c15-7-2-1-6(10(17)12(7)19)14(22)23-9-4-5(13(20)21)3-8(16)11(9)18/h1-4,15-19H,(H,20,21)
DMNWU83	CS	C1=CC(=C(C(=C1C(=O)OC2=CC(=CC(=C2O)O)C(=O)O)O)O)O
DMNWU83	IK	PTBZQGDFAUQSCW-UHFFFAOYSA-N
DMNWU83	IU	3,4-dihydroxy-5-(2,3,4-trihydroxybenzoyl)oxybenzoic acid
DMNWU83	DE	Discovery agent

DM6Y3A0	ID	DM6Y3A0
DM6Y3A0	DN	GALLICACID
DM6Y3A0	HS	Investigative
DM6Y3A0	SN	Gallic acid; 3,4,5-Trihydroxybenzoic acid; 149-91-7; gallate; Benzoic acid, 3,4,5-trihydroxy-; Gallic acid, tech.; GALOP; Pyrogallol-5-carboxylic acid; Kyselina gallova; HSDB 2117; 3,4,5-Trihydroxybenzoate; CCRIS 5523; Kyselina gallova [Czech]; Gallic acid polymer; UNII-632XD903SP; NSC 674319; Gallicum acidum; CHEBI:30778; AI3-16412; Kyselina 3,4,5-trihydroxybenzoova; EINECS 205-749-9; NSC 20103; BRN 2050274; GALLIC ACID ANHYDROUS; Kyselina 3,4,5-trihydroxybenzoova [Czech]; CHEMBL288114; LNTHITQWFMADLM-UHFFFAOYSA-N; 632XD903SP
DM6Y3A0	DT	Small molecular drug
DM6Y3A0	PC	370
DM6Y3A0	MW	170.12
DM6Y3A0	FM	C7H6O5
DM6Y3A0	IC	InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)
DM6Y3A0	CS	C1=C(C=C(C(=C1O)O)O)C(=O)O
DM6Y3A0	IK	LNTHITQWFMADLM-UHFFFAOYSA-N
DM6Y3A0	IU	3,4,5-trihydroxybenzoic acid
DM6Y3A0	CA	CAS 149-91-7
DM6Y3A0	CB	CHEBI:30778
DM6Y3A0	DE	Discovery agent

DMX2084	ID	DMX2084
DMX2084	DN	GALLOCATECHIN GALLATE
DMX2084	HS	Investigative
DMX2084	SN	(-)-Gallocatechin gallate; 4233-96-9; Gallocatechin gallate; (-)-Gallocatechol gallate; UNII-IRW3C4Y31Q; (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Gallocatechin gallate (Gcg); IRW3C4Y31Q; CHEMBL264938; (-)-gallocatechin-3-O-gallate; (2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); [(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, 3,
DMX2084	DT	Small molecular drug
DMX2084	PC	5276890
DMX2084	MW	458.4
DMX2084	FM	C22H18O11
DMX2084	IC	InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21+/m0/s1
DMX2084	CS	C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMX2084	IK	WMBWREPUVVBILR-GHTZIAJQSA-N
DMX2084	IU	[(2R,3S)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMX2084	CA	CAS 5127-64-0
DMX2084	CB	CHEBI:156284
DMX2084	DE	Discovery agent

DML9DH8	ID	DML9DH8
DML9DH8	DN	galmic
DML9DH8	HS	Investigative
DML9DH8	SN	galmic; CHEMBL1187471; GTPL6119
DML9DH8	DT	Small molecular drug
DML9DH8	PC	24748735
DML9DH8	MW	989.1
DML9DH8	FM	C51H60N10O11
DML9DH8	IC	InChI=1S/C51H60N10O11/c1-26-36-41(64)61-51(6,45(68)55-38-32-21-13-11-19-30(32)31-20-12-14-22-33(31)38)48-58-37(28(3)72-48)40(63)60-50(5,44(67)54-34(42(65)69-7)23-15-16-24-52)47-57-35(27(2)71-47)39(62)59-49(4,46(56-36)70-26)43(66)53-25-29-17-9-8-10-18-29/h11-14,19-22,29,34,38H,8-10,15-18,23-25,52H2,1-7H3,(H,53,66)(H,54,67)(H,55,68)(H,59,62)(H,60,63)(H,61,64)/t34-,49-,50-,51-/m0/s1
DML9DH8	CS	CC1=C2C(=O)N[C@@](C3=NC(=C(O3)C)C(=O)N[C@@](C4=NC(=C(O4)C)C(=O)N[C@@](C(=N2)O1)(C)C(=O)NCC5CCCCC5)(C)C(=O)N[C@@H](CCCCN)C(=O)OC)(C)C(=O)NC6C7=CC=CC=C7C8=CC=CC=C68
DML9DH8	IK	DOHGPSDHRIKTDB-KBAHWNQNSA-N
DML9DH8	IU	methyl (2S)-6-amino-2-[[(4R,11R,18R)-11-(cyclohexylmethylcarbamoyl)-18-(9H-fluoren-9-ylcarbamoyl)-4,7,11,14,18,21-hexamethyl-2,9,16-trioxo-6,13,20-trioxa-3,10,17,22,23,24-hexazatetracyclo[17.2.1.15,8.112,15]tetracosa-1(21),5(24),7,12(23),14,19(22)-hexaene-4-carbonyl]amino]hexanoate
DML9DH8	DE	Discovery agent

DMB8HCW	ID	DMB8HCW
DMB8HCW	DN	Galnon
DMB8HCW	HS	Investigative
DMB8HCW	SN	Galnon; 475115-35-6; CHEMBL592414; 9H-fluoren-9-ylmethyl N-[(2S)-1-[[(2S)-6-amino-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]carbamate; AC1NSKC5; SCHEMBL4464884; GTPL6118; CHEMBL451433; MolPort-023-276-322; ZINC49756387; AKOS024456937; NCGC00165798-01; B5256
DMB8HCW	DT	Small molecular drug
DMB8HCW	PC	5311268
DMB8HCW	MW	678.8
DMB8HCW	FM	C40H46N4O6
DMB8HCW	IC	InChI=1S/C40H46N4O6/c1-25-21-37(45)50-36-23-27(18-19-28(25)36)42-38(46)34(17-9-10-20-41)43-39(47)35(22-26-11-3-2-4-12-26)44-40(48)49-24-33-31-15-7-5-13-29(31)30-14-6-8-16-32(30)33/h5-8,13-16,18-19,21,23,26,33-35H,2-4,9-12,17,20,22,24,41H2,1H3,(H,42,46)(H,43,47)(H,44,48)/t34-,35-/m0/s1
DMB8HCW	CS	CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3CCCCC3)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46
DMB8HCW	IK	IKNOZZKXIDSTRN-PXLJZGITSA-N
DMB8HCW	IU	9H-fluoren-9-ylmethyl N-[(2S)-1-[[(2S)-6-amino-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]carbamate
DMB8HCW	CA	CAS 475115-35-6
DMB8HCW	DE	Discovery agent

DMI7RPT	ID	DMI7RPT
DMI7RPT	DN	GalR3ant
DMI7RPT	HS	Investigative
DMI7RPT	SN	GalR3ant; GTPL6127; SCHEMBL5362026; 3-(3,4-dichlorophenyl)imino-1-(6-methoxypyridin-3-yl)indol-2-one
DMI7RPT	DT	Small molecular drug
DMI7RPT	PC	9800980
DMI7RPT	MW	398.2
DMI7RPT	FM	C20H13Cl2N3O2
DMI7RPT	IC	InChI=1S/C20H13Cl2N3O2/c1-27-18-9-7-13(11-23-18)25-17-5-3-2-4-14(17)19(20(25)26)24-12-6-8-15(21)16(22)10-12/h2-11H,1H3
DMI7RPT	CS	COC1=NC=C(C=C1)N2C3=CC=CC=C3C(=NC4=CC(=C(C=C4)Cl)Cl)C2=O
DMI7RPT	IK	YZFBJQVMOLTGFZ-UHFFFAOYSA-N
DMI7RPT	IU	3-(3,4-dichlorophenyl)imino-1-(6-methoxypyridin-3-yl)indol-2-one
DMI7RPT	DE	Discovery agent

DMFSXOM	ID	DMFSXOM
DMFSXOM	DN	Gamma-acetylenic GABA
DMFSXOM	HS	Investigative
DMFSXOM	SN	gamma-Acetylenic gaba; 4-Aminohex-5-ynoic acid; gamma-Acetylinic GABA; 4-Amino-5-hexynoic acid; 57659-38-8; RMI 71645; 5-Hexynoic acid, 4-amino-; RMI-71645; 4-aminohexynoate; gamma-acetylenic-GABA; Acetylenic GABA-7; AC1L1FYW; 4-ami-nohex-5-ynoic acid; AC1Q5VT0; 4-Amino-hex-5-ynoic acid; Lopac0_000138; SCHEMBL690785; CHEMBL330129; 4-Amino-5-hexynoic acid, solid; CTK5A7233; BDBM81477; HMS3260K18; Tox21_500138; PDSP2_000141; PDSP1_000142; AKOS006272245; LP00138; CCG-204233; NCGC00015019-02; NCGC00093628-02; NCGC00260823-01
DMFSXOM	DT	Small molecular drug
DMFSXOM	PC	3452
DMFSXOM	MW	127.14
DMFSXOM	FM	C6H9NO2
DMFSXOM	IC	InChI=1S/C6H9NO2/c1-2-5(7)3-4-6(8)9/h1,5H,3-4,7H2,(H,8,9)
DMFSXOM	CS	C#CC(CCC(=O)O)N
DMFSXOM	IK	BJNIHWSOVCDBHS-UHFFFAOYSA-N
DMFSXOM	IU	4-aminohex-5-ynoic acid
DMFSXOM	CA	CAS 57659-38-8
DMFSXOM	DE	Discovery agent

DMDCZWY	ID	DMDCZWY
DMDCZWY	DN	Gamma-butyrolactone
DMDCZWY	HS	Investigative
DMDCZWY	SN	4-butanolide; 2-oxolanone
DMDCZWY	DT	Small molecular drug
DMDCZWY	PC	7302
DMDCZWY	MW	86.09
DMDCZWY	FM	C4H6O2
DMDCZWY	IC	InChI=1S/C4H6O2/c5-4-2-1-3-6-4/h1-3H2
DMDCZWY	CS	C1CC(=O)OC1
DMDCZWY	IK	YEJRWHAVMIAJKC-UHFFFAOYSA-N
DMDCZWY	IU	oxolan-2-one
DMDCZWY	CA	CAS 96-48-0
DMDCZWY	CB	CHEBI:42639
DMDCZWY	DE	Discovery agent

DMZMCT0	ID	DMZMCT0
DMZMCT0	DN	Gamma-Carboxy-Glutamic Acid
DMZMCT0	HS	Investigative
DMZMCT0	SN	H-GLA-OH; 53861-57-7; gamma-Carboxyglutamic acid; Gamma-Carboxy-Glutamic Acid; g-carboxyglutamic acid; gamma-Carboxy-L-glutamic acid; L-Gla-OH; H-L-Gla-OH; (S)-3-Aminopropane-1,1,3-tricarboxylic acid; (3S)-3-aminopropane-1,1,3-tricarboxylic acid; CHEMBL38397; CHEBI:41450; (3S)-3-amino-1,1,3-propanetricarboxylic acid; gamma-carboxy-glutamic acid zwitterion; EINECS 258-825-9; AC1Q5RNZ; H-Gamma-Carboxy-Glu-OH; AC1L2X6R; SCHEMBL39093; 1,1,3-Propanetricarboxylic acid, 3-amino-, (3S)-; CTK1H2562; UHBYWPGGCSDKFX-VKHMYHEASA-N
DMZMCT0	DT	Small molecular drug
DMZMCT0	PC	104625
DMZMCT0	MW	191.14
DMZMCT0	FM	C6H9NO6
DMZMCT0	IC	InChI=1S/C6H9NO6/c7-3(6(12)13)1-2(4(8)9)5(10)11/h2-3H,1,7H2,(H,8,9)(H,10,11)(H,12,13)/t3-/m0/s1
DMZMCT0	CS	C([C@@H](C(=O)O)N)C(C(=O)O)C(=O)O
DMZMCT0	IK	UHBYWPGGCSDKFX-VKHMYHEASA-N
DMZMCT0	IU	(3S)-3-aminopropane-1,1,3-tricarboxylic acid
DMZMCT0	CA	CAS 53861-57-7
DMZMCT0	CB	CHEBI:41450
DMZMCT0	DE	Discovery agent

DMHNJDE	ID	DMHNJDE
DMHNJDE	DN	Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine
DMHNJDE	HS	Investigative
DMHNJDE	SN	GAMMA-GLUTAMYL[S-(2-IODOBENZYL)CYSTEINYL]GLYCINE; IBG; AC1L9KH0; SCHEMBL433962; DB03597; L-gamma-glutamyl-S-(2-iodobenzyl)-L-cysteinylglycine; (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[(2-iodophenyl)methylsulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMHNJDE	DT	Small molecular drug
DMHNJDE	PC	447108
DMHNJDE	MW	523.299
DMHNJDE	FM	C17H22IN3O6S
DMHNJDE	IC	InChI=1S/C17H22IN3O6S/c18-11-4-2-1-3-10(11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)6-5-12(19)17(26)27/h1-4,12-13H,5-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1
DMHNJDE	CS	C1=CC=C(C(=C1)CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)I
DMHNJDE	IK	QFYJAEOZTBVJQM-STQMWFEESA-N
DMHNJDE	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[(2-iodophenyl)methylsulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMHNJDE	DE	Discovery agent

DMC0OVP	ID	DMC0OVP
DMC0OVP	DN	Gamma-mangostin
DMC0OVP	HS	Investigative
DMC0OVP	SN	gamma-Mangostin; 31271-07-5; 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; CHEMBL260553; CHEBI:67548; Q-100393; 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one; 9H-Xanthen-9-one, 1,3,6,7-tetrahydroxy-2,8-bis(3-methyl-2-butenyl)-; Normangostin; g-Mangostin; gamma- Mangostin; Mangostin, gamma-; AC1NUYXQ; 1,3,6,7-Tetrahydroxy-2,5-bis(3-methyl-2-butenyl)-9H-xanthen-9-one; SCHEMBL3753526; DTXSID50185194; VEZXFTKZUMARDU-UHFFFAOYSA-N; MolPort-019-937-259; ZINC5195818; gamma-Mangostin, &gt
DMC0OVP	DT	Small molecular drug
DMC0OVP	PC	5464078
DMC0OVP	MW	396.4
DMC0OVP	FM	C23H24O6
DMC0OVP	IC	InChI=1S/C23H24O6/c1-11(2)5-7-13-15(24)9-18-20(22(13)27)23(28)19-14(8-6-12(3)4)21(26)16(25)10-17(19)29-18/h5-6,9-10,24-27H,7-8H2,1-4H3
DMC0OVP	CS	CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C(=C(C(=C3)O)O)CC=C(C)C)O)C
DMC0OVP	IK	VEZXFTKZUMARDU-UHFFFAOYSA-N
DMC0OVP	IU	1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one
DMC0OVP	CA	CAS 31271-07-5
DMC0OVP	CB	CHEBI:67548
DMC0OVP	DE	Discovery agent

DMG7UPR	ID	DMG7UPR
DMG7UPR	DN	Gamma-secretase modulators
DMG7UPR	HS	Investigative
DMG7UPR	SN	Gamma-secretase modulators (Alzheimer's disease); Gamma-secretase modulators (Alzheimer's disease), F Hoffmann-La Roche
DMG7UPR	CP	F Hoffmann-La Roche Ltd
DMG7UPR	DT	Small molecular drug
DMG7UPR	PC	24781184
DMG7UPR	MW	483.5
DMG7UPR	FM	C26H24F3N3O3
DMG7UPR	IC	InChI=1S/C26H24F3N3O3/c1-15-11-31(14-30-15)22-6-3-16(8-24(22)34-2)7-17-4-5-19-12-35-13-23(32(19)26(17)33)18-9-20(27)25(29)21(28)10-18/h3,6-11,14,19,23H,4-5,12-13H2,1-2H3/b17-7+/t19-,23-/m0/s1
DMG7UPR	CS	CC1=CN(C=N1)C2=C(C=C(C=C2)/C=C/3\\CC[C@H]4COC[C@H](N4C3=O)C5=CC(=C(C(=C5)F)F)F)OC
DMG7UPR	IK	VHNYOQKVZQVBLC-RTCGXNAVSA-N
DMG7UPR	IU	(4R,7E,9aS)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one
DMG7UPR	CA	CAS 937812-80-1
DMG7UPR	DE	Alzheimer disease

DM83HUI	ID	DM83HUI
DM83HUI	DN	Gamma-thiobutyrolactone
DM83HUI	HS	Investigative
DM83HUI	SN	Dihydro-2(3H)-thiophenone; Dihydro-2-(3H)-thiophenone; KMSNYNIWEORQDJ-UHFFFAOYSA-N; Tetrahydro-2-thiophenone; Thiacyclopentan-2-one; Thiacyclopentanone-2; Thiolan-2-one; dihydrothiophen-2(3H)-one; gamma-Thiobutyrolactone; thiolanone; .gamma.-Thiobutyrolactone; 1003-10-7; 2(3H)-Thiophenone, dihydro-; 2-Oxothiolane; 2-THIOPHENONE, TETRAHYDRO-; 2-Thiolanone; 2-oxotetrahydrothiophene; 4-Butyrothiolactone; 4-Thiobutyrolactone; A3ERZ734SN; AC1L22MB; BRN 0105273; CHEBI:89059; EINECS 213-700-8; NSC 54087; SCHEMBL13480; UNII-A3ERZ734SN
DM83HUI	PC	13852
DM83HUI	MW	102.16
DM83HUI	FM	C4H6OS
DM83HUI	IC	KMSNYNIWEORQDJ-UHFFFAOYSA-N
DM83HUI	CS	C1CC(=O)SC1
DM83HUI	IK	1S/C4H6OS/c5-4-2-1-3-6-4/h1-3H2
DM83HUI	IU	thiolan-2-one
DM83HUI	CA	CAS 1003-10-7
DM83HUI	CB	CHEBI:89059
DM83HUI	DE	Discovery agent

DM42EVG	ID	DM42EVG
DM42EVG	DN	Ganoderic acid A
DM42EVG	HS	Investigative
DM42EVG	SN	Ganoderic acid A; 81907-62-2; UNII-548G37DF65; 548G37DF65; (2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid; (2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxo-heptanoic acid; CHEMBL602899; Ganoderic-acid-A; AC1LAM6R; HY-N1447; ZINC49767216; CS-5856; Lanost-8-en-26-oic 
DM42EVG	DT	Small molecular drug
DM42EVG	PC	471002
DM42EVG	MW	516.7
DM42EVG	FM	C30H44O7
DM42EVG	IC	InChI=1S/C30H44O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21,23,32,35H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,23+,28+,29-,30+/m1/s1
DM42EVG	CS	C[C@H](CC(=O)C[C@@H](C)C(=O)O)[C@H]1C[C@@H]([C@@]2([C@@]1(CC(=O)C3=C2[C@H](C[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)O)C)C)O
DM42EVG	IK	DYOKDAQBNHPJFD-JNTBEZBXSA-N
DM42EVG	IU	(2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
DM42EVG	CA	CAS 81907-62-2
DM42EVG	DE	Discovery agent

DMFT4GU	ID	DMFT4GU
DMFT4GU	DN	GANSTIGMINE
DMFT4GU	HS	Investigative
DMFT4GU	DT	Small molecular drug
DMFT4GU	PC	9823294
DMFT4GU	MW	381.5
DMFT4GU	FM	C22H27N3O3
DMFT4GU	IC	InChI=1S/C22H27N3O3/c1-5-15-8-6-7-9-18(15)23-21(26)27-16-10-11-19-17(14-16)22(2)12-13-24(3)28-20(22)25(19)4/h6-11,14,20H,5,12-13H2,1-4H3,(H,23,26)/t20-,22-/m0/s1
DMFT4GU	CS	CCC1=CC=CC=C1NC(=O)OC2=CC3=C(C=C2)N([C@@H]4[C@]3(CCN(O4)C)C)C
DMFT4GU	IK	ZOBDWFRKFSPCRB-UNMCSNQZSA-N
DMFT4GU	IU	[(4aS,9aS)-2,4a,9-trimethyl-4,9a-dihydro-3H-oxazino[6,5-b]indol-6-yl] N-(2-ethylphenyl)carbamate
DMFT4GU	CA	CAS 457075-21-7
DMFT4GU	DE	Discovery agent

DM6B9ZG	ID	DM6B9ZG
DM6B9ZG	DN	garcinol
DM6B9ZG	HS	Investigative
DM6B9ZG	SN	Garcinol; Camboginol; 78824-30-3; AC1Q1NUM; GTPL7001; QDKLRKZQSOQWJQ-SMDXAGPFSA-N; ZINC4098424; AKOS025142024; (1S,5R,7R)-3-[(3,4-dihydroxyphenyl)(hydroxy)methylidene]-6,6-dimethyl-1-[(2S)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-5,7-bis(3-methylbut-2-en-1-yl)bicyclo[3.3.1]nonane-2,4,9-trione; (1R,5R,7R)-3-(3,4-Dihydroxybenzoyl)-4-hydroxy-8,8-dimethyl-1,7-bis(3-methyl-2-buten-1-yl)-5-[(2S)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-Bicyclo[3.3.1]non-3-ene-2,9-dione
DM6B9ZG	DT	Small molecular drug
DM6B9ZG	PC	5281560
DM6B9ZG	MW	602.8
DM6B9ZG	FM	C38H50O6
DM6B9ZG	IC	InChI=1S/C38H50O6/c1-22(2)11-13-27(25(7)8)20-37-21-28(15-12-23(3)4)36(9,10)38(35(37)44,18-17-24(5)6)34(43)31(33(37)42)32(41)26-14-16-29(39)30(40)19-26/h11-12,14,16-17,19,27-28,39-41H,7,13,15,18,20-21H2,1-6,8-10H3/b32-31-/t27-,28+,37+,38-/m0/s1
DM6B9ZG	CS	CC(=CC[C@@H]1C[C@@]2(C(=O)/C(=C(\\C3=CC(=C(C=C3)O)O)/O)/C(=O)[C@@](C2=O)(C1(C)C)CC=C(C)C)C[C@H](CC=C(C)C)C(=C)C)C
DM6B9ZG	IK	DTTONLKLWRTCAB-BZSUNBQASA-N
DM6B9ZG	IU	(1S,3Z,5R,7R)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)-1-[(2S)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]bicyclo[3.3.1]nonane-2,4,9-trione
DM6B9ZG	CA	CAS 78824-30-3
DM6B9ZG	CB	CHEBI:5276
DM6B9ZG	DE	Discovery agent

DMQDV3U	ID	DMQDV3U
DMQDV3U	DN	GARCINONE D
DMQDV3U	HS	Investigative
DMQDV3U	SN	GARCINONE D; 107390-08-9; CHEMBL462879; Q-100046; Garcinone-D; AC1NUY2Y; Garcinia mangostana (Mangosteen); DTXSID00420547; MolPort-039-142-002; ZINC14727633; 9439AF; BDBM50250510; AB3000023; N2173; FT-0686619; 1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-trihydroxy-8-(3-hydroxy-3-methyl-butyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one; 9H-Xanthen-9-one, 1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methyl-2-butenyl)-
DMQDV3U	DT	Small molecular drug
DMQDV3U	PC	5495926
DMQDV3U	MW	428.5
DMQDV3U	FM	C24H28O7
DMQDV3U	IC	InChI=1S/C24H28O7/c1-12(2)6-7-13-15(25)10-18-20(21(13)27)22(28)19-14(8-9-24(3,4)29)23(30-5)16(26)11-17(19)31-18/h6,10-11,25-27,29H,7-9H2,1-5H3
DMQDV3U	CS	CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C(=C(C(=C3)O)OC)CCC(C)(C)O)O)C
DMQDV3U	IK	TYALNCRUIKOKGP-UHFFFAOYSA-N
DMQDV3U	IU	1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one
DMQDV3U	CA	CAS 107390-08-9
DMQDV3U	DE	Discovery agent

DMZ5AD8	ID	DMZ5AD8
DMZ5AD8	DN	GARTANIN
DMZ5AD8	HS	Investigative
DMZ5AD8	SN	Gartanin; 33390-42-0; 1,3,5,8-Tetrahydroxy-2,4-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; Gartinin; 9H-Xanthen-9-one, 1,3,5,8-tetrahydroxy-2,4-bis(3-methyl-2-butenyl)-; CHEBI:5279; CHEMBL487992; 1,3,5,8-Tetrahydroxy-2,4-diprenylxanthone; 1,3,5,8-TETRAHYDROXY-2,4-BIS(3-METHYL-2-BUTENYL)-9H-XANTHEN-9-ONE; Q-100408; 1,3,5,8-tetrahydroxy-2,4-bis(3-methylbut-2-enyl)xanthen-9-one; AC1NQYRY; C10063; SCHEMBL1516414; DTXSID20187024; MolPort-023-221-573; ZINC5854400; BDBM50311743; NSC692946; AKOS016009589; NSC-692946; P165; AK111266
DMZ5AD8	DT	Small molecular drug
DMZ5AD8	PC	5281633
DMZ5AD8	MW	396.4
DMZ5AD8	FM	C23H24O6
DMZ5AD8	IC	InChI=1S/C23H24O6/c1-11(2)5-7-13-19(26)14(8-6-12(3)4)22-18(20(13)27)21(28)17-15(24)9-10-16(25)23(17)29-22/h5-6,9-10,24-27H,7-8H2,1-4H3
DMZ5AD8	CS	CC(=CCC1=C(C(=C2C(=C1O)C(=O)C3=C(C=CC(=C3O2)O)O)CC=C(C)C)O)C
DMZ5AD8	IK	OJXQLGQIDIPMTE-UHFFFAOYSA-N
DMZ5AD8	IU	1,3,5,8-tetrahydroxy-2,4-bis(3-methylbut-2-enyl)xanthen-9-one
DMZ5AD8	CA	CAS 33390-42-0
DMZ5AD8	CB	CHEBI:5279
DMZ5AD8	DE	Discovery agent

DM7GX1S	ID	DM7GX1S
DM7GX1S	DN	GARVEATIN A
DM7GX1S	HS	Investigative
DM7GX1S	SN	garveatin A; SCHEMBL3090239
DM7GX1S	DT	Small molecular drug
DM7GX1S	PC	15940065
DM7GX1S	MW	340.4
DM7GX1S	FM	C20H20O5
DM7GX1S	IC	InChI=1S/C20H20O5/c1-8-6-11-7-12-15(16(22)9(2)19(25)20(12,4)5)18(24)14(11)17(23)13(8)10(3)21/h6-7,22-24H,1-5H3
DM7GX1S	CS	CC1=CC2=CC3=C(C(=C(C(=O)C3(C)C)C)O)C(=C2C(=C1C(=O)C)O)O
DM7GX1S	IK	WVQSFFSLBOWMAA-UHFFFAOYSA-N
DM7GX1S	IU	6-acetyl-4,5,10-trihydroxy-1,1,3,7-tetramethylanthracen-2-one
DM7GX1S	DE	Discovery agent

DMXNQ15	ID	DMXNQ15
DMXNQ15	DN	Garveatin C
DMXNQ15	HS	Investigative
DMXNQ15	SN	Garveatin C; NSC611985; CHEMBL505049; AC1L78CY; AC1Q1K0O; SCHEMBL3086612; BDBM50241725; NSC-611985; 7-acetyl-9-hydroxy-8-methoxy-2,2,4,4,6-pentamethylanthracene-1,3-dione; 1,3(2H,4H)-anthracenedione, 7-acetyl-9-hydroxy-8-methoxy-2,2,4,4,6-pentamethyl-
DMXNQ15	DT	Small molecular drug
DMXNQ15	PC	356405
DMXNQ15	MW	368.4
DMXNQ15	FM	C22H24O5
DMXNQ15	IC	InChI=1S/C22H24O5/c1-10-8-12-9-13-16(19(25)22(5,6)20(26)21(13,3)4)17(24)15(12)18(27-7)14(10)11(2)23/h8-9,24H,1-7H3
DMXNQ15	CS	CC1=CC2=CC3=C(C(=C2C(=C1C(=O)C)OC)O)C(=O)C(C(=O)C3(C)C)(C)C
DMXNQ15	IK	BRECKZGJFRHNPM-UHFFFAOYSA-N
DMXNQ15	IU	7-acetyl-9-hydroxy-8-methoxy-2,2,4,4,6-pentamethylanthracene-1,3-dione
DMXNQ15	DE	Discovery agent

DMUFZ18	ID	DMUFZ18
DMUFZ18	DN	Garveatin E
DMUFZ18	HS	Investigative
DMUFZ18	SN	garveatin E
DMUFZ18	DT	Small molecular drug
DMUFZ18	PC	16091659
DMUFZ18	MW	340.4
DMUFZ18	FM	C20H20O5
DMUFZ18	IC	InChI=1S/C20H20O5/c1-6-10-8(2)15(21)11-7-12-14(18(24)13(11)17(10)23)16(22)9(3)19(25)20(12,4)5/h7,22,24H,6H2,1-5H3
DMUFZ18	CS	CCC1=C(C(=O)C2=CC3=C(C(=C(C(=O)C3(C)C)C)O)C(=C2C1=O)O)C
DMUFZ18	IK	XUTUGWZITVPISM-UHFFFAOYSA-N
DMUFZ18	IU	2-ethyl-8,9-dihydroxy-3,5,5,7-tetramethylanthracene-1,4,6-trione
DMUFZ18	DE	Discovery agent

DMWFYJ4	ID	DMWFYJ4
DMWFYJ4	DN	GB110
DMWFYJ4	HS	Investigative
DMWFYJ4	SN	GB 110; GB-110
DMWFYJ4	DT	Small molecular drug
DMWFYJ4	PC	49843508
DMWFYJ4	MW	608.8
DMWFYJ4	FM	C33H48N6O5
DMWFYJ4	IC	InChI=1S/C33H48N6O5/c1-3-22(2)29(38-30(40)27(19-23-8-5-4-6-9-23)37-31(41)28-12-15-36-44-28)32(42)35-21-25-10-7-11-26(18-25)33(43)39-16-13-24(20-34)14-17-39/h7,10-12,15,18,22-24,27,29H,3-6,8-9,13-14,16-17,19-21,34H2,1-2H3,(H,35,42)(H,37,41)(H,38,40)/t22?,27-,29-/m0/s1
DMWFYJ4	CS	CCC(C)[C@@H](C(=O)NCC1=CC(=CC=C1)C(=O)N2CCC(CC2)CN)NC(=O)[C@H](CC3CCCCC3)NC(=O)C4=CC=NO4
DMWFYJ4	IK	HXLQLJFWNKMGET-KCPQSXFMSA-N
DMWFYJ4	IU	N-[(2S)-1-[[(2S)-1-[[3-[4-(aminomethyl)piperidine-1-carbonyl]phenyl]methylamino]-3-methyl-1-oxopentan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]-1,2-oxazole-5-carboxamide
DMWFYJ4	DE	Discovery agent

DM7B5HA	ID	DM7B5HA
DM7B5HA	DN	GB-12819
DM7B5HA	HS	Investigative
DM7B5HA	SN	GB-12819; CHEMBL433138; BDBM50116806; 4-{2-[bis-(4-fluoro-phenyl)-methoxy]-ethyl}-1-(3-phenyl-propyl)-piperazin-1-ium
DM7B5HA	DT	Small molecular drug
DM7B5HA	PC	44316307
DM7B5HA	MW	449.6
DM7B5HA	FM	C29H33F2NO
DM7B5HA	IC	InChI=1S/C29H33F2NO/c30-27-13-9-25(10-14-27)29(26-11-15-28(31)16-12-26)33-22-21-32-19-17-24(18-20-32)8-4-7-23-5-2-1-3-6-23/h1-3,5-6,9-16,24,29H,4,7-8,17-22H2
DM7B5HA	CS	C1CN(CCC1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DM7B5HA	IK	VMIZSAUBUHOYHI-UHFFFAOYSA-N
DM7B5HA	IU	1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperidine
DM7B5HA	DE	Discovery agent

DMLDVFM	ID	DMLDVFM
DMLDVFM	DN	GB88
DMLDVFM	HS	Investigative
DMLDVFM	SN	GB 88; GB-88
DMLDVFM	DT	Small molecular drug
DMLDVFM	PC	73755230
DMLDVFM	MW	546.7
DMLDVFM	FM	C32H42N4O4
DMLDVFM	IC	InChI=1S/C32H42N4O4/c1-3-22(2)28(31(39)36-19-16-32(17-20-36)15-13-24-11-7-8-12-25(24)32)35-29(37)26(21-23-9-5-4-6-10-23)34-30(38)27-14-18-33-40-27/h7-8,11-15,18,22-23,26,28H,3-6,9-10,16-17,19-21H2,1-2H3,(H,34,38)(H,35,37)/t22-,26+,28+/m1/s1
DMLDVFM	CS	CC[C@@H](C)[C@@H](C(=O)N1CCC2(CC1)C=CC3=CC=CC=C23)NC(=O)[C@H](CC4CCCCC4)NC(=O)C5=CC=NO5
DMLDVFM	IK	DCUDDCGUKZLQLN-ZEZZXZOMSA-N
DMLDVFM	IU	N-[(2S)-3-cyclohexyl-1-[[(2S,3R)-3-methyl-1-oxo-1-spiro[indene-1,4'-piperidine]-1'-ylpentan-2-yl]amino]-1-oxopropan-2-yl]-1,2-oxazole-5-carboxamide
DMLDVFM	DE	Discovery agent

DMPOML4	ID	DMPOML4
DMPOML4	DN	GBR 12530
DMPOML4	HS	Investigative
DMPOML4	SN	GBR 12530; CHEMBL203446
DMPOML4	DT	Small molecular drug
DMPOML4	PC	44409554
DMPOML4	MW	326.5
DMPOML4	FM	C25H26
DMPOML4	IC	InChI=1S/C25H26/c1-17-21-12-13-22(17)15-18(14-21)16-25-23-8-4-2-6-19(23)10-11-20-7-3-5-9-24(20)25/h2-9,14,16-17,21-22H,10-13,15H2,1H3
DMPOML4	CS	CC1C2CCC1C=C(C2)C=C3C4=CC=CC=C4CCC5=CC=CC=C53
DMPOML4	IK	RMNZMKPVCVYBDK-UHFFFAOYSA-N
DMPOML4	IU	2-[(8-methyl-3-bicyclo[3.2.1]oct-2-enyl)methylidene]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene
DMPOML4	DE	Discovery agent

DM2CUNP	ID	DM2CUNP
DM2CUNP	DN	GBR-12289
DM2CUNP	HS	Investigative
DM2CUNP	SN	GBR-12289; CHEMBL381386; BDBM50185251
DM2CUNP	DT	Small molecular drug
DM2CUNP	PC	44409490
DM2CUNP	MW	290.4
DM2CUNP	FM	C19H18N2O
DM2CUNP	IC	InChI=1S/C19H18N2O/c1-21-13-12-20-19(21)18(22)14-17(15-8-4-2-5-9-15)16-10-6-3-7-11-16/h2-14,18,22H,1H3
DM2CUNP	CS	CN1C=CN=C1C(C=C(C2=CC=CC=C2)C3=CC=CC=C3)O
DM2CUNP	IK	ZNOUJOFQAABUAP-UHFFFAOYSA-N
DM2CUNP	IU	1-(1-methylimidazol-2-yl)-3,3-diphenylprop-2-en-1-ol
DM2CUNP	DE	Discovery agent

DMYMGBA	ID	DMYMGBA
DMYMGBA	DN	GC-14
DMYMGBA	HS	Investigative
DMYMGBA	DT	Small molecular drug
DMYMGBA	PC	23724977
DMYMGBA	MW	1989.1
DMYMGBA	FM	C86H103Cl3N10O34P2
DMYMGBA	IC	InChI=1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66+,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1
DMYMGBA	CS	C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O
DMYMGBA	IK	PWTROOMOPLCZHB-UBFSLMEUSA-N
DMYMGBA	IU	(1S,2R,18R,19R,22S,25R,28R,40R)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid;phosphoric acid
DMYMGBA	DE	Discovery agent

DM46HAS	ID	DM46HAS
DM46HAS	DN	GC-2107
DM46HAS	HS	Investigative
DM46HAS	SN	Factor Xa inhibitor (oral/injectable, thrombosis), Green Cross/ LegoChem
DM46HAS	CP	LegoChem Bioscience Inc
DM46HAS	DE	Thrombosis

DMSF8B9	ID	DMSF8B9
DMSF8B9	DN	GC-24
DMSF8B9	HS	Investigative
DMSF8B9	SN	GC 24; N-[2-(dimethylamino)ethyl]-2-methylpropanamide; Propanamide, N-(2-(dimethylamino)ethyl)-2-methyl-; BRN 2350680; 63224-17-9; N-(2-(Dimethylamino)ethyl)-2-methylpropanamide; AC1MIL8W; SCHEMBL2624391; DTXSID70212592; MolPort-008-439-279; ZINC11638438; AKOS009104316; MCULE-5485385679; NE11932; LS-119191; N-(2-dimethylaminoethyl)-2-methylpropanamide; EN300-86303
DMSF8B9	DT	Small molecular drug
DMSF8B9	PC	448011
DMSF8B9	MW	376.4
DMSF8B9	FM	C24H24O4
DMSF8B9	IC	InChI=1S/C24H24O4/c1-16-10-21(28-15-24(26)27)11-17(2)22(16)14-19-8-9-23(25)20(13-19)12-18-6-4-3-5-7-18/h3-11,13,25H,12,14-15H2,1-2H3,(H,26,27)
DMSF8B9	CS	CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)CC3=CC=CC=C3)C)OCC(=O)O
DMSF8B9	IK	JYHIGYLGYNCMGI-UHFFFAOYSA-N
DMSF8B9	IU	2-[4-[(3-benzyl-4-hydroxyphenyl)methyl]-3,5-dimethylphenoxy]acetic acid
DMSF8B9	DE	Hyperthyroidism

DM4BZEC	ID	DM4BZEC
DM4BZEC	DN	GCCSHPACAGNNQHIC*
DM4BZEC	HS	Investigative
DM4BZEC	SN	CHEMBL437423; GCCSHPACAGNNQHIC*
DM4BZEC	PC	44274422
DM4BZEC	MW	1613.8
DM4BZEC	FM	C61H96N24O20S4
DM4BZEC	IC	InChI=1S/C61H96N24O20S4/c1-5-26(2)47(60(104)81-37(20-106)48(66)92)84-54(98)32(11-29-16-67-24-70-29)77-51(95)31(8-9-42(63)87)76-53(97)34(14-44(65)89)78-52(96)33(13-43(64)88)74-46(91)18-69-49(93)27(3)72-56(100)39(22-108)82-50(94)28(4)73-59(103)41-7-6-10-85(41)61(105)35(12-30-17-68-25-71-30)79-55(99)36(19-86)80-58(102)40(23-109)83-57(101)38(21-107)75-45(90)15-62/h16-17,24-28,31-41,47,86,106-109H,5-15,18-23,62H2,1-4H3,(H2,63,87)(H2,64,88)(H2,65,89)(H2,66,92)(H,67,70)(H,68,71)(H,69,93)(H,72,100)(H,73,103)(H,74,91)(H,75,90)(H,76,97)(H,77,95)(H,78,96)(H,79,99)(H,80,102)(H,81,104)(H,82,94)(H,83,101)(H,84,98)/t26-,27-,28-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,47-/m0/s1
DM4BZEC	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CN
DM4BZEC	IK	UCMCIMRDJCGRNT-KLMBZYLCSA-N
DM4BZEC	IU	(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[(2-aminoacetyl)amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-N-[(2S)-1-[[(2S,3S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]pentanediamide
DM4BZEC	DE	Discovery agent

DMJ0ICN	ID	DMJ0ICN
DMJ0ICN	DN	GCCSNPVCHLEHSNLC*
DMJ0ICN	HS	Investigative
DMJ0ICN	SN	CHEMBL265198; GCCSNPVCHLEHSNLC*
DMJ0ICN	PC	44274190
DMJ0ICN	MW	1715
DMJ0ICN	FM	C67H107N23O22S4
DMJ0ICN	IC	InChI=1S/C67H107N23O22S4/c1-29(2)12-35(55(100)77-34(9-10-51(96)97)54(99)80-38(15-33-20-73-28-75-33)58(103)84-41(21-91)60(105)82-39(16-48(69)93)59(104)79-36(13-30(3)4)56(101)86-43(23-113)53(71)98)78-57(102)37(14-32-19-72-27-74-32)81-63(108)46(26-116)88-66(111)52(31(5)6)89-65(110)47-8-7-11-90(47)67(112)40(17-49(70)94)83-61(106)42(22-92)85-64(109)45(25-115)87-62(107)44(24-114)76-50(95)18-68/h19-20,27-31,34-47,52,91-92,113-116H,7-18,21-26,68H2,1-6H3,(H2,69,93)(H2,70,94)(H2,71,98)(H,72,74)(H,73,75)(H,76,95)(H,77,100)(H,78,102)(H,79,104)(H,80,99)(H,81,108)(H,82,105)(H,83,106)(H,84,103)(H,85,109)(H,86,101)(H,87,107)(H,88,111)(H,89,110)(H,96,97)/t34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,52-/m0/s1
DMJ0ICN	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CN
DMJ0ICN	IK	MLPOWHAMUPIMTC-XCQLYXDWSA-N
DMJ0ICN	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[(2-aminoacetyl)amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMJ0ICN	DE	Discovery agent

DMVFDYU	ID	DMVFDYU
DMVFDYU	DN	G-CSF
DMVFDYU	HS	Investigative
DMVFDYU	SN	G-CSF (leukemia)
DMVFDYU	CP	Medexgen Co Ltd
DMVFDYU	DE	leukaemia

DMF6MUB	ID	DMF6MUB
DMF6MUB	DN	GDP-alpha-D-glucose
DMF6MUB	HS	Investigative
DMF6MUB	SN	GDP-D-glucose; GDP-alpha-D-glucose; GDP-alpha-delta-glucose; GDP-glucose; Guanosine 5-pyrophosphate; Guanosine diphosphate glucose; Guanosine diphosphoglucose; P-alpha-D-glucopyranosyl ester; ZINC8215895; (GDP-Glc)1; 5750-57-2; AC1LD8KB; CHEBI:62254; CHEMBL228228; GDG; GDPG; Guanosine 5'-(trihydrogen diphosphate), P'-alpha-D-glucopyranosyl ester; Guanosine 5-(trihydrogen diphosphate); P-alpha-delta-glucopyranosyl ester; guanosine 5'-[3-(alpha-D-glucopyranosyl) dihydrogen diphosphate]
DMF6MUB	PC	135398625
DMF6MUB	MW	605.3
DMF6MUB	FM	C16H25N5O16P2
DMF6MUB	IC	MVMSCBBUIHUTGJ-LRJDVEEWSA-N
DMF6MUB	CS	C1=NC2=C(N1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OC4C(C(C(C(O4)CO)O)O)O)O)O)N=C(NC2=O)N
DMF6MUB	IK	1S/C16H25N5O16P2/c17-16-19-12-6(13(28)20-16)18-3-21(12)14-10(26)8(24)5(34-14)2-33-38(29,30)37-39(31,32)36-15-11(27)9(25)7(23)4(1-22)35-15/h3-5,7-11,14-15,22-27H,1-2H2,(H,29,30)(H,31,32)(H3,17,19,20,28)/t4-,5-,7-,8-,9+,10-,11-,14-,15-/m1/s1
DMF6MUB	IU	[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
DMF6MUB	CA	CAS 5750-57-2
DMF6MUB	CB	CHEBI:62254
DMF6MUB	DE	Discovery agent

DMZMULS	ID	DMZMULS
DMZMULS	DN	Gdp-Fucose
DMZMULS	HS	Investigative
DMZMULS	SN	guanosine diphosphate fucose; GDP-L-fucose
DMZMULS	DT	Small molecular drug
DMZMULS	PC	135412609
DMZMULS	MW	589.3
DMZMULS	FM	C16H25N5O15P2
DMZMULS	IC	InChI=1S/C16H25N5O15P2/c1-4-7(22)9(24)11(26)15(33-4)35-38(30,31)36-37(28,29)32-2-5-8(23)10(25)14(34-5)21-3-18-6-12(21)19-16(17)20-13(6)27/h3-5,7-11,14-15,22-26H,2H2,1H3,(H,28,29)(H,30,31)(H3,17,19,20,27)/t4-,5+,7+,8+,9+,10+,11-,14+,15?/m0/s1
DMZMULS	CS	C[C@H]1[C@H]([C@H]([C@@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=C(NC4=O)N)O)O)O)O)O
DMZMULS	IK	LQEBEXMHBLQMDB-QIXZNPMTSA-N
DMZMULS	IU	[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl] hydrogen phosphate
DMZMULS	CA	CAS 15839-70-0
DMZMULS	CB	CHEBI:17009
DMZMULS	DE	Discovery agent

DM9ARQ1	ID	DM9ARQ1
DM9ARQ1	DN	GDP-l-fucose
DM9ARQ1	HS	Investigative
DM9ARQ1	SN	GDP-L-fucose; GDP-fucose; Gdp fucose; guanosine diphosphate fucose; (6-deoxy-beta-l-galactopyranosyl) ester; AC1L96W5; CHEBI:17009; GTPL4578; [(2R,3S,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [hydroxy-[(3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphosphoryl] hydrogen phosphate; guanosine 5'-[3-(6-deoxy-L-galactopyranosyl) dihydrogen diphosphate]
DM9ARQ1	PC	135412609
DM9ARQ1	MW	589.3
DM9ARQ1	FM	C16H25N5O15P2
DM9ARQ1	IC	LQEBEXMHBLQMDB-QIXZNPMTSA-N
DM9ARQ1	CS	CC1C(C(C(C(O1)OP(=O)(O)OP(=O)(O)OCC2C(C(C(O2)N3C=NC4=C3N=C(NC4=O)N)O)O)O)O)O
DM9ARQ1	IK	1S/C16H25N5O15P2/c1-4-7(22)9(24)11(26)15(33-4)35-38(30,31)36-37(28,29)32-2-5-8(23)10(25)14(34-5)21-3-18-6-12(21)19-16(17)20-13(6)27/h3-5,7-11,14-15,22-26H,2H2,1H3,(H,28,29)(H,30,31)(H3,17,19,20,27)/t4-,5+,7+,8+,9+,10+,11-,14+,15?/m0/s1
DM9ARQ1	IU	[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl] hydrogen phosphate
DM9ARQ1	CA	CAS 15839-70-0
DM9ARQ1	CB	CHEBI:17009
DM9ARQ1	DE	Discovery agent

DMOC25M	ID	DMOC25M
DMOC25M	DN	GDP-mannose
DMOC25M	HS	Investigative
DMOC25M	SN	GDP-D-mannose; GDP-alpha-D-mannose; GDP-mannose; Gdp mannose; SA0B77H8CS; guanosine diphosphate mannose; guanosine diphosphomannose; guanosine pyrophosphate mannose; 3123-67-9; GUANOSINE-5'-DIPHOSPHATE-ALPHA-D-MANNOSE; Guanosine 5'-(trihydrogen diphosphate) P'-mannosyl ester; Guanosine 5'-(trihydrogen pyrophosphate) mono-D-mannosyl ester; Guanosine 5'-(trihydrogen pyrophosphate) monomannopyranosyl ester; Guanosine 5'-diphosphate D-mannose; Guanosine 5'-pyrophosphate D-mannosyl ester; UNII-SA0B77H8CS
DMOC25M	PC	135398627
DMOC25M	MW	605.3
DMOC25M	FM	C16H25N5O16P2
DMOC25M	IC	MVMSCBBUIHUTGJ-GDJBGNAASA-N
DMOC25M	CS	C1=NC2=C(N1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OC4C(C(C(C(O4)CO)O)O)O)O)O)N=C(NC2=O)N
DMOC25M	IK	1S/C16H25N5O16P2/c17-16-19-12-6(13(28)20-16)18-3-21(12)14-10(26)8(24)5(34-14)2-33-38(29,30)37-39(31,32)36-15-11(27)9(25)7(23)4(1-22)35-15/h3-5,7-11,14-15,22-27H,1-2H2,(H,29,30)(H,31,32)(H3,17,19,20,28)/t4-,5-,7-,8-,9+,10-,11+,14-,15-/m1/s1
DMOC25M	IU	[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
DMOC25M	CA	CAS 3123-67-9
DMOC25M	CB	CHEBI:15820
DMOC25M	DE	Discovery agent

DMB813H	ID	DMB813H
DMB813H	DN	GE-137
DMB813H	HS	Investigative
DMB813H	SN	GE-137
DMB813H	DT	Small molecular drug
DMB813H	PC	91827375
DMB813H	MW	3652
DMB813H	FM	C156H212N34O52S8
DMB813H	IC	InChI=1S/C156H212N34O52S8/c1-85(169-88(4)195)135(212)165-76-126(202)171-111(80-192)145(222)184-114-83-245-244-82-113(183-144(221)109(69-92-72-162-100-31-17-16-30-97(92)100)179-148(225)112-81-243-246-84-115(182-143(220)108(178-147(114)224)68-91-41-45-94(197)46-42-91)149(226)180-110(79-191)137(214)168-78-128(204)189-62-27-35-119(189)153(230)190-63-26-34-118(190)150(227)174-102(33-25-59-161-154(158)159)138(215)176-106(66-89-28-11-8-12-29-89)141(218)172-104(139(216)181-112)50-55-130(207)208)146(223)177-107(67-90-39-43-93(196)44-40-90)142(219)173-105(51-56-131(209)210)140(217)186-133(87(3)194)152(229)175-103(49-54-129(205)206)136(213)166-77-127(203)185-132(86(2)193)151(228)167-74-124(200)163-73-123(199)164-75-125(201)170-101(134(157)211)32-18-20-58-160-122(198)38-15-10-21-60-187-116-52-47-95(249(237,238)239)70-98(116)155(5,6)120(187)36-13-9-14-37-121-156(7,57-19-23-64-247(231,232)233)99-71-96(250(240,241)242)48-53-117(99)188(121)61-22-24-65-248(234,235)236/h8-9,11-14,16-17,28-31,36-37,39-48,52-53,70-72,85-87,101-115,118-119,132-133,162,191-194H,10,15,18-27,32-35,38,49-51,54-69,73-84H2,1-7H3,(H39-,157,158,159,160,161,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,195,196,197,198,199,200,201,202,203,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,231,232,233,234,235,236,237,238,239,240,241,242)/t85-,86+,87+,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,118-,119-,132-,133-,156?/m0/s1
DMB813H	CS	C[C@H]([C@@H](C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCCCCN\\1C2=C(C=C(C=C2)S(=O)(=O)O)C(/C1=C/C=C/C=C/C3=[N+](C4=C(C3(C)CCCCS(=O)(=O)O)C=C(C=C4)S(=O)(=O)[O-])CCCCS(=O)(=O)O)(C)C)C(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@@H]6CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]7CSSC[C@@H](C(=O)N[C@H](C(=O)N6)CC8=CNC9=CC=CC=C98)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC7=O)CO)CCCNC(=N)N)CC1=CC=CC=C1)CCC(=O)O)CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)C)O
DMB813H	IK	UQYUYHHXESUXGH-ABPLELQPSA-N
DMB813H	IU	2-[(1E,3E,5Z)-5-[1-[6-[[(5S)-5-[[2-[[2-[[2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(1R,4S,13S,19S,22S,25S,28S,31R,34S,37R,42R,45S)-42-[[(2S)-2-[[2-[[(2S)-2-acetamidopropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-25-benzyl-22-(3-carbamimidamidopropyl)-28-(2-carboxyethyl)-4-(hydroxymethyl)-45-[(4-hydroxyphenyl)methyl]-34-(1H-indol-3-ylmethyl)-2,5,8,14,20,23,26,29,32,35,43,46-dodecaoxo-39,40,49,50-tetrathia-3,6,9,15,21,24,27,30,33,36,44,47-dodecazatetracyclo[29.16.4.09,13.015,19]henpentacontane-37-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-6-amino-6-oxohexyl]amino]-6-oxohexyl]-3,3-dimethyl-5-sulfoindol-2-ylidene]penta-1,3-dienyl]-3-methyl-1,3-bis(4-sulfobutyl)indol-1-ium-5-sulfonate
DMB813H	DE	Discovery agent

DMBGWEK	ID	DMBGWEK
DMBGWEK	DN	GEA 3162
DMBGWEK	HS	Investigative
DMBGWEK	SN	GEA-3162; GEA3162
DMBGWEK	DT	Small molecular drug
DMBGWEK	PC	3035443
DMBGWEK	MW	231.04
DMBGWEK	FM	C7H4Cl2N4O
DMBGWEK	IC	InChI=1S/C7H4Cl2N4O/c8-5-2-1-4(3-6(5)9)13-11-7(10)14-12-13/h1-3,10H
DMBGWEK	CS	C1=CC(=C(C=C1[N+]2=NOC(=N)[N-]2)Cl)Cl
DMBGWEK	IK	VXGYFEOSZYEJBK-UHFFFAOYSA-N
DMBGWEK	IU	3-(3,4-dichlorophenyl)-1-oxa-2-aza-3-azonia-4-azanidacyclopent-2-en-5-imine
DMBGWEK	CA	CAS 144576-10-3
DMBGWEK	DE	Discovery agent

DMUSJ96	ID	DMUSJ96
DMUSJ96	DN	Geldanamycin-estradiol hybrid
DMUSJ96	HS	Investigative
DMUSJ96	DE	Discovery agent

DML0OUY	ID	DML0OUY
DML0OUY	DN	Gelsolin
DML0OUY	HS	Investigative
DML0OUY	SN	OYQRWBFWLSYDIZ-NATPOTRJSA-N; GEM 231
DML0OUY	DT	Antibody
DML0OUY	DE	Discovery agent

DMETRIS	ID	DMETRIS
DMETRIS	DN	gemini
DMETRIS	HS	Investigative
DMETRIS	SN	1R,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)vitamin D3; KH
DMETRIS	DT	Small molecular drug
DMETRIS	PC	10436120
DMETRIS	MW	502.8
DMETRIS	FM	C32H54O4
DMETRIS	IC	InChI=1S/C32H54O4/c1-22-25(20-26(33)21-29(22)34)14-13-24-12-9-19-32(6)27(15-16-28(24)32)23(10-7-17-30(2,3)35)11-8-18-31(4,5)36/h13-14,23,26-29,33-36H,1,7-12,15-21H2,2-6H3/b24-13+,25-14-/t26-,27-,28+,29+,32-/m1/s1
DMETRIS	CS	C[C@]12CCC/C(=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)/[C@@H]1CC[C@@H]2C(CCCC(C)(C)O)CCCC(C)(C)O
DMETRIS	IK	WTQXZYVWLNPNEX-LKUPKUSPSA-N
DMETRIS	IU	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-(2,10-dihydroxy-2,10-dimethylundecan-6-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMETRIS	DE	Discovery agent

DMAUFLQ	ID	DMAUFLQ
DMAUFLQ	DN	GENESERINE
DMAUFLQ	HS	Investigative
DMAUFLQ	SN	Eseridine; Geneserine; Eserine oxide; Eserine aminoxide; Eseridinum [Latin]; Eseridina [Spanish]; Eseridine [INN]; UNII-LW9S78L4M8; 25573-43-7; EINECS 247-111-2; NSC 340071; CHEBI:4855; LW9S78L4M8; Eseridine (INN); Eseridinum; C15H21N3O3; Eseridina; [(4aS,9aS)-2,4a,9-trimethyl-4,9a-dihydro-3H-oxazino[6,5-b]indol-6-yl] N-methylcarbamate; (4aS,9aS)-2,3,4,4a,9,9a-Hexahydro-2,4a,9-trimethyl-1,2-oxazino(6,5-b)indol-6-ylmethylcarbamate; eseridin; geneserine oxazine; 1,2-Oxazino(6,5-b)indol-6-ol, 2,3,4,4a,9,9a-hexahydro-2,4a,9-trimeth
DMAUFLQ	DT	Small molecular drug
DMAUFLQ	PC	65719
DMAUFLQ	MW	291.35
DMAUFLQ	FM	C15H21N3O3
DMAUFLQ	IC	InChI=1S/C15H21N3O3/c1-15-7-8-17(3)21-13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15-/m0/s1
DMAUFLQ	CS	C[C@@]12CCN(O[C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C
DMAUFLQ	IK	CNBHDDBNEKKMJH-ZFWWWQNUSA-N
DMAUFLQ	IU	[(4aS,9aS)-2,4a,9-trimethyl-4,9a-dihydro-3H-oxazino[6,5-b]indol-6-yl] N-methylcarbamate
DMAUFLQ	CA	CAS 25573-43-7
DMAUFLQ	CB	CHEBI:4855
DMAUFLQ	DE	Discovery agent

DMMLNTW	ID	DMMLNTW
DMMLNTW	DN	Genistein-7-glucoside
DMMLNTW	HS	Investigative
DMMLNTW	SN	1POG3SCN5T; 4',5,7-trihydroxyisoflavone 7-D-glucoside; BRN 0064479; C21H20O10; CHEBI:27514; Genistein 7-O-beta-D-glucoside; Genistein 7-glucoside; Genistein glucoside; Genistein, 7-O-beta-D-glucoside; Genistein, 7-beta-D-glucopyranoside; Genistein-7-glucoside; Genisteol 7-monoglucoside; Genistin; Genistine; Genistoside; Glucopyranoside, genistein-7, beta-D-; Glucosyl-7-genistein; Isoflavone, 4',5,7-trihydroxy-, 7-D-glucoside; MFCD00016883; NSC 5112; UNII-1POG3SCN5T; ZCOLJUOHXJRHDI-CMWLGVBASA-N; genistein 7-O-glucoside
DMMLNTW	DT	Small molecular drug
DMMLNTW	PC	5281377
DMMLNTW	MW	432.381
DMMLNTW	FM	C21H20O10
DMMLNTW	IC	InChI=1S/C21H20O10/c22-7-15-18(26)19(27)20(28)21(31-15)30-11-5-13(24)16-14(6-11)29-8-12(17(16)25)9-1-3-10(23)4-2-9/h1-6,8,15,18-24,26-28H,7H2/t15-,18-,19+,20-,21-/m1/s1
DMMLNTW	CS	C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)OC4C(C(C(C(O4)CO)O)O)O)O
DMMLNTW	IK	ZCOLJUOHXJRHDI-CMWLGVBASA-N
DMMLNTW	IU	5-hydroxy-3-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMMLNTW	CA	CAS 529-59-9
DMMLNTW	CB	CHEBI:27514
DMMLNTW	DE	Cancer; Rotavirus infections

DMB70WC	ID	DMB70WC
DMB70WC	DN	Genz-10850
DMB70WC	HS	Investigative
DMB70WC	SN	Genz-10850; 5-{[4-(9H-FLUOREN-9-YL)PIPERAZIN-1-YL]CARBONYL}-1H-INDOLE; [4-(9H-fluoren-9-yl)piperazin-1-yl]-(1H-indol-5-yl)methanone; [4-(9H-Fluoren-9-yl)-piperazin-1-yl]-(1H-indol-5-yl)-methanone; GEQ; piperazine, p3; AC1L9L7I; SCHEMBL7664894; CHEMBL216579; BDBM25796; YYMZSGIXLQPFAC-UHFFFAOYSA-N; DB04289
DMB70WC	DT	Small molecular drug
DMB70WC	PC	447767
DMB70WC	MW	393.5
DMB70WC	FM	C26H23N3O
DMB70WC	IC	InChI=1S/C26H23N3O/c30-26(19-9-10-24-18(17-19)11-12-27-24)29-15-13-28(14-16-29)25-22-7-3-1-5-20(22)21-6-2-4-8-23(21)25/h1-12,17,25,27H,13-16H2
DMB70WC	CS	C1CN(CCN1C2C3=CC=CC=C3C4=CC=CC=C24)C(=O)C5=CC6=C(C=C5)NC=C6
DMB70WC	IK	YYMZSGIXLQPFAC-UHFFFAOYSA-N
DMB70WC	IU	[4-(9H-fluoren-9-yl)piperazin-1-yl]-(1H-indol-5-yl)methanone
DMB70WC	DE	Discovery agent

DMB5I03	ID	DMB5I03
DMB5I03	DN	GERANIIN
DMB5I03	HS	Investigative
DMB5I03	SN	Geraniin; 60976-49-0; AC1L3GGN; AC1Q6OHG; SCHEMBL13242673; HY-N0472; AN-8034; 3,4,4,6,7,15,16,17,18,19,20-undecahydroxy-2,9,13,22,27-pentaoxo-2,3,4,4a,9,11a,13,22,24,25,25a,27-dodecahydro-11h-3,5-epoxy-25,11-(epoxymethano)dibenzo[h,j]dibenzo[7,8:9,10][1,5]dioxacycloundecino[3,2-b][1,6]dioxacyclododecin-29-yl 3,4,5-trihydroxybenzoate; beta-D-Glucopyranose, cyclic 3,6-(4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1-(3,4,5-trihydroxybenzoate), cyclic 2-2:4-1-ester with 2-(2-carboxy-4,5,6-trioxo-2-cycl
DMB5I03	DT	Small molecular drug
DMB5I03	PC	3001497
DMB5I03	MW	952.6
DMB5I03	FM	C41H28O27
DMB5I03	IC	InChI=1S/C41H28O27/c42-13-1-8(2-14(43)24(13)48)34(54)67-39-33-32-30(64-38(58)12-6-19(47)41(61)40(59,60)23(12)22-11(37(57)66-33)5-17(46)27(51)31(22)68-41)18(63-39)7-62-35(55)9-3-15(44)25(49)28(52)20(9)21-10(36(56)65-32)4-16(45)26(50)29(21)53/h1-6,18,23,30,32-33,39,42-46,48-53,59-61H,7H2/t18-,23+,30-,32+,33-,39+,41+/m1/s1
DMB5I03	CS	C1[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@@H]7C(=CC(=O)[C@@](C7(O)O)(O6)O)C(=O)O3)O)O)OC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O)O
DMB5I03	IK	JQQBXPCJFAKSPG-SVYIMCMUSA-N
DMB5I03	IU	[(1R,7R,8S,26R,28S,29R,38R)-1,13,14,15,18,19,20,34,35,39,39-undecahydroxy-2,5,10,23,31-pentaoxo-6,9,24,27,30,40-hexaoxaoctacyclo[34.3.1.04,38.07,26.08,29.011,16.017,22.032,37]tetraconta-3,11,13,15,17,19,21,32,34,36-decaen-28-yl] 3,4,5-trihydroxybenzoate
DMB5I03	CB	CHEBI:5328
DMB5I03	DE	Discovery agent

DMS3CBD	ID	DMS3CBD
DMS3CBD	DN	geraniol
DMS3CBD	HS	Investigative
DMS3CBD	SN	GERANIOL; 106-24-1; Lemonol; Geranyl alcohol; trans-Geraniol; (E)-Geraniol; (2E)-3,7-dimethylocta-2,6-dien-1-ol; (E)-Nerol; trans-3,7-Dimethyl-2,6-octadien-1-ol; (E)-3,7-Dimethylocta-2,6-dien-1-ol; Geraniol Extra; Geraniol alcohol; 3,7-Dimethyl-2,6-octadien-1-ol; (E)-3,7-Dimethyl-2,6-octadien-1-ol; beta-Geraniol; 3,7-Dimethyl-trans-2,6-octadien-1-ol; 2,6-Octadien-1-ol, 3,7-dimethyl-, (2E)-; Guaniol; t-geraniol; 2E-geraniol; Geraniol (natural); 2-trans-3,7-Dimethyl-2,6-octadien-1-ol; 2,6-Octadien-1-ol, 3,7-dimethyl-; CHEBI:17447
DMS3CBD	DT	Small molecular drug
DMS3CBD	PC	637566
DMS3CBD	MW	154.25
DMS3CBD	FM	C10H18O
DMS3CBD	IC	InChI=1S/C10H18O/c1-9(2)5-4-6-10(3)7-8-11/h5,7,11H,4,6,8H2,1-3H3/b10-7+
DMS3CBD	CS	CC(=CCC/C(=C/CO)/C)C
DMS3CBD	IK	GLZPCOQZEFWAFX-JXMROGBWSA-N
DMS3CBD	IU	(2E)-3,7-dimethylocta-2,6-dien-1-ol
DMS3CBD	CA	CAS 106-24-1
DMS3CBD	CB	CHEBI:17447
DMS3CBD	DE	Discovery agent

DMB9LE1	ID	DMB9LE1
DMB9LE1	DN	Geranyl Diphosphate
DMB9LE1	HS	Investigative
DMB9LE1	SN	Geranyl diphosphate; geranyl pyrophosphate; 763-10-0; Neryl pyrophosphate; Polyprenyl diphosphate; CHEBI:17211; Polyisopentenyldiphosphate; Polyisopentenylpyrophosphate; trans-Geranyl pyrophosphate; trans-Polyisopentenyldiphosphate; geranyl-PP; all-trans-Polyprenyl diphosphate; GPP; GVVPGTZRZFNKDS-JXMROGBWSA-N; geranyl-diphosphate; (2E)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate; geranyl-pyrophosphate; trans-3,7-Dimethyl-2,6-octadienyl pyrophosphate; [(2E)-3,7-dimethylocta-2,6-dienyl] phosphono hydrogen phosphate
DMB9LE1	DT	Small molecular drug
DMB9LE1	PC	445995
DMB9LE1	MW	314.21
DMB9LE1	FM	C10H20O7P2
DMB9LE1	IC	InChI=1S/C10H20O7P2/c1-9(2)5-4-6-10(3)7-8-16-19(14,15)17-18(11,12)13/h5,7H,4,6,8H2,1-3H3,(H,14,15)(H2,11,12,13)/b10-7+
DMB9LE1	CS	CC(=CCC/C(=C/COP(=O)(O)OP(=O)(O)O)/C)C
DMB9LE1	IK	GVVPGTZRZFNKDS-JXMROGBWSA-N
DMB9LE1	IU	[(2E)-3,7-dimethylocta-2,6-dienyl] phosphono hydrogen phosphate
DMB9LE1	CA	CAS 763-10-0
DMB9LE1	CB	CHEBI:17211
DMB9LE1	DE	Discovery agent

DMRPWGL	ID	DMRPWGL
DMRPWGL	DN	Geranylcoumarin
DMRPWGL	HS	Investigative
DMRPWGL	SN	geranylcoumarin; CHEMBL241896
DMRPWGL	DT	Small molecular drug
DMRPWGL	PC	44429171
DMRPWGL	MW	298.4
DMRPWGL	FM	C19H22O3
DMRPWGL	IC	InChI=1S/C19H22O3/c1-14(2)5-4-6-15(3)11-12-21-17-9-7-16-8-10-19(20)22-18(16)13-17/h4-5,7-11,13-14H,6,12H2,1-3H3/b5-4+,15-11+
DMRPWGL	CS	CC(C)/C=C/C/C(=C/COC1=CC2=C(C=C1)C=CC(=O)O2)/C
DMRPWGL	IK	KAYCKFWCZGZEHA-WEPZFIBGSA-N
DMRPWGL	IU	7-[(2E,5E)-3,7-dimethylocta-2,5-dienoxy]chromen-2-one
DMRPWGL	DE	Discovery agent

DMJZ0AM	ID	DMJZ0AM
DMJZ0AM	DN	GERANYLGERANYL DIPHOSPHATE
DMJZ0AM	HS	Investigative
DMJZ0AM	SN	Geranylgeranyl pyrophosphate; Geranylgeranyl diphosphate; GGDP; 6699-20-3; geranylgeranyl-PP; GGPP; UNII-N21T0D88LX; (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl trihydrogen diphosphate; N21T0D88LX; Geranylgeraniol diphosphate; CHEBI:48861; all-trans-Geranylgeranyl pyrophosphate; all-trans-Geranylgeranyl diphosphate; Diphosphoric acid, mono(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl) ester, (E,E,E)-; Geranylgeranyl pyrophosphate ammonium salt; 2-trans,6-trans,10-trans-geranylgeranyl diphosphate
DMJZ0AM	DT	Small molecular drug
DMJZ0AM	PC	447277
DMJZ0AM	MW	450.4
DMJZ0AM	FM	C20H36O7P2
DMJZ0AM	IC	InChI=1S/C20H36O7P2/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-26-29(24,25)27-28(21,22)23/h9,11,13,15H,6-8,10,12,14,16H2,1-5H3,(H,24,25)(H2,21,22,23)/b18-11+,19-13+,20-15+
DMJZ0AM	CS	CC(=CCC/C(=C/CC/C(=C/CC/C(=C/COP(=O)(O)OP(=O)(O)O)/C)/C)/C)C
DMJZ0AM	IK	OINNEUNVOZHBOX-QIRCYJPOSA-N
DMJZ0AM	IU	phosphono [(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl] hydrogen phosphate
DMJZ0AM	CA	CAS 6699-20-3
DMJZ0AM	CB	CHEBI:48861
DMJZ0AM	DE	Discovery agent

DMLM02I	ID	DMLM02I
DMLM02I	DN	GFPDGG
DMLM02I	HS	Investigative
DMLM02I	SN	CHEMBL261622; GFPDGG
DMLM02I	DT	Small molecular drug
DMLM02I	PC	24873518
DMLM02I	MW	548.5
DMLM02I	FM	C24H32N6O9
DMLM02I	IC	InChI=1S/C24H32N6O9/c25-11-18(31)28-16(9-14-5-2-1-3-6-14)24(39)30-8-4-7-17(30)23(38)29-15(10-20(33)34)22(37)27-12-19(32)26-13-21(35)36/h1-3,5-6,15-17H,4,7-13,25H2,(H,26,32)(H,27,37)(H,28,31)(H,29,38)(H,33,34)(H,35,36)/t15-,16-,17-/m0/s1
DMLM02I	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)NCC(=O)O
DMLM02I	IK	NLYXJKKWVSCTSP-ULQDDVLXSA-N
DMLM02I	IU	(3S)-3-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-[[2-(carboxymethylamino)-2-oxoethyl]amino]-4-oxobutanoic acid
DMLM02I	DE	Discovery agent

DMGZTQW	ID	DMGZTQW
DMGZTQW	DN	GFPEGG
DMGZTQW	HS	Investigative
DMGZTQW	SN	CHEMBL261621; GFPEGG
DMGZTQW	DT	Small molecular drug
DMGZTQW	PC	24873519
DMGZTQW	MW	562.6
DMGZTQW	FM	C25H34N6O9
DMGZTQW	IC	InChI=1S/C25H34N6O9/c26-12-19(32)29-17(11-15-5-2-1-3-6-15)25(40)31-10-4-7-18(31)24(39)30-16(8-9-21(34)35)23(38)28-13-20(33)27-14-22(36)37/h1-3,5-6,16-18H,4,7-14,26H2,(H,27,33)(H,28,38)(H,29,32)(H,30,39)(H,34,35)(H,36,37)/t16-,17-,18-/m0/s1
DMGZTQW	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)O
DMGZTQW	IK	WXUQGIGEEDNHIW-BZSNNMDCSA-N
DMGZTQW	IU	(4S)-4-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-[[2-(carboxymethylamino)-2-oxoethyl]amino]-5-oxopentanoic acid
DMGZTQW	DE	Discovery agent

DM9D8VH	ID	DM9D8VH
DM9D8VH	DN	GFPTGG
DM9D8VH	HS	Investigative
DM9D8VH	SN	CHEMBL258999; GFPTGG
DM9D8VH	DT	Small molecular drug
DM9D8VH	PC	25254902
DM9D8VH	MW	534.6
DM9D8VH	FM	C24H34N6O8
DM9D8VH	IC	InChI=1S/C24H34N6O8/c1-14(31)21(23(37)27-12-19(33)26-13-20(34)35)29-22(36)17-8-5-9-30(17)24(38)16(28-18(32)11-25)10-15-6-3-2-4-7-15/h2-4,6-7,14,16-17,21,31H,5,8-13,25H2,1H3,(H,26,33)(H,27,37)(H,28,32)(H,29,36)(H,34,35)/t14-,16+,17+,21+/m1/s1
DM9D8VH	CS	C[C@H]([C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)O
DM9D8VH	IK	JWBSOWVZSDHJSP-IOFRSVQKSA-N
DM9D8VH	IU	2-[[2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetic acid
DM9D8VH	DE	Discovery agent

DMU82JV	ID	DMU82JV
DMU82JV	DN	GG-818
DMU82JV	HS	Investigative
DMU82JV	SN	GI-231818; GW-1818
DMU82JV	CP	Glaxo Wellcome plc
DMU82JV	DE	Prostate disease

DMU92RC	ID	DMU92RC
DMU92RC	DN	GI-3000
DMU92RC	HS	Investigative
DMU92RC	SN	GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune
DMU92RC	CP	GlobeImmune Inc
DMU92RC	DT	Vaccine
DMU92RC	DE	Non-small-cell lung cancer

DMASR6T	ID	DMASR6T
DMASR6T	DN	GIDAZEPAM
DMASR6T	HS	Investigative
DMASR6T	SN	2-(7-Bromo-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)acetic acid hydrazide
DMASR6T	DT	Small molecular drug
DMASR6T	PC	121919
DMASR6T	MW	387.2
DMASR6T	FM	C17H15BrN4O2
DMASR6T	IC	InChI=1S/C17H15BrN4O2/c18-12-6-7-14-13(8-12)17(11-4-2-1-3-5-11)20-9-16(24)22(14)10-15(23)21-19/h1-8H,9-10,19H2,(H,21,23)
DMASR6T	CS	C1C(=O)N(C2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=C3)CC(=O)NN
DMASR6T	IK	XLGCMZLSEXRBSG-UHFFFAOYSA-N
DMASR6T	IU	2-(7-bromo-2-oxo-5-phenyl-3H-1,4-benzodiazepin-1-yl)acetohydrazide
DMASR6T	CA	CAS 129186-29-4
DMASR6T	DE	Anxiety disorder

DMNXYSM	ID	DMNXYSM
DMNXYSM	DN	gingerol
DMNXYSM	HS	Investigative
DMNXYSM	SN	[6]-Gingerol; 6-Gingerol
DMNXYSM	DT	Small molecular drug
DMNXYSM	PC	442793
DMNXYSM	MW	294.4
DMNXYSM	FM	C17H26O4
DMNXYSM	IC	InChI=1S/C17H26O4/c1-3-4-5-6-14(18)12-15(19)9-7-13-8-10-16(20)17(11-13)21-2/h8,10-11,14,18,20H,3-7,9,12H2,1-2H3/t14-/m0/s1
DMNXYSM	CS	CCCCC[C@@H](CC(=O)CCC1=CC(=C(C=C1)O)OC)O
DMNXYSM	IK	NLDDIKRKFXEWBK-AWEZNQCLSA-N
DMNXYSM	IU	(5S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)decan-3-one
DMNXYSM	CA	CAS 23513-14-6
DMNXYSM	CB	CHEBI:10136
DMNXYSM	DE	Discovery agent

DMKZJ7T	ID	DMKZJ7T
DMKZJ7T	DN	GINKGOLIDE A
DMKZJ7T	HS	Investigative
DMKZJ7T	SN	Ginkgolide A; 15291-75-5; CHEBI:5355; SCHEMBL340234; GTPL1861; LMPR0104540001; AB2000432; C07601
DMKZJ7T	DT	Small molecular drug
DMKZJ7T	PC	9909368
DMKZJ7T	MW	408.4
DMKZJ7T	FM	C20H24O9
DMKZJ7T	IC	InChI=1S/C20H24O9/c1-7-12(22)26-10-6-17-9-5-8(16(2,3)4)18(17)11(21)13(23)28-15(18)29-20(17,14(24)27-9)19(7,10)25/h7-11,15,21,25H,5-6H2,1-4H3/t7-,8+,9-,10+,11+,15+,17-,18+,19-,20-/m1/s1
DMKZJ7T	CS	C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5[C@]3(C2)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O
DMKZJ7T	IK	FPUXKXIZEIDQKW-VKMVSBOZSA-N
DMKZJ7T	IU	(1R,3R,6R,7S,8S,10R,11S,13S,16S,17R)-8-tert-butyl-6,17-dihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMKZJ7T	CA	CAS 15291-75-5
DMKZJ7T	DE	Discovery agent

DMVN374	ID	DMVN374
DMVN374	DN	Ginkgolide C
DMVN374	HS	Investigative
DMVN374	SN	Ginkgolide C; BN 52022; SCHEMBL500086; GTPL1863; 15291-76-6; AKOS032961923; LMPR0104540003; C07603
DMVN374	DT	Small molecular drug
DMVN374	PC	24721502
DMVN374	MW	440.4
DMVN374	FM	C20H24O11
DMVN374	IC	InChI=1S/C20H24O11/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,21-23,27H,1-4H3/t5-,6-,7+,8-,9+,10-,11+,15+,17+,18-,19-,20-/m1/s1
DMVN374	CS	C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5[C@]3([C@@H]2O)[C@@]6([C@@H]([C@H]5O)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O
DMVN374	IK	AMOGMTLMADGEOQ-PYLUGNSCSA-N
DMVN374	IU	(1R,3R,6R,7S,8S,9R,10S,11R,12S,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMVN374	CA	CAS 15291-76-6
DMVN374	DE	Discovery agent

DMUOMP1	ID	DMUOMP1
DMUOMP1	DN	Ginkgolide J
DMUOMP1	HS	Investigative
DMUOMP1	SN	Ginkgolide J; BN 52024; GTPL1864; 107438-79-9; LMPR0104540004; C07604
DMUOMP1	DT	Small molecular drug
DMUOMP1	PC	24721483
DMUOMP1	MW	424.4
DMUOMP1	FM	C20H24O10
DMUOMP1	IC	InChI=1S/C20H24O10/c1-6-12(23)27-7-5-17-11-8(21)9(16(2,3)4)18(17)10(22)13(24)29-15(18)30-20(17,14(25)28-11)19(6,7)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9+,10+,11-,15+,17?,18+,19-,20-/m1/s1
DMUOMP1	CS	C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3(C2)[C@@]6([C@@H]([C@H]5O)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O
DMUOMP1	IK	LMEHVEUFNRJAAV-XNSMQBOTSA-N
DMUOMP1	IU	(1R,3R,6R,7S,8S,9R,10S,13S,16S,17R)-8-tert-butyl-6,9,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMUOMP1	DE	Discovery agent

DMHWIG6	ID	DMHWIG6
DMHWIG6	DN	Ginkgolide M
DMHWIG6	HS	Investigative
DMHWIG6	SN	Ginkgolide M; 15291-78-8
DMHWIG6	DT	Small molecular drug
DMHWIG6	PC	12310208
DMHWIG6	MW	424.4
DMHWIG6	FM	C20H24O10
DMHWIG6	IC	InChI=1S/C20H24O10/c1-5-6-8(27-13(5)24)10(22)19-12-7(21)9(17(2,3)4)18(19)11(23)14(25)29-16(18)30-20(6,19)15(26)28-12/h5-12,16,21-23H,1-4H3
DMHWIG6	CS	CC1C2C(C(C34C25C(=O)OC3C(C(C46C(C(=O)OC6O5)O)C(C)(C)C)O)O)OC1=O
DMHWIG6	IK	KDKROYXEHCYLJQ-UHFFFAOYSA-N
DMHWIG6	IU	8-tert-butyl-6,9,12-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMHWIG6	CA	CAS 15291-78-8
DMHWIG6	DE	Discovery agent

DMK543E	ID	DMK543E
DMK543E	DN	ginkgolide X
DMK543E	HS	Investigative
DMK543E	SN	ginkgolide X; GTPL4201
DMK543E	DT	Small molecular drug
DMK543E	PC	73755085
DMK543E	MW	376.4
DMK543E	FM	C20H24O7
DMK543E	IC	InChI=1S/C20H24O7/c1-8-9-5-13-19(7-10(9)25-15(8)23)12(21)6-11(18(2,3)4)20(19)14(22)16(24)27-17(20)26-13/h5,10-12,14,17,21-22H,6-7H2,1-4H3/t10-,11-,12-,14-,17+,19-,20-/m0/s1
DMK543E	CS	CC1=C2C=C3[C@]4(C[C@@H]2OC1=O)[C@H](C[C@H]([C@@]45[C@H](C(=O)O[C@H]5O3)O)C(C)(C)C)O
DMK543E	IK	SPCYYGUOUYOYPX-FUDPCSHESA-N
DMK543E	IU	(1S,2S,4S,5S,6R,9R,17S)-4-tert-butyl-2,6-dihydroxy-14-methyl-8,10,16-trioxapentacyclo[9.7.0.01,5.05,9.013,17]octadeca-11,13-diene-7,15-dione
DMK543E	DE	Discovery agent

DMF70AB	ID	DMF70AB
DMF70AB	DN	Ginsenoside Rb1
DMF70AB	HS	Investigative
DMF70AB	SN	Arasaponin E1; Ginsenoside rb1; Gynosaponin C; Panax saponin E; Panaxsaponin E; Pseudoginsenoside D; Sanchinoside E1; ginsenoside-Rb1; (20S)-ginsenoside Rb1; 2-O-beta-Glucopyranosyl-(3beta,12beta)-20-((6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl-beta-D-glucopyranoside; 20(S)-ginsenoside Rb1; 41753-43-9; 7413S0WMH6; BIDD:ER0108; C54H92O23; CHEBI:67989; CHEMBL501515; GRb 1; GS-Rb1; GSRb1; GZYPWOGIYAIIPV-JBDTYSNRSA-N; Gypenoside III; NSC 310103; UNII-7413S0WMH6
DMF70AB	PC	9898279
DMF70AB	MW	1109.3
DMF70AB	FM	C54H92O23
DMF70AB	IC	GZYPWOGIYAIIPV-JBDTYSNRSA-N
DMF70AB	CS	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(C(O8)CO)O)O)O)O)O)O)C
DMF70AB	IK	1S/C54H92O23/c1-23(2)10-9-14-54(8,77-48-44(69)40(65)37(62)29(74-48)22-70-46-42(67)38(63)34(59)26(19-55)71-46)24-11-16-53(7)33(24)25(58)18-31-51(5)15-13-32(50(3,4)30(51)12-17-52(31,53)6)75-49-45(41(66)36(61)28(21-57)73-49)76-47-43(68)39(64)35(60)27(20-56)72-47/h10,24-49,55-69H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28+,29+,30-,31+,32-,33-,34+,35+,36+,37+,38-,39-,40-,41-,42+,43+,44+,45+,46+,47-,48-,49-,51-,52+,53+,54-/m0/s1
DMF70AB	IU	(2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6S)-6-[(2S)-2-[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-3-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
DMF70AB	CA	CAS 41753-43-9
DMF70AB	CB	CHEBI:67989
DMF70AB	DE	Obesity

DMES9Q2	ID	DMES9Q2
DMES9Q2	DN	Ginsenoside Rc
DMES9Q2	HS	Investigative
DMES9Q2	SN	Ginsenoside Rc; Panaxoside RC; ginsenoside-Rc; 0K83B0L786; 11021-14-0; 20-((6-O-alpha-L-Arabinofuranosyl-beta-D-glucopyranosyl)oxy)-12beta-hydroxydammar-24-en-3beta-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside; 20-[(6-O-a-L-arabinofuranosyl-ss-D-glucopyranosyl)oxy]-12ss-hydroxydammar-24-en-3ss-yl 2-O-ss-D-glucopyranosyl-ss-D-glucopyranoside; AB0029025; AKOS037514670; AS-56539; BRN 1677618; CHEBI:77154; CHEMBL451702; CS-3837; EINECS 234-253-5; HY-N0042; MFCD00133368; NCGC00485983-01; NSC 310104; UNII-0K83B0L786; s9266
DMES9Q2	PC	12855889
DMES9Q2	MW	1079.3
DMES9Q2	FM	C53H90O22
DMES9Q2	IC	JDCPEKQWFDWQLI-LUQKBWBOSA-N
DMES9Q2	CS	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(O8)CO)O)O)O)O)O)C
DMES9Q2	IK	1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-68-45-41(65)36(60)28(21-56)69-45)24-11-16-52(7)33(24)25(57)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)35(59)27(20-55)71-48)74-46-42(66)38(62)34(58)26(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28-,29+,30-,31+,32-,33-,34+,35+,36-,37+,38-,39-,40-,41+,42+,43+,44+,45+,46-,47-,48-,50-,51+,52+,53-/m0/s1
DMES9Q2	IU	(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-17-[(2S)-2-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-methylhept-5-en-2-yl]-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMES9Q2	CA	CAS 11021-14-0
DMES9Q2	CB	CHEBI:77154
DMES9Q2	DE	Diabetes mellitus

DM46FVD	ID	DM46FVD
DM46FVD	DN	Ginsenoside Re
DM46FVD	HS	Investigative
DM46FVD	SN	Chikusetsusaponin IVc; Ginsenoside B2; Ginsenoside Re; PWAOOJDMFUQOKB-WCZZMFLVSA-N; Panaxoside RE; SCHEMBL669738; TR-036967; ZINC242620164; ginsenoside-Re; (20S)-ginsenoside Re; 2-O-(6-Deoxy-alpha-L-mannopyranosyl)-(3beta,6alpha,12beta)-20-(beta-D-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl-beta-D-glucopyranoside; 46F3R0BL3I; 51542-56-4; 52286-59-6; AKOS025310861; BDBM50378779; CHEBI:77148; CHEMBL510095; CS-3838; CTK8F0918; DB14815; EINECS 257-814-6; HY-N0044; MFCD00133369; NSC 308877; NSC-308877; UNII-46F3R0BL3I; s3811
DM46FVD	PC	441921
DM46FVD	MW	947.2
DM46FVD	FM	C48H82O18
DM46FVD	IC	PWAOOJDMFUQOKB-WCZZMFLVSA-N
DM46FVD	CS	CC1C(C(C(C(O1)OC2C(C(C(OC2OC3CC4(C(CC(C5C4(CCC5C(C)(CCC=C(C)C)OC6C(C(C(C(O6)CO)O)O)O)C)O)C7(C3C(C(CC7)O)(C)C)C)C)CO)O)O)O)O)O
DM46FVD	IK	1S/C48H82O18/c1-21(2)11-10-14-48(9,66-42-38(60)35(57)32(54)26(19-49)63-42)23-12-16-46(7)30(23)24(51)17-28-45(6)15-13-29(52)44(4,5)40(45)25(18-47(28,46)8)62-43-39(36(58)33(55)27(20-50)64-43)65-41-37(59)34(56)31(53)22(3)61-41/h11,22-43,49-60H,10,12-20H2,1-9H3/t22-,23-,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34+,35-,36-,37+,38+,39+,40-,41-,42-,43+,45+,46+,47+,48-/m0/s1
DM46FVD	IU	(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol
DM46FVD	CA	CAS 52286-59-6
DM46FVD	CB	CHEBI:77148
DM46FVD	DE	Lung cancer

DMYE2SR	ID	DMYE2SR
DMYE2SR	DN	Ginsenoside Rg1
DMYE2SR	HS	Investigative
DMYE2SR	SN	Chikusetsusaponin Ia; ginsenoside-Rg(1); sanchinoside C(1); C17544; CHEBI:81171
DMYE2SR	PC	13386145
DMYE2SR	MW	755
DMYE2SR	FM	C41H70O12
DMYE2SR	IC	DGSOBIYFLJXVQZ-UHFFFAOYSA-N
DMYE2SR	CS	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)COC6C(C(C(CO6)O)O)O)O)O)O)C)C)O)C)O)C
DMYE2SR	IK	1S/C41H70O12/c1-21(2)10-9-14-41(8,49)22-11-16-40(7)29(22)23(42)18-27-38(5)15-13-28(37(3,4)26(38)12-17-39(27,40)6)53-36-34(48)32(46)31(45)25(52-36)20-51-35-33(47)30(44)24(43)19-50-35/h10,22-36,42-49H,9,11-20H2,1-8H3
DMYE2SR	IU	2-[[12-hydroxy-17-(2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxane-3,4,5-triol
DMYE2SR	CA	CAS 59252-86-7
DMYE2SR	CB	CHEBI:81171
DMYE2SR	DE	Insomnia

DMFN58T	ID	DMFN58T
DMFN58T	DN	Ginsenoside RG3
DMFN58T	HS	Investigative
DMFN58T	SN	(20S)-ginsenoside Rg3
DMFN58T	DT	Small molecular drug
DMFN58T	PC	9918693
DMFN58T	MW	785
DMFN58T	FM	C42H72O13
DMFN58T	IC	InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1
DMFN58T	CS	CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O)C
DMFN58T	IK	RWXIFXNRCLMQCD-JBVRGBGGSA-N
DMFN58T	IU	(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMFN58T	CA	CAS 14197-60-5
DMFN58T	CB	CHEBI:67991
DMFN58T	DE	Discovery agent

DM9P62Y	ID	DM9P62Y
DM9P62Y	DN	GKA1
DM9P62Y	HS	Investigative
DM9P62Y	SN	CHEMBL381434; GKA1; SCHEMBL1794696; RTMFZNZPHCZAFG-UHFFFAOYSA-N; ZINC28523790; BDBM50165037; 6-(3-Isobutoxy-5-isopropoxy-benzoylamino)-nicotinic acid; 6-[(3-isobutoxy-5-isopropoxybenzoyl)amino]-3-pyridinecarboxylic acid; 6-[(3-isobutoxy-5-isopropoxvbenzoyl)amino]-3-pyridinecarboxylic acid
DM9P62Y	DT	Small molecular drug
DM9P62Y	PC	10044792
DM9P62Y	MW	372.4
DM9P62Y	FM	C20H24N2O5
DM9P62Y	IC	InChI=1S/C20H24N2O5/c1-12(2)11-26-16-7-15(8-17(9-16)27-13(3)4)19(23)22-18-6-5-14(10-21-18)20(24)25/h5-10,12-13H,11H2,1-4H3,(H,24,25)(H,21,22,23)
DM9P62Y	CS	CC(C)COC1=CC(=CC(=C1)C(=O)NC2=NC=C(C=C2)C(=O)O)OC(C)C
DM9P62Y	IK	RTMFZNZPHCZAFG-UHFFFAOYSA-N
DM9P62Y	IU	6-[[3-(2-methylpropoxy)-5-propan-2-yloxybenzoyl]amino]pyridine-3-carboxylic acid
DM9P62Y	DE	Discovery agent

DMIENSW	ID	DMIENSW
DMIENSW	DN	GKA-23
DMIENSW	HS	Investigative
DMIENSW	SN	GKA-21; GKA-22; GKA-30; GKA-31; GKA-50; GKA-60; Glucokinase activators (diabetes); Glucokinase activators (diabetes), AstraZeneca
DMIENSW	CP	AstraZeneca plc
DMIENSW	PC	25235270
DMIENSW	MW	468.6
DMIENSW	FM	C21H20N6O3S2
DMIENSW	IC	InChI=1S/C21H20N6O3S2/c1-12-6-7-16(13(2)24-12)30-17-9-14(31-18-5-3-4-8-22-18)10-23-20(17)26-21-25-19(27-32-21)15(29)11-28/h3-10,15,28-29H,11H2,1-2H3,(H,23,25,26,27)/t15-/m1/s1
DMIENSW	CS	CC1=NC(=C(C=C1)OC2=C(N=CC(=C2)SC3=CC=CC=N3)NC4=NC(=NS4)[C@@H](CO)O)C
DMIENSW	IK	NARRNXGFBLOLIN-OAHLLOKOSA-N
DMIENSW	IU	(1S)-1-[5-[[3-(2,6-dimethylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol
DMIENSW	DE	Diabetic complication

DMSP7V8	ID	DMSP7V8
DMSP7V8	DN	GLAUCINE
DMSP7V8	HS	Investigative
DMSP7V8	SN	Glaucine; d-Glaucine; 475-81-0; Bromcholitin; Boldine dimethyl ether; Glauvent; S-(+)-Glaucine; (S)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline; Glaucine fumarate; UNII-NU19306XA7; 1,2,9,10-Tetramethoxy-6a-alpha-aporphine; NSC34396; EINECS 207-501-5; NSC 34396; (+)-Glaucine; CHEMBL228082; CHEBI:5373; NU19306XA7; (S)-5,6,6a7-Tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo(de,g)quinoline; 6a-alpha-APORPHINE, 1,2,9,10-TETRAMETHOXY-; Glaucine, d
DMSP7V8	DT	Small molecular drug
DMSP7V8	PC	16754
DMSP7V8	MW	355.4
DMSP7V8	FM	C21H25NO4
DMSP7V8	IC	InChI=1S/C21H25NO4/c1-22-7-6-12-9-18(25-4)21(26-5)20-14-11-17(24-3)16(23-2)10-13(14)8-15(22)19(12)20/h9-11,15H,6-8H2,1-5H3/t15-/m0/s1
DMSP7V8	CS	CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC
DMSP7V8	IK	RUZIUYOSRDWYQF-HNNXBMFYSA-N
DMSP7V8	IU	(6aS)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline
DMSP7V8	CA	CAS 475-81-0
DMSP7V8	CB	CHEBI:5373
DMSP7V8	DE	Discovery agent

DM4QJPU	ID	DM4QJPU
DM4QJPU	DN	Glaxo-11p
DM4QJPU	HS	Investigative
DM4QJPU	SN	CHEMBL345869; Glaxo-11p; GTPL866; CHEMBL1184355; BDBM50422153; N-Isopropyl-N-[4-(dimethylamino)phenyl]-2-[[2,3,4,5-tetrahydro-2,4-dioxo-5-phenyl-3-(3-phenylureido)-1H-1,5-benzodiazepin]-1-yl]acetamide
DM4QJPU	DT	Small molecular drug
DM4QJPU	PC	10348659
DM4QJPU	MW	604.7
DM4QJPU	FM	C35H36N6O4
DM4QJPU	IC	InChI=1S/C35H36N6O4/c1-24(2)40(28-21-19-26(20-22-28)38(3)4)31(42)23-39-29-17-11-12-18-30(29)41(27-15-9-6-10-16-27)34(44)32(33(39)43)37-35(45)36-25-13-7-5-8-14-25/h5-22,24,32H,23H2,1-4H3,(H2,36,37,45)
DM4QJPU	CS	CC(C)N(C1=CC=C(C=C1)N(C)C)C(=O)CN2C3=CC=CC=C3N(C(=O)C(C2=O)NC(=O)NC4=CC=CC=C4)C5=CC=CC=C5
DM4QJPU	IK	GESRVUYUMYPJBC-UHFFFAOYSA-N
DM4QJPU	IU	N-[4-(dimethylamino)phenyl]-2-[2,4-dioxo-5-phenyl-3-(phenylcarbamoylamino)-1,5-benzodiazepin-1-yl]-N-propan-2-ylacetamide
DM4QJPU	DE	Discovery agent

DMNEML0	ID	DMNEML0
DMNEML0	DN	GlaxoSmithKline compound 5h
DMNEML0	HS	Investigative
DMNEML0	DT	Small molecular drug
DMNEML0	PC	46911435
DMNEML0	MW	440.6
DMNEML0	FM	C29H32N2O2
DMNEML0	IC	InChI=1S/C29H32N2O2/c1-4-5-6-10-21-15-17-23(18-16-21)30-29(32)31-26-14-9-11-22-19-27(33-28(22)26)25-13-8-7-12-24(25)20(2)3/h7-9,11-20H,4-6,10H2,1-3H3,(H2,30,31,32)
DMNEML0	CS	CCCCCC1=CC=C(C=C1)NC(=O)NC2=CC=CC3=C2OC(=C3)C4=CC=CC=C4C(C)C
DMNEML0	IK	ASCJIAKBYVUVNZ-UHFFFAOYSA-N
DMNEML0	IU	1-(4-pentylphenyl)-3-[2-(2-propan-2-ylphenyl)-1-benzofuran-7-yl]urea
DMNEML0	DE	Discovery agent

DM1UAWP	ID	DM1UAWP
DM1UAWP	DN	GlaxoSmithKline compound 6i
DM1UAWP	HS	Investigative
DM1UAWP	DT	Small molecular drug
DM1UAWP	PC	73755157
DM1UAWP	MW	439.4
DM1UAWP	FM	C25H24Cl2N2O
DM1UAWP	IC	InChI=1S/C25H24Cl2N2O/c1-3-22-16(2)24(28-20-9-5-4-6-10-20)21-11-7-8-12-23(21)29(22)25(30)17-13-18(26)15-19(27)14-17/h4-16,22,24,28H,3H2,1-2H3/t16-,22-,24+/m1/s1
DM1UAWP	CS	CC[C@@H]1[C@H]([C@@H](C2=CC=CC=C2N1C(=O)C3=CC(=CC(=C3)Cl)Cl)NC4=CC=CC=C4)C
DM1UAWP	IK	DKLLTFTXYHJXHK-OAEOJWKDSA-N
DM1UAWP	IU	[(2R,3S,4S)-4-anilino-2-ethyl-3-methyl-3,4-dihydro-2H-quinolin-1-yl]-(3,5-dichlorophenyl)methanone
DM1UAWP	DE	Discovery agent

DM98CSW	ID	DM98CSW
DM98CSW	DN	Glionitrin A
DM98CSW	HS	Investigative
DM98CSW	SN	Glionitrin A; CHEMBL550491
DM98CSW	CP	Korea Institute of Science and Technology
DM98CSW	DT	Small molecular drug
DM98CSW	PC	25243252
DM98CSW	MW	353.4
DM98CSW	FM	C13H11N3O5S2
DM98CSW	IC	InChI=1S/C13H11N3O5S2/c1-14-10(18)12-5-7-2-3-8(16(20)21)4-9(7)15(12)11(19)13(14,6-17)23-22-12/h2-4,17H,5-6H2,1H3/t12-,13-/m0/s1
DM98CSW	CS	CN1C(=O)[C@@]23CC4=C(N2C(=O)[C@@]1(SS3)CO)C=C(C=C4)[N+](=O)[O-]
DM98CSW	IK	VRFJINVAZRAFHH-STQMWFEESA-N
DM98CSW	IU	(1S,11S)-11-(hydroxymethyl)-15-methyl-6-nitro-12,13-dithia-9,15-diazatetracyclo[9.2.2.01,9.03,8]pentadeca-3(8),4,6-triene-10,14-dione
DM98CSW	CA	CAS 1116153-15-1
DM98CSW	CB	CHEBI:65967
DM98CSW	DE	Solid tumour/cancer

DMBH18C	ID	DMBH18C
DMBH18C	DN	GLP-17-(7-36) derivative
DMBH18C	HS	Investigative
DMBH18C	PC	91933043
DMBH18C	MW	3297.6
DMBH18C	FM	C149H226N40O45
DMBH18C	IC	InChI=1S/C149H226N40O45/c1-17-76(10)119(146(232)167-80(14)126(212)175-104(60-86-63-159-91-36-25-24-35-89(86)91)136(222)177-100(56-73(4)5)137(223)186-117(74(6)7)144(230)174-93(37-26-28-52-150)128(214)160-65-110(197)168-92(122(154)208)39-30-54-158-149(155)156)188-138(224)102(57-83-31-20-18-21-32-83)178-133(219)98(47-51-115(204)205)173-132(218)94(38-27-29-53-151)170-124(210)78(12)164-123(209)77(11)166-131(217)97(44-48-109(153)196)169-111(198)66-161-130(216)96(46-50-114(202)203)172-134(220)99(55-72(2)3)176-135(221)101(59-85-40-42-88(195)43-41-85)179-141(227)106(68-190)182-143(229)108(70-192)183-145(231)118(75(8)9)187-140(226)105(62-116(206)207)180-142(228)107(69-191)184-148(234)121(82(16)194)189-139(225)103(58-84-33-22-19-23-34-84)181-147(233)120(81(15)193)185-112(199)67-162-129(215)95(45-49-113(200)201)171-125(211)79(13)165-127(213)90(152)61-87-64-157-71-163-87/h18-25,31-36,40-43,63-64,71-82,90,92-108,117-121,159,190-195H,17,26-30,37-39,44-62,65-70,150-152H2,1-16H3,(H2,153,196)(H2,154,208)(H,157,163)(H,160,214)(H,161,216)(H,162,215)(H,164,209)(H,165,213)(H,166,217)(H,167,232)(H,168,197)(H,169,198)(H,170,210)(H,171,211)(H,172,220)(H,173,218)(H,174,230)(H,175,212)(H,176,221)(H,177,222)(H,178,219)(H,179,227)(H,180,228)(H,181,233)(H,182,229)(H,183,231)(H,184,234)(H,185,199)(H,186,223)(H,187,226)(H,188,224)(H,189,225)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,155,156,158)/t76-,77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,117-,118-,119-,120-,121-/m0/s1
DMBH18C	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
DMBH18C	IK	DTHNMHAUYICORS-KTKZVXAJSA-N
DMBH18C	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMBH18C	DE	Discovery agent

DMGTPDA	ID	DMGTPDA
DMGTPDA	DN	GLPDGG peptide
DMGTPDA	HS	Investigative
DMGTPDA	SN	CHEMBL412295; GLPDGG; GTPL2980; BDBM50226164; GLPDGG peptide [PMID: 20494585]; (3S)-3-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-4-methylpentanoyl]pyrrolidin-2-yl]formamido}-3-({[(carboxymethyl)carbamoyl]methyl}carbamoyl)propanoic acid
DMGTPDA	DT	Small molecular drug
DMGTPDA	PC	44452237
DMGTPDA	MW	514.5
DMGTPDA	FM	C21H34N6O9
DMGTPDA	IC	InChI=1S/C21H34N6O9/c1-11(2)6-13(25-15(28)8-22)21(36)27-5-3-4-14(27)20(35)26-12(7-17(30)31)19(34)24-9-16(29)23-10-18(32)33/h11-14H,3-10,22H2,1-2H3,(H,23,29)(H,24,34)(H,25,28)(H,26,35)(H,30,31)(H,32,33)/t12-,13-,14-/m0/s1
DMGTPDA	CS	CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)NCC(=O)O)NC(=O)CN
DMGTPDA	IK	SKODABHETMRRBC-IHRRRGAJSA-N
DMGTPDA	IU	(3S)-3-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-[[2-(carboxymethylamino)-2-oxoethyl]amino]-4-oxobutanoic acid
DMGTPDA	DE	Discovery agent

DME2YL6	ID	DME2YL6
DME2YL6	DN	GLPTGG
DME2YL6	HS	Investigative
DME2YL6	SN	CHEMBL261334; GLPTGG
DME2YL6	DT	Small molecular drug
DME2YL6	PC	25254901
DME2YL6	MW	500.5
DME2YL6	FM	C21H36N6O8
DME2YL6	IC	InChI=1S/C21H36N6O8/c1-11(2)7-13(25-15(29)8-22)21(35)27-6-4-5-14(27)19(33)26-18(12(3)28)20(34)24-9-16(30)23-10-17(31)32/h11-14,18,28H,4-10,22H2,1-3H3,(H,23,30)(H,24,34)(H,25,29)(H,26,33)(H,31,32)/t12-,13+,14+,18+/m1/s1
DME2YL6	CS	C[C@H]([C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CN)O
DME2YL6	IK	FYPRIKVHHVQETD-COJSNBRMSA-N
DME2YL6	IU	2-[[2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetic acid
DME2YL6	DE	Discovery agent

DM0HWB1	ID	DM0HWB1
DM0HWB1	DN	Glu20-Lys24][Gly8][GLP-1(7-37)-NH2
DM0HWB1	HS	Investigative
DM0HWB1	PC	91935385
DM0HWB1	MW	3395.7
DM0HWB1	FM	C152H228N42O47
DM0HWB1	IC	InChI=1S/C152H228N42O47/c1-13-78(8)123(149(239)171-80(10)127(217)181-105(61-86-64-163-91-34-21-20-33-89(86)91)139(229)182-101(57-75(2)3)140(230)191-121(76(4)5)147(237)180-93(35-22-25-53-153)130(220)166-68-114(205)172-92(38-28-56-162-152(158)159)129(219)164-66-111(157)202)193-141(231)103(58-83-29-16-14-17-30-83)183-137(227)100(47-52-119(212)213)178-134(224)95(36-23-26-54-154)175-126(216)79(9)170-133(223)94-37-24-27-55-161-112(203)49-44-99(136(226)177-97(46-51-118(210)211)132(222)167-69-115(206)174-98(135(225)176-94)43-48-110(156)201)179-138(228)102(60-85-39-41-88(200)42-40-85)184-144(234)107(71-195)187-146(236)109(73-197)188-148(238)122(77(6)7)192-143(233)106(63-120(214)215)185-145(235)108(72-196)189-151(241)125(82(12)199)194-142(232)104(59-84-31-18-15-19-32-84)186-150(240)124(81(11)198)190-116(207)70-168-131(221)96(45-50-117(208)209)173-113(204)67-165-128(218)90(155)62-87-65-160-74-169-87/h14-21,29-34,39-42,64-65,74-82,90,92-109,121-125,163,195-200H,13,22-28,35-38,43-63,66-73,153-155H2,1-12H3,(H2,156,201)(H2,157,202)(H,160,169)(H,161,203)(H,164,219)(H,165,218)(H,166,220)(H,167,222)(H,168,221)(H,170,223)(H,171,239)(H,172,205)(H,173,204)(H,174,206)(H,175,216)(H,176,225)(H,177,226)(H,178,224)(H,179,228)(H,180,237)(H,181,217)(H,182,229)(H,183,227)(H,184,234)(H,185,235)(H,186,240)(H,187,236)(H,188,238)(H,189,241)(H,190,207)(H,191,230)(H,192,233)(H,193,231)(H,194,232)(H,208,209)(H,210,211)(H,212,213)(H,214,215)(H4,158,159,162)/t78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,121-,122-,123-,124-,125-/m0/s1
DM0HWB1	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N4)CCC(=O)N)CCC(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DM0HWB1	IK	PAMPKNPMNUNCAF-KXYXCEFHSA-N
DM0HWB1	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,9S,12S,21S)-21-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-3-(3-amino-3-oxopropyl)-9-(2-carboxyethyl)-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM0HWB1	DE	Discovery agent

DMVWDHM	ID	DMVWDHM
DMVWDHM	DN	glucagon-(1-6)
DMVWDHM	HS	Investigative
DMVWDHM	SN	glucagon 1-6
DMVWDHM	DT	Small molecular drug
DMVWDHM	PC	194323
DMVWDHM	MW	675.7
DMVWDHM	FM	C29H41N9O10
DMVWDHM	IC	InChI=1S/C29H41N9O10/c1-15(40)24(28(46)36-20(29(47)48)9-16-5-3-2-4-6-16)38-23(42)12-33-26(44)19(7-8-22(31)41)35-27(45)21(13-39)37-25(43)18(30)10-17-11-32-14-34-17/h2-6,11,14-15,18-21,24,39-40H,7-10,12-13,30H2,1H3,(H2,31,41)(H,32,34)(H,33,44)(H,35,45)(H,36,46)(H,37,43)(H,38,42)(H,47,48)/t15-,18+,19+,20+,21+,24+/m1/s1
DMVWDHM	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)O
DMVWDHM	IK	VDWWLJRQDNTHJB-MXAMYCJDSA-N
DMVWDHM	IU	(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoic acid
DMVWDHM	CA	CAS 69658-84-0
DMVWDHM	DE	Discovery agent

DMZLRY2	ID	DMZLRY2
DMZLRY2	DN	Glucagon-like peptide-1 analog
DMZLRY2	HS	Investigative
DMZLRY2	SN	GLP-1 analog (type 2 diabetes), Arisaph; Glucagon-like peptide-1 analog (type 2 diabetes); Glucagon-like peptide-1 analog (type 2 diabetes), Arisaph
DMZLRY2	CP	Arisaph Pharmaceuticals Inc
DMZLRY2	DE	Non-insulin dependent diabetes

DMO071E	ID	DMO071E
DMO071E	DN	Gluconolactone
DMO071E	HS	Investigative
DMO071E	SN	gluconolactone; delta-gluconolactone; 90-80-2; D-glucono-1,5-lactone; D-Gluconolactone; 1,5-Gluconolactone; D-Gluconic acid lactone; Glucono delta-lactone; Gluconic acid lactone; 1,5-D-Gluconolactone; Gluconic lactone; Glucono delta lactone; (3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-one; Gluconic delta-lactone; D-Gluconic acid delta-lactone; d-(+)-Glucono-1,5-lactone; D-delta-Gluconolactone; delta-D-Gluconolactone; Deltagluconolactone; D-Gluconic delta-lactone; Glucarolactone; D-Aldonolactone
DMO071E	DT	Small molecular drug
DMO071E	PC	7027
DMO071E	MW	178.14
DMO071E	FM	C6H10O6
DMO071E	IC	InChI=1S/C6H10O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-5,7-10H,1H2/t2-,3-,4+,5-/m1/s1
DMO071E	CS	C([C@@H]1[C@H]([C@@H]([C@H](C(=O)O1)O)O)O)O
DMO071E	IK	PHOQVHQSTUBQQK-SQOUGZDYSA-N
DMO071E	IU	(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-one
DMO071E	CA	CAS 90-80-2
DMO071E	CB	CHEBI:16217
DMO071E	DE	Discovery agent

DMRHYU8	ID	DMRHYU8
DMRHYU8	DN	Glucopyranosyl oleanolate
DMRHYU8	HS	Investigative
DMRHYU8	SN	Beta-D-glucopyranosyl oleanolate; Oleanolic acid 28-O-beta-D-glucopyranoside; Compound O; Beta-D-glucopyranosyl oleanolate; oleanolic acid beta-D-glucopyranosyl ester; SCHEMBL2999839; BDBM50235153; ZINC49898882; 162H539; Q27136470; CHEBI:67985; CHEMBL510111; 14162-53-9
DMRHYU8	PC	14189384
DMRHYU8	MW	618.8
DMRHYU8	FM	C36H58O8
DMRHYU8	IC	KMKFOIBUKYMVRJ-YHFBEQRYSA-N
DMRHYU8	CS	CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)OC6C(C(C(C(O6)CO)O)O)O)C
DMRHYU8	IK	1S/C36H58O8/c1-31(2)14-16-36(30(42)44-29-28(41)27(40)26(39)22(19-37)43-29)17-15-34(6)20(21(36)18-31)8-9-24-33(5)12-11-25(38)32(3,4)23(33)10-13-35(24,34)7/h8,21-29,37-41H,9-19H2,1-7H3/t21-,22+,23-,24+,25-,26+,27-,28+,29-,33-,34+,35+,36-/m0/s1
DMRHYU8	IU	[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMRHYU8	CA	CAS 14162-53-9
DMRHYU8	CB	CHEBI:67985
DMRHYU8	DE	Discovery agent

DMY590Q	ID	DMY590Q
DMY590Q	DN	Glucosamine 6-Phosphate
DMY590Q	HS	Investigative
DMY590Q	SN	glucosamine 6-phosphate; glucosamine-6-phosphate; D-glucosamine phosphate; D-glucosamine 6-phosphate; 2-amino-2-deoxy-6-O-phosphono-alpha-D-glucopyranose; GlcN-6-P; 1moq; Glucose-6-phosphorate; bmse000189; AC1L96WN; SCHEMBL4363568; CHEBI:15873; XHMJOUIAFHJHBW-UKFBFLRUSA-N; ZINC4097103; alpha-D-Glucosamine 6-phosphoric acid; DB02657; alpha-D-glucosamine 6-(dihydrogen phosphate); 2-amino-2-deoxy-alpha-D-glucopyranose 6-(dihydrogen phosphate); WURCS=2.0/1,1,0/[a2122h-1a_1-5_2*N_6*OPO/3O/3=O]/1/
DMY590Q	DT	Small molecular drug
DMY590Q	PC	439217
DMY590Q	MW	259.149
DMY590Q	FM	C6H14NO8P
DMY590Q	IC	InChI=1S/C6H14NO8P/c7-3-5(9)4(8)2(15-6(3)10)1-14-16(11,12)13/h2-6,8-10H,1,7H2,(H2,11,12,13)/t2-,3-,4-,5-,6+/m1/s1
DMY590Q	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)N)O)O)OP(=O)(O)O
DMY590Q	IK	XHMJOUIAFHJHBW-UKFBFLRUSA-N
DMY590Q	IU	[(2R,3S,4R,5R,6S)-5-amino-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMY590Q	CA	CAS 3616-42-0
DMY590Q	CB	CHEBI:15873
DMY590Q	DE	Discovery agent

DMLISP2	ID	DMLISP2
DMLISP2	DN	Glucose analogue
DMLISP2	HS	Investigative
DMLISP2	DE	Infection of P. falciparum

DMMJQ7O	ID	DMMJQ7O
DMMJQ7O	DN	Glucose-bisphosphate
DMMJQ7O	HS	Investigative
DMMJQ7O	SN	Glucose 1,6-bisphosphate; Alpha-D-Glucose 1,6-bisphosphate; 10139-18-1; alpha-D-Glucose 1,6-bis(dihydrogen phosphate); Glucose 1,6-diphosphate; glucose-1,6-bisphosphate; alpha-D-Glucose 1,6-diphosphate; UNII-DRX17R6AM2; D-Glucose 1,6-biphosphate; D-Glucose 1,6-diphosphate; DRX17R6AM2; alpha-D-Glucose 1,6-biphosphate; alpha-D-Glucose-1,6-diphosphate; RWHOZGRAXYWRNX-VFUOTHLCSA-N; alpha-D-glucopyranose, 1,6-bis(dihydrogen phosphate); 1,6-di-O-phosphono-alpha-D-glucopyranose; 2fkf; Glc-1,6P; G16; EINECS 233-395-5; Glucose-1,3-bisphosphate; glucose 1, 6-diphosphate; bmse000087; a-D-Glucose 1,6-diphosphate; a-D-Glucose 1,6-bisphosphate; alpha-Glucose 1,6-diphosphate; delta-Glucose 1,6-diphosphate; SCHEMBL1266885; CHEBI:18148; alpha-D-Glucose-1,6-bisphosphate; ZINC4095589; .alpha.-D-Glucose 1,6-bisphosphate; alpha-delta-Glucose 1,6-diphosphate; alpha-delta-Glucose 1,6-bisphosphate; Glucose 1,6-diphosphate (6CI,7CI); DB02835; a-D-Glucose 1,6-bis(dihydrogen phosphate); C01231; alpha-delta-Glucose 1,6-bis(dihydrogen phosphate); Alpha-D-1,6-bis(dihydrogen phosphate) Glucopyranose; alpha-D-glucopyranose 1,6-bis(dihydrogen phosphate); Q4122197; Alpha-delta-1,6-bis(dihydrogen phosphate) Glucopyranose; .alpha.-D-Glucose 1,6-bisphosphate potassium salt hydrate; FFE24833-162C-479C-90C5-CDF93D1E899A; alpha-D-Glucopyranose, 1,6-bis(dihydrogen phosphate) (9CI); Glucopyranose, 1,6-bis(dihydrogen phosphate), alpha-D- (8CI); {[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[(phosphonooxy)methyl]oxan-2-yl]oxy}phosphonic acid
DMMJQ7O	PC	82400
DMMJQ7O	IU	[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(phosphonooxymethyl)oxan-2-yl] dihydrogen phosphate
DMMJQ7O	DE	Discovery agent

DMXBQRJ	ID	DMXBQRJ
DMXBQRJ	DN	Glu-Leu-Asp-Leu-(CHOH-CH2)-Ala-Ala-Glu-Phe
DMXBQRJ	HS	Investigative
DMXBQRJ	SN	CHEMBL363255; Glu-Leu-Asp-Leu-(CHOH-CH2)-Ala-Ala-Glu-Phe
DMXBQRJ	DT	Small molecular drug
DMXBQRJ	PC	44397266
DMXBQRJ	MW	979.1
DMXBQRJ	FM	C45H70N8O16
DMXBQRJ	IC	InChI=1S/C45H70N8O16/c1-22(2)17-29(49-43(66)31(20-36(59)60)51-42(65)30(18-23(3)4)50-40(63)27(46)13-15-34(55)56)38(61)33(54)21-47-25(7)39(62)53-37(24(5)6)44(67)48-28(14-16-35(57)58)41(64)52-32(45(68)69)19-26-11-9-8-10-12-26/h8-12,22-25,27-33,37,47,54H,13-21,46H2,1-7H3,(H,48,67)(H,49,66)(H,50,63)(H,51,65)(H,52,64)(H,53,62)(H,55,56)(H,57,58)(H,59,60)(H,68,69)/t25-,27-,28-,29-,30-,31-,32-,33?,37-/m0/s1
DMXBQRJ	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NCC(C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)N)O
DMXBQRJ	IK	WAHCXYBUKGOGCQ-SHELQGHFSA-N
DMXBQRJ	IU	(4S)-4-amino-5-[[(2S)-1-[[(2S)-3-carboxy-1-[[(4S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-hydroxy-6-methyl-3-oxoheptan-4-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMXBQRJ	DE	Discovery agent

DM6EA9B	ID	DM6EA9B
DM6EA9B	DN	Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu
DM6EA9B	HS	Investigative
DM6EA9B	SN	CHEMBL413629; Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu
DM6EA9B	PC	44300176
DM6EA9B	MW	1507.5
DM6EA9B	FM	C67H97F2N12O23P
DM6EA9B	IC	InChI=1S/C67H97F2N12O23P/c1-7-35(5)54(63(97)76-46(33-38-15-19-40(82)20-16-38)60(94)77-47(66(100)101)31-34(3)4)78-62(96)49-12-10-30-81(49)65(99)55(36(6)8-2)79-58(92)44(24-28-53(88)89)72-56(90)43(23-27-52(86)87)73-59(93)45(32-37-13-17-39(18-14-37)67(68,69)105(102,103)104)75-57(91)42(22-25-50(71)83)74-61(95)48-11-9-29-80(48)64(98)41(70)21-26-51(84)85/h13-20,34-36,41-49,54-55,82H,7-12,21-33,70H2,1-6H3,(H2,71,83)(H,72,90)(H,73,93)(H,74,95)(H,75,91)(H,76,97)(H,77,94)(H,78,96)(H,79,92)(H,84,85)(H,86,87)(H,88,89)(H,100,101)(H2,102,103,104)/t35-,36-,41-,42-,43-,44-,45-,46-,47-,48-,49-,54-,55-/m0/s1
DM6EA9B	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)C(F)(F)P(=O)(O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)N
DM6EA9B	IK	FOSUHZNVGWOSJD-VBIHGRSYSA-N
DM6EA9B	IU	(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-amino-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]propanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
DM6EA9B	DE	Discovery agent

DMYZO37	ID	DMYZO37
DMYZO37	DN	Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu
DMYZO37	HS	Investigative
DMYZO37	SN	CHEMBL414123; Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu; BDBM50289749; 147612-86-0
DMYZO37	PC	44300143
DMYZO37	MW	1473.5
DMYZO37	FM	C66H97N12O24P
DMYZO37	IC	InChI=1S/C66H97N12O24P/c1-7-35(5)54(63(94)73-46(32-37-13-17-39(79)18-14-37)60(91)74-47(66(97)98)31-34(3)4)75-62(93)49-12-10-30-78(49)65(96)55(36(6)8-2)76-58(89)44(24-28-53(85)86)69-56(87)43(23-27-52(83)84)70-59(90)45(33-38-15-19-40(20-16-38)102-103(99,100)101)72-57(88)42(22-25-50(68)80)71-61(92)48-11-9-29-77(48)64(95)41(67)21-26-51(81)82/h13-20,34-36,41-49,54-55,79H,7-12,21-33,67H2,1-6H3,(H2,68,80)(H,69,87)(H,70,90)(H,71,92)(H,72,88)(H,73,94)(H,74,91)(H,75,93)(H,76,89)(H,81,82)(H,83,84)(H,85,86)(H,97,98)(H2,99,100,101)/t35-,36-,41-,42-,43-,44-,45-,46-,47-,48-,49-,54-,55-/m0/s1
DMYZO37	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)OP(=O)(O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)N
DMYZO37	IK	DLNQPUNIZRZGQD-VBIHGRSYSA-N
DMYZO37	IU	(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-amino-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-(4-phosphonooxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
DMYZO37	DE	Discovery agent

DMT7K0U	ID	DMT7K0U
DMT7K0U	DN	Glutamine Hydroxamate
DMT7K0U	HS	Investigative
DMT7K0U	SN	glutamine hydroxamate; N-Hydroxy-L-glutamine; 1955-67-5; Glutamyl-gamma-hydroxamate; gamma-Glutamyl hydroxamate; Glutamate-gamma-hydroxamate; L-gamma-Glutamyl hydroxamate; Glutamate-gamma-hydroxamic acid; Glutamic acid gamma-monohydroxamate; CHEMBL63893; CHEBI:75305; HGA; Glunhoh; Amino acid hydroxamates L-glutamic acid gamma- monohydroxamate; AC1L9MTD; gamma-glutamylhydroxylamine; SCHEMBL4321249; L-Glutamic acid -monohydroxamate; L-Glutamic acid gamma-hydroxamate; ZINC2522574; FCH838713; BDBM50129196; L-glutamic acid gamma-hydr
DMT7K0U	DT	Small molecular drug
DMT7K0U	PC	449178
DMT7K0U	MW	162.14
DMT7K0U	FM	C5H10N2O4
DMT7K0U	IC	InChI=1S/C5H10N2O4/c6-3(5(9)10)1-2-4(8)7-11/h3,11H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
DMT7K0U	CS	C(CC(=O)NO)[C@@H](C(=O)O)N
DMT7K0U	IK	YVGZXTQJQNXIAU-VKHMYHEASA-N
DMT7K0U	IU	(2S)-2-amino-5-(hydroxyamino)-5-oxopentanoic acid
DMT7K0U	CA	CAS 1955-67-5
DMT7K0U	CB	CHEBI:75305
DMT7K0U	DE	Discovery agent

DMPUFDS	ID	DMPUFDS
DMPUFDS	DN	Glutarate
DMPUFDS	HS	Investigative
DMPUFDS	SN	GLUTARIC ACID; Pentanedioic acid; 110-94-1; 1,5-Pentanedioic acid; 1,3-Propanedicarboxylic acid; Pentandioic acid; glutarate; n-Pyrotartaric acid; UNII-H849F7N00B; propane-1,3-dicarboxylic acid; Carboxylic acids, di-, C4-6; HSDB 5542; Glutaric acid, 99%; Carboxylic acids, C6-18 and C5-15-di-; NSC 9238; EINECS 203-817-2; (C4-C6) Dibasic acids; BRN 1209725; AI3-24247; CHEBI:17859; NSC9238; JFCQEDHGNNZCLN-UHFFFAOYSA-N; H849F7N00B; MFCD00004410; DSSTox_CID_1654; DSSTox_RID_76266; DSSTox_GSID_21654; CAS-110-94-1; Pentandioate; Glutarsaeure
DMPUFDS	DT	Small molecular drug
DMPUFDS	PC	743
DMPUFDS	MW	132.11
DMPUFDS	FM	C5H8O4
DMPUFDS	IC	InChI=1S/C5H8O4/c6-4(7)2-1-3-5(8)9/h1-3H2,(H,6,7)(H,8,9)
DMPUFDS	CS	C(CC(=O)O)CC(=O)O
DMPUFDS	IK	JFCQEDHGNNZCLN-UHFFFAOYSA-N
DMPUFDS	IU	pentanedioic acid
DMPUFDS	CA	CAS 110-94-1
DMPUFDS	CB	CHEBI:17859
DMPUFDS	DE	Discovery agent

DMAV2I7	ID	DMAV2I7
DMAV2I7	DN	Glutathione ester
DMAV2I7	HS	Investigative
DMAV2I7	SN	Glutathione S-methyl ester; S-Methylglutathione; OOW3025SR1; QTQDDTSVRVWHMO-BQBZGAKWSA-N; S-METHYL-GLUTATHIONE; S-Methyl GSH; S-Methyl glutathione; SCHEMBL1767370; ZINC1532230; 2922-56-7; AC1L3GTT; BDBM225232; C11347; CHEBI:141472; CHEMBL1233129; CTK4G2973; DB04701; DTXSID10183479; GSM; Glycine, L-g-glutamyl-S-methyl-L-cysteinyl-; Glycine, N-(N-L-gamma-glutamyl-S-methyl-L-cysteinyl)-; L-GAMMA-GLUTAMYL-S-METHYLCYSTEINYLGLYCINE; L-gamma-Glutamyl-S-methyl-L-cysteinylglycine; UNII-OOW3025SR1
DMAV2I7	PC	115260
DMAV2I7	MW	321.35
DMAV2I7	FM	C11H19N3O6S
DMAV2I7	IC	QTQDDTSVRVWHMO-BQBZGAKWSA-N
DMAV2I7	CS	CSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N
DMAV2I7	IK	1S/C11H19N3O6S/c1-21-5-7(10(18)13-4-9(16)17)14-8(15)3-2-6(12)11(19)20/h6-7H,2-5,12H2,1H3,(H,13,18)(H,14,15)(H,16,17)(H,19,20)/t6-,7-/m0/s1
DMAV2I7	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-methylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMAV2I7	CA	CAS 2922-56-7
DMAV2I7	CB	CHEBI:141472
DMAV2I7	DE	Discovery agent

DMPX7FR	ID	DMPX7FR
DMPX7FR	DN	Glutathionylspermidine Disulfide
DMPX7FR	HS	Investigative
DMPX7FR	SN	GLUTATHIONYLSPERMIDINE DISULFIDE; TS4; AC1L9N8X; DB02553; (2R)-2-amino-5-[[(2R)-1-[[2-[3-(4-aminobutylamino)propylamino]-2-oxoethyl]amino]-3-[[(2R)-3-[[2-[3-(4-aminobutylamino)propylamino]-2-oxoethyl]amino]-2-[[(4R)-4-amino-5-hydroxy-5-oxopentanoyl]amino]-3-oxopropyl]disulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMPX7FR	DT	Small molecular drug
DMPX7FR	PC	449555
DMPX7FR	MW	867.1
DMPX7FR	FM	C34H66N12O10S2
DMPX7FR	IC	InChI=1S/C34H66N12O10S2/c35-11-1-3-13-39-15-5-17-41-29(49)19-43-31(51)25(45-27(47)9-7-23(37)33(53)54)21-57-58-22-26(46-28(48)10-8-24(38)34(55)56)32(52)44-20-30(50)42-18-6-16-40-14-4-2-12-36/h23-26,39-40H,1-22,35-38H2,(H,41,49)(H,42,50)(H,43,51)(H,44,52)(H,45,47)(H,46,48)(H,53,54)(H,55,56)/t23-,24-,25+,26+/m1/s1
DMPX7FR	CS	C(CCNCCCNC(=O)CNC(=O)[C@H](CSSC[C@@H](C(=O)NCC(=O)NCCCNCCCCN)NC(=O)CC[C@H](C(=O)O)N)NC(=O)CC[C@H](C(=O)O)N)CN
DMPX7FR	IK	HCMZDPYSWPSKSP-XPGKHFPBSA-N
DMPX7FR	IU	(2R)-2-amino-5-[[(2R)-1-[[2-[3-(4-aminobutylamino)propylamino]-2-oxoethyl]amino]-3-[[(2R)-3-[[2-[3-(4-aminobutylamino)propylamino]-2-oxoethyl]amino]-2-[[(4R)-4-amino-4-carboxybutanoyl]amino]-3-oxopropyl]disulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMPX7FR	DE	Discovery agent

DM1Q83B	ID	DM1Q83B
DM1Q83B	DN	Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
DM1Q83B	HS	Investigative
DM1Q83B	SN	Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro; CHEMBL216386; BDBM50027353
DM1Q83B	PC	44346192
DM1Q83B	MW	1119.3
DM1Q83B	FM	C53H78N14O13
DM1Q83B	IC	InChI=1S/C53H78N14O13/c1-3-29(2)43(51(78)66-25-9-16-39(66)50(77)67-26-10-17-40(67)52(79)80)63-45(72)34(19-20-41(55)68)60-46(73)37-14-7-23-64(37)48(75)35(13-6-22-58-53(56)57)61-47(74)38-15-8-24-65(38)49(76)36(62-44(71)32(54)18-21-42(69)70)27-30-28-59-33-12-5-4-11-31(30)33/h4-5,11-12,28-29,32,34-40,43,59H,3,6-10,13-27,54H2,1-2H3,(H2,55,68)(H,60,73)(H,61,74)(H,62,71)(H,63,72)(H,69,70)(H,79,80)(H4,56,57,58)/t29-,32-,34-,35-,36-,37-,38-,39-,40-,43-/m0/s1
DM1Q83B	CS	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCC(=O)O)N
DM1Q83B	IK	RDZJYRCUGADIDN-AXPLDACSSA-N
DM1Q83B	IU	(2S)-1-[(2S)-1-[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid
DM1Q83B	DE	Discovery agent

DMO8LAC	ID	DMO8LAC
DMO8LAC	DN	Gly-Amp-Glu
DMO8LAC	HS	Investigative
DMO8LAC	SN	Gly-Amp-Glu
DMO8LAC	DT	Small molecular drug
DMO8LAC	PC	44408739
DMO8LAC	MW	316.31
DMO8LAC	FM	C12H20N4O6
DMO8LAC	IC	InChI=1S/C12H20N4O6/c13-4-9(17)16-5-6(14)3-8(16)11(20)15-7(12(21)22)1-2-10(18)19/h6-8H,1-5,13-14H2,(H,15,20)(H,18,19)(H,21,22)/t6-,7-,8-/m0/s1
DMO8LAC	CS	C1[C@@H](CN([C@@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)CN)N
DMO8LAC	IK	FVOTXFYXMKNJIH-FXQIFTODSA-N
DMO8LAC	IU	(2S)-2-[[(2S,4S)-4-amino-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]pentanedioic acid
DMO8LAC	DE	Discovery agent

DMACT8D	ID	DMACT8D
DMACT8D	DN	Gly-Arg-Gly-Asp-Ser
DMACT8D	HS	Investigative
DMACT8D	SN	Gly-arg-gly-asp-ser; 96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, &gt; LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-
DMACT8D	DT	Small molecular drug
DMACT8D	PC	123811
DMACT8D	MW	490.5
DMACT8D	FM	C17H30N8O9
DMACT8D	IC	InChI=1S/C17H30N8O9/c18-5-11(27)23-8(2-1-3-21-17(19)20)14(31)22-6-12(28)24-9(4-13(29)30)15(32)25-10(7-26)16(33)34/h8-10,26H,1-7,18H2,(H,22,31)(H,23,27)(H,24,28)(H,25,32)(H,29,30)(H,33,34)(H4,19,20,21)/t8-,9-,10-/m0/s1
DMACT8D	CS	C(C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)CN)CN=C(N)N
DMACT8D	IK	RGNVSYKVCGAEHK-GUBZILKMSA-N
DMACT8D	IU	(3S)-3-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid
DMACT8D	CA	CAS 96426-21-0
DMACT8D	DE	Discovery agent

DMGOIME	ID	DMGOIME
DMGOIME	DN	Gly-Arg-Gly-Asp-Ser-Pro-Lys
DMGOIME	HS	Investigative
DMGOIME	SN	Grgdspk; Gly-arg-gly-asp-ser-pro-lys; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, &gt; glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-
DMGOIME	DT	Small molecular drug
DMGOIME	PC	130667
DMGOIME	MW	715.8
DMGOIME	FM	C28H49N11O11
DMGOIME	IC	InChI=1S/C28H49N11O11/c29-8-2-1-5-16(27(49)50)37-25(47)19-7-4-10-39(19)26(48)18(14-40)38-24(46)17(11-22(43)44)36-21(42)13-34-23(45)15(35-20(41)12-30)6-3-9-33-28(31)32/h15-19,40H,1-14,29-30H2,(H,34,45)(H,35,41)(H,36,42)(H,37,47)(H,38,46)(H,43,44)(H,49,50)(H4,31,32,33)/t15-,16-,17-,18-,19-/m0/s1
DMGOIME	CS	C1C[C@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)O
DMGOIME	IK	ZRVZOBGMZWVJOS-VMXHOPILSA-N
DMGOIME	IU	(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DMGOIME	CA	CAS 111119-28-9
DMGOIME	DE	Discovery agent

DM8L09J	ID	DM8L09J
DM8L09J	DN	Gly-b7Pro-Glu
DM8L09J	HS	Investigative
DM8L09J	SN	Gly-b7Pro-Glu
DM8L09J	DT	Small molecular drug
DM8L09J	PC	44408837
DM8L09J	MW	327.33
DM8L09J	FM	C14H21N3O6
DM8L09J	IC	InChI=1S/C14H21N3O6/c15-7-10(18)17-8-3-5-14(17,6-4-8)13(23)16-9(12(21)22)1-2-11(19)20/h8-9H,1-7,15H2,(H,16,23)(H,19,20)(H,21,22)/t8?,9-,14?/m0/s1
DM8L09J	CS	C1CC2(CCC1N2C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM8L09J	IK	AXVZKZJJSLXCSR-PUUHTONNSA-N
DM8L09J	IU	(2S)-2-[[7-(2-aminoacetyl)-7-azabicyclo[2.2.1]heptane-1-carbonyl]amino]pentanedioic acid
DM8L09J	DE	Discovery agent

DM0J5KF	ID	DM0J5KF
DM0J5KF	DN	Glycerol-2-Phosphate
DM0J5KF	HS	Investigative
DM0J5KF	SN	1,3-dihydroxypropan-2-yl phosphate; Glycerol 2-phosphate; 2-glycerophosphate; NCGC00166037-02; b-glycerol-phosphate; beta-glycerol-phosphate; AC1MU1UF; glycerol 2-phosphate(2-); glycerol 2-phosphate dianion; CHEBI:58083; STL280277; 2-(phosphonatooxy)propane-1,3-diol; AKOS022142160
DM0J5KF	DT	Small molecular drug
DM0J5KF	PC	2526
DM0J5KF	MW	172.07
DM0J5KF	FM	C3H9O6P
DM0J5KF	IC	InChI=1S/C3H9O6P/c4-1-3(2-5)9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)
DM0J5KF	CS	C(C(CO)OP(=O)(O)O)O
DM0J5KF	IK	DHCLVCXQIBBOPH-UHFFFAOYSA-N
DM0J5KF	IU	1,3-dihydroxypropan-2-yl dihydrogen phosphate
DM0J5KF	CA	CAS 17181-54-3
DM0J5KF	CB	CHEBI:17270
DM0J5KF	DE	Discovery agent

DMTCEFV	ID	DMTCEFV
DMTCEFV	DN	Glycinamid
DMTCEFV	HS	Investigative
DMTCEFV	SN	Glycinamide; 2-Aminoacetamide; 598-41-4; Glycine amide; Acetamide, 2-amino-; GLYCINAMID; AMINOMETHYLAMIDE; 2-Amino-Acetamide; CHEBI:42843; BEBCJVAWIBVWNZ-UHFFFAOYSA-N; Glycinamide HCl; AI3-60342; aminoacetamide; glycineamide; glycinamidehcl; glycine-amide; glycine imine; Glycinimidic acid; alpha-aminoacetamide; EINECS 209-932-4; GlyNH2; 2-Aminoacetamide #; Gly-NH2; Glycineamide, G-NH2; AC1L2AXY; H2NCH2CONH2; Glycine amide hydrobromide; AC1Q53MT; CHEMBL86954; 598-41-4 (Parent); DTXSID1060508; 1668-10-6 (hydrochloride); CTK1H1328; CTK1D7741
DMTCEFV	DT	Small molecular drug
DMTCEFV	PC	69020
DMTCEFV	MW	74.08
DMTCEFV	FM	C2H6N2O
DMTCEFV	IC	InChI=1S/C2H6N2O/c3-1-2(4)5/h1,3H2,(H2,4,5)
DMTCEFV	CS	C(C(=O)N)N
DMTCEFV	IK	BEBCJVAWIBVWNZ-UHFFFAOYSA-N
DMTCEFV	IU	2-aminoacetamide
DMTCEFV	CA	CAS 598-41-4
DMTCEFV	CB	CHEBI:42843
DMTCEFV	DE	Discovery agent

DMW180Y	ID	DMW180Y
DMW180Y	DN	Glycinamide Ribonucleotide
DMW180Y	HS	Investigative
DMW180Y	SN	Glycineamide ribonucleotide; Glycineamideribotide; glycinamide ribonucleotide; 10074-18-7; 5'-phosphoribosylglycineamide; GAR; 5'-phosphoribosylglycinamide; N1-(5-Phospho-D-ribosyl)glycinamide; {[(2R,3S,4R,5R)-5-(2-aminoacetamido)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid; N1-(5-phospho-beta-D-ribosyl)glycinamide; Glycineamide ribotide; AC1Q5JNA; AC1L4OGM; n-glycyl-5-o-phosphono-; A-d-ribofuranosylamine; 5'-Phosphoribosyl-glycineamide; SCHEMBL4366354; BDBM22589; DTXSID70143478; C03838
DMW180Y	DT	Small molecular drug
DMW180Y	PC	160913
DMW180Y	MW	286.18
DMW180Y	FM	C7H15N2O8P
DMW180Y	IC	InChI=1S/C7H15N2O8P/c8-1-4(10)9-7-6(12)5(11)3(17-7)2-16-18(13,14)15/h3,5-7,11-12H,1-2,8H2,(H,9,10)(H2,13,14,15)/t3-,5-,6-,7-/m1/s1
DMW180Y	CS	C([C@@H]1[C@H]([C@H]([C@@H](O1)NC(=O)CN)O)O)OP(=O)(O)O
DMW180Y	IK	OBQMLSFOUZUIOB-SHUUEZRQSA-N
DMW180Y	IU	[(2R,3S,4R,5R)-5-[(2-aminoacetyl)amino]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMW180Y	CA	CAS 10074-18-7
DMW180Y	DE	Discovery agent

DM0SXNM	ID	DM0SXNM
DM0SXNM	DN	Glycocholic acid
DM0SXNM	HS	Investigative
DM0SXNM	SN	glycocholate; cholylglycine
DM0SXNM	DT	Small molecular drug
DM0SXNM	PC	10140
DM0SXNM	MW	465.6
DM0SXNM	FM	C26H43NO6
DM0SXNM	IC	InChI=1S/C26H43NO6/c1-14(4-7-22(31)27-13-23(32)33)17-5-6-18-24-19(12-21(30)26(17,18)3)25(2)9-8-16(28)10-15(25)11-20(24)29/h14-21,24,28-30H,4-13H2,1-3H3,(H,27,31)(H,32,33)/t14-,15+,16-,17-,18+,19+,20-,21+,24+,25+,26-/m1/s1
DM0SXNM	CS	C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
DM0SXNM	IK	RFDAIACWWDREDC-FRVQLJSFSA-N
DM0SXNM	IU	2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
DM0SXNM	CA	CAS 475-31-0
DM0SXNM	CB	CHEBI:17687
DM0SXNM	DE	Discovery agent

DM1XEJV	ID	DM1XEJV
DM1XEJV	DN	Glycodeoxycholic acid
DM1XEJV	HS	Investigative
DM1XEJV	SN	glycodeoxycholate
DM1XEJV	DT	Small molecular drug
DM1XEJV	PC	3035026
DM1XEJV	MW	449.6
DM1XEJV	FM	C26H43NO5
DM1XEJV	IC	InChI=1S/C26H43NO5/c1-15(4-9-23(30)27-14-24(31)32)19-7-8-20-18-6-5-16-12-17(28)10-11-25(16,2)21(18)13-22(29)26(19,20)3/h15-22,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16-,17-,18+,19-,20+,21+,22+,25+,26-/m1/s1
DM1XEJV	CS	C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DM1XEJV	IK	WVULKSPCQVQLCU-BUXLTGKBSA-N
DM1XEJV	IU	2-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
DM1XEJV	CA	CAS 360-65-6
DM1XEJV	CB	CHEBI:27471
DM1XEJV	DE	Discovery agent

DM0SCK8	ID	DM0SCK8
DM0SCK8	DN	Glycyl-H 1152
DM0SCK8	HS	Investigative
DM0SCK8	SN	glycyl-H 1152
DM0SCK8	DT	Small molecular drug
DM0SCK8	PC	11976582
DM0SCK8	MW	376.5
DM0SCK8	FM	C18H24N4O3S
DM0SCK8	IC	InChI=1S/C18H24N4O3S/c1-13-10-20-11-15-5-3-6-16(18(13)15)26(24,25)22-8-4-7-21(12-14(22)2)17(23)9-19/h3,5-6,10-11,14H,4,7-9,12,19H2,1-2H3/t14-/m0/s1
DM0SCK8	CS	C[C@H]1CN(CCCN1S(=O)(=O)C2=CC=CC3=C2C(=CN=C3)C)C(=O)CN
DM0SCK8	IK	CMKMGFAUKPAOMG-AWEZNQCLSA-N
DM0SCK8	IU	2-amino-1-[(3S)-3-methyl-4-(4-methylisoquinolin-5-yl)sulfonyl-1,4-diazepan-1-yl]ethanone
DM0SCK8	DE	Discovery agent

DM8FTJN	ID	DM8FTJN
DM8FTJN	DN	Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine
DM8FTJN	HS	Investigative
DM8FTJN	SN	GLYCYL-L-ALPHA-AMINO-EPSILON-PIMELYL-D-ALANINE; REY; AC1L9JH9; DB03927; (2S)-2-[(2-aminoacetyl)amino]-7-[[(2R)-1-hydroxy-1-oxopropan-2-yl]amino]-7-oxoheptanoic acid
DM8FTJN	DT	Small molecular drug
DM8FTJN	PC	446307
DM8FTJN	MW	303.31
DM8FTJN	FM	C12H21N3O6
DM8FTJN	IC	InChI=1S/C12H21N3O6/c1-7(11(18)19)14-9(16)5-3-2-4-8(12(20)21)15-10(17)6-13/h7-8H,2-6,13H2,1H3,(H,14,16)(H,15,17)(H,18,19)(H,20,21)/t7-,8+/m1/s1
DM8FTJN	CS	C[C@H](C(=O)O)NC(=O)CCCC[C@@H](C(=O)O)NC(=O)CN
DM8FTJN	IK	ZMQJQOKNTYQVHO-SFYZADRCSA-N
DM8FTJN	IU	(2S)-2-[(2-aminoacetyl)amino]-7-[[(1R)-1-carboxyethyl]amino]-7-oxoheptanoic acid
DM8FTJN	DE	Discovery agent

DMTOCXZ	ID	DMTOCXZ
DMTOCXZ	DN	GLYCYLRYANODINE
DMTOCXZ	HS	Investigative
DMTOCXZ	SN	glycylryanodine; CHEMBL283836
DMTOCXZ	DT	Small molecular drug
DMTOCXZ	PC	44275859
DMTOCXZ	MW	550.6
DMTOCXZ	FM	C27H38N2O10
DMTOCXZ	IC	InChI=1S/C27H38N2O10/c1-13(2)24(34)19(38-18(31)15-7-6-10-29-15)25(35)20(4)12-23(33)21(24,5)27(25,36)26(39-23)17(37-16(30)11-28)14(3)8-9-22(20,26)32/h6-7,10,13-14,17,19,29,32-36H,8-9,11-12,28H2,1-5H3/t14?,17-,19-,20+,21?,22?,23?,24?,25?,26?,27?/m1/s1
DMTOCXZ	CS	CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CN)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DMTOCXZ	IK	XNUMBOKCFNVRAL-MPGPDOFNSA-N
DMTOCXZ	IU	[(2R,7S,12R)-2-(2-aminoacetyl)oxy-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMTOCXZ	DE	Discovery agent

DM67FQ1	ID	DM67FQ1
DM67FQ1	DN	GlyH-101
DM67FQ1	HS	Investigative
DM67FQ1	SN	CTK8E9894; AGN-PC-005HH0
DM67FQ1	DT	Small molecular drug
DM67FQ1	PC	135476586
DM67FQ1	MW	493.1
DM67FQ1	FM	C19H15Br2N3O3
DM67FQ1	IC	InChI=1S/C19H15Br2N3O3/c20-15-8-13(18(26)17(21)19(15)27)9-23-24-16(25)10-22-14-6-5-11-3-1-2-4-12(11)7-14/h1-9,22,26-27H,10H2,(H,24,25)/b23-9+
DM67FQ1	CS	C1=CC=C2C=C(C=CC2=C1)NCC(=O)N/N=C/C3=CC(=C(C(=C3O)Br)O)Br
DM67FQ1	IK	RMBDLOATEPYBSI-NUGSKGIGSA-N
DM67FQ1	IU	N-[(E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylideneamino]-2-(naphthalen-2-ylamino)acetamide
DM67FQ1	DE	Discovery agent

DM8XR4Y	ID	DM8XR4Y
DM8XR4Y	DN	Gly-Hyp-Glu
DM8XR4Y	HS	Investigative
DM8XR4Y	SN	Gly-Hyp-Glu; CHEMBL380624; SCHEMBL2084290; MPZCPLJCORMPJI-CSMHCCOUSA-N; glycyl-l-hydroxyprolyl-l-glutamic acid; Glycyl-trans-4-hydroxy-L-prolyl-L-glutamic acid
DM8XR4Y	DT	Small molecular drug
DM8XR4Y	PC	11902976
DM8XR4Y	MW	317.3
DM8XR4Y	FM	C12H19N3O7
DM8XR4Y	IC	InChI=1S/C12H19N3O7/c13-4-9(17)15-5-6(16)3-8(15)11(20)14-7(12(21)22)1-2-10(18)19/h6-8,16H,1-5,13H2,(H,14,20)(H,18,19)(H,21,22)/t6-,7+,8+/m1/s1
DM8XR4Y	CS	C1[C@H](CN([C@@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)CN)O
DM8XR4Y	IK	MPZCPLJCORMPJI-CSMHCCOUSA-N
DM8XR4Y	IU	(2S)-2-[[(2S,4R)-1-(2-aminoacetyl)-4-hydroxypyrrolidine-2-carbonyl]amino]pentanedioic acid
DM8XR4Y	CA	CAS 32302-79-7
DM8XR4Y	DE	Discovery agent

DMQUP7O	ID	DMQUP7O
DMQUP7O	DN	Glyoxalate, Glyoxylate
DMQUP7O	HS	Investigative
DMQUP7O	SN	glyoxylic acid; 298-12-4; 2-Oxoacetic Acid; Glyoxalic acid; Oxoacetic acid; Oxoethanoic acid; Formylformic acid; Acetic acid, oxo-; Oxalaldehydic acid; glyoxylate; alpha-Ketoacetic acid; glyoxalate; 2-Oxoacetic acid(50% in water); Formic acid, formyl-; oxaldehydic acid; Kyselina glyoxylova; GLYOXALATE, GLYOXYLATE; 563-96-2; CCRIS 1455; Acetic acid, 2-oxo-; HSDB 5559; Oxo-acetic acid; Kyselina glyoxylova [Czech]; UNII-JQ39C92HH6; NSC 27785; OCHCOOH; .alpha.-Ketoacetic acid; EINECS 206-058-5; BRN 0741891; JQ39C92HH6; Glyoxylic acid, 50% i
DMQUP7O	DT	Small molecular drug
DMQUP7O	PC	760
DMQUP7O	MW	74.04
DMQUP7O	FM	C2H2O3
DMQUP7O	IC	InChI=1S/C2H2O3/c3-1-2(4)5/h1H,(H,4,5)
DMQUP7O	CS	C(=O)C(=O)O
DMQUP7O	IK	HHLFWLYXYJOTON-UHFFFAOYSA-N
DMQUP7O	IU	oxaldehydic acid
DMQUP7O	CA	CAS 298-12-4
DMQUP7O	CB	CHEBI:16891
DMQUP7O	DE	Discovery agent

DMJ9XZO	ID	DMJ9XZO
DMJ9XZO	DN	Glyoxylate
DMJ9XZO	HS	Investigative
DMJ9XZO	SN	Glyoxylat; HHLFWLYXYJOTON-UHFFFAOYSA-M; glyoxylate; oxaldehydate; oxoacetate; AC1MU8DW; CHEBI:36655; glyox
DMJ9XZO	PC	3614358
DMJ9XZO	MW	73.03
DMJ9XZO	FM	C2HO3-
DMJ9XZO	IC	HHLFWLYXYJOTON-UHFFFAOYSA-M
DMJ9XZO	CS	C(=O)C(=O)[O-]
DMJ9XZO	IK	1S/C2H2O3/c3-1-2(4)5/h1H,(H,4,5)/p-1
DMJ9XZO	IU	oxaldehydate
DMJ9XZO	CA	CAS 298-12-4
DMJ9XZO	CB	CHEBI:36655
DMJ9XZO	DE	Discovery agent

DM0AFY7	ID	DM0AFY7
DM0AFY7	DN	Glyphosate
DM0AFY7	HS	Investigative
DM0AFY7	SN	glyphosate; 1071-83-6; N-(Phosphonomethyl)glycine; Glyphosphate; Roundup; Glycine, N-(phosphonomethyl)-; N-Phosphonomethyl-glycine; 2-(phosphonomethylamino)acetic acid; Silglif; Pondmaster; Roundup Max; N-Phosphonomethylglycine; N-Phosphomethylglycine; Caswell No. 661A; MON 2139; C3H8NO5P; N-(Phosphonomethyl) Glycine; NSC151063; Glialka; Phosphonomethyliminoacetic acid; Mon 6000; Glyphosate [ANSI:BSI:ISO]; UNII-4632WW1X5A; CCRIS 1587; CP 67573; HSDB 3432; XDDAORKBJWWYJS-UHFFFAOYSA-N; EINECS 213-997-4; 2-((Phosphonomethyl)amino)acetic 
DM0AFY7	DT	Small molecular drug
DM0AFY7	PC	3496
DM0AFY7	MW	169.07
DM0AFY7	FM	C3H8NO5P
DM0AFY7	IC	InChI=1S/C3H8NO5P/c5-3(6)1-4-2-10(7,8)9/h4H,1-2H2,(H,5,6)(H2,7,8,9)
DM0AFY7	CS	C(C(=O)O)NCP(=O)(O)O
DM0AFY7	IK	XDDAORKBJWWYJS-UHFFFAOYSA-N
DM0AFY7	IU	2-(phosphonomethylamino)acetic acid
DM0AFY7	CA	CAS 1071-83-6
DM0AFY7	CB	CHEBI:27744
DM0AFY7	DE	Malaria

DMM0JA4	ID	DMM0JA4
DMM0JA4	DN	Gly-Pip-Glu
DMM0JA4	HS	Investigative
DMM0JA4	SN	Gly-Pip-Glu; SCHEMBL2084204
DMM0JA4	DT	Small molecular drug
DMM0JA4	PC	25055596
DMM0JA4	MW	315.32
DMM0JA4	FM	C13H21N3O6
DMM0JA4	IC	InChI=1S/C13H21N3O6/c14-7-10(17)16-6-2-1-3-9(16)12(20)15-8(13(21)22)4-5-11(18)19/h8-9H,1-7,14H2,(H,15,20)(H,18,19)(H,21,22)/t8-,9-/m0/s1
DMM0JA4	CS	C1CCN([C@@H](C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)CN
DMM0JA4	IK	NEMPLRJUKFPLSV-IUCAKERBSA-N
DMM0JA4	IU	(2S)-2-[[(2S)-1-(2-aminoacetyl)piperidine-2-carbonyl]amino]pentanedioic acid
DMM0JA4	DE	Discovery agent

DMMDU0K	ID	DMMDU0K
DMMDU0K	DN	GM-109
DMMDU0K	HS	Investigative
DMMDU0K	SN	GM109; GM 109
DMMDU0K	DT	Small molecular drug
DMMDU0K	PC	9850904
DMMDU0K	MW	565.7
DMMDU0K	FM	C31H43N5O5
DMMDU0K	IC	InChI=1S/C31H43N5O5/c1-31(2,3)22-17-21(12-13-26(22)37)19-25-29(40)34-16-14-27(38)33-15-8-7-11-24(30(41)36-25)35-28(39)23(32)18-20-9-5-4-6-10-20/h4-6,9-10,12-13,17,23-25,37H,7-8,11,14-16,18-19,32H2,1-3H3,(H,33,38)(H,34,40)(H,35,39)(H,36,41)/t23-,24-,25-/m0/s1
DMMDU0K	CS	CC(C)(C)C1=C(C=CC(=C1)C[C@H]2C(=O)NCCC(=O)NCCCC[C@@H](C(=O)N2)NC(=O)[C@H](CC3=CC=CC=C3)N)O
DMMDU0K	IK	RRXAKVUZGASTMY-SDHOMARFSA-N
DMMDU0K	IU	(2S)-2-amino-N-[(2S,13S)-2-[(3-tert-butyl-4-hydroxyphenyl)methyl]-3,7,14-trioxo-1,4,8-triazacyclotetradec-13-yl]-3-phenylpropanamide
DMMDU0K	DE	Discovery agent

DMM0ZKQ	ID	DMM0ZKQ
DMM0ZKQ	DN	GMQ
DMM0ZKQ	HS	Investigative
DMM0ZKQ	SN	2-guanidine-4-methylquinazoline; GNF-Pf-3515; 2-GMQ
DMM0ZKQ	DT	Small molecular drug
DMM0ZKQ	PC	345657
DMM0ZKQ	MW	201.23
DMM0ZKQ	FM	C10H11N5
DMM0ZKQ	IC	InChI=1S/C10H11N5/c1-6-7-4-2-3-5-8(7)14-10(13-6)15-9(11)12/h2-5H,1H3,(H4,11,12,13,14,15)
DMM0ZKQ	CS	CC1=NC(=NC2=CC=CC=C12)N=C(N)N
DMM0ZKQ	IK	ONQKSKDLYYDFLL-UHFFFAOYSA-N
DMM0ZKQ	IU	2-(4-methylquinazolin-2-yl)guanidine
DMM0ZKQ	CA	CAS 716-11-0
DMM0ZKQ	DE	Discovery agent

DMYWM56	ID	DMYWM56
DMYWM56	DN	GNE-7915
DMYWM56	HS	Investigative
DMYWM56	SN	GNE7915; GNE 7915
DMYWM56	DT	Small molecular drug
DMYWM56	PC	58539171
DMYWM56	MW	443.4
DMYWM56	FM	C19H21F4N5O3
DMYWM56	IC	InChI=1S/C19H21F4N5O3/c1-3-24-16-12(19(21,22)23)10-25-18(27-16)26-14-9-13(20)11(8-15(14)30-2)17(29)28-4-6-31-7-5-28/h8-10H,3-7H2,1-2H3,(H2,24,25,26,27)
DMYWM56	CS	CCNC1=NC(=NC=C1C(F)(F)F)NC2=C(C=C(C(=C2)F)C(=O)N3CCOCC3)OC
DMYWM56	IK	XCFLWTZSJYBCPF-UHFFFAOYSA-N
DMYWM56	IU	[4-[[4-(ethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-2-fluoro-5-methoxyphenyl]-morpholin-4-ylmethanone
DMYWM56	DE	Discovery agent

DMLXR90	ID	DMLXR90
DMLXR90	DN	GNE-9605
DMLXR90	HS	Investigative
DMLXR90	SN	GNE 9605; GNE9605
DMLXR90	DT	Small molecular drug
DMLXR90	PC	76328936
DMLXR90	MW	449.8
DMLXR90	FM	C17H20ClF4N7O
DMLXR90	IC	InChI=1S/C17H20ClF4N7O/c1-23-15-10(17(20,21)22)4-24-16(27-15)26-12-5-25-29(14(12)18)13-2-3-28(6-11(13)19)9-7-30-8-9/h4-5,9,11,13H,2-3,6-8H2,1H3,(H2,23,24,26,27)/t11-,13-/m0/s1
DMLXR90	CS	CNC1=NC(=NC=C1C(F)(F)F)NC2=C(N(N=C2)[C@H]3CCN(C[C@@H]3F)C4COC4)Cl
DMLXR90	IK	PUXPEQJKNAWNQA-AAEUAGOBSA-N
DMLXR90	IU	2-N-[5-chloro-1-[(3S,4S)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl]pyrazol-4-yl]-4-N-methyl-5-(trifluoromethyl)pyrimidine-2,4-diamine
DMLXR90	DE	Discovery agent

DMGLIPV	ID	DMGLIPV
DMGLIPV	DN	GNF-5
DMGLIPV	HS	Investigative
DMGLIPV	SN	GNF5; GNF 5
DMGLIPV	DT	Small molecular drug
DMGLIPV	PC	44129660
DMGLIPV	MW	418.4
DMGLIPV	FM	C20H17F3N4O3
DMGLIPV	IC	InChI=1S/C20H17F3N4O3/c21-20(22,23)30-16-6-4-15(5-7-16)27-18-11-17(25-12-26-18)13-2-1-3-14(10-13)19(29)24-8-9-28/h1-7,10-12,28H,8-9H2,(H,24,29)(H,25,26,27)
DMGLIPV	CS	C1=CC(=CC(=C1)C(=O)NCCO)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F
DMGLIPV	IK	IIQUYGWWHIHOCF-UHFFFAOYSA-N
DMGLIPV	IU	N-(2-hydroxyethyl)-3-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]benzamide
DMGLIPV	CA	CAS 778277-15-9
DMGLIPV	DE	Discovery agent

DMYJO13	ID	DMYJO13
DMYJO13	DN	GNF-5837
DMYJO13	HS	Investigative
DMYJO13	SN	GNF 5837; GNF5837
DMYJO13	DT	Small molecular drug
DMYJO13	PC	59397065
DMYJO13	MW	535.5
DMYJO13	FM	C28H21F4N5O2
DMYJO13	IC	InChI=1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14,33-34H,1H3,(H,36,38)(H2,35,37,39)/b21-12-
DMYJO13	CS	CC1=C(C=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)F)NC3=CC4=C(C=C3)/C(=C/C5=CC=CN5)/C(=O)N4
DMYJO13	IK	YYDUWLSETXNJJT-MTJSOVHGSA-N
DMYJO13	IU	1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-[4-methyl-3-[[(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-6-yl]amino]phenyl]urea
DMYJO13	DE	Discovery agent

DM3INUK	ID	DM3INUK
DM3INUK	DN	GNF-PF-117
DM3INUK	HS	Investigative
DM3INUK	SN	4-Hydroxy-6-methoxy-2-phenylquinoline; 17282-70-1; GNF-PF-117; 6-methoxy-2-phenylquinolin-4-ol; 6-Methoxy-2-phenyl-4-quinolinol; 6-Methoxy-2-phenyl-1H-quinolin-4-one; CHEMBL14120; 6-Methoxy-2-phenyl-quinolin-4-ol; Maybridge3_005419; AC1L3YAP; Oprea1_238017; SCHEMBL6534282; SCHEMBL10610678; CTK8F6034; CTK7A7980; MolPort-000-677-170; KUC100231N; HMS1446G07; ZINC8649323; 2-Phenyl-4-oxy-6-methoxy-chinolin; KUC100231; BDBM50041130; SBB016283; AKOS009868047; AKOS000273771; MCULE-6727803755; AB10684; CCG-252411; IDI1_016806
DM3INUK	DT	Small molecular drug
DM3INUK	PC	124348
DM3INUK	MW	251.28
DM3INUK	FM	C16H13NO2
DM3INUK	IC	InChI=1S/C16H13NO2/c1-19-12-7-8-14-13(9-12)16(18)10-15(17-14)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
DM3INUK	CS	COC1=CC2=C(C=C1)NC(=CC2=O)C3=CC=CC=C3
DM3INUK	IK	CKFBIYVXNYYXAI-UHFFFAOYSA-N
DM3INUK	IU	6-methoxy-2-phenyl-1H-quinolin-4-one
DM3INUK	CA	CAS 57183-50-3
DM3INUK	DE	Discovery agent

DM183RV	ID	DM183RV
DM183RV	DN	GNF-PF-1399
DM183RV	HS	Investigative
DM183RV	SN	GNF-PF-2708; GNF-PF-4643
DM183RV	DT	Small molecular drug
DM183RV	PC	107464
DM183RV	MW	380.27
DM183RV	FM	C17H21IN2
DM183RV	IC	InChI=1S/C17H21N2.HI/c1-4-19-14-6-5-7-17(19)13-10-15-8-11-16(12-9-15)18(2)3;/h5-14H,4H2,1-3H3;1H/q+1;/p-1
DM183RV	CS	CC[N+]1=CC=CC=C1C=CC2=CC=C(C=C2)N(C)C.[I-]
DM183RV	IK	AMAXNNVXIBDEMV-UHFFFAOYSA-M
DM183RV	IU	4-[2-(1-ethylpyridin-1-ium-2-yl)ethenyl]-N,N-dimethylaniline;iodide
DM183RV	CA	CAS 3785-01-1
DM183RV	CB	CHEBI:38007
DM183RV	DE	Discovery agent

DMVUBGF	ID	DMVUBGF
DMVUBGF	DN	GNF-PF-1550
DMVUBGF	HS	Investigative
DMVUBGF	SN	GNF-PF-1550; CHEMBL196573; MolPort-007-587-167; HMS1621O13; ZINC13671923; BDBM50172447; AKOS001782657; SR-01000549061; SR-01000549061-1; (2E)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]-3-(4-methoxyphenyl)acrylamide
DMVUBGF	DT	Small molecular drug
DMVUBGF	PC	44403742
DMVUBGF	MW	430.5
DMVUBGF	FM	C26H30N4O2
DMVUBGF	IC	InChI=1S/C26H30N4O2/c1-4-29-13-15-30(16-14-29)25-17-19(2)23-18-21(8-11-24(23)28-25)27-26(31)12-7-20-5-9-22(32-3)10-6-20/h5-12,17-18H,4,13-16H2,1-3H3,(H,27,31)/b12-7+
DMVUBGF	CS	CCN1CCN(CC1)C2=NC3=C(C=C(C=C3)NC(=O)/C=C/C4=CC=C(C=C4)OC)C(=C2)C
DMVUBGF	IK	BYSCWUNLAIWJED-KPKJPENVSA-N
DMVUBGF	IU	(E)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]-3-(4-methoxyphenyl)prop-2-enamide
DMVUBGF	DE	Discovery agent

DMHCGBZ	ID	DMHCGBZ
DMHCGBZ	DN	GNF-PF-1591
DMHCGBZ	HS	Investigative
DMHCGBZ	SN	GNF-Pf-1591; MLS000554446; SMR000171400; AC1LKBEY; ChemDiv2_001930; CBMicro_025972; MAIM-1; CHEMBL588954; HDOKKAMQZREOLG-XQNSMLJCSA-N; 4-methyl-N-[4-oxo-3-(1H-1,2,4-triazol-5-ylsulfanyl)naphthalen-1-ylidene]benzenesulfonamide; HMS2542H12; ZINC18213201; ZINC100480724; MCULE-5187110916; J3.505.787K; SR-01000708580; SR-01000708580-2
DMHCGBZ	DT	Small molecular drug
DMHCGBZ	PC	1015540
DMHCGBZ	MW	410.5
DMHCGBZ	FM	C19H14N4O3S2
DMHCGBZ	IC	InChI=1S/C19H14N4O3S2/c1-12-6-8-13(9-7-12)28(25,26)23-16-10-17(27-19-20-11-21-22-19)18(24)15-5-3-2-4-14(15)16/h2-11H,1H3,(H,20,21,22)
DMHCGBZ	CS	CC1=CC=C(C=C1)S(=O)(=O)N=C2C=C(C(=O)C3=CC=CC=C32)SC4=NC=NN4
DMHCGBZ	IK	HDOKKAMQZREOLG-UHFFFAOYSA-N
DMHCGBZ	IU	4-methyl-N-[4-oxo-3-(1H-1,2,4-triazol-5-ylsulfanyl)naphthalen-1-ylidene]benzenesulfonamide
DMHCGBZ	CA	CAS 315698-91-0
DMHCGBZ	DE	Discovery agent

DM4JZ9A	ID	DM4JZ9A
DM4JZ9A	DN	GNF-PF-1694
DM4JZ9A	HS	Investigative
DM4JZ9A	SN	GNF-PF-1694; CHEMBL513104; Oprea1_332906; Oprea1_089499; BDBM50274012
DM4JZ9A	DT	Small molecular drug
DM4JZ9A	PC	23968266
DM4JZ9A	MW	313.4
DM4JZ9A	FM	C19H23NO3
DM4JZ9A	IC	InChI=1S/C19H23NO3/c1-19(2,3)20-11-13(21)12-22-16-9-6-10-17-18(16)14-7-4-5-8-15(14)23-17/h4-10,13,20-21H,11-12H2,1-3H3
DM4JZ9A	CS	CC(C)(C)NCC(COC1=CC=CC2=C1C3=CC=CC=C3O2)O
DM4JZ9A	IK	HGDYQUMVUUMEFM-UHFFFAOYSA-N
DM4JZ9A	IU	1-(tert-butylamino)-3-dibenzofuran-1-yloxypropan-2-ol
DM4JZ9A	DE	Discovery agent

DMUSAYG	ID	DMUSAYG
DMUSAYG	DN	GNF-PF-173
DMUSAYG	HS	Investigative
DMUSAYG	SN	10-Deazaaminopterin; 10-Deazaminopterin; 10-Deaza-aminopterin; GNF-PF-173; UNII-PXJ16PPE04; NSC 311469; PXJ16PPE04; CHEMBL293263; L-Glutamic acid, N-(4-(2-(2,4-diamino-6-pteridinyl)ethyl)benzoyl)-; L-Glutamic acid, N-[4-[2-(2,4-diamino-6-pteridinyl)ethyl]benzoyl]-; 52454-37-2; AC1L2OWJ; AC1Q5QQQ; 10-DAM; SCHEMBL7081697; BDBM50016461; LS-187417; LS-186724; (2S)-2-[[4-[2-(2,4-diaminopteridin-6-yl)ethyl]benzoyl]amino]pentanedioic acid; (S)-2-{4-[2-(2,4-Diamino-pteridin-6-yl)-ethyl]-benzoylamino}-pentanedioic acid
DMUSAYG	DT	Small molecular drug
DMUSAYG	PC	100516
DMUSAYG	MW	439.4
DMUSAYG	FM	C20H21N7O5
DMUSAYG	IC	InChI=1S/C20H21N7O5/c21-16-15-17(27-20(22)26-16)23-9-12(24-15)6-3-10-1-4-11(5-2-10)18(30)25-13(19(31)32)7-8-14(28)29/h1-2,4-5,9,13H,3,6-8H2,(H,25,30)(H,28,29)(H,31,32)(H4,21,22,23,26,27)/t13-/m0/s1
DMUSAYG	CS	C1=CC(=CC=C1CCC2=CN=C3C(=N2)C(=NC(=N3)N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMUSAYG	IK	LGFLRHWJJKLPCC-ZDUSSCGKSA-N
DMUSAYG	IU	(2S)-2-[[4-[2-(2,4-diaminopteridin-6-yl)ethyl]benzoyl]amino]pentanedioic acid
DMUSAYG	CA	CAS 52454-37-2
DMUSAYG	DE	Discovery agent

DMGSRLA	ID	DMGSRLA
DMGSRLA	DN	GNF-PF-1967
DMGSRLA	HS	Investigative
DMGSRLA	SN	GNF-PF-1967; AC1NEHJX; CHEMBL374744; MolPort-007-587-747; AKOS021661170; AKOS001495347; MCULE-7181472168; SR-01000549442; SR-01000549442-1; N-[2-(diethylamino)ethyl]-2-(4-fluorobenzyl)-3-(4-methoxyphenyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide
DMGSRLA	DT	Small molecular drug
DMGSRLA	PC	4617502
DMGSRLA	MW	503.6
DMGSRLA	FM	C30H34FN3O3
DMGSRLA	IC	InChI=1S/C30H34FN3O3/c1-4-33(5-2)19-18-32-29(35)27-25-8-6-7-9-26(25)30(36)34(20-21-10-14-23(31)15-11-21)28(27)22-12-16-24(37-3)17-13-22/h6-17,27-28H,4-5,18-20H2,1-3H3,(H,32,35)
DMGSRLA	CS	CCN(CC)CCNC(=O)C1C(N(C(=O)C2=CC=CC=C12)CC3=CC=C(C=C3)F)C4=CC=C(C=C4)OC
DMGSRLA	IK	ACZABABCHZPYHY-UHFFFAOYSA-N
DMGSRLA	IU	N-[2-(diethylamino)ethyl]-2-[(4-fluorophenyl)methyl]-3-(4-methoxyphenyl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
DMGSRLA	DE	Discovery agent

DM9J35R	ID	DM9J35R
DM9J35R	DN	GNF-PF-2094
DM9J35R	HS	Investigative
DM9J35R	SN	GNF-Pf-2094; CHEMBL578928; AC1LF3VX; ChemDiv3_003176; MLS000555549; REGID_for_CID_697226; ZINC73452; MolPort-002-569-783; HMS2595H06; HMS3382F08; HMS1482A08; DNDI1388215; CCG-20329; BDBM50304834; STK839621; AKOS005624964; MCULE-1058130285; IDI1_021086; SMR000147266; SR-01000110418; SR-01000110418-1; BRD-K84805375-001-01-1; N2-benzyl-N4-cyclohexyl-6-methylpyrimidine-2,4-diamine; 2-N-benzyl-4-N-cyclohexyl-6-methylpyrimidine-2,4-diamine; N*2*-Benzyl-N*4*-cyclohexyl-6-methyl-pyrimidine-2,4-diamine
DM9J35R	DT	Small molecular drug
DM9J35R	PC	697226
DM9J35R	MW	296.4
DM9J35R	FM	C18H24N4
DM9J35R	IC	InChI=1S/C18H24N4/c1-14-12-17(21-16-10-6-3-7-11-16)22-18(20-14)19-13-15-8-4-2-5-9-15/h2,4-5,8-9,12,16H,3,6-7,10-11,13H2,1H3,(H2,19,20,21,22)
DM9J35R	CS	CC1=CC(=NC(=N1)NCC2=CC=CC=C2)NC3CCCCC3
DM9J35R	IK	GDKCAAWSNQLXNX-UHFFFAOYSA-N
DM9J35R	IU	2-N-benzyl-4-N-cyclohexyl-6-methylpyrimidine-2,4-diamine
DM9J35R	DE	Discovery agent

DM26UKN	ID	DM26UKN
DM26UKN	DN	GNF-PF-2224
DM26UKN	HS	Investigative
DM26UKN	SN	8-Cyclopentyl-1,3-dipropylxanthine; DPCPX; 102146-07-6; 8-cyclopentyl-1,3-dipropyl-1H-purine-2,6(3H,7H)-dione; 1,3-Dpcpx; 1,3-dipropyl-8-cyclopentylxanthine; PD-116,948; PD-116948; UNII-9PTP4FOI9E; dipropylcyclopentylxanthine; 9PTP4FOI9E; CHEMBL183; MLS000069347; CHEBI:73282; 8-Cyclopentyl-3,7-dihydro-1,3-dipropyl-1H-purin-2,6-dione; 8-cyclopentyl-1,3-dipropyl-7H-purine-2,6-dione; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE [DPCPX]; SMR000058434; DPCPX, 1,3-Dipropyl-8-cyclopentylxanthine
DM26UKN	DT	Small molecular drug
DM26UKN	PC	1329
DM26UKN	MW	304.39
DM26UKN	FM	C16H24N4O2
DM26UKN	IC	InChI=1S/C16H24N4O2/c1-3-9-19-14-12(15(21)20(10-4-2)16(19)22)17-13(18-14)11-7-5-6-8-11/h11H,3-10H2,1-2H3,(H,17,18)
DM26UKN	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3CCCC3
DM26UKN	IK	FFBDFADSZUINTG-UHFFFAOYSA-N
DM26UKN	IU	8-cyclopentyl-1,3-dipropyl-7H-purine-2,6-dione
DM26UKN	CA	CAS 102146-07-6
DM26UKN	CB	CHEBI:73282
DM26UKN	DE	Discovery agent

DMONK0F	ID	DMONK0F
DMONK0F	DN	GNF-PF-2272
DMONK0F	HS	Investigative
DMONK0F	SN	3-Methyltoxoflavin; GNF-Pf-2272; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117
DMONK0F	DT	Small molecular drug
DMONK0F	PC	460747
DMONK0F	MW	207.19
DMONK0F	FM	C8H9N5O2
DMONK0F	IC	InChI=1S/C8H9N5O2/c1-4-9-5-6(13(3)11-4)10-8(15)12(2)7(5)14/h1-3H3
DMONK0F	CS	CC1=NN(C2=NC(=O)N(C(=O)C2=N1)C)C
DMONK0F	IK	CPXHNWKHOFNPDO-UHFFFAOYSA-N
DMONK0F	IU	1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione
DMONK0F	CB	CHEBI:95315
DMONK0F	DE	Discovery agent

DMP6DBX	ID	DMP6DBX
DMP6DBX	DN	GNF-PF-2307
DMP6DBX	HS	Investigative
DMP6DBX	SN	3-Phenyl-5H-indeno[1,2-c]pyridazin-5-one; GNF-PF-2307; NSC663883; 77152-22-8; CHEMBL421088; 3-phenylindeno[1,2-c]pyridazin-5-one; 5H-Indeno[1,2-c]pyridazin-5-one, 3-phenyl-; AC1Q6KMU; AC1L8E6X; Oprea1_571099; MLS000539984; cid_379337; Aza-heterocyclic Derivative, 1b; KS-00001QSP; CTK2G0333; BDBM19164; DTXSID40327521; MolPort-002-851-051; HMS2177H12; ZINC1383534; STK336084; AKOS005075114; NSC-663883; MCULE-8078785196; SMR000125442; NCI60_021916; 3-(Phenyl)-5H-indeno[1,2-c]pyridazin-5-one; SR-01000694335; 10K-057
DMP6DBX	DT	Small molecular drug
DMP6DBX	PC	379337
DMP6DBX	MW	258.269
DMP6DBX	FM	C17H10N2O
DMP6DBX	IC	InChI=1S/C17H10N2O/c20-17-13-9-5-4-8-12(13)16-14(17)10-15(18-19-16)11-6-2-1-3-7-11/h1-10H
DMP6DBX	CS	C1=CC=C(C=C1)C2=NN=C3C4=CC=CC=C4C(=O)C3=C2
DMP6DBX	IK	ORLUBUYLVCUFDE-UHFFFAOYSA-N
DMP6DBX	IU	3-phenylindeno[1,2-c]pyridazin-5-one
DMP6DBX	CA	CAS 77152-22-8
DMP6DBX	DE	Discovery agent

DMW93IO	ID	DMW93IO
DMW93IO	DN	GNF-PF-2322
DMW93IO	HS	Investigative
DMW93IO	SN	GNF-PF-2322; CHEMBL194986; SR-01000548998
DMW93IO	DT	Small molecular drug
DMW93IO	PC	44403736
DMW93IO	MW	442.5
DMW93IO	FM	C26H26N4O3
DMW93IO	IC	InChI=1S/C26H26N4O3/c1-3-29-10-12-30(13-11-29)25-14-17(2)20-15-18(8-9-21(20)28-25)27-26(32)24-16-22(31)19-6-4-5-7-23(19)33-24/h4-9,14-16H,3,10-13H2,1-2H3,(H,27,32)
DMW93IO	CS	CCN1CCN(CC1)C2=NC3=C(C=C(C=C3)NC(=O)C4=CC(=O)C5=CC=CC=C5O4)C(=C2)C
DMW93IO	IK	GDOKGIIKPLGRMR-UHFFFAOYSA-N
DMW93IO	IU	N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]-4-oxochromene-2-carboxamide
DMW93IO	DE	Discovery agent

DMC56YJ	ID	DMC56YJ
DMC56YJ	DN	GNF-PF-2700
DMC56YJ	HS	Investigative
DMC56YJ	SN	5361-37-5; GNF-Pf-2700; N-(8-ethoxy-4-methylquinazolin-2-yl)guanidine; 1-(8-ethoxy-4-methylquinazolin-2-yl)guanidine; CHEMBL602578; N-(8-Ethoxy-4-methyl-quinazolin-2-yl)-guanidine; Guanidine, N-(8-ethoxy-4-methyl-2-quinazolinyl)-; amino(8-ethoxy-4-methylquinazolin-2-yl)carboxamidine; BAS 00364218; 2-(8-ethoxy-4-methylquinazolin-2-yl)guanidine; AC1MDO65; SCHEMBL4104976; MolPort-000-870-551; ZX-AN037437; ALBB-021848; BDBM50322849; STK091313; SBB041931; ZINC19314134; AKOS000270455; MCULE-2552194685; ST4052426; R3533
DMC56YJ	DT	Small molecular drug
DMC56YJ	PC	2840092
DMC56YJ	MW	245.28
DMC56YJ	FM	C12H15N5O
DMC56YJ	IC	InChI=1S/C12H15N5O/c1-3-18-9-6-4-5-8-7(2)15-12(16-10(8)9)17-11(13)14/h4-6H,3H2,1-2H3,(H4,13,14,15,16,17)
DMC56YJ	CS	CCOC1=CC=CC2=C(N=C(N=C21)N=C(N)N)C
DMC56YJ	IK	NNFBJZLFJMBVGQ-UHFFFAOYSA-N
DMC56YJ	IU	2-(8-ethoxy-4-methylquinazolin-2-yl)guanidine
DMC56YJ	DE	Discovery agent

DMD1QOH	ID	DMD1QOH
DMD1QOH	DN	GNF-PF-2812
DMD1QOH	HS	Investigative
DMD1QOH	SN	3-(4-Methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one; GNF-PF-2812; NSC663884; CHEMBL125044; 147508-58-5; 3-(4-methoxyphenyl)indeno[1,2-c]pyridazin-5-one; 5H-indeno[1,2-c]pyridazin-5-one, 3-(4-methoxyphenyl)-; AC1Q6KMT; AC1L8E6Y; Oprea1_523550; CBDivE_007579; MLS000691948; cid_379338; CTK7A3357; BDBM21618; KS-00001QSJ; MolPort-002-851-046; HMS2631I03; ZINC196663; STK336082; MMV666026; Indeno[1,2-c]pyridazin-5-one, 6; AKOS005075095; MCULE-6151549558; NSC-663884; SMR000333991; NCI60_021917
DMD1QOH	DT	Small molecular drug
DMD1QOH	PC	379338
DMD1QOH	MW	288.3
DMD1QOH	FM	C18H12N2O2
DMD1QOH	IC	InChI=1S/C18H12N2O2/c1-22-12-8-6-11(7-9-12)16-10-15-17(20-19-16)13-4-2-3-5-14(13)18(15)21/h2-10H,1H3
DMD1QOH	CS	COC1=CC=C(C=C1)C2=NN=C3C4=CC=CC=C4C(=O)C3=C2
DMD1QOH	IK	HXQRIHGYIOARQJ-UHFFFAOYSA-N
DMD1QOH	IU	3-(4-methoxyphenyl)indeno[1,2-c]pyridazin-5-one
DMD1QOH	DE	Discovery agent

DML5QFZ	ID	DML5QFZ
DML5QFZ	DN	GNF-PF-2857
DML5QFZ	HS	Investigative
DML5QFZ	SN	GNF-PF-2857; CHEMBL217665; ChemDiv1_019259; N-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4-amine; N-[4-(4-methylpiperazin-1-yl)phenyl]quinolin-4-amine; AC1NCZHO; Oprea1_484208; SCHEMBL7129284; HMS641L09; ZINC1507915; BDBM50196110; AKOS024359777; MCULE-1778420008; ST50989409; [4-(4-methylpiperazinyl)phenyl]-4-quinolylamine; SR-01000394477; SR-01000394477-1
DML5QFZ	DT	Small molecular drug
DML5QFZ	PC	4567175
DML5QFZ	MW	318.4
DML5QFZ	FM	C20H22N4
DML5QFZ	IC	InChI=1S/C20H22N4/c1-23-12-14-24(15-13-23)17-8-6-16(7-9-17)22-20-10-11-21-19-5-3-2-4-18(19)20/h2-11H,12-15H2,1H3,(H,21,22)
DML5QFZ	CS	CN1CCN(CC1)C2=CC=C(C=C2)NC3=CC=NC4=CC=CC=C43
DML5QFZ	IK	RXXDJBWYJTWSKV-UHFFFAOYSA-N
DML5QFZ	IU	N-[4-(4-methylpiperazin-1-yl)phenyl]quinolin-4-amine
DML5QFZ	DE	Discovery agent

DMLP241	ID	DMLP241
DMLP241	DN	GNF-PF-2893
DMLP241	HS	Investigative
DMLP241	SN	GNF-PF-2893; MLS001098045; SMR000657694; ({[4-(dimethylamino)anilino]carbonyl}amino)(4-methylphenyl)dioxo-lambda~6~-sulfane; AC1MDRKI; CHEMBL312032; cid_2815701; BDBM71503; MolPort-002-902-750; ZINC158170; HMS2998H18; CCG-43375; AKOS024379092; MCULE-5924445847; 1-[4-(dimethylamino)phenyl]-3-tosyl-urea; ST51023936; SR-01000633302-1; 1-[4-Dimethylaminophenyl]-3-(4-methylphenylsulfonyl)urea; 1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea; 1-(4-dimethylaminophenyl)-3-(4-methylphenyl)sulfonylurea
DMLP241	DT	Small molecular drug
DMLP241	PC	2815701
DMLP241	MW	333.4
DMLP241	FM	C16H19N3O3S
DMLP241	IC	InChI=1S/C16H19N3O3S/c1-12-4-10-15(11-5-12)23(21,22)18-16(20)17-13-6-8-14(9-7-13)19(2)3/h4-11H,1-3H3,(H2,17,18,20)
DMLP241	CS	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2=CC=C(C=C2)N(C)C
DMLP241	IK	GRIAZRCYPXFJJF-UHFFFAOYSA-N
DMLP241	IU	1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea
DMLP241	DE	Discovery agent

DM4RZSB	ID	DM4RZSB
DM4RZSB	DN	GNF-PF-3037
DM4RZSB	HS	Investigative
DM4RZSB	SN	GNF-Pf-3037; SMR000116549; MLS000526075; Oprea1_099756; Oprea1_432483; Oprea1_261700; CHEMBL600336; cid_1160447; BDBM40315; MolPort-001-513-008; MolPort-001-991-899; C23H16N4O2S2; HMS2507A20; ZINC8671257; STK223484; AKOS003264843; AKOS000636670; MCULE-7239362503; BAS 03422558; MLS-0072644.0001; N-[4-[6-(2-thenoylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide; N-(4-{5-[(thiophen-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)thiophene-2-carboxamide
DM4RZSB	DT	Small molecular drug
DM4RZSB	PC	1160447
DM4RZSB	MW	444.5
DM4RZSB	FM	C23H16N4O2S2
DM4RZSB	IC	InChI=1S/C23H16N4O2S2/c28-22(19-3-1-11-30-19)24-15-7-5-14(6-8-15)21-26-17-10-9-16(13-18(17)27-21)25-23(29)20-4-2-12-31-20/h1-13H,(H,24,28)(H,25,29)(H,26,27)
DM4RZSB	CS	C1=CSC(=C1)C(=O)NC2=CC=C(C=C2)C3=NC4=C(N3)C=C(C=C4)NC(=O)C5=CC=CS5
DM4RZSB	IK	ALZVAGBHXQHAIA-UHFFFAOYSA-N
DM4RZSB	IU	N-[4-[6-(thiophene-2-carbonylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide
DM4RZSB	DE	Discovery agent

DMWAKHD	ID	DMWAKHD
DMWAKHD	DN	GNF-PF-3464
DMWAKHD	HS	Investigative
DMWAKHD	SN	GNF-Pf-3464; MLS000080647; SMR000035446; 3-(4-bromophenyl)-8-(5-methylfuran-2-yl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile; AC1LDF42; MLS002584786; cid_666034; CHEMBL602213; BDBM54721; MolPort-002-638-170; HMS2390G20; CCG-29223; STK849599; AKOS001814539; AKOS022041133; MCULE-2552432292; SR-01000096914; SR-01000096914-1; 3-(4-bromophenyl)-8-(5-methylfuran-2-yl)-6-oxo-3,4,7,8-tetrahydro-2H,6H-pyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile
DMWAKHD	DT	Small molecular drug
DMWAKHD	PC	666034
DMWAKHD	MW	430.3
DMWAKHD	FM	C19H16BrN3O2S
DMWAKHD	IC	InChI=1S/C19H16BrN3O2S/c1-12-2-7-17(25-12)15-8-18(24)23-10-22(11-26-19(23)16(15)9-21)14-5-3-13(20)4-6-14/h2-7,15H,8,10-11H2,1H3
DMWAKHD	CS	CC1=CC=C(O1)C2CC(=O)N3CN(CSC3=C2C#N)C4=CC=C(C=C4)Br
DMWAKHD	IK	DCNZODDMKOTPHQ-UHFFFAOYSA-N
DMWAKHD	IU	3-(4-bromophenyl)-8-(5-methylfuran-2-yl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile
DMWAKHD	DE	Discovery agent

DM17GIV	ID	DM17GIV
DM17GIV	DN	GNF-PF-3645
DM17GIV	HS	Investigative
DM17GIV	SN	GNF-PF-3645; ethyl 6-isopropyl-4-oxo-1,4-dihydroquinoline-3-carboxylate; ethyl 4-hydroxy-6-isopropyl-3-quinolinecarboxylate; AC1LEPYU; Oprea1_718373; CHEMBL202969; SCHEMBL11065820; MolPort-002-693-403; ZINC9761170; STK040682; AKOS005383459; MCULE-2719488867; ST085537; 64321-61-5; EU-0017663; CS-0061597; ethyl 4-hydroxy-6-isopropylquinoline-3-carboxylate; SR-01000511952; AG-670/08515048; SR-01000511952-1; ethyl 4-hydroxy-6-(propan-2-yl)quinoline-3-carboxylate; ethyl 4-oxo-6-propan-2-yl-1H-quinoline-3-carboxylate; ethyl 4-hydroxy-
DM17GIV	DT	Small molecular drug
DM17GIV	PC	690399
DM17GIV	MW	259.3
DM17GIV	FM	C15H17NO3
DM17GIV	IC	InChI=1S/C15H17NO3/c1-4-19-15(18)12-8-16-13-6-5-10(9(2)3)7-11(13)14(12)17/h5-9H,4H2,1-3H3,(H,16,17)
DM17GIV	CS	CCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)C(C)C
DM17GIV	IK	JBFFEVKDAYLOKF-UHFFFAOYSA-N
DM17GIV	IU	ethyl 4-oxo-6-propan-2-yl-1H-quinoline-3-carboxylate
DM17GIV	DE	Discovery agent

DMIY79U	ID	DMIY79U
DMIY79U	DN	GNF-PF-3832
DMIY79U	HS	Investigative
DMIY79U	SN	3-(4-methylphenyl)-5H-indeno[1,2-c]pyridazin-5-one; GNF-PF-3832; 300843-87-2; AC1MCE1I; Cambridge id 5215436; Oprea1_419211; CBDivE_007454; MLS000104226; CHEMBL261693; cid_2767330; KS-00001RTF; BDBM21629; MolPort-002-136-671; HMS1578F11; HMS2748H23; ZINC196662; STK746982; MMV666021; AKOS001704735; MCULE-6620780852; SMR000051275; SR-01000507948; 3-(4-methylphenyl)indeno[1,2-c]pyridazin-5-one; 11K-012; SR-01000507948-1
DMIY79U	DT	Small molecular drug
DMIY79U	PC	2767330
DMIY79U	MW	272.3
DMIY79U	FM	C18H12N2O
DMIY79U	IC	InChI=1S/C18H12N2O/c1-11-6-8-12(9-7-11)16-10-15-17(20-19-16)13-4-2-3-5-14(13)18(15)21/h2-10H,1H3
DMIY79U	CS	CC1=CC=C(C=C1)C2=NN=C3C4=CC=CC=C4C(=O)C3=C2
DMIY79U	IK	ITHVHASAWMAMQC-UHFFFAOYSA-N
DMIY79U	IU	3-(4-methylphenyl)indeno[1,2-c]pyridazin-5-one
DMIY79U	CA	CAS 300843-87-2
DMIY79U	DE	Discovery agent

DM7BXHQ	ID	DM7BXHQ
DM7BXHQ	DN	GNF-PF-3878
DM7BXHQ	HS	Investigative
DM7BXHQ	SN	143069-08-3; GNF-PF-3878; TCMDC-124255; 9-Acridinamine, N-(4-(4-ethyl-1-piperazinyl)phenyl)-; CHEMBL217366; N-(4-(4-Ethyl-1-piperazinyl)phenyl)-9-acridinamine; N-[4-(4-ethylpiperazin-1-yl)phenyl]acridin-9-amine; 9-Acridinamine,N-[4-(4-ethyl-1-piperazinyl)phenyl]-; N-(4-(4-ethylpiperazin-1-yl)phenyl)acridin-9-amine; CBDivE_005028; AC1MILKO; ACMC-20n23a; CTK4C3465; DTXSID10162300; BDBM50196122; AKOS030561802
DM7BXHQ	DT	Small molecular drug
DM7BXHQ	PC	3072540
DM7BXHQ	MW	382.5
DM7BXHQ	FM	C25H26N4
DM7BXHQ	IC	InChI=1S/C25H26N4/c1-2-28-15-17-29(18-16-28)20-13-11-19(12-14-20)26-25-21-7-3-5-9-23(21)27-24-10-6-4-8-22(24)25/h3-14H,2,15-18H2,1H3,(H,26,27)
DM7BXHQ	CS	CCN1CCN(CC1)C2=CC=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53
DM7BXHQ	IK	CUVBGWMAORETGV-UHFFFAOYSA-N
DM7BXHQ	IU	N-[4-(4-ethylpiperazin-1-yl)phenyl]acridin-9-amine
DM7BXHQ	CA	CAS 143069-08-3
DM7BXHQ	DE	Discovery agent

DMOJL61	ID	DMOJL61
DMOJL61	DN	GNF-PF-3955
DMOJL61	HS	Investigative
DMOJL61	SN	GNF-Pf-3955; MLS000073091; SMR000013108; 500276-85-7; 2-Imino-8-methyl-10-oxo-1-phenethyl-1,10-dihydro-2H-1,9,10a-triaza-anthracene-3-carboxylic acid (furan-2-ylmethyl)-amide; BAS 04995279; regid844814; AC1LDF87; MLS001385288; CHEMBL605747; cid_647145; BDBM49996; MolPort-000-197-560; HMS2774A18; STK703431; ZINC100662448; AKOS001655389; MCULE-3107531902; EU-0080883; Z57780857; N-(furan-2-ylmethyl)-2-imino-10-methyl-5-oxo-1-(2-phenylethyl)dipyrido[3,4-c:1'',2''-f]pyrimidine-3-carboxamide
DMOJL61	DT	Small molecular drug
DMOJL61	PC	647145
DMOJL61	MW	453.5
DMOJL61	FM	C26H23N5O3
DMOJL61	IC	InChI=1S/C26H23N5O3/c1-17-7-5-12-31-23(17)29-24-21(26(31)33)15-20(25(32)28-16-19-10-6-14-34-19)22(27)30(24)13-11-18-8-3-2-4-9-18/h2-10,12,14-15,27H,11,13,16H2,1H3,(H,28,32)
DMOJL61	CS	CC1=CC=CN2C1=NC3=C(C2=O)C=C(C(=N)N3CCC4=CC=CC=C4)C(=O)NCC5=CC=CO5
DMOJL61	IK	AINLDDVHMMTZDO-UHFFFAOYSA-N
DMOJL61	IU	N-(furan-2-ylmethyl)-6-imino-11-methyl-2-oxo-7-(2-phenylethyl)-1,7,9-triazatricyclo[8.4.0.03,8]tetradeca-3(8),4,9,11,13-pentaene-5-carboxamide
DMOJL61	DE	Discovery agent

DMXWYMH	ID	DMXWYMH
DMXWYMH	DN	GNF-PF-4292
DMXWYMH	HS	Investigative
DMXWYMH	SN	Hydrocinchonine; GNF-PF-4292; CHEMBL428695; Cinchotine; (8alpha,9R)-10,11-Dihydrocinchonan-9-ol; 485-64-3; Cinchonifine; Pseudocinchonine; y-Cinchonine; 10,11-dihydrocinchonan-9-ol; (9S)-10,11-Dihydrocinchonan-9-ol; 10,11-dihydrocinchonine; AC1Q4XW7; AC1L2RE5; Oprea1_425428; SCHEMBL312806; MolPort-003-871-861; WFJNHVWTKZUUTR-UHFFFAOYSA-N; BDBM50047001; NCGC00142479-01; AC-30196; ST056343; FT-0700733; (9S)-10,11-Dihydrocinchonan-9-ol, 9CI; (1R)(5-ethylquinuclidin-2-yl)-4-quinolylmethan-1-ol; Quinoline 4-(alpha-(7-ethyl-1,4-ethanopip
DMXWYMH	DT	Small molecular drug
DMXWYMH	PC	101711
DMXWYMH	MW	296.4
DMXWYMH	FM	C19H24N2O
DMXWYMH	IC	InChI=1S/C19H24N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h3-7,9,13-14,18-19,22H,2,8,10-12H2,1H3
DMXWYMH	CS	CCC1CN2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O
DMXWYMH	IK	WFJNHVWTKZUUTR-UHFFFAOYSA-N
DMXWYMH	IU	(5-ethyl-1-azabicyclo[2.2.2]octan-2-yl)-quinolin-4-ylmethanol
DMXWYMH	CA	CAS 485-64-3
DMXWYMH	DE	Discovery agent

DMV10UH	ID	DMV10UH
DMV10UH	DN	GNF-PF-4421
DMV10UH	HS	Investigative
DMV10UH	SN	GNF-PF-4421; 85418-73-1; 6-Ethyl-4-hydroxyquinoline-3-carboxylic acid ethyl ester; AURORA 17945; ethyl 6-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylate; ethyl 6-ethyl-4-hydroxyquinoline-3-carboxylate; AC1LECY7; Oprea1_563397; Oprea1_408052; CHEMBL206540; SCHEMBL7291769; SCHEMBL11066821; CTK8F7131; DTXSID00350618; ZFOFJXFVCJQXBL-UHFFFAOYSA-N; MolPort-003-761-637; MolPort-000-653-080; ZINC9761169; STK791819; MMV007116; STK942448; 3-Quinolinecarboxylic acid, 6-ethyl-1,4-dihydro-4-oxo-, ethyl ester; AKOS002674049; AKOS001717599
DMV10UH	DT	Small molecular drug
DMV10UH	PC	684193
DMV10UH	MW	245.27
DMV10UH	FM	C14H15NO3
DMV10UH	IC	InChI=1S/C14H15NO3/c1-3-9-5-6-12-10(7-9)13(16)11(8-15-12)14(17)18-4-2/h5-8H,3-4H2,1-2H3,(H,15,16)
DMV10UH	CS	CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCC
DMV10UH	IK	ZFOFJXFVCJQXBL-UHFFFAOYSA-N
DMV10UH	IU	ethyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMV10UH	CA	CAS 85418-73-1
DMV10UH	DE	Discovery agent

DMPYIA3	ID	DMPYIA3
DMPYIA3	DN	GNF-PF-4453
DMPYIA3	HS	Investigative
DMPYIA3	SN	GNF-Pf-4453; TCMDC-125689; 4-{[3-(3,5-dimethylpiperidin-1-yl)propyl]amino}-N-(3-methoxyphenyl)-3-nitrobenzamide; MLS000689410; CHEMBL579424; MolPort-007-928-102; HMS2706G13; AKOS021653715; AKOS002143414; MCULE-1668730596; SMR000311209; SR-01000581321
DMPYIA3	DT	Small molecular drug
DMPYIA3	PC	16194189
DMPYIA3	MW	440.5
DMPYIA3	FM	C24H32N4O4
DMPYIA3	IC	InChI=1S/C24H32N4O4/c1-17-12-18(2)16-27(15-17)11-5-10-25-22-9-8-19(13-23(22)28(30)31)24(29)26-20-6-4-7-21(14-20)32-3/h4,6-9,13-14,17-18,25H,5,10-12,15-16H2,1-3H3,(H,26,29)
DMPYIA3	CS	CC1CC(CN(C1)CCCNC2=C(C=C(C=C2)C(=O)NC3=CC(=CC=C3)OC)[N+](=O)[O-])C
DMPYIA3	IK	LRAMWMMVZIGQPU-UHFFFAOYSA-N
DMPYIA3	IU	4-[3-(3,5-dimethylpiperidin-1-yl)propylamino]-N-(3-methoxyphenyl)-3-nitrobenzamide
DMPYIA3	DE	Discovery agent

DMCDU8K	ID	DMCDU8K
DMCDU8K	DN	GNF-PF-4478
DMCDU8K	HS	Investigative
DMCDU8K	SN	GNF-Pf-4478; CHEMBL597857; SMR000042305; AC1LD5U9; MLS000036444; cid_661700; MolPort-002-590-307; HMS2349M09; ZINC20191037; MMV006587; STK552090; BDBM50322743; AKOS005479117; MCULE-5579816479; NCGC00019462-02; NCGC00019462-01; 8-chloro-N-(3-morpholinopropyl)-5H-pyrimido[5,4-b]indol-4-amine; 8-chloro-N-[3-(morpholin-4-yl)propyl]-5H-pyrimido[5,4-b]indol-4-amine; 8-chloro-N-(3-morpholin-4-ylpropyl)-5H-pyrimido[5,4-b]indol-4-amine
DMCDU8K	DT	Small molecular drug
DMCDU8K	PC	661700
DMCDU8K	MW	345.8
DMCDU8K	FM	C17H20ClN5O
DMCDU8K	IC	InChI=1S/C17H20ClN5O/c18-12-2-3-14-13(10-12)15-16(22-14)17(21-11-20-15)19-4-1-5-23-6-8-24-9-7-23/h2-3,10-11,22H,1,4-9H2,(H,19,20,21)
DMCDU8K	CS	C1COCCN1CCCNC2=NC=NC3=C2NC4=C3C=C(C=C4)Cl
DMCDU8K	IK	ULJISGNQAXNPOC-UHFFFAOYSA-N
DMCDU8K	IU	8-chloro-N-(3-morpholin-4-ylpropyl)-5H-pyrimido[5,4-b]indol-4-amine
DMCDU8K	DE	Discovery agent

DM1ZMUN	ID	DM1ZMUN
DM1ZMUN	DN	GNF-PF-4599
DM1ZMUN	HS	Investigative
DM1ZMUN	SN	GNF-PF-4599; TCMDC-125680; CHEMBL227704; MolPort-007-928-115; AKOS021616514; AKOS001585537; MCULE-4162592697; SR-01000581334; SR-01000581334-1
DM1ZMUN	DT	Small molecular drug
DM1ZMUN	PC	44422654
DM1ZMUN	MW	478.5
DM1ZMUN	FM	C24H29F3N4O3
DM1ZMUN	IC	InChI=1S/C24H29F3N4O3/c1-16-12-17(2)15-30(14-16)11-3-10-28-21-9-4-18(13-22(21)31(33)34)23(32)29-20-7-5-19(6-8-20)24(25,26)27/h4-9,13,16-17,28H,3,10-12,14-15H2,1-2H3,(H,29,32)
DM1ZMUN	CS	CC1CC(CN(C1)CCCNC2=C(C=C(C=C2)C(=O)NC3=CC=C(C=C3)C(F)(F)F)[N+](=O)[O-])C
DM1ZMUN	IK	VWDZICDNGXUIKB-UHFFFAOYSA-N
DM1ZMUN	IU	4-[3-(3,5-dimethylpiperidin-1-yl)propylamino]-3-nitro-N-[4-(trifluoromethyl)phenyl]benzamide
DM1ZMUN	DE	Discovery agent

DM7850H	ID	DM7850H
DM7850H	DN	GNF-PF-5134
DM7850H	HS	Investigative
DM7850H	SN	GNF-Pf-5134; SMR000176391; MLS000567447; 1-ethyl-2,3-dimethyl-2-phenylbenzimidazole; 1-Ethyl-2,3-dimethyl-2-phenyl-2,3-dihydro-1H-benzoimidazole; AC1MK4BC; Oprea1_386360; Oprea1_275132; CHEMBL602969; cid_3124417; BDBM34775; MolPort-001-953-343; HMS2514O12; 1-ethyl-2,3-dimethyl-2-phenyl-2,3-dihydro-1H-benzimidazole; AKOS030484368; AKOS000562909; MCULE-9973053606; BAS 01044600; 1-ethyl-2,3-dimethyl-2-phenyl-benzimidazole
DM7850H	DT	Small molecular drug
DM7850H	PC	3124417
DM7850H	MW	252.35
DM7850H	FM	C17H20N2
DM7850H	IC	InChI=1S/C17H20N2/c1-4-19-16-13-9-8-12-15(16)18(3)17(19,2)14-10-6-5-7-11-14/h5-13H,4H2,1-3H3
DM7850H	CS	CCN1C2=CC=CC=C2N(C1(C)C3=CC=CC=C3)C
DM7850H	IK	QWPMTQMHWWDYRA-UHFFFAOYSA-N
DM7850H	IU	1-ethyl-2,3-dimethyl-2-phenylbenzimidazole
DM7850H	DE	Discovery agent

DMVI4JG	ID	DMVI4JG
DMVI4JG	DN	GNF-PF-5188
DMVI4JG	HS	Investigative
DMVI4JG	SN	GNF-PF-5188; CHEMBL525381; BAS 02081013; AC1MJHV1; HMS1682E16; ZINC4976718; BDBM50265648; AKOS000639707; 8-hexyl-3,5,5-trimethyl-2,4-dihydro-1H-chromeno[3,4-c]pyridin-10-ol; 8-Hexyl-3,5,5-trimethyl-1,3,4,5-tetrahydro-2H-chromeno[3,4-c]pyridin-10-ol
DMVI4JG	DT	Small molecular drug
DMVI4JG	PC	3137700
DMVI4JG	MW	329.5
DMVI4JG	FM	C21H31NO2
DMVI4JG	IC	InChI=1S/C21H31NO2/c1-5-6-7-8-9-15-12-18(23)20-16-10-11-22(4)14-17(16)21(2,3)24-19(20)13-15/h12-13,23H,5-11,14H2,1-4H3
DMVI4JG	CS	CCCCCCC1=CC(=C2C3=C(CN(CC3)C)C(OC2=C1)(C)C)O
DMVI4JG	IK	CXLQUCPRQKBNSP-UHFFFAOYSA-N
DMVI4JG	IU	8-hexyl-3,5,5-trimethyl-2,4-dihydro-1H-chromeno[3,4-c]pyridin-10-ol
DMVI4JG	DE	Discovery agent

DMZNAEQ	ID	DMZNAEQ
DMZNAEQ	DN	GNF-PF-5411
DMZNAEQ	HS	Investigative
DMZNAEQ	SN	CINCHONIDINE; Cinchonan-9-ol; cinchonine; alpha-Quinidine; 485-71-2; GNF-PF-5411; 118-10-5; MLS002637808; NSC5364; .alpha.-Quinidine; NSC 5364; Cinchonan-9-ol, (8.alpha.,9R)-; Cinchonan-9-ol, (9S)-; (8alpha,9R)Cinchonan-9-ol; a-quinidine; (8-alpha,9R)-Cinchonan-9-ol; EINECS 207-622-3; {5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl}(quinolin-4-yl)methanol; SMR001488502; AI3-15317; 4-quinolyl-(5-vinylquinuclidin-2-yl)methanol; 2-Quinuclidinemethanol, alpha-4-quinolyl-5-vinyl-; (+)-Quinolin-4-yl(5-vinylquinuclidin-2-yl)methanol
DMZNAEQ	DT	Small molecular drug
DMZNAEQ	PC	2757
DMZNAEQ	MW	294.4
DMZNAEQ	FM	C19H22N2O
DMZNAEQ	IC	InChI=1S/C19H22N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h2-7,9,13-14,18-19,22H,1,8,10-12H2
DMZNAEQ	CS	C=CC1CN2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O
DMZNAEQ	IK	KMPWYEUPVWOPIM-UHFFFAOYSA-N
DMZNAEQ	IU	(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-quinolin-4-ylmethanol
DMZNAEQ	CA	CAS 485-71-2
DMZNAEQ	DE	Discovery agent

DMP9AIH	ID	DMP9AIH
DMP9AIH	DN	GNF-PF-5434
DMP9AIH	HS	Investigative
DMP9AIH	SN	GNF-PF-5434; CHEMBL486232; N~2~-(MORPHOLIN-4-YLCARBONYL)-N~1~-[(1S,2E)-1-(2-PHENYLETHYL)-3-(PHENYLSULFONYL)PROP-2-ENYL]-D-LEUCINAMIDE; MORPHOLINE-4-CARBOXYLIC ACID (1-(3-BENZENESULFONYL-1-PHENETHYLALLYLCARBAMOYL)-3-METHYLBUTYL)-AMIDE; N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide; AC1NRAGB; SCHEMBL7352997; BDBM50243232; K-11017; 4-Morpholinecarboxamide, N-[(1S)-3-methyl-1-[[[(1S,2E)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl]amino]carbonyl]butyl]-
DMP9AIH	DT	Small molecular drug
DMP9AIH	PC	5287864
DMP9AIH	MW	527.7
DMP9AIH	FM	C28H37N3O5S
DMP9AIH	IC	InChI=1S/C28H37N3O5S/c1-22(2)21-26(30-28(33)31-16-18-36-19-17-31)27(32)29-24(14-13-23-9-5-3-6-10-23)15-20-37(34,35)25-11-7-4-8-12-25/h3-12,15,20,22,24,26H,13-14,16-19,21H2,1-2H3,(H,29,32)(H,30,33)/b20-15+/t24-,26-/m0/s1
DMP9AIH	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCC1=CC=CC=C1)/C=C/S(=O)(=O)C2=CC=CC=C2)NC(=O)N3CCOCC3
DMP9AIH	IK	YUMYYTORLYHUFW-MSKIIMLESA-N
DMP9AIH	IU	N-[(2S)-1-[[(E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-4-methyl-1-oxopentan-2-yl]morpholine-4-carboxamide
DMP9AIH	DE	Discovery agent

DMT8VUS	ID	DMT8VUS
DMT8VUS	DN	GNF-PF-5618
DMT8VUS	HS	Investigative
DMT8VUS	DT	Small molecular drug
DMT8VUS	PC	3013846
DMT8VUS	MW	757.9
DMT8VUS	FM	C39H59N5O10
DMT8VUS	IC	InChI=1S/C39H59N5O10/c1-4-5-6-7-8-9-10-11-12-23-34(27(2)35(47)40-30-20-15-18-25-44(52)38(30)49)54-39(50)31(21-16-17-24-43(51)28(3)45)41-36(48)32-26-53-37(42-32)29-19-13-14-22-33(29)46/h13-14,19,22,26-27,30-31,34,46,51-52H,4-12,15-18,20-21,23-25H2,1-3H3,(H,40,47)(H,41,48)
DMT8VUS	CS	CCCCCCCCCCCC(C(C)C(=O)NC1CCCCN(C1=O)O)OC(=O)C(CCCCN(C(=O)C)O)NC(=O)C2=COC(=N2)C3=CC=CC=C3O
DMT8VUS	IK	QFWVGKDFYOXTQO-UHFFFAOYSA-N
DMT8VUS	IU	[1-[(1-hydroxy-2-oxoazepan-3-yl)amino]-2-methyl-1-oxotetradecan-3-yl] 6-[acetyl(hydroxy)amino]-2-[[2-(2-hydroxyphenyl)-1,3-oxazole-4-carbonyl]amino]hexanoate
DMT8VUS	DE	Discovery agent

DMWGXBF	ID	DMWGXBF
DMWGXBF	DN	GNF-PF-600
DMWGXBF	HS	Investigative
DMWGXBF	SN	GNF-PF-600; BAS 00282408; CHEMBL199659; BDBM8464; SCHEMBL13056375; ZINC880427; Thiobarbituric acid-furan analogue 29; SR-01000369489; SR-01000369489-1
DMWGXBF	DT	Small molecular drug
DMWGXBF	PC	1138119
DMWGXBF	MW	362.8
DMWGXBF	FM	C16H11ClN2O4S
DMWGXBF	IC	InChI=1S/C16H11ClN2O4S/c1-22-13-4-2-8(6-11(13)17)12-5-3-9(23-12)7-10-14(20)18-16(24)19-15(10)21/h2-7H,1H3,(H2,18,19,20,21,24)
DMWGXBF	CS	COC1=C(C=C(C=C1)C2=CC=C(O2)C=C3C(=O)NC(=S)NC3=O)Cl
DMWGXBF	IK	PKLIDAWVQNGMRD-UHFFFAOYSA-N
DMWGXBF	IU	5-[[5-(3-chloro-4-methoxyphenyl)furan-2-yl]methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
DMWGXBF	DE	Discovery agent

DMJXE6K	ID	DMJXE6K
DMJXE6K	DN	GNF-PF-607
DMJXE6K	HS	Investigative
DMJXE6K	SN	GNF-PF-607; CHEMBL113999; 13794-67-7; N6-[(3,4,5-trimethoxyphenyl)methyl]quinazoline-2,4,6-triamine; NSC156246; AC1L6FHM; AC1Q4YN2; n6-(3,4,5-trimethoxybenzyl)quinazoline-2,4,6-triamine; CTK0I1910; DTXSID70303050; BDBM50066492; NSC-156246; 6-[(3,4,5-Trimethoxybenzyl)amino]quinazoline-2,4-diamine; N*6*-(3,4,5-Trimethoxy-benzyl)-quinazoline-2,4,6-triamine; 6-N-[(3,4,5-trimethoxyphenyl)methyl]quinazoline-2,4,6-triamine
DMJXE6K	DT	Small molecular drug
DMJXE6K	PC	291270
DMJXE6K	MW	355.4
DMJXE6K	FM	C18H21N5O3
DMJXE6K	IC	InChI=1S/C18H21N5O3/c1-24-14-6-10(7-15(25-2)16(14)26-3)9-21-11-4-5-13-12(8-11)17(19)23-18(20)22-13/h4-8,21H,9H2,1-3H3,(H4,19,20,22,23)
DMJXE6K	CS	COC1=CC(=CC(=C1OC)OC)CNC2=CC3=C(C=C2)N=C(N=C3N)N
DMJXE6K	IK	YYJWQABXDCUJEF-UHFFFAOYSA-N
DMJXE6K	IU	6-N-[(3,4,5-trimethoxyphenyl)methyl]quinazoline-2,4,6-triamine
DMJXE6K	CA	CAS 13794-67-7
DMJXE6K	DE	Discovery agent

DM3SYH5	ID	DM3SYH5
DM3SYH5	DN	GNF-PF-67
DM3SYH5	HS	Investigative
DM3SYH5	SN	Toxoflavin; Toxoflavine; Xanthothricin; Xanthotricin; 84-82-2; Xanthothricin (VAN); UNII-5N5YI4IP1P; GNF-Pf-67; NSC 67078; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,6-Dimethylpyrimido(5,4-e)-as-triazine-5,7(1H,6H)-dione; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; BRN 0021014; 5N5YI4IP1P; MLS000087831; CHEBI:80729; NSC67078; 1,6-Dimethyl-5,7-dioxo-1,5,6,7-tetrahydropyrimido(5,4-E)-as-triazine-5,7(1H,6H)-dione; SMR000024051; Pyrimido(5,4-e)-as-triazine-5,7-(1H,6H)-dione, 1,6-dimethyl-
DM3SYH5	DT	Small molecular drug
DM3SYH5	PC	66541
DM3SYH5	MW	193.16
DM3SYH5	FM	C7H7N5O2
DM3SYH5	IC	InChI=1S/C7H7N5O2/c1-11-6(13)4-5(10-7(11)14)12(2)9-3-8-4/h3H,1-2H3
DM3SYH5	CS	CN1C2=NC(=O)N(C(=O)C2=NC=N1)C
DM3SYH5	IK	SLGRAIAQIAUZAQ-UHFFFAOYSA-N
DM3SYH5	IU	1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione
DM3SYH5	CA	CAS 84-82-2
DM3SYH5	CB	CHEBI:80729
DM3SYH5	DE	Discovery agent

DM7SPRJ	ID	DM7SPRJ
DM7SPRJ	DN	GNF-PF-78
DM7SPRJ	HS	Investigative
DM7SPRJ	SN	GNF-Pf-78; MLS000724706; SMR000237577; 2-methyl-4,9-dioxo-N-(pyridin-3-ylmethyl)benzo[f][1]benzofuran-3-carboxamide; 2-methyl-4,9-dioxo-N-(pyridin-3-ylmethyl)-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide; 867135-78-2; AC1M2EUB; CHEMBL579318; cid_2142309; BDBM63230; MolPort-000-336-147; HMS2252C13; STL228961; ZINC37867960; AKOS002232614; MCULE-2786712757; AB00637219-02; BRD-K01762812-001-08-0; F1654-0382; 4,9-diketo-2-methyl-N-(3-pyridylmethyl)benzo[f]benzofuran-3-carboxamide
DM7SPRJ	DT	Small molecular drug
DM7SPRJ	PC	2142309
DM7SPRJ	MW	346.3
DM7SPRJ	FM	C20H14N2O4
DM7SPRJ	IC	InChI=1S/C20H14N2O4/c1-11-15(20(25)22-10-12-5-4-8-21-9-12)16-17(23)13-6-2-3-7-14(13)18(24)19(16)26-11/h2-9H,10H2,1H3,(H,22,25)
DM7SPRJ	CS	CC1=C(C2=C(O1)C(=O)C3=CC=CC=C3C2=O)C(=O)NCC4=CN=CC=C4
DM7SPRJ	IK	HSYUWLOZMGPYKC-UHFFFAOYSA-N
DM7SPRJ	IU	2-methyl-4,9-dioxo-N-(pyridin-3-ylmethyl)benzo[f][1]benzofuran-3-carboxamide
DM7SPRJ	DE	Discovery agent

DM37ORC	ID	DM37ORC
DM37ORC	DN	GNF-PF-826
DM37ORC	HS	Investigative
DM37ORC	SN	GNF-Pf-826; AC1M65LM; CHEMBL599946; N-[3-(4-hydroxyanilino)-4-oxonaphthalen-1-ylidene]thiophene-2-sulfonamide; HMS2671P22; MCULE-4006851150
DM37ORC	DT	Small molecular drug
DM37ORC	PC	2391700
DM37ORC	MW	410.5
DM37ORC	FM	C20H14N2O4S2
DM37ORC	IC	InChI=1S/C20H14N2O4S2/c23-14-9-7-13(8-10-14)21-18-12-17(15-4-1-2-5-16(15)20(18)24)22-28(25,26)19-6-3-11-27-19/h1-12,21,23H
DM37ORC	CS	C1=CC=C2C(=C1)C(=NS(=O)(=O)C3=CC=CS3)C=C(C2=O)NC4=CC=C(C=C4)O
DM37ORC	IK	YXKCWSSSTBYFQS-UHFFFAOYSA-N
DM37ORC	IU	N-[3-(4-hydroxyanilino)-4-oxonaphthalen-1-ylidene]thiophene-2-sulfonamide
DM37ORC	DE	Discovery agent

DMB6FN7	ID	DMB6FN7
DMB6FN7	DN	GNF-PF-85
DMB6FN7	HS	Investigative
DMB6FN7	SN	GNF-PF-85; 3-[(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]naphthalen-2-ol; 3-({5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}amino)naphthalen-2-ol; BAS 01083131; AC1LFFF4; Oprea1_463466; Oprea1_430691; SCHEMBL4939616; CHEMBL487518; BDBM24409; ZINC267589; AKOS024371314; Triazolopyrimidine-Based Compound, 16; MCULE-8335313178; ST51007753; SR-01000326143; SR-01000326143-1; 3-(5-Methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamino)-naphthalen-2-ol
DMB6FN7	DT	Small molecular drug
DMB6FN7	PC	777193
DMB6FN7	MW	291.31
DMB6FN7	FM	C16H13N5O
DMB6FN7	IC	InChI=1S/C16H13N5O/c1-10-6-15(21-16(19-10)17-9-18-21)20-13-7-11-4-2-3-5-12(11)8-14(13)22/h2-9,20,22H,1H3
DMB6FN7	CS	CC1=NC2=NC=NN2C(=C1)NC3=CC4=CC=CC=C4C=C3O
DMB6FN7	IK	OMQCQQGZRWJBCI-UHFFFAOYSA-N
DMB6FN7	IU	3-[(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]naphthalen-2-ol
DMB6FN7	DE	Discovery agent

DMKVTZN	ID	DMKVTZN
DMKVTZN	DN	Go 6983
DMKVTZN	HS	Investigative
DMKVTZN	SN	Goe 6983; Go-6893
DMKVTZN	DT	Small molecular drug
DMKVTZN	PC	3499
DMKVTZN	MW	442.5
DMKVTZN	FM	C26H26N4O3
DMKVTZN	IC	InChI=1S/C26H26N4O3/c1-29(2)11-6-12-30-15-20(18-13-16(33-3)9-10-22(18)30)24-23(25(31)28-26(24)32)19-14-27-21-8-5-4-7-17(19)21/h4-5,7-10,13-15,27H,6,11-12H2,1-3H3,(H,28,31,32)
DMKVTZN	CS	CN(C)CCCN1C=C(C2=C1C=CC(=C2)OC)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54
DMKVTZN	IK	LLJJDLHGZUOMQP-UHFFFAOYSA-N
DMKVTZN	IU	3-[1-[3-(dimethylamino)propyl]-5-methoxyindol-3-yl]-4-(1H-indol-3-yl)pyrrole-2,5-dione
DMKVTZN	CA	CAS 133053-19-7
DMKVTZN	CB	CHEBI:91455
DMKVTZN	DE	Discovery agent

DMS91OR	ID	DMS91OR
DMS91OR	DN	Go7874
DMS91OR	HS	Investigative
DMS91OR	SN	Go 7874; Go-7874
DMS91OR	DT	Small molecular drug
DMS91OR	PC	3500
DMS91OR	MW	470.5
DMS91OR	FM	C27H26N4O4
DMS91OR	IC	InChI=1S/C27H26N4O4/c1-29(2)12-14(32)13-31-19-10-9-15(35-4)11-17(19)21-23-22(26(33)28-27(23)34)20-16-7-5-6-8-18(16)30(3)24(20)25(21)31/h5-11,14,32H,12-13H2,1-4H3,(H,28,33,34)
DMS91OR	CS	CN1C2=CC=CC=C2C3=C4C(=C5C6=C(C=CC(=C6)OC)N(C5=C31)CC(CN(C)C)O)C(=O)NC4=O
DMS91OR	IK	NYBAPNLYWRMTJL-UHFFFAOYSA-N
DMS91OR	IU	3-[3-(dimethylamino)-2-hydroxypropyl]-7-methoxy-23-methyl-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione
DMS91OR	DE	Discovery agent

DMS97A1	ID	DMS97A1
DMS97A1	DN	Gold trichloride sodium chloride
DMS97A1	HS	Investigative
DMS97A1	DE	Discovery agent

DMMT05U	ID	DMMT05U
DMMT05U	DN	GOSSYPETIN
DMMT05U	HS	Investigative
DMMT05U	SN	Gossypetin; Articulatidin; Equisporol; 489-35-0; 3,5,7,8,3',4'-Hexahydroxyflavone; UNII-SET4M23ZTM; 3,3',4',5,7,8-Hexahydroxyflavone; SET4M23ZTM; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxy-4H-chromen-4-one; CHEMBL253570; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxychromen-4-one; CHEBI:16400; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-; 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-chromen-4-one; PubChem9855; AC1NQXCW; BSPBio_002552; SPECTRUM1505143; SCHEMBL157033; BDBM26655; DTXSID50197631
DMMT05U	DT	Small molecular drug
DMMT05U	PC	5280647
DMMT05U	MW	318.23
DMMT05U	FM	C15H10O8
DMMT05U	IC	InChI=1S/C15H10O8/c16-6-2-1-5(3-7(6)17)14-13(22)12(21)10-8(18)4-9(19)11(20)15(10)23-14/h1-4,16-20,22H
DMMT05U	CS	C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C(=C(C=C3O)O)O)O)O)O
DMMT05U	IK	YRRAGUMVDQQZIY-UHFFFAOYSA-N
DMMT05U	IU	2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxychromen-4-one
DMMT05U	CA	CAS 489-35-0
DMMT05U	CB	CHEBI:16400
DMMT05U	DE	Discovery agent

DMZNUAD	ID	DMZNUAD
DMZNUAD	DN	Go-Y022
DMZNUAD	HS	Investigative
DMZNUAD	SN	Go-Y022; CHEMBL128729; 1,5-Bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one; (1E,4E)-1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one; Hylin; AC1O6FK4; 1,5-Bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadien-3-one; SCHEMBL1493282; ZINC6483730; BDBM50067028; 1,5-Bis-(4-hydroxy-3-methoxy-phenyl)-penta-1,4-dien-3-one; 1,5-bis-(4-hydroxy-3-methoxyphenyl)-penta-1,4-dien-3-one; (1E,4E)-1,5-bis(4-hydroxy-3-methoxy-phenyl)penta-1,4-dien-3-one
DMZNUAD	DT	Small molecular drug
DMZNUAD	PC	6474893
DMZNUAD	MW	326.3
DMZNUAD	FM	C19H18O5
DMZNUAD	IC	InChI=1S/C19H18O5/c1-23-18-11-13(5-9-16(18)21)3-7-15(20)8-4-14-6-10-17(22)19(12-14)24-2/h3-12,21-22H,1-2H3/b7-3+,8-4+
DMZNUAD	CS	COC1=C(C=CC(=C1)/C=C/C(=O)/C=C/C2=CC(=C(C=C2)O)OC)O
DMZNUAD	IK	ISIMGBQRFXXNON-FCXRPNKRSA-N
DMZNUAD	IU	(1E,4E)-1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one
DMZNUAD	CA	CAS 131359-25-6
DMZNUAD	DE	Discovery agent

DMUNSLJ	ID	DMUNSLJ
DMUNSLJ	DN	Go-Y026
DMUNSLJ	HS	Investigative
DMUNSLJ	SN	Go-Y026; CHEMBL493001; SCHEMBL2743841; SCHEMBL2743839; GO-Y-026; BDBM50258200; 1,5-bis(4-hydroxy-3,5-dimethoxyphenyl)penta-1,4-dien-3-one; 1,5-Bis(3,5-dimethoxy-4-hydroxyphenyl)-1,4-pentadien-3-one
DMUNSLJ	DT	Small molecular drug
DMUNSLJ	PC	10691533
DMUNSLJ	MW	386.4
DMUNSLJ	FM	C21H22O7
DMUNSLJ	IC	InChI=1S/C21H22O7/c1-25-16-9-13(10-17(26-2)20(16)23)5-7-15(22)8-6-14-11-18(27-3)21(24)19(12-14)28-4/h5-12,23-24H,1-4H3/b7-5+,8-6+
DMUNSLJ	CS	COC1=CC(=CC(=C1O)OC)/C=C/C(=O)/C=C/C2=CC(=C(C(=C2)OC)O)OC
DMUNSLJ	IK	DDGVRFAFSCAHHH-KQQUZDAGSA-N
DMUNSLJ	IU	(1E,4E)-1,5-bis(4-hydroxy-3,5-dimethoxyphenyl)penta-1,4-dien-3-one
DMUNSLJ	DE	Discovery agent

DMRUIX3	ID	DMRUIX3
DMRUIX3	DN	GP515
DMRUIX3	HS	Investigative
DMRUIX3	SN	1H-Pyrazolo(3,4-d)pyrimidin-4-amine, 1-(5-amino-5-deoxy-beta-D-ribofuranosyl)-3-bromo-; GP 1-515; CHEMBL356141; 144928-48-3; GP-515; Adenosine kinase inhibitor GP515; GP-1-515; SCHEMBL2053010; AC1L31E2; DTXSID30162847; BDBM50134744; 1-(5-Amino-5-deoxy-beta-D-ribofuranosyl)-3-bromo-1H-pyrazolo(3,4-d)pyrimidin-4-amine; 4-Amino-1-(5-amino-5-deoxy-1-beta-D-ribofuranosyl)-3-bromopyrazolo(3,4-d)pyrimidine; (2R,3R,4S,5R)-2-(4-amino-3-bromopyrazolo[3,4-d]pyrimidin-1-yl)-5-(aminomethyl)oxolane-3,4-diol; 19-nor-10-azasteroid skeleton
DMRUIX3	DT	Small molecular drug
DMRUIX3	PC	132663
DMRUIX3	MW	345.15
DMRUIX3	FM	C10H13BrN6O3
DMRUIX3	IC	InChI=1S/C10H13BrN6O3/c11-7-4-8(13)14-2-15-9(4)17(16-7)10-6(19)5(18)3(1-12)20-10/h2-3,5-6,10,18-19H,1,12H2,(H2,13,14,15)/t3-,5-,6-,10-/m1/s1
DMRUIX3	CS	C1=NC(=C2C(=N1)N(N=C2Br)[C@H]3[C@@H]([C@@H]([C@H](O3)CN)O)O)N
DMRUIX3	IK	LTTBFVDMHCIDPM-BHBWVORQSA-N
DMRUIX3	IU	(2R,3R,4S,5R)-2-(4-amino-3-bromopyrazolo[3,4-d]pyrimidin-1-yl)-5-(aminomethyl)oxolane-3,4-diol
DMRUIX3	CA	CAS 144928-48-3
DMRUIX3	DE	Discovery agent

DM1W5G9	ID	DM1W5G9
DM1W5G9	DN	GPCR39 pepducins
DM1W5G9	HS	Investigative
DM1W5G9	SN	GPCR39 pepducins (lipopeptide, diabetes/obesity); GPCR39 pepducins (lipopeptide, diabetes/obesity), Anchor Therapeutics; GPCR39 pepducins (lipopeptide, diabetes/obesity), Anchor/Janssen; G-protein coupled receptor-39 modulators (lipopeptide, diabetes/obesity), Anchor Therapeutics; GPCR39 pepducins (lipopeptide, diabetes/obesity), Anchor Therapeutics/ Ortho-McNeil-Janssen
DM1W5G9	CP	Anchor Therapeutics Inc
DM1W5G9	DE	Diabetic complication

DMRJ5OD	ID	DMRJ5OD
DMRJ5OD	DN	GPG-290
DMRJ5OD	HS	Investigative
DMRJ5OD	SN	Platelet adhesion inhibitor, Aarvon Biosciences
DMRJ5OD	CP	Wyeth
DMRJ5OD	DE	Angina pectoris

DMAY48N	ID	DMAY48N
DMAY48N	DN	GPI 18214
DMAY48N	HS	Investigative
DMAY48N	DE	Discovery agent

DMLRTPH	ID	DMLRTPH
DMLRTPH	DN	GPYRMEHFRWGSPPKD-NH2
DMLRTPH	HS	Investigative
DMLRTPH	PC	91936746
DMLRTPH	MW	1959.2
DMLRTPH	FM	C89H127N27O22S
DMLRTPH	IC	InChI=1S/C89H127N27O22S/c1-139-37-30-60(107-76(127)57(19-9-32-98-88(93)94)104-82(133)63(39-50-24-26-53(118)27-25-50)113-84(135)67-21-11-34-114(67)71(120)43-91)80(131)106-59(28-29-72(121)122)79(130)112-65(41-52-45-97-48-102-52)83(134)110-62(38-49-14-3-2-4-15-49)81(132)105-58(20-10-33-99-89(95)96)78(129)111-64(40-51-44-100-55-17-6-5-16-54(51)55)75(126)101-46-70(119)103-66(47-117)86(137)116-36-13-23-69(116)87(138)115-35-12-22-68(115)85(136)108-56(18-7-8-31-90)77(128)109-61(74(92)125)42-73(123)124/h2-6,14-17,24-27,44-45,48,56-69,100,117-118H,7-13,18-23,28-43,46-47,90-91H2,1H3,(H2,92,125)(H,97,102)(H,101,126)(H,103,119)(H,104,133)(H,105,132)(H,106,131)(H,107,127)(H,108,136)(H,109,128)(H,110,134)(H,111,129)(H,112,130)(H,113,135)(H,121,122)(H,123,124)(H4,93,94,98)(H4,95,96,99)/t56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-/m0/s1
DMLRTPH	CS	CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CO)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@@H]8CCCN8C(=O)CN
DMLRTPH	IK	XQMPAWYRHAOJTE-JLQTWWGSSA-N
DMLRTPH	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMLRTPH	DE	Discovery agent

DMMX7KL	ID	DMMX7KL
DMMX7KL	DN	GR 125,743
DMMX7KL	HS	Investigative
DMMX7KL	SN	GR125743; GR 125743
DMMX7KL	DT	Small molecular drug
DMMX7KL	PC	5311130
DMMX7KL	MW	416.5
DMMX7KL	FM	C25H28N4O2
DMMX7KL	IC	InChI=1S/C25H28N4O2/c1-18-16-20(4-6-22(18)19-8-10-26-11-9-19)25(30)27-21-5-7-24(31-3)23(17-21)29-14-12-28(2)13-15-29/h4-11,16-17H,12-15H2,1-3H3,(H,27,30)
DMMX7KL	CS	CC1=C(C=CC(=C1)C(=O)NC2=CC(=C(C=C2)OC)N3CCN(CC3)C)C4=CC=NC=C4
DMMX7KL	IK	GNOXPYACARZYMW-UHFFFAOYSA-N
DMMX7KL	IU	N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-4-pyridin-4-ylbenzamide
DMMX7KL	DE	Discovery agent

DM72B86	ID	DM72B86
DM72B86	DN	GR 125487
DM72B86	HS	Investigative
DM72B86	SN	GR-125487; GR125487
DM72B86	DT	Small molecular drug
DM72B86	PC	4284721
DM72B86	MW	427.5
DM72B86	FM	C19H26FN3O5S
DM72B86	IC	InChI=1S/C19H26FN3O5S/c1-27-18-17(15-11-14(20)3-4-16(15)22-18)19(24)28-12-13-5-8-23(9-6-13)10-7-21-29(2,25)26/h3-4,11,13,21-22H,5-10,12H2,1-2H3
DM72B86	CS	COC1=C(C2=C(N1)C=CC(=C2)F)C(=O)OCC3CCN(CC3)CCNS(=O)(=O)C
DM72B86	IK	SSPCCAYAIDNNJX-UHFFFAOYSA-N
DM72B86	IU	[1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylate
DM72B86	CA	CAS 144625-67-2
DM72B86	DE	Discovery agent

DMAI9Y0	ID	DMAI9Y0
DMAI9Y0	DN	GR 128107
DMAI9Y0	HS	Investigative
DMAI9Y0	SN	L000276; GR-128107; GR128107
DMAI9Y0	DT	Small molecular drug
DMAI9Y0	PC	44208891
DMAI9Y0	MW	272.34
DMAI9Y0	FM	C16H20N2O2
DMAI9Y0	IC	InChI=1S/C16H20N2O2/c1-11(19)18-7-3-4-12(10-18)15-9-17-16-6-5-13(20-2)8-14(15)16/h5-6,8-9,12,17H,3-4,7,10H2,1-2H3
DMAI9Y0	CS	CC(=O)N1CCCC(C1)C2=CNC3=C2C=C(C=C3)OC
DMAI9Y0	IK	RBINAFTXZHPTNU-UHFFFAOYSA-N
DMAI9Y0	IU	1-[3-(5-methoxy-1H-indol-3-yl)piperidin-1-yl]ethanone
DMAI9Y0	DE	Discovery agent

DMHAWYJ	ID	DMHAWYJ
DMHAWYJ	DN	GR 196429
DMHAWYJ	HS	Investigative
DMHAWYJ	SN	GR196429; GR-196429
DMHAWYJ	DT	Small molecular drug
DMHAWYJ	PC	5311134
DMHAWYJ	MW	246.3
DMHAWYJ	FM	C14H18N2O2
DMHAWYJ	IC	InChI=1S/C14H18N2O2/c1-10(17)15-6-8-16-7-4-11-2-3-13-12(14(11)16)5-9-18-13/h2-3H,4-9H2,1H3,(H,15,17)
DMHAWYJ	CS	CC(=O)NCCN1CCC2=C1C3=C(C=C2)OCC3
DMHAWYJ	IK	LTYWTNUOUBBVNZ-UHFFFAOYSA-N
DMHAWYJ	IU	N-[2-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)ethyl]acetamide
DMHAWYJ	CA	CAS 170729-12-1
DMHAWYJ	DE	Discovery agent

DMP1DO4	ID	DMP1DO4
DMP1DO4	DN	GR100679
DMP1DO4	HS	Investigative
DMP1DO4	SN	GR 100679; GR-100679
DMP1DO4	DT	Small molecular drug
DMP1DO4	PC	5311129
DMP1DO4	MW	616.7
DMP1DO4	FM	C34H44N6O5
DMP1DO4	IC	InChI=1S/C34H44N6O5/c1-22(37-30(41)21-36-32(43)24-14-8-5-9-15-24)31(42)38-28(19-25-20-35-27-17-11-10-16-26(25)27)33(44)39-29(34(45)40(2)3)18-23-12-6-4-7-13-23/h4,6-7,10-13,16-17,20,22,24,28-29,35H,5,8-9,14-15,18-19,21H2,1-3H3,(H,36,43)(H,37,41)(H,38,42)(H,39,44)/t22-,28+,29-/m0/s1
DMP1DO4	CS	C[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N(C)C)NC(=O)CNC(=O)C4CCCCC4
DMP1DO4	IK	IBHXDZADSPABSD-GJDOKZOISA-N
DMP1DO4	IU	N-[2-[[(2S)-1-[[(2R)-1-[[(2S)-1-(dimethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]cyclohexanecarboxamide
DMP1DO4	DE	Discovery agent

DMFU9VH	ID	DMFU9VH
DMFU9VH	DN	GR-113808
DMFU9VH	HS	Investigative
DMFU9VH	SN	CHEMBL518682; GTPL259; [3H]GR 113808; GR 125487 [H3]; [1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 1-(tritritiomethyl)indole-3-carboxylate
DMFU9VH	DT	Small molecular drug
DMFU9VH	PC	119376
DMFU9VH	MW	393.5
DMFU9VH	FM	C19H27N3O4S
DMFU9VH	IC	InChI=1S/C19H27N3O4S/c1-21-13-17(16-5-3-4-6-18(16)21)19(23)26-14-15-7-10-22(11-8-15)12-9-20-27(2,24)25/h3-6,13,15,20H,7-12,14H2,1-2H3
DMFU9VH	CS	CN1C=C(C2=CC=CC=C21)C(=O)OCC3CCN(CC3)CCNS(=O)(=O)C
DMFU9VH	IK	MOZPSIXKYJUTKI-UHFFFAOYSA-N
DMFU9VH	IU	[1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 1-methylindole-3-carboxylate
DMFU9VH	CA	CAS 144625-51-4
DMFU9VH	CB	CHEBI:73380
DMFU9VH	DE	Discovery agent

DMQH8PK	ID	DMQH8PK
DMQH8PK	DN	GR-133686
DMQH8PK	HS	Investigative
DMQH8PK	PC	10696098
DMQH8PK	MW	480.6
DMQH8PK	FM	C30H40O5
DMQH8PK	IC	InChI=1S/C30H40O5/c1-16(2)13-17(31)14-18-24-21(34-25(18)32)15-29(5)20-7-8-22-27(3,19(20)9-12-28(24,29)4)11-10-23-30(22,6)26(33)35-23/h7,13,18-19,21-24H,8-12,14-15H2,1-6H3/t18-,19+,21+,22-,23-,24-,27-,28+,29-,30+/m1/s1
DMQH8PK	CS	CC(=CC(=O)C[C@@H]1[C@@H]2[C@H](C[C@]3([C@]2(CC[C@H]4C3=CC[C@@H]5[C@@]4(CC[C@@H]6[C@]5(C(=O)O6)C)C)C)C)OC1=O)C
DMQH8PK	IK	UAKRLLAUOQEYFN-PQNCNOJFSA-N
DMQH8PK	IU	(2S,4S,7R,8S,9S,12R,13R,16R,19S,20R)-2,9,13,19-tetramethyl-7-(4-methyl-2-oxopent-3-enyl)-5,17-dioxahexacyclo[10.10.0.02,9.04,8.013,20.016,19]docos-1(22)-ene-6,18-dione
DMQH8PK	DE	Discovery agent

DMW8YDR	ID	DMW8YDR
DMW8YDR	DN	GR138676
DMW8YDR	HS	Investigative
DMW8YDR	SN	GR 138676; GR-138676
DMW8YDR	DT	Small molecular drug
DMW8YDR	PC	25088319
DMW8YDR	MW	1433.7
DMW8YDR	FM	C75H92N12O15S
DMW8YDR	IC	InChI=1S/C75H92N12O15S/c1-47(2)33-63(73(98)79-55(44-101-42-51-25-15-7-16-26-51)45-102-43-52-27-17-8-18-28-52)87-41-53-29-31-86(66(53)75(87)100)74(99)62(36-50-23-13-6-14-24-50)85-70(95)59(35-49-21-11-5-12-22-49)81-69(94)58(34-48-19-9-4-10-20-48)82-72(97)61(39-65(90)91)84-71(96)60(37-54-40-77-46-78-54)83-68(93)57(30-32-103-3)80-67(92)56(76)38-64(88)89/h4-28,40,46-47,53,55-63,66H,29-39,41-45,76H2,1-3H3,(H,77,78)(H,79,98)(H,80,92)(H,81,94)(H,82,97)(H,83,93)(H,84,96)(H,85,95)(H,88,89)(H,90,91)/t53-,56+,57+,58+,59+,60+,61+,62+,63-,66-/m1/s1
DMW8YDR	CS	CC(C)C[C@H](C(=O)NC(COCC1=CC=CC=C1)COCC2=CC=CC=C2)N3C[C@H]4CCN([C@H]4C3=O)C(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)N
DMW8YDR	IK	SHZVIDXXKGEHEF-QEPUNBJPSA-N
DMW8YDR	IU	(3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(3aR,6aR)-5-[(2R)-1-[1,3-bis(phenylmethoxy)propan-2-ylamino]-4-methyl-1-oxopentan-2-yl]-6-oxo-3,3a,4,6a-tetrahydro-2H-pyrrolo[2,3-c]pyrrol-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-amino-4-oxobutanoic acid
DMW8YDR	DE	Discovery agent

DMIY9UF	ID	DMIY9UF
DMIY9UF	DN	GR-38414
DMIY9UF	HS	Investigative
DMIY9UF	SN	138155-21-2
DMIY9UF	DE	Discovery agent

DM5UOYM	ID	DM5UOYM
DM5UOYM	DN	GR-45809
DM5UOYM	HS	Investigative
DM5UOYM	SN	125104-16-7
DM5UOYM	DT	Small molecular drug
DM5UOYM	PC	9955378
DM5UOYM	MW	413.3
DM5UOYM	FM	C20H26Cl2N2O3
DM5UOYM	IC	InChI=1S/C20H26Cl2N2O3/c21-17-4-3-15(11-18(17)22)12-19(25)24-8-5-20(26-9-10-27-20)13-16(24)14-23-6-1-2-7-23/h3-4,11,16H,1-2,5-10,12-14H2
DM5UOYM	CS	C1CCN(C1)CC2CC3(CCN2C(=O)CC4=CC(=C(C=C4)Cl)Cl)OCCO3
DM5UOYM	IK	LWUQHEXXEFUHHQ-UHFFFAOYSA-N
DM5UOYM	IU	2-(3,4-dichlorophenyl)-1-[7-(pyrrolidin-1-ylmethyl)-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]ethanone
DM5UOYM	DE	Discovery agent

DM8L1Z2	ID	DM8L1Z2
DM8L1Z2	DN	GR55562
DM8L1Z2	HS	Investigative
DM8L1Z2	SN	GR55562; GR-55562; CHEMBL119264; GR 55562; Tocris-1054; Biomol-NT_000120; AC1L2T1B; GTPL113; SCHEMBL3366363; BPBio1_000002; CHEBI:92813; ZINC599925; BDBM50060519; AKOS028111023; NCGC00024970-02; NCGC00024970-01; NCGC00024970-03; L000279; BRD-K46441700-300-01-4; BRD-K46441700-001-01-8; 3-[3-(dimethylamino)propyl]-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide; 3-[3-(dimethylamino)pro-pyl]-4-hydroxy-N-[4-(4-pyridinyl)phenyl]benzamide; 3-(3-dimethylaminopropyl)-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide
DM8L1Z2	DT	Small molecular drug
DM8L1Z2	PC	128018
DM8L1Z2	MW	375.5
DM8L1Z2	FM	C23H25N3O2
DM8L1Z2	IC	InChI=1S/C23H25N3O2/c1-26(2)15-3-4-19-16-20(7-10-22(19)27)23(28)25-21-8-5-17(6-9-21)18-11-13-24-14-12-18/h5-14,16,27H,3-4,15H2,1-2H3,(H,25,28)
DM8L1Z2	CS	CN(C)CCCC1=C(C=CC(=C1)C(=O)NC2=CC=C(C=C2)C3=CC=NC=C3)O
DM8L1Z2	IK	ZAGAUUVCYGSPBP-UHFFFAOYSA-N
DM8L1Z2	IU	3-[3-(dimethylamino)propyl]-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide
DM8L1Z2	CA	CAS 159533-26-3
DM8L1Z2	CB	CHEBI:92813
DM8L1Z2	DE	Discovery agent

DMEO7CP	ID	DMEO7CP
DMEO7CP	DN	GR-86014
DMEO7CP	HS	Investigative
DMEO7CP	SN	132537-24-7
DMEO7CP	DE	Discovery agent

DM9WY1D	ID	DM9WY1D
DM9WY1D	DN	GR-91272
DM9WY1D	HS	Investigative
DM9WY1D	SN	132537-23-6
DM9WY1D	DE	Discovery agent

DMBYK0X	ID	DMBYK0X
DMBYK0X	DN	GR94800
DMBYK0X	HS	Investigative
DMBYK0X	SN	GR-94800; GR 94800
DMBYK0X	DT	Small molecular drug
DMBYK0X	PC	6324620
DMBYK0X	MW	904.1
DMBYK0X	FM	C49H61N9O8
DMBYK0X	IC	InChI=1S/C49H61N9O8/c1-5-29(2)41(42(50)59)56-47(64)39-22-14-24-57(39)49(66)40-23-15-25-58(40)48(65)38(26-32-16-8-6-9-17-32)55-46(63)37(27-34-28-51-36-21-13-12-20-35(34)36)54-44(61)31(4)52-43(60)30(3)53-45(62)33-18-10-7-11-19-33/h6-13,16-21,28-31,37-41,51H,5,14-15,22-27H2,1-4H3,(H2,50,59)(H,52,60)(H,53,62)(H,54,61)(H,55,63)(H,56,64)/t29-,30-,31-,37+,38-,39-,40+,41-/m0/s1
DMBYK0X	CS	CC[C@H](C)[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)C6=CC=CC=C6
DMBYK0X	IK	KIPTYYXCLIQOHM-KKMBCTKYSA-N
DMBYK0X	IU	(2S)-N-[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-1-[(2R)-1-[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-benzamidopropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide
DMBYK0X	DE	Discovery agent

DMVLQUP	ID	DMVLQUP
DMVLQUP	DN	Grandisine C
DMVLQUP	HS	Investigative
DMVLQUP	SN	Grandisine C; CHEMBL509995; BDBM50269339
DMVLQUP	DT	Small molecular drug
DMVLQUP	PC	16086540
DMVLQUP	MW	277.36
DMVLQUP	FM	C16H23NO3
DMVLQUP	IC	InChI=1S/C16H23NO3/c1-9-7-10(18)8-13-14(9)16(19)15-11-3-2-5-17(11)6-4-12(15)20-13/h9-12,15,18H,2-8H2,1H3/t9-,10-,11-,12+,15-/m0/s1
DMVLQUP	CS	C[C@H]1C[C@@H](CC2=C1C(=O)[C@H]3[C@@H]4CCCN4CC[C@H]3O2)O
DMVLQUP	IK	WNDBXOYUMYCREE-NAYUARGSSA-N
DMVLQUP	IU	(6aR,9S,11S,12aS,12bS)-9-hydroxy-11-methyl-1,2,3,5,6,6a,8,9,10,11,12a,12b-dodecahydrochromeno[2,3-g]indolizin-12-one
DMVLQUP	DE	Discovery agent

DM0JHYF	ID	DM0JHYF
DM0JHYF	DN	Grandisine D
DM0JHYF	HS	Investigative
DM0JHYF	SN	grandisine D; (+)-Grandisine D
DM0JHYF	DT	Small molecular drug
DM0JHYF	PC	16040172
DM0JHYF	MW	259.339
DM0JHYF	FM	C16H21NO2
DM0JHYF	IC	InChI=1S/C16H21NO2/c1-11-5-2-8-14(18)15(11)16(19)12-6-3-9-17-10-4-7-13(12)17/h2,6,8,11,13,15H,3-5,7,9-10H2,1H3/t11-,13-,15+/m0/s1
DM0JHYF	CS	C[C@H]1CC=CC(=O)[C@@H]1C(=O)C2=CCCN3[C@H]2CCC3
DM0JHYF	IK	FKYCJVGMJYUVIJ-CORIIIEPSA-N
DM0JHYF	IU	(5S,6R)-6-[(8aS)-1,2,3,5,6,8a-hexahydroindolizine-8-carbonyl]-5-methylcyclohex-2-en-1-one
DM0JHYF	DE	Discovery agent

DM04S2P	ID	DM04S2P
DM04S2P	DN	Grandisine F
DM04S2P	HS	Investigative
DM04S2P	SN	Grandisine F; CHEMBL497516; BDBM50269337
DM04S2P	DT	Small molecular drug
DM04S2P	PC	16086543
DM04S2P	MW	276.37
DM04S2P	FM	C16H24N2O2
DM04S2P	IC	InChI=1S/C16H24N2O2/c1-9-7-10(17)8-13-14(9)16(19)15-11-3-2-5-18(11)6-4-12(15)20-13/h9-12,15H,2-8,17H2,1H3/t9-,10-,11-,12+,15-/m0/s1
DM04S2P	CS	C[C@H]1C[C@@H](CC2=C1C(=O)[C@H]3[C@@H]4CCCN4CC[C@H]3O2)N
DM04S2P	IK	AOYSDZUESPFRDD-NAYUARGSSA-N
DM04S2P	IU	(6aR,9S,11S,12aS,12bS)-9-amino-11-methyl-1,2,3,5,6,6a,8,9,10,11,12a,12b-dodecahydrochromeno[2,3-g]indolizin-12-one
DM04S2P	DE	Discovery agent

DM65SQK	ID	DM65SQK
DM65SQK	DN	GRANULATIMIDE
DM65SQK	HS	Investigative
DM65SQK	SN	GRANULATIMIDE; CHEMBL240747; 219828-99-6; SCHEMBL4238896; CTK1A7209; DTXSID90415922; BDBM50216165; 1,11-dihydro-1,3,5,11-tetraaza-benzo[a]trindene-4,6-dione; 3,11-Dihydro-1,3,5,11-tetraaza-benzo[a]trindene-4,6-dione; 1H-Imidazo[4,5-a]pyrrolo[3,4-c]carbazole-4,6(5H,11H)-dione
DM65SQK	DT	Small molecular drug
DM65SQK	PC	5324595
DM65SQK	MW	276.25
DM65SQK	FM	C15H8N4O2
DM65SQK	IC	InChI=1S/C15H8N4O2/c20-14-9-8-6-3-1-2-4-7(6)18-12(8)13-11(16-5-17-13)10(9)15(21)19-14/h1-5,18H,(H,16,17)(H,19,20,21)
DM65SQK	CS	C1=CC=C2C(=C1)C3=C4C(=C5C(=C3N2)NC=N5)C(=O)NC4=O
DM65SQK	IK	LBTREMHIJGMYQN-UHFFFAOYSA-N
DM65SQK	IU	3,5,9,19-tetrazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1,4,6,11,13,15,17-heptaene-8,10-dione
DM65SQK	CA	CAS 219828-99-6
DM65SQK	DE	Discovery agent

DM1PWX2	ID	DM1PWX2
DM1PWX2	DN	Grassystatin a
DM1PWX2	HS	Investigative
DM1PWX2	SN	Grassystatin A; CHEMBL567893; GTPL8674
DM1PWX2	DT	Small molecular drug
DM1PWX2	PC	44255320
DM1PWX2	MW	1174.4
DM1PWX2	FM	C58H95N9O16
DM1PWX2	IC	InChI=1S/C58H95N9O16/c1-30(2)25-38(43(69)29-45(71)64-46(36(12)68)52(74)60-35(11)54(76)66(15)42(27-37-21-18-17-19-22-37)55(77)67-24-20-23-41(67)56(78)81-16)61-51(73)40(28-44(59)70)62-50(72)39(26-31(3)4)63-53(75)48(33(7)8)82-58(80)49(34(9)10)83-57(79)47(32(5)6)65(13)14/h17-19,21-22,30-36,38-43,46-49,68-69H,20,23-29H2,1-16H3,(H2,59,70)(H,60,74)(H,61,73)(H,62,72)(H,63,75)(H,64,71)/t35-,36+,38-,39-,40-,41-,42+,43-,46-,47-,48+,49-/m0/s1
DM1PWX2	CS	C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N(C)[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)OC)NC(=O)C[C@@H]([C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)OC(=O)[C@H](C(C)C)N(C)C)O)O
DM1PWX2	IK	JZYWSTGTBRHGTL-BIXXXADNSA-N
DM1PWX2	IU	methyl (2S)-1-[(2R)-2-[[(2S)-2-[[(2S,3R)-2-[[(3S,4S)-4-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[(2S)-2-[(2S)-2-(dimethylamino)-3-methylbutanoyl]oxy-3-methylbutanoyl]oxy-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxy-6-methylheptanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]-methylamino]-3-phenylpropanoyl]pyrrolidine-2-carboxylate
DM1PWX2	DE	Discovery agent

DMXSWF6	ID	DMXSWF6
DMXSWF6	DN	grayanotoxin III
DMXSWF6	HS	Investigative
DMXSWF6	SN	grayanotoxin III; UNII-ZKR09NT58C; Andromedol; ZKR09NT58C; Deacylasebotoxin I; Deacetylandromedotoxin; 4678-45-9; NSC 323778; BRN 2059374; Grayanotoxane-3,5,6,10,14,16-hexol, (3-beta,6-beta,14R)-; grayanotoxin-III; (3beta,6beta,14R)-Grayanotoxane-3,5,6,10,14,16-hexol; GTPL2628; CHEMBL454313; SCHEMBL1008212; 7,9a-Methano-9aH-cyclopenta(b)heptalene-2,4,8,11,11a,12(1H)-hexol, dodecahydro-1,1,4,8-tetramethyl-, (2S,3as,4R,4ar,7R,8R,9as,11R,11aR,12R)-; ZINC33913426; Grayanotoxane-3,5,6,10,14,16-hexol, (3beta,6beta,14R)- (9CI)
DMXSWF6	DT	Small molecular drug
DMXSWF6	PC	11057730
DMXSWF6	MW	370.5
DMXSWF6	FM	C20H34O6
DMXSWF6	IC	InChI=1S/C20H34O6/c1-16(2)13(21)7-12-18(4,25)11-6-5-10-15(23)19(11,9-17(10,3)24)8-14(22)20(12,16)26/h10-15,21-26H,5-9H2,1-4H3/t10-,11+,12+,13+,14-,15-,17-,18-,19+,20+/m1/s1
DMXSWF6	CS	C[C@]1(C[C@@]23C[C@H]([C@]4([C@@H](C[C@@H](C4(C)C)O)[C@]([C@@H]2CC[C@@H]1[C@H]3O)(C)O)O)O)O
DMXSWF6	IK	BWMFRQKICHXLSH-FIRPSQKQSA-N
DMXSWF6	IU	(1S,3R,4R,6S,8S,9R,10R,13R,14R,16R)-5,5,9,14-tetramethyltetracyclo[11.2.1.01,10.04,8]hexadecane-3,4,6,9,14,16-hexol
DMXSWF6	CA	CAS 4678-45-9
DMXSWF6	DE	Discovery agent

DMQHJTF	ID	DMQHJTF
DMQHJTF	DN	Green tea
DMQHJTF	HS	Investigative
DMQHJTF	SN	Oxotremorine; Oxytremorine; Oxotremorin; Tremorine, oxo-; 70-22-4; 2'-Oxopyrrolidino-1-pyrrolidino-4-butyne; MLS000766260; UNII-5RY0UWH1JL; EINECS 200-728-0; 5RY0UWH1JL; NSC 330497; 1-(4-pyrrolidin-1-ylbut-2-ynyl)pyrrolidin-2-one; BRN 1530948; CHEMBL7634; 1-(4-(Pyrrolidin-1-yl)but-2-ynyl)pyrrolidin-2-one; CHEBI:7851; 2-PYRROLIDINONE, 1-(4-(1-PYRROLIDINYL)-2-BUTYNYL)-; RSDOPYMFZBJHRL-UHFFFAOYSA-N; 2-Pyrrolidinone, 1-[4-(1-pyrrolidinyl)-2-butynyl]-; Tocris-0843; Spectrum_001875; Spectrum_001448; AC1L1ILJ; Spectrum5_001099
DMQHJTF	DT	Small molecular drug
DMQHJTF	PC	4630
DMQHJTF	MW	206.28
DMQHJTF	FM	C12H18N2O
DMQHJTF	IC	InChI=1S/C12H18N2O/c15-12-6-5-11-14(12)10-4-3-9-13-7-1-2-8-13/h1-2,5-11H2
DMQHJTF	CS	C1CCN(C1)CC#CCN2CCCC2=O
DMQHJTF	IK	RSDOPYMFZBJHRL-UHFFFAOYSA-N
DMQHJTF	IU	1-(4-pyrrolidin-1-ylbut-2-ynyl)pyrrolidin-2-one
DMQHJTF	CA	CAS 70-22-4
DMQHJTF	CB	CHEBI:7851
DMQHJTF	DE	Discovery agent

DM3A0TE	ID	DM3A0TE
DM3A0TE	DN	GRI977143
DM3A0TE	HS	Investigative
DM3A0TE	SN	GRI-977143
DM3A0TE	DT	Small molecular drug
DM3A0TE	PC	73755227
DM3A0TE	MW	375.4
DM3A0TE	FM	C22H17NO3S
DM3A0TE	IC	InChI=1S/C22H17NO3S/c24-14-16-6-1-2-11-19(16)27-13-5-12-23-21(25)17-9-3-7-15-8-4-10-18(20(15)17)22(23)26/h1-4,6-11,14H,5,12-13H2
DM3A0TE	CS	C1=CC=C(C(=C1)C=O)SCCCN2C(=O)C3=CC=CC4=C3C(=CC=C4)C2=O
DM3A0TE	IK	IYUOFUODBWFCBK-UHFFFAOYSA-N
DM3A0TE	IU	2-[3-(1,3-dioxobenzo[de]isoquinolin-2-yl)propylsulfanyl]benzaldehyde
DM3A0TE	DE	Discovery agent

DMGTRZE	ID	DMGTRZE
DMGTRZE	DN	grifolic acid
DMGTRZE	HS	Investigative
DMGTRZE	SN	ilicicolinic acid B
DMGTRZE	DT	Small molecular drug
DMGTRZE	PC	9976563
DMGTRZE	MW	372.5
DMGTRZE	FM	C23H32O4
DMGTRZE	IC	InChI=1S/C23H32O4/c1-15(2)8-6-9-16(3)10-7-11-17(4)12-13-19-20(24)14-18(5)21(22(19)25)23(26)27/h8,10,12,14,24-25H,6-7,9,11,13H2,1-5H3,(H,26,27)/b16-10+,17-12+
DMGTRZE	CS	CC1=CC(=C(C(=C1C(=O)O)O)C/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C)O
DMGTRZE	IK	QPIZDZGIXDKCRC-JTCWOHKRSA-N
DMGTRZE	IU	2,4-dihydroxy-6-methyl-3-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]benzoic acid
DMGTRZE	DE	Discovery agent

DML09OS	ID	DML09OS
DML09OS	DN	GRL-0667
DML09OS	HS	Investigative
DML09OS	SN	BDBM50007789; CHEMBL1173044; GRM; Q27460878; SCHEMBL7938638
DML09OS	TC	Antiviral Agents
DML09OS	DT	Small molecular drug
DML09OS	PC	46174170
DML09OS	MW	416.5
DML09OS	FM	C26H28N2O3
DML09OS	IC	InChI=1S/C26H28N2O3/c1-18(22-8-4-6-20-5-2-3-7-23(20)22)28-13-11-21(12-14-28)26(29)27-16-19-9-10-24-25(15-19)31-17-30-24/h2-10,15,18,21H,11-14,16-17H2,1H3,(H,27,29)/t18-/m1/s1
DML09OS	CS	C[C@H](C1=CC=CC2=CC=CC=C21)N3CCC(CC3)C(=O)NCC4=CC5=C(C=C4)OCO5
DML09OS	IK	IVXBCFLWMPMSAP-GOSISDBHSA-N
DML09OS	IU	N-(1,3-benzodioxol-5-ylmethyl)-1-[(1R)-1-naphthalen-1-ylethyl]piperidine-4-carboxamide
DML09OS	CB	CHEBI:149790
DML09OS	DE	Severe acute respiratory syndrome (SARS)

DMR93MK	ID	DMR93MK
DMR93MK	DN	GRL-7234
DMR93MK	HS	Investigative
DMR93MK	SN	GRL-7234; N-[(1s,2s,4r)-2-Hydroxy-1-Isobutyl-5-({(1s)-1-[(Isopropylamino)carbonyl]-2-Methylpropyl}amino)-4-Methyl-5-Oxopentyl]-5-[methyl(Methylsulfonyl)amino]-N'-[(1r)-1-Phenylethyl]isophthalamide; 2p4j; Isophthalamide Derivative 5d; CHEMBL387771; BDBM16259; 23I; 1-N-[(1R,3S,4S)-3-hydroxy-1,6-dimethyl-1-{[(1S)-2-methyl-1-(propan-2-ylcarbamoyl)propyl]carbamoyl}heptan-4-yl]-5-(N-methylmethanesulfonamido)-3-N-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
DMR93MK	DT	Small molecular drug
DMR93MK	PC	16659106
DMR93MK	MW	701.9
DMR93MK	FM	C36H55N5O7S
DMR93MK	IC	InChI=1S/C36H55N5O7S/c1-21(2)16-30(31(42)17-24(7)33(43)40-32(22(3)4)36(46)37-23(5)6)39-35(45)28-18-27(19-29(20-28)41(9)49(10,47)48)34(44)38-25(8)26-14-12-11-13-15-26/h11-15,18-25,30-32,42H,16-17H2,1-10H3,(H,37,46)(H,38,44)(H,39,45)(H,40,43)/t24-,25-,30+,31+,32+/m1/s1
DMR93MK	CS	C[C@H](C[C@@H]([C@H](CC(C)C)NC(=O)C1=CC(=CC(=C1)C(=O)N[C@H](C)C2=CC=CC=C2)N(C)S(=O)(=O)C)O)C(=O)N[C@@H](C(C)C)C(=O)NC(C)C
DMR93MK	IK	BJOCXJJVELLFKM-LLWRDSBASA-N
DMR93MK	IU	3-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[[(2S)-3-methyl-1-oxo-1-(propan-2-ylamino)butan-2-yl]amino]-8-oxooctan-4-yl]-5-[methyl(methylsulfonyl)amino]-1-N-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
DMR93MK	DE	Discovery agent

DMJ47DM	ID	DMJ47DM
DMJ47DM	DN	GRN-529
DMJ47DM	HS	Investigative
DMJ47DM	SN	IDDBCP263385
DMJ47DM	CP	Pfizer Inc
DMJ47DM	DT	Small molecular drug
DMJ47DM	PC	59548652
DMJ47DM	MW	391.4
DMJ47DM	FM	C22H15F2N3O2
DMJ47DM	IC	InChI=1S/C22H15F2N3O2/c23-22(24)29-20-9-7-16(12-15(20)6-8-18-5-1-2-10-25-18)21(28)27-13-17-4-3-11-26-19(17)14-27/h1-5,7,9-12,22H,13-14H2
DMJ47DM	CS	C1C2=C(CN1C(=O)C3=CC(=C(C=C3)OC(F)F)C#CC4=CC=CC=N4)N=CC=C2
DMJ47DM	IK	JITMSIRHBAVREW-UHFFFAOYSA-N
DMJ47DM	IU	[4-(difluoromethoxy)-3-(2-pyridin-2-ylethynyl)phenyl]-(5,7-dihydropyrrolo[3,4-b]pyridin-6-yl)methanone
DMJ47DM	CA	CAS 1253291-12-1
DMJ47DM	DE	Major depressive disorder

DMO6IM1	ID	DMO6IM1
DMO6IM1	DN	group E 1682-2106
DMO6IM1	HS	Investigative
DMO6IM1	SN	CHEMBL1770295; 3-methyl-2-[(5Z)-5-(1-methyl-2-oxoindol-3-ylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid; AC1NT1C6; GTPL5827; MolPort-000-500-334; BDBM50418364; AKOS016308025; AKOS002200571; ST50147548; UNM000000513101; group E 1682-2106 [PMID:16118363]; 3-METHYL-2-[(5Z)-5-(1-METHYL-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)-4-OXO-2-THIOXO-1,3-THIAZOLIDIN-3-YL]BUTANOIC ACID; 3-methyl-2-[5-(1-methyl-2-oxobenzo[d]azolin-3-ylidene)-4-oxo-2-thioxo(1,3-thia zolidin-3-yl)]butanoic acid
DMO6IM1	DT	Small molecular drug
DMO6IM1	PC	5322194
DMO6IM1	MW	376.5
DMO6IM1	FM	C17H16N2O4S2
DMO6IM1	IC	InChI=1S/C17H16N2O4S2/c1-8(2)12(16(22)23)19-15(21)13(25-17(19)24)11-9-6-4-5-7-10(9)18(3)14(11)20/h4-8,12H,1-3H3,(H,22,23)/b13-11-
DMO6IM1	CS	CC(C)C(C(=O)O)N1C(=O)/C(=C/2\\C3=CC=CC=C3N(C2=O)C)/SC1=S
DMO6IM1	IK	ICRQMQBVDGOOFY-QBFSEMIESA-N
DMO6IM1	IU	3-methyl-2-[(5Z)-5-(1-methyl-2-oxoindol-3-ylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid
DMO6IM1	DE	Discovery agent

DMG0OUD	ID	DMG0OUD
DMG0OUD	DN	GS4071
DMG0OUD	HS	Investigative
DMG0OUD	SN	Oseltamivir acid; 187227-45-8; Oseltamivir carboxylate; Oseltamivir (acid); GS 4071; Ro 64-0802; UNII-K6106LV5Q8; CHEMBL674; CHEBI:73139; K6106LV5Q8; GS-4071; (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid; 5-N-ACETYL-3-(1-ETHYLPROPYL)-1-CYCLOHEXENE-1-CARBOXYLIC ACID; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, (3R,4R,5S)-; (3r,4r,5s)-4-(Acetylamino)-5-Amino-3-(Pentan-3-Yloxy)cyclohex-1-Ene-1-Carboxylic Acid; G39; Oseltamivir-carboxylate; 2,4-diamino triazine
DMG0OUD	DT	Small molecular drug
DMG0OUD	PC	449381
DMG0OUD	MW	284.35
DMG0OUD	FM	C14H24N2O4
DMG0OUD	IC	InChI=1S/C14H24N2O4/c1-4-10(5-2)20-12-7-9(14(18)19)6-11(15)13(12)16-8(3)17/h7,10-13H,4-6,15H2,1-3H3,(H,16,17)(H,18,19)/t11-,12+,13+/m0/s1
DMG0OUD	CS	CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)O
DMG0OUD	IK	NENPYTRHICXVCS-YNEHKIRRSA-N
DMG0OUD	IU	(3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylic acid
DMG0OUD	CA	CAS 187227-45-8
DMG0OUD	CB	CHEBI:73139
DMG0OUD	DE	Discovery agent

DMEGY3Q	ID	DMEGY3Q
DMEGY3Q	DN	GS-9256 + tegobuvir
DMEGY3Q	HS	Investigative
DMEGY3Q	DE	Discovery agent

DMTKGA3	ID	DMTKGA3
DMTKGA3	DN	GSC-1
DMTKGA3	HS	Investigative
DMTKGA3	SN	Alpha-glucosidase inhibitor (hyperglycemia), Dharma Biomedical
DMTKGA3	CP	Dharma Biomedical
DMTKGA3	DE	Hyperglycemia

DMC2ZF6	ID	DMC2ZF6
DMC2ZF6	DN	GSK-008A
DMC2ZF6	HS	Investigative
DMC2ZF6	SN	Progesterone receptor agonists (gynecological disorder); Progesterone receptor agonists (gynecological disorder), GSK
DMC2ZF6	CP	GlaxoSmithKline plc
DMC2ZF6	DE	Gynecological disease

DMNIVOX	ID	DMNIVOX
DMNIVOX	DN	GSK-0660
DMNIVOX	HS	Investigative
DMNIVOX	SN	GSK0660; 1014691-61-2; GSK 0660; GSK-0660; CHEMBL592652; 3-[[[2-Methoxy-4-(phenylamino)phenyl]amino]sulfonyl]-2-thiophenecarboxylicacidmethylester; methyl 3-[(4-anilino-2-methoxyphenyl)sulfamoyl]thiophene-2-carboxylate; C19H18N2O5S2; methyl 3-(N-(2-methoxy-4-(phenylamino)phenyl)sulfamoyl)thiophene-2-carboxylate; 3-(((2-Methoxy-4-(phenylamino)phenyl)amino]sulfonyl)-2-thiophenecarboxylic acid methyl ester; 3-[[[2-METHOXY-4-(PHENYLAMINO)PHENYL]AMINO]SULFONYL]-2-THIOPHENECARBOXYLIC ACID METHYL ESTER
DMNIVOX	DT	Small molecular drug
DMNIVOX	PC	46233311
DMNIVOX	MW	418.5
DMNIVOX	FM	C19H18N2O5S2
DMNIVOX	IC	InChI=1S/C19H18N2O5S2/c1-25-16-12-14(20-13-6-4-3-5-7-13)8-9-15(16)21-28(23,24)17-10-11-27-18(17)19(22)26-2/h3-12,20-21H,1-2H3
DMNIVOX	CS	COC1=C(C=CC(=C1)NC2=CC=CC=C2)NS(=O)(=O)C3=C(SC=C3)C(=O)OC
DMNIVOX	IK	NDFKBGWLUHKMFY-UHFFFAOYSA-N
DMNIVOX	IU	methyl 3-[(4-anilino-2-methoxyphenyl)sulfamoyl]thiophene-2-carboxylate
DMNIVOX	CA	CAS 1014691-61-2
DMNIVOX	CB	CHEBI:94813
DMNIVOX	DE	Discovery agent

DMDHZR1	ID	DMDHZR1
DMDHZR1	DN	GSK1016790A
DMDHZR1	HS	Investigative
DMDHZR1	SN	GSK1016790A; 942206-85-1; GSK 1016790A; GSK-1016790A; GSK101; (N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide; IVYQPSHHYIAUFO-VXKWHMMOSA-N; GTPL4205; SCHEMBL5007988; DTXSID30635248; CHEBI:140524; MolPort-044-560-329; EX-A1885; s8107; MFCD12912413; ZINC95571016; AKOS030527025; CS-5660; NCGC00250409-01
DMDHZR1	DT	Small molecular drug
DMDHZR1	PC	23630211
DMDHZR1	MW	655.6
DMDHZR1	FM	C28H32Cl2N4O6S2
DMDHZR1	IC	InChI=1S/C28H32Cl2N4O6S2/c1-17(2)13-21(31-26(36)24-14-18-5-3-4-6-23(18)41-24)27(37)33-9-11-34(12-10-33)28(38)22(16-35)32-42(39,40)25-8-7-19(29)15-20(25)30/h3-8,14-15,17,21-22,32,35H,9-13,16H2,1-2H3,(H,31,36)/t21-,22-/m0/s1
DMDHZR1	CS	CC(C)C[C@@H](C(=O)N1CCN(CC1)C(=O)[C@H](CO)NS(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)NC(=O)C3=CC4=CC=CC=C4S3
DMDHZR1	IK	IVYQPSHHYIAUFO-VXKWHMMOSA-N
DMDHZR1	IU	N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide
DMDHZR1	CA	CAS 942206-85-1
DMDHZR1	CB	CHEBI:140524
DMDHZR1	DE	Discovery agent

DMIWY7Q	ID	DMIWY7Q
DMIWY7Q	DN	GSK1331268
DMIWY7Q	HS	Investigative
DMIWY7Q	SN	GSK 1331268; GSK-1331268
DMIWY7Q	DT	Small molecular drug
DMIWY7Q	PC	46190878
DMIWY7Q	MW	342.8
DMIWY7Q	FM	C17H19ClN6
DMIWY7Q	IC	InChI=1S/C17H19ClN6/c1-22-15-5-3-2-4-14(15)21-16(22)12-23-6-8-24(9-7-23)17-19-10-13(18)11-20-17/h2-5,10-11H,6-9,12H2,1H3
DMIWY7Q	CS	CN1C2=CC=CC=C2N=C1CN3CCN(CC3)C4=NC=C(C=N4)Cl
DMIWY7Q	IK	IXXZGBOSQDVMTC-UHFFFAOYSA-N
DMIWY7Q	IU	2-[[4-(5-chloropyrimidin-2-yl)piperazin-1-yl]methyl]-1-methylbenzimidazole
DMIWY7Q	CA	CAS 1207197-70-3
DMIWY7Q	DE	Discovery agent

DMHBUG5	ID	DMHBUG5
DMHBUG5	DN	GSK-1344386B
DMHBUG5	HS	Investigative
DMHBUG5	SN	CCR2 antagonist (atherosclerosis); CCR2 antagonist (atherosclerosis), GlaxoSmithKline
DMHBUG5	CP	GlaxoSmithKline plc
DMHBUG5	DE	Arteriosclerosis

DMZUTXW	ID	DMZUTXW
DMZUTXW	DN	GSK1511931
DMZUTXW	HS	Investigative
DMZUTXW	SN	GSK1511931A; GSK-1511931; compound 14 [PMID: 19081716]
DMZUTXW	DT	Small molecular drug
DMZUTXW	PC	44581765
DMZUTXW	MW	508.6
DMZUTXW	FM	C29H32N8O
DMZUTXW	IC	InChI=1S/C29H32N8O/c1-19(2)36-14-16-37(17-15-36)20-9-10-25(26(18-20)38-3)33-29-34-27-22(11-13-31-27)28(35-29)32-24-8-4-7-23-21(24)6-5-12-30-23/h4-13,18-19H,14-17H2,1-3H3,(H3,31,32,33,34,35)
DMZUTXW	CS	CC(C)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)NC5=CC=CC6=C5C=CC=N6)OC
DMZUTXW	IK	PEPOAPKYASCEKL-UHFFFAOYSA-N
DMZUTXW	IU	2-N-[2-methoxy-4-(4-propan-2-ylpiperazin-1-yl)phenyl]-4-N-quinolin-5-yl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
DMZUTXW	DE	Discovery agent

DMKN76P	ID	DMKN76P
DMKN76P	DN	GSK-1564023A
DMKN76P	HS	Investigative
DMKN76P	SN	CHEMBL1093774; GSK-1564023A; SCHEMBL17963371; GSK1564023A
DMKN76P	DT	Small molecular drug
DMKN76P	PC	46830196
DMKN76P	MW	409.9
DMKN76P	FM	C21H20ClN5O2
DMKN76P	IC	InChI=1S/C21H20ClN5O2/c1-11-18-19(22)16(10-23-20(18)27(4)25-11)21(28)24-9-14-5-7-15(8-6-14)17-12(2)26-29-13(17)3/h5-8,10H,9H2,1-4H3,(H,24,28)
DMKN76P	CS	CC1=C(C(=NO1)C)C2=CC=C(C=C2)CNC(=O)C3=CN=C4C(=C3Cl)C(=NN4C)C
DMKN76P	IK	QWZQPWUWGYGVOC-UHFFFAOYSA-N
DMKN76P	IU	4-chloro-N-[[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methyl]-1,3-dimethylpyrazolo[3,4-b]pyridine-5-carboxamide
DMKN76P	DE	Discovery agent

DMG6TL7	ID	DMG6TL7
DMG6TL7	DN	GSK1614343
DMG6TL7	HS	Investigative
DMG6TL7	SN	GSK-1614343; GSK 1614343
DMG6TL7	DT	Small molecular drug
DMG6TL7	PC	25124566
DMG6TL7	MW	487.4
DMG6TL7	FM	C22H23F6N5O
DMG6TL7	IC	InChI=1S/C22H23F6N5O/c23-21(24,25)15-9-16(22(26,27)28)11-17(10-15)30-31-20(34)19(14-3-1-5-29-12-14)33-8-7-32-6-2-4-18(32)13-33/h1,3,5,9-12,18-19,30H,2,4,6-8,13H2,(H,31,34)/t18-,19-/m1/s1
DMG6TL7	CS	C1C[C@@H]2CN(CCN2C1)[C@H](C3=CN=CC=C3)C(=O)NNC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMG6TL7	IK	QNOSCJDGJKVFJR-RTBURBONSA-N
DMG6TL7	IU	(2R)-2-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-N'-[3,5-bis(trifluoromethyl)phenyl]-2-pyridin-3-ylacetohydrazide
DMG6TL7	DE	Discovery agent

DM9IZNP	ID	DM9IZNP
DM9IZNP	DN	GSK-172981
DM9IZNP	HS	Investigative
DM9IZNP	SN	GSK-256471; SB-218795; SB-235375; SB-244487; SB-400238; SB-414240; SK-797230; NK-2 antagonists, GSK; NK-3 antagonists, GlaxoSmithKline; NK-3 antagonists, SB
DM9IZNP	CP	SmithKline Beecham SpA
DM9IZNP	DT	Small molecular drug
DM9IZNP	PC	25195091
DM9IZNP	MW	411.5
DM9IZNP	FM	C26H22FN3O
DM9IZNP	IC	InChI=1S/C26H22FN3O/c27-19-10-6-9-18(15-19)25-23(28)22(20-11-4-5-12-21(20)29-25)26(31)30-24(17-13-14-17)16-7-2-1-3-8-16/h1-12,15,17,24H,13-14,28H2,(H,30,31)/t24-/m1/s1
DM9IZNP	CS	C1CC1[C@@H](C2=CC=CC=C2)NC(=O)C3=C(C(=NC4=CC=CC=C43)C5=CC(=CC=C5)F)N
DM9IZNP	IK	ZKGNLARKIMWKFE-XMMPIXPASA-N
DM9IZNP	IU	3-amino-N-[(S)-cyclopropyl(phenyl)methyl]-2-(3-fluorophenyl)quinoline-4-carboxamide
DM9IZNP	DE	Asthma

DM4HLK3	ID	DM4HLK3
DM4HLK3	DN	GSK-1838705A
DM4HLK3	HS	Investigative
DM4HLK3	SN	GSK 1838705A; GSK1838705A
DM4HLK3	DT	Small molecular drug
DM4HLK3	PC	25182616
DM4HLK3	MW	532.6
DM4HLK3	FM	C27H29FN8O3
DM4HLK3	IC	InChI=1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34)
DM4HLK3	CS	CNC(=O)C1=C(C=CC=C1F)NC2=NC(=NC3=C2C=CN3)NC4=C(C=C5CCN(C5=C4)C(=O)CN(C)C)OC
DM4HLK3	IK	HZTYDQRUAWIZRE-UHFFFAOYSA-N
DM4HLK3	IU	2-[[2-[[1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide
DM4HLK3	CA	CAS 1116235-97-2
DM4HLK3	CB	CHEBI:93768
DM4HLK3	DE	Discovery agent

DM2KT17	ID	DM2KT17
DM2KT17	DN	GSK-1842799C
DM2KT17	HS	Investigative
DM2KT17	SN	PPI-4691; S1P1 agonists, Praecis
DM2KT17	CP	Praecis Pharmaceuticals Inc
DM2KT17	DE	Cardiovascular disease

DMMWBU6	ID	DMMWBU6
DMMWBU6	DN	GSK-188909
DMMWBU6	HS	Investigative
DMMWBU6	SN	GSK188909; CHEMBL253641; SCHEMBL5222560; BMCL181022 Compound 23; BDBM26788
DMMWBU6	DT	Small molecular drug
DMMWBU6	DE	Discovery agent

DMKXPOL	ID	DMKXPOL
DMKXPOL	DN	GSK189254A
DMKXPOL	HS	Investigative
DMKXPOL	SN	720690-73-3; GSK 189254A; GSK-189254; GSK189254A; UNII-5T4TX6CO53; GSK189254; CHEMBL517140; 5T4TX6CO53; 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide; 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide; WROHEWWOCPRMIA-UHFFFAOYSA-N; 854485-15-7; GSK-189254A; SCHEMBL169579; ZINC3961799; AOB87474; EX-A1905; ABP000814; BDBM50247054; AKOS032944981; CS-6206; BCP9000737; GSK-189,254; KB-77605; HY-14111
DMKXPOL	CP	GlaxoSmithKline
DMKXPOL	DT	Small molecular drug
DMKXPOL	PC	9798547
DMKXPOL	MW	351.4
DMKXPOL	FM	C21H25N3O2
DMKXPOL	IC	InChI=1S/C21H25N3O2/c1-22-21(25)17-6-8-20(23-14-17)26-19-7-5-15-9-11-24(18-3-2-4-18)12-10-16(15)13-19/h5-8,13-14,18H,2-4,9-12H2,1H3,(H,22,25)
DMKXPOL	CS	CNC(=O)C1=CN=C(C=C1)OC2=CC3=C(CCN(CC3)C4CCC4)C=C2
DMKXPOL	IK	WROHEWWOCPRMIA-UHFFFAOYSA-N
DMKXPOL	IU	6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide
DMKXPOL	CA	CAS 720690-73-3
DMKXPOL	DE	Cognitive impairment

DM9GPAU	ID	DM9GPAU
DM9GPAU	DN	GSK2033
DM9GPAU	HS	Investigative
DM9GPAU	SN	GSK 2033; GSK-2033
DM9GPAU	DT	Small molecular drug
DM9GPAU	PC	46203250
DM9GPAU	MW	591.7
DM9GPAU	FM	C29H28F3NO5S2
DM9GPAU	IC	InChI=1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4H3
DM9GPAU	CS	CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C)CC4=CC=C(O4)C(F)(F)F)C
DM9GPAU	IK	PSOXOVKYGWBTPB-UHFFFAOYSA-N
DM9GPAU	IU	2,4,6-trimethyl-N-[[4-(3-methylsulfonylphenyl)phenyl]methyl]-N-[[5-(trifluoromethyl)furan-2-yl]methyl]benzenesulfonamide
DM9GPAU	DE	Discovery agent

DMY2XV3	ID	DMY2XV3
DMY2XV3	DN	GSK2193874
DMY2XV3	HS	Investigative
DMY2XV3	SN	GSK 2193874; GSK-2193874
DMY2XV3	DT	Small molecular drug
DMY2XV3	PC	53464483
DMY2XV3	MW	691.6
DMY2XV3	FM	C37H38BrF3N4O
DMY2XV3	IC	InChI=1S/C37H38BrF3N4O/c38-28-12-13-30-32(23-28)42-34(25-8-7-11-27(22-25)37(39,40)41)31(24-44-20-14-29(15-21-44)45-18-5-2-6-19-45)33(30)35(46)43-36(16-17-36)26-9-3-1-4-10-26/h1,3-4,7-13,22-23,29H,2,5-6,14-21,24H2,(H,43,46)
DMY2XV3	CS	C1CCN(CC1)C2CCN(CC2)CC3=C(C4=C(C=C(C=C4)Br)N=C3C5=CC(=CC=C5)C(F)(F)F)C(=O)NC6(CC6)C7=CC=CC=C7
DMY2XV3	IK	UIVOZBSCHXCGPS-UHFFFAOYSA-N
DMY2XV3	IU	7-bromo-N-(1-phenylcyclopropyl)-3-[(4-piperidin-1-ylpiperidin-1-yl)methyl]-2-[3-(trifluoromethyl)phenyl]quinoline-4-carboxamide
DMY2XV3	DE	Discovery agent

DMZ2TD9	ID	DMZ2TD9
DMZ2TD9	DN	GSK2194069
DMZ2TD9	HS	Investigative
DMZ2TD9	SN	GSK-2194069; GSK 2194069
DMZ2TD9	DT	Small molecular drug
DMZ2TD9	PC	67376285
DMZ2TD9	MW	428.5
DMZ2TD9	FM	C25H24N4O3
DMZ2TD9	IC	InChI=1S/C25H24N4O3/c30-24(18-1-2-18)28-11-9-16(15-28)13-23-26-27-25(31)29(23)21-6-3-17(4-7-21)19-5-8-22-20(14-19)10-12-32-22/h3-8,10,12,14,16,18H,1-2,9,11,13,15H2,(H,27,31)/t16-/m0/s1
DMZ2TD9	CS	C1CN(C[C@@H]1CC2=NNC(=O)N2C3=CC=C(C=C3)C4=CC5=C(C=C4)OC=C5)C(=O)C6CC6
DMZ2TD9	IK	AQTPWCUIYUOEMG-INIZCTEOSA-N
DMZ2TD9	IU	4-[4-(1-benzofuran-5-yl)phenyl]-3-[[(3S)-1-(cyclopropanecarbonyl)pyrrolidin-3-yl]methyl]-1H-1,2,4-triazol-5-one
DMZ2TD9	DE	Discovery agent

DM0DKQN	ID	DM0DKQN
DM0DKQN	DN	GSK-2210875
DM0DKQN	HS	Investigative
DM0DKQN	SN	GSK-1222392; GSK-1331258; GSK-1635157; GSK-329771; GSK-355089; GSK-817755
DM0DKQN	CP	GlaxoSmithKline plc
DM0DKQN	DT	Small molecular drug
DM0DKQN	PC	1489963
DM0DKQN	MW	302.35
DM0DKQN	FM	C14H14N4O2S
DM0DKQN	IC	InChI=1S/C14H14N4O2S/c1-9-12(21-13-15-8-16-18(9)13)10(2)20-14(19)17-11-6-4-3-5-7-11/h3-8,10H,1-2H3,(H,17,19)/t10-/m1/s1
DM0DKQN	CS	CC1=C(SC2=NC=NN12)[C@@H](C)OC(=O)NC3=CC=CC=C3
DM0DKQN	IK	AOUUMBPBMVOBSP-SNVBAGLBSA-N
DM0DKQN	IU	[(1R)-1-(6-methyl-[1,3]thiazolo[3,2-b][1,2,4]triazol-5-yl)ethyl] N-phenylcarbamate
DM0DKQN	DE	Anxiety disorder

DM3BI7R	ID	DM3BI7R
DM3BI7R	DN	GSK-2334470
DM3BI7R	HS	Investigative
DM3BI7R	SN	PDK1 inhibitors, GlaxoSmithKline
DM3BI7R	CP	GlaxoSmithKline plc
DM3BI7R	DT	Small molecular drug
DM3BI7R	PC	46215815
DM3BI7R	MW	462.6
DM3BI7R	FM	C25H34N8O
DM3BI7R	IC	InChI=1S/C25H34N8O/c1-15-8-9-17(24(34)28-18-6-4-3-5-7-18)14-33(15)22-13-20(29-25(27-2)30-22)16-10-11-19-21(12-16)31-32-23(19)26/h10-13,15,17-18H,3-9,14H2,1-2H3,(H,28,34)(H3,26,31,32)(H,27,29,30)/t15-,17+/m1/s1
DM3BI7R	CS	C[C@@H]1CC[C@@H](CN1C2=NC(=NC(=C2)C3=CC4=C(C=C3)C(=NN4)N)NC)C(=O)NC5CCCCC5
DM3BI7R	IK	QLPHOXTXAKOFMU-WBVHZDCISA-N
DM3BI7R	IU	(3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl]-N-cyclohexyl-6-methylpiperidine-3-carboxamide
DM3BI7R	CA	CAS 1227911-45-6
DM3BI7R	CB	CHEBI:91465
DM3BI7R	DE	Solid tumour/cancer

DMLASOF	ID	DMLASOF
DMLASOF	DN	GSK2606414
DMLASOF	HS	Investigative
DMLASOF	SN	GSK PERK Inhibitor; 3-fluoro-GSK2606414; compound 38 [PMID: 22827572]
DMLASOF	DT	Small molecular drug
DMLASOF	PC	53469448
DMLASOF	MW	451.4
DMLASOF	FM	C24H20F3N5O
DMLASOF	IC	InChI=1S/C24H20F3N5O/c1-31-12-18(21-22(28)29-13-30-23(21)31)15-5-6-19-16(11-15)7-8-32(19)20(33)10-14-3-2-4-17(9-14)24(25,26)27/h2-6,9,11-13H,7-8,10H2,1H3,(H2,28,29,30)
DMLASOF	CS	CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F
DMLASOF	IK	SIXVRXARNAVBTC-UHFFFAOYSA-N
DMLASOF	IU	1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone
DMLASOF	CA	CAS 1337531-36-8
DMLASOF	DE	Discovery agent

DM325YR	ID	DM325YR
DM325YR	DN	GSK-280
DM325YR	HS	Investigative
DM325YR	SN	P38 kinase inhibitors (inflammation), GSK
DM325YR	CP	GlaxoSmithKline plc
DM325YR	DE	Inflammation

DMDSK9N	ID	DMDSK9N
DMDSK9N	DN	GSK2801
DMDSK9N	HS	Investigative
DMDSK9N	SN	KB-146016
DMDSK9N	DT	Small molecular drug
DMDSK9N	PC	73010930
DMDSK9N	MW	371.5
DMDSK9N	FM	C20H21NO4S
DMDSK9N	IC	InChI=1S/C20H21NO4S/c1-4-11-25-15-9-10-21-18(14(2)22)13-17(19(21)12-15)16-7-5-6-8-20(16)26(3,23)24/h5-10,12-13H,4,11H2,1-3H3
DMDSK9N	CS	CCCOC1=CC2=C(C=C(N2C=C1)C(=O)C)C3=CC=CC=C3S(=O)(=O)C
DMDSK9N	IK	KHWCPNJRJCNVRI-UHFFFAOYSA-N
DMDSK9N	IU	1-[1-(2-methylsulfonylphenyl)-7-propoxyindolizin-3-yl]ethanone
DMDSK9N	DE	Discovery agent

DM1865H	ID	DM1865H
DM1865H	DN	GSK-325971A
DM1865H	HS	Investigative
DM1865H	SN	CHEMBL1093602; GSK-325971A; SCHEMBL4938465; GSK325971A
DM1865H	DT	Small molecular drug
DM1865H	PC	46883841
DM1865H	MW	342.8
DM1865H	FM	C18H19ClN4O
DM1865H	IC	InChI=1S/C18H19ClN4O/c1-4-23-17-14(10-22-23)16(19)15(9-20-17)18(24)21-8-13-6-5-11(2)7-12(13)3/h5-7,9-10H,4,8H2,1-3H3,(H,21,24)
DM1865H	CS	CCN1C2=NC=C(C(=C2C=N1)Cl)C(=O)NCC3=C(C=C(C=C3)C)C
DM1865H	IK	XLMANSLWCIMZAE-UHFFFAOYSA-N
DM1865H	IU	4-chloro-N-[(2,4-dimethylphenyl)methyl]-1-ethylpyrazolo[3,4-b]pyridine-5-carboxamide
DM1865H	DE	Discovery agent

DM5EO3F	ID	DM5EO3F
DM5EO3F	DN	GSK-334429
DM5EO3F	HS	Investigative
DM5EO3F	SN	GSK-357868; GSK-678103; H3 antagonists (cognitive disorder); H3 antagonists (cognitive disorder), GlaxoSmithKline
DM5EO3F	CP	GlaxoSmithKline plc
DM5EO3F	PC	11452311
DM5EO3F	MW	398.5
DM5EO3F	FM	C20H29F3N4O
DM5EO3F	IC	InChI=1S/C20H29F3N4O/c1-15(2)25-8-3-9-27(13-12-25)19(28)16-6-10-26(11-7-16)17-4-5-18(24-14-17)20(21,22)23/h4-5,14-16H,3,6-13H2,1-2H3
DM5EO3F	CS	CC(C)N1CCCN(CC1)C(=O)C2CCN(CC2)C3=CN=C(C=C3)C(F)(F)F
DM5EO3F	IK	AHHPKVQYHXNBQN-UHFFFAOYSA-N
DM5EO3F	IU	(4-propan-2-yl-1,4-diazepan-1-yl)-[1-[6-(trifluoromethyl)pyridin-3-yl]piperidin-4-yl]methanone
DM5EO3F	DE	Cognitive impairment

DM9QU5Y	ID	DM9QU5Y
DM9QU5Y	DN	GSK343
DM9QU5Y	HS	Investigative
DM9QU5Y	SN	compound 6 [PMID 24900432]; GSK 343
DM9QU5Y	DT	Small molecular drug
DM9QU5Y	PC	71268957
DM9QU5Y	MW	541.7
DM9QU5Y	FM	C31H39N7O2
DM9QU5Y	IC	InChI=1S/C31H39N7O2/c1-6-7-23-14-21(4)35-31(40)26(23)18-33-30(39)25-15-24(16-28-27(25)19-34-38(28)20(2)3)22-8-9-32-29(17-22)37-12-10-36(5)11-13-37/h8-9,14-17,19-20H,6-7,10-13,18H2,1-5H3,(H,33,39)(H,35,40)
DM9QU5Y	CS	CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC(=NC=C4)N5CCN(CC5)C)C(C)C
DM9QU5Y	IK	ULNXAWLQFZMIHX-UHFFFAOYSA-N
DM9QU5Y	IU	N-[(6-methyl-2-oxo-4-propyl-1H-pyridin-3-yl)methyl]-6-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-1-propan-2-ylindazole-4-carboxamide
DM9QU5Y	CA	CAS 1346704-33-3
DM9QU5Y	DE	Discovery agent

DMKDLB7	ID	DMKDLB7
DMKDLB7	DN	GSK-3787
DMKDLB7	HS	Investigative
DMKDLB7	SN	GSK3787; 188591-46-0; GSK 3787; GSK-3787; 4-Chloro-N-[2-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]ethyl]benzamide; CHEMBL598608; 4-Chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide; 4-chloro-N-[2-[5-(trifluoromethyl)pyridin-2-yl]sulfonylethyl]benzamide; Benzamide, 4-chloro-N-[2-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]ethyl]-; Maybridge3_000547; AC1MCTIO; C15H12ClF3N2O3S; MLS006012025; SCHEMBL14968834; CTK8E8261; KS-00000XJC; AOB6285; QCR-146; EX-A704; DTXSID00384175; MolPort-002-892-395; HMS1432I19
DMKDLB7	DT	Small molecular drug
DMKDLB7	PC	2800647
DMKDLB7	MW	392.8
DMKDLB7	FM	C15H12ClF3N2O3S
DMKDLB7	IC	InChI=1S/C15H12ClF3N2O3S/c16-12-4-1-10(2-5-12)14(22)20-7-8-25(23,24)13-6-3-11(9-21-13)15(17,18)19/h1-6,9H,7-8H2,(H,20,22)
DMKDLB7	CS	C1=CC(=CC=C1C(=O)NCCS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)Cl
DMKDLB7	IK	JFUIMTGOQCQTPF-UHFFFAOYSA-N
DMKDLB7	IU	4-chloro-N-[2-[5-(trifluoromethyl)pyridin-2-yl]sulfonylethyl]benzamide
DMKDLB7	CA	CAS 188591-46-0
DMKDLB7	DE	Discovery agent

DMQR7TZ	ID	DMQR7TZ
DMQR7TZ	DN	GSK-3beta inhibitor II
DMQR7TZ	HS	Investigative
DMQR7TZ	SN	GSK-3b inhibitor II
DMQR7TZ	DT	Small molecular drug
DMQR7TZ	PC	6539732
DMQR7TZ	MW	395.22
DMQR7TZ	FM	C14H10IN3OS
DMQR7TZ	IC	InChI=1S/C14H10IN3OS/c15-12-3-1-2-10(8-12)9-20-14-18-17-13(19-14)11-4-6-16-7-5-11/h1-8H,9H2
DMQR7TZ	CS	C1=CC(=CC(=C1)I)CSC2=NN=C(O2)C3=CC=NC=C3
DMQR7TZ	IK	ZRHRPGSSSVYBRG-UHFFFAOYSA-N
DMQR7TZ	IU	2-[(3-iodophenyl)methylsulfanyl]-5-pyridin-4-yl-1,3,4-oxadiazole
DMQR7TZ	CA	CAS 478482-75-6
DMQR7TZ	CB	CHEBI:91342
DMQR7TZ	DE	Discovery agent

DM734QB	ID	DM734QB
DM734QB	DN	GSK-3beta inhibitor XI
DM734QB	HS	Investigative
DM734QB	SN	GSK-3b inhibitor XI
DM734QB	DT	Small molecular drug
DM734QB	PC	10020713
DM734QB	MW	349.3
DM734QB	FM	C18H15N5O3
DM734QB	IC	InChI=1S/C18H15N5O3/c24-8-2-7-23-10-12(11-3-1-4-21-16(11)23)14-15(18(26)22-17(14)25)13-9-19-5-6-20-13/h1,3-6,9-10,24H,2,7-8H2,(H,22,25,26)
DM734QB	CS	C1=CC2=C(N=C1)N(C=C2C3=C(C(=O)NC3=O)C4=NC=CN=C4)CCCO
DM734QB	IK	ZDEJZKULWCZIHL-UHFFFAOYSA-N
DM734QB	IU	3-[1-(3-hydroxypropyl)pyrrolo[2,3-b]pyridin-3-yl]-4-pyrazin-2-ylpyrrole-2,5-dione
DM734QB	CA	CAS 626604-39-5
DM734QB	DE	Discovery agent

DMHUMP9	ID	DMHUMP9
DMHUMP9	DN	GSK4716
DMHUMP9	HS	Investigative
DMHUMP9	SN	GSK 4716; GSK-4716
DMHUMP9	DT	Small molecular drug
DMHUMP9	PC	5331325
DMHUMP9	MW	282.34
DMHUMP9	FM	C17H18N2O2
DMHUMP9	IC	InChI=1S/C17H18N2O2/c1-12(2)14-5-3-13(4-6-14)11-18-19-17(21)15-7-9-16(20)10-8-15/h3-12,20H,1-2H3,(H,19,21)/b18-11+
DMHUMP9	CS	CC(C)C1=CC=C(C=C1)/C=N/NC(=O)C2=CC=C(C=C2)O
DMHUMP9	IK	IKPPIUNQWSRCOZ-WOJGMQOQSA-N
DMHUMP9	IU	4-hydroxy-N-[(E)-(4-propan-2-ylphenyl)methylideneamino]benzamide
DMHUMP9	CA	CAS 101574-65-6
DMHUMP9	CB	CHEBI:80000
DMHUMP9	DE	Discovery agent

DMMIWHV	ID	DMMIWHV
DMMIWHV	DN	GSK494581A
DMMIWHV	HS	Investigative
DMMIWHV	SN	GSK494581A; GTPL5562; SCHEMBL4940960; CHEMBL3746420
DMMIWHV	DT	Small molecular drug
DMMIWHV	PC	11855860
DMMIWHV	MW	514.6
DMMIWHV	FM	C27H28F2N2O4S
DMMIWHV	IC	InChI=1S/C27H28F2N2O4S/c1-18(35-2)20-6-11-26(25(29)16-20)30-12-14-31(15-13-30)27(32)24-17-22(36(3,33)34)9-10-23(24)19-4-7-21(28)8-5-19/h4-11,16-18H,12-15H2,1-3H3
DMMIWHV	CS	CC(C1=CC(=C(C=C1)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)S(=O)(=O)C)C4=CC=C(C=C4)F)F)OC
DMMIWHV	IK	JQXZHDOSMUZLML-UHFFFAOYSA-N
DMMIWHV	IU	[4-[2-fluoro-4-(1-methoxyethyl)phenyl]piperazin-1-yl]-[2-(4-fluorophenyl)-5-methylsulfonylphenyl]methanone
DMMIWHV	DE	Discovery agent

DMNGEAY	ID	DMNGEAY
DMNGEAY	DN	GSK-5182
DMNGEAY	HS	Investigative
DMNGEAY	SN	GSK5182; GSK-5182; GSK 5182; 877387-37-6; (Z)-4-(1-{4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL}-5-HYDROXY-2-PHENYLPENT-1-ENYL)PHENOL; TXF; 4-[(1Z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-5-hydroxy-2-phenylpent-1-en-1-yl]phenol; 2ewp; AC1OA9V8; GTPL8908; CHEMBL201013; SCHEMBL20534177; BDBM22435; AOB1629; EX-A2580; ZINC14978677; 4-hydroxytamoxifen (4-OHT) analog, 15; 4-[(z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-hydroxy-2-phenylpent-1-enyl]phenol; 4-[(Z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol
DMNGEAY	DT	Small molecular drug
DMNGEAY	PC	6852176
DMNGEAY	MW	417.5
DMNGEAY	FM	C27H31NO3
DMNGEAY	IC	InChI=1S/C27H31NO3/c1-28(2)18-20-31-25-16-12-23(13-17-25)27(22-10-14-24(30)15-11-22)26(9-6-19-29)21-7-4-3-5-8-21/h3-5,7-8,10-17,29-30H,6,9,18-20H2,1-2H3/b27-26-
DMNGEAY	CS	CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCO)\\C2=CC=CC=C2)/C3=CC=C(C=C3)O
DMNGEAY	IK	ZVSFNBNLNLXEFQ-RQZHXJHFSA-N
DMNGEAY	IU	4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol
DMNGEAY	DE	Discovery agent

DM1I0AN	ID	DM1I0AN
DM1I0AN	DN	GSK575594A
DM1I0AN	HS	Investigative
DM1I0AN	SN	SCHEMBL4938360; GTPL5561; CHEMBL3747673; DAPKZHQMEQRNPY-UHFFFAOYSA-N; ZINC86012924; GSK575594A, &gt; 3-fluoro-4-(4-{[4'-fluoro-4-(methylsulfonyl)-2-biphenylyl]carbonyl}-1-piperazinyl)aniline
DM1I0AN	DT	Small molecular drug
DM1I0AN	PC	59822766
DM1I0AN	MW	471.5
DM1I0AN	FM	C24H23F2N3O3S
DM1I0AN	IC	InChI=1S/C24H23F2N3O3S/c1-33(31,32)19-7-8-20(16-2-4-17(25)5-3-16)21(15-19)24(30)29-12-10-28(11-13-29)23-9-6-18(27)14-22(23)26/h2-9,14-15H,10-13,27H2,1H3
DM1I0AN	CS	CS(=O)(=O)C1=CC(=C(C=C1)C2=CC=C(C=C2)F)C(=O)N3CCN(CC3)C4=C(C=C(C=C4)N)F
DM1I0AN	IK	DAPKZHQMEQRNPY-UHFFFAOYSA-N
DM1I0AN	IU	[4-(4-amino-2-fluorophenyl)piperazin-1-yl]-[2-(4-fluorophenyl)-5-methylsulfonylphenyl]methanone
DM1I0AN	DE	Discovery agent

DMJXHU8	ID	DMJXHU8
DMJXHU8	DN	GSK579289A
DMJXHU8	HS	Investigative
DMJXHU8	SN	compound 25 [PMID 19237286]; GSK-579289A
DMJXHU8	DT	Small molecular drug
DMJXHU8	PC	16051023
DMJXHU8	MW	511
DMJXHU8	FM	C26H27ClN4O3S
DMJXHU8	IC	InChI=1S/C26H27ClN4O3S/c1-16(19-5-3-4-6-20(19)27)33-23-14-24(35-25(23)26(28)32)31-15-29-21-8-7-18(13-22(21)31)34-17-9-11-30(2)12-10-17/h3-8,13-17H,9-12H2,1-2H3,(H2,28,32)/t16-/m1/s1
DMJXHU8	CS	C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)OC5CCN(CC5)C)C(=O)N
DMJXHU8	IK	GILNGUYOGYOZMP-MRXNPFEDSA-N
DMJXHU8	IU	3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(1-methylpiperidin-4-yl)oxybenzimidazol-1-yl]thiophene-2-carboxamide
DMJXHU8	CA	CAS 929095-23-8
DMJXHU8	DE	Discovery agent

DMNRP2L	ID	DMNRP2L
DMNRP2L	DN	GSK-650394
DMNRP2L	HS	Investigative
DMNRP2L	SN	SGK-1 inhibitor (prostate cancer), GlaxoSmithKline
DMNRP2L	CP	GlaxoSmithKline plc
DMNRP2L	DT	Small molecular drug
DMNRP2L	PC	25022668
DMNRP2L	MW	382.5
DMNRP2L	FM	C25H22N2O2
DMNRP2L	IC	InChI=1S/C25H22N2O2/c28-25(29)20-11-10-18(12-21(20)17-8-4-5-9-17)23-15-27-24-22(23)13-19(14-26-24)16-6-2-1-3-7-16/h1-3,6-7,10-15,17H,4-5,8-9H2,(H,26,27)(H,28,29)
DMNRP2L	CS	C1CCC(C1)C2=C(C=CC(=C2)C3=CNC4=C3C=C(C=N4)C5=CC=CC=C5)C(=O)O
DMNRP2L	IK	WVSBGSNVCDAMCF-UHFFFAOYSA-N
DMNRP2L	IU	2-cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid
DMNRP2L	CA	CAS 890842-28-1
DMNRP2L	CB	CHEBI:95066
DMNRP2L	DE	Prostate cancer

DMGW42V	ID	DMGW42V
DMGW42V	DN	GSK-8062
DMGW42V	HS	Investigative
DMGW42V	SN	UNII-37IS6K16XE; 37IS6K16XE; 6-(4-{[3-(2,6-Dichlorophenyl)-5-(1-Methylethyl)isoxazol-4-Yl]methoxy}phenyl)naphthalene-1-Carboxylic Acid; GSK-8062; TUOXXRMLFZBSTB-UHFFFAOYSA-N; 943549-47-1; SCHEMBL2115258; CHEMBL476302; Naphthoic acid-based analog, 1b; BDBM30329; GSK8062; 1-Naphthalenecarboxylic acid, 6-(4-((3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl)methoxy)phenyl)-; 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-1-naphthalenecarboxylic acid
DMGW42V	DT	Small molecular drug
DMGW42V	PC	16214849
DMGW42V	MW	532.4
DMGW42V	FM	C30H23Cl2NO4
DMGW42V	IC	InChI=1S/C30H23Cl2NO4/c1-17(2)29-24(28(33-37-29)27-25(31)7-4-8-26(27)32)16-36-21-12-9-18(10-13-21)19-11-14-22-20(15-19)5-3-6-23(22)30(34)35/h3-15,17H,16H2,1-2H3,(H,34,35)
DMGW42V	CS	CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC=C(C=C3)C4=CC5=C(C=C4)C(=CC=C5)C(=O)O
DMGW42V	IK	TUOXXRMLFZBSTB-UHFFFAOYSA-N
DMGW42V	IU	6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]naphthalene-1-carboxylic acid
DMGW42V	CA	CAS 943549-47-1
DMGW42V	DE	Discovery agent

DMT98PA	ID	DMT98PA
DMT98PA	DN	GSK-812397
DMT98PA	HS	Investigative
DMT98PA	SN	CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline
DMT98PA	CP	GlaxoSmithKline plc
DMT98PA	DT	Small molecular drug
DMT98PA	PC	11718722
DMT98PA	MW	420.6
DMT98PA	FM	C24H32N6O
DMT98PA	IC	InChI=1S/C24H32N6O/c1-27-12-14-29(15-13-27)23-10-4-9-22-26-19(21(17-31)30(22)23)16-28(2)20-8-3-6-18-7-5-11-25-24(18)20/h4-5,7,9-11,20,31H,3,6,8,12-17H2,1-2H3/t20-/m0/s1
DMT98PA	CS	CN1CCN(CC1)C2=CC=CC3=NC(=C(N32)CO)CN(C)[C@H]4CCCC5=C4N=CC=C5
DMT98PA	IK	QUDMHFVRKBVGBY-FQEVSTJZSA-N
DMT98PA	IU	[5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol
DMT98PA	CA	CAS 878197-98-9
DMT98PA	DE	Human immunodeficiency virus-1 infection

DMSOWPE	ID	DMSOWPE
DMSOWPE	DN	GSK-894281
DMSOWPE	HS	Investigative
DMSOWPE	SN	Ghrelin agonists (gastric motility disorder); SB-791016; Ghrelin agonists (gastric motility disorder), GlaxoSmithKline; Ghrelin agonists (gastric motility disorders), GSK
DMSOWPE	CP	GlaxoSmithKline plc
DMSOWPE	DT	Small molecular drug
DMSOWPE	PC	24803511
DMSOWPE	MW	473.6
DMSOWPE	FM	C24H28FN3O4S
DMSOWPE	IC	InChI=1S/C24H28FN3O4S/c1-15-13-28(14-16(2)26-15)18-6-10-24(31-4)22(11-18)27-33(29,30)19-7-8-20(21(25)12-19)23-9-5-17(3)32-23/h5-12,15-16,26-27H,13-14H2,1-4H3/t15-,16+
DMSOWPE	CS	C[C@@H]1CN(C[C@@H](N1)C)C2=CC(=C(C=C2)OC)NS(=O)(=O)C3=CC(=C(C=C3)C4=CC=C(O4)C)F
DMSOWPE	IK	OIWVNMRPHUCLHN-IYBDPMFKSA-N
DMSOWPE	IU	N-[5-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-methoxyphenyl]-3-fluoro-4-(5-methylfuran-2-yl)benzenesulfonamide
DMSOWPE	CA	CAS 874958-63-1
DMSOWPE	DE	Gastric motility disorder

DMIDQ8B	ID	DMIDQ8B
DMIDQ8B	DN	GSK931145
DMIDQ8B	HS	Investigative
DMIDQ8B	SN	GSK931145; GTPL4598
DMIDQ8B	DT	Small molecular drug
DMIDQ8B	PC	73755100
DMIDQ8B	MW	350.5
DMIDQ8B	FM	C23H30N2O
DMIDQ8B	IC	InChI=1S/C23H30N2O/c1-17-11-10-12-18(2)20(17)22(26)24-21(19-13-6-5-7-14-19)23(25(3)4)15-8-9-16-23/h5-7,10-14,21H,8-9,15-16H2,1-4H3,(H,24,26)/t21-/m0/s1
DMIDQ8B	CS	CC1=C(C(=CC=C1)C)C(=O)N[C@@H](C2=CC=CC=C2)C3(CCCC3)N(C)C
DMIDQ8B	IK	BMXRRRIDMAIEKX-NRFANRHFSA-N
DMIDQ8B	IU	N-[(S)-[1-(dimethylamino)cyclopentyl]-phenylmethyl]-2,6-dimethylbenzamide
DMIDQ8B	DE	Discovery agent

DMW9AN1	ID	DMW9AN1
DMW9AN1	DN	GSK-9578
DMW9AN1	HS	Investigative
DMW9AN1	SN	KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic
DMW9AN1	DT	Small molecular drug
DMW9AN1	PC	9870304
DMW9AN1	MW	492.6
DMW9AN1	FM	C26H34F2N2O3S
DMW9AN1	IC	InChI=1S/C26H34F2N2O3S/c1-4-5-6-7-8-16-30(25(33)29-23-14-11-20(27)18-22(23)28)17-15-19-9-12-21(13-10-19)34-26(2,3)24(31)32/h9-14,18H,4-8,15-17H2,1-3H3,(H,29,33)(H,31,32)
DMW9AN1	CS	CCCCCCCN(CCC1=CC=C(C=C1)SC(C)(C)C(=O)O)C(=O)NC2=C(C=C(C=C2)F)F
DMW9AN1	IK	KYQNYMXQHLMADB-UHFFFAOYSA-N
DMW9AN1	IU	2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic acid
DMW9AN1	CA	CAS 247923-29-1
DMW9AN1	DE	Discovery agent

DMNOU59	ID	DMNOU59
DMNOU59	DN	GSK'963
DMNOU59	HS	Investigative
DMNOU59	CP	GlaxoSmithKline
DMNOU59	DT	Small molecular drug
DMNOU59	DE	Myeloid leukaemia

DM4WS3R	ID	DM4WS3R
DM4WS3R	DN	GSK-9772
DM4WS3R	HS	Investigative
DM4WS3R	SN	GSK-9772; CHEMBL493241; 928035-84-1; GSK9772; 4-[[Butyl[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]amino]methyl]-2,6-dichlorophenol; 4-[(Butyl{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}amino)methyl]-2,6-dichlorophenol; SCHEMBL4629551; GTPL8693; GSK 9772; BDBM50252940; ZINC34946707; KB-71932
DM4WS3R	DT	Small molecular drug
DM4WS3R	PC	16049480
DM4WS3R	MW	490.3
DM4WS3R	FM	C20H19Cl2F6NO2
DM4WS3R	IC	InChI=1S/C20H19Cl2F6NO2/c1-2-3-8-29(11-12-9-15(21)17(30)16(22)10-12)14-6-4-13(5-7-14)18(31,19(23,24)25)20(26,27)28/h4-7,9-10,30-31H,2-3,8,11H2,1H3
DM4WS3R	CS	CCCCN(CC1=CC(=C(C(=C1)Cl)O)Cl)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O
DM4WS3R	IK	TYYLMKBOWXDDCT-UHFFFAOYSA-N
DM4WS3R	IU	4-[[N-butyl-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)anilino]methyl]-2,6-dichlorophenol
DM4WS3R	DE	Discovery agent

DMY3SEN	ID	DMY3SEN
DMY3SEN	DN	GSK-J1
DMY3SEN	HS	Investigative
DMY3SEN	SN	GSK-J1; GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; GSKJ1; GSK-J1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240
DMY3SEN	DT	Small molecular drug
DMY3SEN	PC	56963315
DMY3SEN	MW	389.4
DMY3SEN	FM	C22H23N5O2
DMY3SEN	IC	InChI=1S/C22H23N5O2/c28-21(29)8-12-24-19-15-20(26-22(25-19)18-7-3-4-11-23-18)27-13-9-16-5-1-2-6-17(16)10-14-27/h1-7,11,15H,8-10,12-14H2,(H,28,29)(H,24,25,26)
DMY3SEN	CS	C1CN(CCC2=CC=CC=C21)C3=NC(=NC(=C3)NCCC(=O)O)C4=CC=CC=N4
DMY3SEN	IK	AVZCPICCWKMZDT-UHFFFAOYSA-N
DMY3SEN	IU	3-[[2-pyridin-2-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoic acid
DMY3SEN	CB	CHEBI:131152
DMY3SEN	DE	Discovery agent

DMHJU7A	ID	DMHJU7A
DMHJU7A	DN	GSK-LSD1
DMHJU7A	HS	Investigative
DMHJU7A	SN	GSK-LSD1 2HCl; 1431368-48-7; N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine; GSK LSD1 Dihydrochloride; GTPL8241; SCHEMBL14880683; BDBM256459; 1431368-48-7(free base); ZINC44675892; AKOS030573682; GSK-LSD1, &gt; NCGC00356416-07; US9487512, 3
DMHJU7A	DT	Small molecular drug
DMHJU7A	PC	71522234
DMHJU7A	MW	216.32
DMHJU7A	FM	C14H20N2
DMHJU7A	IC	InChI=1S/C14H20N2/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12/h1-5,12-16H,6-10H2/t13-,14+/m0/s1
DMHJU7A	CS	C1CNCCC1N[C@@H]2C[C@H]2C3=CC=CC=C3
DMHJU7A	IK	BASFYRLYJAZPPL-UONOGXRCSA-N
DMHJU7A	IU	N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine
DMHJU7A	DE	Discovery agent

DMNMITH	ID	DMNMITH
DMNMITH	DN	GT-1282
DMNMITH	HS	Investigative
DMNMITH	SN	DDVVRHNNOPQPGB-UHFFFAOYSA-N; NIBR-1282; CHEMBL255858; SCHEMBL619811; BDBM50234723; SB16769; (2,4-dimethyl-1-oxy-pyridin-3-yl)-[4''-methyl-4-(phenyl-pyridin-3-yl-amino)-[1,4'']bipiperidinyl-1''-yl]-methanone;  NIBR-1282
DMNMITH	DT	Small molecular drug
DMNMITH	PC	10278617
DMNMITH	MW	499.6
DMNMITH	FM	C30H37N5O2
DMNMITH	IC	InChI=1S/C30H37N5O2/c1-23-11-19-34(37)24(2)28(23)29(36)32-20-14-30(3,15-21-32)33-17-12-26(13-18-33)35(25-8-5-4-6-9-25)27-10-7-16-31-22-27/h4-11,16,19,22,26H,12-15,17-18,20-21H2,1-3H3
DMNMITH	CS	CC1=C(C(=[N+](C=C1)[O-])C)C(=O)N2CCC(CC2)(C)N3CCC(CC3)N(C4=CC=CC=C4)C5=CN=CC=C5
DMNMITH	IK	DDVVRHNNOPQPGB-UHFFFAOYSA-N
DMNMITH	IU	(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)-[4-methyl-4-[4-(N-pyridin-3-ylanilino)piperidin-1-yl]piperidin-1-yl]methanone
DMNMITH	DE	Autoimmune diabetes

DMH3PDG	ID	DMH3PDG
DMH3PDG	DN	GT2394
DMH3PDG	HS	Investigative
DMH3PDG	SN	GT2394; SCHEMBL649448; GTPL1261; gt-2394; Cyclohexylmethyl N-[(1R,2R)-2-(3H-imidazol-4-yl)cyclopropyl]carbamate
DMH3PDG	DT	Small molecular drug
DMH3PDG	PC	9860053
DMH3PDG	MW	263.34
DMH3PDG	FM	C14H21N3O2
DMH3PDG	IC	InChI=1S/C14H21N3O2/c18-14(19-8-10-4-2-1-3-5-10)17-12-6-11(12)13-7-15-9-16-13/h7,9-12H,1-6,8H2,(H,15,16)(H,17,18)/t11-,12-/m1/s1
DMH3PDG	CS	C1CCC(CC1)COC(=O)N[C@@H]2C[C@H]2C3=CN=CN3
DMH3PDG	IK	SLQAVEDMASVHTL-VXGBXAGGSA-N
DMH3PDG	IU	cyclohexylmethyl N-[(1R,2R)-2-(1H-imidazol-5-yl)cyclopropyl]carbamate
DMH3PDG	DE	Discovery agent

DMW23Y9	ID	DMW23Y9
DMW23Y9	DN	GTP-14564
DMW23Y9	HS	Investigative
DMW23Y9	SN	GTP-14564; GTP 14564; 34823-86-4; 3-Phenyl-1H-benzofuro[3,2-c]pyrazole; 1-Phenyl-3-H-8-oxa-2,3-diaza-cyclopenta[a]inden; CHEMBL406375; 3-phenyl-1H-[1]benzofuro[3,2-c]pyrazole; 3-Phenyl-1H-benzofuro(3,2-c)pyrazole; AC1MPHAI; SCHEMBL2550165; GTPL5982; CHEBI:92300; DTXSID10188363; MolPort-002-816-012; HMS3268J15; HMS3229E17; ZINC5387628; HSCI1_000176; BDBM50375646; AKOS024456938; MCULE-3563628731; CCG-206757; NCGC00159539-01; AI-204/33265070; J-019773; BRD-K16664969-001-02-5; BRD-K16664969-001-01-7
DMW23Y9	DT	Small molecular drug
DMW23Y9	PC	3385203
DMW23Y9	MW	234.25
DMW23Y9	FM	C15H10N2O
DMW23Y9	IC	InChI=1S/C15H10N2O/c1-2-6-10(7-3-1)13-15-14(17-16-13)11-8-4-5-9-12(11)18-15/h1-9H,(H,16,17)
DMW23Y9	CS	C1=CC=C(C=C1)C2=NNC3=C2OC4=CC=CC=C43
DMW23Y9	IK	DZQLVVLATXPWBK-UHFFFAOYSA-N
DMW23Y9	IU	3-phenyl-1H-[1]benzofuro[3,2-c]pyrazole
DMW23Y9	CA	CAS 34823-86-4
DMW23Y9	CB	CHEBI:92300
DMW23Y9	DE	Discovery agent

DMJUXKY	ID	DMJUXKY
DMJUXKY	DN	GTPgammaS
DMJUXKY	HS	Investigative
DMJUXKY	DT	Small molecular drug
DMJUXKY	PC	135476260
DMJUXKY	MW	539.25
DMJUXKY	FM	C10H16N5O13P3S
DMJUXKY	IC	InChI=1S/C10H16N5O13P3S/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(26-9)1-25-29(19,20)27-30(21,22)28-31(23,24)32/h2-3,5-6,9,16-17H,1H2,(H,19,20)(H,21,22)(H2,23,24,32)(H3,11,13,14,18)
DMJUXKY	CS	C1=NC2=C(N1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N=C(NC2=O)N
DMJUXKY	IK	XOFLBQFBSOEHOG-UHFFFAOYSA-N
DMJUXKY	IU	[[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphinothioyl hydrogen phosphate
DMJUXKY	CA	CAS 108964-33-6
DMJUXKY	DE	Discovery agent

DMZQETV	ID	DMZQETV
DMZQETV	DN	GTPL8662
DMZQETV	HS	Investigative
DMZQETV	SN	43574
DMZQETV	DT	Small molecular drug
DMZQETV	PC	54596718
DMZQETV	MW	322.5
DMZQETV	FM	C21H32F2
DMZQETV	IC	InChI=1S/C21H32F2/c1-13-4-7-17-16-6-5-14-12-15(22)8-10-20(14,2)18(16)9-11-21(17,3)19(13)23/h5,13,15-19H,4,6-12H2,1-3H3/t13-,15+,16?,17?,18?,19+,20+,21+/m1/s1
DMZQETV	CS	C[C@@H]1CCC2C3CC=C4C[C@H](CC[C@@]4(C3CC[C@@]2([C@H]1F)C)C)F
DMZQETV	IK	UEILQXVVJHZGQK-KYFJQHFKSA-N
DMZQETV	IU	(1S,2R,8S,10aR,12aS)-1,8-difluoro-2,10a,12a-trimethyl-1,2,3,4,4a,4b,5,7,8,9,10,10b,11,12-tetradecahydrochrysene
DMZQETV	DE	Discovery agent

DM315VL	ID	DM315VL
DM315VL	DN	GTx-027
DM315VL	HS	Investigative
DM315VL	CP	GTx Inc
DM315VL	DE	Solid tumour/cancer

DMEIMVW	ID	DMEIMVW
DMEIMVW	DN	GTx-822
DMEIMVW	HS	Investigative
DMEIMVW	SN	Selective estrogen receptor beta modulator (ocular disease), GTx
DMEIMVW	CP	GTx Inc
DMEIMVW	DE	Ocular disease

DMP9OGC	ID	DMP9OGC
DMP9OGC	DN	GTx-878
DMP9OGC	HS	Investigative
DMP9OGC	SN	Estrogen receptor beta agonist (prostatitis/BPH), GTx
DMP9OGC	CP	GTx Inc
DMP9OGC	DE	Prostate hyperplasia

DMGYMW4	ID	DMGYMW4
DMGYMW4	DN	Guajazulen
DMGYMW4	HS	Investigative
DMGYMW4	SN	AZ-8 beris; Azulen-beris; Azulol; Azulon; Azunol; Azunol (TN); Cuteazul; Eucazulen; Guaiazulene, 99%; Guajazulene; Guiazulene; Gurjunazulen; Kessazulen; Purazulen; S-Guaiazulene; Silazulon; Uroazulen; Vaumigan; Vetivazulen; guaiazulen; guaiazulene; hepatoprotectant; 1,4-Dimethyl-7-(1-methylethyl)azulene; 1,4-Dimethyl-7-isopropylazulene; 1,4-dimethyl-7-(propan-2-yl)azulene; 3,8-Dimethyl-5-(2-propyl)azulene; 489-84-9; 7-Isopropyl-1,4-dimethylazulene; Azulene, 1,4-dimethyl-7-(1-methylethyl)-; NSC 4714; UNII-2OZ1K9JKQC
DMGYMW4	PC	3515
DMGYMW4	MW	198.3
DMGYMW4	FM	C15H18
DMGYMW4	IC	FWKQNCXZGNBPFD-UHFFFAOYSA-N
DMGYMW4	CS	CC1=C2C=CC(=C2C=C(C=C1)C(C)C)C
DMGYMW4	IK	1S/C15H18/c1-10(2)13-7-5-11(3)14-8-6-12(4)15(14)9-13/h5-10H,1-4H3
DMGYMW4	IU	1,4-dimethyl-7-propan-2-ylazulene
DMGYMW4	CA	CAS 489-84-9
DMGYMW4	CB	CHEBI:5550
DMGYMW4	DE	Allergy

DM4GO8H	ID	DM4GO8H
DM4GO8H	DN	Guanidine
DM4GO8H	HS	Investigative
DM4GO8H	SN	(NH2)2C=NH; 4-03-00-00148 (Beilstein Handbook Reference); AC1L1G4E; AC1Q50DT; AC1Q50DU; Aminoformamidine; Aminomethanamidine; Carbamamidine; Carbamidine; GAI; Gu; Guanidin; Guanidine, Hydrochloride; Guanidine, free base;BRN 0506044; H2N-C(=NH)-NH2; HSDB 7603; Imidourea; Iminourea; JU58VJ6Y3B; NCIOpen2_007946; UNII-JU58VJ6Y3B; ZRALSGWEFCBTJO-UHFFFAOYSA-N; guanidine
DM4GO8H	DT	Small molecular drug
DM4GO8H	PC	3520
DM4GO8H	MW	59.072
DM4GO8H	FM	CH5N3
DM4GO8H	IC	InChI=1S/CH5N3/c2-1(3)4/h(H5,2,3,4)
DM4GO8H	CS	C(=N)(N)N
DM4GO8H	IK	ZRALSGWEFCBTJO-UHFFFAOYSA-N
DM4GO8H	IU	guanidine
DM4GO8H	CA	CAS 113-00-8
DM4GO8H	CB	CHEBI:42820
DM4GO8H	DE	Myasthenic syndrome

DMCN56S	ID	DMCN56S
DMCN56S	DN	GUANOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE
DMCN56S	HS	Investigative
DMCN56S	DT	Small molecular drug
DMCN56S	PC	135464486
DMCN56S	MW	389.26
DMCN56S	FM	C12H16N5O8P
DMCN56S	IC	InChI=1S/C12H16N5O8P/c13-12-15-9-6(10(19)16-12)14-3-17(9)11-8-7(4(1-18)23-11)24-5(25-8)2-26(20,21)22/h3-5,7-8,11,18H,1-2H2,(H2,20,21,22)(H3,13,15,16,19)/t4-,5-,7-,8-,11-/m1/s1
DMCN56S	CS	C1=NC2=C(N1[C@H]3[C@H]4[C@@H]([C@H](O3)CO)O[C@H](O4)CP(=O)(O)O)N=C(NC2=O)N
DMCN56S	IK	HYAPEMYRVFIHDJ-QWEIRQIHSA-N
DMCN56S	IU	[(2R,3aR,4R,6R,6aR)-4-(2-amino-6-oxo-1H-purin-9-yl)-6-(hydroxymethyl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-2-yl]methylphosphonic acid
DMCN56S	DE	Discovery agent

DMRITFU	ID	DMRITFU
DMRITFU	DN	GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE
DMRITFU	HS	Investigative
DMRITFU	DT	Small molecular drug
DMRITFU	PC	135464488
DMRITFU	MW	375.23
DMRITFU	FM	C11H14N5O8P
DMRITFU	IC	InChI=1S/C11H14N5O8P/c12-10-14-7-4(8(18)15-10)13-2-16(7)9-6-5(3(1-17)22-9)23-11(24-6)25(19,20)21/h2-3,5-6,9,11,17H,1H2,(H2,19,20,21)(H3,12,14,15,18)/t3-,5-,6-,9-,11+/m1/s1
DMRITFU	CS	C1=NC2=C(N1[C@H]3[C@H]4[C@@H]([C@H](O3)CO)O[C@@H](O4)P(=O)(O)O)N=C(NC2=O)N
DMRITFU	IK	GKAPYWCOOQBBHV-KXSYMAMXSA-N
DMRITFU	IU	[(2S,3aR,4R,6R,6aR)-4-(2-amino-6-oxo-1H-purin-9-yl)-6-(hydroxymethyl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-2-yl]phosphonic acid
DMRITFU	DE	Discovery agent

DMG2ZFV	ID	DMG2ZFV
DMG2ZFV	DN	Guanosine-5',3'-Tetraphosphate
DMG2ZFV	HS	Investigative
DMG2ZFV	DT	Small molecular drug
DMG2ZFV	PC	135398637
DMG2ZFV	MW	603.16
DMG2ZFV	FM	C10H17N5O17P4
DMG2ZFV	IC	InChI=1S/C10H17N5O17P4/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6(30-36(26,27)32-34(21,22)23)3(29-9)1-28-35(24,25)31-33(18,19)20/h2-3,5-6,9,16H,1H2,(H,24,25)(H,26,27)(H2,18,19,20)(H2,21,22,23)(H3,11,13,14,17)/t3-,5-,6-,9-/m1/s1
DMG2ZFV	CS	C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)OP(=O)(O)OP(=O)(O)O)O)N=C(NC2=O)N
DMG2ZFV	IK	BUFLLCUFNHESEH-UUOKFMHZSA-N
DMG2ZFV	IU	[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-[[hydroxy(phosphonooxy)phosphoryl]oxymethyl]oxolan-3-yl] phosphono hydrogen phosphate
DMG2ZFV	CA	CAS 32452-17-8
DMG2ZFV	CB	CHEBI:17633
DMG2ZFV	DE	Discovery agent

DM0MUKQ	ID	DM0MUKQ
DM0MUKQ	DN	Guanosine-5'-Diphosphate
DM0MUKQ	HS	Investigative
DM0MUKQ	DT	Small molecular drug
DM0MUKQ	PC	135398619
DM0MUKQ	MW	443.2
DM0MUKQ	FM	C10H15N5O11P2
DM0MUKQ	IC	InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1
DM0MUKQ	CS	C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N
DM0MUKQ	IK	QGWNDRXFNXRZMB-UUOKFMHZSA-N
DM0MUKQ	IU	[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DM0MUKQ	CA	CAS 146-91-8
DM0MUKQ	CB	CHEBI:17552
DM0MUKQ	DE	Discovery agent

DM3SLZK	ID	DM3SLZK
DM3SLZK	DN	Guanosine-5'-Monophosphate
DM3SLZK	HS	Investigative
DM3SLZK	SN	5'-Guanylic acid; guanylic acid; guanosine-5'-monophosphate; guanosine monophosphate; Guanosine 5'-monophosphate; 85-32-5; 5'-Gmp; Guanosine 5'-phosphate; Guanidine monophosphate; guanylate; CHEBI:17345; guanosine-phosphate; guanosine-monophosphate; Guanosine 5'-monophosphoric acid; AI3-28539; guanosine-5'-phosphate; UNII-16597955EP; EINECS 201-598-8; Guanosine 5'-phosphoric acid; CHEMBL283807; GMP; ((2R,3S,4R,5R)-5-(2-Amino-6-oxo-1H-purin-9(6H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate; E 626; 16597955EP
DM3SLZK	DT	Small molecular drug
DM3SLZK	PC	135398631
DM3SLZK	MW	363.22
DM3SLZK	FM	C10H14N5O8P
DM3SLZK	IC	InChI=1S/C10H14N5O8P/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,16-17H,1H2,(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1
DM3SLZK	CS	C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N=C(NC2=O)N
DM3SLZK	IK	RQFCJASXJCIDSX-UUOKFMHZSA-N
DM3SLZK	IU	[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM3SLZK	CA	CAS 85-32-5
DM3SLZK	CB	CHEBI:17345
DM3SLZK	DE	Discovery agent

DMV2OJX	ID	DMV2OJX
DMV2OJX	DN	Guanosine-5'-Triphosphate
DMV2OJX	HS	Investigative
DMV2OJX	DT	Small molecular drug
DMV2OJX	PC	135398633
DMV2OJX	MW	523.179
DMV2OJX	FM	C10H16N5O14P3
DMV2OJX	IC	InChI=1S/C10H16N5O14P3/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(27-9)1-26-31(22,23)29-32(24,25)28-30(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H,24,25)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1
DMV2OJX	CS	C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N
DMV2OJX	IK	XKMLYUALXHKNFT-UUOKFMHZSA-N
DMV2OJX	IU	[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMV2OJX	CA	CAS 86-01-1
DMV2OJX	CB	CHEBI:15996
DMV2OJX	DE	Discovery agent

DMOUQLB	ID	DMOUQLB
DMOUQLB	DN	guanylpirenzepine
DMOUQLB	HS	Investigative
DMOUQLB	SN	4-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]piperazine-1-carboximidamide dihydrochloride
DMOUQLB	DT	Small molecular drug
DMOUQLB	PC	129786
DMOUQLB	MW	379.4
DMOUQLB	FM	C19H21N7O2
DMOUQLB	IC	InChI=1S/C19H21N7O2/c20-19(21)25-10-8-24(9-11-25)12-16(27)26-15-6-2-1-4-13(15)18(28)23-14-5-3-7-22-17(14)26/h1-7H,8-12H2,(H3,20,21)(H,23,28)
DMOUQLB	CS	C1CN(CCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4)C(=N)N
DMOUQLB	IK	YGBQWISDDSXPRF-UHFFFAOYSA-N
DMOUQLB	IU	4-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]piperazine-1-carboximidamide
DMOUQLB	CA	CAS 122858-76-8
DMOUQLB	DE	Discovery agent

DM89KNT	ID	DM89KNT
DM89KNT	DN	Gue1654
DM89KNT	HS	Investigative
DM89KNT	SN	Gue 1654
DM89KNT	DT	Small molecular drug
DM89KNT	PC	5066134
DM89KNT	MW	447.6
DM89KNT	FM	C23H17N3OS3
DM89KNT	IC	InChI=1S/C23H17N3OS3/c1-28-23-25-17-13-12-16-19(20(17)30-23)29-22(24-16)26-21(27)18(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-13,18H,1H3,(H,24,26,27)
DM89KNT	CS	CSC1=NC2=C(S1)C3=C(C=C2)N=C(S3)NC(=O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM89KNT	IK	UFOBDFMYJABXGK-UHFFFAOYSA-N
DM89KNT	IU	N-(2-methylsulfanyl-[1,3]thiazolo[4,5-g][1,3]benzothiazol-7-yl)-2,2-diphenylacetamide
DM89KNT	DE	Discovery agent

DMBXGVH	ID	DMBXGVH
DMBXGVH	DN	Guttiferone I
DMBXGVH	HS	Investigative
DMBXGVH	SN	Guttiferone I
DMBXGVH	DT	Small molecular drug
DMBXGVH	PC	44584005
DMBXGVH	MW	670.9
DMBXGVH	FM	C43H58O6
DMBXGVH	IC	InChI=1S/C43H58O6/c1-27(2)13-11-15-31(9)16-18-33-26-42(23-20-29(5)6)38(47)36(37(46)32-17-19-34(44)35(45)25-32)39(48)43(40(42)49,24-21-30(7)8)41(33,10)22-12-14-28(3)4/h13-14,16-17,19-21,25,33,44-46H,11-12,15,18,22-24,26H2,1-10H3/b31-16+,37-36+/t33-,41+,42-,43+/m0/s1
DMBXGVH	CS	CC(=CCC/C(=C/C[C@H]1C[C@]2(C(=O)/C(=C(/C3=CC(=C(C=C3)O)O)\\O)/C(=O)[C@](C2=O)([C@]1(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)/C)C
DMBXGVH	IK	HIGOXQQRSUDJCL-KJLWUZBSSA-N
DMBXGVH	IU	(1R,3E,5S,6R,7S)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6-methyl-1,5-bis(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)bicyclo[3.3.1]nonane-2,4,9-trione
DMBXGVH	DE	Discovery agent

DM78KYC	ID	DM78KYC
DM78KYC	DN	GW 627368
DM78KYC	HS	Investigative
DM78KYC	SN	saccharic acid; GW627368; GW-627368
DM78KYC	DT	Small molecular drug
DM78KYC	PC	5312130
DM78KYC	MW	544.6
DM78KYC	FM	C30H28N2O6S
DM78KYC	IC	InChI=1S/C30H28N2O6S/c1-3-37-28-23-12-8-9-13-24(23)29(38-4-2)27-25(28)19-32(30(27)34)21-16-14-20(15-17-21)18-26(33)31-39(35,36)22-10-6-5-7-11-22/h5-17H,3-4,18-19H2,1-2H3,(H,31,33)
DM78KYC	CS	CCOC1=C2CN(C(=O)C2=C(C3=CC=CC=C31)OCC)C4=CC=C(C=C4)CC(=O)NS(=O)(=O)C5=CC=CC=C5
DM78KYC	IK	XREWXJVMYAXCJV-UHFFFAOYSA-N
DM78KYC	IU	N-(benzenesulfonyl)-2-[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)phenyl]acetamide
DM78KYC	CA	CAS 439288-66-1
DM78KYC	DE	Discovery agent

DM3D2R4	ID	DM3D2R4
DM3D2R4	DN	GW0072
DM3D2R4	HS	Investigative
DM3D2R4	SN	GW 0072
DM3D2R4	DT	Small molecular drug
DM3D2R4	PC	449532
DM3D2R4	MW	614.8
DM3D2R4	FM	C37H46N2O4S
DM3D2R4	IC	InChI=1S/C37H46N2O4S/c1-2-3-4-5-12-20-35-39(25-14-13-15-29-21-23-32(24-22-29)37(42)43)36(41)33(44-35)26-34(40)38(27-30-16-8-6-9-17-30)28-31-18-10-7-11-19-31/h6-11,16-19,21-24,33,35H,2-5,12-15,20,25-28H2,1H3,(H,42,43)/t33-,35-/m0/s1
DM3D2R4	CS	CCCCCCC[C@H]1N(C(=O)[C@@H](S1)CC(=O)N(CC2=CC=CC=C2)CC3=CC=CC=C3)CCCCC4=CC=C(C=C4)C(=O)O
DM3D2R4	IK	GHJJBEKMPCOSRH-LRHLLKFHSA-N
DM3D2R4	IU	4-[4-[(2S,5S)-5-[2-(dibenzylamino)-2-oxoethyl]-2-heptyl-4-oxo-1,3-thiazolidin-3-yl]butyl]benzoic acid
DM3D2R4	DE	Discovery agent

DMGKEO5	ID	DMGKEO5
DMGKEO5	DN	GW0742X
DMGKEO5	HS	Investigative
DMGKEO5	SN	GW0742; GW-0742X
DMGKEO5	DT	Small molecular drug
DMGKEO5	PC	9934458
DMGKEO5	MW	471.5
DMGKEO5	FM	C21H17F4NO3S2
DMGKEO5	IC	InChI=1S/C21H17F4NO3S2/c1-11-7-14(4-6-17(11)29-9-19(27)28)30-10-18-12(2)26-20(31-18)13-3-5-15(16(22)8-13)21(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,28)
DMGKEO5	CS	CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC(=C(C=C3)C(F)(F)F)F)C)OCC(=O)O
DMGKEO5	IK	HWVNEWGKWRGSRK-UHFFFAOYSA-N
DMGKEO5	IU	2-[4-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid
DMGKEO5	CA	CAS 317318-84-6
DMGKEO5	CB	CHEBI:79991
DMGKEO5	DE	Discovery agent

DM3DXM0	ID	DM3DXM0
DM3DXM0	DN	GW1100
DM3DXM0	HS	Investigative
DM3DXM0	SN	GW 1100; GW-1100
DM3DXM0	DT	Small molecular drug
DM3DXM0	PC	11692123
DM3DXM0	MW	520.6
DM3DXM0	FM	C27H25FN4O4S
DM3DXM0	IC	InChI=1S/C27H25FN4O4S/c1-3-35-25(34)20-7-11-23(12-8-20)32-16-21(13-19-14-29-26(30-15-19)36-4-2)24(33)31-27(32)37-17-18-5-9-22(28)10-6-18/h5-12,14-16H,3-4,13,17H2,1-2H3
DM3DXM0	CS	CCOC1=NC=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)C4=CC=C(C=C4)C(=O)OCC
DM3DXM0	IK	PTPNCCWOTBBVJR-UHFFFAOYSA-N
DM3DXM0	IU	ethyl 4-[5-[(2-ethoxypyrimidin-5-yl)methyl]-2-[(4-fluorophenyl)methylsulfanyl]-4-oxopyrimidin-1-yl]benzoate
DM3DXM0	CA	CAS 306974-70-9
DM3DXM0	DE	Discovery agent

DMOV980	ID	DMOV980
DMOV980	DN	GW1929
DMOV980	HS	Investigative
DMOV980	SN	GW 1929; GW-1929
DMOV980	DT	Small molecular drug
DMOV980	PC	6518171
DMOV980	MW	495.6
DMOV980	FM	C30H29N3O4
DMOV980	IC	InChI=1S/C30H29N3O4/c1-33(28-13-7-8-18-31-28)19-20-37-24-16-14-22(15-17-24)21-27(30(35)36)32-26-12-6-5-11-25(26)29(34)23-9-3-2-4-10-23/h2-18,27,32H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
DMOV980	CS	CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=CC=CC=C2C(=O)C3=CC=CC=C3)C4=CC=CC=N4
DMOV980	IK	QTQMRBZOBKYXCG-MHZLTWQESA-N
DMOV980	IU	(2S)-2-(2-benzoylanilino)-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]propanoic acid
DMOV980	CA	CAS 196808-24-9
DMOV980	CB	CHEBI:79992
DMOV980	DE	Discovery agent

DMM8V9E	ID	DMM8V9E
DMM8V9E	DN	GW-2331
DMM8V9E	HS	Investigative
DMM8V9E	SN	190844-95-2; PPAR ligand, Glaxo Wellcome
DMM8V9E	DT	Small molecular drug
DMM8V9E	PC	657048
DMM8V9E	MW	490.6
DMM8V9E	FM	C27H36F2N2O4
DMM8V9E	IC	InChI=1S/C27H36F2N2O4/c1-4-6-7-8-9-17-31(26(34)30-24-15-12-21(28)19-23(24)29)18-16-20-10-13-22(14-11-20)35-27(3,5-2)25(32)33/h10-15,19H,4-9,16-18H2,1-3H3,(H,30,34)(H,32,33)/t27-/m0/s1
DMM8V9E	CS	CCCCCCCN(CCC1=CC=C(C=C1)O[C@@](C)(CC)C(=O)O)C(=O)NC2=C(C=C(C=C2)F)F
DMM8V9E	IK	VGSJXSLGVQINOL-MHZLTWQESA-N
DMM8V9E	IU	(2S)-2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid
DMM8V9E	DE	Discovery agent

DMEAIQC	ID	DMEAIQC
DMEAIQC	DN	GW2433
DMEAIQC	HS	Investigative
DMEAIQC	SN	GW 2433; GW-2433
DMEAIQC	DT	Small molecular drug
DMEAIQC	PC	1517
DMEAIQC	MW	581.9
DMEAIQC	FM	C28H28Cl3FN2O4
DMEAIQC	IC	InChI=1S/C28H28Cl3FN2O4/c1-28(2,26(35)36)38-19-13-11-18(12-14-19)6-5-16-34(17-15-20-21(29)7-3-9-23(20)32)27(37)33-24-10-4-8-22(30)25(24)31/h3-4,7-14H,5-6,15-17H2,1-2H3,(H,33,37)(H,35,36)
DMEAIQC	CS	CC(C)(C(=O)O)OC1=CC=C(C=C1)CCCN(CCC2=C(C=CC=C2Cl)F)C(=O)NC3=C(C(=CC=C3)Cl)Cl
DMEAIQC	IK	YMWJDWJXIXITMD-UHFFFAOYSA-N
DMEAIQC	IU	2-[4-[3-[2-(2-chloro-6-fluorophenyl)ethyl-[(2,3-dichlorophenyl)carbamoyl]amino]propyl]phenoxy]-2-methylpropanoic acid
DMEAIQC	DE	Discovery agent

DMTW9GM	ID	DMTW9GM
DMTW9GM	DN	GW-2580
DMTW9GM	HS	Investigative
DMTW9GM	SN	GW2580; cFMS receptor tyrosine kinase inhibitor; GW632580X
DMTW9GM	DT	Small molecular drug
DMTW9GM	PC	11617559
DMTW9GM	MW	366.4
DMTW9GM	FM	C20H22N4O3
DMTW9GM	IC	InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)
DMTW9GM	CS	COC1=CC=C(C=C1)COC2=C(C=C(C=C2)CC3=CN=C(N=C3N)N)OC
DMTW9GM	IK	MYQAUKPBNJWPIE-UHFFFAOYSA-N
DMTW9GM	IU	5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine
DMTW9GM	CA	CAS 870483-87-7
DMTW9GM	DE	Discovery agent

DMG60ET	ID	DMG60ET
DMG60ET	DN	GW-3965
DMG60ET	HS	Investigative
DMG60ET	SN	GW3965; 405911-09-3; GW 3965; UNII-6JI5YOG7RC; GW-3965; 6JI5YOG7RC; CHEMBL59030; CHEBI:79995; (3-{3-[[2-CHLORO-3-(TRIFLUOROMETHYL)BENZYL](2,2-DIPHENYLETHYL)AMINO]PROPOXY}PHENYL)ACETIC ACID; 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-[2,2-di(phenyl)ethyl]amino]propoxy]phenyl]acetic acid; [3-(3-{[2-Chloro-3-(Trifluoromethyl)benzyl](2,2-Diphenylethyl)amino}propoxy)phenyl]acetic Acid; GW-3965A; 3-(3-[[2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)-amino]-propoxy}-phenyl acetic acid; GW 3965A
DMG60ET	DT	Small molecular drug
DMG60ET	PC	447905
DMG60ET	MW	582
DMG60ET	FM	C33H31ClF3NO3
DMG60ET	IC	InChI=1S/C33H31ClF3NO3/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40)
DMG60ET	CS	C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4
DMG60ET	IK	NAXSRXHZFIBFMI-UHFFFAOYSA-N
DMG60ET	IU	2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid
DMG60ET	CA	CAS 405911-09-3
DMG60ET	CB	CHEBI:79995
DMG60ET	DE	Major depressive disorder

DMFRP7H	ID	DMFRP7H
DMFRP7H	DN	GW4065
DMFRP7H	HS	Investigative
DMFRP7H	DE	Discovery agent

DMIHOYF	ID	DMIHOYF
DMIHOYF	DN	GW-5074
DMIHOYF	HS	Investigative
DMIHOYF	SN	gw5074; 220904-83-6; GW 5074; Raf1 Kinase Inhibitor I; UNII-B7W8RS1GG2; B7W8RS1GG2; CHEMBL72365; 5-Iodo-3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-indolinone; 3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one; (3Z)-3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one; (Z)-3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodoindolin-2-one; SR-01000075897; STO521; 3-(3,5-Dibromo-4-hydroxybenzyliden)-5-iodo-1,3-dihydroindol-2-one; Tocris-1381
DMIHOYF	DT	Small molecular drug
DMIHOYF	PC	5924208
DMIHOYF	MW	520.94
DMIHOYF	FM	C15H8Br2INO2
DMIHOYF	IC	InChI=1S/C15H8Br2INO2/c16-11-4-7(5-12(17)14(11)20)3-10-9-6-8(18)1-2-13(9)19-15(10)21/h1-6,20H,(H,19,21)/b10-3-
DMIHOYF	CS	C1=CC2=C(C=C1I)/C(=C/C3=CC(=C(C(=C3)Br)O)Br)/C(=O)N2
DMIHOYF	IK	LMXYVLFTZRPNRV-KMKOMSMNSA-N
DMIHOYF	IU	(3Z)-3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one
DMIHOYF	CA	CAS 1233748-60-1
DMIHOYF	DE	Discovery agent

DMGRKT4	ID	DMGRKT4
DMGRKT4	DN	GW-559768X
DMGRKT4	HS	Investigative
DMGRKT4	SN	GW-569998X; GW-578257A; GW-585550A; RET tyrosine kinase inhibitors (cancer); RET tyrosine kinase inhibitors (cancer), GlaxoSmithKline
DMGRKT4	CP	GlaxoSmithKline plc
DMGRKT4	DE	Solid tumour/cancer

DMCOYF9	ID	DMCOYF9
DMCOYF9	DN	GW-5823
DMCOYF9	HS	Investigative
DMCOYF9	SN	GW5823; GW 5823
DMCOYF9	DT	Small molecular drug
DMCOYF9	PC	5311148
DMCOYF9	MW	587.7
DMCOYF9	FM	C35H33N5O4
DMCOYF9	IC	InChI=1S/C35H33N5O4/c1-23(2)39(25-17-19-26(44-3)20-18-25)33(41)22-38-31-15-9-10-16-32(31)40(24-11-5-4-6-12-24)35(43)28(34(38)42)21-30-27-13-7-8-14-29(27)36-37-30/h4-20,23,28H,21-22H2,1-3H3,(H,36,37)
DMCOYF9	CS	CC(C)N(C1=CC=C(C=C1)OC)C(=O)CN2C3=CC=CC=C3N(C(=O)C(C2=O)CC4=C5C=CC=CC5=NN4)C6=CC=CC=C6
DMCOYF9	IK	LGYKPDHARJMLQN-UHFFFAOYSA-N
DMCOYF9	IU	2-[3-(2H-indazol-3-ylmethyl)-2,4-dioxo-5-phenyl-1,5-benzodiazepin-1-yl]-N-(4-methoxyphenyl)-N-propan-2-ylacetamide
DMCOYF9	DE	Discovery agent

DMX59A0	ID	DMX59A0
DMX59A0	DN	GW-637185X
DMX59A0	HS	Investigative
DMX59A0	SN	CHEMBL539663; GW-637185X; GW637185X; BDBM50297670
DMX59A0	DT	Small molecular drug
DMX59A0	PC	45268661
DMX59A0	MW	373.4
DMX59A0	FM	C16H18F3N3O2S
DMX59A0	IC	InChI=1S/C16H18F3N3O2S/c1-4-10(2)20-15-21-13(9-14(22-15)16(17,18)19)11-5-7-12(8-6-11)25(3,23)24/h5-10H,4H2,1-3H3,(H,20,21,22)
DMX59A0	CS	CCC(C)NC1=NC(=CC(=N1)C(F)(F)F)C2=CC=C(C=C2)S(=O)(=O)C
DMX59A0	IK	BHAFHAMADYHYPJ-UHFFFAOYSA-N
DMX59A0	IU	N-butan-2-yl-4-(4-methylsulfonylphenyl)-6-(trifluoromethyl)pyrimidin-2-amine
DMX59A0	DE	Discovery agent

DMCA4RM	ID	DMCA4RM
DMCA4RM	DN	GW7604
DMCA4RM	HS	Investigative
DMCA4RM	DT	Small molecular drug
DMCA4RM	PC	9799518
DMCA4RM	MW	370.4
DMCA4RM	FM	C25H22O3
DMCA4RM	IC	InChI=1S/C25H22O3/c1-2-23(19-6-4-3-5-7-19)25(21-13-15-22(26)16-14-21)20-11-8-18(9-12-20)10-17-24(27)28/h3-17,26H,2H2,1H3,(H,27,28)/b17-10+,25-23+
DMCA4RM	CS	CC/C(=C(/C1=CC=C(C=C1)/C=C/C(=O)O)\\C2=CC=C(C=C2)O)/C3=CC=CC=C3
DMCA4RM	IK	SCVIEONTACSLJA-YGCRUXFTSA-N
DMCA4RM	IU	(E)-3-[4-[(E)-1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenyl]prop-2-enoic acid
DMCA4RM	DE	Discovery agent

DM9RD0C	ID	DM9RD0C
DM9RD0C	DN	GW7647
DM9RD0C	HS	Investigative
DM9RD0C	SN	GW-7647; GW 7647
DM9RD0C	DT	Small molecular drug
DM9RD0C	PC	3392731
DM9RD0C	MW	502.8
DM9RD0C	FM	C29H46N2O3S
DM9RD0C	IC	InChI=1S/C29H46N2O3S/c1-29(2,27(32)33)35-26-18-16-24(17-19-26)20-22-31(28(34)30-25-14-7-4-8-15-25)21-10-9-13-23-11-5-3-6-12-23/h16-19,23,25H,3-15,20-22H2,1-2H3,(H,30,34)(H,32,33)
DM9RD0C	CS	CC(C)(C(=O)O)SC1=CC=C(C=C1)CCN(CCCCC2CCCCC2)C(=O)NC3CCCCC3
DM9RD0C	IK	PKNYXWMTHFMHKD-UHFFFAOYSA-N
DM9RD0C	IU	2-[4-[2-[4-cyclohexylbutyl(cyclohexylcarbamoyl)amino]ethyl]phenyl]sulfanyl-2-methylpropanoic acid
DM9RD0C	CA	CAS 265129-71-3
DM9RD0C	CB	CHEBI:70778
DM9RD0C	DE	Discovery agent

DMEK2I4	ID	DMEK2I4
DMEK2I4	DN	GW7845
DMEK2I4	HS	Investigative
DMEK2I4	SN	GW7845; GW-7845; GW 7845; CHEMBL106666; 196809-22-0; SCHEMBL614392; GTPL2704; BDBM50085046; ZINC49748569; GW 845; GW 347845; UNII-23Y783RURX component KEGOAFNIGUBYHZ-SANMLTNESA-N; N-(2-(Methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; 2-((S)-1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester; 720711-63-7; 2-(1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester(GW 7845)
DMEK2I4	DT	Small molecular drug
DMEK2I4	PC	9870584
DMEK2I4	MW	500.5
DMEK2I4	FM	C29H28N2O6
DMEK2I4	IC	InChI=1S/C29H28N2O6/c1-19-24(31-27(37-19)21-8-4-3-5-9-21)16-17-36-22-14-12-20(13-15-22)18-26(28(32)33)30-25-11-7-6-10-23(25)29(34)35-2/h3-15,26,30H,16-18H2,1-2H3,(H,32,33)/t26-/m0/s1
DMEK2I4	CS	CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H](C(=O)O)NC4=CC=CC=C4C(=O)OC
DMEK2I4	IK	KEGOAFNIGUBYHZ-SANMLTNESA-N
DMEK2I4	IU	(2S)-2-(2-methoxycarbonylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
DMEK2I4	CA	CAS 196809-22-0
DMEK2I4	DE	Discovery agent

DMIBUW5	ID	DMIBUW5
DMIBUW5	DN	GW-788388
DMIBUW5	HS	Investigative
DMIBUW5	SN	452342-67-5; GW788388; 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide; GW-788388; GW 788388; UNII-N14114957J; CHEMBL202887; N14114957J; 4-[4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydropyran-4-yl)benzamide; N-(oxan-4-yl)-4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzamide; 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydropyran-4-yl)benzamide; cc-69; SCHEMBL373524; SCHEMBL17926774; CTK8C0589; DTXSID70196444; EX-A122; AOB2606
DMIBUW5	DT	Small molecular drug
DMIBUW5	PC	10202642
DMIBUW5	MW	425.5
DMIBUW5	FM	C25H23N5O2
DMIBUW5	IC	InChI=1S/C25H23N5O2/c31-25(29-20-9-13-32-14-10-20)18-6-4-17(5-7-18)23-15-19(8-12-27-23)21-16-28-30-24(21)22-3-1-2-11-26-22/h1-8,11-12,15-16,20H,9-10,13-14H2,(H,28,30)(H,29,31)
DMIBUW5	CS	C1COCCC1NC(=O)C2=CC=C(C=C2)C3=NC=CC(=C3)C4=C(NN=C4)C5=CC=CC=N5
DMIBUW5	IK	SAGZIBJAQGBRQA-UHFFFAOYSA-N
DMIBUW5	IU	N-(oxan-4-yl)-4-[4-(5-pyridin-2-yl-1H-pyrazol-4-yl)pyridin-2-yl]benzamide
DMIBUW5	CA	CAS 452342-67-5
DMIBUW5	DE	Solid tumour/cancer

DMWAEJ3	ID	DMWAEJ3
DMWAEJ3	DN	GW803430
DMWAEJ3	HS	Investigative
DMWAEJ3	SN	6-(4-Chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-4(3H)-one; 515141-51-2; GW 803430; GW-3430; UNII-4R0136W1PR; GW-803430; Thieno[3,2-d]pyrimidin-4(3H)-one, 6-(4-chlorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-; CHEMBL214957; GW-803,430; 4R0136W1PR; GW3430; 6-(4-Chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno(3,2-d)pyrimidin-4(3H)-one; 6-(4-chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-4(3H)-one; Thieno(3,2-d)pyrimidin-4(3H)-one,;  GW-803,430
DMWAEJ3	DT	Small molecular drug
DMWAEJ3	PC	9826520
DMWAEJ3	MW	482
DMWAEJ3	FM	C25H24ClN3O3S
DMWAEJ3	IC	InChI=1S/C25H24ClN3O3S/c1-31-22-14-19(8-9-21(22)32-13-12-28-10-2-3-11-28)29-16-27-20-15-23(33-24(20)25(29)30)17-4-6-18(26)7-5-17/h4-9,14-16H,2-3,10-13H2,1H3
DMWAEJ3	CS	COC1=C(C=CC(=C1)N2C=NC3=C(C2=O)SC(=C3)C4=CC=C(C=C4)Cl)OCCN5CCCC5
DMWAEJ3	IK	MWULMTACIBZPGN-UHFFFAOYSA-N
DMWAEJ3	IU	6-(4-chlorophenyl)-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]thieno[3,2-d]pyrimidin-4-one
DMWAEJ3	CA	CAS 515141-51-2
DMWAEJ3	DE	Discovery agent

DMRL9IN	ID	DMRL9IN
DMRL9IN	DN	GW841819X
DMRL9IN	HS	Investigative
DMRL9IN	SN	KB-75882
DMRL9IN	DT	Small molecular drug
DMRL9IN	PC	13953710
DMRL9IN	MW	423.5
DMRL9IN	FM	C25H21N5O2
DMRL9IN	IC	InChI=1S/C25H21N5O2/c1-17-28-29-24-23(27-25(31)32-16-18-10-4-2-5-11-18)26-22(19-12-6-3-7-13-19)20-14-8-9-15-21(20)30(17)24/h2-15,23H,16H2,1H3,(H,27,31)
DMRL9IN	CS	CC1=NN=C2N1C3=CC=CC=C3C(=NC2NC(=O)OCC4=CC=CC=C4)C5=CC=CC=C5
DMRL9IN	IK	TUWDLUFFAHHNEF-UHFFFAOYSA-N
DMRL9IN	IU	benzyl N-(1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl)carbamate
DMRL9IN	DE	Discovery agent

DMXA5M9	ID	DMXA5M9
DMXA5M9	DN	GW848687X
DMXA5M9	HS	Investigative
DMXA5M9	SN	GW 848687X; GW-848687X
DMXA5M9	DT	Small molecular drug
DMXA5M9	PC	10238338
DMXA5M9	MW	441.9
DMXA5M9	FM	C24H18ClF2NO3
DMXA5M9	IC	InChI=1S/C24H18ClF2NO3/c25-15-8-10-23(31-13-14-7-9-16(26)12-20(14)27)19(11-15)17-3-1-4-18(17)21-5-2-6-22(28-21)24(29)30/h2,5-12H,1,3-4,13H2,(H,29,30)
DMXA5M9	CS	C1CC(=C(C1)C2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)F)F)C4=NC(=CC=C4)C(=O)O
DMXA5M9	IK	PFODPHDNBFSMOX-UHFFFAOYSA-N
DMXA5M9	IU	6-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]cyclopenten-1-yl]pyridine-2-carboxylic acid
DMXA5M9	CA	CAS 612831-24-0
DMXA5M9	DE	Discovery agent

DML4UMT	ID	DML4UMT
DML4UMT	DN	GW-8510
DML4UMT	HS	Investigative
DML4UMT	DT	Small molecular drug
DML4UMT	PC	3536
DML4UMT	MW	449.5
DML4UMT	FM	C21H15N5O3S2
DML4UMT	IC	InChI=1S/C21H15N5O3S2/c27-21-15(19-16(25-21)8-9-17-20(19)30-12-24-17)11-23-13-4-6-14(7-5-13)31(28,29)26-18-3-1-2-10-22-18/h1-12,25,27H,(H,22,26)
DML4UMT	CS	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=CC3=C(NC4=C3C5=C(C=C4)N=CS5)O
DML4UMT	IK	CDNIYBIKHDLGMT-UHFFFAOYSA-N
DML4UMT	IU	4-[(7-hydroxy-6H-pyrrolo[2,3-g][1,3]benzothiazol-8-yl)methylideneamino]-N-pyridin-2-ylbenzenesulfonamide
DML4UMT	CB	CHEBI:95283
DML4UMT	DE	Discovery agent

DMITKX8	ID	DMITKX8
DMITKX8	DN	GW853606
DMITKX8	HS	Investigative
DMITKX8	SN	GW853606X; compound 22 [PMID: 19097784]
DMITKX8	DT	Small molecular drug
DMITKX8	PC	25263088
DMITKX8	MW	496.3
DMITKX8	FM	C20H13BrF3N3O2S
DMITKX8	IC	InChI=1S/C20H13BrF3N3O2S/c21-13-4-2-1-3-11(13)9-29-16-8-17(30-18(16)19(25)28)27-10-26-14-6-5-12(7-15(14)27)20(22,23)24/h1-8,10H,9H2,(H2,25,28)
DMITKX8	CS	C1=CC=C(C(=C1)COC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)C(F)(F)F)C(=O)N)Br
DMITKX8	IK	LOKKVFGDJAVMLU-UHFFFAOYSA-N
DMITKX8	IU	3-[(2-bromophenyl)methoxy]-5-[6-(trifluoromethyl)benzimidazol-1-yl]thiophene-2-carboxamide
DMITKX8	DE	Discovery agent

DMVKZ5I	ID	DMVKZ5I
DMVKZ5I	DN	GW9508
DMVKZ5I	HS	Investigative
DMVKZ5I	SN	GW-9508; GW 9508
DMVKZ5I	DT	Small molecular drug
DMVKZ5I	PC	11595431
DMVKZ5I	MW	347.4
DMVKZ5I	FM	C22H21NO3
DMVKZ5I	IC	InChI=1S/C22H21NO3/c24-22(25)14-11-17-9-12-19(13-10-17)23-16-18-5-4-8-21(15-18)26-20-6-2-1-3-7-20/h1-10,12-13,15,23H,11,14,16H2,(H,24,25)
DMVKZ5I	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)CNC3=CC=C(C=C3)CCC(=O)O
DMVKZ5I	IK	DGENZVKCTGIDRZ-UHFFFAOYSA-N
DMVKZ5I	IU	3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid
DMVKZ5I	CA	CAS 885101-89-3
DMVKZ5I	CB	CHEBI:93259
DMVKZ5I	DE	Discovery agent

DMPIRE0	ID	DMPIRE0
DMPIRE0	DN	GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2
DMPIRE0	HS	Investigative
DMPIRE0	PC	91934075
DMPIRE0	MW	3156.4
DMPIRE0	FM	C139H211N43O42
DMPIRE0	IC	InChI=1S/C139H211N43O42/c1-65(2)38-84(166-122(208)86(40-67(5)6)167-124(210)88(43-75-31-33-79(189)34-32-75)162-106(194)55-152-115(201)70(11)158-132(218)98(60-184)177-128(214)95(49-104(144)192)171-123(209)87(41-68(7)8)174-137(223)112(72(13)187)181-131(217)90(160-105(193)51-141)44-76-52-151-81-27-19-18-26-80(76)81)117(203)155-58-109(197)182-37-23-30-101(182)135(221)173-91(45-77-53-148-63-156-77)121(207)159-71(12)116(202)179-111(69(9)10)136(222)154-57-108(196)163-94(48-103(143)191)127(213)169-92(46-78-54-149-64-157-78)126(212)165-83(29-22-36-150-139(146)147)120(206)176-99(61-185)133(219)168-89(42-74-24-16-15-17-25-74)125(211)178-100(62-186)134(220)172-96(50-110(198)199)129(215)164-82(28-20-21-35-140)119(205)170-93(47-102(142)190)118(204)153-56-107(195)161-85(39-66(3)4)130(216)180-113(73(14)188)138(224)175-97(59-183)114(145)200/h15-19,24-27,31-34,52-54,63-73,82-101,111-113,151,183-189H,20-23,28-30,35-51,55-62,140-141H2,1-14H3,(H2,142,190)(H2,143,191)(H2,144,192)(H2,145,200)(H,148,156)(H,149,157)(H,152,201)(H,153,204)(H,154,222)(H,155,203)(H,158,218)(H,159,207)(H,160,193)(H,161,195)(H,162,194)(H,163,196)(H,164,215)(H,165,212)(H,166,208)(H,167,210)(H,168,219)(H,169,213)(H,170,205)(H,171,209)(H,172,220)(H,173,221)(H,174,223)(H,175,224)(H,176,206)(H,177,214)(H,178,211)(H,179,202)(H,180,216)(H,181,217)(H,198,199)(H4,146,147,150)/t70-,71-,72+,73+,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,111-,112-,113-/m0/s1
DMPIRE0	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC4=CN=CN4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC6=CNC7=CC=CC=C76)NC(=O)CN)O
DMPIRE0	IK	VYHIHGYPAVCHDV-RUKUCZSXSA-N
DMPIRE0	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-oxobutanoic acid
DMPIRE0	DE	Discovery agent

DMZPRIG	ID	DMZPRIG
DMZPRIG	DN	GWTLNSAGYLLGPHAV-NH2
DMZPRIG	HS	Investigative
DMZPRIG	SN	CHEMBL508083; GWTLNSAGYLLGPHAV-NH2
DMZPRIG	PC	44587982
DMZPRIG	MW	1654.9
DMZPRIG	FM	C77H115N21O20
DMZPRIG	IC	InChI=1S/C77H115N21O20/c1-37(2)23-50(68(109)84-34-62(105)98-22-14-17-58(98)76(117)93-55(28-46-32-81-36-85-46)69(110)87-42(10)67(108)96-63(40(7)8)65(80)106)90-70(111)51(24-38(3)4)91-72(113)53(26-44-18-20-47(101)21-19-44)89-61(104)33-83-66(107)41(9)86-75(116)57(35-99)95-73(114)56(29-59(79)102)92-71(112)52(25-39(5)6)94-77(118)64(43(11)100)97-74(115)54(88-60(103)30-78)27-45-31-82-49-16-13-12-15-48(45)49/h12-13,15-16,18-21,31-32,36-43,50-58,63-64,82,99-101H,14,17,22-30,33-35,78H2,1-11H3,(H2,79,102)(H2,80,106)(H,81,85)(H,83,107)(H,84,109)(H,86,116)(H,87,110)(H,88,103)(H,89,104)(H,90,111)(H,91,113)(H,92,112)(H,93,117)(H,94,118)(H,95,114)(H,96,108)(H,97,115)/t41-,42-,43+,50-,51-,52-,53-,54-,55-,56-,57-,58-,63-,64-/m0/s1
DMZPRIG	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CC4=CNC5=CC=CC=C54)NC(=O)CN)O
DMZPRIG	IK	QWMBNRVWDTXENF-LJQDGMHUSA-N
DMZPRIG	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMZPRIG	DE	Discovery agent

DMKFMQ5	ID	DMKFMQ5
DMKFMQ5	DN	GWTLNSAGYLLGPPPALALA-CONH2
DMKFMQ5	HS	Investigative
DMKFMQ5	SN	143896-17-7; CHEMBL604990; M40; GWTLNSAGYLLGPPPALALA-CONH2; GALANIN RECEPTOR LIGAND M40; BDBM50307254; AKOS024457623; Galanin (1-13)-Pro-Pro-(Ala-Leu-)2Ala amide
DMKFMQ5	PC	16133821
DMKFMQ5	MW	1981.3
DMKFMQ5	FM	C94H145N23O24
DMKFMQ5	IC	InChI=1S/C94H145N23O24/c1-46(2)33-61(82(129)100-44-76(124)115-30-19-24-71(115)93(140)117-32-20-25-72(117)94(141)116-31-18-23-70(116)91(138)104-54(14)81(128)108-63(35-48(5)6)84(131)103-53(13)80(127)107-62(34-47(3)4)83(130)101-51(11)78(97)125)109-85(132)64(36-49(7)8)110-87(134)66(38-56-26-28-58(120)29-27-56)106-75(123)43-99-79(126)52(12)102-90(137)69(45-118)113-88(135)68(40-73(96)121)111-86(133)65(37-50(9)10)112-92(139)77(55(15)119)114-89(136)67(105-74(122)41-95)39-57-42-98-60-22-17-16-21-59(57)60/h16-17,21-22,26-29,42,46-55,61-72,77,98,118-120H,18-20,23-25,30-41,43-45,95H2,1-15H3,(H2,96,121)(H2,97,125)(H,99,126)(H,100,129)(H,101,130)(H,102,137)(H,103,131)(H,104,138)(H,105,122)(H,106,123)(H,107,127)(H,108,128)(H,109,132)(H,110,134)(H,111,133)(H,112,139)(H,113,135)(H,114,136)/t51-,52-,53-,54-,55+,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,77-/m0/s1
DMKFMQ5	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)CN)O
DMKFMQ5	IK	OSGCBUDLRBUEGW-JZCUZNMGSA-N
DMKFMQ5	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMKFMQ5	DE	Discovery agent

DMVWGM2	ID	DMVWGM2
DMVWGM2	DN	GWTLNSAGYLLGPPPGFSPFR-CONH2
DMVWGM2	HS	Investigative
DMVWGM2	SN	M35 Peptide; Galanin-(1-13)-bradykinin-(2-9)-amide; 142846-71-7; M-35; L-Argininamide, glycyl-L-tryptophyl-L-threonyl-L-leucyl-L-asparaginyl-L-seryl-L-alanylglycyl-L-tyrosyl-L-leucyl-L-leucylglycyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-; M 35; Galanin(1-13)-bradykinin(2-9)amide; NCGC00167245-01
DMVWGM2	PC	91934871
DMVWGM2	MW	2233.5
DMVWGM2	FM	C107H153N27O26
DMVWGM2	IC	InChI=1S/C107H153N27O26/c1-57(2)42-70(123-93(147)71(43-58(3)4)124-95(149)74(47-64-33-35-66(138)36-34-64)121-86(141)52-115-91(145)60(7)118-100(154)78(55-135)128-98(152)77(49-84(109)139)125-94(148)72(44-59(5)6)127-103(157)89(61(8)137)130-99(153)76(119-85(140)50-108)48-65-51-114-68-27-16-15-26-67(65)68)92(146)117-54-88(143)131-38-20-31-82(131)105(159)134-41-21-32-83(134)106(160)133-40-18-29-80(133)101(155)116-53-87(142)120-73(45-62-22-11-9-12-23-62)96(150)129-79(56-136)104(158)132-39-19-30-81(132)102(156)126-75(46-63-24-13-10-14-25-63)97(151)122-69(90(110)144)28-17-37-113-107(111)112/h9-16,22-27,33-36,51,57-61,69-83,89,114,135-138H,17-21,28-32,37-50,52-56,108H2,1-8H3,(H2,109,139)(H2,110,144)(H,115,145)(H,116,155)(H,117,146)(H,118,154)(H,119,140)(H,120,142)(H,121,141)(H,122,151)(H,123,147)(H,124,149)(H,125,148)(H,126,156)(H,127,157)(H,128,152)(H,129,150)(H,130,153)(H4,111,112,113)/t60-,61+,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-/m0/s1
DMVWGM2	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CO)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)CN)O
DMVWGM2	IK	JWMXJVFGTXYBFM-AEXVMZOXSA-N
DMVWGM2	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[(2S)-2-[(2S)-2-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMVWGM2	DE	Discovery agent

DM5YR4S	ID	DM5YR4S
DM5YR4S	DN	GWTLNSAGYLLGPRHYINLITRQRY-CONH2
DM5YR4S	HS	Investigative
DM5YR4S	PC	91934077
DM5YR4S	MW	2849.2
DM5YR4S	FM	C130H198N40O33
DM5YR4S	IC	InChI=1S/C130H198N40O33/c1-14-67(10)104(125(201)165-95(55-100(134)179)118(194)160-89(48-66(8)9)120(196)168-105(69(12)172)126(202)156-83(25-19-43-145-130(140)141)110(186)154-84(39-40-98(132)177)113(189)153-81(23-17-41-143-128(136)137)111(187)157-85(107(135)183)49-71-27-33-76(174)34-28-71)167-121(197)91(51-73-31-37-78(176)38-32-73)161-117(193)93(53-75-58-142-62-149-75)162-112(188)82(24-18-42-144-129(138)139)155-124(200)97-26-20-44-170(97)103(182)60-148-109(185)86(45-63(2)3)158-114(190)87(46-64(4)5)159-116(192)90(50-72-29-35-77(175)36-30-72)152-102(181)59-147-108(184)68(11)150-123(199)96(61-171)166-119(195)94(54-99(133)178)163-115(191)88(47-65(6)7)164-127(203)106(70(13)173)169-122(198)92(151-101(180)56-131)52-74-57-146-80-22-16-15-21-79(74)80/h15-16,21-22,27-38,57-58,62-70,81-97,104-106,146,171-176H,14,17-20,23-26,39-56,59-61,131H2,1-13H3,(H2,132,177)(H2,133,178)(H2,134,179)(H2,135,183)(H,142,149)(H,147,184)(H,148,185)(H,150,199)(H,151,180)(H,152,181)(H,153,189)(H,154,186)(H,155,200)(H,156,202)(H,157,187)(H,158,190)(H,159,192)(H,160,194)(H,161,193)(H,162,188)(H,163,191)(H,164,203)(H,165,201)(H,166,195)(H,167,197)(H,168,196)(H,169,198)(H4,136,137,143)(H4,138,139,144)(H4,140,141,145)/t67-,68-,69+,70+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,104-,105-,106-/m0/s1
DM5YR4S	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CNC7=CC=CC=C76)NC(=O)CN
DM5YR4S	IK	SQXQKSDIKGRBPX-MNFZLFQXSA-N
DM5YR4S	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DM5YR4S	DE	Discovery agent

DM48AV3	ID	DM48AV3
DM48AV3	DN	GWTLNSAGYLLGPrPKPQQwFwLL-CONH2
DM48AV3	HS	Investigative
DM48AV3	SN	NCGC00167329-01
DM48AV3	PC	91934078
DM48AV3	MW	2828.3
DM48AV3	FM	C138H199N35O30
DM48AV3	IC	InChI=1S/C138H199N35O30/c1-72(2)54-95(117(144)183)160-122(188)97(56-74(5)6)163-127(193)104(63-83-68-150-90-35-21-18-32-87(83)90)166-126(192)101(59-79-28-14-13-15-29-79)164-128(194)103(62-82-67-149-89-34-20-17-31-86(82)89)165-121(187)91(45-47-110(141)177)156-120(186)92(46-48-111(142)178)157-133(199)108-39-26-52-172(108)136(202)93(36-22-23-49-139)158-134(200)109-40-27-53-173(109)137(203)94(37-24-50-147-138(145)146)159-132(198)107-38-25-51-171(107)115(182)70-152-119(185)96(55-73(3)4)161-123(189)98(57-75(7)8)162-125(191)100(60-80-41-43-84(176)44-42-80)155-114(181)69-151-118(184)77(11)153-131(197)106(71-174)169-129(195)105(64-112(143)179)167-124(190)99(58-76(9)10)168-135(201)116(78(12)175)170-130(196)102(154-113(180)65-140)61-81-66-148-88-33-19-16-30-85(81)88/h13-21,28-35,41-44,66-68,72-78,91-109,116,148-150,174-176H,22-27,36-40,45-65,69-71,139-140H2,1-12H3,(H2,141,177)(H2,142,178)(H2,143,179)(H2,144,183)(H,151,184)(H,152,185)(H,153,197)(H,154,180)(H,155,181)(H,156,186)(H,157,199)(H,158,200)(H,159,198)(H,160,188)(H,161,189)(H,162,191)(H,163,193)(H,164,194)(H,165,187)(H,166,192)(H,167,190)(H,168,201)(H,169,195)(H,170,196)(H4,145,146,147)/t77-,78+,91-,92-,93-,94+,95-,96-,97-,98-,99-,100-,101-,102-,103+,104+,105-,106-,107-,108-,109-,116-/m0/s1
DM48AV3	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H](CCCN=C(N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N[C@H](CC8=CNC9=CC=CC=C98)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN)O
DM48AV3	IK	LTAFNTKZCARRFJ-HPWFANMZSA-N
DM48AV3	IU	(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DM48AV3	DE	Discovery agent

DM8GFJP	ID	DM8GFJP
DM8GFJP	DN	GX-C4
DM8GFJP	HS	Investigative
DM8GFJP	SN	CTLA-4/Fc region of a hybrid IgG4/IgD antibody (fusion protein, autoimmune disease), Genexine
DM8GFJP	CP	Genexine Co Ltd
DM8GFJP	DT	Antibody
DM8GFJP	DE	Autoimmune diabetes

DM1RY6Q	ID	DM1RY6Q
DM1RY6Q	DN	GX-G6
DM1RY6Q	HS	Investigative
DM1RY6Q	SN	GX-G9; GLP-1/Fc antibody (fusion protein, diabetes), Genexine; GLP-1/Fc antibody fusion protein (diabetes), Genexine/ IlDong
DM1RY6Q	CP	Genexine Co Ltd
DM1RY6Q	DT	Antibody
DM1RY6Q	DE	Diabetic complication

DM7SLAM	ID	DM7SLAM
DM7SLAM	DN	Gymnochrome E
DM7SLAM	HS	Investigative
DM7SLAM	DT	Small molecular drug
DM7SLAM	PC	135894458
DM7SLAM	MW	778.4
DM7SLAM	FM	C36H26Br2O10
DM7SLAM	IC	InChI=1S/C36H26Br2O10/c1-3-4-10(40)6-12-18-17-11(5-9(2)39)31(37)35(47)29-23(17)27-25-19(13(41)7-15(43)21(25)33(29)45)20-14(42)8-16(44)22-26(20)28(27)24(18)30(34(22)46)36(48)32(12)38/h7-10,39-40,43-48H,3-6H2,1-2H3/t9-,10+/m0/s1
DM7SLAM	CS	CCC[C@H](CC1=C2C3=C(C(=C(C4=C(C5=C6C(=C7C(=O)C=C(C8=C7C(=C2C(=C8O)C(=C1Br)O)C6=C34)O)C(=O)C=C5O)O)O)Br)C[C@H](C)O)O
DM7SLAM	IK	PGSCEVFXDRXNMP-VHSXEESVSA-N
DM7SLAM	IU	12,17-dibromo-7,9,11,18,20,22-hexahydroxy-13-[(2R)-2-hydroxypentyl]-16-[(2S)-2-hydroxypropyl]octacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(27),2(28),3(8),4(25),6,9,11,13,15,17,19,21(26),22-tridecaene-5,24-dione
DM7SLAM	DE	Discovery agent

DM8ENQZ	ID	DM8ENQZ
DM8ENQZ	DN	Gypenoside XVII
DM8ENQZ	HS	Investigative
DM8ENQZ	SN	Ginsenoside XVII; Gynosaponin S; Q27146716; ZINC253387973; 80321-69-3; AKOS027251125; C20736; CHEBI:77155; CHEMBL504441; CS-4163; GYPENOSIDE-XVII; Gypenoside XVII; HY-N0553; N2767; Y0100; s9207
DM8ENQZ	PC	44584555
DM8ENQZ	MW	947.2
DM8ENQZ	FM	C48H82O18
DM8ENQZ	IC	ZRBFCAALKKNCJG-SJYBZOGZSA-N
DM8ENQZ	CS	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)O)C)C)O)C)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)O)O)O)O)O)O)C
DM8ENQZ	IK	1S/C48H82O18/c1-22(2)10-9-14-48(8,66-43-40(60)37(57)34(54)27(64-43)21-61-41-38(58)35(55)32(52)25(19-49)62-41)23-11-16-47(7)31(23)24(51)18-29-45(5)15-13-30(44(3,4)28(45)12-17-46(29,47)6)65-42-39(59)36(56)33(53)26(20-50)63-42/h10,23-43,49-60H,9,11-21H2,1-8H3/t23-,24+,25+,26+,27+,28-,29+,30-,31-,32+,33+,34+,35-,36-,37-,38+,39+,40+,41+,42-,43-,45-,46+,47+,48-/m0/s1
DM8ENQZ	IU	(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S)-2-[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol
DM8ENQZ	CA	CAS 80321-69-3
DM8ENQZ	CB	CHEBI:77155
DM8ENQZ	DE	Arteriosclerosis obliterans

DM9XK05	ID	DM9XK05
DM9XK05	DN	H-[Trp-Arg-Nva-Arg-Tyr]2-NH2
DM9XK05	HS	Investigative
DM9XK05	SN	CHEMBL408891; H-[Trp-Arg-Nva-Arg-Tyr]2-NH2
DM9XK05	PC	44409452
DM9XK05	MW	1538.8
DM9XK05	FM	C74H107N25O12
DM9XK05	IC	InChI=1S/C74H107N25O12/c1-3-13-52(92-65(106)54(19-9-31-85-71(77)78)91-62(103)49(75)37-43-39-89-50-17-7-5-15-47(43)50)64(105)95-57(22-12-34-88-74(83)84)68(109)98-59(36-42-25-29-46(101)30-26-42)69(110)99-60(38-44-40-90-51-18-8-6-16-48(44)51)70(111)96-55(20-10-32-86-72(79)80)66(107)93-53(14-4-2)63(104)94-56(21-11-33-87-73(81)82)67(108)97-58(61(76)102)35-41-23-27-45(100)28-24-41/h5-8,15-18,23-30,39-40,49,52-60,89-90,100-101H,3-4,9-14,19-22,31-38,75H2,1-2H3,(H2,76,102)(H,91,103)(H,92,106)(H,93,107)(H,94,104)(H,95,105)(H,96,111)(H,97,108)(H,98,109)(H,99,110)(H4,77,78,85)(H4,79,80,86)(H4,81,82,87)(H4,83,84,88)/t49-,52-,53-,54-,55-,56-,57-,58-,59-,60-/m0/s1
DM9XK05	CS	CCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)N
DM9XK05	IK	QTWWWOBSQULXHE-MTVPJWGZSA-N
DM9XK05	IU	(2S)-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DM9XK05	DE	Discovery agent

DMKH8PF	ID	DMKH8PF
DMKH8PF	DN	H-[Trp-Arg-Nva-Arg-Tyr]3-NH2
DMKH8PF	HS	Investigative
DMKH8PF	SN	CHEMBL413871; H-[Trp-Arg-Nva-Arg-Tyr]3-NH2
DMKH8PF	PC	44409453
DMKH8PF	MW	2299.7
DMKH8PF	FM	C111H159N37O18
DMKH8PF	IC	InChI=1S/C111H159N37O18/c1-4-19-77(136-96(157)80(28-13-46-126-106(114)115)135-92(153)73(112)55-64-58-132-74-25-10-7-22-70(64)74)94(155)140-84(32-17-50-130-110(122)123)100(161)145-87(53-62-36-42-68(150)43-37-62)102(163)148-90(57-66-60-134-76-27-12-9-24-72(66)76)105(166)143-82(30-15-48-128-108(118)119)98(159)138-79(21-6-3)95(156)141-85(33-18-51-131-111(124)125)101(162)146-88(54-63-38-44-69(151)45-39-63)103(164)147-89(56-65-59-133-75-26-11-8-23-71(65)75)104(165)142-81(29-14-47-127-107(116)117)97(158)137-78(20-5-2)93(154)139-83(31-16-49-129-109(120)121)99(160)144-86(91(113)152)52-61-34-40-67(149)41-35-61/h7-12,22-27,34-45,58-60,73,77-90,132-134,149-151H,4-6,13-21,28-33,46-57,112H2,1-3H3,(H2,113,152)(H,135,153)(H,136,157)(H,137,158)(H,138,159)(H,139,154)(H,140,155)(H,141,156)(H,142,165)(H,143,166)(H,144,160)(H,145,161)(H,146,162)(H,147,164)(H,148,163)(H4,114,115,126)(H4,116,117,127)(H4,118,119,128)(H4,120,121,129)(H4,122,123,130)(H4,124,125,131)/t73-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-/m0/s1
DMKH8PF	CS	CCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)N
DMKH8PF	IK	DRBRBJSYRQHXHE-TWUBVJIJSA-N
DMKH8PF	IU	(2S)-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DMKH8PF	DE	Discovery agent

DMYOADQ	ID	DMYOADQ
DMYOADQ	DN	H-2',6'-dimethyltyrosine-Tic-OH
DMYOADQ	HS	Investigative
DMYOADQ	SN	CHEMBL571492; 2,6-Dimethyl-L-Tyr-L-Tic-OH; BDBM50299565; H-2'',6''-dimethyltyrosine-Tic-OH; (S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
DMYOADQ	DT	Small molecular drug
DMYOADQ	PC	15384271
DMYOADQ	MW	368.4
DMYOADQ	FM	C21H24N2O4
DMYOADQ	IC	InChI=1S/C21H24N2O4/c1-12-7-16(24)8-13(2)17(12)10-18(22)20(25)23-11-15-6-4-3-5-14(15)9-19(23)21(26)27/h3-8,18-19,24H,9-11,22H2,1-2H3,(H,26,27)/t18-,19-/m0/s1
DMYOADQ	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O)N)C)O
DMYOADQ	IK	QBLVXTMPLLWZDE-OALUTQOASA-N
DMYOADQ	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid

DM7IEU2	ID	DM7IEU2
DM7IEU2	DN	H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH
DM7IEU2	HS	Investigative
DM7IEU2	SN	CHEMBL555206; BDBM50299557; H-2'',6''-dimethyltyrosine-Tic-Phe-Phe-OH; (S)-2-((S)-2-((S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-3-phenylpropanamido)-3-phenylpropanoic acid
DM7IEU2	DT	Small molecular drug
DM7IEU2	PC	45273695
DM7IEU2	MW	662.8
DM7IEU2	FM	C39H42N4O6
DM7IEU2	IC	InChI=1S/C39H42N4O6/c1-24-17-30(44)18-25(2)31(24)22-32(40)38(47)43-23-29-16-10-9-15-28(29)21-35(43)37(46)41-33(19-26-11-5-3-6-12-26)36(45)42-34(39(48)49)20-27-13-7-4-8-14-27/h3-18,32-35,44H,19-23,40H2,1-2H3,(H,41,46)(H,42,45)(H,48,49)/t32-,33-,34-,35-/m0/s1
DM7IEU2	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DM7IEU2	IK	SZIMPGYQGJRODH-BBACVFHCSA-N
DM7IEU2	IU	(2S)-2-[[(2S)-2-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
DM7IEU2	DE	Discovery agent

DMOJI0N	ID	DMOJI0N
DMOJI0N	DN	H22xKi-4
DMOJI0N	HS	Investigative
DMOJI0N	DT	Antibody
DMOJI0N	DE	Discovery agent

DM80QF9	ID	DM80QF9
DM80QF9	DN	H-8
DM80QF9	HS	Investigative
DM80QF9	SN	84478-11-5; Protein kinase inhibitor H-8; h-8; H-8 Protein kinase inhibitor; N-(2-(Methylamino)ethyl)-5-isoquinolinesulfonamide; N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE; N-[2-(methylamino)ethyl]isoquinoline-5-sulfonamide; (5-Isoquinolylsulfonyl)[2-(methylamino)ethyl]amine; Lopac-M-9656; CHEMBL148333; CHEBI:43561; H8; N-(2-methylaminoethyl)isoquinoline-5-sulfonamide; (5-Isoquinolylsulfonyl)(2-(methylamino)ethyl)amine; 5-Isoquinolinesulfonamide, N-(2-(methylamino)ethyl)-; N-(2-(Methylamino)ethyl)isoquinoline- 5-s
DM80QF9	DT	Small molecular drug
DM80QF9	PC	3540
DM80QF9	MW	265.33
DM80QF9	FM	C12H15N3O2S
DM80QF9	IC	InChI=1S/C12H15N3O2S/c1-13-7-8-15-18(16,17)12-4-2-3-10-9-14-6-5-11(10)12/h2-6,9,13,15H,7-8H2,1H3
DM80QF9	CS	CNCCNS(=O)(=O)C1=CC=CC2=C1C=CN=C2
DM80QF9	IK	PJWUXKNZVMEPPH-UHFFFAOYSA-N
DM80QF9	IU	N-[2-(methylamino)ethyl]isoquinoline-5-sulfonamide
DM80QF9	CA	CAS 84478-11-5
DM80QF9	CB	CHEBI:43561
DM80QF9	DE	Discovery agent

DM43ODJ	ID	DM43ODJ
DM43ODJ	DN	H87/07
DM43ODJ	HS	Investigative
DM43ODJ	SN	H 87-07
DM43ODJ	DT	Small molecular drug
DM43ODJ	PC	193122
DM43ODJ	MW	283.36
DM43ODJ	FM	C15H25NO4
DM43ODJ	IC	InChI=1S/C15H25NO4/c1-12(2)16-10-13(17)11-20-15-6-4-14(5-7-15)19-9-8-18-3/h4-7,12-13,16-17H,8-11H2,1-3H3
DM43ODJ	CS	CC(C)NCC(COC1=CC=C(C=C1)OCCOC)O
DM43ODJ	IK	FGAPARDHTDKREN-UHFFFAOYSA-N
DM43ODJ	IU	1-[4-(2-methoxyethoxy)phenoxy]-3-(propan-2-ylamino)propan-2-ol
DM43ODJ	CA	CAS 30311-37-6
DM43ODJ	DE	Discovery agent

DM4RVGO	ID	DM4RVGO
DM4RVGO	DN	H-89
DM4RVGO	HS	Investigative
DM4RVGO	SN	H 89
DM4RVGO	DT	Small molecular drug
DM4RVGO	PC	449241
DM4RVGO	MW	446.4
DM4RVGO	FM	C20H20BrN3O2S
DM4RVGO	IC	InChI=1S/C20H20BrN3O2S/c21-18-8-6-16(7-9-18)3-2-11-22-13-14-24-27(25,26)20-5-1-4-17-15-23-12-10-19(17)20/h1-10,12,15,22,24H,11,13-14H2/b3-2+
DM4RVGO	CS	C1=CC2=C(C=CN=C2)C(=C1)S(=O)(=O)NCCNC/C=C/C3=CC=C(C=C3)Br
DM4RVGO	IK	ZKZXNDJNWUTGDK-NSCUHMNNSA-N
DM4RVGO	IU	N-[2-[[(E)-3-(4-bromophenyl)prop-2-enyl]amino]ethyl]isoquinoline-5-sulfonamide
DM4RVGO	CA	CAS 127243-85-0
DM4RVGO	CB	CHEBI:47495
DM4RVGO	DE	Discovery agent

DM61G0I	ID	DM61G0I
DM61G0I	DN	H-Aba-ala-Gly-Phe-leu-OH
DM61G0I	HS	Investigative
DM61G0I	SN	CHEMBL247064; H-Aba-ala-Gly-Phe-leu-OH
DM61G0I	DT	Small molecular drug
DM61G0I	PC	44439877
DM61G0I	MW	625.7
DM61G0I	FM	C30H39N7O6S
DM61G0I	IC	InChI=1S/C30H39N7O6S/c1-16(2)11-23(29(42)43)36-28(41)22(13-18-7-5-4-6-8-18)35-25(38)15-33-26(39)17(3)34-27(40)20(31)12-19-9-10-21-24(14-19)44-30(32)37-21/h4-10,14,16-17,20,22-23H,11-13,15,31H2,1-3H3,(H2,32,37)(H,33,39)(H,34,40)(H,35,38)(H,36,41)(H,42,43)/t17-,20-,22-,23-/m0/s1
DM61G0I	CS	C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC3=C(C=C2)N=C(S3)N)N
DM61G0I	IK	VLIQMZUUPDOVAM-NWZJSZKRSA-N
DM61G0I	IU	(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(2-amino-1,3-benzothiazol-6-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM61G0I	DE	Discovery agent

DMKD94Q	ID	DMKD94Q
DMKD94Q	DN	H-Aba-ala-Gly-Phe-Met-OH
DMKD94Q	HS	Investigative
DMKD94Q	SN	CHEMBL246572; H-Aba-ala-Gly-Phe-Met-OH
DMKD94Q	DT	Small molecular drug
DMKD94Q	PC	44439910
DMKD94Q	MW	643.8
DMKD94Q	FM	C29H37N7O6S2
DMKD94Q	IC	InChI=1S/C29H37N7O6S2/c1-16(33-26(39)19(30)12-18-8-9-20-23(14-18)44-29(31)36-20)25(38)32-15-24(37)34-22(13-17-6-4-3-5-7-17)27(40)35-21(28(41)42)10-11-43-2/h3-9,14,16,19,21-22H,10-13,15,30H2,1-2H3,(H2,31,36)(H,32,38)(H,33,39)(H,34,37)(H,35,40)(H,41,42)/t16-,19-,21-,22-/m0/s1
DMKD94Q	CS	C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC2=CC3=C(C=C2)N=C(S3)N)N
DMKD94Q	IK	NQZMBRNFTRPOCP-PWZKMPOXSA-N
DMKD94Q	IU	(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(2-amino-1,3-benzothiazol-6-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DMKD94Q	DE	Discovery agent

DMH1L3P	ID	DMH1L3P
DMH1L3P	DN	H-Aba-Gly-Gly-Phe-Leu-OH
DMH1L3P	HS	Investigative
DMH1L3P	SN	CHEMBL247759; H-Aba-Gly-Gly-Phe-Leu-OH
DMH1L3P	DT	Small molecular drug
DMH1L3P	PC	44439882
DMH1L3P	MW	611.7
DMH1L3P	FM	C29H37N7O6S
DMH1L3P	IC	InChI=1S/C29H37N7O6S/c1-16(2)10-22(28(41)42)35-27(40)21(12-17-6-4-3-5-7-17)34-25(38)15-32-24(37)14-33-26(39)19(30)11-18-8-9-20-23(13-18)43-29(31)36-20/h3-9,13,16,19,21-22H,10-12,14-15,30H2,1-2H3,(H2,31,36)(H,32,37)(H,33,39)(H,34,38)(H,35,40)(H,41,42)/t19-,21-,22-/m0/s1
DMH1L3P	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC3=C(C=C2)N=C(S3)N)N
DMH1L3P	IK	AHRIYJIWFATUOS-BVSLBCMMSA-N
DMH1L3P	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(2-amino-1,3-benzothiazol-6-yl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMH1L3P	DE	Discovery agent

DMFE3J4	ID	DMFE3J4
DMFE3J4	DN	H-Aba-ser-Gly-Phe-Leu-Thr-OH
DMFE3J4	HS	Investigative
DMFE3J4	SN	CHEMBL246479; H-Aba-ser-Gly-Phe-Leu-Thr-OH
DMFE3J4	DT	Small molecular drug
DMFE3J4	PC	44439907
DMFE3J4	MW	742.8
DMFE3J4	FM	C34H46N8O9S
DMFE3J4	IC	InChI=1S/C34H46N8O9S/c1-17(2)11-23(32(49)42-28(18(3)44)33(50)51)39-31(48)24(13-19-7-5-4-6-8-19)38-27(45)15-37-30(47)25(16-43)40-29(46)21(35)12-20-9-10-22-26(14-20)52-34(36)41-22/h4-10,14,17-18,21,23-25,28,43-44H,11-13,15-16,35H2,1-3H3,(H2,36,41)(H,37,47)(H,38,45)(H,39,48)(H,40,46)(H,42,49)(H,50,51)/t18-,21+,23+,24+,25+,28+/m1/s1
DMFE3J4	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC3=C(C=C2)N=C(S3)N)N)O
DMFE3J4	IK	XSYMBKQKMSKFJU-LEKCGIOJSA-N
DMFE3J4	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(2-amino-1,3-benzothiazol-6-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DMFE3J4	DE	Discovery agent

DMQCGRI	ID	DMQCGRI
DMQCGRI	DN	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-NH2
DMQCGRI	HS	Investigative
DMQCGRI	PC	16200894
DMQCGRI	MW	3354.7
DMQCGRI	FM	C151H229N41O46
DMQCGRI	IC	InChI=1S/C151H229N41O46/c1-17-77(10)121(148(236)170-81(14)127(215)178-105(60-87-63-161-92-36-25-24-35-90(87)92)138(226)180-101(56-74(4)5)139(227)189-119(75(6)7)146(234)177-94(37-26-28-52-152)130(218)163-66-112(201)171-93(39-30-54-160-151(157)158)129(217)162-65-111(156)200)191-140(228)103(57-84-31-20-18-21-32-84)181-135(223)99(47-51-117(208)209)176-134(222)95(38-27-29-53-153)173-125(213)79(12)167-124(212)78(11)169-133(221)98(44-48-110(155)199)172-113(202)67-164-132(220)97(46-50-116(206)207)175-136(224)100(55-73(2)3)179-137(225)102(59-86-40-42-89(198)43-41-86)182-143(231)107(69-193)185-145(233)109(71-195)186-147(235)120(76(8)9)190-142(230)106(62-118(210)211)183-144(232)108(70-194)187-150(238)123(83(16)197)192-141(229)104(58-85-33-22-19-23-34-85)184-149(237)122(82(15)196)188-114(203)68-165-131(219)96(45-49-115(204)205)174-126(214)80(13)168-128(216)91(154)61-88-64-159-72-166-88/h18-25,31-36,40-43,63-64,72-83,91,93-109,119-123,161,193-198H,17,26-30,37-39,44-62,65-71,152-154H2,1-16H3,(H2,155,199)(H2,156,200)(H,159,166)(H,162,217)(H,163,218)(H,164,220)(H,165,219)(H,167,212)(H,168,216)(H,169,221)(H,170,236)(H,171,201)(H,172,202)(H,173,213)(H,174,214)(H,175,224)(H,176,222)(H,177,234)(H,178,215)(H,179,225)(H,180,226)(H,181,223)(H,182,231)(H,183,232)(H,184,237)(H,185,233)(H,186,235)(H,187,238)(H,188,203)(H,189,227)(H,190,230)(H,191,228)(H,192,229)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,157,158,160)/t77-,78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,119-,120-,121-,122-,123-/m0/s1
DMQCGRI	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
DMQCGRI	IK	FZWMHWVGNYURLN-AAEALURTSA-N
DMQCGRI	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMQCGRI	DE	Discovery agent

DMN54LS	ID	DMN54LS
DMN54LS	DN	HAEGTFTSDVSSYLEGQAAKEIFAWLVKGR
DMN54LS	HS	Investigative
DMN54LS	PC	91934873
DMN54LS	MW	3298.6
DMN54LS	FM	C149H225N39O46
DMN54LS	IC	InChI=1S/C149H225N39O46/c1-17-76(10)119(145(230)179-101(57-83-31-20-18-21-32-83)133(218)166-80(14)125(210)174-104(60-86-63-158-91-36-25-24-35-89(86)91)136(221)176-100(56-73(4)5)137(222)185-117(74(6)7)143(228)173-92(37-26-28-52-150)127(212)159-66-111(197)168-98(148(233)234)39-30-54-157-149(154)155)187-132(217)97(47-51-115(203)204)172-131(216)93(38-27-29-53-151)169-123(208)78(12)163-122(207)77(11)165-130(215)96(44-48-109(153)195)167-110(196)65-160-129(214)95(46-50-114(201)202)171-134(219)99(55-72(2)3)175-135(220)102(59-85-40-42-88(194)43-41-85)177-140(225)106(68-189)181-142(227)108(70-191)182-144(229)118(75(8)9)186-139(224)105(62-116(205)206)178-141(226)107(69-190)183-147(232)121(82(16)193)188-138(223)103(58-84-33-22-19-23-34-84)180-146(231)120(81(15)192)184-112(198)67-161-128(213)94(45-49-113(199)200)170-124(209)79(13)164-126(211)90(152)61-87-64-156-71-162-87/h18-25,31-36,40-43,63-64,71-82,90,92-108,117-121,158,189-194H,17,26-30,37-39,44-62,65-70,150-152H2,1-16H3,(H2,153,195)(H,156,162)(H,159,212)(H,160,214)(H,161,213)(H,163,207)(H,164,211)(H,165,215)(H,166,218)(H,167,196)(H,168,197)(H,169,208)(H,170,209)(H,171,219)(H,172,216)(H,173,228)(H,174,210)(H,175,220)(H,176,221)(H,177,225)(H,178,226)(H,179,230)(H,180,231)(H,181,227)(H,182,229)(H,183,232)(H,184,198)(H,185,222)(H,186,224)(H,187,217)(H,188,223)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,233,234)(H4,154,155,157)/t76-,77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,117-,118-,119-,120-,121-/m0/s1
DMN54LS	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
DMN54LS	IK	UVENJQHDPZDEHP-KTKZVXAJSA-N
DMN54LS	IU	(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMN54LS	DE	Discovery agent

DMO6MGJ	ID	DMO6MGJ
DMO6MGJ	DN	Haempatch
DMO6MGJ	HS	Investigative
DMO6MGJ	SN	Haemepatch; Q-8009; Q-8010
DMO6MGJ	CP	University of Queensland
DMO6MGJ	DE	Bleeding disorder

DM5S4AO	ID	DM5S4AO
DM5S4AO	DN	H-Ala-Pro-Phe-Phe-NH2
DM5S4AO	HS	Investigative
DM5S4AO	SN	CHEMBL589082; H-Ala-Pro-Phe-Phe-NH2
DM5S4AO	DT	Small molecular drug
DM5S4AO	PC	46229263
DM5S4AO	MW	479.6
DM5S4AO	FM	C26H33N5O4
DM5S4AO	IC	InChI=1S/C26H33N5O4/c1-17(27)26(35)31-14-8-13-22(31)25(34)30-21(16-19-11-6-3-7-12-19)24(33)29-20(23(28)32)15-18-9-4-2-5-10-18/h2-7,9-12,17,20-22H,8,13-16,27H2,1H3,(H2,28,32)(H,29,33)(H,30,34)/t17-,20+,21+,22+/m1/s1
DM5S4AO	CS	C[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)N
DM5S4AO	IK	PYBNVPBCTAEKPN-MNAPGUCWSA-N
DM5S4AO	IU	(2S)-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-1-[(2R)-2-aminopropanoyl]pyrrolidine-2-carboxamide
DM5S4AO	DE	Discovery agent

DMJB87Q	ID	DMJB87Q
DMJB87Q	DN	Halisulfate 1
DMJB87Q	HS	Investigative
DMJB87Q	SN	CHEBI:69280; CHEMBL387584; halisulfate 1, (rel)-
DMJB87Q	DT	Small molecular drug
DMJB87Q	PC	23662099
DMJB87Q	MW	570.8
DMJB87Q	FM	C31H47NaO6S
DMJB87Q	IC	InChI=1S/C31H48O6S.Na/c1-21(11-13-24-19-25(32)14-15-27(24)33)9-7-10-23(3)28(37-38(34,35)36)20-26-22(2)12-16-29-30(4,5)17-8-18-31(26,29)6;/h11-12,14-15,19,23,26,28-29,32-33H,7-10,13,16-18,20H2,1-6H3,(H,34,35,36);/q;+1/p-1/b21-11+;/t23-,26+,28-,29+,31-;/m1./s1
DMJB87Q	CS	CC1=CC[C@@H]2[C@@]([C@H]1C[C@H]([C@H](C)CCC/C(=C/CC3=C(C=CC(=C3)O)O)/C)OS(=O)(=O)[O-])(CCCC2(C)C)C.[Na+]
DMJB87Q	IK	MWESFEYZPAHLCJ-NHDYRKAGSA-M
DMJB87Q	IU	sodium;[(E,2R,3R)-1-[(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-9-(2,5-dihydroxyphenyl)-3,7-dimethylnon-7-en-2-yl] sulfate
DMJB87Q	CB	CHEBI:69280
DMJB87Q	DE	Discovery agent

DMF6V8W	ID	DMF6V8W
DMF6V8W	DN	HALOPEMIDE
DMF6V8W	HS	Investigative
DMF6V8W	SN	Halopemide; 59831-65-1; UNII-65Q28TV0ZY; R 34,301; MLS003171133; 65Q28TV0ZY; CHEMBL245621; R-34301; N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide; Halopemida; Halopemidum; Halopemide [USAN:INN]; Halopemidum [INN-Latin]; Halopemida [INN-Spanish]; C21H22ClFN4O2; N-[2-[4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino]ethyl]-p-fluorobenzamide; Halopemide, 8; NSC 354856; Halopemide (USAN/INN); AC1L23CG; R 34301; MLS006012046; cid_65490; SCHEMBL121267; Halopemide, &gt; CTK8G0128; AOB5520
DMF6V8W	DT	Small molecular drug
DMF6V8W	PC	65490
DMF6V8W	MW	416.9
DMF6V8W	FM	C21H22ClFN4O2
DMF6V8W	IC	InChI=1S/C21H22ClFN4O2/c22-15-3-6-19-18(13-15)25-21(29)27(19)17-7-10-26(11-8-17)12-9-24-20(28)14-1-4-16(23)5-2-14/h1-6,13,17H,7-12H2,(H,24,28)(H,25,29)
DMF6V8W	CS	C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCNC(=O)C4=CC=C(C=C4)F
DMF6V8W	IK	NBHPRWLFLUBAIE-UHFFFAOYSA-N
DMF6V8W	IU	N-[2-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-4-fluorobenzamide
DMF6V8W	CA	CAS 59831-65-1
DMF6V8W	DE	Discovery agent

DMWCXPK	ID	DMWCXPK
DMWCXPK	DN	Haloperidol
DMWCXPK	HS	Investigative
DMWCXPK	SN	Haldol; Aloperidin; Serenace; Aloperidol; Eukystol; Brotopon; Einalon S; Ulcolind; Serenase; Uliolind; Serenelfi; Aloperidolo; Vesalium; Halopoidol; Galoperidol; Halojust; Pernox; Mixidol; Halopal; Linton; Sernel; Sernas; Dozic; Aldo; Lealgin compositum; Keselan; Peluces; Bioperidolo; Haldol Solutab; McN-JR-1625; Haloperidolum; Aloperidon; Fortunan; Aloperidolo [DCIT]; Aloperidolo [Italian]; Haloperidolum [INN-Latin]
DMWCXPK	TC	Antiviral Agents
DMWCXPK	DT	Small molecular drug
DMWCXPK	PC	3559
DMWCXPK	MW	375.9
DMWCXPK	FM	C21H23ClFNO2
DMWCXPK	IC	InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
DMWCXPK	CS	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
DMWCXPK	IK	LNEPOXFFQSENCJ-UHFFFAOYSA-N
DMWCXPK	IU	4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
DMWCXPK	CA	CAS 52-86-8
DMWCXPK	CB	CHEBI:5613
DMWCXPK	DE	Coronavirus Disease 2019 (COVID-19)

DM5SULN	ID	DM5SULN
DM5SULN	DN	Haloxyfop
DM5SULN	HS	Investigative
DM5SULN	SN	HALOXYFOP; 69806-34-4; 2-(4-((3-Chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)phenoxy)propanoic acid; Haloxyfop [ANSI:BSI:ISO]; Haloxyfop-P; GOCUAJYOYBLQRH-UHFFFAOYSA-N; 2-[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxyphenoxy]propanoic acid; 2-[4-[[3-chloro-5-(trifluoromethyl)-2-pyridyl]oxy]phenoxy]propanoic acid; 2-(4-((3-Chloro-5-(trifluoromethyl)-2-pyridinyl)oxy)phenoxy)propanoic acid; Propanoic acid, 2-[4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]phenoxy]-
DM5SULN	DT	Small molecular drug
DM5SULN	PC	50895
DM5SULN	MW	361.7
DM5SULN	FM	C15H11ClF3NO4
DM5SULN	IC	InChI=1S/C15H11ClF3NO4/c1-8(14(21)22)23-10-2-4-11(5-3-10)24-13-12(16)6-9(7-20-13)15(17,18)19/h2-8H,1H3,(H,21,22)
DM5SULN	CS	CC(C(=O)O)OC1=CC=C(C=C1)OC2=C(C=C(C=N2)C(F)(F)F)Cl
DM5SULN	IK	GOCUAJYOYBLQRH-UHFFFAOYSA-N
DM5SULN	IU	2-[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxyphenoxy]propanoic acid
DM5SULN	CA	CAS 69806-34-4
DM5SULN	CB	CHEBI:365
DM5SULN	DE	Discovery agent

DM4AEGQ	ID	DM4AEGQ
DM4AEGQ	DN	HALOXYSTEROL A
DM4AEGQ	HS	Investigative
DM4AEGQ	SN	haloxysterol A; CHEMBL202221
DM4AEGQ	DT	Small molecular drug
DM4AEGQ	PC	44407168
DM4AEGQ	MW	446.7
DM4AEGQ	FM	C29H50O3
DM4AEGQ	IC	InChI=1S/C29H50O3/c1-7-19(17(2)3)14-26(31)18(4)23-10-11-24-22-9-8-20-15-21(30)16-27(32)29(20,6)25(22)12-13-28(23,24)5/h8,17-19,21-27,30-32H,7,9-16H2,1-6H3/t18-,19+,21+,22?,23+,24?,25?,26+,27-,28+,29-/m0/s1
DM4AEGQ	CS	CC[C@H](C[C@H]([C@@H](C)[C@H]1CCC2[C@@]1(CCC3C2CC=C4[C@@]3([C@H](C[C@@H](C4)O)O)C)C)O)C(C)C
DM4AEGQ	IK	UNBKHVKAEFBHAN-IWAMNEIESA-N
DM4AEGQ	IU	(1S,3R,10R,13S,17R)-17-[(2S,3R,5R)-5-ethyl-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-1,3-diol
DM4AEGQ	DE	Discovery agent

DMD8O7S	ID	DMD8O7S
DMD8O7S	DN	HALOXYSTEROL B
DMD8O7S	HS	Investigative
DMD8O7S	SN	haloxysterol B; CHEMBL202223
DMD8O7S	DT	Small molecular drug
DMD8O7S	PC	11690845
DMD8O7S	MW	444.7
DMD8O7S	FM	C29H48O3
DMD8O7S	IC	InChI=1S/C29H48O3/c1-7-19(17(2)3)14-26(31)18(4)23-10-11-24-22-9-8-20-15-21(30)16-27(32)29(20,6)25(22)12-13-28(23,24)5/h8-9,15,17-19,21-27,30-32H,7,10-14,16H2,1-6H3/t18-,19+,21+,22?,23+,24?,25?,26+,27-,28+,29-/m0/s1
DMD8O7S	CS	CC[C@H](C[C@H]([C@@H](C)[C@H]1CCC2[C@@]1(CCC3C2C=CC4=C[C@H](C[C@@H]([C@]34C)O)O)C)O)C(C)C
DMD8O7S	IK	MVMHIMFXUANMIR-IWAMNEIESA-N
DMD8O7S	IU	(1S,3S,10R,13S,17R)-17-[(2S,3R,5R)-5-ethyl-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-1,3-diol
DMD8O7S	DE	Discovery agent

DMU1DHM	ID	DMU1DHM
DMU1DHM	DN	Haloxysterol C
DMU1DHM	HS	Investigative
DMU1DHM	SN	haloxysterol C; CHEMBL382961
DMU1DHM	DT	Small molecular drug
DMU1DHM	PC	44407175
DMU1DHM	MW	426.7
DMU1DHM	FM	C29H46O2
DMU1DHM	IC	InChI=1S/C29H46O2/c1-7-20(18(2)3)16-27(31)19(4)24-10-11-25-23-9-8-21-17-22(30)12-14-28(21,5)26(23)13-15-29(24,25)6/h13,17-20,23-25,27,31H,7-12,14-16H2,1-6H3/t19-,20+,23?,24+,25?,27+,28-,29+/m0/s1
DMU1DHM	CS	CC[C@H](C[C@H]([C@@H](C)[C@H]1CCC2[C@@]1(CC=C3C2CCC4=CC(=O)CC[C@@]43C)C)O)C(C)C
DMU1DHM	IK	AHQRPBWVJHINRW-XHVUHYHXSA-N
DMU1DHM	IU	(10S,13S,17R)-17-[(2S,3R,5R)-5-ethyl-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,6,7,8,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMU1DHM	DE	Discovery agent

DMWCZLT	ID	DMWCZLT
DMWCZLT	DN	Haloxysterol D
DMWCZLT	HS	Investigative
DMWCZLT	SN	haloxysterol D; CHEMBL201253; SCHEMBL16227159
DMWCZLT	DT	Small molecular drug
DMWCZLT	PC	44407203
DMWCZLT	MW	480.7
DMWCZLT	FM	C29H52O5
DMWCZLT	IC	InChI=1S/C29H52O5/c1-7-18(16(2)3)12-24(31)17(4)21-8-9-22-20-14-26(33)29(34)15-19(30)13-25(32)28(29,6)23(20)10-11-27(21,22)5/h16-26,30-34H,7-15H2,1-6H3/t17-,18+,19-,20?,21+,22?,23?,24+,25-,26+,27+,28-,29-/m0/s1
DMWCZLT	CS	CC[C@H](C[C@H]([C@@H](C)[C@H]1CCC2[C@@]1(CCC3C2C[C@H]([C@@]4([C@@]3([C@H](C[C@@H](C4)O)O)C)O)O)C)O)C(C)C
DMWCZLT	IK	SENGWVUFOJLNFP-QDQFXZLYSA-N
DMWCZLT	IU	(1S,3S,5R,6R,10S,13S,17R)-17-[(2S,3R,5R)-5-ethyl-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-1,3,5,6-tetrol
DMWCZLT	DE	Discovery agent

DMJN0BL	ID	DMJN0BL
DMJN0BL	DN	HAMI3379
DMJN0BL	HS	Investigative
DMJN0BL	SN	HAMI3379; CHEMBL3342944; 712313-35-4; GTPL6197; SCHEMBL4518791; DTXSID80439859; MolPort-027-641-329; BDBM50033098; 3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic Acid
DMJN0BL	DT	Small molecular drug
DMJN0BL	PC	10438479
DMJN0BL	MW	595.7
DMJN0BL	FM	C34H45NO8
DMJN0BL	IC	InChI=1S/C34H45NO8/c36-32(35-27-10-6-9-25(22-27)33(37)38)30-23-26(34(39)40)15-18-31(30)43-21-7-8-24-13-16-29(17-14-24)42-20-5-4-19-41-28-11-2-1-3-12-28/h13-18,23,25,27-28H,1-12,19-22H2,(H,35,36)(H,37,38)(H,39,40)
DMJN0BL	CS	C1CCC(CC1)OCCCCOC2=CC=C(C=C2)CCCOC3=C(C=C(C=C3)C(=O)O)C(=O)NC4CCCC(C4)C(=O)O
DMJN0BL	IK	HRJWSEPIRZRGCL-UHFFFAOYSA-N
DMJN0BL	IU	3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic acid
DMJN0BL	CA	CAS 712313-35-4
DMJN0BL	DE	Discovery agent

DM5SUYP	ID	DM5SUYP
DM5SUYP	DN	H-Apa-ala-Gly-Phe-leu-OH
DM5SUYP	HS	Investigative
DM5SUYP	SN	CHEMBL247363; H-Apa-ala-Gly-Phe-leu-OH
DM5SUYP	DT	Small molecular drug
DM5SUYP	PC	44439872
DM5SUYP	MW	568.7
DM5SUYP	FM	C29H40N6O6
DM5SUYP	IC	InChI=1S/C29H40N6O6/c1-17(2)13-24(29(40)41)35-28(39)23(15-19-7-5-4-6-8-19)34-25(36)16-32-26(37)18(3)33-27(38)22(31)14-20-9-11-21(30)12-10-20/h4-12,17-18,22-24H,13-16,30-31H2,1-3H3,(H,32,37)(H,33,38)(H,34,36)(H,35,39)(H,40,41)/t18-,22-,23-,24-/m0/s1
DM5SUYP	CS	C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)N)N
DM5SUYP	IK	DFYAWCYXKNEWBW-IMNFJDCFSA-N
DM5SUYP	IU	(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(4-aminophenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM5SUYP	DE	Discovery agent

DM9K6H5	ID	DM9K6H5
DM9K6H5	DN	HAp-IFN
DM9K6H5	HS	Investigative
DM9K6H5	SN	Hydroxyapatite-IFN (hepatitis C), LTT Bio-Pharma
DM9K6H5	CP	LTT Bio-Pharma Co Ltd
DM9K6H5	DE	Hepatitis C virus infection

DMENVKA	ID	DMENVKA
DMENVKA	DN	H-Arg-Arg-Pro-Tyr-Ile-Aac-OH
DMENVKA	HS	Investigative
DMENVKA	SN	CHEMBL507382; H-Arg-Arg-Pro-Tyr-Ile-Aac-OH
DMENVKA	DT	Small molecular drug
DMENVKA	PC	44578945
DMENVKA	MW	881.1
DMENVKA	FM	C43H68N12O8
DMENVKA	IC	InChI=1S/C43H68N12O8/c1-3-23(2)34(38(60)54-43(40(62)63)27-18-25-17-26(20-27)21-28(43)19-25)53-36(58)32(22-24-10-12-29(56)13-11-24)52-37(59)33-9-6-16-55(33)39(61)31(8-5-15-50-42(47)48)51-35(57)30(44)7-4-14-49-41(45)46/h10-13,23,25-28,30-34,56H,3-9,14-22,44H2,1-2H3,(H,51,57)(H,52,59)(H,53,58)(H,54,60)(H,62,63)(H4,45,46,49)(H4,47,48,50)/t23-,25?,26?,27?,28?,30-,31-,32-,33-,34-,43?/m0/s1
DMENVKA	CS	CC[C@H](C)[C@@H](C(=O)NC1(C2CC3CC(C2)CC1C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N
DMENVKA	IK	CMCIRTPGPAKLJS-YTNDVNQYSA-N
DMENVKA	IU	2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]adamantane-2-carboxylic acid
DMENVKA	DE	Discovery agent

DM4FKR1	ID	DM4FKR1
DM4FKR1	DN	H-Arg-Arg-Pro-Tyr-Ile-N-Me-Leu-OH
DM4FKR1	HS	Investigative
DM4FKR1	SN	CHEMBL508130; H-Arg-Arg-Pro-Tyr-Ile-N-Me-Leu-OH
DM4FKR1	DT	Small molecular drug
DM4FKR1	PC	44578943
DM4FKR1	MW	831
DM4FKR1	FM	C39H66N12O8
DM4FKR1	IC	InChI=1S/C39H66N12O8/c1-6-23(4)31(36(57)50(5)30(37(58)59)20-22(2)3)49-33(54)28(21-24-13-15-25(52)16-14-24)48-34(55)29-12-9-19-51(29)35(56)27(11-8-18-46-39(43)44)47-32(53)26(40)10-7-17-45-38(41)42/h13-16,22-23,26-31,52H,6-12,17-21,40H2,1-5H3,(H,47,53)(H,48,55)(H,49,54)(H,58,59)(H4,41,42,45)(H4,43,44,46)/t23-,26-,27-,28-,29-,30-,31-/m0/s1
DM4FKR1	CS	CC[C@H](C)[C@@H](C(=O)N(C)[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N
DM4FKR1	IK	DUYQEARXOLBXOJ-VGPFALITSA-N
DM4FKR1	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]-methylamino]-4-methylpentanoic acid
DM4FKR1	DE	Discovery agent

DM107RT	ID	DM107RT
DM107RT	DN	H-Arg-Arg-Pro-Tyr-N-Me-Ile-Leu-OH
DM107RT	HS	Investigative
DM107RT	SN	CHEMBL503059; H-Arg-Arg-Pro-Tyr-N-Me-Ile-Leu-OH
DM107RT	DT	Small molecular drug
DM107RT	PC	44578944
DM107RT	MW	831
DM107RT	FM	C39H66N12O8
DM107RT	IC	InChI=1S/C39H66N12O8/c1-6-23(4)31(34(55)49-29(37(58)59)20-22(2)3)50(5)35(56)28(21-24-13-15-25(52)16-14-24)48-33(54)30-12-9-19-51(30)36(57)27(11-8-18-46-39(43)44)47-32(53)26(40)10-7-17-45-38(41)42/h13-16,22-23,26-31,52H,6-12,17-21,40H2,1-5H3,(H,47,53)(H,48,54)(H,49,55)(H,58,59)(H4,41,42,45)(H4,43,44,46)/t23-,26-,27-,28-,29-,30-,31-/m0/s1
DM107RT	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)N(C)C(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N
DM107RT	IK	AGCKRBKIEACUSP-VGPFALITSA-N
DM107RT	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]-methylamino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DM107RT	DE	Discovery agent

DMSXLKJ	ID	DMSXLKJ
DMSXLKJ	DN	H-Arg-N-Me-Arg-Pro-Tyr-Ile-Leu-OH
DMSXLKJ	HS	Investigative
DMSXLKJ	SN	CHEMBL443967; H-Arg-N-Me-Arg-Pro-Tyr-Ile-Leu-OH
DMSXLKJ	DT	Small molecular drug
DMSXLKJ	PC	10102003
DMSXLKJ	MW	831
DMSXLKJ	FM	C39H66N12O8
DMSXLKJ	IC	InChI=1S/C39H66N12O8/c1-6-23(4)31(34(55)48-28(37(58)59)20-22(2)3)49-32(53)27(21-24-13-15-25(52)16-14-24)47-33(54)29-12-9-19-51(29)36(57)30(11-8-18-46-39(43)44)50(5)35(56)26(40)10-7-17-45-38(41)42/h13-16,22-23,26-31,52H,6-12,17-21,40H2,1-5H3,(H,47,54)(H,48,55)(H,49,53)(H,58,59)(H4,41,42,45)(H4,43,44,46)/t23-,26-,27-,28-,29-,30-,31-/m0/s1
DMSXLKJ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)N(C)C(=O)[C@H](CCCN=C(N)N)N
DMSXLKJ	IK	FMWPNVFPKCUWHA-VGPFALITSA-N
DMSXLKJ	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]-methylamino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DMSXLKJ	DE	Discovery agent

DMJ6N1X	ID	DMJ6N1X
DMJ6N1X	DN	H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH
DMJ6N1X	HS	Investigative
DMJ6N1X	SN	Substance P (1-7); CHEMBL589979; H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH; 68060-49-1; 1-7-SubstanceP; Substance P(1-7); SCHEMBL17887920; HY-P1485; BDBM50308381; MFCD00076789; ZINC169311322; NCGC00167124-01; CS-0044424
DMJ6N1X	DT	Small molecular drug
DMJ6N1X	PC	10440769
DMJ6N1X	MW	900
DMJ6N1X	FM	C41H65N13O10
DMJ6N1X	IC	InChI=1S/C41H65N13O10/c42-19-5-4-12-28(51-37(60)30-13-7-21-53(30)38(61)25(43)11-6-20-48-41(46)47)39(62)54-22-8-14-31(54)36(59)50-27(16-18-33(45)56)34(57)49-26(15-17-32(44)55)35(58)52-29(40(63)64)23-24-9-2-1-3-10-24/h1-3,9-10,25-31H,4-8,11-23,42-43H2,(H2,44,55)(H2,45,56)(H,49,57)(H,50,59)(H,51,60)(H,52,58)(H,63,64)(H4,46,47,48)/t25-,26-,27-,28-,29-,30-,31-/m0/s1
DMJ6N1X	CS	C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O
DMJ6N1X	IK	KPHDBQWTCKBKIL-XIJWKTHWSA-N
DMJ6N1X	IU	(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoic acid
DMJ6N1X	DE	Discovery agent

DM5VDU2	ID	DM5VDU2
DM5VDU2	DN	HBN-2
DM5VDU2	HS	Investigative
DM5VDU2	CP	University of North Carolina
DM5VDU2	DE	Neurological disorder

DMKDBFL	ID	DMKDBFL
DMKDBFL	DN	HBR-985
DMKDBFL	HS	Investigative
DMKDBFL	SN	Glicondamide; 52994-25-9; UNII-876SH4764F; C18H20ClN3O5S; 876SH4764F; 1-[[p-[2-(5-chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-methylurea; Glicondamide [INN]; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-methylurea; AC1Q3LT7; CHEMBL12806; AC1L562G; SCHEMBL1818252; CTK4J6836; DTXSID10201026; ZINC537790; HB-985; AKOS030573774; ACM52994259; W0037; 5-chloro-2-methoxy-N-[2-[4-(methylcarbamoylsulfamoyl)phenyl]ethyl]benzamide
DMKDBFL	DT	Small molecular drug
DMKDBFL	PC	219108
DMKDBFL	MW	425.9
DMKDBFL	FM	C18H20ClN3O5S
DMKDBFL	IC	InChI=1S/C18H20ClN3O5S/c1-20-18(24)22-28(25,26)14-6-3-12(4-7-14)9-10-21-17(23)15-11-13(19)5-8-16(15)27-2/h3-8,11H,9-10H2,1-2H3,(H,21,23)(H2,20,22,24)
DMKDBFL	CS	CNC(=O)NS(=O)(=O)C1=CC=C(C=C1)CCNC(=O)C2=C(C=CC(=C2)Cl)OC
DMKDBFL	IK	RXOBKRPNVDTZQF-UHFFFAOYSA-N
DMKDBFL	IU	5-chloro-2-methoxy-N-[2-[4-(methylcarbamoylsulfamoyl)phenyl]ethyl]benzamide
DMKDBFL	CA	CAS 52994-25-9
DMKDBFL	DE	Discovery agent

DMCQH23	ID	DMCQH23
DMCQH23	DN	H-c[Cys-Phe-DTrp-Lys-Thr-Cys]-OH
DMCQH23	HS	Investigative
DMCQH23	SN	CHEMBL438247; H-c[Cys-Phe-DTrp-Lys-Thr-Cys]-OH
DMCQH23	DT	Small molecular drug
DMCQH23	PC	10581102
DMCQH23	MW	784.9
DMCQH23	FM	C36H48N8O8S2
DMCQH23	IC	InChI=1S/C36H48N8O8S2/c1-20(45)30-35(50)43-29(36(51)52)19-54-53-18-24(38)31(46)41-27(15-21-9-3-2-4-10-21)33(48)42-28(16-22-17-39-25-12-6-5-11-23(22)25)34(49)40-26(32(47)44-30)13-7-8-14-37/h2-6,9-12,17,20,24,26-30,39,45H,7-8,13-16,18-19,37-38H2,1H3,(H,40,49)(H,41,46)(H,42,48)(H,43,50)(H,44,47)(H,51,52)/t20-,24+,26+,27+,28-,29+,30+/m1/s1
DMCQH23	CS	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)N)C(=O)O)O
DMCQH23	IK	XNCLQDHGWMNJRY-XJVQTVDVSA-N
DMCQH23	IU	(4R,7S,10S,13R,16S,19R)-19-amino-10-(4-aminobutyl)-16-benzyl-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxylic acid
DMCQH23	DE	Discovery agent

DMOY2AI	ID	DMOY2AI
DMOY2AI	DN	HC-030031
DMOY2AI	HS	Investigative
DMOY2AI	SN	TRPA1 inhibitor (pain/inflammation), Hydra Biosciences/Cubist Pharmaceuticals
DMOY2AI	CP	Hydra Biosciences Inc
DMOY2AI	DT	Small molecular drug
DMOY2AI	PC	1150897
DMOY2AI	MW	355.4
DMOY2AI	FM	C18H21N5O3
DMOY2AI	IC	InChI=1S/C18H21N5O3/c1-11(2)12-5-7-13(8-6-12)20-14(24)9-23-10-19-16-15(23)17(25)22(4)18(26)21(16)3/h5-8,10-11H,9H2,1-4H3,(H,20,24)
DMOY2AI	CS	CC(C)C1=CC=C(C=C1)NC(=O)CN2C=NC3=C2C(=O)N(C(=O)N3C)C
DMOY2AI	IK	HEQDZPHDVAOBLN-UHFFFAOYSA-N
DMOY2AI	IU	2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(4-propan-2-ylphenyl)acetamide
DMOY2AI	CA	CAS 349085-38-7
DMOY2AI	DE	Inflammation

DMOG1Q4	ID	DMOG1Q4
DMOG1Q4	DN	HC-056456
DMOG1Q4	HS	Investigative
DMOG1Q4	SN	HC056456
DMOG1Q4	DT	Small molecular drug
DMOG1Q4	PC	573747
DMOG1Q4	MW	306.3
DMOG1Q4	FM	C12H6N2O4S2
DMOG1Q4	IC	InChI=1S/C12H6N2O4S2/c15-11(7-3-1-5-19-7)9-10(14(17)18-13-9)12(16)8-4-2-6-20-8/h1-6H
DMOG1Q4	CS	C1=CSC(=C1)C(=O)C2=NO[N+](=C2C(=O)C3=CC=CS3)[O-]
DMOG1Q4	IK	RUQGCDMXFBOTMW-UHFFFAOYSA-N
DMOG1Q4	IU	[5-oxido-4-(thiophene-2-carbonyl)-1,2,5-oxadiazol-5-ium-3-yl]-thiophen-2-ylmethanone
DMOG1Q4	CA	CAS 7733-96-2
DMOG1Q4	DE	Discovery agent

DMIXY1O	ID	DMIXY1O
DMIXY1O	DN	HC067047
DMIXY1O	HS	Investigative
DMIXY1O	SN	HC 067047
DMIXY1O	DT	Small molecular drug
DMIXY1O	PC	2742550
DMIXY1O	MW	471.5
DMIXY1O	FM	C26H28F3N3O2
DMIXY1O	IC	InChI=1S/C26H28F3N3O2/c1-19-23(25(33)30-22-10-5-9-21(17-22)26(27,28)29)18-24(20-7-3-2-4-8-20)32(19)12-6-11-31-13-15-34-16-14-31/h2-5,7-10,17-18H,6,11-16H2,1H3,(H,30,33)
DMIXY1O	CS	CC1=C(C=C(N1CCCN2CCOCC2)C3=CC=CC=C3)C(=O)NC4=CC=CC(=C4)C(F)(F)F
DMIXY1O	IK	NCZYSQOTAYFTNM-UHFFFAOYSA-N
DMIXY1O	IU	2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-N-[3-(trifluoromethyl)phenyl]pyrrole-3-carboxamide
DMIXY1O	CA	CAS 883031-03-6
DMIXY1O	DE	Discovery agent

DM1BLCX	ID	DM1BLCX
DM1BLCX	DN	HC3-1496
DM1BLCX	HS	Investigative
DM1BLCX	SN	RC3 Decomplase; RC3-1
DM1BLCX	CP	InCode BioPharmaceutics Inc
DM1BLCX	DE	Autoimmune diabetes

DMV751G	ID	DMV751G
DMV751G	DN	H-Cdp-ala-Gly-Phe-leu-OH
DMV751G	HS	Investigative
DMV751G	SN	CHEMBL247758; H-Cdp-ala-Gly-Phe-leu-OH
DMV751G	DT	Small molecular drug
DMV751G	PC	44439876
DMV751G	MW	624.7
DMV751G	FM	C32H44N6O7
DMV751G	IC	InChI=1S/C32H44N6O7/c1-17(2)11-26(32(44)45)38-31(43)25(14-21-9-7-6-8-10-21)37-27(39)16-35-29(41)20(5)36-30(42)24(33)15-23-18(3)12-22(28(34)40)13-19(23)4/h6-10,12-13,17,20,24-26H,11,14-16,33H2,1-5H3,(H2,34,40)(H,35,41)(H,36,42)(H,37,39)(H,38,43)(H,44,45)/t20-,24-,25-,26-/m0/s1
DMV751G	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)N)C)C(=O)N
DMV751G	IK	MNNRFUWQCDJULI-CGIBELHQSA-N
DMV751G	IU	(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMV751G	DE	Discovery agent

DMVEB8C	ID	DMVEB8C
DMVEB8C	DN	H-Cdp-Gly-Gly-Phe-Leu-OH
DMVEB8C	HS	Investigative
DMVEB8C	SN	CHEMBL246739; H-Cdp-Gly-Gly-Phe-Leu-OH
DMVEB8C	DT	Small molecular drug
DMVEB8C	PC	44439880
DMVEB8C	MW	610.7
DMVEB8C	FM	C31H42N6O7
DMVEB8C	IC	InChI=1S/C31H42N6O7/c1-17(2)10-25(31(43)44)37-30(42)24(13-20-8-6-5-7-9-20)36-27(39)16-34-26(38)15-35-29(41)23(32)14-22-18(3)11-21(28(33)40)12-19(22)4/h5-9,11-12,17,23-25H,10,13-16,32H2,1-4H3,(H2,33,40)(H,34,38)(H,35,41)(H,36,39)(H,37,42)(H,43,44)/t23-,24-,25-/m0/s1
DMVEB8C	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)N)C)C(=O)N
DMVEB8C	IK	AYRRYHMNASIQTF-SDHOMARFSA-N
DMVEB8C	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMVEB8C	DE	Discovery agent

DMCDLTV	ID	DMCDLTV
DMCDLTV	DN	H-Cdp-ser-Gly-Phe-Leu-Thr-OH
DMCDLTV	HS	Investigative
DMCDLTV	SN	CHEMBL247760; H-Cdp-ser-Gly-Phe-Leu-Thr-OH
DMCDLTV	DT	Small molecular drug
DMCDLTV	PC	44439905
DMCDLTV	MW	741.8
DMCDLTV	FM	C36H51N7O10
DMCDLTV	IC	InChI=1S/C36H51N7O10/c1-18(2)11-26(35(51)43-30(21(5)45)36(52)53)41-34(50)27(14-22-9-7-6-8-10-22)40-29(46)16-39-33(49)28(17-44)42-32(48)25(37)15-24-19(3)12-23(31(38)47)13-20(24)4/h6-10,12-13,18,21,25-28,30,44-45H,11,14-17,37H2,1-5H3,(H2,38,47)(H,39,49)(H,40,46)(H,41,50)(H,42,48)(H,43,51)(H,52,53)/t21-,25+,26+,27+,28+,30+/m1/s1
DMCDLTV	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)C)C(=O)N
DMCDLTV	IK	OCIDAPABHMBEIS-VVPQYXBXSA-N
DMCDLTV	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DMCDLTV	DE	Discovery agent

DM415ZX	ID	DM415ZX
DM415ZX	DN	HCGRPalpha
DM415ZX	HS	Investigative
DM415ZX	PC	44308929
DM415ZX	MW	3789.3
DM415ZX	FM	C163H267N51O49S2
DM415ZX	IC	InChI=1S/C163H267N51O49S2/c1-73(2)52-97(186-116(226)65-179-131(233)82(18)183-139(241)98(53-74(3)4)193-137(239)94(44-35-49-176-162(171)172)188-142(244)101(57-91-62-175-72-182-91)199-159(261)128(88(24)221)213-156(258)123(79(13)14)207-151(253)110-71-265-264-70-109(203-130(232)81(17)166)150(252)198-105(61-119(229)230)147(249)211-125(85(21)218)157(259)185-84(20)133(235)210-126(86(22)219)160(262)204-110)140(242)194-99(54-75(5)6)141(243)202-108(69-217)149(251)190-95(45-36-50-177-163(173)174)138(240)201-106(67-215)134(236)180-63-115(225)178-64-118(228)205-121(77(9)10)155(257)208-122(78(11)12)154(256)191-93(43-32-34-48-165)136(238)196-102(58-112(167)222)144(246)197-103(59-113(168)223)143(245)195-100(56-90-40-29-26-30-41-90)145(247)209-124(80(15)16)161(263)214-51-37-46-111(214)152(254)212-127(87(23)220)158(260)200-104(60-114(169)224)146(248)206-120(76(7)8)153(255)181-66-117(227)187-107(68-216)148(250)189-92(42-31-33-47-164)135(237)184-83(19)132(234)192-96(129(170)231)55-89-38-27-25-28-39-89/h25-30,38-41,62,72-88,92-111,120-128,215-221H,31-37,42-61,63-71,164-166H2,1-24H3,(H2,167,222)(H2,168,223)(H2,169,224)(H2,170,231)(H,175,182)(H,178,225)(H,179,233)(H,180,236)(H,181,255)(H,183,241)(H,184,237)(H,185,259)(H,186,226)(H,187,227)(H,188,244)(H,189,250)(H,190,251)(H,191,256)(H,192,234)(H,193,239)(H,194,242)(H,195,245)(H,196,238)(H,197,246)(H,198,252)(H,199,261)(H,200,260)(H,201,240)(H,202,243)(H,203,232)(H,204,262)(H,205,228)(H,206,248)(H,207,253)(H,208,257)(H,209,247)(H,210,235)(H,211,249)(H,212,254)(H,213,258)(H,229,230)(H4,171,172,176)(H4,173,174,177)/t81-,82+,83+,84-,85+,86+,87-,88-,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105-,106+,107+,108+,109-,110+,111?,120+,121+,122+,123+,124+,125+,126+,127+,128+/m1/s1
DM415ZX	CS	C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)CC(=O)O)NC(=O)[C@@H](C)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)N4CCCC4C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)[C@H](C)O
DM415ZX	IK	JMJJWZFCOWFIBU-NFAXDPBFSA-N
DM415ZX	IU	2-[(4R,7S,10R,13S,16R,19S)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]-19-[[(2R)-2-aminopropanoyl]amino]-7,13-bis[(1S)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-16-yl]acetic acid
DM415ZX	DE	Discovery agent

DM3V4XG	ID	DM3V4XG
DM3V4XG	DN	H-Cpa-c[pen-Gly-Phe-pen]OH
DM3V4XG	HS	Investigative
DM3V4XG	DT	Small molecular drug
DM3V4XG	PC	73354725
DM3V4XG	MW	672.8
DM3V4XG	FM	C31H40N6O7S2
DM3V4XG	IC	InChI=1S/C31H40N6O7S2/c1-30(2)23(36-26(40)20(32)14-18-10-12-19(13-11-18)25(33)39)28(42)34-16-22(38)35-21(15-17-8-6-5-7-9-17)27(41)37-24(29(43)44)31(3,4)46-45-30/h5-13,20-21,23-24H,14-16,32H2,1-4H3,(H2,33,39)(H,34,42)(H,35,38)(H,36,40)(H,37,41)(H,43,44)/t20-,21-,23-,24-/m0/s1
DM3V4XG	CS	CC1([C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(SS1)(C)C)C(=O)O)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)C(=O)N)N)C
DM3V4XG	IK	KFLVOLBPEGAIIK-WMIMKTLMSA-N
DM3V4XG	IU	(4S,7S,13S)-13-[[(2S)-2-amino-3-(4-carbamoylphenyl)propanoyl]amino]-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid
DM3V4XG	DE	Discovery agent

DMU6PV8	ID	DMU6PV8
DMU6PV8	DN	H-Cpa-Gly-Gly-Phe-Met-NH2
DMU6PV8	HS	Investigative
DMU6PV8	SN	CHEMBL246956; H-Cpa-Gly-Gly-Phe-Met-NH2
DMU6PV8	DT	Small molecular drug
DMU6PV8	PC	44439866
DMU6PV8	MW	599.7
DMU6PV8	FM	C28H37N7O6S
DMU6PV8	IC	InChI=1S/C28H37N7O6S/c1-42-12-11-21(26(31)39)35-28(41)22(14-17-5-3-2-4-6-17)34-24(37)16-32-23(36)15-33-27(40)20(29)13-18-7-9-19(10-8-18)25(30)38/h2-10,20-22H,11-16,29H2,1H3,(H2,30,38)(H2,31,39)(H,32,36)(H,33,40)(H,34,37)(H,35,41)/t20-,21-,22-/m0/s1
DMU6PV8	CS	CSCC[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)C(=O)N)N
DMU6PV8	IK	WVSXHGGHIPRNNC-FKBYEOEOSA-N
DMU6PV8	IU	4-[(2S)-2-amino-3-[[2-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-oxopropyl]benzamide
DMU6PV8	DE	Discovery agent

DM154G2	ID	DM154G2
DM154G2	DN	H-Cpa-Gly-Gly-Phe-Met-OH
DM154G2	HS	Investigative
DM154G2	SN	CHEMBL391580; H-Cpa-Gly-Gly-Phe-Met-OH
DM154G2	DT	Small molecular drug
DM154G2	PC	11250396
DM154G2	MW	600.7
DM154G2	FM	C28H36N6O7S
DM154G2	IC	InChI=1S/C28H36N6O7S/c1-42-12-11-21(28(40)41)34-27(39)22(14-17-5-3-2-4-6-17)33-24(36)16-31-23(35)15-32-26(38)20(29)13-18-7-9-19(10-8-18)25(30)37/h2-10,20-22H,11-16,29H2,1H3,(H2,30,37)(H,31,35)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t20-,21-,22-/m0/s1
DM154G2	CS	CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)C(=O)N)N
DM154G2	IK	OOJZMMQHNUJUPF-FKBYEOEOSA-N
DM154G2	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-carbamoylphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DM154G2	DE	Discovery agent

DMPL0BR	ID	DMPL0BR
DMPL0BR	DN	H-Cxp-ala-Gly-Phe-leu-OH
DMPL0BR	HS	Investigative
DMPL0BR	SN	CHEMBL247163; H-Cxp-ala-Gly-Phe-leu-OH
DMPL0BR	DT	Small molecular drug
DMPL0BR	PC	44439873
DMPL0BR	MW	597.7
DMPL0BR	FM	C30H39N5O8
DMPL0BR	IC	InChI=1S/C30H39N5O8/c1-17(2)13-24(30(42)43)35-28(39)23(15-19-7-5-4-6-8-19)34-25(36)16-32-26(37)18(3)33-27(38)22(31)14-20-9-11-21(12-10-20)29(40)41/h4-12,17-18,22-24H,13-16,31H2,1-3H3,(H,32,37)(H,33,38)(H,34,36)(H,35,39)(H,40,41)(H,42,43)/t18-,22-,23-,24-/m0/s1
DMPL0BR	CS	C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)C(=O)O)N
DMPL0BR	IK	YGSPIRVSMFDGND-IMNFJDCFSA-N
DMPL0BR	IU	4-[(2S)-2-amino-3-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-3-methylbutyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]benzoic acid
DMPL0BR	DE	Discovery agent

DM6839G	ID	DM6839G
DM6839G	DN	H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638)
DM6839G	HS	Investigative
DM6839G	SN	CHEMBL216618; H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638); JMV 1638
DM6839G	PC	44316621
DM6839G	MW	1092.2
DM6839G	FM	C49H69N15O12S
DM6839G	IC	InChI=1S/C49H69N15O12S/c50-30(10-5-15-55-48(51)52)41(70)58-31(11-6-16-56-49(53)54)45(74)62-17-7-13-35(62)47(76)63-22-29(66)20-36(63)43(72)57-21-38(67)61-40(28-18-26-8-1-2-9-27(26)19-28)44(73)59-32(24-65)42(71)60-33-25-77-37-14-4-3-12-34(37)64(46(33)75)23-39(68)69/h1-4,8-9,12,14,28-33,35-36,40,65-66H,5-7,10-11,13,15-25,50H2,(H,57,72)(H,58,70)(H,59,73)(H,60,71)(H,61,67)(H,68,69)(H4,51,52,55)(H4,53,54,56)/t29?,30?,31-,32+,33-,35+,36+,40?/m1/s1
DM6839G	CS	C1C[C@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)NC(C3CC4=CC=CC=C4C3)C(=O)N[C@@H](CO)C(=O)N[C@@H]5CSC6=CC=CC=C6N(C5=O)CC(=O)O)O
DM6839G	IK	BBKUNIDRTSPPPW-XBNUIVHSSA-N
DM6839G	IU	2-[(3S)-3-[[(2S)-2-[[2-[[2-[[(2S)-1-[(2S)-1-[(2R)-2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-2-(2,3-dihydro-1H-inden-2-yl)acetyl]amino]-3-hydroxypropanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]acetic acid
DM6839G	DE	Discovery agent

DM9WJZK	ID	DM9WJZK
DM9WJZK	DN	H-Dmt-Aba-Gly-NH-CH2-Bid
DM9WJZK	HS	Investigative
DM9WJZK	SN	CHEMBL211543; H-Dmt-Aba-Gly-NH-CH2-Bid
DM9WJZK	DT	Small molecular drug
DM9WJZK	PC	11721803
DM9WJZK	MW	497.6
DM9WJZK	FM	C29H31N5O3
DM9WJZK	IC	InChI=1S/C29H31N5O3/c1-17-11-21(35)12-18(2)22(17)14-23(30)28(36)33-26-13-19-7-3-4-8-20(19)15-34(29(26)37)16-27-31-24-9-5-6-10-25(24)32-27/h3-12,23,26,35H,13-16,30H2,1-2H3,(H,31,32)(H,33,36)/t23-,26-/m0/s1
DM9WJZK	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@H]2CC3=CC=CC=C3CN(C2=O)CC4=NC5=CC=CC=C5N4)N)C)O
DM9WJZK	IK	KNVMNIVKKSUNLC-OZXSUGGESA-N
DM9WJZK	IU	(2S)-2-amino-N-[(4S)-2-(1H-benzimidazol-2-ylmethyl)-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]-3-(4-hydroxy-2,6-dimethylphenyl)propanamide
DM9WJZK	DE	Discovery agent

DM61CMS	ID	DM61CMS
DM61CMS	DN	H-Dmt-Aba-Gly-NH-CH2-Ph
DM61CMS	HS	Investigative
DM61CMS	SN	CHEMBL208683; H-Dmt-Aba-Gly-NH-CH2-Ph; BDBM50189920
DM61CMS	DT	Small molecular drug
DM61CMS	PC	11664525
DM61CMS	MW	514.6
DM61CMS	FM	C30H34N4O4
DM61CMS	IC	InChI=1S/C30H34N4O4/c1-19-12-24(35)13-20(2)25(19)15-26(31)29(37)33-27-14-22-10-6-7-11-23(22)17-34(30(27)38)18-28(36)32-16-21-8-4-3-5-9-21/h3-13,26-27,35H,14-18,31H2,1-2H3,(H,32,36)(H,33,37)/t26-,27-/m0/s1
DM61CMS	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@H]2CC3=CC=CC=C3CN(C2=O)CC(=O)NCC4=CC=CC=C4)N)C)O
DM61CMS	IK	HAQFBGNRXYPSQF-SVBPBHIXSA-N
DM61CMS	IU	(2S)-2-amino-N-[(4S)-2-[2-(benzylamino)-2-oxoethyl]-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]-3-(4-hydroxy-2,6-dimethylphenyl)propanamide
DM61CMS	DE	Discovery agent

DMCQYIJ	ID	DMCQYIJ
DMCQYIJ	DN	H-Dmt-Aba-Gly-NH-Ph
DMCQYIJ	HS	Investigative
DMCQYIJ	SN	CHEMBL377392; H-Dmt-Aba-Gly-NH-Ph
DMCQYIJ	DT	Small molecular drug
DMCQYIJ	PC	11635818
DMCQYIJ	MW	500.6
DMCQYIJ	FM	C29H32N4O4
DMCQYIJ	IC	InChI=1S/C29H32N4O4/c1-18-12-23(34)13-19(2)24(18)15-25(30)28(36)32-26-14-20-8-6-7-9-21(20)16-33(29(26)37)17-27(35)31-22-10-4-3-5-11-22/h3-13,25-26,34H,14-17,30H2,1-2H3,(H,31,35)(H,32,36)/t25-,26-/m0/s1
DMCQYIJ	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@H]2CC3=CC=CC=C3CN(C2=O)CC(=O)NC4=CC=CC=C4)N)C)O
DMCQYIJ	IK	JYNUREYKNAJNLW-UIOOFZCWSA-N
DMCQYIJ	IU	(2S)-2-amino-N-[(4S)-2-(2-anilino-2-oxoethyl)-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]-3-(4-hydroxy-2,6-dimethylphenyl)propanamide
DMCQYIJ	DE	Discovery agent

DMHK70B	ID	DMHK70B
DMHK70B	DN	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2
DMHK70B	HS	Investigative
DMHK70B	SN	CHEMBL371856; H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2
DMHK70B	DT	Small molecular drug
DMHK70B	PC	44399141
DMHK70B	MW	818.9
DMHK70B	FM	C40H54N10O9
DMHK70B	IC	InChI=1S/C40H54N10O9/c1-25-20-29(51)21-26(2)30(25)23-31(41)36(53)47-33(17-11-19-44-39(43)49-50(57)58)37(54)48-34(22-27-12-5-3-6-13-27)38(55)46-32(35(42)52)16-9-10-18-45-40(56)59-24-28-14-7-4-8-15-28/h3-8,12-15,20-21,31-34,51H,9-11,16-19,22-24,41H2,1-2H3,(H2,42,52)(H,45,56)(H,46,55)(H,47,53)(H,48,54)(H3,43,44,49)/t31?,32-,33+,34-/m0/s1
DMHK70B	CS	CC1=CC(=CC(=C1CC(C(=O)N[C@H](CCCN=C(N)N[N+](=O)[O-])C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCCNC(=O)OCC3=CC=CC=C3)C(=O)N)N)C)O
DMHK70B	IK	LMMJRHRZYGSRLK-OPTRWXFLSA-N
DMHK70B	IU	benzyl N-[(5S)-6-amino-5-[[(2S)-2-[[(2R)-2-[[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-5-[[amino(nitramido)methylidene]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]carbamate
DMHK70B	DE	Discovery agent

DMM9EPQ	ID	DMM9EPQ
DMM9EPQ	DN	H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH
DMM9EPQ	HS	Investigative
DMM9EPQ	SN	CHEMBL370701; H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH
DMM9EPQ	DT	Small molecular drug
DMM9EPQ	PC	44399025
DMM9EPQ	MW	819.9
DMM9EPQ	FM	C40H53N9O10
DMM9EPQ	IC	InChI=1S/C40H53N9O10/c1-25-20-29(50)21-26(2)30(25)23-31(41)35(51)45-32(17-11-19-43-39(42)48-49(57)58)36(52)47-34(22-27-12-5-3-6-13-27)37(53)46-33(38(54)55)16-9-10-18-44-40(56)59-24-28-14-7-4-8-15-28/h3-8,12-15,20-21,31-34,50H,9-11,16-19,22-24,41H2,1-2H3,(H,44,56)(H,45,51)(H,46,53)(H,47,52)(H,54,55)(H3,42,43,48)/t31?,32-,33+,34+/m1/s1
DMM9EPQ	CS	CC1=CC(=CC(=C1CC(C(=O)N[C@H](CCCN=C(N)N[N+](=O)[O-])C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCCNC(=O)OCC3=CC=CC=C3)C(=O)O)N)C)O
DMM9EPQ	IK	DTKHPEUFGZLWTF-OYKWTTPJSA-N
DMM9EPQ	IU	(2S)-2-[[(2S)-2-[[(2R)-2-[[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-5-[[amino(nitramido)methylidene]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-6-(phenylmethoxycarbonylamino)hexanoic acid
DMM9EPQ	DE	Discovery agent

DM1ZDJ6	ID	DM1ZDJ6
DM1ZDJ6	DN	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2
DM1ZDJ6	HS	Investigative
DM1ZDJ6	SN	CHEMBL218781; H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2
DM1ZDJ6	DT	Small molecular drug
DM1ZDJ6	PC	44418916
DM1ZDJ6	MW	681.9
DM1ZDJ6	FM	C40H51N5O5
DM1ZDJ6	IC	InChI=1S/C40H51N5O5/c1-24-18-31(46)19-25(2)32(24)22-33(41)40(50)45-23-30-17-11-10-16-29(30)21-35(45)38(48)44-36(26(3)28-14-8-5-9-15-28)39(49)43-34(37(42)47)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,46H,5,8-9,14-15,20-23,41H2,1-3H3,(H2,42,47)(H,43,49)(H,44,48)/t26-,33+,34+,35?,36-/m1/s1
DM1ZDJ6	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H]([C@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N)C)O
DM1ZDJ6	IK	KIHHZGQBWZPIMS-RUXLTPPNSA-N
DM1ZDJ6	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2R,3R)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxobutan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM1ZDJ6	DE	Discovery agent

DMC3APN	ID	DMC3APN
DMC3APN	DN	H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH
DMC3APN	HS	Investigative
DMC3APN	SN	CHEMBL375094; H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH
DMC3APN	DT	Small molecular drug
DMC3APN	PC	44418912
DMC3APN	MW	682.8
DMC3APN	FM	C40H50N4O6
DMC3APN	IC	InChI=1S/C40H50N4O6/c1-24-18-31(45)19-25(2)32(24)22-33(41)39(48)44-23-30-17-11-10-16-29(30)21-35(44)37(46)43-36(26(3)28-14-8-5-9-15-28)38(47)42-34(40(49)50)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,45H,5,8-9,14-15,20-23,41H2,1-3H3,(H,42,47)(H,43,46)(H,49,50)/t26-,33+,34+,35?,36-/m1/s1
DMC3APN	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H]([C@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DMC3APN	IK	GWHRSTGESQKJIQ-RUXLTPPNSA-N
DMC3APN	IU	(2S)-2-[[(2R,3R)-2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylbutanoyl]amino]-3-phenylpropanoic acid
DMC3APN	DE	Discovery agent

DMY97TN	ID	DMY97TN
DMY97TN	DN	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2
DMY97TN	HS	Investigative
DMY97TN	SN	CHEMBL218782; H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2
DMY97TN	DT	Small molecular drug
DMY97TN	PC	44418918
DMY97TN	MW	681.9
DMY97TN	FM	C40H51N5O5
DMY97TN	IC	InChI=1S/C40H51N5O5/c1-24-18-31(46)19-25(2)32(24)22-33(41)40(50)45-23-30-17-11-10-16-29(30)21-35(45)38(48)44-36(26(3)28-14-8-5-9-15-28)39(49)43-34(37(42)47)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,46H,5,8-9,14-15,20-23,41H2,1-3H3,(H2,42,47)(H,43,49)(H,44,48)/t26-,33-,34-,35?,36+/m0/s1
DMY97TN	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H]([C@@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N)C)O
DMY97TN	IK	KIHHZGQBWZPIMS-FVTMYMNWSA-N
DMY97TN	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2R,3S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxobutan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMY97TN	DE	Discovery agent

DMGPAM0	ID	DMGPAM0
DMGPAM0	DN	H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH
DMGPAM0	HS	Investigative
DMGPAM0	SN	CHEMBL376453; H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH
DMGPAM0	DT	Small molecular drug
DMGPAM0	PC	44418914
DMGPAM0	MW	682.8
DMGPAM0	FM	C40H50N4O6
DMGPAM0	IC	InChI=1S/C40H50N4O6/c1-24-18-31(45)19-25(2)32(24)22-33(41)39(48)44-23-30-17-11-10-16-29(30)21-35(44)37(46)43-36(26(3)28-14-8-5-9-15-28)38(47)42-34(40(49)50)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,45H,5,8-9,14-15,20-23,41H2,1-3H3,(H,42,47)(H,43,46)(H,49,50)/t26-,33-,34-,35?,36+/m0/s1
DMGPAM0	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H]([C@@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DMGPAM0	IK	GWHRSTGESQKJIQ-FVTMYMNWSA-N
DMGPAM0	IU	(2S)-2-[[(2R,3S)-2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylbutanoyl]amino]-3-phenylpropanoic acid
DMGPAM0	DE	Discovery agent

DMOI1U5	ID	DMOI1U5
DMOI1U5	DN	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2
DMOI1U5	HS	Investigative
DMOI1U5	SN	CHEMBL415426; H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2
DMOI1U5	DT	Small molecular drug
DMOI1U5	PC	44418917
DMOI1U5	MW	681.9
DMOI1U5	FM	C40H51N5O5
DMOI1U5	IC	InChI=1S/C40H51N5O5/c1-24-18-31(46)19-25(2)32(24)22-33(41)40(50)45-23-30-17-11-10-16-29(30)21-35(45)38(48)44-36(26(3)28-14-8-5-9-15-28)39(49)43-34(37(42)47)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,46H,5,8-9,14-15,20-23,41H2,1-3H3,(H2,42,47)(H,43,49)(H,44,48)/t26-,33+,34+,35?,36+/m1/s1
DMOI1U5	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H]([C@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N)C)O
DMOI1U5	IK	KIHHZGQBWZPIMS-IAEIRYAQSA-N
DMOI1U5	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S,3R)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxobutan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMOI1U5	DE	Discovery agent

DMZBFJ5	ID	DMZBFJ5
DMZBFJ5	DN	H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH
DMZBFJ5	HS	Investigative
DMZBFJ5	SN	CHEMBL375095; H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH
DMZBFJ5	DT	Small molecular drug
DMZBFJ5	PC	44418913
DMZBFJ5	MW	682.8
DMZBFJ5	FM	C40H50N4O6
DMZBFJ5	IC	InChI=1S/C40H50N4O6/c1-24-18-31(45)19-25(2)32(24)22-33(41)39(48)44-23-30-17-11-10-16-29(30)21-35(44)37(46)43-36(26(3)28-14-8-5-9-15-28)38(47)42-34(40(49)50)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,45H,5,8-9,14-15,20-23,41H2,1-3H3,(H,42,47)(H,43,46)(H,49,50)/t26-,33+,34+,35?,36+/m1/s1
DMZBFJ5	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H]([C@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DMZBFJ5	IK	GWHRSTGESQKJIQ-IAEIRYAQSA-N
DMZBFJ5	IU	(2S)-2-[[(2S,3R)-2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylbutanoyl]amino]-3-phenylpropanoic acid
DMZBFJ5	DE	Discovery agent

DMNS1GX	ID	DMNS1GX
DMNS1GX	DN	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2
DMNS1GX	HS	Investigative
DMNS1GX	SN	CHEMBL269314; H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2
DMNS1GX	DT	Small molecular drug
DMNS1GX	PC	44418915
DMNS1GX	MW	681.9
DMNS1GX	FM	C40H51N5O5
DMNS1GX	IC	InChI=1S/C40H51N5O5/c1-24-18-31(46)19-25(2)32(24)22-33(41)40(50)45-23-30-17-11-10-16-29(30)21-35(45)38(48)44-36(26(3)28-14-8-5-9-15-28)39(49)43-34(37(42)47)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,46H,5,8-9,14-15,20-23,41H2,1-3H3,(H2,42,47)(H,43,49)(H,44,48)/t26-,33-,34-,35?,36-/m0/s1
DMNS1GX	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H]([C@@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N)C)O
DMNS1GX	IK	KIHHZGQBWZPIMS-VERNRBRGSA-N
DMNS1GX	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S,3S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxobutan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMNS1GX	DE	Discovery agent

DMM9TUR	ID	DMM9TUR
DMM9TUR	DN	H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH
DMM9TUR	HS	Investigative
DMM9TUR	SN	CHEMBL219482; H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH
DMM9TUR	DT	Small molecular drug
DMM9TUR	PC	44418911
DMM9TUR	MW	682.8
DMM9TUR	FM	C40H50N4O6
DMM9TUR	IC	InChI=1S/C40H50N4O6/c1-24-18-31(45)19-25(2)32(24)22-33(41)39(48)44-23-30-17-11-10-16-29(30)21-35(44)37(46)43-36(26(3)28-14-8-5-9-15-28)38(47)42-34(40(49)50)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,45H,5,8-9,14-15,20-23,41H2,1-3H3,(H,42,47)(H,43,46)(H,49,50)/t26-,33-,34-,35?,36-/m0/s1
DMM9TUR	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H]([C@@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DMM9TUR	IK	GWHRSTGESQKJIQ-VERNRBRGSA-N
DMM9TUR	IU	(2S)-2-[[(2S,3S)-2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylbutanoyl]amino]-3-phenylpropanoic acid
DMM9TUR	DE	Discovery agent

DM4JP8L	ID	DM4JP8L
DM4JP8L	DN	H-Dmt-Tic-Asp-N(Me)-Ph
DM4JP8L	HS	Investigative
DM4JP8L	SN	CHEMBL448360; H-Dmt-Tic-Asp-N(Me)-Ph
DM4JP8L	DT	Small molecular drug
DM4JP8L	PC	25034014
DM4JP8L	MW	572.7
DM4JP8L	FM	C32H36N4O6
DM4JP8L	IC	InChI=1S/C32H36N4O6/c1-19-13-24(37)14-20(2)25(19)16-26(33)31(41)36-18-22-10-8-7-9-21(22)15-28(36)30(40)34-27(17-29(38)39)32(42)35(3)23-11-5-4-6-12-23/h4-14,26-28,37H,15-18,33H2,1-3H3,(H,34,40)(H,38,39)/t26-,27-,28-/m0/s1
DM4JP8L	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC(=O)O)C(=O)N(C)C4=CC=CC=C4)N)C)O
DM4JP8L	IK	HEKBLCZSNQVJKZ-KCHLEUMXSA-N
DM4JP8L	IU	(3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-(N-methylanilino)-4-oxobutanoic acid
DM4JP8L	DE	Discovery agent

DMBKOJG	ID	DMBKOJG
DMBKOJG	DN	H-Dmt-Tic-Asp-NH-Bzl
DMBKOJG	HS	Investigative
DMBKOJG	SN	CHEMBL450566; H-Dmt-Tic-Asp-NH-Bzl
DMBKOJG	DT	Small molecular drug
DMBKOJG	PC	25034010
DMBKOJG	MW	572.7
DMBKOJG	FM	C32H36N4O6
DMBKOJG	IC	InChI=1S/C32H36N4O6/c1-19-12-24(37)13-20(2)25(19)15-26(33)32(42)36-18-23-11-7-6-10-22(23)14-28(36)31(41)35-27(16-29(38)39)30(40)34-17-21-8-4-3-5-9-21/h3-13,26-28,37H,14-18,33H2,1-2H3,(H,34,40)(H,35,41)(H,38,39)/t26-,27-,28-/m0/s1
DMBKOJG	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC(=O)O)C(=O)NCC4=CC=CC=C4)N)C)O
DMBKOJG	IK	RBFLTKCFTXQSNZ-KCHLEUMXSA-N
DMBKOJG	IU	(3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-(benzylamino)-4-oxobutanoic acid
DMBKOJG	DE	Discovery agent

DM3W9FQ	ID	DM3W9FQ
DM3W9FQ	DN	H-Dmt-Tic-Asp-NH-Ph
DM3W9FQ	HS	Investigative
DM3W9FQ	SN	CHEMBL501202; H-Dmt-Tic-Asp-NH-Ph
DM3W9FQ	DT	Small molecular drug
DM3W9FQ	PC	25033885
DM3W9FQ	MW	558.6
DM3W9FQ	FM	C31H34N4O6
DM3W9FQ	IC	InChI=1S/C31H34N4O6/c1-18-12-23(36)13-19(2)24(18)15-25(32)31(41)35-17-21-9-7-6-8-20(21)14-27(35)30(40)34-26(16-28(37)38)29(39)33-22-10-4-3-5-11-22/h3-13,25-27,36H,14-17,32H2,1-2H3,(H,33,39)(H,34,40)(H,37,38)/t25-,26-,27-/m0/s1
DM3W9FQ	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC(=O)O)C(=O)NC4=CC=CC=C4)N)C)O
DM3W9FQ	IK	ISUHYDNNFIRLMN-QKDODKLFSA-N
DM3W9FQ	IU	(3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-anilino-4-oxobutanoic acid
DM3W9FQ	DE	Discovery agent

DM483BG	ID	DM483BG
DM483BG	DN	H-Dmt-Tic-D-Asp-N(Me)-Ph
DM483BG	HS	Investigative
DM483BG	SN	CHEMBL502302; H-Dmt-Tic-D-Asp-N(Me)-Ph
DM483BG	DT	Small molecular drug
DM483BG	PC	25033947
DM483BG	MW	572.7
DM483BG	FM	C32H36N4O6
DM483BG	IC	InChI=1S/C32H36N4O6/c1-19-13-24(37)14-20(2)25(19)16-26(33)31(41)36-18-22-10-8-7-9-21(22)15-28(36)30(40)34-27(17-29(38)39)32(42)35(3)23-11-5-4-6-12-23/h4-14,26-28,37H,15-18,33H2,1-3H3,(H,34,40)(H,38,39)/t26-,27+,28-/m0/s1
DM483BG	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@H](CC(=O)O)C(=O)N(C)C4=CC=CC=C4)N)C)O
DM483BG	IK	HEKBLCZSNQVJKZ-IARZGTGTSA-N
DM483BG	IU	(3R)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-(N-methylanilino)-4-oxobutanoic acid
DM483BG	DE	Discovery agent

DMUG7X1	ID	DMUG7X1
DMUG7X1	DN	H-Dmt-Tic-D-Asp-NH-Ph
DMUG7X1	HS	Investigative
DMUG7X1	SN	CHEMBL498799; H-Dmt-Tic-D-Asp-NH-Ph
DMUG7X1	DT	Small molecular drug
DMUG7X1	PC	25033945
DMUG7X1	MW	558.6
DMUG7X1	FM	C31H34N4O6
DMUG7X1	IC	InChI=1S/C31H34N4O6/c1-18-12-23(36)13-19(2)24(18)15-25(32)31(41)35-17-21-9-7-6-8-20(21)14-27(35)30(40)34-26(16-28(37)38)29(39)33-22-10-4-3-5-11-22/h3-13,25-27,36H,14-17,32H2,1-2H3,(H,33,39)(H,34,40)(H,37,38)/t25-,26+,27-/m0/s1
DMUG7X1	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@H](CC(=O)O)C(=O)NC4=CC=CC=C4)N)C)O
DMUG7X1	IK	ISUHYDNNFIRLMN-VJGNERBWSA-N
DMUG7X1	IU	(3R)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-anilino-4-oxobutanoic acid
DMUG7X1	DE	Discovery agent

DMQSRPD	ID	DMQSRPD
DMQSRPD	DN	H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)
DMQSRPD	HS	Investigative
DMQSRPD	SN	CHEMBL208916; H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)
DMQSRPD	DT	Small molecular drug
DMQSRPD	PC	44412290
DMQSRPD	MW	805.9
DMQSRPD	FM	C43H47N7O9
DMQSRPD	IC	InChI=1S/C43H47N7O9/c1-21-13-27(51)14-22(2)29(21)19-32(44)38(54)37-28-8-6-5-7-24(28)18-34(46-37)41(57)47-33(11-12-36(52)53)40(56)48-35(39(45)55)20-50-42(58)30-16-23-9-10-26(49(3)4)15-25(23)17-31(30)43(50)59/h5-10,13-17,32-35,37,46,51H,11-12,18-20,44H2,1-4H3,(H2,45,55)(H,47,57)(H,48,56)(H,52,53)/t32-,33-,34?,35?,37?/m0/s1
DMQSRPD	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)C2C3=CC=CC=C3CC(N2)C(=O)N[C@@H](CCC(=O)O)C(=O)NC(CN4C(=O)C5=C(C4=O)C=C6C=C(C=CC6=C5)N(C)C)C(=O)N)N)C)O
DMQSRPD	IK	XJJAERVDDMSANL-TXQDRJNYSA-N
DMQSRPD	IU	(4S)-5-[[1-amino-3-[6-(dimethylamino)-1,3-dioxobenzo[f]isoindol-2-yl]-1-oxopropan-2-yl]amino]-4-[[1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]amino]-5-oxopentanoic acid
DMQSRPD	DE	Discovery agent

DMF52SH	ID	DMF52SH
DMF52SH	DN	H-Dmt-Tic-Glu-NH-(CH2)5-NH2
DMF52SH	HS	Investigative
DMF52SH	SN	CHEMBL225479; H-Dmt-Tic-Glu-NH-(CH2)5-NH2
DMF52SH	DT	Small molecular drug
DMF52SH	PC	44421433
DMF52SH	MW	581.7
DMF52SH	FM	C31H43N5O6
DMF52SH	IC	InChI=1S/C31H43N5O6/c1-19-14-23(37)15-20(2)24(19)17-25(33)31(42)36-18-22-9-5-4-8-21(22)16-27(36)30(41)35-26(10-11-28(38)39)29(40)34-13-7-3-6-12-32/h4-5,8-9,14-15,25-27,37H,3,6-7,10-13,16-18,32-33H2,1-2H3,(H,34,40)(H,35,41)(H,38,39)/t25-,26-,27?/m0/s1
DMF52SH	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H](CCC(=O)O)C(=O)NCCCCCN)N)C)O
DMF52SH	IK	JKBJCPFUZMWEMK-TXIPYEPDSA-N
DMF52SH	IU	(4S)-4-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-(5-aminopentylamino)-5-oxopentanoic acid
DMF52SH	DE	Discovery agent

DM8A573	ID	DM8A573
DM8A573	DN	H-Dmt-Tic-Glu-NH2
DM8A573	HS	Investigative
DM8A573	DT	Small molecular drug
DM8A573	PC	11156202
DM8A573	MW	496.6
DM8A573	FM	C26H32N4O6
DM8A573	IC	InChI=1S/C26H32N4O6/c1-14-9-18(31)10-15(2)19(14)12-20(27)26(36)30-13-17-6-4-3-5-16(17)11-22(30)25(35)29-21(24(28)34)7-8-23(32)33/h3-6,9-10,20-22,31H,7-8,11-13,27H2,1-2H3,(H2,28,34)(H,29,35)(H,32,33)/t20-,21-,22-/m0/s1
DM8A573	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CCC(=O)O)C(=O)N)N)C)O
DM8A573	IK	CXJVHAFXBCEOKB-FKBYEOEOSA-N
DM8A573	IU	(4S)-5-amino-4-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-oxopentanoic acid
DM8A573	DE	Discovery agent

DMHYKBC	ID	DMHYKBC
DMHYKBC	DN	H-Dmt-Tic-Gly-N(Me)-Ph
DMHYKBC	HS	Investigative
DMHYKBC	SN	CHEMBL500937; H-Dmt-Tic-Gly-N(Me)-Ph
DMHYKBC	DT	Small molecular drug
DMHYKBC	PC	25034012
DMHYKBC	MW	514.6
DMHYKBC	FM	C30H34N4O4
DMHYKBC	IC	InChI=1S/C30H34N4O4/c1-19-13-24(35)14-20(2)25(19)16-26(31)30(38)34-18-22-10-8-7-9-21(22)15-27(34)29(37)32-17-28(36)33(3)23-11-5-4-6-12-23/h4-14,26-27,35H,15-18,31H2,1-3H3,(H,32,37)/t26-,27-/m0/s1
DMHYKBC	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC(=O)N(C)C4=CC=CC=C4)N)C)O
DMHYKBC	IK	CADRNJIFUDEZBB-SVBPBHIXSA-N
DMHYKBC	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-(N-methylanilino)-2-oxoethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMHYKBC	DE	Discovery agent

DMM39YW	ID	DMM39YW
DMM39YW	DN	H-Dmt-Tic-Gly-NH-Bzl
DMM39YW	HS	Investigative
DMM39YW	SN	H-Dmt-Tic-Gly-NH-Bzl; CHEMBL458631; H-Dmt-Tic-Gly-NH-CH2-Ph; GTPL9838; BDBM50266025; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (benzylcarbamoyl-methyl)-amide; (S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-N-(2-(benzylamino)-2-oxoethyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; (3S)-N-(Benzylcarbamoylmethyl)-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
DMM39YW	DT	Small molecular drug
DMM39YW	PC	10864183
DMM39YW	MW	514.6
DMM39YW	FM	C30H34N4O4
DMM39YW	IC	InChI=1S/C30H34N4O4/c1-19-12-24(35)13-20(2)25(19)15-26(31)30(38)34-18-23-11-7-6-10-22(23)14-27(34)29(37)33-17-28(36)32-16-21-8-4-3-5-9-21/h3-13,26-27,35H,14-18,31H2,1-2H3,(H,32,36)(H,33,37)/t26-,27-/m0/s1
DMM39YW	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC(=O)NCC4=CC=CC=C4)N)C)O
DMM39YW	IK	SYOVEDOWOXNOJG-SVBPBHIXSA-N
DMM39YW	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-(benzylamino)-2-oxoethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMM39YW	DE	Discovery agent

DMH6JOU	ID	DMH6JOU
DMH6JOU	DN	H-Dmt-Tic-Gly-NH-CH2-Bid
DMH6JOU	HS	Investigative
DMH6JOU	SN	(3S)-N-[(1H-Benzimidazole-2-ylmethyl)carbamoylmethyl]-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
DMH6JOU	DT	Small molecular drug
DMH6JOU	PC	44375729
DMH6JOU	MW	554.6
DMH6JOU	FM	C31H34N6O4
DMH6JOU	IC	InChI=1S/C31H34N6O4/c1-18-11-22(38)12-19(2)23(18)14-24(32)31(41)37-17-21-8-4-3-7-20(21)13-27(37)30(40)34-16-29(39)33-15-28-35-25-9-5-6-10-26(25)36-28/h3-12,24,27,38H,13-17,32H2,1-2H3,(H,33,39)(H,34,40)(H,35,36)/t24-,27?/m0/s1
DMH6JOU	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCC(=O)NCC4=NC5=CC=CC=C5N4)N)C)O
DMH6JOU	IK	LKKOHYJIXKBADA-BXXZMZEQSA-N
DMH6JOU	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-(1H-benzimidazol-2-ylmethylamino)-2-oxoethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMH6JOU	DE	Discovery agent

DMIZ28H	ID	DMIZ28H
DMIZ28H	DN	H-Dmt-Tic-Gly-NH-Ph
DMIZ28H	HS	Investigative
DMIZ28H	SN	CHEMBL501451; H-Dmt-Tic-Gly-NH-Ph; BDBM50272081; (3S)-N-(Phenylcarbamoylmethyl)-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid phenylcarbamoylmethyl-amide
DMIZ28H	DT	Small molecular drug
DMIZ28H	PC	11016572
DMIZ28H	MW	500.6
DMIZ28H	FM	C29H32N4O4
DMIZ28H	IC	InChI=1S/C29H32N4O4/c1-18-12-23(34)13-19(2)24(18)15-25(30)29(37)33-17-21-9-7-6-8-20(21)14-26(33)28(36)31-16-27(35)32-22-10-4-3-5-11-22/h3-13,25-26,34H,14-17,30H2,1-2H3,(H,31,36)(H,32,35)/t25-,26-/m0/s1
DMIZ28H	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC(=O)NC4=CC=CC=C4)N)C)O
DMIZ28H	IK	JQERUKPESNWSQA-UIOOFZCWSA-N
DMIZ28H	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(2-anilino-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMIZ28H	DE	Discovery agent

DM2TY43	ID	DM2TY43
DM2TY43	DN	H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph
DM2TY43	HS	Investigative
DM2TY43	SN	SCHEMBL8222648
DM2TY43	DT	Small molecular drug
DM2TY43	PC	25050225
DM2TY43	MW	627.8
DM2TY43	FM	C36H45N5O5
DM2TY43	IC	InChI=1S/C36H45N5O5/c1-23-17-29(43)18-24(2)30(23)20-31(37)36(46)41-22-28-14-8-7-13-27(28)19-33(41)35(45)40-32(15-9-10-16-38-25(3)42)34(44)39-21-26-11-5-4-6-12-26/h4-8,11-14,17-18,31-33,43H,9-10,15-16,19-22,37H2,1-3H3,(H,38,42)(H,39,44)(H,40,45)
DM2TY43	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)C)C(=O)NCC4=CC=CC=C4)N)C)O
DM2TY43	IK	FSIMYSAKEXUAHH-UHFFFAOYSA-N
DM2TY43	IU	N-[6-acetamido-1-(benzylamino)-1-oxohexan-2-yl]-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM2TY43	DE	Discovery agent

DMZH9P5	ID	DMZH9P5
DMZH9P5	DN	H-Dmt-Tic-Lys(Ac)-NH-Ph
DMZH9P5	HS	Investigative
DMZH9P5	SN	SCHEMBL8228366
DMZH9P5	DT	Small molecular drug
DMZH9P5	PC	25050226
DMZH9P5	MW	613.7
DMZH9P5	FM	C35H43N5O5
DMZH9P5	IC	InChI=1S/C35H43N5O5/c1-22-17-28(42)18-23(2)29(22)20-30(36)35(45)40-21-26-12-8-7-11-25(26)19-32(40)34(44)39-31(15-9-10-16-37-24(3)41)33(43)38-27-13-5-4-6-14-27/h4-8,11-14,17-18,30-32,42H,9-10,15-16,19-21,36H2,1-3H3,(H,37,41)(H,38,43)(H,39,44)
DMZH9P5	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)C)C(=O)NC4=CC=CC=C4)N)C)O
DMZH9P5	IK	VCTWEJIUVCJXEY-UHFFFAOYSA-N
DMZH9P5	IU	N-(6-acetamido-1-anilino-1-oxohexan-2-yl)-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMZH9P5	DE	Discovery agent

DMP8HFA	ID	DMP8HFA
DMP8HFA	DN	H-Dmt-Tic-Lys(Z)-NH-CH2-Ph
DMP8HFA	HS	Investigative
DMP8HFA	DT	Small molecular drug
DMP8HFA	PC	44415603
DMP8HFA	MW	719.9
DMP8HFA	FM	C42H49N5O6
DMP8HFA	IC	InChI=1S/C42H49N5O6/c1-28-21-34(48)22-29(2)35(28)24-36(43)41(51)47-26-33-18-10-9-17-32(33)23-38(47)40(50)46-37(39(49)45-25-30-13-5-3-6-14-30)19-11-12-20-44-42(52)53-27-31-15-7-4-8-16-31/h3-10,13-18,21-22,36-38,48H,11-12,19-20,23-27,43H2,1-2H3,(H,44,52)(H,45,49)(H,46,50)
DMP8HFA	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)OCC4=CC=CC=C4)C(=O)NCC5=CC=CC=C5)N)C)O
DMP8HFA	IK	MVEIALIQEDSFAK-UHFFFAOYSA-N
DMP8HFA	IU	benzyl N-[5-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-6-(benzylamino)-6-oxohexyl]carbamate
DMP8HFA	DE	Discovery agent

DMBXGLA	ID	DMBXGLA
DMBXGLA	DN	H-Dmt-Tic-Lys(Z)-NH-Ph
DMBXGLA	HS	Investigative
DMBXGLA	DT	Small molecular drug
DMBXGLA	PC	25050066
DMBXGLA	MW	705.8
DMBXGLA	FM	C41H47N5O6
DMBXGLA	IC	InChI=1S/C41H47N5O6/c1-27-21-33(47)22-28(2)34(27)24-35(42)40(50)46-25-31-16-10-9-15-30(31)23-37(46)39(49)45-36(38(48)44-32-17-7-4-8-18-32)19-11-12-20-43-41(51)52-26-29-13-5-3-6-14-29/h3-10,13-18,21-22,35-37,47H,11-12,19-20,23-26,42H2,1-2H3,(H,43,51)(H,44,48)(H,45,49)
DMBXGLA	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)OCC4=CC=CC=C4)C(=O)NC5=CC=CC=C5)N)C)O
DMBXGLA	IK	MJVSDWUKXXUPBE-UHFFFAOYSA-N
DMBXGLA	IU	benzyl N-[5-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-6-anilino-6-oxohexyl]carbamate
DMBXGLA	DE	Discovery agent

DMDJ9PE	ID	DMDJ9PE
DMDJ9PE	DN	H-Dmt-Tic-Lys-NH-CH2-Ph
DMDJ9PE	HS	Investigative
DMDJ9PE	DT	Small molecular drug
DMDJ9PE	PC	44415604
DMDJ9PE	MW	585.7
DMDJ9PE	FM	C34H43N5O4
DMDJ9PE	IC	InChI=1S/C34H43N5O4/c1-22-16-27(40)17-23(2)28(22)19-29(36)34(43)39-21-26-13-7-6-12-25(26)18-31(39)33(42)38-30(14-8-9-15-35)32(41)37-20-24-10-4-3-5-11-24/h3-7,10-13,16-17,29-31,40H,8-9,14-15,18-21,35-36H2,1-2H3,(H,37,41)(H,38,42)
DMDJ9PE	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCN)C(=O)NCC4=CC=CC=C4)N)C)O
DMDJ9PE	IK	RMSWGJUPLHHSPI-UHFFFAOYSA-N
DMDJ9PE	IU	N-[6-amino-1-(benzylamino)-1-oxohexan-2-yl]-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMDJ9PE	DE	Discovery agent

DMT3Y6E	ID	DMT3Y6E
DMT3Y6E	DN	H-Dmt-Tic-Lys-NH-Ph
DMT3Y6E	HS	Investigative
DMT3Y6E	SN	SCHEMBL8224099
DMT3Y6E	DT	Small molecular drug
DMT3Y6E	PC	25050067
DMT3Y6E	MW	571.7
DMT3Y6E	FM	C33H41N5O4
DMT3Y6E	IC	InChI=1S/C33H41N5O4/c1-21-16-26(39)17-22(2)27(21)19-28(35)33(42)38-20-24-11-7-6-10-23(24)18-30(38)32(41)37-29(14-8-9-15-34)31(40)36-25-12-4-3-5-13-25/h3-7,10-13,16-17,28-30,39H,8-9,14-15,18-20,34-35H2,1-2H3,(H,36,40)(H,37,41)
DMT3Y6E	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCN)C(=O)NC4=CC=CC=C4)N)C)O
DMT3Y6E	IK	RTMKKGXDPBYWCA-UHFFFAOYSA-N
DMT3Y6E	IU	N-(6-amino-1-anilino-1-oxohexan-2-yl)-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMT3Y6E	DE	Discovery agent

DMMJ9YN	ID	DMMJ9YN
DMMJ9YN	DN	H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H
DMMJ9YN	HS	Investigative
DMMJ9YN	SN	CHEMBL372130; H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H
DMMJ9YN	DT	Small molecular drug
DMMJ9YN	PC	44405653
DMMJ9YN	MW	657.8
DMMJ9YN	FM	C38H51N5O5
DMMJ9YN	IC	InChI=1S/C38H51N5O5/c1-23-15-29(44)16-24(2)31(23)20-33(39)36(46)41-13-9-5-6-10-14-42-37(47)35-19-27-11-7-8-12-28(27)22-43(35)38(48)34(40)21-32-25(3)17-30(45)18-26(32)4/h7-8,11-12,15-18,33-35,44-45H,5-6,9-10,13-14,19-22,39-40H2,1-4H3,(H,41,46)(H,42,47)/t33-,34-,35?/m0/s1
DMMJ9YN	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)NCCCCCCNC(=O)C2CC3=CC=CC=C3CN2C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N)N)C)O
DMMJ9YN	IK	PKRAENCMWFWKSB-IEKJTBOOSA-N
DMMJ9YN	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-[[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMMJ9YN	DE	Discovery agent

DM0BGNE	ID	DM0BGNE
DM0BGNE	DN	H-Dmt-Tic-NH-(CH2)6-NH-Phe-H
DM0BGNE	HS	Investigative
DM0BGNE	SN	CHEMBL198909; H-Dmt-Tic-NH-(CH2)6-NH-Phe-H
DM0BGNE	DT	Small molecular drug
DM0BGNE	PC	44405656
DM0BGNE	MW	613.8
DM0BGNE	FM	C36H47N5O4
DM0BGNE	IC	InChI=1S/C36H47N5O4/c1-24-18-29(42)19-25(2)30(24)22-32(38)36(45)41-23-28-15-9-8-14-27(28)21-33(41)35(44)40-17-11-4-3-10-16-39-34(43)31(37)20-26-12-6-5-7-13-26/h5-9,12-15,18-19,31-33,42H,3-4,10-11,16-17,20-23,37-38H2,1-2H3,(H,39,43)(H,40,44)/t31-,32-,33?/m0/s1
DM0BGNE	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCNC(=O)[C@H](CC4=CC=CC=C4)N)N)C)O
DM0BGNE	IK	VWEMLWZEBKVSHE-KOPQTXDBSA-N
DM0BGNE	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-[[(2S)-2-amino-3-phenylpropanoyl]amino]hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM0BGNE	DE	Discovery agent

DMQ586T	ID	DMQ586T
DMQ586T	DN	H-Dmt-Tic-NH-(CH2)6-NH-Tic-H
DMQ586T	HS	Investigative
DMQ586T	SN	CHEMBL380590; H-Dmt-Tic-NH-(CH2)6-NH-Tic-H
DMQ586T	DT	Small molecular drug
DMQ586T	PC	44405654
DMQ586T	MW	625.8
DMQ586T	FM	C37H47N5O4
DMQ586T	IC	InChI=1S/C37H47N5O4/c1-24-17-30(43)18-25(2)31(24)21-32(38)37(46)42-23-29-14-8-6-12-27(29)20-34(42)36(45)40-16-10-4-3-9-15-39-35(44)33-19-26-11-5-7-13-28(26)22-41-33/h5-8,11-14,17-18,32-34,41,43H,3-4,9-10,15-16,19-23,38H2,1-2H3,(H,39,44)(H,40,45)/t32-,33?,34?/m0/s1
DMQ586T	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCNC(=O)C4CC5=CC=CC=C5CN4)N)C)O
DMQ586T	IK	SIUMEPYYYNRSSX-BGVJURHFSA-N
DMQ586T	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-(1,2,3,4-tetrahydroisoquinoline-3-carbonylamino)hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMQ586T	DE	Discovery agent

DMAU2H6	ID	DMAU2H6
DMAU2H6	DN	H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid
DMAU2H6	HS	Investigative
DMAU2H6	SN	H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid; CHEMBL212172
DMAU2H6	DT	Small molecular drug
DMAU2H6	PC	16082947
DMAU2H6	MW	702.8
DMAU2H6	FM	C41H46N6O5
DMAU2H6	IC	InChI=1S/C41H46N6O5/c1-26-20-31(48)21-27(2)32(26)23-33(42)40(50)47-24-30-15-7-6-14-29(30)22-37(47)39(49)46-36(38-44-34-16-8-9-17-35(34)45-38)18-10-11-19-43-41(51)52-25-28-12-4-3-5-13-28/h3-9,12-17,20-21,33,36-37,48H,10-11,18-19,22-25,42H2,1-2H3,(H,43,51)(H,44,45)(H,46,49)/t33?,36-,37?/m1/s1
DMAU2H6	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H](CCCCNC(=O)OCC4=CC=CC=C4)C5=NC6=CC=CC=C6N5)N)C)O
DMAU2H6	IK	ZHRKDWCBKIOLKI-QNUATKLTSA-N
DMAU2H6	IU	benzyl N-[(5R)-5-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-(1H-benzimidazol-2-yl)pentyl]carbamate
DMAU2H6	DE	Discovery agent

DM5TZ1J	ID	DM5TZ1J
DM5TZ1J	DN	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid
DM5TZ1J	HS	Investigative
DM5TZ1J	SN	CHEMBL444197; H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid
DM5TZ1J	DT	Small molecular drug
DM5TZ1J	PC	25033951
DM5TZ1J	MW	555.6
DM5TZ1J	FM	C31H33N5O5
DM5TZ1J	IC	InChI=1S/C31H33N5O5/c1-17-11-21(37)12-18(2)22(17)14-23(32)31(41)36-16-20-8-4-3-7-19(20)13-27(36)30(40)35-26(15-28(38)39)29-33-24-9-5-6-10-25(24)34-29/h3-12,23,26-27,37H,13-16,32H2,1-2H3,(H,33,34)(H,35,40)(H,38,39)/t23-,26+,27-/m0/s1
DM5TZ1J	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@H](CC(=O)O)C4=NC5=CC=CC=C5N4)N)C)O
DM5TZ1J	IK	USVQTDLSVBRMCR-RNJDCESWSA-N
DM5TZ1J	IU	(3R)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1H-benzimidazol-2-yl)propanoic acid
DM5TZ1J	DE	Discovery agent

DMIDLPT	ID	DMIDLPT
DMIDLPT	DN	H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)
DMIDLPT	HS	Investigative
DMIDLPT	SN	CHEMBL499099; BDBM50272228
DMIDLPT	DT	Small molecular drug
DMIDLPT	PC	25034016
DMIDLPT	MW	569.6
DMIDLPT	FM	C32H35N5O5
DMIDLPT	IC	InChI=1S/C32H35N5O5/c1-18-12-22(38)13-19(2)23(18)15-24(33)32(42)37-17-21-9-5-4-8-20(21)14-28(37)31(41)35-26(16-29(39)40)30-34-25-10-6-7-11-27(25)36(30)3/h4-13,24,26,28,38H,14-17,33H2,1-3H3,(H,35,41)(H,39,40)/t24-,26+,28-/m0/s1
DMIDLPT	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@H](CC(=O)O)C4=NC5=CC=CC=C5N4C)N)C)O
DMIDLPT	IK	XFKPEXYNTQLONY-YIOBJHAYSA-N
DMIDLPT	IU	(3R)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1-methylbenzimidazol-2-yl)propanoic acid
DMIDLPT	DE	Discovery agent

DMNEAQ9	ID	DMNEAQ9
DMNEAQ9	DN	H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)
DMNEAQ9	HS	Investigative
DMNEAQ9	SN	XFKPEXYNTQLONY-MPYJOUPCSA-N; CHEMBL450263
DMNEAQ9	DT	Small molecular drug
DMNEAQ9	PC	25033949
DMNEAQ9	MW	569.6
DMNEAQ9	FM	C32H35N5O5
DMNEAQ9	IC	InChI=1S/C32H35N5O5/c1-18-12-22(38)13-19(2)23(18)15-24(33)32(42)37-17-21-9-5-4-8-20(21)14-28(37)31(41)35-26(16-29(39)40)30-34-25-10-6-7-11-27(25)36(30)3/h4-13,24,26,28,38H,14-17,33H2,1-3H3,(H,35,41)(H,39,40)/t24-,26-,28-/m0/s1
DMNEAQ9	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC(=O)O)C4=NC5=CC=CC=C5N4C)N)C)O
DMNEAQ9	IK	XFKPEXYNTQLONY-MPYJOUPCSA-N
DMNEAQ9	IU	(3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1-methylbenzimidazol-2-yl)propanoic acid
DMNEAQ9	DE	Discovery agent

DMQEDP5	ID	DMQEDP5
DMQEDP5	DN	H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid
DMQEDP5	HS	Investigative
DMQEDP5	SN	H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid; SCHEMBL8230993; CHEMBL377960
DMQEDP5	DT	Small molecular drug
DMQEDP5	PC	25050224
DMQEDP5	MW	568.7
DMQEDP5	FM	C33H40N6O3
DMQEDP5	IC	InChI=1S/C33H40N6O3/c1-20-15-24(40)16-21(2)25(20)18-26(35)33(42)39-19-23-10-4-3-9-22(23)17-30(39)32(41)38-29(13-7-8-14-34)31-36-27-11-5-6-12-28(27)37-31/h3-6,9-12,15-16,26,29-30,40H,7-8,13-14,17-19,34-35H2,1-2H3,(H,36,37)(H,38,41)
DMQEDP5	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCN)C4=NC5=CC=CC=C5N4)N)C)O
DMQEDP5	IK	GDHJQGJCKHJHHZ-UHFFFAOYSA-N
DMQEDP5	IU	N-[5-amino-1-(1H-benzimidazol-2-yl)pentyl]-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMQEDP5	DE	Discovery agent

DM8PJ92	ID	DM8PJ92
DM8PJ92	DN	H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid
DM8PJ92	HS	Investigative
DM8PJ92	SN	H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid; CHEMBL378082
DM8PJ92	DT	Small molecular drug
DM8PJ92	PC	25050370
DM8PJ92	MW	610.7
DM8PJ92	FM	C35H42N6O4
DM8PJ92	IC	InChI=1S/C35H42N6O4/c1-21-16-26(43)17-22(2)27(21)19-28(36)35(45)41-20-25-11-5-4-10-24(25)18-32(41)34(44)40-31(14-8-9-15-37-23(3)42)33-38-29-12-6-7-13-30(29)39-33/h4-7,10-13,16-17,28,31-32,43H,8-9,14-15,18-20,36H2,1-3H3,(H,37,42)(H,38,39)(H,40,44)
DM8PJ92	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)C)C4=NC5=CC=CC=C5N4)N)C)O
DM8PJ92	IK	IOSGXZKTOLVOTQ-UHFFFAOYSA-N
DM8PJ92	IU	N-[5-acetamido-1-(1H-benzimidazol-2-yl)pentyl]-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM8PJ92	DE	Discovery agent

DMQ4ILK	ID	DMQ4ILK
DMQ4ILK	DN	H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid
DMQ4ILK	HS	Investigative
DMQ4ILK	SN	H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid; CHEMBL386309; SCHEMBL8228625
DMQ4ILK	DT	Small molecular drug
DMQ4ILK	PC	25050223
DMQ4ILK	MW	702.8
DMQ4ILK	FM	C41H46N6O5
DMQ4ILK	IC	InChI=1S/C41H46N6O5/c1-26-20-31(48)21-27(2)32(26)23-33(42)40(50)47-24-30-15-7-6-14-29(30)22-37(47)39(49)46-36(38-44-34-16-8-9-17-35(34)45-38)18-10-11-19-43-41(51)52-25-28-12-4-3-5-13-28/h3-9,12-17,20-21,33,36-37,48H,10-11,18-19,22-25,42H2,1-2H3,(H,43,51)(H,44,45)(H,46,49)
DMQ4ILK	CS	CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)OCC4=CC=CC=C4)C5=NC6=CC=CC=C6N5)N)C)O
DMQ4ILK	IK	ZHRKDWCBKIOLKI-UHFFFAOYSA-N
DMQ4ILK	IU	benzyl N-[5-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-(1H-benzimidazol-2-yl)pentyl]carbamate
DMQ4ILK	DE	Discovery agent

DM4IUCW	ID	DM4IUCW
DM4IUCW	DN	H-Dmt-Tic-NH-CH2-Boa
DM4IUCW	HS	Investigative
DM4IUCW	SN	CHEMBL258458
DM4IUCW	DT	Small molecular drug
DM4IUCW	PC	44451689
DM4IUCW	MW	498.6
DM4IUCW	FM	C29H30N4O4
DM4IUCW	IC	InChI=1S/C29H30N4O4/c1-17-11-21(34)12-18(2)22(17)14-23(30)29(36)33-16-20-8-4-3-7-19(20)13-25(33)28(35)31-15-27-32-24-9-5-6-10-26(24)37-27/h3-12,23,25,34H,13-16,30H2,1-2H3,(H,31,35)/t23-,25-/m0/s1
DM4IUCW	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=NC5=CC=CC=C5O4)N)C)O
DM4IUCW	IK	JBEVAWMNEBELDV-ZCYQVOJMSA-N
DM4IUCW	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(1,3-benzoxazol-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM4IUCW	DE	Discovery agent

DMZ8C0U	ID	DMZ8C0U
DMZ8C0U	DN	H-Dmt-Tic-NH-CH2-Bta
DMZ8C0U	HS	Investigative
DMZ8C0U	SN	CHEMBL258704
DMZ8C0U	DT	Small molecular drug
DMZ8C0U	PC	44451667
DMZ8C0U	MW	514.6
DMZ8C0U	FM	C29H30N4O3S
DMZ8C0U	IC	InChI=1S/C29H30N4O3S/c1-17-11-21(34)12-18(2)22(17)14-23(30)29(36)33-16-20-8-4-3-7-19(20)13-25(33)28(35)31-15-27-32-24-9-5-6-10-26(24)37-27/h3-12,23,25,34H,13-16,30H2,1-2H3,(H,31,35)/t23-,25-/m0/s1
DMZ8C0U	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=NC5=CC=CC=C5S4)N)C)O
DMZ8C0U	IK	AWMRTINMSUQIBM-ZCYQVOJMSA-N
DMZ8C0U	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(1,3-benzothiazol-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMZ8C0U	DE	Discovery agent

DMYJAW4	ID	DMYJAW4
DMYJAW4	DN	H-Dmt-Tic-NH-CH2-CH2-NH2
DMYJAW4	HS	Investigative
DMYJAW4	SN	CHEMBL241010; H-Dmt-Tic-NH-CH2-CH2-NH2
DMYJAW4	DT	Small molecular drug
DMYJAW4	PC	44436392
DMYJAW4	MW	410.5
DMYJAW4	FM	C23H30N4O3
DMYJAW4	IC	InChI=1S/C23H30N4O3/c1-14-9-18(28)10-15(2)19(14)12-20(25)23(30)27-13-17-6-4-3-5-16(17)11-21(27)22(29)26-8-7-24/h3-6,9-10,20-21,28H,7-8,11-13,24-25H2,1-2H3,(H,26,29)/t20-,21?/m0/s1
DMYJAW4	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCN)N)C)O
DMYJAW4	IK	VIPTXSCSZKOVSA-BGERDNNASA-N
DMYJAW4	IU	N-(2-aminoethyl)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMYJAW4	DE	Discovery agent

DMJ2F8M	ID	DMJ2F8M
DMJ2F8M	DN	H-Dmt-Tic-NH-CH2-Imid
DMJ2F8M	HS	Investigative
DMJ2F8M	SN	CHEMBL407957
DMJ2F8M	DT	Small molecular drug
DMJ2F8M	PC	44451610
DMJ2F8M	MW	447.5
DMJ2F8M	FM	C25H29N5O3
DMJ2F8M	IC	InChI=1S/C25H29N5O3/c1-15-9-19(31)10-16(2)20(15)12-21(26)25(33)30-14-18-6-4-3-5-17(18)11-22(30)24(32)29-13-23-27-7-8-28-23/h3-10,21-22,31H,11-14,26H2,1-2H3,(H,27,28)(H,29,32)/t21-,22-/m0/s1
DMJ2F8M	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=NC=CN4)N)C)O
DMJ2F8M	IK	PFUVPVAVWLKTQT-VXKWHMMOSA-N
DMJ2F8M	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(1H-imidazol-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMJ2F8M	DE	Discovery agent

DMKGIQJ	ID	DMKGIQJ
DMKGIQJ	DN	H-Dmt-Tic-NH-CH2-ImidPh
DMKGIQJ	HS	Investigative
DMKGIQJ	SN	CHEMBL259917
DMKGIQJ	DT	Small molecular drug
DMKGIQJ	PC	44451637
DMKGIQJ	MW	523.6
DMKGIQJ	FM	C31H33N5O3
DMKGIQJ	IC	InChI=1S/C31H33N5O3/c1-19-12-24(37)13-20(2)25(19)15-26(32)31(39)36-18-23-11-7-6-10-22(23)14-28(36)30(38)34-17-29-33-16-27(35-29)21-8-4-3-5-9-21/h3-13,16,26,28,37H,14-15,17-18,32H2,1-2H3,(H,33,35)(H,34,38)/t26-,28-/m0/s1
DMKGIQJ	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=NC=C(N4)C5=CC=CC=C5)N)C)O
DMKGIQJ	IK	LKMAEHUMCHTBER-XCZPVHLTSA-N
DMKGIQJ	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(5-phenyl-1H-imidazol-2-yl)methyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMKGIQJ	DE	Discovery agent

DMNY3A1	ID	DMNY3A1
DMNY3A1	DN	H-Dmt-Tic-NH-CH2-Indl
DMNY3A1	HS	Investigative
DMNY3A1	SN	CHEMBL408975
DMNY3A1	DT	Small molecular drug
DMNY3A1	PC	44451665
DMNY3A1	MW	496.6
DMNY3A1	FM	C30H32N4O3
DMNY3A1	IC	InChI=1S/C30H32N4O3/c1-18-11-24(35)12-19(2)25(18)15-26(31)30(37)34-17-22-9-4-3-7-20(22)14-28(34)29(36)32-16-23-13-21-8-5-6-10-27(21)33-23/h3-13,26,28,33,35H,14-17,31H2,1-2H3,(H,32,36)/t26-,28-/m0/s1
DMNY3A1	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=CC5=CC=CC=C5N4)N)C)O
DMNY3A1	IK	WOVWFYGUXKNNEL-XCZPVHLTSA-N
DMNY3A1	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(1H-indol-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMNY3A1	DE	Discovery agent

DMZWUFK	ID	DMZWUFK
DMZWUFK	DN	H-Dmt-Tic-NH-CH2-Indn
DMZWUFK	HS	Investigative
DMZWUFK	SN	CHEMBL260127
DMZWUFK	DT	Small molecular drug
DMZWUFK	PC	44451639
DMZWUFK	MW	497.6
DMZWUFK	FM	C31H35N3O3
DMZWUFK	IC	InChI=1S/C31H35N3O3/c1-19-11-26(35)12-20(2)27(19)16-28(32)31(37)34-18-25-10-6-5-9-24(25)15-29(34)30(36)33-17-21-13-22-7-3-4-8-23(22)14-21/h3-12,21,28-29,35H,13-18,32H2,1-2H3,(H,33,36)/t28-,29-/m0/s1
DMZWUFK	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4CC5=CC=CC=C5C4)N)C)O
DMZWUFK	IK	DDWRUPXWANOFLU-VMPREFPWSA-N
DMZWUFK	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(2,3-dihydro-1H-inden-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMZWUFK	DE	Discovery agent

DML8S7J	ID	DML8S7J
DML8S7J	DN	H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2
DML8S7J	HS	Investigative
DML8S7J	SN	CHEMBL376703; H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2
DML8S7J	DT	Small molecular drug
DML8S7J	PC	11847438
DML8S7J	MW	956.1
DML8S7J	FM	C43H61N11O10S2
DML8S7J	IC	InChI=1S/C43H61N11O10S2/c1-22-37(58)50-31(18-26-19-47-29-14-8-7-13-27(26)29)40(61)49-30(15-9-10-16-44)39(60)54-35(24(3)56)43(64)52-33(42(63)53-34(23(2)55)36(46)57)21-66-65-20-32(41(62)48-22)51-38(59)28(45)17-25-11-5-4-6-12-25/h4-8,11-14,19,22-24,28,30-35,47,55-56H,9-10,15-18,20-21,44-45H2,1-3H3,(H2,46,57)(H,48,62)(H,49,61)(H,50,58)(H,51,59)(H,52,64)(H,53,63)(H,54,60)/t22-,23+,24+,28+,30-,31+,32-,33-,34-,35-/m0/s1
DML8S7J	CS	C[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)[C@@H](C)O)CCCCN)CC3=CNC4=CC=CC=C43
DML8S7J	IK	DNIBTKHTGSPUNA-RHSAGAAYSA-N
DML8S7J	IU	(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-16-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DML8S7J	DE	Discovery agent

DMLCIZ8	ID	DMLCIZ8
DMLCIZ8	DN	H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2
DMLCIZ8	HS	Investigative
DMLCIZ8	SN	CHEMBL219375; H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2; BDBM50191271; H-DPhe2-c[Cys3-Phe7-DTrp8-Lys9-Thr10-Cys14]-Thr15-NH2
DMLCIZ8	PC	11847588
DMLCIZ8	MW	1032.2
DMLCIZ8	FM	C49H65N11O10S2
DMLCIZ8	IC	InChI=1S/C49H65N11O10S2/c1-27(61)40(42(52)63)59-48(69)39-26-72-71-25-38(57-43(64)33(51)21-29-13-5-3-6-14-29)47(68)55-36(22-30-15-7-4-8-16-30)45(66)56-37(23-31-24-53-34-18-10-9-17-32(31)34)46(67)54-35(19-11-12-20-50)44(65)60-41(28(2)62)49(70)58-39/h3-10,13-18,24,27-28,33,35-41,53,61-62H,11-12,19-23,25-26,50-51H2,1-2H3,(H2,52,63)(H,54,67)(H,55,68)(H,56,66)(H,57,64)(H,58,70)(H,59,69)(H,60,65)/t27-,28-,33-,35+,36+,37-,38+,39+,40+,41+/m1/s1
DMLCIZ8	CS	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMLCIZ8	IK	SGYDRBBPYPDBRO-WNIOSIORSA-N
DMLCIZ8	IU	(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMLCIZ8	DE	Discovery agent

DM1EGC3	ID	DM1EGC3
DM1EGC3	DN	H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
DM1EGC3	HS	Investigative
DM1EGC3	SN	CHEMBL262017; H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
DM1EGC3	PC	44403230
DM1EGC3	MW	1031.3
DM1EGC3	FM	C50H66N10O10S2
DM1EGC3	IC	InChI=1S/C50H66N10O10S2/c1-28(2)43-50(70)59-42(49(69)57-40(25-61)29(3)62)27-72-71-26-41(58-44(64)35(52)21-30-11-5-4-6-12-30)48(68)55-38(22-31-16-18-33(63)19-17-31)46(66)56-39(23-32-24-53-36-14-8-7-13-34(32)36)47(67)54-37(45(65)60-43)15-9-10-20-51/h4-8,11-14,16-19,24-25,28-29,35,37-43,53,62-63H,9-10,15,20-23,26-27,51-52H2,1-3H3,(H,54,67)(H,55,68)(H,56,66)(H,57,69)(H,58,64)(H,59,70)(H,60,65)/t29-,35+,37+,38+,39-,40-,41+,42-,43-/m1/s1
DM1EGC3	CS	C[C@H]([C@@H](C=O)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=CC=C5)N)O
DM1EGC3	IK	KBXJEGQBFLLJFL-ILNSAXFWSA-N
DM1EGC3	IU	(4S,7R,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2S)-2-amino-3-phenylpropanoyl]amino]-N-[(2S,3R)-3-hydroxy-1-oxobutan-2-yl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM1EGC3	DE	Discovery agent

DMLRUVA	ID	DMLRUVA
DMLRUVA	DN	HDS-029
DMLRUVA	HS	Investigative
DMLRUVA	SN	HDS 029
DMLRUVA	DT	Small molecular drug
DMLRUVA	PC	11566580
DMLRUVA	MW	355.8
DMLRUVA	FM	C17H11ClFN5O
DMLRUVA	IC	InChI=1S/C17H11ClFN5O/c1-2-3-16(25)24-15-7-11-14(8-20-15)21-9-22-17(11)23-10-4-5-13(19)12(18)6-10/h4-9H,1H3,(H,20,24,25)(H,21,22,23)
DMLRUVA	CS	CC#CC(=O)NC1=NC=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl
DMLRUVA	IK	DLPSDPPZXRJQOY-UHFFFAOYSA-N
DMLRUVA	IU	N-[4-(3-chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]but-2-ynamide
DMLRUVA	CA	CAS 881001-19-0
DMLRUVA	DE	Discovery agent

DMY4QE6	ID	DMY4QE6
DMY4QE6	DN	H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMY4QE6	HS	Investigative
DMY4QE6	PC	91931233
DMY4QE6	MW	1082.3
DMY4QE6	FM	C47H63N13O11S3
DMY4QE6	IC	InChI=1S/C47H63N13O11S3/c1-23(61)35(38(48)64)58-45(71)37-47(3,4)74-73-22-34(57-42(68)33-21-72-17-16-51-33)43(69)55-31(18-25-11-13-27(63)14-12-25)40(66)56-32(19-26-20-53-29-9-6-5-8-28(26)29)41(67)54-30(10-7-15-52-46(49)50)39(65)59-36(24(2)62)44(70)60-37/h5-6,8-9,11-14,16,20-21,23-24,30-32,34-37,53,61-63H,7,10,15,17-19,22H2,1-4H3,(H2,48,64)(H,54,67)(H,55,69)(H,56,66)(H,57,68)(H,58,71)(H,59,65)(H,60,70)(H4,49,50,52)/t23-,24-,30+,31+,32+,34+,35+,36-,37+/m1/s1
DMY4QE6	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C5=CSCC=N5)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMY4QE6	IK	AVXONNNWRZHIKA-HVLWERHHSA-N
DMY4QE6	IU	(4S,7R,10S,13S,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-19-(2H-1,4-thiazine-5-carbonylamino)-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMY4QE6	DE	Discovery agent

DM8GC36	ID	DM8GC36
DM8GC36	DN	H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DM8GC36	HS	Investigative
DM8GC36	SN	CHEMBL268162; H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DM8GC36	PC	44369523
DM8GC36	MW	1116.3
DM8GC36	FM	C52H69N13O11S2
DM8GC36	IC	InChI=1S/C52H69N13O11S2/c1-26(66)40(43(53)69)63-50(76)42-52(3,4)78-77-25-39(62-45(71)36-21-29-10-5-6-11-30(29)23-58-36)48(74)60-37(20-28-15-17-32(68)18-16-28)46(72)61-38(22-31-24-57-34-13-8-7-12-33(31)34)47(73)59-35(14-9-19-56-51(54)55)44(70)64-41(27(2)67)49(75)65-42/h5-8,10-13,15-18,24,26-27,35-42,57-58,66-68H,9,14,19-23,25H2,1-4H3,(H2,53,69)(H,59,73)(H,60,74)(H,61,72)(H,62,71)(H,63,76)(H,64,70)(H,65,75)(H4,54,55,56)/t26-,27-,35+,36-,37+,38+,39+,40+,41-,42+/m1/s1
DM8GC36	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@H]5CC6=CC=CC=C6CN5)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DM8GC36	IK	VZDYOAZXFPOIMZ-MDTUBHLHSA-N
DM8GC36	IU	(4S,7R,10S,13S,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-19-[[(3R)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]amino]-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM8GC36	DE	Discovery agent

DMNAE6J	ID	DMNAE6J
DMNAE6J	DN	H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMNAE6J	HS	Investigative
DMNAE6J	SN	CHEMBL384571; H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMNAE6J	PC	44369487
DMNAE6J	MW	1143.3
DMNAE6J	FM	C53H70N14O11S2
DMNAE6J	IC	InChI=1S/C53H70N14O11S2/c1-26(68)41(44(55)71)65-51(78)43-53(3,4)80-79-25-40(64-45(72)34(54)21-29-23-59-35-12-7-5-10-32(29)35)49(76)62-38(20-28-15-17-31(70)18-16-28)47(74)63-39(22-30-24-60-36-13-8-6-11-33(30)36)48(75)61-37(14-9-19-58-52(56)57)46(73)66-42(27(2)69)50(77)67-43/h5-8,10-13,15-18,23-24,26-27,34,37-43,59-60,68-70H,9,14,19-22,25,54H2,1-4H3,(H2,55,71)(H,61,75)(H,62,76)(H,63,74)(H,64,72)(H,65,78)(H,66,73)(H,67,77)(H4,56,57,58)/t26-,27-,34-,37+,38+,39+,40+,41+,42-,43+/m1/s1
DMNAE6J	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CNC6=CC=CC=C65)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMNAE6J	IK	UGJHJTQROKIYLL-CCDPMWLASA-N
DMNAE6J	IU	(4S,7R,10S,13S,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMNAE6J	DE	Discovery agent

DM9I5Y0	ID	DM9I5Y0
DM9I5Y0	DN	Heberkinasa
DM9I5Y0	HS	Investigative
DM9I5Y0	SN	cardiovascular therapy, York Medical; recombinant streptokinase, York Medical
DM9I5Y0	DE	Discovery agent

DMZ4A0R	ID	DMZ4A0R
DMZ4A0R	DN	Hebervis
DMZ4A0R	HS	Investigative
DMZ4A0R	SN	CIGB-400; EGF (buccal local, mucositis), CIGB; EGF (rectal, proctitis), CIGB
DMZ4A0R	CP	Center for Genetic Engineering and Biotechnology
DMZ4A0R	DE	Oral mucositis

DMQPCDG	ID	DMQPCDG
DMQPCDG	DN	Helenalin-2-methylbutyrate
DMQPCDG	HS	Investigative
DMQPCDG	SN	helenalin-2-methylbutyrate
DMQPCDG	DT	Small molecular drug
DMQPCDG	PC	44409560
DMQPCDG	MW	346.4
DMQPCDG	FM	C20H26O5
DMQPCDG	IC	InChI=1S/C20H26O5/c1-6-10(2)18(22)25-17-16-12(4)19(23)24-14(16)9-11(3)13-7-8-15(21)20(13,17)5/h7-8,10-11,13-14,16-17H,4,6,9H2,1-3,5H3/t10?,11-,13+,14-,16-,17-,20+/m1/s1
DMQPCDG	CS	CCC(C)C(=O)O[C@@H]1[C@H]2[C@@H](C[C@H]([C@H]3[C@]1(C(=O)C=C3)C)C)OC(=O)C2=C
DMQPCDG	IK	IFEHNUQNAATZSJ-MXCJSKHRSA-N
DMQPCDG	IU	[(3aR,5R,5aR,8aR,9R,9aR)-5,8a-dimethyl-1-methylidene-2,8-dioxo-3a,4,5,5a,9,9a-hexahydroazuleno[6,5-b]furan-9-yl] 2-methylbutanoate
DMQPCDG	DE	Discovery agent

DMPOALD	ID	DMPOALD
DMPOALD	DN	HELENALINMETHACRYLATE
DMPOALD	HS	Investigative
DMPOALD	SN	helenalinmethacrylate
DMPOALD	DT	Small molecular drug
DMPOALD	PC	25845235
DMPOALD	MW	330.4
DMPOALD	FM	C19H22O5
DMPOALD	IC	InChI=1S/C19H22O5/c1-9(2)17(21)24-16-15-11(4)18(22)23-13(15)8-10(3)12-6-7-14(20)19(12,16)5/h6-7,10,12-13,15-16H,1,4,8H2,2-3,5H3/t10-,12+,13-,15-,16-,19+/m1/s1
DMPOALD	CS	C[C@@H]1C[C@@H]2[C@H]([C@H]([C@]3([C@H]1C=CC3=O)C)OC(=O)C(=C)C)C(=C)C(=O)O2
DMPOALD	IK	USRAFFQOAADTTD-OJIWXCRVSA-N
DMPOALD	IU	[(3aR,5R,5aR,8aR,9R,9aR)-5,8a-dimethyl-1-methylidene-2,8-dioxo-3a,4,5,5a,9,9a-hexahydroazuleno[6,5-b]furan-9-yl] 2-methylprop-2-enoate
DMPOALD	DE	Discovery agent

DM5MOLY	ID	DM5MOLY
DM5MOLY	DN	HELENAQUINONE
DM5MOLY	HS	Investigative
DM5MOLY	SN	Halenaquinone; 86690-14-4; CHEMBL513747; NSC643407; helenaquinone; AC1Q6BZF; (12bs)-12b-methyl-1h-tetrapheno[5,4-bc]furan-3,6,8,11(2h,12bh)-tetrone; AC1L80TG; SCHEMBL12464240; CTK5F7104; DTXSID50235769; BDBM50323927; NSC-643407
DM5MOLY	DT	Small molecular drug
DM5MOLY	PC	370346
DM5MOLY	MW	332.3
DM5MOLY	FM	C20H12O5
DM5MOLY	IC	InChI=1S/C20H12O5/c1-20-5-4-16(23)12-8-25-19(17(12)20)18(24)11-6-9-10(7-13(11)20)15(22)3-2-14(9)21/h2-3,6-8H,4-5H2,1H3/t20-/m0/s1
DM5MOLY	CS	C[C@@]12CCC(=O)C3=COC(=C31)C(=O)C4=C2C=C5C(=O)C=CC(=O)C5=C4
DM5MOLY	IK	SMGBXXZKAPMTBB-FQEVSTJZSA-N
DM5MOLY	IU	(1S)-1-methyl-14-oxapentacyclo[11.6.1.02,11.04,9.016,20]icosa-2(11),3,6,9,13(20),15-hexaene-5,8,12,17-tetrone
DM5MOLY	CA	CAS 86690-14-4
DM5MOLY	DE	Discovery agent

DMIUABO	ID	DMIUABO
DMIUABO	DN	helodermin
DMIUABO	HS	Investigative
DMIUABO	SN	Exendin 2
DMIUABO	DT	Small molecular drug
DMIUABO	PC	16132369
DMIUABO	MW	3843
DMIUABO	FM	C176H285N47O49
DMIUABO	IC	InChI=1S/C176H285N47O49/c1-23-93(15)138(217-146(243)98(20)194-159(256)124(78-137(237)238)210-167(264)126(82-225)214-147(244)107(180)77-104-79-187-86-190-104)169(266)212-123(74-101-38-26-25-27-39-101)164(261)220-140(99(21)229)171(268)202-114(57-60-135(183)235)153(250)200-113(56-59-134(182)234)154(251)209-122(76-103-49-53-106(232)54-50-103)163(260)215-127(83-226)166(263)198-110(42-30-33-63-179)150(247)205-120(73-92(13)14)161(258)206-117(70-89(7)8)157(254)191-95(17)143(240)196-108(40-28-31-61-177)149(246)204-116(69-88(5)6)156(253)192-96(18)144(241)203-119(72-91(11)12)160(257)201-112(55-58-133(181)233)152(249)197-109(41-29-32-62-178)151(248)208-121(75-102-47-51-105(231)52-48-102)162(259)207-118(71-90(9)10)158(255)193-97(19)145(242)213-128(84-227)168(265)218-139(94(16)24-2)170(267)211-115(68-87(3)4)148(245)189-80-136(236)195-125(81-224)165(262)199-111(43-34-64-188-176(185)186)155(252)219-141(100(22)230)172(269)216-129(85-228)173(270)222-66-36-45-131(222)175(272)223-67-37-46-132(223)174(271)221-65-35-44-130(221)142(184)239/h25-27,38-39,47-54,79,86-100,107-132,138-141,224-232H,23-24,28-37,40-46,55-78,80-85,177-180H2,1-22H3,(H2,181,233)(H2,182,234)(H2,183,235)(H2,184,239)(H,187,190)(H,189,245)(H,191,254)(H,192,253)(H,193,255)(H,194,256)(H,195,236)(H,196,240)(H,197,249)(H,198,263)(H,199,262)(H,200,250)(H,201,257)(H,202,268)(H,203,241)(H,204,246)(H,205,247)(H,206,258)(H,207,259)(H,208,248)(H,209,251)(H,210,264)(H,211,267)(H,212,266)(H,213,242)(H,214,244)(H,215,260)(H,216,269)(H,217,243)(H,218,265)(H,219,252)(H,220,261)(H,237,238)(H4,185,186,188)/t93-,94-,95-,96-,97-,98-,99+,100+,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,138-,139-,140-,141-/m0/s1
DMIUABO	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CN=CN7)N
DMIUABO	IK	SSAAJZQUEUTACT-MDBKHZGBSA-N
DMIUABO	IU	(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-carbamoylpyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoic acid
DMIUABO	CA	CAS 89468-62-2
DMIUABO	DE	Discovery agent

DMVK36Q	ID	DMVK36Q
DMVK36Q	DN	Hematoporphyrin
DMVK36Q	HS	Investigative
DMVK36Q	SN	1,3,5,8-Tetramethyl-2,4-bis(alpha-hydroxyethyl)prophine-6,7-dipropionic acid; 2,18-Porphinedipropionic acid, 7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-bis(1-hydroxyethyl); 7,12-Bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoic acid; HEMATOPORPHYRIN; HP; HP (VAN); Haematoporphyrin; Hematoporphyrin I; Hematoporphyrin IX; ISOHEMATOPORPHYRIN IX; NSC 267084; NSC 59265; NSC59265; Photodyn
DMVK36Q	TC	Antiasthenia Agents
DMVK36Q	DT	Small molecular drug
DMVK36Q	PC	11103
DMVK36Q	MW	598.7
DMVK36Q	FM	C34H38N4O6
DMVK36Q	IC	InChI=1S/C34H38N4O6/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27/h11-14,19-20,37-40H,7-10H2,1-6H3,(H,41,42)(H,43,44)
DMVK36Q	CS	CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)O)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C(C)O
DMVK36Q	IK	KFKRXESVMDBTNQ-UHFFFAOYSA-N
DMVK36Q	IU	3-[18-(2-carboxyethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid
DMVK36Q	CA	CAS 14459-29-1
DMVK36Q	CB	ChEBI:36162

DMGC287	ID	DMGC287
DMGC287	DN	Heme
DMGC287	HS	Investigative
DMGC287	SN	heme; protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin
DMGC287	DT	Small molecular drug
DMGC287	PC	26945
DMGC287	MW	616.5
DMGC287	FM	C34H32FeN4O4
DMGC287	IC	InChI=1S/C34H34N4O4.Fe/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);/q;+2/p-2
DMGC287	CS	CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C)CCC(=O)O)CCC(=O)O.[Fe+2]
DMGC287	IK	KABFMIBPWCXCRK-UHFFFAOYSA-L
DMGC287	IU	3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;iron(2+)
DMGC287	CA	CAS 14875-96-8
DMGC287	DE	Discovery agent

DMXP276	ID	DMXP276
DMXP276	DN	Hemi-Babim
DMXP276	HS	Investigative
DMXP276	SN	HEMI-BABIM; CHEMBL46148; (5-amidino-2-benzimidazolyl)(2-benzimidazolyl)methane; 1c1r; 1c1u; AC1L1B4Q; APD-1; SCHEMBL6163820; CTK7D1925; BDBM16303; ZINC2047318; DB01767; 2-(1H-Benzoimidazole-2-ylmethyl)-6-amidino-1H-benzoimidazole; 2-(1H-benzimidazol-2-ylmethyl)-1H-benzimidazole-5-carboximidamide; 2-(1H-benzimidazol-2-ylmethyl)-3H-benzimidazole-5-carboximidamide; 2-(1H-benzimidazol-2-ylmethyl)-1H-benzimidazole-6-carboximidamide
DMXP276	DT	Small molecular drug
DMXP276	PC	1282
DMXP276	MW	290.32
DMXP276	FM	C16H14N6
DMXP276	IC	InChI=1S/C16H14N6/c17-16(18)9-5-6-12-13(7-9)22-15(21-12)8-14-19-10-3-1-2-4-11(10)20-14/h1-7H,8H2,(H3,17,18)(H,19,20)(H,21,22)
DMXP276	CS	C1=CC=C2C(=C1)NC(=N2)CC3=NC4=C(N3)C=C(C=C4)C(=N)N
DMXP276	IK	KKJYVDXDZURHMA-UHFFFAOYSA-N
DMXP276	IU	2-(1H-benzimidazol-2-ylmethyl)-3H-benzimidazole-5-carboximidamide
DMXP276	DE	Discovery agent

DMF7X31	ID	DMF7X31
DMF7X31	DN	Hemoparatide
DMF7X31	HS	Investigative
DMF7X31	SN	hPTH 1-37 (metabolic/bone/skin diseases), Haemopep
DMF7X31	DE	Discovery agent

DMY16VG	ID	DMY16VG
DMY16VG	DN	Heparin Pentasaccharide
DMY16VG	HS	Investigative
DMY16VG	SN	Heparin pentasaccharide; 1azx; AC1L9G9S; 1e03; methyl 3,4-di-O-methyl-2,6-di-O-sulfo-alpha-D-glucopyranosyl-(1-&gt;4)-2,3-di-O-methyl-beta-D-glucopyranuronosyl-(1-&gt;4)-2,3,6-tri-O-sulfo-alpha-D-glucopyranosyl-(1-&gt;4)-3-O-methyl-2-O-sulfo-alpha-L-idopyranuronosyl-(1-&gt;4)-2,3,6-tri-O-sulfo-alpha-D-glucopyranoside
DMY16VG	DT	Small molecular drug
DMY16VG	PC	444410
DMY16VG	MW	1661.4
DMY16VG	FM	C36H60O55S9
DMY16VG	IC	InChI=1S/C36H60O55S9/c1-68-13-10(7-74-92(41,42)43)78-34(26(16(13)69-2)88-97(56,57)58)82-19-17(70-3)25(72-5)33(84-23(19)30(37)38)80-15-12(9-76-94(47,48)49)79-35(29(91-100(65,66)67)22(15)87-96(53,54)55)83-20-18(71-4)27(89-98(59,60)61)36(85-24(20)31(39)40)81-14-11(8-75-93(44,45)46)77-32(73-6)28(90-99(62,63)64)21(14)86-95(50,51)52/h10-29,32-36H,7-9H2,1-6H3,(H,37,38)(H,39,40)(H,41,42,43)(H,44,45,46)(H,47,48,49)(H,50,51,52)(H,53,54,55)(H,56,57,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)/t10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24-,25-,26-,27-,28-,29-,32+,33-,34-,35-,36-/m1/s1
DMY16VG	CS	CO[C@@H]1[C@H](O[C@@H]([C@@H]([C@H]1OC)OS(=O)(=O)O)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]4[C@@H]([C@H]([C@@H](O[C@H]4C(=O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5OS(=O)(=O)O)OS(=O)(=O)O)OC)COS(=O)(=O)O)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O
DMY16VG	IK	MQLWHPBUPXUQHM-XAYBSJBFSA-N
DMY16VG	IU	(2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-4-methoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-5-sulfooxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5R,6R)-4,5-dimethoxy-3-sulfooxy-6-(sulfooxymethyl)oxan-2-yl]oxy-4,5-dimethoxyoxane-2-carboxylic acid
DMY16VG	DE	Discovery agent

DM7U491	ID	DM7U491
DM7U491	DN	Heparin-Cantithrombin III
DM7U491	HS	Investigative
DM7U491	SN	212391-63-4; PD 166285 dihydrochloride; 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-onedihydrochloride; PD166285/PD-166285; SCHEMBL15106017; CHEMBL3545196; CTK8E7972; DTXSID80432749; MolPort-023-219-121; PD 166285 2HCl; EX-A1369; AKOS024457798; BCP9001063; BCP0726000019; KB-309461; RT-014958; FT-0673536; J-013945; 6-(2,6-Dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one dihydrochloride
DM7U491	DT	Small molecular drug
DM7U491	PC	9916391
DM7U491	MW	585.3
DM7U491	FM	C26H29Cl4N5O2
DM7U491	IC	InChI=1S/C26H27Cl2N5O2.2ClH/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28;;/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31);2*1H
DM7U491	CS	CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl.Cl.Cl
DM7U491	IK	NADLBPWBFGTESN-UHFFFAOYSA-N
DM7U491	IU	6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one;dihydrochloride
DM7U491	CA	CAS 212391-63-4
DM7U491	DE	Discovery agent

DMK846H	ID	DMK846H
DMK846H	DN	HEPT
DMK846H	HS	Investigative
DMK846H	SN	HEPT; 6-Hept; HMPTT; 123027-56-5; 1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE; 1-((2-Hydroxyethoxy)methyl)-6-(phenylthio)thymine; 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine; CHEMBL31871; CHEBI:43060; 1-((2-Hydroxyethoxy)methyl)-6-phenylthiothymine; 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine; 1-[(2-hydroxyethoxy)methyl]-5-methyl-6-(phenylsulfanyl)pyrimidine-2,4(1H,3H)-dione; 1-((2-Hydroxyethoxy)methyl)-5-methyl-6-(phenylthio)-2,4(1H,3H)-pyrimidinedione
DMK846H	DT	Small molecular drug
DMK846H	PC	64993
DMK846H	MW	308.35
DMK846H	FM	C14H16N2O4S
DMK846H	IC	InChI=1S/C14H16N2O4S/c1-10-12(18)15-14(19)16(9-20-8-7-17)13(10)21-11-5-3-2-4-6-11/h2-6,17H,7-9H2,1H3,(H,15,18,19)
DMK846H	CS	CC1=C(N(C(=O)NC1=O)COCCO)SC2=CC=CC=C2
DMK846H	IK	HDMHBHNRWDNNCD-UHFFFAOYSA-N
DMK846H	IU	1-(2-hydroxyethoxymethyl)-5-methyl-6-phenylsulfanylpyrimidine-2,4-dione
DMK846H	CA	CAS 123027-56-5
DMK846H	CB	CHEBI:43060
DMK846H	DE	Discovery agent

DMV4GDI	ID	DMV4GDI
DMV4GDI	DN	Heptane-1,2,3-Triol
DMV4GDI	HS	Investigative
DMV4GDI	SN	(2R,3R)-heptane-1,2,3-triol; HTO; AC1L9G8Y; CHEBI:43208; ZINC2043148; LMFA05000549; DB04079
DMV4GDI	DT	Small molecular drug
DMV4GDI	PC	124604
DMV4GDI	MW	148.2
DMV4GDI	FM	C7H16O3
DMV4GDI	IC	InChI=1S/C7H16O3/c1-2-3-4-6(9)7(10)5-8/h6-10H,2-5H2,1H3
DMV4GDI	CS	CCCCC(C(CO)O)O
DMV4GDI	IK	HXYCHJFUBNTKQR-UHFFFAOYSA-N
DMV4GDI	IU	heptane-1,2,3-triol
DMV4GDI	CA	CAS 103404-57-5
DMV4GDI	CB	CHEBI:67095
DMV4GDI	DE	Discovery agent

DMCFTB8	ID	DMCFTB8
DMCFTB8	DN	Heptane-2,3-dione
DMCFTB8	HS	Investigative
DMCFTB8	SN	2,3-HEPTANEDIONE; 96-04-8; Acetyl valeryl; Heptane-2,3-dione; Valerylacetyl; Acetylvaleryl; Acetyl pentanoyl; UNII-DK55DDE86P; DK55DDE86P; Benzil-related compound, 47; CHEBI:88623; MFCD00036550; FR-2294; Heptanedione; FEMA No. 2543; 2,3-Dioxoheptane; EINECS 202-472-5; 2,3-heptane dione; NSC 31668; 2,3 - Heptanedione; AC1L1UAC; SCHEMBL109416; ACMC-20978p; CHEMBL364588; DTXSID4059128; KS-00000YJN; FEMA 2543; CTK0C6666; BDBM22769; MolPort-002-501-994; FJPGAMCQJNLTJC-UHFFFAOYSA-N; NSC31668; ZINC1663926; 2,3-Heptanedione, &gt;=97%, FG
DMCFTB8	DT	Small molecular drug
DMCFTB8	PC	60983
DMCFTB8	MW	128.169
DMCFTB8	FM	C7H12O2
DMCFTB8	IC	InChI=1S/C7H12O2/c1-3-4-5-7(9)6(2)8/h3-5H2,1-2H3
DMCFTB8	CS	CCCCC(=O)C(=O)C
DMCFTB8	IK	FJPGAMCQJNLTJC-UHFFFAOYSA-N
DMCFTB8	IU	heptane-2,3-dione
DMCFTB8	CA	CAS 96-04-8
DMCFTB8	CB	CHEBI:88623
DMCFTB8	DE	Discovery agent

DMGEO8N	ID	DMGEO8N
DMGEO8N	DN	HEPTANOATE
DMGEO8N	HS	Investigative
DMGEO8N	SN	Heptanoate; enanthate; Heptanoic acid, ion(1-); oenanthate; oenanthylate; heptoate; enanthylate; n-heptylate; n-heptanoate; n-heptoate; heptylate; 1-hexanecarboxylate; 7563-37-3; CH3-[CH2]5-COO(-); EINECS 231-459-7; AC1L3PEG; AC1Q2VSF; AC1Q22DU; CTK5E1803; CHEBI:32362; MNWFXJYAOYHMED-UHFFFAOYSA-M; STL483842; BDBM50240408; AKOS024438002; CJ-25028; 9187-EP2316836A1; 9187-EP2316835A1; 9187-EP2316834A1; 9187-EP2298734A2; 9187-EP2295437A1; 9187-EP2295426A1; 9187-EP2295413A1; 9187-EP2292614A1; 9187-EP2292227A2; 9187-EP2275412A1; 9187-EP2270004A1
DMGEO8N	DT	Small molecular drug
DMGEO8N	PC	93052
DMGEO8N	MW	129.18
DMGEO8N	FM	C7H13O2-
DMGEO8N	IC	InChI=1S/C7H14O2/c1-2-3-4-5-6-7(8)9/h2-6H2,1H3,(H,8,9)/p-1
DMGEO8N	CS	CCCCCCC(=O)[O-]
DMGEO8N	IK	MNWFXJYAOYHMED-UHFFFAOYSA-M
DMGEO8N	IU	heptanoate
DMGEO8N	CA	CAS 7563-37-3
DMGEO8N	CB	CHEBI:32362
DMGEO8N	DE	Discovery agent

DM4NY9H	ID	DM4NY9H
DM4NY9H	DN	Heptanoic Acid
DM4NY9H	HS	Investigative
DM4NY9H	SN	2(3H)-Furanone, dihydro-5,5-dimethyl-4-(3-oxobutyl)-; 4436-81-1; NSC45645; 4,5-Dihydro-5,5-dimethyl-4-(3-oxobutyl)furan-2(3H)-one; 16091-70-6; HEPTANOIC ACID,; HEPTANOIC ACID LACTONE DERIV; AC1L3CDV; AC1Q1K5S; SCHEMBL7128855; Heptanoic acid lactone derivative; AWQSAIIDOMEEOD-UHFFFAOYSA-N; NSC36847; NSC140633; NSC-36847; NSC140621; NSC127945; NSC-45645; AKOS006346009; NSC-127945; MCULE-6610625549; NSC-140621; NSC-140633; 5,5-dimethyl-4-(3-oxobutyl)oxolan-2-one; C06066; 2(3H)-Furanone,5-dimethyl-4-(3-oxobutyl)-
DM4NY9H	DT	Small molecular drug
DM4NY9H	PC	8094
DM4NY9H	MW	130.18
DM4NY9H	FM	C7H14O2
DM4NY9H	IC	InChI=1S/C7H14O2/c1-2-3-4-5-6-7(8)9/h2-6H2,1H3,(H,8,9)
DM4NY9H	CS	CCCCCCC(=O)O
DM4NY9H	IK	MNWFXJYAOYHMED-UHFFFAOYSA-N
DM4NY9H	IU	heptanoic acid
DM4NY9H	CA	CAS 111-14-8
DM4NY9H	CB	CHEBI:45571
DM4NY9H	DE	Discovery agent

DMIAQX4	ID	DMIAQX4
DMIAQX4	DN	Heptulose-2-Phosphate
DMIAQX4	HS	Investigative
DMIAQX4	SN	Heptulose-2-Phosphate; 6gpb; H2P; Heptulose-2-P; 1-Deoxygluco-heptulose 2-phosphate; Heptulose 2-phosphate; AC1Q6S5N; AC1L3Z5G; SCHEMBL4312544; 1-deoxy-2-o-phosphono-; A-d-gluco-hept-2-ulopyranose; 1-Deoxy-D-gluco-heptulose 2-phosphate; DB04195; 92642-58-5; 1-deoxy-2-O-phosphono-alpha-D-gluco-hept-2-ulopyranose; alpha-D-gluco-2-Heptulopyranose, 1-deoxy-, 2-(dihydrogen phosphate); [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-methyloxan-2-yl] dihydrogen phosphate
DMIAQX4	DT	Small molecular drug
DMIAQX4	PC	124823
DMIAQX4	MW	274.16
DMIAQX4	FM	C7H15O9P
DMIAQX4	IC	InChI=1S/C7H15O9P/c1-7(16-17(12,13)14)6(11)5(10)4(9)3(2-8)15-7/h3-6,8-11H,2H2,1H3,(H2,12,13,14)/t3-,4-,5+,6-,7-/m1/s1
DMIAQX4	CS	C[C@]1([C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)OP(=O)(O)O
DMIAQX4	IK	QZBAZODTRUGOQS-XUUWZHRGSA-N
DMIAQX4	IU	[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-methyloxan-2-yl] dihydrogen phosphate
DMIAQX4	CA	CAS 92642-58-5
DMIAQX4	DE	Discovery agent

DMKF762	ID	DMKF762
DMKF762	DN	Heptyl 1-Thiohexopyranoside
DMKF762	HS	Investigative
DMKF762	SN	85618-20-8; Heptyl b-D-thioglucopyranoside; Heptyl 1-thiohexopyranoside; Heptyl beta-D-thioglucopyranoside; Heptyl-beta-D-1-thioglucopyranoside; N-HEPTYL-BETA-D-THIOGLUCOPYRANOSIDE; Heptyl 1-thioglucoside; HTG; N-Heptylthioglucoside; Heptyl thioglucoside; AC1LCVPH; SCHEMBL137948; Heptyl  -D-thioglucopyranoside; C13H26O5S; ZINC16052385; n-Heptyl-I(2)-D-thioglucopyranoside; Heptyl-1-thio-beta-D-glucopyranoside; heptyl 1-thio-beta-D-glucopyranoside; GC8635; MFCD00043236; AKOS016846196; beta-D-Glucopyranoside,heptyl 1-thio-
DMKF762	DT	Small molecular drug
DMKF762	PC	656917
DMKF762	MW	294.41
DMKF762	FM	C13H26O5S
DMKF762	IC	InChI=1S/C13H26O5S/c1-2-3-4-5-6-7-19-13-12(17)11(16)10(15)9(8-14)18-13/h9-17H,2-8H2,1H3/t9-,10-,11+,12-,13+/m1/s1
DMKF762	CS	CCCCCCCS[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMKF762	IK	HPEGNLMTTNTJSP-LBELIVKGSA-N
DMKF762	IU	(2S,3R,4S,5S,6R)-2-heptylsulfanyl-6-(hydroxymethyl)oxane-3,4,5-triol
DMKF762	CA	CAS 85618-20-8
DMKF762	DE	Discovery agent

DMPQBN0	ID	DMPQBN0
DMPQBN0	DN	Heptyl-Beta-D-Glucopyranoside
DMPQBN0	HS	Investigative
DMPQBN0	SN	78617-12-6; HEPTYL-BETA-D-GLUCOPYRANOSIDE; Heptyl beta-D-glucopyranoside; (2R,3R,4S,5S,6R)-2-(Heptyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Heptyl-b-D-glucopyranoside; Heptyl b-D-glucopyranoside; B7G; n-Heptyl-I(2)-D-glucopyranoside; AC1L9LOI; heptyl-; n-Heptyl-ss-D-glucopyranosid; SCHEMBL333088; MolPort-003-935-703; C13H26O6; ZINC48016017; MFCD00063299; GC5331; AKOS027251086; DB03338; API0002901; AK187162; W0562; FT-0626931; n-Heptyl beta-D-glucopyranoside, ~98% (GC); A-7798; n-Heptyl beta-D-gluc
DMPQBN0	DT	Small molecular drug
DMPQBN0	PC	448173
DMPQBN0	MW	278.34
DMPQBN0	FM	C13H26O6
DMPQBN0	IC	InChI=1S/C13H26O6/c1-2-3-4-5-6-7-18-13-12(17)11(16)10(15)9(8-14)19-13/h9-17H,2-8H2,1H3/t9-,10-,11+,12-,13-/m1/s1
DMPQBN0	CS	CCCCCCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMPQBN0	IK	NIDYWHLDTIVRJT-UJPOAAIJSA-N
DMPQBN0	IU	(2R,3R,4S,5S,6R)-2-heptoxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMPQBN0	CA	CAS 78617-12-6
DMPQBN0	DE	Discovery agent

DM1NUO5	ID	DM1NUO5
DM1NUO5	DN	Heptyl-methyl-prop-2-ynyl-amine hydrochloride
DM1NUO5	HS	Investigative
DM1NUO5	DE	Discovery agent

DM0VC84	ID	DM0VC84
DM0VC84	DN	Her2- and PSA-targeted TGX-D1
DM0VC84	HS	Investigative
DM0VC84	SN	KCC-TGX; Her2- and PSA-targeted TGX-D1 (prostate cancer); Her2-and PSA-targeted TGX-D1 (prostate cancer), University of Missouri
DM0VC84	CP	University of Missouri
DM0VC84	DE	Prostate cancer

DM8MD52	ID	DM8MD52
DM8MD52	DN	HERBACETIN
DM8MD52	HS	Investigative
DM8MD52	SN	Herbacetin; 527-95-7; CHEMBL611029; 8-Hydroxykaempferol; 3,5,7,8-tetrahydroxy-2-(4-hydroxyphenyl)chromen-4-one; 3,4',5,7,8-Pentahydroxyflavone; 2-(4-hydroxyphenyl)-3,5,7,8-tetrakis(oxidanyl)chromen-4-one; PubChem9861; C02806; AC1NQX74; SCHEMBL872691; Herbacetin, &gt; DTXSID70415061; ZDOTZEDNGNPOEW-UHFFFAOYSA-N; MolPort-019-998-217; 3,5,7,8,4'-Pentahydroxyflavone; ZINC6536276; 8144AH; LMPK12113149; BDBM50304350; AKOS030573690; FT-0688291; A829256; 3,5,7,8-tetrahydroxy-2-(4-hydroxyphenyl)-1-benzopyran-4-one
DM8MD52	DT	Small molecular drug
DM8MD52	PC	5280544
DM8MD52	MW	302.23
DM8MD52	FM	C15H10O7
DM8MD52	IC	InChI=1S/C15H10O7/c16-7-3-1-6(2-4-7)14-13(21)12(20)10-8(17)5-9(18)11(19)15(10)22-14/h1-5,16-19,21H
DM8MD52	CS	C1=CC(=CC=C1C2=C(C(=O)C3=C(O2)C(=C(C=C3O)O)O)O)O
DM8MD52	IK	ZDOTZEDNGNPOEW-UHFFFAOYSA-N
DM8MD52	IU	3,5,7,8-tetrahydroxy-2-(4-hydroxyphenyl)chromen-4-one
DM8MD52	CA	CAS 527-95-7
DM8MD52	CB	CHEBI:27673
DM8MD52	DE	Discovery agent

DMJXBWV	ID	DMJXBWV
DMJXBWV	DN	HERKINORIN
DMJXBWV	HS	Investigative
DMJXBWV	SN	herkinorin; CHEMBL363324; 862073-77-6; BF3DNCA methyl ester; 9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester; SCHEMBL3540059; DTXSID30235444; MolPort-003-983-869; PYDQMXRFUVDCHC-XAGHGKQISA-N; ZINC28461930; BDBM50170678; (3S,4aR,4bS,6S,8R,8aR,10aR)-6-Benzoyloxy-3-furan-3-yl-4a,8a-dimethyl-1,5-dioxo-dodecahydro-2-oxa-phenanthrene-8-carboxylic acid methyl ester
DMJXBWV	DT	Small molecular drug
DMJXBWV	PC	11431898
DMJXBWV	MW	494.5
DMJXBWV	FM	C28H30O8
DMJXBWV	IC	InChI=1S/C28H30O8/c1-27-11-9-18-26(32)36-21(17-10-12-34-15-17)14-28(18,2)23(27)22(29)20(13-19(27)25(31)33-3)35-24(30)16-7-5-4-6-8-16/h4-8,10,12,15,18-21,23H,9,11,13-14H2,1-3H3/t18-,19-,20-,21-,23-,27-,28-/m0/s1
DMJXBWV	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OC(=O)C4=CC=CC=C4)C)C5=COC=C5
DMJXBWV	IK	PYDQMXRFUVDCHC-XAGHGKQISA-N
DMJXBWV	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-benzoyloxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMJXBWV	CA	CAS 862073-77-6
DMJXBWV	DE	Discovery agent

DM9UASM	ID	DM9UASM
DM9UASM	DN	HERNIARIN
DM9UASM	HS	Investigative
DM9UASM	SN	7-Methoxycoumarin; Herniarin; 531-59-9; 7-Methoxy-2H-chromen-2-one; Ayapanin; Herniarine; Methylumbelliferone; 7-Methoxy-2H-1-benzopyran-2-one; 7-methoxychromen-2-one; 2H-1-BENZOPYRAN-2-ONE, 7-METHOXY-; Coumarin, 7-methoxy-; METHOXYCOURMARIN, 7-; Herniarin (6CI); Methyl umbelliferyl ether; UNII-DGK72G008A; 7-methoxy-coumarin; 7-Methoxy Coumarin; NSC 404559; 7-(methyloxy)-2H-chromen-2-one; EINECS 208-513-3; 7-methoxy-chromen-2-one; BRN 0141728; CHEMBL49732; CHEBI:5679; DGK72G008A; Coumarin, 7-methoxy- (8CI)
DM9UASM	DT	Small molecular drug
DM9UASM	PC	10748
DM9UASM	MW	176.17
DM9UASM	FM	C10H8O3
DM9UASM	IC	InChI=1S/C10H8O3/c1-12-8-4-2-7-3-5-10(11)13-9(7)6-8/h2-6H,1H3
DM9UASM	CS	COC1=CC2=C(C=C1)C=CC(=O)O2
DM9UASM	IK	LIIALPBMIOVAHH-UHFFFAOYSA-N
DM9UASM	IU	7-methoxychromen-2-one
DM9UASM	CA	CAS 531-59-9
DM9UASM	CB	CHEBI:5679
DM9UASM	DE	Discovery agent

DM2CK7B	ID	DM2CK7B
DM2CK7B	DN	HESPERADIN
DM2CK7B	HS	Investigative
DM2CK7B	DT	Small molecular drug
DM2CK7B	PC	135421442
DM2CK7B	MW	516.7
DM2CK7B	FM	C29H32N4O3S
DM2CK7B	IC	InChI=1S/C29H32N4O3S/c1-2-37(35,36)32-24-15-16-26-25(19-24)27(29(34)31-26)28(22-9-5-3-6-10-22)30-23-13-11-21(12-14-23)20-33-17-7-4-8-18-33/h3,5-6,9-16,19,31-32,34H,2,4,7-8,17-18,20H2,1H3
DM2CK7B	CS	CCS(=O)(=O)NC1=CC2=C(C=C1)NC(=C2C(=NC3=CC=C(C=C3)CN4CCCCC4)C5=CC=CC=C5)O
DM2CK7B	IK	HYHIYZMIFPJROG-UHFFFAOYSA-N
DM2CK7B	IU	N-[2-hydroxy-3-[C-phenyl-N-[4-(piperidin-1-ylmethyl)phenyl]carbonimidoyl]-1H-indol-5-yl]ethanesulfonamide
DM2CK7B	CA	CAS 422513-13-1
DM2CK7B	CB	CHEBI:70726
DM2CK7B	DE	Discovery agent

DMJCHE1	ID	DMJCHE1
DMJCHE1	DN	Hexadecanal
DMJCHE1	HS	Investigative
DMJCHE1	SN	hexadecanal; palmitaldehyde; 629-80-1; N-hexadecanal; palmitoyl aldehyde; 1-hexadecanal; 16-Hexadecanal; UNII-WQD27655QE; EINECS 211-111-0; AI3-24252; WQD27655QE; CHEBI:17600; NIOYUNMRJMEDGI-UHFFFAOYSA-N; PLY; Hexadecanaldehyde; Palmitic aldehyde; Palmityl Aldehyde; ACMC-209nbe; AC1L1AGZ; SCHEMBL4481; AC1Q6QL1; GTPL6627; QSPL 064; Palmitaldehyde, 16-Hexadecanal; DTXSID5042039; CHEMBL1235338; CTK2F4087; MolPort-001-784-298; ZINC8216082; KS-000016GB; ANW-34488; RB3019; 6369AF; LMFA06000088; AKOS005145523; TRA0026585; DB03381; MCULE-1337115097
DMJCHE1	DT	Small molecular drug
DMJCHE1	PC	984
DMJCHE1	MW	240.42
DMJCHE1	FM	C16H32O
DMJCHE1	IC	InChI=1S/C16H32O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h16H,2-15H2,1H3
DMJCHE1	CS	CCCCCCCCCCCCCCCC=O
DMJCHE1	IK	NIOYUNMRJMEDGI-UHFFFAOYSA-N
DMJCHE1	IU	hexadecanal
DMJCHE1	CA	CAS 629-80-1
DMJCHE1	CB	CHEBI:17600
DMJCHE1	DE	Discovery agent

DMWUXDZ	ID	DMWUXDZ
DMWUXDZ	DN	Hexadecanoic acid
DMWUXDZ	HS	Investigative
DMWUXDZ	SN	Palmitic acid; palmitic acid; 1957/10/3; Cetylic acid; palmitate; n-Hexadecanoic acid; Hexadecylic acid; Hydrofol; n-Hexadecoic acid; 1-Pentadecanecarboxylic acid; Pentadecanecarboxylic acid; Palmitinic acid; C16 fatty acid; hexaectylic acid; Industrene 4516; Emersol 143; Emersol 140; Hystrene 8016; Hystrene 9016; 1-Hexyldecanoic Acid; hexadecoic acid; Palmitinsaeure; Palmitic acid (natural); Palmitic acid, pure; Palmitic acid 95%; Prifac 2960; FEMA No 2832; Fatty acids, C14-18; Pristerene 4934; Edenor C16; Kortacid 1698; Lunac P; Palmitic Acid
DMWUXDZ	DT	Small molecular drug
DMWUXDZ	PC	985
DMWUXDZ	MW	256.42
DMWUXDZ	FM	C16H32O2
DMWUXDZ	IC	InChI=1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)
DMWUXDZ	CS	CCCCCCCCCCCCCCCC(=O)O
DMWUXDZ	IK	IPCSVZSSVZVIGE-UHFFFAOYSA-N
DMWUXDZ	IU	hexadecanoic acid
DMWUXDZ	CA	CAS 57-10-3
DMWUXDZ	CB	CHEBI:15756
DMWUXDZ	DE	Discovery agent

DMNZLD6	ID	DMNZLD6
DMNZLD6	DN	Hexahydro-cyclopenta[b]pyrrol-(2Z)-ylideneamine
DMNZLD6	HS	Investigative
DMNZLD6	SN	CHEMBL361419; Hexahydro-cyclopenta[b]pyrrol-(2Z)-ylideneamine; BDBM50150921
DMNZLD6	DT	Small molecular drug
DMNZLD6	PC	44393534
DMNZLD6	MW	124.18
DMNZLD6	FM	C7H12N2
DMNZLD6	IC	InChI=1S/C7H12N2/c8-7-4-5-2-1-3-6(5)9-7/h5-6H,1-4H2,(H2,8,9)
DMNZLD6	CS	C1CC2CC(=NC2C1)N
DMNZLD6	IK	BJTCDQQHCOHHOO-UHFFFAOYSA-N
DMNZLD6	IU	3,3a,4,5,6,6a-hexahydrocyclopenta[b]pyrrol-2-amine
DMNZLD6	DE	Discovery agent

DMG0UVT	ID	DMG0UVT
DMG0UVT	DN	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine
DMG0UVT	HS	Investigative
DMG0UVT	SN	CHEMBL365849; Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine; BDBM50150935
DMG0UVT	DT	Small molecular drug
DMG0UVT	PC	19049158
DMG0UVT	MW	124.18
DMG0UVT	FM	C7H12N2
DMG0UVT	IC	InChI=1S/C7H12N2/c8-7-6-3-1-2-5(6)4-9-7/h5-6H,1-4H2,(H2,8,9)
DMG0UVT	CS	C1CC2CN=C(C2C1)N
DMG0UVT	IK	QRVPYEUERURUGX-UHFFFAOYSA-N
DMG0UVT	IU	1,3a,4,5,6,6a-hexahydrocyclopenta[c]pyrrol-3-amine
DMG0UVT	DE	Discovery agent

DMH25OD	ID	DMH25OD
DMH25OD	DN	hexahydrodifenidol
DMH25OD	HS	Investigative
DMH25OD	SN	Hexahydrodifenidol; 1-cyclohexyl-1-phenyl-4-piperidin-1-ylbutan-1-ol; 113010-69-8; Hexahydro-diphenidol; GTPL322; AC1L3Y37; BDBM81960; CAS_113010-69-8; Piperidinebutanol, alpha-cyclohexyl-alpha-phenyl-
DMH25OD	DT	Small molecular drug
DMH25OD	PC	124226
DMH25OD	MW	315.5
DMH25OD	FM	C21H33NO
DMH25OD	IC	InChI=1S/C21H33NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1,4-5,11-12,20,23H,2-3,6-10,13-18H2
DMH25OD	CS	C1CCC(CC1)C(CCCN2CCCCC2)(C3=CC=CC=C3)O
DMH25OD	IK	ILHSFCNKNNNPRN-UHFFFAOYSA-N
DMH25OD	IU	1-cyclohexyl-1-phenyl-4-piperidin-1-ylbutan-1-ol
DMH25OD	CA	CAS 113010-69-8
DMH25OD	DE	Discovery agent

DMIB3J2	ID	DMIB3J2
DMIB3J2	DN	Hexahydro-pyrrolizin-(3E)-ylideneamine
DMIB3J2	HS	Investigative
DMIB3J2	SN	Hexahydro-pyrrolizin-(3E)-ylideneamine; CHEMBL185535; 765304-80-1; 3h-pyrrolizin-3-imine,hexahydro-; BDBM50150910
DMIB3J2	DT	Small molecular drug
DMIB3J2	PC	44393480
DMIB3J2	MW	124.18
DMIB3J2	FM	C7H12N2
DMIB3J2	IC	InChI=1S/C7H12N2/c8-7-4-3-6-2-1-5-9(6)7/h6,8H,1-5H2
DMIB3J2	CS	C1CC2CCC(=N)N2C1
DMIB3J2	IK	IGTGCXXJCCYMRS-UHFFFAOYSA-N
DMIB3J2	IU	1,2,5,6,7,8-hexahydropyrrolizin-3-imine
DMIB3J2	DE	Discovery agent

DM6UAV7	ID	DM6UAV7
DM6UAV7	DN	hexahydrosiladifenidol
DM6UAV7	HS	Investigative
DM6UAV7	SN	Hhsi-difenidol; hexahydro-sila-diphenidol; GNF-Pf-5565
DM6UAV7	DT	Small molecular drug
DM6UAV7	PC	3602
DM6UAV7	MW	331.6
DM6UAV7	FM	C20H33NOSi
DM6UAV7	IC	InChI=1S/C20H33NOSi/c22-23(19-11-4-1-5-12-19,20-13-6-2-7-14-20)18-10-17-21-15-8-3-9-16-21/h1,4-5,11-12,20,22H,2-3,6-10,13-18H2
DM6UAV7	CS	C1CCC(CC1)[Si](CCCN2CCCCC2)(C3=CC=CC=C3)O
DM6UAV7	IK	QTBCATBNRIYMPB-UHFFFAOYSA-N
DM6UAV7	IU	cyclohexyl-hydroxy-phenyl-(3-piperidin-1-ylpropyl)silane
DM6UAV7	CA	CAS 98299-40-2
DM6UAV7	DE	Discovery agent

DMSHF0K	ID	DMSHF0K
DMSHF0K	DN	Hexane-1,6-diamine
DMSHF0K	HS	Investigative
DMSHF0K	SN	1,6-Hexanediamine; 1,6-Diaminohexane; Hexamethylenediamine; 124-09-4; HEXANE-1,6-DIAMINE; HMDA; 1,6-Hexylenediamine; 1,6-Hexamethylenediamine; 1,6-Diamino-n-hexane; HEXAMETHYLENE DIAMINE; Hexylenediamine; 1,6-Hexanediamine (solution); Hexane, 1,6-diamino-; UNII-ZRA5J5B2QW; NCI-C61405; NSC 9257; H2N(CH2)6NH2; CCRIS 6224; HSDB 189; EINECS 204-679-6; HEX-NH2; UN2280; UN1783; ZRA5J5B2QW; Hexamethylenediamine solution; BRN 1098307; AI3-37283; CHEMBL303004; CHEBI:39618; NAQMVNRVTILPCV-UHFFFAOYSA-N; MFCD00008243; DSSTox_CID_4922
DMSHF0K	DT	Small molecular drug
DMSHF0K	PC	16402
DMSHF0K	MW	116.2
DMSHF0K	FM	C6H16N2
DMSHF0K	IC	InChI=1S/C6H16N2/c7-5-3-1-2-4-6-8/h1-8H2
DMSHF0K	CS	C(CCCN)CCN
DMSHF0K	IK	NAQMVNRVTILPCV-UHFFFAOYSA-N
DMSHF0K	IU	hexane-1,6-diamine
DMSHF0K	CA	CAS 124-09-4
DMSHF0K	CB	CHEBI:39618
DMSHF0K	DE	Discovery agent

DMWAPGI	ID	DMWAPGI
DMWAPGI	DN	Hexane-1,6-Diol
DMWAPGI	HS	Investigative
DMWAPGI	SN	1,6-HEXANEDIOL; Hexane-1,6-diol; 629-11-8; Hexamethylene glycol; 1,6-Dihydroxyhexane; Hexamethylenediol; alpha,omega-Hexanediol; .alpha.,.omega.-Hexanediol; UNII-ZIA319275I; CCRIS 8982; 6-hydroxy-1-hexanol; 1,6-Hexylene Glycol; HSDB 6488; NSC 508; EINECS 211-074-0; 1,6-Hexanediol, 97%; BRN 1633461; AI3-03307; CHEBI:43078; XXMIOPMDWAUFGU-UHFFFAOYSA-N; ZIA319275I; HEZ; 1,6hexanediol; 1.6-hexanediol; 1,6 hexanediol; 1,6-hexandiol; 1.6-hexandiol; .omega.-Hexanediol; 1,6-hexane diol; hexan-1,6-diol; 1,6-hexan-diol
DMWAPGI	DT	Small molecular drug
DMWAPGI	PC	12374
DMWAPGI	MW	118.17
DMWAPGI	FM	C6H14O2
DMWAPGI	IC	InChI=1S/C6H14O2/c7-5-3-1-2-4-6-8/h7-8H,1-6H2
DMWAPGI	CS	C(CCCO)CCO
DMWAPGI	IK	XXMIOPMDWAUFGU-UHFFFAOYSA-N
DMWAPGI	IU	hexane-1,6-diol
DMWAPGI	CA	CAS 629-11-8
DMWAPGI	CB	CHEBI:43078
DMWAPGI	DE	Discovery agent

DMJOZYG	ID	DMJOZYG
DMJOZYG	DN	Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide
DMJOZYG	HS	Investigative
DMJOZYG	SN	CHEMBL222432; 820961-43-1; hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide; CTK3E2660; DTXSID20464908; BDBM50157668; Pentanamide, N-(2,6-diphenyl-4-pyrimidinyl)-
DMJOZYG	DT	Small molecular drug
DMJOZYG	PC	11404772
DMJOZYG	MW	331.4
DMJOZYG	FM	C21H21N3O
DMJOZYG	IC	InChI=1S/C21H21N3O/c1-2-3-14-20(25)23-19-15-18(16-10-6-4-7-11-16)22-21(24-19)17-12-8-5-9-13-17/h4-13,15H,2-3,14H2,1H3,(H,22,23,24,25)
DMJOZYG	CS	CCCCC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMJOZYG	IK	AJUVVGPOXGXRAI-UHFFFAOYSA-N
DMJOZYG	IU	N-(2,6-diphenylpyrimidin-4-yl)pentanamide
DMJOZYG	CA	CAS 820961-43-1
DMJOZYG	DE	Discovery agent

DM4U0L1	ID	DM4U0L1
DM4U0L1	DN	Hexanoic acid 2,5-diphenyl-thiazol-4-yl ester
DM4U0L1	HS	Investigative
DM4U0L1	SN	CHEMBL67589; Hexanoic acid 2,5-diphenyl-thiazol-4-yl ester; BDBM50012391; Hexanoic acid 2,5-diphenyl-4-thiazolyl ester
DM4U0L1	DT	Small molecular drug
DM4U0L1	PC	15691796
DM4U0L1	MW	351.5
DM4U0L1	FM	C21H21NO2S
DM4U0L1	IC	InChI=1S/C21H21NO2S/c1-2-3-6-15-18(23)24-20-19(16-11-7-4-8-12-16)25-21(22-20)17-13-9-5-10-14-17/h4-5,7-14H,2-3,6,15H2,1H3
DM4U0L1	CS	CCCCCC(=O)OC1=C(SC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DM4U0L1	IK	HQKAVFKKTZEFLJ-UHFFFAOYSA-N
DM4U0L1	IU	(2,5-diphenyl-1,3-thiazol-4-yl) hexanoate
DM4U0L1	DE	Discovery agent

DM0HS7L	ID	DM0HS7L
DM0HS7L	DN	hexocyclium
DM0HS7L	HS	Investigative
DM0HS7L	SN	Tral
DM0HS7L	DT	Small molecular drug
DM0HS7L	PC	24199
DM0HS7L	MW	317.5
DM0HS7L	FM	C20H33N2O+
DM0HS7L	IC	InChI=1S/C20H33N2O/c1-22(2)15-13-21(14-16-22)17-20(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3,5-6,9-10,19,23H,4,7-8,11-17H2,1-2H3/q+1
DM0HS7L	CS	C[N+]1(CCN(CC1)CC(C2CCCCC2)(C3=CC=CC=C3)O)C
DM0HS7L	IK	ZRYHPQCHHOKSMD-UHFFFAOYSA-N
DM0HS7L	IU	1-cyclohexyl-2-(4,4-dimethylpiperazin-4-ium-1-yl)-1-phenylethanol
DM0HS7L	CA	CAS 6004-98-4
DM0HS7L	CB	CHEBI:5707
DM0HS7L	DE	Discovery agent

DMHTWN9	ID	DMHTWN9
DMHTWN9	DN	Hex-RYYRIK-NH2
DMHTWN9	HS	Investigative
DMHTWN9	SN	CHEMBL438383
DMHTWN9	DT	Small molecular drug
DMHTWN9	PC	44456339
DMHTWN9	MW	979.2
DMHTWN9	FM	C48H78N14O8
DMHTWN9	IC	InChI=1S/C48H78N14O8/c1-4-6-8-20-39(64)57-35(18-13-26-55-47(51)52)42(66)60-37(28-31-15-9-7-10-16-31)45(69)61-38(29-32-21-23-33(63)24-22-32)44(68)59-36(19-14-27-56-48(53)54)43(67)62-40(30(3)5-2)46(70)58-34(41(50)65)17-11-12-25-49/h7,9-10,15-16,21-24,30,34-38,40,63H,4-6,8,11-14,17-20,25-29,49H2,1-3H3,(H2,50,65)(H,57,64)(H,58,70)(H,59,68)(H,60,66)(H,61,69)(H,62,67)(H4,51,52,55)(H4,53,54,56)/t30-,34-,35-,36-,37-,38-,40-/m0/s1
DMHTWN9	CS	CCCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N
DMHTWN9	IK	BULLVLNXUBKWQF-GCRPBELOSA-N
DMHTWN9	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(hexanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMHTWN9	DE	Discovery agent

DMBC8KM	ID	DMBC8KM
DMBC8KM	DN	Hexylacrolein
DMBC8KM	HS	Investigative
DMBC8KM	SN	Heptylideneacetaldehyde; 2-Nonenal; Non-2-enal; alpha-Nonenyl aldehyde; beta-Hexylacrolein; trans-2-Nonen-1-al; trans-2-Nonenal; trans-2-Nonenal (natural); (E)-2-Nonenal; (E)-2-nonen-1-al; (E)-Non-2-enal; 18829-56-6; 2-NONENAL; 2-Nonen-1-al; 2-Nonenal, (2E)-; 2-Nonenal, (E)-; 2-trans-Nonenal; 2463-53-8; 3-Hexyl-2-propenal; 3-Hexylacrolein; 3-hexyl-acrolein; 8VEO649985; AI3-36268; BRN 1722170; BSAIUMLZVGUGKX-BQYQJAHWSA-N; CCRIS 3326; CCRIS 9203; EINECS 219-562-5; EINECS 242-609-6; FEMA No. 3213; MFCD00007012; NSC 20746; UNII-8VEO649985
DMBC8KM	PC	5283335
DMBC8KM	MW	140.22
DMBC8KM	FM	C9H16O
DMBC8KM	IC	BSAIUMLZVGUGKX-BQYQJAHWSA-N
DMBC8KM	CS	CCCCCCC=CC=O
DMBC8KM	IK	1S/C9H16O/c1-2-3-4-5-6-7-8-9-10/h7-9H,2-6H2,1H3/b8-7+
DMBC8KM	IU	(E)-non-2-enal
DMBC8KM	CA	CAS 18829-56-6
DMBC8KM	CB	CHEBI:61726
DMBC8KM	DE	Discovery agent

DM3YFG9	ID	DM3YFG9
DM3YFG9	DN	Hexylcarbamoyl fluorouracil
DM3YFG9	HS	Investigative
DM3YFG9	SN	Carmofur; HCFU; Yamaful; 1-hexylcarbamoyl-5-fluorouracil
DM3YFG9	TC	Antiviral Agents
DM3YFG9	DT	Small molecular drug
DM3YFG9	PC	2577
DM3YFG9	MW	257.26
DM3YFG9	FM	C11H16FN3O3
DM3YFG9	IC	InChI=1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)
DM3YFG9	CS	CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F
DM3YFG9	IK	AOCCBINRVIKJHY-UHFFFAOYSA-N
DM3YFG9	IU	5-fluoro-N-hexyl-2,4-dioxopyrimidine-1-carboxamide
DM3YFG9	CA	CAS 61422-45-5
DM3YFG9	CB	CHEBI:31360
DM3YFG9	DE	Cancer; Coronavirus Disease 2019 (COVID-19)

DM9EW7V	ID	DM9EW7V
DM9EW7V	DN	Hexyl-trimethyl-ammonium
DM9EW7V	HS	Investigative
DM9EW7V	DT	Small molecular drug
DM9EW7V	PC	84774
DM9EW7V	MW	144.28
DM9EW7V	FM	C9H22N+
DM9EW7V	IC	InChI=1S/C9H22N/c1-5-6-7-8-9-10(2,3)4/h5-9H2,1-4H3/q+1
DM9EW7V	CS	CCCCCC[N+](C)(C)C
DM9EW7V	IK	XTPRURKTXNFVQT-UHFFFAOYSA-N
DM9EW7V	IU	hexyl(trimethyl)azanium
DM9EW7V	CA	CAS 16208-27-8
DM9EW7V	DE	Discovery agent

DMM4JCA	ID	DMM4JCA
DMM4JCA	DN	HG-1051
DMM4JCA	HS	Investigative
DMM4JCA	SN	CD136 modulator (inflammation/immune disorders), Human Genome Sciences; CD137 antigen modulator (inflammation/immune disorders), Human Genome Sciences; CDw137 modulator (inflammation/immune disorders), Human Genome Sciences; Homolog of mouse Ly63 modulator (inflammation/immune disorders), Human Genome Sciences; ILA modulator (inflammation/immune disorders), Human Genome Sciences; MGC2172 modulator (inflammation/immune disorders), Human Genome Sciences; T cell antigen ILA modulator (inflammation/immune disorders), Human Genome Sciences; TNFRSF9 modulator (inflammation/immune disorders), Human Genome Sciences; Tumor necrosis factor receptor superfamily member 9 modulator (inflammation/immune disorders), Human Genome Sciences; Homolog of mouse 4-1BB modulator (inflammation/immune disorders), Human Genome Sciences; Human 4-1BB receptor splicing varifant modulator (inflammation/immune disorders), Human Genome Sciences; Induced by lymphocyte activation (ILA) modulator (inflammation/immune disorders), Human Genome Sciences; Interleukin-activated receptor modulator (inflammation/immune disorders), Human Genome Sciences; 4-1BB ligand receptor modulator (inflammation/immune disorders), Human Genome Sciences; 4-1BB modulator (inflammation/immune disorders), Human Genome Sciences
DMM4JCA	CP	Human Genome Sciences Inc
DMM4JCA	DE	Immune System disease

DM8FD3Z	ID	DM8FD3Z
DM8FD3Z	DN	HG-9-91-01
DM8FD3Z	HS	Investigative
DM8FD3Z	SN	HY-15776
DM8FD3Z	DT	Small molecular drug
DM8FD3Z	PC	78357808
DM8FD3Z	MW	567.7
DM8FD3Z	FM	C32H37N7O3
DM8FD3Z	IC	InChI=1S/C32H37N7O3/c1-22-7-6-8-23(2)31(22)36-32(40)39(27-14-13-26(41-4)19-28(27)42-5)30-20-29(33-21-34-30)35-24-9-11-25(12-10-24)38-17-15-37(3)16-18-38/h6-14,19-21H,15-18H2,1-5H3,(H,36,40)(H,33,34,35)
DM8FD3Z	CS	CC1=C(C(=CC=C1)C)NC(=O)N(C2=C(C=C(C=C2)OC)OC)C3=NC=NC(=C3)NC4=CC=C(C=C4)N5CCN(CC5)C
DM8FD3Z	IK	UYUHRKLITDJEHB-UHFFFAOYSA-N
DM8FD3Z	IU	1-(2,4-dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea
DM8FD3Z	CB	CHEBI:133818
DM8FD3Z	DE	Discovery agent

DMOIPYD	ID	DMOIPYD
DMOIPYD	DN	hGCGR antagonist
DMOIPYD	HS	Investigative
DMOIPYD	SN	acylated aminothiophene nitrile; glucagon receptor antagonist I
DMOIPYD	DT	Small molecular drug
DMOIPYD	PC	619101
DMOIPYD	MW	346.5
DMOIPYD	FM	C20H30N2OS
DMOIPYD	IC	InChI=1S/C20H30N2OS/c1-6-13(7-2)18(23)22-19-16(12-21)15-10-9-14(11-17(15)24-19)20(4,5)8-3/h13-14H,6-11H2,1-5H3,(H,22,23)
DMOIPYD	CS	CCC(CC)C(=O)NC1=C(C2=C(S1)CC(CC2)C(C)(C)CC)C#N
DMOIPYD	IK	SWIBDWBSJSJQHL-UHFFFAOYSA-N
DMOIPYD	IU	N-[3-cyano-6-(2-methylbutan-2-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-2-ethylbutanamide
DMOIPYD	CA	CAS 438618-32-7
DMOIPYD	DE	Discovery agent

DMX2TGD	ID	DMX2TGD
DMX2TGD	DN	H-Gly-D-dmP-Glu-OH
DMX2TGD	HS	Investigative
DMX2TGD	SN	CHEMBL212694
DMX2TGD	DT	Small molecular drug
DMX2TGD	PC	44413487
DMX2TGD	MW	329.35
DMX2TGD	FM	C14H23N3O6
DMX2TGD	IC	InChI=1S/C14H23N3O6/c1-14(2)6-5-9(17(14)10(18)7-15)12(21)16-8(13(22)23)3-4-11(19)20/h8-9H,3-7,15H2,1-2H3,(H,16,21)(H,19,20)(H,22,23)/t8-,9+/m0/s1
DMX2TGD	CS	CC1(CC[C@@H](N1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C
DMX2TGD	IK	KNUZCBVWBGSPRA-DTWKUNHWSA-N
DMX2TGD	IU	(2S)-2-[[(2R)-1-(2-aminoacetyl)-5,5-dimethylpyrrolidine-2-carbonyl]amino]pentanedioic acid
DMX2TGD	DE	Discovery agent

DMOYQPM	ID	DMOYQPM
DMOYQPM	DN	H-Gly-dmP-Glu-OH
DMOYQPM	HS	Investigative
DMOYQPM	SN	SCHEMBL2085656; CHEMBL193486
DMOYQPM	DT	Small molecular drug
DMOYQPM	PC	11515428
DMOYQPM	MW	329.35
DMOYQPM	FM	C14H23N3O6
DMOYQPM	IC	InChI=1S/C14H23N3O6/c1-14(2)6-5-9(17(14)10(18)7-15)12(21)16-8(13(22)23)3-4-11(19)20/h8-9H,3-7,15H2,1-2H3,(H,16,21)(H,19,20)(H,22,23)/t8-,9-/m0/s1
DMOYQPM	CS	CC1(CC[C@H](N1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C
DMOYQPM	IK	KNUZCBVWBGSPRA-IUCAKERBSA-N
DMOYQPM	IU	(2S)-2-[[(2S)-1-(2-aminoacetyl)-5,5-dimethylpyrrolidine-2-carbonyl]amino]pentanedioic acid
DMOYQPM	CA	CAS 853400-77-8
DMOYQPM	DE	Discovery agent

DMCKAWY	ID	DMCKAWY
DMCKAWY	DN	HI-172
DMCKAWY	HS	Investigative
DMCKAWY	SN	HI-172; CHEMBL288626; BDBM50078260
DMCKAWY	DT	Small molecular drug
DMCKAWY	PC	44287426
DMCKAWY	MW	329.26
DMCKAWY	FM	C12H17BrN4S
DMCKAWY	IC	InChI=1S/C12H17BrN4S/c13-10-4-5-11(14-8-10)16-12(18)15-9-17-6-2-1-3-7-17/h4-5,8H,1-3,6-7,9H2,(H2,14,15,16,18)
DMCKAWY	CS	C1CCN(CC1)CNC(=S)NC2=NC=C(C=C2)Br
DMCKAWY	IK	QIWYYZPJZHMEPR-UHFFFAOYSA-N
DMCKAWY	IU	1-(5-bromopyridin-2-yl)-3-(piperidin-1-ylmethyl)thiourea
DMCKAWY	DE	Discovery agent

DM3R4ZF	ID	DM3R4ZF
DM3R4ZF	DN	HI-236
DM3R4ZF	HS	Investigative
DM3R4ZF	SN	HI-236; CHEMBL240416; D-PBT; AC1MHD7C; DDE236; SCHEMBL6246077; BDBM50206060; 1-(5-bromopyridin-2-yl)-3-(2,5-dimethoxyphenethyl)thiourea; 1-(2,5-dimethoxyphenethyl)-3-(5-bromopyridin-2-yl)thiourea; 1-(5-bromo-2-pyridyl)-3-[2-(2,5-dimethoxyphenyl)ethyl]thiourea; N-[2-(2,5-Dimethoxyphenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea; 1-(5-bromopyridin-2-yl)-3-[2-(2,5-dimethoxyphenyl)ethyl]thiourea
DM3R4ZF	DT	Small molecular drug
DM3R4ZF	PC	3000498
DM3R4ZF	MW	396.3
DM3R4ZF	FM	C16H18BrN3O2S
DM3R4ZF	IC	InChI=1S/C16H18BrN3O2S/c1-21-13-4-5-14(22-2)11(9-13)7-8-18-16(23)20-15-6-3-12(17)10-19-15/h3-6,9-10H,7-8H2,1-2H3,(H2,18,19,20,23)
DM3R4ZF	CS	COC1=CC(=C(C=C1)OC)CCNC(=S)NC2=NC=C(C=C2)Br
DM3R4ZF	IK	GNLVRKKIIIVZHZ-UHFFFAOYSA-N
DM3R4ZF	IU	1-(5-bromopyridin-2-yl)-3-[2-(2,5-dimethoxyphenyl)ethyl]thiourea
DM3R4ZF	DE	Discovery agent

DMQK5RM	ID	DMQK5RM
DMQK5RM	DN	HI-240
DMQK5RM	HS	Investigative
DMQK5RM	SN	HI-240; CHEMBL295585; AC1MHDYL; F-PBT; SCHEMBL5390696; DDE240; BDBM50078263; AKOS030056312; 1-(5-bromo-2-pyridyl)-3-[2-(2-fluorophenyl)ethyl]thiourea; N-[2-(2-Fluorophenethyl)]-N'-[2-(5-bromopyridyl)]thiourea; 1-(5-bromopyridin-2-yl)-3-[2-(2-fluorophenyl)ethyl]thiourea
DMQK5RM	DT	Small molecular drug
DMQK5RM	PC	3001767
DMQK5RM	MW	354.24
DMQK5RM	FM	C14H13BrFN3S
DMQK5RM	IC	InChI=1S/C14H13BrFN3S/c15-11-5-6-13(18-9-11)19-14(20)17-8-7-10-3-1-2-4-12(10)16/h1-6,9H,7-8H2,(H2,17,18,19,20)
DMQK5RM	CS	C1=CC=C(C(=C1)CCNC(=S)NC2=NC=C(C=C2)Br)F
DMQK5RM	IK	MIJLSRZJDIBHJU-UHFFFAOYSA-N
DMQK5RM	IU	1-(5-bromopyridin-2-yl)-3-[2-(2-fluorophenyl)ethyl]thiourea
DMQK5RM	DE	Discovery agent

DMTKCW6	ID	DMTKCW6
DMTKCW6	DN	HI-241
DMTKCW6	HS	Investigative
DMTKCW6	SN	HI-241; CHEMBL40625; N-[2-(3-Fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea; DDE241; AC1MHDYO; SCHEMBL5888383; OEBGVSGGLQGGNH-UHFFFAOYSA-N; BDBM50078255; AKOS030056592; 1-(5-bromopyridin-2-yl)-3-[2-(3-fluorophenyl)ethyl]thiourea; 1-(5-bromo-2-pyridyl)-3-[2-(3-fluorophenyl)ethyl]thiourea
DMTKCW6	DT	Small molecular drug
DMTKCW6	PC	3001770
DMTKCW6	MW	354.24
DMTKCW6	FM	C14H13BrFN3S
DMTKCW6	IC	InChI=1S/C14H13BrFN3S/c15-11-4-5-13(18-9-11)19-14(20)17-7-6-10-2-1-3-12(16)8-10/h1-5,8-9H,6-7H2,(H2,17,18,19,20)
DMTKCW6	CS	C1=CC(=CC(=C1)F)CCNC(=S)NC2=NC=C(C=C2)Br
DMTKCW6	IK	OEBGVSGGLQGGNH-UHFFFAOYSA-N
DMTKCW6	IU	1-(5-bromopyridin-2-yl)-3-[2-(3-fluorophenyl)ethyl]thiourea
DMTKCW6	DE	Discovery agent

DM0QYLP	ID	DM0QYLP
DM0QYLP	DN	HI-242
DM0QYLP	HS	Investigative
DM0QYLP	SN	HI-242; CHEMBL287978; DDE242; AC1MHDYR; SCHEMBL5888407; BDBM50078254; AKOS030051128; 1-(5-bromopyridin-2-yl)-3-[2-(4-fluorophenyl)ethyl]thiourea; 1-(5-bromo-2-pyridyl)-3-[2-(4-fluorophenyl)ethyl]thiourea; N-[2-(4-Fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea
DM0QYLP	DT	Small molecular drug
DM0QYLP	PC	3001773
DM0QYLP	MW	354.24
DM0QYLP	FM	C14H13BrFN3S
DM0QYLP	IC	InChI=1S/C14H13BrFN3S/c15-11-3-6-13(18-9-11)19-14(20)17-8-7-10-1-4-12(16)5-2-10/h1-6,9H,7-8H2,(H2,17,18,19,20)
DM0QYLP	CS	C1=CC(=CC=C1CCNC(=S)NC2=NC=C(C=C2)Br)F
DM0QYLP	IK	SDMLMNPOMWSLBF-UHFFFAOYSA-N
DM0QYLP	IU	1-(5-bromopyridin-2-yl)-3-[2-(4-fluorophenyl)ethyl]thiourea
DM0QYLP	DE	Discovery agent

DMG36BD	ID	DMG36BD
DMG36BD	DN	HI-244
DMG36BD	HS	Investigative
DMG36BD	SN	CHEMBL144604; HI-256; AC1MHE9N; SCHEMBL6847403; BDBM50097041; AKOS030007896; 1-(5-bromo-2-pyridyl)-3-[2-(4-hydroxyphenyl)ethyl]thiourea; N-[2-(4-Hydroxyphenethyl)]-N'-[2-(5-bromopyridyl)]thiourea; 1-(5-bromopyridin-2-yl)-3-[2-(4-hydroxyphenyl)ethyl]thiourea
DMG36BD	DT	Small molecular drug
DMG36BD	PC	3002300
DMG36BD	MW	352.25
DMG36BD	FM	C14H14BrN3OS
DMG36BD	IC	InChI=1S/C14H14BrN3OS/c15-11-3-6-13(17-9-11)18-14(20)16-8-7-10-1-4-12(19)5-2-10/h1-6,9,19H,7-8H2,(H2,16,17,18,20)
DMG36BD	CS	C1=CC(=CC=C1CCNC(=S)NC2=NC=C(C=C2)Br)O
DMG36BD	IK	UAUYJJLEWDLTLK-UHFFFAOYSA-N
DMG36BD	IU	1-(5-bromopyridin-2-yl)-3-[2-(4-hydroxyphenyl)ethyl]thiourea
DMG36BD	DE	Discovery agent

DME4SML	ID	DME4SML
DME4SML	DN	HI-280
DME4SML	HS	Investigative
DME4SML	SN	HI-280; CHEMBL40642; DDE280; AC1LAQRF; SCHEMBL14560609; CTK7B5926; BDBM50078253; 3-(Methylethyl)-6-(methylthiomethylthio)-4-benzylhydropyridin-2-one; 4-benzyl-6-(methylsulfanylmethylsulfanyl)-3-propan-2-yl-1H-pyridin-2-one; 4-benzyl-3-isopropyl-6-(methylsulfanylmethylsulfanyl)-1H-pyridin-2-one; 4-Benzyl-3-isopropyl-6-methylsulfanylmethylsulfanyl-1H-pyridin-2-one
DME4SML	DT	Small molecular drug
DME4SML	PC	473270
DME4SML	MW	319.5
DME4SML	FM	C17H21NOS2
DME4SML	IC	InChI=1S/C17H21NOS2/c1-12(2)16-14(9-13-7-5-4-6-8-13)10-15(18-17(16)19)21-11-20-3/h4-8,10,12H,9,11H2,1-3H3,(H,18,19)
DME4SML	CS	CC(C)C1=C(C=C(NC1=O)SCSC)CC2=CC=CC=C2
DME4SML	IK	CCFCAWLPLYLQBS-UHFFFAOYSA-N
DME4SML	IU	4-benzyl-6-(methylsulfanylmethylsulfanyl)-3-propan-2-yl-1H-pyridin-2-one
DME4SML	DE	Discovery agent

DM7K0PH	ID	DM7K0PH
DM7K0PH	DN	HI-281
DM7K0PH	HS	Investigative
DM7K0PH	SN	HI-281; CHEMBL290312; DDE281; AC1LAQRC; CTK7B5925; BDBM50078262; 4-[(3,5-Dimethylphenyl)methyl]-3-(methylethyl)-6-(methylthiomethylthio)hydropyridin-2-one; 4-(3,5-Dimethyl-benzyl)-3-isopropyl-6-methylsulfanylmethylsulfanyl-1H-pyridin-2-one; 4-(3,5-dimethylbenzyl)-3-(1-methylethyl)-6-{[(methylsulfanyl)methyl]sulfanyl}pyridin-2(1h)-one; 4-[(3,5-dimethylphenyl)methyl]-6-(methylsulfanylmethylsulfanyl)-3-propan-2-yl-1H-pyridin-2-one
DM7K0PH	DT	Small molecular drug
DM7K0PH	PC	473269
DM7K0PH	MW	347.5
DM7K0PH	FM	C19H25NOS2
DM7K0PH	IC	InChI=1S/C19H25NOS2/c1-12(2)18-16(9-15-7-13(3)6-14(4)8-15)10-17(20-19(18)21)23-11-22-5/h6-8,10,12H,9,11H2,1-5H3,(H,20,21)
DM7K0PH	CS	CC1=CC(=CC(=C1)CC2=C(C(=O)NC(=C2)SCSC)C(C)C)C
DM7K0PH	IK	AGRSTTVMWWVJEL-UHFFFAOYSA-N
DM7K0PH	IU	4-[(3,5-dimethylphenyl)methyl]-6-(methylsulfanylmethylsulfanyl)-3-propan-2-yl-1H-pyridin-2-one
DM7K0PH	DE	Discovery agent

DMSUWD8	ID	DMSUWD8
DMSUWD8	DN	HI-443
DMSUWD8	HS	Investigative
DMSUWD8	SN	HI-443; CHEMBL116474; 258340-15-7; AC1MHE5U; SCHEMBL1345282; CTK0J3754; DTXSID40388233; PHI-443; 1-(5-bromopyridin-2-yl)-3-(2-thiophen-2-ylethyl)thiourea; BDBM50083680; AKOS030257616; 1-(5-bromo-2-pyridyl)-3-[2-(2-thienyl)ethyl]thiourea; Thiourea, N-(5-bromo-2-pyridinyl)-N'-[2-(2-thienyl)ethyl]-; 1-(5-Bromo-pyridin-2-yl)-3-(2-thiophen-2-yl-ethyl)-thiourea
DMSUWD8	DT	Small molecular drug
DMSUWD8	PC	3002121
DMSUWD8	MW	342.3
DMSUWD8	FM	C12H12BrN3S2
DMSUWD8	IC	InChI=1S/C12H12BrN3S2/c13-9-3-4-11(15-8-9)16-12(17)14-6-5-10-2-1-7-18-10/h1-4,7-8H,5-6H2,(H2,14,15,16,17)
DMSUWD8	CS	C1=CSC(=C1)CCNC(=S)NC2=NC=C(C=C2)Br
DMSUWD8	IK	GAIBJCKASOWHGH-UHFFFAOYSA-N
DMSUWD8	IU	1-(5-bromopyridin-2-yl)-3-(2-thiophen-2-ylethyl)thiourea
DMSUWD8	CA	CAS 258340-15-7
DMSUWD8	DE	Discovery agent

DMYP0DE	ID	DMYP0DE
DMYP0DE	DN	HI-445
DMYP0DE	HS	Investigative
DMYP0DE	PC	3001929
DMYP0DE	MW	295.8
DMYP0DE	FM	C14H18ClN3S
DMYP0DE	IC	InChI=1S/C14H18ClN3S/c15-12-6-7-13(17-10-12)18-14(19)16-9-8-11-4-2-1-3-5-11/h4,6-7,10H,1-3,5,8-9H2,(H2,16,17,18,19)
DMYP0DE	CS	C1CCC(=CC1)CCNC(=S)NC2=NC=C(C=C2)Cl
DMYP0DE	IK	DVTYONOGIMBZRG-UHFFFAOYSA-N
DMYP0DE	IU	1-(5-chloropyridin-2-yl)-3-[2-(cyclohexen-1-yl)ethyl]thiourea
DMYP0DE	DE	Discovery agent

DMD6NZO	ID	DMD6NZO
DMD6NZO	DN	Hinokinin
DMD6NZO	HS	Investigative
DMD6NZO	SN	Hinokinin; (-)-Hinokinin; 26543-89-5; CHEBI:5722; CHEMBL242011; (3R,4R)-3,4-Bis(benzo[d][1,3]dioxol-5-ylmethyl)dihydrofuran-2(3H)-one; (3R,4R)-3,4-bis(1,3-benzodioxol-5-ylmethyl)dihydrofuran-2(3H)-one; (3R-trans)-3,4-bis(1,3-benzodioxol-5-ylmethyl)dihydrofuran-2(3H)-one; hinoquinin; (-)-hinoquinin; AC1L9DKH; Epitope ID:116880; SCHEMBL1121862; MolPort-039-338-821; ZINC1872258; BDBM50218812; AKOS027324070; LS-190466; C10627; (2r,3r)-2,3-di-(3,4-methylenedioxybenzyl)-butyrolactone
DMD6NZO	DT	Small molecular drug
DMD6NZO	PC	442879
DMD6NZO	MW	354.4
DMD6NZO	FM	C20H18O6
DMD6NZO	IC	InChI=1S/C20H18O6/c21-20-15(6-13-2-4-17-19(8-13)26-11-24-17)14(9-22-20)5-12-1-3-16-18(7-12)25-10-23-16/h1-4,7-8,14-15H,5-6,9-11H2/t14-,15+/m0/s1
DMD6NZO	CS	C1[C@@H]([C@H](C(=O)O1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5
DMD6NZO	IK	DDWGQGZPYDSYEL-LSDHHAIUSA-N
DMD6NZO	IU	(3R,4R)-3,4-bis(1,3-benzodioxol-5-ylmethyl)oxolan-2-one
DMD6NZO	CA	CAS 26543-89-5
DMD6NZO	CB	CHEBI:5722
DMD6NZO	DE	Discovery agent

DMHL9Y6	ID	DMHL9Y6
DMHL9Y6	DN	HINOKITIOL
DMHL9Y6	HS	Investigative
DMHL9Y6	SN	hinokitiol; beta-Thujaplicin; 499-44-5; 4-Isopropyltropolone; Hinokitol; beta-Thujaplicine; THUJAPLICIN, BETA; Tropolone, 4-isopropyl-; beta-Isopropyltropolon; 2-Hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one; Isopropyltropolone; .beta.-Thujaplicin; beta-Isopropyltropolone; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-4-(1-methylethyl)-; .beta.-Isopropyltropolon; UNII-U5335D6EBI; NSC 18804; .beta.-Thujaplicine; 2-hydroxy-4-(propan-2-yl)cyclohepta-2,4,6-trien-1-one; NSC18804; EINECS 207-880-7
DMHL9Y6	DT	Small molecular drug
DMHL9Y6	PC	3611
DMHL9Y6	MW	164.2
DMHL9Y6	FM	C10H12O2
DMHL9Y6	IC	InChI=1S/C10H12O2/c1-7(2)8-4-3-5-9(11)10(12)6-8/h3-7H,1-2H3,(H,11,12)
DMHL9Y6	CS	CC(C)C1=CC(=O)C(=CC=C1)O
DMHL9Y6	IK	FUWUEFKEXZQKKA-UHFFFAOYSA-N
DMHL9Y6	IU	2-hydroxy-6-propan-2-ylcyclohepta-2,4,6-trien-1-one
DMHL9Y6	CA	CAS 499-44-5
DMHL9Y6	CB	CHEBI:10447
DMHL9Y6	DE	Discovery agent

DM0PV2Y	ID	DM0PV2Y
DM0PV2Y	DN	Hippuristanol
DM0PV2Y	HS	Investigative
DM0PV2Y	SN	80442-78-0; SCHEMBL1374807; CHEMBL1098427; DTXSID50433627; BDBM50235738; Q10861089
DM0PV2Y	DT	Small molecular drug
DM0PV2Y	PC	9981822
DM0PV2Y	MW	462.7
DM0PV2Y	FM	C28H46O5
DM0PV2Y	IC	InChI=1S/C28H46O5/c1-15-13-28(33-24(15,2)3)27(6,31)23-21(32-28)12-19-18-8-7-16-11-17(29)9-10-25(16,4)22(18)20(30)14-26(19,23)5/h15-23,29-31H,7-14H2,1-6H3/t15-,16-,17+,18-,19-,20-,21-,22+,23-,25-,26-,27+,28+/m0/s1
DM0PV2Y	CS	C[C@H]1C[C@]2([C@]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(C[C@@H]([C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@H](C6)O)C)O)C)(C)O)OC1(C)C
DM0PV2Y	IK	HPHXKNOXVBFETI-SHCCRYCOSA-N
DM0PV2Y	IU	(1S,2S,3'S,4S,6R,7R,8R,9S,11S,12S,13S,16R,18S)-2',2',3',7,9,13-hexamethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,5'-oxolane]-7,11,16-triol
DM0PV2Y	CA	CAS 80442-78-0
DM0PV2Y	DE	T-cell leukaemia

DMRJGOP	ID	DMRJGOP
DMRJGOP	DN	His-DPhe-Arg-Trp
DMRJGOP	HS	Investigative
DMRJGOP	SN	CHEMBL397413; 4289-02-5; His-DPhe-Arg-Trp; Hisetal; Characteristic MSH-Tetrapeptide; ZINC28707608; BDBM50211182; (MSH fragment H-His-Phe-Arg-Trp-OH)2-(2-{2-[2-Amino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoylamino)-3-(1H-indol-3-yl)-propionic acid
DMRJGOP	DT	Small molecular drug
DMRJGOP	PC	10258635
DMRJGOP	MW	644.7
DMRJGOP	FM	C32H40N10O5
DMRJGOP	IC	InChI=1S/C32H40N10O5/c33-23(15-21-17-36-18-39-21)28(43)41-26(13-19-7-2-1-3-8-19)30(45)40-25(11-6-12-37-32(34)35)29(44)42-27(31(46)47)14-20-16-38-24-10-5-4-9-22(20)24/h1-5,7-10,16-18,23,25-27,38H,6,11-15,33H2,(H,36,39)(H,40,45)(H,41,43)(H,42,44)(H,46,47)(H4,34,35,37)/t23-,25-,26-,27-/m0/s1
DMRJGOP	CS	C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)NC(=O)[C@H](CC4=CN=CN4)N
DMRJGOP	IK	CAYNQHPLZNPBIO-MNUOIFNESA-N
DMRJGOP	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMRJGOP	DE	Discovery agent

DMA9YIB	ID	DMA9YIB
DMA9YIB	DN	histaprodifen
DMA9YIB	HS	Investigative
DMA9YIB	SN	Histaprodifen; SCHEMBL3019488; GTPL4026; CHEMBL275507; BDBM22864; ZINC38881558; 2-[2-(3,3-diphenylpropyl)-1h-imidazol-4-yl]ethanamine; 2-[2-[3,3-di(phenyl)propyl]-3H-imidazol-4-yl]ethanamine
DMA9YIB	DT	Small molecular drug
DMA9YIB	PC	10447834
DMA9YIB	MW	305.4
DMA9YIB	FM	C20H23N3
DMA9YIB	IC	InChI=1S/C20H23N3/c21-14-13-18-15-22-20(23-18)12-11-19(16-7-3-1-4-8-16)17-9-5-2-6-10-17/h1-10,15,19H,11-14,21H2,(H,22,23)
DMA9YIB	CS	C1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3
DMA9YIB	IK	BPZGZNLONLANFE-UHFFFAOYSA-N
DMA9YIB	IU	2-[2-(3,3-diphenylpropyl)-1H-imidazol-5-yl]ethanamine
DMA9YIB	DE	Discovery agent

DM7MUJ3	ID	DM7MUJ3
DM7MUJ3	DN	HITOPK-032
DM7MUJ3	HS	Investigative
DM7MUJ3	SN	HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J
DM7MUJ3	PC	1936439
DM7MUJ3	MW	369.4
DM7MUJ3	FM	C20H11N5OS
DM7MUJ3	IC	InChI=1S/C20H11N5OS/c21-11-13-16-10-12(22-20(26)17-6-3-9-27-17)7-8-25(16)19-18(13)23-14-4-1-2-5-15(14)24-19/h1-10H,(H,22,26)
DM7MUJ3	CS	C1=CC=C2C(=C1)N=C3C(=C4C=C(C=CN4C3=N2)NC(=O)C5=CC=CS5)C#N
DM7MUJ3	IK	BCSBXWKRZUPFHW-UHFFFAOYSA-N
DM7MUJ3	IU	N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide
DM7MUJ3	CA	CAS 799819-78-6
DM7MUJ3	DE	Nasopharyngeal carcinoma

DMNI5FW	ID	DMNI5FW
DMNI5FW	DN	HJC 0350
DMNI5FW	HS	Investigative
DMNI5FW	SN	HJC0350
DMNI5FW	DT	Small molecular drug
DMNI5FW	PC	22200891
DMNI5FW	MW	277.4
DMNI5FW	FM	C15H19NO2S
DMNI5FW	IC	InChI=1S/C15H19NO2S/c1-10-6-12(3)15(13(4)7-10)19(17,18)16-9-11(2)8-14(16)5/h6-9H,1-5H3
DMNI5FW	CS	CC1=CC(=C(C(=C1)C)S(=O)(=O)N2C=C(C=C2C)C)C
DMNI5FW	IK	AFZWZVLPIMHLSE-UHFFFAOYSA-N
DMNI5FW	IU	2,4-dimethyl-1-(2,4,6-trimethylphenyl)sulfonylpyrrole
DMNI5FW	DE	Discovery agent

DMWIOCY	ID	DMWIOCY
DMWIOCY	DN	HJP-272
DMWIOCY	HS	Investigative
DMWIOCY	SN	Endothelin type A receptor antagonist (premature birth, inflammation); ETA antagonist (premature birth, lung inflammation), St Johns University; Endothelin type A receptor antagonist (premature birth, inflammation), St Johns University
DMWIOCY	CP	St Johns University
DMWIOCY	DE	Premature labour

DME13RQ	ID	DME13RQ
DME13RQ	DN	hK2p01 derivative KLK2 inhibitor
DME13RQ	HS	Investigative
DME13RQ	SN	CHEMBL2171880; hK2p01 derivative KLK2 inhibitor; GTPL8672; BDBM50396163; 2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]propanoyl]amino]acetic acid
DME13RQ	DT	Small molecular drug
DME13RQ	PC	11700955
DME13RQ	MW	1191.4
DME13RQ	FM	C59H82N16O11
DME13RQ	IC	InChI=1S/C59H82N16O11/c1-32(2)49(75-54(82)43(22-13-14-24-60)71-56(84)45(26-36-16-7-6-8-17-36)72-53(81)44(70-50(78)33(3)61)23-15-25-64-59(62)63)58(86)74-47(28-38-30-66-42-21-12-10-19-40(38)42)57(85)73-46(27-37-29-65-41-20-11-9-18-39(37)41)55(83)69-35(5)52(80)68-34(4)51(79)67-31-48(76)77/h6-12,16-21,29-30,32-35,43-47,49,65-66H,13-15,22-28,31,60-61H2,1-5H3,(H,67,79)(H,68,80)(H,69,83)(H,70,78)(H,71,84)(H,72,81)(H,73,85)(H,74,86)(H,75,82)(H,76,77)(H4,62,63,64)/t33-,34-,35-,43-,44-,45-,46-,47-,49-/m0/s1
DME13RQ	CS	C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)O)N
DME13RQ	IK	BVRWWHKWGPOKPN-NXOPMQQOSA-N
DME13RQ	IU	2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]propanoyl]amino]acetic acid
DME13RQ	DE	Discovery agent

DM5LR2B	ID	DM5LR2B
DM5LR2B	DN	HKI-9924129
DM5LR2B	HS	Investigative
DM5LR2B	CP	Grunenthal
DM5LR2B	DT	Small molecular drug
DM5LR2B	PC	5311104
DM5LR2B	MW	429.3
DM5LR2B	FM	C21H15Cl2FN4O
DM5LR2B	IC	InChI=1S/C21H15Cl2FN4O/c1-11-8-13(6-7-17(11)24)26-21-25-10-12-9-14(20(29)28(2)19(12)27-21)18-15(22)4-3-5-16(18)23/h3-10H,1-2H3,(H,25,26,27)
DM5LR2B	CS	CC1=C(C=CC(=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl)F
DM5LR2B	IK	SLCFEJAMCRLYRG-UHFFFAOYSA-N
DM5LR2B	IU	6-(2,6-dichlorophenyl)-2-(4-fluoro-3-methylanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one
DM5LR2B	CA	CAS 287204-45-9
DM5LR2B	DE	Gram-positive bacterial infection

DMDINX9	ID	DMDINX9
DMDINX9	DN	H-KPPR-OH
DMDINX9	HS	Investigative
DMDINX9	SN	CHEMBL1091089; H-KPPR-OH
DMDINX9	DT	Small molecular drug
DMDINX9	PC	15858500
DMDINX9	MW	496.6
DMDINX9	FM	C22H40N8O5
DMDINX9	IC	InChI=1S/C22H40N8O5/c23-10-2-1-6-14(24)19(32)30-13-5-9-17(30)20(33)29-12-4-8-16(29)18(31)28-15(21(34)35)7-3-11-27-22(25)26/h14-17H,1-13,23-24H2,(H,28,31)(H,34,35)(H4,25,26,27)/t14-,15-,16-,17-/m0/s1
DMDINX9	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DMDINX9	IK	CKFCCXJQYNXYHI-QAETUUGQSA-N
DMDINX9	IU	(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMDINX9	DE	Discovery agent

DMMW0OF	ID	DMMW0OF
DMMW0OF	DN	HL-034
DMMW0OF	HS	Investigative
DMMW0OF	SN	Oral TPO agent, HanAll Biopharma
DMMW0OF	CP	HanAll Biopharma Co Ltd
DMMW0OF	DE	Discovery agent

DMAPWC2	ID	DMAPWC2
DMAPWC2	DN	H-Leu-Phe-NH2
DMAPWC2	HS	Investigative
DMAPWC2	SN	Leucyl-phenylalanine amide; H-Leu-Phe-NH2; L-Leucyl-L-phenylalaninamide; 38678-60-3; CHEMBL590518; Leu-phe-NH2; AC1MIYXY; SCHEMBL2184039; L-Phenylalaninamide, L-leucyl-; DTXSID30191975; HVNQCDIUFGAINF-STQMWFEESA-N; ZINC1605748; BDBM50308392; AKOS027447855; (2S)-2-[[(2S)-2-Amino-4-methylpentanoyl]amino]-3-phenylpropanamide
DMAPWC2	DT	Small molecular drug
DMAPWC2	PC	3082491
DMAPWC2	MW	277.36
DMAPWC2	FM	C15H23N3O2
DMAPWC2	IC	InChI=1S/C15H23N3O2/c1-10(2)8-12(16)15(20)18-13(14(17)19)9-11-6-4-3-5-7-11/h3-7,10,12-13H,8-9,16H2,1-2H3,(H2,17,19)(H,18,20)/t12-,13-/m0/s1
DMAPWC2	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N
DMAPWC2	IK	HVNQCDIUFGAINF-STQMWFEESA-N
DMAPWC2	IU	(2S)-2-amino-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-4-methylpentanamide
DMAPWC2	CA	CAS 38678-60-3
DMAPWC2	DE	Discovery agent

DM2URWO	ID	DM2URWO
DM2URWO	DN	HLL1-Fab-A3B3
DM2URWO	HS	Investigative
DM2URWO	SN	Milatuzumab-Fab-CEA-loaded dendritic cell vaccine (cancer); Milatuzumab-Fab-CEA-loaded dendritic cell vaccine (cancer), Immunomedics
DM2URWO	CP	Immunomedics Inc
DM2URWO	DT	Vaccine
DM2URWO	DE	Solid tumour/cancer

DMDXIS7	ID	DMDXIS7
DMDXIS7	DN	H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645)
DMDXIS7	HS	Investigative
DMDXIS7	SN	H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645); CHEMBL405182
DMDXIS7	PC	44316376
DMDXIS7	MW	1064.2
DMDXIS7	FM	C49H69N13O12S
DMDXIS7	IC	InChI=1S/C49H69N13O12S/c50-16-6-5-11-31(51)42(68)56-32(12-7-17-54-49(52)53)46(72)60-18-8-14-36(60)48(74)61-23-30(64)21-37(61)44(70)55-22-39(65)59-41(29-19-27-9-1-2-10-28(27)20-29)45(71)57-33(25-63)43(69)58-34-26-75-38-15-4-3-13-35(38)62(47(34)73)24-40(66)67/h1-4,9-10,13,15,29-34,36-37,41,63-64H,5-8,11-12,14,16-26,50-51H2,(H,55,70)(H,56,68)(H,57,71)(H,58,69)(H,59,65)(H,66,67)(H4,52,53,54)/t30?,31?,32-,33+,34-,36+,37+,41?/m1/s1
DMDXIS7	CS	C1C[C@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)C(CCCCN)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)NC(C3CC4=CC=CC=C4C3)C(=O)N[C@@H](CO)C(=O)N[C@@H]5CSC6=CC=CC=C6N(C5=O)CC(=O)O)O
DMDXIS7	IK	DSKXSKYPLRUWNI-XISDYZNSSA-N
DMDXIS7	IU	2-[(3S)-3-[[(2S)-2-[[2-[[2-[[(2S)-1-[(2S)-1-[(2R)-2-(2,6-diaminohexanoylamino)-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-2-(2,3-dihydro-1H-inden-2-yl)acetyl]amino]-3-hydroxypropanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]acetic acid
DMDXIS7	DE	Discovery agent

DMTGU0L	ID	DMTGU0L
DMTGU0L	DN	H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)
DMTGU0L	HS	Investigative
DMTGU0L	SN	CHEMBL412824; H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)
DMTGU0L	PC	44316161
DMTGU0L	MW	1044.2
DMTGU0L	FM	C45H65N13O12S2
DMTGU0L	IC	InChI=1S/C45H65N13O12S2/c46-14-4-3-9-27(47)38(64)53-28(10-5-15-50-45(48)49)42(68)56-16-6-12-33(56)44(70)57-21-25(60)18-34(57)41(67)51-20-36(61)52-29(19-26-8-7-17-71-26)39(65)54-30(23-59)40(66)55-31-24-72-35-13-2-1-11-32(35)58(43(31)69)22-37(62)63/h1-2,7-8,11,13,17,25,27-31,33-34,59-60H,3-6,9-10,12,14-16,18-24,46-47H2,(H,51,67)(H,52,61)(H,53,64)(H,54,65)(H,55,66)(H,62,63)(H4,48,49,50)/t25?,27?,28-,29?,30+,31-,33+,34+/m1/s1
DMTGU0L	CS	C1C[C@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)C(CCCCN)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N[C@@H]4CSC5=CC=CC=C5N(C4=O)CC(=O)O)O
DMTGU0L	IK	UXMVCNAZMAVIBE-SXGBRQJCSA-N
DMTGU0L	IU	2-[(3S)-3-[[(2S)-2-[[2-[[2-[[(2S)-1-[(2S)-1-[(2R)-2-(2,6-diaminohexanoylamino)-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]acetic acid
DMTGU0L	DE	Discovery agent

DMKHVUE	ID	DMKHVUE
DMKHVUE	DN	HM-5016699
DMKHVUE	HS	Investigative
DMKHVUE	SN	Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison
DMKHVUE	CP	Hutchison Medipharma Enterprises Ltd
DMKHVUE	DE	Solid tumour/cancer

DMNOFTX	ID	DMNOFTX
DMNOFTX	DN	HM-61713B
DMNOFTX	HS	Investigative
DMNOFTX	SN	EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi
DMNOFTX	CP	Hanmi Pharmaceutical Co Ltd
DMNOFTX	DE	Solid tumour/cancer

DM17QMV	ID	DM17QMV
DM17QMV	DN	H-mCpa-ala-Gly-Phe-leu-OH
DM17QMV	HS	Investigative
DM17QMV	SN	CHEMBL246682; H-mCpa-ala-Gly-Phe-leu-OH
DM17QMV	DT	Small molecular drug
DM17QMV	PC	44439875
DM17QMV	MW	596.7
DM17QMV	FM	C30H40N6O7
DM17QMV	IC	InChI=1S/C30H40N6O7/c1-17(2)12-24(30(42)43)36-29(41)23(15-19-8-5-4-6-9-19)35-25(37)16-33-27(39)18(3)34-28(40)22(31)14-20-10-7-11-21(13-20)26(32)38/h4-11,13,17-18,22-24H,12,14-16,31H2,1-3H3,(H2,32,38)(H,33,39)(H,34,40)(H,35,37)(H,36,41)(H,42,43)/t18-,22-,23-,24-/m0/s1
DM17QMV	CS	C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC(=CC=C2)C(=O)N)N
DM17QMV	IK	CPTUJVNVSNEVEH-IMNFJDCFSA-N
DM17QMV	IU	(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(3-carbamoylphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM17QMV	DE	Discovery agent

DMKAEQP	ID	DMKAEQP
DMKAEQP	DN	H-mCpa-Gly-Gly-Phe-Leu-OH
DMKAEQP	HS	Investigative
DMKAEQP	SN	CHEMBL392275; H-mCpa-Gly-Gly-Phe-Leu-OH
DMKAEQP	DT	Small molecular drug
DMKAEQP	PC	44439879
DMKAEQP	MW	582.6
DMKAEQP	FM	C29H38N6O7
DMKAEQP	IC	InChI=1S/C29H38N6O7/c1-17(2)11-23(29(41)42)35-28(40)22(14-18-7-4-3-5-8-18)34-25(37)16-32-24(36)15-33-27(39)21(30)13-19-9-6-10-20(12-19)26(31)38/h3-10,12,17,21-23H,11,13-16,30H2,1-2H3,(H2,31,38)(H,32,36)(H,33,39)(H,34,37)(H,35,40)(H,41,42)/t21-,22-,23-/m0/s1
DMKAEQP	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC(=CC=C2)C(=O)N)N
DMKAEQP	IK	MKAKAIMBENCCEJ-VABKMULXSA-N
DMKAEQP	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(3-carbamoylphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMKAEQP	DE	Discovery agent

DM8OUHV	ID	DM8OUHV
DM8OUHV	DN	H-mCpa-ser-Gly-Phe-Leu-Thr-OH
DM8OUHV	HS	Investigative
DM8OUHV	SN	CHEMBL393867; H-mCpa-ser-Gly-Phe-Leu-Thr-OH
DM8OUHV	DT	Small molecular drug
DM8OUHV	PC	44439901
DM8OUHV	MW	713.8
DM8OUHV	FM	C34H47N7O10
DM8OUHV	IC	InChI=1S/C34H47N7O10/c1-18(2)12-24(33(49)41-28(19(3)43)34(50)51)39-32(48)25(15-20-8-5-4-6-9-20)38-27(44)16-37-31(47)26(17-42)40-30(46)23(35)14-21-10-7-11-22(13-21)29(36)45/h4-11,13,18-19,23-26,28,42-43H,12,14-17,35H2,1-3H3,(H2,36,45)(H,37,47)(H,38,44)(H,39,48)(H,40,46)(H,41,49)(H,50,51)/t19-,23+,24+,25+,26+,28+/m1/s1
DM8OUHV	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC(=CC=C2)C(=O)N)N)O
DM8OUHV	IK	LGORGTYVVSKEOB-KXJTVXFKSA-N
DM8OUHV	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(3-carbamoylphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DM8OUHV	DE	Discovery agent

DMXMTA9	ID	DMXMTA9
DMXMTA9	DN	HMR-1556
DMXMTA9	HS	Investigative
DMXMTA9	SN	GTPL2590
DMXMTA9	DT	Small molecular drug
DMXMTA9	PC	9867091
DMXMTA9	MW	425.5
DMXMTA9	FM	C18H26F3NO5S
DMXMTA9	IC	InChI=1S/C18H26F3NO5S/c1-5-28(24,25)22(4)15-13-11-12(26-10-6-9-18(19,20)21)7-8-14(13)27-17(2,3)16(15)23/h7-8,11,15-16,23H,5-6,9-10H2,1-4H3/t15-,16+/m0/s1
DMXMTA9	CS	CCS(=O)(=O)N(C)[C@@H]1[C@H](C(OC2=C1C=C(C=C2)OCCCC(F)(F)F)(C)C)O
DMXMTA9	IK	YBZQPPIQXNWGEX-JKSUJKDBSA-N
DMXMTA9	IU	N-[(3R,4S)-3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydrochromen-4-yl]-N-methylethanesulfonamide
DMXMTA9	DE	Discovery agent

DMNXR17	ID	DMNXR17
DMNXR17	DN	HMR1883
DMNXR17	HS	Investigative
DMNXR17	SN	Clamikalant; Clamikalant [INN]; 158751-64-5; UNII-94301K998R; CHEMBL12531; HMR-1883; 94301K998R; 1-((5-(2-(5-Chloro-o-anisamido)ethyl)-2-methoxyphenyl)sulfonyl)-3-methyl-2-thiourea; HMR1883; AC1MI3H0; SCHEMBL726268; DTXSID30166522; VXTKXGKPBOLHRY-UHFFFAOYSA-N; ZINC599915; BDBM50099573; AKOS027339538; API0011065; NCGC00386636-01; AS-44931; LS-26123; SR-01000945051; SR-01000945051-1; 5-chloro-2-methoxy-N-[2-[4-methoxy-3-(methylcarbamothioylsulfamoyl)phenyl]ethyl]benzamide
DMNXR17	DT	Small molecular drug
DMNXR17	PC	3037766
DMNXR17	MW	472
DMNXR17	FM	C19H22ClN3O5S2
DMNXR17	IC	InChI=1S/C19H22ClN3O5S2/c1-21-19(29)23-30(25,26)17-10-12(4-6-16(17)28-3)8-9-22-18(24)14-11-13(20)5-7-15(14)27-2/h4-7,10-11H,8-9H2,1-3H3,(H,22,24)(H2,21,23,29)
DMNXR17	CS	CNC(=S)NS(=O)(=O)C1=C(C=CC(=C1)CCNC(=O)C2=C(C=CC(=C2)Cl)OC)OC
DMNXR17	IK	VXTKXGKPBOLHRY-UHFFFAOYSA-N
DMNXR17	IU	5-chloro-2-methoxy-N-[2-[4-methoxy-3-(methylcarbamothioylsulfamoyl)phenyl]ethyl]benzamide
DMNXR17	CA	CAS 158751-64-5
DMNXR17	DE	Discovery agent

DMUPS48	ID	DMUPS48
DMUPS48	DN	HMS3229G13
DMUPS48	HS	Investigative
DMUPS48	SN	JAK3 Inhibitor VI; CHEMBL2397013; 856436-16-3; GTPL5995; CCG-206764; RT-013395; (3Z)-5-(pyridin-3-yl)-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one
DMUPS48	DT	Small molecular drug
DMUPS48	PC	16760524
DMUPS48	MW	383.4
DMUPS48	FM	C19H17N3O4S
DMUPS48	IC	InChI=1S/C18H13N3O.CH4O3S/c22-18-16(10-14-4-2-8-20-14)15-9-12(5-6-17(15)21-18)13-3-1-7-19-11-13;1-5(2,3)4/h1-11,20H,(H,21,22);1H3,(H,2,3,4)/b16-10-;
DMUPS48	CS	CS(=O)(=O)O.C1=CC(=CN=C1)C2=CC\\3=C(C=C2)NC(=O)/C3=C\\C4=CC=CN4
DMUPS48	IK	ZUDPNBZMAJGYTE-HYMQDMCPSA-N
DMUPS48	IU	methanesulfonic acid;(3Z)-5-pyridin-3-yl-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
DMUPS48	CA	CAS 856436-16-3
DMUPS48	DE	Discovery agent

DMKOMP2	ID	DMKOMP2
DMKOMP2	DN	HOE-33258
DMKOMP2	HS	Investigative
DMKOMP2	DT	Small molecular drug
DMKOMP2	PC	2392
DMKOMP2	MW	424.5
DMKOMP2	FM	C25H24N6O
DMKOMP2	IC	InChI=1S/C25H24N6O/c1-30-10-12-31(13-11-30)18-5-9-21-23(15-18)29-25(27-21)17-4-8-20-22(14-17)28-24(26-20)16-2-6-19(32)7-3-16/h2-9,14-15,32H,10-13H2,1H3,(H,26,28)(H,27,29)
DMKOMP2	CS	CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC=C(C=C6)O
DMKOMP2	IK	INAAIJLSXJJHOZ-UHFFFAOYSA-N
DMKOMP2	IU	4-[6-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazol-2-yl]phenol
DMKOMP2	CA	CAS 23491-44-3
DMKOMP2	CB	CHEBI:52082
DMKOMP2	DE	Discovery agent

DMJQI7A	ID	DMJQI7A
DMJQI7A	DN	HO-LVA
DMJQI7A	HS	Investigative
DMJQI7A	SN	CHEMBL394602
DMJQI7A	PC	44428111
DMJQI7A	MW	1127.3
DMJQI7A	FM	C53H74N16O12
DMJQI7A	IC	InChI=1S/C53H74N16O12/c1-68(44(74)27-32-13-17-35(71)18-14-32)41(26-31-11-15-34(70)16-12-31)50(80)67-39(25-30-7-3-2-4-8-30)48(78)64-37(19-20-42(54)72)47(77)66-40(28-43(55)73)49(79)65-38(10-6-23-62-53(59)60)51(81)69-24-21-33(29-69)46(76)63-36(45(56)75)9-5-22-61-52(57)58/h2-4,7-8,11-18,33,36-41,70-71H,5-6,9-10,19-29H2,1H3,(H2,54,72)(H2,55,73)(H2,56,75)(H,63,76)(H,64,78)(H,65,79)(H,66,77)(H,67,80)(H4,57,58,61)(H4,59,60,62)/t33-,36-,37-,38-,39-,40-,41+/m0/s1
DMJQI7A	CS	CN([C@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N3CC[C@@H](C3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)C(=O)CC4=CC=C(C=C4)O
DMJQI7A	IK	QSWYUUWOWAFPRH-PDQNOIBYSA-N
DMJQI7A	IU	(2S)-N-[(2S)-4-amino-1-[[(2S)-1-[(3S)-3-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]-2-[[(2S)-2-[[(2R)-3-(4-hydroxyphenyl)-2-[[2-(4-hydroxyphenyl)acetyl]-methylamino]propanoyl]amino]-3-phenylpropanoyl]amino]pentanediamide
DMJQI7A	DE	Discovery agent

DMZYB3S	ID	DMZYB3S
DMZYB3S	DN	Hombreol
DMZYB3S	HS	Investigative
DMZYB3S	SN	Dihydroandrosterone; Etiocholane-3alpha,17beta-diol; Hombreol; J34MX0M30Y; (3alpha,5alpha,17beta)-androstane-3,17-diol; 1852-53-5; 3alpha androstanediol; 3alpha,17beta-Dihydroxy-5alpha-androstane; 3alpha-androstanediol; 5-alpha-ANDROSTANE-3-alpha,17-beta-DIOL; 5a-Androstane-3a,17b-diol; 5alpha-Androstan-3alpha,17beta-diol; 5alpha-Androstane-3alpha,17beta-androstanediol; 5alpha-Androstane-3alpha,17beta-diol; BRN 2694353; CHEBI:36713; CHEMBL335062; EINECS 217-447-4; MLS000028362; NSC 9899; UNII-J34MX0M30Y
DMZYB3S	PC	15818
DMZYB3S	MW	292.5
DMZYB3S	FM	C19H32O2
DMZYB3S	IC	CBMYJHIOYJEBSB-KHOSGYARSA-N
DMZYB3S	CS	CC12CCC(CC1CCC3C2CCC4(C3CCC4O)C)O
DMZYB3S	IK	1S/C19H32O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-17,20-21H,3-11H2,1-2H3/t12-,13+,14-,15-,16-,17-,18-,19-/m0/s1
DMZYB3S	IU	(3R,5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
DMZYB3S	CA	CAS 1852-53-5
DMZYB3S	CB	CHEBI:36713
DMZYB3S	DE	Discovery agent

DMH96AI	ID	DMH96AI
DMH96AI	DN	homo-AMPA
DMH96AI	HS	Investigative
DMH96AI	SN	CHEMBL107768; homo-AMPA; HomoAMPA; AC1N6KQF; 2-Amino-4-(3-hydroxy-5-methyl-isoxazol-4-yl)-butyric acid; GTPL3359; SCHEMBL3731488; CTK8G0203; HMS3267O13; BDBM50052551; NCGC00024946-02; SR-01000597464; SR-01000597464-1; 2-amino-4-(5-methyl-3-oxo-1,2-oxazol-4-yl)butanoic acid; 2-Amino-4-(3-hydroxy-5-methylisoxazole-4-yl)butyric acid; 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid; a-Amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolebutanoic acid; 2-amino-4-(5-methyl-3-oxo-2,3-dihydro-1,2-oxazol-4-yl)butanoic acid
DMH96AI	DT	Small molecular drug
DMH96AI	PC	4236420
DMH96AI	MW	200.19
DMH96AI	FM	C8H12N2O4
DMH96AI	IC	InChI=1S/C8H12N2O4/c1-4-5(7(11)10-14-4)2-3-6(9)8(12)13/h6H,2-3,9H2,1H3,(H,10,11)(H,12,13)
DMH96AI	CS	CC1=C(C(=O)NO1)CCC(C(=O)O)N
DMH96AI	IK	NZDIZJGEDFARSV-UHFFFAOYSA-N
DMH96AI	IU	2-amino-4-(5-methyl-3-oxo-1,2-oxazol-4-yl)butanoic acid
DMH96AI	DE	Discovery agent

DMIHFQY	ID	DMIHFQY
DMIHFQY	DN	HOMOAROMOLINE
DMIHFQY	HS	Investigative
DMIHFQY	SN	Homoaromoline; (+)-Homoaromoline; Thalrugosamine; 6,6',12'-Trimethoxy-2,2'-dimethyloxyacanthan-7-ol; 17132-74-0; NSC 251213; CHEMBL509855; NSC-251213; Oxyacanthan-7-ol, 6,6',12'-trimethoxy-2,2'-dimethyl-; (+)-Thalrugosamine; Homothalicrine; Limacusine (R,S); ( )-Thalrugosamine; Homothalicrine (7CI); SCHEMBL2991819; AC1Q58F3; AC1L410X; DTXSID90169059; NSC251213; BDBM50241641; LS-75888; Oxyacanthan-7-ol,6',12'-trimethoxy-2,2'-dimethyl-; Oxyacanthan-7-ol, 6,6',12'-trimethoxy-2,2'-dimethyl- (9CI)
DMIHFQY	DT	Small molecular drug
DMIHFQY	PC	99620
DMIHFQY	MW	608.7
DMIHFQY	FM	C37H40N2O6
DMIHFQY	IC	InChI=1S/C37H40N2O6/c1-38-14-12-24-19-31(42-4)33-21-27(24)28(38)17-23-8-11-30(41-3)32(18-23)44-26-9-6-22(7-10-26)16-29-35-25(13-15-39(29)2)20-34(43-5)36(40)37(35)45-33/h6-11,18-21,28-29,40H,12-17H2,1-5H3/t28-,29+/m1/s1
DMIHFQY	CS	CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=CC(=C(C=C7CCN6C)OC)O3)OC)O)OC
DMIHFQY	IK	YJRWQNIRFXVBRB-WDYNHAJCSA-N
DMIHFQY	IU	(1R,14S)-6,20,25-trimethoxy-15,30-dimethyl-8,23-dioxa-15,30-diazaheptacyclo[22.6.2.29,12.13,7.114,18.027,31.022,33]hexatriaconta-3(36),4,6,9(35),10,12(34),18,20,22(33),24,26,31-dodecaen-21-ol
DMIHFQY	CA	CAS 17132-74-0
DMIHFQY	DE	Discovery agent

DMCIRY0	ID	DMCIRY0
DMCIRY0	DN	Homocamptothecins (hCPTs)
DMCIRY0	HS	Investigative
DMCIRY0	DE	Discovery agent

DM1SDN8	ID	DM1SDN8
DM1SDN8	DN	HOMOERIODICTYOL
DM1SDN8	HS	Investigative
DM1SDN8	SN	Homoeriodictyol; (-)-Homoeriodictyol; 446-71-9; Eriodictyonone; UNII-EHE7H3705C; Eriodictyol 3'-methyl ether; 5,7,4'-Trihydroxy-3'-methoxyflavanone; CHEMBL490170; EHE7H3705C; CHEBI:74960; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; Q-100585; (+/-)-Homoeriodictyol; cyanidanon-3-methyl ether 1625; EINECS 207-173-3; AC1Q6KID; AC1L2K7J; SCHEMBL39497; DTXSID30196243; FTODBIPDTXRIGS-ZDUSSCGKSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; ZINC4098322; BDBM50325672
DM1SDN8	DT	Small molecular drug
DM1SDN8	PC	73635
DM1SDN8	MW	302.28
DM1SDN8	FM	C16H14O6
DM1SDN8	IC	InChI=1S/C16H14O6/c1-21-14-4-8(2-3-10(14)18)13-7-12(20)16-11(19)5-9(17)6-15(16)22-13/h2-6,13,17-19H,7H2,1H3/t13-/m0/s1
DM1SDN8	CS	COC1=C(C=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O
DM1SDN8	IK	FTODBIPDTXRIGS-ZDUSSCGKSA-N
DM1SDN8	IU	(2S)-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-2,3-dihydrochromen-4-one
DM1SDN8	CA	CAS 446-71-9
DM1SDN8	CB	CHEBI:74960
DM1SDN8	DE	Discovery agent

DMQD0YW	ID	DMQD0YW
DMQD0YW	DN	Homogentisic acid
DMQD0YW	HS	Investigative
DMQD0YW	SN	Homogenestic acid lactone; Homogentisic acid lactone; Homogentisic Acid gamma-Lactone; Homogentisic Acid?-Lactone; Homogentisic lactone; 2(3H)-Benzofuranone, 5-hydroxy-; 2,3-Dihydro-5-hydroxybenzofuran-2-one; 2688-48-4; 5-Hydroxy-2(3H)-benzofuranone; 5-Hydroxy-2-coumaranone; 5-Hydroxybenzofuran-2(3H)-one; 5-Hydroxybenzofuran-2-one; 5-hydroxy-1-benzofuran-2(3H)-one; 5-hydroxy-3-hydrobenzo[b]furan-2-one; 5-hydroxy-3H-1-benzofuran-2-one; A-Lactone; AC1L2PRA; AC1Q6ML0; EINECS 220-252-7; MLS002693363; NSC61996
DMQD0YW	PC	75898
DMQD0YW	MW	150.13
DMQD0YW	FM	C8H6O3
DMQD0YW	IC	POUITAHNNRJWMA-UHFFFAOYSA-N
DMQD0YW	CS	C1C2=C(C=CC(=C2)O)OC1=O
DMQD0YW	IK	1S/C8H6O3/c9-6-1-2-7-5(3-6)4-8(10)11-7/h1-3,9H,4H2
DMQD0YW	IU	5-hydroxy-3H-1-benzofuran-2-one
DMQD0YW	CA	CAS 2688-48-4
DMQD0YW	CB	CHEBI:141343
DMQD0YW	DE	Discovery agent

DMVBTHA	ID	DMVBTHA
DMVBTHA	DN	HOMOPHENYLALANINYLMETHANE
DMVBTHA	HS	Investigative
DMVBTHA	DE	Discovery agent

DMBW5DU	ID	DMBW5DU
DMBW5DU	DN	homoquinolinic acid
DMBW5DU	HS	Investigative
DMBW5DU	SN	HQA
DMBW5DU	DT	Small molecular drug
DMBW5DU	PC	3080554
DMBW5DU	MW	181.15
DMBW5DU	FM	C8H7NO4
DMBW5DU	IC	InChI=1S/C8H7NO4/c10-6(11)4-5-2-1-3-9-7(5)8(12)13/h1-3H,4H2,(H,10,11)(H,12,13)
DMBW5DU	CS	C1=CC(=C(N=C1)C(=O)O)CC(=O)O
DMBW5DU	IK	HQPMJFFEXJELOQ-UHFFFAOYSA-N
DMBW5DU	IU	3-(carboxymethyl)pyridine-2-carboxylic acid
DMBW5DU	CA	CAS 490-75-5
DMBW5DU	DE	Discovery agent

DMX8DC2	ID	DMX8DC2
DMX8DC2	DN	Homorisedronate
DMX8DC2	HS	Investigative
DMX8DC2	SN	NE 58051; 104261-69-0; NE-58051; CHEMBL293522; [1-hydroxy-3-(pyridin-3-yl)propane-1,1-diyl]bis(phosphonic acid); HRX; AC1L2TXU; SCHEMBL8710665; 3-(3-Pyridyl)-1-hydroxypropylidene bisphosphonic acid; (1-Hydroxy-3-(3-pyridinyl)propylidene)bisphosphonic acid; DTXSID70146363; 1-hydroxy-3-(3-pyridyl)propylidene-1,1-bisphosphonic acid; ILROXFQHACCDLA-UHFFFAOYSA-N; BDBM50098382; 3-(3-Hydroxy-3,3-bis-phosphono-propyl)-pyridinium; 3-(3-pyridyl)-1-hydroxy-propane-1,1-bisphosphonate
DMX8DC2	DT	Small molecular drug
DMX8DC2	PC	128523
DMX8DC2	MW	297.14
DMX8DC2	FM	C8H13NO7P2
DMX8DC2	IC	InChI=1S/C8H13NO7P2/c10-8(17(11,12)13,18(14,15)16)4-3-7-2-1-5-9-6-7/h1-2,5-6,10H,3-4H2,(H2,11,12,13)(H2,14,15,16)
DMX8DC2	CS	C1=CC(=CN=C1)CCC(O)(P(=O)(O)O)P(=O)(O)O
DMX8DC2	IK	ILROXFQHACCDLA-UHFFFAOYSA-N
DMX8DC2	IU	(1-hydroxy-1-phosphono-3-pyridin-3-ylpropyl)phosphonic acid
DMX8DC2	CA	CAS 104261-69-0
DMX8DC2	DE	Discovery agent

DMTKN4A	ID	DMTKN4A
DMTKN4A	DN	Homoserine Lactone
DMTKN4A	HS	Investigative
DMTKN4A	SN	homoserinium lactone; 2-oxooxolan-3-aminium; homoserinium lactone(1+); homoserinium lactone cation; (2-oxooxolan-3-yl)azanium; 2-oxotetrahydrofuran-3-aminium; AC1N129K
DMTKN4A	DT	Small molecular drug
DMTKN4A	PC	73509
DMTKN4A	MW	101.1
DMTKN4A	FM	C4H7NO2
DMTKN4A	IC	InChI=1S/C4H7NO2/c5-3-1-2-7-4(3)6/h3H,1-2,5H2
DMTKN4A	CS	C1COC(=O)C1N
DMTKN4A	IK	QJPWUUJVYOJNMH-UHFFFAOYSA-N
DMTKN4A	IU	3-aminooxolan-2-one
DMTKN4A	CA	CAS 1192-20-7
DMTKN4A	CB	CHEBI:17289
DMTKN4A	DE	Discovery agent

DM0SHPY	ID	DM0SHPY
DM0SHPY	DN	Homovanillic acid
DM0SHPY	HS	Investigative
DM0SHPY	SN	Homovanilic acid; Homovanillate; Homovanillic acid; Homovanillic acid, 98%; Homovanillinic acid; Homovaniuic acid; Vanilacetic acid; Vanillacetic acid; (4-HYDROXY-3-METHOXYPHENYL)ACETIC ACID; 2-(4-hydroxy-3-methoxy-phenyl)acetic acid; 2-(4-hydroxy-3-methoxyphenyl)acetic acid; 3-Methoxy-4-hydroxyphenylacetate; 3-Methoxy-4-hydroxyphenylacetic acid; 306-08-1; 4-Hydroxy-3-methoxybenzeneacetic acid; 4-Hydroxy-3-methoxyphenylacetic acid; Benzeneacetic acid, 4-hydroxy-3-methoxy-; HVA; MFCD00004350; NSC 16682; UNII-X77S6GMS36
DM0SHPY	PC	1738
DM0SHPY	MW	182.17
DM0SHPY	FM	C9H10O4
DM0SHPY	IC	QRMZSPFSDQBLIX-UHFFFAOYSA-N
DM0SHPY	CS	COC1=C(C=CC(=C1)CC(=O)O)O
DM0SHPY	IK	1S/C9H10O4/c1-13-8-4-6(5-9(11)12)2-3-7(8)10/h2-4,10H,5H2,1H3,(H,11,12)
DM0SHPY	IU	2-(4-hydroxy-3-methoxyphenyl)acetic acid
DM0SHPY	CA	CAS 306-08-1
DM0SHPY	CB	CHEBI:545959
DM0SHPY	DE	Brain cancer

DMI7258	ID	DMI7258
DMI7258	DN	Homspera
DMI7258	HS	Investigative
DMI7258	SN	Homspera (oral, influenza)
DMI7258	CP	ImmuneRegen BioSciences Inc
DMI7258	PC	129822097
DMI7258	MW	1393.7
DMI7258	FM	C64H100N18O15S
DMI7258	IC	InChI=1S/C64H100N18O15S/c1-38(2)34-46(57(89)74-42(54(69)86)28-33-98(4,96)97)73-53(85)37-80(3)62(94)48(36-40-18-9-6-10-19-40)79-58(90)47(35-39-16-7-5-8-17-39)78-56(88)43(24-26-51(67)83)75-55(87)44(25-27-52(68)84)76-59(91)50-23-15-32-82(50)63(95)45(21-11-12-29-65)77-60(92)49-22-14-31-81(49)61(93)41(66)20-13-30-72-64(70)71/h5-10,16-19,38,41-50H,11-15,20-37,65-66H2,1-4H3,(H2,67,83)(H2,68,84)(H2,69,86)(H,73,85)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,88)(H,79,90)(H4,70,71,72)/t41-,42-,43?,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMI7258	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)N)NC(=O)CN(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)C(CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DMI7258	IK	OUPXSLGGCPUZJJ-HTTPISLZSA-N
DMI7258	IU	(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfonyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DMI7258	DE	Influenza virus infection

DMJWT3X	ID	DMJWT3X
DMJWT3X	DN	HONOKIOL
DMJWT3X	HS	Investigative
DMJWT3X	SN	Honokiol; 35354-74-6; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; Honokiol,(S); UNII-11513CCO0N; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; 3',5-Diallylbiphenyl-2,4'-diol; CPD000387107; CHEMBL16901; CHEBI:5759; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; 11513CCO0N; 3',5-diallyl-2,4'-biphenyldiol; AK-25837; 5,3&amp; -Diallyl-2,4&amp; Q-100425; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; houpa
DMJWT3X	DT	Small molecular drug
DMJWT3X	PC	72303
DMJWT3X	MW	266.3
DMJWT3X	FM	C18H18O2
DMJWT3X	IC	InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2
DMJWT3X	CS	C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C
DMJWT3X	IK	FVYXIJYOAGAUQK-UHFFFAOYSA-N
DMJWT3X	IU	2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol
DMJWT3X	CA	CAS 35354-74-6
DMJWT3X	CB	CHEBI:5759
DMJWT3X	DE	Discovery agent

DMHW2DU	ID	DMHW2DU
DMHW2DU	DN	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2
DMHW2DU	HS	Investigative
DMHW2DU	DT	Small molecular drug
DMHW2DU	PC	73347136
DMHW2DU	MW	955.1
DMHW2DU	FM	C49H63FN10O9
DMHW2DU	IC	InChI=1S/C49H63FN10O9/c1-29(2)17-22-34(43(63)56-38(27-32-18-20-33(50)21-19-32)45(65)55-36(42(52)62)25-30-11-5-3-6-12-30)53-47(67)40-16-10-24-60(40)48(68)35(15-9-23-51)54-44(64)37(26-31-13-7-4-8-14-31)57-46(66)39-28-41(61)59-49(69)58-39/h3-8,11-14,18-21,29,34-40H,9-10,15-17,22-28,51H2,1-2H3,(H2,52,62)(H,53,67)(H,54,64)(H,55,65)(H,56,63)(H,57,66)(H2,58,59,61,69)/t34-,35-,36+,37-,38-,39-,40-/m0/s1
DMHW2DU	CS	CC(C)CC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)F)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H]5CC(=O)NC(=O)N5
DMHW2DU	IK	HXKFHHNEFCZKPG-VEKZNEBUSA-N
DMHW2DU	IU	(4S)-N-[(2S)-1-[[(2S)-5-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-fluorophenyl)-1-oxopropan-2-yl]amino]-5-methyl-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMHW2DU	DE	Discovery agent

DM2OZBL	ID	DM2OZBL
DM2OZBL	DN	Howiinol A (GHM-10)
DM2OZBL	HS	Investigative
DM2OZBL	SN	Howiinol A; (+)-Howiinol A; AC1O5TEF; CHEMBL1170578; D-xylo-Hept-2-enonic acid, 2,3-dideoxy-7-C-phenyl-, delta-lactone, 7-((2E)-3-phenyl-2-propenoate), (7R)-; 190848-69-2; [(1R,2R)-2-hydroxy-2-[(2R,3S)-3-hydroxy-6-oxo-2,3-dihydropyran-2-yl]-1-phenylethyl] (E)-3-phenylprop-2-enoate
DM2OZBL	DT	Small molecular drug
DM2OZBL	PC	6440329
DM2OZBL	MW	380.4
DM2OZBL	FM	C22H20O6
DM2OZBL	IC	InChI=1S/C22H20O6/c23-17-12-14-19(25)28-22(17)20(26)21(16-9-5-2-6-10-16)27-18(24)13-11-15-7-3-1-4-8-15/h1-14,17,20-23,26H/b13-11+/t17-,20+,21+,22+/m0/s1
DM2OZBL	CS	C1=CC=C(C=C1)/C=C/C(=O)O[C@H](C2=CC=CC=C2)[C@H]([C@H]3[C@H](C=CC(=O)O3)O)O
DM2OZBL	IK	HCJURVKKVSCZRL-VTWBULIDSA-N
DM2OZBL	IU	[(1R,2R)-2-hydroxy-2-[(2R,3S)-3-hydroxy-6-oxo-2,3-dihydropyran-2-yl]-1-phenylethyl] (E)-3-phenylprop-2-enoate
DM2OZBL	CA	CAS 190848-69-2
DM2OZBL	DE	Discovery agent

DM9IODG	ID	DM9IODG
DM9IODG	DN	H-Phe-NH2
DM9IODG	HS	Investigative
DM9IODG	SN	5241-58-7; Phenylalanine amide; (S)-2-amino-3-phenylpropanamide; L-Phenylalanine amide; phenylalaninamide; (2S)-2-amino-3-phenylpropanamide; Phe-NH2; L-Phe-NH2; Phenh2; UNII-PV9T9B2S11; CHEMBL350320; PV9T9B2S11; CHEBI:21371; AK-46083; phenylalanylamide; L-phenylalanineamide; Benzenepropanamide, alpha-amino-, (alphaS)-; DL-Phenylalanine amide; 2-Amino-3-phenyl-propionamide; phenylalanine imine; (S)-phenylalaninamide; Benzenepropanamide, alpha-amino-, (S)-; H-L-Phe-NH2; AC1L9IEO; SCHEMBL244302
DM9IODG	DT	Small molecular drug
DM9IODG	PC	445694
DM9IODG	MW	164.2
DM9IODG	FM	C9H12N2O
DM9IODG	IC	InChI=1S/C9H12N2O/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H2,11,12)/t8-/m0/s1
DM9IODG	CS	C1=CC=C(C=C1)C[C@@H](C(=O)N)N
DM9IODG	IK	OBSIQMZKFXFYLV-QMMMGPOBSA-N
DM9IODG	IU	(2S)-2-amino-3-phenylpropanamide
DM9IODG	CA	CAS 5241-58-7
DM9IODG	CB	CHEBI:21371
DM9IODG	DE	Discovery agent

DM0KFW2	ID	DM0KFW2
DM0KFW2	DN	H-Phe-Phe-NH2
DM0KFW2	HS	Investigative
DM0KFW2	SN	CHEMBL108438; 15893-46-6; Phe-phe-amide; Phenylalanylphenylalanylamide; L-Phe-L-phe-amide; H-Phe-Phe-NH2; L-Phenylalanine-L-phenylalanylamide; L-Phe-L-Phe-NH2; AC1L38WX; XXPXQEQOAZMUDD-HOTGVXAUSA-N; L-Phenylalaninamide, L-phenylalanyl-; BDBM50188489; (S)-2-Amino-N-((S)-1-carbamoyl-2-phenyl-ethyl)-3-phenyl-propionamide
DM0KFW2	DT	Small molecular drug
DM0KFW2	PC	85169
DM0KFW2	MW	311.4
DM0KFW2	FM	C18H21N3O2
DM0KFW2	IC	InChI=1S/C18H21N3O2/c19-15(11-13-7-3-1-4-8-13)18(23)21-16(17(20)22)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12,19H2,(H2,20,22)(H,21,23)/t15-,16-/m0/s1
DM0KFW2	CS	C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)N
DM0KFW2	IK	XXPXQEQOAZMUDD-HOTGVXAUSA-N
DM0KFW2	IU	(2S)-2-amino-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
DM0KFW2	CA	CAS 15893-46-6
DM0KFW2	DE	Discovery agent

DME1CT9	ID	DME1CT9
DME1CT9	DN	H-Poa-ser-Gly-Phe-Leu-Thr-OH
DME1CT9	HS	Investigative
DME1CT9	SN	CHEMBL246740; H-Poa-ser-Gly-Phe-Leu-Thr-OH
DME1CT9	DT	Small molecular drug
DME1CT9	PC	44439896
DME1CT9	MW	687.7
DME1CT9	FM	C32H45N7O10
DME1CT9	IC	InChI=1S/C32H45N7O10/c1-18(2)13-23(31(46)38-27(19(3)41)32(47)48)36-30(45)24(15-20-7-5-4-6-8-20)35-26(42)16-34-29(44)25(17-40)37-28(43)22(33)14-21-9-11-39(49)12-10-21/h4-12,18-19,22-25,27,40-41H,13-17,33H2,1-3H3,(H,34,44)(H,35,42)(H,36,45)(H,37,43)(H,38,46)(H,47,48)/t19-,22+,23+,24+,25+,27+/m1/s1
DME1CT9	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=[N+](C=C2)[O-])N)O
DME1CT9	IK	PDLKKPWJIQINFZ-GQHROEFJSA-N
DME1CT9	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(1-oxidopyridin-1-ium-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DME1CT9	DE	Discovery agent

DMXKPQR	ID	DMXKPQR
DMXKPQR	DN	H-Pro-Phe-Phe-NH2
DMXKPQR	HS	Investigative
DMXKPQR	SN	CHEMBL591489; H-Pro-Phe-Phe-NH2
DMXKPQR	DT	Small molecular drug
DMXKPQR	PC	44611435
DMXKPQR	MW	408.5
DMXKPQR	FM	C23H28N4O3
DMXKPQR	IC	InChI=1S/C23H28N4O3/c24-21(28)19(14-16-8-3-1-4-9-16)26-23(30)20(15-17-10-5-2-6-11-17)27-22(29)18-12-7-13-25-18/h1-6,8-11,18-20,25H,7,12-15H2,(H2,24,28)(H,26,30)(H,27,29)/t18-,19-,20-/m0/s1
DMXKPQR	CS	C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N
DMXKPQR	IK	GQTQFZUTXSDLLQ-UFYCRDLUSA-N
DMXKPQR	IU	(2S)-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMXKPQR	DE	Discovery agent

DMRPZD4	ID	DMRPZD4
DMRPZD4	DN	HPTE
DMRPZD4	HS	Investigative
DMRPZD4	SN	Hydroxychlor; HPTE; p,p'-Hydroxy-DDT; 2971-36-0; p,p'-HO-DDT; 2,2-Bis(4-hydroxyphenyl)-1,1,1-trichloroethane; 1,1,1-Trichloro-2,2-bis(4-hydroxyphenyl)ethane; 4,4'-(2,2,2-trichloroethane-1,1-diyl)diphenol; 2,2-Bis(p-hydroxyphenyl)-1,1,1-trichloroethane; 4,4'-(2,2,2-Trichloroethylidene)diphenol; 1,1-Bis(4-hydroxyphenyl)-2,2,2-trichloroethane; 1,1-Bis(p-hydroxyphenyl)-2,2,2-trichloroethane; p,p'-(2,2,2-Trichloroethylidene)diphenol; NSC 7045; 1,1,1-Trichloro-2,2-bis(p-hydroxyphenyl)ethane; Phenol, 4,4'-(2,2,2-trichloroethylid
DMRPZD4	DT	Small molecular drug
DMRPZD4	PC	76302
DMRPZD4	MW	317.6
DMRPZD4	FM	C14H11Cl3O2
DMRPZD4	IC	InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H
DMRPZD4	CS	C1=CC(=CC=C1C(C2=CC=C(C=C2)O)C(Cl)(Cl)Cl)O
DMRPZD4	IK	IUGDILGOLSSKNE-UHFFFAOYSA-N
DMRPZD4	IU	4-[2,2,2-trichloro-1-(4-hydroxyphenyl)ethyl]phenol
DMRPZD4	CA	CAS 2971-36-0
DMRPZD4	CB	CHEBI:34025
DMRPZD4	DE	Discovery agent

DMSHYQ3	ID	DMSHYQ3
DMSHYQ3	DN	HQL-79
DMSHYQ3	HS	Investigative
DMSHYQ3	SN	HQL79; HQL 79
DMSHYQ3	DT	Small molecular drug
DMSHYQ3	PC	6540277
DMSHYQ3	MW	377.5
DMSHYQ3	FM	C22H27N5O
DMSHYQ3	IC	InChI=1S/C22H27N5O/c1-3-8-18(9-4-1)22(19-10-5-2-6-11-19)28-20-13-16-27(17-14-20)15-7-12-21-23-25-26-24-21/h1-6,8-11,20,22H,7,12-17H2,(H,23,24,25,26)
DMSHYQ3	CS	C1CN(CCC1OC(C2=CC=CC=C2)C3=CC=CC=C3)CCCC4=NNN=N4
DMSHYQ3	IK	TZQGXAHOROZEKN-UHFFFAOYSA-N
DMSHYQ3	IU	4-benzhydryloxy-1-[3-(2H-tetrazol-5-yl)propyl]piperidine
DMSHYQ3	CA	CAS 162641-16-9
DMSHYQ3	DE	Discovery agent

DMSTV96	ID	DMSTV96
DMSTV96	DN	H-RYYRIK-NH2
DMSTV96	HS	Investigative
DMSTV96	SN	CHEMBL444110
DMSTV96	DT	Small molecular drug
DMSTV96	PC	44456337
DMSTV96	MW	881.1
DMSTV96	FM	C42H68N14O7
DMSTV96	IC	InChI=1S/C42H68N14O7/c1-3-25(2)34(40(63)52-30(35(45)58)14-7-8-20-43)56-37(60)31(15-10-22-51-42(48)49)53-38(61)33(24-27-16-18-28(57)19-17-27)55-39(62)32(23-26-11-5-4-6-12-26)54-36(59)29(44)13-9-21-50-41(46)47/h4-6,11-12,16-19,25,29-34,57H,3,7-10,13-15,20-24,43-44H2,1-2H3,(H2,45,58)(H,52,63)(H,53,61)(H,54,59)(H,55,62)(H,56,60)(H4,46,47,50)(H4,48,49,51)/t25-,29-,30-,31-,32-,33-,34-/m0/s1
DMSTV96	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N
DMSTV96	IK	NJUUHBQLRQTWGG-QQUOXUDESA-N
DMSTV96	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMSTV96	DE	Discovery agent

DMM3FD2	ID	DMM3FD2
DMM3FD2	DN	HS014
DMM3FD2	HS	Investigative
DMM3FD2	DE	Discovery agent

DM0A2UF	ID	DM0A2UF
DM0A2UF	DN	HS-173
DM0A2UF	HS	Investigative
DM0A2UF	SN	HS-173; 1276110-06-5; Ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxylate; CHEMBL1765463; HS 173; GTPL8243; SCHEMBL20768095; EX-A320; AOB6845; MolPort-035-395-894; HMS3653I16; HS173; BCP09225; BDBM50341493; ZINC71319188; s7356; 2465AH; AKOS026750419; ACN-053037; CS-6015; SB19242; NCGC00386329-02; HY-15868; BC600371; FT-0700155; SW219873-1; J3.560.887G; J-690118; ethyl 6-[5-(benzenesulfonamido)pyridin-3-yl]imidazo[1,2-a]pyridine-3-carboxylate; Ethyl 6-(5-(Phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]-pyridine
DM0A2UF	DT	Small molecular drug
DM0A2UF	PC	52936849
DM0A2UF	MW	422.5
DM0A2UF	FM	C21H18N4O4S
DM0A2UF	IC	InChI=1S/C21H18N4O4S/c1-2-29-21(26)19-13-23-20-9-8-15(14-25(19)20)16-10-17(12-22-11-16)24-30(27,28)18-6-4-3-5-7-18/h3-14,24H,2H2,1H3
DM0A2UF	CS	CCOC(=O)C1=CN=C2N1C=C(C=C2)C3=CC(=CN=C3)NS(=O)(=O)C4=CC=CC=C4
DM0A2UF	IK	SEKOTFCHZNXZMM-UHFFFAOYSA-N
DM0A2UF	IU	ethyl 6-[5-(benzenesulfonamido)pyridin-3-yl]imidazo[1,2-a]pyridine-3-carboxylate
DM0A2UF	DE	Discovery agent

DMA91T4	ID	DMA91T4
DMA91T4	DN	H-SMGLPCVVM-OH
DMA91T4	HS	Investigative
DMA91T4	SN	CHEMBL87258; H-SMGLPCVVM-OH
DMA91T4	DT	Small molecular drug
DMA91T4	PC	44320675
DMA91T4	MW	936.2
DMA91T4	FM	C39H69N9O11S3
DMA91T4	IC	InChI=1S/C39H69N9O11S3/c1-20(2)16-26(42-29(50)17-41-33(52)24(11-14-61-7)43-32(51)23(40)18-49)38(57)48-13-9-10-28(48)35(54)45-27(19-60)34(53)46-31(22(5)6)37(56)47-30(21(3)4)36(55)44-25(39(58)59)12-15-62-8/h20-28,30-31,49,60H,9-19,40H2,1-8H3,(H,41,52)(H,42,50)(H,43,51)(H,44,55)(H,45,54)(H,46,53)(H,47,56)(H,58,59)/t23-,24-,25-,26-,27-,28-,30-,31-/m0/s1
DMA91T4	CS	CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@H](CO)N
DMA91T4	IK	XSTRKZMDUHFCKT-LFPOIMSVSA-N
DMA91T4	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-4-methylsulfanylbutanoic acid
DMA91T4	DE	Discovery agent

DMZRPM5	ID	DMZRPM5
DMZRPM5	DN	HT1042
DMZRPM5	HS	Investigative
DMZRPM5	SN	5-(3-nitrophenyl)-1,3,4-oxathiazol-2-one; CHEMBL3265177; 23589-77-7; NSC294566; AC1L6WL8; GTPL8649; SCHEMBL1781484; DTXSID10315430; BDBM50010993
DMZRPM5	DT	Small molecular drug
DMZRPM5	PC	325597
DMZRPM5	MW	224.2
DMZRPM5	FM	C8H4N2O4S
DMZRPM5	IC	InChI=1S/C8H4N2O4S/c11-8-14-7(9-15-8)5-2-1-3-6(4-5)10(12)13/h1-4H
DMZRPM5	CS	C1=CC(=CC(=C1)[N+](=O)[O-])C2=NSC(=O)O2
DMZRPM5	IK	QBAZATRGWRVUFN-UHFFFAOYSA-N
DMZRPM5	IU	5-(3-nitrophenyl)-1,3,4-oxathiazol-2-one
DMZRPM5	CA	CAS 23589-77-7
DMZRPM5	DE	Discovery agent

DMRF73O	ID	DMRF73O
DMRF73O	DN	HT-2678
DMRF73O	HS	Investigative
DMRF73O	SN	GABA inverse agonist (cognitive disorder) Helicon; HT-4313; GABA A receptor alpha-5 subunit modulator (cognitive disorder), Helicon Therapeutics
DMRF73O	CP	Helicon Therapeutics Inc
DMRF73O	DE	Cognitive impairment

DMPT8JN	ID	DMPT8JN
DMPT8JN	DN	HTMT
DMPT8JN	HS	Investigative
DMPT8JN	SN	histamine-trifluoromethyl-toluidine; histamine-trifluoromethyltoluide; HTFMT
DMPT8JN	DT	Small molecular drug
DMPT8JN	PC	124846
DMPT8JN	MW	382.4
DMPT8JN	FM	C19H25F3N4O
DMPT8JN	IC	InChI=1S/C19H25F3N4O/c1-14(24-11-10-17-12-23-13-25-17)4-2-3-5-18(27)26-16-8-6-15(7-9-16)19(20,21)22/h6-9,12-14,24H,2-5,10-11H2,1H3,(H,23,25)(H,26,27)
DMPT8JN	CS	CC(CCCCC(=O)NC1=CC=C(C=C1)C(F)(F)F)NCCC2=CN=CN2
DMPT8JN	IK	PMKJGGBYYNEYPA-UHFFFAOYSA-N
DMPT8JN	IU	6-[2-(1H-imidazol-5-yl)ethylamino]-N-[4-(trifluoromethyl)phenyl]heptanamide
DMPT8JN	CA	CAS 103827-16-3
DMPT8JN	CB	CHEBI:91812
DMPT8JN	DE	Discovery agent

DMQ8ADE	ID	DMQ8ADE
DMQ8ADE	DN	HTS-00213
DMQ8ADE	HS	Investigative
DMQ8ADE	SN	HTS-00213; CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole
DMQ8ADE	DT	Small molecular drug
DMQ8ADE	PC	2809539
DMQ8ADE	MW	502.3
DMQ8ADE	FM	C19H12Cl2F3N5O2S
DMQ8ADE	IC	InChI=1S/C19H12Cl2F3N5O2S/c20-13-2-1-3-14(21)17(13)30-8-15-26-16(31-28-15)9-32-18-27-25-10-29(18)12-6-4-11(5-7-12)19(22,23)24/h1-7,10H,8-9H2
DMQ8ADE	CS	C1=CC(=C(C(=C1)Cl)OCC2=NOC(=N2)CSC3=NN=CN3C4=CC=C(C=C4)C(F)(F)F)Cl
DMQ8ADE	IK	UUZRVUXGULNUHU-UHFFFAOYSA-N
DMQ8ADE	IU	3-[(2,6-dichlorophenoxy)methyl]-5-[[4-[4-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]sulfanylmethyl]-1,2,4-oxadiazole
DMQ8ADE	DE	Discovery agent

DMXV379	ID	DMXV379
DMXV379	DN	HTS-00798
DMXV379	HS	Investigative
DMXV379	SN	HTS-00798; CHEMBL380201; AC1MDE1P; Maybridge1_004268; MLS000850034; AC1Q78S6; HMS553J24; MolPort-001-806-570; ZINC119025; HMS2791J06; BDBM50191461; AKOS008398059; CCG-233002; MCULE-4306598933; SMR000456052; 1-(4-fluorophenyl)-2-[1-(4-hydroxyphenyl)tetrazol-5-yl]sulfanylethanone; 1-(4-fluorophenyl)-2-(1-(4-hydroxyphenyl)-1H-tetrazol-5-ylthio)ethanone; 1-(4-fluorophenyl)-2-{[1-(4-hydroxyphenyl)-1H-1,2,3,4-tetraazol-5-yl]thio}ethan-1-one
DMXV379	DT	Small molecular drug
DMXV379	PC	2809808
DMXV379	MW	330.3
DMXV379	FM	C15H11FN4O2S
DMXV379	IC	InChI=1S/C15H11FN4O2S/c16-11-3-1-10(2-4-11)14(22)9-23-15-17-18-19-20(15)12-5-7-13(21)8-6-12/h1-8,21H,9H2
DMXV379	CS	C1=CC(=CC=C1C(=O)CSC2=NN=NN2C3=CC=C(C=C3)O)F
DMXV379	IK	WROGOTHXLJWPOD-UHFFFAOYSA-N
DMXV379	IU	1-(4-fluorophenyl)-2-[1-(4-hydroxyphenyl)tetrazol-5-yl]sulfanylethanone
DMXV379	DE	Discovery agent

DMVUTJ5	ID	DMVUTJ5
DMVUTJ5	DN	HTS-02876
DMVUTJ5	HS	Investigative
DMVUTJ5	SN	HTS-02876; AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609
DMVUTJ5	DT	Small molecular drug
DMVUTJ5	PC	2810910
DMVUTJ5	MW	535.6
DMVUTJ5	FM	C24H20F3N3O4S2
DMVUTJ5	IC	InChI=1S/C24H20F3N3O4S2/c25-24(26,27)18-7-4-8-21(15-18)36(32,33)14-13-35-23-29-28-22(31)30(23)19-9-11-20(12-10-19)34-16-17-5-2-1-3-6-17/h1-12,15H,13-14,16H2,(H,28,31)
DMVUTJ5	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)N3C(=O)NN=C3SCCS(=O)(=O)C4=CC=CC(=C4)C(F)(F)F
DMVUTJ5	IK	PCYFSRWJXFMTSN-UHFFFAOYSA-N
DMVUTJ5	IU	4-(4-phenylmethoxyphenyl)-3-[2-[3-(trifluoromethyl)phenyl]sulfonylethylsulfanyl]-1H-1,2,4-triazol-5-one
DMVUTJ5	DE	Discovery agent

DM3F4IQ	ID	DM3F4IQ
DM3F4IQ	DN	HTS-05058
DM3F4IQ	HS	Investigative
DM3F4IQ	SN	MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; HTS-05058; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988
DM3F4IQ	DT	Small molecular drug
DM3F4IQ	PC	5714572
DM3F4IQ	MW	211.22
DM3F4IQ	FM	C12H9N3O
DM3F4IQ	IC	InChI=1S/C12H9N3O/c16-12-10(5-8-6-13-7-14-8)9-3-1-2-4-11(9)15-12/h1-7H,(H,13,14)(H,15,16)/b10-5-
DM3F4IQ	CS	C1=CC=C2C(=C1)/C(=C/C3=CN=CN3)/C(=O)N2
DM3F4IQ	IK	VEEGZPWAAPPXRB-YHYXMXQVSA-N
DM3F4IQ	IU	(3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one
DM3F4IQ	DE	Discovery agent

DM70YTF	ID	DM70YTF
DM70YTF	DN	HTS-466284
DM70YTF	HS	Investigative
DM70YTF	SN	4-(3-Pyridin-2-YL-1H-pyrazol-4-YL)quinoline; 396129-53-6; LY-364947; LY364947; 4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)quinoline; 4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)QUINOLINE; TbetaR-I Inhibitor; LY 364947; ALK5 Inhibitor I; TGF-beta RI Kinase Inhibitor; 4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]quinoline; CHEMBL261454; Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor; 4-(3-pyridin-2-yl)(1h)-pyrazol-4-yl quinoline; 4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]quinoline; [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole; 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
DM70YTF	DT	Small molecular drug
DM70YTF	PC	447966
DM70YTF	MW	272.3
DM70YTF	FM	C17H12N4
DM70YTF	IC	InChI=1S/C17H12N4/c1-2-6-15-13(5-1)12(8-10-19-15)14-11-20-21-17(14)16-7-3-4-9-18-16/h1-11H,(H,20,21)
DM70YTF	CS	C1=CC=C2C(=C1)C(=CC=N2)C3=C(NN=C3)C4=CC=CC=N4
DM70YTF	IK	IBCXZJCWDGCXQT-UHFFFAOYSA-N
DM70YTF	IU	4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline
DM70YTF	CA	CAS 396129-53-6
DM70YTF	CB	CHEBI:91198
DM70YTF	DE	Discovery agent

DMX08FL	ID	DMX08FL
DMX08FL	DN	H-Tyr(OMe)-Phe(2-Me)-NH2
DMX08FL	HS	Investigative
DMX08FL	SN	CHEMBL589543; H-Tyr(OMe)-Phe(2-Me)-NH2; SCHEMBL13538437
DMX08FL	DT	Small molecular drug
DMX08FL	PC	45379600
DMX08FL	MW	355.4
DMX08FL	FM	C20H25N3O3
DMX08FL	IC	InChI=1S/C20H25N3O3/c1-13-5-3-4-6-15(13)12-18(19(22)24)23-20(25)17(21)11-14-7-9-16(26-2)10-8-14/h3-10,17-18H,11-12,21H2,1-2H3,(H2,22,24)(H,23,25)/t17-,18-/m0/s1
DMX08FL	CS	CC1=CC=CC=C1C[C@@H](C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)OC)N
DMX08FL	IK	DZDNCKHJPMLWQZ-ROUUACIJSA-N
DMX08FL	IU	(2S)-2-amino-N-[(2S)-1-amino-3-(2-methylphenyl)-1-oxopropan-2-yl]-3-(4-methoxyphenyl)propanamide
DMX08FL	DE	Discovery agent

DMUHBGC	ID	DMUHBGC
DMUHBGC	DN	H-Tyr-Ala-Phe-Phe-NH2
DMUHBGC	HS	Investigative
DMUHBGC	SN	CHEMBL58178; H-Tyr-Ala-Phe-Phe-NH2; BDBM50308383; NCGC00163200-01
DMUHBGC	DT	Small molecular drug
DMUHBGC	PC	16760005
DMUHBGC	MW	545.6
DMUHBGC	FM	C30H35N5O5
DMUHBGC	IC	InChI=1S/C30H35N5O5/c1-19(33-29(39)24(31)16-22-12-14-23(36)15-13-22)28(38)35-26(18-21-10-6-3-7-11-21)30(40)34-25(27(32)37)17-20-8-4-2-5-9-20/h2-15,19,24-26,36H,16-18,31H2,1H3,(H2,32,37)(H,33,39)(H,34,40)(H,35,38)/t19-,24-,25-,26-/m0/s1
DMUHBGC	CS	C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMUHBGC	IK	MVUYXNQARFGHMJ-UBLBMGLWSA-N
DMUHBGC	IU	(2S)-2-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
DMUHBGC	DE	Discovery agent

DMP8KMV	ID	DMP8KMV
DMP8KMV	DN	H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2
DMP8KMV	HS	Investigative
DMP8KMV	SN	CHEMBL396356; H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2
DMP8KMV	DT	Small molecular drug
DMP8KMV	PC	44439948
DMP8KMV	MW	633.7
DMP8KMV	FM	C26H31N7O8S2
DMP8KMV	IC	InChI=1S/C26H31N7O8S2/c27-18(9-14-3-7-17(34)8-4-14)24(37)32-21-13-43-42-12-20(23(28)36)31-26(39)19(30-22(35)11-29-25(21)38)10-15-1-5-16(6-2-15)33(40)41/h1-8,18-21,34H,9-13,27H2,(H2,28,36)(H,29,38)(H,30,35)(H,31,39)(H,32,37)/t18-,19-,20-,21-/m0/s1
DMP8KMV	CS	C1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N)CC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMP8KMV	IK	NBZQMFLIMSGMAF-TUFLPTIASA-N
DMP8KMV	IU	(4R,7S,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-[(4-nitrophenyl)methyl]-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMP8KMV	DE	Discovery agent

DM48XV0	ID	DM48XV0
DM48XV0	DN	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2
DM48XV0	HS	Investigative
DM48XV0	SN	CHEMBL220219
DM48XV0	DT	Small molecular drug
DM48XV0	PC	16116220
DM48XV0	MW	550.6
DM48XV0	FM	C28H34N6O6
DM48XV0	IC	InChI=1S/C28H34N6O6/c29-20(14-18-10-12-19(35)13-11-18)26(38)34-22-9-5-4-8-21(25(30)37)33-28(40)23(15-17-6-2-1-3-7-17)32-24(36)16-31-27(22)39/h1-7,10-13,20-23,35H,8-9,14-16,29H2,(H2,30,37)(H,31,39)(H,32,36)(H,33,40)(H,34,38)/b5-4+/t20-,21+,22+,23-/m0/s1
DM48XV0	CS	C1/C=C/C[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]1NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CC=CC=C3)C(=O)N
DM48XV0	IK	UYBFKIDGDVZVFM-KLGXLVMCSA-N
DM48XV0	IU	(5S,8R,10E,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxamide
DM48XV0	DE	Discovery agent

DMA2CZL	ID	DMA2CZL
DMA2CZL	DN	H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH
DMA2CZL	HS	Investigative
DMA2CZL	SN	rDADAE (11); CHEMBL229441; BDBM21127; single bond H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH; reduced bond-c[2-D-allylglycine, 5-D-allylglycine]enkephalin; (5S,8R,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradecane-8-carboxylic acid
DMA2CZL	DT	Small molecular drug
DMA2CZL	PC	16733489
DMA2CZL	MW	553.6
DMA2CZL	FM	C28H35N5O7
DMA2CZL	IC	InChI=1S/C28H35N5O7/c29-20(14-18-10-12-19(34)13-11-18)25(36)32-21-8-4-5-9-22(28(39)40)33-27(38)23(15-17-6-2-1-3-7-17)31-24(35)16-30-26(21)37/h1-3,6-7,10-13,20-23,34H,4-5,8-9,14-16,29H2,(H,30,37)(H,31,35)(H,32,36)(H,33,38)(H,39,40)/t20-,21+,22+,23-/m0/s1
DMA2CZL	CS	C1CC[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CC=CC=C3)C(=O)O
DMA2CZL	IK	GDFBPHMKQXUQTN-AFXVXQJMSA-N
DMA2CZL	IU	(5S,8R,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradecane-8-carboxylic acid
DMA2CZL	DE	Discovery agent

DMXPJHB	ID	DMXPJHB
DMXPJHB	DN	H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2
DMXPJHB	HS	Investigative
DMXPJHB	SN	CHEMBL220333
DMXPJHB	DT	Small molecular drug
DMXPJHB	PC	16116088
DMXPJHB	MW	550.6
DMXPJHB	FM	C28H34N6O6
DMXPJHB	IC	InChI=1S/C28H34N6O6/c29-20(14-18-10-12-19(35)13-11-18)26(38)34-22-9-5-4-8-21(25(30)37)33-28(40)23(15-17-6-2-1-3-7-17)32-24(36)16-31-27(22)39/h1-7,10-13,20-23,35H,8-9,14-16,29H2,(H2,30,37)(H,31,39)(H,32,36)(H,33,40)(H,34,38)/b5-4-/t20-,21-,22+,23-/m0/s1
DMXPJHB	CS	C1/C=C\\C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]1NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CC=CC=C3)C(=O)N
DMXPJHB	IK	UYBFKIDGDVZVFM-ODCKOUNNSA-N
DMXPJHB	IU	(5S,8S,10Z,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxamide
DMXPJHB	DE	Discovery agent

DM7QAES	ID	DM7QAES
DM7QAES	DN	H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2
DM7QAES	HS	Investigative
DM7QAES	SN	CHEMBL220327; H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2
DM7QAES	DT	Small molecular drug
DM7QAES	PC	44420667
DM7QAES	MW	588.7
DM7QAES	FM	C26H32N6O6S2
DM7QAES	IC	InChI=1S/C26H32N6O6S2/c27-18(10-16-6-8-17(33)9-7-16)24(36)32-21-14-40-39-13-20(23(28)35)31-26(38)19(11-15-4-2-1-3-5-15)30-22(34)12-29-25(21)37/h1-9,18-21,33H,10-14,27H2,(H2,28,35)(H,29,37)(H,30,34)(H,31,38)(H,32,36)/t18-,19-,20-,21-/m0/s1
DM7QAES	CS	C1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM7QAES	IK	VUVASMYWPNXOGI-TUFLPTIASA-N
DM7QAES	IU	(4R,7S,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DM7QAES	DE	Discovery agent

DMZSTL5	ID	DMZSTL5
DMZSTL5	DN	H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2
DMZSTL5	HS	Investigative
DMZSTL5	SN	CHEMBL373572; H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2
DMZSTL5	DT	Small molecular drug
DMZSTL5	PC	44420674
DMZSTL5	MW	588.7
DMZSTL5	FM	C26H32N6O6S2
DMZSTL5	IC	InChI=1S/C26H32N6O6S2/c27-18(10-16-6-8-17(33)9-7-16)24(36)32-21-14-40-39-13-20(23(28)35)31-26(38)19(11-15-4-2-1-3-5-15)30-22(34)12-29-25(21)37/h1-9,18-21,33H,10-14,27H2,(H2,28,35)(H,29,37)(H,30,34)(H,31,38)(H,32,36)/t18-,19-,20+,21-/m0/s1
DMZSTL5	CS	C1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](CSS1)C(=O)N)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMZSTL5	IK	VUVASMYWPNXOGI-BURNTYAHSA-N
DMZSTL5	IU	(4S,7S,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMZSTL5	DE	Discovery agent

DMI7CR9	ID	DMI7CR9
DMI7CR9	DN	H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2
DMI7CR9	HS	Investigative
DMI7CR9	DT	Small molecular drug
DMI7CR9	PC	15088039
DMI7CR9	MW	578.7
DMI7CR9	FM	C30H38N6O6
DMI7CR9	IC	InChI=1S/C30H38N6O6/c31-22(16-18-7-9-21(37)10-8-18)27(40)34-24-6-3-15-33-25(38)12-11-23(26(32)39)35-29(42)30(36-28(24)41)14-13-19-4-1-2-5-20(19)17-30/h1-2,4-5,7-10,22-24,37H,3,6,11-17,31H2,(H2,32,39)(H,33,38)(H,34,40)(H,35,42)(H,36,41)/t22-,23-,24+,30-/m0/s1
DMI7CR9	CS	C1C[C@H](C(=O)N[C@]2(CCC3=CC=CC=C3C2)C(=O)N[C@@H](CCC(=O)NC1)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMI7CR9	IK	IJZIWUAJVCVWNA-WAHOFHFDSA-N
DMI7CR9	IU	(2S,5S,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3,8,14-trioxospiro[1,4,9-triazacyclotetradecane-2,3'-2,4-dihydro-1H-naphthalene]-5-carboxamide
DMI7CR9	DE	Discovery agent

DMOTI0P	ID	DMOTI0P
DMOTI0P	DN	H-Tyr-c[D-Orn-Aic-Glu]-NH2
DMOTI0P	HS	Investigative
DMOTI0P	SN	CHEMBL106849; H-Tyr-c[D-Orn-Aic-Glu]-NH2
DMOTI0P	DT	Small molecular drug
DMOTI0P	PC	44336496
DMOTI0P	MW	564.6
DMOTI0P	FM	C29H36N6O6
DMOTI0P	IC	InChI=1S/C29H36N6O6/c30-21(14-17-7-9-20(36)10-8-17)26(39)33-23-6-3-13-32-24(37)12-11-22(25(31)38)34-28(41)29(35-27(23)40)15-18-4-1-2-5-19(18)16-29/h1-2,4-5,7-10,21-23,36H,3,6,11-16,30H2,(H2,31,38)(H,32,37)(H,33,39)(H,34,41)(H,35,40)/t21-,22+,23-/m0/s1
DMOTI0P	CS	C1C[C@@H](C(=O)NC2(CC3=CC=CC=C3C2)C(=O)N[C@H](CCC(=O)NC1)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMOTI0P	IK	YFKXNEKIMXIPLT-ZRBLBEILSA-N
DMOTI0P	IU	(5'R,13'S)-13'-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3',8',14'-trioxospiro[1,3-dihydroindene-2,2'-1,4,9-triazacyclotetradecane]-5'-carboxamide
DMOTI0P	DE	Discovery agent

DMAKPM1	ID	DMAKPM1
DMAKPM1	DN	H-Tyr-c[pen-Gly-Phe-pen]OH
DMAKPM1	HS	Investigative
DMAKPM1	SN	H-Tyr-c[pen-Gly-Phe-pen]OH; CHEMBL396103
DMAKPM1	DT	Small molecular drug
DMAKPM1	PC	44439867
DMAKPM1	MW	645.8
DMAKPM1	FM	C30H39N5O7S2
DMAKPM1	IC	InChI=1S/C30H39N5O7S2/c1-29(2)23(34-25(38)20(31)14-18-10-12-19(36)13-11-18)27(40)32-16-22(37)33-21(15-17-8-6-5-7-9-17)26(39)35-24(28(41)42)30(3,4)44-43-29/h5-13,20-21,23-24,36H,14-16,31H2,1-4H3,(H,32,40)(H,33,37)(H,34,38)(H,35,39)(H,41,42)/t20-,21?,23-,24?/m1/s1
DMAKPM1	CS	CC1([C@@H](C(=O)NCC(=O)NC(C(=O)NC(C(SS1)(C)C)C(=O)O)CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=C(C=C3)O)N)C
DMAKPM1	IK	MCMMCRYPQBNCPH-ZNNNFZKMSA-N
DMAKPM1	IU	(13R)-13-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid
DMAKPM1	DE	Discovery agent

DMN2AQO	ID	DMN2AQO
DMN2AQO	DN	H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2
DMN2AQO	HS	Investigative
DMN2AQO	SN	CHEMBL124941; H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2; BDBM50001459; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid
DMN2AQO	DT	Small molecular drug
DMN2AQO	PC	44348645
DMN2AQO	MW	794.9
DMN2AQO	FM	C39H54N8O10
DMN2AQO	IC	InChI=1S/C39H54N8O10/c1-20(2)31(36(55)42-19-29(41)49)46-37(56)32(21(3)4)45-35(54)28(17-30(50)51)44-38(57)39(15-14-24-8-6-7-9-25(24)18-39)47-33(52)22(5)43-34(53)27(40)16-23-10-12-26(48)13-11-23/h6-13,20-22,27-28,31-32,48H,14-19,40H2,1-5H3,(H2,41,49)(H,42,55)(H,43,53)(H,44,57)(H,45,54)(H,46,56)(H,47,52)(H,50,51)/t22-,27+,28+,31+,32+,39?/m1/s1
DMN2AQO	CS	C[C@H](C(=O)NC1(CCC2=CC=CC=C2C1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMN2AQO	IK	WCJNWJPRBIKFOI-RKPARCAKSA-N
DMN2AQO	IU	(3S)-3-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3,4-dihydro-1H-naphthalene-2-carbonyl]amino]-4-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMN2AQO	DE	Discovery agent

DM6ZHWS	ID	DM6ZHWS
DM6ZHWS	DN	H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2
DM6ZHWS	HS	Investigative
DM6ZHWS	SN	CHEMBL124435; H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2; BDBM50001462; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-indane-2-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid
DM6ZHWS	DT	Small molecular drug
DM6ZHWS	PC	10010455
DM6ZHWS	MW	780.9
DM6ZHWS	FM	C38H52N8O10
DM6ZHWS	IC	InChI=1S/C38H52N8O10/c1-19(2)30(35(54)41-18-28(40)48)45-36(55)31(20(3)4)44-34(53)27(15-29(49)50)43-37(56)38(16-23-8-6-7-9-24(23)17-38)46-32(51)21(5)42-33(52)26(39)14-22-10-12-25(47)13-11-22/h6-13,19-21,26-27,30-31,47H,14-18,39H2,1-5H3,(H2,40,48)(H,41,54)(H,42,52)(H,43,56)(H,44,53)(H,45,55)(H,46,51)(H,49,50)/t21-,26+,27+,30+,31+/m1/s1
DM6ZHWS	CS	C[C@H](C(=O)NC1(CC2=CC=CC=C2C1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM6ZHWS	IK	QZYUFPDOTMWDCQ-UZHHEQFGSA-N
DM6ZHWS	IU	(3S)-3-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-1,3-dihydroindene-2-carbonyl]amino]-4-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM6ZHWS	DE	Discovery agent

DMDF9AS	ID	DMDF9AS
DMDF9AS	DN	H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2
DMDF9AS	HS	Investigative
DMDF9AS	SN	H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2; CHEMBL261390; BDBM21007; C-terminal modified bifunctional peptide, 1; [3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanamido]-3-(1H-indol-3-yl)propanoate
DMDF9AS	PC	24768351
DMDF9AS	MW	1079.1
DMDF9AS	FM	C54H60F6N8O9
DMDF9AS	IC	InChI=1S/C54H60F6N8O9/c1-30(2)20-42(49(73)67-44(25-35-27-62-41-13-8-7-12-39(35)41)52(76)77-29-34-21-36(53(55,56)57)26-37(22-34)54(58,59)60)66-50(74)45-14-9-19-68(45)51(75)43(24-32-10-5-4-6-11-32)65-46(70)28-63-47(71)31(3)64-48(72)40(61)23-33-15-17-38(69)18-16-33/h4-8,10-13,15-18,21-22,26-27,30-31,40,42-45,62,69H,9,14,19-20,23-25,28-29,61H2,1-3H3,(H,63,71)(H,64,72)(H,65,70)(H,66,74)(H,67,73)/t31-,40+,42+,43+,44+,45+/m1/s1
DMDF9AS	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)OCC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DMDF9AS	IK	XHJXRHNUFXHMEV-REAJPLCASA-N
DMDF9AS	IU	[3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoate
DMDF9AS	DE	Discovery agent

DM4VBDW	ID	DM4VBDW
DM4VBDW	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac
DM4VBDW	HS	Investigative
DM4VBDW	SN	CHEMBL408889; H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac
DM4VBDW	PC	44408417
DM4VBDW	MW	1090.2
DM4VBDW	FM	C56H67N9O14
DM4VBDW	IC	InChI=1S/C56H67N9O14/c1-5-6-20-41(52(73)62-45(56(78)79)29-38-32-65(34(3)66)46-21-14-13-19-40(38)46)59-53(74)42(30-49(69)70)60-54(75)47(28-36-17-11-8-12-18-36)64(4)63-43(26-35-15-9-7-10-16-35)51(72)57-31-48(68)58-33(2)50(71)61-44(55(76)77)27-37-22-24-39(67)25-23-37/h7-19,21-25,32-33,41-45,47,63,67H,5-6,20,26-31H2,1-4H3,(H,57,72)(H,58,68)(H,59,74)(H,60,75)(H,61,71)(H,62,73)(H,69,70)(H,76,77)(H,78,79)/t33-,41+,42+,43+,44+,45+,47+/m1/s1
DM4VBDW	CS	CCCC[C@@H](C(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)N(C)N[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DM4VBDW	IK	DZRXMQMULMXHKQ-GDYSDZBQSA-N
DM4VBDW	IU	(3S)-4-[[(2S)-1-[[(1S)-2-(1-acetylindol-3-yl)-1-carboxyethyl]amino]-1-oxohexan-2-yl]amino]-3-[[(2S)-2-[[[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-methylamino]-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DM4VBDW	DE	Discovery agent

DM0J8P6	ID	DM0J8P6
DM0J8P6	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H
DM0J8P6	HS	Investigative
DM0J8P6	SN	CHEMBL375359; H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H
DM0J8P6	PC	16100411
DM0J8P6	MW	1032.099
DM0J8P6	FM	C53H65N11O11
DM0J8P6	IC	InChI=1S/C53H65N11O11/c1-3-4-18-41(60-49(71)39(55)28-36-27-35-17-11-12-19-40(35)58-36)50(72)62-44(29-46(67)68)51(73)61-43(26-33-15-9-6-10-16-33)53(75)64-63-52(74)42(25-32-13-7-5-8-14-32)59-45(66)30-56-47(69)31(2)57-48(70)38(54)24-34-20-22-37(65)23-21-34/h5-17,19-23,27,31,38-39,41-44,58,65H,3-4,18,24-26,28-30,54-55H2,1-2H3,(H,56,69)(H,57,70)(H,59,66)(H,60,71)(H,61,73)(H,62,72)(H,63,74)(H,64,75)(H,67,68)/t31-,38+,39+,41-,42+,43-,44-/m1/s1
DM0J8P6	CS	CCCC[C@H](C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)NNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)NC(=O)[C@H](CC4=CC5=CC=CC=C5N4)N
DM0J8P6	IK	NXHWDEQNHXTHJU-KDWYPSCJSA-N
DM0J8P6	IU	(3R)-4-[[(2R)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(1H-indol-2-yl)propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid
DM0J8P6	DE	Discovery agent

DMW50ZQ	ID	DMW50ZQ
DMW50ZQ	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo
DMW50ZQ	HS	Investigative
DMW50ZQ	SN	CHEMBL217957; H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo
DMW50ZQ	PC	16100407
DMW50ZQ	MW	1132.3
DMW50ZQ	FM	C58H73N11O13
DMW50ZQ	IC	InChI=1S/C58H73N11O13/c1-6-7-21-43(64-54(78)47(32-49(72)73)66-53(77)44(28-35-16-10-8-11-17-35)67-57(81)82-58(3,4)5)52(76)65-46(31-39-30-38-20-14-15-22-42(38)62-39)56(80)69-68-55(79)45(29-36-18-12-9-13-19-36)63-48(71)33-60-50(74)34(2)61-51(75)41(59)27-37-23-25-40(70)26-24-37/h8-20,22-26,30,34,41,43-47,62,70H,6-7,21,27-29,31-33,59H2,1-5H3,(H,60,74)(H,61,75)(H,63,71)(H,64,78)(H,65,76)(H,66,77)(H,67,81)(H,68,79)(H,69,80)(H,72,73)/t34-,41+,43+,44+,45+,46-,47+/m1/s1
DMW50ZQ	CS	CCCC[C@@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2N1)C(=O)NNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)OC(C)(C)C
DMW50ZQ	IK	FEOAQCGOOODCEB-RXFVQNAMSA-N
DMW50ZQ	IU	(3S)-4-[[(2S)-1-[[(2R)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-3-(1H-indol-2-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMW50ZQ	DE	Discovery agent

DMF82C1	ID	DMF82C1
DMF82C1	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H
DMF82C1	HS	Investigative
DMF82C1	SN	CHEMBL386212; H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H
DMF82C1	PC	16100410
DMF82C1	MW	1032.099
DMF82C1	FM	C53H65N11O11
DMF82C1	IC	InChI=1S/C53H65N11O11/c1-3-4-18-41(60-51(73)44(29-46(67)68)61-49(71)39(55)24-32-13-7-5-8-14-32)50(72)62-43(28-36-27-35-17-11-12-19-40(35)58-36)53(75)64-63-52(74)42(26-33-15-9-6-10-16-33)59-45(66)30-56-47(69)31(2)57-48(70)38(54)25-34-20-22-37(65)23-21-34/h5-17,19-23,27,31,38-39,41-44,58,65H,3-4,18,24-26,28-30,54-55H2,1-2H3,(H,56,69)(H,57,70)(H,59,66)(H,60,73)(H,61,71)(H,62,72)(H,63,74)(H,64,75)(H,67,68)/t31-,38+,39+,41+,42+,43-,44+/m1/s1
DMF82C1	CS	CCCC[C@@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2N1)C(=O)NNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)N
DMF82C1	IK	KYWMQIRORZGHDH-QOIWPSRPSA-N
DMF82C1	IU	(3S)-4-[[(2S)-1-[[(2R)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-3-(1H-indol-2-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-[[(2S)-2-amino-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMF82C1	DE	Discovery agent

DM6UWKL	ID	DM6UWKL
DM6UWKL	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc
DM6UWKL	HS	Investigative
DM6UWKL	SN	CHEMBL413644; H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc
DM6UWKL	PC	44408590
DM6UWKL	MW	1134.2
DM6UWKL	FM	C58H71N9O15
DM6UWKL	IC	InChI=1S/C58H71N9O15/c1-6-7-21-41(52(74)64-46(56(79)80)30-38-33-67(57(81)82-58(3,4)5)47-22-15-14-20-40(38)47)61-53(75)42(31-49(70)71)62-54(76)44(28-36-18-12-9-13-19-36)66-65-43(27-35-16-10-8-11-17-35)51(73)59-32-48(69)60-34(2)50(72)63-45(55(77)78)29-37-23-25-39(68)26-24-37/h8-20,22-26,33-34,41-46,65-66,68H,6-7,21,27-32H2,1-5H3,(H,59,73)(H,60,69)(H,61,75)(H,62,76)(H,63,72)(H,64,74)(H,70,71)(H,77,78)(H,79,80)/t34-,41+,42+,43+,44+,45+,46-/m1/s1
DM6UWKL	CS	CCCC[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C(=O)OC(C)(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NN[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DM6UWKL	IK	IYNMVGGOTRCWGJ-KSEFKAEUSA-N
DM6UWKL	IU	(3S)-3-[[(2S)-2-[2-[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]hydrazinyl]-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(1R)-1-carboxy-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]ethyl]amino]-1-oxohexan-2-yl]amino]-4-oxobutanoic acid
DM6UWKL	DE	Discovery agent

DMSXD63	ID	DMSXD63
DMSXD63	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H
DMSXD63	HS	Investigative
DMSXD63	SN	CHEMBL375412; H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H
DMSXD63	PC	44408484
DMSXD63	MW	1034.099
DMSXD63	FM	C53H63N9O13
DMSXD63	IC	InChI=1S/C53H63N9O13/c1-3-4-18-39(49(69)60-44(53(74)75)27-35-29-54-38-19-12-11-17-37(35)38)57-50(70)40(28-46(65)66)58-51(71)42(25-33-15-9-6-10-16-33)62-61-41(24-32-13-7-5-8-14-32)48(68)55-30-45(64)56-31(2)47(67)59-43(52(72)73)26-34-20-22-36(63)23-21-34/h5-17,19-23,29,31,39-44,54,61-63H,3-4,18,24-28,30H2,1-2H3,(H,55,68)(H,56,64)(H,57,70)(H,58,71)(H,59,67)(H,60,69)(H,65,66)(H,72,73)(H,74,75)/t31-,39+,40+,41+,42+,43+,44-/m1/s1
DMSXD63	CS	CCCC[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NN[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DMSXD63	IK	LHFDBKUCTFELLO-WMRIFXDUSA-N
DMSXD63	IU	(3S)-3-[[(2S)-2-[2-[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]hydrazinyl]-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(1R)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-1-oxohexan-2-yl]amino]-4-oxobutanoic acid
DMSXD63	DE	Discovery agent

DMRUD37	ID	DMRUD37
DMRUD37	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac
DMRUD37	HS	Investigative
DMRUD37	SN	CHEMBL442483; H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac
DMRUD37	PC	44408525
DMRUD37	MW	1076.2
DMRUD37	FM	C55H65N9O14
DMRUD37	IC	InChI=1S/C55H65N9O14/c1-4-5-19-40(51(72)61-45(55(77)78)28-37-31-64(33(3)65)46-20-13-12-18-39(37)46)58-52(73)41(29-48(68)69)59-53(74)43(26-35-16-10-7-11-17-35)63-62-42(25-34-14-8-6-9-15-34)50(71)56-30-47(67)57-32(2)49(70)60-44(54(75)76)27-36-21-23-38(66)24-22-36/h6-18,20-24,31-32,40-45,62-63,66H,4-5,19,25-30H2,1-3H3,(H,56,71)(H,57,67)(H,58,73)(H,59,74)(H,60,70)(H,61,72)(H,68,69)(H,75,76)(H,77,78)/t32-,40+,41+,42+,43+,44+,45+/m1/s1
DMRUD37	CS	CCCC[C@@H](C(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NN[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DMRUD37	IK	RBNPCZIQGBMFDV-FPWNPRTMSA-N
DMRUD37	IU	(3S)-4-[[(2S)-1-[[(1S)-2-(1-acetylindol-3-yl)-1-carboxyethyl]amino]-1-oxohexan-2-yl]amino]-3-[[(2S)-2-[2-[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]hydrazinyl]-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMRUD37	DE	Discovery agent

DMIPXCZ	ID	DMIPXCZ
DMIPXCZ	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc
DMIPXCZ	HS	Investigative
DMIPXCZ	SN	CHEMBL405192; H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc
DMIPXCZ	PC	44408524
DMIPXCZ	MW	1134.2
DMIPXCZ	FM	C58H71N9O15
DMIPXCZ	IC	InChI=1S/C58H71N9O15/c1-6-7-21-41(52(74)64-46(56(79)80)30-38-33-67(57(81)82-58(3,4)5)47-22-15-14-20-40(38)47)61-53(75)42(31-49(70)71)62-54(76)44(28-36-18-12-9-13-19-36)66-65-43(27-35-16-10-8-11-17-35)51(73)59-32-48(69)60-34(2)50(72)63-45(55(77)78)29-37-23-25-39(68)26-24-37/h8-20,22-26,33-34,41-46,65-66,68H,6-7,21,27-32H2,1-5H3,(H,59,73)(H,60,69)(H,61,75)(H,62,76)(H,63,72)(H,64,74)(H,70,71)(H,77,78)(H,79,80)/t34-,41+,42+,43+,44+,45+,46+/m1/s1
DMIPXCZ	CS	CCCC[C@@H](C(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)OC(C)(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NN[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DMIPXCZ	IK	IYNMVGGOTRCWGJ-CHAGIDMDSA-N
DMIPXCZ	IU	(3S)-3-[[(2S)-2-[2-[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]hydrazinyl]-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]ethyl]amino]-1-oxohexan-2-yl]amino]-4-oxobutanoic acid
DMIPXCZ	DE	Discovery agent

DMFSKDM	ID	DMFSKDM
DMFSKDM	DN	H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H
DMFSKDM	HS	Investigative
DMFSKDM	SN	CHEMBL218651; H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H
DMFSKDM	PC	16100409
DMFSKDM	MW	1032.099
DMFSKDM	FM	C53H65N11O11
DMFSKDM	IC	InChI=1S/C53H65N11O11/c1-3-4-18-41(60-51(73)44(29-46(67)68)61-49(71)39(55)24-32-13-7-5-8-14-32)50(72)62-43(28-36-27-35-17-11-12-19-40(35)58-36)53(75)64-63-52(74)42(26-33-15-9-6-10-16-33)59-45(66)30-56-47(69)31(2)57-48(70)38(54)25-34-20-22-37(65)23-21-34/h5-17,19-23,27,31,38-39,41-44,58,65H,3-4,18,24-26,28-30,54-55H2,1-2H3,(H,56,69)(H,57,70)(H,59,66)(H,60,73)(H,61,71)(H,62,72)(H,63,74)(H,64,75)(H,67,68)/t31-,38+,39-,41-,42+,43+,44-/m1/s1
DMFSKDM	CS	CCCC[C@H](C(=O)N[C@@H](CC1=CC2=CC=CC=C2N1)C(=O)NNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC5=CC=CC=C5)N
DMFSKDM	IK	KYWMQIRORZGHDH-KKSWQRHZSA-N
DMFSKDM	IU	(3R)-4-[[(2R)-1-[[(2S)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-3-(1H-indol-2-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-[[(2R)-2-amino-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMFSKDM	DE	Discovery agent

DM2K16M	ID	DM2K16M
DM2K16M	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2
DM2K16M	HS	Investigative
DM2K16M	SN	CHEMBL438389; H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2; BDBM21012; C-terminal modified bifunctional peptide, 5
DM2K16M	PC	24768355
DM2K16M	MW	1078.1
DM2K16M	FM	C54H61F6N9O8
DM2K16M	IC	InChI=1S/C54H61F6N9O8/c1-30(2)20-42(50(75)67-43(25-35-28-62-41-13-8-7-12-39(35)41)49(74)63-27-34-21-36(53(55,56)57)26-37(22-34)54(58,59)60)68-51(76)45-14-9-19-69(45)52(77)44(24-32-10-5-4-6-11-32)66-46(71)29-64-47(72)31(3)65-48(73)40(61)23-33-15-17-38(70)18-16-33/h4-8,10-13,15-18,21-22,26,28,30-31,40,42-45,62,70H,9,14,19-20,23-25,27,29,61H2,1-3H3,(H,63,74)(H,64,72)(H,65,73)(H,66,71)(H,67,75)(H,68,76)/t31-,40+,42+,43+,44+,45+/m1/s1
DM2K16M	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DM2K16M	IK	LWOMHJBSXPGKKS-REAJPLCASA-N
DM2K16M	IU	(2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-N-[(2S)-1-[[(2S)-1-[[3,5-bis(trifluoromethyl)phenyl]methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DM2K16M	DE	Discovery agent

DMRE4ZI	ID	DMRE4ZI
DMRE4ZI	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl
DMRE4ZI	HS	Investigative
DMRE4ZI	SN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl; CHEMBL271619; BDBM21010; C-terminal modified bifunctional peptide, 3
DMRE4ZI	DT	Small molecular drug
DMRE4ZI	PC	24768353
DMRE4ZI	MW	942.1
DMRE4ZI	FM	C52H63N9O8
DMRE4ZI	IC	InChI=1S/C52H63N9O8/c1-32(2)25-42(50(67)59-43(49(66)55-29-36-15-8-5-9-16-36)28-37-30-54-41-18-11-10-17-39(37)41)60-51(68)45-19-12-24-61(45)52(69)44(27-34-13-6-4-7-14-34)58-46(63)31-56-47(64)33(3)57-48(65)40(53)26-35-20-22-38(62)23-21-35/h4-11,13-18,20-23,30,32-33,40,42-45,54,62H,12,19,24-29,31,53H2,1-3H3,(H,55,66)(H,56,64)(H,57,65)(H,58,63)(H,59,67)(H,60,68)/t33-,40+,42+,43+,44+,45+/m1/s1
DMRE4ZI	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DMRE4ZI	IK	VXHMITAKWYIILS-FDXPNMITSA-N
DMRE4ZI	IU	(2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-N-[(2S)-1-[[(2S)-1-(benzylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMRE4ZI	DE	Discovery agent

DM1ESMZ	ID	DM1ESMZ
DM1ESMZ	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2
DM1ESMZ	HS	Investigative
DM1ESMZ	SN	CHEMBL406030; H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2; BDBM21013; C-terminal modified bifunctional peptide, 6
DM1ESMZ	PC	24768356
DM1ESMZ	MW	1092.1
DM1ESMZ	FM	C55H63F6N9O8
DM1ESMZ	IC	InChI=1S/C55H63F6N9O8/c1-31(2)21-43(50(75)68-45(26-36-28-63-42-14-9-8-13-40(36)42)52(77)69(4)30-35-22-37(54(56,57)58)27-38(23-35)55(59,60)61)67-51(76)46-15-10-20-70(46)53(78)44(25-33-11-6-5-7-12-33)66-47(72)29-64-48(73)32(3)65-49(74)41(62)24-34-16-18-39(71)19-17-34/h5-9,11-14,16-19,22-23,27-28,31-32,41,43-46,63,71H,10,15,20-21,24-26,29-30,62H2,1-4H3,(H,64,73)(H,65,74)(H,66,72)(H,67,76)(H,68,75)/t32-,41+,43+,44+,45+,46+/m1/s1
DM1ESMZ	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N(C)CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DM1ESMZ	IK	IRIFESWSRQBRPW-CKWXOEDFSA-N
DM1ESMZ	IU	(2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-N-[(2S)-1-[[(2S)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl-methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DM1ESMZ	DE	Discovery agent

DM56KDV	ID	DM56KDV
DM56KDV	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl
DM56KDV	HS	Investigative
DM56KDV	SN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl; CHEMBL272665; BDBM21011; C-terminal modified bifunctional peptide, 4
DM56KDV	DT	Small molecular drug
DM56KDV	PC	24768354
DM56KDV	MW	956.1
DM56KDV	FM	C53H65N9O8
DM56KDV	IC	InChI=1S/C53H65N9O8/c1-33(2)26-43(50(67)60-45(29-38-30-55-42-19-12-11-18-40(38)42)52(69)61(4)32-37-16-9-6-10-17-37)59-51(68)46-20-13-25-62(46)53(70)44(28-35-14-7-5-8-15-35)58-47(64)31-56-48(65)34(3)57-49(66)41(54)27-36-21-23-39(63)24-22-36/h5-12,14-19,21-24,30,33-34,41,43-46,55,63H,13,20,25-29,31-32,54H2,1-4H3,(H,56,65)(H,57,66)(H,58,64)(H,59,68)(H,60,67)/t34-,41+,43+,44+,45+,46+/m1/s1
DM56KDV	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N(C)CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DM56KDV	IK	GYOWORZEZSLHIN-NATPVWCTSA-N
DM56KDV	IU	(2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-N-[(2S)-1-[[(2S)-1-[benzyl(methyl)amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DM56KDV	DE	Discovery agent

DMH3YKR	ID	DMH3YKR
DMH3YKR	DN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl
DMH3YKR	HS	Investigative
DMH3YKR	SN	H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl; CHEMBL261608; BDBM21009; C-terminal modified bifunctional peptide, 2; benzyl (2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanamido]-3-(1H-indol-3-yl)propanoate
DMH3YKR	DT	Small molecular drug
DMH3YKR	PC	24768352
DMH3YKR	MW	943.1
DMH3YKR	FM	C52H62N8O9
DMH3YKR	IC	InChI=1S/C52H62N8O9/c1-32(2)25-42(49(65)59-44(52(68)69-31-36-15-8-5-9-16-36)28-37-29-54-41-18-11-10-17-39(37)41)58-50(66)45-19-12-24-60(45)51(67)43(27-34-13-6-4-7-14-34)57-46(62)30-55-47(63)33(3)56-48(64)40(53)26-35-20-22-38(61)23-21-35/h4-11,13-18,20-23,29,32-33,40,42-45,54,61H,12,19,24-28,30-31,53H2,1-3H3,(H,55,63)(H,56,64)(H,57,62)(H,58,66)(H,59,65)/t33-,40+,42+,43+,44+,45+/m1/s1
DMH3YKR	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)OCC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DMH3YKR	IK	AWLKNBWKVMBAKT-FDXPNMITSA-N
DMH3YKR	IU	benzyl (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoate
DMH3YKR	DE	Discovery agent

DMSX8CH	ID	DMSX8CH
DMSX8CH	DN	H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2
DMSX8CH	HS	Investigative
DMSX8CH	SN	CHEMBL330991; H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2; BDBM50001460; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionyl}-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid
DMSX8CH	DT	Small molecular drug
DMSX8CH	PC	10485385
DMSX8CH	MW	780.9
DMSX8CH	FM	C38H52N8O10
DMSX8CH	IC	InChI=1S/C38H52N8O10/c1-19(2)31(36(54)41-17-29(40)48)45-37(55)32(20(3)4)44-34(52)27(16-30(49)50)43-35(53)28-15-23-8-6-7-9-24(23)18-46(28)38(56)21(5)42-33(51)26(39)14-22-10-12-25(47)13-11-22/h6-13,19-21,26-28,31-32,47H,14-18,39H2,1-5H3,(H2,40,48)(H,41,54)(H,42,51)(H,43,53)(H,44,52)(H,45,55)(H,49,50)/t21-,26+,27+,28+,31+,32+/m1/s1
DMSX8CH	CS	C[C@H](C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMSX8CH	IK	JOXXADDFFWZHEE-JMZWVCJUSA-N
DMSX8CH	IU	(3S)-3-[[(3S)-2-[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMSX8CH	DE	Discovery agent

DM25KZE	ID	DM25KZE
DM25KZE	DN	HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2
DM25KZE	HS	Investigative
DM25KZE	SN	CHEMBL216640; Dynorphin A (1-11) amide; Dynorphin A(1-11) amide; HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2; 79985-48-1; Dyn A(1-11)-NH2; Linear Dyn A-(1-11)NH2; BDBM50010704; BDBM50033143; H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-NH2; Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-D-Lys-NH2; TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE-ARG-PRO-LYS-LEU-LYS-TRP-ASP-ASN-GLN-NH2
DM25KZE	PC	10677974
DM25KZE	MW	1361.6
DM25KZE	FM	C63H104N22O12
DM25KZE	IC	InChI=1S/C63H104N22O12/c1-5-37(4)51(59(96)82-45(20-13-29-75-63(71)72)60(97)85-30-14-21-48(85)58(95)79-42(52(66)89)17-9-10-26-64)84-55(92)44(19-12-28-74-62(69)70)80-54(91)43(18-11-27-73-61(67)68)81-56(93)46(31-36(2)3)83-57(94)47(33-38-15-7-6-8-16-38)78-50(88)35-76-49(87)34-77-53(90)41(65)32-39-22-24-40(86)25-23-39/h6-8,15-16,22-25,36-37,41-48,51,86H,5,9-14,17-21,26-35,64-65H2,1-4H3,(H2,66,89)(H,76,87)(H,77,90)(H,78,88)(H,79,95)(H,80,91)(H,81,93)(H,82,96)(H,83,94)(H,84,92)(H4,67,68,73)(H4,69,70,74)(H4,71,72,75)/t37-,41-,42-,43-,44-,45-,46-,47-,48-,51-/m0/s1
DM25KZE	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM25KZE	IK	OKJAOUBQLSWUNX-QFIUEGLPSA-N
DM25KZE	IU	(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2S)-1,6-diamino-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
DM25KZE	DE	Discovery agent

DM6D0ZS	ID	DM6D0ZS
DM6D0ZS	DN	H-Tyr-Gly-Gly-Phe-Met-NH2
DM6D0ZS	HS	Investigative
DM6D0ZS	SN	H-Tyr-Gly-Gly-Phe-Met-NH2; [Met5]-Enkephalin Amide; [Met5]-Enkephalin, amide; CHEMBL247368; 60117-17-1; Tyr-Gly-Gly-Phe-Met-NH2; Met-enkephalinamide; L-Methioninamide, L-tyrosylglycylglycyl-L-phenylalanyl-; Enkephalinamide-met-; Methionine enkephalinamide; AC1L3X5D; CTK2F3118; HY-P1467; ZINC28893234; BDBM50207823; AKOS030610304; CS-0044396; A833448; (2S)-2-[[(2S)-2-[2-[2-[[(2S)-2-azanyl-3-(4-hydroxyphenyl)propanoyl]amino]ethanoylamino]ethanoylamino]-3-phenyl-propanoyl]amino]-4-methylsulfanyl-butanamide
DM6D0ZS	DT	Small molecular drug
DM6D0ZS	PC	123704
DM6D0ZS	MW	572.7
DM6D0ZS	FM	C27H36N6O6S
DM6D0ZS	IC	InChI=1S/C27H36N6O6S/c1-40-12-11-21(25(29)37)33-27(39)22(14-17-5-3-2-4-6-17)32-24(36)16-30-23(35)15-31-26(38)20(28)13-18-7-9-19(34)10-8-18/h2-10,20-22,34H,11-16,28H2,1H3,(H2,29,37)(H,30,35)(H,31,38)(H,32,36)(H,33,39)/t20-,21-,22-/m0/s1
DM6D0ZS	CS	CSCC[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
DM6D0ZS	IK	HBDDEVHKKBWEQT-FKBYEOEOSA-N
DM6D0ZS	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide
DM6D0ZS	CA	CAS 60117-17-1
DM6D0ZS	DE	Discovery agent

DM1NT5G	ID	DM1NT5G
DM1NT5G	DN	H-Tyr-NMe-D-Ala-Phe-Sar-NH2
DM1NT5G	HS	Investigative
DM1NT5G	SN	CHEMBL260120
DM1NT5G	DT	Small molecular drug
DM1NT5G	PC	24853671
DM1NT5G	MW	483.6
DM1NT5G	FM	C25H33N5O5
DM1NT5G	IC	InChI=1S/C25H33N5O5/c1-16(30(3)24(34)20(26)13-18-9-11-19(31)12-10-18)23(33)28-21(14-17-7-5-4-6-8-17)25(35)29(2)15-22(27)32/h4-12,16,20-21,31H,13-15,26H2,1-3H3,(H2,27,32)(H,28,33)/t16-,20+,21+/m1/s1
DM1NT5G	CS	C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N(C)CC(=O)N)N(C)C(=O)[C@H](CC2=CC=C(C=C2)O)N
DM1NT5G	IK	GRHNSLXBGRDMSP-CZAAIQMYSA-N
DM1NT5G	IU	(2S)-2-amino-N-[(2R)-1-[[(2S)-1-[(2-amino-2-oxoethyl)-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)-N-methylpropanamide
DM1NT5G	DE	Discovery agent

DMP0CRD	ID	DMP0CRD
DMP0CRD	DN	H-Tyr-Pro-Ala-Phe-NH2
DMP0CRD	HS	Investigative
DMP0CRD	SN	YPAF-NH2
DMP0CRD	PC	44428865
DMP0CRD	MW	495.6
DMP0CRD	FM	C26H33N5O5
DMP0CRD	IC	InChI=1S/C26H33N5O5/c1-16(24(34)30-21(23(28)33)15-17-6-3-2-4-7-17)29-25(35)22-8-5-13-31(22)26(36)20(27)14-18-9-11-19(32)12-10-18/h2-4,6-7,9-12,16,20-22,32H,5,8,13-15,27H2,1H3,(H2,28,33)(H,29,35)(H,30,34)/t16-,20-,21-,22-/m0/s1
DMP0CRD	CS	C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)N
DMP0CRD	IK	RZZXLHCBXYDTOF-KPQYALRZSA-N
DMP0CRD	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMP0CRD	DE	Discovery agent

DMQUNGC	ID	DMQUNGC
DMQUNGC	DN	H-Tyr-Pro-Dap(6DMN)-Phe-NH2
DMQUNGC	HS	Investigative
DMQUNGC	SN	CHEMBL207661; H-Tyr-Pro-Dap(6DMN)-Phe-NH2
DMQUNGC	DT	Small molecular drug
DMQUNGC	PC	44412206
DMQUNGC	MW	733.8
DMQUNGC	FM	C40H43N7O7
DMQUNGC	IC	InChI=1S/C40H43N7O7/c1-45(2)27-13-12-25-20-29-30(21-26(25)19-27)39(53)47(38(29)52)22-33(36(50)43-32(35(42)49)18-23-7-4-3-5-8-23)44-37(51)34-9-6-16-46(34)40(54)31(41)17-24-10-14-28(48)15-11-24/h3-5,7-8,10-15,19-21,31-34,48H,6,9,16-18,22,41H2,1-2H3,(H2,42,49)(H,43,50)(H,44,51)/t31-,32-,33?,34-/m0/s1
DMQUNGC	CS	CN(C)C1=CC2=CC3=C(C=C2C=C1)C(=O)N(C3=O)CC(C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC6=CC=C(C=C6)O)N
DMQUNGC	IK	OHGKVUSMHZDAKH-SHROADRVSA-N
DMQUNGC	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[6-(dimethylamino)-1,3-dioxobenzo[f]isoindol-2-yl]-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMQUNGC	DE	Discovery agent

DM2F6L9	ID	DM2F6L9
DM2F6L9	DN	H-Tyr-Pro-Phe-Ala-NH2
DM2F6L9	HS	Investigative
DM2F6L9	SN	CHEMBL388265; H-Tyr-Pro-Phe-Ala-NH2; BDBM50209300
DM2F6L9	DT	Small molecular drug
DM2F6L9	PC	44428877
DM2F6L9	MW	495.6
DM2F6L9	FM	C26H33N5O5
DM2F6L9	IC	InChI=1S/C26H33N5O5/c1-16(23(28)33)29-24(34)21(15-17-6-3-2-4-7-17)30-25(35)22-8-5-13-31(22)26(36)20(27)14-18-9-11-19(32)12-10-18/h2-4,6-7,9-12,16,20-22,32H,5,8,13-15,27H2,1H3,(H2,28,33)(H,29,34)(H,30,35)/t16-,20-,21-,22-/m0/s1
DM2F6L9	CS	C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)N
DM2F6L9	IK	WNYNLZIGNIJEJM-KPQYALRZSA-N
DM2F6L9	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM2F6L9	DE	Discovery agent

DM326GJ	ID	DM326GJ
DM326GJ	DN	H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2
DM326GJ	HS	Investigative
DM326GJ	SN	CHEMBL411335; H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2
DM326GJ	DT	Small molecular drug
DM326GJ	PC	44412234
DM326GJ	MW	994.1
DM326GJ	FM	C55H63N9O9
DM326GJ	IC	InChI=1S/C55H63N9O9/c1-62(2)39-22-21-37-31-41-42(32-38(37)30-39)54(72)64(53(41)71)33-46(49(57)67)59-48(66)18-10-5-11-25-58-50(68)44(28-34-13-6-3-7-14-34)60-51(69)45(29-35-15-8-4-9-16-35)61-52(70)47-17-12-26-63(47)55(73)43(56)27-36-19-23-40(65)24-20-36/h3-4,6-9,13-16,19-24,30-32,43-47,65H,5,10-12,17-18,25-29,33,56H2,1-2H3,(H2,57,67)(H,58,68)(H,59,66)(H,60,69)(H,61,70)/t43-,44-,45-,46?,47-/m0/s1
DM326GJ	CS	CN(C)C1=CC2=CC3=C(C=C2C=C1)C(=O)N(C3=O)CC(C(=O)N)NC(=O)CCCCCNC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CC7=CC=C(C=C7)O)N
DM326GJ	IK	FATMKOSWYXDNJL-FCTRPSMQSA-N
DM326GJ	IU	(2S)-N-[(2S)-1-[[(2S)-1-[[6-[[1-amino-3-[6-(dimethylamino)-1,3-dioxobenzo[f]isoindol-2-yl]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DM326GJ	DE	Discovery agent

DMXQUKJ	ID	DMXQUKJ
DMXQUKJ	DN	H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H
DMXQUKJ	HS	Investigative
DMXQUKJ	SN	CHEMBL392469; H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H
DMXQUKJ	DT	Small molecular drug
DMXQUKJ	PC	44436371
DMXQUKJ	MW	965.1
DMXQUKJ	FM	C55H64N8O8
DMXQUKJ	IC	InChI=1S/C55H64N8O8/c1-34-26-42(65)27-35(2)43(34)32-45(57)55(71)63-33-40-17-10-9-16-39(40)31-49(63)52(68)59-24-23-58-50(66)46(29-36-12-5-3-6-13-36)60-51(67)47(30-37-14-7-4-8-15-37)61-53(69)48-18-11-25-62(48)54(70)44(56)28-38-19-21-41(64)22-20-38/h3-10,12-17,19-22,26-27,44-49,64-65H,11,18,23-25,28-33,56-57H2,1-2H3,(H,58,66)(H,59,68)(H,60,67)(H,61,69)/t44-,45-,46-,47-,48-,49?/m0/s1
DMXQUKJ	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCNC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CC7=CC=C(C=C7)O)N)N)C)O
DMXQUKJ	IK	CJBITXMCHBQEBZ-PGXNEIGQSA-N
DMXQUKJ	IU	2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]ethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMXQUKJ	DE	Discovery agent

DMUQLRN	ID	DMUQLRN
DMUQLRN	DN	H-Tyr-Pro-Phe-Phe-OH
DMUQLRN	HS	Investigative
DMUQLRN	SN	CHEMBL589982; 213768-49-1; H-Tyr-Pro-Phe-Phe-OH; CTK0J7647; DTXSID40649492; BDBM50308384; AKOS030610604; L-Tyrosyl-L-prolyl-L-phenylalanyl-L-phenylalanine; L-Phenylalanine, L-tyrosyl-L-prolyl-L-phenylalanyl-
DMUQLRN	DT	Small molecular drug
DMUQLRN	PC	25254709
DMUQLRN	MW	572.7
DMUQLRN	FM	C32H36N4O6
DMUQLRN	IC	InChI=1S/C32H36N4O6/c33-25(18-23-13-15-24(37)16-14-23)31(40)36-17-7-12-28(36)30(39)34-26(19-21-8-3-1-4-9-21)29(38)35-27(32(41)42)20-22-10-5-2-6-11-22/h1-6,8-11,13-16,25-28,37H,7,12,17-20,33H2,(H,34,39)(H,35,38)(H,41,42)/t25-,26-,27-,28-/m0/s1
DMUQLRN	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O
DMUQLRN	IK	SDJCVHZDMZOUDX-LJWNLINESA-N
DMUQLRN	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
DMUQLRN	CA	CAS 213768-49-1
DMUQLRN	DE	Discovery agent

DM1VFLG	ID	DM1VFLG
DM1VFLG	DN	H-Tyr-Tic-Cha-Phe-OH
DM1VFLG	HS	Investigative
DM1VFLG	SN	H-Tyr-Tic-Cha-Phe-OH; CHEMBL197937
DM1VFLG	DT	Small molecular drug
DM1VFLG	PC	9809581
DM1VFLG	MW	640.8
DM1VFLG	FM	C37H44N4O6
DM1VFLG	IC	InChI=1S/C37H44N4O6/c38-30(19-26-15-17-29(42)18-16-26)36(45)41-23-28-14-8-7-13-27(28)22-33(41)35(44)39-31(20-24-9-3-1-4-10-24)34(43)40-32(37(46)47)21-25-11-5-2-6-12-25/h2,5-8,11-18,24,30-33,42H,1,3-4,9-10,19-23,38H2,(H,39,44)(H,40,43)(H,46,47)/t30-,31-,32-,33?/m0/s1
DM1VFLG	CS	C1CCC(CC1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)C3CC4=CC=CC=C4CN3C(=O)[C@H](CC5=CC=C(C=C5)O)N
DM1VFLG	IK	AFTOYBSNHFSKRV-KSTJSZMBSA-N
DM1VFLG	IU	(2S)-2-[[(2S)-2-[[2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylpropanoyl]amino]-3-phenylpropanoic acid
DM1VFLG	DE	Discovery agent

DMIU52O	ID	DMIU52O
DMIU52O	DN	H-Tyr-Tic-OH
DMIU52O	HS	Investigative
DMIU52O	SN	CHEMBL485576; ZINC13765438; BDBM50060080; 2-({2-[(R)-2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl}-amino)-propionic acid
DMIU52O	DT	Small molecular drug
DMIU52O	PC	44588783
DMIU52O	MW	340.4
DMIU52O	FM	C19H20N2O4
DMIU52O	IC	InChI=1S/C19H20N2O4/c20-16(9-12-5-7-15(22)8-6-12)18(23)21-11-14-4-2-1-3-13(14)10-17(21)19(24)25/h1-8,16-17,22H,9-11,20H2,(H,24,25)/t16-,17-/m0/s1
DMIU52O	CS	C1[C@H](N(CC2=CC=CC=C21)C(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O
DMIU52O	IK	VUOZTGVYOFFWCN-IRXDYDNUSA-N
DMIU52O	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMIU52O	DE	Discovery agent

DMI0U87	ID	DMI0U87
DMI0U87	DN	H-Tyr-Tic-Phe-Phe-OH
DMI0U87	HS	Investigative
DMI0U87	SN	Tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine; TIPP; 146369-65-5; Tyr-tic-phe-phe-OH; CHEMBL191751; tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine; L-Phenylalanine, L-tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-phenylalanyl-; Tyr-Tic-Phe-PheOH; AC1LD8RR; TIPP (opioid antagonist); DTXSID60163362; ZINC3942635; BDBM50068664; tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl- phenylalanyl-phenylalanine; L-Tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L- phenylalanyl-L-phenylalanine; 147780-77-6
DMI0U87	DT	Small molecular drug
DMI0U87	PC	644210
DMI0U87	MW	634.7
DMI0U87	FM	C37H38N4O6
DMI0U87	IC	InChI=1S/C37H38N4O6/c38-30(19-26-15-17-29(42)18-16-26)36(45)41-23-28-14-8-7-13-27(28)22-33(41)35(44)39-31(20-24-9-3-1-4-10-24)34(43)40-32(37(46)47)21-25-11-5-2-6-12-25/h1-18,30-33,42H,19-23,38H2,(H,39,44)(H,40,43)(H,46,47)/t30-,31-,32-,33-/m0/s1
DMI0U87	CS	C1[C@H](N(CC2=CC=CC=C21)C(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O
DMI0U87	IK	JYOUATXRHWNDDW-YRCZKMHPSA-N
DMI0U87	IU	(2S)-2-[[(2S)-2-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
DMI0U87	CA	CAS 146369-65-5
DMI0U87	DE	Discovery agent

DM48F3D	ID	DM48F3D
DM48F3D	DN	HU210
DM48F3D	HS	Investigative
DM48F3D	SN	HU-210; HU 210; 112830-95-2; HU210; UNII-191042422P; CHEMBL307696; (-)-HU-210; 191042422P; (6aR-trans-3-(1, 1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; GTPL731; SCHEMBL1517460; DTXSID30150188; HU-210, solid (air sensitive); ZINC2572463; PDSP2_000201; BDBM50067499; MFCD01074786; AKOS024458716; (6aR,10aR)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; 924H455
DM48F3D	DT	Small molecular drug
DM48F3D	PC	9821569
DM48F3D	MW	386.6
DM48F3D	FM	C25H38O3
DM48F3D	IC	InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m1/s1
DM48F3D	CS	CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)CO)O
DM48F3D	IK	SSQJFGMEZBFMNV-WOJBJXKFSA-N
DM48F3D	IU	(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DM48F3D	CA	CAS 112830-95-2
DM48F3D	DE	Discovery agent

DMPLG4R	ID	DMPLG4R
DMPLG4R	DN	HU-433
DMPLG4R	HS	Investigative
DMPLG4R	SN	CB2 activator (osteoporosis); CB2 activator (osteoporosis), Yissum
DMPLG4R	CP	Yissum Research Development Co
DMPLG4R	PC	59386636
DMPLG4R	MW	414.6
DMPLG4R	FM	C27H42O3
DMPLG4R	IC	InChI=1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20?,21-,22+/m0/s1
DMPLG4R	CS	CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)C2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC
DMPLG4R	IK	CFMRIVODIXTERW-JTGIGXABSA-N
DMPLG4R	IU	[(1R,5R)-4-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-2-bicyclo[3.1.1]hept-2-enyl]methanol
DMPLG4R	DE	Osteoporosis

DM8FLVH	ID	DM8FLVH
DM8FLVH	DN	Human CD40 agonist ligand
DM8FLVH	HS	Investigative
DM8FLVH	SN	Human CD40 agonist ligand (TNF receptor, cancer); Human CD40 agonist ligand (TNF receptor, cancer), ISA Pharmaceuticals; Agonistic anti-CD40 mAb (adjuvant, cancer), ISA
DM8FLVH	CP	ISA Pharmaceuticals BV
DM8FLVH	DE	Discovery agent

DMFV5UL	ID	DMFV5UL
DMFV5UL	DN	human monoclonal antibodies (GM-CSF)
DMFV5UL	HS	Investigative
DMFV5UL	DE	Discovery agent

DMARY2Z	ID	DMARY2Z
DMARY2Z	DN	Human recombinant factor VIIa
DMARY2Z	HS	Investigative
DMARY2Z	SN	Human recombinant factor VIIa (hemophilia A and B)
DMARY2Z	CP	Inspiration Biopharmaceuticals Inc
DMARY2Z	DE	Factor IX deficiency

DMG1BYH	ID	DMG1BYH
DMG1BYH	DN	Human recombinant factor VIII
DMG1BYH	HS	Investigative
DMG1BYH	SN	Human recombinant factor VIII (hemophilia A)
DMG1BYH	CP	Inspiration Biopharmaceuticals Inc
DMG1BYH	DE	Factor VIII deficiency

DM4FIZJ	ID	DM4FIZJ
DM4FIZJ	DN	HuMax-CD38b
DM4FIZJ	HS	Investigative
DM4FIZJ	CP	Genmab Inc
DM4FIZJ	DE	Solid tumour/cancer

DM8AG5R	ID	DM8AG5R
DM8AG5R	DN	HuMax-cMet
DM8AG5R	HS	Investigative
DM8AG5R	SN	CMet-targeting human IgG1 antibody (cancer), Genmab
DM8AG5R	CP	Genmab A/S
DM8AG5R	DT	Antibody
DM8AG5R	DE	Solid tumour/cancer

DMTPXB6	ID	DMTPXB6
DMTPXB6	DN	Huprine X
DMTPXB6	HS	Investigative
DMTPXB6	SN	rac-huprine H7; huprine x; CHEMBL143812; AC1L1GD8; SCHEMBL7115053; CTK6D0420; BDBM10597; NCI60_041180; 3-chloro-9-ethyl-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinolin-12-amine; (1S)-7-chloro-15-ethyl-10-azatetracyclo[11.3.1.0^{2,11}.0^{4,9}]heptadeca-2(11),3,5,7,9,14-hexaen-3-amine
DMTPXB6	DT	Small molecular drug
DMTPXB6	PC	3632
DMTPXB6	MW	298.8
DMTPXB6	FM	C18H19ClN2
DMTPXB6	IC	InChI=1S/C18H19ClN2/c1-2-10-5-11-7-12(6-10)17-16(8-11)21-15-9-13(19)3-4-14(15)18(17)20/h3-5,9,11-12H,2,6-8H2,1H3,(H2,20,21)
DMTPXB6	CS	CCC1=CC2CC(C1)C3=C(C4=C(C=C(C=C4)Cl)N=C3C2)N
DMTPXB6	IK	QTPHSDHUHXUYFE-UHFFFAOYSA-N
DMTPXB6	IU	7-chloro-15-ethyl-10-azatetracyclo[11.3.1.02,11.04,9]heptadeca-2,4(9),5,7,10,14-hexaen-3-amine
DMTPXB6	DE	Discovery agent

DMYH0XQ	ID	DMYH0XQ
DMYH0XQ	DN	Huprine Y
DMYH0XQ	HS	Investigative
DMYH0XQ	SN	CHEMBL140476; rac-huprine H3; BDBM10592; BDBM50200340
DMYH0XQ	DT	Small molecular drug
DMYH0XQ	PC	10107976
DMYH0XQ	MW	284.8
DMYH0XQ	FM	C17H17ClN2
DMYH0XQ	IC	InChI=1S/C17H17ClN2/c1-9-4-10-6-11(5-9)16-15(7-10)20-14-8-12(18)2-3-13(14)17(16)19/h2-4,8,10-11H,5-7H2,1H3,(H2,19,20)
DMYH0XQ	CS	CC1=CC2CC(C1)C3=C(C4=C(C=C(C=C4)Cl)N=C3C2)N
DMYH0XQ	IK	UKCBMHDZLYYTMI-UHFFFAOYSA-N
DMYH0XQ	IU	7-chloro-15-methyl-10-azatetracyclo[11.3.1.02,11.04,9]heptadeca-2,4(9),5,7,10,14-hexaen-3-amine

DMJ4ME7	ID	DMJ4ME7
DMJ4ME7	DN	Huprine-Tacrine Heterodimer
DMJ4ME7	HS	Investigative
DMJ4ME7	DE	Discovery agent

DM1D5F0	ID	DM1D5F0
DM1D5F0	DN	HwFwLL-NH2
DM1D5F0	HS	Investigative
DM1D5F0	SN	CHEMBL502208; HwFwLL-NH2
DM1D5F0	DT	Small molecular drug
DM1D5F0	PC	44576249
DM1D5F0	MW	900.1
DM1D5F0	FM	C49H61N11O6
DM1D5F0	IC	InChI=1S/C49H61N11O6/c1-28(2)18-39(44(51)61)56-46(63)40(19-29(3)4)58-49(66)43(22-32-25-54-38-17-11-9-15-35(32)38)60-47(64)41(20-30-12-6-5-7-13-30)59-48(65)42(21-31-24-53-37-16-10-8-14-34(31)37)57-45(62)36(50)23-33-26-52-27-55-33/h5-17,24-29,36,39-43,53-54H,18-23,50H2,1-4H3,(H2,51,61)(H,52,55)(H,56,63)(H,57,62)(H,58,66)(H,59,65)(H,60,64)/t36-,39-,40-,41-,42+,43+/m0/s1
DM1D5F0	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CC6=CN=CN6)N
DM1D5F0	IK	RGMLIBBPSJGIRX-XLAQBFAFSA-N
DM1D5F0	IU	(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanamide
DM1D5F0	DE	Discovery agent

DMJ9KNU	ID	DMJ9KNU
DMJ9KNU	DN	Hyacinthacine B3
DMJ9KNU	HS	Investigative
DMJ9KNU	SN	Hyacinthacine B3; CHEMBL524631
DMJ9KNU	DT	Small molecular drug
DMJ9KNU	PC	10262292
DMJ9KNU	MW	203.24
DMJ9KNU	FM	C9H17NO4
DMJ9KNU	IC	InChI=1S/C9H17NO4/c1-4-2-6(12)7-9(14)8(13)5(3-11)10(4)7/h4-9,11-14H,2-3H2,1H3/t4-,5-,6-,7-,8-,9+/m1/s1
DMJ9KNU	CS	C[C@@H]1C[C@H]([C@H]2N1[C@@H]([C@H]([C@H]2O)O)CO)O
DMJ9KNU	IK	PIBHCJDPQRCONN-MVEQLIQHSA-N
DMJ9KNU	IU	(1S,2R,3R,5R,7R,8R)-3-(hydroxymethyl)-5-methyl-2,3,5,6,7,8-hexahydro-1H-pyrrolizine-1,2,7-triol
DMJ9KNU	DE	Discovery agent

DMY5RDI	ID	DMY5RDI
DMY5RDI	DN	HYDAMTIQ
DMY5RDI	HS	Investigative
DMY5RDI	SN	PARP-1 inhibitor (brain ischemia), University of Perugia
DMY5RDI	CP	Universita di Perugia
DMY5RDI	DE	Brain ischaemia

DMOTXP1	ID	DMOTXP1
DMOTXP1	DN	Hydantocidin-5'-Monophosphate
DMOTXP1	HS	Investigative
DMOTXP1	SN	Hydantocidin-5'-phosphate; HYDANTOCIDIN-5'-PHOSPHATE; PHOSPHOHYDANTOCIDIN; CHEMBL323799; H5P; 1juy; HYDANTOCIDIN-5'-MONOPHOSPHATE; 5'-phosphohydantocidin; AC1L9JTE; HYDANTOCIDIN-5''-PHOSPHATE; BDBM50149203; HYDANTOCIDIN-5''-MONOPHOSPHATE; DB02493; HNP; Phosphoric acid mono-((5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-6-oxa-1,3-diaza-spiro[44]non-7-ylmethyl) ester; [(1R,2S,3R,5S)-1,2-dihydroxy-6,8-dioxo-4-oxa-7,9-diazaspiro[44]nonan-3-yl]methyl dihydrogen phosphate; [(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-6-oxa-1,3-diazaspiro[44]non-7-yl]methyl; Hydantocidin-5'-Phosphate
DMOTXP1	DT	Small molecular drug
DMOTXP1	PC	446561
DMOTXP1	MW	298.14
DMOTXP1	FM	C7H11N2O9P
DMOTXP1	IC	InChI=1S/C7H11N2O9P/c10-3-2(1-17-19(14,15)16)18-7(4(3)11)5(12)8-6(13)9-7/h2-4,10-11H,1H2,(H2,14,15,16)(H2,8,9,12,13)/t2-,3-,4-,7+/m1/s1
DMOTXP1	CS	C([C@@H]1[C@H]([C@H]([C@]2(O1)C(=O)NC(=O)N2)O)O)OP(=O)(O)O
DMOTXP1	IK	HVXIMXHBUJADCC-GTBMBKLPSA-N
DMOTXP1	IU	[(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-6-oxa-1,3-diazaspiro[4.4]nonan-7-yl]methyl dihydrogen phosphate
DMOTXP1	DE	Discovery agent

DMARWG5	ID	DMARWG5
DMARWG5	DN	HYDRAZINECARBOXAMIDE
DMARWG5	HS	Investigative
DMARWG5	SN	Aminourea; 57-56-7; Carbamylhydrazine; Carbazamide; Semikarbazid; Urea, amino-; Aminoharnstoff; Aminomocovina; Hydrazine, carbamoyl-; Carbamoylhydrazine; Carbamic acid, hydrazide; Carbamidsaeurehydrazid; Semikarbazid [Czech]; Aminomocovina [Czech]; UNII-37QUC23K2X; EINECS 200-339-6; CHEMBL903; BRN 0506319; 37QUC23K2X; CHEBI:28306; DUIOPKIIICUYRZ-UHFFFAOYSA-N; 4426-72-6; Hydrazinecarboxamide, hydrochloride (1:1); isosemicarbazide; amino-urea; 1-azanylurea; carbamic acid hydrazide; Lopac-S-2201
DMARWG5	DT	Small molecular drug
DMARWG5	PC	5196
DMARWG5	MW	75.07
DMARWG5	FM	CH5N3O
DMARWG5	IC	InChI=1S/CH5N3O/c2-1(5)4-3/h3H2,(H3,2,4,5)
DMARWG5	CS	C(=O)(N)NN
DMARWG5	IK	DUIOPKIIICUYRZ-UHFFFAOYSA-N
DMARWG5	IU	aminourea
DMARWG5	CA	CAS 57-56-7
DMARWG5	CB	CHEBI:28306
DMARWG5	DE	Discovery agent

DM0HQF6	ID	DM0HQF6
DM0HQF6	DN	Hydrohalisulfate 1
DM0HQF6	HS	Investigative
DM0HQF6	SN	hydrohalisulfate 1; CHEMBL230058; BDBM50206259
DM0HQF6	DT	Small molecular drug
DM0HQF6	PC	10874329
DM0HQF6	MW	468.7
DM0HQF6	FM	C31H48O3
DM0HQF6	IC	InChI=1S/C31H48O3/c1-21(11-13-24-19-25(32)14-15-27(24)33)9-7-10-23(3)28(34)20-26-22(2)12-16-29-30(4,5)17-8-18-31(26,29)6/h11-12,14-15,19,23,26,28-29,32-34H,7-10,13,16-18,20H2,1-6H3/b21-11+/t23-,26+,28-,29+,31-/m1/s1
DM0HQF6	CS	CC1=CC[C@@H]2[C@@]([C@H]1C[C@H]([C@H](C)CCC/C(=C/CC3=C(C=CC(=C3)O)O)/C)O)(CCCC2(C)C)C
DM0HQF6	IK	JZTPEJICPYCDGH-JWMGXGOZSA-N
DM0HQF6	IU	2-[(E,7R,8R)-9-[(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-8-hydroxy-3,7-dimethylnon-2-enyl]benzene-1,4-diol
DM0HQF6	DE	Discovery agent

DMWH92F	ID	DMWH92F
DMWH92F	DN	Hydrolyzed Cephalothin
DMWH92F	HS	Investigative
DMWH92F	SN	HYDROLYZED CEPHALOTHIN; 2-[CARBOXY-(2-THIOPHEN-2-YL-ACETYLAMINO)-METHYL]-5-METHYL-3,6-DIHYDRO-2H-[1,3]THIAZINE-4-CARBOXYLIC ACID; AC1NRBVK; DB02247; (2S)-2-[(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl]-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; (2S)-2-[(1R)-2-hydroxy-2-oxo-1-[(2-thiophen-2-ylacetyl)amino]ethyl]-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; (2S)-2-{(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl}-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMWH92F	DT	Small molecular drug
DMWH92F	PC	5288660
DMWH92F	MW	356.4
DMWH92F	FM	C14H16N2O5S2
DMWH92F	IC	InChI=1S/C14H16N2O5S2/c1-7-6-23-12(16-10(7)13(18)19)11(14(20)21)15-9(17)5-8-3-2-4-22-8/h2-4,11-12,16H,5-6H2,1H3,(H,15,17)(H,18,19)(H,20,21)/t11-,12-/m0/s1
DMWH92F	CS	CC1=C(N[C@@H](SC1)[C@@H](C(=O)O)NC(=O)CC2=CC=CS2)C(=O)O
DMWH92F	IK	JRYZEMHNDUZNMI-RYUDHWBXSA-N
DMWH92F	IU	(2S)-2-[(R)-carboxy-[(2-thiophen-2-ylacetyl)amino]methyl]-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMWH92F	DE	Discovery agent

DMO32HN	ID	DMO32HN
DMO32HN	DN	HYDROSULFIDE
DMO32HN	HS	Investigative
DMO32HN	SN	hydrosulfide; sulfanide; HS anion; CHEMBL38703; CHEBI:29919; 15035-72-0; hydrosulphide; bisulfide; thiolate; Hydridesulfuranion; Hydrosulfide Anion; Hydrogensulfide Ion; hydrogen sulfide ion; sulfur(1-); Sulfide (HS1-); hydrogen(sulfide)(-1); hydrogen(sulfide)(1-); AC1NUTG4; AC1NNM8X; BDBM26990; RWSOTUBLDIXVET-UHFFFAOYSA-M; HS(-); HS(-1)
DMO32HN	DT	Small molecular drug
DMO32HN	PC	5047209
DMO32HN	MW	33.08
DMO32HN	FM	HS-
DMO32HN	IC	InChI=1S/H2S/h1H2/p-1
DMO32HN	CS	[SH-]
DMO32HN	IK	RWSOTUBLDIXVET-UHFFFAOYSA-M
DMO32HN	IU	sulfanide
DMO32HN	CA	CAS 15035-72-0
DMO32HN	CB	CHEBI:29919
DMO32HN	DE	Discovery agent

DMA4SIN	ID	DMA4SIN
DMA4SIN	DN	HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE
DMA4SIN	HS	Investigative
DMA4SIN	SN	N-hydroxy-N-[3-(6-methylpyridin-2-yl)propyl]formamide; SB-505684; HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE; SB9; AC1NRD3B; BDBM21685
DMA4SIN	DT	Small molecular drug
DMA4SIN	PC	5289331
DMA4SIN	MW	194.23
DMA4SIN	FM	C10H14N2O2
DMA4SIN	IC	InChI=1S/C10H14N2O2/c1-9-4-2-5-10(11-9)6-3-7-12(14)8-13/h2,4-5,8,14H,3,6-7H2,1H3
DMA4SIN	CS	CC1=NC(=CC=C1)CCCN(C=O)O
DMA4SIN	IK	FJYUGRZKJXCRFF-UHFFFAOYSA-N
DMA4SIN	IU	N-hydroxy-N-[3-(6-methylpyridin-2-yl)propyl]formamide
DMA4SIN	DE	Discovery agent

DMQFBH6	ID	DMQFBH6
DMQFBH6	DN	Hydroxyacetic acid
DMQFBH6	HS	Investigative
DMQFBH6	SN	glycolic acid; 2-Hydroxyacetic acid; hydroxyacetic acid; 79-14-1; Glycollic acid; Hydroxyethanoic acid; Acetic acid, hydroxy-; glycolate; Caswell No. 470; alpha-Hydroxyacetic acid; Kyselina glykolova; Kyselina glykolova [Czech]; Kyselina hydroxyoctova; HOCH2COOH; 2-Hydroxyethanoic acid; Kyselina hydroxyoctova [Czech]; Glycocide; EPA Pesticide Chemical Code 000101; GlyPure; HSDB 5227; NSC 166; Acetic acid, 2-hydroxy-; AI3-15362; UNII-0WT12SX38S; GlyPure 70; BRN 1209322; GLYCOLLATE; C2H4O3; Acetic acid, hydroxy-, homopolymer; EINECS 201-
DMQFBH6	DT	Small molecular drug
DMQFBH6	PC	757
DMQFBH6	MW	76.05
DMQFBH6	FM	C2H4O3
DMQFBH6	IC	InChI=1S/C2H4O3/c3-1-2(4)5/h3H,1H2,(H,4,5)
DMQFBH6	CS	C(C(=O)O)O
DMQFBH6	IK	AEMRFAOFKBGASW-UHFFFAOYSA-N
DMQFBH6	IU	2-hydroxyacetic acid
DMQFBH6	CA	CAS 79-14-1
DMQFBH6	CB	CHEBI:17497
DMQFBH6	DE	Discovery agent

DM5HWZY	ID	DM5HWZY
DM5HWZY	DN	Hydroxyalanine
DM5HWZY	HS	Investigative
DM5HWZY	PC	18605011
DM5HWZY	MW	105.09
DM5HWZY	FM	C3H7NO3
DM5HWZY	IC	InChI=1S/C3H7NO3/c1-2(4-7)3(5)6/h2,4,7H,1H3,(H,5,6)/t2-/m0/s1
DM5HWZY	CS	C[C@@H](C(=O)O)NO
DM5HWZY	IK	AWOUERYHOVSIAI-REOHCLBHSA-N
DM5HWZY	IU	(2S)-2-(hydroxyamino)propanoic acid
DM5HWZY	CA	CAS 21209-71-2
DM5HWZY	DE	Discovery agent

DMUVCRQ	ID	DMUVCRQ
DMUVCRQ	DN	Hydroxyaminovaline
DMUVCRQ	HS	Investigative
DMUVCRQ	SN	HYDROXYAMINOVALINE; (2R)-2-amino-N-hydroxy-3-methylbutanamide; 88244-32-0; HAV; n-hydroxy-d-valinamide; AC1L9GKY; SCHEMBL2512211; CTK3B5308; DTXSID10332162; ZINC3997609; AKOS006348422; DB02697; (R)-2-Amino-N-hydroxy-3-methylbutanamide; FT-0772977; Butanamide, 2-amino-N-hydroxy-3-methyl-, (2R)-
DMUVCRQ	DT	Small molecular drug
DMUVCRQ	PC	444599
DMUVCRQ	MW	132.16
DMUVCRQ	FM	C5H12N2O2
DMUVCRQ	IC	InChI=1S/C5H12N2O2/c1-3(2)4(6)5(8)7-9/h3-4,9H,6H2,1-2H3,(H,7,8)/t4-/m1/s1
DMUVCRQ	CS	CC(C)[C@H](C(=O)NO)N
DMUVCRQ	IK	USSBBYRBOWZYSB-SCSAIBSYSA-N
DMUVCRQ	IU	(2R)-2-amino-N-hydroxy-3-methylbutanamide
DMUVCRQ	CA	CAS 88244-32-0
DMUVCRQ	DE	Discovery agent

DM9H5EN	ID	DM9H5EN
DM9H5EN	DN	Hydroxybenzo(a)pyrene
DM9H5EN	HS	Investigative
DM9H5EN	SN	3-Hydroxybenzo(a)pyrene; Benzo(a)pyrene, 3-hydroxy-; Benzo[def]chrysen-3-ol; Benzo[pqr]tetraphen-3-ol; SCHEMBL145489; benzo[a]pyren-3-ol; 13345-21-6; 3-Hydroxy Benzopyrene; 3-Hydroxy benzo[a]pyrene; 3-Hydroxy-3,4-benzo[a]pyrene; 3-Hydroxybenzo[a]pyrene; 3-hydroxybenz[a]pyrene; 4-06-00-05133 (Beilstein Handbook Reference); 672ICH1Q4L; 8-Hydroxy-3,4-benzpyrene; BENZO(a)PYREN-3-OL; AC1L19Z3; BIDD:ER0040; BP-3-Hydroxy; BRN 2333868; CCRIS 1071; CHEBI:34337; CHEMBL8020; CTK0H7534; DTXSID7038319; UNII-672ICH1Q4L
DM9H5EN	PC	25890
DM9H5EN	MW	268.3
DM9H5EN	FM	C20H12O
DM9H5EN	IC	SPUUWWRWIAEPDB-UHFFFAOYSA-N
DM9H5EN	CS	C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C(C=CC(=C54)C=C3)O
DM9H5EN	IK	1S/C20H12O/c21-18-10-7-12-5-8-16-15-4-2-1-3-13(15)11-14-6-9-17(18)19(12)20(14)16/h1-11,21H
DM9H5EN	IU	benzo[a]pyren-3-ol
DM9H5EN	CA	CAS 13345-21-6
DM9H5EN	CB	CHEBI:34337
DM9H5EN	DE	Discovery agent

DMFSKYE	ID	DMFSKYE
DMFSKYE	DN	Hydroxybenzo[a]pyrene
DMFSKYE	HS	Investigative
DMFSKYE	SN	Benzo[a]pyren-1-ol; 1-Hydroxybenzo(a)pyrene; 1-Hydroxybenzo[a]pyrene; 13345-23-8; 3-06-00-03808 (Beilstein Handbook Reference); AC1L19Z6; BENZO(a)PYREN-1-OL; SCHEMBL3341439; ZINC5935140; BRN 2380732; CCRIS 1070; CHEMBL1907999; CTK0H6930; DTXSID40158115
DMFSKYE	PC	25891
DMFSKYE	MW	268.3
DMFSKYE	FM	C20H12O
DMFSKYE	IC	GPIRWWPRDKGKPS-UHFFFAOYSA-N
DMFSKYE	CS	C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=C(C=C5)O)C=C3
DMFSKYE	IK	1S/C20H12O/c21-18-10-7-12-5-6-14-11-13-3-1-2-4-15(13)16-8-9-17(18)19(12)20(14)16/h1-11,21H
DMFSKYE	IU	benzo[a]pyren-1-ol
DMFSKYE	CA	CAS 13345-23-8
DMFSKYE	DE	Discovery agent

DM0PCWZ	ID	DM0PCWZ
DM0PCWZ	DN	Hydroxybutyryl-CoA
DM0PCWZ	HS	Investigative
DM0PCWZ	SN	CoA(4:0(OH)); Beta-hydroxybutyryl-CoA; Coenzyme A, 3-hydroxybutyryl-; Coenzyme A, S-(3-hydroxybutanoate); LMFA07050212; QHHKKMYHDBRONY-RMNRSTNRSA-N; S-(3-hydroxybutanoyl)-CoA; S-(3-hydroxybutanoyl)-coenzyme A; S-(3-hydroxybutyryl)-CoA; S-(3-hydroxybutyryl)-coenzyme A; beta-Hydroxybutyryl-coenzyme A; beta-hydroxybutyryl-CoA; 2871-66-1; 3-Hydroxybutyryl CoA; 3-Hydroxybutyryl-coenzyme A; 3-hydroxybutanoyl-CoA; 3-hydroxybutanoyl-coenzyme a; 3-hydroxybutyryl-CoA; 3HC; AC1LD8I5; C05116; CHEBI:37050; DB03612; DTXSID90951355; SCHEMBL60564
DM0PCWZ	PC	644065
DM0PCWZ	MW	853.6
DM0PCWZ	FM	C25H42N7O18P3S
DM0PCWZ	IC	QHHKKMYHDBRONY-RMNRSTNRSA-N
DM0PCWZ	CS	CC(CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O
DM0PCWZ	IK	1S/C25H42N7O18P3S/c1-13(33)8-16(35)54-7-6-27-15(34)4-5-28-23(38)20(37)25(2,3)10-47-53(44,45)50-52(42,43)46-9-14-19(49-51(39,40)41)18(36)24(48-14)32-12-31-17-21(26)29-11-30-22(17)32/h11-14,18-20,24,33,36-37H,4-10H2,1-3H3,(H,27,34)(H,28,38)(H,42,43)(H,44,45)(H2,26,29,30)(H2,39,40,41)/t13?,14-,18-,19-,20+,24-/m1/s1
DM0PCWZ	IU	S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-hydroxybutanethioate
DM0PCWZ	CA	CAS 2871-66-1
DM0PCWZ	CB	CHEBI:37050
DM0PCWZ	DE	Discovery agent

DM6IEKW	ID	DM6IEKW
DM6IEKW	DN	Hydroxy-cholesten-one
DM6IEKW	HS	Investigative
DM6IEKW	SN	A-Hydroxy-4-cholesten-3-one; Cholest-4-en-7alpha-ol-3-one; 7 Alpha-hydroxy-4-cholesten-3-one; (7; (7R,8S,9S,10R,13R,14S,17R)-7-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 3862-25-7; 4-Cholesten-7-alpha-ol-3-one; 7-Hydroxycholest-4-en-3-one; 7a-hydroxy-cholestene-3-one; 7alpha-Hydroxy-4-cholesten-3-one; 7alpha-Hydroxycholest-4-en-3-one; A)-7-Hydroxycholest-4-en-3-one
DM6IEKW	PC	123743
DM6IEKW	MW	400.6
DM6IEKW	FM	C27H44O2
DM6IEKW	IC	IOIZWEJGGCZDOL-RQDYSCIWSA-N
DM6IEKW	CS	CC(C)CCCC(C)C1CCC2C1(CCC3C2C(CC4=CC(=O)CCC34C)O)C
DM6IEKW	IK	1S/C27H44O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h15,17-18,21-25,29H,6-14,16H2,1-5H3/t18-,21-,22+,23+,24-,25+,26+,27-/m1/s1
DM6IEKW	IU	(7R,8S,9S,10R,13R,14S,17R)-7-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DM6IEKW	CA	CAS 3862-25-7
DM6IEKW	CB	CHEBI:17899
DM6IEKW	DE	Discovery agent

DMY0A9E	ID	DMY0A9E
DMY0A9E	DN	Hydroxycitric acid
DMY0A9E	HS	Investigative
DMY0A9E	SN	SCHEMBL4050699; AKOS021667799; AKOS001495053; ES-2021; MCULE-2991610180; EU-0054396; SR-01000546484; SR-01000546484-1
DMY0A9E	DT	Small molecular drug
DMY0A9E	PC	123908
DMY0A9E	MW	208.12
DMY0A9E	FM	C6H8O8
DMY0A9E	IC	InChI=1S/C6H8O8/c7-2(8)1-6(14,5(12)13)3(9)4(10)11/h3,9,14H,1H2,(H,7,8)(H,10,11)(H,12,13)
DMY0A9E	CS	C(C(=O)O)C(C(C(=O)O)O)(C(=O)O)O
DMY0A9E	IK	ZMJBYMUCKBYSCP-UHFFFAOYSA-N
DMY0A9E	IU	1,2-dihydroxypropane-1,2,3-tricarboxylic acid
DMY0A9E	CA	CAS 6205-14-7
DMY0A9E	DE	Discovery agent

DMFHCV9	ID	DMFHCV9
DMFHCV9	DN	hydroxycitronellal
DMFHCV9	HS	Investigative
DMFHCV9	SN	Hydroxycitronellal; 7-Hydroxy-3,7-dimethyloctanal; 107-75-5; 7-Hydroxycitronellal; Citronellal hydrate; 3,7-Dimethyl-7-hydroxyoctanal; Phixia; Laurine; Cyclosia; Cyclalia; Fixol; Lilyl aldehyde; Muguet synthetic; Musuet synthetic; Musuettine principle; Muguettine principle; Octanal, 7-hydroxy-3,7-dimethyl-; Citronellal, hydroxy-; hydroxy citronellal; Oxydihydrocitronellal; 7-Hydroxy-3,7-dimethyloctan-1-al; NSC 406740; FEMA No. 2583; CHEBI:53459; 1-OCTANAL, 3,7-DIMETHYL-7-HYDROXY-; EINECS 203-518-7; BRN 1721290; AI3-05823
DMFHCV9	DT	Small molecular drug
DMFHCV9	PC	7888
DMFHCV9	MW	172.26
DMFHCV9	FM	C10H20O2
DMFHCV9	IC	InChI=1S/C10H20O2/c1-9(6-8-11)5-4-7-10(2,3)12/h8-9,12H,4-7H2,1-3H3
DMFHCV9	CS	CC(CCCC(C)(C)O)CC=O
DMFHCV9	IK	WPFVBOQKRVRMJB-UHFFFAOYSA-N
DMFHCV9	IU	7-hydroxy-3,7-dimethyloctanal
DMFHCV9	CA	CAS 107-75-5
DMFHCV9	CB	CHEBI:53459
DMFHCV9	DE	Discovery agent

DM5DOEC	ID	DM5DOEC
DM5DOEC	DN	Hydroxyclemastine
DM5DOEC	HS	Investigative
DM5DOEC	SN	AC1O52GA; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidin-1-ium
DM5DOEC	DT	Small molecular drug
DM5DOEC	PC	6426695
DM5DOEC	MW	460
DM5DOEC	FM	C25H30ClNO5
DM5DOEC	IC	InChI=1S/C21H26ClNO.C4H4O4/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2;5-3(6)1-2-4(7)8/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t20-,21-;/m1./s1
DM5DOEC	CS	C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCC[NH+]3C.C(=C/C(=O)[O-])\\C(=O)O
DM5DOEC	IK	PMGQWSIVQFOFOQ-YKVZVUFRSA-N
DM5DOEC	IU	(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidin-1-ium;(E)-4-hydroxy-4-oxobut-2-enoate
DM5DOEC	CA	CAS 14976-57-9
DM5DOEC	DE	Discovery agent

DMPS2B1	ID	DMPS2B1
DMPS2B1	DN	Hydroxydimethylarsine Oxide
DMPS2B1	HS	Investigative
DMPS2B1	SN	Cacodylic acid; cacodylic acid; Dimethylarsinic acid; 75-60-5; Hydroxydimethylarsine oxide; Chexmate; Silvisar; Phytar; Arsan; Erase; DIMETHYLARSENIC ACID; Silvisar 510; Arsinic acid, dimethyl-; Phytar 560; Ansar 138; Sylvicor; Moncide; Dilic; Rad-e-cate 35; Agent Blue; Acide cacodylique; Alkargen; Phytar 138; Acide dimethylarsinique; Cotton aide HC; Kyselina kakodylova; RCRA waste number U136; Phytar 600; Caswell No 133; Arsine oxide, hydroxydimethyl-; Ansar; UNII-AJ2HL7EU8K; Acide cacodylique [French]; Kyselina kakodylova [Czech]
DMPS2B1	DT	Small molecular drug
DMPS2B1	PC	2513
DMPS2B1	MW	138
DMPS2B1	FM	C2H7AsO2
DMPS2B1	IC	InChI=1S/C2H7AsO2/c1-3(2,4)5/h1-2H3,(H,4,5)
DMPS2B1	CS	C[As](=O)(C)O
DMPS2B1	IK	OGGXGZAMXPVRFZ-UHFFFAOYSA-N
DMPS2B1	IU	dimethylarsinic acid
DMPS2B1	CA	CAS 75-60-5
DMPS2B1	CB	CHEBI:48765
DMPS2B1	DE	Discovery agent

DMJXQME	ID	DMJXQME
DMJXQME	DN	Hydroxyestradiol
DMJXQME	HS	Investigative
DMJXQME	SN	4-Hydroxy-17-beta-estradiol; 4-Hydroxyestradiol-17beta; 4-OH-Estradiol; 4-hydroxy-estradiol; 4-HYDROXYESTRADIOL; 4-hydroxyestradiol-17 beta; 4OHE2; 5976-61-4; C3ZO03450E; CHEBI:62845; MLS000069567; SMR000058747; UNII-C3ZO03450E; estra-1,3,5(10)-triene-2,4,17beta-triol; 4-Hydroxyestradiol; (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,4,17-triol; 1,3,5(10)-Estratriene-3,4,17beta-triol; 1,3,5[10]-ESTRATRIENE-3,4,17BETA-TRIOL; 3,4,17beta-estriol; 3,4,17beta-trihydroxy-1,3,5[10]-estratriene
DMJXQME	PC	5282360
DMJXQME	MW	288.4
DMJXQME	FM	C18H24O3
DMJXQME	IC	QOZFCKXEVSGWGS-ZHIYBZGJSA-N
DMJXQME	CS	CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4O)O
DMJXQME	IK	1S/C18H24O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,16,19-21H,2-3,5,7-9H2,1H3/t11-,12-,14+,16+,18+/m1/s1
DMJXQME	IU	(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,4,17-triol
DMJXQME	CA	CAS 5976-61-4
DMJXQME	CB	CHEBI:62845
DMJXQME	DE	Discovery agent

DMBO7ZD	ID	DMBO7ZD
DMBO7ZD	DN	Hydroxyestrone
DMBO7ZD	HS	Investigative
DMBO7ZD	SN	Catecholestrone; LMST02010032; SCHEMBL222517; UQS3A06ILY; ZINC4096681; 2,3-Dihydroxyestra-1,3,5(10)-trien-17-one; 2,3-dihydroxy-estra-1,3,5(10)-trien-17-one; 2-HYDROXYESTRONE; 2-Hydroxy Estrone; 2-Hydroxyestrone; 2-OHE1; 362-06-1; 362H061; AC1L99N9; AKOS030254485; C-44096; C05298; CCRIS 9276; CHEBI:1156; CHEMBL1627343; CTK4H6079; DTXSID80904315; Estra-1,3,5(1)-trien-17-one, 2,3-dihydroxy-; Estra-1,3,5(10)-trien-17-one, 2,3-dihydroxy-; Estra-1,3,5(10)-trien-17-one,2,3-dihydroxy-; UNII-UQS3A06ILY
DMBO7ZD	PC	440623
DMBO7ZD	MW	286.4
DMBO7ZD	FM	C18H22O3
DMBO7ZD	IC	SWINWPBPEKHUOD-JPVZDGGYSA-N
DMBO7ZD	CS	CC12CCC3C(C1CCC2=O)CCC4=CC(=C(C=C34)O)O
DMBO7ZD	IK	1S/C18H22O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,19-20H,2-7H2,1H3/t11-,12+,14-,18-/m0/s1
DMBO7ZD	IU	(8R,9S,13S,14S)-2,3-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
DMBO7ZD	CA	CAS 362-06-1
DMBO7ZD	CB	CHEBI:1156
DMBO7ZD	DE	Discovery agent

DMPGAR2	ID	DMPGAR2
DMPGAR2	DN	Hydroxymethylpyrene
DMPGAR2	HS	Investigative
DMPGAR2	SN	1-Hydroxymethylpyrene; 1-Pyrenemethanol; KSC205I9L; MCULE-5243016090; NGDMLQSGYUCLDC-UHFFFAOYSA-N; Pyrenemethanol; RTR-011298; SCHEMBL505806; TRA0091121; ZINC2143350; pyren-1-ylmethanol; pyrenylmethan-1-ol; (1-pyrenyl)methanol; 1-(1-Hydroxymethyl)pyrene; 1-(Hydroxymethyl)pyrene; 1-Pyrenemethanol, 98%; 1-Pyrenylmethanol; 1-Pyrenylmethanol #; 24463-15-8; AC1L2XTN; AC1Q7C1N; AC1Q7CGU; ACMC-1CIST; AKOS005265175; ANW-25453; BIDD:GT0067; C76UX3EH8M; CCRIS 6510; CHEMBL1743299; CTK1A5495; DTXSID90179219; KS-00000WCR; MFCD00029252; UNII-C76UX3EH8M
DMPGAR2	PC	104977
DMPGAR2	MW	232.28
DMPGAR2	FM	C17H12O
DMPGAR2	IC	NGDMLQSGYUCLDC-UHFFFAOYSA-N
DMPGAR2	CS	C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)CO
DMPGAR2	IK	1S/C17H12O/c18-10-14-7-6-13-5-4-11-2-1-3-12-8-9-15(14)17(13)16(11)12/h1-9,18H,10H2
DMPGAR2	IU	pyren-1-ylmethanol
DMPGAR2	CA	CAS 24463-15-8
DMPGAR2	DE	Discovery agent

DMZN3GP	ID	DMZN3GP
DMZN3GP	DN	Hydroxytryptophol
DMZN3GP	HS	Investigative
DMZN3GP	SN	SCHEMBL233744; 5-Hydroxytryptophol; 154-02-9; 1H-Indole-3-ethanol, 5-hydroxy-; 3-(2-Hydroxyethyl)-1H-indol-5-ol; 4-21-00-02181 (Beilstein Handbook Reference); Hydroxytryptophol; INDOLE-3-ETHANOL, 5-HYDROXY-; KQROHCSYOGBQGJ-UHFFFAOYSA-N; 5-HTOL; 5-Hydroxy Tryptophol; 5-Hydroxy-1H-indole-3-ethanol; 5-Hydroxyindole-3-ethanol; 5-hydroxy-indole-acetic acid; 5-hydroxyindoacetic acid; 5-hydroxyindolacetate; 5-hydroxyindole-acetic acid; 52MNE52QA1; AC1L1S8D; BRN 0143517; EINECS 205-820-4; NSC 84416; UNII-52MNE52QA1
DMZN3GP	PC	9061
DMZN3GP	MW	177.2
DMZN3GP	FM	C10H11NO2
DMZN3GP	IC	KQROHCSYOGBQGJ-UHFFFAOYSA-N
DMZN3GP	CS	C1=CC2=C(C=C1O)C(=CN2)CCO
DMZN3GP	IK	1S/C10H11NO2/c12-4-3-7-6-11-10-2-1-8(13)5-9(7)10/h1-2,5-6,11-13H,3-4H2
DMZN3GP	IU	3-(2-hydroxyethyl)-1H-indol-5-ol
DMZN3GP	CA	CAS 154-02-9
DMZN3GP	CB	CHEBI:89825
DMZN3GP	DE	Discovery agent

DM7XISZ	ID	DM7XISZ
DM7XISZ	DN	HYG-440
DM7XISZ	HS	Investigative
DM7XISZ	SN	HYG-410; HYG-420; HYG-430; Androgen receptor antagonists (topical, dermatological disorder), hygeia
DM7XISZ	CP	Yale University
DM7XISZ	DE	Dermatological disease

DMEZ92A	ID	DMEZ92A
DMEZ92A	DN	Hygromycin B
DMEZ92A	HS	Investigative
DMEZ92A	SN	AC1NUSSH
DMEZ92A	DT	Small molecular drug
DMEZ92A	PC	56928061
DMEZ92A	MW	527.5
DMEZ92A	FM	C20H37N3O13
DMEZ92A	IC	InChI=1S/C20H37N3O13/c1-23-7-2-5(21)9(26)15(10(7)27)33-19-17-16(11(28)8(4-25)32-19)35-20(36-17)18(31)13(30)12(29)14(34-20)6(22)3-24/h5-19,23-31H,2-4,21-22H2,1H3/t5-,6+,7+,8-,9+,10-,11+,12-,13+,14-,15-,16+,17+,18-,19+,20?/m1/s1
DMEZ92A	CS	CN[C@H]1C[C@H]([C@@H]([C@H]([C@@H]1O)O[C@H]2[C@@H]3[C@H]([C@H]([C@H](O2)CO)O)OC4(O3)[C@@H]([C@H]([C@H]([C@H](O4)[C@H](CO)N)O)O)O)O)N
DMEZ92A	IK	GRRNUXAQVGOGFE-HUCHGKBZSA-N
DMEZ92A	IU	(3'R,3aS,4S,4'S,5'R,6R,6'R,7S,7aS)-4-[(1R,2S,3R,5S,6R)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-6'-[(1S)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol
DMEZ92A	CA	CAS 31282-04-9
DMEZ92A	DE	Discovery agent

DMETS37	ID	DMETS37
DMETS37	DN	HYNIC Analogue
DMETS37	HS	Investigative
DMETS37	PC	91936660
DMETS37	MW	1018.2
DMETS37	FM	C53H65N10O9S-
DMETS37	IC	InChI=1S/C53H66N10O9S/c1-53(2,26-12-14-32-72-50-38-45(41-17-5-3-6-18-41)37-46(58-50)42-19-7-4-8-20-42)52-60-61-62-63(52)29-13-11-23-49(64)54-27-15-30-69-33-35-71-36-34-70-31-16-28-55-51(65)44-24-25-48(56-39-44)59-57-40-43-21-9-10-22-47(43)73(66,67)68/h3-10,17-22,24-25,37-39H,11-16,23,26-36,40H2,1-2H3,(H,54,64)(H,55,65)(H,66,67,68)/p-1
DMETS37	CS	CC(C)(CCCCOC1=CC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)C4=NN=NN4CCCCC(=O)NCCCOCCOCCOCCCNC(=O)C5=CN=C(C=C5)N=NCC6=CC=CC=C6S(=O)(=O)[O-]
DMETS37	IK	OPZKREHSQYOWCZ-UHFFFAOYSA-M
DMETS37	IU	2-[[[5-[3-[2-[2-[3-[5-[5-[6-(4,6-diphenylpyridin-2-yl)oxy-2-methylhexan-2-yl]tetrazol-1-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propylcarbamoyl]pyridin-2-yl]diazenyl]methyl]benzenesulfonate
DMETS37	DE	Discovery agent

DMSIWD0	ID	DMSIWD0
DMSIWD0	DN	Hyodeoxycholic acid
DMSIWD0	HS	Investigative
DMSIWD0	SN	A-Dihydroxy-5; A-cholan-24-oic acid; DGABKXLVXPYZII-SIBKNCMHSA-N; HYODEOXYCHOLIC ACID; Hyodeoxycholate; Hyodeoxycholic acid (HDCA); Hyodesoxycholic acid; Hyodesoxycholsaeure; Iodeoxycholic acid; alpha-Hyodeoxycholic acid; 3alpha,6alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,6alpha-Dihydroxy-5beta-cholanic acid; 3alpha,6alpha-Dihydroxy-5beta-cholanoic acid; 6alpha-Hydroxylithocholate; 7-Deoxyhyocholic acid; 7A33Y6EHYK; 83-49-8; CHEBI:52023; HDCA; MFCD00003681; NSC 60672; UNII-7A33Y6EHYK
DMSIWD0	PC	5283820
DMSIWD0	MW	392.6
DMSIWD0	FM	C24H40O4
DMSIWD0	IC	DGABKXLVXPYZII-SIBKNCMHSA-N
DMSIWD0	CS	CC(CCC(=O)O)C1CCC2C1(CCC3C2CC(C4C3(CCC(C4)O)C)O)C
DMSIWD0	IK	1S/C24H40O4/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16+,17-,18+,19+,20+,21+,23-,24-/m1/s1
DMSIWD0	IU	(4R)-4-[(3R,5R,6S,8S,9S,10R,13R,14S,17R)-3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMSIWD0	CA	CAS 83-49-8
DMSIWD0	CB	CHEBI:52023
DMSIWD0	DE	Discovery agent

DM0U8IV	ID	DM0U8IV
DM0U8IV	DN	hyp 9
DM0U8IV	HS	Investigative
DM0U8IV	SN	2,4-(1-keto-hexyl) phloroglucinol
DM0U8IV	DT	Small molecular drug
DM0U8IV	PC	15659415
DM0U8IV	MW	322.4
DM0U8IV	FM	C18H26O5
DM0U8IV	IC	InChI=1S/C18H26O5/c1-3-5-7-9-12(19)16-14(21)11-15(22)17(18(16)23)13(20)10-8-6-4-2/h11,21-23H,3-10H2,1-2H3
DM0U8IV	CS	CCCCCC(=O)C1=C(C(=C(C=C1O)O)C(=O)CCCCC)O
DM0U8IV	IK	JRHOSBCIYWDGHN-UHFFFAOYSA-N
DM0U8IV	IU	1-(3-hexanoyl-2,4,6-trihydroxyphenyl)hexan-1-one
DM0U8IV	CA	CAS 3118-34-1
DM0U8IV	DE	Discovery agent

DMW9HTL	ID	DMW9HTL
DMW9HTL	DN	HYP-10
DMW9HTL	HS	Investigative
DMW9HTL	SN	T-type calcium channel blockers (pain), Ewha Woman's University
DMW9HTL	CP	Ewha Woman's University
DMW9HTL	DE	Pain

DM2L3PE	ID	DM2L3PE
DM2L3PE	DN	Hyperforin
DM2L3PE	HS	Investigative
DM2L3PE	SN	hyperforin; 11079-53-1; hyperforine; hiperforina; UNII-RM741E34FP; CHEBI:5834; RM741E34FP; CHEMBL1237210; (1R,5S,6R,7S)-4-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione; (1R,5S,6R,7S)-4-hydroxy-5-isobutyryl-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione; HSDB 7646; (+)-Hyperforin; Spectrum5_002025; SCHEMBL98723; CHEMBL501711; GTPL2764; SCHEMBL15557965; Hyperforin, &gt
DM2L3PE	DT	Small molecular drug
DM2L3PE	PC	441298
DM2L3PE	MW	536.8
DM2L3PE	FM	C35H52O4
DM2L3PE	IC	InChI=1S/C35H52O4/c1-22(2)13-12-19-33(11)27(16-14-23(3)4)21-34(20-18-25(7)8)30(37)28(17-15-24(5)6)31(38)35(33,32(34)39)29(36)26(9)10/h13-15,18,26-27,37H,12,16-17,19-21H2,1-11H3/t27-,33+,34+,35-/m0/s1
DM2L3PE	CS	CC(C)C(=O)[C@]12C(=O)C(=C([C@](C1=O)(C[C@@H]([C@@]2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C
DM2L3PE	IK	KGSZHKRKHXOAMG-HQKKAZOISA-N
DM2L3PE	IU	(1R,5R,7S,8R)-4-hydroxy-8-methyl-3,5,7-tris(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-1-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione
DM2L3PE	CA	CAS 11079-53-1
DM2L3PE	CB	CHEBI:5834
DM2L3PE	DE	Discovery agent

DMJKIUX	ID	DMJKIUX
DMJKIUX	DN	hypoglaucin A
DMJKIUX	HS	Investigative
DMJKIUX	SN	(-)-hypoglaucine A
DMJKIUX	DT	Small molecular drug
DMJKIUX	PC	71446540
DMJKIUX	MW	867.1
DMJKIUX	FM	C46H74O15
DMJKIUX	IC	InChI=1S/C46H74O15/c1-20-9-14-46(55-19-20)22(3)32-29(61-46)17-28-26-8-7-24-16-25(10-12-44(24,5)27(26)11-13-45(28,32)6)57-43-41(58-30-15-21(2)33(48)37(52)35(30)50)40(36(51)31(18-47)59-43)60-42-39(54)38(53)34(49)23(4)56-42/h7,20-23,25-43,47-54H,8-19H2,1-6H3/t20-,21-,22-,23-,25-,26+,27-,28-,29-,30-,31+,32-,33+,34-,35-,36+,37+,38+,39+,40-,41+,42-,43+,44-,45-,46+/m0/s1
DMJKIUX	CS	C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O[C@H]9C[C@@H]([C@H]([C@H]([C@H]9O)O)O)C)C)C)C)OC1
DMJKIUX	IK	SRFKCMVQTOGLCC-NSNPDTTGSA-N
DMJKIUX	IU	(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5R,6R)-3-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'S,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(1S,2R,3R,4R,5S)-2,3,4-trihydroxy-5-methylcyclohexyl]oxyoxan-4-yl]oxy-6-methyloxane-3,4,5-triol
DMJKIUX	DE	Discovery agent

DMLSABI	ID	DMLSABI
DMLSABI	DN	Hypoxanthine
DMLSABI	HS	Investigative
DMLSABI	DT	Small molecular drug
DMLSABI	PC	135398638
DMLSABI	MW	136.11
DMLSABI	FM	C5H4N4O
DMLSABI	IC	InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
DMLSABI	CS	C1=NC2=C(N1)C(=O)NC=N2
DMLSABI	IK	FDGQSTZJBFJUBT-UHFFFAOYSA-N
DMLSABI	IU	1,7-dihydropurin-6-one
DMLSABI	CA	CAS 68-94-0
DMLSABI	CB	CHEBI:17368
DMLSABI	DE	Discovery agent

DMWLJ5S	ID	DMWLJ5S
DMWLJ5S	DN	Hyrtiosulawesine
DMWLJ5S	HS	Investigative
DMWLJ5S	SN	Hyrtiosulawesine; CHEMBL465767; AC1LCSOD; BDBM50250398; (6-Hydroxy-9H-beta-carbolin-1-yl)-(5-hydroxy-1H-indol-3-yl)-methanone; (6-hydroxy-9H-beta-carbolin-1-yl)(5-hydroxy-1H-indol-3-yl)methanone; methanone, (5-hydroxy-1H-indol-3-yl)(6-hydroxy-9H-pyrido[3,4-b]indol-1-yl)-; (5-hydroxy-1H-indol-3-yl)-(6-hydroxy-9H-pyrido[3,4-b]indol-1-yl)methanone
DMWLJ5S	DT	Small molecular drug
DMWLJ5S	PC	636664
DMWLJ5S	MW	343.3
DMWLJ5S	FM	C20H13N3O3
DMWLJ5S	IC	InChI=1S/C20H13N3O3/c24-10-1-3-16-14(8-10)15(9-22-16)20(26)19-18-12(5-6-21-19)13-7-11(25)2-4-17(13)23-18/h1-9,22-25H
DMWLJ5S	CS	C1=CC2=C(C=C1O)C(=CN2)C(=O)C3=NC=CC4=C3NC5=C4C=C(C=C5)O
DMWLJ5S	IK	OATSYJQLKPRTBO-UHFFFAOYSA-N
DMWLJ5S	IU	(5-hydroxy-1H-indol-3-yl)-(6-hydroxy-9H-pyrido[3,4-b]indol-1-yl)methanone
DMWLJ5S	DE	Discovery agent

DMLU6VM	ID	DMLU6VM
DMLU6VM	DN	HZ-166
DMLU6VM	HS	Investigative
DMLU6VM	SN	Benzodiazepine derivatives (neuropathic pain); Benzodiazepine derivatives (neuropathic pain), Addiction Therapeutix
DMLU6VM	CP	University of Wisconsin-Milwaukee
DMLU6VM	PC	10309028
DMLU6VM	MW	356.4
DMLU6VM	FM	C21H16N4O2
DMLU6VM	IC	InChI=1S/C21H16N4O2/c1-3-14-8-9-17-15(11-14)19(16-7-5-6-10-22-16)23-12-18-20(21(26)27-4-2)24-13-25(17)18/h1,5-11,13H,4,12H2,2H3
DMLU6VM	CS	CCOC(=O)C1=C2CN=C(C3=C(N2C=N1)C=CC(=C3)C#C)C4=CC=CC=N4
DMLU6VM	IK	ZSEDMNMFODMQRD-UHFFFAOYSA-N
DMLU6VM	IU	ethyl 8-ethynyl-6-pyridin-2-yl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMLU6VM	DE	Neuropathic pain

DM7QE51	ID	DM7QE51
DM7QE51	DN	I-309
DM7QE51	HS	Investigative
DM7QE51	SN	2050-48-8; bis(4-bromophenyl)sulfone; 4,4'-Sulfonylbis(bromobenzene); Bis(p-bromophenyl) sulfone; Sulfone, bis(p-bromophenyl); 4-Bromophenyl sulfone; 4,4'-Dibromodiphenyl sulfone; 1,1'-sulfonylbis(4-bromobenzene); 4,4'-Dibromodiphenylsulfone; Benzene, 1,1'-sulfonylbis[4-bromo-; 4,4'-DIBROMO DIPHENYL SULFONE; Bis(p-bromophenyl)sulfone; Benzene, 1,1'-sulfonylbis(4-bromo-; NSC 43047; BRN 2505841; 1-bromo-4-(4-bromophenyl)sulfonylbenzene; AI3-22602; AK112394; 1-bromo-4-(4-bromophenyl)sulfonyl-benzene
DM7QE51	DT	Small molecular drug
DM7QE51	PC	95927
DM7QE51	MW	376.07
DM7QE51	FM	C12H8Br2O2S
DM7QE51	IC	InChI=1S/C12H8Br2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H
DM7QE51	CS	C1=CC(=CC=C1S(=O)(=O)C2=CC=C(C=C2)Br)Br
DM7QE51	IK	QBNABJXQGRVIRA-UHFFFAOYSA-N
DM7QE51	IU	1-bromo-4-(4-bromophenyl)sulfonylbenzene
DM7QE51	CA	CAS 2050-48-8
DM7QE51	DE	Discovery agent

DM1TQ7N	ID	DM1TQ7N
DM1TQ7N	DN	I-5
DM1TQ7N	HS	Investigative
DM1TQ7N	SN	SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; I-5; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid
DM1TQ7N	DT	Small molecular drug
DM1TQ7N	PC	448008
DM1TQ7N	MW	377.2
DM1TQ7N	FM	C17H10Cl2N2O4
DM1TQ7N	IC	InChI=1S/C17H10Cl2N2O4/c18-9-3-1-2-8(6-9)13-14(16(23)21-15(13)22)20-10-4-5-12(19)11(7-10)17(24)25/h1-7H,(H,24,25)(H2,20,21,22,23)
DM1TQ7N	CS	C1=CC(=CC(=C1)Cl)C2=C(C(=O)NC2=O)NC3=CC(=C(C=C3)Cl)C(=O)O
DM1TQ7N	IK	ONVZFCHLOZUXRP-UHFFFAOYSA-N
DM1TQ7N	IU	2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid
DM1TQ7N	DE	Discovery agent

DMFSAK3	ID	DMFSAK3
DMFSAK3	DN	IAA-94
DMFSAK3	HS	Investigative
DMFSAK3	SN	indanyloxyacetic acid 94; MK-473
DMFSAK3	DT	Small molecular drug
DMFSAK3	PC	3667
DMFSAK3	MW	357.2
DMFSAK3	FM	C17H18Cl2O4
DMFSAK3	IC	InChI=1S/C17H18Cl2O4/c1-17(10-4-2-3-5-10)7-9-6-11(23-8-12(20)21)14(18)15(19)13(9)16(17)22/h6,10H,2-5,7-8H2,1H3,(H,20,21)
DMFSAK3	CS	CC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C3CCCC3
DMFSAK3	IK	RNOJGTHBMJBOSP-UHFFFAOYSA-N
DMFSAK3	IU	2-[(6,7-dichloro-2-cyclopentyl-2-methyl-1-oxo-3H-inden-5-yl)oxy]acetic acid
DMFSAK3	CA	CAS 53108-00-2
DMFSAK3	DE	Discovery agent

DMIJ2GV	ID	DMIJ2GV
DMIJ2GV	DN	I-ABA
DMIJ2GV	HS	Investigative
DMIJ2GV	SN	N6-(4-amino-3-iodobenzyl)adenosine; IABA
DMIJ2GV	DT	Small molecular drug
DMIJ2GV	PC	125348
DMIJ2GV	MW	498.3
DMIJ2GV	FM	C17H19IN6O4
DMIJ2GV	IC	InChI=1S/C17H19IN6O4/c18-9-3-8(1-2-10(9)19)4-20-15-12-16(22-6-21-15)24(7-23-12)17-14(27)13(26)11(5-25)28-17/h1-3,6-7,11,13-14,17,25-27H,4-5,19H2,(H,20,21,22)/t11-,13-,14-,17-/m1/s1
DMIJ2GV	CS	C1=CC(=C(C=C1CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)I)N
DMIJ2GV	IK	REGZQZHKIFOMRK-LSCFUAHRSA-N
DMIJ2GV	IU	(2R,3R,4S,5R)-2-[6-[(4-amino-3-iodophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMIJ2GV	CA	CAS 95523-14-1
DMIJ2GV	DE	Discovery agent

DM5X0JS	ID	DM5X0JS
DM5X0JS	DN	I-ABOPX
DM5X0JS	HS	Investigative
DM5X0JS	SN	BW-A522
DM5X0JS	DT	Small molecular drug
DM5X0JS	PC	163889
DM5X0JS	MW	575.4
DM5X0JS	FM	C23H22IN5O5
DM5X0JS	IC	InChI=1S/C23H22IN5O5/c1-2-9-28-22(32)19-21(29(23(28)33)11-13-3-8-17(25)16(24)10-13)27-20(26-19)14-4-6-15(7-5-14)34-12-18(30)31/h3-8,10H,2,9,11-12,25H2,1H3,(H,26,27)(H,30,31)
DM5X0JS	CS	CCCN1C(=O)C2=C(N=C(N2)C3=CC=C(C=C3)OCC(=O)O)N(C1=O)CC4=CC(=C(C=C4)N)I
DM5X0JS	IK	DKJMGIXWGPEEFF-UHFFFAOYSA-N
DM5X0JS	IU	2-[4-[3-[(4-amino-3-iodophenyl)methyl]-2,6-dioxo-1-propyl-7H-purin-8-yl]phenoxy]acetic acid
DM5X0JS	CA	CAS 112533-64-9
DM5X0JS	DE	Discovery agent

DMOQIDG	ID	DMOQIDG
DMOQIDG	DN	IAI-100
DMOQIDG	HS	Investigative
DMOQIDG	SN	ADAM inhibitors (cancer); IAI-102; INCB-3531; INCB-3619; A disintegrin and metalloprotease inhibitors (cancer), Incyte;ADAM inhibitors (cancer), Incyte; HER-2 sheddase inhibitors (cancer), Incyte
DMOQIDG	CP	Incyte Corp
DMOQIDG	DT	Small molecular drug
DMOQIDG	PC	11625778
DMOQIDG	MW	413.5
DMOQIDG	FM	C22H27N3O5
DMOQIDG	IC	InChI=1S/C22H27N3O5/c1-30-21(28)25-14-22(9-10-22)13-17(19(26)23-29)18(25)20(27)24-11-7-16(8-12-24)15-5-3-2-4-6-15/h2-7,17-18,29H,8-14H2,1H3,(H,23,26)/t17-,18-/m0/s1
DMOQIDG	CS	COC(=O)N1CC2(CC2)C[C@@H]([C@H]1C(=O)N3CCC(=CC3)C4=CC=CC=C4)C(=O)NO
DMOQIDG	IK	CKZHFOKQZRZCPF-ROUUACIJSA-N
DMOQIDG	IU	methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenyl-3,6-dihydro-2H-pyridine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate
DMOQIDG	CA	CAS 791826-72-7
DMOQIDG	DE	Solid tumour/cancer

DM8U4HE	ID	DM8U4HE
DM8U4HE	DN	IATX-FVIII
DM8U4HE	HS	Investigative
DM8U4HE	SN	ATX-F8 program (hemophilia A); Factor VIII inhibitor apitope (hemophilia A), Apitope; ATX-F8 program (hemophilia A), Apitope Technology
DM8U4HE	CP	Apitope Technology (Bristol) Ltd
DM8U4HE	DE	Factor VIII deficiency

DM8J24A	ID	DM8J24A
DM8J24A	DN	IBC 293
DM8J24A	HS	Investigative
DM8J24A	SN	IBC293; IBC-293
DM8J24A	DT	Small molecular drug
DM8J24A	PC	2736690
DM8J24A	MW	205.21
DM8J24A	FM	C10H11N3O2
DM8J24A	IC	InChI=1S/C10H11N3O2/c1-6(2)13-9-4-3-7(10(14)15)5-8(9)11-12-13/h3-6H,1-2H3,(H,14,15)
DM8J24A	CS	CC(C)N1C2=C(C=C(C=C2)C(=O)O)N=N1
DM8J24A	IK	RUTVRAJKELSHCC-UHFFFAOYSA-N
DM8J24A	IU	1-propan-2-ylbenzotriazole-5-carboxylic acid
DM8J24A	CA	CAS 306935-41-1
DM8J24A	CB	CHEBI:92275
DM8J24A	DE	Discovery agent

DMRIG3O	ID	DMRIG3O
DMRIG3O	DN	iberiotoxin
DMRIG3O	HS	Investigative
DMRIG3O	SN	Iberiotoxin; IbTX; Iberiatoxin; 129203-60-7; Iberiotoxin_Smartox; GTPL4218; 12IBX001; LS-183325; Iberiotoxin, from Buthus tamulus, &gt
DMRIG3O	DT	Small molecular drug
DMRIG3O	PC	16132435
DMRIG3O	MW	4231
DMRIG3O	FM	C179H274N50O55S7
DMRIG3O	IC	InChI=1S/C179H274N50O55S7/c1-87(2)65-111-155(261)208-112(66-93-33-15-13-16-34-93)146(252)195-77-133(239)225-139(88(3)4)172(278)213-117(71-136(244)245)158(264)199-100(44-31-62-190-178(186)187)144(250)193-75-131(237)198-102(40-22-27-58-181)148(254)219-124(167(273)205-109(56-64-285-12)145(251)194-76-132(238)197-101(39-21-26-57-180)147(253)200-105(43-25-30-61-184)151(257)220-123-81-286-288-83-125(221-152(258)106(203-166(123)272)45-32-63-191-179(188)189)169(275)210-113(68-95-46-48-97(234)49-47-95)156(262)206-110(177(283)284)50-53-129(185)235)82-287-291-86-128(168(274)202-104(42-24-29-60-183)150(256)212-116(70-135(242)243)159(265)207-111)224-175(281)142(91(9)10)228-164(270)121(79-231)216-157(263)115(69-96-74-192-99-38-20-19-37-98(96)99)211-170(276)126-84-289-290-85-127(171(277)217-122(80-232)165(271)227-141(90(7)8)174(280)218-120(78-230)163(269)201-103(41-23-28-59-182)149(255)204-108(154(260)222-126)52-55-134(240)241)223-160(266)118(72-137(246)247)214-173(279)140(89(5)6)226-162(268)119(73-138(248)249)215-176(282)143(92(11)233)229-161(267)114(67-94-35-17-14-18-36-94)209-153(259)107-51-54-130(236)196-107/h13-20,33-38,46-49,74,87-92,100-128,139-143,192,230-234H,21-32,39-45,50-73,75-86,180-184H2,1-12H3,(H2,185,235)(H,193,250)(H,194,251)(H,195,252)(H,196,236)(H,197,238)(H,198,237)(H,199,264)(H,200,253)(H,201,269)(H,202,274)(H,203,272)(H,204,255)(H,205,273)(H,206,262)(H,207,265)(H,208,261)(H,209,259)(H,210,275)(H,211,276)(H,212,256)(H,213,278)(H,214,279)(H,215,282)(H,216,263)(H,217,277)(H,218,280)(H,219,254)(H,220,257)(H,221,258)(H,222,260)(H,223,266)(H,224,281)(H,225,239)(H,226,268)(H,227,271)(H,228,270)(H,229,267)(H,240,241)(H,242,243)(H,244,245)(H,246,247)(H,248,249)(H,283,284)(H4,186,187,190)(H4,188,189,191)
DMRIG3O	CS	CC(C)CC1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)O)CCCCN)NC(=O)C(C(C)C)NC(=O)C(CO)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C4CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4)CCC(=O)O)CCCCN)CO)C(C)C)CO)NC(=O)C(CC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C6CCC(=O)N6)C(=O)NC(CCSC)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC7CSSCC(NC(=O)C(NC7=O)CCCNC(=N)N)C(=O)NC(CC8=CC=C(C=C8)O)C(=O)NC(CCC(=O)N)C(=O)O)CCCCN)CCCNC(=N)N)CC(=O)O)C(C)C)CC9=CC=CC=C9
DMRIG3O	IK	VDNVVLOBNHIMQA-UHFFFAOYSA-N
DMRIG3O	IU	5-amino-2-[[2-[[10-[[6-amino-2-[[6-amino-2-[[2-[[2-[[7,34-bis(4-aminobutyl)-37-[[2-[[2-[[2-[[10-(4-aminobutyl)-22-[[3-carboxy-2-[[2-[[3-carboxy-2-[[3-hydroxy-2-[[2-[(5-oxopyrrolidine-2-carbonyl)amino]-3-phenylpropanoyl]amino]butanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-7-(2-carboxyethyl)-13,19-bis(hydroxymethyl)-6,9,12,15,18,21-hexaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-25-benzyl-13-(3-carbamimidamidopropyl)-16,31-bis(carboxymethyl)-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-19-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-7-(3-carbamimidamidopropyl)-6,9-dioxo-1,2-dithia-5,8-diazacycloundecane-4-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoic acid
DMRIG3O	CA	CAS 129203-60-7
DMRIG3O	DE	Discovery agent

DMYRUH2	ID	DMYRUH2
DMYRUH2	DN	I-BET151
DMYRUH2	HS	Investigative
DMYRUH2	SN	GSK1210151A
DMYRUH2	DT	Small molecular drug
DMYRUH2	PC	52912189
DMYRUH2	MW	415.4
DMYRUH2	FM	C23H21N5O3
DMYRUH2	IC	InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1
DMYRUH2	CS	CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)[C@H](C)C5=CC=CC=N5)OC
DMYRUH2	IK	VUVUVNZRUGEAHB-CYBMUJFWSA-N
DMYRUH2	IU	7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1R)-1-pyridin-2-ylethyl]-3H-imidazo[4,5-c]quinolin-2-one
DMYRUH2	CA	CAS 1300031-49-5
DMYRUH2	CB	CHEBI:95083
DMYRUH2	DE	Discovery agent

DM3HJX7	ID	DM3HJX7
DM3HJX7	DN	Ibogaine
DM3HJX7	HS	Investigative
DM3HJX7	DT	Small molecular drug
DM3HJX7	PC	197060
DM3HJX7	MW	310.4
DM3HJX7	FM	C20H26N2O
DM3HJX7	IC	InChI=1S/C20H26N2O/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3/t12-,13+,17+,20+/m1/s1
DM3HJX7	CS	CC[C@H]1C[C@@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC
DM3HJX7	IK	HSIBGVUMFOSJPD-CFDPKNGZSA-N
DM3HJX7	IU	(1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene
DM3HJX7	CA	CAS 83-74-9
DM3HJX7	CB	CHEBI:5852
DM3HJX7	DE	Discovery agent

DMJAPML	ID	DMJAPML
DMJAPML	DN	I-BOP
DMJAPML	HS	Investigative
DMJAPML	SN	I-BOP; 128719-90-4; AC1NSK5B; GTPL1938; CHEMBL2113346; C23H29IO5; BDBM82512; ZINC13649924; 1795AH; CAS_128719-90-4; (Z)-7-[(1S,4R,5R,6R)-5-[(E,3R)-3-hydroxy-4-(4-iodophenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid; (Z)-7-[(1S,2R,3R,4R)-3-[(E,3R)-3-hydroxy-4-(4-iodophenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid; 7-[(1S,2R,3R,4R)-3-[(1E,3R)-3-HYDROXY-4-(4-IODOPHENOXY)-1-BUTENYL]-7-OXABICYCLO[2.2.1]HEPT-2-YL]-5Z-HEPTENOIC ACID
DMJAPML	DT	Small molecular drug
DMJAPML	PC	5311175
DMJAPML	MW	512.4
DMJAPML	FM	C23H29IO5
DMJAPML	IC	InChI=1S/C23H29IO5/c24-16-7-10-18(11-8-16)28-15-17(25)9-12-20-19(21-13-14-22(20)29-21)5-3-1-2-4-6-23(26)27/h1,3,7-12,17,19-22,25H,2,4-6,13-15H2,(H,26,27)/b3-1-,12-9+/t17-,19-,20-,21+,22-/m1/s1
DMJAPML	CS	C1C[C@@H]2[C@@H]([C@H]([C@H]1O2)C/C=C\\CCCC(=O)O)/C=C/[C@H](COC3=CC=C(C=C3)I)O
DMJAPML	IK	UYFMSCHBODMWON-HBHIRWTLSA-N
DMJAPML	IU	(Z)-7-[(1S,2R,3R,4R)-3-[(E,3R)-3-hydroxy-4-(4-iodophenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DMJAPML	DE	Discovery agent

DM8RZE0	ID	DM8RZE0
DM8RZE0	DN	ibotenate
DM8RZE0	HS	Investigative
DM8RZE0	SN	ibotenic acid
DM8RZE0	DT	Small molecular drug
DM8RZE0	PC	1233
DM8RZE0	MW	158.11
DM8RZE0	FM	C5H6N2O4
DM8RZE0	IC	InChI=1S/C5H6N2O4/c6-4(5(9)10)2-1-3(8)7-11-2/h1,4H,6H2,(H,7,8)(H,9,10)
DM8RZE0	CS	C1=C(ONC1=O)C(C(=O)O)N
DM8RZE0	IK	IRJCBFDCFXCWGO-UHFFFAOYSA-N
DM8RZE0	IU	2-amino-2-(3-oxo-1,2-oxazol-5-yl)acetic acid
DM8RZE0	CA	CAS 2552-55-8
DM8RZE0	CB	CHEBI:5854
DM8RZE0	DE	Discovery agent

DM9C8FP	ID	DM9C8FP
DM9C8FP	DN	I-BRD9
DM9C8FP	HS	Investigative
DM9C8FP	SN	GSK602; compound 45 [PMID 25856009]
DM9C8FP	DT	Small molecular drug
DM9C8FP	PC	91668541
DM9C8FP	MW	497.6
DM9C8FP	FM	C22H22F3N3O3S2
DM9C8FP	IC	InChI=1S/C22H22F3N3O3S2/c1-2-28-12-17(13-4-3-5-14(10-13)22(23,24)25)19-16(21(28)29)11-18(32-19)20(26)27-15-6-8-33(30,31)9-7-15/h3-5,10-12,15H,2,6-9H2,1H3,(H2,26,27)
DM9C8FP	CS	CCN1C=C(C2=C(C1=O)C=C(S2)C(=NC3CCS(=O)(=O)CC3)N)C4=CC(=CC=C4)C(F)(F)F
DM9C8FP	IK	WRUWGLUCNBMGPS-UHFFFAOYSA-N
DM9C8FP	IU	N'-(1,1-dioxothian-4-yl)-5-ethyl-4-oxo-7-[3-(trifluoromethyl)phenyl]thieno[3,2-c]pyridine-2-carboximidamide
DM9C8FP	DE	Discovery agent

DMUSRJ8	ID	DMUSRJ8
DMUSRJ8	DN	IBZM
DMUSRJ8	HS	Investigative
DMUSRJ8	SN	IBZM; Iodobenzamide; UNII-9J5D4ZN1JK; 9J5D4ZN1JK; S(-)-IBZM; CHEMBL267723; 123I-IBZM; (S)-(-)-IBZM; BRN 4322848; C15H21IN2O3; IOLOPRIDE; 3-Iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; (S)-N-(1-Ethyl-2-pyrrolidinyl)methyl-2-hydroxy-3-iodo-6-methoxybenzamide; n-{[(2s)-1-ethylpyrrolidin-2-yl]methyl}-2-hydroxy-3-iodo-6-methoxybenzamide; (S)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-hydroxy-3-iodo-6-methoxybenzamide; 84226-06-2; Benzamide, N-(((2S)-1-ethyl-2-pyrrolidinyl)methyl)-2-hydroxy-3-iodo-6-methoxy-
DMUSRJ8	DT	Small molecular drug
DMUSRJ8	PC	107995
DMUSRJ8	MW	404.24
DMUSRJ8	FM	C15H21IN2O3
DMUSRJ8	IC	InChI=1S/C15H21IN2O3/c1-3-18-8-4-5-10(18)9-17-15(20)13-12(21-2)7-6-11(16)14(13)19/h6-7,10,19H,3-5,8-9H2,1-2H3,(H,17,20)/t10-/m0/s1
DMUSRJ8	CS	CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2O)I)OC
DMUSRJ8	IK	CANPFCFJURGKAX-JTQLQIEISA-N
DMUSRJ8	IU	N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide
DMUSRJ8	CA	CAS 84226-06-2
DMUSRJ8	DE	Discovery agent

DMRF5LU	ID	DMRF5LU
DMRF5LU	DN	IC-041
DMRF5LU	HS	Investigative
DMRF5LU	SN	Small molecule PDE 1 inhibitors (cognitive disorder), Intra-Cellular Therapies; PDE 1B inhibitor (small molecule therapeutic, cognitive disorder), Intra-Cellular
DMRF5LU	CP	Intra-Cellular Therapies Inc
DMRF5LU	DE	Cognitive impairment

DMWRVGE	ID	DMWRVGE
DMWRVGE	DN	IC86621
DMWRVGE	HS	Investigative
DMWRVGE	SN	DNA-PK Inhibitor III; 404009-40-1; IC86621; 1-(2-HYDROXY-4-MORPHOLINOPHENYL)ETHANONE; 1-(2-Hydroxy-4-morpholin-4-yl-phenyl)ethanone; CHEMBL1317546; Ethanone, 1-[2-hydroxy-4-(4-morpholinyl)phenyl]-; SCHEMBL600210; GTPL5960; CTK1D4579; CHEBI:95245; DTXSID40431950; MolPort-027-354-881; HMS3229C13; BCP08943; ZINC3817773; BDBM50398036; AR2783; 4512AH; IN1363; AKOS017560291; CCG-206744; NCGC00165807-01; AS-45440; IC 86621; RT-012395; 1-(2-hydroxy-4-morpholinophenyl)ethan-1-one; A-8048; 1-[2-hydroxy-4-(morpholin-4-yl)phenyl]ethan-1-one
DMWRVGE	DT	Small molecular drug
DMWRVGE	PC	9859309
DMWRVGE	MW	221.25
DMWRVGE	FM	C12H15NO3
DMWRVGE	IC	InChI=1S/C12H15NO3/c1-9(14)11-3-2-10(8-12(11)15)13-4-6-16-7-5-13/h2-3,8,15H,4-7H2,1H3
DMWRVGE	CS	CC(=O)C1=C(C=C(C=C1)N2CCOCC2)O
DMWRVGE	IK	YHKSBKQXCWHTQL-UHFFFAOYSA-N
DMWRVGE	IU	1-(2-hydroxy-4-morpholin-4-ylphenyl)ethanone
DMWRVGE	CA	CAS 404009-40-1
DMWRVGE	CB	CHEBI:95245
DMWRVGE	DE	Discovery agent

DMM50ED	ID	DMM50ED
DMM50ED	DN	IC87114
DMM50ED	HS	Investigative
DMM50ED	SN	IC-87114; 371242-69-2; IC87114; 2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one; IC 87114; UNII-9HC746B1KF; 2-[(6-AMINO-9H-PURIN-9-YL)METHYL]-5-METHYL-3-(2-METHYLPHENYL)-4(3H)-QUINAZOLINONE; 9HC746B1KF; CHEMBL1213082; CHEBI:90686; D-030; 2-[(6-aminopurin-9-yl)methyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one; 2-[(6-Amino-9h-Purin-9-Yl)methyl]-5-Methyl-3-(2-Methylphenyl)quinazolin-4(3h)-One; BiomolKI2_000002; GNWHRHGTIBRNSM-UHFFFAOYSA-N; PubChem22453; MLS006011148; SCHEMBL360745; GTPL9376; EX-A326
DMM50ED	DT	Small molecular drug
DMM50ED	PC	9908783
DMM50ED	MW	397.4
DMM50ED	FM	C22H19N7O
DMM50ED	IC	InChI=1S/C22H19N7O/c1-13-6-3-4-9-16(13)29-17(27-15-8-5-7-14(2)18(15)22(29)30)10-28-12-26-19-20(23)24-11-25-21(19)28/h3-9,11-12H,10H2,1-2H3,(H2,23,24,25)
DMM50ED	CS	CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C=NC5=C(N=CN=C54)N
DMM50ED	IK	GNWHRHGTIBRNSM-UHFFFAOYSA-N
DMM50ED	IU	2-[(6-aminopurin-9-yl)methyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one
DMM50ED	CA	CAS 371242-69-2
DMM50ED	CB	CHEBI:90686
DMM50ED	DE	Discovery agent

DM8L6WB	ID	DM8L6WB
DM8L6WB	DN	IC980033
DM8L6WB	HS	Investigative
DM8L6WB	DT	Small molecular drug
DM8L6WB	PC	24738776
DM8L6WB	MW	541.7
DM8L6WB	FM	C25H45N6O7-
DM8L6WB	IC	InChI=1S/C19H32N2O5.C6H14N4O2/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;7-4(5(11)12)2-1-3-10-6(8)9/h12-16,20H,4-11H2,1-3H3,(H,23,24);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/p-1/t12-,13-,14-,15-,16-;4-/m00/s1
DM8L6WB	CS	CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.C(C[C@@H](C(=O)[O-])N)CN=C(N)N
DM8L6WB	IK	RYCSJJXKEWBUTI-YDYAIEMNSA-M
DM8L6WB	IU	(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid;(2S)-2-amino-5-(diaminomethylideneamino)pentanoate
DM8L6WB	DE	Discovery agent

DMS9H2P	ID	DMS9H2P
DMS9H2P	DN	ICA-105574
DMS9H2P	HS	Investigative
DMS9H2P	SN	ICA 105574; ICA105574
DMS9H2P	DT	Small molecular drug
DMS9H2P	PC	715924
DMS9H2P	MW	334.3
DMS9H2P	FM	C19H14N2O4
DMS9H2P	IC	InChI=1S/C19H14N2O4/c22-19(14-5-4-6-16(13-14)21(23)24)20-15-9-11-18(12-10-15)25-17-7-2-1-3-8-17/h1-13H,(H,20,22)
DMS9H2P	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
DMS9H2P	IK	GDWKBKTVROCPNZ-UHFFFAOYSA-N
DMS9H2P	IU	3-nitro-N-(4-phenoxyphenyl)benzamide
DMS9H2P	CA	CAS 316146-57-3
DMS9H2P	DE	Discovery agent

DMO0N3Q	ID	DMO0N3Q
DMO0N3Q	DN	ICA-27243
DMO0N3Q	HS	Investigative
DMO0N3Q	SN	ICA 27243; ICA27243
DMO0N3Q	DT	Small molecular drug
DMO0N3Q	PC	9903497
DMO0N3Q	MW	268.64
DMO0N3Q	FM	C12H7ClF2N2O
DMO0N3Q	IC	InChI=1S/C12H7ClF2N2O/c13-11-4-2-8(6-16-11)17-12(18)7-1-3-9(14)10(15)5-7/h1-6H,(H,17,18)
DMO0N3Q	CS	C1=CC(=C(C=C1C(=O)NC2=CN=C(C=C2)Cl)F)F
DMO0N3Q	IK	GDGUOCFTHNGPBK-UHFFFAOYSA-N
DMO0N3Q	IU	N-(6-chloropyridin-3-yl)-3,4-difluorobenzamide
DMO0N3Q	CA	CAS 325457-89-4
DMO0N3Q	DE	Discovery agent

DM3DB8X	ID	DM3DB8X
DM3DB8X	DN	Icariside II
DM3DB8X	HS	Investigative
DM3DB8X	SN	Baohuoside I; 113558-15-9; Icariside II; CHEBI:82619; Icarlin II; Baohuoside-I; Baohuoside I;; Icarisid II;; AC1NUQWY; 3,5,7-Trihydroxy-4'-methoxyl-8-prenylflavone-3-O-rhamnopyranoside; SCHEMBL4229321; CHEMBL560116; DTXSID40150457; 2h44; MolPort-020-006-007; HY-N0011; ZINC70455423; C27H30O10; CS-3673; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-; AK169968; anhydroicaritin-3-O-alpha-L-rhamnopyranoside; N2538; Y0106; FT-0686579; Q-100071
DM3DB8X	DT	Small molecular drug
DM3DB8X	PC	5488822
DM3DB8X	MW	514.5
DM3DB8X	FM	C27H30O10
DM3DB8X	IC	InChI=1S/C27H30O10/c1-12(2)5-10-16-17(28)11-18(29)19-21(31)26(37-27-23(33)22(32)20(30)13(3)35-27)24(36-25(16)19)14-6-8-15(34-4)9-7-14/h5-9,11,13,20,22-23,27-30,32-33H,10H2,1-4H3/t13-,20-,22+,23+,27-/m0/s1
DM3DB8X	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C(=CC(=C3C2=O)O)O)CC=C(C)C)C4=CC=C(C=C4)OC)O)O)O
DM3DB8X	IK	NGMYNFJANBHLKA-LVKFHIPRSA-N
DM3DB8X	IU	5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DM3DB8X	CA	CAS 113558-15-9
DM3DB8X	CB	CHEBI:82619
DM3DB8X	DE	Discovery agent

DMQX3W6	ID	DMQX3W6
DMQX3W6	DN	I-CBP112
DMQX3W6	HS	Investigative
DMQX3W6	SN	1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt
DMQX3W6	DT	Small molecular drug
DMQX3W6	PC	90488984
DMQX3W6	MW	468.6
DMQX3W6	FM	C27H36N2O5
DMQX3W6	IC	InChI=1S/C27H36N2O5/c1-5-26(30)29-11-12-33-27-22(17-29)13-21(20-8-9-23(31-3)24(14-20)32-4)15-25(27)34-18-19-7-6-10-28(2)16-19/h8-9,13-15,19H,5-7,10-12,16-18H2,1-4H3/t19-/m0/s1
DMQX3W6	CS	CCC(=O)N1CCOC2=C(C1)C=C(C=C2OC[C@H]3CCCN(C3)C)C4=CC(=C(C=C4)OC)OC
DMQX3W6	IK	YKNAKDFZAWQEEO-IBGZPJMESA-N
DMQX3W6	IU	1-[7-(3,4-dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-3,5-dihydro-2H-1,4-benzoxazepin-4-yl]propan-1-one
DMQX3W6	DE	Discovery agent

DMN6UET	ID	DMN6UET
DMN6UET	DN	ICI 154129
DMN6UET	HS	Investigative
DMN6UET	SN	ICI 154129; 83420-94-4; ICI-154129; UNII-97BUE7NR2M; ICI 154,129; N,N-Bis(allyl)-tyr-gly-gly-psi-methylthio-phe-leu; 97BUE7NR2M; M 154,129; M-154,129; N,N-Bis(allyl)-tyrosyl-glycyl-glycyl-psi-methylthio-phenylalanyl-leucine; N,N-Di-2-propenyl-L-tyrosylglycyl-(alphaS)-alpha-((2-aminoethyl)thio)benzenepropanoyl-L-leucine; Glycinamide, N,N-di-2-propenyl-L-tyrosyl-N-(2-((2-((1-carboxy-3-methylbutyl)amino)-2-oxo-1-(phenylmethyl)ethyl)thio)ethyl)-, (S-(R*,R*))-; L-Leucine, N,N-di-2-propenyl-L-tyrosylglycyl-(alphaS)-alpha-((2
DMN6UET	DT	Small molecular drug
DMN6UET	PC	3035055
DMN6UET	MW	638.8
DMN6UET	FM	C34H46N4O6S
DMN6UET	IC	InChI=1S/C34H46N4O6S/c1-5-17-38(18-6-2)29(21-26-12-14-27(39)15-13-26)32(41)36-23-31(40)35-16-19-45-30(22-25-10-8-7-9-11-25)33(42)37-28(34(43)44)20-24(3)4/h5-15,24,28-30,39H,1-2,16-23H2,3-4H3,(H,35,40)(H,36,41)(H,37,42)(H,43,44)/t28-,29-,30-/m0/s1
DMN6UET	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)SCCNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N(CC=C)CC=C
DMN6UET	IK	CZRZYRKTYLLLRL-DTXPUJKBSA-N
DMN6UET	IU	(2S)-2-[[(2S)-2-[2-[[2-[[(2S)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]ethylsulfanyl]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMN6UET	CA	CAS 83420-94-4
DMN6UET	DE	Discovery agent

DMLPZ3N	ID	DMLPZ3N
DMLPZ3N	DN	ICI 200,355
DMLPZ3N	HS	Investigative
DMLPZ3N	DT	Small molecular drug
DMLPZ3N	PC	10078636
DMLPZ3N	MW	731.6
DMLPZ3N	FM	C30H34BrF3N4O7S
DMLPZ3N	IC	InChI=1S/C30H34BrF3N4O7S/c1-16(2)23(25(39)30(32,33)34)35-28(42)22-6-5-15-38(22)29(43)24(17(3)4)36-26(40)18-7-9-19(10-8-18)27(41)37-46(44,45)21-13-11-20(31)12-14-21/h7-14,16-17,22-24H,5-6,15H2,1-4H3,(H,35,42)(H,36,40)(H,37,41)
DMLPZ3N	CS	CC(C)C(C(=O)C(F)(F)F)NC(=O)C1CCCN1C(=O)C(C(C)C)NC(=O)C2=CC=C(C=C2)C(=O)NS(=O)(=O)C3=CC=C(C=C3)Br
DMLPZ3N	IK	UUWIYANOKPHUQZ-UHFFFAOYSA-N
DMLPZ3N	IU	4-N-(4-bromophenyl)sulfonyl-1-N-[3-methyl-1-oxo-1-[2-[(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl]pyrrolidin-1-yl]butan-2-yl]benzene-1,4-dicarboxamide
DMLPZ3N	DE	Discovery agent

DM0PQ37	ID	DM0PQ37
DM0PQ37	DN	ICI 200,880
DM0PQ37	HS	Investigative
DM0PQ37	DT	Small molecular drug
DM0PQ37	PC	59911
DM0PQ37	MW	687.1
DM0PQ37	FM	C30H34ClF3N4O7S
DM0PQ37	IC	InChI=1S/C30H34ClF3N4O7S/c1-16(2)23(29(43)36-28(42)22-6-5-15-38(22)24(17(3)4)25(39)30(32,33)34)35-26(40)18-7-9-19(10-8-18)27(41)37-46(44,45)21-13-11-20(31)12-14-21/h7-14,16-17,22-24H,5-6,15H2,1-4H3,(H,35,40)(H,37,41)(H,36,42,43)/t22-,23-,24?/m0/s1
DM0PQ37	CS	CC(C)[C@@H](C(=O)NC(=O)[C@@H]1CCCN1C(C(C)C)C(=O)C(F)(F)F)NC(=O)C2=CC=C(C=C2)C(=O)NS(=O)(=O)C3=CC=C(C=C3)Cl
DM0PQ37	IK	SMCMGLCPSSSOQE-NTZARQNWSA-N
DM0PQ37	IU	4-N-(4-chlorophenyl)sulfonyl-1-N-[(2S)-3-methyl-1-oxo-1-[[(2S)-1-(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)pyrrolidine-2-carbonyl]amino]butan-2-yl]benzene-1,4-dicarboxamide
DM0PQ37	CA	CAS 105080-50-0
DM0PQ37	DE	Discovery agent

DM1D6CQ	ID	DM1D6CQ
DM1D6CQ	DN	ICI-174864
DM1D6CQ	HS	Investigative
DM1D6CQ	SN	Ici-174864; Ici 174864; N,N-Diallyl-tyr-aib-phe-leu; N,N-Diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine; L-Leucine, N-(N-(N-(N,N-di-2-propenyl-L-tyrosyl)-2-methylalanyl)-L-phenylalanyl)-; L-Leucine, N,N-di-2-propenyl-L-tyrosyl-2-methylalanyl-L-phenylalanyl-; AC1Q5QOV; AC1L32KD; SCHEMBL4402752; GTPL1636; PDSP2_001212; PDSP1_001228; n,n-di(prop-2-en-1-yl)-l-tyrosyl-2-methylalanyl-l-phenylalanyl-l-leucine; ICI-174,864; LS-178085
DM1D6CQ	DT	Small molecular drug
DM1D6CQ	PC	107691
DM1D6CQ	MW	606.8
DM1D6CQ	FM	C34H46N4O6
DM1D6CQ	IC	InChI=1S/C34H46N4O6/c1-7-18-38(19-8-2)29(22-25-14-16-26(39)17-15-25)31(41)37-34(5,6)33(44)36-27(21-24-12-10-9-11-13-24)30(40)35-28(32(42)43)20-23(3)4/h7-17,23,27-29,39H,1-2,18-22H2,3-6H3,(H,35,40)(H,36,44)(H,37,41)(H,42,43)/t27-,28-,29-/m0/s1
DM1D6CQ	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C(C)(C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(CC=C)CC=C
DM1D6CQ	IK	BGJPRBZZLWCLJW-AWCRTANDSA-N
DM1D6CQ	IU	(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM1D6CQ	CA	CAS 89352-67-0
DM1D6CQ	DE	Discovery agent

DMW4L3K	ID	DMW4L3K
DMW4L3K	DN	ICI-198583
DMW4L3K	HS	Investigative
DMW4L3K	SN	112887-62-4; CB-3819
DMW4L3K	DT	Small molecular drug
DMW4L3K	PC	135400203
DMW4L3K	MW	476.5
DMW4L3K	FM	C25H24N4O6
DMW4L3K	IC	InChI=1S/C25H24N4O6/c1-3-12-29(14-16-4-9-20-19(13-16)24(33)27-15(2)26-20)18-7-5-17(6-8-18)23(32)28-21(25(34)35)10-11-22(30)31/h1,4-9,13,21H,10-12,14H2,2H3,(H,28,32)(H,30,31)(H,34,35)(H,26,27,33)/t21-/m0/s1
DMW4L3K	CS	CC1=NC2=C(C=C(C=C2)CN(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N1
DMW4L3K	IK	PMTUUSDTAKQWQJ-NRFANRHFSA-N
DMW4L3K	IU	(2S)-2-[[4-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]benzoyl]amino]pentanedioic acid
DMW4L3K	CA	CAS 112887-62-4
DMW4L3K	DE	Discovery agent

DMEWZ80	ID	DMEWZ80
DMEWZ80	DN	ICI-199441
DMEWZ80	HS	Investigative
DMEWZ80	SN	115199-84-3; ICI-199,441 HYDROCHLORIDE; ICI 199,441 hydrochloride; Ici 199441; Ici 199,441; AC1MIZCX; N-(2-(N-Methyl-3,4-dichlorophenylacetamido)-2-phenylethyl)pyrrolidine; SCHEMBL7647023; CTK8E9897; MolPort-023-275-929; AKOS024458644; (S)-3,4-Dichloro-N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)benzeneacetamide monohydrochloride; RT-013313; B6448; J-003264; Benzeneacetamide, 3,4-dichloro-N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-, monohydrochloride, (S)-
DMEWZ80	DT	Small molecular drug
DMEWZ80	PC	3082718
DMEWZ80	MW	391.3
DMEWZ80	FM	C21H24Cl2N2O
DMEWZ80	IC	InChI=1S/C21H24Cl2N2O/c1-24(21(26)14-16-9-10-18(22)19(23)13-16)20(15-25-11-5-6-12-25)17-7-3-2-4-8-17/h2-4,7-10,13,20H,5-6,11-12,14-15H2,1H3/t20-/m1/s1
DMEWZ80	CS	CN([C@H](CN1CCCC1)C2=CC=CC=C2)C(=O)CC3=CC(=C(C=C3)Cl)Cl
DMEWZ80	IK	AEJOEPSMZCEYJN-HXUWFJFHSA-N
DMEWZ80	IU	2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenyl-2-pyrrolidin-1-ylethyl]acetamide
DMEWZ80	CA	CAS 116508-24-8
DMEWZ80	CB	CHEBI:93291
DMEWZ80	DE	Discovery agent

DMNA8RS	ID	DMNA8RS
DMNA8RS	DN	ICI-204448
DMNA8RS	HS	Investigative
DMNA8RS	SN	121264-04-8
DMNA8RS	DT	Small molecular drug
DMNA8RS	PC	3683
DMNA8RS	MW	465.4
DMNA8RS	FM	C23H26Cl2N2O4
DMNA8RS	IC	InChI=1S/C23H26Cl2N2O4/c1-26(22(28)12-16-7-8-19(24)20(25)11-16)21(14-27-9-2-3-10-27)17-5-4-6-18(13-17)31-15-23(29)30/h4-8,11,13,21H,2-3,9-10,12,14-15H2,1H3,(H,29,30)
DMNA8RS	CS	CN(C(CN1CCCC1)C2=CC(=CC=C2)OCC(=O)O)C(=O)CC3=CC(=C(C=C3)Cl)Cl
DMNA8RS	IK	JKYJSFISYHSNOE-UHFFFAOYSA-N
DMNA8RS	IU	2-[3-[1-[[2-(3,4-dichlorophenyl)acetyl]-methylamino]-2-pyrrolidin-1-ylethyl]phenoxy]acetic acid
DMNA8RS	CB	CHEBI:91666
DMNA8RS	DE	Discovery agent

DMYRILU	ID	DMYRILU
DMYRILU	DN	ICI-211965
DMYRILU	HS	Investigative
DMYRILU	SN	129424-08-4; ZM-211965
DMYRILU	DT	Small molecular drug
DMYRILU	PC	164272
DMYRILU	MW	389.5
DMYRILU	FM	C24H23NO2S
DMYRILU	IC	InChI=1S/C24H23NO2S/c1-3-24(26-2,23-25-13-14-28-23)21-9-6-10-22(16-21)27-17-18-11-12-19-7-4-5-8-20(19)15-18/h4-16H,3,17H2,1-2H3
DMYRILU	CS	CCC(C1=CC(=CC=C1)OCC2=CC3=CC=CC=C3C=C2)(C4=NC=CS4)OC
DMYRILU	IK	XYRDHZXSQUWVCD-UHFFFAOYSA-N
DMYRILU	IU	2-[1-methoxy-1-[3-(naphthalen-2-ylmethoxy)phenyl]propyl]-1,3-thiazole
DMYRILU	CA	CAS 129424-08-4
DMYRILU	DE	Discovery agent

DMYVOL9	ID	DMYVOL9
DMYVOL9	DN	icilin
DMYVOL9	HS	Investigative
DMYVOL9	SN	Icilin; 36945-98-9; AG 3-5; 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one; Icilin(AG 3-5); UNII-CS70PZQ4QJ; ICILLIN; 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-; CS70PZQ4QJ; BRN 0700310; CHEMBL258405; 3,6-Dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-2(1H)-pyrimidinone; AG-3-5; 1-(2-Hydroxyphenyl)-4-(3-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one; 2(1H)-Pyrimidinone,3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-
DMYVOL9	DT	Small molecular drug
DMYVOL9	PC	161930
DMYVOL9	MW	311.29
DMYVOL9	FM	C16H13N3O4
DMYVOL9	IC	InChI=1S/C16H13N3O4/c20-15-7-2-1-6-14(15)18-9-8-13(17-16(18)21)11-4-3-5-12(10-11)19(22)23/h1-8,10,20H,9H2,(H,17,21)
DMYVOL9	CS	C1C=C(NC(=O)N1C2=CC=CC=C2O)C3=CC(=CC=C3)[N+](=O)[O-]
DMYVOL9	IK	RCEFMOGVOYEGJN-UHFFFAOYSA-N
DMYVOL9	IU	3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one
DMYVOL9	CA	CAS 36945-98-9
DMYVOL9	CB	CHEBI:92845
DMYVOL9	DE	Discovery agent

DMF1CM7	ID	DMF1CM7
DMF1CM7	DN	Icosapentum
DMF1CM7	HS	Investigative
DMF1CM7	SN	Eicosapentaenoic acid; Icosapent; Icosapent [INN]; Icosapentaenoic acid; Icosapento; Cis-5,8,11,14,17-eicosapentaenoic acid; Timnodonic acid; (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid; 10417-94-4; 5,8,11,14,17-EICOSAPENTAENOIC ACID; 5,8,11,14,17-Icosapentaenoic acid; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid; AAN7QOV9EA; C20:5 omega-3; CCRIS 3279; CHEBI:28364; CHEMBL460026; EPA; UNII-AAN7QOV9EA; cis-5,8,11,14,17-Eicosapentaenoic acid
DMF1CM7	PC	446284
DMF1CM7	MW	302.5
DMF1CM7	FM	C20H30O2
DMF1CM7	IC	JAZBEHYOTPTENJ-JLNKQSITSA-N
DMF1CM7	CS	CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O
DMF1CM7	IK	1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-
DMF1CM7	IU	(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
DMF1CM7	CA	CAS 10417-94-4
DMF1CM7	CB	CHEBI:28364
DMF1CM7	DE	Discovery agent

DMH4KGX	ID	DMH4KGX
DMH4KGX	DN	ICR 62
DMH4KGX	HS	Investigative
DMH4KGX	DT	Antibody
DMH4KGX	DE	Discovery agent

DM9DXRL	ID	DM9DXRL
DM9DXRL	DN	ICRF-154
DM9DXRL	HS	Investigative
DM9DXRL	SN	Ethyliminum; 1506-47-4; Icrf-154; 1,2-Bis(3,5-dioxopiperazin-1-yl)ethane; UNII-QML51S42CD; QML51S42CD; 4-[2-(3,5-dioxopiperazin-1-yl)ethyl]piperazine-2,6-dione; 4,4'-ethane-1,2-diyldipiperazine-2,6-dione; NSC-129942; NSC 129942; AI3-52846; AC1Q6LVJ; 2, 4,4'-ethylenedi-; AC1L2IM2; salor-int l163228-1ea; SCHEMBL728996; CHEMBL2361164; CTK4C6725; DTXSID40164579; MolPort-002-546-041; GBLIGNUYGOFIKS-UHFFFAOYSA-N; ZINC19367672; NSC129942; STK700954; 2, 4,4'-(1,2-ethanediyl)bis-; AKOS000646070; MCULE-3427635262; API0009072
DM9DXRL	DT	Small molecular drug
DM9DXRL	PC	72760
DM9DXRL	MW	254.24
DM9DXRL	FM	C10H14N4O4
DM9DXRL	IC	InChI=1S/C10H14N4O4/c15-7-3-13(4-8(16)11-7)1-2-14-5-9(17)12-10(18)6-14/h1-6H2,(H,11,15,16)(H,12,17,18)
DM9DXRL	CS	C1C(=O)NC(=O)CN1CCN2CC(=O)NC(=O)C2
DM9DXRL	IK	GBLIGNUYGOFIKS-UHFFFAOYSA-N
DM9DXRL	IU	4-[2-(3,5-dioxopiperazin-1-yl)ethyl]piperazine-2,6-dione
DM9DXRL	CA	CAS 1506-47-4
DM9DXRL	DE	Discovery agent

DMPH8E9	ID	DMPH8E9
DMPH8E9	DN	ICT-037
DMPH8E9	HS	Investigative
DMPH8E9	SN	Anticancer mAbs, Immunocellular Therapeutics; ICT-37; Monoclonal antibodies (cancer), Immunocellular Therapeutics
DMPH8E9	CP	Molecular Discoveries LLC
DMPH8E9	DT	Antibody
DMPH8E9	DE	Solid tumour/cancer

DM3P7W5	ID	DM3P7W5
DM3P7W5	DN	IDD552
DM3P7W5	HS	Investigative
DM3P7W5	SN	IDD552; CHEMBL399598; [5-FLUORO-2-({[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]AMINO}CARBONYL)PHENOXY]ACETIC ACID; ID5; AC1L9M77; SCHEMBL5462044; ZCAGEXZTORJQDZ-UHFFFAOYSA-N; BDBM50222611; DB02834; {5-fluoro-2[(4,5,7-trifluoro-benzothiazol-2-ylmethyl)carbamoyl]-phenoxy}-acetic acid; 5-fluoro-2-{[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]carbamoyl}phenoxyacetic acid; 2-[5-fluoro-2-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methylcarbamoyl]phenoxy]acetic acid
DM3P7W5	DT	Small molecular drug
DM3P7W5	PC	448658
DM3P7W5	MW	414.3
DM3P7W5	FM	C17H10F4N2O4S
DM3P7W5	IC	InChI=1S/C17H10F4N2O4S/c18-7-1-2-8(11(3-7)27-6-13(24)25)17(26)22-5-12-23-15-14(21)9(19)4-10(20)16(15)28-12/h1-4H,5-6H2,(H,22,26)(H,24,25)
DM3P7W5	CS	C1=CC(=C(C=C1F)OCC(=O)O)C(=O)NCC2=NC3=C(C(=CC(=C3S2)F)F)F
DM3P7W5	IK	ZCAGEXZTORJQDZ-UHFFFAOYSA-N
DM3P7W5	IU	2-[5-fluoro-2-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methylcarbamoyl]phenoxy]acetic acid
DM3P7W5	DE	Discovery agent

DMDHLG3	ID	DMDHLG3
DMDHLG3	DN	IDD594
DMDHLG3	HS	Investigative
DMDHLG3	SN	IDD594; CHEMBL395347; {2-[(4-bromo-2-fluorobenzyl)carbamothioyl]-5-fluorophenoxy}acetic acid; [2-(4-BROMO-2-FLUORO-BENZYLTHIOCARBAMOYL)-5-FLUORO-PHENOXY]-ACETIC ACID; AC1N9ZWX; SCHEMBL5467958; BDBM16313; IDD 594; IDD-594; ZINC13137482; AKOS032949406; DB08084; 2-[2-[(4-bromo-2-fluorophenyl)methylcarbamothioyl]-5-fluorophenoxy]acetic acid; 2-(2-{[(4-bromo-2-fluorophenyl)methyl]carbamothioyl}-5-fluorophenoxy)acetic acid; 2-{[(4-bromo-2-fluorophenyl)methyl]carbamothioyl}-5-fluorophenoxyacetic acid
DMDHLG3	DT	Small molecular drug
DMDHLG3	PC	4369325
DMDHLG3	MW	416.2
DMDHLG3	FM	C16H12BrF2NO3S
DMDHLG3	IC	InChI=1S/C16H12BrF2NO3S/c17-10-2-1-9(13(19)5-10)7-20-16(24)12-4-3-11(18)6-14(12)23-8-15(21)22/h1-6H,7-8H2,(H,20,24)(H,21,22)
DMDHLG3	CS	C1=CC(=C(C=C1F)OCC(=O)O)C(=S)NCC2=C(C=C(C=C2)Br)F
DMDHLG3	IK	JCZUIWYXULSXSW-UHFFFAOYSA-N
DMDHLG3	IU	2-[2-[(4-bromo-2-fluorophenyl)methylcarbamothioyl]-5-fluorophenoxy]acetic acid
DMDHLG3	DE	Discovery agent

DMBFX5H	ID	DMBFX5H
DMBFX5H	DN	IDDBCP226234
DMBFX5H	HS	Investigative
DMBFX5H	SN	Serine/threonine-protein kinase PIM-2 inhibitor (inflammation), Boehringer Ingelheim
DMBFX5H	CP	Boehringer Ingelheim Corp
DMBFX5H	DE	Inflammation

DMRQSN2	ID	DMRQSN2
DMRQSN2	DN	IDN-1965
DMRQSN2	HS	Investigative
DMRQSN2	SN	IDN-1965; GONUYDANRODTCF-IBYPIGCZSA-N; IDN 1965; 204919-14-2; CHEMBL198068; SCHEMBL5668068; LS-101833; N-[(1.3-dimethylindole-2-carbonyl)valinyl]-3-amino-4-oxo-5-fluoropentanoic Acid; N-[(1,3-Dimethylindole-2-Carbonyl)Valinyl]-3-Amino-4-Oxo-5-Fluoropentanoic Acid; Pentanoic acid, 3-(((2S)-2-(((1,3-dimethyl-1H-indol-2-yl)carbonyl)amino)-3-methyl-1-oxobutyl)amino)-5-fluoro-4-oxo-
DMRQSN2	DT	Small molecular drug
DMRQSN2	PC	9802179
DMRQSN2	MW	419.4
DMRQSN2	FM	C21H26FN3O5
DMRQSN2	IC	InChI=1S/C21H26FN3O5/c1-11(2)18(20(29)23-14(9-17(27)28)16(26)10-22)24-21(30)19-12(3)13-7-5-6-8-15(13)25(19)4/h5-8,11,14,18H,9-10H2,1-4H3,(H,23,29)(H,24,30)(H,27,28)/t14?,18-/m0/s1
DMRQSN2	CS	CC1=C(N(C2=CC=CC=C12)C)C(=O)N[C@@H](C(C)C)C(=O)NC(CC(=O)O)C(=O)CF
DMRQSN2	IK	GONUYDANRODTCF-IBYPIGCZSA-N
DMRQSN2	IU	3-[[(2S)-2-[(1,3-dimethylindole-2-carbonyl)amino]-3-methylbutanoyl]amino]-5-fluoro-4-oxopentanoic acid
DMRQSN2	CA	CAS 204919-14-2
DMRQSN2	DE	Discovery agent

DMNS9KW	ID	DMNS9KW
DMNS9KW	DN	IDN-5174
DMNS9KW	HS	Investigative
DMNS9KW	SN	Camptothecin analogs (anticancer); Camptothecin analogs (anticancer), Indena
DMNS9KW	CP	Indena SpA
DMNS9KW	DE	Solid tumour/cancer

DM1OMSW	ID	DM1OMSW
DM1OMSW	DN	IDN-5390
DM1OMSW	HS	Investigative
DM1OMSW	SN	IDN-5868; IDN-5869; IDN-6140; Paclitaxel derivatives, Indena; 14-OH DAB
DM1OMSW	CP	Indena SpA
DM1OMSW	DT	Small molecular drug
DM1OMSW	PC	44405214
DM1OMSW	MW	787.9
DM1OMSW	FM	C41H57NO14
DM1OMSW	IC	InChI=1S/C41H57NO14/c1-21(2)18-26(42-37(50)56-38(6,7)8)32(46)36(49)53-27-19-41(51)34(54-35(48)25-14-12-11-13-15-25)30(40(55-24(5)44)20-52-28(40)16-17-43)23(4)31(45)33(47)29(22(27)3)39(41,9)10/h11-15,21,26-28,30,32,34,43,45-46,51H,16-20H2,1-10H3,(H,42,50)/b31-23+/t26-,27-,28+,30+,32+,34-,40-,41+/m0/s1
DM1OMSW	CS	CC1=C2C(=O)/C(=C(\\[C@H]([C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)O)OC(=O)C3=CC=CC=C3)[C@@]4(CO[C@@H]4CCO)OC(=O)C)/C)/O
DM1OMSW	IK	UKFDBDGJFYRBHE-QWSJSTABSA-N
DM1OMSW	IU	[(1S,2S,3R,4E,9S)-3-[(2R,3S)-3-acetyloxy-2-(2-hydroxyethyl)oxetan-3-yl]-1,5-dihydroxy-9-[(2R,3S)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-4,8,11,11-tetramethyl-6-oxo-2-bicyclo[5.3.1]undeca-4,7-dienyl] benzoate
DM1OMSW	DE	Solid tumour/cancer

DM6TEWZ	ID	DM6TEWZ
DM6TEWZ	DN	IDN-6384
DM6TEWZ	HS	Investigative
DM6TEWZ	SN	Topoisomerase Ib inhibitor (cancer), Indena
DM6TEWZ	CP	Indena SpA
DM6TEWZ	DE	Solid tumour/cancer

DMOU234	ID	DMOU234
DMOU234	DN	IGEL1.2
DMOU234	HS	Investigative
DMOU234	DT	Aptamer
DMOU234	DE	Allergy

DMFMY1L	ID	DMFMY1L
DMFMY1L	DN	IGERNELLIN
DMFMY1L	HS	Investigative
DMFMY1L	SN	igernellin; CHEMBL442427; SCHEMBL6834704
DMFMY1L	DT	Small molecular drug
DMFMY1L	PC	9947690
DMFMY1L	MW	372.6
DMFMY1L	FM	C25H40O2
DMFMY1L	IC	InChI=1S/C25H40O2/c1-20(13-14-24-21(2)9-7-16-25(24,3)4)8-5-10-22(18-26)11-6-12-23-15-17-27-19-23/h8-9,15,17,19,22,24,26H,5-7,10-14,16,18H2,1-4H3/b20-8+
DMFMY1L	CS	CC1=CCCC(C1CC/C(=C/CCC(CCCC2=COC=C2)CO)/C)(C)C
DMFMY1L	IK	UJVZMYQCMKGVLL-DNTJNYDQSA-N
DMFMY1L	IU	(E)-2-[3-(furan-3-yl)propyl]-6-methyl-8-(2,6,6-trimethylcyclohex-2-en-1-yl)oct-5-en-1-ol
DMFMY1L	DE	Discovery agent

DMLYIBO	ID	DMLYIBO
DMLYIBO	DN	IIK7
DMLYIBO	HS	Investigative
DMLYIBO	SN	IIK7; CHEMBL10009; IIK7, solid; AC1N5IDZ; Lopac-I-5531; IIK-7; Lopac0_000701; GTPL1350; SCHEMBL19612546; CTK8G0268; ZINC2510569; BDBM50086013; CCG-204786; NCGC00094053-02; NCGC00015557-03; NCGC00015557-02; NCGC00015557-01; NCGC00094053-01; EU-0100701; I 5531; SR-01000075939; L000306; SR-01000075939-1; N-[2-(2-methoxy-6H-isoindolo[2,3-a]indol-11-yl)ethyl]butanamide; N-Butanoyl 2-(9-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine; N-[2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide; N-Butanoyl 2-(9-methoxy-6H-iso-indolo[
DMLYIBO	DT	Small molecular drug
DMLYIBO	PC	4172142
DMLYIBO	MW	348.4
DMLYIBO	FM	C22H24N2O2
DMLYIBO	IC	InChI=1S/C22H24N2O2/c1-3-6-21(25)23-12-11-18-19-13-16(26-2)9-10-20(19)24-14-15-7-4-5-8-17(15)22(18)24/h4-5,7-10,13H,3,6,11-12,14H2,1-2H3,(H,23,25)
DMLYIBO	CS	CCCC(=O)NCCC1=C2C3=CC=CC=C3CN2C4=C1C=C(C=C4)OC
DMLYIBO	IK	RQYIUGOJQFWLAZ-UHFFFAOYSA-N
DMLYIBO	IU	N-[2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide
DMLYIBO	DE	Discovery agent

DMJA4UE	ID	DMJA4UE
DMJA4UE	DN	IK-862
DMJA4UE	HS	Investigative
DMJA4UE	SN	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic;  IK862; IK 862; compound 32; IK-682
DMJA4UE	DT	Small molecular drug
DMJA4UE	PC	6914621
DMJA4UE	MW	433.5
DMJA4UE	FM	C25H27N3O4
DMJA4UE	IC	InChI=1S/C25H27N3O4/c1-16-14-18(21-6-4-5-7-22(21)26-16)15-32-20-10-8-19(9-11-20)25(3)12-13-28(24(25)30)17(2)23(29)27-31/h4-11,14,17,31H,12-13,15H2,1-3H3,(H,27,29)/t17-,25+/m1/s1
DMJA4UE	CS	CC1=NC2=CC=CC=C2C(=C1)COC3=CC=C(C=C3)[C@@]4(CCN(C4=O)[C@H](C)C(=O)NO)C
DMJA4UE	IK	YDMIPBHQKFOFQW-NSYGIPOTSA-N
DMJA4UE	IU	(2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide
DMJA4UE	CB	CHEBI:40083
DMJA4UE	DE	Discovery agent

DM2X3EV	ID	DM2X3EV
DM2X3EV	DN	IkappaB-alphaM
DM2X3EV	HS	Investigative
DM2X3EV	DE	Discovery agent

DM94AIL	ID	DM94AIL
DM94AIL	DN	IKH-25
DM94AIL	HS	Investigative
DM94AIL	SN	HDAC-6 inhibitors (cancer), Ikerchem
DM94AIL	CP	Ikerchem
DM94AIL	DE	Solid tumour/cancer

DM8GQ9X	ID	DM8GQ9X
DM8GQ9X	DN	IKI-1
DM8GQ9X	HS	Investigative
DM8GQ9X	SN	IKK inhibitors (cancer); I kappa B kinase inhibitors (cancer), Pfizer; IKK inhibitor (cancer), Wyeth; IKK inhibitors (cancer), Pfizer
DM8GQ9X	CP	Wyeth
DM8GQ9X	DE	Solid tumour/cancer

DMLY5IF	ID	DMLY5IF
DMLY5IF	DN	IKs124
DMLY5IF	HS	Investigative
DMLY5IF	SN	IKs124; SCHEMBL6559311; GTPL2591
DMLY5IF	DT	Small molecular drug
DMLY5IF	PC	15338746
DMLY5IF	MW	350.5
DMLY5IF	FM	C18H26N2O3S
DMLY5IF	IC	InChI=1S/C18H26N2O3S/c1-5-7-10-20(24(21,22)6-2)16-12-18(3,4)23-17-9-8-14(13-19)11-15(16)17/h8-9,11,16H,5-7,10,12H2,1-4H3
DMLY5IF	CS	CCCCN(C1CC(OC2=C1C=C(C=C2)C#N)(C)C)S(=O)(=O)CC
DMLY5IF	IK	VTICUGOJGKDYJD-UHFFFAOYSA-N
DMLY5IF	IU	N-butyl-N-(6-cyano-2,2-dimethyl-3,4-dihydrochromen-4-yl)ethanesulfonamide
DMLY5IF	DE	Discovery agent

DMU6AMP	ID	DMU6AMP
DMU6AMP	DN	IL-2 antibody (anti-tumor)
DMU6AMP	HS	Investigative
DMU6AMP	SN	DMS-1.10; anti-human rIL-2 antibody, Hybritech
DMU6AMP	DE	Discovery agent

DM10Z5W	ID	DM10Z5W
DM10Z5W	DN	Il-8((3-73))K11R
DM10Z5W	HS	Investigative
DM10Z5W	DE	Discovery agent

DMPNQ27	ID	DMPNQ27
DMPNQ27	DN	Il-94
DMPNQ27	HS	Investigative
DMPNQ27	SN	CHEMBL2386715; Il-94; GTPL8132; SCHEMBL15216595; BDBM50434330
DMPNQ27	DT	Small molecular drug
DMPNQ27	PC	73348907
DMPNQ27	MW	422.5
DMPNQ27	FM	C21H23FN8O
DMPNQ27	IC	InChI=1S/C21H23FN8O/c1-31-7-6-30(12-14-8-15(22)9-18-16(14)11-24-27-18)21-23-5-4-19(26-21)25-20-10-17(28-29-20)13-2-3-13/h4-5,8-11,13H,2-3,6-7,12H2,1H3,(H,24,27)(H2,23,25,26,28,29)
DMPNQ27	CS	COCCN(CC1=C2C=NNC2=CC(=C1)F)C3=NC=CC(=N3)NC4=NNC(=C4)C5CC5
DMPNQ27	IK	FTGUWURNNBVUBC-UHFFFAOYSA-N
DMPNQ27	IU	4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-N-[(6-fluoro-1H-indazol-4-yl)methyl]-2-N-(2-methoxyethyl)pyrimidine-2,4-diamine
DMPNQ27	DE	Discovery agent

DMPIV1G	ID	DMPIV1G
DMPIV1G	DN	Ilatreotide
DMPIV1G	HS	Investigative
DMPIV1G	SN	SDZ-CO-611
DMPIV1G	CP	Novartis AG
DMPIV1G	PC	72046
DMPIV1G	MW	1343.5
DMPIV1G	FM	C61H86N10O20S2
DMPIV1G	IC	InChI=1S/C61H86N10O20S2/c1-31(74)42(25-72)68-58(86)44-29-93-92-28-43(69-54(82)39(21-33-13-5-3-6-14-33)64-30-61(88)52(80)51(45(76)27-89-61)91-60-50(79)49(78)48(77)46(26-73)90-60)57(85)66-40(22-34-15-7-4-8-16-34)55(83)67-41(23-35-24-63-37-18-10-9-17-36(35)37)56(84)65-38(19-11-12-20-62)53(81)71-47(32(2)75)59(87)70-44/h3-10,13-18,24,31-32,38-52,60,63-64,72-80,88H,11-12,19-23,25-30,62H2,1-2H3,(H,65,84)(H,66,85)(H,67,83)(H,68,86)(H,69,82)(H,70,87)(H,71,81)/t31-,32-,38+,39-,40+,41-,42-,43+,44+,45-,46-,47+,48-,49+,50-,51-,52+,60-,61-/m1/s1
DMPIV1G	CS	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)NC[C@@]6([C@H]([C@@H]([C@@H](CO6)O)O[C@@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)C(=O)N[C@H](CO)[C@@H](C)O)O
DMPIV1G	IK	FYSDQQZUTAKKQX-CULBQIHKSA-N
DMPIV1G	IU	(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[[(2R)-3-phenyl-2-[[(2R,3S,4R,5R)-2,3,5-trihydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methylamino]propanoyl]amino]-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMPIV1G	CA	CAS 119719-11-8
DMPIV1G	DE	Duodenal ulcer

DMZW0YO	ID	DMZW0YO
DMZW0YO	DN	IM-023911
DMZW0YO	HS	Investigative
DMZW0YO	SN	IM-023911; CHEMBL193342; AC1NQ014; A2595/0110399; MolPort-002-710-895; ZINC3672574; BDBM50173049; STK765418; AKOS001757037; MCULE-3428588247; 4-[4-[4-[chloro(difluoro)methoxy]anilino]phthalazin-1-yl]benzamide; 4-(4-{4-[chloro(difluoro)methoxy]anilino}-1-phthalazinyl)benzamide; 4-{4-[4-(Chloro-difluoro-methoxy)-phenylamino]-phthalazin-1-yl}-benzamide; 4-[4-({4-[chloro(difluoro)methoxy]phenyl}amino)phthalazin-1-yl]benzamide
DMZW0YO	DT	Small molecular drug
DMZW0YO	PC	5187941
DMZW0YO	MW	440.8
DMZW0YO	FM	C22H15ClF2N4O2
DMZW0YO	IC	InChI=1S/C22H15ClF2N4O2/c23-22(24,25)31-16-11-9-15(10-12-16)27-21-18-4-2-1-3-17(18)19(28-29-21)13-5-7-14(8-6-13)20(26)30/h1-12H,(H2,26,30)(H,27,29)
DMZW0YO	CS	C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=C(C=C4)C(=O)N
DMZW0YO	IK	GUSAPNPQBHFHSX-UHFFFAOYSA-N
DMZW0YO	IU	4-[4-[4-[chloro(difluoro)methoxy]anilino]phthalazin-1-yl]benzamide
DMZW0YO	DE	Discovery agent

DMTFV65	ID	DMTFV65
DMTFV65	DN	IM-094261
DMTFV65	HS	Investigative
DMTFV65	SN	IM-094261; CHEMBL370586; AC1NRUHT; ZINC4624188; STK686670; BDBM50173019; MCULE-9113150619; 4-[4-(4-tert-butylanilino)phthalazin-1-yl]benzamide; 4-(4-(4-tert-butylphenylamino)phthalazin-1-yl)benzamide; A3870/0164436; 4-{4-[(4-tert-butylphenyl)amino]phthalazin-1-yl}benzamide
DMTFV65	DT	Small molecular drug
DMTFV65	PC	5298698
DMTFV65	MW	396.5
DMTFV65	FM	C25H24N4O
DMTFV65	IC	InChI=1S/C25H24N4O/c1-25(2,3)18-12-14-19(15-13-18)27-24-21-7-5-4-6-20(21)22(28-29-24)16-8-10-17(11-9-16)23(26)30/h4-15H,1-3H3,(H2,26,30)(H,27,29)
DMTFV65	CS	CC(C)(C)C1=CC=C(C=C1)NC2=NN=C(C3=CC=CC=C32)C4=CC=C(C=C4)C(=O)N
DMTFV65	IK	FIQNADOCRLODMD-UHFFFAOYSA-N
DMTFV65	IU	4-[4-(4-tert-butylanilino)phthalazin-1-yl]benzamide
DMTFV65	DE	Discovery agent

DMO18YN	ID	DMO18YN
DMO18YN	DN	IM-094882
DMO18YN	HS	Investigative
DMO18YN	SN	IM-094882; CHEMBL380316; BDBM50179881; N-(4-chlorophenyl)-4-(isoquinolin-5-yl)phthalazin-1-amine
DMO18YN	DT	Small molecular drug
DMO18YN	PC	42609931
DMO18YN	MW	382.8
DMO18YN	FM	C23H15ClN4
DMO18YN	IC	InChI=1S/C23H15ClN4/c24-16-8-10-17(11-9-16)26-23-21-6-2-1-5-20(21)22(27-28-23)19-7-3-4-15-14-25-13-12-18(15)19/h1-14H,(H,26,28)
DMO18YN	CS	C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)C4=CC=CC5=C4C=CN=C5
DMO18YN	IK	RXWBASVYZOFLRF-UHFFFAOYSA-N
DMO18YN	IU	N-(4-chlorophenyl)-4-isoquinolin-5-ylphthalazin-1-amine
DMO18YN	DE	Discovery agent

DM58DGY	ID	DM58DGY
DM58DGY	DN	IM-12
DM58DGY	HS	Investigative
DM58DGY	SN	IM-12; 1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587
DM58DGY	DT	Small molecular drug
DM58DGY	PC	25209788
DM58DGY	MW	377.4
DM58DGY	FM	C22H20FN3O2
DM58DGY	IC	InChI=1S/C22H20FN3O2/c1-13-18(16-5-3-4-6-17(16)25-13)19-20(22(28)26(2)21(19)27)24-12-11-14-7-9-15(23)10-8-14/h3-10,24-25H,11-12H2,1-2H3
DM58DGY	CS	CC1=C(C2=CC=CC=C2N1)C3=C(C(=O)N(C3=O)C)NCCC4=CC=C(C=C4)F
DM58DGY	IK	ZKJAZFUFPPSFCO-UHFFFAOYSA-N
DM58DGY	IU	3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione
DM58DGY	CA	CAS 1129669-05-1
DM58DGY	CB	CHEBI:125616
DM58DGY	DE	Discovery agent

DMUQO86	ID	DMUQO86
DMUQO86	DN	IM-491
DMUQO86	HS	Investigative
DMUQO86	SN	IM-491; UNII-UG82Y9C069; CHEMBL134908; UG82Y9C069; SCHEMBL6444631; BDBM50136259; 2,3-Piperidinedicarboxamide, N3-hydroxy-1-methyl-N2-(4-((2-methyl-4-quinolinyl)methoxy)phenyl)-, (2S,3S)-; 252918-63-1; (2S,3S)-N3-hydroxy-1-methyl-N2-(4-((2-methylquinolin-4-yl)methoxy)phenyl)piperidine-2,3-dicarboxamide; (2S,3S)-1-Methyl-piperidine-2,3-dicarboxylic acid 3-hydroxyamide 2-{[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-amide}
DMUQO86	DT	Small molecular drug
DMUQO86	PC	9889867
DMUQO86	MW	448.5
DMUQO86	FM	C25H28N4O4
DMUQO86	IC	InChI=1S/C25H28N4O4/c1-16-14-17(20-6-3-4-8-22(20)26-16)15-33-19-11-9-18(10-12-19)27-25(31)23-21(24(30)28-32)7-5-13-29(23)2/h3-4,6,8-12,14,21,23,32H,5,7,13,15H2,1-2H3,(H,27,31)(H,28,30)/t21-,23-/m0/s1
DMUQO86	CS	CC1=NC2=CC=CC=C2C(=C1)COC3=CC=C(C=C3)NC(=O)[C@@H]4[C@H](CCCN4C)C(=O)NO
DMUQO86	IK	RJSKOAOWDAMMHR-GMAHTHKFSA-N
DMUQO86	IU	(2S,3S)-3-N-hydroxy-1-methyl-2-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]piperidine-2,3-dicarboxamide
DMUQO86	CA	CAS 252918-63-1
DMUQO86	DE	Discovery agent

DMPKWUO	ID	DMPKWUO
DMPKWUO	DN	imbutamine
DMPKWUO	HS	Investigative
DMPKWUO	SN	Imbutamine; 4-(1H-imidazol-5-yl)butan-1-amine; 40546-47-2; 1H-Imidazole-4-butanamine; imidazole-4-butanamine; 4-(4-aminobutyl)imidazole; CHEMBL90019; GTPL1249; SCHEMBL3885328; CTK8I6140; BDBM22907; DTXSID90542303; 4-(1H-imidazol-4-yl)butanamine; VJSUMPPMFYQOMP-UHFFFAOYSA-N; VUF-4701; 4-(1H-Imidazol-4-yl)-butylamine; BDBM50170164; AKOS032954093; AKOS006310860
DMPKWUO	DT	Small molecular drug
DMPKWUO	PC	13499360
DMPKWUO	MW	139.2
DMPKWUO	FM	C7H13N3
DMPKWUO	IC	InChI=1S/C7H13N3/c8-4-2-1-3-7-5-9-6-10-7/h5-6H,1-4,8H2,(H,9,10)
DMPKWUO	CS	C1=C(NC=N1)CCCCN
DMPKWUO	IK	VJSUMPPMFYQOMP-UHFFFAOYSA-N
DMPKWUO	IU	4-(1H-imidazol-5-yl)butan-1-amine
DMPKWUO	CA	CAS 40546-47-2
DMPKWUO	DE	Discovery agent

DMMJ6NS	ID	DMMJ6NS
DMMJ6NS	DN	Imetit
DMMJ6NS	HS	Investigative
DMMJ6NS	SN	imetit; S-(2-(4-Imidazolyl)ethyl)isothiourea; 102203-18-9; UNII-677MJ4VPZC; 2-(1H-Imidazol-4-yl)ethyl carbamimidothioate; 677MJ4VPZC; CHEMBL19439; CHEBI:64156; 2-(1h-imidazol-5-yl)ethyl carbamimidothioate; Carbamimidothioic acid, 2-(1H-imidazol-4-yl)ethyl ester; 2-(3H-imidazol-4-yl)ethylsulfanylmethanimidamide; C6H10N4S; Carbamimidothioic acid,2-(1H-imidazol-5-yl)ethyl ester; S-[2-(4-imidazolyl)ethyl]isothiourea; Tocris-0729; Lopac-I-135; AC1Q7DRW; ACMC-20m57g; AC1L1GI2; Lopac0_000645; SCHEMBL114670; GTPL1250; DTXSID8043737
DMMJ6NS	DT	Small molecular drug
DMMJ6NS	PC	3692
DMMJ6NS	MW	170.24
DMMJ6NS	FM	C6H10N4S
DMMJ6NS	IC	InChI=1S/C6H10N4S/c7-6(8)11-2-1-5-3-9-4-10-5/h3-4H,1-2H2,(H3,7,8)(H,9,10)
DMMJ6NS	CS	C1=C(NC=N1)CCSC(=N)N
DMMJ6NS	IK	PEHSVUKQDJULKE-UHFFFAOYSA-N
DMMJ6NS	IU	2-(1H-imidazol-5-yl)ethyl carbamimidothioate
DMMJ6NS	CA	CAS 102203-18-9
DMMJ6NS	CB	CHEBI:64156
DMMJ6NS	DE	Discovery agent

DMTGRAF	ID	DMTGRAF
DMTGRAF	DN	Imidazolidin-2-ylidene-o-tolyl-amine
DMTGRAF	HS	Investigative
DMTGRAF	SN	36318-56-6; Imidazolidine, 2-(2-methylphenylimino)-; N-(2-methylphenyl)-4,5-dihydro-1H-imidazol-2-amine; CHEMBL50430; 785724-64-3; (4,5-dihydro-1H-imidazol-2-yl)-o-tolyl-amine; Imidazolidine,2-(2-methylphenylimino)-; AC1L3KDH; Benzenamine,N-2-imidazolidinylidene-2-methyl-; SCHEMBL8020019; CTK5E5913; CTK1C4679; DTXSID30189852; WLQWOUULTDRZTQ-UHFFFAOYSA-N; ZINC13835980; BDBM50213213; 2-(2-Methylphenylimino)imidazolidine; 2-(2-methylphenylimino)-imidazolidine; AKOS027415754; KB-298713
DMTGRAF	DT	Small molecular drug
DMTGRAF	PC	142067
DMTGRAF	MW	175.23
DMTGRAF	FM	C10H13N3
DMTGRAF	IC	InChI=1S/C10H13N3/c1-8-4-2-3-5-9(8)13-10-11-6-7-12-10/h2-5H,6-7H2,1H3,(H2,11,12,13)
DMTGRAF	CS	CC1=CC=CC=C1NC2=NCCN2
DMTGRAF	IK	WLQWOUULTDRZTQ-UHFFFAOYSA-N
DMTGRAF	IU	N-(2-methylphenyl)-4,5-dihydro-1H-imidazol-2-amine
DMTGRAF	CA	CAS 36318-56-6
DMTGRAF	DE	Discovery agent

DMZ5ISH	ID	DMZ5ISH
DMZ5ISH	DN	Imidazolidin-2-ylidene-quinoxalin-6-yl-amine
DMZ5ISH	HS	Investigative
DMZ5ISH	SN	91147-43-2; CHEMBL49395; Brimonidine impurity II; 6-Quinoxalinamine, N-(4,5-dihydro-1H-imidazol-2-yl)-; SCHEMBL679239; N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; SCHEMBL12860178; ZINC14042; CTK3I1267; DTXSID00436663; MolPort-039-240-453; N-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)-6-QUINOXALINAMINE; BDBM50213029; N-quinoxalin-6-ylimidazolidin-2-imine; AKOS030240596
DMZ5ISH	DT	Small molecular drug
DMZ5ISH	PC	10198248
DMZ5ISH	MW	213.24
DMZ5ISH	FM	C11H11N5
DMZ5ISH	IC	InChI=1S/C11H11N5/c1-2-9-10(13-4-3-12-9)7-8(1)16-11-14-5-6-15-11/h1-4,7H,5-6H2,(H2,14,15,16)
DMZ5ISH	CS	C1CN=C(N1)NC2=CC3=NC=CN=C3C=C2
DMZ5ISH	IK	PVKUNRLEOHFACD-UHFFFAOYSA-N
DMZ5ISH	IU	N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
DMZ5ISH	CA	CAS 91147-43-2
DMZ5ISH	DE	Discovery agent

DMS4D96	ID	DMS4D96
DMS4D96	DN	imiloxan
DMS4D96	HS	Investigative
DMS4D96	SN	RS-21361; GNF-Pf-2156
DMS4D96	DT	Small molecular drug
DMS4D96	PC	133621
DMS4D96	MW	244.29
DMS4D96	FM	C14H16N2O2
DMS4D96	IC	InChI=1S/C14H16N2O2/c1-2-16-8-7-15-14(16)9-11-10-17-12-5-3-4-6-13(12)18-11/h3-8,11H,2,9-10H2,1H3
DMS4D96	CS	CCN1C=CN=C1CC2COC3=CC=CC=C3O2
DMS4D96	IK	UXABARREKCJULM-UHFFFAOYSA-N
DMS4D96	IU	2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-ethylimidazole
DMS4D96	CA	CAS 81167-16-0
DMS4D96	CB	CHEBI:91522
DMS4D96	DE	Discovery agent

DMSINGH	ID	DMSINGH
DMSINGH	DN	Imino sugars
DMSINGH	HS	Investigative
DMSINGH	SN	Imino sugars (dengue virus infection); PBDNJ-0801; PBDNJ-0803; PBDNJ-0804; CM-10-18; CM-7-98; Imino sugars (dengue virus infection), Enantigen
DMSINGH	CP	Enantigen Therapeutics Inc
DMSINGH	DE	Dengue fever

DMZKABS	ID	DMZKABS
DMZKABS	DN	Imipramine oxide
DMZKABS	HS	Investigative
DMZKABS	SN	Elepsin; Imipramine N-oxide; Imipramine oxide; Imipraminoxide; Imipraminoxide (INN); Imipraminoxide [INN]; Imipraminoxido; Imipraminoxidum; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine 5-oxide; 5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine N-oxide; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, N-oxide; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, N-oxide; 6829-98-7; 8MKS280XJW; UNII-8MKS280XJW
DMZKABS	PC	65589
DMZKABS	MW	296.4
DMZKABS	FM	C19H24N2O
DMZKABS	IC	QZIQORUGXBPDSU-UHFFFAOYSA-N
DMZKABS	CS	C[N+](C)(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)[O-]
DMZKABS	IK	1S/C19H24N2O/c1-21(2,22)15-7-14-20-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)20/h3-6,8-11H,7,12-15H2,1-2H3
DMZKABS	IU	3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine oxide
DMZKABS	CA	CAS 6829-98-7
DMZKABS	CB	CHEBI:135256
DMZKABS	DE	Depression

DMDM3Y1	ID	DMDM3Y1
DMDM3Y1	DN	Immepip
DMDM3Y1	HS	Investigative
DMDM3Y1	SN	Immepip; 151070-83-6; 4-(1H-Imidazol-4-ylmethyl)piperidine; 4-(1H-imidazol-5-ylmethyl)piperidine; CHEBI:81390; Piperidine,4-(1H-imidazol-5-ylmethyl)-; 4-(1H-Imidazol-4-ylmethyl)-piperidine; 4-((1H-imidazol-4-yl)methyl)piperidine; Immepip, Dihydrobromide; 4-IMP; Tocris-0932; AC1MI02O; CHEMBL18661; ACMC-20n643; ZINC5777; SCHEMBL3338054; GTPL1251; BDBM22542; CTK4C6867; DTXSID10164703; FCH842654; BDBM50150945; AKOS006273473; AKOS015964158; 4-(3H-imidazol-4-ylmethyl)piperidine; NCGC00024883-01; NCGC00024883-02; CC-16184; KB-33506
DMDM3Y1	DT	Small molecular drug
DMDM3Y1	PC	3035842
DMDM3Y1	MW	165.24
DMDM3Y1	FM	C9H15N3
DMDM3Y1	IC	InChI=1S/C9H15N3/c1-3-10-4-2-8(1)5-9-6-11-7-12-9/h6-8,10H,1-5H2,(H,11,12)
DMDM3Y1	CS	C1CNCCC1CC2=CN=CN2
DMDM3Y1	IK	MCNGUYXRBCIGOV-UHFFFAOYSA-N
DMDM3Y1	IU	4-(1H-imidazol-5-ylmethyl)piperidine
DMDM3Y1	CA	CAS 151070-83-6
DMDM3Y1	CB	CHEBI:81390
DMDM3Y1	DE	Discovery agent

DM7YQ26	ID	DM7YQ26
DM7YQ26	DN	Immethridine
DM7YQ26	HS	Investigative
DM7YQ26	SN	Immethridine; UNII-F8ZT2IBM1X; F8ZT2IBM1X; 87976-03-2; 4-(1H-imidazol-5-ylmethyl)pyridine; 4-(3H-imidazol-4-ylmethyl)pyridine; SCHEMBL845141; CHEMBL82298; GTPL4024; CHEBI:92859; BDBM22910; DFVSGZHJSIEEQQ-UHFFFAOYSA-N; BCP27655; ZINC12956299; SB17136; 4-(1H-imidazol-4-yl-methyl)-pyridine; Pyridine,4-(1H-imidazol-5-ylmethyl)-; NCGC00092368-02; Pyridine, 4-(1H-imidazol-5-ylmethyl)-
DM7YQ26	DT	Small molecular drug
DM7YQ26	PC	9989505
DM7YQ26	MW	159.19
DM7YQ26	FM	C9H9N3
DM7YQ26	IC	InChI=1S/C9H9N3/c1-3-10-4-2-8(1)5-9-6-11-7-12-9/h1-4,6-7H,5H2,(H,11,12)
DM7YQ26	CS	C1=CN=CC=C1CC2=CN=CN2
DM7YQ26	IK	DFVSGZHJSIEEQQ-UHFFFAOYSA-N
DM7YQ26	IU	4-(1H-imidazol-5-ylmethyl)pyridine
DM7YQ26	CA	CAS 87976-03-2
DM7YQ26	CB	CHEBI:92859
DM7YQ26	DE	Discovery agent

DMX2NKO	ID	DMX2NKO
DMX2NKO	DN	Immucillin-G
DMX2NKO	HS	Investigative
DMX2NKO	DT	Small molecular drug
DMX2NKO	PC	135445969
DMX2NKO	MW	281.27
DMX2NKO	FM	C11H15N5O4
DMX2NKO	IC	InChI=1S/C11H15N5O4/c12-11-15-5-3(1-13-7(5)10(20)16-11)6-9(19)8(18)4(2-17)14-6/h1,4,6,8-9,13-14,17-19H,2H2,(H3,12,15,16,20)/t4-,6+,8-,9+/m1/s1
DMX2NKO	CS	C1=C(C2=C(N1)C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
DMX2NKO	IK	KBIDJCVAURJXFG-PVEDRDFWSA-N
DMX2NKO	IU	2-amino-7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMX2NKO	CB	CHEBI:43467
DMX2NKO	DE	Discovery agent

DM1TQXO	ID	DM1TQXO
DM1TQXO	DN	IMP-731
DM1TQXO	HS	Investigative
DM1TQXO	CP	Immutep SA
DM1TQXO	DE	Autoimmune diabetes

DMPJXZN	ID	DMPJXZN
DMPJXZN	DN	impentamine
DMPJXZN	HS	Investigative
DMPJXZN	SN	PDSP1_000940; PDSP2_000926
DMPJXZN	DT	Small molecular drug
DMPJXZN	PC	9793868
DMPJXZN	MW	153.22
DMPJXZN	FM	C8H15N3
DMPJXZN	IC	InChI=1S/C8H15N3/c9-5-3-1-2-4-8-6-10-7-11-8/h6-7H,1-5,9H2,(H,10,11)
DMPJXZN	CS	C1=C(NC=N1)CCCCCN
DMPJXZN	IK	MZCJWLAXZRFUPI-UHFFFAOYSA-N
DMPJXZN	IU	5-(1H-imidazol-5-yl)pentan-1-amine
DMPJXZN	CA	CAS 34973-91-6
DMPJXZN	DE	Discovery agent

DMVLW6R	ID	DMVLW6R
DMVLW6R	DN	IMPERATORIN
DMVLW6R	HS	Investigative
DMVLW6R	SN	IMPERATORIN; 482-44-0; Ammidin; Marmelosin; Pentosalen; 8-Isoamylenoxypsoralen; 8-Isopentenyloxypsoralene; Marmelide; NSC 402949; CCRIS 4346; UNII-K713N25C78; 9-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one; HSDB 3497; EINECS 207-581-1; 9-(3-Methylbut-2-enyloxy)furo(3,2-g)chromen-7-one; AI3-61725; CHEBI:5885; CHEMBL453805; OLOOJGVNMBJLLR-UHFFFAOYSA-N; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-[(3-methyl-2-butenyl)oxy]-; 9-(3-Methylbut-2-enyloxy)furo[3,2-g]chromen-7-one; K713N25C78
DMVLW6R	DT	Small molecular drug
DMVLW6R	PC	10212
DMVLW6R	MW	270.28
DMVLW6R	FM	C16H14O4
DMVLW6R	IC	InChI=1S/C16H14O4/c1-10(2)5-7-19-16-14-12(6-8-18-14)9-11-3-4-13(17)20-15(11)16/h3-6,8-9H,7H2,1-2H3
DMVLW6R	CS	CC(=CCOC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2)C
DMVLW6R	IK	OLOOJGVNMBJLLR-UHFFFAOYSA-N
DMVLW6R	IU	9-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one
DMVLW6R	CA	CAS 482-44-0
DMVLW6R	CB	CHEBI:5885
DMVLW6R	DE	Discovery agent

DMQ4ICU	ID	DMQ4ICU
DMQ4ICU	DN	improgan
DMQ4ICU	HS	Investigative
DMQ4ICU	SN	improgan; SKF-92374; GTPL1276; CHEMBL2261340
DMQ4ICU	DT	Small molecular drug
DMQ4ICU	PC	10058807
DMQ4ICU	MW	206.25
DMQ4ICU	FM	C9H14N6
DMQ4ICU	IC	InChI=1S/C9H14N6/c1-11-9(14-6-10)13-4-2-3-8-5-12-7-15-8/h5,7H,2-4H2,1H3,(H,12,15)(H2,11,13,14)
DMQ4ICU	CS	CN=C(NCCCC1=CN=CN1)NC#N
DMQ4ICU	IK	CXTGREPICTYOGB-UHFFFAOYSA-N
DMQ4ICU	IU	1-cyano-3-[3-(1H-imidazol-5-yl)propyl]-2-methylguanidine
DMQ4ICU	DE	Discovery agent

DMTDRPM	ID	DMTDRPM
DMTDRPM	DN	impromidine
DMTDRPM	HS	Investigative
DMTDRPM	SN	SK&F-92676-A3
DMTDRPM	DT	Small molecular drug
DMTDRPM	PC	41376
DMTDRPM	MW	321.45
DMTDRPM	FM	C14H23N7S
DMTDRPM	IC	InChI=1S/C14H23N7S/c1-11-13(21-10-19-11)8-22-6-5-18-14(15)17-4-2-3-12-7-16-9-20-12/h7,9-10H,2-6,8H2,1H3,(H,16,20)(H,19,21)(H3,15,17,18)
DMTDRPM	CS	CC1=C(N=CN1)CSCCNC(=NCCCC2=CN=CN2)N
DMTDRPM	IK	MURRAGMMNAYLNA-UHFFFAOYSA-N
DMTDRPM	IU	2-[3-(1H-imidazol-5-yl)propyl]-1-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
DMTDRPM	CA	CAS 55273-05-7
DMTDRPM	DE	Discovery agent

DM3YJXF	ID	DM3YJXF
DM3YJXF	DN	IN-1130
DM3YJXF	HS	Investigative
DM3YJXF	SN	IN-1130; UNII-KW4O83PQ97; 868612-83-3; CHEMBL492634; KW4O83PQ97; IN 1130; SCHEMBL139815; MolPort-042-665-839; ZINC13985930; BDBM50252542; AKOS032962854; Benzamide, 3-((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; Benzamide, 3-((4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; NCGC00386726-01; KB-274188; 3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide
DM3YJXF	DT	Small molecular drug
DM3YJXF	PC	11676119
DM3YJXF	MW	420.5
DM3YJXF	FM	C25H20N6O
DM3YJXF	IC	InChI=1S/C25H20N6O/c1-15-4-2-7-20(29-15)24-23(17-8-9-19-21(14-17)28-11-10-27-19)30-22(31-24)13-16-5-3-6-18(12-16)25(26)32/h2-12,14H,13H2,1H3,(H2,26,32)(H,30,31)
DM3YJXF	CS	CC1=NC(=CC=C1)C2=C(N=C(N2)CC3=CC(=CC=C3)C(=O)N)C4=CC5=NC=CN=C5C=C4
DM3YJXF	IK	RYKSGWSKILPDDY-UHFFFAOYSA-N
DM3YJXF	IU	3-[[5-(6-methylpyridin-2-yl)-4-quinoxalin-6-yl-1H-imidazol-2-yl]methyl]benzamide
DM3YJXF	CA	CAS 868612-83-3
DM3YJXF	DE	Discovery agent

DMMS6D3	ID	DMMS6D3
DMMS6D3	DN	IN-1166
DMMS6D3	HS	Investigative
DMMS6D3	SN	UNII-86NAB50A9A; IN-1166; CHEMBL387748; 86NAB50A9A; SCHEMBL373674; BDBM50214857; Benzonitrile, 3-(((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)amino)-; 945244-71-3
DMMS6D3	DT	Small molecular drug
DMMS6D3	PC	16654987
DMMS6D3	MW	417.5
DMMS6D3	FM	C25H19N7
DMMS6D3	IC	InChI=1S/C25H19N7/c1-16-4-2-7-21(30-16)25-24(18-8-9-20-22(13-18)28-11-10-27-20)31-23(32-25)15-29-19-6-3-5-17(12-19)14-26/h2-13,29H,15H2,1H3,(H,31,32)
DMMS6D3	CS	CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC(=C3)C#N)C4=CC5=NC=CN=C5C=C4
DMMS6D3	IK	SVFWZNDJPVECNU-UHFFFAOYSA-N
DMMS6D3	IU	3-[[5-(6-methylpyridin-2-yl)-4-quinoxalin-6-yl-1H-imidazol-2-yl]methylamino]benzonitrile
DMMS6D3	CA	CAS 945244-71-3
DMMS6D3	DE	Discovery agent

DM4JNUH	ID	DM4JNUH
DM4JNUH	DN	IN1479
DM4JNUH	HS	Investigative
DM4JNUH	SN	Flt-3 Inhibitor III; IN1479; 5-Phenyl-N-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-thiazolamine; (5-Phenyl-thiazol-2-yl)-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-amine; (5-Phenyl-thiazol-2-yl)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine; GTPL5972; SCHEMBL2230201; CHEMBL2218935; MolPort-044-561-828; FNZTULJDGIXMJJ-UHFFFAOYSA-N; HMS3229E21; ZINC35052133; CCG-206753; NCGC00387783-01; 5-phenyl-N-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-1,3-thiazol-2-amine
DM4JNUH	DT	Small molecular drug
DM4JNUH	PC	11772958
DM4JNUH	MW	365.5
DM4JNUH	FM	C21H23N3OS
DM4JNUH	IC	InChI=1S/C21H23N3OS/c1-2-6-17(7-3-1)20-16-22-21(26-20)23-18-8-10-19(11-9-18)25-15-14-24-12-4-5-13-24/h1-3,6-11,16H,4-5,12-15H2,(H,22,23)
DM4JNUH	CS	C1CCN(C1)CCOC2=CC=C(C=C2)NC3=NC=C(S3)C4=CC=CC=C4
DM4JNUH	IK	FNZTULJDGIXMJJ-UHFFFAOYSA-N
DM4JNUH	IU	5-phenyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,3-thiazol-2-amine
DM4JNUH	DE	Discovery agent

DMKFE6X	ID	DMKFE6X
DMKFE6X	DN	IN1535
DMKFE6X	HS	Investigative
DMKFE6X	SN	220792-57-4; CTK8F1119; K00613a; ZINC00582597; NCGC00390411-01; RT-011271
DMKFE6X	DT	Small molecular drug
DMKFE6X	PC	9549304
DMKFE6X	MW	403.9
DMKFE6X	FM	C19H26ClN7O
DMKFE6X	IC	InChI=1S/C19H26ClN7O/c1-10(2)15(8-28)24-19-25-17(23-14-6-12(20)5-13(21)7-14)16-18(26-19)27(9-22-16)11(3)4/h5-7,9-11,15,28H,8,21H2,1-4H3,(H2,23,24,25,26)
DMKFE6X	CS	CC(C)C(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=CC(=C3)N)Cl
DMKFE6X	IK	RAMROQQYRRQPDL-UHFFFAOYSA-N
DMKFE6X	IU	2-[[6-(3-amino-5-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol
DMKFE6X	DE	Discovery agent

DMENHMU	ID	DMENHMU
DMENHMU	DN	IN-3
DMENHMU	HS	Investigative
DMENHMU	SN	IN 3; analogue 24 [PMID: 11551758]
DMENHMU	DT	Small molecular drug
DMENHMU	PC	10231401
DMENHMU	MW	562.8
DMENHMU	FM	C37H46N4O
DMENHMU	IC	InChI=1S/C37H46N4O/c1-24-18-25(2)20-29(19-24)35-34(26(3)22-39-17-14-27-12-15-38-16-13-27)32-21-30(8-11-33(32)40-35)37(4,5)36(42)41-23-28-6-9-31(41)10-7-28/h8,11-13,15-16,18-21,26,28,31,39-40H,6-7,9-10,14,17,22-23H2,1-5H3/t26-,28?,31?/m1/s1
DMENHMU	CS	CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)[C@H](C)CNCCC6=CC=NC=C6)C
DMENHMU	IK	GGVFLXSCFPVLMS-WPCLDFDBSA-N
DMENHMU	IU	1-(2-azabicyclo[2.2.2]octan-2-yl)-2-[2-(3,5-dimethylphenyl)-3-[(2S)-1-(2-pyridin-4-ylethylamino)propan-2-yl]-1H-indol-5-yl]-2-methylpropan-1-one
DMENHMU	DE	Discovery agent

DM8E4HB	ID	DM8E4HB
DM8E4HB	DN	INC-106
DM8E4HB	HS	Investigative
DM8E4HB	SN	Angiotensin II mAb (restenosis), Inncardio/Queen Mary and Westfield College; Angiotensin II type I receptor monoclonal antibody (restenosis), Inncardio/Queen Mary Univeristy
DM8E4HB	CP	Queen Mary University of London
DM8E4HB	DT	Antibody
DM8E4HB	DE	Artery stenosis

DMZCHSD	ID	DMZCHSD
DMZCHSD	DN	INCB-10820
DMZCHSD	HS	Investigative
DMZCHSD	SN	PF-4178903; Dual CCR2/CCR5 antagonist (inflammation), Pfizer
DMZCHSD	CP	Incyte Corp
DMZCHSD	DE	Inflammation

DMONMHK	ID	DMONMHK
DMONMHK	DN	incensole acetate
DMONMHK	HS	Investigative
DMONMHK	SN	34701-53-6; Incensol acetate; GTPL4220; 1,5,9-trimethyl-12-(propan-2-yl)-15-oxabicyclo[10.2.1]pentadeca-5,9-dien-2-yl acetate
DMONMHK	DT	Small molecular drug
DMONMHK	PC	53386731
DMONMHK	MW	348.5
DMONMHK	FM	C22H36O3
DMONMHK	IC	InChI=1S/C22H36O3/c1-16(2)22-13-12-18(4)9-7-8-17(3)10-11-20(24-19(5)23)21(6,25-22)14-15-22/h8,12,16,20H,7,9-11,13-15H2,1-6H3/b17-8+,18-12+/t20-,21+,22+/m0/s1
DMONMHK	CS	C/C/1=C\\CC/C(=C/C[C@@]2(CC[C@@](O2)([C@H](CC1)OC(=O)C)C)C(C)C)/C
DMONMHK	IK	HVBACKJYWZTKCA-XSLBTUIJSA-N
DMONMHK	IU	[(1R,2S,5E,9E,12S)-1,5,9-trimethyl-12-propan-2-yl-15-oxabicyclo[10.2.1]pentadeca-5,9-dien-2-yl] acetate
DMONMHK	DE	Discovery agent

DMMLQZJ	ID	DMMLQZJ
DMMLQZJ	DN	Indan-1-ol
DMMLQZJ	HS	Investigative
DMMLQZJ	SN	Indan-1-ol; 1-Indanol; Indanol; L-INDANOL; SCHEMBL1747186; YIAPLDFPUUJILH-UHFFFAOYSA-N; (-)-indanol; 1-Hydroxyhydrindene; 1-Hydroxyindan; 1-Hydroxyindane; 1-INDANOL; 1-Indanol, 98%; 1-Indanole; 1H-Inden-1-ol, 2,3-dihydro-; 1H-Inden-1-ol,3-dihydro-; 1H-Indenol, 2,3-dihydro-; 1H-Indenol,2,3-dihydro-; 2,3-Dihydro-1H-inden-1-ol; 36643-74-0; 4-06-00-03824 (Beilstein Handbook Reference); AC1L2L5X; AC1Q7AG7; ACMC-1ATT8; ACMC-20aphe; BRN 2042960; CHEBI:16697; CTK4H6942; EINECS 253-146-4; KS-00000MBA; MFCD00003797; NSC31258; SCHEMBL57132
DMMLQZJ	PC	22819
DMMLQZJ	MW	134.17
DMMLQZJ	FM	C9H10O
DMMLQZJ	IC	YIAPLDFPUUJILH-UHFFFAOYSA-N
DMMLQZJ	CS	C1CC2=CC=CC=C2C1O
DMMLQZJ	IK	1S/C9H10O/c10-9-6-5-7-3-1-2-4-8(7)9/h1-4,9-10H,5-6H2
DMMLQZJ	IU	2,3-dihydro-1H-inden-1-ol
DMMLQZJ	CA	CAS 6351-10-6
DMMLQZJ	CB	CHEBI:16697
DMMLQZJ	DE	Discovery agent

DMVZMBU	ID	DMVZMBU
DMVZMBU	DN	Indan-2-ylcarbamic Acid Biphenyl-3-yl Ester
DMVZMBU	HS	Investigative
DMVZMBU	SN	CHEMBL485886; Indan-2-ylcarbamic Acid Biphenyl-3-yl Ester
DMVZMBU	DT	Small molecular drug
DMVZMBU	PC	24881740
DMVZMBU	MW	329.4
DMVZMBU	FM	C22H19NO2
DMVZMBU	IC	InChI=1S/C22H19NO2/c24-22(23-20-13-17-9-4-5-10-18(17)14-20)25-21-12-6-11-19(15-21)16-7-2-1-3-8-16/h1-12,15,20H,13-14H2,(H,23,24)
DMVZMBU	CS	C1C(CC2=CC=CC=C21)NC(=O)OC3=CC=CC(=C3)C4=CC=CC=C4
DMVZMBU	IK	UEEYQEMKIXZIGW-UHFFFAOYSA-N
DMVZMBU	IU	(3-phenylphenyl) N-(2,3-dihydro-1H-inden-2-yl)carbamate
DMVZMBU	DE	Discovery agent

DM4S81A	ID	DM4S81A
DM4S81A	DN	indanidine
DM4S81A	HS	Investigative
DM4S81A	SN	Sgd 101/75
DM4S81A	DT	Small molecular drug
DM4S81A	PC	121925
DM4S81A	MW	215.25
DM4S81A	FM	C11H13N5
DM4S81A	IC	InChI=1S/C11H13N5/c1-16-7-8-9(3-2-4-10(8)15-16)14-11-12-5-6-13-11/h2-4,7H,5-6H2,1H3,(H2,12,13,14)
DM4S81A	CS	CN1C=C2C(=N1)C=CC=C2NC3=NCCN3
DM4S81A	IK	PNHJTLDBYZVCGW-UHFFFAOYSA-N
DM4S81A	IU	N-(4,5-dihydro-1H-imidazol-2-yl)-2-methylindazol-4-amine
DM4S81A	CA	CAS 85392-79-6
DM4S81A	DE	Discovery agent

DMIP9DN	ID	DMIP9DN
DMIP9DN	DN	Indatraline
DMIP9DN	HS	Investigative
DMIP9DN	SN	Indatraline; Lu 19005; CHEMBL341898; 86939-10-8; Indatralinum; Indatraline [INN]; (+)-Indatraline; Lu-19-005; (-)-trans-3-(3,4-dichlorophenyl)-n-methyl-1-indanamine; Lopac-I-119; AC1Q3O5Q; Lopac0_000684; SCHEMBL9252640; AC1L2Q22; DTXSID4043981; CHEBI:94467; (+-)-trans-3-(3,4-Dichlorophenyl)-N-methyl-1-indanamine; ZINC3872906; BDBM50095618; PDSP2_001486; PDSP1_001502; CCG-204769; API0009127; NCGC00025223-04; NCGC00025223-03; NCGC00015532-01; NCGC00025223-02; 97229-15-7; 3-(3,4-Dichlorophenyl)-N-methyl-1-indanamine hcl; UNII-4U40Y96J1Z c
DMIP9DN	DT	Small molecular drug
DMIP9DN	PC	126280
DMIP9DN	MW	292.2
DMIP9DN	FM	C16H15Cl2N
DMIP9DN	IC	InChI=1S/C16H15Cl2N/c1-19-16-9-13(11-4-2-3-5-12(11)16)10-6-7-14(17)15(18)8-10/h2-8,13,16,19H,9H2,1H3/t13-,16+/m0/s1
DMIP9DN	CS	CN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
DMIP9DN	IK	SVFXPTLYMIXFRX-XJKSGUPXSA-N
DMIP9DN	IU	(1R,3S)-3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine
DMIP9DN	CA	CAS 86939-10-8
DMIP9DN	CB	CHEBI:94467
DMIP9DN	DE	Discovery agent

DMYLVQF	ID	DMYLVQF
DMYLVQF	DN	indirubin deriv. 8a
DMYLVQF	HS	Investigative
DMYLVQF	DT	Small molecular drug
DMYLVQF	PC	135398521
DMYLVQF	MW	398.2
DMYLVQF	FM	C18H12BrN3O3
DMYLVQF	IC	InChI=1S/C18H12BrN3O3/c1-9(23)25-22-16-12-4-2-3-5-13(12)20-17(16)15-11-7-6-10(19)8-14(11)21-18(15)24/h2-8,21,24H,1H3/b22-16+
DMYLVQF	CS	CC(=O)O/N=C/1\\C2=CC=CC=C2N=C1C3=C(NC4=C3C=CC(=C4)Br)O
DMYLVQF	IK	HUDSYNWJCPDHLL-CJLVFECKSA-N
DMYLVQF	IU	[(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate
DMYLVQF	CA	CAS 667463-85-6
DMYLVQF	DE	Discovery agent

DMFP1C5	ID	DMFP1C5
DMFP1C5	DN	indirubin derivative E804
DMFP1C5	HS	Investigative
DMFP1C5	SN	indirubin E804; compound 2 [PMID: 21632247]
DMFP1C5	DT	Small molecular drug
DMFP1C5	PC	6419764
DMFP1C5	DE	Discovery agent

DM3UR1E	ID	DM3UR1E
DM3UR1E	DN	Indirubin-3-acetoxime
DM3UR1E	HS	Investigative
DM3UR1E	DT	Small molecular drug
DM3UR1E	PC	136043837
DM3UR1E	MW	319.3
DM3UR1E	FM	C18H13N3O3
DM3UR1E	IC	InChI=1S/C18H13N3O3/c1-10(22)24-21-16-12-7-3-5-9-14(12)19-17(16)15-11-6-2-4-8-13(11)20-18(15)23/h2-9,20,23H,1H3/b21-16-
DM3UR1E	CS	CC(=O)O/N=C\\1/C2=CC=CC=C2N=C1C3=C(NC4=CC=CC=C43)O
DM3UR1E	IK	SPLHCOMFUFSNNE-PGMHBOJBSA-N
DM3UR1E	IU	[(Z)-[2-(2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate
DM3UR1E	DE	Discovery agent

DMZ5ODC	ID	DMZ5ODC
DMZ5ODC	DN	Indirubin-3-methoxime
DMZ5ODC	HS	Investigative
DMZ5ODC	DT	Small molecular drug
DMZ5ODC	PC	136043836
DMZ5ODC	MW	291.3
DMZ5ODC	FM	C17H13N3O2
DMZ5ODC	IC	InChI=1S/C17H13N3O2/c1-22-20-15-11-7-3-5-9-13(11)18-16(15)14-10-6-2-4-8-12(10)19-17(14)21/h2-9,19,21H,1H3/b20-15-
DMZ5ODC	CS	CO/N=C\\1/C2=CC=CC=C2N=C1C3=C(NC4=CC=CC=C43)O
DMZ5ODC	IK	DLJNVUXERDSYFS-HKWRFOASSA-N
DMZ5ODC	IU	3-[(3Z)-3-methoxyiminoindol-2-yl]-1H-indol-2-ol
DMZ5ODC	DE	Discovery agent

DMLRQH0	ID	DMLRQH0
DMLRQH0	DN	Indirubin-3'-monoxime
DMLRQH0	HS	Investigative
DMLRQH0	SN	INDIRUBIN-3'-MONOXIME; indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3&amp; CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070; Indirubin-3-oxime
DMLRQH0	DT	Small molecular drug
DMLRQH0	PC	3707
DMLRQH0	MW	277.28
DMLRQH0	FM	C16H11N3O2
DMLRQH0	IC	InChI=1S/C16H11N3O2/c20-16-13(9-5-1-3-7-11(9)18-16)15-14(19-21)10-6-2-4-8-12(10)17-15/h1-8,17-18,20H
DMLRQH0	CS	C1=CC=C2C(=C1)C(=C(N2)O)C3=C(C4=CC=CC=C4N3)N=O
DMLRQH0	IK	FQCPPVRJPILDIK-UHFFFAOYSA-N
DMLRQH0	IU	3-(3-nitroso-1H-indol-2-yl)-1H-indol-2-ol
DMLRQH0	CA	CAS 160807-49-8
DMLRQH0	CB	CHEBI:43645
DMLRQH0	DE	Discovery agent

DM08VHZ	ID	DM08VHZ
DM08VHZ	DN	Indirubin-5-sulfonate
DM08VHZ	HS	Investigative
DM08VHZ	SN	indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid; Indirubin-5-Sulphonate
DM08VHZ	DT	Small molecular drug
DM08VHZ	PC	3708
DM08VHZ	MW	342.3
DM08VHZ	FM	C16H10N2O5S
DM08VHZ	IC	InChI=1S/C16H10N2O5S/c19-15-9-3-1-2-4-11(9)17-14(15)13-10-7-8(24(21,22)23)5-6-12(10)18-16(13)20/h1-7,18,20H,(H,21,22,23)
DM08VHZ	CS	C1=CC=C2C(=C1)C(=O)C(=N2)C3=C(NC4=C3C=C(C=C4)S(=O)(=O)O)O
DM08VHZ	IK	BYYOTMYLPPUWCF-UHFFFAOYSA-N
DM08VHZ	IU	2-hydroxy-3-(3-oxoindol-2-yl)-1H-indole-5-sulfonic acid
DM08VHZ	CA	CAS 244021-67-8
DM08VHZ	DE	Discovery agent

DMJB876	ID	DMJB876
DMJB876	DN	Indol-1-yl-methyl-pyridin-4-yl-amine
DMJB876	HS	Investigative
DMJB876	SN	CHEMBL152842; Indol-1-yl-methyl-pyridin-4-yl-amine; ZINC3997; SCHEMBL7615812; BDBM50048589
DMJB876	DT	Small molecular drug
DMJB876	PC	10799123
DMJB876	MW	223.27
DMJB876	FM	C14H13N3
DMJB876	IC	InChI=1S/C14H13N3/c1-16(13-6-9-15-10-7-13)17-11-8-12-4-2-3-5-14(12)17/h2-11H,1H3
DMJB876	CS	CN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DMJB876	IK	DZLHSFJMKLMKMN-UHFFFAOYSA-N
DMJB876	IU	N-methyl-N-pyridin-4-ylindol-1-amine
DMJB876	DE	Discovery agent

DMR9GNW	ID	DMR9GNW
DMR9GNW	DN	Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine
DMR9GNW	HS	Investigative
DMR9GNW	SN	CHEMBL348034; Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine; SCHEMBL7609255; BDBM50048602
DMR9GNW	DT	Small molecular drug
DMR9GNW	PC	10490725
DMR9GNW	MW	247.29
DMR9GNW	FM	C16H13N3
DMR9GNW	IC	InChI=1S/C16H13N3/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19/h1,3-11,13H,12H2
DMR9GNW	CS	C#CCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DMR9GNW	IK	KUBLGYWISNGZNK-UHFFFAOYSA-N
DMR9GNW	IU	N-prop-2-ynyl-N-pyridin-4-ylindol-1-amine
DMR9GNW	DE	Discovery agent

DM1F53L	ID	DM1F53L
DM1F53L	DN	Indol-1-yl-pyridin-4-yl-amine
DM1F53L	HS	Investigative
DM1F53L	SN	119257-33-9; N-(4-pyridinyl)-1H-indol-1-amine; N-(PYRIDIN-4-YL)-1H-INDOL-1-AMINE; CHEMBL154488; 1H-Indol-1-amine,N-4-pyridinyl-; N-pyridin-4-ylindol-1-amine; N-4-Pyridinyl-1H-indol-1-amine; AC1MIWH0; ACMC-1C0H7; SCHEMBL3139425; ZINC24994; CTK4B1164; DTXSID90152360; YFXZWVUZIPQSKX-UHFFFAOYSA-N; BDBM50048608; 1H-Indol-1-amine, N-4-pyridinyl-; AKOS015924421; RP26505; KB-139314; J-523178
DM1F53L	DT	Small molecular drug
DM1F53L	PC	3081186
DM1F53L	MW	209.25
DM1F53L	FM	C13H11N3
DM1F53L	IC	InChI=1S/C13H11N3/c1-2-4-13-11(3-1)7-10-16(13)15-12-5-8-14-9-6-12/h1-10H,(H,14,15)
DM1F53L	CS	C1=CC=C2C(=C1)C=CN2NC3=CC=NC=C3
DM1F53L	IK	YFXZWVUZIPQSKX-UHFFFAOYSA-N
DM1F53L	IU	N-pyridin-4-ylindol-1-amine
DM1F53L	CA	CAS 119257-33-9
DM1F53L	DE	Discovery agent

DMP543H	ID	DMP543H
DMP543H	DN	INDOLACTUM
DMP543H	HS	Investigative
DMP543H	SN	(-)-Indolactam V; Indolactam V; 90365-57-4; Indolactum; UNII-8CIY9O1323; (-)-ILV; BRN 4711877; CHEMBL27266; 8CIY9O1323; (2s,5s)-5-(hydroxymethyl)-2-isopropyl-1-methyl-1,2,4,5,6,8-hexahydro-3h-[1,4]diazonino[7,6,5-cd]indol-3-one; 3H-Pyrrolo(4,3,2-gh)-1,4-benzodiazonin-3-one, 1,2,4,5,6,8-hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-, (2S-(2R*,5R*))-; 3H-Pyrrolo(4,3,2-gh)-1,4-benzodiazonin-3-one, 1,2,4,5,6,8-hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-, (2S,5S)-
DMP543H	DT	Small molecular drug
DMP543H	PC	105000
DMP543H	MW	301.4
DMP543H	FM	C17H23N3O2
DMP543H	IC	InChI=1S/C17H23N3O2/c1-10(2)16-17(22)19-12(9-21)7-11-8-18-13-5-4-6-14(15(11)13)20(16)3/h4-6,8,10,12,16,18,21H,7,9H2,1-3H3,(H,19,22)/t12-,16-/m0/s1
DMP543H	CS	CC(C)[C@H]1C(=O)N[C@@H](CC2=CNC3=C2C(=CC=C3)N1C)CO
DMP543H	IK	LUZOFMGZMUZSSK-LRDDRELGSA-N
DMP543H	IU	(10S,13S)-13-(hydroxymethyl)-9-methyl-10-propan-2-yl-3,9,12-triazatricyclo[6.6.1.04,15]pentadeca-1,4(15),5,7-tetraen-11-one
DMP543H	CA	CAS 90365-57-4
DMP543H	DE	Discovery agent

DMEHI15	ID	DMEHI15
DMEHI15	DN	Indole N -acetamide
DMEHI15	HS	Investigative
DMEHI15	SN	1H-Indole-1-acetamide; 2-(1H-indol-1-yl)acetamide; 39597-63-2; 2-indol-1-ylacetamide; 2(N-indolyl) acetamide; 2-(N-indolyl) acetamide; AC1N9C0U; SCHEMBL1519806; CHEMBL3252106; MolPort-003-001-159; IUUZMSMGSOUFTO-UHFFFAOYSA-N; ZINC6393531; STK319340; AKOS003406817; MCULE-8299376429; VU0526183-1
DMEHI15	DT	Small molecular drug
DMEHI15	PC	4408257
DMEHI15	MW	174.2
DMEHI15	FM	C10H10N2O
DMEHI15	IC	InChI=1S/C10H10N2O/c11-10(13)7-12-6-5-8-3-1-2-4-9(8)12/h1-6H,7H2,(H2,11,13)
DMEHI15	CS	C1=CC=C2C(=C1)C=CN2CC(=O)N
DMEHI15	IK	IUUZMSMGSOUFTO-UHFFFAOYSA-N
DMEHI15	IU	2-indol-1-ylacetamide
DMEHI15	DE	Hepatovirus infection

DMB4ZNW	ID	DMB4ZNW
DMB4ZNW	DN	Indole Naphthyridinone
DMB4ZNW	HS	Investigative
DMB4ZNW	SN	INDOLE NAPHTHYRIDINONE; (E)-N-METHYL-N-(1-METHYL-1H-INDOL-3-YLMETHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-[1,8]NAPHTHYRIDIN-3-YL)-ACRYLAMIDE; IDN; (2E)-N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide; AC1NRBS2; indole naphthyridinone 29; SCHEMBL725906; SCHEMBL725904; CHEMBL42208; BDBM8733; DB01691; (e)-n-methyl-n-(1-methyl-1h-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
DMB4ZNW	DT	Small molecular drug
DMB4ZNW	PC	5288607
DMB4ZNW	MW	374.4
DMB4ZNW	FM	C22H22N4O2
DMB4ZNW	IC	InChI=1S/C22H22N4O2/c1-25-13-17(18-5-3-4-6-19(18)25)14-26(2)21(28)10-7-15-11-16-8-9-20(27)24-22(16)23-12-15/h3-7,10-13H,8-9,14H2,1-2H3,(H,23,24,27)/b10-7+
DMB4ZNW	CS	CN1C=C(C2=CC=CC=C21)CN(C)C(=O)/C=C/C3=CC4=C(NC(=O)CC4)N=C3
DMB4ZNW	IK	VAZMNDXVXVUKFY-JXMROGBWSA-N
DMB4ZNW	IU	(E)-N-methyl-N-[(1-methylindol-3-yl)methyl]-3-(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-3-yl)prop-2-enamide
DMB4ZNW	DE	Discovery agent

DMF0VAG	ID	DMF0VAG
DMF0VAG	DN	indole-3-propionic acid
DMF0VAG	HS	Investigative
DMF0VAG	SN	oxigon; 3-indolepropionicacid
DMF0VAG	DT	Small molecular drug
DMF0VAG	PC	3744
DMF0VAG	MW	189.21
DMF0VAG	FM	C11H11NO2
DMF0VAG	IC	InChI=1S/C11H11NO2/c13-11(14)6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6H2,(H,13,14)
DMF0VAG	CS	C1=CC=C2C(=C1)C(=CN2)CCC(=O)O
DMF0VAG	IK	GOLXRNDWAUTYKT-UHFFFAOYSA-N
DMF0VAG	IU	3-(1H-indol-3-yl)propanoic acid
DMF0VAG	CA	CAS 830-96-6
DMF0VAG	CB	CHEBI:43580
DMF0VAG	DE	Discovery agent

DMML9AY	ID	DMML9AY
DMML9AY	DN	Indolin-2-one deriv. 4b
DMML9AY	HS	Investigative
DMML9AY	SN	indolin-2-one deriv. 4b
DMML9AY	DT	Small molecular drug
DMML9AY	PC	5329155
DMML9AY	MW	343.2
DMML9AY	FM	C17H15BrN2O
DMML9AY	IC	InChI=1S/C17H15BrN2O/c18-11-5-6-16-13(8-11)14(17(21)20-16)9-12-7-10-3-1-2-4-15(10)19-12/h5-9,19H,1-4H2,(H,20,21)/b14-9-
DMML9AY	CS	C1CCC2=C(C1)C=C(N2)/C=C\\3/C4=C(C=CC(=C4)Br)NC3=O
DMML9AY	IK	RFHPWPWVGFSLOP-ZROIWOOFSA-N
DMML9AY	IU	(3Z)-5-bromo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indol-2-one
DMML9AY	CA	CAS 288144-20-7
DMML9AY	DE	Discovery agent

DMSBENK	ID	DMSBENK
DMSBENK	DN	Indomethacin glucuronide
DMSBENK	HS	Investigative
DMSBENK	SN	Indomethacin acyl glucuronide; INDOMETHACIN GLUCURONIDE; CHEMBL2074828; Indomethacin Acyl-; INDOMETHACIN ACYL-B-D-GLUCURONIDE; 75523-11-4; ZINC84386263
DMSBENK	PC	70691027
DMSBENK	MW	533.9
DMSBENK	FM	C25H24ClNO10
DMSBENK	IC	QCBWEVBGELGABM-CZLVRFMKSA-N
DMSBENK	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC4C(C(C(C(O4)C(=O)O)O)O)O
DMSBENK	IK	1S/C25H24ClNO10/c1-11-15(10-18(28)36-25-21(31)19(29)20(30)22(37-25)24(33)34)16-9-14(35-2)7-8-17(16)27(11)23(32)12-3-5-13(26)6-4-12/h3-9,19-22,25,29-31H,10H2,1-2H3,(H,33,34)/t19-,20-,21+,22-,25+/m0/s1
DMSBENK	IU	(2S,3S,4S,5R,6S)-6-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMSBENK	CA	CAS 75523-11-4
DMSBENK	DE	Discovery agent

DMBOQ6M	ID	DMBOQ6M
DMBOQ6M	DN	INDUS-815B
DMBOQ6M	HS	Investigative
DMBOQ6M	SN	INDUS-815B (kidney disease); INDUS-815B (kidney disease), Indus Biotech; Protein kinase D-2 modulator (kidney disease),Indus Biotech
DMBOQ6M	CP	Indus Biotech Pvt Ltd
DMBOQ6M	DE	Kidney disease

DMLJ645	ID	DMLJ645
DMLJ645	DN	INDUS-815C
DMLJ645	HS	Investigative
DMLJ645	SN	VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech
DMLJ645	CP	Indus Biotech Pvt Ltd
DMLJ645	DE	Retinopathy

DMV6UJ5	ID	DMV6UJ5
DMV6UJ5	DN	Infractopicrin
DMV6UJ5	HS	Investigative
DMV6UJ5	SN	Infractopicrin
DMV6UJ5	DT	Small molecular drug
DMV6UJ5	PC	46228995
DMV6UJ5	MW	296.7
DMV6UJ5	FM	C17H13ClN2O
DMV6UJ5	IC	InChI=1S/C17H13N2O.ClH/c20-15-10-11-4-3-8-18-9-7-13-12-5-1-2-6-14(12)19(15)17(13)16(11)18;/h1-2,5-7,9-10H,3-4,8H2;1H/q+1;/p-1
DMV6UJ5	CS	C1CC2=CC(=O)N3C4=CC=CC=C4C5=C3C2=[N+](C1)C=C5.[Cl-]
DMV6UJ5	IK	ANXYOVQDHIBQTM-UHFFFAOYSA-M
DMV6UJ5	IU	1-aza-11-azoniapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),9,11(19),15-heptaen-17-one;chloride
DMV6UJ5	DE	Discovery agent

DM487FU	ID	DM487FU
DM487FU	DN	Ingenol-3-bezoate
DM487FU	HS	Investigative
DM487FU	SN	Ingenol-3-bezoate; CHEMBL46094; Ingenol 3-bezoate; BDBM50099646
DM487FU	DT	Small molecular drug
DM487FU	PC	44292399
DM487FU	MW	452.5
DM487FU	FM	C27H32O6
DM487FU	IC	InChI=1S/C27H32O6/c1-14-12-26-15(2)10-19-20(25(19,3)4)18(22(26)30)11-17(13-28)21(29)27(26,32)23(14)33-24(31)16-8-6-5-7-9-16/h5-9,11-12,15,18-21,23,28-29,32H,10,13H2,1-4H3/t15-,18+,19-,20+,21-,23+,26?,27+/m1/s1
DM487FU	CS	C[C@@H]1C[C@@H]2[C@@H](C2(C)C)[C@@H]3C=C([C@H]([C@]4(C1(C3=O)C=C([C@@H]4OC(=O)C5=CC=CC=C5)C)O)O)CO
DM487FU	IK	VYLJAGRINUHTSF-KTOZFIMGSA-N
DM487FU	IU	[(4S,5S,6R,9S,10R,12R,14R)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyl-15-oxo-4-tetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dienyl] benzoate
DM487FU	DE	Discovery agent

DMUQHMP	ID	DMUQHMP
DMUQHMP	DN	Inhibitor 1 [Colombo et al., 2012]
DMUQHMP	HS	Investigative
DMUQHMP	SN	CHEMBL2086421; inhibitor 1 [Colombo et al., 2012]; GTPL8624; SCHEMBL14232816; BDBM50420334
DMUQHMP	DT	Small molecular drug
DMUQHMP	PC	70689167
DMUQHMP	MW	646.8
DMUQHMP	FM	C27H42N12O5S
DMUQHMP	IC	InChI=1S/C27H42N12O5S/c1-14(36-24(44)18(10-11-20(29)40)38-23(43)15(28)6-4-12-34-26(30)31)22(42)37-17(8-5-13-35-27(32)33)21(41)25-39-16-7-2-3-9-19(16)45-25/h2-3,7,9,14-15,17-18H,4-6,8,10-13,28H2,1H3,(H2,29,40)(H,36,44)(H,37,42)(H,38,43)(H4,30,31,34)(H4,32,33,35)/t14-,15-,17-,18-/m0/s1
DMUQHMP	CS	C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)C1=NC2=CC=CC=C2S1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N
DMUQHMP	IK	JRNGHBUUFQDBPT-LAQRGFTBSA-N
DMUQHMP	IU	(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide
DMUQHMP	DE	Discovery agent

DMWIHRX	ID	DMWIHRX
DMWIHRX	DN	inhibitor 19
DMWIHRX	HS	Investigative
DMWIHRX	SN	CHEMBL1782887; GTPL8621; BDBM50346448; inhibitor 19 [PMID: 21476495]; 2-[2-[[[(2S,6S,9E,13S)-13-amino-2-[(4-hydroxyphenyl)methyl]-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carbonyl]amino]methyl]phenyl]acetic acid; 2-(2-(((2S,6S,13S,E)-13-Amino-2-(4-hydroxybenzyl)-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carboxamido)methyl)phenyl)acetic Acid
DMWIHRX	DT	Small molecular drug
DMWIHRX	PC	53259050
DMWIHRX	MW	536.6
DMWIHRX	FM	C29H36N4O6
DMWIHRX	IC	InChI=1S/C29H36N4O6/c30-24-9-3-1-2-4-10-25(29(39)31-18-21-8-6-5-7-20(21)16-27(36)37)33-26(35)17-22(32-28(24)38)15-19-11-13-23(34)14-12-19/h1-2,5-8,11-14,22,24-25,34H,3-4,9-10,15-18,30H2,(H,31,39)(H,32,38)(H,33,35)(H,36,37)/b2-1+/t22-,24-,25-/m0/s1
DMWIHRX	CS	C\\1C[C@@H](C(=O)N[C@H](CC(=O)N[C@@H](CC/C=C1)C(=O)NCC2=CC=CC=C2CC(=O)O)CC3=CC=C(C=C3)O)N
DMWIHRX	IK	QUJXIMWUJGTUEG-CLKUPZDLSA-N
DMWIHRX	IU	2-[2-[[[(2S,6S,9E,13S)-13-amino-2-[(4-hydroxyphenyl)methyl]-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carbonyl]amino]methyl]phenyl]acetic acid
DMWIHRX	DE	Discovery agent

DMBQY3C	ID	DMBQY3C
DMBQY3C	DN	Inhibitor Idd 384
DMBQY3C	HS	Investigative
DMBQY3C	SN	INHIBITOR IDD 384; CHEMBL240719; [2,6-dimethyl-4-(2-o-tolyl-acetylamino)-benzenesulfonyl]-glycine; I84; AC1L1CKR; BDBM50222612; DB01689; 2-(2,6-dimethyl-4-(2-o-tolylacetamido)phenylsulfonamido)acetic acid; N-[(2,6-dimethyl-4-{[(2-methylphenyl)acetyl]amino}phenyl)sulfonyl]glycine; 2-[[2,6-dimethyl-4-[[2-(2-methylphenyl)acetyl]amino]phenyl]sulfonylamino]acetic acid
DMBQY3C	DT	Small molecular drug
DMBQY3C	PC	1944
DMBQY3C	MW	390.5
DMBQY3C	FM	C19H22N2O5S
DMBQY3C	IC	InChI=1S/C19H22N2O5S/c1-12-6-4-5-7-15(12)10-17(22)21-16-8-13(2)19(14(3)9-16)27(25,26)20-11-18(23)24/h4-9,20H,10-11H2,1-3H3,(H,21,22)(H,23,24)
DMBQY3C	CS	CC1=CC=CC=C1CC(=O)NC2=CC(=C(C(=C2)C)S(=O)(=O)NCC(=O)O)C
DMBQY3C	IK	CJKKMQCZOLCXAM-UHFFFAOYSA-N
DMBQY3C	IU	2-[[2,6-dimethyl-4-[[2-(2-methylphenyl)acetyl]amino]phenyl]sulfonylamino]acetic acid
DMBQY3C	DE	Discovery agent

DMI5N23	ID	DMI5N23
DMI5N23	DN	IN-N01
DMI5N23	HS	Investigative
DMI5N23	SN	ANTISENILIN; Beta-amyloid-specific humanized monoclonal antibodies (Alzheimer's disease/glaucoma/age-related macular degeneration/traumatic brain injury), Intellect Neurosciences/IBL
DMI5N23	CP	Immuno-Biological Laboratories Co Ltd
DMI5N23	DT	Antibody
DMI5N23	DE	Brain injury

DMZEXY9	ID	DMZEXY9
DMZEXY9	DN	INO-1002
DMZEXY9	HS	Investigative
DMZEXY9	SN	PARP inhibitors, Inotek; PARP inhibitor (erectile dysfunction), Inotek; PARP inhibitor (prostate nerve damage), Inotek; Poly (ADP ribose) polymerase inhibitor (erectile dysfunction), Inotek; Poly (ADP ribose) polymerase inhibitor (prostate nerve damage), Inotek
DMZEXY9	CP	Inotek Pharmaceuticals Corp
DMZEXY9	DE	Solid tumour/cancer

DMY65AR	ID	DMY65AR
DMY65AR	DN	Inosine
DMY65AR	HS	Investigative
DMY65AR	SN	Atorel; Hypoxanthine D-riboside; Hypoxanthine nucleoside; Hypoxanthine ribonucleoside; Hypoxanthine riboside; Hypoxanthosine; INO 495; Inosie; Inosin; Inosina; Inosina [INN-Spanish]; Inosine [INN:JAN]; Inosinum; Inosinum [INN-Latin]; Oxiamin; Panholic-L; Pantholic-L; Ribonosine; Selfer; Trophicardyl; beta-Inosine; hypoxanthine-ribose; inosine; iso-prinosine; (-)-Inosine; 58-63-9; 9-beta-D-Ribofuranosylhypoxanthine; AI3-52241; Hypoxanthine, 9-beta-D-ribofuranosyl-; Hypoxanthine-9-beta-D-ribofuranoside; MFCD00066770; NSC 20262
DMY65AR	PC	135398641
DMY65AR	MW	268.23
DMY65AR	FM	C10H12N4O5
DMY65AR	IC	UGQMRVRMYYASKQ-KQYNXXCUSA-N
DMY65AR	CS	C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O
DMY65AR	IK	1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1
DMY65AR	IU	9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DMY65AR	CA	CAS 58-63-9
DMY65AR	CB	CHEBI:17596
DMY65AR	DE	Haemorrhagic stroke

DMLR86H	ID	DMLR86H
DMLR86H	DN	Inosinic Acid
DMLR86H	HS	Investigative
DMLR86H	DT	Small molecular drug
DMLR86H	PC	135398640
DMLR86H	MW	348.21
DMLR86H	FM	C10H13N4O8P
DMLR86H	IC	InChI=1S/C10H13N4O8P/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMLR86H	CS	C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
DMLR86H	IK	GRSZFWQUAKGDAV-KQYNXXCUSA-N
DMLR86H	IU	[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMLR86H	CA	CAS 131-99-7
DMLR86H	CB	CHEBI:17202
DMLR86H	DE	Discovery agent

DMIFD35	ID	DMIFD35
DMIFD35	DN	Inositol 1,3,4,5-tetrakisphosphate
DMIFD35	HS	Investigative
DMIFD35	SN	inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate
DMIFD35	DT	Small molecular drug
DMIFD35	PC	107758
DMIFD35	MW	500.08
DMIFD35	FM	C6H16O18P4
DMIFD35	IC	InChI=1S/C6H16O18P4/c7-1-3(21-25(9,10)11)2(8)5(23-27(15,16)17)6(24-28(18,19)20)4(1)22-26(12,13)14/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2-,3?,4-,5+,6?/m0/s1
DMIFD35	CS	[C@H]1([C@H](C([C@H]([C@H](C1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)O
DMIFD35	IK	CIPFCGZLFXVXBG-FTSGZOCFSA-N
DMIFD35	IU	[(1S,2S,4S,5R)-2,4-dihydroxy-3,5,6-triphosphonooxycyclohexyl] dihydrogen phosphate
DMIFD35	CA	CAS 102850-29-3
DMIFD35	CB	CHEBI:16783
DMIFD35	DE	Discovery agent

DM43G5Z	ID	DM43G5Z
DM43G5Z	DN	inositol 2,4,5-trisphosphate
DM43G5Z	HS	Investigative
DM43G5Z	SN	Ins(2,4,5)P3
DM43G5Z	DT	Small molecular drug
DM43G5Z	PC	122195
DM43G5Z	MW	420.1
DM43G5Z	FM	C6H15O15P3
DM43G5Z	IC	InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2-,3-,4-,5+,6+/m0/s1
DM43G5Z	CS	[C@@H]1([C@@H]([C@H]([C@@H]([C@H]([C@H]1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O
DM43G5Z	IK	MMWCIQZXVOZEGG-LKPKBOIGSA-N
DM43G5Z	IU	[(1R,2S,3S,4S,5S,6R)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate
DM43G5Z	CA	CAS 91840-07-2
DM43G5Z	DE	Discovery agent

DMAQU71	ID	DMAQU71
DMAQU71	DN	Ins(3,4,5,6)P4
DMAQU71	HS	Investigative
DMAQU71	SN	1D-myo-inositol 3,4,5,6-tetrakisphosphate
DMAQU71	DT	Small molecular drug
DMAQU71	PC	121920
DMAQU71	MW	500.08
DMAQU71	FM	C6H16O18P4
DMAQU71	IC	InChI=1S/C6H16O18P4/c7-1-2(8)4(22-26(12,13)14)6(24-28(18,19)20)5(23-27(15,16)17)3(1)21-25(9,10)11/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2+,3-,4-,5+,6+/m0/s1
DMAQU71	CS	[C@H]1([C@@H]([C@@H]([C@H]([C@@H]([C@H]1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)O)O
DMAQU71	IK	MRVYFOANPDTYBY-UZAAGFTCSA-N
DMAQU71	IU	[(1S,2S,3R,4S,5R,6R)-2,3-dihydroxy-4,5,6-triphosphonooxycyclohexyl] dihydrogen phosphate
DMAQU71	CA	CAS 112791-61-4
DMAQU71	CB	CHEBI:15844
DMAQU71	DE	Discovery agent

DMLZFTH	ID	DMLZFTH
DMLZFTH	DN	INS48823
DMLZFTH	HS	Investigative
DMLZFTH	SN	INS-48823; INS 48823
DMLZFTH	DT	Small molecular drug
DMLZFTH	PC	44457307
DMLZFTH	MW	812.5
DMLZFTH	FM	C26H31N4O20P3
DMLZFTH	IC	InChI=1S/C26H31N4O20P3/c31-16-6-8-29(25(35)27-16)23-20(34)19(33)14(45-23)11-43-51(37,38)49-53(41,42)50-52(39,40)44-12-15-21-22(24(46-15)30-9-7-17(32)28-26(30)36)48-18(47-21)10-13-4-2-1-3-5-13/h1-9,14-15,18-24,33-34H,10-12H2,(H,37,38)(H,39,40)(H,41,42)(H,27,31,35)(H,28,32,36)/t14-,15+,18?,19-,20-,21+,22+,23-,24+/m0/s1
DMLZFTH	CS	C1=CC=C(C=C1)CC2O[C@@H]3[C@H](O[C@H]([C@@H]3O2)N4C=CC(=O)NC4=O)COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]5[C@@H]([C@@H]([C@H](O5)N6C=CC(=O)NC6=O)O)O
DMLZFTH	IK	FIZCPSOYGRAJHH-LAJHJGSGSA-N
DMLZFTH	IU	[[(3aR,4R,6R,6aR)-2-benzyl-4-(2,4-dioxopyrimidin-1-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methoxy-hydroxyphosphoryl] [[(2S,3R,4S,5S)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DMLZFTH	DE	Discovery agent

DM95BL8	ID	DM95BL8
DM95BL8	DN	INS49266
DM95BL8	HS	Investigative
DM95BL8	SN	INS49266
DM95BL8	DT	Small molecular drug
DM95BL8	PC	91827342
DM95BL8	MW	633.4
DM95BL8	FM	C25H25N5O11P2
DM95BL8	IC	InChI=1S/C25H25N5O11P2/c31-24(16-9-5-2-6-10-16)29-22-19-23(27-13-26-22)30(14-28-19)25-21-20(39-18(40-21)11-15-7-3-1-4-8-15)17(38-25)12-37-43(35,36)41-42(32,33)34/h1-10,13-14,17-18,20-21,25H,11-12H2,(H,35,36)(H2,32,33,34)(H,26,27,29,31)/t17-,18-,20-,21-,25-/m1/s1
DM95BL8	CS	C1=CC=C(C=C1)C[C@@H]2O[C@@H]3[C@H](O[C@H]([C@@H]3O2)N4C=NC5=C(N=CN=C54)NC(=O)C6=CC=CC=C6)COP(=O)(O)OP(=O)(O)O
DM95BL8	IK	VXEHVAOFCPIBTQ-XXXKQHFZSA-N
DM95BL8	IU	[(2R,3aR,4R,6R,6aR)-4-(6-benzamidopurin-9-yl)-2-benzyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl phosphono hydrogen phosphate
DM95BL8	DE	Discovery agent

DMFU92Z	ID	DMFU92Z
DMFU92Z	DN	Insulin molecules, Novo
DMFU92Z	HS	Investigative
DMFU92Z	SN	B10Asp; B28Asp
DMFU92Z	DE	Discovery agent

DMTPB8A	ID	DMTPB8A
DMTPB8A	DN	INT-777
DMTPB8A	HS	Investigative
DMTPB8A	SN	TGR5 agonist (oral, metabolic disorder), Intercept
DMTPB8A	CP	Intercept Pharmaceuticals Inc
DMTPB8A	DT	Small molecular drug
DMTPB8A	PC	45483949
DMTPB8A	MW	450.7
DMTPB8A	FM	C27H46O5
DMTPB8A	IC	InChI=1S/C27H46O5/c1-6-17-20-12-16(28)9-10-26(20,4)21-13-22(29)27(5)18(14(2)11-15(3)25(31)32)7-8-19(27)23(21)24(17)30/h14-24,28-30H,6-13H2,1-5H3,(H,31,32)/t14-,15+,16-,17-,18-,19+,20+,21+,22+,23+,24-,26+,27-/m1/s1
DMTPB8A	CS	CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3C[C@@H]([C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)C[C@H](C)C(=O)O)C)O)C)O
DMTPB8A	IK	NPBCMXATLRCCLF-IRRLEISYSA-N
DMTPB8A	IU	(2S,4R)-4-[(3R,5S,6R,7R,8R,9S,10S,12S,13R,14S,17R)-6-ethyl-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid
DMTPB8A	CA	CAS 1199796-29-6
DMTPB8A	DE	Metabolic disorder

DMB9AIX	ID	DMB9AIX
DMB9AIX	DN	Interleukin-1-alpha - Amgen/Roche
DMB9AIX	HS	Investigative
DMB9AIX	SN	Interleukin-1-alpha - Immunex
DMB9AIX	DE	Discovery agent

DM3D9XY	ID	DM3D9XY
DM3D9XY	DN	interleukin-2, Roussel Uclaf
DM3D9XY	HS	Investigative
DM3D9XY	SN	IL-2, Elf Sanofi; IL-2, Roussel Uclaf; RU-49637; U-49637; interleukin-2, Elf Sanofi
DM3D9XY	DE	Discovery agent

DM8BZVI	ID	DM8BZVI
DM8BZVI	DN	INV-311
DM8BZVI	HS	Investigative
DM8BZVI	SN	Myeloperoxidase inhibitors (vascular/inflammatory disease), InVasc Therapeutics
DM8BZVI	CP	InVasc Therapeutics Inc
DM8BZVI	DE	Inflammation

DM3FZ6P	ID	DM3FZ6P
DM3FZ6P	DN	IODIDE
DM3FZ6P	HS	Investigative
DM3FZ6P	SN	Iodide ion; 20461-54-5; Iodide-127; Iodide(1-); iodinane; trihydridoiodine; iodine anion; Iodide anion; Iodide Salt; lambda(3)-iodane; UNII-09G4I6V86Q; I-; CHEMBL185537; CHEBI:16382; 09G4I6V86Q; Colloidal iodine; Iodine ion; Iodide ion(1-); Iodine(1-); Iodine, ion (I1-); AC1L1IXU; hydriodic acid, ion(1-); CTK1A4386; CHEBI:37181; BDBM26981; XMBWDFGMSWQBCA-UHFFFAOYSA-M; Iodide (6CI,7CI,8CI,9CI); Ba 2796; DB12754; LS-193152
DM3FZ6P	DT	Small molecular drug
DM3FZ6P	PC	30165
DM3FZ6P	MW	126.904
DM3FZ6P	FM	I-
DM3FZ6P	IC	InChI=1S/HI/h1H/p-1
DM3FZ6P	CS	[I-]
DM3FZ6P	IK	XMBWDFGMSWQBCA-UHFFFAOYSA-M
DM3FZ6P	IU	iodide
DM3FZ6P	CA	CAS 20461-54-5
DM3FZ6P	CB	CHEBI:16382
DM3FZ6P	DE	Discovery agent

DMM4XVL	ID	DMM4XVL
DMM4XVL	DN	Iodoacetamide
DMM4XVL	HS	Investigative
DMM4XVL	SN	iodoacetamide; 2-Iodoacetamide; 144-48-9; Monoiodoacetamide; Surauto; ACETAMIDE, 2-IODO-; 2-Iodo-acetamide; USAF D-1; alpha-Iodoacetamide; CCRIS 7710; C2H4INO; UNII-ZRH8M27S79; N-(3-Methoxy-4-butoxybenzyl)thiobarbituric acid; .alpha.-Iodoacetamide; AI3-51841; NSC 9581; EINECS 205-630-1; BRN 1739080; ZRH8M27S79; PGLTVOMIXTUURA-UHFFFAOYSA-N; MFCD00008028; Iodoacetamide, 98%; deltop; iodoacetoamide; a-iodoacetamide; iodo acetamide; 2-iodanylethanamide; sJYHCaVIKTp@; Alpha-iodo acetamide; Iodoacetamide, BioUltra; PubChem12542; ACMC-209csv
DMM4XVL	DT	Small molecular drug
DMM4XVL	PC	3727
DMM4XVL	MW	184.96
DMM4XVL	FM	C2H4INO
DMM4XVL	IC	InChI=1S/C2H4INO/c3-1-2(4)5/h1H2,(H2,4,5)
DMM4XVL	CS	C(C(=O)N)I
DMM4XVL	IK	PGLTVOMIXTUURA-UHFFFAOYSA-N
DMM4XVL	IU	2-iodoacetamide
DMM4XVL	CA	CAS 144-48-9
DMM4XVL	DE	Discovery agent

DM7AHNF	ID	DM7AHNF
DM7AHNF	DN	iodoaminopotentidine
DM7AHNF	HS	Investigative
DM7AHNF	SN	I-APT; CHEMBL72193; 126632-01-7; 4-amino-N-[2-[[N-cyano-N'-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]carbamimidoyl]amino]ethyl]-3-iodobenzamide; AC1L492K; GTPL1232; DTXSID40155260; BDBM50406642; N-(2-(4-Amino-3-iodobenzamido)ethyl)-N'-cyano-N''(3-(3-(1-piperidinylmethyl)phenoxy)propyl)guanidine; L000314; Benzamide, 4-amino-N-(2-(((cyanoamino)((3-(3-(1-piperidinylmethyl)phenoxy)propyl)amino)methylene)amino)ethyl)-3-iodo-
DM7AHNF	DT	Small molecular drug
DM7AHNF	PC	181461
DM7AHNF	MW	603.5
DM7AHNF	FM	C26H34IN7O2
DM7AHNF	IC	InChI=1S/C26H34IN7O2/c27-23-17-21(8-9-24(23)29)25(35)30-11-12-32-26(33-19-28)31-10-5-15-36-22-7-4-6-20(16-22)18-34-13-2-1-3-14-34/h4,6-9,16-17H,1-3,5,10-15,18,29H2,(H,30,35)(H2,31,32,33)
DM7AHNF	CS	C1CCN(CC1)CC2=CC(=CC=C2)OCCCN=C(NCCNC(=O)C3=CC(=C(C=C3)N)I)NC#N
DM7AHNF	IK	VJTYCMQYDRXNNY-UHFFFAOYSA-N
DM7AHNF	IU	4-amino-N-[2-[[N-cyano-N'-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]carbamimidoyl]amino]ethyl]-3-iodobenzamide
DM7AHNF	CA	CAS 126632-01-7
DM7AHNF	DE	Discovery agent

DMOA2J8	ID	DMOA2J8
DMOA2J8	DN	iodocyanopindolol
DMOA2J8	HS	Investigative
DMOA2J8	SN	4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3-iodo-1H-indole-2-carbonitrile; GTPL562; GTPL540
DMOA2J8	DT	Small molecular drug
DMOA2J8	PC	68618
DMOA2J8	MW	399.23
DMOA2J8	FM	C15H18IN3O2
DMOA2J8	IC	InChI=1S/C15H18IN3O2/c1-9(2)18-7-10(20)8-21-13-5-3-4-11-14(13)15(16)12(6-17)19-11/h3-5,9-10,18-20H,7-8H2,1-2H3
DMOA2J8	CS	CC(C)NCC(COC1=CC=CC2=C1C(=C(N2)C#N)I)O
DMOA2J8	IK	WGSPBWSPJOBKNT-UHFFFAOYSA-N
DMOA2J8	IU	4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3-iodo-1H-indole-2-carbonitrile
DMOA2J8	CA	CAS 83498-72-0
DMOA2J8	DE	Discovery agent

DM3BL0G	ID	DM3BL0G
DM3BL0G	DN	IODOINDOMETHACIN
DM3BL0G	HS	Investigative
DM3BL0G	SN	Iodoindomethacin; 1-(4-IODOBENZOYL)-5-METHOXY-2-METHYL INDOLE-3-ACETIC ACID; CHEMBL590284; IMM; AC1L9LAG; SCHEMBL13290295; BDBM50308511; DB07983; 1-(4-iodobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid; [1-(4-iodobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid; 2-[1-(4-iodobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid; {1-[(4-iodophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
DM3BL0G	DT	Small molecular drug
DM3BL0G	PC	447835
DM3BL0G	MW	449.2
DM3BL0G	FM	C19H16INO4
DM3BL0G	IC	InChI=1S/C19H16INO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
DM3BL0G	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)I)C=CC(=C2)OC)CC(=O)O
DM3BL0G	IK	CXBFZYKAVCAPSV-UHFFFAOYSA-N
DM3BL0G	IU	2-[1-(4-iodobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
DM3BL0G	DE	Discovery agent

DMF8EJ6	ID	DMF8EJ6
DMF8EJ6	DN	Iodo-Phenylalanine
DMF8EJ6	HS	Investigative
DMF8EJ6	SN	4-Iodo-L-phenylalanine; 24250-85-9; 4-Iodophenylalanine; L-4-Iodophenylalanine; H-Phe(4-I)-OH; IODO-PHENYLALANINE; (2S)-2-amino-3-(4-iodophenyl)propanoic acid; p-Iodo-l-phenylalanine; (S)-2-Amino-3-(4-iodophenyl)propanoic acid; Phenylalanine, 4-iodo-; p-IODOPHENYLALANINE; L-Phenylalanine, 4-iodo-; UNII-J882Z73MPL; L-4-Iodophe; (L)-4-iodophenylalanine; 1991-81-7; J882Z73MPL; MFCD00002602; (2S)-2-azanyl-3-(4-iodophenyl)propanoic acid; DL-4-iodophenylalanine; para-Iodophenylalanine; 4-iod-l-phenylalanin; 4-Iodo-L-phenylalaine
DMF8EJ6	DT	Small molecular drug
DMF8EJ6	PC	134497
DMF8EJ6	MW	291.09
DMF8EJ6	FM	C9H10INO2
DMF8EJ6	IC	InChI=1S/C9H10INO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m0/s1
DMF8EJ6	CS	C1=CC(=CC=C1C[C@@H](C(=O)O)N)I
DMF8EJ6	IK	PZNQZSRPDOEBMS-QMMMGPOBSA-N
DMF8EJ6	IU	(2S)-2-amino-3-(4-iodophenyl)propanoic acid
DMF8EJ6	CA	CAS 1991-81-7
DMF8EJ6	CB	CHEBI:44964
DMF8EJ6	DE	Discovery agent

DM0749Z	ID	DM0749Z
DM0749Z	DN	IODOPRIDE
DM0749Z	HS	Investigative
DM0749Z	SN	Iodopride; CHEMBL2115023; 115860-70-3; AC1MIZFL; DTXSID40151207; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-iodo-2-methoxybenzamide; BDBM50452484; N-[[(2R)-1-ethylpyrrolidin-2-yl]methyl]-5-iodo-2-methoxybenzamide; Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-iodo-2-methoxy-, (R)-
DM0749Z	DT	Small molecular drug
DM0749Z	PC	3082754
DM0749Z	MW	388.24
DM0749Z	FM	C15H21IN2O2
DM0749Z	IC	InChI=1S/C15H21IN2O2/c1-3-18-8-4-5-12(18)10-17-15(19)13-9-11(16)6-7-14(13)20-2/h6-7,9,12H,3-5,8,10H2,1-2H3,(H,17,19)/t12-/m1/s1
DM0749Z	CS	CCN1CCC[C@@H]1CNC(=O)C2=C(C=CC(=C2)I)OC
DM0749Z	IK	JHMTYLJMPBFCTD-GFCCVEGCSA-N
DM0749Z	IU	N-[[(2R)-1-ethylpyrrolidin-2-yl]methyl]-5-iodo-2-methoxybenzamide
DM0749Z	CA	CAS 115860-70-3
DM0749Z	DE	Discovery agent

DMDA6VL	ID	DMDA6VL
DMDA6VL	DN	IODOPROXYFAN
DMDA6VL	HS	Investigative
DMDA6VL	SN	Iodoproxyfan; CHEMBL19010; 152028-96-1; 5-[3-[(4-iodophenyl)methoxy]propyl]-1H-imidazole; 5-{3-[(4-iodophenyl)methoxy]propyl}-1H-imidazole; 4-[3-[(4-iodophenyl)methoxy]propyl]-3H-imidazole; AC1L31V0; SCHEMBL3089477; GTPL1253; 3-(1H-Imidazol-4-yl)propyl-(4-iodophenyl)methyl ether; BDBM22916; DTXSID30164942; ZINC5117186; PDSP2_000542; PDSP1_000544; L010934; 1H-Imidazole, 4-(3-((4-iodophenyl)methoxy)propyl)-
DMDA6VL	DT	Small molecular drug
DMDA6VL	PC	132937
DMDA6VL	MW	342.18
DMDA6VL	FM	C13H15IN2O
DMDA6VL	IC	InChI=1S/C13H15IN2O/c14-12-5-3-11(4-6-12)9-17-7-1-2-13-8-15-10-16-13/h3-6,8,10H,1-2,7,9H2,(H,15,16)
DMDA6VL	CS	C1=CC(=CC=C1COCCCC2=CN=CN2)I
DMDA6VL	IK	DCQNAFOCXVCDLB-UHFFFAOYSA-N
DMDA6VL	IU	5-[3-[(4-iodophenyl)methoxy]propyl]-1H-imidazole
DMDA6VL	CA	CAS 152028-96-1
DMDA6VL	DE	Discovery agent

DMXYFMB	ID	DMXYFMB
DMXYFMB	DN	IODOSULPIRIDE
DMXYFMB	HS	Investigative
DMXYFMB	SN	CHEMBL307023; BDBM50040082; N-(1-Ethyl-pyrrolidin-2-ylmethyl)-2-methoxy-5-sulfamoyl-benzamide(iodosulpiride); N-(1-Ethyl-pyrrolidin-2-ylmethyl)-2-iodo-6-methoxy-3-sulfamoyl-benzamide (iodosulpride)
DMXYFMB	DT	Small molecular drug
DMXYFMB	PC	44312731
DMXYFMB	MW	467.3
DMXYFMB	FM	C15H22IN3O4S
DMXYFMB	IC	InChI=1S/C15H22IN3O4S/c1-3-19-8-4-5-10(19)9-18-15(20)13-11(23-2)6-7-12(14(13)16)24(17,21)22/h6-7,10H,3-5,8-9H2,1-2H3,(H,18,20)(H2,17,21,22)/t10-/m0/s1
DMXYFMB	CS	CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2I)S(=O)(=O)N)OC
DMXYFMB	IK	HCKMONAVUWHQOT-JTQLQIEISA-N
DMXYFMB	IU	N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-iodo-6-methoxy-3-sulfamoylbenzamide
DMXYFMB	DE	Discovery agent

DMOE8LT	ID	DMOE8LT
DMOE8LT	DN	IODOSUPROFEN
DMOE8LT	HS	Investigative
DMOE8LT	SN	Iodosuprofen; CHEMBL589253; AC1NE3NB; BDBM50308510; 2-[4-(5-iodothiophene-2-carbonyl)phenyl]propanoic
DMOE8LT	DT	Small molecular drug
DMOE8LT	PC	4636051
DMOE8LT	MW	386.21
DMOE8LT	FM	C14H11IO3S
DMOE8LT	IC	InChI=1S/C14H11IO3S/c1-8(14(17)18)9-2-4-10(5-3-9)13(16)11-6-7-12(15)19-11/h2-8H,1H3,(H,17,18)
DMOE8LT	CS	CC(C1=CC=C(C=C1)C(=O)C2=CC=C(S2)I)C(=O)O
DMOE8LT	IK	UIZPHGUBGPJBAR-UHFFFAOYSA-N
DMOE8LT	IU	2-[4-(5-iodothiophene-2-carbonyl)phenyl]propanoic acid
DMOE8LT	DE	Discovery agent

DMQMH6S	ID	DMQMH6S
DMQMH6S	DN	Iodotubercidin
DMQMH6S	HS	Investigative
DMQMH6S	SN	IODOTUBERCIDIN
DMQMH6S	DT	Small molecular drug
DMQMH6S	PC	46875276
DMQMH6S	MW	392.15
DMQMH6S	FM	C11H13IN4O4
DMQMH6S	IC	InChI=1S/C11H13IN4O4/c12-4-1-16(10-6(4)9(13)14-3-15-10)11-8(19)7(18)5(2-17)20-11/h1,3,5,7-8,11,17-19H,2H2,(H2,13,14,15)/t5-,7-,8-,11?/m1/s1
DMQMH6S	CS	C1=C(C2=C(N=CN=C2N1C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)I
DMQMH6S	IK	WHSIXKUPQCKWBY-YNJARDAQSA-N
DMQMH6S	IU	(3R,4S,5R)-2-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMQMH6S	DE	Discovery agent

DMO73M9	ID	DMO73M9
DMO73M9	DN	Iodyl-benzene
DMO73M9	HS	Investigative
DMO73M9	SN	Iodoxybenzene; Iodyl-benzene; Benzene, iodyl-; phenyliodane dioxide; 696-33-3; iodylbenzene; CHEMBL325174; 1-iodylbenzene; NSC 60684; AC1Q6QYY; AC1L2RNB; SCHEMBL751952; CTK2F5229; DTXSID70219869; BDOLQESNFGCNSC-UHFFFAOYSA-N; NSC60684; BDBM50075022; NSC-60684; AKOS000531141; BAS 00121555; SC-90106; FT-0658671; A19070
DMO73M9	DT	Small molecular drug
DMO73M9	PC	101840
DMO73M9	MW	236.01
DMO73M9	FM	C6H5IO2
DMO73M9	IC	InChI=1S/C6H5IO2/c8-7(9)6-4-2-1-3-5-6/h1-5H
DMO73M9	CS	C1=CC=C(C=C1)I(=O)=O
DMO73M9	IK	BDOLQESNFGCNSC-UHFFFAOYSA-N
DMO73M9	IU	iodylbenzene
DMO73M9	CA	CAS 696-33-3
DMO73M9	DE	Discovery agent

DMYG0M5	ID	DMYG0M5
DMYG0M5	DN	IOX1
DMYG0M5	HS	Investigative
DMYG0M5	SN	5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, &gt; AKOS016371793
DMYG0M5	DT	Small molecular drug
DMYG0M5	PC	459617
DMYG0M5	MW	189.17
DMYG0M5	FM	C10H7NO3
DMYG0M5	IC	InChI=1S/C10H7NO3/c12-8-4-3-7(10(13)14)6-2-1-5-11-9(6)8/h1-5,12H,(H,13,14)
DMYG0M5	CS	C1=CC2=C(C=CC(=C2N=C1)O)C(=O)O
DMYG0M5	IK	JGRPKOGHYBAVMW-UHFFFAOYSA-N
DMYG0M5	IU	8-hydroxyquinoline-5-carboxylic acid
DMYG0M5	CA	CAS 5852-78-8
DMYG0M5	CB	CHEBI:93239
DMYG0M5	DE	Discovery agent

DMQ0X7I	ID	DMQ0X7I
DMQ0X7I	DN	IOX2
DMQ0X7I	HS	Investigative
DMQ0X7I	SN	compound 6
DMQ0X7I	DT	Small molecular drug
DMQ0X7I	PC	54685215
DMQ0X7I	MW	352.3
DMQ0X7I	FM	C19H16N2O5
DMQ0X7I	IC	InChI=1S/C19H16N2O5/c22-15(23)10-20-18(25)16-17(24)13-8-4-5-9-14(13)21(19(16)26)11-12-6-2-1-3-7-12/h1-9,24H,10-11H2,(H,20,25)(H,22,23)
DMQ0X7I	CS	C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O
DMQ0X7I	IK	CAOSCCRYLYQBES-UHFFFAOYSA-N
DMQ0X7I	IU	2-[(1-benzyl-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]acetic acid
DMQ0X7I	CA	CAS 931398-72-0
DMQ0X7I	CB	CHEBI:95087
DMQ0X7I	DE	Discovery agent

DMIX7CP	ID	DMIX7CP
DMIX7CP	DN	IP-1200
DMIX7CP	HS	Investigative
DMIX7CP	CP	Shire Pharmaceutical Development Ltd
DMIX7CP	DE	Erectile dysfunction

DMB2YXN	ID	DMB2YXN
DMB2YXN	DN	Ip5I
DMB2YXN	HS	Investigative
DMB2YXN	SN	diinosine-5',5"-pentaphosphate
DMB2YXN	DT	Small molecular drug
DMB2YXN	PC	136203454
DMB2YXN	MW	913.3
DMB2YXN	FM	C20H22N8O24P5-5
DMB2YXN	IC	InChI=1S/C20H27N8O24P5/c29-11-7(47-19(13(11)31)27-5-25-9-15(27)21-3-23-17(9)33)1-45-57(44,52-56(42,43)51-55(40,41)50-54(38,39)49-53(35,36)37)46-2-8-12(30)14(32)20(48-8)28-6-26-10-16(28)22-4-24-18(10)34/h3-8,11-14,19-20,29-32H,1-2H2,(H,38,39)(H,40,41)(H,42,43)(H,21,23,33)(H,22,24,34)(H2,35,36,37)/p-5/t7-,8-,11?,12?,13?,14?,19-,20-,57?/m1/s1
DMB2YXN	CS	C1=NC2=C(C(=O)N1)N=CN2[C@H]3C(C([C@H](O3)COP(=O)(OC[C@@H]4C(C([C@@H](O4)N5C=NC6=C5N=CNC6=O)O)O)OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])[O-])O)O
DMB2YXN	IK	GFFAYTMBCSSULP-ICIWVTHHSA-I
DMB2YXN	IU	[[[bis[[(2R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy]phosphoryloxy-oxidophosphoryl]oxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate
DMB2YXN	DE	Discovery agent

DM6OHVU	ID	DM6OHVU
DM6OHVU	DN	iperoxo
DM6OHVU	HS	Investigative
DM6OHVU	SN	iperoxo; CHEMBL3121473; GTPL6937; BDBM50448377; [4-(2-Isoxazoline-3-yloxy)-2-butynyl]trimethylaminium
DM6OHVU	DT	Small molecular drug
DM6OHVU	PC	10104167
DM6OHVU	MW	197.25
DM6OHVU	FM	C10H17N2O2+
DM6OHVU	IC	InChI=1S/C10H17N2O2/c1-12(2,3)7-4-5-8-13-10-6-9-14-11-10/h6-9H2,1-3H3/q+1
DM6OHVU	CS	C[N+](C)(C)CC#CCOC1=NOCC1
DM6OHVU	IK	WXXOCGISBCTWPW-UHFFFAOYSA-N
DM6OHVU	IU	4-(4,5-dihydro-1,2-oxazol-3-yloxy)but-2-ynyl-trimethylazanium
DM6OHVU	DE	Discovery agent

DM42ENF	ID	DM42ENF
DM42ENF	DN	IPRONIAZIDE
DM42ENF	HS	Investigative
DM42ENF	SN	iproniazid; 54-92-2; N'-Isopropylisonicotinohydrazide; Iprazid; Marsilid; Iproniazide; Euphozid; Rivivol; Marsalid; Yatrozide; 4-Pyridinecarboxylic acid, 2-(1-methylethyl)hydrazide; Iproniazyd [Polish]; Propilniazida; Ipronid; Ro 2-4572; N'-Isopropylisonicotinoylhydrazide; Iproniazide [INN-French]; Iproniazidum [INN-Latin]; UNII-D892HFI3XA; Iproniazida [INN-Spanish]; 1-Isonicotinoyl-2-isopropylhydrazine; N'-isopropylpyridine-4-carbohydrazide; CCRIS 9177; C9H13N3O; P 887; EINECS 200-218-8; Isonicotinic acid 2-isopropylhydrazide; BRN 0
DM42ENF	DT	Small molecular drug
DM42ENF	PC	3748
DM42ENF	MW	179.22
DM42ENF	FM	C9H13N3O
DM42ENF	IC	InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)
DM42ENF	CS	CC(C)NNC(=O)C1=CC=NC=C1
DM42ENF	IK	NYMGNSNKLVNMIA-UHFFFAOYSA-N
DM42ENF	IU	N'-propan-2-ylpyridine-4-carbohydrazide
DM42ENF	CA	CAS 54-92-2
DM42ENF	CB	CHEBI:5958
DM42ENF	DE	Discovery agent

DM0T8ZU	ID	DM0T8ZU
DM0T8ZU	DN	IPS-01003
DM0T8ZU	HS	Investigative
DM0T8ZU	SN	EGFR kinase antagonist (cancer), InnoPharmaScreen
DM0T8ZU	CP	InnoPharmaScreen Inc
DM0T8ZU	DE	Solid tumour/cancer

DMYEM59	ID	DMYEM59
DMYEM59	DN	Ipsalazide
DMYEM59	HS	Investigative
DMYEM59	SN	Ipsalazida; Ipsalazida [Spanish]; Ipsalazide; Ipsalazide [BAN:INN]; Ipsalazide [INN:BAN]; Ipsalazido; Ipsalazido [Spanish]; Ipsalazidum; Ipsalazidum [Latin]; LS-36378; SCHEMBL596652; ZINC4216628; (E)-5-((4-(((Carboxymethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-p-((3-Carboxy-4-hydroxyphenyl)azo)hippuric acid; 499H4332KZ; 80573-03-1; BX 650 A; BX-650A; Benzoic acid, 5-((4-(((carboxymethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, (E)-; CHEMBL2104872; SCHEMBL11165440; UNII-499H4332KZ
DMYEM59	PC	72003
DMYEM59	MW	343.29
DMYEM59	FM	C16H13N3O6
DMYEM59	IC	CQSRTOJJBONKMC-UHFFFAOYSA-N
DMYEM59	CS	C1=CC(=CC=C1C(=O)NCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DMYEM59	IK	1S/C16H13N3O6/c20-13-6-5-11(7-12(13)16(24)25)19-18-10-3-1-9(2-4-10)15(23)17-8-14(21)22/h1-7,20H,8H2,(H,17,23)(H,21,22)(H,24,25)
DMYEM59	IU	5-[[4-(carboxymethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DMYEM59	CA	CAS 80573-03-1
DMYEM59	DE	Inflammatory bowel disease

DM2MXIK	ID	DM2MXIK
DM2MXIK	DN	IQM-97423
DM2MXIK	HS	Investigative
DM2MXIK	SN	IQM-97,423
DM2MXIK	DT	Small molecular drug
DM2MXIK	PC	11757476
DM2MXIK	MW	558.7
DM2MXIK	FM	C31H38N6O4
DM2MXIK	IC	InChI=1S/C31H38N6O4/c1-31(2,3)35-29(40)34-25(16-21-18-32-23-13-8-7-12-22(21)23)28(39)33-24-14-9-15-36-26(24)17-27(38)37(30(36)41)19-20-10-5-4-6-11-20/h4-8,10-13,18,24-26,32H,9,14-17,19H2,1-3H3,(H,33,39)(H2,34,35,40)/t24-,25+,26+/m1/s1
DM2MXIK	CS	CC(C)(C)NC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H]3CCCN4[C@H]3CC(=O)N(C4=O)CC5=CC=CC=C5
DM2MXIK	IK	JQMXXJDAKTTXOB-ZNZIZOMTSA-N
DM2MXIK	IU	(2S)-N-[(4aS,5R)-2-benzyl-1,3-dioxo-4,4a,5,6,7,8-hexahydropyrido[1,2-c]pyrimidin-5-yl]-2-(tert-butylcarbamoylamino)-3-(1H-indol-3-yl)propanamide
DM2MXIK	DE	Discovery agent

DMOQBGP	ID	DMOQBGP
DMOQBGP	DN	IRAK-1/4 inhibitor
DMOQBGP	HS	Investigative
DMOQBGP	SN	IRAK-1-4 Inhibitor I; 509093-47-4; IRAK-1/4 Inhibitor I; IRAK-1/4 Inhibitor; Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor; CHEMBL379787; N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole; N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide; N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitrobenzamide; IRAK-1-4InhibitorI; IRAK1/4 Inhibitor I; MLS006010636; SCHEMBL3600534; GTPL5990; CTK8E9833; DTXSID50475143; QTCFYQHZJIIHBS-UHFFFAOYSA-N; MolPort-028-617-757; HMS3263A20; HMS3229G05
DMOQBGP	DT	Small molecular drug
DMOQBGP	PC	11983295
DMOQBGP	MW	395.4
DMOQBGP	FM	C20H21N5O4
DMOQBGP	IC	InChI=1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
DMOQBGP	CS	C1COCCN1CCN2C3=CC=CC=C3N=C2NC(=O)C4=CC(=CC=C4)[N+](=O)[O-]
DMOQBGP	IK	QTCFYQHZJIIHBS-UHFFFAOYSA-N
DMOQBGP	IU	N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide
DMOQBGP	CA	CAS 509093-47-4
DMOQBGP	DE	Discovery agent

DMC80TA	ID	DMC80TA
DMC80TA	DN	IRAK4 inhibitor 4b
DMC80TA	HS	Investigative
DMC80TA	SN	CHEMBL256713; N-[2-methoxy-4-(morpholin-4-yl)phenyl]-6-(1H-pyrazol-5-yl)pyridine-2-carboxamide; DL1; GTPL8080; SCHEMBL18427794; BDBM50373415; IRAK4 inhibitor 4b [PMID: 18474425]
DMC80TA	DT	Small molecular drug
DMC80TA	PC	44449334
DMC80TA	MW	379.4
DMC80TA	FM	C20H21N5O3
DMC80TA	IC	InChI=1S/C20H21N5O3/c1-27-19-13-14(25-9-11-28-12-10-25)5-6-17(19)23-20(26)18-4-2-3-15(22-18)16-7-8-21-24-16/h2-8,13H,9-12H2,1H3,(H,21,24)(H,23,26)
DMC80TA	CS	COC1=C(C=CC(=C1)N2CCOCC2)NC(=O)C3=CC=CC(=N3)C4=CC=NN4
DMC80TA	IK	RAFFLDOJXQAJPF-UHFFFAOYSA-N
DMC80TA	IU	N-(2-methoxy-4-morpholin-4-ylphenyl)-6-(1H-pyrazol-5-yl)pyridine-2-carboxamide
DMC80TA	DE	Discovery agent

DM1XHNW	ID	DM1XHNW
DM1XHNW	DN	IRAK4 inhibitor rac-45
DM1XHNW	HS	Investigative
DM1XHNW	SN	CHEMBL401633; GTPL8081; SCHEMBL18427753; BDBM50377180; IRAK4 inhibitor rac-45 [PMID: 18501603]
DM1XHNW	DT	Small molecular drug
DM1XHNW	PC	25169383
DM1XHNW	MW	313.78
DM1XHNW	FM	C16H16ClN5
DM1XHNW	IC	InChI=1S/C16H16ClN5/c17-11-4-5-16-19-9-14(22(16)10-11)13-2-1-3-15(21-13)20-12-6-7-18-8-12/h1-5,9-10,12,18H,6-8H2,(H,20,21)
DM1XHNW	CS	C1CNCC1NC2=CC=CC(=N2)C3=CN=C4N3C=C(C=C4)Cl
DM1XHNW	IK	NAMQQRIYZTTYCJ-UHFFFAOYSA-N
DM1XHNW	IU	6-(6-chloroimidazo[1,2-a]pyridin-3-yl)-N-pyrrolidin-3-ylpyridin-2-amine
DM1XHNW	DE	Discovery agent

DM5S7IG	ID	DM5S7IG
DM5S7IG	DN	Irbesartan
DM5S7IG	HS	Investigative
DM5S7IG	SN	Aprovel; Avapro; Karvea; SR-47436; BMS-186295; BMS 186295; SR 47436; UNII-J0E2756Z7N; CHEMBL1513; YOSHYTLCDANDAN-UHFFFAOYSA-N; J0E2756Z7N; NCGC00095122-01; AK-57149; DSSTox_CID_3169; Irbesartan [USAN:INN]
DM5S7IG	TC	Antiviral Agents
DM5S7IG	DT	Small molecular drug
DM5S7IG	PC	3749
DM5S7IG	MW	428.5
DM5S7IG	FM	C25H28N6O
DM5S7IG	IC	InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
DM5S7IG	CS	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DM5S7IG	IK	YOSHYTLCDANDAN-UHFFFAOYSA-N
DM5S7IG	IU	2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
DM5S7IG	CA	CAS 138402-11-6
DM5S7IG	CB	CHEBI:5959
DM5S7IG	DE	Coronavirus Disease 2019 (COVID-19)

DMMGQZ8	ID	DMMGQZ8
DMMGQZ8	DN	IRL-1722
DMMGQZ8	HS	Investigative
DMMGQZ8	SN	CHEMBL418898; IRL-1722; BDBM50287880; (S)-3-(1H-Indol-3-yl)-2-[(2-phenyl-cyclopropanecarbonyl)-amino]-propionic acid
DMMGQZ8	DT	Small molecular drug
DMMGQZ8	PC	9863132
DMMGQZ8	MW	348.4
DMMGQZ8	FM	C21H20N2O3
DMMGQZ8	IC	InChI=1S/C21H20N2O3/c24-20(17-11-16(17)13-6-2-1-3-7-13)23-19(21(25)26)10-14-12-22-18-9-5-4-8-15(14)18/h1-9,12,16-17,19,22H,10-11H2,(H,23,24)(H,25,26)/t16?,17?,19-/m0/s1
DMMGQZ8	CS	C1C(C1C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)C4=CC=CC=C4
DMMGQZ8	IK	DRPGADQFIJJWNZ-TVPLGVNVSA-N
DMMGQZ8	IU	(2S)-3-(1H-indol-3-yl)-2-[(2-phenylcyclopropanecarbonyl)amino]propanoic acid
DMMGQZ8	DE	Discovery agent

DML0S7V	ID	DML0S7V
DML0S7V	DN	IRL-1841
DML0S7V	HS	Investigative
DML0S7V	SN	CHEMBL439759; 169544-71-2; IRL-1841; SCHEMBL8721943; CTK0E5016; DTXSID80431752; BDBM50071431; L-Tryptophan, N-[N-(3,5-dimethylbenzoyl)-N-methyl-D-phenylalanyl]-; (S)-2-{(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-phenyl-propionylamino}-3-(1H-indol-3-yl)-propionic acid
DML0S7V	DT	Small molecular drug
DML0S7V	PC	9848710
DML0S7V	MW	497.6
DML0S7V	FM	C30H31N3O4
DML0S7V	IC	InChI=1S/C30H31N3O4/c1-19-13-20(2)15-22(14-19)29(35)33(3)27(16-21-9-5-4-6-10-21)28(34)32-26(30(36)37)17-23-18-31-25-12-8-7-11-24(23)25/h4-15,18,26-27,31H,16-17H2,1-3H3,(H,32,34)(H,36,37)/t26-,27+/m0/s1
DML0S7V	CS	CC1=CC(=CC(=C1)C(=O)N(C)[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)C
DML0S7V	IK	JFNANCYIHVAEQV-RRPNLBNLSA-N
DML0S7V	IU	(2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DML0S7V	CA	CAS 169544-71-2
DML0S7V	DE	Discovery agent

DMNF70P	ID	DMNF70P
DMNF70P	DN	IS1
DMNF70P	HS	Investigative
DMNF70P	SN	N-{2-Furan-2-yl-1-[(pyridin-3-ylmethyl)-carbamoyl]-vinyl}-benzamide; IS1; AC1MFOLV; SMR000176552; Salor-int l253618-1ea; MLS000551960; GTPL8517; CHEMBL1499206; SCHEMBL10092076; MolPort-000-526-523; HMS2374A20; ZINC4892255; AKOS000531713; BAS 01151561; ACM324562018; ST053578; SR-01000425582; SR-01000425582-1; N-[(Z)-1-furan-2-yl-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide; N~1~-((Z)-2-(2-furyl)-1-{[(3-pyridylmethyl)amino]carbonyl}-1-ethenyl)benzamide
DMNF70P	DT	Small molecular drug
DMNF70P	PC	2874943
DMNF70P	MW	347.4
DMNF70P	FM	C20H17N3O3
DMNF70P	IC	InChI=1S/C20H17N3O3/c24-19(16-7-2-1-3-8-16)23-18(12-17-9-5-11-26-17)20(25)22-14-15-6-4-10-21-13-15/h1-13H,14H2,(H,22,25)(H,23,24)/b18-12-
DMNF70P	CS	C1=CC=C(C=C1)C(=O)N/C(=C\\C2=CC=CO2)/C(=O)NCC3=CN=CC=C3
DMNF70P	IK	ANTQNDKESCDJPE-PDGQHHTCSA-N
DMNF70P	IU	N-[(Z)-1-(furan-2-yl)-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide
DMNF70P	DE	Discovery agent

DMQ5GA9	ID	DMQ5GA9
DMQ5GA9	DN	IS20
DMQ5GA9	HS	Investigative
DMQ5GA9	SN	N-{2-(4-Methoxy-phenyl)-1-[(pyridin-3-ylmethyl)-carbamoyl]-vinyl}-benzamide; N-[(Z)-1-(4-methoxyphenyl)-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide; IS20; AC1NU0FP; MLS001215457; GTPL8518; CHEMBL1387323; SCHEMBL10192303; MolPort-019-741-307; HMS2912O06; ZINC13370608; AKOS000531635; SMR000608280; BAS 01151555; ST50247237; SR-01000425577; SR-01000425577-1; (2Z)-3-(4-methoxyphenyl)-2-(phenylcarbonylamino)-N-(3-pyridylmethyl)prop-2-ena mide
DMQ5GA9	DT	Small molecular drug
DMQ5GA9	PC	5442665
DMQ5GA9	MW	387.4
DMQ5GA9	FM	C23H21N3O3
DMQ5GA9	IC	InChI=1S/C23H21N3O3/c1-29-20-11-9-17(10-12-20)14-21(26-22(27)19-7-3-2-4-8-19)23(28)25-16-18-6-5-13-24-15-18/h2-15H,16H2,1H3,(H,25,28)(H,26,27)/b21-14-
DMQ5GA9	CS	COC1=CC=C(C=C1)/C=C(/C(=O)NCC2=CN=CC=C2)\\NC(=O)C3=CC=CC=C3
DMQ5GA9	IK	KKDANILRTKQMGA-STZFKDTASA-N
DMQ5GA9	IU	N-[(Z)-1-(4-methoxyphenyl)-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide
DMQ5GA9	DE	Discovery agent

DMXPMA6	ID	DMXPMA6
DMXPMA6	DN	IS20I
DMXPMA6	HS	Investigative
DMXPMA6	DE	Discovery agent

DMU6QXV	ID	DMU6QXV
DMU6QXV	DN	ISA-2011B
DMU6QXV	HS	Investigative
DMU6QXV	SN	ISA-2011B; 1395347-24-6; GTPL8444; SCHEMBL10020974; AKOS032946525; CS-6374
DMU6QXV	DT	Small molecular drug
DMU6QXV	PC	49853637
DMU6QXV	MW	423.8
DMU6QXV	FM	C22H18ClN3O4
DMU6QXV	IC	InChI=1S/C22H18ClN3O4/c1-25-9-20(27)26-17(22(25)28)4-11-5-18-19(30-10-29-18)7-13(11)21(26)15-8-24-16-3-2-12(23)6-14(15)16/h2-3,5-8,17,21,24H,4,9-10H2,1H3/t17-,21-/m0/s1
DMU6QXV	CS	CN1CC(=O)N2[C@H](C1=O)CC3=CC4=C(C=C3[C@H]2C5=CNC6=C5C=C(C=C6)Cl)OCO4
DMU6QXV	IK	FSEZESVJDPKRDS-UWJYYQICSA-N
DMU6QXV	IU	(2S,8S)-2-(5-chloro-1H-indol-3-yl)-6-methyl-13,15-dioxa-3,6-diazatetracyclo[8.7.0.03,8.012,16]heptadeca-1(17),10,12(16)-triene-4,7-dione
DMU6QXV	DE	Discovery agent

DMD6U4F	ID	DMD6U4F
DMD6U4F	DN	ISAINDIGOTONE
DMD6U4F	HS	Investigative
DMD6U4F	DT	Small molecular drug
DMD6U4F	PC	135433966
DMD6U4F	MW	350.4
DMD6U4F	FM	C20H18N2O4
DMD6U4F	IC	InChI=1S/C20H18N2O4/c1-25-16-10-12(11-17(26-2)18(16)23)9-13-7-8-22-19(13)21-15-6-4-3-5-14(15)20(22)24/h3-6,9-11,23H,7-8H2,1-2H3/b13-9+
DMD6U4F	CS	COC1=CC(=CC(=C1O)OC)/C=C/2\\CCN3C2=NC4=CC=CC=C4C3=O
DMD6U4F	IK	UBCUTNIGHUVICE-UKTHLTGXSA-N
DMD6U4F	IU	(3E)-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-9-one
DMD6U4F	DE	Discovery agent

DMJ2FQA	ID	DMJ2FQA
DMJ2FQA	DN	I-SAP
DMJ2FQA	HS	Investigative
DMJ2FQA	SN	(Z)-7-[(1R,2S,3S,5S)-3-[(4-iodophenyl)sulfonylamino]-7,7-dimethyl-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DMJ2FQA	DT	Small molecular drug
DMJ2FQA	PC	5312147
DMJ2FQA	MW	531.4
DMJ2FQA	FM	C22H30INO4S
DMJ2FQA	IC	InChI=1S/C22H30INO4S/c1-22(2)15-13-19(22)18(7-5-3-4-6-8-21(25)26)20(14-15)24-29(27,28)17-11-9-16(23)10-12-17/h3,5,9-12,15,18-20,24H,4,6-8,13-14H2,1-2H3,(H,25,26)/b5-3-/t15-,18+,19+,20+/m1/s1
DMJ2FQA	CS	CC1([C@@H]2C[C@H]1[C@@H]([C@H](C2)NS(=O)(=O)C3=CC=C(C=C3)I)C/C=C\\CCCC(=O)O)C
DMJ2FQA	IK	SZNMERGTFJHNSM-JAWYFFTGSA-N
DMJ2FQA	IU	(Z)-7-[(1S,2S,3S,5R)-3-[(4-iodophenyl)sulfonylamino]-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DMJ2FQA	DE	Discovery agent

DMH6YVD	ID	DMH6YVD
DMH6YVD	DN	ISC-4
DMH6YVD	HS	Investigative
DMH6YVD	SN	ISC-6; Isoselenocyanate Akt3 inhibitors (cancer); Isoselenocyanate Akt3 inhibitors (cancer), Penn State Hershey Medical Center
DMH6YVD	CP	Penn State Hershey Medical Center
DMH6YVD	DE	Solid tumour/cancer

DMM2I9G	ID	DMM2I9G
DMM2I9G	DN	ischemin
DMM2I9G	HS	Investigative
DMM2I9G	SN	MS120
DMM2I9G	DT	Small molecular drug
DMM2I9G	PC	135566302
DMM2I9G	MW	335.4
DMM2I9G	FM	C15H17N3O4S
DMM2I9G	IC	InChI=1S/C15H17N3O4S/c1-8-4-10(3)15(23(20,21)22)7-12(8)17-18-13-5-9(2)14(19)6-11(13)16/h4-7,19H,16H2,1-3H3,(H,20,21,22)
DMM2I9G	CS	CC1=CC(=C(C=C1N=NC2=C(C=C(C(=C2)C)O)N)S(=O)(=O)O)C
DMM2I9G	IK	UUECJWRVDTUDCB-UHFFFAOYSA-N
DMM2I9G	IU	5-[(2-amino-4-hydroxy-5-methylphenyl)diazenyl]-2,4-dimethylbenzenesulfonic acid
DMM2I9G	CB	CHEBI:95084
DMM2I9G	DE	Discovery agent

DMIB6JL	ID	DMIB6JL
DMIB6JL	DN	ISIS 100742
DMIB6JL	HS	Investigative
DMIB6JL	CP	Isis Pharmaceuticals
DMIB6JL	DT	Antisense drug
DMIB6JL	SQ	GTCTTCATGTGAGACTGCTC
DMIB6JL	DE	Discovery agent

DMI7PGZ	ID	DMI7PGZ
DMI7PGZ	DN	ISIS 100743
DMI7PGZ	HS	Investigative
DMI7PGZ	CP	Isis Pharmaceuticals
DMI7PGZ	DT	Antisense drug
DMI7PGZ	SQ	CTACACCAGTCATCTGGTAT
DMI7PGZ	DE	Discovery agent

DMFW5VK	ID	DMFW5VK
DMFW5VK	DN	ISIS 100748
DMFW5VK	HS	Investigative
DMFW5VK	CP	Isis Pharmaceuticals
DMFW5VK	DT	Antisense drug
DMFW5VK	SQ	AGCAATTCCCATAAGTAATA
DMFW5VK	DE	Discovery agent

DMSMJ37	ID	DMSMJ37
DMSMJ37	DN	ISIS 100749
DMSMJ37	HS	Investigative
DMSMJ37	CP	Isis Pharmaceuticals
DMSMJ37	DT	Antisense drug
DMSMJ37	SQ	GTGAAGTTTTCCCATTGTAG
DMSMJ37	DE	Discovery agent

DMFJES5	ID	DMFJES5
DMFJES5	DN	ISIS 100750
DMFJES5	HS	Investigative
DMFJES5	CP	Isis Pharmaceuticals
DMFJES5	DT	Antisense drug
DMFJES5	SQ	GGTCTGAGGATATGATCTCT
DMFJES5	DE	Discovery agent

DMZV5A7	ID	DMZV5A7
DMZV5A7	DN	ISIS 100913
DMZV5A7	HS	Investigative
DMZV5A7	CP	Isis Pharmaceuticals
DMZV5A7	DT	Antisense drug
DMZV5A7	SQ	CTGTAGTAACCATTCTTGCA
DMZV5A7	DE	Discovery agent

DMUMVIF	ID	DMUMVIF
DMUMVIF	DN	ISIS 100929
DMUMVIF	HS	Investigative
DMUMVIF	CP	Isis Pharmaceuticals
DMUMVIF	DT	Antisense drug
DMUMVIF	SQ	GAGAAAACTTGCGCTGTGTT
DMUMVIF	DE	Discovery agent

DMHUC1X	ID	DMHUC1X
DMHUC1X	DN	ISIS 100935
DMHUC1X	HS	Investigative
DMHUC1X	CP	Isis Pharmaceuticals
DMHUC1X	DT	Antisense drug
DMHUC1X	SQ	CCACTGGCCTCGTTCATAGC
DMHUC1X	DE	Discovery agent

DM67Q3C	ID	DM67Q3C
DM67Q3C	DN	ISIS 100939
DM67Q3C	HS	Investigative
DM67Q3C	CP	Isis Pharmaceuticals
DM67Q3C	DT	Antisense drug
DM67Q3C	SQ	GCACTAGTTTGGGCTTTTGC
DM67Q3C	DE	Discovery agent

DMS6JD4	ID	DMS6JD4
DMS6JD4	DN	ISIS 101952
DMS6JD4	HS	Investigative
DMS6JD4	CP	Isis Pharmaceuticals
DMS6JD4	DT	Antisense drug
DMS6JD4	SQ	CTACAGGTTGGCCACTCTGG
DMS6JD4	DE	Discovery agent

DMEWXR2	ID	DMEWXR2
DMEWXR2	DN	ISIS 101960
DMEWXR2	HS	Investigative
DMEWXR2	CP	Isis Pharmaceuticals
DMEWXR2	DT	Antisense drug
DMEWXR2	SQ	GATCTTGCAGACGGTAGCTG
DMEWXR2	DE	Discovery agent

DMV9PI7	ID	DMV9PI7
DMV9PI7	DN	ISIS 101983
DMV9PI7	HS	Investigative
DMV9PI7	CP	Isis Pharmaceuticals
DMV9PI7	DT	Antisense drug
DMV9PI7	SQ	ACTGCCTTCTCTGCCCACTT
DMV9PI7	DE	Discovery agent

DMYZ5CX	ID	DMYZ5CX
DMYZ5CX	DN	ISIS 101984
DMYZ5CX	HS	Investigative
DMYZ5CX	CP	Isis Pharmaceuticals
DMYZ5CX	DT	Antisense drug
DMYZ5CX	SQ	CCCGGGCAGCTGAGAGCCCT
DMYZ5CX	DE	Discovery agent

DM8CN2M	ID	DM8CN2M
DM8CN2M	DN	ISIS 101985
DM8CN2M	HS	Investigative
DM8CN2M	CP	Isis Pharmaceuticals
DM8CN2M	DT	Antisense drug
DM8CN2M	SQ	CACCTGCAGCCGCCCCGTCCA
DM8CN2M	DE	Discovery agent

DM5PTQX	ID	DM5PTQX
DM5PTQX	DN	ISIS 101986
DM5PTQX	HS	Investigative
DM5PTQX	CP	Isis Pharmaceuticals
DM5PTQX	DT	Antisense drug
DM5PTQX	SQ	AGCGCCACACGCGACAGTAA
DM5PTQX	DE	Discovery agent

DMWCK8Q	ID	DMWCK8Q
DMWCK8Q	DN	ISIS 101987
DMWCK8Q	HS	Investigative
DMWCK8Q	CP	Isis Pharmaceuticals
DMWCK8Q	DT	Antisense drug
DMWCK8Q	SQ	AGCCAAATGGGAACTCACAG
DMWCK8Q	DE	Discovery agent

DM3EMLB	ID	DM3EMLB
DM3EMLB	DN	ISIS 101995
DM3EMLB	HS	Investigative
DM3EMLB	CP	Isis Pharmaceuticals
DM3EMLB	DT	Antisense drug
DM3EMLB	SQ	CCATCTATGAGCACACTTCG
DM3EMLB	DE	Discovery agent

DM5APGL	ID	DM5APGL
DM5APGL	DN	ISIS 101996
DM5APGL	HS	Investigative
DM5APGL	CP	Isis Pharmaceuticals
DM5APGL	DT	Antisense drug
DM5APGL	SQ	AAGTCCAAGACAGAATCTGT
DM5APGL	DE	Discovery agent

DMUZJCD	ID	DMUZJCD
DMUZJCD	DN	ISIS 101997
DMUZJCD	HS	Investigative
DMUZJCD	CP	Isis Pharmaceuticals
DMUZJCD	DT	Antisense drug
DMUZJCD	SQ	TTTCTATCGTTGAGTTTCTG
DMUZJCD	DE	Discovery agent

DMEH6G1	ID	DMEH6G1
DMEH6G1	DN	ISIS 101998
DMEH6G1	HS	Investigative
DMEH6G1	CP	Isis Pharmaceuticals
DMEH6G1	DT	Antisense drug
DMEH6G1	SQ	TGCTGTCACTCACGCACTCG
DMEH6G1	DE	Discovery agent

DMESKQX	ID	DMESKQX
DMESKQX	DN	ISIS 10228
DMESKQX	HS	Investigative
DMESKQX	CP	Isis Pharmaceuticals
DMESKQX	DT	Antisense drug
DMESKQX	SQ	CATCAGGGCAGAGACGAACA
DMESKQX	DE	Discovery agent

DML40N3	ID	DML40N3
DML40N3	DN	ISIS 102450
DML40N3	HS	Investigative
DML40N3	CP	Isis Pharmaceuticals
DML40N3	DT	Antisense drug
DML40N3	SQ	GCGTTGCCCATCGCGGCGGC
DML40N3	DE	Discovery agent

DMNSEH1	ID	DMNSEH1
DMNSEH1	DN	ISIS 102454
DMNSEH1	HS	Investigative
DMNSEH1	CP	Isis Pharmaceuticals
DMNSEH1	DT	Antisense drug
DMNSEH1	SQ	CGGCGTTGCCCATCGCGGCG
DMNSEH1	DE	Discovery agent

DMBUTFN	ID	DMBUTFN
DMBUTFN	DN	ISIS 102458
DMBUTFN	HS	Investigative
DMBUTFN	CP	Isis Pharmaceuticals
DMBUTFN	DT	Antisense drug
DMBUTFN	SQ	GGCGGCGTTGCCCATCGCGG
DMBUTFN	DE	Discovery agent

DMXNC0B	ID	DMXNC0B
DMXNC0B	DN	ISIS 102462
DMXNC0B	HS	Investigative
DMXNC0B	CP	Isis Pharmaceuticals
DMXNC0B	DT	Antisense drug
DMXNC0B	SQ	GCGGCGGCGTTGCCCATCGC
DMXNC0B	DE	Discovery agent

DMAG8QO	ID	DMAG8QO
DMAG8QO	DN	ISIS 102466
DMAG8QO	HS	Investigative
DMAG8QO	CP	Isis Pharmaceuticals
DMAG8QO	DT	Antisense drug
DMAG8QO	SQ	CGGCGGCGGCGTTGCCCATC
DMAG8QO	DE	Discovery agent

DMU70ND	ID	DMU70ND
DMU70ND	DN	ISIS 102478
DMU70ND	HS	Investigative
DMU70ND	CP	Isis Pharmaceuticals
DMU70ND	DT	Antisense drug
DMU70ND	SQ	CAAACTGATCCAAGTGGGCT
DMU70ND	DE	Discovery agent

DMMBJWK	ID	DMMBJWK
DMMBJWK	DN	ISIS 102482
DMMBJWK	HS	Investigative
DMMBJWK	CP	Isis Pharmaceuticals
DMMBJWK	DT	Antisense drug
DMMBJWK	SQ	CCAGCATCACCCGCCCGAAG
DMMBJWK	DE	Discovery agent

DMTMBEX	ID	DMTMBEX
DMTMBEX	DN	ISIS 102486
DMTMBEX	HS	Investigative
DMTMBEX	CP	Isis Pharmaceuticals
DMTMBEX	DT	Antisense drug
DMTMBEX	SQ	CTTCTGTTTGTCGAGGATCT
DMTMBEX	DE	Discovery agent

DMMWVCH	ID	DMMWVCH
DMMWVCH	DN	ISIS 102490
DMMWVCH	HS	Investigative
DMMWVCH	CP	Isis Pharmaceuticals
DMMWVCH	DT	Antisense drug
DMMWVCH	SQ	GCTTGCAGGATGCGCTTTTC
DMMWVCH	DE	Discovery agent

DMYJO7T	ID	DMYJO7T
DMYJO7T	DN	ISIS 102558
DMYJO7T	HS	Investigative
DMYJO7T	CP	Isis Pharmaceuticals
DMYJO7T	DT	Antisense drug
DMYJO7T	SQ	TGCAGGGATGCCCTCCCCAC
DMYJO7T	DE	Discovery agent

DMTHMF0	ID	DMTHMF0
DMTHMF0	DN	ISIS 102563
DMTHMF0	HS	Investigative
DMTHMF0	CP	Isis Pharmaceuticals
DMTHMF0	DT	Antisense drug
DMTHMF0	SQ	CCTTGAACCCCGGGCCGTGG
DMTHMF0	DE	Discovery agent

DMEDFLA	ID	DMEDFLA
DMEDFLA	DN	ISIS 102584
DMEDFLA	HS	Investigative
DMEDFLA	CP	Isis Pharmaceuticals
DMEDFLA	DT	Antisense drug
DMEDFLA	SQ	CACACAGGTTGAATCGCCCC
DMEDFLA	DE	Discovery agent

DM3RVUY	ID	DM3RVUY
DM3RVUY	DN	ISIS 102599
DM3RVUY	HS	Investigative
DM3RVUY	CP	Isis Pharmaceuticals
DM3RVUY	DT	Antisense drug
DM3RVUY	SQ	GCGGCGGGTGCTGGCTGCGG
DM3RVUY	DE	Discovery agent

DMZ6X9B	ID	DMZ6X9B
DMZ6X9B	DN	ISIS 102604
DMZ6X9B	HS	Investigative
DMZ6X9B	CP	Isis Pharmaceuticals
DMZ6X9B	DT	Antisense drug
DMZ6X9B	SQ	TCGCGGCGGCGGCGGCCGGG
DMZ6X9B	DE	Discovery agent

DM60LT9	ID	DM60LT9
DM60LT9	DN	ISIS 102609
DM60LT9	HS	Investigative
DM60LT9	CP	Isis Pharmaceuticals
DM60LT9	DT	Antisense drug
DM60LT9	SQ	CATCGCGGCGGCGGCGGCCG
DM60LT9	DE	Discovery agent

DMEB36I	ID	DMEB36I
DMEB36I	DN	ISIS 102614
DMEB36I	HS	Investigative
DMEB36I	CP	Isis Pharmaceuticals
DMEB36I	DT	Antisense drug
DMEB36I	SQ	CCCATCGCGGCGGCGGCGGC
DMEB36I	DE	Discovery agent

DMXH9IT	ID	DMXH9IT
DMXH9IT	DN	ISIS 102619
DMXH9IT	HS	Investigative
DMXH9IT	CP	Isis Pharmaceuticals
DMXH9IT	DT	Antisense drug
DMXH9IT	SQ	TGCCCATCGCGGCGGCGGCG
DMXH9IT	DE	Discovery agent

DMGO4TZ	ID	DMGO4TZ
DMGO4TZ	DN	ISIS 102624
DMGO4TZ	HS	Investigative
DMGO4TZ	CP	Isis Pharmaceuticals
DMGO4TZ	DT	Antisense drug
DMGO4TZ	SQ	GTTGCCCATCGCGGCGGCGG
DMGO4TZ	DE	Discovery agent

DMNSZPX	ID	DMNSZPX
DMNSZPX	DN	ISIS 102629
DMNSZPX	HS	Investigative
DMNSZPX	CP	Isis Pharmaceuticals
DMNSZPX	DT	Antisense drug
DMNSZPX	SQ	GCGTTGCCCATCGCGGCGGC
DMNSZPX	DE	Discovery agent

DMWT7BK	ID	DMWT7BK
DMWT7BK	DN	ISIS 102633
DMWT7BK	HS	Investigative
DMWT7BK	CP	Isis Pharmaceuticals
DMWT7BK	DT	Antisense drug
DMWT7BK	SQ	CGGCGTTGCCCATCGCGGCG
DMWT7BK	DE	Discovery agent

DM6KUV9	ID	DM6KUV9
DM6KUV9	DN	ISIS 102660
DM6KUV9	HS	Investigative
DM6KUV9	CP	Isis Pharmaceuticals
DM6KUV9	DT	Antisense drug
DM6KUV9	SQ	CCAGCATCACCCGCCCGAAG
DM6KUV9	DE	Discovery agent

DMKI6L5	ID	DMKI6L5
DMKI6L5	DN	ISIS 102664
DMKI6L5	HS	Investigative
DMKI6L5	CP	Isis Pharmaceuticals
DMKI6L5	DT	Antisense drug
DMKI6L5	SQ	CTTCTGTTTGTCGAGGATCT
DMKI6L5	DE	Discovery agent

DMY87QX	ID	DMY87QX
DMY87QX	DN	ISIS 102668
DMY87QX	HS	Investigative
DMY87QX	CP	Isis Pharmaceuticals
DMY87QX	DT	Antisense drug
DMY87QX	SQ	GCTTGCAGGATGCGCTTTTC
DMY87QX	DE	Discovery agent

DMFP598	ID	DMFP598
DMFP598	DN	ISIS 102676
DMFP598	HS	Investigative
DMFP598	CP	Isis Pharmaceuticals
DMFP598	DT	Antisense drug
DMFP598	SQ	GAACATCTCCCCGCCGGGCA
DMFP598	DE	Discovery agent

DM205TE	ID	DM205TE
DM205TE	DN	ISIS 10303
DM205TE	HS	Investigative
DM205TE	CP	Isis Pharmaceuticals
DM205TE	DT	Antisense drug
DM205TE	SQ	TGCAATCCACGTCCTCCAGG
DM205TE	DE	Discovery agent

DMT6H9S	ID	DMT6H9S
DMT6H9S	DN	ISIS 10310
DMT6H9S	HS	Investigative
DMT6H9S	CP	Isis Pharmaceuticals
DMT6H9S	DT	Antisense drug
DMT6H9S	SQ	GGTGCTGGCCCGGCTCTCCC
DMT6H9S	DE	Discovery agent

DMQ3KUV	ID	DMQ3KUV
DMQ3KUV	DN	ISIS 10311
DMQ3KUV	HS	Investigative
DMQ3KUV	CP	Isis Pharmaceuticals
DMQ3KUV	DT	Antisense drug
DMQ3KUV	SQ	GGACCCCGAAAGACCACCAG
DMQ3KUV	DE	Discovery agent

DMX835E	ID	DMX835E
DMX835E	DN	ISIS 103375
DMX835E	HS	Investigative
DMX835E	CP	Isis Pharmaceuticals
DMX835E	DT	Antisense drug
DMX835E	SQ	CCCAGGCCCGCCCCGCAGCA
DMX835E	DE	Discovery agent

DMBAM5K	ID	DMBAM5K
DMBAM5K	DN	ISIS 103386
DMBAM5K	HS	Investigative
DMBAM5K	CP	Isis Pharmaceuticals
DMBAM5K	DT	Antisense drug
DMBAM5K	SQ	TTGCTGGCGTTGAGGACGTA
DMBAM5K	DE	Discovery agent

DMW8GIT	ID	DMW8GIT
DMW8GIT	DN	ISIS 103387
DMW8GIT	HS	Investigative
DMW8GIT	CP	Isis Pharmaceuticals
DMW8GIT	DT	Antisense drug
DMW8GIT	SQ	TTTCACAGTAGTTGTCGTTG
DMW8GIT	DE	Discovery agent

DM86KWU	ID	DM86KWU
DM86KWU	DN	ISIS 103471
DM86KWU	HS	Investigative
DM86KWU	CP	Isis Pharmaceuticals
DM86KWU	DT	Antisense drug
DM86KWU	SQ	CCGGGCACTGCCCAGATAGA
DM86KWU	DE	Discovery agent

DMQRP32	ID	DMQRP32
DMQRP32	DN	ISIS 103473
DMQRP32	HS	Investigative
DMQRP32	CP	Isis Pharmaceuticals
DMQRP32	DT	Antisense drug
DMQRP32	SQ	AAGAACCGCGACAGGTTCTG
DMQRP32	DE	Discovery agent

DM5BSVQ	ID	DM5BSVQ
DM5BSVQ	DN	ISIS 103486
DM5BSVQ	HS	Investigative
DM5BSVQ	CP	Isis Pharmaceuticals
DM5BSVQ	DT	Antisense drug
DM5BSVQ	SQ	AGGCCATGGATGTGGGCGG
DM5BSVQ	DE	Discovery agent

DM6ZME7	ID	DM6ZME7
DM6ZME7	DN	ISIS 103489
DM6ZME7	HS	Investigative
DM6ZME7	CP	Isis Pharmaceuticals
DM6ZME7	DT	Antisense drug
DM6ZME7	SQ	GGGCCCCGCAGCAGCAAAAG
DM6ZME7	DE	Discovery agent

DME9Q8L	ID	DME9Q8L
DME9Q8L	DN	ISIS 103582
DME9Q8L	HS	Investigative
DME9Q8L	CP	Isis Pharmaceuticals
DME9Q8L	DT	Antisense drug
DME9Q8L	SQ	TCCCAGACTGCTGCCGTACA
DME9Q8L	DE	Discovery agent

DM6BH7K	ID	DM6BH7K
DM6BH7K	DN	ISIS 103601
DM6BH7K	HS	Investigative
DM6BH7K	CP	Isis Pharmaceuticals
DM6BH7K	DT	Antisense drug
DM6BH7K	SQ	CACCATAATCAAGTCCTTCT
DM6BH7K	DE	Discovery agent

DM298KT	ID	DM298KT
DM298KT	DN	ISIS 103612
DM298KT	HS	Investigative
DM298KT	CP	Isis Pharmaceuticals
DM298KT	DT	Antisense drug
DM298KT	SQ	ACTAGAGTGCTTGTAGGTAC
DM298KT	DE	Discovery agent

DMNPMW4	ID	DMNPMW4
DMNPMW4	DN	ISIS 103613
DMNPMW4	HS	Investigative
DMNPMW4	CP	Isis Pharmaceuticals
DMNPMW4	DT	Antisense drug
DMNPMW4	SQ	GAGACGGAGATGAAGGTGTG
DMNPMW4	DE	Discovery agent

DMGTX6O	ID	DMGTX6O
DMGTX6O	DN	ISIS 103615
DMGTX6O	HS	Investigative
DMGTX6O	CP	Isis Pharmaceuticals
DMGTX6O	DT	Antisense drug
DMGTX6O	SQ	GTTGGTGCAAATGAGGATGA
DMGTX6O	DE	Discovery agent

DM3PK2G	ID	DM3PK2G
DM3PK2G	DN	ISIS 103616
DM3PK2G	HS	Investigative
DM3PK2G	CP	Isis Pharmaceuticals
DM3PK2G	DT	Antisense drug
DM3PK2G	SQ	TCAGACACTACTGGAGTACC
DM3PK2G	DE	Discovery agent

DMERJAV	ID	DMERJAV
DMERJAV	DN	ISIS 103619
DMERJAV	HS	Investigative
DMERJAV	CP	Isis Pharmaceuticals
DMERJAV	DT	Antisense drug
DMERJAV	SQ	ATTCCAATTCTGCACTGGTA
DMERJAV	DE	Discovery agent

DM61FYM	ID	DM61FYM
DM61FYM	DN	ISIS 103620
DM61FYM	HS	Investigative
DM61FYM	CP	Isis Pharmaceuticals
DM61FYM	DT	Antisense drug
DM61FYM	SQ	GAATTAGAGGTGTCAGGCTC
DM61FYM	DE	Discovery agent

DMP7VJL	ID	DMP7VJL
DMP7VJL	DN	ISIS 103621
DMP7VJL	HS	Investigative
DMP7VJL	CP	Isis Pharmaceuticals
DMP7VJL	DT	Antisense drug
DMP7VJL	SQ	TGTCTTGATTTGGCTGCTTC
DMP7VJL	DE	Discovery agent

DM9J4I3	ID	DM9J4I3
DM9J4I3	DN	ISIS 103622
DM9J4I3	HS	Investigative
DM9J4I3	CP	Isis Pharmaceuticals
DM9J4I3	DT	Antisense drug
DM9J4I3	SQ	TCCCAGACTGCTGCCGTACA
DM9J4I3	DE	Discovery agent

DMST2QW	ID	DMST2QW
DMST2QW	DN	ISIS 103624
DMST2QW	HS	Investigative
DMST2QW	CP	Isis Pharmaceuticals
DMST2QW	DT	Antisense drug
DMST2QW	SQ	GATCCACATAATAGGTTCTA
DMST2QW	DE	Discovery agent

DMJLHE7	ID	DMJLHE7
DMJLHE7	DN	ISIS 103629
DMJLHE7	HS	Investigative
DMJLHE7	CP	Isis Pharmaceuticals
DMJLHE7	DT	Antisense drug
DMJLHE7	SQ	GCATAGCTCCCTGCAATTGG
DMJLHE7	DE	Discovery agent

DMOK9FA	ID	DMOK9FA
DMOK9FA	DN	ISIS 103631
DMOK9FA	HS	Investigative
DMOK9FA	CP	Isis Pharmaceuticals
DMOK9FA	DT	Antisense drug
DMOK9FA	SQ	CCTGGTGGCAAAGGTCCATA
DMOK9FA	DE	Discovery agent

DMVW7N5	ID	DMVW7N5
DMVW7N5	DN	ISIS 103635
DMVW7N5	HS	Investigative
DMVW7N5	CP	Isis Pharmaceuticals
DMVW7N5	DT	Antisense drug
DMVW7N5	SQ	TCCCATTGCGAGGATCTTTG
DMVW7N5	DE	Discovery agent

DM3TIJD	ID	DM3TIJD
DM3TIJD	DN	ISIS 103669
DM3TIJD	HS	Investigative
DM3TIJD	CP	Isis Pharmaceuticals
DM3TIJD	DT	Antisense drug
DM3TIJD	SQ	CAGCCCTCTTTAGCCTTTCT
DM3TIJD	DE	Discovery agent

DMF9JAH	ID	DMF9JAH
DMF9JAH	DN	ISIS 103671
DMF9JAH	HS	Investigative
DMF9JAH	CP	Isis Pharmaceuticals
DMF9JAH	DT	Antisense drug
DMF9JAH	SQ	CACCTTGGGCTTTGCGGACA
DMF9JAH	DE	Discovery agent

DMQ48YZ	ID	DMQ48YZ
DMQ48YZ	DN	ISIS 103701
DMQ48YZ	HS	Investigative
DMQ48YZ	CP	Isis Pharmaceuticals
DMQ48YZ	DT	Antisense drug
DMQ48YZ	SQ	GGGCCTCCCAAGGGCTGCGG
DMQ48YZ	DE	Discovery agent

DMLVPOA	ID	DMLVPOA
DMLVPOA	DN	ISIS 103708
DMLVPOA	HS	Investigative
DMLVPOA	CP	Isis Pharmaceuticals
DMLVPOA	DT	Antisense drug
DMLVPOA	SQ	GGCAAAGACCCTTGGCGCTC
DMLVPOA	DE	Discovery agent

DM60CBI	ID	DM60CBI
DM60CBI	DN	ISIS 10373
DM60CBI	HS	Investigative
DM60CBI	CP	Isis Pharmaceuticals
DM60CBI	DT	Antisense drug
DM60CBI	SQ	TGCGAGCTCCCCGTACCTCC
DM60CBI	DE	Discovery agent

DMKI6JF	ID	DMKI6JF
DMKI6JF	DN	ISIS 103736
DMKI6JF	HS	Investigative
DMKI6JF	CP	Isis Pharmaceuticals
DMKI6JF	DT	Antisense drug
DMKI6JF	SQ	CGCCCTCCTTCAGCTCGTGG
DMKI6JF	DE	Discovery agent

DM7DOY3	ID	DM7DOY3
DM7DOY3	DN	ISIS 103747
DM7DOY3	HS	Investigative
DM7DOY3	CP	Isis Pharmaceuticals
DM7DOY3	DT	Antisense drug
DM7DOY3	SQ	AGAACCTCCTTTGCTGGCAA
DM7DOY3	DE	Discovery agent

DMBZVW0	ID	DMBZVW0
DMBZVW0	DN	ISIS 103752
DMBZVW0	HS	Investigative
DMBZVW0	CP	Isis Pharmaceuticals
DMBZVW0	DT	Antisense drug
DMBZVW0	SQ	CACCTTGGGCTTTGCGGACA
DMBZVW0	DE	Discovery agent

DM8HDW6	ID	DM8HDW6
DM8HDW6	DN	ISIS 103771
DM8HDW6	HS	Investigative
DM8HDW6	CP	Isis Pharmaceuticals
DM8HDW6	DT	Antisense drug
DM8HDW6	SQ	CAGCATGATGTACTCTTCCT
DM8HDW6	DE	Discovery agent

DMVL8O0	ID	DMVL8O0
DMVL8O0	DN	ISIS 103803
DMVL8O0	HS	Investigative
DMVL8O0	CP	Isis Pharmaceuticals
DMVL8O0	DT	Antisense drug
DMVL8O0	SQ	CGTAGGAGTTAATTCGAGGT
DMVL8O0	DE	Discovery agent

DMA0D8I	ID	DMA0D8I
DMA0D8I	DN	ISIS 103806
DMA0D8I	HS	Investigative
DMA0D8I	CP	Isis Pharmaceuticals
DMA0D8I	DT	Antisense drug
DMA0D8I	SQ	GGTTCAGGGTCAGCTGCATG
DMA0D8I	DE	Discovery agent

DMFQ10R	ID	DMFQ10R
DMFQ10R	DN	ISIS 103819
DMFQ10R	HS	Investigative
DMFQ10R	CP	Isis Pharmaceuticals
DMFQ10R	DT	Antisense drug
DMFQ10R	SQ	GTGGTCCGTTGCTACCGATG
DMFQ10R	DE	Discovery agent

DMPKQ61	ID	DMPKQ61
DMPKQ61	DN	ISIS 104211
DMPKQ61	HS	Investigative
DMPKQ61	CP	Isis Pharmaceuticals
DMPKQ61	DT	Antisense drug
DMPKQ61	SQ	TGGTCCCGGGCGCTCAGGCC
DMPKQ61	DE	Discovery agent

DMME8JP	ID	DMME8JP
DMME8JP	DN	ISIS 104253
DMME8JP	HS	Investigative
DMME8JP	CP	Isis Pharmaceuticals
DMME8JP	DT	Antisense drug
DMME8JP	SQ	TTCATGGTCCCGGGCGCTCA
DMME8JP	DE	Discovery agent

DMDEI9X	ID	DMDEI9X
DMDEI9X	DN	ISIS 104254
DMDEI9X	HS	Investigative
DMDEI9X	CP	Isis Pharmaceuticals
DMDEI9X	DT	Antisense drug
DMDEI9X	SQ	CGTTCATGGTCCCGGGCGCT
DMDEI9X	DE	Discovery agent

DMAI5B8	ID	DMAI5B8
DMAI5B8	DN	ISIS 104255
DMAI5B8	HS	Investigative
DMAI5B8	CP	Isis Pharmaceuticals
DMAI5B8	DT	Antisense drug
DMAI5B8	SQ	CCCGTTCATGGTCCCGGGCG
DMAI5B8	DE	Discovery agent

DMHUX9A	ID	DMHUX9A
DMHUX9A	DN	ISIS 104256
DMHUX9A	HS	Investigative
DMHUX9A	CP	Isis Pharmaceuticals
DMHUX9A	DT	Antisense drug
DMHUX9A	SQ	TCCCCGTTCATGGTCCCGGG
DMHUX9A	DE	Discovery agent

DMSDCGV	ID	DMSDCGV
DMSDCGV	DN	ISIS 104257
DMSDCGV	HS	Investigative
DMSDCGV	CP	Isis Pharmaceuticals
DMSDCGV	DT	Antisense drug
DMSDCGV	SQ	CCTCCCCGTTCATGGTCCCG
DMSDCGV	DE	Discovery agent

DMUC3L0	ID	DMUC3L0
DMUC3L0	DN	ISIS 104258
DMUC3L0	HS	Investigative
DMUC3L0	CP	Isis Pharmaceuticals
DMUC3L0	DT	Antisense drug
DMUC3L0	SQ	GGCCTCCCCGTTCATGGTCC
DMUC3L0	DE	Discovery agent

DMB5F9H	ID	DMB5F9H
DMB5F9H	DN	ISIS 10582
DMB5F9H	HS	Investigative
DMB5F9H	CP	Isis Pharmaceuticals
DMB5F9H	DT	Antisense drug
DMB5F9H	SQ	TCAGCCCCCGACGGTCTCTC
DMB5F9H	DE	Discovery agent

DMIGV0H	ID	DMIGV0H
DMIGV0H	DN	ISIS 105987
DMIGV0H	HS	Investigative
DMIGV0H	CP	Isis Pharmaceuticals
DMIGV0H	DT	Antisense drug
DMIGV0H	SQ	AGATCAATCCGTTAAAAGAA
DMIGV0H	DE	Discovery agent

DMFOSYU	ID	DMFOSYU
DMFOSYU	DN	ISIS 105989
DMFOSYU	HS	Investigative
DMFOSYU	CP	Isis Pharmaceuticals
DMFOSYU	DT	Antisense drug
DMFOSYU	SQ	CAAAAGATCAATCCGTTAAA
DMFOSYU	DE	Discovery agent

DM8FY3H	ID	DM8FY3H
DM8FY3H	DN	ISIS 105990
DM8FY3H	HS	Investigative
DM8FY3H	CP	Isis Pharmaceuticals
DM8FY3H	DT	Antisense drug
DM8FY3H	SQ	AGCAAAAGATCAATCCGTTA
DM8FY3H	DE	Discovery agent

DMTY6O9	ID	DMTY6O9
DMTY6O9	DN	ISIS 106008
DMTY6O9	HS	Investigative
DMTY6O9	CP	Isis Pharmaceuticals
DMTY6O9	DT	Antisense drug
DMTY6O9	SQ	TTTGCTGTAATTCACACTGA
DMTY6O9	DE	Discovery agent

DM4YJQG	ID	DM4YJQG
DM4YJQG	DN	ISIS 10639
DM4YJQG	HS	Investigative
DM4YJQG	CP	Isis Pharmaceuticals
DM4YJQG	DT	Antisense drug
DM4YJQG	SQ	AAGTCCTTGAGGCCCACAGC
DM4YJQG	DE	Discovery agent

DMYG5IO	ID	DMYG5IO
DMYG5IO	DN	ISIS 10707
DMYG5IO	HS	Investigative
DMYG5IO	CP	Isis Pharmaceuticals
DMYG5IO	DT	Antisense drug
DMYG5IO	SQ	3' UTR GCTTCCATTTCCAGGGCAGG
DMYG5IO	DE	Discovery agent

DMBWCZR	ID	DMBWCZR
DMBWCZR	DN	ISIS 107612
DMBWCZR	HS	Investigative
DMBWCZR	CP	Isis Pharmaceuticals
DMBWCZR	DT	Antisense drug
DMBWCZR	SQ	CTGCTCAGACAGCAGATGCT
DMBWCZR	DE	Discovery agent

DMPR7OD	ID	DMPR7OD
DMPR7OD	DN	ISIS 107642
DMPR7OD	HS	Investigative
DMPR7OD	CP	Isis Pharmaceuticals
DMPR7OD	DT	Antisense drug
DMPR7OD	SQ	ATCCAGCAGGTTCATGTCAT
DMPR7OD	DE	Discovery agent

DMOX8JF	ID	DMOX8JF
DMOX8JF	DN	ISIS 107652
DMOX8JF	HS	Investigative
DMOX8JF	CP	Isis Pharmaceuticals
DMOX8JF	DT	Antisense drug
DMOX8JF	SQ	ATTTGGTAAACTTTGTCCAA
DMOX8JF	DE	Discovery agent

DMUE64H	ID	DMUE64H
DMUE64H	DN	ISIS 107676
DMUE64H	HS	Investigative
DMUE64H	CP	Isis Pharmaceuticals
DMUE64H	DT	Antisense drug
DMUE64H	SQ	ACTGGATGTACCAGGTTCCC
DMUE64H	DE	Discovery agent

DMB9VFS	ID	DMB9VFS
DMB9VFS	DN	ISIS 107681
DMB9VFS	HS	Investigative
DMB9VFS	CP	Isis Pharmaceuticals
DMB9VFS	DT	Antisense drug
DMB9VFS	SQ	GCTGAGGCATCTGTTTCCCC
DMB9VFS	DE	Discovery agent

DM37VYR	ID	DM37VYR
DM37VYR	DN	ISIS 107772
DM37VYR	HS	Investigative
DM37VYR	CP	Isis Pharmaceuticals
DM37VYR	DT	Antisense drug
DM37VYR	SQ	CCCGGACTTGTCGATCTGCT
DM37VYR	DE	Discovery agent

DMA3ZGH	ID	DMA3ZGH
DMA3ZGH	DN	ISIS 107773
DMA3ZGH	HS	Investigative
DMA3ZGH	CP	Isis Pharmaceuticals
DMA3ZGH	DT	Antisense drug
DMA3ZGH	SQ	CTGGCTTCATGTCGGATATC
DMA3ZGH	DE	Discovery agent

DMFOTQY	ID	DMFOTQY
DMFOTQY	DN	ISIS 107774
DMFOTQY	HS	Investigative
DMFOTQY	CP	Isis Pharmaceuticals
DMFOTQY	DT	Antisense drug
DMFOTQY	SQ	TTGGCCACTCTACATGGGAA
DMFOTQY	DE	Discovery agent

DMLBX9Z	ID	DMLBX9Z
DMLBX9Z	DN	ISIS 107775
DMLBX9Z	HS	Investigative
DMLBX9Z	CP	Isis Pharmaceuticals
DMLBX9Z	DT	Antisense drug
DMLBX9Z	SQ	GGACTGACGTCTCTGTACCT
DMLBX9Z	DE	Discovery agent

DMNHBGJ	ID	DMNHBGJ
DMNHBGJ	DN	ISIS 107776
DMNHBGJ	HS	Investigative
DMNHBGJ	CP	Isis Pharmaceuticals
DMNHBGJ	DT	Antisense drug
DMNHBGJ	SQ	GATGTAGTTTAATCCGACTA
DMNHBGJ	DE	Discovery agent

DMVTU63	ID	DMVTU63
DMVTU63	DN	ISIS 107791
DMVTU63	HS	Investigative
DMVTU63	CP	Isis Pharmaceuticals
DMVTU63	DT	Antisense drug
DMVTU63	SQ	GCAGTGCACCACAACGGGCC
DMVTU63	DE	Discovery agent

DMV87MP	ID	DMV87MP
DMV87MP	DN	ISIS 107792
DMV87MP	HS	Investigative
DMV87MP	CP	Isis Pharmaceuticals
DMV87MP	DT	Antisense drug
DMV87MP	SQ	AGGTTCCAGACCTGCCGATG
DMV87MP	DE	Discovery agent

DM83TLC	ID	DM83TLC
DM83TLC	DN	ISIS 109110
DM83TLC	HS	Investigative
DM83TLC	CP	Isis Pharmaceuticals
DM83TLC	DT	Antisense drug
DM83TLC	SQ	TGCGCTGCCTGGCTCTCGCC
DM83TLC	DE	Discovery agent

DM0UOL3	ID	DM0UOL3
DM0UOL3	DN	ISIS 109111
DM0UOL3	HS	Investigative
DM0UOL3	CP	Isis Pharmaceuticals
DM0UOL3	DT	Antisense drug
DM0UOL3	SQ	GCAACCATGGTGGCAGCTTC
DM0UOL3	DE	Discovery agent

DM6R5YW	ID	DM6R5YW
DM6R5YW	DN	ISIS 109112
DM6R5YW	HS	Investigative
DM6R5YW	CP	Isis Pharmaceuticals
DM6R5YW	DT	Antisense drug
DM6R5YW	SQ	ATCGTCTTCACCACATTCCC
DM6R5YW	DE	Discovery agent

DM58XT1	ID	DM58XT1
DM58XT1	DN	ISIS 109113
DM58XT1	HS	Investigative
DM58XT1	CP	Isis Pharmaceuticals
DM58XT1	DT	Antisense drug
DM58XT1	SQ	TGCGGCAGGCGTCGTACACC
DM58XT1	DE	Discovery agent

DMUDFZN	ID	DMUDFZN
DMUDFZN	DN	ISIS 109114
DMUDFZN	HS	Investigative
DMUDFZN	CP	Isis Pharmaceuticals
DMUDFZN	DT	Antisense drug
DMUDFZN	SQ	AAAGAGCCCAAAGTCGCTGG
DMUDFZN	DE	Discovery agent

DMBMDG7	ID	DMBMDG7
DMBMDG7	DN	ISIS 109115
DMBMDG7	HS	Investigative
DMBMDG7	CP	Isis Pharmaceuticals
DMBMDG7	DT	Antisense drug
DMBMDG7	SQ	GTAGTAGTCCAAAGCTTTCC
DMBMDG7	DE	Discovery agent

DMQ8K9J	ID	DMQ8K9J
DMQ8K9J	DN	ISIS 109116
DMQ8K9J	HS	Investigative
DMQ8K9J	CP	Isis Pharmaceuticals
DMQ8K9J	DT	Antisense drug
DMQ8K9J	SQ	TGTTTCTTCCTGTACTCCAT
DMQ8K9J	DE	Discovery agent

DM508BS	ID	DM508BS
DM508BS	DN	ISIS 109351
DM508BS	HS	Investigative
DM508BS	CP	Isis Pharmaceuticals
DM508BS	DT	Antisense drug
DM508BS	SQ	TGGCGACATGGTTGCGCCCT
DM508BS	DE	Discovery agent

DMWK1XC	ID	DMWK1XC
DMWK1XC	DN	ISIS 109352
DMWK1XC	HS	Investigative
DMWK1XC	CP	Isis Pharmaceuticals
DMWK1XC	DT	Antisense drug
DMWK1XC	SQ	AGAAATGGCGACATGGTTGC
DMWK1XC	DE	Discovery agent

DM6AJMC	ID	DM6AJMC
DM6AJMC	DN	ISIS 109353
DM6AJMC	HS	Investigative
DM6AJMC	CP	Isis Pharmaceuticals
DM6AJMC	DT	Antisense drug
DM6AJMC	SQ	CAATCCGAAGAAATGGCGAC
DM6AJMC	DE	Discovery agent

DM1REKQ	ID	DM1REKQ
DM1REKQ	DN	ISIS 109354
DM1REKQ	HS	Investigative
DM1REKQ	CP	Isis Pharmaceuticals
DM1REKQ	DT	Antisense drug
DM1REKQ	SQ	CCTGACAAGACTGGCAGGAC
DM1REKQ	DE	Discovery agent

DMFIQGW	ID	DMFIQGW
DMFIQGW	DN	ISIS 109355
DMFIQGW	HS	Investigative
DMFIQGW	CP	Isis Pharmaceuticals
DMFIQGW	DT	Antisense drug
DMFIQGW	SQ	ATACTCTTTGACGAGCACAG
DMFIQGW	DE	Discovery agent

DMDVE6A	ID	DMDVE6A
DMDVE6A	DN	ISIS 109490
DMDVE6A	HS	Investigative
DMDVE6A	CP	Isis Pharmaceuticals
DMDVE6A	DT	Antisense drug
DMDVE6A	SQ	TGGAGGAAAAGGCATCAGAG
DMDVE6A	DE	Discovery agent

DMISNWV	ID	DMISNWV
DMISNWV	DN	ISIS 109491
DMISNWV	HS	Investigative
DMISNWV	CP	Isis Pharmaceuticals
DMISNWV	DT	Antisense drug
DMISNWV	SQ	CCAGGGTCTGCATTTGTCCG
DMISNWV	DE	Discovery agent

DMRPMN6	ID	DMRPMN6
DMRPMN6	DN	ISIS 109502
DMRPMN6	HS	Investigative
DMRPMN6	CP	Isis Pharmaceuticals
DMRPMN6	DT	Antisense drug
DMRPMN6	SQ	TCTCCTCCAGAGTCAGCAGT
DMRPMN6	DE	Discovery agent

DMJ7EDV	ID	DMJ7EDV
DMJ7EDV	DN	ISIS 109524
DMJ7EDV	HS	Investigative
DMJ7EDV	CP	Isis Pharmaceuticals
DMJ7EDV	DT	Antisense drug
DMJ7EDV	SQ	CCAGTGCGGCGGGCTGCTGA
DMJ7EDV	DE	Discovery agent

DMB28D3	ID	DMB28D3
DMB28D3	DN	ISIS 109525
DMB28D3	HS	Investigative
DMB28D3	CP	Isis Pharmaceuticals
DMB28D3	DT	Antisense drug
DMB28D3	SQ	ATTACTGCTGCGAGTTTGAG
DMB28D3	DE	Discovery agent

DMZN60F	ID	DMZN60F
DMZN60F	DN	ISIS 109526
DMZN60F	HS	Investigative
DMZN60F	CP	Isis Pharmaceuticals
DMZN60F	DT	Antisense drug
DMZN60F	SQ	AAAATAGCTGTCATAGTGCC
DMZN60F	DE	Discovery agent

DMXNG1S	ID	DMXNG1S
DMXNG1S	DN	ISIS 110064
DMXNG1S	HS	Investigative
DMXNG1S	CP	Isis Pharmaceuticals
DMXNG1S	DT	Antisense drug
DMXNG1S	SQ	GGCTCCCTTCTTGCCAGGTG
DMXNG1S	DE	Discovery agent

DMBOU16	ID	DMBOU16
DMBOU16	DN	ISIS 110065
DMBOU16	HS	Investigative
DMBOU16	CP	Isis Pharmaceuticals
DMBOU16	DT	Antisense drug
DMBOU16	SQ	GCTACCAATGCTTTGCCTGG
DMBOU16	DE	Discovery agent

DM4B35Y	ID	DM4B35Y
DM4B35Y	DN	ISIS 110066
DM4B35Y	HS	Investigative
DM4B35Y	CP	Isis Pharmaceuticals
DM4B35Y	DT	Antisense drug
DM4B35Y	SQ	AGCACCCTTCTTACCAGGAG
DM4B35Y	DE	Discovery agent

DM0EFHM	ID	DM0EFHM
DM0EFHM	DN	ISIS 110067
DM0EFHM	HS	Investigative
DM0EFHM	CP	Isis Pharmaceuticals
DM0EFHM	DT	Antisense drug
DM0EFHM	SQ	ATTCTTGCCATTCTTTGCCC
DM0EFHM	DE	Discovery agent

DMSLOKM	ID	DMSLOKM
DMSLOKM	DN	ISIS 110068
DMSLOKM	HS	Investigative
DMSLOKM	CP	Isis Pharmaceuticals
DMSLOKM	DT	Antisense drug
DMSLOKM	SQ	ATCACTGTCTTCCTTCTTGG
DMSLOKM	DE	Discovery agent

DMUG4HJ	ID	DMUG4HJ
DMUG4HJ	DN	ISIS 110073
DMUG4HJ	HS	Investigative
DMUG4HJ	CP	Isis Pharmaceuticals
DMUG4HJ	DT	Antisense drug
DMUG4HJ	SQ	CTTCGTCATCCTCATCGTCC
DMUG4HJ	DE	Discovery agent

DM2KECW	ID	DM2KECW
DM2KECW	DN	ISIS 110074
DM2KECW	HS	Investigative
DM2KECW	CP	Isis Pharmaceuticals
DM2KECW	DT	Antisense drug
DM2KECW	SQ	GTCATCGTCATCCTCATCAT
DM2KECW	DE	Discovery agent

DMNKY2R	ID	DMNKY2R
DMNKY2R	DN	ISIS 11061
DMNKY2R	HS	Investigative
DMNKY2R	CP	Isis Pharmaceuticals
DMNKY2R	DT	Antisense drug
DMNKY2R	SQ	5' UTR ATGCATTCTGCCCCCAAGGA
DMNKY2R	DE	Discovery agent

DMF4V58	ID	DMF4V58
DMF4V58	DN	ISIS 111084
DMF4V58	HS	Investigative
DMF4V58	CP	Isis Pharmaceuticals
DMF4V58	DT	Antisense drug
DMF4V58	SQ	CAGGCGCTGAATCTCCACCA
DMF4V58	DE	Discovery agent

DMJQS5O	ID	DMJQS5O
DMJQS5O	DN	ISIS 111085
DMJQS5O	HS	Investigative
DMJQS5O	CP	Isis Pharmaceuticals
DMJQS5O	DT	Antisense drug
DMJQS5O	SQ	GCTTCACTGAGCTCCTCCCG
DMJQS5O	DE	Discovery agent

DMJ86U4	ID	DMJ86U4
DMJ86U4	DN	ISIS 111086
DMJ86U4	HS	Investigative
DMJ86U4	CP	Isis Pharmaceuticals
DMJ86U4	DT	Antisense drug
DMJ86U4	SQ	TCGCTCATGGCTTCACTGAG
DMJ86U4	DE	Discovery agent

DM2VNUW	ID	DM2VNUW
DM2VNUW	DN	ISIS 111105
DM2VNUW	HS	Investigative
DM2VNUW	CP	Isis Pharmaceuticals
DM2VNUW	DT	Antisense drug
DM2VNUW	SQ	GAGGTCGGTGAACTCATGCA
DM2VNUW	DE	Discovery agent

DMAVQK3	ID	DMAVQK3
DMAVQK3	DN	ISIS 111117
DMAVQK3	HS	Investigative
DMAVQK3	CP	Isis Pharmaceuticals
DMAVQK3	DT	Antisense drug
DMAVQK3	SQ	ACGTGTCTGTGGACTGGAAA
DMAVQK3	DE	Discovery agent

DM2N8JX	ID	DM2N8JX
DM2N8JX	DN	ISIS 111118
DM2N8JX	HS	Investigative
DM2N8JX	CP	Isis Pharmaceuticals
DM2N8JX	DT	Antisense drug
DM2N8JX	SQ	GCACATAGCACGTGTCTGTG
DM2N8JX	DE	Discovery agent

DM019LA	ID	DM019LA
DM019LA	DN	ISIS 111119
DM019LA	HS	Investigative
DM019LA	CP	Isis Pharmaceuticals
DM019LA	DT	Antisense drug
DM019LA	SQ	CGGCGAAGGACAGCACATAG
DM019LA	DE	Discovery agent

DM3W8R0	ID	DM3W8R0
DM3W8R0	DN	ISIS 111120
DM3W8R0	HS	Investigative
DM3W8R0	CP	Isis Pharmaceuticals
DM3W8R0	DT	Antisense drug
DM3W8R0	SQ	CATGATGACGGCGAAGGACA
DM3W8R0	DE	Discovery agent

DMIHTPC	ID	DMIHTPC
DMIHTPC	DN	ISIS 111121
DMIHTPC	HS	Investigative
DMIHTPC	CP	Isis Pharmaceuticals
DMIHTPC	DT	Antisense drug
DMIHTPC	SQ	ACTGGTGTTGAGCATGATGA
DMIHTPC	DE	Discovery agent

DMB31GR	ID	DMB31GR
DMB31GR	DN	ISIS 11155
DMB31GR	HS	Investigative
DMB31GR	CP	Isis Pharmaceuticals
DMB31GR	DT	Antisense drug
DMB31GR	DE	Discovery agent

DMX1OI8	ID	DMX1OI8
DMX1OI8	DN	ISIS 11158
DMX1OI8	HS	Investigative
DMX1OI8	CP	Isis Pharmaceuticals
DMX1OI8	DT	Antisense drug
DMX1OI8	DE	Discovery agent

DM9V6FW	ID	DM9V6FW
DM9V6FW	DN	ISIS 11159
DM9V6FW	HS	Investigative
DM9V6FW	CP	Isis Pharmaceuticals
DM9V6FW	DT	Antisense drug
DM9V6FW	DE	Discovery agent

DMNIBTG	ID	DMNIBTG
DMNIBTG	DN	ISIS 111992
DMNIBTG	HS	Investigative
DMNIBTG	CP	Isis Pharmaceuticals
DMNIBTG	DT	Antisense drug
DMNIBTG	SQ	TTTAACGATGCTTCTTCGGC
DMNIBTG	DE	Discovery agent

DMVMDAZ	ID	DMVMDAZ
DMVMDAZ	DN	ISIS 111993
DMVMDAZ	HS	Investigative
DMVMDAZ	CP	Isis Pharmaceuticals
DMVMDAZ	DT	Antisense drug
DMVMDAZ	SQ	CGGCAGGGTGAAGAGAGACT
DMVMDAZ	DE	Discovery agent

DMSXTRI	ID	DMSXTRI
DMSXTRI	DN	ISIS 111997
DMSXTRI	HS	Investigative
DMSXTRI	CP	Isis Pharmaceuticals
DMSXTRI	DT	Antisense drug
DMSXTRI	SQ	CTTAGACATGACGGCAGGGT
DMSXTRI	DE	Discovery agent

DM1NHJ8	ID	DM1NHJ8
DM1NHJ8	DN	ISIS 112000
DM1NHJ8	HS	Investigative
DM1NHJ8	CP	Isis Pharmaceuticals
DM1NHJ8	DT	Antisense drug
DM1NHJ8	SQ	AGACTCTGACTTAGACATGA
DM1NHJ8	DE	Discovery agent

DM2K74C	ID	DM2K74C
DM2K74C	DN	ISIS 112001
DM2K74C	HS	Investigative
DM2K74C	CP	Isis Pharmaceuticals
DM2K74C	DT	Antisense drug
DM2K74C	SQ	AGGAGACTCTGACTTAGACA
DM2K74C	DE	Discovery agent

DMPROW5	ID	DMPROW5
DMPROW5	DN	ISIS 112002
DMPROW5	HS	Investigative
DMPROW5	CP	Isis Pharmaceuticals
DMPROW5	DT	Antisense drug
DMPROW5	SQ	TTTAGGAGACTCTGACTTAG
DMPROW5	DE	Discovery agent

DMHRLYJ	ID	DMHRLYJ
DMHRLYJ	DN	ISIS 112003
DMHRLYJ	HS	Investigative
DMHRLYJ	CP	Isis Pharmaceuticals
DMHRLYJ	DT	Antisense drug
DMHRLYJ	SQ	ATGAAGAGCTTCCTCAGCTG
DMHRLYJ	DE	Discovery agent

DMRJ1L6	ID	DMRJ1L6
DMRJ1L6	DN	ISIS 112004
DMRJ1L6	HS	Investigative
DMRJ1L6	CP	Isis Pharmaceuticals
DMRJ1L6	DT	Antisense drug
DMRJ1L6	SQ	ATCAGTTGTTTCAAAGCTCA
DMRJ1L6	DE	Discovery agent

DMDZY8F	ID	DMDZY8F
DMDZY8F	DN	ISIS 112005
DMDZY8F	HS	Investigative
DMDZY8F	CP	Isis Pharmaceuticals
DMDZY8F	DT	Antisense drug
DMDZY8F	SQ	CCATTGCTCAAAATGGCTCC
DMDZY8F	DE	Discovery agent

DMN6IBS	ID	DMN6IBS
DMN6IBS	DN	ISIS 112019
DMN6IBS	HS	Investigative
DMN6IBS	CP	Isis Pharmaceuticals
DMN6IBS	DT	Antisense drug
DMN6IBS	SQ	CCACGGAGTCATGGTCGTCA
DMN6IBS	DE	Discovery agent

DMO2FY8	ID	DMO2FY8
DMO2FY8	DN	ISIS 112020
DMO2FY8	HS	Investigative
DMO2FY8	CP	Isis Pharmaceuticals
DMO2FY8	DT	Antisense drug
DMO2FY8	SQ	TGACAATCTTATCCACGGAG
DMO2FY8	DE	Discovery agent

DM0E1SH	ID	DM0E1SH
DM0E1SH	DN	ISIS 112021
DM0E1SH	HS	Investigative
DM0E1SH	CP	Isis Pharmaceuticals
DM0E1SH	DT	Antisense drug
DM0E1SH	SQ	CAGTATGGTATTTCTGAATG
DM0E1SH	DE	Discovery agent

DM7R53M	ID	DM7R53M
DM7R53M	DN	ISIS 112022
DM7R53M	HS	Investigative
DM7R53M	CP	Isis Pharmaceuticals
DM7R53M	DT	Antisense drug
DM7R53M	SQ	TTTCTAACTTCACAGTTGTG
DM7R53M	DE	Discovery agent

DM5F4Q6	ID	DM5F4Q6
DM5F4Q6	DN	ISIS 112023
DM5F4Q6	HS	Investigative
DM5F4Q6	CP	Isis Pharmaceuticals
DM5F4Q6	DT	Antisense drug
DM5F4Q6	SQ	CACTAGCCATCTCTTGCTTT
DM5F4Q6	DE	Discovery agent

DMVLHN9	ID	DMVLHN9
DMVLHN9	DN	ISIS 112024
DMVLHN9	HS	Investigative
DMVLHN9	CP	Isis Pharmaceuticals
DMVLHN9	DT	Antisense drug
DMVLHN9	SQ	AACCACTTCGACCTCTTTGG
DMVLHN9	DE	Discovery agent

DMW3145	ID	DMW3145
DMW3145	DN	ISIS 11219
DMW3145	HS	Investigative
DMW3145	CP	Isis Pharmaceuticals
DMW3145	DT	Antisense drug
DMW3145	SQ	CGGGTTCTCCTGGTGGCAAT
DMW3145	DE	Discovery agent

DMNJS0K	ID	DMNJS0K
DMNJS0K	DN	ISIS 11220
DMNJS0K	HS	Investigative
DMNJS0K	CP	Isis Pharmaceuticals
DMNJS0K	DT	Antisense drug
DMNJS0K	SQ	CAGTGTCTGGTCATTTCCGA
DMNJS0K	DE	Discovery agent

DMDUIG3	ID	DMDUIG3
DMDUIG3	DN	ISIS 11221
DMDUIG3	HS	Investigative
DMDUIG3	CP	Isis Pharmaceuticals
DMDUIG3	DT	Antisense drug
DMDUIG3	SQ	AGCCCAGCAGAACCACGCCG
DMDUIG3	DE	Discovery agent

DM7LPI4	ID	DM7LPI4
DM7LPI4	DN	ISIS 11223
DM7LPI4	HS	Investigative
DM7LPI4	CP	Isis Pharmaceuticals
DM7LPI4	DT	Antisense drug
DM7LPI4	SQ	CAGTGCCCCGCCGAAGGAGA
DM7LPI4	DE	Discovery agent

DMMGA6K	ID	DMMGA6K
DMMGA6K	DN	ISIS 11224
DMMGA6K	HS	Investigative
DMMGA6K	CP	Isis Pharmaceuticals
DMMGA6K	DT	Antisense drug
DMMGA6K	SQ	TCGCCTGCCTCCCTCAGCGC
DMMGA6K	DE	Discovery agent

DMXHQSG	ID	DMXHQSG
DMXHQSG	DN	ISIS 112580
DMXHQSG	HS	Investigative
DMXHQSG	CP	Isis Pharmaceuticals
DMXHQSG	DT	Antisense drug
DMXHQSG	SQ	CAGCGTGGGTCCCTGCGGCT
DMXHQSG	DE	Discovery agent

DMU5QRX	ID	DMU5QRX
DMU5QRX	DN	ISIS 112590
DMU5QRX	HS	Investigative
DMU5QRX	CP	Isis Pharmaceuticals
DMU5QRX	DT	Antisense drug
DMU5QRX	SQ	CCAGCGCAGACAGCGTGGGT
DMU5QRX	DE	Discovery agent

DM9OPJW	ID	DM9OPJW
DM9OPJW	DN	ISIS 112592
DM9OPJW	HS	Investigative
DM9OPJW	CP	Isis Pharmaceuticals
DM9OPJW	DT	Antisense drug
DM9OPJW	SQ	AGCCAGCGCAGACAGCGTGG
DM9OPJW	DE	Discovery agent

DMIYCMF	ID	DMIYCMF
DMIYCMF	DN	ISIS 112599
DMIYCMF	HS	Investigative
DMIYCMF	CP	Isis Pharmaceuticals
DMIYCMF	DT	Antisense drug
DMIYCMF	SQ	CGGGTGGAGCCAGCGCAGAC
DMIYCMF	DE	Discovery agent

DM6PO0N	ID	DM6PO0N
DM6PO0N	DN	ISIS 112690
DM6PO0N	HS	Investigative
DM6PO0N	CP	Isis Pharmaceuticals
DM6PO0N	DT	Antisense drug
DM6PO0N	SQ	CCCGCGCAGAGGCACAGACG
DM6PO0N	DE	Discovery agent

DMA4635	ID	DMA4635
DMA4635	DN	ISIS 112694
DMA4635	HS	Investigative
DMA4635	CP	Isis Pharmaceuticals
DMA4635	DT	Antisense drug
DMA4635	SQ	GAGACCCGCGCAGAGGCACA
DMA4635	DE	Discovery agent

DMXZS4Y	ID	DMXZS4Y
DMXZS4Y	DN	ISIS 112696
DMXZS4Y	HS	Investigative
DMXZS4Y	CP	Isis Pharmaceuticals
DMXZS4Y	DT	Antisense drug
DMXZS4Y	SQ	AGGAGACCCGCGCAGAGGCA
DMXZS4Y	DE	Discovery agent

DMIE0GJ	ID	DMIE0GJ
DMIE0GJ	DN	ISIS 112699
DMIE0GJ	HS	Investigative
DMIE0GJ	CP	Isis Pharmaceuticals
DMIE0GJ	DT	Antisense drug
DMIE0GJ	SQ	ACCAGGAGACCCGCGCAGAG
DMIE0GJ	DE	Discovery agent

DM52UGS	ID	DM52UGS
DM52UGS	DN	ISIS 112711
DM52UGS	HS	Investigative
DM52UGS	CP	Isis Pharmaceuticals
DM52UGS	DT	Antisense drug
DM52UGS	SQ	TGGCAGAAGGACCAGGAGAC
DM52UGS	DE	Discovery agent

DMB2O1Y	ID	DMB2O1Y
DMB2O1Y	DN	ISIS 112724
DMB2O1Y	HS	Investigative
DMB2O1Y	CP	Isis Pharmaceuticals
DMB2O1Y	DT	Antisense drug
DMB2O1Y	SQ	AACATCGGCATGATGGCAGA
DMB2O1Y	DE	Discovery agent

DMVCYBG	ID	DMVCYBG
DMVCYBG	DN	ISIS 113019
DMVCYBG	HS	Investigative
DMVCYBG	CP	Isis Pharmaceuticals
DMVCYBG	DT	Antisense drug
DMVCYBG	SQ	GGTCCAGCCTCCGCTTCACC
DMVCYBG	DE	Discovery agent

DMUXN8P	ID	DMUXN8P
DMUXN8P	DN	ISIS 113020
DMUXN8P	HS	Investigative
DMUXN8P	CP	Isis Pharmaceuticals
DMUXN8P	DT	Antisense drug
DMUXN8P	SQ	GCCCACTGCTCTCGGCCAGG
DMUXN8P	DE	Discovery agent

DMQ4GL6	ID	DMQ4GL6
DMQ4GL6	DN	ISIS 113021
DMQ4GL6	HS	Investigative
DMQ4GL6	CP	Isis Pharmaceuticals
DMQ4GL6	DT	Antisense drug
DMQ4GL6	SQ	CACCTTTTCCTGGATGGCGG
DMQ4GL6	DE	Discovery agent

DMOQ0XD	ID	DMOQ0XD
DMOQ0XD	DN	ISIS 113022
DMOQ0XD	HS	Investigative
DMOQ0XD	CP	Isis Pharmaceuticals
DMOQ0XD	DT	Antisense drug
DMOQ0XD	SQ	GTGGTCAGATTCAGTGAGGT
DMOQ0XD	DE	Discovery agent

DMKTNVJ	ID	DMKTNVJ
DMKTNVJ	DN	ISIS 113048
DMKTNVJ	HS	Investigative
DMKTNVJ	CP	Isis Pharmaceuticals
DMKTNVJ	DT	Antisense drug
DMKTNVJ	SQ	GAGTCGGCCGCCACCAGCGG
DMKTNVJ	DE	Discovery agent

DM063XM	ID	DM063XM
DM063XM	DN	ISIS 113131
DM063XM	HS	Investigative
DM063XM	CP	Isis Pharmaceuticals
DM063XM	DT	Antisense drug
DM063XM	SQ	CGTGTGTCTGTGCTAGTCCC
DM063XM	DE	Discovery agent

DM5QEP4	ID	DM5QEP4
DM5QEP4	DN	ISIS 113176
DM5QEP4	HS	Investigative
DM5QEP4	CP	Isis Pharmaceuticals
DM5QEP4	DT	Antisense drug
DM5QEP4	SQ	GCTCCAGCATCTGCTGCTTC
DM5QEP4	DE	Discovery agent

DM4E6Y8	ID	DM4E6Y8
DM4E6Y8	DN	ISIS 113187
DM4E6Y8	HS	Investigative
DM4E6Y8	CP	Isis Pharmaceuticals
DM4E6Y8	DT	Antisense drug
DM4E6Y8	SQ	CCGCTCCACCACAAAGGCAC
DM4E6Y8	DE	Discovery agent

DMGVN7A	ID	DMGVN7A
DMGVN7A	DN	ISIS 113209
DMGVN7A	HS	Investigative
DMGVN7A	CP	Isis Pharmaceuticals
DMGVN7A	DT	Antisense drug
DMGVN7A	SQ	AAAAGTGCCCAGATTGCTCA
DMGVN7A	DE	Discovery agent

DMZWH6E	ID	DMZWH6E
DMZWH6E	DN	ISIS 113210
DMZWH6E	HS	Investigative
DMZWH6E	CP	Isis Pharmaceuticals
DMZWH6E	DT	Antisense drug
DMZWH6E	SQ	TAAAAGTGCCCAGATTGCTC
DMZWH6E	DE	Discovery agent

DM9D3F1	ID	DM9D3F1
DM9D3F1	DN	ISIS 113858
DM9D3F1	HS	Investigative
DM9D3F1	CP	Isis Pharmaceuticals
DM9D3F1	DT	Antisense drug
DM9D3F1	SQ	AATCAGCATTCTTTATGGCC
DM9D3F1	DE	Discovery agent

DMTEUDL	ID	DMTEUDL
DMTEUDL	DN	ISIS 113871
DMTEUDL	HS	Investigative
DMTEUDL	CP	Isis Pharmaceuticals
DMTEUDL	DT	Antisense drug
DMTEUDL	SQ	CTGATCATCCATTATGGCAA
DMTEUDL	DE	Discovery agent

DMR05YO	ID	DMR05YO
DMR05YO	DN	ISIS 113872
DMR05YO	HS	Investigative
DMR05YO	CP	Isis Pharmaceuticals
DMR05YO	DT	Antisense drug
DMR05YO	SQ	TTCAAAGCTTGCTGATCATC
DMR05YO	DE	Discovery agent

DMHUC3Q	ID	DMHUC3Q
DMHUC3Q	DN	ISIS 113873
DMHUC3Q	HS	Investigative
DMHUC3Q	CP	Isis Pharmaceuticals
DMHUC3Q	DT	Antisense drug
DMHUC3Q	SQ	CTTATGAAGGACAGCCAAAT
DMHUC3Q	DE	Discovery agent

DMEMSW1	ID	DMEMSW1
DMEMSW1	DN	ISIS 113874
DMEMSW1	HS	Investigative
DMEMSW1	CP	Isis Pharmaceuticals
DMEMSW1	DT	Antisense drug
DMEMSW1	SQ	ACTGGCCTTATGAAGGACAG
DMEMSW1	DE	Discovery agent

DMI8NYF	ID	DMI8NYF
DMI8NYF	DN	ISIS 113902
DMI8NYF	HS	Investigative
DMI8NYF	CP	Isis Pharmaceuticals
DMI8NYF	DT	Antisense drug
DMI8NYF	SQ	GAGAGACAGATGGTCTGAAG
DMI8NYF	DE	Discovery agent

DM56A89	ID	DM56A89
DM56A89	DN	ISIS 113903
DM56A89	HS	Investigative
DM56A89	CP	Isis Pharmaceuticals
DM56A89	DT	Antisense drug
DM56A89	SQ	GTGACAGACTTCATTCCTGT
DM56A89	DE	Discovery agent

DMBM7HD	ID	DMBM7HD
DMBM7HD	DN	ISIS 113904
DMBM7HD	HS	Investigative
DMBM7HD	CP	Isis Pharmaceuticals
DMBM7HD	DT	Antisense drug
DMBM7HD	SQ	GCAACACTCCAGATGTCTGC
DMBM7HD	DE	Discovery agent

DMPRDXO	ID	DMPRDXO
DMPRDXO	DN	ISIS 113905
DMPRDXO	HS	Investigative
DMPRDXO	CP	Isis Pharmaceuticals
DMPRDXO	DT	Antisense drug
DMPRDXO	SQ	GGCGGCTTTTCAGTTAGCAT
DMPRDXO	DE	Discovery agent

DMPJAB5	ID	DMPJAB5
DMPJAB5	DN	ISIS 113906
DMPJAB5	HS	Investigative
DMPJAB5	CP	Isis Pharmaceuticals
DMPJAB5	DT	Antisense drug
DMPJAB5	SQ	AAATTCAGCCCAAGGCGGCT
DMPJAB5	DE	Discovery agent

DMP6WE0	ID	DMP6WE0
DMP6WE0	DN	ISIS 113907
DMP6WE0	HS	Investigative
DMP6WE0	CP	Isis Pharmaceuticals
DMP6WE0	DT	Antisense drug
DMP6WE0	SQ	GTTGGCTGAGTGGCGATTTT
DMP6WE0	DE	Discovery agent

DMKLZ2H	ID	DMKLZ2H
DMKLZ2H	DN	ISIS 113908
DMKLZ2H	HS	Investigative
DMKLZ2H	CP	Isis Pharmaceuticals
DMKLZ2H	DT	Antisense drug
DMKLZ2H	SQ	ACTGGCTGCTAGTGATAATG
DMKLZ2H	DE	Discovery agent

DM0B9V5	ID	DM0B9V5
DM0B9V5	DN	ISIS 113909
DM0B9V5	HS	Investigative
DM0B9V5	CP	Isis Pharmaceuticals
DM0B9V5	DT	Antisense drug
DM0B9V5	SQ	ACAGGAGAGGTTACTGGCTG
DM0B9V5	DE	Discovery agent

DMUVS0E	ID	DMUVS0E
DMUVS0E	DN	ISIS 114170
DMUVS0E	HS	Investigative
DMUVS0E	CP	Isis Pharmaceuticals
DMUVS0E	DT	Antisense drug
DMUVS0E	SQ	GCTCCTGCTCTTTTTAGTGT
DMUVS0E	DE	Discovery agent

DM60V4N	ID	DM60V4N
DM60V4N	DN	ISIS 114184
DM60V4N	HS	Investigative
DM60V4N	CP	Isis Pharmaceuticals
DM60V4N	DT	Antisense drug
DM60V4N	SQ	GGGCTTTCACAACTATAACA
DM60V4N	DE	Discovery agent

DMVJN4B	ID	DMVJN4B
DMVJN4B	DN	ISIS 114197
DMVJN4B	HS	Investigative
DMVJN4B	CP	Isis Pharmaceuticals
DMVJN4B	DT	Antisense drug
DMVJN4B	SQ	GCAGACCTCAAAGACATGCA
DMVJN4B	DE	Discovery agent

DM2GH8X	ID	DM2GH8X
DM2GH8X	DN	ISIS 114232
DM2GH8X	HS	Investigative
DM2GH8X	CP	Isis Pharmaceuticals
DM2GH8X	DT	Antisense drug
DM2GH8X	SQ	GCATACTTAGTACTTAAAGT
DM2GH8X	DE	Discovery agent

DMBO3YT	ID	DMBO3YT
DMBO3YT	DN	ISIS 114371
DMBO3YT	HS	Investigative
DMBO3YT	CP	Isis Pharmaceuticals
DMBO3YT	DT	Antisense drug
DMBO3YT	SQ	TGCCACTCTGGTCTTGGAAG
DMBO3YT	DE	Discovery agent

DMNTRKI	ID	DMNTRKI
DMNTRKI	DN	ISIS 114372
DMNTRKI	HS	Investigative
DMNTRKI	CP	Isis Pharmaceuticals
DMNTRKI	DT	Antisense drug
DMNTRKI	SQ	GCATCACTACACCTCAAAAG
DMNTRKI	DE	Discovery agent

DMIZH16	ID	DMIZH16
DMIZH16	DN	ISIS 114388
DMIZH16	HS	Investigative
DMIZH16	CP	Isis Pharmaceuticals
DMIZH16	DT	Antisense drug
DMIZH16	SQ	CTGGTTTCCCTGACAGTTGG
DMIZH16	DE	Discovery agent

DM1H428	ID	DM1H428
DM1H428	DN	ISIS 114390
DM1H428	HS	Investigative
DM1H428	CP	Isis Pharmaceuticals
DM1H428	DT	Antisense drug
DM1H428	SQ	AGCCAATCCTCTGTAACCAT
DM1H428	DE	Discovery agent

DMCBXQK	ID	DMCBXQK
DMCBXQK	DN	ISIS 114397
DMCBXQK	HS	Investigative
DMCBXQK	CP	Isis Pharmaceuticals
DMCBXQK	DT	Antisense drug
DMCBXQK	SQ	CAGTACCAGGCACTTCCTTG
DMCBXQK	DE	Discovery agent

DMZVE0S	ID	DMZVE0S
DMZVE0S	DN	ISIS 114399
DMZVE0S	HS	Investigative
DMZVE0S	CP	Isis Pharmaceuticals
DMZVE0S	DT	Antisense drug
DMZVE0S	SQ	GGTTGCCCATCTTCTTTCCT
DMZVE0S	DE	Discovery agent

DMIOWBH	ID	DMIOWBH
DMIOWBH	DN	ISIS 114404
DMIOWBH	HS	Investigative
DMIOWBH	CP	Isis Pharmaceuticals
DMIOWBH	DT	Antisense drug
DMIOWBH	SQ	ATTTGGCAAGCTGCAGTCAC
DMIOWBH	DE	Discovery agent

DMCVP5G	ID	DMCVP5G
DMCVP5G	DN	ISIS 114442
DMCVP5G	HS	Investigative
DMCVP5G	CP	Isis Pharmaceuticals
DMCVP5G	DT	Antisense drug
DMCVP5G	SQ	CCCGCCCACGCGTCACACGG
DMCVP5G	DE	Discovery agent

DM1OVSW	ID	DM1OVSW
DM1OVSW	DN	ISIS 114527
DM1OVSW	HS	Investigative
DM1OVSW	CP	Isis Pharmaceuticals
DM1OVSW	DT	Antisense drug
DM1OVSW	SQ	TCAGTGATGGTGTCACTGGT
DM1OVSW	DE	Discovery agent

DMSEQ61	ID	DMSEQ61
DMSEQ61	DN	ISIS 114530
DMSEQ61	HS	Investigative
DMSEQ61	CP	Isis Pharmaceuticals
DMSEQ61	DT	Antisense drug
DMSEQ61	SQ	TTGTAAGACTTGTCACTCAC
DMSEQ61	DE	Discovery agent

DMZSUA9	ID	DMZSUA9
DMZSUA9	DN	ISIS 114531
DMZSUA9	HS	Investigative
DMZSUA9	CP	Isis Pharmaceuticals
DMZSUA9	DT	Antisense drug
DMZSUA9	SQ	TCCGTTGGGCAATTTCTGGA
DMZSUA9	DE	Discovery agent

DMJ7BOL	ID	DMJ7BOL
DMJ7BOL	DN	ISIS 114532
DMJ7BOL	HS	Investigative
DMJ7BOL	CP	Isis Pharmaceuticals
DMJ7BOL	DT	Antisense drug
DMJ7BOL	SQ	TTCCTGTCACTTTCGATTGC
DMJ7BOL	DE	Discovery agent

DMD9O2H	ID	DMD9O2H
DMD9O2H	DN	ISIS 114537
DMD9O2H	HS	Investigative
DMD9O2H	CP	Isis Pharmaceuticals
DMD9O2H	DT	Antisense drug
DMD9O2H	SQ	TCTTCTGAATGTGTGAAGGT
DMD9O2H	DE	Discovery agent

DMMOPUK	ID	DMMOPUK
DMMOPUK	DN	ISIS 114559
DMMOPUK	HS	Investigative
DMMOPUK	CP	Isis Pharmaceuticals
DMMOPUK	DT	Antisense drug
DMMOPUK	SQ	CTGGGCTGCAGCATATTCAC
DMMOPUK	DE	Discovery agent

DMD2J3Q	ID	DMD2J3Q
DMD2J3Q	DN	ISIS 114563
DMD2J3Q	HS	Investigative
DMD2J3Q	CP	Isis Pharmaceuticals
DMD2J3Q	DT	Antisense drug
DMD2J3Q	SQ	AGGAGGAGTAACATCCGCCT
DMD2J3Q	DE	Discovery agent

DM280AE	ID	DM280AE
DM280AE	DN	ISIS 116359
DM280AE	HS	Investigative
DM280AE	CP	Isis Pharmaceuticals
DM280AE	DT	Antisense drug
DM280AE	SQ	GGCTCTTCACTTGCATAAAG
DM280AE	DE	Discovery agent

DMFEZHM	ID	DMFEZHM
DMFEZHM	DN	ISIS 116360
DMFEZHM	HS	Investigative
DMFEZHM	CP	Isis Pharmaceuticals
DMFEZHM	DT	Antisense drug
DMFEZHM	SQ	GTTTTGATTACTGTCTTGAC
DMFEZHM	DE	Discovery agent

DMWBQHS	ID	DMWBQHS
DMWBQHS	DN	ISIS 116361
DMWBQHS	HS	Investigative
DMWBQHS	CP	Isis Pharmaceuticals
DMWBQHS	DT	Antisense drug
DMWBQHS	SQ	AACCATGGTACCTCTTGGCC
DMWBQHS	DE	Discovery agent

DM7M1UB	ID	DM7M1UB
DM7M1UB	DN	ISIS 116362
DM7M1UB	HS	Investigative
DM7M1UB	CP	Isis Pharmaceuticals
DM7M1UB	DT	Antisense drug
DM7M1UB	SQ	AAAAATGCTTTGCAGTGTTG
DM7M1UB	DE	Discovery agent

DMXKAJP	ID	DMXKAJP
DMXKAJP	DN	ISIS 116363
DMXKAJP	HS	Investigative
DMXKAJP	CP	Isis Pharmaceuticals
DMXKAJP	DT	Antisense drug
DMXKAJP	SQ	CCAGATTCCTGTGGTCGTTG
DMXKAJP	DE	Discovery agent

DM4Q3JO	ID	DM4Q3JO
DM4Q3JO	DN	ISIS 116414
DM4Q3JO	HS	Investigative
DM4Q3JO	CP	Isis Pharmaceuticals
DM4Q3JO	DT	Antisense drug
DM4Q3JO	SQ	TGCATTAAATGAAGCTGCAG
DM4Q3JO	DE	Discovery agent

DMVE5UH	ID	DMVE5UH
DMVE5UH	DN	ISIS 116505
DMVE5UH	HS	Investigative
DMVE5UH	CP	Isis Pharmaceuticals
DMVE5UH	DT	Antisense drug
DMVE5UH	SQ	ACCGATTGCATCAACTTCGA
DMVE5UH	DE	Discovery agent

DM76CYG	ID	DM76CYG
DM76CYG	DN	ISIS 116507
DM76CYG	HS	Investigative
DM76CYG	CP	Isis Pharmaceuticals
DM76CYG	DT	Antisense drug
DM76CYG	SQ	GGTTGCGTCAGTCCCGTGTA
DM76CYG	DE	Discovery agent

DM3XHBR	ID	DM3XHBR
DM3XHBR	DN	ISIS 116508
DM3XHBR	HS	Investigative
DM3XHBR	CP	Isis Pharmaceuticals
DM3XHBR	DT	Antisense drug
DM3XHBR	SQ	CAGGGCCCGGCTGACAGTTA
DM3XHBR	DE	Discovery agent

DMIJES1	ID	DMIJES1
DMIJES1	DN	ISIS 116625
DMIJES1	HS	Investigative
DMIJES1	CP	Isis Pharmaceuticals
DMIJES1	DT	Antisense drug
DMIJES1	SQ	CGGACCAACTGCTTTGCACT
DMIJES1	DE	Discovery agent

DM2X5RT	ID	DM2X5RT
DM2X5RT	DN	ISIS 116631
DM2X5RT	HS	Investigative
DM2X5RT	CP	Isis Pharmaceuticals
DM2X5RT	DT	Antisense drug
DM2X5RT	SQ	AGCTGGTCCACCCCACTGTC
DM2X5RT	DE	Discovery agent

DMW2Q4T	ID	DMW2Q4T
DMW2Q4T	DN	ISIS 116632
DMW2Q4T	HS	Investigative
DMW2Q4T	CP	Isis Pharmaceuticals
DMW2Q4T	DT	Antisense drug
DMW2Q4T	SQ	GCTGGGTTCCCAGACATCGC
DMW2Q4T	DE	Discovery agent

DMUOB3S	ID	DMUOB3S
DMUOB3S	DN	ISIS 116648
DMUOB3S	HS	Investigative
DMUOB3S	CP	Isis Pharmaceuticals
DMUOB3S	DT	Antisense drug
DMUOB3S	SQ	AGCCAATGACACCATACCTT
DMUOB3S	DE	Discovery agent

DMYWINR	ID	DMYWINR
DMYWINR	DN	ISIS 11665
DMYWINR	HS	Investigative
DMYWINR	CP	Isis Pharmaceuticals
DMYWINR	DT	Antisense drug
DMYWINR	DE	Discovery agent

DMBJU2X	ID	DMBJU2X
DMBJU2X	DN	ISIS 116654
DMBJU2X	HS	Investigative
DMBJU2X	CP	Isis Pharmaceuticals
DMBJU2X	DT	Antisense drug
DMBJU2X	SQ	CAGGCAATCCTCTTACCTGA
DMBJU2X	DE	Discovery agent

DM9R51M	ID	DM9R51M
DM9R51M	DN	ISIS 116670
DM9R51M	HS	Investigative
DM9R51M	CP	Isis Pharmaceuticals
DM9R51M	DT	Antisense drug
DM9R51M	SQ	CTCAGTTCCTCTCTCTGCTA
DM9R51M	DE	Discovery agent

DMIS715	ID	DMIS715
DMIS715	DN	ISIS 119262
DMIS715	HS	Investigative
DMIS715	CP	Isis Pharmaceuticals
DMIS715	DT	Antisense drug
DMIS715	SQ	TCATCACGGGATGGATCCAG
DMIS715	DE	Discovery agent

DMD3M9J	ID	DMD3M9J
DMD3M9J	DN	ISIS 119263
DMD3M9J	HS	Investigative
DMD3M9J	CP	Isis Pharmaceuticals
DMD3M9J	DT	Antisense drug
DMD3M9J	SQ	ACACTCATCACGGGATGGAT
DMD3M9J	DE	Discovery agent

DM0P3R5	ID	DM0P3R5
DM0P3R5	DN	ISIS 119264
DM0P3R5	HS	Investigative
DM0P3R5	CP	Isis Pharmaceuticals
DM0P3R5	DT	Antisense drug
DM0P3R5	SQ	TTCAGGACACTCATCACGGG
DM0P3R5	DE	Discovery agent

DMFPM5S	ID	DMFPM5S
DMFPM5S	DN	ISIS 119281
DMFPM5S	HS	Investigative
DMFPM5S	CP	Isis Pharmaceuticals
DMFPM5S	DT	Antisense drug
DMFPM5S	SQ	CTCACATCATCCATGTAGCT
DMFPM5S	DE	Discovery agent

DMLND5S	ID	DMLND5S
DMLND5S	DN	ISIS 119282
DMLND5S	HS	Investigative
DMLND5S	CP	Isis Pharmaceuticals
DMLND5S	DT	Antisense drug
DMLND5S	SQ	TCTGCTCACATCATCCATGT
DMLND5S	DE	Discovery agent

DMKJ57H	ID	DMKJ57H
DMKJ57H	DN	ISIS 119283
DMKJ57H	HS	Investigative
DMKJ57H	CP	Isis Pharmaceuticals
DMKJ57H	DT	Antisense drug
DMKJ57H	SQ	GTCTCTGCTCACATCATCCA
DMKJ57H	DE	Discovery agent

DM7CTVE	ID	DM7CTVE
DM7CTVE	DN	ISIS 119284
DM7CTVE	HS	Investigative
DM7CTVE	CP	Isis Pharmaceuticals
DM7CTVE	DT	Antisense drug
DM7CTVE	SQ	ATGCGTCTCTGCTCACATCA
DM7CTVE	DE	Discovery agent

DMYQR3A	ID	DMYQR3A
DMYQR3A	DN	ISIS 119285
DMYQR3A	HS	Investigative
DMYQR3A	CP	Isis Pharmaceuticals
DMYQR3A	DT	Antisense drug
DMYQR3A	SQ	GTTATGCGTCTCTGCTCACA
DMYQR3A	DE	Discovery agent

DM42LSO	ID	DM42LSO
DM42LSO	DN	ISIS 119286
DM42LSO	HS	Investigative
DM42LSO	CP	Isis Pharmaceuticals
DM42LSO	DT	Antisense drug
DM42LSO	SQ	GATGTTATGCGTCTCTGCTC
DM42LSO	DE	Discovery agent

DMZYOPD	ID	DMZYOPD
DMZYOPD	DN	ISIS 11929
DMZYOPD	HS	Investigative
DMZYOPD	CP	Isis Pharmaceuticals
DMZYOPD	DT	Antisense drug
DMZYOPD	DE	Discovery agent

DM0LMQH	ID	DM0LMQH
DM0LMQH	DN	ISIS 122970
DM0LMQH	HS	Investigative
DM0LMQH	CP	Isis Pharmaceuticals
DM0LMQH	DT	Antisense drug
DM0LMQH	SQ	CTTCATGGTCTCATATCCAG
DM0LMQH	DE	Discovery agent

DM4NBX0	ID	DM4NBX0
DM4NBX0	DN	ISIS 122971
DM4NBX0	HS	Investigative
DM4NBX0	CP	Isis Pharmaceuticals
DM4NBX0	DT	Antisense drug
DM4NBX0	SQ	TGACGTCACTCTGCCTATTT
DM4NBX0	DE	Discovery agent

DMLHA6K	ID	DMLHA6K
DMLHA6K	DN	ISIS 122974
DMLHA6K	HS	Investigative
DMLHA6K	CP	Isis Pharmaceuticals
DMLHA6K	DT	Antisense drug
DMLHA6K	SQ	CACATCTTCATATTTCACAG
DMLHA6K	DE	Discovery agent

DM4Y8EQ	ID	DM4Y8EQ
DM4Y8EQ	DN	ISIS 122975
DM4Y8EQ	HS	Investigative
DM4Y8EQ	CP	Isis Pharmaceuticals
DM4Y8EQ	DT	Antisense drug
DM4Y8EQ	SQ	ACCTTGTGCTCCACATCTTC
DM4Y8EQ	DE	Discovery agent

DM7OSZI	ID	DM7OSZI
DM7OSZI	DN	ISIS 122976
DM7OSZI	HS	Investigative
DM7OSZI	CP	Isis Pharmaceuticals
DM7OSZI	DT	Antisense drug
DM7OSZI	SQ	TTGTCACCTTGTGCTCCACA
DM7OSZI	DE	Discovery agent

DMVZS1D	ID	DMVZS1D
DMVZS1D	DN	ISIS 122984
DMVZS1D	HS	Investigative
DMVZS1D	CP	Isis Pharmaceuticals
DMVZS1D	DT	Antisense drug
DMVZS1D	SQ	ATTGGCAGCTTCCAGACAAG
DMVZS1D	DE	Discovery agent

DM6JVOP	ID	DM6JVOP
DM6JVOP	DN	ISIS 122985
DM6JVOP	HS	Investigative
DM6JVOP	CP	Isis Pharmaceuticals
DM6JVOP	DT	Antisense drug
DM6JVOP	SQ	TCCAAGGATTGGCAGCTTCC
DM6JVOP	DE	Discovery agent

DMU79FD	ID	DMU79FD
DMU79FD	DN	ISIS 122986
DMU79FD	HS	Investigative
DMU79FD	CP	Isis Pharmaceuticals
DMU79FD	DT	Antisense drug
DMU79FD	SQ	CTGTCCAAGGATTGGCAGCT
DMU79FD	DE	Discovery agent

DMLN8XS	ID	DMLN8XS
DMLN8XS	DN	ISIS 122990
DMLN8XS	HS	Investigative
DMLN8XS	CP	Isis Pharmaceuticals
DMLN8XS	DT	Antisense drug
DMLN8XS	SQ	GAAGGATGGGCTGTCTGCTG
DMLN8XS	DE	Discovery agent

DMHAWMV	ID	DMHAWMV
DMHAWMV	DN	ISIS 122991
DMHAWMV	HS	Investigative
DMHAWMV	CP	Isis Pharmaceuticals
DMHAWMV	DT	Antisense drug
DMHAWMV	SQ	TCGTGATTTCCGGAAGGATG
DMHAWMV	DE	Discovery agent

DMZGKHO	ID	DMZGKHO
DMZGKHO	DN	ISIS 12659
DMZGKHO	HS	Investigative
DMZGKHO	CP	Isis Pharmaceuticals
DMZGKHO	DT	Antisense drug
DMZGKHO	SQ	GGCGTCTCCAGGCGATCTGA
DMZGKHO	DE	Discovery agent

DMNOPWB	ID	DMNOPWB
DMNOPWB	DN	ISIS 12660
DMNOPWB	HS	Investigative
DMNOPWB	CP	Isis Pharmaceuticals
DMNOPWB	DT	Antisense drug
DMNOPWB	SQ	TGGATGGCGTCTCCAGGCGA
DMNOPWB	DE	Discovery agent

DMAXB8T	ID	DMAXB8T
DMAXB8T	DN	ISIS 12882
DMAXB8T	HS	Investigative
DMAXB8T	CP	Isis Pharmaceuticals
DMAXB8T	DT	Antisense drug
DMAXB8T	SQ	GTCCCCACCGCCACTCCTGG
DMAXB8T	DE	Discovery agent

DMND0JL	ID	DMND0JL
DMND0JL	DN	ISIS 12883
DMND0JL	HS	Investigative
DMND0JL	CP	Isis Pharmaceuticals
DMND0JL	DT	Antisense drug
DMND0JL	SQ	GTCCCCACCGCCACTCCTGG
DMND0JL	DE	Discovery agent

DMS15A3	ID	DMS15A3
DMS15A3	DN	ISIS 12884
DMS15A3	HS	Investigative
DMS15A3	CP	Isis Pharmaceuticals
DMS15A3	DT	Antisense drug
DMS15A3	SQ	GTCCCCACCGCCACTCCTGG
DMS15A3	DE	Discovery agent

DMKY5LI	ID	DMKY5LI
DMKY5LI	DN	ISIS 133206
DMKY5LI	HS	Investigative
DMKY5LI	CP	Isis Pharmaceuticals
DMKY5LI	DT	Antisense drug
DMKY5LI	SQ	AAGTCTATTGCTTCTTGAAA
DMKY5LI	DE	Discovery agent

DMR3KLF	ID	DMR3KLF
DMR3KLF	DN	ISIS 133207
DMR3KLF	HS	Investigative
DMR3KLF	CP	Isis Pharmaceuticals
DMR3KLF	DT	Antisense drug
DMR3KLF	SQ	AGGACCTTGCCTCCCTTTTC
DMR3KLF	DE	Discovery agent

DMTSKQZ	ID	DMTSKQZ
DMTSKQZ	DN	ISIS 133208
DMTSKQZ	HS	Investigative
DMTSKQZ	CP	Isis Pharmaceuticals
DMTSKQZ	DT	Antisense drug
DMTSKQZ	SQ	GCGGAACTGCTTGGTCTTCA
DMTSKQZ	DE	Discovery agent

DMCGF2P	ID	DMCGF2P
DMCGF2P	DN	ISIS 133211
DMCGF2P	HS	Investigative
DMCGF2P	CP	Isis Pharmaceuticals
DMCGF2P	DT	Antisense drug
DMCGF2P	SQ	GAAGGCCTCCTTCAGGCGGA
DMCGF2P	DE	Discovery agent

DMP60XE	ID	DMP60XE
DMP60XE	DN	ISIS 133242
DMP60XE	HS	Investigative
DMP60XE	CP	Isis Pharmaceuticals
DMP60XE	DT	Antisense drug
DMP60XE	SQ	CAACATCTTGCTACTTCAAC
DMP60XE	DE	Discovery agent

DM2PIAZ	ID	DM2PIAZ
DM2PIAZ	DN	ISIS 133243
DM2PIAZ	HS	Investigative
DM2PIAZ	CP	Isis Pharmaceuticals
DM2PIAZ	DT	Antisense drug
DM2PIAZ	SQ	CATGCCAAAGTCCAAGGTCA
DM2PIAZ	DE	Discovery agent

DMTGFXI	ID	DMTGFXI
DMTGFXI	DN	ISIS 133244
DMTGFXI	HS	Investigative
DMTGFXI	CP	Isis Pharmaceuticals
DMTGFXI	DT	Antisense drug
DMTGFXI	SQ	AGTTCAAGTATGACTAAGAA
DMTGFXI	DE	Discovery agent

DMO09DU	ID	DMO09DU
DMO09DU	DN	ISIS 133245
DMO09DU	HS	Investigative
DMO09DU	CP	Isis Pharmaceuticals
DMO09DU	DT	Antisense drug
DMO09DU	SQ	CAAGTTCAAGTATGACTAAG
DMO09DU	DE	Discovery agent

DMDZ3FU	ID	DMDZ3FU
DMDZ3FU	DN	ISIS 133712
DMDZ3FU	HS	Investigative
DMDZ3FU	CP	Isis Pharmaceuticals
DMDZ3FU	DT	Antisense drug
DMDZ3FU	SQ	AGCTTCTCCATGGTCACGTC
DMDZ3FU	DE	Discovery agent

DMJ56XU	ID	DMJ56XU
DMJ56XU	DN	ISIS 133726
DMJ56XU	HS	Investigative
DMJ56XU	CP	Isis Pharmaceuticals
DMJ56XU	DT	Antisense drug
DMJ56XU	SQ	GCACTCTGGACCCAAACCAG
DMJ56XU	DE	Discovery agent

DM90TOR	ID	DM90TOR
DM90TOR	DN	ISIS 134499
DM90TOR	HS	Investigative
DM90TOR	CP	Isis Pharmaceuticals
DM90TOR	DT	Antisense drug
DM90TOR	SQ	CCTTCTGCAACAGAGTAACA
DM90TOR	DE	Discovery agent

DMFCOA5	ID	DMFCOA5
DMFCOA5	DN	ISIS 134524
DMFCOA5	HS	Investigative
DMFCOA5	CP	Isis Pharmaceuticals
DMFCOA5	DT	Antisense drug
DMFCOA5	SQ	CAAATGCTTATAAATTTTTA
DMFCOA5	DE	Discovery agent

DMYZNIW	ID	DMYZNIW
DMYZNIW	DN	ISIS 134528
DMYZNIW	HS	Investigative
DMYZNIW	CP	Isis Pharmaceuticals
DMYZNIW	DT	Antisense drug
DMYZNIW	SQ	CAGCTTTACCTTTTATAGAA
DMYZNIW	DE	Discovery agent

DMRFMVL	ID	DMRFMVL
DMRFMVL	DN	ISIS 134532
DMRFMVL	HS	Investigative
DMRFMVL	CP	Isis Pharmaceuticals
DMRFMVL	DT	Antisense drug
DMRFMVL	SQ	ATCTGAAAACCTAGTGGTAT
DMRFMVL	DE	Discovery agent

DMWRYA1	ID	DMWRYA1
DMWRYA1	DN	ISIS 134563
DMWRYA1	HS	Investigative
DMWRYA1	CP	Isis Pharmaceuticals
DMWRYA1	DT	Antisense drug
DMWRYA1	SQ	CCCTACTTTTGTAGAAGCCA
DMWRYA1	DE	Discovery agent

DM8J24F	ID	DM8J24F
DM8J24F	DN	ISIS 134564
DM8J24F	HS	Investigative
DM8J24F	CP	Isis Pharmaceuticals
DM8J24F	DT	Antisense drug
DM8J24F	SQ	CTTGTACTGCTCGGCTGGAT
DM8J24F	DE	Discovery agent

DM9FR3A	ID	DM9FR3A
DM9FR3A	DN	ISIS 134565
DM9FR3A	HS	Investigative
DM9FR3A	CP	Isis Pharmaceuticals
DM9FR3A	DT	Antisense drug
DM9FR3A	SQ	TCCATCTTGTACTGCTCGGC
DM9FR3A	DE	Discovery agent

DMCM2S4	ID	DMCM2S4
DMCM2S4	DN	ISIS 134566
DMCM2S4	HS	Investigative
DMCM2S4	CP	Isis Pharmaceuticals
DMCM2S4	DT	Antisense drug
DMCM2S4	SQ	TTGTGGTCCATCTTGTACTG
DMCM2S4	DE	Discovery agent

DM0HWRN	ID	DM0HWRN
DM0HWRN	DN	ISIS 134583
DM0HWRN	HS	Investigative
DM0HWRN	CP	Isis Pharmaceuticals
DM0HWRN	DT	Antisense drug
DM0HWRN	SQ	CGGGTACGTCATGCTGGCTA
DM0HWRN	DE	Discovery agent

DMNP8HG	ID	DMNP8HG
DMNP8HG	DN	ISIS 134601
DMNP8HG	HS	Investigative
DMNP8HG	CP	Isis Pharmaceuticals
DMNP8HG	DT	Antisense drug
DMNP8HG	SQ	CTAGGTTTGGGACAGAAATG
DMNP8HG	DE	Discovery agent

DMDS4BP	ID	DMDS4BP
DMDS4BP	DN	ISIS 134602
DMDS4BP	HS	Investigative
DMDS4BP	CP	Isis Pharmaceuticals
DMDS4BP	DT	Antisense drug
DMDS4BP	SQ	ACCAGCTGGCCTTTGTATAA
DMDS4BP	DE	Discovery agent

DM01UDZ	ID	DM01UDZ
DM01UDZ	DN	ISIS 134603
DM01UDZ	HS	Investigative
DM01UDZ	CP	Isis Pharmaceuticals
DM01UDZ	DT	Antisense drug
DM01UDZ	SQ	TGGGTGAAAGTCTTCCACCA
DM01UDZ	DE	Discovery agent

DM32XGR	ID	DM32XGR
DM32XGR	DN	ISIS 134604
DM32XGR	HS	Investigative
DM32XGR	CP	Isis Pharmaceuticals
DM32XGR	DT	Antisense drug
DM32XGR	SQ	TGAAGCAGTTTACATTGATG
DM32XGR	DE	Discovery agent

DMCPKV9	ID	DMCPKV9
DMCPKV9	DN	ISIS 134605
DMCPKV9	HS	Investigative
DMCPKV9	CP	Isis Pharmaceuticals
DMCPKV9	DT	Antisense drug
DMCPKV9	SQ	GGCATCTACAAAATTGAAGC
DMCPKV9	DE	Discovery agent

DM4OF6C	ID	DM4OF6C
DM4OF6C	DN	ISIS 134606
DM4OF6C	HS	Investigative
DM4OF6C	CP	Isis Pharmaceuticals
DM4OF6C	DT	Antisense drug
DM4OF6C	SQ	TTCTATGGCATCTACAAAAT
DM4OF6C	DE	Discovery agent

DMZDJF3	ID	DMZDJF3
DMZDJF3	DN	ISIS 134607
DMZDJF3	HS	Investigative
DMZDJF3	CP	Isis Pharmaceuticals
DMZDJF3	DT	Antisense drug
DMZDJF3	SQ	AACATTACTTTTCTATGGCA
DMZDJF3	DE	Discovery agent

DMVX9IT	ID	DMVX9IT
DMVX9IT	DN	ISIS 134608
DMVX9IT	HS	Investigative
DMVX9IT	CP	Isis Pharmaceuticals
DMVX9IT	DT	Antisense drug
DMVX9IT	SQ	CACGTCCAACATGATTGAAA
DMVX9IT	DE	Discovery agent

DMYODMN	ID	DMYODMN
DMYODMN	DN	ISIS 134609
DMYODMN	HS	Investigative
DMYODMN	CP	Isis Pharmaceuticals
DMYODMN	DT	Antisense drug
DMYODMN	SQ	CTTCCACCACGTCCAACATG
DMYODMN	DE	Discovery agent

DMCDW4H	ID	DMCDW4H
DMCDW4H	DN	ISIS 13727
DMCDW4H	HS	Investigative
DMCDW4H	CP	Isis Pharmaceuticals
DMCDW4H	DT	Antisense drug
DMCDW4H	SQ	TGTAACTGCTGAGGTGTAGG
DMCDW4H	DE	Discovery agent

DMRJBH4	ID	DMRJBH4
DMRJBH4	DN	ISIS 13730
DMRJBH4	HS	Investigative
DMRJBH4	CP	Isis Pharmaceuticals
DMRJBH4	DT	Antisense drug
DMRJBH4	SQ	ATGGAGATGGTGATACAAGC
DMRJBH4	DE	Discovery agent

DM5Q12D	ID	DM5Q12D
DM5Q12D	DN	ISIS 13740
DM5Q12D	HS	Investigative
DM5Q12D	CP	Isis Pharmaceuticals
DM5Q12D	DT	Antisense drug
DM5Q12D	SQ	TGGATGGGTGTTTTTGGAGA
DM5Q12D	DE	Discovery agent

DMC7Q38	ID	DMC7Q38
DMC7Q38	DN	ISIS 13741
DMC7Q38	HS	Investigative
DMC7Q38	CP	Isis Pharmaceuticals
DMC7Q38	DT	Antisense drug
DMC7Q38	SQ	CTGCCTGGATGGGTGTTTTT
DMC7Q38	DE	Discovery agent

DMO6R1I	ID	DMO6R1I
DMO6R1I	DN	ISIS 13743
DMO6R1I	HS	Investigative
DMO6R1I	CP	Isis Pharmaceuticals
DMO6R1I	DT	Antisense drug
DMO6R1I	SQ	TTTATTTTCCTTTTGTTGCT
DMO6R1I	DE	Discovery agent

DMLVKPD	ID	DMLVKPD
DMLVKPD	DN	ISIS 13805
DMLVKPD	HS	Investigative
DMLVKPD	CP	Isis Pharmaceuticals
DMLVKPD	DT	Antisense drug
DMLVKPD	SQ	CCTGCCTCCGTGTGTGGCCC
DMLVKPD	DE	Discovery agent

DMPXCZ7	ID	DMPXCZ7
DMPXCZ7	DN	ISIS 13812
DMPXCZ7	HS	Investigative
DMPXCZ7	CP	Isis Pharmaceuticals
DMPXCZ7	DT	Antisense drug
DMPXCZ7	SQ	GCCTCATGATCCCCACGATC
DMPXCZ7	DE	Discovery agent

DMLE7YQ	ID	DMLE7YQ
DMLE7YQ	DN	ISIS 138612
DMLE7YQ	HS	Investigative
DMLE7YQ	CP	Isis Pharmaceuticals
DMLE7YQ	DT	Antisense drug
DMLE7YQ	SQ	ATAGATCACTTTTACAAGGC
DMLE7YQ	DE	Discovery agent

DMN3L0Y	ID	DMN3L0Y
DMN3L0Y	DN	ISIS 138613
DMN3L0Y	HS	Investigative
DMN3L0Y	CP	Isis Pharmaceuticals
DMN3L0Y	DT	Antisense drug
DMN3L0Y	SQ	CCTTAGGAAAGTGTCTGTAA
DMN3L0Y	DE	Discovery agent

DM1FX7N	ID	DM1FX7N
DM1FX7N	DN	ISIS 138616
DM1FX7N	HS	Investigative
DM1FX7N	CP	Isis Pharmaceuticals
DM1FX7N	DT	Antisense drug
DM1FX7N	SQ	GGAAAATTTGTCTCTGGCTT
DM1FX7N	DE	Discovery agent

DM73NIE	ID	DM73NIE
DM73NIE	DN	ISIS 138647
DM73NIE	HS	Investigative
DM73NIE	CP	Isis Pharmaceuticals
DM73NIE	DT	Antisense drug
DM73NIE	SQ	TCTCATATATGAAAGGCGGC
DM73NIE	DE	Discovery agent

DMSUKAO	ID	DMSUKAO
DMSUKAO	DN	ISIS 138648
DMSUKAO	HS	Investigative
DMSUKAO	CP	Isis Pharmaceuticals
DMSUKAO	DT	Antisense drug
DMSUKAO	SQ	GCTGACCTTTTTGCTTCTCA
DMSUKAO	DE	Discovery agent

DMNFYZL	ID	DMNFYZL
DMNFYZL	DN	ISIS 138649
DMNFYZL	HS	Investigative
DMNFYZL	CP	Isis Pharmaceuticals
DMNFYZL	DT	Antisense drug
DMNFYZL	SQ	TACAGTTGCTGACCTTTTTG
DMNFYZL	DE	Discovery agent

DMB7E4X	ID	DMB7E4X
DMB7E4X	DN	ISIS 138678
DMB7E4X	HS	Investigative
DMB7E4X	CP	Isis Pharmaceuticals
DMB7E4X	DT	Antisense drug
DMB7E4X	SQ	CATAAACATTTCCATCAGTG
DMB7E4X	DE	Discovery agent

DM4PM1G	ID	DM4PM1G
DM4PM1G	DN	ISIS 13920
DM4PM1G	HS	Investigative
DM4PM1G	CP	Isis Pharmaceuticals
DM4PM1G	TC	Anticancer Agents
DM4PM1G	DT	Antisense drug
DM4PM1G	SQ	TCCGTCATCGCTCCTCAGGG
DM4PM1G	DE	Solid tumour/cancer

DMKYWQ2	ID	DMKYWQ2
DMKYWQ2	DN	ISIS 140148
DMKYWQ2	HS	Investigative
DMKYWQ2	CP	Isis Pharmaceuticals
DMKYWQ2	DT	Antisense drug
DMKYWQ2	SQ	CAGTTGTCCCTGCGCTTGCT
DMKYWQ2	DE	Discovery agent

DMD60BA	ID	DMD60BA
DMD60BA	DN	ISIS 140153
DMD60BA	HS	Investigative
DMD60BA	CP	Isis Pharmaceuticals
DMD60BA	DT	Antisense drug
DMD60BA	SQ	TCCAGGTGCCCCTGGCCCAC
DMD60BA	DE	Discovery agent

DMG2P7B	ID	DMG2P7B
DMG2P7B	DN	ISIS 140157
DMG2P7B	HS	Investigative
DMG2P7B	CP	Isis Pharmaceuticals
DMG2P7B	DT	Antisense drug
DMG2P7B	SQ	GTTCTTGGCCACATAATTCC
DMG2P7B	DE	Discovery agent

DMO87PG	ID	DMO87PG
DMO87PG	DN	ISIS 140158
DMO87PG	HS	Investigative
DMO87PG	CP	Isis Pharmaceuticals
DMO87PG	DT	Antisense drug
DMO87PG	SQ	AACACAGAGGCGGCCCAGGA
DMO87PG	DE	Discovery agent

DMRHSY6	ID	DMRHSY6
DMRHSY6	DN	ISIS 140161
DMRHSY6	HS	Investigative
DMRHSY6	CP	Isis Pharmaceuticals
DMRHSY6	DT	Antisense drug
DMRHSY6	SQ	GTCATGGACCACCACGTTCC
DMRHSY6	DE	Discovery agent

DMP9WOZ	ID	DMP9WOZ
DMP9WOZ	DN	ISIS 140180
DMP9WOZ	HS	Investigative
DMP9WOZ	CP	Isis Pharmaceuticals
DMP9WOZ	DT	Antisense drug
DMP9WOZ	SQ	GTGAACACTTCGCCTTGCAC
DMP9WOZ	DE	Discovery agent

DMWIKD5	ID	DMWIKD5
DMWIKD5	DN	ISIS 14144
DMWIKD5	HS	Investigative
DMWIKD5	CP	Isis Pharmaceuticals
DMWIKD5	DT	Antisense drug
DMWIKD5	SQ	GGACAGGAAACGCACCATA
DMWIKD5	DE	Discovery agent

DMJW4C5	ID	DMJW4C5
DMJW4C5	DN	ISIS 144368
DMJW4C5	HS	Investigative
DMJW4C5	CP	Isis Pharmaceuticals
DMJW4C5	DT	Antisense drug
DMJW4C5	SQ	TCTGCGTCTGAGCATTGCGT
DMJW4C5	DE	Discovery agent

DM1QLB0	ID	DM1QLB0
DM1QLB0	DN	ISIS 144379
DM1QLB0	HS	Investigative
DM1QLB0	CP	Isis Pharmaceuticals
DM1QLB0	DT	Antisense drug
DM1QLB0	SQ	ACCTGACACCGGGATCCCTC
DM1QLB0	DE	Discovery agent

DMY34RB	ID	DMY34RB
DMY34RB	DN	ISIS 144396
DMY34RB	HS	Investigative
DMY34RB	CP	Isis Pharmaceuticals
DMY34RB	DT	Antisense drug
DMY34RB	SQ	TCCTTACCCACGTTTCAGCT
DMY34RB	DE	Discovery agent

DMHWGL0	ID	DMHWGL0
DMHWGL0	DN	ISIS 14548
DMHWGL0	HS	Investigative
DMHWGL0	CP	Isis Pharmaceuticals
DMHWGL0	DT	Antisense drug
DMHWGL0	SQ	GGTGAGATTTTGGTCTCAAG
DMHWGL0	DE	Discovery agent

DMNMXKC	ID	DMNMXKC
DMNMXKC	DN	ISIS 147483
DMNMXKC	HS	Investigative
DMNMXKC	CP	Isis Pharmaceuticals
DMNMXKC	DT	Antisense drug
DMNMXKC	SQ	ATGTCAATGCCACATGTCCA
DMNMXKC	DE	Discovery agent

DM1Z5W8	ID	DM1Z5W8
DM1Z5W8	DN	ISIS 147788
DM1Z5W8	HS	Investigative
DM1Z5W8	CP	Isis Pharmaceuticals
DM1Z5W8	DT	Antisense drug
DM1Z5W8	SQ	TTTCTGTTGCCACATTGCCC
DM1Z5W8	DE	Discovery agent

DMTE3FJ	ID	DMTE3FJ
DMTE3FJ	DN	ISIS 147919
DMTE3FJ	HS	Investigative
DMTE3FJ	CP	Isis Pharmaceuticals
DMTE3FJ	DT	Antisense drug
DMTE3FJ	SQ	TCAGTGACCC
DMTE3FJ	DE	Discovery agent

DMSB27R	ID	DMSB27R
DMSB27R	DN	ISIS 148715
DMSB27R	HS	Investigative
DMSB27R	CP	Isis Pharmaceuticals
DMSB27R	DT	Antisense drug
DMSB27R	SQ	TTGTCCCAGTCCCAGGCCTC
DMSB27R	DE	Discovery agent

DMMBW13	ID	DMMBW13
DMMBW13	DN	ISIS 150450
DMMBW13	HS	Investigative
DMMBW13	CP	Isis Pharmaceuticals
DMMBW13	DT	Antisense drug
DMMBW13	SQ	CAGGCCTTCAGTCAGTCCTT
DMMBW13	DE	Discovery agent

DM1DCFP	ID	DM1DCFP
DM1DCFP	DN	ISIS 150451
DM1DCFP	HS	Investigative
DM1DCFP	CP	Isis Pharmaceuticals
DM1DCFP	DT	Antisense drug
DM1DCFP	SQ	TATCTCCAAACTCATGAACA
DM1DCFP	DE	Discovery agent

DMQE7BH	ID	DMQE7BH
DMQE7BH	DN	ISIS 150452
DMQE7BH	HS	Investigative
DMQE7BH	CP	Isis Pharmaceuticals
DMQE7BH	DT	Antisense drug
DMQE7BH	SQ	GCTGTATTATCTCCAAACTC
DMQE7BH	DE	Discovery agent

DMKCG41	ID	DMKCG41
DMKCG41	DN	ISIS 150453
DMKCG41	HS	Investigative
DMKCG41	CP	Isis Pharmaceuticals
DMKCG41	DT	Antisense drug
DMKCG41	SQ	GTACAGCCTGCTGTATTATC
DMKCG41	DE	Discovery agent

DMW0Y75	ID	DMW0Y75
DMW0Y75	DN	ISIS 150454
DMW0Y75	HS	Investigative
DMW0Y75	CP	Isis Pharmaceuticals
DMW0Y75	DT	Antisense drug
DMW0Y75	SQ	TGCCCAAGTCTCCAACATGC
DMW0Y75	DE	Discovery agent

DMFUM62	ID	DMFUM62
DMFUM62	DN	ISIS 150463
DMFUM62	HS	Investigative
DMFUM62	CP	Isis Pharmaceuticals
DMFUM62	DT	Antisense drug
DMFUM62	SQ	GGCGATCCCAATTACACCAC
DMFUM62	DE	Discovery agent

DM1IC54	ID	DM1IC54
DM1IC54	DN	ISIS 150464
DM1IC54	HS	Investigative
DM1IC54	CP	Isis Pharmaceuticals
DM1IC54	DT	Antisense drug
DM1IC54	SQ	GGAATGTTTATTGGGCGATC
DM1IC54	DE	Discovery agent

DMPB3FH	ID	DMPB3FH
DMPB3FH	DN	ISIS 156449
DMPB3FH	HS	Investigative
DMPB3FH	CP	Isis Pharmaceuticals
DMPB3FH	DT	Antisense drug
DMPB3FH	SQ	GTTCATCTTCTATTCCTGCC
DMPB3FH	DE	Discovery agent

DMPH2W7	ID	DMPH2W7
DMPH2W7	DN	ISIS 156451
DMPH2W7	HS	Investigative
DMPH2W7	CP	Isis Pharmaceuticals
DMPH2W7	DT	Antisense drug
DMPH2W7	SQ	TTAGTCCAACATTGAGGCAG
DMPH2W7	DE	Discovery agent

DMCU6RF	ID	DMCU6RF
DMCU6RF	DN	ISIS 156452
DMCU6RF	HS	Investigative
DMCU6RF	CP	Isis Pharmaceuticals
DMCU6RF	DT	Antisense drug
DMCU6RF	SQ	GCTTCCTAATTAGTCCAACA
DMCU6RF	DE	Discovery agent

DMQ9018	ID	DMQ9018
DMQ9018	DN	ISIS 156453
DMQ9018	HS	Investigative
DMQ9018	CP	Isis Pharmaceuticals
DMQ9018	DT	Antisense drug
DMQ9018	SQ	CCTTCTTGAGGATCAATAAA
DMQ9018	DE	Discovery agent

DMM9ARP	ID	DMM9ARP
DMM9ARP	DN	ISIS 156471
DMM9ARP	HS	Investigative
DMM9ARP	CP	Isis Pharmaceuticals
DMM9ARP	DT	Antisense drug
DMM9ARP	SQ	TCATCTCCATCACTTGAGAA
DMM9ARP	DE	Discovery agent

DM3U0Z6	ID	DM3U0Z6
DM3U0Z6	DN	ISIS 156472
DM3U0Z6	HS	Investigative
DM3U0Z6	CP	Isis Pharmaceuticals
DM3U0Z6	DT	Antisense drug
DM3U0Z6	SQ	GCAATGAACCATTAGGCATG
DM3U0Z6	DE	Discovery agent

DMDFUS8	ID	DMDFUS8
DMDFUS8	DN	ISIS 156473
DMDFUS8	HS	Investigative
DMDFUS8	CP	Isis Pharmaceuticals
DMDFUS8	DT	Antisense drug
DMDFUS8	SQ	CATGTGCCAAGAAAGTGGTG
DMDFUS8	DE	Discovery agent

DMCXP9T	ID	DMCXP9T
DMCXP9T	DN	ISIS 156474
DMCXP9T	HS	Investigative
DMCXP9T	CP	Isis Pharmaceuticals
DMCXP9T	DT	Antisense drug
DMCXP9T	SQ	GCACCCTGAGCAATCTTGCA
DMCXP9T	DE	Discovery agent

DMNB4UJ	ID	DMNB4UJ
DMNB4UJ	DN	ISIS 156475
DMNB4UJ	HS	Investigative
DMNB4UJ	CP	Isis Pharmaceuticals
DMNB4UJ	DT	Antisense drug
DMNB4UJ	SQ	CATTAGCTGCACCCTGAGCA
DMNB4UJ	DE	Discovery agent

DMJCXHM	ID	DMJCXHM
DMJCXHM	DN	ISIS 15770
DMJCXHM	HS	Investigative
DMJCXHM	CP	Isis Pharmaceuticals
DMJCXHM	TC	Anticancer Agents
DMJCXHM	DT	Antisense drug
DMJCXHM	SQ	ATGCATTCTGCCCCCAAGGA
DMJCXHM	DE	Solid tumour/cancer

DMAQ9EB	ID	DMAQ9EB
DMAQ9EB	DN	ISIS 15998
DMAQ9EB	HS	Investigative
DMAQ9EB	CP	Isis Pharmaceuticals
DMAQ9EB	DT	Antisense drug
DMAQ9EB	SQ	TAATAGGGATGGGCTCAACC
DMAQ9EB	DE	Discovery agent

DMMEP6J	ID	DMMEP6J
DMMEP6J	DN	ISIS 15999
DMMEP6J	HS	Investigative
DMMEP6J	CP	Isis Pharmaceuticals
DMMEP6J	DT	Antisense drug
DMMEP6J	SQ	TCCCGGTTGCTCTGAGACAT
DMMEP6J	DE	Discovery agent

DMDORHA	ID	DMDORHA
DMDORHA	DN	ISIS 16005
DMDORHA	HS	Investigative
DMDORHA	CP	Isis Pharmaceuticals
DMDORHA	DT	Antisense drug
DMDORHA	SQ	GCCGGTACCGCAGTTCAAAC
DMDORHA	DE	Discovery agent

DMBRKFC	ID	DMBRKFC
DMBRKFC	DN	ISIS 16009
DMBRKFC	HS	Investigative
DMBRKFC	CP	Isis Pharmaceuticals
DMBRKFC	DT	Antisense drug
DMBRKFC	SQ	CTACGCTTTCCACGCACAGT
DMBRKFC	DE	Discovery agent

DMZID0W	ID	DMZID0W
DMZID0W	DN	ISIS 16010
DMZID0W	HS	Investigative
DMZID0W	CP	Isis Pharmaceuticals
DMZID0W	DT	Antisense drug
DMZID0W	SQ	TCCAAGCTGCGATCCGACTC
DMZID0W	DE	Discovery agent

DM7VQH8	ID	DM7VQH8
DM7VQH8	DN	ISIS 16108
DM7VQH8	HS	Investigative
DM7VQH8	CP	Isis Pharmaceuticals
DM7VQH8	DT	Antisense drug
DM7VQH8	SQ	CGGCTGGTTCATTCTCCTGG
DM7VQH8	DE	Discovery agent

DMS7HQN	ID	DMS7HQN
DMS7HQN	DN	ISIS 16112
DMS7HQN	HS	Investigative
DMS7HQN	CP	Isis Pharmaceuticals
DMS7HQN	DT	Antisense drug
DMS7HQN	SQ	CCATACGCTCGTGCTGGTGC
DMS7HQN	DE	Discovery agent

DM71H65	ID	DM71H65
DM71H65	DN	ISIS 16121
DM71H65	HS	Investigative
DM71H65	CP	Isis Pharmaceuticals
DM71H65	DT	Antisense drug
DM71H65	SQ	TCTGACCGCTTCAGCGTTGG
DM71H65	DE	Discovery agent

DM0AC3S	ID	DM0AC3S
DM0AC3S	DN	ISIS 16123
DM0AC3S	HS	Investigative
DM0AC3S	CP	Isis Pharmaceuticals
DM0AC3S	DT	Antisense drug
DM0AC3S	SQ	ACCAGGCTGACAGCTGGAGG
DM0AC3S	DE	Discovery agent

DMYGOT7	ID	DMYGOT7
DMYGOT7	DN	ISIS 16124
DMYGOT7	HS	Investigative
DMYGOT7	CP	Isis Pharmaceuticals
DMYGOT7	DT	Antisense drug
DMYGOT7	SQ	CCTTCAGTGATATGAGAGAC
DMYGOT7	DE	Discovery agent

DMOTMVP	ID	DMOTMVP
DMOTMVP	DN	ISIS 16179
DMOTMVP	HS	Investigative
DMOTMVP	CP	Isis Pharmaceuticals
DMOTMVP	DT	Antisense drug
DMOTMVP	SQ	TCTTGACCAAATGCAACCCA
DMOTMVP	DE	Discovery agent

DMK69ZR	ID	DMK69ZR
DMK69ZR	DN	ISIS 16507
DMK69ZR	HS	Investigative
DMK69ZR	CP	Isis Pharmaceuticals
DMK69ZR	TC	Anticancer Agents
DMK69ZR	DT	Antisense drug
DMK69ZR	DE	Solid tumour/cancer

DM24L0S	ID	DM24L0S
DM24L0S	DN	ISIS 16518
DM24L0S	HS	Investigative
DM24L0S	CP	Isis Pharmaceuticals
DM24L0S	TC	Anticancer Agents
DM24L0S	DT	Antisense drug
DM24L0S	DE	Solid tumour/cancer

DMXMHJV	ID	DMXMHJV
DMXMHJV	DN	ISIS 17020
DMXMHJV	HS	Investigative
DMXMHJV	CP	Isis Pharmaceuticals
DMXMHJV	DT	Antisense drug
DMXMHJV	SQ	TCACTCTAGACCAAGCTTTG
DMXMHJV	DE	Discovery agent

DMPZ9D3	ID	DMPZ9D3
DMPZ9D3	DN	ISIS 17148
DMPZ9D3	HS	Investigative
DMPZ9D3	CP	Isis Pharmaceuticals
DMPZ9D3	DT	Antisense drug
DMPZ9D3	SQ	ACTCAAACTGCCCTCCTGCT
DMPZ9D3	DE	Discovery agent

DME7VZG	ID	DME7VZG
DME7VZG	DN	ISIS 17152
DME7VZG	HS	Investigative
DME7VZG	CP	Isis Pharmaceuticals
DME7VZG	DT	Antisense drug
DME7VZG	SQ	AAAAAGTGCCCAGATTGCCC
DME7VZG	DE	Discovery agent

DMW40NK	ID	DMW40NK
DMW40NK	DN	ISIS 17252
DMW40NK	HS	Investigative
DMW40NK	CP	Isis Pharmaceuticals
DMW40NK	DT	Antisense drug
DMW40NK	SQ	GGACCCCGAAAGACCACCAG
DMW40NK	DE	Discovery agent

DM8ITFJ	ID	DM8ITFJ
DM8ITFJ	DN	ISIS 173813
DM8ITFJ	HS	Investigative
DM8ITFJ	CP	Isis Pharmaceuticals
DM8ITFJ	DT	Antisense drug
DM8ITFJ	SQ	CTCTCTGCGCAGCTGATGCT
DM8ITFJ	DE	Discovery agent

DM9Y5NX	ID	DM9Y5NX
DM9Y5NX	DN	ISIS 173831
DM9Y5NX	HS	Investigative
DM9Y5NX	CP	Isis Pharmaceuticals
DM9Y5NX	DT	Antisense drug
DM9Y5NX	SQ	GGAGGGCGCATGCACAGACC
DM9Y5NX	DE	Discovery agent

DMIU0QJ	ID	DMIU0QJ
DMIU0QJ	DN	ISIS 173840
DMIU0QJ	HS	Investigative
DMIU0QJ	CP	Isis Pharmaceuticals
DMIU0QJ	DT	Antisense drug
DMIU0QJ	SQ	GGCACTGCTACTCTCCCGGC
DMIU0QJ	DE	Discovery agent

DMSG1NI	ID	DMSG1NI
DMSG1NI	DN	ISIS 173848
DMSG1NI	HS	Investigative
DMSG1NI	CP	Isis Pharmaceuticals
DMSG1NI	DT	Antisense drug
DMSG1NI	SQ	GCCTGGATTTCGATCTCTCT
DMSG1NI	DE	Discovery agent

DMBFK8A	ID	DMBFK8A
DMBFK8A	DN	ISIS 1751
DMBFK8A	HS	Investigative
DMBFK8A	CP	Isis Pharmaceuticals
DMBFK8A	DT	Antisense drug
DMBFK8A	DE	Discovery agent

DMKWT6F	ID	DMKWT6F
DMKWT6F	DN	ISIS 1753
DMKWT6F	HS	Investigative
DMKWT6F	CP	Isis Pharmaceuticals
DMKWT6F	DT	Antisense drug
DMKWT6F	DE	Discovery agent

DMPAXR4	ID	DMPAXR4
DMPAXR4	DN	ISIS 175510
DMPAXR4	HS	Investigative
DMPAXR4	CP	Isis Pharmaceuticals
DMPAXR4	DT	Antisense drug
DMPAXR4	SQ	TGAGCTGTCTGTGATCCAGC
DMPAXR4	DE	Discovery agent

DMHZPJ0	ID	DMHZPJ0
DMHZPJ0	DN	ISIS 18078
DMHZPJ0	HS	Investigative
DMHZPJ0	CP	Isis Pharmaceuticals
DMHZPJ0	TC	Anticancer Agents
DMHZPJ0	DT	Antisense drug
DMHZPJ0	SQ	GTGCGCGCGAGCCCGAAATC
DMHZPJ0	DE	Solid tumour/cancer

DMQ5A4Y	ID	DMQ5A4Y
DMQ5A4Y	DN	ISIS 1820
DMQ5A4Y	HS	Investigative
DMQ5A4Y	CP	Isis Pharmaceuticals
DMQ5A4Y	DT	Antisense drug
DMQ5A4Y	DE	Discovery agent

DMUG2PN	ID	DMUG2PN
DMUG2PN	DN	ISIS 1821
DMUG2PN	HS	Investigative
DMUG2PN	CP	Isis Pharmaceuticals
DMUG2PN	DT	Antisense drug
DMUG2PN	SQ	5'-CATGGCGCGGGCCGCGGG-3'
DMUG2PN	DE	Discovery agent

DMLJBU8	ID	DMLJBU8
DMLJBU8	DN	ISIS 1822
DMLJBU8	HS	Investigative
DMLJBU8	CP	Isis Pharmaceuticals
DMLJBU8	DT	Antisense drug
DMLJBU8	DE	Discovery agent

DMPHWMO	ID	DMPHWMO
DMPHWMO	DN	ISIS 1827
DMPHWMO	HS	Investigative
DMPHWMO	CP	Isis Pharmaceuticals
DMPHWMO	DT	Antisense drug
DMPHWMO	DE	Discovery agent

DM1LWGI	ID	DM1LWGI
DM1LWGI	DN	ISIS 1831
DM1LWGI	HS	Investigative
DM1LWGI	CP	Isis Pharmaceuticals
DM1LWGI	DT	Antisense drug
DM1LWGI	DE	Discovery agent

DMOU9EP	ID	DMOU9EP
DMOU9EP	DN	ISIS 183881
DMOU9EP	HS	Investigative
DMOU9EP	CP	Isis Pharmaceuticals
DMOU9EP	DT	Antisense drug
DMOU9EP	SQ	ATCCAAGTGCTACTGTAGTA
DMOU9EP	DE	Discovery agent

DMT3YI5	ID	DMT3YI5
DMT3YI5	DN	ISIS 183882
DMT3YI5	HS	Investigative
DMT3YI5	CP	Isis Pharmaceuticals
DMT3YI5	DT	Antisense drug
DMT3YI5	SQ	TTTCCTCAAGATTGAGAGAT
DMT3YI5	DE	Discovery agent

DMA46S1	ID	DMA46S1
DMA46S1	DN	ISIS 183883
DMA46S1	HS	Investigative
DMA46S1	CP	Isis Pharmaceuticals
DMA46S1	DT	Antisense drug
DMA46S1	SQ	CAAAGCACAGAATCTCTCTG
DMA46S1	DE	Discovery agent

DMS172K	ID	DMS172K
DMS172K	DN	ISIS 183897
DMS172K	HS	Investigative
DMS172K	CP	Isis Pharmaceuticals
DMS172K	DT	Antisense drug
DMS172K	SQ	CAGTTAGGTTTCCACATTGC
DMS172K	DE	Discovery agent

DMSEJZK	ID	DMSEJZK
DMSEJZK	DN	ISIS 183901
DMSEJZK	HS	Investigative
DMSEJZK	CP	Isis Pharmaceuticals
DMSEJZK	DT	Antisense drug
DMSEJZK	SQ	TACCAGCCAAGGGATCCTCT
DMSEJZK	DE	Discovery agent

DMMQ2L7	ID	DMMQ2L7
DMMQ2L7	DN	ISIS 183910
DMMQ2L7	HS	Investigative
DMMQ2L7	CP	Isis Pharmaceuticals
DMMQ2L7	DT	Antisense drug
DMMQ2L7	SQ	GAGAAGCCATCAGAATCAGC
DMMQ2L7	DE	Discovery agent

DMTB350	ID	DMTB350
DMTB350	DN	ISIS 183911
DMTB350	HS	Investigative
DMTB350	CP	Isis Pharmaceuticals
DMTB350	DT	Antisense drug
DMTB350	SQ	CTCAAGATTGAGAGATGCAG
DMTB350	DE	Discovery agent

DM5QWED	ID	DM5QWED
DM5QWED	DN	ISIS 183912
DM5QWED	HS	Investigative
DM5QWED	CP	Isis Pharmaceuticals
DM5QWED	DT	Antisense drug
DM5QWED	SQ	GTTTCTCATGAGCTGCCTTA
DM5QWED	DE	Discovery agent

DMR6QNA	ID	DMR6QNA
DMR6QNA	DN	ISIS 18473
DMR6QNA	HS	Investigative
DMR6QNA	CP	Isis Pharmaceuticals
DMR6QNA	DT	Antisense drug
DMR6QNA	SQ	GGTCTTCAATGGATGAGGAG
DMR6QNA	DE	Discovery agent

DM0BAX4	ID	DM0BAX4
DM0BAX4	DN	ISIS 188755
DM0BAX4	HS	Investigative
DM0BAX4	CP	Isis Pharmaceuticals
DM0BAX4	DT	Antisense drug
DM0BAX4	SQ	CCGGCCTGGGCAGCGGCCAG
DM0BAX4	DE	Discovery agent

DMFTJD5	ID	DMFTJD5
DMFTJD5	DN	ISIS 188757
DMFTJD5	HS	Investigative
DMFTJD5	CP	Isis Pharmaceuticals
DMFTJD5	DT	Antisense drug
DMFTJD5	SQ	CCCTGGAAGTCCOCGCACAG
DMFTJD5	DE	Discovery agent

DMM8G03	ID	DMM8G03
DMM8G03	DN	ISIS 188759
DMM8G03	HS	Investigative
DMM8G03	CP	Isis Pharmaceuticals
DMM8G03	DT	Antisense drug
DMM8G03	SQ	TTGGTGATGAGGTCGGCGTA
DMM8G03	DE	Discovery agent

DMTY3N6	ID	DMTY3N6
DMTY3N6	DN	ISIS 188761
DMTY3N6	HS	Investigative
DMTY3N6	CP	Isis Pharmaceuticals
DMTY3N6	DT	Antisense drug
DMTY3N6	SQ	TCTCGATGGCCTTGGTGATG
DMTY3N6	DE	Discovery agent

DMOJBHC	ID	DMOJBHC
DMOJBHC	DN	ISIS 188763
DMOJBHC	HS	Investigative
DMOJBHC	CP	Isis Pharmaceuticals
DMOJBHC	DT	Antisense drug
DMOJBHC	SQ	TTGAAGTAGGGCACGCTCTT
DMOJBHC	DE	Discovery agent

DMP9YD3	ID	DMP9YD3
DMP9YD3	DN	ISIS 188778
DMP9YD3	HS	Investigative
DMP9YD3	CP	Isis Pharmaceuticals
DMP9YD3	DT	Antisense drug
DMP9YD3	SQ	TGAGATGCCTGGCTGCCATA
DMP9YD3	DE	Discovery agent

DMVZTU0	ID	DMVZTU0
DMVZTU0	DN	ISIS 188780
DMVZTU0	HS	Investigative
DMVZTU0	CP	Isis Pharmaceuticals
DMVZTU0	DT	Antisense drug
DMVZTU0	SQ	ATCATTTTGTTATGAGATGC
DMVZTU0	DE	Discovery agent

DMOYINM	ID	DMOYINM
DMOYINM	DN	ISIS 188781
DMOYINM	HS	Investigative
DMOYINM	CP	Isis Pharmaceuticals
DMOYINM	DT	Antisense drug
DMOYINM	SQ	CAGGGCACTCATCTGCATGG
DMOYINM	DE	Discovery agent

DM5O4L8	ID	DM5O4L8
DM5O4L8	DN	ISIS 188782
DM5O4L8	HS	Investigative
DM5O4L8	CP	Isis Pharmaceuticals
DM5O4L8	DT	Antisense drug
DM5O4L8	SQ	TAGCCATTGCAGCTGCTCAC
DM5O4L8	DE	Discovery agent

DMOQ27M	ID	DMOQ27M
DMOQ27M	DN	ISIS 191729
DMOQ27M	HS	Investigative
DMOQ27M	CP	Isis Pharmaceuticals
DMOQ27M	DT	Antisense drug
DMOQ27M	SQ	CAGCCGCGTCTCGCACCTCG
DMOQ27M	DE	Discovery agent

DM52ZWB	ID	DM52ZWB
DM52ZWB	DN	ISIS 191731
DM52ZWB	HS	Investigative
DM52ZWB	CP	Isis Pharmaceuticals
DM52ZWB	DT	Antisense drug
DM52ZWB	SQ	CCACGCTGGTCCGCCCGTCT
DM52ZWB	DE	Discovery agent

DMHWMFP	ID	DMHWMFP
DMHWMFP	DN	ISIS 191755
DMHWMFP	HS	Investigative
DMHWMFP	CP	Isis Pharmaceuticals
DMHWMFP	DT	Antisense drug
DMHWMFP	SQ	GTCTGATGCACCACTTGTGC
DMHWMFP	DE	Discovery agent

DMQRZX8	ID	DMQRZX8
DMQRZX8	DN	ISIS 191756
DMQRZX8	HS	Investigative
DMQRZX8	CP	Isis Pharmaceuticals
DMQRZX8	DT	Antisense drug
DMQRZX8	SQ	TGCCATGTCTGAGCATAGGC
DMQRZX8	DE	Discovery agent

DMHPENR	ID	DMHPENR
DMHPENR	DN	ISIS 191759
DMHPENR	HS	Investigative
DMHPENR	CP	Isis Pharmaceuticals
DMHPENR	DT	Antisense drug
DMHPENR	SQ	ATTGCCATAGTTCCCTTGGA
DMHPENR	DE	Discovery agent

DM0VAUR	ID	DM0VAUR
DM0VAUR	DN	ISIS 191761
DM0VAUR	HS	Investigative
DM0VAUR	CP	Isis Pharmaceuticals
DM0VAUR	DT	Antisense drug
DM0VAUR	SQ	CCACCGGTTGCCCAATGATG
DM0VAUR	DE	Discovery agent

DMKFCD5	ID	DMKFCD5
DMKFCD5	DN	ISIS 19211
DMKFCD5	HS	Investigative
DMKFCD5	CP	Isis Pharmaceuticals
DMKFCD5	DT	Antisense drug
DMKFCD5	SQ	CCAGGCGGCAGGACCACT
DMKFCD5	DE	Discovery agent

DMLQT5F	ID	DMLQT5F
DMLQT5F	DN	ISIS 19212
DMLQT5F	HS	Investigative
DMLQT5F	CP	Isis Pharmaceuticals
DMLQT5F	DT	Antisense drug
DMLQT5F	SQ	GACCAGGCGGCAGGACCA
DMLQT5F	DE	Discovery agent

DMD1JVZ	ID	DMD1JVZ
DMD1JVZ	DN	ISIS 19213
DMD1JVZ	HS	Investigative
DMD1JVZ	CP	Isis Pharmaceuticals
DMD1JVZ	DT	Antisense drug
DMD1JVZ	SQ	AGGTGAGACCAGGCGGCA
DMD1JVZ	DE	Discovery agent

DMQK0AL	ID	DMQK0AL
DMQK0AL	DN	ISIS 19217
DMQK0AL	HS	Investigative
DMQK0AL	CP	Isis Pharmaceuticals
DMQK0AL	DT	Antisense drug
DMQK0AL	SQ	GGTCAGCAAGCAGCCCCA
DMQK0AL	DE	Discovery agent

DMX4I5A	ID	DMX4I5A
DMX4I5A	DN	ISIS 19218
DMX4I5A	HS	Investigative
DMX4I5A	CP	Isis Pharmaceuticals
DMX4I5A	DT	Antisense drug
DMX4I5A	SQ	GACAGCGGTCAGCAAGCA
DMX4I5A	DE	Discovery agent

DMFAWGX	ID	DMFAWGX
DMFAWGX	DN	ISIS 19219
DMFAWGX	HS	Investigative
DMFAWGX	CP	Isis Pharmaceuticals
DMFAWGX	DT	Antisense drug
DMFAWGX	SQ	GATGGACAGCGGTCAGCA
DMFAWGX	DE	Discovery agent

DMIKEXD	ID	DMIKEXD
DMIKEXD	DN	ISIS 19220
DMIKEXD	HS	Investigative
DMIKEXD	CP	Isis Pharmaceuticals
DMIKEXD	DT	Antisense drug
DMIKEXD	SQ	TCTGGATGGACAGCGGTC
DMIKEXD	DE	Discovery agent

DMKOFNX	ID	DMKOFNX
DMKOFNX	DN	ISIS 19221
DMKOFNX	HS	Investigative
DMKOFNX	CP	Isis Pharmaceuticals
DMKOFNX	DT	Antisense drug
DMKOFNX	SQ	GGTGGTTCTGGATGGACA
DMKOFNX	DE	Discovery agent

DMBMQNI	ID	DMBMQNI
DMBMQNI	DN	ISIS 1931
DMBMQNI	HS	Investigative
DMBMQNI	CP	Isis Pharmaceuticals
DMBMQNI	DT	Antisense drug
DMBMQNI	DE	Discovery agent

DM1NJD7	ID	DM1NJD7
DM1NJD7	DN	ISIS 196103
DM1NJD7	HS	Investigative
DM1NJD7	CP	Isis Pharmaceuticals
DM1NJD7	DT	Antisense drug
DM1NJD7	SQ	AGCCCATTGCTGGACATGCA
DM1NJD7	DE	Discovery agent

DMVOSN1	ID	DMVOSN1
DMVOSN1	DN	ISIS 19634
DMVOSN1	HS	Investigative
DMVOSN1	CP	Isis Pharmaceuticals
DMVOSN1	DT	Antisense drug
DMVOSN1	SQ	ACTGACTGAGAATCGCTG
DMVOSN1	DE	Discovery agent

DMAW4OE	ID	DMAW4OE
DMAW4OE	DN	ISIS 19639
DMAW4OE	HS	Investigative
DMAW4OE	CP	Isis Pharmaceuticals
DMAW4OE	DT	Antisense drug
DMAW4OE	SQ	ATTCTCCAGAGGCAGGTA
DMAW4OE	DE	Discovery agent

DMS5PZ0	ID	DMS5PZ0
DMS5PZ0	DN	ISIS 19647
DMS5PZ0	HS	Investigative
DMS5PZ0	CP	Isis Pharmaceuticals
DMS5PZ0	DT	Antisense drug
DMS5PZ0	SQ	GTCCTTGTCAAAGTCTGG
DMS5PZ0	DE	Discovery agent

DMBEPGU	ID	DMBEPGU
DMBEPGU	DN	ISIS 19649
DMBEPGU	HS	Investigative
DMBEPGU	CP	Isis Pharmaceuticals
DMBEPGU	DT	Antisense drug
DMBEPGU	SQ	GCCTCCAGCACATTCTCG
DMBEPGU	DE	Discovery agent

DMCZLK1	ID	DMCZLK1
DMCZLK1	DN	ISIS 19650
DMCZLK1	HS	Investigative
DMCZLK1	CP	Isis Pharmaceuticals
DMCZLK1	DT	Antisense drug
DMCZLK1	SQ	GGTCCTGAGCAGCCTCCA
DMCZLK1	DE	Discovery agent

DM8O7EM	ID	DM8O7EM
DM8O7EM	DN	ISIS 19651
DM8O7EM	HS	Investigative
DM8O7EM	CP	Isis Pharmaceuticals
DM8O7EM	DT	Antisense drug
DM8O7EM	SQ	GGCAAAGCAGTCTGTGTC
DM8O7EM	DE	Discovery agent

DMGIMH8	ID	DMGIMH8
DMGIMH8	DN	ISIS 19657
DMGIMH8	HS	Investigative
DMGIMH8	CP	Isis Pharmaceuticals
DMGIMH8	DT	Antisense drug
DMGIMH8	SQ	TGATCCTGTGCCAATGCC
DMGIMH8	DE	Discovery agent

DM8WC4A	ID	DM8WC4A
DM8WC4A	DN	ISIS 19658
DM8WC4A	HS	Investigative
DM8WC4A	CP	Isis Pharmaceuticals
DM8WC4A	DT	Antisense drug
DM8WC4A	SQ	CTGGGTCTATGGCTTCAA
DM8WC4A	DE	Discovery agent

DMQ5UA3	ID	DMQ5UA3
DMQ5UA3	DN	ISIS 19659
DMQ5UA3	HS	Investigative
DMQ5UA3	CP	Isis Pharmaceuticals
DMQ5UA3	DT	Antisense drug
DMQ5UA3	SQ	GACGTTCAGTTTCTCTGG
DMQ5UA3	DE	Discovery agent

DMB5LNC	ID	DMB5LNC
DMB5LNC	DN	ISIS 19675
DMB5LNC	HS	Investigative
DMB5LNC	CP	Isis Pharmaceuticals
DMB5LNC	DT	Antisense drug
DMB5LNC	SQ	CTGTGCCACTGGGAGTTA
DMB5LNC	DE	Discovery agent

DMYEMST	ID	DMYEMST
DMYEMST	DN	ISIS 19676
DMYEMST	HS	Investigative
DMYEMST	CP	Isis Pharmaceuticals
DMYEMST	DT	Antisense drug
DMYEMST	SQ	CCAAAAGCACCTGAGCCA
DMYEMST	DE	Discovery agent

DMN0DR2	ID	DMN0DR2
DMN0DR2	DN	ISIS 19677
DMN0DR2	HS	Investigative
DMN0DR2	CP	Isis Pharmaceuticals
DMN0DR2	DT	Antisense drug
DMN0DR2	SQ	GCCACAGGAATCTTCACA
DMN0DR2	DE	Discovery agent

DM76H35	ID	DM76H35
DM76H35	DN	ISIS 20577
DM76H35	HS	Investigative
DM76H35	CP	Isis Pharmaceuticals
DM76H35	DT	Antisense drug
DM76H35	SQ	GCCATGATGGACTCCAGA
DM76H35	DE	Discovery agent

DM6X9RQ	ID	DM6X9RQ
DM6X9RQ	DN	ISIS 20579
DM6X9RQ	HS	Investigative
DM6X9RQ	CP	Isis Pharmaceuticals
DM6X9RQ	DT	Antisense drug
DM6X9RQ	SQ	CTCATCGCTCAGGCAACA
DM6X9RQ	DE	Discovery agent

DMJRNWK	ID	DMJRNWK
DMJRNWK	DN	ISIS 20585
DMJRNWK	HS	Investigative
DMJRNWK	CP	Isis Pharmaceuticals
DMJRNWK	DT	Antisense drug
DMJRNWK	SQ	CCCGCCGCAGCTGCTTCT
DMJRNWK	DE	Discovery agent

DMHVQ0S	ID	DMHVQ0S
DMHVQ0S	DN	ISIS 20586
DMHVQ0S	HS	Investigative
DMHVQ0S	CP	Isis Pharmaceuticals
DMHVQ0S	DT	Antisense drug
DMHVQ0S	SQ	CTTGAGCTCGCGCCGGGC
DMHVQ0S	DE	Discovery agent

DMLWO70	ID	DMLWO70
DMLWO70	DN	ISIS 20990
DMLWO70	HS	Investigative
DMLWO70	CP	Isis Pharmaceuticals
DMLWO70	DT	Antisense drug
DMLWO70	SQ	CCCGCCGCAGCTGCTTCT
DMLWO70	DE	Discovery agent

DMFYDE4	ID	DMFYDE4
DMFYDE4	DN	ISIS 20993
DMFYDE4	HS	Investigative
DMFYDE4	CP	Isis Pharmaceuticals
DMFYDE4	DT	Antisense drug
DMFYDE4	SQ	GCCCGTGCCGAGCAGCAG
DMFYDE4	DE	Discovery agent

DM85EV7	ID	DM85EV7
DM85EV7	DN	ISIS 20994
DM85EV7	HS	Investigative
DM85EV7	CP	Isis Pharmaceuticals
DM85EV7	DT	Antisense drug
DM85EV7	SQ	ACGTGCTCTTCCCGCTCT
DM85EV7	DE	Discovery agent

DMCXVPG	ID	DMCXVPG
DMCXVPG	DN	ISIS 20995
DMCXVPG	HS	Investigative
DMCXVPG	CP	Isis Pharmaceuticals
DMCXVPG	DT	Antisense drug
DMCXVPG	SQ	ATCTGCTTGATGAACGTG
DMCXVPG	DE	Discovery agent

DM4VZPU	ID	DM4VZPU
DM4VZPU	DN	ISIS 2177
DM4VZPU	HS	Investigative
DM4VZPU	CP	Isis Pharmaceuticals
DM4VZPU	DT	Antisense drug
DM4VZPU	DE	Discovery agent

DMD7HA3	ID	DMD7HA3
DMD7HA3	DN	ISIS 222001
DMD7HA3	HS	Investigative
DMD7HA3	CP	Isis Pharmaceuticals
DMD7HA3	DT	Antisense drug
DMD7HA3	SQ	GCAGCTCCTCAGGGTGGTAA
DMD7HA3	DE	Discovery agent

DMQY2EA	ID	DMQY2EA
DMQY2EA	DN	ISIS 222035
DMQY2EA	HS	Investigative
DMQY2EA	CP	Isis Pharmaceuticals
DMQY2EA	DT	Antisense drug
DMQY2EA	SQ	GCGCTGCTCCCAAGAACTCT
DMQY2EA	DE	Discovery agent

DMVL1SN	ID	DMVL1SN
DMVL1SN	DN	ISIS 222039
DMVL1SN	HS	Investigative
DMVL1SN	CP	Isis Pharmaceuticals
DMVL1SN	DT	Antisense drug
DMVL1SN	SQ	GTGCTGCCACCAGGTGGGTC
DMVL1SN	DE	Discovery agent

DMS03TR	ID	DMS03TR
DMS03TR	DN	ISIS 222041
DMS03TR	HS	Investigative
DMS03TR	CP	Isis Pharmaceuticals
DMS03TR	DT	Antisense drug
DMS03TR	SQ	TGGTCATGTTCTCGGAGTCT
DMS03TR	DE	Discovery agent

DM26M7E	ID	DM26M7E
DM26M7E	DN	ISIS 222043
DM26M7E	HS	Investigative
DM26M7E	CP	Isis Pharmaceuticals
DM26M7E	DT	Antisense drug
DM26M7E	SQ	TCAGTCTGGTCCATGGAGAA
DM26M7E	DE	Discovery agent

DMREFCY	ID	DMREFCY
DMREFCY	DN	ISIS 2324
DMREFCY	HS	Investigative
DMREFCY	CP	Isis Pharmaceuticals
DMREFCY	DT	Antisense drug
DMREFCY	DE	Discovery agent

DMYEPV8	ID	DMYEPV8
DMYEPV8	DN	ISIS 232828
DMYEPV8	HS	Investigative
DMYEPV8	CP	Isis Pharmaceuticals
DMYEPV8	DT	Antisense drug
DMYEPV8	SQ	GTCTGTAGTCATCTTAAAAA
DMYEPV8	DE	Discovery agent

DMJ0LB1	ID	DMJ0LB1
DMJ0LB1	DN	ISIS 23412
DMJ0LB1	HS	Investigative
DMJ0LB1	CP	Isis Pharmaceuticals
DMJ0LB1	DT	Antisense drug
DMJ0LB1	SQ	ACTGAAGACATTTTGAAT
DMJ0LB1	DE	Discovery agent

DMOC0DT	ID	DMOC0DT
DMOC0DT	DN	ISIS 23414
DMOC0DT	HS	Investigative
DMOC0DT	CP	Isis Pharmaceuticals
DMOC0DT	DT	Antisense drug
DMOC0DT	SQ	GCACTTTTATTTCTTAGA
DMOC0DT	DE	Discovery agent

DMHQD76	ID	DMHQD76
DMHQD76	DN	ISIS 23416
DMHQD76	HS	Investigative
DMHQD76	CP	Isis Pharmaceuticals
DMHQD76	DT	Antisense drug
DMHQD76	SQ	ACCATATTTCACTGATTC
DMHQD76	DE	Discovery agent

DM17G39	ID	DM17G39
DM17G39	DN	ISIS 23452
DM17G39	HS	Investigative
DM17G39	CP	Isis Pharmaceuticals
DM17G39	DT	Antisense drug
DM17G39	SQ	ACTGAAGACATTTTGAAT
DM17G39	DE	Discovery agent

DM7FPZV	ID	DM7FPZV
DM7FPZV	DN	ISIS 23454
DM7FPZV	HS	Investigative
DM7FPZV	CP	Isis Pharmaceuticals
DM7FPZV	DT	Antisense drug
DM7FPZV	SQ	GCACTTTTATTTCTTAGA
DM7FPZV	DE	Discovery agent

DM4PGRU	ID	DM4PGRU
DM4PGRU	DN	ISIS 23459
DM4PGRU	HS	Investigative
DM4PGRU	CP	Isis Pharmaceuticals
DM4PGRU	DT	Antisense drug
DM4PGRU	SQ	GCTCTGCTGTCAAGTGTT
DM4PGRU	DE	Discovery agent

DMDHY37	ID	DMDHY37
DMDHY37	DN	ISIS 23544
DMDHY37	HS	Investigative
DMDHY37	CP	Isis Pharmaceuticals
DMDHY37	DT	Antisense drug
DMDHY37	SQ	TGTGTAAGGCTTATTCTC
DMDHY37	DE	Discovery agent

DM7NKRO	ID	DM7NKRO
DM7NKRO	DN	ISIS 23559
DM7NKRO	HS	Investigative
DM7NKRO	CP	Isis Pharmaceuticals
DM7NKRO	DT	Antisense drug
DM7NKRO	SQ	ACATTGCTGCCCTTTGTC
DM7NKRO	DE	Discovery agent

DM5LBQM	ID	DM5LBQM
DM5LBQM	DN	ISIS 23705
DM5LBQM	HS	Investigative
DM5LBQM	CP	Isis Pharmaceuticals
DM5LBQM	DT	Antisense drug
DM5LBQM	SQ	CGATGGPAPGGCGCACTT
DM5LBQM	DE	Discovery agent

DMIK0GR	ID	DMIK0GR
DMIK0GR	DN	ISIS 23707
DMIK0GR	HS	Investigative
DMIK0GR	CP	Isis Pharmaceuticals
DMIK0GR	DT	Antisense drug
DMIK0GR	SQ	ACAGGAAGGCTGGTGGCA
DMIK0GR	DE	Discovery agent

DM1SDN3	ID	DM1SDN3
DM1SDN3	DN	ISIS 23718
DM1SDN3	HS	Investigative
DM1SDN3	CP	Isis Pharmaceuticals
DM1SDN3	DT	Antisense drug
DM1SDN3	SQ	AGGACTGTGACAGCCTCA
DM1SDN3	DE	Discovery agent

DMLHQ2J	ID	DMLHQ2J
DMLHQ2J	DN	ISIS 24448
DMLHQ2J	HS	Investigative
DMLHQ2J	CP	Isis Pharmaceuticals
DMLHQ2J	DT	Antisense drug
DMLHQ2J	SQ	ACTGAAGCGTTGGCGAGC
DMLHQ2J	DE	Discovery agent

DM45WUZ	ID	DM45WUZ
DM45WUZ	DN	ISIS 24453
DM45WUZ	HS	Investigative
DM45WUZ	CP	Isis Pharmaceuticals
DM45WUZ	DT	Antisense drug
DM45WUZ	SQ	GCTTATTTTCATTCTTTA
DM45WUZ	DE	Discovery agent

DMDE3J1	ID	DMDE3J1
DMDE3J1	DN	ISIS 24454
DMDE3J1	HS	Investigative
DMDE3J1	CP	Isis Pharmaceuticals
DMDE3J1	DT	Antisense drug
DMDE3J1	SQ	TTCTTTTACTCAGTTCTG
DMDE3J1	DE	Discovery agent

DMBKZOQ	ID	DMBKZOQ
DMBKZOQ	DN	ISIS 24475
DMBKZOQ	HS	Investigative
DMBKZOQ	CP	Isis Pharmaceuticals
DMBKZOQ	DT	Antisense drug
DMBKZOQ	SQ	GCCCTTATATGAGAAACA
DMBKZOQ	DE	Discovery agent

DMCNBIL	ID	DMCNBIL
DMCNBIL	DN	ISIS 24477
DMCNBIL	HS	Investigative
DMCNBIL	CP	Isis Pharmaceuticals
DMCNBIL	DT	Antisense drug
DMCNBIL	SQ	TCCATTCTCTCAATTTGA 3'-UTR
DMCNBIL	DE	Discovery agent

DMYEC3M	ID	DMYEC3M
DMYEC3M	DN	ISIS 2490
DMYEC3M	HS	Investigative
DMYEC3M	CP	Isis Pharmaceuticals
DMYEC3M	DT	Antisense drug
DMYEC3M	SQ	AGCGCGCCATAGTATTGTGG
DMYEC3M	DE	Discovery agent

DMVI1D0	ID	DMVI1D0
DMVI1D0	DN	ISIS 2491
DMVI1D0	HS	Investigative
DMVI1D0	CP	Isis Pharmaceuticals
DMVI1D0	DT	Antisense drug
DMVI1D0	SQ	GTCCATGCATACTTAATATT
DMVI1D0	DE	Discovery agent

DMYTXBS	ID	DMYTXBS
DMYTXBS	DN	ISIS 2502
DMYTXBS	HS	Investigative
DMYTXBS	CP	Isis Pharmaceuticals
DMYTXBS	DT	Antisense drug
DMYTXBS	SQ	CTTATATTCCGTCATCGCTC
DMYTXBS	DE	Discovery agent

DMUMEST	ID	DMUMEST
DMUMEST	DN	ISIS 25073
DMUMEST	HS	Investigative
DMUMEST	CP	Isis Pharmaceuticals
DMUMEST	DT	Antisense drug
DMUMEST	SQ	CTTCCTCCGGGCCAGCAT
DMUMEST	DE	Discovery agent

DMM0GUN	ID	DMM0GUN
DMM0GUN	DN	ISIS 25074
DMM0GUN	HS	Investigative
DMM0GUN	CP	Isis Pharmaceuticals
DMM0GUN	DT	Antisense drug
DMM0GUN	SQ	GGTAGGGTTGATGGTGAG
DMM0GUN	DE	Discovery agent

DM1EPLC	ID	DM1EPLC
DM1EPLC	DN	ISIS 25075
DM1EPLC	HS	Investigative
DM1EPLC	CP	Isis Pharmaceuticals
DM1EPLC	DT	Antisense drug
DM1EPLC	SQ	TCCACCAGGTTTGCCTCG
DM1EPLC	DE	Discovery agent

DMSZRY0	ID	DMSZRY0
DMSZRY0	DN	ISIS 25078
DMSZRY0	HS	Investigative
DMSZRY0	CP	Isis Pharmaceuticals
DMSZRY0	DT	Antisense drug
DMSZRY0	SQ	TCATCGTCTTTGAGTTCG
DMSZRY0	DE	Discovery agent

DMAKTCH	ID	DMAKTCH
DMAKTCH	DN	ISIS 25079
DMAKTCH	HS	Investigative
DMAKTCH	CP	Isis Pharmaceuticals
DMAKTCH	DT	Antisense drug
DMAKTCH	SQ	TTTCGAAGTCATCGTCTT
DMAKTCH	DE	Discovery agent

DMEI28S	ID	DMEI28S
DMEI28S	DN	ISIS 25080
DMEI28S	HS	Investigative
DMEI28S	CP	Isis Pharmaceuticals
DMEI28S	DT	Antisense drug
DMEI28S	SQ	CCGTTGCCCGCGCCCAGC
DMEI28S	DE	Discovery agent

DM4AZG9	ID	DM4AZG9
DM4AZG9	DN	ISIS 25081
DM4AZG9	HS	Investigative
DM4AZG9	CP	Isis Pharmaceuticals
DM4AZG9	DT	Antisense drug
DM4AZG9	SQ	CTGTGCTGGACTTTGGTG
DM4AZG9	DE	Discovery agent

DM04CUL	ID	DM04CUL
DM04CUL	DN	ISIS 25082
DM04CUL	HS	Investigative
DM04CUL	CP	Isis Pharmaceuticals
DM04CUL	DT	Antisense drug
DM04CUL	SQ	AGCTTCCTGGCCATGATG
DM04CUL	DE	Discovery agent

DM3IR7W	ID	DM3IR7W
DM3IR7W	DN	ISIS 25113
DM3IR7W	HS	Investigative
DM3IR7W	CP	Isis Pharmaceuticals
DM3IR7W	DT	Antisense drug
DM3IR7W	SQ	CTTCCTCCGGGCCAGCAT
DM3IR7W	DE	Discovery agent

DMG6SYP	ID	DMG6SYP
DMG6SYP	DN	ISIS 25114
DMG6SYP	HS	Investigative
DMG6SYP	CP	Isis Pharmaceuticals
DMG6SYP	DT	Antisense drug
DMG6SYP	SQ	GGTAGGGTTGATGGTGAG
DMG6SYP	DE	Discovery agent

DMDH943	ID	DMDH943
DMDH943	DN	ISIS 25115
DMDH943	HS	Investigative
DMDH943	CP	Isis Pharmaceuticals
DMDH943	DT	Antisense drug
DMDH943	SQ	TCCACCAGGTTTGCCTCG
DMDH943	DE	Discovery agent

DM8AHJC	ID	DM8AHJC
DM8AHJC	DN	ISIS 25116
DM8AHJC	HS	Investigative
DM8AHJC	CP	Isis Pharmaceuticals
DM8AHJC	DT	Antisense drug
DM8AHJC	SQ	CTTCTGCTGCTCGTCAAG
DM8AHJC	DE	Discovery agent

DMAN94P	ID	DMAN94P
DMAN94P	DN	ISIS 25117
DMAN94P	HS	Investigative
DMAN94P	CP	Isis Pharmaceuticals
DMAN94P	DT	Antisense drug
DMAN94P	SQ	TTGGCTTTCTGGGTGAGA
DMAN94P	DE	Discovery agent

DMA7KV8	ID	DMA7KV8
DMA7KV8	DN	ISIS 25118
DMA7KV8	HS	Investigative
DMA7KV8	CP	Isis Pharmaceuticals
DMA7KV8	DT	Antisense drug
DMA7KV8	SQ	TCATCGTCTTTGAGTTCG
DMA7KV8	DE	Discovery agent

DMFQO21	ID	DMFQO21
DMFQO21	DN	ISIS 25123
DMFQO21	HS	Investigative
DMFQO21	CP	Isis Pharmaceuticals
DMFQO21	DT	Antisense drug
DMFQO21	SQ	ATCTCAAGGTGGATCAGC
DMFQO21	DE	Discovery agent

DMEI8L2	ID	DMEI8L2
DMEI8L2	DN	ISIS 25124
DMEI8L2	HS	Investigative
DMEI8L2	CP	Isis Pharmaceuticals
DMEI8L2	DT	Antisense drug
DMEI8L2	SQ	ATGATCTGGTTCCGGATG
DMEI8L2	DE	Discovery agent

DML2F3N	ID	DML2F3N
DML2F3N	DN	ISIS 25125
DML2F3N	HS	Investigative
DML2F3N	CP	Isis Pharmaceuticals
DML2F3N	DT	Antisense drug
DML2F3N	SQ	GATGTACGGCGAGTTGCA
DML2F3N	DE	Discovery agent

DM8K4DP	ID	DM8K4DP
DM8K4DP	DN	ISIS 25126
DM8K4DP	HS	Investigative
DM8K4DP	CP	Isis Pharmaceuticals
DM8K4DP	DT	Antisense drug
DM8K4DP	SQ	GTCACTGTAGAAGGCCCC
DM8K4DP	DE	Discovery agent

DM6AQ2X	ID	DM6AQ2X
DM6AQ2X	DN	ISIS 25127
DM6AQ2X	HS	Investigative
DM6AQ2X	CP	Isis Pharmaceuticals
DM6AQ2X	DT	Antisense drug
DM6AQ2X	SQ	TGTGTTCCATGCAAATGC
DM6AQ2X	DE	Discovery agent

DMH3C01	ID	DMH3C01
DMH3C01	DN	ISIS 25128
DMH3C01	HS	Investigative
DMH3C01	CP	Isis Pharmaceuticals
DMH3C01	DT	Antisense drug
DMH3C01	SQ	TCTTTCAGCACCTGGTCC
DMH3C01	DE	Discovery agent

DMD75MP	ID	DMD75MP
DMD75MP	DN	ISIS 25237
DMD75MP	HS	Investigative
DMD75MP	CP	Isis Pharmaceuticals
DMD75MP	DT	Antisense drug
DMD75MP	SQ	GCCCATTGCTGGACATGC
DMD75MP	DE	Discovery agent

DMB9DWH	ID	DMB9DWH
DMB9DWH	DN	ISIS 25544
DMB9DWH	HS	Investigative
DMB9DWH	CP	Isis Pharmaceuticals
DMB9DWH	DT	Antisense drug
DMB9DWH	SQ	AGAGAACCGACGGAGGAC
DMB9DWH	DE	Discovery agent

DM4P15C	ID	DM4P15C
DM4P15C	DN	ISIS 25547
DM4P15C	HS	Investigative
DM4P15C	CP	Isis Pharmaceuticals
DM4P15C	DT	Antisense drug
DM4P15C	SQ	AGCTGAAGACCAGACCGT
DM4P15C	DE	Discovery agent

DMWXQPG	ID	DMWXQPG
DMWXQPG	DN	ISIS 25549
DMWXQPG	HS	Investigative
DMWXQPG	CP	Isis Pharmaceuticals
DMWXQPG	DT	Antisense drug
DMWXQPG	SQ	AATCCGAGTCCAGCCTCT
DMWXQPG	DE	Discovery agent

DM41B62	ID	DM41B62
DM41B62	DN	ISIS 25551
DM41B62	HS	Investigative
DM41B62	CP	Isis Pharmaceuticals
DM41B62	DT	Antisense drug
DM41B62	SQ	TCAGGCAACGAATCCGAG
DM41B62	DE	Discovery agent

DMO8IVA	ID	DMO8IVA
DMO8IVA	DN	ISIS 25552
DMO8IVA	HS	Investigative
DMO8IVA	CP	Isis Pharmaceuticals
DMO8IVA	DT	Antisense drug
DMO8IVA	SQ	CACCAACAATCACCAGTT
DMO8IVA	DE	Discovery agent

DM5PXN4	ID	DM5PXN4
DM5PXN4	DN	ISIS 25554
DM5PXN4	HS	Investigative
DM5PXN4	CP	Isis Pharmaceuticals
DM5PXN4	DT	Antisense drug
DM5PXN4	SQ	ATACACCTCTGGGAACTG
DM5PXN4	DE	Discovery agent

DMBI2PH	ID	DMBI2PH
DMBI2PH	DN	ISIS 25563
DMBI2PH	HS	Investigative
DMBI2PH	CP	Isis Pharmaceuticals
DMBI2PH	DT	Antisense drug
DMBI2PH	SQ	TAGCTCCCGCCTTGTGTG
DMBI2PH	DE	Discovery agent

DMMZW8J	ID	DMMZW8J
DMMZW8J	DN	ISIS 25564
DMMZW8J	HS	Investigative
DMMZW8J	CP	Isis Pharmaceuticals
DMMZW8J	DT	Antisense drug
DMMZW8J	SQ	CCAATCCTGTTTGCCATA
DMMZW8J	DE	Discovery agent

DMB0CJ4	ID	DMB0CJ4
DMB0CJ4	DN	ISIS 25565
DMB0CJ4	HS	Investigative
DMB0CJ4	CP	Isis Pharmaceuticals
DMB0CJ4	DT	Antisense drug
DMB0CJ4	SQ	GTCTTTGCTGAACACTCC
DMB0CJ4	DE	Discovery agent

DMUR2TH	ID	DMUR2TH
DMUR2TH	DN	ISIS 25566
DMUR2TH	HS	Investigative
DMUR2TH	CP	Isis Pharmaceuticals
DMUR2TH	DT	Antisense drug
DMUR2TH	SQ	AAAACCTCTCTCACTCCA
DMUR2TH	DE	Discovery agent

DMX72T6	ID	DMX72T6
DMX72T6	DN	ISIS 25567
DMX72T6	HS	Investigative
DMX72T6	CP	Isis Pharmaceuticals
DMX72T6	DT	Antisense drug
DMX72T6	SQ	AAGACAAGGCAACCAGAT
DMX72T6	DE	Discovery agent

DMRUEM8	ID	DMRUEM8
DMRUEM8	DN	ISIS 2674
DMRUEM8	HS	Investigative
DMRUEM8	CP	Isis Pharmaceuticals
DMRUEM8	DT	Antisense drug
DMRUEM8	SQ	CACAATCCTTAAGAACTCTTT
DMRUEM8	DE	Discovery agent

DMZP5VG	ID	DMZP5VG
DMZP5VG	DN	ISIS 2678
DMZP5VG	HS	Investigative
DMZP5VG	CP	Isis Pharmaceuticals
DMZP5VG	DT	Antisense drug
DMZP5VG	SQ	ACCTCTGCTGTTCTGATCCT
DMZP5VG	DE	Discovery agent

DM78BDU	ID	DM78BDU
DM78BDU	DN	ISIS 2686
DM78BDU	HS	Investigative
DM78BDU	CP	Isis Pharmaceuticals
DM78BDU	DT	Antisense drug
DM78BDU	SQ	TGAAGCAATCATGACTTCAAG
DM78BDU	DE	Discovery agent

DMGMKH3	ID	DMGMKH3
DMGMKH3	DN	ISIS 28405
DMGMKH3	HS	Investigative
DMGMKH3	CP	Isis Pharmaceuticals
DMGMKH3	DT	Antisense drug
DMGMKH3	SQ	CTCCGGCTGCCCCACCCC
DMGMKH3	DE	Discovery agent

DMXKRWN	ID	DMXKRWN
DMXKRWN	DN	ISIS 28407
DMXKRWN	HS	Investigative
DMXKRWN	CP	Isis Pharmaceuticals
DMXKRWN	DT	Antisense drug
DMXKRWN	SQ	CGAACATGACCTCCGCAC
DMXKRWN	DE	Discovery agent

DMR24BS	ID	DMR24BS
DMR24BS	DN	ISIS 28425
DMR24BS	HS	Investigative
DMR24BS	CP	Isis Pharmaceuticals
DMR24BS	DT	Antisense drug
DMR24BS	SQ	GCTCAGCTCACGCTCTGT
DMR24BS	DE	Discovery agent

DMQ5JNT	ID	DMQ5JNT
DMQ5JNT	DN	ISIS 28465
DMQ5JNT	HS	Investigative
DMQ5JNT	CP	Isis Pharmaceuticals
DMQ5JNT	DT	Antisense drug
DMQ5JNT	SQ	GCTCAGCTCACGCTCTGT
DMQ5JNT	DE	Discovery agent

DMH96UP	ID	DMH96UP
DMH96UP	DN	ISIS 28466
DMH96UP	HS	Investigative
DMH96UP	CP	Isis Pharmaceuticals
DMH96UP	DT	Antisense drug
DMH96UP	SQ	TGCATGAAAAGCAAGCAC
DMH96UP	DE	Discovery agent

DMA4U2P	ID	DMA4U2P
DMA4U2P	DN	ISIS 28472
DMA4U2P	HS	Investigative
DMA4U2P	CP	Isis Pharmaceuticals
DMA4U2P	DT	Antisense drug
DMA4U2P	SQ	TTGGGACTGCAAACCTC
DMA4U2P	DE	Discovery agent

DMMOV9U	ID	DMMOV9U
DMMOV9U	DN	ISIS 28477
DMMOV9U	HS	Investigative
DMMOV9U	CP	Isis Pharmaceuticals
DMMOV9U	DT	Antisense drug
DMMOV9U	SQ	ACACACAGGATGGGAGCA
DMMOV9U	DE	Discovery agent

DMECMA6	ID	DMECMA6
DMECMA6	DN	ISIS 29112
DMECMA6	HS	Investigative
DMECMA6	CP	Isis Pharmaceuticals
DMECMA6	DT	Antisense drug
DMECMA6	SQ	AAATGTGTTTGGCTTTGG
DMECMA6	DE	Discovery agent

DMGJURC	ID	DMGJURC
DMGJURC	DN	ISIS 29135
DMGJURC	HS	Investigative
DMGJURC	CP	Isis Pharmaceuticals
DMGJURC	DT	Antisense drug
DMGJURC	SQ	CTGCTCGGCCATAGTCAT
DMGJURC	DE	Discovery agent

DMAMTLR	ID	DMAMTLR
DMAMTLR	DN	ISIS 29136
DMAMTLR	HS	Investigative
DMAMTLR	CP	Isis Pharmaceuticals
DMAMTLR	DT	Antisense drug
DMAMTLR	SQ	AGTCTACTGCTCGGCCAT
DMAMTLR	DE	Discovery agent

DMAR1D6	ID	DMAR1D6
DMAR1D6	DN	ISIS 29137
DMAR1D6	HS	Investigative
DMAR1D6	CP	Isis Pharmaceuticals
DMAR1D6	DT	Antisense drug
DMAR1D6	SQ	CTAGGCCCCACCAGTCTA
DMAR1D6	DE	Discovery agent

DMBY1RS	ID	DMBY1RS
DMBY1RS	DN	ISIS 29138
DMBY1RS	HS	Investigative
DMBY1RS	CP	Isis Pharmaceuticals
DMBY1RS	DT	Antisense drug
DMBY1RS	SQ	CAACCCCTAGGCCCCACC
DMBY1RS	DE	Discovery agent

DM2K0RD	ID	DM2K0RD
DM2K0RD	DN	ISIS 29139
DM2K0RD	HS	Investigative
DM2K0RD	CP	Isis Pharmaceuticals
DM2K0RD	DT	Antisense drug
DM2K0RD	SQ	TCATACATGACAACCCCT
DM2K0RD	DE	Discovery agent

DMT9F15	ID	DMT9F15
DMT9F15	DN	ISIS 29154
DMT9F15	HS	Investigative
DMT9F15	CP	Isis Pharmaceuticals
DMT9F15	DT	Antisense drug
DMT9F15	SQ	GCCCTGAAAGCAATGATT
DMT9F15	DE	Discovery agent

DMSVN1B	ID	DMSVN1B
DMSVN1B	DN	ISIS 29155
DMSVN1B	HS	Investigative
DMSVN1B	CP	Isis Pharmaceuticals
DMSVN1B	DT	Antisense drug
DMSVN1B	SQ	ATCAAGAGCCCTGAAAGC
DMSVN1B	DE	Discovery agent

DMD8KXB	ID	DMD8KXB
DMD8KXB	DN	ISIS 29156
DMD8KXB	HS	Investigative
DMD8KXB	CP	Isis Pharmaceuticals
DMD8KXB	DT	Antisense drug
DMD8KXB	SQ	GATCCTTTATCAAGAGCC
DMD8KXB	DE	Discovery agent

DMLE1IJ	ID	DMLE1IJ
DMLE1IJ	DN	ISIS 29159
DMLE1IJ	HS	Investigative
DMLE1IJ	CP	Isis Pharmaceuticals
DMLE1IJ	DT	Antisense drug
DMLE1IJ	SQ	CTCCACCAAGGCGTTTAT
DMLE1IJ	DE	Discovery agent

DM9NB1A	ID	DM9NB1A
DM9NB1A	DN	ISIS 29160
DM9NB1A	HS	Investigative
DM9NB1A	CP	Isis Pharmaceuticals
DM9NB1A	DT	Antisense drug
DM9NB1A	SQ	TCTGGTCCTCCACCAAGG
DM9NB1A	DE	Discovery agent

DMPS6OQ	ID	DMPS6OQ
DMPS6OQ	DN	ISIS 29161
DMPS6OQ	HS	Investigative
DMPS6OQ	CP	Isis Pharmaceuticals
DMPS6OQ	DT	Antisense drug
DMPS6OQ	SQ	GCGTCATCTGGTCCTCCA
DMPS6OQ	DE	Discovery agent

DMVLU5J	ID	DMVLU5J
DMVLU5J	DN	ISIS 29176
DMVLU5J	HS	Investigative
DMVLU5J	CP	Isis Pharmaceuticals
DMVLU5J	DT	Antisense drug
DMVLU5J	SQ	AGTCTACTGCTCGGCCAT
DMVLU5J	DE	Discovery agent

DMSUWVE	ID	DMSUWVE
DMSUWVE	DN	ISIS 29177
DMSUWVE	HS	Investigative
DMSUWVE	CP	Isis Pharmaceuticals
DMSUWVE	DT	Antisense drug
DMSUWVE	SQ	CTAGGCCCCACCAGTCTA
DMSUWVE	DE	Discovery agent

DMTE7BJ	ID	DMTE7BJ
DMTE7BJ	DN	ISIS 29178
DMTE7BJ	HS	Investigative
DMTE7BJ	CP	Isis Pharmaceuticals
DMTE7BJ	DT	Antisense drug
DMTE7BJ	SQ	CAACCCCTAGGCCCCACC
DMTE7BJ	DE	Discovery agent

DMJTHXY	ID	DMJTHXY
DMJTHXY	DN	ISIS 2918
DMJTHXY	HS	Investigative
DMJTHXY	CP	Isis Pharmaceuticals
DMJTHXY	DT	Antisense drug
DMJTHXY	SQ	AUGGGGTCCTTCATCTGGGAGAGC
DMJTHXY	DE	Discovery agent

DMVMF5X	ID	DMVMF5X
DMVMF5X	DN	ISIS 2919
DMVMF5X	HS	Investigative
DMVMF5X	CP	Isis Pharmaceuticals
DMVMF5X	DT	Antisense drug
DMVMF5X	SQ	CGGCTCAGGTCGTCAATCTTG
DMVMF5X	DE	Discovery agent

DMJFLK0	ID	DMJFLK0
DMJFLK0	DN	ISIS 2920
DMJFLK0	HS	Investigative
DMJFLK0	CP	Isis Pharmaceuticals
DMJFLK0	DT	Antisense drug
DMJFLK0	SQ	GCGCACCATGACCTGTTTGGG
DMJFLK0	DE	Discovery agent

DMN1LHI	ID	DMN1LHI
DMN1LHI	DN	ISIS 29200
DMN1LHI	HS	Investigative
DMN1LHI	CP	Isis Pharmaceuticals
DMN1LHI	DT	Antisense drug
DMN1LHI	SQ	TCTGGTCCTCCACCAAGG
DMN1LHI	DE	Discovery agent

DMSKVWG	ID	DMSKVWG
DMSKVWG	DN	ISIS 29201
DMSKVWG	HS	Investigative
DMSKVWG	CP	Isis Pharmaceuticals
DMSKVWG	DT	Antisense drug
DMSKVWG	SQ	GCGTCATCTGGTCCTCCA
DMSKVWG	DE	Discovery agent

DMDR8V9	ID	DMDR8V9
DMDR8V9	DN	ISIS 29202
DMDR8V9	HS	Investigative
DMDR8V9	CP	Isis Pharmaceuticals
DMDR8V9	DT	Antisense drug
DMDR8V9	SQ	CTTTTGCGTCATCTGGTC
DMDR8V9	DE	Discovery agent

DMDZAKS	ID	DMDZAKS
DMDZAKS	DN	ISIS 2921
DMDZAKS	HS	Investigative
DMDZAKS	CP	Isis Pharmaceuticals
DMDZAKS	DT	Antisense drug
DMDZAKS	SQ	GTTTTGCGCGGTTTCTTACGC
DMDZAKS	DE	Discovery agent

DM37R5F	ID	DM37R5F
DM37R5F	DN	ISIS 29219
DM37R5F	HS	Investigative
DM37R5F	CP	Isis Pharmaceuticals
DM37R5F	DT	Antisense drug
DM37R5F	SQ	AGCTGGCTGGTGGTCCTG
DM37R5F	DE	Discovery agent

DMK8FPR	ID	DMK8FPR
DMK8FPR	DN	ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine
DMK8FPR	HS	Investigative
DMK8FPR	TC	Antisense
DMK8FPR	DT	Combination drug (Antisense drug)
DMK8FPR	DE	Virus infection

DMVT2CJ	ID	DMVT2CJ
DMVT2CJ	DN	ISIS 2922 + Ganciclovir
DMVT2CJ	HS	Investigative
DMVT2CJ	TC	Antisense
DMVT2CJ	DT	Combination drug (Antisense drug)
DMVT2CJ	PC	3454
DMVT2CJ	DE	Virus infection

DMMQPFE	ID	DMMQPFE
DMMQPFE	DN	ISIS 29223
DMMQPFE	HS	Investigative
DMMQPFE	CP	Isis Pharmaceuticals
DMMQPFE	DT	Antisense drug
DMMQPFE	SQ	GGAGGCTGGGCATGCTGC
DMMQPFE	DE	Discovery agent

DM9UNWE	ID	DM9UNWE
DM9UNWE	DN	ISIS 29224
DM9UNWE	HS	Investigative
DM9UNWE	CP	Isis Pharmaceuticals
DM9UNWE	DT	Antisense drug
DM9UNWE	SQ	GAAGTCCTCAGGCCGCTT
DM9UNWE	DE	Discovery agent

DMLES7J	ID	DMLES7J
DMLES7J	DN	ISIS 29232
DMLES7J	HS	Investigative
DMLES7J	CP	Isis Pharmaceuticals
DMLES7J	DT	Antisense drug
DMLES7J	SQ	CAGCTTCTCGTCGTCCTG
DMLES7J	DE	Discovery agent

DMGV4O7	ID	DMGV4O7
DMGV4O7	DN	ISIS 29233
DMGV4O7	HS	Investigative
DMGV4O7	CP	Isis Pharmaceuticals
DMGV4O7	DT	Antisense drug
DMGV4O7	SQ	AAGGCCGAAATACAGCTT
DMGV4O7	DE	Discovery agent

DM1XAPO	ID	DM1XAPO
DM1XAPO	DN	ISIS 29234
DM1XAPO	HS	Investigative
DM1XAPO	CP	Isis Pharmaceuticals
DM1XAPO	DT	Antisense drug
DM1XAPO	SQ	TTTAAGTAGTTCTCCATT
DM1XAPO	DE	Discovery agent

DMAXD7P	ID	DMAXD7P
DMAXD7P	DN	ISIS 29236
DMAXD7P	HS	Investigative
DMAXD7P	CP	Isis Pharmaceuticals
DMAXD7P	DT	Antisense drug
DMAXD7P	SQ	GGTACAGGTCTCATCGAA
DMAXD7P	DE	Discovery agent

DMPYJEB	ID	DMPYJEB
DMPYJEB	DN	ISIS 29237
DMPYJEB	HS	Investigative
DMPYJEB	CP	Isis Pharmaceuticals
DMPYJEB	DT	Antisense drug
DMPYJEB	SQ	CGATCTCAGCCGTGTAAA
DMPYJEB	DE	Discovery agent

DMHQF1J	ID	DMHQF1J
DMHQF1J	DN	ISIS 29239
DMHQF1J	HS	Investigative
DMHQF1J	CP	Isis Pharmaceuticals
DMHQF1J	DT	Antisense drug
DMHQF1J	SQ	GTCCCTGTGAATGATGCC
DMHQF1J	DE	Discovery agent

DMZ7UM2	ID	DMZ7UM2
DMZ7UM2	DN	ISIS 29243
DMZ7UM2	HS	Investigative
DMZ7UM2	CP	Isis Pharmaceuticals
DMZ7UM2	DT	Antisense drug
DMZ7UM2	SQ	TTGGCCCTGGCTTGTTTG
DMZ7UM2	DE	Discovery agent

DMTHVEL	ID	DMTHVEL
DMTHVEL	DN	ISIS 29244
DMTHVEL	HS	Investigative
DMTHVEL	CP	Isis Pharmaceuticals
DMTHVEL	DT	Antisense drug
DMTHVEL	SQ	GCTGTTCCCACGAATGAG
DMTHVEL	DE	Discovery agent

DM0DG1K	ID	DM0DG1K
DM0DG1K	DN	ISIS 29246
DM0DG1K	HS	Investigative
DM0DG1K	CP	Isis Pharmaceuticals
DM0DG1K	DT	Antisense drug
DM0DG1K	SQ	GGACTTCTCCGTGAGCAG
DM0DG1K	DE	Discovery agent

DMK2QPU	ID	DMK2QPU
DMK2QPU	DN	ISIS 29255
DMK2QPU	HS	Investigative
DMK2QPU	CP	Isis Pharmaceuticals
DMK2QPU	DT	Antisense drug
DMK2QPU	SQ	CTGGTATCGCTGCCTCCA
DMK2QPU	DE	Discovery agent

DMF1MJ2	ID	DMF1MJ2
DMF1MJ2	DN	ISIS 29256
DMF1MJ2	HS	Investigative
DMF1MJ2	CP	Isis Pharmaceuticals
DMF1MJ2	DT	Antisense drug
DMF1MJ2	SQ	GCAGGTGTCCTGGCAGCG
DMF1MJ2	DE	Discovery agent

DMUM2H1	ID	DMUM2H1
DMUM2H1	DN	ISIS 29257
DMUM2H1	HS	Investigative
DMUM2H1	CP	Isis Pharmaceuticals
DMUM2H1	DT	Antisense drug
DMUM2H1	SQ	CAAGGTTTCCGCCTCTGC
DMUM2H1	DE	Discovery agent

DMVCFQ5	ID	DMVCFQ5
DMVCFQ5	DN	ISIS 29469
DMVCFQ5	HS	Investigative
DMVCFQ5	CP	Isis Pharmaceuticals
DMVCFQ5	DT	Antisense drug
DMVCFQ5	SQ	AAGGTCCCTGTGAATGAT
DMVCFQ5	DE	Discovery agent

DMPCK7Y	ID	DMPCK7Y
DMPCK7Y	DN	ISIS 29470
DMPCK7Y	HS	Investigative
DMPCK7Y	CP	Isis Pharmaceuticals
DMPCK7Y	DT	Antisense drug
DMPCK7Y	SQ	AGACTTTTGCTGTTCCAA
DMPCK7Y	DE	Discovery agent

DMG4RMZ	ID	DMG4RMZ
DMG4RMZ	DN	ISIS 29471
DMG4RMZ	HS	Investigative
DMG4RMZ	CP	Isis Pharmaceuticals
DMG4RMZ	DT	Antisense drug
DMG4RMZ	SQ	GAGTTGGCCCTGGCTTGT
DMG4RMZ	DE	Discovery agent

DMEBQUN	ID	DMEBQUN
DMEBQUN	DN	ISIS 29475
DMEBQUN	HS	Investigative
DMEBQUN	CP	Isis Pharmaceuticals
DMEBQUN	DT	Antisense drug
DMEBQUN	SQ	GGTCTCTTGCCTTAGGGA
DMEBQUN	DE	Discovery agent

DMKQMXV	ID	DMKQMXV
DMKQMXV	DN	ISIS 29477
DMKQMXV	HS	Investigative
DMKQMXV	CP	Isis Pharmaceuticals
DMKQMXV	DT	Antisense drug
DMKQMXV	SQ	CTTCCATTTCCTCACAGC
DMKQMXV	DE	Discovery agent

DM7K19L	ID	DM7K19L
DM7K19L	DN	ISIS 2974
DM7K19L	HS	Investigative
DM7K19L	CP	Isis Pharmaceuticals
DM7K19L	DT	Antisense drug
DM7K19L	DE	Discovery agent

DM0WH1L	ID	DM0WH1L
DM0WH1L	DN	ISIS 298697
DM0WH1L	HS	Investigative
DM0WH1L	CP	Isis Pharmaceuticals
DM0WH1L	DT	Antisense drug
DM0WH1L	SQ	TCCTCATGGTCACATGGATG
DM0WH1L	DE	Discovery agent

DMB28JW	ID	DMB28JW
DMB28JW	DN	ISIS 298699
DMB28JW	HS	Investigative
DMB28JW	CP	Isis Pharmaceuticals
DMB28JW	DT	Antisense drug
DMB28JW	SQ	GCATTTCTCTCATTTCCTCA
DMB28JW	DE	Discovery agent

DM3DE98	ID	DM3DE98
DM3DE98	DN	ISIS 298700
DM3DE98	HS	Investigative
DM3DE98	CP	Isis Pharmaceuticals
DM3DE98	DT	Antisense drug
DM3DE98	SQ	GTGTGTAAGCATTTCTCTCA
DM3DE98	DE	Discovery agent

DMVIXND	ID	DMVIXND
DMVIXND	DN	ISIS 298701
DMVIXND	HS	Investigative
DMVIXND	CP	Isis Pharmaceuticals
DMVIXND	DT	Antisense drug
DMVIXND	SQ	GGCCATTTCTGTGTGTAAGC
DMVIXND	DE	Discovery agent

DM4L7NE	ID	DM4L7NE
DM4L7NE	DN	ISIS 298702
DM4L7NE	HS	Investigative
DM4L7NE	CP	Isis Pharmaceuticals
DM4L7NE	DT	Antisense drug
DM4L7NE	SQ	TGGTTACTGTTGGTATCATA
DM4L7NE	DE	Discovery agent

DMCDWSG	ID	DMCDWSG
DMCDWSG	DN	ISIS 298711
DMCDWSG	HS	Investigative
DMCDWSG	CP	Isis Pharmaceuticals
DMCDWSG	DT	Antisense drug
DMCDWSG	SQ	TGGTGACTTGTCCTTTAGTA
DMCDWSG	DE	Discovery agent

DMGJ4AO	ID	DMGJ4AO
DMGJ4AO	DN	ISIS 298712
DMGJ4AO	HS	Investigative
DMGJ4AO	CP	Isis Pharmaceuticals
DMGJ4AO	DT	Antisense drug
DMGJ4AO	SQ	TCCTGTGGTGACTTGTCCTT
DMGJ4AO	DE	Discovery agent

DMD3NSQ	ID	DMD3NSQ
DMD3NSQ	DN	ISIS 298743
DMD3NSQ	HS	Investigative
DMD3NSQ	CP	Isis Pharmaceuticals
DMD3NSQ	DT	Antisense drug
DMD3NSQ	SQ	TGAGCCACCAGTGTCCAAAA
DMD3NSQ	DE	Discovery agent

DM8VMQ4	ID	DM8VMQ4
DM8VMQ4	DN	ISIS 298744
DM8VMQ4	HS	Investigative
DM8VMQ4	CP	Isis Pharmaceuticals
DM8VMQ4	DT	Antisense drug
DM8VMQ4	SQ	CCAGGCTTCTAAAATTAGAT
DM8VMQ4	DE	Discovery agent

DM9YMPI	ID	DM9YMPI
DM9YMPI	DN	ISIS 298745
DM9YMPI	HS	Investigative
DM9YMPI	CP	Isis Pharmaceuticals
DM9YMPI	DT	Antisense drug
DM9YMPI	SQ	GTGCAGTATTGTAGCCAGGC
DM9YMPI	DE	Discovery agent

DMHOJ0Z	ID	DMHOJ0Z
DMHOJ0Z	DN	ISIS 298746
DMHOJ0Z	HS	Investigative
DMHOJ0Z	CP	Isis Pharmaceuticals
DMHOJ0Z	DT	Antisense drug
DMHOJ0Z	SQ	AGTTTGTGCAGTATTGTAGC
DMHOJ0Z	DE	Discovery agent

DMC9OL7	ID	DMC9OL7
DMC9OL7	DN	ISIS 3067
DMC9OL7	HS	Investigative
DMC9OL7	CP	Isis Pharmaceuticals
DMC9OL7	DT	Antisense drug
DMC9OL7	SQ	TCTGAGTAGCAGAGGAGCTC
DMC9OL7	DE	Discovery agent

DMOHZKW	ID	DMOHZKW
DMOHZKW	DN	ISIS 31963
DMOHZKW	HS	Investigative
DMOHZKW	CP	Isis Pharmaceuticals
DMOHZKW	DT	Antisense drug
DMOHZKW	SQ	CACCGCCCAGATGTCAAGGA
DMOHZKW	DE	Discovery agent

DMP9IR2	ID	DMP9IR2
DMP9IR2	DN	ISIS 31982
DMP9IR2	HS	Investigative
DMP9IR2	CP	Isis Pharmaceuticals
DMP9IR2	DT	Antisense drug
DMP9IR2	SQ	CTTCCCATGAATAGTCAAAC
DMP9IR2	DE	Discovery agent

DM21ZCQ	ID	DM21ZCQ
DM21ZCQ	DN	ISIS 31996
DM21ZCQ	HS	Investigative
DM21ZCQ	CP	Isis Pharmaceuticals
DM21ZCQ	DT	Antisense drug
DM21ZCQ	SQ	ACTATGTCTGTCACCAATCC
DM21ZCQ	DE	Discovery agent

DM0O9WM	ID	DM0O9WM
DM0O9WM	DN	ISIS 32000
DM0O9WM	HS	Investigative
DM0O9WM	CP	Isis Pharmaceuticals
DM0O9WM	DT	Antisense drug
DM0O9WM	SQ	CATTATGAAACTGAAGCACA
DM0O9WM	DE	Discovery agent

DMEAXV3	ID	DMEAXV3
DMEAXV3	DN	ISIS 32002
DMEAXV3	HS	Investigative
DMEAXV3	CP	Isis Pharmaceuticals
DMEAXV3	DT	Antisense drug
DMEAXV3	SQ	GATGTCTGCCATAGCAGGAG
DMEAXV3	DE	Discovery agent

DM7EVQX	ID	DM7EVQX
DM7EVQX	DN	ISIS 32003
DM7EVQX	HS	Investigative
DM7EVQX	CP	Isis Pharmaceuticals
DM7EVQX	DT	Antisense drug
DM7EVQX	SQ	CACCGCCCAGATGTCAAGGA
DM7EVQX	DE	Discovery agent

DME7VX6	ID	DME7VX6
DME7VX6	DN	ISIS 32004
DME7VX6	HS	Investigative
DME7VX6	CP	Isis Pharmaceuticals
DME7VX6	DT	Antisense drug
DME7VX6	SQ	TGCTATCTGTGAATCCACCG
DME7VX6	DE	Discovery agent

DMT8GWX	ID	DMT8GWX
DMT8GWX	DN	ISIS 32005
DMT8GWX	HS	Investigative
DMT8GWX	CP	Isis Pharmaceuticals
DMT8GWX	DT	Antisense drug
DMT8GWX	SQ	AGGTATGGAGCCATCAGATG
DMT8GWX	DE	Discovery agent

DMFKLUS	ID	DMFKLUS
DMFKLUS	DN	ISIS 32006
DMFKLUS	HS	Investigative
DMFKLUS	CP	Isis Pharmaceuticals
DMFKLUS	DT	Antisense drug
DMFKLUS	SQ	GGGCAAAAGGAAATCCACAG
DMFKLUS	DE	Discovery agent

DME1KXM	ID	DME1KXM
DME1KXM	DN	ISIS 32008
DME1KXM	HS	Investigative
DME1KXM	CP	Isis Pharmaceuticals
DME1KXM	DT	Antisense drug
DME1KXM	SQ	TTCCCGAGGTACCTCCAACT
DME1KXM	DE	Discovery agent

DM8PBCA	ID	DM8PBCA
DM8PBCA	DN	ISIS 32010
DM8PBCA	HS	Investigative
DM8PBCA	CP	Isis Pharmaceuticals
DM8PBCA	DT	Antisense drug
DM8PBCA	SQ	CCATAACATCTGCTTAATAT
DM8PBCA	DE	Discovery agent

DMF5SK8	ID	DMF5SK8
DMF5SK8	DN	ISIS 32014
DMF5SK8	HS	Investigative
DMF5SK8	CP	Isis Pharmaceuticals
DMF5SK8	DT	Antisense drug
DMF5SK8	SQ	ATGCAAACATATAGGAGTCA
DMF5SK8	DE	Discovery agent

DMMV4WX	ID	DMMV4WX
DMMV4WX	DN	ISIS 32015
DMMV4WX	HS	Investigative
DMMV4WX	CP	Isis Pharmaceuticals
DMMV4WX	DT	Antisense drug
DMMV4WX	SQ	CTGGAAGAAAAGGTCTGACA
DMMV4WX	DE	Discovery agent

DMXL9IY	ID	DMXL9IY
DMXL9IY	DN	ISIS 32020
DMXL9IY	HS	Investigative
DMXL9IY	CP	Isis Pharmaceuticals
DMXL9IY	DT	Antisense drug
DMXL9IY	SQ	CATATTAGGAGACACTTGAA
DMXL9IY	DE	Discovery agent

DMISB5V	ID	DMISB5V
DMISB5V	DN	ISIS 32021
DMISB5V	HS	Investigative
DMISB5V	CP	Isis Pharmaceuticals
DMISB5V	DT	Antisense drug
DMISB5V	SQ	TGCCAATTCATTTACTTTGA
DMISB5V	DE	Discovery agent

DMPKGIU	ID	DMPKGIU
DMPKGIU	DN	ISIS 32024
DMPKGIU	HS	Investigative
DMPKGIU	CP	Isis Pharmaceuticals
DMPKGIU	DT	Antisense drug
DMPKGIU	SQ	ATTAGTGGATGATCACCAAA
DMPKGIU	DE	Discovery agent

DMATWDO	ID	DMATWDO
DMATWDO	DN	ISIS 32028
DMATWDO	HS	Investigative
DMATWDO	CP	Isis Pharmaceuticals
DMATWDO	DT	Antisense drug
DMATWDO	SQ	TGTAATATTATGTCTCCAGT
DMATWDO	DE	Discovery agent

DM47B2O	ID	DM47B2O
DM47B2O	DN	ISIS 32035
DM47B2O	HS	Investigative
DM47B2O	CP	Isis Pharmaceuticals
DM47B2O	DT	Antisense drug
DM47B2O	SQ	AGTAGCCAGCACAGGACAGT
DM47B2O	DE	Discovery agent

DMY1R0Q	ID	DMY1R0Q
DMY1R0Q	DN	ISIS 32039
DMY1R0Q	HS	Investigative
DMY1R0Q	CP	Isis Pharmaceuticals
DMY1R0Q	DT	Antisense drug
DMY1R0Q	SQ	TTCACTTTAGTAGTCCAGCT
DMY1R0Q	DE	Discovery agent

DMAFEYG	ID	DMAFEYG
DMAFEYG	DN	ISIS 3224
DMAFEYG	HS	Investigative
DMAFEYG	CP	Isis Pharmaceuticals
DMAFEYG	DT	Antisense drug
DMAFEYG	DE	Discovery agent

DM56EZC	ID	DM56EZC
DM56EZC	DN	ISIS 3246
DM56EZC	HS	Investigative
DM56EZC	CP	Isis Pharmaceuticals
DM56EZC	DT	Antisense drug
DM56EZC	SQ	TGGCGTCTCCAGGCGATCTGA
DM56EZC	DE	Discovery agent

DMA96KW	ID	DMA96KW
DMA96KW	DN	ISIS 329956
DMA96KW	HS	Investigative
DMA96KW	CP	Isis Pharmaceuticals
DMA96KW	DT	Antisense drug
DMA96KW	SQ	CCTGAGGCGGACTCCCAGCT
DMA96KW	DE	Discovery agent

DM2TIO1	ID	DM2TIO1
DM2TIO1	DN	ISIS 3300
DM2TIO1	HS	Investigative
DM2TIO1	CP	Isis Pharmaceuticals
DM2TIO1	DT	Antisense drug
DM2TIO1	SQ	TGGCGTCTCCAGGCGATCTGA
DM2TIO1	DE	Discovery agent

DMWIVS9	ID	DMWIVS9
DMWIVS9	DN	ISIS 330012
DMWIVS9	HS	Investigative
DMWIVS9	CP	Isis Pharmaceuticals
DMWIVS9	DT	Antisense drug
DMWIVS9	SQ	TCCCATTTCAGGAGACCTGG
DMWIVS9	DE	Discovery agent

DM35WFL	ID	DM35WFL
DM35WFL	DN	ISIS 330031
DM35WFL	HS	Investigative
DM35WFL	CP	Isis Pharmaceuticals
DM35WFL	DT	Antisense drug
DM35WFL	SQ	TGGGCTCCTCTGACAGGACA
DM35WFL	DE	Discovery agent

DM0W47U	ID	DM0W47U
DM0W47U	DN	ISIS 3303
DM0W47U	HS	Investigative
DM0W47U	CP	Isis Pharmaceuticals
DM0W47U	DT	Antisense drug
DM0W47U	SQ	CTTTCCATATTGAATATAATAUG
DM0W47U	DE	Discovery agent

DM1K6DX	ID	DM1K6DX
DM1K6DX	DN	ISIS 3304
DM1K6DX	HS	Investigative
DM1K6DX	CP	Isis Pharmaceuticals
DM1K6DX	DT	Antisense drug
DM1K6DX	SQ	ACATCCATTCAAATGGTTTGAUG
DM1K6DX	DE	Discovery agent

DMWD1XH	ID	DMWD1XH
DMWD1XH	DN	ISIS 3306
DMWD1XH	HS	Investigative
DMWD1XH	CP	Isis Pharmaceuticals
DMWD1XH	DT	Antisense drug
DMWD1XH	SQ	GCCTTCATTTTGGTTGTTTTAUG
DMWD1XH	DE	Discovery agent

DMXRL2J	ID	DMXRL2J
DMXRL2J	DN	ISIS 3307
DMXRL2J	HS	Investigative
DMXRL2J	CP	Isis Pharmaceuticals
DMXRL2J	DT	Antisense drug
DMXRL2J	SQ	GACGCCATGATTTTGATGTCAUG
DMXRL2J	DE	Discovery agent

DMSIBWP	ID	DMSIBWP
DMSIBWP	DN	ISIS 3308
DMSIBWP	HS	Investigative
DMSIBWP	CP	Isis Pharmaceuticals
DMSIBWP	DT	Antisense drug
DMSIBWP	SQ	GGATTCATTTTAAACCCCTGAUG
DMSIBWP	DE	Discovery agent

DMDSMJU	ID	DMDSMJU
DMDSMJU	DN	ISIS 3309
DMDSMJU	HS	Investigative
DMDSMJU	CP	Isis Pharmaceuticals
DMDSMJU	DT	Antisense drug
DMDSMJU	SQ	AGACTCATCTTTCAATATCTAUG
DMDSMJU	DE	Discovery agent

DMOYBFQ	ID	DMOYBFQ
DMOYBFQ	DN	ISIS 341881
DMOYBFQ	HS	Investigative
DMOYBFQ	CP	Isis Pharmaceuticals
DMOYBFQ	DT	siRNA drug
DMOYBFQ	SQ	UUUGAAAAUGUUGAUCUCCTT
DMOYBFQ	DE	Discovery agent

DMO7492	ID	DMO7492
DMO7492	DN	ISIS 343867
DMO7492	HS	Investigative
DMO7492	CP	Isis Pharmaceuticals
DMO7492	DT	siRNA drug
DMO7492	SQ	5'-UUUGAAAAUGWUGAUCUCC-3'
DMO7492	DE	Discovery agent

DMAFEX8	ID	DMAFEX8
DMAFEX8	DN	ISIS 347573
DMAFEX8	HS	Investigative
DMAFEX8	CP	Isis Pharmaceuticals
DMAFEX8	DT	Antisense drug
DMAFEX8	SQ	AGAGTTGAACTGTTTTCCTC
DMAFEX8	DE	Discovery agent

DM36SRT	ID	DM36SRT
DM36SRT	DN	ISIS 347577
DM36SRT	HS	Investigative
DM36SRT	CP	Isis Pharmaceuticals
DM36SRT	DT	Antisense drug
DM36SRT	SQ	AAGGGAAAGCAGCTCTCTTT
DM36SRT	DE	Discovery agent

DMBE1T8	ID	DMBE1T8
DMBE1T8	DN	ISIS 3792
DMBE1T8	HS	Investigative
DMBE1T8	CP	Isis Pharmaceuticals
DMBE1T8	DT	Antisense drug
DMBE1T8	SQ	GGCATTTTAAGTTGCTGTCG
DMBE1T8	DE	Discovery agent

DMJDWX5	ID	DMJDWX5
DMJDWX5	DN	ISIS 3801
DMJDWX5	HS	Investigative
DMJDWX5	CP	Isis Pharmaceuticals
DMJDWX5	DT	Antisense drug
DMJDWX5	SQ	AACCCAGTGCTCCCTTTGCT
DMJDWX5	DE	Discovery agent

DM7VAT0	ID	DM7VAT0
DM7VAT0	DN	ISIS 3804
DM7VAT0	HS	Investigative
DM7VAT0	CP	Isis Pharmaceuticals
DM7VAT0	DT	Antisense drug
DM7VAT0	SQ	GGCCACATTGGGAAAGTTGC
DM7VAT0	DE	Discovery agent

DMX927V	ID	DMX927V
DMX927V	DN	ISIS 3805
DMX927V	HS	Investigative
DMX927V	CP	Isis Pharmaceuticals
DMX927V	DT	Antisense drug
DMX927V	SQ	CCCGGCATCTTTACAAAACC
DMX927V	DE	Discovery agent

DMN8OHG	ID	DMN8OHG
DMN8OHG	DN	ISIS 4189
DMN8OHG	HS	Investigative
DMN8OHG	CP	Isis Pharmaceuticals
DMN8OHG	DT	Antisense drug
DMN8OHG	DE	Discovery agent

DMXNBGP	ID	DMXNBGP
DMXNBGP	DN	ISIS 4719
DMXNBGP	HS	Investigative
DMXNBGP	CP	Isis Pharmaceuticals
DMXNBGP	DT	Antisense drug
DMXNBGP	SQ	ACGTTTGGCCTCATGGAAGT
DMXNBGP	DE	Discovery agent

DMD67YO	ID	DMD67YO
DMD67YO	DN	ISIS 4729
DMD67YO	HS	Investigative
DMD67YO	CP	Isis Pharmaceuticals
DMD67YO	DT	Antisense drug
DMD67YO	SQ	GGGCCAGAGACCCGAGGAGA
DMD67YO	DE	Discovery agent

DMKU1PN	ID	DMKU1PN
DMKU1PN	DN	ISIS 4730
DMKU1PN	HS	Investigative
DMKU1PN	CP	Isis Pharmaceuticals
DMKU1PN	DT	Antisense drug
DMKU1PN	SQ	TTCCCCAGATGCACCTGTTT
DMKU1PN	DE	Discovery agent

DMCZK1U	ID	DMCZK1U
DMCZK1U	DN	ISIS 4756
DMCZK1U	HS	Investigative
DMCZK1U	CP	Isis Pharmaceuticals
DMCZK1U	DT	Antisense drug
DMCZK1U	SQ	CCAAAGTGAGAGCTGAGAGA
DMCZK1U	DE	Discovery agent

DM3PZUX	ID	DM3PZUX
DM3PZUX	DN	ISIS 4759
DM3PZUX	HS	Investigative
DM3PZUX	CP	Isis Pharmaceuticals
DM3PZUX	DT	Antisense drug
DM3PZUX	SQ	ACAGGATCTCTCAGGTGGGT
DM3PZUX	DE	Discovery agent

DMLA5I9	ID	DMLA5I9
DMLA5I9	DN	ISIS 4764
DMLA5I9	HS	Investigative
DMLA5I9	CP	Isis Pharmaceuticals
DMLA5I9	DT	Antisense drug
DMLA5I9	SQ	GAAGTCAGCCAAGAACAGCT
DMLA5I9	DE	Discovery agent

DMYVST6	ID	DMYVST6
DMYVST6	DN	ISIS 5874
DMYVST6	HS	Investigative
DMYVST6	CP	Isis Pharmaceuticals
DMYVST6	DT	Antisense drug
DMYVST6	SQ	CTTGAACAATTAATTCCACCT
DMYVST6	DE	Discovery agent

DM8T1Z4	ID	DM8T1Z4
DM8T1Z4	DN	ISIS 5875
DM8T1Z4	HS	Investigative
DM8T1Z4	CP	Isis Pharmaceuticals
DM8T1Z4	DT	Antisense drug
DM8T1Z4	SQ	GTCTTTGTTGTTTTCTCTTCC
DM8T1Z4	DE	Discovery agent

DMRATOH	ID	DMRATOH
DMRATOH	DN	ISIS 5876
DMRATOH	HS	Investigative
DMRATOH	CP	Isis Pharmaceuticals
DMRATOH	DT	Antisense drug
DMRATOH	SQ	CTGTGTCTCCTGTCTCCGCT
DMRATOH	DE	Discovery agent

DME7698	ID	DME7698
DME7698	DN	ISIS 5884
DME7698	HS	Investigative
DME7698	CP	Isis Pharmaceuticals
DME7698	DT	Antisense drug
DME7698	SQ	CGATGCAGATACCGCGGAGT
DME7698	DE	Discovery agent

DMH7LPO	ID	DMH7LPO
DMH7LPO	DN	ISIS 6186
DMH7LPO	HS	Investigative
DMH7LPO	CP	Isis Pharmaceuticals
DMH7LPO	DT	Antisense drug
DMH7LPO	SQ	TATTCCGTCATCGCTCCTCA
DMH7LPO	DE	Discovery agent

DMEUCI2	ID	DMEUCI2
DMEUCI2	DN	ISIS 6431
DMEUCI2	HS	Investigative
DMEUCI2	CP	Isis Pharmaceuticals
DMEUCI2	DT	Antisense drug
DMEUCI2	SQ	CGACATGCCGGCGCCGCTGC
DMEUCI2	DE	Discovery agent

DMQHN43	ID	DMQHN43
DMQHN43	DN	ISIS 6432
DMQHN43	HS	Investigative
DMQHN43	CP	Isis Pharmaceuticals
DMQHN43	DT	Antisense drug
DMQHN43	SQ	ACAGGTGCAGGAGTCGAGGC
DMQHN43	DE	Discovery agent

DMNVLE2	ID	DMNVLE2
DMNVLE2	DN	ISIS 6434
DMNVLE2	HS	Investigative
DMNVLE2	CP	Isis Pharmaceuticals
DMNVLE2	DT	Antisense drug
DMNVLE2	SQ	CGCCTTCGCATAGCCCTTTG
DMNVLE2	DE	Discovery agent

DMI7JQG	ID	DMI7JQG
DMI7JQG	DN	ISIS 6435
DMI7JQG	HS	Investigative
DMI7JQG	CP	Isis Pharmaceuticals
DMI7JQG	DT	Antisense drug
DMI7JQG	SQ	CCTCACCGATGCGGACCCTC
DMI7JQG	DE	Discovery agent

DM7KSRG	ID	DM7KSRG
DM7KSRG	DN	ISIS 6442
DM7KSRG	HS	Investigative
DM7KSRG	CP	Isis Pharmaceuticals
DM7KSRG	DT	Antisense drug
DM7KSRG	SQ	CAGACGACATGCCGGCGCCG
DM7KSRG	DE	Discovery agent

DMGN051	ID	DMGN051
DMGN051	DN	ISIS 6443
DMGN051	HS	Investigative
DMGN051	CP	Isis Pharmaceuticals
DMGN051	DT	Antisense drug
DMGN051	SQ	GCCTGCTTCGCAGCGGGAGA
DMGN051	DE	Discovery agent

DMXJ4SO	ID	DMXJ4SO
DMXJ4SO	DN	ISIS 6445
DMXJ4SO	HS	Investigative
DMXJ4SO	CP	Isis Pharmaceuticals
DMXJ4SO	DT	Antisense drug
DMXJ4SO	SQ	AACACGCCCATTGCCCACCA
DMXJ4SO	DE	Discovery agent

DM5L387	ID	DM5L387
DM5L387	DN	ISIS 6553
DM5L387	HS	Investigative
DM5L387	CP	Isis Pharmaceuticals
DM5L387	DT	Antisense drug
DM5L387	SQ	GCGATGGTTCAGCTGGGCCC
DM5L387	DE	Discovery agent

DMEAVPQ	ID	DMEAVPQ
DMEAVPQ	DN	ISIS 6581
DMEAVPQ	HS	Investigative
DMEAVPQ	CP	Isis Pharmaceuticals
DMEAVPQ	DT	Antisense drug
DMEAVPQ	SQ	TCTCACTCCCCATAAGGCTA
DMEAVPQ	DE	Discovery agent

DMVXC7W	ID	DMVXC7W
DMVXC7W	DN	ISIS 6603
DMVXC7W	HS	Investigative
DMVXC7W	CP	Isis Pharmaceuticals
DMVXC7W	DT	Antisense drug
DMVXC7W	SQ	AAGGCTGATGCTGGGAAGGT
DMVXC7W	DE	Discovery agent

DM5KGQO	ID	DM5KGQO
DM5KGQO	DN	ISIS 6717
DM5KGQO	HS	Investigative
DM5KGQO	CP	Isis Pharmaceuticals
DM5KGQO	DT	Antisense drug
DM5KGQO	SQ	TCCCGCCTGTGACATGCATT
DM5KGQO	DE	Discovery agent

DMJS6B0	ID	DMJS6B0
DMJS6B0	DN	ISIS 6720
DMJS6B0	HS	Investigative
DMJS6B0	CP	Isis Pharmaceuticals
DMJS6B0	DT	Antisense drug
DMJS6B0	SQ	TCCCGCCTGTGACATGCATT
DMJS6B0	DE	Discovery agent

DMWZOQJ	ID	DMWZOQJ
DMWZOQJ	DN	ISIS 6729
DMWZOQJ	HS	Investigative
DMWZOQJ	CP	Isis Pharmaceuticals
DMWZOQJ	DT	Antisense drug
DMWZOQJ	SQ	TCCCGCCTGTGACATGCATT
DMWZOQJ	DE	Discovery agent

DM0B4RD	ID	DM0B4RD
DM0B4RD	DN	ISIS 6739
DM0B4RD	HS	Investigative
DM0B4RD	CP	Isis Pharmaceuticals
DM0B4RD	DT	Antisense drug
DM0B4RD	SQ	AAAGCCCCCCACCAC
DM0B4RD	DE	Discovery agent

DMQONPU	ID	DMQONPU
DMQONPU	DN	ISIS 6748
DMQONPU	HS	Investigative
DMQONPU	CP	Isis Pharmaceuticals
DMQONPU	DT	Antisense drug
DMQONPU	SQ	AGAAGGTGGCGTCGCGCGTG
DMQONPU	DE	Discovery agent

DM4LD1Y	ID	DM4LD1Y
DM4LD1Y	DN	ISIS 6755
DM4LD1Y	HS	Investigative
DM4LD1Y	CP	Isis Pharmaceuticals
DM4LD1Y	DT	Antisense drug
DM4LD1Y	SQ	GCGGCAAAGGCAGCACCCAG
DM4LD1Y	DE	Discovery agent

DMRM5QH	ID	DMRM5QH
DMRM5QH	DN	ISIS 6756
DMRM5QH	HS	Investigative
DMRM5QH	CP	Isis Pharmaceuticals
DMRM5QH	DT	Antisense drug
DMRM5QH	SQ	GCGCCCCATGGTACTGTGGC
DMRM5QH	DE	Discovery agent

DMTHO4A	ID	DMTHO4A
DMTHO4A	DN	ISIS 6957
DMTHO4A	HS	Investigative
DMTHO4A	DT	Antisense drug
DMTHO4A	SQ	CAGTGCCTGCGCCGCGCTCG
DMTHO4A	DE	Discovery agent

DM83EK9	ID	DM83EK9
DM83EK9	DN	ISIS 6958
DM83EK9	HS	Investigative
DM83EK9	CP	Isis Pharmaceuticals
DM83EK9	DT	Antisense drug
DM83EK9	SQ	CTGCCTCCGCCGCCGCGGCC
DM83EK9	DE	Discovery agent

DMOX7FJ	ID	DMOX7FJ
DMOX7FJ	DN	ISIS 7453
DMOX7FJ	HS	Investigative
DMOX7FJ	CP	Isis Pharmaceuticals
DMOX7FJ	DT	Antisense drug
DMOX7FJ	SQ	TACGCCAACAGCTCC
DMOX7FJ	DE	Discovery agent

DMTN1D7	ID	DMTN1D7
DMTN1D7	DN	ISIS 7847
DMTN1D7	HS	Investigative
DMTN1D7	CP	Isis Pharmaceuticals
DMTN1D7	DT	Antisense drug
DMTN1D7	SQ	CTGGCTTCTCCTCCTCCCCT
DMTN1D7	DE	Discovery agent

DMOXBDT	ID	DMOXBDT
DMOXBDT	DN	ISIS 7848
DMOXBDT	HS	Investigative
DMOXBDT	CP	Isis Pharmaceuticals
DMOXBDT	DT	Antisense drug
DMOXBDT	SQ	TCCTCCTCCCCGCGGCGGGT
DMOXBDT	DE	Discovery agent

DMQYB7A	ID	DMQYB7A
DMQYB7A	DN	ISIS 7849
DMQYB7A	HS	Investigative
DMQYB7A	CP	Isis Pharmaceuticals
DMQYB7A	DT	Antisense drug
DMQYB7A	SQ	CTCGCCCGCTCCTCCTCCCC
DMQYB7A	DE	Discovery agent

DMJKC45	ID	DMJKC45
DMJKC45	DN	ISIS 7851
DMJKC45	HS	Investigative
DMJKC45	CP	Isis Pharmaceuticals
DMJKC45	DT	Antisense drug
DMJKC45	SQ	CTCGCCCGCTCCTCCTCCCC
DMJKC45	DE	Discovery agent

DM12E76	ID	DM12E76
DM12E76	DN	ISIS 7853
DM12E76	HS	Investigative
DM12E76	CP	Isis Pharmaceuticals
DM12E76	DT	Antisense drug
DM12E76	SQ	CCTGCTGGCTTCTCCTCCTC
DM12E76	DE	Discovery agent

DMKAQ6U	ID	DMKAQ6U
DMKAQ6U	DN	ISIS 7855
DMKAQ6U	HS	Investigative
DMKAQ6U	CP	Isis Pharmaceuticals
DMKAQ6U	DT	Antisense drug
DMKAQ6U	SQ	TTCTCGCCCGCTCCTCCTCC
DMKAQ6U	DE	Discovery agent

DMN0A1R	ID	DMN0A1R
DMN0A1R	DN	ISIS 7942
DMN0A1R	HS	Investigative
DMN0A1R	CP	Isis Pharmaceuticals
DMN0A1R	DT	Antisense drug
DMN0A1R	SQ	CATGAGGGCCGATGTGACCT
DMN0A1R	DE	Discovery agent

DMYZE8R	ID	DMYZE8R
DMYZE8R	DN	ISIS 7948
DMYZE8R	HS	Investigative
DMYZE8R	CP	Isis Pharmaceuticals
DMYZE8R	DT	Antisense drug
DMYZE8R	SQ	TGCCACACAGCCCAGGCGCA
DMYZE8R	DE	Discovery agent

DMLIRKY	ID	DMLIRKY
DMLIRKY	DN	ISIS 9002
DMLIRKY	HS	Investigative
DMLIRKY	CP	Isis Pharmaceuticals
DMLIRKY	DT	Antisense drug
DMLIRKY	SQ	GGTCAGGCAGGCTGTCCGGC
DMLIRKY	DE	Discovery agent

DMBL2CG	ID	DMBL2CG
DMBL2CG	DN	ISIS 9003
DMBL2CG	HS	Investigative
DMBL2CG	CP	Isis Pharmaceuticals
DMBL2CG	DT	Antisense drug
DMBL2CG	SQ	GTCCCCACCGCCACTCCTGG
DMBL2CG	DE	Discovery agent

DM3PVGC	ID	DM3PVGC
DM3PVGC	DN	ISIS 9005
DM3PVGC	HS	Investigative
DM3PVGC	CP	Isis Pharmaceuticals
DM3PVGC	DT	Antisense drug
DM3PVGC	SQ	GCATGGCAGGTTCCCCTGGA
DM3PVGC	DE	Discovery agent

DMGK2TQ	ID	DMGK2TQ
DMGK2TQ	DN	ISIS 9007
DMGK2TQ	HS	Investigative
DMGK2TQ	CP	Isis Pharmaceuticals
DMGK2TQ	DT	Antisense drug
DMGK2TQ	SQ	AUGCGCCGCTCCCTTCCATCTTG
DMGK2TQ	DE	Discovery agent

DMQDZF2	ID	DMQDZF2
DMQDZF2	DN	ISIS 9008
DMQDZF2	HS	Investigative
DMQDZF2	CP	Isis Pharmaceuticals
DMQDZF2	DT	Antisense drug
DMQDZF2	SQ	CCCCGTAATGCGCCTTGAGG
DMQDZF2	DE	Discovery agent

DM7TRSB	ID	DM7TRSB
DM7TRSB	DN	ISIS 9022
DM7TRSB	HS	Investigative
DM7TRSB	CP	Isis Pharmaceuticals
DM7TRSB	DT	Antisense drug
DM7TRSB	SQ	GGGCTCGCTGGTGAACTGTG
DM7TRSB	DE	Discovery agent

DMO2V5C	ID	DMO2V5C
DMO2V5C	DN	ISIS 9023
DMO2V5C	HS	Investigative
DMO2V5C	CP	Isis Pharmaceuticals
DMO2V5C	DT	Antisense drug
DMO2V5C	SQ	3' UTR GACGCACGCGGCCTCACACC
DMO2V5C	DE	Discovery agent

DMAQ7XH	ID	DMAQ7XH
DMAQ7XH	DN	ISIS 9025
DMAQ7XH	HS	Investigative
DMAQ7XH	CP	Isis Pharmaceuticals
DMAQ7XH	DT	Antisense drug
DMAQ7XH	SQ	3' UTR TCGGAGCCGTGCCCAGCCTG
DMAQ7XH	DE	Discovery agent

DMD1MEZ	ID	DMD1MEZ
DMD1MEZ	DN	ISIS 9058
DMD1MEZ	HS	Investigative
DMD1MEZ	CP	Isis Pharmaceuticals
DMD1MEZ	DT	Antisense drug
DMD1MEZ	SQ	TCCCGCCTGTGACATGCATT
DMD1MEZ	DE	Discovery agent

DMZL7SW	ID	DMZL7SW
DMZL7SW	DN	ISIS 9060
DMZL7SW	HS	Investigative
DMZL7SW	CP	Isis Pharmaceuticals
DMZL7SW	DT	Antisense drug
DMZL7SW	SQ	GTCAAGATGGGCTGAGGTGG
DMZL7SW	DE	Discovery agent

DMFAL2E	ID	DMFAL2E
DMFAL2E	DN	ISIS 9061
DMFAL2E	HS	Investigative
DMFAL2E	CP	Isis Pharmaceuticals
DMFAL2E	DT	Antisense drug
DMFAL2E	SQ	CCATCCCGGACAGTCACCAC
DMFAL2E	DE	Discovery agent

DM5ZGSO	ID	DM5ZGSO
DM5ZGSO	DN	ISIS 9062
DM5ZGSO	HS	Investigative
DM5ZGSO	CP	Isis Pharmaceuticals
DM5ZGSO	DT	Antisense drug
DM5ZGSO	SQ	ATGAGCTCCTCGCCATCCAG
DM5ZGSO	DE	Discovery agent

DM8E5RO	ID	DM8E5RO
DM8E5RO	DN	ISIS 9063
DM8E5RO	HS	Investigative
DM8E5RO	CP	Isis Pharmaceuticals
DM8E5RO	DT	Antisense drug
DM8E5RO	SQ	AATGCTGGTGGAACTTGTAG
DM8E5RO	DE	Discovery agent

DMBMTGP	ID	DMBMTGP
DMBMTGP	DN	ISIS 9064
DMBMTGP	HS	Investigative
DMBMTGP	CP	Isis Pharmaceuticals
DMBMTGP	DT	Antisense drug
DMBMTGP	SQ	CCGGTACCCCAGGTTCTTCA
DMBMTGP	DE	Discovery agent

DMH50RX	ID	DMH50RX
DMH50RX	DN	ISIS 9065
DMH50RX	HS	Investigative
DMH50RX	CP	Isis Pharmaceuticals
DMH50RX	DT	Antisense drug
DMH50RX	SQ	CTGGGCAGTCTGCCGGGCCA
DMH50RX	DE	Discovery agent

DMB8MH0	ID	DMB8MH0
DMB8MH0	DN	ISIS 9066
DMB8MH0	HS	Investigative
DMB8MH0	CP	Isis Pharmaceuticals
DMB8MH0	DT	Antisense drug
DMB8MH0	SQ	CACCTCAGCTGCCATCCACA
DMB8MH0	DE	Discovery agent

DML8HCZ	ID	DML8HCZ
DML8HCZ	DN	ISIS 9067
DML8HCZ	HS	Investigative
DML8HCZ	CP	Isis Pharmaceuticals
DML8HCZ	DT	Antisense drug
DML8HCZ	SQ	GAGATTTTGCTGAGGTCCGG
DML8HCZ	DE	Discovery agent

DM953VY	ID	DM953VY
DM953VY	DN	ISIS 9068
DM953VY	HS	Investigative
DM953VY	CP	Isis Pharmaceuticals
DM953VY	DT	Antisense drug
DM953VY	SQ	GCACTCCGCTCAATCTTGGG
DM953VY	DE	Discovery agent

DM5C86M	ID	DM5C86M
DM5C86M	DN	ISIS 9069
DM5C86M	HS	Investigative
DM5C86M	CP	Isis Pharmaceuticals
DM5C86M	DT	Antisense drug
DM5C86M	SQ	CTAAGGCACAAGGCGGGCTG
DM5C86M	DE	Discovery agent

DMU0HQF	ID	DMU0HQF
DMU0HQF	DN	ISIS 9070
DMU0HQF	HS	Investigative
DMU0HQF	CP	Isis Pharmaceuticals
DMU0HQF	DT	Antisense drug
DMU0HQF	SQ	ACGAACATTGATTGGCTGGT
DMU0HQF	DE	Discovery agent

DMWY2XB	ID	DMWY2XB
DMWY2XB	DN	ISIS 9071
DMWY2XB	HS	Investigative
DMWY2XB	CP	Isis Pharmaceuticals
DMWY2XB	DT	Antisense drug
DMWY2XB	SQ	GTATCCCCAAAGCCAAGAGG
DMWY2XB	DE	Discovery agent

DMDKB1I	ID	DMDKB1I
DMDKB1I	DN	ISIS 9133
DMDKB1I	HS	Investigative
DMDKB1I	CP	Isis Pharmaceuticals
DMDKB1I	DT	Antisense drug
DMDKB1I	SQ	TTCCAGGTCATGAGCCATTA
DMDKB1I	DE	Discovery agent

DMGOPHN	ID	DMGOPHN
DMGOPHN	DN	ISIS 9139
DMGOPHN	HS	Investigative
DMGOPHN	CP	Isis Pharmaceuticals
DMGOPHN	DT	Antisense drug
DMGOPHN	SQ	CCCATAGTGCTGTCACAAAT
DMGOPHN	DE	Discovery agent

DM052M3	ID	DM052M3
DM052M3	DN	ISIS 9606
DM052M3	HS	Investigative
DM052M3	CP	Isis Pharmaceuticals
DM052M3	DT	Antisense drug
DM052M3	SQ	GTTCTCGCTGGTGAGTTTCA
DM052M3	DE	Discovery agent

DM054SL	ID	DM054SL
DM054SL	DN	ISIS 9984
DM054SL	HS	Investigative
DM054SL	CP	Isis Pharmaceuticals
DM054SL	DT	Antisense drug
DM054SL	SQ	GAAGTCAGCCAAGAACAGCT
DM054SL	DE	Discovery agent

DMGN4OQ	ID	DMGN4OQ
DMGN4OQ	DN	ISIS-1939
DMGN4OQ	HS	Investigative
DMGN4OQ	SN	136216-59-6
DMGN4OQ	DE	Discovery agent

DMU64W8	ID	DMU64W8
DMU64W8	DN	ISO24
DMU64W8	HS	Investigative
DMU64W8	SN	ISO24; [(4-ETHYLPHENYL)AMINO]CARBONYLPHOSPHONIC ACID; CHEMBL284362; IS2; 1o4j; AC1L9KY0; CTK8I8170; BDBM14687; 4-Ethylphenylcarbamoylphosphonic acid; AKOS027407805; DB03628; (4-ethylphenyl)carbamoylphosphonic acid; [(4-ethylphenyl)carbamoyl]phosphonic acid
DMU64W8	DT	Small molecular drug
DMU64W8	PC	447534
DMU64W8	MW	229.17
DMU64W8	FM	C9H12NO4P
DMU64W8	IC	InChI=1S/C9H12NO4P/c1-2-7-3-5-8(6-4-7)10-9(11)15(12,13)14/h3-6H,2H2,1H3,(H,10,11)(H2,12,13,14)
DMU64W8	CS	CCC1=CC=C(C=C1)NC(=O)P(=O)(O)O
DMU64W8	IK	KGNSYMGWPCEFDZ-UHFFFAOYSA-N
DMU64W8	IU	(4-ethylphenyl)carbamoylphosphonic acid
DMU64W8	DE	Discovery agent

DMGNFXY	ID	DMGNFXY
DMGNFXY	DN	isoamyl-agomelatine
DMGNFXY	HS	Investigative
DMGNFXY	SN	isoamyl-agomelatine; GTPL7781; CHEMBL1946226
DMGNFXY	DT	Small molecular drug
DMGNFXY	PC	57381997
DMGNFXY	MW	313.4
DMGNFXY	FM	C20H27NO2
DMGNFXY	IC	InChI=1S/C20H27NO2/c1-14(2)5-6-16-11-17-7-8-19(23-4)13-20(17)18(12-16)9-10-21-15(3)22/h7-8,11-14H,5-6,9-10H2,1-4H3,(H,21,22)
DMGNFXY	CS	CC(C)CCC1=CC(=C2C=C(C=CC2=C1)OC)CCNC(=O)C
DMGNFXY	IK	DGWFQLYAVLGONI-UHFFFAOYSA-N
DMGNFXY	IU	N-[2-[7-methoxy-3-(3-methylbutyl)naphthalen-1-yl]ethyl]acetamide
DMGNFXY	DE	Discovery agent

DMTEDHP	ID	DMTEDHP
DMTEDHP	DN	isoamylamine
DMTEDHP	HS	Investigative
DMTEDHP	SN	ISOAMYLAMINE; Isopentylamine; 107-85-7; 3-METHYLBUTAN-1-AMINE; 3-Methylbutylamine; 1-Amino-3-methylbutane; Monoisoamylamine; Leucamine; 1-Butanamine, 3-methyl-; 3-Methylbutanamine; Isovalerylamine; Monoisopentylamine; gamma-Isoamylamine; Isobutylcarbylamine; 3-Methyl-Butylamine; 3-Methyl-1-butylamine; Butylamine, 3-methyl-; 3-Methyl-1-butanamine; 3,3-Dimethylpropylamine; 1-Aminoisopentane; isoamyl amine; UNII-LPO0L33SHY; 2-(2-isopropyl)ethylamine; Propylamine, 3,3-dimethyl-; .gamma.-Isoamylamine; NSC 7907; ISOAMYLAMINE, REAG
DMTEDHP	DT	Small molecular drug
DMTEDHP	PC	7894
DMTEDHP	MW	87.16
DMTEDHP	FM	C5H13N
DMTEDHP	IC	InChI=1S/C5H13N/c1-5(2)3-4-6/h5H,3-4,6H2,1-2H3
DMTEDHP	CS	CC(C)CCN
DMTEDHP	IK	BMFVGAAISNGQNM-UHFFFAOYSA-N
DMTEDHP	IU	3-methylbutan-1-amine
DMTEDHP	CA	CAS 107-85-7
DMTEDHP	CB	CHEBI:43689
DMTEDHP	DE	Discovery agent

DM0B7NO	ID	DM0B7NO
DM0B7NO	DN	Isoarnebin 4
DM0B7NO	HS	Investigative
DM0B7NO	SN	Shikonin; NSC 252844; Shikonin S; Shikonin,(S); Tokyo Violet
DM0B7NO	TC	Antiviral Agents
DM0B7NO	DT	Small molecular drug
DM0B7NO	PC	479503
DM0B7NO	MW	288.29
DM0B7NO	FM	C16H16O5
DM0B7NO	IC	InChI=1S/C16H16O5/c1-8(2)3-4-10(17)9-7-13(20)14-11(18)5-6-12(19)15(14)16(9)21/h3,5-7,10,17-19H,4H2,1-2H3/t10-/m1/s1
DM0B7NO	CS	CC(=CC[C@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C
DM0B7NO	IK	NEZONWMXZKDMKF-SNVBAGLBSA-N
DM0B7NO	IU	5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methylpent-3-enyl]naphthalene-1,4-dione
DM0B7NO	CA	CAS 517-89-5
DM0B7NO	CB	CHEBI:81068
DM0B7NO	DE	Coronavirus Disease 2019 (COVID-19)

DMV8OCF	ID	DMV8OCF
DMV8OCF	DN	IsoBu-RYYRIK-NH2
DMV8OCF	HS	Investigative
DMV8OCF	SN	CHEMBL436852
DMV8OCF	DT	Small molecular drug
DMV8OCF	PC	44456140
DMV8OCF	MW	951.2
DMV8OCF	FM	C46H74N14O8
DMV8OCF	IC	InChI=1S/C46H74N14O8/c1-5-28(4)37(44(68)55-32(38(48)62)15-9-10-22-47)60-41(65)34(17-12-24-54-46(51)52)57-42(66)36(26-30-18-20-31(61)21-19-30)59-43(67)35(25-29-13-7-6-8-14-29)58-40(64)33(56-39(63)27(2)3)16-11-23-53-45(49)50/h6-8,13-14,18-21,27-28,32-37,61H,5,9-12,15-17,22-26,47H2,1-4H3,(H2,48,62)(H,55,68)(H,56,63)(H,57,66)(H,58,64)(H,59,67)(H,60,65)(H4,49,50,53)(H4,51,52,54)/t28-,32-,33-,34-,35-,36-,37-/m0/s1
DMV8OCF	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(C)C
DMV8OCF	IK	WWFAEBUHIGIWNK-KHLMYIKTSA-N
DMV8OCF	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2-methylpropanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMV8OCF	DE	Discovery agent

DM293XH	ID	DM293XH
DM293XH	DN	Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine
DM293XH	HS	Investigative
DM293XH	SN	CHEMBL380191; isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine; SCHEMBL5996834; BDBM50183166
DM293XH	DT	Small molecular drug
DM293XH	PC	44411213
DM293XH	MW	260.399
DM293XH	FM	C17H28N2
DM293XH	IC	InChI=1S/C17H28N2/c1-14(2)12-19(17-8-10-18-11-9-17)13-16-6-4-15(3)5-7-16/h4-7,14,17-18H,8-13H2,1-3H3
DM293XH	CS	CC1=CC=C(C=C1)CN(CC(C)C)C2CCNCC2
DM293XH	IK	GBWQTSFXTHVNTA-UHFFFAOYSA-N
DM293XH	IU	N-[(4-methylphenyl)methyl]-N-(2-methylpropyl)piperidin-4-amine
DM293XH	DE	Discovery agent

DM46F5X	ID	DM46F5X
DM46F5X	DN	isobutylmethylxanthine
DM46F5X	HS	Investigative
DM46F5X	SN	3-Isobutyl-1-methylxanthine; IBMX; 28822-58-4; 1-METHYL-3-ISOBUTYLXANTHINE; Methylisobutylxanthine; 3-Isobutyl-1-methyl-1H-purine-2,6(3H,7H)-dione; Xanthine, 3-isobutyl-1-methyl-; 3-Isobutyl-1-methyxanthine; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-(2-methylpropyl)-; Methyl-isobutylxanthine; 3-isobutyl-1-methylxanthine (ibmx); UNII-TBT296U68M; 3-Isobutyl 1-methylxanthine; NSC 165960; CCRIS 4290; CHEBI:34795; 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione; 3-isobutyl-1-methyl-7H-xanthine;  methylisobutylxanthine; 3-Isobutyl-1-methyl-3,9-dihydro-purine-2,6-dione; 3-ISOBUTYL-1-METHYLXANTHINE
DM46F5X	DT	Small molecular drug
DM46F5X	PC	3758
DM46F5X	MW	222.24
DM46F5X	FM	C10H14N4O2
DM46F5X	IC	InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)
DM46F5X	CS	CC(C)CN1C2=C(C(=O)N(C1=O)C)NC=N2
DM46F5X	IK	APIXJSLKIYYUKG-UHFFFAOYSA-N
DM46F5X	IU	1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione
DM46F5X	CA	CAS 28822-58-4
DM46F5X	CB	CHEBI:34795
DM46F5X	DE	Discovery agent

DMX4VY9	ID	DMX4VY9
DMX4VY9	DN	isobutyric acid
DMX4VY9	HS	Investigative
DMX4VY9	SN	isobutyrate
DMX4VY9	DT	Small molecular drug
DMX4VY9	PC	6590
DMX4VY9	MW	88.11
DMX4VY9	FM	C4H8O2
DMX4VY9	IC	InChI=1S/C4H8O2/c1-3(2)4(5)6/h3H,1-2H3,(H,5,6)
DMX4VY9	CS	CC(C)C(=O)O
DMX4VY9	IK	KQNPFQTWMSNSAP-UHFFFAOYSA-N
DMX4VY9	IU	2-methylpropanoic acid
DMX4VY9	CA	CAS 79-31-2
DMX4VY9	CB	CHEBI:16135
DMX4VY9	DE	Discovery agent

DM861DU	ID	DM861DU
DM861DU	DN	Iso-caffeine
DM861DU	HS	Investigative
DM861DU	SN	Isocaffeine; 1,3,9-Trimethylxanthine; 519-32-4; 1,3,9-trimethylpurine-2,6-dione; 1,3,9-trimethyl-3,9-dihydro-1H-purine-2,6-dione; CHEMBL74063; MLS002639222; Caffeine Impurity C (Isocaffeine); 2,6-Dihydroxy-1,3,9-trimethylpurine; 1,3,9-Trimethyl-3,9-dihydro-purine-2,6-dione; W-202958; isocaffeine(8ci); Isocoffein; EINECS 208-267-7; NSC 28332; Isocaffeine (8CI); ISOCAFFIENE; 1,9-Trimethylxanthine; AC1L1B8B; AC1Q6KE0; 1,3,9-trimethyl-1H-purine-2,6(3H,9H)-dione; SCHEMBL515995; 3,9-Dihydro-1,3,9-trimethyl-1H-purine-2,6-dione
DM861DU	DT	Small molecular drug
DM861DU	PC	1326
DM861DU	MW	194.19
DM861DU	FM	C8H10N4O2
DM861DU	IC	InChI=1S/C8H10N4O2/c1-10-4-9-5-6(10)11(2)8(14)12(3)7(5)13/h4H,1-3H3
DM861DU	CS	CN1C=NC2=C1N(C(=O)N(C2=O)C)C
DM861DU	IK	LPHGQDQBBGAPDZ-UHFFFAOYSA-N
DM861DU	IU	1,3,9-trimethylpurine-2,6-dione
DM861DU	CA	CAS 519-32-4
DM861DU	DE	Discovery agent

DMZR7W6	ID	DMZR7W6
DMZR7W6	DN	isocarbacyclin
DMZR7W6	HS	Investigative
DMZR7W6	SN	9-O-methanoprostaglandin I
DMZR7W6	DT	Small molecular drug
DMZR7W6	PC	5311244
DMZR7W6	MW	350.5
DMZR7W6	FM	C21H34O4
DMZR7W6	IC	InChI=1S/C21H34O4/c1-2-3-4-8-17(22)10-11-18-19-13-15(7-5-6-9-21(24)25)12-16(19)14-20(18)23/h10-12,16-20,22-23H,2-9,13-14H2,1H3,(H,24,25)/b11-10+/t16-,17-,18+,19-,20+/m0/s1
DMZR7W6	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=C2)CCCCC(=O)O)O)O
DMZR7W6	IK	JANVYOZZTKSZGN-WCAFQOMDSA-N
DMZR7W6	IU	5-[(3aS,5R,6R,6aS)-5-hydroxy-6-[(E,3S)-3-hydroxyoct-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoic acid
DMZR7W6	CA	CAS 88911-35-7
DMZR7W6	DE	Discovery agent

DMUB187	ID	DMUB187
DMUB187	DN	Isochroman mono-carboxylic acid
DMUB187	HS	Investigative
DMUB187	SN	CHEMBL564124; isochroman mono-carboxylic acid; BDBM50296382; (3S)-7-{4-[(3R)-1,2-Dithiolan-3-yl]butylcarboxamido}-isochroman-3-carboxylic acid
DMUB187	DT	Small molecular drug
DMUB187	PC	44139929
DMUB187	MW	381.5
DMUB187	FM	C18H23NO4S2
DMUB187	IC	InChI=1S/C18H23NO4S2/c20-17(4-2-1-3-15-7-8-24-25-15)19-14-6-5-12-10-16(18(21)22)23-11-13(12)9-14/h5-6,9,15-16H,1-4,7-8,10-11H2,(H,19,20)(H,21,22)/t15-,16+/m1/s1
DMUB187	CS	C1CSS[C@@H]1CCCCC(=O)NC2=CC3=C(C[C@H](OC3)C(=O)O)C=C2
DMUB187	IK	KRQHPRIBLJFGIT-CVEARBPZSA-N
DMUB187	IU	(3S)-7-[5-[(3R)-dithiolan-3-yl]pentanoylamino]-3,4-dihydro-1H-isochromene-3-carboxylic acid
DMUB187	DE	Discovery agent

DMJKW4S	ID	DMJKW4S
DMJKW4S	DN	Isocitric Acid
DMJKW4S	HS	Investigative
DMJKW4S	SN	Citric acid, tetrakis(trimethylsilyl) deriv.; 1,2,3-Propanetricarboxylic acid, 2-[(trimethylsilyl)oxy]-, tris(trimethylsilyl) ester; Citric acid, (4TMS); Citric acid, tetra-TMS; Citric acid, tetrakis-TMS; CITRIC ACID-TETRA-TMS; Citric acid, 4TMS derivative; AC1LB862; CTK7F4886; VFGAVMGYDWDESE-UHFFFAOYSA-N; 14330-97-3; 3-O-Trimethylsilylcitric acid tri(trimethylsilyl) ester; Citric acid, trimethylsilyl ether, tris(trimethylsilyl) ester; tris(trimethylsilyl) 2-trimethylsilyloxypropane-1,2,3-tricarboxylate
DMJKW4S	DT	Small molecular drug
DMJKW4S	PC	1198
DMJKW4S	MW	192.12
DMJKW4S	FM	C6H8O7
DMJKW4S	IC	InChI=1S/C6H8O7/c7-3(8)1-2(5(10)11)4(9)6(12)13/h2,4,9H,1H2,(H,7,8)(H,10,11)(H,12,13)
DMJKW4S	CS	C(C(C(C(=O)O)O)C(=O)O)C(=O)O
DMJKW4S	IK	ODBLHEXUDAPZAU-UHFFFAOYSA-N
DMJKW4S	IU	1-hydroxypropane-1,2,3-tricarboxylic acid
DMJKW4S	CA	CAS 320-77-4
DMJKW4S	CB	CHEBI:30887
DMJKW4S	DE	Discovery agent

DM52CPU	ID	DM52CPU
DM52CPU	DN	ISOCLOZAPINE
DM52CPU	HS	Investigative
DM52CPU	SN	ISOCLOZAPINE; BRN 0763655; CHEMBL415300; 1977-08-8; 2-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)-5H-benzo(b,e)(1,4)diazepine; 5H-DIBENZO(b,e)(1,4)DIAZEPINE, 2-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-; SCHEMBL140207; AC1L279R; CTK4E2258; DTXSID40173464; MolPort-042-665-648; ZINC25973757; BDBM50010594; 2-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; NCGC00386501-01; LS-60880; 5H-Dibenzo[b,e][1,4]diazepine,2-chloro-11-(4-methyl-1-piperazinyl)-
DM52CPU	DT	Small molecular drug
DM52CPU	PC	16104
DM52CPU	MW	326.8
DM52CPU	FM	C18H19ClN4
DM52CPU	IC	InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-12-13(19)6-7-15(14)20-16-4-2-3-5-17(16)21-18/h2-7,12,20H,8-11H2,1H3
DM52CPU	CS	CN1CCN(CC1)C2=NC3=CC=CC=C3NC4=C2C=C(C=C4)Cl
DM52CPU	IK	APOMSSAGEAOUGO-UHFFFAOYSA-N
DM52CPU	IU	8-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine
DM52CPU	CA	CAS 1977-08-8
DM52CPU	DE	Discovery agent

DMMF1HX	ID	DMMF1HX
DMMF1HX	DN	ISOCONAZOLE
DMMF1HX	HS	Investigative
DMMF1HX	SN	Isoconazole; 27523-40-6; Isoconazolum; Isoconazol; Travogen; Isoconazol [INN-Spanish]; Isoconazolum [INN-Latin]; EINECS 248-508-3; CHEBI:83667; MPIPASJGOJYODL-UHFFFAOYSA-N; 1-[2-(2,4-dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]imidazole; 1-(2,4-Dichloro-beta-((2,6-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2-(2,4-Dichlorophenyl)-2-((2,6-dichlorophenyl)methoxy)ethyl)1H-imidazole; DSSTox_CID_25447; DSSTox_RID_80886; DSSTox_GSID_45447; 1H-Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,6-dichlorophenyl)methoxy)ethyl)-
DMMF1HX	DT	Small molecular drug
DMMF1HX	PC	3760
DMMF1HX	MW	416.1
DMMF1HX	FM	C18H14Cl4N2O
DMMF1HX	IC	InChI=1S/C18H14Cl4N2O/c19-12-4-5-13(17(22)8-12)18(9-24-7-6-23-11-24)25-10-14-15(20)2-1-3-16(14)21/h1-8,11,18H,9-10H2
DMMF1HX	CS	C1=CC(=C(C(=C1)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
DMMF1HX	IK	MPIPASJGOJYODL-UHFFFAOYSA-N
DMMF1HX	IU	1-[2-(2,4-dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]imidazole
DMMF1HX	CA	CAS 27523-40-6
DMMF1HX	CB	CHEBI:83667
DMMF1HX	DE	Discovery agent

DM7ZSVD	ID	DM7ZSVD
DM7ZSVD	DN	ISODISPAR B
DM7ZSVD	HS	Investigative
DM7ZSVD	SN	ISODISPAR B; CHEMBL198873; AC1O5FK1; BDBM50172747; 5,7-dihydroxy-8-(3-methylbutanoyl)-4-phenylchromen-2-one; 5,7-Dihydroxy-8-(3-methyl-butyryl)-4-phenyl-chromen-2-one; 5,7-dihydroxy-8-(3-methylbutanoyl)-4-phenyl-chromen-2-one; 4-Phenyl-5,7-dihydroxy-8-(3-methylbutyryl)-2H-1-benzopyran-2-one; 2H-1-Benzopyran-2-one, 5,7-dihydroxy-8-(3-methyl-1-oxobutyl)-4-phenyl-
DM7ZSVD	DT	Small molecular drug
DM7ZSVD	PC	6483316
DM7ZSVD	MW	338.4
DM7ZSVD	FM	C20H18O5
DM7ZSVD	IC	InChI=1S/C20H18O5/c1-11(2)8-14(21)19-16(23)10-15(22)18-13(9-17(24)25-20(18)19)12-6-4-3-5-7-12/h3-7,9-11,22-23H,8H2,1-2H3
DM7ZSVD	CS	CC(C)CC(=O)C1=C(C=C(C2=C1OC(=O)C=C2C3=CC=CC=C3)O)O
DM7ZSVD	IK	GKEWZBRIASMMCY-UHFFFAOYSA-N
DM7ZSVD	IU	5,7-dihydroxy-8-(3-methylbutanoyl)-4-phenylchromen-2-one
DM7ZSVD	DE	Discovery agent

DMSLO71	ID	DMSLO71
DMSLO71	DN	Isoelaeocarpine
DMSLO71	HS	Investigative
DMSLO71	SN	Isoelaeocarpine
DMSLO71	DT	Small molecular drug
DMSLO71	PC	44423026
DMSLO71	MW	257.329
DMSLO71	FM	C16H19NO2
DMSLO71	IC	InChI=1S/C16H19NO2/c1-10-4-2-6-12-14(10)16(18)15-11-5-3-8-17(11)9-7-13(15)19-12/h2,4,6,11,13,15H,3,5,7-9H2,1H3/t11-,13+,15-/m1/s1
DMSLO71	CS	CC1=C2C(=CC=C1)O[C@H]3CCN4CCC[C@@H]4[C@H]3C2=O
DMSLO71	IK	DXTYYNIKCKARPP-OSAQELSMSA-N
DMSLO71	IU	(6aS,12aR,12bR)-11-methyl-1,2,3,5,6,6a,12a,12b-octahydrochromeno[2,3-g]indolizin-12-one
DMSLO71	DE	Discovery agent

DMN23KT	ID	DMN23KT
DMN23KT	DN	isoferulic acid
DMN23KT	HS	Investigative
DMN23KT	SN	Isoferulic acid; 3-Hydroxy-4-methoxycinnamic acid; 537-73-5; Hesperetic acid; 25522-33-2; 3-(3-Hydroxy-4-methoxyphenyl)acrylic acid; (2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid; (E)-3-(3-hydroxy-4-methoxyphenyl)acrylic acid; Isoferulate; 2-Propenoic acid, 3-(3-hydroxy-4-methoxyphenyl)-; 3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid; 3-hydroxy-4-methoxy-cinnamic acid; CHEMBL233295; CHEBI:27794; QURCVMIEKCOAJU-HWKANZROSA-N; AK-88788; UNII-XSQ2K2G7MC; Cinnamic acid, 3-hydroxy-4-methoxy-; Q-100609
DMN23KT	DT	Small molecular drug
DMN23KT	PC	736186
DMN23KT	MW	194.18
DMN23KT	FM	C10H10O4
DMN23KT	IC	InChI=1S/C10H10O4/c1-14-9-4-2-7(6-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+
DMN23KT	CS	COC1=C(C=C(C=C1)/C=C/C(=O)O)O
DMN23KT	IK	QURCVMIEKCOAJU-HWKANZROSA-N
DMN23KT	IU	(E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid
DMN23KT	CA	CAS 25522-33-2
DMN23KT	CB	CHEBI:27794
DMN23KT	DE	Discovery agent

DM5CMA8	ID	DM5CMA8
DM5CMA8	DN	ISOFORMONENTIN
DM5CMA8	HS	Investigative
DM5CMA8	SN	isoformononetin; 486-63-5; 3-(4-Hydroxyphenyl)-7-methoxy-4H-chromen-4-one; 4'-HYDROXY-7-METHOXYISOFLAVONE; 7-methoxy-4'-hydroxyisoflavone; CHEBI:29608; LNIQZRIHAMVRJA-UHFFFAOYSA-N; HMO; 4H-1-Benzopyran-4-one, 3-(4-hydroxyphenyl)-7-methoxy-; ISOFORMONENTIN; 7-O-methyldaidzein; AC1L1GNQ; SCHEMBL73338; CTK8C3880; DTXSID40274405; ZINC968077; LMPK12050039; 6634AB; ANW-70750; AKOS016007909; DB04202; CCG-214134; AJ-24572; AX8239272; 4,(S); 3-(4-hydroxyphenyl)-7-methoxychromen-4-one; C12125; SR-05000002516
DM5CMA8	DT	Small molecular drug
DM5CMA8	PC	3764
DM5CMA8	MW	268.26
DM5CMA8	FM	C16H12O4
DM5CMA8	IC	InChI=1S/C16H12O4/c1-19-12-6-7-13-15(8-12)20-9-14(16(13)18)10-2-4-11(17)5-3-10/h2-9,17H,1H3
DM5CMA8	CS	COC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O
DM5CMA8	IK	LNIQZRIHAMVRJA-UHFFFAOYSA-N
DM5CMA8	IU	3-(4-hydroxyphenyl)-7-methoxychromen-4-one
DM5CMA8	CA	CAS 486-63-5
DM5CMA8	CB	CHEBI:29608
DM5CMA8	DE	Discovery agent

DM31AXO	ID	DM31AXO
DM31AXO	DN	Isogemichalcone C
DM31AXO	HS	Investigative
DM31AXO	SN	isogemichalcone C; CHEMBL463638; 3'-(4-Feruloyloxy-3-methylbutyl-2(E)-enyl)-2,4,2',4'-tetrahydroxychalcone; BDBM50250978; LMPK12120123; 3-Methoxy-4-hydroxy-trans-cinnamic acid 2-methyl-4-[2,6-dihydroxy-3-[3-(2,4-dihydroxyphenyl)acryloyl]phenyl]-2-butenyl ester; 3-Methoxy-4-hydroxy-trans-cinnamic acid 2-methyl-4-[2,6-dihydroxy-3-[(E)-2,4-dihydroxycinnamoyl]phenyl]-2-butenyl ester
DM31AXO	DT	Small molecular drug
DM31AXO	PC	10143276
DM31AXO	MW	532.5
DM31AXO	FM	C30H28O9
DM31AXO	IC	InChI=1S/C30H28O9/c1-18(17-39-29(36)14-5-19-4-11-26(34)28(15-19)38-2)3-9-22-25(33)13-10-23(30(22)37)24(32)12-7-20-6-8-21(31)16-27(20)35/h3-8,10-16,31,33-35,37H,9,17H2,1-2H3/b12-7+,14-5+,18-3+
DM31AXO	CS	C/C(=C\\CC1=C(C=CC(=C1O)C(=O)/C=C/C2=C(C=C(C=C2)O)O)O)/COC(=O)/C=C/C3=CC(=C(C=C3)O)OC
DM31AXO	IK	OFKHJNZDWNKYOY-MNYVGDBSSA-N
DM31AXO	IU	[(E)-4-[3-[(E)-3-(2,4-dihydroxyphenyl)prop-2-enoyl]-2,6-dihydroxyphenyl]-2-methylbut-2-enyl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
DM31AXO	DE	Discovery agent

DMCF1ZD	ID	DMCF1ZD
DMCF1ZD	DN	ISOGOIAZENSOLIDE
DMCF1ZD	HS	Investigative
DMCF1ZD	SN	isogoiazensolide
DMCF1ZD	DT	Small molecular drug
DMCF1ZD	PC	10247932
DMCF1ZD	MW	360.4
DMCF1ZD	FM	C19H20O7
DMCF1ZD	IC	InChI=1S/C19H20O7/c1-8(2)17(22)24-12-7-19(5)13(20)6-11(26-19)9(3)15(21)16-14(12)10(4)18(23)25-16/h6,12,14-16,21H,1,3-4,7H2,2,5H3/t12-,14+,15+,16-,19+/m0/s1
DMCF1ZD	CS	CC(=C)C(=O)O[C@H]1C[C@@]2(C(=O)C=C(O2)C(=C)[C@H]([C@@H]3[C@@H]1C(=C)C(=O)O3)O)C
DMCF1ZD	IK	QOLGSSCWXRXSJG-FTLZPGDLSA-N
DMCF1ZD	IU	[(3R,4S,8R,9S,11R)-3-hydroxy-11-methyl-2,7-dimethylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradec-1(13)-en-9-yl] 2-methylprop-2-enoate
DMCF1ZD	DE	Discovery agent

DMI6NJ1	ID	DMI6NJ1
DMI6NJ1	DN	Isogranulatimide
DMI6NJ1	HS	Investigative
DMI6NJ1	DT	Small molecular drug
DMI6NJ1	PC	135418335
DMI6NJ1	MW	276.25
DMI6NJ1	FM	C15H8N4O2
DMI6NJ1	IC	InChI=1S/C15H8N4O2/c20-14-11-9-5-16-6-19(9)13-10(12(11)15(21)18-14)7-3-1-2-4-8(7)17-13/h1-6,20H,(H,18,21)
DMI6NJ1	CS	C1=CC=C2C(=C1)C3=C4C(=C(NC4=O)O)C5=CN=CN5C3=N2
DMI6NJ1	IK	KUWAFJHRXZRHJH-UHFFFAOYSA-N
DMI6NJ1	IU	8-hydroxy-2,4,9,19-tetrazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(19),3,5,7,11,13,15,17-octaen-10-one
DMI6NJ1	CA	CAS 219829-00-2
DMI6NJ1	DE	Discovery agent

DMAFLCJ	ID	DMAFLCJ
DMAFLCJ	DN	Isoguanosine
DMAFLCJ	HS	Investigative
DMAFLCJ	SN	2-Hydroxyadenosine; Crotonoside; Isoguanosine; 1818-71-9; Crotonosid; Isoguanine riboside; Adenosine, 1,2-dihydro-2-oxo-; 1,2-Dihydro-2-oxoadenosine; Isoguanosine (7CI,8CI); Isoguanine, 9-beta-D-ribofuranosyl-; NSC 12161; CHEBI:3927; 9H-Purin-2-ol, 6-amino-9-beta-D-ribofuranosyl-; 6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-2-one; Isoguanosin; CCRIS 8240; isoguanineriboside; Isoguanine, 9-.beta.-D-ribofuranosyl-; Isoguanosine (VAN); 2-Oxo-3-hydroadenosine; 2-Oxoado (isoguanosine)
DMAFLCJ	DT	Small molecular drug
DMAFLCJ	PC	65085
DMAFLCJ	MW	283.24
DMAFLCJ	FM	C10H13N5O5
DMAFLCJ	IC	InChI=1S/C10H13N5O5/c11-7-4-8(14-10(19)13-7)15(2-12-4)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)/t3-,5-,6-,9-/m1/s1
DMAFLCJ	CS	C1=NC2=C(NC(=O)N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DMAFLCJ	IK	MIKUYHXYGGJMLM-UUOKFMHZSA-N
DMAFLCJ	IU	6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-2-one
DMAFLCJ	CA	CAS 1818-71-9
DMAFLCJ	CB	CHEBI:3927
DMAFLCJ	DE	Discovery agent

DMZH9PW	ID	DMZH9PW
DMZH9PW	DN	Isohelenin
DMZH9PW	HS	Investigative
DMZH9PW	DT	Small molecular drug
DMZH9PW	PC	605266
DMZH9PW	MW	232.32
DMZH9PW	FM	C15H20O2
DMZH9PW	IC	InChI=1S/C15H20O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h11-13H,1-2,4-8H2,3H3
DMZH9PW	CS	CC12CCCC(=C)C1CC3C(C2)OC(=O)C3=C
DMZH9PW	IK	CVUANYCQTOGILD-UHFFFAOYSA-N
DMZH9PW	IU	8a-methyl-3,5-dimethylidene-3a,4,4a,6,7,8,9,9a-octahydrobenzo[f][1]benzofuran-2-one
DMZH9PW	CA	CAS 470-17-7
DMZH9PW	DE	Discovery agent

DMQC4HV	ID	DMQC4HV
DMQC4HV	DN	Isoindolinone Urea derivative
DMQC4HV	HS	Investigative
DMQC4HV	SN	CHEMBL184971
DMQC4HV	DT	Small molecular drug
DMQC4HV	PC	44394105
DMQC4HV	MW	509.6
DMQC4HV	FM	C32H35N3O3
DMQC4HV	IC	InChI=1S/C32H35N3O3/c1-19(2)38-18-20-12-13-26-23(15-20)29-25-17-33-32(37)30(25)28-22-10-6-5-9-21(22)16-24(28)31(29)35(26)14-8-7-11-27(36)34(3)4/h5-6,9-10,12-13,15,19H,7-8,11,14,16-18H2,1-4H3,(H,33,37)
DMQC4HV	CS	CC(C)OCC1=CC2=C(C=C1)N(C3=C2C4=C(C5=C3CC6=CC=CC=C65)C(=O)NC4)CCCCC(=O)N(C)C
DMQC4HV	IK	FBRQJIGPZJLFIQ-UHFFFAOYSA-N
DMQC4HV	IU	N,N-dimethyl-5-[14-oxo-7-(propan-2-yloxymethyl)-3,13-diazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1(16),2(10),4(9),5,7,11(15),17,19,21-nonaen-3-yl]pentanamide
DMQC4HV	DE	Discovery agent

DMHTBDN	ID	DMHTBDN
DMHTBDN	DN	Isojaspic acid
DMHTBDN	HS	Investigative
DMHTBDN	SN	isojaspic acid; CHEMBL1164369
DMHTBDN	DT	Small molecular drug
DMHTBDN	PC	46907602
DMHTBDN	MW	410.6
DMHTBDN	FM	C27H38O3
DMHTBDN	IC	InChI=1S/C27H38O3/c1-18(2)8-6-13-26(4)14-7-15-27(5)22(19(3)9-12-24(26)27)17-21-16-20(25(29)30)10-11-23(21)28/h8-11,16,22,24,28H,6-7,12-15,17H2,1-5H3,(H,29,30)/t22-,24+,26+,27-/m1/s1
DMHTBDN	CS	CC1=CC[C@H]2[C@@](CCC[C@@]2([C@@H]1CC3=C(C=CC(=C3)C(=O)O)O)C)(C)CCC=C(C)C
DMHTBDN	IK	IIMZFSAVKIVVHG-PPKJMBTNSA-N
DMHTBDN	IU	3-[[(1R,4aS,5R,8aS)-2,5,8a-trimethyl-5-(4-methylpent-3-enyl)-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl]-4-hydroxybenzoic acid
DMHTBDN	DE	Discovery agent

DMYEGBC	ID	DMYEGBC
DMYEGBC	DN	ISOLICOFLAVONOL
DMYEGBC	HS	Investigative
DMYEGBC	SN	Isolicoflavonol; 94805-83-1; MLS000697735; CHEMBL457679; SMR000470986; 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one; AC1NSX1R; SCHEMBL5614138; cid_5318585; MolPort-039-052-689; PGCKDCPTJAQQSQ-UHFFFAOYSA-N; HMS2271L11; ZINC13130924; LMPK12111984; 9577AF; BDBM50251003; 5,7,4'-trihydroxy-3'-prenylflavonol; 4',5,7-Trihydroxy-3'-prenylflavonol; SR-01000765807; SR-01000765807-2; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-
DMYEGBC	DT	Small molecular drug
DMYEGBC	PC	5318585
DMYEGBC	MW	354.4
DMYEGBC	FM	C20H18O6
DMYEGBC	IC	InChI=1S/C20H18O6/c1-10(2)3-4-11-7-12(5-6-14(11)22)20-19(25)18(24)17-15(23)8-13(21)9-16(17)26-20/h3,5-9,21-23,25H,4H2,1-2H3
DMYEGBC	CS	CC(=CCC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)C
DMYEGBC	IK	PGCKDCPTJAQQSQ-UHFFFAOYSA-N
DMYEGBC	IU	3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one
DMYEGBC	CA	CAS 94805-83-1
DMYEGBC	DE	Discovery agent

DMXWOBE	ID	DMXWOBE
DMXWOBE	DN	ISOLONGIFOLOL
DMXWOBE	HS	Investigative
DMXWOBE	SN	Longifolol; CHEMBL388140; ISOLONGIFOLOL; 469-27-2; ZINC28645580; BDBM50211775
DMXWOBE	DT	Small molecular drug
DMXWOBE	PC	12311096
DMXWOBE	MW	222.37
DMXWOBE	FM	C15H26O
DMXWOBE	IC	InChI=1S/C15H26O/c1-14(2)7-4-8-15(3)11-6-5-10(13(11)14)12(15)9-16/h10-13,16H,4-9H2,1-3H3/t10-,11-,12+,13+,15+/m1/s1
DMXWOBE	CS	C[C@]12CCCC([C@@H]3[C@H]1CC[C@@H]3[C@@H]2CO)(C)C
DMXWOBE	IK	VZJHQHUOVIDRCF-BIGJJFBESA-N
DMXWOBE	IU	[(1R,2S,7S,8S,9S)-3,3,7-trimethyl-8-tricyclo[5.4.0.02,9]undecanyl]methanol
DMXWOBE	CA	CAS 1139-17-9
DMXWOBE	DE	Discovery agent

DMH1BN4	ID	DMH1BN4
DMH1BN4	DN	ISOLOXAPINE
DMH1BN4	HS	Investigative
DMH1BN4	SN	ISOLOXAPINE; CHEMBL7828; 8-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine; SCHEMBL2738975; AWHNHDGHHNGACT-UHFFFAOYSA-N; BDBM50028980; LS-61561; 8-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 3-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
DMH1BN4	DT	Small molecular drug
DMH1BN4	PC	10381810
DMH1BN4	MW	327.8
DMH1BN4	FM	C18H18ClN3O
DMH1BN4	IC	InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-4-2-3-5-16(14)23-17-7-6-13(19)12-15(17)20-18/h2-7,12H,8-11H2,1H3
DMH1BN4	CS	CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)OC4=CC=CC=C42
DMH1BN4	IK	AWHNHDGHHNGACT-UHFFFAOYSA-N
DMH1BN4	IU	3-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
DMH1BN4	DE	Discovery agent

DMD1KSW	ID	DMD1KSW
DMD1KSW	DN	Isomaltose
DMD1KSW	HS	Investigative
DMD1KSW	SN	Brachiose; DLRVVLDZNNYCBX-RTPHMHGBSA-N; ISOMALTOSE; Isomalto-oligosaccharide; Isomaltose, ~98% (TLC); SCHEMBL1782423; 499-40-1; 6-O-alpha-D-glucopyranosyl-D-glucopyranose; 6024AF; AKOS026749917; CHEBI:28189; CHEMBL66675; HMS2236B05; I0231; MFCD00065373; MLS001333223; MLS001333224; SMR000857202; alpha-1,6-Glucobiose; alpha-D-Glc-(1-&gt;6)-D-Glc; alpha-D-Glcp-(1-&gt;6)-D-Glcp; alpha-D-Glcp-(1-6)-D-Glcp; alpha-D-glucopyranosyl-(1-6)-D-glucopyranose; alpha-D-glucosyl-(1-&gt;6)-D-glucose
DMD1KSW	PC	439193
DMD1KSW	MW	342.3
DMD1KSW	FM	C12H22O11
DMD1KSW	IC	DLRVVLDZNNYCBX-RTPHMHGBSA-N
DMD1KSW	CS	C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)O)O)O)O)O)O)O)O
DMD1KSW	IK	1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9-,10-,11?,12+/m1/s1
DMD1KSW	IU	(3R,4S,5S,6R)-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
DMD1KSW	CA	CAS 499-40-1
DMD1KSW	CB	CHEBI:28189
DMD1KSW	DE	Discovery agent

DMOJ52F	ID	DMOJ52F
DMOJ52F	DN	ISOMER A
DMOJ52F	HS	Investigative
DMOJ52F	DE	Discovery agent

DM69XT3	ID	DM69XT3
DM69XT3	DN	ISONEORAUTENOL
DM69XT3	HS	Investigative
DM69XT3	SN	Isoneorautenol; 6H,10H-Furo[3,2-c:4,5-g']bis[1]benzopyran-3-ol, 6a,13a-dihydro-10,10-dimethyl-; 98755-24-9; 3-Hydroxy-6'',6''-dimethylpyrano[2'',3'':9,8]pterocarpan; (-)-Isoneorautenol; 6H,10H-Furo(3,2-c:4,5-g')bis(1)benzopyran-3-ol, 6a,13a-dihydro-10,10-dimethyl-; AC1L2K8A; AC1Q70ZR; CTK5I0056
DM69XT3	DT	Small molecular drug
DM69XT3	PC	73649
DM69XT3	MW	322.4
DM69XT3	FM	C20H18O4
DM69XT3	IC	InChI=1S/C20H18O4/c1-20(2)6-5-11-7-14-15-10-22-17-8-12(21)3-4-13(17)19(15)23-18(14)9-16(11)24-20/h3-9,15,19,21H,10H2,1-2H3
DM69XT3	CS	CC1(C=CC2=CC3=C(C=C2O1)OC4C3COC5=C4C=CC(=C5)O)C
DM69XT3	IK	WTKJOOHYNMPGLE-UHFFFAOYSA-N
DM69XT3	IU	7,7-dimethyl-8,12,20-trioxapentacyclo[11.8.0.02,11.04,9.014,19]henicosa-2(11),3,5,9,14(19),15,17-heptaen-17-ol
DM69XT3	CA	CAS 98755-24-9
DM69XT3	DE	Discovery agent

DMUVAIF	ID	DMUVAIF
DMUVAIF	DN	ISONICOTINIC ACID
DMUVAIF	HS	Investigative
DMUVAIF	SN	ISONICOTINIC ACID; 55-22-1; Pyridine-4-carboxylic acid; 4-Pyridinecarboxylic acid; 4-Picolinic acid; 4-Carboxypyridine; p-Pyridinecarboxylic acid; gamma-Picolinic acid; gamma-Pyridinecarboxylic acid; Acide iso-nicotinique; 1,4-Dihydroisonicotinic acid; Acide iso-nicotinique [French]; UNII-Y8SYN761TQ; AI3-19239; .gamma.-Picolinic acid; NSC 1483; Isonicotinic acid, 99%; EINECS 200-228-2; Y8SYN761TQ; CHEBI:6032; TWBYWOBDOCUKOW-UHFFFAOYSA-N; MFCD00006429; g-picolinic acid; Isonicotinic Acids; isonicotinicacid; isonicotonic acid; MN1
DMUVAIF	DT	Small molecular drug
DMUVAIF	PC	5922
DMUVAIF	MW	123.11
DMUVAIF	FM	C6H5NO2
DMUVAIF	IC	InChI=1S/C6H5NO2/c8-6(9)5-1-3-7-4-2-5/h1-4H,(H,8,9)
DMUVAIF	CS	C1=CN=CC=C1C(=O)O
DMUVAIF	IK	TWBYWOBDOCUKOW-UHFFFAOYSA-N
DMUVAIF	IU	pyridine-4-carboxylic acid
DMUVAIF	CA	CAS 55-22-1
DMUVAIF	CB	CHEBI:6032
DMUVAIF	DE	Discovery agent

DM5DKUY	ID	DM5DKUY
DM5DKUY	DN	ISONIPECOTAMIDE
DM5DKUY	HS	Investigative
DM5DKUY	SN	Piperidine-4-carboxamide; Isonipecotamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide
DM5DKUY	DT	Small molecular drug
DM5DKUY	PC	3772
DM5DKUY	MW	128.169
DM5DKUY	FM	C6H12N2O
DM5DKUY	IC	InChI=1S/C6H12N2O/c7-6(9)5-1-3-8-4-2-5/h5,8H,1-4H2,(H2,7,9)
DM5DKUY	CS	C1CNCCC1C(=O)N
DM5DKUY	IK	DPBWFNDFMCCGGJ-UHFFFAOYSA-N
DM5DKUY	IU	piperidine-4-carboxamide
DM5DKUY	CA	CAS 39546-32-2
DM5DKUY	CB	CHEBI:166563
DM5DKUY	DE	Discovery agent

DMO1ZHE	ID	DMO1ZHE
DMO1ZHE	DN	Isonipecotic acid
DMO1ZHE	HS	Investigative
DMO1ZHE	SN	Isonipecotic acid; Piperidine-4-carboxylic acid; 498-94-2; 4-Piperidinecarboxylic acid; 4-Carboxypiperidine; Hexahydroisonicotinic acid; h-inp-oh; dl-isopipecolinic acid; Isonicotinic acid, hexahydro-; Acide isonipecotique; 4-Hexahydroisonicotinic acid; NSC 61049; UNII-M5TZP1RWIE; iso-nipecotic acid; Acide isonipecotique [French]; Acide piperidine-carboxylique-4; M5TZP1RWIE; EINECS 207-872-3; BRN 0112553; 4-Piperidine carboxylic acid; Acide piperidine-carboxylique-4 [French]; CHEMBL279998; SRJOCJYGOFTFLH-UHFFFAOYSA-N
DMO1ZHE	DT	Small molecular drug
DMO1ZHE	PC	3773
DMO1ZHE	MW	129.16
DMO1ZHE	FM	C6H11NO2
DMO1ZHE	IC	InChI=1S/C6H11NO2/c8-6(9)5-1-3-7-4-2-5/h5,7H,1-4H2,(H,8,9)
DMO1ZHE	CS	C1CNCCC1C(=O)O
DMO1ZHE	IK	SRJOCJYGOFTFLH-UHFFFAOYSA-N
DMO1ZHE	IU	piperidine-4-carboxylic acid
DMO1ZHE	CA	CAS 498-94-2
DMO1ZHE	DE	Discovery agent

DMFX16H	ID	DMFX16H
DMFX16H	DN	Iso-OMPA
DMFX16H	HS	Investigative
DMFX16H	SN	iso-OMPA; tetraisopropyl pyrophosphoramide; 513-00-8; TETRAISOPROPYLPYROPHOSPHAMIDE; Diphosphoramide, N,N',N'',N'''-tetrakis(1-methylethyl)-; Tetraisopropylpyrophosphoramide; MLS002153308; CHEMBL494887; EINECS 208-149-5; Tetra(monoisopropyl)pyrophosphortetramide; N,N',N'',N'''-Tetraisopropyldiphosphoramide; n,n'-diisopropylphosphorodiamidic anhydride; AC1L1KBH; Lopac-T-1505; Lopac0_001184; Tetraisoproryl Pyrophosphoramide; AC1Q6T49; SCHEMBL6263949; Tetraisopropyl pyrophos-phoramide; IOIMDJXKIMCMIG-UHFFFAOYSA-; BDBM10625
DMFX16H	DT	Small molecular drug
DMFX16H	PC	5420
DMFX16H	MW	342.36
DMFX16H	FM	C12H32N4O3P2
DMFX16H	IC	InChI=1S/C12H32N4O3P2/c1-9(2)13-20(17,14-10(3)4)19-21(18,15-11(5)6)16-12(7)8/h9-12H,1-8H3,(H2,13,14,17)(H2,15,16,18)
DMFX16H	CS	CC(C)NP(=O)(NC(C)C)OP(=O)(NC(C)C)NC(C)C
DMFX16H	IK	IOIMDJXKIMCMIG-UHFFFAOYSA-N
DMFX16H	IU	N-[bis(propan-2-ylamino)phosphoryloxy-(propan-2-ylamino)phosphoryl]propan-2-amine
DMFX16H	CA	CAS 513-00-8
DMFX16H	DE	Discovery agent

DMTU05Y	ID	DMTU05Y
DMTU05Y	DN	ISOPENTENYL PYROPHOSPHATE
DMTU05Y	HS	Investigative
DMTU05Y	SN	isopentenyl pyrophosphate; isopentenyl diphosphate; 3-Methyl-3-butenyl pyrophosphate; IPPP; Mono(3-methyl-3-butenyl) diphosphate; delta3-Isopentenyl diphosphate; isopentenyl-pp; Diphosphoric acid mono(3-methyl-3-butenyl) ester; delta-3-Isopentenyl pyrophosphat; Isopentenyl-diphosphate; CHEBI:16584; delta3-methyl-3-butenyl diphosphate; 3-methylbut-3-enyl phosphono hydrogen phosphate; 358-71-4; delta-3-Isopentenyl pyrophosphate; 3-methylbut-3-en-1-yl trihydrogen diphosphate; 3-METHYLBUT-3-ENYL TRIHYDROGEN DIPHOSPHATE
DMTU05Y	DT	Small molecular drug
DMTU05Y	PC	1195
DMTU05Y	MW	246.09
DMTU05Y	FM	C5H12O7P2
DMTU05Y	IC	InChI=1S/C5H12O7P2/c1-5(2)3-4-11-14(9,10)12-13(6,7)8/h1,3-4H2,2H3,(H,9,10)(H2,6,7,8)
DMTU05Y	CS	CC(=C)CCOP(=O)(O)OP(=O)(O)O
DMTU05Y	IK	NUHSROFQTUXZQQ-UHFFFAOYSA-N
DMTU05Y	IU	3-methylbut-3-enyl phosphono hydrogen phosphate
DMTU05Y	CA	CAS 358-71-4
DMTU05Y	CB	CHEBI:16584
DMTU05Y	DE	Discovery agent

DM9J5IS	ID	DM9J5IS
DM9J5IS	DN	Isopentyl Pyrophosphate
DM9J5IS	HS	Investigative
DM9J5IS	SN	ISOPENTYL PYROPHOSPHATE; AC1L9LX1; SCHEMBL155704; IPFXNYPSBSIFOB-UHFFFAOYSA-N; ZINC2579357; 3-methylbutyl trihydrogen diphosphate; DB02508; Diphosphoric acid alpha-isopentyl ester; 3-methylbutyl phosphono hydrogen phosphate; Diphosphoric acid, P,P-bis(3-methylbutyl) ester
DM9J5IS	DT	Small molecular drug
DM9J5IS	PC	448400
DM9J5IS	MW	248.11
DM9J5IS	FM	C5H14O7P2
DM9J5IS	IC	InChI=1S/C5H14O7P2/c1-5(2)3-4-11-14(9,10)12-13(6,7)8/h5H,3-4H2,1-2H3,(H,9,10)(H2,6,7,8)
DM9J5IS	CS	CC(C)CCOP(=O)(O)OP(=O)(O)O
DM9J5IS	IK	IPFXNYPSBSIFOB-UHFFFAOYSA-N
DM9J5IS	IU	3-methylbutyl phosphono hydrogen phosphate
DM9J5IS	DE	Discovery agent

DM9ERD6	ID	DM9ERD6
DM9ERD6	DN	ISOPILINE
DM9ERD6	HS	Investigative
DM9ERD6	SN	Isopiline; CHEMBL508011; BDBM50292445
DM9ERD6	DT	Small molecular drug
DM9ERD6	PC	13891896
DM9ERD6	MW	297.3
DM9ERD6	FM	C18H19NO3
DM9ERD6	IC	InChI=1S/C18H19NO3/c1-21-17-12-7-8-19-13-9-10-5-3-4-6-11(10)15(14(12)13)16(20)18(17)22-2/h3-6,13,19-20H,7-9H2,1-2H3/t13-/m1/s1
DM9ERD6	CS	COC1=C(C(=C2C3=CC=CC=C3C[C@@H]4C2=C1CCN4)O)OC
DM9ERD6	IK	XLXSXOHBVGWKMT-CYBMUJFWSA-N
DM9ERD6	IU	(6aR)-2,3-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-1-ol
DM9ERD6	DE	Discovery agent

DMWI0M8	ID	DMWI0M8
DMWI0M8	DN	ISOPPADS
DMWI0M8	HS	Investigative
DMWI0M8	DT	Small molecular drug
DMWI0M8	PC	3978952
DMWI0M8	MW	511.4
DMWI0M8	FM	C14H14N3O12PS2
DMWI0M8	IC	InChI=1S/C14H14N3O12PS2/c1-7-13(19)9(5-18)10(6-29-30(20,21)22)14(15-7)17-16-11-4-8(31(23,24)25)2-3-12(11)32(26,27)28/h2-5,19H,6H2,1H3,(H2,20,21,22)(H,23,24,25)(H,26,27,28)
DMWI0M8	CS	CC1=C(C(=C(C(=N1)N=NC2=C(C=CC(=C2)S(=O)(=O)O)S(=O)(=O)O)COP(=O)(O)O)C=O)O
DMWI0M8	IK	XYBQYEJAMIDMPT-UHFFFAOYSA-N
DMWI0M8	IU	2-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonooxymethyl)pyridin-2-yl]diazenyl]benzene-1,4-disulfonic acid
DMWI0M8	DE	Discovery agent

DMH67J2	ID	DMH67J2
DMH67J2	DN	Isopropyl 10H-phenothiazine-10-carboxylate
DMH67J2	HS	Investigative
DMH67J2	SN	CHEMBL450026; isopropyl 10H-phenothiazine-10-carboxylate
DMH67J2	DT	Small molecular drug
DMH67J2	PC	44568318
DMH67J2	MW	285.4
DMH67J2	FM	C16H15NO2S
DMH67J2	IC	InChI=1S/C16H15NO2S/c1-11(2)19-16(18)17-12-7-3-5-9-14(12)20-15-10-6-4-8-13(15)17/h3-11H,1-2H3
DMH67J2	CS	CC(C)OC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMH67J2	IK	FFXIYTTZCCARMF-UHFFFAOYSA-N
DMH67J2	IU	propan-2-yl phenothiazine-10-carboxylate
DMH67J2	DE	Discovery agent

DMS8MBI	ID	DMS8MBI
DMS8MBI	DN	Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate
DMS8MBI	HS	Investigative
DMS8MBI	SN	SCHEMBL5812186
DMS8MBI	DT	Small molecular drug
DMS8MBI	PC	11630982
DMS8MBI	MW	311.4
DMS8MBI	FM	C18H17NO2S
DMS8MBI	IC	InChI=1S/C18H17NO2S/c1-12(2)21-18(20)16-17(22-13-8-4-3-5-9-13)14-10-6-7-11-15(14)19-16/h3-12,19H,1-2H3
DMS8MBI	CS	CC(C)OC(=O)C1=C(C2=CC=CC=C2N1)SC3=CC=CC=C3
DMS8MBI	IK	CIEJDDRWESEPGF-UHFFFAOYSA-N
DMS8MBI	IU	propan-2-yl 3-phenylsulfanyl-1H-indole-2-carboxylate
DMS8MBI	DE	Discovery agent

DM2VJF4	ID	DM2VJF4
DM2VJF4	DN	Isopropyl 4-nitrophenyl dodecylphosphonate
DM2VJF4	HS	Investigative
DM2VJF4	SN	isopropyl 4-nitrophenyl dodecylphosphonate; CHEMBL512224
DM2VJF4	DT	Small molecular drug
DM2VJF4	PC	44563663
DM2VJF4	MW	413.5
DM2VJF4	FM	C21H36NO5P
DM2VJF4	IC	InChI=1S/C21H36NO5P/c1-4-5-6-7-8-9-10-11-12-13-18-28(25,26-19(2)3)27-21-16-14-20(15-17-21)22(23)24/h14-17,19H,4-13,18H2,1-3H3
DM2VJF4	CS	CCCCCCCCCCCCP(=O)(OC1=CC=C(C=C1)[N+](=O)[O-])OC(C)C
DM2VJF4	IK	VZXZHBVWVCMVBS-UHFFFAOYSA-N
DM2VJF4	IU	1-[dodecyl(propan-2-yloxy)phosphoryl]oxy-4-nitrobenzene
DM2VJF4	DE	Discovery agent

DML54EA	ID	DML54EA
DML54EA	DN	Isopropyl dodecylfluorophosphonate
DML54EA	HS	Investigative
DML54EA	SN	IDFP; Isopropyl dodecylfluorophosphonate; 615250-02-7; CHEMBL333149; Isopropyl Dodecylphosphonofluoridate; isopropyl dodecylphosphonofluoridoate; C15H32FO2P; SCHEMBL6115190; CTK8E7841; DTXSID00647212; MolPort-006-822-693; HMS3648I13; BDBM50132717; 1797AH; Propan-2-yl dodecylphosphonofluoridate; RT-013317; LS-192335; Dodecyl(fluoro)phosphinic acid isopropyl ester; SR-01000946223
DML54EA	DT	Small molecular drug
DML54EA	PC	24762154
DML54EA	MW	294.39
DML54EA	FM	C15H32FO2P
DML54EA	IC	InChI=1S/C15H32FO2P/c1-4-5-6-7-8-9-10-11-12-13-14-19(16,17)18-15(2)3/h15H,4-14H2,1-3H3
DML54EA	CS	CCCCCCCCCCCCP(=O)(OC(C)C)F
DML54EA	IK	SFRALHFBKRAJPW-UHFFFAOYSA-N
DML54EA	IU	1-[fluoro(propan-2-yloxy)phosphoryl]dodecane
DML54EA	CA	CAS 615250-02-7
DML54EA	DE	Discovery agent

DMBR8P1	ID	DMBR8P1
DMBR8P1	DN	Isopropylcarbamic Acid Biphenyl-3-yl Ester
DMBR8P1	HS	Investigative
DMBR8P1	SN	Isopropylcarbamic Acid Biphenyl-3-yl Ester; CHEMBL486494; SCHEMBL12132464
DMBR8P1	DT	Small molecular drug
DMBR8P1	PC	11673293
DMBR8P1	MW	255.31
DMBR8P1	FM	C16H17NO2
DMBR8P1	IC	InChI=1S/C16H17NO2/c1-12(2)17-16(18)19-15-10-6-9-14(11-15)13-7-4-3-5-8-13/h3-12H,1-2H3,(H,17,18)
DMBR8P1	CS	CC(C)NC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DMBR8P1	IK	AOMCLMJYDMDVOF-UHFFFAOYSA-N
DMBR8P1	IU	(3-phenylphenyl) N-propan-2-ylcarbamate
DMBR8P1	DE	Discovery agent

DM92F6Z	ID	DM92F6Z
DM92F6Z	DN	Isopropyl-methyl-prop-2-ynyl-amine hydrochloride
DM92F6Z	HS	Investigative
DM92F6Z	DE	Discovery agent

DMPYAMU	ID	DMPYAMU
DMPYAMU	DN	isopulegol
DMPYAMU	HS	Investigative
DMPYAMU	SN	coolact P
DMPYAMU	DT	Small molecular drug
DMPYAMU	PC	170833
DMPYAMU	MW	154.25
DMPYAMU	FM	C10H18O
DMPYAMU	IC	InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)6-10(9)11/h8-11H,1,4-6H2,2-3H3/t8-,9+,10-/m1/s1
DMPYAMU	CS	C[C@@H]1CC[C@H]([C@@H](C1)O)C(=C)C
DMPYAMU	IK	ZYTMANIQRDEHIO-KXUCPTDWSA-N
DMPYAMU	IU	(1R,2S,5R)-5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol
DMPYAMU	CA	CAS 89-79-2
DMPYAMU	CB	CHEBI:70479
DMPYAMU	DE	Discovery agent

DMDF26N	ID	DMDF26N
DMDF26N	DN	Isoquinolin-1-yl-(3-phenyl-propyl)-amine
DMDF26N	HS	Investigative
DMDF26N	SN	CHEMBL289792; Isoquinolin-1-yl-(3-phenyl-propyl)-amine; BDBM50282107
DMDF26N	DT	Small molecular drug
DMDF26N	PC	44288035
DMDF26N	MW	262.3
DMDF26N	FM	C18H18N2
DMDF26N	IC	InChI=1S/C18H18N2/c1-2-7-15(8-3-1)9-6-13-19-18-17-11-5-4-10-16(17)12-14-20-18/h1-5,7-8,10-12,14H,6,9,13H2,(H,19,20)
DMDF26N	CS	C1=CC=C(C=C1)CCCNC2=NC=CC3=CC=CC=C32
DMDF26N	IK	ZRAIUMVYTFUMKD-UHFFFAOYSA-N
DMDF26N	IU	N-(3-phenylpropyl)isoquinolin-1-amine
DMDF26N	DE	Discovery agent

DMT4RI2	ID	DMT4RI2
DMT4RI2	DN	Isoquinoline-1,3,4(2H)-trione
DMT4RI2	HS	Investigative
DMT4RI2	SN	Phthalonimide; 1,3,4(2H)-Isoquinolinetrione; isoquinoline-1,3,4(2H)-trione; 521-73-3; isoquinoline-1,3,4-trione; 1,3,4-(2H)ISOQUINOLINETRIONE; UNII-BM68CV5X6Q; NSC 407248; BRN 0383773; BM68CV5X6Q; 1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; isoquinoline-1,3,4-(2H)-trione; 3deh; NSC407248; AC1L1VMV; 5-21-11-00575 (Beilstein Handbook Reference); 1,4(2H)-Isoquinolinetrione; SCHEMBL1122624; Isoquinoline-1,3,4-trione 1; CHEMBL206435; CTK1H0848; BDBM10247; DTXSID40200103; ZINC1599708; FCH844329; ACM521733; AKOS006276226; NSC-407248
DMT4RI2	DT	Small molecular drug
DMT4RI2	PC	10640
DMT4RI2	MW	175.14
DMT4RI2	FM	C9H5NO3
DMT4RI2	IC	InChI=1S/C9H5NO3/c11-7-5-3-1-2-4-6(5)8(12)10-9(7)13/h1-4H,(H,10,12,13)
DMT4RI2	CS	C1=CC=C2C(=C1)C(=O)C(=O)NC2=O
DMT4RI2	IK	YIOFGHHAURBGSJ-UHFFFAOYSA-N
DMT4RI2	IU	isoquinoline-1,3,4-trione
DMT4RI2	CA	CAS 521-73-3
DMT4RI2	DE	Discovery agent

DMWIMUZ	ID	DMWIMUZ
DMWIMUZ	DN	Isoquinoline-3-carboxylic acid methyl ester
DMWIMUZ	HS	Investigative
DMWIMUZ	SN	methyl isoquinoline-3-carboxylate; 27104-73-0; Methyl 3-isoquinolinecarboxylate; Isoquinoline-3-carboxylic acid methyl ester; 3-Isoquinolinecarboxylic acid, methyl ester; MFCD00075138; PubChem16888; AC1LDU8C; AC1Q5ZLC; Maybridge1_001945; ACMC-1CRQ5; KSC497K1B; SCHEMBL214090; CHEMBL416152; 3-(Methoxycarbonyl)isoquinoline; Methylisoquinoline-3-carboxylate; KS-00000GIP; HMS547A09; CTK3J7510; DTXSID10352385; MolPort-000-141-870; ZBCGBIZQNMVMPC-UHFFFAOYSA-N; methyl isoquinoline-3-carbo-xylate; ZINC132552; BCP05782; ANW-48722; RW2951
DMWIMUZ	DT	Small molecular drug
DMWIMUZ	PC	725374
DMWIMUZ	MW	187.19
DMWIMUZ	FM	C11H9NO2
DMWIMUZ	IC	InChI=1S/C11H9NO2/c1-14-11(13)10-6-8-4-2-3-5-9(8)7-12-10/h2-7H,1H3
DMWIMUZ	CS	COC(=O)C1=CC2=CC=CC=C2C=N1
DMWIMUZ	IK	ZBCGBIZQNMVMPC-UHFFFAOYSA-N
DMWIMUZ	IU	methyl isoquinoline-3-carboxylate
DMWIMUZ	CA	CAS 27104-73-0
DMWIMUZ	DE	Discovery agent

DMQ4Z6E	ID	DMQ4Z6E
DMQ4Z6E	DN	ISORHAMNETIN
DMQ4Z6E	HS	Investigative
DMQ4Z6E	SN	Isorhamnetin; 480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z
DMQ4Z6E	DT	Small molecular drug
DMQ4Z6E	PC	5281654
DMQ4Z6E	MW	316.26
DMQ4Z6E	FM	C16H12O7
DMQ4Z6E	IC	InChI=1S/C16H12O7/c1-22-11-4-7(2-3-9(11)18)16-15(21)14(20)13-10(19)5-8(17)6-12(13)23-16/h2-6,17-19,21H,1H3
DMQ4Z6E	CS	COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMQ4Z6E	IK	IZQSVPBOUDKVDZ-UHFFFAOYSA-N
DMQ4Z6E	IU	3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one
DMQ4Z6E	CA	CAS 480-19-3
DMQ4Z6E	CB	CHEBI:6052
DMQ4Z6E	DE	Discovery agent

DMFKQ0B	ID	DMFKQ0B
DMFKQ0B	DN	Isorhamnetin 3,7-disulfate
DMFKQ0B	HS	Investigative
DMFKQ0B	SN	Isorhamnetin 3,7-disulfate
DMFKQ0B	DT	Small molecular drug
DMFKQ0B	PC	15290611
DMFKQ0B	MW	552.6
DMFKQ0B	FM	C16H10K2O13S2
DMFKQ0B	IC	InChI=1S/C16H12O13S2.2K/c1-26-11-4-7(2-3-9(11)17)15-16(29-31(23,24)25)14(19)13-10(18)5-8(6-12(13)27-15)28-30(20,21)22;;/h2-6,17-18H,1H3,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2
DMFKQ0B	CS	COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)OS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O.[K+].[K+]
DMFKQ0B	IK	JILXHFDBMPFPLQ-UHFFFAOYSA-L
DMFKQ0B	IU	dipotassium;[5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-oxo-3-sulfonatooxychromen-7-yl] sulfate
DMFKQ0B	DE	Discovery agent

DMZQUY4	ID	DMZQUY4
DMZQUY4	DN	Isorhamnetin 3-O-rhamnoside
DMZQUY4	HS	Investigative
DMZQUY4	SN	isorhamnetin 3-O-rhamnoside; CHEMBL485261; BDBM50260170
DMZQUY4	DT	Small molecular drug
DMZQUY4	PC	23634491
DMZQUY4	MW	462.4
DMZQUY4	FM	C22H22O11
DMZQUY4	IC	InChI=1S/C22H22O11/c1-8-16(26)18(28)19(29)22(31-8)33-21-17(27)15-12(25)6-10(23)7-14(15)32-20(21)9-3-4-11(24)13(5-9)30-2/h3-8,16,18-19,22-26,28-29H,1-2H3/t8-,16-,18+,19+,22-/m0/s1
DMZQUY4	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)OC)O)O)O
DMZQUY4	IK	UXXAEVMOIUAYQT-UFGFRKJLSA-N
DMZQUY4	IU	5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DMZQUY4	DE	Discovery agent

DMJS7MV	ID	DMJS7MV
DMJS7MV	DN	ISOSAKUTANETIN
DMJS7MV	HS	Investigative
DMJS7MV	SN	Isosakuranetin; 480-43-3; 4'-Methylnaringenin; Isosakutanetin; UNII-U02X7TF8UA; naringenin 4'-methyl ether; U02X7TF8UA; CHEMBL470266; CHEBI:27552; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Citrifoliol; (S)-5,7-dihydroxy-2-(4-methoxyphenyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-, (2S)-; 4'-Methoxy-5,7-dihydroxyflavonone
DMJS7MV	DT	Small molecular drug
DMJS7MV	PC	160481
DMJS7MV	MW	286.28
DMJS7MV	FM	C16H14O5
DMJS7MV	IC	InChI=1S/C16H14O5/c1-20-11-4-2-9(3-5-11)14-8-13(19)16-12(18)6-10(17)7-15(16)21-14/h2-7,14,17-18H,8H2,1H3/t14-/m0/s1
DMJS7MV	CS	COC1=CC=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O
DMJS7MV	IK	HMUJXQRRKBLVOO-AWEZNQCLSA-N
DMJS7MV	IU	(2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMJS7MV	CA	CAS 480-43-3
DMJS7MV	CB	CHEBI:27552
DMJS7MV	DE	Discovery agent

DMNM2SQ	ID	DMNM2SQ
DMNM2SQ	DN	ISOSCOPOLETIN
DMNM2SQ	HS	Investigative
DMNM2SQ	SN	Isoscopoletin; 776-86-3; 6-Hydroxy-7-methoxycoumarin; 6-hydroxy-7-methoxy-2H-chromen-2-one; 7-Methoxyesculetin; Isoscopoletine; 6-hydroxy-7-methoxychromen-2-one; 2H-1-Benzopyran-2-one, 6-hydroxy-7-methoxy-; 6-hydroxy-7-methoxy-chromen-2-one; CHEMBL390320; CHEBI:81484; iso-scopoletin; 6-Hydroxy-7-methoxy-2-benzopyrone; EINECS 212-282-4; AC1L2CWN; Esculetin 7-methyl ether; Esculetin, 7-methyl ether; AC1Q4EZ0; 6-Hydroxy-7-methylcoumarin; SCHEMBL2790887; AC1Q69W0; CTK7A0381; DTXSID40228266; MolPort-003-927-047
DMNM2SQ	DT	Small molecular drug
DMNM2SQ	PC	69894
DMNM2SQ	MW	192.17
DMNM2SQ	FM	C10H8O4
DMNM2SQ	IC	InChI=1S/C10H8O4/c1-13-9-5-8-6(4-7(9)11)2-3-10(12)14-8/h2-5,11H,1H3
DMNM2SQ	CS	COC1=C(C=C2C=CC(=O)OC2=C1)O
DMNM2SQ	IK	SYTYLPHCLSSCOJ-UHFFFAOYSA-N
DMNM2SQ	IU	6-hydroxy-7-methoxychromen-2-one
DMNM2SQ	CA	CAS 776-86-3
DMNM2SQ	CB	CHEBI:81484
DMNM2SQ	DE	Discovery agent

DMTRCSV	ID	DMTRCSV
DMTRCSV	DN	Isosorbide-2-(benzylcarbamate)-5-benzoate
DMTRCSV	HS	Investigative
DMTRCSV	SN	CHEMBL523830; Isosorbide-2-(benzylcarbamate)-5-benzoate; BDBM50253231; (3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)hexahydrofuro[3,2-b]furan-3-yl benzoate
DMTRCSV	DT	Small molecular drug
DMTRCSV	PC	25129141
DMTRCSV	MW	383.4
DMTRCSV	FM	C21H21NO6
DMTRCSV	IC	InChI=1S/C21H21NO6/c23-20(15-9-5-2-6-10-15)27-16-12-25-19-17(13-26-18(16)19)28-21(24)22-11-14-7-3-1-4-8-14/h1-10,16-19H,11-13H2,(H,22,24)/t16-,17+,18-,19-/m1/s1
DMTRCSV	CS	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)OC(=O)C4=CC=CC=C4
DMTRCSV	IK	NIWDLVRLOCHGOV-FCGDIQPGSA-N
DMTRCSV	IU	[(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] benzoate
DMTRCSV	DE	Discovery agent

DMG0TW2	ID	DMG0TW2
DMG0TW2	DN	Isosorbide-2-(benzylcarbamate)-5-mononitrate
DMG0TW2	HS	Investigative
DMG0TW2	SN	CHEMBL445695; Isosorbide-2-(benzylcarbamate)-5-mononitrate
DMG0TW2	DT	Small molecular drug
DMG0TW2	PC	11573367
DMG0TW2	MW	324.29
DMG0TW2	FM	C14H16N2O7
DMG0TW2	IC	InChI=1S/C14H16N2O7/c17-14(15-6-9-4-2-1-3-5-9)22-10-7-20-13-11(23-16(18)19)8-21-12(10)13/h1-5,10-13H,6-8H2,(H,15,17)/t10-,11+,12+,13+/m0/s1
DMG0TW2	CS	C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])OC(=O)NCC3=CC=CC=C3
DMG0TW2	IK	XCUJUZNXFHRMEC-UMSGYPCISA-N
DMG0TW2	IU	[(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-benzylcarbamate
DMG0TW2	DE	Discovery agent

DM1ZH2U	ID	DM1ZH2U
DM1ZH2U	DN	Isosorbide-2-(butylcarbamate)-5-benzoate
DM1ZH2U	HS	Investigative
DM1ZH2U	SN	CHEMBL494684; Isosorbide-2-(butylcarbamate)-5-benzoate
DM1ZH2U	DT	Small molecular drug
DM1ZH2U	PC	44568823
DM1ZH2U	MW	349.4
DM1ZH2U	FM	C18H23NO6
DM1ZH2U	IC	InChI=1S/C18H23NO6/c1-3-11(2)19-18(21)25-14-10-23-15-13(9-22-16(14)15)24-17(20)12-7-5-4-6-8-12/h4-8,11,13-16H,3,9-10H2,1-2H3,(H,19,21)/t11?,13-,14+,15-,16-/m1/s1
DM1ZH2U	CS	CCC(C)NC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2OC(=O)C3=CC=CC=C3
DM1ZH2U	IK	PEHJQBISUGKFJH-IXCHPVQKSA-N
DM1ZH2U	IU	[(3R,3aR,6S,6aR)-6-(butan-2-ylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] benzoate
DM1ZH2U	DE	Discovery agent

DMUDS12	ID	DMUDS12
DMUDS12	DN	Isosorbide-2-(butylcarbamate)-5-mononitrate
DMUDS12	HS	Investigative
DMUDS12	SN	Isosorbide-2-(butylcarbamate)-5-mononitrate; CHEMBL494520; BDBM50253227
DMUDS12	DT	Small molecular drug
DMUDS12	PC	25133941
DMUDS12	MW	290.27
DMUDS12	FM	C11H18N2O7
DMUDS12	IC	InChI=1S/C11H18N2O7/c1-2-3-4-12-11(14)19-7-5-17-10-8(20-13(15)16)6-18-9(7)10/h7-10H,2-6H2,1H3,(H,12,14)/t7-,8+,9+,10+/m0/s1
DMUDS12	CS	CCCCNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
DMUDS12	IK	ZRPGNSMQMBUVBC-SGIHWFKDSA-N
DMUDS12	IU	[(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-butylcarbamate
DMUDS12	DE	Discovery agent

DM4ZYRP	ID	DM4ZYRP
DM4ZYRP	DN	Isosorbide-2-(cyclohexylcarbamate)-5-mononitrate
DM4ZYRP	HS	Investigative
DM4ZYRP	SN	CHEMBL521852; Isosorbide-2-(cyclohexylcarbamate)-5-mononitrate
DM4ZYRP	DT	Small molecular drug
DM4ZYRP	PC	25133942
DM4ZYRP	MW	316.31
DM4ZYRP	FM	C13H20N2O7
DM4ZYRP	IC	InChI=1S/C13H20N2O7/c16-13(14-8-4-2-1-3-5-8)21-9-6-19-12-10(22-15(17)18)7-20-11(9)12/h8-12H,1-7H2,(H,14,16)/t9-,10+,11+,12+/m0/s1
DM4ZYRP	CS	C1CCC(CC1)NC(=O)O[C@H]2CO[C@H]3[C@@H]2OC[C@H]3O[N+](=O)[O-]
DM4ZYRP	IK	HHQBHYZANLCQHI-IRCOFANPSA-N
DM4ZYRP	IU	[(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-cyclohexylcarbamate
DM4ZYRP	DE	Discovery agent

DMMH70I	ID	DMMH70I
DMMH70I	DN	Isosorbide-2-(ethylcarbamate)-5-mononitrate
DMMH70I	HS	Investigative
DMMH70I	SN	CHEMBL494518; Isosorbide-2-(ethylcarbamate)-5-mononitrate
DMMH70I	DT	Small molecular drug
DMMH70I	PC	25133940
DMMH70I	MW	262.22
DMMH70I	FM	C9H14N2O7
DMMH70I	IC	InChI=1S/C9H14N2O7/c1-2-10-9(12)17-5-3-15-8-6(18-11(13)14)4-16-7(5)8/h5-8H,2-4H2,1H3,(H,10,12)/t5-,6+,7+,8+/m0/s1
DMMH70I	CS	CCNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
DMMH70I	IK	KSNZOFCCDYSKSB-LXGUWJNJSA-N
DMMH70I	IU	[(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-ethylcarbamate
DMMH70I	DE	Discovery agent

DMC7MLN	ID	DMC7MLN
DMC7MLN	DN	Isosorbide-2-(methylcarbamate)-5-benzoate
DMC7MLN	HS	Investigative
DMC7MLN	SN	CHEMBL523500; Isosorbide-2-(methylcarbamate)-5-benzoate
DMC7MLN	DT	Small molecular drug
DMC7MLN	PC	25129490
DMC7MLN	MW	307.3
DMC7MLN	FM	C15H17NO6
DMC7MLN	IC	InChI=1S/C15H17NO6/c1-16-15(18)22-11-8-20-12-10(7-19-13(11)12)21-14(17)9-5-3-2-4-6-9/h2-6,10-13H,7-8H2,1H3,(H,16,18)/t10-,11+,12-,13-/m1/s1
DMC7MLN	CS	CNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2OC(=O)C3=CC=CC=C3
DMC7MLN	IK	XVQSZSYQBPAKTI-YVECIDJPSA-N
DMC7MLN	IU	[(3R,3aR,6S,6aR)-6-(methylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] benzoate
DMC7MLN	DE	Discovery agent

DMEKMOF	ID	DMEKMOF
DMEKMOF	DN	Isosorbide-2-(methylcarbamate)-5-mononitrate
DMEKMOF	HS	Investigative
DMEKMOF	SN	CHEMBL492179; Isosorbide-2-(methylcarbamate)-5-mononitrate
DMEKMOF	DT	Small molecular drug
DMEKMOF	PC	25129843
DMEKMOF	MW	248.19
DMEKMOF	FM	C8H12N2O7
DMEKMOF	IC	InChI=1S/C8H12N2O7/c1-9-8(11)16-4-2-14-7-5(17-10(12)13)3-15-6(4)7/h4-7H,2-3H2,1H3,(H,9,11)/t4-,5+,6+,7+/m0/s1
DMEKMOF	CS	CNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
DMEKMOF	IK	DEDWFQACIHPQHF-BDVNFPICSA-N
DMEKMOF	IU	[(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-methylcarbamate
DMEKMOF	DE	Discovery agent

DMQAEZP	ID	DMQAEZP
DMQAEZP	DN	Isosorbide-2-(propylcarbamate)-5-mononitrate
DMQAEZP	HS	Investigative
DMQAEZP	SN	CHEMBL494519; Isosorbide-2-(propylcarbamate)-5-mononitrate
DMQAEZP	DT	Small molecular drug
DMQAEZP	PC	25129844
DMQAEZP	MW	276.24
DMQAEZP	FM	C10H16N2O7
DMQAEZP	IC	InChI=1S/C10H16N2O7/c1-2-3-11-10(13)18-6-4-16-9-7(19-12(14)15)5-17-8(6)9/h6-9H,2-5H2,1H3,(H,11,13)/t6-,7+,8+,9+/m0/s1
DMQAEZP	CS	CCCNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
DMQAEZP	IK	HZZGTUOWJWTZKT-JQCXWYLXSA-N
DMQAEZP	IU	[(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-propylcarbamate
DMQAEZP	DE	Discovery agent

DM6FVDO	ID	DM6FVDO
DM6FVDO	DN	Isosorbide-2-benzyl carbamate
DM6FVDO	HS	Investigative
DM6FVDO	SN	isosorbide-2-benzyl carbamate; Isosorbide-2-benzylcarbamate; CHEMBL524046
DM6FVDO	DT	Small molecular drug
DM6FVDO	PC	25129492
DM6FVDO	MW	279.29
DM6FVDO	FM	C14H17NO5
DM6FVDO	IC	InChI=1S/C14H17NO5/c16-10-7-18-13-11(8-19-12(10)13)20-14(17)15-6-9-4-2-1-3-5-9/h1-5,10-13,16H,6-8H2,(H,15,17)/t10-,11+,12-,13-/m1/s1
DM6FVDO	CS	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)O
DM6FVDO	IK	LYJZFQNPWOVWIJ-YVECIDJPSA-N
DM6FVDO	IU	[(3R,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] N-benzylcarbamate
DM6FVDO	DE	Discovery agent

DM5XEZI	ID	DM5XEZI
DM5XEZI	DN	Isosorbide-2-benzylcarbamate-5-(o-toluate)
DM5XEZI	HS	Investigative
DM5XEZI	SN	CHEMBL583687; Isosorbide-2-benzylcarbamate-5-(o-toluate)
DM5XEZI	DT	Small molecular drug
DM5XEZI	PC	45487256
DM5XEZI	MW	397.4
DM5XEZI	FM	C22H23NO6
DM5XEZI	IC	InChI=1S/C22H23NO6/c1-14-7-5-6-10-16(14)21(24)28-17-12-26-20-18(13-27-19(17)20)29-22(25)23-11-15-8-3-2-4-9-15/h2-10,17-20H,11-13H2,1H3,(H,23,25)/t17-,18+,19-,20-/m1/s1
DM5XEZI	CS	CC1=CC=CC=C1C(=O)O[C@@H]2CO[C@H]3[C@@H]2OC[C@@H]3OC(=O)NCC4=CC=CC=C4
DM5XEZI	IK	XMIPVPSZMVVUST-IYWMVGAKSA-N
DM5XEZI	IU	[(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] 2-methylbenzoate
DM5XEZI	DE	Discovery agent

DMD4WRH	ID	DMD4WRH
DMD4WRH	DN	Isosorbide-2-benzylcarbamate-5-acetate
DMD4WRH	HS	Investigative
DMD4WRH	SN	CHEMBL493460; Isosorbide-2-benzylcarbamate-5-acetate
DMD4WRH	DT	Small molecular drug
DMD4WRH	PC	25128786
DMD4WRH	MW	321.32
DMD4WRH	FM	C16H19NO6
DMD4WRH	IC	InChI=1S/C16H19NO6/c1-10(18)22-12-8-20-15-13(9-21-14(12)15)23-16(19)17-7-11-5-3-2-4-6-11/h2-6,12-15H,7-9H2,1H3,(H,17,19)/t12-,13+,14-,15-/m1/s1
DMD4WRH	CS	CC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCC3=CC=CC=C3
DMD4WRH	IK	RMUIRACCZOGQBC-LXTVHRRPSA-N
DMD4WRH	IU	[(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] acetate
DMD4WRH	DE	Discovery agent

DMWDQ90	ID	DMWDQ90
DMWDQ90	DN	Isosorbide-2-benzylcarbamate-5-cyclopentanoate
DMWDQ90	HS	Investigative
DMWDQ90	SN	CHEMBL492635; Isosorbide-2-benzylcarbamate-5-cyclopentanoate
DMWDQ90	DT	Small molecular drug
DMWDQ90	PC	25130201
DMWDQ90	MW	375.4
DMWDQ90	FM	C20H25NO6
DMWDQ90	IC	InChI=1S/C20H25NO6/c22-19(14-8-4-5-9-14)26-15-11-24-18-16(12-25-17(15)18)27-20(23)21-10-13-6-2-1-3-7-13/h1-3,6-7,14-18H,4-5,8-12H2,(H,21,23)/t15-,16+,17-,18-/m1/s1
DMWDQ90	CS	C1CCC(C1)C(=O)O[C@@H]2CO[C@H]3[C@@H]2OC[C@@H]3OC(=O)NCC4=CC=CC=C4
DMWDQ90	IK	UPLFPBDRBGHRQW-XMTFNYHQSA-N
DMWDQ90	IU	[(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] cyclopentanecarboxylate
DMWDQ90	DE	Discovery agent

DM8E2L6	ID	DM8E2L6
DM8E2L6	DN	Isosorbide-2-benzylcarbamate-5-cyclopropanoate
DM8E2L6	HS	Investigative
DM8E2L6	SN	CHEMBL492432; Isosorbide-2-benzylcarbamate-5-cyclopropanoate
DM8E2L6	DT	Small molecular drug
DM8E2L6	PC	25128788
DM8E2L6	MW	347.4
DM8E2L6	FM	C18H21NO6
DM8E2L6	IC	InChI=1S/C18H21NO6/c20-17(12-6-7-12)24-13-9-22-16-14(10-23-15(13)16)25-18(21)19-8-11-4-2-1-3-5-11/h1-5,12-16H,6-10H2,(H,19,21)/t13-,14+,15-,16-/m1/s1
DM8E2L6	CS	C1CC1C(=O)O[C@@H]2CO[C@H]3[C@@H]2OC[C@@H]3OC(=O)NCC4=CC=CC=C4
DM8E2L6	IK	FEYSXVBUKKSWGH-QKPAOTATSA-N
DM8E2L6	IU	[(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] cyclopropanecarboxylate
DM8E2L6	DE	Discovery agent

DMQ3Z17	ID	DMQ3Z17
DMQ3Z17	DN	Isosorbide-2-benzylcarbamate-5-isonicotinate
DMQ3Z17	HS	Investigative
DMQ3Z17	SN	CHEMBL492481; Isosorbide-2-benzylcarbamate-5-isonicotinate
DMQ3Z17	DT	Small molecular drug
DMQ3Z17	PC	25129143
DMQ3Z17	MW	384.4
DMQ3Z17	FM	C20H20N2O6
DMQ3Z17	IC	InChI=1S/C20H20N2O6/c23-19(14-6-8-21-9-7-14)27-15-11-25-18-16(12-26-17(15)18)28-20(24)22-10-13-4-2-1-3-5-13/h1-9,15-18H,10-12H2,(H,22,24)/t15-,16+,17-,18-/m1/s1
DMQ3Z17	CS	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)OC(=O)C4=CC=NC=C4
DMQ3Z17	IK	CPCJEEMJBNMGOE-XMTFNYHQSA-N
DMQ3Z17	IU	[(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] pyridine-4-carboxylate
DMQ3Z17	DE	Discovery agent

DMY49DN	ID	DMY49DN
DMY49DN	DN	Isosorbide-2-benzylcarbamate-5-nicotinate
DMY49DN	HS	Investigative
DMY49DN	SN	CHEMBL492283; Isosorbide-2-benzylcarbamate-5-nicotinate; BDBM50253230; (3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)hexahydrofuro[3,2-b]furan-3-yl nicotinate
DMY49DN	DT	Small molecular drug
DMY49DN	PC	25129142
DMY49DN	MW	384.4
DMY49DN	FM	C20H20N2O6
DMY49DN	IC	InChI=1S/C20H20N2O6/c23-19(14-7-4-8-21-10-14)27-15-11-25-18-16(12-26-17(15)18)28-20(24)22-9-13-5-2-1-3-6-13/h1-8,10,15-18H,9,11-12H2,(H,22,24)/t15-,16+,17-,18-/m1/s1
DMY49DN	CS	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)OC(=O)C4=CN=CC=C4
DMY49DN	IK	FYZLBYYWOFEUSZ-XMTFNYHQSA-N
DMY49DN	IU	[(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] pyridine-3-carboxylate
DMY49DN	DE	Discovery agent

DMSQ538	ID	DMSQ538
DMSQ538	DN	Isosorbide-2-benzylcarbamate-5-pentanoate
DMSQ538	HS	Investigative
DMSQ538	SN	CHEMBL521666; Isosorbide-2-benzylcarbamate-5-pentanoate
DMSQ538	DT	Small molecular drug
DMSQ538	PC	25128787
DMSQ538	MW	363.4
DMSQ538	FM	C19H25NO6
DMSQ538	IC	InChI=1S/C19H25NO6/c1-2-3-9-16(21)25-14-11-23-18-15(12-24-17(14)18)26-19(22)20-10-13-7-5-4-6-8-13/h4-8,14-15,17-18H,2-3,9-12H2,1H3,(H,20,22)/t14-,15+,17-,18-/m1/s1
DMSQ538	CS	CCCCC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCC3=CC=CC=C3
DMSQ538	IK	CFMVNQSTYPRCII-CYGHRXIMSA-N
DMSQ538	IU	[(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] pentanoate
DMSQ538	DE	Discovery agent

DMP6E34	ID	DMP6E34
DMP6E34	DN	Isosorbide-2-benzylcarbamate-5-propionate
DMP6E34	HS	Investigative
DMP6E34	SN	CHEMBL493672; Isosorbide-2-benzylcarbamate-5-propionate
DMP6E34	DT	Small molecular drug
DMP6E34	PC	25129847
DMP6E34	MW	335.4
DMP6E34	FM	C17H21NO6
DMP6E34	IC	InChI=1S/C17H21NO6/c1-2-14(19)23-12-9-21-16-13(10-22-15(12)16)24-17(20)18-8-11-6-4-3-5-7-11/h3-7,12-13,15-16H,2,8-10H2,1H3,(H,18,20)/t12-,13+,15-,16-/m1/s1
DMP6E34	CS	CCC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCC3=CC=CC=C3
DMP6E34	IK	FDUDHTXZERVRTN-OCVGTWLNSA-N
DMP6E34	IU	[(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] propanoate
DMP6E34	DE	Discovery agent

DMCHSWQ	ID	DMCHSWQ
DMCHSWQ	DN	Isosorbide-2-benzylcarbamate-5-tosylate
DMCHSWQ	HS	Investigative
DMCHSWQ	SN	CHEMBL523852
DMCHSWQ	DT	Small molecular drug
DMCHSWQ	PC	44568995
DMCHSWQ	MW	461.5
DMCHSWQ	FM	C22H23NO8S
DMCHSWQ	IC	InChI=1S/C22H23NO8S/c1-14-7-9-16(10-8-14)32(26,27)22(25)31-18-13-29-19-17(12-28-20(18)19)30-21(24)23-11-15-5-3-2-4-6-15/h2-10,17-20H,11-13H2,1H3,(H,23,24)/t17-,18+,19+,20+/m0/s1
DMCHSWQ	CS	CC1=CC=C(C=C1)S(=O)(=O)C(=O)O[C@@H]2CO[C@H]3[C@@H]2OC[C@@H]3OC(=O)NCC4=CC=CC=C4
DMCHSWQ	IK	RGANIXDJVGCBKP-MTQWCTHYSA-N
DMCHSWQ	IU	[(3S,3aR,6R,6aR)-3-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] (4-methylphenyl)sulfonylformate
DMCHSWQ	DE	Discovery agent

DMG69IX	ID	DMG69IX
DMG69IX	DN	Isosorbide-2-benzylcarbamate-5-triflate
DMG69IX	HS	Investigative
DMG69IX	SN	CHEMBL492636; Isosorbide-2-benzylcarbamate-5-triflate
DMG69IX	DT	Small molecular drug
DMG69IX	PC	44568822
DMG69IX	MW	455.4
DMG69IX	FM	C16H16F3NO9S
DMG69IX	IC	InChI=1S/C16H16F3NO9S/c17-16(18,19)30(23,24)29-15(22)28-11-8-26-12-10(7-25-13(11)12)27-14(21)20-6-9-4-2-1-3-5-9/h1-5,10-13H,6-8H2,(H,20,21)/t10-,11+,12+,13+/m0/s1
DMG69IX	CS	C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)OC(=O)OS(=O)(=O)C(F)(F)F)OC(=O)NCC3=CC=CC=C3
DMG69IX	IK	WOSIHMSPFKVEAI-UMSGYPCISA-N
DMG69IX	IU	[(3S,3aR,6R,6aR)-3-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxycarbonyl trifluoromethanesulfonate
DMG69IX	DE	Discovery agent

DMPA2ON	ID	DMPA2ON
DMPA2ON	DN	Isosorbide-di-(4-nitrophenyl carbamate)
DMPA2ON	HS	Investigative
DMPA2ON	SN	CHEMBL603100
DMPA2ON	DT	Small molecular drug
DMPA2ON	PC	46232723
DMPA2ON	MW	474.4
DMPA2ON	FM	C20H18N4O10
DMPA2ON	IC	InChI=1S/C20H18N4O10/c25-19(21-11-1-5-13(6-2-11)23(27)28)33-15-9-31-18-16(10-32-17(15)18)34-20(26)22-12-3-7-14(8-4-12)24(29)30/h1-8,15-18H,9-10H2,(H,21,25)(H,22,26)/t15-,16+,17-,18-/m1/s1
DMPA2ON	CS	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NC3=CC=C(C=C3)[N+](=O)[O-])OC(=O)NC4=CC=C(C=C4)[N+](=O)[O-]
DMPA2ON	IK	DHXOUOFGQLLAMG-XMTFNYHQSA-N
DMPA2ON	IU	[(3S,3aR,6R,6aR)-6-[(4-nitrophenyl)carbamoyloxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-(4-nitrophenyl)carbamate
DMPA2ON	DE	Discovery agent

DMFVN71	ID	DMFVN71
DMFVN71	DN	Isosorbide-di-(benzylcarbamate)
DMFVN71	HS	Investigative
DMFVN71	SN	CHEMBL600013; Isosorbide-di-(benzylcarbamate)
DMFVN71	DT	Small molecular drug
DMFVN71	PC	46232725
DMFVN71	MW	412.4
DMFVN71	FM	C22H24N2O6
DMFVN71	IC	InChI=1S/C22H24N2O6/c25-21(23-11-15-7-3-1-4-8-15)29-17-13-27-20-18(14-28-19(17)20)30-22(26)24-12-16-9-5-2-6-10-16/h1-10,17-20H,11-14H2,(H,23,25)(H,24,26)/t17-,18+,19-,20-/m1/s1
DMFVN71	CS	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)OC(=O)NCC4=CC=CC=C4
DMFVN71	IK	PERBLOUPRPLYHU-IYWMVGAKSA-N
DMFVN71	IU	[(3S,3aR,6R,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-benzylcarbamate
DMFVN71	DE	Discovery agent

DMNSTKD	ID	DMNSTKD
DMNSTKD	DN	Isosorbide-di-(butylcarbamate)
DMNSTKD	HS	Investigative
DMNSTKD	SN	Isosorbide-di-(butylcarbamate); CHEMBL606050
DMNSTKD	DT	Small molecular drug
DMNSTKD	PC	46232686
DMNSTKD	MW	344.4
DMNSTKD	FM	C16H28N2O6
DMNSTKD	IC	InChI=1S/C16H28N2O6/c1-3-5-7-17-15(19)23-11-9-21-14-12(10-22-13(11)14)24-16(20)18-8-6-4-2/h11-14H,3-10H2,1-2H3,(H,17,19)(H,18,20)/t11-,12+,13-,14-/m1/s1
DMNSTKD	CS	CCCCNC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCCCC
DMNSTKD	IK	KFJGIBINELGQIA-XJFOESAGSA-N
DMNSTKD	IU	[(3S,3aR,6R,6aR)-6-(butylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-butylcarbamate
DMNSTKD	DE	Discovery agent

DMTHWXO	ID	DMTHWXO
DMTHWXO	DN	Isosorbide-di-(ethylcarbamate)
DMTHWXO	HS	Investigative
DMTHWXO	SN	Isosorbide-di-(ethylcarbamate); CHEMBL600621; BDBM50306694
DMTHWXO	DT	Small molecular drug
DMTHWXO	PC	46232684
DMTHWXO	MW	288.3
DMTHWXO	FM	C12H20N2O6
DMTHWXO	IC	InChI=1S/C12H20N2O6/c1-3-13-11(15)19-7-5-17-10-8(6-18-9(7)10)20-12(16)14-4-2/h7-10H,3-6H2,1-2H3,(H,13,15)(H,14,16)/t7-,8+,9-,10-/m1/s1
DMTHWXO	CS	CCNC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCC
DMTHWXO	IK	IMAKVWCOCNQBSI-UTINFBMNSA-N
DMTHWXO	IU	[(3S,3aR,6R,6aR)-6-(ethylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-ethylcarbamate
DMTHWXO	DE	Discovery agent

DMV1GLP	ID	DMV1GLP
DMV1GLP	DN	Isosorbide-di-(propylcarbamate)
DMV1GLP	HS	Investigative
DMV1GLP	SN	Isosorbide-di-(propylcarbamate); CHEMBL600622
DMV1GLP	DT	Small molecular drug
DMV1GLP	PC	46232685
DMV1GLP	MW	316.35
DMV1GLP	FM	C14H24N2O6
DMV1GLP	IC	InChI=1S/C14H24N2O6/c1-3-5-15-13(17)21-9-7-19-12-10(8-20-11(9)12)22-14(18)16-6-4-2/h9-12H,3-8H2,1-2H3,(H,15,17)(H,16,18)/t9-,10+,11-,12-/m1/s1
DMV1GLP	CS	CCCNC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCCC
DMV1GLP	IK	FHZOSQQIPPAAMJ-WRWGMCAJSA-N
DMV1GLP	IU	[(3S,3aR,6R,6aR)-6-(propylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-propylcarbamate
DMV1GLP	DE	Discovery agent

DMT1ZGM	ID	DMT1ZGM
DMT1ZGM	DN	Isosorbide-di-phenylcarbamate
DMT1ZGM	HS	Investigative
DMT1ZGM	SN	Isosorbide-di-phenylcarbamate
DMT1ZGM	DT	Small molecular drug
DMT1ZGM	PC	46232722
DMT1ZGM	MW	384.4
DMT1ZGM	FM	C20H20N2O6
DMT1ZGM	IC	InChI=1S/C20H20N2O6/c23-19(21-13-7-3-1-4-8-13)27-15-11-25-18-16(12-26-17(15)18)28-20(24)22-14-9-5-2-6-10-14/h1-10,15-18H,11-12H2,(H,21,23)(H,22,24)/t15-,16+,17-,18-/m1/s1
DMT1ZGM	CS	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NC3=CC=CC=C3)OC(=O)NC4=CC=CC=C4
DMT1ZGM	IK	KDDHNJSIHIMRGH-XMTFNYHQSA-N
DMT1ZGM	IU	[(3S,3aR,6R,6aR)-6-(phenylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-phenylcarbamate
DMT1ZGM	DE	Discovery agent

DM21K0E	ID	DM21K0E
DM21K0E	DN	ISOTETRANDRINE
DM21K0E	HS	Investigative
DM21K0E	SN	O-Methylberbamine; O,O'-Dimethylobamegine; Isosinomenine A; NSC 97338; O,O'-Dimethylstepholine; Isosinomenin A; CHEBI:80898; 1-ISOTETRANDRINE; 6,6',7,12-Tetramethoxy-2,2'-dimethylberbaman; Hanfangchin A; CCRIS 6540; 6,6&amp; ,7,12-Tetramethoxy-2,2&amp; C38H42N2O6; (+)-Isotetrandrine; tetramethoxy(dimethyl)[ ]; Phaeanthin; O,O-Dimethylobamegine; O,O-Dimethylstepholine; AC1L1KBN; AC1Q58ES; (1.beta.)-6,6',7,12-Tetramethoxy-2,2'-dimethylberbaman; SCHEMBL209832; CHEMBL367260; WVTKBKWTSCPRNU-UHFFFAOYSA-N
DM21K0E	DT	Small molecular drug
DM21K0E	PC	457825
DM21K0E	MW	622.7
DM21K0E	FM	C38H42N2O6
DM21K0E	IC	InChI=1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29-,30+/m0/s1
DM21K0E	CS	CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC
DM21K0E	IK	WVTKBKWTSCPRNU-XZWHSSHBSA-N
DM21K0E	IU	(1S,14R)-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene
DM21K0E	CA	CAS 477-57-6
DM21K0E	DE	Discovery agent

DMKTBEH	ID	DMKTBEH
DMKTBEH	DN	ISOTHIAZOLIDINONE ANALOG
DMKTBEH	HS	Investigative
DMKTBEH	SN	ISOTHIAZOLIDINONE ANALOG; CHEMBL382311; IZD; (2S)-N-[(1S)-1-carbamoyl-2-{4-[(5S)-1,1,3-trioxo-1$l^{6},2-thiazolidin-5-yl]phenyl}ethyl]-2-acetamido-3-phenylpropanamide; Saturated (S)-IZD; 2cm7; IZD 8; BDBM13465; Isothiazolidinone (IZD) deriv. 6; DB08003
DMKTBEH	DT	Small molecular drug
DMKTBEH	PC	9547915
DMKTBEH	MW	486.5
DMKTBEH	FM	C23H26N4O6S
DMKTBEH	IC	InChI=1S/C23H26N4O6S/c1-14(28)25-19(12-15-5-3-2-4-6-15)23(31)26-18(22(24)30)11-16-7-9-17(10-8-16)20-13-21(29)27-34(20,32)33/h2-10,18-20H,11-13H2,1H3,(H2,24,30)(H,25,28)(H,26,31)(H,27,29)/t18-,19-,20-/m0/s1
DMKTBEH	CS	CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)[C@@H]3CC(=O)NS3(=O)=O)C(=O)N
DMKTBEH	IK	UILYPHAKDBTKQV-UFYCRDLUSA-N
DMKTBEH	IU	(2S)-2-acetamido-N-[(2S)-1-amino-1-oxo-3-[4-[(5S)-1,1,3-trioxo-1,2-thiazolidin-5-yl]phenyl]propan-2-yl]-3-phenylpropanamide
DMKTBEH	DE	Discovery agent

DMAYOTF	ID	DMAYOTF
DMAYOTF	DN	isothiourea-1a
DMAYOTF	HS	Investigative
DMAYOTF	SN	IT1a
DMAYOTF	DT	Small molecular drug
DMAYOTF	PC	11176403
DMAYOTF	MW	378.6
DMAYOTF	FM	C19H30N4S2
DMAYOTF	IC	InChI=1S/C19H30N4S2/c1-3-7-15(8-4-1)21-18(22-16-9-5-2-6-10-16)24-13-17-14-25-19-20-11-12-23(17)19/h14-16H,1-13H2,(H,21,22)
DMAYOTF	CS	C1CCC(CC1)NC(=NC2CCCCC2)SCC3=CSC4=NCCN34
DMAYOTF	IK	ZEZPDHKACVMMCD-UHFFFAOYSA-N
DMAYOTF	IU	5,6-dihydroimidazo[2,1-b][1,3]thiazol-3-ylmethyl N,N'-dicyclohexylcarbamimidothioate
DMAYOTF	DE	Discovery agent

DMBX4WR	ID	DMBX4WR
DMBX4WR	DN	isothiourea-1t
DMBX4WR	HS	Investigative
DMBX4WR	SN	IT1t
DMBX4WR	DT	Small molecular drug
DMBX4WR	PC	25147749
DMBX4WR	MW	406.7
DMBX4WR	FM	C21H34N4S2
DMBX4WR	IC	InChI=1S/C21H34N4S2/c1-21(2)15-25-18(14-27-20(25)24-21)13-26-19(22-16-9-5-3-6-10-16)23-17-11-7-4-8-12-17/h14,16-17H,3-13,15H2,1-2H3,(H,22,23)
DMBX4WR	CS	CC1(CN2C(=CSC2=N1)CSC(=NC3CCCCC3)NC4CCCCC4)C
DMBX4WR	IK	OOSUDWRRWZVFEB-UHFFFAOYSA-N
DMBX4WR	IU	(6,6-dimethyl-5H-imidazo[2,1-b][1,3]thiazol-3-yl)methyl N,N'-dicyclohexylcarbamimidothioate
DMBX4WR	DE	Discovery agent

DMNL0BK	ID	DMNL0BK
DMNL0BK	DN	IsoVa-RYYRIK-NH2
DMNL0BK	HS	Investigative
DMNL0BK	SN	CHEMBL404530
DMNL0BK	DT	Small molecular drug
DMNL0BK	PC	44456028
DMNL0BK	MW	965.2
DMNL0BK	FM	C47H76N14O8
DMNL0BK	IC	InChI=1S/C47H76N14O8/c1-5-29(4)39(45(69)57-33(40(49)64)15-9-10-22-48)61-42(66)35(17-12-24-55-47(52)53)58-43(67)37(27-31-18-20-32(62)21-19-31)60-44(68)36(26-30-13-7-6-8-14-30)59-41(65)34(16-11-23-54-46(50)51)56-38(63)25-28(2)3/h6-8,13-14,18-21,28-29,33-37,39,62H,5,9-12,15-17,22-27,48H2,1-4H3,(H2,49,64)(H,56,63)(H,57,69)(H,58,67)(H,59,65)(H,60,68)(H,61,66)(H4,50,51,54)(H4,52,53,55)/t29-,33-,34-,35-,36-,37-,39-/m0/s1
DMNL0BK	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CC(C)C
DMNL0BK	IK	WYGLGBXUEUHKTI-INYUMPDKSA-N
DMNL0BK	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(3-methylbutanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMNL0BK	DE	Discovery agent

DMTRGAP	ID	DMTRGAP
DMTRGAP	DN	isovelleral
DMTRGAP	HS	Investigative
DMTRGAP	SN	iso-velleral; (+)-isovelleral
DMTRGAP	DT	Small molecular drug
DMTRGAP	PC	37839
DMTRGAP	MW	232.32
DMTRGAP	FM	C15H20O2
DMTRGAP	IC	InChI=1S/C15H20O2/c1-13(2)5-10-4-11(7-16)15(9-17)8-14(15,3)12(10)6-13/h4,7,9-10,12H,5-6,8H2,1-3H3/t10-,12+,14-,15-/m1/s1
DMTRGAP	CS	C[C@]12C[C@]1(C(=C[C@H]3[C@@H]2CC(C3)(C)C)C=O)C=O
DMTRGAP	IK	PJAAESPGJOSQGZ-DZGBDDFRSA-N
DMTRGAP	IU	(1aS,3aS,6aS,6bR)-5,5,6b-trimethyl-3a,4,6,6a-tetrahydro-1H-cyclopropa[e]indene-1a,2-dicarbaldehyde
DMTRGAP	CA	CAS 37841-91-1
DMTRGAP	CB	CHEBI:6070
DMTRGAP	DE	Discovery agent

DMXAD8E	ID	DMXAD8E
DMXAD8E	DN	Isoxazol
DMXAD8E	HS	Investigative
DMXAD8E	SN	Isoxazol; C23H33NO2; Azastenum [INN-Latin]; Azasteno [INN-Spanish]; WIN 17625; AC1L19IF; 4,4,17-Trimethylandrosta-2,5-dieno(2,3-d)isoxazol-17beta-ol; 4,4,17-alpha-Trimethylandrost-5-eno(2,3-d)isoxazol-17-ol; 17beta-Hydroxy-4,4,17alpha-trimethylandrost-5-en-(2,3d)-isoxazole; (17beta)-4,4,17-Trimethylandrosta-2,5-diene(3,2-d)isoxazol-17-ol; Androsta-2,5-dieno(2,3-d)isoxazol-17-ol, 4,4,17-trimethyl-, (17beta)-; Win 17,625; LS-19331; ANDROSTA-2,5-DIENO(2,3-d)ISOXAZOL-17-beta-OL, 4,4,17-TRIMETHYL-; (17 beta)-4,4,17-trimethyla
DMXAD8E	DT	Small molecular drug
DMXAD8E	PC	25676
DMXAD8E	MW	355.5
DMXAD8E	FM	C23H33NO2
DMXAD8E	IC	InChI=1S/C23H33NO2/c1-20(2)18-7-6-15-16(21(18,3)12-14-13-24-26-19(14)20)8-10-22(4)17(15)9-11-23(22,5)25/h7,13,15-17,25H,6,8-12H2,1-5H3/t15?,16-,17-,21?,22?,23-/m0/s1
DMXAD8E	CS	C[C@@]1(CC[C@@H]2C1(CC[C@H]3C2CC=C4C3(CC5=C(C4(C)C)ON=C5)C)C)O
DMXAD8E	IK	AXLOCHLTNQDFFS-BELXDXCXSA-N
DMXAD8E	IU	(1S,14S,17S)-2,9,9,17,18-pentamethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,10-trien-17-ol
DMXAD8E	DE	Discovery agent

DMAFC3R	ID	DMAFC3R
DMAFC3R	DN	isoxazole azepine compound 3
DMAFC3R	HS	Investigative
DMAFC3R	DT	Small molecular drug
DMAFC3R	PC	57345400
DMAFC3R	MW	399.9
DMAFC3R	FM	C20H18ClN3O2S
DMAFC3R	IC	InChI=1S/C20H18ClN3O2S/c1-9-11(3)27-20-16(9)18(12-4-6-13(21)7-5-12)23-14(8-15(22)25)19-17(20)10(2)24-26-19/h4-7,14H,8H2,1-3H3,(H2,22,25)/t14-/m0/s1
DMAFC3R	CS	CC1=C(SC2=C1C(=N[C@H](C3=C2C(=NO3)C)CC(=O)N)C4=CC=C(C=C4)Cl)C
DMAFC3R	IK	DRSQZZRFHBWKKZ-AWEZNQCLSA-N
DMAFC3R	IU	2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-11-oxa-3-thia-8,12-diazatricyclo[8.3.0.02,6]trideca-1(10),2(6),4,7,12-pentaen-9-yl]acetamide
DMAFC3R	DE	Discovery agent

DMPZURH	ID	DMPZURH
DMPZURH	DN	Isoxazolecarboxylic acid
DMPZURH	HS	Investigative
DMPZURH	SN	CHEMBL133541; SCHEMBL5619846; SCHEMBL5619857; UBNWPQXLFRMMEI-GQCTYLIASA-N; BDBM50133280; isochroman-3-(S)-carboxylic acid methylester; 5-{3-[3-(3-Hydroxy-2-methoxycarbonyl-phenoxy)-propenyl]-phenyl}-isoxazole-3-carboxylic acid; 5-(3-((1e)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid; 5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid
DMPZURH	DT	Small molecular drug
DMPZURH	PC	11286453
DMPZURH	MW	113.07
DMPZURH	FM	C4H3NO3
DMPZURH	IC	InChI=1S/C4H3NO3/c6-4(7)3-1-2-8-5-3/h1-2H,(H,6,7)
DMPZURH	CS	C1=CON=C1C(=O)O
DMPZURH	IK	UXYRXGFUANQKTA-UHFFFAOYSA-N
DMPZURH	IU	1,2-oxazole-3-carboxylic acid
DMPZURH	CA	CAS 3209-71-0
DMPZURH	DE	Discovery agent

DMA8F4N	ID	DMA8F4N
DMA8F4N	DN	ITdU
DMA8F4N	HS	Investigative
DMA8F4N	SN	3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-
DMA8F4N	DT	Small molecular drug
DMA8F4N	PC	76
DMA8F4N	MW	288.4
DMA8F4N	FM	C19H28O2
DMA8F4N	IC	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3
DMA8F4N	CS	CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C
DMA8F4N	IK	FMGSKLZLMKYGDP-UHFFFAOYSA-N
DMA8F4N	IU	3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
DMA8F4N	CB	CHEBI:95212
DMA8F4N	DE	Discovery agent

DMVFITX	ID	DMVFITX
DMVFITX	DN	ITP
DMVFITX	HS	Investigative
DMVFITX	SN	inosine triphosphate
DMVFITX	DT	Small molecular drug
DMVFITX	PC	135398643
DMVFITX	MW	508.17
DMVFITX	FM	C10H15N4O14P3
DMVFITX	IC	InChI=1S/C10H15N4O14P3/c15-6-4(1-25-30(21,22)28-31(23,24)27-29(18,19)20)26-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17/h2-4,6-7,10,15-16H,1H2,(H,21,22)(H,23,24)(H,11,12,17)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMVFITX	CS	C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMVFITX	IK	HAEJPQIATWHALX-KQYNXXCUSA-N
DMVFITX	IU	[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMVFITX	CA	CAS 132-06-9
DMVFITX	CB	CHEBI:16039
DMVFITX	DE	Discovery agent

DMWTDS8	ID	DMWTDS8
DMWTDS8	DN	ITRI-305
DMWTDS8	HS	Investigative
DMWTDS8	SN	RET tyrosine kinase inhibitors, Industrial Technology Research Institute
DMWTDS8	CP	Industrial Technology Research Institute
DMWTDS8	DE	Thyroid cancer

DMFMYIH	ID	DMFMYIH
DMFMYIH	DN	Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2
DMFMYIH	HS	Investigative
DMFMYIH	PC	44295289
DMFMYIH	MW	1077.3
DMFMYIH	FM	C57H80N12O9
DMFMYIH	IC	InChI=1S/C57H80N12O9/c1-35(2)23-44(53(74)66-43(52(58)73)26-38-17-10-6-11-18-38)63-51(72)30-49(70)42(25-37-15-8-5-9-16-37)65-55(76)46(28-40-31-59-33-61-40)67-54(75)45(27-39-19-12-7-13-20-39)68-56(77)48-21-14-22-69(48)57(78)47(29-41-32-60-34-62-41)64-50(71)24-36(3)4/h6-7,10-13,17-20,31-37,42-49,70H,5,8-9,14-16,21-30H2,1-4H3,(H2,58,73)(H,59,61)(H,60,62)(H,63,72)(H,64,71)(H,65,76)(H,66,74)(H,67,75)(H,68,77)
DMFMYIH	CS	CC(C)CC(C(=O)NC(CC1=CC=CC=C1)C(=O)N)NC(=O)CC(C(CC2CCCCC2)NC(=O)C(CC3=CN=CN3)NC(=O)C(CC4=CC=CC=C4)NC(=O)C5CCCN5C(=O)C(CC6=CN=CN6)NC(=O)CC(C)C)O
DMFMYIH	IK	ZOAVSRHEYNKAIW-UHFFFAOYSA-N
DMFMYIH	IU	N-[1-[[1-[[5-[[1-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-1-cyclohexyl-3-hydroxy-5-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-1-[3-(1H-imidazol-5-yl)-2-(3-methylbutanoylamino)propanoyl]pyrrolidine-2-carboxamide
DMFMYIH	DE	Discovery agent

DMZTIU3	ID	DMZTIU3
DMZTIU3	DN	Iva-His-Pro-Phe-His-AHPPA-Leu-Phe-NH2
DMZTIU3	HS	Investigative
DMZTIU3	PC	44295266
DMZTIU3	MW	1071.3
DMZTIU3	FM	C57H74N12O9
DMZTIU3	IC	InChI=1S/C57H74N12O9/c1-35(2)23-44(53(74)66-43(52(58)73)26-38-17-10-6-11-18-38)63-51(72)30-49(70)42(25-37-15-8-5-9-16-37)65-55(76)46(28-40-31-59-33-61-40)67-54(75)45(27-39-19-12-7-13-20-39)68-56(77)48-21-14-22-69(48)57(78)47(29-41-32-60-34-62-41)64-50(71)24-36(3)4/h5-13,15-20,31-36,42-49,70H,14,21-30H2,1-4H3,(H2,58,73)(H,59,61)(H,60,62)(H,63,72)(H,64,71)(H,65,76)(H,66,74)(H,67,75)(H,68,77)
DMZTIU3	CS	CC(C)CC(C(=O)NC(CC1=CC=CC=C1)C(=O)N)NC(=O)CC(C(CC2=CC=CC=C2)NC(=O)C(CC3=CN=CN3)NC(=O)C(CC4=CC=CC=C4)NC(=O)C5CCCN5C(=O)C(CC6=CN=CN6)NC(=O)CC(C)C)O
DMZTIU3	IK	OXZWHUWYDVRMCP-UHFFFAOYSA-N
DMZTIU3	IU	N-[1-[[1-[[5-[[1-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-1-[3-(1H-imidazol-5-yl)-2-(3-methylbutanoylamino)propanoyl]pyrrolidine-2-carboxamide
DMZTIU3	DE	Discovery agent

DM92QIW	ID	DM92QIW
DM92QIW	DN	Iva-His-Pro-Phe-His-Sta-Leu-Phe-NH2
DM92QIW	HS	Investigative
DM92QIW	DT	Peptide
DM92QIW	PC	44297826
DM92QIW	MW	1052.3
DM92QIW	FM	C54H77N13O9
DM92QIW	IC	InChI=1S/C54H77N13O9/c1-7-54(6,56)53(76)66-43(26-37-29-58-31-60-37)52(75)67-20-14-19-44(67)51(74)65-41(24-35-17-12-9-13-18-35)49(72)64-42(25-36-28-57-30-59-36)50(73)62-38(21-32(2)3)45(68)27-46(69)61-40(22-33(4)5)48(71)63-39(47(55)70)23-34-15-10-8-11-16-34/h8-13,15-18,28-33,38-45,68H,7,14,19-27,56H2,1-6H3,(H2,55,70)(H,57,59)(H,58,60)(H,61,69)(H,62,73)(H,63,71)(H,64,72)(H,65,74)(H,66,76)/t38?,39-,40-,41-,42-,43-,44-,45?,54-/m0/s1
DM92QIW	CS	CC[C@@](C)(C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CN=CN4)C(=O)NC(CC(C)C)C(CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)O)N
DM92QIW	IK	YLFGKFNAVPVWDW-AJEFLBOZSA-N
DM92QIW	IU	(2S)-1-[(2S)-2-[[(2S)-2-amino-2-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]-N-[(2S)-1-[[(2S)-1-[[1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-6-methyl-1-oxoheptan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM92QIW	DE	Discovery agent

DMBTWF0	ID	DMBTWF0
DMBTWF0	DN	IW-1221
DMBTWF0	HS	Investigative
DMBTWF0	SN	CRTH2 inhibitor (asthma), Ironwood
DMBTWF0	CP	Ironwood Pharmaceuticals Inc
DMBTWF0	DE	Asthma

DMQSB6N	ID	DMQSB6N
DMQSB6N	DN	J-009747
DMQSB6N	HS	Investigative
DMQSB6N	SN	LMFA06000016; LS-75538; RT-005620; S14-1394; SCHEMBL1269927; SR-01000946533; (E)-4-HYDROXYHEXENAL; (E)-4-Hydroxy-2-hexenal; (E)-4-hydroxy-hex-2-enal; 4-Hydroxy-2-hexenal; JYTUBIHWMKQZRB-ONEGZZNKSA-N; (E)-4-hydroxyhex-2-enal; 1086AH; 160708-91-8; 17427-08-6; 17427-21-3; 2-HEXENAL, 4-HYDROXY-; 2-Hexenal, 4-hydroxy-, (2E)-; 2-Hexenal, 4-hydroxy-, (E)-; 4-Hydroxyhexenal; 4-hydroxy-2E-hexenal; AC1NR205; AKOS006273451; CCRIS 9201; HMS3648N12
DMQSB6N	PC	5283314
DMQSB6N	MW	114.14
DMQSB6N	FM	C6H10O2
DMQSB6N	IC	JYTUBIHWMKQZRB-ONEGZZNKSA-N
DMQSB6N	CS	CCC(C=CC=O)O
DMQSB6N	IK	1S/C6H10O2/c1-2-6(8)4-3-5-7/h3-6,8H,2H2,1H3/b4-3+
DMQSB6N	IU	(E)-4-hydroxyhex-2-enal
DMQSB6N	CA	CAS 17427-08-6
DMQSB6N	DE	Discovery agent

DMQ8J3M	ID	DMQ8J3M
DMQ8J3M	DN	J-104118
DMQ8J3M	HS	Investigative
DMQ8J3M	SN	J 104118
DMQ8J3M	DT	Small molecular drug
DMQ8J3M	PC	10460101
DMQ8J3M	MW	546.4
DMQ8J3M	FM	C28H26Cl2FNO5
DMQ8J3M	IC	InChI=1S/C28H26Cl2FNO5/c1-16(32-26(33)14-20(28(36)37)15-27(34)35)22(11-17-7-10-23(29)24(30)12-17)19-8-9-21(25(31)13-19)18-5-3-2-4-6-18/h2-10,12-13,16,20,22H,11,14-15H2,1H3,(H,32,33)(H,34,35)(H,36,37)/t16-,20-,22+/m0/s1
DMQ8J3M	CS	C[C@@H]([C@@H](CC1=CC(=C(C=C1)Cl)Cl)C2=CC(=C(C=C2)C3=CC=CC=C3)F)NC(=O)C[C@@H](CC(=O)O)C(=O)O
DMQ8J3M	IK	NBRLADMQSZWKGO-XUEUYAKLSA-N
DMQ8J3M	IU	(2S)-2-[2-[[(2S,3S)-4-(3,4-dichlorophenyl)-3-(3-fluoro-4-phenylphenyl)butan-2-yl]amino]-2-oxoethyl]butanedioic acid
DMQ8J3M	DE	Discovery agent

DMWF7RO	ID	DMWF7RO
DMWF7RO	DN	J-104123
DMWF7RO	HS	Investigative
DMWF7RO	SN	CHEMBL143820; J-104123; GTPL3110; SCHEMBL8623891; BDBM50288819; (R)-4-[(E)-(1S,2S)-2-(3,4-Dichloro-benzyl)-1-methyl-4-naphthalen-2-yl-but-3-enylcarbamoyl]-3-methyl-butyric acid; (3R)-4-{[(2S,3S,4E)-3-[(3,4-dichlorophenyl)methyl]-5-(naphthalen-2-yl)pent-4-en-2-yl]carbamoyl}-3-methylbutanoic acid
DMWF7RO	DT	Small molecular drug
DMWF7RO	PC	9848748
DMWF7RO	MW	498.4
DMWF7RO	FM	C28H29Cl2NO3
DMWF7RO	IC	InChI=1S/C28H29Cl2NO3/c1-18(14-28(33)34)13-27(32)31-19(2)23(16-21-9-12-25(29)26(30)17-21)11-8-20-7-10-22-5-3-4-6-24(22)15-20/h3-12,15,17-19,23H,13-14,16H2,1-2H3,(H,31,32)(H,33,34)/b11-8+/t18-,19+,23-/m1/s1
DMWF7RO	CS	C[C@H](CC(=O)N[C@@H](C)[C@@H](CC1=CC(=C(C=C1)Cl)Cl)/C=C/C2=CC3=CC=CC=C3C=C2)CC(=O)O
DMWF7RO	IK	LVRZMZFXRFKCCY-KSYFVSBMSA-N
DMWF7RO	IU	(3R)-5-[[(E,2S,3S)-3-[(3,4-dichlorophenyl)methyl]-5-naphthalen-2-ylpent-4-en-2-yl]amino]-3-methyl-5-oxopentanoic acid
DMWF7RO	DE	Discovery agent

DMAEQS9	ID	DMAEQS9
DMAEQS9	DN	J-104135
DMAEQS9	HS	Investigative
DMAEQS9	SN	UNII-6137X5QNJF; 6137X5QNJF; J-104871; J-104135; SCHEMBL15207668; SCHEMBL15207665; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-pentenyl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-penten-1-yl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 191088-19-4; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-(((2-(1,3-benzodioxol-5-yl)-5-(2-benzoxa
DMAEQS9	CP	MSD Japan
DMAEQS9	DT	Small molecular drug
DMAEQS9	PC	9962301
DMAEQS9	MW	708.7
DMAEQS9	FM	C38H32N2O12
DMAEQS9	IC	InChI=1S/C38H32N2O12/c1-21(26(25-15-16-29-30(18-25)49-20-48-29)9-6-12-31-39-27-10-4-5-11-28(27)50-31)40(19-22-13-14-23-7-2-3-8-24(23)17-22)34(41)32-33(35(42)43)52-38(51-32,36(44)45)37(46)47/h2-8,10-18,21,26,32-33H,9,19-20H2,1H3,(H,42,43)(H,44,45)(H,46,47)/b12-6+/t21-,26+,32+,33-/m1/s1
DMAEQS9	CS	C[C@H]([C@H](C/C=C/C1=NC2=CC=CC=C2O1)C3=CC4=C(C=C3)OCO4)N(CC5=CC6=CC=CC=C6C=C5)C(=O)[C@@H]7[C@@H](OC(O7)(C(=O)O)C(=O)O)C(=O)O
DMAEQS9	IK	CXDSZFRIMJUZKT-MRGWGSTCSA-N
DMAEQS9	IU	(4R,5S)-5-[[(E,2R,3R)-3-(1,3-benzodioxol-5-yl)-6-(1,3-benzoxazol-2-yl)hex-5-en-2-yl]-(naphthalen-2-ylmethyl)carbamoyl]-1,3-dioxolane-2,2,4-tricarboxylic acid
DMAEQS9	CA	CAS 191088-19-4
DMAEQS9	DE	Chronic obstructive pulmonary disease

DMCS4BL	ID	DMCS4BL
DMCS4BL	DN	J-104870
DMCS4BL	HS	Investigative
DMCS4BL	SN	145-13-1; 3-Hydroxypregn-5-en-20-one; 1-(3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanon; 1-(3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone; .DELTA.5-Pregnenolone; 5-Pregnene-3-ol-20-one; 5-Pregnen-3.beta.-ol-20-one; delta5-Pregnen-3beta-ol-20-one; Pregn-5-en-20-one, 3-hydroxy-; 3.beta.-Hydroxypregn-5-en-20-one; Pregn-5-en-20-one, 3.beta.-hydroxy-; AC1L1AKE; AC1Q1K1J; CHEMBL14116
DMCS4BL	DT	Small molecular drug
DMCS4BL	PC	9807770
DMCS4BL	MW	555.7
DMCS4BL	FM	C27H33N5O4S2
DMCS4BL	IC	InChI=1S/C27H33N5O4S2/c1-4-8-36-26(33)31-20-11-19(12-23(14-20)34-3)16-28-25-15-22(32-6-9-35-10-7-32)13-21(30-25)18-37-27-29-17-24(5-2)38-27/h4,11-15,17H,1,5-10,16,18H2,2-3H3,(H,28,30)(H,31,33)
DMCS4BL	CS	CCC1=CN=C(S1)SCC2=NC(=CC(=C2)N3CCOCC3)NCC4=CC(=CC(=C4)OC)NC(=O)OCC=C
DMCS4BL	IK	JNFARUXJNLDBCZ-UHFFFAOYSA-N
DMCS4BL	IU	prop-2-enyl N-[3-[[[6-[(5-ethyl-1,3-thiazol-2-yl)sulfanylmethyl]-4-morpholin-4-ylpyridin-2-yl]amino]methyl]-5-methoxyphenyl]carbamate
DMCS4BL	DE	Discovery agent

DM9SFGB	ID	DM9SFGB
DM9SFGB	DN	J-109,390
DM9SFGB	HS	Investigative
DM9SFGB	DE	Discovery agent

DMXC319	ID	DMXC319
DMXC319	DN	J591-Ac-225
DMXC319	HS	Investigative
DMXC319	SN	PSMA-targeting mAb and Ac-225 conjugate (metastatic prostate cancer), Actinium Pharmaceuticals
DMXC319	CP	Actinium Pharmaceuticals Inc
DMXC319	DT	Antibody
DMXC319	DE	Prostate cancer

DMJAEMT	ID	DMJAEMT
DMJAEMT	DN	JASPAQUINOL
DMJAEMT	HS	Investigative
DMJAEMT	SN	jaspaquinol; Jasplaquinol; CHEMBL425166; SCHEMBL6833479; BDBM50240936
DMJAEMT	DT	Small molecular drug
DMJAEMT	PC	10110469
DMJAEMT	MW	382.6
DMJAEMT	FM	C26H38O2
DMJAEMT	IC	InChI=1S/C26H38O2/c1-19(11-13-22-18-23(27)14-16-25(22)28)8-6-9-20(2)12-15-24-21(3)10-7-17-26(24,4)5/h9,11,14,16,18,27-28H,6-8,10,12-13,15,17H2,1-5H3/b19-11+,20-9+
DMJAEMT	CS	CC1=C(C(CCC1)(C)C)CC/C(=C/CC/C(=C/CC2=C(C=CC(=C2)O)O)/C)/C
DMJAEMT	IK	KUTRNQZRJBENDY-ZQYJZOSASA-N
DMJAEMT	IU	2-[(2E,6E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,6-dienyl]benzene-1,4-diol
DMJAEMT	DE	Discovery agent

DMOF0TB	ID	DMOF0TB
DMOF0TB	DN	Jaspic acid
DMOF0TB	HS	Investigative
DMOF0TB	SN	(-)-jaspic acid; jaspic acid; CHEMBL180947; (-)-Jaspic acid; BDBM50240937; 4-Hydroxy-3-[(1S,4aS,5R,8aS)-2,5,8a-trimethyl-5-(4-methyl-pent-3-enyl)-1,4,4a,5,6,7,8,8a-octahydro-naphthalen-1-ylmethyl]-benzoic acid
DMOF0TB	DT	Small molecular drug
DMOF0TB	PC	10179787
DMOF0TB	MW	410.6
DMOF0TB	FM	C27H38O3
DMOF0TB	IC	InChI=1S/C27H38O3/c1-18(2)8-6-13-26(4)14-7-15-27(5)22(19(3)9-12-24(26)27)17-21-16-20(25(29)30)10-11-23(21)28/h8-11,16,22,24,28H,6-7,12-15,17H2,1-5H3,(H,29,30)/t22-,24-,26-,27+/m0/s1
DMOF0TB	CS	CC1=CC[C@H]2[C@@](CCC[C@@]2([C@H]1CC3=C(C=CC(=C3)C(=O)O)O)C)(C)CCC=C(C)C
DMOF0TB	IK	IIMZFSAVKIVVHG-DAANFHMWSA-N
DMOF0TB	IU	3-[[(1S,4aS,5R,8aS)-2,5,8a-trimethyl-5-(4-methylpent-3-enyl)-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl]-4-hydroxybenzoic acid
DMOF0TB	DE	Discovery agent

DMYFNW9	ID	DMYFNW9
DMYFNW9	DN	JATRORRHIZINE
DMYFNW9	HS	Investigative
DMYFNW9	SN	Jatrorrhizine; 3621-38-3; neprotin; jateorrhizine; Yatrorizine; UNII-091S1F8V5Q; CHEMBL251055; CHEBI:6087; GNF-PF-220; 7,8,13,13a-tetradehydro-3-hydroxy-2,9,10-trimethoxyberbinium; 091S1F8V5Q; 2,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol; Dibenzo[a,g]quinolizinium, 5,6-dihydro-3-hydroxy-2,9,10-trimethoxy-; 3-Hydroxy-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium; 3-Hydroxy-2,9,10-trimethoxy-5,6-dihydroisoquinolino-[3,2-a]isoquinolin-7-ium; NSC645313; NSC150445; NSC209410
DMYFNW9	DT	Small molecular drug
DMYFNW9	PC	72323
DMYFNW9	MW	338.4
DMYFNW9	FM	C20H20NO4+
DMYFNW9	IC	InChI=1S/C20H19NO4/c1-23-18-5-4-12-8-16-14-10-19(24-2)17(22)9-13(14)6-7-21(16)11-15(12)20(18)25-3/h4-5,8-11H,6-7H2,1-3H3/p+1
DMYFNW9	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC
DMYFNW9	IK	MXTLAHSTUOXGQF-UHFFFAOYSA-O
DMYFNW9	IU	2,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol
DMYFNW9	CA	CAS 3621-38-3
DMYFNW9	CB	CHEBI:6087
DMYFNW9	DE	Discovery agent

DMPRTVX	ID	DMPRTVX
DMPRTVX	DN	JB 98064
DMPRTVX	HS	Investigative
DMPRTVX	SN	JB-98064
DMPRTVX	DT	Small molecular drug
DMPRTVX	PC	10810249
DMPRTVX	MW	350.9
DMPRTVX	FM	C19H31ClN4
DMPRTVX	IC	InChI=1S/C19H31ClN4/c20-18-10-8-17(9-11-18)16-24(19(21)22)15-5-3-1-2-4-12-23-13-6-7-14-23/h8-11H,1-7,12-16H2,(H3,21,22)
DMPRTVX	CS	C1CCN(C1)CCCCCCCN(CC2=CC=C(C=C2)Cl)C(=N)N
DMPRTVX	IK	ZRIVDXCYPBUSKL-UHFFFAOYSA-N
DMPRTVX	IU	1-[(4-chlorophenyl)methyl]-1-(7-pyrrolidin-1-ylheptyl)guanidine
DMPRTVX	CA	CAS 485812-42-8
DMPRTVX	DE	Discovery agent

DM38L1B	ID	DM38L1B
DM38L1B	DN	JB-1
DM38L1B	HS	Investigative
DM38L1B	SN	JB1
DM38L1B	CP	Chiron
DM38L1B	DT	Small molecular drug
DM38L1B	PC	25150849
DM38L1B	MW	434.7
DM38L1B	FM	C28H50O3
DM38L1B	IC	InChI=1S/C28H50O3/c1-5-6-8-21(14-16-29)19(2)25-12-13-26-22(9-7-15-28(25,26)4)10-11-23-17-24(30)18-27(31)20(23)3/h19,21-22,24-27,29-31H,5-18H2,1-4H3/t19-,21+,22?,24-,25-,26+,27+,28-/m1/s1
DM38L1B	CS	CCCC[C@@H](CCO)[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CCCC2CCC3=C([C@H](C[C@@H](C3)O)O)C)C
DM38L1B	IK	DHZOGFADXFKXSH-PMMQCNKASA-N
DM38L1B	IU	(1R,3S)-5-[2-[(1R,3aS,7aS)-1-[(2R,3S)-3-(2-hydroxyethyl)heptan-2-yl]-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-4-yl]ethyl]-4-methylcyclohex-4-ene-1,3-diol
DM38L1B	DE	Multiple myeloma

DM0KMPN	ID	DM0KMPN
DM0KMPN	DN	JBP-1
DM0KMPN	HS	Investigative
DM0KMPN	SN	Trypsinogen/chymotrypsinogen/amylase (metastatic cancer), Propanc
DM0KMPN	CP	Propanc Pty Ltd
DM0KMPN	DE	Solid tumour/cancer

DMYF7AE	ID	DMYF7AE
DMYF7AE	DN	JCF 109
DMYF7AE	HS	Investigative
DMYF7AE	SN	JCF109; JCF-109
DMYF7AE	DT	Small molecular drug
DMYF7AE	PC	73755001
DMYF7AE	MW	453.6
DMYF7AE	FM	C24H27N3O4S
DMYF7AE	IC	InChI=1S/C24H27N3O4S/c28-27(29)23-7-3-4-8-24(23)32(30,31)26-17-19-11-9-18(10-12-19)16-25-22-14-13-20-5-1-2-6-21(20)15-22/h1-8,13-15,18-19,25-26H,9-12,16-17H2
DMYF7AE	CS	C1CC(CCC1CNC2=CC3=CC=CC=C3C=C2)CNS(=O)(=O)C4=CC=CC=C4[N+](=O)[O-]
DMYF7AE	IK	BPBPTEVVRMSHTB-UHFFFAOYSA-N
DMYF7AE	IU	N-[[4-[(naphthalen-2-ylamino)methyl]cyclohexyl]methyl]-2-nitrobenzenesulfonamide
DMYF7AE	DE	Discovery agent

DMLBX3Q	ID	DMLBX3Q
DMLBX3Q	DN	JD-0100
DMLBX3Q	HS	Investigative
DMLBX3Q	SN	JD-0100 series; JD-0200 series; JD-0300 series; Monoamine oxidase-B inhibitors (obesity); Monoamine oxidase-B inhibitors (obesity), Jenrin Discovery
DMLBX3Q	CP	Jenrin Discovery Inc
DMLBX3Q	DE	Obesity

DMQP4VG	ID	DMQP4VG
DMQP4VG	DN	JG-365
DMQP4VG	HS	Investigative
DMQP4VG	SN	(S)-JG-365; 127231-42-9; 132748-20-0
DMQP4VG	DT	Small molecular drug
DMQP4VG	PC	131549
DMQP4VG	MW	861
DMQP4VG	FM	C42H68N8O11
DMQP4VG	IC	InChI=1S/C42H68N8O11/c1-9-25(6)36(41(59)48-35(24(4)5)42(60)61-8)49-40(58)32-16-13-17-50(32)21-33(53)28(19-27-14-11-10-12-15-27)45-38(56)30(20-34(43)54)47-37(55)29(18-23(2)3)46-39(57)31(22-51)44-26(7)52/h10-12,14-15,23-25,28-33,35-36,51,53H,9,13,16-22H2,1-8H3,(H2,43,54)(H,44,52)(H,45,56)(H,46,57)(H,47,55)(H,48,59)(H,49,58)/t25-,28?,29-,30-,31-,32-,33?,35-,36-/m0/s1
DMQP4VG	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)OC)NC(=O)[C@@H]1CCCN1CC(C(CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)C)O
DMQP4VG	IK	MJOXWVYKMFPFPL-AIVXTZMUSA-N
DMQP4VG	IU	methyl (2S)-2-[[(2S,3S)-2-[[(2S)-1-[3-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-2-hydroxy-4-phenylbutyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoate
DMQP4VG	CA	CAS 132748-20-0
DMQP4VG	DE	Discovery agent

DM0LD3F	ID	DM0LD3F
DM0LD3F	DN	JL-18
DM0LD3F	HS	Investigative
DM0LD3F	SN	NCGC00094013-01
DM0LD3F	DT	Small molecular drug
DM0LD3F	PC	3802
DM0LD3F	MW	307.4
DM0LD3F	FM	C18H21N5
DM0LD3F	IC	InChI=1S/C18H21N5/c1-13-5-6-15-14(12-13)18(23-10-8-22(2)9-11-23)21-16-4-3-7-19-17(16)20-15/h3-7,12H,8-11H2,1-2H3,(H,19,20)
DM0LD3F	CS	CC1=CC2=C(C=C1)NC3=C(C=CC=N3)N=C2N4CCN(CC4)C
DM0LD3F	IK	MMCMKWDIEUZMQB-UHFFFAOYSA-N
DM0LD3F	IU	8-methyl-6-(4-methylpiperazin-1-yl)-11H-pyrido[2,3-b][1,4]benzodiazepine
DM0LD3F	CA	CAS 147395-65-1
DM0LD3F	DE	Discovery agent

DMWMRO2	ID	DMWMRO2
DMWMRO2	DN	JM-1232(-)
DMWMRO2	HS	Investigative
DMWMRO2	SN	Sedative, Maruishi; Benzodiazepine agonist (sedation), Maruishi
DMWMRO2	CP	Maruishi Pharmaceutical Co Ltd
DMWMRO2	PC	17755150
DMWMRO2	MW	389.5
DMWMRO2	FM	C24H27N3O2
DMWMRO2	IC	InChI=1S/C24H27N3O2/c1-25-10-12-26(13-11-25)23(28)16-22-20-14-17-6-5-7-18(17)15-21(20)24(29)27(22)19-8-3-2-4-9-19/h2-4,8-9,14-15,22H,5-7,10-13,16H2,1H3/t22-/m1/s1
DMWMRO2	CS	CN1CCN(CC1)C(=O)C[C@@H]2C3=C(C=C4CCCC4=C3)C(=O)N2C5=CC=CC=C5
DMWMRO2	IK	MBGOHVUPIPFVMM-JOCHJYFZSA-N
DMWMRO2	IU	(3R)-3-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-phenyl-3,5,6,7-tetrahydrocyclopenta[f]isoindol-1-one
DMWMRO2	CA	CAS 1013427-48-9
DMWMRO2	DE	Anaesthesia

DMP1B9D	ID	DMP1B9D
DMP1B9D	DN	JMV 1535
DMP1B9D	HS	Investigative
DMP1B9D	SN	JMV 1535; CHEMBL437655
DMP1B9D	PC	44315745
DMP1B9D	MW	1081.3
DMP1B9D	FM	C54H76N14O10
DMP1B9D	IC	InChI=1S/C54H76N14O10/c1-30(2)21-41(47(57)71)65-52(76)42(22-31(3)4)66-53(77)44(25-35-27-58-29-60-35)62-46(70)28-68-20-12-11-17-40(54(68)78)64-48(72)32(5)61-51(75)43(24-34-26-59-38-16-10-9-15-36(34)38)67-50(74)39(18-19-45(56)69)63-49(73)37(55)23-33-13-7-6-8-14-33/h6-10,13-16,26-27,29-32,37,39-44,59H,11-12,17-25,28,55H2,1-5H3,(H2,56,69)(H2,57,71)(H,58,60)(H,61,75)(H,62,70)(H,63,73)(H,64,72)(H,65,76)(H,66,77)(H,67,74)/t32?,37-,39?,40?,41?,42?,43?,44?/m1/s1
DMP1B9D	CS	CC(C)CC(C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)[C@@H](CC5=CC=CC=C5)N
DMP1B9D	IK	FTAPYHDWDYGKIH-CJGWHWQJSA-N
DMP1B9D	IU	N-[1-[[1-[[1-[2-[[1-[[1-[(1-amino-4-methyl-1-oxopentan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]pentanediamide
DMP1B9D	DE	Discovery agent

DMARTN3	ID	DMARTN3
DMARTN3	DN	JMV 1693
DMARTN3	HS	Investigative
DMARTN3	SN	JMV 1693; CHEMBL407022
DMARTN3	DT	Small molecular drug
DMARTN3	PC	44315690
DMARTN3	MW	984.1
DMARTN3	FM	C48H65N13O10
DMARTN3	IC	InChI=1S/C48H65N13O10/c1-27(2)19-37(47(69)60-71)58-46(68)39(22-31-24-51-26-53-31)55-41(63)25-61-18-10-9-15-36(48(61)70)57-42(64)28(3)54-45(67)38(21-30-23-52-34-14-8-7-13-32(30)34)59-44(66)35(16-17-40(50)62)56-43(65)33(49)20-29-11-5-4-6-12-29/h4-8,11-14,23-24,26-28,33,35-39,52,71H,9-10,15-22,25,49H2,1-3H3,(H2,50,62)(H,51,53)(H,54,67)(H,55,63)(H,56,65)(H,57,64)(H,58,68)(H,59,66)(H,60,69)/t28?,33-,35?,36?,37-,38?,39?/m1/s1
DMARTN3	CS	CC(C)C[C@H](C(=O)NO)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)[C@@H](CC5=CC=CC=C5)N
DMARTN3	IK	FARKOIUETYEQIK-DBJXSMFVSA-N
DMARTN3	IU	2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-N-[1-[[1-[[1-[2-[[1-[[(2R)-1-(hydroxyamino)-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMARTN3	DE	Discovery agent

DM82HW9	ID	DM82HW9
DM82HW9	DN	JMV 1719
DM82HW9	HS	Investigative
DM82HW9	SN	JMV 1719; CHEMBL406013
DM82HW9	DT	Small molecular drug
DM82HW9	PC	44315688
DM82HW9	MW	985.1
DM82HW9	FM	C48H64N12O11
DM82HW9	IC	InChI=1S/C48H64N12O11/c1-27(2)20-37(47(69)59-71)57-46(68)39(22-31-24-50-26-52-31)55-42(64)25-60-19-7-6-10-36(48(60)70)56-43(65)28(3)53-45(67)38(21-30-23-51-34-9-5-4-8-33(30)34)58-44(66)35(16-17-40(49)62)54-41(63)18-13-29-11-14-32(61)15-12-29/h4-5,8-9,11-12,14-15,23-24,26-28,35-39,51,61,71H,6-7,10,13,16-22,25H2,1-3H3,(H2,49,62)(H,50,52)(H,53,67)(H,54,63)(H,55,64)(H,56,65)(H,57,68)(H,58,66)(H,59,69)/t28?,35?,36?,37-,38?,39?/m1/s1
DM82HW9	CS	CC(C)C[C@H](C(=O)NO)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)CCC5=CC=C(C=C5)O
DM82HW9	IK	SVDHLNPEHKDLER-PGRJMBAQSA-N
DM82HW9	IU	N-[1-[[1-[[1-[2-[[1-[[(2R)-1-(hydroxyamino)-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[3-(4-hydroxyphenyl)propanoylamino]pentanediamide
DM82HW9	DE	Discovery agent

DMX3P68	ID	DMX3P68
DMX3P68	DN	JMV 1799
DMX3P68	HS	Investigative
DMX3P68	SN	JMV 1799; CHEMBL415110
DMX3P68	DT	Small molecular drug
DMX3P68	PC	44315612
DMX3P68	MW	984.1
DMX3P68	FM	C49H65N11O11
DMX3P68	IC	InChI=1S/C49H65N11O11/c1-28(2)21-40(49(70)71-4)59-47(68)39(23-32-25-51-27-53-32)56-43(64)26-60-20-8-7-11-37(48(60)69)57-44(65)29(3)54-46(67)38(22-31-24-52-35-10-6-5-9-34(31)35)58-45(66)36(17-18-41(50)62)55-42(63)19-14-30-12-15-33(61)16-13-30/h5-6,9-10,12-13,15-16,24-25,27-29,36-40,52,61H,7-8,11,14,17-23,26H2,1-4H3,(H2,50,62)(H,51,53)(H,54,67)(H,55,63)(H,56,64)(H,57,65)(H,58,66)(H,59,68)
DMX3P68	CS	CC(C)CC(C(=O)OC)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)CCC5=CC=C(C=C5)O
DMX3P68	IK	SVPHNBMMYLAPKY-UHFFFAOYSA-N
DMX3P68	IU	methyl 2-[[2-[[2-[3-[2-[[2-[[5-amino-2-[3-(4-hydroxyphenyl)propanoylamino]-5-oxopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoylamino]-2-oxoazepan-1-yl]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoate
DMX3P68	DE	Discovery agent

DMTX694	ID	DMTX694
DMTX694	DN	JMV 1801
DMTX694	HS	Investigative
DMTX694	SN	JMV 1801; CHEMBL411016
DMTX694	PC	44315611
DMTX694	MW	1011.2
DMTX694	FM	C52H74N12O9
DMTX694	IC	InChI=1S/C52H74N12O9/c1-5-6-19-44(65)41(23-31(2)3)62-51(72)43(26-35-28-55-30-57-35)59-46(67)29-64-22-13-12-18-40(52(64)73)61-47(68)32(4)58-50(71)42(25-34-27-56-38-17-11-10-16-36(34)38)63-49(70)39(20-21-45(54)66)60-48(69)37(53)24-33-14-8-7-9-15-33/h7-11,14-17,27-28,30-32,37,39-44,56,65H,5-6,12-13,18-26,29,53H2,1-4H3,(H2,54,66)(H,55,57)(H,58,71)(H,59,67)(H,60,69)(H,61,68)(H,62,72)(H,63,70)/t32?,37-,39?,40?,41-,42?,43?,44?/m1/s1
DMTX694	CS	CCCCC([C@@H](CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)[C@@H](CC5=CC=CC=C5)N)O
DMTX694	IK	FJZSPPBJQIVSSX-SCVQECHTSA-N
DMTX694	IU	2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-N-[1-[[1-[[1-[2-[[1-[[(4R)-5-hydroxy-2-methylnonan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMTX694	DE	Discovery agent

DMGT6DN	ID	DMGT6DN
DMGT6DN	DN	JMV 1802
DMGT6DN	HS	Investigative
DMGT6DN	SN	JMV 1802; CHEMBL386480
DMGT6DN	PC	44315691
DMGT6DN	MW	1012.2
DMGT6DN	FM	C52H73N11O10
DMGT6DN	IC	InChI=1S/C52H73N11O10/c1-5-6-14-44(65)41(24-31(2)3)61-51(72)43(26-35-28-54-30-56-35)59-47(68)29-63-23-10-9-13-40(52(63)73)60-48(69)32(4)57-50(71)42(25-34-27-55-38-12-8-7-11-37(34)38)62-49(70)39(20-21-45(53)66)58-46(67)22-17-33-15-18-36(64)19-16-33/h7-8,11-12,15-16,18-19,27-28,30-32,39-44,55,64-65H,5-6,9-10,13-14,17,20-26,29H2,1-4H3,(H2,53,66)(H,54,56)(H,57,71)(H,58,67)(H,59,68)(H,60,69)(H,61,72)(H,62,70)/t32?,39?,40?,41-,42?,43?,44?/m1/s1
DMGT6DN	CS	CCCCC([C@@H](CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)CCC5=CC=C(C=C5)O)O
DMGT6DN	IK	SXWFVLCWIVAJQD-FUEGDDJLSA-N
DMGT6DN	IU	N-[1-[[1-[[1-[2-[[1-[[(4R)-5-hydroxy-2-methylnonan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[3-(4-hydroxyphenyl)propanoylamino]pentanediamide
DMGT6DN	DE	Discovery agent

DM248HC	ID	DM248HC
DM248HC	DN	JMV 1803
DM248HC	HS	Investigative
DM248HC	SN	JMV 1803; CHEMBL265856
DM248HC	PC	44315477
DM248HC	MW	1082.3
DM248HC	FM	C54H75N13O11
DM248HC	IC	InChI=1S/C54H75N13O11/c1-30(2)22-41(48(56)72)64-52(76)42(23-31(3)4)65-53(77)44(25-35-27-57-29-59-35)62-47(71)28-67-21-9-8-12-40(54(67)78)63-49(73)32(5)60-51(75)43(24-34-26-58-38-11-7-6-10-37(34)38)66-50(74)39(18-19-45(55)69)61-46(70)20-15-33-13-16-36(68)17-14-33/h6-7,10-11,13-14,16-17,26-27,29-32,39-44,58,68H,8-9,12,15,18-25,28H2,1-5H3,(H2,55,69)(H2,56,72)(H,57,59)(H,60,75)(H,61,70)(H,62,71)(H,63,73)(H,64,76)(H,65,77)(H,66,74)
DM248HC	CS	CC(C)CC(C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)CCC5=CC=C(C=C5)O
DM248HC	IK	HCLOOVPFXYLTPB-UHFFFAOYSA-N
DM248HC	IU	N-[1-[[1-[[1-[2-[[1-[[1-[(1-amino-4-methyl-1-oxopentan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[3-(4-hydroxyphenyl)propanoylamino]pentanediamide
DM248HC	DE	Discovery agent

DMSICYK	ID	DMSICYK
DMSICYK	DN	JMV 1813
DMSICYK	HS	Investigative
DMSICYK	SN	JMV 1813; CHEMBL415021
DMSICYK	DT	Small molecular drug
DMSICYK	PC	44315476
DMSICYK	MW	983.1
DMSICYK	FM	C49H66N12O10
DMSICYK	IC	InChI=1S/C49H66N12O10/c1-28(2)20-40(49(70)71-4)60-47(68)39(23-32-25-52-27-54-32)56-42(63)26-61-19-11-10-16-37(48(61)69)58-43(64)29(3)55-46(67)38(22-31-24-53-35-15-9-8-14-33(31)35)59-45(66)36(17-18-41(51)62)57-44(65)34(50)21-30-12-6-5-7-13-30/h5-9,12-15,24-25,27-29,34,36-40,53H,10-11,16-23,26,50H2,1-4H3,(H2,51,62)(H,52,54)(H,55,67)(H,56,63)(H,57,65)(H,58,64)(H,59,66)(H,60,68)/t29?,34-,36?,37?,38?,39?,40?/m1/s1
DMSICYK	CS	CC(C)CC(C(=O)OC)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)[C@@H](CC5=CC=CC=C5)N
DMSICYK	IK	LRJRTIDXMDONHY-UEHPUAOMSA-N
DMSICYK	IU	methyl 2-[[2-[[2-[3-[2-[[2-[[5-amino-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoylamino]-2-oxoazepan-1-yl]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoate
DMSICYK	DE	Discovery agent

DMAR3M2	ID	DMAR3M2
DMAR3M2	DN	JMV1431
DMAR3M2	HS	Investigative
DMAR3M2	SN	YMROZBYZFLPAPA-RONNJKQASA-N; JMV 1431; CHEMBL408846; JMV-1431; GTPL656; H-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1431);  JMV 1431
DMAR3M2	DT	Small molecular drug
DMAR3M2	PC	44316620
DMAR3M2	MW	1072.2
DMAR3M2	FM	C45H65N15O12S2
DMAR3M2	IC	InChI=1S/C45H65N15O12S2/c46-26(8-3-13-51-44(47)48)37(66)55-27(9-4-14-52-45(49)50)41(70)58-15-5-11-32(58)43(72)59-20-24(62)17-33(59)40(69)53-19-35(63)54-28(18-25-7-6-16-73-25)38(67)56-29(22-61)39(68)57-30-23-74-34-12-2-1-10-31(34)60(42(30)71)21-36(64)65/h1-2,6-7,10,12,16,24,26-30,32-33,61-62H,3-5,8-9,11,13-15,17-23,46H2,(H,53,69)(H,54,63)(H,55,66)(H,56,67)(H,57,68)(H,64,65)(H4,47,48,51)(H4,49,50,52)/t24?,26?,27-,28?,29+,30-,32+,33+/m1/s1
DMAR3M2	CS	C1C[C@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N[C@@H]4CSC5=CC=CC=C5N(C4=O)CC(=O)O)O
DMAR3M2	IK	YMROZBYZFLPAPA-RONNJKQASA-N
DMAR3M2	IU	2-[(3S)-3-[[(2S)-2-[[2-[[2-[[(2S)-1-[(2S)-1-[(2R)-2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]acetic acid
DMAR3M2	DE	Discovery agent

DM5G0IM	ID	DM5G0IM
DM5G0IM	DN	JMV180
DM5G0IM	HS	Investigative
DM5G0IM	SN	Boc-Tyr(SO3H)Ahx-Gly-Trp-Ahx-Asp2phenylethyl ester; JMV-180; JMV 180
DM5G0IM	DT	Small molecular drug
DM5G0IM	PC	5311195
DM5G0IM	MW	1084.2
DM5G0IM	FM	C51H73N9O15S
DM5G0IM	IC	InChI=1S/C51H67N7O15S.2H3N/c1-6-8-18-38(55-47(64)40(58-50(67)72-51(3,4)5)27-33-21-23-35(24-22-33)73-74(68,69)70)45(62)53-31-43(59)54-41(28-34-30-52-37-20-14-13-17-36(34)37)48(65)56-39(19-9-7-2)46(63)57-42(29-44(60)61)49(66)71-26-25-32-15-11-10-12-16-32;;/h10-17,20-24,30,38-42,52H,6-9,18-19,25-29,31H2,1-5H3,(H,53,62)(H,54,59)(H,55,64)(H,56,65)(H,57,63)(H,58,67)(H,60,61)(H,68,69,70);2*1H3/t38-,39-,40-,41-,42-;;/m0../s1
DM5G0IM	CS	CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)OCCC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)OC(C)(C)C.N.N
DM5G0IM	IK	NKUXFWRTWZIEIT-IKSUPOOSSA-N
DM5G0IM	IU	azane;(3S)-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-4-oxo-4-(2-phenylethoxy)butanoic acid
DM5G0IM	DE	Discovery agent

DMB9U17	ID	DMB9U17
DMB9U17	DN	JMV3008
DMB9U17	HS	Investigative
DMB9U17	SN	JMV3008; GTPL5872
DMB9U17	DT	Small molecular drug
DMB9U17	PC	74015851
DMB9U17	MW	603.7
DMB9U17	FM	C35H37N7O3
DMB9U17	IC	InChI=1S/C35H37N7O3/c1-4-22-21-41(30-14-8-6-11-26(22)30)35-40-39-33(42(35)31-16-15-24(44-2)19-32(31)45-3)29(38-34(43)28-13-9-17-36-28)18-23-20-37-27-12-7-5-10-25(23)27/h5-8,10-12,14-16,19-21,28-29,36-37H,4,9,13,17-18H2,1-3H3,(H,38,43)/t28-,29+/m0/s1
DMB9U17	CS	CCC1=CN(C2=CC=CC=C21)C3=NN=C(N3C4=C(C=C(C=C4)OC)OC)[C@@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@@H]7CCCN7
DMB9U17	IK	YAWJYESYIAWFJX-URLMMPGGSA-N
DMB9U17	IU	(2S)-N-[(1R)-1-[4-(2,4-dimethoxyphenyl)-5-(3-ethylindol-1-yl)-1,2,4-triazol-3-yl]-2-(1H-indol-3-yl)ethyl]pyrrolidine-2-carboxamide
DMB9U17	DE	Discovery agent

DME9GF8	ID	DME9GF8
DME9GF8	DN	JMV449
DME9GF8	HS	Investigative
DME9GF8	SN	JMV 449; JMV-449
DME9GF8	DT	Small molecular drug
DME9GF8	PC	164415
DME9GF8	MW	747
DME9GF8	FM	C38H66N8O7
DME9GF8	IC	InChI=1S/C38H66N8O7/c1-5-25(4)33(36(50)44-31(38(52)53)21-24(2)3)45-34(48)30(22-26-14-16-28(47)17-15-26)43-35(49)32-13-10-20-46(32)37(51)29(12-7-9-19-40)42-23-27(41)11-6-8-18-39/h14-17,24-25,27,29-33,42,47H,5-13,18-23,39-41H2,1-4H3,(H,43,49)(H,44,50)(H,45,48)(H,52,53)/t25-,27-,29-,30-,31-,32-,33-/m0/s1
DME9GF8	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC[C@H](CCCCN)N
DME9GF8	IK	TZCYVPLNMOJUIL-GULBXNHPSA-N
DME9GF8	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2,6-diaminohexyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DME9GF8	CA	CAS 139026-66-7
DME9GF8	DE	Discovery agent

DMC1ARG	ID	DMC1ARG
DMC1ARG	DN	JMV458
DMC1ARG	HS	Investigative
DMC1ARG	SN	JMV 458; JMV-458
DMC1ARG	DT	Small molecular drug
DMC1ARG	PC	5311320
DMC1ARG	MW	940.1
DMC1ARG	FM	C45H73N13O9
DMC1ARG	IC	InChI=1S/C45H73N13O9/c1-8-26(4)35(39(62)55-33(41(64)65)22-25(2)3)57-37(60)32(23-27-24-52-29-15-10-9-14-28(27)29)54-38(61)34-18-13-21-58(34)40(63)31(17-12-20-51-43(48)49)53-36(59)30(16-11-19-50-42(46)47)56-44(66)67-45(5,6)7/h9-10,14-15,24-26,30-35,52H,8,11-13,16-23H2,1-7H3,(H,53,59)(H,54,61)(H,55,62)(H,56,66)(H,57,60)(H,64,65)(H4,46,47,50)(H4,48,49,51)/t26-,30-,31-,32-,33-,34-,35-/m0/s1
DMC1ARG	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)OC(C)(C)C
DMC1ARG	IK	KOHSYJYVCLITLX-OLPQHFNPSA-N
DMC1ARG	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-5-(diaminomethylideneamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DMC1ARG	DE	Discovery agent

DMFU76I	ID	DMFU76I
DMFU76I	DN	JN-711
DMFU76I	HS	Investigative
DMFU76I	SN	Alpha-7 nicotinic acetylcholine receptor agonists (CNS disorders); Alpha-7 nicotinic acetylcholine receptor agonists (CNS disorders), Novartis
DMFU76I	CP	Novartis AG
DMFU76I	DE	Central nervous system disease

DM6P1UA	ID	DM6P1UA
DM6P1UA	DN	JNJ-10191584
DM6P1UA	HS	Investigative
DM6P1UA	SN	VUF 6002; JNJ 10191584; VUF6002; VUF-6002; JNJ10191584; compound 12
DM6P1UA	DT	Small molecular drug
DM6P1UA	PC	10446295
DM6P1UA	MW	278.74
DM6P1UA	FM	C13H15ClN4O
DM6P1UA	IC	InChI=1S/C13H15ClN4O/c1-17-4-6-18(7-5-17)13(19)12-15-10-3-2-9(14)8-11(10)16-12/h2-3,8H,4-7H2,1H3,(H,15,16)
DM6P1UA	CS	CN1CCN(CC1)C(=O)C2=NC3=C(N2)C=C(C=C3)Cl
DM6P1UA	IK	MOIWSUQWIOVGRH-UHFFFAOYSA-N
DM6P1UA	IU	(6-chloro-1H-benzimidazol-2-yl)-(4-methylpiperazin-1-yl)methanone
DM6P1UA	CA	CAS 73903-17-0
DM6P1UA	CB	CHEBI:92272
DM6P1UA	DE	Discovery agent

DM9GDP5	ID	DM9GDP5
DM9GDP5	DN	JNJ-10198409
DM9GDP5	HS	Investigative
DM9GDP5	SN	JNJ-10198409; 627518-40-5; PDGFR Tyrosine Kinase Inhibitor IV; PDGF Receptor Tyrosine Kinase Inhibitor IV; CHEMBL120077; N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine; 3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; ZDNURMVOKAERHZ-UHFFFAOYSA-N; SCHEMBL3088170; GTPL6020; CTK8E8807; jnj10198409; DTXSID70430890; MolPort-009-019-131; HMS3650O03; HMS3229I11; ZINC13677843; BDBM50179207; AKOS030525202; RWJ 540973; CCG-206773; NCGC00343986-02; RT-014973; KB-274227; SR-01000946814
DM9GDP5	DT	Small molecular drug
DM9GDP5	PC	9797370
DM9GDP5	MW	325.3
DM9GDP5	FM	C18H16FN3O2
DM9GDP5	IC	InChI=1S/C18H16FN3O2/c1-23-15-7-10-6-14-17(13(10)9-16(15)24-2)21-22-18(14)20-12-5-3-4-11(19)8-12/h3-5,7-9H,6H2,1-2H3,(H2,20,21,22)
DM9GDP5	CS	COC1=C(C=C2C(=C1)CC3=C2NN=C3NC4=CC(=CC=C4)F)OC
DM9GDP5	IK	ZDNURMVOKAERHZ-UHFFFAOYSA-N
DM9GDP5	IU	N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine
DM9GDP5	CA	CAS 627518-40-5
DM9GDP5	DE	Discovery agent

DMBRJ3C	ID	DMBRJ3C
DMBRJ3C	DN	JNJ-10329670
DMBRJ3C	HS	Investigative
DMBRJ3C	SN	Cathepsin S inhibitors (autoimmune disease); Cathepsin S inhibitors (autoimmune disease), J&J PRD; Cathepsin S inhibitors (autoimmune disease), Johnson & Johnson
DMBRJ3C	CP	Johnson & Johnson Pharmaceutical Research & Development LLC
DMBRJ3C	DT	Small molecular drug
DMBRJ3C	PC	10168449
DMBRJ3C	MW	651.1
DMBRJ3C	FM	C30H34ClF3N6O3S
DMBRJ3C	IC	InChI=1S/C30H34ClF3N6O3S/c1-36-26-9-8-22(31)18-27(26)40(29(36)41)23-10-15-37(16-11-23)13-3-14-39-25-12-17-38(44(2,42)43)19-24(25)28(35-39)20-4-6-21(7-5-20)30(32,33)34/h4-9,18,23H,3,10-17,19H2,1-2H3
DMBRJ3C	CS	CN1C2=C(C=C(C=C2)Cl)N(C1=O)C3CCN(CC3)CCCN4C5=C(CN(CC5)S(=O)(=O)C)C(=N4)C6=CC=C(C=C6)C(F)(F)F
DMBRJ3C	IK	NVAHQQYCEWEDKM-UHFFFAOYSA-N
DMBRJ3C	IU	5-chloro-1-methyl-3-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]benzimidazol-2-one
DMBRJ3C	CA	CAS 400797-24-2
DMBRJ3C	DE	Autoimmune diabetes

DMZH0K8	ID	DMZH0K8
DMZH0K8	DN	JNJ-10392980
DMZH0K8	HS	Investigative
DMZH0K8	SN	841200-46-2; benzoxazole,2-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-; JNJ-10392980; Benzoxazole compound, 10b; CHEMBL481863; SCHEMBL2170316; BDBM24203; ZIQGASWXUSSORV-UHFFFAOYSA-N; ZINC36377694; KB-306080; 2-[4-(2-Piperidin-1-yl-ethoxy)-phenoxy]-benzooxazole
DMZH0K8	DT	Small molecular drug
DMZH0K8	PC	11739248
DMZH0K8	MW	338.4
DMZH0K8	FM	C20H22N2O3
DMZH0K8	IC	InChI=1S/C20H22N2O3/c1-4-12-22(13-5-1)14-15-23-16-8-10-17(11-9-16)24-20-21-18-6-2-3-7-19(18)25-20/h2-3,6-11H,1,4-5,12-15H2
DMZH0K8	CS	C1CCN(CC1)CCOC2=CC=C(C=C2)OC3=NC4=CC=CC=C4O3
DMZH0K8	IK	ZIQGASWXUSSORV-UHFFFAOYSA-N
DMZH0K8	IU	2-[4-(2-piperidin-1-ylethoxy)phenoxy]-1,3-benzoxazole
DMZH0K8	DE	Discovery agent

DMZ8M0K	ID	DMZ8M0K
DMZ8M0K	DN	JNJ-10397049
DMZ8M0K	HS	Investigative
DMZ8M0K	SN	JNJ-10397049; JNJ 10397049; 708275-58-5; UNII-1B419P24AV; CHEMBL359632; 1B419P24AV; N-(2,4-Dibromophenyl)-N'-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]-urea; JNJ10397049; SCHEMBL1818251; GTPL1701; MolPort-035-765-717; ZINC3960325; BDBM50412863; AKOS024458089; compound 9 [PMID: 15261275]; 1-(2,4-Dibromophenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-(1,3)dioxan-5-yl)urea; Urea, N-(2,4-dibromophenyl)-N'-((4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-; NCGC00379105-01; KB-77996; B5553; J3.628.691A
DMZ8M0K	CP	Johnson & Johnson
DMZ8M0K	DT	Small molecular drug
DMZ8M0K	PC	9869934
DMZ8M0K	MW	484.2
DMZ8M0K	FM	C19H20Br2N2O3
DMZ8M0K	IC	InChI=1S/C19H20Br2N2O3/c1-19(2)25-11-16(17(26-19)12-6-4-3-5-7-12)23-18(24)22-15-9-8-13(20)10-14(15)21/h3-10,16-17H,11H2,1-2H3,(H2,22,23,24)/t16-,17-/m0/s1
DMZ8M0K	CS	CC1(OC[C@@H]([C@@H](O1)C2=CC=CC=C2)NC(=O)NC3=C(C=C(C=C3)Br)Br)C
DMZ8M0K	IK	RBKIJGLHFFQHBE-IRXDYDNUSA-N
DMZ8M0K	IU	1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea
DMZ8M0K	CA	CAS 708275-58-5
DMZ8M0K	DE	Insomnia

DMXNFU5	ID	DMXNFU5
DMXNFU5	DN	JNJ-16567083
DMXNFU5	HS	Investigative
DMXNFU5	SN	JNJ-16567083; CHEMBL253345; CHEMBL188906; CHEMBL1645348; EMQMCM; GTPL7442; SCHEMBL8352668; BDBM50231750; BDBM50333368; BDBM50171313; L021349; R-193845; (3-ethyl-2-methylquinolin-6-yl)-(4-methoxycyclohexyl)methanone; (3-ethyl-2-methylquinolin-6-yl)(4-methoxycyclohexyl)methanone; (3-ethyl-2-methyl-quinolin-6-yl)(4-methoxy-cyclohexyl)methanone; (3-Ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone
DMXNFU5	DT	Small molecular drug
DMXNFU5	PC	9948645
DMXNFU5	MW	311.4
DMXNFU5	FM	C20H25NO2
DMXNFU5	IC	InChI=1S/C20H25NO2/c1-4-14-11-17-12-16(7-10-19(17)21-13(14)2)20(22)15-5-8-18(23-3)9-6-15/h7,10-12,15,18H,4-6,8-9H2,1-3H3
DMXNFU5	CS	CCC1=C(N=C2C=CC(=CC2=C1)C(=O)C3CCC(CC3)OC)C
DMXNFU5	IK	VEURHZYLLRSEGL-UHFFFAOYSA-N
DMXNFU5	IU	(3-ethyl-2-methylquinolin-6-yl)-(4-methoxycyclohexyl)methanone
DMXNFU5	DE	Discovery agent

DM3ZNF9	ID	DM3ZNF9
DM3ZNF9	DN	JNJ-1661010
DM3ZNF9	HS	Investigative
DM3ZNF9	SN	681136-29-8; JNJ-1661010; JNJ 1661010; JNJ1661010; N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide; UNII-62521S57AU; 1-Piperazinecarboxamide, N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)-; N-PHENYL-4-(3-PHENYL-1,2,4-THIADIAZOL-5-YL)-1-PIPERAZINECARBOXAMIDE; CHEMBL460273; 62521S57AU; BHBOSTKQCZEAJM-UHFFFAOYSA-N; ACMC-20emff; AC1MDCTI; AC1Q5LMB; Oprea1_746619; MLS001111246; SCHEMBL1164398; GTPL5206; CTK1J2536; cid_2809273; DTXSID00384599; MolPort-001-806-365; HMS3651L15; HMS1662H10; HMS2801K13; BCP06935; EX-A2218
DM3ZNF9	DT	Small molecular drug
DM3ZNF9	PC	2809273
DM3ZNF9	MW	365.5
DM3ZNF9	FM	C19H19N5OS
DM3ZNF9	IC	InChI=1S/C19H19N5OS/c25-18(20-16-9-5-2-6-10-16)23-11-13-24(14-12-23)19-21-17(22-26-19)15-7-3-1-4-8-15/h1-10H,11-14H2,(H,20,25)
DM3ZNF9	CS	C1CN(CCN1C2=NC(=NS2)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DM3ZNF9	IK	BHBOSTKQCZEAJM-UHFFFAOYSA-N
DM3ZNF9	IU	N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide
DM3ZNF9	CA	CAS 681136-29-8
DM3ZNF9	DE	Discovery agent

DMJ1DE9	ID	DMJ1DE9
DMJ1DE9	DN	JNJ-17148066
DMJ1DE9	HS	Investigative
DMJ1DE9	SN	CHEMBL1088485; SCHEMBL14277842; BDBM50310388
DMJ1DE9	DT	Small molecular drug
DMJ1DE9	PC	44597742
DMJ1DE9	MW	485.6
DMJ1DE9	FM	C30H31NO5
DMJ1DE9	IC	InChI=1S/C30H31NO5/c32-21-7-11-26-27(18-21)35-16-12-25-24-10-6-22(33)19-28(24)36-30(29(25)26)20-4-8-23(9-5-20)34-17-15-31-13-2-1-3-14-31/h4-11,18-19,30,32-33H,1-3,12-17H2/t30-/m1/s1
DMJ1DE9	CS	C1CCN(CC1)CCOC2=CC=C(C=C2)[C@@H]3C4=C(CCOC5=C4C=CC(=C5)O)C6=C(O3)C=C(C=C6)O
DMJ1DE9	IK	OFYZVZJXVRFMIW-SSEXGKCCSA-N
DMJ1DE9	IU	(19R)-19-[4-(2-piperidin-1-ylethoxy)phenyl]-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaene-5,15-diol
DMJ1DE9	DE	Discovery agent

DMIXUNB	ID	DMIXUNB
DMIXUNB	DN	JNJ-17156516
DMIXUNB	HS	Investigative
DMIXUNB	SN	JNJ 17156516
DMIXUNB	DT	Small molecular drug
DMIXUNB	PC	11488979
DMIXUNB	MW	481.4
DMIXUNB	FM	C26H22Cl2N2O3
DMIXUNB	IC	InChI=1S/C26H22Cl2N2O3/c1-16-4-3-5-17(12-16)22(26(31)32)14-19-15-25(18-6-11-23(27)24(28)13-18)30(29-19)20-7-9-21(33-2)10-8-20/h3-13,15,22H,14H2,1-2H3,(H,31,32)/t22-/m0/s1
DMIXUNB	CS	CC1=CC(=CC=C1)[C@H](CC2=NN(C(=C2)C3=CC(=C(C=C3)Cl)Cl)C4=CC=C(C=C4)OC)C(=O)O
DMIXUNB	IK	UZCIUKFEIOCAOC-QFIPXVFZSA-N
DMIXUNB	IU	(2S)-3-[5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-2-(3-methylphenyl)propanoic acid
DMIXUNB	CA	CAS 649551-06-4
DMIXUNB	DE	Discovery agent

DMDUWBF	ID	DMDUWBF
DMDUWBF	DN	JNJ-17203212
DMDUWBF	HS	Investigative
DMDUWBF	SN	JNJ-17203212; 821768-06-3; JNJ 17203212; UNII-71JE0C439X; CHEMBL254778; 71JE0C439X; 4-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide; 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide; JFRYYGVYCWYIDQ-UHFFFAOYSA-N; 4-(3-(trifluoromethyl)pyridin-2-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)piperazine-1-carboxamide; JNJ17203212; SCHEMBL138342; GTPL4228; CTK5E9468; C17H15F6N5O; DTXSID50462856; AOB2189; SYN5009; MolPort-006-822-716
DMDUWBF	DT	Small molecular drug
DMDUWBF	PC	11339118
DMDUWBF	MW	419.32
DMDUWBF	FM	C17H15F6N5O
DMDUWBF	IC	InChI=1S/C17H15F6N5O/c18-16(19,20)11-3-4-13(25-10-11)26-15(29)28-8-6-27(7-9-28)14-12(17(21,22)23)2-1-5-24-14/h1-5,10H,6-9H2,(H,25,26,29)
DMDUWBF	CS	C1CN(CCN1C2=C(C=CC=N2)C(F)(F)F)C(=O)NC3=NC=C(C=C3)C(F)(F)F
DMDUWBF	IK	JFRYYGVYCWYIDQ-UHFFFAOYSA-N
DMDUWBF	IU	4-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide
DMDUWBF	CA	CAS 821768-06-3
DMDUWBF	DE	Cough

DMKH9O7	ID	DMKH9O7
DMKH9O7	DN	JNJ-1930942
DMKH9O7	HS	Investigative
DMKH9O7	SN	JNJ-41512549; Alpha-7 nicotinic acetylcholine receptor modulator (cognitive disorder), Johnson & Johnson
DMKH9O7	CP	Johnson & Johnson
DMKH9O7	DT	Small molecular drug
DMKH9O7	PC	44240744
DMKH9O7	MW	369.3
DMKH9O7	FM	C16H11F4N3OS
DMKH9O7	IC	InChI=1S/C16H11F4N3OS/c17-12-2-1-10(7-11(12)16(18,19)20)22-15-23-14(13(8-24)25-15)9-3-5-21-6-4-9/h1-7,24H,8H2,(H,22,23)
DMKH9O7	CS	C1=CC(=C(C=C1NC2=NC(=C(S2)CO)C3=CC=NC=C3)C(F)(F)F)F
DMKH9O7	IK	JBSVHWCIKVSTTH-UHFFFAOYSA-N
DMKH9O7	IU	[2-[4-fluoro-3-(trifluoromethyl)anilino]-4-pyridin-4-yl-1,3-thiazol-5-yl]methanol
DMKH9O7	CA	CAS 929562-28-7
DMKH9O7	DE	Cognitive impairment

DM94IJC	ID	DM94IJC
DM94IJC	DN	JNJ-19398990
DM94IJC	HS	Investigative
DM94IJC	SN	JNJ-19398990; CHEMBL1085429; BDBM50310424
DM94IJC	DT	Small molecular drug
DM94IJC	PC	10029432
DM94IJC	MW	513.6
DM94IJC	FM	C32H35NO5
DM94IJC	IC	InChI=1S/C32H35NO5/c1-34-24-11-13-28-29(20-24)37-18-14-27-26-12-10-25(35-2)21-30(26)38-32(31(27)28)22-6-8-23(9-7-22)36-19-17-33-15-4-3-5-16-33/h6-13,20-21,32H,3-5,14-19H2,1-2H3/t32-/m1/s1
DM94IJC	CS	COC1=CC2=C(C=C1)C3=C([C@H](O2)C4=CC=C(C=C4)OCCN5CCCCC5)C6=C(C=C(C=C6)OC)OCC3
DM94IJC	IK	IFCSDJGUXGRSFR-JGCGQSQUSA-N
DM94IJC	IU	1-[2-[4-[(19R)-5,15-dimethoxy-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaen-19-yl]phenoxy]ethyl]piperidine
DM94IJC	CA	CAS 810668-60-1
DM94IJC	DE	Discovery agent

DMK6TVN	ID	DMK6TVN
DMK6TVN	DN	JNJ-26529126
DMK6TVN	HS	Investigative
DMK6TVN	SN	JNJ-26529126; CHEMBL1088343; BDBM50310407
DMK6TVN	DT	Small molecular drug
DMK6TVN	PC	9848809
DMK6TVN	MW	499.6
DMK6TVN	FM	C31H33NO5
DMK6TVN	IC	InChI=1S/C31H33NO5/c1-34-24-10-12-27-28(20-24)36-17-13-26-25-11-7-22(33)19-29(25)37-31(30(26)27)21-5-8-23(9-6-21)35-18-16-32-14-3-2-4-15-32/h5-12,19-20,31,33H,2-4,13-18H2,1H3/t31-/m1/s1
DMK6TVN	CS	COC1=CC2=C(C=C1)C3=C(CCO2)C4=C(C=C(C=C4)O)O[C@@H]3C5=CC=C(C=C5)OCCN6CCCCC6
DMK6TVN	IK	BHYFKQDXXVAJEL-WJOKGBTCSA-N
DMK6TVN	IU	(19R)-5-methoxy-19-[4-(2-piperidin-1-ylethoxy)phenyl]-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaen-15-ol
DMK6TVN	DE	Discovery agent

DMBZ7MA	ID	DMBZ7MA
DMBZ7MA	DN	JNJ-26529152
DMBZ7MA	HS	Investigative
DMBZ7MA	SN	JNJ-26529152; CHEMBL1088483; BDBM50310372
DMBZ7MA	DT	Small molecular drug
DMBZ7MA	PC	10323679
DMBZ7MA	MW	499.6
DMBZ7MA	FM	C31H33NO5
DMBZ7MA	IC	InChI=1S/C31H33NO5/c1-34-24-10-12-25-26-13-17-36-28-19-22(33)7-11-27(28)30(26)31(37-29(25)20-24)21-5-8-23(9-6-21)35-18-16-32-14-3-2-4-15-32/h5-12,19-20,31,33H,2-4,13-18H2,1H3/t31-/m1/s1
DMBZ7MA	CS	COC1=CC2=C(C=C1)C3=C([C@H](O2)C4=CC=C(C=C4)OCCN5CCCCC5)C6=C(C=C(C=C6)O)OCC3
DMBZ7MA	IK	MEGWHNJGIHFDSO-WJOKGBTCSA-N
DMBZ7MA	IU	(19R)-15-methoxy-19-[4-(2-piperidin-1-ylethoxy)phenyl]-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaen-5-ol
DMBZ7MA	DE	Discovery agent

DMCMH7O	ID	DMCMH7O
DMCMH7O	DN	JNJ-28312141
DMCMH7O	HS	Investigative
DMCMH7O	SN	JNJ 28312141
DMCMH7O	DT	Small molecular drug
DMCMH7O	PC	11676971
DMCMH7O	MW	460.6
DMCMH7O	FM	C26H32N6O2
DMCMH7O	IC	InChI=1S/C26H32N6O2/c1-31(2)17-24(33)32-12-10-18(11-13-32)20-8-9-23(22(14-20)19-6-4-3-5-7-19)30-26(34)25-28-16-21(15-27)29-25/h6,8-9,14,16,18H,3-5,7,10-13,17H2,1-2H3,(H,28,29)(H,30,34)
DMCMH7O	CS	CN(C)CC(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4
DMCMH7O	IK	GUBJNPWVIUFSTR-UHFFFAOYSA-N
DMCMH7O	IU	5-cyano-N-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1H-imidazole-2-carboxamide
DMCMH7O	CA	CAS 885692-52-4
DMCMH7O	DE	Discovery agent

DM84PWI	ID	DM84PWI
DM84PWI	DN	JNJ-28318706
DM84PWI	HS	Investigative
DM84PWI	SN	JNJ-28318706; CHEMBL572138; SCHEMBL1733714; BDBM50302228
DM84PWI	DT	Small molecular drug
DM84PWI	PC	23627612
DM84PWI	MW	485.6
DM84PWI	FM	C29H31N3O4
DM84PWI	IC	InChI=1S/C29H31N3O4/c1-20(22-8-5-4-6-9-22)30-14-16-31(17-15-30)24-11-7-10-23-27(24)29(34)32(28(23)33)19-21-12-13-25(35-2)26(18-21)36-3/h4-13,18,20H,14-17,19H2,1-3H3/t20-/m1/s1
DM84PWI	CS	C[C@H](C1=CC=CC=C1)N2CCN(CC2)C3=CC=CC4=C3C(=O)N(C4=O)CC5=CC(=C(C=C5)OC)OC
DM84PWI	IK	XVYISGJLURJDNX-HXUWFJFHSA-N
DM84PWI	IU	2-[(3,4-dimethoxyphenyl)methyl]-4-[4-[(1R)-1-phenylethyl]piperazin-1-yl]isoindole-1,3-dione
DM84PWI	DE	Discovery agent

DM5LEOR	ID	DM5LEOR
DM5LEOR	DN	JNJ-28583867
DM5LEOR	HS	Investigative
DM5LEOR	SN	JNJ-28583867; CHEMBL257917
DM5LEOR	DT	Small molecular drug
DM5LEOR	PC	44456154
DM5LEOR	MW	412.6
DM5LEOR	FM	C24H32N2O2S
DM5LEOR	IC	InChI=1S/C24H32N2O2S/c1-25-17-20-16-21(28-13-3-10-26-11-14-27-15-12-26)6-9-23(20)24(18-25)19-4-7-22(29-2)8-5-19/h4-9,16,24H,3,10-15,17-18H2,1-2H3/t24-/m0/s1
DM5LEOR	CS	CN1C[C@H](C2=C(C1)C=C(C=C2)OCCCN3CCOCC3)C4=CC=C(C=C4)SC
DM5LEOR	IK	XYYGFCDTBHAUSN-DEOSSOPVSA-N
DM5LEOR	IU	4-[3-[[(4S)-2-methyl-4-(4-methylsulfanylphenyl)-3,4-dihydro-1H-isoquinolin-7-yl]oxy]propyl]morpholine
DM5LEOR	DE	Discovery agent

DM48Y9E	ID	DM48Y9E
DM48Y9E	DN	JNJ-38158471
DM48Y9E	HS	Investigative
DM48Y9E	SN	VEGFR-2 inhibitors (angiogenesis disorder/cancer); VEGFR-2 inhibitors (angiogenesis disorder/cancer), Johnson & Johnson
DM48Y9E	CP	Johnson & Johnson
DM48Y9E	DT	Small molecular drug
DM48Y9E	PC	16742063
DM48Y9E	MW	364.79
DM48Y9E	FM	C15H17ClN6O3
DM48Y9E	IC	InChI=1S/C15H17ClN6O3/c1-3-18-15(23)22-12-5-4-9(6-11(12)16)25-14-10(7-21-24-2)13(17)19-8-20-14/h4-8H,3H2,1-2H3,(H2,17,19,20)(H2,18,22,23)/b21-7+
DM48Y9E	CS	CCNC(=O)NC1=C(C=C(C=C1)OC2=NC=NC(=C2/C=N/OC)N)Cl
DM48Y9E	IK	BJHCYTJNPVGSBZ-QPSGOUHRSA-N
DM48Y9E	IU	1-[4-[6-amino-5-[(E)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea
DM48Y9E	DE	Angiogenesis disorder

DMLOQ92	ID	DMLOQ92
DMLOQ92	DN	JNJ-42153605
DMLOQ92	HS	Investigative
DMLOQ92	SN	JNJ 42153605
DMLOQ92	DT	Small molecular drug
DMLOQ92	PC	49765871
DMLOQ92	MW	400.4
DMLOQ92	FM	C22H23F3N4
DMLOQ92	IC	InChI=1S/C22H23F3N4/c23-22(24,25)20-18(10-13-29-19(14-15-6-7-15)26-27-21(20)29)28-11-8-17(9-12-28)16-4-2-1-3-5-16/h1-5,10,13,15,17H,6-9,11-12,14H2
DMLOQ92	CS	C1CC1CC2=NN=C3N2C=CC(=C3C(F)(F)F)N4CCC(CC4)C5=CC=CC=C5
DMLOQ92	IK	BQAVZGJJQFJSMW-UHFFFAOYSA-N
DMLOQ92	IU	3-(cyclopropylmethyl)-7-(4-phenylpiperidin-1-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine
DMLOQ92	DE	Discovery agent

DMWYU5C	ID	DMWYU5C
DMWYU5C	DN	JNJ-5207787
DMWYU5C	HS	Investigative
DMWYU5C	SN	JNJ5207787
DMWYU5C	DT	Small molecular drug
DMWYU5C	PC	10324083
DMWYU5C	MW	510.7
DMWYU5C	FM	C32H38N4O2
DMWYU5C	IC	InChI=1S/C32H38N4O2/c1-24(37)35-20-14-28-10-11-30(22-31(28)35)36(32(38)12-9-26-7-4-8-27(21-26)23-33)29-15-18-34(19-16-29)17-13-25-5-2-3-6-25/h4,7-12,21-22,25,29H,2-3,5-6,13-20H2,1H3/b12-9+
DMWYU5C	CS	CC(=O)N1CCC2=C1C=C(C=C2)N(C3CCN(CC3)CCC4CCCC4)C(=O)/C=C/C5=CC(=CC=C5)C#N
DMWYU5C	IK	DSEJCLDJIFTPPH-FMIVXFBMSA-N
DMWYU5C	IU	(E)-N-(1-acetyl-2,3-dihydroindol-6-yl)-3-(3-cyanophenyl)-N-[1-(2-cyclopentylethyl)piperidin-4-yl]prop-2-enamide
DMWYU5C	CA	CAS 683746-68-1
DMWYU5C	DE	Discovery agent

DM5L23N	ID	DM5L23N
DM5L23N	DN	JNJ-5207852
DM5L23N	HS	Investigative
DM5L23N	SN	398473-34-2; JNJ-5207852; UNII-4I9OVB1G7D; JNJ 5207852; 1-[4-(3-piperidinopropoxy)benzyl]piperidine; 4I9OVB1G7D; CHEMBL129542; JNJ 5207852 dihydrochloride; 1-[3-[4-(piperidin-1-ylmethyl)phenoxy]propyl]piperidine; Piperidine, 1-(3-(4-(1-piperidinylmethyl)phenoxy)propyl)-; 1-(3-(4-((Piperidin-1-yl)methyl)phenoxy)propyl)piperidine; 1-(3-(4-(piperidin-1-ylmethyl)phenoxy)propyl)piperidine; Piperidine, 1-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]-; 1-(3-{4-[(piperidin-1-yl)methyl]phenoxy}propyl)piperidine; AC1MCCJO
DM5L23N	CP	Johnson & Johnson
DM5L23N	DT	Small molecular drug
DM5L23N	PC	2766326
DM5L23N	MW	316.5
DM5L23N	FM	C20H32N2O
DM5L23N	IC	InChI=1S/C20H32N2O/c1-3-12-21(13-4-1)16-7-17-23-20-10-8-19(9-11-20)18-22-14-5-2-6-15-22/h8-11H,1-7,12-18H2
DM5L23N	CS	C1CCN(CC1)CCCOC2=CC=C(C=C2)CN3CCCCC3
DM5L23N	IK	PTKHFRNHJULJKT-UHFFFAOYSA-N
DM5L23N	IU	1-[3-[4-(piperidin-1-ylmethyl)phenoxy]propyl]piperidine
DM5L23N	CA	CAS 398473-34-2
DM5L23N	DE	Narcolepsy

DMHTYBS	ID	DMHTYBS
DMHTYBS	DN	JNJ-7706621
DMHTYBS	HS	Investigative
DMHTYBS	SN	JNJ-7706621; 443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide
DMHTYBS	DT	Small molecular drug
DMHTYBS	PC	5330790
DMHTYBS	MW	394.4
DMHTYBS	FM	C15H12F2N6O3S
DMHTYBS	IC	InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)
DMHTYBS	CS	C1=CC(=C(C(=C1)F)C(=O)N2C(=NC(=N2)NC3=CC=C(C=C3)S(=O)(=O)N)N)F
DMHTYBS	IK	KDKUVYLMPJIGKA-UHFFFAOYSA-N
DMHTYBS	IU	4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide
DMHTYBS	CA	CAS 443797-96-4
DMHTYBS	CB	CHEBI:94506
DMHTYBS	DE	Discovery agent

DMLWYJB	ID	DMLWYJB
DMLWYJB	DN	JNK-IN-8
DMLWYJB	HS	Investigative
DMLWYJB	SN	JNK-IN-8; 1410880-22-6; JNK Inhibitor XVI; 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; JNK-IN8; GTPL8058; CHEMBL2216824; SCHEMBL14979761; BDBM86633; DTXSID40720937; CHEBI:124918; MolPort-035-395-752; EX-A2206; BCP09744; ZINC89464842; s4901; AKOS030526496; SB19427; CS-0601; NCGC00386243-05; HY-13319; BC600656; Y1469; SW219193-1; W-5897; J-007458; 3-{[(2E)-4-(Dimethylamino)but-2-enoyl]amino}-N-(3-methyl-4-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
DMLWYJB	DT	Small molecular drug
DMLWYJB	PC	57340686
DMLWYJB	MW	507.6
DMLWYJB	FM	C29H29N7O2
DMLWYJB	IC	InChI=1S/C29H29N7O2/c1-20-17-24(11-12-25(20)34-29-31-15-13-26(35-29)22-8-5-14-30-19-22)33-28(38)21-7-4-9-23(18-21)32-27(37)10-6-16-36(2)3/h4-15,17-19H,16H2,1-3H3,(H,32,37)(H,33,38)(H,31,34,35)/b10-6+
DMLWYJB	CS	CC1=C(C=CC(=C1)NC(=O)C2=CC(=CC=C2)NC(=O)/C=C/CN(C)C)NC3=NC=CC(=N3)C4=CN=CC=C4
DMLWYJB	IK	GJFCSAPFHAXMSF-UXBLZVDNSA-N
DMLWYJB	IU	3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMLWYJB	CA	CAS 1410880-22-6
DMLWYJB	CB	CHEBI:124918
DMLWYJB	DE	Discovery agent

DMYBJ4K	ID	DMYBJ4K
DMYBJ4K	DN	joro toxin
DMYBJ4K	HS	Investigative
DMYBJ4K	SN	Joro spider toxin; Joro toxin; JSTX-3; 112163-33-4; Joro Spider Toxin 3; AC1L3P2K; CHEMBL313747; CHEBI:34802; Butanediamide, N1-(5-((3-((4-((3-aminopropyl)amino)butyl)amino)-1-oxopropyl)amino)pentyl)-2-(((2,4-dihydroxyphenyl)acetyl)amino)-, (2S)-; (2S)-N-[5-[3-[4-(3-aminopropylamino)butylamino]propanoylamino]pentyl]-2-[[2-(2,4-dihydroxyphenyl)acetyl]amino]butanediamide; GTPL4229; CTK8E9607; DTXSID50149933; ZINC4654981; BDBM50105843; RT-013407; FT-0771159; C13931; J-002718
DMYBJ4K	DT	Small molecular drug
DMYBJ4K	PC	119582
DMYBJ4K	MW	565.7
DMYBJ4K	FM	C27H47N7O6
DMYBJ4K	IC	InChI=1S/C27H47N7O6/c28-10-6-13-30-11-4-5-12-31-16-9-25(38)32-14-2-1-3-15-33-27(40)22(19-24(29)37)34-26(39)17-20-7-8-21(35)18-23(20)36/h7-8,18,22,30-31,35-36H,1-6,9-17,19,28H2,(H2,29,37)(H,32,38)(H,33,40)(H,34,39)/t22-/m0/s1
DMYBJ4K	CS	C1=CC(=C(C=C1O)O)CC(=O)N[C@@H](CC(=O)N)C(=O)NCCCCCNC(=O)CCNCCCCNCCCN
DMYBJ4K	IK	SJLRBGDPTALRDM-QFIPXVFZSA-N
DMYBJ4K	IU	(2S)-N-[5-[3-[4-(3-aminopropylamino)butylamino]propanoylamino]pentyl]-2-[[2-(2,4-dihydroxyphenyl)acetyl]amino]butanediamide
DMYBJ4K	CA	CAS 112163-33-4
DMYBJ4K	CB	CHEBI:34802
DMYBJ4K	DE	Discovery agent

DMMVBK6	ID	DMMVBK6
DMMVBK6	DN	JP1302
DMMVBK6	HS	Investigative
DMMVBK6	SN	N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine; GNF-PF-3427; TCMDC-123912; BRN 5117597; 80259-18-3; MMV006172; JP 1302; N-[4-(4-methylpiperazin-1-yl)phenyl]acridin-9-amine; CHEMBL106525; QZKGUNQLVFEEBA-UHFFFAOYSA-N; 9-Acridinamine, N-(4-(4-methyl-1-piperazinyl)phenyl)-; Acridin-9-yl-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine; N-(4-(4-methylpiperazin-1-yl)phenyl)acridin-9-amine; N-[4-(4-Methyl-1-piperazinyl)phenyl]-9-acridinamine; 9-Acridinamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-; JP-1302;  JP-1302
DMMVBK6	DT	Small molecular drug
DMMVBK6	PC	540335
DMMVBK6	MW	368.5
DMMVBK6	FM	C24H24N4
DMMVBK6	IC	InChI=1S/C24H24N4/c1-27-14-16-28(17-15-27)19-12-10-18(11-13-19)25-24-20-6-2-4-8-22(20)26-23-9-5-3-7-21(23)24/h2-13H,14-17H2,1H3,(H,25,26)
DMMVBK6	CS	CN1CCN(CC1)C2=CC=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53
DMMVBK6	IK	QZKGUNQLVFEEBA-UHFFFAOYSA-N
DMMVBK6	IU	N-[4-(4-methylpiperazin-1-yl)phenyl]acridin-9-amine
DMMVBK6	CA	CAS 80259-18-3
DMMVBK6	DE	Discovery agent

DM3XQDH	ID	DM3XQDH
DM3XQDH	DN	JQ1
DM3XQDH	HS	Investigative
DM3XQDH	SN	JQ1 compound; JQ-1; UNII-1MRH0IMX0W; (S)-JQ1; Bromodomain Inhibitor, (+)-JQ1; 1MRH0IMX0W
DM3XQDH	TC	Antiviral Agents
DM3XQDH	DT	Small molecular drug
DM3XQDH	PC	46907787
DM3XQDH	MW	457
DM3XQDH	FM	C23H25ClN4O2S
DM3XQDH	IC	InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1
DM3XQDH	CS	CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C
DM3XQDH	IK	DNVXATUJJDPFDM-KRWDZBQOSA-N
DM3XQDH	IU	tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate
DM3XQDH	CA	CAS 1268524-70-4
DM3XQDH	CB	CHEBI:95080
DM3XQDH	DE	Coronavirus Disease 2019 (COVID-19)

DMD9W0B	ID	DMD9W0B
DMD9W0B	DN	JT-2724
DMD9W0B	HS	Investigative
DMD9W0B	DE	Discovery agent

DMXZ9RF	ID	DMXZ9RF
DMXZ9RF	DN	JWB-1-84-1
DMXZ9RF	HS	Investigative
DMXZ9RF	SN	Choline analogs (neurodegenerative diseases); Choline analogs (neurodegenerative diseases), Medical College of Georgia; JWB-1-B4-1
DMXZ9RF	CP	Medical College of Georgia
DMXZ9RF	DE	Neurological disorder

DMYX30S	ID	DMYX30S
DMYX30S	DN	JWH-051
DMYX30S	HS	Investigative
DMYX30S	SN	CB2 receptor agonists (pain); CB2 receptor agonists (pain), Merck
DMYX30S	CP	Merck & Co Inc
DMYX30S	PC	9799540
DMYX30S	MW	370.6
DMYX30S	FM	C25H38O2
DMYX30S	IC	InChI=1S/C25H38O2/c1-6-7-8-9-14-24(2,3)19-11-12-20-21-15-18(17-26)10-13-22(21)25(4,5)27-23(20)16-19/h10-12,16,21-22,26H,6-9,13-15,17H2,1-5H3/t21-,22+/m0/s1
DMYX30S	CS	CCCCCCC(C)(C)C1=CC2=C(C=C1)[C@@H]3CC(=CC[C@H]3C(O2)(C)C)CO
DMYX30S	IK	ORTVDISIJXKUAV-FCHUYYIVSA-N
DMYX30S	IU	[(6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl]methanol
DMYX30S	DE	Pain

DM7JQDS	ID	DM7JQDS
DM7JQDS	DN	JWH-120
DM7JQDS	HS	Investigative
DM7JQDS	SN	JWH-120; UNII-J6M7L6J6PN; J6M7L6J6PN; CHEMBL497811; 824955-98-8; Methanone, (4-methyl-1-naphthalenyl)(1-propyl-1H-indol-3-yl)-; SCHEMBL6325731; CTK3D9085; DTXSID20466689; (4-methylnaphthalen-1-yl)(1-propyl-1H-indol-3-yl)methanone; BDBM50265747
DM7JQDS	DT	Small molecular drug
DM7JQDS	PC	11461586
DM7JQDS	MW	327.4
DM7JQDS	FM	C23H21NO
DM7JQDS	IC	InChI=1S/C23H21NO/c1-3-14-24-15-21(19-10-6-7-11-22(19)24)23(25)20-13-12-16(2)17-8-4-5-9-18(17)20/h4-13,15H,3,14H2,1-2H3
DM7JQDS	CS	CCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=C(C4=CC=CC=C43)C
DM7JQDS	IK	DUBUGSKBMMXSOU-UHFFFAOYSA-N
DM7JQDS	IU	(4-methylnaphthalen-1-yl)-(1-propylindol-3-yl)methanone
DM7JQDS	CA	CAS 824955-98-8
DM7JQDS	DE	Discovery agent

DM1DEYU	ID	DM1DEYU
DM1DEYU	DN	JWH-133
DM1DEYU	HS	Investigative
DM1DEYU	SN	JWH-133; 259869-55-1; JWH 133; JWH133; CHEMBL371214; (6AR,10AR)-3-(1,1-DIMETHYLBUTYL)-6A,7,10,10A-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO[B,D]PYRAN; JW-133/JW133; (6aR,10aR)-6,6,9-trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene; (6aR,10aR)-6,6,9-trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene; (6aR,10aR)-6,6,9-Trimethyl-3-(2-methyl-2-pentanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene; YSBFLLZNALVODA-RBUKOAKNSA-N; JW 133; AC1OCFIJ
DM1DEYU	DT	Small molecular drug
DM1DEYU	PC	6918505
DM1DEYU	MW	312.5
DM1DEYU	FM	C22H32O
DM1DEYU	IC	InChI=1S/C22H32O/c1-7-12-21(3,4)16-9-10-17-18-13-15(2)8-11-19(18)22(5,6)23-20(17)14-16/h8-10,14,18-19H,7,11-13H2,1-6H3/t18-,19+/m0/s1
DM1DEYU	CS	CCCC(C)(C)C1=CC2=C(C=C1)[C@@H]3CC(=CC[C@H]3C(O2)(C)C)C
DM1DEYU	IK	YSBFLLZNALVODA-RBUKOAKNSA-N
DM1DEYU	IU	(6aR,10aR)-6,6,9-trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene
DM1DEYU	CA	CAS 259869-55-1
DM1DEYU	CB	CHEBI:146243
DM1DEYU	DE	Discovery agent

DMZQ31O	ID	DMZQ31O
DMZQ31O	DN	JWH-145
DMZQ31O	HS	Investigative
DMZQ31O	SN	JWH-145; CHEMBL385940; naphthalen-1-yl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)methanone; JLXYYSHMURZHKI-UHFFFAOYSA-N; JWH 145; ZINC36294590
DMZQ31O	DT	Small molecular drug
DMZQ31O	PC	44418304
DMZQ31O	MW	367.5
DMZQ31O	FM	C26H25NO
DMZQ31O	IC	InChI=1S/C26H25NO/c1-2-3-9-17-27-19-22(18-25(27)21-12-5-4-6-13-21)26(28)24-16-10-14-20-11-7-8-15-23(20)24/h4-8,10-16,18-19H,2-3,9,17H2,1H3
DMZQ31O	CS	CCCCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMZQ31O	IK	JLXYYSHMURZHKI-UHFFFAOYSA-N
DMZQ31O	IU	naphthalen-1-yl-(1-pentyl-5-phenylpyrrol-3-yl)methanone
DMZQ31O	CA	CAS 914458-19-8
DMZQ31O	DE	Discovery agent

DMU7E6A	ID	DMU7E6A
DMU7E6A	DN	JWH-146
DMU7E6A	HS	Investigative
DMU7E6A	SN	JWH-146; CHEMBL219970; 914458-21-2; (1-Heptyl-5-phenyl-1H-pyrrol-3-yl)-1-naphthalenylmethanone; ZINC36294593; BDBM50192598
DMU7E6A	DT	Small molecular drug
DMU7E6A	PC	44418308
DMU7E6A	MW	395.5
DMU7E6A	FM	C28H29NO
DMU7E6A	IC	InChI=1S/C28H29NO/c1-2-3-4-5-11-19-29-21-24(20-27(29)23-14-7-6-8-15-23)28(30)26-18-12-16-22-13-9-10-17-25(22)26/h6-10,12-18,20-21H,2-5,11,19H2,1H3
DMU7E6A	CS	CCCCCCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMU7E6A	IK	JDBFNFBWXVCTSA-UHFFFAOYSA-N
DMU7E6A	IU	(1-heptyl-5-phenylpyrrol-3-yl)-naphthalen-1-ylmethanone
DMU7E6A	CA	CAS 914458-21-2
DMU7E6A	DE	Discovery agent

DMEX9GV	ID	DMEX9GV
DMEX9GV	DN	JWH-147
DMEX9GV	HS	Investigative
DMEX9GV	SN	JWH-147; 914458-20-1; CHEMBL374982; (1-hexyl-5-phenyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone; SCHEMBL15435604; JWH 147; DTXSID00658823; FRMYAMAGHYHNKF-UHFFFAOYSA-N; JWH-147"; ZINC36294592; BDBM50192588; AKOS015950991; AB1006809; FT-0669208; 1-Hexyl-2-phenyl-4-(1-naphthoyl)pyrroleJWH-147; 1-Hexyl-2-phenyl-4-(1-naphthoyl)pyrrole JWH-147; (1-Hexyl-5-phenyl-1H-pyrrol-3-yl)-1-naphthalenylmethanone
DMEX9GV	DT	Small molecular drug
DMEX9GV	PC	44418307
DMEX9GV	MW	381.5
DMEX9GV	FM	C27H27NO
DMEX9GV	IC	InChI=1S/C27H27NO/c1-2-3-4-10-18-28-20-23(19-26(28)22-13-6-5-7-14-22)27(29)25-17-11-15-21-12-8-9-16-24(21)25/h5-9,11-17,19-20H,2-4,10,18H2,1H3
DMEX9GV	CS	CCCCCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMEX9GV	IK	FRMYAMAGHYHNKF-UHFFFAOYSA-N
DMEX9GV	IU	(1-hexyl-5-phenylpyrrol-3-yl)-naphthalen-1-ylmethanone
DMEX9GV	CA	CAS 914458-20-1
DMEX9GV	DE	Discovery agent

DM86OZD	ID	DM86OZD
DM86OZD	DN	JWH-150
DM86OZD	HS	Investigative
DM86OZD	SN	JWH-150; CHEMBL216836; BDBM50192593
DM86OZD	DT	Small molecular drug
DM86OZD	PC	44418303
DM86OZD	MW	353.5
DM86OZD	FM	C25H23NO
DM86OZD	IC	InChI=1S/C25H23NO/c1-2-3-16-26-18-21(17-24(26)20-11-5-4-6-12-20)25(27)23-15-9-13-19-10-7-8-14-22(19)23/h4-15,17-18H,2-3,16H2,1H3
DM86OZD	CS	CCCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DM86OZD	IK	PTIAQHRJOQEMCO-UHFFFAOYSA-N
DM86OZD	IU	(1-butyl-5-phenylpyrrol-3-yl)-naphthalen-1-ylmethanone
DM86OZD	DE	Discovery agent

DMGPN61	ID	DMGPN61
DMGPN61	DN	JWH-151
DMGPN61	HS	Investigative
DMGPN61	SN	JWH-151; CHEMBL522550; SCHEMBL6330271; BDBM50265754; 1-propyl-2-methyl-3-(6-methoxy-1-naphthoyl)indole
DMGPN61	DT	Small molecular drug
DMGPN61	PC	11233636
DMGPN61	MW	357.4
DMGPN61	FM	C24H23NO2
DMGPN61	IC	InChI=1S/C24H23NO2/c1-4-14-25-16(2)23(21-9-5-6-11-22(21)25)24(26)20-10-7-8-17-15-18(27-3)12-13-19(17)20/h5-13,15H,4,14H2,1-3H3
DMGPN61	CS	CCCN1C(=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=C3C=CC(=C4)OC)C
DMGPN61	IK	PJQIBVPPWAUFQB-UHFFFAOYSA-N
DMGPN61	IU	(6-methoxynaphthalen-1-yl)-(2-methyl-1-propylindol-3-yl)methanone
DMGPN61	DE	Discovery agent

DMWGSQO	ID	DMWGSQO
DMWGSQO	DN	JWH-156
DMWGSQO	HS	Investigative
DMWGSQO	SN	JWH-156; CHEMBL217969; BDBM50192590
DMWGSQO	DT	Small molecular drug
DMWGSQO	PC	44418301
DMWGSQO	MW	339.4
DMWGSQO	FM	C24H21NO
DMWGSQO	IC	InChI=1S/C24H21NO/c1-2-15-25-17-20(16-23(25)19-10-4-3-5-11-19)24(26)22-14-8-12-18-9-6-7-13-21(18)22/h3-14,16-17H,2,15H2,1H3
DMWGSQO	CS	CCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMWGSQO	IK	CVADUNUZYYADMA-UHFFFAOYSA-N
DMWGSQO	IU	naphthalen-1-yl-(5-phenyl-1-propylpyrrol-3-yl)methanone
DMWGSQO	DE	Discovery agent

DMLDOYV	ID	DMLDOYV
DMLDOYV	DN	JWH-167
DMLDOYV	HS	Investigative
DMLDOYV	SN	1-(1-Pentyl-1H-indol-3-yl)-2-phenylethanone; JWH-167; 864445-37-4; UNII-LQX1W3537N; CHEMBL365878; LQX1W3537N; 1-pentyl-3-phenylacetylindole; SCHEMBL20552905; DTXSID20235554; JWH 167; AMCPOEOUXQWESI-UHFFFAOYSA-N; 3543AC; BDBM50170338; ZINC28460304; AKOS016000818; AJ-83459; KB-212442; AX8250724
DMLDOYV	DT	Small molecular drug
DMLDOYV	PC	44397502
DMLDOYV	MW	305.4
DMLDOYV	FM	C21H23NO
DMLDOYV	IC	InChI=1S/C21H23NO/c1-2-3-9-14-22-16-19(18-12-7-8-13-20(18)22)21(23)15-17-10-5-4-6-11-17/h4-8,10-13,16H,2-3,9,14-15H2,1H3
DMLDOYV	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3
DMLDOYV	IK	AMCPOEOUXQWESI-UHFFFAOYSA-N
DMLDOYV	IU	1-(1-pentylindol-3-yl)-2-phenylethanone
DMLDOYV	CA	CAS 864445-37-4
DMLDOYV	DE	Discovery agent

DMC2XSU	ID	DMC2XSU
DMC2XSU	DN	JWH-201
DMC2XSU	HS	Investigative
DMC2XSU	SN	JWH-201; JWH 201; 864445-47-6; CHEMBL188940; 2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; DTXSID90658736; KQRKUKYSZPHOKC-UHFFFAOYSA-N; ZINC28459373; BDBM50170353; CCG-208746; FT-0670591; 2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one
DMC2XSU	DT	Small molecular drug
DMC2XSU	PC	44397641
DMC2XSU	MW	335.4
DMC2XSU	FM	C22H25NO2
DMC2XSU	IC	InChI=1S/C22H25NO2/c1-3-4-7-14-23-16-20(19-8-5-6-9-21(19)23)22(24)15-17-10-12-18(25-2)13-11-17/h5-6,8-13,16H,3-4,7,14-15H2,1-2H3
DMC2XSU	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)OC
DMC2XSU	IK	KQRKUKYSZPHOKC-UHFFFAOYSA-N
DMC2XSU	IU	2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone
DMC2XSU	CA	CAS 864445-47-6
DMC2XSU	DE	Discovery agent

DMQU2SV	ID	DMQU2SV
DMQU2SV	DN	JWH-202
DMQU2SV	HS	Investigative
DMQU2SV	SN	JWH-202; CHEMBL364111; BDBM50170352; 2-(4-methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone
DMQU2SV	DT	Small molecular drug
DMQU2SV	PC	44397671
DMQU2SV	MW	349.5
DMQU2SV	FM	C23H27NO2
DMQU2SV	IC	InChI=1S/C23H27NO2/c1-4-5-8-15-24-17(2)23(20-9-6-7-10-21(20)24)22(25)16-18-11-13-19(26-3)14-12-18/h6-7,9-14H,4-5,8,15-16H2,1-3H3
DMQU2SV	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)OC)C
DMQU2SV	IK	RNQWQIZOTKYEKJ-UHFFFAOYSA-N
DMQU2SV	IU	2-(4-methoxyphenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMQU2SV	DE	Discovery agent

DMEJ8YA	ID	DMEJ8YA
DMEJ8YA	DN	JWH-203
DMEJ8YA	HS	Investigative
DMEJ8YA	SN	JWH-203; 864445-54-5; 2-(2-Chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; UNII-52CP80V8FY; 1-Pentyl-3-(2-chlorophenylacetyl)indole; JWH 203; CHEMBL189035; 52CP80V8FY; 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone; JWH203; DEA No. 7203; SCHEMBL16201543; DTXSID00235557; YDINKDBAZJOSLV-UHFFFAOYSA-N; ZINC28457100; BDBM50170357; AKOS022186463; CCG-208745; AJ-83455; AK146159; AX8283836; KB-220910; ST24039182; FT-0670592; A20550; JWH-203 (1-pentyl-3-(2-chlorophenylacetyl)indole; 2-(2-Chlorophenyl)-1-(1-pentylindol-3-yl)methanone
DMEJ8YA	DT	Small molecular drug
DMEJ8YA	PC	44397500
DMEJ8YA	MW	339.9
DMEJ8YA	FM	C21H22ClNO
DMEJ8YA	IC	InChI=1S/C21H22ClNO/c1-2-3-8-13-23-15-18(17-10-5-7-12-20(17)23)21(24)14-16-9-4-6-11-19(16)22/h4-7,9-12,15H,2-3,8,13-14H2,1H3
DMEJ8YA	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3Cl
DMEJ8YA	IK	YDINKDBAZJOSLV-UHFFFAOYSA-N
DMEJ8YA	IU	2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMEJ8YA	CA	CAS 864445-54-5
DMEJ8YA	DE	Discovery agent

DMDTILC	ID	DMDTILC
DMDTILC	DN	JWH-204
DMDTILC	HS	Investigative
DMDTILC	SN	JWH-204; CHEMBL361032; 2-(2-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone; BDBM50170356
DMDTILC	DT	Small molecular drug
DMDTILC	PC	44397501
DMDTILC	MW	353.9
DMDTILC	FM	C22H24ClNO
DMDTILC	IC	InChI=1S/C22H24ClNO/c1-3-4-9-14-24-16(2)22(18-11-6-8-13-20(18)24)21(25)15-17-10-5-7-12-19(17)23/h5-8,10-13H,3-4,9,14-15H2,1-2H3
DMDTILC	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3Cl)C
DMDTILC	IK	JUWWNZZHFZTXED-UHFFFAOYSA-N
DMDTILC	IU	2-(2-chlorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMDTILC	CA	CAS 864445-55-6
DMDTILC	DE	Discovery agent

DMKIR63	ID	DMKIR63
DMKIR63	DN	JWH-205
DMKIR63	HS	Investigative
DMKIR63	SN	JWH-205; UNII-13OTY4DTE7; 13OTY4DTE7; CHEMBL186525; 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-phenylethanone; BDBM50170341; Ethanone, 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-phenyl-; 1-(2-Methyl-1-pentyl-1H-indol-3-yl)-2-phenyl-ethanone
DMKIR63	DT	Small molecular drug
DMKIR63	PC	44397436
DMKIR63	MW	319.4
DMKIR63	FM	C22H25NO
DMKIR63	IC	InChI=1S/C22H25NO/c1-3-4-10-15-23-17(2)22(19-13-8-9-14-20(19)23)21(24)16-18-11-6-5-7-12-18/h5-9,11-14H,3-4,10,15-16H2,1-2H3
DMKIR63	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3)C
DMKIR63	IK	BVRXLMVNOFBNCJ-UHFFFAOYSA-N
DMKIR63	IU	1-(2-methyl-1-pentylindol-3-yl)-2-phenylethanone
DMKIR63	CA	CAS 864445-38-5
DMKIR63	DE	Discovery agent

DMGFSQB	ID	DMGFSQB
DMGFSQB	DN	JWH-206
DMGFSQB	HS	Investigative
DMGFSQB	SN	JWH-206; UNII-KC06JV2SNX; KC06JV2SNX; CHEMBL188819; 2-(4-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; 864445-58-9; JWH 203 4-chlorophenyl isomer; GPMUZXUMSOFDBA-UHFFFAOYSA-N; ZINC28461030; BDBM50170348; 2-(4-Chloro-phenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(4-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMGFSQB	DT	Small molecular drug
DMGFSQB	PC	44397532
DMGFSQB	MW	339.9
DMGFSQB	FM	C21H22ClNO
DMGFSQB	IC	InChI=1S/C21H22ClNO/c1-2-3-6-13-23-15-19(18-7-4-5-8-20(18)23)21(24)14-16-9-11-17(22)12-10-16/h4-5,7-12,15H,2-3,6,13-14H2,1H3
DMGFSQB	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)Cl
DMGFSQB	IK	GPMUZXUMSOFDBA-UHFFFAOYSA-N
DMGFSQB	IU	2-(4-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMGFSQB	CA	CAS 864445-58-9
DMGFSQB	DE	Discovery agent

DMF70IM	ID	DMF70IM
DMF70IM	DN	JWH-207
DMF70IM	HS	Investigative
DMF70IM	SN	JWH-207; UNII-828QKW93YY; 828QKW93YY; CHEMBL187813; 2-(4-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone; BDBM50170350; Ethanone, 2-(4-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl); 2-(4-Chloro-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DMF70IM	DT	Small molecular drug
DMF70IM	PC	44397533
DMF70IM	MW	353.9
DMF70IM	FM	C22H24ClNO
DMF70IM	IC	InChI=1S/C22H24ClNO/c1-3-4-7-14-24-16(2)22(19-8-5-6-9-20(19)24)21(25)15-17-10-12-18(23)13-11-17/h5-6,8-13H,3-4,7,14-15H2,1-2H3
DMF70IM	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)Cl)C
DMF70IM	IK	ZFTOVDKPJSCPEE-UHFFFAOYSA-N
DMF70IM	IU	2-(4-chlorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMF70IM	CA	CAS 864445-59-0
DMF70IM	DE	Discovery agent

DMLYHUN	ID	DMLYHUN
DMLYHUN	DN	JWH-208
DMLYHUN	HS	Investigative
DMLYHUN	SN	JWH-208; BDU1DA9SRY; UNII-BDU1DA9SRY; CHEMBL187354; JWH 251 4-methylphenyl isomer; 864445-41-0; GSVYYNBRAJBCQS-UHFFFAOYSA-N; ZINC28462048; BDBM50170351; 1-(1-pentyl-1H-indol-3-yl)-2-p-tolylethanone; 1-(1-Pentyl-1H-indol-3-yl)-2-p-tolyl-ethanone; 2-(4-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; Ethanone, 2-(4-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMLYHUN	DT	Small molecular drug
DMLYHUN	PC	44397464
DMLYHUN	MW	319.4
DMLYHUN	FM	C22H25NO
DMLYHUN	IC	InChI=1S/C22H25NO/c1-3-4-7-14-23-16-20(19-8-5-6-9-21(19)23)22(24)15-18-12-10-17(2)11-13-18/h5-6,8-13,16H,3-4,7,14-15H2,1-2H3
DMLYHUN	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)C
DMLYHUN	IK	GSVYYNBRAJBCQS-UHFFFAOYSA-N
DMLYHUN	IU	2-(4-methylphenyl)-1-(1-pentylindol-3-yl)ethanone
DMLYHUN	CA	CAS 864445-41-0
DMLYHUN	DE	Discovery agent

DMDXCIV	ID	DMDXCIV
DMDXCIV	DN	JWH-209
DMDXCIV	HS	Investigative
DMDXCIV	SN	JWH-209; UNII-2A7P4YEN6H; 2A7P4YEN6H; CHEMBL187771; BDBM50170347; 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-p-tolylethanone; 1-(2-Methyl-1-pentyl-1H-indol-3-yl)-2-p-tolyl-ethanone; 1-(2-Methyl-1-pentyl-1H-indol-3-yl)-2-(4-methylphenyl)ethanone; Ethanone, 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-(4-methylphenyl)-
DMDXCIV	DT	Small molecular drug
DMDXCIV	PC	44397465
DMDXCIV	MW	333.5
DMDXCIV	FM	C23H27NO
DMDXCIV	IC	InChI=1S/C23H27NO/c1-4-5-8-15-24-18(3)23(20-9-6-7-10-21(20)24)22(25)16-19-13-11-17(2)12-14-19/h6-7,9-14H,4-5,8,15-16H2,1-3H3
DMDXCIV	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)C)C
DMDXCIV	IK	RDYZLFKKWNGIJS-UHFFFAOYSA-N
DMDXCIV	IU	1-(2-methyl-1-pentylindol-3-yl)-2-(4-methylphenyl)ethanone
DMDXCIV	CA	CAS 864445-42-1
DMDXCIV	DE	Discovery agent

DMMKYGP	ID	DMMKYGP
DMMKYGP	DN	JWH-229
DMMKYGP	HS	Investigative
DMMKYGP	SN	JWH-229; UNII-8HHX5B1WP5; 8HHX5B1WP5; CHEMBL498346; 1-Methoxy-3-(1',1'-dimethylhexyl)-Delta(8)-THC; BDBM50265755; 832111-99-6; 6H-Dibenzo(b,d)pyran, 3-(1,1-dimethylhexyl)-6a,7,8,10a-tetrahydro-1-methoxy-6,6,9-trimethyl-, (6aR,10aR)-
DMMKYGP	DT	Small molecular drug
DMMKYGP	PC	44581105
DMMKYGP	MW	370.6
DMMKYGP	FM	C25H38O2
DMMKYGP	IC	InChI=1S/C25H38O2/c1-8-9-10-13-24(3,4)18-15-21(26-7)23-19-14-17(2)11-12-20(19)25(5,6)27-22(23)16-18/h14-16,19-20H,8-13H2,1-7H3/t19-,20-/m1/s1
DMMKYGP	CS	CCCCCC(C)(C)C1=CC2=C([C@@H]3C=C(CC[C@H]3C(O2)(C)C)C)C(=C1)OC
DMMKYGP	IK	PUBXDTLETUTKIJ-WOJBJXKFSA-N
DMMKYGP	IU	(6aR,10aR)-1-methoxy-6,6,9-trimethyl-3-(2-methylheptan-2-yl)-6a,7,8,10a-tetrahydrobenzo[c]chromene
DMMKYGP	CA	CAS 832111-99-6
DMMKYGP	DE	Discovery agent

DMRQOL5	ID	DMRQOL5
DMRQOL5	DN	JWH-237
DMRQOL5	HS	Investigative
DMRQOL5	SN	JWH-237; UNII-NR611I7X19; CHEMBL188822; NR611I7X19; 2-(3-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; 864445-56-7; JWH 203 3-chlorophenyl isomer; KURUPMPUIIQATM-UHFFFAOYSA-N; ZINC28463001; BDBM50170332; 2-(3-Chloro-phenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(3-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMRQOL5	DT	Small molecular drug
DMRQOL5	PC	44397713
DMRQOL5	MW	339.9
DMRQOL5	FM	C21H22ClNO
DMRQOL5	IC	InChI=1S/C21H22ClNO/c1-2-3-6-12-23-15-19(18-10-4-5-11-20(18)23)21(24)14-16-8-7-9-17(22)13-16/h4-5,7-11,13,15H,2-3,6,12,14H2,1H3
DMRQOL5	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)Cl
DMRQOL5	IK	KURUPMPUIIQATM-UHFFFAOYSA-N
DMRQOL5	IU	2-(3-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMRQOL5	CA	CAS 864445-56-7
DMRQOL5	DE	Discovery agent

DMGD73A	ID	DMGD73A
DMGD73A	DN	JWH-243
DMGD73A	HS	Investigative
DMGD73A	SN	JWH-243; CHEMBL220413; BDBM50192609
DMGD73A	DT	Small molecular drug
DMGD73A	PC	44418354
DMGD73A	MW	397.5
DMGD73A	FM	C27H27NO2
DMGD73A	IC	InChI=1S/C27H27NO2/c1-3-4-7-17-28-19-22(18-26(28)21-13-15-23(30-2)16-14-21)27(29)25-12-8-10-20-9-5-6-11-24(20)25/h5-6,8-16,18-19H,3-4,7,17H2,1-2H3
DMGD73A	CS	CCCCCN1C=C(C=C1C2=CC=C(C=C2)OC)C(=O)C3=CC=CC4=CC=CC=C43
DMGD73A	IK	IQIAZANEJACDNJ-UHFFFAOYSA-N
DMGD73A	IU	[5-(4-methoxyphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMGD73A	DE	Discovery agent

DMETAOU	ID	DMETAOU
DMETAOU	DN	JWH-244
DMETAOU	HS	Investigative
DMETAOU	SN	JWH-244; CHEMBL385653; BDBM50192596
DMETAOU	DT	Small molecular drug
DMETAOU	PC	44418345
DMETAOU	MW	381.5
DMETAOU	FM	C27H27NO
DMETAOU	IC	InChI=1S/C27H27NO/c1-3-4-7-17-28-19-23(18-26(28)22-15-13-20(2)14-16-22)27(29)25-12-8-10-21-9-5-6-11-24(21)25/h5-6,8-16,18-19H,3-4,7,17H2,1-2H3
DMETAOU	CS	CCCCCN1C=C(C=C1C2=CC=C(C=C2)C)C(=O)C3=CC=CC4=CC=CC=C43
DMETAOU	IK	RZASCFFZBHYWDH-UHFFFAOYSA-N
DMETAOU	IU	[5-(4-methylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMETAOU	DE	Discovery agent

DMC5RZ9	ID	DMC5RZ9
DMC5RZ9	DN	JWH-245
DMC5RZ9	HS	Investigative
DMC5RZ9	SN	JWH-245; CHEMBL219027; BDBM50192587
DMC5RZ9	DT	Small molecular drug
DMC5RZ9	PC	44418367
DMC5RZ9	MW	401.9
DMC5RZ9	FM	C26H24ClNO
DMC5RZ9	IC	InChI=1S/C26H24ClNO/c1-2-3-6-16-28-18-21(17-25(28)20-12-14-22(27)15-13-20)26(29)24-11-7-9-19-8-4-5-10-23(19)24/h4-5,7-15,17-18H,2-3,6,16H2,1H3
DMC5RZ9	CS	CCCCCN1C=C(C=C1C2=CC=C(C=C2)Cl)C(=O)C3=CC=CC4=CC=CC=C43
DMC5RZ9	IK	GBQKSTSSOVRZFN-UHFFFAOYSA-N
DMC5RZ9	IU	[5-(4-chlorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMC5RZ9	CA	CAS 914458-40-5
DMC5RZ9	DE	Discovery agent

DMGTEYB	ID	DMGTEYB
DMGTEYB	DN	JWH-246
DMGTEYB	HS	Investigative
DMGTEYB	SN	JWH-246; CHEMBL374937; BDBM50192612
DMGTEYB	DT	Small molecular drug
DMGTEYB	PC	44418337
DMGTEYB	MW	401.9
DMGTEYB	FM	C26H24ClNO
DMGTEYB	IC	InChI=1S/C26H24ClNO/c1-2-3-6-15-28-18-21(17-25(28)20-11-7-12-22(27)16-20)26(29)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMGTEYB	CS	CCCCCN1C=C(C=C1C2=CC(=CC=C2)Cl)C(=O)C3=CC=CC4=CC=CC=C43
DMGTEYB	IK	UVJANPIKZUBGAE-UHFFFAOYSA-N
DMGTEYB	IU	[5-(3-chlorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMGTEYB	DE	Discovery agent

DMURL8D	ID	DMURL8D
DMURL8D	DN	JWH-248
DMURL8D	HS	Investigative
DMURL8D	SN	JWH-248; CHEMBL190305; BDBM50170349; 2-(4-bromophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone
DMURL8D	DT	Small molecular drug
DMURL8D	PC	44397610
DMURL8D	MW	384.3
DMURL8D	FM	C21H22BrNO
DMURL8D	IC	InChI=1S/C21H22BrNO/c1-2-3-6-13-23-15-19(18-7-4-5-8-20(18)23)21(24)14-16-9-11-17(22)12-10-16/h4-5,7-12,15H,2-3,6,13-14H2,1H3
DMURL8D	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)Br
DMURL8D	IK	BMRAIRSNJUSFSM-UHFFFAOYSA-N
DMURL8D	IU	2-(4-bromophenyl)-1-(1-pentylindol-3-yl)ethanone
DMURL8D	DE	Discovery agent

DMTOUCL	ID	DMTOUCL
DMTOUCL	DN	JWH-249
DMTOUCL	HS	Investigative
DMTOUCL	SN	JWH-249; 1-pentyl-3-(2-bromophenylacetyl)indole; 864445-60-3; UNII-H988KQV4U9; H988KQV4U9; CHEMBL363471; 2-(2-bromophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; DTXSID30658735; JWH 249; CGQRVOHECAULLB-UHFFFAOYSA-N; ZINC28461369; BDBM50170337; 2-(2-Bromo-phenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(2-bromophenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMTOUCL	DT	Small molecular drug
DMTOUCL	PC	44397335
DMTOUCL	MW	384.3
DMTOUCL	FM	C21H22BrNO
DMTOUCL	IC	InChI=1S/C21H22BrNO/c1-2-3-8-13-23-15-18(17-10-5-7-12-20(17)23)21(24)14-16-9-4-6-11-19(16)22/h4-7,9-12,15H,2-3,8,13-14H2,1H3
DMTOUCL	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3Br
DMTOUCL	IK	CGQRVOHECAULLB-UHFFFAOYSA-N
DMTOUCL	IU	2-(2-bromophenyl)-1-(1-pentylindol-3-yl)ethanone
DMTOUCL	CA	CAS 864445-60-3
DMTOUCL	DE	Discovery agent

DMWVS5X	ID	DMWVS5X
DMWVS5X	DN	JWH-250
DMWVS5X	HS	Investigative
DMWVS5X	SN	864445-43-2; 2-(2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; JWH-250; 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; UNII-IP9911R8A0; CHEMBL188031; FFLSJIQJQKDDCM-UHFFFAOYSA-N; IP9911R8A0; Q-200139; 1-Pentyl-3-(2-methoxyphenylacetyl)indole; DEA No. 6250; SCHEMBL11983322; CTK8C5059; JWH 250; DTXSID40235556; MolPort-009-019-586; KS-000024QU; ANW-73903; ZINC28465020; MFCD12911796; BDBM50170335; AKOS015999864; DS-3158; CCG-208724; NCGC00386575-01; AJ-83461; CJ-17680; AK-82232; AN-26990; KB-110367; TC-162648; ST24021676
DMWVS5X	DT	Small molecular drug
DMWVS5X	PC	44397540
DMWVS5X	MW	335.4
DMWVS5X	FM	C22H25NO2
DMWVS5X	IC	InChI=1S/C22H25NO2/c1-3-4-9-14-23-16-19(18-11-6-7-12-20(18)23)21(24)15-17-10-5-8-13-22(17)25-2/h5-8,10-13,16H,3-4,9,14-15H2,1-2H3
DMWVS5X	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3OC
DMWVS5X	IK	FFLSJIQJQKDDCM-UHFFFAOYSA-N
DMWVS5X	IU	2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone
DMWVS5X	CA	CAS 864445-43-2
DMWVS5X	DE	Discovery agent

DMOJAUI	ID	DMOJAUI
DMOJAUI	DN	JWH-251
DMOJAUI	HS	Investigative
DMOJAUI	SN	JWH-251; UNII-55H9NDH32M; 1-Pentyl-3-(2-methylphenylacetyl)indole; 864445-39-6; CHEMBL364820; 55H9NDH32M; 2-(2-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; 2-(2-methylphenyl)-1-(1-pentylindol-3-yl)ethanone; SCHEMBL2473611; JWH 251; DTXSID80235555; YBIPNGRKUAVSBG-UHFFFAOYSA-N; ZINC28463005; BDBM50170339; CCG-208751; FT-0670595; 1-(1-pentyl-1H-indol-3-yl)-2-o-tolylethanone
DMOJAUI	DT	Small molecular drug
DMOJAUI	PC	11616723
DMOJAUI	MW	319.4
DMOJAUI	FM	C22H25NO
DMOJAUI	IC	InChI=1S/C22H25NO/c1-3-4-9-14-23-16-20(19-12-7-8-13-21(19)23)22(24)15-18-11-6-5-10-17(18)2/h5-8,10-13,16H,3-4,9,14-15H2,1-2H3
DMOJAUI	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3C
DMOJAUI	IK	YBIPNGRKUAVSBG-UHFFFAOYSA-N
DMOJAUI	IU	2-(2-methylphenyl)-1-(1-pentylindol-3-yl)ethanone
DMOJAUI	CA	CAS 864445-39-6
DMOJAUI	DE	Discovery agent

DM6IWCZ	ID	DM6IWCZ
DM6IWCZ	DN	JWH-252
DM6IWCZ	HS	Investigative
DM6IWCZ	SN	JWH-252; CHEMBL188494; BDBM50170343; 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-o-tolylethanone
DM6IWCZ	DT	Small molecular drug
DM6IWCZ	PC	44397635
DM6IWCZ	MW	333.5
DM6IWCZ	FM	C23H27NO
DM6IWCZ	IC	InChI=1S/C23H27NO/c1-4-5-10-15-24-18(3)23(20-13-8-9-14-21(20)24)22(25)16-19-12-7-6-11-17(19)2/h6-9,11-14H,4-5,10,15-16H2,1-3H3
DM6IWCZ	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3C)C
DM6IWCZ	IK	NHQVWPJMCINXPI-UHFFFAOYSA-N
DM6IWCZ	IU	1-(2-methyl-1-pentylindol-3-yl)-2-(2-methylphenyl)ethanone
DM6IWCZ	DE	Discovery agent

DML1UMX	ID	DML1UMX
DML1UMX	DN	JWH-253
DML1UMX	HS	Investigative
DML1UMX	SN	JWH-253; UNII-E28U9TD6JM; E28U9TD6JM; CHEMBL188887; 2-(3-methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone; BDBM50170334; Ethanone, 2-(3-methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-; 2-(3-Methoxy-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DML1UMX	DT	Small molecular drug
DML1UMX	PC	44397405
DML1UMX	MW	349.5
DML1UMX	FM	C23H27NO2
DML1UMX	IC	InChI=1S/C23H27NO2/c1-4-5-8-14-24-17(2)23(20-12-6-7-13-21(20)24)22(25)16-18-10-9-11-19(15-18)26-3/h6-7,9-13,15H,4-5,8,14,16H2,1-3H3
DML1UMX	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)OC)C
DML1UMX	IK	QZLRCHSRCYFMFK-UHFFFAOYSA-N
DML1UMX	IU	2-(3-methoxyphenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DML1UMX	CA	CAS 864445-46-5
DML1UMX	DE	Discovery agent

DM07XBG	ID	DM07XBG
DM07XBG	DN	JWH-268
DM07XBG	HS	Investigative
DM07XBG	SN	JWH-268; CHEMBL524822; SCHEMBL6333837; BDBM50265756
DM07XBG	DT	Small molecular drug
DM07XBG	PC	11406508
DM07XBG	MW	385.5
DM07XBG	FM	C26H27NO2
DM07XBG	IC	InChI=1S/C26H27NO2/c1-4-5-10-17-27-18(2)24(21-13-8-9-14-22(21)27)26(28)25-20-12-7-6-11-19(20)15-16-23(25)29-3/h6-9,11-16H,4-5,10,17H2,1-3H3
DM07XBG	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)C3=C(C=CC4=CC=CC=C43)OC)C
DM07XBG	IK	POCUOUJJUBHVTI-UHFFFAOYSA-N
DM07XBG	IU	(2-methoxynaphthalen-1-yl)-(2-methyl-1-pentylindol-3-yl)methanone
DM07XBG	DE	Discovery agent

DM5FAUY	ID	DM5FAUY
DM5FAUY	DN	JWH-292
DM5FAUY	HS	Investigative
DM5FAUY	SN	JWH-292; CHEMBL218202; BDBM50192586
DM5FAUY	DT	Small molecular drug
DM5FAUY	PC	44418317
DM5FAUY	MW	397.5
DM5FAUY	FM	C27H27NO2
DM5FAUY	IC	InChI=1S/C27H27NO2/c1-3-4-9-17-28-19-21(18-25(28)24-14-7-8-16-26(24)30-2)27(29)23-15-10-12-20-11-5-6-13-22(20)23/h5-8,10-16,18-19H,3-4,9,17H2,1-2H3
DM5FAUY	CS	CCCCCN1C=C(C=C1C2=CC=CC=C2OC)C(=O)C3=CC=CC4=CC=CC=C43
DM5FAUY	IK	RWYPPHVLXFTKAG-UHFFFAOYSA-N
DM5FAUY	IU	[5-(2-methoxyphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM5FAUY	DE	Discovery agent

DMCK1XR	ID	DMCK1XR
DMCK1XR	DN	JWH-293
DMCK1XR	HS	Investigative
DMCK1XR	SN	JWH-293; CHEMBL218253; BDBM50192600
DMCK1XR	DT	Small molecular drug
DMCK1XR	PC	44418344
DMCK1XR	MW	412.5
DMCK1XR	FM	C26H24N2O3
DMCK1XR	IC	InChI=1S/C26H24N2O3/c1-2-3-6-15-27-18-21(17-25(27)20-11-7-12-22(16-20)28(30)31)26(29)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMCK1XR	CS	CCCCCN1C=C(C=C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)C3=CC=CC4=CC=CC=C43
DMCK1XR	IK	FQGNQKRWZNTBLM-UHFFFAOYSA-N
DMCK1XR	IU	naphthalen-1-yl-[5-(3-nitrophenyl)-1-pentylpyrrol-3-yl]methanone
DMCK1XR	DE	Discovery agent

DMTMF8X	ID	DMTMF8X
DMTMF8X	DN	JWH-294
DMTMF8X	HS	Investigative
DMTMF8X	SN	JWH-294; CHEMBL259293
DMTMF8X	DT	Small molecular drug
DMTMF8X	PC	44452669
DMTMF8X	MW	246.4
DMTMF8X	FM	C17H26O
DMTMF8X	IC	InChI=1S/C17H26O/c1-4-17(2,3)15-10-8-13(9-11-15)14-6-5-7-16(18)12-14/h8-11,14,16,18H,4-7,12H2,1-3H3/t14-,16+/m0/s1
DMTMF8X	CS	CCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMTMF8X	IK	NGNJEMWGXAUJKO-GOEBONIOSA-N
DMTMF8X	IU	(1R,3S)-3-[4-(2-methylbutan-2-yl)phenyl]cyclohexan-1-ol
DMTMF8X	DE	Discovery agent

DMUMJGD	ID	DMUMJGD
DMUMJGD	DN	JWH-295
DMUMJGD	HS	Investigative
DMUMJGD	SN	JWH-295; CHEMBL407763
DMUMJGD	DT	Small molecular drug
DMUMJGD	PC	44452602
DMUMJGD	MW	246.4
DMUMJGD	FM	C17H26O
DMUMJGD	IC	InChI=1S/C17H26O/c1-4-17(2,3)15-10-8-13(9-11-15)14-6-5-7-16(18)12-14/h8-11,14,16,18H,4-7,12H2,1-3H3/t14-,16-/m1/s1
DMUMJGD	CS	CCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DMUMJGD	IK	NGNJEMWGXAUJKO-GDBMZVCRSA-N
DMUMJGD	IU	(1R,3R)-3-[4-(2-methylbutan-2-yl)phenyl]cyclohexan-1-ol
DMUMJGD	DE	Discovery agent

DMNRXJU	ID	DMNRXJU
DMNRXJU	DN	JWH-296
DMNRXJU	HS	Investigative
DMNRXJU	SN	JWH-296; CHEMBL408060
DMNRXJU	DT	Small molecular drug
DMNRXJU	PC	44452670
DMNRXJU	MW	260.399
DMNRXJU	FM	C18H28O
DMNRXJU	IC	InChI=1S/C18H28O/c1-4-12-18(2,3)16-10-8-14(9-11-16)15-6-5-7-17(19)13-15/h8-11,15,17,19H,4-7,12-13H2,1-3H3/t15-,17+/m0/s1
DMNRXJU	CS	CCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMNRXJU	IK	IWAZRTQOOAVKDN-DOTOQJQBSA-N
DMNRXJU	IU	(1R,3S)-3-[4-(2-methylpentan-2-yl)phenyl]cyclohexan-1-ol
DMNRXJU	DE	Discovery agent

DM4A761	ID	DM4A761
DM4A761	DN	JWH-297
DM4A761	HS	Investigative
DM4A761	SN	JWH-297; CHEMBL260005
DM4A761	DT	Small molecular drug
DM4A761	PC	44452601
DM4A761	MW	260.399
DM4A761	FM	C18H28O
DM4A761	IC	InChI=1S/C18H28O/c1-4-12-18(2,3)16-10-8-14(9-11-16)15-6-5-7-17(19)13-15/h8-11,15,17,19H,4-7,12-13H2,1-3H3/t15-,17-/m1/s1
DM4A761	CS	CCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DM4A761	IK	IWAZRTQOOAVKDN-NVXWUHKLSA-N
DM4A761	IU	(1R,3R)-3-[4-(2-methylpentan-2-yl)phenyl]cyclohexan-1-ol
DM4A761	DE	Discovery agent

DMI7LF1	ID	DMI7LF1
DMI7LF1	DN	JWH-302
DMI7LF1	HS	Investigative
DMI7LF1	SN	JWH-302; UNII-DQF20NHW2M; DQF20NHW2M; CHEMBL186674; 2-(3-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; 864445-45-4; JWH 302; SCHEMBL2471302; DTXSID60467554; XZVYWLVYUAQEIM-UHFFFAOYSA-N; ZINC28456868; BDBM50170333; CCG-208748; 1-pentyl-3-(3-methoxyphenylacetyl)indole; FT-0670596; 2-(3-Methoxy-phenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMI7LF1	DT	Small molecular drug
DMI7LF1	PC	11493740
DMI7LF1	MW	335.4
DMI7LF1	FM	C22H25NO2
DMI7LF1	IC	InChI=1S/C22H25NO2/c1-3-4-7-13-23-16-20(19-11-5-6-12-21(19)23)22(24)15-17-9-8-10-18(14-17)25-2/h5-6,8-12,14,16H,3-4,7,13,15H2,1-2H3
DMI7LF1	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)OC
DMI7LF1	IK	XZVYWLVYUAQEIM-UHFFFAOYSA-N
DMI7LF1	IU	2-(3-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone
DMI7LF1	CA	CAS 864445-45-4
DMI7LF1	DE	Discovery agent

DMCLAHR	ID	DMCLAHR
DMCLAHR	DN	JWH-303
DMCLAHR	HS	Investigative
DMCLAHR	SN	JWH-303; UNII-ZW7N2KTX23; ZW7N2KTX23; CHEMBL188910; 2-(3-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone; BDBM50170355; 2-(3-Chloro-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(3-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-
DMCLAHR	DT	Small molecular drug
DMCLAHR	PC	44397333
DMCLAHR	MW	353.9
DMCLAHR	FM	C22H24ClNO
DMCLAHR	IC	InChI=1S/C22H24ClNO/c1-3-4-7-13-24-16(2)22(19-11-5-6-12-20(19)24)21(25)15-17-9-8-10-18(23)14-17/h5-6,8-12,14H,3-4,7,13,15H2,1-2H3
DMCLAHR	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)Cl)C
DMCLAHR	IK	IVDPZBGEPKPWGK-UHFFFAOYSA-N
DMCLAHR	IU	2-(3-chlorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMCLAHR	CA	CAS 864445-57-8
DMCLAHR	DE	Discovery agent

DM36W9M	ID	DM36W9M
DM36W9M	DN	JWH-305
DM36W9M	HS	Investigative
DM36W9M	SN	JWH-305; CHEMBL187559; BDBM50170345; 2-(2-Bromo-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DM36W9M	DT	Small molecular drug
DM36W9M	PC	44397336
DM36W9M	MW	398.3
DM36W9M	FM	C22H24BrNO
DM36W9M	IC	InChI=1S/C22H24BrNO/c1-3-4-9-14-24-16(2)22(18-11-6-8-13-20(18)24)21(25)15-17-10-5-7-12-19(17)23/h5-8,10-13H,3-4,9,14-15H2,1-2H3
DM36W9M	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3Br)C
DM36W9M	IK	VCQGIPSJKBCBFO-UHFFFAOYSA-N
DM36W9M	IU	2-(2-bromophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DM36W9M	DE	Discovery agent

DMPDJKG	ID	DMPDJKG
DMPDJKG	DN	JWH-306
DMPDJKG	HS	Investigative
DMPDJKG	SN	JWH-306; CHEMBL361088; BDBM50170342; 2-(2-methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone
DMPDJKG	DT	Small molecular drug
DMPDJKG	PC	44397559
DMPDJKG	MW	349.5
DMPDJKG	FM	C23H27NO2
DMPDJKG	IC	InChI=1S/C23H27NO2/c1-4-5-10-15-24-17(2)23(19-12-7-8-13-20(19)24)21(25)16-18-11-6-9-14-22(18)26-3/h6-9,11-14H,4-5,10,15-16H2,1-3H3
DMPDJKG	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3OC)C
DMPDJKG	IK	HGGHYEFHTTXEIQ-UHFFFAOYSA-N
DMPDJKG	IU	2-(2-methoxyphenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMPDJKG	CA	CAS 864445-44-3
DMPDJKG	DE	Discovery agent

DM23RUZ	ID	DM23RUZ
DM23RUZ	DN	JWH-307
DM23RUZ	HS	Investigative
DM23RUZ	SN	914458-26-7; (5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone; JWH-307; UNII-06QTR14ONW; 06QTR14ONW; CHEMBL216857; [5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone; SCHEMBL17464417; CTK8C0835; DTXSID60581542; ZINC34947163; 5343AC; ANW-65338; BDBM50192607; AKOS016005279; AJ-90459; TC-154083; KB-208480; AX8234389; ST24034774; FT-0747021; (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; [5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone
DM23RUZ	DT	Small molecular drug
DM23RUZ	PC	16049783
DM23RUZ	MW	385.5
DM23RUZ	FM	C26H24FNO
DM23RUZ	IC	InChI=1S/C26H24FNO/c1-2-3-8-16-28-18-20(17-25(28)23-13-6-7-15-24(23)27)26(29)22-14-9-11-19-10-4-5-12-21(19)22/h4-7,9-15,17-18H,2-3,8,16H2,1H3
DM23RUZ	CS	CCCCCN1C=C(C=C1C2=CC=CC=C2F)C(=O)C3=CC=CC4=CC=CC=C43
DM23RUZ	IK	WYNZPDDTQGVCLZ-UHFFFAOYSA-N
DM23RUZ	IU	[5-(2-fluorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM23RUZ	CA	CAS 914458-26-7
DM23RUZ	DE	Discovery agent

DMV5ASE	ID	DMV5ASE
DMV5ASE	DN	JWH-308
DMV5ASE	HS	Investigative
DMV5ASE	SN	(5-(4-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone; 914458-39-2; JWH-308; CHEMBL374292; [5-(4-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone; CTK8B4184; DTXSID20658825; ANW-44201; 5345AC; ZINC36294625; BDBM50192602; AKOS015999107; AJ-92571; KB-208490; AX8228513; TC-132946
DMV5ASE	DT	Small molecular drug
DMV5ASE	PC	44418355
DMV5ASE	MW	385.5
DMV5ASE	FM	C26H24FNO
DMV5ASE	IC	InChI=1S/C26H24FNO/c1-2-3-6-16-28-18-21(17-25(28)20-12-14-22(27)15-13-20)26(29)24-11-7-9-19-8-4-5-10-23(19)24/h4-5,7-15,17-18H,2-3,6,16H2,1H3
DMV5ASE	CS	CCCCCN1C=C(C=C1C2=CC=C(C=C2)F)C(=O)C3=CC=CC4=CC=CC=C43
DMV5ASE	IK	PJNACIYIFHTDCK-UHFFFAOYSA-N
DMV5ASE	IU	[5-(4-fluorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMV5ASE	CA	CAS 914458-39-2
DMV5ASE	DE	Discovery agent

DMTV1B9	ID	DMTV1B9
DMTV1B9	DN	JWH-309
DMTV1B9	HS	Investigative
DMTV1B9	SN	JWH-309; CHEMBL376028; ZINC36294630; BDBM50192591
DMTV1B9	DT	Small molecular drug
DMTV1B9	PC	44418371
DMTV1B9	MW	417.5
DMTV1B9	FM	C30H27NO
DMTV1B9	IC	InChI=1S/C30H27NO/c1-2-3-8-19-31-21-24(30(32)28-18-10-14-23-12-5-7-16-26(23)28)20-29(31)27-17-9-13-22-11-4-6-15-25(22)27/h4-7,9-18,20-21H,2-3,8,19H2,1H3
DMTV1B9	CS	CCCCCN1C=C(C=C1C2=CC=CC3=CC=CC=C32)C(=O)C4=CC=CC5=CC=CC=C54
DMTV1B9	IK	WVISOUYKTUUDFW-UHFFFAOYSA-N
DMTV1B9	IU	naphthalen-1-yl-(5-naphthalen-1-yl-1-pentylpyrrol-3-yl)methanone
DMTV1B9	DE	Discovery agent

DMLABGW	ID	DMLABGW
DMLABGW	DN	JWH-311
DMLABGW	HS	Investigative
DMLABGW	SN	JWH-311; CHEMBL187883; BDBM50170331; 2-(2-fluorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone
DMLABGW	DT	Small molecular drug
DMLABGW	PC	44397516
DMLABGW	MW	323.4
DMLABGW	FM	C21H22FNO
DMLABGW	IC	InChI=1S/C21H22FNO/c1-2-3-8-13-23-15-18(17-10-5-7-12-20(17)23)21(24)14-16-9-4-6-11-19(16)22/h4-7,9-12,15H,2-3,8,13-14H2,1H3
DMLABGW	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3F
DMLABGW	IK	RLINGXSUWCVHIQ-UHFFFAOYSA-N
DMLABGW	IU	2-(2-fluorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMLABGW	DE	Discovery agent

DMYIGCU	ID	DMYIGCU
DMYIGCU	DN	JWH-312
DMYIGCU	HS	Investigative
DMYIGCU	SN	JWH-312; CHEMBL189545; BDBM50170344; 2-(3-fluorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone
DMYIGCU	DT	Small molecular drug
DMYIGCU	PC	44397383
DMYIGCU	MW	323.4
DMYIGCU	FM	C21H22FNO
DMYIGCU	IC	InChI=1S/C21H22FNO/c1-2-3-6-12-23-15-19(18-10-4-5-11-20(18)23)21(24)14-16-8-7-9-17(22)13-16/h4-5,7-11,13,15H,2-3,6,12,14H2,1H3
DMYIGCU	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)F
DMYIGCU	IK	ZOBARDBQXUOIQF-UHFFFAOYSA-N
DMYIGCU	IU	2-(3-fluorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMYIGCU	DE	Discovery agent

DMWBHZL	ID	DMWBHZL
DMWBHZL	DN	JWH-313
DMWBHZL	HS	Investigative
DMWBHZL	SN	JWH-313; CHEMBL187412; BDBM50170330; 2-(4-fluorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone
DMWBHZL	DT	Small molecular drug
DMWBHZL	PC	44397491
DMWBHZL	MW	323.4
DMWBHZL	FM	C21H22FNO
DMWBHZL	IC	InChI=1S/C21H22FNO/c1-2-3-6-13-23-15-19(18-7-4-5-8-20(18)23)21(24)14-16-9-11-17(22)12-10-16/h4-5,7-12,15H,2-3,6,13-14H2,1H3
DMWBHZL	CS	CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)F
DMWBHZL	IK	QGDPTDVGZNHCIR-UHFFFAOYSA-N
DMWBHZL	IU	2-(4-fluorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMWBHZL	DE	Discovery agent

DMCEKNJ	ID	DMCEKNJ
DMCEKNJ	DN	JWH-314
DMCEKNJ	HS	Investigative
DMCEKNJ	SN	JWH-314; CHEMBL190469; BDBM50170354; 2-(2-Fluoro-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DMCEKNJ	DT	Small molecular drug
DMCEKNJ	PC	44397542
DMCEKNJ	MW	337.4
DMCEKNJ	FM	C22H24FNO
DMCEKNJ	IC	InChI=1S/C22H24FNO/c1-3-4-9-14-24-16(2)22(18-11-6-8-13-20(18)24)21(25)15-17-10-5-7-12-19(17)23/h5-8,10-13H,3-4,9,14-15H2,1-2H3
DMCEKNJ	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3F)C
DMCEKNJ	IK	SMBDYSPMOWAQKQ-UHFFFAOYSA-N
DMCEKNJ	IU	2-(2-fluorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMCEKNJ	DE	Discovery agent

DMWHN56	ID	DMWHN56
DMWHN56	DN	JWH-315
DMWHN56	HS	Investigative
DMWHN56	SN	JWH-315; CHEMBL427524; BDBM50170336; 2-(3-Fluoro-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DMWHN56	DT	Small molecular drug
DMWHN56	PC	44397406
DMWHN56	MW	337.4
DMWHN56	FM	C22H24FNO
DMWHN56	IC	InChI=1S/C22H24FNO/c1-3-4-7-13-24-16(2)22(19-11-5-6-12-20(19)24)21(25)15-17-9-8-10-18(23)14-17/h5-6,8-12,14H,3-4,7,13,15H2,1-2H3
DMWHN56	CS	CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)F)C
DMWHN56	IK	STCKLQNFQVHGSM-UHFFFAOYSA-N
DMWHN56	IU	2-(3-fluorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMWHN56	DE	Discovery agent

DM63LOX	ID	DM63LOX
DM63LOX	DN	JWH-323
DM63LOX	HS	Investigative
DM63LOX	SN	JWH-323; CHEMBL263399
DM63LOX	DT	Small molecular drug
DM63LOX	PC	44452648
DM63LOX	MW	274.4
DM63LOX	FM	C19H30O
DM63LOX	IC	InChI=1S/C19H30O/c1-4-5-13-19(2,3)17-11-9-15(10-12-17)16-7-6-8-18(20)14-16/h9-12,16,18,20H,4-8,13-14H2,1-3H3/t16-,18+/m0/s1
DM63LOX	CS	CCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DM63LOX	IK	WMICXNJEJDOUPN-FUHWJXTLSA-N
DM63LOX	IU	(1R,3S)-3-[4-(2-methylhexan-2-yl)phenyl]cyclohexan-1-ol
DM63LOX	DE	Discovery agent

DMJ2EI9	ID	DMJ2EI9
DMJ2EI9	DN	JWH-324
DMJ2EI9	HS	Investigative
DMJ2EI9	SN	JWH-324; CHEMBL263386; BDBM50323907; (1R,3S)3-[4-(1,1-dimethylheptyl)phenyl]cyclohexanol
DMJ2EI9	DT	Small molecular drug
DMJ2EI9	PC	44452650
DMJ2EI9	MW	302.5
DMJ2EI9	FM	C21H34O
DMJ2EI9	IC	InChI=1S/C21H34O/c1-4-5-6-7-15-21(2,3)19-13-11-17(12-14-19)18-9-8-10-20(22)16-18/h11-14,18,20,22H,4-10,15-16H2,1-3H3/t18-,20+/m0/s1
DMJ2EI9	CS	CCCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMJ2EI9	IK	CICRJVLFNFCUOX-AZUAARDMSA-N
DMJ2EI9	IU	(1R,3S)-3-[4-(2-methyloctan-2-yl)phenyl]cyclohexan-1-ol
DMJ2EI9	DE	Discovery agent

DMHNTZ8	ID	DMHNTZ8
DMHNTZ8	DN	JWH-325
DMHNTZ8	HS	Investigative
DMHNTZ8	SN	JWH-325; CHEMBL264412
DMHNTZ8	DT	Small molecular drug
DMHNTZ8	PC	44452424
DMHNTZ8	MW	332.5
DMHNTZ8	FM	C22H36O2
DMHNTZ8	IC	InChI=1S/C22H36O2/c1-4-5-14-22(2,3)19-11-8-18(9-12-19)21-16-20(24)13-10-17(21)7-6-15-23/h8-9,11-12,17,20-21,23-24H,4-7,10,13-16H2,1-3H3/t17-,20-,21-/m1/s1
DMHNTZ8	CS	CCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMHNTZ8	IK	RSOWKGHGGWKLRF-DUXKGJEZSA-N
DMHNTZ8	IU	(1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylhexan-2-yl)phenyl]cyclohexan-1-ol
DMHNTZ8	DE	Discovery agent

DMK3DUZ	ID	DMK3DUZ
DMK3DUZ	DN	JWH-337
DMK3DUZ	HS	Investigative
DMK3DUZ	SN	JWH-337; CHEMBL408777
DMK3DUZ	DT	Small molecular drug
DMK3DUZ	PC	44452712
DMK3DUZ	MW	360.6
DMK3DUZ	FM	C24H40O2
DMK3DUZ	IC	InChI=1S/C24H40O2/c1-4-5-6-7-16-24(2,3)21-13-10-20(11-14-21)23-18-22(26)15-12-19(23)9-8-17-25/h10-11,13-14,19,22-23,25-26H,4-9,12,15-18H2,1-3H3/t19-,22-,23-/m1/s1
DMK3DUZ	CS	CCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMK3DUZ	IK	BTHPTUSWFPTQIG-UEVCKROQSA-N
DMK3DUZ	IU	(1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methyloctan-2-yl)phenyl]cyclohexan-1-ol
DMK3DUZ	DE	Discovery agent

DMTSZFB	ID	DMTSZFB
DMTSZFB	DN	JWH-342
DMTSZFB	HS	Investigative
DMTSZFB	SN	CHEMBL260130; JWH-342
DMTSZFB	DT	Small molecular drug
DMTSZFB	PC	49863581
DMTSZFB	MW	302.5
DMTSZFB	FM	C21H34O
DMTSZFB	IC	InChI=1S/C21H34O/c1-4-5-6-7-15-21(2,3)19-13-11-17(12-14-19)18-9-8-10-20(22)16-18/h11-14,18,20,22H,4-10,15-16H2,1-3H3/t18-,20-/m0/s1
DMTSZFB	CS	CCCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@@H](C2)O
DMTSZFB	IK	CICRJVLFNFCUOX-ICSRJNTNSA-N
DMTSZFB	IU	(1S,3S)-3-[4-(2-methyloctan-2-yl)phenyl]cyclohexan-1-ol
DMTSZFB	DE	Discovery agent

DMEU1NS	ID	DMEU1NS
DMEU1NS	DN	JWH-343
DMEU1NS	HS	Investigative
DMEU1NS	SN	JWH-343; CHEMBL263885
DMEU1NS	DT	Small molecular drug
DMEU1NS	PC	44452446
DMEU1NS	MW	304.5
DMEU1NS	FM	C20H32O2
DMEU1NS	IC	InChI=1S/C20H32O2/c1-4-20(2,3)17-10-7-16(8-11-17)19-14-18(22)12-9-15(19)6-5-13-21/h7-8,10-11,15,18-19,21-22H,4-6,9,12-14H2,1-3H3/t15-,18-,19-/m1/s1
DMEU1NS	CS	CCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMEU1NS	IK	FDSWUKCGXVVOCA-ATZDWAIDSA-N
DMEU1NS	IU	(1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylbutan-2-yl)phenyl]cyclohexan-1-ol
DMEU1NS	DE	Discovery agent

DM6VZ3T	ID	DM6VZ3T
DM6VZ3T	DN	JWH-344
DM6VZ3T	HS	Investigative
DM6VZ3T	SN	JWH-344; CHEMBL260253
DM6VZ3T	DT	Small molecular drug
DM6VZ3T	PC	44452397
DM6VZ3T	MW	346.5
DM6VZ3T	FM	C23H38O2
DM6VZ3T	IC	InChI=1S/C23H38O2/c1-4-5-6-15-23(2,3)20-12-9-19(10-13-20)22-17-21(25)14-11-18(22)8-7-16-24/h9-10,12-13,18,21-22,24-25H,4-8,11,14-17H2,1-3H3/t18-,21-,22-/m1/s1
DM6VZ3T	CS	CCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DM6VZ3T	IK	VAVUZZKKXHPBEZ-STZQEDGTSA-N
DM6VZ3T	IU	(1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DM6VZ3T	DE	Discovery agent

DML53SK	ID	DML53SK
DML53SK	DN	JWH-345
DML53SK	HS	Investigative
DML53SK	SN	JWH-345; CHEMBL259723
DML53SK	DT	Small molecular drug
DML53SK	PC	44452688
DML53SK	MW	374.6
DML53SK	FM	C25H42O2
DML53SK	IC	InChI=1S/C25H42O2/c1-4-5-6-7-8-17-25(2,3)22-14-11-21(12-15-22)24-19-23(27)16-13-20(24)10-9-18-26/h11-12,14-15,20,23-24,26-27H,4-10,13,16-19H2,1-3H3/t20-,23-,24-/m1/s1
DML53SK	CS	CCCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DML53SK	IK	RTPUPNNHNNHDQM-AGILITTLSA-N
DML53SK	IU	(1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylnonan-2-yl)phenyl]cyclohexan-1-ol
DML53SK	DE	Discovery agent

DMHNILP	ID	DMHNILP
DMHNILP	DN	JWH-346
DMHNILP	HS	Investigative
DMHNILP	SN	JWH-346; CHEMBL219243; BDBM50192613
DMHNILP	DT	Small molecular drug
DMHNILP	PC	44418326
DMHNILP	MW	381.5
DMHNILP	FM	C27H27NO
DMHNILP	IC	InChI=1S/C27H27NO/c1-3-4-7-16-28-19-23(18-26(28)22-13-8-10-20(2)17-22)27(29)25-15-9-12-21-11-5-6-14-24(21)25/h5-6,8-15,17-19H,3-4,7,16H2,1-2H3
DMHNILP	CS	CCCCCN1C=C(C=C1C2=CC=CC(=C2)C)C(=O)C3=CC=CC4=CC=CC=C43
DMHNILP	IK	SHCDXHJKMSBCOQ-UHFFFAOYSA-N
DMHNILP	IU	[5-(3-methylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMHNILP	DE	Discovery agent

DMK2NQ1	ID	DMK2NQ1
DMK2NQ1	DN	JWH-347
DMK2NQ1	HS	Investigative
DMK2NQ1	SN	JWH-347; CHEMBL374254; BDBM50192599
DMK2NQ1	DT	Small molecular drug
DMK2NQ1	PC	44418372
DMK2NQ1	MW	417.5
DMK2NQ1	FM	C30H27NO
DMK2NQ1	IC	InChI=1S/C30H27NO/c1-2-3-8-18-31-21-26(30(32)28-15-9-13-23-11-6-7-14-27(23)28)20-29(31)25-17-16-22-10-4-5-12-24(22)19-25/h4-7,9-17,19-21H,2-3,8,18H2,1H3
DMK2NQ1	CS	CCCCCN1C=C(C=C1C2=CC3=CC=CC=C3C=C2)C(=O)C4=CC=CC5=CC=CC=C54
DMK2NQ1	IK	WYOWIOBJNTYRNN-UHFFFAOYSA-N
DMK2NQ1	IU	naphthalen-1-yl-(5-naphthalen-2-yl-1-pentylpyrrol-3-yl)methanone
DMK2NQ1	DE	Discovery agent

DMQIVPK	ID	DMQIVPK
DMQIVPK	DN	JWH-348
DMQIVPK	HS	Investigative
DMQIVPK	SN	JWH-348; CHEMBL375791; BDBM50192605
DMQIVPK	DT	Small molecular drug
DMQIVPK	PC	44418368
DMQIVPK	MW	435.5
DMQIVPK	FM	C27H24F3NO
DMQIVPK	IC	InChI=1S/C27H24F3NO/c1-2-3-6-16-31-18-21(17-25(31)20-12-14-22(15-13-20)27(28,29)30)26(32)24-11-7-9-19-8-4-5-10-23(19)24/h4-5,7-15,17-18H,2-3,6,16H2,1H3
DMQIVPK	CS	CCCCCN1C=C(C=C1C2=CC=C(C=C2)C(F)(F)F)C(=O)C3=CC=CC4=CC=CC=C43
DMQIVPK	IK	KFMFBZYLXNTONN-UHFFFAOYSA-N
DMQIVPK	IU	naphthalen-1-yl-[1-pentyl-5-[4-(trifluoromethyl)phenyl]pyrrol-3-yl]methanone
DMQIVPK	DE	Discovery agent

DMFLB1Z	ID	DMFLB1Z
DMFLB1Z	DN	JWH-363
DMFLB1Z	HS	Investigative
DMFLB1Z	SN	JWH-363; CHEMBL219556; BDBM50192611
DMFLB1Z	DT	Small molecular drug
DMFLB1Z	PC	44418338
DMFLB1Z	MW	435.5
DMFLB1Z	FM	C27H24F3NO
DMFLB1Z	IC	InChI=1S/C27H24F3NO/c1-2-3-6-15-31-18-21(17-25(31)20-11-7-12-22(16-20)27(28,29)30)26(32)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMFLB1Z	CS	CCCCCN1C=C(C=C1C2=CC(=CC=C2)C(F)(F)F)C(=O)C3=CC=CC4=CC=CC=C43
DMFLB1Z	IK	GETLFVZYXNFVJS-UHFFFAOYSA-N
DMFLB1Z	IU	naphthalen-1-yl-[1-pentyl-5-[3-(trifluoromethyl)phenyl]pyrrol-3-yl]methanone
DMFLB1Z	DE	Discovery agent

DMP6C4D	ID	DMP6C4D
DMP6C4D	DN	JWH-364
DMP6C4D	HS	Investigative
DMP6C4D	SN	JWH-364; CHEMBL426706; BDBM50192606
DMP6C4D	DT	Small molecular drug
DMP6C4D	PC	44418348
DMP6C4D	MW	395.5
DMP6C4D	FM	C28H29NO
DMP6C4D	IC	InChI=1S/C28H29NO/c1-3-5-8-18-29-20-24(19-27(29)23-16-14-21(4-2)15-17-23)28(30)26-13-9-11-22-10-6-7-12-25(22)26/h6-7,9-17,19-20H,3-5,8,18H2,1-2H3
DMP6C4D	CS	CCCCCN1C=C(C=C1C2=CC=C(C=C2)CC)C(=O)C3=CC=CC4=CC=CC=C43
DMP6C4D	IK	VJWBAPGRMUZBEH-UHFFFAOYSA-N
DMP6C4D	IU	[5-(4-ethylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMP6C4D	DE	Discovery agent

DM2ZXBR	ID	DM2ZXBR
DM2ZXBR	DN	JWH-365
DM2ZXBR	HS	Investigative
DM2ZXBR	SN	JWH-365; CHEMBL220352; BDBM50192589
DM2ZXBR	DT	Small molecular drug
DM2ZXBR	PC	44418313
DM2ZXBR	MW	395.5
DM2ZXBR	FM	C28H29NO
DM2ZXBR	IC	InChI=1S/C28H29NO/c1-3-5-10-18-29-20-23(19-27(29)25-16-9-6-12-21(25)4-2)28(30)26-17-11-14-22-13-7-8-15-24(22)26/h6-9,11-17,19-20H,3-5,10,18H2,1-2H3
DM2ZXBR	CS	CCCCCN1C=C(C=C1C2=CC=CC=C2CC)C(=O)C3=CC=CC4=CC=CC=C43
DM2ZXBR	IK	SNWJCZXZSGPAJM-UHFFFAOYSA-N
DM2ZXBR	IU	[5-(2-ethylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM2ZXBR	DE	Discovery agent

DMSNLFJ	ID	DMSNLFJ
DMSNLFJ	DN	JWH-366
DMSNLFJ	HS	Investigative
DMSNLFJ	SN	JWH-366; CHEMBL218956; BDBM50192592
DMSNLFJ	DT	Small molecular drug
DMSNLFJ	PC	44418373
DMSNLFJ	MW	368.5
DMSNLFJ	FM	C25H24N2O
DMSNLFJ	IC	InChI=1S/C25H24N2O/c1-2-3-6-15-27-18-21(16-24(27)20-11-8-14-26-17-20)25(28)23-13-7-10-19-9-4-5-12-22(19)23/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMSNLFJ	CS	CCCCCN1C=C(C=C1C2=CN=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMSNLFJ	IK	MPQYTRCOFXNOTB-UHFFFAOYSA-N
DMSNLFJ	IU	naphthalen-1-yl-(1-pentyl-5-pyridin-3-ylpyrrol-3-yl)methanone
DMSNLFJ	DE	Discovery agent

DM7ZF2K	ID	DM7ZF2K
DM7ZF2K	DN	JWH-367
DM7ZF2K	HS	Investigative
DM7ZF2K	SN	JWH-367; CHEMBL385994; BDBM50192604
DM7ZF2K	DT	Small molecular drug
DM7ZF2K	PC	44418330
DM7ZF2K	MW	397.5
DM7ZF2K	FM	C27H27NO2
DM7ZF2K	IC	InChI=1S/C27H27NO2/c1-3-4-7-16-28-19-22(18-26(28)21-12-8-13-23(17-21)30-2)27(29)25-15-9-11-20-10-5-6-14-24(20)25/h5-6,8-15,17-19H,3-4,7,16H2,1-2H3
DM7ZF2K	CS	CCCCCN1C=C(C=C1C2=CC(=CC=C2)OC)C(=O)C3=CC=CC4=CC=CC=C43
DM7ZF2K	IK	RGYBGMOZXHKLRI-UHFFFAOYSA-N
DM7ZF2K	IU	[5-(3-methoxyphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM7ZF2K	DE	Discovery agent

DMK0FNX	ID	DMK0FNX
DMK0FNX	DN	JWH-368
DMK0FNX	HS	Investigative
DMK0FNX	SN	(5-(3-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone; 914458-31-4; JWH-368; CHEMBL220304; [5-(3-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone; CTK8B4185; DTXSID60658824; MolPort-023-278-971; 5344AC; ZINC36294609; BDBM50192608; ANW-44202; AKOS015999106; AJ-92570; AK-88831; DS-18529; TC-132947; KB-208485; AX8228512
DMK0FNX	DT	Small molecular drug
DMK0FNX	PC	44418331
DMK0FNX	MW	385.5
DMK0FNX	FM	C26H24FNO
DMK0FNX	IC	InChI=1S/C26H24FNO/c1-2-3-6-15-28-18-21(17-25(28)20-11-7-12-22(27)16-20)26(29)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMK0FNX	CS	CCCCCN1C=C(C=C1C2=CC(=CC=C2)F)C(=O)C3=CC=CC4=CC=CC=C43
DMK0FNX	IK	OCOICOMCAJNSCA-UHFFFAOYSA-N
DMK0FNX	IU	[5-(3-fluorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMK0FNX	CA	CAS 914458-31-4
DMK0FNX	DE	Discovery agent

DMPDTWY	ID	DMPDTWY
DMPDTWY	DN	JWH-369
DMPDTWY	HS	Investigative
DMPDTWY	SN	JWH-369; CHEMBL216837; ZINC34947165; BDBM50192601; 1-pentyl-2-(2-chlorophenyl)-4-(1-naphthoyl) pyrrole
DMPDTWY	DT	Small molecular drug
DMPDTWY	PC	16049784
DMPDTWY	MW	401.9
DMPDTWY	FM	C26H24ClNO
DMPDTWY	IC	InChI=1S/C26H24ClNO/c1-2-3-8-16-28-18-20(17-25(28)23-13-6-7-15-24(23)27)26(29)22-14-9-11-19-10-4-5-12-21(19)22/h4-7,9-15,17-18H,2-3,8,16H2,1H3
DMPDTWY	CS	CCCCCN1C=C(C=C1C2=CC=CC=C2Cl)C(=O)C3=CC=CC4=CC=CC=C43
DMPDTWY	IK	SUELCWQJMQQCTF-UHFFFAOYSA-N
DMPDTWY	IU	[5-(2-chlorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMPDTWY	CA	CAS 914458-27-8
DMPDTWY	DE	Discovery agent

DM6IG7P	ID	DM6IG7P
DM6IG7P	DN	JWH-370
DM6IG7P	HS	Investigative
DM6IG7P	SN	JWH-370; CHEMBL220180; HZMLAMXVETUEJZ-UHFFFAOYSA-N; 914458-22-3; JWH 370; BDBM50192595; ZINC36294595; [5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
DM6IG7P	DT	Small molecular drug
DM6IG7P	PC	44418312
DM6IG7P	MW	381.5
DM6IG7P	FM	C27H27NO
DM6IG7P	IC	InChI=1S/C27H27NO/c1-3-4-9-17-28-19-22(18-26(28)23-14-7-5-11-20(23)2)27(29)25-16-10-13-21-12-6-8-15-24(21)25/h5-8,10-16,18-19H,3-4,9,17H2,1-2H3
DM6IG7P	CS	CCCCCN1C=C(C=C1C2=CC=CC=C2C)C(=O)C3=CC=CC4=CC=CC=C43
DM6IG7P	IK	HZMLAMXVETUEJZ-UHFFFAOYSA-N
DM6IG7P	IU	[5-(2-methylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM6IG7P	DE	Discovery agent

DME0URP	ID	DME0URP
DME0URP	DN	JWH-371
DME0URP	HS	Investigative
DME0URP	SN	JWH-371; CHEMBL219580; BDBM50192594
DME0URP	DT	Small molecular drug
DME0URP	PC	44418349
DME0URP	MW	423.6
DME0URP	FM	C30H33NO
DME0URP	IC	InChI=1S/C30H33NO/c1-3-5-9-20-31-22-26(21-29(31)25-18-16-23(17-19-25)11-6-4-2)30(32)28-15-10-13-24-12-7-8-14-27(24)28/h7-8,10,12-19,21-22H,3-6,9,11,20H2,1-2H3
DME0URP	CS	CCCCCN1C=C(C=C1C2=CC=C(C=C2)CCCC)C(=O)C3=CC=CC4=CC=CC=C43
DME0URP	IK	PKNGYYSGLHBRGC-UHFFFAOYSA-N
DME0URP	IU	[5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DME0URP	DE	Discovery agent

DM9D3GM	ID	DM9D3GM
DM9D3GM	DN	JWH-372
DM9D3GM	HS	Investigative
DM9D3GM	SN	JWH-372; CHEMBL384897; BDBM50192610
DM9D3GM	DT	Small molecular drug
DM9D3GM	PC	44418325
DM9D3GM	MW	435.5
DM9D3GM	FM	C27H24F3NO
DM9D3GM	IC	InChI=1S/C27H24F3NO/c1-2-3-8-16-31-18-20(17-25(31)23-13-6-7-15-24(23)27(28,29)30)26(32)22-14-9-11-19-10-4-5-12-21(19)22/h4-7,9-15,17-18H,2-3,8,16H2,1H3
DM9D3GM	CS	CCCCCN1C=C(C=C1C2=CC=CC=C2C(F)(F)F)C(=O)C3=CC=CC4=CC=CC=C43
DM9D3GM	IK	CYPUIQJYGVOHMM-UHFFFAOYSA-N
DM9D3GM	IU	naphthalen-1-yl-[1-pentyl-5-[2-(trifluoromethyl)phenyl]pyrrol-3-yl]methanone
DM9D3GM	DE	Discovery agent

DMWP84R	ID	DMWP84R
DMWP84R	DN	JWH-373
DMWP84R	HS	Investigative
DMWP84R	SN	JWH-373; CHEMBL375802; BDBM50192597
DMWP84R	DT	Small molecular drug
DMWP84R	PC	44418316
DMWP84R	MW	423.6
DMWP84R	FM	C30H33NO
DMWP84R	IC	InChI=1S/C30H33NO/c1-3-5-11-20-31-22-25(21-29(31)27-18-10-8-15-24(27)13-6-4-2)30(32)28-19-12-16-23-14-7-9-17-26(23)28/h7-10,12,14-19,21-22H,3-6,11,13,20H2,1-2H3
DMWP84R	CS	CCCCCN1C=C(C=C1C2=CC=CC=C2CCCC)C(=O)C3=CC=CC4=CC=CC=C43
DMWP84R	IK	LDGBUSJKRUNXPK-UHFFFAOYSA-N
DMWP84R	IU	[5-(2-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMWP84R	DE	Discovery agent

DMU1HA7	ID	DMU1HA7
DMU1HA7	DN	JWH-385
DMU1HA7	HS	Investigative
DMU1HA7	SN	JWH-385; CHEMBL259518
DMU1HA7	DT	Small molecular drug
DMU1HA7	PC	44452687
DMU1HA7	MW	388.6
DMU1HA7	FM	C26H44O2
DMU1HA7	IC	InChI=1S/C26H44O2/c1-4-5-6-7-8-9-18-26(2,3)23-15-12-22(13-16-23)25-20-24(28)17-14-21(25)11-10-19-27/h12-13,15-16,21,24-25,27-28H,4-11,14,17-20H2,1-3H3/t21-,24-,25-/m1/s1
DMU1HA7	CS	CCCCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMU1HA7	IK	ZWVZYXMEZOIWEQ-NQHRYMMQSA-N
DMU1HA7	IU	(1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methyldecan-2-yl)phenyl]cyclohexan-1-ol
DMU1HA7	DE	Discovery agent

DMMUBIF	ID	DMMUBIF
DMMUBIF	DN	JWH-392
DMMUBIF	HS	Investigative
DMMUBIF	SN	JWH-392; CHEMBL260483
DMMUBIF	DT	Small molecular drug
DMMUBIF	PC	44452426
DMMUBIF	MW	318.5
DMMUBIF	FM	C21H34O2
DMMUBIF	IC	InChI=1S/C21H34O2/c1-4-13-21(2,3)18-10-7-17(8-11-18)20-15-19(23)12-9-16(20)6-5-14-22/h7-8,10-11,16,19-20,22-23H,4-6,9,12-15H2,1-3H3/t16-,19-,20-/m1/s1
DMMUBIF	CS	CCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMMUBIF	IK	VIGWEDJLUIAROG-NSISKUIASA-N
DMMUBIF	IU	(1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylpentan-2-yl)phenyl]cyclohexan-1-ol
DMMUBIF	DE	Discovery agent

DMFL6B9	ID	DMFL6B9
DMFL6B9	DN	JWH-401
DMFL6B9	HS	Investigative
DMFL6B9	SN	JWH-401; CHEMBL262337
DMFL6B9	DT	Small molecular drug
DMFL6B9	PC	44452623
DMFL6B9	MW	330.5
DMFL6B9	FM	C23H38O
DMFL6B9	IC	InChI=1S/C23H38O/c1-4-5-6-7-8-9-17-23(2,3)21-15-13-19(14-16-21)20-11-10-12-22(24)18-20/h13-16,20,22,24H,4-12,17-18H2,1-3H3/t20-,22+/m0/s1
DMFL6B9	CS	CCCCCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMFL6B9	IK	DQKOXMDLNBLQTB-RBBKRZOGSA-N
DMFL6B9	IU	(1R,3S)-3-[4-(2-methyldecan-2-yl)phenyl]cyclohexan-1-ol
DMFL6B9	DE	Discovery agent

DM8TQIF	ID	DM8TQIF
DM8TQIF	DN	JWH-402
DM8TQIF	HS	Investigative
DM8TQIF	SN	JWH-402; CHEMBL265934
DM8TQIF	DT	Small molecular drug
DM8TQIF	PC	44452507
DM8TQIF	MW	330.5
DM8TQIF	FM	C23H38O
DM8TQIF	IC	InChI=1S/C23H38O/c1-4-5-6-7-8-9-17-23(2,3)21-15-13-19(14-16-21)20-11-10-12-22(24)18-20/h13-16,20,22,24H,4-12,17-18H2,1-3H3/t20-,22-/m1/s1
DM8TQIF	CS	CCCCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DM8TQIF	IK	DQKOXMDLNBLQTB-IFMALSPDSA-N
DM8TQIF	IU	(1R,3R)-3-[4-(2-methyldecan-2-yl)phenyl]cyclohexan-1-ol
DM8TQIF	DE	Discovery agent

DMRG1VI	ID	DMRG1VI
DMRG1VI	DN	JWH-403
DMRG1VI	HS	Investigative
DMRG1VI	SN	JWH-403; CHEMBL263385
DMRG1VI	DT	Small molecular drug
DMRG1VI	PC	44452649
DMRG1VI	MW	288.5
DMRG1VI	FM	C20H32O
DMRG1VI	IC	InChI=1S/C20H32O/c1-4-5-6-14-20(2,3)18-12-10-16(11-13-18)17-8-7-9-19(21)15-17/h10-13,17,19,21H,4-9,14-15H2,1-3H3/t17-,19+/m0/s1
DMRG1VI	CS	CCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMRG1VI	IK	RGRMJFXCHLLHAS-PKOBYXMFSA-N
DMRG1VI	IU	(1R,3S)-3-[4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DMRG1VI	DE	Discovery agent

DM3KWER	ID	DM3KWER
DM3KWER	DN	JWH-404
DM3KWER	HS	Investigative
DM3KWER	SN	JWH-404; CHEMBL262336
DM3KWER	DT	Small molecular drug
DM3KWER	PC	44452622
DM3KWER	MW	316.5
DM3KWER	FM	C22H36O
DM3KWER	IC	InChI=1S/C22H36O/c1-4-5-6-7-8-16-22(2,3)20-14-12-18(13-15-20)19-10-9-11-21(23)17-19/h12-15,19,21,23H,4-11,16-17H2,1-3H3/t19-,21+/m0/s1
DM3KWER	CS	CCCCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DM3KWER	IK	SHSCKELICBAALI-PZJWPPBQSA-N
DM3KWER	IU	(1R,3S)-3-[4-(2-methylnonan-2-yl)phenyl]cyclohexan-1-ol
DM3KWER	DE	Discovery agent

DM57TN3	ID	DM57TN3
DM57TN3	DN	JWH-405
DM57TN3	HS	Investigative
DM57TN3	SN	JWH-405; CHEMBL265933
DM57TN3	DT	Small molecular drug
DM57TN3	PC	44452506
DM57TN3	MW	316.5
DM57TN3	FM	C22H36O
DM57TN3	IC	InChI=1S/C22H36O/c1-4-5-6-7-8-16-22(2,3)20-14-12-18(13-15-20)19-10-9-11-21(23)17-19/h12-15,19,21,23H,4-11,16-17H2,1-3H3/t19-,21-/m1/s1
DM57TN3	CS	CCCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DM57TN3	IK	SHSCKELICBAALI-TZIWHRDSSA-N
DM57TN3	IU	(1R,3R)-3-[4-(2-methylnonan-2-yl)phenyl]cyclohexan-1-ol
DM57TN3	DE	Discovery agent

DMNP7GD	ID	DMNP7GD
DMNP7GD	DN	JWH-406
DMNP7GD	HS	Investigative
DMNP7GD	SN	JWH-406; CHEMBL261495
DMNP7GD	DT	Small molecular drug
DMNP7GD	PC	44452581
DMNP7GD	MW	288.5
DMNP7GD	FM	C20H32O
DMNP7GD	IC	InChI=1S/C20H32O/c1-4-5-6-14-20(2,3)18-12-10-16(11-13-18)17-8-7-9-19(21)15-17/h10-13,17,19,21H,4-9,14-15H2,1-3H3/t17-,19-/m1/s1
DMNP7GD	CS	CCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DMNP7GD	IK	RGRMJFXCHLLHAS-IEBWSBKVSA-N
DMNP7GD	IU	(1R,3R)-3-[4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DMNP7GD	DE	Discovery agent

DMZQ0V9	ID	DMZQ0V9
DMZQ0V9	DN	JWH-407
DMZQ0V9	HS	Investigative
DMZQ0V9	SN	JWH-407; CHEMBL261494
DMZQ0V9	DT	Small molecular drug
DMZQ0V9	PC	44452580
DMZQ0V9	MW	274.4
DMZQ0V9	FM	C19H30O
DMZQ0V9	IC	InChI=1S/C19H30O/c1-4-5-13-19(2,3)17-11-9-15(10-12-17)16-7-6-8-18(20)14-16/h9-12,16,18,20H,4-8,13-14H2,1-3H3/t16-,18-/m1/s1
DMZQ0V9	CS	CCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DMZQ0V9	IK	WMICXNJEJDOUPN-SJLPKXTDSA-N
DMZQ0V9	IU	(1R,3R)-3-[4-(2-methylhexan-2-yl)phenyl]cyclohexan-1-ol
DMZQ0V9	DE	Discovery agent

DM89602	ID	DM89602
DM89602	DN	JWH-440
DM89602	HS	Investigative
DM89602	SN	JWH-440; CHEMBL1214644; BDBM50323906
DM89602	DT	Small molecular drug
DM89602	PC	46918944
DM89602	MW	318.5
DM89602	FM	C21H34O2
DM89602	IC	InChI=1S/C21H34O2/c1-5-6-7-13-21(2,3)17-11-12-19(20(15-17)23-4)16-9-8-10-18(22)14-16/h11-12,15-16,18,22H,5-10,13-14H2,1-4H3/t16-,18+/m0/s1
DM89602	CS	CCCCCC(C)(C)C1=CC(=C(C=C1)[C@H]2CCC[C@H](C2)O)OC
DM89602	IK	GZSDLXNECOWUFY-FUHWJXTLSA-N
DM89602	IU	(1R,3S)-3-[2-methoxy-4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DM89602	DE	Discovery agent

DM7R1XS	ID	DM7R1XS
DM7R1XS	DN	JWH-441
DM7R1XS	HS	Investigative
DM7R1XS	SN	JWH-441; CHEMBL1212958; BDBM50323908
DM7R1XS	DT	Small molecular drug
DM7R1XS	PC	49863973
DM7R1XS	MW	332.5
DM7R1XS	FM	C22H36O2
DM7R1XS	IC	InChI=1S/C22H36O2/c1-5-6-7-8-14-22(2,3)18-12-13-20(21(16-18)24-4)17-10-9-11-19(23)15-17/h12-13,16-17,19,23H,5-11,14-15H2,1-4H3/t17-,19+/m0/s1
DM7R1XS	CS	CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@H]2CCC[C@H](C2)O)OC
DM7R1XS	IK	ZVQYLLPGZZZCSV-PKOBYXMFSA-N
DM7R1XS	IU	(1R,3S)-3-[2-methoxy-4-(2-methyloctan-2-yl)phenyl]cyclohexan-1-ol
DM7R1XS	DE	Discovery agent

DMX6F1L	ID	DMX6F1L
DMX6F1L	DN	JWH-442
DMX6F1L	HS	Investigative
DMX6F1L	SN	JWH-442; CHEMBL1213721; BDBM50323905
DMX6F1L	DT	Small molecular drug
DMX6F1L	PC	49863580
DMX6F1L	MW	318.5
DMX6F1L	FM	C21H34O2
DMX6F1L	IC	InChI=1S/C21H34O2/c1-5-6-7-13-21(2,3)17-11-12-19(20(15-17)23-4)16-9-8-10-18(22)14-16/h11-12,15-16,18,22H,5-10,13-14H2,1-4H3/t16-,18-/m0/s1
DMX6F1L	CS	CCCCCC(C)(C)C1=CC(=C(C=C1)[C@H]2CCC[C@@H](C2)O)OC
DMX6F1L	IK	GZSDLXNECOWUFY-WMZOPIPTSA-N
DMX6F1L	IU	(1S,3S)-3-[2-methoxy-4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DMX6F1L	DE	Discovery agent

DMWA8B0	ID	DMWA8B0
DMWA8B0	DN	JZL184
DMWA8B0	HS	Investigative
DMWA8B0	SN	JZL 184; JZL-184
DMWA8B0	DT	Small molecular drug
DMWA8B0	PC	25021165
DMWA8B0	MW	520.5
DMWA8B0	FM	C27H24N2O9
DMWA8B0	IC	InChI=1S/C27H24N2O9/c30-26(38-21-5-3-20(4-6-21)29(32)33)28-11-9-17(10-12-28)27(31,18-1-7-22-24(13-18)36-15-34-22)19-2-8-23-25(14-19)37-16-35-23/h1-8,13-14,17,31H,9-12,15-16H2
DMWA8B0	CS	C1CN(CCC1C(C2=CC3=C(C=C2)OCO3)(C4=CC5=C(C=C4)OCO5)O)C(=O)OC6=CC=C(C=C6)[N+](=O)[O-]
DMWA8B0	IK	SEGYOKHGGFKMCX-UHFFFAOYSA-N
DMWA8B0	IU	(4-nitrophenyl) 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate
DMWA8B0	CA	CAS 1101854-58-3
DMWA8B0	CB	CHEBI:95015
DMWA8B0	DE	Discovery agent

DMEOCKZ	ID	DMEOCKZ
DMEOCKZ	DN	JZL195
DMEOCKZ	HS	Investigative
DMEOCKZ	SN	JZL-195; JZL 195
DMEOCKZ	DT	Small molecular drug
DMEOCKZ	PC	46232606
DMEOCKZ	MW	433.5
DMEOCKZ	FM	C24H23N3O5
DMEOCKZ	IC	InChI=1S/C24H23N3O5/c28-24(32-22-11-9-20(10-12-22)27(29)30)26-15-13-25(14-16-26)18-19-5-4-8-23(17-19)31-21-6-2-1-3-7-21/h1-12,17H,13-16,18H2
DMEOCKZ	CS	C1CN(CCN1CC2=CC(=CC=C2)OC3=CC=CC=C3)C(=O)OC4=CC=C(C=C4)[N+](=O)[O-]
DMEOCKZ	IK	QNYRAEKLMNDRFY-UHFFFAOYSA-N
DMEOCKZ	IU	(4-nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate
DMEOCKZ	DE	Discovery agent

DMP8M9Q	ID	DMP8M9Q
DMP8M9Q	DN	K00024
DMP8M9Q	HS	Investigative
DMP8M9Q	SN	indolocarbazole deriv. 4(d)
DMP8M9Q	DT	Small molecular drug
DMP8M9Q	PC	5330797
DMP8M9Q	MW	404.2
DMP8M9Q	FM	C20H10BrN3O2
DMP8M9Q	IC	InChI=1S/C20H10BrN3O2/c21-8-5-6-10-12(7-8)23-18-14(10)16-15(19(25)24-20(16)26)13-9-3-1-2-4-11(9)22-17(13)18/h1-7,22-23H,(H,24,25,26)
DMP8M9Q	CS	C1=CC=C2C(=C1)C3=C4C(=C5C6=C(C=C(C=C6)Br)NC5=C3N2)C(=O)NC4=O
DMP8M9Q	IK	NMFKDDRQSNVETB-UHFFFAOYSA-N
DMP8M9Q	IU	6-bromo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione
DMP8M9Q	CA	CAS 546102-60-7
DMP8M9Q	DE	Discovery agent

DM2BKU8	ID	DM2BKU8
DM2BKU8	DN	K00244
DM2BKU8	HS	Investigative
DM2BKU8	SN	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; K00244; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine
DM2BKU8	DT	Small molecular drug
DM2BKU8	PC	6419766
DM2BKU8	MW	301.3
DM2BKU8	FM	C18H15N5
DM2BKU8	IC	InChI=1S/C18H15N5/c1-12-11-16(23-22-12)20-18-14-9-5-6-10-15(14)19-17(21-18)13-7-3-2-4-8-13/h2-11H,1H3,(H2,19,20,21,22,23)
DM2BKU8	CS	CC1=CC(=NN1)NC2=NC(=NC3=CC=CC=C32)C4=CC=CC=C4
DM2BKU8	IK	JYCUVOXSZBECAY-UHFFFAOYSA-N
DM2BKU8	IU	N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine
DM2BKU8	CB	CHEBI:78544
DM2BKU8	DE	Discovery agent

DMWZJG6	ID	DMWZJG6
DMWZJG6	DN	K00248
DMWZJG6	HS	Investigative
DMWZJG6	SN	PKCbeta Inhibitor; 257879-35-9; K00248; CHEMBL366266; 3-(1-(3-Imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione; PKC  Inhibitor; AC1O4WCS; SCHEMBL7841474; GTPL6025; CHEBI:94140; CTK8F0351; DTXSID20423555; HMS3229K09; BDBM50153461; IN1136; CCG-206785; RT-015068; J-016132; BRD-K89687904-001-01-8; 3-anilino-4-[1-(3-imidazol-1-ylpropyl)indol-3-yl]pyrrole-2,5-dione; 3-[1-[3-(1H-Imidazole-1-yl)propyl]-1H-indole-3-yl]-4-anilino-1H-pyrrole-2,5-dione
DMWZJG6	DT	Small molecular drug
DMWZJG6	PC	6419755
DMWZJG6	MW	411.5
DMWZJG6	FM	C24H21N5O2
DMWZJG6	IC	InChI=1S/C24H21N5O2/c30-23-21(22(24(31)27-23)26-17-7-2-1-3-8-17)19-15-29(20-10-5-4-9-18(19)20)13-6-12-28-14-11-25-16-28/h1-5,7-11,14-16H,6,12-13H2,(H2,26,27,30,31)
DMWZJG6	CS	C1=CC=C(C=C1)NC2=C(C(=O)NC2=O)C3=CN(C4=CC=CC=C43)CCCN5C=CN=C5
DMWZJG6	IK	KIWODJBCHRADND-UHFFFAOYSA-N
DMWZJG6	IU	3-anilino-4-[1-(3-imidazol-1-ylpropyl)indol-3-yl]pyrrole-2,5-dione
DMWZJG6	CA	CAS 257879-35-9
DMWZJG6	CB	CHEBI:94140
DMWZJG6	DE	Discovery agent

DM1RP5Q	ID	DM1RP5Q
DM1RP5Q	DN	K00592a
DM1RP5Q	HS	Investigative
DM1RP5Q	SN	K00592a; CHEMBL471901; SCHEMBL1222899; GTPL6047; MolPort-044-561-482; ZINC2007259; BDBM50249319; 2-(2-aminoethylamino)-4-(3-(trifluoromethyl)phenylamino)pyrimidine-5-carboxamide; 2-[(2-aminoethyl)amino]-4-{[3-(trifluoromethyl)phenyl]amino}pyrimidine-5-carboxamide
DM1RP5Q	DT	Small molecular drug
DM1RP5Q	PC	9549296
DM1RP5Q	MW	340.3
DM1RP5Q	FM	C14H15F3N6O
DM1RP5Q	IC	InChI=1S/C14H15F3N6O/c15-14(16,17)8-2-1-3-9(6-8)22-12-10(11(19)24)7-21-13(23-12)20-5-4-18/h1-3,6-7H,4-5,18H2,(H2,19,24)(H2,20,21,22,23)
DM1RP5Q	CS	C1=CC(=CC(=C1)NC2=NC(=NC=C2C(=O)N)NCCN)C(F)(F)F
DM1RP5Q	IK	FQNFLNSVHWCZML-UHFFFAOYSA-N
DM1RP5Q	IU	2-(2-aminoethylamino)-4-[3-(trifluoromethyl)anilino]pyrimidine-5-carboxamide
DM1RP5Q	DE	Discovery agent

DME65H8	ID	DME65H8
DME65H8	DN	K185
DME65H8	HS	Investigative
DME65H8	SN	K-185; K 185
DME65H8	DT	Small molecular drug
DME65H8	PC	5311198
DME65H8	MW	376.5
DME65H8	FM	C24H28N2O2
DME65H8	IC	InChI=1S/C24H28N2O2/c1-3-7-23(27)25-14-13-20-21-16-18(28-2)11-12-22(21)26-15-6-9-17-8-4-5-10-19(17)24(20)26/h4-5,8,10-12,16H,3,6-7,9,13-15H2,1-2H3,(H,25,27)
DME65H8	CS	CCCC(=O)NCCC1=C2C3=CC=CC=C3CCCN2C4=C1C=C(C=C4)OC
DME65H8	IK	SPIFQXPRSJKRAO-UHFFFAOYSA-N
DME65H8	IU	N-[2-(11-methoxy-6,7-dihydro-5H-indolo[2,1-a][2]benzazepin-13-yl)ethyl]butanamide
DME65H8	CA	CAS 32223-82-8
DME65H8	DE	Discovery agent

DMT68RG	ID	DMT68RG
DMT68RG	DN	K252a
DMT68RG	HS	Investigative
DMT68RG	SN	K-252a, Nocardiopsis sp.; k-252a; ST50826373; (+)-K-252A; k-252a deriva-tives; AC1LAL9C; GTPL336; BDBM2580; CHEMBL416056; SCHEMBL13485248; HMS3229K08; ZINC3776578; 99533-80-9; CCG-206861; methyl hydroxy-methyl-oxo-[ ]carboxylate; B6828; methyl (15R,16S,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8(13),9,11,20(25),21,23-nonaene-16-carboxylate; methyl (16S,18S,15R)-1
DMT68RG	DT	Small molecular drug
DMT68RG	PC	3035817
DMT68RG	MW	467.5
DMT68RG	FM	C27H21N3O5
DMT68RG	IC	InChI=1S/C27H21N3O5/c1-26-27(33,25(32)34-2)11-18(35-26)29-16-9-5-3-7-13(16)20-21-15(12-28-24(21)31)19-14-8-4-6-10-17(14)30(26)23(19)22(20)29/h3-10,18,33H,11-12H2,1-2H3,(H,28,31)/t18-,26+,27+/m1/s1
DMT68RG	CS	C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(C(=O)OC)O
DMT68RG	IK	KOZFSFOOLUUIGY-SOLYNIJKSA-N
DMT68RG	IU	methyl (15S,16R,18R)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate
DMT68RG	CA	CAS 99533-80-9
DMT68RG	CB	CHEBI:43616
DMT68RG	DE	Solid tumour/cancer

DMCZPH4	ID	DMCZPH4
DMCZPH4	DN	K-252a analogue
DMCZPH4	HS	Investigative
DMCZPH4	DT	Small molecular drug
DMCZPH4	PC	44400432
DMCZPH4	MW	455.5
DMCZPH4	FM	C27H25N3O4
DMCZPH4	IC	InChI=1S/C27H25N3O4/c1-26(2)27(33,13-31)11-19(34-26)30-18-10-6-4-8-15(18)21-22-16(12-28-25(22)32)20-14-7-3-5-9-17(14)29-23(20)24(21)30/h3-10,19,29,31,33H,11-13H2,1-2H3,(H,28,32)/t19-,27-/m1/s1
DMCZPH4	CS	CC1([C@@](C[C@@H](O1)N2C3=CC=CC=C3C4=C5C(=C6C7=CC=CC=C7NC6=C42)CNC5=O)(CO)O)C
DMCZPH4	IK	ONSKSKMJNHEONW-XHCCPWGMSA-N
DMCZPH4	IU	3-[(2R,4R)-4-hydroxy-4-(hydroxymethyl)-5,5-dimethyloxolan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-12-one
DMCZPH4	DE	Discovery agent

DMYSMWI	ID	DMYSMWI
DMYSMWI	DN	K-454
DMYSMWI	HS	Investigative
DMYSMWI	SN	JAK2 kinase inhibitor (cancer), Kyowa
DMYSMWI	CP	Kyowa Hakko Kirin Co Ltd
DMYSMWI	DE	Solid tumour/cancer

DMUKTBF	ID	DMUKTBF
DMUKTBF	DN	K-6015
DMUKTBF	HS	Investigative
DMUKTBF	SN	Thymol-beta-D-glucopyranoside; LS-71596; MCULE-2137662265; THYMOL-B-D-GLUCOPYRANOSIDE; THYMOL-BETA-D-GLUCOPYRANOSIDE; Thymol glucoside; Thymol-beta-D-glucoside; W-201820; ZINC5765311; (2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-(2-isopropyl-5-methylphenoxy)tetrahydro-2H-pyran-3,4,5-triol; 1-O-Thymyl-beta-D-glucopyranoside; 2-isopropyl-5-methylphenol-O-beta-d-glucopyranoside; 20772-23-0; FT-0771734; Glucopyranoside, 1-O-thymyl-, beta-D-; NCGC00380175-01; beta-D-Glucopyranoside, 5-methyl-2-(1-methylethyl)phenyl
DMUKTBF	PC	88687
DMUKTBF	MW	312.36
DMUKTBF	FM	C16H24O6
DMUKTBF	IC	GKQGIQVSMCHAFX-IBEHDNSVSA-N
DMUKTBF	CS	CC1=CC(=C(C=C1)C(C)C)OC2C(C(C(C(O2)CO)O)O)O
DMUKTBF	IK	1S/C16H24O6/c1-8(2)10-5-4-9(3)6-11(10)21-16-15(20)14(19)13(18)12(7-17)22-16/h4-6,8,12-20H,7H2,1-3H3/t12-,13-,14+,15-,16-/m1/s1
DMUKTBF	IU	(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(5-methyl-2-propan-2-ylphenoxy)oxane-3,4,5-triol
DMUKTBF	CA	CAS 20772-23-0
DMUKTBF	DE	Campylobacter gastroenteritis

DMIFCMW	ID	DMIFCMW
DMIFCMW	DN	K-777
DMIFCMW	HS	Investigative
DMIFCMW	SN	K-777; UNII-320A4L58IZ; APC-3316; CRA-3316; K777; CHEMBL91704; 320A4L58IZ; K-11777; 4-methyl-N-((S)-1-oxo-3-phenyl-1-((S,E)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-ylamino)propan-2-yl)piperazine-1-carboxamide hydrochloride; APC 3316; K 777; K 11777; 233277-99-1; BDBM50229129; 1-Piperazinecarboxamide, 4-methyl-N-((1S)-2-oxo-2-(((1S)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propen-1-yl)amino)-1-(phenylmethyl)ethyl)-; 1-Piperazinecarboxamide, 4-methyl-N-((1S)-2-oxo-2-(((1S)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl)amino)
DMIFCMW	DT	Small molecular drug
DMIFCMW	PC	9851116
DMIFCMW	MW	574.7
DMIFCMW	FM	C32H38N4O4S
DMIFCMW	IC	InChI=1S/C32H38N4O4S/c1-35-20-22-36(23-21-35)32(38)34-30(25-27-13-7-3-8-14-27)31(37)33-28(18-17-26-11-5-2-6-12-26)19-24-41(39,40)29-15-9-4-10-16-29/h2-16,19,24,28,30H,17-18,20-23,25H2,1H3,(H,33,37)(H,34,38)/b24-19+/t28-,30-/m0/s1
DMIFCMW	CS	CN1CCN(CC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC3=CC=CC=C3)/C=C/S(=O)(=O)C4=CC=CC=C4
DMIFCMW	IK	RHJLQMVZXQKJKB-FPHSVDBKSA-N
DMIFCMW	IU	N-[(2S)-1-[[(E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide
DMIFCMW	CA	CAS 233277-99-1
DMIFCMW	DE	Discovery agent

DM4GSHY	ID	DM4GSHY
DM4GSHY	DN	KA-10X
DM4GSHY	HS	Investigative
DM4GSHY	SN	KA-101; KA-102; G3BP antagonist peptides (cancer), Wuhan KatyGen Pharmaceuticals; RasGAP/RasGAP binding protein antagonist peptides (cancer), Wuhan Katygen Pharmaceuticals
DM4GSHY	CP	Wuhan Katygen Pharmaceuticals Inc
DM4GSHY	DE	Solid tumour/cancer

DMUWA2G	ID	DMUWA2G
DMUWA2G	DN	KAEMPFERIDE
DMUWA2G	HS	Investigative
DMUWA2G	SN	Kaempferide; 491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; Kaemperide; Campheride; Kempferide; UNII-508XL61MPD; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 5,7-Dihydroxy-4'-methoxyflavonol; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; EINECS 207-738-4; BRN 0305378; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Flavone, 3,5,7-trihydroxy-4'-methoxy-; CHEMBL40919; CHEBI:6099; 508XL61MPD
DMUWA2G	DT	Small molecular drug
DMUWA2G	PC	5281666
DMUWA2G	MW	300.26
DMUWA2G	FM	C16H12O6
DMUWA2G	IC	InChI=1S/C16H12O6/c1-21-10-4-2-8(3-5-10)16-15(20)14(19)13-11(18)6-9(17)7-12(13)22-16/h2-7,17-18,20H,1H3
DMUWA2G	CS	COC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
DMUWA2G	IK	SQFSKOYWJBQGKQ-UHFFFAOYSA-N
DMUWA2G	IU	3,5,7-trihydroxy-2-(4-methoxyphenyl)chromen-4-one
DMUWA2G	CA	CAS 491-54-3
DMUWA2G	CB	CHEBI:6099
DMUWA2G	DE	Discovery agent

DMHEMUB	ID	DMHEMUB
DMHEMUB	DN	Kaempferol
DMHEMUB	HS	Investigative
DMHEMUB	SN	kaempferol; 520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe
DMHEMUB	DT	Small molecular drug
DMHEMUB	PC	5280863
DMHEMUB	MW	286.24
DMHEMUB	FM	C15H10O6
DMHEMUB	IC	InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H
DMHEMUB	CS	C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMHEMUB	IK	IYRMWMYZSQPJKC-UHFFFAOYSA-N
DMHEMUB	IU	3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one
DMHEMUB	CA	CAS 520-18-3
DMHEMUB	CB	CHEBI:28499
DMHEMUB	DE	Discovery agent

DMUCZ3F	ID	DMUCZ3F
DMUCZ3F	DN	Kaempferol-3-O-(2''-O-galloyl)-glucoside
DMUCZ3F	HS	Investigative
DMUCZ3F	SN	CHEMBL444191; 76343-90-3; AC1NUQQD; Astragalin 2''-gallate; SCHEMBL12470746; BDBM50004199; AKOS030532822; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-((2-O-(3,4,5-trihydroxybenzoyl)-beta-D-glucopyranosyl)oxy)-; [(2S,3R,4S,5S,6R)-2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl] 3,4,5-trihydroxybenzoate
DMUCZ3F	DT	Small molecular drug
DMUCZ3F	PC	5488619
DMUCZ3F	MW	600.5
DMUCZ3F	FM	C28H24O15
DMUCZ3F	IC	InChI=1S/C28H24O15/c29-9-18-21(36)23(38)26(42-27(39)11-5-15(33)20(35)16(34)6-11)28(41-18)43-25-22(37)19-14(32)7-13(31)8-17(19)40-24(25)10-1-3-12(30)4-2-10/h1-8,18,21,23,26,28-36,38H,9H2/t18-,21-,23+,26-,28+/m1/s1
DMUCZ3F	CS	C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)O
DMUCZ3F	IK	UWIQWJHBYRTKAL-KQOASZHBSA-N
DMUCZ3F	IU	[(2S,3R,4S,5S,6R)-2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl] 3,4,5-trihydroxybenzoate
DMUCZ3F	CA	CAS 76343-90-3
DMUCZ3F	DE	Discovery agent

DMBG7X1	ID	DMBG7X1
DMBG7X1	DN	Kaempferol-3-O-methyl ether
DMBG7X1	HS	Investigative
DMBG7X1	SN	Isokaempferide; 1592-70-7; 3-Methylkaempferol; 3-O-Methylkaempferol; Kaempferol 3-methyl ether; kaempferol-3-O-methyl ether; CHEBI:1579; CHEMBL165064; 4H-1-BENZOPYRAN-4-ONE, 5,7-DIHYDROXY-2-(4-HYDROXYPHENYL)-3-METHOXY-; 3-Methylkempferol; AC1NQXOY; MLS000877008; SCHEMBL4637442; SCHEMBL1628023; MEGxp0_000171; 3-MK; cid_5280862; ACon1_001687; DTXSID90166609; MolPort-001-740-349; HMS2271C11; ZINC5732268; BDBM50240899; LMPK12112688; AKOS032949069
DMBG7X1	DT	Small molecular drug
DMBG7X1	PC	5280862
DMBG7X1	MW	300.26
DMBG7X1	FM	C16H12O6
DMBG7X1	IC	InChI=1S/C16H12O6/c1-21-16-14(20)13-11(19)6-10(18)7-12(13)22-15(16)8-2-4-9(17)5-3-8/h2-7,17-19H,1H3
DMBG7X1	CS	COC1=C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O
DMBG7X1	IK	VJJZJBUCDWKPLC-UHFFFAOYSA-N
DMBG7X1	IU	5,7-dihydroxy-2-(4-hydroxyphenyl)-3-methoxychromen-4-one
DMBG7X1	CA	CAS 1592-70-7
DMBG7X1	CB	CHEBI:1579
DMBG7X1	DE	Discovery agent

DMN4EUB	ID	DMN4EUB
DMN4EUB	DN	KAG-308
DMN4EUB	HS	Investigative
DMN4EUB	SN	EP4 agonists (ulcerative colitis), Kaken
DMN4EUB	CP	Kaken Pharmaceutical Co Ltd
DMN4EUB	PC	67108613
DMN4EUB	MW	460.5
DMN4EUB	FM	C24H30F2N4O3
DMN4EUB	IC	InChI=1S/C24H30F2N4O3/c1-14-6-5-7-16(12-14)15(2)18(31)11-10-17-19(32)13-20-23(17)24(25,26)21(33-20)8-3-4-9-22-27-29-30-28-22/h5-8,10-12,15,17-20,23,31-32H,3-4,9,13H2,1-2H3,(H,27,28,29,30)/b11-10+,21-8-/t15-,17+,18-,19-,20+,23-/m1/s1
DMN4EUB	CS	CC1=CC(=CC=C1)[C@@H](C)[C@@H](/C=C/[C@H]2[C@@H](C[C@H]3[C@@H]2C(/C(=C/CCCC4=NNN=N4)/O3)(F)F)O)O
DMN4EUB	IK	KSELABKNBIUMGG-YGBAREPYSA-N
DMN4EUB	IU	(2Z,3aR,4R,5R,6aS)-3,3-difluoro-4-[(E,3R,4R)-3-hydroxy-4-(3-methylphenyl)pent-1-enyl]-2-[4-(2H-tetrazol-5-yl)butylidene]-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]furan-5-ol
DMN4EUB	DE	Ulcerative colitis

DMRT6OP	ID	DMRT6OP
DMRT6OP	DN	kallidin
DMRT6OP	HS	Investigative
DMRT6OP	SN	Lysyl-bradykinin; [Lys]bradykinin; Lys-BK; kallidin II
DMRT6OP	DT	Small molecular drug
DMRT6OP	PC	5311111
DMRT6OP	MW	1188.4
DMRT6OP	FM	C56H85N17O12
DMRT6OP	IC	InChI=1S/C56H85N17O12/c57-24-8-7-18-36(58)46(76)67-37(19-9-25-63-55(59)60)51(81)73-29-13-23-44(73)53(83)72-28-11-21-42(72)49(79)65-32-45(75)66-39(30-34-14-3-1-4-15-34)47(77)70-41(33-74)52(82)71-27-12-22-43(71)50(80)69-40(31-35-16-5-2-6-17-35)48(78)68-38(54(84)85)20-10-26-64-56(61)62/h1-6,14-17,36-44,74H,7-13,18-33,57-58H2,(H,65,79)(H,66,75)(H,67,76)(H,68,78)(H,69,80)(H,70,77)(H,84,85)(H4,59,60,63)(H4,61,62,64)/t36-,37-,38-,39-,40-,41-,42-,43-,44-/m0/s1
DMRT6OP	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DMRT6OP	IK	FYSKZKQBTVLYEQ-FSLKYBNLSA-N
DMRT6OP	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMRT6OP	CA	CAS 342-10-9
DMRT6OP	CB	CHEBI:6102
DMRT6OP	DE	Discovery agent

DM7YAE0	ID	DM7YAE0
DM7YAE0	DN	kallstroemin D
DM7YAE0	HS	Investigative
DM7YAE0	SN	kallstroemin D
DM7YAE0	DT	Small molecular drug
DM7YAE0	PC	73754998
DM7YAE0	MW	1015.2
DM7YAE0	FM	C51H82O20
DM7YAE0	IC	InChI=1S/C51H82O20/c1-21-10-15-50(63-19-21)22(2)34-32(69-50)17-30-28-9-8-26-16-27(11-13-48(26,6)29(28)12-14-49(30,34)7)66-45-42(60)40(58)38(56)33(67-45)20-62-47-44(41(59)37(55)24(4)65-47)70-51(18-31(52)35(53)25(5)68-51)71-46-43(61)39(57)36(54)23(3)64-46/h8,21-25,27-47,52-61H,9-20H2,1-7H3
DM7YAE0	CS	CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)COC8C(C(C(C(O8)C)O)O)OC9(CC(C(C(O9)C)O)O)OC2C(C(C(C(O2)C)O)O)O)O)O)O)C)C)C)OC1
DM7YAE0	IK	JXANHBVHGVNOQZ-UHFFFAOYSA-N
DM7YAE0	IU	2-[2-[4,5-dihydroxy-6-methyl-2-[[3,4,5-trihydroxy-6-(5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl)oxyoxan-2-yl]methoxy]oxan-3-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6-methyloxane-3,4,5-triol
DM7YAE0	DE	Discovery agent

DMFR79L	ID	DMFR79L
DMFR79L	DN	Kaltostat
DMFR79L	HS	Investigative
DMFR79L	SN	Polysaccharide alginic acid; Sodium calcium alginate; calginat; Kalrostat; Vocoloid; Xantalgin; copper alginate; C14H22O13; Alloid G; Kalrostat 2; Polymannuronic acid; poly(mannuronic acid); alginic acid, copper salt; Alginic acid, calcium salt; Alginic acid, ammonium salt; polymannuronic-guluronic acid; Landalgine; Nouralgine
DMFR79L	DE	Gastro-oesophageal reflux disease

DMXAK75	ID	DMXAK75
DMXAK75	DN	KAR-1880
DMXAK75	HS	Investigative
DMXAK75	SN	Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus
DMXAK75	CP	Karus Therapeutics Ltd
DMXAK75	DE	Dermatitis

DMMIA38	ID	DMMIA38
DMMIA38	DN	kassinin
DMMIA38	HS	Investigative
DMMIA38	SN	KASSININ; 63968-82-1; UNII-9BOP147TRT; 9BOP147TRT; AC1L2EKC; GTPL2088; SCHEMBL20639320; BDBM81943; NSC_45749; CAS_45749; L-alpha-Aspartyl-L-valyl-L-prolyl-L-lysyl-L-seryl-L-alpha-aspartyl-L-glutaminyl-L-phenylalanyl-L-valylglycyl-L-leucyl-L-methioninamide; LS-187667; LS-187057; L-Methioninamide, L-alpha-aspartyl-L-valyl-L-prolyl-L-lysyl-L-seryl-L-alpha-aspartyl-L-glutaminyl-L-phenylalanyl-L-valylglycyl-L-leucyl-
DMMIA38	DT	Small molecular drug
DMMIA38	PC	45749
DMMIA38	MW	1334.5
DMMIA38	FM	C59H95N15O18S
DMMIA38	IC	InChI=1S/C59H95N15O18S/c1-30(2)24-38(53(86)66-35(49(63)82)20-23-93-7)65-44(77)28-64-58(91)47(31(3)4)72-55(88)39(25-33-14-9-8-10-15-33)69-52(85)37(18-19-43(62)76)67-54(87)40(27-46(80)81)70-56(89)41(29-75)71-51(84)36(16-11-12-21-60)68-57(90)42-17-13-22-74(42)59(92)48(32(5)6)73-50(83)34(61)26-45(78)79/h8-10,14-15,30-32,34-42,47-48,75H,11-13,16-29,60-61H2,1-7H3,(H2,62,76)(H2,63,82)(H,64,91)(H,65,77)(H,66,86)(H,67,87)(H,68,90)(H,69,85)(H,70,89)(H,71,84)(H,72,88)(H,73,83)(H,78,79)(H,80,81)
DMMIA38	CS	CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C(CC(=O)O)N
DMMIA38	IK	NXTPETCPVNEEOP-UHFFFAOYSA-N
DMMIA38	IU	3-amino-4-[[1-[2-[[6-amino-1-[[1-[[1-[[5-amino-1-[[1-[[1-[[2-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMMIA38	DE	Discovery agent

DM513QY	ID	DM513QY
DM513QY	DN	KATSUMADAIN A
DM513QY	HS	Investigative
DM513QY	SN	katsumadain A; CHEMBL480470
DM513QY	DT	Small molecular drug
DM513QY	PC	9982435
DM513QY	MW	476.6
DM513QY	FM	C32H28O4
DM513QY	IC	InChI=1S/C32H28O4/c33-26(18-16-23-10-4-1-5-11-23)20-28-21-29(25-14-8-3-9-15-25)31-30(35-28)22-27(36-32(31)34)19-17-24-12-6-2-7-13-24/h1-15,17,19,22,28-29H,16,18,20-21H2/b19-17+/t28-,29+/m1/s1
DM513QY	CS	C1[C@H](OC2=C([C@@H]1C3=CC=CC=C3)C(=O)OC(=C2)/C=C/C4=CC=CC=C4)CC(=O)CCC5=CC=CC=C5
DM513QY	IK	IAIGBNIWSBFKNA-FIACUDKOSA-N
DM513QY	IU	(2S,4S)-2-(2-oxo-4-phenylbutyl)-4-phenyl-7-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrano[3,2-c]pyran-5-one
DM513QY	DE	Discovery agent

DMS527J	ID	DMS527J
DMS527J	DN	Kazinol C
DMS527J	HS	Investigative
DMS527J	SN	kazinol C; CHEMBL466200; SCHEMBL14815139
DMS527J	DT	Small molecular drug
DMS527J	PC	21637679
DMS527J	MW	464.6
DMS527J	FM	C30H40O4
DMS527J	IC	InChI=1S/C30H40O4/c1-8-30(6,7)25-16-22(26(31)18-27(25)32)11-9-10-21-17-28(33)29(34)24(15-13-20(4)5)23(21)14-12-19(2)3/h8,12-13,16-18,31-34H,1,9-11,14-15H2,2-7H3
DMS527J	CS	CC(=CCC1=C(C(=C(C=C1CCCC2=CC(=C(C=C2O)O)C(C)(C)C=C)O)O)CC=C(C)C)C
DMS527J	IK	YCJJCTRPAGXWGX-UHFFFAOYSA-N
DMS527J	IU	5-[3-[2,4-dihydroxy-5-(2-methylbut-3-en-2-yl)phenyl]propyl]-3,4-bis(3-methylbut-2-enyl)benzene-1,2-diol
DMS527J	DE	Discovery agent

DMFVT81	ID	DMFVT81
DMFVT81	DN	Kazinol F
DMFVT81	HS	Investigative
DMFVT81	SN	Kazinol F; 104494-35-1; CHEMBL457677; 1,2-Benzenediol, 5-(3-(2,4-dihydroxyphenyl)propyl)-3,4-bis(3-methyl-2-butenyl)-; 5-[3-(2,4-dihydroxyphenyl)propyl]-3,4-bis(3-methylbut-2-enyl)benzene-1,2-diol; 1,2-Benzenediol,5-[3-(2,4-dihydroxyphenyl)propyl]-3,4-bis(3-methyl-2-buten-1-yl)-; ACMC-20cyyd; AC1L4EMW; AC1Q79FB; SCHEMBL7555982; CTK4A3084; DTXSID10146504; BDBM50251001
DMFVT81	DT	Small molecular drug
DMFVT81	PC	184311
DMFVT81	MW	396.5
DMFVT81	FM	C25H32O4
DMFVT81	IC	InChI=1S/C25H32O4/c1-16(2)8-12-21-19(7-5-6-18-10-11-20(26)15-23(18)27)14-24(28)25(29)22(21)13-9-17(3)4/h8-11,14-15,26-29H,5-7,12-13H2,1-4H3
DMFVT81	CS	CC(=CCC1=C(C(=C(C=C1CCCC2=C(C=C(C=C2)O)O)O)O)CC=C(C)C)C
DMFVT81	IK	PNQQDEFGJPUAGZ-UHFFFAOYSA-N
DMFVT81	IU	5-[3-(2,4-dihydroxyphenyl)propyl]-3,4-bis(3-methylbut-2-enyl)benzene-1,2-diol
DMFVT81	CA	CAS 104494-35-1
DMFVT81	DE	Discovery agent

DMEV2AL	ID	DMEV2AL
DMEV2AL	DN	KAZINOL S
DMEV2AL	HS	Investigative
DMEV2AL	SN	CHEMBL469113; KAZINOL S; BDBM50254431; 5''-(2-methylbut-3-en-2-yl)-6''''-(3-methylbut-2-enyl)-5''''-(2,3-epoxy-3-methylbytyl)-2'',4'',3'''',4''''-tetrahydroxy diphenylpropane
DMEV2AL	DT	Small molecular drug
DMEV2AL	PC	44569902
DMEV2AL	MW	480.6
DMEV2AL	FM	C30H40O5
DMEV2AL	IC	InChI=1S/C30H40O5/c1-8-29(4,5)23-14-20(24(31)17-25(23)32)11-9-10-19-15-26(33)28(34)22(16-27-30(6,7)35-27)21(19)13-12-18(2)3/h8,12,14-15,17,27,31-34H,1,9-11,13,16H2,2-7H3
DMEV2AL	CS	CC(=CCC1=C(C(=C(C=C1CCCC2=CC(=C(C=C2O)O)C(C)(C)C=C)O)O)CC3C(O3)(C)C)C
DMEV2AL	IK	YTBAFGRFSDPCBF-UHFFFAOYSA-N
DMEV2AL	IU	5-[3-[2,4-dihydroxy-5-(2-methylbut-3-en-2-yl)phenyl]propyl]-3-[(3,3-dimethyloxiran-2-yl)methyl]-4-(3-methylbut-2-enyl)benzene-1,2-diol
DMEV2AL	DE	Discovery agent

DMO72XF	ID	DMO72XF
DMO72XF	DN	KB-130015
DMO72XF	HS	Investigative
DMO72XF	SN	KB 130015; KB130015
DMO72XF	DT	Small molecular drug
DMO72XF	PC	9872203
DMO72XF	MW	548.1
DMO72XF	FM	C18H14I2O4
DMO72XF	IC	InChI=1S/C18H14I2O4/c1-10-13(12-4-2-3-5-16(12)24-10)6-11-7-14(19)18(15(20)8-11)23-9-17(21)22/h2-5,7-8H,6,9H2,1H3,(H,21,22)
DMO72XF	CS	CC1=C(C2=CC=CC=C2O1)CC3=CC(=C(C(=C3)I)OCC(=O)O)I
DMO72XF	IK	OLIKCJUMYWSDIV-UHFFFAOYSA-N
DMO72XF	IU	2-[2,6-diiodo-4-[(2-methyl-1-benzofuran-3-yl)methyl]phenoxy]acetic acid
DMO72XF	CA	CAS 147030-48-6
DMO72XF	DE	Discovery agent

DMCQRA3	ID	DMCQRA3
DMCQRA3	DN	KB-9520
DMCQRA3	HS	Investigative
DMCQRA3	SN	KB-093823; KB-095285; KB-095508; KB-099520; ER-beta agonists (depression/cancer/inflammation), Karo Bio
DMCQRA3	CP	Karo Bio AB
DMCQRA3	DE	Solid tumour/cancer

DMMD5W3	ID	DMMD5W3
DMMD5W3	DN	KB-R7943
DMMD5W3	HS	Investigative
DMMD5W3	SN	182004-65-5; KB-R7943 mesylate; KB-R7943; 2-[2-[4-(4-NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA MESYLATE; KB-R7943 (mesylate); 4-((4-Nitrobenzyl)oxy)phenethyl carbamimidothioate methanesulfonate; 4-((4-Nitrobenzyl)oxy)phenethyl carbamimidothioatemethanesulfonate; 2-(2-(4-(4-Nitrobenzyloxy)phenyl)ethyl)isothiourea, methane sulfonate; 4-[(4-Nitrobenzyl)oxy]phenethyl Carbamimidothioate Methanesulfonate; KB-R7943  mesylate; SCHEMBL742683; GTPL4232; CTK0H1228; DTXSID50431360; MolPort-003-983-603; C16H17N3O3S.CH4O3S; HMS3267H09
DMMD5W3	DT	Small molecular drug
DMMD5W3	PC	9823846
DMMD5W3	MW	427.5
DMMD5W3	FM	C17H21N3O6S2
DMMD5W3	IC	InChI=1S/C16H17N3O3S.CH4O3S/c17-16(18)23-10-9-12-3-7-15(8-4-12)22-11-13-1-5-14(6-2-13)19(20)21;1-5(2,3)4/h1-8H,9-11H2,(H3,17,18);1H3,(H,2,3,4)
DMMD5W3	CS	CS(=O)(=O)O.C1=CC(=CC=C1CCSC(=N)N)OCC2=CC=C(C=C2)[N+](=O)[O-]
DMMD5W3	IK	WGIKEBHIKKWJLG-UHFFFAOYSA-N
DMMD5W3	IU	methanesulfonic acid;2-[4-[(4-nitrophenyl)methoxy]phenyl]ethyl carbamimidothioate
DMMD5W3	CA	CAS 182004-65-5
DMMD5W3	DE	Discovery agent

DMY6QOR	ID	DMY6QOR
DMY6QOR	DN	KC-12291
DMY6QOR	HS	Investigative
DMY6QOR	SN	KC-12291; CHEMBL452043; SCHEMBL6577701; kc12291; ZINC1545352; NCGC00370808-01
DMY6QOR	DT	Small molecular drug
DMY6QOR	PC	10364418
DMY6QOR	MW	413.5
DMY6QOR	FM	C22H27N3O3S
DMY6QOR	IC	InChI=1S/C22H27N3O3S/c1-25(14-12-17-10-11-19(26-2)20(16-17)27-3)13-7-15-28-22-23-21(29-24-22)18-8-5-4-6-9-18/h4-6,8-11,16H,7,12-15H2,1-3H3
DMY6QOR	CS	CN(CCCOC1=NSC(=N1)C2=CC=CC=C2)CCC3=CC(=C(C=C3)OC)OC
DMY6QOR	IK	RHJGWXNLFGHPHA-UHFFFAOYSA-N
DMY6QOR	IU	N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[(5-phenyl-1,2,4-thiadiazol-3-yl)oxy]propan-1-amine
DMY6QOR	DE	Discovery agent

DMJ2X64	ID	DMJ2X64
DMJ2X64	DN	KD-7332
DMJ2X64	HS	Investigative
DMJ2X64	SN	Inducible nitric oxide synthase dimerization inhibitor (oral, inflammatory diseases), Kalypsys; Inducible nitric oxide synthase dimerization inhibitor (oral, neuropathic pain), Kalypsys
DMJ2X64	CP	Kalypsys Inc
DMJ2X64	DE	Inflammation

DMOX8FD	ID	DMOX8FD
DMOX8FD	DN	KELATORPHAN
DMOX8FD	HS	Investigative
DMOX8FD	SN	kelatorphan; 92175-57-0; UNII-46BBW2U5D6; n-[(2r)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]-l-alanine; 46BBW2U5D6; (3-(N-Hydroxy)carboxamido-2-benzylpropanoyl)alanine; L-Alanine, N-(4-(hydroxyamino)-1,4-dioxo-2-(phenylmethyl)butyl)-, (R)-; 3b7u; AC1L3XO7; CHEMBL85320; SCHEMBL7384459; BDBM92500; DTXSID90238911; ZINC6020153; DB08040; HY-10827; KB-78017; LS-186814; LS-187482; CS-0002846; (2S)-2-[[(2R)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]amino]propanoic acid
DMOX8FD	DT	Small molecular drug
DMOX8FD	PC	123982
DMOX8FD	MW	294.3
DMOX8FD	FM	C14H18N2O5
DMOX8FD	IC	InChI=1S/C14H18N2O5/c1-9(14(19)20)15-13(18)11(8-12(17)16-21)7-10-5-3-2-4-6-10/h2-6,9,11,21H,7-8H2,1H3,(H,15,18)(H,16,17)(H,19,20)/t9-,11+/m0/s1
DMOX8FD	CS	C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)CC(=O)NO
DMOX8FD	IK	OJCFZTVYDSKXNM-GXSJLCMTSA-N
DMOX8FD	IU	(2S)-2-[[(2R)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]amino]propanoic acid
DMOX8FD	CA	CAS 92175-57-0
DMOX8FD	DE	Discovery agent

DM0RC8M	ID	DM0RC8M
DM0RC8M	DN	KETOCYCLAZOCINE
DM0RC8M	HS	Investigative
DM0RC8M	SN	Ketocyclazocine
DM0RC8M	DT	Small molecular drug
DM0RC8M	PC	23724935
DM0RC8M	MW	285.4
DM0RC8M	FM	C18H23NO2
DM0RC8M	IC	InChI=1S/C18H23NO2/c1-11-16-17(21)14-6-5-13(20)9-15(14)18(11,2)7-8-19(16)10-12-3-4-12/h5-6,9,11-12,16,20H,3-4,7-8,10H2,1-2H3/t11-,16-,18-/m0/s1
DM0RC8M	CS	C[C@H]1[C@H]2C(=O)C3=C([C@]1(CCN2CC4CC4)C)C=C(C=C3)O
DM0RC8M	IK	HQBZLVPZOGIAIQ-PBQZTSCYSA-N
DM0RC8M	IU	(1S,9S,13R)-10-(cyclopropylmethyl)-4-hydroxy-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one
DM0RC8M	DE	Discovery agent

DMX2FL3	ID	DMX2FL3
DMX2FL3	DN	Ketoprofen glucuronide
DMX2FL3	HS	Investigative
DMX2FL3	SN	Ketoprofen glucuronide; KETOPROFEN ACYL-B-D-GLUCURONIDE; 76690-94-3; DL-Ketoprofen glucuronide; (R)-Ketoprofen Glucuronide; (S)-Ketoprofen Glucuronide; CHEMBL3526739; DTXSID30998002; FT-0670648; W-203754; 1-O-[2-(3-Benzoylphenyl)propanoyl]hexopyranuronic acid; 1-(3-benzoyl-alpha-methylbenzeneacetate) beta-D-glucopyranuronic acid; beta-D-Glucopyranuronic acid, 1-(3-benzoyl-alpha-methylbenzeneacetate); 1-(3-benzoyl-alpha-methylbenzeneacetate) beta-delta-glucopyranuronic acid
DMX2FL3	PC	131281
DMX2FL3	MW	430.4
DMX2FL3	FM	C22H22O9
DMX2FL3	IC	PBTXSZZKPHBHMA-LYFYOZKASA-N
DMX2FL3	CS	CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)OC3C(C(C(C(O3)C(=O)O)O)O)O
DMX2FL3	IK	1S/C22H22O9/c1-11(13-8-5-9-14(10-13)15(23)12-6-3-2-4-7-12)21(29)31-22-18(26)16(24)17(25)19(30-22)20(27)28/h2-11,16-19,22,24-26H,1H3,(H,27,28)/t11?,16-,17-,18+,19-,22-/m0/s1
DMX2FL3	IU	(2S,3S,4S,5R,6S)-6-[2-(3-benzoylphenyl)propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DMX2FL3	CA	CAS 76690-94-3
DMX2FL3	DE	Discovery agent

DM7W9MT	ID	DM7W9MT
DM7W9MT	DN	KF 17837S
DM7W9MT	HS	Investigative
DM7W9MT	SN	152881-18-0; 8-(3,4-Dimethoxyphenyl)-7-methyl-1,3-dipropyl-1H-purine-2,6(3H,7H)-dione; 8-(3,4-dimethoxyphenyl)-7-methyl-1,3-dipropylpurine-2,6-dione; 1,3-Dipropyl-7-methyl-8-(3,4-dimethoxystyryl)xanthine; AC1L3X7D; GTPL428; CTK8C1262; DTXSID30165151; ZINC5114737; 7673AA; ANW-66125; AKOS016004661; 8-(3,4-Dimethoxyphenyl)-3,7-dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione; AJ-53127; AX8236469; L001123; 1H-Purine-2,6-dione, 8-(3,4-dimethoxyphenyl)-3,7-dihydro-7-methyl-1,3-dipropyl-
DM7W9MT	DT	Small molecular drug
DM7W9MT	PC	123739
DM7W9MT	MW	386.4
DM7W9MT	FM	C20H26N4O4
DM7W9MT	IC	InChI=1S/C20H26N4O4/c1-6-10-23-18-16(19(25)24(11-7-2)20(23)26)22(3)17(21-18)13-8-9-14(27-4)15(12-13)28-5/h8-9,12H,6-7,10-11H2,1-5H3
DM7W9MT	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)N(C(=N2)C3=CC(=C(C=C3)OC)OC)C
DM7W9MT	IK	FSUNYKAEJIVAHY-UHFFFAOYSA-N
DM7W9MT	IU	8-(3,4-dimethoxyphenyl)-7-methyl-1,3-dipropylpurine-2,6-dione
DM7W9MT	CA	CAS 152881-18-0
DM7W9MT	DE	Discovery agent

DMK6SMW	ID	DMK6SMW
DMK6SMW	DN	KF24345
DMK6SMW	HS	Investigative
DMK6SMW	SN	KF-24345; KF 24345
DMK6SMW	DT	Small molecular drug
DMK6SMW	PC	9938824
DMK6SMW	MW	574.7
DMK6SMW	FM	C31H38N6O5
DMK6SMW	IC	InChI=1S/C31H38N6O5/c1-5-41-26-18-22-24(19-27(26)42-6-2)32-30(36-13-15-40-16-14-36)33-28(22)35-11-9-21(10-12-35)37-29(38)23-17-20(3)7-8-25(23)34(4)31(37)39/h7-8,17-19,21H,5-6,9-16H2,1-4H3
DMK6SMW	CS	CCOC1=C(C=C2C(=C1)C(=NC(=N2)N3CCOCC3)N4CCC(CC4)N5C(=O)C6=C(C=CC(=C6)C)N(C5=O)C)OCC
DMK6SMW	IK	MXOWYPVUVPQDNZ-UHFFFAOYSA-N
DMK6SMW	IU	3-[1-(6,7-diethoxy-2-morpholin-4-ylquinazolin-4-yl)piperidin-4-yl]-1,6-dimethylquinazoline-2,4-dione
DMK6SMW	DE	Discovery agent

DMPBDW0	ID	DMPBDW0
DMPBDW0	DN	KF26777
DMPBDW0	HS	Investigative
DMPBDW0	SN	KF 26777
DMPBDW0	DT	Small molecular drug
DMPBDW0	PC	154730657
DMPBDW0	DE	Discovery agent

DMOUW0A	ID	DMOUW0A
DMOUW0A	DN	KF-66490
DMOUW0A	HS	Investigative
DMOUW0A	SN	K-34; PDE 4 inhibitors (dermatitis/rheumatoid arthritis); PDE 4 inhibitors (dermatitis/rheumatoid arthritis), Kyowa Hakko Kirin
DMOUW0A	CP	Kyowa Hakko Kirin Co Ltd
DMOUW0A	DT	Small molecular drug
DMOUW0A	PC	281833
DMOUW0A	MW	374.4
DMOUW0A	FM	C18H22N4O5
DMOUW0A	IC	InChI=1S/C18H22N4O5/c1-8-12(19)15(24)11-9(7-27-17(25)21-4-5-21)18(26-3)16-10(20(16)2)6-22(18)13(11)14(8)23/h9-10,16H,4-7,19H2,1-3H3
DMOUW0A	CS	CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N5CC5)OC)N4C)N
DMOUW0A	IK	FZLZUGFFXNJCRD-UHFFFAOYSA-N
DMOUW0A	IU	(11-amino-7-methoxy-5,12-dimethyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl)methyl aziridine-1-carboxylate
DMOUW0A	DE	Atopic dermatitis

DMFBMYG	ID	DMFBMYG
DMFBMYG	DN	KF-A5
DMFBMYG	HS	Investigative
DMFBMYG	SN	KF-A5; CHEMBL491754; SCHEMBL10704523; BDBM50249782
DMFBMYG	DT	Small molecular drug
DMFBMYG	PC	14014889
DMFBMYG	MW	336.5
DMFBMYG	FM	C22H28N2O
DMFBMYG	IC	InChI=1S/C22H28N2O/c1-3-23(4-2)16-10-5-11-17-24-20-14-8-6-12-18(20)22(25)19-13-7-9-15-21(19)24/h6-9,12-15H,3-5,10-11,16-17H2,1-2H3
DMFBMYG	CS	CCN(CC)CCCCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31
DMFBMYG	IK	YCWGZWYJTIJTHX-UHFFFAOYSA-N
DMFBMYG	IU	10-[5-(diethylamino)pentyl]acridin-9-one
DMFBMYG	DE	Discovery agent

DMQJ3T5	ID	DMQJ3T5
DMQJ3T5	DN	KF-A6
DMQJ3T5	HS	Investigative
DMQJ3T5	SN	KF-A6; CHEMBL491889; SCHEMBL13438391; BDBM50249783
DMQJ3T5	DT	Small molecular drug
DMQJ3T5	PC	44566054
DMQJ3T5	MW	350.5
DMQJ3T5	FM	C23H30N2O
DMQJ3T5	IC	InChI=1S/C23H30N2O/c1-3-24(4-2)17-11-5-6-12-18-25-21-15-9-7-13-19(21)23(26)20-14-8-10-16-22(20)25/h7-10,13-16H,3-6,11-12,17-18H2,1-2H3
DMQJ3T5	CS	CCN(CC)CCCCCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31
DMQJ3T5	IK	YHXSELHUXJAOLR-UHFFFAOYSA-N
DMQJ3T5	IU	10-[6-(diethylamino)hexyl]acridin-9-one
DMQJ3T5	DE	Discovery agent

DMCE8Q9	ID	DMCE8Q9
DMCE8Q9	DN	KH-164
DMCE8Q9	HS	Investigative
DMCE8Q9	SN	115305-61-8; 141109-86-6; KH-161
DMCE8Q9	DT	Small molecular drug
DMCE8Q9	PC	471377
DMCE8Q9	MW	1017.3
DMCE8Q9	FM	C57H76N8O9
DMCE8Q9	IC	InChI=1S/C57H76N8O9/c1-34(2)28-43(49(67)33-50(68)60-45(29-35(3)4)53(70)62-44(52(58)69)30-38-18-10-8-11-19-38)61-56(73)51(36(5)6)64-54(71)46(31-39-20-12-9-13-21-39)63-55(72)48-26-17-27-65(48)57(74)47(59-37(7)66)32-41-24-16-23-40-22-14-15-25-42(40)41/h8-16,18-25,34-36,43-49,51,67H,17,26-33H2,1-7H3,(H2,58,69)(H,59,66)(H,60,68)(H,61,73)(H,62,70)(H,63,72)(H,64,71)/t43-,44-,45-,46-,47-,48-,49-,51-/m0/s1
DMCE8Q9	CS	CC(C)C[C@@H]([C@H](CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=CC5=CC=CC=C54)NC(=O)C
DMCE8Q9	IK	WBMREBMOCPFYEP-FKUHLYKMSA-N
DMCE8Q9	IU	(2S)-1-[(2S)-2-acetamido-3-naphthalen-1-ylpropanoyl]-N-[(2S)-1-[[(2S)-1-[[(3S,4S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-6-methyl-1-oxoheptan-4-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMCE8Q9	DE	Discovery agent

DMSOB3U	ID	DMSOB3U
DMSOB3U	DN	KH-CB19
DMSOB3U	HS	Investigative
DMSOB3U	SN	KH CB19
DMSOB3U	DT	Small molecular drug
DMSOB3U	PC	44237094
DMSOB3U	MW	338.2
DMSOB3U	FM	C15H13Cl2N3O2
DMSOB3U	IC	InChI=1S/C15H13Cl2N3O2/c1-3-22-15(21)14-11(8(6-18)7-19)9-4-5-10(16)12(17)13(9)20(14)2/h4-6H,3,18H2,1-2H3/b8-6-
DMSOB3U	CS	CCOC(=O)C1=C(C2=C(N1C)C(=C(C=C2)Cl)Cl)/C(=C\\N)/C#N
DMSOB3U	IK	CXJCGSPAPOTTSF-VURMDHGXSA-N
DMSOB3U	IU	ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methylindole-2-carboxylate
DMSOB3U	DE	Discovery agent

DMLG2EA	ID	DMLG2EA
DMLG2EA	DN	Ki-11502
DMLG2EA	HS	Investigative
DMLG2EA	SN	Ki 11502; PDGF Receptor Tyrosine Kinase Inhibitor V
DMLG2EA	DT	Small molecular drug
DMLG2EA	PC	11554659
DMLG2EA	MW	473.5
DMLG2EA	FM	C26H23N3O4S
DMLG2EA	IC	InChI=1S/C26H23N3O4S/c1-16-6-4-5-7-19(16)25(30)29-26(34)28-17-8-10-18(11-9-17)33-22-12-13-27-21-15-24(32-3)23(31-2)14-20(21)22/h4-15H,1-3H3,(H2,28,29,30,34)
DMLG2EA	CS	CC1=CC=CC=C1C(=O)NC(=S)NC2=CC=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC
DMLG2EA	IK	ZXGIBSBJQLLUEE-UHFFFAOYSA-N
DMLG2EA	IU	N-[[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]carbamothioyl]-2-methylbenzamide
DMLG2EA	CA	CAS 347155-76-4
DMLG2EA	CB	CHEBI:133397
DMLG2EA	DE	Discovery agent

DMJTDK9	ID	DMJTDK9
DMJTDK9	DN	Ki16425
DMJTDK9	HS	Investigative
DMJTDK9	SN	SCHEMBL13385834
DMJTDK9	DT	Small molecular drug
DMJTDK9	PC	10367662
DMJTDK9	MW	475
DMJTDK9	FM	C23H23ClN2O5S
DMJTDK9	IC	InChI=1S/C23H23ClN2O5S/c1-14-21(25-23(29)30-15(2)18-5-3-4-6-19(18)24)22(31-26-14)17-9-7-16(8-10-17)13-32-12-11-20(27)28/h3-10,15H,11-13H2,1-2H3,(H,25,29)(H,27,28)
DMJTDK9	CS	CC1=NOC(=C1NC(=O)OC(C)C2=CC=CC=C2Cl)C3=CC=C(C=C3)CSCCC(=O)O
DMJTDK9	IK	LLIFMNUXGDHTRO-UHFFFAOYSA-N
DMJTDK9	IU	3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylsulfanyl]propanoic acid
DMJTDK9	CA	CAS 355025-24-0
DMJTDK9	CB	CHEBI:91194
DMJTDK9	DE	Discovery agent

DM9M3VC	ID	DM9M3VC
DM9M3VC	DN	Ki-20227
DM9M3VC	HS	Investigative
DM9M3VC	SN	Ki 20227; Ki20227
DM9M3VC	DT	Small molecular drug
DM9M3VC	PC	9869779
DM9M3VC	MW	480.5
DM9M3VC	FM	C24H24N4O5S
DM9M3VC	IC	InChI=1S/C24H24N4O5S/c1-14(23-26-9-10-34-23)27-24(29)28-17-6-5-15(11-20(17)30-2)33-19-7-8-25-18-13-22(32-4)21(31-3)12-16(18)19/h5-14H,1-4H3,(H2,27,28,29)
DM9M3VC	CS	CC(C1=NC=CS1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)OC
DM9M3VC	IK	SHPFDGWALWEPGS-UHFFFAOYSA-N
DM9M3VC	IU	1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea
DM9M3VC	CA	CAS 623142-96-1
DM9M3VC	DE	Discovery agent

DMHEOBY	ID	DMHEOBY
DMHEOBY	DN	KIN-3031
DMHEOBY	HS	Investigative
DMHEOBY	SN	Mu opioid angonist (CNS formulation, pain), Kinentia
DMHEOBY	CP	Kinentia Biosciences LLC
DMHEOBY	DE	Pain

DMO8JQM	ID	DMO8JQM
DMO8JQM	DN	KIN-4044
DMO8JQM	HS	Investigative
DMO8JQM	SN	Mu opioid antagonist (NSCLC), Kinentia
DMO8JQM	CP	Kinentia Biosciences LLC
DMO8JQM	DE	Non-small-cell lung cancer

DMDL21W	ID	DMDL21W
DMDL21W	DN	kisspeptin-10
DMDL21W	HS	Investigative
DMDL21W	SN	RITKWYDZSSQNJI-INXYWQKQSA-N; Kisspeptin-10; KP-10; CHEMBL376756; 374675-21-5; Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2; KP10; KISS1; Kisspeptin 10 (human); GTPL1283; SCHEMBL15930211; BDBM26349; MolPort-023-276-491; Metastin (45-54) amide, human; BDBM50045513; AKOS024457174; Gene product (112-121) amide, human; Metastin (45-54) amide, human, &gt; H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
DMDL21W	DT	Small molecular drug
DMDL21W	PC	25240297
DMDL21W	MW	1302.4
DMDL21W	FM	C63H83N17O14
DMDL21W	IC	InChI=1S/C63H83N17O14/c1-34(2)24-45(58(90)74-43(18-11-23-70-63(68)69)57(89)75-44(54(67)86)26-35-12-5-3-6-13-35)73-53(85)32-72-56(88)46(27-36-14-7-4-8-15-36)77-62(94)50(33-81)80-61(93)49(30-52(66)84)79-59(91)47(28-38-31-71-42-17-10-9-16-40(38)42)78-60(92)48(29-51(65)83)76-55(87)41(64)25-37-19-21-39(82)22-20-37/h3-10,12-17,19-22,31,34,41,43-50,71,81-82H,11,18,23-30,32-33,64H2,1-2H3,(H2,65,83)(H2,66,84)(H2,67,86)(H,72,88)(H,73,85)(H,74,90)(H,75,89)(H,76,87)(H,77,94)(H,78,92)(H,79,91)(H,80,93)(H4,68,69,70)/t41-,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMDL21W	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC5=CC=C(C=C5)O)N
DMDL21W	IK	RITKWYDZSSQNJI-INXYWQKQSA-N
DMDL21W	IU	(2S)-N-[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]butanediamide
DMDL21W	CA	CAS 374675-21-5
DMDL21W	DE	Discovery agent

DMPJKBV	ID	DMPJKBV
DMPJKBV	DN	KJM429
DMPJKBV	HS	Investigative
DMPJKBV	SN	MK-056; CHEMBL228451; thiourea analogue, 1; SCHEMBL1268701; BDBM20315; N-(4-t-butylbenzyl)-N'-[4-(methyl-sulfonylamino)benzyl]thiourea
DMPJKBV	DT	Small molecular drug
DMPJKBV	PC	10135969
DMPJKBV	MW	405.6
DMPJKBV	FM	C20H27N3O2S2
DMPJKBV	IC	InChI=1S/C20H27N3O2S2/c1-20(2,3)17-9-5-15(6-10-17)13-21-19(26)22-14-16-7-11-18(12-8-16)23-27(4,24)25/h5-12,23H,13-14H2,1-4H3,(H2,21,22,26)
DMPJKBV	CS	CC(C)(C)C1=CC=C(C=C1)CNC(=S)NCC2=CC=C(C=C2)NS(=O)(=O)C
DMPJKBV	IK	LOMAEJPLJSUBML-UHFFFAOYSA-N
DMPJKBV	IU	1-[(4-tert-butylphenyl)methyl]-3-[[4-(methanesulfonamido)phenyl]methyl]thiourea

DMAU1SZ	ID	DMAU1SZ
DMAU1SZ	DN	KKHT-10318
DMAU1SZ	HS	Investigative
DMAU1SZ	SN	KKHT-10318; CHEMBL388401; SCHEMBL8227931; BDBM50196478
DMAU1SZ	DT	Small molecular drug
DMAU1SZ	PC	44422402
DMAU1SZ	MW	426.9
DMAU1SZ	FM	C22H23ClN4O3
DMAU1SZ	IC	InChI=1S/C22H23ClN4O3/c23-17-6-3-15(4-7-17)14-27-21(29)18-8-5-16(13-19(18)25-22(27)30)20(28)24-9-12-26-10-1-2-11-26/h3-8,13H,1-2,9-12,14H2,(H,24,28)(H,25,30)
DMAU1SZ	CS	C1CCN(C1)CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMAU1SZ	IK	VJRGAGPCQUZOLU-UHFFFAOYSA-N
DMAU1SZ	IU	3-[(4-chlorophenyl)methyl]-2,4-dioxo-N-(2-pyrrolidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DMAU1SZ	DE	Discovery agent

DMYT381	ID	DMYT381
DMYT381	DN	KKHT-10608
DMYT381	HS	Investigative
DMYT381	SN	KKHT-10608; CHEMBL223331; SCHEMBL8222478; BDBM50196469
DMYT381	DT	Small molecular drug
DMYT381	PC	25196629
DMYT381	MW	424.5
DMYT381	FM	C23H25FN4O3
DMYT381	IC	InChI=1S/C23H25FN4O3/c24-18-6-4-5-16(13-18)15-28-22(30)19-8-7-17(14-20(19)26-23(28)31)21(29)25-9-12-27-10-2-1-3-11-27/h4-8,13-14H,1-3,9-12,15H2,(H,25,29)(H,26,31)
DMYT381	CS	C1CCN(CC1)CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC(=CC=C4)F
DMYT381	IK	YKQRXGQZAGVEJY-UHFFFAOYSA-N
DMYT381	IU	3-[(3-fluorophenyl)methyl]-2,4-dioxo-N-(2-piperidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DMYT381	DE	Discovery agent

DMMI1H0	ID	DMMI1H0
DMMI1H0	DN	KKHT-10609
DMMI1H0	HS	Investigative
DMMI1H0	SN	KKHT-10609; CHEMBL224778; SCHEMBL8230066; BDBM50196473
DMMI1H0	DT	Small molecular drug
DMMI1H0	PC	25196630
DMMI1H0	MW	424.5
DMMI1H0	FM	C23H25FN4O3
DMMI1H0	IC	InChI=1S/C23H25FN4O3/c24-18-7-4-16(5-8-18)15-28-22(30)19-9-6-17(14-20(19)26-23(28)31)21(29)25-10-13-27-11-2-1-3-12-27/h4-9,14H,1-3,10-13,15H2,(H,25,29)(H,26,31)
DMMI1H0	CS	C1CCN(CC1)CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)F
DMMI1H0	IK	PYCLIFABZLPONX-UHFFFAOYSA-N
DMMI1H0	IU	3-[(4-fluorophenyl)methyl]-2,4-dioxo-N-(2-piperidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DMMI1H0	DE	Discovery agent

DM1H5TO	ID	DM1H5TO
DM1H5TO	DN	KKHT-10613
DM1H5TO	HS	Investigative
DM1H5TO	SN	KKHT-10613; CHEMBL225543; SCHEMBL8230911; BDBM50295829
DM1H5TO	DT	Small molecular drug
DM1H5TO	PC	25196633
DM1H5TO	MW	398.5
DM1H5TO	FM	C22H30N4O3
DM1H5TO	IC	InChI=1S/C22H30N4O3/c27-20(23-11-14-25-12-5-2-6-13-25)16-9-10-18-19(15-16)24-22(29)26(21(18)28)17-7-3-1-4-8-17/h9-10,15,17H,1-8,11-14H2,(H,23,27)(H,24,29)
DM1H5TO	CS	C1CCC(CC1)N2C(=O)C3=C(C=C(C=C3)C(=O)NCCN4CCCCC4)NC2=O
DM1H5TO	IK	NNJAFUNKEIDAAF-UHFFFAOYSA-N
DM1H5TO	IU	3-cyclohexyl-2,4-dioxo-N-(2-piperidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DM1H5TO	DE	Discovery agent

DMW704S	ID	DMW704S
DMW704S	DN	KKHT-10618
DMW704S	HS	Investigative
DMW704S	SN	KKHT-10618; CHEMBL225601; SCHEMBL8230918; BKSKSEWIBBBRSQ-UHFFFAOYSA-N; BDBM50196465; 3-(4-chlorobenzyl)-2,4-dioxo-N-(2-(piperidin-1-yl)ethyl)-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid (2-piperidine-1-yl-ethyl)-amide
DMW704S	DT	Small molecular drug
DMW704S	PC	25196743
DMW704S	MW	440.9
DMW704S	FM	C23H25ClN4O3
DMW704S	IC	InChI=1S/C23H25ClN4O3/c24-18-7-4-16(5-8-18)15-28-22(30)19-9-6-17(14-20(19)26-23(28)31)21(29)25-10-13-27-11-2-1-3-12-27/h4-9,14H,1-3,10-13,15H2,(H,25,29)(H,26,31)
DMW704S	CS	C1CCN(CC1)CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMW704S	IK	BKSKSEWIBBBRSQ-UHFFFAOYSA-N
DMW704S	IU	3-[(4-chlorophenyl)methyl]-2,4-dioxo-N-(2-piperidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DMW704S	DE	Discovery agent

DM4F96I	ID	DM4F96I
DM4F96I	DN	KKHT-11018
DM4F96I	HS	Investigative
DM4F96I	SN	KKHT-11018; CHEMBL225485; BDBM50196480
DM4F96I	DT	Small molecular drug
DM4F96I	PC	44422187
DM4F96I	MW	469
DM4F96I	FM	C25H29ClN4O3
DM4F96I	IC	InChI=1S/C25H29ClN4O3/c1-2-20-5-3-4-13-29(20)14-12-27-23(31)18-8-11-21-22(15-18)28-25(33)30(24(21)32)16-17-6-9-19(26)10-7-17/h6-11,15,20H,2-5,12-14,16H2,1H3,(H,27,31)(H,28,33)
DM4F96I	CS	CCC1CCCCN1CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DM4F96I	IK	FKCDNDBJVOQPJB-UHFFFAOYSA-N
DM4F96I	IU	3-[(4-chlorophenyl)methyl]-N-[2-(2-ethylpiperidin-1-yl)ethyl]-2,4-dioxo-1H-quinazoline-7-carboxamide
DM4F96I	DE	Discovery agent

DMLB4TU	ID	DMLB4TU
DMLB4TU	DN	KKHT-20718
DMLB4TU	HS	Investigative
DMLB4TU	SN	KKHT-20718; CHEMBL224227; YMGCQAHDDYCKLB-UHFFFAOYSA-N; BDBM50196472; 3-(4-chlorobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid [3-(2-methyl-piperidine-1-yl)-propyl]-amide
DMLB4TU	DT	Small molecular drug
DMLB4TU	PC	25196850
DMLB4TU	MW	469
DMLB4TU	FM	C25H29ClN4O3
DMLB4TU	IC	InChI=1S/C25H29ClN4O3/c1-17-5-2-3-13-29(17)14-4-12-27-23(31)19-8-11-21-22(15-19)28-25(33)30(24(21)32)16-18-6-9-20(26)10-7-18/h6-11,15,17H,2-5,12-14,16H2,1H3,(H,27,31)(H,28,33)
DMLB4TU	CS	CC1CCCCN1CCCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMLB4TU	IK	YMGCQAHDDYCKLB-UHFFFAOYSA-N
DMLB4TU	IU	3-[(4-chlorophenyl)methyl]-N-[3-(2-methylpiperidin-1-yl)propyl]-2,4-dioxo-1H-quinazoline-7-carboxamide
DMLB4TU	DE	Discovery agent

DMP1A3C	ID	DMP1A3C
DMP1A3C	DN	KKHT-20818
DMP1A3C	HS	Investigative
DMP1A3C	SN	KKHT-20818; CHEMBL376596; SCHEMBL8230083; PRICKWSOIKQPFF-UHFFFAOYSA-N; BDBM50196466; 3-(4-chlorobenzyl)-N-(3-(2-ethylpiperidin-1-yl)propyl)-2,4-dioxoquinazoline-7-carboxamide; 3-(4-chlorobenzyl)-N-(3-(2-ethylpiperidin-1-yl)propyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid [3-(2-ethyl-piperidine-1-yl)-propyl]-amide
DMP1A3C	DT	Small molecular drug
DMP1A3C	PC	16066792
DMP1A3C	MW	483
DMP1A3C	FM	C26H31ClN4O3
DMP1A3C	IC	InChI=1S/C26H31ClN4O3/c1-2-21-6-3-4-14-30(21)15-5-13-28-24(32)19-9-12-22-23(16-19)29-26(34)31(25(22)33)17-18-7-10-20(27)11-8-18/h7-12,16,21H,2-6,13-15,17H2,1H3,(H,28,32)(H,29,34)
DMP1A3C	CS	CCC1CCCCN1CCCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMP1A3C	IK	PRICKWSOIKQPFF-UHFFFAOYSA-N
DMP1A3C	IU	3-[(4-chlorophenyl)methyl]-N-[3-(2-ethylpiperidin-1-yl)propyl]-2,4-dioxo-1H-quinazoline-7-carboxamide
DMP1A3C	DE	Discovery agent

DMTW4Q1	ID	DMTW4Q1
DMTW4Q1	DN	KKHT-20918
DMTW4Q1	HS	Investigative
DMTW4Q1	SN	KKHT-20918; CHEMBL224246; SCHEMBL8227894; IWAHUQRZIUVMSG-UHFFFAOYSA-N; KUC112514N; BDBM50196475; KSC-323-47-1-1; 3-(4-chlorobenzyl)-2,4-dioxo-N-(3-(piperidin-1-yl)propyl)-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid (3-piperidine-1-yl-propyl)-amide
DMTW4Q1	DT	Small molecular drug
DMTW4Q1	PC	25196851
DMTW4Q1	MW	454.9
DMTW4Q1	FM	C24H27ClN4O3
DMTW4Q1	IC	InChI=1S/C24H27ClN4O3/c25-19-8-5-17(6-9-19)16-29-23(31)20-10-7-18(15-21(20)27-24(29)32)22(30)26-11-4-14-28-12-2-1-3-13-28/h5-10,15H,1-4,11-14,16H2,(H,26,30)(H,27,32)
DMTW4Q1	CS	C1CCN(CC1)CCCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMTW4Q1	IK	IWAHUQRZIUVMSG-UHFFFAOYSA-N
DMTW4Q1	IU	3-[(4-chlorophenyl)methyl]-2,4-dioxo-N-(3-piperidin-1-ylpropyl)-1H-quinazoline-7-carboxamide
DMTW4Q1	DE	Discovery agent

DMG3FDE	ID	DMG3FDE
DMG3FDE	DN	KL044
DMG3FDE	HS	Investigative
DMG3FDE	SN	KL 044; KL-044
DMG3FDE	DT	Small molecular drug
DMG3FDE	PC	91827381
DMG3FDE	MW	359.8
DMG3FDE	FM	C21H14ClN3O
DMG3FDE	IC	InChI=1S/C21H14ClN3O/c22-17-9-5-6-14(12-23)21(17)24-20(26)13-25-18-10-3-1-7-15(18)16-8-2-4-11-19(16)25/h1-11H,13H2,(H,24,26)
DMG3FDE	CS	C1=CC=C2C(=C1)C3=CC=CC=C3N2CC(=O)NC4=C(C=CC=C4Cl)C#N
DMG3FDE	IK	ZDAKKNHUWVTCRS-UHFFFAOYSA-N
DMG3FDE	IU	2-carbazol-9-yl-N-(2-chloro-6-cyanophenyl)acetamide
DMG3FDE	DE	Discovery agent

DMG594K	ID	DMG594K
DMG594K	DN	KM-01221
DMG594K	HS	Investigative
DMG594K	SN	Chymase inhibitors (cardiovascular disease); KM-06864; MWP-00965; TY-51076; Chymase inhibitors (cardiovascular disease), Toa Eiyo
DMG594K	CP	Toa Eiyo KK
DMG594K	DT	Small molecular drug
DMG594K	PC	2819266
DMG594K	MW	442.3
DMG594K	FM	C17H13Cl2N3O3S2
DMG594K	IC	InChI=1S/C17H13Cl2N3O3S2/c1-26-17-14(27(24,25)13-8-6-12(19)7-9-13)15(21-22-17)20-16(23)10-2-4-11(18)5-3-10/h2-9H,1H3,(H2,20,21,22,23)
DMG594K	CS	CSC1=NNC(=C1S(=O)(=O)C2=CC=C(C=C2)Cl)NC(=O)C3=CC=C(C=C3)Cl
DMG594K	IK	OOEJKNSQVFIOEF-UHFFFAOYSA-N
DMG594K	IU	4-chloro-N-[4-(4-chlorophenyl)sulfonyl-3-methylsulfanyl-1H-pyrazol-5-yl]benzamide
DMG594K	DE	Cardiovascular disease

DMZSYKC	ID	DMZSYKC
DMZSYKC	DN	KM-233
DMZSYKC	HS	Investigative
DMZSYKC	SN	628263-22-9; KM-233; DTXSID50745439
DMZSYKC	DT	Small molecular drug
DMZSYKC	PC	10248110
DMZSYKC	MW	362.5
DMZSYKC	FM	C25H30O2
DMZSYKC	IC	InChI=1S/C25H30O2/c1-16-11-12-20-19(13-16)23-21(26)14-18(15-22(23)27-25(20,4)5)24(2,3)17-9-7-6-8-10-17/h6-11,14-15,19-20,26H,12-13H2,1-5H3/t19-,20-/m1/s1
DMZSYKC	CS	CC1=CC[C@@H]2[C@@H](C1)C3=C(C=C(C=C3OC2(C)C)C(C)(C)C4=CC=CC=C4)O
DMZSYKC	IK	GZYXCXRHVALIJD-WOJBJXKFSA-N
DMZSYKC	IU	(6aR,10aR)-6,6,9-trimethyl-3-(2-phenylpropan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DMZSYKC	CA	CAS 628263-22-9
DMZSYKC	DE	Discovery agent

DMK4IBO	ID	DMK4IBO
DMK4IBO	DN	KM-233-M
DMK4IBO	HS	Investigative
DMK4IBO	SN	KM-233-M; CHEMBL512531; BDBM50244322; 3-[1-(3-Fluoro-phenyl)-1-methyl-ethyl]-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol
DMK4IBO	DT	Small molecular drug
DMK4IBO	PC	44593431
DMK4IBO	MW	380.5
DMK4IBO	FM	C25H29FO2
DMK4IBO	IC	InChI=1S/C25H29FO2/c1-15-9-10-20-19(11-15)23-21(27)13-17(14-22(23)28-25(20,4)5)24(2,3)16-7-6-8-18(26)12-16/h6-9,12-14,19-20,27H,10-11H2,1-5H3/t19-,20-/m1/s1
DMK4IBO	CS	CC1=CC[C@@H]2[C@@H](C1)C3=C(C=C(C=C3OC2(C)C)C(C)(C)C4=CC(=CC=C4)F)O
DMK4IBO	IK	IKKCHJJZMJZQEO-WOJBJXKFSA-N
DMK4IBO	IU	(6aR,10aR)-3-[2-(3-fluorophenyl)propan-2-yl]-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DMK4IBO	DE	Discovery agent

DMK17GN	ID	DMK17GN
DMK17GN	DN	KM-4056
DMK17GN	HS	Investigative
DMK17GN	SN	Anti-LGR5 monoclonal antibody (cancer), Kyowa Hakko Kirin
DMK17GN	CP	Kyowa Hakko Kirin Co Ltd
DMK17GN	DT	Antibody
DMK17GN	DE	Solid tumour/cancer

DMLRVEJ	ID	DMLRVEJ
DMLRVEJ	DN	KMI-172
DMLRVEJ	HS	Investigative
DMLRVEJ	SN	KMI-172; CHEMBL239383
DMLRVEJ	PC	44431062
DMLRVEJ	MW	1031.099
DMLRVEJ	FM	C47H66N8O16S
DMLRVEJ	IC	InChI=1S/C47H66N8O16S/c1-24(2)20-31(51-45(68)38(25(3)4)55-41(64)29(48)16-18-35(56)57)44(67)54-34(23-72-28-14-10-7-11-15-28)39(62)46(69)52-32(22-37(60)61)43(66)49-26(5)40(63)50-30(17-19-36(58)59)42(65)53-33(47(70)71)21-27-12-8-6-9-13-27/h6-15,24-26,29-34,38-39,62H,16-23,48H2,1-5H3,(H,49,66)(H,50,63)(H,51,68)(H,52,69)(H,53,65)(H,54,67)(H,55,64)(H,56,57)(H,58,59)(H,60,61)(H,70,71)/t26-,29-,30-,31-,32-,33-,34-,38-,39+/m0/s1
DMLRVEJ	CS	C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]([C@H](CSC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)N)O
DMLRVEJ	IK	FTFBGPHXUHIRHS-OGBCTUIFSA-N
DMLRVEJ	IU	(4S)-4-amino-5-[[(2S)-1-[[(2S)-1-[[(2R,3R)-4-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMLRVEJ	DE	Discovery agent

DMQ4WNB	ID	DMQ4WNB
DMQ4WNB	DN	KMI-494
DMQ4WNB	HS	Investigative
DMQ4WNB	SN	KMI-494
DMQ4WNB	DT	Small molecular drug
DMQ4WNB	PC	44431065
DMQ4WNB	MW	775.8
DMQ4WNB	FM	C39H49N7O10
DMQ4WNB	IC	InChI=1S/C39H49N7O10/c1-20(2)13-30(35(50)44-29(14-22-9-6-5-7-10-22)32(47)37(52)43-27-12-8-11-23(18-27)38(53)54)45-36(51)31(21(3)4)46-34(49)28(41)19-42-33(48)24-15-25(39(55)56)17-26(40)16-24/h5-12,15-18,20-21,28-32,47H,13-14,19,40-41H2,1-4H3,(H,42,48)(H,43,52)(H,44,50)(H,45,51)(H,46,49)(H,53,54)(H,55,56)/t28-,29-,30-,31-,32+/m0/s1
DMQ4WNB	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](C(=O)NC2=CC=CC(=C2)C(=O)O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CNC(=O)C3=CC(=CC(=C3)N)C(=O)O)N
DMQ4WNB	IK	HJXHSIMUTPLJNT-QEUNAIBPSA-N
DMQ4WNB	IU	3-amino-5-[[(2S)-2-amino-3-[[(2S)-1-[[(2S)-1-[[(2S,3R)-4-(3-carboxyanilino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropyl]carbamoyl]benzoic acid
DMQ4WNB	DE	Discovery agent

DMX9EA7	ID	DMX9EA7
DMX9EA7	DN	KMI-538
DMX9EA7	HS	Investigative
DMX9EA7	SN	KMI-538; CHEMBL395967
DMX9EA7	DT	Small molecular drug
DMX9EA7	PC	16725937
DMX9EA7	MW	807.9
DMX9EA7	FM	C39H49N7O10S
DMX9EA7	IC	InChI=1S/C39H49N7O10S/c1-20(2)13-29(44-36(51)31(21(3)4)46-34(49)28(41)18-42-33(48)23-14-24(39(55)56)16-25(40)15-23)35(50)45-30(19-57-27-11-6-5-7-12-27)32(47)37(52)43-26-10-8-9-22(17-26)38(53)54/h5-12,14-17,20-21,28-32,47H,13,18-19,40-41H2,1-4H3,(H,42,48)(H,43,52)(H,44,51)(H,45,50)(H,46,49)(H,53,54)(H,55,56)/t28-,29-,30-,31-,32+/m0/s1
DMX9EA7	CS	CC(C)C[C@@H](C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](C(=O)NC2=CC=CC(=C2)C(=O)O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CNC(=O)C3=CC(=CC(=C3)N)C(=O)O)N
DMX9EA7	IK	DFWUMZBCWONAOR-QEUNAIBPSA-N
DMX9EA7	IU	3-amino-5-[[(2S)-2-amino-3-[[(2S)-1-[[(2S)-1-[[(2R,3R)-4-(3-carboxyanilino)-3-hydroxy-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropyl]carbamoyl]benzoic acid
DMX9EA7	DE	Discovery agent

DMXUETW	ID	DMXUETW
DMXUETW	DN	KMI-596
DMXUETW	HS	Investigative
DMXUETW	DT	Small molecular drug
DMXUETW	PC	136106170
DMXUETW	MW	695.8
DMXUETW	FM	C34H45N7O9
DMXUETW	IC	InChI=1S/C34H45N7O9/c1-18(2)15-25(38-32(47)27(19(3)4)39-30(45)23(35)13-14-26(42)43)31(46)37-24(16-20-9-6-5-7-10-20)28(44)33(48)36-22-12-8-11-21(17-22)29-40-34(49)50-41-29/h5-12,17-19,23-25,27-28,44H,13-16,35H2,1-4H3,(H,36,48)(H,37,46)(H,38,47)(H,39,45)(H,42,43)(H,40,41,49)/t23-,24-,25-,27-,28+/m0/s1
DMXUETW	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](C(=O)NC2=CC=CC(=C2)C3=NOC(=O)N3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)N
DMXUETW	IK	WXPDDAQNFBWSRN-WZFFGLSISA-N
DMXUETW	IU	(4S)-4-amino-5-[[(2S)-1-[[(2S)-1-[[(2S,3R)-3-hydroxy-4-oxo-4-[3-(5-oxo-4H-1,2,4-oxadiazol-3-yl)anilino]-1-phenylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMXUETW	DE	Discovery agent

DMP1GQB	ID	DMP1GQB
DMP1GQB	DN	KMJ-372
DMP1GQB	HS	Investigative
DMP1GQB	SN	MK-271; TRPV1 antagonists (pain), Digital Biotech/Grunenthal; TRPV1 antagonists (pain), Medifron/Grunenthal; VR1 antagonists (pain), Digital Biotech/Grunenthal; Vanilloid antagonists (analgesic), Digital Biotech/Grunenthal; (S)-KMJ-372
DMP1GQB	CP	Digital Biotech Co Ltd
DMP1GQB	DE	Pain

DMFVS16	ID	DMFVS16
DMFVS16	DN	KML110
DMFVS16	HS	Investigative
DMFVS16	SN	KML110
DMFVS16	DT	Small molecular drug
DMFVS16	PC	91827387
DMFVS16	MW	377.4
DMFVS16	FM	C22H23N3O3
DMFVS16	IC	InChI=1S/C22H23N3O3/c1-15-18-9-8-17(25(27)28)14-19(18)21(16-6-4-3-5-7-16)20(15)22(26)24-12-10-23(2)11-13-24/h3-9,14-15H,10-13H2,1-2H3
DMFVS16	CS	CC1C2=C(C=C(C=C2)[N+](=O)[O-])C(=C1C(=O)N3CCN(CC3)C)C4=CC=CC=C4
DMFVS16	IK	BBPOBHFPZPRPGB-UHFFFAOYSA-N
DMFVS16	IU	(1-methyl-5-nitro-3-phenyl-1H-inden-2-yl)-(4-methylpiperazin-1-yl)methanone
DMFVS16	DE	Discovery agent

DM2K81B	ID	DM2K81B
DM2K81B	DN	KMS-88009
DM2K81B	HS	Investigative
DM2K81B	SN	KMS-88016; KMSB-600; Aminostyrylbenzofuran derivative beta amyloid fibril formation inhibitors (Alzheimer's disease), Korea Institute of Science and Technology/Seoul National University/Hanmi Pharmaceutical
DM2K81B	CP	Korea Institute of Science and Technology
DM2K81B	DE	Alzheimer disease

DMLZ89P	ID	DMLZ89P
DMLZ89P	DN	KN-62
DMLZ89P	HS	Investigative
DMLZ89P	SN	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863
DMLZ89P	DT	Small molecular drug
DMLZ89P	PC	5312126
DMLZ89P	MW	721.8
DMLZ89P	FM	C38H35N5O6S2
DMLZ89P	IC	InChI=1S/C38H35N5O6S2/c1-41(50(45,46)36-11-5-7-29-26-39-19-17-33(29)36)35(38(44)43-23-21-42(22-24-43)31-9-3-2-4-10-31)25-28-13-15-32(16-14-28)49-51(47,48)37-12-6-8-30-27-40-20-18-34(30)37/h2-20,26-27,35H,21-25H2,1H3/t35-/m0/s1
DMLZ89P	CS	CN([C@@H](CC1=CC=C(C=C1)OS(=O)(=O)C2=CC=CC3=C2C=CN=C3)C(=O)N4CCN(CC4)C5=CC=CC=C5)S(=O)(=O)C6=CC=CC7=C6C=CN=C7
DMLZ89P	IK	RJVLFQBBRSMWHX-DHUJRADRSA-N
DMLZ89P	IU	[4-[(2S)-2-[isoquinolin-5-ylsulfonyl(methyl)amino]-3-oxo-3-(4-phenylpiperazin-1-yl)propyl]phenyl] isoquinoline-5-sulfonate
DMLZ89P	CA	CAS 127191-97-3
DMLZ89P	CB	CHEBI:131159
DMLZ89P	DE	Discovery agent

DMPTMKH	ID	DMPTMKH
DMPTMKH	DN	KN-93
DMPTMKH	HS	Investigative
DMPTMKH	SN	kn-93; 139298-40-1; KN 93; KN93; Methoxybenzene-sulfonamide; C26H29ClN2O4S; CHEMBL155333; (E)-N-(2-(((3-(4-Chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide; 2-(N-(2-Hydroxyethyl)-N-(4-methoxybenzenesulfonyl))amino-N-(4-chlorocinnamyl)-N-methylbenzylamine; N-(2-(((3-(4-Chlorophenyl)-2-propenyl)methylamino)methyl)phenyl)-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide; Benzenesulfonamide, N-(2-(((3-(4-chlorophenyl)-2-propenyl)methylamino)methyl)ph
DMPTMKH	DT	Small molecular drug
DMPTMKH	PC	5312122
DMPTMKH	MW	501
DMPTMKH	FM	C26H29ClN2O4S
DMPTMKH	IC	InChI=1S/C26H29ClN2O4S/c1-28(17-5-6-21-9-11-23(27)12-10-21)20-22-7-3-4-8-26(22)29(18-19-30)34(31,32)25-15-13-24(33-2)14-16-25/h3-16,30H,17-20H2,1-2H3/b6-5+
DMPTMKH	CS	CN(C/C=C/C1=CC=C(C=C1)Cl)CC2=CC=CC=C2N(CCO)S(=O)(=O)C3=CC=C(C=C3)OC
DMPTMKH	IK	LLLQTDSSHZREGW-AATRIKPKSA-N
DMPTMKH	IU	N-[2-[[[(E)-3-(4-chlorophenyl)prop-2-enyl]-methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide
DMPTMKH	CA	CAS 139298-40-1
DMPTMKH	CB	CHEBI:91460
DMPTMKH	DE	Discovery agent

DMMISH6	ID	DMMISH6
DMMISH6	DN	KNI-10006
DMMISH6	HS	Investigative
DMMISH6	SN	KNI-10006; CHEMBL231522; (4r)-3-[(2s,3s)-3-{[(2,6-Dimethylphenoxy)acetyl]amino}-2-Hydroxy-4-Phenylbutanoyl]-N-[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-5,5-Dimethyl-1,3-Thiazolidine-4-Carboxamide; 3kdb; 3fnu; 3qs1; SCHEMBL13788265; BDBM50209559; 461444-55-3
DMMISH6	DT	Small molecular drug
DMMISH6	PC	9895503
DMMISH6	MW	631.8
DMMISH6	FM	C35H41N3O6S
DMMISH6	IC	InChI=1S/C35H41N3O6S/c1-21-11-10-12-22(2)31(21)44-19-28(40)36-26(17-23-13-6-5-7-14-23)30(41)34(43)38-20-45-35(3,4)32(38)33(42)37-29-25-16-9-8-15-24(25)18-27(29)39/h5-16,26-27,29-30,32,39,41H,17-20H2,1-4H3,(H,36,40)(H,37,42)/t26-,27+,29-,30-,32+/m0/s1
DMMISH6	CS	CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMMISH6	IK	KKTYZYHUPKXLPL-RIQJEONASA-N
DMMISH6	IU	(4R)-3-[(2S,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMMISH6	DE	Discovery agent

DMLOXMQ	ID	DMLOXMQ
DMLOXMQ	DN	KNI-10033
DMLOXMQ	HS	Investigative
DMLOXMQ	SN	KNI-10033; CHEMBL440965; (4r)-N-[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-3-[(2s,3s)-2-Hydroxy-3-({n-[(Isoquinolin-5-Yloxy)acetyl]-S-Methyl-L-Cysteinyl}amino)-4-Phenylbutanoyl]-5,5-Dimethyl-1,3-Thiazolidine-4-Carboxamide; 2pk6; BDBM50209552; O33
DMLOXMQ	DT	Small molecular drug
DMLOXMQ	PC	16122614
DMLOXMQ	MW	771.9
DMLOXMQ	FM	C40H45N5O7S2
DMLOXMQ	IC	InChI=1S/C40H45N5O7S2/c1-40(2)36(38(50)44-34-28-14-8-7-12-25(28)19-31(34)46)45(23-54-40)39(51)35(48)29(18-24-10-5-4-6-11-24)43-37(49)30(22-53-3)42-33(47)21-52-32-15-9-13-26-20-41-17-16-27(26)32/h4-17,20,29-31,34-36,46,48H,18-19,21-23H2,1-3H3,(H,42,47)(H,43,49)(H,44,50)/t29-,30-,31+,34-,35-,36+/m0/s1
DMLOXMQ	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC4=C3C=CN=C4)O)C(=O)N[C@@H]5[C@@H](CC6=CC=CC=C56)O)C
DMLOXMQ	IK	NLPSIHQYIUXYOW-SHJYOGRKSA-N
DMLOXMQ	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[(2-isoquinolin-5-yloxyacetyl)amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMLOXMQ	DE	Discovery agent

DMMZ6AO	ID	DMMZ6AO
DMMZ6AO	DN	KNI-10061
DMMZ6AO	HS	Investigative
DMMZ6AO	SN	KNI-10061; CHEMBL266020; BDBM50209557
DMMZ6AO	DT	Small molecular drug
DMMZ6AO	PC	44425655
DMMZ6AO	MW	812
DMMZ6AO	FM	C43H49N5O7S2
DMMZ6AO	IC	InChI=1S/C43H49N5O7S2/c1-43(2)39(41(53)47-37-32-20-11-10-15-28(32)22-35(37)49)48(26-57-43)42(54)38(51)33(21-27-13-6-4-7-14-27)46-40(52)34(25-56-3)45-36(50)24-55-31-19-12-18-30(23-31)44-29-16-8-5-9-17-29/h4-20,23,33-35,37-39,44,49,51H,21-22,24-26H2,1-3H3,(H,45,50)(H,46,52)(H,47,53)/t33-,34-,35+,37-,38-,39+/m0/s1
DMMZ6AO	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC(=C3)NC4=CC=CC=C4)O)C(=O)N[C@@H]5[C@@H](CC6=CC=CC=C56)O)C
DMMZ6AO	IK	KAHOVIZPKWWDDX-GCELDIMASA-N
DMMZ6AO	IU	(4R)-3-[(2S,3S)-3-[[(2R)-2-[[2-(3-anilinophenoxy)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMMZ6AO	DE	Discovery agent

DMYSDN4	ID	DMYSDN4
DMYSDN4	DN	KNI-10062
DMYSDN4	HS	Investigative
DMYSDN4	SN	KNI-10062; CHEMBL411155; BDBM50209566
DMYSDN4	DT	Small molecular drug
DMYSDN4	PC	44425657
DMYSDN4	MW	758.9
DMYSDN4	FM	C39H42N4O8S2
DMYSDN4	IC	InChI=1S/C39H42N4O8S2/c1-39(2)34(37(49)42-32-24-14-8-7-13-23(24)18-29(32)45)43(21-53-39)38(50)33(46)26(17-22-11-5-4-6-12-22)40-35(47)27(20-52-3)41-36(48)31-19-28(44)25-15-9-10-16-30(25)51-31/h4-16,19,26-27,29,32-34,45-46H,17-18,20-21H2,1-3H3,(H,40,47)(H,41,48)(H,42,49)/t26-,27-,29+,32-,33-,34+/m0/s1
DMYSDN4	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)C3=CC(=O)C4=CC=CC=C4O3)O)C(=O)N[C@@H]5[C@@H](CC6=CC=CC=C56)O)C
DMYSDN4	IK	KMPZTBYBVXRNNV-CJFFKWHBSA-N
DMYSDN4	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-3-methylsulfanyl-2-[(4-oxochromene-2-carbonyl)amino]propanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMYSDN4	DE	Discovery agent

DMM5SDT	ID	DMM5SDT
DMM5SDT	DN	KNI-10074
DMM5SDT	HS	Investigative
DMM5SDT	SN	KNI-10074; CHEMBL510300; (4r)-3-[(2s,3s)-3-{[(2,6-Dichlorophenoxy)acetyl]amino}-2-Hydroxy-4-Phenylbutanoyl]-N-[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-5,5-Dimethyl-1,3-Thiazolidine-4-Carboxamide; 3kdc; BDBM50273738; JZP
DMM5SDT	DT	Small molecular drug
DMM5SDT	PC	44588310
DMM5SDT	MW	672.6
DMM5SDT	FM	C33H35Cl2N3O6S
DMM5SDT	IC	InChI=1S/C33H35Cl2N3O6S/c1-33(2)30(31(42)37-27-21-12-7-6-11-20(21)16-25(27)39)38(18-45-33)32(43)28(41)24(15-19-9-4-3-5-10-19)36-26(40)17-44-29-22(34)13-8-14-23(29)35/h3-14,24-25,27-28,30,39,41H,15-18H2,1-2H3,(H,36,40)(H,37,42)/t24-,25+,27-,28-,30+/m0/s1
DMM5SDT	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C=CC=C3Cl)Cl)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMM5SDT	IK	XMAMZSZKRBFNLW-UPZHSWQNSA-N
DMM5SDT	IU	(4R)-3-[(2S,3S)-3-[[2-(2,6-dichlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMM5SDT	DE	Discovery agent

DMCZOX9	ID	DMCZOX9
DMCZOX9	DN	KNI-10079
DMCZOX9	HS	Investigative
DMCZOX9	SN	KNI-10079; CHEMBL509164; BDBM50273719
DMCZOX9	DT	Small molecular drug
DMCZOX9	PC	44588291
DMCZOX9	MW	617.8
DMCZOX9	FM	C34H39N3O6S
DMCZOX9	IC	InChI=1S/C34H39N3O6S/c1-21-11-7-10-16-27(21)43-19-28(39)35-25(17-22-12-5-4-6-13-22)30(40)33(42)37-20-44-34(2,3)31(37)32(41)36-29-24-15-9-8-14-23(24)18-26(29)38/h4-16,25-26,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t25-,26+,29-,30-,31+/m0/s1
DMCZOX9	CS	CC1=CC=CC=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMCZOX9	IK	LXIUKNRDJTWBGH-XPLSERNMSA-N
DMCZOX9	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(2-methylphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMCZOX9	DE	Discovery agent

DMEN4DZ	ID	DMEN4DZ
DMEN4DZ	DN	KNI-10080
DMEN4DZ	HS	Investigative
DMEN4DZ	SN	KNI-10080; CHEMBL453415; BDBM50273720
DMEN4DZ	DT	Small molecular drug
DMEN4DZ	PC	44588292
DMEN4DZ	MW	617.8
DMEN4DZ	FM	C34H39N3O6S
DMEN4DZ	IC	InChI=1S/C34H39N3O6S/c1-21-10-9-14-24(16-21)43-19-28(39)35-26(17-22-11-5-4-6-12-22)30(40)33(42)37-20-44-34(2,3)31(37)32(41)36-29-25-15-8-7-13-23(25)18-27(29)38/h4-16,26-27,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t26-,27+,29-,30-,31+/m0/s1
DMEN4DZ	CS	CC1=CC(=CC=C1)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMEN4DZ	IK	LAVCSYCCYHZRBK-VFCPCCRCSA-N
DMEN4DZ	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(3-methylphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMEN4DZ	DE	Discovery agent

DM1Z7QK	ID	DM1Z7QK
DM1Z7QK	DN	KNI-10081
DM1Z7QK	HS	Investigative
DM1Z7QK	SN	KNI-10081; CHEMBL508116; BDBM50273721
DM1Z7QK	DT	Small molecular drug
DM1Z7QK	PC	44588293
DM1Z7QK	MW	617.8
DM1Z7QK	FM	C34H39N3O6S
DM1Z7QK	IC	InChI=1S/C34H39N3O6S/c1-21-13-15-24(16-14-21)43-19-28(39)35-26(17-22-9-5-4-6-10-22)30(40)33(42)37-20-44-34(2,3)31(37)32(41)36-29-25-12-8-7-11-23(25)18-27(29)38/h4-16,26-27,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t26-,27+,29-,30-,31+/m0/s1
DM1Z7QK	CS	CC1=CC=C(C=C1)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DM1Z7QK	IK	CJVKWQTVDIZBSG-VFCPCCRCSA-N
DM1Z7QK	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-methylphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM1Z7QK	DE	Discovery agent

DMYN2U4	ID	DMYN2U4
DMYN2U4	DN	KNI-10087
DMYN2U4	HS	Investigative
DMYN2U4	SN	KNI-10087; CHEMBL442632; BDBM50273732
DMYN2U4	DT	Small molecular drug
DMYN2U4	PC	44588304
DMYN2U4	MW	618.7
DMYN2U4	FM	C33H38N4O6S
DMYN2U4	IC	InChI=1S/C33H38N4O6S/c1-33(2)30(31(41)36-28-24-14-7-6-11-21(24)16-26(28)38)37(19-44-33)32(42)29(40)25(15-20-9-4-3-5-10-20)35-27(39)18-43-23-13-8-12-22(34)17-23/h3-14,17,25-26,28-30,38,40H,15-16,18-19,34H2,1-2H3,(H,35,39)(H,36,41)/t25-,26+,28-,29-,30+/m0/s1
DMYN2U4	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMYN2U4	IK	LQEMUNLLUUKMPD-DOWNBTJOSA-N
DMYN2U4	IU	(4R)-3-[(2S,3S)-3-[[2-(3-aminophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMYN2U4	DE	Discovery agent

DM4GASE	ID	DM4GASE
DM4GASE	DN	KNI-10088
DM4GASE	HS	Investigative
DM4GASE	SN	KNI-10088; CHEMBL499956; BDBM50273733
DM4GASE	DT	Small molecular drug
DM4GASE	PC	44588305
DM4GASE	MW	618.7
DM4GASE	FM	C33H38N4O6S
DM4GASE	IC	InChI=1S/C33H38N4O6S/c1-33(2)30(31(41)36-28-24-11-7-6-10-21(24)17-26(28)38)37(19-44-33)32(42)29(40)25(16-20-8-4-3-5-9-20)35-27(39)18-43-23-14-12-22(34)13-15-23/h3-15,25-26,28-30,38,40H,16-19,34H2,1-2H3,(H,35,39)(H,36,41)/t25-,26+,28-,29-,30+/m0/s1
DM4GASE	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM4GASE	IK	YGKGGCBHYIMPFH-DOWNBTJOSA-N
DM4GASE	IU	(4R)-3-[(2S,3S)-3-[[2-(4-aminophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM4GASE	DE	Discovery agent

DMV1KI2	ID	DMV1KI2
DMV1KI2	DN	KNI-10092
DMV1KI2	HS	Investigative
DMV1KI2	SN	KNI-10092; CHEMBL506575; BDBM50273722
DMV1KI2	DT	Small molecular drug
DMV1KI2	PC	44588294
DMV1KI2	MW	633.8
DMV1KI2	FM	C34H39N3O7S
DMV1KI2	IC	InChI=1S/C34H39N3O7S/c1-34(2)31(32(41)36-29-23-14-8-7-13-22(23)18-25(29)38)37(20-45-34)33(42)30(40)24(17-21-11-5-4-6-12-21)35-28(39)19-44-27-16-10-9-15-26(27)43-3/h4-16,24-25,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t24-,25+,29-,30-,31+/m0/s1
DMV1KI2	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMV1KI2	IK	JFCIKXOPSCFWBJ-ZNIFFWLPSA-N
DMV1KI2	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(2-methoxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMV1KI2	DE	Discovery agent

DMGY5Z0	ID	DMGY5Z0
DMGY5Z0	DN	KNI-10093
DMGY5Z0	HS	Investigative
DMGY5Z0	SN	KNI-10093; CHEMBL452345; BDBM50273723
DMGY5Z0	DT	Small molecular drug
DMGY5Z0	PC	44588295
DMGY5Z0	MW	633.8
DMGY5Z0	FM	C34H39N3O7S
DMGY5Z0	IC	InChI=1S/C34H39N3O7S/c1-34(2)31(32(41)36-29-25-15-8-7-12-22(25)17-27(29)38)37(20-45-34)33(42)30(40)26(16-21-10-5-4-6-11-21)35-28(39)19-44-24-14-9-13-23(18-24)43-3/h4-15,18,26-27,29-31,38,40H,16-17,19-20H2,1-3H3,(H,35,39)(H,36,41)/t26-,27+,29-,30-,31+/m0/s1
DMGY5Z0	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMGY5Z0	IK	JUVIZUPSXSIJMO-VFCPCCRCSA-N
DMGY5Z0	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(3-methoxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMGY5Z0	DE	Discovery agent

DMJIQG2	ID	DMJIQG2
DMJIQG2	DN	KNI-10094
DMJIQG2	HS	Investigative
DMJIQG2	SN	KNI-10094; CHEMBL453959; BDBM50273724
DMJIQG2	DT	Small molecular drug
DMJIQG2	PC	44588296
DMJIQG2	MW	633.8
DMJIQG2	FM	C34H39N3O7S
DMJIQG2	IC	InChI=1S/C34H39N3O7S/c1-34(2)31(32(41)36-29-25-12-8-7-11-22(25)18-27(29)38)37(20-45-34)33(42)30(40)26(17-21-9-5-4-6-10-21)35-28(39)19-44-24-15-13-23(43-3)14-16-24/h4-16,26-27,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t26-,27+,29-,30-,31+/m0/s1
DMJIQG2	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMJIQG2	IK	QGAHVOMMQMAYSQ-VFCPCCRCSA-N
DMJIQG2	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-methoxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMJIQG2	CA	CAS 820220-93-7
DMJIQG2	DE	Discovery agent

DMEHPVF	ID	DMEHPVF
DMEHPVF	DN	KNI-10095
DMEHPVF	HS	Investigative
DMEHPVF	SN	KNI-10095; CHEMBL507473; BDBM50273734
DMEHPVF	DT	Small molecular drug
DMEHPVF	PC	44588306
DMEHPVF	MW	648.7
DMEHPVF	FM	C33H36N4O8S
DMEHPVF	IC	InChI=1S/C33H36N4O8S/c1-33(2)30(31(41)35-28-22-13-7-6-12-21(22)17-25(28)38)36(19-46-33)32(42)29(40)23(16-20-10-4-3-5-11-20)34-27(39)18-45-26-15-9-8-14-24(26)37(43)44/h3-15,23,25,28-30,38,40H,16-19H2,1-2H3,(H,34,39)(H,35,41)/t23-,25+,28-,29-,30+/m0/s1
DMEHPVF	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3[N+](=O)[O-])O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMEHPVF	IK	NJMYSVGWPKMYBH-OIRZSGMBSA-N
DMEHPVF	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(2-nitrophenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMEHPVF	DE	Discovery agent

DMBTRHG	ID	DMBTRHG
DMBTRHG	DN	KNI-10106
DMBTRHG	HS	Investigative
DMBTRHG	SN	KNI-10106; CHEMBL448257; BDBM50273731
DMBTRHG	DT	Small molecular drug
DMBTRHG	PC	44588303
DMBTRHG	MW	618.7
DMBTRHG	FM	C33H38N4O6S
DMBTRHG	IC	InChI=1S/C33H38N4O6S/c1-33(2)30(31(41)36-28-22-13-7-6-12-21(22)17-25(28)38)37(19-44-33)32(42)29(40)24(16-20-10-4-3-5-11-20)35-27(39)18-43-26-15-9-8-14-23(26)34/h3-15,24-25,28-30,38,40H,16-19,34H2,1-2H3,(H,35,39)(H,36,41)/t24-,25+,28-,29-,30+/m0/s1
DMBTRHG	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMBTRHG	IK	CTMJCAZSOKTPFA-VOULMWPJSA-N
DMBTRHG	IU	(4R)-3-[(2S,3S)-3-[[2-(2-aminophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMBTRHG	DE	Discovery agent

DM78A6F	ID	DM78A6F
DM78A6F	DN	KNI-10113
DM78A6F	HS	Investigative
DM78A6F	SN	KNI-10113; CHEMBL506609; BDBM50273728
DM78A6F	DT	Small molecular drug
DM78A6F	PC	44588300
DM78A6F	MW	633.8
DM78A6F	FM	C34H39N3O7S
DM78A6F	IC	InChI=1S/C34H39N3O7S/c1-34(2)31(32(42)36-29-24-14-8-6-12-22(24)17-26(29)39)37(20-45-34)33(43)30(41)25(16-21-10-4-3-5-11-21)35-28(40)19-44-27-15-9-7-13-23(27)18-38/h3-15,25-26,29-31,38-39,41H,16-20H2,1-2H3,(H,35,40)(H,36,42)/t25-,26+,29-,30-,31+/m0/s1
DM78A6F	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3CO)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM78A6F	IK	XBWSFLDHKBAMBA-XPLSERNMSA-N
DM78A6F	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-[2-(hydroxymethyl)phenoxy]acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM78A6F	DE	Discovery agent

DMA9104	ID	DMA9104
DMA9104	DN	KNI-10124
DMA9104	HS	Investigative
DMA9104	SN	KNI-10124; CHEMBL448977; BDBM50273729
DMA9104	DT	Small molecular drug
DMA9104	PC	44588301
DMA9104	MW	633.8
DMA9104	FM	C34H39N3O7S
DMA9104	IC	InChI=1S/C34H39N3O7S/c1-34(2)31(32(42)36-29-25-14-7-6-12-23(25)17-27(29)39)37(20-45-34)33(43)30(41)26(16-21-9-4-3-5-10-21)35-28(40)19-44-24-13-8-11-22(15-24)18-38/h3-15,26-27,29-31,38-39,41H,16-20H2,1-2H3,(H,35,40)(H,36,42)/t26-,27+,29-,30-,31+/m0/s1
DMA9104	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)CO)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMA9104	IK	NRLFBLHYKZDHHW-VFCPCCRCSA-N
DMA9104	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-[3-(hydroxymethyl)phenoxy]acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMA9104	DE	Discovery agent

DMDBERC	ID	DMDBERC
DMDBERC	DN	KNI-10125
DMDBERC	HS	Investigative
DMDBERC	SN	KNI-10125; CHEMBL448631; BDBM50273730
DMDBERC	DT	Small molecular drug
DMDBERC	PC	44588302
DMDBERC	MW	633.8
DMDBERC	FM	C34H39N3O7S
DMDBERC	IC	InChI=1S/C34H39N3O7S/c1-34(2)31(32(42)36-29-25-11-7-6-10-23(25)17-27(29)39)37(20-45-34)33(43)30(41)26(16-21-8-4-3-5-9-21)35-28(40)19-44-24-14-12-22(18-38)13-15-24/h3-15,26-27,29-31,38-39,41H,16-20H2,1-2H3,(H,35,40)(H,36,42)/t26-,27+,29-,30-,31+/m0/s1
DMDBERC	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)CO)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMDBERC	IK	RJJNWINGYKEUKL-VFCPCCRCSA-N
DMDBERC	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-[4-(hydroxymethyl)phenoxy]acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMDBERC	DE	Discovery agent

DMNBUS4	ID	DMNBUS4
DMNBUS4	DN	KNI-10152
DMNBUS4	HS	Investigative
DMNBUS4	SN	KNI-10152; CHEMBL509473; BDBM50273740
DMNBUS4	DT	Small molecular drug
DMNBUS4	PC	44588312
DMNBUS4	MW	687.9
DMNBUS4	FM	C39H49N3O6S
DMNBUS4	IC	InChI=1S/C39H49N3O6S/c1-23(2)27-17-12-18-28(24(3)4)35(27)48-21-32(44)40-30(19-25-13-8-7-9-14-25)34(45)38(47)42-22-49-39(5,6)36(42)37(46)41-33-29-16-11-10-15-26(29)20-31(33)43/h7-18,23-24,30-31,33-34,36,43,45H,19-22H2,1-6H3,(H,40,44)(H,41,46)/t30-,31+,33-,34-,36+/m0/s1
DMNBUS4	CS	CC(C)C1=C(C(=CC=C1)C(C)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMNBUS4	IK	QPUVMQNOWWLTBU-SQKWSBCUSA-N
DMNBUS4	IU	(4R)-3-[(2S,3S)-3-[[2-[2,6-di(propan-2-yl)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMNBUS4	DE	Discovery agent

DM1PKWA	ID	DM1PKWA
DM1PKWA	DN	KNI-10155
DM1PKWA	HS	Investigative
DM1PKWA	SN	KNI-10155; CHEMBL503181; BDBM50273742
DM1PKWA	DT	Small molecular drug
DM1PKWA	PC	44588314
DM1PKWA	MW	647.8
DM1PKWA	FM	C35H41N3O7S
DM1PKWA	IC	InChI=1S/C35H41N3O7S/c1-20-14-24(39)15-21(2)31(20)45-18-28(41)36-26(16-22-10-6-5-7-11-22)30(42)34(44)38-19-46-35(3,4)32(38)33(43)37-29-25-13-9-8-12-23(25)17-27(29)40/h5-15,26-27,29-30,32,39-40,42H,16-19H2,1-4H3,(H,36,41)(H,37,43)/t26-,27+,29-,30-,32+/m0/s1
DM1PKWA	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)O
DM1PKWA	IK	RFANRLZGSPNNFF-RIQJEONASA-N
DM1PKWA	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-hydroxy-2,6-dimethylphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM1PKWA	DE	Discovery agent

DM64NBG	ID	DM64NBG
DM64NBG	DN	KNI-10216
DM64NBG	HS	Investigative
DM64NBG	SN	KNI-10216; CHEMBL509323; BDBM50273726
DM64NBG	DT	Small molecular drug
DM64NBG	PC	44588298
DM64NBG	MW	619.7
DM64NBG	FM	C33H37N3O7S
DM64NBG	IC	InChI=1S/C33H37N3O7S/c1-33(2)30(31(41)35-28-24-14-7-6-11-21(24)16-26(28)38)36(19-44-33)32(42)29(40)25(15-20-9-4-3-5-10-20)34-27(39)18-43-23-13-8-12-22(37)17-23/h3-14,17,25-26,28-30,37-38,40H,15-16,18-19H2,1-2H3,(H,34,39)(H,35,41)/t25-,26+,28-,29-,30+/m0/s1
DM64NBG	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM64NBG	IK	KSGNCVYBLWHGKD-DOWNBTJOSA-N
DM64NBG	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(3-hydroxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM64NBG	DE	Discovery agent

DMHLFAE	ID	DMHLFAE
DMHLFAE	DN	KNI-10217
DMHLFAE	HS	Investigative
DMHLFAE	SN	KNI-10217; CHEMBL448365; BDBM50273727
DMHLFAE	DT	Small molecular drug
DMHLFAE	PC	44588299
DMHLFAE	MW	619.7
DMHLFAE	FM	C33H37N3O7S
DMHLFAE	IC	InChI=1S/C33H37N3O7S/c1-33(2)30(31(41)35-28-24-11-7-6-10-21(24)17-26(28)38)36(19-44-33)32(42)29(40)25(16-20-8-4-3-5-9-20)34-27(39)18-43-23-14-12-22(37)13-15-23/h3-15,25-26,28-30,37-38,40H,16-19H2,1-2H3,(H,34,39)(H,35,41)/t25-,26+,28-,29-,30+/m0/s1
DMHLFAE	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMHLFAE	IK	QQMINRBEIWYLOV-DOWNBTJOSA-N
DMHLFAE	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-hydroxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMHLFAE	DE	Discovery agent

DMQY1ST	ID	DMQY1ST
DMQY1ST	DN	KNI-10232
DMQY1ST	HS	Investigative
DMQY1ST	SN	KNI-10232; CHEMBL411559; BDBM50209553
DMQY1ST	DT	Small molecular drug
DMQY1ST	PC	44425659
DMQY1ST	MW	718.9
DMQY1ST	FM	C38H46N4O6S2
DMQY1ST	IC	InChI=1S/C38H46N4O6S2/c1-23-12-8-9-15-25(23)20-31(44)39-29(21-49-4)35(46)40-28(18-24-13-6-5-7-14-24)33(45)37(48)42-22-50-38(2,3)34(42)36(47)41-32-27-17-11-10-16-26(27)19-30(32)43/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DMQY1ST	CS	CC1=CC=CC=C1CC(=O)N[C@@H](CSC)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMQY1ST	IK	BUCXGTGXIGORNK-DYCNJNKSSA-N
DMQY1ST	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(2-methylphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMQY1ST	DE	Discovery agent

DMV3U9Z	ID	DMV3U9Z
DMV3U9Z	DN	KNI-10255
DMV3U9Z	HS	Investigative
DMV3U9Z	SN	KNI-10255; CHEMBL508023; BDBM50273735
DMV3U9Z	DT	Small molecular drug
DMV3U9Z	PC	44588307
DMV3U9Z	MW	648.7
DMV3U9Z	FM	C33H36N4O8S
DMV3U9Z	IC	InChI=1S/C33H36N4O8S/c1-33(2)30(31(41)35-28-24-14-7-6-11-21(24)16-26(28)38)36(19-46-33)32(42)29(40)25(15-20-9-4-3-5-10-20)34-27(39)18-45-23-13-8-12-22(17-23)37(43)44/h3-14,17,25-26,28-30,38,40H,15-16,18-19H2,1-2H3,(H,34,39)(H,35,41)/t25-,26+,28-,29-,30+/m0/s1
DMV3U9Z	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)[N+](=O)[O-])O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMV3U9Z	IK	RFMOODWRTXUAKX-DOWNBTJOSA-N
DMV3U9Z	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(3-nitrophenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMV3U9Z	DE	Discovery agent

DMZFVHT	ID	DMZFVHT
DMZFVHT	DN	KNI-10256
DMZFVHT	HS	Investigative
DMZFVHT	SN	KNI-10256; CHEMBL500010; BDBM50273736
DMZFVHT	DT	Small molecular drug
DMZFVHT	PC	44588308
DMZFVHT	MW	648.7
DMZFVHT	FM	C33H36N4O8S
DMZFVHT	IC	InChI=1S/C33H36N4O8S/c1-33(2)30(31(41)35-28-24-11-7-6-10-21(24)17-26(28)38)36(19-46-33)32(42)29(40)25(16-20-8-4-3-5-9-20)34-27(39)18-45-23-14-12-22(13-15-23)37(43)44/h3-15,25-26,28-30,38,40H,16-19H2,1-2H3,(H,34,39)(H,35,41)/t25-,26+,28-,29-,30+/m0/s1
DMZFVHT	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)[N+](=O)[O-])O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMZFVHT	IK	PABVKNPJQYYVNK-DOWNBTJOSA-N
DMZFVHT	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-nitrophenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMZFVHT	DE	Discovery agent

DMZXI6U	ID	DMZXI6U
DMZXI6U	DN	KNI-10260
DMZXI6U	HS	Investigative
DMZXI6U	SN	KNI-10260; CHEMBL503590; BDBM50273739
DMZXI6U	DT	Small molecular drug
DMZXI6U	PC	44588311
DMZXI6U	MW	663.8
DMZXI6U	FM	C35H41N3O8S
DMZXI6U	IC	InChI=1S/C35H41N3O8S/c1-35(2)32(33(42)37-29-23-14-9-8-13-22(23)18-25(29)39)38(20-47-35)34(43)30(41)24(17-21-11-6-5-7-12-21)36-28(40)19-46-31-26(44-3)15-10-16-27(31)45-4/h5-16,24-25,29-30,32,39,41H,17-20H2,1-4H3,(H,36,40)(H,37,42)/t24-,25+,29-,30-,32+/m0/s1
DMZXI6U	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C=CC=C3OC)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMZXI6U	IK	UXPUZKDVSUQPJT-GBHWDNFXSA-N
DMZXI6U	IU	(4R)-3-[(2S,3S)-3-[[2-(2,6-dimethoxyphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMZXI6U	DE	Discovery agent

DMQLB3T	ID	DMQLB3T
DMQLB3T	DN	KNI-10265
DMQLB3T	HS	Investigative
DMQLB3T	SN	KNI-10265; CHEMBL509191; (4r)-3-[(2s,3s)-3-{[(2,6-Difluorophenoxy)acetyl]amino}-2-Hydroxy-4-Phenylbutanoyl]-N-[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-5,5-Dimethyl-1,3-Thiazolidine-4-Carboxamide; 3kdd; BDBM50273737; JZQ
DMQLB3T	DT	Small molecular drug
DMQLB3T	PC	44588309
DMQLB3T	MW	639.7
DMQLB3T	FM	C33H35F2N3O6S
DMQLB3T	IC	InChI=1S/C33H35F2N3O6S/c1-33(2)30(31(42)37-27-21-12-7-6-11-20(21)16-25(27)39)38(18-45-33)32(43)28(41)24(15-19-9-4-3-5-10-19)36-26(40)17-44-29-22(34)13-8-14-23(29)35/h3-14,24-25,27-28,30,39,41H,15-18H2,1-2H3,(H,36,40)(H,37,42)/t24-,25+,27-,28-,30+/m0/s1
DMQLB3T	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C=CC=C3F)F)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMQLB3T	IK	KCNWMHBIZSWXTB-UPZHSWQNSA-N
DMQLB3T	IU	(4R)-3-[(2S,3S)-3-[[2-(2,6-difluorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMQLB3T	DE	Discovery agent

DMP2E3I	ID	DMP2E3I
DMP2E3I	DN	KNI-10266
DMP2E3I	HS	Investigative
DMP2E3I	SN	KNI-10266; CHEMBL499762; BDBM50273741
DMP2E3I	DT	Small molecular drug
DMP2E3I	PC	44588313
DMP2E3I	MW	649.8
DMP2E3I	FM	C35H40FN3O6S
DMP2E3I	IC	InChI=1S/C35H40FN3O6S/c1-20-14-24(36)15-21(2)31(20)45-18-28(41)37-26(16-22-10-6-5-7-11-22)30(42)34(44)39-19-46-35(3,4)32(39)33(43)38-29-25-13-9-8-12-23(25)17-27(29)40/h5-15,26-27,29-30,32,40,42H,16-19H2,1-4H3,(H,37,41)(H,38,43)/t26-,27+,29-,30-,32+/m0/s1
DMP2E3I	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)F
DMP2E3I	IK	CCRMGTSJDCJISE-RIQJEONASA-N
DMP2E3I	IU	(4R)-3-[(2S,3S)-3-[[2-(4-fluoro-2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMP2E3I	DE	Discovery agent

DMAR35H	ID	DMAR35H
DMAR35H	DN	KNI-10282
DMAR35H	HS	Investigative
DMAR35H	SN	KNI-10282; CHEMBL504596; BDBM50273745
DMAR35H	DT	Small molecular drug
DMAR35H	PC	25147780
DMAR35H	MW	674.9
DMAR35H	FM	C37H46N4O6S
DMAR35H	IC	InChI=1S/C37H46N4O6S/c1-22-16-26(40(5)6)17-23(2)33(22)47-20-30(43)38-28(18-24-12-8-7-9-13-24)32(44)36(46)41-21-48-37(3,4)34(41)35(45)39-31-27-15-11-10-14-25(27)19-29(31)42/h7-17,28-29,31-32,34,42,44H,18-21H2,1-6H3,(H,38,43)(H,39,45)/t28-,29+,31-,32-,34+/m0/s1
DMAR35H	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N(C)C
DMAR35H	IK	MHHYVTRSEKCASG-ZYOXRPPDSA-N
DMAR35H	IU	(4R)-3-[(2S,3S)-3-[[2-[4-(dimethylamino)-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMAR35H	DE	Discovery agent

DMGVBIT	ID	DMGVBIT
DMGVBIT	DN	KNI-10283
DMGVBIT	HS	Investigative
DMGVBIT	DT	Small molecular drug
DMGVBIT	PC	44588316
DMGVBIT	MW	660.8
DMGVBIT	FM	C36H44N4O6S
DMGVBIT	IC	InChI=1S/C36H44N4O6S/c1-21-15-25(37-5)16-22(2)32(21)46-19-29(42)38-27(17-23-11-7-6-8-12-23)31(43)35(45)40-20-47-36(3,4)33(40)34(44)39-30-26-14-10-9-13-24(26)18-28(30)41/h6-16,27-28,30-31,33,37,41,43H,17-20H2,1-5H3,(H,38,42)(H,39,44)/t27-,28+,30-,31-,33+/m0/s1
DMGVBIT	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NC
DMGVBIT	IK	MFQZSFZGLACSHP-LPOYSWGPSA-N
DMGVBIT	IU	(4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(methylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMGVBIT	DE	Discovery agent

DMP7M8O	ID	DMP7M8O
DMP7M8O	DN	KNI-10313
DMP7M8O	HS	Investigative
DMP7M8O	SN	KNI-10313; CHEMBL394359; BDBM50209562
DMP7M8O	DT	Small molecular drug
DMP7M8O	PC	44425663
DMP7M8O	MW	718.9
DMP7M8O	FM	C38H46N4O6S2
DMP7M8O	IC	InChI=1S/C38H46N4O6S2/c1-23-14-16-25(17-15-23)19-31(44)39-29(21-49-4)35(46)40-28(18-24-10-6-5-7-11-24)33(45)37(48)42-22-50-38(2,3)34(42)36(47)41-32-27-13-9-8-12-26(27)20-30(32)43/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DMP7M8O	CS	CC1=CC=C(C=C1)CC(=O)N[C@@H](CSC)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMP7M8O	IK	OMAVDDWHFQLABL-DYCNJNKSSA-N
DMP7M8O	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(4-methylphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMP7M8O	DE	Discovery agent

DMYGNZA	ID	DMYGNZA
DMYGNZA	DN	KNI-10314
DMYGNZA	HS	Investigative
DMYGNZA	SN	KNI-10314; CHEMBL266257; BDBM50209556
DMYGNZA	DT	Small molecular drug
DMYGNZA	PC	44425676
DMYGNZA	MW	734.9
DMYGNZA	FM	C38H46N4O7S2
DMYGNZA	IC	InChI=1S/C38H46N4O7S2/c1-38(2)34(36(47)41-32-26-16-10-8-14-24(26)19-29(32)43)42(22-51-38)37(48)33(45)27(18-23-12-6-5-7-13-23)40-35(46)28(21-50-4)39-31(44)20-25-15-9-11-17-30(25)49-3/h5-17,27-29,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t27-,28-,29+,32-,33-,34+/m0/s1
DMYGNZA	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC=CC=C3OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMYGNZA	IK	IJOKPTZPLSVFMX-CPPBRJAYSA-N
DMYGNZA	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(2-methoxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMYGNZA	DE	Discovery agent

DM1OPYT	ID	DM1OPYT
DM1OPYT	DN	KNI-10315
DM1OPYT	HS	Investigative
DM1OPYT	SN	KNI-10315; CHEMBL389083; BDBM50209563
DM1OPYT	DT	Small molecular drug
DM1OPYT	PC	44425680
DM1OPYT	MW	734.9
DM1OPYT	FM	C38H46N4O7S2
DM1OPYT	IC	InChI=1S/C38H46N4O7S2/c1-38(2)34(36(47)41-32-27-13-9-8-12-25(27)20-30(32)43)42(22-51-38)37(48)33(45)28(18-23-10-6-5-7-11-23)40-35(46)29(21-50-4)39-31(44)19-24-14-16-26(49-3)17-15-24/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DM1OPYT	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC=C(C=C3)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM1OPYT	IK	GJESXLGDWNCUSK-DYCNJNKSSA-N
DM1OPYT	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(4-methoxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM1OPYT	DE	Discovery agent

DMMIDCG	ID	DMMIDCG
DMMIDCG	DN	KNI-10316
DMMIDCG	HS	Investigative
DMMIDCG	SN	KNI-10316; CHEMBL411609; BDBM50209558
DMMIDCG	DT	Small molecular drug
DMMIDCG	PC	44425679
DMMIDCG	MW	734.9
DMMIDCG	FM	C38H46N4O7S2
DMMIDCG	IC	InChI=1S/C38H46N4O7S2/c1-38(2)34(36(47)41-32-27-16-9-8-14-25(27)20-30(32)43)42(22-51-38)37(48)33(45)28(18-23-11-6-5-7-12-23)40-35(46)29(21-50-4)39-31(44)19-24-13-10-15-26(17-24)49-3/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DMMIDCG	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC(=CC=C3)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMMIDCG	IK	CLMDKZSFODILEW-DYCNJNKSSA-N
DMMIDCG	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(3-methoxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMMIDCG	DE	Discovery agent

DMKVPMS	ID	DMKVPMS
DMKVPMS	DN	KNI-10332
DMKVPMS	HS	Investigative
DMKVPMS	SN	KNI-10332; CHEMBL411605; BDBM50209564
DMKVPMS	DT	Small molecular drug
DMKVPMS	PC	44425662
DMKVPMS	MW	718.9
DMKVPMS	FM	C38H46N4O6S2
DMKVPMS	IC	InChI=1S/C38H46N4O6S2/c1-23-11-10-14-25(17-23)19-31(44)39-29(21-49-4)35(46)40-28(18-24-12-6-5-7-13-24)33(45)37(48)42-22-50-38(2,3)34(42)36(47)41-32-27-16-9-8-15-26(27)20-30(32)43/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DMKVPMS	CS	CC1=CC(=CC=C1)CC(=O)N[C@@H](CSC)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMKVPMS	IK	RKUUAMZSZJEKQE-DYCNJNKSSA-N
DMKVPMS	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(3-methylphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMKVPMS	DE	Discovery agent

DMF9P25	ID	DMF9P25
DMF9P25	DN	KNI-10341
DMF9P25	HS	Investigative
DMF9P25	SN	KNI-10341; CHEMBL411607; BDBM50209561
DMF9P25	DT	Small molecular drug
DMF9P25	PC	44425671
DMF9P25	MW	720.9
DMF9P25	FM	C37H44N4O7S2
DMF9P25	IC	InChI=1S/C37H44N4O7S2/c1-37(2)33(35(47)40-31-25-15-9-7-13-23(25)18-29(31)43)41(21-50-37)36(48)32(45)26(17-22-11-5-4-6-12-22)39-34(46)27(20-49-3)38-30(44)19-24-14-8-10-16-28(24)42/h4-16,26-27,29,31-33,42-43,45H,17-21H2,1-3H3,(H,38,44)(H,39,46)(H,40,47)/t26-,27-,29+,31-,32-,33+/m0/s1
DMF9P25	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC=CC=C3O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMF9P25	IK	BJANBLOVCAEXPY-CFLSISTJSA-N
DMF9P25	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(2-hydroxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMF9P25	DE	Discovery agent

DMDM5BL	ID	DMDM5BL
DMDM5BL	DN	KNI-10342
DMDM5BL	HS	Investigative
DMDM5BL	SN	KNI-10342; CHEMBL230510; BDBM50209554
DMDM5BL	DT	Small molecular drug
DMDM5BL	PC	44425672
DMDM5BL	MW	720.9
DMDM5BL	FM	C37H44N4O7S2
DMDM5BL	IC	InChI=1S/C37H44N4O7S2/c1-37(2)33(35(47)40-31-26-15-8-7-13-24(26)19-29(31)43)41(21-50-37)36(48)32(45)27(17-22-10-5-4-6-11-22)39-34(46)28(20-49-3)38-30(44)18-23-12-9-14-25(42)16-23/h4-16,27-29,31-33,42-43,45H,17-21H2,1-3H3,(H,38,44)(H,39,46)(H,40,47)/t27-,28-,29+,31-,32-,33+/m0/s1
DMDM5BL	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC(=CC=C3)O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMDM5BL	IK	RBPFZWDTXSAZMR-ACUZRORGSA-N
DMDM5BL	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(3-hydroxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMDM5BL	DE	Discovery agent

DM8SIRL	ID	DM8SIRL
DM8SIRL	DN	KNI-10368
DM8SIRL	HS	Investigative
DM8SIRL	SN	KNI-10368; CHEMBL410591; BDBM50209560
DM8SIRL	DT	Small molecular drug
DM8SIRL	PC	44425667
DM8SIRL	MW	719.9
DM8SIRL	FM	C37H45N5O6S2
DM8SIRL	IC	InChI=1S/C37H45N5O6S2/c1-37(2)33(35(47)41-31-26-15-8-7-13-24(26)19-29(31)43)42(21-50-37)36(48)32(45)27(17-22-10-5-4-6-11-22)40-34(46)28(20-49-3)39-30(44)18-23-12-9-14-25(38)16-23/h4-16,27-29,31-33,43,45H,17-21,38H2,1-3H3,(H,39,44)(H,40,46)(H,41,47)/t27-,28-,29+,31-,32-,33+/m0/s1
DM8SIRL	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC(=CC=C3)N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM8SIRL	IK	OSOTUWUUAVSXOF-ACUZRORGSA-N
DM8SIRL	IU	(4R)-3-[(2S,3S)-3-[[(2R)-2-[[2-(3-aminophenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM8SIRL	DE	Discovery agent

DM97STY	ID	DM97STY
DM97STY	DN	KNI-10369
DM97STY	HS	Investigative
DM97STY	SN	KNI-10369; CHEMBL502985; BDBM50273725
DM97STY	DT	Small molecular drug
DM97STY	PC	44588297
DM97STY	MW	619.7
DM97STY	FM	C33H37N3O7S
DM97STY	IC	InChI=1S/C33H37N3O7S/c1-33(2)30(31(41)35-28-22-13-7-6-12-21(22)17-25(28)38)36(19-44-33)32(42)29(40)23(16-20-10-4-3-5-11-20)34-27(39)18-43-26-15-9-8-14-24(26)37/h3-15,23,25,28-30,37-38,40H,16-19H2,1-2H3,(H,34,39)(H,35,41)/t23-,25+,28-,29-,30+/m0/s1
DM97STY	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM97STY	IK	ZHDZQXHOQVYYCG-OIRZSGMBSA-N
DM97STY	IU	(4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(2-hydroxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM97STY	DE	Discovery agent

DM4AUCE	ID	DM4AUCE
DM4AUCE	DN	KNI-10372
DM4AUCE	HS	Investigative
DM4AUCE	SN	KNI-10372; CHEMBL266256; BDBM50209565
DM4AUCE	DT	Small molecular drug
DM4AUCE	PC	44425666
DM4AUCE	MW	719.9
DM4AUCE	FM	C37H45N5O6S2
DM4AUCE	IC	InChI=1S/C37H45N5O6S2/c1-37(2)33(35(47)41-31-25-15-9-7-13-23(25)18-29(31)43)42(21-50-37)36(48)32(45)27(17-22-11-5-4-6-12-22)40-34(46)28(20-49-3)39-30(44)19-24-14-8-10-16-26(24)38/h4-16,27-29,31-33,43,45H,17-21,38H2,1-3H3,(H,39,44)(H,40,46)(H,41,47)/t27-,28-,29+,31-,32-,33+/m0/s1
DM4AUCE	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC=CC=C3N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM4AUCE	IK	JXPOIFQLOPSPRM-ACUZRORGSA-N
DM4AUCE	IU	(4R)-3-[(2S,3S)-3-[[(2R)-2-[[2-(2-aminophenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM4AUCE	DE	Discovery agent

DMEN2L3	ID	DMEN2L3
DMEN2L3	DN	KNI-10526
DMEN2L3	HS	Investigative
DMEN2L3	SN	KNI-10526; CHEMBL444759; BDBM50273750
DMEN2L3	DT	Small molecular drug
DMEN2L3	PC	44588320
DMEN2L3	MW	737.9
DMEN2L3	FM	C41H47N5O6S
DMEN2L3	IC	InChI=1S/C41H47N5O6S/c1-25-17-30(43-22-28-13-10-16-42-21-28)18-26(2)37(25)52-23-34(48)44-32(19-27-11-6-5-7-12-27)36(49)40(51)46-24-53-41(3,4)38(46)39(50)45-35-31-15-9-8-14-29(31)20-33(35)47/h5-18,21,32-33,35-36,38,43,47,49H,19-20,22-24H2,1-4H3,(H,44,48)(H,45,50)/t32-,33+,35-,36-,38+/m0/s1
DMEN2L3	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCC6=CN=CC=C6
DMEN2L3	IK	HBTCIJNHNMLBFP-CTRNRRKFSA-N
DMEN2L3	IU	(4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(pyridin-3-ylmethylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMEN2L3	DE	Discovery agent

DMU4K7O	ID	DMU4K7O
DMU4K7O	DN	KNI-10527
DMU4K7O	HS	Investigative
DMU4K7O	SN	KNI-10527; CHEMBL452725; BDBM50273751
DMU4K7O	DT	Small molecular drug
DMU4K7O	PC	44588321
DMU4K7O	MW	737.9
DMU4K7O	FM	C41H47N5O6S
DMU4K7O	IC	InChI=1S/C41H47N5O6S/c1-25-18-30(43-22-28-14-16-42-17-15-28)19-26(2)37(25)52-23-34(48)44-32(20-27-10-6-5-7-11-27)36(49)40(51)46-24-53-41(3,4)38(46)39(50)45-35-31-13-9-8-12-29(31)21-33(35)47/h5-19,32-33,35-36,38,43,47,49H,20-24H2,1-4H3,(H,44,48)(H,45,50)/t32-,33+,35-,36-,38+/m0/s1
DMU4K7O	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCC6=CC=NC=C6
DMU4K7O	IK	LZKUFQZJJUVPHA-CTRNRRKFSA-N
DMU4K7O	IU	(4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(pyridin-4-ylmethylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMU4K7O	DE	Discovery agent

DMDRWYG	ID	DMDRWYG
DMDRWYG	DN	KNI-10529
DMDRWYG	HS	Investigative
DMDRWYG	SN	KNI-10529; CHEMBL449918; BDBM50273746
DMDRWYG	DT	Small molecular drug
DMDRWYG	PC	44588317
DMDRWYG	MW	674.9
DMDRWYG	FM	C37H46N4O6S
DMDRWYG	IC	InChI=1S/C37H46N4O6S/c1-6-38-26-16-22(2)33(23(3)17-26)47-20-30(43)39-28(18-24-12-8-7-9-13-24)32(44)36(46)41-21-48-37(4,5)34(41)35(45)40-31-27-15-11-10-14-25(27)19-29(31)42/h7-17,28-29,31-32,34,38,42,44H,6,18-21H2,1-5H3,(H,39,43)(H,40,45)/t28-,29+,31-,32-,34+/m0/s1
DMDRWYG	CS	CCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMDRWYG	IK	MWCQAFKRDJYAQP-ZYOXRPPDSA-N
DMDRWYG	IU	(4R)-3-[(2S,3S)-3-[[2-[4-(ethylamino)-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMDRWYG	DE	Discovery agent

DM7XEIY	ID	DM7XEIY
DM7XEIY	DN	KNI-10538
DM7XEIY	HS	Investigative
DM7XEIY	SN	KNI-10538; CHEMBL508668; BDBM50273749; (R)-3-((2S,3S)-3-(2-(2,6-dimethyl-4-(pyridin-2-ylmethylamino)phenoxy)acetamido)-2-hydroxy-4-phenylbutanoyl)-N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-5,5-dimethylthiazolidine-4-carboxamide
DM7XEIY	DT	Small molecular drug
DM7XEIY	PC	25147781
DM7XEIY	MW	737.9
DM7XEIY	FM	C41H47N5O6S
DM7XEIY	IC	InChI=1S/C41H47N5O6S/c1-25-18-30(43-22-29-15-10-11-17-42-29)19-26(2)37(25)52-23-34(48)44-32(20-27-12-6-5-7-13-27)36(49)40(51)46-24-53-41(3,4)38(46)39(50)45-35-31-16-9-8-14-28(31)21-33(35)47/h5-19,32-33,35-36,38,43,47,49H,20-24H2,1-4H3,(H,44,48)(H,45,50)/t32-,33+,35-,36-,38+/m0/s1
DM7XEIY	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCC6=CC=CC=N6
DM7XEIY	IK	IEOXTIHUYRYEJG-CTRNRRKFSA-N
DM7XEIY	IU	(4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(pyridin-2-ylmethylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM7XEIY	DE	Discovery agent

DMLWOFY	ID	DMLWOFY
DMLWOFY	DN	KNI-10539
DMLWOFY	HS	Investigative
DMLWOFY	SN	KNI-10539; CHEMBL502445; BDBM50273747
DMLWOFY	DT	Small molecular drug
DMLWOFY	PC	44588318
DMLWOFY	MW	702.9
DMLWOFY	FM	C39H50N4O6S
DMLWOFY	IC	InChI=1S/C39H50N4O6S/c1-6-7-17-40-28-18-24(2)35(25(3)19-28)49-22-32(45)41-30(20-26-13-9-8-10-14-26)34(46)38(48)43-23-50-39(4,5)36(43)37(47)42-33-29-16-12-11-15-27(29)21-31(33)44/h8-16,18-19,30-31,33-34,36,40,44,46H,6-7,17,20-23H2,1-5H3,(H,41,45)(H,42,47)/t30-,31+,33-,34-,36+/m0/s1
DMLWOFY	CS	CCCCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMLWOFY	IK	YFOGAJAJKAWILS-SQKWSBCUSA-N
DMLWOFY	IU	(4R)-3-[(2S,3S)-3-[[2-[4-(butylamino)-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMLWOFY	DE	Discovery agent

DMP87U4	ID	DMP87U4
DMP87U4	DN	KNI-10541
DMP87U4	HS	Investigative
DMP87U4	SN	KNI-10541; CHEMBL507484; BDBM50273748
DMP87U4	DT	Small molecular drug
DMP87U4	PC	44588319
DMP87U4	MW	716.9
DMP87U4	FM	C40H52N4O6S
DMP87U4	IC	InChI=1S/C40H52N4O6S/c1-6-7-13-18-41-29-19-25(2)36(26(3)20-29)50-23-33(46)42-31(21-27-14-9-8-10-15-27)35(47)39(49)44-24-51-40(4,5)37(44)38(48)43-34-30-17-12-11-16-28(30)22-32(34)45/h8-12,14-17,19-20,31-32,34-35,37,41,45,47H,6-7,13,18,21-24H2,1-5H3,(H,42,46)(H,43,48)/t31-,32+,34-,35-,37+/m0/s1
DMP87U4	CS	CCCCCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMP87U4	IK	MLHPSGOBOHSFGF-IVJJLKHCSA-N
DMP87U4	IU	(4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(pentylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMP87U4	DE	Discovery agent

DMGUABP	ID	DMGUABP
DMGUABP	DN	KNI-10737
DMGUABP	HS	Investigative
DMGUABP	SN	KNI-10737; CHEMBL1209492; BDBM50323464
DMGUABP	DT	Small molecular drug
DMGUABP	PC	49862498
DMGUABP	MW	689.9
DMGUABP	FM	C37H47N5O6S
DMGUABP	IC	InChI=1S/C37H47N5O6S/c1-22-16-26(39-15-14-38)17-23(2)33(22)48-20-30(44)40-28(18-24-10-6-5-7-11-24)32(45)36(47)42-21-49-37(3,4)34(42)35(46)41-31-27-13-9-8-12-25(27)19-29(31)43/h5-13,16-17,28-29,31-32,34,39,43,45H,14-15,18-21,38H2,1-4H3,(H,40,44)(H,41,46)/t28-,29+,31-,32-,34+/m0/s1
DMGUABP	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCCN
DMGUABP	IK	KGNXIOMLRKTRJD-ZYOXRPPDSA-N
DMGUABP	IU	(4R)-3-[(2S,3S)-3-[[2-[4-(2-aminoethylamino)-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMGUABP	DE	Discovery agent

DMPWY6H	ID	DMPWY6H
DMPWY6H	DN	KNI-10740
DMPWY6H	HS	Investigative
DMPWY6H	SN	KNI-10740; CHEMBL1209496; BDBM50323468
DMPWY6H	DT	Small molecular drug
DMPWY6H	PC	49862502
DMPWY6H	MW	717.9
DMPWY6H	FM	C39H51N5O6S
DMPWY6H	IC	InChI=1S/C39H51N5O6S/c1-24-18-28(43(6)17-16-40-5)19-25(2)35(24)50-22-32(46)41-30(20-26-12-8-7-9-13-26)34(47)38(49)44-23-51-39(3,4)36(44)37(48)42-33-29-15-11-10-14-27(29)21-31(33)45/h7-15,18-19,30-31,33-34,36,40,45,47H,16-17,20-23H2,1-6H3,(H,41,46)(H,42,48)/t30-,31+,33-,34-,36+/m0/s1
DMPWY6H	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N(C)CCNC
DMPWY6H	IK	LDLOTPBPEFKMMQ-SQKWSBCUSA-N
DMPWY6H	IU	(4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-[methyl-[2-(methylamino)ethyl]amino]phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMPWY6H	DE	Discovery agent

DM7TW4C	ID	DM7TW4C
DM7TW4C	DN	KNI-10741
DM7TW4C	HS	Investigative
DM7TW4C	SN	KNI-10741; CHEMBL1209497; BDBM50323470
DM7TW4C	DT	Small molecular drug
DM7TW4C	PC	49862504
DM7TW4C	MW	717.9
DM7TW4C	FM	C39H51N5O6S
DM7TW4C	IC	InChI=1S/C39H51N5O6S/c1-6-40-16-17-41-28-18-24(2)35(25(3)19-28)50-22-32(46)42-30(20-26-12-8-7-9-13-26)34(47)38(49)44-23-51-39(4,5)36(44)37(48)43-33-29-15-11-10-14-27(29)21-31(33)45/h7-15,18-19,30-31,33-34,36,40-41,45,47H,6,16-17,20-23H2,1-5H3,(H,42,46)(H,43,48)/t30-,31+,33-,34-,36+/m0/s1
DM7TW4C	CS	CCNCCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DM7TW4C	IK	QWIMGFUQWCHOOH-SQKWSBCUSA-N
DM7TW4C	IU	(4R)-3-[(2S,3S)-3-[[2-[4-[2-(ethylamino)ethylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM7TW4C	DE	Discovery agent

DM4D9T3	ID	DM4D9T3
DM4D9T3	DN	KNI-10742
DM4D9T3	HS	Investigative
DM4D9T3	SN	KNI-10742; CHEMBL1209499; (4R)-3-[(2S,3S)-3-[2-[4-[2-azanylethyl(ethyl)amino]-2,6-dimethyl-phenoxy]ethanoylamino]-2-oxidanyl-4-phenyl-butanoyl]-5,5-dimethyl-N-[(1S,2R)-2-oxidanyl-2,3-dihydro-1H-inden-1-yl]-1,3-thiazolidine-4-carboxamide; BDBM50323472; 8VF
DM4D9T3	DT	Small molecular drug
DM4D9T3	PC	49862506
DM4D9T3	MW	717.9
DM4D9T3	FM	C39H51N5O6S
DM4D9T3	IC	InChI=1S/C39H51N5O6S/c1-6-43(17-16-40)28-18-24(2)35(25(3)19-28)50-22-32(46)41-30(20-26-12-8-7-9-13-26)34(47)38(49)44-23-51-39(4,5)36(44)37(48)42-33-29-15-11-10-14-27(29)21-31(33)45/h7-15,18-19,30-31,33-34,36,45,47H,6,16-17,20-23,40H2,1-5H3,(H,41,46)(H,42,48)/t30-,31+,33-,34-,36+/m0/s1
DM4D9T3	CS	CCN(CCN)C1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DM4D9T3	IK	QVEVEYWLPLMZQY-SQKWSBCUSA-N
DM4D9T3	IU	(4R)-3-[(2S,3S)-3-[[2-[4-[2-aminoethyl(ethyl)amino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM4D9T3	DE	Discovery agent

DM0VSPE	ID	DM0VSPE
DM0VSPE	DN	KNI-10743
DM0VSPE	HS	Investigative
DM0VSPE	SN	KNI-10743; CHEMBL1208799; (4R)-3-[(2S,3S)-3-[2-[4-[2-(dimethylamino)ethyl-methyl-amino]-2,6-dimethyl-phenoxy]ethanoylamino]-2-oxidanyl-4-phenyl-butanoyl]-5,5-dimethyl-N-[(1S,2R)-2-oxidanyl-2,3-dihydro-1H-inden-1-yl]-1,3-thiazolidine-4-carboxamide; BDBM50323469; (R)-3-((2S,3S)-3-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2,6-dimethylphenoxy)acetamido)-2-hydroxy-4-phenylbutanoyl)-N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-5,5-dimethylthiazolidine-4-carboxamide
DM0VSPE	DT	Small molecular drug
DM0VSPE	PC	49862503
DM0VSPE	MW	731.9
DM0VSPE	FM	C40H53N5O6S
DM0VSPE	IC	InChI=1S/C40H53N5O6S/c1-25-19-29(44(7)18-17-43(5)6)20-26(2)36(25)51-23-33(47)41-31(21-27-13-9-8-10-14-27)35(48)39(50)45-24-52-40(3,4)37(45)38(49)42-34-30-16-12-11-15-28(30)22-32(34)46/h8-16,19-20,31-32,34-35,37,46,48H,17-18,21-24H2,1-7H3,(H,41,47)(H,42,49)/t31-,32+,34-,35-,37+/m0/s1
DM0VSPE	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N(C)CCN(C)C
DM0VSPE	IK	IZETWNQXMIHLNU-IVJJLKHCSA-N
DM0VSPE	IU	(4R)-3-[(2S,3S)-3-[[2-[4-[2-(dimethylamino)ethyl-methylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM0VSPE	DE	Discovery agent

DMM2A5Q	ID	DMM2A5Q
DMM2A5Q	DN	KNI-10758
DMM2A5Q	HS	Investigative
DMM2A5Q	SN	KNI-10758; CHEMBL1209500; BDBM50323473
DMM2A5Q	DT	Small molecular drug
DMM2A5Q	PC	49862507
DMM2A5Q	MW	746
DMM2A5Q	FM	C41H55N5O6S
DMM2A5Q	IC	InChI=1S/C41H55N5O6S/c1-7-42-18-19-45(8-2)30-20-26(3)37(27(4)21-30)52-24-34(48)43-32(22-28-14-10-9-11-15-28)36(49)40(51)46-25-53-41(5,6)38(46)39(50)44-35-31-17-13-12-16-29(31)23-33(35)47/h9-17,20-21,32-33,35-36,38,42,47,49H,7-8,18-19,22-25H2,1-6H3,(H,43,48)(H,44,50)/t32-,33+,35-,36-,38+/m0/s1
DMM2A5Q	CS	CCNCCN(CC)C1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMM2A5Q	IK	TYAUZZDMTCDBHN-CTRNRRKFSA-N
DMM2A5Q	IU	(4R)-3-[(2S,3S)-3-[[2-[4-[ethyl-[2-(ethylamino)ethyl]amino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMM2A5Q	DE	Discovery agent

DMAF1W3	ID	DMAF1W3
DMAF1W3	DN	KNI-10759
DMAF1W3	HS	Investigative
DMAF1W3	SN	KNI-10759; CHEMBL1209501; BDBM50323474
DMAF1W3	DT	Small molecular drug
DMAF1W3	PC	49862508
DMAF1W3	MW	774
DMAF1W3	FM	C43H59N5O6S
DMAF1W3	IC	InChI=1S/C43H59N5O6S/c1-8-46(9-2)20-21-47(10-3)32-22-28(4)39(29(5)23-32)54-26-36(50)44-34(24-30-16-12-11-13-17-30)38(51)42(53)48-27-55-43(6,7)40(48)41(52)45-37-33-19-15-14-18-31(33)25-35(37)49/h11-19,22-23,34-35,37-38,40,49,51H,8-10,20-21,24-27H2,1-7H3,(H,44,50)(H,45,52)/t34-,35+,37-,38-,40+/m0/s1
DMAF1W3	CS	CCN(CC)CCN(CC)C1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMAF1W3	IK	FEJYRCRZYXAOJX-MQKWNYJDSA-N
DMAF1W3	IU	(4R)-3-[(2S,3S)-3-[[2-[4-[2-(diethylamino)ethyl-ethylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMAF1W3	DE	Discovery agent

DMT5FIP	ID	DMT5FIP
DMT5FIP	DN	KNI-10760
DMT5FIP	HS	Investigative
DMT5FIP	SN	KNI-10760; CHEMBL1209498; BDBM50323471
DMT5FIP	DT	Small molecular drug
DMT5FIP	PC	49862505
DMT5FIP	MW	746
DMT5FIP	FM	C41H55N5O6S
DMT5FIP	IC	InChI=1S/C41H55N5O6S/c1-7-45(8-2)19-18-42-30-20-26(3)37(27(4)21-30)52-24-34(48)43-32(22-28-14-10-9-11-15-28)36(49)40(51)46-25-53-41(5,6)38(46)39(50)44-35-31-17-13-12-16-29(31)23-33(35)47/h9-17,20-21,32-33,35-36,38,42,47,49H,7-8,18-19,22-25H2,1-6H3,(H,43,48)(H,44,50)/t32-,33+,35-,36-,38+/m0/s1
DMT5FIP	CS	CCN(CC)CCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMT5FIP	IK	MOXFYRJTMGBJQV-CTRNRRKFSA-N
DMT5FIP	IU	(4R)-3-[(2S,3S)-3-[[2-[4-[2-(diethylamino)ethylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMT5FIP	DE	Discovery agent

DMXUTWZ	ID	DMXUTWZ
DMXUTWZ	DN	KNI-10761
DMXUTWZ	HS	Investigative
DMXUTWZ	SN	KNI-10761; CHEMBL1209494; BDBM50323466
DMXUTWZ	DT	Small molecular drug
DMXUTWZ	PC	49862500
DMXUTWZ	MW	717.9
DMXUTWZ	FM	C39H51N5O6S
DMXUTWZ	IC	InChI=1S/C39H51N5O6S/c1-24-18-28(40-16-17-43(5)6)19-25(2)35(24)50-22-32(46)41-30(20-26-12-8-7-9-13-26)34(47)38(49)44-23-51-39(3,4)36(44)37(48)42-33-29-15-11-10-14-27(29)21-31(33)45/h7-15,18-19,30-31,33-34,36,40,45,47H,16-17,20-23H2,1-6H3,(H,41,46)(H,42,48)/t30-,31+,33-,34-,36+/m0/s1
DMXUTWZ	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCCN(C)C
DMXUTWZ	IK	MXFYEUZYULOCTL-SQKWSBCUSA-N
DMXUTWZ	IU	(4R)-3-[(2S,3S)-3-[[2-[4-[2-(dimethylamino)ethylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMXUTWZ	DE	Discovery agent

DM73WB2	ID	DM73WB2
DM73WB2	DN	KNI-10762
DM73WB2	HS	Investigative
DM73WB2	SN	KNI-10762; CHEMBL1209495; BDBM50323467
DM73WB2	DT	Small molecular drug
DM73WB2	PC	49862501
DM73WB2	MW	703.9
DM73WB2	FM	C38H49N5O6S
DM73WB2	IC	InChI=1S/C38H49N5O6S/c1-23-17-27(42(5)16-15-39)18-24(2)34(23)49-21-31(45)40-29(19-25-11-7-6-8-12-25)33(46)37(48)43-22-50-38(3,4)35(43)36(47)41-32-28-14-10-9-13-26(28)20-30(32)44/h6-14,17-18,29-30,32-33,35,44,46H,15-16,19-22,39H2,1-5H3,(H,40,45)(H,41,47)/t29-,30+,32-,33-,35+/m0/s1
DM73WB2	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N(C)CCN
DM73WB2	IK	DQMDEHSLPXZFSC-WLYLRDIASA-N
DM73WB2	IU	(4R)-3-[(2S,3S)-3-[[2-[4-[2-aminoethyl(methyl)amino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM73WB2	DE	Discovery agent

DMKAY5G	ID	DMKAY5G
DMKAY5G	DN	KNI-10763
DMKAY5G	HS	Investigative
DMKAY5G	SN	KNI-10763; CHEMBL1209493; BDBM50323465
DMKAY5G	DT	Small molecular drug
DMKAY5G	PC	49862499
DMKAY5G	MW	703.9
DMKAY5G	FM	C38H49N5O6S
DMKAY5G	IC	InChI=1S/C38H49N5O6S/c1-23-17-27(40-16-15-39-5)18-24(2)34(23)49-21-31(45)41-29(19-25-11-7-6-8-12-25)33(46)37(48)43-22-50-38(3,4)35(43)36(47)42-32-28-14-10-9-13-26(28)20-30(32)44/h6-14,17-18,29-30,32-33,35,39-40,44,46H,15-16,19-22H2,1-5H3,(H,41,45)(H,42,47)/t29-,30+,32-,33-,35+/m0/s1
DMKAY5G	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCCNC
DMKAY5G	IK	MGDBCLMLZKHXCE-WLYLRDIASA-N
DMKAY5G	IU	(4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-[2-(methylamino)ethylamino]phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMKAY5G	DE	Discovery agent

DMZX430	ID	DMZX430
DMZX430	DN	KNI-1293
DMZX430	HS	Investigative
DMZX430	SN	KNI-1293; CHEMBL466535; (R)-N-[(1S,2R)-2-Hydroxyindan-1-yl]-3-[(2S,3S)-3-(4-amino-2,6-dimethyphenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide; BDBM50273743; (R)-N-[(1S,2R)-2-Hydroxyindan-1-yl]-3-[(2S,3S)-3-(4-amino-2,6-dimethylphenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMZX430	DT	Small molecular drug
DMZX430	PC	44588315
DMZX430	MW	646.8
DMZX430	FM	C35H42N4O6S
DMZX430	IC	InChI=1S/C35H42N4O6S/c1-20-14-24(36)15-21(2)31(20)45-18-28(41)37-26(16-22-10-6-5-7-11-22)30(42)34(44)39-19-46-35(3,4)32(39)33(43)38-29-25-13-9-8-12-23(25)17-27(29)40/h5-15,26-27,29-30,32,40,42H,16-19,36H2,1-4H3,(H,37,41)(H,38,43)/t26-,27+,29-,30-,32+/m0/s1
DMZX430	CS	CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N
DMZX430	IK	ABHNHNZCHPWXFW-RIQJEONASA-N
DMZX430	IU	(4R)-3-[(2S,3S)-3-[[2-(4-amino-2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMZX430	DE	Discovery agent

DMS61DB	ID	DMS61DB
DMS61DB	DN	KNI-227
DMS61DB	HS	Investigative
DMS61DB	SN	Kynostatin 227; Kni-227; Kynostatin-227; 147384-69-8; CHEMBL231622; KYNOSTATIN; Qoa-Mta-Apns-Thz-NH-tBu; AC1L22EK; AC1Q5L2G; BDBM719; SCHEMBL2772022; DTXSID30163692; N-(1,1-Dimethylethyl)-3-[2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3-methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-5,5-dimethyl]-4-thiazolidinecarboxamide,[4R-[3[2S*,3S*(R*)],4R*]]; (4R)-N-tert-Butyl-3-[(2S,3S)-2-hydroxy-3-[S-methyl-N-(5-isoquinolinyloxyacetyl)-L-cysteinylamino]-4-phenylbutyryl]-5,5-dimethylthiazolidine-4alpha-carboxamide
DMS61DB	DT	Small molecular drug
DMS61DB	PC	65012
DMS61DB	MW	695.9
DMS61DB	FM	C35H45N5O6S2
DMS61DB	IC	InChI=1S/C35H45N5O6S2/c1-34(2,3)39-32(44)30-35(4,5)48-21-40(30)33(45)29(42)25(17-22-11-8-7-9-12-22)38-31(43)26(20-47-6)37-28(41)19-46-27-14-10-13-23-18-36-16-15-24(23)27/h7-16,18,25-26,29-30,42H,17,19-21H2,1-6H3,(H,37,41)(H,38,43)(H,39,44)/t25-,26-,29-,30+/m0/s1
DMS61DB	CS	CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC4=C3C=CN=C4)O)C(=O)NC(C)(C)C)C
DMS61DB	IK	AHWCYDXQIXZVRK-RPQLRNILSA-N
DMS61DB	IU	(4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[(2-isoquinolin-5-yloxyacetyl)amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMS61DB	CA	CAS 147384-69-8
DMS61DB	DE	Discovery agent

DM105NU	ID	DM105NU
DM105NU	DN	KNI-727
DM105NU	HS	Investigative
DM105NU	SN	KNI-727; KNI 727; 189357-33-3; JE-1482; N-(3-((4R)-4-(N-(tert-Butyl)carbamoyl)-5,5-dimethyl(1,3-thiazolidin-3-yl))(1S,2S)-2-hydroxy-3-oxo-1-benzylpropyl)-2-(2,6-dimethylphenoxy)acetamide; Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[(2S,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-1-oxo-4-phenylbutyl]-5,5-dimethyl-, (4R)-; N-(3-{(4R)-4-[N-(tert-Butyl)carbamoyl]-5,5-dimethyl(1,3-thiazolidin-3-yl)}(1S,2S)-2-hydroxy-3-oxo-1-benzylpropyl)-2-(2,6-dimethylphenoxy)acetamide
DM105NU	DT	Small molecular drug
DM105NU	PC	451416
DM105NU	MW	555.7
DM105NU	FM	C30H41N3O5S
DM105NU	IC	InChI=1S/C30H41N3O5S/c1-19-12-11-13-20(2)25(19)38-17-23(34)31-22(16-21-14-9-8-10-15-21)24(35)28(37)33-18-39-30(6,7)26(33)27(36)32-29(3,4)5/h8-15,22,24,26,35H,16-18H2,1-7H3,(H,31,34)(H,32,36)/t22-,24-,26+/m0/s1
DM105NU	CS	CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)NC(C)(C)C)(C)C)O
DM105NU	IK	CSWRAOHDICNMPU-LLZJGCNPSA-N
DM105NU	IU	(4R)-N-tert-butyl-3-[(2S,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM105NU	CA	CAS 189357-33-3
DM105NU	DE	Discovery agent

DMZF3E9	ID	DMZF3E9
DMZF3E9	DN	KNT-5
DMZF3E9	HS	Investigative
DMZF3E9	SN	KNT-5
DMZF3E9	DT	Small molecular drug
DMZF3E9	PC	46232162
DMZF3E9	MW	391.9
DMZF3E9	FM	C21H26ClNO4
DMZF3E9	IC	InChI=1S/C21H25NO4.ClH/c1-22(11-12-2-3-12)16-10-13-4-5-14(23)18-17(13)20-8-9-25-21(16,20)7-6-15(24)19(20)26-18;/h4-5,12,16,19,23H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-;/m1./s1
DMZF3E9	CS	CN(CC1CC1)[C@@H]2CC3=C4C(=C(C=C3)O)O[C@@H]5[C@@]46[C@]2(CCC5=O)OCC6.Cl
DMZF3E9	IK	BJCCGWJRMXDEPD-OPHZJPRHSA-N
DMZF3E9	IU	(1S,5R,13S,17R)-17-[cyclopropylmethyl(methyl)amino]-8-hydroxy-6,16-dioxapentacyclo[9.5.2.01,13.05,13.07,12]octadeca-7,9,11-trien-4-one;hydrochloride
DMZF3E9	DE	Discovery agent

DM9M5HC	ID	DM9M5HC
DM9M5HC	DN	KNT-62
DM9M5HC	HS	Investigative
DM9M5HC	SN	CHEMBL594654
DM9M5HC	DT	Small molecular drug
DM9M5HC	PC	46906981
DM9M5HC	MW	474.5
DM9M5HC	FM	C28H30N2O5
DM9M5HC	IC	InChI=1S/C28H30N2O5/c31-19-9-8-17-14-20-28-11-10-27(33,23(35-28)24(32)29-18-4-2-1-3-5-18)25-26(28,21(17)22(19)34-25)12-13-30(20)15-16-6-7-16/h1-5,8-9,16,20,23,25,31,33H,6-7,10-15H2,(H,29,32)/t20-,23+,25-,26+,27+,28-/m1/s1
DM9M5HC	CS	C1CC1CN2CC[C@]34[C@@H]5[C@@]6(CC[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O[C@H]6C(=O)NC8=CC=CC=C8)O
DM9M5HC	IK	YYNRSCGPLWDLNI-VQBGKWCDSA-N
DM9M5HC	IU	(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-11,15-dihydroxy-N-phenyl-13,17-dioxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-triene-16-carboxamide
DM9M5HC	DE	Discovery agent

DM0U5N9	ID	DM0U5N9
DM0U5N9	DN	KNT-63
DM0U5N9	HS	Investigative
DM0U5N9	SN	CHEMBL593980
DM0U5N9	DT	Small molecular drug
DM0U5N9	PC	46225291
DM0U5N9	MW	474.5
DM0U5N9	FM	C28H30N2O5
DM0U5N9	IC	InChI=1S/C28H30N2O5/c31-19-9-8-17-14-20-28-11-10-27(33,23(35-28)24(32)29-18-4-2-1-3-5-18)25-26(28,21(17)22(19)34-25)12-13-30(20)15-16-6-7-16/h1-5,8-9,16,20,23,25,31,33H,6-7,10-15H2,(H,29,32)/t20-,23+,25+,26-,27-,28+/m0/s1
DM0U5N9	CS	C1CC1CN2CC[C@]34[C@@H]5[C@@]6(CC[C@]3([C@@H]2CC7=C4C(=C(C=C7)O)O5)O[C@@H]6C(=O)NC8=CC=CC=C8)O
DM0U5N9	IK	YYNRSCGPLWDLNI-PEBCJGEWSA-N
DM0U5N9	IU	(1S,2S,6S,14R,15R,16S)-5-(cyclopropylmethyl)-11,15-dihydroxy-N-phenyl-13,17-dioxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-triene-16-carboxamide
DM0U5N9	DE	Discovery agent

DMNWXCA	ID	DMNWXCA
DMNWXCA	DN	KNX-Monoclonal204
DMNWXCA	HS	Investigative
DMNWXCA	SN	KNX-Monoclonal205; KNX-Monoclonal205); Passive immunotherapy (Alzheimers disease), Kinexis
DMNWXCA	CP	University of California Irvine
DMNWXCA	DT	Antibody
DMNWXCA	DE	Alzheimer disease

DMVGNZJ	ID	DMVGNZJ
DMVGNZJ	DN	KO-286011
DMVGNZJ	HS	Investigative
DMVGNZJ	SN	132657-47-7
DMVGNZJ	DT	Small molecular drug
DMVGNZJ	PC	131539
DMVGNZJ	MW	600.8
DMVGNZJ	FM	C32H61N2O6P
DMVGNZJ	IC	InChI=1S/C32H61N2O6P/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-20-27-37-29-32(38-6-2)30-40-41(35,36)39-28-21-19-24-34-25-22-31(23-26-34)33(3)4/h22-23,25-26,32H,5-21,24,27-30H2,1-4H3
DMVGNZJ	CS	CCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCCCC[N+]1=CC=C(C=C1)N(C)C)OCC
DMVGNZJ	IK	ZVLFCHBGXDQHSD-UHFFFAOYSA-N
DMVGNZJ	IU	4-[4-(dimethylamino)pyridin-1-ium-1-yl]butyl (2-ethoxy-3-hexadecoxypropyl) phosphate
DMVGNZJ	CA	CAS 132657-47-7
DMVGNZJ	DE	Discovery agent

DMAJKRX	ID	DMAJKRX
DMAJKRX	DN	Kodaistatin A
DMAJKRX	HS	Investigative
DMAJKRX	SN	Kodaistatin A
DMAJKRX	DT	Small molecular drug
DMAJKRX	PC	54708847
DMAJKRX	MW	630.6
DMAJKRX	FM	C35H34O11
DMAJKRX	IC	InChI=1S/C35H34O11/c1-5-17(2)12-18(3)6-9-22(38)14-25-30(35(45,19(4)36)33(43)31(25)41)24-16-27(40)26(39)15-23(24)29-32(42)28(46-34(29)44)13-20-7-10-21(37)11-8-20/h6-13,15-17,33,37,39-40,42-43,45H,5,14H2,1-4H3/b9-6+,18-12+,28-13-
DMAJKRX	CS	CCC(C)/C=C(\\C)/C=C/C(=O)CC1=C(C(C(C1=O)O)(C(=O)C)O)C2=CC(=C(C=C2C3=C(/C(=C/C4=CC=C(C=C4)O)/OC3=O)O)O)O
DMAJKRX	IK	YACYONYLJTYMLP-AIXQLNHRSA-N
DMAJKRX	IU	(5Z)-3-[2-[5-acetyl-2-[(3E,5E)-5,7-dimethyl-2-oxonona-3,5-dienyl]-4,5-dihydroxy-3-oxocyclopenten-1-yl]-4,5-dihydroxyphenyl]-4-hydroxy-5-[(4-hydroxyphenyl)methylidene]furan-2-one
DMAJKRX	DE	Discovery agent

DM72WQ3	ID	DM72WQ3
DM72WQ3	DN	Kodaistatin C
DM72WQ3	HS	Investigative
DM72WQ3	PC	54721310
DM72WQ3	MW	646.6
DM72WQ3	FM	C35H34O12
DM72WQ3	IC	InChI=1S/C35H34O12/c1-5-16(2)10-17(3)6-8-20(37)13-23-30(35(46,18(4)36)33(44)31(23)42)22-15-27(41)26(40)14-21(22)29-32(43)28(47-34(29)45)12-19-7-9-24(38)25(39)11-19/h6-12,14-16,33,38-41,43-44,46H,5,13H2,1-4H3/b8-6+,17-10+,28-12-
DM72WQ3	CS	CCC(C)/C=C(\\C)/C=C/C(=O)CC1=C(C(C(C1=O)O)(C(=O)C)O)C2=CC(=C(C=C2C3=C(/C(=C/C4=CC(=C(C=C4)O)O)/OC3=O)O)O)O
DM72WQ3	IK	KFMTUTLQSGURRM-MARNYXESSA-N
DM72WQ3	IU	(5Z)-3-[2-[5-acetyl-2-[(3E,5E)-5,7-dimethyl-2-oxonona-3,5-dienyl]-4,5-dihydroxy-3-oxocyclopenten-1-yl]-4,5-dihydroxyphenyl]-5-[(3,4-dihydroxyphenyl)methylidene]-4-hydroxyfuran-2-one
DM72WQ3	DE	Discovery agent

DMP84CS	ID	DMP84CS
DMP84CS	DN	KOJIC ACID
DMP84CS	HS	Investigative
DMP84CS	SN	kojic acid; 501-30-4; 5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 5-Hydroxy-2-(hydroxymethyl)-4-pyrone; 5-Hydroxy-2-hydroxymethyl-4-pyrone; 4H-PYRAN-4-ONE, 5-HYDROXY-2-(HYDROXYMETHYL)-; 5-hydroxy-2-(hydroxymethyl)pyran-4-one; acido kojico; 2-Hydroxymethyl-5-hydroxy-gamma-pyrone; 2-(Hydroxymethyl)-5-hydroxy-4H-pyran-4-one; UNII-6K23F1TT52; CCRIS 4131; 5-Hydroxy-2-hydroxymethyl-4H-4-pyranone; NSC 1942; EINECS 207-922-4; BRN 0120895; Pyran-4-one, 5-hydroxy-2-(hydroxymethyl); 5-Hydroxy-2-hydroxymethyl-4H-pyran-4-one; AI3-02549
DMP84CS	DT	Small molecular drug
DMP84CS	PC	3840
DMP84CS	MW	142.11
DMP84CS	FM	C6H6O4
DMP84CS	IC	InChI=1S/C6H6O4/c7-2-4-1-5(8)6(9)3-10-4/h1,3,7,9H,2H2
DMP84CS	CS	C1=C(OC=C(C1=O)O)CO
DMP84CS	IK	BEJNERDRQOWKJM-UHFFFAOYSA-N
DMP84CS	IU	5-hydroxy-2-(hydroxymethyl)pyran-4-one
DMP84CS	CA	CAS 501-30-4
DMP84CS	CB	CHEBI:43572
DMP84CS	DE	Discovery agent

DMRB1AT	ID	DMRB1AT
DMRB1AT	DN	Kojic acid-phenylalanine amide
DMRB1AT	HS	Investigative
DMRB1AT	SN	Kojic acid-phenylalanine amide; CHEMBL573709
DMRB1AT	DT	Small molecular drug
DMRB1AT	PC	45482673
DMRB1AT	MW	332.31
DMRB1AT	FM	C16H16N2O6
DMRB1AT	IC	InChI=1S/C16H16N2O6/c17-15(21)12(6-10-4-2-1-3-5-10)18-16(22)24-8-11-7-13(19)14(20)9-23-11/h1-5,7,9,12,20H,6,8H2,(H2,17,21)(H,18,22)/t12-/m0/s1
DMRB1AT	CS	C1=CC=C(C=C1)C[C@@H](C(=O)N)NC(=O)OCC2=CC(=O)C(=CO2)O
DMRB1AT	IK	FIDUCYJXWXTROD-LBPRGKRZSA-N
DMRB1AT	IU	(5-hydroxy-4-oxopyran-2-yl)methyl N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]carbamate
DMRB1AT	DE	Discovery agent

DMYDGA7	ID	DMYDGA7
DMYDGA7	DN	KOS1326
DMYDGA7	HS	Investigative
DMYDGA7	SN	4'' deoxy EM-A enolether
DMYDGA7	DT	Small molecular drug
DMYDGA7	PC	10259168
DMYDGA7	MW	699.9
DMYDGA7	FM	C37H65NO11
DMYDGA7	IC	InChI=1S/C37H65NO11/c1-14-26-37(10,42)31(40)22(5)29-19(2)16-36(9,49-29)32(48-34-28(39)25(38(11)12)15-20(3)45-34)23(6)30(24(7)33(41)46-26)47-27-18-35(8,43-13)17-21(4)44-27/h20-28,30-32,34,39-40,42H,14-18H2,1-13H3/t20-,21+,22+,23+,24-,25+,26-,27+,28-,30+,31-,32-,34+,35+,36-,37-/m1/s1
DMYDGA7	CS	CC[C@@H]1[C@@]([C@@H]([C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@](C[C@@H](O3)C)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)C)C)C)O)(C)O
DMYDGA7	IK	UJUXMUPAZCCNTJ-ANUGEFLXSA-N
DMYDGA7	IU	(2R,3R,4S,5R,8R,9S,10S,11R,12R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-ethyl-3,4-dihydroxy-9-[(2S,4S,6S)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DMYDGA7	DE	Discovery agent

DM1SKNP	ID	DM1SKNP
DM1SKNP	DN	KOSN1559
DM1SKNP	HS	Investigative
DM1SKNP	CP	Kosan Bioscience
DM1SKNP	TC	Anticancer Agents
DM1SKNP	DE	Solid tumour/cancer

DMT1H9Z	ID	DMT1H9Z
DMT1H9Z	DN	KOTALANOL
DMT1H9Z	HS	Investigative
DMT1H9Z	SN	Kotalanol; 214491-07-3; CHEMBL1093264; (1S,2R,3R,4S)-1-{(1S)-2-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrothiophenium-1-yl]-1-hydroxyethyl}-2,3,4,5-tetrahydroxypentyl sulfate; CHEMBL1233894; DTXSID10655282; BDBM50316179; FT-0670687; 1,4-Dideoxy-1,4-[(S)-[7-deoxy-5-O-sulfo-D-glycero-D-galacto-heptitol-7-yl]episulfoniumylidene]-D-arabinitol Inner Salt; 1,4-Dideoxy-1,4-[[2S,3S,4R,5R,6S-2,4,5,6,7-pentahydroxy-3-(sulfooxy)heptyl]-(R-)epi-sulfoniumylidine]-D-arabinitol
DMT1H9Z	DT	Small molecular drug
DMT1H9Z	PC	42632210
DMT1H9Z	MW	424.4
DMT1H9Z	FM	C12H24O12S2
DMT1H9Z	IC	InChI=1S/C12H24O12S2/c13-1-5(15)10(19)11(20)12(24-26(21,22)23)7(17)4-25-3-6(16)9(18)8(25)2-14/h5-20H,1-4H2/t5-,6+,7+,8+,9-,10+,11+,12+,25?/m0/s1
DMT1H9Z	CS	C1[C@H]([C@@H]([C@H]([S+]1C[C@H]([C@H]([C@@H]([C@@H]([C@H](CO)O)O)O)OS(=O)(=O)[O-])O)CO)O)O
DMT1H9Z	IK	OMKXVFDVAGCPBS-GTEYUELZSA-N
DMT1H9Z	IU	[(2S,3S,4R,5R,6S)-1-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-2,4,5,6,7-pentahydroxyheptan-3-yl] sulfate
DMT1H9Z	CA	CAS 214491-07-3
DMT1H9Z	DE	Discovery agent

DMUZSJ2	ID	DMUZSJ2
DMUZSJ2	DN	KP772
DMUZSJ2	HS	Investigative
DMUZSJ2	DE	Discovery agent

DMC4YGT	ID	DMC4YGT
DMC4YGT	DN	KR-33889
DMC4YGT	HS	Investigative
DMC4YGT	SN	KR-34285; PARP-1 inhibitors (myocardial infarction), KRICT
DMC4YGT	CP	Korea Research Institute of Chemical Technology
DMC4YGT	DE	Myocardial infarction

DMIEKJ4	ID	DMIEKJ4
DMIEKJ4	DN	KR61639
DMIEKJ4	HS	Investigative
DMIEKJ4	DT	Small molecular drug
DMIEKJ4	PC	56603772
DMIEKJ4	MW	495.6
DMIEKJ4	FM	C31H29NO5
DMIEKJ4	IC	InChI=1S/C31H29NO5/c1-31(2,3)37-27(33)18-36-20-14-12-19(13-15-20)16-24-28(25-17-32-26-11-7-6-8-21(25)26)22-9-4-5-10-23(22)29(34)30(24)35/h4-15,17,21,26,32H,16,18H2,1-3H3
DMIEKJ4	CS	CC(C)(C)OC(=O)COC1=CC=C(C=C1)CC2=C(C3=CC=CC=C3C(=O)C2=O)C4=CNC5C4C=CC=C5
DMIEKJ4	IK	FUPVNXIRQSPKMZ-UHFFFAOYSA-N
DMIEKJ4	IU	tert-butyl 2-[4-[[1-(3a,7a-dihydro-1H-indol-3-yl)-3,4-dioxonaphthalen-2-yl]methyl]phenoxy]acetate
DMIEKJ4	DE	Discovery agent

DM7G8KR	ID	DM7G8KR
DM7G8KR	DN	KR-62436
DM7G8KR	HS	Investigative
DM7G8KR	SN	KR-62436; CHEMBL184651; 761414-79-3; KR-60436 free base; SCHEMBL1083441; AOB5513; BDBM50150854; NCGC00165817-01; 6-{2-[2-(5-Cyano-4,5-dihydro-pyrazol-1-yl)-2-oxo-ethylamino]-ethylamino}-nicotinonitrile; 6-(2-(2-(5-cyano-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethylamino)ethylamino)nicotinonitrile; 3-Pyridinecarbonitrile, 6-((2-((2-(5-cyano-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethyl)amino)ethyl)amino)-; 1H-Pyrazole-5-carbonitrile, 1-(((2-((5-cyano-2-pyridinyl)amino)ethyl)amino)acetyl)-4,5-dihydro-
DM7G8KR	DT	Small molecular drug
DM7G8KR	PC	11403745
DM7G8KR	MW	297.32
DM7G8KR	FM	C14H15N7O
DM7G8KR	IC	InChI=1S/C14H15N7O/c15-7-11-1-2-13(19-9-11)18-6-5-17-10-14(22)21-12(8-16)3-4-20-21/h1-2,4,9,12,17H,3,5-6,10H2,(H,18,19)
DM7G8KR	CS	C1C=NN(C1C#N)C(=O)CNCCNC2=NC=C(C=C2)C#N
DM7G8KR	IK	XNYVGGJJENHRBZ-UHFFFAOYSA-N
DM7G8KR	IU	6-[2-[[2-(3-cyano-3,4-dihydropyrazol-2-yl)-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile
DM7G8KR	CA	CAS 761414-79-3
DM7G8KR	DE	Non-insulin dependent diabetes

DMXFBER	ID	DMXFBER
DMXFBER	DN	KRH-102053
DMXFBER	HS	Investigative
DMXFBER	SN	PHD2 activators (hypoxic cancer), Chonbuk National University/SK Chemicals
DMXFBER	CP	Chonbuk National University
DMXFBER	DE	Solid tumour/cancer

DMLIK7X	ID	DMLIK7X
DMLIK7X	DN	KRP 203-phosphate
DMLIK7X	HS	Investigative
DMLIK7X	SN	GTPL2923; SCHEMBL20478074; [2-amino-2-(2-{2-chloro-4-[(3-phenoxyphenyl)sulfanyl]phenyl}ethyl)-3-hydroxypropoxy]phosphonic acid
DMLIK7X	DT	Small molecular drug
DMLIK7X	PC	56947075
DMLIK7X	MW	509.9
DMLIK7X	FM	C23H25ClNO6PS
DMLIK7X	IC	InChI=1S/C23H25ClNO6PS/c24-22-14-21(10-9-17(22)11-12-23(25,15-26)16-30-32(27,28)29)33-20-8-4-7-19(13-20)31-18-5-2-1-3-6-18/h1-10,13-14,26H,11-12,15-16,25H2,(H2,27,28,29)
DMLIK7X	CS	C1=CC=C(C=C1)OC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(COP(=O)(O)O)N)Cl
DMLIK7X	IK	BZVUYJGCYLMFGX-UHFFFAOYSA-N
DMLIK7X	IU	[2-amino-4-[2-chloro-4-(3-phenoxyphenyl)sulfanylphenyl]-2-(hydroxymethyl)butyl] dihydrogen phosphate
DMLIK7X	DE	Discovery agent

DMJX9E1	ID	DMJX9E1
DMJX9E1	DN	KRP-100
DMJX9E1	HS	Investigative
DMJX9E1	SN	Mu opioid receptor antagonist, Kyorin
DMJX9E1	CP	Kyorin Holdings Inc
DMJX9E1	DE	Discovery agent

DM5KFBP	ID	DM5KFBP
DM5KFBP	DN	KRP-107
DM5KFBP	HS	Investigative
DM5KFBP	CP	Kyorin Pharmaceutical Co Ltd
DM5KFBP	DE	Autoimmune diabetes

DME9HZC	ID	DME9HZC
DME9HZC	DN	KRP-110
DME9HZC	HS	Investigative
DME9HZC	SN	IDDBCP262221
DME9HZC	CP	Kyorin Pharmaceutical Co Ltd
DME9HZC	DE	Constipation

DMC92ER	ID	DMC92ER
DMC92ER	DN	KSG-504
DMC92ER	HS	Investigative
DMC92ER	SN	4(R)-[N-(3-Methoxypropyl)-N-pentylcarbamoyl]-5-(2-naphthylsulfonyl)pentanoic acid L-arginine salt monohydrate
DMC92ER	DT	Small molecular drug
DMC92ER	PC	74030547
DMC92ER	MW	669.8
DMC92ER	FM	C31H51N5O9S
DMC92ER	IC	InChI=1S/C25H35NO6S.C6H14N4O2.H2O/c1-3-4-7-15-26(16-8-17-32-2)25(29)22(12-14-24(27)28)19-33(30,31)23-13-11-20-9-5-6-10-21(20)18-23;7-4(5(11)12)2-1-3-10-6(8)9;/h5-6,9-11,13,18,22H,3-4,7-8,12,14-17,19H2,1-2H3,(H,27,28);4H,1-3,7H2,(H,11,12)(H4,8,9,10);1H2
DMC92ER	CS	CCCCCN(CCCOC)C(=O)C(CCC(=O)O)CS(=O)(=O)C1=CC2=CC=CC=C2C=C1.C(CC(C(=O)O)N)CN=C(N)N.O
DMC92ER	IK	XIGWXYNWZKIGCQ-UHFFFAOYSA-N
DMC92ER	IU	2-amino-5-(diaminomethylideneamino)pentanoic acid;5-[3-methoxypropyl(pentyl)amino]-4-(naphthalen-2-ylsulfonylmethyl)-5-oxopentanoic acid;hydrate
DMC92ER	DE	Pancreatic malfunction

DM5DTMQ	ID	DM5DTMQ
DM5DTMQ	DN	KSG-LDTKNYKQTSV
DM5DTMQ	HS	Investigative
DM5DTMQ	SN	CHEMBL505051; KSG-LDTKNYKQTSV
DM5DTMQ	PC	44568938
DM5DTMQ	MW	1568.7
DM5DTMQ	FM	C67H113N19O24
DM5DTMQ	IC	InChI=1S/C67H113N19O24/c1-32(2)25-42(75-50(94)29-74-56(98)46(30-87)82-55(97)38(71)13-7-10-22-68)60(102)81-45(28-51(95)96)63(105)86-53(34(5)89)65(107)78-40(15-9-12-24-70)58(100)80-44(27-49(73)93)62(104)79-43(26-36-16-18-37(91)19-17-36)61(103)76-39(14-8-11-23-69)57(99)77-41(20-21-48(72)92)59(101)85-54(35(6)90)66(108)83-47(31-88)64(106)84-52(33(3)4)67(109)110/h16-19,32-35,38-47,52-54,87-91H,7-15,20-31,68-71H2,1-6H3,(H2,72,92)(H2,73,93)(H,74,98)(H,75,94)(H,76,103)(H,77,99)(H,78,107)(H,79,104)(H,80,100)(H,81,102)(H,82,97)(H,83,108)(H,84,106)(H,85,101)(H,86,105)(H,95,96)(H,109,110)/t34-,35-,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,52+,53+,54+/m1/s1
DM5DTMQ	CS	C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N)O
DM5DTMQ	IK	LZIFLRQJFWVNPC-NBGMAUTBSA-N
DM5DTMQ	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid
DM5DTMQ	DE	Discovery agent

DMPLFRC	ID	DMPLFRC
DMPLFRC	DN	KSG-YEKLSSIESDV
DMPLFRC	HS	Investigative
DMPLFRC	SN	CHEMBL445253; KSG-YEKLSSIESDV
DMPLFRC	PC	44568937
DMPLFRC	MW	1541.7
DMPLFRC	FM	C66H108N16O26
DMPLFRC	IC	InChI=1S/C66H108N16O26/c1-7-34(6)53(65(106)74-40(19-21-50(91)92)58(99)78-45(29-84)62(103)76-43(26-51(93)94)61(102)81-52(33(4)5)66(107)108)82-64(105)47(31-86)80-63(104)46(30-85)79-59(100)41(24-32(2)3)75-56(97)38(13-9-11-23-68)72-57(98)39(18-20-49(89)90)73-60(101)42(25-35-14-16-36(87)17-15-35)71-48(88)27-70-55(96)44(28-83)77-54(95)37(69)12-8-10-22-67/h14-17,32-34,37-47,52-53,83-87H,7-13,18-31,67-69H2,1-6H3,(H,70,96)(H,71,88)(H,72,98)(H,73,101)(H,74,106)(H,75,97)(H,76,103)(H,77,95)(H,78,99)(H,79,100)(H,80,104)(H,81,102)(H,82,105)(H,89,90)(H,91,92)(H,93,94)(H,107,108)/t34-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,52-,53-/m0/s1
DMPLFRC	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N
DMPLFRC	IK	OYOJPGJCPOXGEB-QBAAMSOUSA-N
DMPLFRC	IU	(4S)-5-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoic acid
DMPLFRC	DE	Discovery agent

DMXBITO	ID	DMXBITO
DMXBITO	DN	KSP-BCS-1-alpha-CHF2-1624F2-2
DMXBITO	HS	Investigative
DMXBITO	SN	CHEMBL220140; KSP-BCS-1-alpha-CHF2-1624F2-2
DMXBITO	DT	Small molecular drug
DMXBITO	PC	16094778
DMXBITO	MW	512.7
DMXBITO	FM	C30H44F4O2
DMXBITO	IC	InChI=1S/C30H44F4O2/c1-6-29(36,7-2)30(33,34)16-14-19(3)25-12-13-26-21(9-8-15-28(25,26)5)10-11-22-17-23(35)18-24(20(22)4)27(31)32/h10-12,19,23-24,26-27,35-36H,4,6-9,13-18H2,1-3,5H3/b21-10+,22-11-/t19-,23-,24+,26+,28-/m1/s1
DMXBITO	CS	CCC(CC)(C(CC[C@@H](C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)C(F)F)O)C)(F)F)O
DMXBITO	IK	CUKDGTJRZFQGCK-HBXJJCJFSA-N
DMXBITO	IU	(1S,3Z,5S)-3-[(2E)-2-[(3aS,7aS)-1-[(2R)-6-ethyl-5,5-difluoro-6-hydroxyoctan-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-5-(difluoromethyl)-4-methylidenecyclohexan-1-ol
DMXBITO	DE	Discovery agent

DMJV3R7	ID	DMJV3R7
DMJV3R7	DN	KSP-BCS-1-alpha-CHF2-20-epi-22-oxabishomo-26-OH
DMJV3R7	HS	Investigative
DMJV3R7	SN	CHEMBL376093; KSP-BCS-1-alpha-CHF2-20-epi-22-oxabishomo-26-OH
DMJV3R7	DT	Small molecular drug
DMJV3R7	PC	16094779
DMJV3R7	MW	494.7
DMJV3R7	FM	C30H48F2O3
DMJV3R7	IC	InChI=1S/C30H48F2O3/c1-6-30(34,7-2)16-9-17-35-21(4)26-13-14-27-22(10-8-15-29(26,27)5)11-12-23-18-24(33)19-25(20(23)3)28(31)32/h11-12,21,24-28,33-34H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25+,26-,27+,29-/m1/s1
DMJV3R7	CS	CCC(CC)(CCCO[C@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)C(F)F)O)C)O
DMJV3R7	IK	JHEXIWJRXZGBMA-AFLZJIMUSA-N
DMJV3R7	IU	(1S,3Z,5S)-3-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-5-(difluoromethyl)-4-methylidenecyclohexan-1-ol
DMJV3R7	DE	Discovery agent

DMT0CR5	ID	DMT0CR5
DMT0CR5	DN	KST-5468
DMT0CR5	HS	Investigative
DMT0CR5	SN	T-type calcium channel antagonist (pain); T-type calcium channel antagonist (pain), SNU/KIST
DMT0CR5	CP	Seoul National University
DMT0CR5	DE	Pain

DMOBYU3	ID	DMOBYU3
DMOBYU3	DN	KT 5823
DMOBYU3	HS	Investigative
DMOBYU3	SN	kt 5823; KT-5823; KT5823; UNII-WY40BAB02W; 126643-37-6; WY40BAB02W; 9-Methoxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epxoy-1H,8H,11H-2,7b-11a-triazadibenzo(a,g)cycloocta(cde)-trinden-1-one; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-, methyl ester, (9R-(9alpha,10beta,12alpha))-; C29H25N3O5; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10
DMOBYU3	DT	Small molecular drug
DMOBYU3	PC	108152
DMOBYU3	MW	495.5
DMOBYU3	FM	C29H25N3O5
DMOBYU3	IC	InChI=1S/C29H25N3O5/c1-28-29(36-4,27(34)35-3)13-20(37-28)31-18-11-7-5-9-15(18)22-23-17(14-30(2)26(23)33)21-16-10-6-8-12-19(16)32(28)25(21)24(22)31/h5-12,20H,13-14H2,1-4H3/t20-,28+,29+/m1/s1
DMOBYU3	CS	C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CN(C6=O)C)(C(=O)OC)OC
DMOBYU3	IK	QTYMDECKVKSGSM-YMUMJAELSA-N
DMOBYU3	IU	methyl (15S,16R,18R)-16-methoxy-4,15-dimethyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate
DMOBYU3	CA	CAS 126643-37-6
DMOBYU3	CB	CHEBI:85102
DMOBYU3	DE	Discovery agent

DM9J50F	ID	DM9J50F
DM9J50F	DN	KT-5720
DM9J50F	HS	Investigative
DM9J50F	SN	KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c
DM9J50F	DT	Small molecular drug
DM9J50F	PC	454202
DM9J50F	MW	537.6
DM9J50F	FM	C32H31N3O5
DM9J50F	IC	InChI=1S/C32H31N3O5/c1-3-4-5-10-15-39-30(37)32(38)16-23-34-21-13-8-6-11-18(21)25-26-20(17-33-29(26)36)24-19-12-7-9-14-22(19)35(28(24)27(25)34)31(32,2)40-23/h6-9,11-14,23,38H,3-5,10,15-17H2,1-2H3,(H,33,36)/t23-,31+,32+/m0/s1
DM9J50F	CS	CCCCCCOC(=O)[C@@]1(C[C@H]2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N(C7=C53)[C@@]1(O2)C)CNC6=O)O
DM9J50F	IK	ZHEHVZXPFVXKEY-RUAOOFDTSA-N
DM9J50F	IU	hexyl (15R,16S,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate
DM9J50F	CA	CAS 108068-98-0
DM9J50F	CB	CHEBI:85085
DM9J50F	DE	Discovery agent

DMXIUO5	ID	DMXIUO5
DMXIUO5	DN	KT6006
DMXIUO5	HS	Investigative
DMXIUO5	SN	KT 6006; 118736-03-1; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-5,10,16-trihydroxy-9-methyl-1-oxo-, methyl ester, (9S-(9alpha,10alpha,12alpha))-
DMXIUO5	DT	Small molecular drug
DMXIUO5	PC	196744
DMXIUO5	MW	499.5
DMXIUO5	FM	C27H21N3O7
DMXIUO5	IC	InChI=1S/C27H21N3O7/c1-27-16(26(34)37-35-2)9-19(36-27)29-17-5-3-11(31)7-13(17)21-22-15(10-28-25(22)33)20-14-8-12(32)4-6-18(14)30(27)24(20)23(21)29/h3-8,16,19,31-32H,9-10H2,1-2H3,(H,28,33)/t16-,19-,27+/m1/s1
DMXIUO5	CS	C[C@@]12[C@H](C[C@@H](O1)N3C4=C(C=C(C=C4)O)C5=C6C(=C7C8=C(N2C7=C53)C=CC(=C8)O)CNC6=O)C(=O)OOC
DMXIUO5	IK	JKEBWJSRGQOXNU-TUZCJGOLSA-N
DMXIUO5	IU	methyl (15S,16S,18R)-10,23-dihydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8(13),9,11,20(25),21,23,26-nonaene-16-carboperoxoate
DMXIUO5	CA	CAS 118736-03-1
DMXIUO5	DE	Discovery agent

DMRDZ7I	ID	DMRDZ7I
DMRDZ7I	DN	KT6528
DMRDZ7I	HS	Investigative
DMRDZ7I	SN	AC1L31GQ
DMRDZ7I	DT	Small molecular drug
DMRDZ7I	PC	132714
DMRDZ7I	MW	469.4
DMRDZ7I	FM	C26H19N3O6
DMRDZ7I	IC	InChI=1S/C26H19N3O6/c1-25-26(33,11-30)10-16(35-25)27-14-8-4-2-6-12(14)17-19-20(24(32)29(34)23(19)31)18-13-7-3-5-9-15(13)28(25)22(18)21(17)27/h2-9,16,30,33-34H,10-11H2,1H3/t16-,25-,26-/m0/s1
DMRDZ7I	CS	C[C@@]12[C@](C[C@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)C(=O)N(C6=O)O)(CO)O
DMRDZ7I	IK	KNJUOEDHHOTPLA-LADPQGRPSA-N
DMRDZ7I	IU	(15S,16S,18S)-4,16-dihydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-3,5-dione
DMRDZ7I	DE	Discovery agent

DMQWS6U	ID	DMQWS6U
DMQWS6U	DN	KU-0060648
DMQWS6U	HS	Investigative
DMQWS6U	SN	KU 0060648
DMQWS6U	DT	Small molecular drug
DMQWS6U	PC	11964036
DMQWS6U	MW	582.7
DMQWS6U	FM	C33H34N4O4S
DMQWS6U	IC	InChI=1S/C33H34N4O4S/c1-2-35-12-14-36(15-13-35)21-29(39)34-26-11-10-23(33-31(26)25-6-3-4-9-28(25)42-33)22-7-5-8-24-27(38)20-30(41-32(22)24)37-16-18-40-19-17-37/h3-11,20H,2,12-19,21H2,1H3,(H,34,39)
DMQWS6U	CS	CCN1CCN(CC1)CC(=O)NC2=C3C4=CC=CC=C4SC3=C(C=C2)C5=CC=CC6=C5OC(=CC6=O)N7CCOCC7
DMQWS6U	IK	AATCBLYHOUOCTO-UHFFFAOYSA-N
DMQWS6U	IU	2-(4-ethylpiperazin-1-yl)-N-[4-(2-morpholin-4-yl-4-oxochromen-8-yl)dibenzothiophen-1-yl]acetamide
DMQWS6U	CB	CHEBI:94302
DMQWS6U	DE	Discovery agent

DMDT42X	ID	DMDT42X
DMDT42X	DN	KU-55933
DMDT42X	HS	Investigative
DMDT42X	SN	KU-55933; 587871-26-9; ATM Kinase Inhibitor; KU55933; 2-Morpholino-6-(thianthren-1-yl)-4H-pyran-4-one; 2-Morpholin-4-yl-6-thianthren-1-ylpyran-4-one; KU 55933; 2-Morpholin-4-yl-6-thianthren-1-yl-pyran-4-one; UNII-O549494L5D; CHEMBL222102; KU-55933 (ATM Kinase Inhibitor); O549494L5D; 2-morpholino-6-thianthren-1-yl-pyran-4-one; 2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one; 4H-Pyran-4-one, 2-(4-morpholinyl)-6-(1-thianthrenyl)-; AC1NQSSP; PubChem22474; cc-73; SCHEMBL1984941; GTPL5928
DMDT42X	DT	Small molecular drug
DMDT42X	PC	5278396
DMDT42X	MW	395.5
DMDT42X	FM	C21H17NO3S2
DMDT42X	IC	InChI=1S/C21H17NO3S2/c23-14-12-16(25-20(13-14)22-8-10-24-11-9-22)15-4-3-7-19-21(15)27-18-6-2-1-5-17(18)26-19/h1-7,12-13H,8-11H2
DMDT42X	CS	C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4
DMDT42X	IK	XRKYMMUGXMWDAO-UHFFFAOYSA-N
DMDT42X	IU	2-morpholin-4-yl-6-thianthren-1-ylpyran-4-one
DMDT42X	CA	CAS 587871-26-9
DMDT42X	CB	CHEBI:91372
DMDT42X	DE	Solid tumour/cancer

DMVGY6K	ID	DMVGY6K
DMVGY6K	DN	KU-58684
DMVGY6K	HS	Investigative
DMVGY6K	SN	SCHEMBL863338; 623578-11-0
DMVGY6K	DT	Small molecular drug
DMVGY6K	PC	11725479
DMVGY6K	MW	351.3
DMVGY6K	FM	C19H14FN3O3
DMVGY6K	IC	InChI=1S/C19H14FN3O3/c20-14-6-5-11(10-16(14)23-17(24)7-8-18(23)25)9-15-12-3-1-2-4-13(12)19(26)22-21-15/h1-6,10H,7-9H2,(H,22,26)
DMVGY6K	CS	C1CC(=O)N(C1=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F
DMVGY6K	IK	YQSZNYLPVBOGPO-UHFFFAOYSA-N
DMVGY6K	IU	1-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]phenyl]pyrrolidine-2,5-dione
DMVGY6K	DE	Discovery agent

DMAVM94	ID	DMAVM94
DMAVM94	DN	Kuanoniamine D
DMAVM94	HS	Investigative
DMAVM94	SN	Kuanoniamine D; CHEMBL127872; BDBM50030271; N-[2-(8H-6-Thia-3,4,8-triaza-benzo[de]cyclopenta[b]anthracen-7-yl)-ethyl]-acetamide; Acetamide, N-(2-(8H-pyrido(4,3,2-mn)thiazolo(4,5-b)acridin-9-yl)ethyl)-
DMAVM94	DT	Small molecular drug
DMAVM94	PC	10067080
DMAVM94	MW	360.4
DMAVM94	FM	C20H16N4OS
DMAVM94	IC	InChI=1S/C20H16N4OS/c1-11(25)21-8-7-14-17-16-13(12-4-2-3-5-15(12)24-17)6-9-22-18(16)19-20(14)26-10-23-19/h2-6,9-10,24H,7-8H2,1H3,(H,21,25)
DMAVM94	CS	CC(=O)NCCC1=C2C3=C(C=CN=C3C4=C1SC=N4)C5=CC=CC=C5N2
DMAVM94	IK	GUSIRVISUKPQFL-UHFFFAOYSA-N
DMAVM94	IU	N-[2-(4-thia-6,9,19-triazapentacyclo[10.7.1.03,7.08,20.013,18]icosa-1,3(7),5,8,10,12(20),13,15,17-nonaen-2-yl)ethyl]acetamide
DMAVM94	CA	CAS 133401-13-5
DMAVM94	DE	Discovery agent

DMLDUJ1	ID	DMLDUJ1
DMLDUJ1	DN	Kuraidin
DMLDUJ1	HS	Investigative
DMLDUJ1	SN	KURAIDIN; kuraridin; CHEMBL243362; PIAPWPAWQGDOMN-SXAWMYDMSA-N; ZINC13817033
DMLDUJ1	DT	Small molecular drug
DMLDUJ1	PC	44428631
DMLDUJ1	MW	438.5
DMLDUJ1	FM	C26H30O6
DMLDUJ1	IC	InChI=1S/C26H30O6/c1-15(2)6-7-18(16(3)4)12-20-23(30)14-24(32-5)25(26(20)31)21(28)11-9-17-8-10-19(27)13-22(17)29/h6,8-11,13-14,18,27,29-31H,3,7,12H2,1-2,4-5H3/b11-9+/t18-/m1/s1
DMLDUJ1	CS	CC(=CC[C@H](CC1=C(C(=C(C=C1O)OC)C(=O)/C=C/C2=C(C=C(C=C2)O)O)O)C(=C)C)C
DMLDUJ1	IK	PIAPWPAWQGDOMN-SXAWMYDMSA-N
DMLDUJ1	IU	(E)-1-[2,4-dihydroxy-6-methoxy-3-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]phenyl]-3-(2,4-dihydroxyphenyl)prop-2-en-1-one
DMLDUJ1	CA	CAS 34981-25-4
DMLDUJ1	DE	Discovery agent

DMRV5YE	ID	DMRV5YE
DMRV5YE	DN	KURARINOL
DMRV5YE	HS	Investigative
DMRV5YE	SN	Kurarinol; CHEBI:81093; 855746-98-4; CHEMBL455667; MolPort-039-338-650; ZINC13817026; BDBM50366788; C17444
DMRV5YE	DT	Small molecular drug
DMRV5YE	PC	44563198
DMRV5YE	MW	456.5
DMRV5YE	FM	C26H32O7
DMRV5YE	IC	InChI=1S/C26H32O7/c1-14(2)15(8-9-26(3,4)31)10-18-20(29)12-23(32-5)24-21(30)13-22(33-25(18)24)17-7-6-16(27)11-19(17)28/h6-7,11-12,15,22,27-29,31H,1,8-10,13H2,2-5H3/t15-,22+/m1/s1
DMRV5YE	CS	CC(=C)[C@H](CCC(C)(C)O)CC1=C2C(=C(C=C1O)OC)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)O
DMRV5YE	IK	XMUPAAIHKAIUSU-QRQCRPRQSA-N
DMRV5YE	IU	(2S)-2-(2,4-dihydroxyphenyl)-7-hydroxy-8-[(2R)-5-hydroxy-5-methyl-2-prop-1-en-2-ylhexyl]-5-methoxy-2,3-dihydrochromen-4-one
DMRV5YE	CA	CAS 855746-98-4
DMRV5YE	CB	CHEBI:81093
DMRV5YE	DE	Discovery agent

DMH0G8W	ID	DMH0G8W
DMH0G8W	DN	Kurarinone
DMH0G8W	HS	Investigative
DMH0G8W	SN	(-)-kurarinone; Kurarinone; CHEMBL243796; SCHEMBL10307523; BDBM50208612
DMH0G8W	DT	Small molecular drug
DMH0G8W	PC	11982640
DMH0G8W	MW	438.5
DMH0G8W	FM	C26H30O6
DMH0G8W	IC	InChI=1S/C26H30O6/c1-14(2)6-7-16(15(3)4)10-19-21(29)12-24(31-5)25-22(30)13-23(32-26(19)25)18-9-8-17(27)11-20(18)28/h6,8-9,11-12,16,23,27-29H,3,7,10,13H2,1-2,4-5H3/t16-,23+/m1/s1
DMH0G8W	CS	CC(=CC[C@H](CC1=C2C(=C(C=C1O)OC)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)O)C(=C)C)C
DMH0G8W	IK	LTTQKYMNTNISSZ-MWTRTKDXSA-N
DMH0G8W	IU	(2S)-2-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
DMH0G8W	CA	CAS 34981-26-5
DMH0G8W	CB	CHEBI:66150
DMH0G8W	DE	Discovery agent

DMPKDJ4	ID	DMPKDJ4
DMPKDJ4	DN	KUR-CXCR4
DMPKDJ4	HS	Investigative
DMPKDJ4	CP	Tobira Therapeutics Inc
DMPKDJ4	DE	Discovery agent

DMCFHPD	ID	DMCFHPD
DMCFHPD	DN	KUSHENOL A
DMCFHPD	HS	Investigative
DMCFHPD	SN	Kushenol A; 99217-63-7; CHEMBL455679; MolPort-039-337-120; BDBM50377945; ZINC33832185; AKOS032948966
DMCFHPD	DT	Small molecular drug
DMCFHPD	PC	44563121
DMCFHPD	MW	408.5
DMCFHPD	FM	C25H28O5
DMCFHPD	IC	InChI=1S/C25H28O5/c1-14(2)9-10-16(15(3)4)11-18-20(27)12-21(28)24-22(29)13-23(30-25(18)24)17-7-5-6-8-19(17)26/h5-9,12,16,23,26-28H,3,10-11,13H2,1-2,4H3/t16-,23+/m1/s1
DMCFHPD	CS	CC(=CC[C@H](CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=CC=C3O)C(=C)C)C
DMCFHPD	IK	OGBMVWVBHWHRGD-MWTRTKDXSA-N
DMCFHPD	IU	(2S)-5,7-dihydroxy-2-(2-hydroxyphenyl)-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
DMCFHPD	CA	CAS 99217-63-7
DMCFHPD	DE	Discovery agent

DMY13UR	ID	DMY13UR
DMY13UR	DN	Kushenol N
DMY13UR	HS	Investigative
DMY13UR	SN	NSC668937; Kushenol N; 2-(2,4-Dihydroxyphenyl)-3,7-dihydroxy-8-(2-isopropenyl-5-methyl-4-hexenyl)-5-methoxy-2,3-dihydro-4H-chromen-4-one; 102490-65-3; 4H-1-Benzopyran-4-one,2-(2,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-5-methoxy-8-[(2R)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-,(2R,3S)-; ACMC-20bulp; AC1Q6KJK; AC1L8I5S; CTK4A1130; DTXSID50327597; NSC-668937; NCI60_024046; 2-(2,4-dihydroxyphenyl)-3,7-dihydroxy-8-(2-isopropenyl-5-methyl-hex-4-enyl)-5-methoxy-chroman-4-one
DMY13UR	DT	Small molecular drug
DMY13UR	PC	381851
DMY13UR	MW	454.5
DMY13UR	FM	C26H30O7
DMY13UR	IC	InChI=1S/C26H30O7/c1-13(2)6-7-15(14(3)4)10-18-20(29)12-21(32-5)22-23(30)24(31)26(33-25(18)22)17-9-8-16(27)11-19(17)28/h6,8-9,11-12,15,24,26-29,31H,3,7,10H2,1-2,4-5H3
DMY13UR	CS	CC(=CCC(CC1=C2C(=C(C=C1O)OC)C(=O)C(C(O2)C3=C(C=C(C=C3)O)O)O)C(=C)C)C
DMY13UR	IK	QKEDJCCCNZWOBS-UHFFFAOYSA-N
DMY13UR	IU	2-(2,4-dihydroxyphenyl)-3,7-dihydroxy-5-methoxy-8-(5-methyl-2-prop-1-en-2-ylhex-4-enyl)-2,3-dihydrochromen-4-one
DMY13UR	CA	CAS 102490-65-3
DMY13UR	DE	Discovery agent

DMVQDNR	ID	DMVQDNR
DMVQDNR	DN	kuwanon H
DMVQDNR	HS	Investigative
DMVQDNR	SN	Kuwanon H; Kuwanone H; 76472-87-2; CHEBI:6147; kumanon H; AC1NQYUS; GTPL622; SCHEMBL150578; CHEMBL506234; ZINC8234329; 8-[(1S,5R,6S)-6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methyl-1-cyclohex-2-enyl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-enyl)chromen-4-one; C10100
DMVQDNR	DT	Small molecular drug
DMVQDNR	PC	5281668
DMVQDNR	MW	760.8
DMVQDNR	FM	C45H44O11
DMVQDNR	IC	InChI=1S/C45H44O11/c1-21(2)6-10-27-33(48)15-14-29(41(27)53)42(54)38-31(26-12-8-24(46)18-34(26)49)16-23(5)17-32(38)39-36(51)20-37(52)40-43(55)30(11-7-22(3)4)44(56-45(39)40)28-13-9-25(47)19-35(28)50/h6-9,12-15,17-20,31-32,38,46-53H,10-11,16H2,1-5H3/t31-,32-,38-/m0/s1
DMVQDNR	CS	CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C(=C(C=C3)O)CC=C(C)C)O)C4=C(C=C(C5=C4OC(=C(C5=O)CC=C(C)C)C6=C(C=C(C=C6)O)O)O)O
DMVQDNR	IK	DKBPTKFKCCNXNH-QXGWMLRCSA-N
DMVQDNR	IU	8-[(1S,5R,6S)-6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-enyl)chromen-4-one
DMVQDNR	CA	CAS 76472-87-2
DMVQDNR	CB	CHEBI:6147
DMVQDNR	DE	Discovery agent

DMFSUJB	ID	DMFSUJB
DMFSUJB	DN	Kuwanon J
DMFSUJB	HS	Investigative
DMFSUJB	SN	CHEMBL570475
DMFSUJB	DT	Small molecular drug
DMFSUJB	PC	10394786
DMFSUJB	MW	678.7
DMFSUJB	FM	C40H38O10
DMFSUJB	IC	InChI=1S/C40H38O10/c1-20(2)4-9-26-32(44)14-12-28(38(26)48)40(50)36-29(25-10-8-24(42)19-35(25)47)16-21(3)17-30(36)37-33(45)15-11-27(39(37)49)31(43)13-6-22-5-7-23(41)18-34(22)46/h4-8,10-15,17-19,29-30,36,41-42,44-49H,9,16H2,1-3H3/b13-6+
DMFSUJB	CS	CC1=CC(C(C(C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C(=C(C=C3)O)CC=C(C)C)O)C4=C(C=CC(=C4O)C(=O)/C=C/C5=C(C=C(C=C5)O)O)O
DMFSUJB	IK	KBAPHKOHTBBCTO-AWNIVKPZSA-N
DMFSUJB	IU	(E)-1-[3-[6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-3-(2,4-dihydroxyphenyl)prop-2-en-1-one
DMFSUJB	CA	CAS 83709-26-6
DMFSUJB	DE	Discovery agent

DMX4D1Q	ID	DMX4D1Q
DMX4D1Q	DN	Kuwanon L
DMX4D1Q	HS	Investigative
DMX4D1Q	SN	Kuwanon L; CHEMBL377937; 88524-65-6; AC1L4FQH; CTK5G0055; 4H-1-Benzopyran-4-one,2-[3-[(1S,5R,6S)-6- (2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)- 3-methyl-2-cyclohexen-1-yl]-2,4- dihydroxyphenyl]-2,3-dihydro-5,7-dihydroxy-,(2S)-; BDBM50179009; AKOS030566805; 4H-1-Benzopyran-4-one, 2-(3-(6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methyl-2-cyclohexen-1-yl)-2,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (1S-(1alpha(R*),5alpha,6beta))-
DMX4D1Q	DT	Small molecular drug
DMX4D1Q	PC	184877
DMX4D1Q	MW	626.6
DMX4D1Q	FM	C35H30O11
DMX4D1Q	IC	InChI=1S/C35H30O11/c1-15-8-22(19-4-2-16(36)10-25(19)40)31(34(44)20-5-3-17(37)11-26(20)41)23(9-15)32-24(39)7-6-21(35(32)45)29-14-28(43)33-27(42)12-18(38)13-30(33)46-29/h2-7,9-13,22-23,29,31,36-42,45H,8,14H2,1H3/t22-,23-,29-,31-/m0/s1
DMX4D1Q	CS	CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C(C=CC(=C4O)[C@@H]5CC(=O)C6=C(C=C(C=C6O5)O)O)O
DMX4D1Q	IK	ZEZOBFSLMMTYFF-HQSFFLIMSA-N
DMX4D1Q	IU	(2S)-2-[3-[(1S,5R,6S)-6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-5,7-dihydroxy-2,3-dihydrochromen-4-one
DMX4D1Q	CA	CAS 88524-65-6
DMX4D1Q	DE	Discovery agent

DMEZOT9	ID	DMEZOT9
DMEZOT9	DN	Kuwanon R
DMEZOT9	HS	Investigative
DMEZOT9	SN	CHEMBL570526
DMEZOT9	DT	Small molecular drug
DMEZOT9	PC	45485202
DMEZOT9	MW	662.7
DMEZOT9	FM	C40H38O9
DMEZOT9	IC	InChI=1S/C40H38O9/c1-21(2)4-11-28-34(45)18-24(19-35(28)46)39(48)37-30(27-12-10-26(42)20-36(27)47)16-22(3)17-31(37)38-33(44)15-13-29(40(38)49)32(43)14-7-23-5-8-25(41)9-6-23/h4-10,12-15,17-20,30-31,37,41-42,44-47,49H,11,16H2,1-3H3/b14-7+/t30-,31+,37-/m1/s1
DMEZOT9	CS	CC1=C[C@@H]([C@@H]([C@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=CC(=C(C(=C3)O)CC=C(C)C)O)C4=C(C=CC(=C4O)C(=O)/C=C/C5=CC=C(C=C5)O)O
DMEZOT9	IK	PXFKYAIDSYKIJA-DLBCFTNOSA-N
DMEZOT9	IU	(E)-1-[3-[(1S,5S,6R)-6-[3,5-dihydroxy-4-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
DMEZOT9	DE	Discovery agent

DM84M20	ID	DM84M20
DM84M20	DN	Kuwanon V
DM84M20	HS	Investigative
DM84M20	SN	CHEMBL570609
DM84M20	DT	Small molecular drug
DM84M20	PC	45485203
DM84M20	MW	646.7
DM84M20	FM	C40H38O8
DM84M20	IC	InChI=1S/C40H38O8/c1-22(2)4-14-29-35(45)20-26(21-36(29)46)39(47)37-31(25-8-12-28(42)13-9-25)18-23(3)19-32(37)38-34(44)17-15-30(40(38)48)33(43)16-7-24-5-10-27(41)11-6-24/h4-13,15-17,19-21,31-32,37,41-42,44-46,48H,14,18H2,1-3H3/b16-7+/t31-,32+,37-/m1/s1
DM84M20	CS	CC1=C[C@@H]([C@@H]([C@H](C1)C2=CC=C(C=C2)O)C(=O)C3=CC(=C(C(=C3)O)CC=C(C)C)O)C4=C(C=CC(=C4O)C(=O)/C=C/C5=CC=C(C=C5)O)O
DM84M20	IK	MYKDNKGHXHALEF-SJIVMEQQSA-N
DM84M20	IU	(E)-1-[3-[(1S,5S,6R)-6-[3,5-dihydroxy-4-(3-methylbut-2-enyl)benzoyl]-5-(4-hydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
DM84M20	DE	Discovery agent

DM7RFUC	ID	DM7RFUC
DM7RFUC	DN	KwFwLL-NH2
DM7RFUC	HS	Investigative
DM7RFUC	SN	CHEMBL506986; KwFwLL-NH2
DM7RFUC	DT	Small molecular drug
DM7RFUC	PC	44576247
DM7RFUC	MW	891.1
DM7RFUC	FM	C49H66N10O6
DM7RFUC	IC	InChI=1S/C49H66N10O6/c1-29(2)22-39(44(52)60)55-46(62)40(23-30(3)4)57-49(65)43(26-33-28-54-38-20-11-9-17-35(33)38)59-47(63)41(24-31-14-6-5-7-15-31)58-48(64)42(56-45(61)36(51)18-12-13-21-50)25-32-27-53-37-19-10-8-16-34(32)37/h5-11,14-17,19-20,27-30,36,39-43,53-54H,12-13,18,21-26,50-51H2,1-4H3,(H2,52,60)(H,55,62)(H,56,61)(H,57,65)(H,58,64)(H,59,63)/t36-,39-,40-,41-,42+,43+/m0/s1
DM7RFUC	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCCCN)N
DM7RFUC	IK	ZGQSDHNDIKTEJD-XLAQBFAFSA-N
DM7RFUC	IU	(2S)-2,6-diamino-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]hexanamide
DM7RFUC	DE	Discovery agent

DMA9VBD	ID	DMA9VBD
DMA9VBD	DN	KY-382
DMA9VBD	HS	Investigative
DMA9VBD	CP	Kyoto Pharmaceutical Industries Ltd
DMA9VBD	PC	10454368
DMA9VBD	MW	412.5
DMA9VBD	FM	C19H32N4O4S
DMA9VBD	IC	InChI=1S/C19H32N4O4S/c1-7-27-11-10-23-9-8-14-12(2)15(22-28(20,25)26)13(3)16(17(14)23)21-18(24)19(4,5)6/h22H,7-11H2,1-6H3,(H,21,24)(H2,20,25,26)
DMA9VBD	CS	CCOCCN1CCC2=C(C(=C(C(=C21)NC(=O)C(C)(C)C)C)NS(=O)(=O)N)C
DMA9VBD	IK	PXCNVWWWTVXCME-UHFFFAOYSA-N
DMA9VBD	IU	N-[1-(2-ethoxyethyl)-4,6-dimethyl-5-(sulfamoylamino)-2,3-dihydroindol-7-yl]-2,2-dimethylpropanamide
DMA9VBD	DE	Arteriosclerosis

DM3MID9	ID	DM3MID9
DM3MID9	DN	KYS-05001
DM3MID9	HS	Investigative
DM3MID9	SN	KYS-05001; CHEMBL114695; SCHEMBL14417320; BDBM50148175; N-Benzyl-2-(3-phenyl-2-piperidin-1-yl-3,4-dihydro-quinazolin-4-yl)-acetamide
DM3MID9	DT	Small molecular drug
DM3MID9	PC	9980573
DM3MID9	MW	438.6
DM3MID9	FM	C28H30N4O
DM3MID9	IC	InChI=1S/C28H30N4O/c33-27(29-21-22-12-4-1-5-13-22)20-26-24-16-8-9-17-25(24)30-28(31-18-10-3-11-19-31)32(26)23-14-6-2-7-15-23/h1-2,4-9,12-17,26H,3,10-11,18-21H2,(H,29,33)
DM3MID9	CS	C1CCN(CC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=CC=C5
DM3MID9	IK	IROXHJVGJHVBSD-UHFFFAOYSA-N
DM3MID9	IU	N-benzyl-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DM3MID9	DE	Discovery agent

DM1JU8F	ID	DM1JU8F
DM1JU8F	DN	KYS-05040
DM1JU8F	HS	Investigative
DM1JU8F	SN	KYS-05040; CHEMBL115159; SCHEMBL14417350; BDBM50148177; N-(4-Amino-benzyl)-2-(3-phenyl-2-piperidin-1-yl-3,4-dihydro-quinazolin-4-yl)-acetamide
DM1JU8F	DT	Small molecular drug
DM1JU8F	PC	44342044
DM1JU8F	MW	453.6
DM1JU8F	FM	C28H31N5O
DM1JU8F	IC	InChI=1S/C28H31N5O/c29-22-15-13-21(14-16-22)20-30-27(34)19-26-24-11-5-6-12-25(24)31-28(32-17-7-2-8-18-32)33(26)23-9-3-1-4-10-23/h1,3-6,9-16,26H,2,7-8,17-20,29H2,(H,30,34)
DM1JU8F	CS	C1CCN(CC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=C(C=C5)N
DM1JU8F	IK	NEMYASVJMUEWED-UHFFFAOYSA-N
DM1JU8F	IU	N-[(4-aminophenyl)methyl]-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DM1JU8F	DE	Discovery agent

DMVA6LH	ID	DMVA6LH
DMVA6LH	DN	KYS-05041
DMVA6LH	HS	Investigative
DMVA6LH	PC	10031616
DMVA6LH	MW	607.8
DMVA6LH	FM	C35H37N5O3S
DMVA6LH	IC	InChI=1S/C35H37N5O3S/c1-26-14-20-30(21-15-26)44(42,43)38-28-18-16-27(17-19-28)25-36-34(41)24-33-31-12-6-7-13-32(31)37-35(39-22-8-3-9-23-39)40(33)29-10-4-2-5-11-29/h2,4-7,10-21,33,38H,3,8-9,22-25H2,1H3,(H,36,41)
DMVA6LH	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CNC(=O)CC3C4=CC=CC=C4N=C(N3C5=CC=CC=C5)N6CCCCC6
DMVA6LH	IK	TWRWYNXGPAASHN-UHFFFAOYSA-N
DMVA6LH	IU	N-[[4-[(4-methylphenyl)sulfonylamino]phenyl]methyl]-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DMVA6LH	DE	Discovery agent

DMM6G4H	ID	DMM6G4H
DMM6G4H	DN	KYS-05042
DMM6G4H	HS	Investigative
DMM6G4H	PC	10416322
DMM6G4H	MW	611.7
DMM6G4H	FM	C34H34FN5O3S
DMM6G4H	IC	InChI=1S/C34H34FN5O3S/c35-26-15-19-29(20-16-26)44(42,43)38-27-17-13-25(14-18-27)24-36-33(41)23-32-30-11-5-6-12-31(30)37-34(39-21-7-2-8-22-39)40(32)28-9-3-1-4-10-28/h1,3-6,9-20,32,38H,2,7-8,21-24H2,(H,36,41)
DMM6G4H	CS	C1CCN(CC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=C(C=C5)NS(=O)(=O)C6=CC=C(C=C6)F
DMM6G4H	IK	RMQZAKOLGVUVAD-UHFFFAOYSA-N
DMM6G4H	IU	N-[[4-[(4-fluorophenyl)sulfonylamino]phenyl]methyl]-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DMM6G4H	DE	Discovery agent

DMXR3V4	ID	DMXR3V4
DMXR3V4	DN	KYS-05050
DMXR3V4	HS	Investigative
DMXR3V4	DT	Small molecular drug
DMXR3V4	PC	135401968
DMXR3V4	MW	531.7
DMXR3V4	FM	C34H37N5O
DMXR3V4	IC	InChI=1S/C34H37N5O/c35-22-10-3-11-23-36-34-38-31-17-9-8-16-30(31)32(24-33(40)37-25-26-12-4-1-5-13-26)39(34)29-20-18-28(19-21-29)27-14-6-2-7-15-27/h1-2,4-9,12-21,32H,3,10-11,22-25,35H2,(H,36,38)(H,37,40)
DMXR3V4	CS	C1=CC=C(C=C1)CNC(=O)CC2C3=CC=CC=C3NC(=NCCCCCN)N2C4=CC=C(C=C4)C5=CC=CC=C5
DMXR3V4	IK	PHOBNPDRNIKURV-UHFFFAOYSA-N
DMXR3V4	IU	2-[2-(5-aminopentylimino)-3-(4-phenylphenyl)-1,4-dihydroquinazolin-4-yl]-N-benzylacetamide
DMXR3V4	DE	Solid tumour/cancer

DMRVOT7	ID	DMRVOT7
DMRVOT7	DN	KYS-05055
DMRVOT7	HS	Investigative
DMRVOT7	SN	KYS-05055; CHEMBL457084; SCHEMBL14417339; BDBM50251383; N-(4-nitrobenzyl)-2-(2-(dimethylamino)-3-phenyl-3,4-dihydroquinazolin-4-yl)acetamide
DMRVOT7	DT	Small molecular drug
DMRVOT7	PC	44567629
DMRVOT7	MW	443.5
DMRVOT7	FM	C25H25N5O3
DMRVOT7	IC	InChI=1S/C25H25N5O3/c1-28(2)25-27-22-11-7-6-10-21(22)23(29(25)19-8-4-3-5-9-19)16-24(31)26-17-18-12-14-20(15-13-18)30(32)33/h3-15,23H,16-17H2,1-2H3,(H,26,31)
DMRVOT7	CS	CN(C)C1=NC2=CC=CC=C2C(N1C3=CC=CC=C3)CC(=O)NCC4=CC=C(C=C4)[N+](=O)[O-]
DMRVOT7	IK	HCOLRSVHDDZVKO-UHFFFAOYSA-N
DMRVOT7	IU	2-[2-(dimethylamino)-3-phenyl-4H-quinazolin-4-yl]-N-[(4-nitrophenyl)methyl]acetamide
DMRVOT7	DE	Discovery agent

DMP6S0L	ID	DMP6S0L
DMP6S0L	DN	KYS-05056
DMP6S0L	HS	Investigative
DMP6S0L	SN	KYS-05056; CHEMBL459245; SCHEMBL14417338; BDBM50251382
DMP6S0L	DT	Small molecular drug
DMP6S0L	PC	44567628
DMP6S0L	MW	413.5
DMP6S0L	FM	C25H27N5O
DMP6S0L	IC	InChI=1S/C25H27N5O/c1-29(2)25-28-22-11-7-6-10-21(22)23(30(25)20-8-4-3-5-9-20)16-24(31)27-17-18-12-14-19(26)15-13-18/h3-15,23H,16-17,26H2,1-2H3,(H,27,31)
DMP6S0L	CS	CN(C)C1=NC2=CC=CC=C2C(N1C3=CC=CC=C3)CC(=O)NCC4=CC=C(C=C4)N
DMP6S0L	IK	ADQNFSXMHBVQJA-UHFFFAOYSA-N
DMP6S0L	IU	N-[(4-aminophenyl)methyl]-2-[2-(dimethylamino)-3-phenyl-4H-quinazolin-4-yl]acetamide
DMP6S0L	DE	Discovery agent

DM7BYG8	ID	DM7BYG8
DM7BYG8	DN	KYS-05057
DM7BYG8	HS	Investigative
DM7BYG8	SN	KYS-05057; CHEMBL460646; SCHEMBL14417341; BDBM50251823; N-(4-(4-methylphenylsulfonamido)benzyl)-2-(2-(dimethylamino)-3-phenyl-3,4-dihydroquinazolin-4-yl)acetamide
DM7BYG8	DT	Small molecular drug
DM7BYG8	PC	44568141
DM7BYG8	MW	567.7
DM7BYG8	FM	C32H33N5O3S
DM7BYG8	IC	InChI=1S/C32H33N5O3S/c1-23-13-19-27(20-14-23)41(39,40)35-25-17-15-24(16-18-25)22-33-31(38)21-30-28-11-7-8-12-29(28)34-32(36(2)3)37(30)26-9-5-4-6-10-26/h4-20,30,35H,21-22H2,1-3H3,(H,33,38)
DM7BYG8	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CNC(=O)CC3C4=CC=CC=C4N=C(N3C5=CC=CC=C5)N(C)C
DM7BYG8	IK	BUARRUHMMCHOQJ-UHFFFAOYSA-N
DM7BYG8	IU	2-[2-(dimethylamino)-3-phenyl-4H-quinazolin-4-yl]-N-[[4-[(4-methylphenyl)sulfonylamino]phenyl]methyl]acetamide
DM7BYG8	DE	Discovery agent

DM61GPQ	ID	DM61GPQ
DM61GPQ	DN	KYS-05064
DM61GPQ	HS	Investigative
DM61GPQ	SN	KYS-05064; CHEMBL217660; SCHEMBL14417343; BDBM50192101; 2-(3-ethyl-2-(piperidin-1-yl)-3,4-dihydroquinazolin-4-yl)-N-(4-(4-methylphenylsulfonamido)benzyl)acetamide
DM61GPQ	DT	Small molecular drug
DM61GPQ	PC	11964508
DM61GPQ	MW	559.7
DM61GPQ	FM	C31H37N5O3S
DM61GPQ	IC	InChI=1S/C31H37N5O3S/c1-3-36-29(27-9-5-6-10-28(27)33-31(36)35-19-7-4-8-20-35)21-30(37)32-22-24-13-15-25(16-14-24)34-40(38,39)26-17-11-23(2)12-18-26/h5-6,9-18,29,34H,3-4,7-8,19-22H2,1-2H3,(H,32,37)
DM61GPQ	CS	CCN1C(C2=CC=CC=C2N=C1N3CCCCC3)CC(=O)NCC4=CC=C(C=C4)NS(=O)(=O)C5=CC=C(C=C5)C
DM61GPQ	IK	AAULUGZZFCAQJP-UHFFFAOYSA-N
DM61GPQ	IU	2-(3-ethyl-2-piperidin-1-yl-4H-quinazolin-4-yl)-N-[[4-[(4-methylphenyl)sulfonylamino]phenyl]methyl]acetamide
DM61GPQ	DE	Discovery agent

DMA8LFD	ID	DMA8LFD
DMA8LFD	DN	KYS-05065
DMA8LFD	HS	Investigative
DMA8LFD	SN	KYS-05065; CHEMBL480968; SCHEMBL14417346; BDBM50251822; N-(4-(4-fluorophenylsulfonamido)benzyl)-2-(3-ethyl-2-(piperidin-1-yl)-3,4-dihydroquinazolin-4-yl)acetamide
DMA8LFD	DT	Small molecular drug
DMA8LFD	PC	44568140
DMA8LFD	MW	563.7
DMA8LFD	FM	C30H34FN5O3S
DMA8LFD	IC	InChI=1S/C30H34FN5O3S/c1-2-36-28(26-8-4-5-9-27(26)33-30(36)35-18-6-3-7-19-35)20-29(37)32-21-22-10-14-24(15-11-22)34-40(38,39)25-16-12-23(31)13-17-25/h4-5,8-17,28,34H,2-3,6-7,18-21H2,1H3,(H,32,37)
DMA8LFD	CS	CCN1C(C2=CC=CC=C2N=C1N3CCCCC3)CC(=O)NCC4=CC=C(C=C4)NS(=O)(=O)C5=CC=C(C=C5)F
DMA8LFD	IK	PEIFDCMYVCGNKX-UHFFFAOYSA-N
DMA8LFD	IU	2-(3-ethyl-2-piperidin-1-yl-4H-quinazolin-4-yl)-N-[[4-[(4-fluorophenyl)sulfonylamino]phenyl]methyl]acetamide
DMA8LFD	DE	Discovery agent

DMRJQY3	ID	DMRJQY3
DMRJQY3	DN	KYS-05070
DMRJQY3	HS	Investigative
DMRJQY3	SN	KYS-05070; CHEMBL214498; SCHEMBL14417348
DMRJQY3	DT	Small molecular drug
DMRJQY3	PC	44416787
DMRJQY3	MW	519.7
DMRJQY3	FM	C28H33N5O3S
DMRJQY3	IC	InChI=1S/C28H33N5O3S/c1-5-33-26(24-8-6-7-9-25(24)30-28(33)32(3)4)18-27(34)29-19-21-12-14-22(15-13-21)31-37(35,36)23-16-10-20(2)11-17-23/h6-17,26,31H,5,18-19H2,1-4H3,(H,29,34)
DMRJQY3	CS	CCN1C(C2=CC=CC=C2N=C1N(C)C)CC(=O)NCC3=CC=C(C=C3)NS(=O)(=O)C4=CC=C(C=C4)C
DMRJQY3	IK	UBFZYFFOQNFRPD-UHFFFAOYSA-N
DMRJQY3	IU	2-[2-(dimethylamino)-3-ethyl-4H-quinazolin-4-yl]-N-[[4-[(4-methylphenyl)sulfonylamino]phenyl]methyl]acetamide
DMRJQY3	DE	Discovery agent

DM7K5Z3	ID	DM7K5Z3
DM7K5Z3	DN	KYS-05071
DM7K5Z3	HS	Investigative
DM7K5Z3	SN	KYS-05071; CHEMBL214951
DM7K5Z3	DT	Small molecular drug
DM7K5Z3	PC	44416758
DM7K5Z3	MW	523.6
DM7K5Z3	FM	C27H30FN5O3S
DM7K5Z3	IC	InChI=1S/C27H30FN5O3S/c1-4-33-25(23-7-5-6-8-24(23)30-27(33)32(2)3)17-26(34)29-18-19-9-13-21(14-10-19)31-37(35,36)22-15-11-20(28)12-16-22/h5-16,25,31H,4,17-18H2,1-3H3,(H,29,34)
DM7K5Z3	CS	CCN1C(C2=CC=CC=C2N=C1N(C)C)CC(=O)NCC3=CC=C(C=C3)NS(=O)(=O)C4=CC=C(C=C4)F
DM7K5Z3	IK	HWGHVXQPQONJBP-UHFFFAOYSA-N
DM7K5Z3	IU	2-[2-(dimethylamino)-3-ethyl-4H-quinazolin-4-yl]-N-[[4-[(4-fluorophenyl)sulfonylamino]phenyl]methyl]acetamide
DM7K5Z3	DE	Discovery agent

DMYRWQ3	ID	DMYRWQ3
DMYRWQ3	DN	KYS-05074
DMYRWQ3	HS	Investigative
DMYRWQ3	SN	KYS-05074; CHEMBL384090
DMYRWQ3	DT	Small molecular drug
DMYRWQ3	PC	44416844
DMYRWQ3	MW	390.5
DMYRWQ3	FM	C24H30N4O
DMYRWQ3	IC	InChI=1S/C24H30N4O/c1-2-28-22(17-23(29)25-18-19-11-5-3-6-12-19)20-13-7-8-14-21(20)26-24(28)27-15-9-4-10-16-27/h3,5-8,11-14,22H,2,4,9-10,15-18H2,1H3,(H,25,29)
DMYRWQ3	CS	CCN1C(C2=CC=CC=C2N=C1N3CCCCC3)CC(=O)NCC4=CC=CC=C4
DMYRWQ3	IK	OTPISXIISBCQOC-UHFFFAOYSA-N
DMYRWQ3	IU	N-benzyl-2-(3-ethyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DMYRWQ3	DE	Discovery agent

DMHW40F	ID	DMHW40F
DMHW40F	DN	KYS-05077
DMHW40F	HS	Investigative
DMHW40F	SN	KYS-05077; CHEMBL393304; BDBM50197241; BDBM50005356
DMHW40F	DT	Small molecular drug
DMHW40F	PC	25112470
DMHW40F	MW	523.7
DMHW40F	FM	C33H41N5O
DMHW40F	IC	InChI=1S/C33H41N5O/c1-36(21-11-4-12-22-37-23-13-14-24-37)33-35-30-20-10-9-19-29(30)31(38(33)28-17-7-3-8-18-28)25-32(39)34-26-27-15-5-2-6-16-27/h2-3,5-10,15-20,31H,4,11-14,21-26H2,1H3,(H,34,39)
DMHW40F	CS	CN(CCCCCN1CCCC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=CC=C5
DMHW40F	IK	DKHAGFIMNLTLHC-UHFFFAOYSA-N
DMHW40F	IU	N-benzyl-2-[2-[methyl(5-pyrrolidin-1-ylpentyl)amino]-3-phenyl-4H-quinazolin-4-yl]acetamide
DMHW40F	DE	Discovery agent

DM57BXZ	ID	DM57BXZ
DM57BXZ	DN	KYS-05080
DM57BXZ	HS	Investigative
DM57BXZ	SN	KYS-05080; CHEMBL248088; SCHEMBL10019252; BDBM50197240; N-benzyl-2-{3-biphenyl-4-yl-2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3,4-dihydro-quinazolin-4-yl}-acetamide
DM57BXZ	DT	Small molecular drug
DM57BXZ	PC	16048644
DM57BXZ	MW	599.8
DM57BXZ	FM	C39H45N5O
DM57BXZ	IC	InChI=1S/C39H45N5O/c1-42(25-11-4-12-26-43-27-13-14-28-43)39-41-36-20-10-9-19-35(36)37(29-38(45)40-30-31-15-5-2-6-16-31)44(39)34-23-21-33(22-24-34)32-17-7-3-8-18-32/h2-3,5-10,15-24,37H,4,11-14,25-30H2,1H3,(H,40,45)
DM57BXZ	CS	CN(CCCCCN1CCCC1)C2=NC3=CC=CC=C3C(N2C4=CC=C(C=C4)C5=CC=CC=C5)CC(=O)NCC6=CC=CC=C6
DM57BXZ	IK	SXLKSZQOUGOJGV-UHFFFAOYSA-N
DM57BXZ	IU	N-benzyl-2-[2-[methyl(5-pyrrolidin-1-ylpentyl)amino]-3-(4-phenylphenyl)-4H-quinazolin-4-yl]acetamide
DM57BXZ	DE	Discovery agent

DM92RHP	ID	DM92RHP
DM92RHP	DN	KYS-05090
DM92RHP	HS	Investigative
DM92RHP	SN	KYS-05090; CHEMBL394956; CHEMBL1269457; SCHEMBL10019253; BDBM50222222; N-benzyl-2-(3-(biphenyl-4-yl)-2-((5-(dimethylamino)pentyl)(methyl)amino)-3,4-dihydroquinazolin-4-yl)acetamide; N-Benzyl-3-(4-biphenylyl)-2-[5-(dimethylamino)pentyl(methyl)amino]-3,4-dihydroquinazoline-4-acetamide
DM92RHP	DT	Small molecular drug
DM92RHP	PC	23661603
DM92RHP	MW	573.8
DM92RHP	FM	C37H43N5O
DM92RHP	IC	InChI=1S/C37H43N5O/c1-40(2)25-13-6-14-26-41(3)37-39-34-20-12-11-19-33(34)35(27-36(43)38-28-29-15-7-4-8-16-29)42(37)32-23-21-31(22-24-32)30-17-9-5-10-18-30/h4-5,7-12,15-24,35H,6,13-14,25-28H2,1-3H3,(H,38,43)
DM92RHP	CS	CN(C)CCCCCN(C)C1=NC2=CC=CC=C2C(N1C3=CC=C(C=C3)C4=CC=CC=C4)CC(=O)NCC5=CC=CC=C5
DM92RHP	IK	QVXCZTNUVKNCGU-UHFFFAOYSA-N
DM92RHP	IU	N-benzyl-2-[2-[5-(dimethylamino)pentyl-methylamino]-3-(4-phenylphenyl)-4H-quinazolin-4-yl]acetamide
DM92RHP	DE	Discovery agent

DMB73Y4	ID	DMB73Y4
DMB73Y4	DN	L 691121
DMB73Y4	HS	Investigative
DMB73Y4	SN	L 691121 001X
DMB73Y4	DT	Small molecular drug
DMB73Y4	PC	164390
DMB73Y4	MW	493
DMB73Y4	FM	C22H25ClN4O5S
DMB73Y4	IC	InChI=1S/C22H24N4O5S.ClH/c1-32(28,29)25-16-3-5-21-17(13-16)20(27)14-22(30-21)7-10-26(11-8-22)9-6-15-2-4-18-19(12-15)24-31-23-18;/h2-5,12-13,25H,6-11,14H2,1H3;1H
DMB73Y4	CS	CS(=O)(=O)NC1=CC2=C(C=C1)OC3(CCN(CC3)CCC4=CC5=NON=C5C=C4)CC2=O.Cl
DMB73Y4	IK	NHRIUQWDVKKIAZ-UHFFFAOYSA-N
DMB73Y4	IU	N-[1'-[2-(2,1,3-benzoxadiazol-5-yl)ethyl]-4-oxospiro[3H-chromene-2,4'-piperidine]-6-yl]methanesulfonamide;hydrochloride
DMB73Y4	CA	CAS 136075-60-0
DMB73Y4	DE	Discovery agent

DMK07MI	ID	DMK07MI
DMK07MI	DN	L-(cis)-diltiazem
DMK07MI	HS	Investigative
DMK07MI	SN	L-cis-diltiazem; CHEBI:82813; [(2R,3R)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; L-(cis)-diltiazem; ent-diltiazem; cis-3-Acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one; (-)-cis-diltiazem; Lopac-D-2521; BSPBio_001357; SCHEMBL676914; GTPL2349; AC1L54N5; CHEMBL1397935; ZINC601259; HMS1791D19; HMS1989D19; NCGC00016818-04; NCGC00015332-01; NCGC00163133-03; NCGC00015332-02; NCGC00016818-01; CAS-33286-22-5; BRD-K81029756-001-02-8
DMK07MI	DT	Small molecular drug
DMK07MI	PC	198107
DMK07MI	MW	414.5
DMK07MI	FM	C22H26N2O4S
DMK07MI	IC	InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m0/s1
DMK07MI	CS	CC(=O)O[C@H]1[C@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DMK07MI	IK	HSUGRBWQSSZJOP-LEWJYISDSA-N
DMK07MI	IU	[(2R,3R)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMK07MI	CA	CAS 56209-45-1
DMK07MI	CB	CHEBI:82813
DMK07MI	DE	Discovery agent

DMYWD6C	ID	DMYWD6C
DMYWD6C	DN	L000021649
DMYWD6C	HS	Investigative
DMYWD6C	SN	pyrazolo[1,5-a]pyrimidine 4e; AC1NS6UK; SCHEMBL7622425; L000021649; CHEMBL333021; BDBM5413; VOYMOBPSYVKQGF-UHFFFAOYSA-N; 3-(3-Thienyl)-6-[4-(2-piperidinoethoxy)phenyl]pyrazolo[1,5-a]pyrimidine; 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-thiophen-3-ylpyrazolo[1,5-a]pyrimidine; 1-(2-{4-[3-(thiophen-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenoxy}ethyl)piperidine
DMYWD6C	DT	Small molecular drug
DMYWD6C	PC	5329450
DMYWD6C	MW	404.5
DMYWD6C	FM	C23H24N4OS
DMYWD6C	IC	InChI=1S/C23H24N4OS/c1-2-9-26(10-3-1)11-12-28-21-6-4-18(5-7-21)20-14-24-23-22(15-25-27(23)16-20)19-8-13-29-17-19/h4-8,13-17H,1-3,9-12H2
DMYWD6C	CS	C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CSC=C5)N=C3
DMYWD6C	IK	VOYMOBPSYVKQGF-UHFFFAOYSA-N
DMYWD6C	IU	6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-thiophen-3-ylpyrazolo[1,5-a]pyrimidine
DMYWD6C	DE	Discovery agent

DM9KWUR	ID	DM9KWUR
DM9KWUR	DN	L023103
DM9KWUR	HS	Investigative
DM9KWUR	SN	L 023103; L-023103
DM9KWUR	DT	Small molecular drug
DM9KWUR	PC	135413562
DM9KWUR	MW	625.1
DM9KWUR	FM	C30H33ClN6O5S
DM9KWUR	IC	InChI=1S/C30H33ClN6O5S/c1-36(2)19-5-18-32-27(38)17-10-21-8-15-24(16-9-21)43(41,42)37(23-13-11-22(31)12-14-23)20-28(39)34-35-29-25-6-3-4-7-26(25)33-30(29)40/h3-4,6-9,11-16,33,40H,5,10,17-20H2,1-2H3,(H,32,38)
DM9KWUR	CS	CN(C)CCCNC(=O)CCC1=CC=C(C=C1)S(=O)(=O)N(CC(=O)N=NC2=C(NC3=CC=CC=C32)O)C4=CC=C(C=C4)Cl
DM9KWUR	IK	BOPHFCQTNVDEDL-UHFFFAOYSA-N
DM9KWUR	IU	3-[4-[(4-chlorophenyl)-[2-[(2-hydroxy-1H-indol-3-yl)diazenyl]-2-oxoethyl]sulfamoyl]phenyl]-N-[3-(dimethylamino)propyl]propanamide
DM9KWUR	DE	Discovery agent

DMQR6ZX	ID	DMQR6ZX
DMQR6ZX	DN	L-054,522
DMQR6ZX	HS	Investigative
DMQR6ZX	SN	L054522; L 054522
DMQR6ZX	DT	Small molecular drug
DMQR6ZX	PC	15965425
DMQR6ZX	MW	645.8
DMQR6ZX	FM	C35H47N7O5
DMQR6ZX	IC	InChI=1S/C35H47N7O5/c1-22(25-21-37-26-12-6-5-11-24(25)26)30(31(43)38-28(14-9-10-18-36)32(44)47-35(2,3)4)40-33(45)41-19-16-23(17-20-41)42-29-15-8-7-13-27(29)39-34(42)46/h5-8,11-13,15,21-23,28,30,37H,9-10,14,16-20,36H2,1-4H3,(H,38,43)(H,39,46)(H,40,45)/t22-,28-,30+/m0/s1
DMQR6ZX	CS	C[C@@H](C1=CNC2=CC=CC=C21)[C@H](C(=O)N[C@@H](CCCCN)C(=O)OC(C)(C)C)NC(=O)N3CCC(CC3)N4C5=CC=CC=C5NC4=O
DMQR6ZX	IK	WFCIXKAZBUIFTR-PKIMSIDOSA-N
DMQR6ZX	IU	tert-butyl (2S)-6-amino-2-[[(2R,3S)-3-(1H-indol-3-yl)-2-[[4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1-carbonyl]amino]butanoyl]amino]hexanoate
DMQR6ZX	DE	Discovery agent

DMXB7G5	ID	DMXB7G5
DMXB7G5	DN	L-054852
DMXB7G5	HS	Investigative
DMXB7G5	CP	Merck
DMXB7G5	DT	Small molecular drug
DMXB7G5	PC	56603773
DMXB7G5	MW	561.8
DMXB7G5	FM	C32H43N5O2S
DMXB7G5	IC	InChI=1S/C32H43N5O2S/c1-21(2)30(40-19-16-33)36-29(38)28(22(3)25-20-34-27-11-7-5-9-24(25)27)35-31(39)37-17-14-32(15-18-37)13-12-23-8-4-6-10-26(23)32/h4-11,20-22,28,30,34H,12-19,33H2,1-3H3,(H,35,39)(H,36,38)
DMXB7G5	CS	CC(C)C(NC(=O)C(C(C)C1=CNC2=CC=CC=C21)NC(=O)N3CCC4(CCC5=CC=CC=C54)CC3)SCCN
DMXB7G5	IK	UDRSIUYQZOTMRD-UHFFFAOYSA-N
DMXB7G5	IU	N-[1-[[1-(2-aminoethylsulfanyl)-2-methylpropyl]amino]-3-(1H-indol-3-yl)-1-oxobutan-2-yl]spiro[1,2-dihydroindene-3,4'-piperidine]-1'-carboxamide
DMXB7G5	DE	Acromegaly

DMWNJV0	ID	DMWNJV0
DMWNJV0	DN	L-136662
DMWNJV0	HS	Investigative
DMWNJV0	SN	CHEMBL1222280; L-136662; AC1M5I9D; BDBM50324737; AKOS008966462; 3-(2-aminoethyl)-5-(4-(dimethylamino)benzylidene)thiazolidine-2,4-dione
DMWNJV0	DT	Small molecular drug
DMWNJV0	PC	2329349
DMWNJV0	MW	291.37
DMWNJV0	FM	C14H17N3O2S
DMWNJV0	IC	InChI=1S/C14H17N3O2S/c1-16(2)11-5-3-10(4-6-11)9-12-13(18)17(8-7-15)14(19)20-12/h3-6,9H,7-8,15H2,1-2H3/b12-9-
DMWNJV0	CS	CN(C)C1=CC=C(C=C1)/C=C\\2/C(=O)N(C(=O)S2)CCN
DMWNJV0	IK	BOQIVKJIDMTNLR-XFXZXTDPSA-N
DMWNJV0	IU	(5Z)-3-(2-aminoethyl)-5-[[4-(dimethylamino)phenyl]methylidene]-1,3-thiazolidine-2,4-dione
DMWNJV0	DE	Discovery agent

DMVGX7Z	ID	DMVGX7Z
DMVGX7Z	DN	L-152,804
DMVGX7Z	HS	Investigative
DMVGX7Z	SN	L-152804; L152804
DMVGX7Z	DT	Small molecular drug
DMVGX7Z	PC	3765615
DMVGX7Z	MW	366.4
DMVGX7Z	FM	C23H26O4
DMVGX7Z	IC	InChI=1S/C23H26O4/c1-22(2)9-14(24)20(15(25)10-22)19-13-7-5-6-8-17(13)27-18-12-23(3,4)11-16(26)21(18)19/h5-8,19-20H,9-12H2,1-4H3
DMVGX7Z	CS	CC1(CC(=O)C(C(=O)C1)C2C3=CC=CC=C3OC4=C2C(=O)CC(C4)(C)C)C
DMVGX7Z	IK	XQDXIHYKAGHZRX-UHFFFAOYSA-N
DMVGX7Z	IU	2-(3,3-dimethyl-1-oxo-4,9-dihydro-2H-xanthen-9-yl)-5,5-dimethylcyclohexane-1,3-dione
DMVGX7Z	CA	CAS 6508-43-6
DMVGX7Z	CB	CHEBI:91696
DMVGX7Z	DE	Discovery agent

DMOX8JE	ID	DMOX8JE
DMOX8JE	DN	L-159093
DMOX8JE	HS	Investigative
DMOX8JE	SN	CHEMBL24322; L-159093; BDBM50041969; L006880; 3-{2-Butyl-4-oxo-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,4-dihydro-quinazolin-6-yl}-1-isopropyl-1-methyl-urea
DMOX8JE	DT	Small molecular drug
DMOX8JE	PC	9829012
DMOX8JE	MW	550.7
DMOX8JE	FM	C31H34N8O2
DMOX8JE	IC	InChI=1S/C31H34N8O2/c1-5-6-11-28-33-27-17-16-23(32-31(41)38(4)20(2)3)18-26(27)30(40)39(28)19-21-12-14-22(15-13-21)24-9-7-8-10-25(24)29-34-36-37-35-29/h7-10,12-18,20H,5-6,11,19H2,1-4H3,(H,32,41)(H,34,35,36,37)
DMOX8JE	CS	CCCCC1=NC2=C(C=C(C=C2)NC(=O)N(C)C(C)C)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMOX8JE	IK	XUXPOYGCLABTCS-UHFFFAOYSA-N
DMOX8JE	IU	3-[2-butyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-6-yl]-1-methyl-1-propan-2-ylurea
DMOX8JE	DE	Discovery agent

DMZOW96	ID	DMZOW96
DMZOW96	DN	L-162313
DMZOW96	HS	Investigative
DMZOW96	SN	L-162,313; 151488-11-8; L-162313; CHEMBL288174; butyl 3-(4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)-5-isobutylthiophen-2-ylsulfonylcarbamate; 5,7-Dimethyl-2-ethyl-3-[[4-[2-(n-butyloxycarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]imidazo-[4,5-b]-pyridine; 5,7-Dimethyl-2-ethyl-3-[[4-[2(N-butyloxycarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]Imidazo[4,5,6]pyridine; L 162313; Lopac-L-1415; AC1O7G4F; Lopac0_000697; MLS002153426; SCHEMBL9132197; GTPL3936; C30H38N4O4S2; HMS3262K15
DMZOW96	DT	Small molecular drug
DMZOW96	PC	6603900
DMZOW96	MW	582.8
DMZOW96	FM	C30H38N4O4S2
DMZOW96	IC	InChI=1S/C30H38N4O4S2/c1-7-9-14-38-30(35)33-40(36,37)29-25(17-24(39-29)15-19(3)4)23-12-10-22(11-13-23)18-34-26(8-2)32-27-20(5)16-21(6)31-28(27)34/h10-13,16-17,19H,7-9,14-15,18H2,1-6H3,(H,33,35)
DMZOW96	CS	CCCCOC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C(=NC4=C3N=C(C=C4C)C)CC
DMZOW96	IK	RINPELQWLUGERM-UHFFFAOYSA-N
DMZOW96	IU	butyl N-[3-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate
DMZOW96	DE	Discovery agent

DMWSP6H	ID	DMWSP6H
DMWSP6H	DN	L-162782
DMWSP6H	HS	Investigative
DMWSP6H	SN	L-162782; CHEMBL289614; SCHEMBL9133104; BDBM50141059; butyl (4'-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-5-isobutyl-[1,1'-biphenyl]-2-yl)sulfonylcarbamate; N-Butyloxycarbonyl-4''-(2-Ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-ylmethyl)-5-isobutyl-biphenyl-2-sulfonic acid amide
DMWSP6H	DT	Small molecular drug
DMWSP6H	PC	10031067
DMWSP6H	MW	576.8
DMWSP6H	FM	C32H40N4O4S
DMWSP6H	IC	InChI=1S/C32H40N4O4S/c1-7-9-16-40-32(37)35-41(38,39)28-15-12-25(17-21(3)4)19-27(28)26-13-10-24(11-14-26)20-36-29(8-2)34-30-22(5)18-23(6)33-31(30)36/h10-15,18-19,21H,7-9,16-17,20H2,1-6H3,(H,35,37)
DMWSP6H	CS	CCCCOC(=O)NS(=O)(=O)C1=C(C=C(C=C1)CC(C)C)C2=CC=C(C=C2)CN3C(=NC4=C3N=C(C=C4C)C)CC
DMWSP6H	IK	GABMQILPAPONQS-UHFFFAOYSA-N
DMWSP6H	IU	butyl N-[2-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-(2-methylpropyl)phenyl]sulfonylcarbamate
DMWSP6H	DE	Discovery agent

DMYC7AK	ID	DMYC7AK
DMYC7AK	DN	L-163,101
DMYC7AK	HS	Investigative
DMYC7AK	SN	L-163101
DMYC7AK	DT	Small molecular drug
DMYC7AK	PC	73755245
DMYC7AK	MW	580.7
DMYC7AK	FM	C34H36N4O3S
DMYC7AK	IC	InChI=1S/C34H36N4O3S/c1-6-31-36-32-23(4)19-24(5)35-33(32)38(31)21-25-12-15-27(16-13-25)29-20-26(18-22(2)3)14-17-30(29)42(40,41)37-34(39)28-10-8-7-9-11-28/h7-17,19-20,22H,6,18,21H2,1-5H3,(H,37,39)
DMYC7AK	CS	CCC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC(=C4)CC(C)C)S(=O)(=O)NC(=O)C5=CC=CC=C5)N=C(C=C2C)C
DMYC7AK	IK	BRUYKNQQCIYYNP-UHFFFAOYSA-N
DMYC7AK	IU	N-[2-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-(2-methylpropyl)phenyl]sulfonylbenzamide
DMYC7AK	DE	Discovery agent

DMZP7YM	ID	DMZP7YM
DMZP7YM	DN	L-165041
DMZP7YM	HS	Investigative
DMZP7YM	SN	L165041
DMZP7YM	DT	Small molecular drug
DMZP7YM	PC	6603901
DMZP7YM	MW	402.4
DMZP7YM	FM	C22H26O7
DMZP7YM	IC	InChI=1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25)
DMZP7YM	CS	CCCC1=C(C=CC(=C1O)C(=O)C)OCCCOC2=CC=C(C=C2)OCC(=O)O
DMZP7YM	IK	HBBVCKCCQCQCTJ-UHFFFAOYSA-N
DMZP7YM	IU	2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid
DMZP7YM	CA	CAS 79558-09-1
DMZP7YM	CB	CHEBI:94812
DMZP7YM	DE	Discovery agent

DMKBSGN	ID	DMKBSGN
DMKBSGN	DN	L-165461
DMKBSGN	HS	Investigative
DMKBSGN	SN	L-165461; CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
DMKBSGN	DT	Small molecular drug
DMKBSGN	PC	9889841
DMKBSGN	MW	448
DMKBSGN	FM	C23H26ClNO4S
DMKBSGN	IC	InChI=1S/C23H26ClNO4S/c1-3-6-17-20(9-8-16-19(4-2)25-29-23(16)17)28-11-5-12-30-21-10-7-15(13-18(21)24)14-22(26)27/h7-10,13H,3-6,11-12,14H2,1-2H3,(H,26,27)
DMKBSGN	CS	CCCC1=C(C=CC2=C1ON=C2CC)OCCCSC3=C(C=C(C=C3)CC(=O)O)Cl
DMKBSGN	IK	LBEYMGDIPDOUKK-UHFFFAOYSA-N
DMKBSGN	IU	2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
DMKBSGN	DE	Discovery agent

DM3UGMD	ID	DM3UGMD
DM3UGMD	DN	L-168049
DM3UGMD	HS	Investigative
DM3UGMD	SN	Glucagon antagonists (diabetes); SCH-900822; Glucagon antagonists (diabetes), Merck & Co
DM3UGMD	CP	Merck Research Laboratories
DM3UGMD	DT	Small molecular drug
DM3UGMD	PC	5311276
DM3UGMD	MW	467.8
DM3UGMD	FM	C24H20BrClN2O
DM3UGMD	IC	InChI=1S/C24H20BrClN2O/c1-2-13-29-23-8-5-18(25)14-20(23)21-15-22(16-3-6-19(26)7-4-16)28-24(21)17-9-11-27-12-10-17/h3-12,14-15,28H,2,13H2,1H3
DM3UGMD	CS	CCCOC1=C(C=C(C=C1)Br)C2=C(NC(=C2)C3=CC=C(C=C3)Cl)C4=CC=NC=C4
DM3UGMD	IK	HHBOWXZOLYQFNY-UHFFFAOYSA-N
DM3UGMD	IU	4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]pyridine
DM3UGMD	CA	CAS 191034-25-0
DM3UGMD	CB	CHEBI:92326
DM3UGMD	DE	Diabetic complication

DMZ4KO0	ID	DMZ4KO0
DMZ4KO0	DN	L17
DMZ4KO0	HS	Investigative
DMZ4KO0	SN	Hydroxybutorphanol tartrate; AC1MI7CW; Morphinan-3,14-diol, 17-((3-trans-hydroxycyclobutyl)methyl)-, tartrate (2:1), l-; l-17-((3-trans-Hydroxycyclobutyl)methyl)morphinan-3,14-diol tartrate (2:1); Morphinan-3,14-diol, 17-((3-hydroxycyclobutyl)methyl)-, (17(trans))-, (R-(R*,R*))-2,3-dihydroxybutanedioate (2:1) (salt)
DMZ4KO0	DT	Small molecular drug
DMZ4KO0	PC	3064245
DMZ4KO0	MW	837
DMZ4KO0	FM	C46H64N2O12
DMZ4KO0	IC	InChI=1S/2C21H29NO3.C4H6O6/c2*23-16-4-3-15-11-19-21(25)6-2-1-5-20(21,18(15)12-16)7-8-22(19)13-14-9-17(24)10-14;5-1(3(7)8)2(6)4(9)10/h2*3-4,12,14,17,19,23-25H,1-2,5-11,13H2;1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1
DMZ4KO0	CS	C1CCC2(C3CC4=C(C2(C1)CCN3CC5CC(C5)O)C=C(C=C4)O)O.C1CCC2(C3CC4=C(C2(C1)CCN3CC5CC(C5)O)C=C(C=C4)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMZ4KO0	IK	HIJHYZCQDMUGEP-CEAXSRTFSA-N
DMZ4KO0	IU	(2R,3R)-2,3-dihydroxybutanedioic acid;17-[(3-hydroxycyclobutyl)methyl]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
DMZ4KO0	DE	Discovery agent

DMEK65F	ID	DMEK65F
DMEK65F	DN	L-249313
DMEK65F	HS	Investigative
DMEK65F	SN	L-249313; CHEMBL52735; AC1N966E; SCHEMBL13932309; BDBM50059376; methyl 9-methyl-2-phenyl-5H-[1,2,4]triazolo[5,1-a][2,7]naphthyridine-6-carboxylate; 9-Methyl-2-phenyl-5,9-dihydro-[1,2,4]triazolo[5,1-a][2,7]naphthyridine-6-carboxylic acid methyl ester
DMEK65F	DT	Small molecular drug
DMEK65F	PC	4355631
DMEK65F	MW	320.3
DMEK65F	FM	C18H16N4O2
DMEK65F	IC	InChI=1S/C18H16N4O2/c1-21-9-8-13-14(10-21)17-19-16(12-6-4-3-5-7-12)20-22(17)11-15(13)18(23)24-2/h3-10H,11H2,1-2H3
DMEK65F	CS	CN1C=CC2=C(CN3C(=NC(=N3)C4=CC=CC=C4)C2=C1)C(=O)OC
DMEK65F	IK	DBROFPXBIMMIMF-UHFFFAOYSA-N
DMEK65F	IU	methyl 9-methyl-2-phenyl-5H-[1,2,4]triazolo[5,1-a][2,7]naphthyridine-6-carboxylate
DMEK65F	DE	Discovery agent

DMV6018	ID	DMV6018
DMV6018	DN	L-269,289
DMV6018	HS	Investigative
DMV6018	SN	L-269289; AC1O6807; AE-641/30108011; [2-(2-{2-Aza-2-[4-(8-chloro(10H,11H-dibenzo[b,f]thiepin-10-yl))piperazinyl]vinyl}phenoxy)ethyl]dimethylamine; 2-[2-[(Z)-[4-(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]iminomethyl]phenoxy]-N,N-dimethyl-ethanamine; N-[4-(8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-1-piperazinyl]-N-{2-[2-(dimethylamino)ethoxy]benzylidene}amine
DMV6018	DT	Small molecular drug
DMV6018	PC	6448387
DMV6018	MW	521.1
DMV6018	FM	C29H33ClN4OS
DMV6018	IC	InChI=1S/C29H33ClN4OS/c1-32(2)17-18-35-27-9-5-3-8-23(27)21-31-34-15-13-33(14-16-34)26-19-22-7-4-6-10-28(22)36-29-12-11-24(30)20-25(26)29/h3-12,20-21,26H,13-19H2,1-2H3/b31-21-
DMV6018	CS	CN(C)CCOC1=CC=CC=C1/C=N\\N2CCN(CC2)C3CC4=CC=CC=C4SC5=C3C=C(C=C5)Cl
DMV6018	IK	OKSZYIOFSXRHJB-YQYKVWLJSA-N
DMV6018	IU	2-[2-[(Z)-[4-(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]iminomethyl]phenoxy]-N,N-dimethylethanamine
DMV6018	DE	Discovery agent

DMWQCRD	ID	DMWQCRD
DMWQCRD	DN	L-2-Amino-4-(Guanidinooxy)Butyric Acid
DMWQCRD	HS	Investigative
DMWQCRD	SN	L-canavanine; canavanine; Canavanin; 543-38-4; 2-Amino-4-(guanidinooxy)butyric acid; L-2-AMINO-4-(GUANIDINOOXY)BUTYRIC ACID; UNII-3HZV514J4B; O-((Aminoiminomethyl)amino)-L-homoserine; O-carbamimidamido-L-homoserine; 3HZV514J4B; CHEMBL443732; CHEBI:609827; (L)-CANAVANINE; O-((Aminoiminomethyl)amino)homoserine; GGB; HSDB 3471; AI3-52153; L-Homoserine, O-((aminoiminomethyl)amino)-; Butyric acid, 2-amino-4-(guanidinooxy)-, L-; C5H12N4O3; L(+)-Canavanine; Tocris-0673; Spectrum_001137; Spectrum3_001206; Spectrum2_000800
DMWQCRD	DT	Small molecular drug
DMWQCRD	PC	439202
DMWQCRD	MW	176.17
DMWQCRD	FM	C5H12N4O3
DMWQCRD	IC	InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9)/t3-/m0/s1
DMWQCRD	CS	C(CON=C(N)N)[C@@H](C(=O)O)N
DMWQCRD	IK	FSBIGDSBMBYOPN-VKHMYHEASA-N
DMWQCRD	IU	(2S)-2-amino-4-(diaminomethylideneamino)oxybutanoic acid
DMWQCRD	CA	CAS 543-38-4
DMWQCRD	CB	CHEBI:609827
DMWQCRD	DE	Discovery agent

DM1WMHO	ID	DM1WMHO
DM1WMHO	DN	L-365,209
DM1WMHO	HS	Investigative
DM1WMHO	SN	L-365209; L 365209
DM1WMHO	DT	Small molecular drug
DM1WMHO	PC	9810632
DM1WMHO	MW	738.9
DM1WMHO	FM	C40H50N8O6
DM1WMHO	IC	InChI=1S/C40H50N8O6/c1-4-26(2)34-40(54)48-32(19-12-22-42-48)39(53)47-31(18-11-21-41-47)37(51)45(3)33(25-28-16-9-6-10-17-28)38(52)46-23-13-20-30(46)36(50)43-29(35(49)44-34)24-27-14-7-5-8-15-27/h5-10,14-17,21-22,26,29-34H,4,11-13,18-20,23-25H2,1-3H3,(H,43,50)(H,44,49)/t26-,29+,30-,31-,32+,33+,34-/m0/s1
DM1WMHO	CS	CC[C@H](C)[C@H]1C(=O)N2[C@H](CCC=N2)C(=O)N3[C@@H](CCC=N3)C(=O)N([C@@H](C(=O)N4CCC[C@H]4C(=O)N[C@@H](C(=O)N1)CC5=CC=CC=C5)CC6=CC=CC=C6)C
DM1WMHO	IK	IFHSSGUGRIXWQU-NSTWBPGMSA-N
DM1WMHO	IU	(1R,8S,11R,17S,20R,23S)-11,20-dibenzyl-23-[(2S)-butan-2-yl]-10-methyl-3,4,10,13,19,22,25,26-octazatetracyclo[23.4.0.03,8.013,17]nonacosa-4,26-diene-2,9,12,18,21,24-hexone
DM1WMHO	DE	Discovery agent

DMGQE1B	ID	DMGQE1B
DMGQE1B	DN	L-366,509
DMGQE1B	HS	Investigative
DMGQE1B	SN	L-366509
DMGQE1B	DT	Small molecular drug
DMGQE1B	PC	3083288
DMGQE1B	MW	459.6
DMGQE1B	FM	C25H33NO5S
DMGQE1B	IC	InChI=1S/C25H33NO5S/c1-22(2)19-8-10-24(22,25(29,15-19)16-21(27)28)17-32(30,31)26-13-11-23(12-14-26)9-7-18-5-3-4-6-20(18)23/h3-7,9,19,29H,8,10-17H2,1-2H3,(H,27,28)
DMGQE1B	CS	CC1(C2CCC1(C(C2)(CC(=O)O)O)CS(=O)(=O)N3CCC4(CC3)C=CC5=CC=CC=C45)C
DMGQE1B	IK	XKVDTEPESVJNPJ-UHFFFAOYSA-N
DMGQE1B	IU	2-[2-hydroxy-7,7-dimethyl-1-(spiro[indene-1,4'-piperidine]-1'-ylsulfonylmethyl)-2-bicyclo[2.2.1]heptanyl]acetic acid
DMGQE1B	CA	CAS 138382-23-7
DMGQE1B	DE	Discovery agent

DMAS5P8	ID	DMAS5P8
DMAS5P8	DN	L-366,682
DMAS5P8	HS	Investigative
DMAS5P8	SN	cyclo(Pro-Trp-Ile-Pip-Pip-His); L 366682
DMAS5P8	DT	Small molecular drug
DMAS5P8	PC	196819
DMAS5P8	MW	755.9
DMAS5P8	FM	C40H53N9O6
DMAS5P8	IC	InChI=1S/C40H53N9O6/c1-3-26(2)34(38(54)49-19-10-7-15-40(49,24-50)39(55)47-16-8-4-9-17-47)46-35(51)32(20-27-22-43-31-13-6-5-12-29(27)31)45-36(52)33-14-11-18-48(33)37(53)30(41)21-28-23-42-25-44-28/h3,5-6,12-13,22-26,30,32-34,43H,1,4,7-11,14-21,41H2,2H3,(H,42,44)(H,45,52)(H,46,51)/t26-,30+,32+,33-,34-,40-/m0/s1
DMAS5P8	CS	C[C@@H](C=C)[C@@H](C(=O)N1CCCC[C@]1(C=O)C(=O)N2CCCCC2)NC(=O)[C@@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CN=CN6)N
DMAS5P8	IK	QHUGACUEEILSLD-NNWJBWDNSA-N
DMAS5P8	IU	(2S)-1-[(2R)-2-amino-3-(1H-imidazol-5-yl)propanoyl]-N-[(2R)-1-[[(2S,3S)-1-[(2S)-2-formyl-2-(piperidine-1-carbonyl)piperidin-1-yl]-3-methyl-1-oxopent-4-en-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMAS5P8	DE	Discovery agent

DM31NXF	ID	DM31NXF
DM31NXF	DN	L-366,948
DM31NXF	HS	Investigative
DM31NXF	SN	L 366948; L-366948
DM31NXF	DT	Small molecular drug
DM31NXF	PC	188397
DM31NXF	MW	768.9
DM31NXF	FM	C42H56N8O6
DM31NXF	IC	InChI=1S/C42H56N8O6/c1-3-28(2)35(46-37(53)33(43)24-29-15-16-30-13-6-7-14-31(30)23-29)36(52)41(27-51)17-12-22-50(41)38(54)34(44)25-32-26-45-42(47-32,39(55)48-18-8-4-9-19-48)40(56)49-20-10-5-11-21-49/h6-7,13-16,23,26-28,33-35H,3-5,8-12,17-22,24-25,43-44H2,1-2H3,(H,46,53)/t28-,33-,34+,35-,41-/m0/s1
DM31NXF	CS	CC[C@H](C)[C@@H](C(=O)[C@]1(CCCN1C(=O)[C@@H](CC2=NC(N=C2)(C(=O)N3CCCCC3)C(=O)N4CCCCC4)N)C=O)NC(=O)[C@H](CC5=CC6=CC=CC=C6C=C5)N
DM31NXF	IK	OCVKQRQVXSMCCJ-HWFQYKCLSA-N
DM31NXF	IU	(2S)-2-amino-N-[(2S,3S)-1-[(2S)-1-[(2R)-2-amino-3-[2,2-bis(piperidine-1-carbonyl)imidazol-4-yl]propanoyl]-2-formylpyrrolidin-2-yl]-3-methyl-1-oxopentan-2-yl]-3-naphthalen-2-ylpropanamide
DM31NXF	DE	Discovery agent

DMQ369D	ID	DMQ369D
DMQ369D	DN	L-367,773
DMQ369D	HS	Investigative
DMQ369D	SN	L-367773; L 367773
DMQ369D	DT	Small molecular drug
DMQ369D	PC	10413997
DMQ369D	MW	510.7
DMQ369D	FM	C28H38N4O3S
DMQ369D	IC	InChI=1S/C28H38N4O3S/c1-26(2)21-8-10-28(26,24(15-21)31-25(33)16-22-17-29-19-30-22)18-36(34,35)32-13-11-27(12-14-32)9-7-20-5-3-4-6-23(20)27/h3-6,17,19,21,24H,7-16,18H2,1-2H3,(H,29,30)(H,31,33)/t21-,24+,28-/m1/s1
DMQ369D	CS	CC1([C@@H]2CC[C@]1([C@H](C2)NC(=O)CC3=CN=CN3)CS(=O)(=O)N4CCC5(CCC6=CC=CC=C65)CC4)C
DMQ369D	IK	VQAVBHLGXVZOKM-RASJMTDNSA-N
DMQ369D	IU	N-[(1S,2S,4R)-7,7-dimethyl-1-(spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylsulfonylmethyl)-2-bicyclo[2.2.1]heptanyl]-2-(1H-imidazol-5-yl)acetamide
DMQ369D	DE	Discovery agent

DMC1Z0L	ID	DMC1Z0L
DMC1Z0L	DN	L-370,518
DMC1Z0L	HS	Investigative
DMC1Z0L	SN	CHEMBL2062141; L-370518; CHEMBL442024; BDBM50454822; BDBM50056772; (S)-1-((R)-2-Methylamino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid [(S)-1-(4-amino-cyclohexyl)-2-methylcarbamoyl-2-oxo-ethyl]-amide
DMC1Z0L	DT	Small molecular drug
DMC1Z0L	PC	10322542
DMC1Z0L	MW	471.6
DMC1Z0L	FM	C25H37N5O4
DMC1Z0L	IC	InChI=1S/C25H37N5O4/c1-27-19(15-16-7-4-3-5-8-16)25(34)30-14-6-9-20(30)23(32)29-21(22(31)24(33)28-2)17-10-12-18(26)13-11-17/h3-5,7-8,17-21,27H,6,9-15,26H2,1-2H3,(H,28,33)(H,29,32)/t17?,18?,19-,20+,21+/m1/s1
DMC1Z0L	CS	CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C3CCC(CC3)N)C(=O)C(=O)NC
DMC1Z0L	IK	ISJCFAFNSYZJRO-KJFGXLEFSA-N
DMC1Z0L	IU	(2S)-N-[(1S)-1-(4-aminocyclohexyl)-3-(methylamino)-2,3-dioxopropyl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMC1Z0L	DE	Discovery agent

DMQV974	ID	DMQV974
DMQV974	DN	L-372662
DMQV974	HS	Investigative
DMQV974	SN	L-372662; CHEMBL306645; L372662; L012255; 1-[1-[2-methoxy-4-[1-[(2-methyl-1-oxidopyridin-1-ium-3-yl)methyl]piperidin-4-yl]oxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one; AC1NSK7B; GTPL2253; SCHEMBL17423352; BDBM50064711; 162045-26-3; 1-(1-{2-Methoxy-4-[1-(2-methyl-1-oxy-pyridin-3-ylmethyl)-piperidin-4-yloxy]-benzoyl}-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
DMQV974	DT	Small molecular drug
DMQV974	PC	5311202
DMQV974	MW	586.7
DMQV974	FM	C33H38N4O6
DMQV974	IC	InChI=1S/C33H38N4O6/c1-23-24(7-5-15-36(23)40)21-34-16-13-27(14-17-34)43-28-9-10-29(31(20-28)41-2)32(38)35-18-11-26(12-19-35)37-30-8-4-3-6-25(30)22-42-33(37)39/h3-10,15,20,26-27H,11-14,16-19,21-22H2,1-2H3
DMQV974	CS	CC1=C(C=CC=[N+]1[O-])CN2CCC(CC2)OC3=CC(=C(C=C3)C(=O)N4CCC(CC4)N5C6=CC=CC=C6COC5=O)OC
DMQV974	IK	SKWSXDUHUVMPBT-UHFFFAOYSA-N
DMQV974	IU	1-[1-[2-methoxy-4-[1-[(2-methyl-1-oxidopyridin-1-ium-3-yl)methyl]piperidin-4-yl]oxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one
DMQV974	DE	Discovery agent

DMQWKPM	ID	DMQWKPM
DMQWKPM	DN	L-375378
DMQWKPM	HS	Investigative
DMQWKPM	SN	CHEMBL19080; L-37378; 199294-70-7; AC1L4BPU; L-375378; DTXSID80276443; ZINC1487441; BDBM50067797; N-[(6-amino-2-methyl-3-pyridinyl)methyl]-2-[6-methyl-2-oxo-3-(2-phenylethylamino)-1-pyrazinyl]acetamide; A814081; N-(6-Amino-2-methyl-pyridin-3-ylmethyl)-2-(6-methyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide; N-[(6-azanyl-2-methyl-pyridin-3-yl)methyl]-2-[6-methyl-2-oxidanylidene-3-(2-phenylethylamino)pyrazin-1-yl]ethanamide
DMQWKPM	DT	Small molecular drug
DMQWKPM	PC	154118
DMQWKPM	MW	406.5
DMQWKPM	FM	C22H26N6O2
DMQWKPM	IC	InChI=1S/C22H26N6O2/c1-15-12-26-21(24-11-10-17-6-4-3-5-7-17)22(30)28(15)14-20(29)25-13-18-8-9-19(23)27-16(18)2/h3-9,12H,10-11,13-14H2,1-2H3,(H2,23,27)(H,24,26)(H,25,29)
DMQWKPM	CS	CC1=CN=C(C(=O)N1CC(=O)NCC2=C(N=C(C=C2)N)C)NCCC3=CC=CC=C3
DMQWKPM	IK	PVDHYBJORRALSQ-UHFFFAOYSA-N
DMQWKPM	IU	N-[(6-amino-2-methylpyridin-3-yl)methyl]-2-[6-methyl-2-oxo-3-(2-phenylethylamino)pyrazin-1-yl]acetamide
DMQWKPM	CA	CAS 199294-70-7
DMQWKPM	DE	Discovery agent

DM0P4V6	ID	DM0P4V6
DM0P4V6	DN	L-454560
DM0P4V6	HS	Investigative
DM0P4V6	SN	MK-0359; UNII-G6GSO9SDNJ; L-454560; G6GSO9SDNJ; 346629-30-9; CHEMBL372575; Quinoline, 6-(1-methyl-1-(methylsulfonyl)ethyl)-8-(3-((1E)-2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)ethenyl)phenyl)-; SCHEMBL4027148; GTPL9852; MolPort-042-665-643; ZINC3964061; BDBM50174022; MK0359; KB-78879; L-454,560; 8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline
DM0P4V6	DT	Small molecular drug
DM0P4V6	PC	9853498
DM0P4V6	MW	587.7
DM0P4V6	FM	C31H29N3O5S2
DM0P4V6	IC	InChI=1S/C31H29N3O5S2/c1-20-33-30(39-34-20)28(22-11-13-26(14-12-22)40(4,35)36)17-21-8-6-9-23(16-21)27-19-25(31(2,3)41(5,37)38)18-24-10-7-15-32-29(24)27/h6-19H,1-5H3/b28-17+
DM0P4V6	CS	CC1=NOC(=N1)/C(=C/C2=CC(=CC=C2)C3=C4C(=CC(=C3)C(C)(C)S(=O)(=O)C)C=CC=N4)/C5=CC=C(C=C5)S(=O)(=O)C
DM0P4V6	IK	YYGZHVJDHMMABU-OGLMXYFKSA-N
DM0P4V6	IU	3-methyl-5-[(E)-1-(4-methylsulfonylphenyl)-2-[3-[6-(2-methylsulfonylpropan-2-yl)quinolin-8-yl]phenyl]ethenyl]-1,2,4-oxadiazole
DM0P4V6	CA	CAS 346629-30-9
DM0P4V6	DE	Discovery agent

DMHL901	ID	DMHL901
DMHL901	DN	L-5-(bromovinyl)deoxyuridine
DMHL901	HS	Investigative
DMHL901	SN	CHEMBL261850; L-5-(bromovinyl)deoxyuridine; SCHEMBL4314668; BDBM50375781
DMHL901	DT	Small molecular drug
DMHL901	PC	25323027
DMHL901	MW	333.13
DMHL901	FM	C11H13BrN2O5
DMHL901	IC	InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9-/m0/s1
DMHL901	CS	C1[C@@H]([C@H](O[C@@H]1N2C=C(C(=O)NC2=O)/C=C/Br)CO)O
DMHL901	IK	ODZBBRURCPAEIQ-RNVICZODSA-N
DMHL901	IU	5-[(E)-2-bromoethenyl]-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMHL901	DE	Discovery agent

DM3Q0JL	ID	DM3Q0JL
DM3Q0JL	DN	L-5-iodo-2'-deoxyuridine
DM3Q0JL	HS	Investigative
DM3Q0JL	SN	CHEMBL408518; URIDINE, 2'-DEOXY-5-IODO-; AC1LAEAG; SCHEMBL51859; XQFRJNBWHJMXHO-XVMARJQXSA-N; ZINC5223557; BDBM50375780; FT-0620507; 5-Iodo-1-(2-deoxy-alpha-D-ribofuranosyl)uracil
DM3Q0JL	DT	Small molecular drug
DM3Q0JL	PC	512326
DM3Q0JL	MW	354.1
DM3Q0JL	FM	C9H11IN2O5
DM3Q0JL	IC	InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7-/m0/s1
DM3Q0JL	CS	C1[C@@H]([C@H](O[C@@H]1N2C=C(C(=O)NC2=O)I)CO)O
DM3Q0JL	IK	XQFRJNBWHJMXHO-XVMARJQXSA-N
DM3Q0JL	IU	1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
DM3Q0JL	CA	CAS 54-42-2
DM3Q0JL	DE	Discovery agent

DMENUOD	ID	DMENUOD
DMENUOD	DN	L-644,698
DMENUOD	HS	Investigative
DMENUOD	SN	L644698; L-644698
DMENUOD	DT	Small molecular drug
DMENUOD	PC	9908595
DMENUOD	MW	393.5
DMENUOD	FM	C21H31NO4S
DMENUOD	IC	InChI=1S/C21H31NO4S/c1-2-3-4-7-18(23)13-14-22-19(24)15-27-20(22)8-5-6-16-9-11-17(12-10-16)21(25)26/h9-12,18,20,23H,2-8,13-15H2,1H3,(H,25,26)
DMENUOD	CS	CCCCCC(CCN1C(SCC1=O)CCCC2=CC=C(C=C2)C(=O)O)O
DMENUOD	IK	NDAXAJCKSWCWQI-UHFFFAOYSA-N
DMENUOD	IU	4-[3-[3-(3-hydroxyoctyl)-4-oxo-1,3-thiazolidin-2-yl]propyl]benzoic acid
DMENUOD	DE	Discovery agent

DMA23LP	ID	DMA23LP
DMA23LP	DN	L-652,343
DMA23LP	HS	Investigative
DMA23LP	DT	Small molecular drug
DMA23LP	PC	3035865
DMA23LP	MW	445.5
DMA23LP	FM	C22H14F3NO2S2
DMA23LP	IC	InChI=1S/C22H14F3NO2S2/c23-22(24,25)14-8-9-18-15(11-14)19(27)20(30-18)21(28)26-12-16(17-7-4-10-29-17)13-5-2-1-3-6-13/h1-12,27H,(H,26,28)/b16-12+
DMA23LP	CS	C1=CC=C(C=C1)/C(=C\\NC(=O)C2=C(C3=C(S2)C=CC(=C3)C(F)(F)F)O)/C4=CC=CS4
DMA23LP	IK	MWRHQMNEBAXDOF-FOWTUZBSSA-N
DMA23LP	IU	3-hydroxy-N-[(E)-2-phenyl-2-thiophen-2-ylethenyl]-5-(trifluoromethyl)-1-benzothiophene-2-carboxamide
DMA23LP	CA	CAS 102565-09-3
DMA23LP	DE	Discovery agent

DM360VU	ID	DM360VU
DM360VU	DN	L-652731
DM360VU	HS	Investigative
DM360VU	SN	CHEMBL297624; L-652731; AC1OCET6; SCHEMBL7018011; BDBM50366241; U-80271; (2R,5R)-2,5-bis(3,4,5-trimethoxyphenyl)oxolane; ([trans-2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran])
DM360VU	DT	Small molecular drug
DM360VU	PC	6917920
DM360VU	MW	404.5
DM360VU	FM	C22H28O7
DM360VU	IC	InChI=1S/C22H28O7/c1-23-17-9-13(10-18(24-2)21(17)27-5)15-7-8-16(29-15)14-11-19(25-3)22(28-6)20(12-14)26-4/h9-12,15-16H,7-8H2,1-6H3/t15-,16-/m1/s1
DM360VU	CS	COC1=CC(=CC(=C1OC)OC)[C@H]2CC[C@@H](O2)C3=CC(=C(C(=C3)OC)OC)OC
DM360VU	IK	YCCPYTPBHUIHGW-HZPDHXFCSA-N
DM360VU	IU	(2R,5R)-2,5-bis(3,4,5-trimethoxyphenyl)oxolane
DM360VU	DE	Discovery agent

DM4CDIB	ID	DM4CDIB
DM4CDIB	DN	L-655708
DM4CDIB	HS	Investigative
DM4CDIB	SN	130477-52-0; CHEMBL52030; NCGC00025115-02; Ethyl (S)-11,12,13,13a-Tetrahydro-7-methoxy-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate; Lopac0_000700; SCHEMBL5533646; YKYOQIXTECBVBB-AWEZNQCLSA-N; MolPort-003-983-605; HMS3262K21; ZINC2584032; Tox21_500700; MFCD02684528; BN0287; BDBM50067424; AKOS024456530; FG-8094; API0007742; LP00700; CCG-204785; CS-4943; NCGC00261385-01; NCGC00025115-04; NCGC00025115-03; HY-14426; KB-78047; EU-0100700; L-655,708, &gt
DM4CDIB	DT	Small molecular drug
DM4CDIB	PC	5311203
DM4CDIB	MW	341.4
DM4CDIB	FM	C18H19N3O4
DM4CDIB	IC	InChI=1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3/t14-/m0/s1
DM4CDIB	CS	CCOC(=O)C1=C2[C@@H]3CCCN3C(=O)C4=C(N2C=N1)C=CC(=C4)OC
DM4CDIB	IK	YKYOQIXTECBVBB-AWEZNQCLSA-N
DM4CDIB	IU	ethyl (7S)-15-methoxy-12-oxo-2,4,11-triazatetracyclo[11.4.0.02,6.07,11]heptadeca-1(17),3,5,13,15-pentaene-5-carboxylate
DM4CDIB	DE	Discovery agent

DMY0IQ6	ID	DMY0IQ6
DMY0IQ6	DN	L-658,758
DMY0IQ6	HS	Investigative
DMY0IQ6	SN	L-658758; L 658758; L-658,758; CHEMBL446371; L 658,758; (6R-cis)-1-((3-((Acetyloxy)methyl)-7-methoxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-yl)carbonyl)-L-proline S,S-dioxide; 3-Acetoxymethyl-7-methoxy-1-aza-5-thia-8-oxo-bicyclo(4.2.0)oct-2-ene-2-carboxypyrrolidine carboxamide; 116507-04-1; L-Proline, 1-((3-((acetyloxy)methyl)-7-methoxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-yl)carbonyl)-, S,S-dioxide, (6R-cis)-; AC1L3TQJ; SCHEMBL18498419; BDBM50368407; LS-186924; LS-187574; UNII-YMN4MD1ZGQ component SMZXYXKZTNLA
DMY0IQ6	DT	Small molecular drug
DMY0IQ6	PC	121963
DMY0IQ6	MW	416.4
DMY0IQ6	FM	C16H20N2O9S
DMY0IQ6	IC	InChI=1S/C16H20N2O9S/c1-8(19)27-6-9-7-28(24,25)15-12(26-2)14(21)18(15)11(9)13(20)17-5-3-4-10(17)16(22)23/h10,12,15H,3-7H2,1-2H3,(H,22,23)/t10-,12-,15+/m0/s1
DMY0IQ6	CS	CC(=O)OCC1=C(N2[C@@H]([C@H](C2=O)OC)S(=O)(=O)C1)C(=O)N3CCC[C@H]3C(=O)O
DMY0IQ6	IK	SMZXYXKZTNLAKY-ITDIGPHOSA-N
DMY0IQ6	IU	(2S)-1-[(6R,7S)-3-(acetyloxymethyl)-7-methoxy-5,5,8-trioxo-5lambda6-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbonyl]pyrrolidine-2-carboxylic acid
DMY0IQ6	CA	CAS 116507-04-1
DMY0IQ6	DE	Discovery agent

DMDF0KZ	ID	DMDF0KZ
DMDF0KZ	DN	L-659,699
DMDF0KZ	HS	Investigative
DMDF0KZ	SN	L 659699; hymeglusin; antibiotic 1233A
DMDF0KZ	DT	Small molecular drug
DMDF0KZ	PC	6440895
DMDF0KZ	MW	324.4
DMDF0KZ	FM	C18H28O5
DMDF0KZ	IC	InChI=1S/C18H28O5/c1-12(8-13(2)9-14(3)10-17(20)21)6-4-5-7-16-15(11-19)18(22)23-16/h9-10,12,15-16,19H,4-8,11H2,1-3H3,(H,20,21)/b13-9+,14-10+/t12-,15-,16-/m1/s1
DMDF0KZ	CS	C[C@H](CCCC[C@@H]1[C@H](C(=O)O1)CO)C/C(=C/C(=C/C(=O)O)/C)/C
DMDF0KZ	IK	ODCZJZWSXPVLAW-KXCGKLMDSA-N
DMDF0KZ	IU	(2E,4E,7R)-11-[(2R,3R)-3-(hydroxymethyl)-4-oxooxetan-2-yl]-3,5,7-trimethylundeca-2,4-dienoic acid
DMDF0KZ	CA	CAS 29066-42-0
DMDF0KZ	DE	Discovery agent

DMP4QCJ	ID	DMP4QCJ
DMP4QCJ	DN	L-671,480
DMP4QCJ	HS	Investigative
DMP4QCJ	DE	Discovery agent

DMJUQT1	ID	DMJUQT1
DMJUQT1	DN	L-685,818
DMJUQT1	HS	Investigative
DMJUQT1	DT	Small molecular drug
DMJUQT1	PC	445642
DMJUQT1	MW	808
DMJUQT1	FM	C43H69NO13
DMJUQT1	IC	InChI=1S/C43H69NO13/c1-10-29-18-23(2)37(48)24(3)19-35(54-8)39-36(55-9)20-26(5)43(52,57-39)40(49)41(50)44-16-12-11-13-30(44)42(51)56-38(27(6)32(46)22-33(29)47)25(4)17-28-14-15-31(45)34(21-28)53-7/h17-18,24,26-32,34-39,45-46,48,52H,10-16,19-22H2,1-9H3/b23-18+,25-17+/t24-,26-,27-,28+,29-,30+,31-,32+,34-,35+,36+,37-,38-,39-,43-/m1/s1
DMJUQT1	CS	CC[C@@H]1/C=C(/[C@H]([C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC)C)O)\\C
DMJUQT1	IK	NOQNPBXNHMZMTC-UGTSZWOVSA-N
DMJUQT1	IU	(1R,9S,12S,13R,14S,17R,18E,20S,21R,23S,24R,25S,27R)-17-ethyl-1,14,20-trihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMJUQT1	DE	Discovery agent

DMCH3ZK	ID	DMCH3ZK
DMCH3ZK	DN	L-689,037
DMCH3ZK	HS	Investigative
DMCH3ZK	SN	L-689037; CHEMBL314337; 136668-50-3; 1-((4-Chlorophenyl)methyl)-3-(3,3-dimethyl-1-oxobutyl)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-indole-2-propanoic acid; L 689037; L-689,037; ACMC-20mw95; L 689,037; SCHEMBL2108178; CTK0H7100; BDBM50229761; 1H-Indole-2-propanoic acid, 1-((4-chlorophenyl)methyl)-3-(3,3-dimethyl-1-oxobutyl)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-
DMCH3ZK	DT	Small molecular drug
DMCH3ZK	PC	11758240
DMCH3ZK	MW	597.1
DMCH3ZK	FM	C36H37ClN2O4
DMCH3ZK	IC	InChI=1S/C36H37ClN2O4/c1-35(2,3)20-32(40)33-28-18-27(43-22-26-15-12-24-8-6-7-9-29(24)38-26)16-17-30(28)39(21-23-10-13-25(37)14-11-23)31(33)19-36(4,5)34(41)42/h6-18H,19-22H2,1-5H3,(H,41,42)
DMCH3ZK	CS	CC(C)(C)CC(=O)C1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)O
DMCH3ZK	IK	IUHIISLXVJPCRU-UHFFFAOYSA-N
DMCH3ZK	IU	3-[1-[(4-chlorophenyl)methyl]-3-(3,3-dimethylbutanoyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid
DMCH3ZK	CA	CAS 136668-50-3
DMCH3ZK	DE	Discovery agent

DM42BGX	ID	DM42BGX
DM42BGX	DN	L-689065
DM42BGX	HS	Investigative
DM42BGX	SN	CHEMBL295761; L-689065; SCHEMBL9581325; BDBM50045667; 3-[1-(4-Chloro-benzyl)-4-methyl-6-(5-phenyl-pyridin-2-ylmethoxy)-4,5-dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]-2,2-dimethyl-propionic acid; 3-[1-(4-Chloro-benzyl)-4-methyl-6-(5-phenyl-pyridin-2-ylmethoxy)-4,5-dihydro-1H-3-thia-1-aza-acenaphthylen-2-yl]-2,2-dimethyl-propionic acid
DM42BGX	DT	Small molecular drug
DM42BGX	PC	9960281
DM42BGX	MW	597.2
DM42BGX	FM	C35H33ClN2O3S
DM42BGX	IC	InChI=1S/C35H33ClN2O3S/c1-22-17-28-31(41-21-27-14-11-25(19-37-27)24-7-5-4-6-8-24)16-15-29-32(28)33(42-22)30(18-35(2,3)34(39)40)38(29)20-23-9-12-26(36)13-10-23/h4-16,19,22H,17-18,20-21H2,1-3H3,(H,39,40)
DM42BGX	CS	CC1CC2=C(C=CC3=C2C(=C(N3CC4=CC=C(C=C4)Cl)CC(C)(C)C(=O)O)S1)OCC5=NC=C(C=C5)C6=CC=CC=C6
DM42BGX	IK	UWFKZJIWHDTXTG-UHFFFAOYSA-N
DM42BGX	IU	3-[2-[(4-chlorophenyl)methyl]-6-methyl-9-[(5-phenylpyridin-2-yl)methoxy]-5-thia-2-azatricyclo[6.3.1.04,12]dodeca-1(12),3,8,10-tetraen-3-yl]-2,2-dimethylpropanoic acid
DM42BGX	DE	Discovery agent

DMAB1RW	ID	DMAB1RW
DMAB1RW	DN	L-692289
DMAB1RW	HS	Investigative
DMAB1RW	SN	CHEMBL437438; L-692289; AC1MHQQ8; BDBM50285493; N-{(2R,6S,9S,11R,14aS,15S,20S,23S,25aS)-20-[(1R)-3-Amino-1-hydroxy-3-oxopropyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-23-[(1R)-1-hydroxy-2-(4-hydroxyphenyl)ethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
DMAB1RW	PC	3009699
DMAB1RW	MW	1033.2
DMAB1RW	FM	C50H80N8O15
DMAB1RW	IC	InChI=1S/C50H80N8O15/c1-5-27(2)20-28(3)12-10-8-6-7-9-11-13-40(67)53-34-22-32(61)25-52-48(71)44-36(63)18-19-57(44)50(73)43(38(65)24-39(51)66)56-47(70)42(37(64)21-30-14-16-31(60)17-15-30)55-46(69)35-23-33(62)26-58(35)49(72)41(29(4)59)54-45(34)68/h14-17,27-29,32-38,41-44,59-65H,5-13,18-26H2,1-4H3,(H2,51,66)(H,52,71)(H,53,67)(H,54,68)(H,55,69)(H,56,70)/t27?,28?,29-,32-,33-,34+,35+,36+,37-,38-,41+,42+,43+,44+/m1/s1
DMAB1RW	CS	CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H](CNC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H](CC4=CC=C(C=C4)O)O)[C@@H](CC(=O)N)O)O)O
DMAB1RW	IK	ZDGSWUBIMMFISL-IQTRWBIESA-N
DMAB1RW	IU	N-[(3S,6S,9S,11R,15S,18S,20R,24S,25S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-6-[(1R)-1-hydroxy-2-(4-hydroxyphenyl)ethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
DMAB1RW	DE	Discovery agent

DMMUYHX	ID	DMMUYHX
DMMUYHX	DN	L-693612
DMMUYHX	HS	Investigative
DMMUYHX	SN	(-)-(2S,4S)-6-(3-Methoxypropyl)-4-(propylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; 138301-71-0
DMMUYHX	DT	Small molecular drug
DMMUYHX	PC	67668482
DMMUYHX	MW	396.6
DMMUYHX	FM	C14H24N2O5S3
DMMUYHX	IC	InChI=1S/C14H24N2O5S3/c1-3-6-16-12-8-10(5-4-7-21-2)23(17,18)14-11(12)9-13(22-14)24(15,19)20/h9-10,12,16H,3-8H2,1-2H3,(H2,15,19,20)/t10-,12-/m0/s1
DMMUYHX	CS	CCCN[C@H]1C[C@@H](S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC
DMMUYHX	IK	JNPHBSXNRNBLCV-JQWIXIFHSA-N
DMMUYHX	IU	(4S,6S)-6-(3-methoxypropyl)-7,7-dioxo-4-(propylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
DMMUYHX	CA	CAS 138301-71-0
DMMUYHX	DE	Glaucoma/ocular hypertension

DM92X5T	ID	DM92X5T
DM92X5T	DN	L-702-539
DM92X5T	HS	Investigative
DM92X5T	SN	CHEMBL97380; SCHEMBL9300407; L-702-539
DM92X5T	DT	Small molecular drug
DM92X5T	PC	44329500
DM92X5T	MW	453.5
DM92X5T	FM	C28H23NO5
DM92X5T	IC	InChI=1S/C28H23NO5/c29-14-19-8-21-11-23(4-5-25(21)26(10-19)20-6-7-31-16-20)32-15-18-2-1-3-22(9-18)28(30)12-24-17-33-27(13-28)34-24/h1-11,16,24,27,30H,12-13,15,17H2
DM92X5T	CS	C1C2COC(O2)CC1(C3=CC=CC(=C3)COC4=CC5=C(C=C4)C(=CC(=C5)C#N)C6=COC=C6)O
DM92X5T	IK	CHLJRXIFRPILDX-UHFFFAOYSA-N
DM92X5T	IU	4-(furan-3-yl)-7-[[3-(3-hydroxy-6,8-dioxabicyclo[3.2.1]octan-3-yl)phenyl]methoxy]naphthalene-2-carbonitrile
DM92X5T	DE	Discovery agent

DMUOPRT	ID	DMUOPRT
DMUOPRT	DN	L-703,606
DMUOPRT	HS	Investigative
DMUOPRT	SN	L-703606
DMUOPRT	DT	Small molecular drug
DMUOPRT	PC	132629
DMUOPRT	MW	508.4
DMUOPRT	FM	C27H29IN2
DMUOPRT	IC	InChI=1S/C27H29IN2/c28-24-14-8-7-13-23(24)19-29-26-22-15-17-30(18-16-22)27(26)25(20-9-3-1-4-10-20)21-11-5-2-6-12-21/h1-14,22,25-27,29H,15-19H2/t26-,27-/m1/s1
DMUOPRT	CS	C1CN2CCC1[C@H]([C@H]2C(C3=CC=CC=C3)C4=CC=CC=C4)NCC5=CC=CC=C5I
DMUOPRT	IK	WSLTYZVXORBNLB-KAYWLYCHSA-N
DMUOPRT	IU	(2R,3R)-2-benzhydryl-N-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
DMUOPRT	CA	CAS 144425-84-3
DMUOPRT	DE	Discovery agent

DMWYIJ3	ID	DMWYIJ3
DMWYIJ3	DN	L-708,906
DMWYIJ3	HS	Investigative
DMWYIJ3	SN	L-708906; CHEMBL19977; SCHEMBL4935528; L-708,906; AC1L9T47; CTK7I3759; BDBM107681; 4-(3,5-dibenzyloxyphenyl)-2,4-dioxo-butanoic acid; 4-[3,5-bis(benzyloxy)phenyl]-2,4-dioxobutanoic acid; 4-(3,5-Bis-benzyloxy-phenyl)-2,4-dioxo-butyric acid; 4-[3,5-bis(phenylmethoxy)phenyl]-2,4-dioxobutanoic acid; (2Z)-4-[3,5-bis(benzyloxy)phenyl]-2-hydroxy-4- oxobut-2-enoic acid (Compound 2)
DMWYIJ3	DT	Small molecular drug
DMWYIJ3	PC	475514
DMWYIJ3	MW	404.4
DMWYIJ3	FM	C24H20O6
DMWYIJ3	IC	InChI=1S/C24H20O6/c25-22(14-23(26)24(27)28)19-11-20(29-15-17-7-3-1-4-8-17)13-21(12-19)30-16-18-9-5-2-6-10-18/h1-13H,14-16H2,(H,27,28)
DMWYIJ3	CS	C1=CC=C(C=C1)COC2=CC(=CC(=C2)C(=O)CC(=O)C(=O)O)OCC3=CC=CC=C3
DMWYIJ3	IK	SLRLQBRWUMWEOZ-UHFFFAOYSA-N
DMWYIJ3	IU	4-[3,5-bis(phenylmethoxy)phenyl]-2,4-dioxobutanoic acid
DMWYIJ3	DE	Discovery agent

DM3QUCS	ID	DM3QUCS
DM3QUCS	DN	L-708474
DM3QUCS	HS	Investigative
DM3QUCS	SN	CHEMBL58699; L-708474; SCHEMBL9301528; BDBM50040666
DM3QUCS	DT	Small molecular drug
DM3QUCS	PC	9953071
DM3QUCS	MW	404.5
DM3QUCS	FM	C24H28N4O2
DM3QUCS	IC	InChI=1S/C24H28N4O2/c1-16-9-8-12-18(15-16)25-24(30)27-22-23(29)28(2)20-14-7-6-13-19(20)21(26-22)17-10-4-3-5-11-17/h6-9,12-15,17,22H,3-5,10-11H2,1-2H3,(H2,25,27,30)/t22-/m0/s1
DM3QUCS	CS	CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)C4CCCCC4)C
DM3QUCS	IK	MYNLMIGJXBPKMR-QFIPXVFZSA-N
DM3QUCS	IU	1-[(3R)-5-cyclohexyl-1-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DM3QUCS	DE	Discovery agent

DMLMV9P	ID	DMLMV9P
DMLMV9P	DN	L-708568
DMLMV9P	HS	Investigative
DMLMV9P	SN	L-708568; CHEMBL23129; 2-Acetylamino-3-(1H-indol-3-yl)-propionic acid 3,5-dimethyl-benzyl ester; BDBM50030133; (S)-2-Acetylamino-3-(1H-indol-3-yl)-propionic acid 3,5-dimethyl-benzyl ester
DMLMV9P	DT	Small molecular drug
DMLMV9P	PC	10473960
DMLMV9P	MW	364.4
DMLMV9P	FM	C22H24N2O3
DMLMV9P	IC	InChI=1S/C22H24N2O3/c1-14-8-15(2)10-17(9-14)13-27-22(26)21(24-16(3)25)11-18-12-23-20-7-5-4-6-19(18)20/h4-10,12,21,23H,11,13H2,1-3H3,(H,24,25)/t21-/m0/s1
DMLMV9P	CS	CC1=CC(=CC(=C1)COC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)C)C
DMLMV9P	IK	YIHWPQQGVKFHTC-NRFANRHFSA-N
DMLMV9P	IU	(3,5-dimethylphenyl)methyl (2S)-2-acetamido-3-(1H-indol-3-yl)propanoate
DMLMV9P	DE	Discovery agent

DM9KCYQ	ID	DM9KCYQ
DM9KCYQ	DN	L-709,587
DM9KCYQ	HS	Investigative
DM9KCYQ	SN	L-709,587; C32-O-(1-METHYL-INDOL-5-YL) 18-HYDROXY-ASCOMYCIN; 1qpl; DB03621
DM9KCYQ	DT	Small molecular drug
DM9KCYQ	PC	5496872
DM9KCYQ	MW	937.2
DM9KCYQ	FM	C52H76N2O13
DM9KCYQ	IC	InChI=1S/C52H76N2O13/c1-11-35-23-29(2)46(57)30(3)24-44(63-9)48-45(64-10)25-32(5)52(61,67-48)49(58)50(59)54-20-13-12-14-39(54)51(60)66-47(33(6)40(55)28-41(35)56)31(4)22-34-15-18-42(43(26-34)62-8)65-37-16-17-38-36(27-37)19-21-53(38)7/h16-17,19,21-23,27,30,32-35,39-40,42-48,55,57,61H,11-15,18,20,24-26,28H2,1-10H3/b29-23+,31-22+/t30-,32-,33-,34+,35-,39+,40+,42-,43-,44+,45+,46-,47-,48-,52-/m1/s1
DM9KCYQ	CS	CC[C@@H]1/C=C(/[C@H]([C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)OC5=CC6=C(C=C5)N(C=C6)C)/C)O)C)OC)OC)C)O)\\C
DM9KCYQ	IK	APSPCHLQXFEUHG-CPBVNLROSA-N
DM9KCYQ	IU	(1R,9S,12S,13R,14S,17R,18E,20S,21R,23S,24R,25S,27R)-17-ethyl-1,14,20-trihydroxy-23,25-dimethoxy-12-[(E)-1-[(1R,3R,4R)-3-methoxy-4-(1-methylindol-5-yl)oxycyclohexyl]prop-1-en-2-yl]-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DM9KCYQ	DE	Discovery agent

DM7YVUT	ID	DM7YVUT
DM7YVUT	DN	L-731,988
DM7YVUT	HS	Investigative
DM7YVUT	SN	L-731988; CHEMBL50605; 251922-77-7; AC1Q5RH2; SCHEMBL4936294; AC1L9T44; CTK4F5172; BDBM23399; 4-[1-(4-fluorobenzyl)-1h-pyrrol-2-yl]-2,4-dioxobutanoic acid; 4-[1-[(4-fluorophenyl)methyl]pyrrol-2-yl]-2,4-dioxobutanoic acid; 4-(1-(4-Fluoro-benzyl)-1H-pyrrol-2-yl)-2,4-dioxo-butyric acid; 1H-Pyrrole-2-butanoicacid, 1-[(4-fluorophenyl)methyl]-a,g-dioxo-; 4-{1-[(4-fluorophenyl)methyl]-1H-pyrrol-2-yl}-2,4-dioxobutanoic acid; 1H-Pyrrole-2-butanoic acid, 1-((4-fluorophenyl)methyl)-alpha,gamma-dioxo-
DM7YVUT	DT	Small molecular drug
DM7YVUT	PC	475513
DM7YVUT	MW	289.26
DM7YVUT	FM	C15H12FNO4
DM7YVUT	IC	InChI=1S/C15H12FNO4/c16-11-5-3-10(4-6-11)9-17-7-1-2-12(17)13(18)8-14(19)15(20)21/h1-7H,8-9H2,(H,20,21)
DM7YVUT	CS	C1=CN(C(=C1)C(=O)CC(=O)C(=O)O)CC2=CC=C(C=C2)F
DM7YVUT	IK	PJIBKQJSMPMZCH-UHFFFAOYSA-N
DM7YVUT	IU	4-[1-[(4-fluorophenyl)methyl]pyrrol-2-yl]-2,4-dioxobutanoic acid
DM7YVUT	CA	CAS 251922-77-7
DM7YVUT	DE	Discovery agent

DM8WCUY	ID	DM8WCUY
DM8WCUY	DN	L-731120
DM8WCUY	HS	Investigative
DM8WCUY	SN	L 731120
DM8WCUY	DT	Small molecular drug
DM8WCUY	PC	9931928
DM8WCUY	MW	420.5
DM8WCUY	FM	C23H32O7
DM8WCUY	IC	InChI=1S/C23H32O7/c1-16(13-17(2)14-18-10-6-4-7-11-18)9-5-3-8-12-19(21(26)27)23(30,22(28)29)15-20(24)25/h4,6-7,10-11,13,17,19,30H,3,5,8-9,12,14-15H2,1-2H3,(H,24,25)(H,26,27)(H,28,29)/b16-13+
DM8WCUY	CS	CC(CC1=CC=CC=C1)/C=C(\\C)/CCCCCC(C(=O)O)C(CC(=O)O)(C(=O)O)O
DM8WCUY	IK	NLNJIEVMUWDLAZ-DTQAZKPQSA-N
DM8WCUY	IU	(E)-2-hydroxy-9,11-dimethyl-12-phenyldodec-9-ene-1,2,3-tricarboxylic acid
DM8WCUY	DE	Discovery agent

DMTHLUN	ID	DMTHLUN
DMTHLUN	DN	L-731128
DMTHLUN	HS	Investigative
DMTHLUN	SN	L 731128
DMTHLUN	DT	Small molecular drug
DMTHLUN	PC	9889873
DMTHLUN	MW	448.5
DMTHLUN	FM	C25H36O7
DMTHLUN	IC	InChI=1S/C25H36O7/c1-18(16-19(2)11-9-14-20-12-6-4-7-13-20)10-5-3-8-15-21(23(28)29)25(32,24(30)31)17-22(26)27/h4,6-7,9,12-14,18-19,21,32H,3,5,8,10-11,15-17H2,1-2H3,(H,26,27)(H,28,29)(H,30,31)/b14-9+
DMTHLUN	CS	CC(CCCCCC(C(=O)O)C(CC(=O)O)(C(=O)O)O)CC(C)C/C=C/C1=CC=CC=C1
DMTHLUN	IK	DSEOFKAKDCUIFI-NTEUORMPSA-N
DMTHLUN	IU	(E)-2-hydroxy-9,11-dimethyl-14-phenyltetradec-13-ene-1,2,3-tricarboxylic acid
DMTHLUN	DE	Discovery agent

DMDNVTF	ID	DMDNVTF
DMDNVTF	DN	L-734115
DMDNVTF	HS	Investigative
DMDNVTF	SN	CHEMBL40502; L-734115; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)
DMDNVTF	DT	Small molecular drug
DMDNVTF	PC	9913833
DMDNVTF	MW	498.6
DMDNVTF	FM	C21H34N6O6S
DMDNVTF	IC	InChI=1S/C21H34N6O6S/c1-2-3-12-34(32,33)25-17(21(30)31)14-23-19(28)16-13-18-20(29)26(10-11-27(18)24-16)9-6-15-4-7-22-8-5-15/h13,15,17,22,25H,2-12,14H2,1H3,(H,23,28)(H,30,31)/t17-/m0/s1
DMDNVTF	CS	CCCCS(=O)(=O)N[C@@H](CNC(=O)C1=NN2CCN(C(=O)C2=C1)CCC3CCNCC3)C(=O)O
DMDNVTF	IK	FXBDPMBWPSLDQZ-KRWDZBQOSA-N
DMDNVTF	IU	(2S)-2-(butylsulfonylamino)-3-[[4-oxo-5-(2-piperidin-4-ylethyl)-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carbonyl]amino]propanoic acid
DMDNVTF	DE	Discovery agent

DMY60MG	ID	DMY60MG
DMY60MG	DN	L-735,821
DMY60MG	HS	Investigative
DMY60MG	SN	CHEMBL332826; AC1NQZS7; C13853; CHEBI:34807; L 735821; (E)-3-(2,4-dichlorophenyl)-N-[(3R)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]prop-2-enamide; SureCN8611879; SCHEMBL8837547; SCHEMBL8611879; GTPL2592; CHEBI:303776; BDBM50061218; L735821; N-[[(3R)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin]-3-yl]-2,4-dichlorobenzeneacrylamide; 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acrylamide
DMY60MG	DT	Small molecular drug
DMY60MG	PC	5282279
DMY60MG	MW	464.3
DMY60MG	FM	C25H19Cl2N3O2
DMY60MG	IC	InChI=1S/C25H19Cl2N3O2/c1-30-21-10-6-5-9-19(21)23(17-7-3-2-4-8-17)29-24(25(30)32)28-22(31)14-12-16-11-13-18(26)15-20(16)27/h2-15,24H,1H3,(H,28,31)/b14-12+/t24-/m1/s1
DMY60MG	CS	CN1C2=CC=CC=C2C(=N[C@H](C1=O)NC(=O)/C=C/C3=C(C=C(C=C3)Cl)Cl)C4=CC=CC=C4
DMY60MG	IK	BYULDQRRUINTAA-SWDTZWKESA-N
DMY60MG	IU	(E)-3-(2,4-dichlorophenyl)-N-[(3R)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]prop-2-enamide
DMY60MG	CB	CHEBI:34807
DMY60MG	DE	Discovery agent

DM8BVJQ	ID	DM8BVJQ
DM8BVJQ	DN	L-735021
DM8BVJQ	HS	Investigative
DM8BVJQ	SN	L 735021
DM8BVJQ	DT	Small molecular drug
DM8BVJQ	PC	9853075
DM8BVJQ	MW	696.8
DM8BVJQ	FM	C38H48O12
DM8BVJQ	IC	InChI=1S/C38H48O12/c1-25(16-13-21-27-17-5-3-6-18-27)14-9-10-22-29(39)48-31-30(40)36(23-12-11-15-26(2)24-28-19-7-4-8-20-28)49-32(33(41)42)37(47,34(43)44)38(31,50-36)35(45)46/h3-9,14,17-20,25-26,30-32,40,47H,10-13,15-16,21-24H2,1-2H3,(H,41,42)(H,43,44)(H,45,46)/b14-9+/t25?,26?,30-,31-,32?,36?,37?,38?/m1/s1
DM8BVJQ	CS	CC(CCCCC12[C@@H]([C@H](C(O1)(C(C(O2)C(=O)O)(C(=O)O)O)C(=O)O)OC(=O)CC/C=C/C(C)CCCC3=CC=CC=C3)O)CC4=CC=CC=C4
DM8BVJQ	IK	ZOTNYZYRJOAANS-OIAIRNFISA-N
DM8BVJQ	IU	(6R,7R)-4,7-dihydroxy-1-(5-methyl-6-phenylhexyl)-6-[(E)-6-methyl-9-phenylnon-4-enoyl]oxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DM8BVJQ	DE	Discovery agent

DMJNLSI	ID	DMJNLSI
DMJNLSI	DN	L-736281
DMJNLSI	HS	Investigative
DMJNLSI	SN	L-736281; CHEMBL27003; SCHEMBL19440986; BDBM50052283; 2-[3-(3,5-Bis-trifluoromethyl-benzyloxy)-2-phenyl-piperidin-1-yl]-acetamide
DMJNLSI	DT	Small molecular drug
DMJNLSI	PC	9890435
DMJNLSI	MW	460.4
DMJNLSI	FM	C22H22F6N2O2
DMJNLSI	IC	InChI=1S/C22H22F6N2O2/c23-21(24,25)16-9-14(10-17(11-16)22(26,27)28)13-32-18-7-4-8-30(12-19(29)31)20(18)15-5-2-1-3-6-15/h1-3,5-6,9-11,18,20H,4,7-8,12-13H2,(H2,29,31)/t18-,20-/m0/s1
DMJNLSI	CS	C1C[C@@H]([C@@H](N(C1)CC(=O)N)C2=CC=CC=C2)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMJNLSI	IK	SUZSWSSXVHSRLT-ICSRJNTNSA-N
DMJNLSI	IU	2-[(2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidin-1-yl]acetamide
DMJNLSI	DE	Discovery agent

DMM5AYL	ID	DMM5AYL
DMM5AYL	DN	L-736380
DMM5AYL	HS	Investigative
DMM5AYL	SN	L 736380; L736380
DMM5AYL	DT	Small molecular drug
DMM5AYL	PC	9935175
DMM5AYL	MW	487.6
DMM5AYL	FM	C25H29N9O2
DMM5AYL	IC	InChI=1S/C25H29N9O2/c1-33(24-29-31-32-30-24)18-12-8-11-17(15-18)26-25(36)28-22-23(35)34(2)20-14-7-6-13-19(20)21(27-22)16-9-4-3-5-10-16/h6-8,11-16,22H,3-5,9-10H2,1-2H3,(H2,26,28,36)(H,29,30,31,32)/t22-/m0/s1
DMM5AYL	CS	CN1C2=CC=CC=C2C(=N[C@H](C1=O)NC(=O)NC3=CC(=CC=C3)N(C)C4=NNN=N4)C5CCCCC5
DMM5AYL	IK	MYPNMQPMQUAOTH-QFIPXVFZSA-N
DMM5AYL	IU	1-[(3R)-5-cyclohexyl-1-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-[3-[methyl(2H-tetrazol-5-yl)amino]phenyl]urea
DMM5AYL	DE	Discovery agent

DMAHC9Z	ID	DMAHC9Z
DMAHC9Z	DN	L-739750
DMAHC9Z	HS	Investigative
DMAHC9Z	SN	L-739,750; 2(S)-{2(S)-[2(R)-AMINO-3-MERCAPTO]PROPYLAMINO-3(S)-METHYL}PENTYLOXY-3-PHENYLPROPIONYLMETHIONINE SULFONE; (2S)-2-[[(2S)-2-[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoic acid; AC1NR9VU; L 739750; GTPL8030; SCHEMBL2723214; (2S)-2-{[(2S)-2-{[(2S,3S)-2-{[(2R)-2-amino-3-sulfanylpropyl]amino}-3-methylpentyl]oxy}-3-phenylpropanoyl]amino}-4-(methylsulfonyl)butanoic acid
DMAHC9Z	DT	Small molecular drug
DMAHC9Z	PC	5287548
DMAHC9Z	MW	517.7
DMAHC9Z	FM	C23H39N3O6S2
DMAHC9Z	IC	InChI=1S/C23H39N3O6S2/c1-4-16(2)20(25-13-18(24)15-33)14-32-21(12-17-8-6-5-7-9-17)22(27)26-19(23(28)29)10-11-34(3,30)31/h5-9,16,18-21,25,33H,4,10-15,24H2,1-3H3,(H,26,27)(H,28,29)/t16-,18+,19-,20+,21-/m0/s1
DMAHC9Z	CS	CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)O)NC[C@H](CS)N
DMAHC9Z	IK	SIEXHGZWGJLLAC-OSTWSGHESA-N
DMAHC9Z	IU	(2S)-2-[[(2S)-2-[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoic acid
DMAHC9Z	DE	Discovery agent

DM5IAXN	ID	DM5IAXN
DM5IAXN	DN	L-739758
DM5IAXN	HS	Investigative
DM5IAXN	SN	CHEMBL78760; L-739758; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid
DM5IAXN	DT	Small molecular drug
DM5IAXN	PC	9958398
DM5IAXN	MW	522.7
DM5IAXN	FM	C22H26N4O5S3
DM5IAXN	IC	InChI=1S/C22H26N4O5S3/c27-20(25-13-18(21(28)29)26-34(30,31)17-2-1-7-24-12-17)19-11-15-10-16(32-22(15)33-19)4-3-14-5-8-23-9-6-14/h1-2,7,10-12,14,18,23,26H,3-6,8-9,13H2,(H,25,27)(H,28,29)/t18-/m0/s1
DM5IAXN	CS	C1CNCCC1CCC2=CC3=C(S2)SC(=C3)C(=O)NC[C@@H](C(=O)O)NS(=O)(=O)C4=CN=CC=C4
DM5IAXN	IK	QDIFCBMBPLLNGR-SFHVURJKSA-N
DM5IAXN	IU	(2S)-3-[[2-(2-piperidin-4-ylethyl)thieno[2,3-b]thiophene-5-carbonyl]amino]-2-(pyridin-3-ylsulfonylamino)propanoic acid
DM5IAXN	DE	Discovery agent

DMVA2D0	ID	DMVA2D0
DMVA2D0	DN	L-740093
DMVA2D0	HS	Investigative
DMVA2D0	SN	L-740093; CHEMBL420783; L 740093; L-740,093; CHEMBL545122; 1-[(3R)-5-(3-azabicyclo[3.2.2]nonan-3-yl)-1-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea; PDSP1_000900; L740093; GTPL881; 154967-59-6; SCHEMBL7627122; L 740,093; AC1L31Y3; PDSP2_000886; BDBM50059319; BDBM50040667; N-(5-(3-Azabicyclo(3.2.2)nonan-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)urea; L-741545
DMVA2D0	DT	Small molecular drug
DMVA2D0	PC	132980
DMVA2D0	MW	445.6
DMVA2D0	FM	C26H31N5O2
DMVA2D0	IC	InChI=1S/C26H31N5O2/c1-17-6-5-7-20(14-17)27-26(33)29-23-25(32)30(2)22-9-4-3-8-21(22)24(28-23)31-15-18-10-11-19(16-31)13-12-18/h3-9,14,18-19,23H,10-13,15-16H2,1-2H3,(H2,27,29,33)/t18?,19?,23-/m0/s1
DMVA2D0	CS	CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)N4CC5CCC(C4)CC5)C
DMVA2D0	IK	QYERABWMFRRINX-XWEVFREBSA-N
DMVA2D0	IU	1-[(3R)-5-(3-azabicyclo[3.2.2]nonan-3-yl)-1-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DMVA2D0	CA	CAS 154967-59-6
DMVA2D0	DE	Discovery agent

DMCYQJF	ID	DMCYQJF
DMCYQJF	DN	L-741626
DMCYQJF	HS	Investigative
DMCYQJF	SN	L-741,626; 81226-60-0; L-741626; 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole; L 741626; L 741,626; CHEMBL445102; 4-(4-Chlorophenyl)-1-(1H-indol-3-ylmethyl)-4-piperidinol; 4-(4-chlorophenyl)-1-(1h-indol-3-ylmethyl)piperidin-4-ol; C20H21ClN2O; 4-Piperidinol, 4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)-; SR-01000075973; Tocris-1003; NCGC00015591-01; Lopac-L-135; Biomol-NT_000036; AC1Q3NO6; Lopac0_000742; GTPL177; MLS000860079; ZINC6788; BPBio1_001094; AC1L335F; SCHEMBL11253588; CHEBI:92090; CTK3I9542; DTXSID30230974
DMCYQJF	DT	Small molecular drug
DMCYQJF	PC	133633
DMCYQJF	MW	340.8
DMCYQJF	FM	C20H21ClN2O
DMCYQJF	IC	InChI=1S/C20H21ClN2O/c21-17-7-5-16(6-8-17)20(24)9-11-23(12-10-20)14-15-13-22-19-4-2-1-3-18(15)19/h1-8,13,22,24H,9-12,14H2
DMCYQJF	CS	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CC3=CNC4=CC=CC=C43
DMCYQJF	IK	LLBLNMUONVVVPG-UHFFFAOYSA-N
DMCYQJF	IU	4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)piperidin-4-ol
DMCYQJF	CA	CAS 81226-60-0
DMCYQJF	CB	CHEBI:92090
DMCYQJF	DE	Discovery agent

DMP75YK	ID	DMP75YK
DMP75YK	DN	L-741742
DMP75YK	HS	Investigative
DMP75YK	SN	L-741742; UNII-C5B89UM05U; CHEMBL444309; C5B89UM05U; L 741742; L-741,742; L741742; Cmpepi-3; Tocris-1004; Biomol-NT_000048; GTPL3302; SCHEMBL1388774; BPBio1_001096; DTXSID0043894; CHEBI:92229; ZINC602172; AC1L3203; BDBM50050476; NCGC00024933-02; NCGC00024933-01; L016523; L 741,742; BRD-K13211965-001-02-2; BRD-K13211965-003-01-0; BRD-K13211965-001-01-4; 5-(4-chlorophenyl)-4-methyl-3-(1-phenethylpiperidin-4-yl)-1,2-oxazole; 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole
DMP75YK	DT	Small molecular drug
DMP75YK	PC	133008
DMP75YK	MW	380.9
DMP75YK	FM	C23H25ClN2O
DMP75YK	IC	InChI=1S/C23H25ClN2O/c1-17-22(25-27-23(17)20-7-9-21(24)10-8-20)19-12-15-26(16-13-19)14-11-18-5-3-2-4-6-18/h2-10,19H,11-16H2,1H3
DMP75YK	CS	CC1=C(ON=C1C2CCN(CC2)CCC3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMP75YK	IK	QDMAKDIDFJTXEL-UHFFFAOYSA-N
DMP75YK	IU	5-(4-chlorophenyl)-4-methyl-3-[1-(2-phenylethyl)piperidin-4-yl]-1,2-oxazole
DMP75YK	CA	CAS 156337-32-5
DMP75YK	CB	CHEBI:92229
DMP75YK	DE	Discovery agent

DMRC8MT	ID	DMRC8MT
DMRC8MT	DN	L-746233
DMRC8MT	HS	Investigative
DMRC8MT	SN	CHEMBL79294; L-746233; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid
DMRC8MT	DT	Small molecular drug
DMRC8MT	PC	10324223
DMRC8MT	MW	515.6
DMRC8MT	FM	C24H29N5O6S
DMRC8MT	IC	InChI=1S/C24H29N5O6S/c30-22(27-14-21(24(32)33)28-36(34,35)19-2-1-8-26-13-19)17-3-4-18-15-29(23(31)20(18)12-17)11-7-16-5-9-25-10-6-16/h1-4,8,12-13,16,21,25,28H,5-7,9-11,14-15H2,(H,27,30)(H,32,33)/t21-/m0/s1
DMRC8MT	CS	C1CNCCC1CCN2CC3=C(C2=O)C=C(C=C3)C(=O)NC[C@@H](C(=O)O)NS(=O)(=O)C4=CN=CC=C4
DMRC8MT	IK	FVGFTYFYGPWTIR-NRFANRHFSA-N
DMRC8MT	IU	(2S)-3-[[3-oxo-2-(2-piperidin-4-ylethyl)-1H-isoindole-5-carbonyl]amino]-2-(pyridin-3-ylsulfonylamino)propanoic acid
DMRC8MT	DE	Discovery agent

DMUY8MP	ID	DMUY8MP
DMUY8MP	DN	L-746530
DMUY8MP	HS	Investigative
DMUY8MP	SN	L-746530; CHEMBL207057; BDBM50182300
DMUY8MP	DT	Small molecular drug
DMUY8MP	PC	44410706
DMUY8MP	MW	472.5
DMUY8MP	FM	C27H21FN2O5
DMUY8MP	IC	InChI=1S/C27H21FN2O5/c28-19-6-18(27(31)10-22-15-34-26(11-27)35-22)7-21(8-19)33-13-16-1-2-23-24(17-3-4-32-14-17)9-20(12-29)30-25(23)5-16/h1-9,14,22,26,31H,10-11,13,15H2/t22-,26+,27-/m0/s1
DMUY8MP	CS	C1[C@H]2CO[C@H](O2)C[C@@]1(C3=CC(=CC(=C3)F)OCC4=CC5=NC(=CC(=C5C=C4)C6=COC=C6)C#N)O
DMUY8MP	IK	GZOVJNIKHQXVIU-FDJWOJMMSA-N
DMUY8MP	IU	7-[[3-fluoro-5-[(1S,3S,5R)-3-hydroxy-6,8-dioxabicyclo[3.2.1]octan-3-yl]phenoxy]methyl]-4-(furan-3-yl)quinoline-2-carbonitrile
DMUY8MP	DE	Discovery agent

DMBPWSJ	ID	DMBPWSJ
DMBPWSJ	DN	L-747201
DMBPWSJ	HS	Investigative
DMBPWSJ	SN	CHEMBL116092; L-747201; SCHEMBL9075818; BDBM50060419; L010227; 3-(2-Pyrrolizinoethyl)-5-(4H-1,2,4-triazol-4-yl)-1H-indole
DMBPWSJ	DT	Small molecular drug
DMBPWSJ	PC	10468938
DMBPWSJ	MW	281.36
DMBPWSJ	FM	C16H19N5
DMBPWSJ	IC	InChI=1S/C16H19N5/c1-2-7-20(6-1)8-5-13-10-17-16-4-3-14(9-15(13)16)21-11-18-19-12-21/h3-4,9-12,17H,1-2,5-8H2
DMBPWSJ	CS	C1CCN(C1)CCC2=CNC3=C2C=C(C=C3)N4C=NN=C4
DMBPWSJ	IK	WYXPLVWYFDBFBS-UHFFFAOYSA-N
DMBPWSJ	IU	3-(2-pyrrolidin-1-ylethyl)-5-(1,2,4-triazol-4-yl)-1H-indole
DMBPWSJ	DE	Discovery agent

DMEGU5J	ID	DMEGU5J
DMEGU5J	DN	L748328
DMEGU5J	HS	Investigative
DMEGU5J	SN	L-748328; L-748,328
DMEGU5J	DT	Small molecular drug
DMEGU5J	PC	10323892
DMEGU5J	MW	505.6
DMEGU5J	FM	C23H27N3O6S2
DMEGU5J	IC	InChI=1S/C23H27N3O6S2/c24-33(28,29)23-8-4-5-21(15-23)32-17-20(27)16-25-14-13-18-9-11-19(12-10-18)26-34(30,31)22-6-2-1-3-7-22/h1-12,15,20,25-27H,13-14,16-17H2,(H2,24,28,29)/t20-/m0/s1
DMEGU5J	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CCNC[C@@H](COC3=CC(=CC=C3)S(=O)(=O)N)O
DMEGU5J	IK	CVPJSQZQNBKALR-FQEVSTJZSA-N
DMEGU5J	IU	3-[(2S)-3-[2-[4-(benzenesulfonamido)phenyl]ethylamino]-2-hydroxypropoxy]benzenesulfonamide
DMEGU5J	DE	Discovery agent

DM7CPBU	ID	DM7CPBU
DM7CPBU	DN	L-748337
DM7CPBU	HS	Investigative
DM7CPBU	SN	L-748,337; L 748337
DM7CPBU	DT	Small molecular drug
DM7CPBU	PC	10028830
DM7CPBU	MW	497.6
DM7CPBU	FM	C26H31N3O5S
DM7CPBU	IC	InChI=1S/C26H31N3O5S/c1-20(30)28-17-22-6-5-7-25(16-22)34-19-24(31)18-27-15-14-21-10-12-23(13-11-21)29-35(32,33)26-8-3-2-4-9-26/h2-13,16,24,27,29,31H,14-15,17-19H2,1H3,(H,28,30)/t24-/m0/s1
DM7CPBU	CS	CC(=O)NCC1=CC(=CC=C1)OC[C@H](CNCCC2=CC=C(C=C2)NS(=O)(=O)C3=CC=CC=C3)O
DM7CPBU	IK	AWIONHVPTYTSHZ-DEOSSOPVSA-N
DM7CPBU	IU	N-[[3-[(2S)-3-[2-[4-(benzenesulfonamido)phenyl]ethylamino]-2-hydroxypropoxy]phenyl]methyl]acetamide
DM7CPBU	DE	Discovery agent

DMJZXAF	ID	DMJZXAF
DMJZXAF	DN	L-748780
DMJZXAF	HS	Investigative
DMJZXAF	SN	L-748780; CHEMBL159315; 168086-64-4; L 748780; L 748,780; AC1L2SX2; SCHEMBL3240332; L-748,780; CTK0H7371; DTXSID40168476; WUJUBERMAKRECF-UHFFFAOYSA-N; BDBM50289085; 5-Methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-1H-indole-3-acetic acid; 1 -(2,4,6-Trichlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetic acid; 1H-Indole-3-aceticacid, 5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-; 1-(2,4,6-Trichlorobenzoyl)-2-methyl-5-methoxy-1H-indole-3-acetic acid; 2-[5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)indol-3-yl]acetic acid
DMJZXAF	DT	Small molecular drug
DMJZXAF	PC	127942
DMJZXAF	MW	426.7
DMJZXAF	FM	C19H14Cl3NO4
DMJZXAF	IC	InChI=1S/C19H14Cl3NO4/c1-9-12(8-17(24)25)13-7-11(27-2)3-4-16(13)23(9)19(26)18-14(21)5-10(20)6-15(18)22/h3-7H,8H2,1-2H3,(H,24,25)
DMJZXAF	CS	CC1=C(C2=C(N1C(=O)C3=C(C=C(C=C3Cl)Cl)Cl)C=CC(=C2)OC)CC(=O)O
DMJZXAF	IK	WUJUBERMAKRECF-UHFFFAOYSA-N
DMJZXAF	IU	2-[5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)indol-3-yl]acetic acid
DMJZXAF	CA	CAS 168086-64-4
DMJZXAF	DE	Discovery agent

DM2WUKF	ID	DM2WUKF
DM2WUKF	DN	L-750,667
DM2WUKF	HS	Investigative
DM2WUKF	SN	Lopac-L-133; L750667; L-750667
DM2WUKF	DT	Small molecular drug
DM2WUKF	PC	6603897
DM2WUKF	MW	418.3
DM2WUKF	FM	C18H19IN4
DM2WUKF	IC	InChI=1S/C18H19IN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)
DM2WUKF	CS	C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)I
DM2WUKF	IK	OOEUHRGMLFVKQO-UHFFFAOYSA-N
DM2WUKF	IU	3-[[4-(4-iodophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine
DM2WUKF	CA	CAS 1021868-80-3
DM2WUKF	CB	CHEBI:92507
DM2WUKF	DE	Discovery agent

DM9QAP4	ID	DM9QAP4
DM9QAP4	DN	L-750034
DM9QAP4	HS	Investigative
DM9QAP4	SN	L-750034; CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid
DM9QAP4	DT	Small molecular drug
DM9QAP4	PC	11743533
DM9QAP4	MW	432.5
DM9QAP4	FM	C20H24N4O5S
DM9QAP4	IC	InChI=1S/C20H24N4O5S/c25-19(15-6-8-16(9-7-15)24-12-10-21-11-13-24)22-14-18(20(26)27)23-30(28,29)17-4-2-1-3-5-17/h1-9,18,21,23H,10-14H2,(H,22,25)(H,26,27)/t18-/m0/s1
DM9QAP4	CS	C1CN(CCN1)C2=CC=C(C=C2)C(=O)NC[C@@H](C(=O)O)NS(=O)(=O)C3=CC=CC=C3
DM9QAP4	IK	PXSDSRKJCWOYNE-SFHVURJKSA-N
DM9QAP4	IU	(2S)-2-(benzenesulfonamido)-3-[(4-piperazin-1-ylbenzoyl)amino]propanoic acid
DM9QAP4	DE	Discovery agent

DMEQWSB	ID	DMEQWSB
DMEQWSB	DN	L-756568
DMEQWSB	HS	Investigative
DMEQWSB	SN	CHEMBL96097; L-756568; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)
DMEQWSB	DT	Small molecular drug
DMEQWSB	PC	9805998
DMEQWSB	MW	500.6
DMEQWSB	FM	C24H28N4O6S
DMEQWSB	IC	InChI=1S/C24H28N4O6S/c29-23(26-14-22(24(30)31)28-35(32,33)19-4-2-1-3-5-19)21-13-17-12-18(6-7-20(17)27-21)34-15-16-8-10-25-11-9-16/h1-7,12-13,16,22,25,27-28H,8-11,14-15H2,(H,26,29)(H,30,31)/t22-/m0/s1
DMEQWSB	CS	C1CNCCC1COC2=CC3=C(C=C2)NC(=C3)C(=O)NC[C@@H](C(=O)O)NS(=O)(=O)C4=CC=CC=C4
DMEQWSB	IK	CFKZYRJYUHWTIW-QFIPXVFZSA-N
DMEQWSB	IU	(2S)-2-(benzenesulfonamido)-3-[[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]amino]propanoic acid
DMEQWSB	DE	Discovery agent

DMQJNDX	ID	DMQJNDX
DMQJNDX	DN	L-759,633
DMQJNDX	HS	Investigative
DMQJNDX	SN	L759633; L-759633
DMQJNDX	DT	Small molecular drug
DMQJNDX	PC	5311215
DMQJNDX	MW	384.6
DMQJNDX	FM	C26H40O2
DMQJNDX	IC	InChI=1S/C26H40O2/c1-8-9-10-11-14-25(3,4)19-16-22(27-7)24-20-15-18(2)12-13-21(20)26(5,6)28-23(24)17-19/h12,16-17,20-21H,8-11,13-15H2,1-7H3/t20-,21-/m1/s1
DMQJNDX	CS	CCCCCCC(C)(C)C1=CC2=C([C@@H]3CC(=CC[C@H]3C(O2)(C)C)C)C(=C1)OC
DMQJNDX	IK	SUFMHSFGODDLKI-NHCUHLMSSA-N
DMQJNDX	IU	(6aR,10aR)-1-methoxy-6,6,9-trimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene
DMQJNDX	DE	Discovery agent

DM5SOR4	ID	DM5SOR4
DM5SOR4	DN	L-759,656
DM5SOR4	HS	Investigative
DM5SOR4	SN	L759656; L-759656
DM5SOR4	DT	Small molecular drug
DM5SOR4	PC	5311216
DM5SOR4	MW	384.6
DM5SOR4	FM	C26H40O2
DM5SOR4	IC	InChI=1S/C26H40O2/c1-8-9-10-11-14-25(3,4)19-16-22(27-7)24-20-15-18(2)12-13-21(20)26(5,6)28-23(24)17-19/h16-17,20-21H,2,8-15H2,1,3-7H3/t20-,21-/m1/s1
DM5SOR4	CS	CCCCCCC(C)(C)C1=CC2=C([C@@H]3CC(=C)CC[C@H]3C(O2)(C)C)C(=C1)OC
DM5SOR4	IK	BJIIKHXAZBTGLF-NHCUHLMSSA-N
DM5SOR4	IU	(6aR,10aR)-1-methoxy-6,6-dimethyl-9-methylidene-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromene
DM5SOR4	DE	Discovery agent

DMA9VDN	ID	DMA9VDN
DMA9VDN	DN	L-760790
DMA9VDN	HS	Investigative
DMA9VDN	SN	L-760790; CHEMBL420965; SCHEMBL4358113; JCFDYNJSFCXYRT-FQEVSTJZSA-N; BDBM50060425; Benzyl-{(S)-1-[2-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-ethyl]-pyrrolidin-3-ylmethyl}-amine
DMA9VDN	DT	Small molecular drug
DMA9VDN	PC	10386282
DMA9VDN	MW	400.5
DMA9VDN	FM	C24H28N6
DMA9VDN	IC	InChI=1S/C24H28N6/c1-2-4-19(5-3-1)13-25-14-20-8-10-29(16-20)11-9-21-15-26-24-7-6-22(12-23(21)24)30-17-27-28-18-30/h1-7,12,15,17-18,20,25-26H,8-11,13-14,16H2/t20-/m0/s1
DMA9VDN	CS	C1CN(C[C@@H]1CNCC2=CC=CC=C2)CCC3=CNC4=C3C=C(C=C4)N5C=NN=C5
DMA9VDN	IK	JCFDYNJSFCXYRT-FQEVSTJZSA-N
DMA9VDN	IU	N-benzyl-1-[(3S)-1-[2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethyl]pyrrolidin-3-yl]methanamine
DMA9VDN	DE	Discovery agent

DM0A2MG	ID	DM0A2MG
DM0A2MG	DN	L-761000
DM0A2MG	HS	Investigative
DM0A2MG	SN	CHEMBL352174; L-761000; SCHEMBL7070915; AXFSURYONUFFTK-UHFFFAOYSA-N; BDBM50289087; 4-(1-(4-Bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)-3-methylbutanoic acid; 4-[1-(4-Bromo-benzyl)-5-methoxy-2-methyl-1H-indol-3-yl]-3-methyl-butyric acid
DM0A2MG	DT	Small molecular drug
DM0A2MG	PC	9867333
DM0A2MG	MW	430.3
DM0A2MG	FM	C22H24BrNO3
DM0A2MG	IC	InChI=1S/C22H24BrNO3/c1-14(11-22(25)26)10-19-15(2)24(13-16-4-6-17(23)7-5-16)21-9-8-18(27-3)12-20(19)21/h4-9,12,14H,10-11,13H2,1-3H3,(H,25,26)
DM0A2MG	CS	CC1=C(C2=C(N1CC3=CC=C(C=C3)Br)C=CC(=C2)OC)CC(C)CC(=O)O
DM0A2MG	IK	AXFSURYONUFFTK-UHFFFAOYSA-N
DM0A2MG	IU	4-[1-[(4-bromophenyl)methyl]-5-methoxy-2-methylindol-3-yl]-3-methylbutanoic acid
DM0A2MG	CA	CAS 176045-83-3
DM0A2MG	DE	Discovery agent

DMG5KVS	ID	DMG5KVS
DMG5KVS	DN	L-764406
DMG5KVS	HS	Investigative
DMG5KVS	SN	L 764406; L764406
DMG5KVS	DT	Small molecular drug
DMG5KVS	PC	9818466
DMG5KVS	MW	318.8
DMG5KVS	FM	C15H11ClN2O2S
DMG5KVS	IC	InChI=1S/C15H11ClN2O2S/c16-15-14(17-12-8-4-5-9-13(12)18-15)10-21(19,20)11-6-2-1-3-7-11/h1-9H,10H2
DMG5KVS	CS	C1=CC=C(C=C1)S(=O)(=O)CC2=NC3=CC=CC=C3N=C2Cl
DMG5KVS	IK	AMNQYONRCBZMGT-UHFFFAOYSA-N
DMG5KVS	IU	2-(benzenesulfonylmethyl)-3-chloroquinoxaline
DMG5KVS	DE	Discovery agent

DMH0TUZ	ID	DMH0TUZ
DMH0TUZ	DN	L-765314
DMH0TUZ	HS	Investigative
DMH0TUZ	SN	L-765314; CHEMBL19476; CGWOIDCAGBKOQL-FQEVSTJZSA-N; NCGC00094440-01; 189349-50-6; NCGC00015604-01; Lopac-L-3040; AC1O7G4J; GTPL506; SCHEMBL7820114; ZINC84638100; BDBM50063907; AKOS032960320; NCGC00165822-01; HY-101385; CS-0021271; benzyl (S)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2-(tert-butylcarbamoyl)piperazine-1-carboxylate; 1-piperazinecarboxylic acid, 4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-2-[[(1,1-dimethylethyl)amino]carbonyl]-, phenylmethyl ester, (S)-
DMH0TUZ	DT	Small molecular drug
DMH0TUZ	PC	6603904
DMH0TUZ	MW	522.6
DMH0TUZ	FM	C27H34N6O5
DMH0TUZ	IC	InChI=1S/C27H34N6O5/c1-27(2,3)31-24(34)20-15-32(11-12-33(20)26(35)38-16-17-9-7-6-8-10-17)25-29-19-14-22(37-5)21(36-4)13-18(19)23(28)30-25/h6-10,13-14,20H,11-12,15-16H2,1-5H3,(H,31,34)(H2,28,29,30)/t20-/m0/s1
DMH0TUZ	CS	CC(C)(C)NC(=O)[C@@H]1CN(CCN1C(=O)OCC2=CC=CC=C2)C3=NC4=CC(=C(C=C4C(=N3)N)OC)OC
DMH0TUZ	IK	CGWOIDCAGBKOQL-FQEVSTJZSA-N
DMH0TUZ	IU	benzyl (2S)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2-(tert-butylcarbamoyl)piperazine-1-carboxylate
DMH0TUZ	DE	Discovery agent

DM96SPJ	ID	DM96SPJ
DM96SPJ	DN	L-767679
DM96SPJ	HS	Investigative
DM96SPJ	SN	L-767679; CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-
DM96SPJ	DT	Small molecular drug
DM96SPJ	PC	177364
DM96SPJ	MW	384.4
DM96SPJ	FM	C20H24N4O4
DM96SPJ	IC	InChI=1S/C20H24N4O4/c1-2-15(11-19(26)27)22-18(25)13-24-8-5-14-3-4-16(12-17(14)20(24)28)23-9-6-21-7-10-23/h1,3-4,12,15,21H,5-11,13H2,(H,22,25)(H,26,27)/t15-/m1/s1
DM96SPJ	CS	C#C[C@H](CC(=O)O)NC(=O)CN1CCC2=C(C1=O)C=C(C=C2)N3CCNCC3
DM96SPJ	IK	QTVKUFZTCJLGEJ-OAHLLOKOSA-N
DM96SPJ	IU	(3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid
DM96SPJ	CA	CAS 182198-53-4
DM96SPJ	DE	Discovery agent

DM5O0CM	ID	DM5O0CM
DM5O0CM	DN	L-772,405
DM5O0CM	HS	Investigative
DM5O0CM	SN	L-772405; L 772405
DM5O0CM	DT	Small molecular drug
DM5O0CM	PC	9847194
DM5O0CM	MW	462.6
DM5O0CM	FM	C26H31FN6O
DM5O0CM	IC	InChI=1S/C26H31FN6O/c27-21-5-3-19(4-6-21)26(16-34)31-22-9-12-32(13-10-22)11-1-2-20-15-28-25-8-7-23(14-24(20)25)33-17-29-30-18-33/h3-8,14-15,17-18,22,26,28,31,34H,1-2,9-13,16H2/t26-/m0/s1
DM5O0CM	CS	C1CN(CCC1N[C@@H](CO)C2=CC=C(C=C2)F)CCCC3=CNC4=C3C=C(C=C4)N5C=NN=C5
DM5O0CM	IK	HNKDAQNYMJNLCC-SANMLTNESA-N
DM5O0CM	IU	(2R)-2-(4-fluorophenyl)-2-[[1-[3-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]propyl]piperidin-4-yl]amino]ethanol
DM5O0CM	DE	Discovery agent

DMMUAW5	ID	DMMUAW5
DMMUAW5	DN	L-779,976
DMMUAW5	HS	Investigative
DMMUAW5	SN	L 779976; L-779976
DMMUAW5	DT	Small molecular drug
DMMUAW5	PC	5311372
DMMUAW5	MW	585.7
DMMUAW5	FM	C33H43N7O3
DMMUAW5	IC	InChI=1S/C33H43N7O3/c1-21(26-20-35-27-10-3-2-9-25(26)27)30(31(41)36-19-23-8-6-7-22(17-23)18-34)38-32(42)39-15-13-24(14-16-39)40-29-12-5-4-11-28(29)37-33(40)43/h2-5,9-12,20-24,30,35H,6-8,13-19,34H2,1H3,(H,36,41)(H,37,43)(H,38,42)/t21-,22+,23+,30+/m0/s1
DMMUAW5	CS	C[C@@H](C1=CNC2=CC=CC=C21)[C@H](C(=O)NC[C@@H]3CCC[C@H](C3)CN)NC(=O)N4CCC(CC4)N5C6=CC=CC=C6NC5=O
DMMUAW5	IK	DDVPVAOEMZRZQU-JONNCTARSA-N
DMMUAW5	IU	N-[(2R,3S)-1-[[(1R,3R)-3-(aminomethyl)cyclohexyl]methylamino]-3-(1H-indol-3-yl)-1-oxobutan-2-yl]-4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1-carboxamide
DMMUAW5	DE	Discovery agent

DM51B74	ID	DM51B74
DM51B74	DN	L-779450
DM51B74	HS	Investigative
DM51B74	SN	303727-31-3; L-779450; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol
DM51B74	DT	Small molecular drug
DM51B74	PC	9950176
DM51B74	MW	347.8
DM51B74	FM	C20H14ClN3O
DM51B74	IC	InChI=1S/C20H14ClN3O/c21-16-7-6-15(12-17(16)25)19-18(13-8-10-22-11-9-13)23-20(24-19)14-4-2-1-3-5-14/h1-12,25H,(H,23,24)
DM51B74	CS	C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC(=C(C=C4)Cl)O
DM51B74	IK	WXJLXRNWMLWVFB-UHFFFAOYSA-N
DM51B74	IU	2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol
DM51B74	CA	CAS 303727-31-3
DM51B74	CB	CHEBI:93773
DM51B74	DE	Discovery agent

DM6OTGE	ID	DM6OTGE
DM6OTGE	DN	L-783483
DM6OTGE	HS	Investigative
DM6OTGE	SN	F3MethylAA
DM6OTGE	DT	Small molecular drug
DM6OTGE	PC	9935197
DM6OTGE	MW	487.9
DM6OTGE	FM	C22H21ClF3NO4S
DM6OTGE	IC	InChI=1S/C22H21ClF3NO4S/c1-2-4-14-17(7-6-15-20(14)31-27-21(15)22(24,25)26)30-9-3-10-32-18-8-5-13(11-16(18)23)12-19(28)29/h5-8,11H,2-4,9-10,12H2,1H3,(H,28,29)
DM6OTGE	CS	CCCC1=C(C=CC2=C1ON=C2C(F)(F)F)OCCCSC3=C(C=C(C=C3)CC(=O)O)Cl
DM6OTGE	IK	TZBRFAASYWFUGK-UHFFFAOYSA-N
DM6OTGE	IU	2-[3-chloro-4-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzoxazol-6-yl]oxy]propylsulfanyl]phenyl]acetic acid
DM6OTGE	DE	Discovery agent

DMJKAQR	ID	DMJKAQR
DMJKAQR	DN	L-790070
DMJKAQR	HS	Investigative
DMJKAQR	SN	L-790070; CHEMBL303144; 189442-43-1; MRK-48; SCHEMBL4025110; BDBM15459; CTK4E0131; DTXSID50430959; 4-[1-methyl-2-(piperidin-4-yl)-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-N-[(1S)-1-phenylethyl]pyridin-2-amine; 4-{1-methyl-2-piperidin-4-yl-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl}-N-[(1S)-1-phenylethyl]pyridin-2-amine; 2-PYRIDINAMINE, 4-[1-METHYL-2-(4-PIPERIDINYL)-4-[3-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOL-5-YL]-N-[(1S)-1-PHENYLETHYL]-
DMJKAQR	DT	Small molecular drug
DMJKAQR	PC	9806182
DMJKAQR	MW	505.6
DMJKAQR	FM	C29H30F3N5
DMJKAQR	IC	InChI=1S/C29H30F3N5/c1-19(20-7-4-3-5-8-20)35-25-18-23(13-16-34-25)27-26(22-9-6-10-24(17-22)29(30,31)32)36-28(37(27)2)21-11-14-33-15-12-21/h3-10,13,16-19,21,33H,11-12,14-15H2,1-2H3,(H,34,35)/t19-/m0/s1
DMJKAQR	CS	C[C@@H](C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(N=C(N3C)C4CCNCC4)C5=CC(=CC=C5)C(F)(F)F
DMJKAQR	IK	ZLQKJFNLHHGAQF-IBGZPJMESA-N
DMJKAQR	IU	4-[3-methyl-2-piperidin-4-yl-5-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-N-[(1S)-1-phenylethyl]pyridin-2-amine
DMJKAQR	CA	CAS 189442-43-1
DMJKAQR	DE	Autoimmune diabetes

DM5D892	ID	DM5D892
DM5D892	DN	L-791943
DM5D892	HS	Investigative
DM5D892	SN	L-791943; CHEMBL286224; SCHEMBL12013401; BDBM50113425; 4-{2-(3,4-Bis-difluoromethoxy-phenyl)-2-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-ethyl}-pyridin-1-ol anion
DM5D892	DT	Small molecular drug
DM5D892	PC	9808191
DM5D892	MW	573.4
DM5D892	FM	C24H17F10NO4
DM5D892	IC	InChI=1S/C24H17F10NO4/c25-20(26)38-18-6-3-15(12-19(18)39-21(27)28)17(11-13-7-9-35(37)10-8-13)14-1-4-16(5-2-14)22(36,23(29,30)31)24(32,33)34/h1-10,12,17,20-21,36H,11H2
DM5D892	CS	C1=CC(=CC=C1C(CC2=CC=[N+](C=C2)[O-])C3=CC(=C(C=C3)OC(F)F)OC(F)F)C(C(F)(F)F)(C(F)(F)F)O
DM5D892	IK	VIOWRSXFEPSZFI-UHFFFAOYSA-N
DM5D892	IU	2-[4-[1-[3,4-bis(difluoromethoxy)phenyl]-2-(1-oxidopyridin-1-ium-4-yl)ethyl]phenyl]-1,1,1,3,3,3-hexafluoropropan-2-ol
DM5D892	DE	Discovery agent

DMINOFE	ID	DMINOFE
DMINOFE	DN	L-796,778
DMINOFE	HS	Investigative
DMINOFE	SN	L796778; L-796778
DMINOFE	DT	Small molecular drug
DMINOFE	PC	5311373
DMINOFE	MW	584.7
DMINOFE	FM	C29H40N6O7
DMINOFE	IC	InChI=1S/C29H40N6O7/c1-3-4-12-23(26(36)32-24(28(38)42-2)13-8-9-18-30)33-29(39)34-25(19-20-10-6-5-7-11-20)27(37)31-21-14-16-22(17-15-21)35(40)41/h5-7,10-11,14-17,23-25H,3-4,8-9,12-13,18-19,30H2,1-2H3,(H,31,37)(H,32,36)(H2,33,34,39)/t23-,24+,25+/m1/s1
DMINOFE	CS	CCCC[C@H](C(=O)N[C@@H](CCCCN)C(=O)OC)NC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-]
DMINOFE	IK	KEATTYUTWJKTRT-DSITVLBTSA-N
DMINOFE	IU	methyl (2S)-6-amino-2-[[(2R)-2-[[(2S)-1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoylamino]hexanoyl]amino]hexanoate
DMINOFE	DE	Discovery agent

DMWTGQM	ID	DMWTGQM
DMWTGQM	DN	L-796449
DMWTGQM	HS	Investigative
DMWTGQM	SN	L-796449; UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
DMWTGQM	DT	Small molecular drug
DMWTGQM	PC	9891946
DMWTGQM	MW	495
DMWTGQM	FM	C28H27ClO4S
DMWTGQM	IC	InChI=1S/C28H27ClO4S/c1-2-7-22-25(12-11-21-23(18-33-28(21)22)20-8-4-3-5-9-20)32-14-6-15-34-26-13-10-19(16-24(26)29)17-27(30)31/h3-5,8-13,16,18H,2,6-7,14-15,17H2,1H3,(H,30,31)
DMWTGQM	CS	CCCC1=C(C=CC2=C1OC=C2C3=CC=CC=C3)OCCCSC4=C(C=C(C=C4)CC(=O)O)Cl
DMWTGQM	IK	KAPDPGZDHUCILF-UHFFFAOYSA-N
DMWTGQM	IU	2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
DMWTGQM	CA	CAS 194608-80-5
DMWTGQM	DE	Discovery agent

DM96ASN	ID	DM96ASN
DM96ASN	DN	L-797,591
DM96ASN	HS	Investigative
DM96ASN	SN	L797591
DM96ASN	DT	Small molecular drug
DM96ASN	PC	9938757
DM96ASN	MW	607.8
DM96ASN	FM	C38H49N5O2
DM96ASN	IC	InChI=1S/C38H49N5O2/c1-29(19-22-39)27-38(2,3)28-41-36(44)35(26-32-16-11-15-31-14-7-8-18-34(31)32)42-37(45)43(24-20-30-12-5-4-6-13-30)25-21-33-17-9-10-23-40-33/h4-18,23,29,35H,19-22,24-28,39H2,1-3H3,(H,41,44)(H,42,45)/t29?,35-/m1/s1
DM96ASN	CS	CC(CCN)CC(C)(C)CNC(=O)[C@@H](CC1=CC=CC2=CC=CC=C21)NC(=O)N(CCC3=CC=CC=C3)CCC4=CC=CC=N4
DM96ASN	IK	MZKKCMXXGCRPGX-LMZJGDDPSA-N
DM96ASN	IU	(2R)-N-(6-amino-2,2,4-trimethylhexyl)-3-naphthalen-1-yl-2-[[2-phenylethyl(2-pyridin-2-ylethyl)carbamoyl]amino]propanamide
DM96ASN	DE	Discovery agent

DM4FMGJ	ID	DM4FMGJ
DM4FMGJ	DN	L-798,106
DM4FMGJ	HS	Investigative
DM4FMGJ	SN	L798106; L-798106
DM4FMGJ	DT	Small molecular drug
DM4FMGJ	PC	15551229
DM4FMGJ	MW	536.4
DM4FMGJ	FM	C27H22BrNO4S
DM4FMGJ	IC	InChI=1S/C27H22BrNO4S/c1-33-25-14-13-24(28)18-26(25)34(31,32)29-27(30)15-12-21-7-3-5-9-23(21)17-19-10-11-20-6-2-4-8-22(20)16-19/h2-16,18H,17H2,1H3,(H,29,30)/b15-12+
DM4FMGJ	CS	COC1=C(C=C(C=C1)Br)S(=O)(=O)NC(=O)/C=C/C2=CC=CC=C2CC3=CC4=CC=CC=C4C=C3
DM4FMGJ	IK	ODTKFNUPVBULRJ-NTCAYCPXSA-N
DM4FMGJ	IU	(E)-N-(5-bromo-2-methoxyphenyl)sulfonyl-3-[2-(naphthalen-2-ylmethyl)phenyl]prop-2-enamide
DM4FMGJ	CA	CAS 244101-02-8
DM4FMGJ	CB	CHEBI:138743
DM4FMGJ	DE	Discovery agent

DMWBRDK	ID	DMWBRDK
DMWBRDK	DN	L-803,087
DMWBRDK	HS	Investigative
DMWBRDK	SN	L803087
DMWBRDK	DT	Small molecular drug
DMWBRDK	PC	5311374
DMWBRDK	MW	485.5
DMWBRDK	FM	C25H29F2N5O3
DMWBRDK	IC	InChI=1S/C25H29F2N5O3/c1-35-24(34)20(10-6-12-30-25(28)29)31-21(33)11-5-9-17-18-13-16(26)14-19(27)23(18)32-22(17)15-7-3-2-4-8-15/h2-4,7-8,13-14,20,32H,5-6,9-12H2,1H3,(H,31,33)(H4,28,29,30)/t20-/m0/s1
DMWBRDK	CS	COC(=O)[C@H](CCCN=C(N)N)NC(=O)CCCC1=C(NC2=C1C=C(C=C2F)F)C3=CC=CC=C3
DMWBRDK	IK	OPNMQSFIGUSHDH-FQEVSTJZSA-N
DMWBRDK	IU	methyl (2S)-5-(diaminomethylideneamino)-2-[4-(5,7-difluoro-2-phenyl-1H-indol-3-yl)butanoylamino]pentanoate
DMWBRDK	DE	Discovery agent

DM8YT7X	ID	DM8YT7X
DM8YT7X	DN	L-817,818
DM8YT7X	HS	Investigative
DM8YT7X	SN	L 817818; L817818; L-817818
DM8YT7X	DT	Small molecular drug
DM8YT7X	PC	5311375
DM8YT7X	MW	536.7
DM8YT7X	FM	C33H36N4O3
DM8YT7X	IC	InChI=1S/C33H36N4O3/c1-21(35)20-40-33(39)29(12-6-7-17-34)36-30(38)19-28-27-16-15-23-9-4-5-11-26(23)32(27)37-31(28)25-14-13-22-8-2-3-10-24(22)18-25/h2-5,8-11,13-16,18,21,29,37H,6-7,12,17,19-20,34-35H2,1H3,(H,36,38)/t21-,29-/m0/s1
DM8YT7X	CS	C[C@@H](COC(=O)[C@H](CCCCN)NC(=O)CC1=C(NC2=C1C=CC3=CC=CC=C32)C4=CC5=CC=CC=C5C=C4)N
DM8YT7X	IK	NFVRGDRCCNEGBS-LGGPFLRQSA-N
DM8YT7X	IU	[(2S)-2-aminopropyl] (2S)-6-amino-2-[[2-(2-naphthalen-2-yl-1H-benzo[g]indol-3-yl)acetyl]amino]hexanoate
DM8YT7X	DE	Discovery agent

DMYJ6QZ	ID	DMYJ6QZ
DMYJ6QZ	DN	L-826266
DMYJ6QZ	HS	Investigative
DMYJ6QZ	SN	MF266-3; LS-193774; compound 10b [PMID: 11504634]
DMYJ6QZ	DT	Small molecular drug
DMYJ6QZ	PC	9808643
DMYJ6QZ	MW	570.9
DMYJ6QZ	FM	C27H21BrClNO4S
DMYJ6QZ	IC	InChI=1S/C27H21BrClNO4S/c1-34-25-12-10-23(28)17-26(25)35(32,33)30-27(31)13-9-22-16-24(29)11-8-21(22)15-18-6-7-19-4-2-3-5-20(19)14-18/h2-14,16-17H,15H2,1H3,(H,30,31)/b13-9+
DMYJ6QZ	CS	COC1=C(C=C(C=C1)Br)S(=O)(=O)NC(=O)/C=C/C2=C(C=CC(=C2)Cl)CC3=CC4=CC=CC=C4C=C3
DMYJ6QZ	IK	DYXFUJYHEDGCLS-UKTHLTGXSA-N
DMYJ6QZ	IU	(E)-N-(5-bromo-2-methoxyphenyl)sulfonyl-3-[5-chloro-2-(naphthalen-2-ylmethyl)phenyl]prop-2-enamide
DMYJ6QZ	DE	Discovery agent

DMKEDU6	ID	DMKEDU6
DMKEDU6	DN	L-869298
DMKEDU6	HS	Investigative
DMKEDU6	SN	L-869298; UNII-2I921E370K; CHEMBL199015; 2I921E370K; MK-298; 362718-73-8; SCHEMBL3225083; (+)-L-869298; BDBM50174020; 2-Thiazolemethanol, 5-((1S)-1-(3-(cyclopropyloxy)-4-(difluoromethoxy)phenyl)-2-(1-oxido-3-pyridinyl)ethyl)-alpha,alpha-bis(trifluoromethyl)-; 3-[(S)-beta-[2-[1-Hydroxy-1-(trifluoromethyl)-2,2,2-trifluoroethyl]-5-thiazolyl]-3-(cyclopropyloxy)-4-(difluoromethoxy)phenethyl]pyridine 1-oxide
DMKEDU6	DT	Small molecular drug
DMKEDU6	PC	11039077
DMKEDU6	MW	570.5
DMKEDU6	FM	C23H18F8N2O4S
DMKEDU6	IC	InChI=1S/C23H18F8N2O4S/c24-20(25)37-16-6-3-13(9-17(16)36-14-4-5-14)15(8-12-2-1-7-33(35)11-12)18-10-32-19(38-18)21(34,22(26,27)28)23(29,30)31/h1-3,6-7,9-11,14-15,20,34H,4-5,8H2/t15-/m0/s1
DMKEDU6	CS	C1CC1OC2=C(C=CC(=C2)[C@H](CC3=C[N+](=CC=C3)[O-])C4=CN=C(S4)C(C(F)(F)F)(C(F)(F)F)O)OC(F)F
DMKEDU6	IK	YDLQPURWTSDWCC-HNNXBMFYSA-N
DMKEDU6	IU	2-[5-[(1S)-1-[3-cyclopropyloxy-4-(difluoromethoxy)phenyl]-2-(1-oxidopyridin-1-ium-3-yl)ethyl]-1,3-thiazol-2-yl]-1,1,1,3,3,3-hexafluoropropan-2-ol
DMKEDU6	CA	CAS 362718-73-8
DMKEDU6	DE	Discovery agent

DMUP516	ID	DMUP516
DMUP516	DN	L-873724
DMUP516	HS	Investigative
DMUP516	SN	L-873724; UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth
DMUP516	DT	Small molecular drug
DMUP516	PC	9913088
DMUP516	MW	481.5
DMUP516	FM	C23H26F3N3O3S
DMUP516	IC	InChI=1S/C23H26F3N3O3S/c1-15(2)14-20(22(30)28-13-12-27)29-21(23(24,25)26)18-6-4-16(5-7-18)17-8-10-19(11-9-17)33(3,31)32/h4-11,15,20-21,29H,13-14H2,1-3H3,(H,28,30)/t20-,21-/m0/s1
DMUP516	CS	CC(C)C[C@@H](C(=O)NCC#N)N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)C)C(F)(F)F
DMUP516	IK	VYFDSJLOCIGIKP-SFTDATJTSA-N
DMUP516	IU	(2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide
DMUP516	CA	CAS 603139-12-4
DMUP516	DE	Asthma

DMMAIQ2	ID	DMMAIQ2
DMMAIQ2	DN	L-888,291
DMMAIQ2	HS	Investigative
DMMAIQ2	SN	L-883,595
DMMAIQ2	DT	Small molecular drug
DMMAIQ2	PC	44450494
DMMAIQ2	MW	375.8
DMMAIQ2	FM	C19H15ClFNO2S
DMMAIQ2	IC	InChI=1S/C19H15ClFNO2S/c20-12-1-4-14(5-2-12)25-19-15-6-3-13(21)10-16(15)22-8-7-11(18(19)22)9-17(23)24/h1-6,10-11H,7-9H2,(H,23,24)
DMMAIQ2	CS	C1CN2C3=C(C=CC(=C3)F)C(=C2C1CC(=O)O)SC4=CC=C(C=C4)Cl
DMMAIQ2	IK	GSBAVONRPNJJOH-UHFFFAOYSA-N
DMMAIQ2	IU	2-[4-(4-chlorophenyl)sulfanyl-7-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-3-yl]acetic acid
DMMAIQ2	CA	CAS 1030017-51-6
DMMAIQ2	DE	Discovery agent

DMJCTWO	ID	DMJCTWO
DMJCTWO	DN	L-888607
DMJCTWO	HS	Investigative
DMJCTWO	SN	L-888607; UNII-LMX71OP17X; LMX71OP17X; CHEMBL370606; L 888607; 860033-06-3; GTPL1907; ZINC6745293; BDBM50174361; AJ-56816; 1H-Pyrrolo(1,2-a)indole-1-acetic acid, 9-((4-chlorophenyl)thio)-6-fluoro-2,3-dihydro-, (1S)-; HY-111271; CS-0034796; L-888,607; [(S)-9-(4-Chloro-phenylsulfanyl)-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]-acetic acid; 2-[(1S)-9-[(4-chlorophenyl)sulfanyl]-6-fluoro-1H,2H,3H-benzo[b]pyrrolizin-1-yl]acetic acid
DMJCTWO	DT	Small molecular drug
DMJCTWO	PC	44403763
DMJCTWO	MW	375.8
DMJCTWO	FM	C19H15ClFNO2S
DMJCTWO	IC	InChI=1S/C19H15ClFNO2S/c20-12-1-4-14(5-2-12)25-19-15-6-3-13(21)10-16(15)22-8-7-11(18(19)22)9-17(23)24/h1-6,10-11H,7-9H2,(H,23,24)/t11-/m0/s1
DMJCTWO	CS	C1CN2C3=C(C=CC(=C3)F)C(=C2[C@@H]1CC(=O)O)SC4=CC=C(C=C4)Cl
DMJCTWO	IK	GSBAVONRPNJJOH-NSHDSACASA-N
DMJCTWO	IU	2-[(3S)-4-(4-chlorophenyl)sulfanyl-7-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-3-yl]acetic acid
DMJCTWO	CA	CAS 860033-06-3
DMJCTWO	DE	Discovery agent

DMIORW9	ID	DMIORW9
DMIORW9	DN	L902688
DMIORW9	HS	Investigative
DMIORW9	SN	8-aza-1-decarboxy-11-deoxy-16,16-difluoro-16-phenyl-omega-tetranor-1-(5-tetrazolo) PGE1
DMIORW9	DT	Small molecular drug
DMIORW9	PC	11316084
DMIORW9	MW	419.5
DMIORW9	FM	C21H27F2N5O2
DMIORW9	IC	InChI=1S/C21H27F2N5O2/c22-21(23,16-8-4-3-5-9-16)18(29)13-11-17-12-14-20(30)28(17)15-7-2-1-6-10-19-24-26-27-25-19/h3-5,8-9,11,13,17-18,29H,1-2,6-7,10,12,14-15H2,(H,24,25,26,27)/b13-11+/t17-,18+/m0/s1
DMIORW9	CS	C1CC(=O)N([C@H]1/C=C/[C@H](C(C2=CC=CC=C2)(F)F)O)CCCCCCC3=NNN=N3
DMIORW9	IK	WPTLQOYLIXWRNN-SLKVGHROSA-N
DMIORW9	IU	(5R)-5-[(E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-1-[6-(2H-tetrazol-5-yl)hexyl]pyrrolidin-2-one
DMIORW9	CA	CAS 634193-54-7
DMIORW9	DE	Discovery agent

DMYDR2N	ID	DMYDR2N
DMYDR2N	DN	L-97-1 intravenous
DMYDR2N	HS	Investigative
DMYDR2N	SN	L-97-1; L-97-1 (intravenous, sepsis/pneumonic plague), Endacea; L-97-1 (oral, asthma/pneumonic plague/renal failure),Endacea
DMYDR2N	CP	Endacea Inc
DMYDR2N	DT	Small molecular drug
DMYDR2N	PC	11627742
DMYDR2N	MW	518.6
DMYDR2N	FM	C29H38N6O3
DMYDR2N	IC	InChI=1S/C29H38N6O3/c1-3-15-35-28(37)26-27(34(29(35)38)16-14-22-10-12-24(30)13-11-22)31-25(21-23-8-6-5-7-9-23)33(26)18-17-32(4-2)19-20-36/h5-13,36H,3-4,14-21,30H2,1-2H3
DMYDR2N	CS	CCCN1C(=O)C2=C(N=C(N2CCN(CC)CCO)CC3=CC=CC=C3)N(C1=O)CCC4=CC=C(C=C4)N
DMYDR2N	IK	QVEHDKFBFDUCEZ-UHFFFAOYSA-N
DMYDR2N	IU	3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-1-propylpurine-2,6-dione
DMYDR2N	CA	CAS 770703-20-3
DMYDR2N	DE	Sepsis

DMY6K2A	ID	DMY6K2A
DMY6K2A	DN	LA22-radioimmunoconjugates
DMY6K2A	HS	Investigative
DMY6K2A	SN	LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22
DMY6K2A	CP	Welson Pharmaceuticals Inc
DMY6K2A	DE	Solid tumour/cancer

DMP1V8Y	ID	DMP1V8Y
DMP1V8Y	DN	LA-480
DMP1V8Y	HS	Investigative
DMP1V8Y	SN	Bispecific c-Met monoclonal antibody (cancer), Lilly
DMP1V8Y	CP	Eli Lilly & Co
DMP1V8Y	DT	Antibody
DMP1V8Y	DE	Solid tumour/cancer

DMJIU3Y	ID	DMJIU3Y
DMJIU3Y	DN	Lactoferrin
DMJIU3Y	HS	Investigative
DMJIU3Y	PC	126456119
DMJIU3Y	MW	3125.8
DMJIU3Y	FM	C141H226N46O29S3
DMJIU3Y	IC	InChI=1S/C141H226N46O29S3/c1-11-77(6)111(133(212)186-112(80(9)189)134(213)183-106(74-218)130(209)184-110(76(4)5)132(211)176-97(49-32-61-161-141(155)156)120(199)170-93(45-28-57-157-137(147)148)116(195)166-78(7)113(192)180-103(136(215)216)66-82-36-16-13-17-37-82)185-128(207)104(72-188)181-131(210)107-50-33-62-187(107)135(214)79(8)165-109(191)71-164-115(194)100(64-75(2)3)177-121(200)92(44-24-27-56-144)168-117(196)91(43-23-26-55-143)169-125(204)99(53-63-219-10)175-119(198)94(46-29-58-158-138(149)150)172-126(205)101(67-83-69-162-88-40-20-18-38-85(83)88)179-124(203)98(51-52-108(146)190)174-127(206)102(68-84-70-163-89-41-21-19-39-86(84)89)178-122(201)96(48-31-60-160-140(153)154)171-118(197)95(47-30-59-159-139(151)152)173-129(208)105(73-217)182-123(202)90(42-22-25-54-142)167-114(193)87(145)65-81-34-14-12-15-35-81/h12-21,34-41,69-70,75-80,87,90-107,110-112,162-163,188-189,217-218H,11,22-33,42-68,71-74,142-145H2,1-10H3,(H2,146,190)(H,164,194)(H,165,191)(H,166,195)(H,167,193)(H,168,196)(H,169,204)(H,170,199)(H,171,197)(H,172,205)(H,173,208)(H,174,206)(H,175,198)(H,176,211)(H,177,200)(H,178,201)(H,179,203)(H,180,192)(H,181,210)(H,182,202)(H,183,213)(H,184,209)(H,185,207)(H,186,212)(H,215,216)(H4,147,148,157)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t77-,78-,79-,80+,87-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,110-,111-,112-/m0/s1
DMJIU3Y	CS	CC[C@H](C)[C@@H](C(=N[C@@H]([C@@H](C)O)C(=N[C@@H](CS)C(=N[C@@H](C(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](C)C(=N[C@@H](CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C([C@H](CO)N=C([C@@H]2CCCN2C(=O)[C@H](C)N=C(CN=C([C@H](CC(C)C)N=C([C@H](CCCCN)N=C([C@H](CCCCN)N=C([C@H](CCSC)N=C([C@H](CCCNC(=N)N)N=C([C@H](CC3=CNC4=CC=CC=C43)N=C([C@H](CCC(=N)O)N=C([C@H](CC5=CNC6=CC=CC=C65)N=C([C@H](CCCNC(=N)N)N=C([C@H](CCCNC(=N)N)N=C([C@H](CS)N=C([C@H](CCCCN)N=C([C@H](CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O
DMJIU3Y	IK	CSSYQJWUGATIHM-IKGCZBKSSA-N
DMJIU3Y	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-4-methylsulfanylbutylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-4-methylpentylidene]amino]-1-hydroxyethylidene]amino]propanoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-methylpentylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxypropylidene]amino]-3-phenylpropanoic acid
DMJIU3Y	CA	339615-76-8
DMJIU3Y	DE	Discovery agent

DMZ0O1X	ID	DMZ0O1X
DMZ0O1X	DN	Lactoquinomycin
DMZ0O1X	HS	Investigative
DMZ0O1X	SN	Lactoquinomycin; SCHEMBL12324296
DMZ0O1X	TC	Anticancer Agents
DMZ0O1X	DT	Small molecular drug
DMZ0O1X	PC	12967404
DMZ0O1X	MW	457.5
DMZ0O1X	FM	C24H27NO8
DMZ0O1X	IC	InChI=1S/C24H27NO8/c1-9-17-19(24-15(31-9)8-16(26)33-24)22(29)12-6-5-11(21(28)18(12)23(17)30)14-7-13(25(3)4)20(27)10(2)32-14/h5-6,9-10,13-15,20,24,27-28H,7-8H2,1-4H3/t9-,10-,13-,14-,15-,20-,24+/m1/s1
DMZ0O1X	CS	C[C@@H]1[C@H]([C@@H](C[C@@H](O1)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)[C@H](O[C@H]5[C@@H]4OC(=O)C5)C)O)N(C)C)O
DMZ0O1X	IK	NYJGMJFBEVSQNN-CNRHASOASA-N
DMZ0O1X	IU	(11R,15R,17R)-5-[(2R,4R,5S,6R)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]-4-hydroxy-17-methyl-12,16-dioxatetracyclo[8.7.0.03,8.011,15]heptadeca-1(10),3(8),4,6-tetraene-2,9,13-trione
DMZ0O1X	CA	CAS 60227-09-0
DMZ0O1X	CB	CHEBI:31808
DMZ0O1X	DE	Haematological malignancy

DMM0Z6Y	ID	DMM0Z6Y
DMM0Z6Y	DN	Lactose
DMM0Z6Y	HS	Investigative
DMM0Z6Y	SN	D(+)Cellobiose; Glcbeta1,4Glc; Lactose, beta-; D-(+)-Cellobiose; D-Glucose, 4-O-beta-D-glucopyranosyl-; NSC2559; beta-D-Glucopyranose, 4-O-beta-D-galactopyranosyl-; 4-O-beta-D-Glucopyranosyl-D-glucose; 528-50-7; beta-Lactose; Cellobiose, beta-; Lactopress; 4-O-Hexopyranosylhexopyranose; ss-Lactose; Lactose NF; beta-Cellobiose; beta-D-Lactose; D-Glucose, 4-O-beta-D-galactopyranosyl-; beta-Maltose monohydrate; SCHEMBL684118; AC1Q28M2; AC1L18X1; SCHEMBL20276017
DMM0Z6Y	DT	Small molecular drug
DMM0Z6Y	PC	6134
DMM0Z6Y	MW	342.3
DMM0Z6Y	FM	C12H22O11
DMM0Z6Y	IC	InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12+/m1/s1
DMM0Z6Y	CS	C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O
DMM0Z6Y	IK	GUBGYTABKSRVRQ-DCSYEGIMSA-N
DMM0Z6Y	IU	(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DMM0Z6Y	CA	CAS 63-42-3
DMM0Z6Y	CB	CHEBI:36218
DMM0Z6Y	DE	Discovery agent

DMTZ17V	ID	DMTZ17V
DMTZ17V	DN	Laevulinic Acid
DMTZ17V	HS	Investigative
DMTZ17V	SN	Levulinic acid; LEVULINIC ACID; 4-Oxopentanoic acid; 123-76-2; Laevulinic acid; Pentanoic acid, 4-oxo-; 4-Oxovaleric acid; Levulic acid; 3-Acetylpropionic acid; 4-Ketovaleric acid; LEVA; gamma-Ketovaleric acid; Acetopropionic acid; Levulinsaeure; Laevulic acid; Valeric acid, 4-oxo-; beta-Acetylpropionic acid; USAF CZ-1; 4-oxo-pentanoic acid; Propionic acid, 3-acetyl-; 4-Oxopentansaeure; Acidum laevulinicum; 3-Acetylpropionsaeure; 3-Ketobutane-1-carboxylic acid; UNII-RYX5QG61EI; NSC 3716; Acetylpropionic acid; FEMA No 2627; Pentanoic acid, 4-oxo; Levulinic Acid
DMTZ17V	DT	Small molecular drug
DMTZ17V	PC	11579
DMTZ17V	MW	116.11
DMTZ17V	FM	C5H8O3
DMTZ17V	IC	InChI=1S/C5H8O3/c1-4(6)2-3-5(7)8/h2-3H2,1H3,(H,7,8)
DMTZ17V	CS	CC(=O)CCC(=O)O
DMTZ17V	IK	JOOXCMJARBKPKM-UHFFFAOYSA-N
DMTZ17V	IU	4-oxopentanoic acid
DMTZ17V	CA	CAS 123-76-2
DMTZ17V	CB	CHEBI:45630
DMTZ17V	DE	Discovery agent

DMH6XTP	ID	DMH6XTP
DMH6XTP	DN	L-Ala-L-boroPro
DMH6XTP	HS	Investigative
DMH6XTP	DT	Small molecular drug
DMH6XTP	PC	44422917
DMH6XTP	MW	187.03
DMH6XTP	FM	C7H16BN2O3+
DMH6XTP	IC	InChI=1S/C7H15BN2O3/c1-5(9)7(11)10-4-2-3-6(10)8(12)13/h5-6,12-13H,2-4,9H2,1H3/p+1/t5-,6-/m0/s1
DMH6XTP	CS	B([C@@H]1CCCN1C(=O)[C@H](C)[NH3+])(O)O
DMH6XTP	IK	WDFZXMUIFGGBQF-WDSKDSINSA-O
DMH6XTP	IU	[(2S)-1-[(2R)-2-boronopyrrolidin-1-yl]-1-oxopropan-2-yl]azanium
DMH6XTP	DE	Discovery agent

DMLGK27	ID	DMLGK27
DMLGK27	DN	LA-N8
DMLGK27	HS	Investigative
DMLGK27	SN	GlycoPEG-FVIII; Long-acting recombinant FVIIII (N8), Novo Nordisk; Factor VIII (recombinant/GlycoPEGylated, hemophilia A), Novo Nordisk/Neose
DMLGK27	CP	Neose Technologies Inc
DMLGK27	DE	Factor VIII deficiency

DMHN74V	ID	DMHN74V
DMHN74V	DN	Lanosterol
DMHN74V	HS	Investigative
DMHN74V	SN	lanosterol; 79-63-0; Lanosterin; Lanster; Botalan base 138; Lanosta-8,24-dienol; Lanosta-8,24-dien-3beta-ol; (3beta)-lanosta-8,24-dien-3-ol; UNII-1J05Z83K3M; NSC60677; Botalan base; CHEBI:16521; Lanosta-8,24-dien-3.beta.-ol; CAHGCLMLTWQZNJ-BQNIITSRSA-N; 1J05Z83K3M; MFCD00021108; Lanostadien-3-beta-ol; NSC 60677; Lanosta-8,24-dien-3-ol, (3beta)-; Lanosta-8,24-dien-3-ol; Lanosta-8,24-dien-3-ol, (3.beta.)-; Lanosta-8,24-dien-3-beta-ol; 4,4',14alpha-Trimethyl-5alpha-cholesta-8,24-dien-3beta-ol; EINECS 201-214-9
DMHN74V	DT	Small molecular drug
DMHN74V	PC	246983
DMHN74V	MW	426.7
DMHN74V	FM	C30H50O
DMHN74V	IC	InChI=1S/C30H50O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h10,21-22,25-26,31H,9,11-19H2,1-8H3/t21-,22-,25+,26+,28-,29-,30+/m1/s1
DMHN74V	CS	C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C
DMHN74V	IK	CAHGCLMLTWQZNJ-BQNIITSRSA-N
DMHN74V	IU	(3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DMHN74V	CA	CAS 79-63-0
DMHN74V	CB	CHEBI:16521
DMHN74V	DE	Discovery agent

DMPJFGI	ID	DMPJFGI
DMPJFGI	DN	L-AP4
DMPJFGI	HS	Investigative
DMPJFGI	SN	(2S)-2-Amino-4-phosphonobutanoic acid; 23052-81-5; (2S)-2-amino-4-phosphonobutanoic acid; L-(+)-2-Amino-4-phosphonobutyric acid; L-APB; (S)-2-amino-4-phosphonobutanoic acid; CHEMBL33567; L-AP-4; S-2-amino-4-phosphonobutyrate; [3H]AP4; L-2-amino-4-phosphonobutiric acid; L-1-amino-4-phosphonobutanoic acid; Tocris-0103; NCIStruc2_000128; NCIStruc1_000162; SCHEMBL1969235; GTPL1410; GTPL1412; AC1L456H; MolPort-002-514-399; NCI30079; ZINC2033983; BN0084; CCG-37553; NCGC00013365
DMPJFGI	DT	Small molecular drug
DMPJFGI	PC	179394
DMPJFGI	MW	183.1
DMPJFGI	FM	C4H10NO5P
DMPJFGI	IC	InChI=1S/C4H10NO5P/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H2,8,9,10)/t3-/m0/s1
DMPJFGI	CS	C(CP(=O)(O)O)[C@@H](C(=O)O)N
DMPJFGI	IK	DDOQBQRIEWHWBT-VKHMYHEASA-N
DMPJFGI	IU	(2S)-2-amino-4-phosphonobutanoic acid
DMPJFGI	CA	CAS 23052-81-5
DMPJFGI	CB	CHEBI:143992
DMPJFGI	DE	Discovery agent

DMSYLIJ	ID	DMSYLIJ
DMSYLIJ	DN	LARGAZOLE
DMSYLIJ	HS	Investigative
DMSYLIJ	SN	LARGAZOLE; CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395
DMSYLIJ	DT	Small molecular drug
DMSYLIJ	PC	24757913
DMSYLIJ	MW	622.9
DMSYLIJ	FM	C29H42N4O5S3
DMSYLIJ	IC	InChI=1S/C29H42N4O5S3/c1-5-6-7-8-9-13-24(35)39-14-11-10-12-20-15-22(34)30-16-23-31-21(17-40-23)26-33-29(4,18-41-26)28(37)32-25(19(2)3)27(36)38-20/h10,12,17,19-20,25H,5-9,11,13-16,18H2,1-4H3,(H,30,34)(H,32,37)/b12-10+/t20-,25+,29+/m1/s1
DMSYLIJ	CS	CCCCCCCC(=O)SCC/C=C/[C@@H]1CC(=O)NCC2=NC(=CS2)C3=N[C@@](CS3)(C(=O)N[C@H](C(=O)O1)C(C)C)C
DMSYLIJ	IK	AXESYCSCGBQJBL-SZPBEECKSA-N
DMSYLIJ	IU	S-[(E)-4-[(5R,8S,11S)-5-methyl-6,9,13-trioxo-8-propan-2-yl-10-oxa-3,17-dithia-7,14,19,20-tetrazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-enyl] octanethioate
DMSYLIJ	CA	CAS 1009815-87-5
DMSYLIJ	DE	Discovery agent

DMWGPO6	ID	DMWGPO6
DMWGPO6	DN	L-aspartic acid
DMWGPO6	HS	Investigative
DMWGPO6	SN	L-Asp; L-aspartate; Aspatofort
DMWGPO6	DT	Small molecular drug
DMWGPO6	PC	5960
DMWGPO6	MW	133.1
DMWGPO6	FM	C4H7NO4
DMWGPO6	IC	InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1
DMWGPO6	CS	C([C@@H](C(=O)O)N)C(=O)O
DMWGPO6	IK	CKLJMWTZIZZHCS-REOHCLBHSA-N
DMWGPO6	IU	(2S)-2-aminobutanedioic acid
DMWGPO6	CA	CAS 56-84-8
DMWGPO6	CB	CHEBI:17053

DMYNL40	ID	DMYNL40
DMYNL40	DN	LASSBio-881
DMYNL40	HS	Investigative
DMYNL40	CP	Universidade Federal do Rio de Janeiro
DMYNL40	DT	Small molecular drug
DMYNL40	PC	135779789
DMYNL40	MW	441.5
DMYNL40	FM	C23H27N3O6
DMYNL40	IC	InChI=1S/C23H27N3O6/c1-22(2,3)15-7-13(8-16(20(15)27)23(4,5)6)11-24-25-21(28)14-9-18-19(32-12-31-18)10-17(14)26(29)30/h7-11,27H,12H2,1-6H3,(H,25,28)/b24-11+
DMYNL40	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=N/NC(=O)C2=CC3=C(C=C2[N+](=O)[O-])OCO3
DMYNL40	IK	XEYZVZBNMMRXSN-BHGWPJFGSA-N
DMYNL40	IU	N-[(E)-(3,5-ditert-butyl-4-hydroxyphenyl)methylideneamino]-6-nitro-1,3-benzodioxole-5-carboxamide
DMYNL40	DE	Pain

DMMDZ4B	ID	DMMDZ4B
DMMDZ4B	DN	LAU-0901
DMMDZ4B	HS	Investigative
DMMDZ4B	SN	PAF receptor antagonist (brain ischemia/ corneal disease), Louisiana State University; Platelet-activating factor receptor antagonist (brain ischemia/ corneal disease), Louisiana State University
DMMDZ4B	CP	Louisiana State University
DMMDZ4B	DE	Brain ischaemia

DM9C8KQ	ID	DM9C8KQ
DM9C8KQ	DN	Lauric Acid
DM9C8KQ	HS	Investigative
DM9C8KQ	SN	lauric acid; DODECANOIC ACID; 143-07-7; n-Dodecanoic acid; Dodecylic acid; Vulvic acid; Laurostearic acid; Dodecoic acid; Duodecylic acid; 1-Undecanecarboxylic acid; Aliphat No. 4; Neo-fat 12; C12 fatty acid; Ninol AA62 Extra; Wecoline 1295; Neo-fat 12-43; Hydrofol acid 1295; Hydrofol acid 1255; Duodecyclic acid; Hystrene 9512; Dodecylcarboxylate; Lauric acid (natural); Univol U-314; Lauric acid, pure; Coconut oil fatty acids; ABL; Undecane-1-carboxylic acid; Laurinsaeure; NSC-5026; CCRIS 669; C-1297; UNII-1160N9NU9U; n-Dodecanoate
DM9C8KQ	DT	Small molecular drug
DM9C8KQ	PC	3893
DM9C8KQ	MW	200.32
DM9C8KQ	FM	C12H24O2
DM9C8KQ	IC	InChI=1S/C12H24O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h2-11H2,1H3,(H,13,14)
DM9C8KQ	CS	CCCCCCCCCCCC(=O)O
DM9C8KQ	IK	POULHZVOKOAJMA-UHFFFAOYSA-N
DM9C8KQ	IU	dodecanoic acid
DM9C8KQ	CA	CAS 143-07-7
DM9C8KQ	CB	CHEBI:30805
DM9C8KQ	DE	Discovery agent

DM3W2OE	ID	DM3W2OE
DM3W2OE	DN	Lauryl Dimethylamine-N-Oxide
DM3W2OE	HS	Investigative
DM3W2OE	SN	1643-20-5; Lauramine oxide; Lauryldimethylamine oxide; Lauryldimethylamine N-oxide; Dodecyldimethylamine oxide; LDAO; Empigen OB; Ammonyx LO; Ammonyx AO; Aromox DMCD; Conco XAL; Dimethyldodecylamine oxide; Dimethylaurylamine oxide; 1-Dodecanamine, N,N-dimethyl-, N-oxide; DDNO; n-Dodecyldimethylamine oxide; Dodecyldimethylamine N-oxide; dodecyl(dimethyl)amine oxide; Dimethyldodecylamine N-oxide; N,N-dimethyldodecan-1-amine oxide; LAURYL DIMETHYLAMINE-N-OXIDE; Aromox dmmc-W; Dimethyllaurylamine oxide; Amonyx AO; Refan [Russian]
DM3W2OE	DT	Small molecular drug
DM3W2OE	PC	15433
DM3W2OE	MW	229.4
DM3W2OE	FM	C14H31NO
DM3W2OE	IC	InChI=1S/C14H31NO/c1-4-5-6-7-8-9-10-11-12-13-14-15(2,3)16/h4-14H2,1-3H3
DM3W2OE	CS	CCCCCCCCCCCC[N+](C)(C)[O-]
DM3W2OE	IK	SYELZBGXAIXKHU-UHFFFAOYSA-N
DM3W2OE	IU	N,N-dimethyldodecan-1-amine oxide
DM3W2OE	CA	CAS 1643-20-5
DM3W2OE	CB	CHEBI:131762
DM3W2OE	DE	Discovery agent

DMH3X06	ID	DMH3X06
DMH3X06	DN	LAVENDUSTIN A
DMH3X06	HS	Investigative
DMH3X06	SN	Lavendustin A; 125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid
DMH3X06	DT	Small molecular drug
DMH3X06	PC	3894
DMH3X06	MW	381.4
DMH3X06	FM	C21H19NO6
DMH3X06	IC	InChI=1S/C21H19NO6/c23-16-6-8-19(25)14(9-16)12-22(11-13-3-1-2-4-18(13)24)15-5-7-20(26)17(10-15)21(27)28/h1-10,23-26H,11-12H2,(H,27,28)
DMH3X06	CS	C1=CC=C(C(=C1)CN(CC2=C(C=CC(=C2)O)O)C3=CC(=C(C=C3)O)C(=O)O)O
DMH3X06	IK	ULTTYPMRMMDONC-UHFFFAOYSA-N
DMH3X06	IU	5-[(2,5-dihydroxyphenyl)methyl-[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid
DMH3X06	CA	CAS 125697-92-9
DMH3X06	CB	CHEBI:92413
DMH3X06	DE	Discovery agent

DMOK6IP	ID	DMOK6IP
DMOK6IP	DN	LAVYPWT
DMOK6IP	HS	Investigative
DMOK6IP	SN	CHEMBL395723; LAVYPWT
DMOK6IP	DT	Small molecular drug
DMOK6IP	PC	25054651
DMOK6IP	MW	849
DMOK6IP	FM	C43H60N8O10
DMOK6IP	IC	InChI=1S/C43H60N8O10/c1-22(2)18-30(44)38(55)46-24(5)37(54)49-35(23(3)4)41(58)48-33(19-26-13-15-28(53)16-14-26)42(59)51-17-9-12-34(51)40(57)47-32(39(56)50-36(25(6)52)43(60)61)20-27-21-45-31-11-8-7-10-29(27)31/h7-8,10-11,13-16,21-25,30,32-36,45,52-53H,9,12,17-20,44H2,1-6H3,(H,46,55)(H,47,57)(H,48,58)(H,49,54)(H,50,56)(H,60,61)/t24-,25+,30-,32-,33-,34-,35-,36-/m0/s1
DMOK6IP	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N)O
DMOK6IP	IK	HOZWDBPFSGBJBM-DTSDQQARSA-N
DMOK6IP	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DMOK6IP	DE	Discovery agent

DM5GNFO	ID	DM5GNFO
DM5GNFO	DN	LAWSARITOL
DM5GNFO	HS	Investigative
DM5GNFO	SN	lawsaritol; CHEMBL202496; stigmast-4-en-3beta-ol
DM5GNFO	DT	Small molecular drug
DM5GNFO	PC	14890646
DM5GNFO	MW	414.7
DM5GNFO	FM	C29H50O
DM5GNFO	IC	InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h18-21,23-27,30H,7-17H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1
DM5GNFO	CS	CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C[C@H](CC[C@]34C)O)C)C(C)C
DM5GNFO	IK	BBTIMXAYZRWPNG-VJSFXXLFSA-N
DM5GNFO	IU	(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM5GNFO	DE	Discovery agent

DM3H9ZY	ID	DM3H9ZY
DM3H9ZY	DN	LB30812
DM3H9ZY	HS	Investigative
DM3H9ZY	DT	Small molecular drug
DM3H9ZY	PC	56603775
DM3H9ZY	MW	662.7
DM3H9ZY	FM	C30H33F3N6O6S
DM3H9ZY	IC	InChI=1S/C28H32N6O4S.C2HF3O2/c29-26(30)22-13-11-19(12-14-22)17-32-27(35)23-15-16-34(18-23)28(36)25(33-39(31,37)38)24(20-7-3-1-4-8-20)21-9-5-2-6-10-21;3-2(4,5)1(6)7/h1-14,23-25,33H,15-18H2,(H3,29,30)(H,32,35)(H2,31,37,38);(H,6,7)/t23-,25-;/m1./s1
DM3H9ZY	CS	C1CN(C[C@@H]1C(=O)NCC2=CC=C(C=C2)C(=N)N)C(=O)[C@@H](C(C3=CC=CC=C3)C4=CC=CC=C4)NS(=O)(=O)N.C(=O)(C(F)(F)F)O
DM3H9ZY	IK	RNDLEWFHHMPODL-ZHEQYFEDSA-N
DM3H9ZY	IU	(3R)-N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-3,3-diphenyl-2-(sulfamoylamino)propanoyl]pyrrolidine-3-carboxamide;2,2,2-trifluoroacetic acid
DM3H9ZY	DE	Discovery agent

DM6RH19	ID	DM6RH19
DM6RH19	DN	LB42908
DM6RH19	HS	Investigative
DM6RH19	SN	LB 42908
DM6RH19	DT	Small molecular drug
DM6RH19	PC	91623355
DM6RH19	MW	535.6
DM6RH19	FM	C32H33N5O3
DM6RH19	IC	InChI=1S/C32H33N5O3/c1-34-11-13-36(14-12-34)32(38)29-20-35(19-28(29)27-8-4-6-24-5-2-3-7-26(24)27)18-25-16-33-21-37(25)17-23-9-10-30-31(15-23)40-22-39-30/h2-10,15-16,19-21,30-31H,11-14,17-18,22H2,1H3
DM6RH19	CS	CN1CCN(CC1)C(=O)C2=CN(C=C2C3=CC=CC4=CC=CC=C43)CC5=CN=CN5CC6=CC7C(C=C6)OCO7
DM6RH19	IK	VZWZHIJGBPHRDI-UHFFFAOYSA-N
DM6RH19	IU	[1-[[3-(3a,7a-dihydro-1,3-benzodioxol-5-ylmethyl)imidazol-4-yl]methyl]-4-naphthalen-1-ylpyrrol-3-yl]-(4-methylpiperazin-1-yl)methanone
DM6RH19	DE	Discovery agent

DMENM1B	ID	DMENM1B
DMENM1B	DN	L-beta-BA
DMENM1B	HS	Investigative
DMENM1B	SN	L-beta-threo-benzyl-aspartate
DMENM1B	DT	Small molecular drug
DMENM1B	PC	11622683
DMENM1B	MW	223.22
DMENM1B	FM	C11H13NO4
DMENM1B	IC	InChI=1S/C11H13NO4/c12-9(11(15)16)8(10(13)14)6-7-4-2-1-3-5-7/h1-5,8-9H,6,12H2,(H,13,14)(H,15,16)/t8-,9-/m0/s1
DMENM1B	CS	C1=CC=C(C=C1)C[C@@H]([C@@H](C(=O)O)N)C(=O)O
DMENM1B	IK	KMVYGTIPJNGNRD-IUCAKERBSA-N
DMENM1B	IU	(2S,3S)-2-amino-3-benzylbutanedioic acid
DMENM1B	DE	Discovery agent

DMTNQCE	ID	DMTNQCE
DMTNQCE	DN	L-betagamma-meATP
DMTNQCE	HS	Investigative
DMTNQCE	SN	UFZTZBNSLXELAL-IOSLPCCCSA-N; AMP-PCP; beta,gamma-Methylene ATP; phosphomethylphosphonic acid adenylate ester; CHEMBL133463; CHEBI:40532; 5'-O-(hydroxy{[hydroxy(phosphonomethyl)phosphoryl]oxy}phosphoryl)adenosine; ADENOSINE 5'-[BETA,GAMMA-METHYLENE]TRIPHOSPHATE; ADENOSINE-5'-[BETA, GAMMA-METHYLENE]TRIPHOSPHATE; 3469-78-1; adenosine 5'-beta,gamma-mu-methylenetriphosphate; ({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}methyl)phosphonic acid; AMPPCP;  betagamma-methylene-adenosine 5'-triphosphate; Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
DMTNQCE	DT	Small molecular drug
DMTNQCE	PC	91532
DMTNQCE	MW	505.21
DMTNQCE	FM	C11H18N5O12P3
DMTNQCE	IC	InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-31(24,25)28-30(22,23)4-29(19,20)21/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H,24,25)(H2,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1
DMTNQCE	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(CP(=O)(O)O)O)O)O)N
DMTNQCE	IK	UFZTZBNSLXELAL-IOSLPCCCSA-N
DMTNQCE	IU	[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methylphosphonic acid
DMTNQCE	CA	CAS 3469-78-1
DMTNQCE	CB	CHEBI:40532
DMTNQCE	DE	Discovery agent

DMQ2DFN	ID	DMQ2DFN
DMQ2DFN	DN	LBQ657
DMQ2DFN	HS	Investigative
DMQ2DFN	SN	LBQ-657
DMQ2DFN	DT	Small molecular drug
DMQ2DFN	PC	10430040
DMQ2DFN	MW	383.4
DMQ2DFN	FM	C22H25NO5
DMQ2DFN	IC	InChI=1S/C22H25NO5/c1-15(22(27)28)13-19(23-20(24)11-12-21(25)26)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h2-10,15,19H,11-14H2,1H3,(H,23,24)(H,25,26)(H,27,28)/t15-,19+/m1/s1
DMQ2DFN	CS	C[C@H](C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O)C(=O)O
DMQ2DFN	IK	DOBNVUFHFMVMDB-BEFAXECRSA-N
DMQ2DFN	IU	(2R,4S)-4-(3-carboxypropanoylamino)-2-methyl-5-(4-phenylphenyl)pentanoic acid
DMQ2DFN	CA	CAS 149709-44-4
DMQ2DFN	DE	Discovery agent

DMGWSCI	ID	DMGWSCI
DMGWSCI	DN	LC34AD3
DMGWSCI	HS	Investigative
DMGWSCI	SN	GPR119 agonists (type 2 diabetes), LG Life Sciences; G-protein coupled receptor 119 agonist (type 2 diabetes), LG Life Sciences
DMGWSCI	CP	LG Life Sciences Ltd
DMGWSCI	DE	Non-insulin dependent diabetes

DMYONVF	ID	DMYONVF
DMYONVF	DN	LC-445
DMYONVF	HS	Investigative
DMYONVF	CP	Alkermes
DMYONVF	TC	Anticancer Agents
DMYONVF	DT	Small molecular drug
DMYONVF	PC	35595
DMYONVF	DE	Solid tumour/cancer

DMPZ8XH	ID	DMPZ8XH
DMPZ8XH	DN	L-CCG-I
DMPZ8XH	HS	Investigative
DMPZ8XH	SN	3,4-Cyclopropylglutamate; CCPG; L-2-(Carboxypropyl)glycine
DMPZ8XH	DT	Small molecular drug
DMPZ8XH	PC	1271
DMPZ8XH	MW	159.14
DMPZ8XH	FM	C6H9NO4
DMPZ8XH	IC	InChI=1S/C6H9NO4/c7-4(6(10)11)2-1-3(2)5(8)9/h2-4H,1,7H2,(H,8,9)(H,10,11)
DMPZ8XH	CS	C1C(C1C(=O)O)C(C(=O)O)N
DMPZ8XH	IK	GZOVEPYOCJWRFC-UHFFFAOYSA-N
DMPZ8XH	IU	2-[amino(carboxy)methyl]cyclopropane-1-carboxylic acid
DMPZ8XH	CA	CAS 22255-17-0
DMPZ8XH	DE	Discovery agent

DME4TUQ	ID	DME4TUQ
DME4TUQ	DN	Lck inhibitor
DME4TUQ	HS	Investigative
DME4TUQ	SN	213743-31-8; 7-Cyclopentyl-5-(4-phenoxy)phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine; CHEMBL47940; KIN001-051; RK-24466; 7-Cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine; 4-Amino-5-(4-Phenoxyphenyl)-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl-Cyclopentane; 7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[3,2-d]pyrimidin-7-yl-cyclopentane; 3vry; 3gen; B43; NCGC00015280-01; Lopac-C-8863; AC1O7G1S; Lopac0_000450; MLS002153184
DME4TUQ	DT	Small molecular drug
DME4TUQ	PC	11785878
DME4TUQ	MW	530.6
DME4TUQ	FM	C31H30N8O
DME4TUQ	IC	InChI=1S/C31H30N8O/c1-20-7-6-8-21(2)27(20)39-29(40)24-19-32-30(35-28(24)38-26-10-5-4-9-25(26)34-31(38)39)33-22-11-13-23(14-12-22)37-17-15-36(3)16-18-37/h4-14,19H,15-18H2,1-3H3,(H,32,33,35)
DME4TUQ	CS	CC1=C(C(=CC=C1)C)N2C(=O)C3=CN=C(N=C3N4C2=NC5=CC=CC=C54)NC6=CC=C(C=C6)N7CCN(CC7)C
DME4TUQ	IK	BHJJWVDKNXABFS-UHFFFAOYSA-N
DME4TUQ	IU	9-(2,6-dimethylphenyl)-4-[4-(4-methylpiperazin-1-yl)anilino]-1,3,5,9,11-pentazatetracyclo[8.7.0.02,7.012,17]heptadeca-2,4,6,10,12,14,16-heptaen-8-one
DME4TUQ	DE	Discovery agent

DMD5GO0	ID	DMD5GO0
DMD5GO0	DN	LD-101
DMD5GO0	HS	Investigative
DMD5GO0	SN	AKT-SI-1
DMD5GO0	CP	H Lee Moffitt Cancer Center and Research Institute
DMD5GO0	PC	24773090
DMD5GO0	MW	337.29
DMD5GO0	FM	C13H15N5O6
DMD5GO0	IC	InChI=1S/C13H15N5O6/c14-10-6-7(20)4(11(15)23)1-18(12(6)17-3-16-10)13-9(22)8(21)5(2-19)24-13/h1,3,5,8-9,13,19,21-22H,2H2,(H2,15,23)(H2,14,16,17)/t5-,8-,9-,13-/m1/s1
DMD5GO0	CS	C1=C(C(=O)C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N
DMD5GO0	IK	SPBWHPXCWJLQRU-FITJORAGSA-N
DMD5GO0	IU	4-amino-8-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide
DMD5GO0	CA	CAS 36707-00-3
DMD5GO0	DE	Solid tumour/cancer

DMC5XQ6	ID	DMC5XQ6
DMC5XQ6	DN	LD201t1
DMC5XQ6	HS	Investigative
DMC5XQ6	DT	Aptamer
DMC5XQ6	DE	Inflammation

DMH7R6L	ID	DMH7R6L
DMH7R6L	DN	LDC1267
DMH7R6L	HS	Investigative
DMH7R6L	SN	LDC1267; 1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide
DMH7R6L	DT	Small molecular drug
DMH7R6L	PC	56847486
DMH7R6L	MW	560.5
DMH7R6L	FM	C30H26F2N4O5
DMH7R6L	IC	InChI=1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)
DMH7R6L	CS	CCOC1=CN(N=C1C(=O)NC2=CC(=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)F)C5=C(C=C(C=C5)F)C
DMH7R6L	IK	ISPBCAXOSOLFME-UHFFFAOYSA-N
DMH7R6L	IU	N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluoro-2-methylphenyl)pyrazole-3-carboxamide
DMH7R6L	DE	Discovery agent

DM57Z8J	ID	DM57Z8J
DM57Z8J	DN	LDN-214117
DM57Z8J	HS	Investigative
DM57Z8J	SN	compound 10 [PMID: 25101911]
DM57Z8J	DT	Small molecular drug
DM57Z8J	PC	91754554
DM57Z8J	MW	419.5
DM57Z8J	FM	C25H29N3O3
DM57Z8J	IC	InChI=1S/C25H29N3O3/c1-17-22(19-14-23(29-2)25(31-4)24(15-19)30-3)13-20(16-27-17)18-5-7-21(8-6-18)28-11-9-26-10-12-28/h5-8,13-16,26H,9-12H2,1-4H3
DM57Z8J	CS	CC1=C(C=C(C=N1)C2=CC=C(C=C2)N3CCNCC3)C4=CC(=C(C(=C4)OC)OC)OC
DM57Z8J	IK	BHUXVRVMMYAXKN-UHFFFAOYSA-N
DM57Z8J	IU	1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenyl]piperazine
DM57Z8J	DE	Discovery agent

DMTSLGF	ID	DMTSLGF
DMTSLGF	DN	LDN-91946
DMTSLGF	HS	Investigative
DMTSLGF	SN	compound 7
DMTSLGF	DT	Small molecular drug
DMTSLGF	PC	950368
DMTSLGF	MW	314.3
DMTSLGF	FM	C15H10N2O4S
DMTSLGF	IC	InChI=1S/C15H10N2O4S/c16-10-8-6-9(15(20)21)13(19)17-14(8)22-12(10)11(18)7-4-2-1-3-5-7/h1-6H,16H2,(H,17,19)(H,20,21)
DMTSLGF	CS	C1=CC=C(C=C1)C(=O)C2=C(C3=C(S2)NC(=O)C(=C3)C(=O)O)N
DMTSLGF	IK	OJHMDRZMENMQFP-UHFFFAOYSA-N
DMTSLGF	IU	3-amino-2-benzoyl-6-oxo-7H-thieno[2,3-b]pyridine-5-carboxylic acid
DMTSLGF	DE	Discovery agent

DMZ21HU	ID	DMZ21HU
DMZ21HU	DN	LEACHIANONE A
DMZ21HU	HS	Investigative
DMZ21HU	SN	leachianone A; 97938-31-3; Isokurarinone; (S)-5,7-Dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-((R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl)chroman-4-one; CHEBI:66559; (2S)-5,7,4'-trihydroxy-8-lavandulyl-2'-methoxyflavanone; (2S)-5,7-dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-[(2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-[(2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-3,4-dihydro-2H-1-benzopyran-4-one; CHEMBL453642; MolPort-028-754-113
DMZ21HU	DT	Small molecular drug
DMZ21HU	PC	44593449
DMZ21HU	MW	438.5
DMZ21HU	FM	C26H30O6
DMZ21HU	IC	InChI=1S/C26H30O6/c1-14(2)6-7-16(15(3)4)10-19-20(28)12-21(29)25-22(30)13-24(32-26(19)25)18-9-8-17(27)11-23(18)31-5/h6,8-9,11-12,16,24,27-29H,3,7,10,13H2,1-2,4-5H3/t16-,24+/m1/s1
DMZ21HU	CS	CC(=CC[C@H](CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)OC)C(=C)C)C
DMZ21HU	IK	YLTPWCZXKJSORQ-GYCJOSAFSA-N
DMZ21HU	IU	(2S)-5,7-dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
DMZ21HU	CA	CAS 97938-31-3
DMZ21HU	CB	CHEBI:66559
DMZ21HU	DE	Discovery agent

DML0GZ2	ID	DML0GZ2
DML0GZ2	DN	Lead acetate
DML0GZ2	HS	Investigative
DML0GZ2	SN	LEAD ACETATE; Lead diacetate; Lead(II) acetate; Lead(2+) acetate; 301-04-2; Acetic acid, lead salt; Unichem PBA; Lead di(acetate); Normal lead acetate; Dibasic lead acetate; Lead dibasic acetate; Bleiacetat [German]; lead(2+) diacetate; Plumbous acetate; Salt of saturn; Sugar of lead; Caswell No. 523A; Lead acetate (anhydrous); RCRA waste number U144; Acetate de plomb [French]; Lead acetate (Pb(Ac)2); Acetic acid lead(2+) salt; CCRIS 356; Acetic acid, lead(2+) salt; Acetic acid, lead(2 +) salt; UNII-KL498O6790; Acetate de plomb
DML0GZ2	DT	Small molecular drug
DML0GZ2	PC	9317
DML0GZ2	MW	325
DML0GZ2	FM	C4H6O4Pb
DML0GZ2	IC	InChI=1S/2C2H4O2.Pb/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
DML0GZ2	CS	CC(=O)[O-].CC(=O)[O-].[Pb+2]
DML0GZ2	IK	GUWSLQUAAYEZAF-UHFFFAOYSA-L
DML0GZ2	IU	lead(2+);diacetate
DML0GZ2	CA	CAS 301-04-2
DML0GZ2	DE	Discovery agent

DMZ7OHP	ID	DMZ7OHP
DMZ7OHP	DN	Lecanindole D
DMZ7OHP	HS	Investigative
DMZ7OHP	SN	Lecanindole D; CHEMBL1076438
DMZ7OHP	DT	Small molecular drug
DMZ7OHP	PC	44605900
DMZ7OHP	MW	353.5
DMZ7OHP	FM	C23H31NO2
DMZ7OHP	IC	InChI=1S/C23H31NO2/c1-20(2)18(25)10-11-21(3)22(4)14(9-12-23(20,21)26)13-16-15-7-5-6-8-17(15)24-19(16)22/h5-8,14,18,24-26H,9-13H2,1-4H3/t14-,18+,21+,22+,23+/m0/s1
DMZ7OHP	CS	C[C@]12CC[C@H](C([C@@]1(CC[C@@H]3[C@@]2(C4=C(C3)C5=CC=CC=C5N4)C)O)(C)C)O
DMZ7OHP	IK	QJRNEHJGTLWRJJ-BVYMYZFFSA-N
DMZ7OHP	IU	(1S,12S,15S,17R,20R)-1,16,16,20-tetramethyl-3-azapentacyclo[10.8.0.02,10.04,9.015,20]icosa-2(10),4,6,8-tetraene-15,17-diol
DMZ7OHP	DE	Discovery agent

DM0CEY3	ID	DM0CEY3
DM0CEY3	DN	Lefaxin
DM0CEY3	HS	Investigative
DM0CEY3	SN	PYRIDOSTIGMINE BROMIDE; 101-26-8; Mestinon; Kalimin; Regonal; Kalymin; Mestinon bromide; 3-((Dimethylcarbamoyl)oxy)-1-methylpyridin-1-ium bromide; 3-(Dimethylcarbamoyloxy)-1-methylpyridinium Bromide; Pyridostigmine (bromide); UNII-KVI301NA53; Piridostigmina bromuro [DCIT]; CCRIS 6798; HSDB 3924; 3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium bromide; Pyridostigmini bromidum [INN-Latin]; EINECS 202-929-9; Ro 1-5130; Bromure de pyridostigmine [INN-French]; Pyridostigmini bromidum; Bromuro de piridostigmina [INN-Spanish
DM0CEY3	DT	Small molecular drug
DM0CEY3	PC	7550
DM0CEY3	MW	261.12
DM0CEY3	FM	C9H13BrN2O2
DM0CEY3	IC	InChI=1S/C9H13N2O2.BrH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1
DM0CEY3	CS	C[N+]1=CC=CC(=C1)OC(=O)N(C)C.[Br-]
DM0CEY3	IK	VNYBTNPBYXSMOO-UHFFFAOYSA-M
DM0CEY3	IU	(1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate;bromide
DM0CEY3	CA	CAS 101-26-8
DM0CEY3	CB	CHEBI:8666
DM0CEY3	DE	Discovery agent

DM5LY1H	ID	DM5LY1H
DM5LY1H	DN	Leptin
DM5LY1H	HS	Investigative
DM5LY1H	SN	Leptin (Alzheimer's disease)
DM5LY1H	CP	Neurotez Inc
DM5LY1H	DE	Alzheimer disease

DME91CG	ID	DME91CG
DME91CG	DN	Lerdelimumab
DME91CG	HS	Investigative
DME91CG	DT	Antibody
DME91CG	DE	Discovery agent

DMDV67S	ID	DMDV67S
DMDV67S	DN	lergotrile
DMDV67S	HS	Investigative
DMDV67S	SN	LY 79907
DMDV67S	DT	Small molecular drug
DMDV67S	PC	6918447
DMDV67S	MW	299.8
DMDV67S	FM	C17H18ClN3
DMDV67S	IC	InChI=1S/C17H18ClN3/c1-21-9-10(5-6-19)7-12-11-3-2-4-14-16(11)13(8-15(12)21)17(18)20-14/h2-4,10,12,15,20H,5,7-9H2,1H3/t10-,12-,15-/m1/s1
DMDV67S	CS	CN1C[C@@H](C[C@H]2[C@H]1CC3=C(NC4=CC=CC2=C34)Cl)CC#N
DMDV67S	IK	JKAHWGPTNVUTNB-IXPVHAAZSA-N
DMDV67S	IU	2-[(6aR,9S,10aR)-5-chloro-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]acetonitrile
DMDV67S	CA	CAS 36945-03-6
DMDV67S	DE	Discovery agent

DMV4OKR	ID	DMV4OKR
DMV4OKR	DN	L-erythro-3-hydroxyaspartate
DMV4OKR	HS	Investigative
DMV4OKR	SN	(3R)-3-hydroxy-L-aspartate; erythro-3-Hydroxy-L-aspartate; L-erythro-3-hydroxyaspartate; L-erythro-beta-hydroxyaspartate; erythro-3-hydroxy-aspartic acid; CHEBI:58196; (3R)-3-hydroxy-L-aspartate anion; (3R)-3-hydroxy-L-aspartate(1-); ZB015320
DMV4OKR	DT	Small molecular drug
DMV4OKR	PC	28125549
DMV4OKR	MW	148.09
DMV4OKR	FM	C4H6NO5-
DMV4OKR	IC	InChI=1S/C4H7NO5/c5-1(3(7)8)2(6)4(9)10/h1-2,6H,5H2,(H,7,8)(H,9,10)/p-1/t1-,2+/m0/s1
DMV4OKR	CS	[C@H]([C@H](C(=O)[O-])O)(C(=O)[O-])[NH3+]
DMV4OKR	IK	YYLQUHNPNCGKJQ-NHYDCYSISA-M
DMV4OKR	IU	(2S,3R)-2-azaniumyl-3-hydroxybutanedioate
DMV4OKR	CB	CHEBI:58196
DMV4OKR	DE	Neurodegenerative disorder

DMV40XH	ID	DMV40XH
DMV40XH	DN	leualacin
DMV40XH	HS	Investigative
DMV40XH	SN	128140-12-5
DMV40XH	DT	Small molecular drug
DMV40XH	PC	197283
DMV40XH	MW	573.7
DMV40XH	FM	C31H47N3O7
DMV40XH	IC	InChI=1S/C31H47N3O7/c1-19(2)15-23(33)27(39)30(18-35,34(7)29(41)25(37)17-21(5)6)31(26(38)13-14-32,22-11-9-8-10-12-22)28(40)24(36)16-20(3)4/h8-12,18-20,23-25,36-37H,5,13-17,32-33H2,1-4,6-7H3/t23-,24?,25-,30-,31?/m0/s1
DMV40XH	CS	CC(C)C[C@@H](C(=O)[C@@](C=O)(C(C1=CC=CC=C1)(C(=O)CCN)C(=O)C(CC(C)C)O)N(C)C(=O)[C@H](CC(=C)C)O)N
DMV40XH	IK	ZPYMSTAWPQJBRU-DJQJIUKYSA-N
DMV40XH	IU	(2S)-N-[(4S,6S)-4-amino-7-(3-aminopropanoyl)-6-formyl-9-hydroxy-2,11-dimethyl-5,8-dioxo-7-phenyldodecan-6-yl]-2-hydroxy-N,4-dimethylpent-4-enamide
DMV40XH	CA	CAS 128140-12-5
DMV40XH	DE	Discovery agent

DM94JXH	ID	DM94JXH
DM94JXH	DN	Leucettamidine
DM94JXH	HS	Investigative
DM94JXH	SN	leucettamidine; CHEMBL485054
DM94JXH	DT	Small molecular drug
DM94JXH	PC	20704716
DM94JXH	MW	488.5
DM94JXH	FM	C25H24N6O5
DM94JXH	IC	InChI=1S/C25H24N6O5/c1-29-17(9-15-5-7-19-21(11-15)36-13-34-19)16(8-14-4-6-18-20(10-14)35-12-33-18)27-25(29)28-22-23(32)31(3)24(26)30(22)2/h4-7,10-11,26H,8-9,12-13H2,1-3H3/b26-24?,28-22+
DM94JXH	CS	CN1C(=C(N=C1/N=C/2\\C(=O)N(C(=N)N2C)C)CC3=CC4=C(C=C3)OCO4)CC5=CC6=C(C=C5)OCO6
DM94JXH	IK	RZKRATQHPLTYSI-GQZUJQTPSA-N
DM94JXH	IU	(5E)-5-[4,5-bis(1,3-benzodioxol-5-ylmethyl)-1-methylimidazol-2-yl]imino-2-imino-1,3-dimethylimidazolidin-4-one
DM94JXH	DE	Discovery agent

DMIZVA6	ID	DMIZVA6
DMIZVA6	DN	LEUCETTAMINE A
DMIZVA6	HS	Investigative
DMIZVA6	SN	Leucettamol A; Leucettamine A (lipid); 151124-32-2; AC1O5ZHI; 5,8,11,14,17,20-Triacontahexaene-3,28-diol, 2,29-diamino-, (2R*,3S*,5Z,8Z,11Z,14Z,20Z,28S*,29R*)-(+-)-; 334010-39-8; 5,8,11,14,17,20-Triacontahexaene-3,28-diol, 2,29-diamino-, (2R*,3S*,5Z,8Z,11Z,14Z,20Z,28S*,29R*)-; 5,8,11,14,17,20-Triacontahexaene-3,28-diol, 2,29-diamino-,  (2R,3S,5Z,8Z,11Z,14Z,20Z,28S,29R)-rel-
DMIZVA6	DT	Small molecular drug
DMIZVA6	PC	10021742
DMIZVA6	MW	365.4
DMIZVA6	FM	C20H19N3O4
DMIZVA6	IC	InChI=1S/C20H19N3O4/c1-23-15(7-13-3-5-17-19(9-13)27-11-25-17)14(22-20(23)21)6-12-2-4-16-18(8-12)26-10-24-16/h2-5,8-9H,6-7,10-11H2,1H3,(H2,21,22)
DMIZVA6	CS	CN1C(=C(N=C1N)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5
DMIZVA6	IK	CHUHMZZQHYOKBF-UHFFFAOYSA-N
DMIZVA6	IU	4,5-bis(1,3-benzodioxol-5-ylmethyl)-1-methylimidazol-2-amine
DMIZVA6	DE	Discovery agent

DMFQEWM	ID	DMFQEWM
DMFQEWM	DN	LEUCETTAMINE B
DMFQEWM	HS	Investigative
DMFQEWM	SN	leucettamine B; CHEMBL485053; SCHEMBL13219029
DMFQEWM	DT	Small molecular drug
DMFQEWM	PC	10037501
DMFQEWM	MW	245.23
DMFQEWM	FM	C12H11N3O3
DMFQEWM	IC	InChI=1S/C12H11N3O3/c1-15-11(16)8(14-12(15)13)4-7-2-3-9-10(5-7)18-6-17-9/h2-5H,6H2,1H3,(H2,13,14)/b8-4-
DMFQEWM	CS	CN1C(=O)/C(=C/C2=CC3=C(C=C2)OCO3)/N=C1N
DMFQEWM	IK	PKEDBIGNILOTHW-YWEYNIOJSA-N
DMFQEWM	IU	(5Z)-2-amino-5-(1,3-benzodioxol-5-ylmethylidene)-3-methylimidazol-4-one
DMFQEWM	DE	Discovery agent

DMBYND6	ID	DMBYND6
DMBYND6	DN	leucettine L41
DMBYND6	HS	Investigative
DMBYND6	DT	Small molecular drug
DMBYND6	PC	135398522
DMBYND6	MW	307.3
DMBYND6	FM	C17H13N3O3
DMBYND6	IC	InChI=1S/C17H13N3O3/c21-16-13(8-11-6-7-14-15(9-11)23-10-22-14)19-17(20-16)18-12-4-2-1-3-5-12/h1-9H,10H2,(H2,18,19,20,21)/b13-8-
DMBYND6	CS	C1OC2=C(O1)C=C(C=C2)/C=C\\3/C(=O)NC(=N3)NC4=CC=CC=C4
DMBYND6	IK	PGPHHJBZEGSUNE-JYRVWZFOSA-N
DMBYND6	IU	(4Z)-2-anilino-4-(1,3-benzodioxol-5-ylmethylidene)-1H-imidazol-5-one
DMBYND6	DE	Discovery agent

DMT2CZK	ID	DMT2CZK
DMT2CZK	DN	Leucine-enkephalin
DMT2CZK	HS	Investigative
DMT2CZK	SN	YGGFL; URLZCHNOLZSCCA-UHFFFAOYSA-N; 2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid; Spectrum_001429; AC1L1GYW; Spectrum5_000656; Spectrum4_001048; Spectrum2_001177; Spectrum3_001521; AC1Q1P3H; KBioSS_001909; KBioGR_001316; BSPBio_002902
DMT2CZK	DT	Small molecular drug
DMT2CZK	PC	461776
DMT2CZK	MW	555.6
DMT2CZK	FM	C28H37N5O7
DMT2CZK	IC	InChI=1S/C28H37N5O7/c1-17(2)12-23(28(39)40)33-27(38)22(14-18-6-4-3-5-7-18)32-25(36)16-30-24(35)15-31-26(37)21(29)13-19-8-10-20(34)11-9-19/h3-11,17,21-23,34H,12-16,29H2,1-2H3,(H,30,35)(H,31,37)(H,32,36)(H,33,38)(H,39,40)/t21-,22-,23-/m0/s1
DMT2CZK	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMT2CZK	IK	URLZCHNOLZSCCA-VABKMULXSA-N
DMT2CZK	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMT2CZK	CA	CAS 58822-25-6
DMT2CZK	CB	CHEBI:89656
DMT2CZK	DE	Discovery agent

DM6W27F	ID	DM6W27F
DM6W27F	DN	LEUCOSCEPTOSIDE A
DM6W27F	HS	Investigative
DM6W27F	DT	Small molecular drug
DM6W27F	PC	10394343
DM6W27F	MW	638.6
DM6W27F	FM	C30H38O15
DM6W27F	IC	InChI=1S/C30H38O15/c1-14-23(36)24(37)25(38)30(42-14)45-28-26(39)29(41-10-9-16-3-6-17(32)19(34)11-16)43-21(13-31)27(28)44-22(35)8-5-15-4-7-18(33)20(12-15)40-2/h3-8,11-12,14,21,23-34,36-39H,9-10,13H2,1-2H3/b8-5+/t14-,21+,23-,24+,25+,26+,27+,28+,29+,30-/m0/s1
DM6W27F	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)OC)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O
DM6W27F	IK	ZMYQRHSOVRDQDL-CPPDSBOHSA-N
DM6W27F	IU	[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
DM6W27F	DE	Discovery agent

DMYX2NJ	ID	DMYX2NJ
DMYX2NJ	DN	Leukotoxin
DMYX2NJ	HS	Investigative
DMYX2NJ	SN	Leukothera; Leukotoxin (cancer treatment); Leukotoxin (cancer treatment), Actinobac Biomed
DMYX2NJ	CP	Actinobac Biomed Inc
DMYX2NJ	DT	Small molecular drug
DMYX2NJ	PC	9966640
DMYX2NJ	MW	314.5
DMYX2NJ	FM	C18H34O4
DMYX2NJ	IC	InChI=1S/C18H34O4/c1-2-3-4-5-7-10-13-16(19)17(20)14-11-8-6-9-12-15-18(21)22/h7,10,16-17,19-20H,2-6,8-9,11-15H2,1H3,(H,21,22)/b10-7-
DMYX2NJ	CS	CCCCC/C=C\\CC(C(CCCCCCCC(=O)O)O)O
DMYX2NJ	IK	XEBKSQSGNGRGDW-YFHOEESVSA-N
DMYX2NJ	IU	(Z)-9,10-dihydroxyoctadec-12-enoic acid
DMYX2NJ	CA	CAS 53734-70-6
DMYX2NJ	CB	CHEBI:72663
DMYX2NJ	DE	Autoimmune diabetes

DMU075F	ID	DMU075F
DMU075F	DN	Leupeptin
DMU075F	HS	Investigative
DMU075F	SN	2-(2-Acetamido-4-methylvaleramido)-N-(1-formyl-4-guanidinobutyl)-4-methylvaleramide; AC1L97IT; Valeramide, 2-(2-acetamido-4-methylvaleramido)-N-(1-formyl-4-guanidinobutyl)-4-methyl-; 24365-55-7; (2S)-2-acetamido-N-[1-[[5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide
DMU075F	DT	Small molecular drug
DMU075F	PC	72429
DMU075F	MW	426.6
DMU075F	FM	C20H38N6O4
DMU075F	IC	InChI=1S/C20H38N6O4/c1-12(2)9-16(24-14(5)28)19(30)26-17(10-13(3)4)18(29)25-15(11-27)7-6-8-23-20(21)22/h11-13,15-17H,6-10H2,1-5H3,(H,24,28)(H,25,29)(H,26,30)(H4,21,22,23)/t15-,16-,17-/m0/s1
DMU075F	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C=O)NC(=O)C
DMU075F	IK	GDBQQVLCIARPGH-ULQDDVLXSA-N
DMU075F	IU	(2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide
DMU075F	CA	CAS 55123-66-5
DMU075F	CB	CHEBI:6426
DMU075F	DE	Malaria

DMPYSIT	ID	DMPYSIT
DMPYSIT	DN	levetimide
DMPYSIT	HS	Investigative
DMPYSIT	SN	l-benzetimide
DMPYSIT	DT	Small molecular drug
DMPYSIT	PC	30844
DMPYSIT	MW	362.5
DMPYSIT	FM	C23H26N2O2
DMPYSIT	IC	InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)/t23-/m0/s1
DMPYSIT	CS	C1CN(CCC1[C@]2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4
DMPYSIT	IK	LQQIVYSCPWCSSD-QHCPKHFHSA-N
DMPYSIT	IU	(3R)-3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione
DMPYSIT	CA	CAS 21888-99-3
DMPYSIT	DE	Discovery agent

DMWDJ0H	ID	DMWDJ0H
DMWDJ0H	DN	LEVONORDEFRIN
DMWDJ0H	HS	Investigative
DMWDJ0H	SN	levonordefrin; Corbadrine; Neo-Cobefrin; Nordefrin; 829-74-3; Corbadrinum; Corbadrina; alpha-Methylnoradrenaline; Corbadrinum [INN-Latin]; Corbadrina [INN-Spanish]; L-alpha-Methylnoradrenaline; Levonordefrin [USP]; Nordefrin, (-)-; UNII-V008L6478D; CHEBI:10304; 4-[(1R,2S)-2-amino-1-hydroxypropyl]benzene-1,2-diol; Corbadrine (INN); Corbadrine [INN]; Levonordefrin (USP); V008L6478D; CAS-829-74-3; DSSTox_RID_81553; DSSTox_CID_26349
DMWDJ0H	DT	Small molecular drug
DMWDJ0H	PC	164739
DMWDJ0H	MW	183.2
DMWDJ0H	FM	C9H13NO3
DMWDJ0H	IC	InChI=1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3/t5-,9-/m0/s1
DMWDJ0H	CS	C[C@@H]([C@@H](C1=CC(=C(C=C1)O)O)O)N
DMWDJ0H	IK	GEFQWZLICWMTKF-CDUCUWFYSA-N
DMWDJ0H	IU	4-[(1R,2S)-2-amino-1-hydroxypropyl]benzene-1,2-diol
DMWDJ0H	CA	CAS 829-74-3
DMWDJ0H	CB	CHEBI:10304
DMWDJ0H	DE	Discovery agent

DMV3P89	ID	DMV3P89
DMV3P89	DN	Levoverbenone
DMV3P89	HS	Investigative
DMV3P89	SN	Levoverbenone; DCSCXTJOXBUFGB-JGVFFNPUSA-N; L(-)-Verbenone; Pin-2-en-4-one; VERBENONE; VERBENONE,(L); Verbenone, (L)-; l-Verbenone; l-verbenoe; (-)-2-Pinen-4-one; (-)-Verbenone; (-)-cis-verbenone; (1S)-(-)-Verbenone; (1S)-(-)-Verbenone, 94%; (1S,5S)-4,6,6-Trimethylbicyclo[3.1.1]hept-3-en-2-one; (S)-(-)-Verbenone; 1196-01-6; 2XP0J7754U; 80-57-9; AI3-23128; Bicyclo(3.1.1)hept-3-en-2-one, 4,6,6-trimethyl-, (1S,5S)-; Bicyclo[3.1.1]hept-3-en-2-one, 4,6,6-trimethyl-, (1S,5S)-; CHEBI:78316; EINECS 214-807-2; NSC 6831; UNII-2XP0J7754U
DMV3P89	PC	92874
DMV3P89	MW	150.22
DMV3P89	FM	C10H14O
DMV3P89	IC	DCSCXTJOXBUFGB-JGVFFNPUSA-N
DMV3P89	CS	CC1=CC(=O)C2CC1C2(C)C
DMV3P89	IK	1S/C10H14O/c1-6-4-9(11)8-5-7(6)10(8,2)3/h4,7-8H,5H2,1-3H3/t7-,8+/m0/s1
DMV3P89	IU	(1S,5S)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one
DMV3P89	CA	CAS 1196-01-6
DMV3P89	CB	CHEBI:78316
DMV3P89	DE	Pulmonary tuberculosis

DMOEQTN	ID	DMOEQTN
DMOEQTN	DN	LF-160335
DMOEQTN	HS	Investigative
DMOEQTN	PC	9853328
DMOEQTN	MW	723.7
DMOEQTN	FM	C35H36Cl2N6O5S
DMOEQTN	IC	InChI=1S/C35H36Cl2N6O5S/c1-21-19-22(2)40-32-25(21)5-3-7-29(32)48-20-26-27(36)12-13-30(31(26)37)49(46,47)43-14-4-6-28(43)35(45)42-17-15-41(16-18-42)34(44)24-10-8-23(9-11-24)33(38)39/h3,5,7-13,19,28H,4,6,14-18,20H2,1-2H3,(H3,38,39)/t28-/m0/s1
DMOEQTN	CS	CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)N4CCC[C@H]4C(=O)N5CCN(CC5)C(=O)C6=CC=C(C=C6)C(=N)N)Cl)C
DMOEQTN	IK	XJEBAAYNUNGRSF-NDEPHWFRSA-N
DMOEQTN	IU	4-[4-[(2S)-1-[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylpyrrolidine-2-carbonyl]piperazine-1-carbonyl]benzenecarboximidamide
DMOEQTN	DE	Discovery agent

DM5G307	ID	DM5G307
DM5G307	DN	LFA703
DM5G307	HS	Investigative
DM5G307	SN	LFA703; 8-[2-((2S)-4-HYDROXY-1-{[5-(HYDROXYMETHYL)-6-METHOXY-2-NAPHTHYL]METHYL}-6-OXOPIPERIDIN-2-YL)ETHYL]-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2-METHYLBUTANOATE; AAY; 1xdd; AC1L9MT5; LFA-703; DB03932; (1S,3R,7S,8S,8aR)-8-{2-[(2S,4R)-4-hydroxy-1-{[5-(hydroxymethyl)-6-methoxynaphthalen-2-yl]methyl}-6-oxopiperidin-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
DM5G307	DT	Small molecular drug
DM5G307	PC	449169
DM5G307	MW	603.8
DM5G307	FM	C37H49NO6
DM5G307	IC	InChI=1S/C37H49NO6/c1-6-23(3)37(42)44-34-16-22(2)15-27-9-7-24(4)30(36(27)34)13-11-28-18-29(40)19-35(41)38(28)20-25-8-12-31-26(17-25)10-14-33(43-5)32(31)21-39/h7-10,12,14-15,17,22-24,28-30,34,36,39-40H,6,11,13,16,18-21H2,1-5H3/t22-,23-,24-,28-,29+,30-,34-,36-/m0/s1
DM5G307	CS	CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H]3C[C@H](CC(=O)N3CC4=CC5=C(C=C4)C(=C(C=C5)OC)CO)O)C
DM5G307	IK	WPVRNXUYVXQXPY-YFAYRSKXSA-N
DM5G307	IU	[(1S,3R,7S,8S,8aR)-8-[2-[(2S,4R)-4-hydroxy-1-[[5-(hydroxymethyl)-6-methoxynaphthalen-2-yl]methyl]-6-oxopiperidin-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
DM5G307	DE	Discovery agent

DMTXWCZ	ID	DMTXWCZ
DMTXWCZ	DN	LFM-A13
DMTXWCZ	HS	Investigative
DMTXWCZ	SN	lfm-a13; 244240-24-2; (Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide; SMR001230714; SR-01000075965; 62004-35-7; C11H8Br2N2O2; 2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide; BiomolKI_000050; LFMA13; BiomolKI2_000056; AC1L1H0E; AC1NS4I5; Lopac0_000650; SCHEMBL51142; BSPBio_001239; BMK1-F2; MLS006010694; MLS002153290; GTPL9262; CHEBI:95065; 2-cyano-N-(2,5-dibromophenyl); MolPort-003-958-579; HMS1362M21; HMS3403M21; HMS2235P16; HMS1990M21; HMS1792M21; BCP12817; 3781AH; s7734; BS0111; ZINC37868487; AKOS024456516; CS-3890
DMTXWCZ	DT	Small molecular drug
DMTXWCZ	PC	54676905
DMTXWCZ	MW	360
DMTXWCZ	FM	C11H8Br2N2O2
DMTXWCZ	IC	InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-
DMTXWCZ	CS	C/C(=C(\\C#N)/C(=O)NC1=C(C=CC(=C1)Br)Br)/O
DMTXWCZ	IK	UVSVTDVJQAJIFG-VURMDHGXSA-N
DMTXWCZ	IU	(Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
DMTXWCZ	CB	CHEBI:95065
DMTXWCZ	DE	Discovery agent

DMEK4FY	ID	DMEK4FY
DMEK4FY	DN	LG100754
DMEK4FY	HS	Investigative
DMEK4FY	SN	LG 100754; LG754
DMEK4FY	DT	Small molecular drug
DMEK4FY	PC	6442223
DMEK4FY	MW	396.6
DMEK4FY	FM	C26H36O3
DMEK4FY	IC	InChI=1S/C26H36O3/c1-8-14-29-23-17-22-21(25(4,5)12-13-26(22,6)7)16-20(23)19(3)11-9-10-18(2)15-24(27)28/h9-11,15-17H,8,12-14H2,1-7H3,(H,27,28)/b10-9+,18-15+,19-11-
DMEK4FY	CS	CCCOC1=CC2=C(C=C1/C(=C\\C=C\\C(=C\\C(=O)O)\\C)/C)C(CCC2(C)C)(C)C
DMEK4FY	IK	HNODNXQAYXJFMQ-LQUSFLDPSA-N
DMEK4FY	IU	(2E,4E,6Z)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)octa-2,4,6-trienoic acid
DMEK4FY	CA	CAS 180713-37-5
DMEK4FY	DE	Discovery agent

DMG1UOR	ID	DMG1UOR
DMG1UOR	DN	LG-120838
DMG1UOR	HS	Investigative
DMG1UOR	SN	LG-120838; CHEMBL302362; SCHEMBL4175160; SCHEMBL4175162; BDBM50067684; 5-(2-Methylbenzylidene)-2,2,4-trimethyl-1,2-dihydro-5H-1-aza-6-oxachrysene
DMG1UOR	DT	Small molecular drug
DMG1UOR	PC	9951771
DMG1UOR	MW	379.5
DMG1UOR	FM	C27H25NO
DMG1UOR	IC	InChI=1S/C27H25NO/c1-17-9-5-6-10-19(17)15-24-26-21(20-11-7-8-12-23(20)29-24)13-14-22-25(26)18(2)16-27(3,4)28-22/h5-16,28H,1-4H3/b24-15-
DMG1UOR	CS	CC1=CC=CC=C1/C=C\\2/C3=C(C=CC4=C3C(=CC(N4)(C)C)C)C5=CC=CC=C5O2
DMG1UOR	IK	YXKBVHXOKVRRKO-IWIPYMOSSA-N
DMG1UOR	IU	(5Z)-2,2,4-trimethyl-5-[(2-methylphenyl)methylidene]-1H-chromeno[3,4-f]quinoline
DMG1UOR	DE	Discovery agent

DMMHYQ4	ID	DMMHYQ4
DMMHYQ4	DN	LG-121071
DMMHYQ4	HS	Investigative
DMMHYQ4	SN	LGD-121071
DMMHYQ4	DT	Small molecular drug
DMMHYQ4	PC	9839132
DMMHYQ4	MW	296.29
DMMHYQ4	FM	C15H15F3N2O
DMMHYQ4	IC	InChI=1S/C15H15F3N2O/c1-2-8-3-4-19-12-7-13-10(5-9(8)12)11(15(16,17)18)6-14(21)20-13/h5-8,19H,2-4H2,1H3,(H,20,21)
DMMHYQ4	CS	CCC1CCNC2=C1C=C3C(=CC(=O)NC3=C2)C(F)(F)F
DMMHYQ4	IK	SZPPQFARTYXRKU-UHFFFAOYSA-N
DMMHYQ4	IU	6-ethyl-4-(trifluoromethyl)-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one
DMMHYQ4	DE	Discovery agent

DMO1FCU	ID	DMO1FCU
DMO1FCU	DN	LG190178
DMO1FCU	HS	Investigative
DMO1FCU	SN	LG-190178
DMO1FCU	DT	Small molecular drug
DMO1FCU	PC	15521397
DMO1FCU	MW	458.6
DMO1FCU	FM	C28H42O5
DMO1FCU	IC	InChI=1S/C28H42O5/c1-8-28(9-2,21-10-12-24(19(3)14-21)32-17-23(30)16-29)22-11-13-25(20(4)15-22)33-18-26(31)27(5,6)7/h10-15,23,26,29-31H,8-9,16-18H2,1-7H3
DMO1FCU	CS	CCC(CC)(C1=CC(=C(C=C1)OCC(CO)O)C)C2=CC(=C(C=C2)OCC(C(C)(C)C)O)C
DMO1FCU	IK	AIKLCYAFOOBGEV-UHFFFAOYSA-N
DMO1FCU	IU	3-[4-[3-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]pentan-3-yl]-2-methylphenoxy]propane-1,2-diol
DMO1FCU	DE	Discovery agent

DM1W8Y0	ID	DM1W8Y0
DM1W8Y0	DN	LG-888
DM1W8Y0	HS	Investigative
DM1W8Y0	SN	Coagulation stimulator (factor VIII deficiency, protein recombinant), Lentigen; Factor VIII agonist (factor VIII deficiency, protein chimeric), Lentigen
DM1W8Y0	CP	Lentigen Corp
DM1W8Y0	DE	Factor VIII deficiency

DMIHDEB	ID	DMIHDEB
DMIHDEB	DN	LG-889
DMIHDEB	HS	Investigative
DMIHDEB	SN	Adult multipotent stem cell (hemophilia A), Lentigen/Expression/Emory
DMIHDEB	CP	Lentigen Corp
DMIHDEB	DE	Factor VIII deficiency

DMKRSZY	ID	DMKRSZY
DMKRSZY	DN	LGD-2226
DMKRSZY	HS	Investigative
DMKRSZY	SN	LGD-2226; UNII-RI376RM5MT; LGD2226; RI376RM5MT; CHEMBL436784; 328947-93-9; 6-[bis(2,2,2-Trifluoroethyl)amino]-4-(Trifluoromethyl)quinolin-2(1h)-One; 2hvc; SCHEMBL1771552; BDBM18524; DTXSID10186546; ZINC14968232; 6-(Bis-(2,2,2-trifluoroethyl)amino)-4-trifluoromethyl-1H-quinolin-2-one; DB08089; 4-(Trifluoromethyl)-6-[bis(2,2,2-trifluoroethyl)amino]quinoline-2(1H)-one; 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1H-quinolin-2-one; 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1,2-dihydroquinolin-2-one
DMKRSZY	DT	Small molecular drug
DMKRSZY	PC	11560224
DMKRSZY	MW	392.22
DMKRSZY	FM	C14H9F9N2O
DMKRSZY	IC	InChI=1S/C14H9F9N2O/c15-12(16,17)5-25(6-13(18,19)20)7-1-2-10-8(3-7)9(14(21,22)23)4-11(26)24-10/h1-4H,5-6H2,(H,24,26)
DMKRSZY	CS	C1=CC2=C(C=C1N(CC(F)(F)F)CC(F)(F)F)C(=CC(=O)N2)C(F)(F)F
DMKRSZY	IK	ULBPQWIGZUGPHU-UHFFFAOYSA-N
DMKRSZY	IU	6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1H-quinolin-2-one
DMKRSZY	CA	CAS 328947-93-9
DMKRSZY	DE	Discovery agent

DM67KWM	ID	DM67KWM
DM67KWM	DN	LGD-5552
DM67KWM	HS	Investigative
DM67KWM	SN	LGD-5552; CHEMBL259820; SCHEMBL4166143
DM67KWM	DT	Small molecular drug
DM67KWM	PC	24816375
DM67KWM	MW	443.5
DM67KWM	FM	C28H26FNO3
DM67KWM	IC	InChI=1S/C28H26FNO3/c1-15-7-6-8-17(26(15)29)13-22-24-18(25-21(33-22)12-11-20(31)27(25)32-5)9-10-19-23(24)16(2)14-28(3,4)30-19/h6-14,30-31H,1-5H3/b22-13-
DM67KWM	CS	CC1=C(C(=CC=C1)/C=C\\2/C3=C(C=CC4=C3C(=CC(N4)(C)C)C)C5=C(O2)C=CC(=C5OC)O)F
DM67KWM	IK	ACYYHAZVNHMRMQ-XKZIYDEJSA-N
DM67KWM	IU	(5Z)-5-[(2-fluoro-3-methylphenyl)methylidene]-10-methoxy-2,2,4-trimethyl-1H-chromeno[3,4-f]quinolin-9-ol
DM67KWM	DE	Discovery agent

DMKI70D	ID	DMKI70D
DMKI70D	DN	LHD-4
DMKI70D	HS	Investigative
DMKI70D	SN	Conjugated low molecular weight heparin derivatives (cancer); Conjugated low molecular weight heparin derivatives (cancer), Seoul National University; LHD-1.5
DMKI70D	CP	Seoul National University
DMKI70D	DE	Solid tumour/cancer

DML83XP	ID	DML83XP
DML83XP	DN	L-homoarginine
DML83XP	HS	Investigative
DML83XP	SN	L-Homoarginine; homoarginine; 156-86-5; H-HoArg-OH; homo-l-arginine; L-N(sup 6)-Amidinolysine; n6-amidino-lysine; UNII-JF751CK38I; (S)-2-Amino-6-guanidinohexanoic acid; N6-amidino-L-Lysine; L-Lysine, N(sup 6)-(aminoiminomethyl)-; NSC 27429; LYSINE, N(sup 6)-AMIDINO-, L-; CHEMBL589752; JF751CK38I; N6-(Aminoiminomethyl)-L-lysine; CHEBI:27747; QUOGESRFPZDMMT-YFKPBYRVSA-N; AK-49431; L-Lysine, N6-(aminoiminomethyl)- (9CI); L-alpha-Amino-epsilon-guanidinohexanoic acid; Q-201303; h-Homoarginine; h-har-oh; L-N(6)-amidinolysine
DML83XP	DT	Small molecular drug
DML83XP	PC	9085
DML83XP	MW	188.23
DML83XP	FM	C7H16N4O2
DML83XP	IC	InChI=1S/C7H16N4O2/c8-5(6(12)13)3-1-2-4-11-7(9)10/h5H,1-4,8H2,(H,12,13)(H4,9,10,11)/t5-/m0/s1
DML83XP	CS	C(CCN=C(N)N)C[C@@H](C(=O)O)N
DML83XP	IK	QUOGESRFPZDMMT-YFKPBYRVSA-N
DML83XP	IU	(2S)-2-amino-6-(diaminomethylideneamino)hexanoic acid
DML83XP	CA	CAS 156-86-5
DML83XP	CB	CHEBI:27747
DML83XP	DE	Discovery agent

DMB4ACY	ID	DMB4ACY
DMB4ACY	DN	LHRH
DMB4ACY	HS	Investigative
DMB4ACY	SN	SCHEMBL7378993
DMB4ACY	PC	36523
DMB4ACY	MW	1182.3
DMB4ACY	FM	C55H75N17O13
DMB4ACY	IC	InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)
DMB4ACY	CS	CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6
DMB4ACY	IK	XLXSAKCOAKORKW-UHFFFAOYSA-N
DMB4ACY	IU	N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMB4ACY	CA	CAS 33515-09-2
DMB4ACY	DE	Endometriosis

DMWY0TN	ID	DMWY0TN
DMWY0TN	DN	LICOAGROCHACONE A
DMWY0TN	HS	Investigative
DMWY0TN	SN	licochalcone a; 58749-22-7; Licochalcone-A; UNII-JTV5467968; 3-Dimethylallyl-4,4'-dihydroxy-6-methoxychalcone; CHEMBL139702; C21H22O4; JTV5467968; (E)-3-[5-(1,1-Dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-2-propen-1-one; Licochalcone-A, Synthetic; Q-100677; (E)-3-[5-(1,1-dimethylallyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one, 3-(5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (E)-
DMWY0TN	DT	Small molecular drug
DMWY0TN	PC	5318998
DMWY0TN	MW	338.4
DMWY0TN	FM	C21H22O4
DMWY0TN	IC	InChI=1S/C21H22O4/c1-5-21(2,3)17-12-15(20(25-4)13-19(17)24)8-11-18(23)14-6-9-16(22)10-7-14/h5-13,22,24H,1H2,2-4H3/b11-8+
DMWY0TN	CS	CC(C)(C=C)C1=C(C=C(C(=C1)/C=C/C(=O)C2=CC=C(C=C2)O)OC)O
DMWY0TN	IK	KAZSKMJFUPEHHW-DHZHZOJOSA-N
DMWY0TN	IU	(E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
DMWY0TN	CA	CAS 58749-22-7
DMWY0TN	CB	CHEBI:125689
DMWY0TN	DE	Discovery agent

DMY65ZP	ID	DMY65ZP
DMY65ZP	DN	LICOAGROCHALCONE A
DMY65ZP	HS	Investigative
DMY65ZP	SN	licoagrochalcone A; 3-Prenyl-4,2',4'-trihydroxychalcone; CHEMBL229885; 2',4,4'-trihydroxy-3-prenylchalcone; 202815-28-9; SCHEMBL632907; LMPK12120068; BDBM50212400; ACM202815289; (E)-2',4,4'-Trihydroxy-3-prenylchalcone; 1-(2,4-Dihydroxyphenyl)-3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-prop-2-en-1-one
DMY65ZP	DT	Small molecular drug
DMY65ZP	PC	11099375
DMY65ZP	MW	324.4
DMY65ZP	FM	C20H20O4
DMY65ZP	IC	InChI=1S/C20H20O4/c1-13(2)3-6-15-11-14(4-9-18(15)22)5-10-19(23)17-8-7-16(21)12-20(17)24/h3-5,7-12,21-22,24H,6H2,1-2H3/b10-5+
DMY65ZP	CS	CC(=CCC1=C(C=CC(=C1)/C=C/C(=O)C2=C(C=C(C=C2)O)O)O)C
DMY65ZP	IK	TVUGLERLRIQATC-BJMVGYQFSA-N
DMY65ZP	IU	(E)-1-(2,4-dihydroxyphenyl)-3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]prop-2-en-1-one
DMY65ZP	CA	CAS 202815-28-9
DMY65ZP	DE	Discovery agent

DM2UBQ8	ID	DM2UBQ8
DM2UBQ8	DN	LIM-5310
DM2UBQ8	HS	Investigative
DM2UBQ8	SN	LNS-5310; Efflux transport activator (neurotoxicity), Limerick
DM2UBQ8	CP	Limerick BioPharma Inc
DM2UBQ8	DE	Toxicity

DMGZQ5P	ID	DMGZQ5P
DMGZQ5P	DN	Linalool
DMGZQ5P	HS	Investigative
DMGZQ5P	SN	Linalool; 78-70-6; 3,7-Dimethylocta-1,6-dien-3-ol; Linalol; 3,7-Dimethyl-1,6-octadien-3-ol; beta-Linalool; allo-Ocimenol; LINALYL ALCOHOL; 1,6-Octadien-3-ol, 3,7-dimethyl-; p-Linalool; (+-)-Linalool; Linanool; 2,6-Dimethyl-2,7-octadien-6-ol; 2,6-Dimethylocta-2,7-dien-6-ol; .beta.-Linalool; Linalool (natural); 2,6-Dimethyl-2,7-octadiene-6-ol; Caswell No. 526A; Linolool; FEMA Number 2635; NSC 3789; FEMA No. 2635; CCRIS 3726; CCRIS 6557; HSDB 645; Linalool, 97%; EINECS 201-134-4; EINECS 245-083-6; 3,7-dimethyl-octa-1,6-dien-3-ol; EPA Pest
DMGZQ5P	DT	Small molecular drug
DMGZQ5P	PC	6549
DMGZQ5P	MW	154.25
DMGZQ5P	FM	C10H18O
DMGZQ5P	IC	InChI=1S/C10H18O/c1-5-10(4,11)8-6-7-9(2)3/h5,7,11H,1,6,8H2,2-4H3
DMGZQ5P	CS	CC(=CCCC(C)(C=C)O)C
DMGZQ5P	IK	CDOSHBSSFJOMGT-UHFFFAOYSA-N
DMGZQ5P	IU	3,7-dimethylocta-1,6-dien-3-ol
DMGZQ5P	CA	CAS 78-70-6
DMGZQ5P	CB	CHEBI:17580
DMGZQ5P	DE	Discovery agent

DMD3AJH	ID	DMD3AJH
DMD3AJH	DN	Linear peptide of RES-701-1
DMD3AJH	HS	Investigative
DMD3AJH	PC	77282233
DMD3AJH	MW	2061.199
DMD3AJH	FM	C103H117N23O24
DMD3AJH	IC	InChI=1S/C103H117N23O24/c1-54(113-101(147)89(55(2)127)125-87(133)52-111-90(136)78(43-63-51-107-53-112-63)121-96(142)77(41-61-49-109-70-24-13-10-21-67(61)70)119-97(143)79(44-84(105)130)114-86(132)47-104)102(148)126-35-15-26-83(126)100(146)123-81(46-88(134)135)99(145)120-76(40-60-48-108-69-23-12-9-20-66(60)69)95(141)117-72(36-56-16-5-3-6-17-56)91(137)115-73(37-57-18-7-4-8-19-57)93(139)122-80(45-85(106)131)98(144)118-74(38-58-27-31-64(128)32-28-58)92(138)116-75(39-59-29-33-65(129)34-30-59)94(140)124-82(103(149)150)42-62-50-110-71-25-14-11-22-68(62)71/h3-14,16-25,27-34,48-51,53-55,72-83,89,108-110,127-129H,15,26,35-47,52,104H2,1-2H3,(H2,105,130)(H2,106,131)(H,107,112)(H,111,136)(H,113,147)(H,114,132)(H,115,137)(H,116,138)(H,117,141)(H,118,144)(H,119,143)(H,120,145)(H,121,142)(H,122,139)(H,123,146)(H,124,140)(H,125,133)(H,134,135)(H,149,150)/t54-,55+,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-/m0/s1
DMD3AJH	CS	C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H](CC8=CNC9=CC=CC=C98)C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)CN)O
DMD3AJH	IK	ZUENRBCVCNXGQC-RYIFUXPHSA-N
DMD3AJH	IU	(3S)-3-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[(2-aminoacetyl)amino]-4-oxobutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMD3AJH	DE	Discovery agent

DMDGPY9	ID	DMDGPY9
DMDGPY9	DN	Linoleic acid
DMDGPY9	HS	Investigative
DMDGPY9	SN	linoleic acid; 60-33-3; Linolic acid; Telfairic acid; (9Z,12Z)-octadeca-9,12-dienoic acid; cis,cis-Linoleic acid; Grape seed oil; Linoleate; cis,cis-9,12-Octadecadienoic acid; Emersol 315; cis-9,cis-12-Octadecadienoic acid; 9,12-Linoleic acid; Unifac 6550; 9Z,12Z-Linoleic acid; Extra Linoleic 90; 9-cis,12-cis-Linoleic acid; Polylin 515; Emersol 310; Polylin No. 515; Oils, grape; 9Z,12Z-octadecadienoic acid; alpha-Linoleic acid; all-cis-9,12-Octadecadienoic acid; Linoleic; acide linoleique; (Z,Z)-9,12-Octadecadienoic acid; acido lino
DMDGPY9	DT	Small molecular drug
DMDGPY9	PC	5280450
DMDGPY9	MW	280.4
DMDGPY9	FM	C18H32O2
DMDGPY9	IC	InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-
DMDGPY9	CS	CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)O
DMDGPY9	IK	OYHQOLUKZRVURQ-HZJYTTRNSA-N
DMDGPY9	IU	(9Z,12Z)-octadeca-9,12-dienoic acid
DMDGPY9	CA	CAS 60-33-3
DMDGPY9	CB	CHEBI:17351
DMDGPY9	DE	Discovery agent

DMW9Z7N	ID	DMW9Z7N
DMW9Z7N	DN	Lipid Fragment
DMW9Z7N	HS	Investigative
DMW9Z7N	SN	2,10,23-TRIMETHYL-TETRACOSANE
DMW9Z7N	DT	Small molecular drug
DMW9Z7N	PC	17754177
DMW9Z7N	MW	380.7
DMW9Z7N	FM	C27H56
DMW9Z7N	IC	InChI=1S/C27H56/c1-25(2)21-17-13-10-8-6-7-9-11-15-19-23-27(5)24-20-16-12-14-18-22-26(3)4/h25-27H,6-24H2,1-5H3/t27-/m1/s1
DMW9Z7N	CS	C[C@H](CCCCCCCCCCCCC(C)C)CCCCCCCC(C)C
DMW9Z7N	IK	ZADHKSJXSZBQFB-HHHXNRCGSA-N
DMW9Z7N	IU	(10R)-2,10,23-trimethyltetracosane
DMW9Z7N	DE	Discovery agent

DMUIVCX	ID	DMUIVCX
DMUIVCX	DN	LIPOCRINE
DMUIVCX	HS	Investigative
DMUIVCX	SN	CHEMBL194823; LIPOCRINE; Rac-Lipocrine; tacrine-lipoic acid hybrid 7; SCHEMBL14341601; BDBM10512
DMUIVCX	DT	Small molecular drug
DMUIVCX	PC	11375002
DMUIVCX	MW	478.1
DMUIVCX	FM	C24H32ClN3OS2
DMUIVCX	IC	InChI=1S/C24H32ClN3OS2/c25-17-10-11-20-22(16-17)28-21-8-3-2-7-19(21)24(20)27-14-5-13-26-23(29)9-4-1-6-18-12-15-30-31-18/h10-11,16,18H,1-9,12-15H2,(H,26,29)(H,27,28)
DMUIVCX	CS	C1CCC2=NC3=C(C=CC(=C3)Cl)C(=C2C1)NCCCNC(=O)CCCCC4CCSS4
DMUIVCX	IK	QVGXTQPZHCDXRZ-UHFFFAOYSA-N
DMUIVCX	IU	N-[3-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]propyl]-5-(dithiolan-3-yl)pentanamide
DMUIVCX	DE	Discovery agent

DM6YSG3	ID	DM6YSG3
DM6YSG3	DN	LIQUIRTIGENIN
DM6YSG3	HS	Investigative
DM6YSG3	SN	578-86-9; 4',7-Dihydroxyflavanone; (S)-7-Hydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2S)-liquiritigenin; 5-DEOXYFLAVANONE; UNII-T194LKP9W6; 7-hydroxy-2-(4-hydroxy-phenyl)-chroman-4-one; T194LKP9W6; CHEMBL252642; CHEBI:28777; AK121923; (2S)-7-Hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one; (2S)-7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-2-(4-hydroxyphenyl)-7-oxidanyl-2,3-dihydrochromen-4-one
DM6YSG3	DT	Small molecular drug
DM6YSG3	PC	114829
DM6YSG3	MW	256.25
DM6YSG3	FM	C15H12O4
DM6YSG3	IC	InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2/t14-/m0/s1
DM6YSG3	CS	C1[C@H](OC2=C(C1=O)C=CC(=C2)O)C3=CC=C(C=C3)O
DM6YSG3	IK	FURUXTVZLHCCNA-AWEZNQCLSA-N
DM6YSG3	IU	(2S)-7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DM6YSG3	CA	CAS 578-86-9
DM6YSG3	CB	CHEBI:28777
DM6YSG3	DE	Discovery agent

DM54D1G	ID	DM54D1G
DM54D1G	DN	Lisinopril
DM54D1G	HS	Investigative
DM54D1G	SN	Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)
DM54D1G	CP	Merck & Co
DM54D1G	TC	Antiviral Agents
DM54D1G	DT	Small molecular drug
DM54D1G	PC	5362119
DM54D1G	MW	405.5
DM54D1G	FM	C21H31N3O5
DM54D1G	IC	InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
DM54D1G	CS	C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
DM54D1G	IK	RLAWWYSOJDYHDC-BZSNNMDCSA-N
DM54D1G	IU	(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
DM54D1G	CA	CAS 76547-98-3
DM54D1G	CB	CHEBI:43755
DM54D1G	DE	Hypertension; Coronavirus Disease 2019 (COVID-19)

DMQ42KU	ID	DMQ42KU
DMQ42KU	DN	lisinopril-tryptophan
DMQ42KU	HS	Investigative
DMQ42KU	SN	(S)-1-N2-(1-Carboxy-3-Phenylpropyl)-L-Lysyl-L-Tryptophan; Lisinopril-tryptophan; GTPL7893; N~2~-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-D-tryptophan; X95; (2S)-2-[[(2S)-6-amino-1-[[(1R)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-1-oxohexan-2-yl]amino]-4-phenylbutanoic acid
DMQ42KU	DT	Small molecular drug
DMQ42KU	PC	45480144
DMQ42KU	MW	494.6
DMQ42KU	FM	C27H34N4O5
DMQ42KU	IC	InChI=1S/C27H34N4O5/c28-15-7-6-12-22(30-23(26(33)34)14-13-18-8-2-1-3-9-18)25(32)31-24(27(35)36)16-19-17-29-21-11-5-4-10-20(19)21/h1-5,8-11,17,22-24,29-30H,6-7,12-16,28H2,(H,31,32)(H,33,34)(H,35,36)/t22-,23-,24+/m0/s1
DMQ42KU	CS	C1=CC=C(C=C1)CC[C@@H](C(=O)O)N[C@@H](CCCCN)C(=O)N[C@H](CC2=CNC3=CC=CC=C32)C(=O)O
DMQ42KU	IK	JXNGDSIPMBNTNL-KMDXXIMOSA-N
DMQ42KU	IU	(2S)-2-[[(2S)-6-amino-1-[[(1R)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-1-oxohexan-2-yl]amino]-4-phenylbutanoic acid
DMQ42KU	DE	Discovery agent

DM26AB4	ID	DM26AB4
DM26AB4	DN	L-Iso-Aspartate
DM26AB4	HS	Investigative
DM26AB4	SN	L-Iso-Aspartate
DM26AB4	DT	Small molecular drug
DM26AB4	PC	12049686
DM26AB4	MW	132.09
DM26AB4	FM	C4H6NO4-
DM26AB4	IC	InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/p-1/t2-/m1/s1
DM26AB4	CS	C([C@H](C(=O)[O-])N)C(=O)O
DM26AB4	IK	CKLJMWTZIZZHCS-UWTATZPHSA-M
DM26AB4	IU	(2R)-2-amino-4-hydroxy-4-oxobutanoate
DM26AB4	DE	Discovery agent

DM6RKOC	ID	DM6RKOC
DM6RKOC	DN	L-Isofagomine
DM6RKOC	HS	Investigative
DM6RKOC	SN	L-Isofagomine; CHEMBL501385; ( )-Isofagomine; SCHEMBL2435882; BDBM50263043
DM6RKOC	DT	Small molecular drug
DM6RKOC	PC	44578588
DM6RKOC	MW	147.17
DM6RKOC	FM	C6H13NO3
DM6RKOC	IC	InChI=1S/C6H13NO3/c8-3-4-1-7-2-5(9)6(4)10/h4-10H,1-3H2/t4-,5-,6-/m0/s1
DM6RKOC	CS	C1[C@H]([C@@H]([C@H](CN1)O)O)CO
DM6RKOC	IK	QPYJXFZUIJOGNX-ZLUOBGJFSA-N
DM6RKOC	IU	(3S,4S,5S)-5-(hydroxymethyl)piperidine-3,4-diol
DM6RKOC	DE	Discovery agent

DM4B6H3	ID	DM4B6H3
DM4B6H3	DN	L-isoleucine
DM4B6H3	HS	Investigative
DM4B6H3	SN	l-isoleucine; Isoleucine; 73-32-5; (2S,3S)-2-Amino-3-methylpentanoic acid; H-Ile-OH; (S)-Isoleucine; 2S,3S-Isoleucine; (S,S)-Isoleucine; 2-Amino-3-methylvaleric acid; erythro-L-Isoleucine; L-(+)-Isoleucine; L-Ile; alpha-Amino-beta-methylvaleric acid; 443-79-8; Isoleucine (VAN); Isoleucinum [Latin]; Isoleucina [Spanish]; Valeric acid, 2-amino-3-methyl-; Norvaline, 3-methyl-; L-Norvaline, 3-methyl-, erythro-; ISOLEUCINE, L-; Acetic acid, amino-sec-butyl-; Pentanoic acid, 2-amino-3-methyl-; CCRIS 5229; iso-leucine
DM4B6H3	DT	Small molecular drug
DM4B6H3	PC	6306
DM4B6H3	MW	131.17
DM4B6H3	FM	C6H13NO2
DM4B6H3	IC	InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1
DM4B6H3	CS	CC[C@H](C)[C@@H](C(=O)O)N
DM4B6H3	IK	AGPKZVBTJJNPAG-WHFBIAKZSA-N
DM4B6H3	IU	(2S,3S)-2-amino-3-methylpentanoic acid
DM4B6H3	CA	CAS 443-79-8
DM4B6H3	CB	CHEBI:17191
DM4B6H3	DE	Discovery agent

DMVSAUL	ID	DMVSAUL
DMVSAUL	DN	L-isoleucyl-L-prolinamide
DMVSAUL	HS	Investigative
DMVSAUL	SN	L-isoleucyl-L-prolinamide; CHEMBL224341
DMVSAUL	DT	Small molecular drug
DMVSAUL	PC	11673051
DMVSAUL	MW	227.3
DMVSAUL	FM	C11H21N3O2
DMVSAUL	IC	InChI=1S/C11H21N3O2/c1-3-7(2)9(12)11(16)14-6-4-5-8(14)10(13)15/h7-9H,3-6,12H2,1-2H3,(H2,13,15)/t7?,8-,9-/m0/s1
DMVSAUL	CS	CCC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DMVSAUL	IK	HCKIVERTZIJTOT-NPPUSCPJSA-N
DMVSAUL	IU	(2S)-1-[(2S)-2-amino-3-methylpentanoyl]pyrrolidine-2-carboxamide
DMVSAUL	DE	Discovery agent

DMHYLQ2	ID	DMHYLQ2
DMHYLQ2	DN	Lithium chloride
DMHYLQ2	HS	Investigative
DMHYLQ2	SN	LITHIUM CHLORIDE; 7447-41-8; Lithiumchloride; Lithium chloride (LiCl); LiCl; chlorure de lithium; Chlorku litu; chlorolithium; Lithiumchlorid; Chlorku litu [Polish]; Luthium chloride; Chlorure de lithium [French]; CCRIS 5924; UNII-G4962QA067; HSDB 4281; EINECS 231-212-3; lithium(1+) ion chloride; NSC 327172; CHEMBL69710; CHEBI:48607; NSC327172; MFCD00011078; G4962QA067; Lithium chloride, 99%, extra pure; ClLi; Lithium chloride, 99+%, ACS reagent; Lithium chloride, 99%, for molecular biology; Lithium chloride, 99%, for analysis, anhyd
DMHYLQ2	DT	Small molecular drug
DMHYLQ2	PC	433294
DMHYLQ2	MW	42.4
DMHYLQ2	FM	ClLi
DMHYLQ2	IC	InChI=1S/ClH.Li/h1H;/q;+1/p-1
DMHYLQ2	CS	[Li+].[Cl-]
DMHYLQ2	IK	KWGKDLIKAYFUFQ-UHFFFAOYSA-M
DMHYLQ2	IU	lithium;chloride
DMHYLQ2	CA	CAS 7447-41-8
DMHYLQ2	CB	CHEBI:48607
DMHYLQ2	DE	Discovery agent

DME76CQ	ID	DME76CQ
DME76CQ	DN	lithocholylcholine
DME76CQ	HS	Investigative
DME76CQ	SN	lithocholylcholine; GTPL326; BDBM86049
DME76CQ	DT	Small molecular drug
DME76CQ	PC	22991950
DME76CQ	MW	448.7
DME76CQ	FM	C29H54NO2+
DME76CQ	IC	InChI=1S/C29H54NO2/c1-20(8-7-9-23(32)19-30(4,5)6)25-12-13-26-24-11-10-21-18-22(31)14-16-28(21,2)27(24)15-17-29(25,26)3/h20-27,31-32H,7-19H2,1-6H3/q+1
DME76CQ	CS	CC(CCCC(C[N+](C)(C)C)O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C
DME76CQ	IK	KWEWGNPMETZMTR-UHFFFAOYSA-N
DME76CQ	IU	[2-hydroxy-6-(3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptyl]-trimethylazanium
DME76CQ	DE	Discovery agent

DMPAKQV	ID	DMPAKQV
DMPAKQV	DN	Lithospermic acid
DMPAKQV	HS	Investigative
DMPAKQV	SN	Lithospermic acid; 28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr
DMPAKQV	DT	Small molecular drug
DMPAKQV	PC	6441498
DMPAKQV	MW	538.5
DMPAKQV	FM	C27H22O12
DMPAKQV	IC	InChI=1S/C27H22O12/c28-15-5-1-12(9-18(15)31)10-20(26(34)35)38-21(33)8-4-13-2-7-17(30)25-22(13)23(27(36)37)24(39-25)14-3-6-16(29)19(32)11-14/h1-9,11,20,23-24,28-32H,10H2,(H,34,35)(H,36,37)/b8-4+/t20-,23+,24-/m1/s1
DMPAKQV	CS	C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3[C@@H]([C@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O)O)O
DMPAKQV	IK	UJZQBMQZMKFSRV-RGKBJLTCSA-N
DMPAKQV	IU	(2S,3S)-4-[(E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid
DMPAKQV	CA	CAS 28831-65-4
DMPAKQV	DE	Discovery agent

DM6J1BY	ID	DM6J1BY
DM6J1BY	DN	LIVIDOMYCIN A
DM6J1BY	HS	Investigative
DM6J1BY	SN	lividomycin A; Lividomycin; Quintomycin B; Mannosyldeoxyparomomycin; Antibiotic 503-2; Antibiotic SF 767 A; Lividomycinum; Lividomycine; 36441-41-5; Lividomicina; SF 767 A; Livodymycin; Lividomycin [INN:DCF]; Lividomycinum [INN-Latin]; Lividomycine [INN-French]; Lividomicina [INN-Spanish]; UNII-A606AJ494W; BRN 6763509; CHEBI:71961; Lividomycin A sulfate salt; A606AJ494W
DM6J1BY	DT	Small molecular drug
DM6J1BY	PC	72394
DM6J1BY	MW	761.8
DM6J1BY	FM	C29H55N5O18
DM6J1BY	IC	InChI=1S/C29H55N5O18/c30-3-11-23(51-28-20(43)19(42)17(40)13(5-36)47-28)18(41)15(34)27(45-11)50-24-14(6-37)48-29(21(24)44)52-25-16(39)7(31)1-8(32)22(25)49-26-9(33)2-10(38)12(4-35)46-26/h7-29,35-44H,1-6,30-34H2/t7-,8+,9-,10+,11+,12-,13-,14-,15-,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27-,28-,29+/m1/s1
DM6J1BY	CS	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H](C[C@@H]([C@H](O2)CO)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)N)O)O)N
DM6J1BY	IK	DBLVDAUGBTYDFR-SWMBIRFSSA-N
DM6J1BY	IU	(2R,3S,4S,5S,6R)-2-[(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,5S,6R)-3-amino-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy-4-hydroxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM6J1BY	CA	CAS 36441-41-5
DM6J1BY	CB	CHEBI:71961
DM6J1BY	DE	Discovery agent

DMJ108U	ID	DMJ108U
DMJ108U	DN	LJP-1207
DMJ108U	HS	Investigative
DMJ108U	SN	LJP-1200; LJP-1233; LJP-1586; SSAO inhibitors (inflammation); SSAO inhibitors, La Jolla; VAP-1 inhibitors, La Jolla; Vascular adhesion protein-1 inhibitors, La Jolla; Semi-carbazide-sensitive amine oxidase, La Jolla
DMJ108U	CP	La Jolla Pharmaceutical Co
DMJ108U	PC	11615193
DMJ108U	MW	148.2
DMJ108U	FM	C9H12N2
DMJ108U	IC	InChI=1S/C9H12N2/c1-8(7-11-10)9-5-3-2-4-6-9/h2-6,11H,1,7,10H2
DMJ108U	CS	C=C(CNN)C1=CC=CC=C1
DMJ108U	IK	IHEVYQFGSZLVRV-UHFFFAOYSA-N
DMJ108U	IU	2-phenylprop-2-enylhydrazine
DMJ108U	DE	Cerebrovascular ischaemia

DMLVTXM	ID	DMLVTXM
DMLVTXM	DN	LK 204-545
DMLVTXM	HS	Investigative
DMLVTXM	SN	LK-204545
DMLVTXM	DT	Small molecular drug
DMLVTXM	PC	5311116
DMLVTXM	MW	484.5
DMLVTXM	FM	C25H32N4O6
DMLVTXM	IC	InChI=1S/C25H32N4O6/c26-14-19-13-23(34-12-11-33-16-18-1-2-18)7-8-24(19)35-17-22(31)15-27-9-10-28-25(32)29-20-3-5-21(30)6-4-20/h3-8,13,18,22,27,30-31H,1-2,9-12,15-17H2,(H2,28,29,32)
DMLVTXM	CS	C1CC1COCCOC2=CC(=C(C=C2)OCC(CNCCNC(=O)NC3=CC=C(C=C3)O)O)C#N
DMLVTXM	IK	VAWYRUMIUGPAEX-UHFFFAOYSA-N
DMLVTXM	IU	1-[2-[[3-[2-cyano-4-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-2-hydroxypropyl]amino]ethyl]-3-(4-hydroxyphenyl)urea
DMLVTXM	DE	Discovery agent

DM6RCES	ID	DM6RCES
DM6RCES	DN	LL-6531
DM6RCES	HS	Investigative
DM6RCES	SN	PPAR modulators (diabetes), Lupin
DM6RCES	CP	Lupin Ltd
DM6RCES	DE	Diabetic complication

DMO1Z5Q	ID	DMO1Z5Q
DMO1Z5Q	DN	L-lactic acid
DMO1Z5Q	HS	Investigative
DMO1Z5Q	SN	L-lactate; lactate; (S)-lactate; (S)-lactic acid
DMO1Z5Q	DT	Small molecular drug
DMO1Z5Q	PC	107689
DMO1Z5Q	MW	90.08
DMO1Z5Q	FM	C3H6O3
DMO1Z5Q	IC	InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m0/s1
DMO1Z5Q	CS	C[C@@H](C(=O)O)O
DMO1Z5Q	IK	JVTAAEKCZFNVCJ-REOHCLBHSA-N
DMO1Z5Q	IU	(2S)-2-hydroxypropanoic acid
DMO1Z5Q	CA	CAS 79-33-4
DMO1Z5Q	CB	CHEBI:422
DMO1Z5Q	DE	Discovery agent

DMQHN7I	ID	DMQHN7I
DMQHN7I	DN	L-leucine
DMQHN7I	HS	Investigative
DMQHN7I	SN	leucine; 61-90-5; (S)-2-Amino-4-methylpentanoic acid; H-Leu-OH; (S)-Leucine; (2S)-2-amino-4-methylpentanoic acid; (S)-(+)-Leucine; Leucin; L-Norvaline, 4-methyl-; (S)-2-Amino-4-methylvaleric acid; L-leucin; L-alpha-Aminoisocaproic acid; Leucin [German]; LEUCINE, L-; Leucine (VAN); leu; Leucinum; (2S)-alpha-leucine; L-(-)-2-Amino-4-methylpentanoic acid; 2-amino-4-methylvaleric acid; Leucinum [INN-Latin]; Leucine [USAN:INN]; L-Leuzin; Leucina [INN-Spanish]; Leucina [Latin,Spanish]; alpha-Aminoisocaproic acid
DMQHN7I	DT	Small molecular drug
DMQHN7I	PC	6106
DMQHN7I	MW	131.17
DMQHN7I	FM	C6H13NO2
DMQHN7I	IC	InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1
DMQHN7I	CS	CC(C)C[C@@H](C(=O)O)N
DMQHN7I	IK	ROHFNLRQFUQHCH-YFKPBYRVSA-N
DMQHN7I	IU	(2S)-2-amino-4-methylpentanoic acid
DMQHN7I	CA	CAS 61-90-5
DMQHN7I	CB	CHEBI:15603
DMQHN7I	DE	Discovery agent

DM41MS3	ID	DM41MS3
DM41MS3	DN	L-leucyl-L-prolinamide
DM41MS3	HS	Investigative
DM41MS3	SN	L-leucyl-L-prolinamide; CHEMBL224340; Leu-Pro-NH2; leucyl-l-proline amide; SCHEMBL4411036; DZWHFXYOHKJJJA-IUCAKERBSA-N
DM41MS3	DT	Small molecular drug
DM41MS3	PC	11557656
DM41MS3	MW	227.3
DM41MS3	FM	C11H21N3O2
DM41MS3	IC	InChI=1S/C11H21N3O2/c1-7(2)6-8(12)11(16)14-5-3-4-9(14)10(13)15/h7-9H,3-6,12H2,1-2H3,(H2,13,15)/t8-,9-/m0/s1
DM41MS3	CS	CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DM41MS3	IK	DZWHFXYOHKJJJA-IUCAKERBSA-N
DM41MS3	IU	(2S)-1-[(2S)-2-amino-4-methylpentanoyl]pyrrolidine-2-carboxamide
DM41MS3	DE	Discovery agent

DMOD5CK	ID	DMOD5CK
DMOD5CK	DN	L-lysine
DMOD5CK	HS	Investigative
DMOD5CK	SN	Enisyl
DMOD5CK	DT	Small molecular drug
DMOD5CK	PC	5962
DMOD5CK	MW	146.19
DMOD5CK	FM	C6H14N2O2
DMOD5CK	IC	InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1
DMOD5CK	CS	C(CCN)C[C@@H](C(=O)O)N
DMOD5CK	IK	KDXKERNSBIXSRK-YFKPBYRVSA-N
DMOD5CK	IU	(2S)-2,6-diaminohexanoic acid
DMOD5CK	CA	CAS 56-87-1
DMOD5CK	CB	CHEBI:18019
DMOD5CK	DE	Discovery agent

DMOGZLU	ID	DMOGZLU
DMOGZLU	DN	LLZ16406
DMOGZLU	HS	Investigative
DMOGZLU	SN	hydrogen chloride; Muriatic acid; 7647-01-0; Chlorohydric acid; Acide chlorhydrique; Chlorwasserstoff; Spirits of salt; Hydrogen chloride (HCl); chlorane; Chlorowodor; Chloorwaterstof; Anhydrous hydrochloric acid; Bowl Cleaner; Acido cloridrico; Aqueous hydrogen chloride; chlorure d'hydrogene; Hydrochloric acid gas; 4-D Bowl Sanitizer; Chlorowodor [Polish]; Emulsion Bowl Cleaner; Caswell No. 486; Chloorwaterstof [Dutch]; Marine acid; Hydrochloric acid [JAN]; Spirit of salt; Chlorwasserstoff [German]; UN 1789 (solut
DMOGZLU	DT	Small molecular drug
DMOGZLU	DE	Discovery agent

DM783BP	ID	DM783BP
DM783BP	DN	LLZ16407
DM783BP	HS	Investigative
DM783BP	DE	Discovery agent

DMWLMTD	ID	DMWLMTD
DMWLMTD	DN	LM-4108
DMWLMTD	HS	Investigative
DMWLMTD	SN	N-(2-Phenylethyl)indomethacin Amide; 261766-32-9; CHEMBL95311; N-(2-Phenylethyl)indomethacinamide; C27H25ClN2O3; 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-phenethylacetamide; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}-N-(2-phenylethyl)acetamide; LM-4108; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-n-phenethylacetamide; LM 4108; AC1L1HU5; Indomethacin derivative, 19; SCHEMBL678111; BDBM22966; CTK8E8937; DTXSID80274424; MolPort-001-581-215; HMS3649K21; ZINC602343; STK226516
DMWLMTD	DT	Small molecular drug
DMWLMTD	PC	4292
DMWLMTD	MW	460.9
DMWLMTD	FM	C27H25ClN2O3
DMWLMTD	IC	InChI=1S/C27H25ClN2O3/c1-18-23(17-26(31)29-15-14-19-6-4-3-5-7-19)24-16-22(33-2)12-13-25(24)30(18)27(32)20-8-10-21(28)11-9-20/h3-13,16H,14-15,17H2,1-2H3,(H,29,31)
DMWLMTD	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)NCCC4=CC=CC=C4
DMWLMTD	IK	VYDBTNADENXYSN-UHFFFAOYSA-N
DMWLMTD	IU	2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(2-phenylethyl)acetamide
DMWLMTD	CA	CAS 261766-32-9
DMWLMTD	DE	Discovery agent

DMK12C0	ID	DMK12C0
DMK12C0	DN	L-mannitol derivative
DMK12C0	HS	Investigative
DMK12C0	SN	CHEMBL410049; L-mannitol derivative; BDBM50173733
DMK12C0	DT	Small molecular drug
DMK12C0	PC	11578664
DMK12C0	MW	796.5
DMK12C0	FM	C34H44Br2N4O8
DMK12C0	IC	InChI=1S/C34H44Br2N4O8/c1-33(2,3)23-13-9-21(10-14-23)29(43)37-39-31(45)27(47-19-7-17-35)25(41)26(42)28(48-20-8-18-36)32(46)40-38-30(44)22-11-15-24(16-12-22)34(4,5)6/h7-18,25-28,41-42H,19-20H2,1-6H3,(H,37,43)(H,38,44)(H,39,45)(H,40,46)/b17-7+,18-8+/t25-,26-,27-,28-/m1/s1
DMK12C0	CS	CC(C1=CC=C(C=C1)C(=O)NNC(=O)[C@H](OC/C=C/Br)[C@H](O)[C@@H](O)[C@@H](OC/C=C/Br)C(=O)NNC(=O)C2=CC=C(C=C2)C(C)(C)C)(C)C
DMK12C0	IK	GBIFQWZWWHMHND-MNSGAQFXSA-N
DMK12C0	IU	(2R,3R,4R,5R)-2,5-bis[(E)-3-bromoprop-2-enoxy]-1-N',6-N'-bis(4-tert-butylbenzoyl)-3,4-dihydroxyhexanedihydrazide
DMK12C0	DE	Discovery agent

DME8G1U	ID	DME8G1U
DME8G1U	DN	L-methionine
DME8G1U	HS	Investigative
DME8G1U	SN	Acimethin; Cymethion
DME8G1U	DT	Small molecular drug
DME8G1U	PC	6137
DME8G1U	MW	149.21
DME8G1U	FM	C5H11NO2S
DME8G1U	IC	InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1
DME8G1U	CS	CSCC[C@@H](C(=O)O)N
DME8G1U	IK	FFEARJCKVFRZRR-BYPYZUCNSA-N
DME8G1U	IU	(2S)-2-amino-4-methylsulfanylbutanoic acid
DME8G1U	CA	CAS 63-68-3
DME8G1U	CB	CHEBI:16643
DME8G1U	DE	Discovery agent

DM8LVQF	ID	DM8LVQF
DM8LVQF	DN	L-Myo-Inositol-1-Phosphate
DM8LVQF	HS	Investigative
DM8LVQF	SN	(1R,2S,3R,4R,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl phosphate; AC1NRBXQ; CHEBI:58401; 1D-myo-inositol 3-phosphate(2-); DB03542; [(2S,3R,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl]
DM8LVQF	DT	Small molecular drug
DM8LVQF	PC	5288700
DM8LVQF	MW	258.12
DM8LVQF	FM	C6H11O9P-2
DM8LVQF	IC	InChI=1S/C6H13O9P/c7-1-2(8)4(10)6(5(11)3(1)9)15-16(12,13)14/h1-11H,(H2,12,13,14)/p-2/t1?,2-,3+,4-,5-,6?/m0/s1
DM8LVQF	CS	[C@H]1([C@@H](C([C@H]([C@@H](C1O)O)O)OP(=O)([O-])[O-])O)O
DM8LVQF	IK	INAPMGSXUVUWAF-LXOASSSBSA-L
DM8LVQF	IU	[(2S,3R,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl] phosphate
DM8LVQF	CB	CHEBI:58401
DM8LVQF	DE	Discovery agent

DME9FAV	ID	DME9FAV
DME9FAV	DN	L-NIO
DME9FAV	HS	Investigative
DME9FAV	SN	n5-Iminoethyl-l-ornithine; n5-iminoethyl-l-ornithine; N5-(1-Iminoethyl)-L-ornithine; N(G)-Iminoethylornithine; CHEMBL11471; 36889-13-1; L-Ornithine, N5-(1-iminoethyl)-; ILO; C7H15N3O2; (e)-n5-(1-aminoethylidene)-l-ornithine; Tocris-0546; AC1Q5QLF; Lopac-I-8768; Lopac0_000683; SCHEMBL1569333; AC1L333Z; l-n5-(1-iminoethyl)-ornithine; L-NIO, 12; MolPort-006-394-636; UYZFAUAYFLEHRC-LURJTMIESA-N; BDBM152697; ZINC1886324; BDBM50072297; HSCI1_000259; AKOS030623044; (S)-5-Acetimidoylamino-2-amino-pent; CCG-204768; DB03305; NCGC00024644-01; NCGC00015568-01; N5-Iminoethyl-L-Ornithine
DME9FAV	DT	Small molecular drug
DME9FAV	PC	107984
DME9FAV	MW	173.21
DME9FAV	FM	C7H15N3O2
DME9FAV	IC	InChI=1S/C7H15N3O2/c1-5(8)10-4-2-3-6(9)7(11)12/h6H,2-4,9H2,1H3,(H2,8,10)(H,11,12)/t6-/m0/s1
DME9FAV	CS	CC(=NCCC[C@@H](C(=O)O)N)N
DME9FAV	IK	UYZFAUAYFLEHRC-LURJTMIESA-N
DME9FAV	IU	(2S)-2-amino-5-(1-aminoethylideneamino)pentanoic acid
DME9FAV	CA	CAS 36889-13-1
DME9FAV	DE	Discovery agent

DM7V30L	ID	DM7V30L
DM7V30L	DN	L-norleucyl-L-prolinamide
DM7V30L	HS	Investigative
DM7V30L	SN	CHEMBL388843; L-norleucyl-L-prolinamide
DM7V30L	DT	Small molecular drug
DM7V30L	PC	11615534
DM7V30L	MW	227.3
DM7V30L	FM	C11H21N3O2
DM7V30L	IC	InChI=1S/C11H21N3O2/c1-2-3-5-8(12)11(16)14-7-4-6-9(14)10(13)15/h8-9H,2-7,12H2,1H3,(H2,13,15)/t8-,9-/m0/s1
DM7V30L	CS	CCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DM7V30L	IK	AXARLGGBMIBEIZ-IUCAKERBSA-N
DM7V30L	IU	(2S)-1-[(2S)-2-aminohexanoyl]pyrrolidine-2-carboxamide
DM7V30L	DE	Discovery agent

DMIXFGC	ID	DMIXFGC
DMIXFGC	DN	L-norvalyl-L-prolinamide
DMIXFGC	HS	Investigative
DMIXFGC	SN	L-norvalyl-L-prolinamide; CHEMBL224628; 127896-84-8; Nva-Pro-NH2; NOBVHVGPMMOHAE-YUMQZZPRSA-N
DMIXFGC	DT	Small molecular drug
DMIXFGC	PC	11687141
DMIXFGC	MW	213.28
DMIXFGC	FM	C10H19N3O2
DMIXFGC	IC	InChI=1S/C10H19N3O2/c1-2-4-7(11)10(15)13-6-3-5-8(13)9(12)14/h7-8H,2-6,11H2,1H3,(H2,12,14)/t7-,8-/m0/s1
DMIXFGC	CS	CCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DMIXFGC	IK	NOBVHVGPMMOHAE-YUMQZZPRSA-N
DMIXFGC	IU	(2S)-1-[(2S)-2-aminopentanoyl]pyrrolidine-2-carboxamide
DMIXFGC	DE	Discovery agent

DM2GBEW	ID	DM2GBEW
DM2GBEW	DN	Lobatamide A
DM2GBEW	HS	Investigative
DM2GBEW	SN	SCHEMBL82913
DM2GBEW	DT	Small molecular drug
DM2GBEW	PC	10505925
DM2GBEW	MW	512.6
DM2GBEW	FM	C27H32N2O8
DM2GBEW	IC	InChI=1S/C27H32N2O8/c1-18-11-13-20-7-4-9-23(31)26(20)27(34)37-21(17-25(33)36-19(2)12-14-22(18)30)8-5-15-28-24(32)10-6-16-29-35-3/h4-7,9-12,14-16,19,21-22,30-31H,8,13,17H2,1-3H3,(H,28,32)/b10-6-,14-12+,15-5+,18-11-,29-16-
DM2GBEW	CS	CC1/C=C/C(/C(=C\\CC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)O1)C/C=C/NC(=O)/C=C\\C=N/OC)/C)O
DM2GBEW	IK	JYHIHHYYXXKTTJ-JSFHDESQSA-N
DM2GBEW	IU	(Z,4Z)-N-[(E)-3-[(9E,12Z)-11,19-dihydroxy-8,12-dimethyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DM2GBEW	DE	Discovery agent

DMD91RI	ID	DMD91RI
DMD91RI	DN	Lobatamide B
DMD91RI	HS	Investigative
DMD91RI	SN	SCHEMBL81777
DMD91RI	DT	Small molecular drug
DMD91RI	PC	5353727
DMD91RI	MW	512.6
DMD91RI	FM	C27H32N2O8
DMD91RI	IC	InChI=1S/C27H32N2O8/c1-18-11-13-20-7-4-9-23(31)26(20)27(34)37-21(17-25(33)36-19(2)12-14-22(18)30)8-5-15-28-24(32)10-6-16-29-35-3/h4-7,9-12,14-16,19,21-22,30-31H,8,13,17H2,1-3H3,(H,28,32)/b10-6+,14-12-,15-5+,18-11-,29-16-
DMD91RI	CS	CC1/C=C\\C(/C(=C\\CC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)O1)C/C=C/NC(=O)/C=C/C=N\\OC)/C)O
DMD91RI	IK	JYHIHHYYXXKTTJ-PZRNTLOJSA-N
DMD91RI	IU	(E,4Z)-N-[(E)-3-[(9Z,12Z)-11,19-dihydroxy-8,12-dimethyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DMD91RI	DE	Discovery agent

DMFIDJS	ID	DMFIDJS
DMFIDJS	DN	Lobatamide C
DMFIDJS	HS	Investigative
DMFIDJS	DT	Small molecular drug
DMFIDJS	PC	6519828
DMFIDJS	MW	512.6
DMFIDJS	FM	C27H32N2O8
DMFIDJS	IC	InChI=1S/C27H32N2O8/c1-18-11-13-20-7-4-9-23(31)26(20)27(34)37-21(17-25(33)36-19(2)12-14-22(18)30)8-5-15-28-24(32)10-6-16-29-35-3/h4-7,9-12,14-16,19,21-22,30-31H,8,13,17H2,1-3H3,(H,28,32)/b10-6+,14-12+,15-5+,18-11?,29-16-
DMFIDJS	CS	CC1/C=C/C(C(=CCC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)O1)C/C=C/NC(=O)/C=C/C=N\\OC)C)O
DMFIDJS	IK	JYHIHHYYXXKTTJ-HPPATNPVSA-N
DMFIDJS	IU	(E,4Z)-N-[(E)-3-[(9E)-11,19-dihydroxy-8,12-dimethyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DMFIDJS	DE	Discovery agent

DMG706J	ID	DMG706J
DMG706J	DN	Lobatamide D
DMG706J	HS	Investigative
DMG706J	SN	Lobatamide E
DMG706J	DT	Small molecular drug
DMG706J	PC	10792270
DMG706J	MW	528.5
DMG706J	FM	C27H32N2O9
DMG706J	IC	InChI=1S/C27H32N2O9/c1-18-10-11-19-6-3-8-23(32)26(19)27(35)38-20(7-4-14-28-24(33)9-5-15-29-36-2)16-25(34)37-21(17-30)12-13-22(18)31/h3-6,8-10,12-15,20-22,30-32H,7,11,16-17H2,1-2H3,(H,28,33)/b9-5-,13-12+,14-4+,18-10-,29-15-
DMG706J	CS	C/C/1=C/CC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)OC(/C=C/C1O)CO)C/C=C/NC(=O)/C=C\\C=N/OC
DMG706J	IK	JIRIKJKTSMGHQG-ZBKQNIHQSA-N
DMG706J	IU	(Z,4Z)-N-[(E)-3-[(9E,12Z)-11,19-dihydroxy-8-(hydroxymethyl)-12-methyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DMG706J	DE	Discovery agent

DM6BWGQ	ID	DM6BWGQ
DM6BWGQ	DN	Lobatamide F
DM6BWGQ	HS	Investigative
DM6BWGQ	SN	Lobatamide F
DM6BWGQ	DT	Small molecular drug
DM6BWGQ	PC	45027775
DM6BWGQ	MW	528.5
DM6BWGQ	FM	C27H32N2O9
DM6BWGQ	IC	InChI=1S/C27H32N2O9/c1-18-10-11-19-6-3-8-23(32)26(19)27(35)38-20(7-4-14-28-24(33)9-5-15-29-36-2)16-25(34)37-21(17-30)12-13-22(18)31/h3-6,8-10,12-15,20-22,30-32H,7,11,16-17H2,1-2H3,(H,28,33)/b9-5+,13-12+,14-4+,18-10-,29-15-
DM6BWGQ	CS	C/C/1=C/CC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)OC(/C=C/C1O)CO)C/C=C/NC(=O)/C=C/C=N\\OC
DM6BWGQ	IK	JIRIKJKTSMGHQG-CFMTYHAKSA-N
DM6BWGQ	IU	(E,4Z)-N-[(E)-3-[(9E,12Z)-11,19-dihydroxy-8-(hydroxymethyl)-12-methyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DM6BWGQ	DE	Discovery agent

DMR2WQE	ID	DMR2WQE
DMR2WQE	DN	LOFENTANIL
DMR2WQE	HS	Investigative
DMR2WQE	SN	Lofentanil oxalate; Lofentanil oxalate [USAN]; Lofentanil oxalate (USAN); 61380-41-4; Lofentaniloxalat; R 34995; EINECS 262-750-7; cis-(-)-4-(Methoxycarbonyl)-3-methyl-1-phenethyl-4-(N-phenylpropionylamino)piperidinium hydrogen oxalate; R 34,995; AC1L23D4; (-)-Methyl cis-3-methyl-1-phenethyl-4-(N-phenylpropionamido)isonipecotate oxalate (1:1); FT-0670830; D04764; UNII-6C1599T3OQ component CBKLICUQYUTWQL-XWGBWKJCSA-N; methyl (3S,4R)-3-methyl-1-phenethyl-4-(N-propanoylanilino)piperidine-4-carboxylate
DMR2WQE	DT	Small molecular drug
DMR2WQE	PC	10070040
DMR2WQE	MW	408.5
DMR2WQE	FM	C25H32N2O3
DMR2WQE	IC	InChI=1S/C25H32N2O3/c1-4-23(28)27(22-13-9-6-10-14-22)25(24(29)30-3)16-18-26(19-20(25)2)17-15-21-11-7-5-8-12-21/h5-14,20H,4,15-19H2,1-3H3/t20-,25+/m1/s1
DMR2WQE	CS	CCC(=O)N(C1=CC=CC=C1)[C@]2(CCN(C[C@H]2C)CCC3=CC=CC=C3)C(=O)OC
DMR2WQE	IK	IMYHGORQCPYVBZ-NLFFAJNJSA-N
DMR2WQE	IU	methyl (3R,4S)-3-methyl-1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
DMR2WQE	CA	CAS 61380-40-3
DMR2WQE	DE	Discovery agent

DMWFAPJ	ID	DMWFAPJ
DMWFAPJ	DN	LONCHOCARPUSONE
DMWFAPJ	HS	Investigative
DMWFAPJ	SN	Lonchocarpusone; CHEMBL455604; SCHEMBL14139263
DMWFAPJ	DT	Small molecular drug
DMWFAPJ	PC	44559034
DMWFAPJ	MW	396.4
DMWFAPJ	FM	C23H24O6
DMWFAPJ	IC	InChI=1S/C23H24O6/c1-23(2)9-8-13-17(29-23)7-6-14-21(24)16(12-28-22(13)14)15-10-19(26-4)20(27-5)11-18(15)25-3/h6-11,16H,12H2,1-5H3
DMWFAPJ	CS	CC1(C=CC2=C(O1)C=CC3=C2OCC(C3=O)C4=CC(=C(C=C4OC)OC)OC)C
DMWFAPJ	IK	FHQIUPHJETXRLG-UHFFFAOYSA-N
DMWFAPJ	IU	8,8-dimethyl-3-(2,4,5-trimethoxyphenyl)-2,3-dihydropyrano[2,3-f]chromen-4-one
DMWFAPJ	DE	Discovery agent

DMAH0RZ	ID	DMAH0RZ
DMAH0RZ	DN	Long-acting Factor VII conjugate
DMAH0RZ	HS	Investigative
DMAH0RZ	SN	HM-12260B; LAPS-Factor VII; Long-acting Factor VII conjugate (LAPS, hemorrhage); Long-acting Factor VII conjugate (LAPS, hemorrhage), Hanmi
DMAH0RZ	CP	Hanmi Pharmaceutical Co Ltd
DMAH0RZ	DE	Bleeding disorder

DMZUSJD	ID	DMZUSJD
DMZUSJD	DN	Long-acting factor VIII
DMZUSJD	HS	Investigative
DMZUSJD	SN	PolyXen PSA-Factor VIII; Long-acting factor VIII (PolyXen, blood clotting disorder); Polysialic factor VIII (PolyXen, blood clotting disorder), Lipoxen/Baxter; Long-acting factor VIII (PolyXen, blood clotting disorder), Lipoxen/Baxter
DMZUSJD	CP	Baxter International Inc
DMZUSJD	DE	Coagulation defect

DMD32IN	ID	DMD32IN
DMD32IN	DN	Long-acting FSH conjugate
DMD32IN	HS	Investigative
DMD32IN	SN	HM-12160B; LAPS-FSH; Long-acting FSH conjugate (LAPS); Long-acting FSH conjugate (LAPS), Hanmi; Long-acting follicle-stimulating hormone conjugate (LAPS, female infertility), Hanmi
DMD32IN	CP	Hanmi Pharmaceutical Co Ltd
DMD32IN	DE	Female infertility

DMH106Y	ID	DMH106Y
DMH106Y	DN	LONGANINE
DMH106Y	HS	Investigative
DMH106Y	SN	longanine; CHEMBL1097805
DMH106Y	DT	Small molecular drug
DMH106Y	PC	46888588
DMH106Y	MW	363.4
DMH106Y	FM	C19H25NO6
DMH106Y	IC	InChI=1S/C19H25NO6/c1-20-7-6-17-8-11(21)16(25-3)19(23)18(17,20)9-13(26-19)10-4-5-12(24-2)15(22)14(10)17/h4-5,11,13,16,21-23H,6-9H2,1-3H3/t11-,13-,16-,17-,18-,19+/m0/s1
DMH106Y	CS	CN1CC[C@@]23[C@]14C[C@@H](C5=C2C(=C(C=C5)OC)O)O[C@@]4([C@H]([C@H](C3)O)OC)O
DMH106Y	IK	UHRGPVJRLXHZFG-OOXWPESWSA-N
DMH106Y	IU	(1S,8S,10S,11S,12S,13S)-4,12-dimethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.18,11.01,10.02,7]octadeca-2(7),3,5-triene-3,11,13-triol
DMH106Y	DE	Discovery agent

DM5OHVN	ID	DM5OHVN
DM5OHVN	DN	Lophocladine a
DM5OHVN	HS	Investigative
DM5OHVN	SN	Lophocladine A; 887705-27-3; Lophocladines A; 2,7-Naphthyridin-1(2H)-one,4-phenyl-; CHEMBL472895; CTK2I1445; DTXSID90470935; AKOS030621149; 4-phenyl[2,7]naphthyridin-1(2H)-one; 2,7-Naphthyridin-1(2H)-one, 4-phenyl-
DM5OHVN	DT	Small molecular drug
DM5OHVN	PC	11708368
DM5OHVN	MW	222.24
DM5OHVN	FM	C14H10N2O
DM5OHVN	IC	InChI=1S/C14H10N2O/c17-14-13-8-15-7-6-11(13)12(9-16-14)10-4-2-1-3-5-10/h1-9H,(H,16,17)
DM5OHVN	CS	C1=CC=C(C=C1)C2=CNC(=O)C3=C2C=CN=C3
DM5OHVN	IK	JIWHQPVTDQXELV-UHFFFAOYSA-N
DM5OHVN	IU	4-phenyl-2H-2,7-naphthyridin-1-one
DM5OHVN	CA	CAS 887705-27-3
DM5OHVN	DE	Discovery agent

DMASPV9	ID	DMASPV9
DMASPV9	DN	Lopinavir + ritonavir + interferon beta
DMASPV9	HS	Investigative
DMASPV9	SN	Aluviran + norvir + interferon beta
DMASPV9	TC	Antiviral Agents
DMASPV9	DT	Combination drug
DMASPV9	DE	Middle East Respiratory Syndrome (MERS)

DM71BIC	ID	DM71BIC
DM71BIC	DN	LOR-220
DM71BIC	HS	Investigative
DM71BIC	SN	ML-220; PI3K-targeting small molecules (cancer), Lorus; Phosphoinositide-3 kinase-targeting small molecules (cancer), Lorus
DM71BIC	CP	Lorus Therapeutics Inc
DM71BIC	DT	Small molecular drug
DM71BIC	PC	11851317
DM71BIC	MW	412.3
DM71BIC	FM	C23H14BrN3
DM71BIC	IC	InChI=1S/C23H14BrN3/c24-13-9-10-20-18(11-13)19(12-25-20)23-26-21-16-7-3-1-5-14(16)15-6-2-4-8-17(15)22(21)27-23/h1-12,25H,(H,26,27)
DM71BIC	CS	C1=CC=C2C(=C1)C3=CC=CC=C3C4=C2NC(=N4)C5=CNC6=C5C=C(C=C6)Br
DM71BIC	IK	XFVVNPCUAYGFFE-UHFFFAOYSA-N
DM71BIC	IU	2-(5-bromo-1H-indol-3-yl)-1H-phenanthro[9,10-d]imidazole
DM71BIC	DE	Bacterial infection

DM0ECUK	ID	DM0ECUK
DM0ECUK	DN	LORNEIC ACID A
DM0ECUK	HS	Investigative
DM0ECUK	SN	Lorneic acid A; CHEMBL1079947
DM0ECUK	DT	Small molecular drug
DM0ECUK	PC	44605341
DM0ECUK	MW	258.35
DM0ECUK	FM	C17H22O2
DM0ECUK	IC	InChI=1S/C17H22O2/c1-3-4-5-6-8-16-13-14(2)11-12-15(16)9-7-10-17(18)19/h6-9,11-13H,3-5,10H2,1-2H3,(H,18,19)/b8-6+,9-7+
DM0ECUK	CS	CCCC/C=C/C1=C(C=CC(=C1)C)/C=C/CC(=O)O
DM0ECUK	IK	BPISPUIKHXBPSU-CDJQDVQCSA-N
DM0ECUK	IU	(E)-4-[2-[(E)-hex-1-enyl]-4-methylphenyl]but-3-enoic acid
DM0ECUK	DE	Discovery agent

DMHKGCM	ID	DMHKGCM
DMHKGCM	DN	L-Ornithine
DMHKGCM	HS	Investigative
DMHKGCM	SN	OKG
DMHKGCM	DT	Small molecular drug
DMHKGCM	PC	6262
DMHKGCM	MW	132.16
DMHKGCM	FM	C5H12N2O2
DMHKGCM	IC	InChI=1S/C5H12N2O2/c6-3-1-2-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1
DMHKGCM	CS	C(C[C@@H](C(=O)O)N)CN
DMHKGCM	IK	AHLPHDHHMVZTML-BYPYZUCNSA-N
DMHKGCM	IU	(2S)-2,5-diaminopentanoic acid
DMHKGCM	CA	CAS 70-26-8
DMHKGCM	CB	CHEBI:15729
DMHKGCM	DE	Discovery agent

DMK5J9M	ID	DMK5J9M
DMK5J9M	DN	Lorpiprazole
DMK5J9M	HS	Investigative
DMK5J9M	SN	Lorpiprazole; Lorpiprazole [INN]; (-)-cis-5,5a,6,7,8,8a-Hexahydro-3-(2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)cyclopenta(3,4)pyrrolo(2,1-c)-s-triazole; 108785-69-9; AC1MIILX; DTXSID30883181; UNII-0M14O7T47Q component BNRMWKUVWLKDQJ-CRAIPNDOSA-N
DMK5J9M	PC	3045380
DMK5J9M	MW	405.5
DMK5J9M	FM	C21H26F3N5
DMK5J9M	IC	BNRMWKUVWLKDQJ-CRAIPNDOSA-N
DMK5J9M	CS	C1CC2CN3C(=NN=C3C2C1)CCN4CCN(CC4)C5=CC=CC(=C5)C(F)(F)F
DMK5J9M	IK	1S/C21H26F3N5/c22-21(23,24)16-4-2-5-17(13-16)28-11-9-27(10-12-28)8-7-19-25-26-20-18-6-1-3-15(18)14-29(19)20/h2,4-5,13,15,18H,1,3,6-12,14H2/t15-,18-/m1/s1
DMK5J9M	IU	(1R,8S)-5-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-3,4,6-triazatricyclo[6.3.0.02,6]undeca-2,4-diene
DMK5J9M	CA	CAS 108785-69-9
DMK5J9M	DE	Anxiety disorder

DMWTJ3E	ID	DMWTJ3E
DMWTJ3E	DN	LP-0067
DMWTJ3E	HS	Investigative
DMWTJ3E	SN	CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma
DMWTJ3E	CP	LEO Pharma A/S
DMWTJ3E	DE	Autoimmune diabetes

DM8ZR17	ID	DM8ZR17
DM8ZR17	DN	LP-12
DM8ZR17	HS	Investigative
DM8ZR17	SN	compound 21 [PMID 17649988]
DM8ZR17	DT	Small molecular drug
DM8ZR17	PC	23643664
DM8ZR17	MW	481.7
DM8ZR17	FM	C32H39N3O
DM8ZR17	IC	InChI=1S/C32H39N3O/c36-32(33-30-18-11-15-26-14-6-7-16-28(26)30)20-5-2-10-21-34-22-24-35(25-23-34)31-19-9-8-17-29(31)27-12-3-1-4-13-27/h1,3-4,6-9,12-14,16-17,19,30H,2,5,10-11,15,18,20-25H2,(H,33,36)
DM8ZR17	CS	C1CC(C2=CC=CC=C2C1)NC(=O)CCCCCN3CCN(CC3)C4=CC=CC=C4C5=CC=CC=C5
DM8ZR17	IK	NMZIDFFHGCRAJV-UHFFFAOYSA-N
DM8ZR17	IU	6-[4-(2-phenylphenyl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide
DM8ZR17	DE	Discovery agent

DMKDGLA	ID	DMKDGLA
DMKDGLA	DN	LP-211
DMKDGLA	HS	Investigative
DMKDGLA	SN	compound 25 [PMID 18800769]
DMKDGLA	DT	Small molecular drug
DMKDGLA	PC	25107716
DMKDGLA	MW	466.6
DMKDGLA	FM	C30H34N4O
DMKDGLA	IC	InChI=1S/C30H34N4O/c31-23-25-14-16-26(17-15-25)24-32-30(35)13-5-2-8-18-33-19-21-34(22-20-33)29-12-7-6-11-28(29)27-9-3-1-4-10-27/h1,3-4,6-7,9-12,14-17H,2,5,8,13,18-22,24H2,(H,32,35)
DMKDGLA	CS	C1CN(CCN1CCCCCC(=O)NCC2=CC=C(C=C2)C#N)C3=CC=CC=C3C4=CC=CC=C4
DMKDGLA	IK	BQEDZLDNNBDKDS-UHFFFAOYSA-N
DMKDGLA	IU	N-[(4-cyanophenyl)methyl]-6-[4-(2-phenylphenyl)piperazin-1-yl]hexanamide
DMKDGLA	CA	CAS 1052147-86-0
DMKDGLA	DE	Discovery agent

DMIWMZY	ID	DMIWMZY
DMIWMZY	DN	LP-403812
DMIWMZY	HS	Investigative
DMIWMZY	SN	LP 403812; LP403812
DMIWMZY	DT	Small molecular drug
DMIWMZY	PC	59001466
DMIWMZY	MW	494.7
DMIWMZY	FM	C26H34N6O2S
DMIWMZY	IC	InChI=1S/C26H34N6O2S/c1-17-9-11-18(12-10-17)23(33)28-25-27-22-21(35-25)20(29-32(22)26(2,3)4)24(34)31-15-7-8-19(31)16-30-13-5-6-14-30/h9-12,19H,5-8,13-16H2,1-4H3,(H,27,28,33)/t19-/m0/s1
DMIWMZY	CS	CC1=CC=C(C=C1)C(=O)NC2=NC3=C(S2)C(=NN3C(C)(C)C)C(=O)N4CCC[C@H]4CN5CCCC5
DMIWMZY	IK	GJBQMIZKUFMWPV-IBGZPJMESA-N
DMIWMZY	IU	N-[1-tert-butyl-3-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]pyrazolo[3,4-d][1,3]thiazol-5-yl]-4-methylbenzamide
DMIWMZY	CA	CAS 1142050-84-7
DMIWMZY	DE	Discovery agent

DM0C3SF	ID	DM0C3SF
DM0C3SF	DN	LP-44
DM0C3SF	HS	Investigative
DM0C3SF	SN	compound 5 [PMID 17649988]
DM0C3SF	DT	Small molecular drug
DM0C3SF	PC	11224758
DM0C3SF	MW	451.7
DM0C3SF	FM	C27H37N3OS
DM0C3SF	IC	InChI=1S/C27H37N3OS/c1-32-26-15-7-6-14-25(26)30-20-18-29(19-21-30)17-8-2-3-16-27(31)28-24-13-9-11-22-10-4-5-12-23(22)24/h4-7,10,12,14-15,24H,2-3,8-9,11,13,16-21H2,1H3,(H,28,31)
DM0C3SF	CS	CSC1=CC=CC=C1N2CCN(CC2)CCCCCC(=O)NC3CCCC4=CC=CC=C34
DM0C3SF	IK	JNBBJUHCODFLEG-UHFFFAOYSA-N
DM0C3SF	IU	6-[4-(2-methylsulfanylphenyl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide
DM0C3SF	DE	Discovery agent

DMGMO3Q	ID	DMGMO3Q
DMGMO3Q	DN	LP-661438
DMGMO3Q	HS	Investigative
DMGMO3Q	SN	deoxycytidine kinase inhibitors (cancer), Lexicon
DMGMO3Q	DE	Discovery agent

DMTZYQ3	ID	DMTZYQ3
DMTZYQ3	DN	LP99
DMTZYQ3	HS	Investigative
DMTZYQ3	SN	compound 60 [PMID: 25864491]
DMTZYQ3	DT	Small molecular drug
DMTZYQ3	PC	91827372
DMTZYQ3	MW	516.1
DMTZYQ3	FM	C26H30ClN3O4S
DMTZYQ3	IC	InChI=1S/C26H30ClN3O4S/c1-16(2)15-35(33,34)28-22-11-12-24(31)30(26(22)18-5-7-19(27)8-6-18)20-9-10-21-17(3)13-25(32)29(4)23(21)14-20/h5-10,13-14,16,22,26,28H,11-12,15H2,1-4H3/t22-,26+/m0/s1
DMTZYQ3	CS	CC1=CC(=O)N(C2=C1C=CC(=C2)N3[C@@H]([C@H](CCC3=O)NS(=O)(=O)CC(C)C)C4=CC=C(C=C4)Cl)C
DMTZYQ3	IK	LVDRREOUMKACNJ-BKMJKUGQSA-N
DMTZYQ3	IU	N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide
DMTZYQ3	DE	Discovery agent

DMI5XR1	ID	DMI5XR1
DMI5XR1	DN	LPA
DMI5XR1	HS	Investigative
DMI5XR1	SN	2-Hydroxy-3-(phosphonooxy)propyl oleate; lysophosphatidic acid; 1-Oleoyl-lyso-phosphatidic acid; Monooleylphosphatidic acid; Oleoyl lysophosphatidic acid; 1-Oleyllysophosphatidic acid; 22002-87-5; (2-hydroxy-3-phosphonooxypropyl) (Z)-octadec-9-enoate; 1-oleoyl-LPA; monooleylphosphatidate; [3H]1-oleoyl-LPA; [3H]lysophosphatidic acid; [3H]LPA; 1-oleoyl-lysophosphatidic acid; [3H]-LPA; AC1NUZKL; Lysophosphophatidic acid; Oleoyl lysophosphatidate; 1-Oleyllysophosphatidate; 1-Oleoyl-lysophosphatidate;  lysophosphatidic acid
DMI5XR1	DT	Small molecular drug
DMI5XR1	PC	5497152
DMI5XR1	MW	436.5
DMI5XR1	FM	C21H41O7P
DMI5XR1	IC	InChI=1S/C21H41O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)27-18-20(22)19-28-29(24,25)26/h9-10,20,22H,2-8,11-19H2,1H3,(H2,24,25,26)/b10-9-
DMI5XR1	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OCC(COP(=O)(O)O)O
DMI5XR1	IK	WRGQSWVCFNIUNZ-KTKRTIGZSA-N
DMI5XR1	IU	(2-hydroxy-3-phosphonooxypropyl) (Z)-octadec-9-enoate
DMI5XR1	CA	CAS 22002-87-5
DMI5XR1	DE	Discovery agent

DM1JGDM	ID	DM1JGDM
DM1JGDM	DN	Lpc-Ether
DM1JGDM	HS	Investigative
DM1JGDM	SN	LPC-ETHER; 1-O-OCTADECYL-SN-GLYCERO-3-PHOSPHOCHOLINE; LPE; 1-Octadecyl-sn-glycero-3-phosphocholine; AC1L9K7A; CBiol_001783; SCHEMBL11889677; Bio1_000558; Bio1_000069; Bio1_001047; ZINC8860508; DB03633; O-(1-O-Octadecyl-L-glycero-3-phospho)choline; SR-01000946544; SR-01000946544-1; (4S,7R)-4,7-dihydroxy-N,N,N-trimethyl-3,5,9-trioxa-4-phosphaheptacosan-1-aminium 4-oxide
DM1JGDM	DT	Small molecular drug
DM1JGDM	PC	446876
DM1JGDM	MW	510.7
DM1JGDM	FM	C26H57NO6P+
DM1JGDM	IC	InChI=1S/C26H56NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-31-24-26(28)25-33-34(29,30)32-23-21-27(2,3)4/h26,28H,5-25H2,1-4H3/p+1/t26-/m1/s1
DM1JGDM	CS	CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCC[N+](C)(C)C)O
DM1JGDM	IK	XKBJVQHMEXMFDZ-AREMUKBSSA-O
DM1JGDM	IU	2-[hydroxy-[(2R)-2-hydroxy-3-octadecoxypropoxy]phosphoryl]oxyethyl-trimethylazanium
DM1JGDM	DE	Discovery agent

DMY1807	ID	DMY1807
DMY1807	DN	LRHYLNLLTRQRY-NH2
DMY1807	HS	Investigative
DMY1807	SN	Ac(Leu-28,31)npy(24-36)amide; NCGC00167292-01; N-Acetyl(leu(28),leu(31))npy(24-36)-amide; Neuropeptide Y (24-36) amide, N-acetyl-(leu(28,31))-; L-Tyrosinamide, N-acetyl-L-leucyl-L-arginyl-L-histidyl-L-tyrosyl-L-leucyl-L-asparaginyl-L-leucyl-L-leucyl-L-threonyl-L-arginyl-L-glutaminyl-L-arginyl-
DMY1807	PC	91971032
DMY1807	MW	1787.1
DMY1807	FM	C81H131N27O19
DMY1807	IC	InChI=1S/C81H131N27O19/c1-40(2)30-56(96-45(10)110)71(120)98-52(15-12-28-93-80(87)88)69(118)106-61(36-48-38-91-39-95-48)75(124)105-60(35-47-19-23-50(112)24-20-47)74(123)102-58(32-42(5)6)73(122)107-62(37-64(83)114)76(125)103-57(31-41(3)4)72(121)104-59(33-43(7)8)77(126)108-65(44(9)109)78(127)100-53(16-13-29-94-81(89)90)67(116)99-54(25-26-63(82)113)70(119)97-51(14-11-27-92-79(85)86)68(117)101-55(66(84)115)34-46-17-21-49(111)22-18-46/h17-24,38-44,51-62,65,109,111-112H,11-16,25-37H2,1-10H3,(H2,82,113)(H2,83,114)(H2,84,115)(H,91,95)(H,96,110)(H,97,119)(H,98,120)(H,99,116)(H,100,127)(H,101,117)(H,102,123)(H,103,125)(H,104,121)(H,105,124)(H,106,118)(H,107,122)(H,108,126)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t44-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,65+/m1/s1
DMY1807	CS	C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)C)O
DMY1807	IK	LZKBNKKHNKAGAE-ZQWBWPFKSA-N
DMY1807	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMY1807	DE	Discovery agent

DMUBF53	ID	DMUBF53
DMUBF53	DN	LS-192629
DMUBF53	HS	Investigative
DMUBF53	SN	LS 192629; LS192629
DMUBF53	DT	Small molecular drug
DMUBF53	PC	6918604
DMUBF53	MW	471.5
DMUBF53	FM	C28H29N3O4
DMUBF53	IC	InChI=1S/C28H29N3O4/c1-19-8-6-7-11-24(19)20-12-14-22(15-13-20)28(34)31-18-23(30-35-2)16-25(31)27(33)29-17-26(32)21-9-4-3-5-10-21/h3-15,25-26,32H,16-18H2,1-2H3,(H,29,33)/b30-23+/t25-,26+/m0/s1
DMUBF53	CS	CC1=CC=CC=C1C2=CC=C(C=C2)C(=O)N3C/C(=N/OC)/C[C@H]3C(=O)NC[C@H](C4=CC=CC=C4)O
DMUBF53	IK	IBXGJPAYWMFXSF-OLFRMSBUSA-N
DMUBF53	IU	(2S,4E)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-methoxyimino-1-[4-(2-methylphenyl)benzoyl]pyrrolidine-2-carboxamide
DMUBF53	DE	Discovery agent

DM6WPIS	ID	DM6WPIS
DM6WPIS	DN	L-Serine
DM6WPIS	HS	Investigative
DM6WPIS	SN	L-serine; serine; 56-45-1; (S)-2-Amino-3-hydroxypropanoic acid; H-Ser-OH; (S)-Serine; beta-Hydroxyalanine; L-ser; L-(-)-Serine; Polyserine; Serine, L-; (2S)-2-amino-3-hydroxypropanoic acid; L-3-Hydroxy-alanine; Poly-L-serine; 2-Amino-3-hydroxypropionic acid; beta-Hydroxy-L-alanine; Serinum [Latin]; Serina [Spanish]; L-2-Amino-3-hydroxypropionic acid; Serine (VAN); L-3-Hydroxy-2-aminopropionic acid; Serine [USAN:INN]; SER (IUPAC abbrev); 3-Hydroxyalanine; L-Serin; (S)-(-)-Serine; (-)-Serine; alpha-Amino-beta-hydroxypropionic acid
DM6WPIS	DT	Small molecular drug
DM6WPIS	PC	5951
DM6WPIS	MW	105.09
DM6WPIS	FM	C3H7NO3
DM6WPIS	IC	InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1
DM6WPIS	CS	C([C@@H](C(=O)O)N)O
DM6WPIS	IK	MTCFGRXMJLQNBG-REOHCLBHSA-N
DM6WPIS	IU	(2S)-2-amino-3-hydroxypropanoic acid
DM6WPIS	CA	CAS 56-45-1
DM6WPIS	CB	CHEBI:17115
DM6WPIS	DE	Discovery agent

DMTJ1NH	ID	DMTJ1NH
DMTJ1NH	DN	L-serine-O-phosphate
DMTJ1NH	HS	Investigative
DMTJ1NH	SN	Phosphoserine; O-phospho-L-serine; Dexfosfoserine; phosphoserine; 407-41-0; L-O-Phosphoserine; Fosforina; O-Phosphoserine; L-SOP; L-Phosphoserine; PHOSPHONOSERINE; 3-phosphoserine; L-Serine O-phosphate; Dexfosfoserine [INN]; Phosphatidalserine; 3-O-Phosphoserine; H-Ser(PO3H2)-OH; O-phosphono-L-serine; serine, O-phosphono-; (+)-L-Serine dihydrogen phosphate (ester); L-Seryl phosphate; UNII-VI4F0K069V; L-3-Phosphoserine; L-O-Serine phosphate; L-Serinephosphoric acid; H-Ser(PO)-OH; L-2-amino-3-hydroxypropanoic acid 3-phosphate;  LSOP; Phosphonoserine
DMTJ1NH	DT	Small molecular drug
DMTJ1NH	PC	68841
DMTJ1NH	MW	185.07
DMTJ1NH	FM	C3H8NO6P
DMTJ1NH	IC	InChI=1S/C3H8NO6P/c4-2(3(5)6)1-10-11(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9)/t2-/m0/s1
DMTJ1NH	CS	C([C@@H](C(=O)O)N)OP(=O)(O)O
DMTJ1NH	IK	BZQFBWGGLXLEPQ-REOHCLBHSA-N
DMTJ1NH	IU	(2S)-2-amino-3-phosphonooxypropanoic acid
DMTJ1NH	CA	CAS 407-41-0
DMTJ1NH	CB	CHEBI:15811
DMTJ1NH	DE	Discovery agent

DMWVTS3	ID	DMWVTS3
DMWVTS3	DN	LSN2463359
DMWVTS3	HS	Investigative
DMWVTS3	SN	LSN 2463359
DMWVTS3	DT	Small molecular drug
DMWVTS3	PC	72551298
DMWVTS3	MW	265.31
DMWVTS3	FM	C16H15N3O
DMWVTS3	IC	InChI=1S/C16H15N3O/c1-12(2)19-16(20)15-6-5-14(11-18-15)4-3-13-7-9-17-10-8-13/h5-12H,1-2H3,(H,19,20)
DMWVTS3	CS	CC(C)NC(=O)C1=NC=C(C=C1)C#CC2=CC=NC=C2
DMWVTS3	IK	STAFRSGTRKNXHF-UHFFFAOYSA-N
DMWVTS3	IU	N-propan-2-yl-5-(2-pyridin-4-ylethynyl)pyridine-2-carboxamide
DMWVTS3	CA	CAS 1401031-52-4
DMWVTS3	DE	Discovery agent

DMV9NP6	ID	DMV9NP6
DMV9NP6	DN	LSN2814617
DMV9NP6	HS	Investigative
DMV9NP6	SN	CHEMBL2431211; LSN2814617; SCHEMBL2161736; GTPL6395; BDBM50441231; ZINC72315650; BCP9000877; 5-[(7S)-3-tert-butyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyridin-7-yl]-3-(4-fluorophenyl)-1,2,4-oxadiazole
DMV9NP6	DT	Small molecular drug
DMV9NP6	PC	53252525
DMV9NP6	MW	341.4
DMV9NP6	FM	C18H20FN5O
DMV9NP6	IC	InChI=1S/C18H20FN5O/c1-18(2,3)17-22-21-14-10-12(8-9-24(14)17)16-20-15(23-25-16)11-4-6-13(19)7-5-11/h4-7,12H,8-10H2,1-3H3/t12-/m0/s1
DMV9NP6	CS	CC(C)(C)C1=NN=C2N1CC[C@@H](C2)C3=NC(=NO3)C4=CC=C(C=C4)F
DMV9NP6	IK	NPRJTKMKUYJGAL-LBPRGKRZSA-N
DMV9NP6	IU	5-[(7S)-3-tert-butyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl]-3-(4-fluorophenyl)-1,2,4-oxadiazole
DMV9NP6	DE	Discovery agent

DM74J10	ID	DM74J10
DM74J10	DN	LSP1-2111
DM74J10	HS	Investigative
DM74J10	SN	LSP1-2111; SCHEMBL4091094; GTPL6739; SCHEMBL10000472; (2S)-2-amino-4-{hydroxy[hydroxy(4-hydroxy-3-methoxy-5-nitrophenyl)methyl]phosphoryl}butanoic acid; (2s)-2-amino-4-[hydroxy[hydroxy(4-hydroxy-3-methoxy-5-nitrophenyl)methyl]phosphoryl] butanoic acid
DM74J10	DT	Small molecular drug
DM74J10	PC	46898088
DM74J10	MW	364.24
DM74J10	FM	C12H17N2O9P
DM74J10	IC	InChI=1S/C12H17N2O9P/c1-23-9-5-6(4-8(10(9)15)14(19)20)12(18)24(21,22)3-2-7(13)11(16)17/h4-5,7,12,15,18H,2-3,13H2,1H3,(H,16,17)(H,21,22)/t7-,12?/m0/s1
DM74J10	CS	COC1=CC(=CC(=C1O)[N+](=O)[O-])C(O)P(=O)(CC[C@@H](C(=O)O)N)O
DM74J10	IK	PEXVMHLARUAHNC-KAJCPDDVSA-N
DM74J10	IU	(2S)-2-amino-4-[hydroxy-[hydroxy-(4-hydroxy-3-methoxy-5-nitrophenyl)methyl]phosphoryl]butanoic acid
DM74J10	DE	Discovery agent

DMBWHGP	ID	DMBWHGP
DMBWHGP	DN	LSP4-2022
DMBWHGP	HS	Investigative
DMBWHGP	SN	LSP4-2022; GTPL6706; CHEMBL3114673; US9212196, Derivative 2; SCHEMBL13975986; BDBM196906; (2s)-2-amino-4-({[4-(carboxymethoxy)phenyl] (hydroxy)methyl}-(hydroxy)phosphoryl)butanoic acid; (2S)-2-amino-4-({[4-(carboxymethoxy)phenyl](hydroxy)methyl}(hydroxy)phosphoryl)butanoic acid
DMBWHGP	DT	Small molecular drug
DMBWHGP	PC	71041983
DMBWHGP	MW	347.26
DMBWHGP	FM	C13H18NO8P
DMBWHGP	IC	InChI=1S/C13H18NO8P/c14-10(12(17)18)5-6-23(20,21)13(19)8-1-3-9(4-2-8)22-7-11(15)16/h1-4,10,13,19H,5-7,14H2,(H,15,16)(H,17,18)(H,20,21)/t10-,13?/m0/s1
DMBWHGP	CS	C1=CC(=CC=C1C(O)P(=O)(CC[C@@H](C(=O)O)N)O)OCC(=O)O
DMBWHGP	IK	BGOFVWMHMQISHB-NKUHCKNESA-N
DMBWHGP	IU	(2S)-2-amino-4-[[[4-(carboxymethoxy)phenyl]-hydroxymethyl]-hydroxyphosphoryl]butanoic acid
DMBWHGP	DE	Discovery agent

DM702WR	ID	DM702WR
DM702WR	DN	LTC4
DM702WR	HS	Investigative
DM702WR	SN	leukotriene C4
DM702WR	DT	Small molecular drug
DM702WR	PC	5280493
DM702WR	MW	625.8
DM702WR	FM	C30H47N3O9S
DM702WR	IC	InChI=1S/C30H47N3O9S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-25(24(34)15-14-17-27(36)37)43-21-23(29(40)32-20-28(38)39)33-26(35)19-18-22(31)30(41)42/h6-7,9-13,16,22-25,34H,2-5,8,14-15,17-21,31H2,1H3,(H,32,40)(H,33,35)(H,36,37)(H,38,39)(H,41,42)/b7-6-,10-9-,12-11+,16-13+/t22-,23-,24-,25+/m0/s1
DM702WR	CS	CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N
DM702WR	IK	GWNVDXQDILPJIG-NXOLIXFESA-N
DM702WR	IU	(5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
DM702WR	CA	CAS 72025-60-6
DM702WR	CB	CHEBI:16978
DM702WR	DE	Discovery agent

DMIUZX3	ID	DMIUZX3
DMIUZX3	DN	LTD4
DMIUZX3	HS	Investigative
DMIUZX3	SN	S-[(4S,5R,6E,8E,10Z,13Z)-1-Carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]cysteinylglycine; 5(S)-Hydroxy-6(R)-S-cysteinylglycinyl-7-trans-9-trans-11-cis-14-cis-eicosatetraenoic Acid; Leukotriene D(sub 4); (5S,6R,7E,9E,11Z,14Z)-6-({2-amino-2-[(carboxymethyl)carbamoyl]ethyl}sulfanyl)-5-hydroxyicosa-7,9,11,14-tetraenoic acid; LTD (sub 4); [3H]LTD4; [3H]-LTD4; S-[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]cysteinylglycine; AC1O5JI4; SCHEMBL4295683; GTPL3412; BML1-E08; GTPL3353; CHEMBL1521056; DTXSID6040533; YEESKJGWJFYOOK-LDDGIIIKSA-N; 73836-78-9; LTD; leukotriene D4
DMIUZX3	DT	Small molecular drug
DMIUZX3	PC	5280878
DMIUZX3	MW	496.7
DMIUZX3	FM	C25H40N2O6S
DMIUZX3	IC	InChI=1S/C25H40N2O6S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22(21(28)15-14-17-23(29)30)34-19-20(26)25(33)27-18-24(31)32/h6-7,9-13,16,20-22,28H,2-5,8,14-15,17-19,26H2,1H3,(H,27,33)(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t20-,21-,22+/m0/s1
DMIUZX3	CS	CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)NCC(=O)O)N
DMIUZX3	IK	YEESKJGWJFYOOK-IJHYULJSSA-N
DMIUZX3	IU	(5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
DMIUZX3	CA	CAS 73836-78-9
DMIUZX3	CB	CHEBI:28666
DMIUZX3	DE	Discovery agent

DMCPB0Q	ID	DMCPB0Q
DMCPB0Q	DN	LTE4
DMCPB0Q	HS	Investigative
DMCPB0Q	SN	Leukotriene E4; leukotriene E4; Leukotriene E; UNII-8EYT8ATL7G; 75715-89-8; 8EYT8ATL7G; CHEMBL509456; CHEBI:15650; OTZRAYGBFWZKMX-FRFVZSDQSA-N; 5S-hydroxy,6R-(S-cysteinyl),7E,9E,11Z,14Z-eicosatetraenoic acid; C23H37NO5S; (5S-(5R*,6S*(S*),7E,9E,11Z,14Z))-6-((2-Amino-2-carboxyethyl)thio)-5-hydroxy-7,9,11,14-eicosatetraenoic acid; (5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid; [3H]LTE4; AC1NQXPM; LEUKOTRIEN E4; BSPBio_001370;  leukotriene E
DMCPB0Q	DT	Small molecular drug
DMCPB0Q	PC	5280879
DMCPB0Q	MW	439.6
DMCPB0Q	FM	C23H37NO5S
DMCPB0Q	IC	InChI=1S/C23H37NO5S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-21(30-18-19(24)23(28)29)20(25)15-14-17-22(26)27/h6-7,9-13,16,19-21,25H,2-5,8,14-15,17-18,24H2,1H3,(H,26,27)(H,28,29)/b7-6-,10-9-,12-11+,16-13+/t19-,20-,21+/m0/s1
DMCPB0Q	CS	CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)O)N
DMCPB0Q	IK	OTZRAYGBFWZKMX-FRFVZSDQSA-N
DMCPB0Q	IU	(5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-amino-2-carboxyethyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
DMCPB0Q	CA	CAS 75715-89-8
DMCPB0Q	CB	CHEBI:15650
DMCPB0Q	DE	Discovery agent

DMDU6F4	ID	DMDU6F4
DMDU6F4	DN	LTERHKILHRLLQEGSPSD
DMDU6F4	HS	Investigative
DMDU6F4	PC	91935928
DMDU6F4	MW	2229.5
DMDU6F4	FM	C96H161N31O30
DMDU6F4	IC	InChI=1S/C96H161N31O30/c1-12-50(10)75(125-83(145)55(18-13-14-28-97)113-87(149)64(36-52-39-104-44-109-52)120-80(142)56(19-15-29-106-95(100)101)112-82(144)60(24-27-73(135)136)117-92(154)76(51(11)130)126-77(139)54(98)32-46(2)3)91(153)122-63(35-49(8)9)86(148)121-65(37-53-40-105-45-110-53)88(150)114-57(20-16-30-107-96(102)103)79(141)118-62(34-48(6)7)85(147)119-61(33-47(4)5)84(146)116-59(22-25-70(99)131)81(143)115-58(23-26-72(133)134)78(140)108-41-71(132)111-68(43-129)93(155)127-31-17-21-69(127)90(152)124-67(42-128)89(151)123-66(94(156)157)38-74(137)138/h39-40,44-51,54-69,75-76,128-130H,12-38,41-43,97-98H2,1-11H3,(H2,99,131)(H,104,109)(H,105,110)(H,108,140)(H,111,132)(H,112,144)(H,113,149)(H,114,150)(H,115,143)(H,116,146)(H,117,154)(H,118,141)(H,119,147)(H,120,142)(H,121,148)(H,122,153)(H,123,151)(H,124,152)(H,125,145)(H,126,139)(H,133,134)(H,135,136)(H,137,138)(H,156,157)(H4,100,101,106)(H4,102,103,107)/t50-,51+,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69?,75-,76-/m0/s1
DMDU6F4	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N2CCCC2C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)N
DMDU6F4	IK	QPHCCOQIWMPOQX-KTGODZLYSA-N
DMDU6F4	IU	(2S)-2-[[(2S)-2-[[1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]butanedioic acid
DMDU6F4	DE	Discovery agent

DMP8O6R	ID	DMP8O6R
DMP8O6R	DN	L-Thiocitrulline
DMP8O6R	HS	Investigative
DMP8O6R	SN	L-thiocitrulline; (S)-2-Amino-5-(thioureido)pentanoic acid; CHEMBL93247; SCI; (2S)-2-amino-5-[(aminothioxomethyl)amino]pentanoic acid; AC1MBZ2U; KBioGR_000498; BSPBio_001158; KBioSS_000498; SCHEMBL156220; KBio3_000915; KBio2_005634; KBio2_003066; KBio2_000498; KBio3_000916; Thio-L-citrulline, &gt; BKGWACHYAMTLAF-BYPYZUCNSA-N; HMS3403J19; HMS1990J19; Bio1_000374; HMS1362J19; Bio2_000899; HMS1792J19; Bio2_000419; Bio1_001352; Bio1_000863
DMP8O6R	DT	Small molecular drug
DMP8O6R	PC	2733514
DMP8O6R	MW	191.25
DMP8O6R	FM	C6H13N3O2S
DMP8O6R	IC	InChI=1S/C6H13N3O2S/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1
DMP8O6R	CS	C(C[C@@H](C(=O)O)N)CNC(=S)N
DMP8O6R	IK	BKGWACHYAMTLAF-BYPYZUCNSA-N
DMP8O6R	IU	(2S)-2-amino-5-(carbamothioylamino)pentanoic acid
DMP8O6R	CA	CAS 156719-37-8
DMP8O6R	DE	Discovery agent

DMFHTBX	ID	DMFHTBX
DMFHTBX	DN	L-threonine
DMFHTBX	HS	Investigative
DMFHTBX	SN	L-threonine; threonine; 72-19-5; H-Thr-OH; Threonin; L-(-)-Threonine; (2S,3R)-2-amino-3-hydroxybutanoic acid; (S)-Threonine; 2-amino-3-hydroxybutyric acid; H-DL-Thr-OH; Threonine (VAN); Treonina [Spanish]; Threoninum [Latin]; Threonine [USAN:INN]; Threonine, L-; (2S,3R)-2-Amino-3-hydroxybutyric acid; thre; L-Threonin; L-thr; (2S)-threonine; L-alpha-Amino-beta-hydroxybutyric acid; (2S,3R)-(-)-Threonine; 2-Amino-3-hydroxybutanoic acid, (R-(R*,S*))-; UNII-2ZD004190S; Butanoic acid, 2-amino-3-hydroxy-, (R-(R*,S*))-
DMFHTBX	DT	Small molecular drug
DMFHTBX	PC	6288
DMFHTBX	MW	119.12
DMFHTBX	FM	C4H9NO3
DMFHTBX	IC	InChI=1S/C4H9NO3/c1-2(6)3(5)4(7)8/h2-3,6H,5H2,1H3,(H,7,8)/t2-,3+/m1/s1
DMFHTBX	CS	C[C@H]([C@@H](C(=O)O)N)O
DMFHTBX	IK	AYFVYJQAPQTCCC-GBXIJSLDSA-N
DMFHTBX	IU	(2S,3R)-2-amino-3-hydroxybutanoic acid
DMFHTBX	CA	CAS 72-19-5
DMFHTBX	CB	CHEBI:16857
DMFHTBX	DE	Discovery agent

DM83HWL	ID	DM83HWL
DM83HWL	DN	L-thyroxine
DM83HWL	HS	Investigative
DM83HWL	SN	DL-Thyroxin; L-3,5,3',5'-Tetraiodothyronine; L-Thyroxin; L-thyroxine; Laevothyroxinum; Laevothyroxinum (acid); Levothyroxin; Levothyroxinum (acid); T4 (Hormone); Tetraiodothyronine; Tetramet; Thyratabs; Thyrax; Thyreoideum; Thyroxinal; Thyroxine (VAN); Thyroxine (l); Thyroxine I 125; Thyroxine iodine; levothyroxine; thyroxin; thyroxine; (-)-Thyroxine; 3,3',5,5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodothyronine; 51-48-9; L-T4; t4
DM83HWL	PC	5819
DM83HWL	MW	776.87
DM83HWL	FM	C15H11I4NO4
DM83HWL	IC	XUIIKFGFIJCVMT-LBPRGKRZSA-N
DM83HWL	CS	C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N
DM83HWL	IK	1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1
DM83HWL	IU	(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
DM83HWL	CA	CAS 51-48-9
DM83HWL	CB	CHEBI:18332
DM83HWL	DE	Hypogonadism

DMW09LB	ID	DMW09LB
DMW09LB	DN	LTK-14
DMW09LB	HS	Investigative
DMW09LB	SN	14-methoxy IG (isogarcinol); LTK14
DMW09LB	DT	Small molecular drug
DMW09LB	PC	25226432
DMW09LB	MW	616.8
DMW09LB	FM	C39H52O6
DMW09LB	IC	InChI=1S/C39H52O6/c1-23(2)12-15-27-21-38-22-28(16-13-24(3)4)37(9,10)45-34(38)31(32(41)26-14-17-30(44-11)29(40)20-26)33(42)39(35(38)43,36(27,7)8)19-18-25(5)6/h12-14,17-18,20,27-28,40H,15-16,19,21-22H2,1-11H3/t27-,28+,38+,39+/m1/s1
DMW09LB	CS	CC(=CC[C@@H]1C[C@]23C[C@@H](C(OC2=C(C(=O)[C@@](C3=O)(C1(C)C)CC=C(C)C)C(=O)C4=CC(=C(C=C4)OC)O)(C)C)CC=C(C)C)C
DMW09LB	IK	GEMUMPJYCDKSDU-OAKZDBKWSA-N
DMW09LB	IU	(1S,3S,9R,11R)-7-(3-hydroxy-4-methoxybenzoyl)-4,4,10,10-tetramethyl-3,9,11-tris(3-methylbut-2-enyl)-5-oxatricyclo[7.3.1.01,6]tridec-6-ene-8,13-dione
DMW09LB	DE	Discovery agent

DMYLONS	ID	DMYLONS
DMYLONS	DN	L-Tryptophan-L-2-aminoadipic acid
DMYLONS	HS	Investigative
DMYLONS	SN	CHEMBL515773; L-Tryptophan-L-2-aminoadipic acid
DMYLONS	DT	Small molecular drug
DMYLONS	PC	25185696
DMYLONS	MW	347.4
DMYLONS	FM	C17H21N3O5
DMYLONS	IC	InChI=1S/C17H21N3O5/c18-12(8-10-9-19-13-5-2-1-4-11(10)13)16(23)20-14(17(24)25)6-3-7-15(21)22/h1-2,4-5,9,12,14,19H,3,6-8,18H2,(H,20,23)(H,21,22)(H,24,25)/t12-,14-/m0/s1
DMYLONS	CS	C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCC(=O)O)C(=O)O)N
DMYLONS	IK	LKKDYAZRMNSFJN-JSGCOSHPSA-N
DMYLONS	IU	(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]hexanedioic acid
DMYLONS	DE	Discovery agent

DMYU65F	ID	DMYU65F
DMYU65F	DN	L-Tryptophan-L-arginine
DMYU65F	HS	Investigative
DMYU65F	SN	CHEMBL477417; CHEBI:74866; 88831-09-8; Tryptophyl-Arginine; L-tryptophyl-L-arginine; L-Arginine, L-tryptophyl-; L-Tryptophan-L-arginine; tryptophanyl-arginine; L-Trp-L-Arg; SCHEMBL4947728; CTK3A5775; WR; ZINC2561117; BDBM50266680; AKOS030606594; H-Trp-Arg-OH  inverted exclamation mark currency 2 HCl
DMYU65F	DT	Small molecular drug
DMYU65F	PC	25186251
DMYU65F	MW	360.4
DMYU65F	FM	C17H24N6O3
DMYU65F	IC	InChI=1S/C17H24N6O3/c18-12(8-10-9-22-13-5-2-1-4-11(10)13)15(24)23-14(16(25)26)6-3-7-21-17(19)20/h1-2,4-5,9,12,14,22H,3,6-8,18H2,(H,23,24)(H,25,26)(H4,19,20,21)/t12-,14-/m0/s1
DMYU65F	CS	C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N
DMYU65F	IK	LCPVBXOHXMBLFW-JSGCOSHPSA-N
DMYU65F	IU	(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMYU65F	CB	CHEBI:74866
DMYU65F	DE	Discovery agent

DMWZMCA	ID	DMWZMCA
DMWZMCA	DN	L-Tryptophan-L-asparagine
DMWZMCA	HS	Investigative
DMWZMCA	SN	CHEMBL513911; 175027-11-9; WN dipeptide; H-Trp-Asn-OH; W-N Dipeptide; L-Tryptophyl-L-Asparagine; Tryptophan Asparagine dipeptide; L-Tryptophan-L-asparagine; CHEBI:141447; WN; ZINC2561118; BDBM50266679; (2S)-4-amino-2-{[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino}-4-oxobutanoic acid
DMWZMCA	DT	Small molecular drug
DMWZMCA	PC	7020170
DMWZMCA	MW	318.33
DMWZMCA	FM	C15H18N4O4
DMWZMCA	IC	InChI=1S/C15H18N4O4/c16-10(14(21)19-12(15(22)23)6-13(17)20)5-8-7-18-11-4-2-1-3-9(8)11/h1-4,7,10,12,18H,5-6,16H2,(H2,17,20)(H,19,21)(H,22,23)/t10-,12-/m0/s1
DMWZMCA	CS	C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)N
DMWZMCA	IK	GRQCSEWEPIHLBI-JQWIXIFHSA-N
DMWZMCA	IU	(2S)-4-amino-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoic acid
DMWZMCA	CB	CHEBI:141447
DMWZMCA	DE	Discovery agent

DMVFAD5	ID	DMVFAD5
DMVFAD5	DN	L-Tryptophan-L-aspartic acid
DMVFAD5	HS	Investigative
DMVFAD5	SN	H-TRP-ASP-OH; 71835-78-4; CHEMBL476008; CHEBI:74868; L-TRYPTOPHYL-L-ASPARTIC ACID; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)Propanamido)succinic acid; Tryptophyl-Aspartate; tryptophylaspartic acid; L-Tryptophan-L-aspartic acid; L-Trp-L-Asp; SCHEMBL10434701; CTK7I5235; WD; ZINC2556664; BDBM50266632
DMVFAD5	DT	Small molecular drug
DMVFAD5	PC	7019108
DMVFAD5	MW	319.31
DMVFAD5	FM	C15H17N3O5
DMVFAD5	IC	InChI=1S/C15H17N3O5/c16-10(14(21)18-12(15(22)23)6-13(19)20)5-8-7-17-11-4-2-1-3-9(8)11/h1-4,7,10,12,17H,5-6,16H2,(H,18,21)(H,19,20)(H,22,23)/t10-,12-/m0/s1
DMVFAD5	CS	C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)N
DMVFAD5	IK	PEEAINPHPNDNGE-JQWIXIFHSA-N
DMVFAD5	IU	(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]butanedioic acid
DMVFAD5	CB	CHEBI:74868
DMVFAD5	DE	Discovery agent

DMNMRHX	ID	DMNMRHX
DMNMRHX	DN	L-Tryptophan-L-glutamine
DMNMRHX	HS	Investigative
DMNMRHX	SN	CHEMBL476173; L-Tryptophan-L-glutamine; SCHEMBL5970454
DMNMRHX	DT	Small molecular drug
DMNMRHX	PC	25187914
DMNMRHX	MW	332.35
DMNMRHX	FM	C16H20N4O4
DMNMRHX	IC	InChI=1S/C16H20N4O4/c17-11(7-9-8-19-12-4-2-1-3-10(9)12)15(22)20-13(16(23)24)5-6-14(18)21/h1-4,8,11,13,19H,5-7,17H2,(H2,18,21)(H,20,22)(H,23,24)/t11-,13-/m0/s1
DMNMRHX	CS	C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DMNMRHX	IK	NZCPCJCJZHKFGZ-AAEUAGOBSA-N
DMNMRHX	IU	(2S)-5-amino-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoic acid
DMNMRHX	CB	CHEBI:157897
DMNMRHX	DE	Discovery agent

DMPV5D0	ID	DMPV5D0
DMPV5D0	DN	L-Tryptophan-L-leucine
DMPV5D0	HS	Investigative
DMPV5D0	SN	H-Trp-Leu-OH; 13123-35-8; L-tryptophyl-L-leucine; CHEMBL477627; CHEBI:74871; Tryptophyl-Leucine; L-Tryptophan-L-leucine; L-Trp-L-Leu; L-Trp-L-Leu-OH; L-Leucine,L-tryptophyl-; AC1OE28P; SCHEMBL7622341; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)propanamido)-4-methylpentanoic acid; CTK4B7168; ZINC1865984; WL; BDBM50266681; AKOS022180848; AJ-32151; FT-0772989; C-48470; (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid
DMPV5D0	DT	Small molecular drug
DMPV5D0	PC	6997510
DMPV5D0	MW	317.4
DMPV5D0	FM	C17H23N3O3
DMPV5D0	IC	InChI=1S/C17H23N3O3/c1-10(2)7-15(17(22)23)20-16(21)13(18)8-11-9-19-14-6-4-3-5-12(11)14/h3-6,9-10,13,15,19H,7-8,18H2,1-2H3,(H,20,21)(H,22,23)/t13-,15-/m0/s1
DMPV5D0	CS	CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N
DMPV5D0	IK	LYMVXFSTACVOLP-ZFWWWQNUSA-N
DMPV5D0	IU	(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid
DMPV5D0	CB	CHEBI:74871
DMPV5D0	DE	Discovery agent

DMGVELK	ID	DMGVELK
DMGVELK	DN	L-Tyrosinamide
DMGVELK	HS	Investigative
DMGVELK	SN	ACMC-20muar; 131948-41-9; L-Tyrosinamide,(4R)-4-hydroxy-1-(1H-indol-3-ylcarbonyl)-L-prolyl-N-methyl-N-(phenylmethyl)-(9CI)
DMGVELK	DT	Small molecular drug
DMGVELK	PC	151243
DMGVELK	MW	180.2
DMGVELK	FM	C9H12N2O2
DMGVELK	IC	InChI=1S/C9H12N2O2/c10-8(9(11)13)5-6-1-3-7(12)4-2-6/h1-4,8,12H,5,10H2,(H2,11,13)/t8-/m0/s1
DMGVELK	CS	C1=CC(=CC=C1C[C@@H](C(=O)N)N)O
DMGVELK	IK	PQFMNVGMJJMLAE-QMMMGPOBSA-N
DMGVELK	IU	(2S)-2-amino-3-(4-hydroxyphenyl)propanamide
DMGVELK	CA	CAS 4985-46-0
DMGVELK	CB	CHEBI:21412
DMGVELK	DE	Discovery agent

DMH693E	ID	DMH693E
DMH693E	DN	Lu AF21934
DMH693E	HS	Investigative
DMH693E	SN	(1S,2R)-2-[(aminooxy)methyl]-N-(3,4-dichlorophenyl)cyclohexane-1-carboxamide
DMH693E	DT	Small molecular drug
DMH693E	PC	66553157
DMH693E	MW	315.2
DMH693E	FM	C14H16Cl2N2O2
DMH693E	IC	InChI=1S/C14H16Cl2N2O2/c15-11-6-5-8(7-12(11)16)18-14(20)10-4-2-1-3-9(10)13(17)19/h5-7,9-10H,1-4H2,(H2,17,19)(H,18,20)/t9-,10+/m1/s1
DMH693E	CS	C1CC[C@@H]([C@@H](C1)C(=O)N)C(=O)NC2=CC(=C(C=C2)Cl)Cl
DMH693E	IK	AVKZWCJNDWOBAM-ZJUUUORDSA-N
DMH693E	IU	(1R,2S)-2-N-(3,4-dichlorophenyl)cyclohexane-1,2-dicarboxamide
DMH693E	DE	Discovery agent

DM7F3SE	ID	DM7F3SE
DM7F3SE	DN	LU302872
DM7F3SE	HS	Investigative
DM7F3SE	SN	CHEMBL102405; AC1O5FKI; SCHEMBL3894792; lu224332; BDBM50079417; L017653; 3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yl)oxy-3,3-diphenylpropanoic acid; 3-[2-(3,4-Dimethoxy-phenyl)-ethoxy]-2-(4,6-dimethyl-pyrimidin-2-yloxy)-3,3-diphenyl-propionic acid; 2-[(4,6-Dimethylpyrimidine-2-yl)oxy]-3-[2-(3,4-dimethoxyphenyl)ethoxy]-3,3-diphenylpropionic acid
DM7F3SE	DT	Small molecular drug
DM7F3SE	PC	9893800
DM7F3SE	MW	528.6
DM7F3SE	FM	C31H32N2O6
DM7F3SE	IC	InChI=1S/C31H32N2O6/c1-21-19-22(2)33-30(32-21)39-28(29(34)35)31(24-11-7-5-8-12-24,25-13-9-6-10-14-25)38-18-17-23-15-16-26(36-3)27(20-23)37-4/h5-16,19-20,28H,17-18H2,1-4H3,(H,34,35)/t28-/m1/s1
DM7F3SE	CS	CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCCC4=CC(=C(C=C4)OC)OC)C
DM7F3SE	IK	CLSJNXXMIVKULC-MUUNZHRXSA-N
DM7F3SE	IU	(2S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yl)oxy-3,3-diphenylpropanoic acid
DM7F3SE	CA	CAS 204267-33-4
DM7F3SE	DE	Discovery agent

DM2YOVC	ID	DM2YOVC
DM2YOVC	DN	LU32-176B
DM2YOVC	HS	Investigative
DM2YOVC	SN	LU32-176B; GTPL4756; SCHEMBL5726290
DM2YOVC	DT	Small molecular drug
DM2YOVC	PC	11749893
DM2YOVC	MW	398.4
DM2YOVC	FM	C23H24F2N2O2
DM2YOVC	IC	InChI=1S/C23H24F2N2O2/c24-17-10-6-15(7-11-17)19(16-8-12-18(25)13-9-16)3-2-14-26-20-4-1-5-21-22(20)23(28)27-29-21/h6-13,19-20,26H,1-5,14H2,(H,27,28)
DM2YOVC	CS	C1CC(C2=C(C1)ONC2=O)NCCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DM2YOVC	IK	QOSIKKDOOCQXMT-UHFFFAOYSA-N
DM2YOVC	IU	4-[4,4-bis(4-fluorophenyl)butylamino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-one
DM2YOVC	DE	Discovery agent

DMGYBSC	ID	DMGYBSC
DMGYBSC	DN	LU-53439
DMGYBSC	HS	Investigative
DMGYBSC	SN	153420-96-3
DMGYBSC	DT	Small molecular drug
DMGYBSC	PC	179342
DMGYBSC	MW	330.4
DMGYBSC	FM	C17H18N2O3S
DMGYBSC	IC	InChI=1S/C17H18N2O3S/c1-9(2)16-19-18-15(23-16)8-21-12-5-6-13-10(3)11(4)17(20)22-14(13)7-12/h5-7,9H,8H2,1-4H3
DMGYBSC	CS	CC1=C(C(=O)OC2=C1C=CC(=C2)OCC3=NN=C(S3)C(C)C)C
DMGYBSC	IK	HQTNJPCZUQAYAB-UHFFFAOYSA-N
DMGYBSC	IU	3,4-dimethyl-7-[(5-propan-2-yl-1,3,4-thiadiazol-2-yl)methoxy]chromen-2-one
DMGYBSC	CA	CAS 153420-96-3
DMGYBSC	DE	Discovery agent

DM34AYV	ID	DM34AYV
DM34AYV	DN	LU-AA33810
DM34AYV	HS	Investigative
DM34AYV	SN	LU-AE00654; Neuropeptide Y receptor subtype Y5 antagonists (depression); NPY5 antagonists (depression), Lundbeck; Neuropeptide Y receptor subtype Y5 antagonists (depression), Lundbeck
DM34AYV	CP	H Lundbeck A/S
DM34AYV	DE	Major depressive disorder

DMI9VNO	ID	DMI9VNO
DMI9VNO	DN	LUDARTIN
DMI9VNO	HS	Investigative
DMI9VNO	SN	Ludartin; CHEMBL1097764; 36149-87-8; BDBM50318394; 6,8a-Dimethyl-3-methylene-3a,4,5,7,7a,8a,8b,8c-octahydro-3H-1,8-dioxa-cyclopenta[h]cyclopropa[a]azulen-2-one (Ludartin)
DMI9VNO	DT	Small molecular drug
DMI9VNO	PC	14355826
DMI9VNO	MW	246.3
DMI9VNO	FM	C15H18O3
DMI9VNO	IC	InChI=1S/C15H18O3/c1-7-4-5-9-8(2)14(16)17-13(9)12-10(7)6-11-15(12,3)18-11/h9,11-13H,2,4-6H2,1,3H3/t9-,11+,12-,13-,15+/m0/s1
DMI9VNO	CS	CC1=C2C[C@@H]3[C@]([C@@H]2[C@@H]4[C@@H](CC1)C(=C)C(=O)O4)(O3)C
DMI9VNO	IK	QXJYIGSXUBOSID-JZEMPJKHSA-N
DMI9VNO	IU	(1S,2S,6S,12R,14S)-9,14-dimethyl-5-methylidene-3,13-dioxatetracyclo[8.4.0.02,6.012,14]tetradec-9-en-4-one
DMI9VNO	DE	Discovery agent

DMUPQED	ID	DMUPQED
DMUPQED	DN	LUF-5417
DMUPQED	HS	Investigative
DMUPQED	SN	LUF-5417; 4-methoxy-N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide; CHEMBL305322; 331472-31-2; AC1LDIQV; SCHEMBL6942413; ZINC26474; MolPort-000-646-916; STL203008; BDBM50097423; AKOS000813206; MCULE-5464374219; VU0618369-1; F3394-1093; Z275024144; 4-Methoxy-N-(3-phenyl-[1,2,4]thiadiazol-5-yl)-benzamide
DMUPQED	DT	Small molecular drug
DMUPQED	PC	667741
DMUPQED	MW	311.4
DMUPQED	FM	C16H13N3O2S
DMUPQED	IC	InChI=1S/C16H13N3O2S/c1-21-13-9-7-12(8-10-13)15(20)18-16-17-14(19-22-16)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18,19,20)
DMUPQED	CS	COC1=CC=C(C=C1)C(=O)NC2=NC(=NS2)C3=CC=CC=C3
DMUPQED	IK	RGVXOHBJCGPTQH-UHFFFAOYSA-N
DMUPQED	IU	4-methoxy-N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide
DMUPQED	DE	Discovery agent

DME4O5D	ID	DME4O5D
DME4O5D	DN	LUF-5433
DME4O5D	HS	Investigative
DME4O5D	SN	LUF-5433; CHEMBL60156; 15850-34-7; 4-methoxy-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; (Z)-4-methoxy-N-(4-phenylthiazol-2(3H)-ylidene)benzamide; AC1LDKPI; N-(4-phenylthiazol-2-yl)-4-methoxybenzamide; Oprea1_747035; Oprea1_074264; Oprea1_345855; AC1Q49Y1; SCHEMBL2753298; MolPort-001-029-705; MolPort-003-712-982; ZINC1508173; STK401912; BDBM50097431; AKOS001303429; AKOS024573980; MCULE-3254711297; ST042073; 4-methoxy-N-(4-phenylthiazol-2-yl)benzamide; 4-Methoxy-N-(4-phenyl-thiazol-2-yl)-benzamide; SR-01000394983; SR-01000394983-1
DME4O5D	DT	Small molecular drug
DME4O5D	PC	668712
DME4O5D	MW	310.4
DME4O5D	FM	C17H14N2O2S
DME4O5D	IC	InChI=1S/C17H14N2O2S/c1-21-14-9-7-13(8-10-14)16(20)19-17-18-15(11-22-17)12-5-3-2-4-6-12/h2-11H,1H3,(H,18,19,20)
DME4O5D	CS	COC1=CC=C(C=C1)C(=O)NC2=NC(=CS2)C3=CC=CC=C3
DME4O5D	IK	FVWGKRAXWKLEHX-UHFFFAOYSA-N
DME4O5D	IU	4-methoxy-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DME4O5D	DE	Discovery agent

DM0DRO8	ID	DM0DRO8
DM0DRO8	DN	LUF-5437
DM0DRO8	HS	Investigative
DM0DRO8	SN	LUF-5437; CHEMBL164745; SCHEMBL4243345; BDBM50097451
DM0DRO8	DT	Small molecular drug
DM0DRO8	PC	9994776
DM0DRO8	MW	297.3
DM0DRO8	FM	C15H11N3O2S
DM0DRO8	IC	InChI=1S/C15H11N3O2S/c19-12-8-6-11(7-9-12)14(20)17-15-16-13(18-21-15)10-4-2-1-3-5-10/h1-9,19H,(H,16,17,18,20)
DM0DRO8	CS	C1=CC=C(C=C1)C2=NSC(=N2)NC(=O)C3=CC=C(C=C3)O
DM0DRO8	IK	MIJWZALSSVTKAQ-UHFFFAOYSA-N
DM0DRO8	IU	4-hydroxy-N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide
DM0DRO8	DE	Discovery agent

DM89FBX	ID	DM89FBX
DM89FBX	DN	LUF-5735
DM89FBX	HS	Investigative
DM89FBX	SN	CHEMBL222719; LUF-5735; 820961-65-7; N-(4,6-diphenylpyrimidin-2-yl)butanamide; SCHEMBL6499771; CTK3E2643; DTXSID60464548; MolPort-007-705-553; ZINC6716086; BDBM50157673; AKOS001552900; MCULE-5627024228; N-(4,6-diphenylpyrimidin-2-yl)butyramide; Butanamide, N-(4,6-diphenyl-2-pyrimidinyl)-
DM89FBX	DT	Small molecular drug
DM89FBX	PC	11392960
DM89FBX	MW	317.4
DM89FBX	FM	C20H19N3O
DM89FBX	IC	InChI=1S/C20H19N3O/c1-2-9-19(24)23-20-21-17(15-10-5-3-6-11-15)14-18(22-20)16-12-7-4-8-13-16/h3-8,10-14H,2,9H2,1H3,(H,21,22,23,24)
DM89FBX	CS	CCCC(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DM89FBX	IK	IGXLAZUQYPCBKI-UHFFFAOYSA-N
DM89FBX	IU	N-(4,6-diphenylpyrimidin-2-yl)butanamide
DM89FBX	CA	CAS 820961-65-7
DM89FBX	DE	Discovery agent

DMXFD3S	ID	DMXFD3S
DMXFD3S	DN	LUF-5737
DMXFD3S	HS	Investigative
DMXFD3S	SN	CHEMBL376778; LUF-5737; 820961-68-0; SCHEMBL6502989; CTK3E2640; DTXSID50464193; BDBM50157654; N-(4,6-diphenylpyrimidin-2-yl)isobutyramide; L023249; Propanamide, N-(4,6-diphenyl-2-pyrimidinyl)-2-methyl-
DMXFD3S	DT	Small molecular drug
DMXFD3S	PC	11381543
DMXFD3S	MW	317.4
DMXFD3S	FM	C20H19N3O
DMXFD3S	IC	InChI=1S/C20H19N3O/c1-14(2)19(24)23-20-21-17(15-9-5-3-6-10-15)13-18(22-20)16-11-7-4-8-12-16/h3-14H,1-2H3,(H,21,22,23,24)
DMXFD3S	CS	CC(C)C(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMXFD3S	IK	AGCKGTMTDBKSHH-UHFFFAOYSA-N
DMXFD3S	IU	N-(4,6-diphenylpyrimidin-2-yl)-2-methylpropanamide
DMXFD3S	CA	CAS 820961-68-0
DMXFD3S	DE	Discovery agent

DMQ3VHR	ID	DMQ3VHR
DMQ3VHR	DN	LUF-5764
DMQ3VHR	HS	Investigative
DMQ3VHR	SN	CHEMBL222504; LUF-5764; 820961-49-7; SCHEMBL4822595; CTK3E2654; DTXSID00466708; BDBM50157682; AKOS030569391; L023251; N-(2,6-diphenylpyrimidin-4-yl)-3,3-dimethylbutyramide; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-3,3-dimethyl-
DMQ3VHR	DT	Small molecular drug
DMQ3VHR	PC	11462102
DMQ3VHR	MW	345.4
DMQ3VHR	FM	C22H23N3O
DMQ3VHR	IC	InChI=1S/C22H23N3O/c1-22(2,3)15-20(26)24-19-14-18(16-10-6-4-7-11-16)23-21(25-19)17-12-8-5-9-13-17/h4-14H,15H2,1-3H3,(H,23,24,25,26)
DMQ3VHR	CS	CC(C)(C)CC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMQ3VHR	IK	HRLXAMBTUIRRBL-UHFFFAOYSA-N
DMQ3VHR	IU	N-(2,6-diphenylpyrimidin-4-yl)-3,3-dimethylbutanamide
DMQ3VHR	CA	CAS 820961-49-7
DMQ3VHR	DE	Discovery agent

DMP08QO	ID	DMP08QO
DMP08QO	DN	LUF-5767
DMP08QO	HS	Investigative
DMP08QO	SN	CHEMBL223977; LUF-5767; 820961-47-5; SCHEMBL4829114; CTK3E2656; DTXSID70465602; BDBM50157656; AKOS030569390; L023253; N-(2,6-diphenylpyrimidin-4-yl)-2-methylbutyramide; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-2-methyl-
DMP08QO	DT	Small molecular drug
DMP08QO	PC	11427528
DMP08QO	MW	331.4
DMP08QO	FM	C21H21N3O
DMP08QO	IC	InChI=1S/C21H21N3O/c1-3-15(2)21(25)24-19-14-18(16-10-6-4-7-11-16)22-20(23-19)17-12-8-5-9-13-17/h4-15H,3H2,1-2H3,(H,22,23,24,25)
DMP08QO	CS	CCC(C)C(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMP08QO	IK	OWPSSUJQRJLQHE-UHFFFAOYSA-N
DMP08QO	IU	N-(2,6-diphenylpyrimidin-4-yl)-2-methylbutanamide
DMP08QO	CA	CAS 820961-47-5
DMP08QO	DE	Discovery agent

DMQZDMH	ID	DMQZDMH
DMQZDMH	DN	LUF-5816
DMQZDMH	HS	Investigative
DMQZDMH	SN	LUF-5816; CHEMBL219625; BDBM50205286
DMQZDMH	DT	Small molecular drug
DMQZDMH	PC	16109430
DMQZDMH	MW	339.4
DMQZDMH	FM	C23H21N3
DMQZDMH	IC	InChI=1S/C23H21N3/c1-3-9-16(10-4-1)19-15-20(17-11-5-2-6-12-17)24-23-21(19)25-22(26-23)18-13-7-8-14-18/h1-6,9-12,15,18H,7-8,13-14H2,(H,24,25,26)
DMQZDMH	CS	C1CCC(C1)C2=NC3=C(N2)C(=CC(=N3)C4=CC=CC=C4)C5=CC=CC=C5
DMQZDMH	IK	LEUPSQCQJOFTFI-UHFFFAOYSA-N
DMQZDMH	IU	2-cyclopentyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMQZDMH	DE	Discovery agent

DMYZGIK	ID	DMYZGIK
DMYZGIK	DN	LUF5831
DMYZGIK	HS	Investigative
DMYZGIK	SN	LUF 5831; LUF-5831
DMYZGIK	DT	Small molecular drug
DMYZGIK	PC	135494270
DMYZGIK	MW	312.3
DMYZGIK	FM	C15H12N4O2S
DMYZGIK	IC	InChI=1S/C15H12N4O2S/c16-7-11-13(9-1-3-10(21)4-2-9)12(8-17)15(19-14(11)18)22-6-5-20/h1-4,20-21H,5-6H2,(H2,18,19)
DMYZGIK	CS	C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCCO)N)C#N)O
DMYZGIK	IK	GYIHPWFWFRELQC-UHFFFAOYSA-N
DMYZGIK	IU	2-amino-6-(2-hydroxyethylsulfanyl)-4-(4-hydroxyphenyl)pyridine-3,5-dicarbonitrile
DMYZGIK	DE	Discovery agent

DMDHUL8	ID	DMDHUL8
DMDHUL8	DN	LUF-5833
DMDHUL8	HS	Investigative
DMDHUL8	SN	A3 adenosine receptor allosteric enhancers (ischemia); LUF-6000; A3 adenosine receptor allosteric enhancers (ischemia), NIH/University of Leiden
DMDHUL8	CP	Leiden; Amsterdam Center for Drug Research
DMDHUL8	DE	Ischemia

DMZQU90	ID	DMZQU90
DMZQU90	DN	LUF-5853
DMZQU90	HS	Investigative
DMZQU90	SN	LUF-5853; CHEMBL176295; SCHEMBL6105939; KQKVGJJOJHCKQA-UHFFFAOYSA-N; BDBM50163463; 2-amino-4-(benzo[d][1,3]dioxol-5-yl)-6-(2-hydroxyethylthio)pyridine-3,5-dicarbonitrile; 2-Amino4-(1,3-benzodioxol-5-yl)-6-(2-hydroxyethyl)sulfanyl-3,5-pyridinedicarbonitrile; 2-Amino-4-benzo[1,3]dioxol-5-yl-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile
DMZQU90	DT	Small molecular drug
DMZQU90	PC	9884349
DMZQU90	MW	340.4
DMZQU90	FM	C16H12N4O3S
DMZQU90	IC	InChI=1S/C16H12N4O3S/c17-6-10-14(9-1-2-12-13(5-9)23-8-22-12)11(7-18)16(20-15(10)19)24-4-3-21/h1-2,5,21H,3-4,8H2,(H2,19,20)
DMZQU90	CS	C1OC2=C(O1)C=C(C=C2)C3=C(C(=NC(=C3C#N)SCCO)N)C#N
DMZQU90	IK	KQKVGJJOJHCKQA-UHFFFAOYSA-N
DMZQU90	IU	2-amino-4-(1,3-benzodioxol-5-yl)-6-(2-hydroxyethylsulfanyl)pyridine-3,5-dicarbonitrile
DMZQU90	DE	Discovery agent

DMG4YWM	ID	DMG4YWM
DMG4YWM	DN	LUF-5956
DMG4YWM	HS	Investigative
DMG4YWM	SN	LUF-5956; CHEMBL204780; BDBM50186590
DMG4YWM	DT	Small molecular drug
DMG4YWM	PC	11536936
DMG4YWM	MW	314.4
DMG4YWM	FM	C20H18N4
DMG4YWM	IC	InChI=1S/C20H18N4/c1-13(2)18-22-17-16(14-9-5-3-6-10-14)21-19(24-20(17)23-18)15-11-7-4-8-12-15/h3-13H,1-2H3,(H,21,22,23,24)
DMG4YWM	CS	CC(C)C1=NC2=NC(=NC(=C2N1)C3=CC=CC=C3)C4=CC=CC=C4
DMG4YWM	IK	WOKKQPCDRVUEPM-UHFFFAOYSA-N
DMG4YWM	IU	2,6-diphenyl-8-propan-2-yl-7H-purine
DMG4YWM	DE	Discovery agent

DMJFMH9	ID	DMJFMH9
DMJFMH9	DN	LUF-5957
DMJFMH9	HS	Investigative
DMJFMH9	SN	LUF-5957; CHEMBL207529; BDBM50186599
DMJFMH9	DT	Small molecular drug
DMJFMH9	PC	11523232
DMJFMH9	MW	354.4
DMJFMH9	FM	C23H22N4
DMJFMH9	IC	InChI=1S/C23H22N4/c1-4-10-16(11-5-1)19-20-23(26-21(24-19)17-12-6-2-7-13-17)27-22(25-20)18-14-8-3-9-15-18/h1-2,4-7,10-13,18H,3,8-9,14-15H2,(H,24,25,26,27)
DMJFMH9	CS	C1CCC(CC1)C2=NC3=NC(=NC(=C3N2)C4=CC=CC=C4)C5=CC=CC=C5
DMJFMH9	IK	IGJKVZBNIOTBGI-UHFFFAOYSA-N
DMJFMH9	IU	8-cyclohexyl-2,6-diphenyl-7H-purine
DMJFMH9	DE	Discovery agent

DMR6LIE	ID	DMR6LIE
DMR6LIE	DN	LUF-5962
DMR6LIE	HS	Investigative
DMR6LIE	SN	LUF-5962; CHEMBL207824; 8-cyclopentyl-2,6-diphenyl-7H-purine; GTPL9813; LUF5962; LUF 5962; BDBM50186588
DMR6LIE	DT	Small molecular drug
DMR6LIE	PC	11617054
DMR6LIE	MW	340.4
DMR6LIE	FM	C22H20N4
DMR6LIE	IC	InChI=1S/C22H20N4/c1-3-9-15(10-4-1)18-19-22(26-21(24-19)17-13-7-8-14-17)25-20(23-18)16-11-5-2-6-12-16/h1-6,9-12,17H,7-8,13-14H2,(H,23,24,25,26)
DMR6LIE	CS	C1CCC(C1)C2=NC3=NC(=NC(=C3N2)C4=CC=CC=C4)C5=CC=CC=C5
DMR6LIE	IK	NDJOQVVSPLVIDN-UHFFFAOYSA-N
DMR6LIE	IU	8-cyclopentyl-2,6-diphenyl-7H-purine
DMR6LIE	DE	Discovery agent

DMCTM3L	ID	DMCTM3L
DMCTM3L	DN	LUF-5978
DMCTM3L	HS	Investigative
DMCTM3L	SN	LUF-5978; CHEMBL221486; BDBM50205280
DMCTM3L	DT	Small molecular drug
DMCTM3L	PC	44418996
DMCTM3L	MW	327.4
DMCTM3L	FM	C22H21N3
DMCTM3L	IC	InChI=1S/C22H21N3/c1-15(2)13-20-24-21-18(16-9-5-3-6-10-16)14-19(23-22(21)25-20)17-11-7-4-8-12-17/h3-12,14-15H,13H2,1-2H3,(H,23,24,25)
DMCTM3L	CS	CC(C)CC1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DMCTM3L	IK	PPFWSQNEFCXMGP-UHFFFAOYSA-N
DMCTM3L	IU	2-(2-methylpropyl)-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMCTM3L	DE	Discovery agent

DMGOIF5	ID	DMGOIF5
DMGOIF5	DN	LUF-5980
DMGOIF5	HS	Investigative
DMGOIF5	SN	LUF-5980; CHEMBL221343; BDBM50205281
DMGOIF5	DT	Small molecular drug
DMGOIF5	PC	16109428
DMGOIF5	MW	313.4
DMGOIF5	FM	C21H19N3
DMGOIF5	IC	InChI=1S/C21H19N3/c1-14(2)20-23-19-17(15-9-5-3-6-10-15)13-18(22-21(19)24-20)16-11-7-4-8-12-16/h3-14H,1-2H3,(H,22,23,24)
DMGOIF5	CS	CC(C)C1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DMGOIF5	IK	REXYMDQLBZWOMA-UHFFFAOYSA-N
DMGOIF5	IU	5,7-diphenyl-2-propan-2-yl-1H-imidazo[4,5-b]pyridine
DMGOIF5	DE	Discovery agent

DMHO3XL	ID	DMHO3XL
DMHO3XL	DN	LUF-5981
DMHO3XL	HS	Investigative
DMHO3XL	SN	LUF-5981; CHEMBL219160; GTPL5607; LUF5981; LUF 5981; BDBM50205283; 2,6-diphenyl-8-cyclohexyl-1-deazapurine
DMHO3XL	DT	Small molecular drug
DMHO3XL	PC	16109435
DMHO3XL	MW	353.5
DMHO3XL	FM	C24H23N3
DMHO3XL	IC	InChI=1S/C24H23N3/c1-4-10-17(11-5-1)20-16-21(18-12-6-2-7-13-18)25-24-22(20)26-23(27-24)19-14-8-3-9-15-19/h1-2,4-7,10-13,16,19H,3,8-9,14-15H2,(H,25,26,27)
DMHO3XL	CS	C1CCC(CC1)C2=NC3=C(N2)C(=CC(=N3)C4=CC=CC=C4)C5=CC=CC=C5
DMHO3XL	IK	DXBBMCIVYYJMJC-UHFFFAOYSA-N
DMHO3XL	IU	2-cyclohexyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMHO3XL	DE	Discovery agent

DM0K75N	ID	DM0K75N
DM0K75N	DN	LUF-6258
DM0K75N	HS	Investigative
DM0K75N	SN	LUF-6258; CHEMBL1090687; BDBM50315855
DM0K75N	DT	Small molecular drug
DM0K75N	PC	46203501
DM0K75N	MW	810.8
DM0K75N	FM	C39H45Cl2N7O6S
DM0K75N	IC	InChI=1S/C39H45Cl2N7O6S/c40-27-13-8-23(18-28(27)41)33(50)31-26-14-16-47(19-30(26)55-36(31)42)15-6-4-2-1-3-5-7-17-53-25-11-9-24(10-12-25)46-37-32-38(44-21-43-37)48(22-45-32)39-35(52)34(51)29(20-49)54-39/h8-13,18,21-22,29,34-35,39,49,51-52H,1-7,14-17,19-20,42H2,(H,43,44,46)/t29-,34-,35-,39-/m1/s1
DM0K75N	CS	C1CN(CC2=C1C(=C(S2)N)C(=O)C3=CC(=C(C=C3)Cl)Cl)CCCCCCCCCOC4=CC=C(C=C4)NC5=C6C(=NC=N5)N(C=N6)[C@H]7[C@@H]([C@@H]([C@H](O7)CO)O)O
DM0K75N	IK	DERHYILBHUKLGL-VMPBLTEISA-N
DM0K75N	IU	[2-amino-6-[9-[4-[[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]phenoxy]nonyl]-5,7-dihydro-4H-thieno[2,3-c]pyridin-3-yl]-(3,4-dichlorophenyl)methanone
DM0K75N	DE	Discovery agent

DMYRCHV	ID	DMYRCHV
DMYRCHV	DN	LUFFARIELLOLIDE
DMYRCHV	HS	Investigative
DMYRCHV	SN	Luffariellolide; 111149-87-2; 3-[(3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohexen-1-yl)deca-3,7-dienyl]-2-hydroxy-2H-furan-5-one; AC1NTS09; CHEMBL451037; SCHEMBL10422020; MolPort-044-561-235; NSC622149; AKOS025294086; NSC-622149; SMP2_000178; RT-013604; C19901; J-002531; 4-((3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-enyl)deca-3,7-dienyl)-5-hydroxyfuran-2(5H)-one; 2(5H)-Furanone, 4-(4,8-dimethyl-10-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3,7-decadienyl)-5-hydroxy-, (E,E)-
DMYRCHV	DT	Small molecular drug
DMYRCHV	PC	5387248
DMYRCHV	MW	386.6
DMYRCHV	FM	C25H38O3
DMYRCHV	IC	InChI=1S/C25H38O3/c1-18(11-7-13-21-17-23(26)28-24(21)27)9-6-10-19(2)14-15-22-20(3)12-8-16-25(22,4)5/h10-11,17,24,27H,6-9,12-16H2,1-5H3/b18-11+,19-10+
DMYRCHV	CS	CC1=C(C(CCC1)(C)C)CC/C(=C/CC/C(=C/CCC2=CC(=O)OC2O)/C)/C
DMYRCHV	IK	JPWPYTMXSXYUPG-QZPYEDBESA-N
DMYRCHV	IU	3-[(3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohexen-1-yl)deca-3,7-dienyl]-2-hydroxy-2H-furan-5-one
DMYRCHV	CA	CAS 111149-87-2
DMYRCHV	DE	Discovery agent

DM4ZLUH	ID	DM4ZLUH
DM4ZLUH	DN	LUPEOL
DM4ZLUH	HS	Investigative
DM4ZLUH	SN	Fagarsterol; Lupenol; EINECS 208-889-9; NSC 90487; (3-beta)-Lup-20(29)-en-3-ol; Lup-20(29)-en-3-ol, (3beta)-; (1R,3aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-1-isopropenyl-3a,5a,5b,8,8,11a-hexamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol; Lup-20(29)-en-3-ol; Lup-20(29)-en-3-beta-ol; Lup-20(29)-en-3-ol, (3-beta)-; Lup-20(29)-en-3-ol, (3.beta.)-; AC1L2J5Q; SCHEMBL561024; Lup-20(29)-en-3beta-ol; LS-88199; AN-14996
DM4ZLUH	DT	Small molecular drug
DM4ZLUH	PC	259846
DM4ZLUH	MW	426.7
DM4ZLUH	FM	C30H50O
DM4ZLUH	IC	InChI=1S/C30H50O/c1-19(2)20-11-14-27(5)17-18-29(7)21(25(20)27)9-10-23-28(6)15-13-24(31)26(3,4)22(28)12-16-30(23,29)8/h20-25,31H,1,9-18H2,2-8H3/t20-,21+,22-,23+,24-,25+,27+,28-,29+,30+/m0/s1
DM4ZLUH	CS	CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C
DM4ZLUH	IK	MQYXUWHLBZFQQO-QGTGJCAVSA-N
DM4ZLUH	IU	(1R,3aR,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol
DM4ZLUH	CA	CAS 545-47-1
DM4ZLUH	CB	CHEBI:6570
DM4ZLUH	DE	Discovery agent

DM68RPD	ID	DM68RPD
DM68RPD	DN	L-valine
DM68RPD	HS	Investigative
DM68RPD	SN	L-valine; valine; 72-18-4; (S)-Valine; H-Val-OH; (S)-2-Amino-3-methylbutanoic acid; 2-Amino-3-methylbutyric acid; (2S)-2-amino-3-methylbutanoic acid; (S)-2-Amino-3-methylbutyric acid; L-alpha-Amino-beta-methylbutyric acid; Valinum [Latin]; Valina [Spanish]; Valine (VAN); Valine [USAN:INN]; Butanoic acid, 2-amino-3-methyl-; VALINE, L-; L(+)-alpha-Aminoisovaleric acid; (S)-alpha-Amino-beta-methylbutyric acid; Butanoic acid, 2-amino-3-methyl-, (S)-; 2-Amino-3-methylbutyric acid, (S)-; 2-Amino-3-methylbutanoic acid, (S)-; L-valin
DM68RPD	DT	Small molecular drug
DM68RPD	PC	6287
DM68RPD	MW	117.15
DM68RPD	FM	C5H11NO2
DM68RPD	IC	InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1
DM68RPD	CS	CC(C)[C@@H](C(=O)O)N
DM68RPD	IK	KZSNJWFQEVHDMF-BYPYZUCNSA-N
DM68RPD	IU	(2S)-2-amino-3-methylbutanoic acid
DM68RPD	CA	CAS 72-18-4
DM68RPD	CB	CHEBI:16414
DM68RPD	DE	Discovery agent

DMPGT80	ID	DMPGT80
DMPGT80	DN	L-Val-L-boroPro
DMPGT80	HS	Investigative
DMPGT80	DT	Small molecular drug
DMPGT80	PC	44422920
DMPGT80	MW	215.08
DMPGT80	FM	C9H20BN2O3+
DMPGT80	IC	InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/p+1/t7-,8-/m0/s1
DMPGT80	CS	B([C@@H]1CCCN1C(=O)[C@H](C(C)C)[NH3+])(O)O
DMPGT80	IK	FKCMADOPPWWGNZ-YUMQZZPRSA-O
DMPGT80	IU	[(2S)-1-[(2R)-2-boronopyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]azanium
DMPGT80	DE	Discovery agent

DMH7TNA	ID	DMH7TNA
DMH7TNA	DN	L-valyl-L-prolinamide
DMH7TNA	HS	Investigative
DMH7TNA	SN	CHEMBL375933; 76362-52-2; L-valyl-L-prolinamide; L-Prolinamide, L-valyl-; CTK2G7856; DTXSID40469490
DMH7TNA	DT	Small molecular drug
DMH7TNA	PC	11615440
DMH7TNA	MW	213.28
DMH7TNA	FM	C10H19N3O2
DMH7TNA	IC	InChI=1S/C10H19N3O2/c1-6(2)8(11)10(15)13-5-3-4-7(13)9(12)14/h6-8H,3-5,11H2,1-2H3,(H2,12,14)/t7-,8-/m0/s1
DMH7TNA	CS	CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DMH7TNA	IK	AGVCUVJROUBIKP-YUMQZZPRSA-N
DMH7TNA	IU	(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidine-2-carboxamide
DMH7TNA	CA	CAS 76362-52-2
DMH7TNA	DE	Discovery agent

DMQZ13A	ID	DMQZ13A
DMQZ13A	DN	L-valyl-L-proline benzylamide
DMQZ13A	HS	Investigative
DMQZ13A	SN	CHEMBL376375; L-valyl-L-proline benzylamide
DMQZ13A	DT	Small molecular drug
DMQZ13A	PC	11645153
DMQZ13A	MW	303.4
DMQZ13A	FM	C17H25N3O2
DMQZ13A	IC	InChI=1S/C17H25N3O2/c1-12(2)15(18)17(22)20-10-6-9-14(20)16(21)19-11-13-7-4-3-5-8-13/h3-5,7-8,12,14-15H,6,9-11,18H2,1-2H3,(H,19,21)/t14-,15-/m0/s1
DMQZ13A	CS	CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NCC2=CC=CC=C2)N
DMQZ13A	IK	LCASDNOITBVYIV-GJZGRUSLSA-N
DMQZ13A	IU	(2S)-1-[(2S)-2-amino-3-methylbutanoyl]-N-benzylpyrrolidine-2-carboxamide
DMQZ13A	DE	Discovery agent

DMX4DRV	ID	DMX4DRV
DMX4DRV	DN	L-valyl-L-proline hexylamide
DMX4DRV	HS	Investigative
DMX4DRV	SN	CHEMBL375490; L-valyl-L-proline hexylamide; SCHEMBL6245007
DMX4DRV	DT	Small molecular drug
DMX4DRV	PC	11623539
DMX4DRV	MW	297.44
DMX4DRV	FM	C16H31N3O2
DMX4DRV	IC	InChI=1S/C16H31N3O2/c1-4-5-6-7-10-18-15(20)13-9-8-11-19(13)16(21)14(17)12(2)3/h12-14H,4-11,17H2,1-3H3,(H,18,20)/t13-,14-/m0/s1
DMX4DRV	CS	CCCCCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)N
DMX4DRV	IK	BWJSLNXXZBEGLH-KBPBESRZSA-N
DMX4DRV	IU	(2S)-1-[(2S)-2-amino-3-methylbutanoyl]-N-hexylpyrrolidine-2-carboxamide
DMX4DRV	DE	Discovery agent

DMIO405	ID	DMIO405
DMIO405	DN	LVAYPWT
DMIO405	HS	Investigative
DMIO405	SN	CHEMBL395724
DMIO405	DT	Small molecular drug
DMIO405	PC	25054652
DMIO405	MW	849
DMIO405	FM	C43H60N8O10
DMIO405	IC	InChI=1S/C43H60N8O10/c1-22(2)18-30(44)38(55)49-35(23(3)4)41(58)46-24(5)37(54)48-33(19-26-13-15-28(53)16-14-26)42(59)51-17-9-12-34(51)40(57)47-32(39(56)50-36(25(6)52)43(60)61)20-27-21-45-31-11-8-7-10-29(27)31/h7-8,10-11,13-16,21-25,30,32-36,45,52-53H,9,12,17-20,44H2,1-6H3,(H,46,58)(H,47,57)(H,48,54)(H,49,55)(H,50,56)(H,60,61)/t24-,25+,30-,32-,33-,34-,35-,36-/m0/s1
DMIO405	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N)O
DMIO405	IK	KBSQBKDKTBPPIE-DTSDQQARSA-N
DMIO405	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DMIO405	DE	Discovery agent

DM78Z9D	ID	DM78Z9D
DM78Z9D	DN	LVVAPWT
DM78Z9D	HS	Investigative
DM78Z9D	SN	CHEMBL241983
DM78Z9D	DT	Small molecular drug
DM78Z9D	PC	25054913
DM78Z9D	MW	784.9
DM78Z9D	FM	C39H60N8O9
DM78Z9D	IC	InChI=1S/C39H60N8O9/c1-19(2)16-26(40)33(49)44-31(21(5)6)37(53)45-30(20(3)4)36(52)42-22(7)38(54)47-15-11-14-29(47)35(51)43-28(34(50)46-32(23(8)48)39(55)56)17-24-18-41-27-13-10-9-12-25(24)27/h9-10,12-13,18-23,26,28-32,41,48H,11,14-17,40H2,1-8H3,(H,42,52)(H,43,51)(H,44,49)(H,45,53)(H,46,50)(H,55,56)/t22-,23+,26-,28-,29-,30-,31-,32-/m0/s1
DM78Z9D	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N)O
DM78Z9D	IK	AHEGGNDTVLEUNO-YIHGEGNXSA-N
DM78Z9D	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DM78Z9D	DE	Discovery agent

DM1QPG7	ID	DM1QPG7
DM1QPG7	DN	LVVYPWT
DM1QPG7	HS	Investigative
DM1QPG7	SN	Spinorphin; 137201-62-8; LVVYPWT; Leu-val-val-tyr-pro-trp-thr; CHEMBL395493; L-Threonine, N-(N-(1-(N-(N-(N-L-leucyl-L-valyl)-L-valyl)-L-tyrosyl)-L-prolyl)-L-tryptophyl)-; (2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid; LVV-hemorphin-4; AC1MIXNC; SPINORPHIN, BOVINE
DM1QPG7	DT	Small molecular drug
DM1QPG7	PC	3081832
DM1QPG7	MW	877
DM1QPG7	FM	C45H64N8O10
DM1QPG7	IC	InChI=1S/C45H64N8O10/c1-23(2)19-31(46)39(56)50-37(25(5)6)43(60)51-36(24(3)4)42(59)49-34(20-27-14-16-29(55)17-15-27)44(61)53-18-10-13-35(53)41(58)48-33(40(57)52-38(26(7)54)45(62)63)21-28-22-47-32-12-9-8-11-30(28)32/h8-9,11-12,14-17,22-26,31,33-38,47,54-55H,10,13,18-21,46H2,1-7H3,(H,48,58)(H,49,59)(H,50,56)(H,51,60)(H,52,57)(H,62,63)/t26-,31+,33+,34+,35+,36+,37+,38+/m1/s1
DM1QPG7	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N)O
DM1QPG7	IK	BXIFNVGZIMFBQB-DYDSHOKNSA-N
DM1QPG7	IU	(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DM1QPG7	CA	CAS 137201-62-8
DM1QPG7	DE	Discovery agent

DMGSVL0	ID	DMGSVL0
DMGSVL0	DN	LXA4
DMGSVL0	HS	Investigative
DMGSVL0	SN	Lipoxin A4; lipoxin A4; 5S,6R-LipoxinA4; 89663-86-5; 5S,6R,15S-trihydroxy-7E,9E,11Z,13E-Eicosatetraenoic acid; CHEBI:6498; (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid; (7E,9E,11Z,13E)-(5S,6R,15S)-5,6,15-Trihydroxyicosa-7,9,11,13-tetraenoic acid; (5S,6R,15S)-Trihydroxy-(7E,9E,11Z,13E)-Eicosatetraenoic acid; Lipoxin A; 5,6,15-trihydroxy-7,9,11,13-eicosatetraenoic acid; 5,6,15-triHETE; 5S,6S-Lipoxin A4; AC1NQXRP; BSPBio_001378; 6R-LXA4; Lipoxin A4, ethanol solution; GTPL1034; BML1-E11; CHEMBL392438;  5,6,15-triHETE ; [3H]LXA4
DMGSVL0	DT	Small molecular drug
DMGSVL0	PC	5280914
DMGSVL0	MW	352.5
DMGSVL0	FM	C20H32O5
DMGSVL0	IC	InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18+,19-/m0/s1
DMGSVL0	CS	CCCCC[C@@H](/C=C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)O)O
DMGSVL0	IK	IXAQOQZEOGMIQS-SSQFXEBMSA-N
DMGSVL0	IU	(5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid
DMGSVL0	CA	CAS 89663-86-5
DMGSVL0	CB	CHEBI:6498
DMGSVL0	DE	Discovery agent

DM0LKPE	ID	DM0LKPE
DM0LKPE	DN	LXT-101
DM0LKPE	HS	Investigative
DM0LKPE	SN	DepoLXT-101; GnRH antagonist (sustained release, prostate cancer), Beijing Institute of Pharmacology and Toxicology
DM0LKPE	CP	Beijing Institute of Pharmacology and Toxicology
DM0LKPE	PC	46174261
DM0LKPE	MW	1414.1
DM0LKPE	FM	C70H93ClN18O12
DM0LKPE	IC	InChI=1S/C70H93ClN18O12/c1-40(2)32-52(61(94)83-51(20-12-30-79-70(75)76)68(101)89-31-13-21-58(89)67(100)80-41(3)59(72)92)84-64(97)56(37-46-16-10-28-77-38-46)85-60(93)50(19-11-29-78-69(73)74)82-66(99)57(39-90)88-65(98)54(34-43-14-6-5-7-15-43)87-63(96)55(35-44-23-26-49(71)27-24-44)86-62(95)53(81-42(4)91)36-45-22-25-47-17-8-9-18-48(47)33-45/h5-10,14-18,22-28,33,38,40-41,50-58,90H,11-13,19-21,29-32,34-37,39H2,1-4H3,(H2,72,92)(H,80,100)(H,81,91)(H,82,99)(H,83,94)(H,84,97)(H,85,93)(H,86,95)(H,87,96)(H,88,98)(H4,73,74,78)(H4,75,76,79)/t41-,50+,51+,52+,53-,54-,55-,56-,57+,58+/m1/s1
DM0LKPE	CS	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM0LKPE	IK	CRMRBNHNJMIODJ-OIIKBFRESA-N
DM0LKPE	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM0LKPE	DE	Prostate cancer

DM9IU21	ID	DM9IU21
DM9IU21	DN	LY 165,163
DM9IU21	HS	Investigative
DM9IU21	SN	PAPP; LY-165163
DM9IU21	DT	Small molecular drug
DM9IU21	PC	121930
DM9IU21	MW	349.4
DM9IU21	FM	C19H22F3N3
DM9IU21	IC	InChI=1S/C19H22F3N3/c20-19(21,22)16-2-1-3-18(14-16)25-12-10-24(11-13-25)9-8-15-4-6-17(23)7-5-15/h1-7,14H,8-13,23H2
DM9IU21	CS	C1CN(CCN1CCC2=CC=C(C=C2)N)C3=CC=CC(=C3)C(F)(F)F
DM9IU21	IK	GAAKALASJNGQKD-UHFFFAOYSA-N
DM9IU21	IU	4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]aniline
DM9IU21	CA	CAS 1814-64-8
DM9IU21	CB	CHEBI:92250
DM9IU21	DE	Discovery agent

DMNB82L	ID	DMNB82L
DMNB82L	DN	LY063518
DMNB82L	HS	Investigative
DMNB82L	SN	LY 063518; LY-063518
DMNB82L	DT	Small molecular drug
DMNB82L	PC	56947076
DMNB82L	MW	278.76
DMNB82L	FM	C12H11ClN4S
DMNB82L	IC	InChI=1S/C12H11ClN4S/c13-10-7-6-9(18-10)11(16-17-12(14)15)8-4-2-1-3-5-8/h1-7H,(H4,14,15,17)/b16-11+
DMNB82L	CS	C1=CC=C(C=C1)/C(=N\\N=C(N)N)/C2=CC=C(S2)Cl
DMNB82L	IK	LXZSGGMOFNDLPW-LFIBNONCSA-N
DMNB82L	IU	2-[(E)-[(5-chlorothiophen-2-yl)-phenylmethylidene]amino]guanidine
DMNB82L	DE	Discovery agent

DMYNCQR	ID	DMYNCQR
DMYNCQR	DN	LY108742
DMYNCQR	HS	Investigative
DMYNCQR	SN	LY-108742; LY 108742
DMYNCQR	DT	Small molecular drug
DMYNCQR	PC	13878027
DMYNCQR	MW	356.5
DMYNCQR	FM	C21H28N2O3
DMYNCQR	IC	InChI=1S/C21H28N2O3/c1-12(24)13(2)26-21(25)15-8-17-16-6-5-7-18-20(16)14(10-22(18)3)9-19(17)23(4)11-15/h5-7,10,12-13,15,17,19,24H,8-9,11H2,1-4H3
DMYNCQR	CS	CC(C(C)OC(=O)C1CC2C(CC3=CN(C4=CC=CC2=C34)C)N(C1)C)O
DMYNCQR	IK	YLCYDARNSJPGCV-UHFFFAOYSA-N
DMYNCQR	IU	3-hydroxybutan-2-yl 4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxylate
DMYNCQR	DE	Discovery agent

DMT0JXC	ID	DMT0JXC
DMT0JXC	DN	LY134046
DMT0JXC	HS	Investigative
DMT0JXC	SN	LY 134046; LY-134046
DMT0JXC	DT	Small molecular drug
DMT0JXC	PC	121938
DMT0JXC	MW	216.1
DMT0JXC	FM	C10H11Cl2N
DMT0JXC	IC	InChI=1S/C10H11Cl2N/c11-9-4-3-7-2-1-5-13-6-8(7)10(9)12/h3-4,13H,1-2,5-6H2
DMT0JXC	CS	C1CC2=C(CNC1)C(=C(C=C2)Cl)Cl
DMT0JXC	IK	IADAQXMUWITWNG-UHFFFAOYSA-N
DMT0JXC	IU	8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine
DMT0JXC	CA	CAS 71274-97-0
DMT0JXC	DE	Discovery agent

DMI01YM	ID	DMI01YM
DMI01YM	DN	LY178002
DMI01YM	HS	Investigative
DMI01YM	SN	LY-178002; 107889-32-7; LY 178002; AC1O5R3B; SCHEMBL3263474; 5-(3,5-Bis(tert-butyl)-4-hydroxyphenyl)methylene-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-
DMI01YM	DT	Small molecular drug
DMI01YM	PC	6439155
DMI01YM	MW	319.5
DMI01YM	FM	C18H25NO2S
DMI01YM	IC	InChI=1S/C18H25NO2S/c1-17(2,3)12-7-11(9-14-16(21)19-10-22-14)8-13(15(12)20)18(4,5)6/h7-9,20H,10H2,1-6H3,(H,19,21)/b14-9-
DMI01YM	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)NCS2
DMI01YM	IK	BUDGLLLMROWLOB-ZROIWOOFSA-N
DMI01YM	IU	(5Z)-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazolidin-4-one
DMI01YM	CA	CAS 107889-32-7
DMI01YM	DE	Discovery agent

DMVHQGF	ID	DMVHQGF
DMVHQGF	DN	LY2033298
DMVHQGF	HS	Investigative
DMVHQGF	SN	LY 2033298; LY-2033298
DMVHQGF	DT	Small molecular drug
DMVHQGF	PC	11536903
DMVHQGF	MW	311.79
DMVHQGF	FM	C13H14ClN3O2S
DMVHQGF	IC	InChI=1S/C13H14ClN3O2S/c1-5-7-9(15)10(11(18)16-6-3-4-6)20-13(7)17-12(19-2)8(5)14/h6H,3-4,15H2,1-2H3,(H,16,18)
DMVHQGF	CS	CC1=C2C(=C(SC2=NC(=C1Cl)OC)C(=O)NC3CC3)N
DMVHQGF	IK	CTEGQKDJTBWFHW-UHFFFAOYSA-N
DMVHQGF	IU	3-amino-5-chloro-N-cyclopropyl-6-methoxy-4-methylthieno[2,3-b]pyridine-2-carboxamide
DMVHQGF	CA	CAS 886047-13-8
DMVHQGF	DE	Discovery agent

DMIS82X	ID	DMIS82X
DMIS82X	DN	LY2087101
DMIS82X	HS	Investigative
DMIS82X	SN	LY 2087101; LY-2087101
DMIS82X	DT	Small molecular drug
DMIS82X	PC	11964458
DMIS82X	MW	318.4
DMIS82X	FM	C15H11FN2OS2
DMIS82X	IC	InChI=1S/C15H11FN2OS2/c1-9-14(13(19)10-6-7-20-8-10)21-15(17-9)18-12-4-2-11(16)3-5-12/h2-8H,1H3,(H,17,18)
DMIS82X	CS	CC1=C(SC(=N1)NC2=CC=C(C=C2)F)C(=O)C3=CSC=C3
DMIS82X	IK	PEAMDZVDNYENPN-UHFFFAOYSA-N
DMIS82X	IU	[2-(4-fluoroanilino)-4-methyl-1,3-thiazol-5-yl]-thiophen-3-ylmethanone
DMIS82X	CA	CAS 913186-74-0
DMIS82X	DE	Discovery agent

DMAWTG3	ID	DMAWTG3
DMAWTG3	DN	LY2109761
DMAWTG3	HS	Investigative
DMAWTG3	SN	LY-2109761; LY 2109761
DMAWTG3	DT	Small molecular drug
DMAWTG3	PC	11655119
DMAWTG3	MW	441.5
DMAWTG3	FM	C26H27N5O2
DMAWTG3	IC	InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2
DMAWTG3	CS	C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6
DMAWTG3	IK	IHLVSLOZUHKNMQ-UHFFFAOYSA-N
DMAWTG3	IU	4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine
DMAWTG3	CA	CAS 700874-71-1
DMAWTG3	DE	Discovery agent

DM4IELQ	ID	DM4IELQ
DM4IELQ	DN	LY2119620
DM4IELQ	HS	Investigative
DM4IELQ	SN	LY 2119620; LY-2119620
DM4IELQ	DT	Small molecular drug
DM4IELQ	PC	57664406
DM4IELQ	MW	437.9
DM4IELQ	FM	C19H24ClN5O3S
DM4IELQ	IC	InChI=1S/C19H24ClN5O3S/c1-10-13-15(21)16(17(27)22-11-3-4-11)29-19(13)23-18(14(10)20)28-9-12(26)25-7-5-24(2)6-8-25/h11H,3-9,21H2,1-2H3,(H,22,27)
DM4IELQ	CS	CC1=C2C(=C(SC2=NC(=C1Cl)OCC(=O)N3CCN(CC3)C)C(=O)NC4CC4)N
DM4IELQ	IK	TYTGOXSAAQWLPJ-UHFFFAOYSA-N
DM4IELQ	IU	3-amino-5-chloro-N-cyclopropyl-4-methyl-6-[2-(4-methylpiperazin-1-yl)-2-oxoethoxy]thieno[2,3-b]pyridine-2-carboxamide
DM4IELQ	DE	Discovery agent

DMKZJVA	ID	DMKZJVA
DMKZJVA	DN	LY214352
DMKZJVA	HS	Investigative
DMKZJVA	SN	8-Chloro-4-(2-chloro-4-fluorophenoxy)quinoline; 124495-31-4; Quinoline,8-chloro-4-(2-chloro-4-fluorophenoxy)-; LY214352; AC1L2WYE; ACMC-1C12P; SCHEMBL7044612; CTK4B3930; DTXSID10154407; ZXLMSTBJMZJAAH-UHFFFAOYSA-N; LY-214352; 8-chloro-4-(2-chloro-4-fluorophenoxy) quinoline
DMKZJVA	DT	Small molecular drug
DMKZJVA	PC	130197
DMKZJVA	MW	308.1
DMKZJVA	FM	C15H8Cl2FNO
DMKZJVA	IC	InChI=1S/C15H8Cl2FNO/c16-11-3-1-2-10-13(6-7-19-15(10)11)20-14-5-4-9(18)8-12(14)17/h1-8H
DMKZJVA	CS	C1=CC2=C(C=CN=C2C(=C1)Cl)OC3=C(C=C(C=C3)F)Cl
DMKZJVA	IK	ZXLMSTBJMZJAAH-UHFFFAOYSA-N
DMKZJVA	IU	8-chloro-4-(2-chloro-4-fluorophenoxy)quinoline
DMKZJVA	CA	CAS 124495-31-4
DMKZJVA	DE	Discovery agent

DM5RG7J	ID	DM5RG7J
DM5RG7J	DN	LY215840
DM5RG7J	HS	Investigative
DM5RG7J	SN	LY 215840; LY-215840; LY-215,840
DM5RG7J	DT	Small molecular drug
DM5RG7J	PC	132049
DM5RG7J	MW	395.5
DM5RG7J	FM	C24H33N3O2
DM5RG7J	IC	InChI=1S/C24H33N3O2/c1-14(2)27-13-15-11-21-18(17-6-4-8-20(27)23(15)17)10-16(12-26(21)3)24(29)25-19-7-5-9-22(19)28/h4,6,8,13-14,16,18-19,21-22,28H,5,7,9-12H2,1-3H3,(H,25,29)/t16-,18?,19+,21-,22-/m1/s1
DM5RG7J	CS	CC(C)N1C=C2C[C@@H]3C(C[C@H](CN3C)C(=O)N[C@H]4CCC[C@H]4O)C5=C2C1=CC=C5
DM5RG7J	IK	IMSDOBUYDTVEHN-LUKLFJNJSA-N
DM5RG7J	IU	(6aR,9R)-N-[(1S,2R)-2-hydroxycyclopentyl]-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
DM5RG7J	CA	CAS 137328-52-0
DM5RG7J	DE	Discovery agent

DM8SU6N	ID	DM8SU6N
DM8SU6N	DN	LY-2183240
DM8SU6N	HS	Investigative
DM8SU6N	SN	LY2183240; 874902-19-9; LY 2183240; UNII-2WBU91OKM7; 2WBU91OKM7; CHEMBL509860; LY-2183240; 5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic acid dimethylamide; LY2183240/LY-2183240; 1H-Tetrazole-1-carboxamide, 5-([1,1'-biphenyl]-4-ylmethyl)-N,N-dimethyl-; 1H-Tetrazole-1-carboxamide, 5-((1,1'-biphenyl)-4-ylmethyl)-N,N-dimethyl-; SCHEMBL2184828; CTK8E8366; CHEBI:92670; KS-00001CUG; BDBM26736; AOB2582; MolPort-023-219-146; HMS3269E15; BCP22610; ZINC13813297; MFCD08703123; 3796AH; AKOS024457108; CS-0913; BCP9000870; LP01268; NCGC00159571-01
DM8SU6N	DT	Small molecular drug
DM8SU6N	PC	11507802
DM8SU6N	MW	307.35
DM8SU6N	FM	C17H17N5O
DM8SU6N	IC	InChI=1S/C17H17N5O/c1-21(2)17(23)22-16(18-19-20-22)12-13-8-10-15(11-9-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
DM8SU6N	CS	CN(C)C(=O)N1C(=NN=N1)CC2=CC=C(C=C2)C3=CC=CC=C3
DM8SU6N	IK	GZNIYOXWFCDBBJ-UHFFFAOYSA-N
DM8SU6N	IU	N,N-dimethyl-5-[(4-phenylphenyl)methyl]tetrazole-1-carboxamide
DM8SU6N	CA	CAS 874902-19-9
DM8SU6N	CB	CHEBI:92670
DM8SU6N	DE	Discovery agent

DM5VWCI	ID	DM5VWCI
DM5VWCI	DN	Ly231514 Tetra Glu
DM5VWCI	HS	Investigative
DM5VWCI	DT	Small molecular drug
DM5VWCI	PC	135678105
DM5VWCI	MW	814.8
DM5VWCI	FM	C35H42N8O15
DM5VWCI	IC	InChI=1S/C35H42N8O15/c36-35-42-28-27(30(50)43-35)18(15-37-28)6-3-16-1-4-17(5-2-16)29(49)41-22(34(57)58)9-13-25(46)39-20(32(53)54)7-11-23(44)38-19(31(51)52)8-12-24(45)40-21(33(55)56)10-14-26(47)48/h1-2,4-5,15,19-22H,3,6-14H2,(H,38,44)(H,39,46)(H,40,45)(H,41,49)(H,47,48)(H,51,52)(H,53,54)(H,55,56)(H,57,58)(H4,36,37,42,43,50)/t19-,20-,21?,22-/m0/s1
DM5VWCI	CS	C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O
DM5VWCI	IK	DICHBVJYDUDAIQ-QEGIFBSNSA-N
DM5VWCI	IU	2-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid
DM5VWCI	DE	Discovery agent

DMPV6N9	ID	DMPV6N9
DMPV6N9	DN	LY-2318912
DMPV6N9	HS	Investigative
DMPV6N9	SN	CHEMBL486037; LY-2318912; BDBM50242639
DMPV6N9	DT	Small molecular drug
DMPV6N9	PC	44560315
DMPV6N9	MW	441.19
DMPV6N9	FM	C12H12IN9O2
DMPV6N9	IC	InChI=1S/C12H12IN9O2/c1-21(2)12(24)22-10(17-19-20-22)6-15-11(23)7-3-4-9(16-18-14)8(13)5-7/h3-5H,6H2,1-2H3,(H,15,23)
DMPV6N9	CS	CN(C)C(=O)N1C(=NN=N1)CNC(=O)C2=CC(=C(C=C2)N=[N+]=[N-])I
DMPV6N9	IK	QJNXEOBTVAWQME-UHFFFAOYSA-N
DMPV6N9	IU	5-[[(4-azido-3-iodobenzoyl)amino]methyl]-N,N-dimethyltetrazole-1-carboxamide
DMPV6N9	DE	Discovery agent

DMC82DA	ID	DMC82DA
DMC82DA	DN	LY233053
DMC82DA	HS	Investigative
DMC82DA	SN	LY-233053; LY 233053
DMC82DA	DT	Small molecular drug
DMC82DA	PC	3035974
DMC82DA	MW	211.22
DMC82DA	FM	C8H13N5O2
DMC82DA	IC	InChI=1S/C8H13N5O2/c14-8(15)6-3-5(1-2-9-6)4-7-10-12-13-11-7/h5-6,9H,1-4H2,(H,14,15)(H,10,11,12,13)/t5-,6+/m0/s1
DMC82DA	CS	C1CN[C@H](C[C@H]1CC2=NNN=N2)C(=O)O
DMC82DA	IK	FAAVTENFCLADRE-NTSWFWBYSA-N
DMC82DA	IU	(2R,4S)-4-(2H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid
DMC82DA	CA	CAS 125546-04-5
DMC82DA	DE	Discovery agent

DMBFLOJ	ID	DMBFLOJ
DMBFLOJ	DN	LY2365109
DMBFLOJ	HS	Investigative
DMBFLOJ	SN	LY-2365109; LY 2365109
DMBFLOJ	DT	Small molecular drug
DMBFLOJ	PC	11552757
DMBFLOJ	MW	385.5
DMBFLOJ	FM	C22H27NO5
DMBFLOJ	IC	InChI=1S/C22H27NO5/c1-22(2,3)17-11-15(16-6-8-19-20(12-16)28-14-27-19)5-7-18(17)26-10-9-23(4)13-21(24)25/h5-8,11-12H,9-10,13-14H2,1-4H3,(H,24,25)
DMBFLOJ	CS	CC(C)(C)C1=C(C=CC(=C1)C2=CC3=C(C=C2)OCO3)OCCN(C)CC(=O)O
DMBFLOJ	IK	FKPLJWGRBCQLTL-UHFFFAOYSA-N
DMBFLOJ	IU	2-[2-[4-(1,3-benzodioxol-5-yl)-2-tert-butylphenoxy]ethyl-methylamino]acetic acid
DMBFLOJ	DE	Discovery agent

DM1KCHN	ID	DM1KCHN
DM1KCHN	DN	LY256548
DM1KCHN	HS	Investigative
DM1KCHN	SN	LY-256548; 107889-31-6; LY 25648; SCHEMBL8532777; AC1O5R38; AKOS030552230; 5-(3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene-N-methyl-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-methyl-
DM1KCHN	DT	Small molecular drug
DM1KCHN	PC	6439154
DM1KCHN	MW	333.5
DM1KCHN	FM	C19H27NO2S
DM1KCHN	IC	InChI=1S/C19H27NO2S/c1-18(2,3)13-8-12(9-14(16(13)21)19(4,5)6)10-15-17(22)20(7)11-23-15/h8-10,21H,11H2,1-7H3/b15-10-
DM1KCHN	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)N(CS2)C
DM1KCHN	IK	IXCMEASJCGKKQS-GDNBJRDFSA-N
DM1KCHN	IU	(5Z)-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-3-methyl-1,3-thiazolidin-4-one
DM1KCHN	CA	CAS 107889-31-6
DM1KCHN	DE	Discovery agent

DMX5H3T	ID	DMX5H3T
DMX5H3T	DN	LY-266111
DMX5H3T	HS	Investigative
DMX5H3T	SN	CHEMBL29166; LY-266111; SCHEMBL7796296; KTBSRSVHEOTHLD-UKRRQHHQSA-N; BDBM50044879; (4aR,10bR)-8-Chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydro-2H-benzo[f]quinolin-3-one; 8-Chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydro-2H-benzo[f]quinolin-3-one; (R)(+)-trans-4-methyl-8-chloro-10b-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one
DMX5H3T	DT	Small molecular drug
DMX5H3T	PC	10106832
DMX5H3T	MW	263.76
DMX5H3T	FM	C15H18ClNO
DMX5H3T	IC	InChI=1S/C15H18ClNO/c1-15-8-7-14(18)17(2)13(15)6-3-10-9-11(16)4-5-12(10)15/h4-5,9,13H,3,6-8H2,1-2H3/t13-,15-/m1/s1
DMX5H3T	CS	C[C@]12CCC(=O)N([C@@H]1CCC3=C2C=CC(=C3)Cl)C
DMX5H3T	IK	KTBSRSVHEOTHLD-UKRRQHHQSA-N
DMX5H3T	IU	(4aR,10bR)-8-chloro-4,10b-dimethyl-2,4a,5,6-tetrahydro-1H-benzo[f]quinolin-3-one
DMX5H3T	DE	Discovery agent

DMHC853	ID	DMHC853
DMHC853	DN	LY266500
DMHC853	HS	Investigative
DMHC853	SN	CHEMBL510900; AC1LDAWE; 2-(3-Chloro-4-fluorophenyl)-3(2H)-isothiazolone; SCHEMBL4700504; OOOJWRSQJXGEDS-UHFFFAOYSA-N; MolPort-002-906-771; ZINC12367067; BDBM50247868; AKOS022310026; MCULE-1464379671; 2-(3-chloro-4-fluorophenyl)-1,2-thiazol-3-one; 2-(3-Chloro-4-fluorophenyl)isothiazole-3(2H)-one
DMHC853	DT	Small molecular drug
DMHC853	PC	615184
DMHC853	MW	229.66
DMHC853	FM	C9H5ClFNOS
DMHC853	IC	InChI=1S/C9H5ClFNOS/c10-7-5-6(1-2-8(7)11)12-9(13)3-4-14-12/h1-5H
DMHC853	CS	C1=CC(=C(C=C1N2C(=O)C=CS2)Cl)F
DMHC853	IK	OOOJWRSQJXGEDS-UHFFFAOYSA-N
DMHC853	IU	2-(3-chloro-4-fluorophenyl)-1,2-thiazol-3-one
DMHC853	DE	Discovery agent

DMBSFDE	ID	DMBSFDE
DMBSFDE	DN	LY-282210
DMBSFDE	HS	Investigative
DMBSFDE	SN	CHEMBL88337; LY-282210; BDBM50029482; L009647; 6-[3-(4-Acetyl-2-ethyl-5-hydroxy-phenoxy)-propoxy]-5-(2-carboxy-ethyl)-9-oxo-9H-xanthene-2-carboxylic acid
DMBSFDE	DT	Small molecular drug
DMBSFDE	PC	9893718
DMBSFDE	MW	548.5
DMBSFDE	FM	C30H28O10
DMBSFDE	IC	InChI=1S/C30H28O10/c1-3-17-13-21(16(2)31)23(32)15-26(17)39-12-4-11-38-24-9-6-20-28(35)22-14-18(30(36)37)5-8-25(22)40-29(20)19(24)7-10-27(33)34/h5-6,8-9,13-15,32H,3-4,7,10-12H2,1-2H3,(H,33,34)(H,36,37)
DMBSFDE	CS	CCC1=CC(=C(C=C1OCCCOC2=C(C3=C(C=C2)C(=O)C4=C(O3)C=CC(=C4)C(=O)O)CCC(=O)O)O)C(=O)C
DMBSFDE	IK	HGMXXGVRUCAMMK-UHFFFAOYSA-N
DMBSFDE	IU	6-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-5-(2-carboxyethyl)-9-oxoxanthene-2-carboxylic acid
DMBSFDE	DE	Discovery agent

DML36ZE	ID	DML36ZE
DML36ZE	DN	LY-292223
DML36ZE	HS	Investigative
DML36ZE	SN	2-(4-Morpholinyl)-4H-1-benzopyran-4-one; 2-morpholinochromone; LY-292223; CHEMBL367315; 2-morpholino-4H-chromen-4-one; 130735-56-7; U67154; AC1L2YUR; U-67154; SCHEMBL3361567; 2-morpholin-4-ylchromen-4-one; DTXSID30156701; 2-Morpholin-4-yl-chromen-4-one; QNFWERYZJLBANZ-UHFFFAOYSA-N; BDBM50098118; 2-(4-Morpholinyl)-4H-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-
DML36ZE	DT	Small molecular drug
DML36ZE	PC	131255
DML36ZE	MW	231.25
DML36ZE	FM	C13H13NO3
DML36ZE	IC	InChI=1S/C13H13NO3/c15-11-9-13(14-5-7-16-8-6-14)17-12-4-2-1-3-10(11)12/h1-4,9H,5-8H2
DML36ZE	CS	C1COCCN1C2=CC(=O)C3=CC=CC=C3O2
DML36ZE	IK	QNFWERYZJLBANZ-UHFFFAOYSA-N
DML36ZE	IU	2-morpholin-4-ylchromen-4-one
DML36ZE	CA	CAS 130735-56-7
DML36ZE	DE	Discovery agent

DM2HQ9O	ID	DM2HQ9O
DM2HQ9O	DN	LY301875
DM2HQ9O	HS	Investigative
DM2HQ9O	SN	LY-301875; LY 301875
DM2HQ9O	DT	Small molecular drug
DM2HQ9O	PC	73755246
DM2HQ9O	MW	642.7
DM2HQ9O	FM	C30H34N4O10S
DM2HQ9O	IC	InChI=1S/C30H34N4O10S/c1-2-3-4-5-9-23(33-17-26(31-18-33)32-27(35)22-8-6-7-10-25(22)45(41,42)43)28(36)34-16-21(15-24(34)30(39)40)44-20-13-11-19(12-14-20)29(37)38/h6-8,10-14,17-18,21,23-24H,2-5,9,15-16H2,1H3,(H,32,35)(H,37,38)(H,39,40)(H,41,42,43)/t21-,23-,24-/m0/s1
DM2HQ9O	CS	CCCCCC[C@@H](C(=O)N1C[C@H](C[C@H]1C(=O)O)OC2=CC=C(C=C2)C(=O)O)N3C=C(N=C3)NC(=O)C4=CC=CC=C4S(=O)(=O)O
DM2HQ9O	IK	HHFYOGBTLFTWQX-XWGVYQGASA-N
DM2HQ9O	IU	(2S,4S)-4-(4-carboxyphenoxy)-1-[(2S)-2-[4-[(2-sulfobenzoyl)amino]imidazol-1-yl]octanoyl]pyrrolidine-2-carboxylic acid
DM2HQ9O	DE	Discovery agent

DMY9WTE	ID	DMY9WTE
DMY9WTE	DN	LY303336
DMY9WTE	HS	Investigative
DMY9WTE	SN	LY 303336; LY-303336
DMY9WTE	DT	Small molecular drug
DMY9WTE	PC	10416728
DMY9WTE	MW	642.7
DMY9WTE	FM	C30H34N4O10S
DMY9WTE	IC	InChI=1S/C30H34N4O10S/c1-2-3-4-5-9-23(33-17-26(31-18-33)32-27(35)22-8-6-7-10-25(22)45(41,42)43)28(36)34-16-21(15-24(34)30(39)40)44-20-13-11-19(12-14-20)29(37)38/h6-8,10-14,17-18,21,23-24H,2-5,9,15-16H2,1H3,(H,32,35)(H,37,38)(H,39,40)(H,41,42,43)/t21-,23+,24-/m0/s1
DMY9WTE	CS	CCCCCC[C@H](C(=O)N1C[C@H](C[C@H]1C(=O)O)OC2=CC=C(C=C2)C(=O)O)N3C=C(N=C3)NC(=O)C4=CC=CC=C4S(=O)(=O)O
DMY9WTE	IK	HHFYOGBTLFTWQX-QTJGBDASSA-N
DMY9WTE	IU	(2S,4S)-4-(4-carboxyphenoxy)-1-[(2R)-2-[4-[(2-sulfobenzoyl)amino]imidazol-1-yl]octanoyl]pyrrolidine-2-carboxylic acid
DMY9WTE	DE	Discovery agent

DMWAHYX	ID	DMWAHYX
DMWAHYX	DN	LY314228
DMWAHYX	HS	Investigative
DMWAHYX	SN	LY 314228; LY-314228
DMWAHYX	DT	Small molecular drug
DMWAHYX	PC	56947077
DMWAHYX	MW	368.4
DMWAHYX	FM	C20H24N4O3
DMWAHYX	IC	InChI=1S/C20H24N4O3/c1-3-4-18-15(7-10-17(13(2)25)19(18)26)12-27-16-8-5-14(6-9-16)11-23-24-20(21)22/h5-11,26H,3-4,12H2,1-2H3,(H4,21,22,24)/b23-11-
DMWAHYX	CS	CCCC1=C(C=CC(=C1O)C(=O)C)COC2=CC=C(C=C2)/C=N\\N=C(N)N
DMWAHYX	IK	TUXHQPAMNGTVLT-KSEXSDGBSA-N
DMWAHYX	IU	2-[(Z)-[4-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]phenyl]methylideneamino]guanidine
DMWAHYX	DE	Discovery agent

DMD2J97	ID	DMD2J97
DMD2J97	DN	LY-314657
DMD2J97	HS	Investigative
DMD2J97	DE	Discovery agent

DMK3Y5U	ID	DMK3Y5U
DMK3Y5U	DN	LY320135
DMK3Y5U	HS	Investigative
DMK3Y5U	SN	LY 320135; LY-320135
DMK3Y5U	DT	Small molecular drug
DMK3Y5U	PC	5311257
DMK3Y5U	MW	383.4
DMK3Y5U	FM	C24H17NO4
DMK3Y5U	IC	InChI=1S/C24H17NO4/c1-27-18-9-7-17(8-10-18)24-22(20-12-11-19(28-2)13-21(20)29-24)23(26)16-5-3-15(14-25)4-6-16/h3-13H,1-2H3
DMK3Y5U	CS	COC1=CC=C(C=C1)C2=C(C3=C(O2)C=C(C=C3)OC)C(=O)C4=CC=C(C=C4)C#N
DMK3Y5U	IK	RYNSGDFWBJWWSZ-UHFFFAOYSA-N
DMK3Y5U	IU	4-[6-methoxy-2-(4-methoxyphenyl)-1-benzofuran-3-carbonyl]benzonitrile
DMK3Y5U	CA	CAS 176977-56-3
DMK3Y5U	CB	CHEBI:93387
DMK3Y5U	DE	Discovery agent

DM3DOI7	ID	DM3DOI7
DM3DOI7	DN	LY320954
DM3DOI7	HS	Investigative
DM3DOI7	SN	PDSP2_001613; PDSP1_001629; LY-320954
DM3DOI7	DT	Small molecular drug
DM3DOI7	PC	56947078
DM3DOI7	MW	382.5
DM3DOI7	FM	C21H26N4O3
DM3DOI7	IC	InChI=1S/C21H26N4O3/c1-3-5-17-15(8-11-18(20(17)27)19(26)4-2)13-28-16-9-6-14(7-10-16)12-24-25-21(22)23/h6-12,27H,3-5,13H2,1-2H3,(H4,22,23,25)/b24-12-
DM3DOI7	CS	CCCC1=C(C=CC(=C1O)C(=O)CC)COC2=CC=C(C=C2)/C=N\\N=C(N)N
DM3DOI7	IK	TUJFUBGJRSXFHG-MSXFZWOLSA-N
DM3DOI7	IU	2-[(Z)-[4-[(3-hydroxy-4-propanoyl-2-propylphenyl)methoxy]phenyl]methylideneamino]guanidine
DM3DOI7	DE	Discovery agent

DMN53M4	ID	DMN53M4
DMN53M4	DN	LY-326449
DMN53M4	HS	Investigative
DMN53M4	SN	LY-326449; CHEMBL292495; BDBM50052039; 3,4-[[(S)-3-Oxa-4-(hydroxymethyl)hexane-1,6-diyl]bis(1H-indole-1,3-diyl)]-3-pyrroline-2,5-dione
DMN53M4	DT	Small molecular drug
DMN53M4	PC	10455969
DMN53M4	MW	441.5
DMN53M4	FM	C26H23N3O4
DMN53M4	IC	InChI=1S/C26H23N3O4/c30-15-16-9-10-28-13-19(17-5-1-3-7-21(17)28)23-24(26(32)27-25(23)31)20-14-29(11-12-33-16)22-8-4-2-6-18(20)22/h1-8,13-14,16,30H,9-12,15H2,(H,27,31,32)/t16-/m0/s1
DMN53M4	CS	C1CN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO[C@@H]1CO)C6=CC=CC=C65)C(=O)NC4=O
DMN53M4	IK	BGVKOUSMQGMSDY-INIZCTEOSA-N
DMN53M4	IU	(18S)-18-(hydroxymethyl)-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione
DMN53M4	DE	Discovery agent

DMFHT3U	ID	DMFHT3U
DMFHT3U	DN	LY334362
DMFHT3U	HS	Investigative
DMFHT3U	SN	LY-334362; LY 334362
DMFHT3U	DT	Small molecular drug
DMFHT3U	PC	56947079
DMFHT3U	MW	372.4
DMFHT3U	FM	C22H20N4O2
DMFHT3U	IC	InChI=1S/C22H20N4O2/c23-22(24)26-25-14-17-5-4-8-20(13-17)28-15-16-9-11-19(12-10-16)21(27)18-6-2-1-3-7-18/h1-14H,15H2,(H4,23,24,26)/b25-14-
DMFHT3U	CS	C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)COC3=CC=CC(=C3)/C=N\\N=C(N)N
DMFHT3U	IK	ROCDIHAUKUGXMY-QFEZKATASA-N
DMFHT3U	IU	2-[(Z)-[3-[(4-benzoylphenyl)methoxy]phenyl]methylideneamino]guanidine
DMFHT3U	DE	Discovery agent

DMUXFZQ	ID	DMUXFZQ
DMUXFZQ	DN	LY-3390334
DMUXFZQ	HS	Investigative
DMUXFZQ	SN	206444-72-6; LY-339840; LY-367366; LY-393053
DMUXFZQ	DE	Discovery agent

DM8S7AO	ID	DM8S7AO
DM8S7AO	DN	LY339434
DM8S7AO	HS	Investigative
DM8S7AO	SN	LY-339434; LY 339434
DM8S7AO	DT	Small molecular drug
DM8S7AO	PC	69636646
DM8S7AO	MW	313.3
DM8S7AO	FM	C18H19NO4
DM8S7AO	IC	InChI=1S/C18H19NO4/c19-16(18(22)23)11-15(17(20)21)7-3-4-12-8-9-13-5-1-2-6-14(13)10-12/h1-6,8-10,15-16H,7,11,19H2,(H,20,21)(H,22,23)/b4-3+
DM8S7AO	CS	C1=CC=C2C=C(C=CC2=C1)/C=C/CC(CC(C(=O)O)N)C(=O)O
DM8S7AO	IK	KNAYYBRIBNEIAL-ONEGZZNKSA-N
DM8S7AO	IU	2-amino-4-[(E)-3-naphthalen-2-ylprop-2-enyl]pentanedioic acid
DM8S7AO	DE	Discovery agent

DMS7KW8	ID	DMS7KW8
DMS7KW8	DN	LY341770
DMS7KW8	HS	Investigative
DMS7KW8	DT	Small molecular drug
DMS7KW8	PC	135488887
DMS7KW8	MW	451.4
DMS7KW8	FM	C20H21N9O4
DMS7KW8	IC	InChI=1S/C20H21N9O4/c21-20-24-16-15(18(31)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(30)23-13(19(32)33)7-8-14-26-28-29-27-14/h1-2,4-5,9,13H,3,6-8H2,(H,23,30)(H,32,33)(H,26,27,28,29)(H4,21,22,24,25,31)/t13-/m0/s1
DMS7KW8	CS	C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC4=NNN=N4)C(=O)O
DMS7KW8	IK	MXAFDBCLWLMXSI-ZDUSSCGKSA-N
DMS7KW8	IU	(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid
DMS7KW8	DE	Discovery agent

DM8LSQP	ID	DM8LSQP
DM8LSQP	DN	LY344864
DM8LSQP	HS	Investigative
DM8LSQP	SN	LY 344864 racemate; LY344864; LY-344864; GTPL21; LY344864 racemate HCl; SCHEMBL7665368; CHEMBL3186179; BDBM85195; GKWHICIUSVVNGX-UHFFFAOYSA-N; BCP23551; PDSP2_001556; PDSP1_001572; HY-13788C; NSC_5311097; CAS_5311097; NCGC00167736-01; 186543-64-6; CS-0022633; L000365; N-(6-dimethylamino-6,7,8,9-tetrahydro-5H-carbazol-3-yl)-4-fluorobenzamide
DM8LSQP	DT	Small molecular drug
DM8LSQP	PC	18971832
DM8LSQP	MW	351.4
DM8LSQP	FM	C21H22FN3O
DM8LSQP	IC	InChI=1S/C21H22FN3O/c1-25(2)16-8-10-20-18(12-16)17-11-15(7-9-19(17)24-20)23-21(26)13-3-5-14(22)6-4-13/h3-7,9,11,16,24H,8,10,12H2,1-2H3,(H,23,26)
DM8LSQP	CS	CN(C)C1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F
DM8LSQP	IK	GKWHICIUSVVNGX-UHFFFAOYSA-N
DM8LSQP	IU	N-[6-(dimethylamino)-6,7,8,9-tetrahydro-5H-carbazol-3-yl]-4-fluorobenzamide
DM8LSQP	DE	Discovery agent

DMME40U	ID	DMME40U
DMME40U	DN	LY-379268
DMME40U	HS	Investigative
DMME40U	SN	LY 379268; LY-379268; CHEMBL275079; LY379268; 191471-52-0; SCHEMBL2454646; GTPL1394; (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid; CTK8F0567; DTXSID90436637; ZINC3952369; BDBM50074749; FCH888149; AKOS006306876; API0003234; NCGC00159572-01; LS-98795; RT-013615; LY-379,268; B7061; J-012378; 4-Amino-2-oxa-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid; (1S,2R,5R,6R)-2-amino-4-oxabicyclo[3.1.0]hexane-2,6-dicarboxylic acid; (1R,4R,5S,6R)-4-Amino-2-oxa-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid
DMME40U	DT	Small molecular drug
DMME40U	PC	10197984
DMME40U	MW	187.15
DMME40U	FM	C7H9NO5
DMME40U	IC	InChI=1S/C7H9NO5/c8-7(6(11)12)1-13-4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1
DMME40U	CS	C1[C@]([C@@H]2[C@H]([C@@H]2O1)C(=O)O)(C(=O)O)N
DMME40U	IK	YASVRZWVUGJELU-MDASVERJSA-N
DMME40U	IU	(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
DMME40U	CA	CAS 191471-52-0
DMME40U	DE	Discovery agent

DMWKYFO	ID	DMWKYFO
DMWKYFO	DN	LY382884
DMWKYFO	HS	Investigative
DMWKYFO	SN	LY-382884; LY 382884
DMWKYFO	DT	Small molecular drug
DMWKYFO	PC	656723
DMWKYFO	MW	317.4
DMWKYFO	FM	C18H23NO4
DMWKYFO	IC	InChI=1S/C18H23NO4/c20-17(21)13-4-1-11(2-5-13)7-12-3-6-14-10-19-16(18(22)23)9-15(14)8-12/h1-2,4-5,12,14-16,19H,3,6-10H2,(H,20,21)(H,22,23)/t12-,14+,15-,16+/m1/s1
DMWKYFO	CS	C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CC3=CC=C(C=C3)C(=O)O)C(=O)O
DMWKYFO	IK	YVMADKYPKNLVGU-BVUBDWEXSA-N
DMWKYFO	IU	(3S,4aR,6S,8aR)-6-[(4-carboxyphenyl)methyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
DMWKYFO	CA	CAS 211566-75-5
DMWKYFO	CB	CHEBI:34808
DMWKYFO	DE	Discovery agent

DM6Y2XG	ID	DM6Y2XG
DM6Y2XG	DN	LY-389795
DM6Y2XG	HS	Investigative
DM6Y2XG	SN	CHEMBL88999; LY389795; LY-389795; GTPL3349; BDBM50089897; LY 389795; (4S,6S)-4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid; 4-Amino-2-thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid(LY389795)
DM6Y2XG	DT	Small molecular drug
DM6Y2XG	PC	10058694
DM6Y2XG	MW	203.22
DM6Y2XG	FM	C7H9NO4S
DM6Y2XG	IC	InChI=1S/C7H9NO4S/c8-7(6(11)12)1-13-4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3?,4?,7+/m1/s1
DM6Y2XG	CS	C1[C@](C2[C@H](C2S1)C(=O)O)(C(=O)O)N
DM6Y2XG	IK	QBHIOYZCUZBIEN-RSWQVWFLSA-N
DM6Y2XG	IU	(4S,6S)-4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
DM6Y2XG	CA	CAS 222529-89-7
DM6Y2XG	DE	Discovery agent

DM1KW0L	ID	DM1KW0L
DM1KW0L	DN	LY-392098
DM1KW0L	HS	Investigative
DM1KW0L	SN	AMPA modulators, Eli Lilly; LY-404187; LY-4516146; LY-451616; LY-451646; LY-503430; PF-4775874
DM1KW0L	CP	Eli Lilly & Co
DM1KW0L	DT	Small molecular drug
DM1KW0L	PC	9873570
DM1KW0L	MW	323.5
DM1KW0L	FM	C16H21NO2S2
DM1KW0L	IC	InChI=1S/C16H21NO2S2/c1-12(2)21(18,19)17-10-13(3)14-4-6-15(7-5-14)16-8-9-20-11-16/h4-9,11-13,17H,10H2,1-3H3
DM1KW0L	CS	CC(C)S(=O)(=O)NCC(C)C1=CC=C(C=C1)C2=CSC=C2
DM1KW0L	IK	QFAUPDBCVKBKSH-UHFFFAOYSA-N
DM1KW0L	IU	N-[2-(4-thiophen-3-ylphenyl)propyl]propane-2-sulfonamide
DM1KW0L	CA	CAS 211311-66-9
DM1KW0L	DE	Cognitive impairment

DMHQ0T2	ID	DMHQ0T2
DMHQ0T2	DN	LY433221
DMHQ0T2	HS	Investigative
DMHQ0T2	CP	Lilly
DMHQ0T2	TC	Psychiatric
DMHQ0T2	DE	Depression

DMP8OXG	ID	DMP8OXG
DMP8OXG	DN	LY433222
DMP8OXG	HS	Investigative
DMP8OXG	CP	Lilly
DMP8OXG	TC	Psychiatric
DMP8OXG	DE	Depression

DM86Y1V	ID	DM86Y1V
DM86Y1V	DN	LY456066
DM86Y1V	HS	Investigative
DM86Y1V	SN	LY-456066; LY 456066
DM86Y1V	DT	Small molecular drug
DM86Y1V	PC	9840951
DM86Y1V	MW	341.5
DM86Y1V	FM	C19H23N3OS
DM86Y1V	IC	InChI=1S/C19H23N3OS/c23-9-10-24-19-21-17-8-4-3-7-16(17)18(22-19)20-15-11-13-5-1-2-6-14(13)12-15/h1-2,5-6,15,23H,3-4,7-12H2,(H,20,21,22)
DM86Y1V	CS	C1CCC2=C(C1)C(=NC(=N2)SCCO)NC3CC4=CC=CC=C4C3
DM86Y1V	IK	VZJHTQZXSTXJNO-UHFFFAOYSA-N
DM86Y1V	IU	2-[[4-(2,3-dihydro-1H-inden-2-ylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]sulfanyl]ethanol
DM86Y1V	DE	Discovery agent

DMROFX8	ID	DMROFX8
DMROFX8	DN	LY456236
DMROFX8	HS	Investigative
DMROFX8	SN	LY-456236; LY 456236
DMROFX8	DT	Small molecular drug
DMROFX8	PC	9926999
DMROFX8	MW	281.31
DMROFX8	FM	C16H15N3O2
DMROFX8	IC	InChI=1S/C16H15N3O2/c1-20-12-5-3-11(4-6-12)19-16-14-9-13(21-2)7-8-15(14)17-10-18-16/h3-10H,1-2H3,(H,17,18,19)
DMROFX8	CS	COC1=CC=C(C=C1)NC2=NC=NC3=C2C=C(C=C3)OC
DMROFX8	IK	XPJOMFBGKIABQW-UHFFFAOYSA-N
DMROFX8	IU	6-methoxy-N-(4-methoxyphenyl)quinazolin-4-amine
DMROFX8	CB	CHEBI:93528
DMROFX8	DE	Discovery agent

DMK64AZ	ID	DMK64AZ
DMK64AZ	DN	LY-465608
DMK64AZ	HS	Investigative
DMK64AZ	SN	LY465608; LY 465608
DMK64AZ	DT	Small molecular drug
DMK64AZ	PC	9890319
DMK64AZ	MW	457.5
DMK64AZ	FM	C28H27NO5
DMK64AZ	IC	InChI=1S/C28H27NO5/c1-19-25(17-18-32-23-13-15-24(16-14-23)34-28(2,3)27(30)31)29-26(33-19)22-11-9-21(10-12-22)20-7-5-4-6-8-20/h4-16H,17-18H2,1-3H3,(H,30,31)
DMK64AZ	CS	CC1=C(N=C(O1)C2=CC=C(C=C2)C3=CC=CC=C3)CCOC4=CC=C(C=C4)OC(C)(C)C(=O)O
DMK64AZ	IK	JDJHTJNBMZSSLK-UHFFFAOYSA-N
DMK64AZ	IU	2-methyl-2-[4-[2-[5-methyl-2-(4-phenylphenyl)-1,3-oxazol-4-yl]ethoxy]phenoxy]propanoic acid
DMK64AZ	DE	Discovery agent

DM97NBO	ID	DM97NBO
DM97NBO	DN	LY466195
DM97NBO	HS	Investigative
DM97NBO	SN	LY-466195; LY 466195
DM97NBO	DT	Small molecular drug
DM97NBO	PC	9935648
DM97NBO	MW	346.37
DM97NBO	FM	C16H24F2N2O4
DM97NBO	IC	InChI=1S/C16H24F2N2O4/c17-16(18)5-13(15(23)24)20(8-16)7-9-1-2-10-6-19-12(14(21)22)4-11(10)3-9/h9-13,19H,1-8H2,(H,21,22)(H,23,24)/t9-,10-,11+,12-,13-/m0/s1
DM97NBO	CS	C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CN3CC(C[C@H]3C(=O)O)(F)F)C(=O)O
DM97NBO	IK	OXQXJYQSWZFDBB-WJTVCTBASA-N
DM97NBO	IU	(3S,4aR,6S,8aR)-6-[[(2S)-2-carboxy-4,4-difluoropyrrolidin-1-yl]methyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
DM97NBO	CA	CAS 317844-33-0
DM97NBO	DE	Discovery agent

DMQVF41	ID	DMQVF41
DMQVF41	DN	LY-593039
DMQVF41	HS	Investigative
DMQVF41	DE	Discovery agent

DMQE89J	ID	DMQE89J
DMQE89J	DN	LY593093
DMQE89J	HS	Investigative
DMQE89J	SN	LY-593093; LY 593093
DMQE89J	DT	Small molecular drug
DMQE89J	PC	9893054
DMQE89J	MW	507.6
DMQE89J	FM	C32H30FN3O2
DMQE89J	IC	InChI=1S/C32H30FN3O2/c1-21(36(2)20-22-8-15-27(33)16-9-22)34-28-17-14-26-18-30(37)31(29(26)19-28)35-32(38)25-12-10-24(11-13-25)23-6-4-3-5-7-23/h3-17,19,30-31,37H,18,20H2,1-2H3,(H,35,38)/t30-,31-/m1/s1
DMQE89J	CS	CC(=NC1=CC2=C(C[C@H]([C@@H]2NC(=O)C3=CC=C(C=C3)C4=CC=CC=C4)O)C=C1)N(C)CC5=CC=C(C=C5)F
DMQE89J	IK	KOQVBYSCBCRVQJ-FIRIVFDPSA-N
DMQE89J	IU	N-[(1R,2R)-6-[1-[(4-fluorophenyl)methyl-methylamino]ethylideneamino]-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-4-phenylbenzamide
DMQE89J	CA	CAS 1108748-12-4
DMQE89J	DE	Discovery agent

DM5TYMG	ID	DM5TYMG
DM5TYMG	DN	LY86057
DM5TYMG	HS	Investigative
DM5TYMG	SN	LY-86057; LY 86057
DM5TYMG	DT	Small molecular drug
DM5TYMG	PC	13878025
DM5TYMG	MW	342.4
DM5TYMG	FM	C20H26N2O3
DM5TYMG	IC	InChI=1S/C20H26N2O3/c1-11(23)12(2)25-20(24)14-7-16-15-5-4-6-17-19(15)13(9-21-17)8-18(16)22(3)10-14/h4-6,9,11-12,14,16,18,21,23H,7-8,10H2,1-3H3
DM5TYMG	CS	CC(C(C)OC(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)C)O
DM5TYMG	IK	GOHDSZGHAHFEHG-UHFFFAOYSA-N
DM5TYMG	IU	3-hydroxybutan-2-yl 7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxylate
DM5TYMG	DE	Discovery agent

DMTNVP4	ID	DMTNVP4
DMTNVP4	DN	LY97241
DMTNVP4	HS	Investigative
DMTNVP4	SN	LY 97241; LY-97241
DMTNVP4	DT	Small molecular drug
DMTNVP4	PC	175064
DMTNVP4	MW	320.5
DMTNVP4	FM	C19H32N2O2
DMTNVP4	IC	InChI=1S/C19H32N2O2/c1-3-5-6-7-9-16-20(4-2)17-10-8-11-18-12-14-19(15-13-18)21(22)23/h12-15H,3-11,16-17H2,1-2H3
DMTNVP4	CS	CCCCCCCN(CC)CCCCC1=CC=C(C=C1)[N+](=O)[O-]
DMTNVP4	IK	YTYATOMQOOFRNA-UHFFFAOYSA-N
DMTNVP4	IU	N-ethyl-N-[4-(4-nitrophenyl)butyl]heptan-1-amine
DMTNVP4	CA	CAS 72456-63-4
DMTNVP4	DE	Discovery agent

DMVX19Q	ID	DMVX19Q
DMVX19Q	DN	LYCOGARUBIN B
DMVX19Q	HS	Investigative
DMVX19Q	SN	LYCOGARUBIN B; CHEMBL439675
DMVX19Q	DT	Small molecular drug
DMVX19Q	PC	11441783
DMVX19Q	MW	429.4
DMVX19Q	FM	C24H19N3O5
DMVX19Q	IC	InChI=1S/C24H19N3O5/c1-31-23(29)21-19(15-10-25-17-6-4-3-5-13(15)17)20(22(27-21)24(30)32-2)16-11-26-18-8-7-12(28)9-14(16)18/h3-11,25-28H,1-2H3
DMVX19Q	CS	COC(=O)C1=C(C(=C(N1)C(=O)OC)C2=CNC3=CC=CC=C32)C4=CNC5=C4C=C(C=C5)O
DMVX19Q	IK	SZBJDRXMLSSPCV-UHFFFAOYSA-N
DMVX19Q	IU	dimethyl 3-(5-hydroxy-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dicarboxylate
DMVX19Q	DE	Discovery agent

DMH0Q9V	ID	DMH0Q9V
DMH0Q9V	DN	Lys[Z(NO2)]-Lys[Z(NO2)]
DMH0Q9V	HS	Investigative
DMH0Q9V	SN	Lys[Z(NO2)]-Lys[Z(NO2)]; GTPL4499
DMH0Q9V	DT	Small molecular drug
DMH0Q9V	PC	73755095
DMH0Q9V	MW	618.6
DMH0Q9V	FM	C27H34N6O11
DMH0Q9V	IC	InChI=1S/C27H34N6O11/c28-22(5-1-3-16-30-27(38)44-21-13-11-20(12-14-21)33(41)42)24(34)31-23(25(35)36)6-2-4-15-29-26(37)43-17-18-7-9-19(10-8-18)32(39)40/h7-14,22-23H,1-6,15-17,28H2,(H,29,37)(H,30,38)(H,31,34)(H,35,36)
DMH0Q9V	CS	C1=CC(=CC=C1COC(=O)NCCCCC(C(=O)[O-])NC(=O)C(CCCCNC(=O)OC2=CC=C(C=C2)[N+](=O)[O-])[NH3+])[N+](=O)[O-]
DMH0Q9V	IK	AJUWOKKXEQNXLT-UHFFFAOYSA-N
DMH0Q9V	IU	2-[[2-azaniumyl-6-[(4-nitrophenoxy)carbonylamino]hexanoyl]amino]-6-[(4-nitrophenyl)methoxycarbonylamino]hexanoate
DMH0Q9V	DE	Discovery agent

DMJX4GA	ID	DMJX4GA
DMJX4GA	DN	Lys[Z(NO2)]-Pro
DMJX4GA	HS	Investigative
DMJX4GA	SN	Lys[Z(NO2)]-Pro; GTPL4498; (2S)-1-{2-amino-6-[(4-nitrophenoxycarbonyl)amino]hexanoyl}pyrrolidine-2-carboxylic acid
DMJX4GA	DT	Small molecular drug
DMJX4GA	PC	73755094
DMJX4GA	MW	408.4
DMJX4GA	FM	C18H24N4O7
DMJX4GA	IC	InChI=1S/C18H24N4O7/c19-14(16(23)21-11-3-5-15(21)17(24)25)4-1-2-10-20-18(26)29-13-8-6-12(7-9-13)22(27)28/h6-9,14-15H,1-5,10-11,19H2,(H,20,26)(H,24,25)/t14?,15-/m0/s1
DMJX4GA	CS	C1C[C@H](N(C1)C(=O)C(CCCCNC(=O)OC2=CC=C(C=C2)[N+](=O)[O-])N)C(=O)O
DMJX4GA	IK	XECWFUGQRJPWRP-LOACHALJSA-N
DMJX4GA	IU	(2S)-1-[2-amino-6-[(4-nitrophenoxy)carbonylamino]hexanoyl]pyrrolidine-2-carboxylic acid
DMJX4GA	DE	Discovery agent

DM4MGAQ	ID	DM4MGAQ
DM4MGAQ	DN	lysergic acid
DM4MGAQ	HS	Investigative
DM4MGAQ	SN	D-lysergic acid; isolysergic acid; (+)-lysergic acid
DM4MGAQ	DT	Small molecular drug
DM4MGAQ	PC	6717
DM4MGAQ	MW	268.31
DM4MGAQ	FM	C16H16N2O2
DM4MGAQ	IC	InChI=1S/C16H16N2O2/c1-18-8-10(16(19)20)5-12-11-3-2-4-13-15(11)9(7-17-13)6-14(12)18/h2-5,7,10,14,17H,6,8H2,1H3,(H,19,20)/t10-,14-/m1/s1
DM4MGAQ	CS	CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)O
DM4MGAQ	IK	ZAGRKAFMISFKIO-QMTHXVAHSA-N
DM4MGAQ	IU	(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxylic acid
DM4MGAQ	CA	CAS 82-58-6
DM4MGAQ	CB	CHEBI:6604
DM4MGAQ	DE	Discovery agent

DM1OHF8	ID	DM1OHF8
DM1OHF8	DN	lysergol
DM1OHF8	HS	Investigative
DM1OHF8	SN	lysergole
DM1OHF8	DT	Small molecular drug
DM1OHF8	PC	14987
DM1OHF8	MW	254.33
DM1OHF8	FM	C16H18N2O
DM1OHF8	IC	InChI=1S/C16H18N2O/c1-18-8-10(9-19)5-13-12-3-2-4-14-16(12)11(7-17-14)6-15(13)18/h2-5,7,10,15,17,19H,6,8-9H2,1H3/t10-,15-/m1/s1
DM1OHF8	CS	CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)CO
DM1OHF8	IK	BIXJFIJYBLJTMK-MEBBXXQBSA-N
DM1OHF8	IU	[(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]methanol
DM1OHF8	CA	CAS 602-85-7
DM1OHF8	CB	CHEBI:60528
DM1OHF8	DE	Discovery agent

DMIZQW6	ID	DMIZQW6
DMIZQW6	DN	LYSICAMINE
DMIZQW6	HS	Investigative
DMIZQW6	SN	Lysicamine; Oxonuciferine; 15444-20-9; CCRIS 3813; NSC 628003; BRN 1486372; UNII-6L30DD6R7O; CHEMBL510090; 6L30DD6R7O; CHEBI:70650; 1,2-Dimethoxy-7H-dibenzo(de,g)quinolin-7-one; NSC628003; 7H-Dibenzo(de,g)quinolin-7-one, 1,2-dimethoxy-; Noraporphin-7-one, 4,5,6,6a-tetradehydro-1,2-dimethoxy-; 7H-Dibenzo[de,g]quinolin-7-one, 1,2-dimethoxy-; 5-21-13-00382 (Beilstein Handbook Reference); (+)-ushinsunine-beta-N-oxide; SCHEMBL2046474; AC1L3V30; DTXSID00165628; MolPort-044-754-181; DPBMWJXWUINLQT-UHFFFAOYSA-N; BDBM50292452
DMIZQW6	DT	Small molecular drug
DMIZQW6	PC	122691
DMIZQW6	MW	291.3
DMIZQW6	FM	C18H13NO3
DMIZQW6	IC	InChI=1S/C18H13NO3/c1-21-13-9-10-7-8-19-16-14(10)15(18(13)22-2)11-5-3-4-6-12(11)17(16)20/h3-9H,1-2H3
DMIZQW6	CS	COC1=C(C2=C3C(=C1)C=CN=C3C(=O)C4=CC=CC=C42)OC
DMIZQW6	IK	DPBMWJXWUINLQT-UHFFFAOYSA-N
DMIZQW6	IU	15,16-dimethoxy-10-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2,4,6,9,11,13,15-octaen-8-one
DMIZQW6	CA	CAS 15444-20-9
DMIZQW6	CB	CHEBI:70650
DMIZQW6	DE	Discovery agent

DMW1YK3	ID	DMW1YK3
DMW1YK3	DN	Lysine Nz-Carboxylic Acid
DMW1YK3	HS	Investigative
DMW1YK3	SN	Lysine Nz-Carboxylic Acid; N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301
DMW1YK3	DT	Small molecular drug
DMW1YK3	PC	17754054
DMW1YK3	MW	190.2
DMW1YK3	FM	C7H14N2O4
DMW1YK3	IC	InChI=1S/C7H14N2O4/c8-5(6(10)11)3-1-2-4-9-7(12)13/h5,9H,1-4,8H2,(H,10,11)(H,12,13)/t5-/m0/s1
DMW1YK3	CS	C(CCNC(=O)O)C[C@@H](C(=O)O)N
DMW1YK3	IK	PWIKLEYMFKCERQ-YFKPBYRVSA-N
DMW1YK3	IU	(2S)-2-amino-6-(carboxyamino)hexanoic acid
DMW1YK3	CB	CHEBI:43575
DMW1YK3	DE	Discovery agent

DMOGFVH	ID	DMOGFVH
DMOGFVH	DN	Lysophosphatidylcholine
DMOGFVH	HS	Investigative
DMOGFVH	SN	Lysophosphatidylcholine; 1-acetyl-sn-glycero-3-phosphocholine; AC1NSKBT; GTPL2508; SCHEMBL19821626; CHEBI:138424; LMGP01050043; [(2R)-3-acetyloxy-2-hydroxypropyl] 2-trimethylazaniumylethyl phosphate; [(2R)-3-acetyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate; 3,5,9-Trioxa-4-phosphaundecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (R)-
DMOGFVH	DT	Small molecular drug
DMOGFVH	PC	5311264
DMOGFVH	MW	299.26
DMOGFVH	FM	C10H22NO7P
DMOGFVH	IC	InChI=1S/C10H22NO7P/c1-9(12)16-7-10(13)8-18-19(14,15)17-6-5-11(2,3)4/h10,13H,5-8H2,1-4H3/t10-/m1/s1
DMOGFVH	CS	CC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)O
DMOGFVH	IK	RYCNUMLMNKHWPZ-SNVBAGLBSA-N
DMOGFVH	IU	[(2R)-3-acetyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMOGFVH	CA	CAS 9008-30-4
DMOGFVH	CB	CHEBI:138424
DMOGFVH	DE	Discovery agent

DMI4FKH	ID	DMI4FKH
DMI4FKH	DN	lysophosphatidylethanolamine
DMI4FKH	HS	Investigative
DMI4FKH	SN	monoacylglycerophosphoethanolamine
DMI4FKH	DT	Small molecular drug
DMI4FKH	PC	73755142
DMI4FKH	MW	256.17
DMI4FKH	FM	C7H15NO7P-
DMI4FKH	IC	InChI=1S/C7H16NO7P/c1-6(9)13-4-7(10)5-15-16(11,12)14-3-2-8/h7,10H,2-5,8H2,1H3,(H,11,12)/p-1/t7-/m1/s1
DMI4FKH	CS	CC(=O)OC[C@H](COP(=O)([O-])OCCN)O
DMI4FKH	IK	CWRILEGKIAOYKP-SSDOTTSWSA-M
DMI4FKH	IU	[(2R)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate
DMI4FKH	DE	Discovery agent

DMETM3R	ID	DMETM3R
DMETM3R	DN	lysophosphatidylinositol
DMETM3R	HS	Investigative
DMETM3R	SN	LPI; L-alpha-lysophosphatidylinositol
DMETM3R	DT	Small molecular drug
DMETM3R	PC	73755067
DMETM3R	MW	376.25
DMETM3R	FM	C11H21O12P
DMETM3R	IC	InChI=1S/C11H21O12P/c1-4(12)21-2-5(13)3-22-24(19,20)23-11-9(17)7(15)6(14)8(16)10(11)18/h5-11,13-18H,2-3H2,1H3,(H,19,20)/t5-,6?,7-,8+,9+,10+,11?/m0/s1
DMETM3R	CS	CC(=O)OC[C@@H](COP(=O)(O)OC1[C@@H]([C@H](C([C@H]([C@H]1O)O)O)O)O)O
DMETM3R	IK	FBDBXJJQMHPGMP-FNFFQOHASA-N
DMETM3R	IU	[(2S)-2-hydroxy-3-[hydroxy-[(2R,3S,5R,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] acetate
DMETM3R	DE	Discovery agent

DMKG7J2	ID	DMKG7J2
DMKG7J2	DN	lysophosphatidylserine
DMKG7J2	HS	Investigative
DMKG7J2	SN	lysoPS; lysophosphatidyl-L-serine
DMKG7J2	DT	Small molecular drug
DMKG7J2	PC	42607474
DMKG7J2	MW	525.6
DMKG7J2	FM	C24H48NO9P
DMKG7J2	IC	InChI=1S/C24H48NO9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(27)32-18-21(26)19-33-35(30,31)34-20-22(25)24(28)29/h21-22,26H,2-20,25H2,1H3,(H,28,29)(H,30,31)/t21-,22+/m1/s1
DMKG7J2	CS	CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](C(=O)O)N)O
DMKG7J2	IK	ZPDQFUYPBVXUKS-YADHBBJMSA-N
DMKG7J2	IU	(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-octadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
DMKG7J2	CA	CAS 119786-67-3
DMKG7J2	CB	CHEBI:85403
DMKG7J2	DE	Discovery agent

DMIG3FX	ID	DMIG3FX
DMIG3FX	DN	Lysophosphotidylserine
DMIG3FX	HS	Investigative
DMIG3FX	SN	LYSOPHOSPHOTIDYLSERINE; O-{HYDROXY[((2R)-2-HYDROXY-3-{[(1S)-1-HYDROXYPENTADECYL]OXY}PROPYL)OXY]PHOSPHORYL}-L-SERINE; AC1NRBY2; O-[(R)-hydroxy{[(2R)-2-hydroxy-3-{[(1R)-1-hydroxypentadecyl]oxy}propyl]oxy}phosphoryl]-L-serine; (2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-(1-hydroxypentadecoxy)propoxy]phosphoryl]oxypropanoic acid
DMIG3FX	DT	Small molecular drug
DMIG3FX	PC	5288706
DMIG3FX	MW	485.5
DMIG3FX	FM	C21H44NO9P
DMIG3FX	IC	InChI=1S/C21H44NO9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-20(24)29-15-18(23)16-30-32(27,28)31-17-19(22)21(25)26/h18-20,23-24H,2-17,22H2,1H3,(H,25,26)(H,27,28)/t18-,19+,20?/m1/s1
DMIG3FX	CS	CCCCCCCCCCCCCCC(O)OC[C@H](COP(=O)(O)OC[C@@H](C(=O)O)N)O
DMIG3FX	IK	RPZLJDFLPRHXGM-LFPSWIHMSA-N
DMIG3FX	IU	(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-(1-hydroxypentadecoxy)propoxy]phosphoryl]oxypropanoic acid
DMIG3FX	DE	Discovery agent

DME15MN	ID	DME15MN
DME15MN	DN	Lys-thiol
DME15MN	HS	Investigative
DME15MN	SN	6-Amino-2-mercapto-hexanoic acid; CHEMBL432852; Lys-thiol; GTPL8667; SCHEMBL11506085; 6-amino-2-sulfanylhexanoic acid; BDBM50036831
DME15MN	DT	Small molecular drug
DME15MN	PC	20384324
DME15MN	MW	163.24
DME15MN	FM	C6H13NO2S
DME15MN	IC	InChI=1S/C6H13NO2S/c7-4-2-1-3-5(10)6(8)9/h5,10H,1-4,7H2,(H,8,9)
DME15MN	CS	C(CCN)CC(C(=O)O)S
DME15MN	IK	JNQDJHCXDRGZJD-UHFFFAOYSA-N
DME15MN	IU	6-amino-2-sulfanylhexanoic acid
DME15MN	DE	Discovery agent

DMJQG82	ID	DMJQG82
DMJQG82	DN	M&B 28767
DMJQG82	HS	Investigative
DMJQG82	SN	M&B-28767; Dpt-prostaglandin E1
DMJQG82	DT	Small molecular drug
DMJQG82	PC	5311223
DMJQG82	MW	374.5
DMJQG82	FM	C22H30O5
DMJQG82	IC	InChI=1S/C22H30O5/c23-18(16-27-19-8-4-3-5-9-19)14-12-17-13-15-21(24)20(17)10-6-1-2-7-11-22(25)26/h3-5,8-9,12,14,17-18,20,23H,1-2,6-7,10-11,13,15-16H2,(H,25,26)/b14-12+/t17-,18+,20+/m0/s1
DMJQG82	CS	C1CC(=O)[C@@H]([C@H]1/C=C/[C@H](COC2=CC=CC=C2)O)CCCCCCC(=O)O
DMJQG82	IK	NZGFSDWJUZOAAX-KAVAACISSA-N
DMJQG82	IU	7-[(1R,2R)-2-[(E,3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]heptanoic acid
DMJQG82	CA	CAS 80558-61-8
DMJQG82	DE	Discovery agent

DMYU3Z7	ID	DMYU3Z7
DMYU3Z7	DN	M372049
DMYU3Z7	HS	Investigative
DMYU3Z7	SN	M 372049; M-372049
DMYU3Z7	DT	Small molecular drug
DMYU3Z7	PC	59787819
DMYU3Z7	MW	887
DMYU3Z7	FM	C43H58N12O9
DMYU3Z7	IC	InChI=1S/C43H58N12O9/c1-5-23(3)35(37(44)59)54-38(60)29(12-9-18-47-43(45)46)52-39(61)31(21-34(57)58)53-41(63)36(24(4)6-2)55-19-17-30(42(55)64)51-33(56)20-25-13-15-26(16-14-25)49-40(62)32-22-48-27-10-7-8-11-28(27)50-32/h7-8,10-11,13-16,22-24,29-31,35-36H,5-6,9,12,17-21H2,1-4H3,(H2,44,59)(H,49,62)(H,51,56)(H,52,61)(H,53,63)(H,54,60)(H,57,58)(H4,45,46,47)/t23-,24-,29+,30+,31-,35-,36-/m0/s1
DMYU3Z7	CS	CC[C@H](C)[C@@H](C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)N1CC[C@H](C1=O)NC(=O)CC2=CC=C(C=C2)NC(=O)C3=NC4=CC=CC=C4N=C3
DMYU3Z7	IK	VINFYKMOVBYUSF-ZCWPROOASA-N
DMYU3Z7	IU	(3S)-4-[[(2R)-1-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-3-methyl-2-[(3R)-2-oxo-3-[[2-[4-(quinoxaline-2-carbonylamino)phenyl]acetyl]amino]pyrrolidin-1-yl]pentanoyl]amino]-4-oxobutanoic acid
DMYU3Z7	DE	Discovery agent

DMJK1RE	ID	DMJK1RE
DMJK1RE	DN	M3A6S
DMJK1RE	HS	Investigative
DMJK1RE	SN	CHEMBL214040; 3-Acetylmorphine 6-sulfate; 3-O-acetylmorphine-6-sulfate
DMJK1RE	DT	Small molecular drug
DMJK1RE	PC	44414842
DMJK1RE	MW	407.4
DMJK1RE	FM	C19H21NO7S
DMJK1RE	IC	InChI=1S/C19H21NO7S/c1-10(21)25-14-5-3-11-9-13-12-4-6-15(27-28(22,23)24)18-19(12,7-8-20(13)2)16(11)17(14)26-18/h3-6,12-13,15,18H,7-9H2,1-2H3,(H,22,23,24)/t12-,13+,15-,18-,19-/m0/s1
DMJK1RE	CS	CC(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DMJK1RE	IK	AVTOGXGTGWUJBM-SSTWWWIQSA-N
DMJK1RE	IU	[(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMJK1RE	DE	Discovery agent

DMAHGBF	ID	DMAHGBF
DMAHGBF	DN	M3B6S
DMAHGBF	HS	Investigative
DMAHGBF	SN	CHEMBL209751
DMAHGBF	DT	Small molecular drug
DMAHGBF	PC	44414877
DMAHGBF	MW	469.5
DMAHGBF	FM	C24H23NO7S
DMAHGBF	IC	InChI=1S/C24H23NO7S/c1-25-12-11-24-16-8-10-19(32-33(27,28)29)22(24)31-21-18(9-7-15(20(21)24)13-17(16)25)30-23(26)14-5-3-2-4-6-14/h2-10,16-17,19,22H,11-13H2,1H3,(H,27,28,29)/t16-,17+,19-,22-,24-/m0/s1
DMAHGBF	CS	C[NH+]1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC(=O)C6=CC=CC=C6)O[C@H]3[C@H](C=C4)OS(=O)(=O)[O-]
DMAHGBF	IK	IQMPFHWIBSSPBS-MJFIPZRTSA-N
DMAHGBF	IU	[(4R,4aR,7S,7aR,12bS)-9-benzoyloxy-3-methyl-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMAHGBF	DE	Discovery agent

DM0UOF1	ID	DM0UOF1
DM0UOF1	DN	M3IBu6S
DM0UOF1	HS	Investigative
DM0UOF1	SN	CHEMBL211576
DM0UOF1	DT	Small molecular drug
DM0UOF1	PC	44414863
DM0UOF1	MW	435.5
DM0UOF1	FM	C21H25NO7S
DM0UOF1	IC	InChI=1S/C21H25NO7S/c1-11(2)20(23)27-15-6-4-12-10-14-13-5-7-16(29-30(24,25)26)19-21(13,8-9-22(14)3)17(12)18(15)28-19/h4-7,11,13-14,16,19H,8-10H2,1-3H3,(H,24,25,26)/t13-,14+,16-,19-,21-/m0/s1
DM0UOF1	CS	CC(C)C(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DM0UOF1	IK	GABBKMMVICEZHE-AYHJQLAQSA-N
DM0UOF1	IU	[(4R,4aR,7S,7aR,12bS)-3-methyl-9-(2-methylpropanoyloxy)-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DM0UOF1	DE	Discovery agent

DMXT87E	ID	DMXT87E
DMXT87E	DN	M3P6S
DMXT87E	HS	Investigative
DMXT87E	SN	CHEMBL213228
DMXT87E	DT	Small molecular drug
DMXT87E	PC	44414864
DMXT87E	MW	449.5
DMXT87E	FM	C22H27NO7S
DMXT87E	IC	InChI=1S/C22H27NO7S/c1-21(2,3)20(24)28-15-7-5-12-11-14-13-6-8-16(30-31(25,26)27)19-22(13,9-10-23(14)4)17(12)18(15)29-19/h5-8,13-14,16,19H,9-11H2,1-4H3,(H,25,26,27)/t13-,14+,16-,19-,22-/m0/s1
DMXT87E	CS	CC(C)(C)C(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DMXT87E	IK	NEUKRIIKAHFBFQ-JYSMHPMOSA-N
DMXT87E	IU	[(4R,4aR,7S,7aR,12bS)-9-(2,2-dimethylpropanoyloxy)-3-methyl-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMXT87E	DE	Discovery agent

DMMC8RN	ID	DMMC8RN
DMMC8RN	DN	M3Pr6S
DMMC8RN	HS	Investigative
DMMC8RN	SN	CHEMBL385048; 3-Propionylmorphine 6-sulfate
DMMC8RN	DT	Small molecular drug
DMMC8RN	PC	44414843
DMMC8RN	MW	421.5
DMMC8RN	FM	C20H23NO7S
DMMC8RN	IC	InChI=1S/C20H23NO7S/c1-3-16(22)26-14-6-4-11-10-13-12-5-7-15(28-29(23,24)25)19-20(12,8-9-21(13)2)17(11)18(14)27-19/h4-7,12-13,15,19H,3,8-10H2,1-2H3,(H,23,24,25)/t12-,13+,15-,19-,20-/m0/s1
DMMC8RN	CS	CCC(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DMMC8RN	IK	LWKYBVFQVUJKDT-ILIJTDRLSA-N
DMMC8RN	IU	[(4R,4aR,7S,7aR,12bS)-3-methyl-9-propanoyloxy-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMMC8RN	DE	Discovery agent

DMWADOY	ID	DMWADOY
DMWADOY	DN	M3S
DMWADOY	HS	Investigative
DMWADOY	DE	Discovery agent

DM3IX2E	ID	DM3IX2E
DM3IX2E	DN	M5
DM3IX2E	HS	Investigative
DM3IX2E	SN	Fibrinolytic agent, Vascular Laboratory/Thrombolytic Sciences; M5, Vascular Laboratory/Thrombolytic Science
DM3IX2E	CP	Vascular Laboratory Inc
DM3IX2E	DT	Small molecular drug
DM3IX2E	PC	15345559
DM3IX2E	MW	411.4
DM3IX2E	FM	C17H12F3N3O2S2
DM3IX2E	IC	InChI=1S/C17H12F3N3O2S2/c18-17(19,20)16-13-9-26-14-4-2-1-3-12(14)15(13)23(22-16)10-5-7-11(8-6-10)27(21,24)25/h1-8H,9H2,(H2,21,24,25)
DM3IX2E	CS	C1C2=C(C3=CC=CC=C3S1)N(N=C2C(F)(F)F)C4=CC=C(C=C4)S(=O)(=O)N
DM3IX2E	IK	ACFQQDXFCVFBIX-UHFFFAOYSA-N
DM3IX2E	IU	4-[3-(trifluoromethyl)-4H-thiochromeno[4,3-c]pyrazol-1-yl]benzenesulfonamide
DM3IX2E	DE	Cerebrovascular ischaemia

DMM5X8Z	ID	DMM5X8Z
DMM5X8Z	DN	M55113
DMM5X8Z	HS	Investigative
DMM5X8Z	SN	SCHEMBL8124161; 6-Chloro-2-naphthyl 4-[1-(4-pyridyl)-4-piperidinylmethyl]piperazino sulfone
DMM5X8Z	DT	Small molecular drug
DMM5X8Z	PC	9826652
DMM5X8Z	MW	485
DMM5X8Z	FM	C25H29ClN4O2S
DMM5X8Z	IC	InChI=1S/C25H29ClN4O2S/c26-23-3-1-22-18-25(4-2-21(22)17-23)33(31,32)30-15-13-28(14-16-30)19-20-7-11-29(12-8-20)24-5-9-27-10-6-24/h1-6,9-10,17-18,20H,7-8,11-16,19H2
DMM5X8Z	CS	C1CN(CCC1CN2CCN(CC2)S(=O)(=O)C3=CC4=C(C=C3)C=C(C=C4)Cl)C5=CC=NC=C5
DMM5X8Z	IK	BFNYDPSXRNYUIS-UHFFFAOYSA-N
DMM5X8Z	IU	1-(6-chloronaphthalen-2-yl)sulfonyl-4-[(1-pyridin-4-ylpiperidin-4-yl)methyl]piperazine
DMM5X8Z	DE	Discovery agent

DMFS7QK	ID	DMFS7QK
DMFS7QK	DN	M-5MPEP
DMFS7QK	HS	Investigative
DMFS7QK	SN	M-5MPEP; 872428-47-2; 2-[2-(3-methoxyphenyl)ethynyl]-5-methylpyridine; GTPL6396; CHEMBL504706; SCHEMBL3955131; CCQPQKFLWKYOMJ-UHFFFAOYSA-N; ZINC34874630; ACN-053377; KB-274285
DMFS7QK	DT	Small molecular drug
DMFS7QK	PC	16036762
DMFS7QK	MW	223.27
DMFS7QK	FM	C15H13NO
DMFS7QK	IC	InChI=1S/C15H13NO/c1-12-6-8-14(16-11-12)9-7-13-4-3-5-15(10-13)17-2/h3-6,8,10-11H,1-2H3
DMFS7QK	CS	CC1=CN=C(C=C1)C#CC2=CC(=CC=C2)OC
DMFS7QK	IK	CCQPQKFLWKYOMJ-UHFFFAOYSA-N
DMFS7QK	IU	2-[2-(3-methoxyphenyl)ethynyl]-5-methylpyridine
DMFS7QK	DE	Discovery agent

DMRB4YV	ID	DMRB4YV
DMRB4YV	DN	M6G thiosaccharide analogue
DMRB4YV	HS	Investigative
DMRB4YV	DE	Discovery agent

DMFCUN4	ID	DMFCUN4
DMFCUN4	DN	M6S
DMFCUN4	HS	Investigative
DMFCUN4	DE	Discovery agent

DM9NPE4	ID	DM9NPE4
DM9NPE4	DN	M826
DM9NPE4	HS	Investigative
DM9NPE4	SN	compound 4sx
DM9NPE4	DT	Small molecular drug
DM9NPE4	PC	9851134
DM9NPE4	MW	575.7
DM9NPE4	FM	C28H45N7O6
DM9NPE4	IC	InChI=1S/C28H45N7O6/c1-8-10-11-12-13-34(7)16-22(36)19(14-24(37)38)30-26(39)21(9-2)35-17-23(28(4,5)6)31-25(27(35)40)29-15-20-18(3)32-41-33-20/h17,19,21H,8-16H2,1-7H3,(H,29,31)(H,30,39)(H,37,38)
DM9NPE4	CS	CCCCCCN(C)CC(=O)C(CC(=O)O)NC(=O)C(CC)N1C=C(N=C(C1=O)NCC2=NON=C2C)C(C)(C)C
DM9NPE4	IK	XIMITGPWYYFUQF-UHFFFAOYSA-N
DM9NPE4	IU	3-[2-[5-tert-butyl-3-[(4-methyl-1,2,5-oxadiazol-3-yl)methylamino]-2-oxopyrazin-1-yl]butanoylamino]-5-[hexyl(methyl)amino]-4-oxopentanoic acid
DM9NPE4	DE	Discovery agent

DM8I0TY	ID	DM8I0TY
DM8I0TY	DN	M8-B
DM8I0TY	HS	Investigative
DM8I0TY	SN	GTPL6376; SCHEMBL14078338; CHEMBL2442052; ZINC38225225; NCGC00370691-03
DM8I0TY	DT	Small molecular drug
DM8I0TY	PC	11675630
DM8I0TY	MW	396.5
DM8I0TY	FM	C22H24N2O3S
DM8I0TY	IC	InChI=1S/C22H24N2O3S/c1-26-20-14-18(9-10-19(20)27-16-17-6-3-2-4-7-17)15-24(12-11-23)22(25)21-8-5-13-28-21/h2-10,13-14H,11-12,15-16,23H2,1H3
DM8I0TY	CS	COC1=C(C=CC(=C1)CN(CCN)C(=O)C2=CC=CS2)OCC3=CC=CC=C3
DM8I0TY	IK	UOGGWHBYFVBUIY-UHFFFAOYSA-N
DM8I0TY	IU	N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]thiophene-2-carboxamide
DM8I0TY	DE	Discovery agent

DMKWQ52	ID	DMKWQ52
DMKWQ52	DN	MA-2029
DMKWQ52	HS	Investigative
DMKWQ52	SN	MA2029
DMKWQ52	DT	Small molecular drug
DMKWQ52	PC	73755070
DMKWQ52	MW	593.2
DMKWQ52	FM	C31H46ClFN4O4
DMKWQ52	IC	InChI=1S/C31H45FN4O4.ClH/c1-9-34-28(38)24(18-21-12-15-26(37)23(16-21)31(4,5)6)35-29(39)27(19(2)3)36(8)30(40)25(33-7)17-20-10-13-22(32)14-11-20;/h10-16,19,24-25,27,33,37H,9,17-18H2,1-8H3,(H,34,38)(H,35,39);1H/t24-,25-,27-;/m0./s1
DMKWQ52	CS	CCNC(=O)[C@H](CC1=CC(=C(C=C1)O)C(C)(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC2=CC=C(C=C2)F)NC.Cl
DMKWQ52	IK	AMSDRHOIAWZBTJ-PBQYMGKRSA-N
DMKWQ52	IU	(2S)-N-[(2S)-3-(3-tert-butyl-4-hydroxyphenyl)-1-(ethylamino)-1-oxopropan-2-yl]-2-[[(2S)-3-(4-fluorophenyl)-2-(methylamino)propanoyl]-methylamino]-3-methylbutanamide;hydrochloride
DMKWQ52	DE	Discovery agent

DMDHGM2	ID	DMDHGM2
DMDHGM2	DN	Maackiain
DMDHGM2	HS	Investigative
DMDHGM2	SN	Maackiain; (-)-Maackiain; Inermin; Inermine; 2035-15-6; L-Maackiain; CHEBI:99; UNII-TF360D25IJ; (6ar,12ar)-6a,12a-dihydro-6h-[1,3]dioxolo[5,6][1]benzofuro[3,2-c]chromen-3-ol; TF360D25IJ; HUKSJTUUSUGIDC-ZBEGNZNMSA-N; 19908-48-6; 3-Hydroxy-8,9-methylenedioxypterocarpan; ST077155; (6aR,12aR)-3-hydroxy-8,9-methylenedioxypterocarpane; (6aR,12aR)-6a,12a-Dihydro-6H-[1,3]dioxolo[4',5':5,6]benzofuro[3,2-c]chromen-3-ol; Maackiaine; Trifolirhizin aglycone; (+/-)-Maackiain; AC1Q70VV; CHEMBL334918; AC1L3M84; (-)-(6aR,12aR)-maackiain
DMDHGM2	DT	Small molecular drug
DMDHGM2	PC	91510
DMDHGM2	MW	284.26
DMDHGM2	FM	C16H12O5
DMDHGM2	IC	InChI=1S/C16H12O5/c17-8-1-2-9-12(3-8)18-6-11-10-4-14-15(20-7-19-14)5-13(10)21-16(9)11/h1-5,11,16-17H,6-7H2/t11-,16-/m0/s1
DMDHGM2	CS	C1[C@@H]2[C@H](C3=C(O1)C=C(C=C3)O)OC4=CC5=C(C=C24)OCO5
DMDHGM2	IK	HUKSJTUUSUGIDC-ZBEGNZNMSA-N
DMDHGM2	IU	(1R,12R)-5,7,11,19-tetraoxapentacyclo[10.8.0.02,10.04,8.013,18]icosa-2,4(8),9,13(18),14,16-hexaen-16-ol
DMDHGM2	CA	CAS 2035-15-6
DMDHGM2	CB	CHEBI:99
DMDHGM2	DE	Discovery agent

DM1ICOW	ID	DM1ICOW
DM1ICOW	DN	mab 224G11
DM1ICOW	HS	Investigative
DM1ICOW	SN	MAb 224G11; C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott
DM1ICOW	CP	Pierre Fabre SA
DM1ICOW	DT	Antibody
DM1ICOW	DE	Solid tumour/cancer

DMJX2CS	ID	DMJX2CS
DMJX2CS	DN	mabionHER2
DMJX2CS	HS	Investigative
DMJX2CS	SN	Humanized monoclonal antibody (breast cancer), Mabion
DMJX2CS	CP	Mabion Ltd
DMJX2CS	DT	Antibody
DMJX2CS	DE	Breast cancer

DMDLF0J	ID	DMDLF0J
DMDLF0J	DN	Macbecin
DMDLF0J	HS	Investigative
DMDLF0J	TC	Anticancer Agents
DMDLF0J	DT	Small molecular drug
DMDLF0J	PC	433447
DMDLF0J	MW	558.7
DMDLF0J	FM	C30H42N2O8
DMDLF0J	IC	InChI=1S/C30H42N2O8/c1-16-10-9-11-17(2)29(35)32-23-15-21(33)14-22(25(23)34)27(38-7)20(5)13-24(37-6)28(39-8)19(4)12-18(3)26(16)40-30(31)36/h9-12,14-16,19-20,24,26-28H,13H2,1-8H3,(H2,31,36)(H,32,35)
DMDLF0J	CS	CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C=C(C1OC)C2=O)C)C)OC(=O)N)C)C)OC)OC
DMDLF0J	IK	PLTGBUPHJAKFMA-UHFFFAOYSA-N
DMDLF0J	IU	(13,14,17-trimethoxy-4,8,10,12,16-pentamethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl) carbamate
DMDLF0J	DE	Solid tumour/cancer

DMOMG7S	ID	DMOMG7S
DMOMG7S	DN	MACLURAXANTHONE
DMOMG7S	HS	Investigative
DMOMG7S	SN	Macluraxanthone; 5848-14-6; NSC107228; 3-Hydroxyblancoxanthone; Spectrum_000523; SpecPlus_000294; CHEBI:6623; 12-(1,1-dimethylallyl)-5,9,10-trihydroxy-2,2-dimethyl-pyrano[3,2-b]xanthen-6-one; MACLUROXANTHONE; NSC 107228; AC1NQYT1; Spectrum3_000165; Spectrum2_000431; Spectrum5_000191; Spectrum4_001486; C10076; KBioSS_001003; KBioGR_002091; BSPBio_001629; DivK1c_006390; SPBio_000442; SCHEMBL2546452; CHEMBL478960; KBio2_003571; KBio2_006139; KBio2_001003; KBio1_001334; KBio3_001129; DTXSID40207172; MolPort-001-736-557; ZINC5447704
DMOMG7S	DT	Small molecular drug
DMOMG7S	PC	5281646
DMOMG7S	MW	394.4
DMOMG7S	FM	C23H22O6
DMOMG7S	IC	InChI=1S/C23H22O6/c1-6-22(2,3)15-19-12(9-10-23(4,5)29-19)17(26)14-16(25)11-7-8-13(24)18(27)20(11)28-21(14)15/h6-10,24,26-27H,1H2,2-5H3
DMOMG7S	CS	CC1(C=CC2=C(C3=C(C(=C2O1)C(C)(C)C=C)OC4=C(C3=O)C=CC(=C4O)O)O)C
DMOMG7S	IK	XRVLGJCHUWXTDX-UHFFFAOYSA-N
DMOMG7S	IU	5,9,10-trihydroxy-2,2-dimethyl-12-(2-methylbut-3-en-2-yl)pyrano[3,2-b]xanthen-6-one
DMOMG7S	CA	CAS 5848-14-6
DMOMG7S	CB	CHEBI:6623
DMOMG7S	DE	Discovery agent

DMFULZO	ID	DMFULZO
DMFULZO	DN	Macrocyclic tripeptide motif
DMFULZO	HS	Investigative
DMFULZO	SN	macrocyclic tripeptide motif; CHEMBL317974
DMFULZO	DT	Small molecular drug
DMFULZO	PC	44331282
DMFULZO	MW	731.8
DMFULZO	FM	C36H45N9O8
DMFULZO	IC	InChI=1S/C36H45N9O8/c37-36(38)39-16-4-8-26-31(49)34(52)44-27(19-22-6-2-1-3-7-22)32(50)42-24(18-23-10-13-25(47)14-11-23)12-15-30(48)40-20-28(41-21-46)35(53)45-17-5-9-29(45)33(51)43-26/h1-3,6-7,10-15,21,24,26-29,47H,4-5,8-9,16-20H2,(H,40,48)(H,41,46)(H,42,50)(H,43,51)(H,44,52)(H4,37,38,39)/b15-12-/t24-,26+,27-,28+,29+/m0/s1
DMFULZO	CS	C1C[C@@H]2C(=O)N[C@@H](C(=O)C(=O)N[C@H](C(=O)N[C@@H](/C=C\\C(=O)NC[C@H](C(=O)N2C1)NC=O)CC3=CC=C(C=C3)O)CC4=CC=CC=C4)CCCN=C(N)N
DMFULZO	IK	CDWXSPKJKIUEQF-SMUYMMTFSA-N
DMFULZO	IU	N-[(3R,7Z,9R,12S,16R,19R)-12-benzyl-16-[3-(diaminomethylideneamino)propyl]-9-[(4-hydroxyphenyl)methyl]-2,6,11,14,15,18-hexaoxo-1,5,10,13,17-pentazabicyclo[17.3.0]docos-7-en-3-yl]formamide
DMFULZO	DE	Discovery agent

DMSQL19	ID	DMSQL19
DMSQL19	DN	MAGGIEMYCIN
DMSQL19	HS	Investigative
DMSQL19	SN	Maggiemycin; 81341-47-1; methyl (1R,2R)-2-ethyl-2,5,7,12-tetrahydroxy-4,6,11-trioxo-1,3-dihydrotetracene-1-carboxylate; AC1Q6OOS; CTK3E8246; DTXSID70231061; AC1L3370; 1-naphthacenecarboxylic acid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetrahydroxy-4,6,11-trioxo-, methyl ester,(1r-trans)-; 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetrahydroxy-4,6,11-trioxo-, methyl ester, (1R-trans)-
DMSQL19	DT	Small molecular drug
DMSQL19	PC	133657
DMSQL19	MW	426.4
DMSQL19	FM	C22H18O9
DMSQL19	IC	InChI=1S/C22H18O9/c1-3-22(30)7-10(24)12-13(16(22)21(29)31-2)20(28)14-15(19(12)27)18(26)11-8(17(14)25)5-4-6-9(11)23/h4-6,16,23,27-28,30H,3,7H2,1-2H3/t16-,22+/m0/s1
DMSQL19	CS	CC[C@]1(CC(=O)C2=C([C@H]1C(=O)OC)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O)O
DMSQL19	IK	FCUPTGDGQULLKX-KSFYIVLOSA-N
DMSQL19	IU	methyl (1R,2R)-2-ethyl-2,5,7,12-tetrahydroxy-4,6,11-trioxo-1,3-dihydrotetracene-1-carboxylate
DMSQL19	CA	CAS 81341-47-1
DMSQL19	DE	Discovery agent

DM5WNH8	ID	DM5WNH8
DM5WNH8	DN	Mahureone D
DM5WNH8	HS	Investigative
DM5WNH8	SN	Mahureone D
DM5WNH8	DT	Small molecular drug
DM5WNH8	PC	54708912
DM5WNH8	MW	528.7
DM5WNH8	FM	C32H48O6
DM5WNH8	IC	InChI=1S/C32H48O6/c1-10-11-22(17-25(34)35)27-29-32(15-14-20(4)5,18-23(31(27,8)9)13-12-19(2)3)28(36)26(30(37)38-29)24(33)16-21(6)7/h12,14,21-23,36H,10-11,13,15-18H2,1-9H3,(H,34,35)
DM5WNH8	CS	CCCC(CC(=O)O)C1=C2C(CC(C1(C)C)CC=C(C)C)(C(=C(C(=O)O2)C(=O)CC(C)C)O)CC=C(C)C
DM5WNH8	IK	MEQHOADCAUKYIE-UHFFFAOYSA-N
DM5WNH8	IU	3-[4-hydroxy-7,7-dimethyl-3-(3-methylbutanoyl)-4a,6-bis(3-methylbut-2-enyl)-2-oxo-5,6-dihydrochromen-8-yl]hexanoic acid
DM5WNH8	DE	Discovery agent

DMKE03Q	ID	DMKE03Q
DMKE03Q	DN	Makaluvamine N
DMKE03Q	HS	Investigative
DMKE03Q	SN	CHEMBL1162277
DMKE03Q	DT	Small molecular drug
DMKE03Q	PC	135496970
DMKE03Q	MW	266.09
DMKE03Q	FM	C10H8BrN3O
DMKE03Q	IC	InChI=1S/C10H8BrN3O/c11-6-7(12)10(15)9-5-4(3-14-9)1-2-13-8(5)6/h3,15H,1-2,12H2
DMKE03Q	CS	C1CN=C2C3=C1C=NC3=C(C(=C2Br)N)O
DMKE03Q	IK	UMVGTIHJQQYCQI-UHFFFAOYSA-N
DMKE03Q	IU	10-amino-9-bromo-2,7-diazatricyclo[6.3.1.04,12]dodeca-1(11),2,4(12),7,9-pentaen-11-ol
DMKE03Q	DE	Discovery agent

DMMCJLH	ID	DMMCJLH
DMMCJLH	DN	Malate
DMMCJLH	HS	Investigative
DMMCJLH	SN	Apple acid; Butanedioic acid, hydroxy-, (2S)-; J3TZF807X5; L(-)-Malic acid; L-(-)-Malic acid; L-2-Hydroxybutanedioic acid; L-Apple acid; L-Hydroxybutanedioic acid; L-Hydroxysuccinic acid; L-Malic acid; L-malate; Malic acid, L-; S-(-)-Malic acid; S-2-Hydroxybutanedioic acid; (-)-(S)-Malic acid; (-)-Hydroxysuccinic acid; (-)-L-Malic acid; (-)-Malic acid; (2S)-2-Hydroxybutanedioic acid; (S)-(-)-Hydroxysuccinic acid; (S)-2-hydroxysuccinic acid; (S)-Malic acid; (S)-malate; 97-67-6; MFCD00064213; NSC9232; UNII-J3TZF807X5
DMMCJLH	PC	222656
DMMCJLH	MW	134.09
DMMCJLH	FM	C4H6O5
DMMCJLH	IC	BJEPYKJPYRNKOW-REOHCLBHSA-N
DMMCJLH	CS	C(C(C(=O)O)O)C(=O)O
DMMCJLH	IK	1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9)/t2-/m0/s1
DMMCJLH	IU	(2S)-2-hydroxybutanedioic acid
DMMCJLH	CA	CAS 636-61-3
DMMCJLH	CB	CHEBI:30797
DMMCJLH	DE	Discovery agent

DM4OQWZ	ID	DM4OQWZ
DM4OQWZ	DN	Malate Like Intermediate
DM4OQWZ	HS	Investigative
DM4OQWZ	SN	MALATE LIKE INTERMEDIATE; AC1NRDBV; DB03343; (Z,2R)-2,4-dihydroxy-4-oxidobut-3-enoate
DM4OQWZ	DT	Small molecular drug
DM4OQWZ	PC	5289457
DM4OQWZ	MW	132.07
DM4OQWZ	FM	C4H4O5-2
DM4OQWZ	IC	InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h1-2,5-7H,(H,8,9)/p-2/t2-/m1/s1
DM4OQWZ	CS	C(=C(\\O)/[O-])\\[C@H](C(=O)[O-])O
DM4OQWZ	IK	QFBHYOKSQPPXHZ-UWTATZPHSA-L
DM4OQWZ	IU	(Z,2R)-2,4-dihydroxy-4-oxidobut-3-enoate
DM4OQWZ	DE	Discovery agent

DM4L0R7	ID	DM4L0R7
DM4L0R7	DN	Maleic Acid
DM4L0R7	HS	Investigative
DM4L0R7	SN	2-(2-ethoxyethyl)-3-ethylbut-2-enedioic acid; 6309-80-4; AC1L5ZJW; CTK6G3643; CTK5B7536; DTXSID10285386; Maleic acid,(2-ethoxyethyl)ethyl- (8CI)
DM4L0R7	DT	Small molecular drug
DM4L0R7	PC	444266
DM4L0R7	MW	116.07
DM4L0R7	FM	C4H4O4
DM4L0R7	IC	InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1-
DM4L0R7	CS	C(=C\\C(=O)O)\\C(=O)O
DM4L0R7	IK	VZCYOOQTPOCHFL-UPHRSURJSA-N
DM4L0R7	IU	(Z)-but-2-enedioic acid
DM4L0R7	CA	CAS 110-16-7
DM4L0R7	CB	CHEBI:18300
DM4L0R7	DE	Discovery agent

DMU3O5H	ID	DMU3O5H
DMU3O5H	DN	malic acid
DMU3O5H	HS	Investigative
DMU3O5H	SN	malate
DMU3O5H	DT	Small molecular drug
DMU3O5H	PC	525
DMU3O5H	MW	134.09
DMU3O5H	FM	C4H6O5
DMU3O5H	IC	InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9)
DMU3O5H	CS	C(C(C(=O)O)O)C(=O)O
DMU3O5H	IK	BJEPYKJPYRNKOW-UHFFFAOYSA-N
DMU3O5H	IU	2-hydroxybutanedioic acid
DMU3O5H	CA	CAS 6915-15-7
DMU3O5H	CB	CHEBI:6650
DMU3O5H	DE	Discovery agent

DM9ECWN	ID	DM9ECWN
DM9ECWN	DN	Mallotinic acid
DM9ECWN	HS	Investigative
DM9ECWN	SN	Mallotinic acid; CHEMBL448796; CHEBI:81154; SCHEMBL5381585; BDBM50250994; C17521; Galloyl 3-O,6-O-[4-(2,3,4-trihydroxy-6-carboxyphenoxy)-4',5,5',6,6'-pentahydroxybiphenyl-2,2'-diylbis(carbonyl)]-beta-D-glucopyranoside
DM9ECWN	DT	Small molecular drug
DM9ECWN	PC	10056140
DM9ECWN	MW	802.6
DM9ECWN	FM	C34H26O23
DM9ECWN	IC	InChI=1S/C34H26O23/c35-11-1-7(2-12(36)19(11)39)31(50)57-34-27(47)29-23(43)16(55-34)6-53-32(51)8-3-13(37)20(40)24(44)17(8)18-9(33(52)56-29)5-15(22(42)25(18)45)54-28-10(30(48)49)4-14(38)21(41)26(28)46/h1-5,16,23,27,29,34-47H,6H2,(H,48,49)/t16-,23-,27-,29+,34+/m1/s1
DM9ECWN	CS	C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O1)O)O)O)O)O)OC6=C(C(=C(C=C6C(=O)O)O)O)O)O
DM9ECWN	IK	AJIFASHLGBHDDS-GEFDNOIESA-N
DM9ECWN	IU	2-[[(1S,19R,21S,22R,23R)-7,8,11,12,13,22,23-heptahydroxy-3,16-dioxo-21-(3,4,5-trihydroxybenzoyl)oxy-2,17,20-trioxatetracyclo[17.3.1.04,9.010,15]tricosa-4,6,8,10,12,14-hexaen-6-yl]oxy]-3,4,5-trihydroxybenzoic acid
DM9ECWN	CB	CHEBI:81154
DM9ECWN	DE	Discovery agent

DMHX9P8	ID	DMHX9P8
DMHX9P8	DN	Mallotusinic acid
DMHX9P8	HS	Investigative
DMHX9P8	SN	Mallotusinic acid; C10235; 66421-47-4; beta-D-Glucopyranose, cyclic 3-2:6-2'-(4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) cyclic 2-7:4-5-(3,6-dihydro-2,9,10,11,11-pentahydroxy-3-oxo-2,6-methano-2H-1-benzoxocin-5,7-dicarboxylate) 1-(3,4,5-trihydroxybenzoate), stereoisomer
DMHX9P8	DT	Small molecular drug
DMHX9P8	PC	16131237
DMHX9P8	MW	1120.7
DMHX9P8	FM	C48H32O32
DMHX9P8	IC	InChI=1S/C48H32O32/c49-15-1-9(2-16(50)27(15)55)41(65)79-46-39-38-36(76-45(69)13-7-22(54)48(72)47(70,71)26(13)25-11(43(67)78-39)4-19(53)30(58)37(25)80-48)21(75-46)8-73-42(66)10-3-17(51)28(56)32(60)23(10)24-12(44(68)77-38)6-20(31(59)33(24)61)74-35-14(40(63)64)5-18(52)29(57)34(35)62/h1-7,21,26,36,38-39,46,49-53,55-62,70-72H,8H2,(H,63,64)
DMHX9P8	CS	C1C2C3C(C(C(O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5C7C(=CC(=O)C(C7(O)O)(O6)O)C(=O)O3)O)O)OC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O)OC1=C(C(=C(C=C1C(=O)O)O)O)O
DMHX9P8	IK	MWPRJJBXNINUTQ-UHFFFAOYSA-N
DMHX9P8	IU	2-[[1,14,15,18,19,20,34,35,39,39-decahydroxy-2,5,10,23,31-pentaoxo-28-(3,4,5-trihydroxybenzoyl)oxy-6,9,24,27,30,40-hexaoxaoctacyclo[34.3.1.04,38.07,26.08,29.011,16.017,22.032,37]tetraconta-3,11,13,15,17,19,21,32,34,36-decaen-13-yl]oxy]-3,4,5-trihydroxybenzoic acid
DMHX9P8	CA	CAS 66421-47-4
DMHX9P8	DE	Discovery agent

DMAJDU7	ID	DMAJDU7
DMAJDU7	DN	Malonate sodium
DMAJDU7	HS	Investigative
DMAJDU7	DE	Discovery agent

DMM5QXL	ID	DMM5QXL
DMM5QXL	DN	Malonic acid
DMM5QXL	HS	Investigative
DMM5QXL	SN	malonic acid; propanedioic acid; 141-82-2; Dicarboxymethane; Carboxyacetic acid; Methanedicarboxylic acid; Kyselina malonova; USAF EK-695; Dicarboxylate; Dicarboxylic acid; Kyselina malonova [Czech]; PROPANEDIOLIC ACID; UNII-9KX7ZMG0MK; NSC 8124; METAHNEDICARBOXYLIC ACID; Methanedicarbonic acid; Malonic acid, 99%; Thallium malonate; AI3-15375; 1,3-Propanedioic acid; EINECS 205-503-0; 9KX7ZMG0MK; BRN 1751370; DICARBOXYLIC ACID C3; alpha,omega-Dicarboxylic acid; CHEBI:30794; NSC8124; OFOBLEOULBTSOW-UHFFFAOYSA-N; MFCD00002707; malons
DMM5QXL	DT	Small molecular drug
DMM5QXL	PC	867
DMM5QXL	MW	104.06
DMM5QXL	FM	C3H4O4
DMM5QXL	IC	InChI=1S/C3H4O4/c4-2(5)1-3(6)7/h1H2,(H,4,5)(H,6,7)
DMM5QXL	CS	C(C(=O)O)C(=O)O
DMM5QXL	IK	OFOBLEOULBTSOW-UHFFFAOYSA-N
DMM5QXL	IU	propanedioic acid
DMM5QXL	CA	CAS 141-82-2
DMM5QXL	CB	CHEBI:30794
DMM5QXL	DE	Neurodegenerative disorder

DMMY542	ID	DMMY542
DMMY542	DN	Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam
DMMY542	HS	Investigative
DMMY542	DT	Small molecular drug
DMMY542	PC	46936258
DMMY542	MW	516.5
DMMY542	FM	C18H32N2O15
DMMY542	IC	InChI=1S/C18H32N2O15/c21-1-4-14(9(26)11(28)16(19-4)20-31)34-18-13(30)10(27)15(6(3-23)33-18)35-17-12(29)8(25)7(24)5(2-22)32-17/h4-15,17-18,21-31H,1-3H2,(H,19,20)/t4-,5+,6-,7+,8-,9-,10-,11+,12+,13-,14+,15-,17-,18+/m1/s1
DMMY542	CS	C([C@@H]1[C@@H]([C@@H]([C@@H](C(=N1)NO)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)O)O)O)O
DMMY542	IK	AHRWQUNEPBVNOT-JUQSOTOUSA-N
DMMY542	IU	(2R,3S,4R,5R,6S)-2-[(2R,3S,4R,5R,6R)-6-[[(2R,3S,4R,5R)-4,5-dihydroxy-6-(hydroxyamino)-2-(hydroxymethyl)-2,3,4,5-tetrahydropyridin-3-yl]oxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMMY542	DE	Discovery agent

DM213MD	ID	DM213MD
DM213MD	DN	M-Aminophenylboronic Acid
DM213MD	HS	Investigative
DM213MD	SN	3-Aminophenylboronic acid; 30418-59-8; 3-Aminobenzeneboronic acid; (3-aminophenyl)boronic acid; M-AMINOPHENYLBORONIC ACID; 3-aminophenyl boronic acid; m-aminophenyl boronic acid; 3-amino phenylboronic acid; CHEMBL20852; Boronic acid, (3-aminophenyl)-; MFCD00007755; 280563-63-5; (m-Aminophenyl)metaboric acid; 3-Boronoaniline; EINECS 250-189-0; zlchem 430; 3-Aminophenylboronicacid; ACMC-1CTTO; 3amino phenylboronic acid; 3aminophenyl boronic acid; AC1L3NRS; (3-aminophenyl)boranediol; 3-amino-phenylboronic acid; AC1Q51DZ
DM213MD	DT	Small molecular drug
DM213MD	PC	92269
DM213MD	MW	136.95
DM213MD	FM	C6H8BNO2
DM213MD	IC	InChI=1S/C6H8BNO2/c8-6-3-1-2-5(4-6)7(9)10/h1-4,9-10H,8H2
DM213MD	CS	B(C1=CC(=CC=C1)N)(O)O
DM213MD	IK	JMZFEHDNIAQMNB-UHFFFAOYSA-N
DM213MD	IU	(3-aminophenyl)boronic acid
DM213MD	CA	CAS 30418-59-8
DM213MD	DE	Discovery agent

DMNUA6S	ID	DMNUA6S
DMNUA6S	DN	Man-b-4MU
DMNUA6S	HS	Investigative
DMNUA6S	SN	VZ29453; Man-b-4MU; 4-methylumbelliferyl beta-d-mannopyranoside; SCHEMBL308899; ZINC13536768; ZX-AFC001336; 4-Methyl-7-(((2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2H-chromen-2-one; 4-Methylumbelliferyl beta-D-mannopyranoside; 4-Methylumbelliferyl mannoside; 4-Methylumbelliferyl-beta-D-mannopyranoside; 4MUBM; 67909-30-2; 7-((2S,3R,4S,5S)-tetrahydro-3,4,5-trihydroxy-6-(hydroxymethyl)-2H-pyran-2-yloxy)-4-methyl-2H-chromen-2-one; CHEMBL3797837; para-Methylumbelliferyl-beta-D-mannopyranoside
DMNUA6S	PC	194267
DMNUA6S	MW	338.31
DMNUA6S	FM	C16H18O8
DMNUA6S	IC	YUDPTGPSBJVHCN-NZBFACKJSA-N
DMNUA6S	CS	CC1=CC(=O)OC2=C1C=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O
DMNUA6S	IK	1S/C16H18O8/c1-7-4-12(18)23-10-5-8(2-3-9(7)10)22-16-15(21)14(20)13(19)11(6-17)24-16/h2-5,11,13-17,19-21H,6H2,1H3/t11-,13-,14+,15+,16-/m1/s1
DMNUA6S	IU	4-methyl-7-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
DMNUA6S	CA	CAS 67909-30-2
DMNUA6S	DE	Discovery agent

DMKT129	ID	DMKT129
DMKT129	DN	Manganese
DMKT129	HS	Investigative
DMKT129	SN	Colloidal manganese; Cutaval; MANGANESE COMPOUNDS; Magnacat; Mangan; Mangan [Polish]; Mangan nitridovany; Mangan nitridovany [Czech]; Manganese; Manganese element; Manganese fume; Manganese ion(4 ); Manganese metal alloy; Manganese(1-); Manganese(4 ); Manganese(7+); Manganese, 99+%, powder, -40 mesh; Manganese, elemental; Manganese, ion (Mn1-); Manganese, ion (Mn4 ); Manganese-55; Teprosyn M; Tronamang; manganeso; manganide; manganum
DMKT129	DT	Small molecular drug
DMKT129	PC	23930
DMKT129	MW	54.938
DMKT129	FM	Mn
DMKT129	IC	InChI=1S/Mn
DMKT129	CS	[Mn]
DMKT129	IK	PWHULOQIROXLJO-UHFFFAOYSA-N
DMKT129	IU	manganese
DMKT129	CA	CAS 7439-96-5
DMKT129	CB	ChEBI:18291

DMWAF5Z	ID	DMWAF5Z
DMWAF5Z	DN	MANGIFERIN
DMWAF5Z	HS	Investigative
DMWAF5Z	SN	Mangiferin; 4773-96-0; Hedysarid; Chinomin; Alpizarin; Chinonin; Aphloiol; Alpizarine; UNII-1M84LD0UMD; 1M84LD0UMD; CHEBI:6682; 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one; (1S)-1,5-anhydro-1-(1,3,6,7-tetrahydroxy-9-oxo-9H-xanthen-2-yl)-D-glucitol; 1,3,6,7-Tetrahydroxyxanthone-C2-b-D-glucoside; Chinoinin; 9H-Xanthen-9-one, 2-.beta.-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; C19H18O11; NSC 248870; 9H-Xanthen-9-one, 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; cid_5358385; Mangiferin;; Alpizarine;; Chinomin;
DMWAF5Z	DT	Small molecular drug
DMWAF5Z	PC	5281647
DMWAF5Z	MW	422.3
DMWAF5Z	FM	C19H18O11
DMWAF5Z	IC	InChI=1S/C19H18O11/c20-4-11-15(25)17(27)18(28)19(30-11)12-8(23)3-10-13(16(12)26)14(24)5-1-6(21)7(22)2-9(5)29-10/h1-3,11,15,17-23,25-28H,4H2/t11-,15-,17+,18-,19+/m1/s1
DMWAF5Z	CS	C1=C2C(=CC(=C1O)O)OC3=C(C2=O)C(=C(C(=C3)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
DMWAF5Z	IK	AEDDIBAIWPIIBD-ZJKJAXBQSA-N
DMWAF5Z	IU	1,3,6,7-tetrahydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]xanthen-9-one
DMWAF5Z	CA	CAS 4773-96-0
DMWAF5Z	CB	CHEBI:6682
DMWAF5Z	DE	Discovery agent

DMOWZUB	ID	DMOWZUB
DMOWZUB	DN	MANGOSTANIN
DMOWZUB	HS	Investigative
DMOWZUB	SN	9-Hydroxycalabaxanthone; Mangostanin; 35349-68-9; CHEMBL561643; Q-100424; 5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyl)pyrano[3,2-b]xanthen-6-one; AC1NUY37; SCHEMBL5617031; MolPort-029-887-080; ZINC13382495; BDBM50311741; AKOS032962410; W2653; 2H,6H-Pyrano[3,2-b]xanthen-6-one,5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methyl-2-butenyl)-; 1,6-dihydroxy-7-methoxy-8-(3-methylbut-2-enyl)-6'',6''-dimethylpyrano(2'',3'':3,2)xanthone
DMOWZUB	DT	Small molecular drug
DMOWZUB	PC	5495929
DMOWZUB	MW	408.4
DMOWZUB	FM	C24H24O6
DMOWZUB	IC	InChI=1S/C24H24O6/c1-12(2)6-7-14-19-17(10-15(25)23(14)28-5)29-18-11-16-13(8-9-24(3,4)30-16)21(26)20(18)22(19)27/h6,8-11,25-26H,7H2,1-5H3
DMOWZUB	CS	CC(=CCC1=C(C(=CC2=C1C(=O)C3=C(C4=C(C=C3O2)OC(C=C4)(C)C)O)O)OC)C
DMOWZUB	IK	HQWHKELJHUFLGD-UHFFFAOYSA-N
DMOWZUB	IU	5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyl)pyrano[3,2-b]xanthen-6-one
DMOWZUB	CA	CAS 35349-68-9
DMOWZUB	DE	Discovery agent

DMG3DUE	ID	DMG3DUE
DMG3DUE	DN	MANGOSTANOL
DMG3DUE	HS	Investigative
DMG3DUE	SN	MANGOSTANOL; 184587-72-2; CHEMBL1224250; (+)-Mangostanol; MolPort-035-706-483; BDBM50325676; AKOS032961774; W2661; 2H,6H-Pyrano[3,2-b]xanthen-6-one,3,4-dihydro-3,5,9-trihydroxy-8-methoxy-2,2-dimethyl-7-(3-methyl-2-buten-1-yl)-,(+)-
DMG3DUE	DT	Small molecular drug
DMG3DUE	PC	10048103
DMG3DUE	MW	426.5
DMG3DUE	FM	C24H26O7
DMG3DUE	IC	InChI=1S/C24H26O7/c1-11(2)6-7-12-19-16(9-14(25)23(12)29-5)30-17-10-15-13(21(27)20(17)22(19)28)8-18(26)24(3,4)31-15/h6,9-10,18,25-27H,7-8H2,1-5H3
DMG3DUE	CS	CC(=CCC1=C(C(=CC2=C1C(=O)C3=C(C4=C(C=C3O2)OC(C(C4)O)(C)C)O)O)OC)C
DMG3DUE	IK	KCMPFWGUVNEDHW-UHFFFAOYSA-N
DMG3DUE	IU	3,5,9-trihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyl)-3,4-dihydropyrano[3,2-b]xanthen-6-one
DMG3DUE	CA	CAS 184587-72-2
DMG3DUE	DE	Discovery agent

DMNRZ3S	ID	DMNRZ3S
DMNRZ3S	DN	MANGOSTENONE F
DMNRZ3S	HS	Investigative
DMNRZ3S	SN	CHEMBL1224411; MANGOSTENONE F; BDBM50325677
DMNRZ3S	DT	Small molecular drug
DMNRZ3S	PC	49866102
DMNRZ3S	MW	408.4
DMNRZ3S	FM	C24H24O6
DMNRZ3S	IC	InChI=1S/C24H24O6/c1-11(2)6-7-13-20-18(9-15(25)24(13)28-5)30-19-10-17-14(8-16(29-17)12(3)4)22(26)21(19)23(20)27/h6,9-10,16,25-26H,3,7-8H2,1-2,4-5H3
DMNRZ3S	CS	CC(=CCC1=C(C(=CC2=C1C(=O)C3=C(C4=C(C=C3O2)OC(C4)C(=C)C)O)O)OC)C
DMNRZ3S	IK	AWFULCQUYOKYCM-UHFFFAOYSA-N
DMNRZ3S	IU	4,8-dihydroxy-7-methoxy-6-(3-methylbut-2-enyl)-2-prop-1-en-2-yl-2,3-dihydrofuro[3,2-b]xanthen-5-one
DMNRZ3S	DE	Discovery agent

DM4I2NR	ID	DM4I2NR
DM4I2NR	DN	MANGOSTENONE G
DM4I2NR	HS	Investigative
DM4I2NR	SN	CHEMBL1224412; MANGOSTENONE G; BDBM50325678
DM4I2NR	DT	Small molecular drug
DM4I2NR	PC	49866103
DM4I2NR	MW	394.4
DM4I2NR	FM	C23H22O6
DM4I2NR	IC	InChI=1S/C23H22O6/c1-10(2)5-6-12-14(24)8-18-20(21(12)26)22(27)19-13-7-16(11(3)4)29-23(13)15(25)9-17(19)28-18/h5,8-9,16,24-26H,3,6-7H2,1-2,4H3
DM4I2NR	CS	CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C4=C(C(=C3)O)OC(C4)C(=C)C)O)C
DM4I2NR	IK	SEGCUVJLNASWOR-UHFFFAOYSA-N
DM4I2NR	IU	4,8,10-trihydroxy-9-(3-methylbut-2-enyl)-2-prop-1-en-2-yl-1,2-dihydrofuro[3,2-a]xanthen-11-one
DM4I2NR	DE	Discovery agent

DMYQGDV	ID	DMYQGDV
DMYQGDV	DN	MANGOSTIN
DMYQGDV	HS	Investigative
DMYQGDV	SN	alpha-Mangostin; Mangostin; 6147/11/1; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; Mangostine; NSC30552; NSC27593; NSC-30552; UNII-U6RIV93RU1; U6RIV93RU1; CHEMBL323197; CHEBI:67547; GNRIZKKCNOBBMO-UHFFFAOYSA-N; 1,3,6-trihydroxy-7-methoxy-2,8-diprenylxanthone; TNP00140; NSC 27593; NSC 30552; NSC 139154; AK105375; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-9H-xanthen-9-one; Q-100010
DMYQGDV	DT	Small molecular drug
DMYQGDV	PC	5281650
DMYQGDV	MW	410.5
DMYQGDV	FM	C24H26O6
DMYQGDV	IC	InChI=1S/C24H26O6/c1-12(2)6-8-14-16(25)10-19-21(22(14)27)23(28)20-15(9-7-13(3)4)24(29-5)17(26)11-18(20)30-19/h6-7,10-11,25-27H,8-9H2,1-5H3
DMYQGDV	CS	CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C(=C(C(=C3)O)OC)CC=C(C)C)O)C
DMYQGDV	IK	GNRIZKKCNOBBMO-UHFFFAOYSA-N
DMYQGDV	IU	1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one
DMYQGDV	CA	CAS 6147-11-1
DMYQGDV	CB	CHEBI:67547
DMYQGDV	DE	Discovery agent

DMSO8EU	ID	DMSO8EU
DMSO8EU	DN	Mannotetraose
DMSO8EU	HS	Investigative
DMSO8EU	SN	Mannotetraose; Q27132313; 51327-76-5; CHEBI:62973; Mannose, O-beta-D-mannopyranosyl-(1-4)-O-beta-D-mannopyranosyl-(1-4)-O-beta-D-mannopyranosyl-(1-4)-, D-; O-MTE; beta-D-Manp-(1-&gt;4)-beta-D-Manp-(1-&gt;4)-beta-D-Manp-(1-&gt;4)-D-Manp; beta-D-mannopyranosyl-(1-&gt;4)-beta-D-mannopyranosyl-(1-&gt;4)-beta-D-mannopyranosyl-(1-&gt;4)-D-mannopyranose
DMSO8EU	PC	53477669
DMSO8EU	MW	666.6
DMSO8EU	FM	C24H42O21
DMSO8EU	IC	LUEWUZLMQUOBSB-MHJOMNRISA-N
DMSO8EU	CS	C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)O)CO)CO)CO)O)O)O)O
DMSO8EU	IK	1S/C24H42O21/c25-1-5-9(29)10(30)15(35)22(40-5)44-19-7(3-27)42-24(17(37)12(19)32)45-20-8(4-28)41-23(16(36)13(20)33)43-18-6(2-26)39-21(38)14(34)11(18)31/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10+,11-,12-,13-,14+,15+,16+,17+,18-,19-,20-,21?,22+,23+,24+/m1/s1
DMSO8EU	IU	(2S,3S,4S,5S,6R)-2-[(2R,3S,4R,5S,6S)-6-[(2R,3S,4R,5S,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMSO8EU	CA	CAS 51327-76-5
DMSO8EU	CB	CHEBI:62973
DMSO8EU	DE	Alzheimer disease

DMB3GNC	ID	DMB3GNC
DMB3GNC	DN	MANZAMINE A
DMB3GNC	HS	Investigative
DMB3GNC	SN	Manzamine A; 104196-68-1; CHEMBL611781; SCHEMBL11915472
DMB3GNC	DT	Small molecular drug
DMB3GNC	PC	6509753
DMB3GNC	MW	548.8
DMB3GNC	FM	C36H44N4O
DMB3GNC	IC	InChI=1S/C36H44N4O/c41-36-18-10-4-1-2-5-11-20-39-22-17-30(35(25-39)23-26-13-7-3-6-12-21-40(26)34(35)36)29(24-36)32-33-28(16-19-37-32)27-14-8-9-15-31(27)38-33/h1,4,7-9,13-16,19,24,26,30,34,38,41H,2-3,5-6,10-12,17-18,20-23,25H2/b4-1-,13-7-/t26-,30-,34+,35-,36-/m0/s1
DMB3GNC	CS	C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]/5N4CCCC/C=C5)O)C6=NC=CC7=C6NC8=CC=CC=C78
DMB3GNC	IK	FUCSLKWLLSEMDQ-MKYGIPPKSA-N
DMB3GNC	IU	(1R,2R,4R,5Z,12R,13S,16Z)-25-(9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DMB3GNC	CA	CAS 104196-68-1
DMB3GNC	CB	CHEBI:66667
DMB3GNC	DE	Discovery agent

DMOI9RT	ID	DMOI9RT
DMOI9RT	DN	Manzamine E
DMOI9RT	HS	Investigative
DMOI9RT	SN	Manzamine E
DMOI9RT	DT	Small molecular drug
DMOI9RT	PC	6474830
DMOI9RT	MW	564.8
DMOI9RT	FM	C36H44N4O2
DMOI9RT	IC	InChI=1S/C36H44N4O2/c41-26-10-9-20-40-25(13-14-26)22-35-24-39-19-8-4-2-1-3-7-17-36(42,34(35)40)23-29(30(35)16-21-39)32-33-28(15-18-37-32)27-11-5-6-12-31(27)38-33/h1,3,5-6,11-12,15,18,23,25,30,34,38,42H,2,4,7-10,13-14,16-17,19-22,24H2/b3-1-/t25?,30-,34?,35-,36-/m0/s1
DMOI9RT	CS	C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)(C4[C@]3(C2)CC5N4CCCC(=O)CC5)O)C6=NC=CC7=C6NC8=CC=CC=C78
DMOI9RT	IK	LTHULOBARTYAMF-JUOMLHCBSA-N
DMOI9RT	IU	(1R,2R,13S,16Z)-13-hydroxy-25-(9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-16,25-dien-7-one
DMOI9RT	DE	Discovery agent

DMC7ADZ	ID	DMC7ADZ
DMC7ADZ	DN	Manzamine Y
DMC7ADZ	HS	Investigative
DMC7ADZ	SN	manzamine Y; CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol
DMC7ADZ	DT	Small molecular drug
DMC7ADZ	PC	10393120
DMC7ADZ	MW	564.8
DMC7ADZ	FM	C36H44N4O2
DMC7ADZ	IC	InChI=1S/C36H44N4O2/c41-26-12-13-31-28(21-26)27-14-17-37-32(33(27)38-31)29-23-36(42)16-8-4-1-2-5-9-18-39-20-15-30(29)35(24-39)22-25-11-7-3-6-10-19-40(25)34(35)36/h1,4,7,11-14,17,21,23,25,30,34,38,41-42H,2-3,5-6,8-10,15-16,18-20,22,24H2/b4-1-,11-7-/t25-,30-,34+,35-,36-/m0/s1
DMC7ADZ	CS	C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]/5N4CCCC/C=C5)O)C6=NC=CC7=C6NC8=C7C=C(C=C8)O
DMC7ADZ	IK	CANRNZBVKKQKEQ-FFMUKQARSA-N
DMC7ADZ	IU	(1R,2R,4R,5Z,12R,13S,16Z)-25-(6-hydroxy-9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DMC7ADZ	CB	CHEBI:66668

DMUCE93	ID	DMUCE93
DMUCE93	DN	MAP4
DMUCE93	HS	Investigative
DMUCE93	SN	MAP4; (S)-2-Amino-2-methyl-4-phosphonobutanoic acid; 157381-42-5; (2S)-2-amino-2-methyl-4-phosphonobutanoic acid; Tocris-0711; AC1LX6MM; MAP-4; SCHEMBL179781; GTPL1414; CHEMBL1488784; MolPort-003-983-618; ZINC2139819; BN0320; AKOS006272533; NCGC00024744-02; NCGC00024744-01; B6414; SR-01000597625; 381A425; J-009412
DMUCE93	DT	Small molecular drug
DMUCE93	PC	1795545
DMUCE93	MW	197.13
DMUCE93	FM	C5H12NO5P
DMUCE93	IC	InChI=1S/C5H12NO5P/c1-5(6,4(7)8)2-3-12(9,10)11/h2-3,6H2,1H3,(H,7,8)(H2,9,10,11)/t5-/m0/s1
DMUCE93	CS	C[C@](CCP(=O)(O)O)(C(=O)O)N
DMUCE93	IK	HONKEGXLWUDTCF-YFKPBYRVSA-N
DMUCE93	IU	(2S)-2-amino-2-methyl-4-phosphonobutanoic acid
DMUCE93	DE	Discovery agent

DMKT21X	ID	DMKT21X
DMKT21X	DN	MAR-531
DMKT21X	HS	Investigative
DMKT21X	SN	Glucagon analogs (injector pen, hypoglycemia); Glucagon analogs (injector pen, hypoglycemia), Marcadia/ Eli Lilly
DMKT21X	CP	Marcadia Biotech Inc
DMKT21X	DE	Hypoglycemia

DMGF7XC	ID	DMGF7XC
DMGF7XC	DN	MAR--99
DMGF7XC	HS	Investigative
DMGF7XC	SN	BRN 5609020
DMGF7XC	CP	Roussel Morishita Pharmaceutical Co Ltd
DMGF7XC	DT	Small molecular drug
DMGF7XC	PC	127154
DMGF7XC	MW	303.31
DMGF7XC	FM	C15H17N3O4
DMGF7XC	IC	InChI=1S/C15H17N3O4/c1-3-9(2)22-12-7-5-4-6-11(12)17-15-16-8-10(14(20)21)13(19)18-15/h4-9H,3H2,1-2H3,(H,20,21)(H2,16,17,18,19)
DMGF7XC	CS	CCC(C)OC1=CC=CC=C1NC2=NC=C(C(=O)N2)C(=O)O
DMGF7XC	IK	GPASXNHOXQCREW-UHFFFAOYSA-N
DMGF7XC	IU	2-(2-butan-2-yloxyanilino)-6-oxo-1H-pyrimidine-5-carboxylic acid
DMGF7XC	CA	CAS 98772-05-5
DMGF7XC	DE	Asthma

DMN9UX3	ID	DMN9UX3
DMN9UX3	DN	MASLINIC ACID
DMN9UX3	HS	Investigative
DMN9UX3	SN	Maslinic acid; 4373-41-5; Crategolic acid; Masilinic acid; Crataegolic acid; UNII-E233J88OHQ; E233J88OHQ; CHEMBL201515; CHEBI:66682; Maslic acid; 2alpha,3beta-dihydroxyurs-12-en-29-oic acid; (4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid; Maslinicacid
DMN9UX3	DT	Small molecular drug
DMN9UX3	PC	73659
DMN9UX3	MW	472.7
DMN9UX3	FM	C30H48O4
DMN9UX3	IC	InChI=1S/C30H48O4/c1-25(2)12-14-30(24(33)34)15-13-28(6)18(19(30)16-25)8-9-22-27(5)17-20(31)23(32)26(3,4)21(27)10-11-29(22,28)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20+,21-,22+,23-,27-,28+,29+,30-/m0/s1
DMN9UX3	CS	C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@@H](C3(C)C)O)O)C
DMN9UX3	IK	MDZKJHQSJHYOHJ-LLICELPBSA-N
DMN9UX3	IU	(4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMN9UX3	CA	CAS 4373-41-5
DMN9UX3	CB	CHEBI:66682
DMN9UX3	DE	Discovery agent

DMDZIHT	ID	DMDZIHT
DMDZIHT	DN	mast cell degranulating peptide
DMDZIHT	HS	Investigative
DMDZIHT	SN	MCDP; MCD peptide; Peptide 401
DMDZIHT	DT	Small molecular drug
DMDZIHT	PC	16132290
DMDZIHT	MW	2587.2
DMDZIHT	FM	C110H192N40O24S4
DMDZIHT	IC	InChI=1S/C110H192N40O24S4/c1-11-58(7)83(118)103(169)136-66(30-17-22-38-113)94(160)142-77-53-176-175-51-75(89(155)128-50-82(153)131-64(28-15-20-36-111)90(156)138-71(88(119)154)46-80(116)151)144-106(172)85(59(8)12-2)147-95(161)67(31-18-23-39-114)132-92(158)68(33-25-41-126-109(120)121)135-100(166)78-54-178-177-52-76(143-96(162)74(47-81(117)152)140-101(77)167)99(165)134-65(29-16-21-37-112)91(157)133-69(34-26-42-127-110(122)123)93(159)139-72(44-62-48-124-55-129-62)97(163)146-84(57(5)6)104(170)149-87(61(10)14-4)105(171)137-70(32-19-24-40-115)108(174)150-43-27-35-79(150)102(168)141-73(45-63-49-125-56-130-63)98(164)148-86(60(9)13-3)107(173)145-78/h48-49,55-79,83-87H,11-47,50-54,111-115,118H2,1-10H3,(H2,116,151)(H2,117,152)(H2,119,154)(H,128,155)(H,131,153)(H,132,158)(H,133,157)(H,134,165)(H,135,166)(H,136,169)(H,137,171)(H,138,156)(H,139,159)(H,140,167)(H,141,168)(H,142,160)(H,143,162)(H,144,172)(H,145,173)(H,146,163)(H,147,161)(H,148,164)(H,149,170)(H4,120,121,126)(H4,122,123,127)
DMDZIHT	CS	CCC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CCCNC(=N)N)NC(=O)C(NC(=O)C(NC(=O)C3CCCN3C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCCCN)CCCNC(=N)N)CC4C=NC=N4)C(C)C)C(C)CC)CCCCN)CC5C=NC=N5)C(C)CC)CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)N)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N
DMDZIHT	IK	QMBRLNFAEHGOLY-UHFFFAOYSA-N
DMDZIHT	IU	2-[[6-amino-2-[[2-[[40-[[6-amino-2-[(2-amino-3-methylpentanoyl)amino]hexanoyl]amino]-16,31,51-tris(4-aminobutyl)-37-(2-amino-2-oxoethyl)-4,19,48-tri(butan-2-yl)-28,54-bis(3-carbamimidamidopropyl)-7,25-bis(4H-imidazol-4-ylmethyl)-3,6,9,15,18,21,24,27,30,33,36,39,47,50,53,56-hexadecaoxo-22-propan-2-yl-42,43,58,59-tetrathia-2,5,8,14,17,20,23,26,29,32,35,38,46,49,52,55-hexadecazatricyclo[32.22.4.010,14]hexacontane-45-carbonyl]amino]acetyl]amino]hexanoyl]amino]butanediamide
DMDZIHT	CA	CAS 32908-73-9
DMDZIHT	DE	Discovery agent

DM9KLQC	ID	DM9KLQC
DM9KLQC	DN	MB-03966
DM9KLQC	HS	Investigative
DM9KLQC	SN	AK inhibitors, Gensia; AK inhibitors, SICOR; Adenosine kinase inhibitors, Metabasis; Adenosine kinase inhibitors, SICOR; GP-3966; GP-4364; MB-03691; MB-4587; Tubercidin derivatives, Metabasis
DM9KLQC	CP	SICOR Inc
DM9KLQC	DE	Epileptic seizures

DMNRMKA	ID	DMNRMKA
DMNRMKA	DN	MB-3
DMNRMKA	HS	Investigative
DMNRMKA	SN	alpha-methylene-gamma-butyrolactone 3
DMNRMKA	DT	Small molecular drug
DMNRMKA	PC	91827357
DMNRMKA	MW	186.16
DMNRMKA	FM	C8H10O5
DMNRMKA	IC	InChI=1S/C8H10O5/c1-2-3-4-5(7(10)11)6(9)8(12)13-4/h4-5H,2-3H2,1H3,(H,10,11)/t4-,5-/m0/s1
DMNRMKA	CS	CCC[C@H]1[C@@H](C(=O)C(=O)O1)C(=O)O
DMNRMKA	IK	AKWJFOMNTDKSRR-WHFBIAKZSA-N
DMNRMKA	IU	(2S,3S)-4,5-dioxo-2-propyloxolane-3-carboxylic acid
DMNRMKA	DE	Discovery agent

DM89WA1	ID	DM89WA1
DM89WA1	DN	MBX-3254
DM89WA1	HS	Investigative
DM89WA1	SN	GPR119 follow-on compounds (diabetes); GPR119 follow-on compounds (diabetes), Metabolex; MBX-2982 follow-on compounds (diabetes), Metabolex
DM89WA1	CP	Metabolex Inc
DM89WA1	DE	Non-insulin dependent diabetes

DMPTNUQ	ID	DMPTNUQ
DMPTNUQ	DN	MC-113
DMPTNUQ	HS	Investigative
DMPTNUQ	SN	Sigma opoid receptor agonist (oral, CNS diseases), M's Science
DMPTNUQ	CP	M's Science Corp
DMPTNUQ	DE	Central nervous system disease

DMQC9UB	ID	DMQC9UB
DMQC9UB	DN	MC-116
DMQC9UB	HS	Investigative
DMQC9UB	SN	MC-116 series; Sigma opioid receptor-1 agonists (oral, CNS diseases), M's Science
DMQC9UB	CP	M's Science Corp
DMQC9UB	DE	Central nervous system disease

DM5RVO0	ID	DM5RVO0
DM5RVO0	DN	MC-1301
DM5RVO0	HS	Investigative
DM5RVO0	SN	134523-85-6
DM5RVO0	DT	Small molecular drug
DM5RVO0	PC	6439378
DM5RVO0	MW	458.7
DM5RVO0	FM	C30H50O3
DM5RVO0	IC	InChI=1S/C30H50O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h13-14,21,25-28,31-33H,4,6-12,15-20H2,1-3,5H3/b23-13+,24-14+/t21?,25-,26?,27+,28+,29-/m1/s1
DM5RVO0	CS	CCC(CC)(CCCCC(C)C1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C\\3/C[C@H](C[C@@H](C3=C)O)O)C)O
DM5RVO0	IK	DFOWDEBIOXYKFC-WIAGJZICSA-N
DM5RVO0	IU	(1R,3S,5E)-5-[(2E)-2-[(3aS,7aR)-1-(7-ethyl-7-hydroxynonan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM5RVO0	CA	CAS 134523-85-6
DM5RVO0	DE	Discovery agent

DM6J2UZ	ID	DM6J2UZ
DM6J2UZ	DN	MCC950
DM6J2UZ	HS	Investigative
DM6J2UZ	SN	MCC950; 210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea
DM6J2UZ	DT	Small molecular drug
DM6J2UZ	PC	9910393
DM6J2UZ	MW	404.5
DM6J2UZ	FM	C20H24N2O5S
DM6J2UZ	IC	InChI=1S/C20H24N2O5S/c1-20(2,24)14-10-17(27-11-14)28(25,26)22-19(23)21-18-15-7-3-5-12(15)9-13-6-4-8-16(13)18/h9-11,24H,3-8H2,1-2H3,(H2,21,22,23)
DM6J2UZ	CS	CC(C)(C1=COC(=C1)S(=O)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4)O
DM6J2UZ	IK	HUUSXLKCTQDPGL-UHFFFAOYSA-N
DM6J2UZ	IU	1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea
DM6J2UZ	CA	CAS 210826-40-7
DM6J2UZ	DE	Discovery agent

DMAHN4L	ID	DMAHN4L
DMAHN4L	DN	MC-CAM
DMAHN4L	HS	Investigative
DMAHN4L	SN	CHEMBL386272; MC-CAM; BDBM50195674; BDBM50091405; 14-[(4-Chlorocinnamoyl)amino]-4,5alpha-epoxy-17-(cyclopropylmethyl)-3-methoxymorphinan-6-one; 1N-[4-cyclopropylmethyl-10-methoxy-14-oxo-(17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18)-trien-17-yl]-3-(4-chlorophenyl)-(E)-2-propenamide(Methyoclocinnamox (MC-CAM))
DMAHN4L	DT	Small molecular drug
DMAHN4L	PC	44417373
DMAHN4L	MW	519
DMAHN4L	FM	C30H31ClN2O4
DMAHN4L	IC	InChI=1S/C30H31ClN2O4/c1-36-23-10-7-20-16-24-30(32-25(35)11-6-18-4-8-21(31)9-5-18)13-12-22(34)28-29(30,26(20)27(23)37-28)14-15-33(24)17-19-2-3-19/h4-11,19,24,28H,2-3,12-17H2,1H3,(H,32,35)/b11-6+/t24-,28+,29+,30-/m1/s1
DMAHN4L	CS	COC1=C2C3=C(C[C@@H]4[C@]5([C@]3(CCN4CC6CC6)[C@@H](O2)C(=O)CC5)NC(=O)/C=C/C7=CC=C(C=C7)Cl)C=C1
DMAHN4L	IK	LZSMGMMAKBCSRL-WDJVXPEUSA-N
DMAHN4L	IU	(E)-N-[(4R,4aS,7aR,12bR)-3-(cyclopropylmethyl)-9-methoxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-chlorophenyl)prop-2-enamide
DMAHN4L	DE	Discovery agent

DMKTX1A	ID	DMKTX1A
DMKTX1A	DN	MCCG
DMKTX1A	HS	Investigative
DMKTX1A	SN	MCCG-I
DMKTX1A	DT	Small molecular drug
DMKTX1A	PC	5311457
DMKTX1A	MW	173.17
DMKTX1A	FM	C7H11NO4
DMKTX1A	IC	InChI=1S/C7H11NO4/c1-7(8,6(11)12)4-2-3(4)5(9)10/h3-4H,2,8H2,1H3,(H,9,10)(H,11,12)/t3-,4-,7-/m0/s1
DMKTX1A	CS	C[C@]([C@H]1C[C@@H]1C(=O)O)(C(=O)O)N
DMKTX1A	IK	KFACHLANPCGTFI-FVSJBQLASA-N
DMKTX1A	IU	(1S,2S)-2-[(1S)-1-amino-1-carboxyethyl]cyclopropane-1-carboxylic acid
DMKTX1A	CB	CHEBI:125551
DMKTX1A	DE	Discovery agent

DMM1J2D	ID	DMM1J2D
DMM1J2D	DN	m-chlorophenylpiperazine
DMM1J2D	HS	Investigative
DMM1J2D	SN	1-(m-chlorophenyl)piperazine; meta chlorophenyl piperazine
DMM1J2D	DT	Small molecular drug
DMM1J2D	PC	1355
DMM1J2D	MW	196.67
DMM1J2D	FM	C10H13ClN2
DMM1J2D	IC	InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2
DMM1J2D	CS	C1CN(CCN1)C2=CC(=CC=C2)Cl
DMM1J2D	IK	VHFVKMTVMIZMIK-UHFFFAOYSA-N
DMM1J2D	IU	1-(3-chlorophenyl)piperazine
DMM1J2D	CA	CAS 6640-24-0
DMM1J2D	CB	CHEBI:10588
DMM1J2D	DE	Discovery agent

DMZ1YGI	ID	DMZ1YGI
DMZ1YGI	DN	MCI
DMZ1YGI	HS	Investigative
DMZ1YGI	SN	AC1L1B35; CTK8A8774; (2-mercaptomethyl-4-phenyl-butyrylimino)-(5-tetrazol-1-ylmethyl-thiophen-2-yl)-acetic acid; 2-[4-phenyl-2-(sulfanylmethyl)butanoyl]imino-2-[5-(tetrazol-1-ylmethyl)thiophen-2-yl]acetic acid
DMZ1YGI	DT	Small molecular drug
DMZ1YGI	PC	1263
DMZ1YGI	MW	429.5
DMZ1YGI	FM	C19H19N5O3S2
DMZ1YGI	IC	InChI=1S/C19H19N5O3S2/c25-18(14(11-28)7-6-13-4-2-1-3-5-13)21-17(19(26)27)16-9-8-15(29-16)10-24-12-20-22-23-24/h1-5,8-9,12,14,28H,6-7,10-11H2,(H,26,27)
DMZ1YGI	CS	C1=CC=C(C=C1)CCC(CS)C(=O)N=C(C2=CC=C(S2)CN3C=NN=N3)C(=O)O
DMZ1YGI	IK	DUKDFMPUZRDWLT-UHFFFAOYSA-N
DMZ1YGI	IU	2-[4-phenyl-2-(sulfanylmethyl)butanoyl]imino-2-[5-(tetrazol-1-ylmethyl)thiophen-2-yl]acetic acid
DMZ1YGI	DE	Discovery agent

DMFTPMX	ID	DMFTPMX
DMFTPMX	DN	MCL0129
DMFTPMX	HS	Investigative
DMFTPMX	SN	MCL-0129; TCMDC-134847
DMFTPMX	DT	Small molecular drug
DMFTPMX	PC	6918688
DMFTPMX	MW	546.8
DMFTPMX	FM	C34H47FN4O
DMFTPMX	IC	InChI=1S/C34H47FN4O/c1-27(2)38-22-24-39(25-23-38)33(29-11-14-30(35)15-12-29)26-37-20-18-36(19-21-37)17-7-6-10-32-31-9-5-4-8-28(31)13-16-34(32)40-3/h4-5,8-9,11-16,27,33H,6-7,10,17-26H2,1-3H3/t33-/m1/s1
DMFTPMX	CS	CC(C)N1CCN(CC1)[C@H](CN2CCN(CC2)CCCCC3=C(C=CC4=CC=CC=C43)OC)C5=CC=C(C=C5)F
DMFTPMX	IK	SLGLZEJKMBCODK-MGBGTMOVSA-N
DMFTPMX	IU	1-[(1S)-1-(4-fluorophenyl)-2-[4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazin-1-yl]ethyl]-4-propan-2-ylpiperazine
DMFTPMX	DE	Discovery agent

DMQIGZ7	ID	DMQIGZ7
DMQIGZ7	DN	MCL-117
DMQIGZ7	HS	Investigative
DMQIGZ7	SN	MCL-117; CHEMBL1790045; (-)3-hydroxy-N-propargylmorphinan; BDBM50366764
DMQIGZ7	DT	Small molecular drug
DMQIGZ7	PC	6602241
DMQIGZ7	MW	281.4
DMQIGZ7	FM	C19H23NO
DMQIGZ7	IC	InChI=1S/C19H23NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h1,6-7,13,16,18,21H,3-5,8-12H2/t16-,18+,19+/m0/s1
DMQIGZ7	CS	C#CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O
DMQIGZ7	IK	OKICQDFBWUMTDE-QXAKKESOSA-N
DMQIGZ7	IU	(1R,9R,10R)-17-prop-2-ynyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMQIGZ7	DE	Discovery agent

DMQZC0U	ID	DMQZC0U
DMQZC0U	DN	MCL-129
DMQZC0U	HS	Investigative
DMQZC0U	SN	MCL-129; CHEMBL362985; SCHEMBL5318500; SLGLZEJKMBCODK-UHFFFAOYSA-N; BDBM50166529; PDSP2_001273; PDSP1_001289; 1-(2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl)-4-(4-(2-methoxynaphthalen-1-yl)butyl)piperazine; 1-[2-(4-fluorophenyl)-2-(4-isopropylhexahydro-1-pyrazinyl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]hexahydropyrazine; (+/-)-1-[2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]piperazine
DMQZC0U	DT	Small molecular drug
DMQZC0U	PC	10098971
DMQZC0U	MW	546.8
DMQZC0U	FM	C34H47FN4O
DMQZC0U	IC	InChI=1S/C34H47FN4O/c1-27(2)38-22-24-39(25-23-38)33(29-11-14-30(35)15-12-29)26-37-20-18-36(19-21-37)17-7-6-10-32-31-9-5-4-8-28(31)13-16-34(32)40-3/h4-5,8-9,11-16,27,33H,6-7,10,17-26H2,1-3H3
DMQZC0U	CS	CC(C)N1CCN(CC1)C(CN2CCN(CC2)CCCCC3=C(C=CC4=CC=CC=C43)OC)C5=CC=C(C=C5)F
DMQZC0U	IK	SLGLZEJKMBCODK-UHFFFAOYSA-N
DMQZC0U	IU	1-[1-(4-fluorophenyl)-2-[4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazin-1-yl]ethyl]-4-propan-2-ylpiperazine
DMQZC0U	DE	Discovery agent

DMQ1BDZ	ID	DMQ1BDZ
DMQ1BDZ	DN	MCL-139
DMQ1BDZ	HS	Investigative
DMQ1BDZ	SN	MCL-139; CHEMBL203251
DMQ1BDZ	DT	Small molecular drug
DMQ1BDZ	PC	44406697
DMQ1BDZ	MW	705
DMQ1BDZ	FM	C46H60N2O4
DMQ1BDZ	IC	InChI=1S/C46H60N2O4/c49-43(51-35-15-13-33-25-41-37-11-1-3-19-45(37,39(33)27-35)21-23-47(41)29-31-7-5-8-31)17-18-44(50)52-36-16-14-34-26-42-38-12-2-4-20-46(38,40(34)28-36)22-24-48(42)30-32-9-6-10-32/h13-16,27-28,31-32,37-38,41-42H,1-12,17-26,29-30H2/t37?,38?,41-,42-,45-,46-/m1/s1
DMQ1BDZ	CS	C1CC[C@@]23CCN([C@@H](C2C1)CC4=C3C=C(C=C4)OC(=O)CCC(=O)OC5=CC6=C(C[C@@H]7C8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DMQ1BDZ	IK	XZOSATCOBKLHCF-JNDXSTKLSA-N
DMQ1BDZ	IU	bis[(1R,9R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] butanedioate
DMQ1BDZ	DE	Discovery agent

DMW7ZF8	ID	DMW7ZF8
DMW7ZF8	DN	MCL-144
DMW7ZF8	HS	Investigative
DMW7ZF8	SN	MCL-144; CHEMBL147511; BDBM50135806; di[17-cyclobutylmethyl-(1R,9R,10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] sebacate
DMW7ZF8	DT	Small molecular drug
DMW7ZF8	PC	9897164
DMW7ZF8	MW	789.1
DMW7ZF8	FM	C52H72N2O4
DMW7ZF8	IC	InChI=1S/C52H72N2O4/c55-49(57-41-23-21-39-31-47-43-17-7-9-25-51(43,45(39)33-41)27-29-53(47)35-37-13-11-14-37)19-5-3-1-2-4-6-20-50(56)58-42-24-22-40-32-48-44-18-8-10-26-52(44,46(40)34-42)28-30-54(48)36-38-15-12-16-38/h21-24,33-34,37-38,43-44,47-48H,1-20,25-32,35-36H2/t43-,44-,47+,48+,51+,52+/m0/s1
DMW7ZF8	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)OC(=O)CCCCCCCCC(=O)OC5=CC6=C(C[C@@H]7[C@H]8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DMW7ZF8	IK	LWMXWHIOMHIBJP-SPKNWQAQSA-N
DMW7ZF8	IU	bis[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] decanedioate
DMW7ZF8	DE	Discovery agent

DMJXU67	ID	DMJXU67
DMJXU67	DN	MCL-145
DMJXU67	HS	Investigative
DMJXU67	DT	Small molecular drug
DMJXU67	PC	10462426
DMJXU67	MW	703
DMJXU67	FM	C46H58N2O4
DMJXU67	IC	InChI=1S/C46H58N2O4/c49-43(51-35-15-13-33-25-41-37-11-1-3-19-45(37,39(33)27-35)21-23-47(41)29-31-7-5-8-31)17-18-44(50)52-36-16-14-34-26-42-38-12-2-4-20-46(38,40(34)28-36)22-24-48(42)30-32-9-6-10-32/h13-18,27-28,31-32,37-38,41-42H,1-12,19-26,29-30H2/b18-17+/t37-,38-,41+,42+,45+,46+/m0/s1
DMJXU67	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)OC(=O)/C=C/C(=O)OC5=CC6=C(C[C@@H]7[C@H]8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DMJXU67	IK	AJIAOWVCYKDFGH-KBJNHENKSA-N
DMJXU67	IU	bis[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] (E)-but-2-enedioate
DMJXU67	DE	Discovery agent

DMH5SMT	ID	DMH5SMT
DMH5SMT	DN	MCL-147
DMH5SMT	HS	Investigative
DMH5SMT	SN	MCL-147; CHEMBL242756; SCHEMBL14419222; Aminothiazolo-N-Cyclopropylmorphinan
DMH5SMT	DT	Small molecular drug
DMH5SMT	PC	9798655
DMH5SMT	MW	353.5
DMH5SMT	FM	C21H27N3S
DMH5SMT	IC	InChI=1S/C21H27N3S/c22-20-23-17-11-16-14(10-19(17)25-20)9-18-15-3-1-2-6-21(15,16)7-8-24(18)12-13-4-5-13/h10-11,13,15,18H,1-9,12H2,(H2,22,23)/t15-,18+,21+/m0/s1
DMH5SMT	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=CC5=C(C=C34)N=C(S5)N)CC6CC6
DMH5SMT	IK	OQGLRMIBYLADSW-RRMPHLOHSA-N
DMH5SMT	IU	(1R,12R,13R)-20-(cyclopropylmethyl)-7-thia-5,20-diazapentacyclo[10.5.3.01,13.02,10.04,8]icosa-2,4(8),5,9-tetraen-6-amine
DMH5SMT	DE	Discovery agent

DMTWY94	ID	DMTWY94
DMTWY94	DN	MCL-149
DMTWY94	HS	Investigative
DMTWY94	SN	MCL-149; CHEMBL299220; 3-aminocyclorphan; SCHEMBL13383188; 3-Amino-N-cyclopropylmethylmorphinan; ZINC13532322
DMTWY94	DT	Small molecular drug
DMTWY94	PC	11392313
DMTWY94	MW	296.4
DMTWY94	FM	C20H28N2
DMTWY94	IC	InChI=1S/C20H28N2/c21-16-7-6-15-11-19-17-3-1-2-8-20(17,18(15)12-16)9-10-22(19)13-14-4-5-14/h6-7,12,14,17,19H,1-5,8-11,13,21H2/t17-,19+,20+/m0/s1
DMTWY94	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)N)CC5CC5
DMTWY94	IK	JUWFFFGTHLQORF-DFQSSKMNSA-N
DMTWY94	IU	(1R,9R,10R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DMTWY94	DE	Discovery agent

DMCPW5F	ID	DMCPW5F
DMCPW5F	DN	MCL-153
DMCPW5F	HS	Investigative
DMCPW5F	DT	Small molecular drug
DMCPW5F	PC	11411315
DMCPW5F	MW	677
DMCPW5F	FM	C46H64N2O2
DMCPW5F	IC	InChI=1S/C46H64N2O2/c1-3-19-45-21-23-47(31-33-9-7-10-33)43(39(45)13-1)27-35-15-17-37(29-41(35)45)49-25-5-6-26-50-38-18-16-36-28-44-40-14-2-4-20-46(40,42(36)30-38)22-24-48(44)32-34-11-8-12-34/h15-18,29-30,33-34,39-40,43-44H,1-14,19-28,31-32H2/t39-,40-,43+,44+,45+,46+/m0/s1
DMCPW5F	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)OCCCCOC5=CC6=C(C[C@@H]7[C@H]8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DMCPW5F	IK	FETCHTUKZYXAPU-DODYBPFYSA-N
DMCPW5F	IU	(1R,9R,10R)-17-(cyclobutylmethyl)-4-[4-[[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]oxy]butoxy]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DMCPW5F	DE	Discovery agent

DM3PIHV	ID	DM3PIHV
DM3PIHV	DN	MCL-154
DM3PIHV	HS	Investigative
DM3PIHV	SN	CHEMBL151872; BDBM50135811; (1R,9R,10R)-17-(cyclobutylmethyl)-4-[(10-{[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-yl]oxy}decyl)oxy]-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene
DM3PIHV	DT	Small molecular drug
DM3PIHV	PC	44365804
DM3PIHV	MW	761.2
DM3PIHV	FM	C52H76N2O2
DM3PIHV	IC	InChI=1S/C52H76N2O2/c1(3-5-11-31-55-43-23-21-41-33-49-45-19-7-9-25-51(45,47(41)35-43)27-29-53(49)37-39-15-13-16-39)2-4-6-12-32-56-44-24-22-42-34-50-46-20-8-10-26-52(46,48(42)36-44)28-30-54(50)38-40-17-14-18-40/h21-24,35-36,39-40,45-46,49-50H,1-20,25-34,37-38H2/t45-,46-,49+,50+,51+,52+/m0/s1
DM3PIHV	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)OCCCCCCCCCCOC5=CC6=C(C[C@@H]7[C@H]8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DM3PIHV	IK	NDMWWBDABLNMKI-YMWIEQFASA-N
DM3PIHV	IU	(1R,9R,10R)-17-(cyclobutylmethyl)-4-[10-[[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]oxy]decoxy]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DM3PIHV	DE	Discovery agent

DM39YW1	ID	DM39YW1
DM39YW1	DN	MCL-182
DM39YW1	HS	Investigative
DM39YW1	SN	MCL-182; CHEMBL49143; 3-aminobutorphan; 3-Amino-N-cyclobutylmethylmorphinan
DM39YW1	DT	Small molecular drug
DM39YW1	PC	11255361
DM39YW1	MW	310.5
DM39YW1	FM	C21H30N2
DM39YW1	IC	InChI=1S/C21H30N2/c22-17-8-7-16-12-20-18-6-1-2-9-21(18,19(16)13-17)10-11-23(20)14-15-4-3-5-15/h7-8,13,15,18,20H,1-6,9-12,14,22H2/t18-,20+,21+/m0/s1
DM39YW1	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)N)CC5CCC5
DM39YW1	IK	HXKMQQLYEGWJQB-CEWLAPEOSA-N
DM39YW1	IU	(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DM39YW1	DE	Discovery agent

DMVR51Z	ID	DMVR51Z
DMVR51Z	DN	MCL-183
DMVR51Z	HS	Investigative
DMVR51Z	SN	MCL-183; CHEMBL390866; SCHEMBL14419223
DMVR51Z	DT	Small molecular drug
DMVR51Z	PC	11303119
DMVR51Z	MW	367.6
DMVR51Z	FM	C22H29N3S
DMVR51Z	IC	InChI=1S/C22H29N3S/c23-21-24-18-12-17-15(11-20(18)26-21)10-19-16-6-1-2-7-22(16,17)8-9-25(19)13-14-4-3-5-14/h11-12,14,16,19H,1-10,13H2,(H2,23,24)/t16-,19+,22+/m0/s1
DMVR51Z	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=CC5=C(C=C34)N=C(S5)N)CC6CCC6
DMVR51Z	IK	HEIQNYAVPBPIJD-DKZVUGQWSA-N
DMVR51Z	IU	(1R,12R,13R)-20-(cyclobutylmethyl)-7-thia-5,20-diazapentacyclo[10.5.3.01,13.02,10.04,8]icosa-2,4(8),5,9-tetraen-6-amine
DMVR51Z	DE	Discovery agent

DM78F6A	ID	DM78F6A
DM78F6A	DN	MCL-1-specific antisense oligonucleotide + midostaurin(PKC412)
DM78F6A	HS	Investigative
DM78F6A	TC	Antisense
DM78F6A	DT	Combination drug (Antisense drug)
DM78F6A	DE	Systemic mastocytosis

DM72GLY	ID	DM72GLY
DM72GLY	DN	MCL-1-specific antisense oligonucleotide + nilotinib (AMN107)
DM72GLY	HS	Investigative
DM72GLY	SN	641571-10-0; UNII-F41401512X; Nilotinib (AMN-107); CHEMBL255863; CHEBI:52172; C28H22F3N7O; HHZIURLSWUIHRB-UHFFFAOYSA-N; NSC747599
DM72GLY	TC	Antisense
DM72GLY	DT	Combination drug (Antisense drug)
DM72GLY	DE	Systemic mastocytosis

DMXBHE4	ID	DMXBHE4
DMXBHE4	DN	MCL-428
DMXBHE4	HS	Investigative
DMXBHE4	SN	MCL-428; CHEMBL242048
DMXBHE4	DT	Small molecular drug
DMXBHE4	PC	44427183
DMXBHE4	MW	430.6
DMXBHE4	FM	C28H34N2O2
DMXBHE4	IC	InChI=1S/C28H34N2O2/c31-27(29-22-9-2-1-3-10-22)32-23-13-12-21-17-26-24-11-4-5-14-28(24,25(21)18-23)15-16-30(26)19-20-7-6-8-20/h1-3,9-10,12-13,18,20,24,26H,4-8,11,14-17,19H2,(H,29,31)
DMXBHE4	CS	C1CCC23CCN(C(C2C1)CC4=C3C=C(C=C4)OC(=O)NC5=CC=CC=C5)CC6CCC6
DMXBHE4	IK	UDWPHJLFGHTIHV-UHFFFAOYSA-N
DMXBHE4	IU	[17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-phenylcarbamate
DMXBHE4	DE	Discovery agent

DM1XH04	ID	DM1XH04
DM1XH04	DN	MCL-429
DM1XH04	HS	Investigative
DM1XH04	SN	MCL-429; CHEMBL397035
DM1XH04	DT	Small molecular drug
DM1XH04	PC	44427178
DM1XH04	MW	416.6
DM1XH04	FM	C27H32N2O2
DM1XH04	IC	InChI=1S/C27H32N2O2/c30-26(28-21-6-2-1-3-7-21)31-22-12-11-20-16-25-23-8-4-5-13-27(23,24(20)17-22)14-15-29(25)18-19-9-10-19/h1-3,6-7,11-12,17,19,23,25H,4-5,8-10,13-16,18H2,(H,28,30)
DM1XH04	CS	C1CCC23CCN(C(C2C1)CC4=C3C=C(C=C4)OC(=O)NC5=CC=CC=C5)CC6CC6
DM1XH04	IK	PNQVNINMHSUQSR-UHFFFAOYSA-N
DM1XH04	IU	[17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-phenylcarbamate
DM1XH04	DE	Discovery agent

DMISHCW	ID	DMISHCW
DMISHCW	DN	MCL-431
DMISHCW	HS	Investigative
DMISHCW	SN	MCL-431; CHEMBL241823
DMISHCW	DT	Small molecular drug
DMISHCW	PC	44427175
DMISHCW	MW	328.4
DMISHCW	FM	C20H28N2O2
DMISHCW	IC	InChI=1S/C20H28N2O2/c1-3-21-19(23)24-15-8-7-14-12-18-16-6-4-5-9-20(16,17(14)13-15)10-11-22(18)2/h7-8,13,16,18H,3-6,9-12H2,1-2H3,(H,21,23)
DMISHCW	CS	CCNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3C)C=C1
DMISHCW	IK	ZNJDUQHDGFWNKK-UHFFFAOYSA-N
DMISHCW	IU	(17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl) N-ethylcarbamate
DMISHCW	DE	Discovery agent

DMPOFAR	ID	DMPOFAR
DMPOFAR	DN	MCL-432
DMPOFAR	HS	Investigative
DMPOFAR	SN	MCL-432; CHEMBL242047
DMPOFAR	DT	Small molecular drug
DMPOFAR	PC	44427182
DMPOFAR	MW	382.5
DMPOFAR	FM	C24H34N2O2
DMPOFAR	IC	InChI=1S/C24H34N2O2/c1-2-25-23(27)28-19-10-9-18-14-22-20-8-3-4-11-24(20,21(18)15-19)12-13-26(22)16-17-6-5-7-17/h9-10,15,17,20,22H,2-8,11-14,16H2,1H3,(H,25,27)
DMPOFAR	CS	CCNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3CC5CCC5)C=C1
DMPOFAR	IK	CDJRHRPFKCSONV-UHFFFAOYSA-N
DMPOFAR	IU	[17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-ethylcarbamate
DMPOFAR	DE	Discovery agent

DMD3OAQ	ID	DMD3OAQ
DMD3OAQ	DN	MCL-433
DMD3OAQ	HS	Investigative
DMD3OAQ	SN	MCL-433; CHEMBL245049
DMD3OAQ	DT	Small molecular drug
DMD3OAQ	PC	44427174
DMD3OAQ	MW	314.4
DMD3OAQ	FM	C19H26N2O2
DMD3OAQ	IC	InChI=1S/C19H26N2O2/c1-20-18(22)23-14-7-6-13-11-17-15-5-3-4-8-19(15,16(13)12-14)9-10-21(17)2/h6-7,12,15,17H,3-5,8-11H2,1-2H3,(H,20,22)
DMD3OAQ	CS	CNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3C)C=C1
DMD3OAQ	IK	YJGQAUOQIDQXIT-UHFFFAOYSA-N
DMD3OAQ	IU	(17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl) N-methylcarbamate
DMD3OAQ	DE	Discovery agent

DMR31VO	ID	DMR31VO
DMR31VO	DN	MCL-434
DMR31VO	HS	Investigative
DMR31VO	SN	MCL-434; CHEMBL241824
DMR31VO	DT	Small molecular drug
DMR31VO	PC	44427176
DMR31VO	MW	354.5
DMR31VO	FM	C22H30N2O2
DMR31VO	IC	InChI=1S/C22H30N2O2/c1-23-21(25)26-17-8-7-16-12-20-18-4-2-3-9-22(18,19(16)13-17)10-11-24(20)14-15-5-6-15/h7-8,13,15,18,20H,2-6,9-12,14H2,1H3,(H,23,25)
DMR31VO	CS	CNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3CC5CC5)C=C1
DMR31VO	IK	SGHKXPYOPVKZJP-UHFFFAOYSA-N
DMR31VO	IU	[17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-methylcarbamate
DMR31VO	DE	Discovery agent

DMLSYD9	ID	DMLSYD9
DMLSYD9	DN	MCL-435
DMLSYD9	HS	Investigative
DMLSYD9	SN	MCL-435; CHEMBL242046
DMLSYD9	DT	Small molecular drug
DMLSYD9	PC	44427180
DMLSYD9	MW	368.5
DMLSYD9	FM	C23H32N2O2
DMLSYD9	IC	InChI=1S/C23H32N2O2/c1-24-22(26)27-18-9-8-17-13-21-19-7-2-3-10-23(19,20(17)14-18)11-12-25(21)15-16-5-4-6-16/h8-9,14,16,19,21H,2-7,10-13,15H2,1H3,(H,24,26)
DMLSYD9	CS	CNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3CC5CCC5)C=C1
DMLSYD9	IK	NHTWPKUCTUYFEM-UHFFFAOYSA-N
DMLSYD9	IU	[17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-methylcarbamate
DMLSYD9	DE	Discovery agent

DM8LTQ4	ID	DM8LTQ4
DM8LTQ4	DN	MCL-443
DM8LTQ4	HS	Investigative
DM8LTQ4	SN	MCL-443; CHEMBL394624
DM8LTQ4	DT	Small molecular drug
DM8LTQ4	PC	44427184
DM8LTQ4	MW	444.6
DM8LTQ4	FM	C29H36N2O2
DM8LTQ4	IC	InChI=1S/C29H36N2O2/c32-28(30-19-21-7-2-1-3-8-21)33-24-13-12-23-17-27-25-11-4-5-14-29(25,26(23)18-24)15-16-31(27)20-22-9-6-10-22/h1-3,7-8,12-13,18,22,25,27H,4-6,9-11,14-17,19-20H2,(H,30,32)
DM8LTQ4	CS	C1CCC23CCN(C(C2C1)CC4=C3C=C(C=C4)OC(=O)NCC5=CC=CC=C5)CC6CCC6
DM8LTQ4	IK	VTNMTWBEHGIRGV-UHFFFAOYSA-N
DM8LTQ4	IU	[17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-benzylcarbamate
DM8LTQ4	DE	Discovery agent

DM8HALS	ID	DM8HALS
DM8HALS	DN	MCL-444
DM8HALS	HS	Investigative
DM8HALS	SN	MCL-444; CHEMBL263096
DM8HALS	DT	Small molecular drug
DM8HALS	PC	44427179
DM8HALS	MW	430.6
DM8HALS	FM	C28H34N2O2
DM8HALS	IC	InChI=1S/C28H34N2O2/c31-27(29-18-20-6-2-1-3-7-20)32-23-12-11-22-16-26-24-8-4-5-13-28(24,25(22)17-23)14-15-30(26)19-21-9-10-21/h1-3,6-7,11-12,17,21,24,26H,4-5,8-10,13-16,18-19H2,(H,29,31)
DM8HALS	CS	C1CCC23CCN(C(C2C1)CC4=C3C=C(C=C4)OC(=O)NCC5=CC=CC=C5)CC6CC6
DM8HALS	IK	VSBFHNWLJXFFTK-UHFFFAOYSA-N
DM8HALS	IU	[17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-benzylcarbamate
DM8HALS	DE	Discovery agent

DMR2K4F	ID	DMR2K4F
DMR2K4F	DN	MCL-445
DMR2K4F	HS	Investigative
DMR2K4F	SN	MCL-445; CHEMBL243195; BDBM50210553
DMR2K4F	DT	Small molecular drug
DMR2K4F	PC	44429065
DMR2K4F	MW	367.5
DMR2K4F	FM	C23H33N3O
DMR2K4F	IC	InChI=1S/C23H33N3O/c1-24-22(27)25-18-9-8-17-13-21-19-7-2-3-10-23(19,20(17)14-18)11-12-26(21)15-16-5-4-6-16/h8-9,14,16,19,21H,2-7,10-13,15H2,1H3,(H2,24,25,27)/t19-,21+,23+/m0/s1
DMR2K4F	CS	CNC(=O)NC1=CC2=C(C[C@@H]3[C@H]4[C@@]2(CCCC4)CCN3CC5CCC5)C=C1
DMR2K4F	IK	URMRSPJBIISGIL-XKCSPQBFSA-N
DMR2K4F	IU	1-[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]-3-methylurea
DMR2K4F	DE	Discovery agent

DMXF73G	ID	DMXF73G
DMXF73G	DN	MCL-446
DMXF73G	HS	Investigative
DMXF73G	SN	MCL-446; CHEMBL428038; BDBM50210549
DMXF73G	DT	Small molecular drug
DMXF73G	PC	44429064
DMXF73G	MW	353.5
DMXF73G	FM	C22H31N3O
DMXF73G	IC	InChI=1S/C22H31N3O/c1-23-21(26)24-17-8-7-16-12-20-18-4-2-3-9-22(18,19(16)13-17)10-11-25(20)14-15-5-6-15/h7-8,13,15,18,20H,2-6,9-12,14H2,1H3,(H2,23,24,26)/t18-,20+,22+/m0/s1
DMXF73G	CS	CNC(=O)NC1=CC2=C(C[C@@H]3[C@H]4[C@@]2(CCCC4)CCN3CC5CC5)C=C1
DMXF73G	IK	NXVBILHYMWWGLP-CZTZKLFOSA-N
DMXF73G	IU	1-[(1R,9R,10R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]-3-methylurea
DMXF73G	DE	Discovery agent

DMSTGNH	ID	DMSTGNH
DMSTGNH	DN	MCL-447
DMSTGNH	HS	Investigative
DMSTGNH	SN	MCL-447; CHEMBL394573; BDBM50210555
DMSTGNH	DT	Small molecular drug
DMSTGNH	PC	44429063
DMSTGNH	MW	353.5
DMSTGNH	FM	C22H31N3O
DMSTGNH	IC	InChI=1S/C22H31N3O/c23-21(26)24-17-8-7-16-12-20-18-6-1-2-9-22(18,19(16)13-17)10-11-25(20)14-15-4-3-5-15/h7-8,13,15,18,20H,1-6,9-12,14H2,(H3,23,24,26)/t18-,20+,22+/m0/s1
DMSTGNH	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NC(=O)N)CC5CCC5
DMSTGNH	IK	UYFRBZFZZCVVGT-CZTZKLFOSA-N
DMSTGNH	IU	[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]urea
DMSTGNH	DE	Discovery agent

DMSJGA9	ID	DMSJGA9
DMSJGA9	DN	MCL-448
DMSJGA9	HS	Investigative
DMSJGA9	SN	MCL-448; CHEMBL242968; BDBM50210550
DMSJGA9	DT	Small molecular drug
DMSJGA9	PC	44429062
DMSJGA9	MW	339.5
DMSJGA9	FM	C21H29N3O
DMSJGA9	IC	InChI=1S/C21H29N3O/c22-20(25)23-16-7-6-15-11-19-17-3-1-2-8-21(17,18(15)12-16)9-10-24(19)13-14-4-5-14/h6-7,12,14,17,19H,1-5,8-11,13H2,(H3,22,23,25)/t17-,19+,21+/m0/s1
DMSJGA9	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NC(=O)N)CC5CC5
DMSJGA9	IK	HEUGOTHWUMOSSR-FBBABVLZSA-N
DMSJGA9	IU	[(1R,9R,10R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]urea
DMSJGA9	DE	Discovery agent

DMQ890N	ID	DMQ890N
DMQ890N	DN	MCL-449
DMQ890N	HS	Investigative
DMQ890N	SN	MCL-449; CHEMBL427862
DMQ890N	DT	Small molecular drug
DMQ890N	PC	44427177
DMQ890N	MW	368.5
DMQ890N	FM	C23H32N2O2
DMQ890N	IC	InChI=1S/C23H32N2O2/c1-2-24-22(26)27-18-9-8-17-13-21-19-5-3-4-10-23(19,20(17)14-18)11-12-25(21)15-16-6-7-16/h8-9,14,16,19,21H,2-7,10-13,15H2,1H3,(H,24,26)
DMQ890N	CS	CCNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3CC5CC5)C=C1
DMQ890N	IK	RVWFZRGYOXCUSN-UHFFFAOYSA-N
DMQ890N	IU	[17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-ethylcarbamate
DMQ890N	DE	Discovery agent

DM7I6U8	ID	DM7I6U8
DM7I6U8	DN	MCL-450
DM7I6U8	HS	Investigative
DM7I6U8	SN	CHEMBL373984; MCL-450; BDBM50194274
DM7I6U8	DT	Small molecular drug
DM7I6U8	PC	16083055
DM7I6U8	MW	732.9
DM7I6U8	FM	C45H56N4O5
DM7I6U8	IC	InChI=1S/C45H56N4O5/c1-28-20-34(50)21-29(2)36(28)25-39(46)44(53)49-27-33-11-4-3-10-31(33)22-41(49)43(52)47-18-15-42(51)54-35-14-13-32-23-40-37-12-5-6-16-45(37,38(32)24-35)17-19-48(40)26-30-8-7-9-30/h3-4,10-11,13-14,20-21,24,30,37,39-41,50H,5-9,12,15-19,22-23,25-27,46H2,1-2H3,(H,47,52)/t37-,39-,40+,41-,45+/m0/s1
DM7I6U8	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCCC(=O)OC4=CC5=C(C[C@@H]6[C@H]7[C@@]5(CCCC7)CCN6CC8CCC8)C=C4)N)C)O
DM7I6U8	IK	FYEXOHKTNZXZQH-KKEISOQISA-N
DM7I6U8	IU	[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] 3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]propanoate
DM7I6U8	DE	Discovery agent

DMP523A	ID	DMP523A
DMP523A	DN	MCL-451
DMP523A	HS	Investigative
DMP523A	SN	MCL-451; CHEMBL384915; H-Dmt-Tic-beta-Ala-OH
DMP523A	DT	Small molecular drug
DMP523A	PC	16083058
DMP523A	MW	439.5
DMP523A	FM	C24H29N3O5
DMP523A	IC	InChI=1S/C24H29N3O5/c1-14-9-18(28)10-15(2)19(14)12-20(25)24(32)27-13-17-6-4-3-5-16(17)11-21(27)23(31)26-8-7-22(29)30/h3-6,9-10,20-21,28H,7-8,11-13,25H2,1-2H3,(H,26,31)(H,29,30)/t20-,21-/m0/s1
DMP523A	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCCC(=O)O)N)C)O
DMP523A	IK	FEJBKZCTAXWTTN-SFTDATJTSA-N
DMP523A	IU	3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]propanoic acid
DMP523A	DE	Discovery agent

DMORMGU	ID	DMORMGU
DMORMGU	DN	MCL-457
DMORMGU	HS	Investigative
DMORMGU	SN	MCL-457; CHEMBL242967; BDBM50210558
DMORMGU	DT	Small molecular drug
DMORMGU	PC	44429060
DMORMGU	MW	338.4
DMORMGU	FM	C21H26N2O2
DMORMGU	IC	InChI=1S/C21H26N2O2/c24-20-22-17-9-14-10-18-15-3-1-2-6-21(15,16(14)11-19(17)25-20)7-8-23(18)12-13-4-5-13/h9,11,13,15,18H,1-8,10,12H2,(H,22,24)/t15-,18+,21+/m0/s1
DMORMGU	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=CC5=C(C=C34)OC(=O)N5)CC6CC6
DMORMGU	IK	QLWCMBZVQJGYTM-RRMPHLOHSA-N
DMORMGU	IU	(1R,12R,13R)-20-(cyclopropylmethyl)-5-oxa-7,20-diazapentacyclo[10.5.3.01,13.02,10.04,8]icosa-2,4(8),9-trien-6-one
DMORMGU	DE	Discovery agent

DMZN93Y	ID	DMZN93Y
DMZN93Y	DN	MCL-458
DMZN93Y	HS	Investigative
DMZN93Y	SN	MCL-458; CHEMBL390912; BDBM50210556
DMZN93Y	DT	Small molecular drug
DMZN93Y	PC	44429061
DMZN93Y	MW	352.5
DMZN93Y	FM	C22H28N2O2
DMZN93Y	IC	InChI=1S/C22H28N2O2/c25-21-23-18-10-15-11-19-16-6-1-2-7-22(16,17(15)12-20(18)26-21)8-9-24(19)13-14-4-3-5-14/h10,12,14,16,19H,1-9,11,13H2,(H,23,25)/t16-,19+,22+/m0/s1
DMZN93Y	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=CC5=C(C=C34)OC(=O)N5)CC6CCC6
DMZN93Y	IK	PSLNEDDFOIXXGT-DKZVUGQWSA-N
DMZN93Y	IU	(1R,12R,13R)-20-(cyclobutylmethyl)-5-oxa-7,20-diazapentacyclo[10.5.3.01,13.02,10.04,8]icosa-2,4(8),9-trien-6-one
DMZN93Y	DE	Discovery agent

DMTB8D4	ID	DMTB8D4
DMTB8D4	DN	MCL-515
DMTB8D4	HS	Investigative
DMTB8D4	SN	MCL-515; CHEMBL513174; BDBM50254065
DMTB8D4	DT	Small molecular drug
DMTB8D4	PC	25181482
DMTB8D4	MW	351.4
DMTB8D4	FM	C22H25NO3
DMTB8D4	IC	InChI=1S/C22H25NO3/c1-4-9-23-10-8-16-11-17(25-3)13-18-21(16)19(23)12-15-6-5-7-20(22(15)18)26-14(2)24/h5-7,11,13,19H,4,8-10,12H2,1-3H3/t19-/m1/s1
DMTB8D4	CS	CCCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=CC=C4)OC(=O)C
DMTB8D4	IK	ICIICPHBNXIOKJ-LJQANCHMSA-N
DMTB8D4	IU	[(6aR)-2-methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] acetate
DMTB8D4	CA	CAS 1100920-50-0
DMTB8D4	DE	Discovery agent

DMQA7ZI	ID	DMQA7ZI
DMQA7ZI	DN	MCL-516
DMQA7ZI	HS	Investigative
DMQA7ZI	SN	MCL-516; CHEMBL482276; BDBM50252323; (R)-2-Methoxyaporphin-11-yl pentanoate
DMQA7ZI	DT	Small molecular drug
DMQA7ZI	PC	44593524
DMQA7ZI	MW	365.5
DMQA7ZI	FM	C23H27NO3
DMQA7ZI	IC	InChI=1S/C23H27NO3/c1-4-5-9-21(25)27-20-8-6-7-15-13-19-22-16(10-11-24(19)2)12-17(26-3)14-18(22)23(15)20/h6-8,12,14,19H,4-5,9-11,13H2,1-3H3/t19-/m1/s1
DMQA7ZI	CS	CCCCC(=O)OC1=CC=CC2=C1C3=CC(=CC4=C3[C@@H](C2)N(CC4)C)OC
DMQA7ZI	IK	NMUGDOOOAXACRK-LJQANCHMSA-N
DMQA7ZI	IU	[(6aR)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] pentanoate
DMQA7ZI	DE	Discovery agent

DML3AZG	ID	DML3AZG
DML3AZG	DN	McN-A-343
DML3AZG	HS	Investigative
DML3AZG	SN	McN-A-343; 55-45-8; MCN A-343 chloride; McN-A 343; MCN A-343; UNII-CW55R761RE; (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride; CW55R761RE; A 343; 4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; 2-Butyn-1-aminium, 4-((((3-chlorophenyl)amino)carbonyl)oxy)-N,N,N-trimethyl-, chloride; Carbanilic acid, m-chloro-, ester with (4-hydroxy-2-butynyl)trimethylammonium chloride; Butyl-1-aminium, 4-((((3-chlorophenyl)amino)carbonyl)oxy)-N,N,N-trimethyl-, chloride
DML3AZG	DT	Small molecular drug
DML3AZG	PC	5926
DML3AZG	MW	317.2
DML3AZG	FM	C14H18Cl2N2O2
DML3AZG	IC	InChI=1S/C14H17ClN2O2.ClH/c1-17(2,3)9-4-5-10-19-14(18)16-13-8-6-7-12(15)11-13;/h6-8,11H,9-10H2,1-3H3;1H
DML3AZG	CS	C[N+](C)(C)CC#CCOC(=O)NC1=CC(=CC=C1)Cl.[Cl-]
DML3AZG	IK	CXFZFEJJLNLOTA-UHFFFAOYSA-N
DML3AZG	IU	4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl-trimethylazanium;chloride
DML3AZG	CA	CAS 55-45-8
DML3AZG	DE	Discovery agent

DM0GLYB	ID	DM0GLYB
DM0GLYB	DN	MCP-203
DM0GLYB	HS	Investigative
DM0GLYB	SN	Delta opioid receptor agonist (depression/Parkinson's disease), Mt Cook Pharma
DM0GLYB	CP	Mt Cook Pharma
DM0GLYB	DE	Major depressive disorder

DM0RZDF	ID	DM0RZDF
DM0RZDF	DN	MCP-204
DM0RZDF	HS	Investigative
DM0RZDF	SN	Delta opioid receptor agonist (urology therapy/neuropathic pain), Mt Cook Pharma
DM0RZDF	CP	Mt Cook Pharma
DM0RZDF	DE	Bladder disease

DM3RYUZ	ID	DM3RYUZ
DM3RYUZ	DN	MCP-205
DM3RYUZ	HS	Investigative
DM3RYUZ	SN	Delta opioid receptor agonist (cardiac ischemia), Mt Cook Pharma
DM3RYUZ	CP	Mt Cook Pharma
DM3RYUZ	DE	Ischemic heart disease

DMEUWB8	ID	DMEUWB8
DMEUWB8	DN	MDA-19
DMEUWB8	HS	Investigative
DMEUWB8	SN	Cannabinoid CB2 agonist (neuropathic pain), MD Anderson Cancer Center
DMEUWB8	CP	MD Anderson Cancer Center
DMEUWB8	DT	Small molecular drug
DMEUWB8	PC	135743701
DMEUWB8	MW	349.4
DMEUWB8	FM	C21H23N3O2
DMEUWB8	IC	InChI=1S/C21H23N3O2/c1-2-3-4-10-15-24-18-14-9-8-13-17(18)19(21(24)26)22-23-20(25)16-11-6-5-7-12-16/h5-9,11-14,26H,2-4,10,15H2,1H3
DMEUWB8	CS	CCCCCCN1C2=CC=CC=C2C(=C1O)N=NC(=O)C3=CC=CC=C3
DMEUWB8	IK	ICNRTDOKKSWDRL-UHFFFAOYSA-N
DMEUWB8	IU	N-(1-hexyl-2-hydroxyindol-3-yl)iminobenzamide
DMEUWB8	CA	CAS 1048973-47-2
DMEUWB8	DE	Neuropathic pain

DMZJPOB	ID	DMZJPOB
DMZJPOB	DN	MDDR 287569
DMZJPOB	HS	Investigative
DMZJPOB	SN	N-[1-[3-(4-Methylpiperazin-1-ylsulfonyl)propyl]piperidin-4-ylmethyl]-2,3-dihydro-1,4-benzodioxin-5-carboxamide
DMZJPOB	DE	Urinary incontinence

DMLI5VH	ID	DMLI5VH
DMLI5VH	DN	MDL 100,453
DMLI5VH	HS	Investigative
DMLI5VH	SN	D-Norvaline, 4-oxo-5-phosphono-; CHEMBL431029; MDL-100483; 129938-34-7; 4-Opnv; Mdl 100453; 4-Oxo-5-phosphononorvaline; AC1MHZND; SCHEMBL195547; (r)-4-oxo-5-phosphononorvaline; BDBM50010893; AKOS030593176; MDL-100453; 2-Amino-4-oxo-5-phosphono-pentanoic acid; (2R)-2-amino-4-oxo-5-phosphonopentanoic acid; (R)-2-Amino-4-oxo-5-phosphono-pentanoic acid
DMLI5VH	DT	Small molecular drug
DMLI5VH	PC	3035602
DMLI5VH	MW	211.11
DMLI5VH	FM	C5H10NO6P
DMLI5VH	IC	InChI=1S/C5H10NO6P/c6-4(5(8)9)1-3(7)2-13(10,11)12/h4H,1-2,6H2,(H,8,9)(H2,10,11,12)/t4-/m1/s1
DMLI5VH	CS	C([C@H](C(=O)O)N)C(=O)CP(=O)(O)O
DMLI5VH	IK	OLCWOBHEVRCMLO-SCSAIBSYSA-N
DMLI5VH	IU	(2R)-2-amino-4-oxo-5-phosphonopentanoic acid
DMLI5VH	CA	CAS 129938-34-7
DMLI5VH	DE	Discovery agent

DMTVOWC	ID	DMTVOWC
DMTVOWC	DN	MDL-18962
DMTVOWC	HS	Investigative
DMTVOWC	SN	Plomestane; UNII-FL3VS913TW; MDL-18962; 77016-85-4; FL3VS913TW; 10-(2-Propynyl)estr-4-ene-3,17-dione; Plomestane [USAN:INN]; MDL 18,962; 10-propargylestr-4-ene-3,17-dione; Estr-4-ene-3,17-dione, 10-(2-propynyl)-; Plomestane (USAN/INN); SCHEMBL3434; CHEMBL2105261; JKPDEYAOCSQBSZ-OEUJLIAZSA-N; ZINC4217337; BDBM50421840; 10beta-propargyl-estra-4-ene-3,17-dione; 10-(2-propynyl)-estr-4-ene-3,17-dione
DMTVOWC	DT	Small molecular drug
DMTVOWC	PC	9904788
DMTVOWC	MW	310.4
DMTVOWC	FM	C21H26O2
DMTVOWC	IC	InChI=1S/C21H26O2/c1-3-10-21-12-8-15(22)13-14(21)4-5-16-17-6-7-19(23)20(17,2)11-9-18(16)21/h1,13,16-18H,4-12H2,2H3/t16-,17-,18-,20-,21-/m0/s1
DMTVOWC	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=O)CC[C@]34CC#C
DMTVOWC	IK	JKPDEYAOCSQBSZ-OEUJLIAZSA-N
DMTVOWC	IU	(8R,9S,10S,13S,14S)-13-methyl-10-prop-2-ynyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMTVOWC	CA	CAS 77016-85-4
DMTVOWC	DE	Discovery agent

DMUHJ2C	ID	DMUHJ2C
DMUHJ2C	DN	MDL-28163
DMUHJ2C	HS	Investigative
DMUHJ2C	SN	MDL-28163; CHEMBL95051; SCHEMBL9196398; DIPBPGRFGZKMEF-UHFFFAOYSA-N; BDBM50175511; 1-(4-Fluorobenzyl)-2-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylcarbonyl]-1H-benzimidazole; [1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl][1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]methanone
DMUHJ2C	DT	Small molecular drug
DMUHJ2C	PC	10917690
DMUHJ2C	MW	471.6
DMUHJ2C	FM	C29H30FN3O2
DMUHJ2C	IC	InChI=1S/C29H30FN3O2/c1-35-25-12-8-21(9-13-25)14-17-32-18-15-23(16-19-32)28(34)29-31-26-4-2-3-5-27(26)33(29)20-22-6-10-24(30)11-7-22/h2-13,23H,14-20H2,1H3
DMUHJ2C	CS	COC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
DMUHJ2C	IK	DIPBPGRFGZKMEF-UHFFFAOYSA-N
DMUHJ2C	IU	[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]methanone
DMUHJ2C	CA	CAS 124461-07-0
DMUHJ2C	DE	Discovery agent

DMF76M8	ID	DMF76M8
DMF76M8	DN	MDL-28618
DMF76M8	HS	Investigative
DMF76M8	SN	MDL-28618; UNII-9O1J7OU9Q5; 9O1J7OU9Q5; CHEMBL497666; BDBM50272710; MDL-28618A, (+)-; 1H-Indene-2-methanamine, 2,3-dihydro-N-methyl-1-(4-(trifluoromethyl)phenoxy)-, (1R-cis)-; (1R,2S)-2,3-Dihydro-N-methyl-1-[4-(trifluoromethyl)phenoxy]-1H-indene-2-methanamine; N-methyl((1R,2S)-1-(4-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-2-yl)methanamine
DMF76M8	DT	Small molecular drug
DMF76M8	PC	14595987
DMF76M8	MW	321.3
DMF76M8	FM	C18H18F3NO
DMF76M8	IC	InChI=1S/C18H18F3NO/c1-22-11-13-10-12-4-2-3-5-16(12)17(13)23-15-8-6-14(7-9-15)18(19,20)21/h2-9,13,17,22H,10-11H2,1H3/t13-,17+/m0/s1
DMF76M8	CS	CNC[C@@H]1CC2=CC=CC=C2[C@@H]1OC3=CC=C(C=C3)C(F)(F)F
DMF76M8	IK	BDCMARKCSKLIKU-SUMWQHHRSA-N
DMF76M8	IU	N-methyl-1-[(1R,2S)-1-[4-(trifluoromethyl)phenoxy]-2,3-dihydro-1H-inden-2-yl]methanamine
DMF76M8	CA	CAS 130182-74-0
DMF76M8	DE	Discovery agent

DMF8VX3	ID	DMF8VX3
DMF8VX3	DN	MDL-74156
DMF8VX3	HS	Investigative
DMF8VX3	SN	Mdl 74156; Hydrodolasetron; Mdl-74156; 127951-99-9; 1H-Indole-3-carboxylicacid, octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester; 1-H-Indole-3-carboxylic acid, trans-octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester; ACMC-20msnw; AC1L4LYC; CHEMBL498572; SCHEMBL7281981; AC1Q60Y9; CTK4B5810; 1H-Indole-3-carboxylic acid, octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester; BDBM50412171; AKOS030254922; 10-hydroxy-8-azatricyclo[5.3.1.03,8]undec-5-yl 1h-indole-3-carboxylate; LS-172694; J-005559
DMF8VX3	DT	Small molecular drug
DMF8VX3	PC	159502
DMF8VX3	MW	326.4
DMF8VX3	FM	C19H22N2O3
DMF8VX3	IC	InChI=1S/C19H22N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,18,20,22H,5-8,10H2
DMF8VX3	CS	C1C2CC3CC(CC1N3CC2O)OC(=O)C4=CNC5=CC=CC=C54
DMF8VX3	IK	MLWGAEVSWJXOQJ-UHFFFAOYSA-N
DMF8VX3	IU	(10-hydroxy-8-azatricyclo[5.3.1.03,8]undecan-5-yl) 1H-indole-3-carboxylate
DMF8VX3	CA	CAS 127951-99-9
DMF8VX3	DE	Discovery agent

DM8ZK12	ID	DM8ZK12
DM8ZK12	DN	MDP-01
DM8ZK12	HS	Investigative
DM8ZK12	SN	Peptabody-EGF (anticancer), Med Discovery
DM8ZK12	CP	Med Discovery SA
DM8ZK12	DE	Solid tumour/cancer

DMSF4UI	ID	DMSF4UI
DMSF4UI	DN	MDT-006
DMSF4UI	HS	Investigative
DMSF4UI	SN	EPX-16006; Chronic constipation, IBS-C therapy (PolyCap), MicroDose Therapeutx; P2Y2 agonist (oral, constipation/irritable bowel syndrome), EPIX; Purinoceptor P2Y2 agonist (oral, constipation/IBS), EPIX
DMSF4UI	CP	EPIX Pharmaceuticals Inc
DMSF4UI	DE	Constipation

DM9ZTX4	ID	DM9ZTX4
DM9ZTX4	DN	MDX-1147
DM9ZTX4	HS	Investigative
DM9ZTX4	CP	Medarex Inc
DM9ZTX4	DE	Prostate cancer

DMMFYP9	ID	DMMFYP9
DMMFYP9	DN	ME bromodomain inhibitor
DMMFYP9	HS	Investigative
DMMFYP9	SN	CHEMBL3769729; Methyl (2r)-2-[(4s)-6-(4-Chlorophenyl)-8-Methoxy-1-Methyl-4h-[1,2,4]triazolo[4,3-A][1,4]benzodiazepin-4-Yl]propanoate; ME bromodomain inhibitor; GTPL7807; SCHEMBL16771925
DMMFYP9	DT	Small molecular drug
DMMFYP9	PC	86277842
DMMFYP9	MW	424.9
DMMFYP9	FM	C22H21ClN4O3
DMMFYP9	IC	InChI=1S/C22H21ClN4O3/c1-12(22(28)30-4)19-21-26-25-13(2)27(21)18-10-9-16(29-3)11-17(18)20(24-19)14-5-7-15(23)8-6-14/h5-12,19H,1-4H3/t12-,19+/m1/s1
DMMFYP9	CS	CC1=NN=C2N1C3=C(C=C(C=C3)OC)C(=N[C@H]2[C@@H](C)C(=O)OC)C4=CC=C(C=C4)Cl
DMMFYP9	IK	FENXDXHDXYVGRJ-BLVKFPJESA-N
DMMFYP9	IU	methyl (2R)-2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]propanoate
DMMFYP9	DE	Discovery agent

DMCLT1V	ID	DMCLT1V
DMCLT1V	DN	ME0328
DMCLT1V	HS	Investigative
DMCLT1V	SN	ME-0328; compound 5b [PMID 24188023]
DMCLT1V	DT	Small molecular drug
DMCLT1V	PC	135566764
DMCLT1V	MW	321.4
DMCLT1V	FM	C19H19N3O2
DMCLT1V	IC	InChI=1S/C19H19N3O2/c1-13(14-7-3-2-4-8-14)20-18(23)12-11-17-21-16-10-6-5-9-15(16)19(24)22-17/h2-10,13H,11-12H2,1H3,(H,20,23)(H,21,22,24)/t13-/m0/s1
DMCLT1V	CS	C[C@@H](C1=CC=CC=C1)NC(=O)CCC2=NC3=CC=CC=C3C(=O)N2
DMCLT1V	IK	QIHBWVVVRYYYRO-ZDUSSCGKSA-N
DMCLT1V	IU	3-(4-oxo-3H-quinazolin-2-yl)-N-[(1S)-1-phenylethyl]propanamide
DMCLT1V	DE	Discovery agent

DMOZAQ6	ID	DMOZAQ6
DMOZAQ6	DN	ME36
DMOZAQ6	HS	Investigative
DMOZAQ6	SN	N-ethyl,N-methyl EM-A
DMOZAQ6	DT	Small molecular drug
DMOZAQ6	PC	14487390
DMOZAQ6	MW	748
DMOZAQ6	FM	C38H69NO13
DMOZAQ6	IC	InChI=1S/C38H69NO13/c1-14-26-38(11,46)31(42)21(5)28(40)19(3)17-36(9,45)33(52-35-29(41)25(39(12)15-2)16-20(4)48-35)22(6)30(23(7)34(44)50-26)51-27-18-37(10,47-13)32(43)24(8)49-27/h19-27,29-33,35,41-43,45-46H,14-18H2,1-13H3
DMOZAQ6	CS	CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)CC)O)(C)O)C)C)O)(C)O
DMOZAQ6	IK	DYYAPFZVDGCKCL-UHFFFAOYSA-N
DMOZAQ6	IU	14-ethyl-6-[4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DMOZAQ6	DE	Discovery agent

DMO5E2L	ID	DMO5E2L
DMO5E2L	DN	ME4
DMO5E2L	HS	Investigative
DMO5E2L	SN	EM-A enolether; erythromycin enol ether; ME-4
DMO5E2L	DT	Small molecular drug
DMO5E2L	PC	83954
DMO5E2L	MW	715.9
DMO5E2L	FM	C37H65NO12
DMO5E2L	IC	InChI=1S/C37H65NO12/c1-14-25-37(10,43)30(40)20(4)28-18(2)16-36(9,50-28)32(49-34-27(39)24(38(11)12)15-19(3)45-34)21(5)29(22(6)33(42)47-25)48-26-17-35(8,44-13)31(41)23(7)46-26/h19-27,29-32,34,39-41,43H,14-17H2,1-13H3/t19-,20+,21+,22-,23+,24+,25-,26+,27-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
DMO5E2L	CS	CC[C@@H]1[C@@]([C@@H]([C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)C)C)C)O)(C)O
DMO5E2L	IK	JFVYXJKGJMUGRG-KJPZRSJGSA-N
DMO5E2L	IU	(2R,3R,4S,5R,8R,9S,10S,11R,12R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-ethyl-3,4-dihydroxy-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DMO5E2L	CA	CAS 33396-29-1
DMO5E2L	DE	Discovery agent

DM3C6X2	ID	DM3C6X2
DM3C6X2	DN	ME67
DM3C6X2	HS	Investigative
DM3C6X2	SN	EM-B enolether
DM3C6X2	DT	Small molecular drug
DM3C6X2	PC	10032648
DM3C6X2	MW	699.9
DM3C6X2	FM	C37H65NO11
DM3C6X2	IC	InChI=1S/C37H65NO11/c1-14-26-20(4)28(39)21(5)30-18(2)16-37(10,49-30)33(48-35-29(40)25(38(11)12)15-19(3)44-35)22(6)31(23(7)34(42)46-26)47-27-17-36(9,43-13)32(41)24(8)45-27/h19-29,31-33,35,39-41H,14-17H2,1-13H3/t19-,20-,21-,22+,23-,24+,25+,26-,27+,28+,29-,31+,32+,33-,35+,36-,37+/m1/s1
DM3C6X2	CS	CC[C@@H]1[C@H]([C@@H]([C@H](C2=C(C[C@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)C)C)C)O)C
DM3C6X2	IK	RVWZXQUMKFWVJM-GKMPZCCESA-N
DM3C6X2	IU	(2R,3S,4S,5R,8R,9S,10S,11R,12S)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-ethyl-3-hydroxy-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DM3C6X2	DE	Discovery agent

DM0P59E	ID	DM0P59E
DM0P59E	DN	MEBUDIPINE
DM0P59E	HS	Investigative
DM0P59E	SN	mebudipine; CHEMBL1095098; BAY-n-6391
DM0P59E	DT	Small molecular drug
DM0P59E	PC	10407950
DM0P59E	MW	388.4
DM0P59E	FM	C20H24N2O6
DM0P59E	IC	InChI=1S/C20H24N2O6/c1-11-15(18(23)27-6)17(13-8-7-9-14(10-13)22(25)26)16(12(2)21-11)19(24)28-20(3,4)5/h7-10,17,21H,1-6H3
DM0P59E	CS	CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC
DM0P59E	IK	YXPRKGBMFPQBDH-UHFFFAOYSA-N
DM0P59E	IU	5-O-tert-butyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM0P59E	DE	Discovery agent

DMYQOKX	ID	DMYQOKX
DMYQOKX	DN	MeBut-RYYRIK-NH2
DMYQOKX	HS	Investigative
DMYQOKX	SN	CHEMBL270394
DMYQOKX	DT	Small molecular drug
DMYQOKX	PC	44455999
DMYQOKX	MW	965.2
DMYQOKX	FM	C47H76N14O8
DMYQOKX	IC	InChI=1S/C47H76N14O8/c1-5-28(3)38(45(69)56-33(39(49)63)16-10-11-23-48)61-42(66)35(18-13-25-55-47(52)53)58-43(67)37(27-31-19-21-32(62)22-20-31)60-44(68)36(26-30-14-8-7-9-15-30)59-41(65)34(17-12-24-54-46(50)51)57-40(64)29(4)6-2/h7-9,14-15,19-22,28-29,33-38,62H,5-6,10-13,16-18,23-27,48H2,1-4H3,(H2,49,63)(H,56,69)(H,57,64)(H,58,67)(H,59,65)(H,60,68)(H,61,66)(H4,50,51,54)(H4,52,53,55)/t28-,29?,33-,34-,35-,36-,37-,38-/m0/s1
DMYQOKX	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(C)CC
DMYQOKX	IK	XDTYNZLRQJEAAQ-QABIKYMTSA-N
DMYQOKX	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2-methylbutanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMYQOKX	DE	Discovery agent

DMNKSX3	ID	DMNKSX3
DMNKSX3	DN	Medazepam
DMNKSX3	HS	Investigative
DMNKSX3	SN	Aensius; Ansilan; Azepamide; Benaon; Enobrin; Lerisum; Medaurin; Medazepam [INN:BAN:JAN]; Medazepamum [INN-Latin]; Narsis; Navizil; Nivelton; Nobraksin; Nobral; Nobrium; Nobrium HCl; P0J3387W3S; RB 252; Resmit; Rudotel; Stratium; YLCXGBZIZBEVPZ-UHFFFAOYSA-N; medazepam; 1H-1,4-BENZODIAZEPINE, 7-CHLORO-2,3-DIHYDRO-1-METHYL-5-PHENYL-; 7-Chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine; BRN 0407983; CHEMBL28333; DEA No. 2836; EINECS 220-783-4; NCGC00164523-01; UNII-P0J3387W3S
DMNKSX3	PC	4041
DMNKSX3	MW	270.75
DMNKSX3	FM	C16H15ClN2
DMNKSX3	IC	YLCXGBZIZBEVPZ-UHFFFAOYSA-N
DMNKSX3	CS	CN1CCN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DMNKSX3	IK	1S/C16H15ClN2/c1-19-10-9-18-16(12-5-3-2-4-6-12)14-11-13(17)7-8-15(14)19/h2-8,11H,9-10H2,1H3
DMNKSX3	IU	7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine
DMNKSX3	CA	CAS 2898-12-6
DMNKSX3	CB	CHEBI:31807
DMNKSX3	DE	Discovery agent

DMQ5S9C	ID	DMQ5S9C
DMQ5S9C	DN	MEDI-552
DMQ5S9C	HS	Investigative
DMQ5S9C	SN	B-cell depleting anti-CD20 monoclonal antibody, Cellective; B-cell depleting anti-CD20 monoclonal antibody, MedImmune
DMQ5S9C	DE	Discovery agent

DM960DQ	ID	DM960DQ
DM960DQ	DN	MEDI-553
DM960DQ	HS	Investigative
DM960DQ	SN	B-cell depleting anti-CD22 monoclonal antibody, Cellective; B-cell depleting anti-CD22 monoclonal antibody, MedImmune
DM960DQ	CP	Cellective Therapeutics Inc
DM960DQ	DT	Antibody
DM960DQ	DE	Autoimmune diabetes

DML2GFB	ID	DML2GFB
DML2GFB	DN	medica 16
DML2GFB	HS	Investigative
DML2GFB	SN	medic-16
DML2GFB	DT	Small molecular drug
DML2GFB	PC	121871
DML2GFB	MW	342.5
DML2GFB	FM	C20H38O4
DML2GFB	IC	InChI=1S/C20H38O4/c1-19(2,15-17(21)22)13-11-9-7-5-6-8-10-12-14-20(3,4)16-18(23)24/h5-16H2,1-4H3,(H,21,22)(H,23,24)
DML2GFB	CS	CC(C)(CCCCCCCCCCC(C)(C)CC(=O)O)CC(=O)O
DML2GFB	IK	HYSMCRNFENOHJH-UHFFFAOYSA-N
DML2GFB	IU	3,3,14,14-tetramethylhexadecanedioic acid
DML2GFB	CA	CAS 87272-20-6
DML2GFB	CB	CHEBI:149582
DML2GFB	DE	Discovery agent

DMDJ6RE	ID	DMDJ6RE
DMDJ6RE	DN	MEDIORESINOL
DMDJ6RE	HS	Investigative
DMDJ6RE	SN	MEDIORESINOL; CHEMBL513023; (-) Medioresinol; AC1L7B3T; BDBM50259877; NSC329245; NSC-329245
DMDJ6RE	DT	Small molecular drug
DMDJ6RE	PC	181681
DMDJ6RE	MW	388.4
DMDJ6RE	FM	C21H24O7
DMDJ6RE	IC	InChI=1S/C21H24O7/c1-24-16-6-11(4-5-15(16)22)20-13-9-28-21(14(13)10-27-20)12-7-17(25-2)19(23)18(8-12)26-3/h4-8,13-14,20-23H,9-10H2,1-3H3/t13-,14-,20+,21+/m0/s1
DMDJ6RE	CS	COC1=CC(=CC(=C1O)OC)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C=C4)O)OC
DMDJ6RE	IK	VJOBNGRIBLNUKN-BMHXQBNDSA-N
DMDJ6RE	IU	4-[(3S,3aR,6S,6aR)-3-(4-hydroxy-3-methoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-2,6-dimethoxyphenol
DMDJ6RE	CA	CAS 40957-99-1
DMDJ6RE	CB	CHEBI:67644
DMDJ6RE	DE	Discovery agent

DMNEAJG	ID	DMNEAJG
DMNEAJG	DN	Medrogestone
DMNEAJG	HS	Investigative
DMNEAJG	SN	Colpro; Colprone; Etogyn; MEDROGESTONE; Medrogesterone; Medrogeston; Medrogestona; Medrogestona [INN-Spanish]; Medrogestone (USAN/INN); Medrogestone [USAN:INN:BAN]; Medrogestonum; Medrogestonum [INN-Latin]; Metrogestone; Prothil; R 13615; SCHEMBL140614; 077DN93G5B; 6,17-Dimethyl-6-dehydroprogesterone; 6,17-Dimethylpregna-4,6-diene-3,20-dione; 6-Methyl-6-dehydro-17-methylprogesterone; 977-79-7; AY 13615S; AY-62022; BRN 2302887; EINECS 213-555-0; NSC 123018; NSC-123018; Pregna-4,6-diene-3,20-dione, 6,17-dimethyl-; UNII-077DN93G5B
DMNEAJG	PC	9949848
DMNEAJG	MW	340.5
DMNEAJG	FM	C23H32O2
DMNEAJG	IC	HCFSGRMEEXUOSS-JXEXPEPMSA-N
DMNEAJG	CS	CC1=CC2C(CCC3(C2CCC3(C)C(=O)C)C)C4(C1=CC(=O)CC4)C
DMNEAJG	IK	1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1
DMNEAJG	IU	(8R,9S,10R,13S,14S,17S)-17-acetyl-6,10,13,17-tetramethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
DMNEAJG	CA	CAS 977-79-7
DMNEAJG	CB	CHEBI:135446
DMNEAJG	DE	Corpus luteum cyst

DMYJI90	ID	DMYJI90
DMYJI90	DN	MEK inhibitor I
DMYJI90	HS	Investigative
DMYJI90	SN	MEK Inhibitor I; SCHEMBL6749464; GTPL6006; HMS3229K14; CCG-206865; J-017629
DMYJI90	DT	Small molecular drug
DMYJI90	PC	9951490
DMYJI90	MW	374.5
DMYJI90	FM	C21H18N4OS
DMYJI90	IC	InChI=1S/C21H18N4OS/c22-13-17(21(24)27-19-7-2-1-6-18(19)23)15-4-3-5-16(12-15)20(26)14-8-10-25-11-9-14/h1-12,20,26H,23-24H2/b21-17+
DMYJI90	CS	C1=CC=C(C(=C1)N)S/C(=C(\\C#N)/C2=CC=CC(=C2)C(C3=CC=NC=C3)O)/N
DMYJI90	IK	NHBMKTBZZSJUGA-HEHNFIMWSA-N
DMYJI90	IU	(Z)-3-amino-3-(2-aminophenyl)sulfanyl-2-[3-[hydroxy(pyridin-4-yl)methyl]phenyl]prop-2-enenitrile
DMYJI90	DE	Discovery agent

DM08SVH	ID	DM08SVH
DM08SVH	DN	MEL57A
DM08SVH	HS	Investigative
DM08SVH	SN	CHEMBL1253475; MEL57A; GTPL6260; SCHEMBL16410080; BDBM50326990; 3-[(Z)-4-[[(Z)-4-(7, 8-dimethoxy-2-oxo-1H-3-benzazepin-3-yl)but-2-enyl]-[(2R)-2-(3, 4-dimethoxyphenyl)propyl]amino]but-2-enyl]-7, 8-dimethoxy-1H-3-benzazepin-2-one
DM08SVH	DT	Small molecular drug
DM08SVH	PC	46937420
DM08SVH	MW	737.9
DM08SVH	FM	C43H51N3O8
DM08SVH	IC	InChI=1S/C43H51N3O8/c1-30(31-12-13-36(49-2)37(22-31)50-3)29-44(16-8-10-18-45-20-14-32-23-38(51-4)40(53-6)25-34(32)27-42(45)47)17-9-11-19-46-21-15-33-24-39(52-5)41(54-7)26-35(33)28-43(46)48/h8-15,20-26,30H,16-19,27-29H2,1-7H3/b10-8-,11-9-/t30-/m0/s1
DM08SVH	CS	C[C@H](C1=CC(=C(C=C1)OC)OC)CN(C/C=C\\CN2C(=O)CC3=CC(=C(C=C3C=C2)OC)OC)C/C=C\\CN4C(=O)CC5=CC(=C(C=C5C=C4)OC)OC
DM08SVH	IK	WCJGGTAAPIAIJS-PSEQGZRXSA-N
DM08SVH	IU	3-[(Z)-4-[[(Z)-4-(7,8-dimethoxy-2-oxo-1H-3-benzazepin-3-yl)but-2-enyl]-[(2R)-2-(3,4-dimethoxyphenyl)propyl]amino]but-2-enyl]-7,8-dimethoxy-1H-3-benzazepin-2-one
DM08SVH	DE	Discovery agent

DMY57L0	ID	DMY57L0
DMY57L0	DN	melanin-concentrating hormone
DMY57L0	HS	Investigative
DMY57L0	SN	Melanin-concentrating hormone; Melanin concentrating hormone; GTPL1298
DMY57L0	DT	Small molecular drug
DMY57L0	PC	16167454
DMY57L0	MW	2099.5
DMY57L0	FM	C89H139N27O24S4
DMY57L0	IC	InChI=1S/C89H139N27O24S4/c1-43(2)67-82(135)101-40-64(119)102-53(18-12-30-97-87(91)92)74(127)113-68(44(3)4)83(136)109-59(36-47-22-24-49(118)25-23-47)77(130)107-58(20-14-32-99-89(95)96)85(138)116-33-15-21-63(116)81(134)111-62(80(133)108-60(37-48-39-100-52-17-11-10-16-50(48)52)78(131)104-55(26-27-65(120)121)75(128)114-69(45(5)6)86(139)140)42-144-143-41-61(79(132)105-57(29-35-142-9)76(129)112-67)110-72(125)54(19-13-31-98-88(93)94)103-73(126)56(28-34-141-8)106-84(137)70(46(7)117)115-71(124)51(90)38-66(122)123/h10-11,16-17,22-25,39,43-46,51,53-63,67-70,100,117-118H,12-15,18-21,26-38,40-42,90H2,1-9H3,(H,101,135)(H,102,119)(H,103,126)(H,104,131)(H,105,132)(H,106,137)(H,107,130)(H,108,133)(H,109,136)(H,110,125)(H,111,134)(H,112,129)(H,113,127)(H,114,128)(H,115,124)(H,120,121)(H,122,123)(H,139,140)(H4,91,92,97)(H4,93,94,98)(H4,95,96,99)
DMY57L0	CS	CC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CCSC)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCSC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)O)CCCNC(=N)N)CC5=CC=C(C=C5)O)C(C)C)CCCNC(=N)N
DMY57L0	IK	ORRDHOMWDPJSNL-UHFFFAOYSA-N
DMY57L0	IU	4-[[2-[[24-[[2-[[2-[[2-[(2-amino-3-carboxypropanoyl)amino]-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3,12-bis(3-carbamimidamidopropyl)-6-[(4-hydroxyphenyl)methyl]-21-(2-methylsulfanylethyl)-2,5,8,11,14,17,20,23,31-nonaoxo-9,18-di(propan-2-yl)-26,27-dithia-1,4,7,10,13,16,19,22,30-nonazabicyclo[30.3.0]pentatriacontane-29-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[(1-carboxy-2-methylpropyl)amino]-5-oxopentanoic acid
DMY57L0	DE	Discovery agent

DM2ES7Z	ID	DM2ES7Z
DM2ES7Z	DN	Melanocortin-4 Receptor antagonist
DM2ES7Z	HS	Investigative
DM2ES7Z	SN	Methyl 16-hydroxyhexadecanoate; AOTMRIXFFOGWDT-UHFFFAOYSA-N; 36575-67-4; Methyl juniperate; MC4 Receptor antagonist; AC1MRQ5C; SCHEMBL1245383; Methyl 16-hydroxy-hexadecanoate; CTK1B6241; DTXSID80393043; Melanocortin 4 Receptor antagonist; HS028; AKOS005066798; 16-hydroxyhexadecanoic Acid Methyl Ester; Hexadecanoic acid, 16-hydroxy-, methyl ester
DM2ES7Z	CP	Santhera
DM2ES7Z	DT	Small molecular drug
DM2ES7Z	PC	3496888
DM2ES7Z	MW	286.4
DM2ES7Z	FM	C17H34O3
DM2ES7Z	IC	InChI=1S/C17H34O3/c1-20-17(19)15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18/h18H,2-16H2,1H3
DM2ES7Z	CS	COC(=O)CCCCCCCCCCCCCCCO
DM2ES7Z	IK	AOTMRIXFFOGWDT-UHFFFAOYSA-N
DM2ES7Z	IU	methyl 16-hydroxyhexadecanoate
DM2ES7Z	CA	CAS 36575-67-4
DM2ES7Z	DE	Anorexia nervosa cachexia

DMTKLH8	ID	DMTKLH8
DMTKLH8	DN	Melibiose
DMTKLH8	HS	Investigative
DMTKLH8	SN	D-Gal-alpha(1-&gt;6)-D-glucose; D-Gal-alpha1-&gt;6D-Glucose; D-Melibiose; D-mellibiose; Gal-alpha(1,6)Glc; SCHEMBL2504901; alpha-D-Gal-(1-&gt;6)-D-Glc; melibiose; 585-99-9; 6-(alpha-D-galactosido)-D-glucose; 6-O-(alpha-D-Galactopyranosyl)-D-glucopyranose; 6-O-alpha-D-Galactopyranosyl-D-glucopyranose; CHEBI:28053; Epitope ID:140529; M0050; alpha-D-Galp-(1-&gt;6)-D-Glc; alpha-D-Galp-(1-&gt;6)-D-Glcp; alpha-D-galactopyranosyl-1-6-D-glucopyranose; alpha-D-galactosyl-(1-&gt;6)-D-glucose; bmse000233
DMTKLH8	PC	440658
DMTKLH8	MW	342.3
DMTKLH8	FM	C12H22O11
DMTKLH8	IC	DLRVVLDZNNYCBX-ABXHMFFYSA-N
DMTKLH8	CS	C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)O)O)O)O)O)O)O)O
DMTKLH8	IK	1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5+,6-,7+,8+,9-,10-,11?,12+/m1/s1
DMTKLH8	IU	(3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
DMTKLH8	CA	CAS 585-99-9
DMTKLH8	CB	CHEBI:28053
DMTKLH8	DE	Discovery agent

DME54M7	ID	DME54M7
DME54M7	DN	Melogatran
DME54M7	HS	Investigative
DME54M7	DE	Discovery agent

DM3492O	ID	DM3492O
DM3492O	DN	MELOSMINE
DM3492O	HS	Investigative
DM3492O	DT	Small molecular drug
DM3492O	PC	72329
DM3492O	MW	337.4
DM3492O	FM	C20H19NO4
DM3492O	IC	InChI=1S/C20H19NO4/c1-20(2)13-9-10(22)5-6-11(13)14-15-12(7-8-21-19(15)20)17(24-3)18(25-4)16(14)23/h5-9,22-23H,1-4H3
DM3492O	CS	CC1(C2=C(C=CC(=C2)O)C3=C(C(=C(C4=C3C1=NC=C4)OC)OC)O)C
DM3492O	IK	CUEIWVZJOPCMPT-UHFFFAOYSA-N
DM3492O	IU	14,15-dimethoxy-8,8-dimethyl-10-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17),14-octaene-5,16-diol
DM3492O	CA	CAS 81525-68-0
DM3492O	DE	Discovery agent

DM9S30P	ID	DM9S30P
DM9S30P	DN	MEMOQUIN
DM9S30P	HS	Investigative
DM9S30P	SN	MEMOQUIN; 616885-87-1; SCHEMBL4365745; ZINC101086292
DM9S30P	DT	Small molecular drug
DM9S30P	PC	9917279
DM9S30P	MW	632.9
DM9S30P	FM	C38H56N4O4
DM9S30P	IC	InChI=1S/C38H56N4O4/c1-5-41(29-31-19-11-13-21-37(31)45-3)25-17-9-7-15-23-39-33-27-36(44)34(28-35(33)43)40-24-16-8-10-18-26-42(6-2)30-32-20-12-14-22-38(32)46-4/h11-14,19-22,27-28,39-40H,5-10,15-18,23-26,29-30H2,1-4H3
DM9S30P	CS	CCN(CCCCCCNC1=CC(=O)C(=CC1=O)NCCCCCCN(CC)CC2=CC=CC=C2OC)CC3=CC=CC=C3OC
DM9S30P	IK	VPXVPJQOPRBXPO-UHFFFAOYSA-N
DM9S30P	IU	2,5-bis[6-[ethyl-[(2-methoxyphenyl)methyl]amino]hexylamino]cyclohexa-2,5-diene-1,4-dione
DM9S30P	DE	Discovery agent

DMEIRDX	ID	DMEIRDX
DMEIRDX	DN	MEN-14295
DMEIRDX	HS	Investigative
DMEIRDX	SN	MEN-14536; MEN-15658; Rebeccamycin analogs, Menarini; Topoisomerase inhibitors (cancer); Topoisomerase inhibitors (cancer), Menarini
DMEIRDX	CP	The Menarini Group
DMEIRDX	DE	Solid tumour/cancer

DMU8L7C	ID	DMU8L7C
DMU8L7C	DN	Mepacrine
DMU8L7C	HS	Investigative
DMU8L7C	SN	quinacrine; mepacrine; atabrine; Acrinamine; Acriquine; 83-89-6; Quinactine; Antimalarina; Haffkinine; Akrichin; Italchine; acrichine; Erion; Mepacrinum; Quinacrine hydrochloride; Mepacrine [INN:BAN]; St 439; Mepacrinum [INN-Latin]; Mepacrina [INN-Spanish]; atebrin; Malaricida; Methoquine; Palacrin; Italchin; Pentilen; Palusan; Atebrine; Metochin; Mecryl; Quinacrine, Mepacrine; 3-Chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine; 2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine; HSDB 3253
DMU8L7C	DT	Small molecular drug
DMU8L7C	PC	237
DMU8L7C	MW	400
DMU8L7C	FM	C23H30ClN3O
DMU8L7C	IC	InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)
DMU8L7C	CS	CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC
DMU8L7C	IK	GPKJTRJOBQGKQK-UHFFFAOYSA-N
DMU8L7C	IU	4-N-(6-chloro-2-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine
DMU8L7C	CA	CAS 83-89-6
DMU8L7C	CB	CHEBI:8711
DMU8L7C	DE	Discovery agent

DMZIA1R	ID	DMZIA1R
DMZIA1R	DN	mercaptoacrylate inhibitor of calpain 1
DMZIA1R	HS	Investigative
DMZIA1R	SN	mercaptoacrylate inhibitor of calpain 1; GTPL8570; CHEMBL3221938; (Z)-3-(5-bromo-1H-indol-3-yl)-2-sulfanylprop-2-enoic acid
DMZIA1R	DT	Small molecular drug
DMZIA1R	PC	90668184
DMZIA1R	MW	298.16
DMZIA1R	FM	C11H8BrNO2S
DMZIA1R	IC	InChI=1S/C11H8BrNO2S/c12-7-1-2-9-8(4-7)6(5-13-9)3-10(16)11(14)15/h1-5,13,16H,(H,14,15)/b10-3-
DMZIA1R	CS	C1=CC2=C(C=C1Br)C(=CN2)/C=C(/C(=O)O)\\S
DMZIA1R	IK	RLEKFRNXGFHPHZ-KMKOMSMNSA-N
DMZIA1R	IU	(Z)-3-(5-bromo-1H-indol-3-yl)-2-sulfanylprop-2-enoic acid
DMZIA1R	DE	Discovery agent

DM68FZK	ID	DM68FZK
DM68FZK	DN	Mercaptosuccinate
DM68FZK	HS	Investigative
DM68FZK	SN	Butanedioic acid, mercapto-; DL-Mercaptosuccinic acid; Malic acid, 2-thio-; Mercaptosuccinate; Mercaptosuccinic acid; Monomercaptosuccinic acid; NJRXVEJTAYWCQJ-UHFFFAOYSA-N; SUCCINIC ACID, MERCAPTO-; Thiomalate; Thiomalic acid; USAF EK-P-6297; USAF M-2; butanedioic acid, 2-mercapto-; (+/-)-Mercaptosuccinic acid; (1)-Mercaptosuccinic acid; .alpha.-Mercaptosuccinic acid; 2-Mercaptosuccinic acid; 2-Thiomalic acid; 2-sulfanylbutanedioic acid; 70-49-5; AI3-22956; BRN 1099858; C4H6O4S; EINECS 200-736-4; EINECS 211-423-7; NSC 7302
DM68FZK	PC	6268
DM68FZK	MW	150.16
DM68FZK	FM	C4H6O4S
DM68FZK	IC	NJRXVEJTAYWCQJ-UHFFFAOYSA-N
DM68FZK	CS	C(C(C(=O)O)S)C(=O)O
DM68FZK	IK	1S/C4H6O4S/c5-3(6)1-2(9)4(7)8/h2,9H,1H2,(H,5,6)(H,7,8)
DM68FZK	IU	2-sulfanylbutanedioic acid
DM68FZK	CA	CAS 70-49-5
DM68FZK	CB	CHEBI:38705
DM68FZK	DE	Discovery agent

DMD25I6	ID	DMD25I6
DMD25I6	DN	MERCK-544
DMD25I6	HS	Investigative
DMD25I6	SN	MERCK-544; 327093-42-5; CHEMBL256777; 3-ADAMANTAN-1-YL-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[4.3-A]AZEPINE; Compound 544; 3-(Adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine; AC1MTUPG; Merck 544; Oprea1_175789; SCHEMBL5095978; DTXSID40394475; ZINC5494877; BDBM50239401; AKOS015969399; 3-(1-adamantyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine; MCULE-4943397141; SR-01000029295; SR-01000029295-1; Z55729757; 3-(adamantan-1-yl)-5H,6H,7H,8H,9H-[1,2,4]triazolo[4,3-a]azepine
DMD25I6	DT	Small molecular drug
DMD25I6	PC	3630776
DMD25I6	MW	271.4
DMD25I6	FM	C17H25N3
DMD25I6	IC	InChI=1S/C17H25N3/c1-2-4-15-18-19-16(20(15)5-3-1)17-9-12-6-13(10-17)8-14(7-12)11-17/h12-14H,1-11H2
DMD25I6	CS	C1CCC2=NN=C(N2CC1)C34CC5CC(C3)CC(C5)C4
DMD25I6	IK	VFTQRHWULYJKCI-UHFFFAOYSA-N
DMD25I6	IU	3-(1-adamantyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
DMD25I6	CA	CAS 327093-42-5
DMD25I6	DE	Discovery agent

DMT56ER	ID	DMT56ER
DMT56ER	DN	Mercuribenzoic Acid
DMT56ER	HS	Investigative
DMT56ER	SN	Mercuribenzoic acid; MERCURIBENZOIC ACID; (4-carboxyphenyl)mercury; p-mercuribenzoic acid; (4-CARBOXYPHENYL)(CHLORO)MERCURY; BE7; MBO; HGB; 4-mercuribenzoic acid; AC1L1RM7; SCHEMBL677378; CTK7I7797; CHEBI:28886
DMT56ER	DT	Small molecular drug
DMT56ER	PC	8747
DMT56ER	MW	321.7
DMT56ER	FM	C7H5HgO2
DMT56ER	IC	InChI=1S/C7H5O2.Hg/c8-7(9)6-4-2-1-3-5-6;/h2-5H,(H,8,9);
DMT56ER	CS	C1=CC(=CC=C1C(=O)O)[Hg]
DMT56ER	IK	FVFZSVRSDNUCGG-UHFFFAOYSA-N
DMT56ER	IU	(4-carboxyphenyl)mercury
DMT56ER	CB	CHEBI:28886
DMT56ER	DE	Discovery agent

DMPZ0XJ	ID	DMPZ0XJ
DMPZ0XJ	DN	Merimepodib
DMPZ0XJ	HS	Investigative
DMPZ0XJ	SN	Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
DMPZ0XJ	CP	GSK
DMPZ0XJ	TC	Antiviral Agents
DMPZ0XJ	DT	Small molecular drug
DMPZ0XJ	PC	153241
DMPZ0XJ	MW	452.5
DMPZ0XJ	FM	C23H24N4O6
DMPZ0XJ	IC	InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1
DMPZ0XJ	CS	COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4
DMPZ0XJ	IK	JBPUGFODGPKTDW-SFHVURJKSA-N
DMPZ0XJ	IU	[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
DMPZ0XJ	CA	CAS 198821-22-6
DMPZ0XJ	DE	Gastric adenocarcinoma; Head and neck squamous cell carcinoma; Hepatitis C virus infection; Hepatitis virus infection; Refractory breast cancer; Coronavirus Disease 2019 (COVID-19)

DMJT93H	ID	DMJT93H
DMJT93H	DN	MERIOLIN 1
DMJT93H	HS	Investigative
DMJT93H	SN	MERIOLIN 1; 341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine
DMJT93H	DT	Small molecular drug
DMJT93H	PC	11637090
DMJT93H	MW	211.22
DMJT93H	FM	C11H9N5
DMJT93H	IC	InChI=1S/C11H9N5/c12-11-14-5-3-9(16-11)8-6-15-10-7(8)2-1-4-13-10/h1-6H,(H,13,15)(H2,12,14,16)
DMJT93H	CS	C1=CC2=C(NC=C2C3=NC(=NC=C3)N)N=C1
DMJT93H	IK	HQHSJJZIICGOIX-UHFFFAOYSA-N
DMJT93H	IU	4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMJT93H	CA	CAS 341998-55-8
DMJT93H	DE	Discovery agent

DM413XJ	ID	DM413XJ
DM413XJ	DN	MERIOLIN 2
DM413XJ	HS	Investigative
DM413XJ	SN	MERIOLIN 2; SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6
DM413XJ	DT	Small molecular drug
DM413XJ	PC	24801699
DM413XJ	MW	227.22
DM413XJ	FM	C11H9N5O
DM413XJ	IC	InChI=1S/C11H9N5O/c12-11-14-3-1-7(16-11)6-5-15-10-9(6)8(17)2-4-13-10/h1-5H,(H2,12,14,16)(H2,13,15,17)
DM413XJ	CS	C1=CNC2=C(C1=O)C(=CN2)C3=NC(=NC=C3)N
DM413XJ	IK	JYGNOLIKBUTZNC-UHFFFAOYSA-N
DM413XJ	IU	3-(2-aminopyrimidin-4-yl)-1,7-dihydropyrrolo[2,3-b]pyridin-4-one
DM413XJ	DE	Discovery agent

DMVE95S	ID	DMVE95S
DMVE95S	DN	MERIOLIN 3
DMVE95S	HS	Investigative
DMVE95S	SN	MERIOLIN 3; 954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295
DMVE95S	DT	Small molecular drug
DMVE95S	PC	23727981
DMVE95S	MW	241.25
DMVE95S	FM	C12H11N5O
DMVE95S	IC	InChI=1S/C12H11N5O/c1-18-9-3-5-14-11-10(9)7(6-16-11)8-2-4-15-12(13)17-8/h2-6H,1H3,(H,14,16)(H2,13,15,17)
DMVE95S	CS	COC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DMVE95S	IK	GGEWEQJWGGJUHO-UHFFFAOYSA-N
DMVE95S	IU	4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMVE95S	DE	Discovery agent

DMIJMZQ	ID	DMIJMZQ
DMIJMZQ	DN	MERIOLIN 4
DMIJMZQ	HS	Investigative
DMIJMZQ	SN	MERIOLIN 4; SCHEMBL3001373; CHEMBL406464
DMIJMZQ	DT	Small molecular drug
DMIJMZQ	PC	24801697
DMIJMZQ	MW	255.28
DMIJMZQ	FM	C13H13N5O
DMIJMZQ	IC	InChI=1S/C13H13N5O/c1-2-19-10-4-6-15-12-11(10)8(7-17-12)9-3-5-16-13(14)18-9/h3-7H,2H2,1H3,(H,15,17)(H2,14,16,18)
DMIJMZQ	CS	CCOC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DMIJMZQ	IK	CJJMNECGBUPMAV-UHFFFAOYSA-N
DMIJMZQ	IU	4-(4-ethoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMIJMZQ	DE	Discovery agent

DMGVLR0	ID	DMGVLR0
DMGVLR0	DN	MERIOLIN 5
DMGVLR0	HS	Investigative
DMGVLR0	SN	MERIOLIN 5; 1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182
DMGVLR0	DT	Small molecular drug
DMGVLR0	PC	23727982
DMGVLR0	MW	269.3
DMGVLR0	FM	C14H15N5O
DMGVLR0	IC	InChI=1S/C14H15N5O/c1-2-7-20-11-4-6-16-13-12(11)9(8-18-13)10-3-5-17-14(15)19-10/h3-6,8H,2,7H2,1H3,(H,16,18)(H2,15,17,19)
DMGVLR0	CS	CCCOC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DMGVLR0	IK	ZHMRPXZRUZLCNL-UHFFFAOYSA-N
DMGVLR0	IU	4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMGVLR0	DE	Discovery agent

DMW5AXC	ID	DMW5AXC
DMW5AXC	DN	MERIOLIN 6
DMW5AXC	HS	Investigative
DMW5AXC	SN	MERIOLIN 6; CHEMBL406463; SCHEMBL2999009
DMW5AXC	DT	Small molecular drug
DMW5AXC	PC	24801185
DMW5AXC	MW	269.3
DMW5AXC	FM	C14H15N5O
DMW5AXC	IC	InChI=1S/C14H15N5O/c1-8(2)20-11-4-6-16-13-12(11)9(7-18-13)10-3-5-17-14(15)19-10/h3-8H,1-2H3,(H,16,18)(H2,15,17,19)
DMW5AXC	CS	CC(C)OC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DMW5AXC	IK	YRURITXEWXPMAI-UHFFFAOYSA-N
DMW5AXC	IU	4-(4-propan-2-yloxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMW5AXC	DE	Discovery agent

DM8D3NY	ID	DM8D3NY
DM8D3NY	DN	MERIOLIN 7
DM8D3NY	HS	Investigative
DM8D3NY	SN	MERIOLIN 7; SCHEMBL2239805; CHEMBL405074
DM8D3NY	DT	Small molecular drug
DM8D3NY	PC	24801186
DM8D3NY	MW	285.3
DM8D3NY	FM	C14H15N5O2
DM8D3NY	IC	InChI=1S/C14H15N5O2/c1-20-6-7-21-11-3-5-16-13-12(11)9(8-18-13)10-2-4-17-14(15)19-10/h2-5,8H,6-7H2,1H3,(H,16,18)(H2,15,17,19)
DM8D3NY	CS	COCCOC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DM8D3NY	IK	NFOHQNIARGGZFN-UHFFFAOYSA-N
DM8D3NY	IU	4-[4-(2-methoxyethoxy)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-amine
DM8D3NY	DE	Discovery agent

DM0E95B	ID	DM0E95B
DM0E95B	DN	MERIOLIN 8
DM0E95B	HS	Investigative
DM0E95B	SN	MERIOLIN 8; SCHEMBL2991886; CHEMBL406102
DM0E95B	DT	Small molecular drug
DM0E95B	PC	24801181
DM0E95B	MW	241.25
DM0E95B	FM	C12H11N5O
DM0E95B	IC	InChI=1S/C12H11N5O/c1-17-6-7(8-2-4-15-12(13)16-8)10-9(18)3-5-14-11(10)17/h2-6H,1H3,(H,14,18)(H2,13,15,16)
DM0E95B	CS	CN1C=C(C2=C1NC=CC2=O)C3=NC(=NC=C3)N
DM0E95B	IK	PYDJIICXCHAWOI-UHFFFAOYSA-N
DM0E95B	IU	3-(2-aminopyrimidin-4-yl)-1-methyl-7H-pyrrolo[2,3-b]pyridin-4-one
DM0E95B	DE	Discovery agent

DMYVUCE	ID	DMYVUCE
DMYVUCE	DN	MESCALINE
DMYVUCE	HS	Investigative
DMYVUCE	SN	mescaline; Mescalin; Tmpea; Mezcaline; 3,4,5-Trimethoxyphenethylamine; 54-04-6; 2-(3,4,5-Trimethoxyphenyl)ethanamine; 3,4,5-Trimethoxyphenylethylamine; Mezcalin; 3,4,5-Trimethoxybenzeneethanamine; mezcalina; mescalina; Meskalin; Benzeneethanamine, 3,4,5-trimethoxy-; Mescalin [German]; Mescline; Mezcline; Phenethylamine, 3,4,5-trimethoxy-; UNII-RHO99102VC; NSC 30419; Ethane, 1-amino-2-(3,4,5-trimethoxyphenyl)-; EINECS 200-190-7; BRN 1374088; 2-(3,4,5-trimethoxy-phenyl)-ethylamine; CHEMBL26687; RHO99102VC
DMYVUCE	DT	Small molecular drug
DMYVUCE	PC	4076
DMYVUCE	MW	211.26
DMYVUCE	FM	C11H17NO3
DMYVUCE	IC	InChI=1S/C11H17NO3/c1-13-9-6-8(4-5-12)7-10(14-2)11(9)15-3/h6-7H,4-5,12H2,1-3H3
DMYVUCE	CS	COC1=CC(=CC(=C1OC)OC)CCN
DMYVUCE	IK	RHCSKNNOAZULRK-UHFFFAOYSA-N
DMYVUCE	IU	2-(3,4,5-trimethoxyphenyl)ethanamine
DMYVUCE	CA	CAS 54-04-6
DMYVUCE	CB	CHEBI:28346
DMYVUCE	DE	Discovery agent

DM86WRO	ID	DM86WRO
DM86WRO	DN	meso-DAP
DM86WRO	HS	Investigative
DM86WRO	SN	meso-diaminopimeilic acid
DM86WRO	DT	Small molecular drug
DM86WRO	PC	99290
DM86WRO	MW	190.2
DM86WRO	FM	C7H14N2O4
DM86WRO	IC	InChI=1S/C7H14N2O4/c8-4(6(10)11)2-1-3-5(9)7(12)13/h4-5H,1-3,8-9H2,(H,10,11)(H,12,13)/t4-,5+
DM86WRO	CS	C(C[C@H](C(=O)O)N)C[C@@H](C(=O)O)N
DM86WRO	IK	GMKMEZVLHJARHF-SYDPRGILSA-N
DM86WRO	IU	(2S,6R)-2,6-diaminoheptanedioic acid
DM86WRO	CA	CAS 922-54-3
DM86WRO	CB	CHEBI:16488
DM86WRO	DE	Discovery agent

DMZ12GE	ID	DMZ12GE
DMZ12GE	DN	MESUAGENIN A
DMZ12GE	HS	Investigative
DMZ12GE	SN	MESUAGENIN A; CHEMBL1277495
DMZ12GE	DT	Small molecular drug
DMZ12GE	PC	49870983
DMZ12GE	MW	472.6
DMZ12GE	FM	C30H32O5
DMZ12GE	IC	InChI=1S/C30H32O5/c1-18(2)10-9-14-30(5)15-13-21-27(33)26(23(31)16-19(3)4)29-25(28(21)35-30)22(17-24(32)34-29)20-11-7-6-8-12-20/h6-8,10-13,15,17,19,33H,9,14,16H2,1-5H3
DMZ12GE	CS	CC(C)CC(=O)C1=C2C(=C3C(=C1O)C=CC(O3)(C)CCC=C(C)C)C(=CC(=O)O2)C4=CC=CC=C4
DMZ12GE	IK	STYQYOHXCPHKKX-UHFFFAOYSA-N
DMZ12GE	IU	5-hydroxy-2-methyl-6-(3-methylbutanoyl)-2-(4-methylpent-3-enyl)-10-phenylpyrano[2,3-f]chromen-8-one
DMZ12GE	DE	Discovery agent

DMKXG3V	ID	DMKXG3V
DMKXG3V	DN	MESUAGENIN B
DMKXG3V	HS	Investigative
DMKXG3V	SN	MESUAGENIN B; CHEMBL1277588
DMKXG3V	DT	Small molecular drug
DMKXG3V	PC	13917758
DMKXG3V	MW	472.6
DMKXG3V	FM	C30H32O5
DMKXG3V	IC	InChI=1S/C30H32O5/c1-6-19(4)26(32)25-27(33)21-14-16-30(5,15-10-11-18(2)3)35-28(21)24-22(17-23(31)34-29(24)25)20-12-8-7-9-13-20/h7-9,11-14,16-17,19,33H,6,10,15H2,1-5H3
DMKXG3V	CS	CCC(C)C(=O)C1=C2C(=C3C(=C1O)C=CC(O3)(C)CCC=C(C)C)C(=CC(=O)O2)C4=CC=CC=C4
DMKXG3V	IK	GEYVIFNRNUBPHZ-UHFFFAOYSA-N
DMKXG3V	IU	5-hydroxy-2-methyl-6-(2-methylbutanoyl)-2-(4-methylpent-3-enyl)-10-phenylpyrano[2,3-f]chromen-8-one
DMKXG3V	DE	Discovery agent

DMLZGO7	ID	DMLZGO7
DMLZGO7	DN	Mesuagenin D
DMLZGO7	HS	Investigative
DMLZGO7	SN	Mesuagenin D; CHEMBL1277681
DMLZGO7	DT	Small molecular drug
DMLZGO7	PC	52945557
DMLZGO7	MW	492.6
DMLZGO7	FM	C30H36O6
DMLZGO7	IC	InChI=1S/C30H36O6/c1-17(2)12-13-29(5,34)30(6)16-21-26(33)25(22(31)14-18(3)4)28-24(27(21)36-30)20(15-23(32)35-28)19-10-8-7-9-11-19/h7-11,15,17-18,33-34H,12-14,16H2,1-6H3
DMLZGO7	CS	CC(C)CCC(C)(C1(CC2=C(C(=C3C(=C2O1)C(=CC(=O)O3)C4=CC=CC=C4)C(=O)CC(C)C)O)C)O
DMLZGO7	IK	PABMLJMVAOFHKY-UHFFFAOYSA-N
DMLZGO7	IU	4-hydroxy-2-(2-hydroxy-5-methylhexan-2-yl)-2-methyl-5-(3-methylbutanoyl)-9-phenyl-3H-furo[2,3-f]chromen-7-one
DMLZGO7	DE	Discovery agent

DMKGWAH	ID	DMKGWAH
DMKGWAH	DN	MESULERGINE
DMKGWAH	HS	Investigative
DMKGWAH	SN	Mesulergine; Mesulerginum; Mesulergina; Mesulergine [INN]; Mesulerginum [INN-Latin]; UNII-SML95FK06I; Mesulergina [INN-Spanish]; 64795-35-3; N'-(1,6-Dimethylergolin-8alpha-yl)-N,N-dimethylsulfamide; SML95FK06I; CQ 32085; CHEMBL12314; C18H26N4O2S; CHEBI:73378; 3-(1,6-Dimethyl-8alpha-ergolinyl)-1,1-dimethylsulfamid; NCGC00163168-01; DSSTox_RID_81540; DSSTox_CID_26324; DSSTox_GSID_46324; CU-32085; N'-[(8alpha)-1,6-dimethylergolin-8-yl]-N,N-dimethylsulfuric diamide; CAS-64795-35-3; AC1L2AKM; Biomol-NT_000077; AC1Q6V4R; GTPL206
DMKGWAH	DT	Small molecular drug
DMKGWAH	PC	68848
DMKGWAH	MW	362.5
DMKGWAH	FM	C18H26N4O2S
DMKGWAH	IC	InChI=1S/C18H26N4O2S/c1-20(2)25(23,24)19-13-9-15-14-6-5-7-16-18(14)12(10-21(16)3)8-17(15)22(4)11-13/h5-7,10,13,15,17,19H,8-9,11H2,1-4H3/t13-,15+,17+/m0/s1
DMKGWAH	CS	CN1C[C@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C
DMKGWAH	IK	JLVHTNZNKOSCNB-YSVLISHTSA-N
DMKGWAH	IU	(6aR,9S,10aR)-9-(dimethylsulfamoylamino)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline
DMKGWAH	CA	CAS 64795-35-3
DMKGWAH	CB	CHEBI:73378
DMKGWAH	DE	Discovery agent

DMEA8GP	ID	DMEA8GP
DMEA8GP	DN	meta-chlorphenylbiguanide
DMEA8GP	HS	Investigative
DMEA8GP	SN	m-Chlorophenylbiguanide; mCPBG; 1-(3-Chlorophenyl)biguanide; 1-(m-Chlorophenyl)biguanide; N-(3-Chlorophenyl)imidodicarbonimidic diamide; 48144-44-1; Imidodicarbonimidic diamide, N-(3-chlorophenyl)-; UNII-910A4X901V; M-Chlorophenylbiguanidine; 3-Chloro-Phenyl biguanide; 2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine; CHEMBL13790; CHEBI:32347; N-(3-chlorophenyl)-N'-(diaminomethylene)guanidine; 910A4X901V; C8H10ClN5; Imidodicarbonimidicdiamide, N-(3-chlorophenyl)-; 1-carbamimidamido-N-(3-chlorophenyl)methanimidamide;  1-(3-chlorophenyl)biguanide; m-chlorophenylbiguanide; 3-chlorophenyl-biguanide; [3H]meta-chlorophenylbiguanide
DMEA8GP	DT	Small molecular drug
DMEA8GP	PC	1354
DMEA8GP	MW	211.65
DMEA8GP	FM	C8H10ClN5
DMEA8GP	IC	InChI=1S/C8H10ClN5/c9-5-2-1-3-6(4-5)13-8(12)14-7(10)11/h1-4H,(H6,10,11,12,13,14)
DMEA8GP	CS	C1=CC(=CC(=C1)Cl)N=C(N)N=C(N)N
DMEA8GP	IK	DIHXJZHAIHGSAW-UHFFFAOYSA-N
DMEA8GP	IU	2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine
DMEA8GP	CA	CAS 48144-44-1
DMEA8GP	CB	CHEBI:32347
DMEA8GP	DE	Discovery agent

DMTGMB1	ID	DMTGMB1
DMTGMB1	DN	Metanephrine
DMTGMB1	HS	Investigative
DMTGMB1	SN	Metanephrine; Metadrenaline; 5001-33-2; DL-Metanephrine; 3-Methoxyadrenaline; m-O-Methyladrenaline; (+/-)-Metanephrine; 4-[1-Hydroxy-2-(methylamino)ethyl]-2-methoxyphenol; CHEBI:89633; JWJCTZKFYGDABJ-UHFFFAOYSA-N; 3-methoxy-adrenaline; epinephrine metabolite; 3-O-Methylepinephrine; 3-O-methyl-Adrenaline; Adrenaline, 3-methoxy-; AC1L2HML; Prestwick2_000122; Prestwick0_000122; DL-3-O-Methyladrenaline; Prestwick3_000122; Prestwick1_000122; Adrenaline, 3-O-methyl-; DL-METANEPHRINE HCI; CHEMBL775; Vanillyl alcohol, .alpha.-[(methylamin
DMTGMB1	DT	Small molecular drug
DMTGMB1	PC	21100
DMTGMB1	MW	197.23
DMTGMB1	FM	C10H15NO3
DMTGMB1	IC	InChI=1S/C10H15NO3/c1-11-6-9(13)7-3-4-8(12)10(5-7)14-2/h3-5,9,11-13H,6H2,1-2H3
DMTGMB1	CS	CNCC(C1=CC(=C(C=C1)O)OC)O
DMTGMB1	IK	JWJCTZKFYGDABJ-UHFFFAOYSA-N
DMTGMB1	IU	4-[1-hydroxy-2-(methylamino)ethyl]-2-methoxyphenol
DMTGMB1	CA	CAS 5001-33-2
DMTGMB1	CB	CHEBI:89633
DMTGMB1	DE	Discovery agent

DMITMN9	ID	DMITMN9
DMITMN9	DN	Meta-Nitro-Tyrosine
DMITMN9	HS	Investigative
DMITMN9	SN	3-Nitro-L-tyrosine; 621-44-3; 3-Nitrotyrosine; H-Tyr(3-NO2)-OH; L-3-Nitrotyrosine; Meta-Nitro-Tyrosine; Tyrosine, 3-nitro-; L-Tyrosine, 3-nitro-; H-3-Nitro-Tyr-OH; UNII-7COY1HA6HK; Tyrosine, 3-nitro-, L-; 3-Mononitrotyrosine; CCRIS 3566; (S)-2-Amino-3-(4-hydroxy-3-nitrophenyl)propanoic acid; (2S)-2-amino-3-(4-hydroxy-3-nitrophenyl)propanoic acid; EINECS 210-688-6; NSC 37413; 7COY1HA6HK; AI3-63160; H-4-Hydroxy-3-nitro-Phe-OH; CHEBI:44454; FBTSQILOGYXGMD-LURJTMIESA-N; MFCD00007123; 3-Nitro-L-tyrosine crystalline; m-Nitrotyrosine
DMITMN9	DT	Small molecular drug
DMITMN9	PC	65124
DMITMN9	MW	226.19
DMITMN9	FM	C9H10N2O5
DMITMN9	IC	InChI=1S/C9H10N2O5/c10-6(9(13)14)3-5-1-2-8(12)7(4-5)11(15)16/h1-2,4,6,12H,3,10H2,(H,13,14)/t6-/m0/s1
DMITMN9	CS	C1=CC(=C(C=C1C[C@@H](C(=O)O)N)[N+](=O)[O-])O
DMITMN9	IK	FBTSQILOGYXGMD-LURJTMIESA-N
DMITMN9	IU	(2S)-2-amino-3-(4-hydroxy-3-nitrophenyl)propanoic acid
DMITMN9	CA	CAS 621-44-3
DMITMN9	CB	CHEBI:44454
DMITMN9	DE	Discovery agent

DMSK0QX	ID	DMSK0QX
DMSK0QX	DN	Meta-sirtinol
DMSK0QX	HS	Investigative
DMSK0QX	DT	Small molecular drug
DMSK0QX	PC	135461039
DMSK0QX	MW	394.5
DMSK0QX	FM	C26H22N2O2
DMSK0QX	IC	InChI=1S/C26H22N2O2/c1-18(19-8-3-2-4-9-19)28-26(30)21-11-7-12-22(16-21)27-17-24-23-13-6-5-10-20(23)14-15-25(24)29/h2-18,29H,1H3,(H,28,30)
DMSK0QX	CS	CC(C1=CC=CC=C1)NC(=O)C2=CC(=CC=C2)N=CC3=C(C=CC4=CC=CC=C43)O
DMSK0QX	IK	USDKSBHPFQRCGR-UHFFFAOYSA-N
DMSK0QX	IU	3-[(2-hydroxynaphthalen-1-yl)methylideneamino]-N-(1-phenylethyl)benzamide
DMSK0QX	DE	Discovery agent

DM0748C	ID	DM0748C
DM0748C	DN	Meta-Tyrosine
DM0748C	HS	Investigative
DM0748C	SN	L-m-Tyrosine; 587-33-7; 3-HYDROXY-L-PHENYLALANINE; Meta-Tyrosine; (S)-2-amino-3-(3-hydroxyphenyl)propanoic acid; m-Tyrosine; 3-tyrosine; m-L-Tyrosine; 3-Hydroxyphenylalanine; UNII-D5YF57V4QW; 3-(m-Hydroxyphenyl)alanine; L-mTyr; (2S)-2-amino-3-(3-hydroxyphenyl)propanoic acid; L-M-TYR; D5YF57V4QW; L-Phenylalanine, 3-hydroxy-; MFCD00063059; AK-86473; L-META-TYROSINE; 3-(3-HYDROXYPHENYL)-L-ALANINE; D-3-hydroxyphenylalanine; L-PHE(3-OH)-OH; (2S)-2-azaniumyl-3-(3-hydroxyphenyl)propanoate; Tyrosine, meta-; MTY; m-Tyrosine, L-
DM0748C	DT	Small molecular drug
DM0748C	PC	6950578
DM0748C	MW	181.19
DM0748C	FM	C9H11NO3
DM0748C	IC	InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-2-1-3-7(11)4-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1
DM0748C	CS	C1=CC(=CC(=C1)O)C[C@@H](C(=O)O)N
DM0748C	IK	JZKXXXDKRQWDET-QMMMGPOBSA-N
DM0748C	IU	(2S)-2-amino-3-(3-hydroxyphenyl)propanoic acid
DM0748C	CA	CAS 587-33-7
DM0748C	CB	CHEBI:44303
DM0748C	DE	Discovery agent

DMQBGH9	ID	DMQBGH9
DMQBGH9	DN	Metazamide
DMQBGH9	HS	Investigative
DMQBGH9	SN	METAZAMIDE; UNII-T3Y0F5VOB8; 14058-90-3; GPA-878; T3Y0F5VOB8; Metazamidum; 1-(4-methoxyphenyl)-5-methyl-2,3-dihydro-1H-imidazol-2-one; Metazamide [INN]; Metazamid; GPA 878; AC1L1B4L; 3-(4-methoxyphenyl)-4-methyl-1H-imidazol-2-one; 1-(4-Methoxyphenyl)-5-methyl-4-imidazolin-2-on; ZINC472; SCHEMBL193544; CHEMBL2104723; DTXSID80161441; MolPort-027-352-367; AKOS017548002; 1-(p-Methoxyphenyl)-5-methyl-4-imidazolin-2-one; 4-Imidazolin-2-one, 1-(4-methoxyphenyl)-5-methyl-
DMQBGH9	DT	Small molecular drug
DMQBGH9	PC	26433
DMQBGH9	MW	204.22
DMQBGH9	FM	C11H12N2O2
DMQBGH9	IC	InChI=1S/C11H12N2O2/c1-8-7-12-11(14)13(8)9-3-5-10(15-2)6-4-9/h3-7H,1-2H3,(H,12,14)
DMQBGH9	CS	CC1=CNC(=O)N1C2=CC=C(C=C2)OC
DMQBGH9	IK	NHUPEUMBGMETKD-UHFFFAOYSA-N
DMQBGH9	IU	3-(4-methoxyphenyl)-4-methyl-1H-imidazol-2-one
DMQBGH9	CA	CAS 14058-90-3
DMQBGH9	DE	Discovery agent

DMB6T23	ID	DMB6T23
DMB6T23	DN	METAZOCINE
DMB6T23	HS	Investigative
DMB6T23	SN	Methobenzmorphan; METAZOCINE; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3,6,11-trimethyl-; NSC611380; 3734-52-9; 2'-Hydroxy-2,5,9-trimethyl-6,7-benzomorphan; AC1Q7AHP; AC1L1XA2; SCHEMBL26347; CHEMBL33376; YGSVZRIZCHZUHB-UHFFFAOYSA-N; PDSP1_001246; PDSP2_001230; NSC-611380; LS-90663; LS-90665
DMB6T23	DT	Small molecular drug
DMB6T23	PC	62518
DMB6T23	MW	231.33
DMB6T23	FM	C15H21NO
DMB6T23	IC	InChI=1S/C15H21NO/c1-10-14-8-11-4-5-12(17)9-13(11)15(10,2)6-7-16(14)3/h4-5,9-10,14,17H,6-8H2,1-3H3
DMB6T23	CS	CC1C2CC3=C(C1(CCN2C)C)C=C(C=C3)O
DMB6T23	IK	YGSVZRIZCHZUHB-UHFFFAOYSA-N
DMB6T23	IU	1,10,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMB6T23	CA	CAS 3734-52-9
DMB6T23	DE	Discovery agent

DMDASC6	ID	DMDASC6
DMDASC6	DN	Metformin
DMDASC6	HS	Investigative
DMDASC6	SN	Fortamet
DMDASC6	TC	Antiviral Agents
DMDASC6	DT	Small molecular drug
DMDASC6	PC	4091
DMDASC6	MW	129.16
DMDASC6	FM	C4H11N5
DMDASC6	IC	InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
DMDASC6	CS	CN(C)C(=N)N=C(N)N
DMDASC6	IK	XZWYZXLIPXDOLR-UHFFFAOYSA-N
DMDASC6	IU	3-(diaminomethylidene)-1,1-dimethylguanidine
DMDASC6	CA	CAS 657-24-9
DMDASC6	CB	CHEBI:6801
DMDASC6	DE	Coronavirus Disease 2019 (COVID-19)

DMZVF6M	ID	DMZVF6M
DMZVF6M	DN	Methanandamide
DMZVF6M	HS	Investigative
DMZVF6M	SN	methanandamide; (R)-methanandamide; R(+)-Methanandamide; AM-356; (R)-(+)-Methanandamide; CHEMBL120526; 157182-49-5; N-(1R-methyl-2-hydroxy-ethyl) arachidonoyl amine; N-(1R-methyl-2-hydroxy-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine; (5Z,8Z,11Z,14Z)-N-[(2R)-1-hydroxypropan-2-yl]icosa-5,8,11,14-tetraenamide; (R)-N-(2-Hydroxy-1-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide; R-1 Methanandamide; R-(+)-methanandamide; BSPBio_001285; SCHEMBL338871; AC1O424C; GTPL2506; BML2-C03; BCBcMAP01_000201; MolPort-003-958-659
DMZVF6M	DT	Small molecular drug
DMZVF6M	PC	6321351
DMZVF6M	MW	361.6
DMZVF6M	FM	C23H39NO2
DMZVF6M	IC	InChI=1S/C23H39NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23(26)24-22(2)21-25/h7-8,10-11,13-14,16-17,22,25H,3-6,9,12,15,18-21H2,1-2H3,(H,24,26)/b8-7-,11-10-,14-13-,17-16-/t22-/m1/s1
DMZVF6M	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N[C@H](C)CO
DMZVF6M	IK	SQKRUBZPTNJQEM-FQPARAGTSA-N
DMZVF6M	IU	(5Z,8Z,11Z,14Z)-N-[(2R)-1-hydroxypropan-2-yl]icosa-5,8,11,14-tetraenamide
DMZVF6M	CA	CAS 157182-49-5
DMZVF6M	DE	Discovery agent

DMVQSEH	ID	DMVQSEH
DMVQSEH	DN	Methimepip
DMVQSEH	HS	Investigative
DMVQSEH	SN	Methimepip; GTPL1254; CHEMBL175782; SCHEMBL8320104; BDBM22909; ZINC6716245; AKOS027324257; 4-(3H-imidazol-4-ylmethyl)-1-methylpiperidine; 4-(1H-imidazol-5-ylmethyl)-1-methylpiperidine; L009044
DMVQSEH	DT	Small molecular drug
DMVQSEH	PC	11313837
DMVQSEH	MW	179.26
DMVQSEH	FM	C10H17N3
DMVQSEH	IC	InChI=1S/C10H17N3/c1-13-4-2-9(3-5-13)6-10-7-11-8-12-10/h7-9H,2-6H2,1H3,(H,11,12)
DMVQSEH	CS	CN1CCC(CC1)CC2=CN=CN2
DMVQSEH	IK	KIAVPENCSGKVQP-UHFFFAOYSA-N
DMVQSEH	IU	4-(1H-imidazol-5-ylmethyl)-1-methylpiperidine
DMVQSEH	CA	CAS 151070-80-3
DMVQSEH	DE	Discovery agent

DMEIP6H	ID	DMEIP6H
DMEIP6H	DN	methionine benzimidazole 6
DMEIP6H	HS	Investigative
DMEIP6H	SN	CHEMBL1770297; N-[1-(1H-benzimidazol-2-yl)-3-methylsulfanylpropyl]-5-ethoxy-3-methyl-1-benzofuran-2-carboxamide; methionine benzimidazole 6; AC1N7MKZ; GTPL5829
DMEIP6H	DT	Small molecular drug
DMEIP6H	PC	4329947
DMEIP6H	MW	423.5
DMEIP6H	FM	C23H25N3O3S
DMEIP6H	IC	InChI=1S/C23H25N3O3S/c1-4-28-15-9-10-20-16(13-15)14(2)21(29-20)23(27)26-19(11-12-30-3)22-24-17-7-5-6-8-18(17)25-22/h5-10,13,19H,4,11-12H2,1-3H3,(H,24,25)(H,26,27)
DMEIP6H	CS	CCOC1=CC2=C(C=C1)OC(=C2C)C(=O)NC(CCSC)C3=NC4=CC=CC=C4N3
DMEIP6H	IK	AIMYRLXVAOYQLA-UHFFFAOYSA-N
DMEIP6H	IU	N-[1-(1H-benzimidazol-2-yl)-3-methylsulfanylpropyl]-5-ethoxy-3-methyl-1-benzofuran-2-carboxamide
DMEIP6H	DE	Discovery agent

DMOUTNA	ID	DMOUTNA
DMOUTNA	DN	Methionine Phosphonate
DMOUTNA	HS	Investigative
DMOUTNA	SN	METHIONINE PHOSPHONATE; (1-AMINO-3-METHYLSULFANYL-PROPYL)-PHOSPHONIC ACID; 1pfu; AC1L9GS3; SCHEMBL4321583; DB02151; [(R)-1-Amino-3-(methylthio)propyl]phosphonic acid; [(1R)-1-amino-3-methylsulfanylpropyl]phosphonic acid; [(1R)-1-amino-3-(methylsulfanyl)propyl]phosphonic acid
DMOUTNA	DT	Small molecular drug
DMOUTNA	PC	444719
DMOUTNA	MW	185.18
DMOUTNA	FM	C4H12NO3PS
DMOUTNA	IC	InChI=1S/C4H12NO3PS/c1-10-3-2-4(5)9(6,7)8/h4H,2-3,5H2,1H3,(H2,6,7,8)/t4-/m1/s1
DMOUTNA	CS	CSCC[C@H](N)P(=O)(O)O
DMOUTNA	IK	XKCSXHUCPYVQIW-SCSAIBSYSA-N
DMOUTNA	IU	[(1R)-1-amino-3-methylsulfanylpropyl]phosphonic acid
DMOUTNA	DE	Discovery agent

DMKE18W	ID	DMKE18W
DMKE18W	DN	Methionine Sulfoxide
DMKE18W	HS	Investigative
DMKE18W	SN	Methionine sulfoxide; DL-Methionine sulfoxide; methionine sulfoxide; 62697-73-8; 454-41-1; dl-methioninesulfoxide; 2-Amino-4-(methylsulfinyl)butanoic acid; Uethionine, S-oxide; Methionine, S-oxide; Butanoic acid, 2-amino-4-(methylsulfinyl)-; 2-Amino-4-(methylsulfinyl)butyric acid; H-DL-Met(O)-OH; 2-amino-4-methanesulfinylbutanoic acid; BUTYRIC ACID, 2-AMINO-4-(METHYLSULFINYL)-; SQ 2292; 2-Amino-4-(methylsulphinyl)butyric acid; MFCD00002620; S-OXYMETHIONINE; (1)-2-Amino-4-(methylsulphinyl)butyric acid; 4241-59-2; methioninsulfoxid; S-Oxymethionine
DMKE18W	DT	Small molecular drug
DMKE18W	PC	847
DMKE18W	MW	165.21
DMKE18W	FM	C5H11NO3S
DMKE18W	IC	InChI=1S/C5H11NO3S/c1-10(9)3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)
DMKE18W	CS	CS(=O)CCC(C(=O)O)N
DMKE18W	IK	QEFRNWWLZKMPFJ-UHFFFAOYSA-N
DMKE18W	IU	2-amino-4-methylsulfinylbutanoic acid
DMKE18W	CA	CAS 62697-73-8
DMKE18W	CB	CHEBI:49033
DMKE18W	DE	Discovery agent

DMMC0I7	ID	DMMC0I7
DMMC0I7	DN	METHIOTHEPIN
DMMC0I7	HS	Investigative
DMMC0I7	SN	methiothepin; Metitepine; Methiothepine; Metitepinum; Metitepina; Metitepine [INN]; Metitepinum [INN-Latin]; Metitepina [INN-Spanish]; BRN 0626221; 20229-30-5; (+-)-10-(4-Methylpiperazinyl)-8-(methylthio)-10,11-dihydrodibenzo(b,f)thiepin; (+-)-8-Methylthio-10-(4-methylpiperazino)-10,11-dihydrodibenzo(b,f)thiepin; (+-)-1-(10,11-Dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)-4-methylpiperazine; CHEBI:64203; 1-(10,11-Dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)-4-methylpiperazine; NCGC00024665-03; DSSTox_CID_24000
DMMC0I7	DT	Small molecular drug
DMMC0I7	PC	4106
DMMC0I7	MW	356.6
DMMC0I7	FM	C20H24N2S2
DMMC0I7	IC	InChI=1S/C20H24N2S2/c1-21-9-11-22(12-10-21)18-13-15-5-3-4-6-19(15)24-20-8-7-16(23-2)14-17(18)20/h3-8,14,18H,9-13H2,1-2H3
DMMC0I7	CS	CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)SC
DMMC0I7	IK	RLJFTICUTYVZDG-UHFFFAOYSA-N
DMMC0I7	IU	1-methyl-4-(3-methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazine
DMMC0I7	CA	CAS 20229-30-5
DMMC0I7	CB	CHEBI:64203
DMMC0I7	DE	Discovery agent

DMH2CKX	ID	DMH2CKX
DMH2CKX	DN	METHOCTRAMINE
DMH2CKX	HS	Investigative
DMH2CKX	SN	Methoctramine; CHEBI:73339; UNII-NVJ76B897D; CHEMBL27673; NVJ76B897D; n,n'-bis{6-[(2-methoxybenzyl)amino]hexyl}octane-1,8-diamine; N1,N8-bis(6-(2-methoxybenzylamino)hexyl)octane-1,8-diamine; N,N'-bis[6-[(2-Methoxyphenyl)methylamino]hexyl]octane-1,8-diamine; N,N'-Bis(6-((2-methoxyphenyl)methylamino)hexyl)octane-1,8-diamine; N,N'-Bis[6-[[(2-methoxyphenyl)methyl]amino]hexyl]-1,8-octanediamine; N,N'-Bis(6-(((2-methoxyphenyl)methyl)amino)hexyl)-1,8-octanediamine; Methoctramine free base; NCGC00015626-01; Lopac-M-105
DMH2CKX	DT	Small molecular drug
DMH2CKX	PC	107759
DMH2CKX	MW	728.7
DMH2CKX	FM	C36H66Cl4N4O2
DMH2CKX	IC	InChI=1S/C36H62N4O2.4ClH/c1-41-35-23-13-11-21-33(35)31-39-29-19-9-7-17-27-37-25-15-5-3-4-6-16-26-38-28-18-8-10-20-30-40-32-34-22-12-14-24-36(34)42-2;;;;/h11-14,21-24,37-40H,3-10,15-20,25-32H2,1-2H3;4*1H
DMH2CKX	CS	COC1=CC=CC=C1CNCCCCCCNCCCCCCCCNCCCCCCNCC2=CC=CC=C2OC.Cl.Cl.Cl.Cl
DMH2CKX	IK	CDKGGOUDHGSFAF-UHFFFAOYSA-N
DMH2CKX	IU	N,N'-bis[6-[(2-methoxyphenyl)methylamino]hexyl]octane-1,8-diamine;tetrahydrochloride
DMH2CKX	CA	CAS 104807-46-7
DMH2CKX	CB	CHEBI:73452
DMH2CKX	DE	Discovery agent

DM58A0W	ID	DM58A0W
DM58A0W	DN	methoprene acid
DM58A0W	HS	Investigative
DM58A0W	SN	Methoprene acid; 53092-52-7; 11-Methoxy-3,7,11-trimethyl-2E,4E-dodecadienoic acid; (2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID; 2,4-Dodecadienoic acid, 11-methoxy-3,7,11-trimethyl-, (2E,4E)-; EINECS 258-355-4; ZR-725; AC1NS4JK; Spectrum5_001945; AC1Q5T6M; BSPBio_001416; SCHEMBL3052148; GTPL2812; CHEMBL289635; BML2-E11; SCHEMBL3052151; CHEBI:91685; HMS3402G18; HMS1989G18; HMS1791G18; HMS1361G18; Methoprene acid, &gt;=98% (TLC); MFCD01317817; (+-)-(2E,4E)-11-Methoxy-3,7,11-trimethyl-2,4-dodecadienoic acid
DM58A0W	DT	Small molecular drug
DM58A0W	PC	5353760
DM58A0W	MW	268.39
DM58A0W	FM	C16H28O3
DM58A0W	IC	InChI=1S/C16H28O3/c1-13(10-7-11-16(3,4)19-5)8-6-9-14(2)12-15(17)18/h6,9,12-13H,7-8,10-11H2,1-5H3,(H,17,18)/b9-6+,14-12+
DM58A0W	CS	CC(CCCC(C)(C)OC)C/C=C/C(=C/C(=O)O)/C
DM58A0W	IK	MNYBEULOKRVZKY-TZOAMJEDSA-N
DM58A0W	IU	(2E,4E)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoic acid
DM58A0W	CA	CAS 53092-52-7
DM58A0W	CB	CHEBI:91685
DM58A0W	DE	Discovery agent

DM8P526	ID	DM8P526
DM8P526	DN	Methotrexate gamma-hydroxamic acid
DM8P526	HS	Investigative
DM8P526	SN	methotrexate gamma-hydroxamic acid; CHEMBL244883
DM8P526	DT	Small molecular drug
DM8P526	PC	44428664
DM8P526	MW	469.5
DM8P526	FM	C20H23N9O5
DM8P526	IC	InChI=1S/C20H23N9O5/c1-29(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(30)28-34/h2-5,8,13,34H,6-7,9H2,1H3,(H,25,31)(H,28,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
DM8P526	CS	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)NO)C(=O)O
DM8P526	IK	YUQBNZUBNMWBAQ-ZDUSSCGKSA-N
DM8P526	IU	(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-(hydroxyamino)-5-oxopentanoic acid
DM8P526	DE	Discovery agent

DMELK2A	ID	DMELK2A
DMELK2A	DN	Methotrexate gamma-L-phenylalaninehydroxamic acid
DMELK2A	HS	Investigative
DMELK2A	SN	CHEMBL396296; methotrexate gamma-L-phenylalaninehydroxamic acid
DMELK2A	DT	Small molecular drug
DMELK2A	PC	16216218
DMELK2A	MW	616.6
DMELK2A	FM	C29H32N10O6
DMELK2A	IC	InChI=1S/C29H32N10O6/c1-39(15-18-14-32-25-23(33-18)24(30)36-29(31)37-25)19-9-7-17(8-10-19)26(41)35-20(28(43)44)11-12-22(40)34-21(27(42)38-45)13-16-5-3-2-4-6-16/h2-10,14,20-21,45H,11-13,15H2,1H3,(H,34,40)(H,35,41)(H,38,42)(H,43,44)(H4,30,31,32,36,37)/t20-,21-/m0/s1
DMELK2A	CS	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)N[C@@H](CC4=CC=CC=C4)C(=O)NO)C(=O)O
DMELK2A	IK	QHQOEZXEZMHMER-SFTDATJTSA-N
DMELK2A	IU	(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-[[(2S)-1-(hydroxyamino)-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid
DMELK2A	DE	Discovery agent

DMPYJLA	ID	DMPYJLA
DMPYJLA	DN	Methotrexate gamma-L-proline-hydroxamic acid
DMPYJLA	HS	Investigative
DMPYJLA	SN	CHEMBL388879; methotrexate gamma-L-proline-hydroxamic acid
DMPYJLA	DT	Small molecular drug
DMPYJLA	PC	44428667
DMPYJLA	MW	566.6
DMPYJLA	FM	C25H30N10O6
DMPYJLA	IC	InChI=1S/C25H30N10O6/c1-34(12-14-11-28-21-19(29-14)20(26)31-25(27)32-21)15-6-4-13(5-7-15)22(37)30-16(24(39)40)8-9-18(36)35-10-2-3-17(35)23(38)33-41/h4-7,11,16-17,41H,2-3,8-10,12H2,1H3,(H,30,37)(H,33,38)(H,39,40)(H4,26,27,28,31,32)/t16-,17-/m0/s1
DMPYJLA	CS	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)N4CCC[C@H]4C(=O)NO)C(=O)O
DMPYJLA	IK	UYVVHTPVCDOQRA-IRXDYDNUSA-N
DMPYJLA	IU	(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-[(2S)-2-(hydroxycarbamoyl)pyrrolidin-1-yl]-5-oxopentanoic acid
DMPYJLA	DE	Discovery agent

DMX8QK0	ID	DMX8QK0
DMX8QK0	DN	Methoxy arachidonyl fluorophosphonate
DMX8QK0	HS	Investigative
DMX8QK0	SN	MAFP; MAPF; AC1NS4JN; SCHEMBL8253710; 188404-10-6; AKOS015909076; RT-013646; I14-33366; Phosphonofluoridic acid, methyl-5Z,8Z,11Z,14Z-eicosatetraenyl ester
DMX8QK0	DT	Small molecular drug
DMX8QK0	PC	10429254
DMX8QK0	MW	370.5
DMX8QK0	FM	C21H36FO2P
DMX8QK0	IC	InChI=1S/C21H36FO2P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(22,23)24-2/h7-8,10-11,13-14,16-17H,3-6,9,12,15,18-21H2,1-2H3/b8-7-,11-10-,14-13-,17-16-
DMX8QK0	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCP(=O)(OC)F
DMX8QK0	IK	KWKZCGMJGHHOKJ-ZKWNWVNESA-N
DMX8QK0	IU	(5Z,8Z,11Z,14Z)-1-[fluoro(methoxy)phosphoryl]icosa-5,8,11,14-tetraene
DMX8QK0	DE	Discovery agent

DMN8HRU	ID	DMN8HRU
DMN8HRU	DN	Methoxyphenamine
DMN8HRU	HS	Investigative
DMN8HRU	SN	Euspirol; METHOXYPHENAMINE; Methamphetamine, 2-methoxy; Methoxifenaminio; Methoxiphenadrin; Methoxiphenadrinum; Methoxyphenadrine; Methoxyphenamin; Methoxyphenamine [INN:BAN]; Methoxyphenaminum; Methoxyphenaminum [INN-Latin]; Metossifenamina [DCIT]; Metoxifenaminio [INN-Spanish]; Orthoxine; Ortodrinex; Ortoxine; Oxalacetic acid orthoxine; Proasma; 2-Methoxy-N,alpha-dimethylphenethylamin; 2-Methoxy-N-methylamphetamine; 2-Methoxymethamphetamine; 93-30-1; Asmi; EINECS 202-237-7; o-Methoxy-N,alpha-dimethylphenethylamine
DMN8HRU	PC	4117
DMN8HRU	MW	179.26
DMN8HRU	FM	C11H17NO
DMN8HRU	IC	OEHAYUOVELTAPG-UHFFFAOYSA-N
DMN8HRU	CS	CC(CC1=CC=CC=C1OC)NC
DMN8HRU	IK	1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3
DMN8HRU	IU	1-(2-methoxyphenyl)-N-methylpropan-2-amine
DMN8HRU	CA	CAS 93-30-1
DMN8HRU	CB	CHEBI:134817
DMN8HRU	DE	Chronic obstructive pulmonary disease

DMY0O7X	ID	DMY0O7X
DMY0O7X	DN	METHOXYUNDECYLPHOSPHINIC ACID
DMY0O7X	HS	Investigative
DMY0O7X	SN	Methoxyundecylphosphinic Acid; MUP; AC1L9KBG; methoxy(undecyl)phosphinic acid; methoxy undecyl phosphinic acid; SCHEMBL9079355; SCHEMBL20553273; methyl hydrogen (S)-undecylphosphonate
DMY0O7X	DT	Small molecular drug
DMY0O7X	PC	446977
DMY0O7X	MW	250.31
DMY0O7X	FM	C12H27O3P
DMY0O7X	IC	InChI=1S/C12H27O3P/c1-3-4-5-6-7-8-9-10-11-12-16(13,14)15-2/h3-12H2,1-2H3,(H,13,14)
DMY0O7X	CS	CCCCCCCCCCCP(=O)(O)OC
DMY0O7X	IK	JBVUSHKPEBKWQP-UHFFFAOYSA-N
DMY0O7X	IU	methoxy(undecyl)phosphinic acid
DMY0O7X	DE	Discovery agent

DMGYZHU	ID	DMGYZHU
DMGYZHU	DN	Methyl 10H-phenothiazine-10-carboxylate
DMGYZHU	HS	Investigative
DMGYZHU	SN	methyl 10H-phenothiazine-10-carboxylate; CHEMBL480755; methyl phenothiazine-10-carboxylate; Phenothiazine-10-carboxylic acid methyl ester; AC1MJ71I; SCHEMBL8739119; MolPort-001-898-173; ZINC4007353; STK373134; BDBM50292600; AKOS005447210; MCULE-7901457115; BAS 00444618; 68825-31-0; ST50909034; 10H-Phenothiazine-10-carboxylic acid methyl ester; SR-01000320795; SR-01000320795-1; 10H-Phenothiazine-10-carboxylic acid, methyl ester
DMGYZHU	DT	Small molecular drug
DMGYZHU	PC	3107576
DMGYZHU	MW	257.31
DMGYZHU	FM	C14H11NO2S
DMGYZHU	IC	InChI=1S/C14H11NO2S/c1-17-14(16)15-10-6-2-4-8-12(10)18-13-9-5-3-7-11(13)15/h2-9H,1H3
DMGYZHU	CS	COC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMGYZHU	IK	WWHYODNLUNCVDI-UHFFFAOYSA-N
DMGYZHU	IU	methyl phenothiazine-10-carboxylate
DMGYZHU	DE	Discovery agent

DMV1AL5	ID	DMV1AL5
DMV1AL5	DN	Methyl 14-(3-n-butylureido)tetradec-8(Z)-enoate
DMV1AL5	HS	Investigative
DMV1AL5	SN	CHEMBL555832; Methyl 14-(3-n-butylureido)tetradec-8(Z)-enoate
DMV1AL5	DT	Small molecular drug
DMV1AL5	PC	45267095
DMV1AL5	MW	354.5
DMV1AL5	FM	C20H38N2O3
DMV1AL5	IC	InChI=1S/C20H38N2O3/c1-3-4-17-21-20(24)22-18-15-13-11-9-7-5-6-8-10-12-14-16-19(23)25-2/h5,7H,3-4,6,8-18H2,1-2H3,(H2,21,22,24)/b7-5-
DMV1AL5	CS	CCCCNC(=O)NCCCCC/C=C\\CCCCCCC(=O)OC
DMV1AL5	IK	CGNYGIBRDHWVDW-ALCCZGGFSA-N
DMV1AL5	IU	methyl (Z)-14-(butylcarbamoylamino)tetradec-8-enoate
DMV1AL5	DE	Discovery agent

DMBKU9M	ID	DMBKU9M
DMBKU9M	DN	Methyl 2-(2-oxo-8-phenyloctanamido)acetate
DMBKU9M	HS	Investigative
DMBKU9M	SN	CHEMBL488440
DMBKU9M	DT	Small molecular drug
DMBKU9M	PC	44563076
DMBKU9M	MW	305.4
DMBKU9M	FM	C17H23NO4
DMBKU9M	IC	InChI=1S/C17H23NO4/c1-22-16(20)13-18-17(21)15(19)12-8-3-2-5-9-14-10-6-4-7-11-14/h4,6-7,10-11H,2-3,5,8-9,12-13H2,1H3,(H,18,21)
DMBKU9M	CS	COC(=O)CNC(=O)C(=O)CCCCCCC1=CC=CC=C1
DMBKU9M	IK	MUJNYULVHMASQZ-UHFFFAOYSA-N
DMBKU9M	IU	methyl 2-[(2-oxo-8-phenyloctanoyl)amino]acetate
DMBKU9M	DE	Discovery agent

DMVYGBU	ID	DMVYGBU
DMVYGBU	DN	Methyl 2-(2-oxohexadecanamido)acetate
DMVYGBU	HS	Investigative
DMVYGBU	SN	Methyl 2-(2-oxohexadecanamido)acetate; SCHEMBL1873320
DMVYGBU	DT	Small molecular drug
DMVYGBU	PC	25166397
DMVYGBU	MW	341.5
DMVYGBU	FM	C19H35NO4
DMVYGBU	IC	InChI=1S/C19H35NO4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-17(21)19(23)20-16-18(22)24-2/h3-16H2,1-2H3,(H,20,23)
DMVYGBU	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCC(=O)OC
DMVYGBU	IK	PZEVUHTWLYMLFR-UHFFFAOYSA-N
DMVYGBU	IU	methyl 2-(2-oxohexadecanoylamino)acetate
DMVYGBU	DE	Discovery agent

DMA82IQ	ID	DMA82IQ
DMA82IQ	DN	Methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate
DMA82IQ	HS	Investigative
DMA82IQ	SN	CHEMBL247131; methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate; BDBM50213924
DMA82IQ	DT	Small molecular drug
DMA82IQ	PC	43091550
DMA82IQ	MW	282.76
DMA82IQ	FM	C15H19ClO3
DMA82IQ	IC	InChI=1S/C15H19ClO3/c1-18-15(17)10-19-14-8-7-12(16)9-13(14)11-5-3-2-4-6-11/h7-9,11H,2-6,10H2,1H3
DMA82IQ	CS	COC(=O)COC1=C(C=C(C=C1)Cl)C2CCCCC2
DMA82IQ	IK	AZDVRVGZFMVXTH-UHFFFAOYSA-N
DMA82IQ	IU	methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate
DMA82IQ	DE	Discovery agent

DMP06I3	ID	DMP06I3
DMP06I3	DN	Methyl 2-(7-phenylheptanoyl)oxazole-4-carboxylate
DMP06I3	HS	Investigative
DMP06I3	SN	CHEMBL461539; methyl 2-(7-phenylheptanoyl)oxazole-4-carboxylate; SCHEMBL2164164; CRHSFDPXTRFSMK-UHFFFAOYSA-N
DMP06I3	DT	Small molecular drug
DMP06I3	PC	44554610
DMP06I3	MW	315.4
DMP06I3	FM	C18H21NO4
DMP06I3	IC	InChI=1S/C18H21NO4/c1-22-18(21)15-13-23-17(19-15)16(20)12-8-3-2-5-9-14-10-6-4-7-11-14/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DMP06I3	CS	COC(=O)C1=COC(=N1)C(=O)CCCCCCC2=CC=CC=C2
DMP06I3	IK	CRHSFDPXTRFSMK-UHFFFAOYSA-N
DMP06I3	IU	methyl 2-(7-phenylheptanoyl)-1,3-oxazole-4-carboxylate
DMP06I3	DE	Discovery agent

DM9FA26	ID	DM9FA26
DM9FA26	DN	Methyl 2-(7-phenylheptanoyl)oxazole-5-carboxylate
DM9FA26	HS	Investigative
DM9FA26	SN	CHEMBL220784; methyl 2-(7-phenylheptanoyl)oxazole-5-carboxylate; SCHEMBL3140826; Methyl 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylate; BIKPWTFTYRRSPI-UHFFFAOYSA-N
DM9FA26	DT	Small molecular drug
DM9FA26	PC	11991809
DM9FA26	MW	315.4
DM9FA26	FM	C18H21NO4
DM9FA26	IC	InChI=1S/C18H21NO4/c1-22-18(21)16-13-19-17(23-16)15(20)12-8-3-2-5-9-14-10-6-4-7-11-14/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DM9FA26	CS	COC(=O)C1=CN=C(O1)C(=O)CCCCCCC2=CC=CC=C2
DM9FA26	IK	BIKPWTFTYRRSPI-UHFFFAOYSA-N
DM9FA26	IU	methyl 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylate
DM9FA26	DE	Discovery agent

DMB1PXR	ID	DMB1PXR
DMB1PXR	DN	Methyl 2-(Benzylamino)-1H-indole-3-carboxylate
DMB1PXR	HS	Investigative
DMB1PXR	SN	CHEMBL483067; BDBM31109; 2-substituted indole-3-carboxylate, 27f
DMB1PXR	DT	Small molecular drug
DMB1PXR	PC	44158012
DMB1PXR	MW	280.32
DMB1PXR	FM	C17H16N2O2
DMB1PXR	IC	InChI=1S/C17H16N2O2/c1-21-17(20)15-13-9-5-6-10-14(13)19-16(15)18-11-12-7-3-2-4-8-12/h2-10,18-19H,11H2,1H3
DMB1PXR	CS	COC(=O)C1=C(NC2=CC=CC=C21)NCC3=CC=CC=C3
DMB1PXR	IK	TWNCELFDSJZJAX-UHFFFAOYSA-N
DMB1PXR	IU	methyl 2-(benzylamino)-1H-indole-3-carboxylate
DMB1PXR	DE	Discovery agent

DMB74WP	ID	DMB74WP
DMB74WP	DN	Methyl 2-(Diallylamino)-1H-indole-3-carboxylate
DMB74WP	HS	Investigative
DMB74WP	SN	CHEMBL483269; BDBM31111; 2-substituted indole-3-carboxylate, 27h
DMB74WP	DT	Small molecular drug
DMB74WP	PC	44158013
DMB74WP	MW	270.33
DMB74WP	FM	C16H18N2O2
DMB74WP	IC	InChI=1S/C16H18N2O2/c1-4-10-18(11-5-2)15-14(16(19)20-3)12-8-6-7-9-13(12)17-15/h4-9,17H,1-2,10-11H2,3H3
DMB74WP	CS	COC(=O)C1=C(NC2=CC=CC=C21)N(CC=C)CC=C
DMB74WP	IK	VOAOXYYRHVDNNJ-UHFFFAOYSA-N
DMB74WP	IU	methyl 2-[bis(prop-2-enyl)amino]-1H-indole-3-carboxylate
DMB74WP	DE	Discovery agent

DMF6MRS	ID	DMF6MRS
DMF6MRS	DN	Methyl 2-(naphthalen-2-yl)benzoate
DMF6MRS	HS	Investigative
DMF6MRS	SN	CHEMBL103936; methyl 2-(naphthalen-2-yl)benzoate; SCHEMBL16683936; BDBM50090973; ZINC13809589; 2-(2-Naphthyl)benzoic acid methyl ester; 2-Naphthalen-2-yl-benzoic acid methyl ester
DMF6MRS	DT	Small molecular drug
DMF6MRS	PC	44332186
DMF6MRS	MW	262.3
DMF6MRS	FM	C18H14O2
DMF6MRS	IC	InChI=1S/C18H14O2/c1-20-18(19)17-9-5-4-8-16(17)15-11-10-13-6-2-3-7-14(13)12-15/h2-12H,1H3
DMF6MRS	CS	COC(=O)C1=CC=CC=C1C2=CC3=CC=CC=C3C=C2
DMF6MRS	IK	SKSUKRWKVAZHJI-UHFFFAOYSA-N
DMF6MRS	IU	methyl 2-naphthalen-2-ylbenzoate
DMF6MRS	DE	Discovery agent

DMWM814	ID	DMWM814
DMWM814	DN	Methyl 3-(1-Benzyl-1H-imidazol-5-yl)-propanoate
DMWM814	HS	Investigative
DMWM814	SN	CHEMBL608140; Methyl 3-(1-Benzyl-1H-imidazol-5-yl)-propanoate; SCHEMBL9642312; FEWHBUJYQHXFMV-UHFFFAOYSA-N; BDBM50307219; 1-benzyl-5-imidazole propionic acid methyl ester
DMWM814	DT	Small molecular drug
DMWM814	PC	14535954
DMWM814	MW	244.29
DMWM814	FM	C14H16N2O2
DMWM814	IC	InChI=1S/C14H16N2O2/c1-18-14(17)8-7-13-9-15-11-16(13)10-12-5-3-2-4-6-12/h2-6,9,11H,7-8,10H2,1H3
DMWM814	CS	COC(=O)CCC1=CN=CN1CC2=CC=CC=C2
DMWM814	IK	FEWHBUJYQHXFMV-UHFFFAOYSA-N
DMWM814	IU	methyl 3-(3-benzylimidazol-4-yl)propanoate
DMWM814	DE	Discovery agent

DMWG9BE	ID	DMWG9BE
DMWG9BE	DN	Methyl 3beta-hydroxyolean-12-en-28-oate
DMWG9BE	HS	Investigative
DMWG9BE	SN	CHEMBL381707; methyl 3beta-hydroxyolean-12-en-28-oate
DMWG9BE	DT	Small molecular drug
DMWG9BE	PC	44411771
DMWG9BE	MW	456.7
DMWG9BE	FM	C30H48O3
DMWG9BE	IC	InChI=1S/C30H48O3/c1-26(2)16-17-30(25(32)33-7)15-10-20-19(21(30)18-26)8-9-23-28(20,5)13-11-22-27(3,4)24(31)12-14-29(22,23)6/h8,20-24,31H,9-18H2,1-7H3/t20?,21-,22?,23-,24-,28-,29-,30+/m0/s1
DMWG9BE	CS	C[C@@]12CCC3[C@@]([C@H]1CC=C4C2CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OC)(CC[C@@H](C3(C)C)O)C
DMWG9BE	IK	QQTTYKDXVIONSQ-HHKCSUCSSA-N
DMWG9BE	IU	methyl (4aR,6aS,6bR,10S,12aR,14bS)-10-hydroxy-2,2,6b,9,9,12a-hexamethyl-3,4,5,6,6a,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylate
DMWG9BE	DE	Discovery agent

DM9S210	ID	DM9S210
DM9S210	DN	Methyl 4-(3-cyclohexylureido)butanoate
DM9S210	HS	Investigative
DM9S210	SN	methyl 4-(3-cyclohexylureido)butanoate; CHEMBL220415; BDBM50192957
DM9S210	DT	Small molecular drug
DM9S210	PC	11160856
DM9S210	MW	242.31
DM9S210	FM	C12H22N2O3
DM9S210	IC	InChI=1S/C12H22N2O3/c1-17-11(15)8-5-9-13-12(16)14-10-6-3-2-4-7-10/h10H,2-9H2,1H3,(H2,13,14,16)
DM9S210	CS	COC(=O)CCCNC(=O)NC1CCCCC1
DM9S210	IK	QDXXGVVKSQMYHV-UHFFFAOYSA-N
DM9S210	IU	methyl 4-(cyclohexylcarbamoylamino)butanoate
DM9S210	DE	Discovery agent

DMUROGX	ID	DMUROGX
DMUROGX	DN	Methyl 4-(4-hydroxybenzylideneamino)benzoate
DMUROGX	HS	Investigative
DMUROGX	DT	Small molecular drug
DMUROGX	PC	969280
DMUROGX	MW	255.27
DMUROGX	FM	C15H13NO3
DMUROGX	IC	InChI=1S/C15H13NO3/c1-19-15(18)12-4-6-13(7-5-12)16-10-11-2-8-14(17)9-3-11/h2-10,17H,1H3
DMUROGX	CS	COC(=O)C1=CC=C(C=C1)N=CC2=CC=C(C=C2)O
DMUROGX	IK	RMGZSIQUVXIPDP-UHFFFAOYSA-N
DMUROGX	IU	methyl 4-[(4-hydroxyphenyl)methylideneamino]benzoate
DMUROGX	DE	Discovery agent

DMSBCL6	ID	DMSBCL6
DMSBCL6	DN	Methyl 4-(4-tert-butylbenzylideneamino)benzoate
DMSBCL6	HS	Investigative
DMSBCL6	SN	CHEMBL572526; methyl 4-(4-tert-butylbenzylideneamino)benzoate
DMSBCL6	DT	Small molecular drug
DMSBCL6	PC	45483180
DMSBCL6	MW	295.4
DMSBCL6	FM	C19H21NO2
DMSBCL6	IC	InChI=1S/C19H21NO2/c1-19(2,3)16-9-5-14(6-10-16)13-20-17-11-7-15(8-12-17)18(21)22-4/h5-13H,1-4H3
DMSBCL6	CS	CC(C)(C)C1=CC=C(C=C1)C=NC2=CC=C(C=C2)C(=O)OC
DMSBCL6	IK	SONMMTHLONHMSH-UHFFFAOYSA-N
DMSBCL6	IU	methyl 4-[(4-tert-butylphenyl)methylideneamino]benzoate
DMSBCL6	DE	Discovery agent

DM9BPQ1	ID	DM9BPQ1
DM9BPQ1	DN	Methyl 6-(3-cyclohexylureido)hexanoate
DM9BPQ1	HS	Investigative
DM9BPQ1	SN	methyl 6-(3-cyclohexylureido)hexanoate; CHEMBL219974; BDBM50192964
DM9BPQ1	DT	Small molecular drug
DM9BPQ1	PC	43608139
DM9BPQ1	MW	270.37
DM9BPQ1	FM	C14H26N2O3
DM9BPQ1	IC	InChI=1S/C14H26N2O3/c1-19-13(17)10-6-3-7-11-15-14(18)16-12-8-4-2-5-9-12/h12H,2-11H2,1H3,(H2,15,16,18)
DM9BPQ1	CS	COC(=O)CCCCCNC(=O)NC1CCCCC1
DM9BPQ1	IK	WHXVJNIBTQCTJK-UHFFFAOYSA-N
DM9BPQ1	IU	methyl 6-(cyclohexylcarbamoylamino)hexanoate
DM9BPQ1	DE	Discovery agent

DMBLW1A	ID	DMBLW1A
DMBLW1A	DN	Methyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate
DMBLW1A	HS	Investigative
DMBLW1A	SN	CHEMBL598251
DMBLW1A	DT	Small molecular drug
DMBLW1A	PC	46216786
DMBLW1A	MW	297.3
DMBLW1A	FM	C17H15NO4
DMBLW1A	IC	InChI=1S/C17H15NO4/c1-20-14-9-8-12(11-6-4-3-5-7-11)13-10-15(22-16(13)14)18-17(19)21-2/h3-10H,1-2H3,(H,18,19)
DMBLW1A	CS	COC1=C2C(=C(C=C1)C3=CC=CC=C3)C=C(O2)NC(=O)OC
DMBLW1A	IK	CJZGJASKUWFLQA-UHFFFAOYSA-N
DMBLW1A	IU	methyl N-(7-methoxy-4-phenyl-1-benzofuran-2-yl)carbamate
DMBLW1A	DE	Discovery agent

DM9HLXD	ID	DM9HLXD
DM9HLXD	DN	Methyl 7-tert-butyl-9H-carbazole-3-carboxylate
DM9HLXD	HS	Investigative
DM9HLXD	SN	CHEMBL1173167; methyl 7-tert-butyl-9H-carbazole-3-carboxylate; BDBM50322578; ZINC53299021; 7-tert-Butyl-9H-carbazole-3-carboxylic acid methyl ester
DM9HLXD	DT	Small molecular drug
DM9HLXD	PC	46244082
DM9HLXD	MW	281.3
DM9HLXD	FM	C18H19NO2
DM9HLXD	IC	InChI=1S/C18H19NO2/c1-18(2,3)12-6-7-13-14-9-11(17(20)21-4)5-8-15(14)19-16(13)10-12/h5-10,19H,1-4H3
DM9HLXD	CS	CC(C)(C)C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)C(=O)OC
DM9HLXD	IK	UIUMIPOASYICHI-UHFFFAOYSA-N
DM9HLXD	IU	methyl 7-tert-butyl-9H-carbazole-3-carboxylate
DM9HLXD	DE	Discovery agent

DM4DIS3	ID	DM4DIS3
DM4DIS3	DN	Methyl 9H-carbazole-2-carboxylate
DM4DIS3	HS	Investigative
DM4DIS3	SN	Methyl 9H-carbazole-2-carboxylate; 26000-33-9; CHEMBL1172394; C14H11NO2; 9H-CARBAZOLE-2-CARBOXYLIC ACID METHYL ESTER; SCHEMBL2483277; CTK4F6920; DTXSID40461636; WDNZNDZRMLZWNC-UHFFFAOYSA-N; MolPort-005-941-204; ZINC22003793; BDBM50322587; ANW-71443; AKOS015967094; ACM26000339; OR340090; AJ-80205; DS-17387; KB-257852; TC-160188; AX8111765; 9H-Carbazole-2-carboxylicacid, methyl ester; X5228; 9H-Carbazole-2-carboxylic acid, methyl ester
DM4DIS3	DT	Small molecular drug
DM4DIS3	PC	11299083
DM4DIS3	MW	225.24
DM4DIS3	FM	C14H11NO2
DM4DIS3	IC	InChI=1S/C14H11NO2/c1-17-14(16)9-6-7-11-10-4-2-3-5-12(10)15-13(11)8-9/h2-8,15H,1H3
DM4DIS3	CS	COC(=O)C1=CC2=C(C=C1)C3=CC=CC=C3N2
DM4DIS3	IK	WDNZNDZRMLZWNC-UHFFFAOYSA-N
DM4DIS3	IU	methyl 9H-carbazole-2-carboxylate
DM4DIS3	CA	CAS 26000-33-9
DM4DIS3	DE	Discovery agent

DMAXEH3	ID	DMAXEH3
DMAXEH3	DN	Methyl arachidonyl fluorophosphonate
DMAXEH3	HS	Investigative
DMAXEH3	SN	(5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenyl methyl phosphorofluoridate; SCHEMBL177496; GTPL5218; methylarachidonoylflurophosphonate; methyl arachidonyl fluorophosphate; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl methyl fluorophosphonate; Fluorophosphonic acid methyl(5Z,8Z,11Z,14Z)-5,8,11,14-icosatetrenyl ester
DMAXEH3	DT	Small molecular drug
DMAXEH3	PC	25021170
DMAXEH3	MW	386.5
DMAXEH3	FM	C21H36FO3P
DMAXEH3	IC	InChI=1S/C21H36FO3P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-26(22,23)24-2/h7-8,10-11,13-14,16-17H,3-6,9,12,15,18-21H2,1-2H3/b8-7-,11-10-,14-13-,17-16-
DMAXEH3	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCOP(=O)(OC)F
DMAXEH3	IK	HNVKMEOEBANRAT-ZKWNWVNESA-N
DMAXEH3	IU	(5Z,8Z,11Z,14Z)-1-[fluoro(methoxy)phosphoryl]oxyicosa-5,8,11,14-tetraene
DMAXEH3	DE	Discovery agent

DMG8XD1	ID	DMG8XD1
DMG8XD1	DN	Methyl estradiol-16-beta-carboxylate
DMG8XD1	HS	Investigative
DMG8XD1	DT	Small molecular drug
DMG8XD1	PC	44407416
DMG8XD1	MW	330.4
DMG8XD1	FM	C20H26O4
DMG8XD1	IC	InChI=1S/C20H26O4/c1-20-8-7-14-13-6-4-12(21)9-11(13)3-5-15(14)17(20)10-16(18(20)22)19(23)24-2/h4,6,9,14-18,21-22H,3,5,7-8,10H2,1-2H3/t14?,15?,16-,17?,18-,20-/m0/s1
DMG8XD1	CS	C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)C(=O)OC)CCC4=C3C=CC(=C4)O
DMG8XD1	IK	ATXQVYDXJMHPHM-ASCAHHBESA-N
DMG8XD1	IU	methyl (13S,16S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxylate
DMG8XD1	DE	Discovery agent

DM9O5S6	ID	DM9O5S6
DM9O5S6	DN	Methyl icosylphosphonofluoridate
DM9O5S6	HS	Investigative
DM9O5S6	SN	methyl icosylphosphonofluoridate; CHEMBL462609; BDBM50247048; Fluoroicosylphosphinic acid methyl ester
DM9O5S6	DT	Small molecular drug
DM9O5S6	PC	44563660
DM9O5S6	MW	378.5
DM9O5S6	FM	C21H44FO2P
DM9O5S6	IC	InChI=1S/C21H44FO2P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(22,23)24-2/h3-21H2,1-2H3
DM9O5S6	CS	CCCCCCCCCCCCCCCCCCCCP(=O)(OC)F
DM9O5S6	IK	IRQAGEYFWAZZPI-UHFFFAOYSA-N
DM9O5S6	IU	1-[fluoro(methoxy)phosphoryl]icosane
DM9O5S6	DE	Discovery agent

DME4JGF	ID	DME4JGF
DME4JGF	DN	methyl isocyanate
DME4JGF	HS	Investigative
DME4JGF	SN	isocyanatomethane; methyl carbonimide; isocyanic acid
DME4JGF	DT	Small molecular drug
DME4JGF	PC	12228
DME4JGF	MW	57.05
DME4JGF	FM	C2H3NO
DME4JGF	IC	InChI=1S/C2H3NO/c1-3-2-4/h1H3
DME4JGF	CS	CN=C=O
DME4JGF	IK	HAMGRBXTJNITHG-UHFFFAOYSA-N
DME4JGF	IU	methylimino(oxo)methane
DME4JGF	CA	CAS 624-83-9
DME4JGF	CB	CHEBI:59059
DME4JGF	DE	Discovery agent

DMBHUKV	ID	DMBHUKV
DMBHUKV	DN	Methyl L-phenylalaninate
DMBHUKV	HS	Investigative
DMBHUKV	SN	Methyl 2-amino-3-phenylpropanoate; 15028-44-1; Methyl 3-phenyl-DL-alaninate; H-DL-Phe-OMe HCl; DL-phenylalanine methyl ester; VSDUZFOSJDMAFZ-UHFFFAOYSA-N; 2-Amino-3-phenyl-propionic acid methyl ester; phenylalanine, methyl ester; F2147-0643; l-phe methyl ester; EINECS 239-109-5; AC1L2PEY; Phenylalanine, methylester; AC1Q41SQ; AC1Q41SP; AC1Q41RL; SCHEMBL74887; D,L-phenylalanine methyl ester; DL-Phenylalanine, methyl ester; Methyl L-phenylalaninate (HCl); CTK4C6579; STK019373; MFCD00044582; NSC522409; BBL009783; AKOS016042462
DMBHUKV	DT	Small molecular drug
DMBHUKV	PC	736234
DMBHUKV	MW	179.22
DMBHUKV	FM	C10H13NO2
DMBHUKV	IC	InChI=1S/C10H13NO2/c1-13-10(12)9(11)7-8-5-3-2-4-6-8/h2-6,9H,7,11H2,1H3/t9-/m0/s1
DMBHUKV	CS	COC(=O)[C@H](CC1=CC=CC=C1)N
DMBHUKV	IK	VSDUZFOSJDMAFZ-VIFPVBQESA-N
DMBHUKV	IU	methyl (2S)-2-amino-3-phenylpropanoate
DMBHUKV	CA	CAS 2577-90-4
DMBHUKV	CB	CHEBI:49339
DMBHUKV	DE	Discovery agent

DM6YEW4	ID	DM6YEW4
DM6YEW4	DN	Methyl Mercury Ion
DM6YEW4	HS	Investigative
DM6YEW4	SN	Methylmercury(1+); Methylmercury II; Methyl Mercury Ion; Methylmercury ion; Methyl mercury; METHYLMERCURY(II) CATION; Monomethylmercury cation; Methylmercury ion(1+); CH3Hg+; Mercury(1+), methyl-; 22967-92-6; methylmercury(II); AC1L1NGS; Methyl mercury(II) cation; CH3Hg(+); [HgMe](+); Mercury(1+), methyl-, ion; DTXSID9024198; [HgCH3](+); CTK8D8906; HSDB 3930; CHEBI:49747; AKOS015903545; BRN 3902999; LS-89823; C18672; I14-18601; I14-114322
DM6YEW4	DT	Small molecular drug
DM6YEW4	PC	6860
DM6YEW4	MW	215.63
DM6YEW4	FM	CH3Hg+
DM6YEW4	IC	InChI=1S/CH3.Hg/h1H3;/q;+1
DM6YEW4	CS	C[Hg+]
DM6YEW4	IK	DBUXSCUEGJMZAE-UHFFFAOYSA-N
DM6YEW4	IU	methylmercury(1+)
DM6YEW4	CA	CAS 22967-92-6
DM6YEW4	CB	CHEBI:49747
DM6YEW4	DE	Discovery agent

DMOCXLW	ID	DMOCXLW
DMOCXLW	DN	Methyl Methylsulfinylmethyl Sulfide
DMOCXLW	HS	Investigative
DMOCXLW	SN	33577-16-1; methyl methylsulfinylmethyl sulfide; Methyl (methylsulfinyl)methyl sulfide; FAMSO; Methanesulfinyl-methylsulfanyl-methane; Methane, (methylsulfinyl)(methylthio)-; Formaldehyde dimethyl mercaptal S-oxide; Methyl (methylthio)methyl sulfoxide; (Methylsulfinyl)(methylthio)methane; Formaldehyde methyl mercaptal S-oxide; Sulfide, methyl (methylsulfinyl)methyl; Methyl methylthiomethyl sulfoxide; Methyl methylthiomethyl sulphoxide; NSC 181492; (Methylthio)dimethyl sulfoxide; OTKFCIVOVKCFHR-UHFFFAOYSA-N
DMOCXLW	DT	Small molecular drug
DMOCXLW	PC	99129
DMOCXLW	MW	124.23
DMOCXLW	FM	C3H8OS2
DMOCXLW	IC	InChI=1S/C3H8OS2/c1-5-3-6(2)4/h3H2,1-2H3
DMOCXLW	CS	CSCS(=O)C
DMOCXLW	IK	OTKFCIVOVKCFHR-UHFFFAOYSA-N
DMOCXLW	IU	methylsulfanyl(methylsulfinyl)methane
DMOCXLW	CA	CAS 33577-16-1
DMOCXLW	CB	CHEBI:167080
DMOCXLW	DE	Discovery agent

DM096SI	ID	DM096SI
DM096SI	DN	Methyl Phosphinic Acid
DM096SI	HS	Investigative
DM096SI	SN	METHYL PHOSPHINIC ACID; AC1MQ62K; AC1O4J1T; hydroxy-methyl-oxophosphanium; CTK4I5667; AKOS006290593; DB02845; Phosphinic acid,methyl- (7CI,8CI,9CI)
DM096SI	DT	Small molecular drug
DM096SI	PC	6369390
DM096SI	MW	79.015
DM096SI	FM	CH4O2P+
DM096SI	IC	InChI=1S/CH3O2P/c1-4(2)3/h1H3/p+1
DM096SI	CS	C[P+](=O)O
DM096SI	IK	OFSFQGSFEXXHNH-UHFFFAOYSA-O
DM096SI	IU	hydroxy-methyl-oxophosphanium
DM096SI	CA	CAS 4206-94-4
DM096SI	DE	Discovery agent

DMO58UW	ID	DMO58UW
DMO58UW	DN	methyl p-hydroxybenzoate
DMO58UW	HS	Investigative
DMO58UW	SN	methylparaben; nipagin
DMO58UW	DT	Small molecular drug
DMO58UW	PC	7456
DMO58UW	MW	152.15
DMO58UW	FM	C8H8O3
DMO58UW	IC	InChI=1S/C8H8O3/c1-11-8(10)6-2-4-7(9)5-3-6/h2-5,9H,1H3
DMO58UW	CS	COC(=O)C1=CC=C(C=C1)O
DMO58UW	IK	LXCFILQKKLGQFO-UHFFFAOYSA-N
DMO58UW	IU	methyl 4-hydroxybenzoate
DMO58UW	CA	CAS 99-76-3
DMO58UW	CB	CHEBI:31835
DMO58UW	DE	Discovery agent

DMW2R3M	ID	DMW2R3M
DMW2R3M	DN	Methyl piperate
DMW2R3M	HS	Investigative
DMW2R3M	SN	Methyl piperate; CHEMBL42965; (2E,4E)-methyl 5-(benzo[d][1,3]dioxol-5-yl)penta-2,4-dienoate; Piperinic acid methyl ester; Piperinsaure-methylester; Piperic acid methyl ester; SCHEMBL3244271; VOZJBFJHMHRLDN-ZUVMSYQZSA-N; 2,4-Pentadienoic acid, 5-(1,3-benzodioxol-5-yl)-, methyl ester, (2E,4E)-; BDBM50305644; 2,4-Pentadienoic acid, 5-(1,3-benzodioxol-5-yl)-, methyl ester, (E,E)-; (2E,4E)-5-Benzo[1,3]dioxol-5-yl-penta-2,4-dienoic acid methyl ester
DMW2R3M	DT	Small molecular drug
DMW2R3M	PC	9921021
DMW2R3M	MW	232.23
DMW2R3M	FM	C13H12O4
DMW2R3M	IC	InChI=1S/C13H12O4/c1-15-13(14)5-3-2-4-10-6-7-11-12(8-10)17-9-16-11/h2-8H,9H2,1H3/b4-2+,5-3+
DMW2R3M	CS	COC(=O)/C=C/C=C/C1=CC2=C(C=C1)OCO2
DMW2R3M	IK	VOZJBFJHMHRLDN-ZUVMSYQZSA-N
DMW2R3M	IU	methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
DMW2R3M	DE	Discovery agent

DMKCG8H	ID	DMKCG8H
DMKCG8H	DN	methyl salicylate
DMKCG8H	HS	Investigative
DMKCG8H	SN	methyl salicylate; Methyl 2-hydroxybenzoate; 119-36-8; Wintergreen oil; Gaultheria oil; Betula oil; Teaberry oil; Sweet birch oil; OIL OF WINTERGREEN; Analgit; Spicewood Oil; Wintergruenoel; 2-Hydroxybenzoic acid methyl ester; Gaultheriaoel; Flucarmit; Exagien; Betula; Methyl o-hydroxybenzoate; 2-Carbomethoxyphenol; 2-(Methoxycarbonyl)phenol; Natural Wintergreen Oil; Betula Lenta; BIRCH-ME; Salicylic acid, methyl ester; Synthetic Wintergreen Oil; Benzoic acid, 2-hydroxy-, methyl ester; Gaultheria oil, artificial; Wintergreen Oil, syn
DMKCG8H	DT	Small molecular drug
DMKCG8H	PC	4133
DMKCG8H	MW	152.15
DMKCG8H	FM	C8H8O3
DMKCG8H	IC	InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3
DMKCG8H	CS	COC(=O)C1=CC=CC=C1O
DMKCG8H	IK	OSWPMRLSEDHDFF-UHFFFAOYSA-N
DMKCG8H	IU	methyl 2-hydroxybenzoate
DMKCG8H	CA	CAS 119-36-8
DMKCG8H	CB	CHEBI:31832
DMKCG8H	DE	Discovery agent

DM9Y4FL	ID	DM9Y4FL
DM9Y4FL	DN	Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine
DM9Y4FL	HS	Investigative
DM9Y4FL	SN	N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; 10409-15-1; N-methyl-N-1,2,3,4-tetrahydronaphthalen-1-ylamine; Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine; 64037-95-2; ACMC-20mk8d; AC1L2G4R; 1-Naphthalenamine,1,2,3,4-tetrahydro-N-methyl-, (1R)-; SCHEMBL61095; 1-Naphthalenamine, 1,2,3,4-tetrahydro-N-methyl-; AC1Q410F; AC1Q410E; CTK4A2694; DTXSID70275501; JQEUPNKUYMHYPW-UHFFFAOYSA-N; MolPort-001-794-098; HMS1783D04; AKOS017269129; AKOS000118469; ENAMINE-BB EN300-11723; MCULE-6929246555; MB03780; NCGC00338944-02
DM9Y4FL	DT	Small molecular drug
DM9Y4FL	PC	46475
DM9Y4FL	MW	161.24
DM9Y4FL	FM	C11H15N
DM9Y4FL	IC	InChI=1S/C11H15N/c1-12-11-8-4-6-9-5-2-3-7-10(9)11/h2-3,5,7,11-12H,4,6,8H2,1H3
DM9Y4FL	CS	CNC1CCCC2=CC=CC=C12
DM9Y4FL	IK	JQEUPNKUYMHYPW-UHFFFAOYSA-N
DM9Y4FL	IU	N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
DM9Y4FL	CA	CAS 10409-15-1
DM9Y4FL	DE	Discovery agent

DMQU9VD	ID	DMQU9VD
DMQU9VD	DN	Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine
DMQU9VD	HS	Investigative
DMQU9VD	SN	CHEMBL179529; Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine
DMQU9VD	DT	Small molecular drug
DMQU9VD	PC	44388719
DMQU9VD	MW	190.27
DMQU9VD	FM	C10H10N2S
DMQU9VD	IC	InChI=1S/C10H10N2S/c1-11-10-5-4-9(13-10)8-3-2-6-12-7-8/h2-7,11H,1H3
DMQU9VD	CS	CNC1=CC=C(S1)C2=CN=CC=C2
DMQU9VD	IK	OUEHWWLIEPNPDR-UHFFFAOYSA-N
DMQU9VD	IU	N-methyl-5-pyridin-3-ylthiophen-2-amine
DMQU9VD	DE	Discovery agent

DMZVBLT	ID	DMZVBLT
DMZVBLT	DN	Methyl[4'-(trifluoromethyl)-4-biphenylyl]amine
DMZVBLT	HS	Investigative
DMZVBLT	SN	CHEMBL243640; SCHEMBL5428301; KPEUWXDPXPGBFC-UHFFFAOYSA-N; ZINC28711877; BDBM50220158; AKOS023382952; N-methyl-4'-(trifluoromethyl)-4-biphenylamine
DMZVBLT	DT	Small molecular drug
DMZVBLT	PC	23625978
DMZVBLT	MW	251.25
DMZVBLT	FM	C14H12F3N
DMZVBLT	IC	InChI=1S/C14H12F3N/c1-18-13-8-4-11(5-9-13)10-2-6-12(7-3-10)14(15,16)17/h2-9,18H,1H3
DMZVBLT	CS	CNC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F
DMZVBLT	IK	KPEUWXDPXPGBFC-UHFFFAOYSA-N
DMZVBLT	IU	N-methyl-4-[4-(trifluoromethyl)phenyl]aniline
DMZVBLT	DE	Discovery agent

DMOA54M	ID	DMOA54M
DMOA54M	DN	Methyl3beta-hydroxyolean-12-en-27-oate
DMOA54M	HS	Investigative
DMOA54M	SN	CHEMBL207494; methyl3beta-hydroxyolean-12-en-27-oate
DMOA54M	DT	Small molecular drug
DMOA54M	PC	44411982
DMOA54M	MW	470.7
DMOA54M	FM	C31H50O3
DMOA54M	IC	InChI=1S/C31H50O3/c1-26(2)15-16-28(5)17-18-31(25(33)34-8)20(21(28)19-26)9-10-23-29(6)13-12-24(32)27(3,4)22(29)11-14-30(23,31)7/h9,21-24,32H,10-19H2,1-8H3/t21-,22?,23+,24-,28+,29-,30+,31+/m0/s1
DMOA54M	CS	C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]1CC(CC2)(C)C)C(=O)OC
DMOA54M	IK	HEDYWHFMTAMIIX-IPZPPPCKSA-N
DMOA54M	IU	methyl (4aR,6aR,6aR,6bR,10S,12aR,14bR)-10-hydroxy-2,2,4a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylate
DMOA54M	DE	Discovery agent

DMTPL4W	ID	DMTPL4W
DMTPL4W	DN	Methylamine
DMTPL4W	HS	Investigative
DMTPL4W	SN	Aminomethane; Anhydrous Methylamine; BAVYZALUXZFZLV-UHFFFAOYSA-N; Carbinamine; METHYLAMINE; Mercurialin; Methanamine; Methylamine aq; Methylamine solutions; Methylamine, anhydrous; Methylamine, in aqueous solution; Methylaminen; Methylaminen [Dutch]; Metilamine; Metilamine [Italian]; Metyloamina; Metyloamina [Polish]; Monomethylamine; N-Methylamine; UN1061; UN1235; methyl-amine; monomethyl amine; 74-89-5; AI3-15637-X; BSF23SJ79E; CCRIS 2508; CH3NH2; CHEBI:16830; EINECS 200-820-0; HSDB 810; MeNH2; UNII-BSF23SJ79E
DMTPL4W	PC	6329
DMTPL4W	MW	31.057
DMTPL4W	FM	CH5N
DMTPL4W	IC	BAVYZALUXZFZLV-UHFFFAOYSA-N
DMTPL4W	CS	CN
DMTPL4W	IK	1S/CH5N/c1-2/h2H2,1H3
DMTPL4W	IU	methanamine
DMTPL4W	CA	CAS 74-89-5
DMTPL4W	CB	CHEBI:16830
DMTPL4W	DE	Discovery agent

DM9JECY	ID	DM9JECY
DM9JECY	DN	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID
DM9JECY	HS	Investigative
DM9JECY	SN	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID; CHEMBL11306; PLH; (n-(2-hydroxamatemethylene-4-methyl-pentoyl)phenylalanyl)methyl amine; 1mnc; 3-BMMHMH; AC1Q5QCC; AC1L4YVK; (2r)-n4-hydroxy-n1-[(2s)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-(2-methylpropyl)butanediamide; SCHEMBL5502507; PNU-99533; BDBM50031795; DB08403; 108383-58-0; (R)-N*4*-Hydroxy-2-isobutyl-N*1*-((S)-1-methylcarbamoyl-2-phenyl-ethyl)-succinamide; 3-((Benzyl)(methylaminocarbonyl)methylaminocarbonyl)N-hydroxy-5-methylhexanamide
DM9JECY	DT	Small molecular drug
DM9JECY	PC	194777
DM9JECY	MW	349.4
DM9JECY	FM	C18H27N3O4
DM9JECY	IC	InChI=1S/C18H27N3O4/c1-12(2)9-14(11-16(22)21-25)17(23)20-15(18(24)19-3)10-13-7-5-4-6-8-13/h4-8,12,14-15,25H,9-11H2,1-3H3,(H,19,24)(H,20,23)(H,21,22)/t14-,15+/m1/s1
DM9JECY	CS	CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC
DM9JECY	IK	MOPRTFSMCQNUCT-CABCVRRESA-N
DM9JECY	IU	(2R)-N'-hydroxy-N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-(2-methylpropyl)butanediamide
DM9JECY	CA	CAS 108383-58-0
DM9JECY	DE	Discovery agent

DMDP84X	ID	DMDP84X
DMDP84X	DN	Methylcarbamic Acid Biphenyl-3-yl Ester
DMDP84X	HS	Investigative
DMDP84X	SN	CHEMBL486290; Methylcarbamic Acid Biphenyl-3-yl Ester; SCHEMBL12133520; BDBM50270688
DMDP84X	DT	Small molecular drug
DMDP84X	PC	44585603
DMDP84X	MW	227.26
DMDP84X	FM	C14H13NO2
DMDP84X	IC	InChI=1S/C14H13NO2/c1-15-14(16)17-13-9-5-8-12(10-13)11-6-3-2-4-7-11/h2-10H,1H3,(H,15,16)
DMDP84X	CS	CNC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DMDP84X	IK	NYOGSYRWQAQOKA-UHFFFAOYSA-N
DMDP84X	IU	(3-phenylphenyl) N-methylcarbamate
DMDP84X	DE	Discovery agent

DMV865Q	ID	DMV865Q
DMV865Q	DN	methylcarbamyl PAF
DMV865Q	HS	Investigative
DMV865Q	SN	methyl-carbamyl platelet-activating factor; mc-PAF
DMV865Q	DT	Small molecular drug
DMV865Q	PC	124663
DMV865Q	MW	538.7
DMV865Q	FM	C26H55N2O7P
DMV865Q	IC	InChI=1S/C26H55N2O7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-32-23-25(35-26(29)27-2)24-34-36(30,31)33-22-20-28(3,4)5/h25H,6-24H2,1-5H3,(H-,27,29,30,31)/t25-/m1/s1
DMV865Q	CS	CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)NC
DMV865Q	IK	FNFHZBKBDFRYHS-RUZDIDTESA-N
DMV865Q	IU	[(2R)-3-hexadecoxy-2-(methylcarbamoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
DMV865Q	CA	CAS 91575-58-5
DMV865Q	DE	Discovery agent

DMP204G	ID	DMP204G
DMP204G	DN	Methylenedioxyamphetamine
DMP204G	HS	Investigative
DMP204G	SN	Tenamfetamine; 3,4-methylenedioxyamphetamine; Methylenedioxyamphetamine; 4764-17-4; 3,4-Methylenedioxy-amphetamine; MDA (pharmaceutical); Tenamfetamine [INN]; Tenamfetaminum [Latin]; Tenamfetamina [Spanish]; 1-(1,3-benzodioxol-5-yl)propan-2-amine; BRN 0150196; DEA No. 7400; AI3-24882; alpha-Methyl-1,3-benzodioxole-5-ethanamine; 1,3-Benzodioxole-5-ethanamine, alpha-methyl-; CHEMBL6731; ALPHA-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE; NGBBVGZWCFBOGO-UHFFFAOYSA-N; 5-19-08-00417 (Beilstein Handbook Reference); Phenethylamine, alp
DMP204G	DT	Small molecular drug
DMP204G	PC	1614
DMP204G	MW	179.22
DMP204G	FM	C10H13NO2
DMP204G	IC	InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3
DMP204G	CS	CC(CC1=CC2=C(C=C1)OCO2)N
DMP204G	IK	NGBBVGZWCFBOGO-UHFFFAOYSA-N
DMP204G	IU	1-(1,3-benzodioxol-5-yl)propan-2-amine
DMP204G	CA	CAS 4764-17-4
DMP204G	CB	CHEBI:166520
DMP204G	DE	Discovery agent

DMYVU47	ID	DMYVU47
DMYVU47	DN	Methylenedioxymethamphetamine
DMYVU47	HS	Investigative
DMYVU47	SN	3,4-Methylenedioxymethamphetamine; MDMA; 3,4-methylenedioxymethamphetamine; Ecstasy; Methylenedioxymethamphetamine; 42542-10-9; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; DL-(3,4-Methylenedioxy)methamphetamine; (RS)-3,4-(methylenedioxy)methamphetamine; Midomafetamine; MDMA (unspecified); N,alpha-Dimethyl-1,3-benzodioxole-5-ethanamine; HSDB 6929; 1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine; CHEBI:1391; DEA No 7405; (+-)-(3,4-Methylenedioxy)methamphetamine; (+-)-N-Methyl-3,4-(methylenedioxy)amphetamine; 1,3-Benzodioxole-5-ethanamine, N,alpha-dimethyl-
DMYVU47	DT	Small molecular drug
DMYVU47	PC	1615
DMYVU47	MW	193.24
DMYVU47	FM	C11H15NO2
DMYVU47	IC	InChI=1S/C11H15NO2/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10/h3-4,6,8,12H,5,7H2,1-2H3
DMYVU47	CS	CC(CC1=CC2=C(C=C1)OCO2)NC
DMYVU47	IK	SHXWCVYOXRDMCX-UHFFFAOYSA-N
DMYVU47	IU	1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine
DMYVU47	CA	CAS 42542-10-9
DMYVU47	CB	CHEBI:1391
DMYVU47	DE	Discovery agent

DMZ318I	ID	DMZ318I
DMZ318I	DN	methylfurmethide
DMZ318I	HS	Investigative
DMZ318I	SN	5-methylfurmithide; 5 MFT
DMZ318I	DT	Small molecular drug
DMZ318I	PC	4141
DMZ318I	MW	154.23
DMZ318I	FM	C9H16NO+
DMZ318I	IC	InChI=1S/C9H16NO/c1-8-5-6-9(11-8)7-10(2,3)4/h5-6H,7H2,1-4H3/q+1
DMZ318I	CS	CC1=CC=C(O1)C[N+](C)(C)C
DMZ318I	IK	KOWVJDFMEZKDDT-UHFFFAOYSA-N
DMZ318I	IU	trimethyl-[(5-methylfuran-2-yl)methyl]azanium
DMZ318I	CA	CAS 14172-53-3
DMZ318I	CB	CHEBI:94038
DMZ318I	DE	Discovery agent

DMRC3OZ	ID	DMRC3OZ
DMRC3OZ	DN	methylglyoxal
DMRC3OZ	HS	Investigative
DMRC3OZ	SN	pyruvaldehyde; pyruvic aldehyde; 2-Oxopropanal; acetylformaldehyde; 78-98-8; Acetylformyl; Propanal, 2-oxo-; 2-Ketopropionaldehyde; Propanedione; Propanolone; Pyroracemic aldehyde; Glyoxal, methyl; 2-Oxopropionaldehyde; alpha-Ketopropionaldehyde; 1-Ketopropionaldehyde; Propionaldehyde, 2-keto; Propionaldehyde, 2-oxo-; 1,2-Propanedione; Acetalformaldehyde; alpha-Ketopropionic aldehyde; 2-oxo-Propionaldehyde; CH3COCHO; FEMA No 2969; CCRIS 1741; 2-oxo-propanal; NSC 79019; NSC 626580; Pyruvoyl Group
DMRC3OZ	DT	Small molecular drug
DMRC3OZ	PC	880
DMRC3OZ	MW	72.06
DMRC3OZ	FM	C3H4O2
DMRC3OZ	IC	InChI=1S/C3H4O2/c1-3(5)2-4/h2H,1H3
DMRC3OZ	CS	CC(=O)C=O
DMRC3OZ	IK	AIJULSRZWUXGPQ-UHFFFAOYSA-N
DMRC3OZ	IU	2-oxopropanal
DMRC3OZ	CA	CAS 78-98-8
DMRC3OZ	CB	CHEBI:17158
DMRC3OZ	DE	Discovery agent

DMUBY4J	ID	DMUBY4J
DMUBY4J	DN	Methylglyoxal
DMUBY4J	HS	Investigative
DMUBY4J	SN	Acetylformyl; Glyoxal, methyl; METHYL GLYOXAL; Propanal, 2-oxo-; Propanedione; Propanolone; Propionaldehyde, 2-keto; Propionaldehyde, 2-oxo-; Pyroracemic aldehyde; acetylformaldehyde; alpha-Ketopropionaldehyde; alpha-Ketopropionic aldehyde; methyl-glyoxal; methylglyoxal; pyruvaldehyde; pyruvic aldehyde; 1,2-Propanedione; 1-Ketopropionaldehyde; 2-Ketopropionaldehyde; 2-Oxopropanal; 2-Oxopropionaldehyde; 2-oxo-Propionaldehyde; 2-oxo-propanal; 78-98-8; Acetalformaldehyde; CCRIS 1741; CH3COCHO; FEMA No. 2969; NSC 626580; NSC 79019
DMUBY4J	PC	880
DMUBY4J	MW	72.06
DMUBY4J	FM	C3H4O2
DMUBY4J	IC	AIJULSRZWUXGPQ-UHFFFAOYSA-N
DMUBY4J	CS	CC(=O)C=O
DMUBY4J	IK	1S/C3H4O2/c1-3(5)2-4/h2H,1H3
DMUBY4J	IU	2-oxopropanal
DMUBY4J	CA	CAS 78-98-8
DMUBY4J	CB	CHEBI:17158
DMUBY4J	DE	Alzheimer disease

DM7PRDY	ID	DM7PRDY
DM7PRDY	DN	methylhistaprodifen
DM7PRDY	HS	Investigative
DM7PRDY	SN	N-methylhistaprodifen
DM7PRDY	DT	Small molecular drug
DM7PRDY	PC	10403687
DM7PRDY	MW	319.4
DM7PRDY	FM	C21H25N3
DM7PRDY	IC	InChI=1S/C21H25N3/c1-22-15-14-19-16-23-21(24-19)13-12-20(17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,16,20,22H,12-15H2,1H3,(H,23,24)
DM7PRDY	CS	CNCCC1=CN=C(N1)CCC(C2=CC=CC=C2)C3=CC=CC=C3
DM7PRDY	IK	YMVWDVNGNLXSKR-UHFFFAOYSA-N
DM7PRDY	IU	2-[2-(3,3-diphenylpropyl)-1H-imidazol-5-yl]-N-methylethanamine
DM7PRDY	DE	Discovery agent

DM9YE6K	ID	DM9YE6K
DM9YE6K	DN	METHYLHONOKIOL
DM9YE6K	HS	Investigative
DM9YE6K	SN	4-O-Methylhonokiol; 68592-15-4; METHYLHONOKIOL; 4-O-Methyl honokiol; 4-methoxyhonokiol; HONOKIOL MONO-METHYL ETHER; CHEMBL89700; (1,1'-Biphenyl)-2-ol, 4'-methoxy-3',5-di-2-propenyl-; [1,1'-Biphenyl]-2-ol, 4'-methoxy-3',5-di-2-propenyl-; Magreth-14a; NSC293101; 4'-O-Methylhonokiol; AC1L4DQF; 4'-O-methylhonokiol, MH; SCHEMBL12391677; CTK5C8246; DTXSID50218693; ZINC1566147; HY-U00450; BDBM50295926; AKOS028111321; NSC-293101; CS-0035406; 5,3''-Diallyl-4''-methoxy-biphenyl-2-ol; 3,5'-diallyl-2'-hydroxy-4-methoxybiphenyl
DM9YE6K	DT	Small molecular drug
DM9YE6K	PC	155160
DM9YE6K	MW	280.4
DM9YE6K	FM	C19H20O2
DM9YE6K	IC	InChI=1S/C19H20O2/c1-4-6-14-8-10-18(20)17(12-14)15-9-11-19(21-3)16(13-15)7-5-2/h4-5,8-13,20H,1-2,6-7H2,3H3
DM9YE6K	CS	COC1=C(C=C(C=C1)C2=C(C=CC(=C2)CC=C)O)CC=C
DM9YE6K	IK	OQFHJKZVOALSPV-UHFFFAOYSA-N
DM9YE6K	IU	2-(4-methoxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol
DM9YE6K	CA	CAS 68592-15-4
DM9YE6K	DE	Discovery agent

DMOWMPL	ID	DMOWMPL
DMOWMPL	DN	METHYLNORADRENALINE
DMOWMPL	HS	Investigative
DMOWMPL	SN	Methylnoradrenaline; Isoadrenaline; Nordephrine; alpha-Methylnorepinephrine; Dioxynorepinephrine; Dihydroxyphenylpropanolamine; l-alpha-Methylnorepinephrine; 6539-57-7; 1,2-Benzenediol, 4-(2-amino-1-hydroxypropyl)-; 2-Amino-1-(3,4-dihydroxyphenyl)propan-1-ol; 4-(2-amino-1-hydroxypropyl)benzene-1,2-diol; 3,4-Dihydrophenyl-1-amino-2-propanol-1; 4-(2-Amino-1-hydroxypropyl)-1,2-benzenediol; EINECS 229-452-9; CHEMBL764; CHEBI:81386
DMOWMPL	DT	Small molecular drug
DMOWMPL	PC	3917
DMOWMPL	MW	183.2
DMOWMPL	FM	C9H13NO3
DMOWMPL	IC	InChI=1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3
DMOWMPL	CS	CC(C(C1=CC(=C(C=C1)O)O)O)N
DMOWMPL	IK	GEFQWZLICWMTKF-UHFFFAOYSA-N
DMOWMPL	IU	4-(2-amino-1-hydroxypropyl)benzene-1,2-diol
DMOWMPL	CA	CAS 6539-57-7
DMOWMPL	CB	CHEBI:81386
DMOWMPL	DE	Discovery agent

DMQ7THK	ID	DMQ7THK
DMQ7THK	DN	Methyl-pentyl-prop-2-ynyl-amine oxalic acid
DMQ7THK	HS	Investigative
DMQ7THK	DE	Discovery agent

DMR7HV3	ID	DMR7HV3
DMR7HV3	DN	METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE
DMR7HV3	HS	Investigative
DMR7HV3	SN	METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE; CHEMBL125181; L-371912; MIN; (2S)-N-[(4-aminocyclohexyl)methyl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide; 1tom; AC1L9MBI; SCHEMBL7585036; BDBM50366827; BDBM50056771; DB08187; N-methyl-D-phenylalanyl-N-[(trans-4-aminocyclohexyl)methyl]-L-prolinamide; (2S)-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]-N-{[(1s,4s)-4-aminocyclohexyl]methyl}pyrrolidine-2-carboxamide
DMR7HV3	DT	Small molecular drug
DMR7HV3	PC	448763
DMR7HV3	MW	386.5
DMR7HV3	FM	C22H34N4O2
DMR7HV3	IC	InChI=1S/C22H34N4O2/c1-24-19(14-16-6-3-2-4-7-16)22(28)26-13-5-8-20(26)21(27)25-15-17-9-11-18(23)12-10-17/h2-4,6-7,17-20,24H,5,8-15,23H2,1H3,(H,25,27)/t17?,18?,19-,20+/m1/s1
DMR7HV3	CS	CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)NCC3CCC(CC3)N
DMR7HV3	IK	MDSVGJAUFNXYRR-TUNPWDSISA-N
DMR7HV3	IU	(2S)-N-[(4-aminocyclohexyl)methyl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMR7HV3	DE	Discovery agent

DMKTOPJ	ID	DMKTOPJ
DMKTOPJ	DN	methyl-piperidino-pyrazole
DMKTOPJ	HS	Investigative
DMKTOPJ	DT	Small molecular drug
DMKTOPJ	PC	135484659
DMKTOPJ	MW	469.6
DMKTOPJ	FM	C29H31N3O3
DMKTOPJ	IC	InChI=1S/C29H31N3O3/c1-21-28(22-5-11-25(33)12-6-22)30-32(24-9-13-26(34)14-10-24)29(21)23-7-15-27(16-8-23)35-20-19-31-17-3-2-4-18-31/h5-16,33-34H,2-4,17-20H2,1H3
DMKTOPJ	CS	CC1=C(N(N=C1C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)C4=CC=C(C=C4)OCCN5CCCCC5
DMKTOPJ	IK	TXLGPGWHIIHRHH-UHFFFAOYSA-N
DMKTOPJ	IU	4-[1-(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidin-1-ylethoxy)phenyl]pyrazol-3-yl]phenol
DMKTOPJ	DE	Discovery agent

DMU3JBL	ID	DMU3JBL
DMU3JBL	DN	Methylthioribose phosphate
DMU3JBL	HS	Investigative
DMU3JBL	SN	D-ribofuranoside; S5-methyl-5-thio-D-ribose-1-phosphate; 5-methylthio-5-deoxy-D-ribose-1-phosphate; 5-Methylthioribose 1-phosphate; 5-Methylthioribose 1-phosphate; 5-Methylthio-5-deoxy-D-ribose 1-phosphate
DMU3JBL	PC	53477720
DMU3JBL	MW	260.2
DMU3JBL	FM	C6H13O7PS
DMU3JBL	IC	JTFITTQBRJDSTL-WATOWXBHSA-N
DMU3JBL	CS	CSCC1C(C(C(O1)OP(=O)(O)O)O)O
DMU3JBL	IK	1S/C6H13O7PS/c1-15-2-3-4(7)5(8)6(12-3)13-14(9,10)11/h3-8H,2H2,1H3,(H2,9,10,11)/t3?,4-,5-,6?/m1/s1
DMU3JBL	IU	[(3R,4S)-3,4-dihydroxy-5-(methylsulfanylmethyl)oxolan-2-yl] dihydrogen phosphate
DMU3JBL	CA	CAS 72843-83-5
DMU3JBL	DE	Discovery agent

DMAEQB6	ID	DMAEQB6
DMAEQB6	DN	Methylurea
DMAEQB6	HS	Investigative
DMAEQB6	SN	METHYLUREA; 1-Methylurea; N-Methylurea; 598-50-5; Monomethylurea; Urea, methyl-; Methyl urea; urea, N-methyl-; Methylmocovina; N-methyl urea; Methylmocovina [Czech]; Methylharnstoff [German]; CCRIS 9137; EINECS 209-935-0; 1-Methylurea;1-Methylurea; UNII-VZ89YBW3P8; VZ89YBW3P8; AI3-15088; XGEGHDBEHXKFPX-UHFFFAOYSA-N; Methylurea, 97%; Methylharnstoff; methylisourea; methyl-urea; 3-methyl-urea; N-Methylurea, 97%; CH3NHCONH2; ACMC-1AKB9; bmse000738; EC 209-935-0; AC1L1XZ6; KSC271C6B; GTPL4662; DTXSID5060510; CTK1H1160; CHEBI:44383
DMAEQB6	DT	Small molecular drug
DMAEQB6	PC	11719
DMAEQB6	MW	74.08
DMAEQB6	FM	C2H6N2O
DMAEQB6	IC	InChI=1S/C2H6N2O/c1-4-2(3)5/h1H3,(H3,3,4,5)
DMAEQB6	CS	CNC(=O)N
DMAEQB6	IK	XGEGHDBEHXKFPX-UHFFFAOYSA-N
DMAEQB6	IU	methylurea
DMAEQB6	CA	CAS 598-50-5
DMAEQB6	CB	CHEBI:44383
DMAEQB6	DE	Discovery agent

DMO7JGS	ID	DMO7JGS
DMO7JGS	DN	Metiamide
DMO7JGS	HS	Investigative
DMO7JGS	SN	METIAMIDE; 34839-70-8; Methiamide; Metiamidum; Metiamida; F 92058; 1-Methyl-3-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)thiourea; Metiamidum [INN-Latin]; Metiamida [INN-Spanish]; SKF 92058; NSC 307755; F-92058; CHEBI:6896; C9H16N4S2; UNII-3K7670861M; FPBPLBWLMYGIQR-UHFFFAOYSA-N; 1-Methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)-2-thiourea; Thiourea, N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-; 3-Methyl-1-(2-((5-methyl-4-imidazolyl)methylthio)ethyl)thiourea; 3K7670861M; Urea, 1-
DMO7JGS	DT	Small molecular drug
DMO7JGS	PC	1548992
DMO7JGS	MW	244.4
DMO7JGS	FM	C9H16N4S2
DMO7JGS	IC	InChI=1S/C9H16N4S2/c1-7-8(13-6-12-7)5-15-4-3-11-9(14)10-2/h6H,3-5H2,1-2H3,(H,12,13)(H2,10,11,14)
DMO7JGS	CS	CC1=C(N=CN1)CSCCNC(=S)NC
DMO7JGS	IK	FPBPLBWLMYGIQR-UHFFFAOYSA-N
DMO7JGS	IU	1-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]thiourea
DMO7JGS	CA	CAS 34839-70-8
DMO7JGS	CB	CHEBI:6896
DMO7JGS	DE	Discovery agent

DMZBLQD	ID	DMZBLQD
DMZBLQD	DN	Met-Lys-bradykinin
DMZBLQD	HS	Investigative
DMZBLQD	SN	Met-kallidin
DMZBLQD	DT	Small molecular drug
DMZBLQD	PC	3035449
DMZBLQD	MW	1319.6
DMZBLQD	FM	C61H94N18O13S
DMZBLQD	IC	InChI=1S/C61H94N18O13S/c1-93-32-25-39(63)50(82)72-40(19-8-9-26-62)51(83)73-41(20-10-27-68-60(64)65)56(88)79-31-14-24-48(79)58(90)78-30-12-22-46(78)54(86)70-35-49(81)71-43(33-37-15-4-2-5-16-37)52(84)76-45(36-80)57(89)77-29-13-23-47(77)55(87)75-44(34-38-17-6-3-7-18-38)53(85)74-42(59(91)92)21-11-28-69-61(66)67/h2-7,15-18,39-48,80H,8-14,19-36,62-63H2,1H3,(H,70,86)(H,71,81)(H,72,82)(H,73,83)(H,74,85)(H,75,87)(H,76,84)(H,91,92)(H4,64,65,68)(H4,66,67,69)/t39-,40-,41-,42-,43-,44-,45-,46-,47-,48-/m0/s1
DMZBLQD	CS	CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N
DMZBLQD	IK	SSXPFNXUSFJJEI-BHEJXMHWSA-N
DMZBLQD	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMZBLQD	CA	CAS 550-19-6
DMZBLQD	DE	Discovery agent

DM70RDZ	ID	DM70RDZ
DM70RDZ	DN	Metrenperone
DM70RDZ	HS	Investigative
DM70RDZ	SN	Metrenperone; 81043-56-3; UNII-W1O4FV809G; W1O4FV809G; R 50 970; Metrenperona; Metrenperonum; 3-[2-[4-(4-Fluorobenzoyl)-1-piperidyl]ethyl]-2,7-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; Metrenperonum [INN-Latin]; Metrenperona [INN-Spanish]; Sinomedol; Metrenperone [USAN:INN:BAN]; 3-(2-(4-(4-Fluorobenzoyl)-1-piperidyl)ethyl)-2,7-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; EINECS 279-678-7; Metrenperone (USAN/INN); AC1Q4NI9; AC1L2H8G; SCHEMBL2109868; CHEMBL2104852; BDBM82382; DTXSID20230867; ZINC537997; NSC_72005; CAS_72005
DM70RDZ	DT	Small molecular drug
DM70RDZ	PC	72005
DM70RDZ	MW	407.5
DM70RDZ	FM	C24H26FN3O2
DM70RDZ	IC	InChI=1S/C24H26FN3O2/c1-16-3-8-22-26-17(2)21(24(30)28(22)15-16)11-14-27-12-9-19(10-13-27)23(29)18-4-6-20(25)7-5-18/h3-8,15,19H,9-14H2,1-2H3
DM70RDZ	CS	CC1=CN2C(=NC(=C(C2=O)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F)C)C=C1
DM70RDZ	IK	AXQRPYKSPHUOGZ-UHFFFAOYSA-N
DM70RDZ	IU	3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2,7-dimethylpyrido[1,2-a]pyrimidin-4-one
DM70RDZ	CA	CAS 81043-56-3
DM70RDZ	DE	Discovery agent

DMGH8WV	ID	DMGH8WV
DMGH8WV	DN	MeTRH
DMGH8WV	HS	Investigative
DMGH8WV	SN	38983-06-1; His(1-methyl)-TRH; [3H]MeTRH; (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]-1-methyl-5-oxopyrrolidine-2-carboxamide; [3H]Me-thyrotropin-releasing hormone; AC1NSKDH; His(1-methyl)-thyrotropin-releasing hormone; GTPL2141; GTPL2137; CTK1A8669; DTXSID50415524; pGlu-His(1(tau)-methyl)-ProNH2; [3H]pGlu-His(1(tau)-methyl)-ProNH2; L-Prolinamide, 1-methyl-5-oxo-L-prolyl-L-histidyl-;  His(1-methyl)-TRH; pGlu-His(1(t)-methyl)-ProNH2
DMGH8WV	DT	Small molecular drug
DMGH8WV	PC	5311291
DMGH8WV	MW	376.4
DMGH8WV	FM	C17H24N6O4
DMGH8WV	IC	InChI=1S/C17H24N6O4/c1-22-13(4-5-14(22)24)16(26)21-11(7-10-8-19-9-20-10)17(27)23-6-2-3-12(23)15(18)25/h8-9,11-13H,2-7H2,1H3,(H2,18,25)(H,19,20)(H,21,26)/t11-,12-,13-/m0/s1
DMGH8WV	CS	CN1[C@@H](CCC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N
DMGH8WV	IK	DJLHRAHTTSWYAW-AVGNSLFASA-N
DMGH8WV	IU	(2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-1-methyl-5-oxopyrrolidine-2-carboxamide
DMGH8WV	CA	CAS 38983-06-1
DMGH8WV	DE	Discovery agent

DMHTGCR	ID	DMHTGCR
DMHTGCR	DN	METYRAPOL
DMHTGCR	HS	Investigative
DMHTGCR	SN	Metyrapol; 17159-42-1; CHEMBL933; 2-Methyl-1,2-bis(3-pyridyl)-1-propanol; 3-Pyridineethanol, b,b-dimethyl-a-3-pyridinyl-; SU-5236; 2-methyl-1,2-dipyridin-3-ylpropan-1-ol; METYRAPOL (MPOL); AC1Q773J; AC1L4P01; CTK4D3983; BDBM50028160; AKOS030241945; 2-Methyl-1,2-di-pyridin-3-yl-propan-1-ol
DMHTGCR	DT	Small molecular drug
DMHTGCR	PC	161210
DMHTGCR	MW	228.29
DMHTGCR	FM	C14H16N2O
DMHTGCR	IC	InChI=1S/C14H16N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10,13,17H,1-2H3
DMHTGCR	CS	CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)O
DMHTGCR	IK	DDFNHFXLQJLFSX-UHFFFAOYSA-N
DMHTGCR	IU	2-methyl-1,2-dipyridin-3-ylpropan-1-ol
DMHTGCR	CA	CAS 17159-42-1
DMHTGCR	DE	Discovery agent

DMVYWJS	ID	DMVYWJS
DMVYWJS	DN	MEZILAMINE
DMVYWJS	HS	Investigative
DMVYWJS	SN	Mezilamine; Mezilamine [INN]; Mezilaminum [INN-Latin]; Mezilamina [INN-Spanish]; UNII-V243ORA40X; 50335-55-2; BRN 0666978; CHEMBL407641; V243ORA40X; 4-Chloro-2-methylamino-5-methylthio-6-(4-methyl-1-piperazinyl)pyrimidine; 4-Chloro-N-methyl-6-(4-methyl-1-piperazinyl)-5-(methylthio)-2-pyrimidinamine; Mezilaminum; Mezilamina; 4-Chloro-2-(methylamino)-6-(4-methyl-1-piperazinyl)-5-(methylthio)pyrimidine; Pyrimidine, 4-chloro-2-(methylamino)-5-(methylthio)-6-(4-methyl-1-piperazinyl)-; 2-Pyridinamine, 4-chloro-N-methyl-6-(4-met
DMVYWJS	DT	Small molecular drug
DMVYWJS	PC	68678
DMVYWJS	MW	287.81
DMVYWJS	FM	C11H18ClN5S
DMVYWJS	IC	InChI=1S/C11H18ClN5S/c1-13-11-14-9(12)8(18-3)10(15-11)17-6-4-16(2)5-7-17/h4-7H2,1-3H3,(H,13,14,15)
DMVYWJS	CS	CNC1=NC(=C(C(=N1)Cl)SC)N2CCN(CC2)C
DMVYWJS	IK	ITYXRJDDBZMFAY-UHFFFAOYSA-N
DMVYWJS	IU	4-chloro-N-methyl-6-(4-methylpiperazin-1-yl)-5-methylsulfanylpyrimidin-2-amine
DMVYWJS	CA	CAS 50335-55-2
DMVYWJS	DE	Discovery agent

DMBLUSA	ID	DMBLUSA
DMBLUSA	DN	MF-152
DMBLUSA	HS	Investigative
DMBLUSA	SN	916888-66-9; 2-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)thiazole-5-carboxamide; CHEMBL576820; MF-152; SCHEMBL3467167; KS-00000RND; DTXSID60474965; MolPort-035-675-701; ZINC45288748; BDBM50301057; AKOS022171752; 2-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]-1,3-thiazole-5-carboxamide; DS-5323; ACN-025269; BC261397; AK136241; SC-94064; KB-222046; AJ-110396
DMBLUSA	DT	Small molecular drug
DMBLUSA	PC	11973722
DMBLUSA	MW	384.4
DMBLUSA	FM	C16H15F3N4O2S
DMBLUSA	IC	InChI=1S/C16H15F3N4O2S/c17-16(18,19)11-4-2-1-3-10(11)14(25)22-5-7-23(8-6-22)15-21-9-12(26-15)13(20)24/h1-4,9H,5-8H2,(H2,20,24)
DMBLUSA	CS	C1CN(CCN1C2=NC=C(S2)C(=O)N)C(=O)C3=CC=CC=C3C(F)(F)F
DMBLUSA	IK	XCYAUDKMHBMJSP-UHFFFAOYSA-N
DMBLUSA	IU	2-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]-1,3-thiazole-5-carboxamide
DMBLUSA	CA	CAS 916888-66-9
DMBLUSA	DE	Discovery agent

DMSYQP9	ID	DMSYQP9
DMSYQP9	DN	MF266-1
DMSYQP9	HS	Investigative
DMSYQP9	SN	CHEMBL185346; MF266-1; GTPL6068; BDBM50160909; 1-[5-[3-[5-chloro-2-(phenylmethoxy)phenyl]thiophen-2-yl]pyridin-3-yl]-2,2,2-trifluoroethane-1,1-diol
DMSYQP9	DT	Small molecular drug
DMSYQP9	PC	11306423
DMSYQP9	MW	491.9
DMSYQP9	FM	C24H17ClF3NO3S
DMSYQP9	IC	InChI=1S/C24H17ClF3NO3S/c25-18-6-7-21(32-14-15-4-2-1-3-5-15)20(11-18)19-8-9-33-22(19)16-10-17(13-29-12-16)23(30,31)24(26,27)28/h1-13,30-31H,14H2
DMSYQP9	CS	C1=CC=C(C=C1)COC2=C(C=C(C=C2)Cl)C3=C(SC=C3)C4=CC(=CN=C4)C(C(F)(F)F)(O)O
DMSYQP9	IK	JCCQFQOPADDTRS-UHFFFAOYSA-N
DMSYQP9	IU	1-[5-[3-(5-chloro-2-phenylmethoxyphenyl)thiophen-2-yl]pyridin-3-yl]-2,2,2-trifluoroethane-1,1-diol
DMSYQP9	DE	Discovery agent

DM1FEVB	ID	DM1FEVB
DM1FEVB	DN	MF-8623
DM1FEVB	HS	Investigative
DM1FEVB	DE	Discovery agent

DM3RUT8	ID	DM3RUT8
DM3RUT8	DN	MG-101
DM3RUT8	HS	Investigative
DM3RUT8	SN	110044-82-1
DM3RUT8	DT	Small molecular drug
DM3RUT8	PC	443118
DM3RUT8	MW	383.5
DM3RUT8	FM	C20H37N3O4
DM3RUT8	IC	InChI=1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1
DM3RUT8	CS	CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C
DM3RUT8	IK	FMYKJLXRRQTBOR-BZSNNMDCSA-N
DM3RUT8	IU	(2S)-2-acetamido-4-methyl-N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxohexan-2-yl]amino]pentan-2-yl]pentanamide
DM3RUT8	CA	CAS 110044-82-1
DM3RUT8	CB	CHEBI:2423
DM3RUT8	DE	Discovery agent

DM710KZ	ID	DM710KZ
DM710KZ	DN	MG-1101
DM710KZ	HS	Investigative
DM710KZ	SN	MBR-193.02; MBRI-93.02; PTH (osteoporosis), Green Cross/BDD/CCDRD; parathyroid gland-secreted peptide (osteoporosis), Green Cross; parathyroid hormone, Green Cross/BDD/CCDRD
DM710KZ	DE	Discovery agent

DMHR1GX	ID	DMHR1GX
DMHR1GX	DN	MG-1104
DMHR1GX	HS	Investigative
DMHR1GX	CP	Green Cross Corp
DMHR1GX	DE	Factor IX deficiency

DMG56EU	ID	DMG56EU
DMG56EU	DN	MG-111
DMG56EU	HS	Investigative
DMG56EU	SN	134865-04-6; EGF, Hitachi
DMG56EU	PC	16143379
DMG56EU	MW	6222
DMG56EU	FM	C270H401N73O83S7
DMG56EU	IC	InChI=1S/C270H401N73O83S7/c1-24-134(19)217(262(420)293-112-201(355)298-161(69-74-205(359)360)229(387)301-160(45-35-82-286-269(279)280)228(386)333-192(119-428)255(413)307-162(68-73-198(274)352)230(388)316-176(94-141-54-64-150(350)65-55-141)241(399)304-159(44-34-81-285-268(277)278)227(385)325-186(105-212(373)374)248(406)313-169(87-127(5)6)235(393)302-158(43-31-33-80-272)226(384)318-179(97-144-108-289-156-41-29-27-39-153(144)156)243(401)319-178(96-143-107-288-155-40-28-26-38-152(143)155)242(400)305-164(71-76-207(363)364)231(389)312-170(88-128(7)8)236(394)310-167(267(425)426)46-36-83-287-270(281)282)341-250(408)174(92-139-50-60-148(348)61-51-139)300-203(357)113-292-261(419)214(131(13)14)340-264(422)216(133(17)18)339-259(417)195(122-431)335-246(404)182(101-200(276)354)322-257(415)191(118-427)332-220(378)137(22)297-234(392)175(93-140-52-62-149(349)63-53-140)315-225(383)157(42-30-32-79-271)303-247(405)185(104-211(371)372)326-237(395)168(86-126(3)4)311-219(377)136(21)296-224(382)163(70-75-206(361)362)309-265(423)218(135(20)25-2)342-251(409)177(95-142-56-66-151(351)67-57-142)317-233(391)166(78-85-433-23)308-256(414)194(121-430)336-263(421)215(132(15)16)338-204(358)114-291-223(381)184(103-210(369)370)323-244(402)180(98-145-109-283-124-294-145)320-238(396)171(89-129(9)10)314-258(416)193(120-429)334-240(398)173(91-138-48-58-147(347)59-49-138)299-202(356)111-290-222(380)183(102-209(367)368)324-245(403)181(99-146-110-284-125-295-146)321-254(412)190(117-346)330-239(397)172(90-130(11)12)328-260(418)197-47-37-84-343(197)266(424)196(123-432)337-232(390)165(72-77-208(365)366)306-252(410)189(116-345)331-249(407)187(106-213(375)376)327-253(411)188(115-344)329-221(379)154(273)100-199(275)353/h26-29,38-41,48-67,107-110,124-137,154,157-197,214-218,288-289,344-351,427-432H,24-25,30-37,42-47,68-106,111-123,271-273H2,1-23H3,(H2,274,352)(H2,275,353)(H2,276,354)(H,283,294)(H,284,295)(H,290,380)(H,291,381)(H,292,419)(H,293,420)(H,296,382)(H,297,392)(H,298,355)(H,299,356)(H,300,357)(H,301,387)(H,302,393)(H,303,405)(H,304,399)(H,305,400)(H,306,410)(H,307,413)(H,308,414)(H,309,423)(H,310,394)(H,311,377)(H,312,389)(H,313,406)(H,314,416)(H,315,383)(H,316,388)(H,317,391)(H,318,384)(H,319,401)(H,320,396)(H,321,412)(H,322,415)(H,323,402)(H,324,403)(H,325,385)(H,326,395)(H,327,411)(H,328,418)(H,329,379)(H,330,397)(H,331,407)(H,332,378)(H,333,386)(H,334,398)(H,335,404)(H,336,421)(H,337,390)(H,338,358)(H,339,417)(H,340,422)(H,341,408)(H,342,409)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,371,372)(H,373,374)(H,375,376)(H,425,426)(H4,277,278,285)(H4,279,280,286)(H4,281,282,287)/t134-,135-,136-,137-,154-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,214-,215-,216-,217-,218-/m0/s1
DMG56EU	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC9=CN=CN9)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N
DMG56EU	IK	GVUGOAYIVIDWIO-UFWWTJHBSA-N
DMG56EU	IU	(4S)-5-[[(2S)-1-[[(2R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-[[2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-carboxy-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[(2S)-4-carboxy-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]butanoyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]butanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMG56EU	CA	CAS 62253-63-8
DMG56EU	DE	Discovery agent

DM7V58G	ID	DM7V58G
DM7V58G	DN	MG149
DM7V58G	HS	Investigative
DM7V58G	SN	MG-149; MG 149
DM7V58G	DT	Small molecular drug
DM7V58G	PC	49864204
DM7V58G	MW	340.5
DM7V58G	FM	C22H28O3
DM7V58G	IC	InChI=1S/C22H28O3/c1-2-3-4-5-6-8-17-11-13-18(14-12-17)15-16-19-9-7-10-20(23)21(19)22(24)25/h7,9-14,23H,2-6,8,15-16H2,1H3,(H,24,25)
DM7V58G	CS	CCCCCCCC1=CC=C(C=C1)CCC2=C(C(=CC=C2)O)C(=O)O
DM7V58G	IK	WBHQYBZRTAEHRR-UHFFFAOYSA-N
DM7V58G	IU	2-[2-(4-heptylphenyl)ethyl]-6-hydroxybenzoic acid
DM7V58G	DE	Discovery agent

DMN1F7Z	ID	DMN1F7Z
DMN1F7Z	DN	MG-28
DMN1F7Z	HS	Investigative
DMN1F7Z	SN	FAS inhibitor (cancer), Institut Catala d'Oncologia; Fatty acid synthase inhibitor (cancer), Institut Catala d'Oncologia
DMN1F7Z	CP	Institut Catala d'Oncologia
DMN1F7Z	DE	Solid tumour/cancer

DMIMKFZ	ID	DMIMKFZ
DMIMKFZ	DN	MGS0028
DMIMKFZ	HS	Investigative
DMIMKFZ	SN	MGS 0028; MGS-0028
DMIMKFZ	DT	Small molecular drug
DMIMKFZ	PC	9837317
DMIMKFZ	MW	217.15
DMIMKFZ	FM	C8H8FNO5
DMIMKFZ	IC	InChI=1S/C8H8FNO5/c9-8(6(14)15)3-2(11)1-7(10,4(3)8)5(12)13/h3-4H,1,10H2,(H,12,13)(H,14,15)/t3-,4-,7+,8-/m1/s1
DMIMKFZ	CS	C1C(=O)[C@@H]2[C@H]([C@@]1(C(=O)O)N)[C@]2(C(=O)O)F
DMIMKFZ	IK	KFAGJPNFERWZJA-JKBXLQNXSA-N
DMIMKFZ	IU	(1R,2S,5S,6S)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DMIMKFZ	CA	CAS 321963-33-1
DMIMKFZ	DE	Discovery agent

DMZ9MCR	ID	DMZ9MCR
DMZ9MCR	DN	MHL cyclohexylthiosemicarbazone
DMZ9MCR	HS	Investigative
DMZ9MCR	DT	Small molecular drug
DMZ9MCR	PC	135529100
DMZ9MCR	MW	645.7
DMZ9MCR	FM	C33H31N3O9S
DMZ9MCR	IC	InChI=1S/C33H31N3O9S/c1-13-19(37)11-18-23(26(13)38)30(42)25-24(27(18)39)29(41)22-17(31(25)45-2)9-8-14-10-15(21(32(43)44)28(40)20(14)22)12-34-36-33(46)35-16-6-4-3-5-7-16/h10-12,16,37-38,40-41H,3-9H2,1-2H3,(H,43,44)(H2,35,36,46)/b34-12+
DMZ9MCR	CS	CC1=C(C=C2C(=C1O)C(=O)C3=C(C4=C(C5=C(C(=C(C=C5CC4)/C=N/NC(=S)NC6CCCCC6)C(=O)O)O)C(=C3C2=O)O)OC)O
DMZ9MCR	IK	FVWBMJCLBWIYFZ-PONZDJLKSA-N
DMZ9MCR	IU	3-[(E)-(cyclohexylcarbamothioylhydrazinylidene)methyl]-1,9,11,14-tetrahydroxy-7-methoxy-10-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carboxylic acid
DMZ9MCR	DE	Discovery agent

DMCN91V	ID	DMCN91V
DMCN91V	DN	MI-1148
DMCN91V	HS	Investigative
DMCN91V	SN	4-guanidinomethyl-phenylacteyl-Arg-Tle-Arg-4-amidinobenzylamide; para-guanidinomethyl-Phac-R-Tle-R-Amba
DMCN91V	DT	Small molecular drug
DMCN91V	PC	91758390
DMCN91V	MW	763.9
DMCN91V	FM	C36H57N15O4
DMCN91V	IC	InChI=1S/C36H57N15O4/c1-36(2,3)28(32(55)50-25(6-4-16-45-33(39)40)30(53)47-19-23-12-14-24(15-13-23)29(37)38)51-31(54)26(7-5-17-46-34(41)42)49-27(52)18-21-8-10-22(11-9-21)20-48-35(43)44/h8-15,25-26,28H,4-7,16-20H2,1-3H3,(H3,37,38)(H,47,53)(H,49,52)(H,50,55)(H,51,54)(H4,39,40,45)(H4,41,42,46)(H4,43,44,48)/t25-,26-,28+/m0/s1
DMCN91V	CS	CC(C)(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC1=CC=C(C=C1)C(=N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CC2=CC=C(C=C2)CN=C(N)N
DMCN91V	IK	HXVPWVPTVOOCMV-UNCTUWKVSA-N
DMCN91V	IU	(2S)-N-[(2S)-1-[(4-carbamimidoylphenyl)methylamino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-[4-[(diaminomethylideneamino)methyl]phenyl]acetyl]amino]pentanoyl]amino]-3,3-dimethylbutanamide
DMCN91V	DE	Discovery agent

DM196LK	ID	DM196LK
DM196LK	DN	MI-219
DM196LK	HS	Investigative
DM196LK	SN	CHEMBL572933; (2'R,3S,4'R,5'R)-6-chloro-4'-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide; 908027-55-4; SCHEMBL2624351; BDBM50300121; US8680132, MI- 219; (2''R,3S,4''R,5''R)-6-chloro-4''-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2''-neopentyl-2-oxospiro[indoline-3,3''-pyrrolidine]-5''-carboxamide; (3S)-N-[(3S)-3,4-Dihydroxybutyl]-5-fluoro-6-chloro-2-oxo-2'alpha-(2,2-dimethylpropyl)-4'beta-(3-chlorophenyl)spiro[1H-indole-3(2H),3'-pyrrolidine]-5'alpha-carboxamide
DM196LK	DT	Small molecular drug
DM196LK	PC	24877503
DM196LK	MW	552.5
DM196LK	FM	C27H32Cl2FN3O4
DM196LK	IC	InChI=1S/C27H32Cl2FN3O4/c1-26(2,3)12-21-27(17-10-19(30)18(29)11-20(17)32-25(27)37)22(14-5-4-6-15(28)9-14)23(33-21)24(36)31-8-7-16(35)13-34/h4-6,9-11,16,21-23,33-35H,7-8,12-13H2,1-3H3,(H,31,36)(H,32,37)/t16-,21+,22-,23+,27-/m0/s1
DM196LK	CS	CC(C)(C)C[C@@H]1[C@]2([C@H]([C@@H](N1)C(=O)NCC[C@@H](CO)O)C3=CC(=CC=C3)Cl)C4=CC(=C(C=C4NC2=O)Cl)F
DM196LK	IK	UNXQGBMZYKHQCO-NVHWNKAKSA-N
DM196LK	IU	(2'R,3S,3'R,5'R)-6-chloro-3'-(3-chlorophenyl)-N-[(3S)-3,4-dihydroxybutyl]-5'-(2,2-dimethylpropyl)-5-fluoro-2-oxospiro[1H-indole-3,4'-pyrrolidine]-2'-carboxamide
DM196LK	DE	Triple negative breast cancer

DMJ4D1P	ID	DMJ4D1P
DMJ4D1P	DN	Micrococcin
DMJ4D1P	HS	Investigative
DMJ4D1P	SN	Micrococcin P1; BRN 1070340; Micrococcin P, 13',19'-didehydro-19'-deoxy-28,44-dihydro-44-hydroxy-; 67401-56-3
DMJ4D1P	DT	Small molecular drug
DMJ4D1P	PC	5282052
DMJ4D1P	MW	1144.4
DMJ4D1P	FM	C48H49N13O9S6
DMJ4D1P	IC	InChI=1S/C48H49N13O9S6/c1-8-24(37(65)49-12-20(5)62)51-38(66)28-15-73-46(56-28)32-18-74-45(58-32)26-11-10-23-36(50-26)27-13-75-48(53-27)35(22(7)64)61-41(69)31-17-76-47(57-31)33(19(3)4)59-39(67)30-16-72-44(55-30)25(9-2)52-42(70)34(21(6)63)60-40(68)29-14-71-43(23)54-29/h8-11,13-22,33-35,62-64H,12H2,1-7H3,(H,49,65)(H,51,66)(H,52,70)(H,59,67)(H,60,68)(H,61,69)/b24-8-,25-9-/t20-,21+,22+,33+,34-,35-/m0/s1
DMJ4D1P	CS	C/C=C\\1/C2=NC(=CS2)C(=O)N[C@@H](C3=NC(=CS3)C(=O)N[C@H](C4=NC(=CS4)C5=C(C=CC(=N5)C6=NC(=CS6)C7=NC(=CS7)C(=O)N/C(=C\\C)/C(=O)NC[C@H](C)O)C8=NC(=CS8)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)[C@@H](C)O)C(C)C
DMJ4D1P	IK	MQGFYNRGFWXAKA-GXSYYHJRSA-N
DMJ4D1P	IU	2-[2-[(12S,19R,26Z,29S)-26-ethylidene-12,29-bis[(1R)-1-hydroxyethyl]-14,21,28,31-tetraoxo-19-propan-2-yl-10,17,24,34-tetrathia-6,13,20,27,30,35,36,37,38-nonazahexacyclo[30.2.1.18,11.115,18.122,25.02,7]octatriaconta-1(35),2(7),3,5,8,11(38),15,18(37),22,25(36),32-undecaen-5-yl]-1,3-thiazol-4-yl]-N-[(Z)-1-[[(2S)-2-hydroxypropyl]amino]-1-oxobut-2-en-2-yl]-1,3-thiazole-4-carboxamide
DMJ4D1P	CB	CHEBI:29631
DMJ4D1P	DE	Discovery agent

DMTMLRN	ID	DMTMLRN
DMTMLRN	DN	Microcystin-LR
DMTMLRN	HS	Investigative
DMTMLRN	SN	Akerstox; Microcystin-a; 5-L-Argininecyanoginosin LA; Toxin I (Microcystis aeruginosa); Cyanoginosin LA, 5-L-arginine-; Toxin T 17 (Microcystis aeruginosa); BRN 4779759; Toxin, blue green alga, Microcystis aeruginosa; AC1O5MXK; DTXSID00424146; 128657-50-1; LS-55782
DMTMLRN	DT	Small molecular drug
DMTMLRN	PC	445434
DMTMLRN	MW	995.2
DMTMLRN	FM	C49H74N10O12
DMTMLRN	IC	InChI=1S/C49H74N10O12/c1-26(2)23-37-46(66)58-40(48(69)70)30(6)42(62)55-35(17-14-22-52-49(50)51)45(65)54-34(19-18-27(3)24-28(4)38(71-10)25-33-15-12-11-13-16-33)29(5)41(61)56-36(47(67)68)20-21-39(60)59(9)32(8)44(64)53-31(7)43(63)57-37/h11-13,15-16,18-19,24,26,28-31,34-38,40H,8,14,17,20-23,25H2,1-7,9-10H3,(H,53,64)(H,54,65)(H,55,62)(H,56,61)(H,57,63)(H,58,66)(H,67,68)(H,69,70)(H4,50,51,52)/b19-18+,27-24+/t28-,29-,30-,31+,34-,35-,36+,37-,38-,40+/m0/s1
DMTMLRN	CS	C[C@H]1[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)C(=C)N(C(=O)CC[C@@H](NC1=O)C(=O)O)C)C)CC(C)C)C(=O)O)C)CCCN=C(N)N)/C=C/C(=C/[C@H](C)[C@H](CC2=CC=CC=C2)OC)/C
DMTMLRN	IK	ZYZCGGRZINLQBL-GWRQVWKTSA-N
DMTMLRN	IU	(5R,8S,11R,12S,15S,18S,19S,22R)-15-[3-(diaminomethylideneamino)propyl]-18-[(1E,3E,5S,6S)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl]-1,5,12,19-tetramethyl-2-methylidene-8-(2-methylpropyl)-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxylic acid
DMTMLRN	CA	CAS 101043-37-2
DMTMLRN	CB	CHEBI:6925
DMTMLRN	DE	Discovery agent

DM7Y9AD	ID	DM7Y9AD
DM7Y9AD	DN	Microxine
DM7Y9AD	HS	Investigative
DM7Y9AD	SN	microxine; CHEMBL478797; SCHEMBL18686351; BDBM50269842
DM7Y9AD	TC	Analgesics
DM7Y9AD	DT	Small molecular drug
DM7Y9AD	PC	10061827
DM7Y9AD	MW	273.27
DM7Y9AD	FM	C8H11N5O4S
DM7Y9AD	IC	InChI=1S/C8H11N5O4S/c1-13-5-6(9-2-3-18(15,16)17)10-4-11-7(5)12-8(13)14/h4H,2-3H2,1H3,(H,15,16,17)(H2,9,10,11,12,14)
DM7Y9AD	CS	CN1C2=C(NC1=O)N=CN=C2NCCS(=O)(=O)O
DM7Y9AD	IK	OTYWCUOKKIHICD-UHFFFAOYSA-N
DM7Y9AD	IU	2-[(7-methyl-8-oxo-9H-purin-6-yl)amino]ethanesulfonic acid
DM7Y9AD	DE	Pain

DM462BT	ID	DM462BT
DM462BT	DN	Milchsaure
DM462BT	HS	Investigative
DM462BT	SN	(+/-)-Lactic acid; 1-Hydroxyethanecarboxylic acid; 2-hydroxypropanoic acid; 2-hydroxypropionic acid; 26100-51-6; Acidum lacticum; Aethylidenmilchsaeure; DL-Lactic acid; DL-Milchsaeure; Ethylidenelactic acid; Kyselina 2-hydroxypropanova; Kyselina mlecna; Lactic acid; Lactic acid (natural); Lactic acid USP; Lacticum acidum; Lactovagan; Milchsaeure; Milchsaure; Milchsaure [German]; Milk acid; Ordinary lactic acid; Polylactic acid; Propanoic acid, 2-hydroxy-; Racemic lactic acid; Tonsillosan; alpha-Hydroxypropionic acid; lactate; lactic acid
DM462BT	DT	Small molecular drug
DM462BT	PC	612
DM462BT	MW	90.078
DM462BT	FM	C3H6O3
DM462BT	IC	InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)
DM462BT	CS	CC(C(=O)O)O
DM462BT	IK	JVTAAEKCZFNVCJ-UHFFFAOYSA-N
DM462BT	IU	2-hydroxypropanoic acid
DM462BT	CA	CAS 50-21-5
DM462BT	CB	CHEBI:78320
DM462BT	DE	Cardiotonic; Metabolic acidosis

DM6BANS	ID	DM6BANS
DM6BANS	DN	Miller-9E-enolide
DM6BANS	HS	Investigative
DM6BANS	SN	miller-9E-enolide; CHEMBL187789; (4R,5E,11S)-2,3,3abeta,4,7,8,9,10,11,11aalpha-Decahydro-2-oxo-3,10-bismethylene-11-hydroxy-4-(methacryloyloxy)cyclodeca[b]furan-6-carbaldehyde
DM6BANS	DT	Small molecular drug
DM6BANS	PC	44398214
DM6BANS	MW	346.4
DM6BANS	FM	C19H22O6
DM6BANS	IC	InChI=1S/C19H22O6/c1-10(2)18(22)24-14-8-13(9-20)7-5-6-11(3)16(21)17-15(14)12(4)19(23)25-17/h8-9,14-17,21H,1,3-7H2,2H3/b13-8+/t14-,15-,16+,17+/m1/s1
DM6BANS	CS	CC(=C)C(=O)O[C@@H]1/C=C(\\CCCC(=C)[C@@H]([C@@H]2[C@@H]1C(=C)C(=O)O2)O)/C=O
DM6BANS	IK	CCWGXWKAXMNGSZ-PBMXCAIQSA-N
DM6BANS	IU	[(3aR,4R,5E,11S,11aS)-6-formyl-11-hydroxy-3,10-dimethylidene-2-oxo-4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DM6BANS	DE	Discovery agent

DMFMOX5	ID	DMFMOX5
DMFMOX5	DN	Miller-9Z-enolide
DMFMOX5	HS	Investigative
DMFMOX5	SN	miller-9Z-enolide
DMFMOX5	DT	Small molecular drug
DMFMOX5	PC	12015910
DMFMOX5	MW	346.4
DMFMOX5	FM	C19H22O6
DMFMOX5	IC	InChI=1S/C19H22O6/c1-10(2)18(22)24-14-8-13(9-20)7-5-6-11(3)16(21)17-15(14)12(4)19(23)25-17/h8-9,14-17,21H,1,3-7H2,2H3/b13-8-/t14-,15-,16+,17+/m1/s1
DMFMOX5	CS	CC(=C)C(=O)O[C@@H]1/C=C(/CCCC(=C)[C@@H]([C@@H]2[C@@H]1C(=C)C(=O)O2)O)\\C=O
DMFMOX5	IK	CCWGXWKAXMNGSZ-KSKPACDFSA-N
DMFMOX5	IU	[(3aR,4R,5Z,11S,11aS)-6-formyl-11-hydroxy-3,10-dimethylidene-2-oxo-4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DMFMOX5	DE	Discovery agent

DM7DT20	ID	DM7DT20
DM7DT20	DN	Mimovax
DM7DT20	HS	Investigative
DM7DT20	SN	MV-01; AFFITOPE-based vaccine targeting truncated Abeta40/42 (Alzheimer's disease), AFFiRiS
DM7DT20	CP	AFFiRiS AG
DM7DT20	DT	Vaccine
DM7DT20	DE	Alzheimer disease

DMDQK9G	ID	DMDQK9G
DMDQK9G	DN	Miocamycin
DMDQK9G	HS	Investigative
DMDQK9G	SN	Macroral; Midecamycin acetate (JP17); Midecamycin acetate [JAN]; Miocamen; Miocamycin; Miocamycin (TN); Miocamycine; Miokamycin; Myocamicin; Ponsinomycin; SCHEMBL139293; ZINC169677000; midecamycin acetate; 3'',9-Diacetylmydecamycin; 3T48CPS7U2; 55881-07-7; 9,3''-Di-O-Acetylmidecamycin; 9,3''-Diacetylmidecamycin; AC1NQZMS; Acecamycin; C45H71NO17; CHEMBL1091024; DTXSID60905087; EINECS 259-879-6; Leucomycin V, 3(sup B),9-diacetate 3,4(sup B)-dipropanoate; Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate; MOM; Mosil; UNII-3T48CPS7U2
DMDQK9G	PC	5282188
DMDQK9G	MW	898
DMDQK9G	FM	C45H71NO17
DMDQK9G	IC	GQNZGCARKRHPOH-RQIKCTSVSA-N
DMDQK9G	CS	CCC(=O)OC1CC(=O)OC(CC=CC=CC(C(CC(C(C1OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)OC(=O)CC)(C)OC(=O)C)N(C)C)O)CC=O)C)OC(=O)C)C
DMDQK9G	IK	1S/C45H71NO17/c1-13-34(50)59-33-23-36(52)55-26(4)18-16-15-17-19-32(58-29(7)48)25(3)22-31(20-21-47)41(42(33)54-12)62-44-39(53)38(46(10)11)40(27(5)57-44)61-37-24-45(9,63-30(8)49)43(28(6)56-37)60-35(51)14-2/h15-17,19,21,25-28,31-33,37-44,53H,13-14,18,20,22-24H2,1-12H3/b16-15+,19-17+/t25-,26-,27-,28+,31+,32+,33-,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1
DMDQK9G	IU	[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-10-acetyloxy-6-[(2S,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4-acetyloxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-4-yl] propanoate
DMDQK9G	CA	CAS 55881-07-7
DMDQK9G	DE	Pulmonary tuberculosis

DM2IGD1	ID	DM2IGD1
DM2IGD1	DN	MIP-1231
DM2IGD1	HS	Investigative
DM2IGD1	SN	MIP-1232; MIP-1233; MIP-1259; MIP-1260; MIP-1271; MIP-1272; Seprase inhibitors (cancer, imaging); Iodine-131-MIP-1232; Seprase inhibitors (cancer, imaging), Molecular Insight; FAP-alpha antagonists (cancer, imaging), Molecular Insight; Fibroblast-activating protein antagonists (cancer, imaging), Molecular Insight
DM2IGD1	CP	Molecular Insight Pharmaceuticals Inc
DM2IGD1	DE	Solid tumour/cancer

DM0J38I	ID	DM0J38I
DM0J38I	DN	MIP-1375
DM0J38I	HS	Investigative
DM0J38I	SN	PSMA inhibitor (prostate cancer), Molecular Insight; Prostate-specific membrane antigen inhibitor (prostate cancer), Molecular Insight
DM0J38I	CP	Molecular Insight Pharmaceuticals Inc
DM0J38I	DE	Prostate cancer

DM4P9LJ	ID	DM4P9LJ
DM4P9LJ	DN	MiR-375
DM4P9LJ	HS	Investigative
DM4P9LJ	DE	Discovery agent

DMYB0HK	ID	DMYB0HK
DMYB0HK	DN	Misonidazole
DMYB0HK	HS	Investigative
DMYB0HK	SN	Misonidazol [INN-Spanish]; Misonidazole; Misonidazolum [INN-Latin]; Ro 7-0582; SR 1354; SRI 1354; 1-(2'-hydroxy-3'-methoxypropyl)-2-nitroimidazole; 1-(2-Hydroxy-3-methoxypropyl)-2-nitroimidazole; 1-(2-NITRO-1-IMIDAZOLYL)-3-METHOXY-2-PROPANOL; 1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol; 1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol; 13551-87-6; BRN 0613655; CCRIS 1160; EINECS 236-931-6; MLS003115361; NSC-261,037; NSC-261037; NSC261037; alpha-(Methoxymethyl)-2-nitro-1H-imidazole-1-ethanol
DMYB0HK	PC	26105
DMYB0HK	MW	201.18
DMYB0HK	FM	C7H11N3O4
DMYB0HK	IC	OBBCSXFCDPPXOL-UHFFFAOYSA-N
DMYB0HK	CS	COCC(CN1C=CN=C1[N+](=O)[O-])O
DMYB0HK	IK	1S/C7H11N3O4/c1-14-5-6(11)4-9-3-2-8-7(9)10(12)13/h2-3,6,11H,4-5H2,1H3
DMYB0HK	IU	1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol
DMYB0HK	CA	CAS 13551-87-6
DMYB0HK	DE	Discovery agent

DM13TUY	ID	DM13TUY
DM13TUY	DN	MIV-710
DM13TUY	HS	Investigative
DM13TUY	SN	MIV-711; MIV-711); Cathepsin K inhibitor (oral, osteoporosis), Medivir
DM13TUY	CP	Medivir AB
DM13TUY	DE	Bone metastases

DMMP6YH	ID	DMMP6YH
DMMP6YH	DN	MJ-451
DMMP6YH	HS	Investigative
DMMP6YH	SN	129655-17-0; potassium channel openers, National Taiwan University
DMMP6YH	PC	9818365
DMMP6YH	MW	316.35
DMMP6YH	FM	C17H20N2O4
DMMP6YH	IC	InChI=1S/C17H20N2O4/c1-17(2)16(22)15(19-11(9-20)4-6-14(19)21)12-7-10(8-18)3-5-13(12)23-17/h3,5,7,11,15-16,20,22H,4,6,9H2,1-2H3/t11-,15+,16-/m0/s1
DMMP6YH	CS	CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N3[C@@H](CCC3=O)CO)O)C
DMMP6YH	IK	PBEGNZBJXJTFMB-XZJROXQQSA-N
DMMP6YH	IU	(3S,4R)-3-hydroxy-4-[(2S)-2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile
DMMP6YH	CA	CAS 129655-17-0
DMMP6YH	DE	Discovery agent

DMRSBWT	ID	DMRSBWT
DMRSBWT	DN	MJN228
DMRSBWT	HS	Investigative
DMRSBWT	SN	MJN228; SCHEMBL602647; GTPL8515; MolPort-044-561-486; ZINC114193322
DMRSBWT	DT	Small molecular drug
DMRSBWT	PC	22660592
DMRSBWT	MW	364.4
DMRSBWT	FM	C20H20N4O3
DMRSBWT	IC	InChI=1S/C20H20N4O3/c1-22-9-11-23(12-10-22)20(25)19-18(14-5-3-2-4-6-14)16-13-15(24(26)27)7-8-17(16)21-19/h2-8,13,21H,9-12H2,1H3
DMRSBWT	CS	CN1CCN(CC1)C(=O)C2=C(C3=C(N2)C=CC(=C3)[N+](=O)[O-])C4=CC=CC=C4
DMRSBWT	IK	BLSWPPPBUQFKHH-UHFFFAOYSA-N
DMRSBWT	IU	(4-methylpiperazin-1-yl)-(5-nitro-3-phenyl-1H-indol-2-yl)methanone
DMRSBWT	DE	Discovery agent

DMTFRLO	ID	DMTFRLO
DMTFRLO	DN	MK-0343
DMTFRLO	HS	Investigative
DMTFRLO	SN	GABA-A alpha-2/alpha-3 agonists (anxiolytics), Merck & Co; IDDBCP174406; MRK-409; TPA-023B
DMTFRLO	PC	22609888
DMTFRLO	MW	397.4
DMTFRLO	FM	C19H17F2N7O
DMTFRLO	IC	InChI=1S/C19H17F2N7O/c1-27-16(22-10-23-27)9-29-19-12(11-4-2-5-11)8-15-24-25-18(28(15)26-19)17-13(20)6-3-7-14(17)21/h3,6-8,10-11H,2,4-5,9H2,1H3
DMTFRLO	CS	CN1C(=NC=N1)COC2=NN3C(=NN=C3C4=C(C=CC=C4F)F)C=C2C5CCC5
DMTFRLO	IK	GOIFCXRIFSYPFG-UHFFFAOYSA-N
DMTFRLO	IU	7-cyclobutyl-3-(2,6-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine
DMTFRLO	CA	CAS 233275-76-8
DMTFRLO	DE	Discovery agent

DMVBFJP	ID	DMVBFJP
DMVBFJP	DN	MK-0668
DMVBFJP	HS	Investigative
DMVBFJP	SN	MK-0668; UNII-S441P37178; CHEMBL506044; S441P37178; 865110-07-2; SCHEMBL13884454; BDBM50423686; N-(N-((3-Cyanophenyl)sulfonyl)-4(R)-cyclobutylamino-(l)-prolyl)-4-((3',5'-dichloroisonicotinoyl) amino)-(l)-phenylalanine; L-Phenylalanine, (4R)-1-((3-cyanophenyl)sulfonyl)-4-(cyclobutylamino)-L-prolyl-4-(((3,5-dichloro-4-pyridinyl)carbonyl)amino)-
DMVBFJP	DT	Small molecular drug
DMVBFJP	PC	11433918
DMVBFJP	MW	685.6
DMVBFJP	FM	C31H30Cl2N6O6S
DMVBFJP	IC	InChI=1S/C31H30Cl2N6O6S/c32-24-15-35-16-25(33)28(24)30(41)37-21-9-7-18(8-10-21)12-26(31(42)43)38-29(40)27-13-22(36-20-4-2-5-20)17-39(27)46(44,45)23-6-1-3-19(11-23)14-34/h1,3,6-11,15-16,20,22,26-27,36H,2,4-5,12-13,17H2,(H,37,41)(H,38,40)(H,42,43)/t22-,26+,27+/m1/s1
DMVBFJP	CS	C1CC(C1)N[C@@H]2C[C@H](N(C2)S(=O)(=O)C3=CC=CC(=C3)C#N)C(=O)N[C@@H](CC4=CC=C(C=C4)NC(=O)C5=C(C=NC=C5Cl)Cl)C(=O)O
DMVBFJP	IK	USYYNLPEWBGIMJ-ICTDUYRTSA-N
DMVBFJP	IU	(2S)-2-[[(2S,4R)-1-(3-cyanophenyl)sulfonyl-4-(cyclobutylamino)pyrrolidine-2-carbonyl]amino]-3-[4-[(3,5-dichloropyridine-4-carbonyl)amino]phenyl]propanoic acid
DMVBFJP	CA	CAS 865110-07-2
DMVBFJP	DE	Discovery agent

DMI7859	ID	DMI7859
DMI7859	DN	MK-10
DMI7859	HS	Investigative
DMI7859	SN	MK-10
DMI7859	DT	Small molecular drug
DMI7859	PC	46877881
DMI7859	MW	813.9
DMI7859	FM	C41H55N11O7
DMI7859	IC	InChI=1S/C41H55N11O7/c42-36(55)29-14-6-7-19-45-34(53)17-18-35(54)52-21-9-16-33(52)40(59)51-31(22-25-10-2-1-3-11-25)38(57)49-30(15-8-20-46-41(43)44)37(56)50-32(39(58)48-29)23-26-24-47-28-13-5-4-12-27(26)28/h1-5,10-13,24,29-33,47H,6-9,14-23H2,(H2,42,55)(H,45,53)(H,48,58)(H,49,57)(H,50,56)(H,51,59)(H4,43,44,46)/t29-,30+,31-,32-,33+/m0/s1
DMI7859	CS	C1CCNC(=O)CCC(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5
DMI7859	IK	RSZGGZUMSYSTES-HJCKZFGESA-N
DMI7859	IU	(11S,14S,17R,20S,23R)-20-benzyl-17-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-2,5,13,16,19,22-hexaoxo-1,6,12,15,18,21-hexazabicyclo[21.3.0]hexacosane-11-carboxamide
DMI7859	DE	Discovery agent

DM4FG32	ID	DM4FG32
DM4FG32	DN	MK-11
DM4FG32	HS	Investigative
DM4FG32	SN	Menaquinone 11; Vitamin MK 11; 19228-10-5; MK-11; menaquinone-11; 2-METHYL-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-UNDECAMETHYLTETRATETRACONTA-2,6,10,14,18,22,26,30,34,38,42-UNDECAEN-1-YL]NAPHTHALENE-1,4-DIONE; AC1O5WR2; MK11; SCHEMBL14164358; MK 11; ZINC150341901; 2-methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaenyl]naphthalene-1,4-dione
DM4FG32	DT	Small molecular drug
DM4FG32	PC	6442190
DM4FG32	MW	921.5
DM4FG32	FM	C66H96O2
DM4FG32	IC	InChI=1S/C66H96O2/c1-50(2)26-16-27-51(3)28-17-29-52(4)30-18-31-53(5)32-19-33-54(6)34-20-35-55(7)36-21-37-56(8)38-22-39-57(9)40-23-41-58(10)42-24-43-59(11)44-25-45-60(12)48-49-62-61(13)65(67)63-46-14-15-47-64(63)66(62)68/h14-15,26,28,30,32,34,36,38,40,42,44,46-48H,16-25,27,29,31,33,35,37,39,41,43,45,49H2,1-13H3/b51-28+,52-30+,53-32+,54-34+,55-36+,56-38+,57-40+,58-42+,59-44+,60-48+
DM4FG32	CS	CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DM4FG32	IK	YYDMANIEKFAEJC-RYZSZPJESA-N
DM4FG32	IU	2-methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaenyl]naphthalene-1,4-dione
DM4FG32	CA	CAS 19228-10-5
DM4FG32	DE	Discovery agent

DM3NDWK	ID	DM3NDWK
DM3NDWK	DN	MK-1925
DM3NDWK	HS	Investigative
DM3NDWK	SN	CHEMBL560667; MK-1925; SCHEMBL3540877; BDBM50296579
DM3NDWK	DT	Small molecular drug
DM3NDWK	PC	44178080
DM3NDWK	MW	362.4
DM3NDWK	FM	C19H21F3N4
DM3NDWK	IC	InChI=1S/C19H21F3N4/c1-12-18(11-24-17-4-3-14(20)10-17)25-26(6-2-5-23)19(12)13-7-15(21)9-16(22)8-13/h7-9,14,17,24H,2-4,6,10-11H2,1H3/t14-,17+/m1/s1
DM3NDWK	CS	CC1=C(N(N=C1CN[C@H]2CC[C@H](C2)F)CCC#N)C3=CC(=CC(=C3)F)F
DM3NDWK	IK	LJTOZIFFXNLWEQ-PBHICJAKSA-N
DM3NDWK	IU	3-[5-(3,5-difluorophenyl)-3-[[[(1S,3R)-3-fluorocyclopentyl]amino]methyl]-4-methylpyrazol-1-yl]propanenitrile
DM3NDWK	DE	Discovery agent

DMYO8T6	ID	DMYO8T6
DMYO8T6	DN	MK-212
DMYO8T6	HS	Investigative
DMYO8T6	SN	64022-27-1
DMYO8T6	DT	Small molecular drug
DMYO8T6	PC	107992
DMYO8T6	MW	198.65
DMYO8T6	FM	C8H11ClN4
DMYO8T6	IC	InChI=1S/C8H11ClN4/c9-7-5-11-6-8(12-7)13-3-1-10-2-4-13/h5-6,10H,1-4H2
DMYO8T6	CS	C1CN(CCN1)C2=CN=CC(=N2)Cl
DMYO8T6	IK	CJAWPFJGFFNXQI-UHFFFAOYSA-N
DMYO8T6	IU	2-chloro-6-piperazin-1-ylpyrazine
DMYO8T6	CA	CAS 64022-27-1
DMYO8T6	CB	CHEBI:92360
DMYO8T6	DE	Discovery agent

DMP4Q0J	ID	DMP4Q0J
DMP4Q0J	DN	MK-2894
DMP4Q0J	HS	Investigative
DMP4Q0J	SN	EP4 antagonists (inflammatory pain); L-161982; MF-310; MF-498; MF-592; MF-766; EP4 antagonists (inflammatory pain), Merck Frosst Canada; Prostaglandin E2 subtype 4 receptor antagonists (pain/inflammation), Merck Frosst
DMP4Q0J	CP	Merck Frosst Canada & Co
DMP4Q0J	DT	Small molecular drug
DMP4Q0J	PC	24952929
DMP4Q0J	MW	473.5
DMP4Q0J	FM	C25H22F3NO3S
DMP4Q0J	IC	InChI=1S/C25H22F3NO3S/c1-14-20(13-16-3-7-19(8-4-16)25(26,27)28)21(15(2)33-14)22(30)29-24(11-12-24)18-9-5-17(6-10-18)23(31)32/h3-10H,11-13H2,1-2H3,(H,29,30)(H,31,32)
DMP4Q0J	CS	CC1=C(C(=C(S1)C)C(=O)NC2(CC2)C3=CC=C(C=C3)C(=O)O)CC4=CC=C(C=C4)C(F)(F)F
DMP4Q0J	IK	QJZQFVRFJCGDKF-UHFFFAOYSA-N
DMP4Q0J	IU	4-[1-[[2,5-dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]thiophene-3-carbonyl]amino]cyclopropyl]benzoic acid
DMP4Q0J	CA	CAS 1006036-87-8
DMP4Q0J	DE	Inflammation

DM5EQ7F	ID	DM5EQ7F
DM5EQ7F	DN	MK-3901
DM5EQ7F	HS	Investigative
DM5EQ7F	SN	P2X3 receptor antagonists (pain); P2X3 receptor antagonists (pain), Merck
DM5EQ7F	CP	Merck & Co Inc
DM5EQ7F	DE	Pain

DMS7C6R	ID	DMS7C6R
DMS7C6R	DN	MK-5046
DMS7C6R	HS	Investigative
DMS7C6R	SN	MK 5046; MK5046
DMS7C6R	DT	Small molecular drug
DMS7C6R	PC	49871766
DMS7C6R	MW	444.4
DMS7C6R	FM	C20H18F6N4O
DMS7C6R	IC	InChI=1S/C20H18F6N4O/c21-19(22,23)17(6-7-17)10-14-12-27-16(29-14)11-18(31,20(24,25)26)13-2-4-15(5-3-13)30-9-1-8-28-30/h1-5,8-9,12,31H,6-7,10-11H2,(H,27,29)/t18-/m0/s1
DMS7C6R	CS	C1CC1(CC2=CN=C(N2)C[C@](C3=CC=C(C=C3)N4C=CC=N4)(C(F)(F)F)O)C(F)(F)F
DMS7C6R	IK	UJINBEQCDMOAHM-SFHVURJKSA-N
DMS7C6R	IU	(2S)-1,1,1-trifluoro-2-(4-pyrazol-1-ylphenyl)-3-[5-[[1-(trifluoromethyl)cyclopropyl]methyl]-1H-imidazol-2-yl]propan-2-ol
DMS7C6R	DE	Discovery agent

DMU8VRB	ID	DMU8VRB
DMU8VRB	DN	MK-5435
DMU8VRB	HS	Investigative
DMU8VRB	SN	DFMTI; CHEMBL579062; 864864-86-8; MK-5435; SCHEMBL1500017; GTPL6335; KKZVYGIANGOHBS-UHFFFAOYSA-N; MolPort-044-724-496; KS-00001CM3; BDBM50301804; ZINC13983201; AKOS032944969; CS-5849; HY-100404; M-265; L023906; 2-Isopropyl-5-[1-(2,4-difluorophenyl)-5-methyl-1H-1,2,3-triazole-4-yl]isoindoline-1-one; 5-[1-(2,4-difluorophenyl)-5-methyltriazol-4-yl]-2-propan-2-yl-3H-isoindol-1-one.; 5-[1-(2,4-difluorophenyl)-5-methyltriazol-4-yl]-2-propan-2-yl-3H-isoindol-1-one
DMU8VRB	DT	Small molecular drug
DMU8VRB	PC	15985251
DMU8VRB	MW	368.4
DMU8VRB	FM	C20H18F2N4O
DMU8VRB	IC	InChI=1S/C20H18F2N4O/c1-11(2)25-10-14-8-13(4-6-16(14)20(25)27)19-12(3)26(24-23-19)18-7-5-15(21)9-17(18)22/h4-9,11H,10H2,1-3H3
DMU8VRB	CS	CC1=C(N=NN1C2=C(C=C(C=C2)F)F)C3=CC4=C(C=C3)C(=O)N(C4)C(C)C
DMU8VRB	IK	KKZVYGIANGOHBS-UHFFFAOYSA-N
DMU8VRB	IU	5-[1-(2,4-difluorophenyl)-5-methyltriazol-4-yl]-2-propan-2-yl-3H-isoindol-1-one
DMU8VRB	DE	Discovery agent

DMLWMZ4	ID	DMLWMZ4
DMLWMZ4	DN	MK-5596
DMLWMZ4	HS	Investigative
DMLWMZ4	SN	CB1 inverse agonists (obesity), Merck
DMLWMZ4	CP	Merck Research Laboratories
DMLWMZ4	DT	Small molecular drug
DMLWMZ4	PC	24871527
DMLWMZ4	MW	541.9
DMLWMZ4	FM	C27H23Cl3N4O2
DMLWMZ4	IC	InChI=1S/C27H23Cl3N4O2/c1-14-10-22(34-33-14)25(35)31-23-13-27(2,3)36-26-20(23)12-19(15-4-6-16(28)7-5-15)24(32-26)18-9-8-17(29)11-21(18)30/h4-12,23H,13H2,1-3H3,(H,31,35)(H,33,34)/t23-/m1/s1
DMLWMZ4	CS	CC1=CC(=NN1)C(=O)N[C@@H]2CC(OC3=C2C=C(C(=N3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)(C)C
DMLWMZ4	IK	IDUFEEHNNASCMH-HSZRJFAPSA-N
DMLWMZ4	IU	N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide
DMLWMZ4	DE	Obesity

DMR9C4Q	ID	DMR9C4Q
DMR9C4Q	DN	MK-6892
DMR9C4Q	HS	Investigative
DMR9C4Q	SN	Nicotinic acid 1 receptor (GPR109A) agonists, Merck
DMR9C4Q	CP	Merck Frosst Canada & Co
DMR9C4Q	DT	Small molecular drug
DMR9C4Q	PC	135416394
DMR9C4Q	MW	386.4
DMR9C4Q	FM	C19H22N4O5
DMR9C4Q	IC	InChI=1S/C19H22N4O5/c1-19(2,18(27)21-13-6-4-3-5-12(13)17(25)26)9-15-22-16(23-28-15)14-8-7-11(24)10-20-14/h7-8,10,24H,3-6,9H2,1-2H3,(H,21,27)(H,25,26)
DMR9C4Q	CS	CC(C)(CC1=NC(=NO1)C2=NC=C(C=C2)O)C(=O)NC3=C(CCCC3)C(=O)O
DMR9C4Q	IK	CJHXBFSJXDUJHP-UHFFFAOYSA-N
DMR9C4Q	IU	2-[[3-[3-(5-hydroxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylpropanoyl]amino]cyclohexene-1-carboxylic acid
DMR9C4Q	CA	CAS 917910-45-3
DMR9C4Q	DE	Arteriosclerosis

DM4YQV0	ID	DM4YQV0
DM4YQV0	DN	MK-771
DM4YQV0	HS	Investigative
DM4YQV0	SN	66537-55-1
DM4YQV0	DT	Small molecular drug
DM4YQV0	PC	163122
DM4YQV0	MW	394.5
DM4YQV0	FM	C16H22N6O4S
DM4YQV0	IC	InChI=1S/C16H22N6O4S/c17-14(24)12-6-27-8-22(12)16(26)11(4-9-5-18-7-19-9)21-15(25)10-2-1-3-13(23)20-10/h5,7,10-12H,1-4,6,8H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12+/m0/s1
DM4YQV0	CS	C1C[C@H](NC(=O)C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CSC[C@@H]3C(=O)N
DM4YQV0	IK	OGUDACTYCTVDNZ-SDDRHHMPSA-N
DM4YQV0	IU	(4S)-3-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-6-oxopiperidine-2-carbonyl]amino]propanoyl]-1,3-thiazolidine-4-carboxamide
DM4YQV0	CA	CAS 66537-55-1
DM4YQV0	DE	Discovery agent

DM3EP59	ID	DM3EP59
DM3EP59	DN	MK-7725
DM3EP59	HS	Investigative
DM3EP59	SN	BRS-3 agonists (obesity); BRS-3 agonists (obesity), Merck; Bombesin receptor subtype-3 agonists (obesity), Merck
DM3EP59	CP	Merck & Co Inc
DM3EP59	DT	Small molecular drug
DM3EP59	PC	46200989
DM3EP59	MW	615.5
DM3EP59	FM	C25H19F6N5O5S
DM3EP59	IC	InChI=1S/C25H19F6N5O5S/c1-23(2,37)22-34-21(35-41-22)16-4-3-5-17-19(16)36(12-13-6-11-18(24(26,27)28)33-20(13)32-17)42(38,39)15-9-7-14(8-10-15)40-25(29,30)31/h3-11,37H,12H2,1-2H3,(H,32,33)
DM3EP59	CS	CC(C)(C1=NC(=NO1)C2=C3C(=CC=C2)NC4=C(CN3S(=O)(=O)C5=CC=C(C=C5)OC(F)(F)F)C=CC(=N4)C(F)(F)F)O
DM3EP59	IK	WQQNCCUPGPFWOI-UHFFFAOYSA-N
DM3EP59	IU	2-[3-[6-[4-(trifluoromethoxy)phenyl]sulfonyl-2-(trifluoromethyl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-7-yl]-1,2,4-oxadiazol-5-yl]propan-2-ol
DM3EP59	CA	CAS 1034152-95-8
DM3EP59	DE	Obesity

DMKEG2B	ID	DMKEG2B
DMKEG2B	DN	MK-9
DMKEG2B	HS	Investigative
DMKEG2B	PC	6289935
DMKEG2B	MW	785.2
DMKEG2B	FM	C56H80O2
DMKEG2B	IC	InChI=1S/C56H80O2/c1-42(2)22-14-23-43(3)24-15-25-44(4)26-16-27-45(5)28-17-29-46(6)30-18-31-47(7)32-19-33-48(8)34-20-35-49(9)36-21-37-50(10)40-41-52-51(11)55(57)53-38-12-13-39-54(53)56(52)58/h12-13,22,24,26,28,30,32,34,36,38-40H,14-21,23,25,27,29,31,33,35,37,41H2,1-11H3/b43-24+,44-26+,45-28+,46-30+,47-32+,48-34+,49-36+,50-40+
DMKEG2B	CS	CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DMKEG2B	IK	WCRXHNIUHQUASO-UVZVDVBNSA-N
DMKEG2B	IU	2-methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]naphthalene-1,4-dione
DMKEG2B	CA	CAS 523-39-7
DMKEG2B	CB	CHEBI:44147
DMKEG2B	DE	Discovery agent

DM4ZNOU	ID	DM4ZNOU
DM4ZNOU	DN	ML 10375
DM4ZNOU	HS	Investigative
DM4ZNOU	SN	ML-10375; ML10375
DM4ZNOU	DT	Small molecular drug
DM4ZNOU	PC	9905972
DM4ZNOU	MW	340.8
DM4ZNOU	FM	C17H25ClN2O3
DM4ZNOU	IC	InChI=1S/C17H25ClN2O3/c1-11-6-12(2)10-20(9-11)4-5-23-17(21)13-7-14(18)15(19)8-16(13)22-3/h7-8,11-12H,4-6,9-10,19H2,1-3H3
DM4ZNOU	CS	CC1CC(CN(C1)CCOC(=O)C2=CC(=C(C=C2OC)N)Cl)C
DM4ZNOU	IK	BUEFUOFMOXJXAR-UHFFFAOYSA-N
DM4ZNOU	IU	2-(3,5-dimethylpiperidin-1-yl)ethyl 4-amino-5-chloro-2-methoxybenzoate
DM4ZNOU	DE	Discovery agent

DMM5P8Q	ID	DMM5P8Q
DMM5P8Q	DN	ML-10302
DMM5P8Q	HS	Investigative
DMM5P8Q	SN	148868-55-7
DMM5P8Q	DT	Small molecular drug
DMM5P8Q	PC	5311299
DMM5P8Q	MW	312.79
DMM5P8Q	FM	C15H21ClN2O3
DMM5P8Q	IC	InChI=1S/C15H21ClN2O3/c1-20-14-10-13(17)12(16)9-11(14)15(19)21-8-7-18-5-3-2-4-6-18/h9-10H,2-8,17H2,1H3
DMM5P8Q	CS	COC1=CC(=C(C=C1C(=O)OCCN2CCCCC2)Cl)N
DMM5P8Q	IK	RVFIAQAAZUEPPE-UHFFFAOYSA-N
DMM5P8Q	IU	2-piperidin-1-ylethyl 4-amino-5-chloro-2-methoxybenzoate
DMM5P8Q	CA	CAS 148868-55-7
DMM5P8Q	DE	Discovery agent

DMPB7EL	ID	DMPB7EL
DMPB7EL	DN	ML169
DMPB7EL	HS	Investigative
DMPB7EL	SN	VU0405652; ML-169
DMPB7EL	DT	Small molecular drug
DMPB7EL	PC	44475955
DMPB7EL	MW	506.3
DMPB7EL	FM	C21H17BrFN3O4S
DMPB7EL	IC	InChI=1S/C21H17BrFN3O4S/c1-13-8-20(25-30-13)24-21(27)12-31(28,29)19-11-26(18-5-3-2-4-16(18)19)10-14-9-15(22)6-7-17(14)23/h2-9,11H,10,12H2,1H3,(H,24,25,27)
DMPB7EL	CS	CC1=CC(=NO1)NC(=O)CS(=O)(=O)C2=CN(C3=CC=CC=C32)CC4=C(C=CC(=C4)Br)F
DMPB7EL	IK	RUYRNYRGPSAXTK-UHFFFAOYSA-N
DMPB7EL	IU	2-[1-[(5-bromo-2-fluorophenyl)methyl]indol-3-yl]sulfonyl-N-(5-methyl-1,2-oxazol-3-yl)acetamide
DMPB7EL	DE	Discovery agent

DMHJCN6	ID	DMHJCN6
DMHJCN6	DN	ML-18
DMHJCN6	HS	Investigative
DMHJCN6	SN	ML-18; ML 18; 1422269-30-4; GTPL8505; MolPort-039-338-066; ZINC263621864; AKOS027470221; CS-6869; HY-101844; ML-18,,ML18,ML-18,ML 18,BRS-3 antagonist,1422269-30-4; (2S)-3-(1H-indol-3-yl)-N-{[1-(4-methoxyphenyl)cyclohexyl]methyl}-2-{[(4-nitrophenyl)carbamoyl]amino}propanamide
DMHJCN6	DT	Small molecular drug
DMHJCN6	PC	91827363
DMHJCN6	MW	569.6
DMHJCN6	FM	C32H35N5O5
DMHJCN6	IC	InChI=1S/C32H35N5O5/c1-42-26-15-9-23(10-16-26)32(17-5-2-6-18-32)21-34-30(38)29(19-22-20-33-28-8-4-3-7-27(22)28)36-31(39)35-24-11-13-25(14-12-24)37(40)41/h3-4,7-16,20,29,33H,2,5-6,17-19,21H2,1H3,(H,34,38)(H2,35,36,39)/t29-/m0/s1
DMHJCN6	CS	COC1=CC=C(C=C1)C2(CCCCC2)CNC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)NC5=CC=C(C=C5)[N+](=O)[O-]
DMHJCN6	IK	JOKVJNCYOSFDGC-LJAQVGFWSA-N
DMHJCN6	IU	(2S)-3-(1H-indol-3-yl)-N-[[1-(4-methoxyphenyl)cyclohexyl]methyl]-2-[(4-nitrophenyl)carbamoylamino]propanamide
DMHJCN6	DE	Discovery agent

DM15YL0	ID	DM15YL0
DM15YL0	DN	ML204
DM15YL0	HS	Investigative
DM15YL0	SN	5465-86-1; ML204; ML 204; 4-methyl-2-(piperidin-1-yl)quinoline; 4-Methyl-2-(1-piperidinyl)-quinoline; 4-methyl-2-piperidin-1-ylquinoline; 4-Methyl-2-(1-piperidinyl)quinoline; VU0024172-3; NSC25850; AC1Q4W9R; Cambridge id 5563912; AC1L5K4A; MLS001007138; 4-methyl-2-piperidylquinoline; 4-methyl-2-piperidinoquinoline; 2-Piperidino-4-methylquinoline; GTPL4255; cid_230710; 4-methyl-2-piperidino-quinoline; SCHEMBL14975993; CHEMBL1459962; CTK5A2131; BDBM77617; DTXSID30282438; EX-A938; AOB1526; MolPort-000-220-757; HMS2704E20; BCP28617
DM15YL0	DT	Small molecular drug
DM15YL0	PC	230710
DM15YL0	MW	226.32
DM15YL0	FM	C15H18N2
DM15YL0	IC	InChI=1S/C15H18N2/c1-12-11-15(17-9-5-2-6-10-17)16-14-8-4-3-7-13(12)14/h3-4,7-8,11H,2,5-6,9-10H2,1H3
DM15YL0	CS	CC1=CC(=NC2=CC=CC=C12)N3CCCCC3
DM15YL0	IK	USYRQXDHKXGTCK-UHFFFAOYSA-N
DM15YL0	IU	4-methyl-2-piperidin-1-ylquinoline
DM15YL0	CA	CAS 5465-86-1
DM15YL0	DE	Discovery agent

DMFAUGP	ID	DMFAUGP
DMFAUGP	DN	ML213
DMFAUGP	HS	Investigative
DMFAUGP	SN	ML 213; ML-213
DMFAUGP	DT	Small molecular drug
DMFAUGP	PC	3111211
DMFAUGP	MW	257.37
DMFAUGP	FM	C17H23NO
DMFAUGP	IC	InChI=1S/C17H23NO/c1-10-6-11(2)16(12(3)7-10)18-17(19)15-9-13-4-5-14(15)8-13/h6-7,13-15H,4-5,8-9H2,1-3H3,(H,18,19)
DMFAUGP	CS	CC1=CC(=C(C(=C1)C)NC(=O)C2CC3CCC2C3)C
DMFAUGP	IK	SIQGKPGBLYKQBB-UHFFFAOYSA-N
DMFAUGP	IU	N-(2,4,6-trimethylphenyl)bicyclo[2.2.1]heptane-2-carboxamide
DMFAUGP	CA	CAS 489402-47-3
DMFAUGP	CB	CHEBI:91537
DMFAUGP	DE	Discovery agent

DM3D21X	ID	DM3D21X
DM3D21X	DN	ML218
DM3D21X	HS	Investigative
DM3D21X	SN	ML-218; ML 218
DM3D21X	DT	Small molecular drug
DM3D21X	PC	45115620
DM3D21X	MW	369.3
DM3D21X	FM	C19H26Cl2N2O
DM3D21X	IC	InChI=1S/C19H26Cl2N2O/c1-19(2,3)4-5-23-10-16-15(17(16)11-23)9-22-18(24)12-6-13(20)8-14(21)7-12/h6-8,15-17H,4-5,9-11H2,1-3H3,(H,22,24)/t15?,16-,17+
DM3D21X	CS	CC(C)(C)CCN1C[C@@H]2[C@H](C1)C2CNC(=O)C3=CC(=CC(=C3)Cl)Cl
DM3D21X	IK	GSJIGYLGKSBYBC-ALOPSCKCSA-N
DM3D21X	IU	3,5-dichloro-N-[[(1R,5S)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]benzamide
DM3D21X	CB	CHEBI:91745
DM3D21X	DE	Discovery agent

DM3OEP4	ID	DM3OEP4
DM3OEP4	DN	ML221
DM3OEP4	HS	Investigative
DM3OEP4	SN	ML221; 877636-42-5; ML 221; CHEMBL2158347; ML-221; 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate; [4-oxo-6-(pyrimidin-2-ylsulfanylmethyl)pyran-3-yl] 4-nitrobenzoate; AC1OHVTH; MLS003389520; GTPL6282; SCHEMBL17326564; CHEBI:92965; AOB1262; MolPort-003-127-646; ZINC4377282; BCP28945; BDBM50393964; AKOS016372065; MCULE-7007021256; SB19613; AS-16633; SMR002078184; HY-103254; CS-0026651; J3.654.307H; MLS-0437359.0002; MLS-0437359.0001; AB00687545-01; SR-01000020403; SR-01000020403-1; F2510-0124
DM3OEP4	DT	Small molecular drug
DM3OEP4	PC	7217941
DM3OEP4	MW	385.4
DM3OEP4	FM	C17H11N3O6S
DM3OEP4	IC	InChI=1S/C17H11N3O6S/c21-14-8-13(10-27-17-18-6-1-7-19-17)25-9-15(14)26-16(22)11-2-4-12(5-3-11)20(23)24/h1-9H,10H2
DM3OEP4	CS	C1=CN=C(N=C1)SCC2=CC(=O)C(=CO2)OC(=O)C3=CC=C(C=C3)[N+](=O)[O-]
DM3OEP4	IK	UASIRTUMPRQVFY-UHFFFAOYSA-N
DM3OEP4	IU	[4-oxo-6-(pyrimidin-2-ylsulfanylmethyl)pyran-3-yl] 4-nitrobenzoate
DM3OEP4	CB	CHEBI:92965
DM3OEP4	DE	Discovery agent

DM8CIE4	ID	DM8CIE4
DM8CIE4	DN	ML233
DM8CIE4	HS	Investigative
DM8CIE4	SN	ML233; CHEMBL3819625; GTPL6314; AOB1202; ZINC96024633; BDBM50183380; MLS-0437644.0001; [(1E)-5-cyclohexyl-2-methyl-4-oxocyclohexa-2,5-dien-1-ylidene]amino benzenesulfonate
DM8CIE4	DT	Small molecular drug
DM8CIE4	PC	46905036
DM8CIE4	MW	359.4
DM8CIE4	FM	C19H21NO4S
DM8CIE4	IC	InChI=1S/C19H21NO4S/c1-14-12-19(21)17(15-8-4-2-5-9-15)13-18(14)20-24-25(22,23)16-10-6-3-7-11-16/h3,6-7,10-13,15H,2,4-5,8-9H2,1H3/b20-18-
DM8CIE4	CS	CC\\1=CC(=O)C(=C/C1=N/OS(=O)(=O)C2=CC=CC=C2)C3CCCCC3
DM8CIE4	IK	RSMZOLWJZGIWOV-ZZEZOPTASA-N
DM8CIE4	IU	[(Z)-(5-cyclohexyl-2-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)amino] benzenesulfonate
DM8CIE4	DE	Discovery agent

DMK6YC1	ID	DMK6YC1
DMK6YC1	DN	ML-253764
DMK6YC1	HS	Investigative
DMK6YC1	SN	CHEMBL40711; ML-253764; SCHEMBL3728758; ZINC3938671; BDBM50142895; 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1h-imidazole; 2-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-phenyl}-4,5-dihydro-1H-imidazole
DMK6YC1	DT	Small molecular drug
DMK6YC1	PC	9842665
DMK6YC1	MW	377.2
DMK6YC1	FM	C18H18BrFN2O
DMK6YC1	IC	InChI=1S/C18H18BrFN2O/c1-23-17-8-6-13(19)11-12(17)5-7-14-15(3-2-4-16(14)20)18-21-9-10-22-18/h2-4,6,8,11H,5,7,9-10H2,1H3,(H,21,22)
DMK6YC1	CS	COC1=C(C=C(C=C1)Br)CCC2=C(C=CC=C2F)C3=NCCN3
DMK6YC1	IK	WCPPZGPJRHLSKP-UHFFFAOYSA-N
DMK6YC1	IU	2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole
DMK6YC1	DE	Discovery agent

DMQ98RS	ID	DMQ98RS
DMQ98RS	DN	ML277
DMQ98RS	HS	Investigative
DMQ98RS	SN	ML-277; ML 277
DMQ98RS	DT	Small molecular drug
DMQ98RS	PC	53347902
DMQ98RS	MW	471.6
DMQ98RS	FM	C23H25N3O4S2
DMQ98RS	IC	InChI=1S/C23H25N3O4S2/c1-16-6-12-19(13-7-16)32(28,29)26-14-4-3-5-21(26)22(27)25-23-24-20(15-31-23)17-8-10-18(30-2)11-9-17/h6-13,15,21H,3-5,14H2,1-2H3,(H,24,25,27)/t21-/m1/s1
DMQ98RS	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCCC[C@@H]2C(=O)NC3=NC(=CS3)C4=CC=C(C=C4)OC
DMQ98RS	IK	OXQNLLVUVDAEHC-OAQYLSRUSA-N
DMQ98RS	IU	(2R)-N-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-1-(4-methylphenyl)sulfonylpiperidine-2-carboxamide
DMQ98RS	DE	Discovery agent

DMPOX4Q	ID	DMPOX4Q
DMPOX4Q	DN	ML290
DMPOX4Q	HS	Investigative
DMPOX4Q	SN	ML 290; compound 8 [PMID: 23764525]
DMPOX4Q	DT	Small molecular drug
DMPOX4Q	PC	56593349
DMPOX4Q	MW	506.5
DMPOX4Q	FM	C24H21F3N2O5S
DMPOX4Q	IC	InChI=1S/C24H21F3N2O5S/c1-15(2)34-21-13-6-4-11-19(21)23(31)29-20-12-5-3-10-18(20)22(30)28-16-8-7-9-17(14-16)35(32,33)24(25,26)27/h3-15H,1-2H3,(H,28,30)(H,29,31)
DMPOX4Q	CS	CC(C)OC1=CC=CC=C1C(=O)NC2=CC=CC=C2C(=O)NC3=CC(=CC=C3)S(=O)(=O)C(F)(F)F
DMPOX4Q	IK	RSYHJSDOGMSLDH-UHFFFAOYSA-N
DMPOX4Q	IU	2-[(2-propan-2-yloxybenzoyl)amino]-N-[3-(trifluoromethylsulfonyl)phenyl]benzamide
DMPOX4Q	DE	Discovery agent

DMY40UG	ID	DMY40UG
DMY40UG	DN	ML297
DMY40UG	HS	Investigative
DMY40UG	SN	ML-297; ML 297
DMY40UG	DT	Small molecular drug
DMY40UG	PC	56642816
DMY40UG	MW	328.32
DMY40UG	FM	C17H14F2N4O
DMY40UG	IC	InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24)
DMY40UG	CS	CC1=NN(C(=C1)NC(=O)NC2=CC(=C(C=C2)F)F)C3=CC=CC=C3
DMY40UG	IK	IEKSMUSSYJUQMY-UHFFFAOYSA-N
DMY40UG	IU	1-(3,4-difluorophenyl)-3-(5-methyl-2-phenylpyrazol-3-yl)urea
DMY40UG	DE	Discovery agent

DMNOREK	ID	DMNOREK
DMNOREK	DN	ML315
DMNOREK	HS	Investigative
DMNOREK	SN	ML315; CHEMBL1885748; 1440251-53-5; MLS004256649; GTPL8162; KUC107550N; BDBM50435474; ML 315; AKOS032952995; KSC-14-101; NCGC00241342-01; NCGC00241342-02; SMR003081704; BRD-K98168317-001-01-9; 5-(benzo[d][1,3]dioxol-5-yl)-N-(3,5-dichlorobenzyl)pyrimidin-4-amine
DMNOREK	DT	Small molecular drug
DMNOREK	PC	46926514
DMNOREK	MW	374.2
DMNOREK	FM	C18H13Cl2N3O2
DMNOREK	IC	InChI=1S/C18H13Cl2N3O2/c19-13-3-11(4-14(20)6-13)7-22-18-15(8-21-9-23-18)12-1-2-16-17(5-12)25-10-24-16/h1-6,8-9H,7,10H2,(H,21,22,23)
DMNOREK	CS	C1OC2=C(O1)C=C(C=C2)C3=CN=CN=C3NCC4=CC(=CC(=C4)Cl)Cl
DMNOREK	IK	JQSJAVBMIMDUFO-UHFFFAOYSA-N
DMNOREK	IU	5-(1,3-benzodioxol-5-yl)-N-[(3,5-dichlorophenyl)methyl]pyrimidin-4-amine
DMNOREK	DE	Discovery agent

DM3S5UC	ID	DM3S5UC
DM3S5UC	DN	ML-3163
DM3S5UC	HS	Investigative
DM3S5UC	SN	ML 3163; CHEMBL111456; 4-[5-(4-Fluorophenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-3H-imidazol-4-yl]pyridine; SCHEMBL4106398; BDBM50114690; IN1229; 4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine; 4-(2-(4-(methylsulfinyl)benzylthio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine
DM3S5UC	DT	Small molecular drug
DM3S5UC	PC	9845197
DM3S5UC	MW	423.5
DM3S5UC	FM	C22H18FN3OS2
DM3S5UC	IC	InChI=1S/C22H18FN3OS2/c1-29(27)19-8-2-15(3-9-19)14-28-22-25-20(16-4-6-18(23)7-5-16)21(26-22)17-10-12-24-13-11-17/h2-13H,14H2,1H3,(H,25,26)
DM3S5UC	CS	CS(=O)C1=CC=C(C=C1)CSC2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
DM3S5UC	IK	PRYUWQSCZBKGMW-UHFFFAOYSA-N
DM3S5UC	IU	4-[4-(4-fluorophenyl)-2-[(4-methylsulfinylphenyl)methylsulfanyl]-1H-imidazol-5-yl]pyridine
DM3S5UC	DE	Discovery agent

DMVELYW	ID	DMVELYW
DMVELYW	DN	ML321
DMVELYW	HS	Investigative
DMVELYW	SN	compound 65 [PMID 24666157]
DMVELYW	DT	Small molecular drug
DMVELYW	PC	57377246
DMVELYW	MW	410.5
DMVELYW	FM	C21H18N2O3S2
DMVELYW	IC	InChI=1S/C21H18N2O3S2/c1-23-17-13-14(20(24)22-11-10-15-5-4-12-27-15)8-9-19(17)28(26)18-7-3-2-6-16(18)21(23)25/h2-9,12-13H,10-11H2,1H3,(H,22,24)/t28-/m0/s1
DMVELYW	CS	CN1C2=C(C=CC(=C2)C(=O)NCCC3=CC=CS3)[S@@](=O)C4=CC=CC=C4C1=O
DMVELYW	IK	YXLLQNMKIDBOGH-NDEPHWFRSA-N
DMVELYW	IU	(11S)-5-methyl-6,11-dioxo-N-(2-thiophen-2-ylethyl)benzo[b][1,4]benzothiazepine-3-carboxamide
DMVELYW	DE	Discovery agent

DMXJY6W	ID	DMXJY6W
DMXJY6W	DN	ML-3375
DMXJY6W	HS	Investigative
DMXJY6W	SN	ML-3375; CHEMBL113419; SCHEMBL4460547; SCHEMBL13712659; ZINC13491685; BDBM50119524; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine; 2-(Methylthio)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole
DMXJY6W	DT	Small molecular drug
DMXJY6W	PC	9795838
DMXJY6W	MW	285.3
DMXJY6W	FM	C15H12FN3S
DMXJY6W	IC	InChI=1S/C15H12FN3S/c1-20-15-18-13(10-2-4-12(16)5-3-10)14(19-15)11-6-8-17-9-7-11/h2-9H,1H3,(H,18,19)
DMXJY6W	CS	CSC1=NC(=C(N1)C2=CC=NC=C2)C3=CC=C(C=C3)F
DMXJY6W	IK	IKQIPPKRAFLUKQ-UHFFFAOYSA-N
DMXJY6W	IU	4-[4-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-5-yl]pyridine
DMXJY6W	DE	Discovery agent

DMTQWI8	ID	DMTQWI8
DMTQWI8	DN	ML-3403
DMTQWI8	HS	Investigative
DMTQWI8	SN	p38 MAP Kinase Inhibitor III; ML3403; 549505-65-9; ML 3403; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-N-(1-phenylethyl)pyridin-2-amine; CHEMBL111364; (RS)-{4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}-(1-phenylethyl)amine]; K00568a; AC1O4WCF; SCHEMBL2896072; GTPL6014; ml-3043; SCHEMBL15013352; MolPort-023-278-904; HMS3229M04; {4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine
DMTQWI8	DT	Small molecular drug
DMTQWI8	PC	6419739
DMTQWI8	MW	404.5
DMTQWI8	FM	C23H21FN4S
DMTQWI8	IC	InChI=1S/C23H21FN4S/c1-15(16-6-4-3-5-7-16)26-20-14-18(12-13-25-20)22-21(27-23(28-22)29-2)17-8-10-19(24)11-9-17/h3-15H,1-2H3,(H,25,26)(H,27,28)
DMTQWI8	CS	CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(NC(=N3)SC)C4=CC=C(C=C4)F
DMTQWI8	IK	VXPWQNBKEIVYIS-UHFFFAOYSA-N
DMTQWI8	IU	4-[5-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-4-yl]-N-(1-phenylethyl)pyridin-2-amine
DMTQWI8	CA	CAS 549505-65-9
DMTQWI8	DE	Discovery agent

DMR8N36	ID	DMR8N36
DMR8N36	DN	ML347
DMR8N36	HS	Investigative
DMR8N36	SN	ML-347
DMR8N36	DT	Small molecular drug
DMR8N36	PC	44577753
DMR8N36	MW	352.4
DMR8N36	FM	C22H16N4O
DMR8N36	IC	InChI=1S/C22H16N4O/c1-27-17-9-7-15(8-10-17)16-12-24-22-20(13-25-26(22)14-16)18-4-2-6-21-19(18)5-3-11-23-21/h2-14H,1H3
DMR8N36	CS	COC1=CC=C(C=C1)C2=CN3C(=C(C=N3)C4=C5C=CC=NC5=CC=C4)N=C2
DMR8N36	IK	FVRYPYDPKSZGNS-UHFFFAOYSA-N
DMR8N36	IU	5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
DMR8N36	DE	Discovery agent

DMXJASC	ID	DMXJASC
DMXJASC	DN	ML375
DMXJASC	HS	Investigative
DMXJASC	SN	VU0483253-3
DMXJASC	DT	Small molecular drug
DMXJASC	PC	71598521
DMXJASC	MW	424.8
DMXJASC	FM	C23H15ClF2N2O2
DMXJASC	IC	InChI=1S/C23H15ClF2N2O2/c24-16-8-6-15(7-9-16)23-18-4-2-1-3-17(18)22(30)28(23)12-11-27(23)21(29)14-5-10-19(25)20(26)13-14/h1-10,13H,11-12H2/t23-/m0/s1
DMXJASC	CS	C1CN([C@]2(N1C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)C5=CC(=C(C=C5)F)F
DMXJASC	IK	GXBAKXRLQAPKEE-QHCPKHFHSA-N
DMXJASC	IU	(9bS)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydroimidazo[2,1-a]isoindol-5-one
DMXJASC	DE	Discovery agent

DMQROC3	ID	DMQROC3
DMQROC3	DN	ML380
DMQROC3	HS	Investigative
DMQROC3	SN	VU0481443-3
DMQROC3	DT	Small molecular drug
DMQROC3	PC	71737672
DMQROC3	MW	494.5
DMQROC3	FM	C23H25F3N4O3S
DMQROC3	IC	InChI=1S/C23H25F3N4O3S/c1-2-29(15-17-5-3-4-6-20(17)23(24,25)26)22(31)16-9-11-30(12-10-16)34(32,33)19-7-8-21-18(13-19)14-27-28-21/h3-8,13-14,16H,2,9-12,15H2,1H3,(H,27,28)
DMQROC3	CS	CCN(CC1=CC=CC=C1C(F)(F)F)C(=O)C2CCN(CC2)S(=O)(=O)C3=CC4=C(C=C3)NN=C4
DMQROC3	IK	FJPQEOQGIZSLES-UHFFFAOYSA-N
DMQROC3	IU	N-ethyl-1-(1H-indazol-5-ylsulfonyl)-N-[[2-(trifluoromethyl)phenyl]methyl]piperidine-4-carboxamide
DMQROC3	DE	Discovery agent

DMKCIP0	ID	DMKCIP0
DMKCIP0	DN	ML381
DMKCIP0	HS	Investigative
DMKCIP0	SN	VU0488130-1
DMKCIP0	DT	Small molecular drug
DMKCIP0	PC	42519285
DMKCIP0	MW	379.4
DMKCIP0	FM	C21H21N3O4
DMKCIP0	IC	InChI=1S/C21H21N3O4/c1-14(19-9-4-5-10-22-19)24(3)21(26)20-12-18(28-23-20)13-27-17-8-6-7-16(11-17)15(2)25/h4-12,14H,13H2,1-3H3/t14-/m0/s1
DMKCIP0	CS	C[C@@H](C1=CC=CC=N1)N(C)C(=O)C2=NOC(=C2)COC3=CC=CC(=C3)C(=O)C
DMKCIP0	IK	JMYDHMCYZKRDPD-AWEZNQCLSA-N
DMKCIP0	IU	5-[(3-acetylphenoxy)methyl]-N-methyl-N-[(1S)-1-pyridin-2-ylethyl]-1,2-oxazole-3-carboxamide
DMKCIP0	DE	Discovery agent

DMA0E2Q	ID	DMA0E2Q
DMA0E2Q	DN	ML398
DMA0E2Q	HS	Investigative
DMA0E2Q	SN	ML398; CHEMBL3335556; GTPL8440; BDBM50027083; VU0603865-1; VU0603865-2
DMA0E2Q	DT	Small molecular drug
DMA0E2Q	PC	72737723
DMA0E2Q	MW	315.8
DMA0E2Q	FM	C19H22ClNO
DMA0E2Q	IC	InChI=1S/C19H22ClNO/c20-18-9-6-17(7-10-18)14-21-12-13-22-19(15-21)11-8-16-4-2-1-3-5-16/h1-7,9-10,19H,8,11-15H2/t19-/m1/s1
DMA0E2Q	CS	C1CO[C@@H](CN1CC2=CC=C(C=C2)Cl)CCC3=CC=CC=C3
DMA0E2Q	IK	CVKXGRRJHJHUFY-LJQANCHMSA-N
DMA0E2Q	IU	(2R)-4-[(4-chlorophenyl)methyl]-2-(2-phenylethyl)morpholine
DMA0E2Q	DE	Discovery agent

DMP13VE	ID	DMP13VE
DMP13VE	DN	ML9
DMP13VE	HS	Investigative
DMP13VE	SN	ML-9 free base; UNII-LTJ3F5128V; 110448-31-2; LTJ3F5128V; CHEMBL429298; ML9; 1-[(5-chloro-1-naphthyl)sulfonyl]-1,4-diazepane; 1H-1,4-Diazepine, 1-[(5-chloro-1-naphthalenyl)sulfonyl]hexahydro-; Tocris-0431; ACMC-20mde5; BiomolKI_000043; AC1L1HOD; Lopac-C-1172; BiomolKI2_000008; Lopac0_000209; BSPBio_001271; GTPL4256; SCHEMBL2869228; CTK0D4761; CHEBI:93202; DTXSID00149246; ZINC402771; HMS1792O13; Bio1_000938; Bio1_001427; Bio1_000449; HMS3403O13; HMS1990O13; BDBM50216681; 1H-1,4-Diazepine, 1-((5-chloro-1-naphthalenyl)sulfonyl)hexahydro-)
DMP13VE	DT	Small molecular drug
DMP13VE	PC	4217
DMP13VE	MW	324.8
DMP13VE	FM	C15H17ClN2O2S
DMP13VE	IC	InChI=1S/C15H17ClN2O2S/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18/h1-2,4-7,17H,3,8-11H2
DMP13VE	CS	C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CC=C3Cl
DMP13VE	IK	OZSMSRIUUDGTEP-UHFFFAOYSA-N
DMP13VE	IU	1-(5-chloronaphthalen-1-yl)sulfonyl-1,4-diazepane
DMP13VE	CA	CAS 110448-31-2
DMP13VE	CB	CHEBI:93202
DMP13VE	DE	Discovery agent

DMTU0IG	ID	DMTU0IG
DMTU0IG	DN	MLN-0905
DMTU0IG	HS	Investigative
DMTU0IG	SN	PLK-1 inhibitor (lymphoma), Millennium
DMTU0IG	CP	Millennium Pharmaceuticals Inc
DMTU0IG	DT	Small molecular drug
DMTU0IG	PC	46235922
DMTU0IG	MW	486.6
DMTU0IG	FM	C24H25F3N6S
DMTU0IG	IC	InChI=1S/C24H25F3N6S/c1-14-19(9-15(12-28-14)5-4-8-33(2)3)31-23-29-13-16-10-21(34)30-20-11-17(24(25,26)27)6-7-18(20)22(16)32-23/h6-7,9,11-13H,4-5,8,10H2,1-3H3,(H,30,34)(H,29,31,32)
DMTU0IG	CS	CC1=C(C=C(C=N1)CCCN(C)C)NC2=NC=C3CC(=S)NC4=C(C3=N2)C=CC(=C4)C(F)(F)F
DMTU0IG	IK	CODBZFJPKJDNDT-UHFFFAOYSA-N
DMTU0IG	IU	2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione
DMTU0IG	CA	CAS 1228960-69-7
DMTU0IG	DE	Lymphoma

DMYKNSP	ID	DMYKNSP
DMYKNSP	DN	MLN-120B
DMYKNSP	HS	Investigative
DMYKNSP	SN	MLN 120B; ML-120B; MLN120B; ML120B
DMYKNSP	DT	Small molecular drug
DMYKNSP	PC	9929127
DMYKNSP	MW	366.8
DMYKNSP	FM	C19H15ClN4O2
DMYKNSP	IC	InChI=1S/C19H15ClN4O2/c1-10-11(4-3-6-22-10)19(25)24-17-16-13(8-14(20)18(17)26-2)12-5-7-21-9-15(12)23-16/h3-9,23H,1-2H3,(H,24,25)
DMYKNSP	CS	CC1=C(C=CC=N1)C(=O)NC2=C3C(=CC(=C2OC)Cl)C4=C(N3)C=NC=C4
DMYKNSP	IK	ZNOLRTPMNMPLHY-UHFFFAOYSA-N
DMYKNSP	IU	N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methylpyridine-3-carboxamide
DMYKNSP	CA	CAS 783348-36-7
DMYKNSP	DE	Discovery agent

DMPTBJZ	ID	DMPTBJZ
DMPTBJZ	DN	MLS1547
DMPTBJZ	HS	Investigative
DMPTBJZ	SN	MLS000051547
DMPTBJZ	DT	Small molecular drug
DMPTBJZ	PC	1093278
DMPTBJZ	MW	354.8
DMPTBJZ	FM	C19H19ClN4O
DMPTBJZ	IC	InChI=1S/C19H19ClN4O/c20-16-12-14(19(25)18-15(16)4-3-7-22-18)13-23-8-10-24(11-9-23)17-5-1-2-6-21-17/h1-7,12,25H,8-11,13H2
DMPTBJZ	CS	C1CN(CCN1CC2=CC(=C3C=CC=NC3=C2O)Cl)C4=CC=CC=N4
DMPTBJZ	IK	OPEJNANYABTIGC-UHFFFAOYSA-N
DMPTBJZ	IU	5-chloro-7-[(4-pyridin-2-ylpiperazin-1-yl)methyl]quinolin-8-ol
DMPTBJZ	DE	Discovery agent

DMT1NP8	ID	DMT1NP8
DMT1NP8	DN	MM 11253
DMT1NP8	HS	Investigative
DMT1NP8	SN	MM-11253; MM11253
DMT1NP8	DT	Small molecular drug
DMT1NP8	PC	10389639
DMT1NP8	MW	462.7
DMT1NP8	FM	C28H30O2S2
DMT1NP8	IC	InChI=1S/C28H30O2S2/c1-26(2)11-12-27(3,4)24-17-22(9-10-23(24)26)28(31-13-14-32-28)21-8-7-18-15-20(25(29)30)6-5-19(18)16-21/h5-10,15-17H,11-14H2,1-4H3,(H,29,30)
DMT1NP8	CS	CC1(CCC(C2=C1C=CC(=C2)C3(SCCS3)C4=CC5=C(C=C4)C=C(C=C5)C(=O)O)(C)C)C
DMT1NP8	IK	DPVGXUNWCVEIGT-UHFFFAOYSA-N
DMT1NP8	IU	6-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dithiolan-2-yl]naphthalene-2-carboxylic acid
DMT1NP8	CA	CAS 345952-44-5
DMT1NP8	DE	Discovery agent

DMB74MS	ID	DMB74MS
DMB74MS	DN	MM3A6S
DMB74MS	HS	Investigative
DMB74MS	SN	CHEMBL379928; MM3A6S
DMB74MS	DT	Small molecular drug
DMB74MS	PC	10454860
DMB74MS	MW	421.5
DMB74MS	FM	C20H23NO7S
DMB74MS	IC	InChI=1S/C20H23NO7S/c1-11(22)26-15-6-4-12-10-14-13-5-7-16(28-29(23,24)25)19-20(13,8-9-21(14,2)3)17(12)18(15)27-19/h4-7,13-14,16,19H,8-10H2,1-3H3/t13-,14+,16-,19-,20-/m0/s1
DMB74MS	CS	CC(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[N+]4(C)C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DMB74MS	IK	QNHZSCHPVZZALI-BKRJIHRRSA-N
DMB74MS	IU	[(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3,3-dimethyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMB74MS	DE	Discovery agent

DM9PGQI	ID	DM9PGQI
DM9PGQI	DN	MM3B6S
DM9PGQI	HS	Investigative
DM9PGQI	SN	CHEMBL211374; MM3B6S
DM9PGQI	DT	Small molecular drug
DM9PGQI	PC	44414811
DM9PGQI	MW	483.5
DM9PGQI	FM	C25H25NO7S
DM9PGQI	IC	InChI=1S/C25H25NO7S/c1-26(2)13-12-25-17-9-11-20(33-34(28,29)30)23(25)32-22-19(10-8-16(21(22)25)14-18(17)26)31-24(27)15-6-4-3-5-7-15/h3-11,17-18,20,23H,12-14H2,1-2H3/t17-,18+,20-,23-,25-/m0/s1
DM9PGQI	CS	C[N+]1(CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC(=O)C6=CC=CC=C6)O[C@H]3[C@H](C=C4)OS(=O)(=O)[O-])C
DM9PGQI	IK	RMPWVEGPFQZBPZ-SDSLYQAOSA-N
DM9PGQI	IU	[(4R,4aR,7S,7aR,12bS)-9-benzoyloxy-3,3-dimethyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DM9PGQI	DE	Discovery agent

DMUL4PE	ID	DMUL4PE
DMUL4PE	DN	MMB-4
DMUL4PE	HS	Investigative
DMUL4PE	SN	Acetocholinesterase reactivator (poison intoxication), SwRI; Dimethanesulfonate (poison intoxication), SwRI
DMUL4PE	CP	Southwest Research Institute
DMUL4PE	DT	Small molecular drug
DMUL4PE	PC	135545784
DMUL4PE	MW	418.08
DMUL4PE	FM	C13H14Br2N4O2
DMUL4PE	IC	InChI=1S/C13H12N4O2.2BrH/c18-14-9-12-1-5-16(6-2-12)11-17-7-3-13(4-8-17)10-15-19;;/h1-10H,11H2;2*1H
DMUL4PE	CS	C1=C[N+](=CC=C1/C=N/O)C[N+]2=CC=C(C=C2)/C=N/O.[Br-].[Br-]
DMUL4PE	IK	ZKQNRRLCBJUEBC-UHFFFAOYSA-N
DMUL4PE	IU	(NE)-N-[[1-[[4-[(E)-hydroxyiminomethyl]pyridin-1-ium-1-yl]methyl]pyridin-1-ium-4-yl]methylidene]hydroxylamine;dibromide
DMUL4PE	CA	CAS 2058-89-1
DMUL4PE	DE	Poison intoxication

DMUWVGP	ID	DMUWVGP
DMUWVGP	DN	MMDA
DMUWVGP	HS	Investigative
DMUWVGP	SN	MMDA; 5-Methoxy-3,4-methylenedioxyamphetamine; (+-)-MMDA; DEA No. 7401; 13674-05-0; 3-Methoxy-4,5-methylenedioxyphenylisopropylamine; Amphetamine, 3,4-methylenedioxy-5-methoxy; 3-Methoxy-alpha-methyl-4,5-methylenedioxyphenethylamine; BRN 1246630; Phenethylamine, alpha-methyl-3-methoxy-4,5-(methylenedioxy)-; 1,3-benzodioxole-5-ethanamine, 7-methoxy-alpha-methyl-; 3-Methoxy-4,5-methylenedioxyamphetamine; beta-Methoxy-alpha-methyl-4,5-(methylenedioxy)phenethyl amine; Phenethylamine, 3-methoxy-alpha-methyl-4,5-(methylenedio
DMUWVGP	DT	Small molecular drug
DMUWVGP	PC	26175
DMUWVGP	MW	209.24
DMUWVGP	FM	C11H15NO3
DMUWVGP	IC	InChI=1S/C11H15NO3/c1-7(12)3-8-4-9(13-2)11-10(5-8)14-6-15-11/h4-5,7H,3,6,12H2,1-2H3
DMUWVGP	CS	CC(CC1=CC2=C(C(=C1)OC)OCO2)N
DMUWVGP	IK	YQYUWUKDEVZFDB-UHFFFAOYSA-N
DMUWVGP	IU	1-(7-methoxy-1,3-benzodioxol-5-yl)propan-2-amine
DMUWVGP	CA	CAS 13674-05-0
DMUWVGP	DE	Discovery agent

DMH1YN6	ID	DMH1YN6
DMH1YN6	DN	MMI-175
DMH1YN6	HS	Investigative
DMH1YN6	SN	MMI-175; N-[(4S,5S,7R)-8-({(S)-1-[(BENZYLAMINO)OXOMETHYL]-2-METHYLPROPYL}AMINO)-5-HYDROXY-2,7-DIMETHYL-8-OXO-OCT-4-YL]-(4S,7S)-4-ISOPROPYL-2,5,9-TRIOXO-1-OXA-3,6,10-TRIAZACYCLOHEXADECANE-7-CARBOXAMIDE; 1xs7; AC1L9MVD; SCHEMBL8270563; CHEMBL362592; BDBM16271; amide-urethane derived inhibitor 2c; DB02378; (4S,7S)-N-[(1S,2S,4R)-5-{[(1S)-1-(benzylcarbamoyl)-2-methylpropyl]amino}-2-hydroxy-4-methyl-1-(2-methylpropyl)-5-oxopentyl]-4-(1-methylethyl)-2,5,9-trioxo-1-oxa-3,6,10-triazacyclohexadecane-7-carboxamide
DMH1YN6	DT	Small molecular drug
DMH1YN6	PC	449218
DMH1YN6	MW	730.9
DMH1YN6	FM	C38H62N6O8
DMH1YN6	IC	InChI=1S/C38H62N6O8/c1-23(2)19-28(30(45)20-26(7)34(47)43-32(24(3)4)36(49)40-22-27-15-11-10-12-16-27)41-35(48)29-21-31(46)39-17-13-8-9-14-18-52-38(51)44-33(25(5)6)37(50)42-29/h10-12,15-16,23-26,28-30,32-33,45H,8-9,13-14,17-22H2,1-7H3,(H,39,46)(H,40,49)(H,41,48)(H,42,50)(H,43,47)(H,44,51)/t26-,28+,29+,30+,32+,33+/m1/s1
DMH1YN6	CS	C[C@H](C[C@@H]([C@H](CC(C)C)NC(=O)[C@@H]1CC(=O)NCCCCCCOC(=O)N[C@H](C(=O)N1)C(C)C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC2=CC=CC=C2
DMH1YN6	IK	QJAPFAZHNSZLJE-CWURXVSKSA-N
DMH1YN6	IU	(4S,7S)-N-[(4S,5S,7R)-8-[[(2S)-1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amino]-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-2,5,9-trioxo-4-propan-2-yl-1-oxa-3,6,10-triazacyclohexadecane-7-carboxamide
DMH1YN6	DE	Discovery agent

DM38N2K	ID	DM38N2K
DM38N2K	DN	MMI270
DM38N2K	HS	Investigative
DM38N2K	SN	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; MMI270; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1
DM38N2K	DT	Small molecular drug
DM38N2K	PC	446504
DM38N2K	MW	393.5
DM38N2K	FM	C18H23N3O5S
DM38N2K	IC	InChI=1S/C18H23N3O5S/c1-13(2)17(18(22)20-23)21(12-14-5-4-10-19-11-14)27(24,25)16-8-6-15(26-3)7-9-16/h4-11,13,17,23H,12H2,1-3H3,(H,20,22)/t17-/m1/s1
DM38N2K	CS	CC(C)[C@H](C(=O)NO)N(CC1=CN=CC=C1)S(=O)(=O)C2=CC=C(C=C2)OC
DM38N2K	IK	BSIZUMJRKYHEBR-QGZVFWFLSA-N
DM38N2K	IU	(2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide
DM38N2K	CA	CAS 161314-70-1
DM38N2K	DE	Discovery agent

DMVCNBH	ID	DMVCNBH
DMVCNBH	DN	MMP-408
DMVCNBH	HS	Investigative
DMVCNBH	SN	MMP-118; MMP-145; MMP-12 inhibitors (COPD); MMP-12 inhibitors (COPD), Pfizer; MMP-12 inhibitors (COPD), Wyeth
DMVCNBH	CP	Wyeth
DMVCNBH	DE	Chronic obstructive pulmonary disease

DMWMZL7	ID	DMWMZL7
DMWMZL7	DN	MMPIP
DMWMZL7	HS	Investigative
DMWMZL7	SN	mmpip hydrochloride; 479077-02-6; CHEMBL593489; 6-(4-methoxyphenyl)-5-methyl-3-(pyridin-4-yl)isoxazolo[4,5-c]pyridin-4(5H)-one; GTPL3341; SCHEMBL3014586; CTK8D4056; DTXSID90433202; MolPort-006-069-049; MMPIP, &gt; BCP23933; BDBM50305877; ZINC34042470; BN0822; AKOS015851872; API0008470; NCGC00378759-01; QC-10186; KB-274653; S14-1930; 6-(4-Methoxyphenyl)-5-methyl-3-(4-pyridyl)isoxazolo[4,5-c]pyridine-4(5H)-one; 6-(4-Methoxyphenyl)-5-methyl-3-(4-pyridinyl)-isoxazolo[ 4,5-c]pyridin-4(5H)-one
DMWMZL7	DT	Small molecular drug
DMWMZL7	PC	9945530
DMWMZL7	MW	333.3
DMWMZL7	FM	C19H15N3O3
DMWMZL7	IC	InChI=1S/C19H15N3O3/c1-22-15(12-3-5-14(24-2)6-4-12)11-16-17(19(22)23)18(21-25-16)13-7-9-20-10-8-13/h3-11H,1-2H3
DMWMZL7	CS	CN1C(=CC2=C(C1=O)C(=NO2)C3=CC=NC=C3)C4=CC=C(C=C4)OC
DMWMZL7	IK	PDWYBOZNEVALOV-UHFFFAOYSA-N
DMWMZL7	IU	6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-yl-[1,2]oxazolo[4,5-c]pyridin-4-one
DMWMZL7	CA	CAS 479077-02-6
DMWMZL7	DE	Discovery agent

DM1XY5F	ID	DM1XY5F
DM1XY5F	DN	MN-462
DM1XY5F	HS	Investigative
DM1XY5F	SN	EF-6265; CPB/TAFIa inhibitor, MediciNova; CPB/TAFIa inhibitor, Meiji Seika Kaisha/MediciNova; Carboxypeptidase B/thrombin-activated fibrinolysis inhibitor, Meiji Seika Kaisha/MediciNova
DM1XY5F	CP	Meiji Seika Kaisha Ltd
DM1XY5F	DE	Thrombosis

DMBJFH9	ID	DMBJFH9
DMBJFH9	DN	MNI-135
DMBJFH9	HS	Investigative
DMBJFH9	SN	MNI 135
DMBJFH9	DT	Small molecular drug
DMBJFH9	PC	73755191
DMBJFH9	MW	401.2
DMBJFH9	FM	C17H12IN3O
DMBJFH9	IC	InChI=1S/C17H12IN3O/c18-13-4-5-15-16(9-13)21-17(22)7-6-14(20-15)12-3-1-2-11(8-12)10-19/h1-5,8-9H,6-7H2,(H,21,22)
DMBJFH9	CS	C1CC(=O)NC2=C(C=CC(=C2)I)N=C1C3=CC=CC(=C3)C#N
DMBJFH9	IK	SJYIGECDHTXFFG-UHFFFAOYSA-N
DMBJFH9	IU	3-(9-iodo-2-oxo-3,4-dihydro-1H-1,6-benzodiazocin-5-yl)benzonitrile
DMBJFH9	DE	Discovery agent

DM5C9VI	ID	DM5C9VI
DM5C9VI	DN	MNI-136
DM5C9VI	HS	Investigative
DM5C9VI	SN	MNI 136
DM5C9VI	DT	Small molecular drug
DM5C9VI	PC	73755192
DM5C9VI	MW	406.3
DM5C9VI	FM	C21H16BrN3O
DM5C9VI	IC	InChI=1S/C21H16BrN3O/c22-17-4-5-19-20(13-17)24-18(6-7-21(26)25-19)16-3-1-2-15(12-16)14-8-10-23-11-9-14/h1-5,8-13H,6-7H2,(H,25,26)
DM5C9VI	CS	C1CC(=O)NC2=C(C=C(C=C2)Br)N=C1C3=CC=CC(=C3)C4=CC=NC=C4
DM5C9VI	IK	BLAQAVITPVXJJS-UHFFFAOYSA-N
DM5C9VI	IU	8-bromo-5-(3-pyridin-4-ylphenyl)-3,4-dihydro-1H-1,6-benzodiazocin-2-one
DM5C9VI	DE	Discovery agent

DMKRI1J	ID	DMKRI1J
DMKRI1J	DN	MNI-137
DMKRI1J	HS	Investigative
DMKRI1J	SN	MNI 137
DMKRI1J	DT	Small molecular drug
DMKRI1J	PC	73755193
DMKRI1J	MW	355.19
DMKRI1J	FM	C16H11BrN4O
DMKRI1J	IC	InChI=1S/C16H11BrN4O/c17-11-1-2-14-15(8-11)21-16(22)4-3-13(20-14)10-5-6-19-12(7-10)9-18/h1-2,5-8H,3-4H2,(H,21,22)
DMKRI1J	CS	C1CC(=O)NC2=C(C=CC(=C2)Br)N=C1C3=CC(=NC=C3)C#N
DMKRI1J	IK	JNLRDCDCGXPNKH-UHFFFAOYSA-N
DMKRI1J	IU	4-(9-bromo-2-oxo-3,4-dihydro-1H-1,6-benzodiazocin-5-yl)pyridine-2-carbonitrile
DMKRI1J	DE	Discovery agent

DMLYVQB	ID	DMLYVQB
DMLYVQB	DN	MOD-3012
DMLYVQB	HS	Investigative
DMLYVQB	SN	Factor IX-CTP (sustained release/injectable/CTP, hemophilia), PROLOR; Long-acting Factor IX (sustained release/injectable/CTP, hemophilia), PROLOR
DMLYVQB	CP	PROLOR Biotech Inc
DMLYVQB	DE	Factor IX deficiency

DMKWBNA	ID	DMKWBNA
DMKWBNA	DN	MOD-5023
DMKWBNA	HS	Investigative
DMKWBNA	SN	Factor VII-CTP; FactroVIIa-CTP; Long-acting Factor VIIa (injectable/CTP, hemophilia), PROLOR; Long-acting Factor VIIa (peptide/injectable, hemophilia), PROLOR
DMKWBNA	CP	PROLOR Biotech Inc
DMKWBNA	DE	Hemophilia

DMB5OG8	ID	DMB5OG8
DMB5OG8	DN	modified HA14-1 compounds (cancer)
DMB5OG8	HS	Investigative
DMB5OG8	SN	Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals
DMB5OG8	DE	Discovery agent

DMPYBHI	ID	DMPYBHI
DMPYBHI	DN	moexiprilat
DMPYBHI	HS	Investigative
DMPYBHI	SN	103775-14-0
DMPYBHI	DT	Small molecular drug
DMPYBHI	PC	55331
DMPYBHI	MW	470.5
DMPYBHI	FM	C25H30N2O7
DMPYBHI	IC	InChI=1S/C25H30N2O7/c1-15(26-19(24(29)30)10-9-16-7-5-4-6-8-16)23(28)27-14-18-13-22(34-3)21(33-2)12-17(18)11-20(27)25(31)32/h4-8,12-13,15,19-20,26H,9-11,14H2,1-3H3,(H,29,30)(H,31,32)/t15-,19-,20-/m0/s1
DMPYBHI	CS	C[C@@H](C(=O)N1CC2=CC(=C(C=C2C[C@H]1C(=O)O)OC)OC)N[C@@H](CCC3=CC=CC=C3)C(=O)O
DMPYBHI	IK	CMPAGYDKASJORH-YSSFQJQWSA-N
DMPYBHI	IU	(3S)-2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMPYBHI	CA	CAS 103775-14-0
DMPYBHI	DE	Discovery agent

DMSF8UC	ID	DMSF8UC
DMSF8UC	DN	MOL 6131
DMSF8UC	HS	Investigative
DMSF8UC	DT	Small molecular drug
DMSF8UC	PC	56603779
DMSF8UC	MW	752.9
DMSF8UC	FM	C44H48N8O4
DMSF8UC	IC	InChI=1S/C44H48N8O4/c1-30-50(29-36-8-4-7-34-6-2-3-9-38(34)36)44(56)52-40(43(55)48-28-33-13-11-32(27-45)12-14-33)20-19-39(51(30)52)35-21-24-49(25-22-35)42(54)10-5-23-47-41(53)26-31-15-17-37(46)18-16-31/h2-4,6-9,11-20,35H,1,5,10,21-29,45-46H2,(H,47,53)(H,48,55)
DMSF8UC	CS	C=C1N(C(=O)N2N1C(=CC=C2C(=O)NCC3=CC=C(C=C3)CN)C4CCN(CC4)C(=O)CCCNC(=O)CC5=CC=C(C=C5)N)CC6=CC=CC7=CC=CC=C76
DMSF8UC	IK	VVCVJEWENXURHU-UHFFFAOYSA-N
DMSF8UC	IU	N-[[4-(aminomethyl)phenyl]methyl]-8-[1-[4-[[2-(4-aminophenyl)acetyl]amino]butanoyl]piperidin-4-yl]-1-methylidene-2-(naphthalen-1-ylmethyl)-3-oxo-[1,2,4]triazolo[1,2-a]pyridazine-5-carboxamide
DMSF8UC	DE	Discovery agent

DM0OWTS	ID	DM0OWTS
DM0OWTS	DN	MOLASSAMIDE
DM0OWTS	HS	Investigative
DM0OWTS	SN	molassamide; CHEMBL1077010
DM0OWTS	DT	Small molecular drug
DM0OWTS	PC	45379965
DM0OWTS	MW	963.1
DM0OWTS	FM	C48H66N8O13
DM0OWTS	IC	InChI=1S/C48H66N8O13/c1-9-14-36(59)49-26(5)41(61)53-39(27(6)57)44(64)54-40-28(7)69-48(68)38(25(3)4)52-43(63)34(23-30-17-19-31(58)20-18-30)55(8)47(67)35(24-29-15-12-11-13-16-29)56-37(60)22-21-33(46(56)66)51-42(62)32(10-2)50-45(40)65/h10-13,15-20,25-28,33-35,37-40,57-58,60H,9,14,21-24H2,1-8H3,(H,49,59)(H,50,65)(H,51,62)(H,52,63)(H,53,61)(H,54,64)/b32-10-/t26-,27+,28+,33-,34-,35-,37+,38-,39-,40-/m0/s1
DM0OWTS	CS	CCCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H]1[C@H](OC(=O)[C@@H](NC(=O)[C@@H](N(C(=O)[C@@H](N2[C@@H](CC[C@@H](C2=O)NC(=O)/C(=C/C)/NC1=O)O)CC3=CC=CC=C3)C)CC4=CC=C(C=C4)O)C(C)C)C
DM0OWTS	IK	KXSGCAPYMUMVSH-VFYPFKDGSA-N
DM0OWTS	IU	(2S,3R)-N-[(2S,5S,8S,11R,12S,15Z,18S,21R)-2-benzyl-15-ethylidene-21-hydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]-2-[[(2S)-2-(butanoylamino)propanoyl]amino]-3-hydroxybutanamide
DM0OWTS	DE	Discovery agent

DMZ6H1X	ID	DMZ6H1X
DMZ6H1X	DN	Molecule 11
DMZ6H1X	HS	Investigative
DMZ6H1X	SN	38293-71-9; AC1L1YVB; CTK4H9638; 2-CHLOROACETOPHENONE 2,4-DINITROPHENYLHYDRAZONE
DMZ6H1X	DT	Small molecular drug
DMZ6H1X	PC	38003
DMZ6H1X	MW	334.71
DMZ6H1X	FM	C14H11ClN4O4
DMZ6H1X	IC	InChI=1S/C14H11ClN4O4/c15-9-13(10-4-2-1-3-5-10)17-16-12-7-6-11(18(20)21)8-14(12)19(22)23/h1-8,16H,9H2
DMZ6H1X	CS	C1=CC=C(C=C1)C(=NNC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])CCl
DMZ6H1X	IK	HNLCJXKVYWWDTN-UHFFFAOYSA-N
DMZ6H1X	IU	N-[(2-chloro-1-phenylethylidene)amino]-2,4-dinitroaniline
DMZ6H1X	DE	Discovery agent

DMA7T0N	ID	DMA7T0N
DMA7T0N	DN	Molecule 21
DMA7T0N	HS	Investigative
DMA7T0N	SN	EP3 antagonists (pain/ uterine disease), Ono Pharmaceutical; Prostaglandin-E receptor 3 antagonists (pain/ uterine disease); Prostaglandin-E receptor 3 antagonists (pain/ uterine disease), Ono Pharmaceutical
DMA7T0N	CP	Ono Pharmaceutical Co Ltd
DMA7T0N	DE	Pain

DM4OLAZ	ID	DM4OLAZ
DM4OLAZ	DN	MOLEPHANTIN
DM4OLAZ	HS	Investigative
DM4OLAZ	SN	Molephantin; BRN 1329450; 2-Propenoic acid, 2-methyl-, 2,3,3a,4,5,8,11,11a-octahydro-11-hydroxy-6,10-dimethyl-3-methylene-2,8-dioxocyclodeca(b)furan-4-yl ester, (3aR-(3aR*,4S*,6E,9Z,11S*,11aS*))-; AC1O5UKZ; LS-123706; 5-18-04-00355 (Beilstein Handbook Reference); [(3aR,4S,6Z,9Z,11S,11aS)-11-hydroxy-6,10-dimethyl-3-methylidene-2,8-dioxo-4,5,11,11a-tetrahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DM4OLAZ	DT	Small molecular drug
DM4OLAZ	PC	5281484
DM4OLAZ	MW	346.4
DM4OLAZ	FM	C19H22O6
DM4OLAZ	IC	InChI=1S/C19H22O6/c1-9(2)18(22)24-14-7-10(3)6-13(20)8-11(4)16(21)17-15(14)12(5)19(23)25-17/h6,8,14-17,21H,1,5,7H2,2-4H3/b10-6+,11-8-/t14-,15+,16-,17-/m0/s1
DM4OLAZ	CS	C/C/1=C\\C(=O)/C=C(\\[C@@H]([C@@H]2[C@@H]([C@H](C1)OC(=O)C(=C)C)C(=C)C(=O)O2)O)/C
DM4OLAZ	IK	LXINRHXYVUTAMQ-UKKSPWLWSA-N
DM4OLAZ	IU	[(3aR,4S,6E,9Z,11S,11aS)-11-hydroxy-6,10-dimethyl-3-methylidene-2,8-dioxo-4,5,11,11a-tetrahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DM4OLAZ	CB	CHEBI:6962
DM4OLAZ	DE	Discovery agent

DMGNX6M	ID	DMGNX6M
DMGNX6M	DN	MOLEPHANTININ
DMGNX6M	HS	Investigative
DMGNX6M	SN	Molephantinin; MLS000728554; CHEMBL1992486
DMGNX6M	DT	Small molecular drug
DMGNX6M	PC	5281485
DMGNX6M	MW	360.4
DMGNX6M	FM	C20H24O6
DMGNX6M	IC	InChI=1S/C20H24O6/c1-6-11(3)19(23)25-15-8-10(2)7-14(21)9-12(4)17(22)18-16(15)13(5)20(24)26-18/h6-7,9,15-18,22H,5,8H2,1-4H3/b10-7+,11-6+,12-9-/t15-,16+,17-,18-/m0/s1
DMGNX6M	CS	C/C=C(\\C)/C(=O)O[C@H]1C/C(=C/C(=O)/C=C(\\[C@@H]([C@@H]2[C@@H]1C(=C)C(=O)O2)O)/C)/C
DMGNX6M	IK	VUURQISRHJCAJY-CXRMMEALSA-N
DMGNX6M	IU	[(3aR,4S,6E,9Z,11S,11aS)-11-hydroxy-6,10-dimethyl-3-methylidene-2,8-dioxo-4,5,11,11a-tetrahydro-3aH-cyclodeca[b]furan-4-yl] (E)-2-methylbut-2-enoate
DMGNX6M	CB	CHEBI:6963
DMGNX6M	DE	Discovery agent

DMLSEJN	ID	DMLSEJN
DMLSEJN	DN	Monastrol
DMLSEJN	HS	Investigative
DMLSEJN	SN	monastrol; 329689-23-8; 254753-54-3; ETHYL 4-(3-HYDROXYPHENYL)-6-METHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXYLATE; 4-(3-Hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-4H-pyrimidin-5-carboxylic Acid Ethyl Ester; CHEBI:75382; ( inverted exclamation markA)-Monastrol; SR-01000357662; AC1MGLGQ; Probes2_000257; Probes2_000376; Probes1_000312; Probes1_000042; Probes1_000001; Oprea1_487786; Lopac0_000821; KBioSS_000613; CBDivE_015834; KBioGR_000613; BSPBio_001273; MLS006011746; SCHEMBL3168349; KBio3_001085; KBio2_000613
DMLSEJN	DT	Small molecular drug
DMLSEJN	PC	2987927
DMLSEJN	MW	292.36
DMLSEJN	FM	C14H16N2O3S
DMLSEJN	IC	InChI=1S/C14H16N2O3S/c1-3-19-13(18)11-8(2)15-14(20)16-12(11)9-5-4-6-10(17)7-9/h4-7,12,17H,3H2,1-2H3,(H2,15,16,20)
DMLSEJN	CS	CCOC(=O)C1=C(NC(=S)NC1C2=CC(=CC=C2)O)C
DMLSEJN	IK	LOBCDGHHHHGHFA-UHFFFAOYSA-N
DMLSEJN	IU	ethyl 4-(3-hydroxyphenyl)-6-methyl-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-5-carboxylate
DMLSEJN	CA	CAS 329689-23-8
DMLSEJN	CB	CHEBI:75382
DMLSEJN	DE	Discovery agent

DMNWCPB	ID	DMNWCPB
DMNWCPB	DN	Monocarboxylic acids
DMNWCPB	HS	Investigative

DM31YGM	ID	DM31YGM
DM31YGM	DN	Monoctanoin component C
DM31YGM	HS	Investigative
DM31YGM	SN	DICAPRYLIN; MONOCTANOIN COMPONENT C; 1069-87-0; 3-Hydroxypropane-1,2-diyl dioctanoate; 36354-80-0; diC8; Octanoic acid, 1-(hydroxymethyl)-1,2-ethanediyl ester; 1,2-Dicapryloylglycerol; 1,2-Dioctanoyl-rac-glycerol; 1,2-Dioctanoin; Octanoin, 1,2-di-; Glycerol 1,2-dicaprylate; AC1Q5YA4; SCHEMBL825310; CHEMBL24609; AC1L1B82; CTK4A4899; ZQBULZYTDGUSSK-UHFFFAOYSA-N; HSCI1_000084; IN1353; AKOS027383004; ACM36354800; (3-hydroxy-2-octanoyloxypropyl) octanoate; FT-0748382; 1-hydroxy-3-(octanoyloxy)propan-2-yl octa
DM31YGM	DT	Small molecular drug
DM31YGM	PC	1323
DM31YGM	MW	344.5
DM31YGM	FM	C19H36O5
DM31YGM	IC	InChI=1S/C19H36O5/c1-3-5-7-9-11-13-18(21)23-16-17(15-20)24-19(22)14-12-10-8-6-4-2/h17,20H,3-16H2,1-2H3
DM31YGM	CS	CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC
DM31YGM	IK	ZQBULZYTDGUSSK-UHFFFAOYSA-N
DM31YGM	IU	(3-hydroxy-2-octanoyloxypropyl) octanoate
DM31YGM	CA	CAS 1069-87-0
DM31YGM	DE	Discovery agent

DM59CR0	ID	DM59CR0
DM59CR0	DN	MONODICTYOCHROMONE B
DM59CR0	HS	Investigative
DM59CR0	SN	Monodictyochromone B; CHEMBL576579; CHEBI:66397; (2S,2'R)-5,5'-dihydroxy-2-[(2R,3R)-3-hydroxy-5-oxotetrahydrofuran-2-yl]-2,2',7-trimethyl-2'-[(2R,3S)-3-methyl-5-oxotetrahydrofuran-2-yl]-2,2',3,3'-tetrahydro-4H,4'H-6,6'-bichromene-4,4'-dione; Monodictyochromes B
DM59CR0	DT	Small molecular drug
DM59CR0	PC	25256842
DM59CR0	MW	566.6
DM59CR0	FM	C30H30O11
DM59CR0	IC	InChI=1S/C30H30O11/c1-12-7-19-24(17(33)11-30(4,41-19)28-15(31)9-21(35)39-28)26(37)22(12)14-5-6-18-23(25(14)36)16(32)10-29(3,40-18)27-13(2)8-20(34)38-27/h5-7,13,15,27-28,31,36-37H,8-11H2,1-4H3/t13-,15+,27+,28+,29+,30-/m0/s1
DM59CR0	CS	C[C@H]1CC(=O)O[C@H]1[C@]2(CC(=O)C3=C(O2)C=CC(=C3O)C4=C(C5=C(C=C4C)O[C@](CC5=O)(C)[C@H]6[C@@H](CC(=O)O6)O)O)C
DM59CR0	IK	YSURVZRGQKOUAG-QXBVHLSASA-N
DM59CR0	IU	(2S)-5-hydroxy-6-[(2R)-5-hydroxy-2-methyl-2-[(2R,3S)-3-methyl-5-oxooxolan-2-yl]-4-oxo-3H-chromen-6-yl]-2-[(2R,3R)-3-hydroxy-5-oxooxolan-2-yl]-2,7-dimethyl-3H-chromen-4-one
DM59CR0	CB	CHEBI:66397
DM59CR0	DE	Discovery agent

DMNJXHF	ID	DMNJXHF
DMNJXHF	DN	Monoisopropyl Ester Phosphonic Acid Group
DMNJXHF	HS	Investigative
DMNJXHF	SN	AC1NAQP0; MONOISOPROPYL ESTER PHOSPHONIC ACID GROUP; propan-2-yloxyphosphinic acid; SCHEMBL333601; Phosphonic acid isopropyl ester; AC1O4B47; ZINC5381386
DMNJXHF	DT	Small molecular drug
DMNJXHF	PC	6383950
DMNJXHF	MW	123.07
DMNJXHF	FM	C3H8O3P+
DMNJXHF	IC	InChI=1S/C3H7O3P/c1-3(2)6-7(4)5/h3H,1-2H3/p+1
DMNJXHF	CS	CC(C)O[P+](=O)O
DMNJXHF	IK	XZSFYYSNTQXWBM-UHFFFAOYSA-O
DMNJXHF	IU	hydroxy-oxo-propan-2-yloxyphosphanium
DMNJXHF	DE	Discovery agent

DM0OFT6	ID	DM0OFT6
DM0OFT6	DN	Monoisopropylphosphorylserine
DM0OFT6	HS	Investigative
DM0OFT6	DT	Small molecular drug
DM0OFT6	PC	46936220
DM0OFT6	MW	227.15
DM0OFT6	FM	C6H14NO6P
DM0OFT6	IC	InChI=1S/C6H14NO6P/c1-4(2)13-14(10,11)12-3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)(H,10,11)/t5-/m1/s1
DM0OFT6	CS	CC(C)OP(=O)(O)OC[C@H](C(=O)O)N
DM0OFT6	IK	DALHHSOTZKMXMV-RXMQYKEDSA-N
DM0OFT6	IU	(2R)-2-amino-3-[hydroxy(propan-2-yloxy)phosphoryl]oxypropanoic acid
DM0OFT6	DE	Discovery agent

DMU4JWM	ID	DMU4JWM
DMU4JWM	DN	monomethylfumarate
DMU4JWM	HS	Investigative
DMU4JWM	SN	Monomethyl fumarate; 2756-87-8; 4-methoxy-4-oxobut-2-enoic acid; Methyl hydrogen fumarate; mono-Methyl fumarate; (E)-4-methoxy-4-oxobut-2-enoic acid; Fumaric acid monomethyl ester; UNII-45IUB1PX8R; 45IUB1PX8R; CHEMBL589586; NKHAVTQWNUWKEO-NSCUHMNNSA-N; AK114632; (2E)-3-(methoxycarbonyl)prop-2-enoic acid; (E)-4-methoxy-4-oxobut-2-enoic acid(98%); 44836-34-2; EINECS 220-412-6; Fumaric acid 1-methyl; AC1NSSIL; Monomethyl fumarate [USAN]; mono-Methyl fumarate, 97%; SCHEMBL60132; SCHEMBL60133; GTPL5786; AC1Q5T88; MolPort-002-472-973
DMU4JWM	DT	Small molecular drug
DMU4JWM	PC	21721168
DMU4JWM	MW	129.09
DMU4JWM	FM	C5H5O4-
DMU4JWM	IC	InChI=1S/C5H6O4/c1-9-5(8)3-2-4(6)7/h2-3H,1H3,(H,6,7)/p-1/b3-2+
DMU4JWM	CS	COC(=O)/C=C/C(=O)[O-]
DMU4JWM	IK	NKHAVTQWNUWKEO-NSCUHMNNSA-M
DMU4JWM	IU	(E)-4-methoxy-4-oxobut-2-enoate
DMU4JWM	DE	Discovery agent

DM4QO9G	ID	DM4QO9G
DM4QO9G	DN	Mononitrophenol
DM4QO9G	HS	Investigative
DM4QO9G	SN	Paranitrofenol; Paranitrofenol [Dutch]; Paranitrofenolo; Paranitrofenolo [Italian]; Paranitrophenol; Paranitrophenol [French,German]; Phenol, 4-nitro-; 4-Nitrophenol; Niphen; Phenol, p-nitro-; RCRA waste no. U170; RCRA waste number U170; UN1663; p-Hydroxynitrobenzene; p-Nitrofenol; p-Nitrofenol [Czech]; p-nitrophenol; para-nitrophenol; 1-Hydroxy-4-nitrobenzene; 100-02-7; 4-Hydroxynitrobenzene; 4-Nitrofenol; 4-Nitrofenol [Dutch]; 4-nitro-phenol; Caswell No. 603; NCI-C55992; NSC 1317; PNP; UNII-Y92ZL45L4R
DM4QO9G	PC	980
DM4QO9G	MW	139.11
DM4QO9G	FM	C6H5NO3
DM4QO9G	IC	BTJIUGUIPKRLHP-UHFFFAOYSA-N
DM4QO9G	CS	C1=CC(=CC=C1[N+](=O)[O-])O
DM4QO9G	IK	1S/C6H5NO3/c8-6-3-1-5(2-4-6)7(9)10/h1-4,8H
DM4QO9G	IU	4-nitrophenol
DM4QO9G	CA	CAS 100-02-7
DM4QO9G	CB	CHEBI:16836
DM4QO9G	DE	Discovery agent

DMENSOZ	ID	DMENSOZ
DMENSOZ	DN	Monothioglycerol
DMENSOZ	HS	Investigative
DMENSOZ	SN	3-Mercapto-1,2-propanediol; Monothioglycerol; 1-Thioglycerol; 96-27-5; THIOGLYCEROL; 3-Mercaptopropane-1,2-diol; Thioglycerine; Thioglycerin; Thiovanol; alpha-Thioglycerol; Glycerol-1-thiol; 1-Monothioglycerol; 1-Mercaptoglycerol; Monothioglycerin; 2,3-Dihydroxypropanethiol; alpha-Thiolglycerol; 3-Sulfanylpropane-1,2-diol; 1-Mercapto-2,3-propanediol; Glycerol, 1-thio-; alpha-Monothioglycerol; 1-Thio-2,3-propanediol; USAF CB-37; USAF B-40; 3-Mercapto-1,2-propanediole; 1,2-Propanediol, 3-mercapto-; NSC 5370; .alpha.-Thioglycerol
DMENSOZ	DT	Small molecular drug
DMENSOZ	PC	7291
DMENSOZ	MW	108.16
DMENSOZ	FM	C3H8O2S
DMENSOZ	IC	InChI=1S/C3H8O2S/c4-1-3(5)2-6/h3-6H,1-2H2
DMENSOZ	CS	C(C(CS)O)O
DMENSOZ	IK	PJUIMOJAAPLTRJ-UHFFFAOYSA-N
DMENSOZ	IU	3-sulfanylpropane-1,2-diol
DMENSOZ	CA	CAS 96-27-5
DMENSOZ	CB	CHEBI:74537
DMENSOZ	DE	Discovery agent

DMWR0J1	ID	DMWR0J1
DMWR0J1	DN	MORACHALCONE A
DMWR0J1	HS	Investigative
DMWR0J1	SN	MORACHALCONE A; 76472-88-3; CHEMBL465880; SCHEMBL6818973; MolPort-035-705-759; BDBM50251013; LMPK12120119; ZINC14762498; W1241; 2,4,2'',4''-tetrahydroxy-3''-prenylchalcone; 2,2',4,4'-Tetrahydroxy-3'-(3-methyl-2-butenyl)chalcone
DMWR0J1	DT	Small molecular drug
DMWR0J1	PC	9862769
DMWR0J1	MW	340.4
DMWR0J1	FM	C20H20O5
DMWR0J1	IC	InChI=1S/C20H20O5/c1-12(2)3-7-15-18(23)10-8-16(20(15)25)17(22)9-5-13-4-6-14(21)11-19(13)24/h3-6,8-11,21,23-25H,7H2,1-2H3/b9-5+
DMWR0J1	CS	CC(=CCC1=C(C=CC(=C1O)C(=O)/C=C/C2=C(C=C(C=C2)O)O)O)C
DMWR0J1	IK	NXBYIJSAISXPKJ-WEVVVXLNSA-N
DMWR0J1	IU	(E)-1-[2,4-dihydroxy-3-(3-methylbut-2-enyl)phenyl]-3-(2,4-dihydroxyphenyl)prop-2-en-1-one
DMWR0J1	CA	CAS 76472-88-3
DMWR0J1	DE	Discovery agent

DM2OGZ5	ID	DM2OGZ5
DM2OGZ5	DN	Morin
DM2OGZ5	HS	Investigative
DM2OGZ5	SN	morin; 480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; Morin hydrate; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; Zlut prirodni 11; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'arc [French]
DM2OGZ5	DT	Small molecular drug
DM2OGZ5	PC	5281670
DM2OGZ5	MW	302.23
DM2OGZ5	FM	C15H10O7
DM2OGZ5	IC	InChI=1S/C15H10O7/c16-6-1-2-8(9(18)3-6)15-14(21)13(20)12-10(19)4-7(17)5-11(12)22-15/h1-5,16-19,21H
DM2OGZ5	CS	C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
DM2OGZ5	IK	YXOLAZRVSSWPPT-UHFFFAOYSA-N
DM2OGZ5	IU	2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
DM2OGZ5	CA	CAS 480-16-0
DM2OGZ5	CB	CHEBI:75092
DM2OGZ5	DE	Discovery agent

DMB91UL	ID	DMB91UL
DMB91UL	DN	morphanthridine
DMB91UL	HS	Investigative
DMB91UL	SN	MORPHANTHRIDINE; 11H-Dibenz[b,e]azepine; 11H-dibenzo[b,e]azepine; 256-86-0; CHEMBL1085101; Homoacridan; 11H-benzo[c][1]benzazepine; SCHEMBL1150250; GTPL6473; CTK1A3708; DTXSID00446803; IDWNSAXOQLJYOF-UHFFFAOYSA-N
DMB91UL	DT	Small molecular drug
DMB91UL	PC	10878016
DMB91UL	MW	193.24
DMB91UL	FM	C14H11N
DMB91UL	IC	InChI=1S/C14H11N/c1-2-7-13-10-15-14-8-4-3-6-12(14)9-11(13)5-1/h1-8,10H,9H2
DMB91UL	CS	C1C2=CC=CC=C2C=NC3=CC=CC=C31
DMB91UL	IK	IDWNSAXOQLJYOF-UHFFFAOYSA-N
DMB91UL	IU	11H-benzo[c][1]benzazepine
DMB91UL	CA	CAS 256-86-0
DMB91UL	DE	Discovery agent

DM9A1RY	ID	DM9A1RY
DM9A1RY	DN	MORPHICEPTIN
DM9A1RY	HS	Investigative
DM9A1RY	SN	Morphiceptin; Deproceptin; Tyr-pro-phe-pro amide; Tyr-pro-phe-D-pro-NH2; beta-Casomorphine(1-4) amide; NH(4)-Tyr-pro-phe-pro-conh(2); Tyr-Pro-Phe-Pro-NH2; Tyrosyl-prolyl-phenylalanyl-D-prolinamide; UNII-97TZA8ANPC; H-Tyr-Pro-Phe-Pro-NH2; L-Tyrosyl-L-prolyl-L-phenylalanyl-L-prolinamide; 74135-04-9; b-Casomorphin-4-amide; 97TZA8ANPC; CHEMBL362991; L-Prolinamide, L-tyrosyl-L-prolyl-L-phenylalanyl-
DM9A1RY	DT	Small molecular drug
DM9A1RY	PC	119303
DM9A1RY	MW	521.6
DM9A1RY	FM	C28H35N5O5
DM9A1RY	IC	InChI=1S/C28H35N5O5/c29-21(16-19-10-12-20(34)13-11-19)27(37)33-15-5-9-24(33)26(36)31-22(17-18-6-2-1-3-7-18)28(38)32-14-4-8-23(32)25(30)35/h1-3,6-7,10-13,21-24,34H,4-5,8-9,14-17,29H2,(H2,30,35)(H,31,36)/t21-,22-,23-,24-/m0/s1
DM9A1RY	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N4CCC[C@H]4C(=O)N
DM9A1RY	IK	LSQXZIUREIDSHZ-ZJZGAYNASA-N
DM9A1RY	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM9A1RY	CA	CAS 74135-04-9
DM9A1RY	DE	Discovery agent

DMTHFSE	ID	DMTHFSE
DMTHFSE	DN	Morphinan Cyclic Imine analogue
DMTHFSE	HS	Investigative
DMTHFSE	DE	Discovery agent

DM9LQIA	ID	DM9LQIA
DM9LQIA	DN	MORPHINONE
DM9LQIA	HS	Investigative
DM9LQIA	SN	Morphinone; 467-02-7; UNII-28MBK63MAW; EINECS 207-384-0; BRN 0042464; 28MBK63MAW; Didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-one; CHEBI:16315; (5alpha)-7,8-Didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-one; Morphinan-6-one, 7,8-didehydro-4,5-epoxy-3-hydroxy-17-methyl-, (5-alpha)-; SCHEMBL427946; CHEMBL255467; CTK1D7902; DTXSID50196907; ZINC4095712; AKOS030240636; LS-92113; C01735; 3-hydroxy-17-methyl-7,8-didehydro-4,5-epoxy-5alpha-morphinan-6-one
DM9LQIA	DT	Small molecular drug
DM9LQIA	PC	5459823
DM9LQIA	MW	283.32
DM9LQIA	FM	C17H17NO3
DM9LQIA	IC	InChI=1S/C17H17NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,16,19H,6-8H2,1H3/t10-,11+,16-,17-/m0/s1
DM9LQIA	CS	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)C=C4
DM9LQIA	IK	PFBSOANQDDTNGJ-YNHQPCIGSA-N
DM9LQIA	IU	(4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM9LQIA	CA	CAS 467-02-7
DM9LQIA	CB	CHEBI:16315
DM9LQIA	DE	Discovery agent

DM05L3S	ID	DM05L3S
DM05L3S	DN	Morpholino(1'H-phenothiazin-1'-yl)methanone
DM05L3S	HS	Investigative
DM05L3S	SN	CHEMBL590511; 10-(4-morpholinylcarbonyl)-10H-phenothiazine; Morpholin-4-yl-phenothiazin-10-yl-methanone; AC1LE3IO; morpholin-4-yl(phenothiazin-10-yl)methanone; Oprea1_836979; MLS000557099; ARONIS009572; ZINC91251; MolPort-019-748-219; MolPort-001-510-993; HMS2479C10; BDBM50308416; STK144997; AKOS000498790; MCULE-6825355538; KS-0000415F; BAS 04087810; SMR000178119; morpholin-4-yl phenothiazin-10-yl ketone; BB0286549; ST45046313; Morpholino(1''H-phenothiazin-1''-yl)methanone; AN-329/40200546
DM05L3S	DT	Small molecular drug
DM05L3S	PC	705776
DM05L3S	MW	312.4
DM05L3S	FM	C17H16N2O2S
DM05L3S	IC	InChI=1S/C17H16N2O2S/c20-17(18-9-11-21-12-10-18)19-13-5-1-3-7-15(13)22-16-8-4-2-6-14(16)19/h1-8H,9-12H2
DM05L3S	CS	C1COCCN1C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM05L3S	IK	PWLGMYUBQYNSQV-UHFFFAOYSA-N
DM05L3S	IU	morpholin-4-yl(phenothiazin-10-yl)methanone
DM05L3S	DE	Discovery agent

DMV5T1I	ID	DMV5T1I
DMV5T1I	DN	MP-529
DMV5T1I	HS	Investigative
DMV5T1I	SN	SGI-1097; SGI-1215; SGI-498; SGI-503; Oral aurora kinase inhibitor (cancer), Montigen
DMV5T1I	CP	Montigen Pharmaceuticals Inc
DMV5T1I	DE	Solid tumour/cancer

DMONDP1	ID	DMONDP1
DMONDP1	DN	MPC-MECA
DMONDP1	HS	Investigative
DMONDP1	SN	CHEMBL2113610; GTPL460; BNXGNSTUSRFBCI-KSVNGYGVSA-N; BDBM50453540; Adenosine, N(6)-4-methoxybenzyl-4'-N-ethylcarbamoyl-4'-dehydroxymethyl-; 5'-Ethylamino-N-(4-methoxybenzyl)-5'-oxo-5'-deoxyadenosine
DMONDP1	DT	Small molecular drug
DMONDP1	PC	10432715
DMONDP1	MW	428.4
DMONDP1	FM	C20H24N6O5
DMONDP1	IC	InChI=1S/C20H24N6O5/c1-3-21-19(29)16-14(27)15(28)20(31-16)26-10-25-13-17(23-9-24-18(13)26)22-8-11-4-6-12(30-2)7-5-11/h4-7,9-10,14-16,20,27-28H,3,8H2,1-2H3,(H,21,29)(H,22,23,24)/t14-,15+,16-,20+/m0/s1
DMONDP1	CS	CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)OC)O)O
DMONDP1	IK	BNXGNSTUSRFBCI-KSVNGYGVSA-N
DMONDP1	IU	(2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-[(4-methoxyphenyl)methylamino]purin-9-yl]oxolane-2-carboxamide
DMONDP1	DE	Discovery agent

DMYX31S	ID	DMYX31S
DMYX31S	DN	MPDT
DMYX31S	HS	Investigative
DMYX31S	SN	BGC 20-761; 17375-63-2; UNII-6G5F6ESV5I; 6G5F6ESV5I; CHEMBL7318; BGC-20-761; 5-Methoxy-N,N-dimethyl-2-phenyl-1H-indole-3-ethanamine; 2-(5-methoxy-2-phenyl-1H-indol-3-yl)-N,N-dimethylethanamine; MPDT; AC1OCFJ3; GTPL71; SCHEMBL5763578; N,N-Dimethyl-2-(5-methoxy-2-phenylindol-3-yl)ethylamine; Indole, 3-(2-(dimethylamino)ethyl)-5-methoxy-2-phenyl-; 1H-Indole-3-ethanamine, 5-methoxy-N,N-dimethyl-2-phenyl-; MolPort-023-276-754; PDSP2_001402; BDBM50085970; PDSP1_001418; ZINC13805807; AKOS024457555; NCGC00370860-01
DMYX31S	DT	Small molecular drug
DMYX31S	PC	6918515
DMYX31S	MW	294.4
DMYX31S	FM	C19H22N2O
DMYX31S	IC	InChI=1S/C19H22N2O/c1-21(2)12-11-16-17-13-15(22-3)9-10-18(17)20-19(16)14-7-5-4-6-8-14/h4-10,13,20H,11-12H2,1-3H3
DMYX31S	CS	CN(C)CCC1=C(NC2=C1C=C(C=C2)OC)C3=CC=CC=C3
DMYX31S	IK	VSGPGYWZVPDDSK-UHFFFAOYSA-N
DMYX31S	IU	2-(5-methoxy-2-phenyl-1H-indol-3-yl)-N,N-dimethylethanamine
DMYX31S	CA	CAS 17375-63-2
DMYX31S	DE	Discovery agent

DMJRK47	ID	DMJRK47
DMJRK47	DN	M-Phenoxybenzoic Acid For Cis-Isomer
DMJRK47	HS	Investigative
DMJRK47	SN	3-Phenoxybenzoic acid; 3739-38-6; m-Phenoxybenzoic acid; Benzoic acid, 3-phenoxy-; 3-Carboxydiphenyl ether; UNII-69DC2655VH; BENZOIC ACID, m-PHENOXY-; 3-Phenoxy-benzoic acid; EINECS 223-121-2; CHEMBL663; BRN 2105574; M-PHENOXYBENZOIC ACID FOR CIS-ISOMER; CHEBI:72631; NXTDJHZGHOFSQG-UHFFFAOYSA-N; 69DC2655VH; VJJ; 3-Phenoxybenzoicacid; m-phenoxy benzoic acid; m-carboxydiphenyl ether; PubChem14424; 3-phenoxy benzoic acid; meta-phenoxybenzoic acid; ACMC-1CJQX; Enamine_000396; AC1L2EBV; Benzoic acid,3-phenoxy-; 3-PhOC6H4COOH
DMJRK47	DT	Small molecular drug
DMJRK47	PC	19539
DMJRK47	MW	214.22
DMJRK47	FM	C13H10O3
DMJRK47	IC	InChI=1S/C13H10O3/c14-13(15)10-5-4-8-12(9-10)16-11-6-2-1-3-7-11/h1-9H,(H,14,15)
DMJRK47	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)O
DMJRK47	IK	NXTDJHZGHOFSQG-UHFFFAOYSA-N
DMJRK47	IU	3-phenoxybenzoic acid
DMJRK47	CA	CAS 3739-38-6
DMJRK47	CB	CHEBI:72631
DMJRK47	DE	Discovery agent

DMJHQ9T	ID	DMJHQ9T
DMJHQ9T	DN	MPPG
DMJHQ9T	HS	Investigative
DMJHQ9T	SN	MPPG; 169209-65-8; 2-amino-2-(4-phosphonophenyl)propanoic acid; CHEMBL86508; AC1N11KO; GTPL1415; SCHEMBL12648709; CTK8F0596; DTXSID80398316; MolPort-003-983-629; MPPG, &gt;=97% (NMR), solid; BDBM50089910; MFCD00672651; BN0344; AKOS024458668; API0007557; (RS)- -Methyl-4-phosphonophenylglycine; NCGC00024826-02; (RS)-; A-Methyl-4-phosphonophenylglycine; RT-013949; 2-Amino-2-(4-phosphono-phenyl)-propionic acid; L000410; SR-01000597457; J-010517; SR-01000597457-1; 2-Amino-2-(4-phosphono-phenyl)-propionic acid(RS-MPPG)
DMJHQ9T	DT	Small molecular drug
DMJHQ9T	PC	3972752
DMJHQ9T	MW	245.17
DMJHQ9T	FM	C9H12NO5P
DMJHQ9T	IC	InChI=1S/C9H12NO5P/c1-9(10,8(11)12)6-2-4-7(5-3-6)16(13,14)15/h2-5H,10H2,1H3,(H,11,12)(H2,13,14,15)
DMJHQ9T	CS	CC(C1=CC=C(C=C1)P(=O)(O)O)(C(=O)O)N
DMJHQ9T	IK	PAONCRJPUQXPRW-UHFFFAOYSA-N
DMJHQ9T	IU	2-amino-2-(4-phosphonophenyl)propanoic acid
DMJHQ9T	CA	CAS 169209-65-8
DMJHQ9T	DE	Discovery agent

DMFKG7C	ID	DMFKG7C
DMFKG7C	DN	MP-RM-1
DMFKG7C	HS	Investigative
DMFKG7C	SN	Erbb-3 receptor-targeted mouse monoclonal antibody (cancer), Mediapharma
DMFKG7C	CP	MediaPharma Srl
DMFKG7C	DT	Antibody
DMFKG7C	DE	Solid tumour/cancer

DMWUK9G	ID	DMWUK9G
DMWUK9G	DN	MPrP
DMWUK9G	HS	Investigative
DMWUK9G	DT	Small molecular drug
DMWUK9G	PC	135857091
DMWUK9G	MW	467.6
DMWUK9G	FM	C30H33N3O2
DMWUK9G	IC	InChI=1S/C30H33N3O2/c1-22-29(24-11-15-27(34)16-12-24)31-33(26-13-17-28(35)18-14-26)30(22)25-9-7-23(8-10-25)6-5-21-32-19-3-2-4-20-32/h7-18,34-35H,2-6,19-21H2,1H3
DMWUK9G	CS	CC1=C(N(N=C1C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)C4=CC=C(C=C4)CCCN5CCCCC5
DMWUK9G	IK	XXRGLZUCVWZDBP-UHFFFAOYSA-N
DMWUK9G	IU	4-[1-(4-hydroxyphenyl)-4-methyl-5-[4-(3-piperidin-1-ylpropyl)phenyl]pyrazol-3-yl]phenol
DMWUK9G	DE	Discovery agent

DMQ357C	ID	DMQ357C
DMQ357C	DN	MQ1
DMQ357C	HS	Investigative
DMQ357C	SN	MQ-1; compound (R)-10a
DMQ357C	DT	Small molecular drug
DMQ357C	PC	57521365
DMQ357C	MW	429.6
DMQ357C	FM	C27H31N3O2
DMQ357C	IC	InChI=1S/C27H31N3O2/c1-18-25(29-27(31)21-7-10-24(11-8-21)32-17-20-5-6-20)12-9-22-15-23(16-28-26(18)22)19(2)30-13-3-4-14-30/h7-12,15-16,19-20H,3-6,13-14,17H2,1-2H3,(H,29,31)/t19-/m1/s1
DMQ357C	CS	CC1=C(C=CC2=CC(=CN=C12)[C@@H](C)N3CCCC3)NC(=O)C4=CC=C(C=C4)OCC5CC5
DMQ357C	IK	DFWKNBVJNXPUBW-LJQANCHMSA-N
DMQ357C	IU	4-(cyclopropylmethoxy)-N-[8-methyl-3-[(1R)-1-pyrrolidin-1-ylethyl]quinolin-7-yl]benzamide
DMQ357C	DE	Discovery agent

DMS7FC6	ID	DMS7FC6
DMS7FC6	DN	MR-1029
DMS7FC6	HS	Investigative
DMS7FC6	DT	Small molecular drug
DMS7FC6	PC	71716573
DMS7FC6	MW	297.4
DMS7FC6	FM	C19H23NO2
DMS7FC6	IC	InChI=1S/C19H23NO2/c1-13-18-10-14-5-6-15(21)11-17(14)19(13,2)7-8-20(18)12-16-4-3-9-22-16/h3-6,9,11,13,18,21H,7-8,10,12H2,1-2H3/t13-,18+,19+/m0/s1
DMS7FC6	CS	C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC4=CC=CO4)C)C=C(C=C3)O
DMS7FC6	IK	ICHXZERPLTYYPM-MJXNMMHHSA-N
DMS7FC6	IU	(1R,9R,13R)-10-(furan-2-ylmethyl)-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMS7FC6	DE	Discovery agent

DM5WMXJ	ID	DM5WMXJ
DM5WMXJ	DN	MR-1526
DM5WMXJ	HS	Investigative
DM5WMXJ	DT	Small molecular drug
DM5WMXJ	PC	73352838
DM5WMXJ	MW	315.4
DM5WMXJ	FM	C19H25NO3
DM5WMXJ	IC	InChI=1S/C19H25NO3/c1-12-17-9-13-3-4-14(21)10-16(13)19(12,2)7-8-20(17)11-15-5-6-18(22)23-15/h3-4,10,12,15,17,21H,5-9,11H2,1-2H3/t12-,15+,17+,19-/m0/s1
DM5WMXJ	CS	C[C@H]1[C@H]2CC3=C([C@]1(CCN2C[C@H]4CCC(=O)O4)C)C=C(C=C3)O
DM5WMXJ	IK	HHASRPPPJAXSNL-IQRRUJBNSA-N
DM5WMXJ	IU	(5R)-5-[[(1S,9R,13R)-4-hydroxy-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-10-yl]methyl]oxolan-2-one
DM5WMXJ	DE	Discovery agent

DMM2WG7	ID	DMM2WG7
DMM2WG7	DN	MR-16089
DMM2WG7	HS	Investigative
DMM2WG7	SN	MR-16089; CHEMBL1095413; BDBM50318402
DMM2WG7	DT	Small molecular drug
DMM2WG7	PC	46887422
DMM2WG7	MW	370.3
DMM2WG7	FM	C20H13F3N2O2
DMM2WG7	IC	InChI=1S/C20H13F3N2O2/c21-20(22,23)27-15-7-5-14(6-8-15)18-16(11-13-3-1-9-24-12-13)19(26)17-4-2-10-25(17)18/h1-12,18H/b16-11-
DMM2WG7	CS	C1=CC(=CN=C1)/C=C\\2/C(N3C=CC=C3C2=O)C4=CC=C(C=C4)OC(F)(F)F
DMM2WG7	IK	NUADOLYUKJMRKY-WJDWOHSUSA-N
DMM2WG7	IU	(2Z)-2-(pyridin-3-ylmethylidene)-3-[4-(trifluoromethoxy)phenyl]-3H-pyrrolizin-1-one
DMM2WG7	DE	Discovery agent

DMF04AG	ID	DMF04AG
DMF04AG	DN	MR-2034
DMF04AG	HS	Investigative
DMF04AG	SN	MR 2034; MR-2034; (-)-alpha-(1R,5R,9R)-5,9-Dimethyl-2-(L-tetrahydrofurfuryl)-2'-hydroxy-6,7-benzomorphan; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-((tetrahydro-2-furanyl)methyl)-, (2R-(2-alpha,3(R*),6-alpha,11R*))-; 57236-85-8; AC1Q7AHJ; (2r,6r)-6,11-dimethyl-3-[(2r)-tetrahydrofuran-2-ylmethyl]-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; BDBM81932; MR2034; LS-90624; CAS_57236-85-8
DMF04AG	DT	Small molecular drug
DMF04AG	PC	123980
DMF04AG	MW	301.4
DMF04AG	FM	C19H27NO2
DMF04AG	IC	InChI=1S/C19H27NO2/c1-13-18-10-14-5-6-15(21)11-17(14)19(13,2)7-8-20(18)12-16-4-3-9-22-16/h5-6,11,13,16,18,21H,3-4,7-10,12H2,1-2H3/t13?,16-,18-,19-/m1/s1
DMF04AG	CS	CC1[C@H]2CC3=C([C@@]1(CCN2C[C@H]4CCCO4)C)C=C(C=C3)O
DMF04AG	IK	NLKLXMMOJZHSCB-SENCRUMESA-N
DMF04AG	IU	(1R,9R)-1,13-dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMF04AG	CA	CAS 57236-85-8
DMF04AG	DE	Discovery agent

DMEBQLK	ID	DMEBQLK
DMEBQLK	DN	MR-20492
DMEBQLK	HS	Investigative
DMEBQLK	SN	MR-20492; CHEMBL9165; SCHEMBL6064449; BDBM50070097; 6-(4-Chloro-phenyl)-7-[1-pyridin-4-yl-meth-(Z)-ylidene]-6,7-dihydro-5H-indolizin-8-one; 6-(4-Chlorophenyl)-7-(4-pyridylmethylene)-5,6-dihydroindolizine-8(7H)-one
DMEBQLK	DT	Small molecular drug
DMEBQLK	PC	9819080
DMEBQLK	MW	334.8
DMEBQLK	FM	C20H15ClN2O
DMEBQLK	IC	InChI=1S/C20H15ClN2O/c21-16-5-3-15(4-6-16)18-13-23-11-1-2-19(23)20(24)17(18)12-14-7-9-22-10-8-14/h1-12,18H,13H2/b17-12-
DMEBQLK	CS	C1C(/C(=C/C2=CC=NC=C2)/C(=O)C3=CC=CN31)C4=CC=C(C=C4)Cl
DMEBQLK	IK	OMGJLQMHGRFTAP-ATVHPVEESA-N
DMEBQLK	IU	(7Z)-6-(4-chlorophenyl)-7-(pyridin-4-ylmethylidene)-5,6-dihydroindolizin-8-one
DMEBQLK	DE	Discovery agent

DMC79YF	ID	DMC79YF
DMC79YF	DN	MR-20494
DMC79YF	HS	Investigative
DMC79YF	SN	MR-20494; CHEMBL1098737; BDBM50318405
DMC79YF	DT	Small molecular drug
DMC79YF	PC	10019821
DMC79YF	MW	334.8
DMC79YF	FM	C20H15ClN2O
DMC79YF	IC	InChI=1S/C20H15ClN2O/c21-16-7-5-15(6-8-16)18-13-23-10-2-4-19(23)20(24)17(18)11-14-3-1-9-22-12-14/h1-12,18H,13H2/b17-11-
DMC79YF	CS	C1C(/C(=C/C2=CN=CC=C2)/C(=O)C3=CC=CN31)C4=CC=C(C=C4)Cl
DMC79YF	IK	UQXVMFWGYFYXDC-BOPFTXTBSA-N
DMC79YF	IU	(7Z)-6-(4-chlorophenyl)-7-(pyridin-3-ylmethylidene)-5,6-dihydroindolizin-8-one
DMC79YF	DE	Discovery agent

DMTCG8M	ID	DMTCG8M
DMTCG8M	DN	MR-20496
DMTCG8M	HS	Investigative
DMTCG8M	SN	CHEMBL9179; MR-20496; BDBM50070095
DMTCG8M	DT	Small molecular drug
DMTCG8M	PC	44265823
DMTCG8M	MW	297.3
DMTCG8M	FM	C21H15NO
DMTCG8M	IC	InChI=1S/C21H15NO/c23-21-18-9-5-4-8-17(18)20(16-6-2-1-3-7-16)19(21)14-15-10-12-22-13-11-15/h1-14,20H/b19-14-
DMTCG8M	CS	C1=CC=C(C=C1)C\\2C3=CC=CC=C3C(=O)/C2=C\\C4=CC=NC=C4
DMTCG8M	IK	ALLOQIRZHVQYIA-RGEXLXHISA-N
DMTCG8M	IU	(2Z)-3-phenyl-2-(pyridin-4-ylmethylidene)-3H-inden-1-one
DMTCG8M	DE	Discovery agent

DMSR3OI	ID	DMSR3OI
DMSR3OI	DN	MR-20814
DMSR3OI	HS	Investigative
DMSR3OI	DE	Discovery agent

DMIQ8GL	ID	DMIQ8GL
DMIQ8GL	DN	MR-22388
DMIQ8GL	HS	Investigative
DMIQ8GL	SN	MR-22388; CHEMBL287508; 3-(3-hydroxy-4-methoxyphenyl)-8h-thieno[2,3-b]pyrrolizin-8-one; SCHEMBL7001747; Thienopyrrolizine derivative, 4g; IXGRUAKWRHZSAP-UHFFFAOYSA-N; BDBM50103203; 3-(3-Hydroxy-4-methoxy-phenyl)-thieno[2,3-b]pyrrolizin-8-one
DMIQ8GL	DT	Small molecular drug
DMIQ8GL	PC	9904289
DMIQ8GL	MW	297.3
DMIQ8GL	FM	C16H11NO3S
DMIQ8GL	IC	InChI=1S/C16H11NO3S/c1-20-13-5-4-9(7-12(13)18)10-8-21-16-14(10)17-6-2-3-11(17)15(16)19/h2-8,18H,1H3
DMIQ8GL	CS	COC1=C(C=C(C=C1)C2=CSC3=C2N4C=CC=C4C3=O)O
DMIQ8GL	IK	IXGRUAKWRHZSAP-UHFFFAOYSA-N
DMIQ8GL	IU	3-(3-hydroxy-4-methoxyphenyl)thieno[2,3-b]pyrrolizin-8-one
DMIQ8GL	DE	Discovery agent

DMXWSIU	ID	DMXWSIU
DMXWSIU	DN	MR-2266
DMXWSIU	HS	Investigative
DMXWSIU	SN	Mrz 2266 BS; MR 2266; MR-2266; MR-2266-BS; (-)-Mr 2266; (-)-2-(3-Furylmethyl)-5,9-diethyl-2'-hydroxy-6,7-benzomorphan; 56649-76-4; (+/-)-2-(3-Furylmethyl)-2'-hydroxy-5,9alpha-diethyl-6,7-benzomorphan hydrochloride; 2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R,6R,11R)-; 2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R-(2alpha,6alpha,11R*))-; Mr1302 MS; Mr2267; Mr 2267; SCHEMBL4404993; BDBM82508; Mr2266; ZINC5492542; CAS_56649-76-4
DMXWSIU	DT	Small molecular drug
DMXWSIU	PC	3034816
DMXWSIU	MW	325.4
DMXWSIU	FM	C21H27NO2
DMXWSIU	IC	InChI=1S/C21H27NO2/c1-3-18-20-11-16-5-6-17(23)12-19(16)21(18,4-2)8-9-22(20)13-15-7-10-24-14-15/h5-7,10,12,14,18,20,23H,3-4,8-9,11,13H2,1-2H3/t18-,20+,21+/m0/s1
DMXWSIU	CS	CC[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC4=COC=C4)CC)C=C(C=C3)O
DMXWSIU	IK	HEYXXBUDMDVUNQ-CEWLAPEOSA-N
DMXWSIU	IU	(1R,9R,13R)-1,13-diethyl-10-(furan-3-ylmethyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMXWSIU	CA	CAS 56649-76-4
DMXWSIU	DE	Discovery agent

DMUK1PA	ID	DMUK1PA
DMUK1PA	DN	MRE 2029F20
DMUK1PA	HS	Investigative
DMUK1PA	SN	MRE-2029F20
DMUK1PA	DT	Small molecular drug
DMUK1PA	PC	135484064
DMUK1PA	MW	509.5
DMUK1PA	FM	C24H27N7O6
DMUK1PA	IC	InChI=1S/C24H27N7O6/c1-4-8-30-22-20(23(33)31(9-5-2)24(30)34)26-21(27-22)15-11-19(28-29(15)3)35-12-18(32)25-14-6-7-16-17(10-14)37-13-36-16/h6-7,10-11H,4-5,8-9,12-13H2,1-3H3,(H,25,32)(H,26,27)
DMUK1PA	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC5=C(C=C4)OCO5
DMUK1PA	IK	DBWQRFKXNBVPGA-UHFFFAOYSA-N
DMUK1PA	IU	N-(1,3-benzodioxol-5-yl)-2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetamide
DMUK1PA	DE	Discovery agent

DM72US0	ID	DM72US0
DM72US0	DN	MRE 3008F20
DM72US0	HS	Investigative
DM72US0	SN	CJRNHKSLHHWUAB-UHFFFAOYSA-N; MRE 3008-F20; 252979-43-4; CHEMBL302765; MCP-NECA; 3-[4-(furan-2-yl)-11-propyl-3,5,6,8,10,11-hexaazatricyclo[7300^{2,6}]dodeca-1(12),2,4,7,9-pentaen-7-yl]-1-(4-methoxyphenyl)urea; [3H]MRE 3008F20; GTPL477; GTPL459; SCHEMBL958405; BDBM85618; MolPort-023-277-046; ZINC602413; MRE-3008F-20; AKOS024457944; NCGC00378820-01; KB-274663; J1251181G; L000411; N-[2-(2-Furanyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N'-(4-methoxyphenyl)urea;  MRE 3008-F20
DM72US0	DT	Small molecular drug
DM72US0	PC	5310960
DM72US0	MW	432.4
DM72US0	FM	C21H20N8O3
DM72US0	IC	InChI=1S/C21H20N8O3/c1-3-10-28-12-15-17(26-28)24-20(25-21(30)22-13-6-8-14(31-2)9-7-13)29-19(15)23-18(27-29)16-5-4-11-32-16/h4-9,11-12H,3,10H2,1-2H3,(H2,22,24,25,26,30)
DM72US0	CS	CCCN1C=C2C(=N1)N=C(N3C2=NC(=N3)C4=CC=CO4)NC(=O)NC5=CC=C(C=C5)OC
DM72US0	IK	CJRNHKSLHHWUAB-UHFFFAOYSA-N
DM72US0	IU	1-[4-(furan-2-yl)-11-propyl-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(12),2,4,7,9-pentaen-7-yl]-3-(4-methoxyphenyl)urea
DM72US0	DE	Discovery agent

DMMFJA8	ID	DMMFJA8
DMMFJA8	DN	MRE 3010F20
DMMFJA8	HS	Investigative
DMMFJA8	SN	MRE-3010F20
DMMFJA8	DT	Small molecular drug
DMMFJA8	PC	73754994
DMMFJA8	MW	439.9
DMMFJA8	FM	C21H22ClN7O2
DMMFJA8	IC	InChI=1S/C21H22ClN7O2/c1-2-8-29-11-14-16-17(25-19(24-16)15-7-4-9-31-15)20(26-18(14)28-29)27-21(30)23-13-6-3-5-12(22)10-13/h3,5-6,10-11,15,17H,2,4,7-9H2,1H3,(H2,23,26,27,28,30)
DMMFJA8	CS	CCCN1C=C2C3=NC(=NC3C(=NC2=N1)NC(=O)NC4=CC(=CC=C4)Cl)C5CCCO5
DMMFJA8	IK	AQJYVSDITBKWSI-UHFFFAOYSA-N
DMMFJA8	IU	1-(3-chlorophenyl)-3-[4-(oxolan-2-yl)-11-propyl-3,5,8,10,11-pentazatricyclo[7.3.0.02,6]dodeca-1(12),2,4,7,9-pentaen-7-yl]urea
DMMFJA8	DE	Discovery agent

DM7VQTO	ID	DM7VQTO
DM7VQTO	DN	MRK016
DM7VQTO	HS	Investigative
DM7VQTO	SN	MRK-016; MRK 016
DM7VQTO	DT	Small molecular drug
DM7VQTO	PC	6918583
DM7VQTO	MW	368.4
DM7VQTO	FM	C17H20N8O2
DM7VQTO	IC	InChI=1S/C17H20N8O2/c1-10-6-11(23-27-10)15-21-19-7-12-14(17(2,3)4)16(22-25(12)15)26-8-13-18-9-20-24(13)5/h6-7,9H,8H2,1-5H3
DM7VQTO	CS	CC1=CC(=NO1)C2=NN=CC3=C(C(=NN32)OCC4=NC=NN4C)C(C)(C)C
DM7VQTO	IK	QYSYOGCIDRANAR-UHFFFAOYSA-N
DM7VQTO	IU	3-[3-tert-butyl-2-[(2-methyl-1,2,4-triazol-3-yl)methoxy]pyrazolo[1,5-d][1,2,4]triazin-7-yl]-5-methyl-1,2-oxazole
DM7VQTO	CA	CAS 342652-67-9
DM7VQTO	DE	Discovery agent

DM7IK68	ID	DM7IK68
DM7IK68	DN	MRS 2219
DM7IK68	HS	Investigative
DM7IK68	SN	MRS2219; MRS-2220
DM7IK68	DT	Small molecular drug
DM7IK68	PC	3960826
DM7IK68	MW	231.14
DM7IK68	FM	C8H10NO5P
DM7IK68	IC	InChI=1S/C8H10NO5P/c1-5-8(10)7-4-14-15(11,12)13-3-6(7)2-9-5/h2,10H,3-4H2,1H3,(H,11,12)
DM7IK68	CS	CC1=NC=C2COP(=O)(OCC2=C1O)O
DM7IK68	IK	KCAJHODRYGNBSX-UHFFFAOYSA-N
DM7IK68	IU	3-hydroxy-8-methyl-3-oxo-1,5-dihydro-[1,3,2]dioxaphosphepino[5,6-c]pyridin-9-ol
DM7IK68	CA	CAS 14141-47-0
DM7IK68	DE	Discovery agent

DMBXKYR	ID	DMBXKYR
DMBXKYR	DN	MRS1041
DMBXKYR	HS	Investigative
DMBXKYR	SN	3,5,7-Triethoxyflavone; MRS-1041; CHEMBL72862; 3,5,7-triethoxy-2-phenyl-chromen-4-one; GTPL392; SCHEMBL1663784; BDBM50051347;  3,5,7-triethoxyflavone; 3,5,7-Triethoxy-2-phenyl-chromen-4-one
DMBXKYR	DT	Small molecular drug
DMBXKYR	PC	10247549
DMBXKYR	MW	354.4
DMBXKYR	FM	C21H22O5
DMBXKYR	IC	InChI=1S/C21H22O5/c1-4-23-15-12-16(24-5-2)18-17(13-15)26-20(14-10-8-7-9-11-14)21(19(18)22)25-6-3/h7-13H,4-6H2,1-3H3
DMBXKYR	CS	CCOC1=CC2=C(C(=C1)OCC)C(=O)C(=C(O2)C3=CC=CC=C3)OCC
DMBXKYR	IK	YMQQPRDUZIXHBJ-UHFFFAOYSA-N
DMBXKYR	IU	3,5,7-triethoxy-2-phenylchromen-4-one
DMBXKYR	DE	Discovery agent

DMVT865	ID	DMVT865
DMVT865	DN	MRS1042
DMVT865	HS	Investigative
DMVT865	SN	MRS-1042
DMVT865	DT	Small molecular drug
DMVT865	PC	10500941
DMVT865	MW	396.5
DMVT865	FM	C24H28O5
DMVT865	IC	InChI=1S/C24H28O5/c1-4-12-26-18-15-19(27-13-5-2)21-20(16-18)29-23(17-10-8-7-9-11-17)24(22(21)25)28-14-6-3/h7-11,15-16H,4-6,12-14H2,1-3H3
DMVT865	CS	CCCOC1=CC2=C(C(=C1)OCCC)C(=O)C(=C(O2)C3=CC=CC=C3)OCCC
DMVT865	IK	ABZJCSJCNNCZRY-UHFFFAOYSA-N
DMVT865	IU	2-phenyl-3,5,7-tripropoxychromen-4-one
DMVT865	DE	Discovery agent

DM50QBR	ID	DM50QBR
DM50QBR	DN	MRS1062
DM50QBR	HS	Investigative
DM50QBR	SN	MRS-1062
DM50QBR	DT	Small molecular drug
DM50QBR	PC	18784677
DM50QBR	MW	370.4
DM50QBR	FM	C24H18O4
DM50QBR	IC	InChI=1S/C24H18O4/c1-27-19-12-13-21-20(16-19)22(25)23(26)24(28-21,18-10-6-3-7-11-18)15-14-17-8-4-2-5-9-17/h2-13,16,23,26H,1H3
DM50QBR	CS	COC1=CC2=C(C=C1)OC(C(C2=O)O)(C#CC3=CC=CC=C3)C4=CC=CC=C4
DM50QBR	IK	ITOHYACNWAMSCT-UHFFFAOYSA-N
DM50QBR	IU	3-hydroxy-6-methoxy-2-phenyl-2-(2-phenylethynyl)-3H-chromen-4-one
DM50QBR	DE	Discovery agent

DMYAHU3	ID	DMYAHU3
DMYAHU3	DN	MRS1065
DMYAHU3	HS	Investigative
DMYAHU3	SN	MRS 1065
DMYAHU3	DT	Small molecular drug
DMYAHU3	PC	10710647
DMYAHU3	MW	318.3
DMYAHU3	FM	C20H14O4
DMYAHU3	IC	InChI=1S/C20H14O4/c1-22-20-15-9-10-23-17(15)12-18-19(20)16(21)11-14(24-18)8-7-13-5-3-2-4-6-13/h2-12H,1H3/b8-7+
DMYAHU3	CS	COC1=C2C=COC2=CC3=C1C(=O)C=C(O3)/C=C/C4=CC=CC=C4
DMYAHU3	IK	HTBFQFPYNPJVLO-BQYQJAHWSA-N
DMYAHU3	IU	4-methoxy-7-[(E)-2-phenylethenyl]furo[3,2-g]chromen-5-one
DMYAHU3	CA	CAS 138565-05-6
DMYAHU3	DE	Discovery agent

DMAEW9M	ID	DMAEW9M
DMAEW9M	DN	MRS1067
DMAEW9M	HS	Investigative
DMAEW9M	SN	MRS-1067
DMAEW9M	DT	Small molecular drug
DMAEW9M	PC	252716
DMAEW9M	MW	363.2
DMAEW9M	FM	C19H16Cl2O3
DMAEW9M	IC	InChI=1S/C19H16Cl2O3/c1-10(2)23-16-8-11(3)4-6-13(16)19-17(21)18(22)14-9-12(20)5-7-15(14)24-19/h4-10H,1-3H3
DMAEW9M	CS	CC1=CC(=C(C=C1)C2=C(C(=O)C3=C(O2)C=CC(=C3)Cl)Cl)OC(C)C
DMAEW9M	IK	PWGZOUCWGRTPSM-UHFFFAOYSA-N
DMAEW9M	IU	3,6-dichloro-2-(4-methyl-2-propan-2-yloxyphenyl)chromen-4-one
DMAEW9M	CA	CAS 70460-45-6
DMAEW9M	DE	Discovery agent

DMKELWG	ID	DMKELWG
DMKELWG	DN	MRS1084
DMKELWG	HS	Investigative
DMKELWG	SN	4-(propyloxy)-7-trans-styrylvisnagin
DMKELWG	DT	Small molecular drug
DMKELWG	PC	10593671
DMKELWG	MW	346.4
DMKELWG	FM	C22H18O4
DMKELWG	IC	InChI=1S/C22H18O4/c1-2-11-25-22-17-10-12-24-19(17)14-20-21(22)18(23)13-16(26-20)9-8-15-6-4-3-5-7-15/h3-10,12-14H,2,11H2,1H3/b9-8+
DMKELWG	CS	CCCOC1=C2C=COC2=CC3=C1C(=O)C=C(O3)/C=C/C4=CC=CC=C4
DMKELWG	IK	RCPBGBWHKGZPFO-CMDGGOBGSA-N
DMKELWG	IU	7-[(E)-2-phenylethenyl]-4-propoxyfuro[3,2-g]chromen-5-one
DMKELWG	DE	Discovery agent

DM1K5E2	ID	DM1K5E2
DM1K5E2	DN	MRS1086
DM1K5E2	HS	Investigative
DM1K5E2	SN	MRS-1086
DM1K5E2	DT	Small molecular drug
DM1K5E2	PC	10813088
DM1K5E2	MW	442.5
DM1K5E2	FM	C25H30O7
DM1K5E2	IC	InChI=1S/C25H30O7/c1-6-27-16-11-12-18(19(13-16)29-8-3)24-25(31-10-5)23(26)22-20(30-9-4)14-17(28-7-2)15-21(22)32-24/h11-15H,6-10H2,1-5H3
DM1K5E2	CS	CCOC1=CC(=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C=C3OCC)OCC)OCC)OCC
DM1K5E2	IK	JVGSHXMDRPGOQM-UHFFFAOYSA-N
DM1K5E2	IU	2-(2,4-diethoxyphenyl)-3,5,7-triethoxychromen-4-one
DM1K5E2	DE	Discovery agent

DMSKWL7	ID	DMSKWL7
DMSKWL7	DN	MRS1088
DMSKWL7	HS	Investigative
DMSKWL7	SN	3,6-dichloroflavone; MRS-1088; NSC-74876
DMSKWL7	DT	Small molecular drug
DMSKWL7	PC	252696
DMSKWL7	MW	291.1
DMSKWL7	FM	C15H8Cl2O2
DMSKWL7	IC	InChI=1S/C15H8Cl2O2/c16-10-6-7-12-11(8-10)14(18)13(17)15(19-12)9-4-2-1-3-5-9/h1-8H
DMSKWL7	CS	C1=CC=C(C=C1)C2=C(C(=O)C3=C(O2)C=CC(=C3)Cl)Cl
DMSKWL7	IK	PTNKLWUWHUGKTA-UHFFFAOYSA-N
DMSKWL7	IU	3,6-dichloro-2-phenylchromen-4-one
DMSKWL7	CA	CAS 13179-00-5
DMSKWL7	DE	Discovery agent

DM801AO	ID	DM801AO
DM801AO	DN	MRS1093
DM801AO	HS	Investigative
DM801AO	SN	3,7-Diethoxy-5-hydroxyflavone; MRS-1093
DM801AO	DT	Small molecular drug
DM801AO	PC	10568125
DM801AO	MW	326.3
DM801AO	FM	C19H18O5
DM801AO	IC	InChI=1S/C19H18O5/c1-3-22-13-10-14(20)16-15(11-13)24-18(12-8-6-5-7-9-12)19(17(16)21)23-4-2/h5-11,20H,3-4H2,1-2H3
DM801AO	CS	CCOC1=CC(=C2C(=C1)OC(=C(C2=O)OCC)C3=CC=CC=C3)O
DM801AO	IK	ZPEWNDIPSPULBP-UHFFFAOYSA-N
DM801AO	IU	3,7-diethoxy-5-hydroxy-2-phenylchromen-4-one
DM801AO	DE	Discovery agent

DMLOHAZ	ID	DMLOHAZ
DMLOHAZ	DN	MRS1097
DMLOHAZ	HS	Investigative
DMLOHAZ	SN	MRS-1097
DMLOHAZ	DT	Small molecular drug
DMLOHAZ	PC	9953766
DMLOHAZ	MW	417.5
DMLOHAZ	FM	C26H27NO4
DMLOHAZ	IC	InChI=1S/C26H27NO4/c1-4-30-25(28)22-18(3)27-24(20-14-10-7-11-15-20)23(26(29)31-5-2)21(22)17-16-19-12-8-6-9-13-19/h6-17,21,27H,4-5H2,1-3H3/b17-16+
DMLOHAZ	CS	CCOC(=O)C1=C(NC(=C(C1/C=C/C2=CC=CC=C2)C(=O)OCC)C3=CC=CC=C3)C
DMLOHAZ	IK	XCXCNPNUEPMYRS-WUKNDPDISA-N
DMLOHAZ	IU	diethyl 2-methyl-6-phenyl-4-[(E)-2-phenylethenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMLOHAZ	DE	Discovery agent

DMY4C0G	ID	DMY4C0G
DMY4C0G	DN	MRS1132
DMY4C0G	HS	Investigative
DMY4C0G	DT	Small molecular drug
DMY4C0G	PC	736736
DMY4C0G	MW	256.68
DMY4C0G	FM	C15H9ClO2
DMY4C0G	IC	InChI=1S/C15H9ClO2/c16-13-14(17)11-8-4-5-9-12(11)18-15(13)10-6-2-1-3-7-10/h1-9H
DMY4C0G	CS	C1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C3O2)Cl
DMY4C0G	IK	FHXDSQYFCFWKAW-UHFFFAOYSA-N
DMY4C0G	IU	3-chloro-2-phenylchromen-4-one
DMY4C0G	DE	Discovery agent

DMBXTPU	ID	DMBXTPU
DMBXTPU	DN	MRS1177
DMBXTPU	HS	Investigative
DMBXTPU	SN	MRS1177; CHEMBL317382; GTPL468; SCHEMBL1663767; MRS-1177; BDBM50053925; HY-120090; CS-0069480; N-(9-chloro-2-furan-2-yl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)benzamide; N-(9-Chloro-2-furan-2-yl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-benzamide
DMBXTPU	DT	Small molecular drug
DMBXTPU	PC	10045876
DMBXTPU	MW	389.8
DMBXTPU	FM	C20H12ClN5O2
DMBXTPU	IC	InChI=1S/C20H12ClN5O2/c21-13-8-9-15-14(11-13)18-23-17(16-7-4-10-28-16)25-26(18)20(22-15)24-19(27)12-5-2-1-3-6-12/h1-11H,(H,22,24,27)
DMBXTPU	CS	C1=CC=C(C=C1)C(=O)NC2=NC3=C(C=C(C=C3)Cl)C4=NC(=NN42)C5=CC=CO5
DMBXTPU	IK	XIEBLXLGWFCYEP-UHFFFAOYSA-N
DMBXTPU	IU	N-[9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]benzamide
DMBXTPU	DE	Discovery agent

DMGJ0IE	ID	DMGJ0IE
DMGJ0IE	DN	MRS1186
DMGJ0IE	HS	Investigative
DMGJ0IE	SN	MRS-1186
DMGJ0IE	DT	Small molecular drug
DMGJ0IE	PC	10065929
DMGJ0IE	MW	341.75
DMGJ0IE	FM	C16H12ClN5O2
DMGJ0IE	IC	InChI=1S/C16H12ClN5O2/c1-2-13(23)19-16-18-11-6-5-9(17)8-10(11)15-20-14(21-22(15)16)12-4-3-7-24-12/h3-8H,2H2,1H3,(H,18,19,23)
DMGJ0IE	CS	CCC(=O)NC1=NC2=C(C=C(C=C2)Cl)C3=NC(=NN31)C4=CC=CO4
DMGJ0IE	IK	SPZIDRYLSXDAEF-UHFFFAOYSA-N
DMGJ0IE	IU	N-[9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]propanamide
DMGJ0IE	DE	Discovery agent

DM9WX3C	ID	DM9WX3C
DM9WX3C	DN	MRS1191
DM9WX3C	HS	Investigative
DM9WX3C	SN	MRS-1191
DM9WX3C	DT	Small molecular drug
DM9WX3C	PC	393594
DM9WX3C	MW	477.5
DM9WX3C	FM	C31H27NO4
DM9WX3C	IC	InChI=1S/C31H27NO4/c1-3-35-30(33)27-22(2)32-29(25-17-11-6-12-18-25)28(26(27)20-19-23-13-7-4-8-14-23)31(34)36-21-24-15-9-5-10-16-24/h4-18,26,32H,3,21H2,1-2H3
DM9WX3C	CS	CCOC(=O)C1=C(NC(=C(C1C#CC2=CC=CC=C2)C(=O)OCC3=CC=CC=C3)C4=CC=CC=C4)C
DM9WX3C	IK	SNVFDPHQAOXWJZ-UHFFFAOYSA-N
DM9WX3C	IU	5-O-benzyl 3-O-ethyl 2-methyl-6-phenyl-4-(2-phenylethynyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM9WX3C	CA	CAS 185222-90-6
DM9WX3C	DE	Discovery agent

DMT6JH9	ID	DMT6JH9
DMT6JH9	DN	MRS-1220
DMT6JH9	HS	Investigative
DMT6JH9	SN	MRS 1220; 183721-15-5; MRS-1220; CHEMBL88147; N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide; MRS1220; N-[9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-2-phenylacetamide; MRS 1200; NSC 695674; Tocris-1217; MRS 1220, solid; AC1Q3QZX; 9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline; GTPL448; SCHEMBL927261; AC1L96H4; CTK8F0085; CHEBI:92667; MolPort-003-958-674; ZINC602092; HMS3267D09; NSC695674; BDBM50053929; AKOS024456471; NSC-695674
DMT6JH9	DT	Small molecular drug
DMT6JH9	PC	393595
DMT6JH9	MW	403.8
DMT6JH9	FM	C21H14ClN5O2
DMT6JH9	IC	InChI=1S/C21H14ClN5O2/c22-14-8-9-16-15(12-14)20-25-19(17-7-4-10-29-17)26-27(20)21(23-16)24-18(28)11-13-5-2-1-3-6-13/h1-10,12H,11H2,(H,23,24,28)
DMT6JH9	CS	C1=CC=C(C=C1)CC(=O)NC2=NC3=C(C=C(C=C3)Cl)C4=NC(=NN42)C5=CC=CO5
DMT6JH9	IK	TWWFAXQOKNBUCR-UHFFFAOYSA-N
DMT6JH9	IU	N-[9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-2-phenylacetamide
DMT6JH9	CA	CAS 183721-15-5
DMT6JH9	CB	CHEBI:92667
DMT6JH9	DE	Discovery agent

DMLQYN7	ID	DMLQYN7
DMLQYN7	DN	MRS1476
DMLQYN7	HS	Investigative
DMLQYN7	SN	MRS-1476
DMLQYN7	DT	Small molecular drug
DMLQYN7	PC	9885773
DMLQYN7	MW	371.5
DMLQYN7	FM	C21H25NO3S
DMLQYN7	IC	InChI=1S/C21H25NO3S/c1-5-15-17(21(24)26-8-4)16(6-2)22-19(14-12-10-9-11-13-14)18(15)20(23)25-7-3/h9-13H,5-8H2,1-4H3
DMLQYN7	CS	CCC1=C(C(=NC(=C1C(=O)OCC)C2=CC=CC=C2)CC)C(=O)SCC
DMLQYN7	IK	WYZGZKCWULQWSH-UHFFFAOYSA-N
DMLQYN7	IU	ethyl 4,6-diethyl-5-ethylsulfanylcarbonyl-2-phenylpyridine-3-carboxylate
DMLQYN7	DE	Discovery agent

DMFJHMQ	ID	DMFJHMQ
DMFJHMQ	DN	MRS1486
DMFJHMQ	HS	Investigative
DMFJHMQ	SN	MRS-1486
DMFJHMQ	DT	Small molecular drug
DMFJHMQ	PC	9843120
DMFJHMQ	MW	385.5
DMFJHMQ	FM	C22H27NO3S
DMFJHMQ	IC	InChI=1S/C22H27NO3S/c1-5-12-17-18(22(25)27-8-4)16(6-2)19(21(24)26-7-3)20(23-17)15-13-10-9-11-14-15/h9-11,13-14H,5-8,12H2,1-4H3
DMFJHMQ	CS	CCCC1=NC(=C(C(=C1C(=O)SCC)CC)C(=O)OCC)C2=CC=CC=C2
DMFJHMQ	IK	GSMBGLUYORHXJR-UHFFFAOYSA-N
DMFJHMQ	IU	ethyl 4-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-6-propylpyridine-3-carboxylate
DMFJHMQ	DE	Discovery agent

DM3Q5NO	ID	DM3Q5NO
DM3Q5NO	DN	MRS1505
DM3Q5NO	HS	Investigative
DM3Q5NO	SN	MRS-1505
DM3Q5NO	DT	Small molecular drug
DM3Q5NO	PC	9802941
DM3Q5NO	MW	434
DM3Q5NO	FM	C23H28ClNO3S
DM3Q5NO	IC	InChI=1S/C23H28ClNO3S/c1-5-12-28-22(26)20-17(7-3)19(23(27)29-13-6-2)18(8-4)25-21(20)15-10-9-11-16(24)14-15/h9-11,14H,5-8,12-13H2,1-4H3
DM3Q5NO	CS	CCCOC(=O)C1=C(N=C(C(=C1CC)C(=O)SCCC)CC)C2=CC(=CC=C2)Cl
DM3Q5NO	IK	RPTCJTNYKDJGHU-UHFFFAOYSA-N
DM3Q5NO	IU	propyl 2-(3-chlorophenyl)-4,6-diethyl-5-propylsulfanylcarbonylpyridine-3-carboxylate
DM3Q5NO	DE	Discovery agent

DM4AONZ	ID	DM4AONZ
DM4AONZ	DN	MRS1523
DM4AONZ	HS	Investigative
DM4AONZ	SN	MRS 1523  ; MRS-1523
DM4AONZ	DT	Small molecular drug
DM4AONZ	PC	3661570
DM4AONZ	MW	399.5
DM4AONZ	FM	C23H29NO3S
DM4AONZ	IC	InChI=1S/C23H29NO3S/c1-5-12-17-19(23(26)28-8-4)18(7-3)24-21(16-13-10-9-11-14-16)20(17)22(25)27-15-6-2/h9-11,13-14H,5-8,12,15H2,1-4H3
DM4AONZ	CS	CCCC1=C(C(=NC(=C1C(=O)SCC)CC)C2=CC=CC=C2)C(=O)OCCC
DM4AONZ	IK	UUSHFEVEROROSP-UHFFFAOYSA-N
DM4AONZ	IU	propyl 6-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-4-propylpyridine-3-carboxylate
DM4AONZ	CA	CAS 212329-37-8
DM4AONZ	DE	Discovery agent

DM5I7PL	ID	DM5I7PL
DM5I7PL	DN	MRS1706
DM5I7PL	HS	Investigative
DM5I7PL	SN	MRS-1706; MRS 1706
DM5I7PL	DT	Small molecular drug
DM5I7PL	PC	5139184
DM5I7PL	MW	503.5
DM5I7PL	FM	C27H29N5O5
DM5I7PL	IC	InChI=1S/C27H29N5O5/c1-4-14-31-25-23(26(35)32(15-5-2)27(31)36)29-24(30-25)19-8-12-21(13-9-19)37-16-22(34)28-20-10-6-18(7-11-20)17(3)33/h6-13H,4-5,14-16H2,1-3H3,(H,28,34)(H,29,30)
DM5I7PL	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)NC4=CC=C(C=C4)C(=O)C
DM5I7PL	IK	ZKUCFFYOQOJLGT-UHFFFAOYSA-N
DM5I7PL	IU	N-(4-acetylphenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide
DM5I7PL	CA	CAS 264622-53-9
DM5I7PL	DE	Discovery agent

DMHJ47A	ID	DMHJ47A
DMHJ47A	DN	MRS-2160
DMHJ47A	HS	Investigative
DMHJ47A	DT	Small molecular drug
DMHJ47A	PC	135539037
DMHJ47A	MW	429.7
DMHJ47A	FM	C15H13ClN3O8P
DMHJ47A	IC	InChI=1S/C15H13ClN3O8P/c1-7-13(21)10(5-20)11(6-27-28(24,25)26)14(17-7)19-18-8-2-3-9(15(22)23)12(16)4-8/h2-5,21H,6H2,1H3,(H,22,23)(H2,24,25,26)
DMHJ47A	CS	CC1=C(C(=C(C(=N1)N=NC2=CC(=C(C=C2)C(=O)O)Cl)COP(=O)(O)O)C=O)O
DMHJ47A	IK	KMRWDYZPXRUNAQ-UHFFFAOYSA-N
DMHJ47A	IU	2-chloro-4-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonooxymethyl)pyridin-2-yl]diazenyl]benzoic acid
DMHJ47A	DE	Discovery agent

DMIVGHB	ID	DMIVGHB
DMIVGHB	DN	MRS-2179
DMIVGHB	HS	Investigative
DMIVGHB	SN	MRS-2179; MRS2179; MRS 2179; GTPL1720; CCG-204841; NCGC00162239-02; NCGC00162239-01; [2-[(hydroxy-oxidophosphoryl)oxymethyl]-5-(6-methylaminopurin-9-yl)oxolan-3-yl] hydrogen phosphate
DMIVGHB	DT	Small molecular drug
DMIVGHB	PC	24867852
DMIVGHB	MW	423.21
DMIVGHB	FM	C11H15N5O9P2-2
DMIVGHB	IC	InChI=1S/C11H17N5O9P2/c1-12-10-9-11(14-4-13-10)16(5-15-9)8-2-6(25-27(20,21)22)7(24-8)3-23-26(17,18)19/h4-8H,2-3H2,1H3,(H,12,13,14)(H2,17,18,19)(H2,20,21,22)/p-2/t6-,7+,8+/m0/s1
DMIVGHB	CS	CNC1=C2C(=NC=N1)N(C=N2)[C@H]3C[C@@H]([C@H](O3)COP(=O)(O)[O-])OP(=O)(O)[O-]
DMIVGHB	IK	CCPLITQNIFLYQB-XLPZGREQSA-L
DMIVGHB	IU	[(2R,3S,5R)-3-[hydroxy(oxido)phosphoryl]oxy-5-[6-(methylamino)purin-9-yl]oxolan-2-yl]methyl hydrogen phosphate
DMIVGHB	DE	Discovery agent

DM2G5ZE	ID	DM2G5ZE
DM2G5ZE	DN	MRS2211
DM2G5ZE	HS	Investigative
DM2G5ZE	SN	MRS-2211
DM2G5ZE	DT	Small molecular drug
DM2G5ZE	PC	136078744
DM2G5ZE	MW	432.71
DM2G5ZE	FM	C14H14ClN4O8P
DM2G5ZE	IC	InChI=1S/C14H14ClN4O8P/c1-7-13(21)9(5-20)10(6-27-28(24,25)26)14(16-7)18-17-12-4-8(19(22)23)2-3-11(12)15/h2-4,20-21H,5-6H2,1H3,(H2,24,25,26)
DM2G5ZE	CS	CC1=C(C(=C(C(=N1)N=NC2=C(C=CC(=C2)[N+](=O)[O-])Cl)COP(=O)(O)O)CO)O
DM2G5ZE	IK	RYOZMXBRDOGYMB-UHFFFAOYSA-N
DM2G5ZE	IU	[2-[(2-chloro-5-nitrophenyl)diazenyl]-5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl dihydrogen phosphate
DM2G5ZE	DE	Discovery agent

DM0QGF3	ID	DM0QGF3
DM0QGF3	DN	MRS2279
DM0QGF3	HS	Investigative
DM0QGF3	SN	LPZJKPSGEADHTQ-HLTSFMKQSA-N; [(1S,2R,4R)-4-[(2-chloro-6-methylaminopurin-9-yl)methyl]-2-(phosphonooxymethyl)cyclopentyl] dihydrogen phosphate; [3H]MRS2279; [3H]-MRS2279; AC1NSKE5; GTPL1727; GTPL1721; [(1R,2S,4R)-4-[[2-chloro-6-(methylamino)purin-9-yl]methyl]-2-phosphonooxycyclopentyl]methyl dihydrogen;  MRS-2279
DM0QGF3	DT	Small molecular drug
DM0QGF3	PC	5311301
DM0QGF3	MW	471.73
DM0QGF3	FM	C13H20ClN5O8P2
DM0QGF3	IC	InChI=1S/C13H20ClN5O8P2/c1-15-11-10-12(18-13(14)17-11)19(6-16-10)4-7-2-8(5-26-28(20,21)22)9(3-7)27-29(23,24)25/h6-9H,2-5H2,1H3,(H,15,17,18)(H2,20,21,22)(H2,23,24,25)/t7-,8-,9+/m1/s1
DM0QGF3	CS	CNC1=C2C(=NC(=N1)Cl)N(C=N2)C[C@@H]3C[C@@H]([C@H](C3)OP(=O)(O)O)COP(=O)(O)O
DM0QGF3	IK	LPZJKPSGEADHTQ-HLTSFMKQSA-N
DM0QGF3	IU	[(1R,2S,4R)-4-[[2-chloro-6-(methylamino)purin-9-yl]methyl]-2-phosphonooxycyclopentyl]methyl dihydrogen phosphate
DM0QGF3	DE	Discovery agent

DMZ6EGA	ID	DMZ6EGA
DMZ6EGA	DN	MRS2298
DMZ6EGA	HS	Investigative
DMZ6EGA	SN	MRS-2298; MRS 2298
DMZ6EGA	DT	Small molecular drug
DMZ6EGA	PC	10432920
DMZ6EGA	MW	431.66
DMZ6EGA	FM	C10H16ClN5O8P2
DMZ6EGA	IC	InChI=1S/C10H16ClN5O8P2/c1-12-8-7-9(15-10(11)14-8)16(5-13-7)2-6(3-23-25(17,18)19)4-24-26(20,21)22/h5-6H,2-4H2,1H3,(H,12,14,15)(H2,17,18,19)(H2,20,21,22)
DMZ6EGA	CS	CNC1=C2C(=NC(=N1)Cl)N(C=N2)CC(COP(=O)(O)O)COP(=O)(O)O
DMZ6EGA	IK	GMCUIIHBWNOHIM-UHFFFAOYSA-N
DMZ6EGA	IU	[2-[[2-chloro-6-(methylamino)purin-9-yl]methyl]-3-phosphonooxypropyl] dihydrogen phosphate
DMZ6EGA	DE	Discovery agent

DM0CS3V	ID	DM0CS3V
DM0CS3V	DN	MRS2365
DM0CS3V	HS	Investigative
DM0CS3V	SN	(N)-methanocarba-2-MeSADP; MRS 2365
DM0CS3V	DT	Small molecular drug
DM0CS3V	PC	73755043
DM0CS3V	MW	549.28
DM0CS3V	FM	C13H16N5Na3O9P2S
DM0CS3V	IC	InChI=1S/C13H19N5O9P2S.3Na/c1-30-12-16-10(14)6-11(17-12)18(4-15-6)7-5-2-13(5,9(20)8(7)19)3-26-29(24,25)27-28(21,22)23;;;/h4-5,7-9,19-20H,2-3H2,1H3,(H,24,25)(H2,14,16,17)(H2,21,22,23);;;/q;3*+1/p-3/t5-,7?,8+,9+,13+;;;/m1.../s1
DM0CS3V	CS	CSC1=NC(=C2C(=N1)N(C=N2)C3[C@H]4C[C@]4([C@H]([C@H]3O)O)COP(=O)([O-])OP(=O)([O-])[O-])N.[Na+].[Na+].[Na+]
DM0CS3V	IK	ZYPJOXVKTCEBCA-PVMCGCOJSA-K
DM0CS3V	IU	trisodium;[[(1R,2R,3S,5S)-4-(6-amino-2-methylsulfanylpurin-9-yl)-2,3-dihydroxy-1-bicyclo[3.1.0]hexanyl]methoxy-oxidophosphoryl] phosphate
DM0CS3V	DE	Discovery agent

DM0CAKS	ID	DM0CAKS
DM0CAKS	DN	MRS2496
DM0CAKS	HS	Investigative
DM0CAKS	SN	MRS-2496
DM0CAKS	DT	Small molecular drug
DM0CAKS	PC	10894633
DM0CAKS	MW	399.66
DM0CAKS	FM	C10H16ClN5O6P2
DM0CAKS	IC	InChI=1S/C10H16ClN5O6P2/c1-12-8-7-9(15-10(11)14-8)16(5-13-7)2-6(3-23(17,18)19)4-24(20,21)22/h5-6H,2-4H2,1H3,(H,12,14,15)(H2,17,18,19)(H2,20,21,22)
DM0CAKS	CS	CNC1=C2C(=NC(=N1)Cl)N(C=N2)CC(CP(=O)(O)O)CP(=O)(O)O
DM0CAKS	IK	FFBIISIICFTESN-UHFFFAOYSA-N
DM0CAKS	IU	[2-[[2-chloro-6-(methylamino)purin-9-yl]methyl]-3-phosphonopropyl]phosphonic acid
DM0CAKS	DE	Discovery agent

DMNGTOY	ID	DMNGTOY
DMNGTOY	DN	MRS2500
DMNGTOY	HS	Investigative
DMNGTOY	SN	MRS-2500; MRS 2500
DMNGTOY	DT	Small molecular drug
DMNGTOY	PC	44448831
DMNGTOY	MW	561.16
DMNGTOY	FM	C13H18IN5O8P2
DMNGTOY	IC	InChI=1S/C13H18IN5O8P2/c1-15-10-9-11(18-12(14)17-10)19(5-16-9)7-2-8(27-29(23,24)25)13(3-6(7)13)4-26-28(20,21)22/h5-8H,2-4H2,1H3,(H,15,17,18)(H2,20,21,22)(H2,23,24,25)/t6-,7+,8+,13+/m1/s1
DMNGTOY	CS	CNC1=C2C(=NC(=N1)I)N(C=N2)[C@H]3C[C@@H]([C@]4([C@@H]3C4)COP(=O)(O)O)OP(=O)(O)O
DMNGTOY	IK	NMVWLEUONAKGCD-SMWKGLLFSA-N
DMNGTOY	IU	[(1R,2S,4S,5S)-4-[2-iodo-6-(methylamino)purin-9-yl]-2-phosphonooxy-1-bicyclo[3.1.0]hexanyl]methyl dihydrogen phosphate
DMNGTOY	DE	Discovery agent

DMUJEA9	ID	DMUJEA9
DMUJEA9	DN	MRS2567
DMUJEA9	HS	Investigative
DMUJEA9	SN	MRS2567; 4,4'-Diisothiocyanatobibenzyl; SCHEMBL1853024; GTPL1752; 1-isothiocyanato-4-[2-(4-isothiocyanatophenyl)ethyl]benzene
DMUJEA9	DT	Small molecular drug
DMUJEA9	PC	11266452
DMUJEA9	MW	296.4
DMUJEA9	FM	C16H12N2S2
DMUJEA9	IC	InChI=1S/C16H12N2S2/c19-11-17-15-7-3-13(4-8-15)1-2-14-5-9-16(10-6-14)18-12-20/h3-10H,1-2H2
DMUJEA9	CS	C1=CC(=CC=C1CCC2=CC=C(C=C2)N=C=S)N=C=S
DMUJEA9	IK	KGPFLJVFCCOOEO-UHFFFAOYSA-N
DMUJEA9	IU	1-isothiocyanato-4-[2-(4-isothiocyanatophenyl)ethyl]benzene
DMUJEA9	DE	Discovery agent

DMKMPS6	ID	DMKMPS6
DMKMPS6	DN	MRS2578
DMKMPS6	HS	Investigative
DMKMPS6	SN	MRS-2578; MRS 2578
DMKMPS6	DT	Small molecular drug
DMKMPS6	PC	16078986
DMKMPS6	MW	472.7
DMKMPS6	FM	C20H20N6S4
DMKMPS6	IC	InChI=1S/C20H20N6S4/c27-13-23-15-5-3-7-17(11-15)25-19(29)21-9-1-2-10-22-20(30)26-18-8-4-6-16(12-18)24-14-28/h3-8,11-12H,1-2,9-10H2,(H2,21,25,29)(H2,22,26,30)
DMKMPS6	CS	C1=CC(=CC(=C1)N=C=S)NC(=S)NCCCCNC(=S)NC2=CC(=CC=C2)N=C=S
DMKMPS6	IK	QOHNRGHTJPFMSL-UHFFFAOYSA-N
DMKMPS6	IU	1-(3-isothiocyanatophenyl)-3-[4-[(3-isothiocyanatophenyl)carbamothioylamino]butyl]thiourea
DMKMPS6	CA	CAS 711019-86-2
DMKMPS6	DE	Discovery agent

DMNGC79	ID	DMNGC79
DMNGC79	DN	MRS2603
DMNGC79	HS	Investigative
DMNGC79	SN	MRS 2603
DMNGC79	DT	Small molecular drug
DMNGC79	PC	135545444
DMNGC79	MW	430.69
DMNGC79	FM	C14H12ClN4O8P
DMNGC79	IC	InChI=1S/C14H12ClN4O8P/c1-7-13(21)9(5-20)10(6-27-28(24,25)26)14(16-7)18-17-8-2-3-11(15)12(4-8)19(22)23/h2-5,21H,6H2,1H3,(H2,24,25,26)
DMNGC79	CS	CC1=C(C(=C(C(=N1)N=NC2=CC(=C(C=C2)Cl)[N+](=O)[O-])COP(=O)(O)O)C=O)O
DMNGC79	IK	AIYCSQYPGGJSRN-UHFFFAOYSA-N
DMNGC79	IU	[2-[(4-chloro-3-nitrophenyl)diazenyl]-4-formyl-5-hydroxy-6-methylpyridin-3-yl]methyl dihydrogen phosphate
DMNGC79	DE	Discovery agent

DMNS3RT	ID	DMNS3RT
DMNS3RT	DN	MRS2690
DMNS3RT	HS	Investigative
DMNS3RT	SN	MRS 2690; MRS-2690
DMNS3RT	DT	Small molecular drug
DMNS3RT	PC	73755042
DMNS3RT	MW	626.3
DMNS3RT	FM	C15H22N2Na2O16P2S
DMNS3RT	IC	InChI=1S/C15H24N2O16P2S.2Na/c18-3-5-8(20)10(22)12(24)14(31-5)32-35(27,28)33-34(25,26)29-4-6-9(21)11(23)13(30-6)17-2-1-7(19)16-15(17)36;;/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,25,26)(H,27,28)(H,16,19,36);;/q;2*+1/p-2/t5-,6-,8-,9-,10+,11-,12-,13-,14-;;/m1../s1
DMNS3RT	CS	C1=CN(C(=S)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O.[Na+].[Na+]
DMNS3RT	IK	TYVFMVSNSGMZPA-QBNUFUENSA-L
DMNS3RT	IU	disodium;[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl] [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate
DMNS3RT	DE	Discovery agent

DM2L3CJ	ID	DM2L3CJ
DM2L3CJ	DN	MRS2693
DM2L3CJ	HS	Investigative
DM2L3CJ	SN	MRS-2693; MRS 2693; 5-iodo-uridine-5'-diphosphate; 5-iodo-UDP
DM2L3CJ	DT	Small molecular drug
DM2L3CJ	PC	44415771
DM2L3CJ	MW	530.06
DM2L3CJ	FM	C9H13IN2O12P2
DM2L3CJ	IC	InChI=1S/C9H13IN2O12P2/c10-4-1-5(13)11-9(16)12(4)8-7(15)6(14)3(23-8)2-22-26(20,21)24-25(17,18)19/h1,3,6-8,14-15H,2H2,(H,20,21)(H,11,13,16)(H2,17,18,19)/t3-,6-,7-,8-/m1/s1
DM2L3CJ	CS	C1=C(N(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)O)O)I
DM2L3CJ	IK	ZPKIYZBENSTKTC-YXZULKJRSA-N
DM2L3CJ	IU	[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate
DM2L3CJ	DE	Discovery agent

DM7EZBU	ID	DM7EZBU
DM7EZBU	DN	MRS2698
DM7EZBU	HS	Investigative
DM7EZBU	SN	MRS-2698; 2'-amino-2-thio-UTP
DM7EZBU	DT	Small molecular drug
DM7EZBU	PC	16116566
DM7EZBU	MW	499.22
DM7EZBU	FM	C9H16N3O13P3S
DM7EZBU	IC	InChI=1S/C9H16N3O13P3S/c10-6-7(14)4(23-8(6)12-2-1-5(13)11-9(12)29)3-22-27(18,19)25-28(20,21)24-26(15,16)17/h1-2,4,6-8,14H,3,10H2,(H,18,19)(H,20,21)(H,11,13,29)(H2,15,16,17)/t4-,6-,7-,8-/m1/s1
DM7EZBU	CS	C1=CN(C(=S)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)N
DM7EZBU	IK	UWTUUIWWVPWHAA-XVFCMESISA-N
DM7EZBU	IU	[[(2R,3S,4R,5R)-4-amino-3-hydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM7EZBU	DE	Discovery agent

DMO5J39	ID	DMO5J39
DMO5J39	DN	MRS2768
DMO5J39	HS	Investigative
DMO5J39	SN	uridine-5'-tetraphosphate Delta-phenyl ester
DMO5J39	DT	Small molecular drug
DMO5J39	PC	73755072
DMO5J39	MW	636.3
DMO5J39	FM	C17H24N2O16P4
DMO5J39	IC	InChI=1S/C17H24N2O16P4/c1-11-12(2)16(19-9-8-15(20)18-17(19)21)31-14(11)10-30-36(22,23)33-38(26,27)35-39(28,29)34-37(24,25)32-13-6-4-3-5-7-13/h3-9,11-12,14,16H,10H2,1-2H3,(H,22,23)(H,24,25)(H,26,27)(H,28,29)(H,18,20,21)/t11-,12+,14+,16+/m0/s1
DMO5J39	CS	C[C@H]1[C@H]([C@@H](O[C@@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC2=CC=CC=C2)N3C=CC(=O)NC3=O)C
DMO5J39	IK	ACRDMMYBLHHSSD-KLZCAUPSSA-N
DMO5J39	IU	[[(2S,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dimethyloxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy(phenoxy)phosphoryl]oxyphosphoryl] hydrogen phosphate
DMO5J39	DE	Discovery agent

DMZSO4R	ID	DMZSO4R
DMZSO4R	DN	MRS2782
DMZSO4R	HS	Investigative
DMZSO4R	SN	Uridine-5'-alpha,beta-methylene-diphosphate triethylammonium salt
DMZSO4R	DT	Small molecular drug
DMZSO4R	PC	44585949
DMZSO4R	MW	402.19
DMZSO4R	FM	C10H16N2O11P2
DMZSO4R	IC	InChI=1S/C10H16N2O11P2/c13-6-1-2-12(10(16)11-6)9-8(15)7(14)5(23-9)3-22-25(20,21)4-24(17,18)19/h1-2,5,7-9,14-15H,3-4H2,(H,20,21)(H,11,13,16)(H2,17,18,19)/t5-,7-,8-,9-/m1/s1
DMZSO4R	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(CP(=O)(O)O)O)O)O
DMZSO4R	IK	PDEGDTTUBZXACY-ZOQUXTDFSA-N
DMZSO4R	IU	[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
DMZSO4R	DE	Discovery agent

DMWKZCY	ID	DMWKZCY
DMWKZCY	DN	MRS2802
DMWKZCY	HS	Investigative
DMWKZCY	SN	MRS2802
DMWKZCY	DT	Small molecular drug
DMWKZCY	PC	91827349
DMWKZCY	MW	438.17
DMWKZCY	FM	C10H14F2N2O11P2
DMWKZCY	IC	InChI=1S/C10H14F2N2O11P2/c11-10(12,26(19,20)21)27(22,23)24-3-4-6(16)7(17)8(25-4)14-2-1-5(15)13-9(14)18/h1-2,4,6-8,16-17H,3H2,(H,22,23)(H,13,15,18)(H2,19,20,21)/t4-,6+,7+,8-/m1/s1
DMWKZCY	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@H]([C@H](O2)COP(=O)(C(F)(F)P(=O)(O)O)O)O)O
DMWKZCY	IK	JKJYHYKRGKKASI-YDKYIBAVSA-N
DMWKZCY	IU	[[[(2R,3R,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]-difluoromethyl]phosphonic acid
DMWKZCY	DE	Discovery agent

DMGCPHO	ID	DMGCPHO
DMGCPHO	DN	MRS2905
DMGCPHO	HS	Investigative
DMGCPHO	SN	MRS2905
DMGCPHO	DT	Small molecular drug
DMGCPHO	PC	91827348
DMGCPHO	MW	432.28
DMGCPHO	FM	C11H18N2O10P2S
DMGCPHO	IC	InChI=1S/C11H18N2O10P2S/c14-7-1-2-13(11(26)12-7)10-9(16)8(15)6(23-10)5-22-25(20,21)4-3-24(17,18)19/h1-2,6,8-10,15-16H,3-5H2,(H,20,21)(H,12,14,26)(H2,17,18,19)/t6-,8+,9+,10-/m1/s1
DMGCPHO	CS	C1=CN(C(=S)NC1=O)[C@H]2[C@H]([C@H]([C@H](O2)COP(=O)(CCP(=O)(O)O)O)O)O
DMGCPHO	IK	RCFKBLDZKDFBNO-DOWZNPNQSA-N
DMGCPHO	IU	2-[[(2R,3R,4S,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]ethylphosphonic acid
DMGCPHO	DE	Discovery agent

DMB2A7Q	ID	DMB2A7Q
DMB2A7Q	DN	MRS2927
DMB2A7Q	HS	Investigative
DMB2A7Q	SN	Up4 -[1]3'-deoxy-3'-fluoroglucose; compound 34 [PMID:21528910]
DMB2A7Q	DT	Small molecular drug
DMB2A7Q	PC	91827350
DMB2A7Q	MW	727.3
DMB2A7Q	FM	C16H26FNO22P4
DMB2A7Q	IC	InChI=1S/C16H26FNO22P4/c17-9-10(21)6(3-19)36-16(12(9)23)37-42(28,29)39-44(32,33)40-43(30,31)38-41(26,27)34-4-7-11(22)13(24)14(35-7)5-1-2-8(20)18-15(5)25/h1-2,5-7,9-14,16,19,21-24H,3-4H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,18,20,25)/t5?,6-,7-,9+,10-,11-,12-,13-,14+,16-/m1/s1
DMB2A7Q	CS	C1=CC(=O)NC(=O)C1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)F)O)O)O
DMB2A7Q	IK	SMNRFWMNPDABKZ-WVALLCKVSA-N
DMB2A7Q	IU	[[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DMB2A7Q	DE	Discovery agent

DMDSB1F	ID	DMDSB1F
DMDSB1F	DN	MRS2950
DMDSB1F	HS	Investigative
DMDSB1F	SN	MRS2950; GTPL5809
DMDSB1F	DT	Small molecular drug
DMDSB1F	PC	73755158
DMDSB1F	MW	451.4
DMDSB1F	FM	C20H20Cl2N4O2S
DMDSB1F	IC	InChI=1S/C20H20Cl2N4O2S/c1-12-13(2)25-28-19(12)26-29(3,4)16-8-5-14(6-9-16)23-20(27)24-15-7-10-17(21)18(22)11-15/h5-11,26H,3-4H2,1-2H3,(H2,23,24,27)
DMDSB1F	CS	CC1=C(ON=C1C)NS(=C)(=C)C2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)Cl
DMDSB1F	IK	ZRNSPTWPSVBOTC-UHFFFAOYSA-N
DMDSB1F	IU	1-(3,4-dichlorophenyl)-3-[4-[[(3,4-dimethyl-1,2-oxazol-5-yl)amino]-dimethylidene-lambda6-sulfanyl]phenyl]urea
DMDSB1F	DE	Discovery agent

DMROQP6	ID	DMROQP6
DMROQP6	DN	MRS2957
DMROQP6	HS	Investigative
DMROQP6	SN	MRS 2957
DMROQP6	DT	Small molecular drug
DMROQP6	PC	91827347
DMROQP6	MW	739.4
DMROQP6	FM	C19H28N5O20P3
DMROQP6	IC	InChI=1S/C19H28N5O20P3/c1-38-22-10-2-4-23(18(30)20-10)16-14(28)12(26)8(41-16)6-39-45(32,33)43-47(36,37)44-46(34,35)40-7-9-13(27)15(29)17(42-9)24-5-3-11(25)21-19(24)31/h2-5,8-9,12-17,26-29H,6-7H2,1H3,(H,32,33)(H,34,35)(H,36,37)(H,20,22,30)(H,21,25,31)/t8-,9-,12+,13+,14+,15+,16-,17-/m1/s1
DMROQP6	CS	CONC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]3[C@@H]([C@@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O
DMROQP6	IK	SIKKMGJHOOQSAP-AOUMTEFLSA-N
DMROQP6	IU	[[(2R,3R,4S,5R)-3,4-dihydroxy-5-[4-(methoxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] [[(2R,3R,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DMROQP6	DE	Discovery agent

DMWKXGP	ID	DMWKXGP
DMWKXGP	DN	MRS4062
DMWKXGP	HS	Investigative
DMWKXGP	SN	N4-phenylpropoxycytidine-5'-triphosphate; MRS-4062; MRS 4062
DMWKXGP	DT	Small molecular drug
DMWKXGP	PC	53262902
DMWKXGP	MW	617.3
DMWKXGP	FM	C18H26N3O15P3
DMWKXGP	IC	InChI=1S/C18H26N3O15P3/c22-15-13(11-33-38(28,29)36-39(30,31)35-37(25,26)27)34-17(16(15)23)21-9-8-14(19-18(21)24)20-32-10-4-7-12-5-2-1-3-6-12/h1-3,5-6,8-9,13,15-17,22-23H,4,7,10-11H2,(H,28,29)(H,30,31)(H,19,20,24)(H2,25,26,27)/t13-,15-,16-,17-/m1/s1
DMWKXGP	CS	C1=CC=C(C=C1)CCCONC2=NC(=O)N(C=C2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMWKXGP	IK	FAYLMQPZASAIOS-MWQQHZPXSA-N
DMWKXGP	IU	[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[2-oxo-4-(3-phenylpropoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMWKXGP	DE	Discovery agent

DM1GUTC	ID	DM1GUTC
DM1GUTC	DN	MRS5151
DM1GUTC	HS	Investigative
DM1GUTC	SN	MRS5151
DM1GUTC	DT	Small molecular drug
DM1GUTC	PC	91827346
DM1GUTC	MW	539
DM1GUTC	FM	C26H27ClN6O5
DM1GUTC	IC	InChI=1S/C26H27ClN6O5/c1-28-25(38)26-10-16(26)20(21(36)22(26)37)33-13-32-19-23(30-12-31-24(19)33)29-11-14-6-5-8-17(27)15(14)7-3-2-4-9-18(34)35/h5-6,8,12-13,16,20-22,36-37H,2,4,9-11H2,1H3,(H,28,38)(H,34,35)(H,29,30,31)/t16-,20-,21+,22+,26+/m1/s1
DM1GUTC	CS	CNC(=O)[C@@]12C[C@@H]1[C@H]([C@@H]([C@@H]2O)O)N3C=NC4=C(N=CN=C43)NCC5=C(C(=CC=C5)Cl)C#CCCCC(=O)O
DM1GUTC	IK	CYQQUPOETXXUCK-CSTWGOEFSA-N
DM1GUTC	IU	6-[2-chloro-6-[[[9-[(1S,2R,3S,4R,5S)-3,4-dihydroxy-5-(methylcarbamoyl)-2-bicyclo[3.1.0]hexanyl]purin-6-yl]amino]methyl]phenyl]hex-5-ynoic acid
DM1GUTC	DE	Discovery agent

DMDF6WG	ID	DMDF6WG
DMDF6WG	DN	MRS5698
DMDF6WG	HS	Investigative
DMDF6WG	SN	MRS-5698; MRS 5698
DMDF6WG	DT	Small molecular drug
DMDF6WG	PC	57523213
DMDF6WG	MW	565
DMDF6WG	FM	C28H23ClF2N6O3
DMDF6WG	IC	InChI=1S/C28H23ClF2N6O3/c1-32-27(40)28-11-17(28)22(23(38)24(28)39)37-13-34-21-25(33-12-15-3-2-4-16(29)9-15)35-20(36-26(21)37)8-6-14-5-7-18(30)19(31)10-14/h2-5,7,9-10,13,17,22-24,38-39H,11-12H2,1H3,(H,32,40)(H,33,35,36)/t17-,22-,23+,24+,28+/m1/s1
DMDF6WG	CS	CNC(=O)[C@@]12C[C@@H]1[C@H]([C@@H]([C@@H]2O)O)N3C=NC4=C(N=C(N=C43)C#CC5=CC(=C(C=C5)F)F)NCC6=CC(=CC=C6)Cl
DMDF6WG	IK	LYLLLJJYBWLGHW-CIZVZKTGSA-N
DMDF6WG	IU	(1S,2R,3S,4R,5S)-4-[6-[(3-chlorophenyl)methylamino]-2-[2-(3,4-difluorophenyl)ethynyl]purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide
DMDF6WG	DE	Discovery agent

DMMN42V	ID	DMMN42V
DMMN42V	DN	MRS923
DMMN42V	HS	Investigative
DMMN42V	SN	CHEMBL75169; 7555-80-8; 4H-1-Benzopyran-4-one, 2-(2,4-dimethoxyphenyl)-3,5,7-trimethoxy-; 2-(2,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one; Flavone, 2',3,4',5,7-pentamethoxy-; MRS923; Pentamethyl morin; AC1LCIM3; GTPL401; SCHEMBL1664225; CTK2G8883; MRS-923; DTXSID80348154; KPJGABLCRGWDRB-UHFFFAOYSA-N; 3,5,7,2',4'-pentamethoxyflavone; BDBM50049399; 2',3,4',5,7-Pentamethoxy flavone; AKOS030552861; 2-(2,4-Dimethoxy-phenyl)-3,5,7-trimethoxy-chromen-4-one; 2-(2,4-Dimethoxyphenyl)-3,5,7-trimethoxy-4H-chromen-4-one #
DMMN42V	DT	Small molecular drug
DMMN42V	PC	631105
DMMN42V	MW	372.4
DMMN42V	FM	C20H20O7
DMMN42V	IC	InChI=1S/C20H20O7/c1-22-11-6-7-13(14(8-11)24-3)19-20(26-5)18(21)17-15(25-4)9-12(23-2)10-16(17)27-19/h6-10H,1-5H3
DMMN42V	CS	COC1=CC(=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C=C3OC)OC)OC)OC
DMMN42V	IK	KPJGABLCRGWDRB-UHFFFAOYSA-N
DMMN42V	IU	2-(2,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one
DMMN42V	CA	CAS 7555-80-8
DMMN42V	DE	Discovery agent

DMKJ9WM	ID	DMKJ9WM
DMKJ9WM	DN	MRS928
DMKJ9WM	HS	Investigative
DMKJ9WM	SN	3,5,7-Trimethoxyflavone; 3,5,7-Trimethoxy-2-phenyl-4H-chromen-4-one; Galangin trimethyl ether; 26964-29-4; Galangin 3,5,7-trimethyl ether; 3,5,7-Trimethoxy-2-phenylchromen-4-one; Chromen-4-one, 3,5,7-trimethoxy-2-phenyl-; CHEMBL75772; CHEBI:5263; CBTHKWVPSIGKMI-UHFFFAOYSA-N; Flavone, 3,5,7-trimethoxy-; 3,5,7-Trimethoxy-2-phenyl-chromen-4-one; AC1L3LSQ; C10045; AC1Q6E1K; GTPL402; 3,5,7-Tri-O-methylgalangin; MEGxp0_001894; 4H-1-Benzopyran-4-one, 3,5,7-trimethoxy-2-phenyl-; SCHEMBL1664287; CTK8D5933; ACon1_000793;  galangin trimethyl ether
DMKJ9WM	DT	Small molecular drug
DMKJ9WM	PC	117900
DMKJ9WM	MW	312.3
DMKJ9WM	FM	C18H16O5
DMKJ9WM	IC	InChI=1S/C18H16O5/c1-20-12-9-13(21-2)15-14(10-12)23-17(18(22-3)16(15)19)11-7-5-4-6-8-11/h4-10H,1-3H3
DMKJ9WM	CS	COC1=CC2=C(C(=C1)OC)C(=O)C(=C(O2)C3=CC=CC=C3)OC
DMKJ9WM	IK	CBTHKWVPSIGKMI-UHFFFAOYSA-N
DMKJ9WM	IU	3,5,7-trimethoxy-2-phenylchromen-4-one
DMKJ9WM	CA	CAS 26964-29-4
DMKJ9WM	CB	CHEBI:5263
DMKJ9WM	DE	Discovery agent

DMYRCHG	ID	DMYRCHG
DMYRCHG	DN	MRT67307
DMYRCHG	HS	Investigative
DMYRCHG	SN	MRT-67307
DMYRCHG	DT	Small molecular drug
DMYRCHG	PC	44464263
DMYRCHG	MW	464.6
DMYRCHG	FM	C26H36N6O2
DMYRCHG	IC	InChI=1S/C26H36N6O2/c33-25(21-5-2-6-21)28-11-3-10-27-24-23(20-8-9-20)17-29-26(31-24)30-22-7-1-4-19(16-22)18-32-12-14-34-15-13-32/h1,4,7,16-17,20-21H,2-3,5-6,8-15,18H2,(H,28,33)(H2,27,29,30,31)
DMYRCHG	CS	C1CC(C1)C(=O)NCCCNC2=NC(=NC=C2C3CC3)NC4=CC=CC(=C4)CN5CCOCC5
DMYRCHG	IK	UKBGBACORPRCGG-UHFFFAOYSA-N
DMYRCHG	IU	N-[3-[[5-cyclopropyl-2-[3-(morpholin-4-ylmethyl)anilino]pyrimidin-4-yl]amino]propyl]cyclobutanecarboxamide
DMYRCHG	CA	CAS 1190378-57-4
DMYRCHG	CB	CHEBI:124930
DMYRCHG	DE	Discovery agent

DMTPGQ3	ID	DMTPGQ3
DMTPGQ3	DN	MS1943
DMTPGQ3	HS	Investigative
DMTPGQ3	SN	2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide
DMTPGQ3	DT	Small molecular drug
DMTPGQ3	PC	139211327
DMTPGQ3	MW	718.9
DMTPGQ3	FM	C42H54N8O3
DMTPGQ3	IC	InChI=1S/C42H54N8O3/c1-26(2)50-37-18-33(17-34(36(37)25-46-50)40(52)45-24-35-27(3)13-28(4)47-41(35)53)32-5-6-38(44-23-32)49-11-9-48(10-12-49)8-7-43-39(51)22-42-19-29-14-30(20-42)16-31(15-29)21-42/h5-6,13,17-18,23,25-26,29-31H,7-12,14-16,19-22,24H2,1-4H3,(H,43,51)(H,45,52)(H,47,53)
DMTPGQ3	CS	CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CN=C(C=C4)N5CCN(CC5)CCNC(=O)CC67CC8CC(C6)CC(C8)C7)C(C)C)C
DMTPGQ3	IK	WQIQJFXBAJJKNT-UHFFFAOYSA-N
DMTPGQ3	IU	6-[6-[4-[2-[[2-(1-adamantyl)acetyl]amino]ethyl]piperazin-1-yl]pyridin-3-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylindazole-4-carboxamide
DMTPGQ3	DE	Breast cancer

DMXC30P	ID	DMXC30P
DMXC30P	DN	MS417
DMXC30P	HS	Investigative
DMXC30P	SN	MS417; Methyl [(6s)-4-(4-Chlorophenyl)-2,3,9-Trimethyl-6h-Thieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepin-6-Yl]acetate; 916489-36-6; GGRCIHACOIMRKY-HNNXBMFYSA-N; 0S6; 4f3i; US9125915, compound 6; GTPL7512; CHEMBL3769755; SCHEMBL12228301; CHEBI:83406; BDBM179283; MS-417; ZINC95921068; HY-111139; CS-0034388; Methyl 2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; methyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6
DMXC30P	DT	Small molecular drug
DMXC30P	PC	59190723
DMXC30P	MW	414.9
DMXC30P	FM	C20H19ClN4O2S
DMXC30P	IC	InChI=1S/C20H19ClN4O2S/c1-10-11(2)28-20-17(10)18(13-5-7-14(21)8-6-13)22-15(9-16(26)27-4)19-24-23-12(3)25(19)20/h5-8,15H,9H2,1-4H3/t15-/m0/s1
DMXC30P	CS	CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC)C4=CC=C(C=C4)Cl)C
DMXC30P	IK	GGRCIHACOIMRKY-HNNXBMFYSA-N
DMXC30P	IU	methyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate
DMXC30P	CB	CHEBI:83406
DMXC30P	DE	Discovery agent

DMNBFX0	ID	DMNBFX0
DMNBFX0	DN	MS436
DMNBFX0	HS	Investigative
DMNBFX0	DT	Small molecular drug
DMNBFX0	PC	135566899
DMNBFX0	MW	383.4
DMNBFX0	FM	C18H17N5O3S
DMNBFX0	IC	InChI=1S/C18H17N5O3S/c1-12-10-16(15(19)11-17(12)24)22-21-13-5-7-14(8-6-13)27(25,26)23-18-4-2-3-9-20-18/h2-11,24H,19H2,1H3,(H,20,23)
DMNBFX0	CS	CC1=CC(=C(C=C1O)N)N=NC2=CC=C(C=C2)S(=O)(=O)NC3=CC=CC=N3
DMNBFX0	IK	DZTGIRNXWSZBIM-UHFFFAOYSA-N
DMNBFX0	IU	4-[(2-amino-4-hydroxy-5-methylphenyl)diazenyl]-N-pyridin-2-ylbenzenesulfonamide
DMNBFX0	DE	Discovery agent

DMBTPDL	ID	DMBTPDL
DMBTPDL	DN	MS453
DMBTPDL	HS	Investigative
DMBTPDL	SN	2059892-29-2; N-(3-((6,7-dimethoxy-2-(pyrrolidin-1-yl)quinazolin-4-yl)amino)propyl)acrylamide; MS-453
DMBTPDL	DT	Small molecular drug
DMBTPDL	PC	129896910
DMBTPDL	MW	385.5
DMBTPDL	FM	C20H27N5O3
DMBTPDL	IC	InChI=1S/C20H27N5O3/c1-4-18(26)21-8-7-9-22-19-14-12-16(27-2)17(28-3)13-15(14)23-20(24-19)25-10-5-6-11-25/h4,12-13H,1,5-11H2,2-3H3,(H,21,26)(H,22,23,24)
DMBTPDL	CS	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCCC3)NCCCNC(=O)C=C)OC
DMBTPDL	IK	QTHRXIUTSUVNPH-UHFFFAOYSA-N
DMBTPDL	IU	N-[3-[(6,7-dimethoxy-2-pyrrolidin-1-ylquinazolin-4-yl)amino]propyl]prop-2-enamide
DMBTPDL	DE	Discovery agent

DMS3O9H	ID	DMS3O9H
DMS3O9H	DN	MSC2032964A
DMS3O9H	HS	Investigative
DMS3O9H	SN	CHEMBL3330170; MSC 2032964A; 1124381-43-6; N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-3-pyridinecarboxamide; XUKGFHHTSUKORV-UHFFFAOYSA-N; MSC2032964A; SCHEMBL2788575; GTPL8076; MolPort-039-338-069; ZINC59102467; BDBM50023727; AKOS027470238; MRF-0000032; NCGC00479218-01; N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide
DMS3O9H	DT	Small molecular drug
DMS3O9H	PC	25214468
DMS3O9H	MW	362.31
DMS3O9H	FM	C16H13F3N6O
DMS3O9H	IC	InChI=1S/C16H13F3N6O/c17-16(18,19)10-6-12(21-11-3-4-11)25-13(7-10)22-15(24-25)23-14(26)9-2-1-5-20-8-9/h1-2,5-8,11,21H,3-4H2,(H,23,24,26)
DMS3O9H	CS	C1CC1NC2=CC(=CC3=NC(=NN23)NC(=O)C4=CN=CC=C4)C(F)(F)F
DMS3O9H	IK	XUKGFHHTSUKORV-UHFFFAOYSA-N
DMS3O9H	IU	N-[5-(cyclopropylamino)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]pyridine-3-carboxamide
DMS3O9H	DE	Discovery agent

DMU67CE	ID	DMU67CE
DMU67CE	DN	MSOPPE
DMU67CE	HS	Investigative
DMU67CE	SN	alpha-methylserine-O-phosphate monophenyl ester
DMU67CE	DT	Small molecular drug
DMU67CE	PC	5311463
DMU67CE	MW	275.19
DMU67CE	FM	C10H14NO6P
DMU67CE	IC	InChI=1S/C10H14NO6P/c1-10(11,9(12)13)7-16-18(14,15)17-8-5-3-2-4-6-8/h2-6H,7,11H2,1H3,(H,12,13)(H,14,15)
DMU67CE	CS	CC(COP(=O)(O)OC1=CC=CC=C1)(C(=O)O)N
DMU67CE	IK	GBCGDIQJCHNFKA-UHFFFAOYSA-N
DMU67CE	IU	2-amino-3-[hydroxy(phenoxy)phosphoryl]oxy-2-methylpropanoic acid
DMU67CE	DE	Discovery agent

DMUKWJ2	ID	DMUKWJ2
DMUKWJ2	DN	MST-400
DMUKWJ2	HS	Investigative
DMUKWJ2	SN	MST-400 series; MST-500 series; Integrin-linked kinase inhibitors (cancer); Integrin-linked kinase inhibitors (cancer), MetaSignal
DMUKWJ2	CP	MetaSignal Therapeutics
DMUKWJ2	DE	Solid tumour/cancer

DM4KM91	ID	DM4KM91
DM4KM91	DN	MSVIII-19
DM4KM91	HS	Investigative
DM4KM91	SN	8,9-dideoxyneodysiherbaine
DM4KM91	DT	Small molecular drug
DM4KM91	PC	72199906
DM4KM91	MW	258.25
DM4KM91	FM	C11H16NO6-
DM4KM91	IC	InChI=1S/C11H17NO6/c12-6(9(13)14)4-11(10(15)16)5-8-7(18-11)2-1-3-17-8/h6-8H,1-5,12H2,(H,13,14)(H,15,16)/p-1/t6-,7+,8+,11+/m0/s1
DM4KM91	CS	C1C[C@@H]2[C@@H](C[C@](O2)(C[C@@H](C(=O)[O-])[NH3+])C(=O)[O-])OC1
DM4KM91	IK	RZIYCCQNKHONBB-PRKAOEEVSA-M
DM4KM91	IU	(2R,3aR,7aR)-2-[(2S)-2-azaniumyl-2-carboxylatoethyl]-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-carboxylate
DM4KM91	DE	Discovery agent

DMF9HYI	ID	DMF9HYI
DMF9HYI	DN	MSX-3
DMF9HYI	HS	Investigative
DMF9HYI	SN	MSX-2
DMF9HYI	CP	Universitat Wurzburg
DMF9HYI	DT	Small molecular drug
DMF9HYI	PC	10256041
DMF9HYI	MW	518.4
DMF9HYI	FM	C21H21N4Na2O7P
DMF9HYI	IC	InChI=1S/C21H23N4O7P.2Na/c1-4-11-25-20(26)18-19(24(21(25)27)12-6-13-32-33(28,29)30)22-17(23(18)2)10-9-15-7-5-8-16(14-15)31-3;;/h1,5,7-10,14H,6,11-13H2,2-3H3,(H2,28,29,30);;/q;2*+1/p-2/b10-9+;;
DMF9HYI	CS	CN1C(=NC2=C1C(=O)N(C(=O)N2CCCOP(=O)([O-])[O-])CC#C)/C=C/C3=CC(=CC=C3)OC.[Na+].[Na+]
DMF9HYI	IK	ZYVZWCILYQDHNU-TTWKNDKESA-L
DMF9HYI	IU	disodium;3-[8-[(E)-2-(3-methoxyphenyl)ethenyl]-7-methyl-2,6-dioxo-1-prop-2-ynylpurin-3-yl]propyl phosphate
DMF9HYI	DE	Parkinson disease

DM7KIVX	ID	DM7KIVX
DM7KIVX	DN	MT-001
DM7KIVX	HS	Investigative
DM7KIVX	SN	Simvastatin (oral liquid formulation, pediatric hypercholesterolemia), Madeira Therapeutics
DM7KIVX	CP	Madeira Therapeutics LLC
DM7KIVX	DE	Hypercholesterolaemia

DMDK6BP	ID	DMDK6BP
DMDK6BP	DN	MT-061
DMDK6BP	HS	Investigative
DMDK6BP	SN	MT-061; Fatty acid biosynthesis inhibitor (Gram positive bacterial infection), MaxThera; MT-061 lead series, Biota; MT-061 lead series, MaxThera
DMDK6BP	CP	MaxThera Inc
DMDK6BP	DE	Gram-positive bacterial infection

DM5PD0G	ID	DM5PD0G
DM5PD0G	DN	MT-062
DM5PD0G	HS	Investigative
DM5PD0G	SN	EGFR inhibitor (melanoma), Medisyn Technologies
DM5PD0G	CP	Medisyn Technologies Inc
DM5PD0G	DE	Melanoma

DMKT1DA	ID	DMKT1DA
DMKT1DA	DN	MT-II
DMKT1DA	HS	Investigative
DMKT1DA	SN	Melanotan II; 121062-08-6; Melanotan-II; Melanotan (MT)-II; Melatonan; Melanotan II acetate salt; CHEMBL430239; L-Lysinamide, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-7)-peptide; (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide; Melanotan -Ii; C50H69N15O9; Asp5; Melanotan II acetate; D-Phe7;  melanotan II; MTII; MTII Melanotan-II; Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2
DMKT1DA	DT	Small molecular drug
DMKT1DA	PC	92432
DMKT1DA	MW	1024.2
DMKT1DA	FM	C50H69N15O9
DMKT1DA	IC	InChI=1S/C50H69N15O9/c1-3-4-16-36(59-29(2)66)44(69)65-41-25-42(67)55-20-11-10-18-35(43(51)68)60-47(72)39(23-31-26-57-34-17-9-8-15-33(31)34)63-45(70)37(19-12-21-56-50(52)53)61-46(71)38(22-30-13-6-5-7-14-30)62-48(73)40(64-49(41)74)24-32-27-54-28-58-32/h5-9,13-15,17,26-28,35-41,57H,3-4,10-12,16,18-25H2,1-2H3,(H2,51,68)(H,54,58)(H,55,67)(H,59,66)(H,60,72)(H,61,71)(H,62,73)(H,63,70)(H,64,74)(H,65,69)(H4,52,53,56)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
DMKT1DA	CS	CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N)NC(=O)C
DMKT1DA	IK	JDKLPDJLXHXHNV-MFVUMRCOSA-N
DMKT1DA	IU	(3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
DMKT1DA	CA	CAS 121062-08-6
DMKT1DA	DE	Female sexual arousal dysfunction

DMK2FOX	ID	DMK2FOX
DMK2FOX	DN	MT-Immucillin-H
DMK2FOX	HS	Investigative
DMK2FOX	DT	Small molecular drug
DMK2FOX	PC	152743083
DMK2FOX	MW	297.36
DMK2FOX	FM	C12H17N4O3S+
DMK2FOX	IC	InChI=1S/C12H16N4O3S/c1-20-3-6-10(17)11(18)8(16-6)5-2-13-9-7(5)14-4-15-12(9)19/h2,4,6-8,10-11,16-18H,3H2,1H3,(H,14,15,19)/p+1/t6-,7?,8-,10-,11-/m0/s1
DMK2FOX	CS	CSC[C@H]1[C@@H]([C@H]([C@@H]([NH2+]1)C2=CN=C3C2N=CNC3=O)O)O
DMK2FOX	IK	BRUVQLYKVACVPE-KTEKBNEVSA-O
DMK2FOX	IU	7-[(2S,3S,4S,5R)-3,4-dihydroxy-5-(methylsulfanylmethyl)pyrrolidin-1-ium-2-yl]-3,7a-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMK2FOX	DE	Discovery agent

DMXPIKT	ID	DMXPIKT
DMXPIKT	DN	M-tolyl 10H-phenothiazine-10-carboxylate
DMXPIKT	HS	Investigative
DMXPIKT	SN	CHEMBL481162; m-tolyl 10H-phenothiazine-10-carboxylate
DMXPIKT	DT	Small molecular drug
DMXPIKT	PC	24905593
DMXPIKT	MW	333.4
DMXPIKT	FM	C20H15NO2S
DMXPIKT	IC	InChI=1S/C20H15NO2S/c1-14-7-6-8-15(13-14)23-20(22)21-16-9-2-4-11-18(16)24-19-12-5-3-10-17(19)21/h2-13H,1H3
DMXPIKT	CS	CC1=CC(=CC=C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMXPIKT	IK	NSTBBOKFDNCGRF-UHFFFAOYSA-N
DMXPIKT	IU	(3-methylphenyl) phenothiazine-10-carboxylate
DMXPIKT	DE	Discovery agent

DM8KPWM	ID	DM8KPWM
DM8KPWM	DN	MTSEA
DM8KPWM	HS	Investigative
DM8KPWM	SN	methanethiosulfonate ethylammonium
DM8KPWM	DT	Small molecular drug
DM8KPWM	PC	53443082
DM8KPWM	MW	155.2
DM8KPWM	FM	C3H9NO2S2
DM8KPWM	IC	InChI=1S/C3H9NO2S2/c1-8(5,7)6-3-2-4/h2-4H2,1H3
DM8KPWM	CS	CS(=O)(=S)OCCN
DM8KPWM	IK	HKERMLQDWIEJQS-UHFFFAOYSA-N
DM8KPWM	IU	2-methylsulfonothioyloxyethanamine
DM8KPWM	DE	Discovery agent

DM16F75	ID	DM16F75
DM16F75	DN	MUG trihydrate
DM16F75	HS	Investigative
DM16F75	SN	4-methylumbelliferyl-beta-d-glucuronide; 4-Methylumbelliferone glucuronide; ARQXEQLMMNGFDU-JHZZJYKESA-N; MolMap_000057; ST044517; (2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid; 4-Methyl-2-oxo-2H-1-benzopyran-7-yl beta-D-glucopyranosiduronic acid; 4-Methylumbelliferyl beta-glucuronide; 4-Methylumbelliferyl glucuronide; 4-Methylumbelliferyl-beta-D-glucuronide; 4-methylumbelliferone beta-d-glucuronide; 6160-80-1; CHEBI:1904; MFCD00036772
DM16F75	PC	91553
DM16F75	MW	352.29
DM16F75	FM	C16H16O9
DM16F75	IC	ARQXEQLMMNGFDU-JHZZJYKESA-N
DM16F75	CS	CC1=CC(=O)OC2=C1C=CC(=C2)OC3C(C(C(C(O3)C(=O)O)O)O)O
DM16F75	IK	1S/C16H16O9/c1-6-4-10(17)24-9-5-7(2-3-8(6)9)23-16-13(20)11(18)12(19)14(25-16)15(21)22/h2-5,11-14,16,18-20H,1H3,(H,21,22)/t11-,12-,13+,14-,16+/m0/s1
DM16F75	IU	(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methyl-2-oxochromen-7-yl)oxyoxane-2-carboxylic acid
DM16F75	CA	CAS 6160-80-1
DM16F75	CB	CHEBI:1904
DM16F75	DE	Discovery agent

DMYV49C	ID	DMYV49C
DMYV49C	DN	Mulberrofuran C
DMYV49C	HS	Investigative
DMYV49C	SN	Mulberrofuran C; 77996-04-4; CHEBI:7018; CHEMBL378806; AC1L4HGH; C08928; SCHEMBL2790659; MolPort-039-338-387; ZINC4097826; BDBM50179010; 4CN-0560; Methanone, ((1S,2R,6R)-2-(2,6-dihydroxy-4-(6-hydroxy-2-benzofuranyl)phenyl)-6-(2,4-dihydroxyphenyl)-4-methyl-3-cyclohexen-1-yl)(2,4-dihydroxyphenyl)-
DMYV49C	DT	Small molecular drug
DMYV49C	PC	157143
DMYV49C	MW	580.6
DMYV49C	FM	C34H28O9
DMYV49C	IC	InChI=1S/C34H28O9/c1-16-8-24(22-6-4-19(35)13-26(22)38)32(34(42)23-7-5-20(36)14-27(23)39)25(9-16)33-28(40)10-18(11-29(33)41)30-12-17-2-3-21(37)15-31(17)43-30/h2-7,9-15,24-25,32,35-41H,8H2,1H3/t24-,25+,32-/m0/s1
DMYV49C	CS	CC1=C[C@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C(C=C(C=C4O)C5=CC6=C(O5)C=C(C=C6)O)O
DMYV49C	IK	WTGKDESIYCVAOP-UNTHUGQZSA-N
DMYV49C	IU	[(1S,2R,6R)-2-[2,6-dihydroxy-4-(6-hydroxy-1-benzofuran-2-yl)phenyl]-6-(2,4-dihydroxyphenyl)-4-methylcyclohex-3-en-1-yl]-(2,4-dihydroxyphenyl)methanone
DMYV49C	CA	CAS 77996-04-4
DMYV49C	CB	CHEBI:7018
DMYV49C	DE	Discovery agent

DMMKH72	ID	DMMKH72
DMMKH72	DN	Mulberrofuran D
DMMKH72	HS	Investigative
DMMKH72	SN	Mulberrofuran D; NSC649227; CHEMBL517247; AC1Q7B8J; AC1NV3E8; SCHEMBL13233447; 5-[7-(3,7-dimethylocta-2,6-dien-1-yl)-6-hydroxy-1-benzofuran-2-yl]-4-(3-methylbut-2-en-1-yl)benzene-1,3-diol; BDBM50303006; NSC-649227; 5-[7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6-hydroxy-benzofuran-2-yl]-4-(3-methylbut-2-enyl)benzene-1,3-diol; 5-[7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6-hydroxy-1-benzofuran-2-yl]-4-(3-methylbut-2-enyl)benzene-1,3-diol
DMMKH72	DT	Small molecular drug
DMMKH72	PC	5467256
DMMKH72	MW	446.6
DMMKH72	FM	C29H34O4
DMMKH72	IC	InChI=1S/C29H34O4/c1-18(2)7-6-8-20(5)10-13-24-26(31)14-11-21-15-28(33-29(21)24)25-16-22(30)17-27(32)23(25)12-9-19(3)4/h7,9-11,14-17,30-32H,6,8,12-13H2,1-5H3/b20-10+
DMMKH72	CS	CC(=CCC/C(=C/CC1=C(C=CC2=C1OC(=C2)C3=C(C(=CC(=C3)O)O)CC=C(C)C)O)/C)C
DMMKH72	IK	WCJPAQJEARHLGS-KEBDBYFISA-N
DMMKH72	IU	5-[7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6-hydroxy-1-benzofuran-2-yl]-4-(3-methylbut-2-enyl)benzene-1,3-diol
DMMKH72	DE	Discovery agent

DMTV9P3	ID	DMTV9P3
DMTV9P3	DN	Mulberrofuran W
DMTV9P3	HS	Investigative
DMTV9P3	SN	mulberrofuran W; CHEMBL562810
DMTV9P3	DT	Small molecular drug
DMTV9P3	PC	45273151
DMTV9P3	MW	446.6
DMTV9P3	FM	C29H34O4
DMTV9P3	IC	InChI=1S/C29H34O4/c1-19(2)7-5-8-20(3)9-6-10-21(4)11-14-25-26(16-24(31)17-27(25)32)29-15-22-12-13-23(30)18-28(22)33-29/h7,9,11-13,15-18,30-32H,5-6,8,10,14H2,1-4H3/b20-9-,21-11-
DMTV9P3	CS	CC(=CCC/C(=C\\CC/C(=C\\CC1=C(C=C(C=C1O)O)C2=CC3=C(O2)C=C(C=C3)O)/C)/C)C
DMTV9P3	IK	YUFBSQFJPYHMTK-QUYCRGELSA-N
DMTV9P3	IU	5-(6-hydroxy-1-benzofuran-2-yl)-4-[(2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trienyl]benzene-1,3-diol
DMTV9P3	DE	Discovery agent

DMW2Z4I	ID	DMW2Z4I
DMW2Z4I	DN	Multiform PI3K inhibitors
DMW2Z4I	HS	Investigative
DMW2Z4I	SN	Multiform PI3K inhibitors (inflammation); Multiform PI3K inhibitors (inflammation), UCB
DMW2Z4I	CP	UCB Celltech
DMW2Z4I	DE	Inflammation

DM6SYMH	ID	DM6SYMH
DM6SYMH	DN	Mumbaistatin
DM6SYMH	HS	Investigative
DM6SYMH	SN	MUMBAISTATIN; CHEMBL238371
DM6SYMH	DT	Small molecular drug
DM6SYMH	PC	9850474
DM6SYMH	MW	548.4
DM6SYMH	FM	C28H20O12
DM6SYMH	IC	InChI=1S/C28H20O12/c29-11(9-19(34)35)7-8-15(30)12-3-1-5-16(31)20(12)27(38)24-22-14(10-18(33)23(24)28(39)40)25(36)13-4-2-6-17(32)21(13)26(22)37/h1-6,10-11,29,31-33H,7-9H2,(H,34,35)(H,39,40)
DM6SYMH	CS	C1=CC2=C(C(=C1)O)C(=O)C3=C(C(=C(C=C3C2=O)O)C(=O)O)C(=O)C4=C(C=CC=C4O)C(=O)CCC(CC(=O)O)O
DM6SYMH	IK	XFESZXMDORIFAO-UHFFFAOYSA-N
DM6SYMH	IU	1-[2-(5-carboxy-4-hydroxypentanoyl)-6-hydroxybenzoyl]-3,8-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid
DM6SYMH	DE	Discovery agent

DM4FR71	ID	DM4FR71
DM4FR71	DN	muramyl dipeptide
DM4FR71	HS	Investigative
DM4FR71	SN	Muramyl Dipeptide; N-Acetylmuramyl-L-alanyl-D-isoglutamine; muramyldipeptide; CHEBI:59414; MurNAc-L-Ala-gamma-D-Glu; Acetylmuramyl-L-alanyl-D-isoglutamine; Acetylmuramyl-alanyl-isoglutamine; 87420-48-2; 53678-77-6; (4r)-4-[[(2s)-2-[[(2r)-2-[(2r,3s,4r,5r,6r)-5-Acetamido-2-(Hydroxymethyl)-3,6-Bis(Oxidanyl)oxan-4-Yl]oxypropanoyl]amino]propanoyl]amino]-5-Azanyl-5-Oxidanylidene-Pentanoic Acid
DM4FR71	DT	Small molecular drug
DM4FR71	PC	451714
DM4FR71	MW	492.5
DM4FR71	FM	C19H32N4O11
DM4FR71	IC	InChI=1S/C19H32N4O11/c1-7(17(30)23-10(16(20)29)4-5-12(26)27)21-18(31)8(2)33-15-13(22-9(3)25)19(32)34-11(6-24)14(15)28/h7-8,10-11,13-15,19,24,28,32H,4-6H2,1-3H3,(H2,20,29)(H,21,31)(H,22,25)(H,23,30)(H,26,27)/t7-,8+,10+,11+,13+,14+,15+,19+/m0/s1
DM4FR71	CS	C[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N)NC(=O)[C@@H](C)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1O)CO)O)NC(=O)C
DM4FR71	IK	BSOQXXWZTUDTEL-ZUYCGGNHSA-N
DM4FR71	IU	(4R)-4-[[(2S)-2-[[(2R)-2-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoic acid
DM4FR71	CA	CAS 87420-48-2
DM4FR71	CB	CHEBI:59414
DM4FR71	DE	Discovery agent

DMNDUJ5	ID	DMNDUJ5
DMNDUJ5	DN	Muscarine
DMNDUJ5	HS	Investigative
DMNDUJ5	SN	MUSCARINE; Muscarin; L-(+)-Muscarine; Muskarin; (+)-Muscarine; Muscarine (alkaloid); Muscarine (the alkaloid); UNII-7T101UWZ5W; (+)-(2S,4R,5S)-Muscarine; 300-54-9; EINECS 206-094-1; CHEMBL12587; CHEBI:7034; MUSCARINE CHLORIDE; 7T101UWZ5W; 2-Furanmethanaminium, tetrahydro-4-hydroxy-N,N,N,5-tetramethyl-, (2S-(2alpha,4beta,5alpha))-; Ammonium, trimethyl(tetrahydro-4-hydroxy-5-methylfurfuryl)-; D-ribo-Hexitol, 2,5-anhydro-1,4,6-trideoxy-6-(trimethyl)ammonio)-; CHEMBL292911; CHEMBL1255785
DMNDUJ5	DT	Small molecular drug
DMNDUJ5	PC	9308
DMNDUJ5	MW	174.26
DMNDUJ5	FM	C9H20NO2+
DMNDUJ5	IC	InChI=1S/C9H20NO2/c1-7-9(11)5-8(12-7)6-10(2,3)4/h7-9,11H,5-6H2,1-4H3/q+1/t7-,8-,9+/m0/s1
DMNDUJ5	CS	C[C@H]1[C@@H](C[C@H](O1)C[N+](C)(C)C)O
DMNDUJ5	IK	UQOFGTXDASPNLL-XHNCKOQMSA-N
DMNDUJ5	IU	[(2S,4R,5S)-4-hydroxy-5-methyloxolan-2-yl]methyl-trimethylazanium
DMNDUJ5	CA	CAS 300-54-9
DMNDUJ5	CB	CHEBI:7034
DMNDUJ5	DE	Discovery agent

DMNTF2O	ID	DMNTF2O
DMNTF2O	DN	Muscimol
DMNTF2O	HS	Investigative
DMNTF2O	SN	muscimol; 2763-96-4; Pantherine; Agarin; Agarine; 3(2H)-Isoxazolone, 5-(aminomethyl)-; Pantherin; 5-Aminomethyl-3-isoxyzole; 3-Hydroxy-5-aminomethylisoxazole; 5-Aminomethyl-3-hydroxyisoxazole; 5-(Aminomethyl)-3-isoxazolol; 3-Isoxazolol, 5-(aminomethyl)-; 5-(Aminomethyl)-3(2H)-isoxazolone; RCRA waste number P007; NSC 333569; 3-Hydroxy-5-aminomethyl-isoxazole; UNII-D5M179TY2E; 3-Hydroxy-5-aminomethylisoxazole-agarin; CCRIS 3720; C4H6N2O2; CHEBI:7035; HSDB 6036; EINECS 220-430-4; RCRA waste no. P007; 5-(Aminomethyl)isoxazol-3-ol hydr
DMNTF2O	DT	Small molecular drug
DMNTF2O	PC	4266
DMNTF2O	MW	114.1
DMNTF2O	FM	C4H6N2O2
DMNTF2O	IC	InChI=1S/C4H6N2O2/c5-2-3-1-4(7)6-8-3/h1H,2,5H2,(H,6,7)
DMNTF2O	CS	C1=C(ONC1=O)CN
DMNTF2O	IK	ZJQHPWUVQPJPQT-UHFFFAOYSA-N
DMNTF2O	IU	5-(aminomethyl)-1,2-oxazol-3-one
DMNTF2O	CA	CAS 2763-96-4
DMNTF2O	CB	CHEBI:7035
DMNTF2O	DE	Discovery agent

DMAY50R	ID	DMAY50R
DMAY50R	DN	Mutated growth hormone
DMAY50R	HS	Investigative
DMAY50R	CP	JCR Pharmaceuticals
DMAY50R	DE	Acromegaly

DMU65NK	ID	DMU65NK
DMU65NK	DN	Mycophenolic acid
DMU65NK	HS	Investigative
DMU65NK	SN	Acide mycophenolique; Acide mycophenolique [INN-French]; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycoph; Acidum mycophenolicum; CCRIS 5565; Lilly-68618; Ly 68618; Melbex; Micofenolico acido; Micofenolico acido [Spanish]; Mycophenolate; Mycophenolsaeure; Myfortic; NSC 129185; NSC-129185; UNII-HU9DX48N0T
DMU65NK	TC	Antiviral Agents
DMU65NK	DT	Small molecular drug
DMU65NK	PC	446541
DMU65NK	MW	320.3
DMU65NK	FM	C17H20O6
DMU65NK	IC	InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
DMU65NK	CS	CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)O)O
DMU65NK	IK	HPNSFSBZBAHARI-RUDMXATFSA-N
DMU65NK	IU	(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
DMU65NK	CA	CAS 24280-93-1
DMU65NK	CB	CHEBI:168396
DMU65NK	DE	Middle East Respiratory Syndrome (MERS); Middle East Respiratory Syndrome (MERS)

DMUQP3J	ID	DMUQP3J
DMUQP3J	DN	Mycophenolic bis(sulfonamide)
DMUQP3J	HS	Investigative
DMUQP3J	SN	Mycophenolic bis(sulfonamide); CHEMBL476562
DMUQP3J	DT	Small molecular drug
DMUQP3J	PC	44578788
DMUQP3J	MW	394.4
DMUQP3J	FM	C13H18N2O8S2
DMUQP3J	IC	InChI=1S/C13H18N2O8S2/c1-7-9-5-23-13(17)10(9)11(16)8(12(7)22-2)3-4-15-25(20,21)6-24(14,18)19/h15-16H,3-6H2,1-2H3,(H2,14,18,19)
DMUQP3J	CS	CC1=C2COC(=O)C2=C(C(=C1OC)CCNS(=O)(=O)CS(=O)(=O)N)O
DMUQP3J	IK	IVAOVFUEHDFBPQ-UHFFFAOYSA-N
DMUQP3J	IU	N'-[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)ethyl]methanedisulfonamide
DMUQP3J	DE	Discovery agent

DM4YRAH	ID	DM4YRAH
DM4YRAH	DN	Mycophenolic hydroxamic acid
DM4YRAH	HS	Investigative
DM4YRAH	SN	CHEMBL238461; mycophenolic hydroxamic acid; BDBM50228085; N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enamide
DM4YRAH	DT	Small molecular drug
DM4YRAH	PC	24749070
DM4YRAH	MW	335.4
DM4YRAH	FM	C17H21NO6
DM4YRAH	IC	InChI=1S/C17H21NO6/c1-9(5-7-13(19)18-22)4-6-11-15(20)14-12(8-24-17(14)21)10(2)16(11)23-3/h4,20,22H,5-8H2,1-3H3,(H,18,19)/b9-4+
DM4YRAH	CS	CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)NO)O
DM4YRAH	IK	XUEGRBSFQYYISJ-RUDMXATFSA-N
DM4YRAH	IU	(E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enamide
DM4YRAH	DE	Discovery agent

DMX1POR	ID	DMX1POR
DMX1POR	DN	MYOSEVERIN
DMX1POR	HS	Investigative
DMX1POR	SN	myoseverin; 267402-71-1; 9-Isopropyl-N2,N6-bis-(4-methoxybenzyl)-9H-purine-2,6-diamine; 9-Isopropyl-N2,N6-bis(4-methoxybenzyl)-9H-purine-2,6-diamine; AC1L1HSM; AC1Q4VJQ; 9-Isopropyl-2,6-bis(4-methoxybenzylamino)purine; CHEMBL141689; SCHEMBL13325947; CTK8E8888; MolPort-003-958-703; HMS2043N15; KS-000012SJ; ZINC2583630; n,n'-bis(4-methoxybenzyl)-9-(propan-2-yl)-9h-purine-2,6-diamine; HSCI1_000041; IN1218; AKOS027326433; TRA0035814; SMP2_000092; NCGC00165829-01; ACM267402711; RT-013973; M2373; J-016534
DMX1POR	DT	Small molecular drug
DMX1POR	PC	4273
DMX1POR	MW	432.5
DMX1POR	FM	C24H28N6O2
DMX1POR	IC	InChI=1S/C24H28N6O2/c1-16(2)30-15-27-21-22(25-13-17-5-9-19(31-3)10-6-17)28-24(29-23(21)30)26-14-18-7-11-20(32-4)12-8-18/h5-12,15-16H,13-14H2,1-4H3,(H2,25,26,28,29)
DMX1POR	CS	CC(C)N1C=NC2=C(N=C(N=C21)NCC3=CC=C(C=C3)OC)NCC4=CC=C(C=C4)OC
DMX1POR	IK	IDCOTQWQVPRTNK-UHFFFAOYSA-N
DMX1POR	IU	2-N,6-N-bis[(4-methoxyphenyl)methyl]-9-propan-2-ylpurine-2,6-diamine
DMX1POR	DE	Discovery agent

DMTV4L0	ID	DMTV4L0
DMTV4L0	DN	Myricetin
DMTV4L0	HS	Investigative
DMTV4L0	SN	myricetin; 529-44-2; Cannabiscetin; Myricetol; Myricitin; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one; 3,3',4',5,5',7-Hexahydroxyflavone; 3,5,7,3',4',5'-Hexahydroxyflavone; UNII-76XC01FTOJ; NSC 407290; CCRIS 5838; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one; EINECS 208-463-2; NSC407290; CHEMBL164; NSC-407290; BRN 0332331; 76XC01FTOJ
DMTV4L0	DT	Small molecular drug
DMTV4L0	PC	5281672
DMTV4L0	MW	318.23
DMTV4L0	FM	C15H10O8
DMTV4L0	IC	InChI=1S/C15H10O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,16-20,22H
DMTV4L0	CS	C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
DMTV4L0	IK	IKMDFBPHZNJCSN-UHFFFAOYSA-N
DMTV4L0	IU	3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
DMTV4L0	CA	CAS 529-44-2
DMTV4L0	CB	CHEBI:18152
DMTV4L0	DE	Discovery agent

DMVXW4L	ID	DMVXW4L
DMVXW4L	DN	MYRIOCIN
DMVXW4L	HS	Investigative
DMVXW4L	SN	Myriocin; thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid
DMVXW4L	DT	Small molecular drug
DMVXW4L	PC	6438394
DMVXW4L	MW	401.5
DMVXW4L	FM	C21H39NO6
DMVXW4L	IC	InChI=1S/C21H39NO6/c1-2-3-4-10-13-17(24)14-11-8-6-5-7-9-12-15-18(25)19(26)21(22,16-23)20(27)28/h9,12,18-19,23,25-26H,2-8,10-11,13-16,22H2,1H3,(H,27,28)/b12-9+/t18-,19+,21+/m1/s1
DMVXW4L	CS	CCCCCCC(=O)CCCCCC/C=C/C[C@H]([C@@H]([C@@](CO)(C(=O)O)N)O)O
DMVXW4L	IK	ZZIKIHCNFWXKDY-GNTQXERDSA-N
DMVXW4L	IU	(E,2S,3R,4R)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid
DMVXW4L	CA	CAS 35891-70-4
DMVXW4L	CB	CHEBI:582124
DMVXW4L	DE	Discovery agent

DMVMHTC	ID	DMVMHTC
DMVMHTC	DN	Myrisglycerol-phosphate
DMVMHTC	HS	Investigative
DMVMHTC	SN	Myristoyl lysophosphatidic acid; PA(14:0/0:0); (2R)-2-hydroxy-3-(phosphonooxy)propyl myristate; 1-Myristoyl-sn-glycerol 3-phosphate; 1-O-myristoyl-sn-glycerol 3-phosphate; 1-O-tetradecanoyl-sn-glycerol 3-phosphate; 1-myristoyl LPA; 1-myristoyl lysophosphatidic acid; 1-myristoyl-2-lyso-sn-glycerol 3-phosphatidic acid; 1-myristoylglycerol 3-phosphate; 1-tetradecanoyl-sn-glycero-3-phosphate; 1-tetradecanoyl-sn-glycerol 3-phosphate; 1-tetradecanoylglycerol 3-phosphate; CHEBI:62833
DMVMHTC	PC	9547180
DMVMHTC	MW	382.4
DMVMHTC	FM	C17H35O7P
DMVMHTC	IC	FAZBDRGXCKPVJU-MRXNPFEDSA-N
DMVMHTC	CS	CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)O
DMVMHTC	IK	1S/C17H35O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-17(19)23-14-16(18)15-24-25(20,21)22/h16,18H,2-15H2,1H3,(H2,20,21,22)/t16-/m1/s1
DMVMHTC	IU	[(2R)-2-hydroxy-3-phosphonooxypropyl] tetradecanoate
DMVMHTC	CA	CAS 65446-07-3
DMVMHTC	CB	CHEBI:62833
DMVMHTC	DE	Discovery agent

DMYX0BL	ID	DMYX0BL
DMYX0BL	DN	MYRISTIC ACID
DMYX0BL	HS	Investigative
DMYX0BL	SN	Tetradecanoic acid; MYRISTIC ACID; 544-63-8; n-Tetradecanoic acid; n-Tetradecoic acid; Crodacid; n-Tetradecan-1-oic acid; 1-Tridecanecarboxylic acid; Univol U 316S; Hydrofol acid 1495; Emery 655; Myristinsaeure; Myristate; tetradecoic acid; Hystrene 9014; Neo-fat 14; Myristic acid (natural); C14 fatty acid; Myristic acid, pure; n-Myristic acid; Tetradecanoate; acide tetradecanoique; NSC 5028; FEMA No. 2764; CCRIS 4724; CH3-[CH2]12-COOH; HSDB 5686; UNII-0I3V7S25AW; Philacid 1400; CHEBI:28875; AI3-15381; Prifac 2942; C14:0; EINECS 208-875-2
DMYX0BL	DT	Small molecular drug
DMYX0BL	PC	11005
DMYX0BL	MW	228.37
DMYX0BL	FM	C14H28O2
DMYX0BL	IC	InChI=1S/C14H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H,15,16)
DMYX0BL	CS	CCCCCCCCCCCCCC(=O)O
DMYX0BL	IK	TUNFSRHWOTWDNC-UHFFFAOYSA-N
DMYX0BL	IU	tetradecanoic acid
DMYX0BL	CA	CAS 544-63-8
DMYX0BL	CB	CHEBI:28875
DMYX0BL	DE	Discovery agent

DMV7NGS	ID	DMV7NGS
DMV7NGS	DN	Myristoyl-Coa
DMV7NGS	HS	Investigative
DMV7NGS	SN	MYA; AC1L9JG6; S-[2-[3-[[(2S)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] tetradecanethioate
DMV7NGS	DT	Small molecular drug
DMV7NGS	PC	11966124
DMV7NGS	MW	977.9
DMV7NGS	FM	C35H62N7O17P3S
DMV7NGS	IC	InChI=1S/C35H62N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42/h22-24,28-30,34,45-46H,4-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50)/t24-,28-,29-,30+,34-/m1/s1
DMV7NGS	CS	CCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DMV7NGS	IK	DUAFKXOFBZQTQE-QSGBVPJFSA-N
DMV7NGS	IU	S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] tetradecanethioate
DMV7NGS	CA	CAS 3130-72-1
DMV7NGS	CB	CHEBI:15532
DMV7NGS	DE	Discovery agent

DMGJYIZ	ID	DMGJYIZ
DMGJYIZ	DN	MystiLol
DMGJYIZ	HS	Investigative
DMGJYIZ	SN	MystiLol (non-selective beta blocker, glaucoma), Mystic
DMGJYIZ	CP	Mystic Pharmaceuticals Inc
DMGJYIZ	DE	Glaucoma/ocular hypertension

DM16SVM	ID	DM16SVM
DM16SVM	DN	Myxopyronin B
DM16SVM	HS	Investigative
DM16SVM	DT	Small molecular drug
DM16SVM	PC	135423114
DM16SVM	MW	431.5
DM16SVM	FM	C24H33NO6
DM16SVM	IC	InChI=1S/C24H33NO6/c1-6-7-10-16(2)12-13-18(4)22(27)21-19(26)15-20(31-23(21)28)17(3)11-8-9-14-25-24(29)30-5/h9,12-15,17,26H,6-8,10-11H2,1-5H3,(H,25,29)/b14-9+,16-12+,18-13+/t17-/m1/s1
DM16SVM	CS	CCCC/C(=C/C=C(\\C)/C(=O)C1=C(C=C(OC1=O)[C@H](C)CC/C=C/NC(=O)OC)O)/C
DM16SVM	IK	SPQDIDVJAZFBRL-WXFBSNOUSA-N
DM16SVM	IU	methyl N-[(E,5R)-5-[5-[(2E,4E)-2,5-dimethylnona-2,4-dienoyl]-4-hydroxy-6-oxopyran-2-yl]hex-1-enyl]carbamate
DM16SVM	CA	CAS 88192-99-8
DM16SVM	DE	Discovery agent

DM093GO	ID	DM093GO
DM093GO	DN	N-((1H-indol-2-yl)methyl)(phenyl)methanamine
DM093GO	HS	Investigative
DM093GO	SN	CHEMBL45511; N-((1H-indol-2-yl)methyl)(phenyl)methanamine; Oprea1_729586; SCHEMBL4104078; MolPort-003-806-990; ZINC13807947; BDBM50087789; AKOS006041743; 2-[(phenylmethylamino)-methyl]-indole; Benzyl-(1H-indol-2-ylmethyl)-amine (FA4)
DM093GO	DT	Small molecular drug
DM093GO	PC	13680885
DM093GO	MW	236.31
DM093GO	FM	C16H16N2
DM093GO	IC	InChI=1S/C16H16N2/c1-2-6-13(7-3-1)11-17-12-15-10-14-8-4-5-9-16(14)18-15/h1-10,17-18H,11-12H2
DM093GO	CS	C1=CC=C(C=C1)CNCC2=CC3=CC=CC=C3N2
DM093GO	IK	CCDCVAKHGAIARI-UHFFFAOYSA-N
DM093GO	IU	N-(1H-indol-2-ylmethyl)-1-phenylmethanamine
DM093GO	DE	Discovery agent

DMYUAXR	ID	DMYUAXR
DMYUAXR	DN	N-((1H-indol-2-yl)methyl)-2-phenylethanamine
DMYUAXR	HS	Investigative
DMYUAXR	SN	CHEMBL446960; N-((1H-indol-2-yl)methyl)-2-phenylethanamine
DMYUAXR	DT	Small molecular drug
DMYUAXR	PC	44588174
DMYUAXR	MW	250.34
DMYUAXR	FM	C17H18N2
DMYUAXR	IC	InChI=1S/C17H18N2/c1-2-6-14(7-3-1)10-11-18-13-16-12-15-8-4-5-9-17(15)19-16/h1-9,12,18-19H,10-11,13H2
DMYUAXR	CS	C1=CC=C(C=C1)CCNCC2=CC3=CC=CC=C3N2
DMYUAXR	IK	LMNUEZRZRYCQSM-UHFFFAOYSA-N
DMYUAXR	IU	N-(1H-indol-2-ylmethyl)-2-phenylethanamine
DMYUAXR	DE	Discovery agent

DMBQ5NS	ID	DMBQ5NS
DMBQ5NS	DN	N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide
DMBQ5NS	HS	Investigative
DMBQ5NS	SN	N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide
DMBQ5NS	DT	Small molecular drug
DMBQ5NS	PC	17945750
DMBQ5NS	MW	285.34
DMBQ5NS	FM	C16H19N3O2
DMBQ5NS	IC	InChI=1S/C16H19N3O2/c17-11-12-18-15(21)16(9-5-2-6-10-16)19-14(20)13-7-3-1-4-8-13/h1,3-4,7-8H,2,5-6,9-10,12H2,(H,18,21)(H,19,20)
DMBQ5NS	CS	C1CCC(CC1)(C(=O)NCC#N)NC(=O)C2=CC=CC=C2
DMBQ5NS	IK	CSOZFSBRJJRGIA-UHFFFAOYSA-N
DMBQ5NS	IU	N-[1-(cyanomethylcarbamoyl)cyclohexyl]benzamide
DMBQ5NS	DE	Discovery agent

DMJWTH9	ID	DMJWTH9
DMJWTH9	DN	N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide
DMJWTH9	HS	Investigative
DMJWTH9	SN	CHEMBL228865; N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide
DMJWTH9	DT	Small molecular drug
DMJWTH9	PC	44426498
DMJWTH9	MW	358.5
DMJWTH9	FM	C24H26N2O
DMJWTH9	IC	InChI=1S/C24H26N2O/c1-18(19-8-3-2-4-9-19)26-16-14-21(15-17-26)25-24(27)23-13-7-11-20-10-5-6-12-22(20)23/h2-13,18,21H,14-17H2,1H3,(H,25,27)
DMJWTH9	CS	CC(C1=CC=CC=C1)N2CCC(CC2)NC(=O)C3=CC=CC4=CC=CC=C43
DMJWTH9	IK	ZNKBVXRAPNKVHW-UHFFFAOYSA-N
DMJWTH9	IU	N-[1-(1-phenylethyl)piperidin-4-yl]naphthalene-1-carboxamide
DMJWTH9	DE	Discovery agent

DMMCGL3	ID	DMMCGL3
DMMCGL3	DN	N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide
DMMCGL3	HS	Investigative
DMMCGL3	SN	CHEMBL229023; N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide
DMMCGL3	DT	Small molecular drug
DMMCGL3	PC	44426508
DMMCGL3	MW	358.5
DMMCGL3	FM	C24H26N2O
DMMCGL3	IC	InChI=1S/C24H26N2O/c1-18(19-7-3-2-4-8-19)26-15-13-23(14-16-26)25-24(27)22-12-11-20-9-5-6-10-21(20)17-22/h2-12,17-18,23H,13-16H2,1H3,(H,25,27)
DMMCGL3	CS	CC(C1=CC=CC=C1)N2CCC(CC2)NC(=O)C3=CC4=CC=CC=C4C=C3
DMMCGL3	IK	LVIBIBUWEMTPMC-UHFFFAOYSA-N
DMMCGL3	IU	N-[1-(1-phenylethyl)piperidin-4-yl]naphthalene-2-carboxamide
DMMCGL3	DE	Discovery agent

DMGYLC1	ID	DMGYLC1
DMGYLC1	DN	N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide
DMGYLC1	HS	Investigative
DMGYLC1	SN	CHEMBL395631; N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide
DMGYLC1	DT	Small molecular drug
DMGYLC1	PC	44431465
DMGYLC1	MW	423.3
DMGYLC1	FM	C23H23BrN2O
DMGYLC1	IC	InChI=1S/C23H23BrN2O/c24-19-8-3-5-17(15-19)16-26-13-11-20(12-14-26)25-23(27)22-10-4-7-18-6-1-2-9-21(18)22/h1-10,15,20H,11-14,16H2,(H,25,27)
DMGYLC1	CS	C1CN(CCC1NC(=O)C2=CC=CC3=CC=CC=C32)CC4=CC(=CC=C4)Br
DMGYLC1	IK	USZMCEOIEOTIGM-UHFFFAOYSA-N
DMGYLC1	IU	N-[1-[(3-bromophenyl)methyl]piperidin-4-yl]naphthalene-1-carboxamide
DMGYLC1	DE	Discovery agent

DMRQKYC	ID	DMRQKYC
DMRQKYC	DN	N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMRQKYC	HS	Investigative
DMRQKYC	SN	CHEMBL395867; N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMRQKYC	DT	Small molecular drug
DMRQKYC	PC	16725931
DMRQKYC	MW	423.3
DMRQKYC	FM	C23H23BrN2O
DMRQKYC	IC	InChI=1S/C23H23BrN2O/c24-21-7-3-4-17(14-21)16-26-12-10-22(11-13-26)25-23(27)20-9-8-18-5-1-2-6-19(18)15-20/h1-9,14-15,22H,10-13,16H2,(H,25,27)
DMRQKYC	CS	C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CC4=CC(=CC=C4)Br
DMRQKYC	IK	KMQWTBGTEFASGU-UHFFFAOYSA-N
DMRQKYC	IU	N-[1-[(3-bromophenyl)methyl]piperidin-4-yl]naphthalene-2-carboxamide
DMRQKYC	DE	Discovery agent

DMS9RDW	ID	DMS9RDW
DMS9RDW	DN	N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMS9RDW	HS	Investigative
DMS9RDW	SN	CHEMBL234472; N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMS9RDW	DT	Small molecular drug
DMS9RDW	PC	44431481
DMS9RDW	MW	423.3
DMS9RDW	FM	C23H23BrN2O
DMS9RDW	IC	InChI=1S/C23H23BrN2O/c24-21-9-5-17(6-10-21)16-26-13-11-22(12-14-26)25-23(27)20-8-7-18-3-1-2-4-19(18)15-20/h1-10,15,22H,11-14,16H2,(H,25,27)
DMS9RDW	CS	C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)Br
DMS9RDW	IK	WZCSZVSNRKEGGN-UHFFFAOYSA-N
DMS9RDW	IU	N-[1-[(4-bromophenyl)methyl]piperidin-4-yl]naphthalene-2-carboxamide
DMS9RDW	DE	Discovery agent

DMAP4R8	ID	DMAP4R8
DMAP4R8	DN	N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide
DMAP4R8	HS	Investigative
DMAP4R8	SN	CHEMBL234644; N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide
DMAP4R8	DT	Small molecular drug
DMAP4R8	PC	44431485
DMAP4R8	MW	389.4
DMAP4R8	FM	C23H23N3O3
DMAP4R8	IC	InChI=1S/C23H23N3O3/c27-23(20-8-7-18-3-1-2-4-19(18)15-20)24-21-11-13-25(14-12-21)16-17-5-9-22(10-6-17)26(28)29/h1-10,15,21H,11-14,16H2,(H,24,27)
DMAP4R8	CS	C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)[N+](=O)[O-]
DMAP4R8	IK	BAYSOSKDAJWQFJ-UHFFFAOYSA-N
DMAP4R8	IU	N-[1-[(4-nitrophenyl)methyl]piperidin-4-yl]naphthalene-2-carboxamide
DMAP4R8	DE	Discovery agent

DMQSLJI	ID	DMQSLJI
DMQSLJI	DN	N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide
DMQSLJI	HS	Investigative
DMQSLJI	SN	CHEMBL387952; N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide
DMQSLJI	DT	Small molecular drug
DMQSLJI	PC	44426502
DMQSLJI	MW	386.5
DMQSLJI	FM	C26H30N2O
DMQSLJI	IC	InChI=1S/C26H30N2O/c29-26(25-15-8-13-22-12-4-5-14-24(22)25)27-23-16-19-28(20-17-23)18-7-6-11-21-9-2-1-3-10-21/h1-5,8-10,12-15,23H,6-7,11,16-20H2,(H,27,29)
DMQSLJI	CS	C1CN(CCC1NC(=O)C2=CC=CC3=CC=CC=C32)CCCCC4=CC=CC=C4
DMQSLJI	IK	JATDEOORDLHCRO-UHFFFAOYSA-N
DMQSLJI	IU	N-[1-(4-phenylbutyl)piperidin-4-yl]naphthalene-1-carboxamide
DMQSLJI	DE	Discovery agent

DMZ84JH	ID	DMZ84JH
DMZ84JH	DN	N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide
DMZ84JH	HS	Investigative
DMZ84JH	SN	CHEMBL229025; N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide
DMZ84JH	DT	Small molecular drug
DMZ84JH	PC	44426510
DMZ84JH	MW	386.5
DMZ84JH	FM	C26H30N2O
DMZ84JH	IC	InChI=1S/C26H30N2O/c29-26(24-14-13-22-11-4-5-12-23(22)20-24)27-25-15-18-28(19-16-25)17-7-6-10-21-8-2-1-3-9-21/h1-5,8-9,11-14,20,25H,6-7,10,15-19H2,(H,27,29)
DMZ84JH	CS	C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CCCCC4=CC=CC=C4
DMZ84JH	IK	XYKZGGUQORZZTO-UHFFFAOYSA-N
DMZ84JH	IU	N-[1-(4-phenylbutyl)piperidin-4-yl]naphthalene-2-carboxamide
DMZ84JH	DE	Discovery agent

DMWP6OZ	ID	DMWP6OZ
DMWP6OZ	DN	N-(1,3,4-thiadiazol-2-yl)benzamide
DMWP6OZ	HS	Investigative
DMWP6OZ	SN	N-(1,3,4-Thiadiazol-2-yl)benzamide; RWOUBULBQYRRNL-UHFFFAOYSA-N; N-1,3,4-thiadiazol-2-yl-benzamide; 26861-95-0; BAS 03031913; AC1LC4SO; TimTec1_007967; CHEMBL390098; SCHEMBL3379803; CTK0I5904; DTXSID40341040; MolPort-001-017-069; HMS1556K03; ZINC892651; STK158583; AKOS000646792; MCULE-9389828263; N-[1,3,4]Thiadiazol-2-yl-benzamide; IDI1_033621; Benzamide, N-1,3,4-thiadiazol-2-yl-; N-([1,3,4]thiadiazol-2-yl)-benzamide; N~1~-(1,3,4-thiadiazol-2-yl)benzamide; ST50015221; phenyl-N-(1,3,4-thiadiazol-2-yl)carboxamide; SR-01000365353
DMWP6OZ	DT	Small molecular drug
DMWP6OZ	PC	569548
DMWP6OZ	MW	205.24
DMWP6OZ	FM	C9H7N3OS
DMWP6OZ	IC	InChI=1S/C9H7N3OS/c13-8(7-4-2-1-3-5-7)11-9-12-10-6-14-9/h1-6H,(H,11,12,13)
DMWP6OZ	CS	C1=CC=C(C=C1)C(=O)NC2=NN=CS2
DMWP6OZ	IK	RWOUBULBQYRRNL-UHFFFAOYSA-N
DMWP6OZ	IU	N-(1,3,4-thiadiazol-2-yl)benzamide
DMWP6OZ	CA	CAS 26861-95-0
DMWP6OZ	DE	Discovery agent

DMDW8VX	ID	DMDW8VX
DMDW8VX	DN	N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMDW8VX	HS	Investigative
DMDW8VX	SN	N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; CHEMBL191039; 77746-90-8; N-(2,5-diphenylpyrazol-3-yl)benzamide; AC1N4KII; Oprea1_790904; SCHEMBL2482825; CTK2G6100; DTXSID00400046; MolPort-003-805-392; HMS3519K01; ZINC3185886; BDBM50156065; AKOS005002190; MCULE-3316862201; DA-03411; FT-0732104; N-(1,3-Diphenyl-1H-pyrazole-5-yl)benzamide; N-(2,5-Diphenyl-2H-pyrazol-3-yl)-benzamide; Benzamide, N-(1,3-diphenyl-1H-pyrazol-5-yl)-
DMDW8VX	DT	Small molecular drug
DMDW8VX	PC	4156919
DMDW8VX	MW	339.4
DMDW8VX	FM	C22H17N3O
DMDW8VX	IC	InChI=1S/C22H17N3O/c26-22(18-12-6-2-7-13-18)23-21-16-20(17-10-4-1-5-11-17)24-25(21)19-14-8-3-9-15-19/h1-16H,(H,23,26)
DMDW8VX	CS	C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC=CC=C3)C4=CC=CC=C4
DMDW8VX	IK	AYVLYDAJDALPHK-UHFFFAOYSA-N
DMDW8VX	IU	N-(2,5-diphenylpyrazol-3-yl)benzamide
DMDW8VX	CA	CAS 77746-90-8
DMDW8VX	DE	Discovery agent

DMEDJ7X	ID	DMEDJ7X
DMEDJ7X	DN	N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DMEDJ7X	HS	Investigative
DMEDJ7X	SN	CHEMBL206574; N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DMEDJ7X	DT	Small molecular drug
DMEDJ7X	PC	11566992
DMEDJ7X	MW	339.4
DMEDJ7X	FM	C22H17N3O
DMEDJ7X	IC	InChI=1S/C22H17N3O/c26-22(18-12-6-2-7-13-18)24-21-20(17-10-4-1-5-11-17)16-23-25(21)19-14-8-3-9-15-19/h1-16H,(H,24,26)
DMEDJ7X	CS	C1=CC=C(C=C1)C2=C(N(N=C2)C3=CC=CC=C3)NC(=O)C4=CC=CC=C4
DMEDJ7X	IK	HIJQHIKXNPDXIT-UHFFFAOYSA-N
DMEDJ7X	IU	N-(2,4-diphenylpyrazol-3-yl)benzamide
DMEDJ7X	DE	Discovery agent

DMW460V	ID	DMW460V
DMW460V	DN	N-(14-methylallyl)norgalanthamine
DMW460V	HS	Investigative
DMW460V	SN	N-(14-methylallyl)norgalanthamine; CHEMBL442287
DMW460V	DT	Small molecular drug
DMW460V	PC	24863955
DMW460V	MW	327.4
DMW460V	FM	C20H25NO3
DMW460V	IC	InChI=1S/C20H25NO3/c1-13(2)11-21-9-8-20-7-6-15(22)10-17(20)24-19-16(23-3)5-4-14(12-21)18(19)20/h4-7,15,17,22H,1,8-12H2,2-3H3/t15-,17-,20-/m0/s1
DMW460V	CS	CC(=C)CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
DMW460V	IK	FEKQBPRIVQKBRM-KNBMTAEXSA-N
DMW460V	IU	(1S,12S,14R)-9-methoxy-4-(2-methylprop-2-enyl)-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
DMW460V	DE	Discovery agent

DMFRQ2U	ID	DMFRQ2U
DMFRQ2U	DN	N-(17-Methylmorphinan-3-yl)-N'-phenylurea
DMFRQ2U	HS	Investigative
DMFRQ2U	SN	CHEMBL568829; BDBM50303599
DMFRQ2U	DT	Small molecular drug
DMFRQ2U	PC	44628003
DMFRQ2U	MW	375.5
DMFRQ2U	FM	C24H29N3O
DMFRQ2U	IC	InChI=1S/C24H29N3O/c1-27-14-13-24-12-6-5-9-20(24)22(27)15-17-10-11-19(16-21(17)24)26-23(28)25-18-7-3-2-4-8-18/h2-4,7-8,10-11,16,20,22H,5-6,9,12-15H2,1H3,(H2,25,26,28)/t20-,22+,24+/m0/s1
DMFRQ2U	CS	CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)NC(=O)NC5=CC=CC=C5
DMFRQ2U	IK	CVZRQQXQPKBKNJ-BGWNEDDSSA-N
DMFRQ2U	IU	1-[(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]-3-phenylurea
DMFRQ2U	DE	Discovery agent

DMD6N8V	ID	DMD6N8V
DMD6N8V	DN	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea
DMD6N8V	HS	Investigative
DMD6N8V	SN	n-(1-adamantyl)-n'-(4-guanidinobenzyl)urea; AGB; 1ejn; AC1L1HTN; SCHEMBL4328331; WX293T; SCHEMBL14524522; CTK7G4253; BDBM16176; WX-293T; DB03782; 3-adamantan-1-yl-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(1-adamantyl)-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea; 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea; 1-{4-[(diaminomethylidene)amino]benzyl}-3-tricyclo[3.3.1.13,7]dec-1-ylurea
DMD6N8V	DT	Small molecular drug
DMD6N8V	PC	4286
DMD6N8V	MW	341.5
DMD6N8V	FM	C19H27N5O
DMD6N8V	IC	InChI=1S/C19H27N5O/c20-17(21)23-16-3-1-12(2-4-16)11-22-18(25)24-19-8-13-5-14(9-19)7-15(6-13)10-19/h1-4,13-15H,5-11H2,(H4,20,21,23)(H2,22,24,25)
DMD6N8V	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)NCC4=CC=C(C=C4)N=C(N)N
DMD6N8V	IK	YQPLKJCBEOVDBS-UHFFFAOYSA-N
DMD6N8V	IU	1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea
DMD6N8V	DE	Discovery agent

DM29QT4	ID	DM29QT4
DM29QT4	DN	N-(1-adamantyl)-N'-propylsulfamide
DM29QT4	HS	Investigative
DM29QT4	SN	CHEMBL374746; SCHEMBL3107083; ZINC35091097; BDBM50300769
DM29QT4	DT	Small molecular drug
DM29QT4	PC	16103193
DM29QT4	MW	272.41
DM29QT4	FM	C13H24N2O2S
DM29QT4	IC	InChI=1S/C13H24N2O2S/c1-2-3-14-18(16,17)15-13-7-10-4-11(8-13)6-12(5-10)9-13/h10-12,14-15H,2-9H2,1H3
DM29QT4	CS	CCCNS(=O)(=O)NC12CC3CC(C1)CC(C3)C2
DM29QT4	IK	LLVZKPBHOPZCRW-UHFFFAOYSA-N
DM29QT4	IU	N-(propylsulfamoyl)adamantan-1-amine
DM29QT4	DE	Discovery agent

DM3WBZP	ID	DM3WBZP
DM3WBZP	DN	N-(1-benzofuran-3-ylmethyl)sulfamide
DM3WBZP	HS	Investigative
DM3WBZP	SN	CHEMBL1077117; N-(1-benzofuran-3-ylmethyl)sulfamide; Sulfamide, N-(3-benzofuranylmethyl)-; SCHEMBL4279478; XOBOZYKTCAJRGO-UHFFFAOYSA-N; N-(3-benzofuranylmethyl)-sulfamide; BDBM50310434
DM3WBZP	DT	Small molecular drug
DM3WBZP	PC	11521450
DM3WBZP	MW	226.25
DM3WBZP	FM	C9H10N2O3S
DM3WBZP	IC	InChI=1S/C9H10N2O3S/c10-15(12,13)11-5-7-6-14-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H2,10,12,13)
DM3WBZP	CS	C1=CC=C2C(=C1)C(=CO2)CNS(=O)(=O)N
DM3WBZP	IK	XOBOZYKTCAJRGO-UHFFFAOYSA-N
DM3WBZP	IU	3-[(sulfamoylamino)methyl]-1-benzofuran
DM3WBZP	DE	Discovery agent

DMP9A7L	ID	DMP9A7L
DMP9A7L	DN	N-(1-Benzyl-2-oxo-ethyl)-benzamide
DMP9A7L	HS	Investigative
DMP9A7L	SN	CHEMBL287136; N-(1-Benzyl-2-oxo-ethyl)-benzamide; N-Benzoyl-L-phenylalaninal; benzamide, n-[(1s)-1-formyl-2-phenylethyl]-; AC1L4VU2; SCHEMBL40781; AC1Q6A59; ZINC3650451; BDBM50014566; N-[(2S)-1-oxo-3-phenylpropan-2-yl]benzamide; (2S)-2-(Benzoylamino)-3-phenylpropionaldehyde; Benzamide, N-(1-formyl-2-phenylethyl)-, (S)-
DMP9A7L	DT	Small molecular drug
DMP9A7L	PC	193218
DMP9A7L	MW	253.29
DMP9A7L	FM	C16H15NO2
DMP9A7L	IC	InChI=1S/C16H15NO2/c18-12-15(11-13-7-3-1-4-8-13)17-16(19)14-9-5-2-6-10-14/h1-10,12,15H,11H2,(H,17,19)/t15-/m0/s1
DMP9A7L	CS	C1=CC=C(C=C1)C[C@@H](C=O)NC(=O)C2=CC=CC=C2
DMP9A7L	IK	HIVDFHSZNYCJQH-HNNXBMFYSA-N
DMP9A7L	IU	N-[(2S)-1-oxo-3-phenylpropan-2-yl]benzamide
DMP9A7L	CA	CAS 35593-57-8
DMP9A7L	DE	Discovery agent

DM4HB7S	ID	DM4HB7S
DM4HB7S	DN	N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide
DM4HB7S	HS	Investigative
DM4HB7S	SN	CHEMBL214684; N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide; MolPort-008-305-779; STK491511; BDBM50192158; ZINC16603986; AKOS003382300; MCULE-7382461624; ST50942897
DM4HB7S	DT	Small molecular drug
DM4HB7S	PC	14514271
DM4HB7S	MW	354.4
DM4HB7S	FM	C21H26N2O3
DM4HB7S	IC	InChI=1S/C21H26N2O3/c1-25-19-12-17(13-20(14-19)26-2)21(24)22-18-8-10-23(11-9-18)15-16-6-4-3-5-7-16/h3-7,12-14,18H,8-11,15H2,1-2H3,(H,22,24)
DM4HB7S	CS	COC1=CC(=CC(=C1)C(=O)NC2CCN(CC2)CC3=CC=CC=C3)OC
DM4HB7S	IK	CBCISEXIJPDIBB-UHFFFAOYSA-N
DM4HB7S	IU	N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide
DM4HB7S	DE	Discovery agent

DMEKSHG	ID	DMEKSHG
DMEKSHG	DN	N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
DMEKSHG	HS	Investigative
DMEKSHG	SN	N-(1-Benzylpiperidin-4-Yl)-4-Sulfanylbutanamide; DB07734; N-(1-Benzylpiperidine-4-yl)-4-mercaptobutanamide; N-(1-benzyl-piperidin-4-yl)-4-mercapto-butyramide
DMEKSHG	DT	Small molecular drug
DMEKSHG	PC	25134249
DMEKSHG	MW	292.4
DMEKSHG	FM	C16H24N2OS
DMEKSHG	IC	InChI=1S/C16H24N2OS/c19-16(7-4-12-20)17-15-8-10-18(11-9-15)13-14-5-2-1-3-6-14/h1-3,5-6,15,20H,4,7-13H2,(H,17,19)
DMEKSHG	CS	C1CN(CCC1NC(=O)CCCS)CC2=CC=CC=C2
DMEKSHG	IK	XNIXPLIQGKQSIE-UHFFFAOYSA-N
DMEKSHG	IU	N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
DMEKSHG	DE	Discovery agent

DMUQ6P4	ID	DMUQ6P4
DMUQ6P4	DN	N-(1-benzylpiperidine-4-yl)-2-naphthamide
DMUQ6P4	HS	Investigative
DMUQ6P4	SN	CHEMBL228972; N-(1-benzylpiperidin-4-yl)naphthalene-2-carboxamide; N-(1-benzylpiperidine-4-yl)-2-naphthamide; MolPort-005-630-484; BDBM50203383; ZINC12985947; STK491618; AKOS003382305; MCULE-1935524858; N-(1-benzylpiperidin-4-yl)-2-naphthamide; ST50877721; 2-naphthyl-N-[1-benzyl(4-piperidyl)]carboxamide; Z32353863
DMUQ6P4	DT	Small molecular drug
DMUQ6P4	PC	16725912
DMUQ6P4	MW	344.4
DMUQ6P4	FM	C23H24N2O
DMUQ6P4	IC	InChI=1S/C23H24N2O/c26-23(21-11-10-19-8-4-5-9-20(19)16-21)24-22-12-14-25(15-13-22)17-18-6-2-1-3-7-18/h1-11,16,22H,12-15,17H2,(H,24,26)
DMUQ6P4	CS	C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CC4=CC=CC=C4
DMUQ6P4	IK	RQEOFDOXFRRFQL-UHFFFAOYSA-N
DMUQ6P4	IU	N-(1-benzylpiperidin-4-yl)naphthalene-2-carboxamide
DMUQ6P4	DE	Discovery agent

DM054NF	ID	DM054NF
DM054NF	DN	N-(1H-benzo[d]imidazol-2-yl)-3-cyanobenzamide
DM054NF	HS	Investigative
DM054NF	SN	CHEMBL426133; AC1MAT99; N-(1H-benzo[d]imidazol-2-yl)-3-cyanobenzamide; MolPort-004-136-030; ZINC6082995; BDBM50184703; AKOS008916776; MCULE-9954960051; N-(1H-benzimidazol-2-yl)-3-cyanobenzamide; N-(1H-1,3-benzodiazol-2-yl)-3-cyanobenzamide; Z27664939
DM054NF	DT	Small molecular drug
DM054NF	PC	2635761
DM054NF	MW	262.27
DM054NF	FM	C15H10N4O
DM054NF	IC	InChI=1S/C15H10N4O/c16-9-10-4-3-5-11(8-10)14(20)19-15-17-12-6-1-2-7-13(12)18-15/h1-8H,(H2,17,18,19,20)
DM054NF	CS	C1=CC=C2C(=C1)NC(=N2)NC(=O)C3=CC=CC(=C3)C#N
DM054NF	IK	JSWLIGOCNPPDTR-UHFFFAOYSA-N
DM054NF	IU	N-(1H-benzimidazol-2-yl)-3-cyanobenzamide
DM054NF	DE	Discovery agent

DM0CWPX	ID	DM0CWPX
DM0CWPX	DN	N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide
DM0CWPX	HS	Investigative
DM0CWPX	SN	N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide; 301675-24-1; CHEMBL210658; N-(1H-benzimidazol-2-yl)-3-nitrobenzamide; AC1MTB3N; Cambridge id 7283005; Oprea1_384876; Oprea1_144350; MLS000418401; SCHEMBL3597174; MolPort-007-653-805; QPKROMNIEAEFQA-UHFFFAOYSA-N; MolPort-001-543-036; ZINC5033955; CS-M1436; STK433528; BDBM50184701; AKOS001825502; AKOS001141441; MCULE-1403873826; KB-78995; SMR000264931; CS-13909; ST50927847; N-benzimidazol-2-yl(3-nitrophenyl)carboxamide; 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide
DM0CWPX	DT	Small molecular drug
DM0CWPX	PC	3572750
DM0CWPX	MW	282.25
DM0CWPX	FM	C14H10N4O3
DM0CWPX	IC	InChI=1S/C14H10N4O3/c19-13(9-4-3-5-10(8-9)18(20)21)17-14-15-11-6-1-2-7-12(11)16-14/h1-8H,(H2,15,16,17,19)
DM0CWPX	CS	C1=CC=C2C(=C1)NC(=N2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
DM0CWPX	IK	QPKROMNIEAEFQA-UHFFFAOYSA-N
DM0CWPX	IU	N-(1H-benzimidazol-2-yl)-3-nitrobenzamide
DM0CWPX	DE	Discovery agent

DMIMJNU	ID	DMIMJNU
DMIMJNU	DN	N-(1H-indazol-5-yl)acetamide
DMIMJNU	HS	Investigative
DMIMJNU	SN	N-(1H-indazol-5-yl)acetamide; 95574-27-9; CHEMBL503641; Acetamide, N-1H-indazol-5-yl-; 5-acetylaminoindazole; SCHEMBL2565558; XGVHKKOLBJMLLQ-UHFFFAOYSA-N; MolPort-020-329-884; ZINC20495645; BDBM50246684; AKOS008998989
DMIMJNU	DT	Small molecular drug
DMIMJNU	PC	17164245
DMIMJNU	MW	175.19
DMIMJNU	FM	C9H9N3O
DMIMJNU	IC	InChI=1S/C9H9N3O/c1-6(13)11-8-2-3-9-7(4-8)5-10-12-9/h2-5H,1H3,(H,10,12)(H,11,13)
DMIMJNU	CS	CC(=O)NC1=CC2=C(C=C1)NN=C2
DMIMJNU	IK	XGVHKKOLBJMLLQ-UHFFFAOYSA-N
DMIMJNU	IU	N-(1H-indazol-5-yl)acetamide
DMIMJNU	DE	Discovery agent

DM63YJV	ID	DM63YJV
DM63YJV	DN	N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide
DM63YJV	HS	Investigative
DM63YJV	SN	CHEMBL472897; N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide
DM63YJV	DT	Small molecular drug
DM63YJV	PC	25178128
DM63YJV	MW	419.6
DM63YJV	FM	C27H37N3O
DM63YJV	IC	InChI=1S/C27H37N3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(31)29-25-20-21-26-24(22-25)23-28-30-26/h6-7,9-10,12-13,15-16,20-23H,2-5,8,11,14,17-19H2,1H3,(H,28,30)(H,29,31)/b7-6-,10-9-,13-12-,16-15-
DM63YJV	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NC1=CC2=C(C=C1)NN=C2
DM63YJV	IK	UYWJHPBUSXDXOJ-DOFZRALJSA-N
DM63YJV	IU	(5Z,8Z,11Z,14Z)-N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide
DM63YJV	DE	Discovery agent

DMHAGSW	ID	DMHAGSW
DMHAGSW	DN	N-(1H-Indol-2-ylmethyl)-N-(4-phenylbutyl)amine
DMHAGSW	HS	Investigative
DMHAGSW	SN	CHEMBL455981; N-(1H-Indol-2-ylmethyl)-N-(4-phenylbutyl)amine
DMHAGSW	DT	Small molecular drug
DMHAGSW	PC	44588208
DMHAGSW	MW	278.4
DMHAGSW	FM	C19H22N2
DMHAGSW	IC	InChI=1S/C19H22N2/c1-2-8-16(9-3-1)10-6-7-13-20-15-18-14-17-11-4-5-12-19(17)21-18/h1-5,8-9,11-12,14,20-21H,6-7,10,13,15H2
DMHAGSW	CS	C1=CC=C(C=C1)CCCCNCC2=CC3=CC=CC=C3N2
DMHAGSW	IK	OLWLANFDDNVPCZ-UHFFFAOYSA-N
DMHAGSW	IU	N-(1H-indol-2-ylmethyl)-4-phenylbutan-1-amine
DMHAGSW	DE	Discovery agent

DMCM51R	ID	DMCM51R
DMCM51R	DN	N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine
DMCM51R	HS	Investigative
DMCM51R	SN	CHEMBL461245; N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine
DMCM51R	DT	Small molecular drug
DMCM51R	PC	44588139
DMCM51R	MW	236.31
DMCM51R	FM	C16H16N2
DMCM51R	IC	InChI=1S/C16H16N2/c1-18(15-8-3-2-4-9-15)12-14-11-13-7-5-6-10-16(13)17-14/h2-11,17H,12H2,1H3
DMCM51R	CS	CN(CC1=CC2=CC=CC=C2N1)C3=CC=CC=C3
DMCM51R	IK	KHSLYBCUWUKVBX-UHFFFAOYSA-N
DMCM51R	IU	N-(1H-indol-2-ylmethyl)-N-methylaniline
DMCM51R	DE	Discovery agent

DMXD592	ID	DMXD592
DMXD592	DN	N-(1H-Indol-2-ylmethyl)-N-phenylamine
DMXD592	HS	Investigative
DMXD592	SN	CHEMBL447043; N-(1H-Indol-2-ylmethyl)-N-phenylamine; (phenylamino)methylindole; SCHEMBL10549005; MolPort-013-783-264; BDBM50273565; ZINC40829296
DMXD592	DT	Small molecular drug
DMXD592	PC	20037787
DMXD592	MW	222.28
DMXD592	FM	C15H14N2
DMXD592	IC	InChI=1S/C15H14N2/c1-2-7-13(8-3-1)16-11-14-10-12-6-4-5-9-15(12)17-14/h1-10,16-17H,11H2
DMXD592	CS	C1=CC=C(C=C1)NCC2=CC3=CC=CC=C3N2
DMXD592	IK	SSQTZURIXXHEKY-UHFFFAOYSA-N
DMXD592	IU	N-(1H-indol-2-ylmethyl)aniline
DMXD592	DE	Discovery agent

DMY3UZH	ID	DMY3UZH
DMY3UZH	DN	N-(1-Methyl-1H-indol-2-ylmethyl)-N-phenylamine
DMY3UZH	HS	Investigative
DMY3UZH	SN	CHEMBL449889; N-(1-Methyl-1H-indol-2-ylmethyl)-N-phenylamine
DMY3UZH	DT	Small molecular drug
DMY3UZH	PC	42776886
DMY3UZH	MW	236.31
DMY3UZH	FM	C16H16N2
DMY3UZH	IC	InChI=1S/C16H16N2/c1-18-15(11-13-7-5-6-10-16(13)18)12-17-14-8-3-2-4-9-14/h2-11,17H,12H2,1H3
DMY3UZH	CS	CN1C2=CC=CC=C2C=C1CNC3=CC=CC=C3
DMY3UZH	IK	HTRZQOWAQJHGBR-UHFFFAOYSA-N
DMY3UZH	IU	N-[(1-methylindol-2-yl)methyl]aniline
DMY3UZH	DE	Discovery agent

DMI1HBR	ID	DMI1HBR
DMI1HBR	DN	N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide
DMI1HBR	HS	Investigative
DMI1HBR	SN	CHEMBL1288588; N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide
DMI1HBR	DT	Small molecular drug
DMI1HBR	PC	52945617
DMI1HBR	MW	259.22
DMI1HBR	FM	C12H12F3NO2
DMI1HBR	IC	InChI=1S/C12H12F3NO2/c1-2-10(7-17)16-11(18)8-4-3-5-9(6-8)12(13,14)15/h3-7,10H,2H2,1H3,(H,16,18)
DMI1HBR	CS	CCC(C=O)NC(=O)C1=CC(=CC=C1)C(F)(F)F
DMI1HBR	IK	BXZCQIXITWILKZ-UHFFFAOYSA-N
DMI1HBR	IU	N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide
DMI1HBR	DE	Discovery agent

DMU9YF6	ID	DMU9YF6
DMU9YF6	DN	N-(1-phenethylpiperidin-4-yl)-1-naphthamide
DMU9YF6	HS	Investigative
DMU9YF6	SN	CHEMBL229021; N-(1-phenethylpiperidin-4-yl)-1-naphthamide; MolPort-027-939-937; ZINC27938740; BDBM50203472; AKOS034266808; MCULE-9720193295; Z384293848; N-[1-(2-phenylethyl)piperidin-4-yl]naphthalene-1-carboxamide
DMU9YF6	DT	Small molecular drug
DMU9YF6	PC	35295787
DMU9YF6	MW	358.5
DMU9YF6	FM	C24H26N2O
DMU9YF6	IC	InChI=1S/C24H26N2O/c27-24(23-12-6-10-20-9-4-5-11-22(20)23)25-21-14-17-26(18-15-21)16-13-19-7-2-1-3-8-19/h1-12,21H,13-18H2,(H,25,27)
DMU9YF6	CS	C1CN(CCC1NC(=O)C2=CC=CC3=CC=CC=C32)CCC4=CC=CC=C4
DMU9YF6	IK	BTQGBMYNQGZVOI-UHFFFAOYSA-N
DMU9YF6	IU	N-[1-(2-phenylethyl)piperidin-4-yl]naphthalene-1-carboxamide
DMU9YF6	DE	Discovery agent

DM9QA7Z	ID	DM9QA7Z
DM9QA7Z	DN	N-(1-phenethylpiperidin-4-yl)-2-naphthamide
DM9QA7Z	HS	Investigative
DM9QA7Z	SN	CHEMBL388620; N-(1-phenethylpiperidin-4-yl)-2-naphthamide; MolPort-027-676-242; ZINC27939121; BDBM50203471; AKOS034266810; MCULE-8266051883; Z384294180; N-[1-(2-phenylethyl)piperidin-4-yl]naphthalene-2-carboxamide
DM9QA7Z	DT	Small molecular drug
DM9QA7Z	PC	35296170
DM9QA7Z	MW	358.5
DM9QA7Z	FM	C24H26N2O
DM9QA7Z	IC	InChI=1S/C24H26N2O/c27-24(22-11-10-20-8-4-5-9-21(20)18-22)25-23-13-16-26(17-14-23)15-12-19-6-2-1-3-7-19/h1-11,18,23H,12-17H2,(H,25,27)
DM9QA7Z	CS	C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CCC4=CC=CC=C4
DM9QA7Z	IK	JJJGQIPMMVJBLD-UHFFFAOYSA-N
DM9QA7Z	IU	N-[1-(2-phenylethyl)piperidin-4-yl]naphthalene-2-carboxamide
DM9QA7Z	DE	Discovery agent

DM6DEZ4	ID	DM6DEZ4
DM6DEZ4	DN	N-(1'-Phenyl-ethyl) estradiol-16-carboxamide
DM6DEZ4	HS	Investigative
DM6DEZ4	SN	SCHEMBL12379495
DM6DEZ4	DT	Small molecular drug
DM6DEZ4	PC	44407376
DM6DEZ4	MW	419.6
DM6DEZ4	FM	C27H33NO3
DM6DEZ4	IC	InChI=1S/C27H33NO3/c1-16(17-6-4-3-5-7-17)28-26(31)23-15-24-22-10-8-18-14-19(29)9-11-20(18)21(22)12-13-27(24,2)25(23)30/h3-7,9,11,14,16,21-25,29-30H,8,10,12-13,15H2,1-2H3,(H,28,31)/t16?,21?,22?,23?,24?,25-,27-/m0/s1
DM6DEZ4	CS	CC(C1=CC=CC=C1)NC(=O)C2CC3C4CCC5=C(C4CC[C@@]3([C@H]2O)C)C=CC(=C5)O
DM6DEZ4	IK	NLFQZGZNWSXJNG-CDPVEVCASA-N
DM6DEZ4	IU	(13S,17S)-3,17-dihydroxy-13-methyl-N-(1-phenylethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DM6DEZ4	DE	Discovery agent

DMSHWYU	ID	DMSHWYU
DMSHWYU	DN	N-(1-PHENYL-PROPYL)-FORMAMIDE
DMSHWYU	HS	Investigative
DMSHWYU	SN	N-(1-PHENYL-PROPYL)-FORMAMIDE; AC1L9JS4; N-[(1R)-1-phenylpropyl]formamide; N-[(R)-alpha-Ethylbenzyl]formamide
DMSHWYU	DT	Small molecular drug
DMSHWYU	PC	446532
DMSHWYU	MW	163.22
DMSHWYU	FM	C10H13NO
DMSHWYU	IC	InChI=1S/C10H13NO/c1-2-10(11-8-12)9-6-4-3-5-7-9/h3-8,10H,2H2,1H3,(H,11,12)/t10-/m1/s1
DMSHWYU	CS	CC[C@H](C1=CC=CC=C1)NC=O
DMSHWYU	IK	UERJGKDKJBSKQN-SNVBAGLBSA-N
DMSHWYU	IU	N-[(1R)-1-phenylpropyl]formamide
DMSHWYU	DE	Discovery agent

DM6NC8G	ID	DM6NC8G
DM6NC8G	DN	N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide
DM6NC8G	HS	Investigative
DM6NC8G	SN	CHEMBL521733; N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide; N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-carboxamide; AC1LG1FS; Oprea1_829316; Oprea1_192683; MolPort-001-987-537; ZINC285233; STK129364; BDBM50272836; AKOS000554028; MCULE-1062167425; NCGC00304458-01; BAS 03049800; ST45172084; AB01300868-01; N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide; N-(2-indol-3-ylethyl)(4-phenylphenyl)carboxamide; Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide
DM6NC8G	DT	Small molecular drug
DM6NC8G	PC	787236
DM6NC8G	MW	340.4
DM6NC8G	FM	C23H20N2O
DM6NC8G	IC	InChI=1S/C23H20N2O/c26-23(19-12-10-18(11-13-19)17-6-2-1-3-7-17)24-15-14-20-16-25-22-9-5-4-8-21(20)22/h1-13,16,25H,14-15H2,(H,24,26)
DM6NC8G	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NCCC3=CNC4=CC=CC=C43
DM6NC8G	IK	GYEGDDXJVFNDOP-UHFFFAOYSA-N
DM6NC8G	IU	N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide
DM6NC8G	DE	Discovery agent

DM97Q6T	ID	DM97Q6T
DM97Q6T	DN	N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine
DM97Q6T	HS	Investigative
DM97Q6T	SN	CHEMBL233385; N-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]ethanamine; AC1NFZZ9; N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine; SCHEMBL5700011; ZINC8227211; BDBM50205773; AKOS002615028; MCULE-5007100183; Benzenemethanamine, 5-bromo-2-[(4-chlorophenyl)methoxy]-N-ethyl-
DM97Q6T	DT	Small molecular drug
DM97Q6T	PC	4716524
DM97Q6T	MW	354.7
DM97Q6T	FM	C16H17BrClNO
DM97Q6T	IC	InChI=1S/C16H17BrClNO/c1-2-19-10-13-9-14(17)5-8-16(13)20-11-12-3-6-15(18)7-4-12/h3-9,19H,2,10-11H2,1H3
DM97Q6T	CS	CCNCC1=C(C=CC(=C1)Br)OCC2=CC=C(C=C2)Cl
DM97Q6T	IK	ORVDFXFQIBURPI-UHFFFAOYSA-N
DM97Q6T	IU	N-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]ethanamine
DM97Q6T	DE	Discovery agent

DM57GQN	ID	DM57GQN
DM57GQN	DN	N-(2-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide
DM57GQN	HS	Investigative
DM57GQN	SN	CHEMBL264176
DM57GQN	DT	Small molecular drug
DM57GQN	PC	44450092
DM57GQN	MW	327.4
DM57GQN	FM	C20H25NO3
DM57GQN	IC	InChI=1S/C20H25NO3/c1-3-4-5-6-9-16-12-13-20(18(23)14-16)24-19-11-8-7-10-17(19)21-15(2)22/h7-8,10-14,23H,3-6,9H2,1-2H3,(H,21,22)
DM57GQN	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2NC(=O)C)O
DM57GQN	IK	UNZWUCCAARAPNJ-UHFFFAOYSA-N
DM57GQN	IU	N-[2-(4-hexyl-2-hydroxyphenoxy)phenyl]acetamide
DM57GQN	DE	Discovery agent

DM4V7AS	ID	DM4V7AS
DM4V7AS	DN	N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide
DM4V7AS	HS	Investigative
DM4V7AS	SN	CHEMBL323332; N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide; SCHEMBL7018941; ACETAMIDE,N-[2-(5-METHOXY-3-BENZOFURANYL)- ETHYL]-; ZINC13474338; BDBM50037242; ACM27404359; 27404-35-9; 3-[2-(Acetylamino)ethyl]-5-methoxybenzofuran
DM4V7AS	DT	Small molecular drug
DM4V7AS	PC	10059864
DM4V7AS	MW	233.26
DM4V7AS	FM	C13H15NO3
DM4V7AS	IC	InChI=1S/C13H15NO3/c1-9(15)14-6-5-10-8-17-13-4-3-11(16-2)7-12(10)13/h3-4,7-8H,5-6H2,1-2H3,(H,14,15)
DM4V7AS	CS	CC(=O)NCCC1=COC2=C1C=C(C=C2)OC
DM4V7AS	IK	BTVRPXLAXZPZPV-UHFFFAOYSA-N
DM4V7AS	IU	N-[2-(5-methoxy-1-benzofuran-3-yl)ethyl]acetamide
DM4V7AS	CA	CAS 27404-35-9
DM4V7AS	DE	Discovery agent

DMLTROU	ID	DMLTROU
DMLTROU	DN	N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide
DMLTROU	HS	Investigative
DMLTROU	SN	CHEMBL1081811; BDBM50312964
DMLTROU	DT	Small molecular drug
DMLTROU	PC	46880333
DMLTROU	MW	279.29
DMLTROU	FM	C16H13N3O2
DMLTROU	IC	InChI=1S/C16H13N3O2/c1-11(20)18-15-5-4-13(12-6-8-17-9-7-12)16(19-15)14-3-2-10-21-14/h2-10H,1H3,(H,18,19,20)
DMLTROU	CS	CC(=O)NC1=NC(=C(C=C1)C2=CC=NC=C2)C3=CC=CO3
DMLTROU	IK	STFZQXRQDWXSGW-UHFFFAOYSA-N
DMLTROU	IU	N-[6-(furan-2-yl)-5-pyridin-4-ylpyridin-2-yl]acetamide
DMLTROU	DE	Discovery agent

DMWC70I	ID	DMWC70I
DMWC70I	DN	N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide
DMWC70I	HS	Investigative
DMWC70I	SN	60480-69-5; N-(2,3,4,9-TETRAHYDRO-1H-CARBAZOL-3-YL)ACETAMIDE; CHEMBL41973; 3-Acetamido-1,2,3,4-tetrahydrocarbazole; N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide; SCHEMBL7406266; KS-00000TMN; CTK2F0321; DTXSID90494196; MolPort-042-663-532; DNJBLXBGYRYOBT-UHFFFAOYSA-N; BDBM50212923; AKOS027461084; 3-Acetamido-1,2,3,4-tetrahydrocarbazol; DS-19200; AK543106; Acetamide, N-(2,3,4,9-tetrahydro-1H-carbazol-3-yl)-
DMWC70I	DT	Small molecular drug
DMWC70I	PC	12361788
DMWC70I	MW	228.29
DMWC70I	FM	C14H16N2O
DMWC70I	IC	InChI=1S/C14H16N2O/c1-9(17)15-10-6-7-14-12(8-10)11-4-2-3-5-13(11)16-14/h2-5,10,16H,6-8H2,1H3,(H,15,17)
DMWC70I	CS	CC(=O)NC1CCC2=C(C1)C3=CC=CC=C3N2
DMWC70I	IK	DNJBLXBGYRYOBT-UHFFFAOYSA-N
DMWC70I	IU	N-(2,3,4,9-tetrahydro-1H-carbazol-3-yl)acetamide
DMWC70I	CA	CAS 60480-69-5
DMWC70I	DE	Discovery agent

DMUZL3J	ID	DMUZL3J
DMUZL3J	DN	N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE
DMUZL3J	HS	Investigative
DMUZL3J	SN	N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE; N-[(2,3-difluorophenyl)methyl]-4-sulfamoylbenzamide; F2B; N-(2,3-Difluorobenzyl)-4-sulfamoylbenzamide; 235088-49-0; 2,3-difluoro-SBB; AC1L1C1I; CTK0I7898; BDBM12016; DTXSID80274323; 1g52; 1g46; AKOS030577745; DB07742; Benzamide, 4-(aminosulfonyl)-N-[(2,3-difluorophenyl)methyl]-
DMUZL3J	DT	Small molecular drug
DMUZL3J	PC	1700
DMUZL3J	MW	326.32
DMUZL3J	FM	C14H12F2N2O3S
DMUZL3J	IC	InChI=1S/C14H12F2N2O3S/c15-12-3-1-2-10(13(12)16)8-18-14(19)9-4-6-11(7-5-9)22(17,20)21/h1-7H,8H2,(H,18,19)(H2,17,20,21)
DMUZL3J	CS	C1=CC(=C(C(=C1)F)F)CNC(=O)C2=CC=C(C=C2)S(=O)(=O)N
DMUZL3J	IK	QASSMVGOSBNFQY-UHFFFAOYSA-N
DMUZL3J	IU	N-[(2,3-difluorophenyl)methyl]-4-sulfamoylbenzamide
DMUZL3J	CA	CAS 235088-49-0
DMUZL3J	DE	Discovery agent

DMTLPDZ	ID	DMTLPDZ
DMTLPDZ	DN	N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine
DMTLPDZ	HS	Investigative
DMTLPDZ	SN	CHEMBL470205; N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine
DMTLPDZ	DT	Small molecular drug
DMTLPDZ	PC	44591990
DMTLPDZ	MW	260.3
DMTLPDZ	FM	C18H16N2
DMTLPDZ	IC	InChI=1S/C18H16N2/c1-2-7-15-12-16(11-14(15)6-1)20-18-17-8-4-3-5-13(17)9-10-19-18/h1-10,16H,11-12H2,(H,19,20)
DMTLPDZ	CS	C1C(CC2=CC=CC=C21)NC3=NC=CC4=CC=CC=C43
DMTLPDZ	IK	LJNDWVYBQFLXJV-UHFFFAOYSA-N
DMTLPDZ	IU	N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine
DMTLPDZ	DE	Discovery agent

DMJ6LI8	ID	DMJ6LI8
DMJ6LI8	DN	N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine
DMJ6LI8	HS	Investigative
DMJ6LI8	SN	CHEMBL471242; N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine; SCHEMBL9040263
DMJ6LI8	DT	Small molecular drug
DMJ6LI8	PC	23186964
DMJ6LI8	MW	261.32
DMJ6LI8	FM	C17H15N3
DMJ6LI8	IC	InChI=1S/C17H15N3/c1-2-6-13-10-14(9-12(13)5-1)20-17-15-7-3-4-8-16(15)18-11-19-17/h1-8,11,14H,9-10H2,(H,18,19,20)
DMJ6LI8	CS	C1C(CC2=CC=CC=C21)NC3=NC=NC4=CC=CC=C43
DMJ6LI8	IK	CLVFUKGYGOFREN-UHFFFAOYSA-N
DMJ6LI8	IU	N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine
DMJ6LI8	DE	Discovery agent

DMPL26K	ID	DMPL26K
DMPL26K	DN	N-(2,3-Dihydro-1H-phenalen-2-yl)-acetamide
DMPL26K	HS	Investigative
DMPL26K	SN	N-(2,3-dihydro-1H-phenalen-2-yl)acetamide; SCHEMBL8406961; CHEMBL320810; ZINC21623; NSODBKSYAOTJPJ-UHFFFAOYSA-N; N-[(2,3-Dihydro-1H-phenalen)-2-yl]acetamide
DMPL26K	DT	Small molecular drug
DMPL26K	PC	9859366
DMPL26K	MW	225.28
DMPL26K	FM	C15H15NO
DMPL26K	IC	InChI=1S/C15H15NO/c1-10(17)16-14-8-12-6-2-4-11-5-3-7-13(9-14)15(11)12/h2-7,14H,8-9H2,1H3,(H,16,17)
DMPL26K	CS	CC(=O)NC1CC2=CC=CC3=C2C(=CC=C3)C1
DMPL26K	IK	NSODBKSYAOTJPJ-UHFFFAOYSA-N
DMPL26K	IU	N-(2,3-dihydro-1H-phenalen-2-yl)acetamide
DMPL26K	DE	Discovery agent

DM5R3ZG	ID	DM5R3ZG
DM5R3ZG	DN	N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide
DM5R3ZG	HS	Investigative
DM5R3ZG	SN	CHEMBL1093043; BDBM50314143
DM5R3ZG	DT	Small molecular drug
DM5R3ZG	PC	45141955
DM5R3ZG	MW	292.37
DM5R3ZG	FM	C16H24N2O3
DM5R3ZG	IC	InChI=1S/C16H24N2O3/c1-12-8-7-9-14(13(12)2)17-15(19)10-5-3-4-6-11-16(20)18-21/h7-9,21H,3-6,10-11H2,1-2H3,(H,17,19)(H,18,20)
DM5R3ZG	CS	CC1=C(C(=CC=C1)NC(=O)CCCCCCC(=O)NO)C
DM5R3ZG	IK	HBVNZQXOOFVNBV-UHFFFAOYSA-N
DM5R3ZG	IU	N-(2,3-dimethylphenyl)-N'-hydroxyoctanediamide
DM5R3ZG	DE	Discovery agent

DMHI4Y6	ID	DMHI4Y6
DMHI4Y6	DN	N-(2,4-Dichloro-benzoyl)-benzenesulfonamide
DMHI4Y6	HS	Investigative
DMHI4Y6	SN	N-[2,4-dichlorobenzoyl]phenylsulfonamide; CHEMBL181855; SCHEMBL5491628; TXHQSKPOVJIXCS-UHFFFAOYSA-N; ZINC1492181; AKOS002221669
DMHI4Y6	DT	Small molecular drug
DMHI4Y6	PC	9968373
DMHI4Y6	MW	330.2
DMHI4Y6	FM	C13H9Cl2NO3S
DMHI4Y6	IC	InChI=1S/C13H9Cl2NO3S/c14-9-6-7-11(12(15)8-9)13(17)16-20(18,19)10-4-2-1-3-5-10/h1-8H,(H,16,17)
DMHI4Y6	CS	C1=CC=C(C=C1)S(=O)(=O)NC(=O)C2=C(C=C(C=C2)Cl)Cl
DMHI4Y6	IK	TXHQSKPOVJIXCS-UHFFFAOYSA-N
DMHI4Y6	IU	N-(benzenesulfonyl)-2,4-dichlorobenzamide
DMHI4Y6	DE	Discovery agent

DM5COQ9	ID	DM5COQ9
DM5COQ9	DN	N-(2,4-dichlorophenyl)-2-nitrobenzamide
DM5COQ9	HS	Investigative
DM5COQ9	SN	N-(2,4-dichlorophenyl)-2-nitrobenzamide; CHEMBL558336; AC1LEZX8; Oprea1_748203; CBDivE_011688; ZINC69333; MolPort-001-485-938; STK416331; BDBM50297540; AKOS002953648; MCULE-3862746701; ST011164; AB00076626-01; AK-968/40072495
DM5COQ9	DT	Small molecular drug
DM5COQ9	PC	695266
DM5COQ9	MW	311.12
DM5COQ9	FM	C13H8Cl2N2O3
DM5COQ9	IC	InChI=1S/C13H8Cl2N2O3/c14-8-5-6-11(10(15)7-8)16-13(18)9-3-1-2-4-12(9)17(19)20/h1-7H,(H,16,18)
DM5COQ9	CS	C1=CC=C(C(=C1)C(=O)NC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-]
DM5COQ9	IK	YDNSNBQUGLSJRG-UHFFFAOYSA-N
DM5COQ9	IU	N-(2,4-dichlorophenyl)-2-nitrobenzamide
DM5COQ9	DE	Discovery agent

DMHJOBQ	ID	DMHJOBQ
DMHJOBQ	DN	N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide
DMHJOBQ	HS	Investigative
DMHJOBQ	SN	N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide; CHEMBL551683; AC1Q2ECP; AC1LEFA7; Oprea1_406651; ZINC102894; BDBM50297547; AKOS002953737; MCULE-2443287207; ST011073
DMHJOBQ	DT	Small molecular drug
DMHJOBQ	PC	711291
DMHJOBQ	MW	325.1
DMHJOBQ	FM	C14H10Cl2N2O3
DMHJOBQ	IC	InChI=1S/C14H10Cl2N2O3/c1-8-2-3-9(6-13(8)18(20)21)14(19)17-12-5-4-10(15)7-11(12)16/h2-7H,1H3,(H,17,19)
DMHJOBQ	CS	CC1=C(C=C(C=C1)C(=O)NC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-]
DMHJOBQ	IK	VNKILQNNNYOVJY-UHFFFAOYSA-N
DMHJOBQ	IU	N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide
DMHJOBQ	DE	Discovery agent

DMNT3JV	ID	DMNT3JV
DMNT3JV	DN	N-(2,4-dihydroxybenzyl)-3,4,5-trihydroxybenzamide
DMNT3JV	HS	Investigative
DMNT3JV	SN	CHEMBL207146; N-(2,4-dihydroxybenzyl)-3,4,5-trihydroxybenzamide
DMNT3JV	DT	Small molecular drug
DMNT3JV	PC	44411127
DMNT3JV	MW	291.26
DMNT3JV	FM	C14H13NO6
DMNT3JV	IC	InChI=1S/C14H13NO6/c16-9-2-1-7(10(17)5-9)6-15-14(21)8-3-11(18)13(20)12(19)4-8/h1-5,16-20H,6H2,(H,15,21)
DMNT3JV	CS	C1=CC(=C(C=C1O)O)CNC(=O)C2=CC(=C(C(=C2)O)O)O
DMNT3JV	IK	NWUBAFGVRZLIOR-UHFFFAOYSA-N
DMNT3JV	IU	N-[(2,4-dihydroxyphenyl)methyl]-3,4,5-trihydroxybenzamide
DMNT3JV	DE	Discovery agent

DM3IMXF	ID	DM3IMXF
DM3IMXF	DN	N-(2,4-dihydroxybenzyl)-3,4-dihydroxybenzamide
DM3IMXF	HS	Investigative
DM3IMXF	SN	CHEMBL206902; N-(2,4-dihydroxybenzyl)-3,4-dihydroxybenzamide
DM3IMXF	DT	Small molecular drug
DM3IMXF	PC	44410889
DM3IMXF	MW	275.26
DM3IMXF	FM	C14H13NO5
DM3IMXF	IC	InChI=1S/C14H13NO5/c16-10-3-1-9(12(18)6-10)7-15-14(20)8-2-4-11(17)13(19)5-8/h1-6,16-19H,7H2,(H,15,20)
DM3IMXF	CS	C1=CC(=C(C=C1C(=O)NCC2=C(C=C(C=C2)O)O)O)O
DM3IMXF	IK	QWXDIFRZEIADFB-UHFFFAOYSA-N
DM3IMXF	IU	N-[(2,4-dihydroxyphenyl)methyl]-3,4-dihydroxybenzamide
DM3IMXF	DE	Discovery agent

DM6U8SL	ID	DM6U8SL
DM6U8SL	DN	N-(2,4-dihydroxybenzyl)-3,5-dihydroxybenzamide
DM6U8SL	HS	Investigative
DM6U8SL	SN	CHEMBL437510; N-(2,4-dihydroxybenzyl)-3,5-dihydroxybenzamide
DM6U8SL	DT	Small molecular drug
DM6U8SL	PC	11558153
DM6U8SL	MW	275.26
DM6U8SL	FM	C14H13NO5
DM6U8SL	IC	InChI=1S/C14H13NO5/c16-10-2-1-8(13(19)6-10)7-15-14(20)9-3-11(17)5-12(18)4-9/h1-6,16-19H,7H2,(H,15,20)
DM6U8SL	CS	C1=CC(=C(C=C1O)O)CNC(=O)C2=CC(=CC(=C2)O)O
DM6U8SL	IK	OFDRVQUXDYIMFW-UHFFFAOYSA-N
DM6U8SL	IU	N-[(2,4-dihydroxyphenyl)methyl]-3,5-dihydroxybenzamide
DM6U8SL	DE	Discovery agent

DM3QWZU	ID	DM3QWZU
DM3QWZU	DN	N-(2,4-dimethoxyphenethyl)docos-13-enamide
DM3QWZU	HS	Investigative
DM3QWZU	SN	CHEMBL200121; N-(2,4-dimethoxyphenethyl)docos-13-enamide
DM3QWZU	DT	Small molecular drug
DM3QWZU	PC	44406095
DM3QWZU	MW	501.8
DM3QWZU	FM	C32H55NO3
DM3QWZU	IC	InChI=1S/C32H55NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-32(34)33-27-26-29-24-25-30(35-2)28-31(29)36-3/h11-12,24-25,28H,4-10,13-23,26-27H2,1-3H3,(H,33,34)/b12-11-
DM3QWZU	CS	CCCCCCCC/C=C\\CCCCCCCCCCCC(=O)NCCC1=C(C=C(C=C1)OC)OC
DM3QWZU	IK	VUAYHPSOKPDUPI-QXMHVHEDSA-N
DM3QWZU	IU	(Z)-N-[2-(2,4-dimethoxyphenyl)ethyl]docos-13-enamide
DM3QWZU	DE	Discovery agent

DMRQSD2	ID	DMRQSD2
DMRQSD2	DN	N-(2,4-dimethoxyphenethyl)oleamide
DMRQSD2	HS	Investigative
DMRQSD2	SN	N-(2,4-dimethoxyphenethyl)oleamide; CHEMBL199649
DMRQSD2	DT	Small molecular drug
DMRQSD2	PC	44406080
DMRQSD2	MW	445.7
DMRQSD2	FM	C28H47NO3
DMRQSD2	IC	InChI=1S/C28H47NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(30)29-23-22-25-20-21-26(31-2)24-27(25)32-3/h11-12,20-21,24H,4-10,13-19,22-23H2,1-3H3,(H,29,30)/b12-11-
DMRQSD2	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=C(C=C(C=C1)OC)OC
DMRQSD2	IK	YDMFQRINHJCRDN-QXMHVHEDSA-N
DMRQSD2	IU	(Z)-N-[2-(2,4-dimethoxyphenyl)ethyl]octadec-9-enamide
DMRQSD2	DE	Discovery agent

DME0YBF	ID	DME0YBF
DME0YBF	DN	N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide
DME0YBF	HS	Investigative
DME0YBF	SN	N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide; CHEMBL42427; Oprea1_091011; N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide; MolPort-002-962-230; ZINC3192499; AC1M5424; BDBM50108051; STK167661; AKOS001091335; MCULE-2861059800; ST50986910
DME0YBF	DT	Small molecular drug
DME0YBF	PC	2321450
DME0YBF	MW	317.34
DME0YBF	FM	C17H19NO5
DME0YBF	IC	InChI=1S/C17H19NO5/c1-20-12-5-6-15(16(10-12)23-4)18-17(19)11-7-13(21-2)9-14(8-11)22-3/h5-10H,1-4H3,(H,18,19)
DME0YBF	CS	COC1=CC(=C(C=C1)NC(=O)C2=CC(=CC(=C2)OC)OC)OC
DME0YBF	IK	MEYNLPQFSDKAAL-UHFFFAOYSA-N
DME0YBF	IU	N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide
DME0YBF	DE	Discovery agent

DMFZAS9	ID	DMFZAS9
DMFZAS9	DN	N-(2,4-dimethylphenyl)-2-nitrobenzamide
DMFZAS9	HS	Investigative
DMFZAS9	SN	N-(2,4-Dimethylphenyl)-2-nitrobenzamide; CHEMBL560086; AC1LB6XS; CBMicro_019379; Oprea1_664172; Oprea1_360147; WGMMCHJMOXWGPL-UHFFFAOYSA-N; MolPort-001-026-827; ZINC101882; CCG-7135; 2',4'-Dimethyl-2-nitrobenzanilide; BDBM50297545; STK017239; AKOS001297224; MCULE-5832294393; ST010752; BIM-0019204.P001; KB-100850; N-(2,4-Dimethylphenyl)-2-nitrobenzamide #; EU-0017382; N~1~-(2,4-dimethylphenyl)-2-nitrobenzamide; AB00082465-01; SR-01000509562; N-(2,4-dimethylphenyl)(2-nitrophenyl)carboxamide; AE-848/33212050; SR-01000509562-1
DMFZAS9	DT	Small molecular drug
DMFZAS9	PC	577479
DMFZAS9	MW	270.28
DMFZAS9	FM	C15H14N2O3
DMFZAS9	IC	InChI=1S/C15H14N2O3/c1-10-7-8-13(11(2)9-10)16-15(18)12-5-3-4-6-14(12)17(19)20/h3-9H,1-2H3,(H,16,18)
DMFZAS9	CS	CC1=CC(=C(C=C1)NC(=O)C2=CC=CC=C2[N+](=O)[O-])C
DMFZAS9	IK	WGMMCHJMOXWGPL-UHFFFAOYSA-N
DMFZAS9	IU	N-(2,4-dimethylphenyl)-2-nitrobenzamide
DMFZAS9	CA	CAS 102630-95-5
DMFZAS9	DE	Discovery agent

DMXA9MR	ID	DMXA9MR
DMXA9MR	DN	N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide
DMXA9MR	HS	Investigative
DMXA9MR	SN	CHEMBL1092032; BDBM50314141
DMXA9MR	DT	Small molecular drug
DMXA9MR	PC	45141956
DMXA9MR	MW	292.37
DMXA9MR	FM	C16H24N2O3
DMXA9MR	IC	InChI=1S/C16H24N2O3/c1-12-9-10-14(13(2)11-12)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-11,21H,3-8H2,1-2H3,(H,17,19)(H,18,20)
DMXA9MR	CS	CC1=CC(=C(C=C1)NC(=O)CCCCCCC(=O)NO)C
DMXA9MR	IK	MIPPPENLVLVVIQ-UHFFFAOYSA-N
DMXA9MR	IU	N-(2,4-dimethylphenyl)-N'-hydroxyoctanediamide
DMXA9MR	DE	Discovery agent

DMUVSM1	ID	DMUVSM1
DMUVSM1	DN	N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DMUVSM1	HS	Investigative
DMUVSM1	SN	N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide; CHEMBL558073; AC1LEFVJ; Cambridge id 5309469; Oprea1_724345; MolPort-002-143-797; ZINC103357; BDBM50297553; AKOS008477850; MCULE-4612892000; ST011243; AB00079960-01; AE-848/32724040; SR-01000203933; SR-01000203933-1; N-(2,5-dichlorophenyl)-3-nitro-4-methoxybenzamide
DMUVSM1	DT	Small molecular drug
DMUVSM1	PC	711551
DMUVSM1	MW	341.1
DMUVSM1	FM	C14H10Cl2N2O4
DMUVSM1	IC	InChI=1S/C14H10Cl2N2O4/c1-22-13-5-2-8(6-12(13)18(20)21)14(19)17-11-7-9(15)3-4-10(11)16/h2-7H,1H3,(H,17,19)
DMUVSM1	CS	COC1=C(C=C(C=C1)C(=O)NC2=C(C=CC(=C2)Cl)Cl)[N+](=O)[O-]
DMUVSM1	IK	NGRNRPWPJLMWBI-UHFFFAOYSA-N
DMUVSM1	IU	N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DMUVSM1	DE	Discovery agent

DMOL79W	ID	DMOL79W
DMOL79W	DN	N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide
DMOL79W	HS	Investigative
DMOL79W	SN	CHEMBL1093357; BDBM50314144
DMOL79W	DT	Small molecular drug
DMOL79W	PC	45141957
DMOL79W	MW	292.37
DMOL79W	FM	C16H24N2O3
DMOL79W	IC	InChI=1S/C16H24N2O3/c1-12-9-10-13(2)14(11-12)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-11,21H,3-8H2,1-2H3,(H,17,19)(H,18,20)
DMOL79W	CS	CC1=CC(=C(C=C1)C)NC(=O)CCCCCCC(=O)NO
DMOL79W	IK	QLSOBWNGPFAWKY-UHFFFAOYSA-N
DMOL79W	IU	N-(2,5-dimethylphenyl)-N'-hydroxyoctanediamide
DMOL79W	DE	Discovery agent

DM9ATQ6	ID	DM9ATQ6
DM9ATQ6	DN	N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide
DM9ATQ6	HS	Investigative
DM9ATQ6	SN	N-[(2,6-difluorophenyl)methyl]-4-sulfamoylbenzamide; n-(2,6-diflouro-benzyl)-4-sulfamoyl-benzamide; n-(2,6-difluoro-benzyl)-4-sulfamoyl-benzamide; F6B; 2,6-difluoro-SBB; AC1L1HTT; SCHEMBL678297; BDBM12019; 1g53; 1g48; DB03844; N-(2,6-Difluorobenzyl)-4-sulfamoylbenzamide
DM9ATQ6	DT	Small molecular drug
DM9ATQ6	PC	4288
DM9ATQ6	MW	326.32
DM9ATQ6	FM	C14H12F2N2O3S
DM9ATQ6	IC	InChI=1S/C14H12F2N2O3S/c15-12-2-1-3-13(16)11(12)8-18-14(19)9-4-6-10(7-5-9)22(17,20)21/h1-7H,8H2,(H,18,19)(H2,17,20,21)
DM9ATQ6	CS	C1=CC(=C(C(=C1)F)CNC(=O)C2=CC=C(C=C2)S(=O)(=O)N)F
DM9ATQ6	IK	ZFNCKGXGCCDDFN-UHFFFAOYSA-N
DM9ATQ6	IU	N-[(2,6-difluorophenyl)methyl]-4-sulfamoylbenzamide
DM9ATQ6	DE	Discovery agent

DMTBAPH	ID	DMTBAPH
DMTBAPH	DN	N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide
DMTBAPH	HS	Investigative
DMTBAPH	SN	CHEMBL1093358; BDBM50314145
DMTBAPH	DT	Small molecular drug
DMTBAPH	PC	45141958
DMTBAPH	MW	292.37
DMTBAPH	FM	C16H24N2O3
DMTBAPH	IC	InChI=1S/C16H24N2O3/c1-12-8-7-9-13(2)16(12)17-14(19)10-5-3-4-6-11-15(20)18-21/h7-9,21H,3-6,10-11H2,1-2H3,(H,17,19)(H,18,20)
DMTBAPH	CS	CC1=C(C(=CC=C1)C)NC(=O)CCCCCCC(=O)NO
DMTBAPH	IK	ZFUIPWQRONDTNH-UHFFFAOYSA-N
DMTBAPH	IU	N-(2,6-dimethylphenyl)-N'-hydroxyoctanediamide
DMTBAPH	DE	Discovery agent

DMK5AU4	ID	DMK5AU4
DMK5AU4	DN	N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide
DMK5AU4	HS	Investigative
DMK5AU4	SN	CHEMBL390535; 820961-46-4; N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide; SCHEMBL4827158; CTK3E2657; DTXSID00463914; BDBM50157671; AKOS030569389; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-2-ethyl-
DMK5AU4	DT	Small molecular drug
DMK5AU4	PC	11371386
DMK5AU4	MW	345.4
DMK5AU4	FM	C22H23N3O
DMK5AU4	IC	InChI=1S/C22H23N3O/c1-3-16(4-2)22(26)25-20-15-19(17-11-7-5-8-12-17)23-21(24-20)18-13-9-6-10-14-18/h5-16H,3-4H2,1-2H3,(H,23,24,25,26)
DMK5AU4	CS	CCC(CC)C(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMK5AU4	IK	ZMYSFVQFZFGCMP-UHFFFAOYSA-N
DMK5AU4	IU	N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutanamide
DMK5AU4	CA	CAS 820961-46-4
DMK5AU4	DE	Discovery agent

DM6HGK4	ID	DM6HGK4
DM6HGK4	DN	N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide
DM6HGK4	HS	Investigative
DM6HGK4	SN	CHEMBL387322; 820961-45-3; N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide; SCHEMBL4829224; CTK3E2658; DTXSID90471528; BDBM50157665; AKOS030569392; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-3-methyl-
DM6HGK4	DT	Small molecular drug
DM6HGK4	PC	11739042
DM6HGK4	MW	331.4
DM6HGK4	FM	C21H21N3O
DM6HGK4	IC	InChI=1S/C21H21N3O/c1-15(2)13-20(25)23-19-14-18(16-9-5-3-6-10-16)22-21(24-19)17-11-7-4-8-12-17/h3-12,14-15H,13H2,1-2H3,(H,22,23,24,25)
DM6HGK4	CS	CC(C)CC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DM6HGK4	IK	LUPWFOJGRCESTC-UHFFFAOYSA-N
DM6HGK4	IU	N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutanamide
DM6HGK4	CA	CAS 820961-45-3
DM6HGK4	DE	Discovery agent

DMQ0DMU	ID	DMQ0DMU
DMQ0DMU	DN	N-(2,6-diphenylpyrimidin-4-yl)acetamide
DMQ0DMU	HS	Investigative
DMQ0DMU	SN	CHEMBL426565; 820961-40-8; N-(2,6-diphenylpyrimidin-4-yl)acetamide; SCHEMBL4823120; CTK3E2663; DTXSID10458098; ZINC13586450; BDBM50157676; AKOS030563968; Acetamide, N-(2,6-diphenyl-4-pyrimidinyl)-
DMQ0DMU	DT	Small molecular drug
DMQ0DMU	PC	11185362
DMQ0DMU	MW	289.3
DMQ0DMU	FM	C18H15N3O
DMQ0DMU	IC	InChI=1S/C18H15N3O/c1-13(22)19-17-12-16(14-8-4-2-5-9-14)20-18(21-17)15-10-6-3-7-11-15/h2-12H,1H3,(H,19,20,21,22)
DMQ0DMU	CS	CC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMQ0DMU	IK	ZFBASLSZDCISGS-UHFFFAOYSA-N
DMQ0DMU	IU	N-(2,6-diphenylpyrimidin-4-yl)acetamide
DMQ0DMU	CA	CAS 820961-40-8
DMQ0DMU	DE	Discovery agent

DMBW752	ID	DMBW752
DMBW752	DN	N-(2,6-diphenylpyrimidin-4-yl)benzamide
DMBW752	HS	Investigative
DMBW752	SN	CHEMBL441555; N-(2,6-diphenylpyrimidin-4-yl)benzamide; SCHEMBL4825271
DMBW752	DT	Small molecular drug
DMBW752	PC	11245073
DMBW752	MW	351.4
DMBW752	FM	C23H17N3O
DMBW752	IC	InChI=1S/C23H17N3O/c27-23(19-14-8-3-9-15-19)26-21-16-20(17-10-4-1-5-11-17)24-22(25-21)18-12-6-2-7-13-18/h1-16H,(H,24,25,26,27)
DMBW752	CS	C1=CC=C(C=C1)C2=CC(=NC(=N2)C3=CC=CC=C3)NC(=O)C4=CC=CC=C4
DMBW752	IK	GQFWFPVBIHHTGX-UHFFFAOYSA-N
DMBW752	IU	N-(2,6-diphenylpyrimidin-4-yl)benzamide
DMBW752	DE	Discovery agent

DM5EF71	ID	DM5EF71
DM5EF71	DN	N-(2,6-diphenylpyrimidin-4-yl)butyramide
DM5EF71	HS	Investigative
DM5EF71	SN	CHEMBL222384; 820961-42-0; N-(2,6-diphenylpyrimidin-4-yl)butyramide; SCHEMBL4827120; CTK3E2661; DTXSID60463536; BDBM50157659; AKOS030569388; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-
DM5EF71	DT	Small molecular drug
DM5EF71	PC	11359018
DM5EF71	MW	317.4
DM5EF71	FM	C20H19N3O
DM5EF71	IC	InChI=1S/C20H19N3O/c1-2-9-19(24)22-18-14-17(15-10-5-3-6-11-15)21-20(23-18)16-12-7-4-8-13-16/h3-8,10-14H,2,9H2,1H3,(H,21,22,23,24)
DM5EF71	CS	CCCC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DM5EF71	IK	UBJLQDSZSYHXLE-UHFFFAOYSA-N
DM5EF71	IU	N-(2,6-diphenylpyrimidin-4-yl)butanamide
DM5EF71	CA	CAS 820961-42-0
DM5EF71	DE	Discovery agent

DMWPZCS	ID	DMWPZCS
DMWPZCS	DN	N-(2,6-diphenylpyrimidin-4-yl)isobutyramide
DMWPZCS	HS	Investigative
DMWPZCS	SN	CHEMBL222433; 820961-44-2; N-(2,6-diphenylpyrimidin-4-yl)isobutyramide; SCHEMBL4822464; CTK3E2659; DTXSID20462085; BDBM50157658; Propanamide, N-(2,6-diphenyl-4-pyrimidinyl)-2-methyl-
DMWPZCS	DT	Small molecular drug
DMWPZCS	PC	11313151
DMWPZCS	MW	317.4
DMWPZCS	FM	C20H19N3O
DMWPZCS	IC	InChI=1S/C20H19N3O/c1-14(2)20(24)23-18-13-17(15-9-5-3-6-10-15)21-19(22-18)16-11-7-4-8-12-16/h3-14H,1-2H3,(H,21,22,23,24)
DMWPZCS	CS	CC(C)C(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMWPZCS	IK	ONJOWWUQGQUDTK-UHFFFAOYSA-N
DMWPZCS	IU	N-(2,6-diphenylpyrimidin-4-yl)-2-methylpropanamide
DMWPZCS	CA	CAS 820961-44-2
DMWPZCS	DE	Discovery agent

DM89NGE	ID	DM89NGE
DM89NGE	DN	N-(2,6-diphenylpyrimidin-4-yl)propionamide
DM89NGE	HS	Investigative
DM89NGE	SN	CHEMBL222474; 820961-41-9; N-(2,6-diphenylpyrimidin-4-yl)propionamide; SCHEMBL4825106; CTK3E2662; DTXSID00465933; BDBM50157672; Propanamide, N-(2,6-diphenyl-4-pyrimidinyl)-
DM89NGE	DT	Small molecular drug
DM89NGE	PC	11438116
DM89NGE	MW	303.4
DM89NGE	FM	C19H17N3O
DM89NGE	IC	InChI=1S/C19H17N3O/c1-2-18(23)21-17-13-16(14-9-5-3-6-10-14)20-19(22-17)15-11-7-4-8-12-15/h3-13H,2H2,1H3,(H,20,21,22,23)
DM89NGE	CS	CCC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DM89NGE	IK	GFLZXPLJINFGKI-UHFFFAOYSA-N
DM89NGE	IU	N-(2,6-diphenylpyrimidin-4-yl)propanamide
DM89NGE	CA	CAS 820961-41-9
DM89NGE	DE	Discovery agent

DM7D3GL	ID	DM7D3GL
DM7D3GL	DN	N-(2-Acetamido)Iminodiacetic Acid
DM7D3GL	HS	Investigative
DM7D3GL	SN	26239-55-4; N-(2-Acetamido)iminodiacetic acid; 2,2'-((2-Amino-2-oxoethyl)azanediyl)diacetic acid; Carbamoylmethylaminodiacetic acid; ADA; 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid; Glycine, N-(2-amino-2-oxoethyl)-N-(carboxymethyl)-; N-(Carbamoylmethyl)iminodiacetic acid; N-Carbamoylmethyliminodi(acetic acid); UNII-5C4R3O704E; (CARBAMOYLMETHYL-CARBOXYMETHYL-AMINO)-ACETIC ACID; 5C4R3O704E; N-[2-Acetamido]iminodiacetic acid; MFCD00008031; AK-41593; ADA, 99%, for biochemistry
DM7D3GL	DT	Small molecular drug
DM7D3GL	PC	117765
DM7D3GL	MW	190.15
DM7D3GL	FM	C6H10N2O5
DM7D3GL	IC	InChI=1S/C6H10N2O5/c7-4(9)1-8(2-5(10)11)3-6(12)13/h1-3H2,(H2,7,9)(H,10,11)(H,12,13)
DM7D3GL	CS	C(C(=O)N)N(CC(=O)O)CC(=O)O
DM7D3GL	IK	QZTKDVCDBIDYMD-UHFFFAOYSA-N
DM7D3GL	IU	2-[(2-amino-2-oxoethyl)-(carboxymethyl)amino]acetic acid
DM7D3GL	CA	CAS 26239-55-4
DM7D3GL	CB	CHEBI:43960
DM7D3GL	DE	Discovery agent

DM6QZPH	ID	DM6QZPH
DM6QZPH	DN	N-(2-adamantyl)-N'-propylsulfamide
DM6QZPH	HS	Investigative
DM6QZPH	SN	CHEMBL218643; SCHEMBL3117688; BDBM50202584; ZINC35091103
DM6QZPH	DT	Small molecular drug
DM6QZPH	PC	16103199
DM6QZPH	MW	272.41
DM6QZPH	FM	C13H24N2O2S
DM6QZPH	IC	InChI=1S/C13H24N2O2S/c1-2-3-14-18(16,17)15-13-11-5-9-4-10(7-11)8-12(13)6-9/h9-15H,2-8H2,1H3
DM6QZPH	CS	CCCNS(=O)(=O)NC1C2CC3CC(C2)CC1C3
DM6QZPH	IK	HVLBCVJJDOICDV-UHFFFAOYSA-N
DM6QZPH	IU	N-(propylsulfamoyl)adamantan-2-amine
DM6QZPH	DE	Discovery agent

DM7VN9P	ID	DM7VN9P
DM7VN9P	DN	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide
DM7VN9P	HS	Investigative
DM7VN9P	SN	CHEMBL1097063; N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide
DM7VN9P	DT	Small molecular drug
DM7VN9P	PC	46887475
DM7VN9P	MW	328.4
DM7VN9P	FM	C21H16N2O2
DM7VN9P	IC	InChI=1S/C21H16N2O2/c22-17-11-10-16(20-13-15-8-4-5-9-19(15)25-20)12-18(17)23-21(24)14-6-2-1-3-7-14/h1-13H,22H2,(H,23,24)
DM7VN9P	CS	C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC4=CC=CC=C4O3)N
DM7VN9P	IK	ABLQYLIPCDUOQX-UHFFFAOYSA-N
DM7VN9P	IU	N-[2-amino-5-(1-benzofuran-2-yl)phenyl]benzamide
DM7VN9P	DE	Discovery agent

DMY9HO8	ID	DMY9HO8
DMY9HO8	DN	N-(2-amino-5-(furan-2-yl)phenyl)benzamide
DMY9HO8	HS	Investigative
DMY9HO8	SN	CHEMBL1097651; N-(2-amino-5-(furan-2-yl)phenyl)benzamide
DMY9HO8	DT	Small molecular drug
DMY9HO8	PC	46830328
DMY9HO8	MW	278.3
DMY9HO8	FM	C17H14N2O2
DMY9HO8	IC	InChI=1S/C17H14N2O2/c18-14-9-8-13(16-7-4-10-21-16)11-15(14)19-17(20)12-5-2-1-3-6-12/h1-11H,18H2,(H,19,20)
DMY9HO8	CS	C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CO3)N
DMY9HO8	IK	POPIQEQSLAJUGU-UHFFFAOYSA-N
DMY9HO8	IU	N-[2-amino-5-(furan-2-yl)phenyl]benzamide
DMY9HO8	DE	Discovery agent

DMI7W9N	ID	DMI7W9N
DMI7W9N	DN	N-(2-amino-5-(furan-3-yl)phenyl)benzamide
DMI7W9N	HS	Investigative
DMI7W9N	SN	CHEMBL1095095; N-(2-amino-5-(furan-3-yl)phenyl)benzamide; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000
DMI7W9N	DT	Small molecular drug
DMI7W9N	PC	46830327
DMI7W9N	MW	278.3
DMI7W9N	FM	C17H14N2O2
DMI7W9N	IC	InChI=1S/C17H14N2O2/c18-15-7-6-13(14-8-9-21-11-14)10-16(15)19-17(20)12-4-2-1-3-5-12/h1-11H,18H2,(H,19,20)
DMI7W9N	CS	C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=COC=C3)N
DMI7W9N	IK	MHJRDSWPLXKJLI-UHFFFAOYSA-N
DMI7W9N	IU	N-[2-amino-5-(furan-3-yl)phenyl]benzamide
DMI7W9N	DE	Discovery agent

DM1KVPG	ID	DM1KVPG
DM1KVPG	DN	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide
DM1KVPG	HS	Investigative
DM1KVPG	SN	CHEMBL1095096; N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide
DM1KVPG	DT	Small molecular drug
DM1KVPG	PC	46887378
DM1KVPG	MW	289.3
DM1KVPG	FM	C18H15N3O
DM1KVPG	IC	InChI=1S/C18H15N3O/c19-16-7-6-15(13-8-10-20-11-9-13)12-17(16)21-18(22)14-4-2-1-3-5-14/h1-12H,19H2,(H,21,22)
DM1KVPG	CS	C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=NC=C3)N
DM1KVPG	IK	HVVKXFHTJQLADE-UHFFFAOYSA-N
DM1KVPG	IU	N-(2-amino-5-pyridin-4-ylphenyl)benzamide
DM1KVPG	DE	Discovery agent

DM2K0AJ	ID	DM2K0AJ
DM2K0AJ	DN	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide
DM2K0AJ	HS	Investigative
DM2K0AJ	SN	CHEMBL1097278; N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide
DM2K0AJ	DT	Small molecular drug
DM2K0AJ	PC	46887333
DM2K0AJ	MW	295.4
DM2K0AJ	FM	C16H13N3OS
DM2K0AJ	IC	InChI=1S/C16H13N3OS/c17-13-7-6-12(16-18-8-9-21-16)10-14(13)19-15(20)11-4-2-1-3-5-11/h1-10H,17H2,(H,19,20)
DM2K0AJ	CS	C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=NC=CS3)N
DM2K0AJ	IK	FHTINQMYYLCTSM-UHFFFAOYSA-N
DM2K0AJ	IU	N-[2-amino-5-(1,3-thiazol-2-yl)phenyl]benzamide
DM2K0AJ	DE	Discovery agent

DMFYG79	ID	DMFYG79
DMFYG79	DN	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide
DMFYG79	HS	Investigative
DMFYG79	SN	CHEMBL256440; N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide; SCHEMBL1066609
DMFYG79	DT	Small molecular drug
DMFYG79	PC	44454416
DMFYG79	MW	295.4
DMFYG79	FM	C16H13N3OS
DMFYG79	IC	InChI=1S/C16H13N3OS/c17-13-6-5-11(15-4-2-8-21-15)9-14(13)19-16(20)12-3-1-7-18-10-12/h1-10H,17H2,(H,19,20)
DMFYG79	CS	C1=CC(=CN=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
DMFYG79	IK	VHWNADCYYRKHOX-UHFFFAOYSA-N
DMFYG79	IU	N-(2-amino-5-thiophen-2-ylphenyl)pyridine-3-carboxamide
DMFYG79	DE	Discovery agent

DMRK4FA	ID	DMRK4FA
DMRK4FA	DN	N-(2-aminoethyl)-1-aziridine-ethanamine
DMRK4FA	HS	Investigative
DMRK4FA	SN	NAAE; N-(2-aminoethyl)-1-aziridineethanamine
DMRK4FA	TC	Antiviral Agents
DMRK4FA	DT	Small molecular drug
DMRK4FA	PC	98888
DMRK4FA	MW	129.199
DMRK4FA	FM	C6H15N3
DMRK4FA	IC	InChI=1S/C6H15N3/c7-1-2-8-3-4-9-5-6-9/h8H,1-7H2
DMRK4FA	CS	C1CN1CCNCCN
DMRK4FA	IK	XJNAQZHMIAKQOK-UHFFFAOYSA-N
DMRK4FA	IU	N'-[2-(aziridin-1-yl)ethyl]ethane-1,2-diamine
DMRK4FA	CA	CAS 23435-23-6
DMRK4FA	CB	CHEBI:145998
DMRK4FA	DE	Severe acute respiratory syndrome (SARS)

DM7SUTQ	ID	DM7SUTQ
DM7SUTQ	DN	N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide
DM7SUTQ	HS	Investigative
DM7SUTQ	SN	3-carboxamido coumarin, 5; CHEMBL472638; SCHEMBL15892984; BDBM29156; AKOS005787848
DM7SUTQ	DT	Small molecular drug
DM7SUTQ	PC	10657190
DM7SUTQ	MW	232.23
DM7SUTQ	FM	C12H12N2O3
DM7SUTQ	IC	InChI=1S/C12H12N2O3/c13-5-6-14-11(15)9-7-8-3-1-2-4-10(8)17-12(9)16/h1-4,7H,5-6,13H2,(H,14,15)
DM7SUTQ	CS	C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)NCCN
DM7SUTQ	IK	ZZZHRZHNTZJEMF-UHFFFAOYSA-N
DM7SUTQ	IU	N-(2-aminoethyl)-2-oxochromene-3-carboxamide
DM7SUTQ	DE	Discovery agent

DMG2MSX	ID	DMG2MSX
DMG2MSX	DN	N-(2-aminoethyl)isoquinoline-5-sulfonamide
DMG2MSX	HS	Investigative
DMG2MSX	SN	N-(2-aminoethyl)isoquinoline-5-sulfonamide; AEIQS; 84468-17-7; N-(2-aminoethyl)-5-isoquinolinesulfonamide; Protein kinase C inhibitor H-9; H-9; (2-Aminoethyl)(5-isoquinolylsulfonyl)amine; 5-Isoquinolinesulfonamide, N-(2-aminoethyl)-; CHEMBL344314; DCVZSHVZGVWQKV-UHFFFAOYSA-N; H9; Isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide; C11H13N3O2S; BRD7657; BRD-7657; N-(2-aminoethyl]-5-isoquinolinesulfonamide; IQU; N-(2-Aminoethyl)isoquinoline-5-sulfonamide hydrochloride (H9); Tocris-0396; Lopac-H-123; AC1Q6ULL; H-9, DiHCl; AC1L1G6B
DMG2MSX	DT	Small molecular drug
DMG2MSX	PC	3544
DMG2MSX	MW	251.31
DMG2MSX	FM	C11H13N3O2S
DMG2MSX	IC	InChI=1S/C11H13N3O2S/c12-5-7-14-17(15,16)11-3-1-2-9-8-13-6-4-10(9)11/h1-4,6,8,14H,5,7,12H2
DMG2MSX	CS	C1=CC2=C(C=CN=C2)C(=C1)S(=O)(=O)NCCN
DMG2MSX	IK	DCVZSHVZGVWQKV-UHFFFAOYSA-N
DMG2MSX	IU	N-(2-aminoethyl)isoquinoline-5-sulfonamide
DMG2MSX	CA	CAS 84468-17-7
DMG2MSX	DE	Discovery agent

DMLSFQI	ID	DMLSFQI
DMLSFQI	DN	N-(2-aminoethyl)-p-chlorobenzamide
DMLSFQI	HS	Investigative
DMLSFQI	DE	Discovery agent

DMT7JUC	ID	DMT7JUC
DMT7JUC	DN	N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide
DMT7JUC	HS	Investigative
DMT7JUC	SN	CHEMBL238569; N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide; SCHEMBL1064835
DMT7JUC	DT	Small molecular drug
DMT7JUC	PC	9924962
DMT7JUC	MW	358.4
DMT7JUC	FM	C23H22N2O2
DMT7JUC	IC	InChI=1S/C23H22N2O2/c24-20-6-2-3-7-21(20)25-23(26)18-11-9-16(10-12-18)13-17-14-19-5-1-4-8-22(19)27-15-17/h1-12,17H,13-15,24H2,(H,25,26)
DMT7JUC	CS	C1C(COC2=CC=CC=C21)CC3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N
DMT7JUC	IK	COJSUOYKFQWDMR-UHFFFAOYSA-N
DMT7JUC	IU	N-(2-aminophenyl)-4-(3,4-dihydro-2H-chromen-3-ylmethyl)benzamide
DMT7JUC	DE	Discovery agent

DMTKWUM	ID	DMTKWUM
DMTKWUM	DN	N-(2-aminophenyl)-4-methoxybenzamide
DMTKWUM	HS	Investigative
DMTKWUM	SN	N-(2-aminophenyl)-4-methoxybenzamide; AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394
DMTKWUM	DT	Small molecular drug
DMTKWUM	PC	785232
DMTKWUM	MW	242.27
DMTKWUM	FM	C14H14N2O2
DMTKWUM	IC	InChI=1S/C14H14N2O2/c1-18-11-8-6-10(7-9-11)14(17)16-13-5-3-2-4-12(13)15/h2-9H,15H2,1H3,(H,16,17)
DMTKWUM	CS	COC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N
DMTKWUM	IK	BDYVCYUXCNZYRW-UHFFFAOYSA-N
DMTKWUM	IU	N-(2-aminophenyl)-4-methoxybenzamide
DMTKWUM	CA	CAS 103517-57-3
DMTKWUM	DE	Discovery agent

DM8PB90	ID	DM8PB90
DM8PB90	DN	N-(2-aminophenyl)benzamide
DM8PB90	HS	Investigative
DM8PB90	SN	N-(2-aminophenyl)benzamide; 2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046
DM8PB90	DT	Small molecular drug
DM8PB90	PC	759408
DM8PB90	MW	212.25
DM8PB90	FM	C13H12N2O
DM8PB90	IC	InChI=1S/C13H12N2O/c14-11-8-4-5-9-12(11)15-13(16)10-6-2-1-3-7-10/h1-9H,14H2,(H,15,16)
DM8PB90	CS	C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N
DM8PB90	IK	RFDVMOUXHKTCDO-UHFFFAOYSA-N
DM8PB90	IU	N-(2-aminophenyl)benzamide
DM8PB90	CA	CAS 721-47-1
DM8PB90	DE	Discovery agent

DMRDQ1B	ID	DMRDQ1B
DMRDQ1B	DN	N-(2-aminophenyl)nicotinamide
DMRDQ1B	HS	Investigative
DMRDQ1B	SN	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)nicotinamide; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6
DMRDQ1B	DT	Small molecular drug
DMRDQ1B	PC	1133083
DMRDQ1B	MW	213.23
DMRDQ1B	FM	C12H11N3O
DMRDQ1B	IC	InChI=1S/C12H11N3O/c13-10-5-1-2-6-11(10)15-12(16)9-4-3-7-14-8-9/h1-8H,13H2,(H,15,16)
DMRDQ1B	CS	C1=CC=C(C(=C1)N)NC(=O)C2=CN=CC=C2
DMRDQ1B	IK	CEZRXCCXPZWXNX-UHFFFAOYSA-N
DMRDQ1B	IU	N-(2-aminophenyl)pyridine-3-carboxamide
DMRDQ1B	CA	CAS 436089-31-5
DMRDQ1B	CB	CHEBI:125506
DMRDQ1B	DE	Discovery agent

DMJXV7C	ID	DMJXV7C
DMJXV7C	DN	N-(2-aminophenyl)quinoxaline-6-carboxamide
DMJXV7C	HS	Investigative
DMJXV7C	SN	N-(2-aminophenyl)quinoxaline-6-carboxamide; benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424
DMJXV7C	DT	Small molecular drug
DMJXV7C	PC	23648267
DMJXV7C	MW	264.28
DMJXV7C	FM	C15H12N4O
DMJXV7C	IC	InChI=1S/C15H12N4O/c16-11-3-1-2-4-12(11)19-15(20)10-5-6-13-14(9-10)18-8-7-17-13/h1-9H,16H2,(H,19,20)
DMJXV7C	CS	C1=CC=C(C(=C1)N)NC(=O)C2=CC3=NC=CN=C3C=C2
DMJXV7C	IK	DINRLSVFUAZDMZ-UHFFFAOYSA-N
DMJXV7C	IU	N-(2-aminophenyl)quinoxaline-6-carboxamide
DMJXV7C	DE	Discovery agent

DM72BSO	ID	DM72BSO
DM72BSO	DN	N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine
DM72BSO	HS	Investigative
DM72BSO	SN	Benzyl-(1-methyl-1H-pyrrol-2-ylmethyl)-amine; 73325-58-3; CHEMBL223300; [(1-methylpyrrol-2-yl)methyl]benzylamine; N-benzyl-1-(1-methyl-1H-pyrrol-2-yl)methanamine; pyrrole inhibitor 18; BAS 10796078; AC1M3ZOX; N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine; SCHEMBL11567290; CTK6I2711; BDBM15593; MolPort-000-863-754; ZINC2868930; SBB010992; STK511232; BBL030414; 8940AE; AKOS000285009; MCULE-8292930001; ST063683; benzyl[(1-methylpyrrol-2-yl)methyl]amine; TR-044376; KB-250848; benzyl (1-methyl-1h-pyrrol-2-ylmethyl)amine
DM72BSO	DT	Small molecular drug
DM72BSO	PC	2222065
DM72BSO	MW	200.28
DM72BSO	FM	C13H16N2
DM72BSO	IC	InChI=1S/C13H16N2/c1-15-9-5-8-13(15)11-14-10-12-6-3-2-4-7-12/h2-9,14H,10-11H2,1H3
DM72BSO	CS	CN1C=CC=C1CNCC2=CC=CC=C2
DM72BSO	IK	RFBDIJWXYJNKSB-UHFFFAOYSA-N
DM72BSO	IU	N-[(1-methylpyrrol-2-yl)methyl]-1-phenylmethanamine
DM72BSO	DE	Discovery agent

DMW5XLG	ID	DMW5XLG
DMW5XLG	DN	N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide
DMW5XLG	HS	Investigative
DMW5XLG	SN	CHEMBL223108; SCHEMBL3295792; MolPort-028-745-458; ZINC35324154
DMW5XLG	DT	Small molecular drug
DMW5XLG	PC	16125122
DMW5XLG	MW	322.34
DMW5XLG	FM	C14H14N2O5S
DMW5XLG	IC	InChI=1S/C14H14N2O5S/c1-22(19,20)15-13-8-7-12(16(17)18)9-14(13)21-10-11-5-3-2-4-6-11/h2-9,15H,10H2,1H3
DMW5XLG	CS	CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OCC2=CC=CC=C2
DMW5XLG	IK	XDQFGDRBMTXPFY-UHFFFAOYSA-N
DMW5XLG	IU	N-(4-nitro-2-phenylmethoxyphenyl)methanesulfonamide
DMW5XLG	DE	Discovery agent

DMFC564	ID	DMFC564
DMFC564	DN	N-(2-bromobenzoyloxy)-4-chlorobenzamide
DMFC564	HS	Investigative
DMFC564	SN	CHEMBL1253383; N-{[(2-bromophenyl)carbonyl]oxy}-4-chlorobenzamide; N-(2-bromobenzoyloxy)-4-chlorobenzamide; AC1LQE9K; CBMicro_012071; MolPort-002-189-016; ZINC1186119; SMSF0017521; STK185858; BDBM50326572; AKOS005412260; MCULE-4091237725; CB15272; [(4-chlorobenzoyl)amino] 2-bromobenzoate; BIM-0012056.P001; SR-01000230575
DMFC564	DT	Small molecular drug
DMFC564	PC	1348789
DMFC564	MW	354.58
DMFC564	FM	C14H9BrClNO3
DMFC564	IC	InChI=1S/C14H9BrClNO3/c15-12-4-2-1-3-11(12)14(19)20-17-13(18)9-5-7-10(16)8-6-9/h1-8H,(H,17,18)
DMFC564	CS	C1=CC=C(C(=C1)C(=O)ONC(=O)C2=CC=C(C=C2)Cl)Br
DMFC564	IK	XBZVDYJKCJLDSB-UHFFFAOYSA-N
DMFC564	IU	[(4-chlorobenzoyl)amino] 2-bromobenzoate
DMFC564	DE	Discovery agent

DM4IEWG	ID	DM4IEWG
DM4IEWG	DN	N-(2-chlorobenzyl)-5-(4-chlorophenyl)nicotinamide
DM4IEWG	HS	Investigative
DM4IEWG	SN	CHEMBL1269883; N-(2-chlorobenzyl)-5-(4-chlorophenyl)nicotinamide
DM4IEWG	DT	Small molecular drug
DM4IEWG	PC	52948346
DM4IEWG	MW	357.2
DM4IEWG	FM	C19H14Cl2N2O
DM4IEWG	IC	InChI=1S/C19H14Cl2N2O/c20-17-7-5-13(6-8-17)15-9-16(11-22-10-15)19(24)23-12-14-3-1-2-4-18(14)21/h1-11H,12H2,(H,23,24)
DM4IEWG	CS	C1=CC=C(C(=C1)CNC(=O)C2=CN=CC(=C2)C3=CC=C(C=C3)Cl)Cl
DM4IEWG	IK	CKNIOMWTEPBNFF-UHFFFAOYSA-N
DM4IEWG	IU	5-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]pyridine-3-carboxamide
DM4IEWG	DE	Discovery agent

DMU5R2O	ID	DMU5R2O
DMU5R2O	DN	N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
DMU5R2O	HS	Investigative
DMU5R2O	SN	AC1L1CNE; CTK8E7690; DTXSID60274346
DMU5R2O	DT	Small molecular drug
DMU5R2O	PC	1977
DMU5R2O	MW	366
DMU5R2O	FM	C22H36ClNO
DMU5R2O	IC	InChI=1S/C22H36ClNO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)24-21-20-23/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,24,25)
DMU5R2O	CS	CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCCl
DMU5R2O	IK	SCJNCDSAIRBRIA-UHFFFAOYSA-N
DMU5R2O	IU	N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
DMU5R2O	CA	CAS 220556-69-4
DMU5R2O	DE	Discovery agent

DMZ4A2X	ID	DMZ4A2X
DMZ4A2X	DN	N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide
DMZ4A2X	HS	Investigative
DMZ4A2X	SN	CHEMBL122865; N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide; BDBM50106170; AKOS016689088
DMZ4A2X	DT	Small molecular drug
DMZ4A2X	PC	11023656
DMZ4A2X	MW	320.5
DMZ4A2X	FM	C19H32N2O2
DMZ4A2X	IC	InChI=1S/C19H32N2O2/c1-4-7-8-9-16-23-18-12-10-17(11-13-18)19(22)20-14-15-21(5-2)6-3/h10-13H,4-9,14-16H2,1-3H3,(H,20,22)
DMZ4A2X	CS	CCCCCCOC1=CC=C(C=C1)C(=O)NCCN(CC)CC
DMZ4A2X	IK	ZVGROIFLIDCWLT-UHFFFAOYSA-N
DMZ4A2X	IU	N-[2-(diethylamino)ethyl]-4-hexoxybenzamide
DMZ4A2X	DE	Discovery agent

DMMDXEO	ID	DMMDXEO
DMMDXEO	DN	N-(2-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMMDXEO	HS	Investigative
DMMDXEO	SN	CHEMBL1269649; N-(2-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMMDXEO	DT	Small molecular drug
DMMDXEO	PC	52940635
DMMDXEO	MW	252.31
DMMDXEO	FM	C16H16N2O
DMMDXEO	IC	InChI=1S/C16H16N2O/c1-3-12-6-4-5-7-13(12)17-16-18-14-10-11(2)8-9-15(14)19-16/h4-10H,3H2,1-2H3,(H,17,18)
DMMDXEO	CS	CCC1=CC=CC=C1NC2=NC3=C(O2)C=CC(=C3)C
DMMDXEO	IK	KQXHDGZITMHOPQ-UHFFFAOYSA-N
DMMDXEO	IU	N-(2-ethylphenyl)-5-methyl-1,3-benzoxazol-2-amine
DMMDXEO	DE	Discovery agent

DMDM50P	ID	DMDM50P
DMDM50P	DN	N-(2-Ethylphenyl)-N'-hydroxyoctanediamide
DMDM50P	HS	Investigative
DMDM50P	SN	CHEMBL1093040; BDBM50314142
DMDM50P	DT	Small molecular drug
DMDM50P	PC	45141752
DMDM50P	MW	292.37
DMDM50P	FM	C16H24N2O3
DMDM50P	IC	InChI=1S/C16H24N2O3/c1-2-13-9-7-8-10-14(13)17-15(19)11-5-3-4-6-12-16(20)18-21/h7-10,21H,2-6,11-12H2,1H3,(H,17,19)(H,18,20)
DMDM50P	CS	CCC1=CC=CC=C1NC(=O)CCCCCCC(=O)NO
DMDM50P	IK	COKQAZFZACGKGP-UHFFFAOYSA-N
DMDM50P	IU	N-(2-ethylphenyl)-N'-hydroxyoctanediamide
DMDM50P	DE	Discovery agent

DM3CZVW	ID	DM3CZVW
DM3CZVW	DN	N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide
DM3CZVW	HS	Investigative
DM3CZVW	SN	n-(2-flouro-benzyl)-4-sulfamoyl-benzamide; N-[(2-fluorophenyl)methyl]-4-sulfamoylbenzamide; n-(2-fluoro-benzyl)-4-sulfamoyl-benzamide; 2-fluoro-SBB; 1g1d; AC1L1HTZ; SCHEMBL678599; BDBM12014; 1g45; AKOS008607291; DB02069; n-(2-fluorobenzyl)-4-sulfamoylbenzamide
DM3CZVW	DT	Small molecular drug
DM3CZVW	PC	4290
DM3CZVW	MW	308.33
DM3CZVW	FM	C14H13FN2O3S
DM3CZVW	IC	InChI=1S/C14H13FN2O3S/c15-13-4-2-1-3-11(13)9-17-14(18)10-5-7-12(8-6-10)21(16,19)20/h1-8H,9H2,(H,17,18)(H2,16,19,20)
DM3CZVW	CS	C1=CC=C(C(=C1)CNC(=O)C2=CC=C(C=C2)S(=O)(=O)N)F
DM3CZVW	IK	ULYMHSXFSKOHGH-UHFFFAOYSA-N
DM3CZVW	IU	N-[(2-fluorophenyl)methyl]-4-sulfamoylbenzamide
DM3CZVW	DE	Discovery agent

DM7BKUQ	ID	DM7BKUQ
DM7BKUQ	DN	N'-(2-fluorobenzoyl)-2-naphthohydrazide
DM7BKUQ	HS	Investigative
DM7BKUQ	SN	CHEMBL108888; N'-(2-fluorobenzoyl)naphthalene-2-carbohydrazide; NSC88634; AC1L60EG; ZINC1569432; BDBM50066318; NSC-88634; AKOS008432264; N''-(2-fluorobenzoyl)-2-naphthohydrazide; (2-Fluorophenyl)-N-(2-naphthylcarbonylamino)carboxamide; Naphthalene-2-carboxylic acid N''-(2-fluoro-benzoyl)-hydrazide
DM7BKUQ	DT	Small molecular drug
DM7BKUQ	PC	259098
DM7BKUQ	MW	308.3
DM7BKUQ	FM	C18H13FN2O2
DM7BKUQ	IC	InChI=1S/C18H13FN2O2/c19-16-8-4-3-7-15(16)18(23)21-20-17(22)14-10-9-12-5-1-2-6-13(12)11-14/h1-11H,(H,20,22)(H,21,23)
DM7BKUQ	CS	C1=CC=C2C=C(C=CC2=C1)C(=O)NNC(=O)C3=CC=CC=C3F
DM7BKUQ	IK	BHGKYYRQGUSTGE-UHFFFAOYSA-N
DM7BKUQ	IU	N'-(2-fluorobenzoyl)naphthalene-2-carbohydrazide
DM7BKUQ	DE	Discovery agent

DM27L53	ID	DM27L53
DM27L53	DN	N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide
DM27L53	HS	Investigative
DM27L53	SN	CHEMBL202471; N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3294121; BDBM50182531
DM27L53	DT	Small molecular drug
DM27L53	PC	11493409
DM27L53	MW	316.38
DM27L53	FM	C13H20N2O5S
DM27L53	IC	InChI=1S/C13H20N2O5S/c1-3-4-5-6-9-20-13-10-11(15(16)17)7-8-12(13)14-21(2,18)19/h7-8,10,14H,3-6,9H2,1-2H3
DM27L53	CS	CCCCCCOC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C
DM27L53	IK	ZYLWBHCVEZSQJB-UHFFFAOYSA-N
DM27L53	IU	N-(2-hexoxy-4-nitrophenyl)methanesulfonamide
DM27L53	DE	Discovery agent

DM97MGE	ID	DM97MGE
DM97MGE	DN	N-(2-hydroxyethyl)linoleoylamide
DM97MGE	HS	Investigative
DM97MGE	SN	Linoleamide MEA; Linoleoyl ethanolamide; Linoleic ethanolamide; n-linoleoylethanolamine; N-(2-Hydroxyethyl)linoleamide; Anandamide (18:2, n-6); Linoleoyl monoethanolamide; UNII-889DYX0816; N-(2-hydroxyethyl)linoleoylamide; Linoleylethanolamide; 68171-52-8; Monoethanolamine linoleic acid amide; EINECS 269-029-6; N-(9Z,12Z-octadecadienoyl)-ethanolamine; CHEMBL149859; N-(2-Hydroxyethyl)-linoleamide; C20H37NO2; CHEBI:64032; 889DYX0816; (9Z,12Z)-N-(2-Hydroxyethyl)octadeca-9,12-dien-1-amide
DM97MGE	DT	Small molecular drug
DM97MGE	PC	5283446
DM97MGE	MW	323.5
DM97MGE	FM	C20H37NO2
DM97MGE	IC	InChI=1S/C20H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h6-7,9-10,22H,2-5,8,11-19H2,1H3,(H,21,23)/b7-6-,10-9-
DM97MGE	CS	CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)NCCO
DM97MGE	IK	KQXDGUVSAAQARU-HZJYTTRNSA-N
DM97MGE	IU	(9Z,12Z)-N-(2-hydroxyethyl)octadeca-9,12-dienamide
DM97MGE	CA	CAS 68171-52-8
DM97MGE	CB	CHEBI:64032
DM97MGE	DE	Discovery agent

DM8ORQ4	ID	DM8ORQ4
DM8ORQ4	DN	N-(2-iodethyl)arachidonylamide
DM8ORQ4	HS	Investigative
DM8ORQ4	SN	N-(2-iodethyl)arachidonylamide; CHEMBL509376
DM8ORQ4	DT	Small molecular drug
DM8ORQ4	PC	44569685
DM8ORQ4	MW	457.4
DM8ORQ4	FM	C22H36INO
DM8ORQ4	IC	InChI=1S/C22H36INO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)24-21-20-23/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,24,25)/b7-6-,10-9-,13-12-,16-15-
DM8ORQ4	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCI
DM8ORQ4	IK	KOHVJRAXSGONGW-DOFZRALJSA-N
DM8ORQ4	IU	(5Z,8Z,11Z,14Z)-N-(2-iodoethyl)icosa-5,8,11,14-tetraenamide
DM8ORQ4	DE	Discovery agent

DMV84PQ	ID	DMV84PQ
DMV84PQ	DN	N-(2-iodoethyl)linoleoylamide
DMV84PQ	HS	Investigative
DMV84PQ	SN	N-(2-iodoethyl)linoleoylamide; CHEMBL448660
DMV84PQ	DT	Small molecular drug
DMV84PQ	PC	44569684
DMV84PQ	MW	433.4
DMV84PQ	FM	C20H36INO
DMV84PQ	IC	InChI=1S/C20H36INO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)22-19-18-21/h6-7,9-10H,2-5,8,11-19H2,1H3,(H,22,23)/b7-6-,10-9-
DMV84PQ	CS	CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)NCCI
DMV84PQ	IK	WVKIJZMEKURTIW-HZJYTTRNSA-N
DMV84PQ	IU	(9Z,12Z)-N-(2-iodoethyl)octadeca-9,12-dienamide
DMV84PQ	DE	Discovery agent

DM0GOPV	ID	DM0GOPV
DM0GOPV	DN	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide
DM0GOPV	HS	Investigative
DM0GOPV	SN	CHEMBL193979
DM0GOPV	DT	Small molecular drug
DM0GOPV	PC	44401305
DM0GOPV	MW	224.28
DM0GOPV	FM	C10H12N2O2S
DM0GOPV	IC	InChI=1S/C10H12N2O2S/c13-9(11-6-7-15)10(14)12-8-4-2-1-3-5-8/h1-5,15H,6-7H2,(H,11,13)(H,12,14)
DM0GOPV	CS	C1=CC=C(C=C1)NC(=O)C(=O)NCCS
DM0GOPV	IK	NDECTIXXLKUOQM-UHFFFAOYSA-N
DM0GOPV	IU	N'-phenyl-N-(2-sulfanylethyl)oxamide
DM0GOPV	DE	Discovery agent

DMJLFOQ	ID	DMJLFOQ
DMJLFOQ	DN	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide
DMJLFOQ	HS	Investigative
DMJLFOQ	SN	CHEMBL193959
DMJLFOQ	DT	Small molecular drug
DMJLFOQ	PC	44401339
DMJLFOQ	MW	252.33
DMJLFOQ	FM	C12H16N2O2S
DMJLFOQ	IC	InChI=1S/C12H16N2O2S/c15-11(13-8-9-17)6-7-12(16)14-10-4-2-1-3-5-10/h1-5,17H,6-9H2,(H,13,15)(H,14,16)
DMJLFOQ	CS	C1=CC=C(C=C1)NC(=O)CCC(=O)NCCS
DMJLFOQ	IK	DQJPTXLXOUGDMC-UHFFFAOYSA-N
DMJLFOQ	IU	N'-phenyl-N-(2-sulfanylethyl)butanediamide
DMJLFOQ	DE	Discovery agent

DM06S5Z	ID	DM06S5Z
DM06S5Z	DN	N-(2-methoxybenzyl)cinnamamidine
DM06S5Z	HS	Investigative
DM06S5Z	SN	N-(2-methoxybenzyl)cinnamamidine; CHEMBL158737; SCHEMBL4624632; BDBM50124885; N-(2-Methoxybenzyl)-trans-cinnamamidine; n-(2-methoxybenzyl)-3-phenylacrylamidine
DM06S5Z	DT	Small molecular drug
DM06S5Z	PC	9900027
DM06S5Z	MW	266.34
DM06S5Z	FM	C17H18N2O
DM06S5Z	IC	InChI=1S/C17H18N2O/c1-20-16-10-6-5-9-15(16)13-19-17(18)12-11-14-7-3-2-4-8-14/h2-12H,13H2,1H3,(H2,18,19)/b12-11+
DM06S5Z	CS	COC1=CC=CC=C1CN=C(/C=C/C2=CC=CC=C2)N
DM06S5Z	IK	YYJKWRHOJBQQMG-VAWYXSNFSA-N
DM06S5Z	IU	(E)-N'-[(2-methoxyphenyl)methyl]-3-phenylprop-2-enimidamide
DM06S5Z	DE	Discovery agent

DMH42YF	ID	DMH42YF
DMH42YF	DN	N-(2-Methyl-1H-indol-5-yl)benzamide
DMH42YF	HS	Investigative
DMH42YF	SN	CHEMBL1253578; N-(2-Methyl-1H-indol-5-yl)benzamide; BDBM50326842
DMH42YF	DT	Small molecular drug
DMH42YF	PC	24219274
DMH42YF	MW	250.29
DMH42YF	FM	C16H14N2O
DMH42YF	IC	InChI=1S/C16H14N2O/c1-11-9-13-10-14(7-8-15(13)17-11)18-16(19)12-5-3-2-4-6-12/h2-10,17H,1H3,(H,18,19)
DMH42YF	CS	CC1=CC2=C(N1)C=CC(=C2)NC(=O)C3=CC=CC=C3
DMH42YF	IK	GXRAVFCYXQCDLO-UHFFFAOYSA-N
DMH42YF	IU	N-(2-methyl-1H-indol-5-yl)benzamide
DMH42YF	DE	Discovery agent

DM3SF5M	ID	DM3SF5M
DM3SF5M	DN	N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide
DM3SF5M	HS	Investigative
DM3SF5M	SN	CHEMBL1253605; N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide; MolPort-007-401-898; ZINC43771600; BDBM50326846
DM3SF5M	DT	Small molecular drug
DM3SF5M	PC	46400456
DM3SF5M	MW	256.339
DM3SF5M	FM	C16H20N2O
DM3SF5M	IC	InChI=1S/C16H20N2O/c1-11-9-13-10-14(7-8-15(13)17-11)18-16(19)12-5-3-2-4-6-12/h7-10,12,17H,2-6H2,1H3,(H,18,19)
DM3SF5M	CS	CC1=CC2=C(N1)C=CC(=C2)NC(=O)C3CCCCC3
DM3SF5M	IK	VFQGCSZINPSFBG-UHFFFAOYSA-N
DM3SF5M	IU	N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
DM3SF5M	DE	Discovery agent

DMXRSM1	ID	DMXRSM1
DMXRSM1	DN	N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide
DMXRSM1	HS	Investigative
DMXRSM1	SN	CHEMBL246026; N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide; 923600-01-5; CTK3F8796; DTXSID50653166; BDBM50197260; AKOS027754505; 2-Pyrazinecarboxamide, N-(2-methyl-2-phenylpropyl)-
DMXRSM1	DT	Small molecular drug
DMXRSM1	PC	36039661
DMXRSM1	MW	255.31
DMXRSM1	FM	C15H17N3O
DMXRSM1	IC	InChI=1S/C15H17N3O/c1-15(2,12-6-4-3-5-7-12)11-18-14(19)13-10-16-8-9-17-13/h3-10H,11H2,1-2H3,(H,18,19)
DMXRSM1	CS	CC(C)(CNC(=O)C1=NC=CN=C1)C2=CC=CC=C2
DMXRSM1	IK	HMOMSNPWNJNCOE-UHFFFAOYSA-N
DMXRSM1	IU	N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide
DMXRSM1	CA	CAS 923600-01-5
DMXRSM1	DE	Discovery agent

DMI4KNB	ID	DMI4KNB
DMI4KNB	DN	N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide
DMI4KNB	HS	Investigative
DMI4KNB	SN	CHEMBL251369; N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide; AC1MH48W; MLS001162447; SCHEMBL13148062; cid_2996093; N-[2-(morpholin-4-yl)phenyl]-5-nitrofuran-2-carboxamide; MolPort-002-305-194; HMS2967E08; ZINC4842600; STK355602; BDBM50223675; AKOS000458368; MCULE-3330873928; SMR000670465; VU0465060-1; N-(2-morpholin-4-ylphenyl)-5-nitro-2-furamide; AP-970/43481542; N-[2-(4-morpholinyl)phenyl]-5-nitro-2-furamide
DMI4KNB	DT	Small molecular drug
DMI4KNB	PC	2996093
DMI4KNB	MW	317.3
DMI4KNB	FM	C15H15N3O5
DMI4KNB	IC	InChI=1S/C15H15N3O5/c19-15(13-5-6-14(23-13)18(20)21)16-11-3-1-2-4-12(11)17-7-9-22-10-8-17/h1-6H,7-10H2,(H,16,19)
DMI4KNB	CS	C1COCCN1C2=CC=CC=C2NC(=O)C3=CC=C(O3)[N+](=O)[O-]
DMI4KNB	IK	BIQWNNXDPVEAPZ-UHFFFAOYSA-N
DMI4KNB	IU	N-(2-morpholin-4-ylphenyl)-5-nitrofuran-2-carboxamide
DMI4KNB	DE	Discovery agent

DMF5N4O	ID	DMF5N4O
DMF5N4O	DN	N-(2-naphthylsulfonyl)-glycyl-glycine-nitrile
DMF5N4O	HS	Investigative
DMF5N4O	SN	dipeptide-derived nitrile, 38; CHEMBL200338; BDBM20117
DMF5N4O	DT	Small molecular drug
DMF5N4O	PC	11652399
DMF5N4O	MW	303.34
DMF5N4O	FM	C14H13N3O3S
DMF5N4O	IC	InChI=1S/C14H13N3O3S/c15-7-8-16-14(18)10-17-21(19,20)13-6-5-11-3-1-2-4-12(11)9-13/h1-6,9,17H,8,10H2,(H,16,18)
DMF5N4O	CS	C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)NCC(=O)NCC#N
DMF5N4O	IK	LVYWXNHSBUSHNC-UHFFFAOYSA-N
DMF5N4O	IU	N-(cyanomethyl)-2-(naphthalen-2-ylsulfonylamino)acetamide
DMF5N4O	DE	Discovery agent

DMU6FPL	ID	DMU6FPL
DMU6FPL	DN	N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide
DMU6FPL	HS	Investigative
DMU6FPL	SN	CHEMBL202469; N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3295100; BDBM50182532
DMU6FPL	DT	Small molecular drug
DMU6FPL	PC	11646165
DMU6FPL	MW	358.5
DMU6FPL	FM	C16H26N2O5S
DMU6FPL	IC	InChI=1S/C16H26N2O5S/c1-3-4-5-6-7-8-9-12-23-16-13-14(18(19)20)10-11-15(16)17-24(2,21)22/h10-11,13,17H,3-9,12H2,1-2H3
DMU6FPL	CS	CCCCCCCCCOC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C
DMU6FPL	IK	QXUZIGSBVCSGCD-UHFFFAOYSA-N
DMU6FPL	IU	N-(4-nitro-2-nonoxyphenyl)methanesulfonamide
DMU6FPL	DE	Discovery agent

DMVGP02	ID	DMVGP02
DMVGP02	DN	N-(2-oxazolemethyl)milnacipran
DMVGP02	HS	Investigative
DMVGP02	SN	CHEMBL256408; N-(2-oxazolemethyl)milnacipran
DMVGP02	DT	Small molecular drug
DMVGP02	PC	44454825
DMVGP02	MW	327.4
DMVGP02	FM	C19H25N3O2
DMVGP02	IC	InChI=1S/C19H25N3O2/c1-3-22(4-2)18(23)19(15-8-6-5-7-9-15)12-16(19)13-20-14-17-21-10-11-24-17/h5-11,16,20H,3-4,12-14H2,1-2H3
DMVGP02	CS	CCN(CC)C(=O)C1(CC1CNCC2=NC=CO2)C3=CC=CC=C3
DMVGP02	IK	NCRFMJNGTNNKEE-UHFFFAOYSA-N
DMVGP02	IU	N,N-diethyl-2-[(1,3-oxazol-2-ylmethylamino)methyl]-1-phenylcyclopropane-1-carboxamide
DMVGP02	DE	Discovery agent

DMBR1MX	ID	DMBR1MX
DMBR1MX	DN	N'-(2-phenylallyl)hydrazine hydrochloride
DMBR1MX	HS	Investigative
DMBR1MX	SN	CHEMBL536057; SCHEMBL18953115; N'-(2-Phenylallyl)Hydrazine HCl; LS-193138; N'-(2-phenyl-allyl)-hydrazine hydrochloride
DMBR1MX	DT	Small molecular drug
DMBR1MX	PC	11679937
DMBR1MX	MW	184.66
DMBR1MX	FM	C9H13ClN2
DMBR1MX	IC	InChI=1S/C9H12N2.ClH/c1-8(7-11-10)9-5-3-2-4-6-9;/h2-6,11H,1,7,10H2;1H
DMBR1MX	CS	C=C(CNN)C1=CC=CC=C1.Cl
DMBR1MX	IK	SSRWZZHWIPKMCQ-UHFFFAOYSA-N
DMBR1MX	IU	2-phenylprop-2-enylhydrazine;hydrochloride
DMBR1MX	DE	Discovery agent

DM1ADE5	ID	DM1ADE5
DM1ADE5	DN	N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine
DM1ADE5	HS	Investigative
DM1ADE5	SN	pyrrole inhibitor 20; N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine; CHEMBL222368; BDBM15595; ZINC14959045; AKOS009004338
DM1ADE5	DT	Small molecular drug
DM1ADE5	PC	16110292
DM1ADE5	MW	200.28
DM1ADE5	FM	C13H16N2
DM1ADE5	IC	InChI=1S/C13H16N2/c1-2-5-12(6-3-1)8-10-14-11-13-7-4-9-15-13/h1-7,9,14-15H,8,10-11H2
DM1ADE5	CS	C1=CC=C(C=C1)CCNCC2=CC=CN2
DM1ADE5	IK	HKFLTDDIRURSLM-UHFFFAOYSA-N
DM1ADE5	IU	2-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
DM1ADE5	DE	Discovery agent

DMJCO7F	ID	DMJCO7F
DMJCO7F	DN	N-(2-Phenylethyl)-1H-indole-2-carboxamide
DMJCO7F	HS	Investigative
DMJCO7F	SN	N-(2-phenylethyl)-1H-indole-2-carboxamide; CHEMBL460610; MolPort-003-002-251; ZINC12653902; STK321421; BDBM50273527; AKOS003377424; MCULE-6495379337; NCGC00317146-01; 57980-68-4; AB01204586-02
DMJCO7F	DT	Small molecular drug
DMJCO7F	PC	12627221
DMJCO7F	MW	264.32
DMJCO7F	FM	C17H16N2O
DMJCO7F	IC	InChI=1S/C17H16N2O/c20-17(18-11-10-13-6-2-1-3-7-13)16-12-14-8-4-5-9-15(14)19-16/h1-9,12,19H,10-11H2,(H,18,20)
DMJCO7F	CS	C1=CC=C(C=C1)CCNC(=O)C2=CC3=CC=CC=C3N2
DMJCO7F	IK	LANZFLJGXZCWQM-UHFFFAOYSA-N
DMJCO7F	IU	N-(2-phenylethyl)-1H-indole-2-carboxamide
DMJCO7F	DE	Discovery agent

DMUILX8	ID	DMUILX8
DMUILX8	DN	N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide
DMUILX8	HS	Investigative
DMUILX8	SN	N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide; CHEMBL379553; 171628-57-2; N-{2-phenylimidazo[1,2-a]pyridin-3-yl}benzamide; AC1LF77Z; Oprea1_830806; MLS001162915; CTK0E4651; DTXSID60353680; MolPort-002-132-975; HMS2842E11; ZINC193750; BDBM50187634; STK367224; AKOS001415177; MCULE-3771425109; SMR000495823; SR-01000196826; N-(2-Phenylimidazo[1,2-a]pyridine-3-yl)benzamide; SR-01000196826-1; Benzamide, N-(2-phenylimidazo[1,2-a]pyridin-3-yl)-
DMUILX8	DT	Small molecular drug
DMUILX8	PC	748028
DMUILX8	MW	313.4
DMUILX8	FM	C20H15N3O
DMUILX8	IC	InChI=1S/C20H15N3O/c24-20(16-11-5-2-6-12-16)22-19-18(15-9-3-1-4-10-15)21-17-13-7-8-14-23(17)19/h1-14H,(H,22,24)
DMUILX8	CS	C1=CC=C(C=C1)C2=C(N3C=CC=CC3=N2)NC(=O)C4=CC=CC=C4
DMUILX8	IK	MFEAOWRPVOQOEV-UHFFFAOYSA-N
DMUILX8	IU	N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide
DMUILX8	CA	CAS 171628-57-2
DMUILX8	DE	Discovery agent

DMA1LRF	ID	DMA1LRF
DMA1LRF	DN	N-(2-phenylpropyl)quinoxaline-2-carboxamide
DMA1LRF	HS	Investigative
DMA1LRF	SN	CHEMBL241699; N-(2-phenylpropyl)quinoxaline-2-carboxamide; SCHEMBL6083525; UWOAOBCILHACGX-UHFFFAOYSA-N; BDBM50197265
DMA1LRF	DT	Small molecular drug
DMA1LRF	PC	22136331
DMA1LRF	MW	291.3
DMA1LRF	FM	C18H17N3O
DMA1LRF	IC	InChI=1S/C18H17N3O/c1-13(14-7-3-2-4-8-14)11-20-18(22)17-12-19-15-9-5-6-10-16(15)21-17/h2-10,12-13H,11H2,1H3,(H,20,22)
DMA1LRF	CS	CC(CNC(=O)C1=NC2=CC=CC=C2N=C1)C3=CC=CC=C3
DMA1LRF	IK	UWOAOBCILHACGX-UHFFFAOYSA-N
DMA1LRF	IU	N-(2-phenylpropyl)quinoxaline-2-carboxamide
DMA1LRF	DE	Discovery agent

DMAQMXJ	ID	DMAQMXJ
DMAQMXJ	DN	N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide
DMAQMXJ	HS	Investigative
DMAQMXJ	SN	CHEMBL204184; N-(2-n-propyloxy-4-nitrophenyl)methanesulfonamide; 880145-98-2; N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3301465; CTK6E5797; BDBM50182536; AKOS015965877; N-(4-nitro-2-propoxyphenyl)methanesulfonamide
DMAQMXJ	DT	Small molecular drug
DMAQMXJ	PC	11680642
DMAQMXJ	MW	274.3
DMAQMXJ	FM	C10H14N2O5S
DMAQMXJ	IC	InChI=1S/C10H14N2O5S/c1-3-6-17-10-7-8(12(13)14)4-5-9(10)11-18(2,15)16/h4-5,7,11H,3,6H2,1-2H3
DMAQMXJ	CS	CCCOC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C
DMAQMXJ	IK	GUPXOWXEFMIHHE-UHFFFAOYSA-N
DMAQMXJ	IU	N-(4-nitro-2-propoxyphenyl)methanesulfonamide
DMAQMXJ	DE	Discovery agent

DME9HNO	ID	DME9HNO
DME9HNO	DN	N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide
DME9HNO	HS	Investigative
DME9HNO	SN	n-(2-thienylmethyl)-2,5-thiophenedisulfonamide; 2-N-(thiophen-2-ylmethyl)thiophene-2,5-disulfonamide; 1bnw; AC1L1HU8; SCHEMBL677620; BDBM11931; STOTVDLYLKWVJB-UHFFFAOYSA-N; AL5415; DB02986; N-(2-Thienyl)methyl-2,5-thiophenedisulfonamide; N-(2-Thienylmethyl)thiophene-2,5-disulfonamide
DME9HNO	DT	Small molecular drug
DME9HNO	PC	4293
DME9HNO	MW	338.5
DME9HNO	FM	C9H10N2O4S4
DME9HNO	IC	InChI=1S/C9H10N2O4S4/c10-18(12,13)8-3-4-9(17-8)19(14,15)11-6-7-2-1-5-16-7/h1-5,11H,6H2,(H2,10,12,13)
DME9HNO	CS	C1=CSC(=C1)CNS(=O)(=O)C2=CC=C(S2)S(=O)(=O)N
DME9HNO	IK	STOTVDLYLKWVJB-UHFFFAOYSA-N
DME9HNO	IU	2-N-(thiophen-2-ylmethyl)thiophene-2,5-disulfonamide
DME9HNO	DE	Discovery agent

DM0JE7H	ID	DM0JE7H
DM0JE7H	DN	N-(3-(1H-indol-4-yloxy)propyl)cyclohexanamine
DM0JE7H	HS	Investigative
DM0JE7H	SN	CHEMBL237790; N-(3-(1H-indol-4-yloxy)propyl)cyclohexanamine
DM0JE7H	DT	Small molecular drug
DM0JE7H	PC	44433247
DM0JE7H	MW	272.4
DM0JE7H	FM	C17H24N2O
DM0JE7H	IC	InChI=1S/C17H24N2O/c1-2-6-14(7-3-1)18-11-5-13-20-17-9-4-8-16-15(17)10-12-19-16/h4,8-10,12,14,18-19H,1-3,5-7,11,13H2
DM0JE7H	CS	C1CCC(CC1)NCCCOC2=CC=CC3=C2C=CN3
DM0JE7H	IK	QVATUGJQJMJAPA-UHFFFAOYSA-N
DM0JE7H	IU	N-[3-(1H-indol-4-yloxy)propyl]cyclohexanamine
DM0JE7H	DE	Discovery agent

DM2URTK	ID	DM2URTK
DM2URTK	DN	N-(3-(1H-indol-4-yloxy)propyl)cyclopentanamine
DM2URTK	HS	Investigative
DM2URTK	SN	CHEMBL392392; N-(3-(1H-indol-4-yloxy)propyl)cyclopentanamine
DM2URTK	DT	Small molecular drug
DM2URTK	PC	44433248
DM2URTK	MW	258.36
DM2URTK	FM	C16H22N2O
DM2URTK	IC	InChI=1S/C16H22N2O/c1-2-6-13(5-1)17-10-4-12-19-16-8-3-7-15-14(16)9-11-18-15/h3,7-9,11,13,17-18H,1-2,4-6,10,12H2
DM2URTK	CS	C1CCC(C1)NCCCOC2=CC=CC3=C2C=CN3
DM2URTK	IK	IYOLOIDWTZSJFT-UHFFFAOYSA-N
DM2URTK	IU	N-[3-(1H-indol-4-yloxy)propyl]cyclopentanamine
DM2URTK	DE	Discovery agent

DM4ZTF1	ID	DM4ZTF1
DM4ZTF1	DN	N-(3-(2,5-dimethoxyphenyl)propyl)acetamide
DM4ZTF1	HS	Investigative
DM4ZTF1	SN	CHEMBL1092400; N-(3-(2,5-dimethoxyphenyl)propyl)acetamide
DM4ZTF1	DT	Small molecular drug
DM4ZTF1	PC	46885283
DM4ZTF1	MW	237.29
DM4ZTF1	FM	C13H19NO3
DM4ZTF1	IC	InChI=1S/C13H19NO3/c1-10(15)14-8-4-5-11-9-12(16-2)6-7-13(11)17-3/h6-7,9H,4-5,8H2,1-3H3,(H,14,15)
DM4ZTF1	CS	CC(=O)NCCCC1=C(C=CC(=C1)OC)OC
DM4ZTF1	IK	JFAQPXCGWLODGO-UHFFFAOYSA-N
DM4ZTF1	IU	N-[3-(2,5-dimethoxyphenyl)propyl]acetamide
DM4ZTF1	DE	Discovery agent

DMP8547	ID	DMP8547
DMP8547	DN	N-(3-(2-aminoethyl)phenyl)benzenesulfonamide
DMP8547	HS	Investigative
DMP8547	SN	CHEMBL212063; N-(3-(2-aminoethyl)phenyl)benzenesulfonamide; BDBM50193463
DMP8547	DT	Small molecular drug
DMP8547	PC	11849194
DMP8547	MW	276.36
DMP8547	FM	C14H16N2O2S
DMP8547	IC	InChI=1S/C14H16N2O2S/c15-10-9-12-5-4-6-13(11-12)16-19(17,18)14-7-2-1-3-8-14/h1-8,11,16H,9-10,15H2
DMP8547	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)CCN
DMP8547	IK	SMDOJINITBXUQJ-UHFFFAOYSA-N
DMP8547	IU	N-[3-(2-aminoethyl)phenyl]benzenesulfonamide
DMP8547	DE	Discovery agent

DMLWGPC	ID	DMLWGPC
DMLWGPC	DN	N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide
DMLWGPC	HS	Investigative
DMLWGPC	SN	CHEMBL1091561; N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide
DMLWGPC	DT	Small molecular drug
DMLWGPC	PC	46885284
DMLWGPC	MW	251.32
DMLWGPC	FM	C14H21NO3
DMLWGPC	IC	InChI=1S/C14H21NO3/c1-4-18-14-8-7-13(17-3)10-12(14)6-5-9-15-11(2)16/h7-8,10H,4-6,9H2,1-3H3,(H,15,16)
DMLWGPC	CS	CCOC1=C(C=C(C=C1)OC)CCCNC(=O)C
DMLWGPC	IK	GTXCCVOUHCBPES-UHFFFAOYSA-N
DMLWGPC	IU	N-[3-(2-ethoxy-5-methoxyphenyl)propyl]acetamide
DMLWGPC	DE	Discovery agent

DMI452E	ID	DMI452E
DMI452E	DN	N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide
DMI452E	HS	Investigative
DMI452E	SN	CHEMBL1092062; N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide
DMI452E	DT	Small molecular drug
DMI452E	PC	46885230
DMI452E	MW	223.27
DMI452E	FM	C12H17NO3
DMI452E	IC	InChI=1S/C12H17NO3/c1-9(14)13-7-3-4-10-8-11(16-2)5-6-12(10)15/h5-6,8,15H,3-4,7H2,1-2H3,(H,13,14)
DMI452E	CS	CC(=O)NCCCC1=C(C=CC(=C1)OC)O
DMI452E	IK	OMOWUWLCRNGXCM-UHFFFAOYSA-N
DMI452E	IU	N-[3-(2-hydroxy-5-methoxyphenyl)propyl]acetamide
DMI452E	DE	Discovery agent

DMW59AY	ID	DMW59AY
DMW59AY	DN	N-(3-(3-aminopropyl)phenyl)benzenesulfonamide
DMW59AY	HS	Investigative
DMW59AY	SN	CHEMBL378179; N-(3-(3-aminopropyl)phenyl)benzenesulfonamide; SCHEMBL3125892; ZINC36093367
DMW59AY	DT	Small molecular drug
DMW59AY	PC	11849197
DMW59AY	MW	290.4
DMW59AY	FM	C15H18N2O2S
DMW59AY	IC	InChI=1S/C15H18N2O2S/c16-11-5-7-13-6-4-8-14(12-13)17-20(18,19)15-9-2-1-3-10-15/h1-4,6,8-10,12,17H,5,7,11,16H2
DMW59AY	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)CCCN
DMW59AY	IK	GTXNQXVWASTZFN-UHFFFAOYSA-N
DMW59AY	IU	N-[3-(3-aminopropyl)phenyl]benzenesulfonamide
DMW59AY	DE	Discovery agent

DMXL70A	ID	DMXL70A
DMXL70A	DN	N-(3-(3-cyanobenzamido)phenyl)-2-methoxybenzamide
DMXL70A	HS	Investigative
DMXL70A	SN	CHEMBL1081367; N-(3-(3-cyanobenzamido)phenyl)-2-methoxybenzamide
DMXL70A	DT	Small molecular drug
DMXL70A	PC	46879969
DMXL70A	MW	371.4
DMXL70A	FM	C22H17N3O3
DMXL70A	IC	InChI=1S/C22H17N3O3/c1-28-20-11-3-2-10-19(20)22(27)25-18-9-5-8-17(13-18)24-21(26)16-7-4-6-15(12-16)14-23/h2-13H,1H3,(H,24,26)(H,25,27)
DMXL70A	CS	COC1=CC=CC=C1C(=O)NC2=CC=CC(=C2)NC(=O)C3=CC=CC(=C3)C#N
DMXL70A	IK	YTAQUZZUBZVOFI-UHFFFAOYSA-N
DMXL70A	IU	N-[3-[(3-cyanobenzoyl)amino]phenyl]-2-methoxybenzamide
DMXL70A	DE	Discovery agent

DMH0LOT	ID	DMH0LOT
DMH0LOT	DN	N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide
DMH0LOT	HS	Investigative
DMH0LOT	SN	CHEMBL218708; N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide; BDBM50241105; AKOS030564511
DMH0LOT	DT	Small molecular drug
DMH0LOT	PC	16094584
DMH0LOT	MW	281.3
DMH0LOT	FM	C18H19NO2
DMH0LOT	IC	InChI=1S/C18H19NO2/c1-14(20)19-12-11-18(15-7-4-3-5-8-15)16-9-6-10-17(13-16)21-2/h3-11,13H,12H2,1-2H3,(H,19,20)/b18-11+
DMH0LOT	CS	CC(=O)NC/C=C(\\C1=CC=CC=C1)/C2=CC(=CC=C2)OC
DMH0LOT	IK	SJNURYXTMIYOKB-WOJGMQOQSA-N
DMH0LOT	IU	N-[(E)-3-(3-methoxyphenyl)-3-phenylprop-2-enyl]acetamide
DMH0LOT	DE	Discovery agent

DMSZ03N	ID	DMSZ03N
DMSZ03N	DN	N-(3-(3-methoxyphenyl)propyl)acetamide
DMSZ03N	HS	Investigative
DMSZ03N	SN	N-[3-(3-methoxyphenyl)propyl]acetamide; CHEMBL50398; N-(3-(3-methoxyphenyl)propyl)acetamide; Acetamide, N-[3-(3-methoxyphenyl)propyl]-; SCHEMBL8928104; BDBM50049516; 174688-91-6
DMSZ03N	DT	Small molecular drug
DMSZ03N	PC	10750842
DMSZ03N	MW	207.27
DMSZ03N	FM	C12H17NO2
DMSZ03N	IC	InChI=1S/C12H17NO2/c1-10(14)13-8-4-6-11-5-3-7-12(9-11)15-2/h3,5,7,9H,4,6,8H2,1-2H3,(H,13,14)
DMSZ03N	CS	CC(=O)NCCCC1=CC(=CC=C1)OC
DMSZ03N	IK	LOVJFNACINEBJW-UHFFFAOYSA-N
DMSZ03N	IU	N-[3-(3-methoxyphenyl)propyl]acetamide
DMSZ03N	DE	Discovery agent

DMKSM5A	ID	DMKSM5A
DMKSM5A	DN	N-(3-(3-methoxyphenyl)propyl)propionamide
DMKSM5A	HS	Investigative
DMKSM5A	SN	CHEMBL297947; N-(3-(3-methoxyphenyl)propyl)propionamide; N-[3-(3-Methoxyphenyl)propyl]propionamide; SCHEMBL8928118; BDBM50049554; ZINC13755749
DMKSM5A	DT	Small molecular drug
DMKSM5A	PC	10104923
DMKSM5A	MW	221.29
DMKSM5A	FM	C13H19NO2
DMKSM5A	IC	InChI=1S/C13H19NO2/c1-3-13(15)14-9-5-7-11-6-4-8-12(10-11)16-2/h4,6,8,10H,3,5,7,9H2,1-2H3,(H,14,15)
DMKSM5A	CS	CCC(=O)NCCCC1=CC(=CC=C1)OC
DMKSM5A	IK	VVTCACGOXCPEPB-UHFFFAOYSA-N
DMKSM5A	IU	N-[3-(3-methoxyphenyl)propyl]propanamide
DMKSM5A	DE	Discovery agent

DMOCZVB	ID	DMOCZVB
DMOCZVB	DN	N-(3-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide
DMOCZVB	HS	Investigative
DMOCZVB	SN	CHEMBL404983
DMOCZVB	DT	Small molecular drug
DMOCZVB	PC	44450093
DMOCZVB	MW	327.4
DMOCZVB	FM	C20H25NO3
DMOCZVB	IC	InChI=1S/C20H25NO3/c1-3-4-5-6-8-16-11-12-20(19(23)13-16)24-18-10-7-9-17(14-18)21-15(2)22/h7,9-14,23H,3-6,8H2,1-2H3,(H,21,22)
DMOCZVB	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=CC(=C2)NC(=O)C)O
DMOCZVB	IK	DCPQCSKZPKBKGX-UHFFFAOYSA-N
DMOCZVB	IU	N-[3-(4-hexyl-2-hydroxyphenoxy)phenyl]acetamide
DMOCZVB	DE	Discovery agent

DMILWPS	ID	DMILWPS
DMILWPS	DN	N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide
DMILWPS	HS	Investigative
DMILWPS	SN	CHEMBL1092047; N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide
DMILWPS	DT	Small molecular drug
DMILWPS	PC	46884598
DMILWPS	MW	223.27
DMILWPS	FM	C12H17NO3
DMILWPS	IC	InChI=1S/C12H17NO3/c1-9(14)13-7-3-4-10-5-6-11(15)12(8-10)16-2/h5-6,8,15H,3-4,7H2,1-2H3,(H,13,14)
DMILWPS	CS	CC(=O)NCCCC1=CC(=C(C=C1)O)OC
DMILWPS	IK	YOLSQHAXCLGSKL-UHFFFAOYSA-N
DMILWPS	IU	N-[3-(4-hydroxy-3-methoxyphenyl)propyl]acetamide
DMILWPS	DE	Discovery agent

DMHM0WI	ID	DMHM0WI
DMHM0WI	DN	N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide
DMHM0WI	HS	Investigative
DMHM0WI	SN	CHEMBL1091894; N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide
DMHM0WI	DT	Small molecular drug
DMHM0WI	PC	46885285
DMHM0WI	MW	265.35
DMHM0WI	FM	C15H23NO3
DMHM0WI	IC	InChI=1S/C15H23NO3/c1-4-10-19-15-8-7-14(18-3)11-13(15)6-5-9-16-12(2)17/h7-8,11H,4-6,9-10H2,1-3H3,(H,16,17)
DMHM0WI	CS	CCCOC1=C(C=C(C=C1)OC)CCCNC(=O)C
DMHM0WI	IK	WEZUVBIENKYWSC-UHFFFAOYSA-N
DMHM0WI	IU	N-[3-(5-methoxy-2-propoxyphenyl)propyl]acetamide
DMHM0WI	DE	Discovery agent

DMSC862	ID	DMSC862
DMSC862	DN	N-(3-(aminomethyl)phenyl)benzenesulfonamide
DMSC862	HS	Investigative
DMSC862	SN	CHEMBL209909; N-(3-(aminomethyl)phenyl)benzenesulfonamide; N-[3-(aminomethyl)phenyl]benzenesulfonamide; CTK7E5754; BDBM50193462; ZINC22142484
DMSC862	DT	Small molecular drug
DMSC862	PC	11849791
DMSC862	MW	262.33
DMSC862	FM	C13H14N2O2S
DMSC862	IC	InChI=1S/C13H14N2O2S/c14-10-11-5-4-6-12(9-11)15-18(16,17)13-7-2-1-3-8-13/h1-9,15H,10,14H2
DMSC862	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)CN
DMSC862	IK	RMWBQRLIFOIUFM-UHFFFAOYSA-N
DMSC862	IU	N-[3-(aminomethyl)phenyl]benzenesulfonamide
DMSC862	DE	Discovery agent

DMSJX1H	ID	DMSJX1H
DMSJX1H	DN	N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide
DMSJX1H	HS	Investigative
DMSJX1H	SN	CHEMBL224122; N-(3-phenylsulfanyl-4-pyridinyl)methanesulfonamide; 833455-58-6; N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide; CTK3D2868; DTXSID10466638; BDBM50158452; Methanesulfonamide, N-[3-(phenylthio)-4-pyridinyl]-
DMSJX1H	DT	Small molecular drug
DMSJX1H	PC	11460185
DMSJX1H	MW	280.4
DMSJX1H	FM	C12H12N2O2S2
DMSJX1H	IC	InChI=1S/C12H12N2O2S2/c1-18(15,16)14-11-7-8-13-9-12(11)17-10-5-3-2-4-6-10/h2-9H,1H3,(H,13,14)
DMSJX1H	CS	CS(=O)(=O)NC1=C(C=NC=C1)SC2=CC=CC=C2
DMSJX1H	IK	SQQJATJQZCRBEZ-UHFFFAOYSA-N
DMSJX1H	IU	N-(3-phenylsulfanylpyridin-4-yl)methanesulfonamide
DMSJX1H	CA	CAS 833455-58-6
DMSJX1H	DE	Discovery agent

DM6UC8Y	ID	DM6UC8Y
DM6UC8Y	DN	N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide
DM6UC8Y	HS	Investigative
DM6UC8Y	SN	CHEMBL198832; N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide
DM6UC8Y	DT	Small molecular drug
DM6UC8Y	PC	44405454
DM6UC8Y	MW	387.4
DM6UC8Y	FM	C21H16F3NO3
DM6UC8Y	IC	InChI=1S/C21H16F3NO3/c22-21(23,24)28-19-8-4-5-15(13-19)14-25-20(26)16-9-11-18(12-10-16)27-17-6-2-1-3-7-17/h1-13H,14H2,(H,25,26)
DM6UC8Y	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC(=CC=C3)OC(F)(F)F
DM6UC8Y	IK	CPWFANWMCRGXMG-UHFFFAOYSA-N
DM6UC8Y	IU	4-phenoxy-N-[[3-(trifluoromethoxy)phenyl]methyl]benzamide
DM6UC8Y	DE	Discovery agent

DMSMRF9	ID	DMSMRF9
DMSMRF9	DN	N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMSMRF9	HS	Investigative
DMSMRF9	SN	CHEMBL198563; N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMSMRF9	DT	Small molecular drug
DMSMRF9	PC	11703439
DMSMRF9	MW	371.4
DMSMRF9	FM	C21H16F3NO2
DMSMRF9	IC	InChI=1S/C21H16F3NO2/c22-21(23,24)17-6-4-5-15(13-17)14-25-20(26)16-9-11-19(12-10-16)27-18-7-2-1-3-8-18/h1-13H,14H2,(H,25,26)
DMSMRF9	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC(=CC=C3)C(F)(F)F
DMSMRF9	IK	FWPNYHMMZRISQJ-UHFFFAOYSA-N
DMSMRF9	IU	4-phenoxy-N-[[3-(trifluoromethyl)phenyl]methyl]benzamide
DMSMRF9	DE	Discovery agent

DM2Y5AP	ID	DM2Y5AP
DM2Y5AP	DN	N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide
DM2Y5AP	HS	Investigative
DM2Y5AP	SN	CHEMBL122341; N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide; ZINC13864671; BDBM50106166
DM2Y5AP	DT	Small molecular drug
DM2Y5AP	PC	10979664
DM2Y5AP	MW	305.5
DM2Y5AP	FM	C19H31NO2
DM2Y5AP	IC	InChI=1S/C19H31NO2/c1-5-6-7-8-15-22-17-11-9-16(10-12-17)18(21)20-14-13-19(2,3)4/h9-12H,5-8,13-15H2,1-4H3,(H,20,21)
DM2Y5AP	CS	CCCCCCOC1=CC=C(C=C1)C(=O)NCCC(C)(C)C
DM2Y5AP	IK	JPQPUSQXWSSOFH-UHFFFAOYSA-N
DM2Y5AP	IU	N-(3,3-dimethylbutyl)-4-hexoxybenzamide
DM2Y5AP	DE	Discovery agent

DMEUXOQ	ID	DMEUXOQ
DMEUXOQ	DN	N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide
DMEUXOQ	HS	Investigative
DMEUXOQ	SN	CHEMBL431682; N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide; SCHEMBL7214961; BDBM50106177
DMEUXOQ	DT	Small molecular drug
DMEUXOQ	PC	11023651
DMEUXOQ	MW	320.4
DMEUXOQ	FM	C21H24N2O
DMEUXOQ	IC	InChI=1S/C21H24N2O/c1-21(2,3)13-14-22-20(24)17-8-10-18(11-9-17)23-15-12-16-6-4-5-7-19(16)23/h4-12,15H,13-14H2,1-3H3,(H,22,24)
DMEUXOQ	CS	CC(C)(C)CCNC(=O)C1=CC=C(C=C1)N2C=CC3=CC=CC=C32
DMEUXOQ	IK	WFFDNQLEAMWQBV-UHFFFAOYSA-N
DMEUXOQ	IU	N-(3,3-dimethylbutyl)-4-indol-1-ylbenzamide
DMEUXOQ	DE	Discovery agent

DM6EJQ4	ID	DM6EJQ4
DM6EJQ4	DN	N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide
DM6EJQ4	HS	Investigative
DM6EJQ4	SN	CHEMBL121751; N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide; SCHEMBL7219320; BDBM50106184
DM6EJQ4	DT	Small molecular drug
DM6EJQ4	PC	10870843
DM6EJQ4	MW	317.5
DM6EJQ4	FM	C20H31NO2
DM6EJQ4	IC	InChI=1S/C20H31NO2/c1-4-5-6-7-14-23-18-10-8-16(9-11-18)19(22)21-17-12-13-20(2,3)15-17/h8-11,17H,4-7,12-15H2,1-3H3,(H,21,22)
DM6EJQ4	CS	CCCCCCOC1=CC=C(C=C1)C(=O)NC2CCC(C2)(C)C
DM6EJQ4	IK	SPDGMSMRHOXECU-UHFFFAOYSA-N
DM6EJQ4	IU	N-(3,3-dimethylcyclopentyl)-4-hexoxybenzamide
DM6EJQ4	DE	Discovery agent

DMAXLVQ	ID	DMAXLVQ
DMAXLVQ	DN	N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide
DMAXLVQ	HS	Investigative
DMAXLVQ	SN	CHEMBL476529; N-(3,3-diphenylpropyl)-2,2-diphenylacetamide; N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide; AC1N5W5U; Oprea1_456266; ZINC3166084; BDBM50263033; AKOS003236993; MCULE-9181870252; ST45008037; SR-01000512723
DMAXLVQ	DT	Small molecular drug
DMAXLVQ	PC	4225440
DMAXLVQ	MW	405.5
DMAXLVQ	FM	C29H27NO
DMAXLVQ	IC	InChI=1S/C29H27NO/c31-29(28(25-17-9-3-10-18-25)26-19-11-4-12-20-26)30-22-21-27(23-13-5-1-6-14-23)24-15-7-2-8-16-24/h1-20,27-28H,21-22H2,(H,30,31)
DMAXLVQ	CS	C1=CC=C(C=C1)C(CCNC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMAXLVQ	IK	LMRDWMVRJNJYIQ-UHFFFAOYSA-N
DMAXLVQ	IU	N-(3,3-diphenylpropyl)-2,2-diphenylacetamide
DMAXLVQ	DE	Discovery agent

DMBX0K1	ID	DMBX0K1
DMBX0K1	DN	N-(3,3-Diphenyl)propyl-2-phenylacetamide
DMBX0K1	HS	Investigative
DMBX0K1	SN	N-(3,3-diphenylpropyl)-2-phenylacetamide; CHEMBL502133; AC1LPTMM; N-(3,3-Diphenyl)propyl-2-phenylacetamide; MolPort-001-541-705; ZINC1115339; STK439151; BDBM50263154; AKOS003282986; MCULE-4189132608; ST50924105
DMBX0K1	DT	Small molecular drug
DMBX0K1	PC	1293167
DMBX0K1	MW	329.4
DMBX0K1	FM	C23H23NO
DMBX0K1	IC	InChI=1S/C23H23NO/c25-23(18-19-10-4-1-5-11-19)24-17-16-22(20-12-6-2-7-13-20)21-14-8-3-9-15-21/h1-15,22H,16-18H2,(H,24,25)
DMBX0K1	CS	C1=CC=C(C=C1)CC(=O)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
DMBX0K1	IK	JFOKDVSVRVUJTI-UHFFFAOYSA-N
DMBX0K1	IU	N-(3,3-diphenylpropyl)-2-phenylacetamide
DMBX0K1	DE	Discovery agent

DM4PTR3	ID	DM4PTR3
DM4PTR3	DN	N-(3,3-Diphenyl-propyl)-2-pyridine-3-ylacetamide
DM4PTR3	HS	Investigative
DM4PTR3	SN	CHEMBL563527; N-(3,3-Diphenyl-propyl)-2-pyridine-3-ylacetamide; SCHEMBL4619635
DM4PTR3	DT	Small molecular drug
DM4PTR3	PC	11976254
DM4PTR3	MW	330.4
DM4PTR3	FM	C22H22N2O
DM4PTR3	IC	InChI=1S/C22H22N2O/c25-22(16-18-8-7-14-23-17-18)24-15-13-21(19-9-3-1-4-10-19)20-11-5-2-6-12-20/h1-12,14,17,21H,13,15-16H2,(H,24,25)
DM4PTR3	CS	C1=CC=C(C=C1)C(CCNC(=O)CC2=CN=CC=C2)C3=CC=CC=C3
DM4PTR3	IK	FNEXDTNOFQXKRJ-UHFFFAOYSA-N
DM4PTR3	IU	N-(3,3-diphenylpropyl)-2-pyridin-3-ylacetamide
DM4PTR3	DE	Discovery agent

DMOXR4K	ID	DMOXR4K
DMOXR4K	DN	N-(3,3-Diphenyl-propyl)-isonicotinamide
DMOXR4K	HS	Investigative
DMOXR4K	SN	CHEMBL571898; N-(3,3-diphenylpropyl)pyridine-4-carboxamide; N-(3,3-Diphenyl-propyl)-isonicotinamide; AC1NQBE3; SCHEMBL5948064; MolPort-003-323-378; ZINC5509004; STK483446; BDBM50297397; AKOS001272797; MCULE-6529824249; ST50922884
DMOXR4K	DT	Small molecular drug
DMOXR4K	PC	5193384
DMOXR4K	MW	316.4
DMOXR4K	FM	C21H20N2O
DMOXR4K	IC	InChI=1S/C21H20N2O/c24-21(19-11-14-22-15-12-19)23-16-13-20(17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-12,14-15,20H,13,16H2,(H,23,24)
DMOXR4K	CS	C1=CC=C(C=C1)C(CCNC(=O)C2=CC=NC=C2)C3=CC=CC=C3
DMOXR4K	IK	FNZXNCPUNGHMCJ-UHFFFAOYSA-N
DMOXR4K	IU	N-(3,3-diphenylpropyl)pyridine-4-carboxamide
DMOXR4K	DE	Discovery agent

DMDYZ9K	ID	DMDYZ9K
DMDYZ9K	DN	N-(3,3-diphenyl-propyl)-nicotinamide
DMDYZ9K	HS	Investigative
DMDYZ9K	SN	N-(3,3-diphenyl-propyl)-nicotinamide; N-(3,3-diphenylpropyl)pyridine-3-carboxamide; CHEMBL560537; N-(3,3-Diphenylpropyl)Nicotinamide; 3i1y; AC1MS8VU; Oprea1_527290; Oprea1_467641; SCHEMBL5947875; AC1Q5P23; MolPort-001-843-393; ZINC4401896; STK414850; BDBM50297413; AKOS000975778; MCULE-6217519118; ST45002043; N-(3,3-diphenylpropyl)-3-pyridylcarboxamide; SR-01000509857; SR-01000509857-1
DMDYZ9K	DT	Small molecular drug
DMDYZ9K	PC	3530525
DMDYZ9K	MW	316.4
DMDYZ9K	FM	C21H20N2O
DMDYZ9K	IC	InChI=1S/C21H20N2O/c24-21(19-12-7-14-22-16-19)23-15-13-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-12,14,16,20H,13,15H2,(H,23,24)
DMDYZ9K	CS	C1=CC=C(C=C1)C(CCNC(=O)C2=CN=CC=C2)C3=CC=CC=C3
DMDYZ9K	IK	GDHXZIQAOUBZCC-UHFFFAOYSA-N
DMDYZ9K	IU	N-(3,3-diphenylpropyl)pyridine-3-carboxamide
DMDYZ9K	CA	CAS 303064-42-8
DMDYZ9K	DE	Discovery agent

DMQ5USA	ID	DMQ5USA
DMQ5USA	DN	N-(3,4,5-trihydroxyphenethyl)oleamide
DMQ5USA	HS	Investigative
DMQ5USA	SN	N-(3,4,5-trihydroxyphenethyl)oleamide; CHEMBL251733
DMQ5USA	DT	Small molecular drug
DMQ5USA	PC	23661707
DMQ5USA	MW	433.6
DMQ5USA	FM	C26H43NO4
DMQ5USA	IC	InChI=1S/C26H43NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-25(30)27-19-18-22-20-23(28)26(31)24(29)21-22/h9-10,20-21,28-29,31H,2-8,11-19H2,1H3,(H,27,30)/b10-9-
DMQ5USA	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=CC(=C(C(=C1)O)O)O
DMQ5USA	IK	MGJONYQVBJKXRL-KTKRTIGZSA-N
DMQ5USA	IU	(Z)-N-[2-(3,4,5-trihydroxyphenyl)ethyl]octadec-9-enamide
DMQ5USA	DE	Discovery agent

DMTERF6	ID	DMTERF6
DMTERF6	DN	N-(3,4-Dichlorophenyl)propyl-ETAV
DMTERF6	HS	Investigative
DMTERF6	SN	N-(3,4-Dichlorophenyl)propyl-ETAV; CHEMBL495100
DMTERF6	DT	Small molecular drug
DMTERF6	PC	44568811
DMTERF6	MW	591.5
DMTERF6	FM	C25H36Cl2N4O8
DMTERF6	IC	InChI=1S/C25H36Cl2N4O8/c1-12(2)20(25(38)39)30-22(35)13(3)29-24(37)21(14(4)32)31-23(36)18(7-8-19(33)34)28-10-9-15-5-6-16(26)17(27)11-15/h5-6,11-14,18,20-21,28,32H,7-10H2,1-4H3,(H,29,37)(H,30,35)(H,31,36)(H,33,34)(H,38,39)/t13-,14?,18-,20-,21-/m0/s1
DMTERF6	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCC1=CC(=C(C=C1)Cl)Cl
DMTERF6	IK	QVZKLLUMEYWUMT-WHJBMRRRSA-N
DMTERF6	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-[2-(3,4-dichlorophenyl)ethylamino]-5-oxopentanoic acid
DMTERF6	DE	Discovery agent

DMF2D4O	ID	DMF2D4O
DMF2D4O	DN	N-(3,4-Difluorophenyl)propyl-ETAV
DMF2D4O	HS	Investigative
DMF2D4O	SN	N-(3,4-Difluorophenyl)propyl-ETAV; CHEMBL538410
DMF2D4O	DT	Small molecular drug
DMF2D4O	PC	44568812
DMF2D4O	MW	558.6
DMF2D4O	FM	C25H36F2N4O8
DMF2D4O	IC	InChI=1S/C25H36F2N4O8/c1-12(2)20(25(38)39)30-22(35)13(3)29-24(37)21(14(4)32)31-23(36)18(7-8-19(33)34)28-10-9-15-5-6-16(26)17(27)11-15/h5-6,11-14,18,20-21,28,32H,7-10H2,1-4H3,(H,29,37)(H,30,35)(H,31,36)(H,33,34)(H,38,39)/t13-,14?,18-,20-,21-/m0/s1
DMF2D4O	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCC1=CC(=C(C=C1)F)F
DMF2D4O	IK	VPSVLXPCERTAAH-WHJBMRRRSA-N
DMF2D4O	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-[2-(3,4-difluorophenyl)ethylamino]-5-oxopentanoic acid
DMF2D4O	DE	Discovery agent

DM67XSW	ID	DM67XSW
DM67XSW	DN	N-(3,4-dihydroxybenzyl)oleamide
DM67XSW	HS	Investigative
DM67XSW	SN	CHEMBL403034; N-(3,4-dihydroxybenzyl)oleamide; SCHEMBL10713028
DM67XSW	DT	Small molecular drug
DM67XSW	PC	44454145
DM67XSW	MW	403.6
DM67XSW	FM	C25H41NO3
DM67XSW	IC	InChI=1S/C25H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-25(29)26-21-22-18-19-23(27)24(28)20-22/h9-10,18-20,27-28H,2-8,11-17,21H2,1H3,(H,26,29)/b10-9-
DM67XSW	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCC1=CC(=C(C=C1)O)O
DM67XSW	IK	DMFNZWDAFAVBIA-KTKRTIGZSA-N
DM67XSW	IU	(Z)-N-[(3,4-dihydroxyphenyl)methyl]octadec-9-enamide
DM67XSW	DE	Discovery agent

DMEP2VM	ID	DMEP2VM
DMEP2VM	DN	N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide
DMEP2VM	HS	Investigative
DMEP2VM	SN	CHEMBL1093359; BDBM50314135
DMEP2VM	DT	Small molecular drug
DMEP2VM	PC	45141959
DMEP2VM	MW	292.37
DMEP2VM	FM	C16H24N2O3
DMEP2VM	IC	InChI=1S/C16H24N2O3/c1-12-9-10-14(11-13(12)2)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-11,21H,3-8H2,1-2H3,(H,17,19)(H,18,20)
DMEP2VM	CS	CC1=C(C=C(C=C1)NC(=O)CCCCCCC(=O)NO)C
DMEP2VM	IK	NJRGPRXJOLGSNN-UHFFFAOYSA-N
DMEP2VM	IU	N-(3,4-dimethylphenyl)-N'-hydroxyoctanediamide
DMEP2VM	DE	Discovery agent

DM9B1ID	ID	DM9B1ID
DM9B1ID	DN	N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide
DM9B1ID	HS	Investigative
DM9B1ID	SN	N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide; 331846-06-1; benzamide compound 3; AC1LGPDD; Asinex compound no. 6; Oprea1_295970; Oprea1_049304; CHEMBL217893; SCHEMBL18120561; CTK1B1898; BDBM14711; DTXSID50355395; MolPort-001-496-487; ZINC304714; STK020274; AKOS003270080; MCULE-1240652686; ST50693254; Benzamide, N-(3,5-dichlorophenyl)-2-methyl-3-nitro-; N-(3,5-dichlorophenyl)(2-methyl-3-nitrophenyl)carboxamide
DM9B1ID	DT	Small molecular drug
DM9B1ID	PC	799096
DM9B1ID	MW	325.1
DM9B1ID	FM	C14H10Cl2N2O3
DM9B1ID	IC	InChI=1S/C14H10Cl2N2O3/c1-8-12(3-2-4-13(8)18(20)21)14(19)17-11-6-9(15)5-10(16)7-11/h2-7H,1H3,(H,17,19)
DM9B1ID	CS	CC1=C(C=CC=C1[N+](=O)[O-])C(=O)NC2=CC(=CC(=C2)Cl)Cl
DM9B1ID	IK	NKIJNFMSYDSAJK-UHFFFAOYSA-N
DM9B1ID	IU	N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide
DM9B1ID	CA	CAS 331846-06-1
DM9B1ID	DE	Discovery agent

DMDNUCL	ID	DMDNUCL
DMDNUCL	DN	N-(3,5-dichlorophenyl)-2-nitrobenzamide
DMDNUCL	HS	Investigative
DMDNUCL	SN	N-(3,5-dichlorophenyl)-2-nitrobenzamide; CHEMBL564612; AC1LEFLS; AC1Q1WV0; Oprea1_875451; Oprea1_856946; ZINC103151; BDBM50297529; AKOS002518902; MCULE-6306742768; ST011167; KB-101427
DMDNUCL	DT	Small molecular drug
DMDNUCL	PC	711431
DMDNUCL	MW	311.12
DMDNUCL	FM	C13H8Cl2N2O3
DMDNUCL	IC	InChI=1S/C13H8Cl2N2O3/c14-8-5-9(15)7-10(6-8)16-13(18)11-3-1-2-4-12(11)17(19)20/h1-7H,(H,16,18)
DMDNUCL	CS	C1=CC=C(C(=C1)C(=O)NC2=CC(=CC(=C2)Cl)Cl)[N+](=O)[O-]
DMDNUCL	IK	RHMRIXDZQJDDKE-UHFFFAOYSA-N
DMDNUCL	IU	N-(3,5-dichlorophenyl)-2-nitrobenzamide
DMDNUCL	CA	CAS 316142-28-6
DMDNUCL	DE	Discovery agent

DM8DAGL	ID	DM8DAGL
DM8DAGL	DN	N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DM8DAGL	HS	Investigative
DM8DAGL	SN	N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide; CHEMBL560684; AC1LEFV7; AC1Q44SN; MolPort-001-508-011; ZINC103353; STK082881; BDBM50297552; AKOS003266964; MCULE-2399924405; ST011242; AG-690/12072790; N-(3,5-dichlorophenyl)-3-nitro-4-(methyloxy)benzamide
DM8DAGL	DT	Small molecular drug
DM8DAGL	PC	711547
DM8DAGL	MW	341.1
DM8DAGL	FM	C14H10Cl2N2O4
DM8DAGL	IC	InChI=1S/C14H10Cl2N2O4/c1-22-13-3-2-8(4-12(13)18(20)21)14(19)17-11-6-9(15)5-10(16)7-11/h2-7H,1H3,(H,17,19)
DM8DAGL	CS	COC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)Cl)Cl)[N+](=O)[O-]
DM8DAGL	IK	BDZYJQMEFCDSIR-UHFFFAOYSA-N
DM8DAGL	IU	N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DM8DAGL	DE	Discovery agent

DMQ0LF2	ID	DMQ0LF2
DMQ0LF2	DN	N-(3,5-dichlorophenyl)imidodicarbonimidic diamide
DMQ0LF2	HS	Investigative
DMQ0LF2	SN	N-(3,5-dichlorophenyl)imidodicarbonimidic diamide; CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01
DMQ0LF2	DT	Small molecular drug
DMQ0LF2	PC	558969
DMQ0LF2	MW	246.09
DMQ0LF2	FM	C8H9Cl2N5
DMQ0LF2	IC	InChI=1S/C8H9Cl2N5/c9-4-1-5(10)3-6(2-4)14-8(13)15-7(11)12/h1-3H,(H6,11,12,13,14,15)
DMQ0LF2	CS	C1=C(C=C(C=C1Cl)Cl)N=C(N)N=C(N)N
DMQ0LF2	IK	BUXACHZAYWAZJL-UHFFFAOYSA-N
DMQ0LF2	IU	1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine
DMQ0LF2	CA	CAS 1672-93-1
DMQ0LF2	DE	Discovery agent

DM95SJU	ID	DM95SJU
DM95SJU	DN	N-(3,5-dimethoxyphenethyl)docos-13-enamide
DM95SJU	HS	Investigative
DM95SJU	SN	CHEMBL199870; N-(3,5-dimethoxyphenethyl)docos-13-enamide
DM95SJU	DT	Small molecular drug
DM95SJU	PC	44406087
DM95SJU	MW	501.8
DM95SJU	FM	C32H55NO3
DM95SJU	IC	InChI=1S/C32H55NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-32(34)33-25-24-29-26-30(35-2)28-31(27-29)36-3/h11-12,26-28H,4-10,13-25H2,1-3H3,(H,33,34)/b12-11-
DM95SJU	CS	CCCCCCCC/C=C\\CCCCCCCCCCCC(=O)NCCC1=CC(=CC(=C1)OC)OC
DM95SJU	IK	WGUQNXILGCVNIV-QXMHVHEDSA-N
DM95SJU	IU	(Z)-N-[2-(3,5-dimethoxyphenyl)ethyl]docos-13-enamide
DM95SJU	DE	Discovery agent

DM1C40H	ID	DM1C40H
DM1C40H	DN	N-(3,5-dimethoxyphenethyl)oleamide
DM1C40H	HS	Investigative
DM1C40H	SN	N-(3,5-dimethoxyphenethyl)oleamide; CHEMBL199402
DM1C40H	DT	Small molecular drug
DM1C40H	PC	44406076
DM1C40H	MW	445.7
DM1C40H	FM	C28H47NO3
DM1C40H	IC	InChI=1S/C28H47NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(30)29-21-20-25-22-26(31-2)24-27(23-25)32-3/h11-12,22-24H,4-10,13-21H2,1-3H3,(H,29,30)/b12-11-
DM1C40H	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=CC(=CC(=C1)OC)OC
DM1C40H	IK	HOCMLWROGBYBPA-QXMHVHEDSA-N
DM1C40H	IU	(Z)-N-[2-(3,5-dimethoxyphenyl)ethyl]octadec-9-enamide
DM1C40H	DE	Discovery agent

DM43QHV	ID	DM43QHV
DM43QHV	DN	N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide
DM43QHV	HS	Investigative
DM43QHV	SN	CHEMBL558660; N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide
DM43QHV	DT	Small molecular drug
DM43QHV	PC	45272830
DM43QHV	MW	316.31
DM43QHV	FM	C16H16N2O5
DM43QHV	IC	InChI=1S/C16H16N2O5/c1-10-4-5-14(15(6-10)18(20)21)16(19)17-11-7-12(22-2)9-13(8-11)23-3/h4-9H,1-3H3,(H,17,19)
DM43QHV	CS	CC1=CC(=C(C=C1)C(=O)NC2=CC(=CC(=C2)OC)OC)[N+](=O)[O-]
DM43QHV	IK	GFSKVJZKSAGFJY-UHFFFAOYSA-N
DM43QHV	IU	N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide
DM43QHV	DE	Discovery agent

DM1L3FM	ID	DM1L3FM
DM1L3FM	DN	N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide
DM1L3FM	HS	Investigative
DM1L3FM	SN	CHEMBL1093713; BDBM50314133
DM1L3FM	DT	Small molecular drug
DM1L3FM	PC	45141960
DM1L3FM	MW	292.37
DM1L3FM	FM	C16H24N2O3
DM1L3FM	IC	InChI=1S/C16H24N2O3/c1-12-9-13(2)11-14(10-12)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-11,21H,3-8H2,1-2H3,(H,17,19)(H,18,20)
DM1L3FM	CS	CC1=CC(=CC(=C1)NC(=O)CCCCCCC(=O)NO)C
DM1L3FM	IK	PWVUDHKPAQOCJC-UHFFFAOYSA-N
DM1L3FM	IU	N-(3,5-dimethylphenyl)-N'-hydroxyoctanediamide
DM1L3FM	DE	Discovery agent

DMH3R21	ID	DMH3R21
DMH3R21	DN	N-(3-acetamidophenyl)-3-chlorobenzamide
DMH3R21	HS	Investigative
DMH3R21	SN	N-(3-acetamidophenyl)-3-chlorobenzamide; CHEMBL1080810; N-[3-(acetylamino)phenyl]-3-chlorobenzamide; 3-chloro-N-(3-acetamidophenyl)benzamide; AC1LDLQ1; AC1Q1KO6; Cambridge id 5554516; Oprea1_130541; Oprea1_356143; MLS002699912; CHEBI:93070; ZINC29723; MolPort-001-508-240; STK036460; BDBM50312136; AKOS001296542; MCULE-8869105852; 312632-92-1; ST042764; SMR001530668; EU-0002463; AB00088853-01; SR-01000407944; SR-01000407944-1; N-{3-[(3-chlorophenyl)carbonylamino]phenyl}acetamide; Z28281866
DMH3R21	DT	Small molecular drug
DMH3R21	PC	669190
DMH3R21	MW	288.73
DMH3R21	FM	C15H13ClN2O2
DMH3R21	IC	InChI=1S/C15H13ClN2O2/c1-10(19)17-13-6-3-7-14(9-13)18-15(20)11-4-2-5-12(16)8-11/h2-9H,1H3,(H,17,19)(H,18,20)
DMH3R21	CS	CC(=O)NC1=CC(=CC=C1)NC(=O)C2=CC(=CC=C2)Cl
DMH3R21	IK	XZMOBKLRYXTSSS-UHFFFAOYSA-N
DMH3R21	IU	N-(3-acetamidophenyl)-3-chlorobenzamide
DMH3R21	CB	CHEBI:93070
DMH3R21	DE	Discovery agent

DMYJB1A	ID	DMYJB1A
DMYJB1A	DN	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide
DMYJB1A	HS	Investigative
DMYJB1A	SN	CHEMBL1097746; BDBM50317992
DMYJB1A	DT	Small molecular drug
DMYJB1A	PC	46887437
DMYJB1A	MW	330.4
DMYJB1A	FM	C21H18N2O2
DMYJB1A	IC	InChI=1S/C21H18N2O2/c1-14(24)16-8-5-9-17(12-16)18-10-11-19(22)20(13-18)23-21(25)15-6-3-2-4-7-15/h2-13H,22H2,1H3,(H,23,25)
DMYJB1A	CS	CC(=O)C1=CC=CC(=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMYJB1A	IK	CJDOOJYNFYUEAC-UHFFFAOYSA-N
DMYJB1A	IU	N-[5-(3-acetylphenyl)-2-aminophenyl]benzamide
DMYJB1A	DE	Discovery agent

DMJ6FP7	ID	DMJ6FP7
DMJ6FP7	DN	N-(3-aminophenyl)benzenesulfonamide
DMJ6FP7	HS	Investigative
DMJ6FP7	SN	N-(3-aminophenyl)benzenesulfonamide; 104997-09-3; Benzenesulfonamide, N-(3-aminophenyl)-; CHEMBL378618; ACMC-20f7rf; 3-phenylsulfonamidoaniline; AC1Q51QH; 3-benzenesulfonylaminoaniline; SCHEMBL2723618; CTK0G5849; DTXSID40474387; MolPort-004-296-827; RUYQFOIEMVGGQT-UHFFFAOYSA-N; ZINC22145186; BDBM50193461; AKOS000132984; NE22031; ACN-049935; MCULE-1854488236; EN300-40178; A839866
DMJ6FP7	DT	Small molecular drug
DMJ6FP7	PC	11849198
DMJ6FP7	MW	248.3
DMJ6FP7	FM	C12H12N2O2S
DMJ6FP7	IC	InChI=1S/C12H12N2O2S/c13-10-5-4-6-11(9-10)14-17(15,16)12-7-2-1-3-8-12/h1-9,14H,13H2
DMJ6FP7	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)N
DMJ6FP7	IK	RUYQFOIEMVGGQT-UHFFFAOYSA-N
DMJ6FP7	IU	N-(3-aminophenyl)benzenesulfonamide
DMJ6FP7	CA	CAS 104997-09-3
DMJ6FP7	DE	Discovery agent

DMYSURL	ID	DMYSURL
DMYSURL	DN	N-(3-Benzooxazol-7-yl-propyl)-acetamide
DMYSURL	HS	Investigative
DMYSURL	SN	CHEMBL124488; N-(3-Benzooxazol-7-yl-propyl)-acetamide; SCHEMBL6787351
DMYSURL	DT	Small molecular drug
DMYSURL	PC	22718532
DMYSURL	MW	218.25
DMYSURL	FM	C12H14N2O2
DMYSURL	IC	InChI=1S/C12H14N2O2/c1-9(15)13-7-3-5-10-4-2-6-11-12(10)16-8-14-11/h2,4,6,8H,3,5,7H2,1H3,(H,13,15)
DMYSURL	CS	CC(=O)NCCCC1=C2C(=CC=C1)N=CO2
DMYSURL	IK	UVCQHPPYUDDOEQ-UHFFFAOYSA-N
DMYSURL	IU	N-[3-(1,3-benzoxazol-7-yl)propyl]acetamide
DMYSURL	DE	Discovery agent

DMKMESD	ID	DMKMESD
DMKMESD	DN	N-(3-Benzooxazol-7-yl-propyl)-butyramide
DMKMESD	HS	Investigative
DMKMESD	SN	CHEMBL124914; N-(3-Benzooxazol-7-yl-propyl)-butyramide
DMKMESD	DT	Small molecular drug
DMKMESD	PC	44349108
DMKMESD	MW	246.3
DMKMESD	FM	C14H18N2O2
DMKMESD	IC	InChI=1S/C14H18N2O2/c1-2-5-13(17)15-9-4-7-11-6-3-8-12-14(11)18-10-16-12/h3,6,8,10H,2,4-5,7,9H2,1H3,(H,15,17)
DMKMESD	CS	CCCC(=O)NCCCC1=C2C(=CC=C1)N=CO2
DMKMESD	IK	ADFZAUSXPZLXMN-UHFFFAOYSA-N
DMKMESD	IU	N-[3-(1,3-benzoxazol-7-yl)propyl]butanamide
DMKMESD	DE	Discovery agent

DMEMYS1	ID	DMEMYS1
DMEMYS1	DN	N-(3-Benzooxazol-7-yl-propyl)-propionamide
DMEMYS1	HS	Investigative
DMEMYS1	SN	CHEMBL124476; N-(3-Benzooxazol-7-yl-propyl)-propionamide; SCHEMBL6780633
DMEMYS1	DT	Small molecular drug
DMEMYS1	PC	22718564
DMEMYS1	MW	232.28
DMEMYS1	FM	C13H16N2O2
DMEMYS1	IC	InChI=1S/C13H16N2O2/c1-2-12(16)14-8-4-6-10-5-3-7-11-13(10)17-9-15-11/h3,5,7,9H,2,4,6,8H2,1H3,(H,14,16)
DMEMYS1	CS	CCC(=O)NCCCC1=C2C(=CC=C1)N=CO2
DMEMYS1	IK	KCCKMLVZBSMOBW-UHFFFAOYSA-N
DMEMYS1	IU	N-[3-(1,3-benzoxazol-7-yl)propyl]propanamide
DMEMYS1	DE	Discovery agent

DMOQ08F	ID	DMOQ08F
DMOQ08F	DN	N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide
DMOQ08F	HS	Investigative
DMOQ08F	SN	CHEMBL186746; ZINC16740683
DMOQ08F	DT	Small molecular drug
DMOQ08F	PC	11245786
DMOQ08F	MW	374.64
DMOQ08F	FM	C13H9BrClNO3S
DMOQ08F	IC	InChI=1S/C13H9BrClNO3S/c14-10-3-1-2-9(8-10)13(17)16-20(18,19)12-6-4-11(15)5-7-12/h1-8H,(H,16,17)
DMOQ08F	CS	C1=CC(=CC(=C1)Br)C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl
DMOQ08F	IK	PCSRHSZMCDEYGU-UHFFFAOYSA-N
DMOQ08F	IU	3-bromo-N-(4-chlorophenyl)sulfonylbenzamide
DMOQ08F	DE	Discovery agent

DM0Z1HJ	ID	DM0Z1HJ
DM0Z1HJ	DN	N-(3-Bromophenyl)-5-methoxybenzo[d]oxazol-2-amine
DM0Z1HJ	HS	Investigative
DM0Z1HJ	SN	CHEMBL1269727; N-(3-Bromophenyl)-5-methoxybenzo[d]oxazol-2-amine
DM0Z1HJ	DT	Small molecular drug
DM0Z1HJ	PC	16117936
DM0Z1HJ	MW	319.15
DM0Z1HJ	FM	C14H11BrN2O2
DM0Z1HJ	IC	InChI=1S/C14H11BrN2O2/c1-18-11-5-6-13-12(8-11)17-14(19-13)16-10-4-2-3-9(15)7-10/h2-8H,1H3,(H,16,17)
DM0Z1HJ	CS	COC1=CC2=C(C=C1)OC(=N2)NC3=CC(=CC=C3)Br
DM0Z1HJ	IK	ACSVVIUPZPFHSQ-UHFFFAOYSA-N
DM0Z1HJ	IU	N-(3-bromophenyl)-5-methoxy-1,3-benzoxazol-2-amine
DM0Z1HJ	DE	Discovery agent

DMEWQCN	ID	DMEWQCN
DMEWQCN	DN	N-(3-bromophenyl)-6-chloroquinazolin-4-amine
DMEWQCN	HS	Investigative
DMEWQCN	SN	CHEMBL1075626; N-(3-bromophenyl)-6-chloroquinazolin-4-amine; SCHEMBL4586988; BDBM50311876
DMEWQCN	DT	Small molecular drug
DMEWQCN	PC	11056756
DMEWQCN	MW	334.6
DMEWQCN	FM	C14H9BrClN3
DMEWQCN	IC	InChI=1S/C14H9BrClN3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DMEWQCN	CS	C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=C(C=C3)Cl
DMEWQCN	IK	NBEFPXHBLZGXNK-UHFFFAOYSA-N
DMEWQCN	IU	N-(3-bromophenyl)-6-chloroquinazolin-4-amine
DMEWQCN	DE	Discovery agent

DMRIK7P	ID	DMRIK7P
DMRIK7P	DN	N-(3-bromophenyl)-6-fluoroquinazolin-4-amine
DMRIK7P	HS	Investigative
DMRIK7P	SN	CHEMBL1076333; N-(3-bromophenyl)-6-fluoroquinazolin-4-amine; BDBM50311858
DMRIK7P	DT	Small molecular drug
DMRIK7P	PC	45375910
DMRIK7P	MW	318.14
DMRIK7P	FM	C14H9BrFN3
DMRIK7P	IC	InChI=1S/C14H9BrFN3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DMRIK7P	CS	C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=C(C=C3)F
DMRIK7P	IK	FQRFQQLJZXACCG-UHFFFAOYSA-N
DMRIK7P	IU	N-(3-bromophenyl)-6-fluoroquinazolin-4-amine
DMRIK7P	DE	Discovery agent

DME6IKT	ID	DME6IKT
DME6IKT	DN	N-(3-Chloro-phenyl)-2-cyclohexyl-acetamide
DME6IKT	HS	Investigative
DME6IKT	SN	CHEMBL192470; N-(3-Chloro-phenyl)-2-cyclohexyl-acetamide; SCHEMBL12931994; ZINC13644475; BDBM50167059
DME6IKT	DT	Small molecular drug
DME6IKT	PC	11379743
DME6IKT	MW	251.75
DME6IKT	FM	C14H18ClNO
DME6IKT	IC	InChI=1S/C14H18ClNO/c15-12-7-4-8-13(10-12)16-14(17)9-11-5-2-1-3-6-11/h4,7-8,10-11H,1-3,5-6,9H2,(H,16,17)
DME6IKT	CS	C1CCC(CC1)CC(=O)NC2=CC(=CC=C2)Cl
DME6IKT	IK	POFHQQJQPBOESX-UHFFFAOYSA-N
DME6IKT	IU	N-(3-chlorophenyl)-2-cyclohexylacetamide
DME6IKT	DE	Discovery agent

DM3RQHG	ID	DM3RQHG
DM3RQHG	DN	N-(3-chlorophenyl)-3-cyano-5-fluorobenzamide
DM3RQHG	HS	Investigative
DM3RQHG	SN	N-(3-Chlorophenyl)-3-cyano-5-fluorobenzamide; CHEMBL1209202; GTPL6437; BDBM50323289; compound 27 [PMID:;  N-(3-Chlorophenyl)-3-cyano-5-fluorobenzamide; compound 27 [PMID: 20598884]; compound 27
DM3RQHG	DT	Small molecular drug
DM3RQHG	PC	46911385
DM3RQHG	MW	274.68
DM3RQHG	FM	C14H8ClFN2O
DM3RQHG	IC	InChI=1S/C14H8ClFN2O/c15-11-2-1-3-13(7-11)18-14(19)10-4-9(8-17)5-12(16)6-10/h1-7H,(H,18,19)
DM3RQHG	CS	C1=CC(=CC(=C1)Cl)NC(=O)C2=CC(=CC(=C2)C#N)F
DM3RQHG	IK	FNDUFJARTKDXEF-UHFFFAOYSA-N
DM3RQHG	IU	N-(3-chlorophenyl)-3-cyano-5-fluorobenzamide
DM3RQHG	DE	Discovery agent

DM3AGJH	ID	DM3AGJH
DM3AGJH	DN	N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine
DM3AGJH	HS	Investigative
DM3AGJH	SN	CHEMBL1081540; N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine; SCHEMBL4738649; BDBM50311880
DM3AGJH	DT	Small molecular drug
DM3AGJH	PC	24991329
DM3AGJH	MW	273.69
DM3AGJH	FM	C14H9ClFN3
DM3AGJH	IC	InChI=1S/C14H9ClFN3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DM3AGJH	CS	C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)F
DM3AGJH	IK	FKNWIVATYZCUKH-UHFFFAOYSA-N
DM3AGJH	IU	N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine
DM3AGJH	DE	Discovery agent

DMQEPV0	ID	DMQEPV0
DMQEPV0	DN	N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine
DMQEPV0	HS	Investigative
DMQEPV0	SN	CHEMBL1080998; N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine; SCHEMBL2101452; BDBM50311878
DMQEPV0	DT	Small molecular drug
DMQEPV0	PC	19595108
DMQEPV0	MW	285.73
DMQEPV0	FM	C15H12ClN3O
DMQEPV0	IC	InChI=1S/C15H12ClN3O/c1-20-12-5-6-14-13(8-12)15(18-9-17-14)19-11-4-2-3-10(16)7-11/h2-9H,1H3,(H,17,18,19)
DMQEPV0	CS	COC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Cl
DMQEPV0	IK	JDEKFVYZUIPHET-UHFFFAOYSA-N
DMQEPV0	IU	N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine
DMQEPV0	CA	CAS 153437-82-2
DMQEPV0	DE	Discovery agent

DMIKP5Y	ID	DMIKP5Y
DMIKP5Y	DN	N-(3-chlorophenyl)-6-nitroquinazolin-4-amine
DMIKP5Y	HS	Investigative
DMIKP5Y	SN	N-(3-chlorophenyl)-6-nitroquinazolin-4-amine; 153436-72-7; CHEMBL1080816; SCHEMBL8871973; DTXSID00470764; BDBM50311879; ZINC38265601; AKOS027252204
DMIKP5Y	DT	Small molecular drug
DMIKP5Y	PC	11695129
DMIKP5Y	MW	300.7
DMIKP5Y	FM	C14H9ClN4O2
DMIKP5Y	IC	InChI=1S/C14H9ClN4O2/c15-9-2-1-3-10(6-9)18-14-12-7-11(19(20)21)4-5-13(12)16-8-17-14/h1-8H,(H,16,17,18)
DMIKP5Y	CS	C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)[N+](=O)[O-]
DMIKP5Y	IK	USAMIYATKINXLP-UHFFFAOYSA-N
DMIKP5Y	IU	N-(3-chlorophenyl)-6-nitroquinazolin-4-amine
DMIKP5Y	CA	CAS 153436-72-7
DMIKP5Y	DE	Discovery agent

DMC5G6Y	ID	DMC5G6Y
DMC5G6Y	DN	N-(3-Ethylphenyl)-N'-hydroxyoctanediamide
DMC5G6Y	HS	Investigative
DMC5G6Y	SN	CHEMBL1093041; BDBM50314134
DMC5G6Y	DT	Small molecular drug
DMC5G6Y	PC	45141753
DMC5G6Y	MW	292.37
DMC5G6Y	FM	C16H24N2O3
DMC5G6Y	IC	InChI=1S/C16H24N2O3/c1-2-13-8-7-9-14(12-13)17-15(19)10-5-3-4-6-11-16(20)18-21/h7-9,12,21H,2-6,10-11H2,1H3,(H,17,19)(H,18,20)
DMC5G6Y	CS	CCC1=CC(=CC=C1)NC(=O)CCCCCCC(=O)NO
DMC5G6Y	IK	HABCYDNCOYWETL-UHFFFAOYSA-N
DMC5G6Y	IU	N-(3-ethylphenyl)-N'-hydroxyoctanediamide
DMC5G6Y	DE	Discovery agent

DM0H8CK	ID	DM0H8CK
DM0H8CK	DN	N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine
DM0H8CK	HS	Investigative
DM0H8CK	SN	CHEMBL61273
DM0H8CK	DT	Small molecular drug
DM0H8CK	PC	19096134
DM0H8CK	MW	271.3
DM0H8CK	FM	C10H13N3O4S
DM0H8CK	IC	InChI=1S/C10H13N3O4S/c1-17-7-4-3-6(9(14)13-10(11)12)5-8(7)18(2,15)16/h3-5H,1-2H3,(H4,11,12,13,14)
DM0H8CK	CS	COC1=C(C=C(C=C1)C(=O)N=C(N)N)S(=O)(=O)C
DM0H8CK	IK	JWTRVDCAXVYZOB-UHFFFAOYSA-N
DM0H8CK	IU	N-(diaminomethylidene)-4-methoxy-3-methylsulfonylbenzamide
DM0H8CK	DE	Discovery agent

DMSVQJP	ID	DMSVQJP
DMSVQJP	DN	N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine
DMSVQJP	HS	Investigative
DMSVQJP	SN	SCHEMBL9194592
DMSVQJP	DT	Small molecular drug
DMSVQJP	PC	19096138
DMSVQJP	MW	255.3
DMSVQJP	FM	C10H13N3O3S
DMSVQJP	IC	InChI=1S/C10H13N3O3S/c1-6-3-4-7(9(14)13-10(11)12)5-8(6)17(2,15)16/h3-5H,1-2H3,(H4,11,12,13,14)
DMSVQJP	CS	CC1=C(C=C(C=C1)C(=O)N=C(N)N)S(=O)(=O)C
DMSVQJP	IK	LHXXNXYVTIIVIY-UHFFFAOYSA-N
DMSVQJP	IU	N-(diaminomethylidene)-4-methyl-3-methylsulfonylbenzamide
DMSVQJP	DE	Discovery agent

DM2D4KY	ID	DM2D4KY
DM2D4KY	DN	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
DM2D4KY	HS	Investigative
DM2D4KY	SN	2365-40-4; Isopentenyladenine; N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-
DM2D4KY	DT	Small molecular drug
DM2D4KY	PC	92180
DM2D4KY	MW	203.24
DM2D4KY	FM	C10H13N5
DM2D4KY	IC	InChI=1S/C10H13N5/c1-7(2)3-4-11-9-8-10(13-5-12-8)15-6-14-9/h3,5-6H,4H2,1-2H3,(H2,11,12,13,14,15)
DM2D4KY	CS	CC(=CCNC1=NC=NC2=C1NC=N2)C
DM2D4KY	IK	HYVABZIGRDEKCD-UHFFFAOYSA-N
DM2D4KY	IU	N-(3-methylbut-2-enyl)-7H-purin-6-amine
DM2D4KY	CA	CAS 2365-40-4
DM2D4KY	CB	CHEBI:17660
DM2D4KY	DE	Discovery agent

DMHZU8K	ID	DMHZU8K
DMHZU8K	DN	N-(3-phenethoxybenzyl)-4-hydroxybenzamide
DMHZU8K	HS	Investigative
DMHZU8K	SN	CHEMBL248875; N-(3-phenethoxybenzyl)-4-hydroxybenzamide; BDBM50220592; CJ 036878; Benzamide, 4-hydroxy-N-((3-(2-phenylethoxy)phenyl)methyl)-
DMHZU8K	DT	Small molecular drug
DMHZU8K	PC	44442088
DMHZU8K	MW	347.4
DMHZU8K	FM	C22H21NO3
DMHZU8K	IC	InChI=1S/C22H21NO3/c24-20-11-9-19(10-12-20)22(25)23-16-18-7-4-8-21(15-18)26-14-13-17-5-2-1-3-6-17/h1-12,15,24H,13-14,16H2,(H,23,25)
DMHZU8K	CS	C1=CC=C(C=C1)CCOC2=CC=CC(=C2)CNC(=O)C3=CC=C(C=C3)O
DMHZU8K	IK	VZKHCMVEWLIXIC-UHFFFAOYSA-N
DMHZU8K	IU	4-hydroxy-N-[[3-(2-phenylethoxy)phenyl]methyl]benzamide
DMHZU8K	CA	CAS 951248-25-2
DMHZU8K	DE	Discovery agent

DMXF46V	ID	DMXF46V
DMXF46V	DN	N-(3-phenoxy-4-pyridinyl)ethanesulfonamide
DMXF46V	HS	Investigative
DMXF46V	SN	CHEMBL376143; 833455-54-2; N-(3-phenoxy-4-pyridinyl)ethanesulfonamide; CTK3D2870; DTXSID30457028; BDBM50158446; AKOS030595655; Ethanesulfonamide, N-(3-phenoxy-4-pyridinyl)-
DMXF46V	DT	Small molecular drug
DMXF46V	PC	11150126
DMXF46V	MW	278.33
DMXF46V	FM	C13H14N2O3S
DMXF46V	IC	InChI=1S/C13H14N2O3S/c1-2-19(16,17)15-12-8-9-14-10-13(12)18-11-6-4-3-5-7-11/h3-10H,2H2,1H3,(H,14,15)
DMXF46V	CS	CCS(=O)(=O)NC1=C(C=NC=C1)OC2=CC=CC=C2
DMXF46V	IK	FOUBNASCZPSQBW-UHFFFAOYSA-N
DMXF46V	IU	N-(3-phenoxypyridin-4-yl)ethanesulfonamide
DMXF46V	CA	CAS 833455-54-2
DMXF46V	DE	Discovery agent

DMN1DPJ	ID	DMN1DPJ
DMN1DPJ	DN	N-(3-phenoxy-4-pyridinyl)propanesulfonamide
DMN1DPJ	HS	Investigative
DMN1DPJ	SN	CHEMBL389485; N-(3-phenoxy-4-pyridinyl)propanesulfonamide
DMN1DPJ	DT	Small molecular drug
DMN1DPJ	PC	11277773
DMN1DPJ	MW	292.36
DMN1DPJ	FM	C14H16N2O3S
DMN1DPJ	IC	InChI=1S/C14H16N2O3S/c1-2-10-20(17,18)16-13-8-9-15-11-14(13)19-12-6-4-3-5-7-12/h3-9,11H,2,10H2,1H3,(H,15,16)
DMN1DPJ	CS	CCCS(=O)(=O)NC1=C(C=NC=C1)OC2=CC=CC=C2
DMN1DPJ	IK	LHXILNAQPGRTDA-UHFFFAOYSA-N
DMN1DPJ	IU	N-(3-phenoxypyridin-4-yl)propane-1-sulfonamide
DMN1DPJ	DE	Discovery agent

DM7CM3F	ID	DM7CM3F
DM7CM3F	DN	N-(3-phenoxypyridin-4-yl)methanesulfonamide
DM7CM3F	HS	Investigative
DM7CM3F	SN	CHEMBL148542; N-(3-phenoxy-4-pyridinyl)methanesulfonamide; 180194-78-9; N-(3-phenoxypyridin-4-yl)methanesulfonamide; CTK0E3181; DTXSID30437284; BDBM50120980; N-(3-Phenoxy-4-pyridyl)methanesulfonamide; N-(3-Phenoxy-pyridin-4-yl)-methanesulfonamide; Methanesulfonamide, N-(3-phenoxy-4-pyridinyl)-
DM7CM3F	DT	Small molecular drug
DM7CM3F	PC	10244543
DM7CM3F	MW	264.3
DM7CM3F	FM	C12H12N2O3S
DM7CM3F	IC	InChI=1S/C12H12N2O3S/c1-18(15,16)14-11-7-8-13-9-12(11)17-10-5-3-2-4-6-10/h2-9H,1H3,(H,13,14)
DM7CM3F	CS	CS(=O)(=O)NC1=C(C=NC=C1)OC2=CC=CC=C2
DM7CM3F	IK	CQEDUEBRINEBGP-UHFFFAOYSA-N
DM7CM3F	IU	N-(3-phenoxypyridin-4-yl)methanesulfonamide
DM7CM3F	CA	CAS 180194-78-9
DM7CM3F	DE	Discovery agent

DMSNF7W	ID	DMSNF7W
DMSNF7W	DN	N-(3-Phenyl)propyl-2-(4-bromophenylacetamide)
DMSNF7W	HS	Investigative
DMSNF7W	SN	CHEMBL478643; N-(3-Phenyl)propyl-2-(4-bromophenylacetamide)
DMSNF7W	DT	Small molecular drug
DMSNF7W	PC	44578696
DMSNF7W	MW	408.3
DMSNF7W	FM	C23H22BrNO
DMSNF7W	IC	InChI=1S/C23H22BrNO/c24-21-15-13-20(14-16-21)22(19-11-5-2-6-12-19)23(26)25-17-7-10-18-8-3-1-4-9-18/h1-6,8-9,11-16,22H,7,10,17H2,(H,25,26)
DMSNF7W	CS	C1=CC=C(C=C1)CCCNC(=O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Br
DMSNF7W	IK	ACZAPKHQBWGJHX-UHFFFAOYSA-N
DMSNF7W	IU	2-(4-bromophenyl)-2-phenyl-N-(3-phenylpropyl)acetamide
DMSNF7W	DE	Discovery agent

DM9XH18	ID	DM9XH18
DM9XH18	DN	N-(3-Phenyl)propyl-2,2-diphenylacetamide
DM9XH18	HS	Investigative
DM9XH18	SN	2,2-diphenyl-N-(3-phenylpropyl)acetamide; CHEMBL476336; N-(3-Phenyl)propyl-2,2-diphenylacetamide; AC1M5U8J; MolPort-003-249-505; ZINC3269206; STK437441; BDBM50263151; AKOS001062446; MCULE-9627491940; N-(3-Phenylpropyl)-2,2-diphenylacetamide; ST50913753; Z26437312
DM9XH18	DT	Small molecular drug
DM9XH18	PC	2385541
DM9XH18	MW	329.4
DM9XH18	FM	C23H23NO
DM9XH18	IC	InChI=1S/C23H23NO/c25-23(24-18-10-13-19-11-4-1-5-12-19)22(20-14-6-2-7-15-20)21-16-8-3-9-17-21/h1-9,11-12,14-17,22H,10,13,18H2,(H,24,25)
DM9XH18	CS	C1=CC=C(C=C1)CCCNC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3
DM9XH18	IK	GGASESVHBWYDKY-UHFFFAOYSA-N
DM9XH18	IU	2,2-diphenyl-N-(3-phenylpropyl)acetamide
DM9XH18	DE	Discovery agent

DM4IA92	ID	DM4IA92
DM4IA92	DN	N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-benzamide
DM4IA92	HS	Investigative
DM4IA92	SN	N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide; CHEMBL165783; AC1M3OE0; N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-benzamide; MolPort-000-646-915; HMS3451M02; ZINC2889428; STL202734; BDBM50097440; AKOS000813205; MCULE-2440953367; UPCMLD0ENAT5889812:001; ST45223360; VU0618368-1; N-(3-Phenyl-1,2,4-thiadiazole-5-yl)benzamide; phenyl-N-(3-phenyl(1,2,4-thiadiazol-5-yl))carboxamide; F3394-1092
DM4IA92	DT	Small molecular drug
DM4IA92	PC	2241548
DM4IA92	MW	281.3
DM4IA92	FM	C15H11N3OS
DM4IA92	IC	InChI=1S/C15H11N3OS/c19-14(12-9-5-2-6-10-12)17-15-16-13(18-20-15)11-7-3-1-4-8-11/h1-10H,(H,16,17,18,19)
DM4IA92	CS	C1=CC=C(C=C1)C2=NSC(=N2)NC(=O)C3=CC=CC=C3
DM4IA92	IK	AYSLYXJUYHXKHV-UHFFFAOYSA-N
DM4IA92	IU	N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide
DM4IA92	DE	Discovery agent

DMJB7SE	ID	DMJB7SE
DMJB7SE	DN	N-(3-phenylamino-4-pyridinyl)methanesulfonamide
DMJB7SE	HS	Investigative
DMJB7SE	SN	N-(3-phenylamino-4-pyridinyl)methanesulfonamide; CHEMBL1079877; BDBM50311367
DMJB7SE	DT	Small molecular drug
DMJB7SE	PC	44475843
DMJB7SE	MW	263.32
DMJB7SE	FM	C12H13N3O2S
DMJB7SE	IC	InChI=1S/C12H13N3O2S/c1-18(16,17)15-11-7-8-13-9-12(11)14-10-5-3-2-4-6-10/h2-9,14H,1H3,(H,13,15)
DMJB7SE	CS	CS(=O)(=O)NC1=C(C=NC=C1)NC2=CC=CC=C2
DMJB7SE	IK	QOJPQADRTOBBQV-UHFFFAOYSA-N
DMJB7SE	IU	N-(3-anilinopyridin-4-yl)methanesulfonamide
DMJB7SE	DE	Discovery agent

DMKAX3Q	ID	DMKAX3Q
DMKAX3Q	DN	N-(3-Phenylpropyl)-1H-indole-2-carboxamide
DMKAX3Q	HS	Investigative
DMKAX3Q	SN	CHEMBL460609; N-(3-Phenylpropyl)-1H-indole-2-carboxamide; BDBM50273530; STL028133; AKOS005679593
DMKAX3Q	DT	Small molecular drug
DMKAX3Q	PC	27647057
DMKAX3Q	MW	278.3
DMKAX3Q	FM	C18H18N2O
DMKAX3Q	IC	InChI=1S/C18H18N2O/c21-18(17-13-15-10-4-5-11-16(15)20-17)19-12-6-9-14-7-2-1-3-8-14/h1-5,7-8,10-11,13,20H,6,9,12H2,(H,19,21)
DMKAX3Q	CS	C1=CC=C(C=C1)CCCNC(=O)C2=CC3=CC=CC=C3N2
DMKAX3Q	IK	RUVMVFFYHGKXTD-UHFFFAOYSA-N
DMKAX3Q	IU	N-(3-phenylpropyl)-1H-indole-2-carboxamide
DMKAX3Q	DE	Discovery agent

DMZ3I6U	ID	DMZ3I6U
DMZ3I6U	DN	N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide
DMZ3I6U	HS	Investigative
DMZ3I6U	SN	pyrrole inhibitor 13; N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide; CHEMBL221171; BDBM15587
DMZ3I6U	DT	Small molecular drug
DMZ3I6U	PC	16110288
DMZ3I6U	MW	228.29
DMZ3I6U	FM	C14H16N2O
DMZ3I6U	IC	InChI=1S/C14H16N2O/c17-14(13-9-5-10-15-13)16-11-4-8-12-6-2-1-3-7-12/h1-3,5-7,9-10,15H,4,8,11H2,(H,16,17)
DMZ3I6U	CS	C1=CC=C(C=C1)CCCNC(=O)C2=CC=CN2
DMZ3I6U	IK	FQRIYWSUESDLNK-UHFFFAOYSA-N
DMZ3I6U	IU	N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide
DMZ3I6U	DE	Discovery agent

DMA7X62	ID	DMA7X62
DMA7X62	DN	N-(3-Phenyl-propyl)-nicotinamide
DMA7X62	HS	Investigative
DMA7X62	SN	N-(3-phenylpropyl)pyridine-3-carboxamide; CHEMBL560538; N-(3-Phenyl-propyl)-nicotinamide; AC1NEVG1; SCHEMBL4182430; MolPort-001-620-971; ZINC2736778; BDBM50297409; STK440753; AKOS003254198; MCULE-2570363469; N-(3-phenylpropyl)-3-pyridylcarboxamide
DMA7X62	DT	Small molecular drug
DMA7X62	PC	4648643
DMA7X62	MW	240.3
DMA7X62	FM	C15H16N2O
DMA7X62	IC	InChI=1S/C15H16N2O/c18-15(14-9-5-10-16-12-14)17-11-4-8-13-6-2-1-3-7-13/h1-3,5-7,9-10,12H,4,8,11H2,(H,17,18)
DMA7X62	CS	C1=CC=C(C=C1)CCCNC(=O)C2=CN=CC=C2
DMA7X62	IK	DGVNUZBITSWBPL-UHFFFAOYSA-N
DMA7X62	IU	N-(3-phenylpropyl)pyridine-3-carboxamide
DMA7X62	DE	Discovery agent

DM1V83P	ID	DM1V83P
DM1V83P	DN	N-(4-(2-aminoethyl)phenyl)benzenesulfonamide
DM1V83P	HS	Investigative
DM1V83P	SN	N-[4-(2-aminoethyl)phenyl]Benzenesulfonamide; CHEMBL434365; N-(4-(2-aminoethyl)phenyl)benzenesulfonamide; 159182-12-4; N-(4-[2-Aminoethyl]phenyl)Benzenesulfonamide; SCHEMBL5830405; PRODIAPRPOSQSM-UHFFFAOYSA-N; ZINC20224442; BDBM50193473; AKOS011587141; MCULE-5428014421; DA-09746; FT-0710145; N-(4-[2-aminoethyl]phenyl) benzenesulfonamide
DM1V83P	DT	Small molecular drug
DM1V83P	PC	15281645
DM1V83P	MW	276.36
DM1V83P	FM	C14H16N2O2S
DM1V83P	IC	InChI=1S/C14H16N2O2S/c15-11-10-12-6-8-13(9-7-12)16-19(17,18)14-4-2-1-3-5-14/h1-9,16H,10-11,15H2
DM1V83P	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CCN
DM1V83P	IK	PRODIAPRPOSQSM-UHFFFAOYSA-N
DM1V83P	IU	N-[4-(2-aminoethyl)phenyl]benzenesulfonamide
DM1V83P	DE	Discovery agent

DMRH987	ID	DMRH987
DMRH987	DN	N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide
DMRH987	HS	Investigative
DMRH987	SN	AC1O17NE; CHEMBL425789
DMRH987	DT	Small molecular drug
DMRH987	PC	6114166
DMRH987	MW	266.29
DMRH987	FM	C16H14N2O2
DMRH987	IC	InChI=1S/C16H14N2O2/c1-12(19)18-15-7-5-13(6-8-15)16(20)10-9-14-4-2-3-11-17-14/h2-11H,1H3,(H,18,19)/b10-9+
DMRH987	CS	CC(=O)NC1=CC=C(C=C1)C(=O)/C=C/C2=CC=CC=N2
DMRH987	IK	LAXKVXCZXLEVKG-MDZDMXLPSA-N
DMRH987	IU	N-[4-[(E)-3-pyridin-2-ylprop-2-enoyl]phenyl]acetamide
DMRH987	DE	Discovery agent

DMQDI5H	ID	DMQDI5H
DMQDI5H	DN	N-(4-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide
DMQDI5H	HS	Investigative
DMQDI5H	SN	CHEMBL262360
DMQDI5H	DT	Small molecular drug
DMQDI5H	PC	44450061
DMQDI5H	MW	327.4
DMQDI5H	FM	C20H25NO3
DMQDI5H	IC	InChI=1S/C20H25NO3/c1-3-4-5-6-7-16-8-13-20(19(23)14-16)24-18-11-9-17(10-12-18)21-15(2)22/h8-14,23H,3-7H2,1-2H3,(H,21,22)
DMQDI5H	CS	CCCCCCC1=CC(=C(C=C1)OC2=CC=C(C=C2)NC(=O)C)O
DMQDI5H	IK	MQSIKLFXBKTOER-UHFFFAOYSA-N
DMQDI5H	IU	N-[4-(4-hexyl-2-hydroxyphenoxy)phenyl]acetamide
DMQDI5H	DE	Discovery agent

DMIPKNQ	ID	DMIPKNQ
DMIPKNQ	DN	N-(4-(benzyloxy)phenethyl)pyridin-4-amine
DMIPKNQ	HS	Investigative
DMIPKNQ	SN	CHEMBL48029; N-(4-(benzyloxy)phenethyl)pyridin-4-amine; 212506-01-9; CTK0I9588; DTXSID00658166; ZINC29412450; BDBM50070788; AKOS030550684; N-{2-[4-(Benzyloxy)phenyl]ethyl}pyridin-4-amine; [2-(4-Benzyloxy-phenyl)-ethyl]-pyridin-4-yl-amine; 4-Pyridinamine, N-[2-[4-(phenylmethoxy)phenyl]ethyl]-
DMIPKNQ	DT	Small molecular drug
DMIPKNQ	PC	44292136
DMIPKNQ	MW	304.4
DMIPKNQ	FM	C20H20N2O
DMIPKNQ	IC	InChI=1S/C20H20N2O/c1-2-4-18(5-3-1)16-23-20-8-6-17(7-9-20)10-15-22-19-11-13-21-14-12-19/h1-9,11-14H,10,15-16H2,(H,21,22)
DMIPKNQ	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)CCNC3=CC=NC=C3
DMIPKNQ	IK	WPBRSJXCRWSAHJ-UHFFFAOYSA-N
DMIPKNQ	IU	N-[2-(4-phenylmethoxyphenyl)ethyl]pyridin-4-amine
DMIPKNQ	CA	CAS 212506-01-9
DMIPKNQ	DE	Discovery agent

DMZAOVG	ID	DMZAOVG
DMZAOVG	DN	N-(4-(diethylamino)phenyl)-2-nitrobenzamide
DMZAOVG	HS	Investigative
DMZAOVG	SN	N-[4-(diethylamino)phenyl]-2-nitrobenzamide; CHEMBL552222; N-(4-(diethylamino)phenyl)-2-nitrobenzamide; AC1LDVIK; CBMicro_033668; Oprea1_547325; Oprea1_003763; ARONIS021166; ZINC38831; KS-00004CPP; MolPort-001-026-902; BDBM50297531; STK073585; AKOS000487910; MCULE-3866338057; ST055105; BIM-0033840.P001; SR-01000220066; AN-329/12072549; SR-01000220066-1
DMZAOVG	DT	Small molecular drug
DMZAOVG	PC	675939
DMZAOVG	MW	313.35
DMZAOVG	FM	C17H19N3O3
DMZAOVG	IC	InChI=1S/C17H19N3O3/c1-3-19(4-2)14-11-9-13(10-12-14)18-17(21)15-7-5-6-8-16(15)20(22)23/h5-12H,3-4H2,1-2H3,(H,18,21)
DMZAOVG	CS	CCN(CC)C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2[N+](=O)[O-]
DMZAOVG	IK	ILACFEJISPLWOY-UHFFFAOYSA-N
DMZAOVG	IU	N-[4-(diethylamino)phenyl]-2-nitrobenzamide
DMZAOVG	DE	Discovery agent

DMI74KM	ID	DMI74KM
DMI74KM	DN	N-(4-(phenylamino)quinazolin-6-yl)acrylamide
DMI74KM	HS	Investigative
DMI74KM	SN	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide
DMI74KM	DT	Small molecular drug
DMI74KM	PC	10401956
DMI74KM	MW	290.32
DMI74KM	FM	C17H14N4O
DMI74KM	IC	InChI=1S/C17H14N4O/c1-2-16(22)20-13-8-9-15-14(10-13)17(19-11-18-15)21-12-6-4-3-5-7-12/h2-11H,1H2,(H,20,22)(H,18,19,21)
DMI74KM	CS	C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC=CC=C3
DMI74KM	IK	JGWHILNNHLDARR-UHFFFAOYSA-N
DMI74KM	IU	N-(4-anilinoquinazolin-6-yl)prop-2-enamide

DMZ0V8O	ID	DMZ0V8O
DMZ0V8O	DN	N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMZ0V8O	HS	Investigative
DMZ0V8O	SN	CHEMBL199074; N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMZ0V8O	DT	Small molecular drug
DMZ0V8O	PC	44405448
DMZ0V8O	MW	371.4
DMZ0V8O	FM	C21H16F3NO2
DMZ0V8O	IC	InChI=1S/C21H16F3NO2/c22-21(23,24)17-10-6-15(7-11-17)14-25-20(26)16-8-12-19(13-9-16)27-18-4-2-1-3-5-18/h1-13H,14H2,(H,25,26)
DMZ0V8O	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC=C(C=C3)C(F)(F)F
DMZ0V8O	IK	JDGSUZBWUUXJCN-UHFFFAOYSA-N
DMZ0V8O	IU	4-phenoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide
DMZ0V8O	DE	Discovery agent

DM086VJ	ID	DM086VJ
DM086VJ	DN	N-(4,4-Diphenyl-butyl)-nicotinamide
DM086VJ	HS	Investigative
DM086VJ	SN	CHEMBL561479; N-(4,4-Diphenyl-butyl)-nicotinamide
DM086VJ	DT	Small molecular drug
DM086VJ	PC	44475209
DM086VJ	MW	330.4
DM086VJ	FM	C22H22N2O
DM086VJ	IC	InChI=1S/C22H22N2O/c25-22(20-13-7-15-23-17-20)24-16-8-14-21(18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-7,9-13,15,17,21H,8,14,16H2,(H,24,25)
DM086VJ	CS	C1=CC=C(C=C1)C(CCCNC(=O)C2=CN=CC=C2)C3=CC=CC=C3
DM086VJ	IK	OIJGKBCGOHTERP-UHFFFAOYSA-N
DM086VJ	IU	N-(4,4-diphenylbutyl)pyridine-3-carboxamide
DM086VJ	DE	Discovery agent

DM34R10	ID	DM34R10
DM34R10	DN	N-(4,5-diphenylpyrimidin-2-yl)acetamide
DM34R10	HS	Investigative
DM34R10	SN	CHEMBL225244; 58413-41-5; N-(4,5-diphenylpyrimidin-2-yl)acetamide; CTK1E9829; DTXSID90482573; 2-acetamido-4,6-diphenylpyrimidine; ZINC13586468; BDBM50157675; AKOS030564193; Acetamide, N-(4,6-diphenyl-2-pyrimidinyl)-
DM34R10	DT	Small molecular drug
DM34R10	PC	12253310
DM34R10	MW	289.3
DM34R10	FM	C18H15N3O
DM34R10	IC	InChI=1S/C18H15N3O/c1-13(22)19-18-20-16(14-8-4-2-5-9-14)12-17(21-18)15-10-6-3-7-11-15/h2-12H,1H3,(H,19,20,21,22)
DM34R10	CS	CC(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DM34R10	IK	ZDCIIHIXQUEUCV-UHFFFAOYSA-N
DM34R10	IU	N-(4,6-diphenylpyrimidin-2-yl)acetamide
DM34R10	CA	CAS 58413-41-5
DM34R10	DE	Discovery agent

DMDP1QG	ID	DMDP1QG
DMDP1QG	DN	N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide
DMDP1QG	HS	Investigative
DMDP1QG	SN	CHEMBL374366; 820961-71-5; N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide; SCHEMBL6497567; CTK3E2637; DTXSID20461437; BDBM50157660; AKOS030569446; Butanamide, N-(4,6-diphenyl-2-pyrimidinyl)-2-ethyl-
DMDP1QG	DT	Small molecular drug
DMDP1QG	PC	11290921
DMDP1QG	MW	345.4
DMDP1QG	FM	C22H23N3O
DMDP1QG	IC	InChI=1S/C22H23N3O/c1-3-16(4-2)21(26)25-22-23-19(17-11-7-5-8-12-17)15-20(24-22)18-13-9-6-10-14-18/h5-16H,3-4H2,1-2H3,(H,23,24,25,26)
DMDP1QG	CS	CCC(CC)C(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMDP1QG	IK	YOARGGKKYZIYSU-UHFFFAOYSA-N
DMDP1QG	IU	N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutanamide
DMDP1QG	CA	CAS 820961-71-5
DMDP1QG	DE	Discovery agent

DMQVPK9	ID	DMQVPK9
DMQVPK9	DN	N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide
DMQVPK9	HS	Investigative
DMQVPK9	SN	CHEMBL426390; 820961-63-5; 3-chloro-N-(4,6-diphenylpyrimidin-2-yl)benzamide; N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide; CTK3E2645; DTXSID50459660; MolPort-007-705-564; BDBM50157667; ZINC13586467; AKOS001552650; MCULE-8841696019; Benzamide, 3-chloro-N-(4,6-diphenyl-2-pyrimidinyl)-
DMQVPK9	DT	Small molecular drug
DMQVPK9	PC	11234532
DMQVPK9	MW	385.8
DMQVPK9	FM	C23H16ClN3O
DMQVPK9	IC	InChI=1S/C23H16ClN3O/c24-19-13-7-12-18(14-19)22(28)27-23-25-20(16-8-3-1-4-9-16)15-21(26-23)17-10-5-2-6-11-17/h1-15H,(H,25,26,27,28)
DMQVPK9	CS	C1=CC=C(C=C1)C2=CC(=NC(=N2)NC(=O)C3=CC(=CC=C3)Cl)C4=CC=CC=C4
DMQVPK9	IK	BYALFPUQWRIWML-UHFFFAOYSA-N
DMQVPK9	IU	3-chloro-N-(4,6-diphenylpyrimidin-2-yl)benzamide
DMQVPK9	CA	CAS 820961-63-5
DMQVPK9	DE	Discovery agent

DMOAPJ1	ID	DMOAPJ1
DMOAPJ1	DN	N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutyramide
DMOAPJ1	HS	Investigative
DMOAPJ1	SN	CHEMBL376672; 820961-70-4; N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutyramide; SCHEMBL6501467; CTK3E2638; DTXSID50461763; MolPort-007-705-567; HMS3459C01; ZINC13586473; BDBM50157677; AKOS001873749; MCULE-2375799118; N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutanamide; Butanamide, N-(4,6-diphenyl-2-pyrimidinyl)-3-methyl-
DMOAPJ1	DT	Small molecular drug
DMOAPJ1	PC	11301995
DMOAPJ1	MW	331.4
DMOAPJ1	FM	C21H21N3O
DMOAPJ1	IC	InChI=1S/C21H21N3O/c1-15(2)13-20(25)24-21-22-18(16-9-5-3-6-10-16)14-19(23-21)17-11-7-4-8-12-17/h3-12,14-15H,13H2,1-2H3,(H,22,23,24,25)
DMOAPJ1	CS	CC(C)CC(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMOAPJ1	IK	RLCNDGHLHOXEDS-UHFFFAOYSA-N
DMOAPJ1	IU	N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutanamide
DMOAPJ1	CA	CAS 820961-70-4
DMOAPJ1	DE	Discovery agent

DM1PSR7	ID	DM1PSR7
DM1PSR7	DN	N-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide
DM1PSR7	HS	Investigative
DM1PSR7	SN	CHEMBL376034; 820961-59-9; N-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide; CTK3E2649; DTXSID20458923; BDBM50157674; AKOS030577991; Benzamide, 4-chloro-N-(4,6-diphenyl-2-pyrimidinyl)-
DM1PSR7	DT	Small molecular drug
DM1PSR7	PC	11211335
DM1PSR7	MW	385.8
DM1PSR7	FM	C23H16ClN3O
DM1PSR7	IC	InChI=1S/C23H16ClN3O/c24-19-13-11-18(12-14-19)22(28)27-23-25-20(16-7-3-1-4-8-16)15-21(26-23)17-9-5-2-6-10-17/h1-15H,(H,25,26,27,28)
DM1PSR7	CS	C1=CC=C(C=C1)C2=CC(=NC(=N2)NC(=O)C3=CC=C(C=C3)Cl)C4=CC=CC=C4
DM1PSR7	IK	GXFPQKORTZOVLZ-UHFFFAOYSA-N
DM1PSR7	IU	4-chloro-N-(4,6-diphenylpyrimidin-2-yl)benzamide
DM1PSR7	CA	CAS 820961-59-9
DM1PSR7	DE	Discovery agent

DMA214F	ID	DMA214F
DMA214F	DN	N-(4,6-diphenylpyrimidin-2-yl)benzamide
DMA214F	HS	Investigative
DMA214F	SN	N-(4,6-diphenylpyrimidin-2-yl)benzamide; CHEMBL221455; SCHEMBL6498848; MolPort-007-705-557; HMS3458N22; ZINC13586462; BDBM50157680; AKOS001552924
DMA214F	DT	Small molecular drug
DMA214F	PC	11314132
DMA214F	MW	351.4
DMA214F	FM	C23H17N3O
DMA214F	IC	InChI=1S/C23H17N3O/c27-22(19-14-8-3-9-15-19)26-23-24-20(17-10-4-1-5-11-17)16-21(25-23)18-12-6-2-7-13-18/h1-16H,(H,24,25,26,27)
DMA214F	CS	C1=CC=C(C=C1)C2=CC(=NC(=N2)NC(=O)C3=CC=CC=C3)C4=CC=CC=C4
DMA214F	IK	YAAODHHMHPMCPL-UHFFFAOYSA-N
DMA214F	IU	N-(4,6-diphenylpyrimidin-2-yl)benzamide
DMA214F	DE	Discovery agent

DMJZ2IP	ID	DMJZ2IP
DMJZ2IP	DN	N-(4,6-diphenylpyrimidin-2-yl)propionamide
DMJZ2IP	HS	Investigative
DMJZ2IP	SN	CHEMBL222718; 820961-64-6; N-(4,6-diphenylpyrimidin-2-yl)propionamide; SCHEMBL6505603; CTK3E2644; DTXSID70461023; BDBM50157663; ZINC13586469; N-(4,6-Diphenylpyrimidine-2-yl)propanamide; Propanamide, N-(4,6-diphenyl-2-pyrimidinyl)-
DMJZ2IP	DT	Small molecular drug
DMJZ2IP	PC	11278089
DMJZ2IP	MW	303.4
DMJZ2IP	FM	C19H17N3O
DMJZ2IP	IC	InChI=1S/C19H17N3O/c1-2-18(23)22-19-20-16(14-9-5-3-6-10-14)13-17(21-19)15-11-7-4-8-12-15/h3-13H,2H2,1H3,(H,20,21,22,23)
DMJZ2IP	CS	CCC(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMJZ2IP	IK	AZXIPRTZIQWIHR-UHFFFAOYSA-N
DMJZ2IP	IU	N-(4,6-diphenylpyrimidin-2-yl)propanamide
DMJZ2IP	CA	CAS 820961-64-6
DMJZ2IP	DE	Discovery agent

DMIJLX6	ID	DMIJLX6
DMIJLX6	DN	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide
DMIJLX6	HS	Investigative
DMIJLX6	SN	CHEMBL1099078; BDBM50317997
DMIJLX6	DT	Small molecular drug
DMIJLX6	PC	46887380
DMIJLX6	MW	330.4
DMIJLX6	FM	C21H18N2O2
DMIJLX6	IC	InChI=1S/C21H18N2O2/c1-14(24)15-7-9-16(10-8-15)18-11-12-19(22)20(13-18)23-21(25)17-5-3-2-4-6-17/h2-13H,22H2,1H3,(H,23,25)
DMIJLX6	CS	CC(=O)C1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMIJLX6	IK	NWHQDZJUELCUHQ-UHFFFAOYSA-N
DMIJLX6	IU	N-[5-(4-acetylphenyl)-2-aminophenyl]benzamide
DMIJLX6	DE	Discovery agent

DMCLRBK	ID	DMCLRBK
DMCLRBK	DN	N-(4-amino-2-propylquinolin-6-yl)cinnamamide
DMCLRBK	HS	Investigative
DMCLRBK	SN	CHEMBL385639; N-(4-amino-2-propylquinolin-6-yl)cinnamamide
DMCLRBK	DT	Small molecular drug
DMCLRBK	PC	44418001
DMCLRBK	MW	331.4
DMCLRBK	FM	C21H21N3O
DMCLRBK	IC	InChI=1S/C21H21N3O/c1-2-6-16-14-19(22)18-13-17(10-11-20(18)23-16)24-21(25)12-9-15-7-4-3-5-8-15/h3-5,7-14H,2,6H2,1H3,(H2,22,23)(H,24,25)/b12-9+
DMCLRBK	CS	CCCC1=CC(=C2C=C(C=CC2=N1)NC(=O)/C=C/C3=CC=CC=C3)N
DMCLRBK	IK	PWQSXBRFDPQGOC-FMIVXFBMSA-N
DMCLRBK	IU	(E)-N-(4-amino-2-propylquinolin-6-yl)-3-phenylprop-2-enamide
DMCLRBK	DE	Discovery agent

DMV6154	ID	DMV6154
DMV6154	DN	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide
DMV6154	HS	Investigative
DMV6154	SN	CHEMBL1097747; BDBM50317991
DMV6154	DT	Small molecular drug
DMV6154	PC	46887438
DMV6154	MW	318.4
DMV6154	FM	C20H18N2O2
DMV6154	IC	InChI=1S/C20H18N2O2/c1-24-17-9-5-8-15(12-17)16-10-11-18(21)19(13-16)22-20(23)14-6-3-2-4-7-14/h2-13H,21H2,1H3,(H,22,23)
DMV6154	CS	COC1=CC=CC(=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMV6154	IK	YILNPZMVPAGFAT-UHFFFAOYSA-N
DMV6154	IU	N-[2-amino-5-(3-methoxyphenyl)phenyl]benzamide
DMV6154	DE	Discovery agent

DM910BF	ID	DM910BF
DM910BF	DN	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide
DM910BF	HS	Investigative
DM910BF	SN	CHEMBL1094108; BDBM50317995
DM910BF	DT	Small molecular drug
DM910BF	PC	46887381
DM910BF	MW	302.4
DM910BF	FM	C20H18N2O
DM910BF	IC	InChI=1S/C20H18N2O/c1-14-6-5-9-16(12-14)17-10-11-18(21)19(13-17)22-20(23)15-7-3-2-4-8-15/h2-13H,21H2,1H3,(H,22,23)
DM910BF	CS	CC1=CC(=CC=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DM910BF	IK	VPXVDXWJQKJAAI-UHFFFAOYSA-N
DM910BF	IU	N-[2-amino-5-(3-methylphenyl)phenyl]benzamide
DM910BF	DE	Discovery agent

DMIAGS8	ID	DMIAGS8
DMIAGS8	DN	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide
DMIAGS8	HS	Investigative
DMIAGS8	SN	CHEMBL1097748; BDBM50317990
DMIAGS8	DT	Small molecular drug
DMIAGS8	PC	46887439
DMIAGS8	MW	367.2
DMIAGS8	FM	C19H15BrN2O
DMIAGS8	IC	InChI=1S/C19H15BrN2O/c20-16-9-6-13(7-10-16)15-8-11-17(21)18(12-15)22-19(23)14-4-2-1-3-5-14/h1-12H,21H2,(H,22,23)
DMIAGS8	CS	C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=C(C=C3)Br)N
DMIAGS8	IK	MPUICDSEVNEGIC-UHFFFAOYSA-N
DMIAGS8	IU	N-[2-amino-5-(4-bromophenyl)phenyl]benzamide
DMIAGS8	DE	Discovery agent

DMR5D16	ID	DMR5D16
DMR5D16	DN	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide
DMR5D16	HS	Investigative
DMR5D16	SN	CHEMBL1098337; SCHEMBL15398027; BDBM50317988
DMR5D16	DT	Small molecular drug
DMR5D16	PC	46830345
DMR5D16	MW	306.3
DMR5D16	FM	C19H15FN2O
DMR5D16	IC	InChI=1S/C19H15FN2O/c20-16-9-6-13(7-10-16)15-8-11-17(21)18(12-15)22-19(23)14-4-2-1-3-5-14/h1-12H,21H2,(H,22,23)
DMR5D16	CS	C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=C(C=C3)F)N
DMR5D16	IK	LKRDHRWKHHRCOQ-UHFFFAOYSA-N
DMR5D16	IU	N-[2-amino-5-(4-fluorophenyl)phenyl]benzamide
DMR5D16	DE	Discovery agent

DM93PDA	ID	DM93PDA
DM93PDA	DN	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide
DM93PDA	HS	Investigative
DM93PDA	SN	CHEMBL1095412; BDBM50317998
DM93PDA	DT	Small molecular drug
DM93PDA	PC	46887379
DM93PDA	MW	318.4
DM93PDA	FM	C20H18N2O2
DM93PDA	IC	InChI=1S/C20H18N2O2/c1-24-17-10-7-14(8-11-17)16-9-12-18(21)19(13-16)22-20(23)15-5-3-2-4-6-15/h2-13H,21H2,1H3,(H,22,23)
DM93PDA	CS	COC1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DM93PDA	IK	YOKIWEOZLFOUFK-UHFFFAOYSA-N
DM93PDA	IU	N-[2-amino-5-(4-methoxyphenyl)phenyl]benzamide
DM93PDA	DE	Discovery agent

DMSUJDH	ID	DMSUJDH
DMSUJDH	DN	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide
DMSUJDH	HS	Investigative
DMSUJDH	SN	CHEMBL1096397; BDBM50318002
DMSUJDH	DT	Small molecular drug
DMSUJDH	PC	46887334
DMSUJDH	MW	314.4
DMSUJDH	FM	C21H18N2O
DMSUJDH	IC	InChI=1S/C21H18N2O/c1-2-15-8-10-16(11-9-15)18-12-13-19(22)20(14-18)23-21(24)17-6-4-3-5-7-17/h2-14H,1,22H2,(H,23,24)
DMSUJDH	CS	C=CC1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMSUJDH	IK	GUBGWFHGNFMNFP-UHFFFAOYSA-N
DMSUJDH	IU	N-[2-amino-5-(4-ethenylphenyl)phenyl]benzamide
DMSUJDH	DE	Discovery agent

DMY1FMG	ID	DMY1FMG
DMY1FMG	DN	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide
DMY1FMG	HS	Investigative
DMY1FMG	SN	894803-94-2; Acetamide,N-(4-amino-5-cyano-6-ethoxy-2-pyridinyl)-; Kinome_3025; aminopyridine deriv. 1; N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide; CHEMBL208637; SCHEMBL1145395; Acetamide, N-(4-amino-5-cyano-6-ethoxy-2-pyridinyl)-; BDBM15907; Aminopyridine-Based Inhibitor 6a; DXAJWOOLPAIVJG-UHFFFAOYSA-N; ZINC14959957; KB-74421
DMY1FMG	DT	Small molecular drug
DMY1FMG	PC	11715520
DMY1FMG	MW	220.23
DMY1FMG	FM	C10H12N4O2
DMY1FMG	IC	InChI=1S/C10H12N4O2/c1-3-16-10-7(5-11)8(12)4-9(14-10)13-6(2)15/h4H,3H2,1-2H3,(H3,12,13,14,15)
DMY1FMG	CS	CCOC1=C(C(=CC(=N1)NC(=O)C)N)C#N
DMY1FMG	IK	DXAJWOOLPAIVJG-UHFFFAOYSA-N
DMY1FMG	IU	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide
DMY1FMG	DE	Discovery agent

DMUFVM6	ID	DMUFVM6
DMUFVM6	DN	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
DMUFVM6	HS	Investigative
DMUFVM6	SN	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide; Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24
DMUFVM6	DT	Small molecular drug
DMUFVM6	PC	11658882
DMUFVM6	MW	252.27
DMUFVM6	FM	C14H12N4O
DMUFVM6	IC	InChI=1S/C14H12N4O/c1-9(19)17-13-7-12(16)11(8-15)14(18-13)10-5-3-2-4-6-10/h2-7H,1H3,(H3,16,17,18,19)
DMUFVM6	CS	CC(=O)NC1=NC(=C(C(=C1)N)C#N)C2=CC=CC=C2
DMUFVM6	IK	GTMGQYXCPKUZAD-UHFFFAOYSA-N
DMUFVM6	IU	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
DMUFVM6	DE	Discovery agent

DMSAD87	ID	DMSAD87
DMSAD87	DN	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide
DMSAD87	HS	Investigative
DMSAD87	SN	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide; CHEMBL378980; SCHEMBL1145050; BDBM15960; Aminopyridine-Based Inhibitor 19d
DMSAD87	DT	Small molecular drug
DMSAD87	PC	11507052
DMSAD87	MW	248.28
DMSAD87	FM	C12H16N4O2
DMSAD87	IC	InChI=1S/C12H16N4O2/c1-3-4-5-18-12-9(7-13)10(14)6-11(16-12)15-8(2)17/h6H,3-5H2,1-2H3,(H3,14,15,16,17)
DMSAD87	CS	CCCCOC1=C(C(=CC(=N1)NC(=O)C)N)C#N
DMSAD87	IK	BOEQDOKWKLSDFP-UHFFFAOYSA-N
DMSAD87	IU	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide
DMSAD87	DE	Discovery agent

DMLA92O	ID	DMLA92O
DMLA92O	DN	N-(4-aminobiphenyl-3-yl)benzamide
DMLA92O	HS	Investigative
DMLA92O	SN	N-(4-aminobiphenyl-3-yl)benzamide; CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide
DMLA92O	DT	Small molecular drug
DMLA92O	PC	44454143
DMLA92O	MW	288.3
DMLA92O	FM	C19H16N2O
DMLA92O	IC	InChI=1S/C19H16N2O/c20-17-12-11-16(14-7-3-1-4-8-14)13-18(17)21-19(22)15-9-5-2-6-10-15/h1-13H,20H2,(H,21,22)
DMLA92O	CS	C1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMLA92O	IK	ZWLFHHHQRUYIBT-UHFFFAOYSA-N
DMLA92O	IU	N-(2-amino-5-phenylphenyl)benzamide
DMLA92O	DE	Discovery agent

DMXVZIY	ID	DMXVZIY
DMXVZIY	DN	N-(4-aminobiphenyl-3-yl)nicotinamide
DMXVZIY	HS	Investigative
DMXVZIY	SN	CHEMBL255805; N-(4-aminobiphenyl-3-yl)nicotinamide; BDBM50232035
DMXVZIY	DT	Small molecular drug
DMXVZIY	PC	44454415
DMXVZIY	MW	289.3
DMXVZIY	FM	C18H15N3O
DMXVZIY	IC	InChI=1S/C18H15N3O/c19-16-9-8-14(13-5-2-1-3-6-13)11-17(16)21-18(22)15-7-4-10-20-12-15/h1-12H,19H2,(H,21,22)
DMXVZIY	CS	C1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CN=CC=C3
DMXVZIY	IK	RAJXTGVDLBIWMD-UHFFFAOYSA-N
DMXVZIY	IU	N-(2-amino-5-phenylphenyl)pyridine-3-carboxamide
DMXVZIY	DE	Discovery agent

DMSNZV1	ID	DMSNZV1
DMSNZV1	DN	N-(4-bromo-2-methylphenyl)-2-naphthamide
DMSNZV1	HS	Investigative
DMSNZV1	SN	N-(4-bromo-2-methylphenyl)-2-naphthamide; N-(4-bromo-2-methylphenyl)naphthalene-2-carboxamide; 429627-41-8; naphthamide compound 2; AC1LGMF3; ChemBridge compound no. 2; CHEMBL217951; CTK1C8257; BDBM14710; DTXSID40356417; MolPort-002-208-677; ZINC342068; STK222653; AKOS000202277; MCULE-5174732523; AG-670/40742092; 2-Naphthalenecarboxamide, N-(4-bromo-2-methylphenyl)-
DMSNZV1	DT	Small molecular drug
DMSNZV1	PC	823850
DMSNZV1	MW	340.2
DMSNZV1	FM	C18H14BrNO
DMSNZV1	IC	InChI=1S/C18H14BrNO/c1-12-10-16(19)8-9-17(12)20-18(21)15-7-6-13-4-2-3-5-14(13)11-15/h2-11H,1H3,(H,20,21)
DMSNZV1	CS	CC1=C(C=CC(=C1)Br)NC(=O)C2=CC3=CC=CC=C3C=C2
DMSNZV1	IK	QDOYRUBXBHREAH-UHFFFAOYSA-N
DMSNZV1	IU	N-(4-bromo-2-methylphenyl)naphthalene-2-carboxamide
DMSNZV1	CA	CAS 429627-41-8
DMSNZV1	DE	Discovery agent

DMWHYOJ	ID	DMWHYOJ
DMWHYOJ	DN	N-(4'-bromo-3,3'-difluoro-4-biphenylyl)urea
DMWHYOJ	HS	Investigative
DMWHYOJ	SN	CHEMBL244510; SCHEMBL5436772; BDBM50220178
DMWHYOJ	DT	Small molecular drug
DMWHYOJ	PC	11595053
DMWHYOJ	MW	327.12
DMWHYOJ	FM	C13H9BrF2N2O
DMWHYOJ	IC	InChI=1S/C13H9BrF2N2O/c14-9-3-1-7(5-10(9)15)8-2-4-12(11(16)6-8)18-13(17)19/h1-6H,(H3,17,18,19)
DMWHYOJ	CS	C1=CC(=C(C=C1C2=CC(=C(C=C2)Br)F)F)NC(=O)N
DMWHYOJ	IK	SKBUTANQYXWCNX-UHFFFAOYSA-N
DMWHYOJ	IU	[4-(4-bromo-3-fluorophenyl)-2-fluorophenyl]urea
DMWHYOJ	DE	Discovery agent

DMC28SN	ID	DMC28SN
DMC28SN	DN	N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine
DMC28SN	HS	Investigative
DMC28SN	SN	CHEMBL62468
DMC28SN	DT	Small molecular drug
DMC28SN	PC	23359276
DMC28SN	MW	320.17
DMC28SN	FM	C9H10BrN3O3S
DMC28SN	IC	InChI=1S/C9H10BrN3O3S/c1-17(15,16)7-4-5(2-3-6(7)10)8(14)13-9(11)12/h2-4H,1H3,(H4,11,12,13,14)
DMC28SN	CS	CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)Br
DMC28SN	IK	PWHJRANRUUKGBX-UHFFFAOYSA-N
DMC28SN	IU	4-bromo-N-(diaminomethylidene)-3-methylsulfonylbenzamide
DMC28SN	DE	Discovery agent

DMFG6MU	ID	DMFG6MU
DMFG6MU	DN	N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine
DMFG6MU	HS	Investigative
DMFG6MU	SN	CHEMBL62469
DMFG6MU	DT	Small molecular drug
DMFG6MU	PC	19096151
DMFG6MU	MW	275.71
DMFG6MU	FM	C9H10ClN3O3S
DMFG6MU	IC	InChI=1S/C9H10ClN3O3S/c1-17(15,16)7-4-5(2-3-6(7)10)8(14)13-9(11)12/h2-4H,1H3,(H4,11,12,13,14)
DMFG6MU	CS	CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)Cl
DMFG6MU	IK	AXVSLAVXNQSEKO-UHFFFAOYSA-N
DMFG6MU	IU	4-chloro-N-(diaminomethylidene)-3-methylsulfonylbenzamide
DMFG6MU	DE	Discovery agent

DM0ARP8	ID	DM0ARP8
DM0ARP8	DN	N-(4'-chloro-4-biphenylyl)methanesulfonamide
DM0ARP8	HS	Investigative
DM0ARP8	SN	CHEMBL242150; SCHEMBL4661119; BDBM50220160; ZINC28711996
DM0ARP8	DT	Small molecular drug
DM0ARP8	PC	11254540
DM0ARP8	MW	281.76
DM0ARP8	FM	C13H12ClNO2S
DM0ARP8	IC	InChI=1S/C13H12ClNO2S/c1-18(16,17)15-13-8-4-11(5-9-13)10-2-6-12(14)7-3-10/h2-9,15H,1H3
DM0ARP8	CS	CS(=O)(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)Cl
DM0ARP8	IK	XUCHFNFYOSJPDH-UHFFFAOYSA-N
DM0ARP8	IU	N-[4-(4-chlorophenyl)phenyl]methanesulfonamide
DM0ARP8	DE	Discovery agent

DMNO46U	ID	DMNO46U
DMNO46U	DN	N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine
DMNO46U	HS	Investigative
DMNO46U	SN	CHEMBL109274; N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine
DMNO46U	DT	Small molecular drug
DMNO46U	PC	44339119
DMNO46U	MW	310.8
DMNO46U	FM	C17H15ClN4
DMNO46U	IC	InChI=1S/C17H15ClN4/c1-10-2-4-11(5-3-10)12-6-7-13-14(8-12)16(22-17(19)20)21-9-15(13)18/h2-9H,1H3,(H4,19,20,21,22)
DMNO46U	CS	CC1=CC=C(C=C1)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl
DMNO46U	IK	CHWRGRHMWONZIO-UHFFFAOYSA-N
DMNO46U	IU	2-[4-chloro-7-(4-methylphenyl)isoquinolin-1-yl]guanidine
DMNO46U	DE	Discovery agent

DMGI9EA	ID	DMGI9EA
DMGI9EA	DN	N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine
DMGI9EA	HS	Investigative
DMGI9EA	SN	CHEMBL303297
DMGI9EA	DT	Small molecular drug
DMGI9EA	PC	10849356
DMGI9EA	MW	266.28
DMGI9EA	FM	C10H10N4O3S
DMGI9EA	IC	InChI=1S/C10H10N4O3S/c1-18(16,17)8-4-6(2-3-7(8)5-11)9(15)14-10(12)13/h2-4H,1H3,(H4,12,13,14,15)
DMGI9EA	CS	CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)C#N
DMGI9EA	IK	ASFBPCUWKPJTES-UHFFFAOYSA-N
DMGI9EA	IU	4-cyano-N-(diaminomethylidene)-3-methylsulfonylbenzamide
DMGI9EA	DE	Discovery agent

DMW8S2D	ID	DMW8S2D
DMW8S2D	DN	N-(4-cyanophenyl)sulfamide
DMW8S2D	HS	Investigative
DMW8S2D	SN	N-(4-cyanophenyl)sulfamide; 164648-70-8; (4-cyanophenyl)sulfamide; CHEMBL166340; N-(4-cyanophenyl)aminosulfonamide; N-(4-cyanophenyl)sulfuric diamide; EN300-34005; AC1Q55HF; Sulfamide, (4-cyanophenyl)-; SCHEMBL1646278; Sulfamide, N-(4-cyanophenyl)-; CTK0E5869; DTXSID50597031; MolPort-004-336-840; 4-(Aminosulfonylamino)benzonitrile; ZINC13013704; BDBM50124179; AKOS000176530; FCH5272297; BBV-070788; NE46233; MCULE-1558116315; NCGC00338522-01; KB-299386; 79489-EP2305695A2; 79489-EP2305697A2; AB01330899-02; 79489-EP2305698A2
DMW8S2D	DT	Small molecular drug
DMW8S2D	PC	18975977
DMW8S2D	MW	197.22
DMW8S2D	FM	C7H7N3O2S
DMW8S2D	IC	InChI=1S/C7H7N3O2S/c8-5-6-1-3-7(4-2-6)10-13(9,11)12/h1-4,10H,(H2,9,11,12)
DMW8S2D	CS	C1=CC(=CC=C1C#N)NS(=O)(=O)N
DMW8S2D	IK	XFOYAXPHCAOZCA-UHFFFAOYSA-N
DMW8S2D	IU	1-cyano-4-(sulfamoylamino)benzene
DMW8S2D	CA	CAS 164648-70-8
DMW8S2D	DE	Discovery agent

DMB3E7H	ID	DMB3E7H
DMB3E7H	DN	N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide
DMB3E7H	HS	Investigative
DMB3E7H	SN	CHEMBL75358; 18327-42-9; Acetamide, N-[4-(dimethylamino)-2-butyn-1-yl]-N-methyl-; AC1Q5IBV; AC1L2EPN; N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide; SCHEMBL11727547; CTK0A6148; DTXSID20274645; BDBM50009291; AKOS030565254; N-Methyl-N-[4-dimethylamino-2-butynyl]acetamide; N-[4-(dimethylamino)but-2-ynyl]-N-methylacetamide; n-[4-(dimethylamino)but-2-yn-1-yl]-n-methylacetamide; Acetamide, N-[4-(dimethylamino)-2-butynyl]-N-methyl-
DMB3E7H	DT	Small molecular drug
DMB3E7H	PC	19718
DMB3E7H	MW	168.24
DMB3E7H	FM	C9H16N2O
DMB3E7H	IC	InChI=1S/C9H16N2O/c1-9(12)11(4)8-6-5-7-10(2)3/h7-8H2,1-4H3
DMB3E7H	CS	CC(=O)N(C)CC#CCN(C)C
DMB3E7H	IK	FPUURHVXHFAVKC-UHFFFAOYSA-N
DMB3E7H	IU	N-[4-(dimethylamino)but-2-ynyl]-N-methylacetamide
DMB3E7H	CA	CAS 18327-42-9
DMB3E7H	DE	Discovery agent

DMU1ATH	ID	DMU1ATH
DMU1ATH	DN	N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide
DMU1ATH	HS	Investigative
DMU1ATH	SN	CHEMBL484204; N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide
DMU1ATH	DT	Small molecular drug
DMU1ATH	PC	25139332
DMU1ATH	MW	352.5
DMU1ATH	FM	C23H32N2O
DMU1ATH	IC	InChI=1S/C23H32N2O/c1-3-17-25(18-4-2)19-9-8-16-24-23(26)22-14-12-21(13-15-22)20-10-6-5-7-11-20/h5-7,10-15H,3-4,8-9,16-19H2,1-2H3,(H,24,26)
DMU1ATH	CS	CCCN(CCC)CCCCNC(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DMU1ATH	IK	HXCWGVSINJYYSW-UHFFFAOYSA-N
DMU1ATH	IU	N-[4-(dipropylamino)butyl]-4-phenylbenzamide
DMU1ATH	DE	Discovery agent

DM012TN	ID	DM012TN
DM012TN	DN	N-(4-Ethoxybutyl)-2-oxohexadecanamide
DM012TN	HS	Investigative
DM012TN	SN	CHEMBL461318
DM012TN	DT	Small molecular drug
DM012TN	PC	16118461
DM012TN	MW	369.6
DM012TN	FM	C22H43NO3
DM012TN	IC	InChI=1S/C22H43NO3/c1-3-5-6-7-8-9-10-11-12-13-14-15-18-21(24)22(25)23-19-16-17-20-26-4-2/h3-20H2,1-2H3,(H,23,25)
DM012TN	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCCCCOCC
DM012TN	IK	ADDZROPIKDXVSC-UHFFFAOYSA-N
DM012TN	IU	N-(4-ethoxybutyl)-2-oxohexadecanamide
DM012TN	DE	Discovery agent

DMWTVJH	ID	DMWTVJH
DMWTVJH	DN	N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide
DMWTVJH	HS	Investigative
DMWTVJH	SN	N-(4-ethylphenyl)-2-oxo-2H-chromene-3-carboxamide; 2-Oxo-2H-chromene-3-carboxylic acid (4-ethyl-phenyl)-amide; AC1LF7IS; ChemDiv3_001051; AC1Q2TK3; 3-carboxamido coumarin, 13; Oprea1_789803; Oprea1_049912; CHEMBL469583; BDBM29163; MolPort-000-375-251; HMS1475P17; ZINC130255; STK421228; AKOS000533669; MCULE-8672204127; IDI1_020017; BAS 00837926; ST45140661; EU-0002704; N-(4-ethylphenyl)-2-oxochromene-3-carboxamide; SR-01000410412; N-(4-ethylphenyl)(2-oxochromen-3-yl)carboxamide; SR-01000410412-1
DMWTVJH	DT	Small molecular drug
DMWTVJH	PC	724200
DMWTVJH	MW	293.3
DMWTVJH	FM	C18H15NO3
DMWTVJH	IC	InChI=1S/C18H15NO3/c1-2-12-7-9-14(10-8-12)19-17(20)15-11-13-5-3-4-6-16(13)22-18(15)21/h3-11H,2H2,1H3,(H,19,20)
DMWTVJH	CS	CCC1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMWTVJH	IK	CCRNXJJERVYHEO-UHFFFAOYSA-N
DMWTVJH	IU	N-(4-ethylphenyl)-2-oxochromene-3-carboxamide
DMWTVJH	DE	Discovery agent

DMIWNAY	ID	DMIWNAY
DMIWNAY	DN	N-(4-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMIWNAY	HS	Investigative
DMIWNAY	SN	CHEMBL1269648; N-(4-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMIWNAY	DT	Small molecular drug
DMIWNAY	PC	24759786
DMIWNAY	MW	252.31
DMIWNAY	FM	C16H16N2O
DMIWNAY	IC	InChI=1S/C16H16N2O/c1-3-12-5-7-13(8-6-12)17-16-18-14-10-11(2)4-9-15(14)19-16/h4-10H,3H2,1-2H3,(H,17,18)
DMIWNAY	CS	CCC1=CC=C(C=C1)NC2=NC3=C(O2)C=CC(=C3)C
DMIWNAY	IK	NQAKLIGQCZLYKC-UHFFFAOYSA-N
DMIWNAY	IU	N-(4-ethylphenyl)-5-methyl-1,3-benzoxazol-2-amine
DMIWNAY	DE	Discovery agent

DMJ73T6	ID	DMJ73T6
DMJ73T6	DN	N-(4-Ethylphenyl)benzo[d]oxazol-2-amine
DMJ73T6	HS	Investigative
DMJ73T6	SN	CHEMBL1269619; N-(4-Ethylphenyl)benzo[d]oxazol-2-amine; SCHEMBL11966141; MolPort-009-215-967; BDBM50329392; ZINC32686273; N-(4-Ethylphenyl)benzoxazole-2-amine; AKOS034448323; MCULE-8409538696; SC-56930; N-(4-ethylphenyl)-1,3-benzoxazol-2-amine; BENZOOXAZOL-2-YL-(4-ETHYL-PHENYL)-AMINE; Z55890479
DMJ73T6	DT	Small molecular drug
DMJ73T6	PC	39918957
DMJ73T6	MW	238.28
DMJ73T6	FM	C15H14N2O
DMJ73T6	IC	InChI=1S/C15H14N2O/c1-2-11-7-9-12(10-8-11)16-15-17-13-5-3-4-6-14(13)18-15/h3-10H,2H2,1H3,(H,16,17)
DMJ73T6	CS	CCC1=CC=C(C=C1)NC2=NC3=CC=CC=C3O2
DMJ73T6	IK	KKIDKWUGBUWNPR-UHFFFAOYSA-N
DMJ73T6	IU	N-(4-ethylphenyl)-1,3-benzoxazol-2-amine
DMJ73T6	DE	Discovery agent

DMKN8U6	ID	DMKN8U6
DMKN8U6	DN	N-(4-Ethylphenyl)-N'-hydroxyoctanediamide
DMKN8U6	HS	Investigative
DMKN8U6	SN	CHEMBL1093042; BDBM50314139
DMKN8U6	DT	Small molecular drug
DMKN8U6	PC	45141954
DMKN8U6	MW	292.37
DMKN8U6	FM	C16H24N2O3
DMKN8U6	IC	InChI=1S/C16H24N2O3/c1-2-13-9-11-14(12-10-13)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-12,21H,2-8H2,1H3,(H,17,19)(H,18,20)
DMKN8U6	CS	CCC1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
DMKN8U6	IK	OMRKYIIKVIYNKK-UHFFFAOYSA-N
DMKN8U6	IU	N-(4-ethylphenyl)-N'-hydroxyoctanediamide
DMKN8U6	DE	Discovery agent

DMP1ICB	ID	DMP1ICB
DMP1ICB	DN	N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide
DMP1ICB	HS	Investigative
DMP1ICB	SN	CHEMBL1091737; N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide
DMP1ICB	DT	Small molecular drug
DMP1ICB	PC	46886448
DMP1ICB	MW	356.4
DMP1ICB	FM	C23H17FN2O
DMP1ICB	IC	InChI=1S/C23H17FN2O/c24-21-9-5-17(6-10-21)16-26(22-11-13-25-14-12-22)23(27)20-8-7-18-3-1-2-4-19(18)15-20/h1-15H,16H2
DMP1ICB	CS	C1=CC=C2C=C(C=CC2=C1)C(=O)N(CC3=CC=C(C=C3)F)C4=CC=NC=C4
DMP1ICB	IK	MQJXOIDGELXEHE-UHFFFAOYSA-N
DMP1ICB	IU	N-[(4-fluorophenyl)methyl]-N-pyridin-4-ylnaphthalene-2-carboxamide
DMP1ICB	DE	Discovery agent

DM7O5WS	ID	DM7O5WS
DM7O5WS	DN	N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide
DM7O5WS	HS	Investigative
DM7O5WS	SN	CHEMBL434069; N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide; BDBM50054470; (5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenoic acid 4-hydroxy-benzylamide
DM7O5WS	DT	Small molecular drug
DM7O5WS	PC	10811495
DM7O5WS	MW	409.6
DM7O5WS	FM	C27H39NO2
DM7O5WS	IC	InChI=1S/C27H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(30)28-24-25-20-22-26(29)23-21-25/h6-7,9-10,12-13,15-16,20-23,29H,2-5,8,11,14,17-19,24H2,1H3,(H,28,30)/b7-6-,10-9-,13-12-,16-15-
DM7O5WS	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCC1=CC=C(C=C1)O
DM7O5WS	IK	YSOGPKZWDUJRGP-DOFZRALJSA-N
DM7O5WS	IU	(5Z,8Z,11Z,14Z)-N-[(4-hydroxyphenyl)methyl]icosa-5,8,11,14-tetraenamide
DM7O5WS	DE	Discovery agent

DMC5H8G	ID	DMC5H8G
DMC5H8G	DN	N-(4-hydroxybiphenyl-3-yl)benzamide
DMC5H8G	HS	Investigative
DMC5H8G	SN	CHEMBL269935; N-(4-hydroxybiphenyl-3-yl)benzamide; SCHEMBL5724398; BDBM50232005
DMC5H8G	DT	Small molecular drug
DMC5H8G	PC	44454650
DMC5H8G	MW	289.3
DMC5H8G	FM	C19H15NO2
DMC5H8G	IC	InChI=1S/C19H15NO2/c21-18-12-11-16(14-7-3-1-4-8-14)13-17(18)20-19(22)15-9-5-2-6-10-15/h1-13,21H,(H,20,22)
DMC5H8G	CS	C1=CC=C(C=C1)C2=CC(=C(C=C2)O)NC(=O)C3=CC=CC=C3
DMC5H8G	IK	INXWGOLWSBWSOQ-UHFFFAOYSA-N
DMC5H8G	IU	N-(2-hydroxy-5-phenylphenyl)benzamide
DMC5H8G	DE	Discovery agent

DM4QR2C	ID	DM4QR2C
DM4QR2C	DN	N-(4-hydroxyphenylpropanyl)-spermine
DM4QR2C	HS	Investigative
DM4QR2C	SN	CHEMBL1096289; N-(4-hydroxyphenylpropanyl)-spermine
DM4QR2C	DT	Small molecular drug
DM4QR2C	PC	46886661
DM4QR2C	MW	334.5
DM4QR2C	FM	C19H34N4O
DM4QR2C	IC	InChI=1S/C19H34N4O/c20-12-6-15-21-13-4-5-14-22-16-7-17-23-19(24)11-10-18-8-2-1-3-9-18/h1-3,8-9,21-22H,4-7,10-17,20H2,(H,23,24)
DM4QR2C	CS	C1=CC=C(C=C1)CCC(=O)NCCCNCCCCNCCCN
DM4QR2C	IK	GLVZEIGFWZGDFV-UHFFFAOYSA-N
DM4QR2C	IU	N-[3-[4-(3-aminopropylamino)butylamino]propyl]-3-phenylpropanamide
DM4QR2C	DE	Discovery agent

DM6GFRP	ID	DM6GFRP
DM6GFRP	DN	N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide
DM6GFRP	HS	Investigative
DM6GFRP	SN	CHEMBL252013; N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide; AC1OW6PA
DM6GFRP	DT	Small molecular drug
DM6GFRP	PC	7927254
DM6GFRP	MW	407.13
DM6GFRP	FM	C14H9F3INO2
DM6GFRP	IC	InChI=1S/C14H9F3INO2/c15-14(16,17)21-12-7-1-9(2-8-12)13(20)19-11-5-3-10(18)4-6-11/h1-8H,(H,19,20)
DM6GFRP	CS	C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)I)OC(F)(F)F
DM6GFRP	IK	IUHUCVXLTXIWPU-UHFFFAOYSA-N
DM6GFRP	IU	N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide
DM6GFRP	DE	Discovery agent

DMK9FQG	ID	DMK9FQG
DMK9FQG	DN	N-(4-iodophenyl)-4-(trifluoromethyl)benzamide
DMK9FQG	HS	Investigative
DMK9FQG	SN	N-(4-iodophenyl)-4-(trifluoromethyl)benzamide; CHEMBL401308; AC1LKJKC; SCHEMBL7557294; MolPort-002-827-048; ZINC682493; BDBM50231097; AKOS008920216; MCULE-1341396811
DMK9FQG	DT	Small molecular drug
DMK9FQG	PC	1019468
DMK9FQG	MW	391.13
DMK9FQG	FM	C14H9F3INO
DMK9FQG	IC	InChI=1S/C14H9F3INO/c15-14(16,17)10-3-1-9(2-4-10)13(20)19-12-7-5-11(18)6-8-12/h1-8H,(H,19,20)
DMK9FQG	CS	C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)I)C(F)(F)F
DMK9FQG	IK	VTVLWVLMDYRPGZ-UHFFFAOYSA-N
DMK9FQG	IU	N-(4-iodophenyl)-4-(trifluoromethyl)benzamide
DMK9FQG	DE	Discovery agent

DMHANU5	ID	DMHANU5
DMHANU5	DN	N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea
DMHANU5	HS	Investigative
DMHANU5	SN	CHEMBL569724; BDBM50303601
DMHANU5	DT	Small molecular drug
DMHANU5	PC	44626534
DMHANU5	MW	501.4
DMHANU5	FM	C24H28IN3O
DMHANU5	IC	InChI=1S/C24H28IN3O/c1-28-13-12-24-11-3-2-4-20(24)22(28)14-16-5-8-19(15-21(16)24)27-23(29)26-18-9-6-17(25)7-10-18/h5-10,15,20,22H,2-4,11-14H2,1H3,(H2,26,27,29)/t20-,22+,24+/m0/s1
DMHANU5	CS	CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)NC(=O)NC5=CC=C(C=C5)I
DMHANU5	IK	PNKGWKXKIPIROR-BGWNEDDSSA-N
DMHANU5	IU	1-(4-iodophenyl)-3-[(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]urea
DMHANU5	DE	Discovery agent

DM2N3TG	ID	DM2N3TG
DM2N3TG	DN	N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide
DM2N3TG	HS	Investigative
DM2N3TG	SN	CHEMBL1215730; BDBM50324614
DM2N3TG	DT	Small molecular drug
DM2N3TG	PC	46901613
DM2N3TG	MW	302.4
DM2N3TG	FM	C20H18N2O
DM2N3TG	IC	InChI=1S/C20H18N2O/c1-15(23)22-20-4-2-3-19(14-20)18-7-5-16(6-8-18)13-17-9-11-21-12-10-17/h2-12,14H,13H2,1H3,(H,22,23)
DM2N3TG	CS	CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)CC3=CC=NC=C3
DM2N3TG	IK	HURKLDLRCGKBKL-UHFFFAOYSA-N
DM2N3TG	IU	N-[3-[4-(pyridin-4-ylmethyl)phenyl]phenyl]acetamide
DM2N3TG	DE	Discovery agent

DM2MGSO	ID	DM2MGSO
DM2MGSO	DN	N-(4'-isopropyl-4-biphenylyl)urea
DM2MGSO	HS	Investigative
DM2MGSO	SN	CHEMBL397249; SCHEMBL5427819; BDBM50220192; ZINC28712010
DM2MGSO	DT	Small molecular drug
DM2MGSO	PC	11630239
DM2MGSO	MW	254.33
DM2MGSO	FM	C16H18N2O
DM2MGSO	IC	InChI=1S/C16H18N2O/c1-11(2)12-3-5-13(6-4-12)14-7-9-15(10-8-14)18-16(17)19/h3-11H,1-2H3,(H3,17,18,19)
DM2MGSO	CS	CC(C)C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)N
DM2MGSO	IK	COFIGWCWVNQCFO-UHFFFAOYSA-N
DM2MGSO	IU	[4-(4-propan-2-ylphenyl)phenyl]urea
DM2MGSO	DE	Discovery agent

DMHM3LC	ID	DMHM3LC
DMHM3LC	DN	N-(4-methoxybenzyl)oleamide
DMHM3LC	HS	Investigative
DMHM3LC	SN	N-(4-methoxybenzyl)oleamide; CHEMBL372530; SCHEMBL18255425
DMHM3LC	DT	Small molecular drug
DMHM3LC	PC	11502240
DMHM3LC	MW	401.6
DMHM3LC	FM	C26H43NO2
DMHM3LC	IC	InChI=1S/C26H43NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26(28)27-23-24-19-21-25(29-2)22-20-24/h10-11,19-22H,3-9,12-18,23H2,1-2H3,(H,27,28)/b11-10-
DMHM3LC	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCC1=CC=C(C=C1)OC
DMHM3LC	IK	AABDRJHZBVPFLI-KHPPLWFESA-N
DMHM3LC	IU	(Z)-N-[(4-methoxyphenyl)methyl]octadec-9-enamide
DMHM3LC	DE	Discovery agent

DM5NOSM	ID	DM5NOSM
DM5NOSM	DN	N-(4-methoxyphenethyl)oleamide
DM5NOSM	HS	Investigative
DM5NOSM	SN	N-(4-methoxyphenethyl)oleamide; CHEMBL199702; BDBM50175120; N-[2-(4-Methoxyphenyl)ethyl]oleic amide
DM5NOSM	DT	Small molecular drug
DM5NOSM	PC	44406075
DM5NOSM	MW	415.7
DM5NOSM	FM	C27H45NO2
DM5NOSM	IC	InChI=1S/C27H45NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27(29)28-24-23-25-19-21-26(30-2)22-20-25/h10-11,19-22H,3-9,12-18,23-24H2,1-2H3,(H,28,29)/b11-10-
DM5NOSM	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=CC=C(C=C1)OC
DM5NOSM	IK	LWJMRSYDIYWZOL-KHPPLWFESA-N
DM5NOSM	IU	(Z)-N-[2-(4-methoxyphenyl)ethyl]octadec-9-enamide
DM5NOSM	DE	Discovery agent

DMJVPK6	ID	DMJVPK6
DMJVPK6	DN	N-(4-methoxyphenyl)oleamide
DMJVPK6	HS	Investigative
DMJVPK6	SN	N-(4-methoxyphenyl)oleamide; CHEMBL199960; SCHEMBL20777965
DMJVPK6	DT	Small molecular drug
DMJVPK6	PC	44406102
DMJVPK6	MW	387.6
DMJVPK6	FM	C25H41NO2
DMJVPK6	IC	InChI=1S/C25H41NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-25(27)26-23-19-21-24(28-2)22-20-23/h10-11,19-22H,3-9,12-18H2,1-2H3,(H,26,27)/b11-10-
DMJVPK6	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NC1=CC=C(C=C1)OC
DMJVPK6	IK	GVVBDSXGTXGHEV-KHPPLWFESA-N
DMJVPK6	IU	(Z)-N-(4-methoxyphenyl)octadec-9-enamide
DMJVPK6	DE	Discovery agent

DMO8L57	ID	DMO8L57
DMO8L57	DN	N-(4'-methyl-4-biphenylyl)urea
DMO8L57	HS	Investigative
DMO8L57	SN	CHEMBL244125; SCHEMBL5428805; N-(4''-methyl-4-biphenylyl)urea; ZINC28712009
DMO8L57	DT	Small molecular drug
DMO8L57	PC	11593788
DMO8L57	MW	226.27
DMO8L57	FM	C14H14N2O
DMO8L57	IC	InChI=1S/C14H14N2O/c1-10-2-4-11(5-3-10)12-6-8-13(9-7-12)16-14(15)17/h2-9H,1H3,(H3,15,16,17)
DMO8L57	CS	CC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)N
DMO8L57	IK	VXTBCYRTEKXSFH-UHFFFAOYSA-N
DMO8L57	IU	[4-(4-methylphenyl)phenyl]urea
DMO8L57	DE	Discovery agent

DMCZD37	ID	DMCZD37
DMCZD37	DN	N-(4-Methyl-benzoyl)-N'-phenethyl-guanidine
DMCZD37	HS	Investigative
DMCZD37	SN	CHEMBL107354; SCHEMBL4629436; BDBM50107044
DMCZD37	DT	Small molecular drug
DMCZD37	PC	22149251
DMCZD37	MW	281.35
DMCZD37	FM	C17H19N3O
DMCZD37	IC	InChI=1S/C17H19N3O/c1-13-7-9-15(10-8-13)16(21)20-17(18)19-12-11-14-5-3-2-4-6-14/h2-10H,11-12H2,1H3,(H3,18,19,20,21)
DMCZD37	CS	CC1=CC=C(C=C1)C(=O)NC(=NCCC2=CC=CC=C2)N
DMCZD37	IK	ZVURELUSYUBEQF-UHFFFAOYSA-N
DMCZD37	IU	4-methyl-N-[N'-(2-phenylethyl)carbamimidoyl]benzamide
DMCZD37	DE	Discovery agent

DMZX2BH	ID	DMZX2BH
DMZX2BH	DN	N-(4-methyl-benzyl)-4-phenoxy-benzamide
DMZX2BH	HS	Investigative
DMZX2BH	SN	CHEMBL199174; N-(4-methyl-benzyl)-4-phenoxy-benzamide; AC1OVMY0; BDBM50174096
DMZX2BH	DT	Small molecular drug
DMZX2BH	PC	7916852
DMZX2BH	MW	317.4
DMZX2BH	FM	C21H19NO2
DMZX2BH	IC	InChI=1S/C21H19NO2/c1-16-7-9-17(10-8-16)15-22-21(23)18-11-13-20(14-12-18)24-19-5-3-2-4-6-19/h2-14H,15H2,1H3,(H,22,23)
DMZX2BH	CS	CC1=CC=C(C=C1)CNC(=O)C2=CC=C(C=C2)OC3=CC=CC=C3
DMZX2BH	IK	ZMFAZMUZJXZNMY-UHFFFAOYSA-N
DMZX2BH	IU	N-[(4-methylphenyl)methyl]-4-phenoxybenzamide
DMZX2BH	DE	Discovery agent

DMXNMTD	ID	DMXNMTD
DMXNMTD	DN	N-(4'-methyl-piperazinyl) estradiol-16-carboxamide
DMXNMTD	HS	Investigative
DMXNMTD	SN	SCHEMBL12379484
DMXNMTD	DT	Small molecular drug
DMXNMTD	PC	44407682
DMXNMTD	MW	398.5
DMXNMTD	FM	C24H34N2O3
DMXNMTD	IC	InChI=1S/C24H34N2O3/c1-24-8-7-18-17-6-4-16(27)13-15(17)3-5-19(18)21(24)14-20(22(24)28)23(29)26-11-9-25(2)10-12-26/h4,6,13,18-22,27-28H,3,5,7-12,14H2,1-2H3/t18?,19?,20?,21?,22-,24-/m0/s1
DMXNMTD	CS	C[C@]12CCC3C(C1CC([C@@H]2O)C(=O)N4CCN(CC4)C)CCC5=C3C=CC(=C5)O
DMXNMTD	IK	VNXBDWUNAYPTRF-OOBULCBASA-N
DMXNMTD	IU	[(13S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]-(4-methylpiperazin-1-yl)methanone
DMXNMTD	DE	Discovery agent

DM03VXN	ID	DM03VXN
DM03VXN	DN	N-(4-methylthiazol-2-yl)-2-phenylacetamide
DM03VXN	HS	Investigative
DM03VXN	SN	N-(4-methylthiazol-2-yl)-2-phenylacetamide; 91392-19-7; N-(4-methyl-1,3-thiazol-2-yl)-2-phenylacetamide; AC1LIKML; CHEMBL388116; MolPort-000-563-422; ZINC563269; AKOS001315153; MCULE-5254964555; ST50771861; N-(4-methylthiazol-2-yl)-2-phenyl-acetamide; N-(4-methyl(1,3-thiazol-2-yl))-2-phenylacetamide
DM03VXN	DT	Small molecular drug
DM03VXN	PC	956653
DM03VXN	MW	232.3
DM03VXN	FM	C12H12N2OS
DM03VXN	IC	InChI=1S/C12H12N2OS/c1-9-8-16-12(13-9)14-11(15)7-10-5-3-2-4-6-10/h2-6,8H,7H2,1H3,(H,13,14,15)
DM03VXN	CS	CC1=CSC(=N1)NC(=O)CC2=CC=CC=C2
DM03VXN	IK	YUZOFWPNYHCMMW-UHFFFAOYSA-N
DM03VXN	IU	N-(4-methyl-1,3-thiazol-2-yl)-2-phenylacetamide
DM03VXN	DE	Discovery agent

DMTCA2Z	ID	DMTCA2Z
DMTCA2Z	DN	N-(4-methylthiazol-2-yl)benzamide
DMTCA2Z	HS	Investigative
DMTCA2Z	SN	N-(4-methylthiazol-2-yl)benzamide; N-(4-methyl-1,3-thiazol-2-yl)benzamide; 37529-67-2; N-(4-Methyl-thiazol-2-yl)-benzamide; CHEMBL209410; AC1LEZPY; BAS 00470405; Enamine_001521; TimTec1_007096; MLS001212480; SCHEMBL1270190; MolPort-000-432-004; HMS2828E18; HMS1554C12; HMS1398F03; ZINC5712475; BDBM50186335; AKOS000591433; AKOS002234121; MCULE-9983922498; DA-42608; SMR000514239; KB-109083; N-(4-Methylthiazol-2-yl)benzenecarboxamide; N-(4-methyl(1,3-thiazol-2-yl))benzamide; ST50002848; FT-0770347; EU-0040062; BB 0221669; SR-01000449566
DMTCA2Z	DT	Small molecular drug
DMTCA2Z	PC	695178
DMTCA2Z	MW	218.28
DMTCA2Z	FM	C11H10N2OS
DMTCA2Z	IC	InChI=1S/C11H10N2OS/c1-8-7-15-11(12-8)13-10(14)9-5-3-2-4-6-9/h2-7H,1H3,(H,12,13,14)
DMTCA2Z	CS	CC1=CSC(=N1)NC(=O)C2=CC=CC=C2
DMTCA2Z	IK	NEPIZAVYXKHUCD-UHFFFAOYSA-N
DMTCA2Z	IU	N-(4-methyl-1,3-thiazol-2-yl)benzamide
DMTCA2Z	DE	Discovery agent

DMGRFYV	ID	DMGRFYV
DMGRFYV	DN	N-(4-morpholinophenyl)docos-13-enamide
DMGRFYV	HS	Investigative
DMGRFYV	SN	CHEMBL199906; N-(4-morpholinophenyl)docos-13-enamide
DMGRFYV	DT	Small molecular drug
DMGRFYV	PC	44406101
DMGRFYV	MW	498.8
DMGRFYV	FM	C32H54N2O2
DMGRFYV	IC	InChI=1S/C32H54N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-32(35)33-30-22-24-31(25-23-30)34-26-28-36-29-27-34/h9-10,22-25H,2-8,11-21,26-29H2,1H3,(H,33,35)/b10-9-
DMGRFYV	CS	CCCCCCCC/C=C\\CCCCCCCCCCCC(=O)NC1=CC=C(C=C1)N2CCOCC2
DMGRFYV	IK	BNCLSGYMSOUADZ-KTKRTIGZSA-N
DMGRFYV	IU	(Z)-N-(4-morpholin-4-ylphenyl)docos-13-enamide
DMGRFYV	DE	Discovery agent

DMEBGF1	ID	DMEBGF1
DMEBGF1	DN	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide
DMEBGF1	HS	Investigative
DMEBGF1	SN	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244
DMEBGF1	DT	Small molecular drug
DMEBGF1	PC	9995195
DMEBGF1	MW	304.3
DMEBGF1	FM	C18H16N4O
DMEBGF1	IC	InChI=1S/C18H16N4O/c1-3-17(23)21-14-7-8-16-15(10-14)18(20-11-19-16)22-13-6-4-5-12(2)9-13/h3-11H,1H2,2H3,(H,21,23)(H,19,20,22)
DMEBGF1	CS	CC1=CC(=CC=C1)NC2=NC=NC3=C2C=C(C=C3)NC(=O)C=C
DMEBGF1	IK	AWQLTDUXGVCRBV-UHFFFAOYSA-N
DMEBGF1	IU	N-[4-(3-methylanilino)quinazolin-6-yl]prop-2-enamide
DMEBGF1	DE	Discovery agent

DMG6RTJ	ID	DMG6RTJ
DMG6RTJ	DN	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide
DMG6RTJ	HS	Investigative
DMG6RTJ	SN	CHEMBL297968; N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide
DMG6RTJ	DT	Small molecular drug
DMG6RTJ	PC	10494722
DMG6RTJ	MW	304.3
DMG6RTJ	FM	C18H16N4O
DMG6RTJ	IC	InChI=1S/C18H16N4O/c1-3-17(23)21-14-7-8-15-16(10-14)19-11-20-18(15)22-13-6-4-5-12(2)9-13/h3-11H,1H2,2H3,(H,21,23)(H,19,20,22)
DMG6RTJ	CS	CC1=CC(=CC=C1)NC2=NC=NC3=C2C=CC(=C3)NC(=O)C=C
DMG6RTJ	IK	FAGJCAQBJKSOOS-UHFFFAOYSA-N
DMG6RTJ	IU	N-[4-(3-methylanilino)quinazolin-7-yl]prop-2-enamide
DMG6RTJ	DE	Discovery agent

DMUJS4Y	ID	DMUJS4Y
DMUJS4Y	DN	N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile
DMUJS4Y	HS	Investigative
DMUJS4Y	SN	phenylalanine derivative, 44; CHEMBL200235; BDBM20120
DMUJS4Y	DT	Small molecular drug
DMUJS4Y	PC	11696652
DMUJS4Y	MW	383.4
DMUJS4Y	FM	C24H21N3O2
DMUJS4Y	IC	InChI=1S/C24H21N3O2/c25-15-16-26-24(29)22(17-18-7-3-1-4-8-18)27-23(28)21-13-11-20(12-14-21)19-9-5-2-6-10-19/h1-14,22H,16-17H2,(H,26,29)(H,27,28)/t22-/m0/s1
DMUJS4Y	CS	C1=CC=C(C=C1)C[C@@H](C(=O)NCC#N)NC(=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMUJS4Y	IK	DWFFMEGYLGKXHE-QFIPXVFZSA-N
DMUJS4Y	IU	N-[(2S)-1-(cyanomethylamino)-1-oxo-3-phenylpropan-2-yl]-4-phenylbenzamide
DMUJS4Y	DE	Discovery agent

DMTCMUG	ID	DMTCMUG
DMTCMUG	DN	N-(4-Phenylbutyl)-1H-indole-2-carboxamide
DMTCMUG	HS	Investigative
DMTCMUG	SN	CHEMBL459543; N-(4-Phenylbutyl)-1H-indole-2-carboxamide
DMTCMUG	DT	Small molecular drug
DMTCMUG	PC	44588136
DMTCMUG	MW	292.4
DMTCMUG	FM	C19H20N2O
DMTCMUG	IC	InChI=1S/C19H20N2O/c22-19(18-14-16-11-4-5-12-17(16)21-18)20-13-7-6-10-15-8-2-1-3-9-15/h1-5,8-9,11-12,14,21H,6-7,10,13H2,(H,20,22)
DMTCMUG	CS	C1=CC=C(C=C1)CCCCNC(=O)C2=CC3=CC=CC=C3N2
DMTCMUG	IK	LYMIBNDEHCKPTI-UHFFFAOYSA-N
DMTCMUG	IU	N-(4-phenylbutyl)-1H-indole-2-carboxamide
DMTCMUG	CA	CAS 1084920-00-2
DMTCMUG	DE	Discovery agent

DMSREW5	ID	DMSREW5
DMSREW5	DN	N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide
DMSREW5	HS	Investigative
DMSREW5	SN	pyrrole inhibitor 15; N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide; CHEMBL220677
DMSREW5	DT	Small molecular drug
DMSREW5	PC	16110290
DMSREW5	MW	242.32
DMSREW5	FM	C15H18N2O
DMSREW5	IC	InChI=1S/C15H18N2O/c18-15(14-10-6-12-16-14)17-11-5-4-9-13-7-2-1-3-8-13/h1-3,6-8,10,12,16H,4-5,9,11H2,(H,17,18)
DMSREW5	CS	C1=CC=C(C=C1)CCCCNC(=O)C2=CC=CN2
DMSREW5	IK	KBYBNLUYYDZWAT-UHFFFAOYSA-N
DMSREW5	IU	N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide
DMSREW5	DE	Discovery agent

DMYD4PC	ID	DMYD4PC
DMYD4PC	DN	N-(4-Phenyl-pyridin-2-yl)-guanidine
DMYD4PC	HS	Investigative
DMYD4PC	SN	CHEMBL54467; N-(4-Phenyl-pyridin-2-yl)-guanidine; Guanidine, N-(4-phenyl-2-pyridinyl)-; 2-(4-Phenyl-2-pyridinyl)guanidine; BDBM50108355
DMYD4PC	DT	Small molecular drug
DMYD4PC	PC	10219978
DMYD4PC	MW	212.25
DMYD4PC	FM	C12H12N4
DMYD4PC	IC	InChI=1S/C12H12N4/c13-12(14)16-11-8-10(6-7-15-11)9-4-2-1-3-5-9/h1-8H,(H4,13,14,15,16)
DMYD4PC	CS	C1=CC=C(C=C1)C2=CC(=NC=C2)N=C(N)N
DMYD4PC	IK	LQYVUDQYWIIZAV-UHFFFAOYSA-N
DMYD4PC	IU	2-(4-phenylpyridin-2-yl)guanidine
DMYD4PC	DE	Discovery agent

DMQS9OH	ID	DMQS9OH
DMQS9OH	DN	N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide
DMQS9OH	HS	Investigative
DMQS9OH	SN	CHEMBL222110; N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide; SCHEMBL1337989
DMQS9OH	DT	Small molecular drug
DMQS9OH	PC	11774008
DMQS9OH	MW	402.5
DMQS9OH	FM	C23H18N2O3S
DMQS9OH	IC	InChI=1S/C23H18N2O3S/c26-23(17-9-3-1-4-10-17)24-21-15-16-22(20-14-8-7-13-19(20)21)29(27,28)25-18-11-5-2-6-12-18/h1-16,25H,(H,24,26)
DMQS9OH	CS	C1=CC=C(C=C1)C(=O)NC2=CC=C(C3=CC=CC=C32)S(=O)(=O)NC4=CC=CC=C4
DMQS9OH	IK	WLKYPFNFQJMVGH-UHFFFAOYSA-N
DMQS9OH	IU	N-[4-(phenylsulfamoyl)naphthalen-1-yl]benzamide
DMQS9OH	DE	Discovery agent

DMPA91F	ID	DMPA91F
DMPA91F	DN	N-(4-Phenyl-thiazol-2-yl)-benzamide
DMPA91F	HS	Investigative
DMPA91F	SN	CHEMBL60334; N-(4-phenyl-1,3-thiazol-2-yl)benzamide; N-(4-Phenyl-thiazol-2-yl)-benzamide; 14269-45-5; N-(4-phenylthiazol-2-yl)benzamide; Enamine_004302; AC1LF3YD; AC1Q5LQ8; Cambridge id 5149845; Oprea1_016303; Oprea1_462006; Oprea1_007140; CBDivE_004384; SCHEMBL1270375; SCHEMBL18874193; CTK0F0159; DTXSID10353610; MolPort-000-432-183; HMS1406D12; 2-(Benzoylamino)-4-phenylthiazole; ZINC18022084; BDBM50101790; STK972349; STK337540; AKOS002233837; AKOS000478692; MCULE-8414212509; Benzamide, N-(4-phenyl-2-thiazolyl)-; NCGC00262409-01; BAS 0
DMPA91F	DT	Small molecular drug
DMPA91F	PC	746475
DMPA91F	MW	280.3
DMPA91F	FM	C16H12N2OS
DMPA91F	IC	InChI=1S/C16H12N2OS/c19-15(13-9-5-2-6-10-13)18-16-17-14(11-20-16)12-7-3-1-4-8-12/h1-11H,(H,17,18,19)
DMPA91F	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=CC=C3
DMPA91F	IK	NIRMZOKDACPPER-UHFFFAOYSA-N
DMPA91F	IU	N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMPA91F	CA	CAS 14269-45-5
DMPA91F	DE	Discovery agent

DM2OHVJ	ID	DM2OHVJ
DM2OHVJ	DN	N-(4-Phenylthiazol-2-yl)isonicotinamide
DM2OHVJ	HS	Investigative
DM2OHVJ	SN	N-(4-phenyl-1,3-thiazol-2-yl)pyridine-4-carboxamide; CHEMBL482012; 5245-66-9; N-(4-Phenylthiazol-2-yl)isonicotinamide; BAS 03572091; AC1Q5OBS; AC1LG7OX; CBMicro_015073; n-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Cambridge id 5245669; Oprea1_303023; Oprea1_553111; SCHEMBL17107144; CTK4J5937; DTXSID30355050; MolPort-001-992-732; ZINC290573; STK483947; BDBM50255300; AKOS000569765; MCULE-9247268363; BIM-0015234.P001; N-(4-Phenyl-thiazol-2-yl)-isonicotinamide; ST50017829; N~4~-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Z27772062
DM2OHVJ	DT	Small molecular drug
DM2OHVJ	PC	790259
DM2OHVJ	MW	281.3
DM2OHVJ	FM	C15H11N3OS
DM2OHVJ	IC	InChI=1S/C15H11N3OS/c19-14(12-6-8-16-9-7-12)18-15-17-13(10-20-15)11-4-2-1-3-5-11/h1-10H,(H,17,18,19)
DM2OHVJ	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=NC=C3
DM2OHVJ	IK	PUUUVNHZQJNJSV-UHFFFAOYSA-N
DM2OHVJ	IU	N-(4-phenyl-1,3-thiazol-2-yl)pyridine-4-carboxamide
DM2OHVJ	CA	CAS 5245-66-9
DM2OHVJ	DE	Discovery agent

DMG9D7A	ID	DMG9D7A
DMG9D7A	DN	N-(4-Propylaminobutyl)-4-biphenylcarboxamide
DMG9D7A	HS	Investigative
DMG9D7A	SN	CHEMBL444128; N-(4-Propylaminobutyl)-4-biphenylcarboxamide
DMG9D7A	DT	Small molecular drug
DMG9D7A	PC	25139331
DMG9D7A	MW	310.4
DMG9D7A	FM	C20H26N2O
DMG9D7A	IC	InChI=1S/C20H26N2O/c1-2-14-21-15-6-7-16-22-20(23)19-12-10-18(11-13-19)17-8-4-3-5-9-17/h3-5,8-13,21H,2,6-7,14-16H2,1H3,(H,22,23)
DMG9D7A	CS	CCCNCCCCNC(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DMG9D7A	IK	QAAKBUYWNXINKR-UHFFFAOYSA-N
DMG9D7A	IU	4-phenyl-N-[4-(propylamino)butyl]benzamide
DMG9D7A	DE	Discovery agent

DMHBWM9	ID	DMHBWM9
DMHBWM9	DN	N-(4-Pyridin-2-yl-thiazol-2-yl)-benzamide
DMHBWM9	HS	Investigative
DMHBWM9	SN	CHEMBL164087; N-(4-Pyridin-2-yl-thiazol-2-yl)-benzamide; AC1N3WC4; N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide; Oprea1_401409; MolPort-004-132-922; BDBM50097430; AKOS017070888; N-[4-(2-pyridyl)thiazol-2-yl]benzamide
DMHBWM9	DT	Small molecular drug
DMHBWM9	PC	4119262
DMHBWM9	MW	281.3
DMHBWM9	FM	C15H11N3OS
DMHBWM9	IC	InChI=1S/C15H11N3OS/c19-14(11-6-2-1-3-7-11)18-15-17-13(10-20-15)12-8-4-5-9-16-12/h1-10H,(H,17,18,19)
DMHBWM9	CS	C1=CC=C(C=C1)C(=O)NC2=NC(=CS2)C3=CC=CC=N3
DMHBWM9	IK	NNBHDRDMPNNEKO-UHFFFAOYSA-N
DMHBWM9	IU	N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide
DMHBWM9	DE	Discovery agent

DMOMYDV	ID	DMOMYDV
DMOMYDV	DN	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
DMOMYDV	HS	Investigative
DMOMYDV	SN	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide; N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide
DMOMYDV	DT	Small molecular drug
DMOMYDV	PC	9926933
DMOMYDV	MW	316.34
DMOMYDV	FM	C14H12N4O3S
DMOMYDV	IC	InChI=1S/C14H12N4O3S/c15-22(20,21)10-7-5-9(6-8-10)16-14(19)13-11-3-1-2-4-12(11)17-18-13/h1-8H,(H,16,19)(H,17,18)(H2,15,20,21)
DMOMYDV	CS	C1=CC=C2C(=C1)C(=NN2)C(=O)NC3=CC=C(C=C3)S(=O)(=O)N
DMOMYDV	IK	MNHPHKFLWAPNOV-UHFFFAOYSA-N
DMOMYDV	IU	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
DMOMYDV	DE	Discovery agent

DMZDACT	ID	DMZDACT
DMZDACT	DN	N-(4-Sulfamoyl-phenyl)-benzamide
DMZDACT	HS	Investigative
DMZDACT	SN	N-(4-sulfamoylphenyl)benzamide; CHEMBL23559; 4389-07-5; N-(4-Sulfamoyl-phenyl)-benzamide; AC1LF2IT; Cambridge id 5227171; Oprea1_273437; CBDivE_015411; ARONIS016836; SCHEMBL8422583; aromatic sulfonamide compound 17; BDBM16652; 4-Benzoylamino-benzenesulfonamide; VGYAUYNBRQPION-UHFFFAOYSA-N; MolPort-000-656-907; ZINC125245; KS-000049EF; p-(N-benzoylamino)benzenesulfonamide; STK056377; N-[4-(aminosulfonyl)phenyl]benzamide; AKOS000484672; MCULE-6142099718; phenyl-N-(4-sulfamoylphenyl)carboxamide
DMZDACT	DT	Small molecular drug
DMZDACT	PC	721954
DMZDACT	MW	276.31
DMZDACT	FM	C13H12N2O3S
DMZDACT	IC	InChI=1S/C13H12N2O3S/c14-19(17,18)12-8-6-11(7-9-12)15-13(16)10-4-2-1-3-5-10/h1-9H,(H,15,16)(H2,14,17,18)
DMZDACT	CS	C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMZDACT	IK	VGYAUYNBRQPION-UHFFFAOYSA-N
DMZDACT	IU	N-(4-sulfamoylphenyl)benzamide
DMZDACT	DE	Discovery agent

DM3FW9Q	ID	DM3FW9Q
DM3FW9Q	DN	N-(4-Sulfamoyl-phenyl)-butyramide
DM3FW9Q	HS	Investigative
DM3FW9Q	SN	N-(4-sulfamoylphenyl)butanamide; CHEMBL23591; AC1MQZRR; Butanamide, N-[4-(aminosulfonyl)phenyl]-; SCHEMBL6254979; aromatic sulfonamide compound 11; BDBM16646; 4-n-Butanamido-benzenesulfonamide; ZINC6039278; AKOS003870402
DM3FW9Q	DT	Small molecular drug
DM3FW9Q	PC	3510137
DM3FW9Q	MW	242.3
DM3FW9Q	FM	C10H14N2O3S
DM3FW9Q	IC	InChI=1S/C10H14N2O3S/c1-2-3-10(13)12-8-4-6-9(7-5-8)16(11,14)15/h4-7H,2-3H2,1H3,(H,12,13)(H2,11,14,15)
DM3FW9Q	CS	CCCC(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DM3FW9Q	IK	ZQNHPPBUHNMQIO-UHFFFAOYSA-N
DM3FW9Q	IU	N-(4-sulfamoylphenyl)butanamide
DM3FW9Q	DE	Discovery agent

DMJCXYQ	ID	DMJCXYQ
DMJCXYQ	DN	N-(4-Sulfamoyl-phenyl)-isobutyramide
DMJCXYQ	HS	Investigative
DMJCXYQ	SN	2-methyl-N-(4-sulfamoylphenyl)propanamide; Propanamide, N-[4-(aminosulfonyl)phenyl]-2-methyl-; 114841-20-2; CHEMBL23417; ACMC-20mkv1; AC1MM1G7; SCHEMBL13391029; CTK0G0891; BDBM16647; aromatic sulfonamide compound 12; DTXSID70390682; 4-Isobutanamido-benzenesulfonamide; MolPort-006-401-341; ZINC5384022; AKOS003848097; MCULE-4244298519; N-[4-(Aminosulfonyl)phenyl]-2-methylpropanamide, AldrichCPR
DMJCXYQ	DT	Small molecular drug
DMJCXYQ	PC	3253857
DMJCXYQ	MW	242.3
DMJCXYQ	FM	C10H14N2O3S
DMJCXYQ	IC	InChI=1S/C10H14N2O3S/c1-7(2)10(13)12-8-3-5-9(6-4-8)16(11,14)15/h3-7H,1-2H3,(H,12,13)(H2,11,14,15)
DMJCXYQ	CS	CC(C)C(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DMJCXYQ	IK	VVHPZBGPXIXCQI-UHFFFAOYSA-N
DMJCXYQ	IU	2-methyl-N-(4-sulfamoylphenyl)propanamide
DMJCXYQ	CA	CAS 114841-20-2
DMJCXYQ	DE	Discovery agent

DM7MHQD	ID	DM7MHQD
DM7MHQD	DN	N-(4-Sulfamoyl-phenyl)-propionamide
DM7MHQD	HS	Investigative
DM7MHQD	SN	N-(4-sulfamoylphenyl)propanamide; 4-propionamidobenzenesulfonamide; CHEMBL278395; 4708-37-6; AC1LI2CK; SCHEMBL13263684; aromatic sulfonamide compound 10; 4-Propionamido-benzenesulfonamide; BDBM16645; MolPort-001-490-167; ZINC381801; AKOS003252339; N-[4-(aminosulfonyl)phenyl]propanamide; MCULE-9928658311; ST45021659; AO-080/11989809
DM7MHQD	DT	Small molecular drug
DM7MHQD	PC	847760
DM7MHQD	MW	228.27
DM7MHQD	FM	C9H12N2O3S
DM7MHQD	IC	InChI=1S/C9H12N2O3S/c1-2-9(12)11-7-3-5-8(6-4-7)15(10,13)14/h3-6H,2H2,1H3,(H,11,12)(H2,10,13,14)
DM7MHQD	CS	CCC(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DM7MHQD	IK	KEFCIQSZJXXOLO-UHFFFAOYSA-N
DM7MHQD	IU	N-(4-sulfamoylphenyl)propanamide
DM7MHQD	DE	Discovery agent

DM7QX03	ID	DM7QX03
DM7QX03	DN	N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide
DM7QX03	HS	Investigative
DM7QX03	SN	CHEMBL51668; Benzamide, 4-(aminosulfonyl)-N-[2-[4-(aminosulfonyl)phenyl]ethyl]-; 361438-75-7; 4-sulfamoyl-N-[2-(4-sulfamoylphenyl)ethyl]benzamide; CTK1B0192; BDBM11635; DTXSID30439107; AKOS001421782
DM7QX03	DT	Small molecular drug
DM7QX03	PC	10385283
DM7QX03	MW	383.4
DM7QX03	FM	C15H17N3O5S2
DM7QX03	IC	InChI=1S/C15H17N3O5S2/c16-24(20,21)13-5-1-11(2-6-13)9-10-18-15(19)12-3-7-14(8-4-12)25(17,22)23/h1-8H,9-10H2,(H,18,19)(H2,16,20,21)(H2,17,22,23)
DM7QX03	CS	C1=CC(=CC=C1CCNC(=O)C2=CC=C(C=C2)S(=O)(=O)N)S(=O)(=O)N
DM7QX03	IK	DTWPVNTYGDBHCV-UHFFFAOYSA-N
DM7QX03	IU	4-sulfamoyl-N-[2-(4-sulfamoylphenyl)ethyl]benzamide
DM7QX03	CA	CAS 361438-75-7
DM7QX03	DE	Discovery agent

DMHX4F2	ID	DMHX4F2
DMHX4F2	DN	N-(4'-t-butyl-4-biphenylyl)urea
DMHX4F2	HS	Investigative
DMHX4F2	SN	CHEMBL244126; SCHEMBL5425660; N-(4''-t-butyl-4-biphenylyl)urea; BDBM50220188
DMHX4F2	DT	Small molecular drug
DMHX4F2	PC	11659042
DMHX4F2	MW	268.35
DMHX4F2	FM	C17H20N2O
DMHX4F2	IC	InChI=1S/C17H20N2O/c1-17(2,3)14-8-4-12(5-9-14)13-6-10-15(11-7-13)19-16(18)20/h4-11H,1-3H3,(H3,18,19,20)
DMHX4F2	CS	CC(C)(C)C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)N
DMHX4F2	IK	CQQWFWURFCAFPP-UHFFFAOYSA-N
DMHX4F2	IU	[4-(4-tert-butylphenyl)phenyl]urea
DMHX4F2	DE	Discovery agent

DMN6DAZ	ID	DMN6DAZ
DMN6DAZ	DN	N-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide
DMN6DAZ	HS	Investigative
DMN6DAZ	SN	CHEMBL183121; N-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide; SCHEMBL3873012; JWPYMHAYISNKIC-UHFFFAOYSA-N; BDBM50160036; N-(4-tert-butylphenyl)-4-(2-pyridinyl)benzamide
DMN6DAZ	DT	Small molecular drug
DMN6DAZ	PC	11472986
DMN6DAZ	MW	330.4
DMN6DAZ	FM	C22H22N2O
DMN6DAZ	IC	InChI=1S/C22H22N2O/c1-22(2,3)18-11-13-19(14-12-18)24-21(25)17-9-7-16(8-10-17)20-6-4-5-15-23-20/h4-15H,1-3H3,(H,24,25)
DMN6DAZ	CS	CC(C)(C)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)C3=CC=CC=N3
DMN6DAZ	IK	JWPYMHAYISNKIC-UHFFFAOYSA-N
DMN6DAZ	IU	N-(4-tert-butylphenyl)-4-pyridin-2-ylbenzamide
DMN6DAZ	DE	Discovery agent

DMFUBQ8	ID	DMFUBQ8
DMFUBQ8	DN	N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine
DMFUBQ8	HS	Investigative
DMFUBQ8	SN	CHEMBL207479; N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine; SCHEMBL5966378
DMFUBQ8	DT	Small molecular drug
DMFUBQ8	PC	21866574
DMFUBQ8	MW	271.4
DMFUBQ8	FM	C15H17N3S
DMFUBQ8	IC	InChI=1S/C15H17N3S/c1-15(2,3)13-9-19-14(18-13)17-12-6-4-5-11-10(12)7-8-16-11/h4-9,16H,1-3H3,(H,17,18)
DMFUBQ8	CS	CC(C)(C)C1=CSC(=N1)NC2=CC=CC3=C2C=CN3
DMFUBQ8	IK	ITGYBDHDFLFUCN-UHFFFAOYSA-N
DMFUBQ8	IU	4-tert-butyl-N-(1H-indol-4-yl)-1,3-thiazol-2-amine
DMFUBQ8	DE	Discovery agent

DMMUX86	ID	DMMUX86
DMMUX86	DN	N-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine
DMMUX86	HS	Investigative
DMMUX86	SN	CHEMBL378272; N-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine
DMMUX86	DT	Small molecular drug
DMMUX86	PC	44411492
DMMUX86	MW	283.4
DMMUX86	FM	C16H17N3S
DMMUX86	IC	InChI=1S/C16H17N3S/c1-16(2,3)14-10-20-15(19-14)18-13-6-4-5-11-9-17-8-7-12(11)13/h4-10H,1-3H3,(H,18,19)
DMMUX86	CS	CC(C)(C)C1=CSC(=N1)NC2=CC=CC3=C2C=CN=C3
DMMUX86	IK	JVTUKUHMGYMFFT-UHFFFAOYSA-N
DMMUX86	IU	4-tert-butyl-N-isoquinolin-5-yl-1,3-thiazol-2-amine
DMMUX86	DE	Discovery agent

DMBMAKG	ID	DMBMAKG
DMBMAKG	DN	N-(4-tert-butylthiazol-2-yl)quinolin-5-amine
DMBMAKG	HS	Investigative
DMBMAKG	SN	CHEMBL207857; N-(4-tert-butylthiazol-2-yl)quinolin-5-amine; SCHEMBL14433246
DMBMAKG	DT	Small molecular drug
DMBMAKG	PC	9900444
DMBMAKG	MW	283.4
DMBMAKG	FM	C16H17N3S
DMBMAKG	IC	InChI=1S/C16H17N3S/c1-16(2,3)14-10-20-15(19-14)18-13-8-4-7-12-11(13)6-5-9-17-12/h4-10H,1-3H3,(H,18,19)
DMBMAKG	CS	CC(C)(C)C1=CSC(=N1)NC2=CC=CC3=C2C=CC=N3
DMBMAKG	IK	RGBQNFYMCAUMHK-UHFFFAOYSA-N
DMBMAKG	IU	4-tert-butyl-N-quinolin-5-yl-1,3-thiazol-2-amine
DMBMAKG	DE	Discovery agent

DMEW3L0	ID	DMEW3L0
DMEW3L0	DN	N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE
DMEW3L0	HS	Investigative
DMEW3L0	SN	(5,6-Diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-acetic acid; N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE; 701223-63-4; DFW; 2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]acetic acid; 2-({5,6-diphenylfuro[2,3-d]pyrimidin-4-yl}amino)acetic acid; 2brh; CBKinase1_018018; furanopyrimidine compound 4; CBKinase1_005618; AC1LI48C; SCHEMBL6748456; CHEMBL363302; BDBM14802; MolPort-002-125-656; ZINC383023; AKOS015957210; MCULE-9828982030; DB07653; L-3296; SR-01000273355; SR-01000273355-1; BRD-K42410867-001-01-6; F1684-0511
DMEW3L0	DT	Small molecular drug
DMEW3L0	PC	848641
DMEW3L0	MW	345.4
DMEW3L0	FM	C20H15N3O3
DMEW3L0	IC	InChI=1S/C20H15N3O3/c24-15(25)11-21-19-17-16(13-7-3-1-4-8-13)18(14-9-5-2-6-10-14)26-20(17)23-12-22-19/h1-10,12H,11H2,(H,24,25)(H,21,22,23)
DMEW3L0	CS	C1=CC=C(C=C1)C2=C(OC3=NC=NC(=C23)NCC(=O)O)C4=CC=CC=C4
DMEW3L0	IK	VXTCEUDVOCLEJG-UHFFFAOYSA-N
DMEW3L0	IU	2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]acetic acid
DMEW3L0	DE	Discovery agent

DM47XR8	ID	DM47XR8
DM47XR8	DN	N-(5-Amino-6-oxo-heptyl)-acetamidine
DM47XR8	HS	Investigative
DM47XR8	DT	Small molecular drug
DM47XR8	PC	44393463
DM47XR8	MW	185.27
DM47XR8	FM	C9H19N3O
DM47XR8	IC	InChI=1S/C9H19N3O/c1-7(13)9(11)5-3-4-6-12-8(2)10/h9H,3-6,11H2,1-2H3,(H2,10,12)
DM47XR8	CS	CC(=O)C(CCCCN=C(C)N)N
DM47XR8	IK	ADHBRNMPDLVKQT-UHFFFAOYSA-N
DM47XR8	IU	N'-(5-amino-6-oxoheptyl)ethanimidamide
DM47XR8	DE	Discovery agent

DMTF8US	ID	DMTF8US
DMTF8US	DN	N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide
DMTF8US	HS	Investigative
DMTF8US	SN	N-(5-benzoyl-4-phenyl-1,3-thiazol-2-yl)benzamide; CHEMBL600232; N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide; 305851-70-1; AC1LJXJU; Oprea1_574683; MolPort-000-184-059; ZINC626960; BDBM50308494; AKOS001011200; MCULE-6547152460; AB00666822-01; AQ-360/10877054
DMTF8US	DT	Small molecular drug
DMTF8US	PC	981611
DMTF8US	MW	384.5
DMTF8US	FM	C23H16N2O2S
DMTF8US	IC	InChI=1S/C23H16N2O2S/c26-20(17-12-6-2-7-13-17)21-19(16-10-4-1-5-11-16)24-23(28-21)25-22(27)18-14-8-3-9-15-18/h1-15H,(H,24,25,27)
DMTF8US	CS	C1=CC=C(C=C1)C2=C(SC(=N2)NC(=O)C3=CC=CC=C3)C(=O)C4=CC=CC=C4
DMTF8US	IK	PCQHQQZQXRSVDE-UHFFFAOYSA-N
DMTF8US	IU	N-(5-benzoyl-4-phenyl-1,3-thiazol-2-yl)benzamide
DMTF8US	DE	Discovery agent

DMGAITY	ID	DMGAITY
DMGAITY	DN	N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine
DMGAITY	HS	Investigative
DMGAITY	SN	CHEMBL325094; N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine; SCHEMBL6998909; KMGPZVZUHUMNQX-UHFFFAOYSA-N; BDBM50147411
DMGAITY	DT	Small molecular drug
DMGAITY	PC	21192457
DMGAITY	MW	292.33
DMGAITY	FM	C17H16N4O
DMGAITY	IC	InChI=1S/C17H16N4O/c18-17(19)21-16-14-7-4-8-15(13(14)9-10-20-16)22-11-12-5-2-1-3-6-12/h1-10H,11H2,(H4,18,19,20,21)
DMGAITY	CS	C1=CC=C(C=C1)COC2=CC=CC3=C2C=CN=C3N=C(N)N
DMGAITY	IK	KMGPZVZUHUMNQX-UHFFFAOYSA-N
DMGAITY	IU	2-(5-phenylmethoxyisoquinolin-1-yl)guanidine
DMGAITY	DE	Discovery agent

DMD5E8G	ID	DMD5E8G
DMD5E8G	DN	N-(5-Bromo-quinoxalin-6-yl)-guanidine
DMD5E8G	HS	Investigative
DMD5E8G	SN	CHEMBL883; 168329-48-4; BDBM50213216; AKOS027322398; Guanidine, N-(5-bromo-6-quinoxalinyl)-; (5-Bromo-6-quinoxalinyl)guanidine Hydrochloride
DMD5E8G	DT	Small molecular drug
DMD5E8G	PC	14928441
DMD5E8G	MW	266.1
DMD5E8G	FM	C9H8BrN5
DMD5E8G	IC	InChI=1S/C9H8BrN5/c10-7-5(15-9(11)12)1-2-6-8(7)14-4-3-13-6/h1-4H,(H4,11,12,15)
DMD5E8G	CS	C1=CC2=NC=CN=C2C(=C1N=C(N)N)Br
DMD5E8G	IK	WBGSURPVIDDDHF-UHFFFAOYSA-N
DMD5E8G	IU	2-(5-bromoquinoxalin-6-yl)guanidine
DMD5E8G	DE	Discovery agent

DMHZ256	ID	DMHZ256
DMHZ256	DN	N-(5-chloro-2-(phenylthio)phenyl)butyramide
DMHZ256	HS	Investigative
DMHZ256	SN	CHEMBL371088; N-(5-chloro-2-(phenylthio)phenyl)butyramide
DMHZ256	DT	Small molecular drug
DMHZ256	PC	11507784
DMHZ256	MW	305.8
DMHZ256	FM	C16H16ClNOS
DMHZ256	IC	InChI=1S/C16H16ClNOS/c1-2-6-16(19)18-14-11-12(17)9-10-15(14)20-13-7-4-3-5-8-13/h3-5,7-11H,2,6H2,1H3,(H,18,19)
DMHZ256	CS	CCCC(=O)NC1=C(C=CC(=C1)Cl)SC2=CC=CC=C2
DMHZ256	IK	XBVVQFDKYKYIDI-UHFFFAOYSA-N
DMHZ256	IU	N-(5-chloro-2-phenylsulfanylphenyl)butanamide
DMHZ256	DE	Discovery agent

DM2TFJE	ID	DM2TFJE
DM2TFJE	DN	N-(5-chlorobenzo[d]oxazol-2-yl)benzenesulfonamide
DM2TFJE	HS	Investigative
DM2TFJE	SN	CHEMBL207096; N-(5-chlorobenzo[d]oxazol-2-yl)benzenesulfonamide
DM2TFJE	DT	Small molecular drug
DM2TFJE	PC	44410037
DM2TFJE	MW	308.74
DM2TFJE	FM	C13H9ClN2O3S
DM2TFJE	IC	InChI=1S/C13H9ClN2O3S/c14-9-6-7-12-11(8-9)15-13(19-12)16-20(17,18)10-4-2-1-3-5-10/h1-8H,(H,15,16)
DM2TFJE	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=NC3=C(O2)C=CC(=C3)Cl
DM2TFJE	IK	AGIHDQSDUKQVDK-UHFFFAOYSA-N
DM2TFJE	IU	N-(5-chloro-1,3-benzoxazol-2-yl)benzenesulfonamide
DM2TFJE	DE	Discovery agent

DM9JCD3	ID	DM9JCD3
DM9JCD3	DN	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
DM9JCD3	HS	Investigative
DM9JCD3	SN	N-(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)BENZAMIDE; CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647
DM9JCD3	DT	Small molecular drug
DM9JCD3	PC	449088
DM9JCD3	MW	227.26
DM9JCD3	FM	C13H13N3O
DM9JCD3	IC	InChI=1S/C13H13N3O/c17-13(10-4-2-1-3-5-10)14-12-8-11(15-16-12)9-6-7-9/h1-5,8-9H,6-7H2,(H2,14,15,16,17)
DM9JCD3	CS	C1CC1C2=CC(=NN2)NC(=O)C3=CC=CC=C3
DM9JCD3	IK	LUCORKWTQSQFFU-UHFFFAOYSA-N
DM9JCD3	IU	N-(5-cyclopropyl-1H-pyrazol-3-yl)benzamide
DM9JCD3	DE	Discovery agent

DMNQDLC	ID	DMNQDLC
DMNQDLC	DN	N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide
DMNQDLC	HS	Investigative
DMNQDLC	SN	CHEMBL500977; 30457-35-3; N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide; CTK8I1084; ZINC39121736; BDBM50256510; AKOS027393952; KB-299693; N-(5-ethyl-1,3,4-thiadiazol-2-yl)aminosulfonamide; N-(5-Ethyl-1,3,4-thiadiazol-2-yl)sulfuric diamide
DMNQDLC	DT	Small molecular drug
DMNQDLC	PC	25154730
DMNQDLC	MW	208.3
DMNQDLC	FM	C4H8N4O2S2
DMNQDLC	IC	InChI=1S/C4H8N4O2S2/c1-2-3-6-7-4(11-3)8-12(5,9)10/h2H2,1H3,(H,7,8)(H2,5,9,10)
DMNQDLC	CS	CCC1=NN=C(S1)NS(=O)(=O)N
DMNQDLC	IK	HVRGNGCSIVHKLU-UHFFFAOYSA-N
DMNQDLC	IU	2-ethyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DMNQDLC	DE	Discovery agent

DMUHKYW	ID	DMUHKYW
DMUHKYW	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide
DMUHKYW	HS	Investigative
DMUHKYW	SN	CHEMBL143802; N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide; SCHEMBL1233091; BDBM50082663; ZINC13801951; 6-[(4-Methoxybenzoyl)amino]hexanehydroxamic acid
DMUHKYW	DT	Small molecular drug
DMUHKYW	PC	9835402
DMUHKYW	MW	280.32
DMUHKYW	FM	C14H20N2O4
DMUHKYW	IC	InChI=1S/C14H20N2O4/c1-20-12-8-6-11(7-9-12)14(18)15-10-4-2-3-5-13(17)16-19/h6-9,19H,2-5,10H2,1H3,(H,15,18)(H,16,17)
DMUHKYW	CS	COC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NO
DMUHKYW	IK	ZSXRABTZDFXDGV-UHFFFAOYSA-N
DMUHKYW	IU	N-[6-(hydroxyamino)-6-oxohexyl]-4-methoxybenzamide
DMUHKYW	DE	Discovery agent

DMSUW7M	ID	DMSUW7M
DMSUW7M	DN	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide
DMSUW7M	HS	Investigative
DMSUW7M	SN	CHEMBL139999; N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide; SCHEMBL1232700; BDBM50082661; ZINC13472309
DMSUW7M	DT	Small molecular drug
DMSUW7M	PC	9943996
DMSUW7M	MW	295.29
DMSUW7M	FM	C13H17N3O5
DMSUW7M	IC	InChI=1S/C13H17N3O5/c17-12(15-19)4-2-1-3-9-14-13(18)10-5-7-11(8-6-10)16(20)21/h5-8,19H,1-4,9H2,(H,14,18)(H,15,17)
DMSUW7M	CS	C1=CC(=CC=C1C(=O)NCCCCCC(=O)NO)[N+](=O)[O-]
DMSUW7M	IK	GDAAHZPABCCCFD-UHFFFAOYSA-N
DMSUW7M	IU	N-[6-(hydroxyamino)-6-oxohexyl]-4-nitrobenzamide
DMSUW7M	DE	Discovery agent

DMZSGPB	ID	DMZSGPB
DMZSGPB	DN	N-(5-Hydroxycarbamoyl-pentyl)-benzamide
DMZSGPB	HS	Investigative
DMZSGPB	SN	CHEMBL143849; N-(5-Hydroxycarbamoyl-pentyl)-benzamide; SCHEMBL1232912; BDBM50082658; ZINC13801954; M-354
DMZSGPB	DT	Small molecular drug
DMZSGPB	PC	9921260
DMZSGPB	MW	250.29
DMZSGPB	FM	C13H18N2O3
DMZSGPB	IC	InChI=1S/C13H18N2O3/c16-12(15-18)9-5-2-6-10-14-13(17)11-7-3-1-4-8-11/h1,3-4,7-8,18H,2,5-6,9-10H2,(H,14,17)(H,15,16)
DMZSGPB	CS	C1=CC=C(C=C1)C(=O)NCCCCCC(=O)NO
DMZSGPB	IK	WOSZGUVOSPLDAN-UHFFFAOYSA-N
DMZSGPB	IU	N-[6-(hydroxyamino)-6-oxohexyl]benzamide
DMZSGPB	DE	Discovery agent

DMSQEXP	ID	DMSQEXP
DMSQEXP	DN	N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide
DMSQEXP	HS	Investigative
DMSQEXP	SN	32873-56-6; 2-Acetylamino-5-mercapto-1,3,4-thiadiazole; N-(5-sulfanyl-1,3,4-thiadiazol-2-yl)acetamide; 2-Acetamido-5-mercapto-1,3,4-Thiadiazole; UNII-6B8475348K; MLS002703417; CHEMBL382111; DWSMAMSVZRCQMP-UHFFFAOYSA-N; N-(5-mercapto-1,3,4-thiadiazol-2-yl)acetamide; N-(5-sulfanylidene-4,5-dihydro-1,3,4-thiadiazol-2-yl)acetamide; 6B8475348K; {N}-(5-mercapto-1,3,4-thiadiazol-2-yl)acetamide; N-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)acetamide; Acetamide,N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-; C4H5N3OS2; NSC97893
DMSQEXP	DT	Small molecular drug
DMSQEXP	PC	2723687
DMSQEXP	MW	175.2
DMSQEXP	FM	C4H5N3OS2
DMSQEXP	IC	InChI=1S/C4H5N3OS2/c1-2(8)5-3-6-7-4(9)10-3/h1H3,(H,7,9)(H,5,6,8)
DMSQEXP	CS	CC(=O)NC1=NNC(=S)S1
DMSQEXP	IK	DWSMAMSVZRCQMP-UHFFFAOYSA-N
DMSQEXP	IU	N-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)acetamide
DMSQEXP	CA	CAS 32873-56-6
DMSQEXP	DE	Discovery agent

DM91463	ID	DM91463
DM91463	DN	N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine
DM91463	HS	Investigative
DM91463	SN	CHEMBL539413; SCHEMBL7125185
DM91463	DT	Small molecular drug
DM91463	PC	9992527
DM91463	MW	255.3
DM91463	FM	C10H13N3O3S
DM91463	IC	InChI=1S/C10H13N3O3S/c1-6-3-4-7(17(2,15)16)5-8(6)9(14)13-10(11)12/h3-5H,1-2H3,(H4,11,12,13,14)
DM91463	CS	CC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N=C(N)N
DM91463	IK	SSLQVRLYNHXNIS-UHFFFAOYSA-N
DM91463	IU	N-(diaminomethylidene)-2-methyl-5-methylsulfonylbenzamide
DM91463	DE	Discovery agent

DM8PNKC	ID	DM8PNKC
DM8PNKC	DN	N-(5-methylthiazol-2-yl)-2-phenylacetamide
DM8PNKC	HS	Investigative
DM8PNKC	SN	N-(5-methyl-1,3-thiazol-2-yl)-2-phenylacetamide; AC1NMTHK; CHEMBL425300; MolPort-006-386-848; ZINC3160947; STK408984; AKOS003243303; MCULE-9670423324; ST004442
DM8PNKC	DT	Small molecular drug
DM8PNKC	PC	5015763
DM8PNKC	MW	232.3
DM8PNKC	FM	C12H12N2OS
DM8PNKC	IC	InChI=1S/C12H12N2OS/c1-9-8-13-12(16-9)14-11(15)7-10-5-3-2-4-6-10/h2-6,8H,7H2,1H3,(H,13,14,15)
DM8PNKC	CS	CC1=CN=C(S1)NC(=O)CC2=CC=CC=C2
DM8PNKC	IK	BZGKXQSOFFPEDI-UHFFFAOYSA-N
DM8PNKC	IU	N-(5-methyl-1,3-thiazol-2-yl)-2-phenylacetamide
DM8PNKC	DE	Discovery agent

DMFI057	ID	DMFI057
DMFI057	DN	N-(5-methylthiazol-2-yl)benzamide
DMFI057	HS	Investigative
DMFI057	SN	N-(5-methyl-1,3-thiazol-2-yl)benzamide; AC1MBAM0; SCHEMBL1270133; CHEMBL390097; MolPort-006-054-218; ZINC3555837; STL456150; AKOS008918901; MCULE-4605210896; KB-102415; N-(5-Methylthiazol-2-yl)benzenecarboxamide; N~1~-(5-methyl-1,3-thiazol-2-yl)benzamide; Z29325335
DMFI057	DT	Small molecular drug
DMFI057	PC	2673074
DMFI057	MW	218.28
DMFI057	FM	C11H10N2OS
DMFI057	IC	InChI=1S/C11H10N2OS/c1-8-7-12-11(15-8)13-10(14)9-5-3-2-4-6-9/h2-7H,1H3,(H,12,13,14)
DMFI057	CS	CC1=CN=C(S1)NC(=O)C2=CC=CC=C2
DMFI057	IK	HEGBNFORMCPFKO-UHFFFAOYSA-N
DMFI057	IU	N-(5-methyl-1,3-thiazol-2-yl)benzamide
DMFI057	DE	Discovery agent

DMS2X69	ID	DMS2X69
DMS2X69	DN	N-(5-m-Tolyl-furan-2-carbonyl)-guanidine
DMS2X69	HS	Investigative
DMS2X69	SN	CHEMBL364735; N-(5-m-Tolyl-furan-2-carbonyl)-guanidine; SCHEMBL4936806
DMS2X69	DT	Small molecular drug
DMS2X69	PC	11390872
DMS2X69	MW	243.26
DMS2X69	FM	C13H13N3O2
DMS2X69	IC	InChI=1S/C13H13N3O2/c1-8-3-2-4-9(7-8)10-5-6-11(18-10)12(17)16-13(14)15/h2-7H,1H3,(H4,14,15,16,17)
DMS2X69	CS	CC1=CC(=CC=C1)C2=CC=C(O2)C(=O)N=C(N)N
DMS2X69	IK	BBOVVXJXVOJLSK-UHFFFAOYSA-N
DMS2X69	IU	N-(diaminomethylidene)-5-(3-methylphenyl)furan-2-carboxamide
DMS2X69	DE	Discovery agent

DMFNZSL	ID	DMFNZSL
DMFNZSL	DN	N-(5-o-Tolyl-furan-2-carbonyl)-guanidine
DMFNZSL	HS	Investigative
DMFNZSL	SN	CHEMBL192634; N-(5-o-Tolyl-furan-2-carbonyl)-guanidine
DMFNZSL	DT	Small molecular drug
DMFNZSL	PC	11218749
DMFNZSL	MW	243.26
DMFNZSL	FM	C13H13N3O2
DMFNZSL	IC	InChI=1S/C13H13N3O2/c1-8-4-2-3-5-9(8)10-6-7-11(18-10)12(17)16-13(14)15/h2-7H,1H3,(H4,14,15,16,17)
DMFNZSL	CS	CC1=CC=CC=C1C2=CC=C(O2)C(=O)N=C(N)N
DMFNZSL	IK	ACPWXEWIQCMXFE-UHFFFAOYSA-N
DMFNZSL	IU	N-(diaminomethylidene)-5-(2-methylphenyl)furan-2-carboxamide
DMFNZSL	DE	Discovery agent

DMA21WB	ID	DMA21WB
DMA21WB	DN	N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide
DMA21WB	HS	Investigative
DMA21WB	SN	CHEMBL475776; N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide
DMA21WB	DT	Small molecular drug
DMA21WB	PC	44571849
DMA21WB	MW	256.3
DMA21WB	FM	C8H8N4O2S2
DMA21WB	IC	InChI=1S/C8H8N4O2S2/c9-16(13,14)12-8-11-10-7(15-8)6-4-2-1-3-5-6/h1-5H,(H,11,12)(H2,9,13,14)
DMA21WB	CS	C1=CC=C(C=C1)C2=NN=C(S2)NS(=O)(=O)N
DMA21WB	IK	AYAZOMSTWAJWHN-UHFFFAOYSA-N
DMA21WB	IU	2-phenyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DMA21WB	DE	Discovery agent

DMNU68D	ID	DMNU68D
DMNU68D	DN	N-(5-Phenyl-furan-2-carbonyl)-guanidine
DMNU68D	HS	Investigative
DMNU68D	SN	CHEMBL192690; N-(5-Phenyl-furan-2-carbonyl)-guanidine; SCHEMBL4943707
DMNU68D	DT	Small molecular drug
DMNU68D	PC	11470226
DMNU68D	MW	229.23
DMNU68D	FM	C12H11N3O2
DMNU68D	IC	InChI=1S/C12H11N3O2/c13-12(14)15-11(16)10-7-6-9(17-10)8-4-2-1-3-5-8/h1-7H,(H4,13,14,15,16)
DMNU68D	CS	C1=CC=C(C=C1)C2=CC=C(O2)C(=O)N=C(N)N
DMNU68D	IK	SYROHGCLRGCTIR-UHFFFAOYSA-N
DMNU68D	IU	N-(diaminomethylidene)-5-phenylfuran-2-carboxamide
DMNU68D	DE	Discovery agent

DM3FCAI	ID	DM3FCAI
DM3FCAI	DN	N-(5'-Phosphopyridoxyl)-D-Alanine
DM3FCAI	HS	Investigative
DM3FCAI	SN	N-(5'-Phosphopyridoxyl)-D-alanine; N-(5'-PHOSPHOPYRIDOXYL)-D-ALANINE; N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-D-alanine; 2bmk; AC1L9K6I; SCHEMBL4997474; CHEBI:44743; DB01993; N-[2-Methyl-3-hydroxy-5-(phosphonooxymethyl)pyridine-4-ylmethyl]-D-alanine; (2R)-2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]propanoic
DM3FCAI	DT	Small molecular drug
DM3FCAI	PC	446862
DM3FCAI	MW	320.24
DM3FCAI	FM	C11H17N2O7P
DM3FCAI	IC	InChI=1S/C11H17N2O7P/c1-6-10(14)9(4-13-7(2)11(15)16)8(3-12-6)5-20-21(17,18)19/h3,7,13-14H,4-5H2,1-2H3,(H,15,16)(H2,17,18,19)/t7-/m1/s1
DM3FCAI	CS	CC1=NC=C(C(=C1O)CN[C@H](C)C(=O)O)COP(=O)(O)O
DM3FCAI	IK	WACJCHFWJNNBPR-SSDOTTSWSA-N
DM3FCAI	IU	(2R)-2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]propanoic acid
DM3FCAI	CB	CHEBI:44743
DM3FCAI	DE	Discovery agent

DMDZ9BY	ID	DMDZ9BY
DMDZ9BY	DN	N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-benzamide
DMDZ9BY	HS	Investigative
DMDZ9BY	SN	NSC698990; CHEMBL281376; N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)benzamide; 86029-44-9; N-(2-sulfamoyl-1,3,4-thiadiazol-5-yl)benzamide; Benzamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-; SCHEMBL9795960; AC1L997Y; BDBM16669; CTK2I3789; DTXSID30327878; ZINC5925092; heterocyclic sulfonamide compound 34; AKOS030579978; NSC-698990; NCI60_035393; LS-25666; 2-benzoylamino-1,3,4-thiadiazole 5-sulfonamide
DMDZ9BY	DT	Small molecular drug
DMDZ9BY	PC	394898
DMDZ9BY	MW	284.3
DMDZ9BY	FM	C9H8N4O3S2
DMDZ9BY	IC	InChI=1S/C9H8N4O3S2/c10-18(15,16)9-13-12-8(17-9)11-7(14)6-4-2-1-3-5-6/h1-5H,(H2,10,15,16)(H,11,12,14)
DMDZ9BY	CS	C1=CC=C(C=C1)C(=O)NC2=NN=C(S2)S(=O)(=O)N
DMDZ9BY	IK	PMNNJWNEWDGYIV-UHFFFAOYSA-N
DMDZ9BY	IU	N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)benzamide
DMDZ9BY	CA	CAS 86029-44-9
DMDZ9BY	DE	Discovery agent

DM5E7OC	ID	DM5E7OC
DM5E7OC	DN	N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide
DM5E7OC	HS	Investigative
DM5E7OC	SN	CHEMBL475775; N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide
DM5E7OC	DT	Small molecular drug
DM5E7OC	PC	44571846
DM5E7OC	MW	236.3
DM5E7OC	FM	C6H12N4O2S2
DM5E7OC	IC	InChI=1S/C6H12N4O2S2/c1-6(2,3)4-8-9-5(13-4)10-14(7,11)12/h1-3H3,(H,9,10)(H2,7,11,12)
DM5E7OC	CS	CC(C)(C)C1=NN=C(S1)NS(=O)(=O)N
DM5E7OC	IK	JJBJNTIFYMQMKH-UHFFFAOYSA-N
DM5E7OC	IU	2-tert-butyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DM5E7OC	DE	Discovery agent

DMDCX5O	ID	DMDCX5O
DMDCX5O	DN	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide
DMDCX5O	HS	Investigative
DMDCX5O	SN	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N
DMDCX5O	DT	Small molecular drug
DMDCX5O	PC	10380885
DMDCX5O	MW	313.8
DMDCX5O	FM	C17H16ClN3O
DMDCX5O	IC	InChI=1S/C17H16ClN3O/c1-2-5-16(22)19-17-13-9-8-11(10-15(13)20-21-17)12-6-3-4-7-14(12)18/h3-4,6-10H,2,5H2,1H3,(H2,19,20,21,22)
DMDCX5O	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=CC=C3Cl
DMDCX5O	IK	WPJGFQOEGTUKTE-UHFFFAOYSA-N
DMDCX5O	IU	N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide
DMDCX5O	DE	Discovery agent

DMKGBZA	ID	DMKGBZA
DMKGBZA	DN	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide
DMKGBZA	HS	Investigative
DMKGBZA	SN	CHEMBL1086639; N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706
DMKGBZA	DT	Small molecular drug
DMKGBZA	PC	22319573
DMKGBZA	MW	295.34
DMKGBZA	FM	C17H17N3O2
DMKGBZA	IC	InChI=1S/C17H17N3O2/c1-2-4-16(22)18-17-14-8-7-12(10-15(14)19-20-17)11-5-3-6-13(21)9-11/h3,5-10,21H,2,4H2,1H3,(H2,18,19,20,22)
DMKGBZA	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC(=CC=C3)O
DMKGBZA	IK	UKQRPDHIQLHFNS-UHFFFAOYSA-N
DMKGBZA	IU	N-[6-(3-hydroxyphenyl)-1H-indazol-3-yl]butanamide
DMKGBZA	DE	Discovery agent

DMDQEZG	ID	DMDQEZG
DMDQEZG	DN	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide
DMDQEZG	HS	Investigative
DMDQEZG	SN	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N
DMDQEZG	DT	Small molecular drug
DMDQEZG	PC	10085818
DMDQEZG	MW	294.35
DMDQEZG	FM	C17H18N4O
DMDQEZG	IC	InChI=1S/C17H18N4O/c1-2-3-16(22)19-17-14-9-6-12(10-15(14)20-21-17)11-4-7-13(18)8-5-11/h4-10H,2-3,18H2,1H3,(H2,19,20,21,22)
DMDQEZG	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=C(C=C3)N
DMDQEZG	IK	DCCRABAZYMVLJU-UHFFFAOYSA-N
DMDQEZG	IU	N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide
DMDQEZG	DE	Discovery agent

DMP7UZB	ID	DMP7UZB
DMP7UZB	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)
DMP7UZB	HS	Investigative
DMP7UZB	SN	CHEMBL1083014; N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX); SCHEMBL1404548; BDBM50320174
DMP7UZB	DT	Small molecular drug
DMP7UZB	PC	24996885
DMP7UZB	MW	491.8
DMP7UZB	FM	C24H21Cl3N2O3
DMP7UZB	IC	InChI=1S/C24H21Cl3N2O3/c1-24(2)11-20(28-21(31)12-30)18-10-17(13-3-5-14(25)6-4-13)22(29-23(18)32-24)16-8-7-15(26)9-19(16)27/h3-10,20,30H,11-12H2,1-2H3,(H,28,31)
DMP7UZB	CS	CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)NC(=O)CO)C
DMP7UZB	IK	LGJVWHPVWBOBEW-UHFFFAOYSA-N
DMP7UZB	IU	N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-2-hydroxyacetamide
DMP7UZB	DE	Discovery agent

DMDPXUA	ID	DMDPXUA
DMDPXUA	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX)
DMDPXUA	HS	Investigative
DMDPXUA	SN	CHEMBL1083016; N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX); SCHEMBL1404523; BDBM50320175
DMDPXUA	DT	Small molecular drug
DMDPXUA	PC	24992105
DMDPXUA	MW	533.9
DMDPXUA	FM	C27H27Cl3N2O3
DMDPXUA	IC	InChI=1S/C27H27Cl3N2O3/c1-26(2,14-33)25(34)31-22-13-27(3,4)35-24-20(22)12-19(15-5-7-16(28)8-6-15)23(32-24)18-10-9-17(29)11-21(18)30/h5-12,22,33H,13-14H2,1-4H3,(H,31,34)
DMDPXUA	CS	CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)NC(=O)C(C)(C)CO)C
DMDPXUA	IK	BRSUJFVKAISEFW-UHFFFAOYSA-N
DMDPXUA	IU	N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-3-hydroxy-2,2-dimethylpropanamide
DMDPXUA	DE	Discovery agent

DMSX5DI	ID	DMSX5DI
DMSX5DI	DN	N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMSX5DI	HS	Investigative
DMSX5DI	SN	CHEMBL1083025; N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX); BDBM50320176
DMSX5DI	DT	Small molecular drug
DMSX5DI	PC	46891225
DMSX5DI	MW	505.8
DMSX5DI	FM	C25H23Cl3N2O3
DMSX5DI	IC	InChI=1S/C25H23Cl3N2O3/c1-25(2)13-21(29-22(32)9-10-31)19-12-18(14-3-5-15(26)6-4-14)23(30-24(19)33-25)17-8-7-16(27)11-20(17)28/h3-8,11-12,21,31H,9-10,13H2,1-2H3,(H,29,32)
DMSX5DI	CS	CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)NC(=O)CCO)C
DMSX5DI	IK	CQVVMULTZQAZBA-UHFFFAOYSA-N
DMSX5DI	IU	N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-3-hydroxypropanamide
DMSX5DI	DE	Discovery agent

DM4M12J	ID	DM4M12J
DM4M12J	DN	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide
DM4M12J	HS	Investigative
DM4M12J	SN	CHEMBL1084681; N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680
DM4M12J	DT	Small molecular drug
DM4M12J	PC	22319694
DM4M12J	MW	297.33
DM4M12J	FM	C17H16FN3O
DM4M12J	IC	InChI=1S/C17H16FN3O/c1-2-3-16(22)19-17-14-9-6-12(10-15(14)20-21-17)11-4-7-13(18)8-5-11/h4-10H,2-3H2,1H3,(H2,19,20,21,22)
DM4M12J	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=C(C=C3)F
DM4M12J	IK	ORRUGYIZWSJRJU-UHFFFAOYSA-N
DM4M12J	IU	N-[6-(4-fluorophenyl)-1H-indazol-3-yl]butanamide
DM4M12J	DE	Discovery agent

DM8JLR4	ID	DM8JLR4
DM8JLR4	DN	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide
DM8JLR4	HS	Investigative
DM8JLR4	DT	Small molecular drug
DM8JLR4	PC	135458003
DM8JLR4	MW	295.34
DM8JLR4	FM	C17H17N3O2
DM8JLR4	IC	InChI=1S/C17H17N3O2/c1-2-3-16(22)18-17-14-9-6-12(10-15(14)19-20-17)11-4-7-13(21)8-5-11/h4-10,21H,2-3H2,1H3,(H2,18,19,20,22)
DM8JLR4	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=C(C=C3)O
DM8JLR4	IK	VCIZMGNKKFEEHA-UHFFFAOYSA-N
DM8JLR4	IU	N-[6-(4-hydroxyphenyl)-1H-indazol-3-yl]butanamide
DM8JLR4	DE	Discovery agent

DMRGQTM	ID	DMRGQTM
DMRGQTM	DN	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide
DMRGQTM	HS	Investigative
DMRGQTM	SN	CHEMBL1086781; N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709
DMRGQTM	DT	Small molecular drug
DMRGQTM	PC	9993220
DMRGQTM	MW	269.3
DMRGQTM	FM	C15H15N3O2
DMRGQTM	IC	InChI=1S/C15H15N3O2/c1-2-3-14(19)16-15-12-5-4-10(8-13(12)17-18-15)11-6-7-20-9-11/h4-9H,2-3H2,1H3,(H2,16,17,18,19)
DMRGQTM	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=COC=C3
DMRGQTM	IK	ZGQZPFJWHPTRAH-UHFFFAOYSA-N
DMRGQTM	IU	N-[6-(furan-3-yl)-1H-indazol-3-yl]butanamide
DMRGQTM	DE	Discovery agent

DM3FOKL	ID	DM3FOKL
DM3FOKL	DN	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide
DM3FOKL	HS	Investigative
DM3FOKL	SN	CHEMBL1085918; N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686
DM3FOKL	DT	Small molecular drug
DM3FOKL	PC	10016510
DM3FOKL	MW	280.32
DM3FOKL	FM	C16H16N4O
DM3FOKL	IC	InChI=1S/C16H16N4O/c1-2-4-15(21)18-16-13-7-6-11(9-14(13)19-20-16)12-5-3-8-17-10-12/h3,5-10H,2,4H2,1H3,(H2,18,19,20,21)
DM3FOKL	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CN=CC=C3
DM3FOKL	IK	CZTAWAQITKVBNQ-UHFFFAOYSA-N
DM3FOKL	IU	N-(6-pyridin-3-yl-1H-indazol-3-yl)butanamide
DM3FOKL	DE	Discovery agent

DM4GRK8	ID	DM4GRK8
DM4GRK8	DN	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide
DM4GRK8	HS	Investigative
DM4GRK8	SN	CHEMBL1086782; N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652
DM4GRK8	DT	Small molecular drug
DM4GRK8	PC	10085059
DM4GRK8	MW	280.32
DM4GRK8	FM	C16H16N4O
DM4GRK8	IC	InChI=1S/C16H16N4O/c1-2-3-15(21)18-16-13-5-4-12(10-14(13)19-20-16)11-6-8-17-9-7-11/h4-10H,2-3H2,1H3,(H2,18,19,20,21)
DM4GRK8	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=NC=C3
DM4GRK8	IK	BBNQSWZLWJBJIN-UHFFFAOYSA-N
DM4GRK8	IU	N-(6-pyridin-4-yl-1H-indazol-3-yl)butanamide
DM4GRK8	DE	Discovery agent

DMNRSYP	ID	DMNRSYP
DMNRSYP	DN	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide
DMNRSYP	HS	Investigative
DMNRSYP	SN	CHEMBL1083208; N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653
DMNRSYP	DT	Small molecular drug
DMNRSYP	PC	22319580
DMNRSYP	MW	285.4
DMNRSYP	FM	C15H15N3OS
DMNRSYP	IC	InChI=1S/C15H15N3OS/c1-2-3-14(19)16-15-12-5-4-10(8-13(12)17-18-15)11-6-7-20-9-11/h4-9H,2-3H2,1H3,(H2,16,17,18,19)
DMNRSYP	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CSC=C3
DMNRSYP	IK	KEXXQGBZRBKVRC-UHFFFAOYSA-N
DMNRSYP	IU	N-(6-thiophen-3-yl-1H-indazol-3-yl)butanamide
DMNRSYP	DE	Discovery agent

DMMHD9Z	ID	DMMHD9Z
DMMHD9Z	DN	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide
DMMHD9Z	HS	Investigative
DMMHD9Z	SN	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N
DMMHD9Z	DT	Small molecular drug
DMMHD9Z	PC	10265187
DMMHD9Z	MW	271.24
DMMHD9Z	FM	C12H12F3N3O
DMMHD9Z	IC	InChI=1S/C12H12F3N3O/c1-2-3-10(19)16-11-8-5-4-7(12(13,14)15)6-9(8)17-18-11/h4-6H,2-3H2,1H3,(H2,16,17,18,19)
DMMHD9Z	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C(F)(F)F
DMMHD9Z	IK	RVYSDAGRNRYYML-UHFFFAOYSA-N
DMMHD9Z	IU	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide
DMMHD9Z	DE	Discovery agent

DMHINE0	ID	DMHINE0
DMHINE0	DN	N(6)-cyclohexyladenosine
DMHINE0	HS	Investigative
DMHINE0	SN	N6-Cyclohexyladenosine; 36396-99-3; (2R,3R,4S,5R)-2-(6-(Cyclohexylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; N(6)-Cyclohexyladenosine; C16H23N5O4; Adenosine, N-cyclohexyl-; CHEMBL45891; (2R,3R,4S,5R)-2-[6-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; n-cyclohexyladenosine; N6 -cyclohexyladenosine; N-6-cyclohexyladenosine; N6-Cyclohexylado (CHA); n6-cyclohexyl[3h]adenosine; Lopac0_000331; GTPL423; SCHEMBL145856; SZBULDQSDUXAPJ-XNIJJKJLSA-N; MolPort-027-835-536; HMS3261C03; ZINC4217017
DMHINE0	DT	Small molecular drug
DMHINE0	PC	9841284
DMHINE0	MW	349.38
DMHINE0	FM	C16H23N5O4
DMHINE0	IC	InChI=1S/C16H23N5O4/c22-6-10-12(23)13(24)16(25-10)21-8-19-11-14(17-7-18-15(11)21)20-9-4-2-1-3-5-9/h7-10,12-13,16,22-24H,1-6H2,(H,17,18,20)/t10-,12-,13-,16-/m1/s1
DMHINE0	CS	C1CCC(CC1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMHINE0	IK	SZBULDQSDUXAPJ-XNIJJKJLSA-N
DMHINE0	IU	(2R,3R,4S,5R)-2-[6-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMHINE0	DE	Discovery agent

DMKWYMP	ID	DMKWYMP
DMKWYMP	DN	N-(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate
DMKWYMP	HS	Investigative
DMKWYMP	DE	Discovery agent

DM0OCLU	ID	DM0OCLU
DM0OCLU	DN	N-(6-benzyl-1H-indazol-3-yl)butyramide
DM0OCLU	HS	Investigative
DM0OCLU	SN	CHEMBL1077260; N-(6-benzyl-1H-indazol-3-yl)butyramide; SCHEMBL6490520
DM0OCLU	DT	Small molecular drug
DM0OCLU	PC	10266409
DM0OCLU	MW	293.4
DM0OCLU	FM	C18H19N3O
DM0OCLU	IC	InChI=1S/C18H19N3O/c1-2-6-17(22)19-18-15-10-9-14(12-16(15)20-21-18)11-13-7-4-3-5-8-13/h3-5,7-10,12H,2,6,11H2,1H3,(H2,19,20,21,22)
DM0OCLU	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)CC3=CC=CC=C3
DM0OCLU	IK	UUOMNVRBMQQPLH-UHFFFAOYSA-N
DM0OCLU	IU	N-(6-benzyl-1H-indazol-3-yl)butanamide
DM0OCLU	DE	Discovery agent

DMJPL7E	ID	DMJPL7E
DMJPL7E	DN	N-(6-bromo-1H-indazol-3-yl)butyramide
DMJPL7E	HS	Investigative
DMJPL7E	SN	CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; N-(6-bromo-1H-indazol-3-yl)butyramide; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708
DMJPL7E	DT	Small molecular drug
DMJPL7E	PC	10423871
DMJPL7E	MW	282.14
DMJPL7E	FM	C11H12BrN3O
DMJPL7E	IC	InChI=1S/C11H12BrN3O/c1-2-3-10(16)13-11-8-5-4-7(12)6-9(8)14-15-11/h4-6H,2-3H2,1H3,(H2,13,14,15,16)
DMJPL7E	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)Br
DMJPL7E	IK	QQVNXRROZHWJNS-UHFFFAOYSA-N
DMJPL7E	IU	N-(6-bromo-1H-indazol-3-yl)butanamide
DMJPL7E	DE	Discovery agent

DMHGXPY	ID	DMHGXPY
DMHGXPY	DN	N-(6-chloro-1H-indazol-3-yl)butyramide
DMHGXPY	HS	Investigative
DMHGXPY	SN	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; N-(6-chloro-1H-indazol-3-yl)butyramide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N
DMHGXPY	DT	Small molecular drug
DMHGXPY	PC	10421683
DMHGXPY	MW	237.68
DMHGXPY	FM	C11H12ClN3O
DMHGXPY	IC	InChI=1S/C11H12ClN3O/c1-2-3-10(16)13-11-8-5-4-7(12)6-9(8)14-15-11/h4-6H,2-3H2,1H3,(H2,13,14,15,16)
DMHGXPY	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)Cl
DMHGXPY	IK	VHQZZDZWVQELLJ-UHFFFAOYSA-N
DMHGXPY	IU	N-(6-chloro-1H-indazol-3-yl)butanamide
DMHGXPY	DE	Discovery agent

DMJV3UO	ID	DMJV3UO
DMJV3UO	DN	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide
DMJV3UO	HS	Investigative
DMJV3UO	SN	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide
DMJV3UO	DT	Small molecular drug
DMJV3UO	PC	22319604
DMJV3UO	MW	313.8
DMJV3UO	FM	C17H16ClN3O
DMJV3UO	IC	InChI=1S/C17H16ClN3O/c1-2-6-16(22)19-17-13-9-12(11-7-4-3-5-8-11)14(18)10-15(13)20-21-17/h3-5,7-10H,2,6H2,1H3,(H2,19,20,21,22)
DMJV3UO	CS	CCCC(=O)NC1=NNC2=CC(=C(C=C21)C3=CC=CC=C3)Cl
DMJV3UO	IK	WGVVIVGNBSSANI-UHFFFAOYSA-N
DMJV3UO	IU	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide
DMJV3UO	DE	Discovery agent

DMIN128	ID	DMIN128
DMIN128	DN	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide
DMIN128	HS	Investigative
DMIN128	SN	CHEMBL1097694; N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666
DMIN128	DT	Small molecular drug
DMIN128	PC	22319511
DMIN128	MW	327.8
DMIN128	FM	C18H18ClN3O
DMIN128	IC	InChI=1S/C18H18ClN3O/c1-3-4-17(23)20-18-14-9-13(12-7-5-11(2)6-8-12)15(19)10-16(14)21-22-18/h5-10H,3-4H2,1-2H3,(H2,20,21,22,23)
DMIN128	CS	CCCC(=O)NC1=NNC2=CC(=C(C=C21)C3=CC=C(C=C3)C)Cl
DMIN128	IK	REESNWQQNIKZJK-UHFFFAOYSA-N
DMIN128	IU	N-[6-chloro-5-(4-methylphenyl)-1H-indazol-3-yl]butanamide
DMIN128	DE	Discovery agent

DM90KGB	ID	DM90KGB
DM90KGB	DN	N-(6-ethoxypyridin-2-yl)acetamide
DM90KGB	HS	Investigative
DM90KGB	SN	N-(6-ethoxypyridin-2-yl)acetamide; N-(6-ethoxy-pyridin-2-yl)-acetamide; 775-38-2; AC1LGO22; CHEMBL210256; BDBM15972; Aminopyridine-Based Inhibitor 46
DM90KGB	DT	Small molecular drug
DM90KGB	PC	824661
DM90KGB	MW	180.2
DM90KGB	FM	C9H12N2O2
DM90KGB	IC	InChI=1S/C9H12N2O2/c1-3-13-9-6-4-5-8(11-9)10-7(2)12/h4-6H,3H2,1-2H3,(H,10,11,12)
DM90KGB	CS	CCOC1=CC=CC(=N1)NC(=O)C
DM90KGB	IK	NSIROEGSOFOSDV-UHFFFAOYSA-N
DM90KGB	IU	N-(6-ethoxypyridin-2-yl)acetamide
DM90KGB	DE	Discovery agent

DMIZVMT	ID	DMIZVMT
DMIZVMT	DN	N-(6-Hydroxycarbamoyl-hexyl)-benzamide
DMIZVMT	HS	Investigative
DMIZVMT	SN	CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-
DMIZVMT	DT	Small molecular drug
DMIZVMT	PC	9965141
DMIZVMT	MW	264.32
DMIZVMT	FM	C14H20N2O3
DMIZVMT	IC	InChI=1S/C14H20N2O3/c17-13(16-19)10-6-1-2-7-11-15-14(18)12-8-4-3-5-9-12/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,18)(H,16,17)
DMIZVMT	CS	C1=CC=C(C=C1)C(=O)NCCCCCCC(=O)NO
DMIZVMT	IK	ATWJTSVDLBPZQP-UHFFFAOYSA-N
DMIZVMT	IU	N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
DMIZVMT	CA	CAS 174664-71-2
DMIZVMT	DE	Discovery agent

DM01Y37	ID	DM01Y37
DM01Y37	DN	N-(6-Mercapto-hexyl)-benzamide
DM01Y37	HS	Investigative
DM01Y37	SN	CHEMBL112364; BDBM50223650
DM01Y37	DT	Small molecular drug
DM01Y37	PC	11447748
DM01Y37	MW	237.36
DM01Y37	FM	C13H19NOS
DM01Y37	IC	InChI=1S/C13H19NOS/c15-13(12-8-4-3-5-9-12)14-10-6-1-2-7-11-16/h3-5,8-9,16H,1-2,6-7,10-11H2,(H,14,15)
DM01Y37	CS	C1=CC=C(C=C1)C(=O)NCCCCCCS
DM01Y37	IK	HCPPYAZFTICCOW-UHFFFAOYSA-N
DM01Y37	IU	N-(6-sulfanylhexyl)benzamide
DM01Y37	DE	Discovery agent

DMQRE5D	ID	DMQRE5D
DMQRE5D	DN	N-(6-methylpyridin-2-yl)-5-phenylpicolinamide
DMQRE5D	HS	Investigative
DMQRE5D	SN	CHEMBL396078; N-(6-methylpyridin-2-yl)-5-phenylpicolinamide
DMQRE5D	DT	Small molecular drug
DMQRE5D	PC	44440732
DMQRE5D	MW	289.3
DMQRE5D	FM	C18H15N3O
DMQRE5D	IC	InChI=1S/C18H15N3O/c1-13-6-5-9-17(20-13)21-18(22)16-11-10-15(12-19-16)14-7-3-2-4-8-14/h2-12H,1H3,(H,20,21,22)
DMQRE5D	CS	CC1=NC(=CC=C1)NC(=O)C2=NC=C(C=C2)C3=CC=CC=C3
DMQRE5D	IK	RDRCRZMPPOKVOV-UHFFFAOYSA-N
DMQRE5D	IU	N-(6-methylpyridin-2-yl)-5-phenylpyridine-2-carboxamide
DMQRE5D	DE	Discovery agent

DMQZMRG	ID	DMQZMRG
DMQZMRG	DN	N-(6-methylpyridin-2-yl)-6-phenylnicotinamide
DMQZMRG	HS	Investigative
DMQZMRG	SN	CHEMBL525384; N-(6-methylpyridin-2-yl)-6-phenylnicotinamide
DMQZMRG	DT	Small molecular drug
DMQZMRG	PC	44157178
DMQZMRG	MW	289.3
DMQZMRG	FM	C18H15N3O
DMQZMRG	IC	InChI=1S/C18H15N3O/c1-13-6-5-9-17(20-13)21-18(22)15-10-11-16(19-12-15)14-7-3-2-4-8-14/h2-12H,1H3,(H,20,21,22)
DMQZMRG	CS	CC1=NC(=CC=C1)NC(=O)C2=CN=C(C=C2)C3=CC=CC=C3
DMQZMRG	IK	SJCQCBNYZNABCO-UHFFFAOYSA-N
DMQZMRG	IU	N-(6-methylpyridin-2-yl)-6-phenylpyridine-3-carboxamide
DMQZMRG	DE	Discovery agent

DMBNJ2L	ID	DMBNJ2L
DMBNJ2L	DN	N-(6-methylpyridin-2-yl)biphenyl-3-carboxamide
DMBNJ2L	HS	Investigative
DMBNJ2L	SN	CHEMBL377935; N-(6-methylpyridin-2-yl)biphenyl-3-carboxamide; BDBM50186331; biphenyl-3-carboxylic acid (6-methyl-pyridin-2-yl)-amide
DMBNJ2L	DT	Small molecular drug
DMBNJ2L	PC	44412879
DMBNJ2L	MW	288.3
DMBNJ2L	FM	C19H16N2O
DMBNJ2L	IC	InChI=1S/C19H16N2O/c1-14-7-5-12-18(20-14)21-19(22)17-11-6-10-16(13-17)15-8-3-2-4-9-15/h2-13H,1H3,(H,20,21,22)
DMBNJ2L	CS	CC1=NC(=CC=C1)NC(=O)C2=CC=CC(=C2)C3=CC=CC=C3
DMBNJ2L	IK	WRRMPYACQDSPSL-UHFFFAOYSA-N
DMBNJ2L	IU	N-(6-methylpyridin-2-yl)-3-phenylbenzamide
DMBNJ2L	DE	Discovery agent

DM9K4WP	ID	DM9K4WP
DM9K4WP	DN	N-(6-phenethyl-1H-indazol-3-yl)butyramide
DM9K4WP	HS	Investigative
DM9K4WP	SN	CHEMBL1084684; N-(6-phenethyl-1H-indazol-3-yl)butyramide; SCHEMBL6489338
DM9K4WP	DT	Small molecular drug
DM9K4WP	PC	22319484
DM9K4WP	MW	307.4
DM9K4WP	FM	C19H21N3O
DM9K4WP	IC	InChI=1S/C19H21N3O/c1-2-6-18(23)20-19-16-12-11-15(13-17(16)21-22-19)10-9-14-7-4-3-5-8-14/h3-5,7-8,11-13H,2,6,9-10H2,1H3,(H2,20,21,22,23)
DM9K4WP	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)CCC3=CC=CC=C3
DM9K4WP	IK	FEGHHCWVRCSXNL-UHFFFAOYSA-N
DM9K4WP	IU	N-[6-(2-phenylethyl)-1H-indazol-3-yl]butanamide
DM9K4WP	DE	Discovery agent

DM2E5OX	ID	DM2E5OX
DM2E5OX	DN	N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide
DM2E5OX	HS	Investigative
DM2E5OX	SN	CHEMBL481289; N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide; SCHEMBL4239343; KBQZTNRCKHEJQM-UHFFFAOYSA-N; BDBM50251685; 1h-indole-3-carboxylic acid(6-phenoxy-pyridine-3-yl)-amide
DM2E5OX	DT	Small molecular drug
DM2E5OX	PC	44250365
DM2E5OX	MW	329.4
DM2E5OX	FM	C20H15N3O2
DM2E5OX	IC	InChI=1S/C20H15N3O2/c24-20(17-13-21-18-9-5-4-8-16(17)18)23-14-10-11-19(22-12-14)25-15-6-2-1-3-7-15/h1-13,21H,(H,23,24)
DM2E5OX	CS	C1=CC=C(C=C1)OC2=NC=C(C=C2)NC(=O)C3=CNC4=CC=CC=C43
DM2E5OX	IK	KBQZTNRCKHEJQM-UHFFFAOYSA-N
DM2E5OX	IU	N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide
DM2E5OX	DE	Discovery agent

DMVCPLU	ID	DMVCPLU
DMVCPLU	DN	N-(6-phenyl-1H-indazol-3-yl)butyramide
DMVCPLU	HS	Investigative
DMVCPLU	SN	CHEMBL1086174; N-(6-phenyl-1H-indazol-3-yl)butyramide; SCHEMBL4493121
DMVCPLU	DT	Small molecular drug
DMVCPLU	PC	10085013
DMVCPLU	MW	279.34
DMVCPLU	FM	C17H17N3O
DMVCPLU	IC	InChI=1S/C17H17N3O/c1-2-6-16(21)18-17-14-10-9-13(11-15(14)19-20-17)12-7-4-3-5-8-12/h3-5,7-11H,2,6H2,1H3,(H2,18,19,20,21)
DMVCPLU	CS	CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=CC=C3
DMVCPLU	IK	BVIWKIBBSPTOPO-UHFFFAOYSA-N
DMVCPLU	IU	N-(6-phenyl-1H-indazol-3-yl)butanamide
DMVCPLU	DE	Discovery agent

DMO3Y0B	ID	DMO3Y0B
DMO3Y0B	DN	N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)
DMO3Y0B	HS	Investigative
DMO3Y0B	SN	CHEMBL1085261; N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX); SCHEMBL1404507; BDBM50320173
DMO3Y0B	DT	Small molecular drug
DMO3Y0B	PC	24996566
DMO3Y0B	MW	457.3
DMO3Y0B	FM	C24H22Cl2N2O3
DMO3Y0B	IC	InChI=1S/C24H22Cl2N2O3/c1-24(2)12-20(27-21(30)13-29)18-11-17(14-7-9-15(25)10-8-14)22(28-23(18)31-24)16-5-3-4-6-19(16)26/h3-11,20,29H,12-13H2,1-2H3,(H,27,30)
DMO3Y0B	CS	CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4Cl)NC(=O)CO)C
DMO3Y0B	IK	XFJREZUFRMFGKX-UHFFFAOYSA-N
DMO3Y0B	IU	N-[7-(2-chlorophenyl)-6-(4-chlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-2-hydroxyacetamide
DMO3Y0B	DE	Discovery agent

DM5F27T	ID	DM5F27T
DM5F27T	DN	N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX)
DM5F27T	HS	Investigative
DM5F27T	SN	CHEMBL1085566; SCHEMBL1404756; BDBM50320185; N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX); N-(7''-(2-CHLOROPHENYL)-6''-(4-CHLOROPHENYL)-3'',4''-DIHYDROSPIRO[CYCLOHEXANE-1,2''-PYRANO[2,3-B]PYRIDINE]-4''-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX)
DM5F27T	DT	Small molecular drug
DM5F27T	PC	24995605
DM5F27T	MW	525.5
DM5F27T	FM	C29H30Cl2N2O3
DM5F27T	IC	InChI=1S/C29H30Cl2N2O3/c1-28(2,35)27(34)32-24-17-29(14-6-3-7-15-29)36-26-22(24)16-21(18-10-12-19(30)13-11-18)25(33-26)20-8-4-5-9-23(20)31/h4-5,8-13,16,24,35H,3,6-7,14-15,17H2,1-2H3,(H,32,34)
DM5F27T	CS	CC(C)(C(=O)NC1CC2(CCCCC2)OC3=C1C=C(C(=N3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl)O
DM5F27T	IK	UTPSWDIIQDVVTK-UHFFFAOYSA-N
DM5F27T	IU	N-[7-(2-chlorophenyl)-6-(4-chlorophenyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclohexane]-4-yl]-2-hydroxy-2-methylpropanamide
DM5F27T	DE	Discovery agent

DMPMBC2	ID	DMPMBC2
DMPMBC2	DN	N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine
DMPMBC2	HS	Investigative
DMPMBC2	SN	CHEMBL107872; N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine
DMPMBC2	DT	Small molecular drug
DMPMBC2	PC	44339283
DMPMBC2	MW	292.33
DMPMBC2	FM	C17H16N4O
DMPMBC2	IC	InChI=1S/C17H16N4O/c18-17(19)21-16-15-10-14(7-6-13(15)8-9-20-16)22-11-12-4-2-1-3-5-12/h1-10H,11H2,(H4,18,19,20,21)
DMPMBC2	CS	C1=CC=C(C=C1)COC2=CC3=C(C=C2)C=CN=C3N=C(N)N
DMPMBC2	IK	XOCIIIGBOXCOGZ-UHFFFAOYSA-N
DMPMBC2	IU	2-(7-phenylmethoxyisoquinolin-1-yl)guanidine
DMPMBC2	DE	Discovery agent

DMH42L8	ID	DMH42L8
DMH42L8	DN	N-(7-methoxy-4-phenylbenzofuran-2-yl)acetamide
DMH42L8	HS	Investigative
DMH42L8	SN	CHEMBL598250
DMH42L8	DT	Small molecular drug
DMH42L8	PC	46230982
DMH42L8	MW	281.3
DMH42L8	FM	C17H15NO3
DMH42L8	IC	InChI=1S/C17H15NO3/c1-11(19)18-16-10-14-13(12-6-4-3-5-7-12)8-9-15(20-2)17(14)21-16/h3-10H,1-2H3,(H,18,19)
DMH42L8	CS	CC(=O)NC1=CC2=C(C=CC(=C2O1)OC)C3=CC=CC=C3
DMH42L8	IK	QFMYZXFFZWTGIP-UHFFFAOYSA-N
DMH42L8	IU	N-(7-methoxy-4-phenyl-1-benzofuran-2-yl)acetamide
DMH42L8	DE	Discovery agent

DMHFPE3	ID	DMHFPE3
DMHFPE3	DN	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide
DMHFPE3	HS	Investigative
DMHFPE3	SN	CHEMBL1210476; N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide
DMHFPE3	DT	Small molecular drug
DMHFPE3	PC	49863103
DMHFPE3	MW	320.3
DMHFPE3	FM	C17H16N6O
DMHFPE3	IC	InChI=1S/C17H16N6O/c1-2-3-7-13(24)21-16-14-17(20-10-19-16)23-15(22-14)12-6-4-5-11(8-12)9-18/h4-6,8,10H,2-3,7H2,1H3,(H2,19,20,21,22,23,24)
DMHFPE3	CS	CCCCC(=O)NC1=NC=NC2=C1NC(=N2)C3=CC=CC(=C3)C#N
DMHFPE3	IK	FKLAKSOWIZORFH-UHFFFAOYSA-N
DMHFPE3	IU	N-[8-(3-cyanophenyl)-7H-purin-6-yl]pentanamide
DMHFPE3	DE	Discovery agent

DMBD52I	ID	DMBD52I
DMBD52I	DN	N-(9H-beta-Carbolin-3-yl)-acetamide
DMBD52I	HS	Investigative
DMBD52I	SN	91985-75-0; N-9h-pyrido[3,4-b]indol-3-yl-acetamide; 3-acetamino-beta-carboline; CHEMBL167732; SCHEMBL10645219; ZINC25307; JZIFOHJMLBAWQZ-UHFFFAOYSA-N; N-(beta-Carboline-3-yl)acetamide; N-(9H-pyrido[3,4-b]indol-3-yl)acetamide
DMBD52I	DT	Small molecular drug
DMBD52I	PC	13315120
DMBD52I	MW	225.25
DMBD52I	FM	C13H11N3O
DMBD52I	IC	InChI=1S/C13H11N3O/c1-8(17)15-13-6-10-9-4-2-3-5-11(9)16-12(10)7-14-13/h2-7,16H,1H3,(H,14,15,17)
DMBD52I	CS	CC(=O)NC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMBD52I	IK	JZIFOHJMLBAWQZ-UHFFFAOYSA-N
DMBD52I	IU	N-(9H-pyrido[3,4-b]indol-3-yl)acetamide
DMBD52I	DE	Discovery agent

DM3KNSY	ID	DM3KNSY
DM3KNSY	DN	N-(9H-beta-Carbolin-3-yl)-formamide
DM3KNSY	HS	Investigative
DM3KNSY	SN	95935-50-5; Formamide, N-9H-pyrido[3,4-b]indol-3-yl-; CHEMBL353110
DM3KNSY	DT	Small molecular drug
DM3KNSY	PC	13450924
DM3KNSY	MW	211.22
DM3KNSY	FM	C12H9N3O
DM3KNSY	IC	InChI=1S/C12H9N3O/c16-7-14-12-5-9-8-3-1-2-4-10(8)15-11(9)6-13-12/h1-7,15H,(H,13,14,16)
DM3KNSY	CS	C1=CC=C2C(=C1)C3=CC(=NC=C3N2)NC=O
DM3KNSY	IK	YLIKNFBWEFRNOD-UHFFFAOYSA-N
DM3KNSY	IU	N-(9H-pyrido[3,4-b]indol-3-yl)formamide
DM3KNSY	DE	Discovery agent

DMFONC1	ID	DMFONC1
DMFONC1	DN	N-(Adamant-1-yl)-1'H-phenothiazine-1'-carboxamide
DMFONC1	HS	Investigative
DMFONC1	SN	CHEMBL591468; AC1MLZYY; N-(1-adamantyl)phenothiazine-10-carboxamide; Oprea1_167795; ZINC6252722; BDBM50308401; AKOS004107814
DMFONC1	DT	Small molecular drug
DMFONC1	PC	3253193
DMFONC1	MW	376.5
DMFONC1	FM	C23H24N2OS
DMFONC1	IC	InChI=1S/C23H24N2OS/c26-22(24-23-12-15-9-16(13-23)11-17(10-15)14-23)25-18-5-1-3-7-20(18)27-21-8-4-2-6-19(21)25/h1-8,15-17H,9-14H2,(H,24,26)
DMFONC1	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)N4C5=CC=CC=C5SC6=CC=CC=C64
DMFONC1	IK	YTNHIPMOCAHDRX-UHFFFAOYSA-N
DMFONC1	IU	N-(1-adamantyl)phenothiazine-10-carboxamide
DMFONC1	DE	Discovery agent

DM87YJW	ID	DM87YJW
DM87YJW	DN	N-(benzyl),N-(pyrrol-2-ylmethyl)amine
DM87YJW	HS	Investigative
DM87YJW	SN	pyrrole inhibitor 17; N-(benzyl),N-(pyrrol-2-ylmethyl)amine; 1H-Pyrrole-2-methanamine, N-(phenylmethyl)-; CHEMBL223618; AC1L95K6; BDBM15591; benzyl(1H-pyrrol-2-ylmethyl)amine; ZINC1679613; AKOS009004155; 95116-31-7
DM87YJW	DT	Small molecular drug
DM87YJW	PC	413448
DM87YJW	MW	186.25
DM87YJW	FM	C12H14N2
DM87YJW	IC	InChI=1S/C12H14N2/c1-2-5-11(6-3-1)9-13-10-12-7-4-8-14-12/h1-8,13-14H,9-10H2
DM87YJW	CS	C1=CC=C(C=C1)CNCC2=CC=CN2
DM87YJW	IK	YOGRUDYQEJQNLR-UHFFFAOYSA-N
DM87YJW	IU	1-phenyl-N-(1H-pyrrol-2-ylmethyl)methanamine
DM87YJW	DE	Discovery agent

DMR18YI	ID	DMR18YI
DMR18YI	DN	N-(benzyloxycarbonyl)-leucyl-glycine-nitrile
DMR18YI	HS	Investigative
DMR18YI	SN	dipeptidyl nitrile, 1; Cbz-Leu-NH-CH2-CN; JMC487688 Compound 8; CHEMBL200161; SCHEMBL6183068; BDBM19768; UFXQLUZNMRVTPU-AWEZNQCLSA-N; 2-[(Z-L-Leu-)Amino]ethanenitrile; benzyl (S)-1-cyanomethylcarbamoyl-3-methylbutylcarbamate; benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate
DMR18YI	DT	Small molecular drug
DMR18YI	PC	11702208
DMR18YI	MW	303.36
DMR18YI	FM	C16H21N3O3
DMR18YI	IC	InChI=1S/C16H21N3O3/c1-12(2)10-14(15(20)18-9-8-17)19-16(21)22-11-13-6-4-3-5-7-13/h3-7,12,14H,9-11H2,1-2H3,(H,18,20)(H,19,21)/t14-/m0/s1
DMR18YI	CS	CC(C)C[C@@H](C(=O)NCC#N)NC(=O)OCC1=CC=CC=C1
DMR18YI	IK	UFXQLUZNMRVTPU-AWEZNQCLSA-N
DMR18YI	IU	benzyl N-[(2S)-1-(cyanomethylamino)-4-methyl-1-oxopentan-2-yl]carbamate
DMR18YI	DE	Discovery agent

DMRCYB8	ID	DMRCYB8
DMRCYB8	DN	N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide
DMRCYB8	HS	Investigative
DMRCYB8	SN	CHEMBL475301; N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide; SCHEMBL5327672
DMRCYB8	DT	Small molecular drug
DMRCYB8	PC	23634372
DMRCYB8	MW	361.5
DMRCYB8	FM	C18H23N3O3S
DMRCYB8	IC	InChI=1S/C18H23N3O3S/c19-25(23,24)20-13-6-2-5-12-18(22)21-17-11-7-10-16(14-17)15-8-3-1-4-9-15/h1,3-4,7-11,14,20H,2,5-6,12-13H2,(H,21,22)(H2,19,23,24)
DMRCYB8	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)CCCCCNS(=O)(=O)N
DMRCYB8	IK	XZBFBJMQHOJIMB-UHFFFAOYSA-N
DMRCYB8	IU	N-(3-phenylphenyl)-6-(sulfamoylamino)hexanamide
DMRCYB8	DE	Discovery agent

DM2ZQBS	ID	DM2ZQBS
DM2ZQBS	DN	N-(biphenyl-3-yl)benzo[d]isoxazol-3-amine
DM2ZQBS	HS	Investigative
DM2ZQBS	SN	CHEMBL565950; N-(biphenyl-3-yl)benzo[d]isoxazol-3-amine
DM2ZQBS	DT	Small molecular drug
DM2ZQBS	PC	45484883
DM2ZQBS	MW	286.3
DM2ZQBS	FM	C19H14N2O
DM2ZQBS	IC	InChI=1S/C19H14N2O/c1-2-7-14(8-3-1)15-9-6-10-16(13-15)20-19-17-11-4-5-12-18(17)22-21-19/h1-13H,(H,20,21)
DM2ZQBS	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)NC3=NOC4=CC=CC=C43
DM2ZQBS	IK	RPYFHXRGVNEECB-UHFFFAOYSA-N
DM2ZQBS	IU	N-(3-phenylphenyl)-1,2-benzoxazol-3-amine
DM2ZQBS	DE	Discovery agent

DMSO7FW	ID	DMSO7FW
DMSO7FW	DN	N-(Biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
DMSO7FW	HS	Investigative
DMSO7FW	SN	(2z)-N-Biphenyl-4-Yl-2-Cyano-3-Hydroxybut-2-Enamide; CHEMBL519160; DB07443; (2Z)-2-cyano-3-hydroxy-N-(4-phenylphenyl)but-2-enamide
DMSO7FW	DT	Small molecular drug
DMSO7FW	PC	54727972
DMSO7FW	MW	278.3
DMSO7FW	FM	C17H14N2O2
DMSO7FW	IC	InChI=1S/C17H14N2O2/c1-12(20)16(11-18)17(21)19-15-9-7-14(8-10-15)13-5-3-2-4-6-13/h2-10,20H,1H3,(H,19,21)/b16-12-
DMSO7FW	CS	C/C(=C(\\C#N)/C(=O)NC1=CC=C(C=C1)C2=CC=CC=C2)/O
DMSO7FW	IK	MUVPBAIVOHJDOC-VBKFSLOCSA-N
DMSO7FW	IU	(Z)-2-cyano-3-hydroxy-N-(4-phenylphenyl)but-2-enamide
DMSO7FW	DE	Discovery agent

DML10NT	ID	DML10NT
DML10NT	DN	N-(biphenyl-4-yl)benzo[d]isoxazol-3-amine
DML10NT	HS	Investigative
DML10NT	SN	CHEMBL578782; N-(biphenyl-4-yl)benzo[d]isoxazol-3-amine
DML10NT	DT	Small molecular drug
DML10NT	PC	45484855
DML10NT	MW	286.3
DML10NT	FM	C19H14N2O
DML10NT	IC	InChI=1S/C19H14N2O/c1-2-6-14(7-3-1)15-10-12-16(13-11-15)20-19-17-8-4-5-9-18(17)22-21-19/h1-13H,(H,20,21)
DML10NT	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)NC3=NOC4=CC=CC=C43
DML10NT	IK	BKHHQJRHPIBTJZ-UHFFFAOYSA-N
DML10NT	IU	N-(4-phenylphenyl)-1,2-benzoxazol-3-amine
DML10NT	DE	Discovery agent

DMHPITZ	ID	DMHPITZ
DMHPITZ	DN	N-(biphenyl-4-ylsulfonyl)-D-leucine
DMHPITZ	HS	Investigative
DMHPITZ	SN	N-(biphenyl-4-ylsulfonyl)-D-leucine; DB07446; (R)-2-(biphenyl-4-ylsulfonamido)-4-methylpentanoic acid; (2R)-4-methyl-2-(4-phenylbenzenesulfonamido)pentanoic acid
DMHPITZ	DT	Small molecular drug
DMHPITZ	PC	25271580
DMHPITZ	MW	347.4
DMHPITZ	FM	C18H21NO4S
DMHPITZ	IC	InChI=1S/C18H21NO4S/c1-13(2)12-17(18(20)21)19-24(22,23)16-10-8-15(9-11-16)14-6-4-3-5-7-14/h3-11,13,17,19H,12H2,1-2H3,(H,20,21)/t17-/m1/s1
DMHPITZ	CS	CC(C)C[C@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DMHPITZ	IK	FBSVJQQVDISETN-QGZVFWFLSA-N
DMHPITZ	IU	(2R)-4-methyl-2-[(4-phenylphenyl)sulfonylamino]pentanoic acid
DMHPITZ	DE	Discovery agent

DMFGSLO	ID	DMFGSLO
DMFGSLO	DN	N-(Chlorophenyl)-N'-Hydroxyguanidine
DMFGSLO	HS	Investigative
DMFGSLO	SN	130974-86-6; N-(CHLOROPHENYL)-N'-HYDROXYGUANIDINE; Guanidine, N-(4-chlorophenyl)-N'-hydroxy-; N-(4-chloro)phenyl-N'-hydroxyguanidine; Guanidine,N-(4-chlorophenyl)-N'-hydroxy-; C7H8ClN3O; ACMC-1CA1V; SCHEMBL2213727; CHEMBL323202; AC1L490B; CTK4B7016; DTXSID90156823; AKOS017474904; AKOS011771250; AKOS030602610; 1-(4-Chlorophenyl)-3-hydroxyguanidine; DB04559; 2-(4-chlorophenyl)-1-hydroxyguanidine
DMFGSLO	DT	Small molecular drug
DMFGSLO	PC	181426
DMFGSLO	MW	185.61
DMFGSLO	FM	C7H8ClN3O
DMFGSLO	IC	InChI=1S/C7H8ClN3O/c8-5-1-3-6(4-2-5)10-7(9)11-12/h1-4,12H,(H3,9,10,11)
DMFGSLO	CS	C1=CC(=CC=C1N=C(N)NO)Cl
DMFGSLO	IK	JYBXKTLYOMPMQY-UHFFFAOYSA-N
DMFGSLO	IU	2-(4-chlorophenyl)-1-hydroxyguanidine
DMFGSLO	CA	CAS 130974-86-6
DMFGSLO	DE	Discovery agent

DM1TA5R	ID	DM1TA5R
DM1TA5R	DN	N-(cis-9-cis-12-octadecadienyl)sulfamide
DM1TA5R	HS	Investigative
DM1TA5R	SN	CHEMBL570988; N-(cis-9-cis-12-octadecadienyl)sulfamide; SCHEMBL3107035
DM1TA5R	DT	Small molecular drug
DM1TA5R	PC	44614165
DM1TA5R	MW	344.6
DM1TA5R	FM	C18H36N2O2S
DM1TA5R	IC	InChI=1S/C18H36N2O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-23(19,21)22/h6-7,9-10,20H,2-5,8,11-18H2,1H3,(H2,19,21,22)/b7-6-,10-9-
DM1TA5R	CS	CCCCC/C=C\\C/C=C\\CCCCCCCCNS(=O)(=O)N
DM1TA5R	IK	DGNCNCVVPPGGNM-HZJYTTRNSA-N
DM1TA5R	IU	(6Z,9Z)-18-(sulfamoylamino)octadeca-6,9-diene
DM1TA5R	DE	Discovery agent

DMTKREZ	ID	DMTKREZ
DMTKREZ	DN	N-(cyanomethyl)cyclohex-1-ene-1-carboxamide
DMTKREZ	HS	Investigative
DMTKREZ	SN	1-Cyclohexene-1-carboxamide, N-(cyanomethyl)-; 875142-19-1
DMTKREZ	DT	Small molecular drug
DMTKREZ	PC	11550059
DMTKREZ	MW	164.2
DMTKREZ	FM	C9H12N2O
DMTKREZ	IC	InChI=1S/C9H12N2O/c10-6-7-11-9(12)8-4-2-1-3-5-8/h4H,1-3,5,7H2,(H,11,12)
DMTKREZ	CS	C1CCC(=CC1)C(=O)NCC#N
DMTKREZ	IK	ZVHMBSSCZBPAIY-UHFFFAOYSA-N
DMTKREZ	IU	N-(cyanomethyl)cyclohexene-1-carboxamide
DMTKREZ	DE	Discovery agent

DMI245K	ID	DMI245K
DMI245K	DN	N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine
DMI245K	HS	Investigative
DMI245K	SN	N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine; DB07683; N-(dibenzo[b,d]thiophene-3-sulfonyl) valine; (2S)-3-methyl-2-{8-thiatricyclo[7.4.0.0^{2,7}]trideca-1(13),2,4,6,9,11-hexaene-5-sulfonamido}butanoic acid
DMI245K	DT	Small molecular drug
DMI245K	PC	24794392
DMI245K	MW	363.5
DMI245K	FM	C17H17NO4S2
DMI245K	IC	InChI=1S/C17H17NO4S2/c1-10(2)16(17(19)20)18-24(21,22)11-7-8-13-12-5-3-4-6-14(12)23-15(13)9-11/h3-10,16,18H,1-2H3,(H,19,20)/t16-/m0/s1
DMI245K	CS	CC(C)[C@@H](C(=O)O)NS(=O)(=O)C1=CC2=C(C=C1)C3=CC=CC=C3S2
DMI245K	IK	RZWYSEXQXOXWKA-INIZCTEOSA-N
DMI245K	IU	(2S)-2-(dibenzothiophen-3-ylsulfonylamino)-3-methylbutanoic acid
DMI245K	DE	Discovery agent

DMJ6U4H	ID	DMJ6U4H
DMJ6U4H	DN	N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3
DMJ6U4H	HS	Investigative
DMJ6U4H	SN	CHEMBL1160624
DMJ6U4H	DT	Small molecular drug
DMJ6U4H	PC	44324667
DMJ6U4H	MW	437.4
DMJ6U4H	FM	C20H30N4O5P-
DMJ6U4H	IC	InChI=1S/C20H31N4O5P/c1-5-13(3)18(24-30(27,28)29-6-2)20(26)23-17(19(25)21-4)11-14-12-22-16-10-8-7-9-15(14)16/h7-10,12-13,17-18,22H,5-6,11H2,1-4H3,(H,21,25)(H,23,26)(H2,24,27,28)/p-1/t13-,17?,18-/m0/s1
DMJ6U4H	CS	CC[C@H](C)[C@@H](C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC)NP(=O)([O-])OCC
DMJ6U4H	IK	IHAZHCJWGLQJQS-VCMPKCBFSA-M
DMJ6U4H	IU	ethoxy-[[(2S,3S)-1-[[3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]phosphinate
DMJ6U4H	DE	Discovery agent

DMLJZGD	ID	DMLJZGD
DMLJZGD	DN	N-(furan-2-ylmethyl)estradiol-16-carboxamide
DMLJZGD	HS	Investigative
DMLJZGD	SN	SCHEMBL12379478
DMLJZGD	DT	Small molecular drug
DMLJZGD	PC	44407336
DMLJZGD	MW	395.5
DMLJZGD	FM	C24H29NO4
DMLJZGD	IC	InChI=1S/C24H29NO4/c1-24-9-8-18-17-7-5-15(26)11-14(17)4-6-19(18)21(24)12-20(22(24)27)23(28)25-13-16-3-2-10-29-16/h2-3,5,7,10-11,18-22,26-27H,4,6,8-9,12-13H2,1H3,(H,25,28)/t18?,19?,20?,21?,22-,24-/m0/s1
DMLJZGD	CS	C[C@]12CCC3C(C1CC([C@@H]2O)C(=O)NCC4=CC=CO4)CCC5=C3C=CC(=C5)O
DMLJZGD	IK	JKEJHEHCKBFOBU-OOBULCBASA-N
DMLJZGD	IU	(13S,17S)-N-(furan-2-ylmethyl)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DMLJZGD	DE	Discovery agent

DM0DZ9J	ID	DM0DZ9J
DM0DZ9J	DN	N-(furan-2-ylmethyl)-estrone-16-methyl carboxamide
DM0DZ9J	HS	Investigative
DM0DZ9J	SN	SCHEMBL12379521
DM0DZ9J	DT	Small molecular drug
DM0DZ9J	PC	44407578
DM0DZ9J	MW	407.5
DM0DZ9J	FM	C25H29NO4
DM0DZ9J	IC	InChI=1S/C25H29NO4/c1-25-9-8-20-19-7-5-17(27)11-15(19)4-6-21(20)22(25)12-16(24(25)29)13-23(28)26-14-18-3-2-10-30-18/h2-3,5,7,10-11,16,20-22,27H,4,6,8-9,12-14H2,1H3,(H,26,28)/t16?,20?,21?,22?,25-/m0/s1
DM0DZ9J	CS	C[C@]12CCC3C(C1CC(C2=O)CC(=O)NCC4=CC=CO4)CCC5=C3C=CC(=C5)O
DM0DZ9J	IK	NSHKXWHQUTUXRS-HIUOCNRYSA-N
DM0DZ9J	IU	N-(furan-2-ylmethyl)-2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]acetamide
DM0DZ9J	DE	Discovery agent

DMW378C	ID	DMW378C
DMW378C	DN	N-(naphthalen-1-yl)-4-neopentylthiazol-2-amine
DMW378C	HS	Investigative
DMW378C	SN	CHEMBL424689; N-(naphthalen-1-yl)-4-neopentylthiazol-2-amine; SCHEMBL14433281
DMW378C	DT	Small molecular drug
DMW378C	PC	9922232
DMW378C	MW	296.4
DMW378C	FM	C18H20N2S
DMW378C	IC	InChI=1S/C18H20N2S/c1-18(2,3)11-14-12-21-17(19-14)20-16-10-6-8-13-7-4-5-9-15(13)16/h4-10,12H,11H2,1-3H3,(H,19,20)
DMW378C	CS	CC(C)(C)CC1=CSC(=N1)NC2=CC=CC3=CC=CC=C32
DMW378C	IK	RIPVNQXJGQJLHV-UHFFFAOYSA-N
DMW378C	IU	4-(2,2-dimethylpropyl)-N-naphthalen-1-yl-1,3-thiazol-2-amine
DMW378C	DE	Discovery agent

DMFZPCD	ID	DMFZPCD
DMFZPCD	DN	N-(naphthalen-1-yl)-4-phenylthiazol-2-amine
DMFZPCD	HS	Investigative
DMFZPCD	SN	CHEMBL208452; N-(naphthalen-1-yl)-4-phenylthiazol-2-amine; AC1N24LJ; BDBM50183105; AKOS001583269; EU-0001073; N-naphthalen-1-yl-4-phenyl-1,3-thiazol-2-amine; SR-01000396392
DMFZPCD	DT	Small molecular drug
DMFZPCD	PC	4015979
DMFZPCD	MW	302.4
DMFZPCD	FM	C19H14N2S
DMFZPCD	IC	InChI=1S/C19H14N2S/c1-2-8-15(9-3-1)18-13-22-19(21-18)20-17-12-6-10-14-7-4-5-11-16(14)17/h1-13H,(H,20,21)
DMFZPCD	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC3=CC=CC4=CC=CC=C43
DMFZPCD	IK	JWZVJRBKXQFLBH-UHFFFAOYSA-N
DMFZPCD	IU	N-naphthalen-1-yl-4-phenyl-1,3-thiazol-2-amine
DMFZPCD	DE	Discovery agent

DM2CBNG	ID	DM2CBNG
DM2CBNG	DN	N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine
DM2CBNG	HS	Investigative
DM2CBNG	SN	CHEMBL565960; N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine
DM2CBNG	DT	Small molecular drug
DM2CBNG	PC	45484885
DM2CBNG	MW	260.29
DM2CBNG	FM	C17H12N2O
DM2CBNG	IC	InChI=1S/C17H12N2O/c1-2-8-13-12(6-1)7-5-10-15(13)18-17-14-9-3-4-11-16(14)20-19-17/h1-11H,(H,18,19)
DM2CBNG	CS	C1=CC=C2C(=C1)C=CC=C2NC3=NOC4=CC=CC=C43
DM2CBNG	IK	SOIDHQDYGYBXPJ-UHFFFAOYSA-N
DM2CBNG	IU	N-naphthalen-1-yl-1,2-benzoxazol-3-amine
DM2CBNG	DE	Discovery agent

DM2NHVX	ID	DM2NHVX
DM2NHVX	DN	N-(naphthalen-2-yl)benzo[d]isoxazol-3-amine
DM2NHVX	HS	Investigative
DM2NHVX	SN	CHEMBL577471; N-(naphthalen-2-yl)benzo[d]isoxazol-3-amine
DM2NHVX	DT	Small molecular drug
DM2NHVX	PC	45484884
DM2NHVX	MW	260.29
DM2NHVX	FM	C17H12N2O
DM2NHVX	IC	InChI=1S/C17H12N2O/c1-2-6-13-11-14(10-9-12(13)5-1)18-17-15-7-3-4-8-16(15)20-19-17/h1-11H,(H,18,19)
DM2NHVX	CS	C1=CC=C2C=C(C=CC2=C1)NC3=NOC4=CC=CC=C43
DM2NHVX	IK	KQZPQVBDFIHPIN-UHFFFAOYSA-N
DM2NHVX	IU	N-naphthalen-2-yl-1,2-benzoxazol-3-amine
DM2NHVX	DE	Discovery agent

DMG8KXR	ID	DMG8KXR
DMG8KXR	DN	N-(Naphthalene-2-yl)ethyl-ETAV
DMG8KXR	HS	Investigative
DMG8KXR	SN	N-(Naphthalene-2-yl)ethyl-ETAV; CHEMBL493689
DMG8KXR	DT	Small molecular drug
DMG8KXR	PC	44568837
DMG8KXR	MW	572.6
DMG8KXR	FM	C29H40N4O8
DMG8KXR	IC	InChI=1S/C29H40N4O8/c1-16(2)24(29(40)41)32-26(37)17(3)31-28(39)25(18(4)34)33-27(38)22(11-12-23(35)36)30-14-13-19-9-10-20-7-5-6-8-21(20)15-19/h5-10,15-18,22,24-25,30,34H,11-14H2,1-4H3,(H,31,39)(H,32,37)(H,33,38)(H,35,36)(H,40,41)/t17-,18?,22-,24-,25-/m0/s1
DMG8KXR	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCC1=CC2=CC=CC=C2C=C1
DMG8KXR	IK	BVNXVJDQOOZPCM-FZDDQCGTSA-N
DMG8KXR	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-(2-naphthalen-2-ylethylamino)-5-oxopentanoic acid
DMG8KXR	DE	Discovery agent

DME45J8	ID	DME45J8
DME45J8	DN	N-(pentafluorophenyl)sulfamide
DME45J8	HS	Investigative
DME45J8	SN	N-(pentafluorophenyl)sulfamide; CHEMBL169486
DME45J8	DT	Small molecular drug
DME45J8	PC	44380941
DME45J8	MW	262.16
DME45J8	FM	C6H3F5N2O2S
DME45J8	IC	InChI=1S/C6H3F5N2O2S/c7-1-2(8)4(10)6(5(11)3(1)9)13-16(12,14)15/h13H,(H2,12,14,15)
DME45J8	CS	C1(=C(C(=C(C(=C1F)F)F)F)F)NS(=O)(=O)N
DME45J8	IK	UPYNRFQXRYOBBD-UHFFFAOYSA-N
DME45J8	IU	1,2,3,4,5-pentafluoro-6-(sulfamoylamino)benzene
DME45J8	DE	Discovery agent

DMJO3B1	ID	DMJO3B1
DMJO3B1	DN	N'-(phenylsulfonyl)benzofuran-2-carbohydrazide
DMJO3B1	HS	Investigative
DMJO3B1	SN	CHEMBL205220; SCHEMBL6240233; AMGAILKMHSFVNJ-UHFFFAOYSA-N; BDBM50172929; N''-(phenylsulfonyl)benzofuran-2-carbohydrazide; Benzofuran-2-carboxylic acid 2-(phenylsulfonyl)hydrazide
DMJO3B1	DT	Small molecular drug
DMJO3B1	PC	9879950
DMJO3B1	MW	316.3
DMJO3B1	FM	C15H12N2O4S
DMJO3B1	IC	InChI=1S/C15H12N2O4S/c18-15(14-10-11-6-4-5-9-13(11)21-14)16-17-22(19,20)12-7-2-1-3-8-12/h1-10,17H,(H,16,18)
DMJO3B1	CS	C1=CC=C(C=C1)S(=O)(=O)NNC(=O)C2=CC3=CC=CC=C3O2
DMJO3B1	IK	AMGAILKMHSFVNJ-UHFFFAOYSA-N
DMJO3B1	IU	N'-(benzenesulfonyl)-1-benzofuran-2-carbohydrazide
DMJO3B1	DE	Discovery agent

DMQETUY	ID	DMQETUY
DMQETUY	DN	N'-(phenylsulfonyl)quinoline-6-carbohydrazide
DMQETUY	HS	Investigative
DMQETUY	SN	CHEMBL437697; SCHEMBL6235703; YPRPLJAGGWUKMX-UHFFFAOYSA-N; BDBM50172936; N''-(phenylsulfonyl)quinoline-6-carbohydrazide; Quinoline-6-carboxylic acid 2-(phenylsulfonyl)hydrazide
DMQETUY	DT	Small molecular drug
DMQETUY	PC	9967156
DMQETUY	MW	327.4
DMQETUY	FM	C16H13N3O3S
DMQETUY	IC	InChI=1S/C16H13N3O3S/c20-16(13-8-9-15-12(11-13)5-4-10-17-15)18-19-23(21,22)14-6-2-1-3-7-14/h1-11,19H,(H,18,20)
DMQETUY	CS	C1=CC=C(C=C1)S(=O)(=O)NNC(=O)C2=CC3=C(C=C2)N=CC=C3
DMQETUY	IK	YPRPLJAGGWUKMX-UHFFFAOYSA-N
DMQETUY	IU	N'-(benzenesulfonyl)quinoline-6-carbohydrazide
DMQETUY	DE	Discovery agent

DMGHQJ8	ID	DMGHQJ8
DMGHQJ8	DN	N-(phosphonacetyl)-L-aspartate
DMGHQJ8	HS	Investigative
DMGHQJ8	SN	Sparfosic acid; PALA; n-(phosphonacetyl)-l-aspartic acid; N-(Phosphonoacetyl)-L-aspartic acid; Sparfosic Acid [INN]; NSC-224131; UNII-78QVZ7RG8L; 51321-79-0; L-ASPARTIC ACID, N-(PHOSPHONOACETYL)-; N-Phosphonacetyl-L-aspartate; Phosphonacetyl-L-aspartic acid; Acidum sparfosicum [INN-Latin]; Acido sparfosico [INN-Spanish]; Acide sparfosique [INN-French]; N-(Phosphonoacetyl)-asparaginsaeure; N-(Phosphonacetyl)-L-Aspartate; 78QVZ7RG8L; (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid; Acido sparfosico; Acide sparfosique; Acidum; SPARFOSIC ACID
DMGHQJ8	DT	Small molecular drug
DMGHQJ8	PC	46926274
DMGHQJ8	MW	252.1
DMGHQJ8	FM	C6H7NO8P-3
DMGHQJ8	IC	InChI=1S/C6H10NO8P/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H2,13,14,15)/p-3/t3-/m0/s1
DMGHQJ8	CS	C([C@@H](C(=O)[O-])NC(=O)CP(=O)(O)[O-])C(=O)[O-]
DMGHQJ8	IK	ZZKNRXZVGOYGJT-VKHMYHEASA-K
DMGHQJ8	IU	(2S)-2-[[2-[hydroxy(oxido)phosphoryl]acetyl]amino]butanedioate
DMGHQJ8	DE	Discovery agent

DM9QIH4	ID	DM9QIH4
DM9QIH4	DN	N-(piperidin-4-yl)-N-propyl-2-naphthamide
DM9QIH4	HS	Investigative
DM9QIH4	SN	CHEMBL565638; N-(piperidin-4-yl)-N-propyl-2-naphthamide
DM9QIH4	DT	Small molecular drug
DM9QIH4	PC	45487772
DM9QIH4	MW	296.4
DM9QIH4	FM	C19H24N2O
DM9QIH4	IC	InChI=1S/C19H24N2O/c1-2-13-21(18-9-11-20-12-10-18)19(22)17-8-7-15-5-3-4-6-16(15)14-17/h3-8,14,18,20H,2,9-13H2,1H3
DM9QIH4	CS	CCCN(C1CCNCC1)C(=O)C2=CC3=CC=CC=C3C=C2
DM9QIH4	IK	KPOGSLKDEJXGPM-UHFFFAOYSA-N
DM9QIH4	IU	N-piperidin-4-yl-N-propylnaphthalene-2-carboxamide
DM9QIH4	DE	Discovery agent

DMULBO9	ID	DMULBO9
DMULBO9	DN	N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide
DMULBO9	HS	Investigative
DMULBO9	SN	CHEMBL223707; N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide
DMULBO9	DT	Small molecular drug
DMULBO9	PC	16124785
DMULBO9	MW	337.3
DMULBO9	FM	C18H15N3O4
DMULBO9	IC	InChI=1S/C18H15N3O4/c1-11-2-4-12(5-3-11)9-20-18(23)17(22)15-10-19-16-7-6-13(21(24)25)8-14(15)16/h2-8,10,19H,9H2,1H3,(H,20,23)
DMULBO9	CS	CC1=CC=C(C=C1)CNC(=O)C(=O)C2=CNC3=C2C=C(C=C3)[N+](=O)[O-]
DMULBO9	IK	CXKKDMBQHWZSKG-UHFFFAOYSA-N
DMULBO9	IU	N-[(4-methylphenyl)methyl]-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMULBO9	DE	Discovery agent

DMTJ5WL	ID	DMTJ5WL
DMTJ5WL	DN	N-(propargyl),N-(pyrrol-2-ylmethyl)amine
DMTJ5WL	HS	Investigative
DMTJ5WL	SN	pyrrole inhibitor 35; N-(propargyl),N-(pyrrol-2-ylmethyl)amine; CHEMBL220832; BDBM15610; AKOS009008559
DMTJ5WL	DT	Small molecular drug
DMTJ5WL	PC	16110306
DMTJ5WL	MW	134.18
DMTJ5WL	FM	C8H10N2
DMTJ5WL	IC	InChI=1S/C8H10N2/c1-2-5-9-7-8-4-3-6-10-8/h1,3-4,6,9-10H,5,7H2
DMTJ5WL	CS	C#CCNCC1=CC=CN1
DMTJ5WL	IK	KRAVBWUZLLIIPH-UHFFFAOYSA-N
DMTJ5WL	IU	N-(1H-pyrrol-2-ylmethyl)prop-2-yn-1-amine
DMTJ5WL	DE	Discovery agent

DMXI4V8	ID	DMXI4V8
DMXI4V8	DN	N-(Propylamide-acetophenone)-1-deoxynojirimycin
DMXI4V8	HS	Investigative
DMXI4V8	SN	CHEMBL589341; N-(Propylamide-acetophenone)-1-deoxynojirimycin
DMXI4V8	DT	Small molecular drug
DMXI4V8	PC	46229705
DMXI4V8	MW	434.5
DMXI4V8	FM	C22H30N2O7
DMXI4V8	IC	InChI=1S/C22H30N2O7/c1-2-12-31-16-6-4-15(5-7-16)18(26)8-9-20(28)23-10-3-11-24-13-19(27)22(30)21(29)17(24)14-25/h1,4-7,17,19,21-22,25,27,29-30H,3,8-14H2,(H,23,28)/t17-,19+,21-,22-/m1/s1
DMXI4V8	CS	C#CCOC1=CC=C(C=C1)C(=O)CCC(=O)NCCCN2C[C@@H]([C@H]([C@@H]([C@H]2CO)O)O)O
DMXI4V8	IK	AAWCULUAQOJFJX-HGIWEUDGSA-N
DMXI4V8	IU	4-oxo-4-(4-prop-2-ynoxyphenyl)-N-[3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propyl]butanamide
DMXI4V8	DE	Discovery agent

DMCZHBI	ID	DMCZHBI
DMCZHBI	DN	N-(Propylamide-benzophenone)-1-deoxynojirimycin
DMCZHBI	HS	Investigative
DMCZHBI	SN	CHEMBL590070; N-(Propylamide-benzophenone)-1-deoxynojirimycin; BDBM50308672
DMCZHBI	DT	Small molecular drug
DMCZHBI	PC	46229704
DMCZHBI	MW	482.5
DMCZHBI	FM	C26H30N2O7
DMCZHBI	IC	InChI=1S/C26H30N2O7/c1-2-14-35-20-10-8-18(9-11-20)23(31)17-4-6-19(7-5-17)26(34)27-12-3-13-28-15-22(30)25(33)24(32)21(28)16-29/h1,4-11,21-22,24-25,29-30,32-33H,3,12-16H2,(H,27,34)/t21-,22+,24-,25-/m1/s1
DMCZHBI	CS	C#CCOC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C(=O)NCCCN3C[C@@H]([C@H]([C@@H]([C@H]3CO)O)O)O
DMCZHBI	IK	ISWDTKRAKJESLP-PEISPCAHSA-N
DMCZHBI	IU	4-(4-prop-2-ynoxybenzoyl)-N-[3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propyl]benzamide
DMCZHBI	DE	Discovery agent

DMTHJL4	ID	DMTHJL4
DMTHJL4	DN	N-(pyridin-3-yl)indoline-1-carboxamide
DMTHJL4	HS	Investigative
DMTHJL4	SN	CHEMBL42327; N-(pyridin-3-yl)indoline-1-carboxamide; SCHEMBL9035888; 1-(3-pyridylcarbamoyl) indoline; MolPort-003-287-500; BDBM50321878; AKOS001223824; N-(3-Pyridinyl)-2,3-dihydro-1H-indole-1-carboxamide; 2,3-Dihydro-indole-1-carboxylic acid pyridin-3-ylamide
DMTHJL4	DT	Small molecular drug
DMTHJL4	PC	10823903
DMTHJL4	MW	239.27
DMTHJL4	FM	C14H13N3O
DMTHJL4	IC	InChI=1S/C14H13N3O/c18-14(16-12-5-3-8-15-10-12)17-9-7-11-4-1-2-6-13(11)17/h1-6,8,10H,7,9H2,(H,16,18)
DMTHJL4	CS	C1CN(C2=CC=CC=C21)C(=O)NC3=CN=CC=C3
DMTHJL4	IK	ODXHNGJYIWHPAG-UHFFFAOYSA-N
DMTHJL4	IU	N-pyridin-3-yl-2,3-dihydroindole-1-carboxamide
DMTHJL4	DE	Discovery agent

DMBJKH1	ID	DMBJKH1
DMBJKH1	DN	N-(pyridin-3-ylmethyl) estradiol-16-carboxamide
DMBJKH1	HS	Investigative
DMBJKH1	SN	SCHEMBL12379481
DMBJKH1	DT	Small molecular drug
DMBJKH1	PC	44407373
DMBJKH1	MW	406.5
DMBJKH1	FM	C25H30N2O3
DMBJKH1	IC	InChI=1S/C25H30N2O3/c1-25-9-8-19-18-7-5-17(28)11-16(18)4-6-20(19)22(25)12-21(23(25)29)24(30)27-14-15-3-2-10-26-13-15/h2-3,5,7,10-11,13,19-23,28-29H,4,6,8-9,12,14H2,1H3,(H,27,30)/t19?,20?,21?,22?,23-,25-/m0/s1
DMBJKH1	CS	C[C@]12CCC3C(C1CC([C@@H]2O)C(=O)NCC4=CN=CC=C4)CCC5=C3C=CC(=C5)O
DMBJKH1	IK	JLDAJRITWUSQME-GYDLEPMTSA-N
DMBJKH1	IU	(13S,17S)-3,17-dihydroxy-13-methyl-N-(pyridin-3-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DMBJKH1	DE	Discovery agent

DMIN60B	ID	DMIN60B
DMIN60B	DN	N-(pyridin-3-ylmethyl)aniline
DMIN60B	HS	Investigative
DMIN60B	SN	N-(pyridin-3-ylmethyl)aniline; Phenyl-pyridin-3-ylmethyl-amine; 73570-11-3; phenylpyridin-3-ylmethylamine; CHEMBL264669; N-((pyridine-3-yl)methyl)benzeneamine; BAS 06103406; 3ftv; 3ftw; 11X; 3-anilinomethylpyridine; AC1LLDK0; n-(3-pyridylmethyl)aniline; phenyl(3-pyridylmethyl)amine; 3-(phenylaminomethyl)pyridine; MLS000527027; SCHEMBL523753; BJXLHKJBRORJJJ-UHFFFAOYSA-N; N-[(pyridin-3-yl)methyl]aniline; MolPort-002-003-387; ZINC798246; HMS3604C11; HMS2177I23; N-(pyridin-3-ylmethyl)benzenamine; HMS1684G18
DMIN60B	DT	Small molecular drug
DMIN60B	PC	1082702
DMIN60B	MW	184.24
DMIN60B	FM	C12H12N2
DMIN60B	IC	InChI=1S/C12H12N2/c1-2-6-12(7-3-1)14-10-11-5-4-8-13-9-11/h1-9,14H,10H2
DMIN60B	CS	C1=CC=C(C=C1)NCC2=CN=CC=C2
DMIN60B	IK	BJXLHKJBRORJJJ-UHFFFAOYSA-N
DMIN60B	IU	N-(pyridin-3-ylmethyl)aniline
DMIN60B	DE	Discovery agent

DMYFAQV	ID	DMYFAQV
DMYFAQV	DN	N-(pyridin-4-ylmethyl) estradiol-16-carboxamide
DMYFAQV	HS	Investigative
DMYFAQV	SN	SCHEMBL12379498
DMYFAQV	DT	Small molecular drug
DMYFAQV	PC	44407377
DMYFAQV	MW	406.5
DMYFAQV	FM	C25H30N2O3
DMYFAQV	IC	InChI=1S/C25H30N2O3/c1-25-9-6-19-18-5-3-17(28)12-16(18)2-4-20(19)22(25)13-21(23(25)29)24(30)27-14-15-7-10-26-11-8-15/h3,5,7-8,10-12,19-23,28-29H,2,4,6,9,13-14H2,1H3,(H,27,30)/t19?,20?,21?,22?,23-,25-/m0/s1
DMYFAQV	CS	C[C@]12CCC3C(C1CC([C@@H]2O)C(=O)NCC4=CC=NC=C4)CCC5=C3C=CC(=C5)O
DMYFAQV	IK	PHCMYYPTUPNLMJ-GYDLEPMTSA-N
DMYFAQV	IU	(13S,17S)-3,17-dihydroxy-13-methyl-N-(pyridin-4-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DMYFAQV	DE	Discovery agent

DMYEQXH	ID	DMYEQXH
DMYEQXH	DN	N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide
DMYEQXH	HS	Investigative
DMYEQXH	SN	CHEMBL475714; N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide; SCHEMBL5458681
DMYEQXH	DT	Small molecular drug
DMYEQXH	PC	44591342
DMYEQXH	MW	336.4
DMYEQXH	FM	C15H20N4O3S
DMYEQXH	IC	InChI=1S/C15H20N4O3S/c16-23(21,22)18-9-5-1-2-8-15(20)19-13-10-12-6-3-4-7-14(12)17-11-13/h3-4,6-7,10-11,18H,1-2,5,8-9H2,(H,19,20)(H2,16,21,22)
DMYEQXH	CS	C1=CC=C2C(=C1)C=C(C=N2)NC(=O)CCCCCNS(=O)(=O)N
DMYEQXH	IK	HIRQWWZRMZTUFZ-UHFFFAOYSA-N
DMYEQXH	IU	N-quinolin-3-yl-6-(sulfamoylamino)hexanamide
DMYEQXH	DE	Discovery agent

DMFC3XI	ID	DMFC3XI
DMFC3XI	DN	N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide
DMFC3XI	HS	Investigative
DMFC3XI	SN	CHEMBL454438; N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide; SCHEMBL5359458; CGIYOYXFUHZSMD-UHFFFAOYSA-N
DMFC3XI	DT	Small molecular drug
DMFC3XI	PC	25216938
DMFC3XI	MW	336.4
DMFC3XI	FM	C15H20N4O3S
DMFC3XI	IC	InChI=1S/C15H20N4O3S/c16-23(21,22)18-10-3-1-2-6-15(20)19-13-7-8-14-12(11-13)5-4-9-17-14/h4-5,7-9,11,18H,1-3,6,10H2,(H,19,20)(H2,16,21,22)
DMFC3XI	CS	C1=CC2=C(C=CC(=C2)NC(=O)CCCCCNS(=O)(=O)N)N=C1
DMFC3XI	IK	CGIYOYXFUHZSMD-UHFFFAOYSA-N
DMFC3XI	IU	N-quinolin-6-yl-6-(sulfamoylamino)hexanamide
DMFC3XI	DE	Discovery agent

DML8EVA	ID	DML8EVA
DML8EVA	DN	N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide
DML8EVA	HS	Investigative
DML8EVA	SN	CHEMBL507114; N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide; SCHEMBL5330834
DML8EVA	DT	Small molecular drug
DML8EVA	PC	25216936
DML8EVA	MW	336.4
DML8EVA	FM	C15H20N4O3S
DML8EVA	IC	InChI=1S/C15H20N4O3S/c16-23(21,22)18-11-3-1-2-9-14(20)19-13-8-4-6-12-7-5-10-17-15(12)13/h4-8,10,18H,1-3,9,11H2,(H,19,20)(H2,16,21,22)
DML8EVA	CS	C1=CC2=C(C(=C1)NC(=O)CCCCCNS(=O)(=O)N)N=CC=C2
DML8EVA	IK	IQEBALPYRTUOEG-UHFFFAOYSA-N
DML8EVA	IU	N-quinolin-8-yl-6-(sulfamoylamino)hexanamide
DML8EVA	DE	Discovery agent

DM7O1F3	ID	DM7O1F3
DM7O1F3	DN	N-(quinolin-8-yl)thiophene-2-sulfonamide
DM7O1F3	HS	Investigative
DM7O1F3	SN	CHEMBL257234; N-(quinolin-8-yl)thiophene-2-sulfonamide; AC1LH19W; Oprea1_700618; SCHEMBL7190921; MolPort-003-066-216; ZINC353084; BDBM50372518; AKOS001422726; N-quinolin-8-ylthiophene-2-sulfonamide; MCULE-3746564892; N-(8-Quinolyl)-2-thiophenesulfonamide; NCGC00161717-01; SR-01000012975; CU-00000000139-1; SR-01000012975-1; Z115639124
DM7O1F3	DT	Small molecular drug
DM7O1F3	PC	830459
DM7O1F3	MW	290.4
DM7O1F3	FM	C13H10N2O2S2
DM7O1F3	IC	InChI=1S/C13H10N2O2S2/c16-19(17,12-7-3-9-18-12)15-11-6-1-4-10-5-2-8-14-13(10)11/h1-9,15H
DM7O1F3	CS	C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=CS3)N=CC=C2
DM7O1F3	IK	CPSRVVXBTZFZPM-UHFFFAOYSA-N
DM7O1F3	IU	N-quinolin-8-ylthiophene-2-sulfonamide
DM7O1F3	DE	Discovery agent

DM2SNXB	ID	DM2SNXB
DM2SNXB	DN	N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)
DM2SNXB	HS	Investigative
DM2SNXB	SN	N-(R-CARBOXY-ETHYL)-ALPHA-(S)-(2-PHENYLETHYL); Inhibitor 1; IH4; AC1LCW3V; DB02505; methyl 2-[4-[4-[[[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl]-(4-pentylbenzoyl)amino]methyl]phenyl]phenyl]acetate; methyl 2-{4-[4-({N-[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl]-1-(4-pentylphenyl)formamido}methyl)phenyl]phenyl}acetate; methyl [4'-({[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino}methyl)biphenyl-4-yl]acetate
DM2SNXB	DT	Small molecular drug
DM2SNXB	PC	657149
DM2SNXB	MW	592.8
DM2SNXB	FM	C37H44N4O3
DM2SNXB	IC	InChI=1S/C37H44N4O3/c1-3-4-5-6-28-7-17-33(18-8-28)37(43)41(34-19-23-40(24-20-34)27-35-38-21-22-39-35)26-30-11-15-32(16-12-30)31-13-9-29(10-14-31)25-36(42)44-2/h7-18,21-22,34H,3-6,19-20,23-27H2,1-2H3,(H,38,39)
DM2SNXB	CS	CCCCCC1=CC=C(C=C1)C(=O)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)CC(=O)OC)C4CCN(CC4)CC5=NC=CN5
DM2SNXB	IK	JJVQUUYZGJWBPW-UHFFFAOYSA-N
DM2SNXB	IU	methyl 2-[4-[4-[[[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl]-(4-pentylbenzoyl)amino]methyl]phenyl]phenyl]acetate
DM2SNXB	DE	Discovery agent

DMWJDYZ	ID	DMWJDYZ
DMWJDYZ	DN	N-(Sulfanylacetyl)Tyrosylprolylmethioninamide
DMWJDYZ	HS	Investigative
DMWJDYZ	SN	N-(SULFANYLACETYL)TYROSYLPROLYLMETHIONINAMIDE; SD2; 1pwq; AC1NRD4A; SCHEMBL4315756; DB01883; N-(sulfanylacetyl)-L-tyrosyl-L-prolyl-L-methioninamide; (2S)-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-1-[(2S)-3-(4-hydroxyphenyl)-2-[(2-sulfanylacetyl)amino]propanoyl]pyrrolidine-2-carboxamide
DMWJDYZ	DT	Small molecular drug
DMWJDYZ	PC	5289343
DMWJDYZ	MW	482.6
DMWJDYZ	FM	C21H30N4O5S2
DMWJDYZ	IC	InChI=1S/C21H30N4O5S2/c1-32-10-8-15(19(22)28)24-20(29)17-3-2-9-25(17)21(30)16(23-18(27)12-31)11-13-4-6-14(26)7-5-13/h4-7,15-17,26,31H,2-3,8-12H2,1H3,(H2,22,28)(H,23,27)(H,24,29)/t15-,16-,17-/m0/s1
DMWJDYZ	CS	CSCC[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CS
DMWJDYZ	IK	LNLWXWOYQHAKTD-ULQDDVLXSA-N
DMWJDYZ	IU	(2S)-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-1-[(2S)-3-(4-hydroxyphenyl)-2-[(2-sulfanylacetyl)amino]propanoyl]pyrrolidine-2-carboxamide
DMWJDYZ	DE	Discovery agent

DMJ0S5C	ID	DMJ0S5C
DMJ0S5C	DN	N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile
DMJ0S5C	HS	Investigative
DMJ0S5C	SN	dipeptide-derived nitrile, 9; CHEMBL197113; BDBM20088; tert-butyl N-[(1S,2R)-1-[(cyanomethyl)carbamoyl]-2-methylbutyl]carbamate
DMJ0S5C	DT	Small molecular drug
DMJ0S5C	PC	23648531
DMJ0S5C	MW	269.34
DMJ0S5C	FM	C13H23N3O3
DMJ0S5C	IC	InChI=1S/C13H23N3O3/c1-6-9(2)10(11(17)15-8-7-14)16-12(18)19-13(3,4)5/h9-10H,6,8H2,1-5H3,(H,15,17)(H,16,18)/t9-,10+/m1/s1
DMJ0S5C	CS	CC[C@@H](C)[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMJ0S5C	IK	HNTBSHVGXMFKKB-ZJUUUORDSA-N
DMJ0S5C	IU	tert-butyl N-[(2S,3R)-1-(cyanomethylamino)-3-methyl-1-oxopentan-2-yl]carbamate
DMJ0S5C	DE	Discovery agent

DMXYQWG	ID	DMXYQWG
DMXYQWG	DN	N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile
DMXYQWG	HS	Investigative
DMXYQWG	SN	dipeptide-derived nitrile, 7; CHEMBL200160; SCHEMBL6257676; BDBM20087; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate
DMXYQWG	DT	Small molecular drug
DMXYQWG	PC	11492732
DMXYQWG	MW	269.34
DMXYQWG	FM	C13H23N3O3
DMXYQWG	IC	InChI=1S/C13H23N3O3/c1-9(2)8-10(11(17)15-7-6-14)16-12(18)19-13(3,4)5/h9-10H,7-8H2,1-5H3,(H,15,17)(H,16,18)/t10-/m0/s1
DMXYQWG	CS	CC(C)C[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMXYQWG	IK	OMQSGXGRANQGLE-JTQLQIEISA-N
DMXYQWG	IU	tert-butyl N-[(2S)-1-(cyanomethylamino)-4-methyl-1-oxopentan-2-yl]carbamate
DMXYQWG	DE	Discovery agent

DM3I0WZ	ID	DM3I0WZ
DM3I0WZ	DN	N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile
DM3I0WZ	HS	Investigative
DM3I0WZ	SN	dipeptide-derived nitrile, 12; CHEMBL381847; BDBM20091; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-(methylsulfanyl)propyl]carbamate
DM3I0WZ	DT	Small molecular drug
DM3I0WZ	PC	11709032
DM3I0WZ	MW	287.38
DM3I0WZ	FM	C12H21N3O3S
DM3I0WZ	IC	InChI=1S/C12H21N3O3S/c1-12(2,3)18-11(17)15-9(5-8-19-4)10(16)14-7-6-13/h9H,5,7-8H2,1-4H3,(H,14,16)(H,15,17)/t9-/m0/s1
DM3I0WZ	CS	CC(C)(C)OC(=O)N[C@@H](CCSC)C(=O)NCC#N
DM3I0WZ	IK	PDUKBZKBRGAZFC-VIFPVBQESA-N
DM3I0WZ	IU	tert-butyl N-[(2S)-1-(cyanomethylamino)-4-methylsulfanyl-1-oxobutan-2-yl]carbamate
DM3I0WZ	DE	Discovery agent

DMGF4XC	ID	DMGF4XC
DMGF4XC	DN	N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile
DMGF4XC	HS	Investigative
DMGF4XC	SN	dipeptide-derived nitrile, 13; CHEMBL383584; BDBM20092; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]pentyl]carbamate
DMGF4XC	DT	Small molecular drug
DMGF4XC	PC	11637576
DMGF4XC	MW	269.34
DMGF4XC	FM	C13H23N3O3
DMGF4XC	IC	InChI=1S/C13H23N3O3/c1-5-6-7-10(11(17)15-9-8-14)16-12(18)19-13(2,3)4/h10H,5-7,9H2,1-4H3,(H,15,17)(H,16,18)/t10-/m0/s1
DMGF4XC	CS	CCCC[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMGF4XC	IK	KXUSXCUMFSXFIW-JTQLQIEISA-N
DMGF4XC	IU	tert-butyl N-[(2S)-1-(cyanomethylamino)-1-oxohexan-2-yl]carbamate
DMGF4XC	DE	Discovery agent

DMOP5N7	ID	DMOP5N7
DMOP5N7	DN	N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile
DMOP5N7	HS	Investigative
DMOP5N7	SN	dipeptide-derived nitrile, 6; CHEMBL383816; BDBM20086; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]butyl]carbamate
DMOP5N7	DT	Small molecular drug
DMOP5N7	PC	11514386
DMOP5N7	MW	255.31
DMOP5N7	FM	C12H21N3O3
DMOP5N7	IC	InChI=1S/C12H21N3O3/c1-5-6-9(10(16)14-8-7-13)15-11(17)18-12(2,3)4/h9H,5-6,8H2,1-4H3,(H,14,16)(H,15,17)/t9-/m0/s1
DMOP5N7	CS	CCC[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMOP5N7	IK	PBHMIOPVNIIFHR-VIFPVBQESA-N
DMOP5N7	IU	tert-butyl N-[(2S)-1-(cyanomethylamino)-1-oxopentan-2-yl]carbamate
DMOP5N7	DE	Discovery agent

DMP9JVT	ID	DMP9JVT
DMP9JVT	DN	N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile
DMP9JVT	HS	Investigative
DMP9JVT	SN	dipeptide-derived nitrile, 23; CHEMBL371893; BDBM20102; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamate
DMP9JVT	DT	Small molecular drug
DMP9JVT	PC	11551481
DMP9JVT	MW	319.36
DMP9JVT	FM	C16H21N3O4
DMP9JVT	IC	InChI=1S/C16H21N3O4/c1-16(2,3)23-15(22)19-13(14(21)18-9-8-17)10-11-4-6-12(20)7-5-11/h4-7,13,20H,9-10H2,1-3H3,(H,18,21)(H,19,22)/t13-/m0/s1
DMP9JVT	CS	CC(C)(C)OC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC#N
DMP9JVT	IK	ZMDCVKGQECBOGN-ZDUSSCGKSA-N
DMP9JVT	IU	tert-butyl N-[(2S)-1-(cyanomethylamino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamate
DMP9JVT	DE	Discovery agent

DMUQBOP	ID	DMUQBOP
DMUQBOP	DN	N-(tert-butoxycarbonyl)-valyl-glycine-nitrile
DMUQBOP	HS	Investigative
DMUQBOP	SN	N-(tert-butoxycarbonyl)-L-valyl-glycine-nitrile; 191033-03-1; dipeptide-derived nitrile, 5; CHEMBL200004; BDBM20085; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-methylpropyl]carbamate
DMUQBOP	DT	Small molecular drug
DMUQBOP	PC	14774521
DMUQBOP	MW	255.31
DMUQBOP	FM	C12H21N3O3
DMUQBOP	IC	InChI=1S/C12H21N3O3/c1-8(2)9(10(16)14-7-6-13)15-11(17)18-12(3,4)5/h8-9H,7H2,1-5H3,(H,14,16)(H,15,17)/t9-/m0/s1
DMUQBOP	CS	CC(C)[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMUQBOP	IK	OHPJKVGJQUYVFQ-VIFPVBQESA-N
DMUQBOP	IU	tert-butyl N-[(2S)-1-(cyanomethylamino)-3-methyl-1-oxobutan-2-yl]carbamate
DMUQBOP	DE	Discovery agent

DM1N7AG	ID	DM1N7AG
DM1N7AG	DN	N-(thiazol-2-yl)benzamide
DM1N7AG	HS	Investigative
DM1N7AG	SN	N-(1,3-Thiazol-2-yl)benzamide; N-Thiazol-2-yl-benzamide; SCQBDADQAVXTMZ-UHFFFAOYSA-N; 13053-82-2; N-(thiazol-2-yl)benzamide; Benzamide, N-2-thiazolyl-; AC1LC4SL; AC1Q5LQU; n-thiazol-2-yl benzamide; N-(2-Thiazolyl)benzamide; MLS000711892; SCHEMBL995829; CHEMBL90846; Benzamide, N-(2-thiazolyl)-; IFLab1_003538; ZINC39994; MolPort-000-557-753; HMS1422A18; HMS2643F11; N-(1,3-Thiazol-2-yl)benzamide #; STK018313; AKOS005145274; AKOS000638160; MCULE-9395155160; IDI1_009645; SMR000281659; phenyl-N-(1,3-thiazol-2-yl)carboxamide; BAS 00332640
DM1N7AG	DT	Small molecular drug
DM1N7AG	PC	569547
DM1N7AG	MW	204.25
DM1N7AG	FM	C10H8N2OS
DM1N7AG	IC	InChI=1S/C10H8N2OS/c13-9(8-4-2-1-3-5-8)12-10-11-6-7-14-10/h1-7H,(H,11,12,13)
DM1N7AG	CS	C1=CC=C(C=C1)C(=O)NC2=NC=CS2
DM1N7AG	IK	SCQBDADQAVXTMZ-UHFFFAOYSA-N
DM1N7AG	IU	N-(1,3-thiazol-2-yl)benzamide
DM1N7AG	CA	CAS 13053-82-2
DM1N7AG	DE	Discovery agent

DM8JQEO	ID	DM8JQEO
DM8JQEO	DN	N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine
DM8JQEO	HS	Investigative
DM8JQEO	SN	CHEMBL89454; 1,4-Butanediamine, N1-(5-methyl-2-nitrophenyl)-; N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine; BDBM50065369; AKOS018628293
DM8JQEO	DT	Small molecular drug
DM8JQEO	PC	10489277
DM8JQEO	MW	223.27
DM8JQEO	FM	C11H17N3O2
DM8JQEO	IC	InChI=1S/C11H17N3O2/c1-9-4-5-11(14(15)16)10(8-9)13-7-3-2-6-12/h4-5,8,13H,2-3,6-7,12H2,1H3
DM8JQEO	CS	CC1=CC(=C(C=C1)[N+](=O)[O-])NCCCCN
DM8JQEO	IK	ANIBJVLRYPKMKX-UHFFFAOYSA-N
DM8JQEO	IU	N'-(5-methyl-2-nitrophenyl)butane-1,4-diamine
DM8JQEO	DE	Discovery agent

DME8KXT	ID	DME8KXT
DME8KXT	DN	N*1*-(6-Nitro-quinolin-2-yl)-ethane-1,2-diamine
DME8KXT	HS	Investigative
DME8KXT	SN	CHEMBL38754; N*1*-(6-Nitro-quinolin-2-yl)-ethane-1,2-diamine; BDBM50090212; AKOS009510501
DME8KXT	DT	Small molecular drug
DME8KXT	PC	43450811
DME8KXT	MW	232.24
DME8KXT	FM	C11H12N4O2
DME8KXT	IC	InChI=1S/C11H12N4O2/c12-5-6-13-11-4-1-8-7-9(15(16)17)2-3-10(8)14-11/h1-4,7H,5-6,12H2,(H,13,14)
DME8KXT	CS	C1=CC2=C(C=CC(=N2)NCCN)C=C1[N+](=O)[O-]
DME8KXT	IK	ULJORSRDDXAXJZ-UHFFFAOYSA-N
DME8KXT	IU	N'-(6-nitroquinolin-2-yl)ethane-1,2-diamine
DME8KXT	DE	Discovery agent

DM41TQB	ID	DM41TQB
DM41TQB	DN	N*2*-Benzyl-N*6*-cyclohexyl-9H-purine-2,6-diamine
DM41TQB	HS	Investigative
DM41TQB	SN	CHEMBL190147; N*2*-Benzyl-N*6*-cyclohexyl-9H-purine-2,6-diamine; BDBM50170836
DM41TQB	DT	Small molecular drug
DM41TQB	PC	15366659
DM41TQB	MW	322.4
DM41TQB	FM	C18H22N6
DM41TQB	IC	InChI=1S/C18H22N6/c1-3-7-13(8-4-1)11-19-18-23-16-15(20-12-21-16)17(24-18)22-14-9-5-2-6-10-14/h1,3-4,7-8,12,14H,2,5-6,9-11H2,(H3,19,20,21,22,23,24)
DM41TQB	CS	C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)NCC4=CC=CC=C4
DM41TQB	IK	NPPHTZNKBUCRPG-UHFFFAOYSA-N
DM41TQB	IU	2-N-benzyl-6-N-cyclohexyl-7H-purine-2,6-diamine
DM41TQB	DE	Discovery agent

DMFWN5U	ID	DMFWN5U
DMFWN5U	DN	N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine
DMFWN5U	HS	Investigative
DMFWN5U	SN	bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514
DMFWN5U	DT	Small molecular drug
DMFWN5U	PC	2426
DMFWN5U	MW	330.18
DMFWN5U	FM	C14H12BrN5
DMFWN5U	IC	InChI=1S/C14H12BrN5/c15-8-2-1-3-9(4-8)20-14-10-5-11(16)12(17)6-13(10)18-7-19-14/h1-7H,16-17H2,(H,18,19,20)
DMFWN5U	CS	C1=CC(=CC(=C1)Br)NC2=NC=NC3=CC(=C(C=C32)N)N
DMFWN5U	IK	ADXSZLCTQCWMTE-UHFFFAOYSA-N
DMFWN5U	IU	4-N-(3-bromophenyl)quinazoline-4,6,7-triamine
DMFWN5U	CA	CAS 169205-87-2
DMFWN5U	DE	Discovery agent

DMUI8RC	ID	DMUI8RC
DMUI8RC	DN	N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine
DMUI8RC	HS	Investigative
DMUI8RC	SN	N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221
DMUI8RC	DT	Small molecular drug
DMUI8RC	PC	5328042
DMUI8RC	MW	315.17
DMUI8RC	FM	C14H11BrN4
DMUI8RC	IC	InChI=1S/C14H11BrN4/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,16H2,(H,17,18,19)
DMUI8RC	CS	C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=C(C=C3)N
DMUI8RC	IK	IZQHULBHKPGOAP-UHFFFAOYSA-N
DMUI8RC	IU	4-N-(3-bromophenyl)quinazoline-4,6-diamine
DMUI8RC	CA	CAS 169205-78-1
DMUI8RC	DE	Discovery agent

DMO56XY	ID	DMO56XY
DMO56XY	DN	N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine
DMO56XY	HS	Investigative
DMO56XY	SN	CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline
DMO56XY	DT	Small molecular drug
DMO56XY	PC	5328045
DMO56XY	MW	315.17
DMO56XY	FM	C14H11BrN4
DMO56XY	IC	InChI=1S/C14H11BrN4/c15-9-2-1-3-11(6-9)19-14-12-5-4-10(16)7-13(12)17-8-18-14/h1-8H,16H2,(H,17,18,19)
DMO56XY	CS	C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=CC(=C3)N
DMO56XY	IK	GHVBIROTJQDRQB-UHFFFAOYSA-N
DMO56XY	IU	4-N-(3-bromophenyl)quinazoline-4,7-diamine
DMO56XY	DE	Discovery agent

DMNGSQK	ID	DMNGSQK
DMNGSQK	DN	N*4*-Benzyl-6-chloro-pyrimidine-2,4-diamine
DMNGSQK	HS	Investigative
DMNGSQK	SN	91066-67-0; CHEMBL158113; N4-Benzyl-6-chloropyrimidine-2,4-diamine; N~4~-benzyl-6-chloropyrimidine-2,4-diamine; 4-N-benzyl-6-chloropyrimidine-2,4-diamine; N~4~-benzyl-6-chloro-2,4-pyrimidinediamine; 2,4-Pyrimidinediamine, 6-chloro-N4-(phenylmethyl)-; N*4*-Benzyl-6-chloro-pyrimidine-2,4-diamine; Oprea1_700029; AC1Q52S4; AC1LS938; SCHEMBL1319082; CTK6G7145; DTXSID50363293; GXNJAZPAQIPYMJ-UHFFFAOYSA-N; MolPort-001-843-083; KS-00003D1N; ALBB-022867; ZINC1398022; SBB098322; BDBM50022150; AKOS015993366
DMNGSQK	DT	Small molecular drug
DMNGSQK	PC	1484270
DMNGSQK	MW	234.68
DMNGSQK	FM	C11H11ClN4
DMNGSQK	IC	InChI=1S/C11H11ClN4/c12-9-6-10(16-11(13)15-9)14-7-8-4-2-1-3-5-8/h1-6H,7H2,(H3,13,14,15,16)
DMNGSQK	CS	C1=CC=C(C=C1)CNC2=CC(=NC(=N2)N)Cl
DMNGSQK	IK	GXNJAZPAQIPYMJ-UHFFFAOYSA-N
DMNGSQK	IU	4-N-benzyl-6-chloropyrimidine-2,4-diamine
DMNGSQK	CA	CAS 91066-67-0
DMNGSQK	DE	Discovery agent

DMK674I	ID	DMK674I
DMK674I	DN	N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine
DMK674I	HS	Investigative
DMK674I	SN	CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882
DMK674I	DT	Small molecular drug
DMK674I	PC	5328077
DMK674I	MW	251.29
DMK674I	FM	C14H13N5
DMK674I	IC	InChI=1S/C14H13N5/c15-13-6-12-11(8-16-13)14(19-9-18-12)17-7-10-4-2-1-3-5-10/h1-6,8-9H,7H2,(H2,15,16)(H,17,18,19)
DMK674I	CS	C1=CC=C(C=C1)CNC2=NC=NC3=CC(=NC=C32)N
DMK674I	IK	JBRBEQRTMVYDCU-UHFFFAOYSA-N
DMK674I	IU	4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine
DMK674I	DE	Discovery agent

DMRNGV0	ID	DMRNGV0
DMRNGV0	DN	N*6*-Benzyl-quinazoline-2,4,6-triamine
DMRNGV0	HS	Investigative
DMRNGV0	SN	CHEMBL115474; N*6*-Benzyl-quinazoline-2,4,6-triamine; AC1LA5GO; ZINC5974540; BDBM50066486; N6-benzylquinazoline-2,4,6-triamine; 6-N-benzylquinazoline-2,4,6-triamine; 2,4-diamino-6-(benzylamino)quinazoline; 6-(Benzylamino)-2,4-quinazolinediamine
DMRNGV0	DT	Small molecular drug
DMRNGV0	PC	462120
DMRNGV0	MW	265.31
DMRNGV0	FM	C15H15N5
DMRNGV0	IC	InChI=1S/C15H15N5/c16-14-12-8-11(6-7-13(12)19-15(17)20-14)18-9-10-4-2-1-3-5-10/h1-8,18H,9H2,(H4,16,17,19,20)
DMRNGV0	CS	C1=CC=C(C=C1)CNC2=CC3=C(C=C2)N=C(N=C3N)N
DMRNGV0	IK	PTWJNRZKGULCMJ-UHFFFAOYSA-N
DMRNGV0	IU	6-N-benzylquinazoline-2,4,6-triamine
DMRNGV0	DE	Discovery agent

DM1K2A4	ID	DM1K2A4
DM1K2A4	DN	N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine
DM1K2A4	HS	Investigative
DM1K2A4	SN	CHEMBL191551; N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine
DM1K2A4	DT	Small molecular drug
DM1K2A4	PC	11334464
DM1K2A4	MW	260.339
DM1K2A4	FM	C13H20N6
DM1K2A4	IC	InChI=1S/C13H20N6/c1-2-14-13-18-11-10(15-8-16-11)12(19-13)17-9-6-4-3-5-7-9/h8-9H,2-7H2,1H3,(H3,14,15,16,17,18,19)
DM1K2A4	CS	CCNC1=NC2=C(C(=N1)NC3CCCCC3)NC=N2
DM1K2A4	IK	XHOVJLBZYXEITR-UHFFFAOYSA-N
DM1K2A4	IU	6-N-cyclohexyl-2-N-ethyl-7H-purine-2,6-diamine
DM1K2A4	DE	Discovery agent

DM3C8PJ	ID	DM3C8PJ
DM3C8PJ	DN	N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine
DM3C8PJ	HS	Investigative
DM3C8PJ	SN	CHEMBL188592; N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine
DM3C8PJ	DT	Small molecular drug
DM3C8PJ	PC	11243768
DM3C8PJ	MW	308.4
DM3C8PJ	FM	C17H20N6
DM3C8PJ	IC	InChI=1S/C17H20N6/c1-3-7-12(8-4-1)20-16-14-15(19-11-18-14)22-17(23-16)21-13-9-5-2-6-10-13/h2,5-6,9-12H,1,3-4,7-8H2,(H3,18,19,20,21,22,23)
DM3C8PJ	CS	C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)NC4=CC=CC=C4
DM3C8PJ	IK	FDFMDLSSHFEJOS-UHFFFAOYSA-N
DM3C8PJ	IU	6-N-cyclohexyl-2-N-phenyl-7H-purine-2,6-diamine
DM3C8PJ	DE	Discovery agent

DMCOPR3	ID	DMCOPR3
DMCOPR3	DN	N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine
DMCOPR3	HS	Investigative
DMCOPR3	SN	CHEMBL365026; N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine
DMCOPR3	DT	Small molecular drug
DMCOPR3	PC	11484484
DMCOPR3	MW	336.4
DMCOPR3	FM	C19H24N6
DMCOPR3	IC	InChI=1S/C19H24N6/c1-2-5-9-14(10-6-3-1)22-18-16-17(21-13-20-16)24-19(25-18)23-15-11-7-4-8-12-15/h4,7-8,11-14H,1-3,5-6,9-10H2,(H3,20,21,22,23,24,25)
DMCOPR3	CS	C1CCCC(CCC1)NC2=NC(=NC3=C2NC=N3)NC4=CC=CC=C4
DMCOPR3	IK	MSEVQUIRSAPIPS-UHFFFAOYSA-N
DMCOPR3	IU	6-N-cyclooctyl-2-N-phenyl-7H-purine-2,6-diamine
DMCOPR3	DE	Discovery agent

DMWKRJX	ID	DMWKRJX
DMWKRJX	DN	N',2-diphenylquinoline-4-carbohydrazide
DMWKRJX	HS	Investigative
DMWKRJX	SN	compound 2g [PMID: 16950620]
DMWKRJX	DT	Small molecular drug
DMWKRJX	PC	16049828
DMWKRJX	MW	427.5
DMWKRJX	FM	C25H21N3O4
DMWKRJX	IC	InChI=1S/C25H21N3O4/c1-31-23-21(24(29)27-28(25(30)32-2)18-13-7-4-8-14-18)19-15-9-10-16-20(19)26-22(23)17-11-5-3-6-12-17/h3-16H,1-2H3,(H,27,29)
DMWKRJX	CS	COC1=C(C2=CC=CC=C2N=C1C3=CC=CC=C3)C(=O)NN(C4=CC=CC=C4)C(=O)OC
DMWKRJX	IK	JLSTVOPSMZBZSR-UHFFFAOYSA-N
DMWKRJX	IU	methyl N-[(3-methoxy-2-phenylquinoline-4-carbonyl)amino]-N-phenylcarbamate
DMWKRJX	DE	Discovery agent

DMNJA3C	ID	DMNJA3C
DMNJA3C	DN	N',2-diphenylquinoline-4-carbohydrazide 8m
DMNJA3C	HS	Investigative
DMNJA3C	SN	compound 8m [PMID:16950617]
DMNJA3C	DT	Small molecular drug
DMNJA3C	PC	11989776
DMNJA3C	MW	569.7
DMNJA3C	FM	C33H36FN5O3
DMNJA3C	IC	InChI=1S/C33H36FN5O3/c1-33(2,3)38-20-18-37(19-21-38)22-26-28(31(40)36-39(32(41)42-4)24-14-9-6-10-15-24)25-16-11-17-27(34)30(25)35-29(26)23-12-7-5-8-13-23/h5-17H,18-22H2,1-4H3,(H,36,40)
DMNJA3C	CS	CC(C)(C)N1CCN(CC1)CC2=C(N=C3C(=C2C(=O)NN(C4=CC=CC=C4)C(=O)OC)C=CC=C3F)C5=CC=CC=C5
DMNJA3C	IK	KQNYTTDHCMFOME-UHFFFAOYSA-N
DMNJA3C	IU	methyl N-[[3-[(4-tert-butylpiperazin-1-yl)methyl]-8-fluoro-2-phenylquinoline-4-carbonyl]amino]-N-phenylcarbamate
DMNJA3C	DE	Discovery agent

DMOG37L	ID	DMOG37L
DMOG37L	DN	N,4-dibenzhydrylpiperazine-1-carboxamide
DMOG37L	HS	Investigative
DMOG37L	SN	CHEMBL599217; 381248-72-2; SCHEMBL3396540; CTK1A9093; DTXSID50435823; PPVBMJIAJXVQFX-UHFFFAOYSA-N; AKOS029837741; 1-Piperazinecarboxamide, N,4-bis(diphenylmethyl)-; 4-Benzhydryl-piperazine-1-carboxylic acid benzhydryl amide; 1-[(diphenylmethyl)aminocarbonyl]-4-(diphenylmethyl) piperazine
DMOG37L	DT	Small molecular drug
DMOG37L	PC	10115592
DMOG37L	MW	461.6
DMOG37L	FM	C31H31N3O
DMOG37L	IC	InChI=1S/C31H31N3O/c35-31(32-29(25-13-5-1-6-14-25)26-15-7-2-8-16-26)34-23-21-33(22-24-34)30(27-17-9-3-10-18-27)28-19-11-4-12-20-28/h1-20,29-30H,21-24H2,(H,32,35)
DMOG37L	CS	C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NC(C4=CC=CC=C4)C5=CC=CC=C5
DMOG37L	IK	PPVBMJIAJXVQFX-UHFFFAOYSA-N
DMOG37L	IU	N,4-dibenzhydrylpiperazine-1-carboxamide
DMOG37L	CA	CAS 381248-72-2
DMOG37L	DE	Discovery agent

DMMTQ3N	ID	DMMTQ3N
DMMTQ3N	DN	N,4-dimethyl-3,4-dihydroquinazolin-2-amine
DMMTQ3N	HS	Investigative
DMMTQ3N	DT	Small molecular drug
DMMTQ3N	PC	44455897
DMMTQ3N	DE	Discovery agent

DM8G0WX	ID	DM8G0WX
DM8G0WX	DN	N,8-dihydroxy-8-(naphthalen-2-yl)octanamide
DM8G0WX	HS	Investigative
DM8G0WX	SN	CHEMBL319738; N,8-dihydroxy-8-(naphthalen-2-yl)octanamide; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide
DM8G0WX	DT	Small molecular drug
DM8G0WX	PC	11044829
DM8G0WX	MW	301.4
DM8G0WX	FM	C18H23NO3
DM8G0WX	IC	InChI=1S/C18H23NO3/c20-17(9-3-1-2-4-10-18(21)19-22)16-12-11-14-7-5-6-8-15(14)13-16/h5-8,11-13,17,20,22H,1-4,9-10H2,(H,19,21)
DM8G0WX	CS	C1=CC=C2C=C(C=CC2=C1)C(CCCCCCC(=O)NO)O
DM8G0WX	IK	JWCSCYWHCCHTEF-UHFFFAOYSA-N
DM8G0WX	IU	N,8-dihydroxy-8-naphthalen-2-yloctanamide
DM8G0WX	DE	Discovery agent

DMZXF36	ID	DMZXF36
DMZXF36	DN	N,8-diphenyl-9H-purin-6-amine
DMZXF36	HS	Investigative
DMZXF36	SN	CHEMBL1210175; N,8-diphenyl-9H-purin-6-amine; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492
DMZXF36	DT	Small molecular drug
DMZXF36	PC	46894037
DMZXF36	MW	287.32
DMZXF36	FM	C17H13N5
DMZXF36	IC	InChI=1S/C17H13N5/c1-3-7-12(8-4-1)15-21-14-16(18-11-19-17(14)22-15)20-13-9-5-2-6-10-13/h1-11H,(H2,18,19,20,21,22)
DMZXF36	CS	C1=CC=C(C=C1)C2=NC3=C(N2)C(=NC=N3)NC4=CC=CC=C4
DMZXF36	IK	OKZNIBWRMMFNQY-UHFFFAOYSA-N
DMZXF36	IU	N,8-diphenyl-7H-purin-6-amine
DMZXF36	DE	Discovery agent

DMIX0CT	ID	DMIX0CT
DMIX0CT	DN	N,N'-(1',10'-decylene)-bis-(-)-nor-MEP
DMIX0CT	HS	Investigative
DMIX0CT	SN	CHEMBL259523
DMIX0CT	DT	Small molecular drug
DMIX0CT	PC	24827759
DMIX0CT	MW	576.9
DMIX0CT	FM	C38H60N2O2
DMIX0CT	IC	InChI=1S/C38H60N2O2/c1-3-37(33-19-17-21-35(41)29-33)23-11-15-27-39(31-37)25-13-9-7-5-6-8-10-14-26-40-28-16-12-24-38(4-2,32-40)34-20-18-22-36(42)30-34/h17-22,29-30,41-42H,3-16,23-28,31-32H2,1-2H3/t37-,38-/m1/s1
DMIX0CT	CS	CC[C@]1(CCCCN(C1)CCCCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMIX0CT	IK	PCOSLLZEMYSIRZ-XPSQVAKYSA-N
DMIX0CT	IU	3-[(3S)-3-ethyl-1-[10-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]decyl]azepan-3-yl]phenol
DMIX0CT	DE	Discovery agent

DM5NVIO	ID	DM5NVIO
DM5NVIO	DN	N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP
DM5NVIO	HS	Investigative
DM5NVIO	SN	CHEMBL406885
DM5NVIO	DT	Small molecular drug
DM5NVIO	PC	24827761
DM5NVIO	MW	590.9
DM5NVIO	FM	C39H62N2O2
DM5NVIO	IC	InChI=1S/C39H62N2O2/c1-3-38(34-20-18-22-36(42)30-34)24-12-16-28-40(32-38)26-14-10-8-6-5-7-9-11-15-27-41-29-17-13-25-39(4-2,33-41)35-21-19-23-37(43)31-35/h18-23,30-31,42-43H,3-17,24-29,32-33H2,1-2H3/t38-,39-/m1/s1
DM5NVIO	CS	CC[C@]1(CCCCN(C1)CCCCCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DM5NVIO	IK	IMWJSGSESWBQFI-LJEWAXOPSA-N
DM5NVIO	IU	3-[(3S)-3-ethyl-1-[11-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]undecyl]azepan-3-yl]phenol
DM5NVIO	DE	Discovery agent

DMWI06H	ID	DMWI06H
DMWI06H	DN	N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP
DMWI06H	HS	Investigative
DMWI06H	SN	CHEMBL265214
DMWI06H	DT	Small molecular drug
DMWI06H	PC	24827896
DMWI06H	MW	604.9
DMWI06H	FM	C40H64N2O2
DMWI06H	IC	InChI=1S/C40H64N2O2/c1-3-39(35-21-19-23-37(43)31-35)25-13-17-29-41(33-39)27-15-11-9-7-5-6-8-10-12-16-28-42-30-18-14-26-40(4-2,34-42)36-22-20-24-38(44)32-36/h19-24,31-32,43-44H,3-18,25-30,33-34H2,1-2H3/t39-,40-/m1/s1
DMWI06H	CS	CC[C@]1(CCCCN(C1)CCCCCCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMWI06H	IK	ZWQWXPDQHDYQPH-XRSDMRJBSA-N
DMWI06H	IU	3-[(3S)-3-ethyl-1-[12-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]dodecyl]azepan-3-yl]phenol
DMWI06H	DE	Discovery agent

DM1LKEP	ID	DM1LKEP
DM1LKEP	DN	N,N'-(1',2'-ethylene)-bis-(-)-nor-MEP
DM1LKEP	HS	Investigative
DM1LKEP	SN	CHEMBL411226
DM1LKEP	DT	Small molecular drug
DM1LKEP	PC	24827287
DM1LKEP	MW	464.7
DM1LKEP	FM	C30H44N2O2
DM1LKEP	IC	InChI=1S/C30H44N2O2/c1-3-29(25-11-9-13-27(33)21-25)15-5-7-17-31(23-29)19-20-32-18-8-6-16-30(4-2,24-32)26-12-10-14-28(34)22-26/h9-14,21-22,33-34H,3-8,15-20,23-24H2,1-2H3/t29-,30-/m1/s1
DM1LKEP	CS	CC[C@]1(CCCCN(C1)CCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DM1LKEP	IK	RMHAJXOOJPBLSR-LOYHVIPDSA-N
DM1LKEP	IU	3-[(3S)-3-ethyl-1-[2-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]ethyl]azepan-3-yl]phenol
DM1LKEP	DE	Discovery agent

DM4G6BT	ID	DM4G6BT
DM4G6BT	DN	N,N'-(1',3'-propylene)-bis-(-)-nor-MEP
DM4G6BT	HS	Investigative
DM4G6BT	SN	CHEMBL258468
DM4G6BT	DT	Small molecular drug
DM4G6BT	PC	24827411
DM4G6BT	MW	478.7
DM4G6BT	FM	C31H46N2O2
DM4G6BT	IC	InChI=1S/C31H46N2O2/c1-3-30(26-12-9-14-28(34)22-26)16-5-7-18-32(24-30)20-11-21-33-19-8-6-17-31(4-2,25-33)27-13-10-15-29(35)23-27/h9-10,12-15,22-23,34-35H,3-8,11,16-21,24-25H2,1-2H3/t30-,31-/m1/s1
DM4G6BT	CS	CC[C@]1(CCCCN(C1)CCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DM4G6BT	IK	SKYWWOFBHWQWFU-FIRIVFDPSA-N
DM4G6BT	IU	3-[(3S)-3-ethyl-1-[3-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]propyl]azepan-3-yl]phenol
DM4G6BT	DE	Discovery agent

DMZHBTA	ID	DMZHBTA
DMZHBTA	DN	N,N'-(1',4'-butylene)-bis-(-)-nor-MEP
DMZHBTA	HS	Investigative
DMZHBTA	SN	CHEMBL409858
DMZHBTA	DT	Small molecular drug
DMZHBTA	PC	24827413
DMZHBTA	MW	492.7
DMZHBTA	FM	C32H48N2O2
DMZHBTA	IC	InChI=1S/C32H48N2O2/c1-3-31(27-13-11-15-29(35)23-27)17-5-7-19-33(25-31)21-9-10-22-34-20-8-6-18-32(4-2,26-34)28-14-12-16-30(36)24-28/h11-16,23-24,35-36H,3-10,17-22,25-26H2,1-2H3/t31-,32-/m1/s1
DMZHBTA	CS	CC[C@]1(CCCCN(C1)CCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMZHBTA	IK	QRRZAKFYWBRJNH-ROJLCIKYSA-N
DMZHBTA	IU	3-[(3S)-3-ethyl-1-[4-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]butyl]azepan-3-yl]phenol
DMZHBTA	DE	Discovery agent

DMBPC0K	ID	DMBPC0K
DMBPC0K	DN	N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP
DMBPC0K	HS	Investigative
DMBPC0K	SN	CHEMBL408463
DMBPC0K	DT	Small molecular drug
DMBPC0K	PC	44450568
DMBPC0K	MW	506.8
DMBPC0K	FM	C33H50N2O2
DMBPC0K	IC	InChI=1S/C33H50N2O2/c1-3-32(28-14-12-16-30(36)24-28)18-6-10-22-34(26-32)20-8-5-9-21-35-23-11-7-19-33(4-2,27-35)29-15-13-17-31(37)25-29/h12-17,24-25,36-37H,3-11,18-23,26-27H2,1-2H3/t32-,33?/m1/s1
DMBPC0K	CS	CC[C@]1(CCCCN(C1)CCCCCN2CCCCC(C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMBPC0K	IK	XNVOHDDYQCZZQX-KWRHIPAJSA-N
DMBPC0K	IU	3-[3-ethyl-1-[5-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]pentyl]azepan-3-yl]phenol
DMBPC0K	DE	Discovery agent

DMU4BIW	ID	DMU4BIW
DMU4BIW	DN	N,N'-(1',6-hexylene)-bis-(-)-nor-MEP
DMU4BIW	HS	Investigative
DMU4BIW	SN	CHEMBL258505
DMU4BIW	DT	Small molecular drug
DMU4BIW	PC	24827524
DMU4BIW	MW	520.799
DMU4BIW	FM	C34H52N2O2
DMU4BIW	IC	InChI=1S/C34H52N2O2/c1-3-33(29-15-13-17-31(37)25-29)19-7-11-23-35(27-33)21-9-5-6-10-22-36-24-12-8-20-34(4-2,28-36)30-16-14-18-32(38)26-30/h13-18,25-26,37-38H,3-12,19-24,27-28H2,1-2H3/t33-,34-/m1/s1
DMU4BIW	CS	CC[C@]1(CCCCN(C1)CCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMU4BIW	IK	YBOHCXLIWATJCJ-KKLWWLSJSA-N
DMU4BIW	IU	3-[(3S)-3-ethyl-1-[6-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]hexyl]azepan-3-yl]phenol
DMU4BIW	DE	Discovery agent

DMSORHA	ID	DMSORHA
DMSORHA	DN	N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP
DMSORHA	HS	Investigative
DMSORHA	SN	CHEMBL258935
DMSORHA	DT	Small molecular drug
DMSORHA	PC	24827526
DMSORHA	MW	534.8
DMSORHA	FM	C35H54N2O2
DMSORHA	IC	InChI=1S/C35H54N2O2/c1-3-34(30-16-14-18-32(38)26-30)20-8-12-24-36(28-34)22-10-6-5-7-11-23-37-25-13-9-21-35(4-2,29-37)31-17-15-19-33(39)27-31/h14-19,26-27,38-39H,3-13,20-25,28-29H2,1-2H3/t34-,35-/m1/s1
DMSORHA	CS	CC[C@]1(CCCCN(C1)CCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMSORHA	IK	VZGOFBLWSLPNDR-VSJLXWSYSA-N
DMSORHA	IU	3-[(3S)-3-ethyl-1-[7-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]heptyl]azepan-3-yl]phenol
DMSORHA	DE	Discovery agent

DMHFYK2	ID	DMHFYK2
DMHFYK2	DN	N,N'-(1',8'-octylene)-bis-(-)-nor-MEP
DMHFYK2	HS	Investigative
DMHFYK2	SN	CHEMBL410915
DMHFYK2	DT	Small molecular drug
DMHFYK2	PC	24827639
DMHFYK2	MW	548.8
DMHFYK2	FM	C36H56N2O2
DMHFYK2	IC	InChI=1S/C36H56N2O2/c1-3-35(31-17-15-19-33(39)27-31)21-9-13-25-37(29-35)23-11-7-5-6-8-12-24-38-26-14-10-22-36(4-2,30-38)32-18-16-20-34(40)28-32/h15-20,27-28,39-40H,3-14,21-26,29-30H2,1-2H3/t35-,36-/m1/s1
DMHFYK2	CS	CC[C@]1(CCCCN(C1)CCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMHFYK2	IK	XFXBGPOUAKCCMC-LQFQNGICSA-N
DMHFYK2	IU	3-[(3S)-3-ethyl-1-[8-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]octyl]azepan-3-yl]phenol
DMHFYK2	DE	Discovery agent

DMIWF7U	ID	DMIWF7U
DMIWF7U	DN	N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP
DMIWF7U	HS	Investigative
DMIWF7U	SN	CHEMBL406645; Bis(9)-( )-meptazinol
DMIWF7U	DT	Small molecular drug
DMIWF7U	PC	24827641
DMIWF7U	MW	562.9
DMIWF7U	FM	C37H58N2O2
DMIWF7U	IC	InChI=1S/C37H58N2O2/c1-3-36(32-18-16-20-34(40)28-32)22-10-14-26-38(30-36)24-12-8-6-5-7-9-13-25-39-27-15-11-23-37(4-2,31-39)33-19-17-21-35(41)29-33/h16-21,28-29,40-41H,3-15,22-27,30-31H2,1-2H3/t36-,37-/m1/s1
DMIWF7U	CS	CC[C@]1(CCCCN(C1)CCCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMIWF7U	IK	ZZKZUUMHRSWLQQ-FZNHDDJXSA-N
DMIWF7U	IU	3-[(3S)-3-ethyl-1-[9-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]nonyl]azepan-3-yl]phenol
DMIWF7U	DE	Discovery agent

DMLU27Y	ID	DMLU27Y
DMLU27Y	DN	N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine
DMLU27Y	HS	Investigative
DMLU27Y	SN	CHEMBL494706; N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine; BDBM50253380
DMLU27Y	DT	Small molecular drug
DMLU27Y	PC	25128814
DMLU27Y	MW	293.45
DMLU27Y	FM	C16H31N5
DMLU27Y	IC	InChI=1S/C16H31N5/c1-11(2)8-17-14-7-15(18-9-12(3)4)21-16(20-14)19-10-13(5)6/h7,11-13H,8-10H2,1-6H3,(H3,17,18,19,20,21)
DMLU27Y	CS	CC(C)CNC1=CC(=NC(=N1)NCC(C)C)NCC(C)C
DMLU27Y	IK	HVZSNANIMUMCPH-UHFFFAOYSA-N
DMLU27Y	IU	2-N,4-N,6-N-tris(2-methylpropyl)pyrimidine-2,4,6-triamine
DMLU27Y	DE	Discovery agent

DMNZKCL	ID	DMNZKCL
DMNZKCL	DN	N,N`-bis-alkyl butylimmidazole 12b
DMNZKCL	HS	Investigative
DMNZKCL	SN	compound 12b [PMID: 23376252]
DMNZKCL	DT	Small molecular drug
DMNZKCL	PC	73755247
DMNZKCL	MW	717.6
DMNZKCL	FM	C35H31BrN10Na2
DMNZKCL	IC	InChI=1S/C35H30N10.BrH.2Na/c1-2-3-12-33-32(21-24-13-17-26(18-14-24)28-8-4-6-10-30(28)34-37-41-42-38-34)36-23-45(33)22-25-15-19-27(20-16-25)29-9-5-7-11-31(29)35-39-43-44-40-35;;;/h4-11,13-20,23H,2-3,12,21-22H2,1H3;1H;;/q-2;;2*+1
DMNZKCL	CS	CCCCC1=C(NC=[N+]1CC2=CC=C(C=C2)C3=CC=CC=C3C4=N[N-]N=N4)CC5=CC=C(C=C5)C6=CC=CC=C6C7=N[N-]N=N7.[Na+].[Na+].[Br-]
DMNZKCL	IK	JJOQDSLKSULNDS-UHFFFAOYSA-N
DMNZKCL	IU	disodium;5-[2-[4-[[4-butyl-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]-1H-imidazol-3-ium-5-yl]methyl]phenyl]phenyl]-1,2,4-triaza-3-azanidacyclopenta-1,4-diene;bromide
DMNZKCL	DE	Discovery agent

DMT4USP	ID	DMT4USP
DMT4USP	DN	N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea
DMT4USP	HS	Investigative
DMT4USP	SN	Aminoquinuride; Surfen; aminokinuride; UNII-08T7936572; 3811-56-1; N,N'-BIS(4-AMINO-2-METHYLQUINOLIN-6-YL)UREA; 1,3-bis(4-amino-2-methylquinolin-6-yl)urea; N,N'-Bis(4-amino-2-methyl-6-quinolinyl)urea; Aminochinurid; 08T7936572; Aminochinuridum; Aminoquinuridum; Aminoquinurida; Aminokinuridum; Aminochincarbamidum; Aminoquin carbamide; NSC12155; Aminoquinuride [INN]; NCGC00013130-04; NCGC00013130-03; 5424-37-3; Aminoquinuridum [INN-Latin]; Aminoquinurida [INN-Spanish]; 1pwp; N,N-Bis(4-aminochinaldyl-6)harnstoff
DMT4USP	DT	Small molecular drug
DMT4USP	PC	71166
DMT4USP	MW	372.4
DMT4USP	FM	C21H20N6O
DMT4USP	IC	InChI=1S/C21H20N6O/c1-11-7-17(22)15-9-13(3-5-19(15)24-11)26-21(28)27-14-4-6-20-16(10-14)18(23)8-12(2)25-20/h3-10H,1-2H3,(H2,22,24)(H2,23,25)(H2,26,27,28)
DMT4USP	CS	CC1=CC(=C2C=C(C=CC2=N1)NC(=O)NC3=CC4=C(C=C(N=C4C=C3)C)N)N
DMT4USP	IK	HOUSDILKOJMENG-UHFFFAOYSA-N
DMT4USP	IU	1,3-bis(4-amino-2-methylquinolin-6-yl)urea
DMT4USP	CA	CAS 3811-56-1
DMT4USP	DE	Discovery agent

DMLOP2B	ID	DMLOP2B
DMLOP2B	DN	N,N'-Bis-(4-butoxy-phenyl)-guanidine
DMLOP2B	HS	Investigative
DMLOP2B	SN	CHEMBL326502; SCHEMBL4983215; n,n'-bis(4-butoxyphenyl)guanidine; BDBM50066423
DMLOP2B	DT	Small molecular drug
DMLOP2B	PC	10594376
DMLOP2B	MW	355.5
DMLOP2B	FM	C21H29N3O2
DMLOP2B	IC	InChI=1S/C21H29N3O2/c1-3-5-15-25-19-11-7-17(8-12-19)23-21(22)24-18-9-13-20(14-10-18)26-16-6-4-2/h7-14H,3-6,15-16H2,1-2H3,(H3,22,23,24)
DMLOP2B	CS	CCCCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)OCCCC)N
DMLOP2B	IK	UEKORNPZBHKKRD-UHFFFAOYSA-N
DMLOP2B	IU	1,2-bis(4-butoxyphenyl)guanidine
DMLOP2B	DE	Discovery agent

DMOS2GH	ID	DMOS2GH
DMOS2GH	DN	N,N'-Bis-(4-butyl-phenyl)-guanidine
DMOS2GH	HS	Investigative
DMOS2GH	SN	CHEMBL109210; SCHEMBL4980235; N,N'-Bis(4-butylphenyl)guanidine; BDBM50066427
DMOS2GH	DT	Small molecular drug
DMOS2GH	PC	10496171
DMOS2GH	MW	323.5
DMOS2GH	FM	C21H29N3
DMOS2GH	IC	InChI=1S/C21H29N3/c1-3-5-7-17-9-13-19(14-10-17)23-21(22)24-20-15-11-18(12-16-20)8-6-4-2/h9-16H,3-8H2,1-2H3,(H3,22,23,24)
DMOS2GH	CS	CCCCC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)CCCC)N
DMOS2GH	IK	XDEXLYGQRYSUON-UHFFFAOYSA-N
DMOS2GH	IU	1,2-bis(4-butylphenyl)guanidine
DMOS2GH	DE	Discovery agent

DM0CTG7	ID	DM0CTG7
DM0CTG7	DN	N,N'-Bis-(4-ethyl-phenyl)-guanidine
DM0CTG7	HS	Investigative
DM0CTG7	SN	CHEMBL78083; Guanidine, N,N'-bis(4-ethylphenyl)-; 128413-47-8; ACMC-20msu7; SCHEMBL6155127; SCHEMBL10825147; CTK0C1708; DTXSID70563854; 1,3-Bis(4-ethylphenyl)guanidine; N,N''-Bis(4-ethylphenyl)guanidine; BDBM50010736; ZINC13733770; AKOS030602502
DM0CTG7	DT	Small molecular drug
DM0CTG7	PC	14771671
DM0CTG7	MW	267.37
DM0CTG7	FM	C17H21N3
DM0CTG7	IC	InChI=1S/C17H21N3/c1-3-13-5-9-15(10-6-13)19-17(18)20-16-11-7-14(4-2)8-12-16/h5-12H,3-4H2,1-2H3,(H3,18,19,20)
DM0CTG7	CS	CCC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)CC)N
DM0CTG7	IK	DXGARAMIKHFTJV-UHFFFAOYSA-N
DM0CTG7	IU	1,2-bis(4-ethylphenyl)guanidine
DM0CTG7	CA	CAS 128413-47-8
DM0CTG7	DE	Discovery agent

DM0RQGU	ID	DM0RQGU
DM0RQGU	DN	N,N'-Bis-(4-hexyl-phenyl)-guanidine
DM0RQGU	HS	Investigative
DM0RQGU	SN	CHEMBL326741; SCHEMBL4985473; N,N'-Bis(4-hexylphenyl)guanidine; BDBM50066419
DM0RQGU	DT	Small molecular drug
DM0RQGU	PC	9821194
DM0RQGU	MW	379.6
DM0RQGU	FM	C25H37N3
DM0RQGU	IC	InChI=1S/C25H37N3/c1-3-5-7-9-11-21-13-17-23(18-14-21)27-25(26)28-24-19-15-22(16-20-24)12-10-8-6-4-2/h13-20H,3-12H2,1-2H3,(H3,26,27,28)
DM0RQGU	CS	CCCCCCC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)CCCCCC)N
DM0RQGU	IK	UVGVWBZLIZBOEY-UHFFFAOYSA-N
DM0RQGU	IU	1,2-bis(4-hexylphenyl)guanidine
DM0RQGU	DE	Discovery agent

DMM38BC	ID	DMM38BC
DMM38BC	DN	N,N'-Bis-(4-isopropyl-phenyl)-guanidine
DMM38BC	HS	Investigative
DMM38BC	SN	CHEMBL81626; SCHEMBL6154563; BDBM50010754; ZINC13733773; 1,3-Bis(4-isopropylphenyl)guanidine
DMM38BC	DT	Small molecular drug
DMM38BC	PC	13781937
DMM38BC	MW	295.4
DMM38BC	FM	C19H25N3
DMM38BC	IC	InChI=1S/C19H25N3/c1-13(2)15-5-9-17(10-6-15)21-19(20)22-18-11-7-16(8-12-18)14(3)4/h5-14H,1-4H3,(H3,20,21,22)
DMM38BC	CS	CC(C)C1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)C(C)C)N
DMM38BC	IK	WIULPOAMZNPPJM-UHFFFAOYSA-N
DMM38BC	IU	1,2-bis(4-propan-2-ylphenyl)guanidine
DMM38BC	DE	Discovery agent

DMFDXLB	ID	DMFDXLB
DMFDXLB	DN	N,N'-Bis-(4-sec-butyl-phenyl)-guanidine
DMFDXLB	HS	Investigative
DMFDXLB	SN	CHEMBL110909; CHEMBL320199; SCHEMBL4979578; BDBM50066057; 1,3-Bis(4-sec-butylphenyl)guanidine; AKOS030602595; N,N''-Bis-(4-sec-butyl-phenyl)-guanidine
DMFDXLB	DT	Small molecular drug
DMFDXLB	PC	10526122
DMFDXLB	MW	323.5
DMFDXLB	FM	C21H29N3
DMFDXLB	IC	InChI=1S/C21H29N3/c1-5-15(3)17-7-11-19(12-8-17)23-21(22)24-20-13-9-18(10-14-20)16(4)6-2/h7-16H,5-6H2,1-4H3,(H3,22,23,24)
DMFDXLB	CS	CCC(C)C1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)C(C)CC)N
DMFDXLB	IK	CSOJBDHYOONOPF-UHFFFAOYSA-N
DMFDXLB	IU	1,2-bis(4-butan-2-ylphenyl)guanidine
DMFDXLB	DE	Discovery agent

DMBQ0TY	ID	DMBQ0TY
DMBQ0TY	DN	N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide
DMBQ0TY	HS	Investigative
DMBQ0TY	SN	N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide; AC1LDLXQ; Cambridge id 5654537; Oprea1_349431; CHEMBL244919; ZINC29912; BDBM23727; MolPort-001-507-799; HMS1584M04; STK002684; AKOS003266947; MCULE-7184403963; ST042963; N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide, 11; SR-01000215998; N~1~,N~1~-bis(cyanomethyl)-3,4-dimethoxybenzamide; SR-01000215998-1
DMBQ0TY	DT	Small molecular drug
DMBQ0TY	PC	669334
DMBQ0TY	MW	259.26
DMBQ0TY	FM	C13H13N3O3
DMBQ0TY	IC	InChI=1S/C13H13N3O3/c1-18-11-4-3-10(9-12(11)19-2)13(17)16(7-5-14)8-6-15/h3-4,9H,7-8H2,1-2H3
DMBQ0TY	CS	COC1=C(C=C(C=C1)C(=O)N(CC#N)CC#N)OC
DMBQ0TY	IK	GZUJYYKDHAQDKU-UHFFFAOYSA-N
DMBQ0TY	IU	N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide
DMBQ0TY	DE	Discovery agent

DMM678B	ID	DMM678B
DMM678B	DN	N,N-bis(tosylmethyl)hexan-1-amine
DMM678B	HS	Investigative
DMM678B	SN	CHEMBL252145; N,N-bis(tosylmethyl)hexan-1-amine; AC1MWCYZ; N,N-bis[(4-methylphenyl)sulfonylmethyl]hexan-1-amine; N,N-Bis(tosylmethyl)hexane-1-amine
DMM678B	DT	Small molecular drug
DMM678B	PC	3747253
DMM678B	MW	437.6
DMM678B	FM	C22H31NO4S2
DMM678B	IC	InChI=1S/C22H31NO4S2/c1-4-5-6-7-16-23(17-28(24,25)21-12-8-19(2)9-13-21)18-29(26,27)22-14-10-20(3)11-15-22/h8-15H,4-7,16-18H2,1-3H3
DMM678B	CS	CCCCCCN(CS(=O)(=O)C1=CC=C(C=C1)C)CS(=O)(=O)C2=CC=C(C=C2)C
DMM678B	IK	JNUXLFWPSMEIDT-UHFFFAOYSA-N
DMM678B	IU	N,N-bis[(4-methylphenyl)sulfonylmethyl]hexan-1-amine
DMM678B	DE	Discovery agent

DM8TA0M	ID	DM8TA0M
DM8TA0M	DN	N,N'-Di-acenaphthen-5-yl-guanidine
DM8TA0M	HS	Investigative
DM8TA0M	SN	CHEMBL307395; 157970-69-9; Cns 1145; 1,3-di(1,2-dihydroacenaphthylen-5-yl)guanidine; AC1L4RHN; AC1Q4SU4; Cns-1145; SCHEMBL6155294; CTK4C9538; N,N'-Bis(5-acenaphthyl)guanidine; BDBM50285278; N,N''-Di-acenaphthen-5-yl-guanidine; AKOS030602590; 1,2-bis(1,2-dihydroacenaphthylen-5-yl)guanidine
DM8TA0M	DT	Small molecular drug
DM8TA0M	PC	190902
DM8TA0M	MW	363.5
DM8TA0M	FM	C25H21N3
DM8TA0M	IC	InChI=1S/C25H21N3/c26-25(27-21-13-11-17-9-7-15-3-1-5-19(21)23(15)17)28-22-14-12-18-10-8-16-4-2-6-20(22)24(16)18/h1-6,11-14H,7-10H2,(H3,26,27,28)
DM8TA0M	CS	C1CC2=CC=C(C3=CC=CC1=C23)NC(=NC4=CC=C5CCC6=C5C4=CC=C6)N
DM8TA0M	IK	DPWVUEQXMOBVOQ-UHFFFAOYSA-N
DM8TA0M	IU	1,2-bis(1,2-dihydroacenaphthylen-5-yl)guanidine
DM8TA0M	CA	CAS 157970-69-9
DM8TA0M	DE	Discovery agent

DMSY571	ID	DMSY571
DMSY571	DN	N,N-diallyl[D-Pro-10]Dyn A-(1-11)
DMSY571	HS	Investigative
DMSY571	SN	CHEMBL266782; N,N-diallyl[D-Pro-10]Dyn A-(1-11)
DMSY571	PC	44325420
DMSY571	MW	1442.8
DMSY571	FM	C69H111N21O13
DMSY571	IC	InChI=1S/C69H111N21O13/c1-7-34-89(35-8-2)54(39-45-26-28-46(91)29-27-45)62(98)81-40-55(92)80-41-56(93)82-52(38-44-19-11-10-12-20-44)61(97)87-51(37-42(4)5)60(96)84-47(22-15-31-77-67(71)72)58(94)83-48(23-16-32-78-68(73)74)59(95)88-57(43(6)9-3)64(100)85-49(24-17-33-79-69(75)76)65(101)90-36-18-25-53(90)63(99)86-50(66(102)103)21-13-14-30-70/h7-8,10-12,19-20,26-29,42-43,47-54,57,91H,1-2,9,13-18,21-25,30-41,70H2,3-6H3,(H,80,92)(H,81,98)(H,82,93)(H,83,94)(H,84,96)(H,85,100)(H,86,99)(H,87,97)(H,88,95)(H,102,103)(H4,71,72,77)(H4,73,74,78)(H4,75,76,79)/t43-,47-,48-,49-,50-,51-,52-,53-,54-,57-/m0/s1
DMSY571	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N(CC=C)CC=C
DMSY571	IK	PUPCCTCXOWBBTI-JHLTVMAUSA-N
DMSY571	IU	(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DMSY571	DE	Discovery agent

DMILJUE	ID	DMILJUE
DMILJUE	DN	N,N-dibenzyl[D-Pro-10]Dyn A-(1-11)
DMILJUE	HS	Investigative
DMILJUE	SN	CHEMBL267215; N,N-dibenzyl[D-Pro-10]Dyn A-(1-11)
DMILJUE	PC	44325184
DMILJUE	MW	1542.9
DMILJUE	FM	C77H115N21O13
DMILJUE	IC	InChI=1S/C77H115N21O13/c1-5-49(4)65(72(108)93-57(30-19-39-87-77(83)84)73(109)98-40-20-31-61(98)71(107)94-58(74(110)111)27-15-16-36-78)96-67(103)56(29-18-38-86-76(81)82)91-66(102)55(28-17-37-85-75(79)80)92-68(104)59(41-48(2)3)95-69(105)60(42-50-21-9-6-10-22-50)90-64(101)45-88-63(100)44-89-70(106)62(43-51-32-34-54(99)35-33-51)97(46-52-23-11-7-12-24-52)47-53-25-13-8-14-26-53/h6-14,21-26,32-35,48-49,55-62,65,99H,5,15-20,27-31,36-47,78H2,1-4H3,(H,88,100)(H,89,106)(H,90,101)(H,91,102)(H,92,104)(H,93,108)(H,94,107)(H,95,105)(H,96,103)(H,110,111)(H4,79,80,85)(H4,81,82,86)(H4,83,84,87)/t49-,55-,56-,57-,58-,59-,60-,61-,62-,65-/m0/s1
DMILJUE	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N(CC4=CC=CC=C4)CC5=CC=CC=C5
DMILJUE	IK	OHPCANLMUJRLSF-GOWLZWIFSA-N
DMILJUE	IU	(2S)-6-amino-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-(dibenzylamino)-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DMILJUE	DE	Discovery agent

DM1UCZ9	ID	DM1UCZ9
DM1UCZ9	DN	N,N-diCPM[D-Pro-10]Dyn A-(1-11)
DM1UCZ9	HS	Investigative
DM1UCZ9	SN	CHEMBL406893; N,N-diCPM[D-Pro-10]Dyn A-(1-11)
DM1UCZ9	PC	44325183
DM1UCZ9	MW	1470.8
DM1UCZ9	FM	C71H115N21O13
DM1UCZ9	IC	InChI=1S/C71H115N21O13/c1-5-43(4)59(66(102)87-51(20-13-33-81-71(77)78)67(103)92-34-14-21-55(92)65(101)88-52(68(104)105)17-9-10-30-72)90-61(97)50(19-12-32-80-70(75)76)85-60(96)49(18-11-31-79-69(73)74)86-62(98)53(35-42(2)3)89-63(99)54(36-44-15-7-6-8-16-44)84-58(95)39-82-57(94)38-83-64(100)56(37-45-26-28-48(93)29-27-45)91(40-46-22-23-46)41-47-24-25-47/h6-8,15-16,26-29,42-43,46-47,49-56,59,93H,5,9-14,17-25,30-41,72H2,1-4H3,(H,82,94)(H,83,100)(H,84,95)(H,85,96)(H,86,98)(H,87,102)(H,88,101)(H,89,99)(H,90,97)(H,104,105)(H4,73,74,79)(H4,75,76,80)(H4,77,78,81)/t43-,49-,50-,51-,52-,53-,54-,55-,56-,59-/m0/s1
DM1UCZ9	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N(CC4CC4)CC5CC5
DM1UCZ9	IK	XMFJUPAXGQSFIW-FOMVZIENSA-N
DM1UCZ9	IU	(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[bis(cyclopropylmethyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DM1UCZ9	DE	Discovery agent

DMLVMJH	ID	DMLVMJH
DMLVMJH	DN	N,N'-dicyclohexyl-urea
DMLVMJH	HS	Investigative
DMLVMJH	SN	1,3-Dicyclohexylurea; n,n'-dicyclohexylurea; 2387-23-7; Dicyclohexylurea; Urea, N,N'-dicyclohexyl-; UNII-ZV7823VVIM; ZV7823VVIM; CHEMBL1458; N,N'-Dicyclohexylurea, 98%; ADFXKUOMJKEIND-UHFFFAOYSA-N; MFCD00003829; Urea,3-dicyclohexyl-; Urea,N'-dicyclohexyl-; N,N inverted exclamation marka-Dicyclohexylurea; Urea, 1,3-dicyclohexyl-; dicylohexylurea; dicylcohexylurea; dicylohexyl urea; dicyclohexyl-urea; dicyclohexyl urea; DCW; EINECS 219-213-7; NSC 30023; NSC 17013; n.n'-dicyclohexylurea; Rupatadine Impurity 1; 1,3-dicyclohexyl-urea
DMLVMJH	DT	Small molecular drug
DMLVMJH	PC	4277
DMLVMJH	MW	224.34
DMLVMJH	FM	C13H24N2O
DMLVMJH	IC	InChI=1S/C13H24N2O/c16-13(14-11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h11-12H,1-10H2,(H2,14,15,16)
DMLVMJH	CS	C1CCC(CC1)NC(=O)NC2CCCCC2
DMLVMJH	IK	ADFXKUOMJKEIND-UHFFFAOYSA-N
DMLVMJH	IU	1,3-dicyclohexylurea
DMLVMJH	CA	CAS 2387-23-7
DMLVMJH	CB	CHEBI:93429
DMLVMJH	DE	Discovery agent

DMZ3EA1	ID	DMZ3EA1
DMZ3EA1	DN	N,N-diethyl estrone-16-methyl carboxamide
DMZ3EA1	HS	Investigative
DMZ3EA1	SN	SCHEMBL12379552
DMZ3EA1	DT	Small molecular drug
DMZ3EA1	PC	44407575
DMZ3EA1	MW	383.5
DMZ3EA1	FM	C24H33NO3
DMZ3EA1	IC	InChI=1S/C24H33NO3/c1-4-25(5-2)22(27)14-16-13-21-20-8-6-15-12-17(26)7-9-18(15)19(20)10-11-24(21,3)23(16)28/h7,9,12,16,19-21,26H,4-6,8,10-11,13-14H2,1-3H3/t16?,19?,20?,21?,24-/m0/s1
DMZ3EA1	CS	CCN(CC)C(=O)CC1CC2C3CCC4=C(C3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMZ3EA1	IK	NUYXZZNRVPOMFS-HEYBVSAXSA-N
DMZ3EA1	IU	N,N-diethyl-2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]acetamide
DMZ3EA1	DE	Discovery agent

DM5K3D2	ID	DM5K3D2
DM5K3D2	DN	N,N-Diethyl-1'H-phenothiazine-1'-carboxamide
DM5K3D2	HS	Investigative
DM5K3D2	SN	CHEMBL589062; Phenothiazine-10-carboxylic acid diethylamide; N,N-diethyl-10H-phenothiazine-10-carboxamide; N,N-diethylphenothiazine-10-carboxamide; BAS 04087804; AC1LE3I9; MLS001212486; ARONIS009570; SCHEMBL7343904; ZINC91243; MolPort-001-593-657; MolPort-019-785-999; HMS1680D13; HMS2821P21; STK017216; CCG-22244; BDBM50308411; AKOS000498788; MCULE-7627155893; KS-0000415D; N,N-diethylphenothiazin-10-ylcarboxamide; SMR000518964; BB0286547; ST45046311; N,N-Diethyl-1''H-phenothiazine-1''-carboxamide; SR-01000506178; AN-329/41195338
DM5K3D2	DT	Small molecular drug
DM5K3D2	PC	705771
DM5K3D2	MW	298.4
DM5K3D2	FM	C17H18N2OS
DM5K3D2	IC	InChI=1S/C17H18N2OS/c1-3-18(4-2)17(20)19-13-9-5-7-11-15(13)21-16-12-8-6-10-14(16)19/h5-12H,3-4H2,1-2H3
DM5K3D2	CS	CCN(CC)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM5K3D2	IK	VZWXJPGNJLOWRM-UHFFFAOYSA-N
DM5K3D2	IU	N,N-diethylphenothiazine-10-carboxamide
DM5K3D2	DE	Discovery agent

DM0UBI9	ID	DM0UBI9
DM0UBI9	DN	N,N-diethyl-2-(1H-indol-3-yl)ethanamine
DM0UBI9	HS	Investigative
DM0UBI9	SN	Diethyltryptamine; N,N-Diethyltryptamine; 61-51-8; N,N-Diethyl-2-(1H-indol-3-yl)ethanamine; 3-(2-Diethylaminoethyl)indole; UNII-916E8V4S2V; INDOLE, 3-(2-(DIETHYLAMINO)ETHYL)-; BRN 0153320; D.E.T.; CHEMBL142936; DEA No. 7434; 916E8V4S2V; 1H-Indole-3-ethanamine, N,N-diethyl-; AC1L1LS6; Oprea1_105894; 5-22-10-00050 (Beilstein Handbook Reference); SCHEMBL517713; DTXSID9052763; CTK5B3364; LSSUMOWDTKZHHT-UHFFFAOYSA-N; ZINC1999162; BDBM50094676; STK368075; AKOS005444987; 1H-Indole-3-ethanamine,N,N-diethyl-; 63938-63-6 (mono-hydrochloride)
DM0UBI9	DT	Small molecular drug
DM0UBI9	PC	6090
DM0UBI9	MW	216.32
DM0UBI9	FM	C14H20N2
DM0UBI9	IC	InChI=1S/C14H20N2/c1-3-16(4-2)10-9-12-11-15-14-8-6-5-7-13(12)14/h5-8,11,15H,3-4,9-10H2,1-2H3
DM0UBI9	CS	CCN(CC)CCC1=CNC2=CC=CC=C21
DM0UBI9	IK	LSSUMOWDTKZHHT-UHFFFAOYSA-N
DM0UBI9	IU	N,N-diethyl-2-(1H-indol-3-yl)ethanamine
DM0UBI9	CA	CAS 61-51-8
DM0UBI9	DE	Discovery agent

DMBFASY	ID	DMBFASY
DMBFASY	DN	N,N-Diethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DMBFASY	HS	Investigative
DMBFASY	SN	CHEMBL99509; N,N-Diethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide; BDBM50045858
DMBFASY	DT	Small molecular drug
DMBFASY	PC	9995335
DMBFASY	MW	306.4
DMBFASY	FM	C20H22N2O
DMBFASY	IC	InChI=1S/C20H22N2O/c1-3-22(4-2)19(23)14-17-16-12-8-9-13-18(16)21-20(17)15-10-6-5-7-11-15/h5-13,21H,3-4,14H2,1-2H3
DMBFASY	CS	CCN(CC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DMBFASY	IK	JAQRBHPLECRUHQ-UHFFFAOYSA-N
DMBFASY	IU	N,N-diethyl-2-(2-phenyl-1H-indol-3-yl)acetamide
DMBFASY	DE	Discovery agent

DMV8QTR	ID	DMV8QTR
DMV8QTR	DN	N,N-Dihexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DMV8QTR	HS	Investigative
DMV8QTR	SN	CHEMBL98081; 142720-26-1; 1H-Indole-3-acetamide,N,N-dihexyl-2-phenyl-; ACMC-20n1pu; N,N-DIHEXYL-2-PHENYLINDOLE-3-ACETAMIDE; N,N-Dihexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide; CTK4C3254; DTXSID30440213; ZINC13833112; BDBM50045894; AKOS015965050
DMV8QTR	DT	Small molecular drug
DMV8QTR	PC	10454732
DMV8QTR	MW	418.6
DMV8QTR	FM	C28H38N2O
DMV8QTR	IC	InChI=1S/C28H38N2O/c1-3-5-7-14-20-30(21-15-8-6-4-2)27(31)22-25-24-18-12-13-19-26(24)29-28(25)23-16-10-9-11-17-23/h9-13,16-19,29H,3-8,14-15,20-22H2,1-2H3
DMV8QTR	CS	CCCCCCN(CCCCCC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DMV8QTR	IK	GGNLGBYSSQXGBN-UHFFFAOYSA-N
DMV8QTR	IU	N,N-dihexyl-2-(2-phenyl-1H-indol-3-yl)acetamide
DMV8QTR	CA	CAS 142720-26-1
DMV8QTR	DE	Discovery agent

DM4E8C9	ID	DM4E8C9
DM4E8C9	DN	N,N-Diisopropyl-1'H-phenothiazine-1'-carboxamide
DM4E8C9	HS	Investigative
DM4E8C9	SN	CHEMBL588172; Oprea1_258691; BDBM50308413
DM4E8C9	DT	Small molecular drug
DM4E8C9	PC	12851057
DM4E8C9	MW	326.5
DM4E8C9	FM	C19H22N2OS
DM4E8C9	IC	InChI=1S/C19H22N2OS/c1-13(2)20(14(3)4)19(22)21-15-9-5-7-11-17(15)23-18-12-8-6-10-16(18)21/h5-14H,1-4H3
DM4E8C9	CS	CC(C)N(C(C)C)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM4E8C9	IK	RSDPPDLPSMZJPP-UHFFFAOYSA-N
DM4E8C9	IU	N,N-di(propan-2-yl)phenothiazine-10-carboxamide
DM4E8C9	DE	Discovery agent

DMTWK7L	ID	DMTWK7L
DMTWK7L	DN	N,Ndimethyl milnacipran
DMTWK7L	HS	Investigative
DMTWK7L	SN	N,Ndimethyl milnacipran
DMTWK7L	DT	Small molecular drug
DMTWK7L	PC	44454695
DMTWK7L	MW	274.4
DMTWK7L	FM	C17H26N2O
DMTWK7L	IC	InChI=1S/C17H26N2O/c1-5-19(6-2)16(20)17(12-15(17)13-18(3)4)14-10-8-7-9-11-14/h7-11,15H,5-6,12-13H2,1-4H3
DMTWK7L	CS	CCN(CC)C(=O)C1(CC1CN(C)C)C2=CC=CC=C2
DMTWK7L	IK	NMRSWXVEITZBIQ-UHFFFAOYSA-N
DMTWK7L	IU	2-[(dimethylamino)methyl]-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DMTWK7L	DE	Discovery agent

DMWK91T	ID	DMWK91T
DMWK91T	DN	N,N-dimethyl(2-phenoxyphenyl)methanamine
DMWK91T	HS	Investigative
DMWK91T	SN	CHEMBL256058; AC1LGTAP; MolPort-002-800-902; ZINC346601; N,N-Dimethyl-2-phenoxybenzylamine; BDBM50371640; AKOS005066321; N,N-dimethyl-1-(2-phenoxyphenyl)methanamine
DMWK91T	DT	Small molecular drug
DMWK91T	PC	826600
DMWK91T	MW	227.3
DMWK91T	FM	C15H17NO
DMWK91T	IC	InChI=1S/C15H17NO/c1-16(2)12-13-8-6-7-11-15(13)17-14-9-4-3-5-10-14/h3-11H,12H2,1-2H3
DMWK91T	CS	CN(C)CC1=CC=CC=C1OC2=CC=CC=C2
DMWK91T	IK	BBLALPDUHCRAKZ-UHFFFAOYSA-N
DMWK91T	IU	N,N-dimethyl-1-(2-phenoxyphenyl)methanamine
DMWK91T	DE	Discovery agent

DM41C8E	ID	DM41C8E
DM41C8E	DN	N,N-dimethyl(pyridin-3-yl)methanamine
DM41C8E	HS	Investigative
DM41C8E	SN	Dimethyl-pyridin-3-ylmethyl-amine; 2055-21-2; N,N-Dimethyl-1-(pyridin-3-yl)methanamine; CHEMBL331904; N,N-dimethyl-3-Pyridinemethanamine; 3-Pyridinemethanamine, N,N-dimethyl-; N,N-dimethyl(pyridin-3-yl)methanamine; AC1OK4VN; 3-pyridylmethyl dimethylamine; 3-Pyridinylmethyldimethylamine; SCHEMBL3460939; dimethyl(pyridin-3-ylmethyl)amine; MolPort-000-165-254; ZINC4716433; BDBM50119559; AKOS009071365; N,N-dimethyl-1-pyridin-3-ylmethanamine; DB-066238
DM41C8E	DT	Small molecular drug
DM41C8E	PC	7330459
DM41C8E	MW	136.19
DM41C8E	FM	C8H12N2
DM41C8E	IC	InChI=1S/C8H12N2/c1-10(2)7-8-4-3-5-9-6-8/h3-6H,7H2,1-2H3
DM41C8E	CS	CN(C)CC1=CN=CC=C1
DM41C8E	IK	SLZCOYDOFRTTHF-UHFFFAOYSA-N
DM41C8E	IU	N,N-dimethyl-1-pyridin-3-ylmethanamine
DM41C8E	DE	Discovery agent

DM4CDYG	ID	DM4CDYG
DM4CDYG	DN	N,N-Dimethyl-1'H-phenothiazine-1'-carboxamide
DM4CDYG	HS	Investigative
DM4CDYG	SN	N,N-dimethyl-10H-phenothiazine-10-carboxamide; CHEMBL592674; ARONIS26337; AC1M461Y; MolPort-003-255-540; HMS1760L14; ZINC3014186; KS-000047ZJ; STL261388; BDBM50308410; AKOS001144998; MCULE-9126277852; N,N-dimethylphenothiazine-10-carboxamide; 51858-81-2; BB0294327; SR-01000030731; N,N-Dimethyl-1''H-phenothiazine-1''-carboxamide; SR-01000030731-1
DM4CDYG	DT	Small molecular drug
DM4CDYG	PC	2301676
DM4CDYG	MW	270.4
DM4CDYG	FM	C15H14N2OS
DM4CDYG	IC	InChI=1S/C15H14N2OS/c1-16(2)15(18)17-11-7-3-5-9-13(11)19-14-10-6-4-8-12(14)17/h3-10H,1-2H3
DM4CDYG	CS	CN(C)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM4CDYG	IK	JVEMOBBCUXTLCS-UHFFFAOYSA-N
DM4CDYG	IU	N,N-dimethylphenothiazine-10-carboxamide
DM4CDYG	DE	Discovery agent

DMYUQDK	ID	DMYUQDK
DMYUQDK	DN	N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine
DMYUQDK	HS	Investigative
DMYUQDK	SN	CHEMBL248071; N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine
DMYUQDK	DT	Small molecular drug
DMYUQDK	PC	44438719
DMYUQDK	MW	342.5
DMYUQDK	FM	C19H22N2O2S
DMYUQDK	IC	InChI=1S/C19H22N2O2S/c1-15-8-10-17(11-9-15)24(22,23)21-14-16(12-13-20(2)3)18-6-4-5-7-19(18)21/h4-11,14H,12-13H2,1-3H3
DMYUQDK	CS	CC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=CC=CC=C32)CCN(C)C
DMYUQDK	IK	RJGTUGOGNODPPC-UHFFFAOYSA-N
DMYUQDK	IU	N,N-dimethyl-2-[1-(4-methylphenyl)sulfonylindol-3-yl]ethanamine
DMYUQDK	DE	Discovery agent

DM1DZEL	ID	DM1DZEL
DM1DZEL	DN	N,N-dimethyl-2-(2'-methylbiphenyl-3-yl)ethanamine
DM1DZEL	HS	Investigative
DM1DZEL	SN	CHEMBL395870; BDBM50210123; N,N-dimethyl-2-(2''-methylbiphenyl-3-yl)ethanamine
DM1DZEL	DT	Small molecular drug
DM1DZEL	PC	16747715
DM1DZEL	MW	239.35
DM1DZEL	FM	C17H21N
DM1DZEL	IC	InChI=1S/C17H21N/c1-14-7-4-5-10-17(14)16-9-6-8-15(13-16)11-12-18(2)3/h4-10,13H,11-12H2,1-3H3
DM1DZEL	CS	CC1=CC=CC=C1C2=CC=CC(=C2)CCN(C)C
DM1DZEL	IK	HOMNPSYKSQTOHK-UHFFFAOYSA-N
DM1DZEL	IU	N,N-dimethyl-2-[3-(2-methylphenyl)phenyl]ethanamine
DM1DZEL	DE	Discovery agent

DM73PXI	ID	DM73PXI
DM73PXI	DN	N,N-Dimethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DM73PXI	HS	Investigative
DM73PXI	SN	CHEMBL320626; N,N-Dimethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide; BDBM50045869
DM73PXI	DT	Small molecular drug
DM73PXI	PC	10446279
DM73PXI	MW	278.3
DM73PXI	FM	C18H18N2O
DM73PXI	IC	InChI=1S/C18H18N2O/c1-20(2)17(21)12-15-14-10-6-7-11-16(14)19-18(15)13-8-4-3-5-9-13/h3-11,19H,12H2,1-2H3
DM73PXI	CS	CN(C)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DM73PXI	IK	RVPIQASKQHYEBT-UHFFFAOYSA-N
DM73PXI	IU	N,N-dimethyl-2-(2-phenyl-1H-indol-3-yl)acetamide
DM73PXI	DE	Discovery agent

DMMD9A0	ID	DMMD9A0
DMMD9A0	DN	N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine
DMMD9A0	HS	Investigative
DMMD9A0	SN	CHEMBL61616; 228272-02-4; N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine; SCHEMBL12827198; CTK0J6066; DTXSID40436622; BDBM50115808; AKOS030595283; Dimethyl 2-(3-pyridinyloxy)ethylamine; Dimethyl-[2-(pyridin-3-yloxy)-ethyl]-amine; N,N-dimethyl-2-(pyridin-3-yloxy)ethanaminium; Ethanamine, N,N-dimethyl-2-(3-pyridinyloxy)-
DMMD9A0	DT	Small molecular drug
DMMD9A0	PC	10197862
DMMD9A0	MW	166.22
DMMD9A0	FM	C9H14N2O
DMMD9A0	IC	InChI=1S/C9H14N2O/c1-11(2)6-7-12-9-4-3-5-10-8-9/h3-5,8H,6-7H2,1-2H3
DMMD9A0	CS	CN(C)CCOC1=CN=CC=C1
DMMD9A0	IK	NNKLMOMWOOXRDH-UHFFFAOYSA-N
DMMD9A0	IU	N,N-dimethyl-2-pyridin-3-yloxyethanamine
DMMD9A0	CA	CAS 228272-02-4
DMMD9A0	DE	Discovery agent

DM9XZJN	ID	DM9XZJN
DM9XZJN	DN	N,N-dimethyl-2,2,2-triphenylacetamide
DM9XZJN	HS	Investigative
DM9XZJN	SN	N,N-Dimethyl-2,2,2-triphenylacetamide; AC1LDGNY; N,N-Dimethyl-triphenylacetamide; JGBIXOAQARJTNI-UHFFFAOYSA-N; N,N-Dimethyl-2,2,2-triphenylacetamide #; Acetamide, N,N-dimethyl-2,2,2-triphenyl-
DM9XZJN	DT	Small molecular drug
DM9XZJN	PC	618190
DM9XZJN	MW	315.4
DM9XZJN	FM	C22H21NO
DM9XZJN	IC	InChI=1S/C22H21NO/c1-23(2)21(24)22(18-12-6-3-7-13-18,19-14-8-4-9-15-19)20-16-10-5-11-17-20/h3-17H,1-2H3
DM9XZJN	CS	CN(C)C(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3
DM9XZJN	IK	JGBIXOAQARJTNI-UHFFFAOYSA-N
DM9XZJN	IU	N,N-dimethyl-2,2,2-triphenylacetamide
DM9XZJN	DE	Discovery agent

DMJDQGR	ID	DMJDQGR
DMJDQGR	DN	N,N-dimethyl-2,2-diphenylethanamine
DMJDQGR	HS	Investigative
DMJDQGR	SN	UNII-MXF0417QII; MXF0417QII; AC1L35TO; CHEMBL10602; diphenylalkylamine (DPA), 4c; BDBM35931; ZINC1249433; 2-Dimethylamino-1,1-diphenylethane; 2-Dimethylamino-1,1-diphenyl-aethan; N,N-Dimethyl-2,2-diphenylethylamine; STL298137; AKOS022110055; MCULE-9768764141; NCGC00246407-01; Ethylamine, N,N-dimethyl-2,2-diphenyl-; Benzeneethanamine, N,N-dimethyl-beta-phenyl-; 2,2-diphenylethyl(dimethyl)amine; 2-Dimethylamino-1,1-diphenyl-aethan [WHO-DD]
DMJDQGR	DT	Small molecular drug
DMJDQGR	PC	83632
DMJDQGR	MW	225.33
DMJDQGR	FM	C16H19N
DMJDQGR	IC	InChI=1S/C16H19N/c1-17(2)13-16(14-9-5-3-6-10-14)15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3
DMJDQGR	CS	CN(C)CC(C1=CC=CC=C1)C2=CC=CC=C2
DMJDQGR	IK	UAUJDKBNVRSJBD-UHFFFAOYSA-N
DMJDQGR	IU	N,N-dimethyl-2,2-diphenylethanamine
DMJDQGR	CA	CAS 7647-54-3
DMJDQGR	DE	Discovery agent

DMIP5K7	ID	DMIP5K7
DMIP5K7	DN	N,N-Dimethyl-3,3-diphenylpropan-1-amine
DMIP5K7	HS	Investigative
DMIP5K7	SN	3,3-Diphenyl-N-dimethylpropylamine; 4646-55-3; Oprea1_032403; N,N-Dimethyl-3,3-diphenylpropan-1-amine; AC1Q3WP9; AC1L45WF; diphenylalkylamine (DPA), 5c; SCHEMBL1802493; 3,3-Diphenylpropyldimethylamine; CHEMBL610739; CTK1C5217; BDBM35934; DTXSID90196845; (3,3-diphenylpropyl)dimethylamine; ZINC1679452; 3,3-diphenyl-N,N-dimethylpropylamine; AKOS016035475; Benzenepropanamine, N,N-dimethyl-gamma-phenyl-
DMIP5K7	DT	Small molecular drug
DMIP5K7	PC	151221
DMIP5K7	MW	239.35
DMIP5K7	FM	C17H21N
DMIP5K7	IC	InChI=1S/C17H21N/c1-18(2)14-13-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
DMIP5K7	CS	CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=C2
DMIP5K7	IK	YHDCGYWZEFIUHE-UHFFFAOYSA-N
DMIP5K7	IU	N,N-dimethyl-3,3-diphenylpropan-1-amine
DMIP5K7	CA	CAS 4646-55-3
DMIP5K7	DE	Discovery agent

DMI3CUZ	ID	DMI3CUZ
DMI3CUZ	DN	N,N-dimethyl-3,4-dihydroquinazolin-2-amine
DMI3CUZ	HS	Investigative
DMI3CUZ	SN	CHEMBL270409; N,N-dimethyl-3,4-dihydroquinazolin-2-amine
DMI3CUZ	DT	Small molecular drug
DMI3CUZ	PC	12683497
DMI3CUZ	MW	175.23
DMI3CUZ	FM	C10H13N3
DMI3CUZ	IC	InChI=1S/C10H13N3/c1-13(2)10-11-7-8-5-3-4-6-9(8)12-10/h3-6H,7H2,1-2H3,(H,11,12)
DMI3CUZ	CS	CN(C)C1=NCC2=CC=CC=C2N1
DMI3CUZ	IK	MNTBAXGKERZVOZ-UHFFFAOYSA-N
DMI3CUZ	IU	N,N-dimethyl-1,4-dihydroquinazolin-2-amine
DMI3CUZ	DE	Discovery agent

DMLX0PI	ID	DMLX0PI
DMLX0PI	DN	N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMLX0PI	HS	Investigative
DMLX0PI	SN	CHEMBL150893; N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine; BDBM50138494; Dimethyl-(4-pyridin-3-yl-but-3-ynyl)-amine
DMLX0PI	DT	Small molecular drug
DMLX0PI	PC	44366245
DMLX0PI	MW	174.24
DMLX0PI	FM	C11H14N2
DMLX0PI	IC	InChI=1S/C11H14N2/c1-13(2)9-4-3-6-11-7-5-8-12-10-11/h5,7-8,10H,4,9H2,1-2H3
DMLX0PI	CS	CN(C)CCC#CC1=CN=CC=C1
DMLX0PI	IK	SGURIVLPISZAAK-UHFFFAOYSA-N
DMLX0PI	IU	N,N-dimethyl-4-pyridin-3-ylbut-3-yn-1-amine
DMLX0PI	DE	Discovery agent

DMX9U7S	ID	DMX9U7S
DMX9U7S	DN	N,N-dimethyl-4,4-diphenylbutan-1-amine
DMX9U7S	HS	Investigative
DMX9U7S	SN	N,N-dimethyl-4,4-diphenylbutan-1-amine; AC1L3QT1; diphenylalkylamine (DPA), 6c; CHEMBL608689; BDBM35937; ZINC5957503; AKOS016035539
DMX9U7S	DT	Small molecular drug
DMX9U7S	PC	120445
DMX9U7S	MW	253.4
DMX9U7S	FM	C18H23N
DMX9U7S	IC	InChI=1S/C18H23N/c1-19(2)15-9-14-18(16-10-5-3-6-11-16)17-12-7-4-8-13-17/h3-8,10-13,18H,9,14-15H2,1-2H3
DMX9U7S	CS	CN(C)CCCC(C1=CC=CC=C1)C2=CC=CC=C2
DMX9U7S	IK	BDSUMBDGCUOHGR-UHFFFAOYSA-N
DMX9U7S	IU	N,N-dimethyl-4,4-diphenylbutan-1-amine
DMX9U7S	DE	Discovery agent

DMWJ2PM	ID	DMWJ2PM
DMWJ2PM	DN	N,N-Dimethylaminoethyl 18-methoxycoronaridinate
DMWJ2PM	HS	Investigative
DMWJ2PM	SN	CHEMBL607047
DMWJ2PM	DT	Small molecular drug
DMWJ2PM	PC	44324799
DMWJ2PM	MW	425.6
DMWJ2PM	FM	C25H35N3O3
DMWJ2PM	IC	InChI=1S/C25H35N3O3/c1-27(2)11-13-31-24(29)25-15-17-14-18(9-12-30-3)23(25)28(16-17)10-8-20-19-6-4-5-7-21(19)26-22(20)25/h4-7,17-18,23,26H,8-16H2,1-3H3/t17?,18-,23?,25+/m0/s1
DMWJ2PM	CS	CN(C)CCOC(=O)[C@@]12CC3C[C@@H](C1N(C3)CCC4=C2NC5=CC=CC=C45)CCOC
DMWJ2PM	IK	NLVQALDWFSJMGA-WXPGHXCBSA-N
DMWJ2PM	IU	2-(dimethylamino)ethyl (1S,17R)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMWJ2PM	DE	Discovery agent

DM0Y8OW	ID	DM0Y8OW
DM0Y8OW	DN	N,N-dimethylarginine
DM0Y8OW	HS	Investigative
DM0Y8OW	SN	N,N-dimethylarginine; ADMA; Asymmetric dimethylarginine; 30315-93-6; Dimethyl-L-arginine; NG,NG-dimethyl-L-arginine; N(G)-Dimethylarginine; Guanidino-N,N-dimethylarginine; N(G),N(G)-Dimethylarginine; (S)-2-Amino-5-(3,3-dimethylguanidino)pentanoic acid; N(G1),N(G1)-Dimethylarginine; Lopac-D-4268; N(5)-((Dimethylamino)iminomethyl)-L-ornithine; N(omega),N(omega)-dimethyl-L-arginine; NG,NG-DIMETHYLARGININE HYDROCHLORIDE; CHEBI:17929; YDGMGEXADBMOMJ-LURJTMIESA-N; N5-[(Dimethylamino)iminomethyl]-L-ornithine
DM0Y8OW	DT	Small molecular drug
DM0Y8OW	PC	123831
DM0Y8OW	MW	202.25
DM0Y8OW	FM	C8H18N4O2
DM0Y8OW	IC	InChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)/t6-/m0/s1
DM0Y8OW	CS	CN(C)C(=NCCC[C@@H](C(=O)O)N)N
DM0Y8OW	IK	YDGMGEXADBMOMJ-LURJTMIESA-N
DM0Y8OW	IU	(2S)-2-amino-5-[[amino(dimethylamino)methylidene]amino]pentanoic acid
DM0Y8OW	CA	CAS 30315-93-6
DM0Y8OW	CB	CHEBI:17929
DM0Y8OW	DE	Discovery agent

DM8WPD2	ID	DM8WPD2
DM8WPD2	DN	N,N-dimethylhistamine
DM8WPD2	HS	Investigative
DM8WPD2	SN	N,N-Dimethylhistamine; 4-(2-Dimethylaminoethyl)imidazole; SU-416; Na,Na-Dimethylhistamine; 673-46-1; N(sup alpha),N(sup alpha)-Dimethylhistamine; N',N'-Dimethylhistamine; [2-(1H-imidazol-4-yl)ethyl]dimethylamine; 1H-Imidazole-4-ethanamine, N,N-dimethyl-; Imidazole, 4-[2-(dimethylamino)ethyl]-; IMIDAZOLE, 4-(2-(DIMETHYLAMINO)ETHYL)-; 4-[2-(Dimethylamino)ethyl]-Imidazole; 4-(2-(Dimethylamino)ethyl)-Imidazole; Hippospongine ; N-dimethylhistamine; CHEMBL12704; Nalpha,Nalpha-Dimethylhistamine; SCHEMBL1239352; AC1L202F; GTPL1270
DM8WPD2	DT	Small molecular drug
DM8WPD2	PC	12656
DM8WPD2	MW	139.2
DM8WPD2	FM	C7H13N3
DM8WPD2	IC	InChI=1S/C7H13N3/c1-10(2)4-3-7-5-8-6-9-7/h5-6H,3-4H2,1-2H3,(H,8,9)
DM8WPD2	CS	CN(C)CCC1=CN=CN1
DM8WPD2	IK	ZJDIMSMQXMWMCF-UHFFFAOYSA-N
DM8WPD2	IU	2-(1H-imidazol-5-yl)-N,N-dimethylethanamine
DM8WPD2	CA	CAS 673-46-1
DM8WPD2	DE	Discovery agent

DM8769D	ID	DM8769D
DM8769D	DN	N,N-Dipropyl-1'H-phenothiazine-1'-carboxamide
DM8769D	HS	Investigative
DM8769D	SN	CHEMBL589063; N,N-dipropyl-10H-phenothiazine-10-carboxamide; 81225-62-9; N,N-dipropylphenothiazine-10-carboxamide; AC1M3CI8; SCHEMBL8428712; ARONIS009768; MolPort-001-593-661; ZINC2883002; KS-000041AV; BDBM50308412; STL064303; AKOS000499526; MCULE-9250306994; phenothiazin-10-yl-N,N-dipropylcarboxamide; BB0286744; ST45046508; N,N-Dipropyl-1''H-phenothiazine-1''-carboxamide
DM8769D	DT	Small molecular drug
DM8769D	PC	2235291
DM8769D	MW	326.5
DM8769D	FM	C19H22N2OS
DM8769D	IC	InChI=1S/C19H22N2OS/c1-3-13-20(14-4-2)19(22)21-15-9-5-7-11-17(15)23-18-12-8-6-10-16(18)21/h5-12H,3-4,13-14H2,1-2H3
DM8769D	CS	CCCN(CCC)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM8769D	IK	VELWLEWVSKZOLN-UHFFFAOYSA-N
DM8769D	IU	N,N-dipropylphenothiazine-10-carboxamide
DM8769D	DE	Discovery agent

DMYCV7U	ID	DMYCV7U
DMYCV7U	DN	N,O6-Disulfo-Glucosamine
DMYCV7U	HS	Investigative
DMYCV7U	SN	N,O6-Disulfo-Glucosamine; 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose; SGN; AC1L9G8A; SCHEMBL1009127; DB03959; 6-O-sulfo-N-sulfo-alpha-d-glucosamine; J3.578.180C; 6-O-Sulfo-2-(sulfoamino)-2-deoxy-alpha-D-glucopyranose; [(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(sulfooxymethyl)oxan-3-yl]sulfamic acid; WURCS=2.0/1,1,0/[a2122h-1a_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O]/1/
DMYCV7U	DT	Small molecular drug
DMYCV7U	PC	444389
DMYCV7U	MW	339.3
DMYCV7U	FM	C6H13NO11S2
DMYCV7U	IC	InChI=1S/C6H13NO11S2/c8-4-2(1-17-20(14,15)16)18-6(10)3(5(4)9)7-19(11,12)13/h2-10H,1H2,(H,11,12,13)(H,14,15,16)/t2-,3-,4-,5-,6+/m1/s1
DMYCV7U	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O
DMYCV7U	IK	DQTRACMFIGDHSN-UKFBFLRUSA-N
DMYCV7U	IU	[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(sulfooxymethyl)oxan-3-yl]sulfamic acid
DMYCV7U	DE	Discovery agent

DM7FT8D	ID	DM7FT8D
DM7FT8D	DN	N,O-Didansyl-L-Tyrosine
DM7FT8D	HS	Investigative
DM7FT8D	SN	N,O-DIDANSYL-L-TYROSINE; CHEMBL176072; 1jg0; N,O-diansyl-L-tyrosine; AC1L9JPF; Dansyl derivative, DDT, 1L; Dansyltyrosine deriviative 21B; SCHEMBL4325460; ZINC24640039; BDBM50161779; Dansyl derivatives 18A, (R) isomer; DB03157; N,O-bis{[5-(dimethylamino)naphthalen-1-yl]sulfonyl}-L-tyrosine; (S)-2-(5-Dimethylamino-naphthalene-1-sulfonylamino)-3-[4-(5-dimethylamino-naphthalene-1-sulfonyloxy)-phenyl]-propionic acid
DM7FT8D	DT	Small molecular drug
DM7FT8D	PC	446468
DM7FT8D	MW	647.8
DM7FT8D	FM	C33H33N3O7S2
DM7FT8D	IC	InChI=1S/C33H33N3O7S2/c1-35(2)29-13-5-11-26-24(29)9-7-15-31(26)44(39,40)34-28(33(37)38)21-22-17-19-23(20-18-22)43-45(41,42)32-16-8-10-25-27(32)12-6-14-30(25)36(3)4/h5-20,28,34H,21H2,1-4H3,(H,37,38)/t28-/m0/s1
DM7FT8D	CS	CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)N[C@@H](CC3=CC=C(C=C3)OS(=O)(=O)C4=CC=CC5=C4C=CC=C5N(C)C)C(=O)O
DM7FT8D	IK	LUBOPDUYHWABFG-NDEPHWFRSA-N
DM7FT8D	IU	(2S)-2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-3-[4-[5-(dimethylamino)naphthalen-1-yl]sulfonyloxyphenyl]propanoic acid
DM7FT8D	DE	Discovery agent

DMCGVAB	ID	DMCGVAB
DMCGVAB	DN	N/OFQ-(1-13)-NH2
DMCGVAB	HS	Investigative
DMCGVAB	SN	RHMALYOXPBRJBG-CGUXNFSNSA-N; nociceptin(1-13)NH2; CHEMBL384755; 178064-02-3; OFQ/N; FGGFTGARKSARK; nociceptin(1-13)-NH2; Nociceptin (1-13)NH2; orphanin FQ(1-13)NH2; Demethyl-AMPA; nociceptin/orphanin FQ(1-13)NH2; Nociceptin Orphanin FQ1-13-NH2; H-FGGFTGARKSARK-NH2; AC1O44IO; GTPL1682; BDBM85822; N/OFQ(1-13)NH2; NC(1-13)NH2; Nociceptin analogueNC(1-13)-NH2; BDBM50106479; OFQ/N (1-11); AKOS024456547; NCGC00167157-01;  nociceptin(1-13)NH2
DMCGVAB	DT	Small molecular drug
DMCGVAB	PC	6324645
DMCGVAB	MW	1381.6
DMCGVAB	FM	C61H100N22O15
DMCGVAB	IC	InChI=1S/C61H100N22O15/c1-34(75-47(87)32-74-59(98)49(36(3)85)83-57(96)44(29-38-18-8-5-9-19-38)77-48(88)31-72-46(86)30-73-53(92)39(64)28-37-16-6-4-7-17-37)51(90)79-43(23-15-27-71-61(68)69)55(94)81-41(21-11-13-25-63)56(95)82-45(33-84)58(97)76-35(2)52(91)80-42(22-14-26-70-60(66)67)54(93)78-40(50(65)89)20-10-12-24-62/h4-9,16-19,34-36,39-45,49,84-85H,10-15,20-33,62-64H2,1-3H3,(H2,65,89)(H,72,86)(H,73,92)(H,74,98)(H,75,87)(H,76,97)(H,77,88)(H,78,93)(H,79,90)(H,80,91)(H,81,94)(H,82,95)(H,83,96)(H4,66,67,70)(H4,68,69,71)/t34-,35-,36+,39-,40-,41-,42-,43-,44-,45-,49-/m0/s1
DMCGVAB	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMCGVAB	IK	RHMALYOXPBRJBG-CGUXNFSNSA-N
DMCGVAB	IU	(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanamide
DMCGVAB	DE	Discovery agent

DMLTYPS	ID	DMLTYPS
DMLTYPS	DN	N-[(4-bromo-1-benzothien-3-yl)methyl]sulfamide
DMLTYPS	HS	Investigative
DMLTYPS	SN	CHEMBL1084919; N-[(4-bromo-1-benzothien-3-yl)methyl]sulfamide; SCHEMBL4276579; FBZAPOBZDNKPQH-UHFFFAOYSA-N; BDBM50310430
DMLTYPS	DT	Small molecular drug
DMLTYPS	PC	11623927
DMLTYPS	MW	321.2
DMLTYPS	FM	C9H9BrN2O2S2
DMLTYPS	IC	InChI=1S/C9H9BrN2O2S2/c10-7-2-1-3-8-9(7)6(5-15-8)4-12-16(11,13)14/h1-3,5,12H,4H2,(H2,11,13,14)
DMLTYPS	CS	C1=CC2=C(C(=C1)Br)C(=CS2)CNS(=O)(=O)N
DMLTYPS	IK	FBZAPOBZDNKPQH-UHFFFAOYSA-N
DMLTYPS	IU	4-bromo-3-[(sulfamoylamino)methyl]-1-benzothiophene
DMLTYPS	DE	Discovery agent

DMVOJFW	ID	DMVOJFW
DMVOJFW	DN	N-[(4-methoxyphenyl)sulfonyl]-D-alanine
DMVOJFW	HS	Investigative
DMVOJFW	SN	n-4'-methoxybenzenesulfonyl-d-alanine; N-[(4-methoxyphenyl)sulfonyl]-D-alanine; 918330-60-6; AC1LE3DF; SCHEMBL4618694; CTK3H8025; ZINC91137; DTXSID60351641; MolPort-013-146-011; AKOS017427177; DB08599; D-Alanine, N-[(4-methoxyphenyl)sulfonyl]-; (R)-2-(4-Methoxyphenylsulfonamido)propanoic acid; (2R)-2-(4-methoxybenzenesulfonamido)propanoic acid; (2R)-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid
DMVOJFW	DT	Small molecular drug
DMVOJFW	PC	705712
DMVOJFW	MW	259.279
DMVOJFW	FM	C10H13NO5S
DMVOJFW	IC	InChI=1S/C10H13NO5S/c1-7(10(12)13)11-17(14,15)9-5-3-8(16-2)4-6-9/h3-7,11H,1-2H3,(H,12,13)/t7-/m1/s1
DMVOJFW	CS	C[C@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)OC
DMVOJFW	IK	XTCIPBHRVYICGT-SSDOTTSWSA-N
DMVOJFW	IU	(2R)-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid
DMVOJFW	CA	CAS 918330-60-6
DMVOJFW	DE	Discovery agent

DMYJHRV	ID	DMYJHRV
DMYJHRV	DN	N-[(5-chloro-1-benzothien-3-yl)methyl]sulfamide
DMYJHRV	HS	Investigative
DMYJHRV	SN	CHEMBL1084675; N-[(5-chloro-1-benzothien-3-yl)methyl]sulfamide; SCHEMBL4274889; PURBZUVIUSNPGZ-UHFFFAOYSA-N; BDBM50310436
DMYJHRV	DT	Small molecular drug
DMYJHRV	PC	11572651
DMYJHRV	MW	276.8
DMYJHRV	FM	C9H9ClN2O2S2
DMYJHRV	IC	InChI=1S/C9H9ClN2O2S2/c10-7-1-2-9-8(3-7)6(5-15-9)4-12-16(11,13)14/h1-3,5,12H,4H2,(H2,11,13,14)
DMYJHRV	CS	C1=CC2=C(C=C1Cl)C(=CS2)CNS(=O)(=O)N
DMYJHRV	IK	PURBZUVIUSNPGZ-UHFFFAOYSA-N
DMYJHRV	IU	5-chloro-3-[(sulfamoylamino)methyl]-1-benzothiophene
DMYJHRV	DE	Discovery agent

DMHNR36	ID	DMHNR36
DMHNR36	DN	N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE
DMHNR36	HS	Investigative
DMHNR36	SN	N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE; 2-[(cyclohexylcarbamoyl)amino]acetic acid; CHEMBL66380; 33557-91-4; 2-(3-cyclohexylureido)acetic acid; Glycine, N-[(cyclohexylamino)carbonyl]-; 4-(3-CYCLOHEXYLURIEDO)-ETHANOIC ACID; NC3; 2-(cyclohexylcarbamoylamino)acetic acid; 1zd2; N-(cyclohexylcarbamoyl)glycine; AC1Q760W; AC1N5Q71; CTK1B1676; DTXSID90399930; MolPort-002-472-569; HMS3604L13; (3-Cyclohexyl-ureido)-acetic acid; ZINC6691828; BDBM50143914; AKOS000132958; NE25644; MCULE-8014113453; DB08256; [(cyclohexylcarbamoyl)amino]acetic acid
DMHNR36	DT	Small molecular drug
DMHNR36	PC	4149241
DMHNR36	MW	200.23
DMHNR36	FM	C9H16N2O3
DMHNR36	IC	InChI=1S/C9H16N2O3/c12-8(13)6-10-9(14)11-7-4-2-1-3-5-7/h7H,1-6H2,(H,12,13)(H2,10,11,14)
DMHNR36	CS	C1CCC(CC1)NC(=O)NCC(=O)O
DMHNR36	IK	NVORCMBCUHQRDL-UHFFFAOYSA-N
DMHNR36	IU	2-(cyclohexylcarbamoylamino)acetic acid
DMHNR36	CA	CAS 33557-91-4
DMHNR36	DE	Discovery agent

DMI9GQV	ID	DMI9GQV
DMI9GQV	DN	N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMI9GQV	HS	Investigative
DMI9GQV	SN	CHEMBL233863; N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMI9GQV	DT	Small molecular drug
DMI9GQV	PC	44430730
DMI9GQV	MW	279.3
DMI9GQV	FM	C15H13N5O
DMI9GQV	IC	InChI=1S/C15H13N5O/c16-15(17)20-14(21)10-6-2-1-5-9(10)13-18-11-7-3-4-8-12(11)19-13/h1-8H,(H,18,19)(H4,16,17,20,21)
DMI9GQV	CS	C1=CC=C(C(=C1)C2=NC3=CC=CC=C3N2)C(=O)N=C(N)N
DMI9GQV	IK	FJRZRURKRDCIKZ-UHFFFAOYSA-N
DMI9GQV	IU	2-(1H-benzimidazol-2-yl)-N-(diaminomethylidene)benzamide
DMI9GQV	DE	Discovery agent

DMM7T13	ID	DMM7T13
DMM7T13	DN	N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide
DMM7T13	HS	Investigative
DMM7T13	SN	N-[2-(1H-INDOL-5-YL)-BUTYL]-4-SULFAMOYL-BENZAMIDE; N-[(2S)-2-(1H-indol-5-yl)butyl]-4-sulfamoylbenzamide; SBB; AC1NUYV7
DMM7T13	DT	Small molecular drug
DMM7T13	PC	5496599
DMM7T13	MW	371.5
DMM7T13	FM	C19H21N3O3S
DMM7T13	IC	InChI=1S/C19H21N3O3S/c1-2-13(15-5-8-18-16(11-15)9-10-21-18)12-22-19(23)14-3-6-17(7-4-14)26(20,24)25/h3-11,13,21H,2,12H2,1H3,(H,22,23)(H2,20,24,25)/t13-/m1/s1
DMM7T13	CS	CC[C@H](CNC(=O)C1=CC=C(C=C1)S(=O)(=O)N)C2=CC3=C(C=C2)NC=C3
DMM7T13	IK	FSRPBGBMEKDSIJ-CYBMUJFWSA-N
DMM7T13	IU	N-[(2S)-2-(1H-indol-5-yl)butyl]-4-sulfamoylbenzamide
DMM7T13	DE	Discovery agent

DMPKBT1	ID	DMPKBT1
DMPKBT1	DN	N-[2-(4'-Nitrophenyl)ethyl]-imidazole
DMPKBT1	HS	Investigative
DMPKBT1	SN	1-(4-nitrophenethyl)-1H-imidazole; 56643-91-5; 1-[2-(4-nitrophenyl)ethyl]-1H-imidazole; CHEMBL1098425; 1H-Imidazole, 1-[2-(4-nitrophenyl)ethyl]-; 1-[2-(4-nitrophenyl)ethyl]imidazole; AC1MOACC; MLS001195428; SCHEMBL9663626; CTK1F4146; DTXSID30391397; MolPort-002-886-896; HCPMKJOVCNZGSD-UHFFFAOYSA-N; HMS2885O15; ZINC4025449; BDBM50318407; AKOS010189447; MCULE-3977633271; MS-1973; KS-0000281S; SMR000550723; N-[2-(4''-Nitrophenyl)ethyl]-imidazole; SR-01000308458
DMPKBT1	DT	Small molecular drug
DMPKBT1	PC	3317166
DMPKBT1	MW	217.22
DMPKBT1	FM	C11H11N3O2
DMPKBT1	IC	InChI=1S/C11H11N3O2/c15-14(16)11-3-1-10(2-4-11)5-7-13-8-6-12-9-13/h1-4,6,8-9H,5,7H2
DMPKBT1	CS	C1=CC(=CC=C1CCN2C=CN=C2)[N+](=O)[O-]
DMPKBT1	IK	HCPMKJOVCNZGSD-UHFFFAOYSA-N
DMPKBT1	IU	1-[2-(4-nitrophenyl)ethyl]imidazole
DMPKBT1	CA	CAS 56643-91-5
DMPKBT1	DE	Discovery agent

DM5FQH8	ID	DM5FQH8
DM5FQH8	DN	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]lauramide
DM5FQH8	HS	Investigative
DM5FQH8	SN	CHEMBL394636; BDBM22995; N-arachidonoylserotonin analogue, 1h
DM5FQH8	DT	Small molecular drug
DM5FQH8	PC	24749271
DM5FQH8	MW	358.5
DM5FQH8	FM	C22H34N2O2
DM5FQH8	IC	InChI=1S/C22H34N2O2/c1-2-3-4-5-6-7-8-9-10-11-22(26)23-15-14-18-17-24-21-13-12-19(25)16-20(18)21/h12-13,16-17,24-25H,2-11,14-15H2,1H3,(H,23,26)
DM5FQH8	CS	CCCCCCCCCCCC(=O)NCCC1=CNC2=C1C=C(C=C2)O
DM5FQH8	IK	MOQBGJJXYJJJFQ-UHFFFAOYSA-N
DM5FQH8	IU	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]dodecanamide
DM5FQH8	DE	Discovery agent

DMG5PL7	ID	DMG5PL7
DMG5PL7	DN	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]linoleamide
DMG5PL7	HS	Investigative
DMG5PL7	SN	CHEMBL236385; BDBM22991; N-arachidonoylserotonin analogue, 1d
DMG5PL7	DT	Small molecular drug
DMG5PL7	PC	24749267
DMG5PL7	MW	438.6
DMG5PL7	FM	C28H42N2O2
DMG5PL7	IC	InChI=1S/C28H42N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(32)29-21-20-24-23-30-27-19-18-25(31)22-26(24)27/h6-7,9-10,18-19,22-23,30-31H,2-5,8,11-17,20-21H2,1H3,(H,29,32)/b7-6-,10-9-
DMG5PL7	CS	CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)NCCC1=CNC2=C1C=C(C=C2)O
DMG5PL7	IK	YJVMJUDLMFBYFZ-HZJYTTRNSA-N
DMG5PL7	IU	(9Z,12Z)-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]octadeca-9,12-dienamide
DMG5PL7	DE	Discovery agent

DMC1GYH	ID	DMC1GYH
DMC1GYH	DN	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide
DMC1GYH	HS	Investigative
DMC1GYH	SN	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide; CHEMBL394635; BDBM22994; N-arachidonoylserotonin analogue, 1g
DMC1GYH	DT	Small molecular drug
DMC1GYH	PC	24749270
DMC1GYH	MW	344.5
DMC1GYH	FM	C21H32N2O2
DMC1GYH	IC	InChI=1S/C21H32N2O2/c1-2-3-4-5-6-7-8-9-10-21(25)22-14-13-17-16-23-20-12-11-18(24)15-19(17)20/h11-12,15-16,23-24H,2-10,13-14H2,1H3,(H,22,25)
DMC1GYH	CS	CCCCCCCCCCC(=O)NCCC1=CNC2=C1C=C(C=C2)O
DMC1GYH	IK	RNYSECALLZNZML-UHFFFAOYSA-N
DMC1GYH	IU	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide
DMC1GYH	DE	Discovery agent

DMJ8W6F	ID	DMJ8W6F
DMJ8W6F	DN	N-[2-(Indol-3-yl)ethyl]-S-benzyl-dithiocarbamate
DMJ8W6F	HS	Investigative
DMJ8W6F	SN	CHEMBL202881
DMJ8W6F	DT	Small molecular drug
DMJ8W6F	PC	44406804
DMJ8W6F	MW	326.5
DMJ8W6F	FM	C18H18N2S2
DMJ8W6F	IC	InChI=1S/C18H18N2S2/c21-18(22-13-14-6-2-1-3-7-14)19-11-10-16-12-15-8-4-5-9-17(15)20-16/h1-9,12,20H,10-11,13H2,(H,19,21)
DMJ8W6F	CS	C1=CC=C(C=C1)CSC(=S)NCCC2=CC3=CC=CC=C3N2
DMJ8W6F	IK	UDMBZULQHCKYPT-UHFFFAOYSA-N
DMJ8W6F	IU	benzyl N-[2-(1H-indol-2-yl)ethyl]carbamodithioate
DMJ8W6F	DE	Discovery agent

DMU89FH	ID	DMU89FH
DMU89FH	DN	N-[3-(2-Ethyl-benzooxazol-7-yl)-propyl]-acetamide
DMU89FH	HS	Investigative
DMU89FH	SN	CHEMBL125665; N-[3-(2-Ethyl-benzooxazol-7-yl)-propyl]-acetamide; SCHEMBL6789609
DMU89FH	DT	Small molecular drug
DMU89FH	PC	22718561
DMU89FH	MW	246.3
DMU89FH	FM	C14H18N2O2
DMU89FH	IC	InChI=1S/C14H18N2O2/c1-3-13-16-12-8-4-6-11(14(12)18-13)7-5-9-15-10(2)17/h4,6,8H,3,5,7,9H2,1-2H3,(H,15,17)
DMU89FH	CS	CCC1=NC2=CC=CC(=C2O1)CCCNC(=O)C
DMU89FH	IK	UGHYQTDENFVMRW-UHFFFAOYSA-N
DMU89FH	IU	N-[3-(2-ethyl-1,3-benzoxazol-7-yl)propyl]acetamide
DMU89FH	DE	Discovery agent

DM7OA4R	ID	DM7OA4R
DM7OA4R	DN	N-[3'-(trifluoromethyl)-4-biphenylyl]urea
DM7OA4R	HS	Investigative
DM7OA4R	SN	CHEMBL244690; BDBM50220199
DM7OA4R	DT	Small molecular drug
DM7OA4R	PC	23626453
DM7OA4R	MW	280.24
DM7OA4R	FM	C14H11F3N2O
DM7OA4R	IC	InChI=1S/C14H11F3N2O/c15-14(16,17)11-3-1-2-10(8-11)9-4-6-12(7-5-9)19-13(18)20/h1-8H,(H3,18,19,20)
DM7OA4R	CS	C1=CC(=CC(=C1)C(F)(F)F)C2=CC=C(C=C2)NC(=O)N
DM7OA4R	IK	MHFIGSQWRVHNRG-UHFFFAOYSA-N
DM7OA4R	IU	[4-[3-(trifluoromethyl)phenyl]phenyl]urea
DM7OA4R	DE	Discovery agent

DMKPYEU	ID	DMKPYEU
DMKPYEU	DN	N-[3,3-Bis-(4-fluorophenyl)-propyl]-benzamide
DMKPYEU	HS	Investigative
DMKPYEU	SN	N-(3,3-diphenylpropyl)benzamide; CHEMBL556303; AC1LOGD3; Oprea1_468003; N-[3,3-Bis-(4-fluorophenyl)-propyl]-benzamide; SCHEMBL5948102; MolPort-001-492-275; ZINC995229; STK448927; BDBM50297396; AKOS003256160; MCULE-7987321913; ST50916006
DMKPYEU	DT	Small molecular drug
DMKPYEU	PC	1220236
DMKPYEU	MW	315.4
DMKPYEU	FM	C22H21NO
DMKPYEU	IC	InChI=1S/C22H21NO/c24-22(20-14-8-3-9-15-20)23-17-16-21(18-10-4-1-5-11-18)19-12-6-2-7-13-19/h1-15,21H,16-17H2,(H,23,24)
DMKPYEU	CS	C1=CC=C(C=C1)C(CCNC(=O)C2=CC=CC=C2)C3=CC=CC=C3
DMKPYEU	IK	NSSSSHDNQFPODZ-UHFFFAOYSA-N
DMKPYEU	IU	N-(3,3-diphenylpropyl)benzamide
DMKPYEU	DE	Discovery agent

DMIP8AK	ID	DMIP8AK
DMIP8AK	DN	N-[3,3-Bis-(4-fluorophenyl)-propyl]-nicotinamide
DMIP8AK	HS	Investigative
DMIP8AK	SN	CHEMBL563216; N-[3,3-Bis-(4-fluorophenyl)-propyl]-nicotinamide; SCHEMBL5947860; PGLSPMQRWMIFOQ-UHFFFAOYSA-N; BDBM50297398
DMIP8AK	DT	Small molecular drug
DMIP8AK	PC	11976535
DMIP8AK	MW	352.4
DMIP8AK	FM	C21H18F2N2O
DMIP8AK	IC	InChI=1S/C21H18F2N2O/c22-18-7-3-15(4-8-18)20(16-5-9-19(23)10-6-16)11-13-25-21(26)17-2-1-12-24-14-17/h1-10,12,14,20H,11,13H2,(H,25,26)
DMIP8AK	CS	C1=CC(=CN=C1)C(=O)NCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F
DMIP8AK	IK	PGLSPMQRWMIFOQ-UHFFFAOYSA-N
DMIP8AK	IU	N-[3,3-bis(4-fluorophenyl)propyl]pyridine-3-carboxamide
DMIP8AK	DE	Discovery agent

DMWDCV1	ID	DMWDCV1
DMWDCV1	DN	N-[3H]alpha-methylhistamine
DMWDCV1	HS	Investigative
DMWDCV1	SN	N-alpha-methylhistamine; 1H-Imidazole-4-ethanamine, N-methyl-; 4-(2-Methylaminoethyl)imidazole; N(sup alpha)-Methylhistamine; NAMH; Nalpha-Methylhistamine; UNII-Y7QR253130; N(alpha)-methylhistamine; Y7QR253130; Imidazole, 4-[2-(methylamino)ethyl]-; Imidazole, 4-(2-(methylamino)ethyl)-; [2-(1H-imidazol-5-yl)ethyl](methyl)amine; 2-(3H-imidazol-4-yl)-N-methylethanamine; [3H]-Na-methylhistamine; [3H]NAMH; N-alpha-methyl histamine
DMWDCV1	DT	Small molecular drug
DMWDCV1	PC	912
DMWDCV1	MW	125.17
DMWDCV1	FM	C6H11N3
DMWDCV1	IC	InChI=1S/C6H11N3/c1-7-3-2-6-4-8-5-9-6/h4-5,7H,2-3H2,1H3,(H,8,9)
DMWDCV1	CS	CNCCC1=CN=CN1
DMWDCV1	IK	PHSPJQZRQAJPPF-UHFFFAOYSA-N
DMWDCV1	IU	2-(1H-imidazol-5-yl)-N-methylethanamine
DMWDCV1	CA	CAS 673-50-7
DMWDCV1	DE	Discovery agent

DM0CI4L	ID	DM0CI4L
DM0CI4L	DN	N-[3H]methylhistamine
DM0CI4L	HS	Investigative
DM0CI4L	SN	1-Methylhistamine; Tele-methylhistamine; 501-75-7; N1-Methylhistamine; N-Telle-methylhistamine; 2-(1-methyl-1H-imidazol-4-yl)ethanamine; 2-(1-methyl-1H-imidazol-4-yl)ethan-1-amine; 1-Methyl-1H-imidazole-4-ethanamine; 1H-Imidazole-4-ethanamine, 1-methyl-; 1-Methyl-4-histamine; UNII-KCB81T4EOF; N(sup 1)-Methylhistamine; NSC 66736; N-tele-Methylhistamine; CHEBI:29009; 1-methyl-4-(b-aminoethyl)imidazole; 1-Methyl-4-(2-aminoethyl)imidazole; KCB81T4EOF; 1-Methyl-4-(beta-aminoethyl)imidazole; BRN 0110757
DM0CI4L	DT	Small molecular drug
DM0CI4L	PC	3614
DM0CI4L	MW	125.17
DM0CI4L	FM	C6H11N3
DM0CI4L	IC	InChI=1S/C6H11N3/c1-9-4-6(2-3-7)8-5-9/h4-5H,2-3,7H2,1H3
DM0CI4L	CS	CN1C=C(N=C1)CCN
DM0CI4L	IK	FHQDWPCFSJMNCT-UHFFFAOYSA-N
DM0CI4L	IU	2-(1-methylimidazol-4-yl)ethanamine
DM0CI4L	CA	CAS 501-75-7
DM0CI4L	CB	CHEBI:29009
DM0CI4L	DE	Discovery agent

DMITN82	ID	DMITN82
DMITN82	DN	N-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide
DMITN82	HS	Investigative
DMITN82	SN	CHEMBL242180; N-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide; SCHEMBL5535049
DMITN82	DT	Small molecular drug
DMITN82	PC	11737887
DMITN82	MW	292.31
DMITN82	FM	C13H12N2O4S
DMITN82	IC	InChI=1S/C13H12N2O4S/c14-20(16,17)15-11-4-1-9(2-5-11)10-3-6-12-13(7-10)19-8-18-12/h1-7,15H,8H2,(H2,14,16,17)
DMITN82	CS	C1OC2=C(O1)C=C(C=C2)C3=CC=C(C=C3)NS(=O)(=O)N
DMITN82	IK	ZFMUZDFMEJBCPQ-UHFFFAOYSA-N
DMITN82	IU	5-[4-(sulfamoylamino)phenyl]-1,3-benzodioxole
DMITN82	DE	Discovery agent

DMT6LX9	ID	DMT6LX9
DMT6LX9	DN	N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMT6LX9	HS	Investigative
DMT6LX9	SN	CHEMBL233862; N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMT6LX9	DT	Small molecular drug
DMT6LX9	PC	44430728
DMT6LX9	MW	279.3
DMT6LX9	FM	C15H13N5O
DMT6LX9	IC	InChI=1S/C15H13N5O/c16-15(17)20-14(21)10-7-5-9(6-8-10)13-18-11-3-1-2-4-12(11)19-13/h1-8H,(H,18,19)(H4,16,17,20,21)
DMT6LX9	CS	C1=CC=C2C(=C1)NC(=N2)C3=CC=C(C=C3)C(=O)N=C(N)N
DMT6LX9	IK	RAYGWMJYTDFZDD-UHFFFAOYSA-N
DMT6LX9	IU	4-(1H-benzimidazol-2-yl)-N-(diaminomethylidene)benzamide
DMT6LX9	DE	Discovery agent

DMLV18K	ID	DMLV18K
DMLV18K	DN	N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide
DMLV18K	HS	Investigative
DMLV18K	SN	CHEMBL223185; N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide; N-(4-(3-amino-1H-indazol-4-yl)phenyl)benzamide; benzamide,n-[4-(3-amino-1h-indazol-4-yl)phenyl]-; BDBM50207504; ZINC35324132; 935660-76-7
DMLV18K	DT	Small molecular drug
DMLV18K	PC	16125109
DMLV18K	MW	328.4
DMLV18K	FM	C20H16N4O
DMLV18K	IC	InChI=1S/C20H16N4O/c21-19-18-16(7-4-8-17(18)23-24-19)13-9-11-15(12-10-13)22-20(25)14-5-2-1-3-6-14/h1-12H,(H,22,25)(H3,21,23,24)
DMLV18K	CS	C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N
DMLV18K	IK	ZBWAOEUPXWDTQS-UHFFFAOYSA-N
DMLV18K	IU	N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide
DMLV18K	DE	Discovery agent

DMC62K1	ID	DMC62K1
DMC62K1	DN	N-[4-(3-pyridylethynyl)-2-thiazolyl]acetamide
DMC62K1	HS	Investigative
DMC62K1	SN	CHEMBL381482; N-[4-(3-pyridylethynyl)-2-thiazolyl]acetamide; SCHEMBL4153643
DMC62K1	DT	Small molecular drug
DMC62K1	PC	11615675
DMC62K1	MW	243.29
DMC62K1	FM	C12H9N3OS
DMC62K1	IC	InChI=1S/C12H9N3OS/c1-9(16)14-12-15-11(8-17-12)5-4-10-3-2-6-13-7-10/h2-3,6-8H,1H3,(H,14,15,16)
DMC62K1	CS	CC(=O)NC1=NC(=CS1)C#CC2=CN=CC=C2
DMC62K1	IK	LNYMBABMFUHLAP-UHFFFAOYSA-N
DMC62K1	IU	N-[4-(2-pyridin-3-ylethynyl)-1,3-thiazol-2-yl]acetamide
DMC62K1	DE	Discovery agent

DMA4L5P	ID	DMA4L5P
DMA4L5P	DN	N-[4-(4-Phenyl-piperazin-1-yl)-butyl]-benzamide
DMA4L5P	HS	Investigative
DMA4L5P	SN	CHEMBL27393; N-[4-(4-Phenyl-piperazin-1-yl)-butyl]-benzamide; BDBM50022717
DMA4L5P	DT	Small molecular drug
DMA4L5P	PC	14162480
DMA4L5P	MW	337.5
DMA4L5P	FM	C21H27N3O
DMA4L5P	IC	InChI=1S/C21H27N3O/c25-21(19-9-3-1-4-10-19)22-13-7-8-14-23-15-17-24(18-16-23)20-11-5-2-6-12-20/h1-6,9-12H,7-8,13-18H2,(H,22,25)
DMA4L5P	CS	C1CN(CCN1CCCCNC(=O)C2=CC=CC=C2)C3=CC=CC=C3
DMA4L5P	IK	SPKHLKULRLEZKZ-UHFFFAOYSA-N
DMA4L5P	IU	N-[4-(4-phenylpiperazin-1-yl)butyl]benzamide
DMA4L5P	DE	Discovery agent

DMD5F6Z	ID	DMD5F6Z
DMD5F6Z	DN	N-[4'-(ethylsulfonyl)-3-fluoro-4-biphenylyl]urea
DMD5F6Z	HS	Investigative
DMD5F6Z	SN	CHEMBL244512; BDBM50220161
DMD5F6Z	DT	Small molecular drug
DMD5F6Z	PC	23626454
DMD5F6Z	MW	322.4
DMD5F6Z	FM	C15H15FN2O3S
DMD5F6Z	IC	InChI=1S/C15H15FN2O3S/c1-2-22(20,21)12-6-3-10(4-7-12)11-5-8-14(13(16)9-11)18-15(17)19/h3-9H,2H2,1H3,(H3,17,18,19)
DMD5F6Z	CS	CCS(=O)(=O)C1=CC=C(C=C1)C2=CC(=C(C=C2)NC(=O)N)F
DMD5F6Z	IK	FGSMXSWRTDKBBK-UHFFFAOYSA-N
DMD5F6Z	IU	[4-(4-ethylsulfonylphenyl)-2-fluorophenyl]urea
DMD5F6Z	DE	Discovery agent

DMCTZFP	ID	DMCTZFP
DMCTZFP	DN	N-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide
DMCTZFP	HS	Investigative
DMCTZFP	SN	CHEMBL390629; N-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide; SCHEMBL5531754; WELQTBDQZUFHMC-UHFFFAOYSA-N; ZINC28711911; BDBM50220182
DMCTZFP	DT	Small molecular drug
DMCTZFP	PC	11232325
DMCTZFP	MW	316.3
DMCTZFP	FM	C13H11F3N2O2S
DMCTZFP	IC	InChI=1S/C13H11F3N2O2S/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(8-4-10)18-21(17,19)20/h1-8,18H,(H2,17,19,20)
DMCTZFP	CS	C1=CC(=CC=C1C2=CC=C(C=C2)NS(=O)(=O)N)C(F)(F)F
DMCTZFP	IK	WELQTBDQZUFHMC-UHFFFAOYSA-N
DMCTZFP	IU	1-[4-(sulfamoylamino)phenyl]-4-(trifluoromethyl)benzene
DMCTZFP	DE	Discovery agent

DMPVKWG	ID	DMPVKWG
DMPVKWG	DN	N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea
DMPVKWG	HS	Investigative
DMPVKWG	SN	CHEMBL243885; N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea; SCHEMBL5427766; VTGXCQVBAHHGLK-UHFFFAOYSA-N; BDBM50220195
DMPVKWG	DT	Small molecular drug
DMPVKWG	PC	11652296
DMPVKWG	MW	296.31
DMPVKWG	FM	C14H11F3N2S
DMPVKWG	IC	InChI=1S/C14H11F3N2S/c15-14(16,17)11-5-1-9(2-6-11)10-3-7-12(8-4-10)19-13(18)20/h1-8H,(H3,18,19,20)
DMPVKWG	CS	C1=CC(=CC=C1C2=CC=C(C=C2)NC(=S)N)C(F)(F)F
DMPVKWG	IK	VTGXCQVBAHHGLK-UHFFFAOYSA-N
DMPVKWG	IU	[4-[4-(trifluoromethyl)phenyl]phenyl]thiourea
DMPVKWG	DE	Discovery agent

DMMHQRT	ID	DMMHQRT
DMMHQRT	DN	N-[4'-(trifluoromethyl)-4-biphenylyl]urea
DMMHQRT	HS	Investigative
DMMHQRT	SN	CHEMBL243883; SCHEMBL5427711; ZINC28711905; BDBM50220162
DMMHQRT	DT	Small molecular drug
DMMHQRT	PC	11623295
DMMHQRT	MW	280.24
DMMHQRT	FM	C14H11F3N2O
DMMHQRT	IC	InChI=1S/C14H11F3N2O/c15-14(16,17)11-5-1-9(2-6-11)10-3-7-12(8-4-10)19-13(18)20/h1-8H,(H3,18,19,20)
DMMHQRT	CS	C1=CC(=CC=C1C2=CC=C(C=C2)NC(=O)N)C(F)(F)F
DMMHQRT	IK	SUCPPONDZMGXRQ-UHFFFAOYSA-N
DMMHQRT	IU	[4-[4-(trifluoromethyl)phenyl]phenyl]urea
DMMHQRT	DE	Discovery agent

DMMX65T	ID	DMMX65T
DMMX65T	DN	N-[4-(trifluoromethyl)phenyl]sulfamide
DMMX65T	HS	Investigative
DMMX65T	SN	N-[4-(trifluoromethyl)phenyl]sulfamide; CHEMBL167179; N-[4-(trifluoromethyl)phenyl]sulfuric diamide; 556068-13-4; (4-trifluoromethylphenyl)sulfamide; SCHEMBL1645153; ZINC13488092; BDBM50124177; AKOS027393975; KB-300897; 79478-EP2305698A2; 79478-EP2305696A2; 79478-EP2305697A2
DMMX65T	DT	Small molecular drug
DMMX65T	PC	10421755
DMMX65T	MW	240.21
DMMX65T	FM	C7H7F3N2O2S
DMMX65T	IC	InChI=1S/C7H7F3N2O2S/c8-7(9,10)5-1-3-6(4-2-5)12-15(11,13)14/h1-4,12H,(H2,11,13,14)
DMMX65T	CS	C1=CC(=CC=C1C(F)(F)F)NS(=O)(=O)N
DMMX65T	IK	LTJDGKNETMQCBO-UHFFFAOYSA-N
DMMX65T	IU	1-(sulfamoylamino)-4-(trifluoromethyl)benzene
DMMX65T	DE	Discovery agent

DMP5A8K	ID	DMP5A8K
DMP5A8K	DN	N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine
DMP5A8K	HS	Investigative
DMP5A8K	SN	CHEMBL372051; N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine; SCHEMBL4939618
DMP5A8K	DT	Small molecular drug
DMP5A8K	PC	11172909
DMP5A8K	MW	257.29
DMP5A8K	FM	C14H15N3O2
DMP5A8K	IC	InChI=1S/C14H15N3O2/c1-2-9-5-3-4-6-10(9)11-7-8-12(19-11)13(18)17-14(15)16/h3-8H,2H2,1H3,(H4,15,16,17,18)
DMP5A8K	CS	CCC1=CC=CC=C1C2=CC=C(O2)C(=O)N=C(N)N
DMP5A8K	IK	CCKFOHBQWASBLB-UHFFFAOYSA-N
DMP5A8K	IU	N-(diaminomethylidene)-5-(2-ethylphenyl)furan-2-carboxamide
DMP5A8K	DE	Discovery agent

DMZ9V18	ID	DMZ9V18
DMZ9V18	DN	N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine
DMZ9V18	HS	Investigative
DMZ9V18	SN	CHEMBL425186; N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine
DMZ9V18	DT	Small molecular drug
DMZ9V18	PC	11349219
DMZ9V18	MW	274.23
DMZ9V18	FM	C12H10N4O4
DMZ9V18	IC	InChI=1S/C12H10N4O4/c13-12(14)15-11(17)10-6-5-9(20-10)7-3-1-2-4-8(7)16(18)19/h1-6H,(H4,13,14,15,17)
DMZ9V18	CS	C1=CC=C(C(=C1)C2=CC=C(O2)C(=O)N=C(N)N)[N+](=O)[O-]
DMZ9V18	IK	KLPHIGVDYLBNDU-UHFFFAOYSA-N
DMZ9V18	IU	N-(diaminomethylidene)-5-(2-nitrophenyl)furan-2-carboxamide
DMZ9V18	DE	Discovery agent

DMSI4PE	ID	DMSI4PE
DMSI4PE	DN	N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMSI4PE	HS	Investigative
DMSI4PE	SN	CHEMBL451538; N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMSI4PE	DT	Small molecular drug
DMSI4PE	PC	25154731
DMSI4PE	MW	240.3
DMSI4PE	FM	C4H8N4O2S3
DMSI4PE	IC	InChI=1S/C4H8N4O2S3/c1-2-11-4-7-6-3(12-4)8-13(5,9)10/h2H2,1H3,(H,6,8)(H2,5,9,10)
DMSI4PE	CS	CCSC1=NN=C(S1)NS(=O)(=O)N
DMSI4PE	IK	CHUOTDNKSODBJL-UHFFFAOYSA-N
DMSI4PE	IU	2-ethylsulfanyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DMSI4PE	DE	Discovery agent

DMH7QOF	ID	DMH7QOF
DMH7QOF	DN	N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide
DMH7QOF	HS	Investigative
DMH7QOF	SN	CHEMBL337584; N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide; TWZ-109
DMH7QOF	DT	Small molecular drug
DMH7QOF	PC	44359538
DMH7QOF	MW	250.29
DMH7QOF	FM	C13H18N2O3
DMH7QOF	IC	InChI=1S/C13H18N2O3/c16-11-15(18)10-6-2-5-9-14-13(17)12-7-3-1-4-8-12/h1,3-4,7-8,11,18H,2,5-6,9-10H2,(H,14,17)
DMH7QOF	CS	C1=CC=C(C=C1)C(=O)NCCCCCN(C=O)O
DMH7QOF	IK	XZVIJIAWKVHBTR-UHFFFAOYSA-N
DMH7QOF	IU	N-[5-[formyl(hydroxy)amino]pentyl]benzamide
DMH7QOF	DE	Discovery agent

DMXLJGR	ID	DMXLJGR
DMXLJGR	DN	N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMXLJGR	HS	Investigative
DMXLJGR	SN	CHEMBL459356; N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMXLJGR	DT	Small molecular drug
DMXLJGR	PC	44571848
DMXLJGR	MW	226.3
DMXLJGR	FM	C3H6N4O2S3
DMXLJGR	IC	InChI=1S/C3H6N4O2S3/c1-10-3-6-5-2(11-3)7-12(4,8)9/h1H3,(H,5,7)(H2,4,8,9)
DMXLJGR	CS	CSC1=NN=C(S1)NS(=O)(=O)N
DMXLJGR	IK	AJEMPSSJQSOJKR-UHFFFAOYSA-N
DMXLJGR	IU	2-methylsulfanyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DMXLJGR	DE	Discovery agent

DMVY7RX	ID	DMVY7RX
DMVY7RX	DN	N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX)
DMVY7RX	HS	Investigative
DMVY7RX	SN	CHEMBL1097456; N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX); SCHEMBL1404641; BDBM50316519
DMVY7RX	DT	Small molecular drug
DMVY7RX	PC	24996886
DMVY7RX	MW	573.8
DMVY7RX	FM	C26H22Cl3F3N2O3
DMVY7RX	IC	InChI=1S/C26H22Cl3F3N2O3/c1-25(2)12-20(33-22(36)11-21(35)26(30,31)32)18-10-17(13-3-5-14(27)6-4-13)23(34-24(18)37-25)16-8-7-15(28)9-19(16)29/h3-10,20-21,35H,11-12H2,1-2H3,(H,33,36)
DMVY7RX	CS	CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)NC(=O)CC(C(F)(F)F)O)C
DMVY7RX	IK	ONIULYGRFWGEHO-UHFFFAOYSA-N
DMVY7RX	IU	N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-4,4,4-trifluoro-3-hydroxybutanamide
DMVY7RX	DE	Discovery agent

DM6EICU	ID	DM6EICU
DM6EICU	DN	N-[O-Phosphono-Pyridoxyl]-Isoleucine
DM6EICU	HS	Investigative
DM6EICU	SN	ILP; AC1L9K3U; (3S)-2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]-3-methylpentanoic acid
DM6EICU	DT	Small molecular drug
DM6EICU	PC	46936443
DM6EICU	MW	362.32
DM6EICU	FM	C14H23N2O7P
DM6EICU	IC	InChI=1S/C14H23N2O7P/c1-4-8(2)12(14(18)19)16-6-11-10(7-23-24(20,21)22)5-15-9(3)13(11)17/h5,8,12,16-17H,4,6-7H2,1-3H3,(H,18,19)(H2,20,21,22)/t8-,12+/m1/s1
DM6EICU	CS	CC[C@@H](C)[C@@H](C(=O)O)NCC1=C(C(=NC=C1COP(=O)(O)O)C)O
DM6EICU	IK	GZZDWFDWHXPWJK-PELKAZGASA-N
DM6EICU	IU	(2S,3R)-2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]-3-methylpentanoic acid
DM6EICU	DE	Discovery agent

DMN493F	ID	DMN493F
DMN493F	DN	N-[Tosyl-D-Prolinyl]Amino-Ethanethiol
DMN493F	HS	Investigative
DMN493F	SN	N-[TOSYL-D-PROLINYL]AMINO-ETHANETHIOL; TP2; AC1L9I3U; SCHEMBL4308892; DB03818; 1-[(4-methylphenyl)sulfonyl]-N-(2-sulfanylethyl)-D-prolinamide
DMN493F	DT	Small molecular drug
DMN493F	PC	445503
DMN493F	MW	328.5
DMN493F	FM	C14H20N2O3S2
DMN493F	IC	InChI=1S/C14H20N2O3S2/c1-11-4-6-12(7-5-11)21(18,19)16-9-2-3-13(16)14(17)15-8-10-20/h4-7,13,20H,2-3,8-10H2,1H3,(H,15,17)/t13-/m1/s1
DMN493F	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@@H]2C(=O)NCCS
DMN493F	IK	NWUYDTGYTUQMDG-CYBMUJFWSA-N
DMN493F	IU	(2R)-1-(4-methylphenyl)sulfonyl-N-(2-sulfanylethyl)pyrrolidine-2-carboxamide
DMN493F	DE	Discovery agent

DMX4QKU	ID	DMX4QKU
DMX4QKU	DN	N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE
DMX4QKU	HS	Investigative
DMX4QKU	SN	41472-49-5; N-(4-Sulfamoylphenethyl)acetamide; N-[2-(4-sulfamoylphenyl)ethyl]acetamide; N-{2-[4-(Aminosulfonyl)phenyl]ethyl}acetamide; N-(2-(4-(Aminosulphonyl)phenyl)ethyl)acetamide; N-Acetyl-4-(2-aminoethyl)benzenesulfonamide; 2nns; 2nmx; EINECS 255-386-5; 4-(2-Acetylaminoethyl)benzenesulfonamide; AC1LF2Y7; Oprea1_087799; CBDivE_010614; SCHEMBL9016571; DTXSID10194368; MolPort-000-563-758; IIMGUEXQORZTID-UHFFFAOYSA-N; ZINC188952; HMS3604G22; HMS1786I07; DK-42; p-(2-acetamidoethyl)benzenesulfonamide; AKOS000987732
DMX4QKU	DT	Small molecular drug
DMX4QKU	PC	745994
DMX4QKU	MW	242.3
DMX4QKU	FM	C10H14N2O3S
DMX4QKU	IC	InChI=1S/C10H14N2O3S/c1-8(13)12-7-6-9-2-4-10(5-3-9)16(11,14)15/h2-5H,6-7H2,1H3,(H,12,13)(H2,11,14,15)
DMX4QKU	CS	CC(=O)NCCC1=CC=C(C=C1)S(=O)(=O)N
DMX4QKU	IK	IIMGUEXQORZTID-UHFFFAOYSA-N
DMX4QKU	IU	N-[2-(4-sulfamoylphenyl)ethyl]acetamide
DMX4QKU	CA	CAS 41472-49-5
DMX4QKU	DE	Discovery agent

DM74KHG	ID	DM74KHG
DM74KHG	DN	N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide
DM74KHG	HS	Investigative
DM74KHG	SN	CHEMBL222111; N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide; SCHEMBL1339724
DM74KHG	DT	Small molecular drug
DM74KHG	PC	11270007
DM74KHG	MW	416.5
DM74KHG	FM	C24H20N2O3S
DM74KHG	IC	InChI=1S/C24H20N2O3S/c27-24(19-11-5-2-6-12-19)26-22-15-16-23(21-14-8-7-13-20(21)22)30(28,29)25-17-18-9-3-1-4-10-18/h1-16,25H,17H2,(H,26,27)
DM74KHG	CS	C1=CC=C(C=C1)CNS(=O)(=O)C2=CC=C(C3=CC=CC=C32)NC(=O)C4=CC=CC=C4
DM74KHG	IK	QPJKMKVTEJYYGG-UHFFFAOYSA-N
DM74KHG	IU	N-[4-(benzylsulfamoyl)naphthalen-1-yl]benzamide
DM74KHG	DE	Discovery agent

DM90U5P	ID	DM90U5P
DM90U5P	DN	N-{4'-[(trifluoromethyl)sulfonyl]-4-biphenyl}urea
DM90U5P	HS	Investigative
DM90U5P	SN	CHEMBL389588; SCHEMBL5434550; BDBM50220177
DM90U5P	DT	Small molecular drug
DM90U5P	PC	11695867
DM90U5P	MW	344.31
DM90U5P	FM	C14H11F3N2O3S
DM90U5P	IC	InChI=1S/C14H11F3N2O3S/c15-14(16,17)23(21,22)12-7-3-10(4-8-12)9-1-5-11(6-2-9)19-13(18)20/h1-8H,(H3,18,19,20)
DM90U5P	CS	C1=CC(=CC=C1C2=CC=C(C=C2)S(=O)(=O)C(F)(F)F)NC(=O)N
DM90U5P	IK	ISQOEHFLTNIEGX-UHFFFAOYSA-N
DM90U5P	IU	[4-[4-(trifluoromethylsulfonyl)phenyl]phenyl]urea
DM90U5P	DE	Discovery agent

DMEIB69	ID	DMEIB69
DMEIB69	DN	N-{4'-[(trifluoromethyl)thio]-4-biphenyl}urea
DMEIB69	HS	Investigative
DMEIB69	SN	CHEMBL244511; SCHEMBL5434921; BDBM50220203
DMEIB69	DT	Small molecular drug
DMEIB69	PC	11695302
DMEIB69	MW	312.31
DMEIB69	FM	C14H11F3N2OS
DMEIB69	IC	InChI=1S/C14H11F3N2OS/c15-14(16,17)21-12-7-3-10(4-8-12)9-1-5-11(6-2-9)19-13(18)20/h1-8H,(H3,18,19,20)
DMEIB69	CS	C1=CC(=CC=C1C2=CC=C(C=C2)SC(F)(F)F)NC(=O)N
DMEIB69	IK	FHOBREWUJUOKGZ-UHFFFAOYSA-N
DMEIB69	IU	[4-[4-(trifluoromethylsulfanyl)phenyl]phenyl]urea
DMEIB69	DE	Discovery agent

DMO3VLJ	ID	DMO3VLJ
DMO3VLJ	DN	N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMO3VLJ	HS	Investigative
DMO3VLJ	SN	CHEMBL574107; N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMO3VLJ	DT	Small molecular drug
DMO3VLJ	PC	45481863
DMO3VLJ	MW	343.4
DMO3VLJ	FM	C22H17NO3
DMO3VLJ	IC	InChI=1S/C22H17NO3/c24-18-5-3-4-16(14-18)9-8-15-10-12-17(13-11-15)23-21(25)19-6-1-2-7-20(19)22(23)26/h1-7,10-14,24H,8-9H2
DMO3VLJ	CS	C1=CC=C2C(=C1)C(=O)N(C2=O)C3=CC=C(C=C3)CCC4=CC(=CC=C4)O
DMO3VLJ	IK	TUMZBTITCWKZAT-UHFFFAOYSA-N
DMO3VLJ	IU	2-[4-[2-(3-hydroxyphenyl)ethyl]phenyl]isoindole-1,3-dione
DMO3VLJ	DE	Discovery agent

DMZ4N7Q	ID	DMZ4N7Q
DMZ4N7Q	DN	N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide
DMZ4N7Q	HS	Investigative
DMZ4N7Q	SN	CHEMBL572484; N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide
DMZ4N7Q	DT	Small molecular drug
DMZ4N7Q	PC	45481844
DMZ4N7Q	MW	357.4
DMZ4N7Q	FM	C23H19NO3
DMZ4N7Q	IC	InChI=1S/C23H19NO3/c1-27-19-6-4-5-17(15-19)10-9-16-11-13-18(14-12-16)24-22(25)20-7-2-3-8-21(20)23(24)26/h2-8,11-15H,9-10H2,1H3
DMZ4N7Q	CS	COC1=CC=CC(=C1)CCC2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C3=O
DMZ4N7Q	IK	CNZNMDJWLSHLJZ-UHFFFAOYSA-N
DMZ4N7Q	IU	2-[4-[2-(3-methoxyphenyl)ethyl]phenyl]isoindole-1,3-dione
DMZ4N7Q	DE	Discovery agent

DMXU5IS	ID	DMXU5IS
DMXU5IS	DN	N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMXU5IS	HS	Investigative
DMXU5IS	SN	CHEMBL575857; N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMXU5IS	DT	Small molecular drug
DMXU5IS	PC	45481821
DMXU5IS	MW	343.4
DMXU5IS	FM	C22H17NO3
DMXU5IS	IC	InChI=1S/C22H17NO3/c24-18-13-9-16(10-14-18)6-5-15-7-11-17(12-8-15)23-21(25)19-3-1-2-4-20(19)22(23)26/h1-4,7-14,24H,5-6H2
DMXU5IS	CS	C1=CC=C2C(=C1)C(=O)N(C2=O)C3=CC=C(C=C3)CCC4=CC=C(C=C4)O
DMXU5IS	IK	OFQPQJJVXCUPFR-UHFFFAOYSA-N
DMXU5IS	IU	2-[4-[2-(4-hydroxyphenyl)ethyl]phenyl]isoindole-1,3-dione
DMXU5IS	DE	Discovery agent

DM0S71O	ID	DM0S71O
DM0S71O	DN	N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide
DM0S71O	HS	Investigative
DM0S71O	SN	CHEMBL575856; N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide; BDBM50298668
DM0S71O	DT	Small molecular drug
DM0S71O	PC	44537911
DM0S71O	MW	357.4
DM0S71O	FM	C23H19NO3
DM0S71O	IC	InChI=1S/C23H19NO3/c1-27-19-14-10-17(11-15-19)7-6-16-8-12-18(13-9-16)24-22(25)20-4-2-3-5-21(20)23(24)26/h2-5,8-15H,6-7H2,1H3
DM0S71O	CS	COC1=CC=C(C=C1)CCC2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C3=O
DM0S71O	IK	CRWGIKAUSJNKIC-UHFFFAOYSA-N
DM0S71O	IU	2-[4-[2-(4-methoxyphenyl)ethyl]phenyl]isoindole-1,3-dione
DM0S71O	DE	Discovery agent

DML35GB	ID	DML35GB
DML35GB	DN	N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE
DML35GB	HS	Investigative
DML35GB	SN	N~3~-(3-Pyridin-3-Ylbenzyl)pyridine-2,3-Diamine; 2ohr; SCHEMBL8264924; CHEMBL220346; BDBM15782; 3-Substituted 2-Aminopyridine 6a; ZINC10339547; DB07284; 3-N-{[3-(pyridin-3-yl)phenyl]methyl}pyridine-2,3-diamine
DML35GB	DT	Small molecular drug
DML35GB	PC	11701820
DML35GB	MW	276.34
DML35GB	FM	C17H16N4
DML35GB	IC	InChI=1S/C17H16N4/c18-17-16(7-3-9-20-17)21-11-13-4-1-5-14(10-13)15-6-2-8-19-12-15/h1-10,12,21H,11H2,(H2,18,20)
DML35GB	CS	C1=CC(=CC(=C1)C2=CN=CC=C2)CNC3=C(N=CC=C3)N
DML35GB	IK	NQSBHBFOOVYRNM-UHFFFAOYSA-N
DML35GB	IU	3-N-[(3-pyridin-3-ylphenyl)methyl]pyridine-2,3-diamine
DML35GB	DE	Discovery agent

DMOCQ9I	ID	DMOCQ9I
DMOCQ9I	DN	N~3~-BENZYLPYRIDINE-2,3-DIAMINE
DMOCQ9I	HS	Investigative
DMOCQ9I	SN	N3-benzylpyridine-2,3-diamine; 79707-12-3; N~3~-Benzylpyridine-2,3-Diamine; N3-BENZYL-PYRIDINE-2,3-DIAMINE; 2-amino-3-benzylaminopyridine; 3-N-benzylpyridine-2,3-diamine; N~3~-Benzyl-2,3-pyridinediamine; aminopyridine 3; N'-benzylpyridine-2,3-diamine; 2ohm; 2,3-Pyridinediamine, N3-(phenylmethyl)-; CHEMBL435747; SCHEMBL11069733; CTK5E7044; BDBM15781; DTXSID40439234; 3-Substituted 2-Aminopyridine 5; MUKAGFLFIMVSQN-UHFFFAOYSA-N; MolPort-008-154-365; ALBB-013372; ZINC10339550; 9869AE; AKOS005174206; MCULE-5416742943; DB07281
DMOCQ9I	DT	Small molecular drug
DMOCQ9I	PC	10397869
DMOCQ9I	MW	199.25
DMOCQ9I	FM	C12H13N3
DMOCQ9I	IC	InChI=1S/C12H13N3/c13-12-11(7-4-8-14-12)15-9-10-5-2-1-3-6-10/h1-8,15H,9H2,(H2,13,14)
DMOCQ9I	CS	C1=CC=C(C=C1)CNC2=C(N=CC=C2)N
DMOCQ9I	IK	MUKAGFLFIMVSQN-UHFFFAOYSA-N
DMOCQ9I	IU	3-N-benzylpyridine-2,3-diamine
DMOCQ9I	CA	CAS 79707-12-3
DMOCQ9I	DE	Discovery agent

DM6HM5S	ID	DM6HM5S
DM6HM5S	DN	N1-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S	HS	Investigative
DM6HM5S	SN	DIETHYLENETRIAMINE; 111-40-0; Bis(2-aminoethyl)amine; 2,2'-Diaminodiethylamine; Diethylene triamine; Barsamide 115; Epicure T; Ancamine DETA; 1,4,7-Triazaheptane; 2,2'-Iminodiethylamine; N,N-Bis(2-aminoethyl)amine; Aminoethylethandiamine; 3-Azapentane-1,5-diamine; 1,2-Ethanediamine, N-(2-aminoethyl)-; Imino-bis-ethylamine; ChS-P 1; N-(2-Aminoethyl)-1,2-ethanediamine; N-(2-aminoethyl)ethane-1,2-diamine; 1,5-Diamino-3-azapentane; 2,2'-Iminobis(ethanamine); Bis(beta-aminoethyl)amine; 2-(2-Aminoethylamino)ethylamine; Epon 3223
DM6HM5S	DT	Small molecular drug
DM6HM5S	PC	8111
DM6HM5S	MW	103.17
DM6HM5S	FM	C4H13N3
DM6HM5S	IC	InChI=1S/C4H13N3/c5-1-3-7-4-2-6/h7H,1-6H2
DM6HM5S	CS	C(CNCCN)N
DM6HM5S	IK	RPNUMPOLZDHAAY-UHFFFAOYSA-N
DM6HM5S	IU	N'-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S	CA	CAS 111-40-0
DM6HM5S	CB	CHEBI:30629
DM6HM5S	DE	Discovery agent

DM5F04D	ID	DM5F04D
DM5F04D	DN	N1-(3,3-diphenylpropyl)-N3-hydroxymalonamide
DM5F04D	HS	Investigative
DM5F04D	SN	CHEMBL219785
DM5F04D	DT	Small molecular drug
DM5F04D	PC	44420656
DM5F04D	MW	312.4
DM5F04D	FM	C18H20N2O3
DM5F04D	IC	InChI=1S/C18H20N2O3/c21-17(13-18(22)20-23)19-12-11-16(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-10,16,23H,11-13H2,(H,19,21)(H,20,22)
DM5F04D	CS	C1=CC=C(C=C1)C(CCNC(=O)CC(=O)NO)C2=CC=CC=C2
DM5F04D	IK	UYRUQIFSLBHLGY-UHFFFAOYSA-N
DM5F04D	IU	N-(3,3-diphenylpropyl)-N'-hydroxypropanediamide
DM5F04D	DE	Discovery agent

DMSRHJA	ID	DMSRHJA
DMSRHJA	DN	N1-(3-phenoxybenzyl)-N3-hydroxymalonamide
DMSRHJA	HS	Investigative
DMSRHJA	SN	CHEMBL220392
DMSRHJA	DT	Small molecular drug
DMSRHJA	PC	16116575
DMSRHJA	MW	300.31
DMSRHJA	FM	C16H16N2O4
DMSRHJA	IC	InChI=1S/C16H16N2O4/c19-15(10-16(20)18-21)17-11-12-5-4-8-14(9-12)22-13-6-2-1-3-7-13/h1-9,21H,10-11H2,(H,17,19)(H,18,20)
DMSRHJA	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)CNC(=O)CC(=O)NO
DMSRHJA	IK	AKGLDBDNAJLOMB-UHFFFAOYSA-N
DMSRHJA	IU	N'-hydroxy-N-[(3-phenoxyphenyl)methyl]propanediamide
DMSRHJA	DE	Discovery agent

DMCH7GO	ID	DMCH7GO
DMCH7GO	DN	N1-(4-bromophenyl)-N2,N2-dipentylphthalamide
DMCH7GO	HS	Investigative
DMCH7GO	SN	CHEMBL523749; N'-(4-bromophenyl)-N,N-dipentylbenzene-1,2-dicarboxamide; AC1MDHAQ; N1-(4-bromophenyl)-N2,N2-dipentylphthalamide; MolPort-002-139-379; ZINC9510931; BDBM50265685; STK055903; AKOS005386817; MCULE-4023922974
DMCH7GO	DT	Small molecular drug
DMCH7GO	PC	2836828
DMCH7GO	MW	459.4
DMCH7GO	FM	C24H31BrN2O2
DMCH7GO	IC	InChI=1S/C24H31BrN2O2/c1-3-5-9-17-27(18-10-6-4-2)24(29)22-12-8-7-11-21(22)23(28)26-20-15-13-19(25)14-16-20/h7-8,11-16H,3-6,9-10,17-18H2,1-2H3,(H,26,28)
DMCH7GO	CS	CCCCCN(CCCCC)C(=O)C1=CC=CC=C1C(=O)NC2=CC=C(C=C2)Br
DMCH7GO	IK	OITHNNNIGWHOAY-UHFFFAOYSA-N
DMCH7GO	IU	1-N-(4-bromophenyl)-2-N,2-N-dipentylbenzene-1,2-dicarboxamide
DMCH7GO	DE	Discovery agent

DMJ025O	ID	DMJ025O
DMJ025O	DN	N1-(4-chlorobenzyl)-2-amino-N3-hydroxymalonamide
DMJ025O	HS	Investigative
DMJ025O	SN	CHEMBL385996
DMJ025O	DT	Small molecular drug
DMJ025O	PC	16115629
DMJ025O	MW	257.67
DMJ025O	FM	C10H12ClN3O3
DMJ025O	IC	InChI=1S/C10H12ClN3O3/c11-7-3-1-6(2-4-7)5-13-9(15)8(12)10(16)14-17/h1-4,8,17H,5,12H2,(H,13,15)(H,14,16)
DMJ025O	CS	C1=CC(=CC=C1CNC(=O)C(C(=O)NO)N)Cl
DMJ025O	IK	OGTJYIPAKYEFNR-UHFFFAOYSA-N
DMJ025O	IU	2-amino-N-[(4-chlorophenyl)methyl]-N'-hydroxypropanediamide
DMJ025O	DE	Discovery agent

DMTMDZ4	ID	DMTMDZ4
DMTMDZ4	DN	N1-(4-chlorobenzyl)-2-benzyl-N3-hydroxymalonamide
DMTMDZ4	HS	Investigative
DMTMDZ4	SN	CHEMBL374577; N1-(4-chlorobenzyl)-2-benzyl-N3-hydroxymalonamide; BDBM50206546
DMTMDZ4	DT	Small molecular drug
DMTMDZ4	PC	16114883
DMTMDZ4	MW	332.8
DMTMDZ4	FM	C17H17ClN2O3
DMTMDZ4	IC	InChI=1S/C17H17ClN2O3/c18-14-8-6-13(7-9-14)11-19-16(21)15(17(22)20-23)10-12-4-2-1-3-5-12/h1-9,15,23H,10-11H2,(H,19,21)(H,20,22)
DMTMDZ4	CS	C1=CC=C(C=C1)CC(C(=O)NCC2=CC=C(C=C2)Cl)C(=O)NO
DMTMDZ4	IK	MDFALTKCDXYVEX-UHFFFAOYSA-N
DMTMDZ4	IU	2-benzyl-N-[(4-chlorophenyl)methyl]-N'-hydroxypropanediamide
DMTMDZ4	DE	Discovery agent

DMS1P85	ID	DMS1P85
DMS1P85	DN	N1-(4-fluorobenzyl)-2-benzyl-N3-hydroxymalonamide
DMS1P85	HS	Investigative
DMS1P85	SN	CHEMBL219618; N1-(4-fluorobenzyl)-2-benzyl-N3-hydroxymalonamide; BDBM50206556
DMS1P85	DT	Small molecular drug
DMS1P85	PC	16114884
DMS1P85	MW	316.33
DMS1P85	FM	C17H17FN2O3
DMS1P85	IC	InChI=1S/C17H17FN2O3/c18-14-8-6-13(7-9-14)11-19-16(21)15(17(22)20-23)10-12-4-2-1-3-5-12/h1-9,15,23H,10-11H2,(H,19,21)(H,20,22)
DMS1P85	CS	C1=CC=C(C=C1)CC(C(=O)NCC2=CC=C(C=C2)F)C(=O)NO
DMS1P85	IK	HPODXRZHNDBMJC-UHFFFAOYSA-N
DMS1P85	IU	2-benzyl-N-[(4-fluorophenyl)methyl]-N'-hydroxypropanediamide
DMS1P85	DE	Discovery agent

DMMQXON	ID	DMMQXON
DMMQXON	DN	N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide
DMMQXON	HS	Investigative
DMMQXON	SN	CHEMBL473270; N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide
DMMQXON	DT	Small molecular drug
DMMQXON	PC	44591267
DMMQXON	MW	340.4
DMMQXON	FM	C20H24N2O3
DMMQXON	IC	InChI=1S/C20H24N2O3/c23-19(13-6-1-2-7-14-20(24)22-25)21-18-12-8-11-17(15-18)16-9-4-3-5-10-16/h3-5,8-12,15,25H,1-2,6-7,13-14H2,(H,21,23)(H,22,24)
DMMQXON	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)CCCCCCC(=O)NO
DMMQXON	IK	RDYLEVRHTUDZCQ-UHFFFAOYSA-N
DMMQXON	IU	N'-hydroxy-N-(3-phenylphenyl)octanediamide
DMMQXON	DE	Discovery agent

DMZA8NC	ID	DMZA8NC
DMZA8NC	DN	N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide
DMZA8NC	HS	Investigative
DMZA8NC	SN	CHEMBL512644; N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide; SCHEMBL8226957
DMZA8NC	DT	Small molecular drug
DMZA8NC	PC	25032059
DMZA8NC	MW	340.4
DMZA8NC	FM	C20H24N2O3
DMZA8NC	IC	InChI=1S/C20H24N2O3/c23-19(10-6-1-2-7-11-20(24)22-25)21-18-14-12-17(13-15-18)16-8-4-3-5-9-16/h3-5,8-9,12-15,25H,1-2,6-7,10-11H2,(H,21,23)(H,22,24)
DMZA8NC	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)CCCCCCC(=O)NO
DMZA8NC	IK	MIYLHRAVWYBTPV-UHFFFAOYSA-N
DMZA8NC	IU	N'-hydroxy-N-(4-phenylphenyl)octanediamide
DMZA8NC	DE	Discovery agent

DMYGCSV	ID	DMYGCSV
DMYGCSV	DN	N1-(naphthalen-1-yl)ethane-1,2-diamine
DMYGCSV	HS	Investigative
DMYGCSV	SN	N-(1-Naphthyl)ethylenediamine; 551-09-7; N1-(naphthalen-1-yl)ethane-1,2-diamine; N-(1-naphthyl)ethane-1,2-diamine; 1,2-Ethanediamine, N-1-naphthalenyl-; UNII-02X37521XE; CHEMBL1214195; CHEBI:53510; NULAJYZBOLVQPQ-UHFFFAOYSA-N; N-naphthalen-1-ylethane-1,2-diamine; 02X37521XE; 1,2-Ethanediamine, N1-1-naphthalenyl-; N-(naphthalen-1-yl)ethane-1,2-diamine; NCGC00163705-03; N-1-naphthylethylenediamine; Oprea1_329986; EINECS 208-992-9; (2-aminoethyl)naphthylamine; N-1-naphthylethylene diamine; SCHEMBL233681
DMYGCSV	DT	Small molecular drug
DMYGCSV	PC	15107
DMYGCSV	MW	186.25
DMYGCSV	FM	C12H14N2
DMYGCSV	IC	InChI=1S/C12H14N2/c13-8-9-14-12-7-3-5-10-4-1-2-6-11(10)12/h1-7,14H,8-9,13H2
DMYGCSV	CS	C1=CC=C2C(=C1)C=CC=C2NCCN
DMYGCSV	IK	NULAJYZBOLVQPQ-UHFFFAOYSA-N
DMYGCSV	IU	N'-naphthalen-1-ylethane-1,2-diamine
DMYGCSV	CA	CAS 551-09-7
DMYGCSV	CB	CHEBI:53510
DMYGCSV	DE	Discovery agent

DMM59IS	ID	DMM59IS
DMM59IS	DN	N1,2-dibenzyl-N3-hydroxymalonamide
DMM59IS	HS	Investigative
DMM59IS	SN	CHEMBL113827; N1,2-dibenzyl-N3-hydroxymalonamide; 2N-dibenzyl-N''-hydroxy-malonamide; BDBM50062474
DMM59IS	DT	Small molecular drug
DMM59IS	PC	10709191
DMM59IS	MW	298.34
DMM59IS	FM	C17H18N2O3
DMM59IS	IC	InChI=1S/C17H18N2O3/c20-16(18-12-14-9-5-2-6-10-14)15(17(21)19-22)11-13-7-3-1-4-8-13/h1-10,15,22H,11-12H2,(H,18,20)(H,19,21)
DMM59IS	CS	C1=CC=C(C=C1)CC(C(=O)NCC2=CC=CC=C2)C(=O)NO
DMM59IS	IK	WKIMWNKNDQXNCK-UHFFFAOYSA-N
DMM59IS	IU	N,2-dibenzyl-N'-hydroxypropanediamide
DMM59IS	DE	Discovery agent

DM1L89K	ID	DM1L89K
DM1L89K	DN	N1,2-dibenzyl-N3-hydroxy-N1-phenethylmalonamide
DM1L89K	HS	Investigative
DM1L89K	SN	CHEMBL426572
DM1L89K	DT	Small molecular drug
DM1L89K	PC	16114768
DM1L89K	MW	402.5
DM1L89K	FM	C25H26N2O3
DM1L89K	IC	InChI=1S/C25H26N2O3/c28-24(26-30)23(18-21-12-6-2-7-13-21)25(29)27(19-22-14-8-3-9-15-22)17-16-20-10-4-1-5-11-20/h1-15,23,30H,16-19H2,(H,26,28)
DM1L89K	CS	C1=CC=C(C=C1)CCN(CC2=CC=CC=C2)C(=O)C(CC3=CC=CC=C3)C(=O)NO
DM1L89K	IK	PQZSZTWFWIQBGX-UHFFFAOYSA-N
DM1L89K	IU	N,2-dibenzyl-N'-hydroxy-N-(2-phenylethyl)propanediamide
DM1L89K	DE	Discovery agent

DMJ10WH	ID	DMJ10WH
DMJ10WH	DN	N-1,3,4-thiadiazol-2-ylsulfamide
DMJ10WH	HS	Investigative
DMJ10WH	SN	CHEMBL449527; N-1,3,4-thiadiazol-2-ylsulfamide
DMJ10WH	DT	Small molecular drug
DMJ10WH	PC	25154729
DMJ10WH	MW	180.21
DMJ10WH	FM	C2H4N4O2S2
DMJ10WH	IC	InChI=1S/C2H4N4O2S2/c3-10(7,8)6-2-5-4-1-9-2/h1H,(H,5,6)(H2,3,7,8)
DMJ10WH	CS	C1=NN=C(S1)NS(=O)(=O)N
DMJ10WH	IK	TXIIDPYBTNXTDC-UHFFFAOYSA-N
DMJ10WH	IU	2-(sulfamoylamino)-1,3,4-thiadiazole
DMJ10WH	DE	Discovery agent

DMVIGCJ	ID	DMVIGCJ
DMVIGCJ	DN	N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
DMVIGCJ	HS	Investigative
DMVIGCJ	SN	N-butyl-S-methyl-isothiourea; NTU; 100319-25-3; AC1L9JBU; SCHEMBL11844558; methyl N'-butylcarbamimidothioate
DMVIGCJ	DT	Small molecular drug
DMVIGCJ	PC	11740154
DMVIGCJ	MW	374.7
DMVIGCJ	FM	C18H38N4S2
DMVIGCJ	IC	InChI=1S/C18H38N4S2/c1-23-17(19)21-15-13-11-9-7-5-3-4-6-8-10-12-14-16-22-18(20)24-2/h3-16H2,1-2H3,(H2,19,21)(H2,20,22)
DMVIGCJ	CS	CSC(=NCCCCCCCCCCCCCCN=C(N)SC)N
DMVIGCJ	IK	IOKDMHHZKWLWKO-UHFFFAOYSA-N
DMVIGCJ	IU	methyl N'-[14-[[amino(methylsulfanyl)methylidene]amino]tetradecyl]carbamimidothioate
DMVIGCJ	DE	Discovery agent

DMSDVGQ	ID	DMSDVGQ
DMSDVGQ	DN	N1,N2-bis(dihydrocaffeoyl)spermine
DMSDVGQ	HS	Investigative
DMSDVGQ	SN	Kukoamine A; 75288-96-9; CHEMBL79129; CHEBI:81220; N1,N2-bis(dihydrocaffeoyl)spermine; AC1NSXD9; SCHEMBL16547596; 1,14-Bis(dihydrocaffeoyl)spermine; BDBM50240622; ZINC13513540; AKOS032945995; FT-0686649; C17615; 3-(3,4-dihydroxyphenyl)-N-[3-[4-[3-[3-(3,4-dihydroxyphenyl)propanoylamino]propylamino]butylamino]propyl]propanamide; 3-(3,4-Dihydroxy-phenyl)-N-[3-(4-{3-[3-(3,4-dihydroxy-phenyl)-propionylamino]-propylamino}-butylamino)-propyl]-propionamide
DMSDVGQ	DT	Small molecular drug
DMSDVGQ	PC	5318865
DMSDVGQ	MW	530.7
DMSDVGQ	FM	C28H42N4O6
DMSDVGQ	IC	InChI=1S/C28H42N4O6/c33-23-9-5-21(19-25(23)35)7-11-27(37)31-17-3-15-29-13-1-2-14-30-16-4-18-32-28(38)12-8-22-6-10-24(34)26(36)20-22/h5-6,9-10,19-20,29-30,33-36H,1-4,7-8,11-18H2,(H,31,37)(H,32,38)
DMSDVGQ	CS	C1=CC(=C(C=C1CCC(=O)NCCCNCCCCNCCCNC(=O)CCC2=CC(=C(C=C2)O)O)O)O
DMSDVGQ	IK	IOLDDENZPBFBHV-UHFFFAOYSA-N
DMSDVGQ	IU	3-(3,4-dihydroxyphenyl)-N-[3-[4-[3-[3-(3,4-dihydroxyphenyl)propanoylamino]propylamino]butylamino]propyl]propanamide
DMSDVGQ	CA	CAS 75288-96-9
DMSDVGQ	CB	CHEBI:81220
DMSDVGQ	DE	Discovery agent

DMA5Z7P	ID	DMA5Z7P
DMA5Z7P	DN	N1,N3-bis(3-methoxybenzyl)isophthalamide
DMA5Z7P	HS	Investigative
DMA5Z7P	SN	CHEMBL605201; N1,N3-bis(3-methoxybenzyl)isophthalamide; SCHEMBL5332068
DMA5Z7P	DT	Small molecular drug
DMA5Z7P	PC	10111838
DMA5Z7P	MW	404.5
DMA5Z7P	FM	C24H24N2O4
DMA5Z7P	IC	InChI=1S/C24H24N2O4/c1-29-21-10-3-6-17(12-21)15-25-23(27)19-8-5-9-20(14-19)24(28)26-16-18-7-4-11-22(13-18)30-2/h3-14H,15-16H2,1-2H3,(H,25,27)(H,26,28)
DMA5Z7P	CS	COC1=CC=CC(=C1)CNC(=O)C2=CC(=CC=C2)C(=O)NCC3=CC(=CC=C3)OC
DMA5Z7P	IK	XDBOLPFDJWTESQ-UHFFFAOYSA-N
DMA5Z7P	IU	1-N,3-N-bis[(3-methoxyphenyl)methyl]benzene-1,3-dicarboxamide
DMA5Z7P	DE	Discovery agent

DMRO7JX	ID	DMRO7JX
DMRO7JX	DN	N1,N4-bis(5-chloro-2-methylphenyl)succinamide
DMRO7JX	HS	Investigative
DMRO7JX	SN	CHEMBL566931; N,N'-bis(5-chloro-2-methylphenyl)butanediamide; N1,N4-bis(5-chloro-2-methylphenyl)succinamide; AC1LK29V; Cambridge id 7313591; Oprea1_225764; MLS000535625; cid_1010578; MolPort-001-547-717; ZINC670958; HMS2360E14; STK435362; BDBM50303376; AKOS003303190; MCULE-2700246651; SMR000143061; ST50923735; N,N'-bis(5-chloro-2-methylphenyl)succinamide
DMRO7JX	DT	Small molecular drug
DMRO7JX	PC	1010578
DMRO7JX	MW	365.2
DMRO7JX	FM	C18H18Cl2N2O2
DMRO7JX	IC	InChI=1S/C18H18Cl2N2O2/c1-11-3-5-13(19)9-15(11)21-17(23)7-8-18(24)22-16-10-14(20)6-4-12(16)2/h3-6,9-10H,7-8H2,1-2H3,(H,21,23)(H,22,24)
DMRO7JX	CS	CC1=C(C=C(C=C1)Cl)NC(=O)CCC(=O)NC2=C(C=CC(=C2)Cl)C
DMRO7JX	IK	GNEGOXDKOUMPJX-UHFFFAOYSA-N
DMRO7JX	IU	N,N'-bis(5-chloro-2-methylphenyl)butanediamide
DMRO7JX	DE	Discovery agent

DM4Q86B	ID	DM4Q86B
DM4Q86B	DN	N1-[4-(Phenylmethoxy)phenyl]-D-aspartamine
DM4Q86B	HS	Investigative
DM4Q86B	SN	Amino acid analog, 4d; CHEMBL478360; BDBM24254; (3R)-3-amino-3-{[4-(benzyloxy)phenyl]carbamoyl}propanoic acid
DM4Q86B	DT	Small molecular drug
DM4Q86B	PC	24901602
DM4Q86B	MW	314.34
DM4Q86B	FM	C17H18N2O4
DM4Q86B	IC	InChI=1S/C17H18N2O4/c18-15(10-16(20)21)17(22)19-13-6-8-14(9-7-13)23-11-12-4-2-1-3-5-12/h1-9,15H,10-11,18H2,(H,19,22)(H,20,21)/t15-/m1/s1
DM4Q86B	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)[C@@H](CC(=O)O)N
DM4Q86B	IK	VTMSXGVEMJOFRJ-OAHLLOKOSA-N
DM4Q86B	IU	(3R)-3-amino-4-oxo-4-(4-phenylmethoxyanilino)butanoic acid
DM4Q86B	DE	Discovery agent

DMK10WX	ID	DMK10WX
DMK10WX	DN	N1-[4-(Phenylmethoxy)phenyl]-D-glutamine
DMK10WX	HS	Investigative
DMK10WX	SN	Amino acid analog, 4c; CHEMBL477478; BDBM24253; (4R)-4-amino-4-{[4-(benzyloxy)phenyl]carbamoyl}butanoic acid
DMK10WX	DT	Small molecular drug
DMK10WX	PC	24901601
DMK10WX	MW	328.4
DMK10WX	FM	C18H20N2O4
DMK10WX	IC	InChI=1S/C18H20N2O4/c19-16(10-11-17(21)22)18(23)20-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H,20,23)(H,21,22)/t16-/m1/s1
DMK10WX	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)[C@@H](CCC(=O)O)N
DMK10WX	IK	IYYBWKOXCQKLHX-MRXNPFEDSA-N
DMK10WX	IU	(4R)-4-amino-5-oxo-5-(4-phenylmethoxyanilino)pentanoic acid
DMK10WX	DE	Discovery agent

DMLEMUX	ID	DMLEMUX
DMLEMUX	DN	N1-[4-(Phenylmethoxy)phenyl]-L-aspartamine
DMLEMUX	HS	Investigative
DMLEMUX	SN	(3S)-3-amino-4-oxo-4-[(4-phenylmethoxyphenyl)amino]butanoic acid; Amino acid analog, 4b; CHEMBL477307; BDBM24252; N-[4-(benzyloxy)phenyl]-L-alpha-asparagine; (3S)-3-amino-3-{[4-(benzyloxy)phenyl]carbamoyl}propanoic acid
DMLEMUX	DT	Small molecular drug
DMLEMUX	PC	24768559
DMLEMUX	MW	314.34
DMLEMUX	FM	C17H18N2O4
DMLEMUX	IC	InChI=1S/C17H18N2O4/c18-15(10-16(20)21)17(22)19-13-6-8-14(9-7-13)23-11-12-4-2-1-3-5-12/h1-9,15H,10-11,18H2,(H,19,22)(H,20,21)/t15-/m0/s1
DMLEMUX	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)[C@H](CC(=O)O)N
DMLEMUX	IK	VTMSXGVEMJOFRJ-HNNXBMFYSA-N
DMLEMUX	IU	(3S)-3-amino-4-oxo-4-(4-phenylmethoxyanilino)butanoic acid
DMLEMUX	DE	Discovery agent

DM9XCZS	ID	DM9XCZS
DM9XCZS	DN	N1-[4-(Phenylmethoxy)phenyl]-L-glutamine
DM9XCZS	HS	Investigative
DM9XCZS	SN	Amino acid analog, 4a; CHEMBL478550; BDBM24251; (4S)-4-amino-4-{[4-(benzyloxy)phenyl]carbamoyl}butanoic acid
DM9XCZS	DT	Small molecular drug
DM9XCZS	PC	24901600
DM9XCZS	MW	328.4
DM9XCZS	FM	C18H20N2O4
DM9XCZS	IC	InChI=1S/C18H20N2O4/c19-16(10-11-17(21)22)18(23)20-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H,20,23)(H,21,22)/t16-/m0/s1
DM9XCZS	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)[C@H](CCC(=O)O)N
DM9XCZS	IK	IYYBWKOXCQKLHX-INIZCTEOSA-N
DM9XCZS	IU	(4S)-4-amino-5-oxo-5-(4-phenylmethoxyanilino)pentanoic acid
DM9XCZS	DE	Discovery agent

DMXSFWK	ID	DMXSFWK
DMXSFWK	DN	N1-benzyl-N3-hydroxy-2-isobutylmalonamide
DMXSFWK	HS	Investigative
DMXSFWK	SN	CHEMBL220253; N1-benzyl-N3-hydroxy-2-isobutylmalonamide; BDBM50197494
DMXSFWK	DT	Small molecular drug
DMXSFWK	PC	16116576
DMXSFWK	MW	264.32
DMXSFWK	FM	C14H20N2O3
DMXSFWK	IC	InChI=1S/C14H20N2O3/c1-10(2)8-12(14(18)16-19)13(17)15-9-11-6-4-3-5-7-11/h3-7,10,12,19H,8-9H2,1-2H3,(H,15,17)(H,16,18)
DMXSFWK	CS	CC(C)CC(C(=O)NCC1=CC=CC=C1)C(=O)NO
DMXSFWK	IK	BOQZRPQZGWWCDJ-UHFFFAOYSA-N
DMXSFWK	IU	N-benzyl-N'-hydroxy-2-(2-methylpropyl)propanediamide
DMXSFWK	DE	Discovery agent

DM76CLF	ID	DM76CLF
DM76CLF	DN	N1-dansyl-spermine
DM76CLF	HS	Investigative
DM76CLF	SN	N1-DnsSpm; N1-dansyl-spermine; dansyl spermine; N1-dansyl-spermidine; GTPL4260; SCHEMBL5361425; CHEMBL1184349; BDBM86164; DNS-343; 191410-24-9
DM76CLF	DT	Small molecular drug
DM76CLF	PC	9889212
DM76CLF	MW	435.6
DM76CLF	FM	C22H37N5O2S
DM76CLF	IC	InChI=1S/C22H37N5O2S/c1-27(2)21-11-5-10-20-19(21)9-6-12-22(20)30(28,29)26-18-8-17-25-15-4-3-14-24-16-7-13-23/h5-6,9-12,24-26H,3-4,7-8,13-18,23H2,1-2H3
DM76CLF	CS	CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCNCCCCNCCCN
DM76CLF	IK	NSUSGNAFCIMCDH-UHFFFAOYSA-N
DM76CLF	IU	N-[3-[4-(3-aminopropylamino)butylamino]propyl]-5-(dimethylamino)naphthalene-1-sulfonamide
DM76CLF	DE	Discovery agent

DMXE8CB	ID	DMXE8CB
DMXE8CB	DN	N1-guanyl-1,7-diaminoheptane
DMXE8CB	HS	Investigative
DMXE8CB	PC	90657844
DMXE8CB	MW	174.29
DMXE8CB	FM	C8H22N4+2
DMXE8CB	IC	InChI=1S/C8H20N4/c9-6-4-2-1-3-5-7-12-8(10)11/h1-7,9H2,(H4,10,11,12)/p+2
DMXE8CB	CS	C(CCC[NH3+])CCC[NH+]=C(N)N
DMXE8CB	IK	YAOAMZOGXBMLFQ-UHFFFAOYSA-P
DMXE8CB	IU	7-azaniumylheptyl(diaminomethylidene)azanium
DMXE8CB	DE	Discovery agent

DMF6RVS	ID	DMF6RVS
DMF6RVS	DN	N1-hydroxy-2-isobutyl-N3-phenethylmalonamide
DMF6RVS	HS	Investigative
DMF6RVS	SN	CHEMBL220010; N1-hydroxy-2-isobutyl-N3-phenethylmalonamide; BDBM50197502
DMF6RVS	DT	Small molecular drug
DMF6RVS	PC	16114635
DMF6RVS	MW	278.35
DMF6RVS	FM	C15H22N2O3
DMF6RVS	IC	InChI=1S/C15H22N2O3/c1-11(2)10-13(15(19)17-20)14(18)16-9-8-12-6-4-3-5-7-12/h3-7,11,13,20H,8-10H2,1-2H3,(H,16,18)(H,17,19)
DMF6RVS	CS	CC(C)CC(C(=O)NCCC1=CC=CC=C1)C(=O)NO
DMF6RVS	IK	WODYKKMWHBZSIB-UHFFFAOYSA-N
DMF6RVS	IU	N-hydroxy-2-(2-methylpropyl)-N'-(2-phenylethyl)propanediamide
DMF6RVS	DE	Discovery agent

DMOZARM	ID	DMOZARM
DMOZARM	DN	N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide
DMOZARM	HS	Investigative
DMOZARM	SN	CHEMBL511212; N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide; BDBM50258645
DMOZARM	DT	Small molecular drug
DMOZARM	PC	10383069
DMOZARM	MW	347.4
DMOZARM	FM	C17H21N3O3S
DMOZARM	IC	InChI=1S/C17H21N3O3S/c21-15(10-6-1-2-7-11-16(22)20-23)19-17-18-14(12-24-17)13-8-4-3-5-9-13/h3-5,8-9,12,23H,1-2,6-7,10-11H2,(H,20,22)(H,18,19,21)
DMOZARM	CS	C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)CCCCCCC(=O)NO
DMOZARM	IK	BDTAPZUZFJRPNM-UHFFFAOYSA-N
DMOZARM	IU	N'-hydroxy-N-(4-phenyl-1,3-thiazol-2-yl)octanediamide
DMOZARM	DE	Discovery agent

DM5LC3D	ID	DM5LC3D
DM5LC3D	DN	N-1-isopropyl-5-MeOT
DM5LC3D	HS	Investigative
DM5LC3D	SN	N-1-isopropyl-5-methoxytryptamine
DM5LC3D	DT	Small molecular drug
DM5LC3D	PC	24820144
DM5LC3D	MW	232.32
DM5LC3D	FM	C14H20N2O
DM5LC3D	IC	InChI=1S/C14H20N2O/c1-10(2)16-9-11(6-7-15)13-8-12(17-3)4-5-14(13)16/h4-5,8-10H,6-7,15H2,1-3H3
DM5LC3D	CS	CC(C)N1C=C(C2=C1C=CC(=C2)OC)CCN
DM5LC3D	IK	WFNIDMQOBQYSBC-UHFFFAOYSA-N
DM5LC3D	IU	2-(5-methoxy-1-propan-2-ylindol-3-yl)ethanamine
DM5LC3D	DE	Discovery agent

DM25NLH	ID	DM25NLH
DM25NLH	DN	N-1-isopropyltryptamine
DM25NLH	HS	Investigative
DM25NLH	SN	1-Isopropyltryptamine; 2-(1-propan-2-ylindol-3-yl)ethanamine; N-1-isopropyltryptamine; AC1NOM56; GTPL159; SCHEMBL7749047; BDBM84943; MolPort-001-788-641; ZINC4600317; SBB081239; STK075425; AKOS000276209; MCULE-5027387412; 40619-60-1; 2-[1-(methylethyl)indol-3-yl]ethylamine
DM25NLH	DT	Small molecular drug
DM25NLH	PC	5115445
DM25NLH	MW	202.3
DM25NLH	FM	C13H18N2
DM25NLH	IC	InChI=1S/C13H18N2/c1-10(2)15-9-11(7-8-14)12-5-3-4-6-13(12)15/h3-6,9-10H,7-8,14H2,1-2H3
DM25NLH	CS	CC(C)N1C=C(C2=CC=CC=C21)CCN
DM25NLH	IK	ARHHZLRATAUACE-UHFFFAOYSA-N
DM25NLH	IU	2-(1-propan-2-ylindol-3-yl)ethanamine
DM25NLH	DE	Discovery agent

DMGJEH9	ID	DMGJEH9
DMGJEH9	DN	N2-(3-trifluoromethylphenyl)guanine
DMGJEH9	HS	Investigative
DMGJEH9	DT	Small molecular drug
DMGJEH9	PC	135435057
DMGJEH9	MW	295.22
DMGJEH9	FM	C12H8F3N5O
DMGJEH9	IC	InChI=1S/C12H8F3N5O/c13-12(14,15)6-2-1-3-7(4-6)18-11-19-9-8(10(21)20-11)16-5-17-9/h1-5H,(H3,16,17,18,19,20,21)
DMGJEH9	CS	C1=CC(=CC(=C1)NC2=NC3=C(C(=O)N2)NC=N3)C(F)(F)F
DMGJEH9	IK	IOWPKEYIXBBDOQ-UHFFFAOYSA-N
DMGJEH9	IU	2-[3-(trifluoromethyl)anilino]-1,7-dihydropurin-6-one
DMGJEH9	CA	CAS 123994-68-3
DMGJEH9	DE	Discovery agent

DMOZ1IY	ID	DMOZ1IY
DMOZ1IY	DN	N2-[4-(benzyloxy)benzyl]glycinamide
DMOZ1IY	HS	Investigative
DMOZ1IY	SN	2-({[4-(benzyloxy)phenyl]methyl}amino)acetamide; CHEMBL348597; EN300-53966; 774506-05-7; N2-[4-(benzyloxy)benzyl]glycinamide; AC1Q4ZPD; SCHEMBL7391510; CTK7D3324; MolPort-004-292-381; ZINC21956233; BDBM50221278; AKOS000127788; MCULE-6620856689; NE46952; BBV-007676; 2-(4-Benzyloxy-benzylamino)-acetamide; 2-[[4-(Benzyloxy)benzyl]amino]acetamide
DMOZ1IY	DT	Small molecular drug
DMOZ1IY	PC	10588118
DMOZ1IY	MW	270.33
DMOZ1IY	FM	C16H18N2O2
DMOZ1IY	IC	InChI=1S/C16H18N2O2/c17-16(19)11-18-10-13-6-8-15(9-7-13)20-12-14-4-2-1-3-5-14/h1-9,18H,10-12H2,(H2,17,19)
DMOZ1IY	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)CNCC(=O)N
DMOZ1IY	IK	QPCKNQVICWJWJF-UHFFFAOYSA-N
DMOZ1IY	IU	2-[(4-phenylmethoxyphenyl)methylamino]acetamide
DMOZ1IY	DE	Discovery agent

DMHJ2IP	ID	DMHJ2IP
DMHJ2IP	DN	N2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide
DMHJ2IP	HS	Investigative
DMHJ2IP	SN	CHEMBL156994; N2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide; SCHEMBL962597; ZBEJIFHLSRYHPP-UHFFFAOYSA-N; BDBM50221276; ZINC53246395; 2-[4-(3-chlorobenzyloxy)benzyl]aminoacetamide; 2-[4-(3-chlorobenzyl)oxybenzyl] aminoacetamide; 2-[4-(3-Chloro-benzyloxy)-benzylamino]-acetamide
DMHJ2IP	DT	Small molecular drug
DMHJ2IP	PC	11324179
DMHJ2IP	MW	304.77
DMHJ2IP	FM	C16H17ClN2O2
DMHJ2IP	IC	InChI=1S/C16H17ClN2O2/c17-14-3-1-2-13(8-14)11-21-15-6-4-12(5-7-15)9-19-10-16(18)20/h1-8,19H,9-11H2,(H2,18,20)
DMHJ2IP	CS	C1=CC(=CC(=C1)Cl)COC2=CC=C(C=C2)CNCC(=O)N
DMHJ2IP	IK	ZBEJIFHLSRYHPP-UHFFFAOYSA-N
DMHJ2IP	IU	2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]acetamide
DMHJ2IP	DE	Discovery agent

DMEWP9L	ID	DMEWP9L
DMEWP9L	DN	N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide
DMEWP9L	HS	Investigative
DMEWP9L	SN	CHEMBL231583; N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide; SCHEMBL963386
DMEWP9L	DT	Small molecular drug
DMEWP9L	PC	23625203
DMEWP9L	MW	288.32
DMEWP9L	FM	C16H17FN2O2
DMEWP9L	IC	InChI=1S/C16H17FN2O2/c17-14-3-1-2-13(8-14)11-21-15-6-4-12(5-7-15)9-19-10-16(18)20/h1-8,19H,9-11H2,(H2,18,20)
DMEWP9L	CS	C1=CC(=CC(=C1)F)COC2=CC=C(C=C2)CNCC(=O)N
DMEWP9L	IK	UZDHMFDYNZICFG-UHFFFAOYSA-N
DMEWP9L	IU	2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide
DMEWP9L	DE	Discovery agent

DMLPJGX	ID	DMLPJGX
DMLPJGX	DN	N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide
DMLPJGX	HS	Investigative
DMLPJGX	SN	CHEMBL396267; N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide
DMLPJGX	DT	Small molecular drug
DMLPJGX	PC	23625353
DMLPJGX	MW	304.77
DMLPJGX	FM	C16H17ClN2O2
DMLPJGX	IC	InChI=1S/C16H17ClN2O2/c17-14-5-1-13(2-6-14)11-21-15-7-3-12(4-8-15)9-19-10-16(18)20/h1-8,19H,9-11H2,(H2,18,20)
DMLPJGX	CS	C1=CC(=CC=C1CNCC(=O)N)OCC2=CC=C(C=C2)Cl
DMLPJGX	IK	OIWXOGDFIRHEKD-UHFFFAOYSA-N
DMLPJGX	IU	2-[[4-[(4-chlorophenyl)methoxy]phenyl]methylamino]acetamide
DMLPJGX	DE	Discovery agent

DMAVB0G	ID	DMAVB0G
DMAVB0G	DN	N2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide
DMAVB0G	HS	Investigative
DMAVB0G	SN	CHEMBL242409; N2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide
DMAVB0G	DT	Small molecular drug
DMAVB0G	PC	23625204
DMAVB0G	MW	315.32
DMAVB0G	FM	C16H17N3O4
DMAVB0G	IC	InChI=1S/C16H17N3O4/c17-16(20)10-18-9-12-3-7-15(8-4-12)23-11-13-1-5-14(6-2-13)19(21)22/h1-8,18H,9-11H2,(H2,17,20)
DMAVB0G	CS	C1=CC(=CC=C1CNCC(=O)N)OCC2=CC=C(C=C2)[N+](=O)[O-]
DMAVB0G	IK	RHNXUKDDIOAEGX-UHFFFAOYSA-N
DMAVB0G	IU	2-[[4-[(4-nitrophenyl)methoxy]phenyl]methylamino]acetamide
DMAVB0G	DE	Discovery agent

DM3WTDL	ID	DM3WTDL
DM3WTDL	DN	N-2-phenylethyl-1H-pyrrole-2-carboxamide
DM3WTDL	HS	Investigative
DM3WTDL	SN	N-(2-phenylethyl)-1H-pyrrole-2-carboxamide; pyrrole inhibitor 11; N-2-phenylethyl-1H-pyrrole-2-carboxamide; CHEMBL426546; BDBM15585; ZINC14959022
DM3WTDL	DT	Small molecular drug
DM3WTDL	PC	16110286
DM3WTDL	MW	214.26
DM3WTDL	FM	C13H14N2O
DM3WTDL	IC	InChI=1S/C13H14N2O/c16-13(12-7-4-9-14-12)15-10-8-11-5-2-1-3-6-11/h1-7,9,14H,8,10H2,(H,15,16)
DM3WTDL	CS	C1=CC=C(C=C1)CCNC(=O)C2=CC=CN2
DM3WTDL	IK	JSHPCVXIXZUURL-UHFFFAOYSA-N
DM3WTDL	IU	N-(2-phenylethyl)-1H-pyrrole-2-carboxamide
DM3WTDL	DE	Discovery agent

DMLK0J8	ID	DMLK0J8
DMLK0J8	DN	N-2-Thiophen-2-Yl-Acetamide Boronic Acid
DMLK0J8	HS	Investigative
DMLK0J8	SN	AC1L9IFX
DMLK0J8	DT	Small molecular drug
DMLK0J8	PC	2671
DMLK0J8	MW	199.04
DMLK0J8	FM	C7H10BNO3S
DMLK0J8	IC	InChI=1S/C7H10BNO3S/c10-7(9-5-8(11)12)4-6-2-1-3-13-6/h1-3,11-12H,4-5H2,(H,9,10)
DMLK0J8	CS	B(CNC(=O)CC1=CC=CS1)(O)O
DMLK0J8	IK	VXAPSUDMBNWYNC-UHFFFAOYSA-N
DMLK0J8	IU	[(2-thiophen-2-ylacetyl)amino]methylboronic acid
DMLK0J8	CA	CAS 448211-54-9
DMLK0J8	DE	Discovery agent

DMFRD09	ID	DMFRD09
DMFRD09	DN	N-3-(4-bromophenyl)propyl imidazole
DMFRD09	HS	Investigative
DMFRD09	SN	CHEMBL386256; N-3-(4-bromophenyl)propyl imidazole; 1H-Imidazole, 1-[3-(4-bromophenyl)propyl]-; SCHEMBL11404089; BDBM50191795
DMFRD09	DT	Small molecular drug
DMFRD09	PC	12870397
DMFRD09	MW	265.15
DMFRD09	FM	C12H13BrN2
DMFRD09	IC	InChI=1S/C12H13BrN2/c13-12-5-3-11(4-6-12)2-1-8-15-9-7-14-10-15/h3-7,9-10H,1-2,8H2
DMFRD09	CS	C1=CC(=CC=C1CCCN2C=CN=C2)Br
DMFRD09	IK	QCQTVUDLIJGAGO-UHFFFAOYSA-N
DMFRD09	IU	1-[3-(4-bromophenyl)propyl]imidazole
DMFRD09	DE	Discovery agent

DMWZTKD	ID	DMWZTKD
DMWZTKD	DN	N-3'-ethylaplysinopsin
DMWZTKD	HS	Investigative
DMWZTKD	DT	Small molecular drug
DMWZTKD	PC	135412764
DMWZTKD	MW	282.34
DMWZTKD	FM	C16H18N4O
DMWZTKD	IC	InChI=1S/C16H18N4O/c1-4-17-16-19(2)14(15(21)20(16)3)9-11-10-18-13-8-6-5-7-12(11)13/h5-10,21H,4H2,1-3H3/b11-9+,17-16?
DMWZTKD	CS	CCN=C1N(C(=C(N1C)O)/C=C/2\\C=NC3=CC=CC=C32)C
DMWZTKD	IK	UIFLDXAMSCVLFF-BKFIXLGBSA-N
DMWZTKD	IU	2-ethylimino-5-[(Z)-indol-3-ylidenemethyl]-1,3-dimethylimidazol-4-ol
DMWZTKD	DE	Discovery agent

DMQEGJU	ID	DMQEGJU
DMQEGJU	DN	N3-GHQMFYYPra-NH2
DMQEGJU	HS	Investigative
DMQEGJU	SN	N3-GHQMFYYPra-NH2; CHEMBL251540
DMQEGJU	PC	44444785
DMQEGJU	MW	1080.2
DMQEGJU	FM	C50H61N15O11S
DMQEGJU	IC	InChI=1S/C50H61N15O11S/c1-3-7-34(43(53)69)57-46(72)38(23-29-10-14-32(66)15-11-29)61-48(74)39(24-30-12-16-33(67)17-13-30)62-47(73)37(22-28-8-5-4-6-9-28)60-45(71)36(20-21-77-2)59-44(70)35(18-19-41(51)68)58-49(75)40(25-31-26-55-27-56-31)63-50(76)42(52)64-65-54/h1,4-6,8-17,26-27,34-40,42,66-67H,7,18-25,52H2,2H3,(H2,51,68)(H2,53,69)(H,55,56)(H,57,72)(H,58,75)(H,59,70)(H,60,71)(H,61,74)(H,62,73)(H,63,76)/t34?,35-,36-,37-,38-,39-,40-,42?/m0/s1
DMQEGJU	CS	CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)NC(CC#C)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C(N)N=[N+]=[N-]
DMQEGJU	IK	WFAPVEQHLBEDFX-OPPKEQMHSA-N
DMQEGJU	IU	(2S)-2-[[(2S)-2-[(2-amino-2-azidoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(1-amino-1-oxopent-4-yn-2-yl)amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]pentanediamide
DMQEGJU	DE	Discovery agent

DM561Z7	ID	DM561Z7
DM561Z7	DN	N4-(3-chlorophenyl)quinazoline-4,6-diamine
DM561Z7	HS	Investigative
DM561Z7	SN	CHEMBL343352; Anilinoquinazoline, 4c; N4-(3-chlorophenyl)quinazoline-4,6-diamine; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline
DM561Z7	DT	Small molecular drug
DM561Z7	PC	11807783
DM561Z7	MW	270.72
DM561Z7	FM	C14H11ClN4
DM561Z7	IC	InChI=1S/C14H11ClN4/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,16H2,(H,17,18,19)
DM561Z7	CS	C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)N
DM561Z7	IK	AWAYNEMCHILZCF-UHFFFAOYSA-N
DM561Z7	IU	4-N-(3-chlorophenyl)quinazoline-4,6-diamine
DM561Z7	DE	Discovery agent

DMDRYJ7	ID	DMDRYJ7
DMDRYJ7	DN	N4-(3-methylphenyl)-4,6-quinazolinediamine
DMDRYJ7	HS	Investigative
DMDRYJ7	SN	CHEMBL336113; Anilinoquinazoline, 4a; N4-(3-methylphenyl)-4,6-quinazolinediamine; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline
DMDRYJ7	DT	Small molecular drug
DMDRYJ7	PC	10220590
DMDRYJ7	MW	250.3
DMDRYJ7	FM	C15H14N4
DMDRYJ7	IC	InChI=1S/C15H14N4/c1-10-3-2-4-12(7-10)19-15-13-8-11(16)5-6-14(13)17-9-18-15/h2-9H,16H2,1H3,(H,17,18,19)
DMDRYJ7	CS	CC1=CC(=CC=C1)NC2=NC=NC3=C2C=C(C=C3)N
DMDRYJ7	IK	NFBCSWGEYDCCDW-UHFFFAOYSA-N
DMDRYJ7	IU	4-N-(3-methylphenyl)quinazoline-4,6-diamine
DMDRYJ7	DE	Discovery agent

DMARZHU	ID	DMARZHU
DMARZHU	DN	N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine
DMARZHU	HS	Investigative
DMARZHU	SN	DNVZYSMOLXCOLY-HNNXBMFYSA-N; UAMC00039; CHEMBL98869; SCHEMBL6824340; GTPL6538; ZINC13561228; BDBM50146972; NCGC00379239-01; 1-[(S)-2-Amino-4-[(4-chlorobenzyl)amino]butyryl]piperidine; (S)-4-(4-chlorobenzylamino)-2-amino-1-(piperidin-1-yl)butan-1-one; (2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-piperidin-1-ylbutan-1-one; 2-(S)-Amino-4-(4-chloro-benzylamino)-1-piperidin-1-yl-butan-1-one
DMARZHU	DT	Small molecular drug
DMARZHU	PC	11232124
DMARZHU	MW	309.83
DMARZHU	FM	C16H24ClN3O
DMARZHU	IC	InChI=1S/C16H24ClN3O/c17-14-6-4-13(5-7-14)12-19-9-8-15(18)16(21)20-10-2-1-3-11-20/h4-7,15,19H,1-3,8-12,18H2/t15-/m0/s1
DMARZHU	CS	C1CCN(CC1)C(=O)[C@H](CCNCC2=CC=C(C=C2)Cl)N
DMARZHU	IK	DNVZYSMOLXCOLY-HNNXBMFYSA-N
DMARZHU	IU	(2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-piperidin-1-ylbutan-1-one
DMARZHU	DE	Discovery agent

DMYPZMO	ID	DMYPZMO
DMYPZMO	DN	N4-(N,N-diphenylcarbamoyl)-aminoguanidine
DMYPZMO	HS	Investigative
DMYPZMO	DE	Discovery agent

DMCR13E	ID	DMCR13E
DMCR13E	DN	N4,N6-dibenzylpyrimidine-4,6-dicarboxamide
DMCR13E	HS	Investigative
DMCR13E	SN	N4,N6-dibenzylpyrimidine-4,6-dicarboxamide; CHEMBL468901; 135002-40-3; ZINC14574; BDBM16594; Pyrimidine Dicarboxamide Inhibitor, 2; N,N -dibenzylpyrimidine-4,6-dicarboxamide; AX8335280
DMCR13E	DT	Small molecular drug
DMCR13E	PC	15052873
DMCR13E	MW	346.4
DMCR13E	FM	C20H18N4O2
DMCR13E	IC	InChI=1S/C20H18N4O2/c25-19(21-12-15-7-3-1-4-8-15)17-11-18(24-14-23-17)20(26)22-13-16-9-5-2-6-10-16/h1-11,14H,12-13H2,(H,21,25)(H,22,26)
DMCR13E	CS	C1=CC=C(C=C1)CNC(=O)C2=CC(=NC=N2)C(=O)NCC3=CC=CC=C3
DMCR13E	IK	WIUCYEOLRGUYEH-UHFFFAOYSA-N
DMCR13E	IU	4-N,6-N-dibenzylpyrimidine-4,6-dicarboxamide
DMCR13E	DE	Discovery agent

DMV7ORJ	ID	DMV7ORJ
DMV7ORJ	DN	N4-[4-(Phenylmethoxy)phenyl]-L-aspartamine
DMV7ORJ	HS	Investigative
DMV7ORJ	SN	Amino acid analog, 4e; CHEMBL517209; BDBM24255; (2S)-2-amino-3-{[4-(benzyloxy)phenyl]carbamoyl}propanoic acid
DMV7ORJ	DT	Small molecular drug
DMV7ORJ	PC	24901603
DMV7ORJ	MW	314.34
DMV7ORJ	FM	C17H18N2O4
DMV7ORJ	IC	InChI=1S/C17H18N2O4/c18-15(17(21)22)10-16(20)19-13-6-8-14(9-7-13)23-11-12-4-2-1-3-5-12/h1-9,15H,10-11,18H2,(H,19,20)(H,21,22)/t15-/m0/s1
DMV7ORJ	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)C[C@@H](C(=O)O)N
DMV7ORJ	IK	MKNOYEISPOGYTN-HNNXBMFYSA-N
DMV7ORJ	IU	(2S)-2-amino-4-oxo-4-(4-phenylmethoxyanilino)butanoic acid
DMV7ORJ	DE	Discovery agent

DM1N73J	ID	DM1N73J
DM1N73J	DN	N4-Butyl-2-cinnamamido-N1-hydroxysuccinamide
DM1N73J	HS	Investigative
DM1N73J	SN	CHEMBL596553; N4-Butyl-2-cinnamamido-N1-hydroxysuccinamide
DM1N73J	DT	Small molecular drug
DM1N73J	PC	45257110
DM1N73J	MW	333.4
DM1N73J	FM	C17H23N3O4
DM1N73J	IC	InChI=1S/C17H23N3O4/c1-2-3-11-18-16(22)12-14(17(23)20-24)19-15(21)10-9-13-7-5-4-6-8-13/h4-10,14,24H,2-3,11-12H2,1H3,(H,18,22)(H,19,21)(H,20,23)/b10-9+/t14-/m1/s1
DM1N73J	CS	CCCCNC(=O)C[C@H](C(=O)NO)NC(=O)/C=C/C1=CC=CC=C1
DM1N73J	IK	INBRHSSIAXLSEI-ATWMFIQVSA-N
DM1N73J	IU	(2R)-N'-butyl-N-hydroxy-2-[[(E)-3-phenylprop-2-enoyl]amino]butanediamide
DM1N73J	DE	Discovery agent

DM7KX2V	ID	DM7KX2V
DM7KX2V	DN	N4-phenylethoxycytidine-5'-triphosphate
DM7KX2V	HS	Investigative
DM7KX2V	SN	N4-(phenylethoxy)-CTP; compound 15 [PMID:21528910]
DM7KX2V	DT	Small molecular drug
DM7KX2V	PC	53262890
DM7KX2V	MW	603.3
DM7KX2V	FM	C17H24N3O15P3
DM7KX2V	IC	InChI=1S/C17H24N3O15P3/c21-14-12(10-32-37(27,28)35-38(29,30)34-36(24,25)26)33-16(15(14)22)20-8-6-13(18-17(20)23)19-31-9-7-11-4-2-1-3-5-11/h1-6,8,12,14-16,21-22H,7,9-10H2,(H,27,28)(H,29,30)(H,18,19,23)(H2,24,25,26)/t12-,14-,15-,16-/m1/s1
DM7KX2V	CS	C1=CC=C(C=C1)CCONC2=NC(=O)N(C=C2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DM7KX2V	IK	WREOTYWODABZMH-DTZQCDIJSA-N
DM7KX2V	IU	[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM7KX2V	DE	Discovery agent

DMY3O6N	ID	DMY3O6N
DMY3O6N	DN	N5-(1-Imino-3-Butenyl)-L-Ornithine
DMY3O6N	HS	Investigative
DMY3O6N	SN	1-{[(4S)-4-amino-4-carboxybutyl]amino}butan-1-iminium
DMY3O6N	DT	Small molecular drug
DMY3O6N	PC	5289554
DMY3O6N	MW	202.27
DMY3O6N	FM	C9H20N3O2+
DMY3O6N	IC	InChI=1S/C9H19N3O2/c1-2-4-8(11)12-6-3-5-7(10)9(13)14/h7H,2-6,10H2,1H3,(H2,11,12)(H,13,14)/p+1/t7-/m0/s1
DMY3O6N	CS	CCCC(=[NH+]CCC[C@@H](C(=O)O)N)N
DMY3O6N	IK	KRILJVOCVSUPMA-ZETCQYMHSA-O
DMY3O6N	IU	1-aminobutylidene-[(4S)-4-amino-4-carboxybutyl]azanium
DMY3O6N	DE	Discovery agent

DMB62OI	ID	DMB62OI
DMB62OI	DN	N5-(1-iminobut-3-enyl)-L-ornithine
DMB62OI	HS	Investigative
DMB62OI	SN	Vinyl-L-NIO; LMDRHVQXMBGSGU-ZETCQYMHSA-N; (2S)-2-amino-5-(1-aminobut-3-enylideneamino)pentanoic Acid; v-NIO; hDDAH inhibitor, 1a; L-VNIO; AC1L9KK2; SCHEMBL2184864; GTPL8830; CTK7D1091; BDBM235685; ZINC2047715; AKOS006278503; compound 2e [PMID: 19013076]; (2S)-2-amino-5-[(Z)-(1-aminobut-3-en-1-ylidene)amino]pentanoic acid
DMB62OI	DT	Small molecular drug
DMB62OI	PC	91935539
DMB62OI	MW	199.25
DMB62OI	FM	C9H17N3O2
DMB62OI	IC	InChI=1S/C9H17N3O2/c1-2-4-8(11)12-6-3-5-7(10)9(13)14/h2,4,7H,3,5-6,10H2,1H3,(H2,11,12)(H,13,14)/b4-2+/t7-/m0/s1
DMB62OI	CS	C/C=C/C(=NCCC[C@@H](C(=O)O)N)N
DMB62OI	IK	RIIDRLUFTKIGSQ-XBBYQOBLSA-N
DMB62OI	IU	(2S)-2-amino-5-[[(E)-1-aminobut-2-enylidene]amino]pentanoic acid
DMB62OI	DE	Discovery agent

DMT893N	ID	DMT893N
DMT893N	DN	N5-(1-iminobutyl)-L-ornithine
DMT893N	HS	Investigative
DMT893N	SN	CHEMBL442896; N5-(1-iminobutyl)-L-ornithine; Ethyl-L-NIO; AC1NRDHJ; (2S)-2-amino-5-(1-aminobutylideneamino)pentanoic acid; BDBM152700; BDBM50255074; ZINC12503853; (S)-2-Amino-5-butyrimidoylamino-pentanoic acid; (S)-2-Amino-5-butyrimidamidopentanoic acid (9)
DMT893N	DT	Small molecular drug
DMT893N	PC	5289555
DMT893N	MW	201.27
DMT893N	FM	C9H19N3O2
DMT893N	IC	InChI=1S/C9H19N3O2/c1-2-4-8(11)12-6-3-5-7(10)9(13)14/h7H,2-6,10H2,1H3,(H2,11,12)(H,13,14)/t7-/m0/s1
DMT893N	CS	CCCC(=NCCC[C@@H](C(=O)O)N)N
DMT893N	IK	KRILJVOCVSUPMA-ZETCQYMHSA-N
DMT893N	IU	(2S)-2-amino-5-(1-aminobutylideneamino)pentanoic acid
DMT893N	DE	Discovery agent

DM0TS21	ID	DM0TS21
DM0TS21	DN	N5-(1-iminopent-3-enyl)-L-ornithine
DM0TS21	HS	Investigative
DM0TS21	SN	Propenyl-L-NIO; hDDAH inhibitor, 1c; L-ENIPO; MolPort-009-019-384; JUSNBVJTFYDFKR-SGJFDWMWSA-N; BDBM235686; ZINC100017163; L-N5-(1-Imino-3-pentenyl) ornithine
DM0TS21	DT	Small molecular drug
DM0TS21	PC	91935312
DM0TS21	MW	213.28
DM0TS21	FM	C10H19N3O2
DM0TS21	IC	InChI=1S/C10H19N3O2/c1-2-3-6-9(12)13-7-4-5-8(11)10(14)15/h3,6,8H,2,4-5,7,11H2,1H3,(H2,12,13)(H,14,15)/b6-3+/t8-/m0/s1
DM0TS21	CS	CC/C=C/C(=NCCC[C@@H](C(=O)O)N)N
DM0TS21	IK	CIYWWIHMEYBDFA-HFSLJOEWSA-N
DM0TS21	IU	(2S)-2-amino-5-[[(E)-1-aminopent-2-enylidene]amino]pentanoic acid
DM0TS21	DE	Discovery agent

DM05O7J	ID	DM05O7J
DM05O7J	DN	N5-(1-iminopropyl)-L-ornithine
DM05O7J	HS	Investigative
DM05O7J	SN	N5-(1-iminopropyl)-L-ornithine; CHEMBL507472; L-IPO, 13; BDBM152699; ZINC40380536; BDBM50254450; N~5~-[(1Z)-propanimidoyl]-L-ornithine; (S)-2-Amino-5-propionimidoylamino-pentanoic acid; (S)-2-Amino-5-propionimidamidopentanoic acid (8); (2S)-2-azanyl-5-(propanimidoylamino)pentanoic acid
DM05O7J	DT	Small molecular drug
DM05O7J	PC	44593548
DM05O7J	MW	187.24
DM05O7J	FM	C8H17N3O2
DM05O7J	IC	InChI=1S/C8H17N3O2/c1-2-7(10)11-5-3-4-6(9)8(12)13/h6H,2-5,9H2,1H3,(H2,10,11)(H,12,13)/t6-/m0/s1
DM05O7J	CS	CCC(=NCCC[C@@H](C(=O)O)N)N
DM05O7J	IK	ZYIBCZWVLDODOL-LURJTMIESA-N
DM05O7J	IU	(2S)-2-amino-5-(1-aminopropylideneamino)pentanoic acid
DM05O7J	DE	Discovery agent

DMNVK6T	ID	DMNVK6T
DMNVK6T	DN	N5-(4-Phenoxyphenyl)-L-glutamine
DMNVK6T	HS	Investigative
DMNVK6T	SN	CHEMBL442816; Modified amino acid analog, 8e; BDBM24270; (2S)-2-amino-4-[(4-phenoxyphenyl)carbamoyl]butanoic acid
DMNVK6T	DT	Small molecular drug
DMNVK6T	PC	24901615
DMNVK6T	MW	314.34
DMNVK6T	FM	C17H18N2O4
DMNVK6T	IC	InChI=1S/C17H18N2O4/c18-15(17(21)22)10-11-16(20)19-12-6-8-14(9-7-12)23-13-4-2-1-3-5-13/h1-9,15H,10-11,18H2,(H,19,20)(H,21,22)/t15-/m0/s1
DMNVK6T	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMNVK6T	IK	YWTHXARKKQRUCI-HNNXBMFYSA-N
DMNVK6T	IU	(2S)-2-amino-5-oxo-5-(4-phenoxyanilino)pentanoic acid
DMNVK6T	DE	Discovery agent

DMXUODT	ID	DMXUODT
DMXUODT	DN	N5-[(4-Phenoxy)-3-pyridyl]-L-glutamamide
DMXUODT	HS	Investigative
DMXUODT	SN	CHEMBL478551; Modified amino acid analog, 8d; BDBM24269
DMXUODT	DT	Small molecular drug
DMXUODT	PC	24901614
DMXUODT	MW	314.34
DMXUODT	FM	C16H18N4O3
DMXUODT	IC	InChI=1S/C16H18N4O3/c17-13(16(18)22)7-8-14(21)20-11-6-9-15(19-10-11)23-12-4-2-1-3-5-12/h1-6,9-10,13H,7-8,17H2,(H2,18,22)(H,20,21)/t13-/m0/s1
DMXUODT	CS	C1=CC=C(C=C1)OC2=NC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMXUODT	IK	LJOISTVTSQVPGY-ZDUSSCGKSA-N
DMXUODT	IU	(2S)-2-amino-N'-(6-phenoxypyridin-3-yl)pentanediamide
DMXUODT	DE	Discovery agent

DMJT4UR	ID	DMJT4UR
DMJT4UR	DN	N5-[4-(1H-pyrrol-1-yl)phenyl]-L-glutamamide
DMJT4UR	HS	Investigative
DMJT4UR	SN	CHEMBL478549; Modified amino acid analog, 8b; BDBM24267
DMJT4UR	DT	Small molecular drug
DMJT4UR	PC	24901612
DMJT4UR	MW	286.33
DMJT4UR	FM	C15H18N4O2
DMJT4UR	IC	InChI=1S/C15H18N4O2/c16-13(15(17)21)7-8-14(20)18-11-3-5-12(6-4-11)19-9-1-2-10-19/h1-6,9-10,13H,7-8,16H2,(H2,17,21)(H,18,20)/t13-/m0/s1
DMJT4UR	CS	C1=CN(C=C1)C2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMJT4UR	IK	XUUJHPOHRREVET-ZDUSSCGKSA-N
DMJT4UR	IU	(2S)-2-amino-N'-(4-pyrrol-1-ylphenyl)pentanediamide
DMJT4UR	DE	Discovery agent

DMR2C94	ID	DMR2C94
DMR2C94	DN	N5-[4-(2-methylphenoxy)phenyl]-L-glutamamide
DMR2C94	HS	Investigative
DMR2C94	SN	CHEMBL478983; Modified amino acid analog, 9c; BDBM24280
DMR2C94	DT	Small molecular drug
DMR2C94	PC	24901625
DMR2C94	MW	327.4
DMR2C94	FM	C18H21N3O3
DMR2C94	IC	InChI=1S/C18H21N3O3/c1-12-4-2-3-5-16(12)24-14-8-6-13(7-9-14)21-17(22)11-10-15(19)18(20)23/h2-9,15H,10-11,19H2,1H3,(H2,20,23)(H,21,22)/t15-/m0/s1
DMR2C94	CS	CC1=CC=CC=C1OC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMR2C94	IK	UHWCMHMPSGPFGU-HNNXBMFYSA-N
DMR2C94	IU	(2S)-2-amino-N'-[4-(2-methylphenoxy)phenyl]pentanediamide
DMR2C94	DE	Discovery agent

DM97H52	ID	DM97H52
DM97H52	DN	N5-[4-(2-Oxo-3-phenylpropoxy)phenyl]-L-glutamine
DM97H52	HS	Investigative
DM97H52	SN	CHEMBL518118; Modified amino acid analog, 8k; BDBM24276; (2S)-2-amino-4-{[4-(2-oxo-2-phenylethoxy)phenyl]carbamoyl}butanoic acid
DM97H52	DT	Small molecular drug
DM97H52	PC	24901621
DM97H52	MW	356.4
DM97H52	FM	C19H20N2O5
DM97H52	IC	InChI=1S/C19H20N2O5/c20-16(19(24)25)10-11-18(23)21-14-6-8-15(9-7-14)26-12-17(22)13-4-2-1-3-5-13/h1-9,16H,10-12,20H2,(H,21,23)(H,24,25)/t16-/m0/s1
DM97H52	CS	C1=CC=C(C=C1)C(=O)COC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DM97H52	IK	JXSYVANIFASLIX-INIZCTEOSA-N
DM97H52	IU	(2S)-2-amino-5-oxo-5-(4-phenacyloxyanilino)pentanoic acid
DM97H52	DE	Discovery agent

DMR1XJN	ID	DMR1XJN
DMR1XJN	DN	N5-[4-(2-phenylethoxy)phenyl]-L-glutamine
DMR1XJN	HS	Investigative
DMR1XJN	SN	CHEMBL478993; Modified amino acid analog, 8i; BDBM24274; (2S)-2-amino-4-{[4-(2-phenylethoxy)phenyl]carbamoyl}butanoic acid
DMR1XJN	DT	Small molecular drug
DMR1XJN	PC	24901619
DMR1XJN	MW	342.4
DMR1XJN	FM	C19H22N2O4
DMR1XJN	IC	InChI=1S/C19H22N2O4/c20-17(19(23)24)10-11-18(22)21-15-6-8-16(9-7-15)25-13-12-14-4-2-1-3-5-14/h1-9,17H,10-13,20H2,(H,21,22)(H,23,24)/t17-/m0/s1
DMR1XJN	CS	C1=CC=C(C=C1)CCOC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMR1XJN	IK	LXNLZSBSUTWVJA-KRWDZBQOSA-N
DMR1XJN	IU	(2S)-2-amino-5-oxo-5-[4-(2-phenylethoxy)anilino]pentanoic acid
DMR1XJN	DE	Discovery agent

DMTO8KS	ID	DMTO8KS
DMTO8KS	DN	N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide
DMTO8KS	HS	Investigative
DMTO8KS	SN	CHEMBL446500; Modified amino acid analog, 9d; BDBM24281
DMTO8KS	DT	Small molecular drug
DMTO8KS	PC	24901626
DMTO8KS	MW	327.4
DMTO8KS	FM	C18H21N3O3
DMTO8KS	IC	InChI=1S/C18H21N3O3/c1-12-3-2-4-15(11-12)24-14-7-5-13(6-8-14)21-17(22)10-9-16(19)18(20)23/h2-8,11,16H,9-10,19H2,1H3,(H2,20,23)(H,21,22)/t16-/m0/s1
DMTO8KS	CS	CC1=CC(=CC=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMTO8KS	IK	JZBKUKPJKVOVGL-INIZCTEOSA-N
DMTO8KS	IU	(2S)-2-amino-N'-[4-(3-methylphenoxy)phenyl]pentanediamide
DMTO8KS	DE	Discovery agent

DMINK9Q	ID	DMINK9Q
DMINK9Q	DN	N5-[4-(3-Phenylpropoxy)phenyl]-L-glutamine
DMINK9Q	HS	Investigative
DMINK9Q	SN	CHEMBL477513; Modified amino acid analog, 8j; BDBM24275; (2S)-2-amino-4-{[4-(3-phenylpropoxy)phenyl]carbamoyl}butanoic acid
DMINK9Q	DT	Small molecular drug
DMINK9Q	PC	24901620
DMINK9Q	MW	356.4
DMINK9Q	FM	C20H24N2O4
DMINK9Q	IC	InChI=1S/C20H24N2O4/c21-18(20(24)25)12-13-19(23)22-16-8-10-17(11-9-16)26-14-4-7-15-5-2-1-3-6-15/h1-3,5-6,8-11,18H,4,7,12-14,21H2,(H,22,23)(H,24,25)/t18-/m0/s1
DMINK9Q	CS	C1=CC=C(C=C1)CCCOC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMINK9Q	IK	NFTAKLODMXBWJT-SFHVURJKSA-N
DMINK9Q	IU	(2S)-2-amino-5-oxo-5-[4-(3-phenylpropoxy)anilino]pentanoic acid
DMINK9Q	DE	Discovery agent

DM6PXMJ	ID	DM6PXMJ
DM6PXMJ	DN	N5-[4-(4-(3-Furyl)phenoxy)phenyl]-L-glutamamide
DM6PXMJ	HS	Investigative
DM6PXMJ	SN	CHEMBL515470; Modified amino acid analog, 9g; BDBM24284
DM6PXMJ	DT	Small molecular drug
DM6PXMJ	PC	24901629
DM6PXMJ	MW	379.4
DM6PXMJ	FM	C21H21N3O4
DM6PXMJ	IC	InChI=1S/C21H21N3O4/c22-19(21(23)26)9-10-20(25)24-16-3-7-18(8-4-16)28-17-5-1-14(2-6-17)15-11-12-27-13-15/h1-8,11-13,19H,9-10,22H2,(H2,23,26)(H,24,25)/t19-/m0/s1
DM6PXMJ	CS	C1=CC(=CC=C1C2=COC=C2)OC3=CC=C(C=C3)NC(=O)CC[C@@H](C(=O)N)N
DM6PXMJ	IK	LYOSKDSEWRJQAH-IBGZPJMESA-N
DM6PXMJ	IU	(2S)-2-amino-N'-[4-[4-(furan-3-yl)phenoxy]phenyl]pentanediamide
DM6PXMJ	DE	Discovery agent

DMMV1CB	ID	DMMV1CB
DMMV1CB	DN	N5-[4-(4-methylphenoxy)phenyl]-L-glutamamide
DMMV1CB	HS	Investigative
DMMV1CB	SN	CHEMBL479157; Modified amino acid analog, 9e; BDBM24282
DMMV1CB	DT	Small molecular drug
DMMV1CB	PC	24901627
DMMV1CB	MW	327.4
DMMV1CB	FM	C18H21N3O3
DMMV1CB	IC	InChI=1S/C18H21N3O3/c1-12-2-6-14(7-3-12)24-15-8-4-13(5-9-15)21-17(22)11-10-16(19)18(20)23/h2-9,16H,10-11,19H2,1H3,(H2,20,23)(H,21,22)/t16-/m0/s1
DMMV1CB	CS	CC1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMMV1CB	IK	SNPCQHHCCJNFNQ-INIZCTEOSA-N
DMMV1CB	IU	(2S)-2-amino-N'-[4-(4-methylphenoxy)phenyl]pentanediamide
DMMV1CB	DE	Discovery agent

DMH8VYM	ID	DMH8VYM
DMH8VYM	DN	N5-[4-(N-Phenylamino)phenyl]-L-glutamine
DMH8VYM	HS	Investigative
DMH8VYM	SN	CHEMBL517211; Modified amino acid analog, 8g; SCHEMBL20238887; BDBM24272; (2S)-2-amino-4-{[4-(phenylamino)phenyl]carbamoyl}butanoic acid
DMH8VYM	DT	Small molecular drug
DMH8VYM	PC	24901617
DMH8VYM	MW	313.35
DMH8VYM	FM	C17H19N3O3
DMH8VYM	IC	InChI=1S/C17H19N3O3/c18-15(17(22)23)10-11-16(21)20-14-8-6-13(7-9-14)19-12-4-2-1-3-5-12/h1-9,15,19H,10-11,18H2,(H,20,21)(H,22,23)/t15-/m0/s1
DMH8VYM	CS	C1=CC=C(C=C1)NC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMH8VYM	IK	CKEDBZVOBFKCJM-HNNXBMFYSA-N
DMH8VYM	IU	(2S)-2-amino-5-(4-anilinoanilino)-5-oxopentanoic acid
DMH8VYM	DE	Discovery agent

DMUVP5L	ID	DMUVP5L
DMUVP5L	DN	N5-[4-(Phenylmethoxy)phenyl]-D-glutamine
DMUVP5L	HS	Investigative
DMUVP5L	SN	Amino acid analog, 4g; CHEMBL478534; BDBM24257; (2R)-2-amino-4-{[4-(benzyloxy)phenyl]carbamoyl}butanoic acid
DMUVP5L	DT	Small molecular drug
DMUVP5L	PC	24901604
DMUVP5L	MW	328.4
DMUVP5L	FM	C18H20N2O4
DMUVP5L	IC	InChI=1S/C18H20N2O4/c19-16(18(22)23)10-11-17(21)20-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H,20,21)(H,22,23)/t16-/m1/s1
DMUVP5L	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CC[C@H](C(=O)O)N
DMUVP5L	IK	BYSBXIPCDJNEBG-MRXNPFEDSA-N
DMUVP5L	IU	(2R)-2-amino-5-oxo-5-(4-phenylmethoxyanilino)pentanoic acid
DMUVP5L	DE	Discovery agent

DMMYIJ0	ID	DMMYIJ0
DMMYIJ0	DN	N5-[4-(Phenylmethoxy)phenyl]-L-glutamamide
DMMYIJ0	HS	Investigative
DMMYIJ0	SN	CHEMBL478717; Modified amino acid analog, 6c
DMMYIJ0	DT	Small molecular drug
DMMYIJ0	PC	24901607
DMMYIJ0	MW	327.4
DMMYIJ0	FM	C18H21N3O3
DMMYIJ0	IC	InChI=1S/C18H21N3O3/c19-16(18(20)23)10-11-17(22)21-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H2,20,23)(H,21,22)/t16-/m0/s1
DMMYIJ0	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMMYIJ0	IK	PKTMQSKBGCPRGD-INIZCTEOSA-N
DMMYIJ0	IU	(2S)-2-amino-N'-(4-phenylmethoxyphenyl)pentanediamide
DMMYIJ0	DE	Discovery agent

DMCG26A	ID	DMCG26A
DMCG26A	DN	N5-[4-(Phenylmethoxy)phenyl]-L-glutamine
DMCG26A	HS	Investigative
DMCG26A	SN	(2S)-2-amino-4-{[4-(benzyloxy)phenyl]carbamoyl}butanoic acid; (2S)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid; Amino acid analog, 4f; CHEMBL478381; BDBM24256; N-[4-(benzyloxy)phenyl]-L-glutamine; DB07102; N-[4-(phenylmethoxy)phenyl]-L-glutamine
DMCG26A	DT	Small molecular drug
DMCG26A	PC	24768560
DMCG26A	MW	328.4
DMCG26A	FM	C18H20N2O4
DMCG26A	IC	InChI=1S/C18H20N2O4/c19-16(18(22)23)10-11-17(21)20-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H,20,21)(H,22,23)/t16-/m0/s1
DMCG26A	CS	C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMCG26A	IK	BYSBXIPCDJNEBG-INIZCTEOSA-N
DMCG26A	IU	(2S)-2-amino-5-oxo-5-(4-phenylmethoxyanilino)pentanoic acid
DMCG26A	DE	Discovery agent

DMH6O4G	ID	DMH6O4G
DMH6O4G	DN	N5-[4-Benzylphenyl]-L-glutamamide
DMH6O4G	HS	Investigative
DMH6O4G	SN	CHEMBL478379; Modified amino acid analog, 8f; BDBM24271
DMH6O4G	DT	Small molecular drug
DMH6O4G	PC	24901616
DMH6O4G	MW	311.4
DMH6O4G	FM	C18H21N3O2
DMH6O4G	IC	InChI=1S/C18H21N3O2/c19-16(18(20)23)10-11-17(22)21-15-8-6-14(7-9-15)12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H2,20,23)(H,21,22)/t16-/m0/s1
DMH6O4G	CS	C1=CC=C(C=C1)CC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMH6O4G	IK	RYHUMGNBCPJDFD-INIZCTEOSA-N
DMH6O4G	IU	(2S)-2-amino-N'-(4-benzylphenyl)pentanediamide
DMH6O4G	DE	Discovery agent

DML0R9M	ID	DML0R9M
DML0R9M	DN	N5-methylfolate
DML0R9M	HS	Investigative
DML0R9M	SN	5-methyl-THF; 5-methyl-tetrahydrofolate; 5-methyltetrahydrofolate
DML0R9M	DT	Small molecular drug
DML0R9M	PC	135483998
DML0R9M	MW	459.5
DML0R9M	FM	C20H25N7O6
DML0R9M	IC	InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12?,13-/m1/s1
DML0R9M	CS	CN1C(CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)N[C@H](CCC(=O)O)C(=O)O
DML0R9M	IK	ZNOVTXRBGFNYRX-ZGTCLIOFSA-N
DML0R9M	IU	(2R)-2-[[4-[(2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DML0R9M	CA	CAS 134-35-0
DML0R9M	DE	Discovery agent

DMXSZ1A	ID	DMXSZ1A
DMXSZ1A	DN	N6 benzyl-cAMP
DMXSZ1A	HS	Investigative
DMXSZ1A	SN	N6-benzyl cyclic AMP
DMXSZ1A	DT	Small molecular drug
DMXSZ1A	PC	161733
DMXSZ1A	MW	419.3
DMXSZ1A	FM	C17H18N5O6P
DMXSZ1A	IC	InChI=1S/C17H18N5O6P/c23-13-14-11(7-26-29(24,25)28-14)27-17(13)22-9-21-12-15(19-8-20-16(12)22)18-6-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,23H,6-7H2,(H,24,25)(H,18,19,20)/t11-,13-,14-,17-/m1/s1
DMXSZ1A	CS	C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)NCC5=CC=CC=C5)O)OP(=O)(O1)O
DMXSZ1A	IK	GDDBIAMRTVTOBL-LSCFUAHRSA-N
DMXSZ1A	IU	(4aR,6R,7R,7aS)-6-[6-(benzylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol
DMXSZ1A	CA	CAS 32115-08-5
DMXSZ1A	DE	Discovery agent

DM30KXV	ID	DM30KXV
DM30KXV	DN	N6-((+/-)-endo-norborn-2-yl)adenosine
DM30KXV	HS	Investigative
DM30KXV	SN	CHEMBL489640; N6-((+/-)-endo-norborn-2-yl)adenosine; N-(2-Norbornyl)adenosine; SCHEMBL10608249
DM30KXV	DT	Small molecular drug
DM30KXV	PC	10021483
DM30KXV	MW	361.4
DM30KXV	FM	C17H23N5O4
DM30KXV	IC	InChI=1S/C17H23N5O4/c23-5-11-13(24)14(25)17(26-11)22-7-20-12-15(18-6-19-16(12)22)21-10-4-8-1-2-9(10)3-8/h6-11,13-14,17,23-25H,1-5H2,(H,18,19,21)/t8?,9?,10?,11-,13-,14-,17-/m1/s1
DM30KXV	CS	C1CC2CC1CC2NC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O
DM30KXV	IK	YKPCEENRZZBDMC-STHLEMNDSA-N
DM30KXV	IU	(2R,3R,4S,5R)-2-[6-(2-bicyclo[2.2.1]heptanylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM30KXV	DE	Discovery agent

DM2W9NO	ID	DM2W9NO
DM2W9NO	DN	N6-(3-Iodobenzyl)-2'-O-methyladenosine
DM2W9NO	HS	Investigative
DM2W9NO	SN	CHEMBL428377; BDBM50215115
DM2W9NO	DT	Small molecular drug
DM2W9NO	PC	44436081
DM2W9NO	MW	497.3
DM2W9NO	FM	C18H20IN5O4
DM2W9NO	IC	InChI=1S/C18H20IN5O4/c1-27-15-14(26)12(7-25)28-18(15)24-9-23-13-16(21-8-22-17(13)24)20-6-10-3-2-4-11(19)5-10/h2-5,8-9,12,14-15,18,25-26H,6-7H2,1H3,(H,20,21,22)/t12-,14-,15-,18-/m1/s1
DM2W9NO	CS	CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)CO)O
DM2W9NO	IK	OATZXEKAXIIRDK-SCFUHWHPSA-N
DM2W9NO	IU	(2R,3R,4R,5R)-2-(hydroxymethyl)-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-4-methoxyoxolan-3-ol
DM2W9NO	DE	Discovery agent

DM5Q71U	ID	DM5Q71U
DM5Q71U	DN	N6-(4-hydroxybenzyl)adenine riboside
DM5Q71U	HS	Investigative
DM5Q71U	SN	N6-(4-Hydroxybenzyl)-adenosine; 110505-75-4; n6-(4-hydroxybenzyl)adenosine; N6-(4-hydroxybenzyl)adenine riboside; CHEMBL224024; C17H19N5O5; p-Topolin riboside; Adenosine, N-[(4-hydroxyphenyl)methyl]-; SCHEMBL639446; N6-(p-hydroxybenzyl)-adenosine; KS-00001DDJ; CTK0D4708; DTXSID00440568; UGVIXKXYLBAZND-LSCFUAHRSA-N; MolPort-023-332-931; ZINC28638129; BDBM50208945; 1962AA; ANW-64712; AKOS016007097; CS-5067; NCGC00484059-01; HY-18775; AJ-83558; TC-153457; KB-258567; AB3000026; AX8235067
DM5Q71U	DT	Small molecular drug
DM5Q71U	PC	10474479
DM5Q71U	MW	373.4
DM5Q71U	FM	C17H19N5O5
DM5Q71U	IC	InChI=1S/C17H19N5O5/c23-6-11-13(25)14(26)17(27-11)22-8-21-12-15(19-7-20-16(12)22)18-5-9-1-3-10(24)4-2-9/h1-4,7-8,11,13-14,17,23-26H,5-6H2,(H,18,19,20)/t11-,13-,14-,17-/m1/s1
DM5Q71U	CS	C1=CC(=CC=C1CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)O
DM5Q71U	IK	UGVIXKXYLBAZND-LSCFUAHRSA-N
DM5Q71U	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[(4-hydroxyphenyl)methylamino]purin-9-yl]oxolane-3,4-diol
DM5Q71U	CA	CAS 110505-75-4
DM5Q71U	DE	Discovery agent

DM0WMKJ	ID	DM0WMKJ
DM0WMKJ	DN	N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine
DM0WMKJ	HS	Investigative
DM0WMKJ	SN	CHEMBL496985; N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine
DM0WMKJ	DT	Small molecular drug
DM0WMKJ	PC	25104892
DM0WMKJ	MW	392.5
DM0WMKJ	FM	C24H20N6
DM0WMKJ	IC	InChI=1S/C24H20N6/c25-19-11-13-20(14-12-19)27-23-21-24(29-22(28-23)18-9-5-2-6-10-18)30(16-26-21)15-17-7-3-1-4-8-17/h1-14,16H,15,25H2,(H,27,28,29)
DM0WMKJ	CS	C1=CC=C(C=C1)CN2C=NC3=C(N=C(N=C32)C4=CC=CC=C4)NC5=CC=C(C=C5)N
DM0WMKJ	IK	RVUVWWRSIWGIQQ-UHFFFAOYSA-N
DM0WMKJ	IU	4-N-(9-benzyl-2-phenylpurin-6-yl)benzene-1,4-diamine
DM0WMKJ	DE	Discovery agent

DMVNLPF	ID	DMVNLPF
DMVNLPF	DN	N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine
DMVNLPF	HS	Investigative
DMVNLPF	SN	CHEMBL496984; N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine
DMVNLPF	DT	Small molecular drug
DMVNLPF	PC	25104891
DMVNLPF	MW	422.4
DMVNLPF	FM	C24H18N6O2
DMVNLPF	IC	InChI=1S/C24H18N6O2/c31-30(32)20-13-11-19(12-14-20)26-23-21-24(28-22(27-23)18-9-5-2-6-10-18)29(16-25-21)15-17-7-3-1-4-8-17/h1-14,16H,15H2,(H,26,27,28)
DMVNLPF	CS	C1=CC=C(C=C1)CN2C=NC3=C(N=C(N=C32)C4=CC=CC=C4)NC5=CC=C(C=C5)[N+](=O)[O-]
DMVNLPF	IK	AQQCBPZYBVKEFU-UHFFFAOYSA-N
DMVNLPF	IU	9-benzyl-N-(4-nitrophenyl)-2-phenylpurin-6-amine
DMVNLPF	DE	Discovery agent

DMBT2HW	ID	DMBT2HW
DMBT2HW	DN	N6-[4-(4-methylphenoxy)phenyl]-L-homoglutamine
DMBT2HW	HS	Investigative
DMBT2HW	SN	CHEMBL478298; Modified amino acid analog, 10; BDBM24285; (3S)-3-amino-5-[(4-phenoxyphenyl)carbamoyl]pentanoic acid
DMBT2HW	DT	Small molecular drug
DMBT2HW	PC	24901630
DMBT2HW	MW	328.4
DMBT2HW	FM	C18H20N2O4
DMBT2HW	IC	InChI=1S/C18H20N2O4/c19-13(12-18(22)23)6-11-17(21)20-14-7-9-16(10-8-14)24-15-4-2-1-3-5-15/h1-5,7-10,13H,6,11-12,19H2,(H,20,21)(H,22,23)/t13-/m0/s1
DMBT2HW	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](CC(=O)O)N
DMBT2HW	IK	YAELJSOADOXCDL-ZDUSSCGKSA-N
DMBT2HW	IU	(3S)-3-amino-6-oxo-6-(4-phenoxyanilino)hexanoic acid
DMBT2HW	DE	Discovery agent

DMDMI7P	ID	DMDMI7P
DMDMI7P	DN	N-6060
DMDMI7P	HS	Investigative
DMDMI7P	SN	N-6338; N-6371; N-6446; N-6463; N-6501; N-6537; N-6603; S-nitrosoglutathione reductase inhibitors, N30
DMDMI7P	CP	N30 Pharmaceuticals LLC
DMDMI7P	DE	Asthma

DM814EQ	ID	DM814EQ
DM814EQ	DN	N-6547
DM814EQ	HS	Investigative
DM814EQ	CP	N30 Pharmaceuticals LLC
DM814EQ	DE	Inflammatory bowel disease

DM71MO2	ID	DM71MO2
DM71MO2	DN	N6-Benzyl Adenosine-5'-Diphosphate
DM71MO2	HS	Investigative
DM71MO2	SN	N6-BENZYL ADENOSINE-5'-DIPHOSPHATE; AC1L9K3K; SCHEMBL4319955; DB01893; N-benzyladenosine 5'-(trihydrogen diphosphate); [(2R,3S,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DM71MO2	DT	Small molecular drug
DM71MO2	PC	446795
DM71MO2	MW	517.299
DM71MO2	FM	C17H21N5O10P2
DM71MO2	IC	InChI=1S/C17H21N5O10P2/c23-13-11(7-30-34(28,29)32-33(25,26)27)31-17(14(13)24)22-9-21-12-15(19-8-20-16(12)22)18-6-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,23-24H,6-7H2,(H,28,29)(H,18,19,20)(H2,25,26,27)/t11-,13-,14-,17-/m1/s1
DM71MO2	CS	C1=CC=C(C=C1)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)OP(=O)(O)O)O)O
DM71MO2	IK	MRHGMAGSDAQUFH-LSCFUAHRSA-N
DM71MO2	IU	[(2R,3S,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DM71MO2	DE	Discovery agent

DMD6AJO	ID	DMD6AJO
DMD6AJO	DN	N6-cyclopentyladenosine
DMD6AJO	HS	Investigative
DMD6AJO	SN	N6-Cyclopentyladenosine; 41552-82-3; n-cyclopentyladenosine; (2R,3R,4S,5R)-2-(6-(Cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; Cyclopentyladenosine; CHEMBL68738; MLS000028368; N(6)-Cyclopentyladenosine; SMR000058639; (2R,3R,4S,5R)-2-[6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; Adenosine, N-cyclopentyl-; UNII-7LG47VG1ID; 7LG47VG1ID; N6-CyclopentylAdo; n-cyclopentyl-adenosine; n6-cyclopentyl-adenosine; AC1LCWG1; Opera_ID_1056; GTPL380; MLS002153196; MLS001077332; SCHEMBL120481
DMD6AJO	DT	Small molecular drug
DMD6AJO	PC	657378
DMD6AJO	MW	335.36
DMD6AJO	FM	C15H21N5O4
DMD6AJO	IC	InChI=1S/C15H21N5O4/c21-5-9-11(22)12(23)15(24-9)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,21-23H,1-5H2,(H,16,17,19)/t9-,11-,12-,15-/m1/s1
DMD6AJO	CS	C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMD6AJO	IK	SQMWSBKSHWARHU-SDBHATRESA-N
DMD6AJO	IU	(2R,3R,4S,5R)-2-[6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMD6AJO	CA	CAS 41552-82-3
DMD6AJO	DE	Discovery agent

DMSEL5W	ID	DMSEL5W
DMSEL5W	DN	N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine
DMSEL5W	HS	Investigative
DMSEL5W	SN	CHEMBL223327; N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine; SCHEMBL4380052; BDBM50205697
DMSEL5W	DT	Small molecular drug
DMSEL5W	PC	10318664
DMSEL5W	MW	398.4
DMSEL5W	FM	C18H18N6O5
DMSEL5W	IC	InChI=1S/C18H18N6O5/c1-28-23-16-13-17(22-12(21-16)6-5-10-4-2-3-7-19-10)24(9-20-13)18-15(27)14(26)11(8-25)29-18/h2-4,7,9,11,14-15,18,25-27H,8H2,1H3,(H,21,22,23)/t11-,14-,15-,18-/m1/s1
DMSEL5W	CS	CONC1=C2C(=NC(=N1)C#CC3=CC=CC=N3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMSEL5W	IK	CMMXTSNUEHRJEY-XKLVTHTNSA-N
DMSEL5W	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-pyridin-2-ylethynyl)purin-9-yl]oxolane-3,4-diol
DMSEL5W	DE	Discovery agent

DMP7246	ID	DMP7246
DMP7246	DN	N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine
DMP7246	HS	Investigative
DMP7246	SN	CHEMBL223328; N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine; SCHEMBL4384438
DMP7246	DT	Small molecular drug
DMP7246	PC	16115478
DMP7246	MW	398.4
DMP7246	FM	C18H18N6O5
DMP7246	IC	InChI=1S/C18H18N6O5/c1-28-23-16-13-17(22-12(21-16)5-4-10-3-2-6-19-7-10)24(9-20-13)18-15(27)14(26)11(8-25)29-18/h2-3,6-7,9,11,14-15,18,25-27H,8H2,1H3,(H,21,22,23)/t11-,14-,15-,18-/m1/s1
DMP7246	CS	CONC1=C2C(=NC(=N1)C#CC3=CN=CC=C3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMP7246	IK	XQAKVNKMDSEKNH-XKLVTHTNSA-N
DMP7246	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-pyridin-3-ylethynyl)purin-9-yl]oxolane-3,4-diol
DMP7246	DE	Discovery agent

DM8LR62	ID	DM8LR62
DM8LR62	DN	N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine
DM8LR62	HS	Investigative
DM8LR62	SN	CHEMBL220158; N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine; SCHEMBL4381643
DM8LR62	DT	Small molecular drug
DM8LR62	PC	10320311
DM8LR62	MW	427.4
DM8LR62	FM	C20H21N5O6
DM8LR62	IC	InChI=1S/C20H21N5O6/c1-29-12-6-3-11(4-7-12)5-8-14-22-18(24-30-2)15-19(23-14)25(10-21-15)20-17(28)16(27)13(9-26)31-20/h3-4,6-7,10,13,16-17,20,26-28H,9H2,1-2H3,(H,22,23,24)/t13-,16-,17-,20-/m1/s1
DM8LR62	CS	COC1=CC=C(C=C1)C#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)NOC
DM8LR62	IK	MZYNTNQYNANXII-AEVYOOLXSA-N
DM8LR62	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-[2-(4-methoxyphenyl)ethynyl]purin-9-yl]oxolane-3,4-diol
DM8LR62	DE	Discovery agent

DM1KA9R	ID	DM1KA9R
DM1KA9R	DN	N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine
DM1KA9R	HS	Investigative
DM1KA9R	SN	CHEMBL426537; N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine; SCHEMBL4386994
DM1KA9R	DT	Small molecular drug
DM1KA9R	PC	9801709
DM1KA9R	MW	411.4
DM1KA9R	FM	C20H21N5O5
DM1KA9R	IC	InChI=1S/C20H21N5O5/c1-11-3-5-12(6-4-11)7-8-14-22-18(24-29-2)15-19(23-14)25(10-21-15)20-17(28)16(27)13(9-26)30-20/h3-6,10,13,16-17,20,26-28H,9H2,1-2H3,(H,22,23,24)/t13-,16-,17-,20-/m1/s1
DM1KA9R	CS	CC1=CC=C(C=C1)C#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)NOC
DM1KA9R	IK	QEUCNKIJAMGFSL-AEVYOOLXSA-N
DM1KA9R	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-[2-(4-methylphenyl)ethynyl]purin-9-yl]oxolane-3,4-diol
DM1KA9R	DE	Discovery agent

DMQ5K8R	ID	DMQ5K8R
DMQ5K8R	DN	N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine
DMQ5K8R	HS	Investigative
DMQ5K8R	SN	CHEMBL374320; N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine; SCHEMBL4381145
DMQ5K8R	DT	Small molecular drug
DMQ5K8R	PC	10389852
DMQ5K8R	MW	467.5
DMQ5K8R	FM	C24H29N5O5
DMQ5K8R	IC	InChI=1S/C24H29N5O5/c1-3-4-5-6-15-7-9-16(10-8-15)11-12-18-26-22(28-33-2)19-23(27-18)29(14-25-19)24-21(32)20(31)17(13-30)34-24/h7-10,14,17,20-21,24,30-32H,3-6,13H2,1-2H3,(H,26,27,28)/t17-,20-,21-,24-/m1/s1
DMQ5K8R	CS	CCCCCC1=CC=C(C=C1)C#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)NOC
DMQ5K8R	IK	SQMZMNPGRAKQJD-FGSUIDRYSA-N
DMQ5K8R	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-[2-(4-pentylphenyl)ethynyl]purin-9-yl]oxolane-3,4-diol
DMQ5K8R	DE	Discovery agent

DM9H3W8	ID	DM9H3W8
DM9H3W8	DN	N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine
DM9H3W8	HS	Investigative
DM9H3W8	SN	CHEMBL220899; N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine; SCHEMBL4384730
DM9H3W8	DT	Small molecular drug
DM9H3W8	PC	16115753
DM9H3W8	MW	398.4
DM9H3W8	FM	C18H18N6O5
DM9H3W8	IC	InChI=1S/C18H18N6O5/c1-28-23-16-13-17(22-12(21-16)3-2-10-4-6-19-7-5-10)24(9-20-13)18-15(27)14(26)11(8-25)29-18/h4-7,9,11,14-15,18,25-27H,8H2,1H3,(H,21,22,23)/t11-,14-,15-,18-/m1/s1
DM9H3W8	CS	CONC1=C2C(=NC(=N1)C#CC3=CC=NC=C3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DM9H3W8	IK	NZIZYIGAKAUPPW-XKLVTHTNSA-N
DM9H3W8	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-pyridin-4-ylethynyl)purin-9-yl]oxolane-3,4-diol
DM9H3W8	DE	Discovery agent

DMRBS50	ID	DMRBS50
DMRBS50	DN	N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine
DMRBS50	HS	Investigative
DMRBS50	SN	CHEMBL267421; N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine; SCHEMBL4378430
DMRBS50	DT	Small molecular drug
DMRBS50	PC	16115477
DMRBS50	MW	393.47
DMRBS50	FM	C16H23N5O5Si
DMRBS50	IC	InChI=1S/C16H23N5O5Si/c1-25-20-14-11-15(19-10(18-14)5-6-27(2,3)4)21(8-17-11)16-13(24)12(23)9(7-22)26-16/h8-9,12-13,16,22-24H,7H2,1-4H3,(H,18,19,20)/t9-,12-,13-,16-/m1/s1
DMRBS50	CS	CONC1=C2C(=NC(=N1)C#C[Si](C)(C)C)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMRBS50	IK	UOJJCTHGWLSJEL-RVXWVPLUSA-N
DMRBS50	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-trimethylsilylethynyl)purin-9-yl]oxolane-3,4-diol
DMRBS50	DE	Discovery agent

DMDG59X	ID	DMDG59X
DMDG59X	DN	N6-methoxy-2-phenylethynyladenosine
DMDG59X	HS	Investigative
DMDG59X	SN	CHEMBL441707; N6-methoxy-2-phenylethynyladenosine
DMDG59X	DT	Small molecular drug
DMDG59X	PC	44420681
DMDG59X	MW	397.4
DMDG59X	FM	C19H19N5O5
DMDG59X	IC	InChI=1S/C19H19N5O5/c1-28-23-17-14-18(22-13(21-17)8-7-11-5-3-2-4-6-11)24(10-20-14)19-16(27)15(26)12(9-25)29-19/h2-6,10,12,15-16,19,25-27H,9H2,1H3,(H,21,22,23)/t12-,15+,16+,19+/m0/s1
DMDG59X	CS	CONC1=C2C(=NC(=N1)C#CC3=CC=CC=C3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@@H](O4)CO)O)O
DMDG59X	IK	GWYJBOYUQUUQGN-GCUGWZBJSA-N
DMDG59X	IU	(2S,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-phenylethynyl)purin-9-yl]oxolane-3,4-diol
DMDG59X	DE	Discovery agent

DM6XDZA	ID	DM6XDZA
DM6XDZA	DN	N7-hydroxy-2-methoxy-N1-phenylheptanediamide
DM6XDZA	HS	Investigative
DM6XDZA	SN	CHEMBL251206; N7-hydroxy-2-methoxy-N1-phenylheptanediamide; SCHEMBL8143763
DM6XDZA	DT	Small molecular drug
DM6XDZA	PC	25065710
DM6XDZA	MW	280.32
DM6XDZA	FM	C14H20N2O4
DM6XDZA	IC	InChI=1S/C14H20N2O4/c1-20-12(9-5-6-10-13(17)16-19)14(18)15-11-7-3-2-4-8-11/h2-4,7-8,12,19H,5-6,9-10H2,1H3,(H,15,18)(H,16,17)
DM6XDZA	CS	COC(CCCCC(=O)NO)C(=O)NC1=CC=CC=C1
DM6XDZA	IK	GTYJNCDOILRMGX-UHFFFAOYSA-N
DM6XDZA	IU	N'-hydroxy-2-methoxy-N-phenylheptanediamide
DM6XDZA	DE	Discovery agent

DMDJUZX	ID	DMDJUZX
DMDJUZX	DN	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide
DMDJUZX	HS	Investigative
DMDJUZX	SN	CHEMBL251406; N7-hydroxy-N1-phenyl-2-propoxyheptanediamide; SCHEMBL8144856
DMDJUZX	DT	Small molecular drug
DMDJUZX	PC	25065713
DMDJUZX	MW	308.37
DMDJUZX	FM	C16H24N2O4
DMDJUZX	IC	InChI=1S/C16H24N2O4/c1-2-12-22-14(10-6-7-11-15(19)18-21)16(20)17-13-8-4-3-5-9-13/h3-5,8-9,14,21H,2,6-7,10-12H2,1H3,(H,17,20)(H,18,19)
DMDJUZX	CS	CCCOC(CCCCC(=O)NO)C(=O)NC1=CC=CC=C1
DMDJUZX	IK	HYIYBZGKHUILKH-UHFFFAOYSA-N
DMDJUZX	IU	N'-hydroxy-N-phenyl-2-propoxyheptanediamide
DMDJUZX	DE	Discovery agent

DMHC32M	ID	DMHC32M
DMHC32M	DN	N8,2-dihydroxy-N1-phenyloctanediamide
DMHC32M	HS	Investigative
DMHC32M	SN	CHEMBL251009; N8,2-dihydroxy-N1-phenyloctanediamide; SCHEMBL8144564
DMHC32M	DT	Small molecular drug
DMHC32M	PC	25065929
DMHC32M	MW	280.32
DMHC32M	FM	C14H20N2O4
DMHC32M	IC	InChI=1S/C14H20N2O4/c17-12(9-5-2-6-10-13(18)16-20)14(19)15-11-7-3-1-4-8-11/h1,3-4,7-8,12,17,20H,2,5-6,9-10H2,(H,15,19)(H,16,18)
DMHC32M	CS	C1=CC=C(C=C1)NC(=O)C(CCCCCC(=O)NO)O
DMHC32M	IK	ZJKUBOBFXFZYHR-UHFFFAOYSA-N
DMHC32M	IU	N',2-dihydroxy-N-phenyloctanediamide
DMHC32M	DE	Discovery agent

DM7OZ2T	ID	DM7OZ2T
DM7OZ2T	DN	N8-hydroxy-2-methoxy-N1-phenyloctanediamide
DM7OZ2T	HS	Investigative
DM7OZ2T	SN	CHEMBL251010; N8-hydroxy-2-methoxy-N1-phenyloctanediamide; SCHEMBL8158442
DM7OZ2T	DT	Small molecular drug
DM7OZ2T	PC	25065930
DM7OZ2T	MW	294.35
DM7OZ2T	FM	C15H22N2O4
DM7OZ2T	IC	InChI=1S/C15H22N2O4/c1-21-13(10-6-3-7-11-14(18)17-20)15(19)16-12-8-4-2-5-9-12/h2,4-5,8-9,13,20H,3,6-7,10-11H2,1H3,(H,16,19)(H,17,18)
DM7OZ2T	CS	COC(CCCCCC(=O)NO)C(=O)NC1=CC=CC=C1
DM7OZ2T	IK	JHNWNLJPMOWGAH-UHFFFAOYSA-N
DM7OZ2T	IU	N'-hydroxy-2-methoxy-N-phenyloctanediamide
DM7OZ2T	DE	Discovery agent

DMML1J4	ID	DMML1J4
DMML1J4	DN	N-9xxx
DMML1J4	HS	Investigative
DMML1J4	SN	N-9xxx (oral, COPD)
DMML1J4	CP	N30 Pharmaceuticals LLC
DMML1J4	DE	Vascular disease

DM51DW6	ID	DM51DW6
DM51DW6	DN	NAADP
DM51DW6	HS	Investigative
DM51DW6	SN	nicotinic acid adenine dinucleotide phosphate; NAADP+
DM51DW6	DT	Small molecular drug
DM51DW6	PC	123953
DM51DW6	MW	745.4
DM51DW6	FM	C21H28N6O18P3+
DM51DW6	IC	InChI=1S/C21H27N6O18P3/c22-17-12-18(24-7-23-17)27(8-25-12)20-16(44-46(33,34)35)14(29)11(43-20)6-41-48(38,39)45-47(36,37)40-5-10-13(28)15(30)19(42-10)26-3-1-2-9(4-26)21(31)32/h1-4,7-8,10-11,13-16,19-20,28-30H,5-6H2,(H6-,22,23,24,31,32,33,34,35,36,37,38,39)/p+1/t10-,11-,13-,14-,15-,16-,19-,20-/m1/s1
DM51DW6	CS	C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)O
DM51DW6	IK	QOTXBMGJKFVZRD-HISDBWNOSA-O
DM51DW6	IU	1-[(2R,3R,4S,5R)-5-[[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylic acid
DM51DW6	CB	CHEBI:76072
DM51DW6	DE	Discovery agent

DMFGOW0	ID	DMFGOW0
DMFGOW0	DN	NAAG
DMFGOW0	HS	Investigative
DMFGOW0	SN	N-acetylaspartylglutamate; spaglumic acid; isospaglumic acid
DMFGOW0	DT	Small molecular drug
DMFGOW0	PC	188803
DMFGOW0	MW	304.25
DMFGOW0	FM	C11H16N2O8
DMFGOW0	IC	InChI=1S/C11H16N2O8/c1-5(14)12-7(4-9(17)18)10(19)13-6(11(20)21)2-3-8(15)16/h6-7H,2-4H2,1H3,(H,12,14)(H,13,19)(H,15,16)(H,17,18)(H,20,21)/t6-,7-/m0/s1
DMFGOW0	CS	CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMFGOW0	IK	OPVPGKGADVGKTG-BQBZGAKWSA-N
DMFGOW0	IU	(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]pentanedioic acid
DMFGOW0	CA	CAS 3106-85-2
DMFGOW0	CB	CHEBI:73688
DMFGOW0	DE	Discovery agent

DMRKIYB	ID	DMRKIYB
DMRKIYB	DN	NA-alpha-D-glucosamine
DMRKIYB	HS	Investigative
DMRKIYB	SN	N-Acetyl-alpha-D-glucosamine; N-acetyl-alpha-D-glucosamine; T13TI5GH3D; alpha-GlcNAc; 10036-64-3; 1rdn; 2-(ACETYLAMINO)-2-DEOXY-A-D-GLUCOPYRANOSE; 2-(acetylamino)-2-deoxy-D-glucose; 2-(acetylamino)-2-deoxy-alpha-D-glucopyranose; 2-Acetamido-2-deoxy-alpha-D-glucopyranose; AC1L335S; AC1Q5JMQ; CHEBI:44278; CHEMBL1234669; EINECS 233-115-1; N-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide; N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; SCHEMBL19899; UNII-T13TI5GH3D; alpha-D-GlcNAc
DMRKIYB	PC	82313
DMRKIYB	MW	221.21
DMRKIYB	FM	C8H15NO6
DMRKIYB	IC	OVRNDRQMDRJTHS-PVFLNQBWSA-N
DMRKIYB	CS	CC(=O)NC1C(C(C(OC1O)CO)O)O
DMRKIYB	IK	1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8+/m1/s1
DMRKIYB	IU	N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DMRKIYB	CA	CAS 10036-64-3
DMRKIYB	CB	CHEBI:44278
DMRKIYB	DE	Discovery agent

DMZW9AC	ID	DMZW9AC
DMZW9AC	DN	N-Acetylalanine
DMZW9AC	HS	Investigative
DMZW9AC	SN	N-Acetyl-DL-alanine; 1115-69-1; 2-acetamidopropanoic acid; Ac-DL-Ala-OH; 2-Acetylaminopropionic acid; N-ACETYLALANINE; Acetyl-DL-Alanine; DL-Alanine, N-acetyl-; N-alpha-Acetyl-DL-alanine; 2-Acetylamino-propionic acid; N-Acetyl-S-alanine; L-Alanine, N-acetyl-; KTHDTJVBEPMMGL-UHFFFAOYSA-N; N-Acetyl-DL-2-aminopropionic Acid; 2-(acetylamino)propanoic acid; n-acetylalanin; Alanine, N-acetyl-; Alanine, N-acetyl-, L-; L-Alanine, N-acetyl- (9CI); Alanine, N-acetyl-, L- (8CI); ac-dl-alanine; n-acetyl-dl-ala; N-Acetylalanine #; EINECS 214-
DMZW9AC	DT	Small molecular drug
DMZW9AC	PC	88064
DMZW9AC	MW	131.13
DMZW9AC	FM	C5H9NO3
DMZW9AC	IC	InChI=1S/C5H9NO3/c1-3(5(8)9)6-4(2)7/h3H,1-2H3,(H,6,7)(H,8,9)/t3-/m0/s1
DMZW9AC	CS	C[C@@H](C(=O)O)NC(=O)C
DMZW9AC	IK	KTHDTJVBEPMMGL-VKHMYHEASA-N
DMZW9AC	IU	(2S)-2-acetamidopropanoic acid
DMZW9AC	CA	CAS 97-69-8
DMZW9AC	CB	CHEBI:40992
DMZW9AC	DE	Discovery agent

DM9WQ6V	ID	DM9WQ6V
DM9WQ6V	DN	N-Acetylmethionine
DM9WQ6V	HS	Investigative
DM9WQ6V	SN	N-Acetyl-DL-methionine; 1115-47-5; Ac-DL-Met-OH; Acetyl-DL-methionine; DL-N-Acetylmethionine; Methionamine; METHIONINE, N-ACETYL-; DL-Methionine, N-acetyl-; Ac-Met-OH; Methionine, N-acetyl-, DL-; 2-Acetamido-4-(methylthio)butanoic acid; dl-Acetylmethionine; Thiomedon; L-Methionine, N-acetyl-; NSC 7633; EINECS 214-224-3; N-ACETYL-METHIONINE; N-Acetyl(methyl)homocysteine; BRN 1725554; Acetylmethionin; Methionin; C7H13NO3S; XUYPXLNMDZIRQH-UHFFFAOYSA-N; MFCD00008681; 2-acetamido-4-methylsulfanylbutanoic acid
DM9WQ6V	DT	Small molecular drug
DM9WQ6V	PC	448580
DM9WQ6V	MW	191.25
DM9WQ6V	FM	C7H13NO3S
DM9WQ6V	IC	InChI=1S/C7H13NO3S/c1-5(9)8-6(7(10)11)3-4-12-2/h6H,3-4H2,1-2H3,(H,8,9)(H,10,11)/t6-/m0/s1
DM9WQ6V	CS	CC(=O)N[C@@H](CCSC)C(=O)O
DM9WQ6V	IK	XUYPXLNMDZIRQH-LURJTMIESA-N
DM9WQ6V	IU	(2S)-2-acetamido-4-methylsulfanylbutanoic acid
DM9WQ6V	CA	CAS 65-82-7
DM9WQ6V	CB	CHEBI:21557
DM9WQ6V	DE	Discovery agent

DMUNCFQ	ID	DMUNCFQ
DMUNCFQ	DN	N-Acetyl-N'-Beta-D-Glucopyranosyl Urea
DMUNCFQ	HS	Investigative
DMUNCFQ	SN	N-ACETYL-N'-BETA-D-GLUCOPYRANOSYL UREA; CHEMBL443455; 1kti; DB03218; AC1L9K3W; SCHEMBL4307948; BDBM50263770; N-Acetyl-N'-(beta-D-glucopyranosyl)urea; N-(acetylcarbamoyl)-beta-D-glucopyranosylamine; N-ACETYL-N''-BETA-D-GLUCOPYRANOSYL UREA; N-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]acetamide; N-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-ylcarbamoyl)acetamide
DMUNCFQ	DT	Small molecular drug
DMUNCFQ	PC	446801
DMUNCFQ	MW	264.23
DMUNCFQ	FM	C9H16N2O7
DMUNCFQ	IC	InChI=1S/C9H16N2O7/c1-3(13)10-9(17)11-8-7(16)6(15)5(14)4(2-12)18-8/h4-8,12,14-16H,2H2,1H3,(H2,10,11,13,17)/t4-,5-,6+,7-,8-/m1/s1
DMUNCFQ	CS	CC(=O)NC(=O)N[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMUNCFQ	IK	UQKBNLXZEGBQAF-JAJWTYFOSA-N
DMUNCFQ	IU	N-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]acetamide
DMUNCFQ	DE	Discovery agent

DME8O69	ID	DME8O69
DME8O69	DN	N-acetyl-phenylalanyl-glycine-nitrile
DME8O69	HS	Investigative
DME8O69	SN	phenylalanine derivative, 42; CHEMBL197181; SCHEMBL15634553; BDBM20118; ITHLBMBCVIAAIX-LBPRGKRZSA-N; ZINC13676602; (N-acetyl-l-phenylalanyl)aminoacetonitrile; SR-03000002938; SR-03000002938-1; (S)-2-Acetamido-N-(cyanomethyl)-3-phenylpropanamide
DME8O69	DT	Small molecular drug
DME8O69	PC	11086036
DME8O69	MW	245.28
DME8O69	FM	C13H15N3O2
DME8O69	IC	InChI=1S/C13H15N3O2/c1-10(17)16-12(13(18)15-8-7-14)9-11-5-3-2-4-6-11/h2-6,12H,8-9H2,1H3,(H,15,18)(H,16,17)/t12-/m0/s1
DME8O69	CS	CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC#N
DME8O69	IK	ITHLBMBCVIAAIX-LBPRGKRZSA-N
DME8O69	IU	(2S)-2-acetamido-N-(cyanomethyl)-3-phenylpropanamide
DME8O69	DE	Discovery agent

DMJ4SBM	ID	DMJ4SBM
DMJ4SBM	DN	N-acetylserotonin
DMJ4SBM	HS	Investigative
DMJ4SBM	SN	N-Acetyl-5-hydroxytryptamine; 1210-83-9; N-ACETYL SEROTONIN; N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]acetamide; acetylserotonin; Normelatonin; O-Demethylmelatonin; 5-Hydroxy-N-acetyltryptamine; UNII-P4TO3C82WV; Acetyl-5-hydroxy-tryptamine; 5-Hydroxymelatonin; N-(2-(5-Hydroxy-1H-indol-3-yl)ethyl)acetamide; 3-(2-Acetamidoethyl)-5-hydroxyindole; P4TO3C82WV; CHEMBL33103; CHEBI:17697; MVAWJSIDNICKHF-UHFFFAOYSA-N; Acetamide, N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-; A-1300; Desmethylmelatonin; N-acetyl-serotonin;  O-demethylmelatonin; N-acetyl-5-hydroxytryptamine; N-[2-(5-Hydroxy-1H-indol-3-yl)-ethyl]-acetamide
DMJ4SBM	DT	Small molecular drug
DMJ4SBM	PC	903
DMJ4SBM	MW	218.25
DMJ4SBM	FM	C12H14N2O2
DMJ4SBM	IC	InChI=1S/C12H14N2O2/c1-8(15)13-5-4-9-7-14-12-3-2-10(16)6-11(9)12/h2-3,6-7,14,16H,4-5H2,1H3,(H,13,15)
DMJ4SBM	CS	CC(=O)NCCC1=CNC2=C1C=C(C=C2)O
DMJ4SBM	IK	MVAWJSIDNICKHF-UHFFFAOYSA-N
DMJ4SBM	IU	N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]acetamide
DMJ4SBM	CA	CAS 1210-83-9
DMJ4SBM	CB	CHEBI:17697
DMJ4SBM	DE	Discovery agent

DM1XH8D	ID	DM1XH8D
DM1XH8D	DN	N'-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine
DM1XH8D	HS	Investigative
DM1XH8D	SN	CHEMBL61092; 1046-70-4; SCHEMBL8288058; CTK0D7916; DTXSID50658232; BDBM50143356; 1,4-Butanediamine, N'-9-acridinyl-N,N-diethyl-; N''-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine
DM1XH8D	DT	Small molecular drug
DM1XH8D	PC	44300061
DM1XH8D	MW	321.5
DM1XH8D	FM	C21H27N3
DM1XH8D	IC	InChI=1S/C21H27N3/c1-3-24(4-2)16-10-9-15-22-21-17-11-5-7-13-19(17)23-20-14-8-6-12-18(20)21/h5-8,11-14H,3-4,9-10,15-16H2,1-2H3,(H,22,23)
DM1XH8D	CS	CCN(CC)CCCCNC1=C2C=CC=CC2=NC3=CC=CC=C31
DM1XH8D	IK	OALXTIRPFIITPC-UHFFFAOYSA-N
DM1XH8D	IU	N-acridin-9-yl-N',N'-diethylbutane-1,4-diamine
DM1XH8D	CA	CAS 1046-70-4
DM1XH8D	DE	Discovery agent

DM3ORGM	ID	DM3ORGM
DM3ORGM	DN	NADA
DM3ORGM	HS	Investigative
DM3ORGM	SN	N-arachidonyl dopamine
DM3ORGM	DT	Small molecular drug
DM3ORGM	PC	5282105
DM3ORGM	MW	439.6
DM3ORGM	FM	C28H41NO3
DM3ORGM	IC	InChI=1S/C28H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(32)29-23-22-25-20-21-26(30)27(31)24-25/h6-7,9-10,12-13,15-16,20-21,24,30-31H,2-5,8,11,14,17-19,22-23H2,1H3,(H,29,32)/b7-6-,10-9-,13-12-,16-15-
DM3ORGM	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCC1=CC(=C(C=C1)O)O
DM3ORGM	IK	MVVPIAAVGAWJNQ-DOFZRALJSA-N
DM3ORGM	IU	(5Z,8Z,11Z,14Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide
DM3ORGM	CA	CAS 199875-69-9
DM3ORGM	CB	CHEBI:31231
DM3ORGM	DE	Discovery agent

DMSR4A6	ID	DMSR4A6
DMSR4A6	DN	N-adamantanemethyloxypentyl-1-deoxynojirimycin
DMSR4A6	HS	Investigative
DMSR4A6	SN	AMP-Deoxynojirimycin; AMP-DNM; 216758-20-2; CHEMBL574645; N-adamantanemethyloxypentyl-1-deoxynojirimycin; SCHEMBL17132950; SCHEMBL13777990; CTK4E7471; MolPort-044-562-021; ZINC33989734; BDBM50299749; 1613AH; AKOS030538164; RT-011277; N-(Adamantanemethyloxypentyl)-Deoxynojirimycin; J-014228; (2R,3R,4R,5S)-1-[5-(1-adamantylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol; 3,4,5-PIPERIDINETRIOL, 2-(HYDROXYMETHYL)-1-[5-(TRICYCLO[3.3.1.13,7]DEC-1-YLMETHOXY)PENTYL]-, (2R,3R,4R,5S)-
DMSR4A6	DT	Small molecular drug
DMSR4A6	PC	9822159
DMSR4A6	MW	397.5
DMSR4A6	FM	C22H39NO5
DMSR4A6	IC	InChI=1S/C22H39NO5/c24-13-18-20(26)21(27)19(25)12-23(18)4-2-1-3-5-28-14-22-9-15-6-16(10-22)8-17(7-15)11-22/h15-21,24-27H,1-14H2/t15?,16?,17?,18-,19+,20-,21-,22?/m1/s1
DMSR4A6	CS	C1[C@@H]([C@H]([C@@H]([C@H](N1CCCCCOCC23CC4CC(C2)CC(C4)C3)CO)O)O)O
DMSR4A6	IK	XVYLNHVEAOOEGI-FAIWKWDXSA-N
DMSR4A6	IU	(2R,3R,4R,5S)-1-[5-(1-adamantylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
DMSR4A6	DE	Discovery agent

DMZ43N1	ID	DMZ43N1
DMZ43N1	DN	N-adamantyl-N'-cyclohexylurea
DMZ43N1	HS	Investigative
DMZ43N1	SN	CHEMBL242255; N-1-adamantyl-N'-cyclohexylurea; AC1NMPQQ; Urea-based compound, 13; ChemDiv3_000178; Oprea1_419513; 1-adamantyl-3-cyclohexylurea; MLS000719875; SCHEMBL653168; BDBM25732; MolPort-003-713-177; HMS2616F12; HMS1473I02; 3-adamantan-1-yl-1-cyclohexylurea; 1-(1-adamantyl)-3-cyclohexylurea; ZINC3895072; AKOS001483388; MCULE-6291906995; 1-(Adamantane-1-yl)-3-cyclohexylurea; IDI1_019496; N-adamantanyl(cyclohexylamino)carboxamide; NCGC00177652-01; SMR000304404; EU-0000129; ST51030996; US8815951, 192; SR-01000389488
DMZ43N1	DT	Small molecular drug
DMZ43N1	PC	5029871
DMZ43N1	MW	276.4
DMZ43N1	FM	C17H28N2O
DMZ43N1	IC	InChI=1S/C17H28N2O/c20-16(18-15-4-2-1-3-5-15)19-17-9-12-6-13(10-17)8-14(7-12)11-17/h12-15H,1-11H2,(H2,18,19,20)
DMZ43N1	CS	C1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMZ43N1	IK	VESXWSWSGQONHC-UHFFFAOYSA-N
DMZ43N1	IU	1-(1-adamantyl)-3-cyclohexylurea
DMZ43N1	DE	Discovery agent

DM75Q34	ID	DM75Q34
DM75Q34	DN	NADPH
DM75Q34	HS	Investigative
DM75Q34	SN	NADP-reduced; reduced Cozymase II; reduced Coenzyme II; b-NADPH; reduced Codehydrase II; Dihydrocodehydrogenase II; dihydronicotinamide adenine dinucleotide-P; GTPL3041; Triphosphopyridine nucleotide reduced; Reduced triphosphopyridine nucleotide; dihydrotriphosphopyridine nucleotide reduced; Nicotinamide-adenine-dinucleotide-phosphorate; b-Nicotinamide-adenine-dinucleotide-phosphorate; Nicotinamide-adenine-dinucleotide-phosphoric acid; beta-Nicotinamide-adenine-dinucleotide-phosphorate
DM75Q34	DT	Small molecular drug
DM75Q34	PC	5884
DM75Q34	MW	745.4
DM75Q34	FM	C21H30N7O17P3
DM75Q34	IC	InChI=1S/C21H30N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1
DM75Q34	CS	C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O
DM75Q34	IK	ACFIXJIJDZMPPO-NNYOXOHSSA-N
DM75Q34	IU	[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM75Q34	CA	CAS 53-57-6
DM75Q34	CB	CHEBI:16474
DM75Q34	DE	Discovery agent

DM38XWZ	ID	DM38XWZ
DM38XWZ	DN	NAEPA
DM38XWZ	HS	Investigative
DM38XWZ	SN	N-acyl ethanolamide phosphate
DM38XWZ	DT	Small molecular drug
DM38XWZ	PC	44343825
DM38XWZ	MW	405.5
DM38XWZ	FM	C20H40NO5P
DM38XWZ	IC	InChI=1S/C20H40NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(22)21-18-19-26-27(23,24)25/h9-10H,2-8,11-19H2,1H3,(H,21,22)(H2,23,24,25)/b10-9-
DM38XWZ	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCCOP(=O)(O)O
DM38XWZ	IK	BCSUWOZFWWBYSX-KTKRTIGZSA-N
DM38XWZ	IU	2-[[(Z)-octadec-9-enoyl]amino]ethyl dihydrogen phosphate
DM38XWZ	CA	CAS 24435-25-4
DM38XWZ	CB	CHEBI:145794
DM38XWZ	DE	Discovery agent

DM79KLR	ID	DM79KLR
DM79KLR	DN	nafadotride
DM79KLR	HS	Investigative
DM79KLR	SN	Nafadotride; 149649-22-9; (+-)-nafadotride; N-[(1-BUTYL-2-PYRROLIDINYL)METHYL]-4-CYANO-1-METHOXY-2-NAPHTHALENECARBOXAMIDE; N-[(1-butylpyrrolidin-2-yl)methyl]-4-cyano-1-methoxynaphthalene-2-carboxamide; CHEMBL286252; CHEBI:64191; A1-01951; SMR000466292; AC1MPBUT; GTPL44; MLS000758952; MLS001424218; SCHEMBL635866; DTXSID1042603; CTK8H0240; MolPort-023-276-076; HMS3394A15; HMS3267P15; HMS2232B11; HMS2052A15; HMS3370D02; BCP27779; BDBM50133923; AKOS024257976; TRA0072321; CCG-101119; NC00369; SAM001247092; CPD000466292; LS-186981; LS-187623
DM79KLR	DT	Small molecular drug
DM79KLR	PC	3408722
DM79KLR	MW	365.5
DM79KLR	FM	C22H27N3O2
DM79KLR	IC	InChI=1S/C22H27N3O2/c1-3-4-11-25-12-7-8-17(25)15-24-22(26)20-13-16(14-23)18-9-5-6-10-19(18)21(20)27-2/h5-6,9-10,13,17H,3-4,7-8,11-12,15H2,1-2H3,(H,24,26)
DM79KLR	CS	CCCCN1CCCC1CNC(=O)C2=C(C3=CC=CC=C3C(=C2)C#N)OC
DM79KLR	IK	IDZASIQMRGPBCQ-UHFFFAOYSA-N
DM79KLR	IU	N-[(1-butylpyrrolidin-2-yl)methyl]-4-cyano-1-methoxynaphthalene-2-carboxamide
DM79KLR	CA	CAS 149649-22-9
DM79KLR	CB	CHEBI:64191
DM79KLR	DE	Discovery agent

DM0FROP	ID	DM0FROP
DM0FROP	DN	Nafoxidine
DM0FROP	HS	Investigative
DM0FROP	SN	Nafoxidine; 1845-11-0; Nafoxidine [INN]; Nafoxidinum [INN-Latin]; Nafoxidina [INN-Spanish]; UNII-4RIY10WM82; U-11000A; BRN 1440873; CHEMBL28211; 4RIY10WM82; CHEBI:34881; NSC 70735; C29H31NO2; JEYWNNAZDLFBFF-UHFFFAOYSA-N; 1-(2-(p-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine; Pyrrolidine, 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)-; 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine; Pyrrolidine, 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl
DM0FROP	DT	Small molecular drug
DM0FROP	PC	4416
DM0FROP	MW	425.6
DM0FROP	FM	C29H31NO2
DM0FROP	IC	InChI=1S/C29H31NO2/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3
DM0FROP	CS	COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5
DM0FROP	IK	JEYWNNAZDLFBFF-UHFFFAOYSA-N
DM0FROP	IU	1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine
DM0FROP	CA	CAS 1845-11-0
DM0FROP	CB	CHEBI:34881
DM0FROP	DE	Discovery agent

DML7UVA	ID	DML7UVA
DML7UVA	DN	NAG 1-phosphate
DML7UVA	HS	Investigative
DML7UVA	SN	N-Acetyl-glucosamine 1-phosphate; N-Acetylglucosamine 1-phosphate; N-Acetylglucosamine-1-phosphate; SCHEMBL5679031; delta-glucosamine 1-phosphate; 2-acetamido-2-deoxy-1-O-phosphono-D-glucopyranose; 2-acetamido-2-deoxy-D-glucopyranose 1-phosphate; 6866-69-9; AC1L990N; C04256; CHEBI:7125; CTK2F5371; DTXSID90988348; N-Acetyl-D-glucosamine 1-phosphate; N-acetyl-alpha-delta-glucosamine 1-phosphate; N-acetyl-delta-glucosamine 1-phosphate; N-ACETYL-D-GLUCOSAMINE-1-P; bmse000163
DML7UVA	PC	440272
DML7UVA	MW	301.19
DML7UVA	FM	C8H16NO9P
DML7UVA	IC	FZLJPEPAYPUMMR-RTRLPJTCSA-N
DML7UVA	CS	CC(=O)NC1C(C(C(OC1OP(=O)(O)O)CO)O)O
DML7UVA	IK	1S/C8H16NO9P/c1-3(11)9-5-7(13)6(12)4(2-10)17-8(5)18-19(14,15)16/h4-8,10,12-13H,2H2,1H3,(H,9,11)(H2,14,15,16)/t4-,5-,6-,7-,8?/m1/s1
DML7UVA	IU	[(3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate
DML7UVA	CA	CAS 6866-69-9
DML7UVA	CB	CHEBI:7125
DML7UVA	DE	Discovery agent

DM1LWMU	ID	DM1LWMU
DM1LWMU	DN	nahuoic acid A
DM1LWMU	HS	Investigative
DM1LWMU	SN	nahuoic acid A; GTPL7022; (2E)-3-[(1R,2R,4aR,5R,7R,8R,8aS)-5,7-dihydroxy-3,4a,8-trimethyl-2-[(2E,5S,7R,8S,9S)-5,7,9-trihydroxy-8,10-dimethylundec-2-en-2-yl]-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-2-methylprop-2-enoic acid
DM1LWMU	DT	Small molecular drug
DM1LWMU	PC	71521340
DM1LWMU	MW	522.7
DM1LWMU	FM	C30H50O7
DM1LWMU	IC	InChI=1S/C30H50O7/c1-15(2)28(35)20(7)23(32)12-21(31)10-9-16(3)26-18(5)14-30(8)25(34)13-24(33)19(6)27(30)22(26)11-17(4)29(36)37/h9,11,14-15,19-28,31-35H,10,12-13H2,1-8H3,(H,36,37)/b16-9+,17-11+/t19-,20-,21-,22-,23+,24+,25+,26+,27+,28-,30+/m0/s1
DM1LWMU	CS	C[C@H]1[C@@H](C[C@H]([C@@]2([C@H]1[C@H]([C@@H](C(=C2)C)/C(=C/C[C@@H](C[C@H]([C@H](C)[C@H](C(C)C)O)O)O)/C)/C=C(\\C)/C(=O)O)C)O)O
DM1LWMU	IK	ZNAYXHSDZPSFLO-UWXUHECCSA-N
DM1LWMU	IU	(E)-3-[(1R,2R,4aR,5R,7R,8R,8aS)-5,7-dihydroxy-3,4a,8-trimethyl-2-[(E,5S,7R,8S,9S)-5,7,9-trihydroxy-8,10-dimethylundec-2-en-2-yl]-2,5,6,7,8,8a-hexahydro-1H-naphthalen-1-yl]-2-methylprop-2-enoic acid
DM1LWMU	DE	Discovery agent

DM0CP36	ID	DM0CP36
DM0CP36	DN	NalBzOH
DM0CP36	HS	Investigative
DM0CP36	SN	Naloxone benzoylhydrazone; Nalbzoh; 119630-94-3; 6-Desoxy-6-benzoylhydrazido-N-allyl-14-hydroxydihydronormorphinone; Benzoic acid, ((5alpha)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene)hydrazide; Lopac0_000882; [(5alpha)-4,5-Epoxy-; MLS000860072; Naloxone benzoylhydrazone, solid; SCHEMBL15423902; CHEMBL1256836; MolPort-003-958-927; MFCD05662358; AKOS024456586; CCG-204964; NCGC00092281-03; NCGC00092281-02; NCGC00092281-04; NCGC00092281-01; SMR000326930; N-165; EU-0100882; SR-01000075513; SR-01000075513-1
DM0CP36	DT	Small molecular drug
DM0CP36	PC	9601084
DM0CP36	MW	445.5
DM0CP36	FM	C26H27N3O4
DM0CP36	IC	InChI=1S/C26H27N3O4/c1-2-13-29-14-12-25-21-17-8-9-19(30)22(21)33-23(25)18(10-11-26(25,32)20(29)15-17)27-28-24(31)16-6-4-3-5-7-16/h2-9,20,23,30,32H,1,10-15H2,(H,28,31)/b27-18+/t20-,23+,25+,26-/m1/s1
DM0CP36	CS	C=CCN1CC[C@]23[C@@H]4/C(=N/NC(=O)C5=CC=CC=C5)/CC[C@]2([C@H]1CC6=C3C(=C(C=C6)O)O4)O
DM0CP36	IK	AKXCFAYOTIEFOH-XTNAHFASSA-N
DM0CP36	IU	N-[(E)-[(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ylidene]amino]benzamide
DM0CP36	CA	CAS 119630-94-3
DM0CP36	DE	Discovery agent

DM9T0OK	ID	DM9T0OK
DM9T0OK	DN	N-alkyl urea hydroxamic acids
DM9T0OK	HS	Investigative
DM9T0OK	DT	Small molecular drug
DM9T0OK	PC	56603781
DM9T0OK	MW	416.5
DM9T0OK	FM	C21H32N6O3
DM9T0OK	IC	InChI=1S/C21H32N6O3/c1-16(25-30)15-26(13-4-9-17-7-2-3-8-17)21(29)27-14-5-10-18(27)19(28)24-20-22-11-6-12-23-20/h6,11-12,17-18,25,30H,1-5,7-10,13-15H2,(H,22,23,24,28)/t18-/m0/s1
DM9T0OK	CS	C=C(CN(CCCC1CCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=NC=CC=N3)NO
DM9T0OK	IK	RQNVLLHARFXNPH-SFHVURJKSA-N
DM9T0OK	IU	(2S)-1-N-(3-cyclopentylpropyl)-1-N-[2-(hydroxyamino)prop-2-enyl]-2-N-pyrimidin-2-ylpyrrolidine-1,2-dicarboxamide
DM9T0OK	DE	Discovery agent

DM30LI6	ID	DM30LI6
DM30LI6	DN	N-allyl[D-Pro-10]Dyn A-(1-11)
DM30LI6	HS	Investigative
DM30LI6	SN	CHEMBL406338; N-allyl[D-Pro-10]Dyn A-(1-11)
DM30LI6	PC	44325372
DM30LI6	MW	1402.7
DM30LI6	FM	C66H107N21O13
DM30LI6	IC	InChI=1S/C66H107N21O13/c1-6-29-74-48(35-42-24-26-43(88)27-25-42)55(91)79-37-52(89)78-38-53(90)80-50(36-41-17-9-8-10-18-41)59(95)85-49(34-39(3)4)58(94)82-44(20-13-30-75-64(68)69)56(92)81-45(21-14-31-76-65(70)71)57(93)86-54(40(5)7-2)61(97)83-46(22-15-32-77-66(72)73)62(98)87-33-16-23-51(87)60(96)84-47(63(99)100)19-11-12-28-67/h6,8-10,17-18,24-27,39-40,44-51,54,74,88H,1,7,11-16,19-23,28-38,67H2,2-5H3,(H,78,89)(H,79,91)(H,80,90)(H,81,92)(H,82,94)(H,83,97)(H,84,96)(H,85,95)(H,86,93)(H,99,100)(H4,68,69,75)(H4,70,71,76)(H4,72,73,77)/t40-,44-,45-,46-,47-,48-,49-,50-,51-,54-/m0/s1
DM30LI6	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)NCC=C
DM30LI6	IK	MKKPRLAUMQVIGT-QNKLTTAESA-N
DM30LI6	IU	(2S)-6-amino-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-3-(4-hydroxyphenyl)-2-(prop-2-enylamino)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DM30LI6	DE	Discovery agent

DMZQUMB	ID	DMZQUMB
DMZQUMB	DN	N-allyl-4-hydroxy-N-phenylbenzenesulfonamide
DMZQUMB	HS	Investigative
DMZQUMB	SN	CHEMBL426849; N-allyl-4-hydroxy-N-phenylbenzenesulfonamide
DMZQUMB	DT	Small molecular drug
DMZQUMB	PC	44407887
DMZQUMB	MW	289.4
DMZQUMB	FM	C15H15NO3S
DMZQUMB	IC	InChI=1S/C15H15NO3S/c1-2-12-16(13-6-4-3-5-7-13)20(18,19)15-10-8-14(17)9-11-15/h2-11,17H,1,12H2
DMZQUMB	CS	C=CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DMZQUMB	IK	CZEIYINPLQLEHQ-UHFFFAOYSA-N
DMZQUMB	IU	4-hydroxy-N-phenyl-N-prop-2-enylbenzenesulfonamide
DMZQUMB	DE	Discovery agent

DMRXA8N	ID	DMRXA8N
DMRXA8N	DN	N-ALLYLNORGALANTHAMINE
DMRXA8N	HS	Investigative
DMRXA8N	SN	N-allylnorgalanthamine; CHEMBL399515; SCHEMBL13043536
DMRXA8N	DT	Small molecular drug
DMRXA8N	PC	44447598
DMRXA8N	MW	313.4
DMRXA8N	FM	C19H23NO3
DMRXA8N	IC	InChI=1S/C19H23NO3/c1-3-9-20-10-8-19-7-6-14(21)11-16(19)23-18-15(22-2)5-4-13(12-20)17(18)19/h3-7,14,16,21H,1,8-12H2,2H3/t14-,16-,19-/m0/s1
DMRXA8N	CS	COC1=C2C3=C(CN(CC[C@]34C=C[C@@H](C[C@@H]4O2)O)CC=C)C=C1
DMRXA8N	IK	BQESVZIPHFRYNG-QOKNQOGYSA-N
DMRXA8N	IU	(1S,12S,14R)-9-methoxy-4-prop-2-enyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
DMRXA8N	DE	Discovery agent

DM5W2VK	ID	DM5W2VK
DM5W2VK	DN	N-allylnorlitebamine
DM5W2VK	HS	Investigative
DM5W2VK	SN	N-allylnorlitebamine; CHEMBL465347; BDBM50250444
DM5W2VK	DT	Small molecular drug
DM5W2VK	PC	10546795
DM5W2VK	MW	365.4
DM5W2VK	FM	C22H23NO4
DM5W2VK	IC	InChI=1S/C22H23NO4/c1-4-8-23-9-7-14-15-6-5-13-10-18(24)19(26-2)11-16(13)20(15)22(27-3)21(25)17(14)12-23/h4-6,10-11,24-25H,1,7-9,12H2,2-3H3
DM5W2VK	CS	COC1=C(C=C2C=CC3=C4CCN(CC4=C(C(=C3C2=C1)OC)O)CC=C)O
DM5W2VK	IK	GFTFQCRSRIGURP-UHFFFAOYSA-N
DM5W2VK	IU	9,11-dimethoxy-2-prop-2-enyl-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DM5W2VK	DE	Discovery agent

DM1SCU5	ID	DM1SCU5
DM1SCU5	DN	Nalorphine
DM1SCU5	HS	Investigative
DM1SCU5	SN	Nalorphine; Allorphine; Nalorphinium; Antorphin; Antorfin; Anthorphine; Nalorphin; Antorphine; N-Allylnormorphine; Anarcon; Nalorfina; Norfin; Nallin; 62-67-9; Acetorfin [Czech]; Nalorfina [DCIT]; NANM; Normorphine, N-allyl-; Nalorphine [INN:BAN]; Nalorphinum [INN-Latin]; UNII-U59WB2WRY2; N-Allyl-N-desmethylmorphine; HSDB 3278; EINECS 200-546-1; U59WB2WRY2; Acetorfin; CHEBI:7458; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-(2-propenyl)-, (5alpha,6alpha)-; N-Allyl-7,8-dehydro-4,5-epoxy-3,6-dihydroxymorphinan; DEA No. 9400
DM1SCU5	DT	Small molecular drug
DM1SCU5	PC	5284595
DM1SCU5	MW	311.4
DM1SCU5	FM	C19H21NO3
DM1SCU5	IC	InChI=1S/C19H21NO3/c1-2-8-20-9-7-19-12-4-6-15(22)18(19)23-17-14(21)5-3-11(16(17)19)10-13(12)20/h2-6,12-13,15,18,21-22H,1,7-10H2/t12-,13+,15-,18-,19-/m0/s1
DM1SCU5	CS	C=CCN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O
DM1SCU5	IK	UIQMVEYFGZJHCZ-SSTWWWIQSA-N
DM1SCU5	IU	(4R,4aR,7S,7aR,12bS)-3-prop-2-enyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
DM1SCU5	CA	CAS 62-67-9
DM1SCU5	CB	CHEBI:7458
DM1SCU5	DE	Discovery agent

DM8ZMNH	ID	DM8ZMNH
DM8ZMNH	DN	naloxonazine
DM8ZMNH	HS	Investigative
DM8ZMNH	SN	NSC 612113
DM8ZMNH	DT	Small molecular drug
DM8ZMNH	PC	9576413
DM8ZMNH	MW	650.8
DM8ZMNH	FM	C38H42N4O6
DM8ZMNH	IC	InChI=1S/C38H42N4O6/c1-3-15-41-17-13-35-29-21-5-7-25(43)31(29)47-33(35)23(9-11-37(35,45)27(41)19-21)39-40-24-10-12-38(46)28-20-22-6-8-26(44)32-30(22)36(38,34(24)48-32)14-18-42(28)16-4-2/h3-8,27-28,33-34,43-46H,1-2,9-20H2/b39-23+,40-24+/t27-,28-,33+,34+,35+,36+,37-,38-/m1/s1
DM8ZMNH	CS	C=CCN1[C@H]2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@H]4/C(=N/N=C\\6/[C@@H]7OC8=C(C=CC9=C8[C@]72[C@]([C@@H](C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O
DM8ZMNH	IK	AJPSBXJNFJCCBI-YOHUGVJRSA-N
DM8ZMNH	IU	(4R,4aS,7E,7aR,12bS)-7-[(E)-[(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ylidene]hydrazinylidene]-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DM8ZMNH	CA	CAS 82824-01-9
DM8ZMNH	DE	Discovery agent

DMFNCQ1	ID	DMFNCQ1
DMFNCQ1	DN	N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2
DMFNCQ1	HS	Investigative
DMFNCQ1	SN	CHEMBL243724; BDBM50201411; N alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2
DMFNCQ1	DT	Small molecular drug
DMFNCQ1	PC	44428306
DMFNCQ1	MW	723.8
DMFNCQ1	FM	C38H45N9O6
DMFNCQ1	IC	InChI=1S/C38H45N9O6/c1-53-26-15-13-24(14-16-26)19-31(46-38(40)41)37(52)47-17-7-12-32(47)36(51)43-22-33(48)44-30(20-25-21-42-28-11-6-5-10-27(25)28)35(50)45-29(34(39)49)18-23-8-3-2-4-9-23/h2-6,8-11,13-16,21,29-32,42H,7,12,17-20,22H2,1H3,(H2,39,49)(H,43,51)(H,44,48)(H,45,50)(H4,40,41,46)/t29-,30-,31-,32+/m0/s1
DMFNCQ1	CS	COC1=CC=C(C=C1)C[C@@H](C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N=C(N)N
DMFNCQ1	IK	OEGSFHSEWVWDGF-RTNMLALUSA-N
DMFNCQ1	IU	(2R)-N-[2-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-1-[(2S)-2-(diaminomethylideneamino)-3-(4-methoxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DMFNCQ1	DE	Discovery agent

DM8QTSU	ID	DM8QTSU
DM8QTSU	DN	N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2
DM8QTSU	HS	Investigative
DM8QTSU	SN	CHEMBL243189; BDBM50201412; N alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2
DM8QTSU	DT	Small molecular drug
DM8QTSU	PC	44428304
DM8QTSU	MW	701.2
DM8QTSU	FM	C36H41ClN8O5
DM8QTSU	IC	InChI=1S/C36H41ClN8O5/c1-50-25-14-10-22(11-15-25)18-30(44-36(39)40)35(49)45-16-4-7-31(45)34(48)43-29(19-23-20-41-27-6-3-2-5-26(23)27)33(47)42-28(32(38)46)17-21-8-12-24(37)13-9-21/h2-3,5-6,8-15,20,28-31,41H,4,7,16-19H2,1H3,(H2,38,46)(H,42,47)(H,43,48)(H4,39,40,44)/t28-,29-,30-,31-/m0/s1
DM8QTSU	CS	COC1=CC=C(C=C1)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=C(C=C5)Cl)C(=O)N)N=C(N)N
DM8QTSU	IK	IEBSBPORJZXBGY-ORYMTKCHSA-N
DM8QTSU	IU	(2S)-N-[(2S)-1-[[(2S)-1-amino-3-(4-chlorophenyl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-1-[(2S)-2-(diaminomethylideneamino)-3-(4-methoxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DM8QTSU	DE	Discovery agent

DMSC9FV	ID	DMSC9FV
DMSC9FV	DN	N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2
DMSC9FV	HS	Investigative
DMSC9FV	SN	CHEMBL390271; BDBM50201414; N alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2
DMSC9FV	DT	Small molecular drug
DMSC9FV	PC	44428305
DMSC9FV	MW	666.8
DMSC9FV	FM	C36H42N8O5
DMSC9FV	IC	InChI=1S/C36H42N8O5/c1-49-25-15-13-23(14-16-25)19-30(43-36(38)39)35(48)44-17-7-12-31(44)34(47)42-29(20-24-21-40-27-11-6-5-10-26(24)27)33(46)41-28(32(37)45)18-22-8-3-2-4-9-22/h2-6,8-11,13-16,21,28-31,40H,7,12,17-20H2,1H3,(H2,37,45)(H,41,46)(H,42,47)(H4,38,39,43)/t28-,29-,30-,31-/m0/s1
DMSC9FV	CS	COC1=CC=C(C=C1)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N=C(N)N
DMSC9FV	IK	QKBVJESURFKHSK-ORYMTKCHSA-N
DMSC9FV	IU	(2S)-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-1-[(2S)-2-(diaminomethylideneamino)-3-(4-methoxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DMSC9FV	DE	Discovery agent

DMRAN5O	ID	DMRAN5O
DMRAN5O	DN	Naltrexone-6-alpha-ol
DMRAN5O	HS	Investigative
DMRAN5O	SN	CHEMBL468469; 20410-98-4; SCHEMBL679581; ZINC1656961; BDBM50254511; FT-0672601; 17-(Cyclopropylmethyl)-4,5; A-epoxy-morphinan-3,6; A,14-triol; A)-17-(Cyclopropylmethyl)-4,5-epoxy-morphinan-3,6,14-triol; 6alpha-Naltrexol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
DMRAN5O	DT	Small molecular drug
DMRAN5O	PC	16099582
DMRAN5O	MW	343.4
DMRAN5O	FM	C20H25NO4
DMRAN5O	IC	InChI=1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15+,18-,19-,20+/m0/s1
DMRAN5O	CS	C1C[C@]2([C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@H]1O)OC5=C(C=C4)O)O
DMRAN5O	IK	JLVNEHKORQFVQJ-SBCNTATESA-N
DMRAN5O	IU	(4R,4aS,7S,7aR,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
DMRAN5O	DE	Discovery agent

DMNDOLZ	ID	DMNDOLZ
DMNDOLZ	DN	naltriben
DMNDOLZ	HS	Investigative
DMNDOLZ	SN	Naltrindole benzofuran; Naltriben; naltrindole benzofuran; 4,8-Methano-5H-bisbenzofuro(3,2-e:2',3'-g)isoquinoline-1,8a(9H)-diol, 7-(cyclopropylmethyl)-6,7,8,14b-tetrahydro-, (8R-(4bS*,8alpha,8beta,14bbeta))-; 111555-58-9; C26H25NO4; [3H]naltriben; [3H]-naltriben; NTB; naltrindolebenzofuran; GTPL1640; SCHEMBL1240717; CHEMBL100940; GTPL3828; BDBM82552; HMS2089G18; ZINC3874478; PDSP2_001551; LS-172157; CAS_111555-58-9; C20166; AB00691672-07;  naltrindole benzofuran
DMNDOLZ	DT	Small molecular drug
DMNDOLZ	PC	5486827
DMNDOLZ	MW	415.5
DMNDOLZ	FM	C26H25NO4
DMNDOLZ	IC	InChI=1S/C26H25NO4/c28-18-8-7-15-11-20-26(29)12-17-16-3-1-2-4-19(16)30-22(17)24-25(26,21(15)23(18)31-24)9-10-27(20)13-14-5-6-14/h1-4,7-8,14,20,24,28-29H,5-6,9-13H2/t20-,24+,25+,26-/m1/s1
DMNDOLZ	CS	C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8O6
DMNDOLZ	IK	ZHVWWEYETMPAMX-IFKAHUTRSA-N
DMNDOLZ	IU	(1S,2S,13R,21R)-22-(cyclopropylmethyl)-11,14-dioxa-22-azaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol
DMNDOLZ	CA	CAS 111555-58-9
DMNDOLZ	DE	Discovery agent

DMWXBYC	ID	DMWXBYC
DMWXBYC	DN	N-Aminoethylmorpholine
DMWXBYC	HS	Investigative
DMWXBYC	SN	4-(2-Aminoethyl)morpholine; 2038-03-1; 2-morpholinoethanamine; 4-Morpholineethanamine; 2-Morpholinoethylamine; N-Aminoethylmorpholine; 2-(Morpholin-4-Yl)Ethan-1-Amine; N-(2-Aminoethyl)morpholine; Morpholine, 4-(2-aminoethyl)-; N-2-Aminoethylmorpholine; 2-morpholin-4-ylethanamine; 2-morpholin-4-ylethylamine; 2-Morpholin-4-yl-ethylamine; N-2-Aminoethylmorfolin [Czech]; n-aminoethyl morpholine; N-2-Aminoethylmorfolin; N-(Aminoethyl)morpholine; beta-Aminoaethyl-morpholin [German]; 2-morpholino-1-ethanamine
DMWXBYC	DT	Small molecular drug
DMWXBYC	PC	408285
DMWXBYC	MW	130.19
DMWXBYC	FM	C6H14N2O
DMWXBYC	IC	InChI=1S/C6H14N2O/c7-1-2-8-3-5-9-6-4-8/h1-7H2
DMWXBYC	CS	C1COCCN1CCN
DMWXBYC	IK	RWIVICVCHVMHMU-UHFFFAOYSA-N
DMWXBYC	IU	2-morpholin-4-ylethanamine
DMWXBYC	CA	CAS 2038-03-1
DMWXBYC	DE	Discovery agent

DM1EZ3N	ID	DM1EZ3N
DM1EZ3N	DN	Namn
DM1EZ3N	HS	Investigative
DM1EZ3N	SN	NaMN; nicotinate mononucleotide; 321-02-8; nicotinic acid mononucleotide; Nicotinic acid mono nucleotide; AC1NRCHP; NCN; DB02382; 3-carboxy-1-[5-O-(hydroxyphosphinato)-beta-D-ribofuranosyl]pyridinium; [(2R,3S,4R,5R)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate; ((2R,3S,4R,5R)-5-(3-carboxypyridinium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate
DM1EZ3N	DT	Small molecular drug
DM1EZ3N	PC	5288991
DM1EZ3N	MW	335.2
DM1EZ3N	FM	C11H14NO9P
DM1EZ3N	IC	InChI=1S/C11H14NO9P/c13-8-7(5-20-22(17,18)19)21-10(9(8)14)12-3-1-2-6(4-12)11(15)16/h1-4,7-10,13-14H,5H2,(H2-,15,16,17,18,19)/t7-,8-,9-,10-/m1/s1
DM1EZ3N	CS	C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)[O-])O)O)C(=O)O
DM1EZ3N	IK	JOUIQRNQJGXQDC-ZYUZMQFOSA-N
DM1EZ3N	IU	[(2R,3S,4R,5R)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM1EZ3N	CA	CAS 321-02-8
DM1EZ3N	DE	Discovery agent

DMYDRB7	ID	DMYDRB7
DMYDRB7	DN	Naphthalen-1-yl 10H-phenothiazine-10-carboxylate
DMYDRB7	HS	Investigative
DMYDRB7	SN	CHEMBL451838; naphthalen-1-yl 10H-phenothiazine-10-carboxylate; naphthyl phenothiazine-10-carboxylate; BDBM50292622; ZINC27529770; AKOS002279100
DMYDRB7	DT	Small molecular drug
DMYDRB7	PC	16645664
DMYDRB7	MW	369.4
DMYDRB7	FM	C23H15NO2S
DMYDRB7	IC	InChI=1S/C23H15NO2S/c25-23(26-20-13-7-9-16-8-1-2-10-17(16)20)24-18-11-3-5-14-21(18)27-22-15-6-4-12-19(22)24/h1-15H
DMYDRB7	CS	C1=CC=C2C(=C1)C=CC=C2OC(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DMYDRB7	IK	BJICBLMMTYZFKB-UHFFFAOYSA-N
DMYDRB7	IU	naphthalen-1-yl phenothiazine-10-carboxylate
DMYDRB7	DE	Discovery agent

DM93CZW	ID	DM93CZW
DM93CZW	DN	Naphthalen-1-yl(10H-phenothiazin-10-yl)methanone
DM93CZW	HS	Investigative
DM93CZW	SN	CHEMBL240899; naphthalen-1-yl(10H-phenothiazin-10-yl)methanone
DM93CZW	DT	Small molecular drug
DM93CZW	PC	44435217
DM93CZW	MW	353.4
DM93CZW	FM	C23H15NOS
DM93CZW	IC	InChI=1S/C23H15NOS/c25-23(18-11-7-9-16-8-1-2-10-17(16)18)24-19-12-3-5-14-21(19)26-22-15-6-4-13-20(22)24/h1-15H
DM93CZW	CS	C1=CC=C2C(=C1)C=CC=C2C(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DM93CZW	IK	JJKRMXKTTVOCBF-UHFFFAOYSA-N
DM93CZW	IU	naphthalen-1-yl(phenothiazin-10-yl)methanone
DM93CZW	DE	Discovery agent

DM08W6U	ID	DM08W6U
DM08W6U	DN	Naphthalen-2-yl 10H-phenothiazine-10-carboxylate
DM08W6U	HS	Investigative
DM08W6U	SN	CHEMBL518302; naphthalen-2-yl 10H-phenothiazine-10-carboxylate
DM08W6U	DT	Small molecular drug
DM08W6U	PC	24905710
DM08W6U	MW	369.4
DM08W6U	FM	C23H15NO2S
DM08W6U	IC	InChI=1S/C23H15NO2S/c25-23(26-18-14-13-16-7-1-2-8-17(16)15-18)24-19-9-3-5-11-21(19)27-22-12-6-4-10-20(22)24/h1-15H
DM08W6U	CS	C1=CC=C2C=C(C=CC2=C1)OC(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DM08W6U	IK	DFCQYZLDLAWXGY-UHFFFAOYSA-N
DM08W6U	IU	naphthalen-2-yl phenothiazine-10-carboxylate
DM08W6U	DE	Discovery agent

DMDXM2A	ID	DMDXM2A
DMDXM2A	DN	Naphthalen-2-yl cyclohexylcarbamate
DMDXM2A	HS	Investigative
DMDXM2A	SN	naphthalen-2-yl cyclohexylcarbamate; CHEMBL77250; NSC204269; AC1L796V; SCHEMBL1690685; ZINC1738803; BDBM50128573; naphthalen-2-yl N-cyclohexylcarbamate; NSC-204269; Cyclohexyl-carbamic acid naphthalen-2-yl ester; US8815951, 110
DMDXM2A	DT	Small molecular drug
DMDXM2A	PC	306585
DMDXM2A	MW	269.34
DMDXM2A	FM	C17H19NO2
DMDXM2A	IC	InChI=1S/C17H19NO2/c19-17(18-15-8-2-1-3-9-15)20-16-11-10-13-6-4-5-7-14(13)12-16/h4-7,10-12,15H,1-3,8-9H2,(H,18,19)
DMDXM2A	CS	C1CCC(CC1)NC(=O)OC2=CC3=CC=CC=C3C=C2
DMDXM2A	IK	ZYHUWMGJJOBBCF-UHFFFAOYSA-N
DMDXM2A	IU	naphthalen-2-yl N-cyclohexylcarbamate
DMDXM2A	DE	Discovery agent

DMW8BXG	ID	DMW8BXG
DMW8BXG	DN	Naphthalen-2-yl(10H-phenothiazin-10-yl)methanone
DMW8BXG	HS	Investigative
DMW8BXG	SN	CHEMBL240900; naphthalen-2-yl(10H-phenothiazin-10-yl)methanone
DMW8BXG	DT	Small molecular drug
DMW8BXG	PC	44435218
DMW8BXG	MW	353.4
DMW8BXG	FM	C23H15NOS
DMW8BXG	IC	InChI=1S/C23H15NOS/c25-23(18-14-13-16-7-1-2-8-17(16)15-18)24-19-9-3-5-11-21(19)26-22-12-6-4-10-20(22)24/h1-15H
DMW8BXG	CS	C1=CC=C2C=C(C=CC2=C1)C(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DMW8BXG	IK	VEKGHAIWOIIXFF-UHFFFAOYSA-N
DMW8BXG	IU	naphthalen-2-yl(phenothiazin-10-yl)methanone
DMW8BXG	DE	Discovery agent

DML6FI3	ID	DML6FI3
DML6FI3	DN	Naphthalene Trisulfonate
DML6FI3	HS	Investigative
DML6FI3	SN	naphthalene-1,3,6-trisulfonic acid; 86-66-8; 1,3,6-Naphthalenetrisulfonic acid; Naphthalene-1,3,6-trisulphonic acid; CHEBI:32916; 123409-01-8; EINECS 201-690-8; AC1Q6WKO; 6321-17-1; 19437-42-4; SCHEMBL305166; AC1L1I64; CHEMBL1160117; DTXSID9058945; CTK2F6984; ZPBSAMLXSQCSOX-UHFFFAOYSA-N; ZINC1664865; Naphtalene-1,3,6-trisulfonic acid; 3611AC; AKOS015964183; OR51840; AJ-28977; AX8143250; KB-258586; ST50826289; 1,3, -Naphthalenetrisulfonicacid, trisodium salt, hydrate (9CI)
DML6FI3	DT	Small molecular drug
DML6FI3	PC	4437
DML6FI3	MW	365.3
DML6FI3	FM	C10H5O9S3-3
DML6FI3	IC	InChI=1S/C10H8O9S3/c11-20(12,13)7-1-2-9-6(3-7)4-8(21(14,15)16)5-10(9)22(17,18)19/h1-5H,(H,11,12,13)(H,14,15,16)(H,17,18,19)/p-3
DML6FI3	CS	C1=CC2=C(C=C(C=C2C=C1S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-]
DML6FI3	IK	ZPBSAMLXSQCSOX-UHFFFAOYSA-K
DML6FI3	IU	naphthalene-1,3,6-trisulfonate
DML6FI3	CA	CAS 19437-42-4
DML6FI3	CB	CHEBI:44434
DML6FI3	DE	Discovery agent

DMOQ43W	ID	DMOQ43W
DMOQ43W	DN	Naphthalene-1,4-diol
DMOQ43W	HS	Investigative
DMOQ43W	SN	Naphthalene-1,4-diol; 1,4-Dihydroxynaphthalene; 571-60-8; 1,4-NAPHTHALENEDIOL; 1,4-Naphthohydroquinone; Hydronaphthoquinone; Naphthohydroquinone; 1,4-Naphthoquinol; alpha-Naphthoquinhydrone; UNII-AML1P6T42C; CCRIS 7897; Naphthalene-1,4-dio; alpha-Naphthohydroquinone; EINECS 209-336-4; BRN 1307689; AML1P6T42C; CHEMBL206816; CHEBI:34063; PCILLCXFKWDRMK-UHFFFAOYSA-N; 1,4-Naphththalenediol; 1-Hydroxy-4-naphthol; 1,4-Naphthalene diol; napthalene- 1,4-diol; ACMC-1AXHC; Naphthalenediol-(1,4); 1,4-Dihydroxy-naphthalene; AC1L1X2M
DMOQ43W	DT	Small molecular drug
DMOQ43W	PC	11305
DMOQ43W	MW	160.17
DMOQ43W	FM	C10H8O2
DMOQ43W	IC	InChI=1S/C10H8O2/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6,11-12H
DMOQ43W	CS	C1=CC=C2C(=C1)C(=CC=C2O)O
DMOQ43W	IK	PCILLCXFKWDRMK-UHFFFAOYSA-N
DMOQ43W	IU	naphthalene-1,4-diol
DMOQ43W	CA	CAS 571-60-8
DMOQ43W	CB	CHEBI:34063
DMOQ43W	DE	Discovery agent

DMLHWNG	ID	DMLHWNG
DMLHWNG	DN	Naphthalene-2,6-disulfonic acid
DMLHWNG	HS	Investigative
DMLHWNG	SN	Naphthalene-2,6-disulfonic acid; 581-75-9; 2,6-NAPHTHALENEDISULFONIC ACID; 2,6-Naphthalene disulfonic acid; Ebert-Merz beta-acid; Naphthalene-2,6-disulphonic acid; UNII-BOR133U3TN; Ebert-Merz .beta.-acid; BOR133U3TN; CHEBI:41070; NSC37041; BIH; EINECS 209-471-9; NSC 37041; AC1L1X9A; 2,6-Naphthalenedisulfonicacid; SCHEMBL300937; CHEMBL1206869; DTXSID2060385; CTK1H0701; 2, 6-Naphthalenedisulfonic acid; FITZJYAVATZPMJ-UHFFFAOYSA-N; ZINC1669723; NSC-37041; AKOS015897573; OR51838; 2,6-NAPHTHALENEDISULPHONIC ACID; VZ33464; 1655-45-4 (di-hyd
DMLHWNG	DT	Small molecular drug
DMLHWNG	PC	11390
DMLHWNG	MW	288.3
DMLHWNG	FM	C10H8O6S2
DMLHWNG	IC	InChI=1S/C10H8O6S2/c11-17(12,13)9-3-1-7-5-10(18(14,15)16)4-2-8(7)6-9/h1-6H,(H,11,12,13)(H,14,15,16)
DMLHWNG	CS	C1=CC2=C(C=CC(=C2)S(=O)(=O)O)C=C1S(=O)(=O)O
DMLHWNG	IK	FITZJYAVATZPMJ-UHFFFAOYSA-N
DMLHWNG	IU	naphthalene-2,6-disulfonic acid
DMLHWNG	CA	CAS 581-75-9
DMLHWNG	CB	CHEBI:41070
DMLHWNG	DE	Discovery agent

DMG8A74	ID	DMG8A74
DMG8A74	DN	Naphthalene-2-carboxylic acid hydroxyamide
DMG8A74	HS	Investigative
DMG8A74	SN	2-Naphthohydroximic acid; 2-Naphthylhydroxamic acid; N,N-Naphthaloylhydroxylamine; 2-NAPHTHOHYDROXAMIC ACID; 10335-79-2; 2-Naphthoylhydroxamic acid; 2-Naphthalenecarboxamide, N-hydroxy-; N-Hydroxy-2-naphthalenecarboxamide; Naphthalene-2-carboxylic acid hydroxyamide; CHEMBL156672; N-hydroxynaphthalene-2-carboxamide; SCHEMBL6010034; AC1L18K7; DTXSID70145795; KUC110312N; BDBM50015160; AKOS000178377; KSC-264-28-1; LS-95339; 2-Naphthalenecarboxamide, N-hydroxy- (9CI)
DMG8A74	DT	Small molecular drug
DMG8A74	PC	25164
DMG8A74	MW	187.19
DMG8A74	FM	C11H9NO2
DMG8A74	IC	InChI=1S/C11H9NO2/c13-11(12-14)10-6-5-8-3-1-2-4-9(8)7-10/h1-7,14H,(H,12,13)
DMG8A74	CS	C1=CC=C2C=C(C=CC2=C1)C(=O)NO
DMG8A74	IK	PCJLUGWQCHMMAG-UHFFFAOYSA-N
DMG8A74	IU	N-hydroxynaphthalene-2-carboxamide
DMG8A74	CA	CAS 10335-79-2
DMG8A74	DE	Discovery agent

DMTWEQP	ID	DMTWEQP
DMTWEQP	DN	Naphthyridinomycin
DMTWEQP	HS	Investigative
DMTWEQP	SN	AC1MJ44U; 62046-87-1; DADMe-ImmH
DMTWEQP	PC	102148112
DMTWEQP	MW	417.5
DMTWEQP	FM	C21H27N3O6
DMTWEQP	IC	InChI=1S/C21H27N3O6/c1-8-17(26)13-12(18(27)19(8)29-3)11(7-25)24-16-14-9(6-10(20(24)28)22(14)2)21-23(15(13)16)4-5-30-21/h9-11,14-16,20-21,25,28H,4-7H2,1-3H3/t9?,10?,11-,14?,15+,16+,20-,21+/m0/s1
DMTWEQP	CS	CC1=C(C(=O)C2=C(C1=O)[C@@H]3[C@H]4C5C(CC(N5C)[C@@H](N4[C@H]2CO)O)[C@@H]6N3CCO6)OC
DMTWEQP	IK	SXDWNOFDSOXRRM-KZXGJYSISA-N
DMTWEQP	IU	(4R,9R,16R,18R,21S)-21-hydroxy-16-(hydroxymethyl)-13-methoxy-12,20-dimethyl-5-oxa-8,17,20-triazahexacyclo[15.3.1.03,19.04,8.09,18.010,15]henicosa-10(15),12-diene-11,14-dione
DMTWEQP	DE	Discovery agent

DM0OEGV	ID	DM0OEGV
DM0OEGV	DN	NAPHTHYRIDINONE
DM0OEGV	HS	Investigative
DM0OEGV	SN	NAPHTHYRIDINONE; CHEMBL204232; N-[3-Acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide; N-(3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl)acetamide; SCHEMBL762298; VHSIAYLBCLUAFT-UHFFFAOYSA-N
DM0OEGV	DT	Small molecular drug
DM0OEGV	PC	11386747
DM0OEGV	MW	514.799
DM0OEGV	FM	C25H18Cl3N3O3
DM0OEGV	IC	InChI=1S/C25H18Cl3N3O3/c1-12(32)21-23(29-13(2)33)19-11-18(14-4-6-15(26)7-5-14)22(30-24(19)31(3)25(21)34)17-9-8-16(27)10-20(17)28/h4-11H,1-3H3,(H,29,33)
DM0OEGV	CS	CC(=O)C1=C(C2=CC(=C(N=C2N(C1=O)C)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl)NC(=O)C
DM0OEGV	IK	VHSIAYLBCLUAFT-UHFFFAOYSA-N
DM0OEGV	IU	N-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide
DM0OEGV	DE	Discovery agent

DM8F5LR	ID	DM8F5LR
DM8F5LR	DN	NAPQI
DM8F5LR	HS	Investigative
DM8F5LR	SN	Napqi; Acetimidoquinone; 50700-49-7; N-acetyl-4-benzoquinone imine; N-Acetyl-4-benzoquinoneimine; N-Acetyl-p-benzoquinone imine; N-Acetylbenzoquinoneimine; N-Acetyl-P-benzoquinoneimine; N-Acetyl-p-quinonimine; N-Acetyl-p-benzoquinone; N-(4-oxocyclohexa-2,5-dien-1-ylidene)acetamide; UNII-G6S9BN13TI; CCRIS 5789; N-acetyl-1,4-benzoquinone imine; BRN 2435621; G6S9BN13TI; 2,5-Cyclohexadien-1-one, 4-acetylimino-; N-(4-Oxo-2,5-cyclohexadienylidene)acetamide; CHEBI:29132; N-(4-Oxo-2,5-cyclohexadien-1-ylidene)acetamide; Acetamide, N-(4
DM8F5LR	DT	Small molecular drug
DM8F5LR	PC	39763
DM8F5LR	MW	149.15
DM8F5LR	FM	C8H7NO2
DM8F5LR	IC	InChI=1S/C8H7NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5H,1H3
DM8F5LR	CS	CC(=O)N=C1C=CC(=O)C=C1
DM8F5LR	IK	URNSECGXFRDEDC-UHFFFAOYSA-N
DM8F5LR	IU	N-(4-oxocyclohexa-2,5-dien-1-ylidene)acetamide
DM8F5LR	CA	CAS 50700-49-7
DM8F5LR	CB	CHEBI:29132
DM8F5LR	DE	Autoimmune disease

DM85RJ1	ID	DM85RJ1
DM85RJ1	DN	N-arachidonoylglycine
DM85RJ1	HS	Investigative
DM85RJ1	SN	NAGly
DM85RJ1	DT	Small molecular drug
DM85RJ1	PC	5283389
DM85RJ1	MW	361.5
DM85RJ1	FM	C22H35NO3
DM85RJ1	IC	InChI=1S/C22H35NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21(24)23-20-22(25)26/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-20H2,1H3,(H,23,24)(H,25,26)/b7-6-,10-9-,13-12-,16-15-
DM85RJ1	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCC(=O)O
DM85RJ1	IK	YLEARPUNMCCKMP-DOFZRALJSA-N
DM85RJ1	IU	2-[[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]amino]acetic acid
DM85RJ1	CA	CAS 179113-91-8
DM85RJ1	CB	CHEBI:58961
DM85RJ1	DE	Discovery agent

DMF9U2O	ID	DMF9U2O
DMF9U2O	DN	N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMF9U2O	HS	Investigative
DMF9U2O	SN	CHEMBL204403; N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMF9U2O	DT	Small molecular drug
DMF9U2O	PC	11559610
DMF9U2O	MW	363.5
DMF9U2O	FM	C22H37NO3
DMF9U2O	IC	InChI=1S/C22H37NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23(26)20-21-24/h6-7,9-10,12-13,15-16,24,26H,2-5,8,11,14,17-21H2,1H3/b7-6-,10-9-,13-12-,16-15-
DMF9U2O	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N(CCO)O
DMF9U2O	IK	GSKSTUBDYCGHNA-DOFZRALJSA-N
DMF9U2O	IU	(5Z,8Z,11Z,14Z)-N-hydroxy-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide
DMF9U2O	DE	Discovery agent

DM49HIO	ID	DM49HIO
DM49HIO	DN	N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine
DM49HIO	HS	Investigative
DM49HIO	SN	CHEMBL382444; N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine; 883296-70-6; MolPort-009-019-187; HMS3650G10; BDBM50185034; ZINC13685181; 1875AH; SR-01000946282; SR-01000946282-1
DM49HIO	DT	Small molecular drug
DM49HIO	PC	11710300
DM49HIO	MW	363.5
DM49HIO	FM	C22H37NO3
DM49HIO	IC	InChI=1S/C22H37NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-26-21-20-24/h6-7,9-10,12-13,15-16,24H,2-5,8,11,14,17-21H2,1H3,(H,23,25)/b7-6-,10-9-,13-12-,16-15-
DM49HIO	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NOCCO
DM49HIO	IK	ANMKTCMIIFBOGG-DOFZRALJSA-N
DM49HIO	IU	(5Z,8Z,11Z,14Z)-N-(2-hydroxyethoxy)icosa-5,8,11,14-tetraenamide
DM49HIO	DE	Discovery agent

DMLVGT8	ID	DMLVGT8
DMLVGT8	DN	N-arachidonylmaleimide
DMLVGT8	HS	Investigative
DMLVGT8	SN	N-Arachidonylmaleimide; N-Arachidonyl Maleimide; CHEMBL561924; BDBM50295658; 876305-42-9; SCHEMBL5086361; BDBM60419; GZNZRHSGGQUYAP-DOFZRALJSA-N; MolPort-019-939-191; HMS3650G15; ZINC27645447; 1913AH; N-Arachidonylmaleimide, &gt; SR-01000946786; SR-01000946786-1; Eicosa-5Z,8Z,11Z,14Z-tetraenyl-1-pyrrole-2,5-dione
DMLVGT8	DT	Small molecular drug
DMLVGT8	PC	25021164
DMLVGT8	MW	369.5
DMLVGT8	FM	C24H35NO2
DMLVGT8	IC	InChI=1S/C24H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22-25-23(26)20-21-24(25)27/h6-7,9-10,12-13,15-16,20-21H,2-5,8,11,14,17-19,22H2,1H3/b7-6-,10-9-,13-12-,16-15-
DMLVGT8	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCN1C(=O)C=CC1=O
DMLVGT8	IK	GZNZRHSGGQUYAP-DOFZRALJSA-N
DMLVGT8	IU	1-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenyl]pyrrole-2,5-dione
DMLVGT8	DE	Discovery agent

DMI7A6R	ID	DMI7A6R
DMI7A6R	DN	Narciclasine
DMI7A6R	HS	Investigative
DMI7A6R	SN	Narciclasine; Lycoricidinol; 29477-83-6; Lycoricidin-A; Narciclasina; NSC 266535; BRN 1087400; NSC266535; Lycorcidinol; Nacriclasine; C14H13NO7; CHEMBL98745; 3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one; CHEBI:70169; (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one; (2S,3R,4S,4aR)-2,3,4,7-Tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one
DMI7A6R	DT	Small molecular drug
DMI7A6R	PC	72376
DMI7A6R	MW	307.25
DMI7A6R	FM	C14H13NO7
DMI7A6R	IC	InChI=1S/C14H13NO7/c16-6-1-5-4-2-7-13(22-3-21-7)11(18)8(4)14(20)15-9(5)12(19)10(6)17/h1-2,6,9-10,12,16-19H,3H2,(H,15,20)/t6-,9+,10+,12-/m0/s1
DMI7A6R	CS	C1OC2=C(O1)C(=C3C(=C2)C4=C[C@@H]([C@H]([C@H]([C@@H]4NC3=O)O)O)O)O
DMI7A6R	IK	LZAZURSABQIKGB-AEKGRLRDSA-N
DMI7A6R	IU	(2S,3R,4S,4aR)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one
DMI7A6R	CA	CAS 29477-83-6
DMI7A6R	CB	CHEBI:70169
DMI7A6R	DE	Melanoma

DM4DG1Y	ID	DM4DG1Y
DM4DG1Y	DN	Naringin
DM4DG1Y	HS	Investigative
DM4DG1Y	SN	Naringoside; AC1NR4U8; 4',5,7-Trihydroxyflavanone-7-rutinoside; 4',5,7-Trihydroxyflavanone-7-rhamnoglucoside
DM4DG1Y	DT	Small molecular drug
DM4DG1Y	PC	442428
DM4DG1Y	MW	580.5
DM4DG1Y	FM	C27H32O14
DM4DG1Y	IC	InChI=1S/C27H32O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-7,10,16,18,20-30,32-36H,8-9H2,1H3/t10-,16-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1
DM4DG1Y	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O
DM4DG1Y	IK	DFPMSGMNTNDNHN-ZPHOTFPESA-N
DM4DG1Y	IU	(2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DM4DG1Y	CA	CAS 10236-47-2
DM4DG1Y	CB	CHEBI:28819
DM4DG1Y	DE	Discovery agent

DMMUABE	ID	DMMUABE
DMMUABE	DN	Naringin
DMMUABE	HS	Investigative
DMMUABE	SN	Naringenin 7-O-neohesperidoside; Naringenin 7-Rhamnoglucoside; Naringenin,(S); Naringenine-7-rhamnosidoglucoside; Naringin hydrate; Naringoside; SR-01000736681; aurantiin; naringin; (2S)-Naringin; 10236-47-2; 4',5,7-trihydroxyflavanone 7-rhamnoglucoside; 4'5-diOH-Flavone-7-rhgluc; AI3-19008; C27H32O14; CHEBI:28819; CHEMBL451532; EINECS 233-566-4; MFCD00148888; N7TD9J649B; Naringenin 7-O-[alpha-L-rhamnosyl-(1-&gt;2)-beta-D-glucoside]; Naringenin-7-beta-neohesperidoside; UNII-N7TD9J649B
DMMUABE	PC	442428
DMMUABE	MW	580.5
DMMUABE	FM	C27H32O14
DMMUABE	IC	DFPMSGMNTNDNHN-ZPHOTFPESA-N
DMMUABE	CS	CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O
DMMUABE	IK	1S/C27H32O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-7,10,16,18,20-30,32-36H,8-9H2,1H3/t10-,16-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1
DMMUABE	IU	(2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMMUABE	CA	CAS 10236-47-2
DMMUABE	CB	CHEBI:28819
DMMUABE	DE	Ovarian cancer

DM3RP25	ID	DM3RP25
DM3RP25	DN	NAVPNLRGDLQVLAQKVART
DM3RP25	HS	Investigative
DM3RP25	PC	91935374
DM3RP25	MW	2163.5
DM3RP25	FM	C93H163N31O28
DM3RP25	IC	InChI=1S/C93H163N31O28/c1-41(2)34-57(82(142)108-47(13)73(133)112-55(26-28-63(96)126)78(138)114-53(22-17-18-30-94)79(139)120-69(44(7)8)88(148)109-48(14)74(134)111-54(24-20-32-105-93(102)103)80(140)123-72(50(16)125)91(151)152)119-89(149)70(45(9)10)121-81(141)56(27-29-64(97)127)115-84(144)59(36-43(5)6)117-86(146)61(39-68(131)132)110-67(130)40-106-77(137)52(23-19-31-104-92(100)101)113-83(143)58(35-42(3)4)116-85(145)60(38-66(99)129)118-87(147)62-25-21-33-124(62)90(150)71(46(11)12)122-75(135)49(15)107-76(136)51(95)37-65(98)128/h41-62,69-72,125H,17-40,94-95H2,1-16H3,(H2,96,126)(H2,97,127)(H2,98,128)(H2,99,129)(H,106,137)(H,107,136)(H,108,142)(H,109,148)(H,110,130)(H,111,134)(H,112,133)(H,113,143)(H,114,138)(H,115,144)(H,116,145)(H,117,146)(H,118,147)(H,119,149)(H,120,139)(H,121,141)(H,122,135)(H,123,140)(H,131,132)(H,151,152)(H4,100,101,104)(H4,102,103,105)/t47-,48-,49-,50+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,69-,70-,71-,72-/m0/s1
DM3RP25	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)N)O
DM3RP25	IK	BIPRZBFRCFOBDQ-KAGUSELOSA-N
DM3RP25	IU	(3S)-4-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DM3RP25	DE	Discovery agent

DMO6T9C	ID	DMO6T9C
DMO6T9C	DN	NAX-5055
DMO6T9C	HS	Investigative
DMO6T9C	DE	Epileptic seizures

DMNM6GQ	ID	DMNM6GQ
DMNM6GQ	DN	NB3178
DMNM6GQ	HS	Investigative
DMNM6GQ	CP	New biotics
DMNM6GQ	DE	Gram-positive bacterial infection

DM7K36E	ID	DM7K36E
DM7K36E	DN	NB-325
DM7K36E	HS	Investigative
DM7K36E	SN	PEHMB; Polyethylene hexamethylene biguanide
DM7K36E	CP	Novaflux Biosciences Inc
DM7K36E	DT	Small molecular drug
DM7K36E	PC	15954275
DM7K36E	MW	495.5
DM7K36E	FM	C16H36Cl2N14
DM7K36E	IC	InChI=1S/C16H34N14.2ClH/c17-5-8-27-15(22)29-13(20)25-6-3-1-2-4-7-26-14(21)30-16(23)28-10-9-24-12(19)11-18;;/h1-10,17H2,(H2,19,24)(H5,20,22,25,27,29)(H5,21,23,26,28,30);2*1H
DM7K36E	CS	C(CCC[NH+]=C(N)NC(=NCCN=C(C#N)N)N)CC[NH+]=C(N)NC(=NCCN)N.[Cl-].[Cl-]
DM7K36E	IK	CNGBVJCBMLEXDO-UHFFFAOYSA-N
DM7K36E	IU	[amino-[[N'-[2-[[amino(cyano)methylidene]amino]ethyl]carbamimidoyl]amino]methylidene]-[6-[amino-[[N'-(2-aminoethyl)carbamimidoyl]amino]methylidene]azaniumylhexyl]azanium;dichloride
DM7K36E	DE	Human immunodeficiency virus infection

DMJHWGS	ID	DMJHWGS
DMJHWGS	DN	NB3322
DMJHWGS	HS	Investigative
DMJHWGS	CP	New biotics
DMJHWGS	DE	Gram-positive bacterial infection

DMTZ1XV	ID	DMTZ1XV
DMTZ1XV	DN	NBBCC
DMTZ1XV	HS	Investigative
DMTZ1XV	SN	N-Butyl-beta-carboline-3-carboxylate; beta-Ccb; 84454-35-3; N-Butyl beta-carboline-3-carboxylate; butyl; butyl 9H-pyrido[3,4-b]indole-3-carboxylate; beta-CARBOLINE-3-CARBOXYLIC ACID BUTYL ESTER; WGNGIELOOKACSB-UHFFFAOYSA-N; Tocris-0405; Biomol-NT_000274; AC1Q66WT; I(2)-CCB; GTPL2374; SCHEMBL2214572; CHEMBL148296; BPBio1_001057; AC1L2U46; CHEBI:34867; Butyl  -carboline-3-carboxylate; DTXSID90233426; MolPort-023-275-884; HMS3266M05; Butyl beta-carboline-3-carboxylate; ZINC2555360; Butyl; n-butyl-beta-carboline-3-carboxylate
DMTZ1XV	DT	Small molecular drug
DMTZ1XV	PC	128618
DMTZ1XV	MW	268.31
DMTZ1XV	FM	C16H16N2O2
DMTZ1XV	IC	InChI=1S/C16H16N2O2/c1-2-3-8-20-16(19)14-9-12-11-6-4-5-7-13(11)18-15(12)10-17-14/h4-7,9-10,18H,2-3,8H2,1H3
DMTZ1XV	CS	CCCCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMTZ1XV	IK	WGNGIELOOKACSB-UHFFFAOYSA-N
DMTZ1XV	IU	butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DMTZ1XV	CA	CAS 84454-35-3
DMTZ1XV	CB	CHEBI:34867
DMTZ1XV	DE	Discovery agent

DMX0Y79	ID	DMX0Y79
DMX0Y79	DN	N-BENZOYL-D-ALANINE
DMX0Y79	HS	Investigative
DMX0Y79	SN	n-benzoyl-d-alanine; Bz-D-Ala-Oh; 17966-60-8; D-Alanine, N-benzoyl-; BZO-D-ALA-OH; 2-Benzoylamino-propionic acid; Benzoyl-D-Alanine; N-Benzoyl-D-Ala-OH; AC1Q5JMF; AC1Q29AE; AC1L3M8G; CHEMBL55771; (R)-2-benzamidopropanoic acid; SCHEMBL2796740; (2R)-2-benzamidopropanoic acid; CTK0H2174; ANW-60729; ZINC82068115; 9422AA; AKOS000352443; DB08508; AB02521; (2R)-2-(phenylformamido)propanoic acid; KB-48541; AS-48959; AJ-11083; TC-149474; FT-0695165
DMX0Y79	DT	Small molecular drug
DMX0Y79	PC	91514
DMX0Y79	MW	193.2
DMX0Y79	FM	C10H11NO3
DMX0Y79	IC	InChI=1S/C10H11NO3/c1-7(10(13)14)11-9(12)8-5-3-2-4-6-8/h2-7H,1H3,(H,11,12)(H,13,14)/t7-/m1/s1
DMX0Y79	CS	C[C@H](C(=O)O)NC(=O)C1=CC=CC=C1
DMX0Y79	IK	UAQVHNZEONHPQG-SSDOTTSWSA-N
DMX0Y79	IU	(2R)-2-benzamidopropanoic acid
DMX0Y79	DE	Discovery agent

DM7U81L	ID	DM7U81L
DM7U81L	DN	N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea
DM7U81L	HS	Investigative
DM7U81L	SN	N-BENZOYL-N'-BETA-D-GLUCOPYRANOSYL UREA; CHEMBL489799; BZD; 2qnb; DB04295; AC1L9JVC; SCHEMBL4311564; 1k08; 1k06; BDBM50263771; 1-(beta-D-Glucopyranosyl)-3-benzoylurea; N-BENZOYL-N''-BETA-D-GLUCOPYRANOSYL UREA; N-[(phenylcarbonyl)carbamoyl]-beta-D-glucopyranosylamine; N-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]benzamide; N-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-ylcarbamoyl)benzamide
DM7U81L	DT	Small molecular drug
DM7U81L	PC	446600
DM7U81L	MW	326.3
DM7U81L	FM	C14H18N2O7
DM7U81L	IC	InChI=1S/C14H18N2O7/c17-6-8-9(18)10(19)11(20)13(23-8)16-14(22)15-12(21)7-4-2-1-3-5-7/h1-5,8-11,13,17-20H,6H2,(H2,15,16,21,22)/t8-,9-,10+,11-,13-/m1/s1
DM7U81L	CS	C1=CC=C(C=C1)C(=O)NC(=O)N[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM7U81L	IK	JSBCZGSPFATCOV-BZNQNGANSA-N
DM7U81L	IU	N-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]benzamide
DM7U81L	DE	Discovery agent

DMRJ4B1	ID	DMRJ4B1
DMRJ4B1	DN	N-benzoyl-phenylalanyl-glycine-nitrile
DMRJ4B1	HS	Investigative
DMRJ4B1	SN	phenylalanine derivative, 43; SCHEMBL5517755; CHEMBL371466; BDBM20119
DMRJ4B1	DT	Small molecular drug
DMRJ4B1	PC	11702265
DMRJ4B1	MW	307.3
DMRJ4B1	FM	C18H17N3O2
DMRJ4B1	IC	InChI=1S/C18H17N3O2/c19-11-12-20-18(23)16(13-14-7-3-1-4-8-14)21-17(22)15-9-5-2-6-10-15/h1-10,16H,12-13H2,(H,20,23)(H,21,22)/t16-/m0/s1
DMRJ4B1	CS	C1=CC=C(C=C1)C[C@@H](C(=O)NCC#N)NC(=O)C2=CC=CC=C2
DMRJ4B1	IK	WEIUVZVWLANUJJ-INIZCTEOSA-N
DMRJ4B1	IU	N-[(2S)-1-(cyanomethylamino)-1-oxo-3-phenylpropan-2-yl]benzamide
DMRJ4B1	DE	Discovery agent

DMOQMEU	ID	DMOQMEU
DMOQMEU	DN	N-benzyl brucine
DMOQMEU	HS	Investigative
DMOQMEU	SN	BNO
DMOQMEU	DT	Small molecular drug
DMOQMEU	PC	44358893
DMOQMEU	MW	485.6
DMOQMEU	FM	C30H33N2O4+
DMOQMEU	IC	InChI=1S/C30H33N2O4/c1-34-23-13-21-22(14-24(23)35-2)31-27(33)15-25-28-20-12-26-30(21,29(28)31)9-10-32(26,17-19(20)8-11-36-25)16-18-6-4-3-5-7-18/h3-8,13-14,20,25-26,28-29H,9-12,15-17H2,1-2H3/q+1/t20-,25-,26-,28-,29-,30+,32?/m0/s1
DMOQMEU	CS	COC1=C(C=C2C(=C1)[C@]34CC[N+]5([C@H]3C[C@@H]6[C@@H]7[C@@H]4N2C(=O)C[C@@H]7OCC=C6C5)CC8=CC=CC=C8)OC
DMOQMEU	IK	XFMQETLKDRNYRE-QIBSSCBHSA-N
DMOQMEU	IU	(4aR,5aS,8aS,13aS,15aS,15bR)-6-benzyl-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-6-ium-14-one
DMOQMEU	DE	Discovery agent

DMN9WZ3	ID	DMN9WZ3
DMN9WZ3	DN	N-Benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
DMN9WZ3	HS	Investigative
DMN9WZ3	SN	CHEMBL456005; N-Benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
DMN9WZ3	DT	Small molecular drug
DMN9WZ3	PC	44590783
DMN9WZ3	MW	347.5
DMN9WZ3	FM	C24H29NO
DMN9WZ3	IC	InChI=1S/C24H29NO/c1-3-4-14-26-24-13-12-22-16-21(10-11-23(22)17-24)15-19(2)25-18-20-8-6-5-7-9-20/h5-13,16-17,19,25H,3-4,14-15,18H2,1-2H3
DMN9WZ3	CS	CCCCOC1=CC2=C(C=C1)C=C(C=C2)CC(C)NCC3=CC=CC=C3
DMN9WZ3	IK	YIPJGAAYIMEAQI-UHFFFAOYSA-N
DMN9WZ3	IU	N-benzyl-1-(6-butoxynaphthalen-2-yl)propan-2-amine
DMN9WZ3	DE	Discovery agent

DMKJ6F8	ID	DMKJ6F8
DMKJ6F8	DN	N-Benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
DMKJ6F8	HS	Investigative
DMKJ6F8	SN	CHEMBL510214; N-Benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
DMKJ6F8	DT	Small molecular drug
DMKJ6F8	PC	44590782
DMKJ6F8	MW	305.4
DMKJ6F8	FM	C21H23NO
DMKJ6F8	IC	InChI=1S/C21H23NO/c1-16(22-15-17-6-4-3-5-7-17)12-18-8-9-20-14-21(23-2)11-10-19(20)13-18/h3-11,13-14,16,22H,12,15H2,1-2H3
DMKJ6F8	CS	CC(CC1=CC2=C(C=C1)C=C(C=C2)OC)NCC3=CC=CC=C3
DMKJ6F8	IK	KYXRSMFSOLANEF-UHFFFAOYSA-N
DMKJ6F8	IU	N-benzyl-1-(6-methoxynaphthalen-2-yl)propan-2-amine
DMKJ6F8	DE	Discovery agent

DMHVRFM	ID	DMHVRFM
DMHVRFM	DN	N-Benzyl,N-methyl-1H-indole-2-carboxamide
DMHVRFM	HS	Investigative
DMHVRFM	SN	CHEMBL456107; N-Benzyl,N-methyl-1H-indole-2-carboxamide; BDBM50273490; AKOS008916266
DMHVRFM	DT	Small molecular drug
DMHVRFM	PC	23020609
DMHVRFM	MW	264.32
DMHVRFM	FM	C17H16N2O
DMHVRFM	IC	InChI=1S/C17H16N2O/c1-19(12-13-7-3-2-4-8-13)17(20)16-11-14-9-5-6-10-15(14)18-16/h2-11,18H,12H2,1H3
DMHVRFM	CS	CN(CC1=CC=CC=C1)C(=O)C2=CC3=CC=CC=C3N2
DMHVRFM	IK	DIVKZMHOMDSMBZ-UHFFFAOYSA-N
DMHVRFM	IU	N-benzyl-N-methyl-1H-indole-2-carboxamide
DMHVRFM	DE	Discovery agent

DM8I7N2	ID	DM8I7N2
DM8I7N2	DN	N-benzyl,N-methyl-1H-pyrrole-2-carboxamide
DM8I7N2	HS	Investigative
DM8I7N2	SN	CHEMBL352538; N-benzyl-N-methyl-1H-pyrrole-2-carboxamide; pyrrole inhibitor 10; N-benzyl,N-methyl-1H-pyrrole-2-carboxamide; BDBM15584; ZINC13493570
DM8I7N2	DT	Small molecular drug
DM8I7N2	PC	11085165
DM8I7N2	MW	214.26
DM8I7N2	FM	C13H14N2O
DM8I7N2	IC	InChI=1S/C13H14N2O/c1-15(10-11-6-3-2-4-7-11)13(16)12-8-5-9-14-12/h2-9,14H,10H2,1H3
DM8I7N2	CS	CN(CC1=CC=CC=C1)C(=O)C2=CC=CN2
DM8I7N2	IK	HDVIQRKATXBZHO-UHFFFAOYSA-N
DM8I7N2	IU	N-benzyl-N-methyl-1H-pyrrole-2-carboxamide
DM8I7N2	DE	Discovery agent

DM2YZC5	ID	DM2YZC5
DM2YZC5	DN	N-benzyl[D-Pro-10]Dyn A-(1-11)
DM2YZC5	HS	Investigative
DM2YZC5	SN	CHEMBL268818; N-benzyl[D-Pro-10]Dyn A-(1-11); BDBM50059583
DM2YZC5	PC	44325182
DM2YZC5	MW	1452.7
DM2YZC5	FM	C70H109N21O13
DM2YZC5	IC	InChI=1S/C70H109N21O13/c1-5-43(4)58(65(101)87-50(25-16-34-80-70(76)77)66(102)91-35-17-26-55(91)64(100)88-51(67(103)104)22-12-13-31-71)90-61(97)49(24-15-33-79-69(74)75)85-60(96)48(23-14-32-78-68(72)73)86-62(98)53(36-42(2)3)89-63(99)54(38-44-18-8-6-9-19-44)84-57(94)41-82-56(93)40-83-59(95)52(37-45-27-29-47(92)30-28-45)81-39-46-20-10-7-11-21-46/h6-11,18-21,27-30,42-43,48-55,58,81,92H,5,12-17,22-26,31-41,71H2,1-4H3,(H,82,93)(H,83,95)(H,84,94)(H,85,96)(H,86,98)(H,87,101)(H,88,100)(H,89,99)(H,90,97)(H,103,104)(H4,72,73,78)(H4,74,75,79)(H4,76,77,80)/t43-,48-,49-,50-,51-,52-,53-,54-,55-,58-/m0/s1
DM2YZC5	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)NCC4=CC=CC=C4
DM2YZC5	IK	SCUDNMPTYPZVCN-RSZDUZASSA-N
DM2YZC5	IU	(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-(benzylamino)-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DM2YZC5	DE	Discovery agent

DM7SEM1	ID	DM7SEM1
DM7SEM1	DN	N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine
DM7SEM1	HS	Investigative
DM7SEM1	SN	CHEMBL571560; N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine; MCL-630
DM7SEM1	DT	Small molecular drug
DM7SEM1	PC	44627901
DM7SEM1	MW	400.6
DM7SEM1	FM	C28H36N2
DM7SEM1	IC	InChI=1S/C28H36N2/c1-2-7-21(8-3-1)19-29-24-13-12-23-17-27-25-11-4-5-14-28(25,26(23)18-24)15-16-30(27)20-22-9-6-10-22/h1-3,7-8,12-13,18,22,25,27,29H,4-6,9-11,14-17,19-20H2/t25-,27+,28+/m0/s1
DM7SEM1	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NCC5=CC=CC=C5)CC6CCC6
DM7SEM1	IK	WFGYABIAABXTFI-KJYTXNCISA-N
DM7SEM1	IU	(1R,9R,10R)-N-benzyl-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DM7SEM1	DE	Discovery agent

DMLP9VM	ID	DMLP9VM
DMLP9VM	DN	N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine
DMLP9VM	HS	Investigative
DMLP9VM	SN	CHEMBL571998; N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine; MCL-610
DMLP9VM	DT	Small molecular drug
DMLP9VM	PC	44627790
DMLP9VM	MW	386.6
DMLP9VM	FM	C27H34N2
DMLP9VM	IC	InChI=1S/C27H34N2/c1-2-6-20(7-3-1)18-28-23-12-11-22-16-26-24-8-4-5-13-27(24,25(22)17-23)14-15-29(26)19-21-9-10-21/h1-3,6-7,11-12,17,21,24,26,28H,4-5,8-10,13-16,18-19H2/t24-,26+,27+/m0/s1
DMLP9VM	CS	C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NCC5=CC=CC=C5)CC6CC6
DMLP9VM	IK	CDLAPAAACNSKLQ-WYMJOSIYSA-N
DMLP9VM	IU	(1R,9R,10R)-N-benzyl-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DMLP9VM	DE	Discovery agent

DMA3YWU	ID	DMA3YWU
DMA3YWU	DN	N-Benzyl-1H-indole-2-carboxamide
DMA3YWU	HS	Investigative
DMA3YWU	SN	N-Benzyl-1H-indole-2-carboxamide; CHEMBL464799; AC1OYZAF; SCHEMBL2735969; MolPort-002-497-469; HMS1751G10; ZINC6649233; STL100558; BDBM50273489; AKOS005715761; MCULE-5762597832; NCGC00300187-01; AB01108905-02; Z27748935
DMA3YWU	DT	Small molecular drug
DMA3YWU	PC	8023988
DMA3YWU	MW	250.29
DMA3YWU	FM	C16H14N2O
DMA3YWU	IC	InChI=1S/C16H14N2O/c19-16(17-11-12-6-2-1-3-7-12)15-10-13-8-4-5-9-14(13)18-15/h1-10,18H,11H2,(H,17,19)
DMA3YWU	CS	C1=CC=C(C=C1)CNC(=O)C2=CC3=CC=CC=C3N2
DMA3YWU	IK	AYMFXIQFBKQBGU-UHFFFAOYSA-N
DMA3YWU	IU	N-benzyl-1H-indole-2-carboxamide
DMA3YWU	DE	Discovery agent

DMC7XST	ID	DMC7XST
DMC7XST	DN	N-Benzyl-1'H-phenothiazine-1'-carboxamide
DMC7XST	HS	Investigative
DMC7XST	SN	CHEMBL589078; N-benzyl-10H-phenothiazine-10-carboxamide; ChemDiv3_004499; AC1LE3H3; Oprea1_734190; ZINC91218; MolPort-000-807-945; HMS1485M11; N-benzylphenothiazine-10-carboxamide; STK825822; BDBM50308407; N-benzylphenothiazin-10-ylcarboxamide; AKOS001676383; MCULE-7023337069; CCG-113838; IDI1_022409; ST51040739; N-Benzyl-1''H-phenothiazine-1''-carboxamide; AB00121381-01; SR-01000506160; SR-01000506160-1; BRD-K82322069-001-01-0
DMC7XST	DT	Small molecular drug
DMC7XST	PC	705757
DMC7XST	MW	332.4
DMC7XST	FM	C20H16N2OS
DMC7XST	IC	InChI=1S/C20H16N2OS/c23-20(21-14-15-8-2-1-3-9-15)22-16-10-4-6-12-18(16)24-19-13-7-5-11-17(19)22/h1-13H,14H2,(H,21,23)
DMC7XST	CS	C1=CC=C(C=C1)CNC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMC7XST	IK	ZGPOCYPNYDVRTG-UHFFFAOYSA-N
DMC7XST	IU	N-benzylphenothiazine-10-carboxamide
DMC7XST	DE	Discovery agent

DM73ZHV	ID	DM73ZHV
DM73ZHV	DN	N-benzyl-1H-pyrrole-2-carboxamide
DM73ZHV	HS	Investigative
DM73ZHV	SN	N-benzyl-1H-pyrrole-2-carboxamide; CHEMBL174040; pyrrole inhibitor 9; 1H-Pyrrole-2-carboxamide, N-(phenylmethyl)-; SCHEMBL2576103; BDBM15583; AKOS027595596
DM73ZHV	DT	Small molecular drug
DM73ZHV	PC	11019886
DM73ZHV	MW	200.24
DM73ZHV	FM	C12H12N2O
DM73ZHV	IC	InChI=1S/C12H12N2O/c15-12(11-7-4-8-13-11)14-9-10-5-2-1-3-6-10/h1-8,13H,9H2,(H,14,15)
DM73ZHV	CS	C1=CC=C(C=C1)CNC(=O)C2=CC=CN2
DM73ZHV	IK	PSYQATYJXPGBDC-UHFFFAOYSA-N
DM73ZHV	IU	N-benzyl-1H-pyrrole-2-carboxamide
DM73ZHV	DE	Discovery agent

DM8A23B	ID	DM8A23B
DM8A23B	DN	N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8A23B	HS	Investigative
DM8A23B	SN	N-benzyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM8A23B	DT	Small molecular drug
DM8A23B	PC	3149447
DM8A23B	MW	278.3
DM8A23B	FM	C17H14N2O2
DM8A23B	IC	InChI=1S/C17H14N2O2/c20-16(14-11-18-15-9-5-4-8-13(14)15)17(21)19-10-12-6-2-1-3-7-12/h1-9,11,18H,10H2,(H,19,21)
DM8A23B	CS	C1=CC=C(C=C1)CNC(=O)C(=O)C2=CNC3=CC=CC=C32
DM8A23B	IK	HWOWPGLTTSFLOQ-UHFFFAOYSA-N
DM8A23B	IU	N-benzyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM8A23B	CA	CAS 55654-71-2
DM8A23B	DE	Discovery agent

DMMT65J	ID	DMMT65J
DMMT65J	DN	N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMMT65J	HS	Investigative
DMMT65J	SN	CHEMBL75307; N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide; N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxo-acetamide
DMMT65J	DT	Small molecular drug
DMMT65J	PC	10426330
DMMT65J	MW	323.3
DMMT65J	FM	C17H13N3O4
DMMT65J	IC	InChI=1S/C17H13N3O4/c21-16(17(22)19-9-11-4-2-1-3-5-11)14-10-18-15-7-6-12(20(23)24)8-13(14)15/h1-8,10,18H,9H2,(H,19,22)
DMMT65J	CS	C1=CC=C(C=C1)CNC(=O)C(=O)C2=CNC3=C2C=C(C=C3)[N+](=O)[O-]
DMMT65J	IK	JYXHNHBKWZQGLB-UHFFFAOYSA-N
DMMT65J	IU	N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMMT65J	DE	Discovery agent

DM0ZXBQ	ID	DM0ZXBQ
DM0ZXBQ	DN	N-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine
DM0ZXBQ	HS	Investigative
DM0ZXBQ	SN	CHEMBL1085780; N-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine; BDBM50319968
DM0ZXBQ	DT	Small molecular drug
DM0ZXBQ	PC	46891014
DM0ZXBQ	MW	254.33
DM0ZXBQ	FM	C15H18N4
DM0ZXBQ	IC	InChI=1S/C15H18N4/c1-2-6-13(7-3-1)12-17-14-8-9-16-15(18-14)19-10-4-5-11-19/h1-3,6-9H,4-5,10-12H2,(H,16,17,18)
DM0ZXBQ	CS	C1CCN(C1)C2=NC=CC(=N2)NCC3=CC=CC=C3
DM0ZXBQ	IK	PGBNXXDXGXQQRQ-UHFFFAOYSA-N
DM0ZXBQ	IU	N-benzyl-2-pyrrolidin-1-ylpyrimidin-4-amine
DM0ZXBQ	DE	Discovery agent

DM3C0P2	ID	DM3C0P2
DM3C0P2	DN	N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide
DM3C0P2	HS	Investigative
DM3C0P2	SN	CHEMBL94764; AC1Q2LMI; N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide; AC1MT671; ZINC5121035; BDBM50146383; AKOS003681368; MCULE-1042732308; N-benzyl-2-[(4-methylphenyl)sulfonylamino]benzamide
DM3C0P2	DT	Small molecular drug
DM3C0P2	PC	3545567
DM3C0P2	MW	380.5
DM3C0P2	FM	C21H20N2O3S
DM3C0P2	IC	InChI=1S/C21H20N2O3S/c1-16-11-13-18(14-12-16)27(25,26)23-20-10-6-5-9-19(20)21(24)22-15-17-7-3-2-4-8-17/h2-14,23H,15H2,1H3,(H,22,24)
DM3C0P2	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC3=CC=CC=C3
DM3C0P2	IK	ASKBFNKCMLTGPX-UHFFFAOYSA-N
DM3C0P2	IU	N-benzyl-2-[(4-methylphenyl)sulfonylamino]benzamide
DM3C0P2	DE	Discovery agent

DMQCGFL	ID	DMQCGFL
DMQCGFL	DN	N-benzyl-2-morpholinopyrimidin-4-amine
DMQCGFL	HS	Investigative
DMQCGFL	SN	CHEMBL1085781; N-benzyl-2-morpholinopyrimidin-4-amine; BDBM50319969; AKOS028689215; SR-01000647481
DMQCGFL	DT	Small molecular drug
DMQCGFL	PC	46891015
DMQCGFL	MW	270.33
DMQCGFL	FM	C15H18N4O
DMQCGFL	IC	InChI=1S/C15H18N4O/c1-2-4-13(5-3-1)12-17-14-6-7-16-15(18-14)19-8-10-20-11-9-19/h1-7H,8-12H2,(H,16,17,18)
DMQCGFL	CS	C1COCCN1C2=NC=CC(=N2)NCC3=CC=CC=C3
DMQCGFL	IK	PKTXFNWLILBNOJ-UHFFFAOYSA-N
DMQCGFL	IU	N-benzyl-2-morpholin-4-ylpyrimidin-4-amine
DMQCGFL	DE	Discovery agent

DMJ29MN	ID	DMJ29MN
DMJ29MN	DN	N-benzyl-2-oxo-2H-chromene-3-carboxamide
DMJ29MN	HS	Investigative
DMJ29MN	SN	3-(Benzylcarbamoyl)coumarin; BRN 0257384; Coumarin, 3-(benzylcarbamoyl)-; 2H-1-Benzopyran-3-carboxamide, 2-oxo-N-(phenylmethyl)-; 1846-90-8; 2-Oxo-2H-chromene-3-carboxylic acid benzylamide; 2-Oxo-N-(phenylmethyl)-2H-1-benzopyran-3-carboxamide; N-benzyl-2-oxo-2H-chromene-3-carboxamide; AC1L3R3J; Oprea1_583472; Oprea1_560940; 3-carboxamido coumarin, 36; MLS001210650; CHEMBL469976; CTK0H5459; BDBM29186; DTXSID90171596; MolPort-000-375-285; ZINC130283; HMS2837I12; STK078064; N-benzyl-2-oxochromene-3-carboxamide; AKOS002234224
DMJ29MN	DT	Small molecular drug
DMJ29MN	PC	120587
DMJ29MN	MW	279.29
DMJ29MN	FM	C17H13NO3
DMJ29MN	IC	InChI=1S/C17H13NO3/c19-16(18-11-12-6-2-1-3-7-12)14-10-13-8-4-5-9-15(13)21-17(14)20/h1-10H,11H2,(H,18,19)
DMJ29MN	CS	C1=CC=C(C=C1)CNC(=O)C2=CC3=CC=CC=C3OC2=O
DMJ29MN	IK	BEUWFLKNYNXOJA-UHFFFAOYSA-N
DMJ29MN	IU	N-benzyl-2-oxochromene-3-carboxamide
DMJ29MN	CA	CAS 1846-90-8
DMJ29MN	DE	Discovery agent

DMRJMGK	ID	DMRJMGK
DMRJMGK	DN	N-benzyl-2-thiomorpholinopyrimidin-4-amine
DMRJMGK	HS	Investigative
DMRJMGK	SN	CHEMBL1086014; N-benzyl-2-thiomorpholinopyrimidin-4-amine
DMRJMGK	DT	Small molecular drug
DMRJMGK	PC	46871648
DMRJMGK	MW	286.4
DMRJMGK	FM	C15H18N4S
DMRJMGK	IC	InChI=1S/C15H18N4S/c1-2-4-13(5-3-1)12-17-14-6-7-16-15(18-14)19-8-10-20-11-9-19/h1-7H,8-12H2,(H,16,17,18)
DMRJMGK	CS	C1CSCCN1C2=NC=CC(=N2)NCC3=CC=CC=C3
DMRJMGK	IK	SPJWTUJGKPIRMF-UHFFFAOYSA-N
DMRJMGK	IU	N-benzyl-2-thiomorpholin-4-ylpyrimidin-4-amine
DMRJMGK	DE	Discovery agent

DMUD85N	ID	DMUD85N
DMUD85N	DN	N-Benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide
DMUD85N	HS	Investigative
DMUD85N	SN	CHEMBL343071; N-Benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide; BDBM50102429
DMUD85N	DT	Small molecular drug
DMUD85N	PC	10593843
DMUD85N	MW	348.4
DMUD85N	FM	C21H20N2O3
DMUD85N	IC	InChI=1S/C21H20N2O3/c24-19-10-11-20(25)17(12-19)14-22-18-8-6-16(7-9-18)21(26)23-13-15-4-2-1-3-5-15/h1-12,22,24-25H,13-14H2,(H,23,26)
DMUD85N	CS	C1=CC=C(C=C1)CNC(=O)C2=CC=C(C=C2)NCC3=C(C=CC(=C3)O)O
DMUD85N	IK	QQMFNDVDKBSOEC-UHFFFAOYSA-N
DMUD85N	IU	N-benzyl-4-[(2,5-dihydroxyphenyl)methylamino]benzamide
DMUD85N	DE	Discovery agent

DMCJWQT	ID	DMCJWQT
DMCJWQT	DN	N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide
DMCJWQT	HS	Investigative
DMCJWQT	SN	CHEMBL492871; N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide
DMCJWQT	DT	Small molecular drug
DMCJWQT	PC	25107518
DMCJWQT	MW	441.6
DMCJWQT	FM	C29H35N3O
DMCJWQT	IC	InChI=1S/C29H35N3O/c33-29(30-24-25-12-4-1-5-13-25)18-8-3-11-19-31-20-22-32(23-21-31)28-17-10-9-16-27(28)26-14-6-2-7-15-26/h1-2,4-7,9-10,12-17H,3,8,11,18-24H2,(H,30,33)
DMCJWQT	CS	C1CN(CCN1CCCCCC(=O)NCC2=CC=CC=C2)C3=CC=CC=C3C4=CC=CC=C4
DMCJWQT	IK	LQFAQQWXFSOOQJ-UHFFFAOYSA-N
DMCJWQT	IU	N-benzyl-6-[4-(2-phenylphenyl)piperazin-1-yl]hexanamide
DMCJWQT	DE	Discovery agent

DMUNL5Q	ID	DMUNL5Q
DMUNL5Q	DN	N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide
DMUNL5Q	HS	Investigative
DMUNL5Q	SN	CHEMBL475493; Cambridge id 5211146; AC1LL0O9; Oprea1_380259; N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide; CBDivE_007294; SCHEMBL5623492; MolPort-002-316-866; BDBM50277135; AKOS008461950; MCULE-3410949273; AB00075261-01; SR-01000198591; SR-01000198591-1
DMUNL5Q	DT	Small molecular drug
DMUNL5Q	PC	1076739
DMUNL5Q	MW	439.3
DMUNL5Q	FM	C18H19BrN2O4S
DMUNL5Q	IC	InChI=1S/C18H19BrN2O4S/c19-16-7-6-15(18(22)20-13-14-4-2-1-3-5-14)12-17(16)26(23,24)21-8-10-25-11-9-21/h1-7,12H,8-11,13H2,(H,20,22)
DMUNL5Q	CS	C1COCCN1S(=O)(=O)C2=C(C=CC(=C2)C(=O)NCC3=CC=CC=C3)Br
DMUNL5Q	IK	DEVYAXBKQQLYGQ-UHFFFAOYSA-N
DMUNL5Q	IU	N-benzyl-4-bromo-3-morpholin-4-ylsulfonylbenzamide
DMUNL5Q	DE	Discovery agent

DMUFR62	ID	DMUFR62
DMUFR62	DN	N-benzyl-4-cyclopentylpiperazine-1-carboxamide
DMUFR62	HS	Investigative
DMUFR62	SN	CHEMBL219757; N-benzyl-4-cyclopentylpiperazine-1-carboxamide; MolPort-009-268-235; ZINC32779618; BDBM50193214; AKOS027663191; MCULE-5408375837; Z332433676
DMUFR62	DT	Small molecular drug
DMUFR62	PC	40012125
DMUFR62	MW	287.4
DMUFR62	FM	C17H25N3O
DMUFR62	IC	InChI=1S/C17H25N3O/c21-17(18-14-15-6-2-1-3-7-15)20-12-10-19(11-13-20)16-8-4-5-9-16/h1-3,6-7,16H,4-5,8-14H2,(H,18,21)
DMUFR62	CS	C1CCC(C1)N2CCN(CC2)C(=O)NCC3=CC=CC=C3
DMUFR62	IK	HVJJGTXESXSGPU-UHFFFAOYSA-N
DMUFR62	IU	N-benzyl-4-cyclopentylpiperazine-1-carboxamide
DMUFR62	DE	Discovery agent

DM5TPEJ	ID	DM5TPEJ
DM5TPEJ	DN	N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide
DM5TPEJ	HS	Investigative
DM5TPEJ	SN	CHEMBL203860; N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide
DM5TPEJ	DT	Small molecular drug
DM5TPEJ	PC	44407802
DM5TPEJ	MW	339.4
DM5TPEJ	FM	C19H17NO3S
DM5TPEJ	IC	InChI=1S/C19H17NO3S/c21-18-11-13-19(14-12-18)24(22,23)20(17-9-5-2-6-10-17)15-16-7-3-1-4-8-16/h1-14,21H,15H2
DM5TPEJ	CS	C1=CC=C(C=C1)CN(C2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)O
DM5TPEJ	IK	IXILNJSCQSTWEB-UHFFFAOYSA-N
DM5TPEJ	IU	N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide
DM5TPEJ	DE	Discovery agent

DMCIJU0	ID	DMCIJU0
DMCIJU0	DN	N-Benzyl-4-Sulfamoyl-Benzamide
DMCIJU0	HS	Investigative
DMCIJU0	SN	n-benzyl-4-sulfamoyl-benzamide; N-benzyl-4-sulfamoylbenzamide; CHEMBL302715; 107619-27-2; Benzamide, 4-(aminosulfonyl)-N-(phenylmethyl)-; 1g4o; ACMC-20mb2s; AC1L1HYJ; SCHEMBL678390; 4-Sulfamoyl-N-benzylbenzamide; CTK0D6518; BDBM12013; DTXSID80274429; MolPort-004-614-705; ZINC403946; HMS3604F04; AKOS001408419; MCULE-1382374853; DB01748; 4-(AMINOSULFONYL)-N-PHENYLMETHYLBENZAMIDE
DMCIJU0	DT	Small molecular drug
DMCIJU0	PC	4347
DMCIJU0	MW	290.34
DMCIJU0	FM	C14H14N2O3S
DMCIJU0	IC	InChI=1S/C14H14N2O3S/c15-20(18,19)13-8-6-12(7-9-13)14(17)16-10-11-4-2-1-3-5-11/h1-9H,10H2,(H,16,17)(H2,15,18,19)
DMCIJU0	CS	C1=CC=C(C=C1)CNC(=O)C2=CC=C(C=C2)S(=O)(=O)N
DMCIJU0	IK	CZKNSZUJCJHTTM-UHFFFAOYSA-N
DMCIJU0	IU	N-benzyl-4-sulfamoylbenzamide
DMCIJU0	CA	CAS 107619-27-2
DMCIJU0	DE	Discovery agent

DM2XLHY	ID	DM2XLHY
DM2XLHY	DN	N-benzyl-5-(4-chlorophenyl)nicotinamide
DM2XLHY	HS	Investigative
DM2XLHY	SN	CHEMBL1271417; N-benzyl-5-(4-chlorophenyl)nicotinamide
DM2XLHY	DT	Small molecular drug
DM2XLHY	PC	46032908
DM2XLHY	MW	322.8
DM2XLHY	FM	C19H15ClN2O
DM2XLHY	IC	InChI=1S/C19H15ClN2O/c20-18-8-6-15(7-9-18)16-10-17(13-21-12-16)19(23)22-11-14-4-2-1-3-5-14/h1-10,12-13H,11H2,(H,22,23)
DM2XLHY	CS	C1=CC=C(C=C1)CNC(=O)C2=CN=CC(=C2)C3=CC=C(C=C3)Cl
DM2XLHY	IK	FWHXSLFSGPLDBM-UHFFFAOYSA-N
DM2XLHY	IU	N-benzyl-5-(4-chlorophenyl)pyridine-3-carboxamide
DM2XLHY	DE	Discovery agent

DM7NHRV	ID	DM7NHRV
DM7NHRV	DN	N-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide
DM7NHRV	HS	Investigative
DM7NHRV	SN	CHEMBL576449; N-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide
DM7NHRV	DT	Small molecular drug
DM7NHRV	PC	45487805
DM7NHRV	MW	324.3
DM7NHRV	FM	C16H15F3N2O2
DM7NHRV	IC	InChI=1S/C16H15F3N2O2/c17-16(18,19)8-9-23-14-7-6-13(11-20-14)15(22)21-10-12-4-2-1-3-5-12/h1-7,11H,8-10H2,(H,21,22)
DM7NHRV	CS	C1=CC=C(C=C1)CNC(=O)C2=CN=C(C=C2)OCCC(F)(F)F
DM7NHRV	IK	KOPBISOWPWQPSS-UHFFFAOYSA-N
DM7NHRV	IU	N-benzyl-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
DM7NHRV	DE	Discovery agent

DMDRE64	ID	DMDRE64
DMDRE64	DN	N-benzyl-9-oxo-9,10-dihydroacridine-3-carboxamide
DMDRE64	HS	Investigative
DMDRE64	SN	Acridone-Based Inhibitor, 8c; N-benzyl-9-oxo-9,10-dihydroacridine-3-carboxamide; CHEMBL230199
DMDRE64	DT	Small molecular drug
DMDRE64	PC	16748635
DMDRE64	MW	328.4
DMDRE64	FM	C21H16N2O2
DMDRE64	IC	InChI=1S/C21H16N2O2/c24-20-16-8-4-5-9-18(16)23-19-12-15(10-11-17(19)20)21(25)22-13-14-6-2-1-3-7-14/h1-12H,13H2,(H,22,25)(H,23,24)
DMDRE64	CS	C1=CC=C(C=C1)CNC(=O)C2=CC3=C(C=C2)C(=O)C4=CC=CC=C4N3
DMDRE64	IK	YUICSGTVFUPFFC-UHFFFAOYSA-N
DMDRE64	IU	N-benzyl-9-oxo-10H-acridine-3-carboxamide
DMDRE64	DE	Discovery agent

DM26R4P	ID	DM26R4P
DM26R4P	DN	N-benzylacetimidamide hydrobromide
DM26R4P	HS	Investigative
DM26R4P	SN	N-Benzylacetamidine Hydrobromide; 186545-76-6; CHEMBL462334; 1-(Benzylamino)ethaniminium bromide; N-benzylacetimidamide hydrobromide; C9H12N2.HBr; CTK8E6104; DTXSID10649404; MolPort-009-019-600; 1916AH; AKOS025294782; RT-023317; J-011977; (1E)-N'-Benzylethanimidamide--hydrogen bromide (1/1)
DM26R4P	DT	Small molecular drug
DM26R4P	PC	25231659
DM26R4P	MW	229.12
DM26R4P	FM	C9H13BrN2
DM26R4P	IC	InChI=1S/C9H12N2.BrH/c1-8(10)11-7-9-5-3-2-4-6-9;/h2-6H,7H2,1H3,(H2,10,11);1H
DM26R4P	CS	CC(=NCC1=CC=CC=C1)N.Br
DM26R4P	IK	RUQJDXJQOUUQHG-UHFFFAOYSA-N
DM26R4P	IU	N'-benzylethanimidamide;hydrobromide
DM26R4P	CA	CAS 186545-76-6
DM26R4P	DE	Discovery agent

DMNPS4R	ID	DMNPS4R
DMNPS4R	DN	N-Benzyl-ETAV
DMNPS4R	HS	Investigative
DMNPS4R	SN	N-Benzyl-ETAV; CHEMBL492643
DMNPS4R	DT	Small molecular drug
DMNPS4R	PC	44568794
DMNPS4R	MW	508.6
DMNPS4R	FM	C24H36N4O8
DMNPS4R	IC	InChI=1S/C24H36N4O8/c1-13(2)19(24(35)36)27-21(32)14(3)26-23(34)20(15(4)29)28-22(33)17(10-11-18(30)31)25-12-16-8-6-5-7-9-16/h5-9,13-15,17,19-20,25,29H,10-12H2,1-4H3,(H,26,34)(H,27,32)(H,28,33)(H,30,31)(H,35,36)/t14-,15?,17-,19-,20-/m0/s1
DMNPS4R	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCC1=CC=CC=C1
DMNPS4R	IK	DETDSGXQMKQDNJ-VFWSWVEUSA-N
DMNPS4R	IU	(4S)-4-(benzylamino)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMNPS4R	DE	Discovery agent

DMDZ5XI	ID	DMDZ5XI
DMDZ5XI	DN	N-Benzylmethylphenidate
DMDZ5XI	HS	Investigative
DMDZ5XI	SN	N-Benzylmethylphenidate; CHEMBL1254757; BDBM50327137; (alphaR,2R)-alpha-Phenyl-1-benzylpiperidine-2beta-acetic acid methyl ester
DMDZ5XI	DT	Small molecular drug
DMDZ5XI	PC	52948224
DMDZ5XI	MW	323.4
DMDZ5XI	FM	C21H25NO2
DMDZ5XI	IC	InChI=1S/C21H25NO2/c1-24-21(23)20(18-12-6-3-7-13-18)19-14-8-9-15-22(19)16-17-10-4-2-5-11-17/h2-7,10-13,19-20H,8-9,14-16H2,1H3/t19-,20-/m1/s1
DMDZ5XI	CS	COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2)C3=CC=CC=C3
DMDZ5XI	IK	BUSOTANDABQRSW-WOJBJXKFSA-N
DMDZ5XI	IU	methyl (2R)-2-[(2R)-1-benzylpiperidin-2-yl]-2-phenylacetate
DMDZ5XI	DE	Discovery agent

DM0NJAL	ID	DM0NJAL
DM0NJAL	DN	N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine
DM0NJAL	HS	Investigative
DM0NJAL	SN	CHEMBL462054; N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine
DM0NJAL	DT	Small molecular drug
DM0NJAL	PC	44588172
DM0NJAL	MW	250.34
DM0NJAL	FM	C17H18N2
DM0NJAL	IC	InChI=1S/C17H18N2/c1-19(12-14-7-3-2-4-8-14)13-16-11-15-9-5-6-10-17(15)18-16/h2-11,18H,12-13H2,1H3
DM0NJAL	CS	CN(CC1=CC=CC=C1)CC2=CC3=CC=CC=C3N2
DM0NJAL	IK	YJDMPOSBUYNPGY-UHFFFAOYSA-N
DM0NJAL	IU	N-(1H-indol-2-ylmethyl)-N-methyl-1-phenylmethanamine
DM0NJAL	DE	Discovery agent

DMT2GSI	ID	DMT2GSI
DMT2GSI	DN	N-benzyl-N-(phenylsulfonyl)benzamide
DMT2GSI	HS	Investigative
DMT2GSI	SN	N-benzyl-N-(phenylsulfonyl)benzamide; CHEMBL241160
DMT2GSI	DT	Small molecular drug
DMT2GSI	PC	10893520
DMT2GSI	MW	351.4
DMT2GSI	FM	C20H17NO3S
DMT2GSI	IC	InChI=1S/C20H17NO3S/c22-20(18-12-6-2-7-13-18)21(16-17-10-4-1-5-11-17)25(23,24)19-14-8-3-9-15-19/h1-15H,16H2
DMT2GSI	CS	C1=CC=C(C=C1)CN(C(=O)C2=CC=CC=C2)S(=O)(=O)C3=CC=CC=C3
DMT2GSI	IK	FRBJVLSQTZFTED-UHFFFAOYSA-N
DMT2GSI	IU	N-(benzenesulfonyl)-N-benzylbenzamide
DMT2GSI	DE	Discovery agent

DM6QK7E	ID	DM6QK7E
DM6QK7E	DN	N-benzyl-N-isobutylpiperidin-4-amine
DM6QK7E	HS	Investigative
DM6QK7E	SN	CHEMBL207837; N-benzyl-N-isobutylpiperidin-4-amine; SCHEMBL5994946; ZINC36093165
DM6QK7E	DT	Small molecular drug
DM6QK7E	PC	44411431
DM6QK7E	MW	246.39
DM6QK7E	FM	C16H26N2
DM6QK7E	IC	InChI=1S/C16H26N2/c1-14(2)12-18(16-8-10-17-11-9-16)13-15-6-4-3-5-7-15/h3-7,14,16-17H,8-13H2,1-2H3
DM6QK7E	CS	CC(C)CN(CC1=CC=CC=C1)C2CCNCC2
DM6QK7E	IK	LDELVNUHOAVIQP-UHFFFAOYSA-N
DM6QK7E	IU	N-benzyl-N-(2-methylpropyl)piperidin-4-amine
DM6QK7E	DE	Discovery agent

DMVEZH1	ID	DMVEZH1
DMVEZH1	DN	N-benzylnorlitebamine
DMVEZH1	HS	Investigative
DMVEZH1	SN	N-benzylnorlitebamine; CHEMBL464944; BDBM50250453
DMVEZH1	DT	Small molecular drug
DMVEZH1	PC	10597941
DMVEZH1	MW	415.5
DMVEZH1	FM	C26H25NO4
DMVEZH1	IC	InChI=1S/C26H25NO4/c1-30-23-13-20-17(12-22(23)28)8-9-19-18-10-11-27(14-16-6-4-3-5-7-16)15-21(18)25(29)26(31-2)24(19)20/h3-9,12-13,28-29H,10-11,14-15H2,1-2H3
DMVEZH1	CS	COC1=C(C=C2C=CC3=C4CCN(CC4=C(C(=C3C2=C1)OC)O)CC5=CC=CC=C5)O
DMVEZH1	IK	ITXWZNATGXDCEV-UHFFFAOYSA-N
DMVEZH1	IU	2-benzyl-9,11-dimethoxy-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DMVEZH1	DE	Discovery agent

DM7S5Y4	ID	DM7S5Y4
DM7S5Y4	DN	NBI-59159
DM7S5Y4	HS	Investigative
DM7S5Y4	SN	CHEMBL1628570; NBI-59159; GTPL4626; BDBM50410451; (2S)-2-amino-3-[(9H-fluoren-2-yl)carbamoyl]propanoic acid
DM7S5Y4	DT	Small molecular drug
DM7S5Y4	PC	11369932
DM7S5Y4	MW	296.32
DM7S5Y4	FM	C17H16N2O3
DM7S5Y4	IC	InChI=1S/C17H16N2O3/c18-15(17(21)22)9-16(20)19-12-5-6-14-11(8-12)7-10-3-1-2-4-13(10)14/h1-6,8,15H,7,9,18H2,(H,19,20)(H,21,22)/t15-/m0/s1
DM7S5Y4	CS	C1C2=CC=CC=C2C3=C1C=C(C=C3)NC(=O)C[C@@H](C(=O)O)N
DM7S5Y4	IK	QDIIRLCSVINDSC-HNNXBMFYSA-N
DM7S5Y4	IU	(2S)-2-amino-4-(9H-fluoren-2-ylamino)-4-oxobutanoic acid
DM7S5Y4	DE	Discovery agent

DMURC6X	ID	DMURC6X
DMURC6X	DN	NBI-74330
DMURC6X	HS	Investigative
DMURC6X	SN	473722-68-8; 855527-92-3; (plusmn)-NBI 74330; GTPL839; SCHEMBL15064525; MolPort-035-765-750; NBI74330; AKOS024458204; NCGC00379149-01; KB-79291; ( inverted exclamation markA)-NBI 74330; (+/-)-NBI 74330; N-1-[(3-4(-Ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-(3-pyridinylmethyl)-3-(trifluoromethyl)benzeneacetamide
DMURC6X	DT	Small molecular drug
DMURC6X	PC	45784923
DMURC6X	MW	605.6
DMURC6X	FM	C32H27F4N5O3
DMURC6X	IC	InChI=1S/C32H27F4N5O3/c1-3-44-24-11-9-23(10-12-24)41-30(39-29-25(31(41)43)7-5-15-38-29)20(2)40(19-22-6-4-14-37-18-22)28(42)17-21-8-13-27(33)26(16-21)32(34,35)36/h4-16,18,20H,3,17,19H2,1-2H3/t20-/m1/s1
DMURC6X	CS	CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
DMURC6X	IK	XMRGQUDUVGRCBS-HXUWFJFHSA-N
DMURC6X	IU	N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-(pyridin-3-ylmethyl)acetamide
DMURC6X	DE	Discovery agent

DMJF9VA	ID	DMJF9VA
DMJF9VA	DN	N-biphenyl-3-ylmethyl-N'-hydroxy-malonamide
DMJF9VA	HS	Investigative
DMJF9VA	SN	CHEMBL376650
DMJF9VA	DT	Small molecular drug
DMJF9VA	PC	16116574
DMJF9VA	MW	284.31
DMJF9VA	FM	C16H16N2O3
DMJF9VA	IC	InChI=1S/C16H16N2O3/c19-15(10-16(20)18-21)17-11-12-5-4-8-14(9-12)13-6-2-1-3-7-13/h1-9,21H,10-11H2,(H,17,19)(H,18,20)
DMJF9VA	CS	C1=CC=C(C=C1)C2=CC=CC(=C2)CNC(=O)CC(=O)NO
DMJF9VA	IK	FKVBZDLUQPPZNE-UHFFFAOYSA-N
DMJF9VA	IU	N'-hydroxy-N-[(3-phenylphenyl)methyl]propanediamide
DMJF9VA	DE	Discovery agent

DMWSDZ9	ID	DMWSDZ9
DMWSDZ9	DN	N-bis-(3-phenyl-propyl)9-oxo-fluorene-2,7-diamide
DMWSDZ9	HS	Investigative
DMWSDZ9	SN	9H-Fluorene-2,7-dicarboxamide, 9-oxo-N,N'-bis(3-phenylpropyl)-; 443794-40-9; SCHEMBL4158879; CTK1C7933
DMWSDZ9	DT	Small molecular drug
DMWSDZ9	PC	10117946
DMWSDZ9	MW	502.6
DMWSDZ9	FM	C33H30N2O3
DMWSDZ9	IC	InChI=1S/C33H30N2O3/c36-31-29-21-25(32(37)34-19-7-13-23-9-3-1-4-10-23)15-17-27(29)28-18-16-26(22-30(28)31)33(38)35-20-8-14-24-11-5-2-6-12-24/h1-6,9-12,15-18,21-22H,7-8,13-14,19-20H2,(H,34,37)(H,35,38)
DMWSDZ9	CS	C1=CC=C(C=C1)CCCNC(=O)C2=CC3=C(C=C2)C4=C(C3=O)C=C(C=C4)C(=O)NCCCC5=CC=CC=C5
DMWSDZ9	IK	OKGPGSVMCACUID-UHFFFAOYSA-N
DMWSDZ9	IU	9-oxo-2-N,7-N-bis(3-phenylpropyl)fluorene-2,7-dicarboxamide
DMWSDZ9	CA	CAS 443794-40-9
DMWSDZ9	DE	Discovery agent

DMVF420	ID	DMVF420
DMVF420	DN	NBTGR
DMVF420	HS	Investigative
DMVF420	SN	nitrobenzylthioguanosine
DMVF420	DT	Small molecular drug
DMVF420	PC	96048
DMVF420	MW	434.4
DMVF420	FM	C17H18N6O6S
DMVF420	IC	InChI=1S/C17H18N6O6S/c18-17-20-14-11(19-7-22(14)16-13(26)12(25)10(5-24)29-16)15(21-17)30-6-8-1-3-9(4-2-8)23(27)28/h1-4,7,10,12-13,16,24-26H,5-6H2,(H2,18,20,21)/t10-,12-,13-,16-/m1/s1
DMVF420	CS	C1=CC(=CC=C1CSC2=NC(=NC3=C2N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N)[N+](=O)[O-]
DMVF420	IK	BRSNNJIJEZWSBU-XNIJJKJLSA-N
DMVF420	IU	(2R,3R,4S,5R)-2-[2-amino-6-[(4-nitrophenyl)methylsulfanyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMVF420	CA	CAS 13153-27-0
DMVF420	DE	Discovery agent

DMAQT6S	ID	DMAQT6S
DMAQT6S	DN	N-Butyl 2beta-hydroxyolean-12-en-28-oate
DMAQT6S	HS	Investigative
DMAQT6S	SN	CHEMBL1077758; n-Butyl 2beta-hydroxyolean-12-en-28-oate
DMAQT6S	DT	Small molecular drug
DMAQT6S	PC	44254244
DMAQT6S	MW	512.799
DMAQT6S	FM	C34H56O3
DMAQT6S	IC	InChI=1S/C34H56O3/c1-9-10-19-37-28(36)34-17-15-29(2,3)22-25(34)24-11-12-27-31(6)21-23(35)20-30(4,5)26(31)13-14-33(27,8)32(24,7)16-18-34/h11,23,25-27,35H,9-10,12-22H2,1-8H3/t23-,25+,26+,27-,31+,32-,33-,34+/m1/s1
DMAQT6S	CS	CCCCOC(=O)[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H](CC5(C)C)O)C)C)[C@@H]1CC(CC2)(C)C)C
DMAQT6S	IK	UZTYAEIRVQJQQC-XXJJMGNBSA-N
DMAQT6S	IU	butyl (4aS,6aR,6aS,6bR,8aS,11R,12aS,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMAQT6S	DE	Discovery agent

DM157LQ	ID	DM157LQ
DM157LQ	DN	N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM157LQ	HS	Investigative
DM157LQ	SN	CHEMBL223476; N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide; N-Butyl-2-(1H-indol-3-yl)-2-oxo-acetamide; BAS 04280181; AC1MK4QP; MolPort-000-249-106; ZINC3635496; BDBM50206948; N-butyl-2-indol-3-yl-2-oxoacetamide; AKOS000530602; MCULE-8866008030; ST50101897
DM157LQ	DT	Small molecular drug
DM157LQ	PC	3149449
DM157LQ	MW	244.29
DM157LQ	FM	C14H16N2O2
DM157LQ	IC	InChI=1S/C14H16N2O2/c1-2-3-8-15-14(18)13(17)11-9-16-12-7-5-4-6-10(11)12/h4-7,9,16H,2-3,8H2,1H3,(H,15,18)
DM157LQ	CS	CCCCNC(=O)C(=O)C1=CNC2=CC=CC=C21
DM157LQ	IK	XTLXOIBNXHXNBR-UHFFFAOYSA-N
DM157LQ	IU	N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM157LQ	DE	Discovery agent

DMH7Z4L	ID	DMH7Z4L
DMH7Z4L	DN	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L	HS	Investigative
DMH7Z4L	SN	CHEMBL222316; N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L	DT	Small molecular drug
DMH7Z4L	PC	16124919
DMH7Z4L	MW	289.29
DMH7Z4L	FM	C14H15N3O4
DMH7Z4L	IC	InChI=1S/C14H15N3O4/c1-2-3-6-15-14(19)13(18)11-8-16-12-5-4-9(17(20)21)7-10(11)12/h4-5,7-8,16H,2-3,6H2,1H3,(H,15,19)
DMH7Z4L	CS	CCCCNC(=O)C(=O)C1=CNC2=C1C=C(C=C2)[N+](=O)[O-]
DMH7Z4L	IK	FFNPFJOEAUFBBY-UHFFFAOYSA-N
DMH7Z4L	IU	N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L	DE	Discovery agent

DMH5GW6	ID	DMH5GW6
DMH5GW6	DN	N-butyl-4-hydroxy-N-phenylbenzenesulfonamide
DMH5GW6	HS	Investigative
DMH5GW6	SN	CHEMBL203810; N-butyl-4-hydroxy-N-phenylbenzenesulfonamide; BDBM50177754
DMH5GW6	DT	Small molecular drug
DMH5GW6	PC	44407804
DMH5GW6	MW	305.4
DMH5GW6	FM	C16H19NO3S
DMH5GW6	IC	InChI=1S/C16H19NO3S/c1-2-3-13-17(14-7-5-4-6-8-14)21(19,20)16-11-9-15(18)10-12-16/h4-12,18H,2-3,13H2,1H3
DMH5GW6	CS	CCCCN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DMH5GW6	IK	PPNFXEDTKPJHLX-UHFFFAOYSA-N
DMH5GW6	IU	N-butyl-4-hydroxy-N-phenylbenzenesulfonamide
DMH5GW6	DE	Discovery agent

DMMI8X4	ID	DMMI8X4
DMMI8X4	DN	N-butyl-4-methyl-3,4-dihydroquinazolin-2-amine
DMMI8X4	HS	Investigative
DMMI8X4	DT	Small molecular drug
DMMI8X4	PC	44456426
DMMI8X4	DE	Discovery agent

DMW7BZT	ID	DMW7BZT
DMW7BZT	DN	N-Butylcarbamic Acid Biphenyl-3-yl Ester
DMW7BZT	HS	Investigative
DMW7BZT	SN	CHEMBL446837; n-Butylcarbamic Acid Biphenyl-3-yl Ester
DMW7BZT	DT	Small molecular drug
DMW7BZT	PC	24881670
DMW7BZT	MW	269.34
DMW7BZT	FM	C17H19NO2
DMW7BZT	IC	InChI=1S/C17H19NO2/c1-2-3-12-18-17(19)20-16-11-7-10-15(13-16)14-8-5-4-6-9-14/h4-11,13H,2-3,12H2,1H3,(H,18,19)
DMW7BZT	CS	CCCCNC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DMW7BZT	IK	KILLQYKNNVPEJL-UHFFFAOYSA-N
DMW7BZT	IU	(3-phenylphenyl) N-butylcarbamate
DMW7BZT	DE	Discovery agent

DMY3HEF	ID	DMY3HEF
DMY3HEF	DN	N-Butyl-ETAV
DMY3HEF	HS	Investigative
DMY3HEF	SN	N-Butyl-ETAV; CHEMBL494485
DMY3HEF	DT	Small molecular drug
DMY3HEF	PC	44568834
DMY3HEF	MW	474.5
DMY3HEF	FM	C21H38N4O8
DMY3HEF	IC	InChI=1S/C21H38N4O8/c1-6-7-10-22-14(8-9-15(27)28)19(30)25-17(13(5)26)20(31)23-12(4)18(29)24-16(11(2)3)21(32)33/h11-14,16-17,22,26H,6-10H2,1-5H3,(H,23,31)(H,24,29)(H,25,30)(H,27,28)(H,32,33)/t12-,13?,14-,16-,17-/m0/s1
DMY3HEF	CS	CCCCN[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O
DMY3HEF	IK	DGLIBFYKWHJASP-UPKCPHKASA-N
DMY3HEF	IU	(4S)-4-(butylamino)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMY3HEF	DE	Discovery agent

DMB06TA	ID	DMB06TA
DMB06TA	DN	N-butylgalactonojirimycin
DMB06TA	HS	Investigative
DMB06TA	SN	N-butylgalactonojirimycin; CHEMBL485842
DMB06TA	DT	Small molecular drug
DMB06TA	PC	44560309
DMB06TA	MW	235.28
DMB06TA	FM	C10H21NO5
DMB06TA	IC	InChI=1S/C10H21NO5/c1-2-3-4-11-6(5-12)7(13)8(14)9(15)10(11)16/h6-10,12-16H,2-5H2,1H3/t6-,7+,8+,9-,10+/m1/s1
DMB06TA	CS	CCCCN1[C@@H]([C@@H]([C@@H]([C@H]([C@@H]1O)O)O)O)CO
DMB06TA	IK	JNYIOZRCMYRRED-KBDSZGMXSA-N
DMB06TA	IU	(2S,3R,4S,5S,6R)-1-butyl-6-(hydroxymethyl)piperidine-2,3,4,5-tetrol
DMB06TA	DE	Discovery agent

DM8U70E	ID	DM8U70E
DM8U70E	DN	N-Butyl-N'-(4-methyl-benzoyl)-guanidine
DM8U70E	HS	Investigative
DM8U70E	SN	CHEMBL432963; SCHEMBL4629393; BDBM50107019; 1-Butyl-2-(4-methylbenzoyl)guanidine
DM8U70E	DT	Small molecular drug
DM8U70E	PC	10955473
DM8U70E	MW	233.31
DM8U70E	FM	C13H19N3O
DM8U70E	IC	InChI=1S/C13H19N3O/c1-3-4-9-15-13(14)16-12(17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H3,14,15,16,17)
DM8U70E	CS	CCCCN=C(N)NC(=O)C1=CC=C(C=C1)C
DM8U70E	IK	ALSYKIYWLYFZIK-UHFFFAOYSA-N
DM8U70E	IU	N-(N'-butylcarbamimidoyl)-4-methylbenzamide
DM8U70E	DE	Discovery agent

DMKCX5N	ID	DMKCX5N
DMKCX5N	DN	N-Butyl-N'-Hydroxyguanidine
DMKCX5N	HS	Investigative
DMKCX5N	SN	N-BUTYL-N'-HYDROXYGUANIDINE; N-BUTYL-N'-HYDROXY-GUANIDINE; 140215-98-1; 1-Butyl-2-hydroxyguanidine; BHH; 2-butyl-1-hydroxyguanidine; 1-butyl-3-hydroxyguanidine; AC1L9KE0; SCHEMBL611006; CHEMBL308745; SCHEMBL10339979; HMS3649P20; 1917AH; ZINC13536006; AKOS017474991; AKOS011771255; DB02727; SR-01000946753
DMKCX5N	DT	Small molecular drug
DMKCX5N	PC	447030
DMKCX5N	MW	131.18
DMKCX5N	FM	C5H13N3O
DMKCX5N	IC	InChI=1S/C5H13N3O/c1-2-3-4-7-5(6)8-9/h9H,2-4H2,1H3,(H3,6,7,8)
DMKCX5N	CS	CCCCN=C(N)NO
DMKCX5N	IK	ULDDTFAPYWLDGF-UHFFFAOYSA-N
DMKCX5N	IU	2-butyl-1-hydroxyguanidine
DMKCX5N	CA	CAS 140215-98-1
DMKCX5N	DE	Discovery agent

DMNFTO6	ID	DMNFTO6
DMNFTO6	DN	N-butylnorlitebamine
DMNFTO6	HS	Investigative
DMNFTO6	SN	N-butylnorlitebamine; CHEMBL465346; BDBM50250442
DMNFTO6	DT	Small molecular drug
DMNFTO6	PC	10619839
DMNFTO6	MW	381.5
DMNFTO6	FM	C23H27NO4
DMNFTO6	IC	InChI=1S/C23H27NO4/c1-4-5-9-24-10-8-15-16-7-6-14-11-19(25)20(27-2)12-17(14)21(16)23(28-3)22(26)18(15)13-24/h6-7,11-12,25-26H,4-5,8-10,13H2,1-3H3
DMNFTO6	CS	CCCCN1CCC2=C3C=CC4=CC(=C(C=C4C3=C(C(=C2C1)O)OC)OC)O
DMNFTO6	IK	XLVUNDMFFLQJMP-UHFFFAOYSA-N
DMNFTO6	IU	2-butyl-9,11-dimethoxy-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DMNFTO6	DE	Discovery agent

DM8STQA	ID	DM8STQA
DM8STQA	DN	N-butylresorcinol
DM8STQA	HS	Investigative
DM8STQA	SN	4-Butylresorcinol; 4-butylbenzene-1,3-diol; 18979-61-8; 4-n-Butylresorcinol; Butylresorcinol; 4-Butylresorcin; N-butylresorcinol; Resorcinol, 4-butyl-; Rucinol; UNII-2IK4UQ3ZGA; 2,4-Dihydroxy-n-butyl benzen; BRN 1942645; 2IK4UQ3ZGA; CHEMBL450195; 2,4-Dihydroxy-N-butyl benzene; CHEBI:81689; AK-81459; Q-200189; Kopcinol; 4-(2,4-dihydroxyphenyl)butane; n-butyl resorcinol; Rucinol (TN); EC 606-191-2; AC1L4FN4; ACMC-1CA91; 1,3-Benzenediol,4-butyl-; SCHEMBL68792; 4-06-00-06003 (Beilstein Handbook Reference); 1,3-Benzenediol, 4-butyl-
DM8STQA	DT	Small molecular drug
DM8STQA	PC	205912
DM8STQA	MW	166.22
DM8STQA	FM	C10H14O2
DM8STQA	IC	InChI=1S/C10H14O2/c1-2-3-4-8-5-6-9(11)7-10(8)12/h5-7,11-12H,2-4H2,1H3
DM8STQA	CS	CCCCC1=C(C=C(C=C1)O)O
DM8STQA	IK	CSHZYWUPJWVTMQ-UHFFFAOYSA-N
DM8STQA	IU	4-butylbenzene-1,3-diol
DM8STQA	CA	CAS 18979-61-8
DM8STQA	CB	CHEBI:81689
DM8STQA	DE	Discovery agent

DMJCYMW	ID	DMJCYMW
DMJCYMW	DN	NC00075159
DMJCYMW	HS	Investigative
DMJCYMW	SN	2-{(5Z)-5-[4-(dimethylamino)benzylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}propanoic acid; AC1NSO7A; NC00075159; GTPL7664; MolPort-000-500-763; SMSF0008623; 2-[5-[(4-dimethylaminophenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid; AKOS001607119; AKOS016042842; CB00089; ST50147973; AB00099445-01; 2-{5-[4-(dimethylamino)benzylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}propanoic acid; 2-[(5Z)-5-[(4-dimethylaminophenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid
DMJCYMW	DT	Small molecular drug
DMJCYMW	PC	5337173
DMJCYMW	MW	336.4
DMJCYMW	FM	C15H16N2O3S2
DMJCYMW	IC	InChI=1S/C15H16N2O3S2/c1-9(14(19)20)17-13(18)12(22-15(17)21)8-10-4-6-11(7-5-10)16(2)3/h4-9H,1-3H3,(H,19,20)/b12-8-
DMJCYMW	CS	CC(C(=O)O)N1C(=O)/C(=C/C2=CC=C(C=C2)N(C)C)/SC1=S
DMJCYMW	IK	XGTGMKYGVNHPTC-WQLSENKSSA-N
DMJCYMW	IU	2-[(5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid
DMJCYMW	DE	Discovery agent

DM6XGFE	ID	DM6XGFE
DM6XGFE	DN	NC1153
DM6XGFE	HS	Investigative
DM6XGFE	DT	Small molecular drug
DM6XGFE	PC	373395
DM6XGFE	MW	296.5
DM6XGFE	FM	C18H36N2O
DM6XGFE	IC	InChI=1S/C18H36N2O/c1-19(2)14-16-12-10-8-6-5-7-9-11-13-17(18(16)21)15-20(3)4/h16-17H,5-15H2,1-4H3
DM6XGFE	CS	CN(C)CC1CCCCCCCCCC(C1=O)CN(C)C
DM6XGFE	IK	HRQRILLGGNNYSD-UHFFFAOYSA-N
DM6XGFE	IU	2,12-bis[(dimethylamino)methyl]cyclododecan-1-one
DM6XGFE	DE	Renal transplantation

DMJKZUC	ID	DMJKZUC
DMJKZUC	DN	NC-2100
DMJKZUC	HS	Investigative
DMJKZUC	SN	NC-2100; nc2100; SCHEMBL377641; NC 2100; 179068-64-5; 2,4-Thiazolidinedione, 5-((7-(phenylmethoxy)-3-quinolinyl)methyl)-
DMJKZUC	DT	Small molecular drug
DMJKZUC	PC	9907086
DMJKZUC	MW	364.4
DMJKZUC	FM	C20H16N2O3S
DMJKZUC	IC	InChI=1S/C20H16N2O3S/c23-19-18(26-20(24)22-19)9-14-8-15-6-7-16(10-17(15)21-11-14)25-12-13-4-2-1-3-5-13/h1-8,10-11,18H,9,12H2,(H,22,23,24)
DMJKZUC	CS	C1=CC=C(C=C1)COC2=CC3=NC=C(C=C3C=C2)CC4C(=O)NC(=O)S4
DMJKZUC	IK	AZKFGOQRYCSQPK-UHFFFAOYSA-N
DMJKZUC	IU	5-[(7-phenylmethoxyquinolin-3-yl)methyl]-1,3-thiazolidine-2,4-dione
DMJKZUC	CA	CAS 179068-64-5
DMJKZUC	DE	Discovery agent

DM45MGZ	ID	DM45MGZ
DM45MGZ	DN	NC-2500
DM45MGZ	HS	Investigative
DM45MGZ	SN	Xanthine oxidoreductase inhibitor (hyperuricemia), Nippon Chemiphar
DM45MGZ	CP	Nippon Chemiphar Co Ltd
DM45MGZ	DE	Hyperuricaemia

DMJ13TR	ID	DMJ13TR
DMJ13TR	DN	N-Carbamoyl-L-Aspartate
DMJ13TR	HS	Investigative
DMJ13TR	SN	N-carbamoyl-L-aspartate; N-Carbamoyl-L-aspartic acid; Ureidosuccinate; L-Ureidosuccinic acid; L-Ureidosuccinate; Carbamyl-L-aspartic acid; Carbamoylaspartic acid; N-Carbamoyl-S-aspartic acid; L-N-Carbamoylaspartic acid; Succinic acid, ureido-; Carbamylaspartic acid; Aspartic acid, N-carbamoyl-; UNII-R2521024DK; N-Carbamoylaspartic acid; 2-Ureidobutanedioic acid; 13184-27-5; EINECS 236-134-3; NSC 14983; L-Aspartic acid, N-(aminocarbonyl)-; N-(aminocarbonyl)-L-aspartic acid; R2521024DK; carbamyl-aspartate
DMJ13TR	DT	Small molecular drug
DMJ13TR	PC	93072
DMJ13TR	MW	176.13
DMJ13TR	FM	C5H8N2O5
DMJ13TR	IC	InChI=1S/C5H8N2O5/c6-5(12)7-2(4(10)11)1-3(8)9/h2H,1H2,(H,8,9)(H,10,11)(H3,6,7,12)/t2-/m0/s1
DMJ13TR	CS	C([C@@H](C(=O)O)NC(=O)N)C(=O)O
DMJ13TR	IK	HLKXYZVTANABHZ-REOHCLBHSA-N
DMJ13TR	IU	(2S)-2-(carbamoylamino)butanedioic acid
DMJ13TR	CA	CAS 13184-27-5
DMJ13TR	CB	CHEBI:15859
DMJ13TR	DE	Discovery agent

DMX80JF	ID	DMX80JF
DMX80JF	DN	N-Carboxymethionine
DMX80JF	HS	Investigative
DMX80JF	SN	N-Carboxymethionine; N-carboxy-L-methionine; carboxyl-methionine; SCHEMBL1298472; CHEBI:41696
DMX80JF	DT	Small molecular drug
DMX80JF	PC	17753927
DMX80JF	MW	193.22
DMX80JF	FM	C6H11NO4S
DMX80JF	IC	InChI=1S/C6H11NO4S/c1-12-3-2-4(5(8)9)7-6(10)11/h4,7H,2-3H2,1H3,(H,8,9)(H,10,11)/t4-/m0/s1
DMX80JF	CS	CSCC[C@@H](C(=O)O)NC(=O)O
DMX80JF	IK	LWQBAQJPCYBWJQ-BYPYZUCNSA-N
DMX80JF	IU	(2S)-2-(carboxyamino)-4-methylsulfanylbutanoic acid
DMX80JF	CB	CHEBI:41696
DMX80JF	DE	Discovery agent

DME9U7Y	ID	DME9U7Y
DME9U7Y	DN	N-Carboxymethyl-N-cyclopentyl-phthalamic acid
DME9U7Y	HS	Investigative
DME9U7Y	SN	CHEMBL115153; N-Carboxymethyl-N-cyclopentyl-phthalamic acid
DME9U7Y	DT	Small molecular drug
DME9U7Y	PC	44340905
DME9U7Y	MW	291.3
DME9U7Y	FM	C15H17NO5
DME9U7Y	IC	InChI=1S/C15H17NO5/c17-13(18)9-16(10-5-1-2-6-10)14(19)11-7-3-4-8-12(11)15(20)21/h3-4,7-8,10H,1-2,5-6,9H2,(H,17,18)(H,20,21)
DME9U7Y	CS	C1CCC(C1)N(CC(=O)O)C(=O)C2=CC=CC=C2C(=O)O
DME9U7Y	IK	KOAQPWKIMYZORZ-UHFFFAOYSA-N
DME9U7Y	IU	2-[carboxymethyl(cyclopentyl)carbamoyl]benzoic acid
DME9U7Y	DE	Discovery agent

DM5KNCX	ID	DM5KNCX
DM5KNCX	DN	N-cetylgallate
DM5KNCX	HS	Investigative
DM5KNCX	SN	Cetyl gallate; 5026-65-3; Hexadecyl Gallate; Hexadecyl 3,4,5-trihydroxybenzoate; Gallic Acid Cetyl Ester; n-cetylgallate; n-Hexadecyl-gallate; UNII-X1J85N35ZO; CHEMBL464675; X1J85N35ZO; 3,4,5-Trihydroxybenzoic acid hexadecyl ester; Cetylgallat; HexadecylGallate; EINECS 225-715-7; ACMC-209kkz; AC1L2VUG; AC1Q67EH; Gallic Acid Hexadecyl Ester; SCHEMBL36506; Benzoic acid, 3,4,5-trihydroxy-, hexadecyl ester; CTK8B1762; DTXSID00198254; MolPort-006-116-598; TYCUSKFOGZNIBO-UHFFFAOYSA-N; KS-000013SR; BDBM50250973; ANW-30945; ZINC33861467
DM5KNCX	DT	Small molecular drug
DM5KNCX	PC	78729
DM5KNCX	MW	394.5
DM5KNCX	FM	C23H38O5
DM5KNCX	IC	InChI=1S/C23H38O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-28-23(27)19-17-20(24)22(26)21(25)18-19/h17-18,24-26H,2-16H2,1H3
DM5KNCX	CS	CCCCCCCCCCCCCCCCOC(=O)C1=CC(=C(C(=C1)O)O)O
DM5KNCX	IK	TYCUSKFOGZNIBO-UHFFFAOYSA-N
DM5KNCX	IU	hexadecyl 3,4,5-trihydroxybenzoate
DM5KNCX	CA	CAS 5026-65-3
DM5KNCX	DE	Discovery agent

DM0JCN2	ID	DM0JCN2
DM0JCN2	DN	NCFP
DM0JCN2	HS	Investigative
DM0JCN2	SN	NCFP; 774548-65-1; GTPL6471; SCHEMBL4069818; ZINC34517852; KB-274800
DM0JCN2	DT	Small molecular drug
DM0JCN2	PC	11373218
DM0JCN2	MW	409.8
DM0JCN2	FM	C21H13ClFN3O3
DM0JCN2	IC	InChI=1S/C21H13ClFN3O3/c22-13-7-8-16(25-19(27)17-6-1-2-9-24-17)12(10-13)11-26-20(28)14-4-3-5-15(23)18(14)21(26)29/h1-10H,11H2,(H,25,27)
DM0JCN2	CS	C1=CC=NC(=C1)C(=O)NC2=C(C=C(C=C2)Cl)CN3C(=O)C4=C(C3=O)C(=CC=C4)F
DM0JCN2	IK	WBXKMHFMMCOTOK-UHFFFAOYSA-N
DM0JCN2	IU	N-[4-chloro-2-[(4-fluoro-1,3-dioxoisoindol-2-yl)methyl]phenyl]pyridine-2-carboxamide
DM0JCN2	DE	Discovery agent

DMMRWJG	ID	DMMRWJG
DMMRWJG	DN	NCG21
DMMRWJG	HS	Investigative
DMMRWJG	SN	compound 12 [PMID: 19007110]; NGC21
DMMRWJG	DT	Small molecular drug
DMMRWJG	PC	25098573
DMMRWJG	MW	376.4
DMMRWJG	FM	C23H24N2O3
DMMRWJG	IC	InChI=1S/C23H24N2O3/c26-23(27)11-6-7-19-12-14-21(15-13-19)28-18-17-25(20-8-2-1-3-9-20)22-10-4-5-16-24-22/h1-5,8-10,12-16H,6-7,11,17-18H2,(H,26,27)
DMMRWJG	CS	C1=CC=C(C=C1)N(CCOC2=CC=C(C=C2)CCCC(=O)O)C3=CC=CC=N3
DMMRWJG	IK	WQXHZCYCKCQFQP-UHFFFAOYSA-N
DMMRWJG	IU	4-[4-[2-(N-pyridin-2-ylanilino)ethoxy]phenyl]butanoic acid
DMMRWJG	DE	Discovery agent

DMY8RT9	ID	DMY8RT9
DMY8RT9	DN	NCGC00167772-01
DMY8RT9	HS	Investigative
DMY8RT9	SN	10-DEBC
DMY8RT9	DT	Small molecular drug
DMY8RT9	PC	10521421
DMY8RT9	MW	344.9
DMY8RT9	FM	C20H25ClN2O
DMY8RT9	IC	InChI=1S/C20H25ClN2O/c1-3-22(4-2)13-7-8-14-23-17-9-5-6-10-19(17)24-20-12-11-16(21)15-18(20)23/h5-6,9-12,15H,3-4,7-8,13-14H2,1-2H3
DMY8RT9	CS	CCN(CC)CCCCN1C2=CC=CC=C2OC3=C1C=C(C=C3)Cl
DMY8RT9	IK	GYBXAGDWMCJZJK-UHFFFAOYSA-N
DMY8RT9	IU	4-(2-chlorophenoxazin-10-yl)-N,N-diethylbutan-1-amine
DMY8RT9	CB	CHEBI:94104
DMY8RT9	DE	Discovery agent

DM6VEON	ID	DM6VEON
DM6VEON	DN	N-chloromethyl-brucine
DM6VEON	HS	Investigative
DM6VEON	SN	N-chloromethylbrucine
DM6VEON	DT	Small molecular drug
DM6VEON	PC	44358908
DM6VEON	MW	443.9
DM6VEON	FM	C24H28ClN2O4+
DM6VEON	IC	InChI=1S/C24H28ClN2O4/c1-29-17-8-15-16(9-18(17)30-2)26-21(28)10-19-22-14-7-20-24(15,23(22)26)4-5-27(20,12-25)11-13(14)3-6-31-19/h3,8-9,14,19-20,22-23H,4-7,10-12H2,1-2H3/q+1/t14-,19-,20-,22-,23-,24+,27?/m0/s1
DM6VEON	CS	COC1=C(C=C2C(=C1)[C@]34CC[N+]5([C@H]3C[C@@H]6[C@@H]7[C@@H]4N2C(=O)C[C@@H]7OCC=C6C5)CCl)OC
DM6VEON	IK	GCEPQLWZBVGLQN-CQIPDZJVSA-N
DM6VEON	IU	(4aR,5aS,8aS,13aS,15aS,15bR)-6-(chloromethyl)-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-6-ium-14-one
DM6VEON	DE	Discovery agent

DMTCBLS	ID	DMTCBLS
DMTCBLS	DN	NCI-159878
DMTCBLS	HS	Investigative
DMTCBLS	DT	Small molecular drug
DMTCBLS	PC	135444922
DMTCBLS	MW	352.5
DMTCBLS	FM	C20H20N2O2S
DMTCBLS	IC	InChI=1S/C20H20N2O2S/c1-14-7-9-16(10-8-14)18-17(11-12-23)19(24)22-20(21-18)25-13-15-5-3-2-4-6-15/h2-10,23H,11-13H2,1H3,(H,21,22,24)
DMTCBLS	CS	CC1=CC=C(C=C1)C2=C(C(=O)NC(=N2)SCC3=CC=CC=C3)CCO
DMTCBLS	IK	MMKBRXXCKNYUMD-UHFFFAOYSA-N
DMTCBLS	IU	2-benzylsulfanyl-5-(2-hydroxyethyl)-4-(4-methylphenyl)-1H-pyrimidin-6-one
DMTCBLS	DE	Discovery agent

DM9C7GP	ID	DM9C7GP
DM9C7GP	DN	NCI-58425
DM9C7GP	HS	Investigative
DM9C7GP	SN	NCI-58425; CHEMBL493092; 1-(4-butoxyphenoxy)-2-nitro-4-(trifluoromethyl)benzene; NSC58425; AC1L6H0N; NCIOpen2_007805; CTK6E3412; ZINC1689072; NSC-58425; BDBM50253286; 1-(4 butoxyphenoxy)-2-nitro-4-(trifluoromethyl)-benzene
DM9C7GP	DT	Small molecular drug
DM9C7GP	PC	245951
DM9C7GP	MW	355.31
DM9C7GP	FM	C17H16F3NO4
DM9C7GP	IC	InChI=1S/C17H16F3NO4/c1-2-3-10-24-13-5-7-14(8-6-13)25-16-9-4-12(17(18,19)20)11-15(16)21(22)23/h4-9,11H,2-3,10H2,1H3
DM9C7GP	CS	CCCCOC1=CC=C(C=C1)OC2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]
DM9C7GP	IK	AOQOXPPRTCVMPF-UHFFFAOYSA-N
DM9C7GP	IU	1-(4-butoxyphenoxy)-2-nitro-4-(trifluoromethyl)benzene
DM9C7GP	DE	Discovery agent

DMH1BVG	ID	DMH1BVG
DMH1BVG	DN	NCL-1
DMH1BVG	HS	Investigative
DMH1BVG	SN	NCL-1; GTPL7024; ZINC94568752
DMH1BVG	DT	Small molecular drug
DMH1BVG	PC	73755256
DMH1BVG	MW	443.5
DMH1BVG	FM	C27H29N3O3
DMH1BVG	IC	InChI=1S/C27H29N3O3/c28-24-17-23(24)21-12-7-13-22(16-21)33-15-14-25(30-26(31)20-10-5-2-6-11-20)27(32)29-18-19-8-3-1-4-9-19/h1-13,16,23-25H,14-15,17-18,28H2,(H,29,32)(H,30,31)/t23-,24+,25+/m0/s1
DMH1BVG	CS	C1[C@H]([C@@H]1N)C2=CC(=CC=C2)OCC[C@H](C(=O)NCC3=CC=CC=C3)NC(=O)C4=CC=CC=C4
DMH1BVG	IK	DTPSXFMGMQOVTG-ISJGIBHGSA-N
DMH1BVG	IU	N-[(2R)-4-[3-[(1S,2R)-2-aminocyclopropyl]phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide
DMH1BVG	DE	Discovery agent

DM1K64F	ID	DM1K64F
DM1K64F	DN	N-CPM[D-Pro-10]Dyn A-(1-11)
DM1K64F	HS	Investigative
DM1K64F	SN	CHEMBL442323; N-CPM[D-Pro-10]Dyn A-(1-11)
DM1K64F	PC	44325419
DM1K64F	MW	1416.7
DM1K64F	FM	C67H109N21O13
DM1K64F	IC	InChI=1S/C67H109N21O13/c1-5-40(4)55(62(98)84-47(20-13-31-77-67(73)74)63(99)88-32-14-21-52(88)61(97)85-48(64(100)101)17-9-10-28-68)87-58(94)46(19-12-30-76-66(71)72)82-57(93)45(18-11-29-75-65(69)70)83-59(95)50(33-39(2)3)86-60(96)51(35-41-15-7-6-8-16-41)81-54(91)38-79-53(90)37-80-56(92)49(78-36-43-22-23-43)34-42-24-26-44(89)27-25-42/h6-8,15-16,24-27,39-40,43,45-52,55,78,89H,5,9-14,17-23,28-38,68H2,1-4H3,(H,79,90)(H,80,92)(H,81,91)(H,82,93)(H,83,95)(H,84,98)(H,85,97)(H,86,96)(H,87,94)(H,100,101)(H4,69,70,75)(H4,71,72,76)(H4,73,74,77)/t40-,45-,46-,47-,48-,49-,50-,51-,52-,55-/m0/s1
DM1K64F	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)NCC4CC4
DM1K64F	IK	CFPWTFGNSPUUJD-RWKXLGHPSA-N
DM1K64F	IU	(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-(cyclopropylmethylamino)-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DM1K64F	DE	Discovery agent

DM09UFT	ID	DM09UFT
DM09UFT	DN	NCT-400
DM09UFT	HS	Investigative
DM09UFT	CP	Nectid Inc
DM09UFT	DE	Major depressive disorder

DM1FOSP	ID	DM1FOSP
DM1FOSP	DN	NCX-1047
DM1FOSP	HS	Investigative
DM1FOSP	SN	GF-015647; GF-015646-00; NO-donating corticosteroids (skin inflammation), NicOx/Grupo Ferrer International
DM1FOSP	CP	NicOx SA
DM1FOSP	DE	Dermatitis

DMUHXRA	ID	DMUHXRA
DMUHXRA	DN	NCX-1067
DMUHXRA	HS	Investigative
DMUHXRA	CP	NicOx SA
DMUHXRA	DE	Discovery agent

DMYBWXR	ID	DMYBWXR
DMYBWXR	DN	NCX-125
DMYBWXR	HS	Investigative
DMYBWXR	SN	NO-donating latanoprost analog (glaucoma), NicOx
DMYBWXR	CP	NicOx SA
DMYBWXR	DE	Glaucoma/ocular hypertension

DM5T23S	ID	DM5T23S
DM5T23S	DN	N-Cyclobutyl-1'H-phenothiazine-1'-carboxamide
DM5T23S	HS	Investigative
DM5T23S	SN	CHEMBL591233; BDBM50308398
DM5T23S	DT	Small molecular drug
DM5T23S	PC	46229054
DM5T23S	MW	296.4
DM5T23S	FM	C17H16N2OS
DM5T23S	IC	InChI=1S/C17H16N2OS/c20-17(18-12-6-5-7-12)19-13-8-1-3-10-15(13)21-16-11-4-2-9-14(16)19/h1-4,8-12H,5-7H2,(H,18,20)
DM5T23S	CS	C1CC(C1)NC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM5T23S	IK	KNYQZMOQFRAHIS-UHFFFAOYSA-N
DM5T23S	IU	N-cyclobutylphenothiazine-10-carboxamide
DM5T23S	DE	Discovery agent

DM1GTVW	ID	DM1GTVW
DM1GTVW	DN	N-cyclobutyl-N-(piperidin-4-yl)-2-naphthamide
DM1GTVW	HS	Investigative
DM1GTVW	SN	CHEMBL578346; N-cyclobutyl-N-(piperidin-4-yl)-2-naphthamide
DM1GTVW	DT	Small molecular drug
DM1GTVW	PC	45487773
DM1GTVW	MW	308.4
DM1GTVW	FM	C20H24N2O
DM1GTVW	IC	InChI=1S/C20H24N2O/c23-20(17-9-8-15-4-1-2-5-16(15)14-17)22(18-6-3-7-18)19-10-12-21-13-11-19/h1-2,4-5,8-9,14,18-19,21H,3,6-7,10-13H2
DM1GTVW	CS	C1CC(C1)N(C2CCNCC2)C(=O)C3=CC4=CC=CC=C4C=C3
DM1GTVW	IK	AZTPZTRJVCAAMX-UHFFFAOYSA-N
DM1GTVW	IU	N-cyclobutyl-N-piperidin-4-ylnaphthalene-2-carboxamide
DM1GTVW	DE	Discovery agent

DMMW8J1	ID	DMMW8J1
DMMW8J1	DN	N-Cyclohexyl-1'H-phenothiazine-1'-carboxamide
DMMW8J1	HS	Investigative
DMMW8J1	SN	CHEMBL591234; N-cyclohexyl-10H-phenothiazine-10-carboxamide; N-cyclohexylphenothiazine-10-carboxamide; AC1LE3I3; Oprea1_381015; ZINC91236; MolPort-002-173-208; BDBM50308400; STK225048; AKOS001676630; MCULE-5781141750; CCG-113839; N-cyclohexylphenothiazin-10-ylcarboxamide; 371937-04-1; ST51023365; AB00099848-01; N-Cyclohexyl-1''H-phenothiazine-1''-carboxamide; SR-01000506168
DMMW8J1	DT	Small molecular drug
DMMW8J1	PC	705769
DMMW8J1	MW	324.4
DMMW8J1	FM	C19H20N2OS
DMMW8J1	IC	InChI=1S/C19H20N2OS/c22-19(20-14-8-2-1-3-9-14)21-15-10-4-6-12-17(15)23-18-13-7-5-11-16(18)21/h4-7,10-14H,1-3,8-9H2,(H,20,22)
DMMW8J1	CS	C1CCC(CC1)NC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMMW8J1	IK	OKOVWMHSIFSGRG-UHFFFAOYSA-N
DMMW8J1	IU	N-cyclohexylphenothiazine-10-carboxamide
DMMW8J1	DE	Discovery agent

DM8HS0B	ID	DM8HS0B
DM8HS0B	DN	N-Cyclohexyl-2-(4-methoxy-phenyl)-acetamide
DM8HS0B	HS	Investigative
DM8HS0B	SN	N-cyclohexyl-2-(4-methoxyphenyl)acetamide; CHEMBL192461; N-Cyclohexyl-2-(4-methoxy-phenyl)-acetamide; AC1LE46L; Oprea1_816678; Oprea1_273819; SCHEMBL5049577; ARONIS000952; MolPort-001-621-938; ZINC142289; KS-00003UJ3; BDBM50167045; STK011304; AKOS000490473; MCULE-1564646854; ST039784; KB-104378; EU-0043158; J3.583.162B; N-cyclohexyl-2-[4-(methyloxy)phenyl]acetamide; SR-01000082042; AG-690/11634830
DM8HS0B	DT	Small molecular drug
DM8HS0B	PC	729989
DM8HS0B	MW	247.33
DM8HS0B	FM	C15H21NO2
DM8HS0B	IC	InChI=1S/C15H21NO2/c1-18-14-9-7-12(8-10-14)11-15(17)16-13-5-3-2-4-6-13/h7-10,13H,2-6,11H2,1H3,(H,16,17)
DM8HS0B	CS	COC1=CC=C(C=C1)CC(=O)NC2CCCCC2
DM8HS0B	IK	OUQSDJMKYLLVED-UHFFFAOYSA-N
DM8HS0B	IU	N-cyclohexyl-2-(4-methoxyphenyl)acetamide
DM8HS0B	CA	CAS 330467-51-1
DM8HS0B	DE	Discovery agent

DMRA548	ID	DMRA548
DMRA548	DN	N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide
DMRA548	HS	Investigative
DMRA548	SN	N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide; N-cyclohexyl-2-oxochromene-3-carboxamide; 2-Oxo-2H-chromene-3-carboxylic acid cyclohexylamide; 4021-23-2; BAS 00837943; ChemDiv2_003298; 3-carboxamido coumarin, 1; AC1Q5N8P; AC1LF7K7; Oprea1_254332; Oprea1_273725; CHEMBL472080; BDBM29152; CTK1C9968; DTXSID70352366; MolPort-001-028-458; ZINC130287; HMS1378F20; CCG-15837; STK408165; AKOS000533315; MCULE-8945496486; N-cyclohexyl(2-oxochromen-3-yl)carboxamide; EU-0035943; ST50185340; SR-01000410421; SR-01000410421-1
DMRA548	DT	Small molecular drug
DMRA548	PC	724217
DMRA548	MW	271.31
DMRA548	FM	C16H17NO3
DMRA548	IC	InChI=1S/C16H17NO3/c18-15(17-12-7-2-1-3-8-12)13-10-11-6-4-5-9-14(11)20-16(13)19/h4-6,9-10,12H,1-3,7-8H2,(H,17,18)
DMRA548	CS	C1CCC(CC1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMRA548	IK	KUWSPPXPGQEHSQ-UHFFFAOYSA-N
DMRA548	IU	N-cyclohexyl-2-oxochromene-3-carboxamide
DMRA548	CA	CAS 4021-23-2
DMRA548	DE	Discovery agent

DM15MQT	ID	DM15MQT
DM15MQT	DN	N-Cyclohexyl-2-phenyl-acetamide
DM15MQT	HS	Investigative
DM15MQT	SN	N-Cyclohexyl-2-phenylacetamide; N-Cyclohexylphenylacetamide; Acetamide, N-cyclohexyl-2-phenyl-; 10264-08-1; EINECS 233-602-9; N-Cyclohexylamide of phenylacetic acid; UNII-VY9DC35P8W; NSC 126805; BRN 2102004; VY9DC35P8W; MLS002919901; CHEMBL191355; SMR001797500; N-Cyclohexyl-2-phenyl-acetamide; NSC126805; N-Cyclohexylbenzeneacetamide; AC1L33JD; MLS006026924; 4-12-00-00045 (Beilstein Handbook Reference); Benzeneacetamide,N-cyclohexyl-; SCHEMBL3397254; CTK4A1359; DTXSID20145427; MolPort-002-799-328; ZINC339690; STK031107; BDBM50167047
DM15MQT	DT	Small molecular drug
DM15MQT	PC	82500
DM15MQT	MW	217.31
DM15MQT	FM	C14H19NO
DM15MQT	IC	InChI=1S/C14H19NO/c16-14(11-12-7-3-1-4-8-12)15-13-9-5-2-6-10-13/h1,3-4,7-8,13H,2,5-6,9-11H2,(H,15,16)
DM15MQT	CS	C1CCC(CC1)NC(=O)CC2=CC=CC=C2
DM15MQT	IK	ZFEBPJQSSNUJGT-UHFFFAOYSA-N
DM15MQT	IU	N-cyclohexyl-2-phenylacetamide
DM15MQT	CA	CAS 10264-08-1
DM15MQT	DE	Discovery agent

DMCDBM5	ID	DMCDBM5
DMCDBM5	DN	N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide
DMCDBM5	HS	Investigative
DMCDBM5	SN	CHEMBL382873; N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide
DMCDBM5	DT	Small molecular drug
DMCDBM5	PC	44407801
DMCDBM5	MW	331.4
DMCDBM5	FM	C18H21NO3S
DMCDBM5	IC	InChI=1S/C18H21NO3S/c20-17-11-13-18(14-12-17)23(21,22)19(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1,3-4,7-8,11-14,16,20H,2,5-6,9-10H2
DMCDBM5	CS	C1CCC(CC1)N(C2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)O
DMCDBM5	IK	INJVHCJLNBTEGC-UHFFFAOYSA-N
DMCDBM5	IU	N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide
DMCDBM5	DE	Discovery agent

DM2COR5	ID	DM2COR5
DM2COR5	DN	N-Cyclohexyl-4-phenyl-butyramide
DM2COR5	HS	Investigative
DM2COR5	SN	N-cyclohexyl-4-phenylbutanamide; CHEMBL192843; benzenebutanamide, n-cyclohexyl-; N-Cyclohexyl-4-phenyl-butyramide; NSC150176; AC1Q5NBS; Cambridge id 5104259; AC1L6AF5; Oprea1_396588; CBDivE_014082; 64353-78-2; SCHEMBL12932000; MolPort-002-130-322; ZINC365623; STL389940; BDBM50167062; AKOS008967884; NSC-150176; MCULE-1526608627
DM2COR5	DT	Small molecular drug
DM2COR5	PC	288831
DM2COR5	MW	245.36
DM2COR5	FM	C16H23NO
DM2COR5	IC	InChI=1S/C16H23NO/c18-16(17-15-11-5-2-6-12-15)13-7-10-14-8-3-1-4-9-14/h1,3-4,8-9,15H,2,5-7,10-13H2,(H,17,18)
DM2COR5	CS	C1CCC(CC1)NC(=O)CCCC2=CC=CC=C2
DM2COR5	IK	NWKPABISVRIQLP-UHFFFAOYSA-N
DM2COR5	IU	N-cyclohexyl-4-phenylbutanamide
DM2COR5	CA	CAS 64353-78-2
DM2COR5	DE	Discovery agent

DMCH5M1	ID	DMCH5M1
DMCH5M1	DN	N-Cyclohexylethyl-ETAV
DMCH5M1	HS	Investigative
DMCH5M1	SN	N-Cyclohexylethyl-ETAV; CHEMBL493688; SCHEMBL17856941
DMCH5M1	DT	Small molecular drug
DMCH5M1	PC	44568836
DMCH5M1	MW	528.6
DMCH5M1	FM	C25H44N4O8
DMCH5M1	IC	InChI=1S/C25H44N4O8/c1-14(2)20(25(36)37)28-22(33)15(3)27-24(35)21(16(4)30)29-23(34)18(10-11-19(31)32)26-13-12-17-8-6-5-7-9-17/h14-18,20-21,26,30H,5-13H2,1-4H3,(H,27,35)(H,28,33)(H,29,34)(H,31,32)(H,36,37)/t15-,16?,18-,20-,21-/m0/s1
DMCH5M1	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCC1CCCCC1
DMCH5M1	IK	APPLGLBBZPGQBX-GDEPEFMTSA-N
DMCH5M1	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-(2-cyclohexylethylamino)-5-oxopentanoic acid
DMCH5M1	DE	Discovery agent

DMIC8Z6	ID	DMIC8Z6
DMIC8Z6	DN	N-Cyclohexylmethyl-ETAV
DMIC8Z6	HS	Investigative
DMIC8Z6	SN	N-Cyclohexylmethyl-ETAV; CHEMBL494486
DMIC8Z6	DT	Small molecular drug
DMIC8Z6	PC	44568835
DMIC8Z6	MW	514.6
DMIC8Z6	FM	C24H42N4O8
DMIC8Z6	IC	InChI=1S/C24H42N4O8/c1-13(2)19(24(35)36)27-21(32)14(3)26-23(34)20(15(4)29)28-22(33)17(10-11-18(30)31)25-12-16-8-6-5-7-9-16/h13-17,19-20,25,29H,5-12H2,1-4H3,(H,26,34)(H,27,32)(H,28,33)(H,30,31)(H,35,36)/t14-,15?,17-,19-,20-/m0/s1
DMIC8Z6	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCC1CCCCC1
DMIC8Z6	IK	NRBYXUOJAWZKTA-VFWSWVEUSA-N
DMIC8Z6	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-(cyclohexylmethylamino)-5-oxopentanoic acid
DMIC8Z6	DE	Discovery agent

DMPSYRW	ID	DMPSYRW
DMPSYRW	DN	N-Cyclohexyl-N'-(4-Iodophenyl)Urea
DMPSYRW	HS	Investigative
DMPSYRW	SN	n-cyclohexyl-n'-(4-iodophenyl)urea; 1-cyclohexyl-3-(4-iodophenyl)urea; CIU; CHEBI:41480; 1-cyclohexyl-3-(p-iodophenyl)urea; N-cyclohexyl-N'-(p-iodophenyl)urea; 1ek1; 1vj5; AC1L1HZD; ARONIS008643; SCHEMBL4319424; CHEMBL1231797; CTK7G5624; MolPort-001-492-073; BDBM129304; HMS3604N07; KS-000040FO; ZINC1003537; STL069107; AKOS000497853; MCULE-2142424658; DB02029; KB-104481; ST45045386; (cyclohexylamino)-N-(4-iodophenyl)carboxamide; US8815951, 53
DMPSYRW	DT	Small molecular drug
DMPSYRW	PC	4357
DMPSYRW	MW	344.19
DMPSYRW	FM	C13H17IN2O
DMPSYRW	IC	InChI=1S/C13H17IN2O/c14-10-6-8-12(9-7-10)16-13(17)15-11-4-2-1-3-5-11/h6-9,11H,1-5H2,(H2,15,16,17)
DMPSYRW	CS	C1CCC(CC1)NC(=O)NC2=CC=C(C=C2)I
DMPSYRW	IK	AQTBUVAFYDVTFD-UHFFFAOYSA-N
DMPSYRW	IU	1-cyclohexyl-3-(4-iodophenyl)urea
DMPSYRW	CB	CHEBI:41480
DMPSYRW	DE	Discovery agent

DMYF243	ID	DMYF243
DMYF243	DN	N-Cyclohexyl-N'-(Propyl)Phenyl Urea
DMYF243	HS	Investigative
DMYF243	SN	1-cyclohexyl-3-(3-phenylpropyl)urea; n-cyclohexyl-n'-(propyl)phenyl urea; 1cr6; AC1L1HZG; Cambridge id 7261612; SCHEMBL4955112; CHEMBL1231909; MolPort-001-541-502; HMS3604O05; BDBM129287; ZINC2047156; STK432683; AKOS003282138; DB04213; MCULE-7021945009; ST50924514; (cyclohexylamino)-N-(3-phenylpropyl)carboxamide; US8815951, 104; SR-01000883953
DMYF243	DT	Small molecular drug
DMYF243	PC	4358
DMYF243	MW	260.37
DMYF243	FM	C16H24N2O
DMYF243	IC	InChI=1S/C16H24N2O/c19-16(18-15-11-5-2-6-12-15)17-13-7-10-14-8-3-1-4-9-14/h1,3-4,8-9,15H,2,5-7,10-13H2,(H2,17,18,19)
DMYF243	CS	C1CCC(CC1)NC(=O)NCCCC2=CC=CC=C2
DMYF243	IK	HBTZVNKXMFGOOJ-UHFFFAOYSA-N
DMYF243	IU	1-cyclohexyl-3-(3-phenylpropyl)urea
DMYF243	DE	Discovery agent

DM17G82	ID	DM17G82
DM17G82	DN	N-Cyclohexyl-N'-Decylurea
DM17G82	HS	Investigative
DM17G82	SN	n-cyclohexyl-n'-decylurea; 1-cyclohexyl-3-decylurea; CHEMBL67158; 287185-28-8; 1ek2; AC1L1HZJ; 1-Cyclohexyl-3-decyl-urea; Urea, N-cyclohexyl-N'-decyl-; SCHEMBL4997375; CTK0J1876; DTXSID50274431; N-CYCLOHEXYL-N''-DECYLUREA; ZINC14880861; BDBM50143925; AKOS003880320; MCULE-7968258309; DB03677; US8815951, 153
DM17G82	DT	Small molecular drug
DM17G82	PC	4359
DM17G82	MW	282.5
DM17G82	FM	C17H34N2O
DM17G82	IC	InChI=1S/C17H34N2O/c1-2-3-4-5-6-7-8-12-15-18-17(20)19-16-13-10-9-11-14-16/h16H,2-15H2,1H3,(H2,18,19,20)
DM17G82	CS	CCCCCCCCCCNC(=O)NC1CCCCC1
DM17G82	IK	LPXYBLIRYGCMPQ-UHFFFAOYSA-N
DM17G82	IU	1-cyclohexyl-3-decylurea
DM17G82	CA	CAS 287185-28-8
DM17G82	DE	Discovery agent

DMJ0T3W	ID	DMJ0T3W
DMJ0T3W	DN	N-cyclohexylquinazolin-4-amine
DMJ0T3W	HS	Investigative
DMJ0T3W	SN	N-cyclohexylquinazolin-4-amine; CHEMBL513012; 81080-06-0; Oprea1_305199; CTK2I7170; DTXSID10530489; 4-Quinazolinamine, N-cyclohexyl-; MolPort-008-958-618; ZINC27534370; BDBM50278114; AKOS008969009; MCULE-5342672910; SR-01000467804; SR-01000467804-1
DMJ0T3W	DT	Small molecular drug
DMJ0T3W	PC	13231190
DMJ0T3W	MW	227.3
DMJ0T3W	FM	C14H17N3
DMJ0T3W	IC	InChI=1S/C14H17N3/c1-2-6-11(7-3-1)17-14-12-8-4-5-9-13(12)15-10-16-14/h4-5,8-11H,1-3,6-7H2,(H,15,16,17)
DMJ0T3W	CS	C1CCC(CC1)NC2=NC=NC3=CC=CC=C32
DMJ0T3W	IK	CIFOBGKTSPXVQX-UHFFFAOYSA-N
DMJ0T3W	IU	N-cyclohexylquinazolin-4-amine
DMJ0T3W	CA	CAS 81080-06-0
DMJ0T3W	DE	Discovery agent

DMJY2PA	ID	DMJY2PA
DMJY2PA	DN	N-cyclohexylquinolin-4-amine
DMJY2PA	HS	Investigative
DMJY2PA	SN	CHEMBL449616; N-cyclohexylquinolin-4-amine; BDBM50278115
DMJY2PA	DT	Small molecular drug
DMJY2PA	PC	44591867
DMJY2PA	MW	226.32
DMJY2PA	FM	C15H18N2
DMJY2PA	IC	InChI=1S/C15H18N2/c1-2-6-12(7-3-1)17-15-10-11-16-14-9-5-4-8-13(14)15/h4-5,8-12H,1-3,6-7H2,(H,16,17)
DMJY2PA	CS	C1CCC(CC1)NC2=CC=NC3=CC=CC=C32
DMJY2PA	IK	XRSBCRPPSASDNY-UHFFFAOYSA-N
DMJY2PA	IU	N-cyclohexylquinolin-4-amine
DMJY2PA	DE	Discovery agent

DM0KDSA	ID	DM0KDSA
DM0KDSA	DN	N-Cyclopentyl-1'H-phenothiazine-1'-carboxamide
DM0KDSA	HS	Investigative
DM0KDSA	SN	CHEMBL601297; AC1LE08W; Cambridge id 6793618; Oprea1_215546; ZINC88021; MolPort-002-222-847; BDBM50308399; AKOS001667643; MCULE-5831533144; N-cyclopentylphenothiazine-10-carboxamide; EU-0013438; AB00119419-01
DM0KDSA	DT	Small molecular drug
DM0KDSA	PC	704267
DM0KDSA	MW	310.4
DM0KDSA	FM	C18H18N2OS
DM0KDSA	IC	InChI=1S/C18H18N2OS/c21-18(19-13-7-1-2-8-13)20-14-9-3-5-11-16(14)22-17-12-6-4-10-15(17)20/h3-6,9-13H,1-2,7-8H2,(H,19,21)
DM0KDSA	CS	C1CCC(C1)NC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM0KDSA	IK	WVGVWICAQSPEPE-UHFFFAOYSA-N
DM0KDSA	IU	N-cyclopentylphenothiazine-10-carboxamide
DM0KDSA	DE	Discovery agent

DMDPKCM	ID	DMDPKCM
DMDPKCM	DN	N-cyclopentyl-6-(2-phenylethynyl)nicotinamide
DMDPKCM	HS	Investigative
DMDPKCM	SN	CHEMBL551958; N-cyclopentyl-6-(2-phenylethynyl)nicotinamide
DMDPKCM	DT	Small molecular drug
DMDPKCM	PC	44224196
DMDPKCM	MW	290.4
DMDPKCM	FM	C19H18N2O
DMDPKCM	IC	InChI=1S/C19H18N2O/c22-19(21-18-8-4-5-9-18)16-11-13-17(20-14-16)12-10-15-6-2-1-3-7-15/h1-3,6-7,11,13-14,18H,4-5,8-9H2,(H,21,22)
DMDPKCM	CS	C1CCC(C1)NC(=O)C2=CN=C(C=C2)C#CC3=CC=CC=C3
DMDPKCM	IK	GKYRUZWYDPUSOV-UHFFFAOYSA-N
DMDPKCM	IU	N-cyclopentyl-6-(2-phenylethynyl)pyridine-3-carboxamide
DMDPKCM	DE	Discovery agent

DMMODRE	ID	DMMODRE
DMMODRE	DN	ND-2110
DMMODRE	HS	Investigative
DMMODRE	SN	CHEMBL3361254; 2-[(3~{R})-12-(4-morpholin-4-ylcyclohexyl)oxy-7-thia-9,11-diazatricyclo[6.4.0.0^{2,6}]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethanamide; ND-2110; GTPL8082; SCHEMBL15228032; SCHEMBL10344171; BDBM50040806; ZINC299825077; 2-[(3R)-12-{[(1r,4r)-4-(morpholin-4-yl)cyclohexyl]oxy}-7-thia-9,11-diazatricyclo[6.4.0.0(2),]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
DMMODRE	DT	Small molecular drug
DMMODRE	PC	68115559
DMMODRE	MW	416.5
DMMODRE	FM	C21H28N4O3S
DMMODRE	IC	InChI=1S/C21H28N4O3S/c22-17(26)11-13-1-6-16-18(13)19-20(23-12-24-21(19)29-16)28-15-4-2-14(3-5-15)25-7-9-27-10-8-25/h12-15H,1-11H2,(H2,22,26)/t13-,14?,15?/m1/s1
DMMODRE	CS	C1CC2=C([C@H]1CC(=O)N)C3=C(N=CN=C3S2)OC4CCC(CC4)N5CCOCC5
DMMODRE	IK	VZOLINZYKOLXAC-WLYUNCDWSA-N
DMMODRE	IU	2-[(3R)-12-(4-morpholin-4-ylcyclohexyl)oxy-7-thia-9,11-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
DMMODRE	DE	Discovery agent

DMH7GLE	ID	DMH7GLE
DMH7GLE	DN	ND-2158
DMH7GLE	HS	Investigative
DMH7GLE	SN	CHEMBL3361255; ND-2158; GTPL8083; SCHEMBL15227691; SCHEMBL15115519; BDBM50040805
DMH7GLE	DT	Small molecular drug
DMH7GLE	PC	86343751
DMH7GLE	MW	446.6
DMH7GLE	FM	C22H30N4O4S
DMH7GLE	IC	InChI=1S/C22H30N4O4S/c23-20(28)16(27)11-13-1-6-17-18(13)19-21(24-12-25-22(19)31-17)30-15-4-2-14(3-5-15)26-7-9-29-10-8-26/h12-16,27H,1-11H2,(H2,23,28)/t13-,14?,15?,16+/m1/s1
DMH7GLE	CS	C1CC2=C([C@H]1C[C@@H](C(=O)N)O)C3=C(N=CN=C3S2)OC4CCC(CC4)N5CCOCC5
DMH7GLE	IK	ZSMULWAVKYFPSS-LMPOIIKSSA-N
DMH7GLE	IU	(2S)-2-hydroxy-3-[(3R)-12-(4-morpholin-4-ylcyclohexyl)oxy-7-thia-9,11-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraen-3-yl]propanamide
DMH7GLE	DE	Discovery agent

DMT0NQS	ID	DMT0NQS
DMT0NQS	DN	ND-401
DMT0NQS	HS	Investigative
DMT0NQS	SN	ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals
DMT0NQS	CP	NeED Pharmaceuticals Srl
DMT0NQS	DE	Human immunodeficiency virus infection

DM7NJI2	ID	DM7NJI2
DM7NJI2	DN	NDC-1022
DM7NJI2	HS	Investigative
DM7NJI2	SN	Estrogen receptor beta agonists (cancer); NDC-1308; Estrogen receptor beta agonists (cancer), Endece
DM7NJI2	CP	Endece LLC
DM7NJI2	DE	Solid tumour/cancer

DMBFC1U	ID	DMBFC1U
DMBFC1U	DN	N-desalkylquetiapine
DMBFC1U	HS	Investigative
DMBFC1U	SN	norquetiapine
DMBFC1U	DT	Small molecular drug
DMBFC1U	PC	11369918
DMBFC1U	MW	295.4
DMBFC1U	FM	C17H17N3S
DMBFC1U	IC	InChI=1S/C17H17N3S/c1-3-7-15-13(5-1)17(20-11-9-18-10-12-20)19-14-6-2-4-8-16(14)21-15/h1-8,18H,9-12H2
DMBFC1U	CS	C1CN(CCN1)C2=NC3=CC=CC=C3SC4=CC=CC=C42
DMBFC1U	IK	JLOAJISUHPIQOX-UHFFFAOYSA-N
DMBFC1U	IU	6-piperazin-1-ylbenzo[b][1,4]benzothiazepine
DMBFC1U	CA	CAS 5747-48-8
DMBFC1U	DE	Discovery agent

DMV5RZM	ID	DMV5RZM
DMV5RZM	DN	N-dodecylgallate
DMV5RZM	HS	Investigative
DMV5RZM	SN	Dodecyl gallate; Lauryl gallate; 1166-52-5; Dodecyl 3,4,5-trihydroxybenzoate; Nipagallin LA; Progallin LA; Gallic acid, dodecyl ester; Gallic acid, lauryl ester; n-Dodecyl gallate; n-dodecylgallate; BENZOIC ACID, 3,4,5-TRIHYDROXY-, DODECYL ESTER; Gallic Acid Dodecyl Ester; Lauryl 3,4,5-trihydroxybenzoate; antioxidant E 312; E-312 antioxidant; E 312 antioxidant; Dodecylester kyseliny gallove; antioxidant E-312; NSC 133463; CCRIS 5568; GALLIC ACID LAURYL ESTER; UNII-45612DY463; EINECS 214-620-6; Dodecylester kyseliny gallove [Czech
DMV5RZM	DT	Small molecular drug
DMV5RZM	PC	14425
DMV5RZM	MW	338.4
DMV5RZM	FM	C19H30O5
DMV5RZM	IC	InChI=1S/C19H30O5/c1-2-3-4-5-6-7-8-9-10-11-12-24-19(23)15-13-16(20)18(22)17(21)14-15/h13-14,20-22H,2-12H2,1H3
DMV5RZM	CS	CCCCCCCCCCCCOC(=O)C1=CC(=C(C(=C1)O)O)O
DMV5RZM	IK	RPWFJAMTCNSJKK-UHFFFAOYSA-N
DMV5RZM	IU	dodecyl 3,4,5-trihydroxybenzoate
DMV5RZM	CA	CAS 1166-52-5
DMV5RZM	DE	Discovery agent

DMTMHW2	ID	DMTMHW2
DMTMHW2	DN	NDP-alpha-MSH
DMTMHW2	HS	Investigative
DMTMHW2	PC	16154396
DMTMHW2	MW	1646.8
DMTMHW2	FM	C78H111N21O19
DMTMHW2	IC	InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1
DMTMHW2	CS	CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
DMTMHW2	IK	UAHFGYDRQSXQEB-LEBBXHLNSA-N
DMTMHW2	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMTMHW2	CA	CAS 75921-69-6
DMTMHW2	CB	CHEBI:136034
DMTMHW2	DE	Discovery agent

DMRV16G	ID	DMRV16G
DMRV16G	DN	NDP-SYSMEHFRWGKPVG
DMRV16G	HS	Investigative
DMRV16G	PC	91936745
DMRV16G	MW	2007.2
DMRV16G	FM	C90H127N25O26S
DMRV16G	IC	InChI=1S/C90H127N25O26S/c1-47(2)74(87(139)100-43-73(125)126)113-86(138)68-21-13-31-114(68)88(140)59(18-9-10-29-91)102-70(120)42-99-76(128)62(36-50-40-98-55-17-8-7-16-53(50)55)108-77(129)56(19-11-30-97-90(94)95)103-80(132)60(34-48-14-5-4-6-15-48)106-82(134)63(37-51-41-96-46-101-51)109-78(130)57(26-27-71(121)122)104-79(131)58(28-33-142-3)105-83(135)65(44-116)111-81(133)61(35-49-22-24-52(118)25-23-49)107-84(136)66(45-117)112-85(137)67-20-12-32-115(67)89(141)64(39-72(123)124)110-75(127)54(92)38-69(93)119/h4-8,14-17,22-25,40-41,46-47,54,56-68,74,98,116-118H,9-13,18-21,26-39,42-45,91-92H2,1-3H3,(H2,93,119)(H,96,101)(H,99,128)(H,100,139)(H,102,120)(H,103,132)(H,104,131)(H,105,135)(H,106,134)(H,107,136)(H,108,129)(H,109,130)(H,110,127)(H,111,133)(H,112,137)(H,113,138)(H,121,122)(H,123,124)(H,125,126)(H4,94,95,97)/t54-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,74-/m0/s1
DMRV16G	CS	CC(C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N
DMRV16G	IK	BUVGQEXSQXRZQG-LBQSHGEUSA-N
DMRV16G	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-(carboxymethylamino)-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-3-carboxy-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoic acid
DMRV16G	DE	Discovery agent

DMFKX7Z	ID	DMFKX7Z
DMFKX7Z	DN	NDT9520492
DMFKX7Z	HS	Investigative
DMFKX7Z	SN	NDT9520492; GTPL578; SCHEMBL5136510; NDT-9520492; 610297-00-2
DMFKX7Z	DT	Small molecular drug
DMFKX7Z	PC	10218379
DMFKX7Z	MW	554.7
DMFKX7Z	FM	C38H35FN2O
DMFKX7Z	IC	InChI=1S/C38H35FN2O/c1-26(38(42)41(25-31-15-6-9-20-36(31)39)32-23-29-13-2-3-14-30(29)24-32)40-22-21-28-12-5-8-18-34(28)37(40)35-19-10-16-27-11-4-7-17-33(27)35/h2-20,26,32,37H,21-25H2,1H3/t26-,37+/m0/s1
DMFKX7Z	CS	C[C@@H](C(=O)N(CC1=CC=CC=C1F)C2CC3=CC=CC=C3C2)N4CCC5=CC=CC=C5[C@@H]4C6=CC=CC7=CC=CC=C76
DMFKX7Z	IK	OEINKGYXWSIVKM-KJICVINHSA-N
DMFKX7Z	IU	(2S)-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluorophenyl)methyl]-2-[(1R)-1-naphthalen-1-yl-3,4-dihydro-1H-isoquinolin-2-yl]propanamide
DMFKX7Z	DE	Discovery agent

DMGSNU4	ID	DMGSNU4
DMGSNU4	DN	NE-10575
DMGSNU4	HS	Investigative
DMGSNU4	SN	NE-10575; CHEMBL99553; 3-(2-Hydroxy-2,2-Diphosphonoethyl)-1-Methylpyridinium; GTPL3184; SCHEMBL8384475; BDBM50373099; NE 10575; 3-(2-hydroxy-2,2-diphosphonoethyl)-1-methylpyridin-1-ium; [1-Hydroxy-2-(1-methylpyridinium-3-yl)ethylidene]bisphosphonic acid
DMGSNU4	DT	Small molecular drug
DMGSNU4	PC	9847474
DMGSNU4	MW	298.15
DMGSNU4	FM	C8H14NO7P2+
DMGSNU4	IC	InChI=1S/C8H13NO7P2/c1-9-4-2-3-7(6-9)5-8(10,17(11,12)13)18(14,15)16/h2-4,6,10H,5H2,1H3,(H3-,11,12,13,14,15,16)/p+1
DMGSNU4	CS	C[N+]1=CC=CC(=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DMGSNU4	IK	BBNRLGQPSIXFHZ-UHFFFAOYSA-O
DMGSNU4	IU	[1-hydroxy-2-(1-methylpyridin-1-ium-3-yl)-1-phosphonoethyl]phosphonic acid
DMGSNU4	DE	Discovery agent

DMVESO2	ID	DMVESO2
DMVESO2	DN	NE10790
DMVESO2	HS	Investigative
DMVESO2	SN	NE 10790
DMVESO2	DT	Small molecular drug
DMVESO2	PC	10014835
DMVESO2	MW	247.14
DMVESO2	FM	C8H10NO6P
DMVESO2	IC	InChI=1S/C8H10NO6P/c10-7(11)8(12,16(13,14)15)4-6-2-1-3-9-5-6/h1-3,5,12H,4H2,(H,10,11)(H2,13,14,15)
DMVESO2	CS	C1=CC(=CN=C1)CC(C(=O)O)(O)P(=O)(O)O
DMVESO2	IK	FJVYPXVLXQXDHM-UHFFFAOYSA-N
DMVESO2	IU	2-hydroxy-2-phosphono-3-pyridin-3-ylpropanoic acid
DMVESO2	CA	CAS 152831-36-2
DMVESO2	DE	Discovery agent

DMR92HV	ID	DMR92HV
DMR92HV	DN	NE11808
DMR92HV	HS	Investigative
DMR92HV	SN	NE 11808
DMR92HV	DT	Small molecular drug
DMR92HV	PC	406401
DMR92HV	MW	282.13
DMR92HV	FM	C7H12N2O6P2
DMR92HV	IC	InChI=1S/C7H12N2O6P2/c10-16(11,12)7(17(13,14)15)5-9-6-3-1-2-4-8-6/h1-4,7H,5H2,(H,8,9)(H2,10,11,12)(H2,13,14,15)
DMR92HV	CS	C1=CC=NC(=C1)NCC(P(=O)(O)O)P(=O)(O)O
DMR92HV	IK	BHVCADPDEFLLGM-UHFFFAOYSA-N
DMR92HV	IU	[1-phosphono-2-(pyridin-2-ylamino)ethyl]phosphonic acid
DMR92HV	CA	CAS 105462-22-4
DMR92HV	DE	Discovery agent

DMILP0F	ID	DMILP0F
DMILP0F	DN	NE-2
DMILP0F	HS	Investigative
DMILP0F	CP	Diamyd Medical AB
DMILP0F	DE	Pain

DM58O3I	ID	DM58O3I
DM58O3I	DN	NE21650
DM58O3I	HS	Investigative
DM58O3I	SN	CHEMBL414849; NE-21650; Ne 21650; GTPL3167; BDBM50173792; 2-(2-aminophenyl)-1-hydroxyethane-1,1-diyldiphosphonic acid; [2-(2-aminophenyl)-1-hydroxy-1-phosphonoethyl]phosphonic acid; [2-(2-Amino-phenyl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid; hydrogen [2-(2-azaniumylphenyl)-1-hydroxy-1-phosphonatoethyl]phosphonate
DM58O3I	DT	Small molecular drug
DM58O3I	PC	9994754
DM58O3I	MW	297.14
DM58O3I	FM	C8H13NO7P2
DM58O3I	IC	InChI=1S/C8H13NO7P2/c9-7-4-2-1-3-6(7)5-8(10,17(11,12)13)18(14,15)16/h1-4,10H,5,9H2,(H2,11,12,13)(H2,14,15,16)
DM58O3I	CS	C1=CC=C(C(=C1)CC(O)(P(=O)(O)O)P(=O)(O)O)N
DM58O3I	IK	VJXYJONFUZXZJZ-UHFFFAOYSA-N
DM58O3I	IU	[2-(2-aminophenyl)-1-hydroxy-1-phosphonoethyl]phosphonic acid
DM58O3I	DE	Discovery agent

DMVSRYH	ID	DMVSRYH
DMVSRYH	DN	NE-28345
DMVSRYH	HS	Investigative
DMVSRYH	SN	Oleylhomovanillamide; NE 28345; N-oleylhomovanillamide; 4-Hydroxy-3-methoxy-N-9-octadecenylbenzeneacetamide (Z)-; Benzeneacetamide, 4-hydroxy-3-methoxy-N-9-octadecenyl-, (Z)-; NE-28345; N-oleyl-homovanillamide; AC1O5R2B; SCHEMBL504255; CHEMBL327447; AKOS030583210; LS-28555
DMVSRYH	DT	Small molecular drug
DMVSRYH	PC	6439143
DMVSRYH	MW	431.7
DMVSRYH	FM	C27H45NO3
DMVSRYH	IC	InChI=1S/C27H45NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21-28-27(30)23-24-19-20-25(29)26(22-24)31-2/h10-11,19-20,22,29H,3-9,12-18,21,23H2,1-2H3,(H,28,30)/b11-10-
DMVSRYH	CS	CCCCCCCC/C=C\\CCCCCCCCNC(=O)CC1=CC(=C(C=C1)O)OC
DMVSRYH	IK	PCZMUTQYZKAXBW-KHPPLWFESA-N
DMVSRYH	IU	2-(4-hydroxy-3-methoxyphenyl)-N-[(Z)-octadec-9-enyl]acetamide
DMVSRYH	CA	CAS 107512-56-1
DMVSRYH	DE	Discovery agent

DM28ZPT	ID	DM28ZPT
DM28ZPT	DN	NE58018
DM28ZPT	HS	Investigative
DM28ZPT	SN	NE 58018; NE-58018
DM28ZPT	DT	Small molecular drug
DM28ZPT	PC	405372
DM28ZPT	MW	283.11
DM28ZPT	FM	C7H11NO7P2
DM28ZPT	IC	InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)5-6-3-1-2-4-8-6/h1-4,9H,5H2,(H2,10,11,12)(H2,13,14,15)
DM28ZPT	CS	C1=CC=NC(=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DM28ZPT	IK	XXNASZAYANFLID-UHFFFAOYSA-N
DM28ZPT	IU	(1-hydroxy-1-phosphono-2-pyridin-2-ylethyl)phosphonic acid
DM28ZPT	CA	CAS 105462-23-5
DM28ZPT	DE	Discovery agent

DMU4I8R	ID	DMU4I8R
DMU4I8R	DN	NE58027
DMU4I8R	HS	Investigative
DMU4I8R	SN	NE 58027
DMU4I8R	DT	Small molecular drug
DMU4I8R	PC	14231197
DMU4I8R	MW	289.16
DMU4I8R	FM	C7H17NO7P2
DMU4I8R	IC	InChI=1S/C7H17NO7P2/c9-7(16(10,11)12,17(13,14)15)5-6-3-1-2-4-8-6/h6,8-9H,1-5H2,(H2,10,11,12)(H2,13,14,15)
DMU4I8R	CS	C1CCNC(C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DMU4I8R	IK	GKUBJNUBGKBXKR-UHFFFAOYSA-N
DMU4I8R	IU	(1-hydroxy-1-phosphono-2-piperidin-2-ylethyl)phosphonic acid
DMU4I8R	DE	Discovery agent

DMS7UNR	ID	DMS7UNR
DMS7UNR	DN	NE58043
DMS7UNR	HS	Investigative
DMS7UNR	SN	NE 58043
DMS7UNR	DT	Small molecular drug
DMS7UNR	PC	10468166
DMS7UNR	MW	267.11
DMS7UNR	FM	C7H11NO6P2
DMS7UNR	IC	InChI=1S/C7H11NO6P2/c9-15(10,11)7(16(12,13)14)4-6-2-1-3-8-5-6/h1-3,5,7H,4H2,(H2,9,10,11)(H2,12,13,14)
DMS7UNR	CS	C1=CC(=CN=C1)CC(P(=O)(O)O)P(=O)(O)O
DMS7UNR	IK	KZMOFWIRXNQJET-UHFFFAOYSA-N
DMS7UNR	IU	(1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
DMS7UNR	CA	CAS 75755-10-1
DMS7UNR	DE	Discovery agent

DMHIM6N	ID	DMHIM6N
DMHIM6N	DN	NE58062
DMHIM6N	HS	Investigative
DMHIM6N	SN	NE 58062
DMHIM6N	DT	Small molecular drug
DMHIM6N	PC	15230201
DMHIM6N	MW	286.16
DMHIM6N	FM	C7H16N2O6P2
DMHIM6N	IC	InChI=1S/C7H16N2O6P2/c1-5-3-2-4-8-6(5)9-7(16(10,11)12)17(13,14)15/h5,7H,2-4H2,1H3,(H,8,9)(H2,10,11,12)(H2,13,14,15)
DMHIM6N	CS	CC1CCCN=C1NC(P(=O)(O)O)P(=O)(O)O
DMHIM6N	IK	XUCBNFJYKWKAMN-UHFFFAOYSA-N
DMHIM6N	IU	[[(5-methyl-2,3,4,5-tetrahydropyridin-6-yl)amino]-phosphonomethyl]phosphonic acid
DMHIM6N	DE	Discovery agent

DMDWESP	ID	DMDWESP
DMDWESP	DN	NE97220
DMDWESP	HS	Investigative
DMDWESP	SN	NE 97220; CGA 103586; Q 332
DMDWESP	DT	Small molecular drug
DMDWESP	PC	5276531
DMDWESP	MW	282.13
DMDWESP	FM	C7H12N2O6P2
DMDWESP	IC	InChI=1S/C7H12N2O6P2/c1-5-3-2-4-8-6(5)9-7(16(10,11)12)17(13,14)15/h2-4,7H,1H3,(H,8,9)(H2,10,11,12)(H2,13,14,15)
DMDWESP	CS	CC1=C(N=CC=C1)NC(P(=O)(O)O)P(=O)(O)O
DMDWESP	IK	NAIJOBGUXRHQJW-UHFFFAOYSA-N
DMDWESP	IU	[[(3-methylpyridin-2-yl)amino]-phosphonomethyl]phosphonic acid
DMDWESP	DE	Discovery agent

DMNCU6H	ID	DMNCU6H
DMNCU6H	DN	Neamine
DMNCU6H	HS	Investigative
DMNCU6H	SN	Neamine; Neomycin A; Negamicin; Nebramycin X; Dekamycin V; 3947-65-7; Neamin; UNII-5981U00LY0; C12H26N4O6; BRN 0026714; 4-O-(2,6-Diamino-2,6-dideoxy-alpha-D-glucopyranosyl)-2-deoxy-D-streptamine; 2-Desoxy-4-O-(2,6-diamino-2,6-didesoxy-alpha-D-glucopyranosyl)-D-streptamin; CHEBI:7489; 5981U00LY0; (1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; D-Streptamine, 2-deoxy-4-O-(2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl)-
DMNCU6H	DT	Small molecular drug
DMNCU6H	PC	72392
DMNCU6H	MW	322.36
DMNCU6H	FM	C12H26N4O6
DMNCU6H	IC	InChI=1S/C12H26N4O6/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20/h3-12,17-20H,1-2,13-16H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1
DMNCU6H	CS	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O)O)N
DMNCU6H	IK	SYJXFKPQNSDJLI-HKEUSBCWSA-N
DMNCU6H	IU	(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxyoxane-3,4-diol
DMNCU6H	CA	CAS 3947-65-7
DMNCU6H	CB	CHEBI:7489
DMNCU6H	DE	Discovery agent

DMO0Q1F	ID	DMO0Q1F
DMO0Q1F	DN	Nectamazin C
DMO0Q1F	HS	Investigative
DMO0Q1F	SN	Nectamazin C; CHEMBL570290
DMO0Q1F	DT	Small molecular drug
DMO0Q1F	PC	45487137
DMO0Q1F	MW	420.5
DMO0Q1F	FM	C23H32O7
DMO0Q1F	IC	InChI=1S/C23H32O7/c1-8-9-14-12-22(29-6)13(2)18(23(30-7,20(14)24)21(22)25)15-10-16(26-3)19(28-5)17(11-15)27-4/h8,10-13,18,20-21,24-25H,1,9H2,2-7H3/t13-,18+,20-,21-,22+,23-/m0/s1
DMO0Q1F	CS	C[C@H]1[C@@H]([C@@]2([C@H](C(=C[C@@]1([C@@H]2O)OC)CC=C)O)OC)C3=CC(=C(C(=C3)OC)OC)OC
DMO0Q1F	IK	OHVTXDBRSOSKKO-BHIPVSGSSA-N
DMO0Q1F	IU	(1S,2S,5S,6S,7R,8S)-1,5-dimethoxy-6-methyl-3-prop-2-enyl-7-(3,4,5-trimethoxyphenyl)bicyclo[3.2.1]oct-3-ene-2,8-diol
DMO0Q1F	DE	Discovery agent

DM5EWIK	ID	DM5EWIK
DM5EWIK	DN	NEODYSIDENIN
DM5EWIK	HS	Investigative
DM5EWIK	SN	neodysidenin; CHEMBL392270
DM5EWIK	DT	Small molecular drug
DM5EWIK	PC	15482063
DM5EWIK	MW	546.2
DM5EWIK	FM	C17H23Cl6N3O2S
DM5EWIK	IC	InChI=1S/C17H23Cl6N3O2S/c1-9(16(18,19)20)7-12(25-13(27)8-10(2)17(21,22)23)15(28)26(4)11(3)14-24-5-6-29-14/h5-6,9-12H,7-8H2,1-4H3,(H,25,27)/t9-,10-,11+,12-/m0/s1
DM5EWIK	CS	C[C@@H](C[C@@H](C(=O)N(C)[C@H](C)C1=NC=CS1)NC(=O)C[C@H](C)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl
DM5EWIK	IK	MBVQTLXBQHZLRO-YFKTTZPYSA-N
DM5EWIK	IU	(2S,4S)-5,5,5-trichloro-N,4-dimethyl-N-[(1R)-1-(1,3-thiazol-2-yl)ethyl]-2-[[(3S)-4,4,4-trichloro-3-methylbutanoyl]amino]pentanamide
DM5EWIK	DE	Discovery agent

DM6D0JC	ID	DM6D0JC
DM6D0JC	DN	Neo-kauluamine
DM6D0JC	HS	Investigative
DM6D0JC	SN	neo-Kauluamine
DM6D0JC	DT	Small molecular drug
DM6D0JC	PC	44448144
DM6D0JC	MW	1163.5
DM6D0JC	FM	C72H90N8O6
DM6D0JC	IC	InChI=1S/C72H90N8O6/c81-58-22-17-37-79-40-29-61(58)86-72-32-23-60(85-47-69-46-78-36-16-8-3-1-5-13-30-70(83,66(69)79)42-53(55(69)27-39-78)63-65-51(25-34-74-63)49-19-10-12-21-57(49)76-65)59(82)28-41-80(72)67-68(44-72)45-77-35-15-7-4-2-6-14-31-71(67,84)43-52(54(68)26-38-77)62-64-50(24-33-73-62)48-18-9-11-20-56(48)75-64/h1-2,5-6,9-12,18-21,24-25,33-34,42-43,54-55,58-61,66-67,75-76,81-84H,3-4,7-8,13-17,22-23,26-32,35-41,44-47H2/b5-1-,6-2-/t54-,55-,58+,59-,60+,61-,66+,67+,68-,69+,70-,71-,72+/m0/s1
DM6D0JC	CS	C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@@]56N4CC[C@@H]([C@@H](CC5)OC[C@@]78CN9CCCC/C=C\\CC[C@@]([C@@H]7N1CCC[C@H]([C@@H](O6)CC1)O)(C=C([C@@H]8CC9)C1=NC=CC2=C1NC1=CC=CC=C21)O)O)O)C1=NC=CC2=C1NC1=CC=CC=C21
DM6D0JC	IK	QBYWKABDYAEEIS-VZMZVYMRSA-N
DM6D0JC	IU	(1R,3S,4R,9R,10S,13Z,22S,23S,26R,27S,31R,32S,35Z,44R,45R)-50,53-bis(9H-pyrido[3,4-b]indol-1-yl)-2,25-dioxa-8,19,30,41-tetrazadecacyclo[24.20.2.23,8.210,22.232,44.119,23.141,45.01,30.09,23.031,45]hexapentaconta-13,35,50,53-tetraene-4,10,27,32-tetrol
DM6D0JC	DE	Discovery agent

DMKFPA9	ID	DMKFPA9
DMKFPA9	DN	NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B
DMKFPA9	HS	Investigative
DMKFPA9	SN	Neolignan 9-nor-7,8-dehydro-isolicarin B; CHEMBL571199; BDBM50303146
DMKFPA9	DT	Small molecular drug
DMKFPA9	PC	11243755
DMKFPA9	MW	308.3
DMKFPA9	FM	C19H16O4
DMKFPA9	IC	InChI=1S/C19H16O4/c1-3-4-12-7-14-10-16(23-19(14)18(8-12)20-2)13-5-6-15-17(9-13)22-11-21-15/h3,5-10H,1,4,11H2,2H3
DMKFPA9	CS	COC1=CC(=CC2=C1OC(=C2)C3=CC4=C(C=C3)OCO4)CC=C
DMKFPA9	IK	QHQQIGTXXBIMFB-UHFFFAOYSA-N
DMKFPA9	IU	5-(7-methoxy-5-prop-2-enyl-1-benzofuran-2-yl)-1,3-benzodioxole
DMKFPA9	DE	Discovery agent

DM5GMOJ	ID	DM5GMOJ
DM5GMOJ	DN	NEORAUTENOL
DM5GMOJ	HS	Investigative
DM5GMOJ	SN	Neorautenol; CHEMBL1098728; BDBM50317432
DM5GMOJ	DT	Small molecular drug
DM5GMOJ	PC	11500744
DM5GMOJ	MW	322.4
DM5GMOJ	FM	C20H18O4
DM5GMOJ	IC	InChI=1S/C20H18O4/c1-20(2)6-5-11-7-14-17(9-16(11)24-20)22-10-15-13-4-3-12(21)8-18(13)23-19(14)15/h3-9,15,19,21H,10H2,1-2H3/t15-,19-/m0/s1
DM5GMOJ	CS	CC1(C=CC2=CC3=C(C=C2O1)OC[C@@H]4[C@H]3OC5=C4C=CC(=C5)O)C
DM5GMOJ	IK	OGFFMQWYZCTXCM-KXBFYZLASA-N
DM5GMOJ	IU	(2R,10R)-17,17-dimethyl-3,12,16-trioxapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(13),4(9),5,7,14,18,20-heptaen-6-ol
DM5GMOJ	DE	Discovery agent

DMXULGK	ID	DMXULGK
DMXULGK	DN	Neplanocin A
DMXULGK	HS	Investigative
DMXULGK	SN	72877-50-0; NPC-A; A-11079-B1B; NEOPLANOCIN A; (1s,2r,5r)-5-(6-amino-9h-purin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; NSC 316458; CHEMBL8771; (-)-9-(trans-2,trans-3-Dihydroxy-4-(hydroxymethyl)-cyclopent-4-enyl)-adenine; 4-Cyclopentene-1,2-diol, 3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)-, (1S,2R,3R)-; (1S,2R,5R)-5-(6-aminopurin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; Nephanocin A; AC1Q4VG9; AC1L2J1E; SCHEMBL10469277; CTK5D6979; MolPort-044-561-069; ZINC3832328; BDBM50006222; CCG-208688; DIBRT
DMXULGK	DT	Small molecular drug
DMXULGK	PC	72968
DMXULGK	MW	263.25
DMXULGK	FM	C11H13N5O3
DMXULGK	IC	InChI=1S/C11H13N5O3/c12-10-7-11(14-3-13-10)16(4-15-7)6-1-5(2-17)8(18)9(6)19/h1,3-4,6,8-9,17-19H,2H2,(H2,12,13,14)/t6-,8-,9+/m1/s1
DMXULGK	CS	C1=C([C@H]([C@H]([C@@H]1N2C=NC3=C(N=CN=C32)N)O)O)CO
DMXULGK	IK	XUGWUUDOWNZAGW-VDAHYXPESA-N
DMXULGK	IU	(1S,2R,5R)-5-(6-aminopurin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
DMXULGK	CA	CAS 72877-50-0
DMXULGK	DE	Discovery agent

DM3AW8X	ID	DM3AW8X
DM3AW8X	DN	Nerve growth factor conjugated RAP peptide
DM3AW8X	HS	Investigative
DM3AW8X	SN	NGF-RAP; Nerve growth factor conjugated RAP peptide (NeuroTrans, neurodegenrative disease); Nerve growth factor conjugated RAP peptide (NeuroTrans, neurodegenrative disease), Raptor
DM3AW8X	CP	Raptor Pharmaceuticals Corp
DM3AW8X	DE	Neurodegenerative disorder

DM1W2GZ	ID	DM1W2GZ
DM1W2GZ	DN	N-ethyl estradiol-16-methyl carboxamide
DM1W2GZ	HS	Investigative
DM1W2GZ	SN	SCHEMBL12379571
DM1W2GZ	DT	Small molecular drug
DM1W2GZ	PC	44407526
DM1W2GZ	MW	357.5
DM1W2GZ	FM	C22H31NO3
DM1W2GZ	IC	InChI=1S/C22H31NO3/c1-3-23-20(25)12-14-11-19-18-6-4-13-10-15(24)5-7-16(13)17(18)8-9-22(19,2)21(14)26/h5,7,10,14,17-19,21,24,26H,3-4,6,8-9,11-12H2,1-2H3,(H,23,25)/t14?,17?,18?,19?,21-,22-/m0/s1
DM1W2GZ	CS	CCNC(=O)CC1CC2C3CCC4=C(C3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DM1W2GZ	IK	ZQUXDOJBDFPTDM-LAULZOBPSA-N
DM1W2GZ	IU	2-[(13S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]-N-ethylacetamide
DM1W2GZ	DE	Discovery agent

DMM9526	ID	DMM9526
DMM9526	DN	N-ethyl estrone-16-methyl carboxamide
DMM9526	HS	Investigative
DMM9526	SN	SCHEMBL12379557
DMM9526	DT	Small molecular drug
DMM9526	PC	44407576
DMM9526	MW	355.5
DMM9526	FM	C22H29NO3
DMM9526	IC	InChI=1S/C22H29NO3/c1-3-23-20(25)12-14-11-19-18-6-4-13-10-15(24)5-7-16(13)17(18)8-9-22(19,2)21(14)26/h5,7,10,14,17-19,24H,3-4,6,8-9,11-12H2,1-2H3,(H,23,25)/t14?,17?,18?,19?,22-/m0/s1
DMM9526	CS	CCNC(=O)CC1CC2C3CCC4=C(C3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMM9526	IK	DGCNLEJTGGXFLE-SSBKPBJFSA-N
DMM9526	IU	N-ethyl-2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]acetamide
DMM9526	DE	Discovery agent

DMQ3184	ID	DMQ3184
DMQ3184	DN	N-ethyl-2,2,2-triphenylacetamide
DMQ3184	HS	Investigative
DMQ3184	DE	Discovery agent

DMWLI4U	ID	DMWLI4U
DMWLI4U	DN	N-Ethyl-2-methylnorapomorphine hydrochloride
DMWLI4U	HS	Investigative
DMWLI4U	SN	CHEMBL562460
DMWLI4U	DT	Small molecular drug
DMWLI4U	PC	45267373
DMWLI4U	MW	295.4
DMWLI4U	FM	C19H21NO2
DMWLI4U	IC	InChI=1S/C19H21NO2/c1-3-20-7-6-13-8-11(2)9-14-17(13)15(20)10-12-4-5-16(21)19(22)18(12)14/h4-5,8-9,15,21-22H,3,6-7,10H2,1-2H3/t15-/m1/s1
DMWLI4U	CS	CCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)C)C(=C(C=C4)O)O
DMWLI4U	IK	VNGYREUWVHTKAV-OAHLLOKOSA-N
DMWLI4U	IU	(6aR)-6-ethyl-2-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMWLI4U	DE	Discovery agent

DM6HMBW	ID	DM6HMBW
DM6HMBW	DN	N-Ethyl-2-phenylnorapomorphine hydrochloride
DM6HMBW	HS	Investigative
DM6HMBW	SN	CHEMBL564909
DM6HMBW	DT	Small molecular drug
DM6HMBW	PC	45271622
DM6HMBW	MW	357.4
DM6HMBW	FM	C24H23NO2
DM6HMBW	IC	InChI=1S/C24H23NO2/c1-2-25-11-10-17-12-18(15-6-4-3-5-7-15)13-19-22(17)20(25)14-16-8-9-21(26)24(27)23(16)19/h3-9,12-13,20,26-27H,2,10-11,14H2,1H3/t20-/m1/s1
DM6HMBW	CS	CCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)C5=CC=CC=C5)C(=C(C=C4)O)O
DM6HMBW	IK	RJCYHSVPFFEYKA-HXUWFJFHSA-N
DM6HMBW	IU	(6aR)-6-ethyl-2-phenyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DM6HMBW	DE	Discovery agent

DMHY35A	ID	DMHY35A
DMHY35A	DN	N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide
DMHY35A	HS	Investigative
DMHY35A	SN	CHEMBL379234; N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide; Enamine_001944; Oprea1_552384; AC1M697W; SCHEMBL10904389; MolPort-004-000-970; HMS1399I08; ZINC3251814; BDBM50177761; AKOS008967166; MCULE-9434872926; N-ethyl-4-hydroxy-N-phenylbenzene-1-sulfonamide; Z56821525
DMHY35A	DT	Small molecular drug
DMHY35A	PC	2368773
DMHY35A	MW	277.34
DMHY35A	FM	C14H15NO3S
DMHY35A	IC	InChI=1S/C14H15NO3S/c1-2-15(12-6-4-3-5-7-12)19(17,18)14-10-8-13(16)9-11-14/h3-11,16H,2H2,1H3
DMHY35A	CS	CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DMHY35A	IK	VGVYBVTUILCGFQ-UHFFFAOYSA-N
DMHY35A	IU	N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide
DMHY35A	DE	Discovery agent

DM873WR	ID	DM873WR
DM873WR	DN	N-ethyl-5,6-dip-tolylpyrazine-2-carboxamide
DM873WR	HS	Investigative
DM873WR	SN	CHEMBL246476; N-ethyl-5,6-dip-tolylpyrazine-2-carboxamide
DM873WR	DT	Small molecular drug
DM873WR	PC	44440707
DM873WR	MW	331.4
DM873WR	FM	C21H21N3O
DM873WR	IC	InChI=1S/C21H21N3O/c1-4-22-21(25)18-13-23-19(16-9-5-14(2)6-10-16)20(24-18)17-11-7-15(3)8-12-17/h5-13H,4H2,1-3H3,(H,22,25)
DM873WR	CS	CCNC(=O)C1=CN=C(C(=N1)C2=CC=C(C=C2)C)C3=CC=C(C=C3)C
DM873WR	IK	BAXIFQMQEGUGGQ-UHFFFAOYSA-N
DM873WR	IU	N-ethyl-5,6-bis(4-methylphenyl)pyrazine-2-carboxamide
DM873WR	DE	Discovery agent

DMPTNI8	ID	DMPTNI8
DMPTNI8	DN	N-Ethyl-ETAV
DMPTNI8	HS	Investigative
DMPTNI8	SN	N-Ethyl-ETAV; CHEMBL492431
DMPTNI8	DT	Small molecular drug
DMPTNI8	PC	44568808
DMPTNI8	MW	446.5
DMPTNI8	FM	C19H34N4O8
DMPTNI8	IC	InChI=1S/C19H34N4O8/c1-6-20-12(7-8-13(25)26)17(28)23-15(11(5)24)18(29)21-10(4)16(27)22-14(9(2)3)19(30)31/h9-12,14-15,20,24H,6-8H2,1-5H3,(H,21,29)(H,22,27)(H,23,28)(H,25,26)(H,30,31)/t10-,11?,12-,14-,15-/m0/s1
DMPTNI8	CS	CCN[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O
DMPTNI8	IK	MEXXBWHVPQDHNP-FYOXFVTASA-N
DMPTNI8	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-(ethylamino)-5-oxopentanoic acid
DMPTNI8	DE	Discovery agent

DMYI87T	ID	DMYI87T
DMYI87T	DN	N-ethylhistamine
DMYI87T	HS	Investigative
DMYI87T	SN	479408-49-6; 2-(1-ethyl-1h-imidazol-4-yl)ethanamine; 1-ETHYL-1H-IMIDAZOLE-4-ETHANAMINE; 2-(1-Ethyl-1H-imidazol-4-yl)ethan-1-amine; N-ethylhistamine; 2-(1-Ethyl-1H-imidazol-4-yl)ethylamine; CHEMBL46296; SCHEMBL589342; GTPL1271; CTK4J0489; DTXSID90658170; LIXGKSRWGHVUHT-UHFFFAOYSA-N; ZINC29412524; 2-(1-ethylimidazol-4-yl)ethanamine; AKOS006337816
DMYI87T	DT	Small molecular drug
DMYI87T	PC	44292270
DMYI87T	MW	139.2
DMYI87T	FM	C7H13N3
DMYI87T	IC	InChI=1S/C7H13N3/c1-2-10-5-7(3-4-8)9-6-10/h5-6H,2-4,8H2,1H3
DMYI87T	CS	CCN1C=C(N=C1)CCN
DMYI87T	IK	LIXGKSRWGHVUHT-UHFFFAOYSA-N
DMYI87T	IU	2-(1-ethylimidazol-4-yl)ethanamine
DMYI87T	CA	CAS 479408-49-6
DMYI87T	DE	Discovery agent

DMMKSGL	ID	DMMKSGL
DMMKSGL	DN	N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMMKSGL	HS	Investigative
DMMKSGL	SN	CHEMBL150948; N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine; BDBM50138487; 1-(3-Pyridinyl)-4-(methylethylamino)-1-butyne
DMMKSGL	DT	Small molecular drug
DMMKSGL	PC	44366246
DMMKSGL	MW	188.27
DMMKSGL	FM	C12H16N2
DMMKSGL	IC	InChI=1S/C12H16N2/c1-3-14(2)10-5-4-7-12-8-6-9-13-11-12/h6,8-9,11H,3,5,10H2,1-2H3
DMMKSGL	CS	CCN(C)CCC#CC1=CN=CC=C1
DMMKSGL	IK	DGPGTYZUJIIMAU-UHFFFAOYSA-N
DMMKSGL	IU	N-ethyl-N-methyl-4-pyridin-3-ylbut-3-yn-1-amine
DMMKSGL	DE	Discovery agent

DMOW2QS	ID	DMOW2QS
DMOW2QS	DN	Netropsin
DMOW2QS	HS	Investigative
DMOW2QS	SN	Netropsin; Antibiotic 1142; Congocidine; Antibiotic T-1384; UNII-64B3O0RD7N; CHEMBL307767; 64B3O0RD7N; NSC 3067; CH-777-A; IA 887; BRN 0376913; K-117; 2814-A; T 1384; N,4'-Bi(pyrrole-2-carboxamide), N'-(2-carbamoylethyl)-4-((2-guanidinoacetimidoyl)amino)-1,1'-dimethyl-; F 6; 1H-Pyrrole-2-carboxamide, 4-((((aminoiminomethyl)amino)acetyl)amino)-N-(5-(((3-amino-3-iminopropyl)amino)carbonyl)-1-methyl-1H-pyrrol-3-yl)-1-methyl-; BDBM17; AC1L1I7V; AC1Q5M1N; SCHEMBL197747; CTK8G1803; IDBIFFKSXLYUOT-UHFFFAOYSA-N; 63770-20-7 (hydrochloride
DMOW2QS	DT	Small molecular drug
DMOW2QS	PC	4461
DMOW2QS	MW	430.5
DMOW2QS	FM	C18H26N10O3
DMOW2QS	IC	InChI=1S/C18H26N10O3/c1-27-9-11(6-12(27)16(30)23-4-3-14(19)20)26-17(31)13-5-10(8-28(13)2)25-15(29)7-24-18(21)22/h5-6,8-9H,3-4,7H2,1-2H3,(H3,19,20)(H,23,30)(H,25,29)(H,26,31)(H4,21,22,24)
DMOW2QS	CS	CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCC(=N)N)C)NC(=O)CN=C(N)N
DMOW2QS	IK	IDBIFFKSXLYUOT-UHFFFAOYSA-N
DMOW2QS	IU	N-[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]-4-[[2-(diaminomethylideneamino)acetyl]amino]-1-methylpyrrole-2-carboxamide
DMOW2QS	CA	CAS 1438-30-8
DMOW2QS	DE	Discovery agent

DM9UXRP	ID	DM9UXRP
DM9UXRP	DN	neurokinin A
DM9UXRP	HS	Investigative
DM9UXRP	SN	substance K
DM9UXRP	DT	Small molecular drug
DM9UXRP	PC	5311311
DM9UXRP	MW	1133.3
DM9UXRP	FM	C50H80N14O14S
DM9UXRP	IC	InChI=1S/C50H80N14O14S/c1-26(2)18-34(45(73)58-32(42(53)70)15-17-79-6)57-38(67)23-55-49(77)40(27(3)4)63-47(75)35(19-29-12-8-7-9-13-29)60-48(76)37(24-65)62-46(74)36(21-39(68)69)61-50(78)41(28(5)66)64-44(72)33(14-10-11-16-51)59-43(71)31(52)20-30-22-54-25-56-30/h7-9,12-13,22,25-28,31-37,40-41,65-66H,10-11,14-21,23-24,51-52H2,1-6H3,(H2,53,70)(H,54,56)(H,55,77)(H,57,67)(H,58,73)(H,59,71)(H,60,76)(H,61,78)(H,62,74)(H,63,75)(H,64,72)(H,68,69)/t28-,31+,32+,33+,34+,35+,36+,37+,40+,41+/m1/s1
DM9UXRP	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CN=CN2)N)O
DM9UXRP	IK	HEAUFJZALFKPBA-JPQUDPSNSA-N
DM9UXRP	IU	(3S)-3-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DM9UXRP	CA	CAS 86933-74-6
DM9UXRP	DE	Discovery agent

DM5O2MJ	ID	DM5O2MJ
DM5O2MJ	DN	NEUROKININ B
DM5O2MJ	HS	Investigative
DM5O2MJ	SN	Neurokinin B; CHEMBL437797; CHEBI:80312; 86933-75-7; NKB; Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2; Neurokinin B (human, porcine); Tachykinin-3; AC1NSKET; GTPL2090; BDBM50079412; AKOS024456682; C16098; SR-05000014260; SR-05000014260-1; (NKB)Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2; Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2(Neurokinin B)
DM5O2MJ	DT	Small molecular drug
DM5O2MJ	PC	5311312
DM5O2MJ	MW	1210.4
DM5O2MJ	FM	C55H79N13O14S2
DM5O2MJ	IC	InChI=1S/C55H79N13O14S2/c1-30(2)21-38(50(77)62-36(47(57)74)17-19-83-5)61-43(69)28-59-55(82)46(31(3)4)68-54(81)40(23-33-15-11-8-12-16-33)65-51(78)39(22-32-13-9-7-10-14-32)64-53(80)42(26-45(72)73)67-52(79)41(24-34-27-58-29-60-34)66-49(76)37(18-20-84-6)63-48(75)35(56)25-44(70)71/h7-16,27,29-31,35-42,46H,17-26,28,56H2,1-6H3,(H2,57,74)(H,58,60)(H,59,82)(H,61,69)(H,62,77)(H,63,75)(H,64,80)(H,65,78)(H,66,76)(H,67,79)(H,68,81)(H,70,71)(H,72,73)/t35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1
DM5O2MJ	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)N
DM5O2MJ	IK	NHXYSAFTNPANFK-HDMCBQFHSA-N
DM5O2MJ	IU	(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM5O2MJ	CB	CHEBI:80312
DM5O2MJ	DE	Discovery agent

DMSJ6T1	ID	DMSJ6T1
DMSJ6T1	DN	Neuromed 2
DMSJ6T1	HS	Investigative
DMSJ6T1	TC	Analgesics
DMSJ6T1	DE	Pain

DMXKT45	ID	DMXKT45
DMXKT45	DN	Neuromed 5
DMXKT45	HS	Investigative
DMXKT45	TC	Analgesics
DMXKT45	DE	Pain

DMCXJLH	ID	DMCXJLH
DMCXJLH	DN	neuromedin B
DMCXJLH	HS	Investigative
DMCXJLH	SN	Neuromedin B; 87096-84-2; Gly-asn-leu-trp-ala-thr-gly-his-phe-met-NH2; NEUROMEDINB; Neuromedin B, porcine; GTPL613; AC1N8M58; Neuromedin B, &gt; 2-[(2-aminoacetyl)amino]-N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide
DMCXJLH	DT	Small molecular drug
DMCXJLH	PC	4345957
DMCXJLH	MW	1132.3
DMCXJLH	FM	C52H73N15O12S
DMCXJLH	IC	InChI=1S/C52H73N15O12S/c1-27(2)17-36(64-51(78)40(21-41(54)69)61-42(70)22-53)48(75)66-38(19-31-23-57-34-14-10-9-13-33(31)34)47(74)60-28(3)46(73)67-44(29(4)68)52(79)58-25-43(71)62-39(20-32-24-56-26-59-32)50(77)65-37(18-30-11-7-6-8-12-30)49(76)63-35(45(55)72)15-16-80-5/h6-14,23-24,26-29,35-40,44,57,68H,15-22,25,53H2,1-5H3,(H2,54,69)(H2,55,72)(H,56,59)(H,58,79)(H,60,74)(H,61,70)(H,62,71)(H,63,76)(H,64,78)(H,65,77)(H,66,75)(H,67,73)
DMCXJLH	CS	CC(C)CC(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(C)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC3=CN=CN3)C(=O)NC(CC4=CC=CC=C4)C(=O)NC(CCSC)C(=O)N)NC(=O)C(CC(=O)N)NC(=O)CN
DMCXJLH	IK	YPFNACALNKVZNK-UHFFFAOYSA-N
DMCXJLH	IU	2-[(2-aminoacetyl)amino]-N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide
DMCXJLH	DE	Discovery agent

DM27WCE	ID	DM27WCE
DM27WCE	DN	NEUROTENSIN
DM27WCE	HS	Investigative
DM27WCE	SN	CHEMBL407196; 55508-42-4; 58889-67-1; Neurotensin (ox); (D-Tyr11)neurotensin; Neurotensin 1-13; 11-Tyr-neurotensin; Neurotensin, tyr(11)-; Neurotensin, tyrosine(11)-; GTPL1579; Neurotensin, &gt; MolPort-016-581-032; Neurotensin (ox), 11-D-tyrosine-; MFCD00076678; BDBM50130880; NCGC00167274-01; NT(1-13); 889N671; pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu; pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH
DM27WCE	DT	Small molecular drug
DM27WCE	PC	25077406
DM27WCE	MW	1672.9
DM27WCE	FM	C78H121N21O20
DM27WCE	IC	InChI=1S/C78H121N21O20/c1-7-43(6)63(73(115)96-57(76(118)119)37-42(4)5)97-70(112)55(39-45-21-25-47(101)26-22-45)95-72(114)59-18-13-35-99(59)75(117)52(16-11-33-86-78(83)84)90-64(106)48(15-10-32-85-77(81)82)89-71(113)58-17-12-34-98(58)74(116)51(14-8-9-31-79)91-69(111)56(40-60(80)102)94-66(108)50(28-30-62(104)105)88-68(110)54(38-44-19-23-46(100)24-20-44)93-67(109)53(36-41(2)3)92-65(107)49-27-29-61(103)87-49/h19-26,41-43,48-59,63,100-101H,7-18,27-40,79H2,1-6H3,(H2,80,102)(H,87,103)(H,88,110)(H,89,113)(H,90,106)(H,91,111)(H,92,107)(H,93,109)(H,94,108)(H,95,114)(H,96,115)(H,97,112)(H,104,105)(H,118,119)(H4,81,82,85)(H4,83,84,86)/t43-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,63-/m0/s1
DM27WCE	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]5CCC(=O)N5
DM27WCE	IK	PCJGZPGTCUMMOT-ISULXFBGSA-N
DM27WCE	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-4-carboxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-4-methyl-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DM27WCE	CA	CAS 39379-15-2
DM27WCE	CB	CHEBI:7542
DM27WCE	DE	Discovery agent

DMOBU62	ID	DMOBU62
DMOBU62	DN	Neurotensin(8-13)
DMOBU62	HS	Investigative
DMOBU62	SN	CHEMBL342252; BDBM50240845; (S)-2-{(2S,3R)-2-[(S)-2-({(S)-1-[(S)-2-((S)-2-Amino-5-guanidino-pentanoylamino)-5-guanidino-pentanoyl]-pyrrolidine-2-carbonyl}-amino)-3-(4-hydroxy-phenyl)-propionylamino]-3-methyl-pentanoylamino}-4-methyl-pentanoic acid; 2-{(S)-2-[2-({(S)-1-[(S)-2-((S)-2-Amino-5-guanidino-pentanoylamino)-5-guanidino-pentanoyl]-pyrrolidine-2-carbonyl}-amino)-3-(4-hydroxy-phenyl)-propionylamino]-3-methyl-pentanoylamino}-4-(S)-methyl-pentanoic acid
DMOBU62	DT	Small molecular drug
DMOBU62	PC	5311318
DMOBU62	MW	817
DMOBU62	FM	C38H64N12O8
DMOBU62	IC	InChI=1S/C38H64N12O8/c1-5-22(4)30(34(55)48-28(36(57)58)19-21(2)3)49-32(53)27(20-23-12-14-24(51)15-13-23)47-33(54)29-11-8-18-50(29)35(56)26(10-7-17-45-38(42)43)46-31(52)25(39)9-6-16-44-37(40)41/h12-15,21-22,25-30,51H,5-11,16-20,39H2,1-4H3,(H,46,52)(H,47,54)(H,48,55)(H,49,53)(H,57,58)(H4,40,41,44)(H4,42,43,45)/t22-,25-,26-,27-,28-,29-,30-/m0/s1
DMOBU62	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N
DMOBU62	IK	DQDBCHHEIKQPJD-ODKJCKIQSA-N
DMOBU62	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid

DM6NS7H	ID	DM6NS7H
DM6NS7H	DN	nexturastat A
DM6NS7H	HS	Investigative
DM6NS7H	SN	S7473
DM6NS7H	DT	Small molecular drug
DM6NS7H	PC	71462653
DM6NS7H	MW	341.4
DM6NS7H	FM	C19H23N3O3
DM6NS7H	IC	InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)
DM6NS7H	CS	CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2
DM6NS7H	IK	JZWXMCPARMXZQV-UHFFFAOYSA-N
DM6NS7H	IU	4-[[butyl(phenylcarbamoyl)amino]methyl]-N-hydroxybenzamide
DM6NS7H	DE	Discovery agent

DMJ4GO9	ID	DMJ4GO9
DMJ4GO9	DN	NF023
DMJ4GO9	HS	Investigative
DMJ4GO9	SN	NF-023
DMJ4GO9	DT	Small molecular drug
DMJ4GO9	PC	4465
DMJ4GO9	MW	1162.9
DMJ4GO9	FM	C35H20N4Na6O21S6
DMJ4GO9	IC	InChI=1S/C35H26N4O21S6.6Na/c40-33(38-25-7-9-27(63(49,50)51)23-13-21(61(43,44)45)15-29(31(23)25)65(55,56)57)17-3-1-5-19(11-17)36-35(42)37-20-6-2-4-18(12-20)34(41)39-26-8-10-28(64(52,53)54)24-14-22(62(46,47)48)16-30(32(24)26)66(58,59)60;;;;;;/h1-16H,(H,38,40)(H,39,41)(H2,36,37,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60);;;;;;/q;6*+1/p-6
DMJ4GO9	CS	C1=CC(=CC(=C1)NC(=O)NC2=CC=CC(=C2)C(=O)NC3=C4C(=CC(=CC4=C(C=C3)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])C(=O)NC5=C6C(=CC(=CC6=C(C=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMJ4GO9	IK	FMQURVHYTBGYSQ-UHFFFAOYSA-H
DMJ4GO9	IU	hexasodium;8-[[3-[[3-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]phenyl]carbamoylamino]benzoyl]amino]naphthalene-1,3,5-trisulfonate
DMJ4GO9	CA	CAS 104869-31-0
DMJ4GO9	DE	Discovery agent

DMGMH8T	ID	DMGMH8T
DMGMH8T	DN	NF157
DMGMH8T	HS	Investigative
DMGMH8T	SN	NF-157
DMGMH8T	DT	Small molecular drug
DMGMH8T	PC	11636757
DMGMH8T	MW	1305.2
DMGMH8T	FM	C49H34F2N6O23S6
DMGMH8T	IC	InChI=1S/C49H34F2N6O23S6/c50-33-9-7-25(47(60)54-35-11-13-39(83(69,70)71)31-19-29(81(63,64)65)21-41(43(31)35)85(75,76)77)17-37(33)56-45(58)23-3-1-5-27(15-23)52-49(62)53-28-6-2-4-24(16-28)46(59)57-38-18-26(8-10-34(38)51)48(61)55-36-12-14-40(84(72,73)74)32-20-30(82(66,67)68)22-42(44(32)36)86(78,79)80/h1-22H,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)
DMGMH8T	CS	C1=CC(=CC(=C1)NC(=O)NC2=CC=CC(=C2)C(=O)NC3=C(C=CC(=C3)C(=O)NC4=C5C(=CC(=CC5=C(C=C4)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)F)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)F
DMGMH8T	IK	UDVIAMRWOLIUAE-UHFFFAOYSA-N
DMGMH8T	IU	8-[[4-fluoro-3-[[3-[[3-[[2-fluoro-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonic acid
DMGMH8T	DE	Discovery agent

DMPSXR8	ID	DMPSXR8
DMPSXR8	DN	NF340
DMPSXR8	HS	Investigative
DMPSXR8	SN	NF-340; NF 340
DMPSXR8	DT	Small molecular drug
DMPSXR8	PC	73755007
DMPSXR8	MW	986.8
DMPSXR8	FM	C37H26N4Na4O15S4
DMPSXR8	IC	InChI=1S/C37H30N4O15S4.4Na/c1-19-3-5-23(35(42)38-33-17-27(59(51,52)53)11-21-7-9-25(15-29(21)33)57(45,46)47)13-31(19)40-37(44)41-32-14-24(6-4-20(32)2)36(43)39-34-18-28(60(54,55)56)12-22-8-10-26(16-30(22)34)58(48,49)50;;;;/h3-18H,1-2H3,(H,38,42)(H,39,43)(H2,40,41,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56);;;;/q;4*+1/p-4
DMPSXR8	CS	CC1=C(C=C(C=C1)C(=O)NC2=C3C=C(C=CC3=CC(=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)NC4=C(C=CC(=C4)C(=O)NC5=C6C=C(C=CC6=CC(=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+].[Na+].[Na+]
DMPSXR8	IK	SJMHXBFWMZYDBY-UHFFFAOYSA-J
DMPSXR8	IU	tetrasodium;4-[[3-[[5-[(3,7-disulfonatonaphthalen-1-yl)carbamoyl]-2-methylphenyl]carbamoylamino]-4-methylbenzoyl]amino]naphthalene-2,6-disulfonate
DMPSXR8	DE	Discovery agent

DM816Z2	ID	DM816Z2
DM816Z2	DN	NF449
DM816Z2	HS	Investigative
DM816Z2	SN	Tocris-1391; NCGC00025139-01; GTPL4267; MolPort-003-983-648; HMS3267D22; 1,3-disodium 4-{[3-({[3,5-bis({2,4-bis[(sodiooxy)sulfonyl]phenyl}carbamoyl)phenyl]carbamoyl}amino)-5-({2,4-bis[(sodiooxy)sulfonyl]phenyl}carbamoyl)benzene]amido}benzene-1,3-disulfonate
DM816Z2	DT	Small molecular drug
DM816Z2	PC	6093161
DM816Z2	MW	1505.1
DM816Z2	FM	C41H24N6Na8O29S8
DM816Z2	IC	InChI=1S/C41H32N6O29S8.8Na/c48-37(44-29-5-1-25(77(53,54)55)15-33(29)81(65,66)67)19-9-20(38(49)45-30-6-2-26(78(56,57)58)16-34(30)82(68,69)70)12-23(11-19)42-41(52)43-24-13-21(39(50)46-31-7-3-27(79(59,60)61)17-35(31)83(71,72)73)10-22(14-24)40(51)47-32-8-4-28(80(62,63)64)18-36(32)84(74,75)76;;;;;;;;/h1-18H,(H,44,48)(H,45,49)(H,46,50)(H,47,51)(H2,42,43,52)(H,53,54,55)(H,56,57,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76);;;;;;;;/q;8*+1/p-8
DM816Z2	CS	C1=CC(=C(C=C1S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)C2=CC(=CC(=C2)NC(=O)NC3=CC(=CC(=C3)C(=O)NC4=C(C=C(C=C4)S(=O)(=O)[O-])S(=O)(=O)[O-])C(=O)NC5=C(C=C(C=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])C(=O)NC6=C(C=C(C=C6)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM816Z2	IK	KCBZSNWCUJBMHF-UHFFFAOYSA-F
DM816Z2	IU	octasodium;4-[[3-[[3,5-bis[(2,4-disulfonatophenyl)carbamoyl]phenyl]carbamoylamino]-5-[(2,4-disulfonatophenyl)carbamoyl]benzoyl]amino]benzene-1,3-disulfonate
DM816Z2	DE	Discovery agent

DMPZB31	ID	DMPZB31
DMPZB31	DN	NF546
DMPZB31	HS	Investigative
DMPZB31	SN	NF-546
DMPZB31	DT	Small molecular drug
DMPZB31	PC	73755075
DMPZB31	MW	1180.7
DMPZB31	FM	C47H44N6Na4O17P4
DMPZB31	IC	InChI=1S/C47H48N6O17P4.4Na/c1-27-9-13-33(45(56)50-39-15-11-29(23-71(59,60)61)17-35(39)25-73(65,66)67)21-41(27)52-43(54)31-5-3-7-37(19-31)48-47(58)49-38-8-4-6-32(20-38)44(55)53-42-22-34(14-10-28(42)2)46(57)51-40-16-12-30(24-72(62,63)64)18-36(40)26-74(68,69)70;;;;/h3-22H,23-26H2,1-2H3,(H,50,56)(H,51,57)(H,52,54)(H,53,55)(H2,48,49,58)(H2,59,60,61)(H2,62,63,64)(H2,65,66,67)(H2,68,69,70);;;;/q;4*+1/p-4
DMPZB31	CS	CC1=C(C=C(C=C1)C(=O)NC2=C(C=C(C=C2)CP(=O)(O)[O-])CP(=O)(O)[O-])NC(=O)C3=CC(=CC=C3)NC(=O)NC4=CC=CC(=C4)C(=O)NC5=C(C=CC(=C5)C(=O)NC6=C(C=C(C=C6)CP(=O)(O)[O-])CP(=O)(O)[O-])C.[Na+].[Na+].[Na+].[Na+]
DMPZB31	IK	GSMUPMANKNAMAS-UHFFFAOYSA-J
DMPZB31	IU	tetrasodium;[2-[[3-[[3-[[3-[[5-[[2,4-bis[[hydroxy(oxido)phosphoryl]methyl]phenyl]carbamoyl]-2-methylphenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]-4-methylbenzoyl]amino]-5-[[hydroxy(oxido)phosphoryl]methyl]phenyl]methyl-hydroxyphosphinate
DMPZB31	DE	Discovery agent

DM7GBDX	ID	DM7GBDX
DM7GBDX	DN	N-Formylmethionine
DM7GBDX	HS	Investigative
DM7GBDX	SN	N-formyl-L-methionine; 4289-98-9; for-met-oh; N-FORMYLMETHIONINE; (S)-2-Formamido-4-(methylthio)butanoic acid; Formyl-L-methionine; formylmethionine; L-Methionine, N-formyl-; UNII-PS9357B4XH; N-Formyl-L -Methionine; PS9357B4XH; PYUSHNKNPOHWEZ-YFKPBYRVSA-N; N-Formyl methionine; L-Formylmethionine; L-N-Formylmethionine; N-Formyl(methyl)homocysteine #; Formyl-methionine; N-formyl-l-met; 2-formamido-4-methylsulfanylbutanoic acid; NSC 334322; Methionine, N-formyl-; AC1L97YW; SCHEMBL38595; CHEBI:16552; CTK1D5830; MolPort-006-116-105
DM7GBDX	DT	Small molecular drug
DM7GBDX	PC	439750
DM7GBDX	MW	177.22
DM7GBDX	FM	C6H11NO3S
DM7GBDX	IC	InChI=1S/C6H11NO3S/c1-11-3-2-5(6(9)10)7-4-8/h4-5H,2-3H2,1H3,(H,7,8)(H,9,10)/t5-/m0/s1
DM7GBDX	CS	CSCC[C@@H](C(=O)O)NC=O
DM7GBDX	IK	PYUSHNKNPOHWEZ-YFKPBYRVSA-N
DM7GBDX	IU	(2S)-2-formamido-4-methylsulfanylbutanoic acid
DM7GBDX	CA	CAS 4289-98-9
DM7GBDX	CB	CHEBI:16552
DM7GBDX	DE	Discovery agent

DMC48D9	ID	DMC48D9
DMC48D9	DN	NG-25
DMC48D9	HS	Investigative
DMC48D9	SN	NG25
DMC48D9	DT	Small molecular drug
DMC48D9	PC	53340664
DMC48D9	MW	537.6
DMC48D9	FM	C29H30F3N5O2
DMC48D9	IC	InChI=1S/C29H30F3N5O2/c1-3-36-12-14-37(15-13-36)18-21-6-7-22(17-24(21)29(30,31)32)35-28(38)20-5-4-19(2)26(16-20)39-25-9-11-34-27-23(25)8-10-33-27/h4-11,16-17H,3,12-15,18H2,1-2H3,(H,33,34)(H,35,38)
DMC48D9	CS	CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=C5C=CNC5=NC=C4)C(F)(F)F
DMC48D9	IK	SMPGEBOIKULBCT-UHFFFAOYSA-N
DMC48D9	IU	N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide
DMC48D9	CA	CAS 1315355-93-1
DMC48D9	DE	Discovery agent

DMMC42Z	ID	DMMC42Z
DMMC42Z	DN	NGB 2904
DMMC42Z	HS	Investigative
DMMC42Z	SN	NGB-2904
DMMC42Z	DT	Small molecular drug
DMMC42Z	PC	19366304
DMMC42Z	MW	530.9
DMMC42Z	FM	C28H30Cl3N3O
DMMC42Z	IC	InChI=1S/C28H29Cl2N3O.ClH/c29-25-8-5-9-26(27(25)30)33-16-14-32(15-17-33)13-4-3-12-31-28(34)21-10-11-24-22(19-21)18-20-6-1-2-7-23(20)24;/h1-2,5-11,19H,3-4,12-18H2,(H,31,34);1H
DMMC42Z	CS	C1CN(CCN1CCCCNC(=O)C2=CC3=C(C=C2)C4=CC=CC=C4C3)C5=C(C(=CC=C5)Cl)Cl.Cl
DMMC42Z	IK	PFIWYJNBKGCVFM-UHFFFAOYSA-N
DMMC42Z	IU	N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-9H-fluorene-2-carboxamide;hydrochloride
DMMC42Z	DE	Discovery agent

DMWD7I3	ID	DMWD7I3
DMWD7I3	DN	NGD 96-3
DMWD7I3	HS	Investigative
DMWD7I3	CP	Neurogen Corporation
DMWD7I3	DE	Insomnia

DMPEZHC	ID	DMPEZHC
DMPEZHC	DN	N-glycylglycinehydroxamic acid
DMPEZHC	HS	Investigative
DMPEZHC	SN	N-glycylglycinehydroxamic acid; CHEMBL462481; AKOS013308170
DMPEZHC	DT	Small molecular drug
DMPEZHC	PC	10057636
DMPEZHC	MW	147.13
DMPEZHC	FM	C4H9N3O3
DMPEZHC	IC	InChI=1S/C4H9N3O3/c5-1-3(8)6-2-4(9)7-10/h10H,1-2,5H2,(H,6,8)(H,7,9)
DMPEZHC	CS	C(C(=O)NCC(=O)NO)N
DMPEZHC	IK	NXTDAODSZSXXAY-UHFFFAOYSA-N
DMPEZHC	IU	2-amino-N-[2-(hydroxyamino)-2-oxoethyl]acetamide
DMPEZHC	DE	Discovery agent

DMBG3ZF	ID	DMBG3ZF
DMBG3ZF	DN	N-guanyl-1,7-diaminoheptane
DMBG3ZF	HS	Investigative
DMBG3ZF	SN	2-(7-aminoheptyl)guanidine; 150333-69-0; CHEMBL229457; Guanidine, N-(7-aminoheptyl)-; 1-(7-aminoheptyl)guanidine; N1-Guanyl-1,7-diaminoheptane (GC7); AC1L9LWV; N-(7-Aminoheptyl)guanidine; N-Guanyl-1,7-heptanediamine; SCHEMBL433609; N-(7-Amino-heptyl)-guanidine; CTK8H0316; CHEBI:133366
DMBG3ZF	DT	Small molecular drug
DMBG3ZF	PC	448393
DMBG3ZF	MW	172.27
DMBG3ZF	FM	C8H20N4
DMBG3ZF	IC	InChI=1S/C8H20N4/c9-6-4-2-1-3-5-7-12-8(10)11/h1-7,9H2,(H4,10,11,12)
DMBG3ZF	CS	C(CCCN)CCCN=C(N)N
DMBG3ZF	IK	YAOAMZOGXBMLFQ-UHFFFAOYSA-N
DMBG3ZF	IU	2-(7-aminoheptyl)guanidine
DMBG3ZF	CB	CHEBI:133366
DMBG3ZF	DE	Discovery agent

DMYAB79	ID	DMYAB79
DMYAB79	DN	NH-3
DMYAB79	HS	Investigative
DMYAB79	SN	thyromimetic, 5b; NH-3; CHEMBL109279; JMC496635 Compound 5; GTPL2633; SCHEMBL16993604; BDBM18885; 2-[4-({4-hydroxy-3-[2-(4-nitrophenyl)ethynyl]-5-(propan-2-yl)phenyl}methyl)-3,5-dimethylphenoxy]acetic acid; 2-[4-[[4-hydroxy-3-[2-(4-nitrophenyl)ethynyl]-5-propan-2-ylphenyl]methyl]-3,5-dimethylphenoxy]acetic acid
DMYAB79	DT	Small molecular drug
DMYAB79	PC	10027822
DMYAB79	MW	473.5
DMYAB79	FM	C28H27NO6
DMYAB79	IC	InChI=1S/C28H27NO6/c1-17(2)25-14-21(15-26-18(3)11-24(12-19(26)4)35-16-27(30)31)13-22(28(25)32)8-5-20-6-9-23(10-7-20)29(33)34/h6-7,9-14,17,32H,15-16H2,1-4H3,(H,30,31)
DMYAB79	CS	CC1=CC(=CC(=C1CC2=CC(=C(C(=C2)C(C)C)O)C#CC3=CC=C(C=C3)[N+](=O)[O-])C)OCC(=O)O
DMYAB79	IK	IXMROOKFPWGDGF-UHFFFAOYSA-N
DMYAB79	IU	2-[4-[[4-hydroxy-3-[2-(4-nitrophenyl)ethynyl]-5-propan-2-ylphenyl]methyl]-3,5-dimethylphenoxy]acetic acid
DMYAB79	DE	Discovery agent

DMSUZFO	ID	DMSUZFO
DMSUZFO	DN	NH-4
DMSUZFO	HS	Investigative
DMSUZFO	SN	ammonium; Ammonium ion; Ammonium(1+); azanium; NH4+; Ammonium cation; 14798-03-9; Ammonia ion; Ammonium ion(+); AMMONIUM CATION WITH D; UNII-54S68520I4; NH4(+); 54S68520I4; Ammonium Compounds; ND4; Quaternary ammonium compounds; Nitrogen cation; Ammonium(+); nitrogen(1+); Nitrogen tetrahydride; Ammonium ion(1+); Ammonium (NH4+); AC1NUTFY; AC1NUTFO; Ammonia ion (NH4+); Ammonium ion (NH4+); nitrogen(1+) trihydride; Ammonium (8CI,9CI); Ammonia, ion (NH41+); AC1Q1W88; AC1L18R7; DTXSID5043974; CHEBI:29352; CHEBI:28938; CTK0H5427
DMSUZFO	DT	Small molecular drug
DMSUZFO	PC	223
DMSUZFO	MW	18.039
DMSUZFO	FM	H4N+
DMSUZFO	IC	InChI=1S/H3N/h1H3/p+1
DMSUZFO	CS	[NH4+]
DMSUZFO	IK	QGZKDVFQNNGYKY-UHFFFAOYSA-O
DMSUZFO	IU	azanium
DMSUZFO	CA	CAS 14798-03-9
DMSUZFO	CB	CHEBI:28938
DMSUZFO	DE	Discovery agent

DMM0F2G	ID	DMM0F2G
DMM0F2G	DN	N-Hexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DMM0F2G	HS	Investigative
DMM0F2G	SN	CHEMBL329499; N-Hexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide; BDBM50045876
DMM0F2G	DT	Small molecular drug
DMM0F2G	PC	10065495
DMM0F2G	MW	334.5
DMM0F2G	FM	C22H26N2O
DMM0F2G	IC	InChI=1S/C22H26N2O/c1-2-3-4-10-15-23-21(25)16-19-18-13-8-9-14-20(18)24-22(19)17-11-6-5-7-12-17/h5-9,11-14,24H,2-4,10,15-16H2,1H3,(H,23,25)
DMM0F2G	CS	CCCCCCNC(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DMM0F2G	IK	SVHWOYODYBUWLL-UHFFFAOYSA-N
DMM0F2G	IU	N-hexyl-2-(2-phenyl-1H-indol-3-yl)acetamide
DMM0F2G	CA	CAS 145040-30-8
DMM0F2G	DE	Discovery agent

DML27CG	ID	DML27CG
DML27CG	DN	N-Hexylcarbamic Acid Biphenyl-3-yl Ester
DML27CG	HS	Investigative
DML27CG	SN	CHEMBL488348; n-Hexylcarbamic Acid Biphenyl-3-yl Ester
DML27CG	DT	Small molecular drug
DML27CG	PC	24881671
DML27CG	MW	297.4
DML27CG	FM	C19H23NO2
DML27CG	IC	InChI=1S/C19H23NO2/c1-2-3-4-8-14-20-19(21)22-18-13-9-12-17(15-18)16-10-6-5-7-11-16/h5-7,9-13,15H,2-4,8,14H2,1H3,(H,20,21)
DML27CG	CS	CCCCCCNC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DML27CG	IK	QPTMPZNXKZNQMF-UHFFFAOYSA-N
DML27CG	IU	(3-phenylphenyl) N-hexylcarbamate
DML27CG	DE	Discovery agent

DMZ2T59	ID	DMZ2T59
DMZ2T59	DN	N-hydroxy-1-naphthamide
DMZ2T59	HS	Investigative
DMZ2T59	SN	1-Naphthohydroxamic acid; 6953-61-3; N-Hydroxy-1-naphthamide; 1-NAPHTHALENECARBOXAMIDE, N-HYDROXY-; NSC 57457; N-Hydroxynaphthalene-1-carboxamide; alpha-Naphthohydroxamic acid; a-Naphthohydroxamic acid; BRN 2094470; CHEMBL115468; Naphthalene-1-carboxylic acid hydroxyamide; 8GK; naphthylhydroxamic acid; AC1L2M8D; N-Hydroxy-1-naphthamide #; 4-09-00-02407 (Beilstein Handbook Reference); .alpha.-Naphthohydroxamic acid; ACMC-209o98; SCHEMBL2230679; CTK5D0341; DTXSID30219789; JRZGPWOEHDOVMC-UHFFFAOYSA-N
DMZ2T59	DT	Small molecular drug
DMZ2T59	PC	23382
DMZ2T59	MW	187.19
DMZ2T59	FM	C11H9NO2
DMZ2T59	IC	InChI=1S/C11H9NO2/c13-11(12-14)10-7-3-5-8-4-1-2-6-9(8)10/h1-7,14H,(H,12,13)
DMZ2T59	CS	C1=CC=C2C(=C1)C=CC=C2C(=O)NO
DMZ2T59	IK	JRZGPWOEHDOVMC-UHFFFAOYSA-N
DMZ2T59	IU	N-hydroxynaphthalene-1-carboxamide
DMZ2T59	CA	CAS 6953-61-3
DMZ2T59	DE	Discovery agent

DM56P1I	ID	DM56P1I
DM56P1I	DN	N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide
DM56P1I	HS	Investigative
DM56P1I	SN	CHEMBL575895; N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide
DM56P1I	DT	Small molecular drug
DM56P1I	PC	44479457
DM56P1I	MW	307.32
DM56P1I	FM	C14H13NO5S
DM56P1I	IC	InChI=1S/C14H13NO5S/c1-20-10-6-8-11(9-7-10)21(18,19)13-5-3-2-4-12(13)14(16)15-17/h2-9,17H,1H3,(H,15,16)
DM56P1I	CS	COC1=CC=C(C=C1)S(=O)(=O)C2=CC=CC=C2C(=O)NO
DM56P1I	IK	QPFIKHZWPMXTRS-UHFFFAOYSA-N
DM56P1I	IU	N-hydroxy-2-(4-methoxyphenyl)sulfonylbenzamide
DM56P1I	DE	Discovery agent

DM50NKS	ID	DM50NKS
DM50NKS	DN	N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide
DM50NKS	HS	Investigative
DM50NKS	SN	CHEMBL83508; N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamide; Hydroxamate 9; Z79; 3lk8; SCHEMBL7410575; BDBM11328; (4-Methoxyphenylsulfonylamino)acetohydroximic acid
DM50NKS	DT	Small molecular drug
DM50NKS	PC	10445302
DM50NKS	MW	260.269
DM50NKS	FM	C9H12N2O5S
DM50NKS	IC	InChI=1S/C9H12N2O5S/c1-16-7-2-4-8(5-3-7)17(14,15)10-6-9(12)11-13/h2-5,10,13H,6H2,1H3,(H,11,12)
DM50NKS	CS	COC1=CC=C(C=C1)S(=O)(=O)NCC(=O)NO
DM50NKS	IK	WLZISXXOYYGJNT-UHFFFAOYSA-N
DM50NKS	IU	N-hydroxy-2-[(4-methoxyphenyl)sulfonylamino]acetamide
DM50NKS	DE	Discovery agent

DM4VADN	ID	DM4VADN
DM4VADN	DN	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN	HS	Investigative
DM4VADN	SN	CHEMBL575896; N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN	DT	Small molecular drug
DM4VADN	PC	10155934
DM4VADN	MW	369.4
DM4VADN	FM	C19H15NO5S
DM4VADN	IC	InChI=1S/C19H15NO5S/c21-19(20-22)17-8-4-5-9-18(17)26(23,24)16-12-10-15(11-13-16)25-14-6-2-1-3-7-14/h1-13,22H,(H,20,21)
DM4VADN	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3C(=O)NO
DM4VADN	IK	MYZHQACPXTZCJY-UHFFFAOYSA-N
DM4VADN	IU	N-hydroxy-2-(4-phenoxyphenyl)sulfonylbenzamide
DM4VADN	DE	Discovery agent

DMISXUM	ID	DMISXUM
DMISXUM	DN	N-Hydroxy-2-(naphthalen-2-ylsulfanyl)-acetamide
DMISXUM	HS	Investigative
DMISXUM	SN	CHEMBL182879; 834918-57-9; N-Hydroxy-2-(naphthalen-2-ylsulfanyl)-acetamide; CTK3D2016; DTXSID40465831; BDBM50157325; AKOS030565680; Acetamide, N-hydroxy-2-(2-naphthalenylthio)-
DMISXUM	DT	Small molecular drug
DMISXUM	PC	11436221
DMISXUM	MW	233.29
DMISXUM	FM	C12H11NO2S
DMISXUM	IC	InChI=1S/C12H11NO2S/c14-12(13-15)8-16-11-6-5-9-3-1-2-4-10(9)7-11/h1-7,15H,8H2,(H,13,14)
DMISXUM	CS	C1=CC=C2C=C(C=CC2=C1)SCC(=O)NO
DMISXUM	IK	GNDJOJQVOFQQBM-UHFFFAOYSA-N
DMISXUM	IU	N-hydroxy-2-naphthalen-2-ylsulfanylacetamide
DMISXUM	CA	CAS 834918-57-9
DMISXUM	DE	Discovery agent

DMWIMR4	ID	DMWIMR4
DMWIMR4	DN	N-hydroxy-2,2'-bithiophene-5-carboxamide
DMWIMR4	HS	Investigative
DMWIMR4	SN	CHEMBL217750; SCHEMBL5903723; BDBM50198479
DMWIMR4	DT	Small molecular drug
DMWIMR4	PC	44418185
DMWIMR4	MW	225.3
DMWIMR4	FM	C9H7NO2S2
DMWIMR4	IC	InChI=1S/C9H7NO2S2/c11-9(10-12)8-4-3-7(14-8)6-2-1-5-13-6/h1-5,12H,(H,10,11)
DMWIMR4	CS	C1=CSC(=C1)C2=CC=C(S2)C(=O)NO
DMWIMR4	IK	PSYPMKKEKUDELT-UHFFFAOYSA-N
DMWIMR4	IU	N-hydroxy-5-thiophen-2-ylthiophene-2-carboxamide
DMWIMR4	DE	Discovery agent

DMX3KRQ	ID	DMX3KRQ
DMX3KRQ	DN	N-hydroxy-2,2-diphenylacetamide
DMX3KRQ	HS	Investigative
DMX3KRQ	SN	Diphenylacetohydroxamic acid; 4099-51-8; N-Hydroxy diphenylacetamide; CHEMBL396097; NSC44620; benzeneacetamide, n-hydroxy-; A-phenyl-; N-Hydroxydiphenylacetamide; BENZENEACETAMIDE,N-HYDROXY-A-PHENYL-; AC1Q5QC3; SCHEMBL2839032; CTK8I6435; DTXSID10286297; AC1L6390; ZINC4522248; NSC-44620; BDBM50207561; MFCD16314231; AKOS022308585; Diphenylacetohydroxamic acid, &gt
DMX3KRQ	DT	Small molecular drug
DMX3KRQ	PC	239512
DMX3KRQ	MW	227.26
DMX3KRQ	FM	C14H13NO2
DMX3KRQ	IC	InChI=1S/C14H13NO2/c16-14(15-17)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13,17H,(H,15,16)
DMX3KRQ	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NO
DMX3KRQ	IK	OFSBBVCLWMCGNY-UHFFFAOYSA-N
DMX3KRQ	IU	N-hydroxy-2,2-diphenylacetamide
DMX3KRQ	CA	CAS 4099-51-8
DMX3KRQ	DE	Discovery agent

DM7I2TD	ID	DM7I2TD
DM7I2TD	DN	N-hydroxy-2,2-diphenylpropanamide
DM7I2TD	HS	Investigative
DM7I2TD	SN	CHEMBL585365; N-hydroxy-2,2-diphenylpropanamide; SCHEMBL2844474
DM7I2TD	DT	Small molecular drug
DM7I2TD	PC	45482660
DM7I2TD	MW	241.28
DM7I2TD	FM	C15H15NO2
DM7I2TD	IC	InChI=1S/C15H15NO2/c1-15(14(17)16-18,12-8-4-2-5-9-12)13-10-6-3-7-11-13/h2-11,18H,1H3,(H,16,17)
DM7I2TD	CS	CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)NO
DM7I2TD	IK	LDAQHFMKFUATRE-UHFFFAOYSA-N
DM7I2TD	IU	N-hydroxy-2,2-diphenylpropanamide
DM7I2TD	DE	Discovery agent

DMZWIVJ	ID	DMZWIVJ
DMZWIVJ	DN	N-hydroxy-2,3-bis(phenylsulfonamido)propanamide
DMZWIVJ	HS	Investigative
DMZWIVJ	SN	CHEMBL496717; N-hydroxy-2,3-bis(phenylsulfonamido)propanamide
DMZWIVJ	DT	Small molecular drug
DMZWIVJ	PC	24857837
DMZWIVJ	MW	399.4
DMZWIVJ	FM	C15H17N3O6S2
DMZWIVJ	IC	InChI=1S/C15H17N3O6S2/c19-15(17-20)14(18-26(23,24)13-9-5-2-6-10-13)11-16-25(21,22)12-7-3-1-4-8-12/h1-10,14,16,18,20H,11H2,(H,17,19)
DMZWIVJ	CS	C1=CC=C(C=C1)S(=O)(=O)NCC(C(=O)NO)NS(=O)(=O)C2=CC=CC=C2
DMZWIVJ	IK	WBWFDDZAXKMHEG-UHFFFAOYSA-N
DMZWIVJ	IU	2,3-bis(benzenesulfonamido)-N-hydroxypropanamide
DMZWIVJ	DE	Discovery agent

DME96RF	ID	DME96RF
DME96RF	DN	N-Hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide
DME96RF	HS	Investigative
DME96RF	SN	CHEMBL367336; N-Hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide; ZINC28109710; BDBM50015187; (E)-2-Methyl-3-(2-naphthalenyl)-2-propenehydroximic acid
DME96RF	DT	Small molecular drug
DME96RF	PC	20238032
DME96RF	MW	227.26
DME96RF	FM	C14H13NO2
DME96RF	IC	InChI=1S/C14H13NO2/c1-10(14(16)15-17)8-11-6-7-12-4-2-3-5-13(12)9-11/h2-9,17H,1H3,(H,15,16)/b10-8+
DME96RF	CS	C/C(=C\\C1=CC2=CC=CC=C2C=C1)/C(=O)NO
DME96RF	IK	NPYWWIHEHONKOF-CSKARUKUSA-N
DME96RF	IU	(E)-N-hydroxy-2-methyl-3-naphthalen-2-ylprop-2-enamide
DME96RF	DE	Discovery agent

DMYDX34	ID	DMYDX34
DMYDX34	DN	N-Hydroxy-2-naphthalen-2-yl-acetamide
DMYDX34	HS	Investigative
DMYDX34	SN	N-hydroxy-2-(naphthalen-2-yl)acetamide; CHEMBL346935; 106359-52-8; 2-Naphthaleneacetamide, N-hydroxy-; N-Hydroxy-2-naphthalen-2-yl-acetamide; AC1Q7DIT; SCHEMBL1520280; CTK8A6801; MolPort-004-327-963; KUC108662N; ZINC19423737; BDBM50015114; AKOS000168393; NE14616; MCULE-5699071643; NCGC00186600-01; NCGC00186600-02; KSC-11-264-7
DMYDX34	DT	Small molecular drug
DMYDX34	PC	24689999
DMYDX34	MW	201.22
DMYDX34	FM	C12H11NO2
DMYDX34	IC	InChI=1S/C12H11NO2/c14-12(13-15)8-9-5-6-10-3-1-2-4-11(10)7-9/h1-7,15H,8H2,(H,13,14)
DMYDX34	CS	C1=CC=C2C=C(C=CC2=C1)CC(=O)NO
DMYDX34	IK	IYXUERDUKOVYLR-UHFFFAOYSA-N
DMYDX34	IU	N-hydroxy-2-naphthalen-2-ylacetamide
DMYDX34	DE	Discovery agent

DMWXUCT	ID	DMWXUCT
DMWXUCT	DN	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
DMWXUCT	HS	Investigative
DMWXUCT	SN	CHEMBL252674; N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963
DMWXUCT	DT	Small molecular drug
DMWXUCT	PC	44446270
DMWXUCT	MW	233.22
DMWXUCT	FM	C12H11NO4
DMWXUCT	IC	InChI=1S/C12H11NO4/c14-11(13-16)6-5-9-7-8-3-1-2-4-10(8)17-12(9)15/h1-4,7,16H,5-6H2,(H,13,14)
DMWXUCT	CS	C1=CC=C2C(=C1)C=C(C(=O)O2)CCC(=O)NO
DMWXUCT	IK	HJRCGMHZQDXQAO-UHFFFAOYSA-N
DMWXUCT	IU	N-hydroxy-3-(2-oxochromen-3-yl)propanamide
DMWXUCT	DE	Discovery agent

DMA6EPH	ID	DMA6EPH
DMA6EPH	DN	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)
DMA6EPH	HS	Investigative
DMA6EPH	SN	CHEMBL402990; N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)
DMA6EPH	DT	Small molecular drug
DMA6EPH	PC	44446277
DMA6EPH	MW	263.25
DMA6EPH	FM	C13H13NO5
DMA6EPH	IC	InChI=1S/C13H13NO5/c1-18-10-3-4-11-9(7-10)6-8(13(16)19-11)2-5-12(15)14-17/h3-4,6-7,17H,2,5H2,1H3,(H,14,15)
DMA6EPH	CS	COC1=CC2=C(C=C1)OC(=O)C(=C2)CCC(=O)NO
DMA6EPH	IK	JUDXBTMVZVWJNP-UHFFFAOYSA-N
DMA6EPH	IU	N-hydroxy-3-(6-methoxy-2-oxochromen-3-yl)propanamide
DMA6EPH	DE	Discovery agent

DMY6Z0U	ID	DMY6Z0U
DMY6Z0U	DN	N-hydroxy-3-(naphthalen-1-yl)acrylamide
DMY6Z0U	HS	Investigative
DMY6Z0U	SN	CHEMBL245548; N-hydroxy-3-(naphthalen-1-yl)acrylamide; SCHEMBL14106948; BDBM50207560; (E)-3-(1-Naphthalenyl)-2-propenehydroximic acid
DMY6Z0U	DT	Small molecular drug
DMY6Z0U	PC	24880249
DMY6Z0U	MW	213.23
DMY6Z0U	FM	C13H11NO2
DMY6Z0U	IC	InChI=1S/C13H11NO2/c15-13(14-16)9-8-11-6-3-5-10-4-1-2-7-12(10)11/h1-9,16H,(H,14,15)/b9-8+
DMY6Z0U	CS	C1=CC=C2C(=C1)C=CC=C2/C=C/C(=O)NO
DMY6Z0U	IK	AOXOYUCWJCCUDO-CMDGGOBGSA-N
DMY6Z0U	IU	(E)-N-hydroxy-3-naphthalen-1-ylprop-2-enamide
DMY6Z0U	DE	Discovery agent

DMZ3INJ	ID	DMZ3INJ
DMZ3INJ	DN	N-Hydroxy-3-naphthalen-2-yl-acrylamide
DMZ3INJ	HS	Investigative
DMZ3INJ	SN	CHEMBL155443; N-Hydroxy-3-naphthalen-2-yl-acrylamide; N-Hydroxy-2-naphthaleneacrylamide; BDBM50015170; ZINC27654302; (E)-3-(2-Naphthalenyl)-2-propenehydroximic acid
DMZ3INJ	DT	Small molecular drug
DMZ3INJ	PC	13687209
DMZ3INJ	MW	213.23
DMZ3INJ	FM	C13H11NO2
DMZ3INJ	IC	InChI=1S/C13H11NO2/c15-13(14-16)8-6-10-5-7-11-3-1-2-4-12(11)9-10/h1-9,16H,(H,14,15)/b8-6+
DMZ3INJ	CS	C1=CC=C2C=C(C=CC2=C1)/C=C/C(=O)NO
DMZ3INJ	IK	NJQJPKBDKOPBGI-SOFGYWHQSA-N
DMZ3INJ	IU	(E)-N-hydroxy-3-naphthalen-2-ylprop-2-enamide
DMZ3INJ	DE	Discovery agent

DMVOPXE	ID	DMVOPXE
DMVOPXE	DN	N-Hydroxy-3-naphthalen-2-yl-N-phenyl-acrylamide
DMVOPXE	HS	Investigative
DMVOPXE	SN	CHEMBL154575; N-Hydroxy-3-naphthalen-2-yl-N-phenyl-acrylamide; BDBM50015102; (E)-3-(2-Naphthalenyl)-N-phenyl-2-propenehydroxamic acid
DMVOPXE	DT	Small molecular drug
DMVOPXE	PC	13687213
DMVOPXE	MW	289.3
DMVOPXE	FM	C19H15NO2
DMVOPXE	IC	InChI=1S/C19H15NO2/c21-19(20(22)18-8-2-1-3-9-18)13-11-15-10-12-16-6-4-5-7-17(16)14-15/h1-14,22H/b13-11+
DMVOPXE	CS	C1=CC=C(C=C1)N(C(=O)/C=C/C2=CC3=CC=CC=C3C=C2)O
DMVOPXE	IK	OSTLUPOHWIAJIK-ACCUITESSA-N
DMVOPXE	IU	(E)-N-hydroxy-3-naphthalen-2-yl-N-phenylprop-2-enamide
DMVOPXE	DE	Discovery agent

DMKBACJ	ID	DMKBACJ
DMKBACJ	DN	N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide
DMKBACJ	HS	Investigative
DMKBACJ	SN	CHEMBL366714; N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide; BDBM50015103; (E)-3-(2-Naphthalenyl)-N-(4-methylphenyl)-2-propenehydroxamic acid
DMKBACJ	DT	Small molecular drug
DMKBACJ	PC	44386467
DMKBACJ	MW	303.4
DMKBACJ	FM	C20H17NO2
DMKBACJ	IC	InChI=1S/C20H17NO2/c1-15-6-11-19(12-7-15)21(23)20(22)13-9-16-8-10-17-4-2-3-5-18(17)14-16/h2-14,23H,1H3/b13-9+
DMKBACJ	CS	CC1=CC=C(C=C1)N(C(=O)/C=C/C2=CC3=CC=CC=C3C=C2)O
DMKBACJ	IK	MXCQZPFMNOZXSH-UKTHLTGXSA-N
DMKBACJ	IU	(E)-N-hydroxy-N-(4-methylphenyl)-3-naphthalen-2-ylprop-2-enamide
DMKBACJ	DE	Discovery agent

DMPIMRC	ID	DMPIMRC
DMPIMRC	DN	N-Hydroxy-3-naphthalen-2-yl-propionamide
DMPIMRC	HS	Investigative
DMPIMRC	SN	CHEMBL154998; N-Hydroxy-3-naphthalen-2-yl-propionamide; SCHEMBL10362477; BDBM50015120
DMPIMRC	DT	Small molecular drug
DMPIMRC	PC	13687220
DMPIMRC	MW	215.25
DMPIMRC	FM	C13H13NO2
DMPIMRC	IC	InChI=1S/C13H13NO2/c15-13(14-16)8-6-10-5-7-11-3-1-2-4-12(11)9-10/h1-5,7,9,16H,6,8H2,(H,14,15)
DMPIMRC	CS	C1=CC=C2C=C(C=CC2=C1)CCC(=O)NO
DMPIMRC	IK	FUEAAJNBAJRTSE-UHFFFAOYSA-N
DMPIMRC	IU	N-hydroxy-3-naphthalen-2-ylpropanamide
DMPIMRC	DE	Discovery agent

DMTZ8RQ	ID	DMTZ8RQ
DMTZ8RQ	DN	N-hydroxy-3-phenoxybenzamide
DMTZ8RQ	HS	Investigative
DMTZ8RQ	SN	CHEMBL245741; N-hydroxy-3-phenoxybenzamide; SCHEMBL6671653
DMTZ8RQ	DT	Small molecular drug
DMTZ8RQ	PC	10192705
DMTZ8RQ	MW	229.23
DMTZ8RQ	FM	C13H11NO3
DMTZ8RQ	IC	InChI=1S/C13H11NO3/c15-13(14-16)10-5-4-8-12(9-10)17-11-6-2-1-3-7-11/h1-9,16H,(H,14,15)
DMTZ8RQ	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)NO
DMTZ8RQ	IK	WFZFBIHVPMBSOS-UHFFFAOYSA-N
DMTZ8RQ	IU	N-hydroxy-3-phenoxybenzamide
DMTZ8RQ	DE	Discovery agent

DM9IPTV	ID	DM9IPTV
DM9IPTV	DN	N-Hydroxy-3-phenyl-acrylamide
DM9IPTV	HS	Investigative
DM9IPTV	SN	Cinnamoylhydroxamic acid; CINNAMOHYDROXAMIC ACID; Hydroxylamine, N-cinnamoyl-; 2-Propenamide, N-hydroxy-3-phenyl-; N-Hydroxycinnamamide; UNII-434STJ4H11; N-Hydroxy-3-phenyl-2-propenamide; NSC 42128; NSC-42128; NSC-44617; NSC 44617; CHEMBL154574; 3669-32-7; 434STJ4H11; WLN: QMV1U1R; N-Hydroxy-3-phenyl-acrylamide; Cinnamohydroxamic acid, (E)-; Cinnamoylhydroxamic acid [INCI]; MAZ 1704; MAZ-1704; 2-Propenamide, N-hydroxy-3-phenyl-, (E)-; 2-Propenamide, N-hydroxy-3-phenyl-, (2E)-; AC1Q5CS7; AC1NS7U4; SCHEMBL559917
DM9IPTV	DT	Small molecular drug
DM9IPTV	PC	5355635
DM9IPTV	MW	163.17
DM9IPTV	FM	C9H9NO2
DM9IPTV	IC	InChI=1S/C9H9NO2/c11-9(10-12)7-6-8-4-2-1-3-5-8/h1-7,12H,(H,10,11)/b7-6+
DM9IPTV	CS	C1=CC=C(C=C1)/C=C/C(=O)NO
DM9IPTV	IK	UVDDFTZLVFIQFL-VOTSOKGWSA-N
DM9IPTV	IU	(E)-N-hydroxy-3-phenylprop-2-enamide
DM9IPTV	CA	CAS 3669-32-7
DM9IPTV	DE	Discovery agent

DMCN91A	ID	DMCN91A
DMCN91A	DN	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide
DMCN91A	HS	Investigative
DMCN91A	SN	SCHEMBL675474
DMCN91A	DT	Small molecular drug
DMCN91A	PC	11231829
DMCN91A	MW	298.34
DMCN91A	FM	C17H18N2O3
DMCN91A	IC	InChI=1S/C17H18N2O3/c1-2-15(12-6-4-3-5-7-12)17(21)18-14-10-8-13(9-11-14)16(20)19-22/h3-11,15,22H,2H2,1H3,(H,18,21)(H,19,20)/t15-/m1/s1
DMCN91A	CS	CC[C@H](C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
DMCN91A	IK	SPLALNOEMVSHPJ-OAHLLOKOSA-N
DMCN91A	IU	N-hydroxy-4-[[(2R)-2-phenylbutanoyl]amino]benzamide
DMCN91A	DE	Discovery agent

DMVK2Y3	ID	DMVK2Y3
DMVK2Y3	DN	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide
DMVK2Y3	HS	Investigative
DMVK2Y3	SN	SCHEMBL676080
DMVK2Y3	DT	Small molecular drug
DMVK2Y3	PC	11312563
DMVK2Y3	MW	298.34
DMVK2Y3	FM	C17H18N2O3
DMVK2Y3	IC	InChI=1S/C17H18N2O3/c1-2-15(12-6-4-3-5-7-12)17(21)18-14-10-8-13(9-11-14)16(20)19-22/h3-11,15,22H,2H2,1H3,(H,18,21)(H,19,20)/t15-/m0/s1
DMVK2Y3	CS	CC[C@@H](C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
DMVK2Y3	IK	SPLALNOEMVSHPJ-HNNXBMFYSA-N
DMVK2Y3	IU	N-hydroxy-4-[[(2S)-2-phenylbutanoyl]amino]benzamide
DMVK2Y3	DE	Discovery agent

DMKELRB	ID	DMKELRB
DMKELRB	DN	N-hydroxy-4-(2-oleamidoethyl)benzamide
DMKELRB	HS	Investigative
DMKELRB	SN	CHEMBL251734; N-hydroxy-4-(2-oleamidoethyl)benzamide
DMKELRB	DT	Small molecular drug
DMKELRB	PC	44441632
DMKELRB	MW	444.6
DMKELRB	FM	C27H44N2O3
DMKELRB	IC	InChI=1S/C27H44N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-26(30)28-23-22-24-18-20-25(21-19-24)27(31)29-32/h9-10,18-21,32H,2-8,11-17,22-23H2,1H3,(H,28,30)(H,29,31)/b10-9-
DMKELRB	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=CC=C(C=C1)C(=O)NO
DMKELRB	IK	NGQCNQPGVUJPCK-KTKRTIGZSA-N
DMKELRB	IU	N-hydroxy-4-[2-[[(Z)-octadec-9-enoyl]amino]ethyl]benzamide
DMKELRB	DE	Discovery agent

DMHEQ41	ID	DMHEQ41
DMHEQ41	DN	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide
DMHEQ41	HS	Investigative
DMHEQ41	SN	SCHEMBL676079
DMHEQ41	DT	Small molecular drug
DMHEQ41	PC	11347053
DMHEQ41	MW	298.34
DMHEQ41	FM	C17H18N2O3
DMHEQ41	IC	InChI=1S/C17H18N2O3/c1-2-15(12-6-4-3-5-7-12)17(21)18-14-10-8-13(9-11-14)16(20)19-22/h3-11,15,22H,2H2,1H3,(H,18,21)(H,19,20)
DMHEQ41	CS	CCC(C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
DMHEQ41	IK	SPLALNOEMVSHPJ-UHFFFAOYSA-N
DMHEQ41	IU	N-hydroxy-4-(2-phenylbutanoylamino)benzamide
DMHEQ41	DE	Discovery agent

DMUOCQB	ID	DMUOCQB
DMUOCQB	DN	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide
DMUOCQB	HS	Investigative
DMUOCQB	SN	N-hydroxy-4-(3-phenylpropanamido)benzamide
DMUOCQB	DE	Discovery agent

DMQN6CL	ID	DMQN6CL
DMQN6CL	DN	N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide
DMQN6CL	HS	Investigative
DMQN6CL	SN	CHEMBL366010; N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide
DMQN6CL	DT	Small molecular drug
DMQN6CL	PC	44404461
DMQN6CL	MW	223.22
DMQN6CL	FM	C11H13NO4
DMQN6CL	IC	InChI=1S/C11H13NO4/c1-16-9-4-2-8(3-5-9)10(13)6-7-11(14)12-15/h2-5,15H,6-7H2,1H3,(H,12,14)
DMQN6CL	CS	COC1=CC=C(C=C1)C(=O)CCC(=O)NO
DMQN6CL	IK	YUAIIHPYXRCTLQ-UHFFFAOYSA-N
DMQN6CL	IU	N-hydroxy-4-(4-methoxyphenyl)-4-oxobutanamide
DMQN6CL	DE	Discovery agent

DMVEOBY	ID	DMVEOBY
DMVEOBY	DN	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide
DMVEOBY	HS	Investigative
DMVEOBY	SN	CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
DMVEOBY	DT	Small molecular drug
DMVEOBY	PC	9994848
DMVEOBY	MW	298.34
DMVEOBY	FM	C17H18N2O3
DMVEOBY	IC	InChI=1S/C17H18N2O3/c20-16(8-4-7-13-5-2-1-3-6-13)18-15-11-9-14(10-12-15)17(21)19-22/h1-3,5-6,9-12,22H,4,7-8H2,(H,18,20)(H,19,21)
DMVEOBY	CS	C1=CC=C(C=C1)CCCC(=O)NC2=CC=C(C=C2)C(=O)NO
DMVEOBY	IK	VZROKPBSFBHVTL-UHFFFAOYSA-N
DMVEOBY	IU	N-hydroxy-4-(4-phenylbutanoylamino)benzamide
DMVEOBY	CA	CAS 656261-24-4
DMVEOBY	DE	Discovery agent

DMISRMT	ID	DMISRMT
DMISRMT	DN	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide
DMISRMT	HS	Investigative
DMISRMT	SN	SCHEMBL7311087
DMISRMT	DT	Small molecular drug
DMISRMT	PC	11472431
DMISRMT	MW	312.4
DMISRMT	FM	C18H20N2O3
DMISRMT	IC	InChI=1S/C18H20N2O3/c21-17(9-5-4-8-14-6-2-1-3-7-14)19-16-12-10-15(11-13-16)18(22)20-23/h1-3,6-7,10-13,23H,4-5,8-9H2,(H,19,21)(H,20,22)
DMISRMT	CS	C1=CC=C(C=C1)CCCCC(=O)NC2=CC=C(C=C2)C(=O)NO
DMISRMT	IK	ZCTKPFZOLLIQQR-UHFFFAOYSA-N
DMISRMT	IU	N-hydroxy-4-(5-phenylpentanoylamino)benzamide
DMISRMT	DE	Discovery agent

DMSHQE3	ID	DMSHQE3
DMSHQE3	DN	N-hydroxy-4-(naphthalen-1-yl)benzamide
DMSHQE3	HS	Investigative
DMSHQE3	SN	N-Hydroxy-4-naphthalen-1-yl-benzamide
DMSHQE3	DT	Small molecular drug
DMSHQE3	PC	17748273
DMSHQE3	MW	263.29
DMSHQE3	FM	C17H13NO2
DMSHQE3	IC	InChI=1S/C17H13NO2/c19-17(18-20)14-10-8-13(9-11-14)16-7-3-5-12-4-1-2-6-15(12)16/h1-11,20H,(H,18,19)
DMSHQE3	CS	C1=CC=C2C(=C1)C=CC=C2C3=CC=C(C=C3)C(=O)NO
DMSHQE3	IK	PKQVYJOPUCLLCD-UHFFFAOYSA-N
DMSHQE3	IU	N-hydroxy-4-naphthalen-1-ylbenzamide
DMSHQE3	DE	Discovery agent

DMUSHZK	ID	DMUSHZK
DMUSHZK	DN	N-hydroxy-4-(oleamidomethyl)benzamide
DMUSHZK	HS	Investigative
DMUSHZK	SN	CHEMBL271701
DMUSHZK	DT	Small molecular drug
DMUSHZK	PC	44454442
DMUSHZK	MW	430.6
DMUSHZK	FM	C26H42N2O3
DMUSHZK	IC	InChI=1S/C26H42N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-25(29)27-22-23-18-20-24(21-19-23)26(30)28-31/h9-10,18-21,31H,2-8,11-17,22H2,1H3,(H,27,29)(H,28,30)/b10-9-
DMUSHZK	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCC1=CC=C(C=C1)C(=O)NO
DMUSHZK	IK	SINCREJZYIHLQD-KTKRTIGZSA-N
DMUSHZK	IU	N-hydroxy-4-[[[(Z)-octadec-9-enoyl]amino]methyl]benzamide
DMUSHZK	DE	Discovery agent

DMGTNQY	ID	DMGTNQY
DMGTNQY	DN	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide
DMGTNQY	HS	Investigative
DMGTNQY	SN	CHEMBL143102
DMGTNQY	DT	Small molecular drug
DMGTNQY	PC	44361923
DMGTNQY	MW	250.29
DMGTNQY	FM	C13H18N2O3
DMGTNQY	IC	InChI=1S/C13H18N2O3/c1-2-3-4-12(16)14-9-10-5-7-11(8-6-10)13(17)15-18/h5-8,18H,2-4,9H2,1H3,(H,14,16)(H,15,17)
DMGTNQY	CS	CCCCC(=O)NCC1=CC=C(C=C1)C(=O)NO
DMGTNQY	IK	ZOLDKKORXZQAQV-UHFFFAOYSA-N
DMGTNQY	IU	N-hydroxy-4-[(pentanoylamino)methyl]benzamide
DMGTNQY	DE	Discovery agent

DMDUOH4	ID	DMDUOH4
DMDUOH4	DN	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide
DMDUOH4	HS	Investigative
DMDUOH4	SN	CHEMBL143674; SCHEMBL673760
DMDUOH4	DT	Small molecular drug
DMDUOH4	PC	11323577
DMDUOH4	MW	284.31
DMDUOH4	FM	C16H16N2O3
DMDUOH4	IC	InChI=1S/C16H16N2O3/c19-15(10-12-4-2-1-3-5-12)17-11-13-6-8-14(9-7-13)16(20)18-21/h1-9,21H,10-11H2,(H,17,19)(H,18,20)
DMDUOH4	CS	C1=CC=C(C=C1)CC(=O)NCC2=CC=C(C=C2)C(=O)NO
DMDUOH4	IK	YHZMFLZXDBVBJK-UHFFFAOYSA-N
DMDUOH4	IU	N-hydroxy-4-[[(2-phenylacetyl)amino]methyl]benzamide
DMDUOH4	DE	Discovery agent

DMEO7L5	ID	DMEO7L5
DMEO7L5	DN	N-Hydroxy-4-iodo-benzamide
DMEO7L5	HS	Investigative
DMEO7L5	SN	N-Hydroxy-4-iodobenzamide; CHEMBL155287; 2593-31-9; p-Iodobenzohydroxamic acid; N-Hydroxy-4-iodo-benzamide; AC1LDBQC; AC1Q7DII; 4-Iodobenzohydroximic acid; N-Hydroxy-4-iodobenzamide #; CTK8A6787; MolPort-005-220-499; HXIKIQLHKIBCOH-UHFFFAOYSA-N; BDBM50015131; ZINC20303936; AKOS008969031; NE46453; MCULE-3184298763; EN300-53710
DMEO7L5	DT	Small molecular drug
DMEO7L5	PC	615643
DMEO7L5	MW	263.03
DMEO7L5	FM	C7H6INO2
DMEO7L5	IC	InChI=1S/C7H6INO2/c8-6-3-1-5(2-4-6)7(10)9-11/h1-4,11H,(H,9,10)
DMEO7L5	CS	C1=CC(=CC=C1C(=O)NO)I
DMEO7L5	IK	HXIKIQLHKIBCOH-UHFFFAOYSA-N
DMEO7L5	IU	N-hydroxy-4-iodobenzamide
DMEO7L5	DE	Discovery agent

DM16G80	ID	DM16G80
DM16G80	DN	N-Hydroxy-4-isobutyl-benzamide
DM16G80	HS	Investigative
DM16G80	SN	CHEMBL439659; N-Hydroxy-4-isobutyl-benzamide; SCHEMBL6919015; BDBM50015175; 4-(2-Methylpropyl)benzohydroximic acid
DM16G80	DT	Small molecular drug
DM16G80	PC	20771934
DM16G80	MW	193.24
DM16G80	FM	C11H15NO2
DM16G80	IC	InChI=1S/C11H15NO2/c1-8(2)7-9-3-5-10(6-4-9)11(13)12-14/h3-6,8,14H,7H2,1-2H3,(H,12,13)
DM16G80	CS	CC(C)CC1=CC=C(C=C1)C(=O)NO
DM16G80	IK	ACMIPAPWWYGZNO-UHFFFAOYSA-N
DM16G80	IU	N-hydroxy-4-(2-methylpropyl)benzamide
DM16G80	DE	Discovery agent

DMMHQE8	ID	DMMHQE8
DMMHQE8	DN	N-Hydroxy-4-naphthalen-2-yl-benzamide
DMMHQE8	HS	Investigative
DMMHQE8	SN	CHEMBL154008; N-Hydroxy-4-naphthalen-2-yl-benzamide; SCHEMBL10361606; ZINC27653366; BDBM50015182; 4-(2-Naphthalenyl)benzohydroximic acid
DMMHQE8	DT	Small molecular drug
DMMHQE8	PC	44369651
DMMHQE8	MW	263.29
DMMHQE8	FM	C17H13NO2
DMMHQE8	IC	InChI=1S/C17H13NO2/c19-17(18-20)14-8-5-13(6-9-14)16-10-7-12-3-1-2-4-15(12)11-16/h1-11,20H,(H,18,19)
DMMHQE8	CS	C1=CC=C2C=C(C=CC2=C1)C3=CC=C(C=C3)C(=O)NO
DMMHQE8	IK	CYVBBSVZKCLSIR-UHFFFAOYSA-N
DMMHQE8	IU	N-hydroxy-4-naphthalen-2-ylbenzamide
DMMHQE8	DE	Discovery agent

DMQSWO8	ID	DMQSWO8
DMQSWO8	DN	N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide
DMQSWO8	HS	Investigative
DMQSWO8	SN	CHEMBL198055; N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide
DMQSWO8	DT	Small molecular drug
DMQSWO8	PC	44404478
DMQSWO8	MW	285.29
DMQSWO8	FM	C16H15NO4
DMQSWO8	IC	InChI=1S/C16H15NO4/c18-15(10-11-16(19)17-20)12-6-8-14(9-7-12)21-13-4-2-1-3-5-13/h1-9,20H,10-11H2,(H,17,19)
DMQSWO8	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)CCC(=O)NO
DMQSWO8	IK	NOELKUBXWDTLKR-UHFFFAOYSA-N
DMQSWO8	IU	N-hydroxy-4-oxo-4-(4-phenoxyphenyl)butanamide
DMQSWO8	DE	Discovery agent

DMCRU17	ID	DMCRU17
DMCRU17	DN	N-Hydroxy-4-phenylacetylamino-benzamide
DMCRU17	HS	Investigative
DMCRU17	SN	CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
DMCRU17	DT	Small molecular drug
DMCRU17	PC	11196500
DMCRU17	MW	270.28
DMCRU17	FM	C15H14N2O3
DMCRU17	IC	InChI=1S/C15H14N2O3/c18-14(10-11-4-2-1-3-5-11)16-13-8-6-12(7-9-13)15(19)17-20/h1-9,20H,10H2,(H,16,18)(H,17,19)
DMCRU17	CS	C1=CC=C(C=C1)CC(=O)NC2=CC=C(C=C2)C(=O)NO
DMCRU17	IK	VQGKLYBEQDAOSV-UHFFFAOYSA-N
DMCRU17	IU	N-hydroxy-4-[(2-phenylacetyl)amino]benzamide
DMCRU17	CA	CAS 656261-23-3
DMCRU17	DE	Discovery agent

DMYKJZ2	ID	DMYKJZ2
DMYKJZ2	DN	N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide
DMYKJZ2	HS	Investigative
DMYKJZ2	SN	CHEMBL216509; N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide; SCHEMBL5903774; BDBM50198477
DMYKJZ2	DT	Small molecular drug
DMYKJZ2	PC	10242569
DMYKJZ2	MW	220.25
DMYKJZ2	FM	C10H8N2O2S
DMYKJZ2	IC	InChI=1S/C10H8N2O2S/c13-10(12-14)9-5-4-8(15-9)7-3-1-2-6-11-7/h1-6,14H,(H,12,13)
DMYKJZ2	CS	C1=CC=NC(=C1)C2=CC=C(S2)C(=O)NO
DMYKJZ2	IK	ASGPYAWVOHEENA-UHFFFAOYSA-N
DMYKJZ2	IU	N-hydroxy-5-pyridin-2-ylthiophene-2-carboxamide
DMYKJZ2	DE	Discovery agent

DMK98LE	ID	DMK98LE
DMK98LE	DN	N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide
DMK98LE	HS	Investigative
DMK98LE	SN	CHEMBL216292; N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide; SCHEMBL5903988
DMK98LE	DT	Small molecular drug
DMK98LE	PC	44418106
DMK98LE	MW	220.25
DMK98LE	FM	C10H8N2O2S
DMK98LE	IC	InChI=1S/C10H8N2O2S/c13-10(12-14)9-4-3-8(15-9)7-2-1-5-11-6-7/h1-6,14H,(H,12,13)
DMK98LE	CS	C1=CC(=CN=C1)C2=CC=C(S2)C(=O)NO
DMK98LE	IK	VJJJKVTXSSPWSW-UHFFFAOYSA-N
DMK98LE	IU	N-hydroxy-5-pyridin-3-ylthiophene-2-carboxamide
DMK98LE	DE	Discovery agent

DM653RM	ID	DM653RM
DM653RM	DN	N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide
DM653RM	HS	Investigative
DM653RM	SN	CHEMBL217816; N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide; SCHEMBL5903934
DM653RM	DT	Small molecular drug
DM653RM	PC	44418125
DM653RM	MW	220.25
DM653RM	FM	C10H8N2O2S
DM653RM	IC	InChI=1S/C10H8N2O2S/c13-10(12-14)9-2-1-8(15-9)7-3-5-11-6-4-7/h1-6,14H,(H,12,13)
DM653RM	CS	C1=CN=CC=C1C2=CC=C(S2)C(=O)NO
DM653RM	IK	MDIKAACRDOZAQR-UHFFFAOYSA-N
DM653RM	IU	N-hydroxy-5-pyridin-4-ylthiophene-2-carboxamide
DM653RM	DE	Discovery agent

DMA2WUQ	ID	DMA2WUQ
DMA2WUQ	DN	N-hydroxy-5-phenylthiophene-2-carboxamide
DMA2WUQ	HS	Investigative
DMA2WUQ	SN	CHEMBL217573; N-hydroxy-5-phenylthiophene-2-carboxamide; SCHEMBL5903684
DMA2WUQ	DT	Small molecular drug
DMA2WUQ	PC	25002768
DMA2WUQ	MW	219.26
DMA2WUQ	FM	C11H9NO2S
DMA2WUQ	IC	InChI=1S/C11H9NO2S/c13-11(12-14)10-7-6-9(15-10)8-4-2-1-3-5-8/h1-7,14H,(H,12,13)
DMA2WUQ	CS	C1=CC=C(C=C1)C2=CC=C(S2)C(=O)NO
DMA2WUQ	IK	XIQUFDAAPVAKOR-UHFFFAOYSA-N
DMA2WUQ	IU	N-hydroxy-5-phenylthiophene-2-carboxamide
DMA2WUQ	DE	Discovery agent

DM0JNO2	ID	DM0JNO2
DM0JNO2	DN	N-hydroxy-6-oxo-6-phenylhexanamide
DM0JNO2	HS	Investigative
DM0JNO2	SN	CHEMBL95152; N-hydroxy-6-oxo-6-phenylhexanamide; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide
DM0JNO2	DT	Small molecular drug
DM0JNO2	PC	11031415
DM0JNO2	MW	221.25
DM0JNO2	FM	C12H15NO3
DM0JNO2	IC	InChI=1S/C12H15NO3/c14-11(10-6-2-1-3-7-10)8-4-5-9-12(15)13-16/h1-3,6-7,16H,4-5,8-9H2,(H,13,15)
DM0JNO2	CS	C1=CC=C(C=C1)C(=O)CCCCC(=O)NO
DM0JNO2	IK	XCXZDISEAMNYJL-UHFFFAOYSA-N
DM0JNO2	IU	N-hydroxy-6-oxo-6-phenylhexanamide
DM0JNO2	DE	Discovery agent

DMUXZL1	ID	DMUXZL1
DMUXZL1	DN	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide
DMUXZL1	HS	Investigative
DMUXZL1	SN	CHEMBL95990; N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide
DMUXZL1	DT	Small molecular drug
DMUXZL1	PC	10858374
DMUXZL1	MW	265.3
DMUXZL1	FM	C14H19NO4
DMUXZL1	IC	InChI=1S/C14H19NO4/c1-19-12-9-7-11(8-10-12)13(16)5-3-2-4-6-14(17)15-18/h7-10,18H,2-6H2,1H3,(H,15,17)
DMUXZL1	CS	COC1=CC=C(C=C1)C(=O)CCCCCC(=O)NO
DMUXZL1	IK	NIGGAQZXTHMKPL-UHFFFAOYSA-N
DMUXZL1	IU	N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide
DMUXZL1	DE	Discovery agent

DM8Z4L0	ID	DM8Z4L0
DM8Z4L0	DN	N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide
DM8Z4L0	HS	Investigative
DM8Z4L0	SN	CHEMBL320909; N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide
DM8Z4L0	DT	Small molecular drug
DM8Z4L0	PC	11129854
DM8Z4L0	MW	285.34
DM8Z4L0	FM	C17H19NO3
DM8Z4L0	IC	InChI=1S/C17H19NO3/c19-16(8-2-1-3-9-17(20)18-21)15-11-10-13-6-4-5-7-14(13)12-15/h4-7,10-12,21H,1-3,8-9H2,(H,18,20)
DM8Z4L0	CS	C1=CC=C2C=C(C=CC2=C1)C(=O)CCCCCC(=O)NO
DM8Z4L0	IK	AQLMJRZLPWGPGD-UHFFFAOYSA-N
DM8Z4L0	IU	N-hydroxy-7-naphthalen-2-yl-7-oxoheptanamide
DM8Z4L0	DE	Discovery agent

DMBUNAP	ID	DMBUNAP
DMBUNAP	DN	N-hydroxy-7-(naphthalen-2-yloxy)heptanamide
DMBUNAP	HS	Investigative
DMBUNAP	SN	CHEMBL217083; N-hydroxy-7-(naphthalen-2-yloxy)heptanamide
DMBUNAP	DT	Small molecular drug
DMBUNAP	PC	16655084
DMBUNAP	MW	287.35
DMBUNAP	FM	C17H21NO3
DMBUNAP	IC	InChI=1S/C17H21NO3/c19-17(18-20)9-3-1-2-6-12-21-16-11-10-14-7-4-5-8-15(14)13-16/h4-5,7-8,10-11,13,20H,1-3,6,9,12H2,(H,18,19)
DMBUNAP	CS	C1=CC=C2C=C(C=CC2=C1)OCCCCCCC(=O)NO
DMBUNAP	IK	KSNWLAUWIDTBGS-UHFFFAOYSA-N
DMBUNAP	IU	N-hydroxy-7-naphthalen-2-yloxyheptanamide
DMBUNAP	DE	Discovery agent

DMQW7JZ	ID	DMQW7JZ
DMQW7JZ	DN	N-hydroxy-7-oxo-7-phenylheptanamide
DMQW7JZ	HS	Investigative
DMQW7JZ	SN	CHEMBL95916; N-hydroxy-7-oxo-7-phenylheptanamide; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide
DMQW7JZ	DT	Small molecular drug
DMQW7JZ	PC	10998964
DMQW7JZ	MW	235.28
DMQW7JZ	FM	C13H17NO3
DMQW7JZ	IC	InChI=1S/C13H17NO3/c15-12(11-7-3-1-4-8-11)9-5-2-6-10-13(16)14-17/h1,3-4,7-8,17H,2,5-6,9-10H2,(H,14,16)
DMQW7JZ	CS	C1=CC=C(C=C1)C(=O)CCCCCC(=O)NO
DMQW7JZ	IK	IHUNPXAEVKBAPH-UHFFFAOYSA-N
DMQW7JZ	IU	N-hydroxy-7-oxo-7-phenylheptanamide
DMQW7JZ	DE	Discovery agent

DMSIMNR	ID	DMSIMNR
DMSIMNR	DN	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide
DMSIMNR	HS	Investigative
DMSIMNR	SN	CHEMBL95885; N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide
DMSIMNR	DT	Small molecular drug
DMSIMNR	PC	11821974
DMSIMNR	MW	279.33
DMSIMNR	FM	C15H21NO4
DMSIMNR	IC	InChI=1S/C15H21NO4/c1-20-14-10-7-6-8-12(14)13(17)9-4-2-3-5-11-15(18)16-19/h6-8,10,19H,2-5,9,11H2,1H3,(H,16,18)
DMSIMNR	CS	COC1=CC=CC=C1C(=O)CCCCCCC(=O)NO
DMSIMNR	IK	MFYBAPSRZVMJKO-UHFFFAOYSA-N
DMSIMNR	IU	N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide
DMSIMNR	DE	Discovery agent

DMD2K4T	ID	DMD2K4T
DMD2K4T	DN	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide
DMD2K4T	HS	Investigative
DMD2K4T	SN	CHEMBL95835; N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide
DMD2K4T	DT	Small molecular drug
DMD2K4T	PC	10923922
DMD2K4T	MW	279.33
DMD2K4T	FM	C15H21NO4
DMD2K4T	IC	InChI=1S/C15H21NO4/c1-20-13-10-8-12(9-11-13)14(17)6-4-2-3-5-7-15(18)16-19/h8-11,19H,2-7H2,1H3,(H,16,18)
DMD2K4T	CS	COC1=CC=C(C=C1)C(=O)CCCCCCC(=O)NO
DMD2K4T	IK	LIOTZVIDBXLBAC-UHFFFAOYSA-N
DMD2K4T	IU	N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide
DMD2K4T	DE	Discovery agent

DMRN1C6	ID	DMRN1C6
DMRN1C6	DN	N-hydroxy-8-(naphthalen-2-yl)non-8-enamide
DMRN1C6	HS	Investigative
DMRN1C6	SN	CHEMBL95535; N-hydroxy-8-(naphthalen-2-yl)non-8-enamide; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide
DMRN1C6	DT	Small molecular drug
DMRN1C6	PC	11822609
DMRN1C6	MW	297.4
DMRN1C6	FM	C19H23NO2
DMRN1C6	IC	InChI=1S/C19H23NO2/c1-15(8-4-2-3-5-11-19(21)20-22)17-13-12-16-9-6-7-10-18(16)14-17/h6-7,9-10,12-14,22H,1-5,8,11H2,(H,20,21)
DMRN1C6	CS	C=C(CCCCCCC(=O)NO)C1=CC2=CC=CC=C2C=C1
DMRN1C6	IK	FMDUQUPDPRRDDD-UHFFFAOYSA-N
DMRN1C6	IU	N-hydroxy-8-naphthalen-2-ylnon-8-enamide
DMRN1C6	DE	Discovery agent

DMGZY1Q	ID	DMGZY1Q
DMGZY1Q	DN	N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide
DMGZY1Q	HS	Investigative
DMGZY1Q	SN	CHEMBL451182; N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide
DMGZY1Q	DT	Small molecular drug
DMGZY1Q	PC	10891349
DMGZY1Q	MW	283.4
DMGZY1Q	FM	C18H21NO2
DMGZY1Q	IC	InChI=1S/C18H21NO2/c20-18(19-21)11-5-3-1-2-4-8-15-12-13-16-9-6-7-10-17(16)14-15/h4,6-10,12-14,21H,1-3,5,11H2,(H,19,20)/b8-4+
DMGZY1Q	CS	C1=CC=C2C=C(C=CC2=C1)/C=C/CCCCCC(=O)NO
DMGZY1Q	IK	PGGPUSMJSOKMEA-XBXARRHUSA-N
DMGZY1Q	IU	(E)-N-hydroxy-8-naphthalen-2-yloct-7-enamide
DMGZY1Q	DE	Discovery agent

DMXQICK	ID	DMXQICK
DMXQICK	DN	N-hydroxy-8-(naphthalen-2-yl)octanamide
DMXQICK	HS	Investigative
DMXQICK	SN	CHEMBL95747; N-hydroxy-8-(naphthalen-2-yl)octanamide; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide
DMXQICK	DT	Small molecular drug
DMXQICK	PC	11833001
DMXQICK	MW	285.4
DMXQICK	FM	C18H23NO2
DMXQICK	IC	InChI=1S/C18H23NO2/c20-18(19-21)11-5-3-1-2-4-8-15-12-13-16-9-6-7-10-17(16)14-15/h6-7,9-10,12-14,21H,1-5,8,11H2,(H,19,20)
DMXQICK	CS	C1=CC=C2C=C(C=CC2=C1)CCCCCCCC(=O)NO
DMXQICK	IK	KWFDCRKEDDNSLQ-UHFFFAOYSA-N
DMXQICK	IU	N-hydroxy-8-naphthalen-2-yloctanamide
DMXQICK	DE	Discovery agent

DMO4CR7	ID	DMO4CR7
DMO4CR7	DN	N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide
DMO4CR7	HS	Investigative
DMO4CR7	SN	CHEMBL98911; N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide
DMO4CR7	DT	Small molecular drug
DMO4CR7	PC	11128726
DMO4CR7	MW	250.29
DMO4CR7	FM	C13H18N2O3
DMO4CR7	IC	InChI=1S/C13H18N2O3/c16-12(11-6-5-9-14-10-11)7-3-1-2-4-8-13(17)15-18/h5-6,9-10,18H,1-4,7-8H2,(H,15,17)
DMO4CR7	CS	C1=CC(=CN=C1)C(=O)CCCCCCC(=O)NO
DMO4CR7	IK	AAHQDWBMLVLXAC-UHFFFAOYSA-N
DMO4CR7	IU	N-hydroxy-8-oxo-8-pyridin-3-yloctanamide
DMO4CR7	DE	Discovery agent

DMID3BF	ID	DMID3BF
DMID3BF	DN	N-hydroxy-9,10-dihydroanthracene-9-carboxamide
DMID3BF	HS	Investigative
DMID3BF	SN	CHEMBL575482; N-hydroxy-9,10-dihydroanthracene-9-carboxamide; SCHEMBL4541357
DMID3BF	DT	Small molecular drug
DMID3BF	PC	45482666
DMID3BF	MW	239.27
DMID3BF	FM	C15H13NO2
DMID3BF	IC	InChI=1S/C15H13NO2/c17-15(16-18)14-12-7-3-1-5-10(12)9-11-6-2-4-8-13(11)14/h1-8,14,18H,9H2,(H,16,17)
DMID3BF	CS	C1C2=CC=CC=C2C(C3=CC=CC=C31)C(=O)NO
DMID3BF	IK	SIYRPEHGIQLXJG-UHFFFAOYSA-N
DMID3BF	IU	N-hydroxy-9,10-dihydroanthracene-9-carboxamide
DMID3BF	DE	Discovery agent

DM0DRHP	ID	DM0DRHP
DM0DRHP	DN	N-hydroxy-9H-xanthene-9-carboxamide
DM0DRHP	HS	Investigative
DM0DRHP	SN	N-hydroxy-9H-xanthene-9-carboxamide; CHEMBL583490; 9H-Xanthene-9-carboxamide,N-hydroxy-; SCHEMBL2843958; BDBM50300446
DM0DRHP	DT	Small molecular drug
DM0DRHP	PC	44626296
DM0DRHP	MW	241.24
DM0DRHP	FM	C14H11NO3
DM0DRHP	IC	InChI=1S/C14H11NO3/c16-14(15-17)13-9-5-1-3-7-11(9)18-12-8-4-2-6-10(12)13/h1-8,13,17H,(H,15,16)
DM0DRHP	CS	C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)C(=O)NO
DM0DRHP	IK	ULUVQBMMAOHWSH-UHFFFAOYSA-N
DM0DRHP	IU	N-hydroxy-9H-xanthene-9-carboxamide
DM0DRHP	DE	Discovery agent

DMIC2A8	ID	DMIC2A8
DMIC2A8	DN	N-hydroxy-9-oxo-9-phenylnonanamide
DMIC2A8	HS	Investigative
DMIC2A8	SN	CHEMBL99810; N-hydroxy-9-oxo-9-phenylnonanamide; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide
DMIC2A8	DT	Small molecular drug
DMIC2A8	PC	11139963
DMIC2A8	MW	263.33
DMIC2A8	FM	C15H21NO3
DMIC2A8	IC	InChI=1S/C15H21NO3/c17-14(13-9-5-4-6-10-13)11-7-2-1-3-8-12-15(18)16-19/h4-6,9-10,19H,1-3,7-8,11-12H2,(H,16,18)
DMIC2A8	CS	C1=CC=C(C=C1)C(=O)CCCCCCCC(=O)NO
DMIC2A8	IK	ZCJNQRRQDXSGEO-UHFFFAOYSA-N
DMIC2A8	IU	N-hydroxy-9-oxo-9-phenylnonanamide
DMIC2A8	DE	Discovery agent

DMR4J8G	ID	DMR4J8G
DMR4J8G	DN	N-hydroxybenzo[b]thiophene-2-carboxamide
DMR4J8G	HS	Investigative
DMR4J8G	SN	CHEMBL245946; N-hydroxybenzo[b]thiophene-2-carboxamide; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid
DMR4J8G	DT	Small molecular drug
DMR4J8G	PC	11708207
DMR4J8G	MW	193.22
DMR4J8G	FM	C9H7NO2S
DMR4J8G	IC	InChI=1S/C9H7NO2S/c11-9(10-12)8-5-6-3-1-2-4-7(6)13-8/h1-5,12H,(H,10,11)
DMR4J8G	CS	C1=CC=C2C(=C1)C=C(S2)C(=O)NO
DMR4J8G	IK	UGJNLGFANIDLSB-UHFFFAOYSA-N
DMR4J8G	IU	N-hydroxy-1-benzothiophene-2-carboxamide
DMR4J8G	CA	CAS 211172-97-3
DMR4J8G	DE	Discovery agent

DM41JIB	ID	DM41JIB
DM41JIB	DN	N-Hydroxycarbamoylmethyl-4-methoxy-benzamide
DM41JIB	HS	Investigative
DM41JIB	SN	BRN 2736542; 2-(p-Methoxybenzamido)acetohydroxamic acid; ACETOHYDROXAMIC ACID, 2-(p-METHOXYBENZAMIDO)-; CHEMBL198048; 65654-08-2; N-Hydroxycarbamoylmethyl-4-methoxy-benzamide; AC1L2IK9; SCHEMBL11668774; CTK5C2963; DTXSID60215890; BDBM50175547; LS-13134; N-[2-(hydroxyamino)-2-oxoethyl]-4-methoxybenzamide; N-(HYDROXYCARBAMOYLMETHYL)-4-METHOXY-BENZAMIDE
DM41JIB	DT	Small molecular drug
DM41JIB	PC	47697
DM41JIB	MW	224.21
DM41JIB	FM	C10H12N2O4
DM41JIB	IC	InChI=1S/C10H12N2O4/c1-16-8-4-2-7(3-5-8)10(14)11-6-9(13)12-15/h2-5,15H,6H2,1H3,(H,11,14)(H,12,13)
DM41JIB	CS	COC1=CC=C(C=C1)C(=O)NCC(=O)NO
DM41JIB	IK	ZJTICILORBZVBV-UHFFFAOYSA-N
DM41JIB	IU	N-[2-(hydroxyamino)-2-oxoethyl]-4-methoxybenzamide
DM41JIB	CA	CAS 65654-08-2
DM41JIB	DE	Discovery agent

DMDTX4L	ID	DMDTX4L
DMDTX4L	DN	N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide
DMDTX4L	HS	Investigative
DMDTX4L	SN	CHEMBL198543; N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide
DMDTX4L	DT	Small molecular drug
DMDTX4L	PC	44404537
DMDTX4L	MW	286.28
DMDTX4L	FM	C15H14N2O4
DMDTX4L	IC	InChI=1S/C15H14N2O4/c18-14(17-20)10-16-15(19)11-6-8-13(9-7-11)21-12-4-2-1-3-5-12/h1-9,20H,10H2,(H,16,19)(H,17,18)
DMDTX4L	CS	C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC(=O)NO
DMDTX4L	IK	NBSITGWGPCATOG-UHFFFAOYSA-N
DMDTX4L	IU	N-[2-(hydroxyamino)-2-oxoethyl]-4-phenoxybenzamide
DMDTX4L	DE	Discovery agent

DM3J5MR	ID	DM3J5MR
DM3J5MR	DN	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide
DM3J5MR	HS	Investigative
DM3J5MR	SN	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365
DM3J5MR	DT	Small molecular drug
DM3J5MR	PC	15986508
DM3J5MR	MW	273.71
DM3J5MR	FM	C15H12ClNO2
DM3J5MR	IC	InChI=1S/C15H12ClNO2/c16-14-8-6-13(7-9-14)12-4-1-11(2-5-12)3-10-15(18)17-19/h1-10,19H,(H,17,18)/b10-3+
DM3J5MR	CS	C1=CC(=CC=C1/C=C/C(=O)NO)C2=CC=C(C=C2)Cl
DM3J5MR	IK	GBZPSEMNRBQROD-XCVCLJGOSA-N
DM3J5MR	IU	(E)-3-[4-(4-chlorophenyl)phenyl]-N-hydroxyprop-2-enamide
DM3J5MR	DE	Discovery agent

DMVFKO4	ID	DMVFKO4
DMVFKO4	DN	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide
DMVFKO4	HS	Investigative
DMVFKO4	SN	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355
DMVFKO4	DT	Small molecular drug
DMVFKO4	PC	15986510
DMVFKO4	MW	264.28
DMVFKO4	FM	C16H12N2O2
DMVFKO4	IC	InChI=1S/C16H12N2O2/c17-11-13-3-8-15(9-4-13)14-6-1-12(2-7-14)5-10-16(19)18-20/h1-10,20H,(H,18,19)/b10-5+
DMVFKO4	CS	C1=CC(=CC=C1/C=C/C(=O)NO)C2=CC=C(C=C2)C#N
DMVFKO4	IK	NJUOLWKIAIFTKT-BJMVGYQFSA-N
DMVFKO4	IU	(E)-3-[4-(4-cyanophenyl)phenyl]-N-hydroxyprop-2-enamide
DMVFKO4	DE	Discovery agent

DMQCK5G	ID	DMQCK5G
DMQCK5G	DN	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide
DMQCK5G	HS	Investigative
DMQCK5G	SN	CHEMBL556532; N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide; SCHEMBL3292226; SCHEMBL3290139
DMQCK5G	DT	Small molecular drug
DMQCK5G	PC	42632368
DMQCK5G	MW	239.27
DMQCK5G	FM	C15H13NO2
DMQCK5G	IC	InChI=1S/C15H13NO2/c17-15(16-18)11-8-12-6-9-14(10-7-12)13-4-2-1-3-5-13/h1-11,18H,(H,16,17)/b11-8+
DMQCK5G	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)/C=C/C(=O)NO
DMQCK5G	IK	YMXJQEHWXZULBO-DHZHZOJOSA-N
DMQCK5G	IU	(E)-N-hydroxy-3-(4-phenylphenyl)prop-2-enamide
DMQCK5G	DE	Discovery agent

DM865Y2	ID	DM865Y2
DM865Y2	DN	N-Hydroxy-N'-(2-methylphenyl)octanediamide
DM865Y2	HS	Investigative
DM865Y2	SN	CHEMBL1076794; BDBM50314140
DM865Y2	DT	Small molecular drug
DM865Y2	PC	46884055
DM865Y2	MW	250.29
DM865Y2	FM	C13H18N2O3
DM865Y2	IC	InChI=1S/C13H18N2O3/c1-10-6-2-3-7-11(10)14-12(16)8-4-5-9-13(17)15-18/h2-3,6-7,18H,4-5,8-9H2,1H3,(H,14,16)(H,15,17)
DM865Y2	CS	CC1=CC=CC=C1NC(=O)CCCCC(=O)NO
DM865Y2	IK	BUBGRWCYPBJWRL-UHFFFAOYSA-N
DM865Y2	IU	N'-hydroxy-N-(2-methylphenyl)hexanediamide
DM865Y2	DE	Discovery agent

DMYRC2M	ID	DMYRC2M
DMYRC2M	DN	N-Hydroxy-N'-(3-methylphenyl)octanediamide
DMYRC2M	HS	Investigative
DMYRC2M	SN	CHEMBL1089339; BDBM50314136
DMYRC2M	DT	Small molecular drug
DMYRC2M	PC	46884056
DMYRC2M	MW	250.29
DMYRC2M	FM	C13H18N2O3
DMYRC2M	IC	InChI=1S/C13H18N2O3/c1-10-5-4-6-11(9-10)14-12(16)7-2-3-8-13(17)15-18/h4-6,9,18H,2-3,7-8H2,1H3,(H,14,16)(H,15,17)
DMYRC2M	CS	CC1=CC(=CC=C1)NC(=O)CCCCC(=O)NO
DMYRC2M	IK	QJSROQKJUVLPRM-UHFFFAOYSA-N
DMYRC2M	IU	N'-hydroxy-N-(3-methylphenyl)hexanediamide
DMYRC2M	DE	Discovery agent

DMELB07	ID	DMELB07
DMELB07	DN	N-Hydroxy-N'-(4-methoxyphenyl)octanediamide
DMELB07	HS	Investigative
DMELB07	SN	CHEMBL1091487; BDBM50314137
DMELB07	DT	Small molecular drug
DMELB07	PC	46884016
DMELB07	MW	266.29
DMELB07	FM	C13H18N2O4
DMELB07	IC	InChI=1S/C13H18N2O4/c1-19-11-8-6-10(7-9-11)14-12(16)4-2-3-5-13(17)15-18/h6-9,18H,2-5H2,1H3,(H,14,16)(H,15,17)
DMELB07	CS	COC1=CC=C(C=C1)NC(=O)CCCCC(=O)NO
DMELB07	IK	QYJANBGLOGFJLV-UHFFFAOYSA-N
DMELB07	IU	N'-hydroxy-N-(4-methoxyphenyl)hexanediamide
DMELB07	DE	Discovery agent

DM3DPZ8	ID	DM3DPZ8
DM3DPZ8	DN	N-Hydroxy-N'-(4-methylphenyl)octanediamide
DM3DPZ8	HS	Investigative
DM3DPZ8	SN	CHEMBL1092762; BDBM50314138
DM3DPZ8	DT	Small molecular drug
DM3DPZ8	PC	46884057
DM3DPZ8	MW	250.29
DM3DPZ8	FM	C13H18N2O3
DM3DPZ8	IC	InChI=1S/C13H18N2O3/c1-10-6-8-11(9-7-10)14-12(16)4-2-3-5-13(17)15-18/h6-9,18H,2-5H2,1H3,(H,14,16)(H,15,17)
DM3DPZ8	CS	CC1=CC=C(C=C1)NC(=O)CCCCC(=O)NO
DM3DPZ8	IK	VUUHXDZTBBCMIT-UHFFFAOYSA-N
DM3DPZ8	IU	N'-hydroxy-N-(4-methylphenyl)hexanediamide
DM3DPZ8	DE	Discovery agent

DM4E8NJ	ID	DM4E8NJ
DM4E8NJ	DN	N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea
DM4E8NJ	HS	Investigative
DM4E8NJ	SN	CHEMBL167577; N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea; SCHEMBL9443901
DM4E8NJ	DT	Small molecular drug
DM4E8NJ	PC	10561814
DM4E8NJ	MW	236.31
DM4E8NJ	FM	C13H20N2O2
DM4E8NJ	IC	InChI=1S/C13H20N2O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)15(17)13(14)16/h4-7,9-10,17H,8H2,1-3H3,(H2,14,16)
DM4E8NJ	CS	CC(C)CC1=CC=C(C=C1)C(C)N(C(=O)N)O
DM4E8NJ	IK	FBLDKAJQWYMCKR-UHFFFAOYSA-N
DM4E8NJ	IU	1-hydroxy-1-[1-[4-(2-methylpropyl)phenyl]ethyl]urea
DM4E8NJ	DE	Discovery agent

DMQ4ST2	ID	DMQ4ST2
DMQ4ST2	DN	N-Hydroxy-N-methyl-2,3,3-triphenyl-acrylamide
DMQ4ST2	HS	Investigative
DMQ4ST2	SN	CHEMBL174161; N-Hydroxy-N-methyl-2,3,3-triphenyl-acrylamide; BDBM50015154; 2,3,3-Triphenyl-N-methyl-2-propenehydroxamic acid
DMQ4ST2	DT	Small molecular drug
DMQ4ST2	PC	44386837
DMQ4ST2	MW	329.4
DMQ4ST2	FM	C22H19NO2
DMQ4ST2	IC	InChI=1S/C22H19NO2/c1-23(25)22(24)21(19-15-9-4-10-16-19)20(17-11-5-2-6-12-17)18-13-7-3-8-14-18/h2-16,25H,1H3
DMQ4ST2	CS	CN(C(=O)C(=C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3)O
DMQ4ST2	IK	ORTZIDPYVDIVSI-UHFFFAOYSA-N
DMQ4ST2	IU	N-hydroxy-N-methyl-2,3,3-triphenylprop-2-enamide
DMQ4ST2	DE	Discovery agent

DMNVD8I	ID	DMNVD8I
DMNVD8I	DN	N-Hydroxy-N-methyl-2-naphthalen-2-yl-propionamide
DMNVD8I	HS	Investigative
DMNVD8I	SN	CHEMBL146477; N-Hydroxy-N-methyl-2-naphthalen-2-yl-propionamide
DMNVD8I	DT	Small molecular drug
DMNVD8I	PC	44364373
DMNVD8I	MW	229.27
DMNVD8I	FM	C14H15NO2
DMNVD8I	IC	InChI=1S/C14H15NO2/c1-10(14(16)15(2)17)12-8-7-11-5-3-4-6-13(11)9-12/h3-10,17H,1-2H3
DMNVD8I	CS	CC(C1=CC2=CC=CC=C2C=C1)C(=O)N(C)O
DMNVD8I	IK	HMSPAZCQILPMIK-UHFFFAOYSA-N
DMNVD8I	IU	N-hydroxy-N-methyl-2-naphthalen-2-ylpropanamide
DMNVD8I	DE	Discovery agent

DMSRPI8	ID	DMSRPI8
DMSRPI8	DN	N-Hydroxy-N-methyl-3-naphthalen-1-yl-acrylamide
DMSRPI8	HS	Investigative
DMSRPI8	SN	CHEMBL175134; N-Hydroxy-N-methyl-3-naphthalen-1-yl-acrylamide; BDBM50015100
DMSRPI8	DT	Small molecular drug
DMSRPI8	PC	15670548
DMSRPI8	MW	227.26
DMSRPI8	FM	C14H13NO2
DMSRPI8	IC	InChI=1S/C14H13NO2/c1-15(17)14(16)10-9-12-7-4-6-11-5-2-3-8-13(11)12/h2-10,17H,1H3/b10-9+
DMSRPI8	CS	CN(C(=O)/C=C/C1=CC=CC2=CC=CC=C21)O
DMSRPI8	IK	AQTNKWXWVAWKHS-MDZDMXLPSA-N
DMSRPI8	IU	(E)-N-hydroxy-N-methyl-3-naphthalen-1-ylprop-2-enamide
DMSRPI8	DE	Discovery agent

DMANTW0	ID	DMANTW0
DMANTW0	DN	N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide
DMANTW0	HS	Investigative
DMANTW0	SN	CHEMBL63882; N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide; BDBM50015178; ZINC26247459; N-Methyl-N-hydroxy-2-naphthaleneacrylamide; (E)-N-hydroxy-N-methyl-3-(naphthalen-2-yl)acrylamide; (E)-3-(2-Naphthalenyl)-N-methyl-2-propenehydroxamic acid
DMANTW0	DT	Small molecular drug
DMANTW0	PC	13687210
DMANTW0	MW	227.26
DMANTW0	FM	C14H13NO2
DMANTW0	IC	InChI=1S/C14H13NO2/c1-15(17)14(16)9-7-11-6-8-12-4-2-3-5-13(12)10-11/h2-10,17H,1H3/b9-7+
DMANTW0	CS	CN(C(=O)/C=C/C1=CC2=CC=CC=C2C=C1)O
DMANTW0	IK	CORKVTFWNIPMDF-VQHVLOKHSA-N
DMANTW0	IU	(E)-N-hydroxy-N-methyl-3-naphthalen-2-ylprop-2-enamide
DMANTW0	DE	Discovery agent

DMMYV34	ID	DMMYV34
DMMYV34	DN	N-Hydroxy-N-methyl-3-naphthalen-2-yl-propionamide
DMMYV34	HS	Investigative
DMMYV34	SN	CHEMBL367401; N-Hydroxy-N-methyl-3-naphthalen-2-yl-propionamide; ZINC28086558
DMMYV34	DT	Small molecular drug
DMMYV34	PC	44386825
DMMYV34	MW	229.27
DMMYV34	FM	C14H15NO2
DMMYV34	IC	InChI=1S/C14H15NO2/c1-15(17)14(16)9-7-11-6-8-12-4-2-3-5-13(12)10-11/h2-6,8,10,17H,7,9H2,1H3
DMMYV34	CS	CN(C(=O)CCC1=CC2=CC=CC=C2C=C1)O
DMMYV34	IK	BLIBCDZMLZUBQT-UHFFFAOYSA-N
DMMYV34	IU	N-hydroxy-N-methyl-3-naphthalen-2-ylpropanamide
DMMYV34	DE	Discovery agent

DMAN57F	ID	DMAN57F
DMAN57F	DN	N-Hydroxy-N-methyl-3-phenanthren-2-yl-acrylamide
DMAN57F	HS	Investigative
DMAN57F	SN	CHEMBL174557; N-Hydroxy-N-methyl-3-phenanthren-2-yl-acrylamide; ZINC28089401
DMAN57F	DT	Small molecular drug
DMAN57F	PC	13746842
DMAN57F	MW	277.3
DMAN57F	FM	C18H15NO2
DMAN57F	IC	InChI=1S/C18H15NO2/c1-19(21)18(20)11-7-13-6-10-17-15(12-13)9-8-14-4-2-3-5-16(14)17/h2-12,21H,1H3/b11-7+
DMAN57F	CS	CN(C(=O)/C=C/C1=CC2=C(C=C1)C3=CC=CC=C3C=C2)O
DMAN57F	IK	YYXIRZNCGWVYCR-YRNVUSSQSA-N
DMAN57F	IU	(E)-N-hydroxy-N-methyl-3-phenanthren-2-ylprop-2-enamide
DMAN57F	DE	Discovery agent

DMV8UCK	ID	DMV8UCK
DMV8UCK	DN	N-Hydroxy-N-methyl-3-phenanthren-3-yl-acrylamide
DMV8UCK	HS	Investigative
DMV8UCK	SN	CHEMBL174898; N-Hydroxy-N-methyl-3-phenanthren-3-yl-acrylamide; BDBM50015157
DMV8UCK	DT	Small molecular drug
DMV8UCK	PC	13746843
DMV8UCK	MW	277.3
DMV8UCK	FM	C18H15NO2
DMV8UCK	IC	InChI=1S/C18H15NO2/c1-19(21)18(20)11-7-13-6-8-15-10-9-14-4-2-3-5-16(14)17(15)12-13/h2-12,21H,1H3/b11-7+
DMV8UCK	CS	CN(C(=O)/C=C/C1=CC2=C(C=CC3=CC=CC=C32)C=C1)O
DMV8UCK	IK	IPSMBZZRHPTXDJ-YRNVUSSQSA-N
DMV8UCK	IU	(E)-N-hydroxy-N-methyl-3-phenanthren-3-ylprop-2-enamide
DMV8UCK	DE	Discovery agent

DMQBD27	ID	DMQBD27
DMQBD27	DN	N-Hydroxy-N-methyl-3-phenanthren-9-yl-acrylamide
DMQBD27	HS	Investigative
DMQBD27	SN	CHEMBL367247; N-Hydroxy-N-methyl-3-phenanthren-9-yl-acrylamide; ZINC28023141; BDBM50015150; (E)-3-(Phenanthren-9-yl)-N-methyl-2-propenehydroxamic acid
DMQBD27	DT	Small molecular drug
DMQBD27	PC	13746844
DMQBD27	MW	277.3
DMQBD27	FM	C18H15NO2
DMQBD27	IC	InChI=1S/C18H15NO2/c1-19(21)18(20)11-10-14-12-13-6-2-3-7-15(13)17-9-5-4-8-16(14)17/h2-12,21H,1H3/b11-10+
DMQBD27	CS	CN(C(=O)/C=C/C1=CC2=CC=CC=C2C3=CC=CC=C31)O
DMQBD27	IK	NKRFCIWHWNMHCB-ZHACJKMWSA-N
DMQBD27	IU	(E)-N-hydroxy-N-methyl-3-phenanthren-9-ylprop-2-enamide
DMQBD27	DE	Discovery agent

DMDQWOB	ID	DMDQWOB
DMDQWOB	DN	N-Hydroxy-N-methyl-benzamide
DMDQWOB	HS	Investigative
DMDQWOB	SN	N-Hydroxy-N-methylbenzamide; N-Hydroxy-N-methyl-benzamide; benzamide, N-hydroxy-N-methyl-; NSC646164; CHEMBL101043; 2446-50-6; AC1Q5INQ; n-methylbenzohydroxamic acid; AC1L83FX; N-Methyl-N-hydroxybenzamide; SCHEMBL125680; N-benzoyl-N-methylhydroxylamine; CTK0J4869; DTXSID20327327; DDSSLJHUWRMSSP-UHFFFAOYSA-N; ZINC5497333; BDBM50015122; AKOS028111405; NSC-646164
DMDQWOB	DT	Small molecular drug
DMDQWOB	PC	371715
DMDQWOB	MW	151.16
DMDQWOB	FM	C8H9NO2
DMDQWOB	IC	InChI=1S/C8H9NO2/c1-9(11)8(10)7-5-3-2-4-6-7/h2-6,11H,1H3
DMDQWOB	CS	CN(C(=O)C1=CC=CC=C1)O
DMDQWOB	IK	DDSSLJHUWRMSSP-UHFFFAOYSA-N
DMDQWOB	IU	N-hydroxy-N-methylbenzamide
DMDQWOB	CA	CAS 2446-50-6
DMDQWOB	DE	Discovery agent

DMCIAJL	ID	DMCIAJL
DMCIAJL	DN	N-hydroxy-nor-L-arginine
DMCIAJL	HS	Investigative
DMCIAJL	PC	446124
DMCIAJL	MW	176.17
DMCIAJL	FM	C5H12N4O3
DMCIAJL	IC	InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-8-5(7)9-12/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9)/t3-/m0/s1
DMCIAJL	CS	C(CN=C(N)NO)[C@@H](C(=O)O)N
DMCIAJL	IK	KOBHCUDVWOTEKO-VKHMYHEASA-N
DMCIAJL	IU	(2S)-2-amino-4-[[amino-(hydroxyamino)methylidene]amino]butanoic acid
DMCIAJL	CA	CAS 189302-40-7

DMTDBMU	ID	DMTDBMU
DMTDBMU	DN	N-hydroxysulfamide
DMTDBMU	HS	Investigative
DMTDBMU	SN	N-hydroxysulfamide; CHEMBL195540; 2o4z; BDBM50165753
DMTDBMU	DT	Small molecular drug
DMTDBMU	PC	16122590
DMTDBMU	MW	112.11
DMTDBMU	FM	H4N2O3S
DMTDBMU	IC	InChI=1S/H4N2O3S/c1-6(4,5)2-3/h2-3H,(H2,1,4,5)
DMTDBMU	CS	NS(=O)(=O)NO
DMTDBMU	IK	FZTCJYJKHSXPEX-UHFFFAOYSA-N
DMTDBMU	DE	Discovery agent

DMJBC03	ID	DMJBC03
DMJBC03	DN	N-hydroxysulfonamides
DMJBC03	HS	Investigative
DMJBC03	DE	Discovery agent

DMPK2JO	ID	DMPK2JO
DMPK2JO	DN	NI-105
DMPK2JO	HS	Investigative
DMPK2JO	SN	Tau protein modulator (neurodegenerative disease); Tau protein modulator (neurodegenerative disease), Biogen Idec; Tau protein modulator (neurodegenerative disease), Neurimmune Therapeutics
DMPK2JO	CP	Neurimmune Therapeutics AG
DMPK2JO	PC	10065825
DMPK2JO	MW	340.3
DMPK2JO	FM	C16H15F3N2O3
DMPK2JO	IC	InChI=1S/C16H15F3N2O3/c1-8-13(10(3)22)14(15(21(23)24)9(2)20-8)11-6-4-5-7-12(11)16(17,18)19/h4-7,14,20H,1-3H3
DMPK2JO	CS	CC1=C(C(C(=C(N1)C)[N+](=O)[O-])C2=CC=CC=C2C(F)(F)F)C(=O)C
DMPK2JO	IK	YYIGWZQIEFYARO-UHFFFAOYSA-N
DMPK2JO	IU	1-[2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridin-3-yl]ethanone
DMPK2JO	DE	Neurodegenerative disorder

DM680XO	ID	DM680XO
DM680XO	DN	NI-1201
DM680XO	HS	Investigative
DM680XO	SN	Anti-interleukin-6 receptor mAb, NovImmune
DM680XO	CP	NovImmune SA
DM680XO	DT	Antibody
DM680XO	DE	Autoimmune diabetes

DMG9OBA	ID	DMG9OBA
DMG9OBA	DN	NI-1401
DMG9OBA	HS	Investigative
DMG9OBA	SN	Anti-interleukin-17 MAb, NovImmune
DMG9OBA	CP	NovImmune SA
DMG9OBA	DT	Antibody
DMG9OBA	DE	Autoimmune diabetes

DM52ITO	ID	DM52ITO
DM52ITO	DN	NI-57
DM52ITO	HS	Investigative
DM52ITO	SN	CHEMBL3752151; 1883548-89-7; 4-Cyano-~{n}-(1,3-Dimethyl-2-Oxidanylidene-Quinolin-6-Yl)-2-Methoxy-Benzenesulfonamide; GTPL8573; SCHEMBL17560720; MolPort-039-101-322; NI 57; EX-A1876; BDBM50157570; ZINC254286814; AKOS027470204; NCGC00483115-01; NI-57, &gt; HY-19537; CS-0015636; 4-cyano-N-(1,3-dimethyl-2-oxoquinolin-6-yl)-2-methoxybenzenesulfonamide; 4-cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxybenzenesulfonamide
DM52ITO	DT	Small molecular drug
DM52ITO	PC	91827373
DM52ITO	MW	383.4
DM52ITO	FM	C19H17N3O4S
DM52ITO	IC	InChI=1S/C19H17N3O4S/c1-12-8-14-10-15(5-6-16(14)22(2)19(12)23)21-27(24,25)18-7-4-13(11-20)9-17(18)26-3/h4-10,21H,1-3H3
DM52ITO	CS	CC1=CC2=C(C=CC(=C2)NS(=O)(=O)C3=C(C=C(C=C3)C#N)OC)N(C1=O)C
DM52ITO	IK	UEMQPCYDWCSVCU-UHFFFAOYSA-N
DM52ITO	IU	4-cyano-N-(1,3-dimethyl-2-oxoquinolin-6-yl)-2-methoxybenzenesulfonamide
DM52ITO	DE	Discovery agent

DMH6MVJ	ID	DMH6MVJ
DMH6MVJ	DN	NIBR-0213
DMH6MVJ	HS	Investigative
DMH6MVJ	SN	GTPL6997; SCHEMBL2796717; CHEMBL3086703; ZINC103273369; NIBR-0213, &gt; (2S)-2-[[4-[3-[[(1R)-1-(4-chloro-3-methylphenyl)ethyl]amino]phenyl]-2,6-dimethylbenzoyl]amino]propanoic acid
DMH6MVJ	DT	Small molecular drug
DMH6MVJ	PC	59393720
DMH6MVJ	MW	465
DMH6MVJ	FM	C27H29ClN2O3
DMH6MVJ	IC	InChI=1S/C27H29ClN2O3/c1-15-11-20(9-10-24(15)28)18(4)29-23-8-6-7-21(14-23)22-12-16(2)25(17(3)13-22)26(31)30-19(5)27(32)33/h6-14,18-19,29H,1-5H3,(H,30,31)(H,32,33)/t18-,19+/m1/s1
DMH6MVJ	CS	CC1=CC(=CC(=C1C(=O)N[C@@H](C)C(=O)O)C)C2=CC(=CC=C2)N[C@H](C)C3=CC(=C(C=C3)Cl)C
DMH6MVJ	IK	KYHUARFFBDLROH-MOPGFXCFSA-N
DMH6MVJ	IU	(2S)-2-[[4-[3-[[(1R)-1-(4-chloro-3-methylphenyl)ethyl]amino]phenyl]-2,6-dimethylbenzoyl]amino]propanoic acid
DMH6MVJ	DE	Discovery agent

DMU0BMQ	ID	DMU0BMQ
DMU0BMQ	DN	NIBR-785
DMU0BMQ	HS	Investigative
DMU0BMQ	SN	NIBR-785
DMU0BMQ	CP	Novartis Institutes for BioMedical Research Inc
DMU0BMQ	DT	Small molecular drug
DMU0BMQ	PC	46184240
DMU0BMQ	MW	396.4
DMU0BMQ	FM	C22H24N2O5
DMU0BMQ	IC	InChI=1S/C22H24N2O5/c1-5-28-19-17(27-4)11-6-13-12-16(21(26)29-18(13)19)20(25)24-15-9-7-14(8-10-15)22(2,3)23/h6-12H,5,23H2,1-4H3,(H,24,25)
DMU0BMQ	CS	CCOC1=C(C=CC2=C1OC(=O)C(=C2)C(=O)NC3=CC=C(C=C3)C(C)(C)N)OC
DMU0BMQ	IK	NFOLAKWLEGGBTA-UHFFFAOYSA-N
DMU0BMQ	IU	N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide
DMU0BMQ	DE	Multiple sclerosis

DM4I6MD	ID	DM4I6MD
DM4I6MD	DN	NICARBAZIN
DM4I6MD	HS	Investigative
DM4I6MD	SN	Nicarbazin; 330-95-0; Nicarbazine; Nicrazine; Nicrazin; Nicoxin; Nirazin; Nicarb; Nicarbasin; Nicarbazin [BAN]; MK 75; UNII-11P9NUA12U; MK 75 (VAN); HSDB 7466; NSC 7171; EINECS 206-359-1; AI3-60130; 11P9NUA12U; CHEBI:81725; Urea, N,N'-bis(4-nitrophenyl)-, compd. with 4,6-dimethyl-2(1H)-pyrimidinone (1:1); 4,4'-Dinitrocarbanilide, 4,6-dimethyl-2-pyrimidinol; 1,3-bis(4-nitrophenyl)urea; 4,6-dimethyl-1H-pyrimidin-2-one; N,N'-Bis(4-nitrophenyl)urea compd. with 4,6-dimethyl-2-pyrimidinol (1:1); W-106788
DM4I6MD	DT	Small molecular drug
DM4I6MD	PC	9507
DM4I6MD	MW	426.4
DM4I6MD	FM	C19H18N6O6
DM4I6MD	IC	InChI=1S/C13H10N4O5.C6H8N2O/c18-13(14-9-1-5-11(6-2-9)16(19)20)15-10-3-7-12(8-4-10)17(21)22;1-4-3-5(2)8-6(9)7-4/h1-8H,(H2,14,15,18);3H,1-2H3,(H,7,8,9)
DM4I6MD	CS	CC1=CC(=NC(=O)N1)C.C1=CC(=CC=C1NC(=O)NC2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-]
DM4I6MD	IK	UKHWDRMMMYWSFL-UHFFFAOYSA-N
DM4I6MD	IU	1,3-bis(4-nitrophenyl)urea;4,6-dimethyl-1H-pyrimidin-2-one
DM4I6MD	CA	CAS 330-95-0
DM4I6MD	CB	CHEBI:81725
DM4I6MD	DE	Discovery agent

DMI12Y8	ID	DMI12Y8
DMI12Y8	DN	Nickel chloride
DMI12Y8	HS	Investigative
DMI12Y8	SN	NICKEL CHLORIDE; Nickel(II) chloride; 7718-54-9; Nickel dichloride; Nickelous chloride; NiCl2; Nickel(2+) chloride; Nickel chloride (NiCl2); dichloronickel; Nickelchloride; Nickel dichloride (nicl2); Nickel(II) chloride (1:2); Nichel(II) chloride; Nickel (II) chloride; Nickel(II) chloride, 98%; Nickel(II) chloride anhydrous; CCRIS 1788; HSDB 860; EINECS 231-743-0; EINECS 253-399-0; NSC 254532; Nickel chloride [Nickel and nickel compounds]; 37211-05-5; dichloro nickel; Nickel(II) chloride, 99.99%, (trace metal basis), anhydrous, po
DMI12Y8	DT	Small molecular drug
DMI12Y8	PC	24385
DMI12Y8	MW	129.6
DMI12Y8	FM	Cl2Ni
DMI12Y8	IC	InChI=1S/2ClH.Ni/h2*1H;/q;;+2/p-2
DMI12Y8	CS	Cl[Ni]Cl
DMI12Y8	IK	QMMRZOWCJAIUJA-UHFFFAOYSA-L
DMI12Y8	IU	dichloronickel
DMI12Y8	CA	CAS 37211-0
DMI12Y8	CB	CHEBI:34887
DMI12Y8	DE	Discovery agent

DM0DFNJ	ID	DM0DFNJ
DM0DFNJ	DN	Nicotinaldehyde O-4-butoxyphenylcarbamoyl oxime
DM0DFNJ	HS	Investigative
DM0DFNJ	SN	CHEMBL597445; nicotinaldehyde O-4-butoxyphenylcarbamoyl oxime
DM0DFNJ	DT	Small molecular drug
DM0DFNJ	PC	20872718
DM0DFNJ	MW	313.35
DM0DFNJ	FM	C17H19N3O3
DM0DFNJ	IC	InChI=1S/C17H19N3O3/c1-2-3-11-22-16-8-6-15(7-9-16)20-17(21)23-19-13-14-5-4-10-18-12-14/h4-10,12-13H,2-3,11H2,1H3,(H,20,21)/b19-13+
DM0DFNJ	CS	CCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CN=CC=C2
DM0DFNJ	IK	GPBQAYXYNOXDEZ-CPNJWEJPSA-N
DM0DFNJ	IU	[(E)-pyridin-3-ylmethylideneamino] N-(4-butoxyphenyl)carbamate
DM0DFNJ	DE	Discovery agent

DM957CK	ID	DM957CK
DM957CK	DN	Nicotinaldehyde O-4-ethoxyphenylcarbamoyl oxime
DM957CK	HS	Investigative
DM957CK	SN	CHEMBL598343; nicotinaldehyde O-4-ethoxyphenylcarbamoyl oxime
DM957CK	DT	Small molecular drug
DM957CK	PC	20872722
DM957CK	MW	285.3
DM957CK	FM	C15H15N3O3
DM957CK	IC	InChI=1S/C15H15N3O3/c1-2-20-14-7-5-13(6-8-14)18-15(19)21-17-11-12-4-3-9-16-10-12/h3-11H,2H2,1H3,(H,18,19)/b17-11+
DM957CK	CS	CCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CN=CC=C2
DM957CK	IK	LKOKEOYUZBYMCC-GZTJUZNOSA-N
DM957CK	IU	[(E)-pyridin-3-ylmethylideneamino] N-(4-ethoxyphenyl)carbamate
DM957CK	DE	Discovery agent

DMC9WAL	ID	DMC9WAL
DMC9WAL	DN	Nicotinaldehyde O-4-propoxyphenylcarbamoyl oxime
DMC9WAL	HS	Investigative
DMC9WAL	SN	CHEMBL598545; nicotinaldehyde O-4-propoxyphenylcarbamoyl oxime
DMC9WAL	DT	Small molecular drug
DMC9WAL	PC	20872731
DMC9WAL	MW	299.32
DMC9WAL	FM	C16H17N3O3
DMC9WAL	IC	InChI=1S/C16H17N3O3/c1-2-10-21-15-7-5-14(6-8-15)19-16(20)22-18-12-13-4-3-9-17-11-13/h3-9,11-12H,2,10H2,1H3,(H,19,20)/b18-12+
DMC9WAL	CS	CCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CN=CC=C2
DMC9WAL	IK	RKEOSRSRXNLQCF-LDADJPATSA-N
DMC9WAL	IU	[(E)-pyridin-3-ylmethylideneamino] N-(4-propoxyphenyl)carbamate
DMC9WAL	DE	Discovery agent

DM9LRKB	ID	DM9LRKB
DM9LRKB	DN	Nicotinamide-Adenine-Dinucleotide
DM9LRKB	HS	Investigative
DM9LRKB	SN	NICOTINAMIDE-ADENINE-DINUCLEOTIDE (ACIDIC FORM); AC1NRCGS; [[(2R,3S,4R,5R)-5-(6-amino-7H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
DM9LRKB	DT	Small molecular drug
DM9LRKB	PC	5892
DM9LRKB	MW	663.4
DM9LRKB	FM	C21H27N7O14P2
DM9LRKB	IC	InChI=1S/C21H27N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1-4,7-8,10-11,13-16,20-21,29-32H,5-6H2,(H5-,22,23,24,25,33,34,35,36,37)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1
DM9LRKB	CS	C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N
DM9LRKB	IK	BAWFJGJZGIEFAR-NNYOXOHSSA-N
DM9LRKB	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
DM9LRKB	CA	CAS 53-84-9
DM9LRKB	CB	CHEBI:44215

DMO7M2N	ID	DMO7M2N
DMO7M2N	DN	Nicotinyl alcohol
DMO7M2N	HS	Investigative
DMO7M2N	SN	Nicotinic alcohol; Nicotinyl alcohol; NU-2121; Niltuvin (free base); Pyridine-3-carbinol; Pyridine-3-methanol; Pyridyl-3-carbinol; Pyridyl-3-methanol; Pyridylcarbinol; Pyridylmethanol; Ro-1-5155; Roniacol; beta-Picolyl alcohol; beta-Pyridinecarbinol; beta-Pyridylcarbinol; pyridin-3-ylmethanol; (Pyridin-3-yl)methanol; .beta.-Pyridylcarbinol; 100-55-0; 3-(Hydroxymethyl)pyridine; 3-Hydroxymethylpyridine; 3-PYRIDINEMETHANOL; 3-PYRIDINYLCARBINOL; 3-Picolyl alcohol; 3-Pyridinylmethanol; 3-Pyridylcarbinol; 3-Pyridylmethanol
DMO7M2N	PC	7510
DMO7M2N	MW	109.13
DMO7M2N	FM	C6H7NO
DMO7M2N	IC	MVQVNTPHUGQQHK-UHFFFAOYSA-N
DMO7M2N	CS	C1=CC(=CN=C1)CO
DMO7M2N	IK	1S/C6H7NO/c8-5-6-2-1-3-7-4-6/h1-4,8H,5H2
DMO7M2N	IU	pyridin-3-ylmethanol
DMO7M2N	CA	CAS 100-55-0
DMO7M2N	CB	CHEBI:45213
DMO7M2N	DE	Hypertriglyceridaemia

DMIK40C	ID	DMIK40C
DMIK40C	DN	Nifeviroc
DMIK40C	HS	Investigative
DMIK40C	SN	NIFEVIROC; CHEMBL1172035; SCHEMBL14895241; BDBM50321682; AKOS027337129; SB16981; 4-Nitrobenzyl allyl(1-(((3S,4R)-1-(cyclopentanecarbonyl)-4-hydroxy-4-phenylpyrrolidin-3-yl)methyl)piperidin-4-yl)carbamate; (4-nitrophenyl)methyl N-allyl-N-[1-[[(3S,4R)-1-(cyclopentanecarbonyl)-4-hydroxy-4-phenyl-pyrrolidin-3-yl]methyl]-4-piperidyl]carbamate; Carbamic acid, [1-[[(3S,4R)-1-(cyclopentylcarbonyl)-4-hydroxy-4-phenyl-3-pyrrolidinyl]methyl]-4-piperidinyl]2-propenyl-, (4-nitrophenyl)methyl ester; 934740-25-7
DMIK40C	DT	Small molecular drug
DMIK40C	PC	16663418
DMIK40C	MW	590.7
DMIK40C	FM	C33H42N4O6
DMIK40C	IC	InChI=1S/C33H42N4O6/c1-2-18-36(32(39)43-23-25-12-14-30(15-13-25)37(41)42)29-16-19-34(20-17-29)21-28-22-35(31(38)26-8-6-7-9-26)24-33(28,40)27-10-4-3-5-11-27/h2-5,10-15,26,28-29,40H,1,6-9,16-24H2/t28-,33-/m0/s1
DMIK40C	CS	C=CCN(C1CCN(CC1)C[C@H]2CN(C[C@@]2(C3=CC=CC=C3)O)C(=O)C4CCCC4)C(=O)OCC5=CC=C(C=C5)[N+](=O)[O-]
DMIK40C	IK	JNSKQYZFEVKYDB-UVMMSNCQSA-N
DMIK40C	IU	(4-nitrophenyl)methyl N-[1-[[(3S,4R)-1-(cyclopentanecarbonyl)-4-hydroxy-4-phenylpyrrolidin-3-yl]methyl]piperidin-4-yl]-N-prop-2-enylcarbamate
DMIK40C	DE	Discovery agent

DMDMG1O	ID	DMDMG1O
DMDMG1O	DN	NIHP
DMDMG1O	HS	Investigative
DMDMG1O	SN	NIHP; GTPL545; SCHEMBL15159029; 1-[4-(3-hydroxypropyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMDMG1O	DT	Small molecular drug
DMDMG1O	PC	10587912
DMDMG1O	MW	267.36
DMDMG1O	FM	C15H25NO3
DMDMG1O	IC	InChI=1S/C15H25NO3/c1-12(2)16-10-14(18)11-19-15-7-5-13(6-8-15)4-3-9-17/h5-8,12,14,16-18H,3-4,9-11H2,1-2H3
DMDMG1O	CS	CC(C)NCC(COC1=CC=C(C=C1)CCCO)O
DMDMG1O	IK	RUZBBQNQBDCLPE-UHFFFAOYSA-N
DMDMG1O	IU	1-[4-(3-hydroxypropyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMDMG1O	DE	Discovery agent

DM0QJSO	ID	DM0QJSO
DM0QJSO	DN	NILTUBACIN
DM0QJSO	HS	Investigative
DM0QJSO	SN	NILTUBACIN; Probes1_000174; Probes2_000141; AC1O7Y2N; CHEMBL1213539; SCHEMBL14476139; DIOX-H_003550; 8-[4-[(2R,4R,6S)-4-[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]anilino]-8-oxooctanoic acid
DM0QJSO	DT	Small molecular drug
DM0QJSO	PC	6675803
DM0QJSO	MW	706.8
DM0QJSO	FM	C41H42N2O7S
DM0QJSO	IC	InChI=1S/C41H42N2O7S/c44-26-28-17-19-29(20-18-28)35-25-34(27-51-41-43-38(30-11-5-3-6-12-30)39(50-41)31-13-7-4-8-14-31)48-40(49-35)32-21-23-33(24-22-32)42-36(45)15-9-1-2-10-16-37(46)47/h3-8,11-14,17-24,34-35,40,44H,1-2,9-10,15-16,25-27H2,(H,42,45)(H,46,47)/t34-,35+,40+/m1/s1
DM0QJSO	CS	C1[C@@H](O[C@@H](O[C@@H]1C2=CC=C(C=C2)CO)C3=CC=C(C=C3)NC(=O)CCCCCCC(=O)O)CSC4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6
DM0QJSO	IK	WLLKRNCIQXOQHG-YXQOSMAKSA-N
DM0QJSO	IU	8-[4-[(2R,4R,6S)-4-[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]anilino]-8-oxooctanoic acid
DM0QJSO	DE	Discovery agent

DM8OGMA	ID	DM8OGMA
DM8OGMA	DN	Niludipine
DM8OGMA	HS	Investigative
DM8OGMA	SN	Niludipin; Niludipina; Niludipina [INN-Spanish]; Niludipine; Niludipine [INN:BAN]; Niludipinum; Niludipinum [INN-Latin]; Nilupidine; 22609-73-0; 9844OS3B0J; BAY-a 7168; BRN 0504197; Bay a 7168; Bis(2-propoxyethyl) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; Bis(2-propoxyethyl) 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; C25H34N2O8; EINECS 245-120-6; UNII-9844OS3B0J; bis(2-propoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM8OGMA	PC	89767
DM8OGMA	MW	490.5
DM8OGMA	FM	C25H34N2O8
DM8OGMA	IC	VZWXXKDFACOXNT-UHFFFAOYSA-N
DM8OGMA	CS	CCCOCCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOCCC)C)C
DM8OGMA	IK	1S/C25H34N2O8/c1-5-10-32-12-14-34-24(28)21-17(3)26-18(4)22(25(29)35-15-13-33-11-6-2)23(21)19-8-7-9-20(16-19)27(30)31/h7-9,16,23,26H,5-6,10-15H2,1-4H3
DM8OGMA	IU	bis(2-propoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM8OGMA	CA	CAS 22609-73-0
DM8OGMA	DE	Cerebral vasospasm

DM8ZMB5	ID	DM8ZMB5
DM8ZMB5	DN	N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8ZMB5	HS	Investigative
DM8ZMB5	DT	Small molecular drug
DM8ZMB5	PC	44313346
DM8ZMB5	MW	304.3
DM8ZMB5	FM	C19H16N2O2
DM8ZMB5	IC	InChI=1S/C19H16N2O2/c22-18(15-11-20-16-8-4-3-7-14(15)16)19(23)21-17-10-9-12-5-1-2-6-13(12)17/h1-8,11,17,20H,9-10H2,(H,21,23)
DM8ZMB5	CS	C1CC2=CC=CC=C2C1NC(=O)C(=O)C3=CNC4=CC=CC=C43
DM8ZMB5	IK	HPOOEGNMALNZJV-UHFFFAOYSA-N
DM8ZMB5	IU	N-(2,3-dihydro-1H-inden-1-yl)-2-(1H-indol-3-yl)-2-oxoacetamide
DM8ZMB5	DE	Discovery agent

DMV53PH	ID	DMV53PH
DMV53PH	DN	NIP-142
DMV53PH	HS	Investigative
DMV53PH	SN	NIP-142; CHEMBL1671910; NIP 142; GTPL2408; BDBM50417965; N-[(3R,4S)-4-(cyclopropylamino)-3-hydroxy-2,2-dimethyl-7-nitrochroman-6-yl]-2-(4-methoxyphenyl)acetamide
DMV53PH	CP	Aventis
DMV53PH	DT	Small molecular drug
DMV53PH	PC	9980734
DMV53PH	MW	441.5
DMV53PH	FM	C23H27N3O6
DMV53PH	IC	InChI=1S/C23H27N3O6/c1-23(2)22(28)21(24-14-6-7-14)16-11-17(18(26(29)30)12-19(16)32-23)25-20(27)10-13-4-8-15(31-3)9-5-13/h4-5,8-9,11-12,14,21-22,24,28H,6-7,10H2,1-3H3,(H,25,27)/t21-,22+/m0/s1
DMV53PH	CS	CC1([C@@H]([C@H](C2=CC(=C(C=C2O1)[N+](=O)[O-])NC(=O)CC3=CC=C(C=C3)OC)NC4CC4)O)C
DMV53PH	IK	HWADWMAQVCHLHJ-FCHUYYIVSA-N
DMV53PH	IU	N-[(3R,4S)-4-(cyclopropylamino)-3-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydrochromen-6-yl]-2-(4-methoxyphenyl)acetamide
DMV53PH	DE	Atrial fibrillation

DMPV450	ID	DMPV450
DMPV450	DN	NIPECOTIC ACID
DMPV450	HS	Investigative
DMPV450	SN	Piperidine-3-carboxylic acid; 498-95-3; h-dl-nip-oh; EINECS 207-873-9; CHEMBL277498; dl-piperidine-3-carboxylic acid; 60252-41-7; CHEBI:116931; XJLSEXAGTJCILF-UHFFFAOYSA-N; MFCD00005992; SR-01000075612; Nipecotic; h-nip-oh; 3-carboxypiperidine; (y)-Nipecotic acid; ( inverted exclamation markA)-Nipecotic acid; PubChem6793; D-nipecotic acid-HCl; h-dl-pic(3)-oh; (RS)-nipecotic acid
DMPV450	DT	Small molecular drug
DMPV450	PC	4498
DMPV450	MW	129.16
DMPV450	FM	C6H11NO2
DMPV450	IC	InChI=1S/C6H11NO2/c8-6(9)5-2-1-3-7-4-5/h5,7H,1-4H2,(H,8,9)
DMPV450	CS	C1CC(CNC1)C(=O)O
DMPV450	IK	XJLSEXAGTJCILF-UHFFFAOYSA-N
DMPV450	IU	piperidine-3-carboxylic acid
DMPV450	CA	CAS 498-95-3
DMPV450	CB	CHEBI:116931
DMPV450	DE	Discovery agent

DM1R0WC	ID	DM1R0WC
DM1R0WC	DN	NIS-62949
DM1R0WC	HS	Investigative
DM1R0WC	DE	Discovery agent

DMO4E9U	ID	DMO4E9U
DMO4E9U	DN	N-isobutyl-2-oxo-2H-chromene-3-carboxamide
DMO4E9U	HS	Investigative
DMO4E9U	SN	N-isobutyl-2-oxo-2H-chromene-3-carboxamide; AC1LGLK5; 3-carboxamido coumarin, 3; Oprea1_019533; CHEMBL512883; BDBM29154; MolPort-002-807-315; HMS1722A09; ZINC341401; AKOS001056674; MCULE-2251500223; 1846-84-0; ST50811140; N-(2-methylpropyl)-2-oxochromene-3-carboxamide; SR-01000051779; AG-670/14532137; N-(2-methylpropyl)(2-oxochromen-3-yl)carboxamide; SR-01000051779-1; N-(2-methylpropyl)-2-oxo-2H-chromene-3-carboxamide
DMO4E9U	DT	Small molecular drug
DMO4E9U	PC	823440
DMO4E9U	MW	245.27
DMO4E9U	FM	C14H15NO3
DMO4E9U	IC	InChI=1S/C14H15NO3/c1-9(2)8-15-13(16)11-7-10-5-3-4-6-12(10)18-14(11)17/h3-7,9H,8H2,1-2H3,(H,15,16)
DMO4E9U	CS	CC(C)CNC(=O)C1=CC2=CC=CC=C2OC1=O
DMO4E9U	IK	BKVFDOZWDVAMFZ-UHFFFAOYSA-N
DMO4E9U	IU	N-(2-methylpropyl)-2-oxochromene-3-carboxamide
DMO4E9U	DE	Discovery agent

DM9Z6VP	ID	DM9Z6VP
DM9Z6VP	DN	N-isobutylnorlitebamine
DM9Z6VP	HS	Investigative
DM9Z6VP	SN	N-isobutylnorlitebamine; CHEMBL517486; BDBM50250443
DM9Z6VP	DT	Small molecular drug
DM9Z6VP	PC	10643561
DM9Z6VP	MW	381.5
DM9Z6VP	FM	C23H27NO4
DM9Z6VP	IC	InChI=1S/C23H27NO4/c1-13(2)11-24-8-7-15-16-6-5-14-9-19(25)20(27-3)10-17(14)21(16)23(28-4)22(26)18(15)12-24/h5-6,9-10,13,25-26H,7-8,11-12H2,1-4H3
DM9Z6VP	CS	CC(C)CN1CCC2=C3C=CC4=CC(=C(C=C4C3=C(C(=C2C1)O)OC)OC)O
DM9Z6VP	IK	WKTMDLQZTZEUIG-UHFFFAOYSA-N
DM9Z6VP	IU	9,11-dimethoxy-2-(2-methylpropyl)-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DM9Z6VP	DE	Discovery agent

DMN1FIU	ID	DMN1FIU
DMN1FIU	DN	N-isobutylnoroxymorphone
DMN1FIU	HS	Investigative
DMN1FIU	SN	N-isobutylnoroxymorphone; CHEMBL490418; 17-Isobutyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; SCHEMBL3835355; OEQLILQNMUXCHV-XFWGSAIBSA-N
DMN1FIU	DT	Small molecular drug
DMN1FIU	PC	25178033
DMN1FIU	MW	343.4
DMN1FIU	FM	C20H25NO4
DMN1FIU	IC	InChI=1S/C20H25NO4/c1-11(2)10-21-8-7-19-16-12-3-4-13(22)17(16)25-18(19)14(23)5-6-20(19,24)15(21)9-12/h3-4,11,15,18,22,24H,5-10H2,1-2H3/t15-,18+,19+,20-/m1/s1
DMN1FIU	CS	CC(C)CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
DMN1FIU	IK	OEQLILQNMUXCHV-XFWGSAIBSA-N
DMN1FIU	IU	(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-(2-methylpropyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMN1FIU	DE	Discovery agent

DM53AS0	ID	DM53AS0
DM53AS0	DN	N-isoleucylthiazolidine
DM53AS0	HS	Investigative
DM53AS0	SN	UNII-SDH8E9EM4L; SDH8E9EM4L; CHEMBL98408; 1-Pentanone, 2-amino-3-methyl-1-(3-thiazolidinyl)-, (2S,3S)-; thiazolidide 2; AC1OCFGU; 3-(L-Ile-)Thiazolidine; BMCL15687 Compound 4; (S)-Isoleucine Thiazolidide; SCHEMBL353709; BDBM11464; ZINC3931585
DM53AS0	DT	Small molecular drug
DM53AS0	PC	6918465
DM53AS0	MW	202.32
DM53AS0	FM	C9H18N2OS
DM53AS0	IC	InChI=1S/C9H18N2OS/c1-3-7(2)8(10)9(12)11-4-5-13-6-11/h7-8H,3-6,10H2,1-2H3/t7-,8-/m0/s1
DM53AS0	CS	CC[C@H](C)[C@@H](C(=O)N1CCSC1)N
DM53AS0	IK	WCRLBFHWFPELKW-YUMQZZPRSA-N
DM53AS0	IU	(2S,3S)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one
DM53AS0	CA	CAS 136259-20-6
DM53AS0	DE	Discovery agent

DMC8L4J	ID	DMC8L4J
DMC8L4J	DN	N-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide
DMC8L4J	HS	Investigative
DMC8L4J	SN	CHEMBL246478; N-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide
DMC8L4J	DT	Small molecular drug
DMC8L4J	PC	44440709
DMC8L4J	MW	373.5
DMC8L4J	FM	C24H27N3O
DMC8L4J	IC	InChI=1S/C24H27N3O/c1-16(2)13-14-25-24(28)21-15-26-22(19-9-5-17(3)6-10-19)23(27-21)20-11-7-18(4)8-12-20/h5-12,15-16H,13-14H2,1-4H3,(H,25,28)
DMC8L4J	CS	CC1=CC=C(C=C1)C2=NC=C(N=C2C3=CC=C(C=C3)C)C(=O)NCCC(C)C
DMC8L4J	IK	DGPFCWKIBMZBAP-UHFFFAOYSA-N
DMC8L4J	IU	N-(3-methylbutyl)-5,6-bis(4-methylphenyl)pyrazine-2-carboxamide
DMC8L4J	DE	Discovery agent

DMFSW5M	ID	DMFSW5M
DMFSW5M	DN	N-isopropyl estradiol-16-carboxamide
DMFSW5M	HS	Investigative
DMFSW5M	SN	SCHEMBL12379487
DMFSW5M	DT	Small molecular drug
DMFSW5M	PC	44407333
DMFSW5M	MW	357.5
DMFSW5M	FM	C22H31NO3
DMFSW5M	IC	InChI=1S/C22H31NO3/c1-12(2)23-21(26)18-11-19-17-6-4-13-10-14(24)5-7-15(13)16(17)8-9-22(19,3)20(18)25/h5,7,10,12,16-20,24-25H,4,6,8-9,11H2,1-3H3,(H,23,26)/t16?,17?,18?,19?,20-,22-/m0/s1
DMFSW5M	CS	CC(C)NC(=O)C1CC2C3CCC4=C(C3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DMFSW5M	IK	MIXZPWBCEXVAQM-GFEBWMDQSA-N
DMFSW5M	IU	(13S,17S)-3,17-dihydroxy-13-methyl-N-propan-2-yl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DMFSW5M	DE	Discovery agent

DMHJMTI	ID	DMHJMTI
DMHJMTI	DN	N-isopropyl estradiol-16-methyl carboxamide
DMHJMTI	HS	Investigative
DMHJMTI	SN	SCHEMBL12379570
DMHJMTI	DT	Small molecular drug
DMHJMTI	PC	44407579
DMHJMTI	MW	371.5
DMHJMTI	FM	C23H33NO3
DMHJMTI	IC	InChI=1S/C23H33NO3/c1-13(2)24-21(26)12-15-11-20-19-6-4-14-10-16(25)5-7-17(14)18(19)8-9-23(20,3)22(15)27/h5,7,10,13,15,18-20,22,25,27H,4,6,8-9,11-12H2,1-3H3,(H,24,26)/t15?,18?,19?,20?,22-,23-/m0/s1
DMHJMTI	CS	CC(C)NC(=O)CC1CC2C3CCC4=C(C3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DMHJMTI	IK	FKSICUOFJYPFSV-XWFZVRCUSA-N
DMHJMTI	IU	2-[(13S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]-N-propan-2-ylacetamide
DMHJMTI	DE	Discovery agent

DMZGMQJ	ID	DMZGMQJ
DMZGMQJ	DN	N-isopropyl estrone-16-methyl carboxamide
DMZGMQJ	HS	Investigative
DMZGMQJ	SN	SCHEMBL12379559
DMZGMQJ	DT	Small molecular drug
DMZGMQJ	PC	44407487
DMZGMQJ	MW	369.5
DMZGMQJ	FM	C23H31NO3
DMZGMQJ	IC	InChI=1S/C23H31NO3/c1-13(2)24-21(26)12-15-11-20-19-6-4-14-10-16(25)5-7-17(14)18(19)8-9-23(20,3)22(15)27/h5,7,10,13,15,18-20,25H,4,6,8-9,11-12H2,1-3H3,(H,24,26)/t15?,18?,19?,20?,23-/m0/s1
DMZGMQJ	CS	CC(C)NC(=O)CC1CC2C3CCC4=C(C3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMZGMQJ	IK	OHQDRZHZEKGJSZ-OOGUNDJRSA-N
DMZGMQJ	IU	2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]-N-propan-2-ylacetamide
DMZGMQJ	DE	Discovery agent

DM14L7O	ID	DM14L7O
DM14L7O	DN	N-Isopropyl-1'H-phenothiazine-1'-carboxamide
DM14L7O	HS	Investigative
DM14L7O	SN	CHEMBL592185; N-isopropyl-10H-phenothiazine-10-carboxamide; N-propan-2-ylphenothiazine-10-carboxamide; Oprea1_607910; MLS001196405; ARONIS009672; AC1LE088; SCHEMBL11315494; ZINC88005; MolPort-000-803-539; MolPort-019-786-000; HMS1587K22; HMS2859K14; STK126366; BDBM50308429; AKOS000498951; MCULE-3571561994; CCG-113325; SMR000556300; 81225-58-3; BB0286649; N-(methylethyl)phenothiazin-10-ylcarboxamide; EU-0046799; ST45046412; KS-00004187; N-Isopropyl-1''H-phenothiazine-1''-carboxamide; AN-329/41195442
DM14L7O	DT	Small molecular drug
DM14L7O	PC	704259
DM14L7O	MW	284.4
DM14L7O	FM	C16H16N2OS
DM14L7O	IC	InChI=1S/C16H16N2OS/c1-11(2)17-16(19)18-12-7-3-5-9-14(12)20-15-10-6-4-8-13(15)18/h3-11H,1-2H3,(H,17,19)
DM14L7O	CS	CC(C)NC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM14L7O	IK	DIHZRSIYRBANNR-UHFFFAOYSA-N
DM14L7O	IU	N-propan-2-ylphenothiazine-10-carboxamide
DM14L7O	DE	Discovery agent

DMRPUCA	ID	DMRPUCA
DMRPUCA	DN	N-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide
DMRPUCA	HS	Investigative
DMRPUCA	SN	CHEMBL246477; N-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide
DMRPUCA	DT	Small molecular drug
DMRPUCA	PC	44440708
DMRPUCA	MW	345.4
DMRPUCA	FM	C22H23N3O
DMRPUCA	IC	InChI=1S/C22H23N3O/c1-14(2)24-22(26)19-13-23-20(17-9-5-15(3)6-10-17)21(25-19)18-11-7-16(4)8-12-18/h5-14H,1-4H3,(H,24,26)
DMRPUCA	CS	CC1=CC=C(C=C1)C2=NC=C(N=C2C3=CC=C(C=C3)C)C(=O)NC(C)C
DMRPUCA	IK	IZKDGGVGSMLFPW-UHFFFAOYSA-N
DMRPUCA	IU	5,6-bis(4-methylphenyl)-N-propan-2-ylpyrazine-2-carboxamide
DMRPUCA	DE	Discovery agent

DMIVO8P	ID	DMIVO8P
DMIVO8P	DN	N-Isopropyl-N'-Hydroxyguanidine
DMIVO8P	HS	Investigative
DMIVO8P	SN	N-ISOPROPYL-N'-HYDROXYGUANIDINE; N-HYDROXY-N'-ISOPROPYLGUANIDIE; 478806-77-8; IHG; AC1L9KDY; SCHEMBL564061; CHEMBL72434; 1-hydroxy-3-isopropylguanidine; SCHEMBL15424726; 1-hydroxy-2-propan-2-ylguanidine; (E)-2-hydroxy-1-isopropylguanidine; ZINC13535998; 2-hydroxy-1-(propan-2-yl)guanidine; AKOS017475215; AKOS011771464; 1-hydroxy-3-(1-methylethyl)guanidine; DB02143; ACM478806778
DMIVO8P	DT	Small molecular drug
DMIVO8P	PC	447029
DMIVO8P	MW	117.15
DMIVO8P	FM	C4H11N3O
DMIVO8P	IC	InChI=1S/C4H11N3O/c1-3(2)6-4(5)7-8/h3,8H,1-2H3,(H3,5,6,7)
DMIVO8P	CS	CC(C)N=C(N)NO
DMIVO8P	IK	OITVEDMMUMUWTL-UHFFFAOYSA-N
DMIVO8P	IU	1-hydroxy-2-propan-2-ylguanidine
DMIVO8P	CA	CAS 478806-77-8
DMIVO8P	DE	Discovery agent

DMG8NB0	ID	DMG8NB0
DMG8NB0	DN	N-isopropylnorlitebamine
DMG8NB0	HS	Investigative
DMG8NB0	SN	N-isopropylnorlitebamine; CHEMBL516841; BDBM50250454
DMG8NB0	DT	Small molecular drug
DMG8NB0	PC	10666657
DMG8NB0	MW	367.4
DMG8NB0	FM	C22H25NO4
DMG8NB0	IC	InChI=1S/C22H25NO4/c1-12(2)23-8-7-14-15-6-5-13-9-18(24)19(26-3)10-16(13)20(15)22(27-4)21(25)17(14)11-23/h5-6,9-10,12,24-25H,7-8,11H2,1-4H3
DMG8NB0	CS	CC(C)N1CCC2=C3C=CC4=CC(=C(C=C4C3=C(C(=C2C1)O)OC)OC)O
DMG8NB0	IK	AWJWBWOWUNPLTO-UHFFFAOYSA-N
DMG8NB0	IU	9,11-dimethoxy-2-propan-2-yl-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DMG8NB0	DE	Discovery agent

DMDVO9T	ID	DMDVO9T
DMDVO9T	DN	N-isopropylnorlitebamineN-methoiodide
DMDVO9T	HS	Investigative
DMDVO9T	SN	N-isopropylnorlitebamineN-methoiodide
DMDVO9T	DT	Small molecular drug
DMDVO9T	PC	10815529
DMDVO9T	MW	509.4
DMDVO9T	FM	C23H28INO4
DMDVO9T	IC	InChI=1S/C23H27NO4.HI/c1-5-9-24(2)10-8-15-16-7-6-14-11-19(25)20(27-3)12-17(14)21(16)23(28-4)22(26)18(15)13-24;/h6-7,11-12H,5,8-10,13H2,1-4H3,(H-,25,26);1H
DMDVO9T	CS	CCC[N+]1(CCC2=C3C=CC4=CC(=C(C=C4C3=C(C(=C2C1)O)OC)OC)O)C.[I-]
DMDVO9T	IK	ATOFDXKLKQOFOQ-UHFFFAOYSA-N
DMDVO9T	IU	9,11-dimethoxy-2-methyl-2-propyl-3,4-dihydro-1H-naphtho[2,1-f]isoquinolin-2-ium-8,12-diol;iodide
DMDVO9T	DE	Discovery agent

DMZBNH0	ID	DMZBNH0
DMZBNH0	DN	Nisoxetine
DMZBNH0	HS	Investigative
DMZBNH0	SN	Nisoxetine; 3-(2-Methoxyphenoxy)-N-methyl-3-phenylpropylamine; Compound 89218; 3-(2-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine; Nisoxetine [USAN:INN]; 3-(o-Methoxyphenoxy)-N-methyl-3-phenylpropylamine; N-Methyl-gamma-(2-methylphenoxy)phenylpropanolamine; Lilly 94939; 57226-61-6; DL-N-Methyl-3-(o-methoxyphenoxy)-N-methyl-3-phenylpropylamine; CHEMBL295467; 53179-07-0; CHEBI:73410; ITJNARMNRKSWTA-UHFFFAOYSA-N; 57754-86-6; NCGC00015715-04; Nisoxetine Inhibitor; DSSTox_RID_80724; DSSTox_CID_25175; DSSTox_GSID_45175
DMZBNH0	DT	Small molecular drug
DMZBNH0	PC	4500
DMZBNH0	MW	271.35
DMZBNH0	FM	C17H21NO2
DMZBNH0	IC	InChI=1S/C17H21NO2/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2/h3-11,15,18H,12-13H2,1-2H3
DMZBNH0	CS	CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC
DMZBNH0	IK	ITJNARMNRKSWTA-UHFFFAOYSA-N
DMZBNH0	IU	3-(2-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine
DMZBNH0	CA	CAS 53179-07-0
DMZBNH0	CB	CHEBI:73410
DMZBNH0	DE	Discovery agent

DMY59KQ	ID	DMY59KQ
DMY59KQ	DN	Nitracrine
DMY59KQ	HS	Investigative
DMY59KQ	SN	4533-39-5; Nitracrine [INN]; Nitracrinum [INN-Latin]; Nitracrina [INN-Spanish]; UNII-712MLZ30SB; CCRIS 1973; 712MLZ30SB; 1-Nitro-9-(dimethylaminopropylamino)acridine; C18H20N4O2; 1-Nitro-9-(3'-dimethylaminopropylamino)-acridine; 9-((3-(Dimethylamino)propyl)amino)-1-nitroacridine; Nitracrinum; Nitracrina; N',N'-dimethyl-N-(1-nitroacridin-9-yl)propane-1,3-diamine; ACRIDINE, 9-(3-(DIMETHYLAMINO)PROPYLAMINO)-1-NITRO-; 1,3-Propanediamine, N,N-dimethyl-N'-
DMY59KQ	DT	Small molecular drug
DMY59KQ	PC	20628
DMY59KQ	MW	324.4
DMY59KQ	FM	C18H20N4O2
DMY59KQ	IC	InChI=1S/C18H20N4O2/c1-21(2)12-6-11-19-18-13-7-3-4-8-14(13)20-15-9-5-10-16(17(15)18)22(23)24/h3-5,7-10H,6,11-12H2,1-2H3,(H,19,20)
DMY59KQ	CS	CN(C)CCCNC1=C2C(=NC3=CC=CC=C31)C=CC=C2[N+](=O)[O-]
DMY59KQ	IK	YMVWGSQGCWCDGW-UHFFFAOYSA-N
DMY59KQ	IU	N',N'-dimethyl-N-(1-nitroacridin-9-yl)propane-1,3-diamine
DMY59KQ	CA	CAS 4533-39-5
DMY59KQ	CB	CHEBI:135384
DMY59KQ	DE	Discovery agent

DMVDM0Q	ID	DMVDM0Q
DMVDM0Q	DN	NITRAQUAZONE
DMVDM0Q	HS	Investigative
DMVDM0Q	SN	Nitraquazone; UNII-1YF1KXP4QF; 1YF1KXP4QF; 56739-21-0; Nitraquazonum; Nitraquazona; nitraquazone[inn]; Nitraquazone [INN]; Nitraquazonum [Latin]; Nitraquazona [Spanish]; AC1L2AEJ; CHEMBL88990; SCHEMBL125623; ZINC1819; AC1Q21K9; GNWCRBFQZDJFTI-UHFFFAOYSA-N; BDBM50218545; 3-ethyl-1-(3-nitrophenyl)quinazoline-2,4-dione; 3-Ethyl-1-(m-nitrophenyl)-2,4(1H,3H)-quinazolinedione; 1-(m-nitrophenyl)-3-ethylquinazoline-2,4 (1H, 3H)-dione; 1-(m-nitrophenyl)- 3-ethylquinazoline-2,4(1H, 3H)-dione; 1-(m-nitrophenyl)-3-ethylquinazoline-2,4(1H, 
DMVDM0Q	DT	Small molecular drug
DMVDM0Q	PC	68765
DMVDM0Q	MW	311.29
DMVDM0Q	FM	C16H13N3O4
DMVDM0Q	IC	InChI=1S/C16H13N3O4/c1-2-17-15(20)13-8-3-4-9-14(13)18(16(17)21)11-6-5-7-12(10-11)19(22)23/h3-10H,2H2,1H3
DMVDM0Q	CS	CCN1C(=O)C2=CC=CC=C2N(C1=O)C3=CC(=CC=C3)[N+](=O)[O-]
DMVDM0Q	IK	GNWCRBFQZDJFTI-UHFFFAOYSA-N
DMVDM0Q	IU	3-ethyl-1-(3-nitrophenyl)quinazoline-2,4-dione
DMVDM0Q	CA	CAS 56739-21-0
DMVDM0Q	DE	Discovery agent

DMVFB93	ID	DMVFB93
DMVFB93	DN	Nitrate
DMVFB93	HS	Investigative
DMVFB93	SN	nitrate; NITRATE ION; 14797-55-8; Nitrate(1-); UNII-T93E9Y2844; Nitrate(6CI,7CI,8CI,9CI); UN3218; CHEMBL186200; NO3-; Nitrates; CHEBI:17632; T93E9Y2844; NO3; trioxidonitrate; trioxonitrate; nitrooxidane; trioxonitrate(V); trioxonitrate(1-); trioxidonitrate(1-); AC1L1ADK; Nitrates, inorganic, n.o.s.; CTK0H4660; BDBM26988; NHNBFGGVMKEFGY-UHFFFAOYSA-N; 84145-82-4 (Parent); NO3(-); AKOS015904030; MCULE-5142506228; [NO3](-); Nitrates, inorganic, aqueous solution, n.o.s.; I14-18318; Nitrates, inorganic, n.o.s. [UN1447]  [Oxidizer]; Nitrates, in
DMVFB93	DT	Small molecular drug
DMVFB93	PC	943
DMVFB93	MW	62.005
DMVFB93	FM	NO3-
DMVFB93	IC	InChI=1S/NO3/c2-1(3)4/q-1
DMVFB93	CS	[N+](=O)([O-])[O-]
DMVFB93	IK	NHNBFGGVMKEFGY-UHFFFAOYSA-N
DMVFB93	IU	nitrate
DMVFB93	CB	CHEBI:17632
DMVFB93	DE	Discovery agent

DMIOQFU	ID	DMIOQFU
DMIOQFU	DN	Nitrilotriacetic Acid
DMIOQFU	HS	Investigative
DMIOQFU	SN	NITRILOTRIACETIC ACID; 139-13-9; 2,2',2''-nitrilotriacetic acid; Triglycollamic acid; Aminotriacetic acid; Nitrilotriacetate; Complexon I; Trilon A; N,N-Bis(carboxymethyl)glycine; Titriplex I; Komplexon I; NTA; Versene NTA acid; Nitrilotriessigsaeure; Hampshire NTA acid; Nitriloacetate; 2-[bis(carboxymethyl)amino]acetic acid; Glycine, N,N-bis(carboxymethyl)-; Tri(carboxymethyl)amine; Tris(carboxymethyl)amine; Acetic acid, nitrilotri-; CHEL 300; NCI-C02766; Nitrilo-2,2',2''-triacetic acid; Nitrilotriacetic acid (NTA); CCRIS 436
DMIOQFU	DT	Small molecular drug
DMIOQFU	PC	8758
DMIOQFU	MW	191.14
DMIOQFU	FM	C6H9NO6
DMIOQFU	IC	InChI=1S/C6H9NO6/c8-4(9)1-7(2-5(10)11)3-6(12)13/h1-3H2,(H,8,9)(H,10,11)(H,12,13)
DMIOQFU	CS	C(C(=O)O)N(CC(=O)O)CC(=O)O
DMIOQFU	IK	MGFYIUFZLHCRTH-UHFFFAOYSA-N
DMIOQFU	IU	2-[bis(carboxymethyl)amino]acetic acid
DMIOQFU	CA	CAS 139-13-9
DMIOQFU	CB	CHEBI:44557
DMIOQFU	DE	Discovery agent

DMR5XT3	ID	DMR5XT3
DMR5XT3	DN	Nitrite
DMR5XT3	HS	Investigative
DMR5XT3	SN	LS-193697; NO2(-); Nitrit; Nitrite (8CI,9CI); Nitrite Ion; Nitrite anion; Nitrite ion (NO2-); Nitrite(1-); Nitrites; Nitrogen Oxide Anion; Nitrogen dioxide ion(1-); Nitrogen peroxide ion(1-); Nitrous acid, ion(1-); dioxidonitrate(1-); dioxonitrate(1-); dioxonitrate(III); nitrite; 14797-65-0; 1937AH; AB01566909_01; AC1L1ADT; BDBM26989; CHEBI:16301; CHEMBL1361; CTK0H5378; DB12529; DTXSID5024219; MFCD00144923; NCGC00090737-03; NCGC00090737-04; NO2; NO2-; ONO-; UNII-J39976L608; IOVCWXUNBOPUCH-UHFFFAOYSA-M; J39976L608; [NO2](-)
DMR5XT3	PC	946
DMR5XT3	MW	46.006
DMR5XT3	FM	NO2-
DMR5XT3	IC	IOVCWXUNBOPUCH-UHFFFAOYSA-M
DMR5XT3	CS	N(=O)[O-]
DMR5XT3	IK	1S/HNO2/c2-1-3/h(H,2,3)/p-1
DMR5XT3	IU	nitrite
DMR5XT3	CA	CAS 14797-65-0
DMR5XT3	CB	CHEBI:16301
DMR5XT3	DE	Discovery agent

DM7T80N	ID	DM7T80N
DM7T80N	DN	Nitroarginine
DM7T80N	HS	Investigative
DM7T80N	SN	Arginine, N(G)-nitro-; L-Ornithine, N5-[imino(nitroamino)methyl]-; C6H13N5O4; omega-Nitroarginine; .omega.-Nitroarginine; Arginine, omega-nitro-; N(G)-Methyl-L-arginine; L-Ornithine, N5-(imino(nitroamino)methyl)-; Arginine, .omega.-nitro-; N(sup G)-Nitro-L-arginine; Arginine, omega-nitro-, L-; nitroarginin; EINECS 218-418-9; n5-(n-nitrocarbamimidoyl)ornithine; Dl-Nitro Arginine; NO2Arg; AI3-62168; NOARG; Norvaline, (+)-; N(omega)-Nitroarginine
DM7T80N	DT	Small molecular drug
DM7T80N	PC	440005
DM7T80N	MW	219.2
DM7T80N	FM	C6H13N5O4
DM7T80N	IC	InChI=1S/C6H13N5O4/c7-4(5(12)13)2-1-3-9-6(8)10-11(14)15/h4H,1-3,7H2,(H,12,13)(H3,8,9,10)/t4-/m0/s1
DM7T80N	CS	C(C[C@@H](C(=O)O)N)CN=C(N)N[N+](=O)[O-]
DM7T80N	IK	MRAUNPAHJZDYCK-BYPYZUCNSA-N
DM7T80N	IU	(2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoic acid
DM7T80N	CA	CAS 2149-70-4
DM7T80N	CB	CHEBI:27960

DM4UHB5	ID	DM4UHB5
DM4UHB5	DN	Nitrobenzaldehyde
DM4UHB5	HS	Investigative
DM4UHB5	SN	Benzaldehyde, 4-nitro-; 4-Nitrobenzaldehyde; Benzaldehyde, p-nitro-; NX859P8MB0; p-Formylnitrobenzene; p-Nitrobenzaldehyde; p-nitro benzaldehyde; p-nitro-benzaldehyde; para-nitrobenzaldehyde; paranitrobenzaldehyde; 4-FORMYLNITROBENZENE; 4-Nitro-benzaldehyde; 4-Nitrobenzaldehydde; 4-Nitrobenzaldehyde, 99%; 4-nitro benzaldehyde; 4-nitrobenz aldehyde; 4-nitrobenzaldehyd; 4-nitrobenzaldehyde; 4-nitrobenzaldhyde; 555-16-8; AI3-52475; BXRFQSNOROATLV-UHFFFAOYSA-N; CCRIS 1675; CHEBI:66926; EINECS 209-084-5; MFCD00007346; NSC 6103; UNII-NX859P8MB0; XXH
DM4UHB5	PC	541
DM4UHB5	MW	151.12
DM4UHB5	FM	C7H5NO3
DM4UHB5	IC	BXRFQSNOROATLV-UHFFFAOYSA-N
DM4UHB5	CS	C1=CC(=CC=C1C=O)[N+](=O)[O-]
DM4UHB5	IK	1S/C7H5NO3/c9-5-6-1-3-7(4-2-6)8(10)11/h1-5H
DM4UHB5	IU	4-nitrobenzaldehyde
DM4UHB5	CA	CAS 555-16-8
DM4UHB5	CB	CHEBI:66926
DM4UHB5	DE	Discovery agent

DMN6L70	ID	DMN6L70
DMN6L70	DN	Nitrobenzanthrone
DMN6L70	HS	Investigative
DMN6L70	SN	3-Nitrobenzanthrone; LS-27953; O4OJW7BC7W; QAJOWHGESRCVLY-UHFFFAOYSA-N; SCHEMBL7168071; ZINC4370589; 17117-34-9; 3-Nitro-7H-benz(de)anthracen-7-one; 3-Nitro-7H-benzo[d,e]anthracen-7-one; 3-Nitrobenzantrone; 3-nitro-7H-benzo[de]anthracen-7-one; 3-nitrobenzo[b]phenalen-7-one; 7H-Benz(de)anthracen-7-one, 3-nitro-; AC1MCTJK; ACM17117349; CCRIS 9003; DTXSID60881271; FT-0710181; UNII-O4OJW7BC7W
DMN6L70	PC	2825690
DMN6L70	MW	275.26
DMN6L70	FM	C17H9NO3
DMN6L70	IC	QAJOWHGESRCVLY-UHFFFAOYSA-N
DMN6L70	CS	C1=CC=C2C(=C1)C3=C4C(=C(C=C3)[N+](=O)[O-])C=CC=C4C2=O
DMN6L70	IK	1S/C17H9NO3/c19-17-12-5-2-1-4-10(12)11-8-9-15(18(20)21)13-6-3-7-14(17)16(11)13/h1-9H
DMN6L70	IU	3-nitrobenzo[b]phenalen-7-one
DMN6L70	CA	CAS 17117-34-9
DMN6L70	DE	Discovery agent

DM6FVHC	ID	DM6FVHC
DM6FVHC	DN	Nitrobenzoate
DM6FVHC	HS	Investigative
DM6FVHC	SN	P-nitrobenzoate; 4-Nitrobenzoate; OTLNPYWUJOZPPA-UHFFFAOYSA-M; SCHEMBL187708; p-nitrophenylformate; 4-nitrobenzoate; 4NBZate; 7227-54-5; BDBM50340073; CHEBI:142863; CHEMBL1762655; DTXSID20403094
DM6FVHC	PC	4419940
DM6FVHC	MW	166.11
DM6FVHC	FM	C7H4NO4-
DM6FVHC	IC	OTLNPYWUJOZPPA-UHFFFAOYSA-M
DM6FVHC	CS	C1=CC(=CC=C1C(=O)[O-])[N+](=O)[O-]
DM6FVHC	IK	1S/C7H5NO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4H,(H,9,10)/p-1
DM6FVHC	IU	4-nitrobenzoate
DM6FVHC	CA	CAS 7227-54-5
DM6FVHC	CB	CHEBI:142863
DM6FVHC	DE	Discovery agent

DM254EW	ID	DM254EW
DM254EW	DN	Nitrobenzodiazepine
DM254EW	HS	Investigative
DM254EW	SN	nitrobenzodiazepine; NBDZ
DM254EW	PC	25022001
DM254EW	MW	189.17
DM254EW	FM	C9H7N3O2
DM254EW	IC	VMGLACFXZWXTMP-UHFFFAOYSA-N
DM254EW	CS	C1=CC=C2C(=C1)C=CC(=NN2)[N+](=O)[O-]
DM254EW	IK	1S/C9H7N3O2/c13-12(14)9-6-5-7-3-1-2-4-8(7)10-11-9/h1-6,10H
DM254EW	IU	3-nitro-1H-1,2-benzodiazepine
DM254EW	DE	Discovery agent

DM7F3RY	ID	DM7F3RY
DM7F3RY	DN	Nitrobenzylthioinosine
DM7F3RY	HS	Investigative
DM7F3RY	SN	Oprea1_621177; ZINC13818312; AC1Q1ZDM; AC1L1JO9; SCHEMBL290702; CHEMBL306550; 4-Nitrobenzyl-6-mercaptoinosine; 6-[(4-nitrobenzyl)sulfanyl]-9-pentofuranosyl-9h-purine; CTK8G3023; MolPort-003-721-850; HMS3370O01; AKOS021983903; MCULE-8321028996; TRA0060654; S-(p-NITROBENZYL)-6-THIOINOSINE; NCGC00163303-01; NCGC00015732-02; ST085314; S-(4-Nitrobenzyl)-6-thioinosine (NBTI, NBMPR); SR-01000393938; SR-01000393938-1; 6-[(4-nitrobenzyl)thio]-9- beta-D
DM7F3RY	DT	Small molecular drug
DM7F3RY	PC	5129
DM7F3RY	MW	419.4
DM7F3RY	FM	C17H17N5O6S
DM7F3RY	IC	InChI=1S/C17H17N5O6S/c23-5-11-13(24)14(25)17(28-11)21-8-20-12-15(21)18-7-19-16(12)29-6-9-1-3-10(4-2-9)22(26)27/h1-4,7-8,11,13-14,17,23-25H,5-6H2
DM7F3RY	CS	C1=CC(=CC=C1CSC2=NC=NC3=C2N=CN3C4C(C(C(O4)CO)O)O)[N+](=O)[O-]
DM7F3RY	IK	DYCJFJRCWPVDHY-UHFFFAOYSA-N
DM7F3RY	IU	2-(hydroxymethyl)-5-[6-[(4-nitrophenyl)methylsulfanyl]purin-9-yl]oxolane-3,4-diol
DM7F3RY	CA	CAS 38048-32-7
DM7F3RY	DE	Discovery agent

DMGUNIL	ID	DMGUNIL
DMGUNIL	DN	Nitrocatechol sulfate
DMGUNIL	HS	Investigative
DMGUNIL	SN	Para-Nitrocatechol sulfate; 4-Nitrocatechol sulfate; (2-hydroxy-5-nitrophenyl) hydrogen sulfate; (2-hydroxy-5-nitrophenyl)oxidanesulfonic acid; 1pa9; 2-HYDROXY-5-NITROPHENOL SULFATE, K SALT; 2-Hydroxy-5-nitrophenyl sulfate; 2-hydroxy-5-nitrophenyl hydrogen sulfate; 4-Nitro-1,2-benzenediol, 2-(hydrogen sulfate); 4-Nitrocatechol 2-sulfate; AC1L4XH3; AC1Q6XY7; CHEBI:41733; CSN; CTK4C4465; DB01800; DTXSID50146785; N,4-DIHYDROXY-N-OXO-3-(SULFOOXY)BENZENAMINIUM; UNII-HD9MHQ536A; HD9MHQ536A; SCHEMBL4308319; ZINC2046903
DMGUNIL	PC	165879
DMGUNIL	MW	235.17
DMGUNIL	FM	C6H5NO7S
DMGUNIL	IC	XMCCOOONGGUOLA-UHFFFAOYSA-N
DMGUNIL	CS	C1=CC(=C(C=C1[N+](=O)[O-])OS(=O)(=O)O)O
DMGUNIL	IK	1S/C6H5NO7S/c8-5-2-1-4(7(9)10)3-6(5)14-15(11,12)13/h1-3,8H,(H,11,12,13)
DMGUNIL	IU	(2-hydroxy-5-nitrophenyl) hydrogen sulfate
DMGUNIL	CA	CAS 10485-66-2
DMGUNIL	CB	CHEBI:41733
DMGUNIL	DE	Discovery agent

DM7M5VY	ID	DM7M5VY
DM7M5VY	DN	NITROCEFIN
DM7M5VY	HS	Investigative
DM7M5VY	DE	Discovery agent

DMWCV48	ID	DMWCV48
DMWCV48	DN	Nitroflurbiprofen
DMWCV48	HS	Investigative
DMWCV48	SN	Flurbinitroxybutylester; Flurbiprofen nitroxybutylester; HCT 1026; NO-flurbiprofen
DMWCV48	DT	Small molecular drug
DMWCV48	PC	119387
DMWCV48	MW	361.4
DMWCV48	FM	C19H20FNO5
DMWCV48	IC	InChI=1S/C19H20FNO5/c1-14(19(22)25-11-5-6-12-26-21(23)24)16-9-10-17(18(20)13-16)15-7-3-2-4-8-15/h2-4,7-10,13-14H,5-6,11-12H2,1H3
DMWCV48	CS	CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)OCCCCO[N+](=O)[O-]
DMWCV48	IK	DLWSRGHNJVLJAH-UHFFFAOYSA-N
DMWCV48	IU	4-nitrooxybutyl 2-(3-fluoro-4-phenylphenyl)propanoate
DMWCV48	CA	CAS 158836-71-6
DMWCV48	CB	CHEBI:77428
DMWCV48	DE	Discovery agent

DMMY2S5	ID	DMMY2S5
DMMY2S5	DN	Nitroimidazole
DMMY2S5	HS	Investigative
DMMY2S5	SN	Nitroimidazole compounds (infection)
DMMY2S5	CP	The Global Alliance for TB Drug Development
DMMY2S5	DT	Small molecular drug
DMMY2S5	PC	10701
DMMY2S5	MW	113.08
DMMY2S5	FM	C3H3N3O2
DMMY2S5	IC	InChI=1S/C3H3N3O2/c7-6(8)3-4-1-2-5-3/h1-2H,(H,4,5)
DMMY2S5	CS	C1=CN=C(N1)[N+](=O)[O-]
DMMY2S5	IK	YZEUHQHUFTYLPH-UHFFFAOYSA-N
DMMY2S5	IU	2-nitro-1H-imidazole
DMMY2S5	CA	CAS 527-73-1
DMMY2S5	CB	CHEBI:67135
DMMY2S5	DE	Trypanosomiasis

DMHSD8A	ID	DMHSD8A
DMHSD8A	DN	Nitrophenyl acetate
DMHSD8A	HS	Investigative
DMHSD8A	SN	Aceticacid,P-Nitrophenylester; 4-Nitrophenyl acetate; P-NITROPHENYL ACETATE; QAUUDNIGJSLPSX-UHFFFAOYSA-N; p-Acetoxynitrobenzene; p-Nitrobenzene acetate; p-Nitrophenol acetate; p-Nitrophenyl acetate (VAN); para-nitrophenyl acetate; (4-nitrophenyl) acetate; 4-Nitrophenyl acetate, 97%; 830-03-5; AI3-00496; Acetic acid 4-nitrophenyl ester; Acetic acid p-nitrophenyl ester; Acetic acid, 4-nitrophenyl ester; Acetic acid, p-nitrophenyl ester; BRN 0515874; CHEBI:82635; EINECS 212-593-5; I902J0QH9S; MFCD00007326; NSC 2633; UNII-I902J0QH9S
DMHSD8A	PC	13243
DMHSD8A	MW	181.15
DMHSD8A	FM	C8H7NO4
DMHSD8A	IC	QAUUDNIGJSLPSX-UHFFFAOYSA-N
DMHSD8A	CS	CC(=O)OC1=CC=C(C=C1)[N+](=O)[O-]
DMHSD8A	IK	1S/C8H7NO4/c1-6(10)13-8-4-2-7(3-5-8)9(11)12/h2-5H,1H3
DMHSD8A	IU	(4-nitrophenyl) acetate
DMHSD8A	CA	CAS 830-03-5
DMHSD8A	CB	CHEBI:82635
DMHSD8A	DE	Discovery agent

DMZ9WI4	ID	DMZ9WI4
DMZ9WI4	DN	Nitrosoglutathione
DMZ9WI4	HS	Investigative
DMZ9WI4	SN	Glutathione thionitrite; Nitrosoglutathione; S-nitrosoglutathione; S-NITROSO-L-GLUTATHIONE; (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-(nitrososulfanyl)ethyl]carbamoyl}butanoic acid; (S)-2-Amino-5-(((R)-1-((carboxymethyl)amino)-3-(nitrosothio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid; 57564-91-7; 78RRI89ZTO; BRN 3566211; C10H16N4O7S; CCRIS 2095; CHEBI:50091; Glycine, N-(N-L-gamma-glutamyl-S-nitroso-L-cysteinyl)-; N-(N-L-gamma-Glutamyl-S-nitroso-L-cysteinyl)glycine; SNOG; UNII-78RRI89ZTO; gsno
DMZ9WI4	PC	104858
DMZ9WI4	MW	336.32
DMZ9WI4	FM	C10H16N4O7S
DMZ9WI4	IC	HYHSBSXUHZOYLX-WDSKDSINSA-N
DMZ9WI4	CS	C(CC(=O)NC(CSN=O)C(=O)NCC(=O)O)C(C(=O)O)N
DMZ9WI4	IK	1S/C10H16N4O7S/c11-5(10(19)20)1-2-7(15)13-6(4-22-14-21)9(18)12-3-8(16)17/h5-6H,1-4,11H2,(H,12,18)(H,13,15)(H,16,17)(H,19,20)/t5-,6-/m0/s1
DMZ9WI4	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-nitrososulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMZ9WI4	CA	CAS 57564-91-7
DMZ9WI4	CB	CHEBI:50091
DMZ9WI4	DE	Discovery agent

DMY729C	ID	DMY729C
DMY729C	DN	NK314
DMY729C	HS	Investigative
DMY729C	SN	208237-49-4; 1-hydroxy-2-methoxy-11a,13,14,15-tetrahydro-6aH-[1,3]dioxolo[4',5':4,5]benzo[1,2-c]pyrrolo[1,2-f]phenanthridin-12-ium chloride
DMY729C	DT	Small molecular drug
DMY729C	PC	137699307
DMY729C	MW	397.8
DMY729C	FM	C22H20ClNO4
DMY729C	IC	InChI=1S/C22H19NO4.ClH/c1-25-17-7-6-13-14-5-4-12-9-18-19(27-11-26-18)10-15(12)21(14)23-8-2-3-16(23)20(13)22(17)24;/h4-7,9-10,12,15H,2-3,8,11H2,1H3;1H
DMY729C	CS	COC1=C(C2=C3CCC[N+]3=C4C5C=C6C(=CC5C=CC4=C2C=C1)OCO6)O.[Cl-]
DMY729C	IK	YLNMBOMTXKNYDO-UHFFFAOYSA-N
DMY729C	IU	17-methoxy-5,7-dioxa-24-azoniahexacyclo[11.11.0.02,10.04,8.014,19.020,24]tetracosa-1(24),3,8,11,13,15,17,19-octaen-18-ol;chloride
DMY729C	DE	T-cell leukaemia

DM9WC1T	ID	DM9WC1T
DM9WC1T	DN	NK3201
DM9WC1T	HS	Investigative
DM9WC1T	SN	NK-3201; NK3201; 204460-24-2; NK 3201; (2-(5-Formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-(3,4-dioxo-1-phenyl-7-(2-pyridyloxy)-2-heptyl)acetamide); N-(3,4-dioxo-1-phenyl-7-pyridin-2-yloxyheptan-2-yl)-2-(5-formamido-6-oxo-2-phenylpyrimidin-1-yl)acetamide; AC1Q5BUH; AC1L4U5M; GTPL6503; SCHEMBL4350497; CTK1A5741; AKOS030531107; LS-9646; n-[3,4-dioxo-1-phenyl-7-(pyridin-2-yloxy)heptan-2-yl]-2-[5-(formylamino)-6-oxo-2-phenylpyrimidin-1(6h)-yl]acetamide; KB-145958
DM9WC1T	DT	Small molecular drug
DM9WC1T	PC	213050
DM9WC1T	MW	567.6
DM9WC1T	FM	C31H29N5O6
DM9WC1T	IC	InChI=1S/C31H29N5O6/c37-21-34-25-19-33-30(23-12-5-2-6-13-23)36(31(25)41)20-27(39)35-24(18-22-10-3-1-4-11-22)29(40)26(38)14-9-17-42-28-15-7-8-16-32-28/h1-8,10-13,15-16,19,21,24H,9,14,17-18,20H2,(H,34,37)(H,35,39)
DM9WC1T	CS	C1=CC=C(C=C1)CC(C(=O)C(=O)CCCOC2=CC=CC=N2)NC(=O)CN3C(=NC=C(C3=O)NC=O)C4=CC=CC=C4
DM9WC1T	IK	QOANBAXBOLUAFA-UHFFFAOYSA-N
DM9WC1T	IU	N-(3,4-dioxo-1-phenyl-7-pyridin-2-yloxyheptan-2-yl)-2-(5-formamido-6-oxo-2-phenylpyrimidin-1-yl)acetamide
DM9WC1T	CA	CAS 204460-24-2
DM9WC1T	DE	Discovery agent

DMSB2YG	ID	DMSB2YG
DMSB2YG	DN	NKY80
DMSB2YG	HS	Investigative
DMSB2YG	SN	NKY 80; NKY-80; adenylyl cyclase type V Inhibitor
DMSB2YG	DT	Small molecular drug
DMSB2YG	PC	2772368
DMSB2YG	MW	229.23
DMSB2YG	FM	C12H11N3O2
DMSB2YG	IC	InChI=1S/C12H11N3O2/c13-12-14-6-8-9(15-12)4-7(5-10(8)16)11-2-1-3-17-11/h1-3,6-7H,4-5H2,(H2,13,14,15)
DMSB2YG	CS	C1C(CC(=O)C2=CN=C(N=C21)N)C3=CC=CO3
DMSB2YG	IK	SOJUSNIBPPMLCC-UHFFFAOYSA-N
DMSB2YG	IU	2-amino-7-(furan-2-yl)-7,8-dihydro-6H-quinazolin-5-one
DMSB2YG	CA	CAS 299442-43-6
DMSB2YG	DE	Discovery agent

DM0FA6B	ID	DM0FA6B
DM0FA6B	DN	Nle-Pro-Glu
DM0FA6B	HS	Investigative
DM0FA6B	SN	Nle-Pro-Glu
DM0FA6B	DT	Small molecular drug
DM0FA6B	PC	44408687
DM0FA6B	MW	357.4
DM0FA6B	FM	C16H27N3O6
DM0FA6B	IC	InChI=1S/C16H27N3O6/c1-2-3-5-10(17)15(23)19-9-4-6-12(19)14(22)18-11(16(24)25)7-8-13(20)21/h10-12H,2-9,17H2,1H3,(H,18,22)(H,20,21)(H,24,25)/t10-,11-,12-/m0/s1
DM0FA6B	CS	CCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N
DM0FA6B	IK	SGASVGGGJFNOSL-SRVKXCTJSA-N
DM0FA6B	IU	(2S)-2-[[(2S)-1-[(2S)-2-aminohexanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid
DM0FA6B	DE	Discovery agent

DM6RA20	ID	DM6RA20
DM6RA20	DN	NM-2014
DM6RA20	HS	Investigative
DM6RA20	CP	NovelMed Therapeutics Inc
DM6RA20	DE	Rheumatoid arthritis

DMC89HI	ID	DMC89HI
DMC89HI	DN	NM-9308
DMC89HI	HS	Investigative
DMC89HI	SN	Bikaciomab; Bikaciomab (AMD), NovelMed Therapeutics; Complement factor B inhibitor (age related maculardegeneration), NovelMed Therapeutics; Anti-factor B monoclonal antibody (age related macular degenration), NovelMed Therapeutics
DMC89HI	CP	NovelMed Therapeutics Inc
DMC89HI	DT	Antibody
DMC89HI	DE	Age-related macular degeneration

DMKMBSJ	ID	DMKMBSJ
DMKMBSJ	DN	NM-9405
DMKMBSJ	HS	Investigative
DMKMBSJ	SN	Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc
DMKMBSJ	CP	NovelMed Therapeutics Inc
DMKMBSJ	DT	Antibody
DMKMBSJ	DE	Rheumatoid arthritis

DM5Q9FG	ID	DM5Q9FG
DM5Q9FG	DN	NMB-T-BMX-OS01
DM5Q9FG	HS	Investigative
DM5Q9FG	SN	Histone deacetylase 8 inhibitor (cancer), NatureWise Biotech & Medicals Corp
DM5Q9FG	CP	NatureWise Biotech & Medicals Corp
DM5Q9FG	DE	Solid tumour/cancer

DMM731A	ID	DMM731A
DMM731A	DN	N-Me-aminopyrimidinone 9
DMM731A	HS	Investigative
DMM731A	SN	N-Me-aminopyrimidinone 9; CHEMBL1938867; 1356834-62-2; GTPL5733; BDBM50362580; ZINC73167698; BC600825; 6-amino-2-[(4-tert-butylphenyl)methylsulfanyl]-3-methylpyrimidin-4-one.
DMM731A	DT	Small molecular drug
DMM731A	PC	56951318
DMM731A	MW	303.4
DMM731A	FM	C16H21N3OS
DMM731A	IC	InChI=1S/C16H21N3OS/c1-16(2,3)12-7-5-11(6-8-12)10-21-15-18-13(17)9-14(20)19(15)4/h5-9H,10,17H2,1-4H3
DMM731A	CS	CC(C)(C)C1=CC=C(C=C1)CSC2=NC(=CC(=O)N2C)N
DMM731A	IK	AJMIFZLEDTUBTN-UHFFFAOYSA-N
DMM731A	IU	6-amino-2-[(4-tert-butylphenyl)methylsulfanyl]-3-methylpyrimidin-4-one
DMM731A	DE	Discovery agent

DMI065U	ID	DMI065U
DMI065U	DN	N-mesityl-4,6-dimethyl-3-tosylpyridin-2-amine
DMI065U	HS	Investigative
DMI065U	SN	CHEMBL203609; N-mesityl-4,6-dimethyl-3-tosylpyridin-2-amine
DMI065U	DT	Small molecular drug
DMI065U	PC	44407869
DMI065U	MW	394.5
DMI065U	FM	C23H26N2O2S
DMI065U	IC	InChI=1S/C23H26N2O2S/c1-14-7-9-20(10-8-14)28(26,27)22-18(5)13-19(6)24-23(22)25-21-16(3)11-15(2)12-17(21)4/h7-13H,1-6H3,(H,24,25)
DMI065U	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=C(N=C(C=C2C)C)NC3=C(C=C(C=C3C)C)C
DMI065U	IK	IJUWFQLWCMTNLD-UHFFFAOYSA-N
DMI065U	IU	4,6-dimethyl-3-(4-methylphenyl)sulfonyl-N-(2,4,6-trimethylphenyl)pyridin-2-amine
DMI065U	DE	Discovery agent

DMEUI8C	ID	DMEUI8C
DMEUI8C	DN	N-mesityl-6-methyl-3-tosylpyridin-2-amine
DMEUI8C	HS	Investigative
DMEUI8C	SN	CHEMBL204967; N-mesityl-6-methyl-3-tosylpyridin-2-amine; SCHEMBL5861890
DMEUI8C	DT	Small molecular drug
DMEUI8C	PC	11245983
DMEUI8C	MW	380.5
DMEUI8C	FM	C22H24N2O2S
DMEUI8C	IC	InChI=1S/C22H24N2O2S/c1-14-6-9-19(10-7-14)27(25,26)20-11-8-18(5)23-22(20)24-21-16(3)12-15(2)13-17(21)4/h6-13H,1-5H3,(H,23,24)
DMEUI8C	CS	CC1=CC=C(C=C1)S(=O)(=O)C2=C(N=C(C=C2)C)NC3=C(C=C(C=C3C)C)C
DMEUI8C	IK	VEYJKVDTZSJZQR-UHFFFAOYSA-N
DMEUI8C	IU	6-methyl-3-(4-methylphenyl)sulfonyl-N-(2,4,6-trimethylphenyl)pyridin-2-amine
DMEUI8C	DE	Discovery agent

DMI9QRO	ID	DMI9QRO
DMI9QRO	DN	N-methoxyethyl estrone-16-methyl carboxamide
DMI9QRO	HS	Investigative
DMI9QRO	SN	SCHEMBL12379530
DMI9QRO	DT	Small molecular drug
DMI9QRO	PC	44407742
DMI9QRO	MW	385.5
DMI9QRO	FM	C23H31NO4
DMI9QRO	IC	InChI=1S/C23H31NO4/c1-23-8-7-18-17-6-4-16(25)11-14(17)3-5-19(18)20(23)12-15(22(23)27)13-21(26)24-9-10-28-2/h4,6,11,15,18-20,25H,3,5,7-10,12-13H2,1-2H3,(H,24,26)/t15?,18?,19?,20?,23-/m0/s1
DMI9QRO	CS	C[C@]12CCC3C(C1CC(C2=O)CC(=O)NCCOC)CCC4=C3C=CC(=C4)O
DMI9QRO	IK	LQHCZQAKWAQLJZ-OOGUNDJRSA-N
DMI9QRO	IU	2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]-N-(2-methoxyethyl)acetamide
DMI9QRO	DE	Discovery agent

DMMB3PG	ID	DMMB3PG
DMMB3PG	DN	N-methoxyquinuclidine-3-carboximidoyl chloride
DMMB3PG	HS	Investigative
DMMB3PG	SN	CHEMBL135604
DMMB3PG	DT	Small molecular drug
DMMB3PG	PC	14939839
DMMB3PG	MW	202.68
DMMB3PG	FM	C9H15ClN2O
DMMB3PG	IC	InChI=1S/C9H15ClN2O/c1-13-11-9(10)8-6-12-4-2-7(8)3-5-12/h7-8H,2-6H2,1H3/b11-9-
DMMB3PG	CS	CO/N=C(/C1CN2CCC1CC2)\\Cl
DMMB3PG	IK	NJVYTBKHLPNMEV-LUAWRHEFSA-N
DMMB3PG	IU	(3Z)-N-methoxy-1-azabicyclo[2.2.2]octane-3-carboximidoyl chloride
DMMB3PG	DE	Discovery agent

DMF8IA6	ID	DMF8IA6
DMF8IA6	DN	N-methoxyquinuclidine-3-carboximidoyl fluoride
DMF8IA6	HS	Investigative
DMF8IA6	SN	CHEMBL341766
DMF8IA6	DT	Small molecular drug
DMF8IA6	PC	10631410
DMF8IA6	MW	186.23
DMF8IA6	FM	C9H15FN2O
DMF8IA6	IC	InChI=1S/C9H15FN2O/c1-13-11-9(10)8-6-12-4-2-7(8)3-5-12/h7-8H,2-6H2,1H3/b11-9-
DMF8IA6	CS	CO/N=C(/C1CN2CCC1CC2)\\F
DMF8IA6	IK	DNYJYFSXGOMRNZ-LUAWRHEFSA-N
DMF8IA6	IU	(3Z)-N-methoxy-1-azabicyclo[2.2.2]octane-3-carboximidoyl fluoride
DMF8IA6	DE	Discovery agent

DM32YID	ID	DM32YID
DM32YID	DN	N-methyl estradiol-16-methyl carboxamide
DM32YID	HS	Investigative
DM32YID	SN	SCHEMBL12379575
DM32YID	DT	Small molecular drug
DM32YID	PC	44407520
DM32YID	MW	343.5
DM32YID	FM	C21H29NO3
DM32YID	IC	InChI=1S/C21H29NO3/c1-21-8-7-16-15-6-4-14(23)9-12(15)3-5-17(16)18(21)10-13(20(21)25)11-19(24)22-2/h4,6,9,13,16-18,20,23,25H,3,5,7-8,10-11H2,1-2H3,(H,22,24)/t13?,16?,17?,18?,20-,21-/m0/s1
DM32YID	CS	C[C@]12CCC3C(C1CC([C@@H]2O)CC(=O)NC)CCC4=C3C=CC(=C4)O
DM32YID	IK	LFTDXZXJMDAPQK-LCKYQJBKSA-N
DM32YID	IU	2-[(13S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]-N-methylacetamide
DM32YID	DE	Discovery agent

DM7XIK5	ID	DM7XIK5
DM7XIK5	DN	N-methyl estrone-16-methyl carboxamide
DM7XIK5	HS	Investigative
DM7XIK5	SN	SCHEMBL12379562
DM7XIK5	DT	Small molecular drug
DM7XIK5	PC	44407573
DM7XIK5	MW	341.4
DM7XIK5	FM	C21H27NO3
DM7XIK5	IC	InChI=1S/C21H27NO3/c1-21-8-7-16-15-6-4-14(23)9-12(15)3-5-17(16)18(21)10-13(20(21)25)11-19(24)22-2/h4,6,9,13,16-18,23H,3,5,7-8,10-11H2,1-2H3,(H,22,24)/t13?,16?,17?,18?,21-/m0/s1
DM7XIK5	CS	C[C@]12CCC3C(C1CC(C2=O)CC(=O)NC)CCC4=C3C=CC(=C4)O
DM7XIK5	IK	VGAXMSUTCOBBFZ-XMTGCZIPSA-N
DM7XIK5	IU	2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]-N-methylacetamide
DM7XIK5	DE	Discovery agent

DM6XYCU	ID	DM6XYCU
DM6XYCU	DN	N-methyl LTC4
DM6XYCU	HS	Investigative
DM6XYCU	SN	N-methyl-leukotriene C4
DM6XYCU	DT	Small molecular drug
DM6XYCU	PC	73755185
DM6XYCU	MW	639.8
DM6XYCU	FM	C31H49N3O9S
DM6XYCU	IC	InChI=1S/C31H49N3O9S/c1-3-4-5-6-7-8-9-10-11-12-13-14-17-26(25(35)16-15-18-28(37)38)44-22-24(30(41)33-21-29(39)40)34-27(36)20-19-23(32-2)31(42)43/h7-8,10-14,17,23-26,32,35H,3-6,9,15-16,18-22H2,1-2H3,(H,33,41)(H,34,36)(H,37,38)(H,39,40)(H,42,43)/b8-7-,11-10-,13-12+,17-14+/t23?,24?,25-,26+/m0/s1
DM6XYCU	CS	CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)NC
DM6XYCU	IK	FPLBRCJNODNRQZ-LZHUJPGBSA-N
DM6XYCU	IU	(5S,6R,7E,9E,11Z,14Z)-6-[3-(carboxymethylamino)-2-[[4-carboxy-4-(methylamino)butanoyl]amino]-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
DM6XYCU	DE	Discovery agent

DMXGY4F	ID	DMXGY4F
DMXGY4F	DN	N-methyl ryanodine-succinamidate
DMXGY4F	HS	Investigative
DMXGY4F	SN	N-methyl ryanodine-succinamidate; CHEMBL432278
DMXGY4F	DT	Small molecular drug
DMXGY4F	PC	44275929
DMXGY4F	MW	606.7
DMXGY4F	FM	C30H42N2O11
DMXGY4F	IC	InChI=1S/C30H42N2O11/c1-15(2)27(38)22(42-21(35)17-8-7-13-32-17)28(39)23(4)14-26(37)24(27,5)30(28,40)29(43-26)20(16(3)11-12-25(23,29)36)41-19(34)10-9-18(33)31-6/h7-8,13,15-16,20,22,32,36-40H,9-12,14H2,1-6H3,(H,31,33)/t16?,20-,22-,23+,24?,25?,26?,27?,28?,29?,30?/m1/s1
DMXGY4F	CS	CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CCC(=O)NC)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DMXGY4F	IK	RWAKHARTDYCRMC-QYQZIFBLSA-N
DMXGY4F	IU	[(2R,7S,12R)-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-2-[4-(methylamino)-4-oxobutanoyl]oxy-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMXGY4F	DE	Discovery agent

DM83AEM	ID	DM83AEM
DM83AEM	DN	N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine
DM83AEM	HS	Investigative
DM83AEM	SN	CHEMBL374335; pyrrole inhibitor 7; N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine; SCHEMBL17045839; BDBM15592; ZINC13493580; benzyl(methyl)(1H-pyrrol-2-ylmethyl)amine
DM83AEM	DT	Small molecular drug
DM83AEM	PC	11805737
DM83AEM	MW	200.28
DM83AEM	FM	C13H16N2
DM83AEM	IC	InChI=1S/C13H16N2/c1-15(11-13-8-5-9-14-13)10-12-6-3-2-4-7-12/h2-9,14H,10-11H2,1H3
DM83AEM	CS	CN(CC1=CC=CC=C1)CC2=CC=CN2
DM83AEM	IK	XQZWJHDHWFGAPS-UHFFFAOYSA-N
DM83AEM	IU	N-methyl-1-phenyl-N-(1H-pyrrol-2-ylmethyl)methanamine
DM83AEM	DE	Discovery agent

DMZ24XT	ID	DMZ24XT
DMZ24XT	DN	N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine
DMZ24XT	HS	Investigative
DMZ24XT	SN	pyrrole inhibitor 4; N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine; CHEMBL220116; BDBM15611; AKOS006355649
DMZ24XT	DT	Small molecular drug
DMZ24XT	PC	10464479
DMZ24XT	MW	148.2
DMZ24XT	FM	C9H12N2
DMZ24XT	IC	InChI=1S/C9H12N2/c1-3-7-11(2)8-9-5-4-6-10-9/h1,4-6,10H,7-8H2,2H3
DMZ24XT	CS	CN(CC#C)CC1=CC=CN1
DMZ24XT	IK	PFQFUSNKIZWHOA-UHFFFAOYSA-N
DMZ24XT	IU	N-methyl-N-(1H-pyrrol-2-ylmethyl)prop-2-yn-1-amine
DMZ24XT	DE	Discovery agent

DMM3B21	ID	DMM3B21
DMM3B21	DN	N-Methyl,N-phenyl-1H-indole-2-carboxamide
DMM3B21	HS	Investigative
DMM3B21	SN	CHEMBL464597; N-methyl-N-phenyl-1H-indole-2-carboxamide; AC1LGHJJ; N-Methyl,N-phenyl-1H-indole-2-carboxamide; MolPort-003-811-419; ZINC338381; BDBM50273486; AKOS008968640
DMM3B21	DT	Small molecular drug
DMM3B21	PC	821483
DMM3B21	MW	250.29
DMM3B21	FM	C16H14N2O
DMM3B21	IC	InChI=1S/C16H14N2O/c1-18(13-8-3-2-4-9-13)16(19)15-11-12-7-5-6-10-14(12)17-15/h2-11,17H,1H3
DMM3B21	CS	CN(C1=CC=CC=C1)C(=O)C2=CC3=CC=CC=C3N2
DMM3B21	IK	MIHVSSWKZWMTEP-UHFFFAOYSA-N
DMM3B21	IU	N-methyl-N-phenyl-1H-indole-2-carboxamide
DMM3B21	DE	Discovery agent

DMUJ18P	ID	DMUJ18P
DMUJ18P	DN	N-methyl-1-(2-thiophen-2-ylphenyl)methanamine
DMUJ18P	HS	Investigative
DMUJ18P	SN	N-Methyl-N-(2-thien-2-ylbenzyl)amine; 852180-66-6; N-methyl-1-(2-thiophen-2-ylphenyl)methanamine; CHEMBL549343; N-Methyl-2-thien-2-ylbenzylamine; N-methyl-1-(2-(thiophen-2-yl)phenyl)methanamine; AC1OEOYY; CTK5F4550; DTXSID00427632; MolPort-000-143-044; HMS3604E04; ZINC3880928; SBB093177; BDBM50294171; AKOS010337666; RP04434; DB07196; n-methyl-n-(2-thiophen-2-ylbenzyl)amine; methyl[(2-(2-thienyl)phenyl)methyl]amine; KB-204244; KB-302285; RT-014485; Benzenemethanamine,N-methyl-2-(2-thienyl)-; Y4269; Benzenemethanamine, N-methyl-2-(2
DMUJ18P	DT	Small molecular drug
DMUJ18P	PC	7060565
DMUJ18P	MW	203.31
DMUJ18P	FM	C12H13NS
DMUJ18P	IC	InChI=1S/C12H13NS/c1-13-9-10-5-2-3-6-11(10)12-7-4-8-14-12/h2-8,13H,9H2,1H3
DMUJ18P	CS	CNCC1=CC=CC=C1C2=CC=CS2
DMUJ18P	IK	MRKJJEJYTBOUTH-UHFFFAOYSA-N
DMUJ18P	IU	N-methyl-1-(2-thiophen-2-ylphenyl)methanamine
DMUJ18P	CA	CAS 852180-66-6
DMUJ18P	DE	Discovery agent

DMK8VZM	ID	DMK8VZM
DMK8VZM	DN	N-Methyl-1'H-phenothiazine-1'-carboxamide
DMK8VZM	HS	Investigative
DMK8VZM	SN	CHEMBL606338; 52985-78-1; CTK1E4142; DTXSID00601293; BDBM50308426; ZINC13717066; AKOS004108104; N-Methyl-1''H-phenothiazine-1''-carboxamide; 10H-Phenothiazine-10-carboxamide, N-methyl-
DMK8VZM	DT	Small molecular drug
DMK8VZM	PC	19916609
DMK8VZM	MW	256.32
DMK8VZM	FM	C14H12N2OS
DMK8VZM	IC	InChI=1S/C14H12N2OS/c1-15-14(17)16-10-6-2-4-8-12(10)18-13-9-5-3-7-11(13)16/h2-9H,1H3,(H,15,17)
DMK8VZM	CS	CNC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMK8VZM	IK	VBZPZJCWSNLVCY-UHFFFAOYSA-N
DMK8VZM	IU	N-methylphenothiazine-10-carboxamide
DMK8VZM	CA	CAS 52985-78-1
DMK8VZM	DE	Discovery agent

DM8LNMY	ID	DM8LNMY
DM8LNMY	DN	N-methyl-2-(pyridin-2-yl)ethanamine
DM8LNMY	HS	Investigative
DM8LNMY	SN	betahistine; 5638-76-6; 2-(2-METHYLAMINOETHYL)PYRIDINE; Vasomotal; Serc base; 2-Pyridineethanamine, N-methyl-; beta-Histine; PT 9 base; Sinmenier (free base); methyl[2-(pyridin-2-yl)ethyl]amine; Betahistina; Betahistinum; 2-[2-(Methylamino)ethyl]pyridine; N-Methyl-2-pyridineethylamine; N-Methyl-2-pyridineethanamine; Betaistina [DCIT]; Serc; Betahistine [INN:BAN]; 2-(2-(Methylamino)ethyl)pyridine; N-methyl-2-pyridin-2-ylethanamine; Betahistinum [INN-Latin]; Betahistina [INN-Spanish]
DM8LNMY	DT	Small molecular drug
DM8LNMY	PC	2366
DM8LNMY	MW	136.19
DM8LNMY	FM	C8H12N2
DM8LNMY	IC	InChI=1S/C8H12N2/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H3
DM8LNMY	CS	CNCCC1=CC=CC=N1
DM8LNMY	IK	UUQMNUMQCIQDMZ-UHFFFAOYSA-N
DM8LNMY	IU	N-methyl-2-pyridin-2-ylethanamine
DM8LNMY	CA	CAS 5638-76-6
DM8LNMY	CB	CHEBI:35677
DM8LNMY	DE	Discovery agent

DMXS43P	ID	DMXS43P
DMXS43P	DN	N-methyl-2-(pyridin-3-yloxy)ethanamine
DMXS43P	HS	Investigative
DMXS43P	SN	CHEMBL112221; 228272-00-2; N-methyl-2-(pyridin-3-yloxy)ethanamine; SCHEMBL7101352; CTK0J6067; DTXSID50430732; HKLZABNBARUZMN-UHFFFAOYSA-N; Methyl(2-(3-pyridyloxy)ethyl)amine; BDBM50120586; Methyl 2-(3-pyridinyloxy)ethylamine; AKOS011738046; N-methyl-2-(pyridin-3-yloxy)ethanaminium; Methyl-[2-(pyridin-3-yloxy)-ethyl]-amine; Ethanamine, N-methyl-2-(3-pyridinyloxy)-
DMXS43P	DT	Small molecular drug
DMXS43P	PC	9793858
DMXS43P	MW	152.19
DMXS43P	FM	C8H12N2O
DMXS43P	IC	InChI=1S/C8H12N2O/c1-9-5-6-11-8-3-2-4-10-7-8/h2-4,7,9H,5-6H2,1H3
DMXS43P	CS	CNCCOC1=CN=CC=C1
DMXS43P	IK	HKLZABNBARUZMN-UHFFFAOYSA-N
DMXS43P	IU	N-methyl-2-pyridin-3-yloxyethanamine
DMXS43P	CA	CAS 228272-00-2
DMXS43P	DE	Discovery agent

DMQGRMO	ID	DMQGRMO
DMQGRMO	DN	N-methyl-2,2,2-triphenylacetamide
DMQGRMO	HS	Investigative
DMQGRMO	PC	20684859
DMQGRMO	MW	301.4
DMQGRMO	FM	C21H19NO
DMQGRMO	IC	InChI=1S/C21H19NO/c1-22-20(23)21(17-11-5-2-6-12-17,18-13-7-3-8-14-18)19-15-9-4-10-16-19/h2-16H,1H3,(H,22,23)
DMQGRMO	CS	CNC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3
DMQGRMO	IK	IYPLXBZQQJCIRI-UHFFFAOYSA-N
DMQGRMO	IU	N-methyl-2,2,2-triphenylacetamide
DMQGRMO	DE	Discovery agent

DM8IHQP	ID	DM8IHQP
DM8IHQP	DN	N-methyl-3,3-diphenylpropan-1-amine
DM8IHQP	HS	Investigative
DM8IHQP	SN	N-Methyl-3,3-diphenylpropylamine; 28075-29-8; N-methyl-3,3-diphenylpropan-1-amine; W-107076; EINECS 248-821-5; n-methyl-3,3-diphenylpropan-1-amin; Diphenylpropyl-methylamin; AC1L3PJ5; AC1Q1HZ6; diphenylalkylamine (DPA), 5b; CHEMBL593494; SCHEMBL3638413; Jsp005413; Methyl(3,3-diphenylpropyl)amine; BDBM35933; CTK4G0777; (3,3-Diphenylpropyl)methylamine; DTXSID00182350; AKEGHAUFMKCWGX-UHFFFAOYSA-N; 3,3-Diphenyl-N-methylpropylamine; MolPort-003-737-089; ZINC5996308; ACT07251; Benzenepropanamine,N-methyl-g-phenyl-
DM8IHQP	DT	Small molecular drug
DM8IHQP	PC	119812
DM8IHQP	MW	225.33
DM8IHQP	FM	C16H19N
DM8IHQP	IC	InChI=1S/C16H19N/c1-17-13-12-16(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-11,16-17H,12-13H2,1H3
DM8IHQP	CS	CNCCC(C1=CC=CC=C1)C2=CC=CC=C2
DM8IHQP	IK	AKEGHAUFMKCWGX-UHFFFAOYSA-N
DM8IHQP	IU	N-methyl-3,3-diphenylpropan-1-amine
DM8IHQP	CA	CAS 28075-29-8
DM8IHQP	DE	Discovery agent

DMMNIRC	ID	DMMNIRC
DMMNIRC	DN	N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMMNIRC	HS	Investigative
DMMNIRC	SN	CHEMBL54860; N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine; SCHEMBL3023293; WBAIXNUCEGCLDC-UHFFFAOYSA-N; BDBM50138489; Methyl-(4-pyridin-3-yl-but-3-ynyl)-amine; N-Methyl-4-(3pyridinyl)-3-butyne-1-amine; 1-(3-Pyridinyl)-4-(methylamino)-1-butyne; N-Methyl-4-(3-pyridinyl)-3-butyne-1-amine
DMMNIRC	DT	Small molecular drug
DMMNIRC	PC	15860335
DMMNIRC	MW	160.22
DMMNIRC	FM	C10H12N2
DMMNIRC	IC	InChI=1S/C10H12N2/c1-11-7-3-2-5-10-6-4-8-12-9-10/h4,6,8-9,11H,3,7H2,1H3
DMMNIRC	CS	CNCCC#CC1=CN=CC=C1
DMMNIRC	IK	WBAIXNUCEGCLDC-UHFFFAOYSA-N
DMMNIRC	IU	N-methyl-4-pyridin-3-ylbut-3-yn-1-amine
DMMNIRC	DE	Discovery agent

DMO3PNF	ID	DMO3PNF
DMO3PNF	DN	N-methyl-4,4-diphenylbutan-1-amine
DMO3PNF	HS	Investigative
DMO3PNF	SN	diphenylalkylamine (DPA), 6b; CHEMBL594138; BDBM35936; ZINC22008119; AC-606; AKOS016035533
DMO3PNF	DT	Small molecular drug
DMO3PNF	PC	20293994
DMO3PNF	MW	239.35
DMO3PNF	FM	C17H21N
DMO3PNF	IC	InChI=1S/C17H21N/c1-18-14-8-13-17(15-9-4-2-5-10-15)16-11-6-3-7-12-16/h2-7,9-12,17-18H,8,13-14H2,1H3
DMO3PNF	CS	CNCCCC(C1=CC=CC=C1)C2=CC=CC=C2
DMO3PNF	IK	GRKYNTKPAFRLLZ-UHFFFAOYSA-N
DMO3PNF	IU	N-methyl-4,4-diphenylbutan-1-amine
DMO3PNF	DE	Discovery agent

DMA0YGE	ID	DMA0YGE
DMA0YGE	DN	N-methyl-4-pentyl-N-(pyridin-3-yl)benzamide
DMA0YGE	HS	Investigative
DMA0YGE	SN	CHEMBL259101
DMA0YGE	DT	Small molecular drug
DMA0YGE	PC	44450379
DMA0YGE	MW	282.4
DMA0YGE	FM	C18H22N2O
DMA0YGE	IC	InChI=1S/C18H22N2O/c1-3-4-5-7-15-9-11-16(12-10-15)18(21)20(2)17-8-6-13-19-14-17/h6,8-14H,3-5,7H2,1-2H3
DMA0YGE	CS	CCCCCC1=CC=C(C=C1)C(=O)N(C)C2=CN=CC=C2
DMA0YGE	IK	NOLPMCFMEHRJFY-UHFFFAOYSA-N
DMA0YGE	IU	N-methyl-4-pentyl-N-pyridin-3-ylbenzamide
DMA0YGE	DE	Discovery agent

DMD621E	ID	DMD621E
DMD621E	DN	N-methyl-5,6-dip-tolylpyrazine-2-carboxamide
DMD621E	HS	Investigative
DMD621E	SN	CHEMBL246273; N-methyl-5,6-dip-tolylpyrazine-2-carboxamide
DMD621E	DT	Small molecular drug
DMD621E	PC	44440706
DMD621E	MW	317.4
DMD621E	FM	C20H19N3O
DMD621E	IC	InChI=1S/C20H19N3O/c1-13-4-8-15(9-5-13)18-19(16-10-6-14(2)7-11-16)23-17(12-22-18)20(24)21-3/h4-12H,1-3H3,(H,21,24)
DMD621E	CS	CC1=CC=C(C=C1)C2=NC=C(N=C2C3=CC=C(C=C3)C)C(=O)NC
DMD621E	IK	PRXVUGFMELNVTA-UHFFFAOYSA-N
DMD621E	IU	N-methyl-5,6-bis(4-methylphenyl)pyrazine-2-carboxamide
DMD621E	DE	Discovery agent

DM5GXIS	ID	DM5GXIS
DM5GXIS	DN	N-methylbicuculline
DM5GXIS	HS	Investigative
DM5GXIS	SN	(5s)-6,6-dimethyl-5-[(6r)-6-methyl-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl]-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-ium chloride; 71538-43-7; AC1Q1SMD; C21H20NO6.Cl; AC1L3X24; CTK8E0474; DTXSID20276265; LS-174735; (6R)-6-[(5S)-6,6-dimethyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6-methylfuro[3,4-g][1,3]benzodioxol-8-one chloride
DM5GXIS	DT	Small molecular drug
DM5GXIS	PC	10047593
DM5GXIS	MW	417.8
DM5GXIS	FM	C21H20ClNO6
DM5GXIS	IC	InChI=1S/C21H20NO6.ClH/c1-22(2)6-5-11-7-15-16(26-9-25-15)8-13(11)18(22)19-12-3-4-14-20(27-10-24-14)17(12)21(23)28-19;/h3-4,7-8,18-19H,5-6,9-10H2,1-2H3;1H/q+1;/p-1/t18-,19+;/m0./s1
DM5GXIS	CS	C[N+]1(CCC2=CC3=C(C=C2[C@H]1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3)C.[Cl-]
DM5GXIS	IK	RLJKFAMYSYWMND-GRTNUQQKSA-M
DM5GXIS	IU	(6R)-6-[(5S)-6,6-dimethyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6H-furo[3,4-g][1,3]benzodioxol-8-one;chloride
DM5GXIS	CA	CAS 38641-83-7
DM5GXIS	DE	Discovery agent

DMP1EF6	ID	DMP1EF6
DMP1EF6	DN	N-Methyl-ETAV
DMP1EF6	HS	Investigative
DMP1EF6	SN	N-Methyl-ETAV; CHEMBL521656
DMP1EF6	DT	Small molecular drug
DMP1EF6	PC	44568789
DMP1EF6	MW	432.5
DMP1EF6	FM	C18H32N4O8
DMP1EF6	IC	InChI=1S/C18H32N4O8/c1-8(2)13(18(29)30)21-15(26)9(3)20-17(28)14(10(4)23)22-16(27)11(19-5)6-7-12(24)25/h8-11,13-14,19,23H,6-7H2,1-5H3,(H,20,28)(H,21,26)(H,22,27)(H,24,25)(H,29,30)/t9-,10?,11-,13-,14-/m0/s1
DMP1EF6	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NC
DMP1EF6	IK	LOKBVOQPMLVOAY-CGTOJEAQSA-N
DMP1EF6	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-(methylamino)-5-oxopentanoic acid
DMP1EF6	DE	Discovery agent

DMCFH5W	ID	DMCFH5W
DMCFH5W	DN	N-methylhistamine
DMCFH5W	HS	Investigative
DMCFH5W	SN	Nalpha-Methylhistamine dihydrochloride; NAMH dihydrochloride; 16503-22-3; N-Methylhistamine dihydrochloride; UNII-S6S98U0517; S6S98U0517; n-alpha-methylhistamine dihydrochloride; N(alpha)-methylhistamine HCl; SCHEMBL614543; 1H-Imidazole-4-ethanamine, N-methyl-, dihydrochloride; Imidazole, 4-(2-(methylamino)ethyl)-, dihydrochloride; CTK8G1926; CTK8G1225; DTXSID90167838
DMCFH5W	DT	Small molecular drug
DMCFH5W	PC	16078977
DMCFH5W	MW	198.09
DMCFH5W	FM	C6H13Cl2N3
DMCFH5W	IC	InChI=1S/C6H11N3.2ClH/c1-7-3-2-6-4-8-5-9-6;;/h4-5,7H,2-3H2,1H3,(H,8,9);2*1H
DMCFH5W	CS	CNCCC1=CN=CN1.Cl.Cl
DMCFH5W	IK	AYUQICXJAMPXPF-UHFFFAOYSA-N
DMCFH5W	IU	2-(1H-imidazol-5-yl)-N-methylethanamine;dihydrochloride
DMCFH5W	CA	CAS 16503-22-3
DMCFH5W	DE	Discovery agent

DMWPBKU	ID	DMWPBKU
DMWPBKU	DN	N-methyllaurotetanine
DMWPBKU	HS	Investigative
DMWPBKU	SN	Lauroscholtzine; N-Methyllaurotetanine; 2169-44-0; Rogersine; NSC 247564; CHEMBL464099; UNII-11558LRZ50; NSC 247506; 11558LRZ50; 1,2,10-Trimethoxy-6a-alpha-aporphin-9-ol; 6a-alpha-APORPHIN-9-OL, 1,2,10-TRIMETHOXY-; 4H-Dibenzo(de,g)quinolin-9-ol, 5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, (S)-; Boldine 2-methyl ether; (+)-N-methyl-laurotetanine; AC1L288L; DTXSID60176073; MolPort-003-804-060; ZINC338123; NSC247506; BDBM50250422; NSC247564; AKOS032948666; NSC-247564; NSC-247506; LS-21503; W1151
DMWPBKU	DT	Small molecular drug
DMWPBKU	PC	16573
DMWPBKU	MW	341.4
DMWPBKU	FM	C20H23NO4
DMWPBKU	IC	InChI=1S/C20H23NO4/c1-21-6-5-11-9-17(24-3)20(25-4)19-13-10-16(23-2)15(22)8-12(13)7-14(21)18(11)19/h8-10,14,22H,5-7H2,1-4H3/t14-/m0/s1
DMWPBKU	CS	CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)O)OC)OC
DMWPBKU	IK	ZFLRVRLYWHNAEC-AWEZNQCLSA-N
DMWPBKU	IU	(6aS)-1,2,10-trimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-9-ol
DMWPBKU	CA	CAS 2169-44-0
DMWPBKU	DE	Discovery agent

DM9AGCV	ID	DM9AGCV
DM9AGCV	DN	N-Methylleucine
DM9AGCV	HS	Investigative
DM9AGCV	SN	N-Methyl-L-leucine; 3060-46-6; (S)-4-Methyl-2-(methylamino)pentanoic acid; N-Methylleucine; L-Leucine, N-methyl-; N-Me-Leu-OH; MeLeu; methyl-L-leucine; UNII-2YT9687ECD; 2YT9687ECD; H-ALPHA-METHYL-L-LEUCINE; AK107655; N-methyl-l-leu; Leucine, N-methyl-; AC1MCSAQ; SCHEMBL93452; AMGLY00163; CTK1A1168; MolPort-003-925-252; XJODGRWDFZVTKW-LURJTMIESA-N; ZINC160405; KS-00000J9G; FCH835634; ANW-74881; AKOS006282756; CS-W008140; ACM3060466; AJ-15591; SC-82208; KB-58630; AC-24158; AS-19192; DB-038132; TC-163626; AX8020112; X5243; ST24036190; FT-0695191
DM9AGCV	DT	Small molecular drug
DM9AGCV	PC	6951123
DM9AGCV	MW	145.2
DM9AGCV	FM	C7H15NO2
DM9AGCV	IC	InChI=1S/C7H15NO2/c1-5(2)4-6(8-3)7(9)10/h5-6,8H,4H2,1-3H3,(H,9,10)/t6-/m1/s1
DM9AGCV	CS	CC(C)C[C@H](C(=O)O)NC
DM9AGCV	IK	XJODGRWDFZVTKW-ZCFIWIBFSA-N
DM9AGCV	IU	(2R)-4-methyl-2-(methylamino)pentanoic acid
DM9AGCV	CA	CAS 31321-74-1
DM9AGCV	DE	Discovery agent

DM4FMZP	ID	DM4FMZP
DM4FMZP	DN	N-Methylmesoporphyrin
DM4FMZP	HS	Investigative
DM4FMZP	SN	N-METHYLMESOPORPHYRIN; 3,3'-(8,13-diethyl-3,7,12,17,22-pentamethylporphyrin-2,18-diyl)dipropanoic acid; 3,3'-(8,13-diethyl-3,7,12,17,22-pentamethyl-22,24-dihydroporphyrin-2,18-diyl)dipropanoic acid; 21-Methylmesoporphyrin; AC1L9GRR; SCHEMBL505199; DB01911; J2.132.966E; 3,8,13,17,23-Pentamethyl-7,12-diethyl-21H,23H-porphyrin-2,18-dipropanoic acid; 3-[18-(2-carboxyethyl)-8,13-diethyl-3,7,12,17,22-pentamethyl-23H-porphyrin-2-yl]propanoic acid
DM4FMZP	DT	Small molecular drug
DM4FMZP	PC	444708
DM4FMZP	MW	580.7
DM4FMZP	FM	C35H40N4O4
DM4FMZP	IC	InChI=1S/C35H40N4O4/c1-8-22-18(3)28-17-33-23(9-2)21(6)32(39(33)7)16-27-20(5)25(11-13-35(42)43)31(38-27)15-30-24(10-12-34(40)41)19(4)26(36-30)14-29(22)37-28/h14-17,37H,8-13H2,1-7H3,(H,40,41)(H,42,43)
DM4FMZP	CS	CCC1=C(C2=CC3=C(C(=C(N3C)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1N2)C)CCC(=O)O)CCC(=O)O)C)C)CC)C
DM4FMZP	IK	ZIBXESYSFXNOJI-UHFFFAOYSA-N
DM4FMZP	IU	3-[18-(2-carboxyethyl)-8,13-diethyl-3,7,12,17,22-pentamethyl-23H-porphyrin-2-yl]propanoic acid
DM4FMZP	CA	CAS 142234-85-3
DM4FMZP	DE	Discovery agent

DMKZL5H	ID	DMKZL5H
DMKZL5H	DN	N-Methylmesoporphyrin Containing Copper
DMKZL5H	HS	Investigative
DMKZL5H	SN	N-METHYLMESOPORPHYRIN CONTAINING COPPER
DMKZL5H	DT	Small molecular drug
DMKZL5H	PC	5162683
DMKZL5H	MW	643.3
DMKZL5H	FM	C35H39CuN4O4+
DMKZL5H	IC	InChI=1S/C35H40N4O4.Cu/c1-8-22-18(3)28-17-33-23(9-2)21(6)32(39(33)7)16-27-20(5)25(11-13-35(42)43)31(38-27)15-30-24(10-12-34(40)41)19(4)26(36-30)14-29(22)37-28;/h14-17H,8-13H2,1-7H3,(H3,36,37,38,40,41,42,43);/q;+2/p-1
DMKZL5H	CS	CCC1=C(C2=CC3=C(C(=C(N3C)C=C4C(=C(C(=N4)C=C5C(=C(C(=CC1=N2)[N-]5)C)CCC(=O)O)CCC(=O)O)C)C)CC)C.[Cu+2]
DMKZL5H	IK	WLMGFVUEDVZKTK-UHFFFAOYSA-M
DMKZL5H	IU	copper;3-[18-(2-carboxyethyl)-7,12-diethyl-3,8,13,17,23-pentamethylporphyrin-21-id-2-yl]propanoic acid
DMKZL5H	DE	Discovery agent

DMYPEX3	ID	DMYPEX3
DMYPEX3	DN	N-Methyl-N-(Methylbenzyl)Formamide
DMYPEX3	HS	Investigative
DMYPEX3	SN	N-Methyl-N-(Methylbenzyl)formamide; N-methyl-N-[(1S)-1-phenylethyl]formamide; AC1L9GJA
DMYPEX3	DT	Small molecular drug
DMYPEX3	PC	444567
DMYPEX3	MW	163.22
DMYPEX3	FM	C10H13NO
DMYPEX3	IC	InChI=1S/C10H13NO/c1-9(11(2)8-12)10-6-4-3-5-7-10/h3-9H,1-2H3/t9-/m0/s1
DMYPEX3	CS	C[C@@H](C1=CC=CC=C1)N(C)C=O
DMYPEX3	IK	YYPINKULTUCCJA-VIFPVBQESA-N
DMYPEX3	IU	N-methyl-N-[(1S)-1-phenylethyl]formamide
DMYPEX3	DE	Discovery agent

DM796AX	ID	DM796AX
DM796AX	DN	N-methyl-N-(prop-2-ynyl)-1H-pyrrole-2-carboxamide
DM796AX	HS	Investigative
DM796AX	SN	CHEMBL353159; pyrrole inhibitor 33; MLS004256862; BDBM15608; AKOS017413443; SMR003081937; N-Methyl,N-propargyl-1H-pyrrole-2-carboxamide
DM796AX	DT	Small molecular drug
DM796AX	PC	11008237
DM796AX	MW	162.19
DM796AX	FM	C9H10N2O
DM796AX	IC	InChI=1S/C9H10N2O/c1-3-7-11(2)9(12)8-5-4-6-10-8/h1,4-6,10H,7H2,2H3
DM796AX	CS	CN(CC#C)C(=O)C1=CC=CN1
DM796AX	IK	IKQLCRCMGYGVMD-UHFFFAOYSA-N
DM796AX	IU	N-methyl-N-prop-2-ynyl-1H-pyrrole-2-carboxamide
DM796AX	DE	Discovery agent

DMOP128	ID	DMOP128
DMOP128	DN	N-methyl-N-(pyridin-3-ylmethyl)ethanamine
DMOP128	HS	Investigative
DMOP128	SN	CHEMBL60792; 3-(N-ethyl-N-methylaminomethyl)pyridine; 90565-29-0; N-methyl-N-(pyridin-3-ylmethyl)ethanamine; SCHEMBL6674571; Methylethyl 3-pyridinylmethylamine; BDBM50115825; Ethyl-methyl-pyridin-3-ylmethyl-amine
DMOP128	DT	Small molecular drug
DMOP128	PC	44302712
DMOP128	MW	150.22
DMOP128	FM	C9H14N2
DMOP128	IC	InChI=1S/C9H14N2/c1-3-11(2)8-9-5-4-6-10-7-9/h4-7H,3,8H2,1-2H3
DMOP128	CS	CCN(C)CC1=CN=CC=C1
DMOP128	IK	DYIAIEHOHKXIMP-UHFFFAOYSA-N
DMOP128	IU	N-methyl-N-(pyridin-3-ylmethyl)ethanamine
DMOP128	DE	Discovery agent

DMXSJH0	ID	DMXSJH0
DMXSJH0	DN	N-Methylnaloxonium
DMXSJH0	HS	Investigative
DMXSJH0	SN	N-METHYLNALOXONIUM; (5A,17R)-4,5-EPOXY-3,14-DIHYDROXY-17-METHYL-6-OXO-17-(2-PROPENYL)-MORPHINANIUM; ZINC247655549; DB04509
DMXSJH0	DT	Small molecular drug
DMXSJH0	PC	6323452
DMXSJH0	MW	342.4
DMXSJH0	FM	C20H24NO4+
DMXSJH0	IC	InChI=1S/C20H23NO4/c1-3-9-21(2)10-8-19-16-12-4-5-13(22)17(16)25-18(19)14(23)6-7-20(19,24)15(21)11-12/h3-5,15,18,24H,1,6-11H2,2H3/p+1/t15-,18+,19+,20-,21-/m1/s1
DMXSJH0	CS	C[N@+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC=C
DMXSJH0	IK	PCSQOABIHJXZMR-YNUHATHGSA-O
DMXSJH0	IU	(3S,4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one
DMXSJH0	DE	Discovery agent

DM6DM4L	ID	DM6DM4L
DM6DM4L	DN	N-methyl-N-ethyl estradiol-16-carboxamide
DM6DM4L	HS	Investigative
DM6DM4L	SN	SCHEMBL12379485
DM6DM4L	DT	Small molecular drug
DM6DM4L	PC	44407332
DM6DM4L	MW	357.5
DM6DM4L	FM	C22H31NO3
DM6DM4L	IC	InChI=1S/C22H31NO3/c1-4-23(3)21(26)18-12-19-17-7-5-13-11-14(24)6-8-15(13)16(17)9-10-22(19,2)20(18)25/h6,8,11,16-20,24-25H,4-5,7,9-10,12H2,1-3H3/t16?,17?,18?,19?,20-,22-/m0/s1
DM6DM4L	CS	CCN(C)C(=O)C1CC2C3CCC4=C(C3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DM6DM4L	IK	UVOQIEBXUFHOKA-GFEBWMDQSA-N
DM6DM4L	IU	(13S,17S)-N-ethyl-3,17-dihydroxy-N,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DM6DM4L	DE	Discovery agent

DM2CUEB	ID	DM2CUEB
DM2CUEB	DN	N-methyl-N-ethyl estrone-16-methyl carboxamide
DM2CUEB	HS	Investigative
DM2CUEB	DE	Discovery agent

DMDB7ZM	ID	DMDB7ZM
DMDB7ZM	DN	N-Methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide
DMDB7ZM	HS	Investigative
DMDB7ZM	SN	Oprea1_148524; 3-carboxamido coumarin, 38; Oprea1_635742; CHEMBL448696; BDBM29188; MolPort-004-219-806
DMDB7ZM	DT	Small molecular drug
DMDB7ZM	PC	16376796
DMDB7ZM	MW	279.29
DMDB7ZM	FM	C17H13NO3
DMDB7ZM	IC	InChI=1S/C17H13NO3/c1-18(13-8-3-2-4-9-13)16(19)14-11-12-7-5-6-10-15(12)21-17(14)20/h2-11H,1H3
DMDB7ZM	CS	CN(C1=CC=CC=C1)C(=O)C2=CC3=CC=CC=C3OC2=O
DMDB7ZM	IK	JRUWEFVSUSZZHI-UHFFFAOYSA-N
DMDB7ZM	IU	N-methyl-2-oxo-N-phenylchromene-3-carboxamide
DMDB7ZM	DE	Discovery agent

DMB9OGI	ID	DMB9OGI
DMB9OGI	DN	N-Methyl-N-Propargyl-1(R)-Aminoindan
DMB9OGI	HS	Investigative
DMB9OGI	SN	124192-87-6; N-METHYL-N-PROPARGYL-1(R)-AMINOINDAN; (R)-N-Methyl-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (R)-2,3-Dihydro-N-methyl-N-2-propynyl-1H-inden-1-amine; (R)-N-Methyl-N-(2-propynyl)-2,3-dihydroinden-1-amine; UNII-1Y7XS87IZR; 1Y7XS87IZR; CHEMBL436947; (1R)-N-methyl-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; N-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YL]-N-METHYL-N-PROP-2-YNYLAMINE; R-MPAI; N-Methyl-N-2-propynyl-1-indanamine, (R)-; AC1NRD15; 1H-Inden-1-amine,2,3-dihydro-N-methyl-N-2-propyn-1-yl-, (1R)-
DMB9OGI	DT	Small molecular drug
DMB9OGI	PC	5289295
DMB9OGI	MW	185.26
DMB9OGI	FM	C13H15N
DMB9OGI	IC	InChI=1S/C13H15N/c1-3-10-14(2)13-9-8-11-6-4-5-7-12(11)13/h1,4-7,13H,8-10H2,2H3/t13-/m1/s1
DMB9OGI	CS	CN(CC#C)[C@@H]1CCC2=CC=CC=C12
DMB9OGI	IK	CSVGVHNFFZWQJU-CYBMUJFWSA-N
DMB9OGI	IU	(1R)-N-methyl-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
DMB9OGI	CA	CAS 124192-87-6
DMB9OGI	DE	Discovery agent

DMDAN0K	ID	DMDAN0K
DMDAN0K	DN	N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi)
DMDAN0K	HS	Investigative
DMDAN0K	SN	Donepezil Fumarate
DMDAN0K	DT	Small molecular drug
DMDAN0K	PC	24801487
DMDAN0K	MW	493.5
DMDAN0K	FM	C28H31NO7-2
DMDAN0K	IC	InChI=1S/C24H29NO3.C4H4O4/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;5-3(6)1-2-4(7)8/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1-2H,(H,5,6)(H,7,8)/p-2/b;2-1+
DMDAN0K	CS	COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC.C(=C/C(=O)[O-])\\C(=O)[O-]
DMDAN0K	IK	APUVNJQYQMJLQQ-WLHGVMLRSA-L
DMDAN0K	IU	2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one;(E)-but-2-enedioate
DMDAN0K	DE	Discovery agent

DMZYSM1	ID	DMZYSM1
DMZYSM1	DN	N-methylstephisoferulin
DMZYSM1	HS	Investigative
DMZYSM1	SN	N-methylstephisoferulin; CHEMBL1097077
DMZYSM1	DT	Small molecular drug
DMZYSM1	PC	46888571
DMZYSM1	MW	493.5
DMZYSM1	FM	C28H31NO7
DMZYSM1	IC	InChI=1S/C28H31NO7/c1-29-14-13-26-15-21(35-22(30)12-9-17-7-5-4-6-8-17)25(32)28(34-3)27(26,29)16-20(36-28)18-10-11-19(33-2)24(31)23(18)26/h4-12,20-21,25,31-32H,13-16H2,1-3H3/b12-9+/t20-,21-,25-,26-,27-,28+/m0/s1
DMZYSM1	CS	CN1CC[C@@]23[C@]14C[C@@H](C5=C2C(=C(C=C5)OC)O)O[C@@]4([C@H]([C@H](C3)OC(=O)/C=C/C6=CC=CC=C6)O)OC
DMZYSM1	IK	ZPAQRVPCPJNTSC-YZVVQLETSA-N
DMZYSM1	IU	[(1S,8S,10S,11S,12S,13S)-3,12-dihydroxy-4,11-dimethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.18,11.01,10.02,7]octadeca-2(7),3,5-trien-13-yl] (E)-3-phenylprop-2-enoate
DMZYSM1	DE	Discovery agent

DM5CR2E	ID	DM5CR2E
DM5CR2E	DN	N-methylstephuline
DM5CR2E	HS	Investigative
DM5CR2E	SN	N-methylstephuline; CHEMBL1096481
DM5CR2E	DT	Small molecular drug
DM5CR2E	PC	46888612
DM5CR2E	MW	377.4
DM5CR2E	FM	C20H27NO6
DM5CR2E	IC	InChI=1S/C20H27NO6/c1-21-8-7-18-9-12(22)17(25-3)20(26-4)19(18,21)10-14(27-20)11-5-6-13(24-2)16(23)15(11)18/h5-6,12,14,17,22-23H,7-10H2,1-4H3/t12-,14-,17-,18-,19-,20+/m0/s1
DM5CR2E	CS	CN1CC[C@@]23[C@]14C[C@@H](C5=C2C(=C(C=C5)OC)O)O[C@@]4([C@H]([C@H](C3)O)OC)OC
DM5CR2E	IK	GAUBYMMEBUOLGW-HMOIBATMSA-N
DM5CR2E	IU	(1S,8S,10S,11S,12S,13S)-4,11,12-trimethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.18,11.01,10.02,7]octadeca-2(7),3,5-triene-3,13-diol
DM5CR2E	DE	Discovery agent

DMS8H5Q	ID	DMS8H5Q
DMS8H5Q	DN	NM-PP1
DMS8H5Q	HS	Investigative
DMS8H5Q	SN	1-NM-PP1; 221244-14-0; PP1 Analog II, 1NM-PP1; 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; NM-PP1; Mutant Kinases Inhibitor II; 1NM-PP1(PP1 Analog II); AC1NP9I6; CHEMBL573578; 1 NM-PP1; CHEBI:52309; 4-Amino-1-tert-butyl-3-(1'-naphthylmethyl)pyrazolo[3,4-d]pyrimidine; 1-(tert-butyl)-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; MMV676599; 1-(1,1-dimethylethyl)-3-(1-naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; W-201917; C20H21N5
DMS8H5Q	DT	Small molecular drug
DMS8H5Q	PC	5154691
DMS8H5Q	MW	331.4
DMS8H5Q	FM	C20H21N5
DMS8H5Q	IC	InChI=1S/C20H21N5/c1-20(2,3)25-19-17(18(21)22-12-23-19)16(24-25)11-14-9-6-8-13-7-4-5-10-15(13)14/h4-10,12H,11H2,1-3H3,(H2,21,22,23)
DMS8H5Q	CS	CC(C)(C)N1C2=NC=NC(=C2C(=N1)CC3=CC=CC4=CC=CC=C43)N
DMS8H5Q	IK	GDQXJQSQYMMKRA-UHFFFAOYSA-N
DMS8H5Q	IU	1-tert-butyl-3-(naphthalen-1-ylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DMS8H5Q	CA	CAS 221244-14-0
DMS8H5Q	CB	CHEBI:52309
DMS8H5Q	DE	Discovery agent

DMX4ZGL	ID	DMX4ZGL
DMX4ZGL	DN	NMS-1
DMX4ZGL	HS	Investigative
DMX4ZGL	CP	NeurAxon
DMX4ZGL	TC	Anticancer Agents
DMX4ZGL	DE	Solid tumour/cancer

DMYKZ6U	ID	DMYKZ6U
DMYKZ6U	DN	NMS-873
DMYKZ6U	HS	Investigative
DMYKZ6U	SN	NMS 873; NM S873; EX-A353; NMS873
DMYKZ6U	TC	Antiviral Agents
DMYKZ6U	DT	Small molecular drug
DMYKZ6U	PC	71521142
DMYKZ6U	MW	520.7
DMYKZ6U	FM	C27H28N4O3S2
DMYKZ6U	IC	InChI=1S/C27H28N4O3S2/c1-19-16-22(11-14-25(19)20-9-12-24(13-10-20)36(2,32)33)34-18-26-29-30-27(35-23-7-3-4-8-23)31(26)21-6-5-15-28-17-21/h5-6,9-17,23H,3-4,7-8,18H2,1-2H3
DMYKZ6U	CS	CC1=C(C=CC(=C1)OCC2=NN=C(N2C3=CN=CC=C3)SC4CCCC4)C5=CC=C(C=C5)S(=O)(=O)C
DMYKZ6U	IK	UJGTUKMAJVCBIS-UHFFFAOYSA-N
DMYKZ6U	IU	3-[3-cyclopentylsulfanyl-5-[[3-methyl-4-(4-methylsulfonylphenyl)phenoxy]methyl]-1,2,4-triazol-4-yl]pyridine
DMYKZ6U	DE	Coronavirus Disease 2019 (COVID-19)

DMSQ4TL	ID	DMSQ4TL
DMSQ4TL	DN	NNC 11-1314
DMSQ4TL	HS	Investigative
DMSQ4TL	SN	NNC 11-1314; CHEMBL99521; 8-[4-(3-phenylprop-2-ynoxy)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[2.2.2]octane; GTPL291; SCHEMBL6198562; 3-[4-(3-Phenyl-prop-2-ynyloxy)-[1,2,5]thiadiazol-3-yl]-1-aza-bicyclo[2.2.2]octane; BDBM50072228
DMSQ4TL	DT	Small molecular drug
DMSQ4TL	PC	10426487
DMSQ4TL	MW	325.4
DMSQ4TL	FM	C18H19N3OS
DMSQ4TL	IC	InChI=1S/C18H19N3OS/c1-2-5-14(6-3-1)7-4-12-22-18-17(19-23-20-18)16-13-21-10-8-15(16)9-11-21/h1-3,5-6,15-16H,8-13H2
DMSQ4TL	CS	C1CN2CCC1C(C2)C3=NSN=C3OCC#CC4=CC=CC=C4
DMSQ4TL	IK	SNSMIIQEKVYNOH-UHFFFAOYSA-N
DMSQ4TL	IU	3-(1-azabicyclo[2.2.2]octan-3-yl)-4-(3-phenylprop-2-ynoxy)-1,2,5-thiadiazole
DMSQ4TL	DE	Discovery agent

DMMX19B	ID	DMMX19B
DMMX19B	DN	NNC 11-1585
DMMX19B	HS	Investigative
DMMX19B	SN	NNC 11-1585; GTPL292; BDBM85817
DMMX19B	DT	Small molecular drug
DMMX19B	PC	11757797
DMMX19B	MW	572.7
DMMX19B	FM	C30H32N6O2S2
DMMX19B	IC	InChI=1S/C30H32N6O2S2/c1(17-37-29-27(31-39-33-29)25-19-35-13-9-23(25)10-14-35)3-21-5-7-22(8-6-21)4-2-18-38-30-28(32-40-34-30)26-20-36-15-11-24(26)12-16-36/h5-8,23-26H,9-20H2
DMMX19B	CS	C1CN2CCC1C(C2)C3=NSN=C3OCC#CC4=CC=C(C=C4)C#CCOC5=NSN=C5C6CN7CCC6CC7
DMMX19B	IK	ROEXPZFFOZZHOY-UHFFFAOYSA-N
DMMX19B	IU	3-(1-azabicyclo[2.2.2]octan-3-yl)-4-[3-[4-[3-[[4-(1-azabicyclo[2.2.2]octan-3-yl)-1,2,5-thiadiazol-3-yl]oxy]prop-1-ynyl]phenyl]prop-2-ynoxy]-1,2,5-thiadiazole
DMMX19B	DE	Discovery agent

DMZJSWI	ID	DMZJSWI
DMZJSWI	DN	NNC 11-1607
DMZJSWI	HS	Investigative
DMZJSWI	SN	NNC 11-1607; GTPL293; BDBM85816; NNC-11-1607
DMZJSWI	DT	Small molecular drug
DMZJSWI	PC	9985526
DMZJSWI	MW	572.7
DMZJSWI	FM	C30H32N6O2S2
DMZJSWI	IC	InChI=1S/C30H32N6O2S2/c1-4-21(6-2-16-37-29-27(31-39-33-29)25-19-35-12-8-23(25)9-13-35)18-22(5-1)7-3-17-38-30-28(32-40-34-30)26-20-36-14-10-24(26)11-15-36/h1,4-5,18,23-26H,8-17,19-20H2
DMZJSWI	CS	C1CN2CCC1C(C2)C3=NSN=C3OCC#CC4=CC(=CC=C4)C#CCOC5=NSN=C5C6CN7CCC6CC7
DMZJSWI	IK	TYLFZULSDOOCRC-UHFFFAOYSA-N
DMZJSWI	IU	3-(1-azabicyclo[2.2.2]octan-3-yl)-4-[3-[3-[3-[[4-(1-azabicyclo[2.2.2]octan-3-yl)-1,2,5-thiadiazol-3-yl]oxy]prop-1-ynyl]phenyl]prop-2-ynoxy]-1,2,5-thiadiazole
DMZJSWI	DE	Discovery agent

DM0C8N3	ID	DM0C8N3
DM0C8N3	DN	NNC 711
DM0C8N3	HS	Investigative
DM0C8N3	SN	NO-711 hydrochloride; 145645-62-1; UNII-500M0G931K; 1-(2-(((Diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid; 500M0G931K; 1-[2-[[(Diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride hydrochloride; 1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE; C21H23ClN2O3; 3-Pyridinecarboxylic acid, 1,2,5,6-tetrahydro-1-(2-(((diphenylmethylene)amino)oxy)ethyl)-,
DM0C8N3	DT	Small molecular drug
DM0C8N3	PC	123738
DM0C8N3	MW	386.9
DM0C8N3	FM	C21H23ClN2O3
DM0C8N3	IC	InChI=1S/C21H22N2O3.ClH/c24-21(25)19-12-7-13-23(16-19)14-15-26-22-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18;/h1-6,8-12H,7,13-16H2,(H,24,25);1H
DM0C8N3	CS	C1CN(CC(=C1)C(=O)O)CCON=C(C2=CC=CC=C2)C3=CC=CC=C3.Cl
DM0C8N3	IK	YZYRTEYMUTWJPL-UHFFFAOYSA-N
DM0C8N3	IU	1-[2-(benzhydrylideneamino)oxyethyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid;hydrochloride
DM0C8N3	CA	CAS 145645-62-1
DM0C8N3	DE	Discovery agent

DMPQ1HL	ID	DMPQ1HL
DMPQ1HL	DN	NNC 92-1687
DMPQ1HL	HS	Investigative
DMPQ1HL	SN	NNC92-1687
DMPQ1HL	DT	Small molecular drug
DMPQ1HL	PC	4206177
DMPQ1HL	MW	300.3
DMPQ1HL	FM	C15H12N2O3S
DMPQ1HL	IC	InChI=1S/C15H12N2O3S/c18-12-6-5-9(7-13(12)19)14(20)8-21-15-16-10-3-1-2-4-11(10)17-15/h1-7,18-19H,8H2,(H,16,17)
DMPQ1HL	CS	C1=CC=C2C(=C1)NC(=N2)SCC(=O)C3=CC(=C(C=C3)O)O
DMPQ1HL	IK	NVYSVDRYESXWBD-UHFFFAOYSA-N
DMPQ1HL	IU	2-(1H-benzimidazol-2-ylsulfanyl)-1-(3,4-dihydroxyphenyl)ethanone
DMPQ1HL	DE	Discovery agent

DMCGF3U	ID	DMCGF3U
DMCGF3U	DN	NNC052090
DMCGF3U	HS	Investigative
DMCGF3U	SN	NNC 05-2090
DMCGF3U	DT	Small molecular drug
DMCGF3U	PC	9888030
DMCGF3U	MW	414.5
DMCGF3U	FM	C27H30N2O2
DMCGF3U	IC	InChI=1S/C27H30N2O2/c1-31-26-14-7-4-11-23(26)27(30)15-19-28(20-16-27)17-8-18-29-24-12-5-2-9-21(24)22-10-3-6-13-25(22)29/h2-7,9-14,30H,8,15-20H2,1H3
DMCGF3U	CS	COC1=CC=CC=C1C2(CCN(CC2)CCCN3C4=CC=CC=C4C5=CC=CC=C53)O
DMCGF3U	IK	XZZYCJOGZYEPPW-UHFFFAOYSA-N
DMCGF3U	IU	1-(3-carbazol-9-ylpropyl)-4-(2-methoxyphenyl)piperidin-4-ol
DMCGF3U	CB	CHEBI:93487
DMCGF3U	DE	Discovery agent

DMDCPFJ	ID	DMDCPFJ
DMDCPFJ	DN	NNC-26-0194
DMDCPFJ	HS	Investigative
DMDCPFJ	SN	171094-42-1
DMDCPFJ	PC	9918732
DMDCPFJ	MW	792
DMDCPFJ	FM	C44H57N9O5
DMDCPFJ	IC	InChI=1S/C44H57N9O5/c1-30(50-43(57)39(23-32-14-6-3-7-15-32)52-41(55)20-19-34-26-46-29-49-34)42(56)53-40(24-33-25-48-38-18-9-8-17-37(33)38)44(58)51-36(22-31-12-4-2-5-13-31)27-47-35(28-54)16-10-11-21-45/h2-9,12-15,17-18,25-26,29-30,35-36,39-40,47-48,54H,10-11,16,19-24,27-28,45H2,1H3,(H,46,49)(H,50,57)(H,51,58)(H,52,55)(H,53,56)/t30-,35-,36+,39+,40-/m0/s1
DMDCPFJ	CS	C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CC=CC=C3)CN[C@@H](CCCCN)CO)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)CCC5=CN=CN5
DMDCPFJ	IK	JSMAHBKHVYKVJD-CIUDAOKXSA-N
DMDCPFJ	IU	(2R)-N-[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-6-amino-1-hydroxyhexan-2-yl]amino]-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-[3-(1H-imidazol-5-yl)propanoylamino]-3-phenylpropanamide
DMDCPFJ	DE	Discovery agent

DMAQTW3	ID	DMAQTW3
DMAQTW3	DN	NNC269100
DMAQTW3	HS	Investigative
DMAQTW3	SN	NNC-269100; NNC 269100
DMAQTW3	DT	Small molecular drug
DMAQTW3	PC	5311371
DMAQTW3	MW	540.3
DMAQTW3	FM	C22H25BrCl2N6O
DMAQTW3	IC	InChI=1S/C22H25BrCl2N6O/c23-17-5-7-21(29-12-17)31(14-16-4-6-19(24)20(25)11-16)10-2-9-28-22(32)27-8-1-3-18-13-26-15-30-18/h4-7,11-13,15H,1-3,8-10,14H2,(H,26,30)(H2,27,28,32)
DMAQTW3	CS	C1=CC(=C(C=C1CN(CCCNC(=O)NCCCC2=CN=CN2)C3=NC=C(C=C3)Br)Cl)Cl
DMAQTW3	IK	QJDXAQZNKZDALD-UHFFFAOYSA-N
DMAQTW3	IU	1-[3-[(5-bromopyridin-2-yl)-[(3,4-dichlorophenyl)methyl]amino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]urea
DMAQTW3	DE	Discovery agent

DMID3F7	ID	DMID3F7
DMID3F7	DN	NNC55-0396
DMID3F7	HS	Investigative
DMID3F7	SN	NNC 55-0396
DMID3F7	DT	Small molecular drug
DMID3F7	PC	9957280
DMID3F7	MW	491.6
DMID3F7	FM	C30H38FN3O2
DMID3F7	IC	InChI=1S/C30H38FN3O2/c1-20(2)28-24-13-12-23(31)19-22(24)14-15-30(28,36-29(35)21-10-11-21)16-18-34(3)17-6-9-27-32-25-7-4-5-8-26(25)33-27/h4-5,7-8,12-13,19-21,28H,6,9-11,14-18H2,1-3H3,(H,32,33)/t28-,30-/m0/s1
DMID3F7	CS	CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)C5CC5)C=C(C=C2)F
DMID3F7	IK	VHHVPDKNKPNKHY-JDXGNMNLSA-N
DMID3F7	IU	[(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] cyclopropanecarboxylate
DMID3F7	CA	CAS 357400-14-7
DMID3F7	CB	CHEBI:93374
DMID3F7	DE	Discovery agent

DMUHZ23	ID	DMUHZ23
DMUHZ23	DN	N-N-diethyl estradiol-16-methyl carboxamide
DMUHZ23	HS	Investigative
DMUHZ23	SN	SCHEMBL12379569
DMUHZ23	DT	Small molecular drug
DMUHZ23	PC	44407521
DMUHZ23	MW	385.5
DMUHZ23	FM	C24H35NO3
DMUHZ23	IC	InChI=1S/C24H35NO3/c1-4-25(5-2)22(27)14-16-13-21-20-8-6-15-12-17(26)7-9-18(15)19(20)10-11-24(21,3)23(16)28/h7,9,12,16,19-21,23,26,28H,4-6,8,10-11,13-14H2,1-3H3/t16?,19?,20?,21?,23-,24-/m0/s1
DMUHZ23	CS	CCN(CC)C(=O)CC1CC2C3CCC4=C(C3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DMUHZ23	IK	VGGFHJKLCAAIOU-CGCZFLRESA-N
DMUHZ23	IU	2-[(13S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]-N,N-diethylacetamide
DMUHZ23	DE	Discovery agent

DMSYOHD	ID	DMSYOHD
DMSYOHD	DN	NN-dimethyl-D-erythrosphingosine
DMSYOHD	HS	Investigative
DMSYOHD	SN	N,N-DMS; UNII-L9QRA71834; C20H41NO2; L9QRA71834; 122314-67-4; 4-Octadecene-1,3-diol, 2-(dimethylamino)-, (S-(R*,S*-(E)))-; AC1O5P5P; GTPL2454; CHEMBL447685; ZINC43706449; 1710AH; LS-172527; N,N-Dimethylsphingosine, &gt; =98.0% (TLC); (E,2R,3S)-2-dimethylaminooctadec-4-ene-1,3-diol; (E,2R,3S)-2-(dimethylamino)octadec-4-ene-1,3-diol; (2R,3S,E)-2-(dimethylamino)octadec-4-ene-1,3-diol; (e,2r,3s)-2-(dimethylamino)-octadec-4-ene-1,3-diol
DMSYOHD	DT	Small molecular drug
DMSYOHD	PC	6438166
DMSYOHD	MW	327.5
DMSYOHD	FM	C20H41NO2
DMSYOHD	IC	InChI=1S/C20H41NO2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)19(18-22)21(2)3/h16-17,19-20,22-23H,4-15,18H2,1-3H3/b17-16+/t19-,20+/m1/s1
DMSYOHD	CS	CCCCCCCCCCCCC/C=C/[C@@H]([C@@H](CO)N(C)C)O
DMSYOHD	IK	YRXOQXUDKDCXME-QWKHPXNBSA-N
DMSYOHD	IU	(E,2R,3S)-2-(dimethylamino)octadec-4-ene-1,3-diol
DMSYOHD	CA	CAS 122314-67-4
DMSYOHD	DE	Discovery agent

DM8FOSR	ID	DM8FOSR
DM8FOSR	DN	N-n-dodecyl-7-methoxytacrine hydrochloride
DM8FOSR	HS	Investigative
DM8FOSR	SN	CHEMBL1257525
DM8FOSR	DT	Small molecular drug
DM8FOSR	PC	52945010
DM8FOSR	MW	396.6
DM8FOSR	FM	C26H40N2O
DM8FOSR	IC	InChI=1S/C26H40N2O/c1-3-4-5-6-7-8-9-10-11-14-19-27-26-22-15-12-13-16-24(22)28-25-18-17-21(29-2)20-23(25)26/h17-18,20H,3-16,19H2,1-2H3,(H,27,28)
DM8FOSR	CS	CCCCCCCCCCCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)OC
DM8FOSR	IK	YFVGMWQTMYFWMS-UHFFFAOYSA-N
DM8FOSR	IU	N-dodecyl-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine
DM8FOSR	DE	Discovery agent

DMSUK2A	ID	DMSUK2A
DMSUK2A	DN	N-Neopentyl-1'H-phenothiazine-1'-carboxamide
DMSUK2A	HS	Investigative
DMSUK2A	SN	CHEMBL592432; BDBM50308432
DMSUK2A	DT	Small molecular drug
DMSUK2A	PC	46229025
DMSUK2A	MW	312.4
DMSUK2A	FM	C18H20N2OS
DMSUK2A	IC	InChI=1S/C18H20N2OS/c1-18(2,3)12-19-17(21)20-13-8-4-6-10-15(13)22-16-11-7-5-9-14(16)20/h4-11H,12H2,1-3H3,(H,19,21)
DMSUK2A	CS	CC(C)(C)CNC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMSUK2A	IK	IOIGXILMSZNTOC-UHFFFAOYSA-N
DMSUK2A	IU	N-(2,2-dimethylpropyl)phenothiazine-10-carboxamide
DMSUK2A	DE	Discovery agent

DMA8R47	ID	DMA8R47
DMA8R47	DN	N-n-heptyl-7-methoxytacrine hydrochloride
DMA8R47	HS	Investigative
DMA8R47	SN	CHEMBL1257767
DMA8R47	DT	Small molecular drug
DMA8R47	PC	10496398
DMA8R47	MW	326.5
DMA8R47	FM	C21H30N2O
DMA8R47	IC	InChI=1S/C21H30N2O/c1-3-4-5-6-9-14-22-21-17-10-7-8-11-19(17)23-20-13-12-16(24-2)15-18(20)21/h12-13,15H,3-11,14H2,1-2H3,(H,22,23)
DMA8R47	CS	CCCCCCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)OC
DMA8R47	IK	XRCKCYUZWSKFGD-UHFFFAOYSA-N
DMA8R47	IU	N-heptyl-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine
DMA8R47	DE	Discovery agent

DM4ZMG6	ID	DM4ZMG6
DM4ZMG6	DN	N-n-hexyl-7-methoxytacrine hydrochloride
DM4ZMG6	HS	Investigative
DM4ZMG6	SN	CHEMBL1257885
DM4ZMG6	DT	Small molecular drug
DM4ZMG6	PC	52941983
DM4ZMG6	MW	312.4
DM4ZMG6	FM	C20H28N2O
DM4ZMG6	IC	InChI=1S/C20H28N2O/c1-3-4-5-8-13-21-20-16-9-6-7-10-18(16)22-19-12-11-15(23-2)14-17(19)20/h11-12,14H,3-10,13H2,1-2H3,(H,21,22)
DM4ZMG6	CS	CCCCCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)OC
DM4ZMG6	IK	FHJNAXWWTVBTEP-UHFFFAOYSA-N
DM4ZMG6	IU	N-hexyl-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine
DM4ZMG6	DE	Discovery agent

DMLH23M	ID	DMLH23M
DMLH23M	DN	N-n-nonyl-7-methoxytacrine hydrochloride
DMLH23M	HS	Investigative
DMLH23M	SN	CHEMBL1257644
DMLH23M	DT	Small molecular drug
DMLH23M	PC	52946279
DMLH23M	MW	354.5
DMLH23M	FM	C23H34N2O
DMLH23M	IC	InChI=1S/C23H34N2O/c1-3-4-5-6-7-8-11-16-24-23-19-12-9-10-13-21(19)25-22-15-14-18(26-2)17-20(22)23/h14-15,17H,3-13,16H2,1-2H3,(H,24,25)
DMLH23M	CS	CCCCCCCCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)OC
DMLH23M	IK	CMKNYPAMAODIKM-UHFFFAOYSA-N
DMLH23M	IU	7-methoxy-N-nonyl-1,2,3,4-tetrahydroacridin-9-amine
DMLH23M	DE	Discovery agent

DMLC257	ID	DMLC257
DMLC257	DN	N-n-octyl-7-methoxytacrine hydrochloride
DMLC257	HS	Investigative
DMLC257	SN	CHEMBL1257766
DMLC257	DT	Small molecular drug
DMLC257	PC	52948017
DMLC257	MW	340.5
DMLC257	FM	C22H32N2O
DMLC257	IC	InChI=1S/C22H32N2O/c1-3-4-5-6-7-10-15-23-22-18-11-8-9-12-20(18)24-21-14-13-17(25-2)16-19(21)22/h13-14,16H,3-12,15H2,1-2H3,(H,23,24)
DMLC257	CS	CCCCCCCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)OC
DMLC257	IK	IFHMPKOJBNGXHV-UHFFFAOYSA-N
DMLC257	IU	7-methoxy-N-octyl-1,2,3,4-tetrahydroacridin-9-amine
DMLC257	DE	Discovery agent

DMH3OUX	ID	DMH3OUX
DMH3OUX	DN	N-nonylphenol
DMH3OUX	HS	Investigative
DMH3OUX	SN	Nonylphenol (mixed); Phenol, 4-nonyl-; Phenol, nonyl derivs.; Phenol, p-nonyl-; p -n -Nonylphenol; p-Nonylphenol; p-n-Nonylphenol; p-nonyl phenol; 4-N-nonylphenol; para Nonyl phenol; para-Nonylphenol; 1-(4-Hydroxyphenyl)nonane; 104-40-5; 4-NP; 4-Nonyl Phenol-13C6; 4-Nonyl-Phenol; 4-n-Nonyl phenol; 4-n-Nonylphenol; 4-nonyl phenol; 4-nonylphenol; 68081-86-7; BRN 2047450; CCRIS 1251; CHEBI:34440; DSSTox_CID_1857; IGFHQQFPSIBGKE-UHFFFAOYSA-N; DSSTox_GSID_33836; DSSTox_RID_79098; EINECS 203-199-4; HSDB 5359; MFCD00002396; P-NONYLPHENOL (ENDOCRINE DISRUPTER)
DMH3OUX	PC	1752
DMH3OUX	MW	220.35
DMH3OUX	FM	C15H24O
DMH3OUX	IC	IGFHQQFPSIBGKE-UHFFFAOYSA-N
DMH3OUX	CS	CCCCCCCCCC1=CC=C(C=C1)O
DMH3OUX	IK	1S/C15H24O/c1-2-3-4-5-6-7-8-9-14-10-12-15(16)13-11-14/h10-13,16H,2-9H2,1H3
DMH3OUX	IU	4-nonylphenol
DMH3OUX	CA	CAS 104-40-5
DMH3OUX	CB	CHEBI:34440
DMH3OUX	DE	Discovery agent

DMWAK5V	ID	DMWAK5V
DMWAK5V	DN	N-n-pentyl-7-methoxytacrine hydrochloride
DMWAK5V	HS	Investigative
DMWAK5V	SN	CHEMBL1257886
DMWAK5V	DT	Small molecular drug
DMWAK5V	PC	52945624
DMWAK5V	MW	298.4
DMWAK5V	FM	C19H26N2O
DMWAK5V	IC	InChI=1S/C19H26N2O/c1-3-4-7-12-20-19-15-8-5-6-9-17(15)21-18-11-10-14(22-2)13-16(18)19/h10-11,13H,3-9,12H2,1-2H3,(H,20,21)
DMWAK5V	CS	CCCCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)OC
DMWAK5V	IK	KBBSAAQAJDSCGH-UHFFFAOYSA-N
DMWAK5V	IU	7-methoxy-N-pentyl-1,2,3,4-tetrahydroacridin-9-amine
DMWAK5V	DE	Discovery agent

DMCN78A	ID	DMCN78A
DMCN78A	DN	N-n-propyl-7-methoxytacrine hydrochloride
DMCN78A	HS	Investigative
DMCN78A	SN	CHEMBL1257996
DMCN78A	DT	Small molecular drug
DMCN78A	PC	52945680
DMCN78A	MW	270.37
DMCN78A	FM	C17H22N2O
DMCN78A	IC	InChI=1S/C17H22N2O/c1-3-10-18-17-13-6-4-5-7-15(13)19-16-9-8-12(20-2)11-14(16)17/h8-9,11H,3-7,10H2,1-2H3,(H,18,19)
DMCN78A	CS	CCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)OC
DMCN78A	IK	GFBWOLCGRWIJDE-UHFFFAOYSA-N
DMCN78A	IU	7-methoxy-N-propyl-1,2,3,4-tetrahydroacridin-9-amine
DMCN78A	DE	Discovery agent

DMN7GO8	ID	DMN7GO8
DMN7GO8	DN	NOCARDIMICIN A
DMN7GO8	HS	Investigative
DMN7GO8	DT	Small molecular drug
DMN7GO8	PC	3013845
DMN7GO8	MW	729.9
DMN7GO8	FM	C37H55N5O10
DMN7GO8	IC	InChI=1S/C37H55N5O10/c1-4-5-6-7-8-9-10-21-32(25(2)33(45)38-28-18-13-16-23-42(50)36(28)47)52-37(48)29(19-14-15-22-41(49)26(3)43)39-34(46)30-24-51-35(40-30)27-17-11-12-20-31(27)44/h11-12,17,20,24-25,28-29,32,44,49-50H,4-10,13-16,18-19,21-23H2,1-3H3,(H,38,45)(H,39,46)
DMN7GO8	CS	CCCCCCCCCC(C(C)C(=O)NC1CCCCN(C1=O)O)OC(=O)C(CCCCN(C(=O)C)O)NC(=O)C2=COC(=N2)C3=CC=CC=C3O
DMN7GO8	IK	LGOZXNLEMXJIMS-UHFFFAOYSA-N
DMN7GO8	IU	[1-[(1-hydroxy-2-oxoazepan-3-yl)amino]-2-methyl-1-oxododecan-3-yl] 6-[acetyl(hydroxy)amino]-2-[[2-(2-hydroxyphenyl)-1,3-oxazole-4-carbonyl]amino]hexanoate
DMN7GO8	DE	Discovery agent

DM4SRL7	ID	DM4SRL7
DM4SRL7	DN	Nocardimicin C
DM4SRL7	HS	Investigative
DM4SRL7	DT	Small molecular drug
DM4SRL7	PC	3013847
DM4SRL7	MW	741.9
DM4SRL7	FM	C39H59N5O9
DM4SRL7	IC	InChI=1S/C39H59N5O9/c1-4-5-6-7-8-9-10-11-12-23-34(27(2)35(47)41-30-20-15-17-24-40-36(30)48)53-39(50)31(21-16-18-25-44(51)28(3)45)42-37(49)32-26-52-38(43-32)29-19-13-14-22-33(29)46/h13-14,19,22,26-27,30-31,34,46,51H,4-12,15-18,20-21,23-25H2,1-3H3,(H,40,48)(H,41,47)(H,42,49)
DM4SRL7	CS	CCCCCCCCCCCC(C(C)C(=O)NC1CCCCNC1=O)OC(=O)C(CCCCN(C(=O)C)O)NC(=O)C2=COC(=N2)C3=CC=CC=C3O
DM4SRL7	IK	ZRSRFOLUVALIAN-UHFFFAOYSA-N
DM4SRL7	IU	[2-methyl-1-oxo-1-[(2-oxoazepan-3-yl)amino]tetradecan-3-yl] 6-[acetyl(hydroxy)amino]-2-[[2-(2-hydroxyphenyl)-1,3-oxazole-4-carbonyl]amino]hexanoate
DM4SRL7	DE	Discovery agent

DM1SABZ	ID	DM1SABZ
DM1SABZ	DN	Nocardimicin D
DM1SABZ	HS	Investigative
DM1SABZ	DT	Small molecular drug
DM1SABZ	PC	135494454
DM1SABZ	MW	786
DM1SABZ	FM	C41H63N5O10
DM1SABZ	IC	InChI=1S/C41H63N5O10/c1-4-5-6-7-8-9-10-11-12-13-14-25-36(29(2)37(49)42-32-22-17-20-27-46(54)40(32)51)56-41(52)33(23-18-19-26-45(53)30(3)47)43-38(50)34-28-55-39(44-34)31-21-15-16-24-35(31)48/h15-16,21,24,28-29,32-33,36,48,53-54H,4-14,17-20,22-23,25-27H2,1-3H3,(H,42,49)(H,43,50)
DM1SABZ	CS	CCCCCCCCCCCCCC(C(C)C(=O)NC1CCCCN(C1=O)O)OC(=O)C(CCCCN(C(=O)C)O)NC(=O)C2=COC(=N2)C3=CC=CC=C3O
DM1SABZ	IK	CILDOHPTQUQJJM-UHFFFAOYSA-N
DM1SABZ	IU	[1-[(1-hydroxy-2-oxoazepan-3-yl)amino]-2-methyl-1-oxohexadecan-3-yl] 6-[acetyl(hydroxy)amino]-2-[[2-(2-hydroxyphenyl)-1,3-oxazole-4-carbonyl]amino]hexanoate
DM1SABZ	DE	Discovery agent

DMK02YC	ID	DMK02YC
DMK02YC	DN	Nocardimicin F
DMK02YC	HS	Investigative
DMK02YC	DT	Small molecular drug
DMK02YC	PC	135423423
DMK02YC	MW	814
DMK02YC	FM	C43H67N5O10
DMK02YC	IC	InChI=1S/C43H67N5O10/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-27-38(31(2)39(51)44-34-24-19-22-29-48(56)42(34)53)58-43(54)35(25-20-21-28-47(55)32(3)49)45-40(52)36-30-57-41(46-36)33-23-17-18-26-37(33)50/h17-18,23,26,30-31,34-35,38,50,55-56H,4-16,19-22,24-25,27-29H2,1-3H3,(H,44,51)(H,45,52)
DMK02YC	CS	CCCCCCCCCCCCCCCC(C(C)C(=O)NC1CCCCN(C1=O)O)OC(=O)C(CCCCN(C(=O)C)O)NC(=O)C2=COC(=N2)C3=CC=CC=C3O
DMK02YC	IK	JJWFEHNQRVSVKR-UHFFFAOYSA-N
DMK02YC	IU	[1-[(1-hydroxy-2-oxoazepan-3-yl)amino]-2-methyl-1-oxooctadecan-3-yl] 6-[acetyl(hydroxy)amino]-2-[[2-(2-hydroxyphenyl)-1,3-oxazole-4-carbonyl]amino]hexanoate
DMK02YC	DE	Discovery agent

DMXOF4Z	ID	DMXOF4Z
DMXOF4Z	DN	Noccardimicin E
DMXOF4Z	HS	Investigative
DMXOF4Z	DT	Small molecular drug
DMXOF4Z	PC	135466875
DMXOF4Z	MW	770
DMXOF4Z	FM	C41H63N5O9
DMXOF4Z	IC	InChI=1S/C41H63N5O9/c1-4-5-6-7-8-9-10-11-12-13-14-25-36(29(2)37(49)43-32-22-17-19-26-42-38(32)50)55-41(52)33(23-18-20-27-46(53)30(3)47)44-39(51)34-28-54-40(45-34)31-21-15-16-24-35(31)48/h15-16,21,24,28-29,32-33,36,48,53H,4-14,17-20,22-23,25-27H2,1-3H3,(H,42,50)(H,43,49)(H,44,51)
DMXOF4Z	CS	CCCCCCCCCCCCCC(C(C)C(=O)NC1CCCCNC1=O)OC(=O)C(CCCCN(C(=O)C)O)NC(=O)C2=COC(=N2)C3=CC=CC=C3O
DMXOF4Z	IK	PIFYJYLXAXDUEB-UHFFFAOYSA-N
DMXOF4Z	IU	[2-methyl-1-oxo-1-[(2-oxoazepan-3-yl)amino]hexadecan-3-yl] 6-[acetyl(hydroxy)amino]-2-[[2-(2-hydroxyphenyl)-1,3-oxazole-4-carbonyl]amino]hexanoate
DMXOF4Z	DE	Discovery agent

DMKTE5V	ID	DMKTE5V
DMKTE5V	DN	N-octadecyl-N'-propylsulfamide
DMKTE5V	HS	Investigative
DMKTE5V	SN	CHEMBL219156; N-octadecyl-N'-propylsulfamide; SCHEMBL3119510; N-octadecyl-N''-propylsulfamide; VOJRCUXNIZFQKR-UHFFFAOYSA-N; MolPort-009-019-252; ZINC38151177
DMKTE5V	DT	Small molecular drug
DMKTE5V	PC	16103197
DMKTE5V	MW	390.7
DMKTE5V	FM	C21H46N2O2S
DMKTE5V	IC	InChI=1S/C21H46N2O2S/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-23-26(24,25)22-20-4-2/h22-23H,3-21H2,1-2H3
DMKTE5V	CS	CCCCCCCCCCCCCCCCCCNS(=O)(=O)NCCC
DMKTE5V	IK	VOJRCUXNIZFQKR-UHFFFAOYSA-N
DMKTE5V	IU	N-(propylsulfamoyl)octadecan-1-amine
DMKTE5V	DE	Discovery agent

DM95JEW	ID	DM95JEW
DM95JEW	DN	N-Octylcarbamic Acid Biphenyl-3-yl Ester
DM95JEW	HS	Investigative
DM95JEW	SN	CHEMBL487317; n-Octylcarbamic Acid Biphenyl-3-yl Ester
DM95JEW	DT	Small molecular drug
DM95JEW	PC	24881672
DM95JEW	MW	325.4
DM95JEW	FM	C21H27NO2
DM95JEW	IC	InChI=1S/C21H27NO2/c1-2-3-4-5-6-10-16-22-21(23)24-20-15-11-14-19(17-20)18-12-8-7-9-13-18/h7-9,11-15,17H,2-6,10,16H2,1H3,(H,22,23)
DM95JEW	CS	CCCCCCCCNC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DM95JEW	IK	ZVIQRVAPSQCQGM-UHFFFAOYSA-N
DM95JEW	IU	(3-phenylphenyl) N-octylcarbamate
DM95JEW	DE	Discovery agent

DM50TCG	ID	DM50TCG
DM50TCG	DN	Nogalamycin
DM50TCG	HS	Investigative
DM50TCG	SN	AC1MBPR2
DM50TCG	DT	Small molecular drug
DM50TCG	PC	5289019
DM50TCG	MW	787.8
DM50TCG	FM	C39H49NO16
DM50TCG	IC	InChI=1S/C39H49NO16/c1-14-32(49-7)39(4,52-10)33(50-8)36(53-14)54-19-13-37(2,48)24(34(47)51-9)15-11-16-21(27(43)20(15)19)28(44)22-18(41)12-17-30(23(22)26(16)42)55-35-29(45)25(40(5)6)31(46)38(17,3)56-35/h11-12,14,19,24-25,29,31-33,35-36,41,43,45-46,48H,13H2,1-10H3/t14-,19-,24-,25-,29-,31+,32-,33-,35+,36-,37-,38+,39+/m0/s1
DM50TCG	CS	C[C@H]1[C@@H]([C@@]([C@H]([C@@H](O1)O[C@H]2C[C@]([C@@H](C3=CC4=C(C(=C23)O)C(=O)C5=C(C=C6C(=C5C4=O)O[C@H]7[C@H]([C@@H]([C@H]([C@@]6(O7)C)O)N(C)C)O)O)C(=O)OC)(C)O)OC)(C)OC)OC
DM50TCG	IK	KGTDRFCXGRULNK-JYOBTZKQSA-N
DM50TCG	IU	methyl (1R,10S,12S,13R,21R,22S,23R,24R)-23-(dimethylamino)-4,8,12,22,24-pentahydroxy-1,12-dimethyl-6,17-dioxo-10-[(2R,3R,4R,5S,6S)-3,4,5-trimethoxy-4,6-dimethyloxan-2-yl]oxy-20,25-dioxahexacyclo[19.3.1.02,19.05,18.07,16.09,14]pentacosa-2,4,7(16),8,14,18-hexaene-13-carboxylate
DM50TCG	CA	CAS 1404-15-5
DM50TCG	CB	CHEBI:44504
DM50TCG	DE	Discovery agent

DMYZRTB	ID	DMYZRTB
DMYZRTB	DN	Nojirimycine Tetrazole
DMYZRTB	HS	Investigative
DMYZRTB	SN	nojirimycine tetrazole; (5R,6R,7S,8S)-5-(hydroxymethyl)-5,6,7,8-tetrahydrotetrazolo[1,5-a]pyridine-6,7,8-triol; Gluco-tetrazole; 1noi; 1nok; 1noj; 2j7b; AC1L9HNU; ZINC17193216
DMYZRTB	DT	Small molecular drug
DMYZRTB	PC	445245
DMYZRTB	MW	202.17
DMYZRTB	FM	C6H10N4O4
DMYZRTB	IC	InChI=1S/C6H10N4O4/c11-1-2-3(12)4(13)5(14)6-7-8-9-10(2)6/h2-5,11-14H,1H2/t2-,3-,4+,5-/m1/s1
DMYZRTB	CS	C([C@@H]1[C@H]([C@@H]([C@H](C2=NN=NN12)O)O)O)O
DMYZRTB	IK	UCJXQRFJERKPOZ-SQOUGZDYSA-N
DMYZRTB	IU	(5R,6R,7S,8S)-5-(hydroxymethyl)-5,6,7,8-tetrahydrotetrazolo[1,5-a]pyridine-6,7,8-triol
DMYZRTB	DE	Discovery agent

DM1AVCZ	ID	DM1AVCZ
DM1AVCZ	DN	N-oleoyl-dopamine
DM1AVCZ	HS	Investigative
DM1AVCZ	SN	N-Oleoyldopamine; OLDA; N-Oleoyl dopamine; N-oleoyl-dopamine; 105955-11-1; OLEOYL DOPAMINE; UNII-T87P7X9XSZ; T87P7X9XSZ; N-[2-(3,4-dihydroxyphenyl)ethyl]-9Z-octadecenamide; CHEMBL250711; CHEBI:31883; (Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]octadec-9-enamide; SR-01000076132; AC1NQZHH; Lopac-O-2139; Lopac0_001058; SCHEMBL93916; MLS002153451; N-(9Z-octadecanoyl)-dopamine; GTPL5552; BML3-G02; cid_5282106; (9Z)- N-(2-(3,4-Dihydroxyphenyl)ethyl)-9-octadecenamide; MolPort-003-959-070; QQBPLXNESPTPNU-KTKRTIGZSA-N; HMS3648E03; HMS3263C18
DM1AVCZ	DT	Small molecular drug
DM1AVCZ	PC	5282106
DM1AVCZ	MW	417.6
DM1AVCZ	FM	C26H43NO3
DM1AVCZ	IC	InChI=1S/C26H43NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-26(30)27-21-20-23-18-19-24(28)25(29)22-23/h9-10,18-19,22,28-29H,2-8,11-17,20-21H2,1H3,(H,27,30)/b10-9-
DM1AVCZ	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=CC(=C(C=C1)O)O
DM1AVCZ	IK	QQBPLXNESPTPNU-KTKRTIGZSA-N
DM1AVCZ	IU	(Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]octadec-9-enamide
DM1AVCZ	CA	CAS 105955-11-1
DM1AVCZ	CB	CHEBI:31883
DM1AVCZ	DE	Discovery agent

DMJQ4L7	ID	DMJQ4L7
DMJQ4L7	DN	N-oleoylethanolamide
DMJQ4L7	HS	Investigative
DMJQ4L7	SN	n-Oleoylethanolamine; n-oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; N-oleoylethanolamine; oleylethanolamide; NOE; OLEOYLETHANOLAMIDE
DMJQ4L7	DT	Small molecular drug
DMJQ4L7	PC	5283454
DMJQ4L7	MW	325.5
DMJQ4L7	FM	C20H39NO2
DMJQ4L7	IC	InChI=1S/C20H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h9-10,22H,2-8,11-19H2,1H3,(H,21,23)/b10-9-
DMJQ4L7	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NCCO
DMJQ4L7	IK	BOWVQLFMWHZBEF-KTKRTIGZSA-N
DMJQ4L7	IU	(Z)-N-(2-hydroxyethyl)octadec-9-enamide
DMJQ4L7	CA	CAS 111-58-0
DMJQ4L7	CB	CHEBI:71466
DMJQ4L7	DE	Discovery agent

DMRU21X	ID	DMRU21X
DMRU21X	DN	N-oleoyl-N-(2-hydroxyethyl)hydroxylamine
DMRU21X	HS	Investigative
DMRU21X	SN	CHEMBL203189; N-oleoyl-N-(2-hydroxyethyl)hydroxylamine; ZINC36294910
DMRU21X	DT	Small molecular drug
DMRU21X	PC	11638703
DMRU21X	MW	341.5
DMRU21X	FM	C20H39NO3
DMRU21X	IC	InChI=1S/C20H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21(24)18-19-22/h9-10,22,24H,2-8,11-19H2,1H3/b10-9-
DMRU21X	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)N(CCO)O
DMRU21X	IK	QINGXEUKNRODNT-KTKRTIGZSA-N
DMRU21X	IU	(Z)-N-hydroxy-N-(2-hydroxyethyl)octadec-9-enamide
DMRU21X	DE	Discovery agent

DMZM3CH	ID	DMZM3CH
DMZM3CH	DN	N-oleoyl-O-(2-hydroxyethyl)hydroxylamine
DMZM3CH	HS	Investigative
DMZM3CH	SN	CHEMBL208270; N-oleoyl-O-(2-hydroxyethyl)hydroxylamine; BDBM50185033
DMZM3CH	DT	Small molecular drug
DMZM3CH	PC	11645841
DMZM3CH	MW	341.5
DMZM3CH	FM	C20H39NO3
DMZM3CH	IC	InChI=1S/C20H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-24-19-18-22/h9-10,22H,2-8,11-19H2,1H3,(H,21,23)/b10-9-
DMZM3CH	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NOCCO
DMZM3CH	IK	NPPFEZUZEVDUDA-KTKRTIGZSA-N
DMZM3CH	IU	(Z)-N-(2-hydroxyethoxy)octadec-9-enamide
DMZM3CH	DE	Discovery agent

DM0BPCT	ID	DM0BPCT
DM0BPCT	DN	N-omega-allyl-L-arginine
DM0BPCT	HS	Investigative
DM0BPCT	DT	Small molecular drug
DM0BPCT	PC	135409360
DM0BPCT	MW	214.27
DM0BPCT	FM	C9H18N4O2
DM0BPCT	IC	InChI=1S/C9H18N4O2/c1-2-5-12-9(11)13-6-3-4-7(10)8(14)15/h2,7H,1,3-6,10H2,(H,14,15)(H3,11,12,13)/t7-/m0/s1
DM0BPCT	CS	C=CCNC(=NCCC[C@@H](C(=O)O)N)N
DM0BPCT	IK	ZPQWZDPOLXVMOU-ZETCQYMHSA-N
DM0BPCT	IU	(2S)-2-amino-5-[[amino-(prop-2-enylamino)methylidene]amino]pentanoic acid
DM0BPCT	CA	CAS 139461-37-3
DM0BPCT	DE	Discovery agent

DMOXQ3N	ID	DMOXQ3N
DMOXQ3N	DN	N-Omega-Hydroxy-L-Arginine
DMOXQ3N	HS	Investigative
DMOXQ3N	SN	N-omega-Hydroxy-L-arginine; NG-Hydroxy-L-arginine acetate; CHEBI:43088; FQWRAVYMZULPNK-BYPYZUCNSA-N; N(omega)-hydroxy-L-arginine; L-hydroxyarginine; N(5)-(N-hydroxycarbamimidoyl)-L-ornithine; N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine; 53054-07-2; HAR; Nomega-hydroxy-L-arginine; NG-HYDROXY-L-ARGININE; CHEMBL260629; 1hqf; 6-Noha; N(G)-Hydroxy-L-arginine; (e)-n5-[amino(hydroxyamino)methylidene]-l-ornithine; omega-hydroxy-l-arginine; AC1L3XHY; AC1Q5QLG; Lopac-H-7278; Lopac0_000615; SCHEMBL448333
DMOXQ3N	DT	Small molecular drug
DMOXQ3N	PC	123895
DMOXQ3N	MW	190.2
DMOXQ3N	FM	C6H14N4O3
DMOXQ3N	IC	InChI=1S/C6H14N4O3/c7-4(5(11)12)2-1-3-9-6(8)10-13/h4,13H,1-3,7H2,(H,11,12)(H3,8,9,10)/t4-/m0/s1
DMOXQ3N	CS	C(C[C@@H](C(=O)O)N)CN=C(N)NO
DMOXQ3N	IK	FQWRAVYMZULPNK-BYPYZUCNSA-N
DMOXQ3N	IU	(2S)-2-amino-5-[[amino-(hydroxyamino)methylidene]amino]pentanoic acid
DMOXQ3N	CA	CAS 53054-07-2
DMOXQ3N	CB	CHEBI:43088
DMOXQ3N	DE	Discovery agent

DM9X3B7	ID	DM9X3B7
DM9X3B7	DN	N-omega-propargyl-L-arginine
DM9X3B7	HS	Investigative
DM9X3B7	DT	Small molecular drug
DM9X3B7	PC	135512453
DM9X3B7	MW	212.25
DM9X3B7	FM	C9H16N4O2
DM9X3B7	IC	InChI=1S/C9H16N4O2/c1-2-5-12-9(11)13-6-3-4-7(10)8(14)15/h1,7H,3-6,10H2,(H,14,15)(H3,11,12,13)/t7-/m0/s1
DM9X3B7	CS	C#CCNC(=NCCC[C@@H](C(=O)O)N)N
DM9X3B7	IK	IAYULXZCALADJD-ZETCQYMHSA-N
DM9X3B7	IU	(2S)-2-amino-5-[[amino-(prop-2-ynylamino)methylidene]amino]pentanoic acid
DM9X3B7	DE	Discovery agent

DM4X0WY	ID	DM4X0WY
DM4X0WY	DN	N-Omega-Propyl-L-Arginine
DM4X0WY	HS	Investigative
DM4X0WY	SN	N-OMEGA-PROPYL-L-ARGININE; 137361-05-8; omega-propyl-l-arginine; CHEMBL107528; (S)-2-Amino-5-(3-propylguanidino)pentanoic acid; Nomega-Propyl-L-arginine hydrochloride; (2S)-2-amino-5-[(N'-propylcarbamimidoyl)amino]pentanoic acid; Nomega-Propyl-L-arginine; hDDAH inhibitor, 2b; Tocris-1200; NCGC00025034-01; Nomegapropyl-L-arginine; N- -Propyl-L-Arginine; 3AR; 2-amino-5-[(N'-propylcarbamimidoyl)amino]pentanoic acid; AC1L9KK0; N.omega.-propyl-L-Arginine; GTPL6525; SCHEMBL1004634; CTK8E7922; DTXSID30332245; MolPort-006-395-775
DM4X0WY	DT	Small molecular drug
DM4X0WY	PC	447180
DM4X0WY	MW	216.28
DM4X0WY	FM	C9H20N4O2
DM4X0WY	IC	InChI=1S/C9H20N4O2/c1-2-5-12-9(11)13-6-3-4-7(10)8(14)15/h7H,2-6,10H2,1H3,(H,14,15)(H3,11,12,13)/t7-/m0/s1
DM4X0WY	CS	CCCN=C(N)NCCC[C@@H](C(=O)O)N
DM4X0WY	IK	AOMXURITGZJPKB-ZETCQYMHSA-N
DM4X0WY	IU	(2S)-2-amino-5-[(N'-propylcarbamimidoyl)amino]pentanoic acid
DM4X0WY	CA	CAS 137361-05-8
DM4X0WY	DE	Discovery agent

DM951PF	ID	DM951PF
DM951PF	DN	Nonanoic acid biphenyl-2-ylamide
DM951PF	HS	Investigative
DM951PF	SN	CHEMBL270041; nonanoic acid biphenyl-2-ylamide; SCHEMBL15472054
DM951PF	DT	Small molecular drug
DM951PF	PC	24806277
DM951PF	MW	309.4
DM951PF	FM	C21H27NO
DM951PF	IC	InChI=1S/C21H27NO/c1-2-3-4-5-6-10-17-21(23)22-20-16-12-11-15-19(20)18-13-8-7-9-14-18/h7-9,11-16H,2-6,10,17H2,1H3,(H,22,23)
DM951PF	CS	CCCCCCCCC(=O)NC1=CC=CC=C1C2=CC=CC=C2
DM951PF	IK	QOVZQINZWUSANF-UHFFFAOYSA-N
DM951PF	IU	N-(2-phenylphenyl)nonanamide
DM951PF	DE	Discovery agent

DMMJFTR	ID	DMMJFTR
DMMJFTR	DN	Non-PEGylated butyrylcholinesterase
DMMJFTR	HS	Investigative
DMMJFTR	SN	Non-PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure); Non-PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene; Non-PEG-rBChE (toxicity/alzheimers disease), PharmAthene
DMMJFTR	CP	Nexia Biotechnologies Inc
DMMJFTR	DE	Toxicity

DMZ2DSK	ID	DMZ2DSK
DMZ2DSK	DN	Non-peptide TPO mimics
DMZ2DSK	HS	Investigative
DMZ2DSK	SN	Non-peptide TPO mimics (thrombocytopenia); Non-peptide TPO mimics (thrombocytopenia), Shanghai Hengrui
DMZ2DSK	CP	Shanghai Hengrui Pharmaceutical Co Ltd
DMZ2DSK	DE	Thrombocytopenia

DMFNB40	ID	DMFNB40
DMFNB40	DN	Noradrenalone (arterenone)
DMFNB40	HS	Investigative
DMFNB40	SN	Arterenone; 499-61-6; Noradrenalone; 2-Amino-1-(3,4-dihydroxyphenyl)ethanone; 2-Amino-1-(3,4-dihydroxyphenyl)ethan-1-one; Arterenon; EINECS 207-883-3; U 0603; 2-Amino-3',4'-dihydroxyacetophenone; BRN 2719260; Ethanone, 2-amino-1-(3,4-dihydroxyphenyl)-; ACETOPHENONE, 2-AMINO-3',4'-DIHYDROXY-; ADROLOP; AC1Q5DI7; SCHEMBL1703207; AC1L1V18; CTK4J1837; 5090-29-9 (hydrochloride); DTXSID10198144; MolPort-001-785-861; ZINC37629258; AKOS006275024; ACN-049173; AS07040; LS-13364; KB-282798; KB-227300; Ethanone,2-amino-1-(3,4-dihydroxyphenyl)-
DMFNB40	DT	Small molecular drug
DMFNB40	PC	10359
DMFNB40	MW	167.16
DMFNB40	FM	C8H9NO3
DMFNB40	IC	InChI=1S/C8H9NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,10-11H,4,9H2
DMFNB40	CS	C1=CC(=C(C=C1C(=O)CN)O)O
DMFNB40	IK	CNFQARFTXUBHJY-UHFFFAOYSA-N
DMFNB40	IU	2-amino-1-(3,4-dihydroxyphenyl)ethanone
DMFNB40	CA	CAS 499-61-6
DMFNB40	DE	Discovery agent

DMZ9024	ID	DMZ9024
DMZ9024	DN	NORARISTEROMYCIN
DMZ9024	HS	Investigative
DMZ9024	SN	noraristeromycin; 5'-Noraristeromycin; CHEMBL129014; (1S,2R,3S,4R)-4-(6-aminopurin-9-yl)cyclopentane-1,2,3-triol; 4-(6-Amino-9H-purin-9-yl)-1,2,3-cyclopentanetriol; AC1L2QRX; (-)-5'-Noraristeromycin; 142635-42-5; (+/-)-5'-Noraristeromycin; SCHEMBL1231088; BDBM50135288; (+-)-(1alpha,2beta,3beta,4alpha)-4-(6-Amino-9H-purin-9-yl)-1,2,3-cyclopentanetriol; NRN; (1S,2R,3S,4R)-4-(6-Amino-purin-9-yl)-cyclopentane-1,2,3-triol; (1S,2R,3S,4R)-4-(6-amino-9H-purin-9-yl)cyclopentane-1,2,3-triol
DMZ9024	DT	Small molecular drug
DMZ9024	PC	126704
DMZ9024	MW	251.24
DMZ9024	FM	C10H13N5O3
DMZ9024	IC	InChI=1S/C10H13N5O3/c11-9-6-10(13-2-12-9)15(3-14-6)4-1-5(16)8(18)7(4)17/h2-5,7-8,16-18H,1H2,(H2,11,12,13)/t4-,5+,7+,8-/m1/s1
DMZ9024	CS	C1[C@H]([C@@H]([C@@H]([C@H]1O)O)O)N2C=NC3=C(N=CN=C32)N
DMZ9024	IK	VFKHECGAEJNAMV-HETMPLHPSA-N
DMZ9024	IU	(1S,2R,3S,4R)-4-(6-aminopurin-9-yl)cyclopentane-1,2,3-triol
DMZ9024	CA	CAS 142635-42-5
DMZ9024	DE	Discovery agent

DMLYZOG	ID	DMLYZOG
DMLYZOG	DN	NORBINALTORPHIMINE
DMLYZOG	HS	Investigative
DMLYZOG	SN	Norbinaltorphimine; nor-Binaltorphimine; UNII-36OOQ86QM1; 36OOQ86QM1; CHEBI:81529; C18130; 4,8:11,15-Dimethano-20H-bisbenzofuro(2,3-a:3',2'-i)dipyrido(4,3-b:3',4'-h)carbazole-1,8a,10a,18-tetrol, 7,12-bis(cyclopropylmethyl)-5,6,7,8,9,10,11,12,13,14,19a,20b-dodecahydro-20-methyl-, (8R-(4bR*,8alpha,8abeta,10aalpha,11beta,14aR*,19aalpha,20bbeta))-; Nor-Binaltorphamine; (-)-norbinaltorphimine; NOR-BNI (HCI)2; Lopac0_000806; GTPL1642; CHEMBL573214; SCHEMBL12013206; BDBM82551; APSUXPSYBJVPPS-YAUKWVCOSA-N
DMLYZOG	DT	Small molecular drug
DMLYZOG	PC	5480230
DMLYZOG	MW	661.8
DMLYZOG	FM	C40H43N3O6
DMLYZOG	IC	InChI=1S/C40H43N3O6/c44-25-7-5-21-13-27-39(46)15-23-24-16-40(47)28-14-22-6-8-26(45)34-30(22)38(40,10-12-43(28)18-20-3-4-20)36(49-34)32(24)41-31(23)35-37(39,29(21)33(25)48-35)9-11-42(27)17-19-1-2-19/h5-8,19-20,27-28,35-36,41,44-47H,1-4,9-18H2/t27-,28-,35+,36+,37+,38+,39-,40-/m1/s1
DMLYZOG	CS	C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)[C@H]9[C@@]12CCN([C@@H]([C@@]1(C8)O)CC1=C2C(=C(C=C1)O)O9)CC1CC1
DMLYZOG	IK	APSUXPSYBJVPPS-YAUKWVCOSA-N
DMLYZOG	IU	(1S,2S,7S,8S,12R,20R,24R,32R)-11,33-bis(cyclopropylmethyl)-19,25-dioxa-11,22,33-triazaundecacyclo[24.9.1.18,14.01,24.02,32.04,23.05,21.07,12.08,20.030,36.018,37]heptatriaconta-4(23),5(21),14(37),15,17,26,28,30(36)-octaene-2,7,17,27-tetrol
DMLYZOG	CA	CAS 105618-26-6
DMLYZOG	CB	CHEBI:81529
DMLYZOG	DE	Discovery agent

DM6HKEC	ID	DM6HKEC
DM6HKEC	DN	Nor-binaltorphimine dihydrochloride
DM6HKEC	HS	Investigative
DM6HKEC	SN	nor-Binaltorphimine dihydrochloride; nor-BNI dihydrochloride; Norbinaltorphimine dihydrochloride; 105618-26-6; EU-0100806; 113158-34-2; CHEMBL2374078; MolPort-003-958-934; Tox21_500806; MFCD00069374; AKOS024457633; LP00806; NCGC00261491-01; NCGC00094139-01; nor-Binaltorphimine dihydrochloride, solid; HY-100903; CS-0020573; N 1771; SR-01000597959; SR-01000075482; SR-01000597959-1; SR-01000075482-1; J-001459
DM6HKEC	DT	Small molecular drug
DM6HKEC	PC	11957626
DM6HKEC	MW	734.7
DM6HKEC	FM	C40H45Cl2N3O6
DM6HKEC	IC	InChI=1S/C40H43N3O6.2ClH/c44-25-7-5-21-13-27-39(46)15-23-24-16-40(47)28-14-22-6-8-26(45)34-30(22)38(40,10-12-43(28)18-20-3-4-20)36(49-34)32(24)41-31(23)35-37(39,29(21)33(25)48-35)9-11-42(27)17-19-1-2-19;;/h5-8,19-20,27-28,35-36,41,44-47H,1-4,9-18H2;2*1H/t27-,28-,35+,36+,37+,38+,39-,40-;;/m1../s1
DM6HKEC	CS	C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)[C@H]9[C@@]12CCN([C@@H]([C@@]1(C8)O)CC1=C2C(=C(C=C1)O)O9)CC1CC1.Cl.Cl
DM6HKEC	IK	JOJPJLHRMGPDPV-LZQROVCBSA-N
DM6HKEC	IU	(1S,2S,7S,8S,12R,20R,24R,32R)-11,33-bis(cyclopropylmethyl)-19,25-dioxa-11,22,33-triazaundecacyclo[24.9.1.18,14.01,24.02,32.04,23.05,21.07,12.08,20.030,36.018,37]heptatriaconta-4(23),5(21),14(37),15,17,26,28,30(36)-octaene-2,7,17,27-tetrol;dihydrochloride
DM6HKEC	CA	CAS 113158-34-2
DM6HKEC	DE	Discovery agent

DM6BNQR	ID	DM6BNQR
DM6BNQR	DN	NORBOLDINE
DM6BNQR	HS	Investigative
DM6BNQR	SN	Laurolitsine; 5890-18-6; Laurolistine; Norboldine; UNII-5MT88IS14F; 1,10-Dimethoxy-6a-alpha-noraporphine-2,9-diol; Dimethoxy-1,10 dihydroxy-2,9 nor-aporphine; 4H-Dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-; CHEMBL487388; 5MT88IS14F; CHEBI:66557; (6aS)-1,10-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol; Dimethoxy-1,10 dihydroxy-2,9 nor-aporphine [French]; 6a-alpha-NORAPORPHINE-2,9-DIOL, 1,10-DIMETHOXY-; (+)-Norboldine; 568-39-8; [(+)-norboldine]; AC1L2JVN; DTXSID30207641
DM6BNQR	DT	Small molecular drug
DM6BNQR	PC	22179
DM6BNQR	MW	313.3
DM6BNQR	FM	C18H19NO4
DM6BNQR	IC	InChI=1S/C18H19NO4/c1-22-15-8-11-10(7-13(15)20)5-12-16-9(3-4-19-12)6-14(21)18(23-2)17(11)16/h6-8,12,19-21H,3-5H2,1-2H3/t12-/m0/s1
DM6BNQR	CS	COC1=C(C=C2C[C@H]3C4=C(C2=C1)C(=C(C=C4CCN3)O)OC)O
DM6BNQR	IK	KYVJVURXKAZJRK-LBPRGKRZSA-N
DM6BNQR	IU	(6aS)-1,10-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DM6BNQR	CA	CAS 5890-18-6
DM6BNQR	CB	CHEBI:66557
DM6BNQR	DE	Discovery agent

DM9B6Y1	ID	DM9B6Y1
DM9B6Y1	DN	NORCANTHARIDIN
DM9B6Y1	HS	Investigative
DM9B6Y1	SN	Norcantharidin; 5442/12/6; Endothall anhydride; Norcantharadine; 7-Oxabicyclo[221]heptane-2,3-dicarboxylic anhydride; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-; 3,6-Endoxohexahydrophthalic anhydride; 29745-04-8; Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; NSC 14003; 7-Oxabicyclo(221)heptane-2,3-dicarboxylic anhydride; FR-0742; 3,6-Endooxyphthalic anhydride, hexahydro-; Phthalic anhydride, hexahydro-3,6-endoxo-; C8H8O4; 4,10-dioxatricyclo[5210&lt; 2,6&gt; ]decane-3,5-dione; NSC 59023; BRN 0084287; DEMETHYL-CANTHARIDIN
DM9B6Y1	DT	Small molecular drug
DM9B6Y1	PC	93004
DM9B6Y1	MW	168.15
DM9B6Y1	FM	C8H8O4
DM9B6Y1	IC	InChI=1S/C8H8O4/c9-7-5-3-1-2-4(11-3)6(5)8(10)12-7/h3-6H,1-2H2
DM9B6Y1	CS	C1CC2C3C(C1O2)C(=O)OC3=O
DM9B6Y1	IK	JAABVEXCGCXWRR-UHFFFAOYSA-N
DM9B6Y1	IU	4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
DM9B6Y1	CA	CAS 5442-12-6
DM9B6Y1	DE	Discovery agent

DMHAWYQ	ID	DMHAWYQ
DMHAWYQ	DN	Nordazepam
DMHAWYQ	HS	Investigative
DMHAWYQ	SN	Calmday; Chlordesmethyldiazepam; Dealkylprazepam; Demadar; Demethyldiazepam; Desalkylprazepam; N-Demethyldiazepam; N-Deoxydemoxapam; N-Deoxydemoxepam; N-Descyclopropylmethylprazepam; N-Desmethyldiazepam; N1-Desmethyldiazepam; Nordaz; Nordazepam; Nordazepam [INN]; Nordazepamum; Nordazepamum [INN-Latin]; Nordiazepam; Norprazepam; Praxadium; Ro 5-2180; Stilny; Vegesan; desmethyldiazepam; 1-Demethyldiazepam; 1088-11-5; 7-Chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; A 101; A101; DMDZ; Lomax; Madar; NSC 46078; Sopax
DMHAWYQ	PC	2997
DMHAWYQ	MW	270.71
DMHAWYQ	FM	C15H11ClN2O
DMHAWYQ	IC	AKPLHCDWDRPJGD-UHFFFAOYSA-N
DMHAWYQ	CS	C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3
DMHAWYQ	IK	1S/C15H11ClN2O/c16-11-6-7-13-12(8-11)15(17-9-14(19)18-13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19)
DMHAWYQ	IU	7-chloro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMHAWYQ	CA	CAS 1088-11-5
DMHAWYQ	CB	CHEBI:111762
DMHAWYQ	DE	Anxiety disorder

DMGI4ZW	ID	DMGI4ZW
DMGI4ZW	DN	norfenfluramine
DMGI4ZW	HS	Investigative
DMGI4ZW	SN	(+/-)-norfenfluramine
DMGI4ZW	DT	Small molecular drug
DMGI4ZW	PC	15897
DMGI4ZW	MW	203.2
DMGI4ZW	FM	C10H12F3N
DMGI4ZW	IC	InChI=1S/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3
DMGI4ZW	CS	CC(CC1=CC(=CC=C1)C(F)(F)F)N
DMGI4ZW	IK	MLBHFBKZUPLWBD-UHFFFAOYSA-N
DMGI4ZW	IU	1-[3-(trifluoromethyl)phenyl]propan-2-amine
DMGI4ZW	CA	CAS 1886-26-6
DMGI4ZW	CB	CHEBI:125411
DMGI4ZW	DE	Discovery agent

DMKNUP3	ID	DMKNUP3
DMKNUP3	DN	norfluoxetine
DMKNUP3	HS	Investigative
DMKNUP3	SN	Norfluoxetine; Desmethylfluoxetine; Norfluoxetin; 56161-73-0; 83891-03-6; 3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; WIQRCHMSJFFONW-UHFFFAOYSA-N; gamma-(4-(Trifluoromethyl)phenoxy)benzenepropanamine; norfluoxetine hcl; 3-Phenyl-3-(4-trifluoromethyl-phenoxy)-propylamine; 3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Benzenepropanamine, gamma-(4-(trifluoromethyl)phenoxy)-; benzenepropanamine, gamma-[4-(trifluoromethyl)phenoxy]-; ( inverted exclamation markA)-
DMKNUP3	DT	Small molecular drug
DMKNUP3	PC	4541
DMKNUP3	MW	295.3
DMKNUP3	FM	C16H16F3NO
DMKNUP3	IC	InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2
DMKNUP3	CS	C1=CC=C(C=C1)C(CCN)OC2=CC=C(C=C2)C(F)(F)F
DMKNUP3	IK	WIQRCHMSJFFONW-UHFFFAOYSA-N
DMKNUP3	IU	3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
DMKNUP3	CA	CAS 83891-03-6
DMKNUP3	DE	Discovery agent

DMKYQWG	ID	DMKYQWG
DMKYQWG	DN	NORHARMANE
DMKYQWG	HS	Investigative
DMKYQWG	SN	9H-Pyrido[3,4-B]indole; Norharman; Norharmane; 244-63-3; beta-Carboline; 2,9-Diazafluorene; Carbazoline; 9H-Beta-carboline; 2-Azacarbazole; 9H-Pyrido(3,4-B)indole; .beta.-Carboline; Carbazoline (VAN); b-carboline; beta Carboline; 2H-Pyrido[3,4-b]indole; UNII-94HMA1I78O; CCRIS 6915; CHEBI:109895; EINECS 205-959-0; NSC 84417; BRN 0128414; MLS000069651; 94HMA1I78O; CHEMBL275224; AIFRHYZBTHREPW-UHFFFAOYSA-N; Norharman, 98%; SMR000058207; AK-25655; N-8720; N-8700; 244-66-6; SR-01000000213; 9h-; Prestwick_363; Norharmane, 98%; zlchem 7
DMKYQWG	DT	Small molecular drug
DMKYQWG	PC	64961
DMKYQWG	MW	168.19
DMKYQWG	FM	C11H8N2
DMKYQWG	IC	InChI=1S/C11H8N2/c1-2-4-10-8(3-1)9-5-6-12-7-11(9)13-10/h1-7,13H
DMKYQWG	CS	C1=CC=C2C(=C1)C3=C(N2)C=NC=C3
DMKYQWG	IK	AIFRHYZBTHREPW-UHFFFAOYSA-N
DMKYQWG	IU	9H-pyrido[3,4-b]indole
DMKYQWG	CA	CAS 244-63-3
DMKYQWG	CB	CHEBI:109895
DMKYQWG	DE	Discovery agent

DMYQGFJ	ID	DMYQGFJ
DMYQGFJ	DN	normorphine
DMYQGFJ	HS	Investigative
DMYQGFJ	SN	Normorphine; 466-97-7; Desmethylmorphine; UNII-XUI1Y24IMI; Demethylmorphine; N-Normorphine; XUI1Y24IMI; NSC 270042; CHEBI:7633; ONBWJWYUHXVEJS-ZTYRTETDSA-N; Normorfina [INN-Spanish]; Normorphinum [INN-Latin]; 4,5-Epoxy-3,6-dihydroxymorphin-7-ene; Normorphine [INN:BAN:DCF]; Normorfina; Normorphinum; EINECS 207-381-4; N-Demethylmorphine; BRN 5297209; CHEMBL1227; DEA No. 9313; Normorphine (7,8-Didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol)
DMYQGFJ	DT	Small molecular drug
DMYQGFJ	PC	5462508
DMYQGFJ	MW	271.31
DMYQGFJ	FM	C16H17NO3
DMYQGFJ	IC	InChI=1S/C16H17NO3/c18-11-3-1-8-7-10-9-2-4-12(19)15-16(9,5-6-17-10)13(8)14(11)20-15/h1-4,9-10,12,15,17-19H,5-7H2/t9-,10+,12-,15-,16-/m0/s1
DMYQGFJ	CS	C1CN[C@@H]2CC3=C4[C@@]15[C@H]2C=C[C@@H]([C@@H]5OC4=C(C=C3)O)O
DMYQGFJ	IK	ONBWJWYUHXVEJS-ZTYRTETDSA-N
DMYQGFJ	IU	(4R,4aR,7S,7aR,12bS)-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
DMYQGFJ	CA	CAS 466-97-7
DMYQGFJ	CB	CHEBI:7633
DMYQGFJ	DE	Discovery agent

DMSZWGN	ID	DMSZWGN
DMSZWGN	DN	NOR-ROEFRACTINE
DMSZWGN	HS	Investigative
DMSZWGN	SN	CHEMBL512542; NOR-ROEFRACTINE; (R)-Norroefractine; AC1OEFB1; ZINC3847479; BDBM50259928; (1R)-7-methoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-6-ol
DMSZWGN	DT	Small molecular drug
DMSZWGN	PC	7055406
DMSZWGN	MW	299.4
DMSZWGN	FM	C18H21NO3
DMSZWGN	IC	InChI=1S/C18H21NO3/c1-21-14-5-3-12(4-6-14)9-16-15-11-18(22-2)17(20)10-13(15)7-8-19-16/h3-6,10-11,16,19-20H,7-9H2,1-2H3/t16-/m1/s1
DMSZWGN	CS	COC1=CC=C(C=C1)C[C@@H]2C3=CC(=C(C=C3CCN2)O)OC
DMSZWGN	IK	HIMHLENXDBHLCU-MRXNPFEDSA-N
DMSZWGN	IU	(1R)-7-methoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-6-ol
DMSZWGN	DE	Discovery agent

DM1VIHC	ID	DM1VIHC
DM1VIHC	DN	NORSTEPHALAGINE
DM1VIHC	HS	Investigative
DM1VIHC	SN	Norstephalagine; CHEMBL257745; (7ar)-4-methoxy-6,7,7a,8-tetrahydro-5h-[1,3]benzodioxolo[6,5,4-de]benzo[g]quinoline; 80151-82-2; AC1Q6ZQH; AC1L32NW; CTK8E0504; BDBM50202300; 5H-Benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7,7a,8-tetrahydro-4-methoxy-, (R)-
DM1VIHC	DT	Small molecular drug
DM1VIHC	PC	133381
DM1VIHC	MW	295.3
DM1VIHC	FM	C18H17NO3
DM1VIHC	IC	InChI=1S/C18H17NO3/c1-20-16-12-6-7-19-13-8-10-4-2-3-5-11(10)15(14(12)13)17-18(16)22-9-21-17/h2-5,13,19H,6-9H2,1H3/t13-/m1/s1
DM1VIHC	CS	COC1=C2C(=C3C4=CC=CC=C4C[C@@H]5C3=C1CCN5)OCO2
DM1VIHC	IK	TYZKUSBTFHNPMV-CYBMUJFWSA-N
DM1VIHC	IU	(12R)-7-methoxy-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1,6,8(20),14,16,18-hexaene
DM1VIHC	CA	CAS 80151-82-2
DM1VIHC	DE	Discovery agent

DMTY43L	ID	DMTY43L
DMTY43L	DN	Nortropinyl-arylsulfonylurea 3
DMTY43L	HS	Investigative
DMTY43L	SN	CHEMBL333727; BDBM50134335; Benzeneacetic acid (1alpha,5alpha)-8-[3-(4-chlorophenylsulfonyl)ureido]-8-azabicyclo[3.2.1]octane-3beta-yl ester; 8-[N-(4-chlorophenylsulfonamido)-carbonyl amino]-8-azabicyclo[3.2.1]oct-3-yl 2-phenylacetate
DMTY43L	DT	Small molecular drug
DMTY43L	PC	10367758
DMTY43L	MW	478
DMTY43L	FM	C22H24ClN3O5S
DMTY43L	IC	InChI=1S/C22H24ClN3O5S/c23-16-6-10-20(11-7-16)32(29,30)25-22(28)24-26-17-8-9-18(26)14-19(13-17)31-21(27)12-15-4-2-1-3-5-15/h1-7,10-11,17-19H,8-9,12-14H2,(H2,24,25,28)/t17-,18+,19?
DMTY43L	CS	C1C[C@H]2CC(C[C@@H]1N2NC(=O)NS(=O)(=O)C3=CC=C(C=C3)Cl)OC(=O)CC4=CC=CC=C4
DMTY43L	IK	JLAXGKPNMOZKMF-DFNIBXOVSA-N
DMTY43L	IU	[(1R,5S)-8-[(4-chlorophenyl)sulfonylcarbamoylamino]-8-azabicyclo[3.2.1]octan-3-yl] 2-phenylacetate
DMTY43L	DE	Discovery agent

DM19FS3	ID	DM19FS3
DM19FS3	DN	Norzimelidine
DM19FS3	HS	Investigative
DM19FS3	SN	Norzimeldine; 3-(4-Bromophenyl)-N-methyl-3-(3-pyridinyl)-2-propen-1-amine; 2-Propen-1-amine, 3-(4-bromophenyl)-N-methyl-3-(3-pyridinyl)-; cholesterol-3-glucose; AC1O5OK9; CHEMBL173745; SCHEMBL11636758; 60324-58-5; LS-175771; A-23889; 3-(4-bromophenyl)-N-methyl-(3-pyiidyl)allylamine oxalate
DM19FS3	DT	Small molecular drug
DM19FS3	PC	5378630
DM19FS3	MW	303.2
DM19FS3	FM	C15H15BrN2
DM19FS3	IC	InChI=1S/C15H15BrN2/c1-17-10-8-15(13-3-2-9-18-11-13)12-4-6-14(16)7-5-12/h2-9,11,17H,10H2,1H3/b15-8-
DM19FS3	CS	CNC/C=C(/C1=CC=C(C=C1)Br)\\C2=CN=CC=C2
DM19FS3	IK	AZFZKANGXPSDEA-NVNXTCNLSA-N
DM19FS3	IU	(Z)-3-(4-bromophenyl)-N-methyl-3-pyridin-3-ylprop-2-en-1-amine
DM19FS3	CA	CAS 60324-59-6

DMS3N4X	ID	DMS3N4X
DMS3N4X	DN	norzotepine
DMS3N4X	HS	Investigative
DMS3N4X	SN	norzotepine; GTPL7537; SCHEMBL7133614
DMS3N4X	DT	Small molecular drug
DMS3N4X	PC	10041551
DMS3N4X	MW	317.8
DMS3N4X	FM	C17H16ClNOS
DMS3N4X	IC	InChI=1S/C17H16ClNOS/c1-19-8-9-20-15-10-12-4-2-3-5-16(12)21-17-7-6-13(18)11-14(15)17/h2-7,10-11,19H,8-9H2,1H3
DMS3N4X	CS	CNCCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMS3N4X	IK	OVVBIIBBRZVPAL-UHFFFAOYSA-N
DMS3N4X	IU	2-(3-chlorobenzo[b][1]benzothiepin-5-yl)oxy-N-methylethanamine
DMS3N4X	DE	Discovery agent

DME5O17	ID	DME5O17
DME5O17	DN	NOSTOCARBOLINE
DME5O17	HS	Investigative
DME5O17	SN	Nostocarboline hydroiodide; Nostacarboline Iodide; CHEMBL499836; MolPort-003-983-847; BN0656; 6-chloro-2-methyl-9H-pyrido[3,4-b]indol-2-ium hydroiodide
DME5O17	DT	Small molecular drug
DME5O17	PC	5326150
DME5O17	MW	217.67
DME5O17	FM	C12H10ClN2+
DME5O17	IC	InChI=1S/C12H9ClN2/c1-15-5-4-9-10-6-8(13)2-3-11(10)14-12(9)7-15/h2-7H,1H3/p+1
DME5O17	CS	C[N+]1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)Cl
DME5O17	IK	RGQUDRQSJYJYAQ-UHFFFAOYSA-O
DME5O17	IU	6-chloro-2-methyl-9H-pyrido[3,4-b]indol-2-ium
DME5O17	CB	CHEBI:66637
DME5O17	DE	Discovery agent

DMLVFUY	ID	DMLVFUY
DMLVFUY	DN	N-o-Tolyl-1'H-phenothiazine-1'-carboxamide
DMLVFUY	HS	Investigative
DMLVFUY	SN	CHEMBL600460; ZINC13717070; BDBM50308406; AKOS004107642
DMLVFUY	DT	Small molecular drug
DMLVFUY	PC	19916610
DMLVFUY	MW	332.4
DMLVFUY	FM	C20H16N2OS
DMLVFUY	IC	InChI=1S/C20H16N2OS/c1-14-8-2-3-9-15(14)21-20(23)22-16-10-4-6-12-18(16)24-19-13-7-5-11-17(19)22/h2-13H,1H3,(H,21,23)
DMLVFUY	CS	CC1=CC=CC=C1NC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMLVFUY	IK	ZYTFFKKLLJLEPW-UHFFFAOYSA-N
DMLVFUY	IU	N-(2-methylphenyl)phenothiazine-10-carboxamide
DMLVFUY	DE	Discovery agent

DM82DNL	ID	DM82DNL
DM82DNL	DN	Nova-EPO
DM82DNL	HS	Investigative
DM82DNL	SN	Recombinant EPO fusion protein (anemia), Genova Biotech/Novagenetics; Recombinant erythropoietin fusion protein (anemia), GenovaBiotech/Novagenetics/Novagen
DM82DNL	CP	Genova Biotech Comp Ltd
DM82DNL	DE	Anemia

DM3C2VA	ID	DM3C2VA
DM3C2VA	DN	Novo Nordisk a/S Compound
DM3C2VA	HS	Investigative
DM3C2VA	DT	Small molecular drug
DM3C2VA	PC	1829
DM3C2VA	MW	335.05
DM3C2VA	FM	C9H6INO5
DM3C2VA	IC	InChI=1S/C9H6INO5/c10-4-1-2-6(5(3-4)8(13)14)11-7(12)9(15)16/h1-3H,(H,11,12)(H,13,14)(H,15,16)
DM3C2VA	CS	C1=CC(=C(C=C1I)C(=O)O)NC(=O)C(=O)O
DM3C2VA	IK	SHSWHSQPJKMCPN-UHFFFAOYSA-N
DM3C2VA	IU	5-iodo-2-(oxaloamino)benzoic acid
DM3C2VA	CB	CHEBI:40326
DM3C2VA	DE	Discovery agent

DMAM5ZO	ID	DMAM5ZO
DMAM5ZO	DN	NOX 2137a/b
DMAM5ZO	HS	Investigative
DMAM5ZO	DT	Aptamer
DMAM5ZO	DE	Stress; Pain

DMZVDLS	ID	DMZVDLS
DMZVDLS	DN	NOX 2149
DMZVDLS	HS	Investigative
DMZVDLS	DT	Aptamer
DMZVDLS	DE	Stress; Pain

DMFW8O5	ID	DMFW8O5
DMFW8O5	DN	NOX-B11
DMFW8O5	HS	Investigative
DMFW8O5	SN	L-NOX-B11; Spiegelmers (ghrelin antagonist, obesity), NOXXON/Pfizer
DMFW8O5	CP	NOXXON Pharma AG
DMFW8O5	DE	Obesity

DMQ84J7	ID	DMQ84J7
DMQ84J7	DN	N-oxo-2-(phenylsulfonylamino)ethanamide
DMQ84J7	HS	Investigative
DMQ84J7	SN	N-oxo-2-(phenylsulfonylamino)ethanamide; SCHEMBL20553203; 2-benzenesulfonamido-N-oxoacetamide; DB07922; N-oxo-N~2~-(phenylsulfonyl)glycinamide
DMQ84J7	DT	Small molecular drug
DMQ84J7	PC	46937108
DMQ84J7	MW	228.23
DMQ84J7	FM	C8H8N2O4S
DMQ84J7	IC	InChI=1S/C8H8N2O4S/c11-8(10-12)6-9-15(13,14)7-4-2-1-3-5-7/h1-5,9H,6H2
DMQ84J7	CS	C1=CC=C(C=C1)S(=O)(=O)NCC(=O)N=O
DMQ84J7	IK	LBEMJFIVKDOIBO-UHFFFAOYSA-N
DMQ84J7	IU	2-(benzenesulfonamido)-N-oxoacetamide
DMQ84J7	DE	Discovery agent

DMHTI5X	ID	DMHTI5X
DMHTI5X	DN	N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide
DMHTI5X	HS	Investigative
DMHTI5X	SN	N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide; DB07920; N-oxo-2-(4-phenylbenzenesulfonamido)acetamide; N~2~-(biphenyl-4-ylsulfonyl)-N-oxoglycinamide
DMHTI5X	DT	Small molecular drug
DMHTI5X	PC	46937106
DMHTI5X	MW	304.32
DMHTI5X	FM	C14H12N2O4S
DMHTI5X	IC	InChI=1S/C14H12N2O4S/c17-14(16-18)10-15-21(19,20)13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-9,15H,10H2
DMHTI5X	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NCC(=O)N=O
DMHTI5X	IK	OGRPZMQLAVBWPV-UHFFFAOYSA-N
DMHTI5X	IU	N-oxo-2-[(4-phenylphenyl)sulfonylamino]acetamide
DMHTI5X	DE	Discovery agent

DMVS6DW	ID	DMVS6DW
DMVS6DW	DN	NOX-S91
DMVS6DW	HS	Investigative
DMVS6DW	SN	NOX-S92; NOX-S93; Spiegelmer sphingosine-1-phosphate inhibitors (cancer, ocular disease), Noxxon
DMVS6DW	CP	NOXXON Pharma AG
DMVS6DW	DE	Solid tumour/cancer

DM906YB	ID	DM906YB
DM906YB	DN	NP-0336
DM906YB	HS	Investigative
DM906YB	SN	Butyrylcholineesterase inhibitor (cognitive disorder), Noscira
DM906YB	CP	Noscira SA
DM906YB	DE	Cognitive impairment

DM51S0B	ID	DM51S0B
DM51S0B	DN	NP16
DM51S0B	HS	Investigative
DM51S0B	DE	Staphylococcus infection

DMVPIF8	ID	DMVPIF8
DMVPIF8	DN	NP-506
DMVPIF8	HS	Investigative
DMVPIF8	SN	CHEMBL480356; NP-506; SCHEMBL20130652; BDBM50256010; 3-{2,4-dimethyl-5-[2-oxo-5-(N''-phenylhydrazinocarbonyl)-1,2-dihydro-indol-3-ylidenemethyl]-1H-pyrrol-3-yl}-propionic acid
DMVPIF8	DT	Small molecular drug
DMVPIF8	PC	25195216
DMVPIF8	MW	444.5
DMVPIF8	FM	C25H24N4O4
DMVPIF8	IC	InChI=1S/C25H24N4O4/c1-14-18(9-11-23(30)31)15(2)26-22(14)13-20-19-12-16(8-10-21(19)27-25(20)33)24(32)29-28-17-6-4-3-5-7-17/h3-8,10,12-13,26,28H,9,11H2,1-2H3,(H,27,33)(H,29,32)(H,30,31)/b20-13-
DMVPIF8	CS	CC1=C(NC(=C1CCC(=O)O)C)/C=C\\2/C3=C(C=CC(=C3)C(=O)NNC4=CC=CC=C4)NC2=O
DMVPIF8	IK	GCZQBFMPHLFNIO-MOSHPQCFSA-N
DMVPIF8	IU	3-[5-[(Z)-[5-(anilinocarbamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]propanoic acid
DMVPIF8	DE	Discovery agent

DMMZXRT	ID	DMMZXRT
DMMZXRT	DN	NP93-31
DMMZXRT	HS	Investigative
DMMZXRT	SN	Neup-93-31; NMDA NR2B antagonists (depression/neuropathic pain/subarachnoid hemorrhage/traumatic brain injury); NMDA NR2B antagonists (depression/neuropathic pain/subarachnoid hemorrhage/TBI), NeurOp/ Bristol-Myers Squibb/Stallion; NMDA NR2B antagonists (depression/neuropathic pain/subarachnoid hemorrhage/traumatic brain injury), NeurOp/ Bristol-Myers Squibb/Stallion
DMMZXRT	CP	NeurOp Corp
DMMZXRT	DE	Brain injury

DMU426Z	ID	DMU426Z
DMU426Z	DN	NPC-349
DMU426Z	HS	Investigative
DMU426Z	SN	[D-Arg0,Hyp2,3,Thi5,8,D-Phe7]bradykinin; NPC 349
DMU426Z	DT	Small molecular drug
DMU426Z	PC	123973
DMU426Z	MW	1294.5
DMU426Z	FM	C56H83N19O13S2
DMU426Z	IC	InChI=1S/C56H83N19O13S2/c57-35(13-4-17-66-53(60)61)45(80)71-38(14-5-18-67-54(62)63)50(85)74-20-6-15-42(74)44(79)34(16-19-68-55(64)65)56(52(87)88,43(78)28-70-47(82)39-24-31(77)27-69-39)75(49(84)37(59)26-33-12-8-22-90-33)51(86)40(23-30-9-2-1-3-10-30)72-48(83)41(29-76)73-46(81)36(58)25-32-11-7-21-89-32/h1-3,7-12,21-22,31,34-42,69,76-77H,4-6,13-20,23-29,57-59H2,(H,70,82)(H,71,80)(H,72,83)(H,73,81)(H,87,88)(H4,60,61,66)(H4,62,63,67)(H4,64,65,68)/t31-,34?,35-,36+,37+,38+,39+,40-,41+,42+,56-/m1/s1
DMU426Z	CS	C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)C(CCN=C(N)N)[C@@](C(=O)CNC(=O)[C@@H]2C[C@H](CN2)O)(C(=O)O)N(C(=O)[C@H](CC3=CC=CS3)N)C(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)N
DMU426Z	IK	MHBUKMPYIGAURU-WIDHDRDXSA-N
DMU426Z	IU	(2R)-3-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-2-[[(2S)-2-amino-3-thiophen-2-ylpropanoyl]-[(2R)-2-[[(2S)-2-[[(2S)-2-amino-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)-2-[2-[[(2S,4R)-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]pentanoic acid
DMU426Z	CA	CAS 103412-42-6
DMU426Z	DE	Discovery agent

DMJQZMH	ID	DMJQZMH
DMJQZMH	DN	N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine
DMJQZMH	HS	Investigative
DMJQZMH	SN	CHEMBL1082978; N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine; BDBM50319973
DMJQZMH	DT	Small molecular drug
DMJQZMH	PC	46891059
DMJQZMH	MW	268.36
DMJQZMH	FM	C16H20N4
DMJQZMH	IC	InChI=1S/C16H20N4/c1-2-6-14(7-3-1)8-10-17-15-9-11-18-16(19-15)20-12-4-5-13-20/h1-3,6-7,9,11H,4-5,8,10,12-13H2,(H,17,18,19)
DMJQZMH	CS	C1CCN(C1)C2=NC=CC(=N2)NCCC3=CC=CC=C3
DMJQZMH	IK	MIALFBONYMMUFB-UHFFFAOYSA-N
DMJQZMH	IU	N-(2-phenylethyl)-2-pyrrolidin-1-ylpyrimidin-4-amine
DMJQZMH	DE	Discovery agent

DM1BU5P	ID	DM1BU5P
DM1BU5P	DN	N-Phenethyl-2-(toluene-4-sulfonylamino)-benzamide
DM1BU5P	HS	Investigative
DM1BU5P	SN	CHEMBL314328; AC1OUGMN; Oprea1_191889; N-Phenethyl-2-(toluene-4-sulfonylamino)-benzamide; MolPort-003-205-548; ZINC5882219; STK825561; BDBM50146384; AKOS000952939; MCULE-7382886996; 2-[(4-methylphenyl)sulfonylamino]-N-phenethylbenzamide; 2-{[(4-methylphenyl)sulfonyl]amino}-N~1~-phenethylbenzamide
DM1BU5P	DT	Small molecular drug
DM1BU5P	PC	7824621
DM1BU5P	MW	394.5
DM1BU5P	FM	C22H22N2O3S
DM1BU5P	IC	InChI=1S/C22H22N2O3S/c1-17-11-13-19(14-12-17)28(26,27)24-21-10-6-5-9-20(21)22(25)23-16-15-18-7-3-2-4-8-18/h2-14,24H,15-16H2,1H3,(H,23,25)
DM1BU5P	CS	CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCCC3=CC=CC=C3
DM1BU5P	IK	QLFGNZRFLMFTDF-UHFFFAOYSA-N
DM1BU5P	IU	2-[(4-methylphenyl)sulfonylamino]-N-(2-phenylethyl)benzamide
DM1BU5P	CA	CAS 19007-51-3
DM1BU5P	DE	Discovery agent

DM4G6LJ	ID	DM4G6LJ
DM4G6LJ	DN	N-phenethyl-2-phenylquinoline-4-carboxamide
DM4G6LJ	HS	Investigative
DM4G6LJ	SN	N-phenethyl-2-phenylquinoline-4-carboxamide; 2-Phenyl-quinoline-4-carboxylic acid phenethyl-amide; 65628-69-5; BAS 00329480; ChemDiv3_013317; AC1MIR97; Oprea1_331981; Oprea1_089083; CBDivE_013546; CHEMBL1278237; CTK1I2246; DTXSID50389216; MolPort-001-924-745; HMS1510N07; ZINC3036412; AKOS000577213; MCULE-8602191420; NCGC00320157-01; EU-0063663; AB01317027-02; SR-01000583017; SR-01000583017-1; BRD-K88997350-001-01-1; 4-Quinolinecarboxamide, 2-phenyl-N-(2-phenylethyl)-
DM4G6LJ	DT	Small molecular drug
DM4G6LJ	PC	3100293
DM4G6LJ	MW	352.4
DM4G6LJ	FM	C24H20N2O
DM4G6LJ	IC	InChI=1S/C24H20N2O/c27-24(25-16-15-18-9-3-1-4-10-18)21-17-23(19-11-5-2-6-12-19)26-22-14-8-7-13-20(21)22/h1-14,17H,15-16H2,(H,25,27)
DM4G6LJ	CS	C1=CC=C(C=C1)CCNC(=O)C2=CC(=NC3=CC=CC=C32)C4=CC=CC=C4
DM4G6LJ	IK	LVSGZPVWALHPET-UHFFFAOYSA-N
DM4G6LJ	IU	2-phenyl-N-(2-phenylethyl)quinoline-4-carboxamide
DM4G6LJ	CA	CAS 65628-69-5
DM4G6LJ	DE	Discovery agent

DM1ZPGY	ID	DM1ZPGY
DM1ZPGY	DN	N-phenethylquinoxaline-2-carboxamide
DM1ZPGY	HS	Investigative
DM1ZPGY	SN	N-phenethylquinoxaline-2-carboxamide; CHEMBL245820; N-(2-phenylethyl)quinoxaline-2-carboxamide; N-(2-phenylethyl)-2-quinoxalinecarboxamide; 2-quinoxalinecarboxamide, N-(2-phenylethyl)-; AC1NRYO0; MLS001198127; SCHEMBL7453913; VCRCXANKNYQHIW-UHFFFAOYSA-N; MolPort-002-738-788; HMS2868E05; ZINC4744930; STK783123; BDBM50197271; AKOS001338925; MCULE-6665471272; N~2~-phenethyl-2-quinoxalinecarboxamide; KB-55566; SMR000559426; ST4122831; N-(2-phenylethyl)quinoxalin-2-ylcarboxamide
DM1ZPGY	DT	Small molecular drug
DM1ZPGY	PC	5300647
DM1ZPGY	MW	277.32
DM1ZPGY	FM	C17H15N3O
DM1ZPGY	IC	InChI=1S/C17H15N3O/c21-17(18-11-10-13-6-2-1-3-7-13)16-12-19-14-8-4-5-9-15(14)20-16/h1-9,12H,10-11H2,(H,18,21)
DM1ZPGY	CS	C1=CC=C(C=C1)CCNC(=O)C2=NC3=CC=CC=C3N=C2
DM1ZPGY	IK	VCRCXANKNYQHIW-UHFFFAOYSA-N
DM1ZPGY	IU	N-(2-phenylethyl)quinoxaline-2-carboxamide
DM1ZPGY	DE	Discovery agent

DM7V025	ID	DM7V025
DM7V025	DN	N-Phenyl-1H-indole-2-carboxamide
DM7V025	HS	Investigative
DM7V025	SN	N-Phenyl-1H-indole-2-carboxamide; Indole, derivative of; 1H-Indole-2-carboxamide, N-phenyl-; CHEMBL454487; 17954-05-1; Indole-2-carboxanilide; AC1LBUC7; MLS000701794; SCHEMBL7208136; CTK0E3276; DTXSID20343340; MolPort-001-788-903; ARBMSJKZZZWLOE-UHFFFAOYSA-N; HMS2544M17; ZINC384465; BDBM50273485; N-Phenyl-1H-indole-2-carboxamide #; AKOS008463534; MCULE-4430477478; SMR000229823; AB00566179-06; AP-122/41076197
DM7V025	DT	Small molecular drug
DM7V025	PC	589138
DM7V025	MW	236.27
DM7V025	FM	C15H12N2O
DM7V025	IC	InChI=1S/C15H12N2O/c18-15(16-12-7-2-1-3-8-12)14-10-11-6-4-5-9-13(11)17-14/h1-10,17H,(H,16,18)
DM7V025	CS	C1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3N2
DM7V025	IK	ARBMSJKZZZWLOE-UHFFFAOYSA-N
DM7V025	IU	N-phenyl-1H-indole-2-carboxamide
DM7V025	CA	CAS 17954-05-1
DM7V025	DE	Discovery agent

DM1LHD3	ID	DM1LHD3
DM1LHD3	DN	N-Phenyl-1'H-phenothiazine-1'-carboxamide
DM1LHD3	HS	Investigative
DM1LHD3	SN	CHEMBL590537; N-phenyl-10H-phenothiazine-10-carboxamide; AC1LFFQA; Oprea1_595012; Oprea1_517446; MolPort-001-903-868; ZINC267871; N-phenylphenothiazine-10-carboxamide; STK067361; BDBM50308402; 10-(N'-phenylcarbamoyl)phenothiazine; N-phenylphenothiazin-10-ylcarboxamide; AKOS003441553; MCULE-6952834566; NCGC00280429-01; BAS 01095156; ST51030212; Phenothiazine-10-carboxylic acid phenylamide; N-Phenyl-1''H-phenothiazine-1''-carboxamide
DM1LHD3	DT	Small molecular drug
DM1LHD3	PC	777336
DM1LHD3	MW	318.4
DM1LHD3	FM	C19H14N2OS
DM1LHD3	IC	InChI=1S/C19H14N2OS/c22-19(20-14-8-2-1-3-9-14)21-15-10-4-6-12-17(15)23-18-13-7-5-11-16(18)21/h1-13H,(H,20,22)
DM1LHD3	CS	C1=CC=C(C=C1)NC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM1LHD3	IK	YNMBQQBSDFDHFH-UHFFFAOYSA-N
DM1LHD3	IU	N-phenylphenothiazine-10-carboxamide
DM1LHD3	DE	Discovery agent

DMP5E1G	ID	DMP5E1G
DMP5E1G	DN	N-phenyl-1H-pyrazole-3-carboxamide
DMP5E1G	HS	Investigative
DMP5E1G	SN	N-phenyl-1H-pyrazole-3-carboxamide; 124828-46-2; CHEMBL445420; N-phenyl-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxylic Acid Phenylamide; MLS000519301; 2vtl; pyrazole amide, 15; pyrazole-5-carboxanilide; ChemDiv2_004267; AC1LE63W; SCHEMBL19748; N-phenylpyrazol-3-ylcarboxamide; SCHEMBL13373589; BDBM24636; MolPort-001-664-649; HMS2155C18; HMS3604B14; HMS1381B21; HMS3323C02; ALBB-018739; ZINC5286379; STK926745; BDBM50109707; AKOS000321787; DB08135; 1H-pyrazole-3-carboxamide, N-phenyl-; MCULE-7079696193; IDI1_002982; ST034406
DMP5E1G	DT	Small molecular drug
DMP5E1G	PC	680935
DMP5E1G	MW	187.2
DMP5E1G	FM	C10H9N3O
DMP5E1G	IC	InChI=1S/C10H9N3O/c14-10(9-6-7-11-13-9)12-8-4-2-1-3-5-8/h1-7H,(H,11,13)(H,12,14)
DMP5E1G	CS	C1=CC=C(C=C1)NC(=O)C2=CC=NN2
DMP5E1G	IK	WMZYZYFPPQOFKY-UHFFFAOYSA-N
DMP5E1G	IU	N-phenyl-1H-pyrazole-5-carboxamide
DMP5E1G	CA	CAS 124828-46-2
DMP5E1G	DE	Discovery agent

DMBGIUE	ID	DMBGIUE
DMBGIUE	DN	N-phenyl-1H-pyrrole-2-carboxamide
DMBGIUE	HS	Investigative
DMBGIUE	SN	N-phenyl-1H-pyrrole-2-carboxamide; anilinoformylpyrrole; pyrrole inhibitor 8; 1H-Pyrrole-2-carboxamide, N-phenyl-; AC1LI7HU; MLS000701844; SCHEMBL4954697; CHEMBL376643; BDBM15582; MZPAQCAPWLAKSD-UHFFFAOYSA-N; HMS3379I18; HMS2596O19; ZINC478140; AKOS009019552; SMR000226375; 4778-75-0
DMBGIUE	DT	Small molecular drug
DMBGIUE	PC	899774
DMBGIUE	MW	186.21
DMBGIUE	FM	C11H10N2O
DMBGIUE	IC	InChI=1S/C11H10N2O/c14-11(10-7-4-8-12-10)13-9-5-2-1-3-6-9/h1-8,12H,(H,13,14)
DMBGIUE	CS	C1=CC=C(C=C1)NC(=O)C2=CC=CN2
DMBGIUE	IK	MZPAQCAPWLAKSD-UHFFFAOYSA-N
DMBGIUE	IU	N-phenyl-1H-pyrrole-2-carboxamide
DMBGIUE	DE	Discovery agent

DM1XV0O	ID	DM1XV0O
DM1XV0O	DN	N-Phenyl-1-methyl-1H-indole-2-carboxamide
DM1XV0O	HS	Investigative
DM1XV0O	SN	CHEMBL464333; N-Phenyl-1-methyl-1H-indole-2-carboxamide; SCHEMBL6017856; BDBM50273487
DM1XV0O	DT	Small molecular drug
DM1XV0O	PC	12209843
DM1XV0O	MW	250.29
DM1XV0O	FM	C16H14N2O
DM1XV0O	IC	InChI=1S/C16H14N2O/c1-18-14-10-6-5-7-12(14)11-15(18)16(19)17-13-8-3-2-4-9-13/h2-11H,1H3,(H,17,19)
DM1XV0O	CS	CN1C2=CC=CC=C2C=C1C(=O)NC3=CC=CC=C3
DM1XV0O	IK	BKBHWENOWTVWOA-UHFFFAOYSA-N
DM1XV0O	IU	1-methyl-N-phenylindole-2-carboxamide
DM1XV0O	DE	Discovery agent

DM0JI2L	ID	DM0JI2L
DM0JI2L	DN	N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide
DM0JI2L	HS	Investigative
DM0JI2L	SN	CHEMBL214965; N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide; SCHEMBL15313847
DM0JI2L	DT	Small molecular drug
DM0JI2L	PC	16090304
DM0JI2L	MW	335.4
DM0JI2L	FM	C20H17NO4
DM0JI2L	IC	InChI=1S/C20H17NO4/c22-17-14(11-13-7-3-1-4-8-13)12-16(18(23)19(17)24)20(25)21-15-9-5-2-6-10-15/h1-10,12,22-24H,11H2,(H,21,25)
DM0JI2L	CS	C1=CC=C(C=C1)CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=CC=C3
DM0JI2L	IK	QFCGWKILQYTRID-UHFFFAOYSA-N
DM0JI2L	IU	5-benzyl-2,3,4-trihydroxy-N-phenylbenzamide
DM0JI2L	DE	Discovery agent

DMWH86J	ID	DMWH86J
DMWH86J	DN	N-phenyl-3-(2-aminoethyl)benzenesulfonamide
DMWH86J	HS	Investigative
DMWH86J	SN	CHEMBL415046; N-phenyl-3-(2-aminoethyl)benzenesulfonamide; BDBM50193460
DMWH86J	DT	Small molecular drug
DMWH86J	PC	11849794
DMWH86J	MW	276.36
DMWH86J	FM	C14H16N2O2S
DMWH86J	IC	InChI=1S/C14H16N2O2S/c15-10-9-12-5-4-8-14(11-12)19(17,18)16-13-6-2-1-3-7-13/h1-8,11,16H,9-10,15H2
DMWH86J	CS	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)CCN
DMWH86J	IK	STRFPXFHEXRQFY-UHFFFAOYSA-N
DMWH86J	IU	3-(2-aminoethyl)-N-phenylbenzenesulfonamide
DMWH86J	DE	Discovery agent

DM7XER1	ID	DM7XER1
DM7XER1	DN	N-phenyl-5,6-dip-tolylpyrazine-2-carboxamide
DM7XER1	HS	Investigative
DM7XER1	SN	CHEMBL225242; N-phenyl-5,6-dip-tolylpyrazine-2-carboxamide; SCHEMBL4450848; BDBM35881; 5,6-diaryl-pyrazine-2-amide derivative, 7b; 5,6-di-p-tolyl-pyrazine-2-carboxylic acid phenylamide
DM7XER1	DT	Small molecular drug
DM7XER1	PC	10215860
DM7XER1	MW	379.5
DM7XER1	FM	C25H21N3O
DM7XER1	IC	InChI=1S/C25H21N3O/c1-17-8-12-19(13-9-17)23-24(20-14-10-18(2)11-15-20)28-22(16-26-23)25(29)27-21-6-4-3-5-7-21/h3-16H,1-2H3,(H,27,29)
DM7XER1	CS	CC1=CC=C(C=C1)C2=NC=C(N=C2C3=CC=C(C=C3)C)C(=O)NC4=CC=CC=C4
DM7XER1	IK	AKCXCZPEESTMSV-UHFFFAOYSA-N
DM7XER1	IU	5,6-bis(4-methylphenyl)-N-phenylpyrazine-2-carboxamide
DM7XER1	DE	Discovery agent

DMGVJBD	ID	DMGVJBD
DMGVJBD	DN	N-Phenyl-5-phenylimidazo[1,5-a]pyrazin-8-amine
DMGVJBD	HS	Investigative
DMGVJBD	SN	CHEMBL426903; 849199-96-8; imidazo[1,5-a]pyrazin-8-amine,n,5-diphenyl-; N-Phenyl-5-phenylimidazo[1,5-a]pyrazin-8-amine; CTK3C9676; DTXSID80658947; BDBM50198371; ZINC28642119; KB-273858; Imidazo[1,5-a]pyrazin-8-amine, N,5-diphenyl-
DMGVJBD	DT	Small molecular drug
DMGVJBD	PC	44422490
DMGVJBD	MW	286.3
DMGVJBD	FM	C18H14N4
DMGVJBD	IC	InChI=1S/C18H14N4/c1-3-7-14(8-4-1)16-12-20-18(17-11-19-13-22(16)17)21-15-9-5-2-6-10-15/h1-13H,(H,20,21)
DMGVJBD	CS	C1=CC=C(C=C1)C2=CN=C(C3=CN=CN32)NC4=CC=CC=C4
DMGVJBD	IK	BJCBFPYPEDWTTE-UHFFFAOYSA-N
DMGVJBD	IU	N,5-diphenylimidazo[1,5-a]pyrazin-8-amine
DMGVJBD	CA	CAS 849199-96-8
DMGVJBD	DE	Discovery agent

DMRHKF8	ID	DMRHKF8
DMRHKF8	DN	N-phenyl-6-(sulfamoylamino)hexanamide
DMRHKF8	HS	Investigative
DMRHKF8	SN	CHEMBL474097; N-phenyl-6-(sulfamoylamino)hexanamide; SCHEMBL5326902
DMRHKF8	DT	Small molecular drug
DMRHKF8	PC	25216937
DMRHKF8	MW	285.36
DMRHKF8	FM	C12H19N3O3S
DMRHKF8	IC	InChI=1S/C12H19N3O3S/c13-19(17,18)14-10-6-2-5-9-12(16)15-11-7-3-1-4-8-11/h1,3-4,7-8,14H,2,5-6,9-10H2,(H,15,16)(H2,13,17,18)
DMRHKF8	CS	C1=CC=C(C=C1)NC(=O)CCCCCNS(=O)(=O)N
DMRHKF8	IK	GJBBLVDVDAQQMI-UHFFFAOYSA-N
DMRHKF8	IU	N-phenyl-6-(sulfamoylamino)hexanamide
DMRHKF8	DE	Discovery agent

DMXANES	ID	DMXANES
DMXANES	DN	N-Phenylbenzo[d]oxazol-2-amine
DMXANES	HS	Investigative
DMXANES	SN	N-phenyl-1,3-benzoxazol-2-amine; 2-benzoxazolamine, n-phenyl-; MLS000564967; CHEMBL1269508; SMR000152172; N-Phenylbenzo[d]oxazol-2-amine; NSC53097; 2-anilinobenzoxazole; Enamine_001986; AC1L6BGG; AC1Q4WEW; 2-(Phenylamino)benzoxazole; Oprea1_506735; Oprea1_258700; cid_243391; SCHEMBL2658434; BDBM49481; BFLIOKCEGCUTNH-UHFFFAOYSA-N; HMS2433J13; HMS1399K06; 1,3-benzoxazol-2-yl(phenyl)amine; ZINC1684315; NSC-53097; BENZOOXAZOL-2-YL-PHENYL-AMINE; AKOS003001295; SC-56852; KB-302380; N-phenyl-2,3-dihydro-1,3-benzoxazol-2-imine
DMXANES	DT	Small molecular drug
DMXANES	PC	243391
DMXANES	MW	210.23
DMXANES	FM	C13H10N2O
DMXANES	IC	InChI=1S/C13H10N2O/c1-2-6-10(7-3-1)14-13-15-11-8-4-5-9-12(11)16-13/h1-9H,(H,14,15)
DMXANES	CS	C1=CC=C(C=C1)NC2=NC3=CC=CC=C3O2
DMXANES	IK	BFLIOKCEGCUTNH-UHFFFAOYSA-N
DMXANES	IU	N-phenyl-1,3-benzoxazol-2-amine
DMXANES	CA	CAS 6631-42-1
DMXANES	DE	Discovery agent

DM1VSO9	ID	DM1VSO9
DM1VSO9	DN	N-Phenylethyl-ETAV
DM1VSO9	HS	Investigative
DM1VSO9	SN	N-Phenylethyl-ETAV; CHEMBL494895
DM1VSO9	DT	Small molecular drug
DM1VSO9	PC	44568795
DM1VSO9	MW	522.6
DM1VSO9	FM	C25H38N4O8
DM1VSO9	IC	InChI=1S/C25H38N4O8/c1-14(2)20(25(36)37)28-22(33)15(3)27-24(35)21(16(4)30)29-23(34)18(10-11-19(31)32)26-13-12-17-8-6-5-7-9-17/h5-9,14-16,18,20-21,26,30H,10-13H2,1-4H3,(H,27,35)(H,28,33)(H,29,34)(H,31,32)(H,36,37)/t15-,16?,18-,20-,21-/m0/s1
DM1VSO9	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCC1=CC=CC=C1
DM1VSO9	IK	DJKUAJMLBSOLFF-GDEPEFMTSA-N
DM1VSO9	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxo-4-(2-phenylethylamino)pentanoic acid
DM1VSO9	DE	Discovery agent

DM90GNC	ID	DM90GNC
DM90GNC	DN	N-Phenylpropyl-ETAV
DM90GNC	HS	Investigative
DM90GNC	SN	N-Phenylpropyl-ETAV; CHEMBL495099
DM90GNC	DT	Small molecular drug
DM90GNC	PC	44568810
DM90GNC	MW	536.6
DM90GNC	FM	C26H40N4O8
DM90GNC	IC	InChI=1S/C26H40N4O8/c1-15(2)21(26(37)38)29-23(34)16(3)28-25(36)22(17(4)31)30-24(35)19(12-13-20(32)33)27-14-8-11-18-9-6-5-7-10-18/h5-7,9-10,15-17,19,21-22,27,31H,8,11-14H2,1-4H3,(H,28,36)(H,29,34)(H,30,35)(H,32,33)(H,37,38)/t16-,17?,19-,21-,22-/m0/s1
DM90GNC	CS	C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCCC1=CC=CC=C1
DM90GNC	IK	UKIJAHRPMGIIOF-DYKQHQKNSA-N
DM90GNC	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxo-4-(3-phenylpropylamino)pentanoic acid
DM90GNC	DE	Discovery agent

DMFIWAN	ID	DMFIWAN
DMFIWAN	DN	NPPB
DMFIWAN	HS	Investigative
DMFIWAN	SN	5-Nitro-2-(3-phenylpropylamino)benzoic acid; 107254-86-4; UNII-3A35O9G3YZ; 5-nitro-2-[(3-phenylpropyl)amino]benzoic acid; 3A35O9G3YZ; CHEBI:34457; Benzoic acid,5-nitro-2-[(3-phenylpropyl)amino]-; Benzoic acid, 5-nitro-2-((3-phenylpropyl)amino)-; 5-NITRO-2-PHENYLPROPYLAMINOBENZOIC ACID [NPPB]; 5-NITRO-2-(3-PHENYLPROPYLAMINO)-BENZOIC ACID; 5-Nitro-2-(3-phenylpropylamino)benzoic Acid (NPPB); SR-01000075336; HOE-144; HOE 144; Tocris-0593; Spectrum_001814; ACMC-20c9kv; AC1L1IEV; Spectrum4_000338; Spectrum2_001477;  HOE 144; 5-nitro-2-(3-phenylpropylamino) benzoic acid
DMFIWAN	DT	Small molecular drug
DMFIWAN	PC	4549
DMFIWAN	MW	300.31
DMFIWAN	FM	C16H16N2O4
DMFIWAN	IC	InChI=1S/C16H16N2O4/c19-16(20)14-11-13(18(21)22)8-9-15(14)17-10-4-7-12-5-2-1-3-6-12/h1-3,5-6,8-9,11,17H,4,7,10H2,(H,19,20)
DMFIWAN	CS	C1=CC=C(C=C1)CCCNC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)O
DMFIWAN	IK	WBSMIPAMAXNXFS-UHFFFAOYSA-N
DMFIWAN	IU	5-nitro-2-(3-phenylpropylamino)benzoic acid
DMFIWAN	CA	CAS 107254-86-4
DMFIWAN	CB	CHEBI:34457
DMFIWAN	DE	Discovery agent

DMHZCLV	ID	DMHZCLV
DMHZCLV	DN	N-Propargyl-1(S)-Aminoindan
DMHZCLV	HS	Investigative
DMHZCLV	SN	185517-74-2; (S)-N-(2-Propynyl)-2,3-dihydroinden-1-amine; TVP1022; N-PROPARGYL-1(S)-AMINOINDAN; (S)-Rasagiline; J-500397; S-PAI; AC1NRD1Z; N-propargyl-1-(s)aminoindan; SCHEMBL332967; CHEMBL1235738; BDBM11000; (S)-N-2-propynyl-1-indanamine; RUOKEQAAGRXIBM-LBPRGKRZSA-N; MolPort-006-666-243; KS-00000LL3; ZINC19875505; ANW-23242; FCH907116; AKOS024256741; TV-1022; DB03894; AJ-75608; AS-32581; HY-14200; CJ-16483; AC-14138; TVP1022, &gt; TC-111987; AB0052190; FT-0694134; FT-0674331; V3968; (1S)-N-methyl-N-prop-2-ynyl-indan-1-amine
DMHZCLV	DT	Small molecular drug
DMHZCLV	PC	5289310
DMHZCLV	MW	171.24
DMHZCLV	FM	C12H13N
DMHZCLV	IC	InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m0/s1
DMHZCLV	CS	C#CCN[C@H]1CCC2=CC=CC=C12
DMHZCLV	IK	RUOKEQAAGRXIBM-LBPRGKRZSA-N
DMHZCLV	IU	(1S)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
DMHZCLV	CA	CAS 185517-74-2
DMHZCLV	DE	Discovery agent

DMNYQ28	ID	DMNYQ28
DMNYQ28	DN	N-propargyl-1H-pyrrole-2-carboxamide
DMNYQ28	HS	Investigative
DMNYQ28	SN	N-propargyl-1H-pyrrole-2-carboxamide; 1H-pyrrole-2-carboxylic acid prop-2-ynylamide; 929537-02-0; pyrrole inhibitor 32; CHEMBL266769; BDBM15607; AKOS009070722
DMNYQ28	DT	Small molecular drug
DMNYQ28	PC	16110305
DMNYQ28	MW	148.16
DMNYQ28	FM	C8H8N2O
DMNYQ28	IC	InChI=1S/C8H8N2O/c1-2-5-10-8(11)7-4-3-6-9-7/h1,3-4,6,9H,5H2,(H,10,11)
DMNYQ28	CS	C#CCNC(=O)C1=CC=CN1
DMNYQ28	IK	AXGVGNDEKWILLM-UHFFFAOYSA-N
DMNYQ28	IU	N-prop-2-ynyl-1H-pyrrole-2-carboxamide
DMNYQ28	DE	Discovery agent

DMKBG1F	ID	DMKBG1F
DMKBG1F	DN	N-Propyl-2-methylnorapomorphine hydrochloride
DMKBG1F	HS	Investigative
DMKBG1F	SN	CHEMBL550180
DMKBG1F	DT	Small molecular drug
DMKBG1F	PC	45269964
DMKBG1F	MW	309.4
DMKBG1F	FM	C20H23NO2
DMKBG1F	IC	InChI=1S/C20H23NO2/c1-3-7-21-8-6-14-9-12(2)10-15-18(14)16(21)11-13-4-5-17(22)20(23)19(13)15/h4-5,9-10,16,22-23H,3,6-8,11H2,1-2H3/t16-/m1/s1
DMKBG1F	CS	CCCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)C)C(=C(C=C4)O)O
DMKBG1F	IK	IQXHLUBOFQZZLM-MRXNPFEDSA-N
DMKBG1F	IU	(6aR)-2-methyl-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMKBG1F	DE	Discovery agent

DML6SAG	ID	DML6SAG
DML6SAG	DN	N-Propyl-2-phenylnorapomorphine hydrochloride
DML6SAG	HS	Investigative
DML6SAG	SN	CHEMBL550792
DML6SAG	DT	Small molecular drug
DML6SAG	PC	45269974
DML6SAG	MW	371.5
DML6SAG	FM	C25H25NO2
DML6SAG	IC	InChI=1S/C25H25NO2/c1-2-11-26-12-10-18-13-19(16-6-4-3-5-7-16)14-20-23(18)21(26)15-17-8-9-22(27)25(28)24(17)20/h3-9,13-14,21,27-28H,2,10-12,15H2,1H3/t21-/m1/s1
DML6SAG	CS	CCCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)C5=CC=CC=C5)C(=C(C=C4)O)O
DML6SAG	IK	DSINXCRDVCZBKB-OAQYLSRUSA-N
DML6SAG	IU	(6aR)-2-phenyl-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DML6SAG	DE	Discovery agent

DMUTDNV	ID	DMUTDNV
DMUTDNV	DN	N-Propyl-ETAV
DMUTDNV	HS	Investigative
DMUTDNV	SN	N-Propyl-ETAV; CHEMBL494287
DMUTDNV	DT	Small molecular drug
DMUTDNV	PC	44568833
DMUTDNV	MW	460.5
DMUTDNV	FM	C20H36N4O8
DMUTDNV	IC	InChI=1S/C20H36N4O8/c1-6-9-21-13(7-8-14(26)27)18(29)24-16(12(5)25)19(30)22-11(4)17(28)23-15(10(2)3)20(31)32/h10-13,15-16,21,25H,6-9H2,1-5H3,(H,22,30)(H,23,28)(H,24,29)(H,26,27)(H,31,32)/t11-,12?,13-,15-,16-/m0/s1
DMUTDNV	CS	CCCN[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O
DMUTDNV	IK	NHQFROHPNIZUKF-VSZKUSEYSA-N
DMUTDNV	IU	(4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxo-4-(propylamino)pentanoic acid
DMUTDNV	DE	Discovery agent

DMO7MTX	ID	DMO7MTX
DMO7MTX	DN	N-propylnorapomorphine
DMO7MTX	HS	Investigative
DMO7MTX	SN	N-n-Propylnorapomorphine; 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-propyl-; 57559-68-9; Propyl-norapomorphine; Propylnorapomorphine; 6-Propyl-5,6,6a,7-tetrahydro-4H-dibenzo(de,g)quinoline-10,11-diol; (+-)-N-n-Propylnorapomorphine; 10,11-Dihydroxy-6-propylnoraporphine; AC1L1IVU; GTPL934; SCHEMBL249729; R(-)-PROPYLNORAPOMORPHINE; 6-Propyl- 5,6,6a,7-tetrahydro-4H-dibenzo(de,g)quinoline-10,11-diol
DMO7MTX	DT	Small molecular drug
DMO7MTX	PC	167715
DMO7MTX	MW	295.4
DMO7MTX	FM	C19H21NO2
DMO7MTX	IC	InChI=1S/C19H21NO2/c1-2-9-20-10-8-12-4-3-5-14-17(12)15(20)11-13-6-7-16(21)19(22)18(13)14/h3-7,15,21-22H,2,8-11H2,1H3/t15-/m1/s1
DMO7MTX	CS	CCCN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
DMO7MTX	IK	BTGAJCKRXPNBFI-OAHLLOKOSA-N
DMO7MTX	IU	(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMO7MTX	CA	CAS 18426-20-5
DMO7MTX	CB	CHEBI:92234

DM3JQYD	ID	DM3JQYD
DM3JQYD	DN	N-propylnorlitebamine
DM3JQYD	HS	Investigative
DM3JQYD	SN	N-propylnorlitebamine; CHEMBL463083; BDBM50250441
DM3JQYD	DT	Small molecular drug
DM3JQYD	PC	10067541
DM3JQYD	MW	367.4
DM3JQYD	FM	C22H25NO4
DM3JQYD	IC	InChI=1S/C22H25NO4/c1-4-8-23-9-7-14-15-6-5-13-10-18(24)19(26-2)11-16(13)20(15)22(27-3)21(25)17(14)12-23/h5-6,10-11,24-25H,4,7-9,12H2,1-3H3
DM3JQYD	CS	CCCN1CCC2=C3C=CC4=CC(=C(C=C4C3=C(C(=C2C1)O)OC)OC)O
DM3JQYD	IK	IFMOVFFRZLWNFZ-UHFFFAOYSA-N
DM3JQYD	IU	9,11-dimethoxy-2-propyl-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DM3JQYD	DE	Discovery agent

DMWTPJH	ID	DMWTPJH
DMWTPJH	DN	N-propynyl amidebenzenesulphonide
DMWTPJH	HS	Investigative
DMWTPJH	SN	N-(prop-2-ynyl)-4-sulfamoylbenzamide
DMWTPJH	DT	Small molecular drug
DMWTPJH	PC	11851424
DMWTPJH	MW	238.27
DMWTPJH	FM	C10H10N2O3S
DMWTPJH	IC	InChI=1S/C10H10N2O3S/c1-2-7-12-10(13)8-3-5-9(6-4-8)16(11,14)15/h1,3-6H,7H2,(H,12,13)(H2,11,14,15)
DMWTPJH	CS	C#CCNC(=O)C1=CC=C(C=C1)S(=O)(=O)N
DMWTPJH	IK	KRDXLVUMSYUYOP-UHFFFAOYSA-N
DMWTPJH	IU	N-prop-2-ynyl-4-sulfamoylbenzamide
DMWTPJH	DE	Discovery agent

DMYB2EZ	ID	DMYB2EZ
DMYB2EZ	DN	NPRx-30
DMYB2EZ	HS	Investigative
DMYB2EZ	CP	Nectid Inc
DMYB2EZ	DE	Neurodegenerative disorder

DMMUY73	ID	DMMUY73
DMMUY73	DN	NPT-500
DMMUY73	HS	Investigative
DMMUY73	CP	Nectid Inc
DMMUY73	DE	Major depressive disorder

DMMR7DI	ID	DMMR7DI
DMMR7DI	DN	N-p-Tolyl-1'H-phenothiazine-1'-carboxamide
DMMR7DI	HS	Investigative
DMMR7DI	SN	CHEMBL590538; AC1LIMLV; BAS 04087749; Oprea1_350347; MolPort-001-995-161; ZINC527341; STK144993; BDBM50308404; AKOS000643478; MCULE-6324715644; ST50274213; Phenothiazine-10-carboxylic acid p-tolylamide; N-(4-methylphenyl)phenothiazine-10-carboxamide; N-p-Tolyl-1''H-phenothiazine-1''-carboxamide; AB00120046-01; N-(4-methylphenyl)phenothiazin-10-ylcarboxamide; N-(4-methylphenyl)-10H-phenothiazine-10-carboxamide
DMMR7DI	DT	Small molecular drug
DMMR7DI	PC	934131
DMMR7DI	MW	332.4
DMMR7DI	FM	C20H16N2OS
DMMR7DI	IC	InChI=1S/C20H16N2OS/c1-14-10-12-15(13-11-14)21-20(23)22-16-6-2-4-8-18(16)24-19-9-5-3-7-17(19)22/h2-13H,1H3,(H,21,23)
DMMR7DI	CS	CC1=CC=C(C=C1)NC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMMR7DI	IK	AGRMZLFVKVZKOP-UHFFFAOYSA-N
DMMR7DI	IU	N-(4-methylphenyl)phenothiazine-10-carboxamide
DMMR7DI	DE	Discovery agent

DM1MOG8	ID	DM1MOG8
DM1MOG8	DN	NPY-1 antagonist
DM1MOG8	HS	Investigative
DM1MOG8	CP	Pfizer
DM1MOG8	DT	Small molecular drug
DM1MOG8	PC	20725582
DM1MOG8	MW	513.6
DM1MOG8	FM	C30H35N5O3
DM1MOG8	IC	InChI=1S/C30H35N5O3/c31-29(35-30(37)34-21-26-15-8-16-38-26)33-20-24-12-7-11-23(17-24)19-32-28(36)27(25-13-5-2-6-14-25)18-22-9-3-1-4-10-22/h1-7,9-14,17,26-27H,8,15-16,18-21H2,(H,32,36)(H4,31,33,34,35,37)
DM1MOG8	CS	C1CC(OC1)CNC(=O)NC(=NCC2=CC=CC(=C2)CNC(=O)C(CC3=CC=CC=C3)C4=CC=CC=C4)N
DM1MOG8	IK	BSGMHDGHMYUSDC-UHFFFAOYSA-N
DM1MOG8	IU	N-[[3-[[[amino-(oxolan-2-ylmethylcarbamoylamino)methylidene]amino]methyl]phenyl]methyl]-2,3-diphenylpropanamide
DM1MOG8	DE	Eating disorder

DMMV1YN	ID	DMMV1YN
DMMV1YN	DN	N-Pyridoxyl-Glycine-5-Monophosphate
DMMV1YN	HS	Investigative
DMMV1YN	SN	N-PYRIDOXYL-GLYCINE-5-MONOPHOSPHATE; N-GLYCINE-[3-HYDROXY-2-METHYL-5-PHOSPHONOOXYMETHYL-PYRIDIN-4-YL-METHANE]; AC1L9HCR; DB02824; N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)glycine; 2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]acetic acid; [({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]acetic acid
DMMV1YN	DT	Small molecular drug
DMMV1YN	PC	445062
DMMV1YN	MW	306.21
DMMV1YN	FM	C10H15N2O7P
DMMV1YN	IC	InChI=1S/C10H15N2O7P/c1-6-10(15)8(3-11-4-9(13)14)7(2-12-6)5-19-20(16,17)18/h2,11,15H,3-5H2,1H3,(H,13,14)(H2,16,17,18)
DMMV1YN	CS	CC1=NC=C(C(=C1O)CNCC(=O)O)COP(=O)(O)O
DMMV1YN	IK	FEVQWBMNLWUBTF-UHFFFAOYSA-N
DMMV1YN	IU	2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]acetic acid
DMMV1YN	DE	Discovery agent

DM3ZHBO	ID	DM3ZHBO
DM3ZHBO	DN	N'-Pyridoxyl-Lysine-5'-Monophosphate
DM3ZHBO	HS	Investigative
DM3ZHBO	DT	Small molecular drug
DM3ZHBO	PC	46936882
DM3ZHBO	MW	377.33
DM3ZHBO	FM	C14H24N3O7P
DM3ZHBO	IC	InChI=1S/C14H24N3O7P/c1-9-13(18)11(10(6-17-9)8-24-25(21,22)23)7-16-5-3-2-4-12(15)14(19)20/h6,12,16,18H,2-5,7-8,15H2,1H3,(H,19,20)(H2,21,22,23)/t12-/m1/s1
DM3ZHBO	CS	CC1=NC=C(C(=C1O)CNCCCC[C@H](C(=O)O)N)COP(=O)(O)O
DM3ZHBO	IK	FIXMYVJXXYQYGI-GFCCVEGCSA-N
DM3ZHBO	IU	(2R)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]hexanoic acid
DM3ZHBO	DE	Discovery agent

DMAXHLK	ID	DMAXHLK
DMAXHLK	DN	NQN-1
DMAXHLK	HS	Investigative
DMAXHLK	SN	PPM-18; NSC 73233
DMAXHLK	DT	Small molecular drug
DMAXHLK	PC	4882
DMAXHLK	MW	277.27
DMAXHLK	FM	C17H11NO3
DMAXHLK	IC	InChI=1S/C17H11NO3/c19-15-10-14(16(20)13-9-5-4-8-12(13)15)18-17(21)11-6-2-1-3-7-11/h1-10H,(H,18,21)
DMAXHLK	CS	C1=CC=C(C=C1)C(=O)NC2=CC(=O)C3=CC=CC=C3C2=O
DMAXHLK	IK	BIVQBWSIGJFXLF-UHFFFAOYSA-N
DMAXHLK	IU	N-(1,4-dioxonaphthalen-2-yl)benzamide
DMAXHLK	CA	CAS 65240-86-0
DMAXHLK	DE	Discovery agent

DMXP03H	ID	DMXP03H
DMXP03H	DN	NRC-2694
DMXP03H	HS	Investigative
DMXP03H	CP	Natco Pharma Ltd
DMXP03H	PC	16129168
DMXP03H	MW	418.5
DMXP03H	FM	C24H26N4O3
DMXP03H	IC	InChI=1S/C24H26N4O3/c1-3-18-6-4-7-19(14-18)27-24-20-15-23(22(29-2)16-21(20)25-17-26-24)31-11-5-8-28-9-12-30-13-10-28/h1,4,6-7,14-17H,5,8-13H2,2H3,(H,25,26,27)
DMXP03H	CS	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCN4CCOCC4
DMXP03H	IK	WBKHQQZRHCECKK-UHFFFAOYSA-N
DMXP03H	IU	N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
DMXP03H	CA	CAS 936446-61-6
DMXP03H	DE	Solid tumour/cancer

DMC9XJA	ID	DMC9XJA
DMC9XJA	DN	NRP290
DMC9XJA	HS	Investigative
DMC9XJA	CP	Shire Pharmaceuticals
DMC9XJA	DE	Pain

DM3IWP5	ID	DM3IWP5
DM3IWP5	DN	NRT-300
DM3IWP5	HS	Investigative
DM3IWP5	SN	NCT-300
DM3IWP5	CP	Nectid Inc
DM3IWP5	DE	Pain

DML0N7D	ID	DML0N7D
DML0N7D	DN	NS 2028
DML0N7D	HS	Investigative
DML0N7D	SN	NS2028
DML0N7D	DT	Small molecular drug
DML0N7D	PC	4551
DML0N7D	MW	269.05
DML0N7D	FM	C9H5BrN2O3
DML0N7D	IC	InChI=1S/C9H5BrN2O3/c10-5-1-2-7-6(3-5)12-8(4-14-7)11-15-9(12)13/h1-3H,4H2
DML0N7D	CS	C1C2=NOC(=O)N2C3=C(O1)C=CC(=C3)Br
DML0N7D	IK	MUDRLQRJCGJJTB-UHFFFAOYSA-N
DML0N7D	IU	8-bromo-4H-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one
DML0N7D	CA	CAS 204326-43-2
DML0N7D	DE	Discovery agent

DM98VMZ	ID	DM98VMZ
DM98VMZ	DN	NS-11757
DM98VMZ	HS	Investigative
DM98VMZ	SN	NS-309; NS-4591; NS-6277; NS-8593; Calcium-activated potassium channel modulators, Neurosearch
DM98VMZ	CP	NeuroSearch A/S
DM98VMZ	DT	Small molecular drug
DM98VMZ	PC	25102784
DM98VMZ	MW	332.2
DM98VMZ	FM	C17H15Cl2N3
DM98VMZ	IC	InChI=1S/C17H15Cl2N3/c18-12-8-10-4-3-7-14(11(10)9-13(12)19)20-17-21-15-5-1-2-6-16(15)22-17/h1-2,5-6,8-9,14H,3-4,7H2,(H2,20,21,22)
DM98VMZ	CS	C1CC(C2=CC(=C(C=C2C1)Cl)Cl)NC3=NC4=CC=CC=C4N3
DM98VMZ	IK	JHLGZRSIUIFADK-UHFFFAOYSA-N
DM98VMZ	IU	N-(6,7-dichloro-1,2,3,4-tetrahydronaphthalen-1-yl)-1H-benzimidazol-2-amine
DM98VMZ	DE	Atrial fibrillation

DMT97KV	ID	DMT97KV
DMT97KV	DN	NS-1643
DMT97KV	HS	Investigative
DMT97KV	SN	HERG potassium channel openers (arrhythmia); NS-3623; NS-373; HERG potassium channel openers (arrhythmia), NeuroSearch; I(Kr) agonists (arrhythmia), NeuroSearch; Rapid delayed-rectifier current activators (acquired long QT syndrome), NeruoSearch
DMT97KV	CP	NeuroSearch A/S
DMT97KV	DT	Small molecular drug
DMT97KV	PC	10177784
DMT97KV	MW	380.24
DMT97KV	FM	C15H10F6N2O3
DMT97KV	IC	InChI=1S/C15H10F6N2O3/c16-14(17,18)7-1-3-11(24)9(5-7)22-13(26)23-10-6-8(15(19,20)21)2-4-12(10)25/h1-6,24-25H,(H2,22,23,26)
DMT97KV	CS	C1=CC(=C(C=C1C(F)(F)F)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)O)O
DMT97KV	IK	NJFVQMRYJZHGME-UHFFFAOYSA-N
DMT97KV	IU	1,3-bis[2-hydroxy-5-(trifluoromethyl)phenyl]urea
DMT97KV	CA	CAS 448895-37-2
DMT97KV	DE	Heart arrhythmia

DM2S5ZF	ID	DM2S5ZF
DM2S5ZF	DN	NS1738
DM2S5ZF	HS	Investigative
DM2S5ZF	SN	NS-1738
DM2S5ZF	DT	Small molecular drug
DM2S5ZF	PC	310378
DM2S5ZF	MW	365.1
DM2S5ZF	FM	C14H9Cl2F3N2O2
DM2S5ZF	IC	InChI=1S/C14H9Cl2F3N2O2/c15-8-2-4-12(22)11(6-8)21-13(23)20-10-5-7(14(17,18)19)1-3-9(10)16/h1-6,22H,(H2,20,21,23)
DM2S5ZF	CS	C1=CC(=C(C=C1C(F)(F)F)NC(=O)NC2=C(C=CC(=C2)Cl)O)Cl
DM2S5ZF	IK	OUDXRNQPVSMGDW-UHFFFAOYSA-N
DM2S5ZF	IU	1-(5-chloro-2-hydroxyphenyl)-3-[2-chloro-5-(trifluoromethyl)phenyl]urea
DM2S5ZF	CA	CAS 501684-93-1
DM2S5ZF	DE	Discovery agent

DMVL5KS	ID	DMVL5KS
DMVL5KS	DN	NS3763
DMVL5KS	HS	Investigative
DMVL5KS	SN	NS-3763
DMVL5KS	DT	Small molecular drug
DMVL5KS	PC	4359312
DMVL5KS	MW	404.4
DMVL5KS	FM	C22H16N2O6
DMVL5KS	IC	InChI=1S/C22H16N2O6/c25-19(13-7-3-1-4-8-13)23-17-12-18(16(22(29)30)11-15(17)21(27)28)24-20(26)14-9-5-2-6-10-14/h1-12H,(H,23,25)(H,24,26)(H,27,28)(H,29,30)
DMVL5KS	CS	C1=CC=C(C=C1)C(=O)NC2=CC(=C(C=C2C(=O)O)C(=O)O)NC(=O)C3=CC=CC=C3
DMVL5KS	IK	UUDYZUDTQPLDDP-UHFFFAOYSA-N
DMVL5KS	IU	4,6-dibenzamidobenzene-1,3-dicarboxylic acid
DMVL5KS	CA	CAS 70553-45-6
DMVL5KS	DE	Discovery agent

DM629TD	ID	DM629TD
DM629TD	DN	NS5818
DM629TD	HS	Investigative
DM629TD	SN	NS-5818
DM629TD	DT	Small molecular drug
DM629TD	PC	69453339
DM629TD	MW	496.3
DM629TD	FM	C23H19Cl2N7O2
DM629TD	IC	InChI=1S/C23H19Cl2N7O2/c1-32(2)22(33)14-5-3-13(4-6-14)19-8-7-17(12-20(19)21-28-30-31-29-21)26-23(34)27-18-10-15(24)9-16(25)11-18/h3-12H,1-2H3,(H2,26,27,34)(H,28,29,30,31)
DM629TD	CS	CN(C)C(=O)C1=CC=C(C=C1)C2=C(C=C(C=C2)NC(=O)NC3=CC(=CC(=C3)Cl)Cl)C4=NNN=N4
DM629TD	IK	FQIPXFVYNAMLDB-UHFFFAOYSA-N
DM629TD	IU	4-[4-[(3,5-dichlorophenyl)carbamoylamino]-2-(2H-tetrazol-5-yl)phenyl]-N,N-dimethylbenzamide
DM629TD	DE	Discovery agent

DMWN8FU	ID	DMWN8FU
DMWN8FU	DN	NS9283
DMWN8FU	HS	Investigative
DMWN8FU	SN	NS-9283
DMWN8FU	DT	Small molecular drug
DMWN8FU	PC	11998180
DMWN8FU	MW	248.24
DMWN8FU	FM	C14H8N4O
DMWN8FU	IC	InChI=1S/C14H8N4O/c15-8-10-3-1-4-11(7-10)14-17-13(18-19-14)12-5-2-6-16-9-12/h1-7,9H
DMWN8FU	CS	C1=CC(=CC(=C1)C2=NC(=NO2)C3=CN=CC=C3)C#N
DMWN8FU	IK	HGFXDSQLRSWUBO-UHFFFAOYSA-N
DMWN8FU	IU	3-(3-pyridin-3-yl-1,2,4-oxadiazol-5-yl)benzonitrile
DMWN8FU	DE	Discovery agent

DMLT8G9	ID	DMLT8G9
DMLT8G9	DN	NSC 19630
DMLT8G9	HS	Investigative
DMLT8G9	DT	Small molecular drug
DMLT8G9	DE	T-cell leukaemia

DMX4DT7	ID	DMX4DT7
DMX4DT7	DN	NSC 665564
DMX4DT7	HS	Investigative
DMX4DT7	SN	NSC665564; AC1L8ESN; AC1Q27AK; SCHEMBL763427; CHEMBL2000628; NSC-665564; NCS-665564; NCI60_022625; 1-(6-bromo-1-phenyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)ethanone; 1-(6-bromo-1-phenyl-1,3,4,9-tetrahydro-2H-
DMX4DT7	DT	Small molecular drug
DMX4DT7	PC	380161
DMX4DT7	MW	369.3
DMX4DT7	FM	C19H17BrN2O
DMX4DT7	IC	InChI=1S/C19H17BrN2O/c1-12(23)22-10-9-15-16-11-14(20)7-8-17(16)21-18(15)19(22)13-5-3-2-4-6-13/h2-8,11,19,21H,9-10H2,1H3
DMX4DT7	CS	CC(=O)N1CCC2=C(C1C3=CC=CC=C3)NC4=C2C=C(C=C4)Br
DMX4DT7	IK	CBMFCUHTQKAALP-UHFFFAOYSA-N
DMX4DT7	IU	1-(6-bromo-1-phenyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)ethanone
DMX4DT7	DE	Discovery agent

DMR6P9S	ID	DMR6P9S
DMR6P9S	DN	NSC-106080
DMR6P9S	HS	Investigative
DMR6P9S	DT	Small molecular drug
DMR6P9S	PC	266986
DMR6P9S	MW	304.3
DMR6P9S	FM	C19H16N2O2
DMR6P9S	IC	InChI=1S/C19H16N2O2/c22-17-12-6-4-10-15(17)19(16-11-5-7-13-18(16)23)21-20-14-8-2-1-3-9-14/h1-13,20,22-23H
DMR6P9S	CS	C1=CC=C(C=C1)NN=C(C2=CC=CC=C2O)C3=CC=CC=C3O
DMR6P9S	IK	YZUKVOKQRHDWBG-UHFFFAOYSA-N
DMR6P9S	IU	2-[N-anilino-C-(2-hydroxyphenyl)carbonimidoyl]phenol
DMR6P9S	DE	Discovery agent

DM6ID8P	ID	DM6ID8P
DM6ID8P	DN	NSC-106084
DM6ID8P	HS	Investigative
DM6ID8P	SN	NSC-106084; CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid
DM6ID8P	DT	Small molecular drug
DM6ID8P	PC	266989
DM6ID8P	MW	409.2
DM6ID8P	FM	C17H13BrO7
DM6ID8P	IC	InChI=1S/C17H13BrO7/c18-11-3-6-14(25-9-16(21)22)13(7-11)17(23)10-1-4-12(5-2-10)24-8-15(19)20/h1-7H,8-9H2,(H,19,20)(H,21,22)
DM6ID8P	CS	C1=CC(=CC=C1C(=O)C2=C(C=CC(=C2)Br)OCC(=O)O)OCC(=O)O
DM6ID8P	IK	PTQLZKRWKHXUJU-UHFFFAOYSA-N
DM6ID8P	IU	2-[4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy]acetic acid
DM6ID8P	DE	Discovery agent

DMR2DTI	ID	DMR2DTI
DMR2DTI	DN	NSC-106547
DMR2DTI	HS	Investigative
DMR2DTI	SN	1,4-Dimethoxyanthracene; 13076-29-4; Anthracene, 1,4-dimethoxy-; NSC-106547; MLS002703923; CHEMBL223575; YCTBFSAWJWMRGO-UHFFFAOYSA-N; NSC106547; NSC 106547; Anthracene,4-dimethoxy-; AC1L34PW; Anthracene,1,4-dimethoxy-; SCHEMBL1061836; DTXSID6065343; CTK4B6912; ZINC1697899; BDBM50195861; SMR001570635; ST50825870
DMR2DTI	DT	Small molecular drug
DMR2DTI	PC	83107
DMR2DTI	MW	238.28
DMR2DTI	FM	C16H14O2
DMR2DTI	IC	InChI=1S/C16H14O2/c1-17-15-7-8-16(18-2)14-10-12-6-4-3-5-11(12)9-13(14)15/h3-10H,1-2H3
DMR2DTI	CS	COC1=CC=C(C2=CC3=CC=CC=C3C=C12)OC
DMR2DTI	IK	YCTBFSAWJWMRGO-UHFFFAOYSA-N
DMR2DTI	IU	1,4-dimethoxyanthracene
DMR2DTI	CA	CAS 13076-29-4
DMR2DTI	DE	Discovery agent

DMHK0F6	ID	DMHK0F6
DMHK0F6	DN	NSC-106970
DMHK0F6	HS	Investigative
DMHK0F6	SN	33429-83-3; Quercetin 3,4'-dimethyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3-methoxy-4H-chromen-4-one; QUERCETIN-3,4'-DIMETHYL ETHER; NSC-106970; 5,7,3'-Trihydroxy-3,4'-dimethoxyflavone; CHEBI:70008; 3,4'-dimethoxy-5,7,3'-trihydroxyflavone; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3-methoxychromen-4-one; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxy-phenyl)-3-methoxy-chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3-methoxy-; NSC106970; 3-O-Methyltamarixetin; AC1NTGVE
DMHK0F6	DT	Small molecular drug
DMHK0F6	PC	5380905
DMHK0F6	MW	330.29
DMHK0F6	FM	C17H14O7
DMHK0F6	IC	InChI=1S/C17H14O7/c1-22-12-4-3-8(5-10(12)19)16-17(23-2)15(21)14-11(20)6-9(18)7-13(14)24-16/h3-7,18-20H,1-2H3
DMHK0F6	CS	COC1=C(C=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC)O
DMHK0F6	IK	ZSPZNFOLWQEVQJ-UHFFFAOYSA-N
DMHK0F6	IU	5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3-methoxychromen-4-one
DMHK0F6	CA	CAS 33429-83-3
DMHK0F6	CB	CHEBI:70008
DMHK0F6	DE	Discovery agent

DMPLUHT	ID	DMPLUHT
DMPLUHT	DN	NSC-115890
DMPLUHT	HS	Investigative
DMPLUHT	SN	1,3-Naphthalenediol; 132-86-5; Naphthalene-1,3-diol; 1,3-DIHYDROXYNAPHTHALENE; Naphthoresorcinol; Naphthoresoucinol; 3-Hydroxybenzocyclohexadien-1-one; Naphthoresorcin; CCRIS 7896; UNII-5X457YEW8Y; NSC 115890; AI3-08780; EINECS 205-079-7; NSC-115890; BRN 2044002; 5X457YEW8Y; XOOMNEFVDUTJPP-UHFFFAOYSA-N; MFCD00003965; AK-47815; N-2150; 1,3-Dihydroxynaphthalene, 99+%; 1-Hydroxy-3-naphthol; ACMC-1BVWB; Naphthalenediol-(1,3); 2,4-dihydroxynaphthalene; AC1L1RBY; 1,3-dihydroxy-naphthalene; WLN: L66J BQ DQ; SCHEMBL28681; 4-06-00-06543 (Beilst
DMPLUHT	DT	Small molecular drug
DMPLUHT	PC	8601
DMPLUHT	MW	160.17
DMPLUHT	FM	C10H8O2
DMPLUHT	IC	InChI=1S/C10H8O2/c11-8-5-7-3-1-2-4-9(7)10(12)6-8/h1-6,11-12H
DMPLUHT	CS	C1=CC=C2C(=C1)C=C(C=C2O)O
DMPLUHT	IK	XOOMNEFVDUTJPP-UHFFFAOYSA-N
DMPLUHT	IU	naphthalene-1,3-diol
DMPLUHT	CA	CAS 132-86-5
DMPLUHT	DE	Discovery agent

DMKHMS4	ID	DMKHMS4
DMKHMS4	DN	NSC-119910
DMKHMS4	HS	Investigative
DMKHMS4	SN	NSC119910; NSC-119910; CHEMBL487046; Gbetagamma Modulator I, M119; 2-(4,5,6-Trihydroxy-3-oxo-3H-xanthen-9-yl)-cyclohexane-1-carboxylic acid; AC1L6U1C; SCHEMBL2778459; cid_274122; SCHEMBL16556406; BDBM50246208; NCI60_000471; MLS-0111618.0001; 2-(4,6-trihydroxy-3-oxo-3H-xanthen-9-yl)cyclohexanecarboxylic acid; 2-(3,4,5-trihydroxy-6-oxo-xanthen-9-yl)cyclohexanecarboxylic acid; Cyclohexanecarboxylic acid, 2-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-; 2-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)cyclohexanecarboxylic acid
DMKHMS4	DT	Small molecular drug
DMKHMS4	PC	274122
DMKHMS4	MW	370.4
DMKHMS4	FM	C20H18O7
DMKHMS4	IC	InChI=1S/C20H18O7/c21-13-7-5-11-15(9-3-1-2-4-10(9)20(25)26)12-6-8-14(22)17(24)19(12)27-18(11)16(13)23/h5-10,21,23-24H,1-4H2,(H,25,26)
DMKHMS4	CS	C1CCC(C(C1)C2=C3C=CC(=O)C(=C3OC4=C2C=CC(=C4O)O)O)C(=O)O
DMKHMS4	IK	CAVIJGGXNIURPI-UHFFFAOYSA-N
DMKHMS4	IU	2-(3,4,5-trihydroxy-6-oxoxanthen-9-yl)cyclohexane-1-carboxylic acid
DMKHMS4	CA	CAS 500533-94-8
DMKHMS4	DE	Cardiac failure

DM1MRFW	ID	DM1MRFW
DM1MRFW	DN	NSC-119911
DM1MRFW	HS	Investigative
DM1MRFW	SN	NSC119911; CHEMBL258670; CHEMBL3260988; NSC-119911; MLS-0111616.0001; AC1OBGP2; AC1NTI1U; AC1NS1JN; SCHEMBL2846330; SCHEMBL2846323; CHEMBL502775; (9Z)-9-(3,3-dihydroxyprop-2-enylidene)-5,6-dihydroxyxanthene-3,4-dione; ZINC3954334; BDBM50011357; NSC158917; NCI119911; CCG-36604; BDBM50373125; NSC-158917; 9-(3,3-dihydroxyprop-2-enylidene)-5,6-dihydroxyxanthene-3,4-dione; (E)-3-(3,4,5-trihydroxy-6-oxo-xanthen-9-yl)prop-2-enoic acid; 2-Propenoic acid, 3-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-, (2E)-
DM1MRFW	DT	Small molecular drug
DM1MRFW	PC	54686376
DM1MRFW	MW	314.25
DM1MRFW	FM	C16H10O7
DM1MRFW	IC	InChI=1S/C16H10O7/c17-10-4-1-8-7(3-6-12(19)20)9-2-5-11(18)14(22)16(9)23-15(8)13(10)21/h1-6,17,21-22H,(H,19,20)/b6-3+
DM1MRFW	CS	C1=CC(=C(C2=C1C(=C3C=CC(=O)C(=C3O2)O)/C=C/C(=O)O)O)O
DM1MRFW	IK	HVUVBNCTBKJHHZ-ZZXKWVIFSA-N
DM1MRFW	IU	(E)-3-(3,4,5-trihydroxy-6-oxoxanthen-9-yl)prop-2-enoic acid
DM1MRFW	DE	Discovery agent

DMVE69Y	ID	DMVE69Y
DMVE69Y	DN	NSC-119913
DMVE69Y	HS	Investigative
DMVE69Y	SN	NSC119913; NSC-119913; MLS-0111619.0001; 7-methyl-2-(3,4,5-trihydroxy-6-oxoxanthen-9-yl)bicyclo[2.2.1]hept-5-ene-3-carboxylic acid; 7-methyl-3-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)bicyclo[2.2.1]hept-5-ene-2-carboxylic acid; 7-methyl-2-(3,4,5-trihydroxy-6-oxo-xanthen-9-yl)bicyclo[2.2.1]hept-5-ene-3-carboxylic acid; AC1L6U1G; CHEMBL471004; cid_274125; SCHEMBL2777685; BDBM42000; CTK6B4006; NCI60_000473; 7-methyl-3-(4,6-trihydroxy-3-oxo-3H-xanthen-9-yl)bicyclo[2.2.1]hept-5-ene-2-carboxylic acid
DMVE69Y	DT	Small molecular drug
DMVE69Y	PC	274125
DMVE69Y	MW	394.4
DMVE69Y	FM	C22H18O7
DMVE69Y	IC	InChI=1S/C22H18O7/c1-8-9-2-3-10(8)17(22(27)28)16(9)15-11-4-6-13(23)18(25)20(11)29-21-12(15)5-7-14(24)19(21)26/h2-10,16-17,23,25-26H,1H3,(H,27,28)
DMVE69Y	CS	CC1C2C=CC1C(C2C3=C4C=CC(=O)C(=C4OC5=C3C=CC(=C5O)O)O)C(=O)O
DMVE69Y	IK	BSAMRWOMXJWVCE-UHFFFAOYSA-N
DMVE69Y	IU	7-methyl-3-(3,4,5-trihydroxy-6-oxoxanthen-9-yl)bicyclo[2.2.1]hept-5-ene-2-carboxylic acid
DMVE69Y	DE	Discovery agent

DMYMB4A	ID	DMYMB4A
DMYMB4A	DN	NSC-122427
DMYMB4A	HS	Investigative
DMYMB4A	SN	NSC-122427; CHEMBL583989; 4-(4-(5-oxothiophen-2(5H)-ylidene)hexan-3-yl)phenyl acetate; NSC122427; AC1O0LAU; BDBM50298487; [4-[(4Z)-4-(5-oxothiophen-2-ylidene)hexan-3-yl]phenyl] acetate
DMYMB4A	DT	Small molecular drug
DMYMB4A	PC	5994480
DMYMB4A	MW	316.4
DMYMB4A	FM	C18H20O3S
DMYMB4A	IC	InChI=1S/C18H20O3S/c1-4-15(16(5-2)17-10-11-18(20)22-17)13-6-8-14(9-7-13)21-12(3)19/h6-11,15H,4-5H2,1-3H3/b17-16-
DMYMB4A	CS	CCC(C1=CC=C(C=C1)OC(=O)C)/C(=C\\2/C=CC(=O)S2)/CC
DMYMB4A	IK	CYZIBHGLFHMMJY-MSUUIHNZSA-N
DMYMB4A	IU	[4-[(4Z)-4-(5-oxothiophen-2-ylidene)hexan-3-yl]phenyl] acetate
DMYMB4A	DE	Discovery agent

DM3NQDW	ID	DM3NQDW
DM3NQDW	DN	NSC-125034
DM3NQDW	HS	Investigative
DM3NQDW	SN	NSC125034; NSC-125034; CHEMBL239439; 8-Quinolinol, 2,2'-dithiobis-; AC1L5KEF; NCIStruc1_001467; NCIStruc2_001671; SCHEMBL2534563; CTK8A0185; 2,2'-disulfanediyldiquinolin-8-ol; NCI125034; BDBM50198307; ZINC37868596; NCGC00014270; CCG-37229; NCGC00097379-01; NCGC00014270-02; NCI60_000583; 2-(8-hydroxyquinolin-2-yl)disulfanylquinolin-8-ol; 2-[(8-hydroxy-2-quinolyl)disulfanyl]quinolin-8-ol; 2-[(8-hydroxyquinolin-2-yl)disulfanyl]quinolin-8-ol
DM3NQDW	DT	Small molecular drug
DM3NQDW	PC	276707
DM3NQDW	MW	352.4
DM3NQDW	FM	C18H12N2O2S2
DM3NQDW	IC	InChI=1S/C18H12N2O2S2/c21-13-5-1-3-11-7-9-15(19-17(11)13)23-24-16-10-8-12-4-2-6-14(22)18(12)20-16/h1-10,21-22H
DM3NQDW	CS	C1=CC2=C(C(=C1)O)N=C(C=C2)SSC3=NC4=C(C=CC=C4O)C=C3
DM3NQDW	IK	XHJJWLOYIZUQTP-UHFFFAOYSA-N
DM3NQDW	IU	2-[(8-hydroxyquinolin-2-yl)disulfanyl]quinolin-8-ol
DM3NQDW	DE	Discovery agent

DMHGIB1	ID	DMHGIB1
DMHGIB1	DN	NSC-126445
DMHGIB1	HS	Investigative
DMHGIB1	SN	CHEMBL376528; NSC-126445; BDBM50158382; ZINC118925239
DMHGIB1	DT	Small molecular drug
DMHGIB1	PC	44421368
DMHGIB1	MW	552.9
DMHGIB1	FM	C34H52N2O2S
DMHGIB1	IC	InChI=1S/C34H52N2O2S/c1-23(2)8-7-9-25(4)30-16-17-31-29-15-12-26-22-27(18-20-33(26,5)32(29)19-21-34(30,31)6)35-36-39(37,38)28-13-10-24(3)11-14-28/h10-11,13-14,22-23,25,29-32,36H,7-9,12,15-21H2,1-6H3/b35-27+/t25-,29+,30-,31+,32+,33+,34-/m1/s1
DMHGIB1	CS	CC1=CC=C(C=C1)S(=O)(=O)N/N=C/2\\CC[C@@]3([C@H]4CC[C@]5([C@H]([C@@H]4CCC3=C2)CC[C@@H]5[C@H](C)CCCC(C)C)C)C
DMHGIB1	IK	PDENTDVQTUHVQO-YEDBHZBASA-N
DMHGIB1	IU	N-[(E)-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ylidene]amino]-4-methylbenzenesulfonamide
DMHGIB1	DE	Discovery agent

DMJAO6Z	ID	DMJAO6Z
DMJAO6Z	DN	NSC-12999
DMJAO6Z	HS	Investigative
DMJAO6Z	SN	CHEMBL495567; NSC-12999; AC1L8UK1; ZINC4366490; BDBM50265443; 6-chloro-2-methoxy-N-pyridin-3-ylacridin-9-amine; 6-chloro-2-methoxy-N-(3-pyridyl)acridin-9-amine
DMJAO6Z	DT	Small molecular drug
DMJAO6Z	PC	408350
DMJAO6Z	MW	335.8
DMJAO6Z	FM	C19H14ClN3O
DMJAO6Z	IC	InChI=1S/C19H14ClN3O/c1-24-14-5-7-17-16(10-14)19(22-13-3-2-8-21-11-13)15-6-4-12(20)9-18(15)23-17/h2-11H,1H3,(H,22,23)
DMJAO6Z	CS	COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CN=CC=C4
DMJAO6Z	IK	LUUDYHCKONVRQY-UHFFFAOYSA-N
DMJAO6Z	IU	6-chloro-2-methoxy-N-pyridin-3-ylacridin-9-amine
DMJAO6Z	DE	Discovery agent

DMYJNS9	ID	DMYJNS9
DMYJNS9	DN	NSC-131736
DMYJNS9	HS	Investigative
DMYJNS9	DT	Small molecular drug
DMYJNS9	PC	135494055
DMYJNS9	MW	310.3
DMYJNS9	FM	C17H14N2O4
DMYJNS9	IC	InChI=1S/C17H14N2O4/c1-23-16-6-5-14-12(9-18-10-15(14)17(16)20)7-11-3-2-4-13(8-11)19(21)22/h2-6,8-10,20H,7H2,1H3
DMYJNS9	CS	COC1=C(C2=C(C=C1)C(=CN=C2)CC3=CC(=CC=C3)[N+](=O)[O-])O
DMYJNS9	IK	DMEADVJDTWAEGN-UHFFFAOYSA-N
DMYJNS9	IU	7-methoxy-4-[(3-nitrophenyl)methyl]isoquinolin-8-ol
DMYJNS9	DE	Discovery agent

DMKQYMX	ID	DMKQYMX
DMKQYMX	DN	NSC-137546
DMKQYMX	HS	Investigative
DMKQYMX	SN	NSC-137546; NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid
DMKQYMX	DT	Small molecular drug
DMKQYMX	PC	283188
DMKQYMX	MW	320.12
DMKQYMX	FM	C12H11Cl2NO5
DMKQYMX	IC	InChI=1S/C12H11Cl2NO5/c13-6-2-1-3-7(14)10(6)11(18)15-8(12(19)20)4-5-9(16)17/h1-3,8H,4-5H2,(H,15,18)(H,16,17)(H,19,20)
DMKQYMX	CS	C1=CC(=C(C(=C1)Cl)C(=O)NC(CCC(=O)O)C(=O)O)Cl
DMKQYMX	IK	DGMFARLQEAXXKN-UHFFFAOYSA-N
DMKQYMX	IU	2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid
DMKQYMX	DE	Discovery agent

DMH684Q	ID	DMH684Q
DMH684Q	DN	NSC-138419
DMH684Q	HS	Investigative
DMH684Q	SN	NSC-138419; NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid
DMH684Q	DT	Small molecular drug
DMH684Q	PC	283555
DMH684Q	MW	280.28
DMH684Q	FM	C13H16N2O5
DMH684Q	IC	InChI=1S/C13H16N2O5/c1-14-9-4-2-8(3-5-9)12(18)15-10(13(19)20)6-7-11(16)17/h2-5,10,14H,6-7H2,1H3,(H,15,18)(H,16,17)(H,19,20)
DMH684Q	CS	CNC1=CC=C(C=C1)C(=O)NC(CCC(=O)O)C(=O)O
DMH684Q	IK	UFBUCKLNZUNJHS-UHFFFAOYSA-N
DMH684Q	IU	2-[[4-(methylamino)benzoyl]amino]pentanedioic acid
DMH684Q	CA	CAS 52980-68-4
DMH684Q	DE	Discovery agent

DMW82SA	ID	DMW82SA
DMW82SA	DN	NSC-154957
DMW82SA	HS	Investigative
DMW82SA	SN	NSC-154957; NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid
DMW82SA	DT	Small molecular drug
DMW82SA	PC	290753
DMW82SA	MW	315.4
DMW82SA	FM	C17H17NO3S
DMW82SA	IC	InChI=1S/C17H17NO3S/c19-12-18-15(17(20)21)11-22-16(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10,12,15-16H,11H2,(H,18,19)(H,20,21)
DMW82SA	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)SCC(C(=O)O)NC=O
DMW82SA	IK	QUWUQXPHWCHJIS-UHFFFAOYSA-N
DMW82SA	IU	3-benzhydrylsulfanyl-2-formamidopropanoic acid
DMW82SA	DE	Discovery agent

DMDR460	ID	DMDR460
DMDR460	DN	NSC-158324
DMDR460	HS	Investigative
DMDR460	SN	Acediasulfone; UNII-30YP2YHH8W; 80-03-5; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; NSC-158324; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid
DMDR460	DT	Small molecular drug
DMDR460	PC	24193827
DMDR460	MW	342.8
DMDR460	FM	C14H15ClN2O4S
DMDR460	IC	InChI=1S/C14H14N2O4S.ClH/c15-10-1-5-12(6-2-10)21(19,20)13-7-3-11(4-8-13)16-9-14(17)18;/h1-8,16H,9,15H2,(H,17,18);1H
DMDR460	CS	C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)NCC(=O)O.Cl
DMDR460	IK	NNALULAMJZHAQK-UHFFFAOYSA-N
DMDR460	IU	2-[4-(4-aminophenyl)sulfonylanilino]acetic acid;hydrochloride
DMDR460	DE	Discovery agent

DM9QW8N	ID	DM9QW8N
DM9QW8N	DN	NSC-172033
DM9QW8N	HS	Investigative
DM9QW8N	SN	NSC-172033; NSC172033; CHEMBL238624; Phenol,4',4'',4'''-(1,2-ethanediylidene)tetrakis(2,6-dichloro-; Phenol,4',4'',4'''-(1,2-ethanediylidene)tetrakis[2,6-dichloro-; AC1L8FA1; NCIStruc1_000231; NCIStruc2_000075; SCHEMBL1595467; ZINC8034768; NCI172033; BDBM50221402; NCGC00014500; CCG-36335; NCGC00097604-01; NCGC00014500-02; Phenol, 4,4',4'',4'''-(1,2-ethanediylidene)tetrakis(2,6-dichloro-
DM9QW8N	DT	Small molecular drug
DM9QW8N	PC	425241
DM9QW8N	MW	674
DM9QW8N	FM	C26H14Cl8O4
DM9QW8N	IC	InChI=1S/C26H14Cl8O4/c27-13-1-9(2-14(28)23(13)35)21(10-3-15(29)24(36)16(30)4-10)22(11-5-17(31)25(37)18(32)6-11)12-7-19(33)26(38)20(34)8-12/h1-8,21-22,35-38H
DM9QW8N	CS	C1=C(C=C(C(=C1Cl)O)Cl)C(C2=CC(=C(C(=C2)Cl)O)Cl)C(C3=CC(=C(C(=C3)Cl)O)Cl)C4=CC(=C(C(=C4)Cl)O)Cl
DM9QW8N	IK	PGVJRDOIJQMGEF-UHFFFAOYSA-N
DM9QW8N	IU	2,6-dichloro-4-[1,2,2-tris(3,5-dichloro-4-hydroxyphenyl)ethyl]phenol
DM9QW8N	DE	Discovery agent

DMNXDGQ	ID	DMNXDGQ
DMNXDGQ	DN	NSC-1771
DMNXDGQ	HS	Investigative
DMNXDGQ	SN	Thiram
DMNXDGQ	DT	Small molecular drug
DMNXDGQ	PC	5455
DMNXDGQ	MW	240.4
DMNXDGQ	FM	C6H12N2S4
DMNXDGQ	IC	InChI=1S/C6H12N2S4/c1-7(2)5(9)11-12-6(10)8(3)4/h1-4H3
DMNXDGQ	CS	CN(C)C(=S)SSC(=S)N(C)C
DMNXDGQ	IK	KUAZQDVKQLNFPE-UHFFFAOYSA-N
DMNXDGQ	IU	dimethylcarbamothioylsulfanyl N,N-dimethylcarbamodithioate
DMNXDGQ	CA	CAS 137-26-8
DMNXDGQ	CB	CHEBI:9495
DMNXDGQ	DE	Discovery agent

DMXBRCI	ID	DMXBRCI
DMXBRCI	DN	NSC-180246
DMXBRCI	HS	Investigative
DMXBRCI	SN	Poriol; NSC180246; 14348-16-4; NSC-180246; MLS000876957; SMR000440646; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-6-methyl-2,3-dihydro-4H-chromen-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methyl-chroman-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methyl-2,3-dihydrochromen-4-one; 6-methylnaringenin; NSC 180246; AC1L6Z6F; CHEMBL484640; cid_301798; MEGxp0_000360; ACon1_000765; BDBM50571; MolPort-001-740-534; HMS2269A20; LMPK12140301; 4',5,7-Trihydroxy-6-methylflavanone; NCGC00169381-01; BRD-A47074844-001-01-5
DMXBRCI	DT	Small molecular drug
DMXBRCI	PC	301798
DMXBRCI	MW	286.28
DMXBRCI	FM	C16H14O5
DMXBRCI	IC	InChI=1S/C16H14O5/c1-8-11(18)6-14-15(16(8)20)12(19)7-13(21-14)9-2-4-10(17)5-3-9/h2-6,13,17-18,20H,7H2,1H3
DMXBRCI	CS	CC1=C(C2=C(C=C1O)OC(CC2=O)C3=CC=C(C=C3)O)O
DMXBRCI	IK	SLFZBNOERHGNMI-UHFFFAOYSA-N
DMXBRCI	IU	5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methyl-2,3-dihydrochromen-4-one
DMXBRCI	CA	CAS 14348-16-4
DMXBRCI	DE	Discovery agent

DMZFHL0	ID	DMZFHL0
DMZFHL0	DN	NSC-180969
DMZFHL0	HS	Investigative
DMZFHL0	SN	NSC-180969; CHEMBL1288074; AC1NBZ4W; BDBM50332198; NSC180969; 7,8-dimethoxy-4-(3,4,5-trimethoxyphenyl)-1,2-dihydrobenzo[e]isoindol-3-one
DMZFHL0	DT	Small molecular drug
DMZFHL0	PC	4550667
DMZFHL0	MW	409.4
DMZFHL0	FM	C23H23NO6
DMZFHL0	IC	InChI=1S/C23H23NO6/c1-26-17-7-12-6-15(13-8-19(28-3)22(30-5)20(9-13)29-4)21-16(11-24-23(21)25)14(12)10-18(17)27-2/h6-10H,11H2,1-5H3,(H,24,25)
DMZFHL0	CS	COC1=CC2=CC(=C3C(=C2C=C1OC)CNC3=O)C4=CC(=C(C(=C4)OC)OC)OC
DMZFHL0	IK	LXPGOZAAMPJFEA-UHFFFAOYSA-N
DMZFHL0	IU	7,8-dimethoxy-4-(3,4,5-trimethoxyphenyl)-1,2-dihydrobenzo[e]isoindol-3-one
DMZFHL0	DE	Discovery agent

DMAQGIW	ID	DMAQGIW
DMAQGIW	DN	NSC-204996
DMAQGIW	HS	Investigative
DMAQGIW	SN	CHEMBL1288104; NSC-204996; 7,8-dimethoxy-4-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1H-benzo[e]isoindole; AC1MTWS1; ZINC1740637
DMAQGIW	DT	Small molecular drug
DMAQGIW	PC	3656761
DMAQGIW	MW	395.4
DMAQGIW	FM	C23H25NO5
DMAQGIW	IC	InChI=1S/C23H25NO5/c1-25-19-7-13-6-15(14-8-21(27-3)23(29-5)22(9-14)28-4)17-11-24-12-18(17)16(13)10-20(19)26-2/h6-10,24H,11-12H2,1-5H3
DMAQGIW	CS	COC1=CC2=CC(=C3CNCC3=C2C=C1OC)C4=CC(=C(C(=C4)OC)OC)OC
DMAQGIW	IK	AECCJUJXNOJGBB-UHFFFAOYSA-N
DMAQGIW	IU	7,8-dimethoxy-4-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1H-benzo[e]isoindole
DMAQGIW	DE	Discovery agent

DMOGV9F	ID	DMOGV9F
DMOGV9F	DN	NSC-2113
DMOGV9F	HS	Investigative
DMOGV9F	SN	1,4-Diethoxybenzene; 122-95-2; Benzene, 1,4-diethoxy-; p-Diethoxybenzene; Hydroquinone diethyl ether; Benzene, p-diethoxy-; NSC-2113; 1,4-diethoxy-benzen; UNII-C6Y51501JB; CHEMBL219898; VWGNFIQXBYRDCH-UHFFFAOYSA-N; C6Y51501JB; Benzene,4-diethoxy-; NSC2113; NSC 2113; EINECS 204-585-5; 1,4-diethoxybenzol; hydroquinonedlethylether; ACMC-209ans; AI3-09458; AC1Q37UB; AC1L26YB; KSC174M8J; SCHEMBL124015; Benzene, p-diethoxy- (8CI); Jsp001542; DTXSID9059549; CTK0H4684; KS-00000WIN; MolPort-001-759-994; ZINC394919; NSC68808; SBB060362
DMOGV9F	DT	Small molecular drug
DMOGV9F	PC	67150
DMOGV9F	MW	166.22
DMOGV9F	FM	C10H14O2
DMOGV9F	IC	InChI=1S/C10H14O2/c1-3-11-9-5-7-10(8-6-9)12-4-2/h5-8H,3-4H2,1-2H3
DMOGV9F	CS	CCOC1=CC=C(C=C1)OCC
DMOGV9F	IK	VWGNFIQXBYRDCH-UHFFFAOYSA-N
DMOGV9F	IU	1,4-diethoxybenzene
DMOGV9F	CA	CAS 122-95-2
DMOGV9F	DE	Discovery agent

DMM9PDR	ID	DMM9PDR
DMM9PDR	DN	NSC-224124
DMM9PDR	HS	Investigative
DMM9PDR	SN	NSC224124; NSC-224124; CHEMBL223007; 57999-04-9; NCIMech_000322; AC1L7M0Y; SCHEMBL13856922; DTXSID40310276; ZINC5566508; CCG-35599; BDBM50195851; NCI60_001848; [3-(carbamoyloxymethyl)-1,4-dihydroxy-5,8-dioxonaphthalen-2-yl]methyl carbamate
DMM9PDR	DT	Small molecular drug
DMM9PDR	PC	312765
DMM9PDR	MW	336.25
DMM9PDR	FM	C14H12N2O8
DMM9PDR	IC	InChI=1S/C14H12N2O8/c15-13(21)23-3-5-6(4-24-14(16)22)12(20)10-8(18)2-1-7(17)9(10)11(5)19/h1-2,19-20H,3-4H2,(H2,15,21)(H2,16,22)
DMM9PDR	CS	C1=CC(=O)C2=C(C(=C(C(=C2C1=O)O)COC(=O)N)COC(=O)N)O
DMM9PDR	IK	VCZBTSKVAAVCJJ-UHFFFAOYSA-N
DMM9PDR	IU	[3-(carbamoyloxymethyl)-1,4-dihydroxy-5,8-dioxonaphthalen-2-yl]methyl carbamate
DMM9PDR	CA	CAS 57999-04-9
DMM9PDR	DE	Discovery agent

DMJ91Y7	ID	DMJ91Y7
DMJ91Y7	DN	NSC-23180
DMJ91Y7	HS	Investigative
DMJ91Y7	SN	2-nitrophenanthrene-9,10-dione; 2-Nitro-9,10-phenanthrenedione; 604-95-5; 9,10-Phenanthrenedione, 2-nitro-; NSC-23180; CHEMBL433282; NSC23180; 9, 2-nitro-; 2-nitro-9,10-dihydrophenanthrene-9,10-dione; NSC5425; 2-nitro-9,10-phenanthrenequinone; 2-Nitrophenanthraquinone; AC1Q1ZPU; AC1Q1Y4O; SCHEMBL2599395; AC1L3T23; BDBM22858; CTK8D5611; DTXSID90209161; MolPort-000-824-665; 1,2-Dione-Based Compound, 15; ZINC1686937; NSC-5425; STK246885; AKOS001483088; MCULE-2114795800; BP-22843; SR-01000388930
DMJ91Y7	DT	Small molecular drug
DMJ91Y7	PC	94860
DMJ91Y7	MW	253.21
DMJ91Y7	FM	C14H7NO4
DMJ91Y7	IC	InChI=1S/C14H7NO4/c16-13-11-4-2-1-3-9(11)10-6-5-8(15(18)19)7-12(10)14(13)17/h1-7H
DMJ91Y7	CS	C1=CC=C2C(=C1)C3=C(C=C(C=C3)[N+](=O)[O-])C(=O)C2=O
DMJ91Y7	IK	KNAXWOBOCVVMST-UHFFFAOYSA-N
DMJ91Y7	IU	2-nitrophenanthrene-9,10-dione
DMJ91Y7	CA	CAS 604-95-5
DMJ91Y7	DE	Discovery agent

DMWXNOI	ID	DMWXNOI
DMWXNOI	DN	NSC-238146
DMWXNOI	HS	Investigative
DMWXNOI	SN	NSC-238146; CHEMBL1288105; NSC238146; 4, N4,N4'-1,6-hexanediylbis[2-methyl-, tetraacetate; 4, N(4),N(4)-1,6-hexanediylbis[2-methyl-, tetraacetate
DMWXNOI	DT	Small molecular drug
DMWXNOI	PC	21123062
DMWXNOI	MW	488.6
DMWXNOI	FM	C28H36N6O2
DMWXNOI	IC	InChI=1S/C26H32N6.C2H4O2/c1-17-13-25(21-15-19(27)7-9-23(21)31-17)29-11-5-3-4-6-12-30-26-14-18(2)32-24-10-8-20(28)16-22(24)26;1-2(3)4/h7-10,13-16H,3-6,11-12,27-28H2,1-2H3,(H,29,31)(H,30,32);1H3,(H,3,4)
DMWXNOI	CS	CC1=CC(=C2C=C(C=CC2=N1)N)NCCCCCCNC3=C4C=C(C=CC4=NC(=C3)C)N.CC(=O)O
DMWXNOI	IK	LSRAVPLRIOILDT-UHFFFAOYSA-N
DMWXNOI	IU	acetic acid;4-N-[6-[(6-amino-2-methylquinolin-4-yl)amino]hexyl]-2-methylquinoline-4,6-diamine
DMWXNOI	DE	Discovery agent

DM4RPBJ	ID	DM4RPBJ
DM4RPBJ	DN	NSC-26699
DM4RPBJ	HS	Investigative
DM4RPBJ	SN	NSC26699; NSC-26699; CHEMBL221721; 7147-36-6; benzenesulfonic acid, 2-[(4-aminobenzoyl)amino]-5-(6-methyl-2-benzothiazolyl)-; 2-((4-aminobenzoyl)amino)-5-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonic acid; 2-[(4-aminobenzoyl)amino]-5-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonic acid; AC1Q6X1J; NCIStruc2_000974; NCIStruc1_001055; AC1L5L01; SCHEMBL14286195; CTK5D4244; DTXSID30282594; NCI26699; ZINC1634079; CCG-37345; NCGC00013335; BDBM50158385; AKOS030586545; NCGC00013335-02; NCGC00096452-01; NCI60_002153
DM4RPBJ	DT	Small molecular drug
DM4RPBJ	PC	231116
DM4RPBJ	MW	439.5
DM4RPBJ	FM	C21H17N3O4S2
DM4RPBJ	IC	InChI=1S/C21H17N3O4S2/c1-12-2-8-16-18(10-12)29-21(24-16)14-5-9-17(19(11-14)30(26,27)28)23-20(25)13-3-6-15(22)7-4-13/h2-11H,22H2,1H3,(H,23,25)(H,26,27,28)
DM4RPBJ	CS	CC1=CC2=C(C=C1)N=C(S2)C3=CC(=C(C=C3)NC(=O)C4=CC=C(C=C4)N)S(=O)(=O)O
DM4RPBJ	IK	OINIYAOVPXPWNV-UHFFFAOYSA-N
DM4RPBJ	IU	2-[(4-aminobenzoyl)amino]-5-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonic acid
DM4RPBJ	CA	CAS 7147-36-6
DM4RPBJ	DE	Discovery agent

DMNX245	ID	DMNX245
DMNX245	DN	NSC-26745
DMNX245	HS	Investigative
DMNX245	SN	5-Hydroxyflavone; 491-78-1; Primuletin; 5-hydroxy-2-phenyl-4H-chromen-4-one; 5-hydroxy-2-phenylchromen-4-one; NSC-26745; 5-Hydroxy-2-phenyl-chromen-4-one; NSC 26745; 5-Hydroxy-2-phenylchromone; UNII-378AE9MHL3; CHEMBL16807; MLS002639146; 378AE9MHL3; IYBLVRRCNVHZQJ-UHFFFAOYSA-N; NSC26745; MFCD00016944; 4H-1-Benzopyran-4-one,5-hydroxy-2-phenyl-; Primuliten; 5-hydroxy-flavone; 5-Hydroxy-2-phenyl-4-benzopyrone; EINECS 207-743-1; 5-hydroxy-2-phenyl-4h-chromen-4-on; AC1Q6AKC; ACMC-209kf5; Oprea1_688541; 5-Hydroxyflavone, &gt;=97%
DMNX245	DT	Small molecular drug
DMNX245	PC	68112
DMNX245	MW	238.24
DMNX245	FM	C15H10O3
DMNX245	IC	InChI=1S/C15H10O3/c16-11-7-4-8-13-15(11)12(17)9-14(18-13)10-5-2-1-3-6-10/h1-9,16H
DMNX245	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(C=CC=C3O2)O
DMNX245	IK	IYBLVRRCNVHZQJ-UHFFFAOYSA-N
DMNX245	IU	5-hydroxy-2-phenylchromen-4-one
DMNX245	CA	CAS 491-78-1
DMNX245	DE	Discovery agent

DMUNIWE	ID	DMUNIWE
DMUNIWE	DN	NSC-270718
DMUNIWE	HS	Investigative
DMUNIWE	SN	NSC-270718; NSC270718; CHEMBL401844; 1755-58-4; Probes2_000249; Probes1_000289; Probes1_000079; Probes2_000235; BCC-8; AC1L8P31; BDBM50198305; 1,2,3,4,5,6,7,8,13,13,14,14-dodecachloro-1,4,4a,4b,5,8,8a,12b-octahydro-11-sulfo-1,4:5,8-dimethanotriphenylene-10-carboxylic acid; 1,4,5,6,7,16,17,18,19,19,20,20-dodecachloro-12-sulfohexacyclo[14.2.1.1^{4,7}.0^{2,15}.0^{3,8}.0^{9,14}]icosa-5,9(14),10,12,17-pentaene-11-carboxylic acid
DMUNIWE	DT	Small molecular drug
DMUNIWE	PC	430297
DMUNIWE	MW	797.8
DMUNIWE	FM	C21H8Cl12O5S
DMUNIWE	IC	InChI=1S/C21H8Cl12O5S/c22-11-13(24)18(28)9-7(16(11,26)20(18,30)31)3-1-5(15(34)35)6(39(36,37)38)2-4(3)8-10(9)19(29)14(25)12(23)17(8,27)21(19,32)33/h1-2,7-10H,(H,34,35)(H,36,37,38)
DMUNIWE	CS	C1=C2C3C(C4C(C2=CC(=C1C(=O)O)S(=O)(=O)O)C5(C(=C(C4(C5(Cl)Cl)Cl)Cl)Cl)Cl)C6(C(=C(C3(C6(Cl)Cl)Cl)Cl)Cl)Cl
DMUNIWE	IK	QCIIYEDWVXHYTF-UHFFFAOYSA-N
DMUNIWE	IU	1,4,5,6,7,16,17,18,19,19,20,20-dodecachloro-12-sulfohexacyclo[14.2.1.14,7.02,15.03,8.09,14]icosa-5,9,11,13,17-pentaene-11-carboxylic acid
DMUNIWE	DE	Discovery agent

DMANZIE	ID	DMANZIE
DMANZIE	DN	NSC-27236
DMANZIE	HS	Investigative
DMANZIE	DT	Small molecular drug
DMANZIE	PC	67316
DMANZIE	MW	321.31
DMANZIE	FM	C13H11N3O5S
DMANZIE	IC	InChI=1S/C13H11N3O5S/c14-22(20,21)10-4-1-8(2-5-10)15-16-9-3-6-12(17)11(7-9)13(18)19/h1-7,17H,(H,18,19)(H2,14,20,21)
DMANZIE	CS	C1=CC(=CC=C1N=NC2=CC(=C(C=C2)O)C(=O)O)S(=O)(=O)N
DMANZIE	IK	NBSRUZQXRUNPNY-UHFFFAOYSA-N
DMANZIE	IU	2-hydroxy-5-[(4-sulfamoylphenyl)diazenyl]benzoic acid
DMANZIE	CA	CAS 139-56-0
DMANZIE	DE	Discovery agent

DMV2D8F	ID	DMV2D8F
DMV2D8F	DN	NSC-275420
DMV2D8F	HS	Investigative
DMV2D8F	SN	CHEMBL220048; NSC-275420; AC1L8512; ZINC5579959; NSC275425; BDBM50195857; NSC-275425
DMV2D8F	DT	Small molecular drug
DMV2D8F	PC	321796
DMV2D8F	MW	315.3
DMV2D8F	FM	C19H13N3O2
DMV2D8F	IC	InChI=1S/C19H13N3O2/c1-22-15-8-10(23)6-7-11(15)17-18-14(9-16(24)19(17)22)20-12-4-2-3-5-13(12)21-18/h2-9,20,24H,1H3
DMV2D8F	CS	CN1C2=CC(=O)C=CC2=C3C1=C(C=C4C3=NC5=CC=CC=C5N4)O
DMV2D8F	IK	ZWIWQBZCWUMNMU-UHFFFAOYSA-N
DMV2D8F	IU	7-hydroxy-8-methyl-5H-indolo[3,2-a]phenazin-10-one
DMV2D8F	DE	Discovery agent

DMZU1L0	ID	DMZU1L0
DMZU1L0	DN	NSC-289311
DMZU1L0	HS	Investigative
DMZU1L0	SN	CHEMBL459502; NSC-289311; AC1L8A89; SCHEMBL11697991; BDBM50254015; 1-[2-(3,4-dichlorophenyl)sulfanyl-2-(4-methoxyphenyl)ethyl]imidazole
DMZU1L0	DT	Small molecular drug
DMZU1L0	PC	324288
DMZU1L0	MW	379.3
DMZU1L0	FM	C18H16Cl2N2OS
DMZU1L0	IC	InChI=1S/C18H16Cl2N2OS/c1-23-14-4-2-13(3-5-14)18(11-22-9-8-21-12-22)24-15-6-7-16(19)17(20)10-15/h2-10,12,18H,11H2,1H3
DMZU1L0	CS	COC1=CC=C(C=C1)C(CN2C=CN=C2)SC3=CC(=C(C=C3)Cl)Cl
DMZU1L0	IK	RUUOJGYNYNPAKU-UHFFFAOYSA-N
DMZU1L0	IU	1-[2-(3,4-dichlorophenyl)sulfanyl-2-(4-methoxyphenyl)ethyl]imidazole
DMZU1L0	DE	Discovery agent

DMNUSKT	ID	DMNUSKT
DMNUSKT	DN	NSC-292213
DMNUSKT	HS	Investigative
DMNUSKT	SN	NSC-292213; NSC292213; CHEMBL222808; AC1L8B2I; NCIStruc2_001766; NCIStruc1_001644; ZINC1565922; NCI292213; BDBM50158387; NCGC00014649; CCG-37867; NCGC00014649-02; NCGC00097752-01; NCI60_002407; 4-[(3-carboxy-4-hydroxy-1-naphthyl)(oxo)acetyl]-1-hydroxy-2-naphthoic acid; 4-[2-(3-carboxy-4-hydroxy-naphthalen-1-yl)-2-oxo-acetyl]-1-hydroxy-naphthalene-2-carboxylic acid; 4-[2-(3-carboxy-4-hydroxynaphthalen-1-yl)-2-oxoacetyl]-1-hydroxynaphthalene-2-carboxylic acid
DMNUSKT	DT	Small molecular drug
DMNUSKT	PC	324974
DMNUSKT	MW	430.4
DMNUSKT	FM	C24H14O8
DMNUSKT	IC	InChI=1S/C24H14O8/c25-19-13-7-3-1-5-11(13)15(9-17(19)23(29)30)21(27)22(28)16-10-18(24(31)32)20(26)14-8-4-2-6-12(14)16/h1-10,25-26H,(H,29,30)(H,31,32)
DMNUSKT	CS	C1=CC=C2C(=C1)C(=CC(=C2O)C(=O)O)C(=O)C(=O)C3=CC(=C(C4=CC=CC=C43)O)C(=O)O
DMNUSKT	IK	BRCWHTNRFUVIQT-UHFFFAOYSA-N
DMNUSKT	IU	4-[2-(3-carboxy-4-hydroxynaphthalen-1-yl)-2-oxoacetyl]-1-hydroxynaphthalene-2-carboxylic acid
DMNUSKT	DE	Discovery agent

DM6IF8N	ID	DM6IF8N
DM6IF8N	DN	NSC-300853
DM6IF8N	HS	Investigative
DM6IF8N	SN	NSC-300853; CHEMBL1288134; NSC300853; AC1L6ZUJ; BDBM50332201; ZINC17750338; ZINC104202918; 9-ethyl-2-[(4-nitrophenyl)diazenyl]carbazol-3-amine
DM6IF8N	DT	Small molecular drug
DM6IF8N	PC	327137
DM6IF8N	MW	359.4
DM6IF8N	FM	C20H17N5O2
DM6IF8N	IC	InChI=1S/C20H17N5O2/c1-2-24-19-6-4-3-5-15(19)16-11-17(21)18(12-20(16)24)23-22-13-7-9-14(10-8-13)25(26)27/h3-12H,2,21H2,1H3
DM6IF8N	CS	CCN1C2=CC=CC=C2C3=CC(=C(C=C31)N=NC4=CC=C(C=C4)[N+](=O)[O-])N
DM6IF8N	IK	WTQFEDKUNFYXPZ-UHFFFAOYSA-N
DM6IF8N	IU	9-ethyl-2-[(4-nitrophenyl)diazenyl]carbazol-3-amine
DM6IF8N	DE	Discovery agent

DMFBZEI	ID	DMFBZEI
DMFBZEI	DN	NSC-30171
DMFBZEI	HS	Investigative
DMFBZEI	SN	NSC-30171; CHEMBL375938; NSC30171; AC1L5O56; CTK7F2166; ZINC4748426; BDBM50158378; 5-(5-sulfamoyl-naphthalen-2-ylazo)-naphthalene-1-sulfonic acid; 5-[(5-sulfamoylnaphthalen-2-yl)diazenyl]naphthalene-1-sulfonic acid; 5-[(e)-(5-sulfamoylnaphthalen-2-yl)diazenyl]naphthalene-1-sulfonic acid
DMFBZEI	DT	Small molecular drug
DMFBZEI	PC	232556
DMFBZEI	MW	441.5
DMFBZEI	FM	C20H15N3O5S2
DMFBZEI	IC	InChI=1S/C20H15N3O5S2/c21-29(24,25)19-8-1-4-13-12-14(10-11-15(13)19)22-23-18-7-2-6-17-16(18)5-3-9-20(17)30(26,27)28/h1-12H,(H2,21,24,25)(H,26,27,28)
DMFBZEI	CS	C1=CC2=C(C=CC(=C2)N=NC3=CC=CC4=C3C=CC=C4S(=O)(=O)O)C(=C1)S(=O)(=O)N
DMFBZEI	IK	PJYDTRSKIYLDEE-UHFFFAOYSA-N
DMFBZEI	IU	5-[(5-sulfamoylnaphthalen-2-yl)diazenyl]naphthalene-1-sulfonic acid
DMFBZEI	DE	Discovery agent

DMZYJU0	ID	DMZYJU0
DMZYJU0	DN	NSC-306843
DMZYJU0	HS	Investigative
DMZYJU0	SN	NSC-306843; NSC306843; CHEMBL1288135; BDBM50332202; 1-methyl-N-[(E)-(1-methyl-4-quinolylidene)amino]quinolin-4-imine; 1-Methyl-4(1H)-quinolinone(1-methyl-4(1H)-quinolinylidene)hydrazone; 1-Methyl-4(1H)-quinolinone (1-methyl-4(1H)-quinolinylidene)hydrazone
DMZYJU0	DT	Small molecular drug
DMZYJU0	PC	9569316
DMZYJU0	MW	314.4
DMZYJU0	FM	C20H18N4
DMZYJU0	IC	InChI=1S/C20H18N4/c1-23-13-11-17(15-7-3-5-9-19(15)23)21-22-18-12-14-24(2)20-10-6-4-8-16(18)20/h3-14H,1-2H3/b21-17+,22-18+
DMZYJU0	CS	CN1C2=CC=CC=C2/C(=N/N=C\\3/C4=CC=CC=C4N(C=C3)C)/C=C1
DMZYJU0	IK	NZJOSTCMDPAPOD-KSTNYAOJSA-N
DMZYJU0	IU	(E)-1-methyl-N-[(E)-(1-methylquinolin-4-ylidene)amino]quinolin-4-imine
DMZYJU0	DE	Discovery agent

DMTPRXI	ID	DMTPRXI
DMTPRXI	DN	NSC-316158
DMTPRXI	HS	Investigative
DMTPRXI	SN	NSC316158; NSC-316158; 1,4-dihydroxy-2-[3-(2-hydroxyethylamino)propylamino]anthracene-9,10-dione; AC1L8UB6; CHEMBL1161925; ZINC5390383; NCI60_002718
DMTPRXI	DT	Small molecular drug
DMTPRXI	PC	432861
DMTPRXI	MW	356.4
DMTPRXI	FM	C19H20N2O5
DMTPRXI	IC	InChI=1S/C19H20N2O5/c22-9-8-20-6-3-7-21-13-10-14(23)15-16(19(13)26)18(25)12-5-2-1-4-11(12)17(15)24/h1-2,4-5,10,20-23,26H,3,6-9H2
DMTPRXI	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=C(C(=C3C2=O)O)NCCCNCCO)O
DMTPRXI	IK	VKQCDUDECMFRJO-UHFFFAOYSA-N
DMTPRXI	IU	1,4-dihydroxy-2-[3-(2-hydroxyethylamino)propylamino]anthracene-9,10-dione
DMTPRXI	DE	Discovery agent

DMF3G06	ID	DMF3G06
DMF3G06	DN	NSC-319745
DMF3G06	HS	Investigative
DMF3G06	SN	61629-60-5; HB 093; NSC-319745; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745
DMF3G06	DT	Small molecular drug
DMF3G06	PC	43709
DMF3G06	MW	361.8
DMF3G06	FM	C19H20ClNO4
DMF3G06	IC	InChI=1S/C19H20ClNO4/c1-25-17-8-7-15(20)12-16(17)19(24)21-11-10-14-4-2-13(3-5-14)6-9-18(22)23/h2-5,7-8,12H,6,9-11H2,1H3,(H,21,24)(H,22,23)
DMF3G06	CS	COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)CCC(=O)O
DMF3G06	IK	AIEFQKOARQRACO-UHFFFAOYSA-N
DMF3G06	IU	3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid
DMF3G06	CA	CAS 61629-60-5
DMF3G06	DE	Discovery agent

DMN50OT	ID	DMN50OT
DMN50OT	DN	NSC-324572
DMN50OT	HS	Investigative
DMN50OT	DT	Small molecular drug
DMN50OT	PC	24825536
DMN50OT	MW	527.6
DMN50OT	FM	C23H21N5O6S2
DMN50OT	IC	InChI=1S/C23H21N5O6S2/c1-15-14-18(8-13-21(15)35(30,31)27-17-6-4-3-5-7-17)24-25-22-16(2)26-28(23(22)29)19-9-11-20(12-10-19)36(32,33)34/h3-14,22,27H,1-2H3,(H,32,33,34)
DMN50OT	CS	CC1=C(C=CC(=C1)N=NC2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)O)C)S(=O)(=O)NC4=CC=CC=C4
DMN50OT	IK	SFQBOTBDUOOSJB-UHFFFAOYSA-N
DMN50OT	IU	4-[3-methyl-4-[[3-methyl-4-(phenylsulfamoyl)phenyl]diazenyl]-5-oxo-4H-pyrazol-1-yl]benzenesulfonic acid
DMN50OT	DE	Discovery agent

DMK0H2P	ID	DMK0H2P
DMK0H2P	DN	NSC-339580
DMK0H2P	HS	Investigative
DMK0H2P	SN	NSC-339580; NSC339580; AC1L8WCZ; CHEMBL608554; ZINC5393058
DMK0H2P	DT	Small molecular drug
DMK0H2P	PC	433914
DMK0H2P	MW	400.4
DMK0H2P	FM	C21H24N2O6
DMK0H2P	IC	InChI=1S/C21H24N2O6/c24-10-8-23(9-11-25)7-3-6-22-15-12-16(26)17-18(21(15)29)20(28)14-5-2-1-4-13(14)19(17)27/h1-2,4-5,12,22,24-26,29H,3,6-11H2
DMK0H2P	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=C(C(=C3C2=O)O)NCCCN(CCO)CCO)O
DMK0H2P	IK	PYKCJLACRZVGNR-UHFFFAOYSA-N
DMK0H2P	IU	2-[3-[bis(2-hydroxyethyl)amino]propylamino]-1,4-dihydroxyanthracene-9,10-dione
DMK0H2P	DE	Discovery agent

DMITE1A	ID	DMITE1A
DMITE1A	DN	NSC-339583
DMITE1A	HS	Investigative
DMITE1A	SN	NSC-339583; NSC339583; AC1L8WD5; CHEMBL608553; ZINC31960099
DMITE1A	DT	Small molecular drug
DMITE1A	PC	433916
DMITE1A	MW	382.4
DMITE1A	FM	C21H22N2O5
DMITE1A	IC	InChI=1S/C21H22N2O5/c24-16-12-15(22-6-3-7-23-8-10-28-11-9-23)21(27)18-17(16)19(25)13-4-1-2-5-14(13)20(18)26/h1-2,4-5,12,22,24,27H,3,6-11H2
DMITE1A	CS	C1COCCN1CCCNC2=CC(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O
DMITE1A	IK	RKTZEDQWXDOHSW-UHFFFAOYSA-N
DMITE1A	IU	1,4-dihydroxy-2-(3-morpholin-4-ylpropylamino)anthracene-9,10-dione
DMITE1A	CA	CAS 126869-09-8
DMITE1A	DE	Discovery agent

DMVGLH7	ID	DMVGLH7
DMVGLH7	DN	NSC-341622
DMVGLH7	HS	Investigative
DMVGLH7	SN	66358-49-4; UNII-Q1G3FJ6TLS; NSC314622; Q1G3FJ6TLS; MLS002701805; NSC-314622; 2,3-Dimethoxy-6-methyl-5H-(1,3)dioxolo(4',5':5,6)indeno(1,2-c)isoquinoline-5,12(6H)-dione; NSC 314622; 2,3-Dimethoxy-6-methyl-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; NSC-341622; NCIMech_000446; AC1L75KV; CHEMBL79513; SCHEMBL14147251; CTK5C4398; DTXSID40216582; ZINC1570831; CCG-35623; SMR001565399; NCI60_002710; 5H-[1,6]indeno[1,2-c]isoquinoline-5,12-dione, 2,3-dimethoxy-6-methyl-
DMVGLH7	DT	Small molecular drug
DMVGLH7	PC	329826
DMVGLH7	MW	365.3
DMVGLH7	FM	C20H15NO6
DMVGLH7	IC	InChI=1S/C20H15NO6/c1-21-18-10-5-15-16(27-8-26-15)6-11(10)19(22)17(18)9-4-13(24-2)14(25-3)7-12(9)20(21)23/h4-7H,8H2,1-3H3
DMVGLH7	CS	CN1C2=C(C3=CC(=C(C=C3C1=O)OC)OC)C(=O)C4=CC5=C(C=C42)OCO5
DMVGLH7	IK	LWLNFIXOPOZENE-UHFFFAOYSA-N
DMVGLH7	IU	15,16-dimethoxy-20-methyl-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione
DMVGLH7	CA	CAS 66358-49-4
DMVGLH7	DE	Discovery agent

DM2UPSV	ID	DM2UPSV
DM2UPSV	DN	NSC-345763
DM2UPSV	HS	Investigative
DM2UPSV	SN	NSC-345763; 7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114
DM2UPSV	DT	Small molecular drug
DM2UPSV	PC	335596
DM2UPSV	MW	301.29
DM2UPSV	FM	C16H15NO5
DM2UPSV	IC	InChI=1S/C16H15NO5/c18-10(4-8-15(21)22)3-6-13(19)11-5-7-14(20)16-12(11)2-1-9-17-16/h1-2,5,7,9,20H,3-4,6,8H2,(H,21,22)
DM2UPSV	CS	C1=CC2=C(C=CC(=C2N=C1)O)C(=O)CCC(=O)CCC(=O)O
DM2UPSV	IK	SDIIGLWXEVMFDA-UHFFFAOYSA-N
DM2UPSV	IU	7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid
DM2UPSV	DE	Discovery agent

DM3TDEO	ID	DM3TDEO
DM3TDEO	DN	NSC-348926
DM3TDEO	HS	Investigative
DM3TDEO	SN	NSC-348926; NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid
DM3TDEO	DT	Small molecular drug
DM3TDEO	PC	336008
DM3TDEO	MW	291.26
DM3TDEO	FM	C14H13NO6
DM3TDEO	IC	InChI=1S/C14H13NO6/c16-11(17)7-3-6-10(14(20)21)15-12(18)8-4-1-2-5-9(8)13(15)19/h1-2,4-5,10H,3,6-7H2,(H,16,17)(H,20,21)
DM3TDEO	CS	C1=CC=C2C(=C1)C(=O)N(C2=O)C(CCCC(=O)O)C(=O)O
DM3TDEO	IK	WJNORNDVKYKEGX-UHFFFAOYSA-N
DM3TDEO	IU	2-(1,3-dioxoisoindol-2-yl)hexanedioic acid
DM3TDEO	DE	Discovery agent

DMVL51I	ID	DMVL51I
DMVL51I	DN	NSC-354279
DMVL51I	HS	Investigative
DMVL51I	SN	NSC-354279; CHEMBL221325
DMVL51I	DT	Small molecular drug
DMVL51I	PC	44420298
DMVL51I	MW	328.3
DMVL51I	FM	C20H12N2O3
DMVL51I	IC	InChI=1S/C20H12N2O3/c23-15-9-14-18(22-13-8-4-3-7-12(13)21-14)17-16(15)19(24)10-5-1-2-6-11(10)20(17)25/h1-9,21-23H
DMVL51I	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=C4C(=C3C2=O)NC5=CC=CC=C5N4)O
DMVL51I	IK	LCEVOWBTRGTTAG-UHFFFAOYSA-N
DMVL51I	IU	7-hydroxy-5,14-dihydronaphtho[3,2-a]phenazine-8,13-dione
DMVL51I	DE	Discovery agent

DMEK5B2	ID	DMEK5B2
DMEK5B2	DN	NSC-356483
DMEK5B2	HS	Investigative
DMEK5B2	SN	NSC-356483; CHEMBL495563; NSC356483; AC1L7M6E; ZINC1583041; BDBM50265441; 1-(furan-2-ylmethyl)-5-(4-methoxyphenyl)triazole; 1-(furan-2-ylmethyl)-5-(4-methoxyphenyl)-1H-1,2,3-triazole
DMEK5B2	DT	Small molecular drug
DMEK5B2	PC	337660
DMEK5B2	MW	255.27
DMEK5B2	FM	C14H13N3O2
DMEK5B2	IC	InChI=1S/C14H13N3O2/c1-18-12-6-4-11(5-7-12)14-9-15-16-17(14)10-13-3-2-8-19-13/h2-9H,10H2,1H3
DMEK5B2	CS	COC1=CC=C(C=C1)C2=CN=NN2CC3=CC=CO3
DMEK5B2	IK	LLARZMIDMIEYKJ-UHFFFAOYSA-N
DMEK5B2	IU	1-(furan-2-ylmethyl)-5-(4-methoxyphenyl)triazole
DMEK5B2	DE	Discovery agent

DM9LI7M	ID	DM9LI7M
DM9LI7M	DN	NSC-356781
DM9LI7M	HS	Investigative
DM9LI7M	SN	NSC-356781; CHEMBL523232; 80477-85-6; NSC356781; AC1L7MCE; DTXSID10320246; 5-nitro-2-pyridin-2-yl-1-(2-pyridin-4-ylethyl)benzimidazole; ZINC13211782; BDBM50265463; 5-nitro-2-(pyridin-2-yl)-1-(2-(pyridin-4-yl)ethyl)-1H-benzo[d]imidazole; 5-nitro-2-(pyridin-2-yl)-1-(2-(pyridin-4-yl) ethyl)-1H-benzo[d]imidazole
DM9LI7M	DT	Small molecular drug
DM9LI7M	PC	337743
DM9LI7M	MW	345.4
DM9LI7M	FM	C19H15N5O2
DM9LI7M	IC	InChI=1S/C19H15N5O2/c25-24(26)15-4-5-18-17(13-15)22-19(16-3-1-2-9-21-16)23(18)12-8-14-6-10-20-11-7-14/h1-7,9-11,13H,8,12H2
DM9LI7M	CS	C1=CC=NC(=C1)C2=NC3=C(N2CCC4=CC=NC=C4)C=CC(=C3)[N+](=O)[O-]
DM9LI7M	IK	DPWNICJBRRYQIR-UHFFFAOYSA-N
DM9LI7M	IU	5-nitro-2-pyridin-2-yl-1-(2-pyridin-4-ylethyl)benzimidazole
DM9LI7M	CA	CAS 80477-85-6
DM9LI7M	DE	Discovery agent

DMXT1EK	ID	DMXT1EK
DMXT1EK	DN	NSC-356819
DMXT1EK	HS	Investigative
DMXT1EK	DT	Small molecular drug
DMXT1EK	PC	434764
DMXT1EK	MW	344.4
DMXT1EK	FM	C19H16N6O
DMXT1EK	IC	InChI=1S/C19H16N6O/c20-19(21)13-6-8-15(9-7-13)23-25-17-12-16(10-11-18(17)26)24-22-14-4-2-1-3-5-14/h1-12,26H,(H3,20,21)
DMXT1EK	CS	C1=CC=C(C=C1)N=NC2=CC(=C(C=C2)O)N=NC3=CC=C(C=C3)C(=N)N
DMXT1EK	IK	NKLDVTYKPPGNGG-UHFFFAOYSA-N
DMXT1EK	IU	4-[(2-hydroxy-5-phenyldiazenylphenyl)diazenyl]benzenecarboximidamide
DMXT1EK	DE	Discovery agent

DM9CM5V	ID	DM9CM5V
DM9CM5V	DN	NSC-356820
DM9CM5V	HS	Investigative
DM9CM5V	DT	Small molecular drug
DM9CM5V	PC	135502354
DM9CM5V	MW	342.4
DM9CM5V	FM	C21H18N4O
DM9CM5V	IC	InChI=1S/C21H18N4O/c22-21(23)17-9-11-18(12-10-17)24-25-19-14-16(8-13-20(19)26)7-6-15-4-2-1-3-5-15/h1-14,26H,(H3,22,23)/b7-6+,25-24?
DM9CM5V	CS	C1=CC=C(C=C1)/C=C/C2=CC(=C(C=C2)O)N=NC3=CC=C(C=C3)C(=N)N
DM9CM5V	IK	HKRFQXBNVMEPED-RAKVFIQRSA-N
DM9CM5V	IU	4-[[2-hydroxy-5-[(E)-2-phenylethenyl]phenyl]diazenyl]benzenecarboximidamide
DM9CM5V	DE	Discovery agent

DMHUG1W	ID	DMHUG1W
DMHUG1W	DN	NSC-359466
DMHUG1W	HS	Investigative
DMHUG1W	DT	Small molecular drug
DMHUG1W	PC	434864
DMHUG1W	MW	409.4
DMHUG1W	FM	C24H19N5O2
DMHUG1W	IC	InChI=1S/C24H19N5O2/c25-23(26)15-10-12-18(13-11-15)28-29-21-19-9-5-4-6-16(19)14-20(22(21)30)24(31)27-17-7-2-1-3-8-17/h1-14,30H,(H3,25,26)(H,27,31)
DMHUG1W	CS	C1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3C(=C2O)N=NC4=CC=C(C=C4)C(=N)N
DMHUG1W	IK	XLJUNSXIULBDTE-UHFFFAOYSA-N
DMHUG1W	IU	4-[(4-carbamimidoylphenyl)diazenyl]-3-hydroxy-N-phenylnaphthalene-2-carboxamide
DMHUG1W	DE	Discovery agent

DMR97X3	ID	DMR97X3
DMR97X3	DN	NSC-368272
DMR97X3	HS	Investigative
DMR97X3	SN	NSC-368272; CHEMBL459503; 5242-64-8; NSC368272; AC1L7R16; DTXSID10321036; 6-(benzo[d][1,3]dioxol-5-ol; BDBM50254016; 6-[1,3-benzodioxol-5-yl(imidazol-1-yl)methyl]-1,3-benzodioxol-5-ol
DMR97X3	DT	Small molecular drug
DMR97X3	PC	339906
DMR97X3	MW	338.3
DMR97X3	FM	C18H14N2O5
DMR97X3	IC	InChI=1S/C18H14N2O5/c21-13-7-17-16(24-10-25-17)6-12(13)18(20-4-3-19-8-20)11-1-2-14-15(5-11)23-9-22-14/h1-8,18,21H,9-10H2
DMR97X3	CS	C1OC2=C(O1)C=C(C=C2)C(C3=CC4=C(C=C3O)OCO4)N5C=CN=C5
DMR97X3	IK	SADZUGZPRKRGTC-UHFFFAOYSA-N
DMR97X3	IU	6-[1,3-benzodioxol-5-yl(imidazol-1-yl)methyl]-1,3-benzodioxol-5-ol
DMR97X3	CA	CAS 5242-64-8
DMR97X3	DE	Discovery agent

DMR3IP5	ID	DMR3IP5
DMR3IP5	DN	NSC-368280
DMR3IP5	HS	Investigative
DMR3IP5	SN	NSC-368280; CHEMBL513615; NSC368280; AC1Q4NLW; AC1L7R1U; BDBM50254017; 6-[(4-fluorophenyl)-imidazol-1-ylmethyl]-1,3-benzodioxol-5-ol; 6-((4-fluorophenyl)(1H-imidazol-1-yl)methyl)benzo[d][1,3]dioxol-5-ol; 6-((4-fluorophenyl)(1H-imidazol-1-yl)methyl) benzo[d][1,3]dioxol-5-ol; 1,3-benzodioxol-5-ol, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-
DMR3IP5	DT	Small molecular drug
DMR3IP5	PC	339914
DMR3IP5	MW	312.29
DMR3IP5	FM	C17H13FN2O3
DMR3IP5	IC	InChI=1S/C17H13FN2O3/c18-12-3-1-11(2-4-12)17(20-6-5-19-9-20)13-7-15-16(8-14(13)21)23-10-22-15/h1-9,17,21H,10H2
DMR3IP5	CS	C1OC2=C(O1)C=C(C(=C2)C(C3=CC=C(C=C3)F)N4C=CN=C4)O
DMR3IP5	IK	WOTHQAYNAPHLDM-UHFFFAOYSA-N
DMR3IP5	IU	6-[(4-fluorophenyl)-imidazol-1-ylmethyl]-1,3-benzodioxol-5-ol
DMR3IP5	DE	Discovery agent

DMAQWM8	ID	DMAQWM8
DMAQWM8	DN	NSC-369087
DMAQWM8	HS	Investigative
DMAQWM8	SN	NSC-369087; CHEMBL522733; NSC369087; AC1Q6ZTK; AC1L7R8L; BDBM50265438; 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-1,3-benzodioxol-5-ol; 6-[imidazol-1-yl-(4-methoxyphenyl)methyl]-1,3-benzodioxol-5-ol; 6-((1H-imidazol-1-yl)(4-methoxyphenyl)methyl)benzo[d][1,3]dioxol-5-ol
DMAQWM8	DT	Small molecular drug
DMAQWM8	PC	340000
DMAQWM8	MW	324.3
DMAQWM8	FM	C18H16N2O4
DMAQWM8	IC	InChI=1S/C18H16N2O4/c1-22-13-4-2-12(3-5-13)18(20-7-6-19-10-20)14-8-16-17(9-15(14)21)24-11-23-16/h2-10,18,21H,11H2,1H3
DMAQWM8	CS	COC1=CC=C(C=C1)C(C2=CC3=C(C=C2O)OCO3)N4C=CN=C4
DMAQWM8	IK	SLZWZNUKPMKGCR-UHFFFAOYSA-N
DMAQWM8	IU	6-[imidazol-1-yl-(4-methoxyphenyl)methyl]-1,3-benzodioxol-5-ol
DMAQWM8	DE	Discovery agent

DMLY6WX	ID	DMLY6WX
DMLY6WX	DN	NSC-37031
DMLY6WX	HS	Investigative
DMLY6WX	SN	NSC37031; NSC-37031; CHEMBL222993; 6271-99-4; 1-Naphthalenesulfonic acid, 3-((4-sulfo-2-naphthalenyl)-NNO-azoxy)-; 1-Naphthalenesulfonic acid, 3-[(4-sulfo-2-naphthalenyl)-NNO-azoxy]-; NSC 37031; AC1L5ULW; AC1Q6WZO; NCIStruc2_001212; NCIStruc1_001108; ZINC3953952; NCI37031; BDBM50158381; NCGC00013430; CCG-37290; 1-naphthalenesulfonic acid, 3,3'-[(z)-1-oxido-1,2-diazenediyl]bis-; ZINC100134612; NCGC00096545-01; NCGC00013430-02; NCI60_003411; (Z)-1,2-bis(4-sulfonaphthalen-2-yl)diazene oxide
DMLY6WX	DT	Small molecular drug
DMLY6WX	PC	235538
DMLY6WX	MW	458.5
DMLY6WX	FM	C20H14N2O7S2
DMLY6WX	IC	InChI=1S/C20H14N2O7S2/c23-22(16-10-14-6-2-4-8-18(14)20(12-16)31(27,28)29)21-15-9-13-5-1-3-7-17(13)19(11-15)30(24,25)26/h1-12H,(H,24,25,26)(H,27,28,29)
DMLY6WX	CS	C1=CC=C2C(=C1)C=C(C=C2S(=O)(=O)O)N=[N+](C3=CC4=CC=CC=C4C(=C3)S(=O)(=O)O)[O-]
DMLY6WX	IK	JOYRCGQZVNLGGX-UHFFFAOYSA-N
DMLY6WX	IU	oxido-(4-sulfonaphthalen-2-yl)-(4-sulfonaphthalen-2-yl)iminoazanium
DMLY6WX	CA	CAS 6271-99-4
DMLY6WX	DE	Discovery agent

DMZFULS	ID	DMZFULS
DMZFULS	DN	NSC-37173
DMZFULS	HS	Investigative
DMZFULS	SN	NSC37173; NSC-37173; CHEMBL221733; 6305-91-5; 4-{[(5-aminonaphthalen-2-yl)sulfonyl]amino}benzoic acid; AC1Q6VU5; AC1L5UQ8; NCIStruc2_001521; NCIStruc1_001028; 4-[(5-aminonaphthalen-2-yl)sulfonylamino]benzoic acid; CTK5B7325; DTXSID10284415; ZINC1669798; NCI37173; BDBM50158388; NCGC00013434; CCG-36845; AKOS030548133; NCGC00013434-02; NCGC00096549-01; NCI60_003431; 4-(1-aminonaphthalene-6-sulfonamido)benzoic acid; 4-(5-aminonaphthalene-2-sulfonamido)benzoic acid; 4-(((5-amino-2-naphthyl)sulfonyl)amino)benzoic acid
DMZFULS	DT	Small molecular drug
DMZFULS	PC	235593
DMZFULS	MW	342.4
DMZFULS	FM	C17H14N2O4S
DMZFULS	IC	InChI=1S/C17H14N2O4S/c18-16-3-1-2-12-10-14(8-9-15(12)16)24(22,23)19-13-6-4-11(5-7-13)17(20)21/h1-10,19H,18H2,(H,20,21)
DMZFULS	CS	C1=CC2=C(C=CC(=C2)S(=O)(=O)NC3=CC=C(C=C3)C(=O)O)C(=C1)N
DMZFULS	IK	BAYMNCHSODLCJV-UHFFFAOYSA-N
DMZFULS	IU	4-[(5-aminonaphthalen-2-yl)sulfonylamino]benzoic acid
DMZFULS	CA	CAS 6305-91-5
DMZFULS	DE	Discovery agent

DMHO40Q	ID	DMHO40Q
DMHO40Q	DN	NSC-380292
DMHO40Q	HS	Investigative
DMHO40Q	SN	NSC-380292; CHEMBL206629; 89110-18-9; NSC380292; Benzo(b)cyclobuta(d)thiophene-2,2a(7bH)-dicarboxylic acid, 1-(1-pyrrolidinyl)-, dimethyl ester; NSC 380292; AC1L7WS8; BDBM50184086; Benzo[b]cyclobuta[d]thiophene-2, 2a,7b-dihydro-1-(1-pyrrolyl)-, dimethyl ester; (R,R/S,S)-dimethyl-1-(1-piperidynyl)cyclobuta[b][1]benzothiophene-2,2a(7bH)-dicarboxylate; dimethyl 1-pyrrolidin-1-yl-7bH-cyclobuta[b][1]benzothiole-2,2a-dicarboxylate
DMHO40Q	DT	Small molecular drug
DMHO40Q	PC	342704
DMHO40Q	MW	345.4
DMHO40Q	FM	C18H19NO4S
DMHO40Q	IC	InChI=1S/C18H19NO4S/c1-22-16(20)14-15(19-9-5-6-10-19)13-11-7-3-4-8-12(11)24-18(13,14)17(21)23-2/h3-4,7-8,13H,5-6,9-10H2,1-2H3
DMHO40Q	CS	COC(=O)C1=C(C2C1(SC3=CC=CC=C23)C(=O)OC)N4CCCC4
DMHO40Q	IK	WEPFRJIQIIGTEM-UHFFFAOYSA-N
DMHO40Q	IU	dimethyl 1-pyrrolidin-1-yl-7bH-cyclobuta[b][1]benzothiole-2,2a-dicarboxylate
DMHO40Q	CA	CAS 89110-18-9
DMHO40Q	DE	Discovery agent

DMLGWHM	ID	DMLGWHM
DMLGWHM	DN	NSC-381864
DMLGWHM	HS	Investigative
DMLGWHM	SN	108957-73-9; NSC-381864; (E)-3'-Hydroxy-3,5,4'-trimethoxystilbene; CHEMBL419378; 5-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]-2-methoxyphenol; 5-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]-2-methoxy-phenol; 4,3',5'-Tri-O-methylpiceatannol; NSC381864; AC1NTOCZ; (E) -3'-hydroxy-3,5,4'-Trimethoxystilbene; SCHEMBL1743354; SCHEMBL1743353; (E)-5-(2-(3,5-Dimethoxyphenyl)ethenyl)-2-methoxyphenol; UQIWTPQGJCCTPA-SNAWJCMRSA-N; MolPort-019-990-180; ZINC1591410; BDBM50332182; AKOS015914978; 4,3'',5''-tri-O-methylpiceatannol; AC-24233; AN-33692
DMLGWHM	DT	Small molecular drug
DMLGWHM	PC	5385086
DMLGWHM	MW	286.32
DMLGWHM	FM	C17H18O4
DMLGWHM	IC	InChI=1S/C17H18O4/c1-19-14-8-13(9-15(11-14)20-2)5-4-12-6-7-17(21-3)16(18)10-12/h4-11,18H,1-3H3/b5-4+
DMLGWHM	CS	COC1=C(C=C(C=C1)/C=C/C2=CC(=CC(=C2)OC)OC)O
DMLGWHM	IK	UQIWTPQGJCCTPA-SNAWJCMRSA-N
DMLGWHM	IU	5-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]-2-methoxyphenol
DMLGWHM	CA	CAS 108957-73-9
DMLGWHM	DE	Discovery agent

DMMXZBK	ID	DMMXZBK
DMMXZBK	DN	NSC-39851
DMMXZBK	HS	Investigative
DMMXZBK	SN	Aminomethanesulfonic acid; Aminomethanesulfonic acid, 97%; Aminomethanesulphonic acid; Methanesulfonic acid, 1-amino-; Methanesulfonic acid, amino-; OBESRABRARNZJB-UHFFFAOYSA-N; OLA224Z482; Sodium aminomethanesulphonate; amino-methanesulfonicaci; aminomethanesulfonic; aminomethanesulfonicacid; aminomethanesulfoniccid; aminomethylsulfonic acid; (Aminomethyl)sulfonic acid; 13881-91-9; 6939-85-1; 87993-99-5; EINECS 230-076-2; EINECS 237-649-6; MFCD00008124; NSC 209983; NSC 39851; NSC39851; UNII-OLA224Z482
DMMXZBK	PC	83791
DMMXZBK	MW	111.12
DMMXZBK	FM	CH5NO3S
DMMXZBK	IC	OBESRABRARNZJB-UHFFFAOYSA-N
DMMXZBK	CS	C(N)S(=O)(=O)O
DMMXZBK	IK	1S/CH5NO3S/c2-1-6(3,4)5/h1-2H2,(H,3,4,5)
DMMXZBK	IU	aminomethanesulfonic acid
DMMXZBK	CA	CAS 13881-91-9
DMMXZBK	DE	Discovery agent

DM0214E	ID	DM0214E
DM0214E	DN	NSC-401077
DM0214E	HS	Investigative
DM0214E	SN	NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; NSC-401077; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060
DM0214E	DT	Small molecular drug
DM0214E	PC	344265
DM0214E	MW	334.3
DM0214E	FM	C19H14N2O4
DM0214E	IC	InChI=1S/C19H14N2O4/c22-17-13-6-1-2-7-14(13)18(23)21(17)16(19(24)25)9-11-10-20-15-8-4-3-5-12(11)15/h1-8,10,16,20H,9H2,(H,24,25)
DM0214E	CS	C1=CC=C2C(=C1)C(=O)N(C2=O)C(CC3=CNC4=CC=CC=C43)C(=O)O
DM0214E	IK	HPTXLHAHLXOAKV-UHFFFAOYSA-N
DM0214E	IU	2-(1,3-dioxoisoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid
DM0214E	CA	CAS 32675-71-1
DM0214E	DE	Discovery agent

DMCFNMK	ID	DMCFNMK
DMCFNMK	DN	NSC-40331
DMCFNMK	HS	Investigative
DMCFNMK	SN	NSC-40331; 6312-41-0; CHEMBL1165143; DTXSID30676757; NSC40331; 2-(4-(4-(diethylamino)phenylamino)phenyl)-1-phenylethanone, hydrochloride; 2-{4-[4-(Diethylamino)anilino]phenyl}-1-phenylethan-1-one--hydrogen chloride (1/1)
DMCFNMK	DT	Small molecular drug
DMCFNMK	PC	46848006
DMCFNMK	MW	394.9
DMCFNMK	FM	C24H27ClN2O
DMCFNMK	IC	InChI=1S/C24H26N2O.ClH/c1-3-26(4-2)23-16-14-22(15-17-23)25-21-12-10-19(11-13-21)18-24(27)20-8-6-5-7-9-20;/h5-17,25H,3-4,18H2,1-2H3;1H
DMCFNMK	CS	CCN(CC)C1=CC=C(C=C1)NC2=CC=C(C=C2)CC(=O)C3=CC=CC=C3.Cl
DMCFNMK	IK	ACVBBILJICBIFG-UHFFFAOYSA-N
DMCFNMK	IU	2-[4-[4-(diethylamino)anilino]phenyl]-1-phenylethanone;hydrochloride
DMCFNMK	CA	CAS 6312-41-0
DMCFNMK	DE	Discovery agent

DMKJWGP	ID	DMKJWGP
DMKJWGP	DN	NSC-407228
DMKJWGP	HS	Investigative
DMKJWGP	SN	5-hydroxy-2-(4-hydroxyphenyl)-7-methoxychroman-4-one; 2957-21-3; 520-29-6; CHEMBL74852; NSC407228; 5-Hydroxy-2-(4-hydroxy-phenyl)-7-methoxy-chroman-4-one; 5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-; Sakauranetin; AC1L88VP; MLS000876793; SCHEMBL555541; MEGxp0_000557; ACon1_000001; CTK7A0392; DJOJDHGQRNZXQQ-UHFFFAOYSA-N; MolPort-000-165-376; HMS2271F13; BDBM50049387; ANW-46713
DMKJWGP	DT	Small molecular drug
DMKJWGP	PC	348130
DMKJWGP	MW	286.28
DMKJWGP	FM	C16H14O5
DMKJWGP	IC	InChI=1S/C16H14O5/c1-20-11-6-12(18)16-13(19)8-14(21-15(16)7-11)9-2-4-10(17)5-3-9/h2-7,14,17-18H,8H2,1H3
DMKJWGP	CS	COC1=CC(=C2C(=O)CC(OC2=C1)C3=CC=C(C=C3)O)O
DMKJWGP	IK	DJOJDHGQRNZXQQ-UHFFFAOYSA-N
DMKJWGP	IU	5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMKJWGP	CA	CAS 2957-21-3
DMKJWGP	DE	Discovery agent

DMQ6GBX	ID	DMQ6GBX
DMQ6GBX	DN	NSC-45592
DMQ6GBX	HS	Investigative
DMQ6GBX	DT	Small molecular drug
DMQ6GBX	PC	413225
DMQ6GBX	MW	512.5
DMQ6GBX	FM	C22H16N4O7S2
DMQ6GBX	IC	InChI=1S/C22H16N4O7S2/c27-20-13-12-19(22-18(20)2-1-3-21(22)35(31,32)33)26-25-15-6-4-14(5-7-15)23-24-16-8-10-17(11-9-16)34(28,29)30/h1-13,27H,(H,28,29,30)(H,31,32,33)
DMQ6GBX	CS	C1=CC2=C(C=CC(=C2C(=C1)S(=O)(=O)O)N=NC3=CC=C(C=C3)N=NC4=CC=C(C=C4)S(=O)(=O)O)O
DMQ6GBX	IK	KRSNYIGWUHIMKB-UHFFFAOYSA-N
DMQ6GBX	IU	5-hydroxy-8-[[4-[(4-sulfophenyl)diazenyl]phenyl]diazenyl]naphthalene-1-sulfonic acid
DMQ6GBX	DE	Discovery agent

DMRZJL1	ID	DMRZJL1
DMRZJL1	DN	NSC-47729
DMRZJL1	HS	Investigative
DMRZJL1	DT	Small molecular drug
DMRZJL1	PC	54611658
DMRZJL1	MW	586
DMRZJL1	FM	C23H19ClN4NaO7S2+
DMRZJL1	IC	InChI=1S/C23H19ClN4O7S2.Na/c1-14-3-10-19(11-4-14)37(33,34)35-18-8-6-17(7-9-18)25-26-22-15(2)27-28(23(22)29)20-12-5-16(24)13-21(20)36(30,31)32;/h3-13,22H,1-2H3,(H,30,31,32);/q;+1
DMRZJL1	CS	CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3C(=NN(C3=O)C4=C(C=C(C=C4)Cl)S(=O)(=O)O)C.[Na+]
DMRZJL1	IK	DXKDBQWDRGRKGC-UHFFFAOYSA-N
DMRZJL1	IU	sodium;5-chloro-2-[3-methyl-4-[[4-(4-methylphenyl)sulfonyloxyphenyl]diazenyl]-5-oxo-4H-pyrazol-1-yl]benzenesulfonic acid
DMRZJL1	CA	CAS 6372-96-9
DMRZJL1	DE	Discovery agent

DMTQP3V	ID	DMTQP3V
DMTQP3V	DN	NSC-50187
DMTQP3V	HS	Investigative
DMTQP3V	SN	4'-Methoxyflavanone; Flavanone, 4'-methoxy-; 3034-08-0; 2-(4-methoxyphenyl)chroman-4-one; NSC-50187; NSC50187; 97005-76-0; 2-(4-Methoxy-phenyl)-chroman-4-one; CHEMBL241909; 2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(4-methoxyphenyl)-; ST070122; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(4-methoxyphenyl)-, (S)-; 4''-Methoxyflavanone; AC1Q6KJS; AC1L2TV7; Oprea1_176638; Oprea1_635195; MLS000574900; SCHEMBL127704; MEGxp0_001700; CTK4G4994; CHEBI:63329; ACon1_000211; QIUYUYOXCGBABP-UHFFFAOYSA-N
DMTQP3V	DT	Small molecular drug
DMTQP3V	PC	102928
DMTQP3V	MW	254.28
DMTQP3V	FM	C16H14O3
DMTQP3V	IC	InChI=1S/C16H14O3/c1-18-12-8-6-11(7-9-12)16-10-14(17)13-4-2-3-5-15(13)19-16/h2-9,16H,10H2,1H3
DMTQP3V	CS	COC1=CC=C(C=C1)C2CC(=O)C3=CC=CC=C3O2
DMTQP3V	IK	QIUYUYOXCGBABP-UHFFFAOYSA-N
DMTQP3V	IU	2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMTQP3V	CA	CAS 3034-08-0
DMTQP3V	CB	CHEBI:63329
DMTQP3V	DE	Discovery agent

DMY689Z	ID	DMY689Z
DMY689Z	DN	NSC-527035
DMY689Z	HS	Investigative
DMY689Z	SN	Dicyclopentamethylenethiuram disulfide; 94-37-1; Dipentamethylenethiuram disulfide; 1-Piperidinethiocarbonyl disulfide; Bis(1-piperidylthiocarbonyl) disulfide; Bis(pentamethylene)thiuram disulfide; Bis(piperidinothiocarbonyl) disulfide; Disulfide, bis(1-piperidinylthioxomethyl); NSC-527035; NSC 527035; UNII-CR113982E5; DISULFIDE, BIS(PIPERIDINOTHIOCARBONYL); Bis(piperidinothiocarbonyl)disulfide; EINECS 202-328-1; Bis(1-piperidylthiocarbonyl)disulfide; Bis(piperidinothiocarbonyl) disulphide; BRN 0247608
DMY689Z	DT	Small molecular drug
DMY689Z	PC	7188
DMY689Z	MW	320.6
DMY689Z	FM	C12H20N2S4
DMY689Z	IC	InChI=1S/C12H20N2S4/c15-11(13-7-3-1-4-8-13)17-18-12(16)14-9-5-2-6-10-14/h1-10H2
DMY689Z	CS	C1CCN(CC1)C(=S)SSC(=S)N2CCCCC2
DMY689Z	IK	KNBRWWCHBRQLNY-UHFFFAOYSA-N
DMY689Z	IU	piperidine-1-carbothioylsulfanyl piperidine-1-carbodithioate
DMY689Z	CA	CAS 94-37-1
DMY689Z	DE	Discovery agent

DMW2Q6N	ID	DMW2Q6N
DMW2Q6N	DN	NSC-54162
DMW2Q6N	HS	Investigative
DMW2Q6N	SN	NSC-54162; NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid
DMW2Q6N	DT	Small molecular drug
DMW2Q6N	PC	243918
DMW2Q6N	MW	288.3
DMW2Q6N	FM	C11H12O5S2
DMW2Q6N	IC	InChI=1S/C11H12O5S2/c12-8-4-2-1-3-7(8)11(17-5-9(13)14)18-6-10(15)16/h1-4,11-12H,5-6H2,(H,13,14)(H,15,16)
DMW2Q6N	CS	C1=CC=C(C(=C1)C(SCC(=O)O)SCC(=O)O)O
DMW2Q6N	IK	DNZSITNGPBYEIL-UHFFFAOYSA-N
DMW2Q6N	IU	2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid
DMW2Q6N	CA	CAS 4265-51-4
DMW2Q6N	DE	Discovery agent

DMLEN4X	ID	DMLEN4X
DMLEN4X	DN	NSC-56071
DMLEN4X	HS	Investigative
DMLEN4X	SN	NSC-56071; 32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid
DMLEN4X	DT	Small molecular drug
DMLEN4X	PC	244824
DMLEN4X	MW	354.5
DMLEN4X	FM	C10H14N2O4S4
DMLEN4X	IC	InChI=1S/C10H14N2O4S4/c13-7(14)5-19-9(17)11-1-2-12(4-3-11)10(18)20-6-8(15)16/h1-6H2,(H,13,14)(H,15,16)
DMLEN4X	CS	C1CN(CCN1C(=S)SCC(=O)O)C(=S)SCC(=O)O
DMLEN4X	IK	DWMIVTUQXUDODL-UHFFFAOYSA-N
DMLEN4X	IU	2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid
DMLEN4X	CA	CAS 32230-52-7
DMLEN4X	DE	Discovery agent

DMIRK41	ID	DMIRK41
DMIRK41	DN	NSC-57893
DMIRK41	HS	Investigative
DMIRK41	SN	NSC-57893; MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711
DMIRK41	DT	Small molecular drug
DMIRK41	PC	245689
DMIRK41	MW	295.29
DMIRK41	FM	C16H13N3O3
DMIRK41	IC	InChI=1S/C16H13N3O3/c20-10-19(12-7-5-11(6-8-12)16(21)22)9-15-17-13-3-1-2-4-14(13)18-15/h1-8,10H,9H2,(H,17,18)(H,21,22)
DMIRK41	CS	C1=CC=C2C(=C1)NC(=N2)CN(C=O)C3=CC=C(C=C3)C(=O)O
DMIRK41	IK	FSCLGIGYPFWUHQ-UHFFFAOYSA-N
DMIRK41	IU	4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid
DMIRK41	CA	CAS 7399-94-2
DMIRK41	DE	Discovery agent

DMI6WA7	ID	DMI6WA7
DMI6WA7	DN	NSC-58046
DMI6WA7	HS	Investigative
DMI6WA7	SN	CHEMBL222994; 84-94-6; 1,5-Naphthalenedisulfonic acid, 3-[(4-amino-2-methylphenyl)azo]-; 1,5-Naphthalenedisulfonic acid, 3-((4-amino-2-methylphenyl)azo)-; 1,5-Naphthalenedisulfonic acid, 3-(2-(4-amino-2-methylphenyl)diazenyl)-; NSC-58046; 1,5-Naphthalenedisulfonic acid, 3-[2-(4-amino-2-methylphenyl)diazenyl]-; EINECS 201-575-2; 6629-26-1; SCHEMBL4650840; AC1L25M6; SCHEMBL12559081; DTXSID2058914; CTK2F6804; ZINC4707344; 3-((4-Amino-2-methylphenyl)azo)-1,5-naphthalenedisulfonic acid; ZINC13586631; BDBM50158380; AKOS030539754
DMI6WA7	DT	Small molecular drug
DMI6WA7	PC	54603237
DMI6WA7	MW	444.4
DMI6WA7	FM	C17H15N3NaO6S2+
DMI6WA7	IC	InChI=1S/C17H15N3O6S2.Na/c1-10-7-11(18)5-6-15(10)20-19-12-8-14-13(17(9-12)28(24,25)26)3-2-4-16(14)27(21,22)23;/h2-9H,18H2,1H3,(H,21,22,23)(H,24,25,26);/q;+1
DMI6WA7	CS	CC1=C(C=CC(=C1)N)N=NC2=CC3=C(C=CC=C3S(=O)(=O)O)C(=C2)S(=O)(=O)O.[Na+]
DMI6WA7	IK	ZOQLBEREMFTVSI-UHFFFAOYSA-N
DMI6WA7	IU	sodium;3-[(4-amino-2-methylphenyl)diazenyl]naphthalene-1,5-disulfonic acid
DMI6WA7	CA	CAS 6629-26-1
DMI6WA7	DE	Discovery agent

DMX2YH7	ID	DMX2YH7
DMX2YH7	DN	NSC-6113
DMX2YH7	HS	Investigative
DMX2YH7	SN	Theophylline, 8-chloro-; 1,3-Dimethyl-8-chloroxanthine; 1H-Purine-2,6-dione, 8-chloro-3,7-dihydro-1,3-dimethyl-; 8-Chloro-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione; 8-Chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-Chloro-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 8-Chloro-theophylline; 8-Chlorotheophylline; 8-chloro-1,3-dimethyl-7H-purine-2,6-dione; 85-18-7; C7H7ClN4O2; CHEBI:59771; CHEMBL88611; EINECS 201-590-4; MFCD00005581; GE2UA340FM; RYIGNEOBDRVTHA-UHFFFAOYSA-N; UNII-GE2UA340FM
DMX2YH7	PC	10661
DMX2YH7	MW	214.61
DMX2YH7	FM	C7H7ClN4O2
DMX2YH7	IC	RYIGNEOBDRVTHA-UHFFFAOYSA-N
DMX2YH7	CS	CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl
DMX2YH7	IK	1S/C7H7ClN4O2/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h1-2H3,(H,9,10)
DMX2YH7	IU	8-chloro-1,3-dimethyl-7H-purine-2,6-dione
DMX2YH7	CA	CAS 85-18-7
DMX2YH7	CB	CHEBI:59771
DMX2YH7	DE	Discovery agent

DMD1XM0	ID	DMD1XM0
DMD1XM0	DN	NSC-613604
DMD1XM0	HS	Investigative
DMD1XM0	SN	NSC-613604; CHEMBL572637; 5-(4-chlorophenylamino)-2-methyl-9-nitro-5H-chromeno[4,3-b]pyridine-3-carbonitrile; NSC613604; AC1Q21JI; AC1L78ZM; BDBM50298486; 5-(4-chloroanilino)-2-methyl-9-nitro-5H-chromeno[4,3-b]pyridine-3-carbonitrile
DMD1XM0	DT	Small molecular drug
DMD1XM0	PC	356713
DMD1XM0	MW	392.8
DMD1XM0	FM	C20H13ClN4O3
DMD1XM0	IC	InChI=1S/C20H13ClN4O3/c1-11-12(10-22)8-17-19(23-11)16-9-15(25(26)27)6-7-18(16)28-20(17)24-14-4-2-13(21)3-5-14/h2-9,20,24H,1H3
DMD1XM0	CS	CC1=NC2=C(C=C1C#N)C(OC3=C2C=C(C=C3)[N+](=O)[O-])NC4=CC=C(C=C4)Cl
DMD1XM0	IK	DAHDDFCIAFXETP-UHFFFAOYSA-N
DMD1XM0	IU	5-(4-chloroanilino)-2-methyl-9-nitro-5H-chromeno[4,3-b]pyridine-3-carbonitrile
DMD1XM0	DE	Discovery agent

DMFXEIK	ID	DMFXEIK
DMFXEIK	DN	NSC-621351
DMFXEIK	HS	Investigative
DMFXEIK	SN	NSC-621351; CHEMBL1288223; NSC621351; AC1L7FC6; AC1Q4O4K; BDBM50332183; NCI60_006226; 2-(2-fluorophenyl)-4-naphthalen-2-yl-2,3-dihydro-1,5-benzothiazepine; 2-(2-fluorophenyl)-4-(naphthalen-2-yl)-2,3-dihydro-1,5-benzothiazepine
DMFXEIK	DT	Small molecular drug
DMFXEIK	PC	359787
DMFXEIK	MW	383.5
DMFXEIK	FM	C25H18FNS
DMFXEIK	IC	InChI=1S/C25H18FNS/c26-21-10-4-3-9-20(21)25-16-23(27-22-11-5-6-12-24(22)28-25)19-14-13-17-7-1-2-8-18(17)15-19/h1-15,25H,16H2
DMFXEIK	CS	C1C(SC2=CC=CC=C2N=C1C3=CC4=CC=CC=C4C=C3)C5=CC=CC=C5F
DMFXEIK	IK	WXTPJZLDXSZFPY-UHFFFAOYSA-N
DMFXEIK	IU	2-(2-fluorophenyl)-4-naphthalen-2-yl-2,3-dihydro-1,5-benzothiazepine
DMFXEIK	DE	Discovery agent

DMM5UT9	ID	DMM5UT9
DMM5UT9	DN	NSC-622444
DMM5UT9	HS	Investigative
DMM5UT9	SN	NSC622444; NSC-622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane
DMM5UT9	DT	Small molecular drug
DMM5UT9	PC	360384
DMM5UT9	MW	357.1
DMM5UT9	FM	C15H10Cl2O6
DMM5UT9	IC	InChI=1S/C15H10Cl2O6/c16-10-4-6(2-8(12(10)18)14(20)21)1-7-3-9(15(22)23)13(19)11(17)5-7/h2-5,18-19H,1H2,(H,20,21)(H,22,23)
DMM5UT9	CS	C1=C(C=C(C(=C1C(=O)O)O)Cl)CC2=CC(=C(C(=C2)Cl)O)C(=O)O
DMM5UT9	IK	BFCJNYJGIGUQJA-UHFFFAOYSA-N
DMM5UT9	IU	5-[(3-carboxy-5-chloro-4-hydroxyphenyl)methyl]-3-chloro-2-hydroxybenzoic acid
DMM5UT9	DE	Discovery agent

DME35CB	ID	DME35CB
DME35CB	DN	NSC-622445
DME35CB	HS	Investigative
DME35CB	SN	5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; NSC-622445; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-
DME35CB	DT	Small molecular drug
DME35CB	PC	67145
DME35CB	MW	288.25
DME35CB	FM	C15H12O6
DME35CB	IC	InChI=1S/C15H12O6/c16-12-3-1-8(6-10(12)14(18)19)5-9-2-4-13(17)11(7-9)15(20)21/h1-4,6-7,16-17H,5H2,(H,18,19)(H,20,21)
DME35CB	CS	C1=CC(=C(C=C1CC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
DME35CB	IK	JWQFKVGACKJIAV-UHFFFAOYSA-N
DME35CB	IU	5-[(3-carboxy-4-hydroxyphenyl)methyl]-2-hydroxybenzoic acid
DME35CB	CA	CAS 122-25-8
DME35CB	DE	Discovery agent

DMW437Z	ID	DMW437Z
DMW437Z	DN	NSC-623548
DMW437Z	HS	Investigative
DMW437Z	SN	2581-36-4; NSC-623548; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095
DMW437Z	DT	Small molecular drug
DMW437Z	PC	17413
DMW437Z	MW	316.3
DMW437Z	FM	C17H16O6
DMW437Z	IC	InChI=1S/C17H16O6/c1-8-3-10(6-12(14(8)18)16(20)21)5-11-4-9(2)15(19)13(7-11)17(22)23/h3-4,6-7,18-19H,5H2,1-2H3,(H,20,21)(H,22,23)
DMW437Z	CS	CC1=CC(=CC(=C1O)C(=O)O)CC2=CC(=C(C(=C2)C)O)C(=O)O
DMW437Z	IK	UPLNCYRSCVJILM-UHFFFAOYSA-N
DMW437Z	IU	5-[(3-carboxy-4-hydroxy-5-methylphenyl)methyl]-2-hydroxy-3-methylbenzoic acid
DMW437Z	CA	CAS 2581-36-4
DMW437Z	DE	Discovery agent

DM0GWAC	ID	DM0GWAC
DM0GWAC	DN	NSC-625409
DM0GWAC	HS	Investigative
DM0GWAC	SN	NSC-625409; CHEMBL496777; 1-benzyl-3-(1H-imidazol-1-ylmethyl)-5-nitro-1H-indole-2-carbaldehyde; 3-((1H-imidazol-1-yl)methyl)-1-benzyl-5-nitro-1H-indole-2-carbaldehyde; NSC625409; AC1Q1ZRX; AC1L7JNH; CTK7H8129; ZINC13220122; BDBM50265439; NCI60_007821
DM0GWAC	DT	Small molecular drug
DM0GWAC	PC	361928
DM0GWAC	MW	360.4
DM0GWAC	FM	C20H16N4O3
DM0GWAC	IC	InChI=1S/C20H16N4O3/c25-13-20-18(12-22-9-8-21-14-22)17-10-16(24(26)27)6-7-19(17)23(20)11-15-4-2-1-3-5-15/h1-10,13-14H,11-12H2
DM0GWAC	CS	C1=CC=C(C=C1)CN2C3=C(C=C(C=C3)[N+](=O)[O-])C(=C2C=O)CN4C=CN=C4
DM0GWAC	IK	QEODFJMVDIPNKP-UHFFFAOYSA-N
DM0GWAC	IU	1-benzyl-3-(imidazol-1-ylmethyl)-5-nitroindole-2-carbaldehyde
DM0GWAC	DE	Discovery agent

DM63G4R	ID	DM63G4R
DM63G4R	DN	NSC-625487
DM63G4R	HS	Investigative
DM63G4R	SN	1-(2,6-Difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole
DM63G4R	DT	Small molecular drug
DM63G4R	PC	122665
DM63G4R	MW	288.32
DM63G4R	FM	C15H10F2N2S
DM63G4R	IC	InChI=1S/C15H10F2N2S/c16-9-4-3-5-10(17)14(9)15-19-12-7-2-1-6-11(12)18-13(19)8-20-15/h1-7,15H,8H2
DM63G4R	CS	C1C2=NC3=CC=CC=C3N2C(S1)C4=C(C=CC=C4F)F
DM63G4R	IK	AMLBAOPYPUXEQF-UHFFFAOYSA-N
DM63G4R	IU	1-(2,6-difluorophenyl)-1,3-dihydro-[1,3]thiazolo[3,4-a]benzimidazole
DM63G4R	CA	CAS 138226-12-7
DM63G4R	DE	Human immunodeficiency virus infection

DMLG05U	ID	DMLG05U
DMLG05U	DN	NSC-625987
DMLG05U	HS	Investigative
DMLG05U	SN	NSC 625987
DMLG05U	DT	Small molecular drug
DMLG05U	PC	3004085
DMLG05U	MW	271.3
DMLG05U	FM	C15H13NO2S
DMLG05U	IC	InChI=1S/C15H13NO2S/c1-17-11-7-8-12(18-2)14-13(11)15(19)9-5-3-4-6-10(9)16-14/h3-8H,1-2H3,(H,16,19)
DMLG05U	CS	COC1=C2C(=C(C=C1)OC)NC3=CC=CC=C3C2=S
DMLG05U	IK	KFAKESMKRPNZTM-UHFFFAOYSA-N
DMLG05U	IU	1,4-dimethoxy-10H-acridine-9-thione
DMLG05U	CA	CAS 141992-47-4
DMLG05U	CB	CHEBI:114175
DMLG05U	DE	Discovery agent

DMY7EAF	ID	DMY7EAF
DMY7EAF	DN	NSC-637991
DMY7EAF	HS	Investigative
DMY7EAF	SN	CCRIS 7538; NSC-637991; 5-((2-(Dimethylamino)ethyl)amino)-8-hydroxy-1-methyl-6H-imidazo(4,5,1-de)acridin-6-one; CHEMBL124373; 138154-38-8; AC1L4CDI; DTXSID50160507; ZINC5116458; BDBM50008352; NCI60_012640; LS-189185; 5-(2-(dimethylamino)ethylamino)-8-hydroxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
DMY7EAF	DT	Small molecular drug
DMY7EAF	PC	154479
DMY7EAF	MW	336.4
DMY7EAF	FM	C19H20N4O2
DMY7EAF	IC	InChI=1S/C19H20N4O2/c1-11-21-15-6-5-14(20-8-9-22(2)3)17-18(15)23(11)16-7-4-12(24)10-13(16)19(17)25/h4-7,10,20,24H,8-9H2,1-3H3
DMY7EAF	CS	CC1=NC2=C3N1C4=C(C=C(C=C4)O)C(=O)C3=C(C=C2)NCCN(C)C
DMY7EAF	IK	RWGHRNQPAMSGPF-UHFFFAOYSA-N
DMY7EAF	IU	10-[2-(dimethylamino)ethylamino]-5-hydroxy-15-methyl-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DMY7EAF	CA	CAS 138154-38-8
DMY7EAF	DE	Discovery agent

DM0U7CK	ID	DM0U7CK
DM0U7CK	DN	NSC-637992
DM0U7CK	HS	Investigative
DM0U7CK	SN	CCRIS 7539; UNII-3S0283Z6W9; C 1310; NSC-637992; CHEMBL125082; 3S0283Z6W9; 138154-40-2; 5-((2-(Diethylamino)ethyl)amino)-8-hydroxy-1-methyl-6H-imidazo(4,5,1-de)acidin-6-one; 6H-Imidazo(4,5,1-de)acridin-6-one, 5-((2-(diethylamino)ethyl)amino)-8-hydroxy-1-methyl-; AC1L30G5; SCHEMBL13526631; DTXSID70160509; ZINC3825293; BDBM50008344; NCI60_012641; LS-183332; 5-(2-(diethylamino)ethylamino)-8-hydroxy-1-methyl-6H-imidazo[4,5,1-de]acridin-6-one
DM0U7CK	DT	Small molecular drug
DM0U7CK	PC	132128
DM0U7CK	MW	364.4
DM0U7CK	FM	C21H24N4O2
DM0U7CK	IC	InChI=1S/C21H24N4O2/c1-4-24(5-2)11-10-22-16-7-8-17-20-19(16)21(27)15-12-14(26)6-9-18(15)25(20)13(3)23-17/h6-9,12,22,26H,4-5,10-11H2,1-3H3
DM0U7CK	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=C(N3C4=C(C2=O)C=C(C=C4)O)C
DM0U7CK	IK	CAHBHXJBZIGLGG-UHFFFAOYSA-N
DM0U7CK	IU	10-[2-(diethylamino)ethylamino]-5-hydroxy-15-methyl-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DM0U7CK	CA	CAS 138154-40-2
DM0U7CK	DE	Discovery agent

DM2HC8L	ID	DM2HC8L
DM2HC8L	DN	NSC-637993
DM2HC8L	HS	Investigative
DM2HC8L	SN	NSC637993; AC1L7VTM; AC1Q3ESJ; SCHEMBL20526868; CTK6E8376; CCG-35774; 6H-Imidazo[4,1-de]acridin-6-one, 5-[2-(diethylamino) ethylamino]-8-methoxy-1-methyl-, dihydrochloride; 5-{[2-(diethylamino)ethyl]amino}-8-methoxy-1-methyl-6h-imidazo[4,5,1-de]acridin-6-one hydrochloride(1:1); 6H-Imidazo[4,5,1-de]acridin-6-one, 5-[2-(diethylamino) ethylamino]-8-methoxy-1-methyl-, dihydrochloride
DM2HC8L	DT	Small molecular drug
DM2HC8L	PC	367850
DM2HC8L	MW	378.5
DM2HC8L	FM	C22H26N4O2
DM2HC8L	IC	InChI=1S/C22H26N4O2/c1-5-25(6-2)12-11-23-17-8-9-18-21-20(17)22(27)16-13-15(28-4)7-10-19(16)26(21)14(3)24-18/h7-10,13,23H,5-6,11-12H2,1-4H3
DM2HC8L	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=C(N3C4=C(C2=O)C=C(C=C4)OC)C
DM2HC8L	IK	URGOPTXSJQVCSA-UHFFFAOYSA-N
DM2HC8L	IU	10-[2-(diethylamino)ethylamino]-5-methoxy-15-methyl-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DM2HC8L	DE	Discovery agent

DMKA8YT	ID	DMKA8YT
DMKA8YT	DN	NSC-637994
DMKA8YT	HS	Investigative
DMKA8YT	SN	CCRIS 7540; 138154-43-5; 5-((3-Diethylamino)propyl)amino-8-hydroxy-6H-imidazo(4,5,1-de)acridin-6-one; CHEMBL123853; AC1L4CDL; SCHEMBL13526642; DTXSID80160510; ZINC5114744; NCI60_012643; LS-189188
DMKA8YT	DT	Small molecular drug
DMKA8YT	PC	367851
DMKA8YT	MW	400.9
DMKA8YT	FM	C21H25ClN4O2
DMKA8YT	IC	InChI=1S/C21H24N4O2.ClH/c1-3-24(4-2)11-5-10-22-16-7-8-17-20-19(16)21(27)15-12-14(26)6-9-18(15)25(20)13-23-17;/h6-9,12-13,22,26H,3-5,10-11H2,1-2H3;1H
DMKA8YT	CS	CCN(CC)CCCNC1=C2C3=C(C=C1)N=CN3C4=C(C2=O)C=C(C=C4)O.Cl
DMKA8YT	IK	JOPXSOWZGARKAE-UHFFFAOYSA-N
DMKA8YT	IU	10-[3-(diethylamino)propylamino]-5-hydroxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one;hydrochloride
DMKA8YT	DE	Discovery agent

DMZCYM1	ID	DMZCYM1
DMZCYM1	DN	NSC-640353
DMZCYM1	HS	Investigative
DMZCYM1	SN	NSC-640353; NSC640353; CHEMBL1288253; AC1NV2EC; AC1Q5G5H; ZINC1626277; 1-[2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-4-methyl-5-phenylpenta-2,4-dien-1-one; BDBM50332207; (2E,4E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-4-methyl-5-phenylpenta-2,4-dien-1-one; 1-(2-(3,5-Diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-4-methyl-5-phenyl-2,4-pentadien-1-one; (2E,4E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-thiazol-5-yl]-4-methyl-5-phenyl-penta-2,4-dien-1-one
DMZCYM1	DT	Small molecular drug
DMZCYM1	PC	5466653
DMZCYM1	MW	487.6
DMZCYM1	FM	C31H25N3OS
DMZCYM1	IC	InChI=1S/C31H25N3OS/c1-22(20-24-12-6-3-7-13-24)18-19-29(35)30-23(2)32-31(36-30)34-28(26-16-10-5-11-17-26)21-27(33-34)25-14-8-4-9-15-25/h3-21H,1-2H3/b19-18+,22-20+
DMZCYM1	CS	CC1=C(SC(=N1)N2C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4)C(=O)/C=C/C(=C/C5=CC=CC=C5)/C
DMZCYM1	IK	FGKMUICUBCAKMJ-RFBAJPLNSA-N
DMZCYM1	IU	(2E,4E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-4-methyl-5-phenylpenta-2,4-dien-1-one
DMZCYM1	DE	Discovery agent

DM3DW6A	ID	DM3DW6A
DM3DW6A	DN	NSC-640556
DM3DW6A	HS	Investigative
DM3DW6A	PC	5934332
DM3DW6A	MW	492.5
DM3DW6A	FM	C28H20N4O3S
DM3DW6A	IC	InChI=1S/C28H20N4O3S/c1-19-27(26(33)17-14-20-12-15-23(16-13-20)32(34)35)36-28(29-19)31-25(22-10-6-3-7-11-22)18-24(30-31)21-8-4-2-5-9-21/h2-18H,1H3/b17-14+
DM3DW6A	CS	CC1=C(SC(=N1)N2C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4)C(=O)/C=C/C5=CC=C(C=C5)[N+](=O)[O-]
DM3DW6A	IK	IPRWXFAJXPKDLK-SAPNQHFASA-N
DM3DW6A	IU	(E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-3-(4-nitrophenyl)prop-2-en-1-one
DM3DW6A	DE	Discovery agent

DMPFC5U	ID	DMPFC5U
DMPFC5U	DN	NSC-640558
DMPFC5U	HS	Investigative
DMPFC5U	SN	NSC-640558; NSC640558; CHEMBL1288281; 1-(2-(3,5-Diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-3-phenyl-2-propen-1-one; AC1NYM1Y; AC1Q5G5M; 1-[2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-3-phenylprop-2-en-1-one; ZINC16957596; BDBM50332209; (E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-thiazol-5-yl]-3-phenyl-prop-2-en-1-one
DMPFC5U	DT	Small molecular drug
DMPFC5U	PC	5884626
DMPFC5U	MW	447.6
DMPFC5U	FM	C28H21N3OS
DMPFC5U	IC	InChI=1S/C28H21N3OS/c1-20-27(26(32)18-17-21-11-5-2-6-12-21)33-28(29-20)31-25(23-15-9-4-10-16-23)19-24(30-31)22-13-7-3-8-14-22/h2-19H,1H3/b18-17+
DMPFC5U	CS	CC1=C(SC(=N1)N2C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4)C(=O)/C=C/C5=CC=CC=C5
DMPFC5U	IK	DDJHJUVZEFZWQV-ISLYRVAYSA-N
DMPFC5U	IU	(E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-3-phenylprop-2-en-1-one
DMPFC5U	DE	Discovery agent

DMMT73G	ID	DMMT73G
DMMT73G	DN	NSC-640559
DMMT73G	HS	Investigative
DMMT73G	SN	NSC-640559; NSC640559; CHEMBL1287866; 1-(2-(3,5-Diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-3-(3-(hydroxy(oxido)amino)phenyl)-2-propen-1-one; AC1Q1ZWL; AC1O0C44; 1-[2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-3-(3-nitrophenyl)prop-2-en-1-one; BDBM50332210; ZINC16957598; (E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-3-(3-nitrophenyl)prop-2-en-1-one
DMMT73G	DT	Small molecular drug
DMMT73G	PC	6035704
DMMT73G	MW	492.5
DMMT73G	FM	C28H20N4O3S
DMMT73G	IC	InChI=1S/C28H20N4O3S/c1-19-27(26(33)16-15-20-9-8-14-23(17-20)32(34)35)36-28(29-19)31-25(22-12-6-3-7-13-22)18-24(30-31)21-10-4-2-5-11-21/h2-18H,1H3/b16-15+
DMMT73G	CS	CC1=C(SC(=N1)N2C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4)C(=O)/C=C/C5=CC(=CC=C5)[N+](=O)[O-]
DMMT73G	IK	CJUKTJXWIFOPJJ-FOCLMDBBSA-N
DMMT73G	IU	(E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-3-(3-nitrophenyl)prop-2-en-1-one
DMMT73G	DE	Discovery agent

DMSJ06G	ID	DMSJ06G
DMSJ06G	DN	NSC-640566
DMSJ06G	HS	Investigative
DMSJ06G	SN	NSC-640566; NSC640566; CHEMBL1287867; AC1NZDHI; AC1Q3NJN; 3-(4-chlorophenyl)-1-[2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]prop-2-en-1-one; ZINC16957611; BDBM50332211; (E)-3-(4-chlorophenyl)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-thiazol-5-yl]prop-2-en-1-one; 3-(4-Chlorophenyl)-1-(2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-2-propen-1-one; (E)-3-(4-chlorophenyl)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]prop-2-en-1-one
DMSJ06G	DT	Small molecular drug
DMSJ06G	PC	5905819
DMSJ06G	MW	482
DMSJ06G	FM	C28H20ClN3OS
DMSJ06G	IC	InChI=1S/C28H20ClN3OS/c1-19-27(26(33)17-14-20-12-15-23(29)16-13-20)34-28(30-19)32-25(22-10-6-3-7-11-22)18-24(31-32)21-8-4-2-5-9-21/h2-18H,1H3/b17-14+
DMSJ06G	CS	CC1=C(SC(=N1)N2C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4)C(=O)/C=C/C5=CC=C(C=C5)Cl
DMSJ06G	IK	CDTBUKVBQVDVBD-SAPNQHFASA-N
DMSJ06G	IU	(E)-3-(4-chlorophenyl)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]prop-2-en-1-one
DMSJ06G	DE	Discovery agent

DMC4Y0R	ID	DMC4Y0R
DMC4Y0R	DN	NSC-640583
DMC4Y0R	HS	Investigative
DMC4Y0R	SN	NSC-640583; NSC640583; CHEMBL1287895; 1-(2-(3,5-Diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-3-(4-methylphenyl)-2-propen-1-one; AC1NYRRZ; AC1Q5G5I; 1-[2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-3-(4-methylphenyl)prop-2-en-1-one; BDBM50332212; ZINC16957625; (E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-thiazol-5-yl]-3-(p-tolyl)prop-2-en-1-one
DMC4Y0R	DT	Small molecular drug
DMC4Y0R	PC	5864101
DMC4Y0R	MW	461.6
DMC4Y0R	FM	C29H23N3OS
DMC4Y0R	IC	InChI=1S/C29H23N3OS/c1-20-13-15-22(16-14-20)17-18-27(33)28-21(2)30-29(34-28)32-26(24-11-7-4-8-12-24)19-25(31-32)23-9-5-3-6-10-23/h3-19H,1-2H3/b18-17+
DMC4Y0R	CS	CC1=CC=C(C=C1)/C=C/C(=O)C2=C(N=C(S2)N3C(=CC(=N3)C4=CC=CC=C4)C5=CC=CC=C5)C
DMC4Y0R	IK	HDPZGEIGUACCAU-ISLYRVAYSA-N
DMC4Y0R	IU	(E)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]-3-(4-methylphenyl)prop-2-en-1-one
DMC4Y0R	DE	Discovery agent

DMY2API	ID	DMY2API
DMY2API	DN	NSC-640584
DMY2API	HS	Investigative
DMY2API	SN	NSC640584; NSC-640584; CHEMBL476968; 3-(3,4-Dichlorophenyl)-1-(2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl)-2-propen-1-one; AC1NS0FC; AC1Q3O7L; 3-(3,4-dichlorophenyl)-1-[2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]prop-2-en-1-one; BDBM50332213; CCG-35484; ZINC16957627; (E)-3-(3,4-dichlorophenyl)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-thiazol-5-yl]prop-2-en-1-one; (E)-3-(3,4-dichlorophenyl)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]prop-2-en-1-one
DMY2API	DT	Small molecular drug
DMY2API	PC	5351382
DMY2API	MW	516.4
DMY2API	FM	C28H19Cl2N3OS
DMY2API	IC	InChI=1S/C28H19Cl2N3OS/c1-18-27(26(34)15-13-19-12-14-22(29)23(30)16-19)35-28(31-18)33-25(21-10-6-3-7-11-21)17-24(32-33)20-8-4-2-5-9-20/h2-17H,1H3/b15-13+
DMY2API	CS	CC1=C(SC(=N1)N2C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4)C(=O)/C=C/C5=CC(=C(C=C5)Cl)Cl
DMY2API	IK	GDGXJFJBRMKYDL-FYWRMAATSA-N
DMY2API	IU	(E)-3-(3,4-dichlorophenyl)-1-[2-(3,5-diphenylpyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]prop-2-en-1-one
DMY2API	DE	Discovery agent

DMMBAR3	ID	DMMBAR3
DMMBAR3	DN	NSC-645808
DMMBAR3	HS	Investigative
DMMBAR3	SN	CHEMBL124374; NSC-645808; 5-{[2-(dimethylamino)ethyl]amino}-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one; NCI60_015697; AC1Q6J9E; Neuro_000341; AC1L832L; SCHEMBL13526627; CTK6I0981; ZINC5502555; SR-01000882454
DMMBAR3	DT	Small molecular drug
DMMBAR3	PC	371510
DMMBAR3	MW	322.4
DMMBAR3	FM	C18H18N4O2
DMMBAR3	IC	InChI=1S/C18H18N4O2/c1-21(2)8-7-19-13-4-5-14-17-16(13)18(24)12-9-11(23)3-6-15(12)22(17)10-20-14/h3-6,9-10,19,23H,7-8H2,1-2H3
DMMBAR3	CS	CN(C)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C2=O)C=C(C=C4)O
DMMBAR3	IK	QKYXFJYABODRFA-UHFFFAOYSA-N
DMMBAR3	IU	10-[2-(dimethylamino)ethylamino]-5-hydroxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DMMBAR3	DE	Discovery agent

DMCNIT2	ID	DMCNIT2
DMCNIT2	DN	NSC-645811
DMCNIT2	HS	Investigative
DMCNIT2	DT	Small molecular drug
DMCNIT2	PC	438548
DMCNIT2	MW	350.4
DMCNIT2	FM	C20H22N4O2
DMCNIT2	IC	InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-7-8-16-19-18(15)20(26)14-6-5-13(25)11-17(14)24(19)12-22-16/h5-8,11-12,21,26H,3-4,9-10H2,1-2H3
DMCNIT2	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=CC(=O)C=CC4=C2O
DMCNIT2	IK	VCSROMHSGSVBHE-UHFFFAOYSA-N
DMCNIT2	IU	10-[2-(diethylamino)ethylamino]-8-hydroxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,5,7,9,11,13(16),14-heptaen-4-one
DMCNIT2	DE	Discovery agent

DM1MPJ9	ID	DM1MPJ9
DM1MPJ9	DN	NSC-645812
DM1MPJ9	HS	Investigative
DM1MPJ9	SN	NSC-645812; CHEMBL124629; C-1330; NCI60_015701; AC1L95Q1; SCHEMBL9385904; WEZYUEYLARXRME-UHFFFAOYSA-N; ZINC5723873; BDBM50008351; 5-(2-Diethylamino-ethylamino)-8-methoxy-2,10b-diaza-aceanthrylen-6-one(1.75MHCl)
DM1MPJ9	DT	Small molecular drug
DM1MPJ9	PC	438550
DM1MPJ9	MW	364.4
DM1MPJ9	FM	C21H24N4O2
DM1MPJ9	IC	InChI=1S/C21H24N4O2/c1-4-24(5-2)11-10-22-16-7-8-17-20-19(16)21(26)15-12-14(27-3)6-9-18(15)25(20)13-23-17/h6-9,12-13,22H,4-5,10-11H2,1-3H3
DM1MPJ9	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C2=O)C=C(C=C4)OC
DM1MPJ9	IK	WEZYUEYLARXRME-UHFFFAOYSA-N
DM1MPJ9	IU	10-[2-(diethylamino)ethylamino]-5-methoxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DM1MPJ9	CA	CAS 138154-31-1
DM1MPJ9	DE	Discovery agent

DMNJLW2	ID	DMNJLW2
DMNJLW2	DN	NSC-645827
DMNJLW2	HS	Investigative
DMNJLW2	SN	NSC-645827; MLS002701557; C 1303; 128113-19-9; NSC645827; AC1L3YJ7; CHEMBL95704; DTXSID30155810; ZINC5140451; 5-(2-(Diethylamino)ethylamino)-8-hydroxy-6H-(1,2,3)triazolo(4,5-1-de)acridin-6-one; SMR001565158; NCI60_015716; 5-[2-Dimethylaminoethylamino]-8-hydroxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one; 5-(2-(dimethylamino)ethylamino)-8-hydroxy-6H-[1,3]triazolo[4,5,1-de]acridin-6-one; 6H-(1,2,3)Triazolo(4,5,1-de)acridin-6-one, 5-((2-(dimethylamino)ethyl)amino)-8-hydroxy-
DMNJLW2	DT	Small molecular drug
DMNJLW2	PC	124496
DMNJLW2	MW	323.35
DMNJLW2	FM	C17H17N5O2
DMNJLW2	IC	InChI=1S/C17H17N5O2/c1-21(2)8-7-18-12-4-5-13-16-15(12)17(24)11-9-10(23)3-6-14(11)22(16)20-19-13/h3-6,9,18,23H,7-8H2,1-2H3
DMNJLW2	CS	CN(C)CCNC1=C2C3=C(C=C1)N=NN3C4=C(C2=O)C=C(C=C4)O
DMNJLW2	IK	OMSFZBMJHQNEQZ-UHFFFAOYSA-N
DMNJLW2	IU	10-[2-(dimethylamino)ethylamino]-5-hydroxy-1,14,15-triazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DMNJLW2	CA	CAS 128113-19-9
DMNJLW2	DE	Discovery agent

DMSO215	ID	DMSO215
DMSO215	DN	NSC-645831
DMSO215	HS	Investigative
DMSO215	SN	NSC-645831; CHEMBL1095188; 5-{[2-(diethylamino)ethyl]amino}-6H-imidazo[4,5,1-de]acridin-6-one; NCI60_015720; AC1Q6JEH; AC1L832R; SCHEMBL13526727; CTK6E8378; BDBM50317132
DMSO215	DT	Small molecular drug
DMSO215	PC	371512
DMSO215	MW	334.4
DMSO215	FM	C20H22N4O
DMSO215	IC	InChI=1S/C20H22N4O/c1-3-23(4-2)12-11-21-15-9-10-16-19-18(15)20(25)14-7-5-6-8-17(14)24(19)13-22-16/h5-10,13,21H,3-4,11-12H2,1-2H3
DMSO215	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=CC=CC=C4C2=O
DMSO215	IK	MKCGFGOLLOOXDP-UHFFFAOYSA-N
DMSO215	IU	10-[2-(diethylamino)ethylamino]-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,6,9,11,13(16),14-heptaen-8-one
DMSO215	DE	Discovery agent

DM1AD8T	ID	DM1AD8T
DM1AD8T	DN	NSC-645833
DM1AD8T	HS	Investigative
DM1AD8T	SN	NSC-645833; CHEMBL151840; NSC645833; AC1L95RM; SCHEMBL13526723; BDBM50317133; NCI60_015722
DM1AD8T	DT	Small molecular drug
DM1AD8T	PC	438569
DM1AD8T	MW	306.4
DM1AD8T	FM	C18H18N4O
DM1AD8T	IC	InChI=1S/C18H18N4O/c1-21(2)10-9-19-13-7-8-14-17-16(13)18(23)12-5-3-4-6-15(12)22(17)11-20-14/h3-8,11,19H,9-10H2,1-2H3
DM1AD8T	CS	CN(C)CCNC1=C2C3=C(C=C1)N=CN3C4=CC=CC=C4C2=O
DM1AD8T	IK	ZRCXWSWJMWWTFD-UHFFFAOYSA-N
DM1AD8T	IU	10-[2-(dimethylamino)ethylamino]-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,6,9,11,13(16),14-heptaen-8-one
DM1AD8T	DE	Discovery agent

DMY5JFB	ID	DMY5JFB
DMY5JFB	DN	NSC-645834
DMY5JFB	HS	Investigative
DMY5JFB	SN	NSC-645834; CHEMBL147350; NSC645834; AC1L95RP; ZINC5723877; BDBM50317134; NCI60_015723
DMY5JFB	DT	Small molecular drug
DMY5JFB	PC	438570
DMY5JFB	MW	320.4
DMY5JFB	FM	C19H20N4O
DMY5JFB	IC	InChI=1S/C19H20N4O/c1-12-21-15-9-8-14(20-10-11-22(2)3)17-18(15)23(12)16-7-5-4-6-13(16)19(17)24/h4-9,20H,10-11H2,1-3H3
DMY5JFB	CS	CC1=NC2=C3N1C4=CC=CC=C4C(=O)C3=C(C=C2)NCCN(C)C
DMY5JFB	IK	WTFFYWWTDRXKDI-UHFFFAOYSA-N
DMY5JFB	IU	10-[2-(dimethylamino)ethylamino]-15-methyl-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,6,9,11,13(16),14-heptaen-8-one
DMY5JFB	DE	Discovery agent

DMKDVP7	ID	DMKDVP7
DMKDVP7	DN	NSC-645835
DMKDVP7	HS	Investigative
DMKDVP7	SN	NSC-645835; CHEMBL148712; NSC645835; Neuro_000347; AC1L95RS; ZINC5723878; BDBM50317135; NCI60_015724
DMKDVP7	DT	Small molecular drug
DMKDVP7	PC	438571
DMKDVP7	MW	334.4
DMKDVP7	FM	C20H22N4O
DMKDVP7	IC	InChI=1S/C20H22N4O/c1-4-17-22-15-10-9-14(21-11-12-23(2)3)18-19(15)24(17)16-8-6-5-7-13(16)20(18)25/h5-10,21H,4,11-12H2,1-3H3
DMKDVP7	CS	CCC1=NC2=C3N1C4=CC=CC=C4C(=O)C3=C(C=C2)NCCN(C)C
DMKDVP7	IK	YUTJBINDHFWKND-UHFFFAOYSA-N
DMKDVP7	IU	10-[2-(dimethylamino)ethylamino]-15-ethyl-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,6,9,11,13(16),14-heptaen-8-one
DMKDVP7	DE	Discovery agent

DMQ13SI	ID	DMQ13SI
DMQ13SI	DN	NSC-645836
DMQ13SI	HS	Investigative
DMQ13SI	SN	NSC-645836; CHEMBL146752; NSC645836; AC1L95RV; ZINC5723879; BDBM50317136; NCI60_015725
DMQ13SI	DT	Small molecular drug
DMQ13SI	PC	438572
DMQ13SI	MW	320.4
DMQ13SI	FM	C19H20N4O
DMQ13SI	IC	InChI=1S/C19H20N4O/c1-22(2)11-5-10-20-14-8-9-15-18-17(14)19(24)13-6-3-4-7-16(13)23(18)12-21-15/h3-4,6-9,12,20H,5,10-11H2,1-2H3
DMQ13SI	CS	CN(C)CCCNC1=C2C3=C(C=C1)N=CN3C4=CC=CC=C4C2=O
DMQ13SI	IK	KWLWSGBEPRFXEU-UHFFFAOYSA-N
DMQ13SI	IU	10-[3-(dimethylamino)propylamino]-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,6,9,11,13(16),14-heptaen-8-one
DMQ13SI	DE	Discovery agent

DM6F3HV	ID	DM6F3HV
DM6F3HV	DN	NSC-649091
DM6F3HV	HS	Investigative
DM6F3HV	SN	NSC-649091; CHEMBL1287951; NSC649091; AC1Q3COI; AC1L866K; CTK6E7916; 2-(diethylaminomethyl)-4-[(10-methylindolo[3,2-b]quinolin-11-yl)amino]phenol hydrochloride; 2-[(diethylamino)methyl]-4-[(10-methyl-10h-indolo[3,2-b]quinolin-11-yl)amino]phenol hydrochloride(1:1); 2-[(diethylamino)methyl]-4-[(10-methyl-10H-indolo[3,2-b]quinolin-11-yl)amino]phenol hydrochloride (1:1)
DM6F3HV	DT	Small molecular drug
DM6F3HV	PC	373149
DM6F3HV	MW	461
DM6F3HV	FM	C27H29ClN4O
DM6F3HV	IC	InChI=1S/C27H28N4O.ClH/c1-4-31(5-2)17-18-16-19(14-15-24(18)32)28-25-20-10-6-8-12-22(20)29-26-21-11-7-9-13-23(21)30(3)27(25)26;/h6-16,32H,4-5,17H2,1-3H3,(H,28,29);1H
DM6F3HV	CS	CCN(CC)CC1=C(C=CC(=C1)NC2=C3C(=NC4=CC=CC=C42)C5=CC=CC=C5N3C)O.Cl
DM6F3HV	IK	IAPNUOYAHQHYQR-UHFFFAOYSA-N
DM6F3HV	IU	2-(diethylaminomethyl)-4-[(10-methylindolo[3,2-b]quinolin-11-yl)amino]phenol;hydrochloride
DM6F3HV	DE	Discovery agent

DMFEGYB	ID	DMFEGYB
DMFEGYB	DN	NSC-65069
DMFEGYB	HS	Investigative
DMFEGYB	SN	Phloroglucide; 491-45-2; 2,3',4,5',6-Biphenylpentol; NSC-65069; 2-(3,5-dihydroxyphenyl)benzene-1,3,5-triol; [1,1'-Biphenyl]-2,3',4,5',6-pentaol; NSC65069; UNII-U4GNW4D2BR; U4GNW4D2BR; Phloroglucide hydrate; CHEMBL1288340; [1,1'-Biphenyl]-2,3',4,5',6-pentol; (1,1'-Biphenyl)-2,3',4,5',6-pentol; Biphenyl-2,3',4,5',6-pentaol; 2,3',4,5',6-Pentahydroxybiphenyl; biphenyl-2,3',4,5',6-pentol; phloroglucid; NSC 65069; AC1Q7AZY; AC1L6M6T; Phloroglucide hydrate, 95%; NCIOpen2_003126; 2,4,5',6-Biphenylpentol; SCHEMBL278516
DMFEGYB	DT	Small molecular drug
DMFEGYB	PC	248349
DMFEGYB	MW	234.2
DMFEGYB	FM	C12H10O5
DMFEGYB	IC	InChI=1S/C12H10O5/c13-7-1-6(2-8(14)3-7)12-10(16)4-9(15)5-11(12)17/h1-5,13-17H
DMFEGYB	CS	C1=C(C=C(C=C1O)O)C2=C(C=C(C=C2O)O)O
DMFEGYB	IK	KICYRZIVKKYRFS-UHFFFAOYSA-N
DMFEGYB	IU	2-(3,5-dihydroxyphenyl)benzene-1,3,5-triol
DMFEGYB	CA	CAS 491-45-2
DMFEGYB	DE	Discovery agent

DMWY39L	ID	DMWY39L
DMWY39L	DN	NSC-651016
DMWY39L	HS	Investigative
DMWY39L	SN	CHEMBL262118
DMWY39L	PC	11636697
DMWY39L	MW	1181
DMWY39L	FM	C43H32N10Na4O17S4
DMWY39L	IC	InChI=1S/C43H36N10O17S4.4Na/c1-52-19-23(13-35(52)41(56)50-31-7-9-37(73(65,66)67)29-15-25(71(59,60)61)3-5-27(29)31)46-39(54)33-11-21(17-44-33)48-43(58)49-22-12-34(45-18-22)40(55)47-24-14-36(53(2)20-24)42(57)51-32-8-10-38(74(68,69)70)30-16-26(72(62,63)64)4-6-28(30)32;;;;/h3-20,44-45H,1-2H3,(H,46,54)(H,47,55)(H,50,56)(H,51,57)(H2,48,49,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)(H,68,69,70);;;;/q;4*+1/p-4
DMWY39L	CS	CN1C=C(C=C1C(=O)NC2=C3C=CC(=CC3=C(C=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)C4=CC(=CN4)NC(=O)NC5=CNC(=C5)C(=O)NC6=CN(C(=C6)C(=O)NC7=C8C=CC(=CC8=C(C=C7)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+].[Na+].[Na+]
DMWY39L	IK	QHDNOGPTZQFRDE-UHFFFAOYSA-J
DMWY39L	IU	tetrasodium;4-[[4-[[4-[[5-[[5-[(4,6-disulfonatonaphthalen-1-yl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1H-pyrrol-3-yl]carbamoylamino]-1H-pyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]naphthalene-1,7-disulfonate
DMWY39L	DE	Discovery agent

DMW3QAK	ID	DMW3QAK
DMW3QAK	DN	NSC-654077
DMW3QAK	HS	Investigative
DMW3QAK	SN	DIBA-1; PD 22551; NSC-654077; PD-22551; PD022551; CHEMBL418037; 171744-39-1; 2,2'-Dithiobis-(N-(4-sulfamoylphenyl)-benzamide); NSC654077; DIBA (Antineoplastic); N-(4-sulfamoylphenyl)-2-[[2-[(4-sulfamoylphenyl)carbamoyl]phenyl]disulfanyl]benzamide; 2,2'-Dithiobis-[N-(4-sulfamoylphenyl)-benzamide]; NSC 654077; N-(4-sulfamoylphenyl)-2-({2-[(4-sulfamoylphenyl)carbamoyl]phenyl}disulfanyl)benzamide; AC1L8BKK; AC1Q6VC8; SCHEMBL6223450; BDBM11052; disulfide-containing sulfonamide 5a
DMW3QAK	DT	Small molecular drug
DMW3QAK	PC	375084
DMW3QAK	MW	614.7
DMW3QAK	FM	C26H22N4O6S4
DMW3QAK	IC	InChI=1S/C26H22N4O6S4/c27-39(33,34)19-13-9-17(10-14-19)29-25(31)21-5-1-3-7-23(21)37-38-24-8-4-2-6-22(24)26(32)30-18-11-15-20(16-12-18)40(28,35)36/h1-16H,(H,29,31)(H,30,32)(H2,27,33,34)(H2,28,35,36)
DMW3QAK	CS	C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)N)SSC3=CC=CC=C3C(=O)NC4=CC=C(C=C4)S(=O)(=O)N
DMW3QAK	IK	FVGJPHFQQMQGFQ-UHFFFAOYSA-N
DMW3QAK	IU	N-(4-sulfamoylphenyl)-2-[[2-[(4-sulfamoylphenyl)carbamoyl]phenyl]disulfanyl]benzamide
DMW3QAK	CA	CAS 171744-39-1
DMW3QAK	DE	Discovery agent

DM52NOI	ID	DM52NOI
DM52NOI	DN	NSC-656158
DM52NOI	HS	Investigative
DM52NOI	SN	CHM-1; NSC-656158; 154554-41-3; CHM 1; CHM-1 hydrate; CHEMBL280099; 6-(2-Fluorophenyl)[1,3]dioxolo[4,5-G]quinolin-8(5h)-One; 1,3-Dioxolo[4,5-g]quinolin-8(5H)-one, 6-(2-fluorophenyl)-; NSC656158; AC1Q4OOR; AC1L8C3G; Neuro_000375; SCHEMBL338729; CTK7C2351; AOB2618; DTXSID80327429; MolPort-009-194-114; HMS3262E04; ZINC5581788; KS-00002WS1; Tox21_500741; BDBM50041119; AKOS015994545; LP00741; CE-0108; NCGC00261426-01; NCGC00186026-01; NCI60_019422; J-009113; 1,5-g]quinolin-8(5H)-one, 6-(2-fluorophenyl)-; BRD-K94145482-001-02-8
DM52NOI	DT	Small molecular drug
DM52NOI	PC	375860
DM52NOI	MW	283.25
DM52NOI	FM	C16H10FNO3
DM52NOI	IC	InChI=1S/C16H10FNO3/c17-11-4-2-1-3-9(11)12-6-14(19)10-5-15-16(21-8-20-15)7-13(10)18-12/h1-7H,8H2,(H,18,19)
DM52NOI	CS	C1OC2=C(O1)C=C3C(=C2)C(=O)C=C(N3)C4=CC=CC=C4F
DM52NOI	IK	ZMYDAPJHGNEFGQ-UHFFFAOYSA-N
DM52NOI	IU	6-(2-fluorophenyl)-5H-[1,3]dioxolo[4,5-g]quinolin-8-one
DM52NOI	CA	CAS 154554-41-3
DM52NOI	DE	Discovery agent

DMXDNQ6	ID	DMXDNQ6
DMXDNQ6	DN	NSC-660838
DMXDNQ6	HS	Investigative
DMXDNQ6	SN	NSC-660838; NSC660838; CHEMBL8238; 5-((2-(Diethylamino)ethyl)amino)-10-methoxy-6H-imidazo[4,5,1-de]acridin-6-one; 5-[[2-(Diethylamino)ethyl]amino]-10-methoxy-6H-imidazo[4,5,1-de]acridin-6-one; AC1L8DKD; AC1Q6J73; CTK6E8377; BDBM50317137; NCI60_021218; (2-diethylaminoethylamino)-methoxy-[ ]one; 5-(2-Diethylamino-ethylamino)-10-methoxy-2,10b-diaza-aceanthrylen-6-one
DMXDNQ6	DT	Small molecular drug
DMXDNQ6	PC	378419
DMXDNQ6	MW	364.4
DMXDNQ6	FM	C21H24N4O2
DMXDNQ6	IC	InChI=1S/C21H24N4O2/c1-4-24(5-2)12-11-22-15-9-10-16-20-18(15)21(26)14-7-6-8-17(27-3)19(14)25(20)13-23-16/h6-10,13,22H,4-5,11-12H2,1-3H3
DMXDNQ6	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C2=O)C=CC=C4OC
DMXDNQ6	IK	UOASRCCYMFZXGC-UHFFFAOYSA-N
DMXDNQ6	IU	10-[2-(diethylamino)ethylamino]-3-methoxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DMXDNQ6	DE	Discovery agent

DM8LOCA	ID	DM8LOCA
DM8LOCA	DN	NSC-660839
DM8LOCA	HS	Investigative
DM8LOCA	SN	NSC-660839; NSC660839; CHEMBL8150; 5-((2-(Diethylamino)ethyl)amino)-7,10-dimethoxy-6H-imidazo[4,5,1-de]acridin-6-one; 5-[[2-(Diethylamino)ethyl]amino]-7,10-dimethoxy-6H-imidazo[4,5,1-de]acridin-6-one; AC1Q6JKA; AC1L8DKE; CTK6E8373; ZINC5499387; BDBM50317138; NCI60_021219; (2-diethylaminoethylamino)-dimethoxy-[ ]one; 5-(2-Diethylamino-ethylamino)-7,10-dimethoxy-2,10b-diaza-aceanthrylen-6-one
DM8LOCA	DT	Small molecular drug
DM8LOCA	PC	378420
DM8LOCA	MW	394.5
DM8LOCA	FM	C22H26N4O3
DM8LOCA	IC	InChI=1S/C22H26N4O3/c1-5-25(6-2)12-11-23-14-7-8-15-20-18(14)22(27)19-16(28-3)9-10-17(29-4)21(19)26(20)13-24-15/h7-10,13,23H,5-6,11-12H2,1-4H3
DM8LOCA	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C=CC(=C4C2=O)OC)OC
DM8LOCA	IK	GVUCPNKYHGBWCF-UHFFFAOYSA-N
DM8LOCA	IU	10-[2-(diethylamino)ethylamino]-3,6-dimethoxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,6,9,11,13(16),14-heptaen-8-one
DM8LOCA	DE	Discovery agent

DMB5PLD	ID	DMB5PLD
DMB5PLD	DN	NSC-660840
DMB5PLD	HS	Investigative
DMB5PLD	DT	Small molecular drug
DMB5PLD	PC	378421
DMB5PLD	MW	380.4
DMB5PLD	FM	C21H24N4O3
DMB5PLD	IC	InChI=1S/C21H24N4O3/c1-4-24(5-2)11-10-22-13-6-7-14-19-17(13)21(27)18-15(26)8-9-16(28-3)20(18)25(19)12-23-14/h6-9,12,22,27H,4-5,10-11H2,1-3H3
DMB5PLD	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C=CC(=O)C4=C2O)OC
DMB5PLD	IK	CCUYKRLXKTWTGP-UHFFFAOYSA-N
DMB5PLD	IU	10-[2-(diethylamino)ethylamino]-8-hydroxy-3-methoxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,7,9,11,13(16),14-heptaen-6-one
DMB5PLD	DE	Discovery agent

DMXHPV0	ID	DMXHPV0
DMXHPV0	DN	NSC-660841
DMXHPV0	HS	Investigative
DMXHPV0	DT	Small molecular drug
DMXHPV0	PC	378422
DMXHPV0	MW	410.5
DMXHPV0	FM	C22H26N4O4
DMXHPV0	IC	InChI=1S/C22H26N4O4/c1-5-25(6-2)10-9-23-13-7-8-14-19-17(13)20(27)18-15(26(19)12-24-14)11-16(29-3)22(30-4)21(18)28/h7-8,11-12,23,27H,5-6,9-10H2,1-4H3
DMXHPV0	CS	CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=CC(=C(C(=O)C4=C2O)OC)OC
DMXHPV0	IK	GRQHDQZNSRJNRZ-UHFFFAOYSA-N
DMXHPV0	IU	10-[2-(diethylamino)ethylamino]-8-hydroxy-4,5-dimethoxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,7,9,11,13(16),14-heptaen-6-one
DMXHPV0	DE	Discovery agent

DMQ0S4B	ID	DMQ0S4B
DMQ0S4B	DN	NSC-66209
DMQ0S4B	HS	Investigative
DMQ0S4B	SN	5407-46-5; Methyl fluorone black; 2,6,7-Trihydroxy-9-methylxanthen-3-one; NSC-66209; 2,6,7-Trihydroxy-9-methyl-xanthen-3-one; NSC 5426; UNII-KQC69H1NAG; KQC69H1NAG; 3H-Xanthen-3-one, 2,6,7-trihydroxy-9-methyl-; MLS000736515; MLS000123248; CHEMBL175266; 2,6,7-trihydroxy-9-methyl-3H-xanthen-3-one; NSC5426; NSC66209; 9-Methyl-2,3,7-trihydroxy-6-fluorone Hemisulfate; ST057760; SMR000123893; BAS 00532150; 9-METHYL-2,3,7-TRIHYDROXY-6-FLUORONE; EINECS 226-468-8; NSC 66209; AC1Q69RP; AC1L2IJ2; cid_72721; SCHEMBL2781454; CTK4J9473
DMQ0S4B	DT	Small molecular drug
DMQ0S4B	PC	72721
DMQ0S4B	MW	258.23
DMQ0S4B	FM	C14H10O5
DMQ0S4B	IC	InChI=1S/C14H10O5/c1-6-7-2-9(15)11(17)4-13(7)19-14-5-12(18)10(16)3-8(6)14/h2-5,15-17H,1H3
DMQ0S4B	CS	CC1=C2C=C(C(=O)C=C2OC3=CC(=C(C=C13)O)O)O
DMQ0S4B	IK	TZVNNUHRZXQCHM-UHFFFAOYSA-N
DMQ0S4B	IU	2,6,7-trihydroxy-9-methylxanthen-3-one
DMQ0S4B	CA	CAS 5407-46-5
DMQ0S4B	DE	Discovery agent

DMEXW31	ID	DMEXW31
DMEXW31	DN	NSC-663284
DMEXW31	HS	Investigative
DMEXW31	SN	NSC 663284; 383907-43-5; NSC-663284; NSC663284; CDC25 Phosphatase Inhibitor II, NSC 663284; 6-Chloro-7-(2-morpholin-4-yl-ethylamino)quinoline-5,8-dione; 6-chloro-7-{[2-(morpholin-4-yl)ethyl]amino}quinoline-5,8-dione; DA3003-1; 6-Chloro-7-((2-morpholinoethyl)amino)quinoline-5,8-dione; AC1Q3HBF; AC1Q3HBE; SPS8I1; MLS006010693; SCHEMBL2556224; AC1L8E02; CTK4H9880; CHEBI:92053; DTXSID50327512; MolPort-003-983-788; HMS3268K22; BCP16027; MFCD08276924; BS0130; ZINC100002044; AKOS024456823; CS-7519; NCGC00092289-01; NCGC00092289-02
DMEXW31	DT	Small molecular drug
DMEXW31	PC	379077
DMEXW31	MW	321.76
DMEXW31	FM	C15H16ClN3O3
DMEXW31	IC	InChI=1S/C15H16ClN3O3/c16-11-13(18-4-5-19-6-8-22-9-7-19)15(21)12-10(14(11)20)2-1-3-17-12/h1-3,18H,4-9H2
DMEXW31	CS	C1COCCN1CCNC2=C(C(=O)C3=C(C2=O)N=CC=C3)Cl
DMEXW31	IK	BMKPVDQDJQWBPD-UHFFFAOYSA-N
DMEXW31	IU	6-chloro-7-(2-morpholin-4-ylethylamino)quinoline-5,8-dione
DMEXW31	CA	CAS 383907-43-5
DMEXW31	CB	CHEBI:92053
DMEXW31	DE	Discovery agent

DMEF603	ID	DMEF603
DMEF603	DN	NSC-664171
DMEF603	HS	Investigative
DMEF603	SN	NSC-664171; CHEMBL15778; 4(1H)-Quinolinone, 6-(1-pyrrolidinyl)-2-(3- methoxyphenyl)-; NSC664171; AC1Q6BII; AC1L8EB7; SCHEMBL7615804; ZINC5503291; BDBM50037450; NCI60_022072; 2-(3-methoxyphenyl)-6-pyrrolinylquinolin-4-one; 2-(3-Methoxy-phenyl)-6-pyrrolidin-1-yl-1H-quinolin-4-one; 2-(3-methoxyphenyl)-6-pyrrolidin-1-yl-1H-quinolin-4-one; 2-(3-Methoxy-phenyl)-6-pyrrolidin-1-yl-1H-quinolin-4-one (PQ-7)
DMEF603	DT	Small molecular drug
DMEF603	PC	379514
DMEF603	MW	320.4
DMEF603	FM	C20H20N2O2
DMEF603	IC	InChI=1S/C20H20N2O2/c1-24-16-6-4-5-14(11-16)19-13-20(23)17-12-15(7-8-18(17)21-19)22-9-2-3-10-22/h4-8,11-13H,2-3,9-10H2,1H3,(H,21,23)
DMEF603	CS	COC1=CC=CC(=C1)C2=CC(=O)C3=C(N2)C=CC(=C3)N4CCCC4
DMEF603	IK	GVMDHCGKOFHSHB-UHFFFAOYSA-N
DMEF603	IU	2-(3-methoxyphenyl)-6-pyrrolidin-1-yl-1H-quinolin-4-one
DMEF603	DE	Discovery agent

DMNQXE0	ID	DMNQXE0
DMNQXE0	DN	NSC-665126
DMNQXE0	HS	Investigative
DMNQXE0	SN	NSC-665126; CHEMBL1287952; NSC665126; 1-[2-(4-nitrophenyl)ethenyl]-3-phenylbenzo[f]quinoline; AC1Q1Z7S; AC1O3J57; 1-(2-(4-(Hydroxy(oxido)amino)phenyl)vinyl)-3-phenylbenzo[f]quinoline; ZINC6575869; BDBM50332186
DMNQXE0	DT	Small molecular drug
DMNQXE0	PC	6305573
DMNQXE0	MW	402.4
DMNQXE0	FM	C27H18N2O2
DMNQXE0	IC	InChI=1S/C27H18N2O2/c30-29(31)23-15-11-19(12-16-23)10-13-22-18-26(21-7-2-1-3-8-21)28-25-17-14-20-6-4-5-9-24(20)27(22)25/h1-18H/b13-10+
DMNQXE0	CS	C1=CC=C(C=C1)C2=NC3=C(C4=CC=CC=C4C=C3)C(=C2)/C=C/C5=CC=C(C=C5)[N+](=O)[O-]
DMNQXE0	IK	TXOPJXIIAAMQKX-JLHYYAGUSA-N
DMNQXE0	IU	1-[(E)-2-(4-nitrophenyl)ethenyl]-3-phenylbenzo[f]quinoline
DMNQXE0	DE	Discovery agent

DMNMF0C	ID	DMNMF0C
DMNMF0C	DN	NSC-666292
DMNMF0C	HS	Investigative
DMNMF0C	SN	CHEMBL495565; BDBM50265440
DMNMF0C	DT	Small molecular drug
DMNMF0C	PC	44580826
DMNMF0C	MW	337.8
DMNMF0C	FM	C18H16ClN5
DMNMF0C	IC	InChI=1S/C18H16ClN5/c1-13-14(4-7-23-8-5-20-11-23)10-15-17(22-13)3-2-16(19)18(15)24-9-6-21-12-24/h2-3,5-6,8-12H,4,7H2,1H3
DMNMF0C	CS	CC1=NC2=C(C=C1CCN3C=CN=C3)C(=C(C=C2)Cl)N4C=CN=C4
DMNMF0C	IK	IYLACPJLCQDSFP-UHFFFAOYSA-N
DMNMF0C	IU	6-chloro-5-imidazol-1-yl-3-(2-imidazol-1-ylethyl)-2-methylquinoline
DMNMF0C	DE	Discovery agent

DMRVMA5	ID	DMRVMA5
DMRVMA5	DN	NSC-66811
DMRVMA5	HS	Investigative
DMRVMA5	SN	NSC 66811; 6964-62-1; NSC-66811; 2-METHYL-7-[PHENYL(PHENYLAMINO)METHYL]-8-QUINOLINOL; 7-[anilino(phenyl)methyl]-2-methylquinolin-8-ol; 7-(Anilino(phenyl)-methyl)-2-methyl-8-quinolinol; 2-methyl-7-(phenyl(phenylamino)methyl)quinolin-8-ol; 8-Hydroxy-2-methyl-7-[phenyl(phenylamino)methyl]quinoline; NSC66811; AC1L6NIN; AC1Q79MP; 7-(anilino(phenyl)methyl)-2-methyl-8-quinolinol; SCHEMBL1241576; CHEMBL210778; BDBM31206; CTK5D0724; DTXSID30290119; MolPort-008-431-978; BCP07490; 2152AH; AKOS003020553; AKOS016050521; AK260645; M2390
DMRVMA5	DT	Small molecular drug
DMRVMA5	PC	248986
DMRVMA5	MW	340.4
DMRVMA5	FM	C23H20N2O
DMRVMA5	IC	InChI=1S/C23H20N2O/c1-16-12-13-18-14-15-20(23(26)22(18)24-16)21(17-8-4-2-5-9-17)25-19-10-6-3-7-11-19/h2-15,21,25-26H,1H3
DMRVMA5	CS	CC1=NC2=C(C=C1)C=CC(=C2O)C(C3=CC=CC=C3)NC4=CC=CC=C4
DMRVMA5	IK	WEENRMPCSWFMTE-UHFFFAOYSA-N
DMRVMA5	IU	7-[anilino(phenyl)methyl]-2-methylquinolin-8-ol
DMRVMA5	CA	CAS 6964-62-1
DMRVMA5	DE	Discovery agent

DMVFZKQ	ID	DMVFZKQ
DMVFZKQ	DN	NSC-669977
DMVFZKQ	HS	Investigative
DMVFZKQ	SN	NSC-669977; NSC669977; CHEMBL1288458; 6-Imino-1-methyl-3-phenyl-2,6-dihydro-5(1H)-quinolinone hydrazone; AC1L8JA7; AC1Q1UC1; CTK7D1361; BDBM50332187; NCI60_024491; 5-diazenyl-1-methyl-3-phenyl-2H-quinolin-6-amine; 6-imino-1-methyl-3-phenyl-2H-quinolin-5-one hydrazone
DMVFZKQ	DT	Small molecular drug
DMVFZKQ	PC	382414
DMVFZKQ	MW	264.32
DMVFZKQ	FM	C16H16N4
DMVFZKQ	IC	InChI=1S/C16H16N4/c1-20-10-12(11-5-3-2-4-6-11)9-13-15(20)8-7-14(17)16(13)19-18/h2-9,18H,10,17H2,1H3
DMVFZKQ	CS	CN1CC(=CC2=C1C=CC(=C2N=N)N)C3=CC=CC=C3
DMVFZKQ	IK	VZQKWRKRDCBNCA-UHFFFAOYSA-N
DMVFZKQ	IU	5-diazenyl-1-methyl-3-phenyl-2H-quinolin-6-amine
DMVFZKQ	DE	Discovery agent

DMY4MPG	ID	DMY4MPG
DMY4MPG	DN	NSC-676468
DMY4MPG	HS	Investigative
DMY4MPG	SN	NSC676468; NSC-676468; AC1O3JUQ; ZINC18252301; ZINC104313270; 4-phenyl-N-[(E)-3-(4-phenylphenyl)iminoprop-1-enyl]aniline; 4-phenyl-N-[(E,3E)-3-(4-phenylphenyl)iminoprop-1-enyl]aniline
DMY4MPG	DT	Small molecular drug
DMY4MPG	PC	6282936
DMY4MPG	MW	374.5
DMY4MPG	FM	C27H22N2
DMY4MPG	IC	InChI=1S/C27H22N2/c1-3-8-22(9-4-1)24-12-16-26(17-13-24)28-20-7-21-29-27-18-14-25(15-19-27)23-10-5-2-6-11-23/h1-21,28H/b20-7+,29-21?
DMY4MPG	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)N/C=C/C=NC3=CC=C(C=C3)C4=CC=CC=C4
DMY4MPG	IK	NMTVOLGEUFUEOW-UUBFXEKFSA-N
DMY4MPG	IU	4-phenyl-N-[(E)-3-(4-phenylphenyl)iminoprop-1-enyl]aniline
DMY4MPG	DE	Discovery agent

DM35V46	ID	DM35V46
DM35V46	DN	NSC-677939
DM35V46	HS	Investigative
DM35V46	SN	NSC-677939; NSC677939; CHEMBL1287982; AC1L8RA1; Diindolo[2,2-h]quinolizine; CTK8D1116; ZINC1647054; BDBM50332189; {Diindolo[2,3-a:3,2-h]quinolizine}; NCI60_027847; 14H-Diindolo[2,3-a:3,2-h]quinolizine; 14h-diindolo[2,3-a:3',2'-h]quinolizine
DM35V46	DT	Small molecular drug
DM35V46	PC	386223
DM35V46	MW	307.3
DM35V46	FM	C21H13N3
DM35V46	IC	InChI=1S/C21H13N3/c1-3-7-17-13(5-1)15-9-11-24-12-10-16-14-6-2-4-8-18(14)23-20(16)21(24)19(15)22-17/h1-12,22H
DM35V46	CS	C1=CC=C2C(=C1)C3=C(N2)C4=C5C(=C6C=CC=CC6=N5)C=CN4C=C3
DM35V46	IK	MNJDUMFRXPRNJB-UHFFFAOYSA-N
DM35V46	IU	3,13,23-triazahexacyclo[11.11.0.02,10.04,9.016,24.017,22]tetracosa-1,3,5,7,9,11,14,16(24),17,19,21-undecaene
DM35V46	DE	Discovery agent

DMPO2RU	ID	DMPO2RU
DMPO2RU	DN	NSC-679036
DMPO2RU	HS	Investigative
DMPO2RU	SN	NSC-679036; CHEMBL49827; 2-(3-chlorophenyl)-6-methyl-1,8-naphthyridin-4(1H)-one; NSC679036; AC1L8S0Y; SCHEMBL7925200; CTK8C9852; ZINC5503957; 1, 2-(3-chlorophenyl)-6-methyl-; BDBM50059961; NCI60_028235; 2-(3-chlorophenyl)-6-methyl-1H-1,8-naphthyridin-4-one; 2-(3-Chloro-phenyl)-6-methyl-1H-[1,8]naphthyridin-4-one; 1,8-Naphthyridin-4(1H)-one, 2-(3-chlorophenyl)-6-methyl-
DMPO2RU	DT	Small molecular drug
DMPO2RU	PC	386588
DMPO2RU	MW	270.71
DMPO2RU	FM	C15H11ClN2O
DMPO2RU	IC	InChI=1S/C15H11ClN2O/c1-9-5-12-14(19)7-13(18-15(12)17-8-9)10-3-2-4-11(16)6-10/h2-8H,1H3,(H,17,18,19)
DMPO2RU	CS	CC1=CC2=C(NC(=CC2=O)C3=CC(=CC=C3)Cl)N=C1
DMPO2RU	IK	FSWIIQLXZOJBSF-UHFFFAOYSA-N
DMPO2RU	IU	2-(3-chlorophenyl)-6-methyl-1H-1,8-naphthyridin-4-one
DMPO2RU	DE	Discovery agent

DMZ2KUB	ID	DMZ2KUB
DMZ2KUB	DN	NSC-683634
DMZ2KUB	HS	Investigative
DMZ2KUB	DT	Small molecular drug
DMZ2KUB	PC	388623
DMZ2KUB	MW	347.8
DMZ2KUB	FM	C20H14ClN3O
DMZ2KUB	IC	InChI=1S/C20H14ClN3O/c21-16-7-3-13(4-8-16)18-19(15-2-1-11-22-12-15)24-20(23-18)14-5-9-17(25)10-6-14/h1-12,25H,(H,23,24)
DMZ2KUB	CS	C1=CC(=CN=C1)C2=C(NC(=N2)C3=CC=C(C=C3)O)C4=CC=C(C=C4)Cl
DMZ2KUB	IK	GOSRVAHFGDUDAX-UHFFFAOYSA-N
DMZ2KUB	IU	4-[5-(4-chlorophenyl)-4-pyridin-3-yl-1H-imidazol-2-yl]phenol
DMZ2KUB	DE	Discovery agent

DM0164B	ID	DM0164B
DM0164B	DN	NSC-686549
DM0164B	HS	Investigative
DM0164B	SN	NSC686549
DM0164B	DT	Small molecular drug
DM0164B	PC	389898
DM0164B	MW	289.67
DM0164B	FM	C14H8ClNO4
DM0164B	IC	InChI=1S/C14H8ClNO4/c15-11-12(16-9(17)5-6-10(16)18)14(20)8-4-2-1-3-7(8)13(11)19/h1-4H,5-6H2
DM0164B	CS	C1CC(=O)N(C1=O)C2=C(C(=O)C3=CC=CC=C3C2=O)Cl
DM0164B	IK	GYQSWJNGTWVFOL-UHFFFAOYSA-N
DM0164B	IU	1-(3-chloro-1,4-dioxonaphthalen-2-yl)pyrrolidine-2,5-dione
DM0164B	CA	CAS 623163-52-0
DM0164B	DE	Discovery agent

DMKMTJ9	ID	DMKMTJ9
DMKMTJ9	DN	NSC-693571
DMKMTJ9	HS	Investigative
DMKMTJ9	SN	NSC-693571
DMKMTJ9	DT	Small molecular drug
DMKMTJ9	PC	15282960
DMKMTJ9	MW	527.6
DMKMTJ9	FM	C27H24F3N3O3S
DMKMTJ9	IC	InChI=1S/C26H24N3.CHF3O3S/c1-27(2)21-15-13-19(14-16-21)17-23-22-11-7-8-12-24(22)29-26(23)18-25(28(29)3)20-9-5-4-6-10-20;2-1(3,4)8(5,6)7/h4-18H,1-3H3;(H,5,6,7)/q+1;/p-1
DMKMTJ9	CS	C[N+]1=C(C=C\\2N1C3=CC=CC=C3/C2=C\\C4=CC=C(C=C4)N(C)C)C5=CC=CC=C5.C(F)(F)(F)S(=O)(=O)[O-]
DMKMTJ9	IK	GWIVOWYTVDQWOM-UHFFFAOYSA-M
DMKMTJ9	IU	N,N-dimethyl-4-[(E)-(1-methyl-2-phenylpyrazolo[1,5-a]indol-1-ium-4-ylidene)methyl]aniline;trifluoromethanesulfonate
DMKMTJ9	DE	Discovery agent

DMCP1I6	ID	DMCP1I6
DMCP1I6	DN	NSC-720622
DMCP1I6	HS	Investigative
DMCP1I6	SN	NSC-720622
DMCP1I6	DT	Small molecular drug
DMCP1I6	PC	52942470
DMCP1I6	MW	572.6
DMCP1I6	FM	C27H23F3N4O5S
DMCP1I6	IC	InChI=1S/C26H23N4O2.CHF3O3S/c1-27(2)20-11-9-18(10-12-20)15-22-23-16-21(30(31)32)13-14-24(23)29-26(22)17-25(28(29)3)19-7-5-4-6-8-19;2-1(3,4)8(5,6)7/h4-17H,1-3H3;(H,5,6,7)/q+1;/p-1
DMCP1I6	CS	C[N+]1=C(C=C\\2N1C3=C(/C2=C\\C4=CC=C(C=C4)N(C)C)C=C(C=C3)[N+](=O)[O-])C5=CC=CC=C5.C(F)(F)(F)S(=O)(=O)[O-]
DMCP1I6	IK	CKJNKVUCIFATCQ-UHFFFAOYSA-M
DMCP1I6	IU	N,N-dimethyl-4-[(E)-(1-methyl-6-nitro-2-phenylpyrazolo[1,5-a]indol-1-ium-4-ylidene)methyl]aniline;trifluoromethanesulfonate
DMCP1I6	DE	Discovery agent

DMX0VQN	ID	DMX0VQN
DMX0VQN	DN	NSC-73410
DMX0VQN	HS	Investigative
DMX0VQN	SN	NSC-73410; CHEMBL435920; 5138-23-8; NSC73410; Alizarine Saphirol SE; NCIOpen2_008926; SCHEMBL10706301; DTXSID50274577; ZINC3846907; 4,8-diamino-1,5-dihydroxy-9,10-dioxoanthracene-2-sulfonic acid; AC1L2850; BDBM50195862; 2-Anthracenesulfonic acid,8-diamino-9,10-dihydro-1,5-dihydroxy-9,10-dioxo-
DMX0VQN	DT	Small molecular drug
DMX0VQN	PC	16528
DMX0VQN	MW	350.31
DMX0VQN	FM	C14H10N2O7S
DMX0VQN	IC	InChI=1S/C14H10N2O7S/c15-4-1-2-6(17)10-8(4)14(20)11-9(13(10)19)5(16)3-7(12(11)18)24(21,22)23/h1-3,17-18H,15-16H2,(H,21,22,23)
DMX0VQN	CS	C1=CC(=C2C(=C1N)C(=O)C3=C(C2=O)C(=CC(=C3O)S(=O)(=O)O)N)O
DMX0VQN	IK	SPHQXPPVJCWUGX-UHFFFAOYSA-N
DMX0VQN	IU	4,8-diamino-1,5-dihydroxy-9,10-dioxoanthracene-2-sulfonic acid
DMX0VQN	CA	CAS 5138-23-8
DMX0VQN	DE	Discovery agent

DMT6CV5	ID	DMT6CV5
DMT6CV5	DN	NSC-73613
DMT6CV5	HS	Investigative
DMT6CV5	SN	NSC-73613; 2-(3-nitrophenyl)-4h-chromen-4-one; CHEMBL291876; 70460-19-4; 3'-nitroflavone; 2-(3-nitrophenyl)chromen-4-one; NSC73613; AC1Q21JU; AC1L5LK2; NCIOpen2_003891; SCHEMBL5064064; CTK5D2423; DTXSID80291176; ZINC1699259; AKOS002389054
DMT6CV5	DT	Small molecular drug
DMT6CV5	PC	252248
DMT6CV5	MW	267.24
DMT6CV5	FM	C15H9NO4
DMT6CV5	IC	InChI=1S/C15H9NO4/c17-13-9-15(20-14-7-2-1-6-12(13)14)10-4-3-5-11(8-10)16(18)19/h1-9H
DMT6CV5	CS	C1=CC=C2C(=C1)C(=O)C=C(O2)C3=CC(=CC=C3)[N+](=O)[O-]
DMT6CV5	IK	NFMFVPFUTZLMGI-UHFFFAOYSA-N
DMT6CV5	IU	2-(3-nitrophenyl)chromen-4-one
DMT6CV5	CA	CAS 70460-19-4
DMT6CV5	DE	Discovery agent

DM1ETX5	ID	DM1ETX5
DM1ETX5	DN	NSC-745794
DM1ETX5	HS	Investigative
DM1ETX5	SN	NSC-745794; CHEMBL604073
DM1ETX5	DT	Small molecular drug
DM1ETX5	PC	44251214
DM1ETX5	MW	367.4
DM1ETX5	FM	C23H17N3O2
DM1ETX5	IC	InChI=1S/C23H17N3O2/c1-26(2)14-9-7-13(8-10-14)23-24-18-12-11-17-19(20(18)25-23)22(28)16-6-4-3-5-15(16)21(17)27/h3-12H,1-2H3,(H,24,25)
DM1ETX5	CS	CN(C)C1=CC=C(C=C1)C2=NC3=C(N2)C=CC4=C3C(=O)C5=CC=CC=C5C4=O
DM1ETX5	IK	ILPRDEDKIAQCMC-UHFFFAOYSA-N
DM1ETX5	IU	2-[4-(dimethylamino)phenyl]-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DM1ETX5	DE	Discovery agent

DMI2GFM	ID	DMI2GFM
DMI2GFM	DN	NSC-745795
DMI2GFM	HS	Investigative
DMI2GFM	SN	NSC-745795; CHEMBL595834
DMI2GFM	DT	Small molecular drug
DMI2GFM	PC	44603286
DMI2GFM	MW	276.29
DMI2GFM	FM	C17H12N2O2
DMI2GFM	IC	InChI=1S/C17H12N2O2/c1-2-13-18-12-8-7-11-14(15(12)19-13)17(21)10-6-4-3-5-9(10)16(11)20/h3-8H,2H2,1H3,(H,18,19)
DMI2GFM	CS	CCC1=NC2=C(N1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O
DMI2GFM	IK	ADOUNJBEKVZHQH-UHFFFAOYSA-N
DMI2GFM	IU	2-ethyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMI2GFM	DE	Discovery agent

DM8JMBI	ID	DM8JMBI
DM8JMBI	DN	NSC-745796
DM8JMBI	HS	Investigative
DM8JMBI	SN	NSC-745796; CHEMBL603842; SCHEMBL12261364; 2-phenyl-anthra[1,2-d]imidazole-6,11-dione
DM8JMBI	DT	Small molecular drug
DM8JMBI	PC	11674223
DM8JMBI	MW	324.3
DM8JMBI	FM	C21H12N2O2
DM8JMBI	IC	InChI=1S/C21H12N2O2/c24-19-13-8-4-5-9-14(13)20(25)17-15(19)10-11-16-18(17)23-21(22-16)12-6-2-1-3-7-12/h1-11H,(H,22,23)
DM8JMBI	CS	C1=CC=C(C=C1)C2=NC3=C(N2)C=CC4=C3C(=O)C5=CC=CC=C5C4=O
DM8JMBI	IK	DONDWNNDTIOAET-UHFFFAOYSA-N
DM8JMBI	IU	2-phenyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DM8JMBI	DE	Discovery agent

DM9YAPX	ID	DM9YAPX
DM9YAPX	DN	NSC-745797
DM9YAPX	HS	Investigative
DM9YAPX	DT	Small molecular drug
DM9YAPX	PC	135908526
DM9YAPX	MW	370.4
DM9YAPX	FM	C22H14N2O4
DM9YAPX	IC	InChI=1S/C22H14N2O4/c1-28-17-10-11(6-9-16(17)25)22-23-15-8-7-14-18(19(15)24-22)21(27)13-5-3-2-4-12(13)20(14)26/h2-10,25H,1H3,(H,23,24)
DM9YAPX	CS	COC1=C(C=CC(=C1)C2=NC3=C(N2)C=CC4=C3C(=O)C5=CC=CC=C5C4=O)O
DM9YAPX	IK	FJEOIDUPEMASKE-UHFFFAOYSA-N
DM9YAPX	IU	2-(4-hydroxy-3-methoxyphenyl)-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DM9YAPX	DE	Discovery agent

DMSPQYV	ID	DMSPQYV
DMSPQYV	DN	NSC-745798
DMSPQYV	HS	Investigative
DMSPQYV	SN	NSC-745798; SCHEMBL2400890
DMSPQYV	DT	Small molecular drug
DMSPQYV	PC	46225787
DMSPQYV	MW	338.4
DMSPQYV	FM	C22H14N2O2
DMSPQYV	IC	InChI=1S/C22H14N2O2/c1-12-6-8-13(9-7-12)22-23-17-11-10-16-18(19(17)24-22)21(26)15-5-3-2-4-14(15)20(16)25/h2-11H,1H3,(H,23,24)
DMSPQYV	CS	CC1=CC=C(C=C1)C2=NC3=C(N2)C=CC4=C3C(=O)C5=CC=CC=C5C4=O
DMSPQYV	IK	MRHQJLSJDVEZQP-UHFFFAOYSA-N
DMSPQYV	IU	2-(4-methylphenyl)-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMSPQYV	DE	Discovery agent

DML6OMH	ID	DML6OMH
DML6OMH	DN	NSC-745799
DML6OMH	HS	Investigative
DML6OMH	SN	NSC-745799; SCHEMBL2397234
DML6OMH	DT	Small molecular drug
DML6OMH	PC	44251287
DML6OMH	MW	403.2
DML6OMH	FM	C21H11BrN2O2
DML6OMH	IC	InChI=1S/C21H11BrN2O2/c22-12-7-5-11(6-8-12)21-23-16-10-9-15-17(18(16)24-21)20(26)14-4-2-1-3-13(14)19(15)25/h1-10H,(H,23,24)
DML6OMH	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C4=C(C=C3)NC(=N4)C5=CC=C(C=C5)Br
DML6OMH	IK	YFGTZSZLHQMMGA-UHFFFAOYSA-N
DML6OMH	IU	2-(4-bromophenyl)-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DML6OMH	DE	Discovery agent

DMVA6R0	ID	DMVA6R0
DMVA6R0	DN	NSC-745883
DMVA6R0	HS	Investigative
DMVA6R0	SN	2-(4-Cyanophenyl)-1H-anthra[1,2-d]imidazole-6,11-dione; 1190059-23-4; NSC-745883; SCHEMBL2399352; CHEMBL603647; ZINC45390864; 2-(4-Cyanophenyl)-1H-anthra-[1,2-d]imidazole-6,11-dione, 97%, AldrichCPR
DMVA6R0	DT	Small molecular drug
DMVA6R0	PC	44251286
DMVA6R0	MW	349.3
DMVA6R0	FM	C22H11N3O2
DMVA6R0	IC	InChI=1S/C22H11N3O2/c23-11-12-5-7-13(8-6-12)22-24-17-10-9-16-18(19(17)25-22)21(27)15-4-2-1-3-14(15)20(16)26/h1-10H,(H,24,25)
DMVA6R0	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C4=C(C=C3)NC(=N4)C5=CC=C(C=C5)C#N
DMVA6R0	IK	KHYKISCIUUOMQS-UHFFFAOYSA-N
DMVA6R0	IU	4-(6,11-dioxo-3H-naphtho[2,3-e]benzimidazol-2-yl)benzonitrile
DMVA6R0	DE	Discovery agent

DM8W0J3	ID	DM8W0J3
DM8W0J3	DN	NSC-745884
DM8W0J3	HS	Investigative
DM8W0J3	SN	NSC-745884; SCHEMBL2394941
DM8W0J3	DT	Small molecular drug
DM8W0J3	PC	44251289
DM8W0J3	MW	368.3
DM8W0J3	FM	C22H12N2O4
DM8W0J3	IC	InChI=1S/C22H12N2O4/c25-20-12-3-1-2-4-13(12)21(26)18-14(20)6-7-15-19(18)24-22(23-15)11-5-8-16-17(9-11)28-10-27-16/h1-9H,10H2,(H,23,24)
DM8W0J3	CS	C1OC2=C(O1)C=C(C=C2)C3=NC4=C(N3)C=CC5=C4C(=O)C6=CC=CC=C6C5=O
DM8W0J3	IK	FHLORIZAZVWSPG-UHFFFAOYSA-N
DM8W0J3	IU	2-(1,3-benzodioxol-5-yl)-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DM8W0J3	DE	Discovery agent

DMZQ803	ID	DMZQ803
DMZQ803	DN	NSC-745885
DMZQ803	HS	Investigative
DMZQ803	SN	NSC-745885; AC1MYPDK; SCHEMBL1217478; CHEMBL594366; SJPXIVLTCBBWKT-UHFFFAOYSA-N; MolPort-002-321-063; ZINC4016501; STK368283; NSC745885; AKOS005445050; MCULE-4713643178; ST50889307; anthra[1,2-c]1,2,5-thiadiazole-6,11-dione; anthra[1,2-c][1,2,5]thiadiazole-6,11-dione; anthra [1,2-c]-1,2,5-thiadiazole-6,11-dione
DMZQ803	DT	Small molecular drug
DMZQ803	PC	3835463
DMZQ803	MW	266.28
DMZQ803	FM	C14H6N2O2S
DMZQ803	IC	InChI=1S/C14H6N2O2S/c17-13-7-3-1-2-4-8(7)14(18)11-9(13)5-6-10-12(11)16-19-15-10/h1-6H
DMZQ803	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C4=NSN=C4C=C3
DMZQ803	IK	SJPXIVLTCBBWKT-UHFFFAOYSA-N
DMZQ803	IU	naphtho[2,3-g][2,1,3]benzothiadiazole-6,11-dione
DMZQ803	DE	Discovery agent

DMHBYN5	ID	DMHBYN5
DMHBYN5	DN	NSC-745886
DMHBYN5	HS	Investigative
DMHBYN5	DT	Small molecular drug
DMHBYN5	PC	135433817
DMHBYN5	MW	278.3
DMHBYN5	FM	C17H14N2O2
DMHBYN5	IC	InChI=1S/C17H14N2O2/c1-17(2)18-12-8-7-11-13(14(12)19-17)16(21)10-6-4-3-5-9(10)15(11)20/h3-8,20-21H,1-2H3
DMHBYN5	CS	CC1(N=C2C=CC3=C(C4=CC=CC=C4C(=C3C2=N1)O)O)C
DMHBYN5	IK	HQLMOIOGHONOJD-UHFFFAOYSA-N
DMHBYN5	IU	2,2-dimethylnaphtho[3,2-e]benzimidazole-6,11-diol
DMHBYN5	DE	Discovery agent

DMG9BWY	ID	DMG9BWY
DMG9BWY	DN	NSC-745887
DMG9BWY	HS	Investigative
DMG9BWY	SN	Naphtho[2,3-f]quinoxaline-7,12-dione; NSC-745887; SCHEMBL2396625; CHEMBL596064
DMG9BWY	DT	Small molecular drug
DMG9BWY	PC	12567021
DMG9BWY	MW	260.25
DMG9BWY	FM	C16H8N2O2
DMG9BWY	IC	InChI=1S/C16H8N2O2/c19-15-9-3-1-2-4-10(9)16(20)13-11(15)5-6-12-14(13)18-8-7-17-12/h1-8H
DMG9BWY	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C4=NC=CN=C4C=C3
DMG9BWY	IK	DGLSEJAACVWJNU-UHFFFAOYSA-N
DMG9BWY	IU	naphtho[3,2-f]quinoxaline-7,12-dione
DMG9BWY	DE	Discovery agent

DMWHYND	ID	DMWHYND
DMWHYND	DN	NSC-745888
DMWHYND	HS	Investigative
DMWHYND	SN	NSC-745888
DMWHYND	DT	Small molecular drug
DMWHYND	PC	46225744
DMWHYND	MW	290.23
DMWHYND	FM	C16H6N2O4
DMWHYND	IC	InChI=1S/C16H6N2O4/c19-13-7-3-1-2-4-8(7)14(20)11-9(13)5-6-10-12(11)18-16(22)15(21)17-10/h1-6H
DMWHYND	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C4=NC(=O)C(=O)N=C4C=C3
DMWHYND	IK	RVDWAIRPSDRIMH-UHFFFAOYSA-N
DMWHYND	IU	naphtho[3,2-f]quinoxaline-2,3,7,12-tetrone
DMWHYND	DE	Discovery agent

DM2GO7N	ID	DM2GO7N
DM2GO7N	DN	NSC-746457
DM2GO7N	HS	Investigative
DM2GO7N	DT	Small molecular drug
DM2GO7N	PC	135903324
DM2GO7N	MW	270.29
DM2GO7N	FM	C14H14N4O2
DM2GO7N	IC	InChI=1S/C14H14N4O2/c19-14(16-20)9-8-13-11-18(17-15-13)10-4-7-12-5-2-1-3-6-12/h1-9,11,20H,10H2,(H,16,19)/b7-4+,9-8+
DM2GO7N	CS	C1=CC=C(C=C1)/C=C/CN2C=C(N=N2)/C=C/C(=O)NO
DM2GO7N	IK	IILXTLMEJJIBSG-NUXDXBQRSA-N
DM2GO7N	IU	(E)-N-hydroxy-3-[1-[(E)-3-phenylprop-2-enyl]triazol-4-yl]prop-2-enamide
DM2GO7N	DE	Discovery agent

DM8GZAM	ID	DM8GZAM
DM8GZAM	DN	NSC-75308
DM8GZAM	HS	Investigative
DM8GZAM	SN	NSC-75308; NSC75308; AC1O4U40; 5,6-dichloro-N-[(E)-[(4-methoxyphenyl)-phenylmethylidene]amino]pyridazin-4-amine
DM8GZAM	DT	Small molecular drug
DM8GZAM	PC	6415854
DM8GZAM	MW	373.2
DM8GZAM	FM	C18H14Cl2N4O
DM8GZAM	IC	InChI=1S/C18H14Cl2N4O/c1-25-14-9-7-13(8-10-14)17(12-5-3-2-4-6-12)23-22-15-11-21-24-18(20)16(15)19/h2-11H,1H3,(H,22,24)/b23-17+
DM8GZAM	CS	COC1=CC=C(C=C1)/C(=N/NC2=CN=NC(=C2Cl)Cl)/C3=CC=CC=C3
DM8GZAM	IK	XOZNAUCJQWYKHM-HAVVHWLPSA-N
DM8GZAM	IU	5,6-dichloro-N-[(E)-[(4-methoxyphenyl)-phenylmethylidene]amino]pyridazin-4-amine
DM8GZAM	DE	Discovery agent

DM82XAU	ID	DM82XAU
DM82XAU	DN	NSC-77833
DM82XAU	HS	Investigative
DM82XAU	SN	NSC-77833; NSC77833; CHEMBL1287981; 1-[2-(1H-indol-3-yl)vinyl]isoquinoline; 1-(2-(1H-Indol-3-yl)vinyl)isoquinoline; 1586-48-7; AC1NZRQZ; AC1Q4YF7; 1-[(E)-2-(1H-indol-3-yl)ethenyl]isoquinoline; MolPort-019-790-899; ZINC8616455; BDBM50332192; AKOS030605780; NCGC00184063-01; NCGC00184063-05; NCGC00184063-02; NCGC00184063-03; NCGC00184063-04; 1-[(E)-2-(1H-indol-3-yl)vinyl]isoquinoline; AT-051/43421284; Isoquinoline, 1-[(E)-2-(1H-indol-3-yl)ethenyl]-
DM82XAU	DT	Small molecular drug
DM82XAU	PC	5940197
DM82XAU	MW	270.3
DM82XAU	FM	C19H14N2
DM82XAU	IC	InChI=1S/C19H14N2/c1-2-6-16-14(5-1)11-12-20-19(16)10-9-15-13-21-18-8-4-3-7-17(15)18/h1-13,21H/b10-9+
DM82XAU	CS	C1=CC=C2C(=C1)C=CN=C2/C=C/C3=CNC4=CC=CC=C43
DM82XAU	IK	GXWLLYOLXFYXAT-MDZDMXLPSA-N
DM82XAU	IU	1-[(E)-2-(1H-indol-3-yl)ethenyl]isoquinoline
DM82XAU	CA	CAS 1586-48-7
DM82XAU	DE	Discovery agent

DM8R12J	ID	DM8R12J
DM8R12J	DN	NSC-78017
DM8R12J	HS	Investigative
DM8R12J	SN	CHEMBL1288342; NSC-78017; AC1MW695; ZINC1713901; BDBM50332193; 2,6-dimethyl-3H-pyrrolo[3,2-f]quinolin-6-ium
DM8R12J	DT	Small molecular drug
DM8R12J	PC	3694504
DM8R12J	MW	197.26
DM8R12J	FM	C13H13N2+
DM8R12J	IC	InChI=1S/C13H12N2/c1-9-8-11-10-4-3-7-15(2)13(10)6-5-12(11)14-9/h3-8H,1-2H3/p+1
DM8R12J	CS	CC1=CC2=C(N1)C=CC3=C2C=CC=[N+]3C
DM8R12J	IK	SAKUMUAGJZFIGP-UHFFFAOYSA-O
DM8R12J	IU	2,6-dimethyl-3H-pyrrolo[3,2-f]quinolin-6-ium
DM8R12J	DE	Discovery agent

DM7L3DE	ID	DM7L3DE
DM7L3DE	DN	NSC-78021
DM7L3DE	HS	Investigative
DM7L3DE	SN	NSC-78021; CHEMBL1288457; AC1NMT0D; ZINC1713905; BDBM50332194; 4,7-dimethylpyrido[2,3-c]carbazol-4-ium
DM7L3DE	DT	Small molecular drug
DM7L3DE	PC	5015534
DM7L3DE	MW	247.31
DM7L3DE	FM	C17H15N2+
DM7L3DE	IC	InChI=1S/C17H15N2/c1-18-11-5-7-12-14(18)9-10-16-17(12)13-6-3-4-8-15(13)19(16)2/h3-11H,1-2H3/q+1
DM7L3DE	CS	CN1C2=C(C3=C(C=C2)[N+](=CC=C3)C)C4=CC=CC=C41
DM7L3DE	IK	IAQYIJJPLDSORP-UHFFFAOYSA-N
DM7L3DE	IU	4,7-dimethylpyrido[2,3-c]carbazol-4-ium
DM7L3DE	DE	Discovery agent

DMA53YD	ID	DMA53YD
DMA53YD	DN	NSC-86715
DMA53YD	HS	Investigative
DMA53YD	SN	NSC-86715; 5-methyl-1-phenyl-6H-pyrido[4,3-b]carbazole; CHEMBL1288011; 5531-75-9; NSC86715; NCIOpen2_009547; AC1L5Y57; CTK6B4044; DTXSID10293002; ZINC13282980; BDBM50332195
DMA53YD	DT	Small molecular drug
DMA53YD	PC	258058
DMA53YD	MW	308.4
DMA53YD	FM	C22H16N2
DMA53YD	IC	InChI=1S/C22H16N2/c1-14-16-11-12-23-22(15-7-3-2-4-8-15)18(16)13-19-17-9-5-6-10-20(17)24-21(14)19/h2-13,24H,1H3
DMA53YD	CS	CC1=C2C(=CC3=C1C=CN=C3C4=CC=CC=C4)C5=CC=CC=C5N2
DMA53YD	IK	ORUPXFHZHTYMFL-UHFFFAOYSA-N
DMA53YD	IU	5-methyl-1-phenyl-6H-pyrido[4,3-b]carbazole
DMA53YD	CA	CAS 5531-75-9
DMA53YD	DE	Discovery agent

DMSYT0A	ID	DMSYT0A
DMSYT0A	DN	NSC-87509
DMSYT0A	HS	Investigative
DMSYT0A	SN	Salazinic acid; SALAZIC ACID; 521-39-1; NSC-87509; NSC87509; CHEMBL172439; Salacinic acid; EINECS 208-312-0; Salazinic acid, 2; NSC 87509; C18H12O10; MLS001049106; SCHEMBL3801772; cid_5320418; BDBM29673; MolPort-002-514-253; AKOS030493208; MCULE-8620897210; NCGC00241204-01; NCI60_041934; SMR000386938; trihydroxy-(hydroxymethyl)-methyl-dioxo-[ ]carbaldehyde; 7H-Isobenzofuro[4,5-b][1,4]benzodioxepin-11-carboxaldehyde,1,3-dihydro-1,4,10-trihydroxy-5-(hydroxymethyl)-8-methyl-3,7-dioxo-
DMSYT0A	DT	Small molecular drug
DMSYT0A	PC	5320418
DMSYT0A	MW	388.3
DMSYT0A	FM	C18H12O10
DMSYT0A	IC	InChI=1S/C18H12O10/c1-5-2-8(21)6(3-19)13-9(5)16(23)27-14-7(4-20)12(22)10-11(15(14)26-13)18(25)28-17(10)24/h2-3,18,20-22,25H,4H2,1H3
DMSYT0A	CS	CC1=CC(=C(C2=C1C(=O)OC3=C(O2)C4=C(C(=C3CO)O)C(=O)OC4O)C=O)O
DMSYT0A	IK	QQTKVXCQLZIJPP-UHFFFAOYSA-N
DMSYT0A	IU	5,13,17-trihydroxy-12-(hydroxymethyl)-7-methyl-9,15-dioxo-2,10,16-trioxatetracyclo[9.7.0.03,8.014,18]octadeca-1(11),3(8),4,6,12,14(18)-hexaene-4-carbaldehyde
DMSYT0A	CA	CAS 521-39-1
DMSYT0A	DE	Discovery agent

DM9WIHJ	ID	DM9WIHJ
DM9WIHJ	DN	NSC-88915
DM9WIHJ	HS	Investigative
DM9WIHJ	SN	3,20-dioxopregn-4-en-21-yl 4-bromobenzenesulfonate; NSC-88915; 21170-34-3; NSC88915; CHEMBL387152; AC1L60NG; AC1Q267H; SCHEMBL13856957; CTK1A5243; ZINC4901407; BDBM50158383; AKOS028112969; NCI60_041972; 170D343; 4-pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate); Pregn-4-ene-3,20-dione, 21-[[(4-bromophenyl)sulfonyl]oxy]-; 2-((8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl 4-bromobenzenesulfonate
DM9WIHJ	DT	Small molecular drug
DM9WIHJ	PC	259210
DM9WIHJ	MW	549.5
DM9WIHJ	FM	C27H33BrO5S
DM9WIHJ	IC	InChI=1S/C27H33BrO5S/c1-26-13-11-19(29)15-17(26)3-8-21-22-9-10-24(27(22,2)14-12-23(21)26)25(30)16-33-34(31,32)20-6-4-18(28)5-7-20/h4-7,15,21-24H,3,8-14,16H2,1-2H3/t21-,22-,23-,24+,26-,27-/m0/s1
DM9WIHJ	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COS(=O)(=O)C4=CC=C(C=C4)Br)CCC5=CC(=O)CC[C@]35C
DM9WIHJ	IK	ZQNARVKYKGBJES-YNHSGCSHSA-N
DM9WIHJ	IU	[2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 4-bromobenzenesulfonate
DM9WIHJ	CA	CAS 21170-34-3
DM9WIHJ	DE	Solid tumour/cancer

DMGS6HB	ID	DMGS6HB
DMGS6HB	DN	NSC-89508
DMGS6HB	HS	Investigative
DMGS6HB	SN	NSC-89508; CHEMBL1165457; N-(4-((4-chlorophenylthio)methyl)phenyl)benzenesulfonamide; NSC89508; AC1L61AV; BDBM50320480
DMGS6HB	DT	Small molecular drug
DMGS6HB	PC	259534
DMGS6HB	MW	389.9
DMGS6HB	FM	C19H16ClNO2S2
DMGS6HB	IC	InChI=1S/C19H16ClNO2S2/c20-16-8-12-18(13-9-16)24-14-15-6-10-17(11-7-15)21-25(22,23)19-4-2-1-3-5-19/h1-13,21H,14H2
DMGS6HB	CS	C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CSC3=CC=C(C=C3)Cl
DMGS6HB	IK	WQKPRWBYNOIBTL-UHFFFAOYSA-N
DMGS6HB	IU	N-[4-[(4-chlorophenyl)sulfanylmethyl]phenyl]benzenesulfonamide
DMGS6HB	DE	Discovery agent

DMTOFS7	ID	DMTOFS7
DMTOFS7	DN	NSC-93358
DMTOFS7	HS	Investigative
DMTOFS7	SN	CHEMBL583076; NSC-93358; NCIOpen2_006063; AC1L655A; CTK7H3397; BDBM50298490; 3a,5b,10-trimethyl-1,2,4,5,5a,6,7,10,10a,10b-decahydrocyclopenta[a]fluorene-3,8-dione; 3a,5b,10-trimethyl-1,2,3a,4,5,5a,5b,6,7,10,10a,10b-dodecahydrocyclopenta[a]fluorene-3,8-dione
DMTOFS7	DT	Small molecular drug
DMTOFS7	PC	261365
DMTOFS7	MW	286.4
DMTOFS7	FM	C19H26O2
DMTOFS7	IC	InChI=1S/C19H26O2/c1-11-15-10-12(20)6-8-18(15,2)14-7-9-19(3)13(17(11)14)4-5-16(19)21/h10-11,13-14,17H,4-9H2,1-3H3
DMTOFS7	CS	CC1C2C3CCC(=O)C3(CCC2C4(C1=CC(=O)CC4)C)C
DMTOFS7	IK	GYXFOOCGIVDNFH-UHFFFAOYSA-N
DMTOFS7	IU	3a,5b,10-trimethyl-1,2,4,5,5a,6,7,10,10a,10b-decahydrocyclopenta[a]fluorene-3,8-dione
DMTOFS7	DE	Discovery agent

DM2JPD4	ID	DM2JPD4
DM2JPD4	DN	NSC-93394
DM2JPD4	HS	Investigative
DM2JPD4	SN	6-Fluoroflavone; 1218-82-2; 6-fluoro-2-phenyl-4h-chromen-4-one; 6-fluoro-2-phenylchromen-4-one; NSC-93394; CHEMBL61745; 4H-1-Benzopyran-4-one,6-fluoro-2-phenyl-; 6-Fluoroflavanone; NSC93394; 4l2g; AC1Q4OEB; SCHEMBL2427741; AC1L657S; CTK4B2868; DTXSID80294001; MolPort-001-776-694; ZINC135415; 6-Fluoro-2-phenyl-chromen-4-one; ZX-AP008247; 5994AH; PC6548; SBB099255; AKOS003623542; ZB004762; DB-041635; 6-Fluoro-2-phenyl-4H-1-benzopyran-4-one; KB-248702; KB-199446; FT-0633494; 4H-1-Benzopyran-4-one, 6-fluoro-2-phenyl-; A-7636; C-41230
DM2JPD4	DT	Small molecular drug
DM2JPD4	PC	261395
DM2JPD4	MW	240.23
DM2JPD4	FM	C15H9FO2
DM2JPD4	IC	InChI=1S/C15H9FO2/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-9H
DM2JPD4	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)F
DM2JPD4	IK	OUYOSBQKQPUNJK-UHFFFAOYSA-N
DM2JPD4	IU	6-fluoro-2-phenylchromen-4-one
DM2JPD4	CA	CAS 1218-82-2
DM2JPD4	DE	Discovery agent

DM3BZ7S	ID	DM3BZ7S
DM3BZ7S	DN	NSC-93405
DM3BZ7S	HS	Investigative
DM3BZ7S	SN	NSC-93405; 7-fluoro-2-phenyl-4H-chromen-4-one; CHEMBL477846; 2558-17-0; 7-FLUORO-2-PHENYL-4H-1-BENZOPYRAN-4-ONE; 7-Fluoroflavone; NSC93405; AC1Q4OJF; AC1L657P; SCHEMBL12961037; 7-fluoro-2-phenylchromen-4-one; DTXSID20294000; 7-fluoro-2-phenyl-chromen-4-one; BDBM50310188; 7-fluoranyl-2-phenyl-chromen-4-one; MB10484; 7-fluoro-2-phenyl-1-benzopyran-4-one
DM3BZ7S	DT	Small molecular drug
DM3BZ7S	PC	261394
DM3BZ7S	MW	240.23
DM3BZ7S	FM	C15H9FO2
DM3BZ7S	IC	InChI=1S/C15H9FO2/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-9H
DM3BZ7S	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)F
DM3BZ7S	IK	ZEYRNYUCQATYPC-UHFFFAOYSA-N
DM3BZ7S	IU	7-fluoro-2-phenylchromen-4-one
DM3BZ7S	CA	CAS 2558-17-0
DM3BZ7S	DE	Discovery agent

DM6VY3P	ID	DM6VY3P
DM6VY3P	DN	NSC-94258
DM6VY3P	HS	Investigative
DM6VY3P	SN	7-Hydroxyflavone; 6665-86-7; 7-Hydroxy-2-phenyl-4H-chromen-4-one; Flavone, 7-hydroxy-; 7-Hydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 7-hydroxy-2-phenyl-; 7-hydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-; 7-Hydroxy-2-phenyl-chromen-4-one; NSC 94258; UNII-ZE72458E4L; EINECS 229-705-3; NSC-94258; MLS002695239; CHEBI:2268; CHEMBL276915; MQGPSCMMNJKMHQ-UHFFFAOYSA-N; ZE72458E4L; NSC94258; MFCD00006835; 7-Hydroxy-2-phenyl-4H-1-benzopyran-4-one; H-5100; SR-01000359106; 7-Hydroxyflavone, 11; 7-Hydroxy-flavone, 
DM6VY3P	DT	Small molecular drug
DM6VY3P	PC	5281894
DM6VY3P	MW	238.24
DM6VY3P	FM	C15H10O3
DM6VY3P	IC	InChI=1S/C15H10O3/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-9,16H
DM6VY3P	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)O
DM6VY3P	IK	MQGPSCMMNJKMHQ-UHFFFAOYSA-N
DM6VY3P	IU	7-hydroxy-2-phenylchromen-4-one
DM6VY3P	CA	CAS 6665-86-7
DM6VY3P	CB	CHEBI:2268
DM6VY3P	DE	Discovery agent

DM31CZK	ID	DM31CZK
DM31CZK	DN	NSC-94891
DM31CZK	HS	Investigative
DM31CZK	SN	NSC-94891; CHEMBL574960; AC1L668K; CTK7H3473; BDBM50298485
DM31CZK	DT	Small molecular drug
DM31CZK	PC	261861
DM31CZK	MW	302.4
DM31CZK	FM	C19H26O3
DM31CZK	IC	InChI=1S/C19H26O3/c1-11-15-10-12(20)6-9-19(3,22-15)14-7-8-18(2)13(17(11)14)4-5-16(18)21/h10-11,13-14,17H,4-9H2,1-3H3/t11-,13-,14-,17-,18-,19?/m0/s1
DM31CZK	CS	C[C@@H]1[C@H]2[C@@H]3CCC(=O)[C@]3(CC[C@@H]2C4(CCC(=O)C=C1O4)C)C
DM31CZK	IK	PCQJXIDDNRAKDR-HXWRFABVSA-N
DM31CZK	IU	(2S,5S,9S,10R,11R)-1,5,11-trimethyl-17-oxatetracyclo[10.4.1.02,10.05,9]heptadec-12-ene-6,14-dione
DM31CZK	DE	Discovery agent

DMX0TAM	ID	DMX0TAM
DMX0TAM	DN	NSC-95397
DMX0TAM	HS	Investigative
DMX0TAM	SN	NSC 95397; 93718-83-3; 2,3-Bis(2-hydroxyethylthio)-1,4-naphthalenedione; NSC95397; NSC-95397; 2,3-bis(2-hydroxyethylsulfanyl)naphthalene-1,4-dione; MLS002153403; CHEMBL429095; SMR001230781; SR-01000075930; 1,4-Naphthalenedione, 2,3-bis[(2-hydroxyethyl)thio]-; Tocris-1547; AC1Q6JAF; Lopac-N-1786; Lopac0_000629; KBioGR_000495; BSPBio_001155; KBioSS_000495; SCHEMBL2530685; AC1L66Q4; cid_262093; KBio3_000910; KBio2_005631; KBio2_003063; CHEBI:93193; KBio3_000909; KBio2_000495; CTK3I8111; DTXSID10294236; MolPort-003-958-936; HMS3268C19
DMX0TAM	DT	Small molecular drug
DMX0TAM	PC	262093
DMX0TAM	MW	310.4
DMX0TAM	FM	C14H14O4S2
DMX0TAM	IC	InChI=1S/C14H14O4S2/c15-5-7-19-13-11(17)9-3-1-2-4-10(9)12(18)14(13)20-8-6-16/h1-4,15-16H,5-8H2
DMX0TAM	CS	C1=CC=C2C(=C1)C(=O)C(=C(C2=O)SCCO)SCCO
DMX0TAM	IK	MAASHDQFQDDECQ-UHFFFAOYSA-N
DMX0TAM	IU	2,3-bis(2-hydroxyethylsulfanyl)naphthalene-1,4-dione
DMX0TAM	CA	CAS 93718-83-3
DMX0TAM	CB	CHEBI:93193
DMX0TAM	DE	Discovery agent

DM96X2U	ID	DM96X2U
DM96X2U	DN	NSC-99495
DM96X2U	HS	Investigative
DM96X2U	SN	NSC-99495; 3-benzo[a]anthracen-12-ylthiophene; CHEMBL1288012; 1236-21-1; AC1N2A41; DTXSID20398719; ZINC1654295; NSC99495; BDBM50332197
DM96X2U	DT	Small molecular drug
DM96X2U	PC	4043484
DM96X2U	MW	310.4
DM96X2U	FM	C22H14S
DM96X2U	IC	InChI=1S/C22H14S/c1-3-7-19-15(5-1)9-10-17-13-16-6-2-4-8-20(16)22(21(17)19)18-11-12-23-14-18/h1-14H
DM96X2U	CS	C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C(=C32)C5=CSC=C5
DM96X2U	IK	FJWVAKJBVCNSHF-UHFFFAOYSA-N
DM96X2U	IU	3-benzo[a]anthracen-12-ylthiophene
DM96X2U	CA	CAS 1236-21-1
DM96X2U	DE	Discovery agent

DMXZAIG	ID	DMXZAIG
DMXZAIG	DN	NSC-99528
DMXZAIG	HS	Investigative
DMXZAIG	SN	NSC-99528; CHEMBL1288044; 2-benzo[a]anthracen-12-yl-1-benzothiophene; NSC99528; AC1L6BVI; CTK5J6950; ZINC1656970; BDBM50332179; 2-(tetraphen-12-yl)-1-benzothiophene
DMXZAIG	DT	Small molecular drug
DMXZAIG	PC	264430
DMXZAIG	MW	360.5
DMXZAIG	FM	C26H16S
DMXZAIG	IC	InChI=1S/C26H16S/c1-4-10-21-17(7-1)13-14-20-15-18-8-2-5-11-22(18)26(25(20)21)24-16-19-9-3-6-12-23(19)27-24/h1-16H
DMXZAIG	CS	C1=CC=C2C(=C1)C=CC3=CC4=CC=CC=C4C(=C32)C5=CC6=CC=CC=C6S5
DMXZAIG	IK	SJVMNTJUTHEADO-UHFFFAOYSA-N
DMXZAIG	IU	2-benzo[a]anthracen-12-yl-1-benzothiophene
DMXZAIG	DE	Discovery agent

DMSLA8X	ID	DMSLA8X
DMSLA8X	DN	NSFQ-105
DMSLA8X	HS	Investigative
DMSLA8X	SN	154269-12-2; NSFQ-104
DMSLA8X	PC	9805427
DMSLA8X	MW	486.5
DMSLA8X	FM	C23H23FN4O5S
DMSLA8X	IC	InChI=1S/C23H23FN4O5S/c24-19-11-17-20(28(15-3-4-15)13-18(22(17)29)23(30)31)12-21(19)26-7-9-27(10-8-26)34(32,33)16-5-1-14(25)2-6-16/h1-2,5-6,11-13,15H,3-4,7-10,25H2,(H,30,31)
DMSLA8X	CS	C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCN(CC4)S(=O)(=O)C5=CC=C(C=C5)N)F)C(=O)O
DMSLA8X	IK	LHQCNYXFOFNLNV-UHFFFAOYSA-N
DMSLA8X	IU	7-[4-(4-aminophenyl)sulfonylpiperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMSLA8X	DE	Discovery agent

DMUHZ2V	ID	DMUHZ2V
DMUHZ2V	DN	NT-69-L
DMUHZ2V	HS	Investigative
DMUHZ2V	CP	Mayo Foundation
DMUHZ2V	DE	Alcohol dependence

DMFIE0U	ID	DMFIE0U
DMFIE0U	DN	NTE-1
DMFIE0U	HS	Investigative
DMFIE0U	SN	Methyl [(2s)-2-[4-({5-[4-({(2s)-2-[(3s)-3-Amino-2-Oxopiperidin-1-Yl]-2-Cyclohexylacetyl}amino)phenyl]pentyl}oxy)phenyl]-3-(Quinolin-3-Yl)propyl]carbamate; NTE-1; GTPL8596; 2Q6; methyl N-[(2S)-2-[4-[5-[4-[[(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl]amino]phenyl]pentoxy]phenyl]-3-quinolin-3-ylpropyl]carbamate
DMFIE0U	DT	Small molecular drug
DMFIE0U	PC	91801116
DMFIE0U	MW	733.9
DMFIE0U	FM	C44H55N5O5
DMFIE0U	IC	InChI=1S/C44H55N5O5/c1-53-44(52)47-30-36(28-32-27-35-14-7-8-16-40(35)46-29-32)33-19-23-38(24-20-33)54-26-9-3-4-11-31-17-21-37(22-18-31)48-42(50)41(34-12-5-2-6-13-34)49-25-10-15-39(45)43(49)51/h7-8,14,16-24,27,29,34,36,39,41H,2-6,9-13,15,25-26,28,30,45H2,1H3,(H,47,52)(H,48,50)/t36-,39+,41+/m1/s1
DMFIE0U	CS	COC(=O)NC[C@@H](CC1=CC2=CC=CC=C2N=C1)C3=CC=C(C=C3)OCCCCCC4=CC=C(C=C4)NC(=O)[C@H](C5CCCCC5)N6CCC[C@@H](C6=O)N
DMFIE0U	IK	IGRIVAWLJUPVMM-UDEWTJCRSA-N
DMFIE0U	IU	methyl N-[(2S)-2-[4-[5-[4-[[(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl]amino]phenyl]pentoxy]phenyl]-3-quinolin-3-ylpropyl]carbamate
DMFIE0U	DE	Discovery agent

DM4DB0W	ID	DM4DB0W
DM4DB0W	DN	NTE-2
DM4DB0W	HS	Investigative
DM4DB0W	SN	Methyl [(2s)-2-(5-{5-[4-({(2s)-2-[(3s)-3-Amino-2-Oxopiperidin-1-Yl]-2-Cyclohexylacetyl}amino)phenyl]pentyl}-2-Fluorophenyl)-3-(Quinolin-3-Yl)propyl]carbamate; NTE-2; GTPL8597; methyl N-[(2S)-2-[5-[5-[4-[[(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl]amino]phenyl]pentyl]-2-fluorophenyl]-3-quinolin-3-ylpropyl]carbamate
DM4DB0W	DT	Small molecular drug
DM4DB0W	PC	91801117
DM4DB0W	MW	735.9
DM4DB0W	FM	C44H54FN5O4
DM4DB0W	IC	InChI=1S/C44H54FN5O4/c1-54-44(53)48-29-35(26-32-25-34-15-8-9-17-40(34)47-28-32)37-27-31(20-23-38(37)45)12-5-2-4-11-30-18-21-36(22-19-30)49-42(51)41(33-13-6-3-7-14-33)50-24-10-16-39(46)43(50)52/h8-9,15,17-23,25,27-28,33,35,39,41H,2-7,10-14,16,24,26,29,46H2,1H3,(H,48,53)(H,49,51)/t35-,39+,41+/m1/s1
DM4DB0W	CS	COC(=O)NC[C@@H](CC1=CC2=CC=CC=C2N=C1)C3=C(C=CC(=C3)CCCCCC4=CC=C(C=C4)NC(=O)[C@H](C5CCCCC5)N6CCC[C@@H](C6=O)N)F
DM4DB0W	IK	SDVPSGCYRLUZSS-WXSHXSFMSA-N
DM4DB0W	IU	methyl N-[(2S)-2-[5-[5-[4-[[(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl]amino]phenyl]pentyl]-2-fluorophenyl]-3-quinolin-3-ylpropyl]carbamate
DM4DB0W	DE	Discovery agent

DMOPSJU	ID	DMOPSJU
DMOPSJU	DN	N-tert-Butyl-1'H-phenothiazine-1'-carboxamide
DMOPSJU	HS	Investigative
DMOPSJU	SN	CHEMBL592431; ChemDiv3_004014; AC1LE08E; Oprea1_837647; MLS001196417; ZINC88008; BRD4081; MolPort-019-755-363; MolPort-002-224-545; HMS2867C08; HMS1484G10; BRD-4081; STK125446; BDBM50308431; AKOS001667641; MCULE-9506670644; CCG-113326; IDI1_021924; N-tert-butylphenothiazine-10-carboxamide; SMR000556301; N-(tert-butyl)phenothiazin-10-ylcarboxamide; ST50857670; EU-0080142; N-tert-butyl-10H-phenothiazine-10-carboxamide; AB00120758-01; N-(tert-butyl)-10H-phenothiazine-10-carboxamide; N-tert-Butyl-1''H-phenothiazine-1''-carboxamide
DMOPSJU	DT	Small molecular drug
DMOPSJU	PC	704261
DMOPSJU	MW	298.4
DMOPSJU	FM	C17H18N2OS
DMOPSJU	IC	InChI=1S/C17H18N2OS/c1-17(2,3)18-16(20)19-12-8-4-6-10-14(12)21-15-11-7-5-9-13(15)19/h4-11H,1-3H3,(H,18,20)
DMOPSJU	CS	CC(C)(C)NC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMOPSJU	IK	VEHORJYPKNVWKA-UHFFFAOYSA-N
DMOPSJU	IU	N-tert-butylphenothiazine-10-carboxamide
DMOPSJU	DE	Discovery agent

DMNZ37C	ID	DMNZ37C
DMNZ37C	DN	N-Tridecanoic Acid
DMNZ37C	HS	Investigative
DMNZ37C	SN	TRIDECANOIC ACID; 638-53-9; n-Tridecanoic acid; Tridecylic acid; n-Tridecoic acid; NSC 25955; UNII-19936LIY2V; EINECS 211-341-1; NSC 69131; BRN 0508317; AI3-04166; CHEBI:45919; SZHOJFHSIKHZHA-UHFFFAOYSA-N; 19936LIY2V; 68002-90-4; C13:0; n-Tridecanoic acid, 97%; Tridecanoic acid, &gt; Tridecanoic acid anion; WLN: QV12; Fatty acids, C10-16; C10-16 fatty acids; Tridecylate; Carboxylic acids, C10-16; tridecoic acid; n-Tridecanoate; n-Tridecoate; (C10-C16) Carboxylic acid; (C10-C16)Alkylcarboxylic acid; EINECS 268-105-6
DMNZ37C	DT	Small molecular drug
DMNZ37C	PC	12530
DMNZ37C	MW	214.34
DMNZ37C	FM	C13H26O2
DMNZ37C	IC	InChI=1S/C13H26O2/c1-2-3-4-5-6-7-8-9-10-11-12-13(14)15/h2-12H2,1H3,(H,14,15)
DMNZ37C	CS	CCCCCCCCCCCCC(=O)O
DMNZ37C	IK	SZHOJFHSIKHZHA-UHFFFAOYSA-N
DMNZ37C	IU	tridecanoic acid
DMNZ37C	CA	CAS 638-53-9
DMNZ37C	CB	CHEBI:45919
DMNZ37C	DE	Discovery agent

DMZQXLS	ID	DMZQXLS
DMZQXLS	DN	N-Trimethyllysine
DMZQXLS	HS	Investigative
DMZQXLS	SN	N-TRIMETHYLLYSINE; Trimethyllysine; epsilon-Trimethyllysine; N(epsilon)-Trimethyllysine; epsilon-Trimethyl-L-lysine; epsilon-N-Trimethyl-L-lysine; UNII-3YGF0495O2; CHEBI:17311; 3YGF0495O2; (S)-5-Amino-5-carboxy-N,N,N-trimethyl-1-pentanaminium; 19253-88-4; 1-Pentanaminium, 5-amino-5-carboxy-N,N,N-trimethyl-, (S)-; M3L; (S)-2-amino-6-(trimethylammonio)hexanoic acid; N-N-N-Trimethyllysine; N-epsilon-trimethyllysine; epsilon-N-Trimethyllysine; AC1L98PV; SCHEMBL181192; CHEMBL1234168; MXNRLFUSFKVQSK-QMMMGPOBSA-O; ZINC1529747
DMZQXLS	DT	Small molecular drug
DMZQXLS	PC	440121
DMZQXLS	MW	189.28
DMZQXLS	FM	C9H21N2O2+
DMZQXLS	IC	InChI=1S/C9H20N2O2/c1-11(2,3)7-5-4-6-8(10)9(12)13/h8H,4-7,10H2,1-3H3/p+1/t8-/m0/s1
DMZQXLS	CS	C[N+](C)(C)CCCC[C@@H](C(=O)O)N
DMZQXLS	IK	MXNRLFUSFKVQSK-QMMMGPOBSA-O
DMZQXLS	IU	[(5S)-5-amino-5-carboxypentyl]-trimethylazanium
DMZQXLS	CA	CAS 19253-88-4
DMZQXLS	CB	CHEBI:17311
DMZQXLS	DE	Discovery agent

DMTHB2Y	ID	DMTHB2Y
DMTHB2Y	DN	nTzDpa
DMTHB2Y	HS	Investigative
DMTHB2Y	SN	nTzDpa; 118414-59-8; 5-Chloro-1-(4-Chlorobenzyl)-3-(Phenylthio)-1h-Indole-2-Carboxylic Acid; 5-CHLORO-1-[(4-CHLOROPHENYL)METHYL]-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID; CHEMBL370152; 1H-Indole-2-carboxylicacid, 5-chloro-1-[(4-chlorophenyl)methyl]-3-(phenylthio)-; NZA; ACMC-1CBOZ; SCHEMBL6709652; GTPL2699; CTK0H3131; DTXSID40433292; MolPort-003-983-790; HMS3268N03; ZINC1492396; BDBM50173365; BS0133; AKOS024456957; NCGC00092313-01; RT-014770; KB-245430; B6955; J-003750; BRD-K54708045-001-01-3
DMTHB2Y	DT	Small molecular drug
DMTHB2Y	PC	9954280
DMTHB2Y	MW	428.3
DMTHB2Y	FM	C22H15Cl2NO2S
DMTHB2Y	IC	InChI=1S/C22H15Cl2NO2S/c23-15-8-6-14(7-9-15)13-25-19-11-10-16(24)12-18(19)21(20(25)22(26)27)28-17-4-2-1-3-5-17/h1-12H,13H2,(H,26,27)
DMTHB2Y	CS	C1=CC=C(C=C1)SC2=C(N(C3=C2C=C(C=C3)Cl)CC4=CC=C(C=C4)Cl)C(=O)O
DMTHB2Y	IK	VUPOTURDKDMIGQ-UHFFFAOYSA-N
DMTHB2Y	IU	5-chloro-1-[(4-chlorophenyl)methyl]-3-phenylsulfanylindole-2-carboxylic acid
DMTHB2Y	CA	CAS 118414-59-8
DMTHB2Y	DE	Discovery agent

DMEHMOK	ID	DMEHMOK
DMEHMOK	DN	NU-1001-41
DMEHMOK	HS	Investigative
DMEHMOK	SN	Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies
DMEHMOK	CP	Nuclea Biotechnologies LLC
DMEHMOK	DT	Antibody
DMEHMOK	DE	Solid tumour/cancer

DMELYAX	ID	DMELYAX
DMELYAX	DN	NU-6027
DMELYAX	HS	Investigative
DMELYAX	PC	398148
DMELYAX	MW	251.29
DMELYAX	FM	C11H17N5O2
DMELYAX	IC	InChI=1S/C11H17N5O2/c12-9-8(16-17)10(15-11(13)14-9)18-6-7-4-2-1-3-5-7/h7H,1-6H2,(H4,12,13,14,15)
DMELYAX	CS	C1CCC(CC1)COC2=NC(=NC(=C2N=O)N)N
DMELYAX	IK	DGWXOLHKVGDQLN-UHFFFAOYSA-N
DMELYAX	IU	6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine
DMELYAX	CA	CAS 220036-08-8
DMELYAX	DE	Discovery agent

DMMOFKD	ID	DMMOFKD
DMMOFKD	DN	NU-6102
DMMOFKD	HS	Investigative
DMMOFKD	SN	nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467
DMMOFKD	DT	Small molecular drug
DMMOFKD	PC	4566
DMMOFKD	MW	402.5
DMMOFKD	FM	C18H22N6O3S
DMMOFKD	IC	InChI=1S/C18H22N6O3S/c19-28(25,26)14-8-6-13(7-9-14)22-18-23-16-15(20-11-21-16)17(24-18)27-10-12-4-2-1-3-5-12/h6-9,11-12H,1-5,10H2,(H2,19,25,26)(H2,20,21,22,23,24)
DMMOFKD	CS	C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)NC4=CC=C(C=C4)S(=O)(=O)N
DMMOFKD	IK	OWXORKPNCHJYOF-UHFFFAOYSA-N
DMMOFKD	IU	4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide
DMMOFKD	CA	CAS 444722-95-6
DMMOFKD	DE	Discovery agent

DMCUSG3	ID	DMCUSG3
DMCUSG3	DN	NU6140
DMCUSG3	HS	Investigative
DMCUSG3	SN	Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide
DMCUSG3	DT	Small molecular drug
DMCUSG3	PC	10202471
DMCUSG3	MW	422.5
DMCUSG3	FM	C23H30N6O2
DMCUSG3	IC	InChI=1S/C23H30N6O2/c1-3-29(4-2)22(30)17-10-12-18(13-11-17)26-23-27-20-19(24-15-25-20)21(28-23)31-14-16-8-6-5-7-9-16/h10-13,15-16H,3-9,14H2,1-2H3,(H2,24,25,26,27,28)
DMCUSG3	CS	CCN(CC)C(=O)C1=CC=C(C=C1)NC2=NC3=C(C(=N2)OCC4CCCCC4)NC=N3
DMCUSG3	IK	XHEQSRJCJTWWAH-UHFFFAOYSA-N
DMCUSG3	IU	4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]-N,N-diethylbenzamide
DMCUSG3	CA	CAS 444723-13-1
DMCUSG3	DE	Discovery agent

DMDNUM5	ID	DMDNUM5
DMDNUM5	DN	NU-7432
DMDNUM5	HS	Investigative
DMDNUM5	SN	NU-7441
DMDNUM5	DT	Small molecular drug
DMDNUM5	PC	11327430
DMDNUM5	MW	413.5
DMDNUM5	FM	C25H19NO3S
DMDNUM5	IC	InChI=1S/C25H19NO3S/c27-21-15-23(26-11-13-28-14-12-26)29-24-17(6-3-9-20(21)24)19-8-4-7-18-16-5-1-2-10-22(16)30-25(18)19/h1-10,15H,11-14H2
DMDNUM5	CS	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56
DMDNUM5	IK	JAMULYFATHSZJM-UHFFFAOYSA-N
DMDNUM5	IU	8-dibenzothiophen-4-yl-2-morpholin-4-ylchromen-4-one
DMDNUM5	CA	CAS 503468-95-9
DMDNUM5	CB	CHEBI:91361
DMDNUM5	DE	Discovery agent

DMEUV5R	ID	DMEUV5R
DMEUV5R	DN	NU-8231
DMEUV5R	HS	Investigative
DMEUV5R	SN	NU-8231; SCHEMBL2454464; CHEMBL360944
DMEUV5R	DT	Small molecular drug
DMEUV5R	PC	11648438
DMEUV5R	MW	467.9
DMEUV5R	FM	C26H26ClNO5
DMEUV5R	IC	InChI=1S/C26H26ClNO5/c1-4-13-28-25(30)20-7-5-6-8-21(20)26(28,18-9-11-19(27)12-10-18)33-16-17-14-22(31-2)24(29)23(15-17)32-3/h5-12,14-15,29H,4,13,16H2,1-3H3
DMEUV5R	CS	CCCN1C(=O)C2=CC=CC=C2C1(C3=CC=C(C=C3)Cl)OCC4=CC(=C(C(=C4)OC)O)OC
DMEUV5R	IK	NDIKZCQEKGERHF-UHFFFAOYSA-N
DMEUV5R	IU	3-(4-chlorophenyl)-3-[(4-hydroxy-3,5-dimethoxyphenyl)methoxy]-2-propylisoindol-1-one
DMEUV5R	DE	Discovery agent

DM5KXFI	ID	DM5KXFI
DM5KXFI	DN	NUTLIN-3
DM5KXFI	HS	Investigative
DM5KXFI	SN	Nutlin-3; 548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one
DM5KXFI	DT	Small molecular drug
DM5KXFI	PC	216345
DM5KXFI	MW	581.5
DM5KXFI	FM	C30H30Cl2N4O4
DM5KXFI	IC	InChI=1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13,16,18,27-28H,14-15,17H2,1-3H3,(H,33,37)
DM5KXFI	CS	CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl
DM5KXFI	IK	BDUHCSBCVGXTJM-UHFFFAOYSA-N
DM5KXFI	IU	4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one
DM5KXFI	CA	CAS 548472-68-0
DM5KXFI	CB	CHEBI:93777
DM5KXFI	DE	Discovery agent

DMWLQV8	ID	DMWLQV8
DMWLQV8	DN	NV-07a
DMWLQV8	HS	Investigative
DMWLQV8	SN	NV-07; NV-07alpha; NV-07beta; Phenolic hormones (anti-inflammatory), Novogen
DMWLQV8	CP	Novogen Ltd
DMWLQV8	DE	Inflammatory bowel disease

DM0BNYU	ID	DM0BNYU
DM0BNYU	DN	NV-31
DM0BNYU	HS	Investigative
DM0BNYU	SN	NV-31; 335259-33-1; GTPL2375; SCHEMBL7752800; SCHEMBL7752805; 4-tert-butyl-1-oxothian-4-ol; CHEMBL1092620; CTK1B8381; DTXSID10436639; 2H-Thiopyran-4-ol, 4-(1,1-dimethylethyl)tetrahydro-, 1-oxide
DM0BNYU	DT	Small molecular drug
DM0BNYU	PC	10198012
DM0BNYU	MW	190.31
DM0BNYU	FM	C9H18O2S
DM0BNYU	IC	InChI=1S/C9H18O2S/c1-8(2,3)9(10)4-6-12(11)7-5-9/h10H,4-7H2,1-3H3
DM0BNYU	CS	CC(C)(C)C1(CCS(=O)CC1)O
DM0BNYU	IK	BKPWCHDEUGQJRG-UHFFFAOYSA-N
DM0BNYU	IU	4-tert-butyl-1-oxothian-4-ol
DM0BNYU	CA	CAS 335259-33-1
DM0BNYU	DE	Discovery agent

DM6DRFC	ID	DM6DRFC
DM6DRFC	DN	NVP 231
DM6DRFC	HS	Investigative
DM6DRFC	SN	NVP231; NVP-231
DM6DRFC	DT	Small molecular drug
DM6DRFC	PC	4096211
DM6DRFC	MW	431.6
DM6DRFC	FM	C25H25N3O2S
DM6DRFC	IC	InChI=1S/C25H25N3O2S/c29-22(18-4-2-1-3-5-18)28-24-27-20-7-6-19(11-21(20)31-24)26-23(30)25-12-15-8-16(13-25)10-17(9-15)14-25/h1-7,11,15-17H,8-10,12-14H2,(H,26,30)(H,27,28,29)
DM6DRFC	CS	C1C2CC3CC1CC(C2)(C3)C(=O)NC4=CC5=C(C=C4)N=C(S5)NC(=O)C6=CC=CC=C6
DM6DRFC	IK	MVSSJPGNLQPWSW-UHFFFAOYSA-N
DM6DRFC	IU	N-(2-benzamido-1,3-benzothiazol-6-yl)adamantane-1-carboxamide
DM6DRFC	CA	CAS 362003-83-6
DM6DRFC	DE	Discovery agent

DM8R16V	ID	DM8R16V
DM8R16V	DN	NVP ACQ090
DM8R16V	HS	Investigative
DM8R16V	SN	NVP ACQ090; ACQ090; SCHEMBL6223981; GTPL2076
DM8R16V	DT	Small molecular drug
DM8R16V	PC	11443899
DM8R16V	MW	526.7
DM8R16V	FM	C30H40F2N4O2
DM8R16V	IC	InChI=1S/C30H40F2N4O2/c1-21(15-22-7-10-29(38-2)33-17-22)18-34-19-23-5-3-4-6-25(23)26(20-34)30(37)36-13-11-35(12-14-36)24-8-9-27(31)28(32)16-24/h7-10,16-17,21,23,25-26H,3-6,11-15,18-20H2,1-2H3/t21?,23-,25-,26+/m0/s1
DM8R16V	CS	CC(CC1=CN=C(C=C1)OC)CN2C[C@@H]3CCCC[C@@H]3[C@@H](C2)C(=O)N4CCN(CC4)C5=CC(=C(C=C5)F)F
DM8R16V	IK	RDSAUPRYZCQORM-RIVQXRJNSA-N
DM8R16V	IU	[(4S,4aS,8aR)-2-[3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone
DM8R16V	DE	Discovery agent

DM9DURZ	ID	DM9DURZ
DM9DURZ	DN	NVP-AAM077
DM9DURZ	HS	Investigative
DM9DURZ	SN	PEAQX
DM9DURZ	DT	Small molecular drug
DM9DURZ	PC	73409722
DM9DURZ	MW	454.2
DM9DURZ	FM	C17H17BrN3O5P
DM9DURZ	IC	InChI=1S/C17H17BrN3O5P/c1-9(10-5-7-11(18)8-6-10)19-17(27(24,25)26)12-3-2-4-13-14(12)21-16(23)15(22)20-13/h2-9,17,19H,1H3,(H,20,22)(H,21,23)(H2,24,25,26)
DM9DURZ	CS	CC(C1=CC=C(C=C1)Br)NC(C2=C3C(=CC=C2)NC(=O)C(=O)N3)P(=O)(O)O
DM9DURZ	IK	XXZGNAZRWCBSBK-UHFFFAOYSA-N
DM9DURZ	IU	[[1-(4-bromophenyl)ethylamino]-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]phosphonic acid
DM9DURZ	DE	Discovery agent

DMXL3CD	ID	DMXL3CD
DMXL3CD	DN	NVP-ADW742
DMXL3CD	HS	Investigative
DMXL3CD	SN	NVP-ADW742; 475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
DMXL3CD	CP	Novartis
DMXL3CD	DT	Small molecular drug
DMXL3CD	PC	9825149
DMXL3CD	MW	453.6
DMXL3CD	FM	C28H31N5O
DMXL3CD	IC	InChI=1S/C28H31N5O/c29-27-26-25(22-9-6-10-24(15-22)34-18-20-7-2-1-3-8-20)17-33(28(26)31-19-30-27)23-13-21(14-23)16-32-11-4-5-12-32/h1-3,6-10,15,17,19,21,23H,4-5,11-14,16,18H2,(H2,29,30,31)
DMXL3CD	CS	C1CCN(C1)CC2CC(C2)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC=C5)OCC6=CC=CC=C6
DMXL3CD	IK	LSFLAQVDISHMNB-UHFFFAOYSA-N
DMXL3CD	IU	5-(3-phenylmethoxyphenyl)-7-[3-(pyrrolidin-1-ylmethyl)cyclobutyl]pyrrolo[2,3-d]pyrimidin-4-amine
DMXL3CD	CA	CAS 475488-23-4
DMXL3CD	DE	Multiple myeloma

DMOV0QT	ID	DMOV0QT
DMOV0QT	DN	NVP-PDF386
DMOV0QT	HS	Investigative
DMOV0QT	DE	Discovery agent

DMN90R6	ID	DMN90R6
DMN90R6	DN	NVP-SAA164
DMN90R6	HS	Investigative
DMN90R6	SN	Bradykinin B1 receptor antagonists (inflammatory pain); Bradykinin B1 receptor antagonists (inflammatory pain), Novartis
DMN90R6	CP	Novartis AG
DMN90R6	DT	Small molecular drug
DMN90R6	PC	9831083
DMN90R6	MW	659.8
DMN90R6	FM	C36H45N5O5S
DMN90R6	IC	InChI=1S/C36H45N5O5S/c1-38-18-20-39(21-19-38)35(42)30-14-16-41(17-15-30)47(44,45)31-12-13-34(32(26-31)36(43)40-22-24-46-25-23-40)37-27-33(28-8-4-2-5-9-28)29-10-6-3-7-11-29/h2-13,26,30,33,37H,14-25,27H2,1H3
DMN90R6	CS	CN1CCN(CC1)C(=O)C2CCN(CC2)S(=O)(=O)C3=CC(=C(C=C3)NCC(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)N6CCOCC6
DMN90R6	IK	VODUCDWVPSEMSZ-UHFFFAOYSA-N
DMN90R6	IU	[1-[4-(2,2-diphenylethylamino)-3-(morpholine-4-carbonyl)phenyl]sulfonylpiperidin-4-yl]-(4-methylpiperazin-1-yl)methanone
DMN90R6	DE	Pain

DMFZXI2	ID	DMFZXI2
DMFZXI2	DN	NVP-TAE684
DMFZXI2	HS	Investigative
DMFZXI2	SN	761439-42-3; NVP-TAE684; NVP-TAE 684; TAE684; TAE-684; 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; TAE684 (NVP-TAE684); TAE 684; UNII-EH1713MN4K; CHEMBL509032; EH1713MN4K; 5-Chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-2,4-pyrimidinediamine; C30H40ClN7O3S
DMFZXI2	DT	Small molecular drug
DMFZXI2	PC	16038120
DMFZXI2	MW	614.2
DMFZXI2	FM	C30H40ClN7O3S
DMFZXI2	IC	InChI=1S/C30H40ClN7O3S/c1-21(2)42(39,40)28-8-6-5-7-26(28)33-29-24(31)20-32-30(35-29)34-25-10-9-23(19-27(25)41-4)37-13-11-22(12-14-37)38-17-15-36(3)16-18-38/h5-10,19-22H,11-18H2,1-4H3,(H2,32,33,34,35)
DMFZXI2	CS	CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC
DMFZXI2	IK	QQWUGDVOUVUTOY-UHFFFAOYSA-N
DMFZXI2	IU	5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
DMFZXI2	CA	CAS 761439-42-3
DMFZXI2	CB	CHEBI:91338
DMFZXI2	DE	Lymphoma

DMBQRA8	ID	DMBQRA8
DMBQRA8	DN	NVX-207
DMBQRA8	HS	Investigative
DMBQRA8	SN	Sterol analog (anticancer), Novelix
DMBQRA8	CP	University of Southern California
DMBQRA8	PC	9960374
DMBQRA8	MW	601.9
DMBQRA8	FM	C36H59NO6
DMBQRA8	IC	InChI=1S/C36H59NO6/c1-22(2)24-11-16-36(30(41)42-21-35(37,19-38)20-39)18-17-33(7)25(29(24)36)9-10-27-32(6)14-13-28(43-23(3)40)31(4,5)26(32)12-15-34(27,33)8/h24-29,38-39H,1,9-21,37H2,2-8H3/t24-,25+,26-,27+,28-,29+,32-,33+,34+,36-/m0/s1
DMBQRA8	CS	CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)C)C)C(=O)OCC(CO)(CO)N
DMBQRA8	IK	KQZVSTAVTJCKDG-DRSBITMPSA-N
DMBQRA8	IU	[2-amino-3-hydroxy-2-(hydroxymethyl)propyl] (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylate
DMBQRA8	DE	Solid tumour/cancer

DMRYBK6	ID	DMRYBK6
DMRYBK6	DN	NW-1772
DMRYBK6	HS	Investigative
DMRYBK6	SN	Monoamine oxidase B inhibitors (neurodegenerative disease), Newron; MAO-B inhibitors (neurodegenerative disease), Newron
DMRYBK6	CP	Newron Pharmaceuticals SpA
DMRYBK6	DE	Neurodegenerative disorder

DM9VISB	ID	DM9VISB
DM9VISB	DN	O-1602
DM9VISB	HS	Investigative
DM9VISB	SN	O 1602
DM9VISB	DT	Small molecular drug
DM9VISB	PC	45073499
DM9VISB	MW	258.35
DM9VISB	FM	C17H22O2
DM9VISB	IC	InChI=1S/C17H22O2/c1-10(2)14-6-5-11(3)7-15(14)17-12(4)8-13(18)9-16(17)19/h7-9,14-15,18-19H,1,5-6H2,2-4H3/t14-,15+/m0/s1
DM9VISB	CS	CC1=C[C@H]([C@@H](CC1)C(=C)C)C2=C(C=C(C=C2C)O)O
DM9VISB	IK	KDZOUSULXZNDJH-LSDHHAIUSA-N
DM9VISB	IU	5-methyl-4-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol
DM9VISB	CA	CAS 317321-41-8
DM9VISB	DE	Discovery agent

DMCXMQJ	ID	DMCXMQJ
DMCXMQJ	DN	O-1812
DMCXMQJ	HS	Investigative
DMCXMQJ	SN	O1812
DMCXMQJ	DT	Small molecular drug
DMCXMQJ	PC	9823107
DMCXMQJ	MW	414.6
DMCXMQJ	FM	C26H42N2O2
DMCXMQJ	IC	InChI=1S/C26H42N2O2/c1-24(23-29)28-25(30)19-15-12-10-8-6-4-5-7-9-11-13-16-20-26(2,3)21-17-14-18-22-27/h4-5,8-11,16,20,24,29H,6-7,12-15,17-19,21,23H2,1-3H3,(H,28,30)/b5-4-,10-8-,11-9-,20-16-/t24-/m1/s1
DMCXMQJ	CS	C[C@H](CO)NC(=O)CCC/C=C\\C/C=C\\C/C=C\\C/C=C\\C(C)(C)CCCCC#N
DMCXMQJ	IK	WZQHSBKOWZOASP-QLZKPENWSA-N
DMCXMQJ	IU	(5Z,8Z,11Z,14Z)-20-cyano-N-[(2R)-1-hydroxypropan-2-yl]-16,16-dimethylicosa-5,8,11,14-tetraenamide
DMCXMQJ	CA	CAS 342882-77-3
DMCXMQJ	DE	Discovery agent

DMK8AGF	ID	DMK8AGF
DMK8AGF	DN	O-2442
DMK8AGF	HS	Investigative
DMK8AGF	SN	DAT specific inhibitors, Organix; Dopamine transporter modulator, Organix; O-2443; O-2642; O-506; O-509
DMK8AGF	CP	Organix Inc
DMK8AGF	DE	Cocaine addiction

DME78MS	ID	DME78MS
DME78MS	DN	O2-Sulfo-Glucuronic Acid
DME78MS	HS	Investigative
DME78MS	SN	IDS
DME78MS	DT	Small molecular drug
DME78MS	PC	46936333
DME78MS	MW	274.2
DME78MS	FM	C6H10O10S
DME78MS	IC	InChI=1S/C6H10O10S/c7-1-2(8)4(16-17(12,13)14)6(11)15-3(1)5(9)10/h1-4,6-8,11H,(H,9,10)(H,12,13,14)/t1-,2-,3-,4+,6+/m1/s1
DME78MS	CS	[C@H]1([C@H]([C@@H](O[C@@H]([C@H]1OS(=O)(=O)O)O)C(=O)O)O)O
DME78MS	IK	COJBCAMFZDFGFK-SZXBDDMQSA-N
DME78MS	IU	(2R,3R,4R,5S,6S)-3,4,6-trihydroxy-5-sulfooxyoxane-2-carboxylic acid
DME78MS	DE	Discovery agent

DMKMH2X	ID	DMKMH2X
DMKMH2X	DN	O5-Acetyl-O7-nitrooxyethyl chrysin
DMKMH2X	HS	Investigative
DMKMH2X	SN	CHEMBL1099063; O5-Acetyl-O7-nitrooxyethyl chrysin; 1227681-47-1; DTXSID50677009; BDBM50318058; 7-[2-(Nitrooxy)ethoxy]-4-oxo-2-phenyl-4H-1-benzopyran-5-yl acetate
DMKMH2X	DT	Small molecular drug
DMKMH2X	PC	46887248
DMKMH2X	MW	385.3
DMKMH2X	FM	C19H15NO8
DMKMH2X	IC	InChI=1S/C19H15NO8/c1-12(21)27-17-9-14(25-7-8-26-20(23)24)10-18-19(17)15(22)11-16(28-18)13-5-3-2-4-6-13/h2-6,9-11H,7-8H2,1H3
DMKMH2X	CS	CC(=O)OC1=CC(=CC2=C1C(=O)C=C(O2)C3=CC=CC=C3)OCCO[N+](=O)[O-]
DMKMH2X	IK	VQDIDXYXZUUTEY-UHFFFAOYSA-N
DMKMH2X	IU	[7-(2-nitrooxyethoxy)-4-oxo-2-phenylchromen-5-yl] acetate
DMKMH2X	CA	CAS 1227681-47-1
DMKMH2X	DE	Discovery agent

DMAUDCW	ID	DMAUDCW
DMAUDCW	DN	O7-Nitrooxyethyl chrysin
DMAUDCW	HS	Investigative
DMAUDCW	SN	CHEMBL459374; O7-Nitrooxyethyl chrysin; 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)ethyl nitrate; 1141487-91-3; DTXSID00659597; BDBM50318055; 2-[(5-Hydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy]ethyl nitrate
DMAUDCW	DT	Small molecular drug
DMAUDCW	PC	44590927
DMAUDCW	MW	343.29
DMAUDCW	FM	C17H13NO7
DMAUDCW	IC	InChI=1S/C17H13NO7/c19-13-8-12(23-6-7-24-18(21)22)9-16-17(13)14(20)10-15(25-16)11-4-2-1-3-5-11/h1-5,8-10,19H,6-7H2
DMAUDCW	CS	C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)OCCO[N+](=O)[O-])O
DMAUDCW	IK	NLJRSLKTBHDLMH-UHFFFAOYSA-N
DMAUDCW	IU	2-(5-hydroxy-4-oxo-2-phenylchromen-7-yl)oxyethyl nitrate
DMAUDCW	CA	CAS 1141487-91-3
DMAUDCW	DE	Discovery agent

DM458IH	ID	DM458IH
DM458IH	DN	OAADPR
DM458IH	HS	Investigative
DM458IH	SN	AC1MMT9E; 2'-O-acetyl-ADP-ribose; 2''-O-acetyl-ADP-D-ribose; OAADPr
DM458IH	DT	Small molecular drug
DM458IH	PC	72193709
DM458IH	MW	601.4
DM458IH	FM	C17H25N5O15P2
DM458IH	IC	InChI=1S/C17H25N5O15P2/c1-6(23)34-13-11(25)8(36-17(13)27)3-33-39(30,31)37-38(28,29)32-2-7-10(24)12(26)16(35-7)22-5-21-9-14(18)19-4-20-15(9)22/h4-5,7-8,10-13,16-17,24-27H,2-3H2,1H3,(H,28,29)(H,30,31)(H2,18,19,20)/t7-,8-,10-,11-,12-,13-,16-,17?/m1/s1
DM458IH	CS	CC(=O)O[C@@H]1[C@@H]([C@H](OC1O)COP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)O)O
DM458IH	IK	BFNOPXRXIQJDHO-YDKGJHSESA-N
DM458IH	IU	[(3R,4R,5R)-5-[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-2,4-dihydroxyoxolan-3-yl] acetate
DM458IH	CB	CHEBI:76279
DM458IH	DE	Discovery agent

DMAEHFT	ID	DMAEHFT
DMAEHFT	DN	O-Acetylserine
DMAEHFT	HS	Investigative
DMAEHFT	SN	O-acetyl-L-serine; O-acetylserine; 5147-00-2; (S)-3-Acetoxy-2-aminopropanoic acid; O3-acetyl-L-serine; O-AC-L-Ser-OH; L-Serine, acetate (ester); acetylserine; Serine, O-acetyl-; Poly-O-acetylserine; (2S)-3-acetoxy-2-ammoniopropanoate; (2S)-3-acetoxy-2-azaniumylpropanoate; Poly-O-acetyl-L-serine; o-acetyl-serine; O-acetyl-l-ser; OAS; NSC 226230; L-Serine, O-acetyl-; bmse000983; AC1L40XB; SCHEMBL598363; AC1Q60A2; CHEBI:17981; CTK1H1469; VZXPDPZARILFQX-BYPYZUCNSA-N; MolPort-001-762-455; ZINC895446; 7170AB; ANW-60944; FCH833665
DMAEHFT	DT	Small molecular drug
DMAEHFT	PC	99478
DMAEHFT	MW	147.13
DMAEHFT	FM	C5H9NO4
DMAEHFT	IC	InChI=1S/C5H9NO4/c1-3(7)10-2-4(6)5(8)9/h4H,2,6H2,1H3,(H,8,9)/t4-/m0/s1
DMAEHFT	CS	CC(=O)OC[C@@H](C(=O)O)N
DMAEHFT	IK	VZXPDPZARILFQX-BYPYZUCNSA-N
DMAEHFT	IU	(2S)-3-acetyloxy-2-aminopropanoic acid
DMAEHFT	CA	CAS 5147-00-2
DMAEHFT	CB	CHEBI:17981
DMAEHFT	DE	Discovery agent

DMOP8IJ	ID	DMOP8IJ
DMOP8IJ	DN	OAG
DMOP8IJ	HS	Investigative
DMOP8IJ	SN	1-oleoyl-2-acetyl-sn-glycerol
DMOP8IJ	DT	Small molecular drug
DMOP8IJ	PC	5353264
DMOP8IJ	MW	398.6
DMOP8IJ	FM	C23H42O5
DMOP8IJ	IC	InChI=1S/C23H42O5/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(26)27-20-22(19-24)28-21(2)25/h10-11,22,24H,3-9,12-20H2,1-2H3/b11-10+
DMOP8IJ	CS	CCCCCCCC/C=C/CCCCCCCC(=O)OCC(CO)OC(=O)C
DMOP8IJ	IK	PWTCCMJTPHCGMS-ZHACJKMWSA-N
DMOP8IJ	IU	(2-acetyloxy-3-hydroxypropyl) (E)-octadec-9-enoate
DMOP8IJ	DE	Discovery agent

DML0P72	ID	DML0P72
DML0P72	DN	O-arachidonoyl ethanolamine
DML0P72	HS	Investigative
DML0P72	SN	Virodhamine
DML0P72	DT	Small molecular drug
DML0P72	PC	5712057
DML0P72	MW	347.5
DML0P72	FM	C22H37NO2
DML0P72	IC	InChI=1S/C22H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(24)25-21-20-23/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21,23H2,1H3/b7-6-,10-9-,13-12-,16-15-
DML0P72	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)OCCN
DML0P72	IK	DLHLOYYQQGSXCC-DOFZRALJSA-N
DML0P72	IU	2-aminoethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
DML0P72	CA	CAS 287937-12-6
DML0P72	DE	Discovery agent

DMWZXH6	ID	DMWZXH6
DMWZXH6	DN	O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMWZXH6	HS	Investigative
DMWZXH6	SN	CHEMBL203380; O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMWZXH6	DT	Small molecular drug
DMWZXH6	PC	11508826
DMWZXH6	MW	363.5
DMWZXH6	FM	C22H37NO3
DMWZXH6	IC	InChI=1S/C22H37NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)26-23-20-21-24/h6-7,9-10,12-13,15-16,23-24H,2-5,8,11,14,17-21H2,1H3/b7-6-,10-9-,13-12-,16-15-
DMWZXH6	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)ONCCO
DMWZXH6	IK	XNXCXJJVMFVWDO-DOFZRALJSA-N
DMWZXH6	IU	(2-hydroxyethylamino) (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
DMWZXH6	DE	Discovery agent

DMY4PMN	ID	DMY4PMN
DMY4PMN	DN	OBABERINE
DMY4PMN	HS	Investigative
DMY4PMN	SN	OBABERINE; (+)-obaberine; CHEMBL464525; 1263-80-5; AC1L2OCJ; CHEBI:7712; Oxyacanthan, 6,6'7,12'-tetramethoxy-2,2'-dimethyl-; NSC 269190; DTXSID50155135; CHEBI:543003; BDBM50241642
DMY4PMN	DT	Small molecular drug
DMY4PMN	PC	100231
DMY4PMN	MW	622.7
DMY4PMN	FM	C38H42N2O6
DMY4PMN	IC	InChI=1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)18-24-9-12-31(41-3)33(19-24)45-27-10-7-23(8-11-27)17-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29-,30+/m1/s1
DMY4PMN	CS	CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=CC(=C(C=C7CCN6C)OC)O3)OC)OC)OC
DMY4PMN	IK	FBCXFKWMGIWMJQ-IHLOFXLRSA-N
DMY4PMN	IU	(1R,14S)-6,20,21,25-tetramethoxy-15,30-dimethyl-8,23-dioxa-15,30-diazaheptacyclo[22.6.2.29,12.13,7.114,18.027,31.022,33]hexatriaconta-3(36),4,6,9(35),10,12(34),18,20,22(33),24,26,31-dodecaene
DMY4PMN	CA	CAS 1263-80-5
DMY4PMN	CB	CHEBI:7712
DMY4PMN	DE	Discovery agent

DMD25HJ	ID	DMD25HJ
DMD25HJ	DN	O-Benzylsulfonyl-Serine
DMD25HJ	HS	Investigative
DMD25HJ	SN	AC1MNK8J; SCHEMBL4313869; 2-amino-3-benzylsulfonyloxypropanoic acid
DMD25HJ	DT	Small molecular drug
DMD25HJ	PC	17754162
DMD25HJ	MW	259.279
DMD25HJ	FM	C10H13NO5S
DMD25HJ	IC	InChI=1S/C10H13NO5S/c11-9(10(12)13)6-16-17(14,15)7-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)/t9-/m0/s1
DMD25HJ	CS	C1=CC=C(C=C1)CS(=O)(=O)OC[C@@H](C(=O)O)N
DMD25HJ	IK	GCZVEKLTOLTWLM-VIFPVBQESA-N
DMD25HJ	IU	(2S)-2-amino-3-benzylsulfonyloxypropanoic acid
DMD25HJ	DE	Discovery agent

DMM98BC	ID	DMM98BC
DMM98BC	DN	OBIDOXIME
DMM98BC	HS	Investigative
DMM98BC	DT	Small molecular drug
DMM98BC	PC	135412781
DMM98BC	MW	288.3
DMM98BC	FM	C14H16N4O3+2
DMM98BC	IC	InChI=1S/C14H14N4O3/c19-15-9-13-1-5-17(6-2-13)11-21-12-18-7-3-14(4-8-18)10-16-20/h1-10H,11-12H2/p+2
DMM98BC	CS	C1=C[N+](=CC=C1/C=N/O)COC[N+]2=CC=C(C=C2)/C=N/O
DMM98BC	IK	HIGRLDNHDGYWQJ-UHFFFAOYSA-P
DMM98BC	IU	(NE)-N-[[1-[[4-[(E)-hydroxyiminomethyl]pyridin-1-ium-1-yl]methoxymethyl]pyridin-1-ium-4-yl]methylidene]hydroxylamine
DMM98BC	CA	CAS 7683-36-5
DMM98BC	DE	Discovery agent

DMA63FQ	ID	DMA63FQ
DMA63FQ	DN	Obtusifoldienol
DMA63FQ	HS	Investigative
DMA63FQ	SN	Ebericol; Eburicol; 24-Methylenedihydrolanosterol; Q27138657; SCHEMBL4169147; XJLZCPIILZRCPS-ANMPWZFDSA-N; ZINC5440303; (3beta)-24-methylidenelanost-8-en-3-ol; 24-Methylene-24,25-dihydrolanosterol; 24-Methylenelanost-8-en-3-ol #; 24-Methylenelanost-8-en-3beta-ol; 24-Methylenelanostenol; 24-methylene-24-dihydrolanosterol; 24-methylidenelanost-8-en-3beta-ol; 6890-88-6; CHEBI:70315; Lanost-8-en-3-ol, 24-methylene-, (3.beta.)-; Lanost-8-en-3.beta.-ol, 24-methylene-; W2396
DMA63FQ	PC	9803310
DMA63FQ	MW	440.7
DMA63FQ	FM	C31H52O
DMA63FQ	IC	XJLZCPIILZRCPS-ANMPWZFDSA-N
DMA63FQ	CS	CC(C)C(=C)CCC(C)C1CCC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)O)C)C)C
DMA63FQ	IK	1S/C31H52O/c1-20(2)21(3)10-11-22(4)23-14-18-31(9)25-12-13-26-28(5,6)27(32)16-17-29(26,7)24(25)15-19-30(23,31)8/h20,22-23,26-27,32H,3,10-19H2,1-2,4-9H3/t22-,23-,26+,27+,29-,30-,31+/m1/s1
DMA63FQ	IU	(3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DMA63FQ	CA	CAS 6890-88-6
DMA63FQ	CB	CHEBI:70315
DMA63FQ	DE	Discovery agent

DMGVDR6	ID	DMGVDR6
DMGVDR6	DN	Ochnaflavone
DMGVDR6	HS	Investigative
DMGVDR6	SN	Ochnaflavone; 50276-96-5; Ochnaflavone7-O-beta-D-gluco-pyranoside; AC1NUSW2; SCHEMBL13829452; DTXSID70198281; ZINC28462577; 6882AB; AKOS016010710; AK120364; KB-282683; AX8245780; 4CH-024764; 2-[4-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenoxy]phenyl]-5,7-dihydroxychromen-4-one; 2-{4-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenoxy]phenyl}-5,7-dihydroxy-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2-(4-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenoxy)phenyl)-5,7-dihydroxy-
DMGVDR6	DT	Small molecular drug
DMGVDR6	PC	5492110
DMGVDR6	MW	538.5
DMGVDR6	FM	C30H18O10
DMGVDR6	IC	InChI=1S/C30H18O10/c31-16-8-20(34)29-22(36)12-24(39-27(29)10-16)14-1-4-18(5-2-14)38-26-7-15(3-6-19(26)33)25-13-23(37)30-21(35)9-17(32)11-28(30)40-25/h1-13,31-35H
DMGVDR6	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)OC4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)O
DMGVDR6	IK	NNPGECDACGBKDH-UHFFFAOYSA-N
DMGVDR6	IU	2-[4-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenoxy]phenyl]-5,7-dihydroxychromen-4-one
DMGVDR6	CA	CAS 50276-96-5
DMGVDR6	DE	Discovery agent

DM69O3S	ID	DM69O3S
DM69O3S	DN	OCID-2987
DM69O3S	HS	Investigative
DM69O3S	SN	PDE IV inhibitor (inflammation); PDE IV inhibitor (inflammation), Orchid; Phosphodiesterase IV inhibitor (inflammation), Orchid
DM69O3S	CP	Orchid Chemicals & Pharmaceuticals Ltd
DM69O3S	DE	Inflammation

DMT59UG	ID	DMT59UG
DMT59UG	DN	OCOPHYLLALS A
DMT59UG	HS	Investigative
DMT59UG	SN	Ocophyllals A; CHEMBL571616; BDBM50303152
DMT59UG	DT	Small molecular drug
DMT59UG	PC	44470605
DMT59UG	MW	310.3
DMT59UG	FM	C18H14O5
DMT59UG	IC	InChI=1S/C18H14O5/c1-10-13-5-11(8-19)6-16(20-2)18(13)23-17(10)12-3-4-14-15(7-12)22-9-21-14/h3-8H,9H2,1-2H3
DMT59UG	CS	CC1=C(OC2=C1C=C(C=C2OC)C=O)C3=CC4=C(C=C3)OCO4
DMT59UG	IK	HCCYBFOBGKSPJH-UHFFFAOYSA-N
DMT59UG	IU	2-(1,3-benzodioxol-5-yl)-7-methoxy-3-methyl-1-benzofuran-5-carbaldehyde
DMT59UG	DE	Discovery agent

DMEUPVF	ID	DMEUPVF
DMEUPVF	DN	Ocophyllals b
DMEUPVF	HS	Investigative
DMEUPVF	SN	Ocophyllals B; CHEMBL571617; BDBM50303153
DMEUPVF	DT	Small molecular drug
DMEUPVF	PC	44470606
DMEUPVF	MW	356.4
DMEUPVF	FM	C20H20O6
DMEUPVF	IC	InChI=1S/C20H20O6/c1-11-14-6-12(10-21)7-15(22-2)19(14)26-18(11)13-8-16(23-3)20(25-5)17(9-13)24-4/h6-10H,1-5H3
DMEUPVF	CS	CC1=C(OC2=C1C=C(C=C2OC)C=O)C3=CC(=C(C(=C3)OC)OC)OC
DMEUPVF	IK	ABGNFLATGXMICB-UHFFFAOYSA-N
DMEUPVF	IU	7-methoxy-3-methyl-2-(3,4,5-trimethoxyphenyl)-1-benzofuran-5-carbaldehyde
DMEUPVF	DE	Discovery agent

DMUFDR6	ID	DMUFDR6
DMUFDR6	DN	Octahydrocurcumin
DMUFDR6	HS	Investigative
DMUFDR6	SN	36062-07-4; 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-diol; SCHEMBL645293; MEGxp0_001209; MEGxp0_001210; (3S,5S)-1,7-BIS(4-HYDROXY-3-METHOXYPHENYL)HEPTANE-3,5-DIOL; CHEMBL1087517; ACon1_001058; ACon1_001138; DTXSID40873750; HY-N0894; MFCD25371921; AKOS030526791; CS-3740; NCGC00169640-01; NCGC00169640-02; 1,7-Bis(3-methoxy-4-hydroxyphenyl)heptane-3,5-diol; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol; BRD-A35096796-001-01-0; BRD-A35096796-001-02-8; 3,5-dihydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)heptane
DMUFDR6	DT	Small molecular drug
DMUFDR6	PC	11068834
DMUFDR6	MW	376.4
DMUFDR6	FM	C21H28O6
DMUFDR6	IC	InChI=1S/C21H28O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h5-6,9-12,16-17,22-25H,3-4,7-8,13H2,1-2H3
DMUFDR6	CS	COC1=C(C=CC(=C1)CCC(CC(CCC2=CC(=C(C=C2)O)OC)O)O)O
DMUFDR6	IK	OELMAFBLFOKZJD-UHFFFAOYSA-N
DMUFDR6	IU	1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-diol
DMUFDR6	CA	CAS 36062-07-4
DMUFDR6	DE	Solid tumour/cancer

DM4C70S	ID	DM4C70S
DM4C70S	DN	Octahydro-isoindol-(1Z)-ylideneamine
DM4C70S	HS	Investigative
DM4C70S	SN	CHEMBL185441; Octahydro-isoindol-(1Z)-ylideneamine; SCHEMBL9117580; BDBM50150929
DM4C70S	DT	Small molecular drug
DM4C70S	PC	18428457
DM4C70S	MW	138.21
DM4C70S	FM	C8H14N2
DM4C70S	IC	InChI=1S/C8H14N2/c9-8-7-4-2-1-3-6(7)5-10-8/h6-7H,1-5H2,(H2,9,10)
DM4C70S	CS	C1CCC2C(C1)CN=C2N
DM4C70S	IK	VVYRMIBCBFMCJN-UHFFFAOYSA-N
DM4C70S	IU	3a,4,5,6,7,7a-hexahydro-3H-isoindol-1-amine
DM4C70S	DE	Discovery agent

DMTN0OK	ID	DMTN0OK
DMTN0OK	DN	Octanal
DMTN0OK	HS	Investigative
DMTN0OK	SN	ALDEHIDO C-8; Aldehyde C-8; Aldehyde C8; Antifoam-LF; Caprylaldehyd; Caprylaldehyde; Caprylic aldehyde; Kaprylaldehyd; OCTYLALDEHYDE; Octaldehyde; Octanal; Octanal (natural); Octanal, tech.; Octanaldehyde; Octanoic aldehyde; Octyl aldehyde; Octyl aldehydes; Octylaldehyd; Oktanal; Oktylaldehyd; n-Caprylaldehyde; n-Octaldehyde; n-Octanal; n-Octanaldehyde; n-Octyl aldehyde; n-Octylal; 1-Caprylaldehyde; 1-Octaldehyde; 1-Octylaldehyde; 1-octanal; 124-13-0; C-8 aldehyde; FEMA No. 2797; HSDB 5147; MFCD00007029; NSC 1508; UNII-XGE9999H19
DMTN0OK	PC	454
DMTN0OK	MW	128.21
DMTN0OK	FM	C8H16O
DMTN0OK	IC	NUJGJRNETVAIRJ-UHFFFAOYSA-N
DMTN0OK	CS	CCCCCCCC=O
DMTN0OK	IK	1S/C8H16O/c1-2-3-4-5-6-7-8-9/h8H,2-7H2,1H3
DMTN0OK	IU	octanal
DMTN0OK	CA	CAS 124-13-0
DMTN0OK	CB	CHEBI:17935
DMTN0OK	DE	Discovery agent

DMBQMGH	ID	DMBQMGH
DMBQMGH	DN	Octane-1,8-diyl disulfamate
DMBQMGH	HS	Investigative
DMBQMGH	SN	Octane-1,8-Diyl Disulfamate; CHEMBL182455; 3ibl; bis-sulfamate, 3; 1,8-Octanediol disulfamate; SCHEMBL10352171; BDBM33281; IPTXSYCLIWBHBX-UHFFFAOYSA-N; 1,8-bis-O-sulfamyl-1,8-octanediol
DMBQMGH	DT	Small molecular drug
DMBQMGH	PC	20043772
DMBQMGH	MW	304.4
DMBQMGH	FM	C8H20N2O6S2
DMBQMGH	IC	InChI=1S/C8H20N2O6S2/c9-17(11,12)15-7-5-3-1-2-4-6-8-16-18(10,13)14/h1-8H2,(H2,9,11,12)(H2,10,13,14)
DMBQMGH	CS	C(CCCCOS(=O)(=O)N)CCCOS(=O)(=O)N
DMBQMGH	IK	IPTXSYCLIWBHBX-UHFFFAOYSA-N
DMBQMGH	IU	8-sulfamoyloxyoctyl sulfamate
DMBQMGH	DE	Discovery agent

DMDBI5S	ID	DMDBI5S
DMDBI5S	DN	Octane-1-sulfonyl fluoride
DMDBI5S	HS	Investigative
DMDBI5S	SN	octane-1-sulfonyl fluoride; 1-Octanesulfonyl fluoride; 40630-63-5; octanesulfonyl fluoride; 1-Octanesulphonyl fluoride; UNII-8G6E848M0E; EINECS 255-012-0; CHEMBL499569; 8G6E848M0E; n-octane-sulfonyl fluoride; N-octanesulfonylfluoride; AC1Q4OYH; AC1L4QJC; SCHEMBL678663; DTXSID3028009; CTK4I3469; BDBM50247008; ACM40630635
DMDBI5S	DT	Small molecular drug
DMDBI5S	PC	162019
DMDBI5S	MW	196.29
DMDBI5S	FM	C8H17FO2S
DMDBI5S	IC	InChI=1S/C8H17FO2S/c1-2-3-4-5-6-7-8-12(9,10)11/h2-8H2,1H3
DMDBI5S	CS	CCCCCCCCS(=O)(=O)F
DMDBI5S	IK	HMRWGKIZOBXNRB-UHFFFAOYSA-N
DMDBI5S	IU	octane-1-sulfonyl fluoride
DMDBI5S	CA	CAS 40630-63-5
DMDBI5S	DE	Discovery agent

DMJNQ9K	ID	DMJNQ9K
DMJNQ9K	DN	Octanedioic acid bis-hydroxyamide
DMJNQ9K	HS	Investigative
DMJNQ9K	SN	Suberohydroxamic acid
DMJNQ9K	DT	Small molecular drug
DMJNQ9K	PC	5173
DMJNQ9K	MW	204.22
DMJNQ9K	FM	C8H16N2O4
DMJNQ9K	IC	InChI=1S/C8H16N2O4/c11-7(9-13)5-3-1-2-4-6-8(12)10-14/h13-14H,1-6H2,(H,9,11)(H,10,12)
DMJNQ9K	CS	C(CCCC(=O)NO)CCC(=O)NO
DMJNQ9K	IK	IDQPVOFTURLJPT-UHFFFAOYSA-N
DMJNQ9K	IU	N,N'-dihydroxyoctanediamide
DMJNQ9K	CB	CHEBI:125584
DMJNQ9K	DE	Discovery agent

DMHNWS1	ID	DMHNWS1
DMHNWS1	DN	Octanedioic acid hydroxyamide pyridin-2-ylamide
DMHNWS1	HS	Investigative
DMHNWS1	SN	Octanedioic acid hydroxyamide pyridin-2-ylamide; SCHEMBL8090513; CHEMBL164872; ZINC13472303
DMHNWS1	DT	Small molecular drug
DMHNWS1	PC	11747496
DMHNWS1	MW	265.31
DMHNWS1	FM	C13H19N3O3
DMHNWS1	IC	InChI=1S/C13H19N3O3/c17-12(15-11-7-5-6-10-14-11)8-3-1-2-4-9-13(18)16-19/h5-7,10,19H,1-4,8-9H2,(H,16,18)(H,14,15,17)
DMHNWS1	CS	C1=CC=NC(=C1)NC(=O)CCCCCCC(=O)NO
DMHNWS1	IK	UVYVSYPVDVIKCC-UHFFFAOYSA-N
DMHNWS1	IU	N'-hydroxy-N-pyridin-2-yloctanediamide
DMHNWS1	DE	Discovery agent

DM945RK	ID	DM945RK
DM945RK	DN	Octanedioic acid hydroxyamide pyridin-4-ylamide
DM945RK	HS	Investigative
DM945RK	SN	Octanedioic acid hydroxyamide pyridin-4-ylamide; SCHEMBL8082656; CHEMBL165162; ZINC13472304
DM945RK	DT	Small molecular drug
DM945RK	PC	10967421
DM945RK	MW	265.31
DM945RK	FM	C13H19N3O3
DM945RK	IC	InChI=1S/C13H19N3O3/c17-12(15-11-7-9-14-10-8-11)5-3-1-2-4-6-13(18)16-19/h7-10,19H,1-6H2,(H,16,18)(H,14,15,17)
DM945RK	CS	C1=CN=CC=C1NC(=O)CCCCCCC(=O)NO
DM945RK	IK	RJMOPRKLNDSPIG-UHFFFAOYSA-N
DM945RK	IU	N'-hydroxy-N-pyridin-4-yloctanediamide
DM945RK	DE	Discovery agent

DM4RGCX	ID	DM4RGCX
DM4RGCX	DN	Octanoic acid biphenyl-2-ylamide
DM4RGCX	HS	Investigative
DM4RGCX	SN	CHEMBL408322; octanoic acid biphenyl-2-ylamide; SCHEMBL15472053
DM4RGCX	DT	Small molecular drug
DM4RGCX	PC	24806280
DM4RGCX	MW	295.4
DM4RGCX	FM	C20H25NO
DM4RGCX	IC	InChI=1S/C20H25NO/c1-2-3-4-5-9-16-20(22)21-19-15-11-10-14-18(19)17-12-7-6-8-13-17/h6-8,10-15H,2-5,9,16H2,1H3,(H,21,22)
DM4RGCX	CS	CCCCCCCC(=O)NC1=CC=CC=C1C2=CC=CC=C2
DM4RGCX	IK	CLTPDJWVYAJEKC-UHFFFAOYSA-N
DM4RGCX	IU	N-(2-phenylphenyl)octanamide
DM4RGCX	DE	Discovery agent

DMBGHPE	ID	DMBGHPE
DMBGHPE	DN	Octanol
DMBGHPE	HS	Investigative
DMBGHPE	SN	1-octanol; Octan-1-ol; octanol; 111-87-5; N-octanol; Capryl alcohol; Octyl alcohol; caprylic alcohol; n-Octyl alcohol; Heptyl carbinol; 1-Hydroxyoctane; Primary octyl alcohol; Alcohol C-8; n-Octan-1-ol; Octilin; Sipol L8; Alfol 8; Lorol 20; Dytol M-83; n-Caprylic alcohol; 1-Octyl alcohol; n-Heptyl carbinol; EPAL 8; octyl-alcohol; Alcohols, C6-12; N-octyl-alcohol; Octyl alcohol, normal-primary; C8 alcohol; Fatty alcohol(C8); Octyl alcohol, primary; Caswell No. 611A; Octyl alcohol (natural); FEMA Number 2800; Lorol C 8-98; n-Capryl alcohol
DMBGHPE	DT	Small molecular drug
DMBGHPE	PC	957
DMBGHPE	MW	130.229
DMBGHPE	FM	C8H18O
DMBGHPE	IC	InChI=1S/C8H18O/c1-2-3-4-5-6-7-8-9/h9H,2-8H2,1H3
DMBGHPE	CS	CCCCCCCCO
DMBGHPE	IK	KBPLFHHGFOOTCA-UHFFFAOYSA-N
DMBGHPE	IU	octan-1-ol
DMBGHPE	CA	CAS 111-87-5
DMBGHPE	CB	CHEBI:16188
DMBGHPE	DE	Discovery agent

DM0UADK	ID	DM0UADK
DM0UADK	DN	OCTOCLOTHEPIN
DM0UADK	HS	Investigative
DM0UADK	SN	Clorotepine; Octoclothepin; Octoclothepine; Clotepin; Clothepin; 13448-22-1; Clorotepine [INN]; Clorotepinum [INN-Latin]; Clorotepina [INN-Spanish]; CHEMBL64249; 1-(8-Chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)-4-methylpiperazine; Piperazine, 1-(8-chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)-4-methyl-; clothepine; clorothepin; Clorotepinum; Clorotepina; 1-(8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-4-methylpiperazine; VUFB-6281; Octoclothepin maleate; CLOROTEPINE(-); AC1Q3SXZ; CLOROTEPINE (+); OCTOCLOTHEPIN,(-)
DM0UADK	DT	Small molecular drug
DM0UADK	PC	1238
DM0UADK	MW	344.9
DM0UADK	FM	C19H21ClN2S
DM0UADK	IC	InChI=1S/C19H21ClN2S/c1-21-8-10-22(11-9-21)17-12-14-4-2-3-5-18(14)23-19-7-6-15(20)13-16(17)19/h2-7,13,17H,8-12H2,1H3
DM0UADK	CS	CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl
DM0UADK	IK	XRYLGRGAWQSVQW-UHFFFAOYSA-N
DM0UADK	IU	1-(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)-4-methylpiperazine
DM0UADK	CA	CAS 13448-22-1
DM0UADK	CB	CHEBI:135459
DM0UADK	DE	Discovery agent

DM40ZCA	ID	DM40ZCA
DM40ZCA	DN	Octyl sulfamate
DM40ZCA	HS	Investigative
DM40ZCA	SN	Octyl Sulfamate; CHEMBL24261; 282725-75-1; n-octyl sulfamate; 3ibi; aliphatic sulfamate, 1; Sulfamic acid octyl ester; Sulfamic acid, octyl ester; SCHEMBL3480117; CTK0J2132; BDBM33279; DTXSID80455817
DM40ZCA	DT	Small molecular drug
DM40ZCA	PC	11117301
DM40ZCA	MW	209.31
DM40ZCA	FM	C8H19NO3S
DM40ZCA	IC	InChI=1S/C8H19NO3S/c1-2-3-4-5-6-7-8-12-13(9,10)11/h2-8H2,1H3,(H2,9,10,11)
DM40ZCA	CS	CCCCCCCCOS(=O)(=O)N
DM40ZCA	IK	ZXWAFSSPWCHAJT-UHFFFAOYSA-N
DM40ZCA	IU	octyl sulfamate
DM40ZCA	CA	CAS 282725-75-1
DM40ZCA	DE	Discovery agent

DM2RJYO	ID	DM2RJYO
DM2RJYO	DN	octyl thiophosphatidic acid
DM2RJYO	HS	Investigative
DM2RJYO	SN	CHEMBL427017; octyl thiophosphatidic acid; GTPL6995; BDBM50176398; (S)-O-2,3-bis(octyloxy)propyl O,O-dihydrogen phosphorothioate
DM2RJYO	DT	Small molecular drug
DM2RJYO	PC	44407389
DM2RJYO	MW	412.6
DM2RJYO	FM	C19H41O5PS
DM2RJYO	IC	InChI=1S/C19H41O5PS/c1-3-5-7-9-11-13-15-22-17-19(18-24-25(20,21)26)23-16-14-12-10-8-6-4-2/h19H,3-18H2,1-2H3,(H2,20,21,26)/t19-/m0/s1
DM2RJYO	CS	CCCCCCCCOC[C@@H](COP(=S)(O)O)OCCCCCCCC
DM2RJYO	IK	PLCCQSPJUXGEHV-IBGZPJMESA-N
DM2RJYO	IU	[(2S)-2,3-dioctoxypropoxy]-dihydroxy-sulfanylidene-lambda5-phosphane
DM2RJYO	DE	Discovery agent

DMXLGUS	ID	DMXLGUS
DMXLGUS	DN	OCTYL_GALLATE
DMXLGUS	HS	Investigative
DMXLGUS	SN	Octyl gallate; 1034-01-1; Octyl 3,4,5-trihydroxybenzoate; n-Octyl gallate; Progallin O; Stabilizer GA 8; n-Octylgallate; Gallic acid n-octyl ester; Gallic acid, octyl ester; Gallic acid octyl ester; BENZOIC ACID, 3,4,5-TRIHYDROXY-, OCTYL ESTER; Oktylester kyseliny gallove; GA 8 (VAN); NSC 97419; n-Octyl ester of 3,4,5-trihydroxybenzoic acid; OCTYLGALLATE; UNII-079IIA2811; Oktylester kyseliny gallove [Czech]; EINECS 213-853-0; BRN 2132305; E311; CHEMBL277346; GA 8; CHEBI:83631; NRPKURNSADTHLJ-UHFFFAOYSA-N; 079IIA2811; Gallic acid oct
DMXLGUS	DT	Small molecular drug
DMXLGUS	PC	61253
DMXLGUS	MW	282.33
DMXLGUS	FM	C15H22O5
DMXLGUS	IC	InChI=1S/C15H22O5/c1-2-3-4-5-6-7-8-20-15(19)11-9-12(16)14(18)13(17)10-11/h9-10,16-18H,2-8H2,1H3
DMXLGUS	CS	CCCCCCCCOC(=O)C1=CC(=C(C(=C1)O)O)O
DMXLGUS	IK	NRPKURNSADTHLJ-UHFFFAOYSA-N
DMXLGUS	IU	octyl 3,4,5-trihydroxybenzoate
DMXLGUS	CA	CAS 1034-01-1
DMXLGUS	CB	CHEBI:83631
DMXLGUS	DE	Discovery agent

DM8ZG2I	ID	DM8ZG2I
DM8ZG2I	DN	O-DESMETHYL TRAMADOL
DM8ZG2I	HS	Investigative
DM8ZG2I	SN	O-Desmethyltramadol; O-DESMETHYL TRAMADOL; CHEMBL1400; (-)-O-Desmethyl Tramadol; 80456-81-1; 2-[(Dimethylamino)methyl]-1-(3-hydroxyphenyl)cyclohexanol; CHEMBL201556; O-Demethyl tramadol; tramadol M1 metabolite; Mono-O-demethyltramadol; 144830-15-9; 3-{(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl}phenol; 3-((1R,2R)-2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol; (+)-O-Desmethyltramadol; SCHEMBL2517055; CTK8E8372; UWJUQVWARXYRCG-HIFRSBDPSA-N; ZINC2509756; BDBM50176258; BDBM50176263; Phenol, 3-(2-((dimethylamino)me
DM8ZG2I	DT	Small molecular drug
DM8ZG2I	PC	9838803
DM8ZG2I	MW	249.35
DM8ZG2I	FM	C15H23NO2
DM8ZG2I	IC	InChI=1S/C15H23NO2/c1-16(2)11-13-6-3-4-9-15(13,18)12-7-5-8-14(17)10-12/h5,7-8,10,13,17-18H,3-4,6,9,11H2,1-2H3/t13-,15+/m1/s1
DM8ZG2I	CS	CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)O)O
DM8ZG2I	IK	UWJUQVWARXYRCG-HIFRSBDPSA-N
DM8ZG2I	IU	3-[(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol
DM8ZG2I	CA	CAS 144830-14-8
DM8ZG2I	CB	CHEBI:165221
DM8ZG2I	DE	Discovery agent

DM0GVZO	ID	DM0GVZO
DM0GVZO	DN	ODN-1411
DM0GVZO	HS	Investigative
DM0GVZO	DT	Oligonucleotide
DM0GVZO	DE	Rheumatoid arthritis

DM692XV	ID	DM692XV
DM692XV	DN	ODN-2088
DM692XV	HS	Investigative
DM692XV	DT	Oligonucleotide
DM692XV	DE	Spinal cord injury

DMSAJO8	ID	DMSAJO8
DMSAJO8	DN	ODQ
DMSAJO8	HS	Investigative
DMSAJO8	SN	1h-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; 41443-28-1; ODQ; [1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; UNII-S57V2NMV38; S57V2NMV38; 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; ODQ, 98%; SR-01000075519; 1-H-[1,2,4]Oxadiazolo-[4,3,2]quinoxalin-1-ine; 1H-ODQ; Tocris-0880; AC1L1BIQ; Lopac-O-3636; AC1Q6H5T; Lopac0_000953; SCHEMBL210817; CHEMBL598952; GTPL5234; DTXSID2036796; CTK1D6485; CHEBI:91215; MolPort-003-959-081; HMS3649K18; HMS3262P08; HMS3266N10; KS-000013GE; ZINC2569341; BCP06748; Tox21_500953; GL1507; 1963AH; MFCD00792620; BS0137
DMSAJO8	DT	Small molecular drug
DMSAJO8	PC	1456
DMSAJO8	MW	187.15
DMSAJO8	FM	C9H5N3O2
DMSAJO8	IC	InChI=1S/C9H5N3O2/c13-9-12-7-4-2-1-3-6(7)10-5-8(12)11-14-9/h1-5H
DMSAJO8	CS	C1=CC=C2C(=C1)N=CC3=NOC(=O)N23
DMSAJO8	IK	LZMHWZHOZLVYDL-UHFFFAOYSA-N
DMSAJO8	IU	[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
DMSAJO8	CA	CAS 41443-28-1
DMSAJO8	CB	CHEBI:91215
DMSAJO8	DE	Discovery agent

DMK8LEC	ID	DMK8LEC
DMK8LEC	DN	OF-1
DMK8LEC	HS	Investigative
DMK8LEC	DT	Small molecular drug
DMK8LEC	PC	35397514
DMK8LEC	MW	440.3
DMK8LEC	FM	C17H18BrN3O4S
DMK8LEC	IC	InChI=1S/C17H18BrN3O4S/c1-10-7-11(18)5-6-16(10)26(23,24)19-12-8-13-14(9-15(12)25-4)21(3)17(22)20(13)2/h5-9,19H,1-4H3
DMK8LEC	CS	CC1=C(C=CC(=C1)Br)S(=O)(=O)NC2=CC3=C(C=C2OC)N(C(=O)N3C)C
DMK8LEC	IK	YUNQZQREIHWDQT-UHFFFAOYSA-N
DMK8LEC	IU	4-bromo-N-(6-methoxy-1,3-dimethyl-2-oxobenzimidazol-5-yl)-2-methylbenzenesulfonamide
DMK8LEC	DE	Discovery agent

DM0PMKW	ID	DM0PMKW
DM0PMKW	DN	OG-L002
DM0PMKW	HS	Investigative
DM0PMKW	SN	OG-L002; 1357302-64-7; 4'-((1R,2S)-2-aminocyclopropyl)-[1,1'-biphenyl]-3-ol; SCHEMBL6837351; GTPL7023; OGL002; AOB2070; MolPort-035-395-885; BDBM179446; BCP12278; EX-A2117; s7237; 2610AH; ZINC114026926; AKOS027422749; SB19352; BC600435; 4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol; 3-{4-[(1R,2S)-2-aminocyclopropyl]phenyl}phenol; J-006764; US9676701, 4 4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride
DM0PMKW	DT	Small molecular drug
DM0PMKW	PC	56639570
DM0PMKW	MW	225.28
DM0PMKW	FM	C15H15NO
DM0PMKW	IC	InChI=1S/C15H15NO/c16-15-9-14(15)11-6-4-10(5-7-11)12-2-1-3-13(17)8-12/h1-8,14-15,17H,9,16H2/t14-,15+/m1/s1
DM0PMKW	CS	C1[C@@H]([C@H]1N)C2=CC=C(C=C2)C3=CC(=CC=C3)O
DM0PMKW	IK	DSOJSZXQRJGBCW-CABCVRRESA-N
DM0PMKW	IU	3-[4-[(1R,2S)-2-aminocyclopropyl]phenyl]phenol
DM0PMKW	DE	Discovery agent

DMXGA12	ID	DMXGA12
DMXGA12	DN	OGX-427 + Paclitaxel
DMXGA12	HS	Investigative
DMXGA12	TC	Antisense
DMXGA12	DT	Combination drug (Antisense drug)
DMXGA12	PC	91866823; 36314
DMXGA12	DE	Lung cancer; Prostate cancer; Bladder cancer; Ovarian cancer; Breast cancer

DMZMTLB	ID	DMZMTLB
DMZMTLB	DN	OHIOENSIN A
DMZMTLB	HS	Investigative
DMZMTLB	SN	Ohioensin A; Ohioensin-A; CHEBI:7732; 121353-47-7; C09956; AC1L9D0W; CHEMBL403093; DTXSID80331864
DMZMTLB	DT	Small molecular drug
DMZMTLB	PC	442531
DMZMTLB	MW	372.4
DMZMTLB	FM	C23H16O5
DMZMTLB	IC	InChI=1S/C23H16O5/c24-10-5-6-12-14(7-10)23-20-13(11-3-1-2-4-18(11)28-23)8-15(25)21-17(27)9-16(26)19(12)22(20)21/h1-7,9,13,20,23-24,26-27H,8H2/t13-,20+,23+/m1/s1
DMZMTLB	CS	C1[C@H]2[C@@H]3[C@H](C4=C(C=CC(=C4)O)C5=C3C(=C(C=C5O)O)C1=O)OC6=CC=CC=C26
DMZMTLB	IK	DBGJQYIYUBGFLT-GQIHDASDSA-N
DMZMTLB	IU	(1R,15S,23S)-4,9,11-trihydroxy-22-oxahexacyclo[10.10.2.02,7.08,24.015,23.016,21]tetracosa-2(7),3,5,8(24),9,11,16,18,20-nonaen-13-one
DMZMTLB	CA	CAS 121353-47-7
DMZMTLB	CB	CHEBI:7732
DMZMTLB	DE	Discovery agent

DMNUGTL	ID	DMNUGTL
DMNUGTL	DN	Ohioensin C
DMNUGTL	HS	Investigative
DMNUGTL	SN	CHEMBL465069; ohioensin C
DMNUGTL	DT	Small molecular drug
DMNUGTL	PC	11740841
DMNUGTL	MW	386.4
DMNUGTL	FM	C24H18O5
DMNUGTL	IC	InChI=1S/C24H18O5/c1-28-18-10-16(27)21-15(26)9-13-11-5-2-3-8-17(11)29-24-12-6-4-7-14(25)19(12)22(18)23(21)20(13)24/h2-8,10,13,20,24-25,27H,9H2,1H3/t13-,20+,24+/m1/s1
DMNUGTL	CS	COC1=C2C3=C(C(=O)C[C@H]4[C@@H]3[C@H](C5=C2C(=CC=C5)O)OC6=CC=CC=C46)C(=C1)O
DMNUGTL	IK	ZVFNSNHXUYAPTP-VVTWNTARSA-N
DMNUGTL	IU	(1R,15S,23S)-6,11-dihydroxy-9-methoxy-22-oxahexacyclo[10.10.2.02,7.08,24.015,23.016,21]tetracosa-2(7),3,5,8,10,12(24),16,18,20-nonaen-13-one
DMNUGTL	DE	Discovery agent

DMCT348	ID	DMCT348
DMCT348	DN	Ohioensin F
DMCT348	HS	Investigative
DMCT348	SN	CHEMBL403094; ohioensin F
DMCT348	DT	Small molecular drug
DMCT348	PC	25033124
DMCT348	MW	388.4
DMCT348	FM	C23H16O6
DMCT348	IC	InChI=1S/C23H16O6/c24-10-5-6-11-12(7-10)22-21-20-18(11)14(25)8-15(26)19(20)16(27)9-23(21,28)13-3-1-2-4-17(13)29-22/h1-8,21-22,24-26,28H,9H2/t21-,22-,23-/m0/s1
DMCT348	CS	C1C(=O)C2=C(C=C(C3=C2[C@@H]4[C@]1(C5=CC=CC=C5O[C@H]4C6=C3C=CC(=C6)O)O)O)O
DMCT348	IK	CJDAIJHZTKDLTJ-VABKMULXSA-N
DMCT348	IU	(1R,15R,23S)-4,9,11,15-tetrahydroxy-22-oxahexacyclo[10.10.2.02,7.08,24.015,23.016,21]tetracosa-2(7),3,5,8(24),9,11,16,18,20-nonaen-13-one
DMCT348	DE	Discovery agent

DMLJBVP	ID	DMLJBVP
DMLJBVP	DN	Ohioensin G
DMLJBVP	HS	Investigative
DMLJBVP	SN	CHEMBL403411; ohioensin G
DMLJBVP	DT	Small molecular drug
DMLJBVP	PC	25033201
DMLJBVP	MW	388.4
DMLJBVP	FM	C23H16O6
DMLJBVP	IC	InChI=1S/C23H16O6/c24-11-6-3-5-10-15(11)17-12(25)8-13(26)18-19(17)20-16(21(27)22(18)28)9-4-1-2-7-14(9)29-23(10)20/h1-8,16,20-21,23-27H/t16-,20+,21-,23+/m1/s1
DMLJBVP	CS	C1=CC=C2C(=C1)[C@@H]3[C@@H]4[C@@H](O2)C5=C(C(=CC=C5)O)C6=C4C(=C(C=C6O)O)C(=O)[C@@H]3O
DMLJBVP	IK	JFOHOILWNMBZGW-QSABTFIQSA-N
DMLJBVP	IU	(1R,14R,15S,23S)-6,9,11,14-tetrahydroxy-22-oxahexacyclo[10.10.2.02,7.08,24.015,23.016,21]tetracosa-2(7),3,5,8(24),9,11,16,18,20-nonaen-13-one
DMLJBVP	DE	Discovery agent

DMN37KO	ID	DMN37KO
DMN37KO	DN	o-hydroxyatorvastatin
DMN37KO	HS	Investigative
DMN37KO	SN	BMS-243887
DMN37KO	DT	Small molecular drug
DMN37KO	PC	9808225
DMN37KO	MW	574.6
DMN37KO	FM	C33H35FN2O6
DMN37KO	IC	InChI=1S/C33H35FN2O6/c1-20(2)31-30(33(42)35-26-10-6-7-11-27(26)39)29(21-8-4-3-5-9-21)32(22-12-14-23(34)15-13-22)36(31)17-16-24(37)18-25(38)19-28(40)41/h3-15,20,24-25,37-39H,16-19H2,1-2H3,(H,35,42)(H,40,41)/t24-,25-/m1/s1
DMN37KO	CS	CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4O
DMN37KO	IK	CZBPKFICAYVHHM-JWQCQUIFSA-N
DMN37KO	IU	(3R,5R)-7-[2-(4-fluorophenyl)-4-[(2-hydroxyphenyl)carbamoyl]-3-phenyl-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
DMN37KO	CA	CAS 214217-86-4
DMN37KO	DE	Discovery agent

DMN7KPQ	ID	DMN7KPQ
DMN7KPQ	DN	OICR-9429
DMN7KPQ	HS	Investigative
DMN7KPQ	SN	OICR-9429; 1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H
DMN7KPQ	DT	Small molecular drug
DMN7KPQ	PC	91623360
DMN7KPQ	MW	555.6
DMN7KPQ	FM	C29H32F3N5O3
DMN7KPQ	IC	InChI=1S/C29H32F3N5O3/c1-35-7-9-37(10-8-35)26-6-5-22(21-4-2-3-20(15-21)19-36-11-13-40-14-12-36)16-25(26)34-28(39)23-18-33-27(38)17-24(23)29(30,31)32/h2-6,15-18H,7-14,19H2,1H3,(H,33,38)(H,34,39)
DMN7KPQ	CS	CN1CCN(CC1)C2=C(C=C(C=C2)C3=CC=CC(=C3)CN4CCOCC4)NC(=O)C5=CNC(=O)C=C5C(F)(F)F
DMN7KPQ	IK	DJOVLOYCGXNVPI-UHFFFAOYSA-N
DMN7KPQ	IU	N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1H-pyridine-3-carboxamide
DMN7KPQ	DE	Discovery agent

DM47CO1	ID	DM47CO1
DM47CO1	DN	Okadaic acid
DM47CO1	HS	Investigative
DM47CO1	SN	78111-17-8; CHEMBL280487; CHEBI:44658; C44H68O13; 9,10-Deepithio-9,10-didehydroacanthifolicin; Ocadaic Acid; OKA; (2R)-3-[(2S,5R,6R,8S)-8-[(2R,3E)-4-[(2R,4'aR,5R,6'S,8'R,8'aS)-8'-hydroxy-6'-[(1S,3S)-1-hydroxy-3-[(2S,3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-7'-methylidene-hexahydro-3'H-spiro[oxolane-2,2'-pyrano[3,2-b]pyran]-5-yl]but-3-en-2-yl]-5-hydroxy-10-methyl-1,7-dioxaspiro[5.5]undec-10-en-2-yl]-2-hydroxy-2-methylpropanoic acid; UNII-1W21G5Q4N2; CCRIS 3329; HSDB 7243; 1W21G5Q4N2; 1jk7
DM47CO1	DT	Small molecular drug
DM47CO1	PC	446512
DM47CO1	MW	805
DM47CO1	FM	C44H68O13
DM47CO1	IC	InChI=1S/C44H68O13/c1-25-21-34(55-44(23-25)35(46)12-11-31(54-44)24-41(6,50)40(48)49)26(2)9-10-30-14-18-43(53-30)19-15-33-39(57-43)36(47)29(5)38(52-33)32(45)22-28(4)37-27(3)13-17-42(56-37)16-7-8-20-51-42/h9-10,23,26-28,30-39,45-47,50H,5,7-8,11-22,24H2,1-4,6H3,(H,48,49)/b10-9+/t26-,27-,28+,30+,31+,32+,33-,34+,35-,36-,37+,38+,39-,41-,42+,43-,44-/m1/s1
DM47CO1	CS	C[C@@H]1CC[C@]2(CCCCO2)O[C@@H]1[C@@H](C)C[C@@H]([C@@H]3C(=C)[C@H]([C@H]4[C@H](O3)CC[C@]5(O4)CC[C@@H](O5)/C=C/[C@@H](C)[C@@H]6CC(=C[C@@]7(O6)[C@@H](CC[C@H](O7)C[C@](C)(C(=O)O)O)O)C)O)O
DM47CO1	IK	QNDVLZJODHBUFM-WFXQOWMNSA-N
DM47CO1	IU	(2R)-3-[(2S,6R,8S,11R)-2-[(E,2R)-4-[(2S,2'R,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(2S,3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-11-hydroxy-4-methyl-1,7-dioxaspiro[5.5]undec-4-en-8-yl]-2-hydroxy-2-methylpropanoic acid
DM47CO1	CA	CAS 78111-17-8
DM47CO1	CB	CHEBI:44658
DM47CO1	DE	Discovery agent

DMT1CZ0	ID	DMT1CZ0
DMT1CZ0	DN	OL-135
DMT1CZ0	HS	Investigative
DMT1CZ0	SN	OL-135; 681135-77-3; CHEMBL177577; 7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one; ILOIOIGZFHGSMS-UHFFFAOYSA-N; SCHEMBL1471932; GTPL5235; BDBM23120; ORL 135; OL135; ZINC3949004; KB-79672; 7-phenyl-1-(5-(pyridin-2-yl)oxazol-2-yl)heptan-1-one
DMT1CZ0	DT	Small molecular drug
DMT1CZ0	PC	10427006
DMT1CZ0	MW	334.4
DMT1CZ0	FM	C21H22N2O2
DMT1CZ0	IC	InChI=1S/C21H22N2O2/c24-19(14-7-2-1-4-10-17-11-5-3-6-12-17)21-23-16-20(25-21)18-13-8-9-15-22-18/h3,5-6,8-9,11-13,15-16H,1-2,4,7,10,14H2
DMT1CZ0	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=C(O2)C3=CC=CC=N3
DMT1CZ0	IK	ILOIOIGZFHGSMS-UHFFFAOYSA-N
DMT1CZ0	IU	7-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one
DMT1CZ0	DE	Pain

DM5ZJ3G	ID	DM5ZJ3G
DM5ZJ3G	DN	OL-92
DM5ZJ3G	HS	Investigative
DM5ZJ3G	SN	OL-92; CHEMBL367966; 288862-84-0; SCHEMBL3964425; BDBM23316; KB-79673; 1-[1,3]oxazolo[4,5-b]pyridin-2-yl-7-phenylheptan-1-one
DM5ZJ3G	DT	Small molecular drug
DM5ZJ3G	PC	11150976
DM5ZJ3G	MW	308.4
DM5ZJ3G	FM	C19H20N2O2
DM5ZJ3G	IC	InChI=1S/C19H20N2O2/c22-16(19-21-18-17(23-19)13-8-14-20-18)12-7-2-1-4-9-15-10-5-3-6-11-15/h3,5-6,8,10-11,13-14H,1-2,4,7,9,12H2
DM5ZJ3G	CS	C1=CC=C(C=C1)CCCCCCC(=O)C2=NC3=C(O2)C=CC=N3
DM5ZJ3G	IK	OVFUWDCWLWBDJD-UHFFFAOYSA-N
DM5ZJ3G	IU	1-([1,3]oxazolo[4,5-b]pyridin-2-yl)-7-phenylheptan-1-one
DM5ZJ3G	CA	CAS 288862-84-0
DM5ZJ3G	DE	Discovery agent

DMVM78Q	ID	DMVM78Q
DMVM78Q	DN	Olean-12-en-3beta,15alpha-diol
DMVM78Q	HS	Investigative
DMVM78Q	SN	CHEMBL491188; Olean-12-en-3beta,15alpha-diol; Oleana-12-ene-3beta,15alpha-diol
DMVM78Q	DT	Small molecular drug
DMVM78Q	PC	15601738
DMVM78Q	MW	442.7
DMVM78Q	FM	C30H50O2
DMVM78Q	IC	InChI=1S/C30H50O2/c1-25(2)15-16-27(5)18-24(32)30(8)19(20(27)17-25)9-10-22-28(6)13-12-23(31)26(3,4)21(28)11-14-29(22,30)7/h9,20-24,31-32H,10-18H2,1-8H3/t20-,21-,22+,23-,24-,27+,28-,29+,30-/m0/s1
DMVM78Q	CS	C[C@]12CCC(C[C@H]1C3=CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3([C@H](C2)O)C)C)(C)C)O)C)(C)C
DMVM78Q	IK	XVKHGUQJCRRKSC-WXIGGWTCSA-N
DMVM78Q	IU	(3S,4aR,6aR,6bS,7S,8aR,12aR,14aR,14bR)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-3,7-diol
DMVM78Q	DE	Discovery agent

DMWDMJ3	ID	DMWDMJ3
DMWDMJ3	DN	OLEANOLIC_ACID
DMWDMJ3	HS	Investigative
DMWDMJ3	SN	OLEANOLIC ACID; Oleanic acid; 508-02-1; Caryophyllin; Astrantiagenin C; Giganteumgenin C; Virgaureagenin B; 3beta-Hydroxyolean-12-en-28-oic acid; UNII-6SMK8R7TGJ; CCRIS 6493; (3-beta)-3-Hydroxyolean-12-en-28-oic acid; EINECS 208-081-6; NSC114945; 6SMK8R7TGJ; NSC-114945; 3-beta-Hydroxyolean-12-en-28-oic acid; CHEBI:37659; Olean-12-en-28-oic acid, 3-hydroxy-, (3beta)-; oleonolic acid; MFCD00064914
DMWDMJ3	DT	Small molecular drug
DMWDMJ3	PC	10494
DMWDMJ3	MW	456.7
DMWDMJ3	FM	C30H48O3
DMWDMJ3	IC	InChI=1S/C30H48O3/c1-25(2)14-16-30(24(32)33)17-15-28(6)19(20(30)18-25)8-9-22-27(5)12-11-23(31)26(3,4)21(27)10-13-29(22,28)7/h8,20-23,31H,9-18H2,1-7H3,(H,32,33)/t20-,21-,22+,23-,27-,28+,29+,30-/m0/s1
DMWDMJ3	CS	C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C)O
DMWDMJ3	IK	MIJYXULNPSFWEK-GTOFXWBISA-N
DMWDMJ3	IU	(4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMWDMJ3	CA	CAS 508-02-1
DMWDMJ3	CB	CHEBI:37659
DMWDMJ3	DE	Discovery agent

DMYPJC3	ID	DMYPJC3
DMYPJC3	DN	Oleanonic acid
DMYPJC3	HS	Investigative
DMYPJC3	SN	3-Oxoolean-12-en-28-oic Acid
DMYPJC3	DT	Small molecular drug
DMYPJC3	PC	12313704
DMYPJC3	MW	454.7
DMYPJC3	FM	C30H46O3
DMYPJC3	IC	InChI=1S/C30H46O3/c1-25(2)14-16-30(24(32)33)17-15-28(6)19(20(30)18-25)8-9-22-27(5)12-11-23(31)26(3,4)21(27)10-13-29(22,28)7/h8,20-22H,9-18H2,1-7H3,(H,32,33)/t20-,21-,22+,27-,28+,29+,30-/m0/s1
DMYPJC3	CS	C[C@]12CCC(=O)C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C
DMYPJC3	IK	FMIMFCRXYXVFTA-FUAOEXFOSA-N
DMYPJC3	IU	(4aS,6aR,6aS,6bR,8aR,12aR,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-4a-carboxylic acid
DMYPJC3	CA	CAS 17990-42-0
DMYPJC3	DE	Discovery agent

DM54O1Z	ID	DM54O1Z
DM54O1Z	DN	Oleic acid
DM54O1Z	HS	Investigative
DM54O1Z	SN	oleic acid; 112-80-1; cis-9-Octadecenoic acid; cis-Oleic acid; Elaidoic acid; oleate; Glycon wo; Wecoline OO; Pamolyn 100; Glycon RO; (Z)-Octadec-9-enoic acid; Metaupon; Oelsauere; Vopcolene 27; Groco 5l; Groco 2; Groco 4; Groco 6; Tego-oleic 130; Emersol 211; Z-9-Octadecenoic acid; Industrene 206; Industrene 105; Pamolyn; Industrene 205; Oleinic acid; Emersol 213; Emersol 210; L'Acide oleique; cis-Octadec-9-enoic acid; Century cd fatty acid; Emersol 6321; Extraolein 90; Oleine 7503; 9-Octadecenoic acid (Z)-; Emersol 205; Emersol 233LL
DM54O1Z	DT	Small molecular drug
DM54O1Z	PC	445639
DM54O1Z	MW	282.5
DM54O1Z	FM	C18H34O2
DM54O1Z	IC	InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H,19,20)/b10-9-
DM54O1Z	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)O
DM54O1Z	IK	ZQPPMHVWECSIRJ-KTKRTIGZSA-N
DM54O1Z	IU	(Z)-octadec-9-enoic acid
DM54O1Z	CA	CAS 112-80-1
DM54O1Z	CB	CHEBI:16196
DM54O1Z	DE	Discovery agent

DMXCSVH	ID	DMXCSVH
DMXCSVH	DN	Oleic acid anilide
DMXCSVH	HS	Investigative
DMXCSVH	SN	Oleanilide; Oleic acid anilide; Oleoylanilide; Oleylanilide; cis-9-Octadecenanilide; Oleyl anilide; (Z)-N-Phenyl-9-octadeceneamide; 5429-85-6; N-Phenyl-9Z-octadecenamide; (Z)-N-phenyl-9-octadecenamide; CHEBI:53721; EINECS 226-584-9; NSC 14233; 9-Octadecenamide, N-phenyl-, (Z)-; BRN 3533033; CHEMBL15611; (9Z)-N-phenyloctadec-9-enamide; Oleic anilide; C24H39NO; Oleanilide (7CI); AC1NS5WI; Epitope ID:117134; 2-12-00-00150 (Beilstein Handbook Reference); SCHEMBL4143902; (Z)-N-phenyloctadec-9-enamide; Octadec-9-enoic acid phenylamide
DMXCSVH	DT	Small molecular drug
DMXCSVH	PC	5354590
DMXCSVH	MW	357.6
DMXCSVH	FM	C24H39NO
DMXCSVH	IC	InChI=1S/C24H39NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-24(26)25-23-20-17-16-18-21-23/h9-10,16-18,20-21H,2-8,11-15,19,22H2,1H3,(H,25,26)/b10-9-
DMXCSVH	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)NC1=CC=CC=C1
DMXCSVH	IK	YPUOCYKJOLQYQS-KTKRTIGZSA-N
DMXCSVH	IU	(Z)-N-phenyloctadec-9-enamide
DMXCSVH	CA	CAS 5429-85-6
DMXCSVH	CB	CHEBI:53721
DMXCSVH	DE	Discovery agent

DMI1CAJ	ID	DMI1CAJ
DMI1CAJ	DN	oleocanthal
DMI1CAJ	HS	Investigative
DMI1CAJ	SN	(-)-oleocanthal
DMI1CAJ	DT	Small molecular drug
DMI1CAJ	PC	11652416
DMI1CAJ	MW	304.34
DMI1CAJ	FM	C17H20O5
DMI1CAJ	IC	InChI=1S/C17H20O5/c1-2-14(12-19)15(7-9-18)11-17(21)22-10-8-13-3-5-16(20)6-4-13/h2-6,9,12,15,20H,7-8,10-11H2,1H3/b14-2-/t15-/m0/s1
DMI1CAJ	CS	C/C=C(/C=O)\\[C@@H](CC=O)CC(=O)OCCC1=CC=C(C=C1)O
DMI1CAJ	IK	VPOVFCBNUOUZGG-VAKDEWRISA-N
DMI1CAJ	IU	2-(4-hydroxyphenyl)ethyl (E,3S)-4-formyl-3-(2-oxoethyl)hex-4-enoate
DMI1CAJ	CA	CAS 289030-99-5
DMI1CAJ	CB	CHEBI:85673
DMI1CAJ	DE	Discovery agent

DMJ1VRU	ID	DMJ1VRU
DMJ1VRU	DN	oleoyl-CoA
DMJ1VRU	HS	Investigative
DMJ1VRU	SN	oleoyl-coenzyme A
DMJ1VRU	DT	Small molecular drug
DMJ1VRU	PC	5497111
DMJ1VRU	MW	1032
DMJ1VRU	FM	C39H68N7O17P3S
DMJ1VRU	IC	InChI=1S/C39H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-30(48)67-23-22-41-29(47)20-21-42-37(51)34(50)39(2,3)25-60-66(57,58)63-65(55,56)59-24-28-33(62-64(52,53)54)32(49)38(61-28)46-27-45-31-35(40)43-26-44-36(31)46/h11-12,26-28,32-34,38,49-50H,4-10,13-25H2,1-3H3,(H,41,47)(H,42,51)(H,55,56)(H,57,58)(H2,40,43,44)(H2,52,53,54)/b12-11-/t28-,32-,33-,34+,38-/m1/s1
DMJ1VRU	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DMJ1VRU	IK	XDUHQPOXLUAVEE-BPMMELMSSA-N
DMJ1VRU	IU	S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (Z)-octadec-9-enethioate
DMJ1VRU	CA	CAS 1716-06-9
DMJ1VRU	CB	CHEBI:15534
DMJ1VRU	DE	Discovery agent

DMB5KQ4	ID	DMB5KQ4
DMB5KQ4	DN	oleoyl-lysophosphatidylcholine
DMB5KQ4	HS	Investigative
DMB5KQ4	SN	lysolecithin; LPC 18:1; lysophosphatidylcholine(18:1); OLPC
DMB5KQ4	DT	Small molecular drug
DMB5KQ4	PC	16081932
DMB5KQ4	MW	521.7
DMB5KQ4	FM	C26H52NO7P
DMB5KQ4	IC	InChI=1S/C26H52NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-26(29)32-23-25(28)24-34-35(30,31)33-22-21-27(2,3)4/h12-13,25,28H,5-11,14-24H2,1-4H3/b13-12-/t25-/m1/s1
DMB5KQ4	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)O
DMB5KQ4	IK	YAMUFBLWGFFICM-PTGWMXDISA-N
DMB5KQ4	IU	[(2R)-2-hydroxy-3-[(Z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMB5KQ4	CA	CAS 19420-56-5
DMB5KQ4	CB	CHEBI:28610
DMB5KQ4	DE	Discovery agent

DM1TAM9	ID	DM1TAM9
DM1TAM9	DN	oleoyl-thiophosphate
DM1TAM9	HS	Investigative
DM1TAM9	SN	oleoyl-thiophosphate; SCHEMBL1691879; GTPL6983; [[(Z)-octadec-9-enoyl]oxy-[(Z)-octadec-9-enoyl]sulfanylphosphoryl] (Z)-octadec-9-enoate
DM1TAM9	DT	Small molecular drug
DM1TAM9	PC	73755251
DM1TAM9	MW	907.4
DM1TAM9	FM	C54H99O6PS
DM1TAM9	IC	InChI=1S/C54H99O6PS/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-52(55)59-61(58,60-53(56)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2)62-54(57)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3/h25-30H,4-24,31-51H2,1-3H3/b28-25-,29-26-,30-27-
DM1TAM9	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OP(=O)(SC(=O)CCCCCCC/C=C\\CCCCCCCC)OC(=O)CCCCCCC/C=C\\CCCCCCCC
DM1TAM9	IK	VZTWVTAPKVGVJL-IUPFWZBJSA-N
DM1TAM9	IU	[[(Z)-octadec-9-enoyl]oxy-[(Z)-octadec-9-enoyl]sulfanylphosphoryl] (Z)-octadec-9-enoate
DM1TAM9	DE	Discovery agent

DM5X76V	ID	DM5X76V
DM5X76V	DN	Oligomycin C
DM5X76V	HS	Investigative
DM5X76V	SN	Ambotz11052-72-5; O5251_SIGMA; Oligomycin C; Q27107578; SCHEMBL454280; ZINC255967246; 11052-72-5; AB01209739-01; AC1NQZ9I; AKOS024418757; BRD-K05350981-001-01-0; C11313; MFCD00043231
DM5X76V	PC	5281901
DM5X76V	MW	775.1
DM5X76V	FM	C45H74O10
DM5X76V	IC	CMMLZMMKTYEOKV-JEKNLLRFSA-N
DM5X76V	CS	CCC1CCC2C(C(C(C3(O2)CCC(C(O3)CC(C)O)C)C)OC(=O)C=CC(C(C(C(=O)C(C(C(C(=O)C(C(C(CC=CC=C1)C)O)C)C)O)C)C)O)C)C
DM5X76V	IK	1S/C45H74O10/c1-12-35-17-15-13-14-16-26(3)39(48)30(7)41(50)32(9)43(52)33(10)42(51)31(8)40(49)27(4)18-21-38(47)53-44-29(6)36(20-19-35)54-45(34(44)11)23-22-25(2)37(55-45)24-28(5)46/h13-15,17-18,21,25-37,39-40,43-44,46,48-49,52H,12,16,19-20,22-24H2,1-11H3/b14-13+,17-15+,21-18+/t25-,26+,27-,28+,29+,30-,31-,32+,33-,34-,35-,36-,37-,39-,40+,43-,44+,45-/m1/s1
DM5X76V	IU	(1S,4E,5'R,6R,6'R,7S,8R,10S,11R,12R,14R,15R,16S,18E,20E,22S,25R,27S,28R,29S)-22-ethyl-7,11,15-trihydroxy-6'-[(2S)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione
DM5X76V	CA	CAS 11052-72-5
DM5X76V	DE	Colon cancer

DM1XJBE	ID	DM1XJBE
DM1XJBE	DN	OLPADRONIC ACID SODIUM SALT
DM1XJBE	HS	Investigative
DM1XJBE	SN	Dimethyl-APD; IG-8801; Olpadronic acid sodium salt; 3-(Dimethylamino)-1-hydroxypropylidene-1,1-diphosphonic acid monosodium salt
DM1XJBE	DT	Small molecular drug
DM1XJBE	PC	23663414
DM1XJBE	MW	285.1
DM1XJBE	FM	C5H14NNaO7P2
DM1XJBE	IC	InChI=1S/C5H15NO7P2.Na/c1-6(2)4-3-5(7,14(8,9)10)15(11,12)13;/h7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13);/q;+1/p-1
DM1XJBE	CS	CN(C)CCC(O)(P(=O)(O)O)P(=O)(O)[O-].[Na+]
DM1XJBE	IK	DXTIBTHCHBZFJG-UHFFFAOYSA-M
DM1XJBE	IU	sodium;[3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]-hydroxyphosphinate
DM1XJBE	DE	Bone resorption

DMTY63G	ID	DMTY63G
DMTY63G	DN	Olterodine
DMTY63G	HS	Investigative
DMTY63G	SN	Sabcomeline hydrochloride; Sabcomeline hydrochloride (USAN); SCHEMBL6392265
DMTY63G	DT	Small molecular drug
DMTY63G	PC	9816017
DMTY63G	MW	229.71
DMTY63G	FM	C10H16ClN3O
DMTY63G	IC	InChI=1S/C10H15N3O.ClH/c1-14-12-10(6-11)9-7-13-4-2-8(9)3-5-13;/h8-9H,2-5,7H2,1H3;1H/b12-10+;
DMTY63G	CS	CO/N=C(\\C#N)/C1CN2CCC1CC2.Cl
DMTY63G	IK	INJWRVWKJFJRFO-VHPXAQPISA-N
DMTY63G	IU	(3Z)-N-methoxy-1-azabicyclo[2.2.2]octane-3-carboximidoyl cyanide;hydrochloride
DMTY63G	DE	Discovery agent

DMXJ2SM	ID	DMXJ2SM
DMXJ2SM	DN	OM00-3
DMXJ2SM	HS	Investigative
DMXJ2SM	SN	OM00-3; OM-00-3; CHEMBL390456; 1m4h; AC1L9KFC; SCHEMBL19502529; BDBM50210579; (4S)-4-amino-5-[[(2S)-1-[[(2S)-4-hydroxy-1-[[(4S,5S,7R)-5-hydroxy-8-[[(2S)-1-[[(2S)-5-hydroxy-1-[[(2S)-1-hydroxy-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2,7-dimethyl-8-oxooctan-4-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMXJ2SM	DT	Small molecular drug
DMXJ2SM	PC	447068
DMXJ2SM	MW	936.1
DMXJ2SM	FM	C44H69N7O15
DMXJ2SM	IC	InChI=1S/C44H69N7O15/c1-22(2)17-29(47-42(63)31(21-36(57)58)49-41(62)30(18-23(3)4)48-39(60)27(45)13-15-34(53)54)33(52)19-25(7)38(59)51-37(24(5)6)43(64)46-28(14-16-35(55)56)40(61)50-32(44(65)66)20-26-11-9-8-10-12-26/h8-12,22-25,27-33,37,52H,13-21,45H2,1-7H3,(H,46,64)(H,47,63)(H,48,60)(H,49,62)(H,50,61)(H,51,59)(H,53,54)(H,55,56)(H,57,58)(H,65,66)/t25-,27+,28+,29+,30+,31+,32+,33+,37+/m1/s1
DMXJ2SM	CS	C[C@H](C[C@@H]([C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)N)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O
DMXJ2SM	IK	CFIWWTUUSMMDDA-IQRKPKHNSA-N
DMXJ2SM	IU	(4S)-4-amino-5-[[(2S)-1-[[(2S)-3-carboxy-1-[[(4S,5S,7R)-8-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMXJ2SM	DE	Discovery agent

DME8RNV	ID	DME8RNV
DME8RNV	DN	OM-197-MP-AC
DME8RNV	HS	Investigative
DME8RNV	CP	OM Pharma
DME8RNV	DE	Solid tumour/cancer

DML5AWQ	ID	DML5AWQ
DML5AWQ	DN	OM-294-DP
DML5AWQ	HS	Investigative
DML5AWQ	CP	OM Pharma
DML5AWQ	DE	Solid tumour/cancer

DMGMIX3	ID	DMGMIX3
DMGMIX3	DN	omega-chloroacetophenone
DMGMIX3	HS	Investigative
DMGMIX3	SN	mace (lacrimator); tear gas; phenacyl chloride; chloromethyl phenyl ketone
DMGMIX3	DT	Small molecular drug
DMGMIX3	PC	10757
DMGMIX3	MW	154.59
DMGMIX3	FM	C8H7ClO
DMGMIX3	IC	InChI=1S/C8H7ClO/c9-6-8(10)7-4-2-1-3-5-7/h1-5H,6H2
DMGMIX3	CS	C1=CC=C(C=C1)C(=O)CCl
DMGMIX3	IK	IMACFCSSMIZSPP-UHFFFAOYSA-N
DMGMIX3	IU	2-chloro-1-phenylethanone
DMGMIX3	CA	CAS 532-27-4
DMGMIX3	DE	Discovery agent

DM4BQFW	ID	DM4BQFW
DM4BQFW	DN	omega-conotoxin GVIA
DM4BQFW	HS	Investigative
DM4BQFW	SN	UNII-CA669FO97Q; CA669FO97Q; omega-Cgtx; omega Cgtx; omega-Cgtx gvia; Conus geographus toxin; omega-Ctx; omega Conus geographus toxin; toxin, omega-Conus geographus; omega-Conopeptide gvia; Snx 124; omega-Conotoxin G VIA (reduced); 92078-76-7; GTPL2535; LS-187069
DM4BQFW	DT	Small molecular drug
DM4BQFW	PC	16133838
DM4BQFW	MW	3037.4
DM4BQFW	FM	C120H182N38O43S6
DM4BQFW	IC	InChI=1S/C120H182N38O43S6/c1-53(165)91-114(197)138-66(10-4-6-26-122)95(178)136-68(12-8-28-132-120(129)130)98(181)149-81(107(190)139-69(93(126)176)29-55-13-19-58(167)20-14-55)49-204-207-52-84-110(193)153-80-48-203-202-47-64(123)94(177)135-65(9-3-5-25-121)97(180)147-78(45-163)117(200)156-38-61(170)32-85(156)111(194)133-37-90(175)134-74(41-159)102(185)145-76(43-161)105(188)152-83(109(192)148-79(46-164)118(201)158-40-63(172)34-87(158)113(196)155-92(54(2)166)115(198)146-77(44-162)103(186)140-70(30-56-15-21-59(168)22-16-56)99(182)141-72(35-88(124)173)100(183)150-84)51-206-205-50-82(151-104(187)75(42-160)144-96(179)67(137-106(80)189)11-7-27-131-119(127)128)108(191)143-73(36-89(125)174)116(199)157-39-62(171)33-86(157)112(195)142-71(101(184)154-91)31-57-17-23-60(169)24-18-57/h13-24,53-54,61-87,91-92,159-172H,3-12,25-52,121-123H2,1-2H3,(H2,124,173)(H2,125,174)(H2,126,176)(H,133,194)(H,134,175)(H,135,177)(H,136,178)(H,137,189)(H,138,197)(H,139,190)(H,140,186)(H,141,182)(H,142,195)(H,143,191)(H,144,179)(H,145,185)(H,146,198)(H,147,180)(H,148,192)(H,149,181)(H,150,183)(H,151,187)(H,152,188)(H,153,193)(H,154,184)(H,155,196)(H4,127,128,131)(H4,129,130,132)/t53-,54-,61-,62-,63-,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,91+,92+/m1/s1
DM4BQFW	CS	C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N5C[C@@H](C[C@H]5C(=O)N1)O)CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CO)CCCNC(=N)N)NC2=O)N)CCCCN)CO)O)CO)CO)CC(=O)N)O)CC7=CC=C(C=C7)O)[C@@H](C)O)CCCCN)CCCNC(=N)N)C(=O)N[C@@H](CC8=CC=C(C=C8)O)C(=O)N)CC(=O)N)CC9=CC=C(C=C9)O)CO)O
DM4BQFW	IK	FDQZTPPHJRQRQQ-NZPQQUJLSA-N
DM4BQFW	IU	(1R,4S,8R,10S,13S,16S,19S,22S,25R,30R,33S,36S,39S,42S,45S,47R,51S,54R,57S,60S,63R,68R,71S,74S,78R,80S,86S,89S)-68-amino-36,71-bis(4-aminobutyl)-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-22,51-bis(2-amino-2-oxoethyl)-33,60-bis(3-carbamimidamidopropyl)-8,47,78-trihydroxy-13,39-bis[(1R)-1-hydroxyethyl]-4,16,57,74,86,89-hexakis(hydroxymethyl)-19,42-bis[(4-hydroxyphenyl)methyl]-2,5,11,14,17,20,23,32,35,38,41,44,50,53,56,59,62,69,72,75,81,84,87,90,97-pentacosaoxo-27,28,65,66,93,94-hexathia-3,6,12,15,18,21,24,31,34,37,40,43,49,52,55,58,61,70,73,76,82,85,88,91,96-pentacosazahexacyclo[52.37.4.225,63.06,10.045,49.076,80]heptanonacontane-30-carboxamide
DM4BQFW	CA	CAS 106375-28-4
DM4BQFW	CB	CHEBI:90630
DM4BQFW	DE	Discovery agent

DMKTA5R	ID	DMKTA5R
DMKTA5R	DN	O-methyldauricine
DMKTA5R	HS	Investigative
DMKTA5R	SN	O-Methyldauricine; 2202-17-7; O,O-Dimethylcuspidaline; O,O-Dimethyldauricinoline; CHEMBL501861; Dauricine, O-methyl- (6CI,7CI,8CI); Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-((4-(2-methoxy-5-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)phenyl)methyl)-2-methyl-, (R-(R*,R*))-; Dauricine, O-methyl-; AC1L44JA; DTXSID50176486; C39H46N2O6; 8192AH; BDBM50292469; ZINC42805235; LS-85912; AN-50531; 202M177; Q-100278
DMKTA5R	DT	Small molecular drug
DMKTA5R	PC	200521
DMKTA5R	MW	638.8
DMKTA5R	FM	C39H46N2O6
DMKTA5R	IC	InChI=1S/C39H46N2O6/c1-40-16-14-27-21-35(43-4)37(45-6)23-30(27)32(40)18-25-8-11-29(12-9-25)47-39-20-26(10-13-34(39)42-3)19-33-31-24-38(46-7)36(44-5)22-28(31)15-17-41(33)2/h8-13,20-24,32-33H,14-19H2,1-7H3/t32-,33-/m1/s1
DMKTA5R	CS	CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)OC)OC)OC)OC
DMKTA5R	IK	UHYCXSGUNAWVBW-CZNDPXEESA-N
DMKTA5R	IU	(1R)-1-[[4-[5-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]phenyl]methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline
DMKTA5R	CA	CAS 2202-17-7
DMKTA5R	DE	Discovery agent

DMGFRSY	ID	DMGFRSY
DMGFRSY	DN	OMPT
DMGFRSY	HS	Investigative
DMGFRSY	SN	(2S)-OMPT
DMGFRSY	DT	Small molecular drug
DMGFRSY	PC	16078994
DMGFRSY	MW	466.6
DMGFRSY	FM	C22H43O6PS
DMGFRSY	IC	InChI=1S/C22H43O6PS/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-22(23)27-19-21(26-2)20-28-29(24,25)30/h10-11,21H,3-9,12-20H2,1-2H3,(H2,24,25,30)/b11-10-/t21-/m0/s1
DMGFRSY	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OC[C@@H](COP(=S)(O)O)OC
DMGFRSY	IK	FCVJYKICQNLXAX-XPTLAUCJSA-N
DMGFRSY	IU	[(2S)-3-dihydroxyphosphinothioyloxy-2-methoxypropyl] (Z)-octadec-9-enoate
DMGFRSY	CB	CHEBI:139223
DMGFRSY	DE	Discovery agent

DMWOHDV	ID	DMWOHDV
DMWOHDV	DN	ON-044580
DMWOHDV	HS	Investigative
DMWOHDV	SN	ON-04 series (cancer), Onconova; JAK2/Bcr-Abl kinase inhibitors (cancer), Onconova
DMWOHDV	CP	Onconova Therapeutics Inc
DMWOHDV	PC	129860730
DMWOHDV	MW	365.2
DMWOHDV	FM	C16H13BrO3S
DMWOHDV	IC	InChI=1S/C16H13BrO3S/c17-14-7-1-11(2-8-14)9-21-10-15(18)12-3-5-13(6-4-12)16(19)20/h1-8H,9-10H2,(H,19,20)
DMWOHDV	CS	C1=CC(=CC=C1CSCC(=O)C2=CC=C(C=C2)C(=O)O)Br
DMWOHDV	IK	KTQGMLFAHVKKNV-UHFFFAOYSA-N
DMWOHDV	IU	4-[2-[(4-bromophenyl)methylsulfanyl]acetyl]benzoic acid
DMWOHDV	DE	Solid tumour/cancer

DMHLEGT	ID	DMHLEGT
DMHLEGT	DN	ON-123
DMHLEGT	HS	Investigative
DMHLEGT	SN	ON-1231320; ON-123 series (cancer); Sulfonyl pyridopyrimidines (cancer), Onconova; ON-123 series (cancer), Onconova; Plk-2 inhibitors (cancer), Onconova; Polo-like kinase 2 inhibitors (cancer), Onconova
DMHLEGT	CP	Onconova Therapeutics Inc
DMHLEGT	DE	Solid tumour/cancer

DMTNKBW	ID	DMTNKBW
DMTNKBW	DN	ON-128
DMTNKBW	HS	Investigative
DMTNKBW	SN	ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova
DMTNKBW	CP	Onconova Therapeutics Inc
DMTNKBW	DE	Solid tumour/cancer

DMSFQHO	ID	DMSFQHO
DMSFQHO	DN	ON-24160
DMSFQHO	HS	Investigative
DMSFQHO	SN	Beta tubulin depolymerizer (cancer), Onconova; Beta-tubulin polymerization inhibitors (cancer), Onconova; ON-24 series (cancer), Onconova
DMSFQHO	CP	Onconova Therapeutics Inc
DMSFQHO	PC	10309597
DMSFQHO	MW	394.4
DMSFQHO	FM	C18H22N2O6S
DMSFQHO	IC	InChI=1S/C18H22N2O6S/c1-23-13-10-17(25-3)14(18(11-13)26-4)7-8-27(21,22)20-12-5-6-16(24-2)15(19)9-12/h5-11,20H,19H2,1-4H3/b8-7+
DMSFQHO	CS	COC1=C(C=C(C=C1)NS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)N
DMSFQHO	IK	OLRRWEXEHIWZJV-BQYQJAHWSA-N
DMSFQHO	IU	(E)-N-(3-amino-4-methoxyphenyl)-2-(2,4,6-trimethoxyphenyl)ethenesulfonamide
DMSFQHO	DE	Solid tumour/cancer

DMSWI4D	ID	DMSWI4D
DMSWI4D	DN	Ono 1
DMSWI4D	HS	Investigative
DMSWI4D	TC	Analgesics
DMSWI4D	DE	Pain

DMCG6H8	ID	DMCG6H8
DMCG6H8	DN	Ono 3
DMCG6H8	HS	Investigative
DMCG6H8	TC	Analgesics
DMCG6H8	DE	Pain

DMSXT0H	ID	DMSXT0H
DMSXT0H	DN	ONO-1581
DMSXT0H	HS	Investigative
DMSXT0H	SN	OKY-1581; UNII-Z5E7R0J67C; Oky 1581; Z5E7R0J67C; (E)-2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid sodium salt; 2-Propenoic acid, 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-, sodium salt, (E)-; 75987-18-7; CHEMBL11811; C16H14NO2.Na; SCHEMBL2924563; API0015168; LS-123715; sodium (e)-3-[4-(3-pyridylmethyl) phenyl]-2-methylacrylate; 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, sodium salt, (E)-isomer
DMSXT0H	DT	Small molecular drug
DMSXT0H	PC	23663937
DMSXT0H	MW	275.28
DMSXT0H	FM	C16H14NNaO2
DMSXT0H	IC	InChI=1S/C16H15NO2.Na/c1-12(16(18)19)9-13-4-6-14(7-5-13)10-15-3-2-8-17-11-15;/h2-9,11H,10H2,1H3,(H,18,19);/q;+1/p-1/b12-9+;
DMSXT0H	CS	C/C(=C\\C1=CC=C(C=C1)CC2=CN=CC=C2)/C(=O)[O-].[Na+]
DMSXT0H	IK	ZAPOSLLMEZKFQS-NBYYMMLRSA-M
DMSXT0H	IU	sodium;(E)-2-methyl-3-[4-(pyridin-3-ylmethyl)phenyl]prop-2-enoate
DMSXT0H	CA	CAS 75987-18-7
DMSXT0H	DE	Discovery agent

DM8LKED	ID	DM8LKED
DM8LKED	DN	ONO-3080573
DM8LKED	HS	Investigative
DM8LKED	SN	ON3
DM8LKED	DT	Small molecular drug
DM8LKED	PC	91799238
DM8LKED	MW	518.6
DM8LKED	FM	C31H34O7
DM8LKED	IC	InChI=1S/C31H34O7/c1-19-26(35-2)16-22(17-27(19)36-3)29(32)28(38-25-14-20-6-4-5-7-21(20)15-25)18-37-24-10-8-23(9-11-24)31(12-13-31)30(33)34/h4-11,16-17,25,28-29,32H,12-15,18H2,1-3H3,(H,33,34)/t28-,29+/m0/s1
DM8LKED	CS	CC1=C(C=C(C=C1OC)[C@H]([C@H](COC2=CC=C(C=C2)C3(CC3)C(=O)O)OC4CC5=CC=CC=C5C4)O)OC
DM8LKED	IK	FVESDCZDESZGHA-URLMMPGGSA-N
DM8LKED	IU	1-[4-[(2S,3R)-2-(2,3-dihydro-1H-inden-2-yloxy)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropoxy]phenyl]cyclopropane-1-carboxylic acid
DM8LKED	DE	Discovery agent

DM84IW9	ID	DM84IW9
DM84IW9	DN	ONO-3708
DM84IW9	HS	Investigative
DM84IW9	SN	BRN 4205392; ONO3708; ONO 3708
DM84IW9	DT	Small molecular drug
DM84IW9	PC	5311334
DM84IW9	MW	391.5
DM84IW9	FM	C23H37NO4
DM84IW9	IC	InChI=1S/C23H37NO4/c1-23(2)16-13-18(23)17(11-5-3-4-6-12-20(25)26)19(14-16)24-22(28)21(27)15-9-7-8-10-15/h3,5,15-19,21,27H,4,6-14H2,1-2H3,(H,24,28)(H,25,26)/b5-3-/t16-,17+,18+,19+,21-/m1/s1
DM84IW9	CS	CC1([C@@H]2C[C@H]1[C@@H]([C@H](C2)NC(=O)[C@@H](C3CCCC3)O)C/C=C\\CCCC(=O)O)C
DM84IW9	IK	SXHUZJPIRVLMHY-AZPSIHDESA-N
DM84IW9	IU	(Z)-7-[(1S,2S,3S,5R)-3-[[(2R)-2-cyclopentyl-2-hydroxyacetyl]amino]-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DM84IW9	CA	CAS 102191-05-9
DM84IW9	DE	Discovery agent

DMD2G65	ID	DMD2G65
DMD2G65	DN	ONO-8713
DMD2G65	HS	Investigative
DMD2G65	SN	ONO8713; ONO 8713
DMD2G65	DT	Small molecular drug
DMD2G65	PC	9936595
DMD2G65	MW	523.5
DMD2G65	FM	C25H24F3NO6S
DMD2G65	IC	InChI=1S/C25H24F3NO6S/c1-17(2)15-29(36(32,33)24-4-3-13-34-24)21-11-10-20(25(26,27)28)14-22(21)35-16-19-7-5-18(6-8-19)9-12-23(30)31/h3-14,17H,15-16H2,1-2H3,(H,30,31)/b12-9+
DMD2G65	CS	CC(C)CN(C1=C(C=C(C=C1)C(F)(F)F)OCC2=CC=C(C=C2)/C=C/C(=O)O)S(=O)(=O)C3=CC=CO3
DMD2G65	IK	LOQMSUDLLHPPHQ-FMIVXFBMSA-N
DMD2G65	IU	(E)-3-[4-[[2-[furan-2-ylsulfonyl(2-methylpropyl)amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid
DMD2G65	DE	Discovery agent

DM5BMA9	ID	DM5BMA9
DM5BMA9	DN	ONO-8809
DM5BMA9	HS	Investigative
DM5BMA9	SN	[1S-(1alpha,2beta(Z),3beta,4alpha)]-6-[3-[[[(4-Bromophenyl)sulfonyl]amino]methyl]bicyclo[2.2.1]hept-2-yl]-5-hexenoic acid decyl ester; (Z)-6-[(1S,2S,3S,4R)-3-(4-Bromobenzenesulfonylaminomethyl)bicyclo[2.2.1]hept-2-yl]-5-hexenoic acid n-decyl ester
DM5BMA9	DT	Small molecular drug
DM5BMA9	PC	6439150
DM5BMA9	MW	596.7
DM5BMA9	FM	C30H46BrNO4S
DM5BMA9	IC	InChI=1S/C30H46BrNO4S/c1-2-3-4-5-6-7-8-12-21-36-30(33)14-11-9-10-13-28-24-15-16-25(22-24)29(28)23-32-37(34,35)27-19-17-26(31)18-20-27/h10,13,17-20,24-25,28-29,32H,2-9,11-12,14-16,21-23H2,1H3/b13-10-/t24-,25+,28-,29+/m0/s1
DM5BMA9	CS	CCCCCCCCCCOC(=O)CCC/C=C\\[C@H]1[C@H]2CC[C@H](C2)[C@H]1CNS(=O)(=O)C3=CC=C(C=C3)Br
DM5BMA9	IK	KLMMNRLRCVRTDN-WHFHORQSSA-N
DM5BMA9	IU	decyl (Z)-6-[(1S,2R,3R,4R)-3-[[(4-bromophenyl)sulfonylamino]methyl]-2-bicyclo[2.2.1]heptanyl]hex-5-enoate
DM5BMA9	CA	CAS 123288-47-1
DM5BMA9	DE	Thrombosis

DMATXHR	ID	DMATXHR
DMATXHR	DN	ONO-9780307
DMATXHR	HS	Investigative
DMATXHR	SN	ON7; ONO9780307
DMATXHR	DT	Small molecular drug
DMATXHR	PC	11785732
DMATXHR	MW	521.6
DMATXHR	FM	C30H35NO7
DMATXHR	IC	InChI=1S/C30H35NO7/c1-18-26(36-2)12-22(13-27(18)37-3)29(34)24(11-19-9-20-7-5-6-8-21(20)10-19)16-31-15-23(14-28(32)33)25(17-31)30(35)38-4/h5-8,12-13,15,17,19,24,29,34H,9-11,14,16H2,1-4H3,(H,32,33)/t24-,29+/m0/s1
DMATXHR	CS	CC1=C(C=C(C=C1OC)[C@H]([C@@H](CC2CC3=CC=CC=C3C2)CN4C=C(C(=C4)C(=O)OC)CC(=O)O)O)OC
DMATXHR	IK	PMPFDANPLYTSTM-PWUYWRBVSA-N
DMATXHR	IU	2-[1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-4-methoxycarbonylpyrrol-3-yl]acetic acid
DMATXHR	DE	Discovery agent

DML4DPV	ID	DML4DPV
DML4DPV	DN	ONO-9910539
DML4DPV	HS	Investigative
DML4DPV	SN	ON9
DML4DPV	DT	Small molecular drug
DML4DPV	PC	91799237
DML4DPV	MW	563.6
DML4DPV	FM	C32H37NO8
DML4DPV	IC	InChI=1S/C32H37NO8/c1-19(34)30-27(39-2)14-24(15-28(30)40-3)31(37)25(13-20-11-21-7-5-6-8-22(21)12-20)17-33-16-23(9-10-29(35)36)26(18-33)32(38)41-4/h5-8,14-16,18,20,25,31,37H,9-13,17H2,1-4H3,(H,35,36)/t25-,31+/m0/s1
DML4DPV	CS	CC(=O)C1=C(C=C(C=C1OC)[C@H]([C@@H](CC2CC3=CC=CC=C3C2)CN4C=C(C(=C4)C(=O)OC)CCC(=O)O)O)OC
DML4DPV	IK	URHZQBASTULQKJ-VVFBEHOQSA-N
DML4DPV	IU	3-[1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxypropyl]-4-methoxycarbonylpyrrol-3-yl]propanoic acid
DML4DPV	DE	Discovery agent

DMS3MZG	ID	DMS3MZG
DMS3MZG	DN	ONO-AE1-329
DMS3MZG	HS	Investigative
DMS3MZG	SN	2-[3-[(1R,2S,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-5-[2-(methoxymethyl)phenyl]pent-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetic acid; ONO-AE-329; AC1NSK9H; GTPL1933; SCHEMBL14150400; 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-5-[2-(methoxymethyl)phenyl]pent-1-enyl]-5-oxo-cyclopentyl]sulfanylpropylsulfanyl]acetic acid
DMS3MZG	DT	Small molecular drug
DMS3MZG	PC	5311230
DMS3MZG	MW	468.6
DMS3MZG	FM	C23H32O6S2
DMS3MZG	IC	InChI=1S/C23H32O6S2/c1-29-14-17-6-3-2-5-16(17)7-8-18(24)9-10-19-20(25)13-21(26)23(19)31-12-4-11-30-15-22(27)28/h2-3,5-6,9-10,18-20,23-25H,4,7-8,11-15H2,1H3,(H,27,28)/b10-9+/t18-,19-,20+,23+/m0/s1
DMS3MZG	CS	COCC1=CC=CC=C1CC[C@@H](/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2SCCCSCC(=O)O)O)O
DMS3MZG	IK	BVGVPUMSPSNRRQ-CNOJNPITSA-N
DMS3MZG	IU	2-[3-[(1R,2S,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-5-[2-(methoxymethyl)phenyl]pent-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetic acid
DMS3MZG	DE	Discovery agent

DM78DO6	ID	DM78DO6
DM78DO6	DN	ONO-AE2-227
DM78DO6	HS	Investigative
DM78DO6	SN	ONO-AE2-227; CHEMBL3260772; 2-[[2-(2-naphthalen-1-ylpropanoylamino)phenyl]methyl]benzoic acid; AC1NSK9N; SCHEMBL5351322; GTPL5824
DM78DO6	DT	Small molecular drug
DM78DO6	PC	5311232
DM78DO6	MW	409.5
DM78DO6	FM	C27H23NO3
DM78DO6	IC	InChI=1S/C27H23NO3/c1-18(22-15-8-12-19-9-2-5-13-23(19)22)26(29)28-25-16-7-4-11-21(25)17-20-10-3-6-14-24(20)27(30)31/h2-16,18H,17H2,1H3,(H,28,29)(H,30,31)
DM78DO6	CS	CC(C1=CC=CC2=CC=CC=C21)C(=O)NC3=CC=CC=C3CC4=CC=CC=C4C(=O)O
DM78DO6	IK	BLJLWFKNTKAUDA-UHFFFAOYSA-N
DM78DO6	IU	2-[[2-(2-naphthalen-1-ylpropanoylamino)phenyl]methyl]benzoic acid
DM78DO6	DE	Discovery agent

DMA7VP5	ID	DMA7VP5
DMA7VP5	DN	ONO-AE-248
DMA7VP5	HS	Investigative
DMA7VP5	SN	11,15-O-dimethyl-PGE2
DMA7VP5	DT	Small molecular drug
DMA7VP5	PC	5311229
DMA7VP5	MW	380.5
DMA7VP5	FM	C22H36O5
DMA7VP5	IC	InChI=1S/C22H36O5/c1-4-5-8-11-17(26-2)14-15-19-18(20(23)16-21(19)27-3)12-9-6-7-10-13-22(24)25/h6,9,14-15,17-19,21H,4-5,7-8,10-13,16H2,1-3H3,(H,24,25)/b9-6-,15-14+/t17-,18+,19+,21+/m0/s1
DMA7VP5	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)OC)OC
DMA7VP5	IK	MXDQOCKVVLKVJS-QKIVIXBWSA-N
DMA7VP5	IU	(Z)-7-[(1R,2R,3R)-3-methoxy-2-[(E,3S)-3-methoxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMA7VP5	DE	Discovery agent

DMEY7T4	ID	DMEY7T4
DMEY7T4	DN	ONO-AE3-208
DMEY7T4	HS	Investigative
DMEY7T4	SN	402473-54-5; 4-Cyano-2-[[2-(4-fluoro-1-naphthalenyl)-1-oxopropyl]amino]benzenebutanoic acid; ONO AE3 208; SCHEMBL679969; GTPL1942; CTK1D4873; KS-00001DVO; DTXSID20435810; MolPort-035-765-695; 3952AH; AKOS024457689; 4-[4-cyano-2-[2-(4-fluoronaphthalen-1-yl)propanoylamino]phenyl]butanoic Acid; CS-0315; NCGC00378671-02; HY-50901; AK547789; DB-030557; FT-0715398; ONO-AE3-208, &gt; W-5560; 473O545; 4-(4-Cyano-2-(2-(4-fluoronaphthalen-1-yl)propanamido)phenyl)butanoic acid
DMEY7T4	DT	Small molecular drug
DMEY7T4	PC	10111831
DMEY7T4	MW	404.4
DMEY7T4	FM	C24H21FN2O3
DMEY7T4	IC	InChI=1S/C24H21FN2O3/c1-15(18-11-12-21(25)20-7-3-2-6-19(18)20)24(30)27-22-13-16(14-26)9-10-17(22)5-4-8-23(28)29/h2-3,6-7,9-13,15H,4-5,8H2,1H3,(H,27,30)(H,28,29)
DMEY7T4	CS	CC(C1=CC=C(C2=CC=CC=C21)F)C(=O)NC3=C(C=CC(=C3)C#N)CCCC(=O)O
DMEY7T4	IK	MTDIMKNAJUQTIO-UHFFFAOYSA-N
DMEY7T4	IU	4-[4-cyano-2-[2-(4-fluoronaphthalen-1-yl)propanoylamino]phenyl]butanoic acid
DMEY7T4	CA	CAS 402473-54-5
DMEY7T4	DE	Discovery agent

DMGA4W5	ID	DMGA4W5
DMGA4W5	DN	ONO-AE3-237
DMGA4W5	HS	Investigative
DMGA4W5	SN	ONO-AE3-237; SCHEMBL991038; GTPL8537; 2-[1-[4-[[(2S)-4,6-dimethyl-2,3-dihydro-1,4-benzoxazin-2-yl]methoxy]benzoyl]-2-methylindol-4-yl]acetic acid
DMGA4W5	DT	Small molecular drug
DMGA4W5	PC	10227892
DMGA4W5	MW	484.5
DMGA4W5	FM	C29H28N2O5
DMGA4W5	IC	InChI=1S/C29H28N2O5/c1-18-7-12-27-26(13-18)30(3)16-23(36-27)17-35-22-10-8-20(9-11-22)29(34)31-19(2)14-24-21(15-28(32)33)5-4-6-25(24)31/h4-14,23H,15-17H2,1-3H3,(H,32,33)/t23-/m0/s1
DMGA4W5	CS	CC1=CC2=C(C=C1)O[C@@H](CN2C)COC3=CC=C(C=C3)C(=O)N4C(=CC5=C(C=CC=C54)CC(=O)O)C
DMGA4W5	IK	PDLHJVXUGHZZQP-QHCPKHFHSA-N
DMGA4W5	IU	2-[1-[4-[[(2S)-4,6-dimethyl-2,3-dihydro-1,4-benzoxazin-2-yl]methoxy]benzoyl]-2-methylindol-4-yl]acetic acid
DMGA4W5	DE	Discovery agent

DMN3OWP	ID	DMN3OWP
DMN3OWP	DN	ONO-AE3-240
DMN3OWP	HS	Investigative
DMN3OWP	SN	ONO-AE3240
DMN3OWP	DT	Small molecular drug
DMN3OWP	PC	15984632
DMN3OWP	MW	531.6
DMN3OWP	FM	C34H33N3O3
DMN3OWP	IC	InChI=1S/C34H33N3O3/c1-23(2)19-31(30-14-7-11-25-9-3-5-12-28(25)30)33(38)36-32-20-24(22-37-18-8-17-35-37)15-16-27(32)21-26-10-4-6-13-29(26)34(39)40/h3-18,20,23,31H,19,21-22H2,1-2H3,(H,36,38)(H,39,40)
DMN3OWP	CS	CC(C)CC(C1=CC=CC2=CC=CC=C21)C(=O)NC3=C(C=CC(=C3)CN4C=CC=N4)CC5=CC=CC=C5C(=O)O
DMN3OWP	IK	WXTQSWUTEXDKIF-UHFFFAOYSA-N
DMN3OWP	IU	2-[[2-[(4-methyl-2-naphthalen-1-ylpentanoyl)amino]-4-(pyrazol-1-ylmethyl)phenyl]methyl]benzoic acid
DMN3OWP	DE	Discovery agent

DMDA7M9	ID	DMDA7M9
DMDA7M9	DN	ONO-AE5-599
DMDA7M9	HS	Investigative
DMDA7M9	SN	ONO-AE5-599; GTPL5823; J3.621.795B; 3-[2-[1-[[(1R)-1-(3,5-dimethylphenyl)-3-methylbutyl]amino]ethenyl]-4-[(2-methylphenoxy)methyl]phenyl]propanoic acid
DMDA7M9	DT	Small molecular drug
DMDA7M9	PC	73755159
DMDA7M9	MW	485.7
DMDA7M9	FM	C32H39NO3
DMDA7M9	IC	InChI=1S/C32H39NO3/c1-21(2)15-30(28-17-22(3)16-23(4)18-28)33-25(6)29-19-26(11-12-27(29)13-14-32(34)35)20-36-31-10-8-7-9-24(31)5/h7-12,16-19,21,30,33H,6,13-15,20H2,1-5H3,(H,34,35)/t30-/m1/s1
DMDA7M9	CS	CC1=CC=CC=C1OCC2=CC(=C(C=C2)CCC(=O)O)C(=C)N[C@H](CC(C)C)C3=CC(=CC(=C3)C)C
DMDA7M9	IK	MIHNFQDPLQJFEZ-SSEXGKCCSA-N
DMDA7M9	IU	3-[2-[1-[[(1R)-1-(3,5-dimethylphenyl)-3-methylbutyl]amino]ethenyl]-4-[(2-methylphenoxy)methyl]phenyl]propanoic acid
DMDA7M9	DE	Discovery agent

DMA1NL9	ID	DMA1NL9
DMA1NL9	DN	ONO-AP-324
DMA1NL9	HS	Investigative
DMA1NL9	SN	ONO AP 324
DMA1NL9	DT	Small molecular drug
DMA1NL9	PC	9867828
DMA1NL9	MW	439.5
DMA1NL9	FM	C28H25NO4
DMA1NL9	IC	InChI=1S/C28H25NO4/c30-26(29-28(21-9-3-1-4-10-21)22-11-5-2-6-12-22)18-17-20-13-7-15-24-23(20)14-8-16-25(24)33-19-27(31)32/h1-16,28H,17-19H2,(H,29,30)(H,31,32)
DMA1NL9	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)NC(=O)CCC3=C4C=CC=C(C4=CC=C3)OCC(=O)O
DMA1NL9	IK	YAPFKFDLARVWDB-UHFFFAOYSA-N
DMA1NL9	IU	2-[5-[3-(benzhydrylamino)-3-oxopropyl]naphthalen-1-yl]oxyacetic acid
DMA1NL9	DE	Discovery agent

DM81RKT	ID	DM81RKT
DM81RKT	DN	ONO-DI-004
DM81RKT	HS	Investigative
DM81RKT	SN	ONO-DI-004; 87-71-8; 4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]acetyl]cyclohexane-1-carboxylic acid; AC1NSK98; 250605-97-1; GTPL1914; SCHEMBL1273561; DTXSID20415516
DM81RKT	DT	Small molecular drug
DM81RKT	PC	5311227
DM81RKT	MW	422.6
DM81RKT	FM	C24H38O6
DM81RKT	IC	InChI=1S/C24H38O6/c1-3-4-5-15(2)12-18(25)10-11-19-20(23(28)14-22(19)27)13-21(26)16-6-8-17(9-7-16)24(29)30/h10-11,15-20,22,25,27H,3-9,12-14H2,1-2H3,(H,29,30)/b11-10+/t15-,16?,17?,18+,19+,20+,22+/m0/s1
DM81RKT	CS	CCCC[C@H](C)C[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CC(=O)C2CCC(CC2)C(=O)O)O)O
DM81RKT	IK	KWRRIFVHVJWXPU-HVCOQRSISA-N
DM81RKT	IU	4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]acetyl]cyclohexane-1-carboxylic acid
DM81RKT	CA	CAS 87-71-8
DM81RKT	DE	Discovery agent

DMDR95N	ID	DMDR95N
DMDR95N	DN	O-oleoyl-N-(2-hydroxyethyl)hydroxylamine
DMDR95N	HS	Investigative
DMDR95N	SN	CHEMBL380925; O-oleoyl-N-(2-hydroxyethyl)hydroxylamine; ZINC36294908
DMDR95N	DT	Small molecular drug
DMDR95N	PC	11702887
DMDR95N	MW	341.5
DMDR95N	FM	C20H39NO3
DMDR95N	IC	InChI=1S/C20H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)24-21-18-19-22/h9-10,21-22H,2-8,11-19H2,1H3/b10-9-
DMDR95N	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)ONCCO
DMDR95N	IK	WVNBOVPUAYEKIK-KTKRTIGZSA-N
DMDR95N	IU	(2-hydroxyethylamino) (Z)-octadec-9-enoate
DMDR95N	DE	Discovery agent

DMQOJY2	ID	DMQOJY2
DMQOJY2	DN	OPC 4392
DMQOJY2	HS	Investigative
DMQOJY2	SN	OPC-4392
DMQOJY2	DT	Small molecular drug
DMQOJY2	PC	163839
DMQOJY2	MW	391.5
DMQOJY2	FM	C24H29N3O2
DMQOJY2	IC	InChI=1S/C24H29N3O2/c1-18-5-3-6-23(19(18)2)27-14-12-26(13-15-27)11-4-16-29-21-9-7-20-8-10-24(28)25-22(20)17-21/h3,5-10,17H,4,11-16H2,1-2H3,(H,25,28)
DMQOJY2	CS	CC1=C(C(=CC=C1)N2CCN(CC2)CCCOC3=CC4=C(C=C3)C=CC(=O)N4)C
DMQOJY2	IK	RRLWEQBPSAFVAS-UHFFFAOYSA-N
DMQOJY2	IU	7-[3-[4-(2,3-dimethylphenyl)piperazin-1-yl]propoxy]-1H-quinolin-2-one
DMQOJY2	CA	CAS 111073-34-8
DMQOJY2	DE	Discovery agent

DMO4WH9	ID	DMO4WH9
DMO4WH9	DN	OPC-22575
DMO4WH9	HS	Investigative
DMO4WH9	SN	OPC-22321; OPC-22381
DMO4WH9	CP	Otsuka Pharmaceutical Co Ltd
DMO4WH9	DE	Ulcerative colitis

DM3O9YW	ID	DM3O9YW
DM3O9YW	DN	O-Phosphoethanolamine
DM3O9YW	HS	Investigative
DM3O9YW	SN	2-Aminoethyl dihydrogen phosphate; O-Phosphorylethanolamine; 1071-23-4; O-Phosphocolamine; Colamine phosphate; Phosphorylethanolamine; ethanolamine phosphate; Phosphonoethanolamine; Ethanolamine O-phosphate; Mono(2-aminoethyl) phosphate; Phosphoryethanolamine; COLAMINE PHOSPHORIC ACID; Colaminephosphoric acid; Pe 104; Colaminphosphoric acid; Ethanol, 2-amino-, phosphate; Ethanolamine acid phosphate; Ethanol, 2-amino-, dihydrogen phosphate (ester); monoaminoethyl phosphate
DM3O9YW	DT	Small molecular drug
DM3O9YW	PC	1015
DM3O9YW	MW	141.06
DM3O9YW	FM	C2H8NO4P
DM3O9YW	IC	InChI=1S/C2H8NO4P/c3-1-2-7-8(4,5)6/h1-3H2,(H2,4,5,6)
DM3O9YW	CS	C(COP(=O)(O)O)N
DM3O9YW	IK	SUHOOTKUPISOBE-UHFFFAOYSA-N
DM3O9YW	IU	2-aminoethyl dihydrogen phosphate
DM3O9YW	CA	CAS 1071-23-4
DM3O9YW	CB	CHEBI:17553

DM0XT69	ID	DM0XT69
DM0XT69	DN	orexin-B
DM0XT69	HS	Investigative
DM0XT69	SN	orexin b; hypocretin-2
DM0XT69	DT	Small molecular drug
DM0XT69	PC	44404987
DM0XT69	MW	2899.3
DM0XT69	FM	C123H212N44O35S
DM0XT69	IC	InChI=1S/C123H212N44O35S/c1-18-63(12)96(164-114(196)80(46-62(10)11)163-119(201)97(67(16)170)165-102(184)69(124)35-41-203-17)118(200)143-50-91(175)146-64(13)99(181)147-65(14)101(183)157-81(47-68-49-136-57-145-68)113(195)162-82(48-90(128)174)105(187)141-52-93(177)150-83(55-168)115(197)148-66(15)100(182)153-74(30-33-88(126)172)108(190)160-79(45-61(8)9)112(194)161-78(44-60(6)7)111(193)155-72(26-21-38-139-123(134)135)106(188)156-75(31-34-89(127)173)109(191)159-77(43-59(4)5)110(192)154-71(25-20-37-138-122(132)133)103(185)140-51-92(176)149-73(29-32-87(125)171)107(189)158-76(42-58(2)3)104(186)144-54-95(179)166-39-23-28-86(166)120(202)167-40-22-27-85(167)117(199)142-53-94(178)151-84(56-169)116(198)152-70(98(129)180)24-19-36-137-121(130)131/h49,57-67,69-86,96-97,168-170H,18-48,50-56,124H2,1-17H3,(H2,125,171)(H2,126,172)(H2,127,173)(H2,128,174)(H2,129,180)(H,136,145)(H,140,185)(H,141,187)(H,142,199)(H,143,200)(H,144,186)(H,146,175)(H,147,181)(H,148,197)(H,149,176)(H,150,177)(H,151,178)(H,152,198)(H,153,182)(H,154,192)(H,155,193)(H,156,188)(H,157,183)(H,158,189)(H,159,191)(H,160,190)(H,161,194)(H,162,195)(H,163,201)(H,164,196)(H,165,184)(H4,130,131,137)(H4,132,133,138)(H4,134,135,139)/t63-,64-,65-,66-,67+,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,96-,97-/m0/s1
DM0XT69	CS	CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)N
DM0XT69	IK	OHOWSYIKESXDMN-WMQZXSDYSA-N
DM0XT69	IU	(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]propanoyl]amino]propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-N-[(2S)-1-[[2-[(2S)-2-[(2S)-2-[[2-[[(2S)-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]pentanediamide
DM0XT69	DE	Discovery agent

DM8JUBG	ID	DM8JUBG
DM8JUBG	DN	Org 12962
DM8JUBG	HS	Investigative
DM8JUBG	SN	Org-12962; Org12962
DM8JUBG	DT	Small molecular drug
DM8JUBG	PC	9796408
DM8JUBG	MW	265.66
DM8JUBG	FM	C10H11ClF3N3
DM8JUBG	IC	InChI=1S/C10H11ClF3N3/c11-9-7(10(12,13)14)1-2-8(16-9)17-5-3-15-4-6-17/h1-2,15H,3-6H2
DM8JUBG	CS	C1CN(CCN1)C2=NC(=C(C=C2)C(F)(F)F)Cl
DM8JUBG	IK	QZYYPQAYSFBKPW-UHFFFAOYSA-N
DM8JUBG	IU	1-[6-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazine
DM8JUBG	CA	CAS 132834-56-1
DM8JUBG	DE	Discovery agent

DMH1M6N	ID	DMH1M6N
DMH1M6N	DN	ORG2058
DMH1M6N	HS	Investigative
DMH1M6N	SN	IJLXLZGJDSJGIQ-BILPMHSYSA-N; Org-2058; Org 2058; CHEMBL2311103; 24320-06-7; (8R,9S,10R,13S,14S,16R,17S)-16-ethyl-17-(2-hydroxyacetyl)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; O-2058; [3H]ORG2058; [3H]-ORG2058; A)-16-ethyl-21-hydroxy-19-norpregn-4-ene-3,20-dione; AC1Q6OBA; AC1L3O6Q; SCHEMBL3273165; GTPL3454; GTPL3453; 16alpha-Ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione; BDBM50422735; (16alpha)-16-Ethyl-21-hydroxy-19-norpregn-4-ene-3,20-dione; 19-Norpregn-4-ene-3,20-dione,; ORG-2058; ORG 2058
DMH1M6N	DT	Small molecular drug
DMH1M6N	PC	119086
DMH1M6N	MW	344.5
DMH1M6N	FM	C22H32O3
DMH1M6N	IC	InChI=1S/C22H32O3/c1-3-13-11-19-18-6-4-14-10-15(24)5-7-16(14)17(18)8-9-22(19,2)21(13)20(25)12-23/h10,13,16-19,21,23H,3-9,11-12H2,1-2H3/t13-,16+,17-,18-,19+,21-,22+/m1/s1
DMH1M6N	CS	CC[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]2([C@H]1C(=O)CO)C
DMH1M6N	IK	IJLXLZGJDSJGIQ-BILPMHSYSA-N
DMH1M6N	IU	(8R,9S,10R,13S,14S,16R,17S)-16-ethyl-17-(2-hydroxyacetyl)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
DMH1M6N	CA	CAS 24320-06-7
DMH1M6N	DE	Discovery agent

DMTFGYH	ID	DMTFGYH
DMTFGYH	DN	Org-231295
DMTFGYH	HS	Investigative
DMTFGYH	SN	3'-Carbamoyl-[1,1'-biphenyl]-3-yl cyclohexylcarbamate; 546141-08-6; URB597; URB-597; URB 597; FAAH Inhibitor II; KDS-4103; UNII-PX47LB88FO; 3-(3-carbamoylphenyl)phenyl N-cyclohexylcarbamate; PX47LB88FO; CHEMBL184238; 3'-Carbamoylbiphenyl-3-yl cyclohexylcarbamate; [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate; Carbamic acid, N-cyclohexyl-, 3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl ester; Cyclohexyl-carbamic acid 3'-carbamoyl-biphenyl-3-yl ester; KDS-1243; FAAH inhibitor, Merck & Co; FAAH inhibitor, Schering-Plough/Kadmus/university of California; 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate
DMTFGYH	CP	University of California
DMTFGYH	DT	Small molecular drug
DMTFGYH	PC	1383884
DMTFGYH	MW	338.4
DMTFGYH	FM	C20H22N2O3
DMTFGYH	IC	InChI=1S/C20H22N2O3/c21-19(23)16-8-4-6-14(12-16)15-7-5-11-18(13-15)25-20(24)22-17-9-2-1-3-10-17/h4-8,11-13,17H,1-3,9-10H2,(H2,21,23)(H,22,24)
DMTFGYH	CS	C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N
DMTFGYH	IK	ROFVXGGUISEHAM-UHFFFAOYSA-N
DMTFGYH	IU	[3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate
DMTFGYH	CA	CAS 546141-08-6
DMTFGYH	DE	Anxiety disorder

DMRU3H0	ID	DMRU3H0
DMRU3H0	DN	Org27569
DMRU3H0	HS	Investigative
DMRU3H0	SN	Org 27569
DMRU3H0	DT	Small molecular drug
DMRU3H0	PC	44828492
DMRU3H0	MW	409.9
DMRU3H0	FM	C24H28ClN3O
DMRU3H0	IC	InChI=1S/C24H28ClN3O/c1-2-20-21-16-18(25)8-11-22(21)27-23(20)24(29)26-13-12-17-6-9-19(10-7-17)28-14-4-3-5-15-28/h6-11,16,27H,2-5,12-15H2,1H3,(H,26,29)
DMRU3H0	CS	CCC1=C(NC2=C1C=C(C=C2)Cl)C(=O)NCCC3=CC=C(C=C3)N4CCCCC4
DMRU3H0	IK	AHFZDNYNXFMRFQ-UHFFFAOYSA-N
DMRU3H0	IU	5-chloro-3-ethyl-N-[2-(4-piperidin-1-ylphenyl)ethyl]-1H-indole-2-carboxamide
DMRU3H0	CA	CAS 868273-06-7
DMRU3H0	DE	Discovery agent

DMXGA56	ID	DMXGA56
DMXGA56	DN	Org-30850
DMXGA56	HS	Investigative
DMXGA56	SN	136208-71-4; Org-300850
DMXGA56	DT	Small molecular drug
DMXGA56	PC	44384543
DMXGA56	MW	1441.5
DMXGA56	FM	C69H91Cl2N15O13S
DMXGA56	IC	InChI=1S/C69H91Cl2N15O13S/c1-38(2)31-51(61(92)80-50(13-9-29-76-69(74)75)68(99)86-30-10-14-57(86)67(98)77-39(3)59(73)90)81-60(91)49(12-7-8-28-72)79-63(94)53(34-43-20-26-47(89)27-21-43)83-66(97)56(36-87)85-65(96)55(35-44-37-100-58-15-6-5-11-48(44)58)84-64(95)54(33-42-18-24-46(71)25-19-42)82-62(93)52(78-40(4)88)32-41-16-22-45(70)23-17-41/h5-6,11,15-27,37-39,49-57,87,89H,7-10,12-14,28-36,72H2,1-4H3,(H2,73,90)(H,77,98)(H,78,88)(H,79,94)(H,80,92)(H,81,91)(H,82,93)(H,83,97)(H,84,95)(H,85,96)(H4,74,75,76)/t39-,49-,50-,51-,52-,53-,54-,55-,56-,57+/m0/s1
DMXGA56	CS	C[C@@H](C(=O)N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CSC4=CC=CC=C43)NC(=O)[C@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@H](CC6=CC=C(C=C6)Cl)NC(=O)C
DMXGA56	IK	ONHXPWXXSUUCDR-IQZQIIRESA-N
DMXGA56	IU	(2R)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-chlorophenyl)propanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1-benzothiophen-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2S)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMXGA56	DE	Discovery agent

DMDY38R	ID	DMDY38R
DMDY38R	DN	Org-33201
DMDY38R	HS	Investigative
DMDY38R	SN	148714-92-5
DMDY38R	DT	Small molecular drug
DMDY38R	PC	196932
DMDY38R	MW	377
DMDY38R	FM	C21H29ClN2S
DMDY38R	IC	InChI=1S/C21H28N2S.ClH/c1-3-21-9-5-6-17-7-8-19(24-4-2)18(20(17)21)12-16(13-21)14-23-11-10-22-15-23;/h7-8,10-11,15-16H,3-6,9,12-14H2,1-2H3;1H/t16-,21-;/m1./s1
DMDY38R	CS	CC[C@]12CCCC3=C1C(=C(C=C3)SCC)C[C@H](C2)CN4C=CN=C4.Cl
DMDY38R	IK	CQCWQGXXUFLLAL-KTWHHOSASA-N
DMDY38R	IU	1-[[(2S,3aR)-3a-ethyl-9-ethylsulfanyl-1,2,3,4,5,6-hexahydrophenalen-2-yl]methyl]imidazole;hydrochloride
DMDY38R	CA	CAS 148714-92-5
DMDY38R	DE	Discovery agent

DM4SFKW	ID	DM4SFKW
DM4SFKW	DN	Org-36764
DM4SFKW	HS	Investigative
DM4SFKW	SN	175890-65-0; ORG-38793; Org-36653; Org-36654; Org-36708
DM4SFKW	DE	Discovery agent

DM3EZDG	ID	DM3EZDG
DM3EZDG	DN	Org-37663
DM3EZDG	HS	Investigative
DM3EZDG	DE	Discovery agent

DMPQGUL	ID	DMPQGUL
DMPQGUL	DN	ORIPAVINE
DMPQGUL	HS	Investigative
DMPQGUL	SN	Oripavine; UNII-575AOU51CR; 467-04-9; EINECS 207-385-6; BRN 0046094; CHEBI:7782; 575AOU51CR; 6,7,8,14-Tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methyl-morphinan-3-ol; (5alpha)-6,7,8,14-Tetradehydro-4,5-epoxy-6-methoxy-17-methylmorphinan-3-ol; Morphinan-3-ol, 6,7,8,14-tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methyl-; 3-O-demethyl-thebaine; SCHEMBL37889; 4-27-00-02270 (Beilstein Handbook Reference); CHEMBL437602; DEA No. 9330; SCHEMBL19880919; DTXSID10196908; ZKLXUUYLEHCAMF-UUWFMWQGSA-N; Oripavine 0.1 mg/ml in Methanol
DMPQGUL	DT	Small molecular drug
DMPQGUL	PC	5462306
DMPQGUL	MW	297.3
DMPQGUL	FM	C18H19NO3
DMPQGUL	IC	InChI=1S/C18H19NO3/c1-19-8-7-18-11-4-6-14(21-2)17(18)22-16-13(20)5-3-10(15(16)18)9-12(11)19/h3-6,12,17,20H,7-9H2,1-2H3/t12-,17+,18+/m1/s1
DMPQGUL	CS	CN1CC[C@]23[C@@H]4C(=CC=C2[C@H]1CC5=C3C(=C(C=C5)O)O4)OC
DMPQGUL	IK	ZKLXUUYLEHCAMF-UUWFMWQGSA-N
DMPQGUL	IU	(4R,7aR,12bS)-7-methoxy-3-methyl-2,4,7a,13-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol
DMPQGUL	CA	CAS 467-04-9
DMPQGUL	CB	CHEBI:7782
DMPQGUL	DE	Discovery agent

DMA2DQT	ID	DMA2DQT
DMA2DQT	DN	OROIDIN
DMA2DQT	HS	Investigative
DMA2DQT	SN	Oroidin; UNII-PF75E92XKM; PF75E92XKM; CHEMBL397591; CHEBI:70037; 34649-22-4; Oroidine; oroidin base; AC1O3Q2I; MLS001250229; SCHEMBL12597862; BDBM50220547; SMR001216083; Oroidin - CASMI2016 Category 1 - Challenge 2; N-[(E)-3-(2-amino-1H-imidazol-5-yl)prop-2-enyl]-4,5-dibromo-1H-pyrrole-2-carboxamide; N-(3-(2-Amino-1H-imidazole-5-yl)allyl)-4,5-dibromo-1H-pyrrole-2-carboxamide; 4,5-Dibromo-1H-pyrrole-2-carboxylic acid [3-(2-amino-1H-imidazol-4-yl)-allyl]-amide; 1H-Pyrrole-2-carboxamide, N-[(2E)-3-(2-amino-1H-imidazol-5-yl)-2-
DMA2DQT	DT	Small molecular drug
DMA2DQT	PC	6312649
DMA2DQT	MW	389.05
DMA2DQT	FM	C11H11Br2N5O
DMA2DQT	IC	InChI=1S/C11H11Br2N5O/c12-7-4-8(18-9(7)13)10(19)15-3-1-2-6-5-16-11(14)17-6/h1-2,4-5,18H,3H2,(H,15,19)(H3,14,16,17)/b2-1+
DMA2DQT	CS	C1=C(NC(=C1Br)Br)C(=O)NC/C=C/C2=CN=C(N2)N
DMA2DQT	IK	QKJAXHBFQSBDAR-OWOJBTEDSA-N
DMA2DQT	IU	N-[(E)-3-(2-amino-1H-imidazol-5-yl)prop-2-enyl]-4,5-dibromo-1H-pyrrole-2-carboxamide
DMA2DQT	CA	CAS 34649-22-4
DMA2DQT	CB	CHEBI:70037
DMA2DQT	DE	Discovery agent

DMMB29S	ID	DMMB29S
DMMB29S	DN	Orotate
DMMB29S	HS	Investigative
DMMB29S	SN	73-97-2; Orotic acidanion; AC1LSPNG; CHEBI:30839; CTK5D9013; DTXSID80363448; PXQPEWDEAKTCGB-UHFFFAOYSA-M; AG-G-93379; 2,4-dioxo-1H-pyrimidine-6-carboxylate; CJ-15820; 21317-EP2314295A1; 21317-EP2284172A1; 21317-EP2281559A1; 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate; 4-Pyrimidinecarboxylicacid, 1,2,3,6-tetrahydro-2,6-dioxo-, ion(1-)
DMMB29S	DT	Small molecular drug
DMMB29S	PC	1492348
DMMB29S	MW	155.09
DMMB29S	FM	C5H3N2O4-
DMMB29S	IC	InChI=1S/C5H4N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h1H,(H,9,10)(H2,6,7,8,11)/p-1
DMMB29S	CS	C1=C(NC(=O)NC1=O)C(=O)[O-]
DMMB29S	IK	PXQPEWDEAKTCGB-UHFFFAOYSA-M
DMMB29S	IU	2,4-dioxo-1H-pyrimidine-6-carboxylate
DMMB29S	CA	CAS 73-97-2
DMMB29S	CB	CHEBI:30839
DMMB29S	DE	Discovery agent

DMP6BSH	ID	DMP6BSH
DMP6BSH	DN	Orotic acid
DMP6BSH	HS	Investigative
DMP6BSH	SN	65-86-1; 6-Carboxyuracil; Oropur; Orodin; Orotonin; Orotonsan; Oroturic; Orotyl; Whey factor; Vitamin B13; 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid; Uracil-6-carboxylic acid; 6-Uracilcarboxylic acid; Animal galactose factor; Orotsaeure; Molkensaeure; Uracil-6-carbosaeure; 4-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-; 2,6-Dihydroxypyrimidine-4-carboxylic acid; 2,6-Dihydroxy-4-pyrimidinecarboxylic acid; Orotsaeure [German]; Acidum oroticum; Acide orotique; Acido orotico; Acidum oroti
DMP6BSH	DT	Small molecular drug
DMP6BSH	PC	967
DMP6BSH	MW	156.1
DMP6BSH	FM	C5H4N2O4
DMP6BSH	IC	InChI=1S/C5H4N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h1H,(H,9,10)(H2,6,7,8,11)
DMP6BSH	CS	C1=C(NC(=O)NC1=O)C(=O)O
DMP6BSH	IK	PXQPEWDEAKTCGB-UHFFFAOYSA-N
DMP6BSH	IU	2,4-dioxo-1H-pyrimidine-6-carboxylic acid
DMP6BSH	CA	CAS 65-86-1
DMP6BSH	CB	CHEBI:16742
DMP6BSH	DE	Discovery agent

DMGRXD4	ID	DMGRXD4
DMGRXD4	DN	Orthovanadate
DMGRXD4	HS	Investigative
DMGRXD4	SN	Vanadic acid; Vanadiumsaeure; trihydroxy(oxo)vanadium; H3VO4; CHEMBL50626; CHEBI:27273; [VO(OH)3]; trihydroxidooxidovanadium; S6508_SIGMA; trihydrogen(tetraoxidovanadate); AC1L9D41; WQEVDHBJGNOKKO-UHFFFAOYSA-K; BDBM50284960
DMGRXD4	DT	Small molecular drug
DMGRXD4	PC	417214
DMGRXD4	MW	117.963
DMGRXD4	FM	H3O4V
DMGRXD4	IC	InChI=1S/3H2O.O.V/h3*1H2;;/q;;;;+3/p-3
DMGRXD4	CS	O[V](=O)(O)O
DMGRXD4	IK	WQEVDHBJGNOKKO-UHFFFAOYSA-K
DMGRXD4	IU	trihydroxy(oxo)vanadium
DMGRXD4	CB	CHEBI:27273
DMGRXD4	DE	Discovery agent

DMK6X5P	ID	DMK6X5P
DMK6X5P	DN	OSCILLARIN
DMK6X5P	HS	Investigative
DMK6X5P	SN	Oscillarin; CHEMBL541173; (2R,3AS,6R,7AS)-N-(2-{1-[AMINO(IMINO)METHYL]-2,5-DIHYDRO-1H-PYRROL-3-YL}ETHYL)-6-HYDROXY-1-{N-[(2S)-2-HYDROXY-3-PHENYLPROPANOYL]PHENYLALANYL}OCTAHYDRO-1H-INDOLE-2-CARBOXAMIDE; AC1NRCN1; BDBM50294877; (2R,3AS,6R,7AS)-6-HYDROXY-1-{(2R)-2-[(2R)-2-HYDROXY-3-PHENYL-PROPIONYLAMINO]-3-PHENYL-PROPIONYL}-OCTAHYDORO-INDOLE-2-CARBOXYLIC ACID [2-(1-CARBAMIMIDOYL-2,5-DIHYDRO-1H-PYRROL-3-YL)-ETHYL]-AMIDE; OSCILLARIN, (2R,3AS,6R,7AS)-6-HYDROXY-1-{(2R)-2-[(2R)-2-HYDROXY-3-PHENYL-PROPIONYLAMINO]-3-PHENYL
DMK6X5P	DT	Small molecular drug
DMK6X5P	PC	5289082
DMK6X5P	MW	616.7
DMK6X5P	FM	C34H44N6O5
DMK6X5P	IC	InChI=1S/C34H44N6O5/c35-34(36)39-16-14-24(21-39)13-15-37-31(43)29-19-25-11-12-26(41)20-28(25)40(29)33(45)27(17-22-7-3-1-4-8-22)38-32(44)30(42)18-23-9-5-2-6-10-23/h1-10,14,25-30,41-42H,11-13,15-21H2,(H3,35,36)(H,37,43)(H,38,44)/t25-,26+,27+,28-,29-,30+/m0/s1
DMK6X5P	CS	C1C[C@H](C[C@H]2[C@@H]1C[C@H](N2C(=O)[C@@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CC=CC=C4)O)C(=O)NCCC5=CCN(C5)C(=N)N)O
DMK6X5P	IK	YNAKQOCSOOKXJP-VCNFNBSBSA-N
DMK6X5P	IU	(2S,3aS,6R,7aS)-N-[2-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)ethyl]-6-hydroxy-1-[(2R)-2-[[(2R)-2-hydroxy-3-phenylpropanoyl]amino]-3-phenylpropanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxamide
DMK6X5P	DE	Discovery agent

DM5IGN7	ID	DM5IGN7
DM5IGN7	DN	OSI-75
DM5IGN7	HS	Investigative
DM5IGN7	DE	Discovery agent

DMCAR7B	ID	DMCAR7B
DMCAR7B	DN	O-Sialic Acid
DMCAR7B	HS	Investigative
DMCAR7B	SN	alpha-Neu5Ac; N-acetyl-alpha-neuraminic acid; O-sialic acid; CHEBI:49026; N-Acetyl-a-neuraminic acid; UNII-04A90EXP8V; sialic acid; 04A90EXP8V; N-acetyl-alpha-neuraminate; NANA; 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosonic acid; 131-48-6; SIA; (2R,4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid; polysialic acid; Alpha-Sialoside; 4lkh; 2qwb; N-Acetyl-a-neuraminate; N-Acetyl-a-D-neuraminate; Epitope ID:136794; SCHEMBL79085; N-Acetyl-a-D-neuraminic acid
DMCAR7B	DT	Small molecular drug
DMCAR7B	PC	444885
DMCAR7B	MW	309.27
DMCAR7B	FM	C11H19NO9
DMCAR7B	IC	InChI=1S/C11H19NO9/c1-4(14)12-7-5(15)2-11(20,10(18)19)21-9(7)8(17)6(16)3-13/h5-9,13,15-17,20H,2-3H2,1H3,(H,12,14)(H,18,19)/t5-,6+,7+,8+,9+,11+/m0/s1
DMCAR7B	CS	CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)O)O
DMCAR7B	IK	SQVRNKJHWKZAKO-YRMXFSIDSA-N
DMCAR7B	IU	(2R,4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMCAR7B	CA	CAS 21646-00-4
DMCAR7B	CB	CHEBI:49026
DMCAR7B	DE	Discovery agent

DM3FS62	ID	DM3FS62
DM3FS62	DN	O-spiroketal glucoside
DM3FS62	HS	Investigative
DM3FS62	SN	CHEMBL565784; O-spiroketal glucoside; SCHEMBL1317722; BDBM50303240
DM3FS62	DT	Small molecular drug
DM3FS62	PC	45488072
DM3FS62	MW	436.9
DM3FS62	FM	C22H25ClO7
DM3FS62	IC	InChI=1S/C22H25ClO7/c1-2-28-15-5-3-12(4-6-15)7-13-8-16-14(9-17(13)23)11-29-22(16)21(27)20(26)19(25)18(10-24)30-22/h3-6,8-9,18-21,24-27H,2,7,10-11H2,1H3/t18-,19-,20+,21-,22+/m1/s1
DM3FS62	CS	CCOC1=CC=C(C=C1)CC2=C(C=C3CO[C@]4(C3=C2)[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
DM3FS62	IK	WUEOKKVPVLUFPP-BDHVOXNPSA-N
DM3FS62	IU	(3S,3'R,4'S,5'S,6'R)-6-chloro-5-[(4-ethoxyphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol
DM3FS62	DE	Discovery agent

DMQPJXT	ID	DMQPJXT
DMQPJXT	DN	OSU-53
DMQPJXT	HS	Investigative
DMQPJXT	SN	CHEMBL597622; 1290069-19-0; n-{4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-4-nitro-3-trifluoromethyl-benzenesulfonamide; SCHEMBL1615001; BDBM50503138
DMQPJXT	DT	Small molecular drug
DMQPJXT	PC	45378798
DMQPJXT	MW	583.6
DMQPJXT	FM	C25H24F3N3O6S2
DMQPJXT	IC	InChI=1S/C25H24F3N3O6S2/c1-24(11-3-2-4-12-24)15-30-22(32)21(38-23(30)33)13-16-5-7-17(8-6-16)29-39(36,37)18-9-10-20(31(34)35)19(14-18)25(26,27)28/h5-10,13-14,29H,2-4,11-12,15H2,1H3/b21-13-
DMQPJXT	CS	CC1(CCCCC1)CN2C(=O)/C(=C/C3=CC=C(C=C3)NS(=O)(=O)C4=CC(=C(C=C4)[N+](=O)[O-])C(F)(F)F)/SC2=O
DMQPJXT	IK	FANMQRSNMHKZCR-BKUYFWCQSA-N
DMQPJXT	IU	N-[4-[(Z)-[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenyl]-4-nitro-3-(trifluoromethyl)benzenesulfonamide
DMQPJXT	DE	Triple negative breast cancer

DM0R6MT	ID	DM0R6MT
DM0R6MT	DN	O-tolyl 10H-phenothiazine-10-carboxylate
DM0R6MT	HS	Investigative
DM0R6MT	SN	CHEMBL481688; o-tolyl 10H-phenothiazine-10-carboxylate
DM0R6MT	DT	Small molecular drug
DM0R6MT	PC	24905592
DM0R6MT	MW	333.4
DM0R6MT	FM	C20H15NO2S
DM0R6MT	IC	InChI=1S/C20H15NO2S/c1-14-8-2-5-11-17(14)23-20(22)21-15-9-3-6-12-18(15)24-19-13-7-4-10-16(19)21/h2-13H,1H3
DM0R6MT	CS	CC1=CC=CC=C1OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM0R6MT	IK	GUKIJFIFHIRCFR-UHFFFAOYSA-N
DM0R6MT	IU	(2-methylphenyl) phenothiazine-10-carboxylate
DM0R6MT	DE	Discovery agent

DMXP72F	ID	DMXP72F
DMXP72F	DN	OTS964
DMXP72F	HS	Investigative
DMXP72F	SN	(R)-9-(4-(1-(dimethylamino)propan-2-yl)phenyl)-8-hydroxy-6-methylthieno[2,3-c]quinolin-4(5H)-one; 1338545-07-5; SCHEMBL2548561; GTPL7813; CHEMBL3672369; MolPort-044-561-385; ZINC149881647; SB19795; NCGC00484799-01; 9-{4-[(2R)-1-(dimethylamino)propan-2-yl]phenyl}-8-hydroxy-6-methyl-4H,5H-thieno[2,3-c]quinolin-4-one
DMXP72F	DT	Small molecular drug
DMXP72F	PC	67448186
DMXP72F	MW	392.5
DMXP72F	FM	C23H24N2O2S
DMXP72F	IC	InChI=1S/C23H24N2O2S/c1-13-11-18(26)19(16-7-5-15(6-8-16)14(2)12-25(3)4)20-17-9-10-28-22(17)23(27)24-21(13)20/h5-11,14,26H,12H2,1-4H3,(H,24,27)/t14-/m0/s1
DMXP72F	CS	CC1=CC(=C(C2=C1NC(=O)C3=C2C=CS3)C4=CC=C(C=C4)[C@@H](C)CN(C)C)O
DMXP72F	IK	XCFRUAOZMVFDPQ-AWEZNQCLSA-N
DMXP72F	IU	9-[4-[(2R)-1-(dimethylamino)propan-2-yl]phenyl]-8-hydroxy-6-methyl-5H-thieno[2,3-c]quinolin-4-one
DMXP72F	DE	Discovery agent

DMM4CE7	ID	DMM4CE7
DMM4CE7	DN	Ovalicin
DMM4CE7	HS	Investigative
DMM4CE7	DT	Small molecular drug
DMM4CE7	PC	10957430
DMM4CE7	MW	296.36
DMM4CE7	FM	C16H24O5
DMM4CE7	IC	InChI=1S/C16H24O5/c1-10(2)5-6-12-14(3,21-12)16(18)13(19-4)11(17)7-8-15(16)9-20-15/h5,12-13,18H,6-9H2,1-4H3/t12-,13-,14+,15+,16+/m1/s1
DMM4CE7	CS	CC(=CC[C@@H]1[C@@](O1)(C)[C@]2([C@@H](C(=O)CC[C@]23CO3)OC)O)C
DMM4CE7	IK	NESRXFGQJARQNM-OWYFMNJBSA-N
DMM4CE7	IU	(3S,4R,5S)-4-hydroxy-5-methoxy-4-[(2S,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-one
DMM4CE7	CA	CAS 19683-98-8
DMM4CE7	DE	Discovery agent

DMAV9PS	ID	DMAV9PS
DMAV9PS	DN	OVI-117
DMAV9PS	HS	Investigative
DMAV9PS	SN	L-117; OVI-110; OVI-151; L-nucleoside conjugates (cancer), OncoVista; 5-FU analogs, OncoVista
DMAV9PS	CP	OncoVista Innovative Therapies Inc
DMAV9PS	DE	Solid tumour/cancer

DMCFM2E	ID	DMCFM2E
DMCFM2E	DN	OXA-01
DMCFM2E	HS	Investigative
DMCFM2E	SN	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals
DMCFM2E	CP	OSI Pharmaceuticals Inc
DMCFM2E	PC	45276387
DMCFM2E	MW	409.9
DMCFM2E	FM	C21H20ClN5O2
DMCFM2E	IC	InChI=1S/C21H20ClN5O2/c22-14-3-1-2-13-10-15(25-16(13)14)17-18-19(23)24-8-9-27(18)20(26-17)11-4-6-12(7-5-11)21(28)29/h1-3,8-12,25H,4-7H2,(H2,23,24)(H,28,29)
DMCFM2E	CS	C1CC(CCC1C2=NC(=C3N2C=CN=C3N)C4=CC5=C(N4)C(=CC=C5)Cl)C(=O)O
DMCFM2E	IK	UXCAKZGNKOZXBM-UHFFFAOYSA-N
DMCFM2E	IU	4-[8-amino-1-(7-chloro-1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxylic acid
DMCFM2E	DE	Solid tumour/cancer

DMPZSV1	ID	DMPZSV1
DMPZSV1	DN	Oxalacetic acid
DMPZSV1	HS	Investigative
DMPZSV1	SN	oxaloacetate
DMPZSV1	DT	Small molecular drug
DMPZSV1	PC	970
DMPZSV1	MW	132.07
DMPZSV1	FM	C4H4O5
DMPZSV1	IC	InChI=1S/C4H4O5/c5-2(4(8)9)1-3(6)7/h1H2,(H,6,7)(H,8,9)
DMPZSV1	CS	C(C(=O)C(=O)O)C(=O)O
DMPZSV1	IK	KHPXUQMNIQBQEV-UHFFFAOYSA-N
DMPZSV1	IU	2-oxobutanedioic acid
DMPZSV1	CA	CAS 328-42-7
DMPZSV1	CB	CHEBI:30744
DMPZSV1	DE	Discovery agent

DM40SEU	ID	DM40SEU
DM40SEU	DN	Oxalate
DM40SEU	HS	Investigative
DM40SEU	SN	oxalate2-
DM40SEU	DT	Small molecular drug
DM40SEU	PC	71081
DM40SEU	MW	88.02
DM40SEU	FM	C2O4-2
DM40SEU	IC	InChI=1S/C2H2O4/c3-1(4)2(5)6/h(H,3,4)(H,5,6)/p-2
DM40SEU	CS	C(=O)(C(=O)[O-])[O-]
DM40SEU	IK	MUBZPKHOEPUJKR-UHFFFAOYSA-L
DM40SEU	IU	oxalate
DM40SEU	CA	CAS 338-70-5
DM40SEU	CB	CHEBI:30623
DM40SEU	DE	Discovery agent

DMLN2GQ	ID	DMLN2GQ
DMLN2GQ	DN	Oxalic Acid
DMLN2GQ	HS	Investigative
DMLN2GQ	SN	ethanedioic acid; 144-62-7; Aktisal; Aquisal; Oxiric acid; Oxalsaeure; Oxaalzuur; Kyselina stavelova; Acide oxalique; Acido ossalico; Acidum oxalicum; Caswell No. 625; Oxaalzuur [Dutch]; Oxalsaeure [German]; NCI-C55209; Ethanedionic acid; Acide oxalique [French]; Acido ossalico [Italian]; Kyselina stavelova [Czech]; CCRIS 1454; EPA Pesticide Chemical Code 009601; Ethane-1,2-dioic acid; HSDB 1100; AI3-26463; NSC 62774; UNII-9E7R5L6H31; BRN 0385686; HOOCCOOH; Oxalic acid anhydrous; C2H2O4; EINECS 205-634-3; CHEBI:16995
DMLN2GQ	DT	Small molecular drug
DMLN2GQ	PC	971
DMLN2GQ	MW	90.03
DMLN2GQ	FM	C2H2O4
DMLN2GQ	IC	InChI=1S/C2H2O4/c3-1(4)2(5)6/h(H,3,4)(H,5,6)
DMLN2GQ	CS	C(=O)(C(=O)O)O
DMLN2GQ	IK	MUBZPKHOEPUJKR-UHFFFAOYSA-N
DMLN2GQ	IU	oxalic acid
DMLN2GQ	CA	CAS 144-62-7
DMLN2GQ	CB	CHEBI:16995
DMLN2GQ	DE	Discovery agent

DMT7XYE	ID	DMT7XYE
DMT7XYE	DN	Oxalylaminobenzoic acid
DMT7XYE	HS	Investigative
DMT7XYE	SN	oxalylaminobenzoic acid; CHEMBL1241315
DMT7XYE	DT	Small molecular drug
DMT7XYE	PC	52946645
DMT7XYE	MW	661.7
DMT7XYE	FM	C34H35N3O11
DMT7XYE	IC	InChI=1S/C34H35N3O11/c1-3-21-17-20(13-14-24(21)37(31(41)33(44)45)25-10-5-4-9-22(25)32(42)43)18-23-30(40)36(19-28(39)35-23)15-6-7-16-48-27-12-8-11-26(38)29(27)34(46)47-2/h4-5,8-14,17,23,38H,3,6-7,15-16,18-19H2,1-2H3,(H,35,39)(H,42,43)(H,44,45)/t23-/m1/s1
DMT7XYE	CS	CCC1=C(C=CC(=C1)C[C@@H]2C(=O)N(CC(=O)N2)CCCCOC3=CC=CC(=C3C(=O)OC)O)N(C4=CC=CC=C4C(=O)O)C(=O)C(=O)O
DMT7XYE	IK	BKPFVUCQPXAMRL-HSZRJFAPSA-N
DMT7XYE	IU	2-[2-ethyl-4-[[(2R)-4-[4-(3-hydroxy-2-methoxycarbonylphenoxy)butyl]-3,6-dioxopiperazin-2-yl]methyl]-N-oxaloanilino]benzoic acid
DMT7XYE	DE	Discovery agent

DMTYBC9	ID	DMTYBC9
DMTYBC9	DN	OXAMATE
DMTYBC9	HS	Investigative
DMTYBC9	SN	Oxamic acid; OXAMIC ACID; 471-47-6; 2-Amino-2-oxoacetic acid; oxamate; Acetic acid, aminooxo-; Oxalamic acid; Oxamidic acid; Oxalic acid monoamide; amino(oxo)acetic acid; Aminooxoacetic acid; Glycine, 2-oxo-; Oxamate (repellent); Glyoxylic acid, amino-; Formic acid, carbamoyl-; UNII-QU60N5OPLG; Oxamate, (aminocarbonyl)-; carbamoylformic acid; Formic acid, (aminocarbonyl)-; QU60N5OPLG; Oxamate (insect repellant); Acetic acid, 2-amino-2-oxo-; CHEBI:18058; Oxamic acid, 98%; OXM; C2H3NO3; Oxalic monoamide; Oxamate, 3; EINECS 207-443-0; NSC 47001; Oxamic Acid
DMTYBC9	DT	Small molecular drug
DMTYBC9	PC	974
DMTYBC9	MW	89.05
DMTYBC9	FM	C2H3NO3
DMTYBC9	IC	InChI=1S/C2H3NO3/c3-1(4)2(5)6/h(H2,3,4)(H,5,6)
DMTYBC9	CS	C(=O)(C(=O)O)N
DMTYBC9	IK	SOWBFZRMHSNYGE-UHFFFAOYSA-N
DMTYBC9	IU	oxamic acid
DMTYBC9	CA	CAS 471-47-6
DMTYBC9	CB	CHEBI:18058
DMTYBC9	DE	Discovery agent

DMWVLG1	ID	DMWVLG1
DMWVLG1	DN	Oxametacin
DMWVLG1	HS	Investigative
DMWVLG1	SN	Oxametacin; Oxamethacin; Flogar; Indoxamic acid; Oxametacine; Oxametacin [INN]; 27035-30-9; Oxametacine [INN-French]; Oxametacinum [INN-Latin]; UNII-8G02RSW5CM; Oxametacina [INN-Spanish]; Acido indoxamico [Italian]; ABC 8/3; EINECS 248-179-6; BRN 0497721; 8G02RSW5CM; CHEMBL295829; Oxametacin (INN); 1-(4-Chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl-1H-indole-3-acetamide; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetohydroxamic acid; 1-(p-Chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetohydroxamic acid; Acido 1-(p-clorobenzoi
DMWVLG1	DT	Small molecular drug
DMWVLG1	PC	33675
DMWVLG1	MW	372.8
DMWVLG1	FM	C19H17ClN2O4
DMWVLG1	IC	InChI=1S/C19H17ClN2O4/c1-11-15(10-18(23)21-25)16-9-14(26-2)7-8-17(16)22(11)19(24)12-3-5-13(20)6-4-12/h3-9,25H,10H2,1-2H3,(H,21,23)
DMWVLG1	CS	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)NO
DMWVLG1	IK	AJRNYCDWNITGHF-UHFFFAOYSA-N
DMWVLG1	IU	2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-hydroxyacetamide
DMWVLG1	CA	CAS 27035-30-9
DMWVLG1	CB	CHEBI:76255
DMWVLG1	DE	Discovery agent

DM8109D	ID	DM8109D
DM8109D	DN	Oxazolidin-(2Z)-ylideneamine
DM8109D	HS	Investigative
DM8109D	SN	24665-93-8; amino oxazoline; 1,3-oxazolidin-2-imine; 4,5-dihydrooxazol-2-amine; Oxazolidin-(2Z)-ylideneamine; 2-oxazolamine, 4,5-dihydro-; 4,5-dihydro-1,3-oxazol-2-amine; CHEMBL69446; aminooxazoline; iminooxazolidine; NSC43138; 2-amino-2-oxazoline; AC1Q4UHD; AC1L61HW; 2-amino-4,5-dihydrooxazole; 2-Oxazolamine,4,5-dihydro-; CTK4F4142; DTXSID50285885; MolPort-023-198-771; YAXGBZDYGZBRBQ-UHFFFAOYSA-N; MolPort-006-013-450; BDBM50078037; NSC-43138; ZINC13588690; AKOS006221228; AKOS009159127; NE22687; MCULE-9912511107; AJ-64218; AJ-64217
DM8109D	DT	Small molecular drug
DM8109D	PC	238663
DM8109D	MW	86.09
DM8109D	FM	C3H6N2O
DM8109D	IC	InChI=1S/C3H6N2O/c4-3-5-1-2-6-3/h1-2H2,(H2,4,5)
DM8109D	CS	C1COC(=N1)N
DM8109D	IK	YAXGBZDYGZBRBQ-UHFFFAOYSA-N
DM8109D	IU	4,5-dihydro-1,3-oxazol-2-amine
DM8109D	CA	CAS 24665-93-8
DM8109D	DE	Discovery agent

DMMEDJT	ID	DMMEDJT
DMMEDJT	DN	OXDEX
DMMEDJT	HS	Investigative
DMMEDJT	SN	Dexamethasone-17-carboxamide; CHEMBL483096; 82137-90-4; DX-17-Carboxamide; OXDEX; 17-Dxb; 17-Carboxamide dexamethasone; Dexamethasone-17beta-carboxamide; AC1L1YA1; DTXSID30231582; BDBM50271344; Androsta-1,4-diene-17-carboxamide, 9-fluoro-11,17-dihydroxy-16-methyl-3-oxo-, (11beta,16alpha,17alpha)-; (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carboxamide
DMMEDJT	DT	Small molecular drug
DMMEDJT	PC	63052
DMMEDJT	MW	377.4
DMMEDJT	FM	C21H28FNO4
DMMEDJT	IC	InChI=1S/C21H28FNO4/c1-11-8-15-14-5-4-12-9-13(24)6-7-18(12,2)20(14,22)16(25)10-19(15,3)21(11,27)17(23)26/h6-7,9,11,14-16,25,27H,4-5,8,10H2,1-3H3,(H2,23,26)/t11-,14+,15+,16+,18+,19+,20+,21+/m1/s1
DMMEDJT	CS	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)N)O)C)O)F)C
DMMEDJT	IK	PILCISDJZUQFIS-AFKBWYBQSA-N
DMMEDJT	IU	(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carboxamide
DMMEDJT	CA	CAS 82137-90-4
DMMEDJT	DE	Discovery agent

DM6RJOI	ID	DM6RJOI
DM6RJOI	DN	OXENDLONE
DM6RJOI	HS	Investigative
DM6RJOI	SN	oxendolone; 33765-68-3; Prostetin; 16b-Ethyl-19-nortestosterone; UNII-MN4I850D4P; TSAA-291; MN4I850D4P; NCGC00183854-01; Tsaa 291; Oxendolonum [INN-Latin]; Oxendolona [INN-Spanish]; Oxendolone [USAN:INN:JAN]; Oxendolona; Oxendolonum; 16-beta-Ethyl-19-nortestosterone; 16-Ethyl-17-hydroxyester-4-en-3-one; (8R,9S,10R,13S,14S,16S,17S)-16-ethyl-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 16beta-Ethyl-17beta-hydroxyestr-4-en-3-one; 16-beta-Ethyl-17-beta-hydroxyestr-4-en-3-one
DM6RJOI	DT	Small molecular drug
DM6RJOI	PC	443947
DM6RJOI	MW	302.5
DM6RJOI	FM	C20H30O2
DM6RJOI	IC	InChI=1S/C20H30O2/c1-3-12-11-18-17-6-4-13-10-14(21)5-7-15(13)16(17)8-9-20(18,2)19(12)22/h10,12,15-19,22H,3-9,11H2,1-2H3/t12-,15-,16+,17+,18-,19-,20-/m0/s1
DM6RJOI	CS	CC[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]2([C@H]1O)C
DM6RJOI	IK	FCKLFGKATYPJPG-SSTBVEFVSA-N
DM6RJOI	IU	(8R,9S,10R,13S,14S,16S,17S)-16-ethyl-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
DM6RJOI	CA	CAS 33765-68-3
DM6RJOI	CB	CHEBI:31946
DM6RJOI	DE	Discovery agent

DMG6O0L	ID	DMG6O0L
DMG6O0L	DN	Oximidine I
DMG6O0L	HS	Investigative
DMG6O0L	DT	Small molecular drug
DMG6O0L	PC	56603782
DMG6O0L	MW	456.5
DMG6O0L	FM	C24H28N2O7
DMG6O0L	IC	InChI=1S/C24H28N2O7/c1-4-9-19-23(32-19)22(29)18(12-7-14-25-20(28)13-8-15-26-31-3)33-24(30)21-16(5-2)10-6-11-17(21)27/h4-11,13-15,18-19,22-23,27,29H,2,12H2,1,3H3,(H,25,28)/b9-4-,13-8-,14-7-,26-15+
DMG6O0L	CS	C/C=C\\C1C(O1)C(C(C/C=C\\NC(=O)/C=C\\C=N\\OC)OC(=O)C2=C(C=CC=C2O)C=C)O
DMG6O0L	IK	HFJXCVFNVNHCKF-XTLNGFDXSA-N
DMG6O0L	IU	[(Z)-1-hydroxy-5-[[(Z,4E)-4-methoxyiminobut-2-enoyl]amino]-1-[3-[(Z)-prop-1-enyl]oxiran-2-yl]pent-4-en-2-yl] 2-ethenyl-6-hydroxybenzoate
DMG6O0L	DE	Discovery agent

DMW6K80	ID	DMW6K80
DMW6K80	DN	Oximidine II
DMW6K80	HS	Investigative
DMW6K80	DT	Small molecular drug
DMW6K80	PC	23645676
DMW6K80	MW	429.4
DMW6K80	FM	C20H26F3N3O4
DMW6K80	IC	InChI=1S/C18H25N3O2.C2HF3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17;3-2(4,5)1(6)7/h10-15,23H,1-7,9,20H2;(H,6,7)/t10?,11?,12-,13+,14+,15-,17?,18?;/m1./s1
DMW6K80	CS	C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N.C(=O)(C(F)(F)F)O
DMW6K80	IK	KVBUVKKLNZGQEE-NHKADLRUSA-N
DMW6K80	IU	(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;2,2,2-trifluoroacetic acid
DMW6K80	CA	CAS 361442-05-9
DMW6K80	DE	Discovery agent

DMM5208	ID	DMM5208
DMM5208	DN	Oxindole 16 (compound 3)
DMM5208	HS	Investigative
DMM5208	DT	Small molecular drug
DMM5208	PC	11692221
DMM5208	DE	Discovery agent

DMPFD6Y	ID	DMPFD6Y
DMPFD6Y	DN	Oxindole 94
DMPFD6Y	HS	Investigative
DMPFD6Y	SN	SB 202190; 152121-30-7; SB202190; SB-202190; FHPI; SB202190 (FHPI); UNII-PVX798P8GI; 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole; CHEBI:79090; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; PVX798P8GI; SB 202190, Immobilized; C20H14FN3O; Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-; 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol; 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol
DMPFD6Y	DT	Small molecular drug
DMPFD6Y	PC	5169
DMPFD6Y	MW	331.3
DMPFD6Y	FM	C20H14FN3O
DMPFD6Y	IC	InChI=1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,25H,(H,23,24)
DMPFD6Y	CS	C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O
DMPFD6Y	IK	QHKYPYXTTXKZST-UHFFFAOYSA-N
DMPFD6Y	IU	4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenol
DMPFD6Y	CA	CAS 152121-30-7
DMPFD6Y	CB	CHEBI:79090
DMPFD6Y	DE	Pain

DM4UL1G	ID	DM4UL1G
DM4UL1G	DN	Oxindole 95
DM4UL1G	HS	Investigative
DM4UL1G	DE	Discovery agent

DM1AU8V	ID	DM1AU8V
DM1AU8V	DN	Oxindole derivative
DM1AU8V	HS	Investigative
DM1AU8V	SN	5-Fluorooxindole; 56341-41-4; 5-fluoroindolin-2-one; 5-Fluoro-2-oxindole; 5-fluoro-1,3-dihydro-2H-indol-2-one; 5-fluoro-1,3-dihydroindol-2-one; 2H-Indol-2-one, 5-fluoro-1,3-dihydro-; 5-fluoro-2,3-dihydro-1H-indol-2-one; 5-Fluoro-1,3-dihydro-indol-2-one; 5-Fluoro-2-indolinone; 5-Fluoro-2,3-dihydro-2-oxoindole; 5-FLUORO-2-OXYINDOLE; 5-Fluoro-2-oxindole, 97%; MFCD02179598; 5-fluoro indoline-2-one; 5-fluoroindolinone; 5-fluoro-oxindole; 5-fluoro oxindole; zlchem 713; FLUOROOXINDOLE; PubChem1687; ACMC-209lrt; AC1MVD5T
DM1AU8V	DT	Small molecular drug
DM1AU8V	PC	3731012
DM1AU8V	MW	151.14
DM1AU8V	FM	C8H6FNO
DM1AU8V	IC	InChI=1S/C8H6FNO/c9-6-1-2-7-5(3-6)4-8(11)10-7/h1-3H,4H2,(H,10,11)
DM1AU8V	CS	C1C2=C(C=CC(=C2)F)NC1=O
DM1AU8V	IK	DDIIYGHHUMKDGI-UHFFFAOYSA-N
DM1AU8V	IU	5-fluoro-1,3-dihydroindol-2-one
DM1AU8V	CA	CAS 56341-41-4
DM1AU8V	DE	Malaria

DMV0KTW	ID	DMV0KTW
DMV0KTW	DN	oxo-arpromidine
DMV0KTW	HS	Investigative
DMV0KTW	SN	UR-PG136
DMV0KTW	DT	Small molecular drug
DMV0KTW	PC	25149244
DMV0KTW	MW	394.4
DMV0KTW	FM	C21H23FN6O
DMV0KTW	IC	InChI=1S/C21H23FN6O/c22-16-8-6-15(7-9-16)18(19-5-1-2-10-25-19)12-20(29)28-21(23)26-11-3-4-17-13-24-14-27-17/h1-2,5-10,13-14,18H,3-4,11-12H2,(H,24,27)(H3,23,26,28,29)
DMV0KTW	CS	C1=CC=NC(=C1)C(CC(=O)NC(=NCCCC2=CN=CN2)N)C3=CC=C(C=C3)F
DMV0KTW	IK	UTJRWVBWVPCMQL-UHFFFAOYSA-N
DMV0KTW	IU	3-(4-fluorophenyl)-N-[N'-[3-(1H-imidazol-5-yl)propyl]carbamimidoyl]-3-pyridin-2-ylpropanamide
DMV0KTW	DE	Discovery agent

DMRKA08	ID	DMRKA08
DMRKA08	DN	Oxolithocholic acid
DMRKA08	HS	Investigative
DMRKA08	SN	12-Ketolithocholic acid; 12-Oxolithocholic acid; 12-Oxolithocholate; 3?-Hydroxy-12 Ketolithocholic Acid; 3alpha-Hydroxy-12-0X0-5beta-cholanoic acid; 3alpha-Hydroxy-12-oxo-5beta-cholan-24-oic Acid; 5130-29-0; 57668172Z5; CCRIS 3990; Cholan-24-oic acid, 3-hydroxy-12-oxo-, (3alpha,5beta)-; UNII-57668172Z5; (4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-12-oxo-1,2,3,4,5,6,7,8,9,11,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid; 12-Dehydrodeoxycholic acid; 12-Ketodeoxycholic acid
DMRKA08	PC	3080612
DMRKA08	MW	390.6
DMRKA08	FM	C24H38O4
DMRKA08	IC	CVNYHSDFZXHMMJ-VPUMZWJWSA-N
DMRKA08	CS	CC(CCC(=O)O)C1CCC2C1(C(=O)CC3C2CCC4C3(CCC(C4)O)C)C
DMRKA08	IK	1S/C24H38O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-20,25H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,23+,24-/m1/s1
DMRKA08	IU	(4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-12-oxo-1,2,3,4,5,6,7,8,9,11,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
DMRKA08	CA	CAS 5130-29-0
DMRKA08	CB	CHEBI:139134
DMRKA08	DE	Discovery agent

DMMZYX6	ID	DMMZYX6
DMMZYX6	DN	OXYBENZONE
DMMZYX6	HS	Investigative
DMMZYX6	SN	oxybenzone; 131-57-7; 2-HYDROXY-4-METHOXYBENZOPHENONE; Benzophenone-3; Oxybenzon; 4-Methoxy-2-hydroxybenzophenone; 2-Benzoyl-5-methoxyphenol; (2-hydroxy-4-methoxyphenyl)(phenyl)methanone; Oxybenzonum; Oxibenzona; Anuvex; Methanone, (2-hydroxy-4-methoxyphenyl)phenyl-; Chimassorb 90; Uvinul 9; Advastab 45; Sunscreen UV-15; Syntase 62; Uvistat 24; Cyasorb UV 9; Usaf cy-9; Spectra-sorb UV 9; Escalol 567; Ongrostab HMB; Oxybenzonum [INN-Latin]; Uvinul M40; Oxibenzonum; Oxibenzona [INN-Spanish]; HMBP; Cyasorb UV 9 Light Absorber
DMMZYX6	DT	Small molecular drug
DMMZYX6	PC	4632
DMMZYX6	MW	228.24
DMMZYX6	FM	C14H12O3
DMMZYX6	IC	InChI=1S/C14H12O3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15H,1H3
DMMZYX6	CS	COC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)O
DMMZYX6	IK	DXGLGDHPHMLXJC-UHFFFAOYSA-N
DMMZYX6	IU	(2-hydroxy-4-methoxyphenyl)-phenylmethanone
DMMZYX6	CA	CAS 131-57-7
DMMZYX6	CB	CHEBI:34283
DMMZYX6	DE	Discovery agent

DMJPBAX	ID	DMJPBAX
DMJPBAX	DN	Oxybutynine
DMJPBAX	HS	Investigative
DMJPBAX	SN	5633-20-5; Ditropan; Oxytrol; Oxibutyninum; Oxybutyninum; Oxibutinina; Oxybutyninum [INN-Latin]; Oxybutynine [INN-French]; Oxybutinin; Cystrin; Oxibutinina [INN-Spanish]; Oxybutynin Base; transdermal patch; Lyrinel XL; Oxybutynin [USAN:INN:BAN]; 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat; CCRIS 1923; oxybutynin topical gel; Ditropan Xl; Oxybutynin (Ditropan); HSDB 3270; 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate; CHEMBL1231; Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-b
DMJPBAX	DT	Small molecular drug
DMJPBAX	PC	4634
DMJPBAX	MW	357.5
DMJPBAX	FM	C22H31NO3
DMJPBAX	IC	InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3
DMJPBAX	CS	CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
DMJPBAX	IK	XIQVNETUBQGFHX-UHFFFAOYSA-N
DMJPBAX	IU	4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
DMJPBAX	CA	CAS 5633-20-5
DMJPBAX	CB	CHEBI:7856
DMJPBAX	DE	Discovery agent

DMTP4S2	ID	DMTP4S2
DMTP4S2	DN	OXYMORPHINDOLE
DMTP4S2	HS	Investigative
DMTP4S2	SN	ACMC-20di42; AC1L9G6X; CHEMBL1985511; CTK7J9928; 4,8-Methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol,5,6,7,8,14,14b-hexahydro-7-methyl-, (4bS,8R,8aS,14bR)-; NSC707844; NSC-707844; NCI60_038277
DMTP4S2	DT	Small molecular drug
DMTP4S2	PC	5491897
DMTP4S2	MW	374.4
DMTP4S2	FM	C23H22N2O3
DMTP4S2	IC	InChI=1S/C23H22N2O3/c1-25-9-8-22-18-12-6-7-16(26)20(18)28-21(22)19-14(11-23(22,27)17(25)10-12)13-4-2-3-5-15(13)24-19/h2-7,17,21,24,26-27H,8-11H2,1H3/t17-,21+,22+,23-/m1/s1
DMTP4S2	CS	CN1CC[C@]23[C@@H]4C5=C(C[C@]2([C@H]1CC6=C3C(=C(C=C6)O)O4)O)C7=CC=CC=C7N5
DMTP4S2	IK	YQNZUKAKYJMEFE-LMDOGRNLSA-N
DMTP4S2	IU	(1S,2S,13R,21R)-22-methyl-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol
DMTP4S2	CA	CAS 111469-88-6
DMTP4S2	DE	Discovery agent

DMTSM61	ID	DMTSM61
DMTSM61	DN	Oxymorphone semicarbazone hydrochloride
DMTSM61	HS	Investigative
DMTSM61	SN	CHEMBL1202432; Oxymorphone Semicarbazone HCl
DMTSM61	DT	Small molecular drug
DMTSM61	PC	49860169
DMTSM61	MW	394.9
DMTSM61	FM	C18H23ClN4O4
DMTSM61	IC	InChI=1S/C18H22N4O4.ClH/c1-22-7-6-17-13-9-2-3-11(23)14(13)26-15(17)10(20-21-16(19)24)4-5-18(17,25)12(22)8-9;/h2-3,12,15,23,25H,4-8H2,1H3,(H3,19,21,24);1H/b20-10-;/t12?,15-,17?,18+;/m0./s1
DMTSM61	CS	CN1CCC23[C@@H]4/C(=N\\NC(=O)N)/CC[C@]2(C1CC5=C3C(=C(C=C5)O)O4)O.Cl
DMTSM61	IK	QIYGMMZVSGQNFS-XVSNUZMHSA-N
DMTSM61	IU	[(Z)-[(4aS,7aR)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ylidene]amino]urea;hydrochloride
DMTSM61	DE	Discovery agent

DMZVS9Y	ID	DMZVS9Y
DMZVS9Y	DN	OXYQUINOLINE
DMZVS9Y	HS	Investigative
DMZVS9Y	SN	8-HYDROXYQUINOLINE; quinolin-8-ol; 8-quinolinol; 148-24-3; Oxyquinoline; Oxine; Quinophenol; 8-Quinol; 8-Oxyquinoline; Phenopyridine; Oxychinolin; Bioquin; Oxybenzopyridine; Oxin; Hydroxybenzopyridine; 1-Azanaphthalene-8-ol; Tumex; 8-Chinolinol; 8-Hydroxychinolin; 8-OQ; 8-Hydroxy-chinolin; Fennosan H 30; Fennosan; o-Oxychinolin; 8-Oxychinolin; Usaf ek-794; Fennosan HF-15; NCI-C55298; NSC 2039; Oxyquinoline [USAN]; Caswell No. 719; Oxoquinoline; 8-Chinolinol [Czech]; o-Oxychinolin [German]; Quinoline, 8-hydroxy-; NSC 615011; UNII-5UTX5635HP
DMZVS9Y	DT	Small molecular drug
DMZVS9Y	PC	1923
DMZVS9Y	MW	145.16
DMZVS9Y	FM	C9H7NO
DMZVS9Y	IC	InChI=1S/C9H7NO/c11-8-5-1-3-7-4-2-6-10-9(7)8/h1-6,11H
DMZVS9Y	CS	C1=CC2=C(C(=C1)O)N=CC=C2
DMZVS9Y	IK	MCJGNVYPOGVAJF-UHFFFAOYSA-N
DMZVS9Y	IU	quinolin-8-ol
DMZVS9Y	CA	CAS 148-24-3
DMZVS9Y	CB	CHEBI:48981
DMZVS9Y	DE	Discovery agent

DMN7S4L	ID	DMN7S4L
DMN7S4L	DN	OXYRESVERATROL
DMN7S4L	HS	Investigative
DMN7S4L	SN	Oxyresveratrol; 29700-22-9; Tetrahydroxystilbene; (E)-4-(3,5-Dihydroxystyryl)benzene-1,3-diol; UNII-6V071CP5CR; trans-oxyresveratrol; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol; OXYLRESVERATROL; 4721-07-7; 4-[2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol; CHEMBL43065; CHEBI:7870; 6V071CP5CR; 2,3',4,5'-Tetrahydroxystilbene; AK158555; 4-(3,5-Dihydroxystyryl)benzene-1,3-diol; J-501984; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,3-diol; 1,3-Benzenediol, 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]-; Puag-haad
DMN7S4L	DT	Small molecular drug
DMN7S4L	PC	5281717
DMN7S4L	MW	244.24
DMN7S4L	FM	C14H12O4
DMN7S4L	IC	InChI=1S/C14H12O4/c15-11-4-3-10(14(18)8-11)2-1-9-5-12(16)7-13(17)6-9/h1-8,15-18H/b2-1+
DMN7S4L	CS	C1=CC(=C(C=C1O)O)/C=C/C2=CC(=CC(=C2)O)O
DMN7S4L	IK	PDHAOJSHSJQANO-OWOJBTEDSA-N
DMN7S4L	IU	4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol
DMN7S4L	CA	CAS 29700-22-9
DMN7S4L	CB	CHEBI:7870
DMN7S4L	DE	Discovery agent

DMOY627	ID	DMOY627
DMOY627	DN	P(1)-(6-Hydroxymethylpterin)-P(4)-(5'-adenosyl)tetraphosphate
DMOY627	HS	Investigative
DMOY627	DT	Small molecular drug
DMOY627	PC	56603783
DMOY627	DE	Discovery agent

DMJ0W43	ID	DMJ0W43
DMJ0W43	DN	P-(2'-Iodo-5'-Thenoyl)Hydrotropic Acid
DMJ0W43	HS	Investigative
DMJ0W43	SN	P-(2'-Iodo-5'-thenoyl)hydrotropic acid; P-(2'-IODO-5'-THENOYL)HYDROTROPIC ACID; (2S)-2-[4-(5-iodothiophene-2-carbonyl)phenyl]propanoic acid; ISF; AC1L9LAE; DB03752; (2S)-2-{4-[(5-iodothiophen-2-yl)carbonyl]phenyl}propanoic
DMJ0W43	DT	Small molecular drug
DMJ0W43	PC	447834
DMJ0W43	MW	386.21
DMJ0W43	FM	C14H11IO3S
DMJ0W43	IC	InChI=1S/C14H11IO3S/c1-8(14(17)18)9-2-4-10(5-3-9)13(16)11-6-7-12(15)19-11/h2-8H,1H3,(H,17,18)/t8-/m0/s1
DMJ0W43	CS	C[C@@H](C1=CC=C(C=C1)C(=O)C2=CC=C(S2)I)C(=O)O
DMJ0W43	IK	UIZPHGUBGPJBAR-QMMMGPOBSA-N
DMJ0W43	IU	(2S)-2-[4-(5-iodothiophene-2-carbonyl)phenyl]propanoic acid
DMJ0W43	DE	Discovery agent

DM9SNFX	ID	DM9SNFX
DM9SNFX	DN	p-[18F]MPPF
DM9SNFX	HS	Investigative
DM9SNFX	SN	P-[18F]MPPF; [(18)F]p-MPPF
DM9SNFX	DT	Small molecular drug
DM9SNFX	PC	5352127
DM9SNFX	MW	434.5
DM9SNFX	FM	C24H26FN5O2
DM9SNFX	IC	InChI=1S/C24H26FN5O2/c1-32-22-6-3-2-5-21(22)29-16-13-28(14-17-29)15-18-30(24-26-11-4-12-27-24)23(31)19-7-9-20(25)10-8-19/h2-12H,13-18H2,1H3/i25-1
DM9SNFX	CS	COC1=CC=CC=C1N2CCN(CC2)CCN(C3=NC=CC=N3)C(=O)C4=CC=C(C=C4)[18F]
DM9SNFX	IK	ADELHWYAKAZUCR-FNNGWQQSSA-N
DM9SNFX	IU	4-(18F)fluoranyl-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyrimidin-2-ylbenzamide
DM9SNFX	DE	Discovery agent

DMM4VWD	ID	DMM4VWD
DMM4VWD	DN	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate
DMM4VWD	HS	Investigative
DMM4VWD	SN	p1-(5'-adenosyl)p5-(5'-thymidyl)pentaphosphate; CHEMBL1236157; T5A; 3tmk; 1mrn; 4TMK; AC1L9KL2; BDBM50366828; DB03280; adenosine 5'-(hexahydrogen pentaphosphate), P"" 5'-ester with thymidine; 103137-88-8; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyphosphoryl] hydrogen phosphate
DMM4VWD	DT	Small molecular drug
DMM4VWD	PC	447202
DMM4VWD	MW	891.4
DMM4VWD	FM	C20H30N7O23P5
DMM4VWD	IC	InChI=1S/C20H30N7O23P5/c1-8-3-26(20(32)25-18(8)31)12-2-9(28)10(45-12)4-43-51(33,34)47-53(37,38)49-55(41,42)50-54(39,40)48-52(35,36)44-5-11-14(29)15(30)19(46-11)27-7-24-13-16(21)22-6-23-17(13)27/h3,6-7,9-12,14-15,19,28-30H,2,4-5H2,1H3,(H,33,34)(H,35,36)(H,37,38)(H,39,40)(H,41,42)(H2,21,22,23)(H,25,31,32)/t9-,10+,11+,12+,14+,15+,19+/m0/s1
DMM4VWD	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O
DMM4VWD	IK	JCFDSPQTEMXXLO-SLFMBYJQSA-N
DMM4VWD	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyphosphoryl] hydrogen phosphate
DMM4VWD	DE	Discovery agent

DMQ6TZE	ID	DMQ6TZE
DMQ6TZE	DN	P-1116
DMQ6TZE	HS	Investigative
DMQ6TZE	SN	Pegylated erythropoietin (anemia), PharmaEssentia; PEG-EPO (anemia), PharmaEssentia
DMQ6TZE	CP	PharmaEssentia Corp
DMQ6TZE	DE	Anemia

DMETL3Z	ID	DMETL3Z
DMETL3Z	DN	P2,P3 Ketoamide derivative
DMETL3Z	HS	Investigative
DMETL3Z	SN	CHEMBL186650; P2,P3 Ketoamide derivative; SCHEMBL14260244; AAYZJXOZLLKNGZ-DEOSSOPVSA-N; BDBM50152530
DMETL3Z	DT	Small molecular drug
DMETL3Z	PC	10129151
DMETL3Z	MW	591.7
DMETL3Z	FM	C28H38FN5O6S
DMETL3Z	IC	InChI=1S/C28H38FN5O6S/c1-34(2)41(38,39)32-16-4-3-8-24(25(35)26(36)31-19-22-7-5-15-30-18-22)33-27(37)40-20-28(13-6-14-28)17-21-9-11-23(29)12-10-21/h5,7,9-12,15,18,24,32H,3-4,6,8,13-14,16-17,19-20H2,1-2H3,(H,31,36)(H,33,37)/t24-/m0/s1
DMETL3Z	CS	CN(C)S(=O)(=O)NCCCC[C@@H](C(=O)C(=O)NCC1=CN=CC=C1)NC(=O)OCC2(CCC2)CC3=CC=C(C=C3)F
DMETL3Z	IK	AAYZJXOZLLKNGZ-DEOSSOPVSA-N
DMETL3Z	IU	[1-[(4-fluorophenyl)methyl]cyclobutyl]methyl N-[(3S)-7-(dimethylsulfamoylamino)-1,2-dioxo-1-(pyridin-3-ylmethylamino)heptan-3-yl]carbamate
DMETL3Z	DE	Discovery agent

DMZI8QW	ID	DMZI8QW
DMZI8QW	DN	P-2281
DMZI8QW	HS	Investigative
DMZI8QW	SN	MTOR inhibitor (ulcerative colitis), Piramal
DMZI8QW	CP	Piramal Life Sciences Ltd
DMZI8QW	DE	Ulcerative colitis

DMJDI7O	ID	DMJDI7O
DMJDI7O	DN	P-6915
DMJDI7O	HS	Investigative
DMJDI7O	SN	PI3K/mTOR inhibitors (cancer), Piramal
DMJDI7O	CP	Piramal Life Sciences Ltd
DMJDI7O	DE	Solid tumour/cancer

DMELTM2	ID	DMELTM2
DMELTM2	DN	PA-10040
DMELTM2	HS	Investigative
DMELTM2	CP	POZEN Inc
DMELTM2	DE	Cardiovascular disease

DMUH203	ID	DMUH203
DMUH203	DN	PA-1637
DMUH203	HS	Investigative
DMUH203	SN	Copper chelating agents (neurodegenerative disease), Palumed
DMUH203	CP	Palumed SA
DMUH203	DE	Neurological disorder

DMTGZ3E	ID	DMTGZ3E
DMTGZ3E	DN	PA451
DMTGZ3E	HS	Investigative
DMTGZ3E	SN	PA 451
DMTGZ3E	DT	Small molecular drug
DMTGZ3E	PC	9823741
DMTGZ3E	MW	425.6
DMTGZ3E	FM	C25H35N3O3
DMTGZ3E	IC	InChI=1S/C25H35N3O3/c1-7-8-9-12-31-21-14-19-18(24(2,3)10-11-25(19,4)5)13-20(21)28(6)23-26-15-17(16-27-23)22(29)30/h13-16H,7-12H2,1-6H3,(H,29,30)
DMTGZ3E	CS	CCCCCOC1=C(C=C2C(=C1)C(CCC2(C)C)(C)C)N(C)C3=NC=C(C=N3)C(=O)O
DMTGZ3E	IK	PMHLEYZHMPYVLJ-UHFFFAOYSA-N
DMTGZ3E	IU	2-[methyl-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)amino]pyrimidine-5-carboxylic acid
DMTGZ3E	DE	Discovery agent

DMKL6IC	ID	DMKL6IC
DMKL6IC	DN	PAC-10649
DMKL6IC	HS	Investigative
DMKL6IC	SN	PAC-10549; COX-2 inhibitors (pain/inflammation), Pacific Corp
DMKL6IC	CP	Pacific Pharmaceuticals Co Ltd
DMKL6IC	DE	Arthritis

DMB26IK	ID	DMB26IK
DMB26IK	DN	PACAP-27
DMB26IK	HS	Investigative
DMB26IK	SN	pituitary adenylate cyclase activating polypeptide-27
DMB26IK	DT	Small molecular drug
DMB26IK	PC	16133238
DMB26IK	MW	3147.6
DMB26IK	FM	C142H224N40O39S
DMB26IK	IC	InChI=1S/C142H224N40O39S/c1-16-75(10)113(179-108(191)66-156-120(201)102(63-109(192)193)173-135(216)104(67-183)176-119(200)88(146)62-84-65-153-70-157-84)139(220)174-101(58-80-28-18-17-19-29-80)133(214)182-114(79(14)186)140(221)175-103(64-110(194)195)132(213)178-106(69-185)136(217)172-100(61-83-39-45-87(189)46-40-83)131(212)177-105(68-184)134(215)164-93(34-27-54-155-142(151)152)126(207)170-98(59-81-35-41-85(187)42-36-81)129(210)163-92(33-26-53-154-141(149)150)124(205)161-89(30-20-23-50-143)122(203)165-94(47-48-107(147)190)127(208)166-95(49-55-222-15)121(202)159-78(13)118(199)180-111(73(6)7)137(218)167-91(32-22-25-52-145)123(204)162-90(31-21-24-51-144)125(206)171-99(60-82-37-43-86(188)44-38-82)130(211)169-97(57-72(4)5)128(209)160-76(11)116(197)158-77(12)117(198)181-112(74(8)9)138(219)168-96(115(148)196)56-71(2)3/h17-19,28-29,35-46,65,70-79,88-106,111-114,183-189H,16,20-27,30-34,47-64,66-69,143-146H2,1-15H3,(H2,147,190)(H2,148,196)(H,153,157)(H,156,201)(H,158,197)(H,159,202)(H,160,209)(H,161,205)(H,162,204)(H,163,210)(H,164,215)(H,165,203)(H,166,208)(H,167,218)(H,168,219)(H,169,211)(H,170,207)(H,171,206)(H,172,217)(H,173,216)(H,174,220)(H,175,221)(H,176,200)(H,177,212)(H,178,213)(H,179,191)(H,180,199)(H,181,198)(H,182,214)(H,192,193)(H,194,195)(H4,149,150,154)(H4,151,152,155)
DMB26IK	CS	CCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)N)C(=O)NC(CCSC)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)N)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC5=CN=CN5)N
DMB26IK	IK	RZGBUJXSKLDAFE-UHFFFAOYSA-N
DMB26IK	IU	4-[[2-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[6-amino-1-[[5-amino-1-[[1-[[1-[[1-[[6-amino-1-[[6-amino-1-[[1-[[1-[[1-[[1-[[1-[(1-amino-4-methyl-1-oxopentan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-[[2-[[2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoic acid
DMB26IK	DE	Discovery agent

DMJ5TAU	ID	DMJ5TAU
DMJ5TAU	DN	Paeoniflorin
DMJ5TAU	HS	Investigative
DMJ5TAU	SN	P1876
DMJ5TAU	CP	Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
DMJ5TAU	DT	Small molecular drug
DMJ5TAU	PC	442534
DMJ5TAU	MW	480.5
DMJ5TAU	FM	C23H28O11
DMJ5TAU	IC	InChI=1S/C23H28O11/c1-20-9-22(29)13-7-23(20,32-18-16(27)15(26)14(25)12(8-24)31-18)21(13,19(33-20)34-22)10-30-17(28)11-5-3-2-4-6-11/h2-6,12-16,18-19,24-27,29H,7-10H2,1H3/t12-,13-,14-,15+,16-,18+,19-,20+,21+,22-,23+/m1/s1
DMJ5TAU	CS	C[C@]12C[C@@]3([C@@H]4C[C@]1([C@@]4([C@H](O2)O3)COC(=O)C5=CC=CC=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O
DMJ5TAU	IK	YKRGDOXKVOZESV-WRJNSLSBSA-N
DMJ5TAU	IU	[(1R,2S,3R,5R,6R,8S)-6-hydroxy-8-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decan-2-yl]methyl benzoate
DMJ5TAU	CA	CAS 23180-57-6
DMJ5TAU	CB	CHEBI:7889
DMJ5TAU	DE	Parkinson disease

DMRZAQW	ID	DMRZAQW
DMRZAQW	DN	PAF
DMRZAQW	HS	Investigative
DMRZAQW	SN	Platelet activating factor; PAF (C16); Platelet-activating factor; 74389-68-7; C16-PAF; 1-O-Hexadecyl-2-acetyl-sn-glycero-3-phosphocholine; Hag-PC; APRL; Hexadecyl-paf-acether; Platelet-activating factor C16; 1-O-Hexadecyl-platelet-activating factor; PAF C-16; 1-O-Hexadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine; 1-O-Hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine; 1-Hexadecyl-2-acetyl-glycero-3-phosphocholine; C16-PAF acether; 1-Hexadecyl-2-acetyl-sn-glycero-3-phosphocholine; Blood platelet-activating factor;  platelet activating factor; [3H]PAF
DMRZAQW	DT	Small molecular drug
DMRZAQW	PC	108156
DMRZAQW	MW	523.7
DMRZAQW	FM	C26H54NO7P
DMRZAQW	IC	InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3/t26-/m1/s1
DMRZAQW	CS	CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)C
DMRZAQW	IK	HVAUUPRFYPCOCA-AREMUKBSSA-N
DMRZAQW	IU	[(2R)-2-acetyloxy-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMRZAQW	CA	CAS 74389-68-7
DMRZAQW	CB	CHEBI:44811
DMRZAQW	DE	Discovery agent

DMDTP1R	ID	DMDTP1R
DMDTP1R	DN	PALASONIN
DMDTP1R	HS	Investigative
DMDTP1R	SN	CHEMBL17096; PALASONIN; BDBM50110675
DMDTP1R	DT	Small molecular drug
DMDTP1R	PC	198727
DMDTP1R	MW	182.17
DMDTP1R	FM	C9H10O4
DMDTP1R	IC	InChI=1S/C9H10O4/c1-9-5-3-2-4(12-5)6(9)7(10)13-8(9)11/h4-6H,2-3H2,1H3/t4-,5+,6+,9+/m1/s1
DMDTP1R	CS	C[C@]12[C@@H]3CC[C@H]([C@H]1C(=O)OC2=O)O3
DMDTP1R	IK	RJXMWQSSXZMNIT-OLHMAJIHSA-N
DMDTP1R	IU	(1S,2R,6S,7R)-2-methyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
DMDTP1R	CA	CAS 127380-62-5
DMDTP1R	DE	Discovery agent

DMN97BF	ID	DMN97BF
DMN97BF	DN	PALBINONE
DMN97BF	HS	Investigative
DMN97BF	SN	139954-00-0; AC1L4U4C; 18-Norandrosta-11,13(17)-diene-15,16-dione,3,17-dihydroxy-4,4,8,14-tetramethyl-, (3b,5a)-
DMN97BF	DT	Small molecular drug
DMN97BF	PC	9841735
DMN97BF	MW	358.5
DMN97BF	FM	C22H30O4
DMN97BF	IC	InChI=1S/C22H30O4/c1-19(2)13-8-11-21(4)14(20(13,3)10-9-15(19)23)7-6-12-16(24)17(25)18(26)22(12,21)5/h6-7,13-15,23-24H,8-11H2,1-5H3/t13-,14+,15-,20-,21+,22-/m0/s1
DMN97BF	CS	C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2C=CC4=C(C(=O)C(=O)[C@]43C)O)C)(C)C)O
DMN97BF	IK	KIAKLFLISZCITK-PPAUHQMUSA-N
DMN97BF	IU	(3S,5R,8R,9R,10S,14S)-3,17-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9-hexahydro-1H-cyclopenta[a]phenanthrene-15,16-dione
DMN97BF	CA	CAS 139954-00-0
DMN97BF	CB	CHEBI:69584
DMN97BF	DE	Discovery agent

DMJCOKV	ID	DMJCOKV
DMJCOKV	DN	PALMATINE
DMJCOKV	HS	Investigative
DMJCOKV	SN	Palmatine; 3486-67-7; Berbericinine; O,O-Dimethyldemethyleneberberine; Palmatin; Burasaine; UNII-G50C034217; 7,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxyberbinium; Dibenzo[a,g]quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-; BRN 1555498; GNF-PF-4086; CHEBI:16096; 5,6-Dihydro-2,3,9,10-tetramethoxydibenzo[a,g]quinolizinium; 2,3,9,10-tetramethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium; 5,6-Dihydro-2,3,9,10-tetramethoxydibenzo(a,g)quinolizinium; Dibenzo(a,g)quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-; G50C034217
DMJCOKV	DT	Small molecular drug
DMJCOKV	PC	19009
DMJCOKV	MW	352.4
DMJCOKV	FM	C21H22NO4+
DMJCOKV	IC	InChI=1S/C21H22NO4/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4/h5-6,9-12H,7-8H2,1-4H3/q+1
DMJCOKV	CS	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)OC)OC
DMJCOKV	IK	QUCQEUCGKKTEBI-UHFFFAOYSA-N
DMJCOKV	IU	2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium
DMJCOKV	CA	CAS 3486-67-7
DMJCOKV	CB	CHEBI:16096
DMJCOKV	DE	Discovery agent

DM4W5X8	ID	DM4W5X8
DM4W5X8	DN	Palmitoleic Acid
DM4W5X8	HS	Investigative
DM4W5X8	SN	palmitoleic acid; (Z)-Hexadec-9-enoic acid; cis-9-Hexadecenoic acid; 373-49-9; 9-cis-Hexadecenoic acid; zoomaric acid; (Z)-9-hexadecenoic acid; cis-9-palmitoleic acid; palmitoleate; (9Z)-Hexadecenoic acid; Palmitolinoleic acid; cis-Palmitoleic acid; 9Z-hexadecenoic acid; (9Z)-hexadec-9-enoic acid; Hexadecenoate; Oleopalmitate; Zoomerate; Zoomeric acid; cis-Palmitoleate; 9-Hexadecenoate; Oleopalmitic acid; UNII-209B6YPZ4I; 9-cis-hexadecenoate; 9Z-palmitoleic acid; cis-Delta(9)-hexadecenoic acid; (Z)-Palmitoleic acid
DM4W5X8	DT	Small molecular drug
DM4W5X8	PC	445638
DM4W5X8	MW	254.41
DM4W5X8	FM	C16H30O2
DM4W5X8	IC	InChI=1S/C16H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h7-8H,2-6,9-15H2,1H3,(H,17,18)/b8-7-
DM4W5X8	CS	CCCCCC/C=C\\CCCCCCCC(=O)O
DM4W5X8	IK	SECPZKHBENQXJG-FPLPWBNLSA-N
DM4W5X8	IU	(Z)-hexadec-9-enoic acid
DM4W5X8	CA	CAS 373-49-9
DM4W5X8	CB	CHEBI:28716
DM4W5X8	DE	Discovery agent

DMKLVSO	ID	DMKLVSO
DMKLVSO	DN	Palodesangren C
DMKLVSO	HS	Investigative
DMKLVSO	SN	Palodesangren C
DMKLVSO	DT	Small molecular drug
DMKLVSO	PC	10696160
DMKLVSO	MW	482.5
DMKLVSO	FM	C30H26O6
DMKLVSO	IC	InChI=1S/C30H26O6/c1-16-11-22(17-3-6-19(31)7-4-17)29-24(12-16)23-13-18-5-10-28(33)35-25(18)15-27(23)36-30(29)21-9-8-20(32)14-26(21)34-2/h3-10,12-15,22,24,29-32H,11H2,1-2H3/t22-,24-,29-,30+/m0/s1
DMKLVSO	CS	CC1=C[C@@H]2[C@H]([C@@H](C1)C3=CC=C(C=C3)O)[C@H](OC4=C2C=C5C=CC(=O)OC5=C4)C6=C(C=C(C=C6)O)OC
DMKLVSO	IK	PRFNZHGCOFIZAC-ZKQAZLPASA-N
DMKLVSO	IU	(4R,4aS,5S,12bR)-5-(4-hydroxy-2-methoxyphenyl)-4-(4-hydroxyphenyl)-2-methyl-4,4a,5,12b-tetrahydro-3H-isochromeno[4,3-g]chromen-9-one
DMKLVSO	DE	Discovery agent

DMY6NRC	ID	DMY6NRC
DMY6NRC	DN	Palodesangren D
DMY6NRC	HS	Investigative
DMY6NRC	SN	Palodesangren D
DMY6NRC	DT	Small molecular drug
DMY6NRC	PC	10005461
DMY6NRC	MW	482.5
DMY6NRC	FM	C30H26O6
DMY6NRC	IC	InChI=1S/C30H26O6/c1-16-11-23(21-9-8-20(32)14-26(21)34-2)29-24(12-16)22-13-18-5-10-28(33)35-25(18)15-27(22)36-30(29)17-3-6-19(31)7-4-17/h3-10,12-15,23-24,29-32H,11H2,1-2H3/t23-,24-,29-,30+/m0/s1
DMY6NRC	CS	CC1=C[C@@H]2[C@H]([C@@H](C1)C3=C(C=C(C=C3)O)OC)[C@H](OC4=C2C=C5C=CC(=O)OC5=C4)C6=CC=C(C=C6)O
DMY6NRC	IK	YECGSLHMDGBPTB-PPSLNNBKSA-N
DMY6NRC	IU	(4R,4aS,5S,12bR)-4-(4-hydroxy-2-methoxyphenyl)-5-(4-hydroxyphenyl)-2-methyl-4,4a,5,12b-tetrahydro-3H-isochromeno[4,3-g]chromen-9-one
DMY6NRC	DE	Discovery agent

DMUEK1N	ID	DMUEK1N
DMUEK1N	DN	Palodesangren E
DMUEK1N	HS	Investigative
DMUEK1N	SN	Palodesangren E
DMUEK1N	DT	Small molecular drug
DMUEK1N	PC	10255841
DMUEK1N	MW	512.5
DMUEK1N	FM	C31H28O7
DMUEK1N	IC	InChI=1S/C31H28O7/c1-16-10-23(20-7-5-18(32)13-26(20)35-2)30-24(11-16)22-12-17-4-9-29(34)37-25(17)15-28(22)38-31(30)21-8-6-19(33)14-27(21)36-3/h4-9,11-15,23-24,30-33H,10H2,1-3H3/t23-,24-,30-,31+/m0/s1
DMUEK1N	CS	CC1=C[C@@H]2[C@H]([C@@H](C1)C3=C(C=C(C=C3)O)OC)[C@H](OC4=C2C=C5C=CC(=O)OC5=C4)C6=C(C=C(C=C6)O)OC
DMUEK1N	IK	BKCPZBIJQGQCCP-ODJQGHGISA-N
DMUEK1N	IU	(4R,4aS,5S,12bR)-4,5-bis(4-hydroxy-2-methoxyphenyl)-2-methyl-4,4a,5,12b-tetrahydro-3H-isochromeno[4,3-g]chromen-9-one
DMUEK1N	DE	Discovery agent

DM7M5AF	ID	DM7M5AF
DM7M5AF	DN	pamoic acid
DM7M5AF	HS	Investigative
DM7M5AF	SN	embonic acid
DM7M5AF	DT	Small molecular drug
DM7M5AF	PC	8546
DM7M5AF	MW	388.4
DM7M5AF	FM	C23H16O6
DM7M5AF	IC	InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)
DM7M5AF	CS	C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O
DM7M5AF	IK	WLJNZVDCPSBLRP-UHFFFAOYSA-N
DM7M5AF	IU	4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid
DM7M5AF	CA	CAS 130-85-8
DM7M5AF	CB	CHEBI:50186
DM7M5AF	DE	Discovery agent

DM8HWS9	ID	DM8HWS9
DM8HWS9	DN	P-Anisic Acid
DM8HWS9	HS	Investigative
DM8HWS9	SN	4-METHOXYBENZOIC ACID; p-Anisic acid; 100-09-4; ANISIC ACID; p-Methoxybenzoic acid; Draconic acid; 4-Anisic acid; Benzoic acid, 4-methoxy-; ANISIC ACID, PARA; para-anisic acid; Anisic acid, p-isomer; 4-methoxy-benzoic acid; Kyselina 4-methoxybenzoova; UNII-4SB6Y7DMM3; P-Methoxy Benzoic Acid; 4-Methoxy benzoic acid; Methoxybenzoic acid; Kyselina 4-methoxybenzoova [Czech]; EINECS 202-818-5; NSC 32742; 1335-08-6; BRN 0508910; 4SB6Y7DMM3; AI3-00893; CHEBI:40813; ZEYHEAKUIGZSGI-UHFFFAOYSA-N; p-methoxybenzoate; p-Anisic acid, 98%
DM8HWS9	DT	Small molecular drug
DM8HWS9	PC	7478
DM8HWS9	MW	152.15
DM8HWS9	FM	C8H8O3
DM8HWS9	IC	InChI=1S/C8H8O3/c1-11-7-4-2-6(3-5-7)8(9)10/h2-5H,1H3,(H,9,10)
DM8HWS9	CS	COC1=CC=C(C=C1)C(=O)O
DM8HWS9	IK	ZEYHEAKUIGZSGI-UHFFFAOYSA-N
DM8HWS9	IU	4-methoxybenzoic acid
DM8HWS9	CA	CAS 100-09-4
DM8HWS9	CB	CHEBI:40813
DM8HWS9	DE	Discovery agent

DM2JUTB	ID	DM2JUTB
DM2JUTB	DN	PARA-(BENZOYL)-PHENYLALANINE
DM2JUTB	HS	Investigative
DM2JUTB	SN	104504-45-2; L-4-Benzoylphenylalanine; (S)-2-Amino-3-(4-benzoylphenyl)propanoic acid; H-Bpa-OH H-Phe(4-Bz)-OH; Para-(Benzoyl)-Phenylalanine; 4-benzoyl-l-phenylalanine; 4-benzoylphenylalanine; H-Bpa-OH; H-p-Bz-Phe-OH; L-p-Benzoylphenylalanine; p-benzoyl-l-phenylalanine; UNII-9RU6KQ9WYD; 9RU6KQ9WYD; Phenylalanine, 4-benzoyl-; AK117086; (2S)-2-amino-3-(4-benzoylphenyl)propanoic acid; H-L-Bpa-OH; para-Benzoyl-L-phenylalanine; SCHEMBL44097; L-Phenylalanine, 4-benzoyl-; L - 4 - Benzoylphenylalanine; BIBA1027; CTK0G6271; KS-00000GGS
DM2JUTB	DT	Small molecular drug
DM2JUTB	PC	7020128
DM2JUTB	MW	269.29
DM2JUTB	FM	C16H15NO3
DM2JUTB	IC	InChI=1S/C16H15NO3/c17-14(16(19)20)10-11-6-8-13(9-7-11)15(18)12-4-2-1-3-5-12/h1-9,14H,10,17H2,(H,19,20)/t14-/m0/s1
DM2JUTB	CS	C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C[C@@H](C(=O)O)N
DM2JUTB	IK	TVIDEEHSOPHZBR-AWEZNQCLSA-N
DM2JUTB	IU	(2S)-2-amino-3-(4-benzoylphenyl)propanoic acid
DM2JUTB	CA	CAS 104504-45-2
DM2JUTB	DE	Discovery agent

DMOH75D	ID	DMOH75D
DMOH75D	DN	Para-chloroamphetamine
DMOH75D	HS	Investigative
DMOH75D	SN	p-CHLOROAMPHETAMINE; para-Chloroamphetamine; p-Chloramphetamine; 1-(4-chlorophenyl)propan-2-amine; 4-Chloramphetamine; 4-Chloroamphetamine; 64-12-0; Para Chloroamphetamine; DL-Chloramphetamine; (+-)-p-Chloramphetamine; C9H12ClN; (+-)-p-Chloroamphetamine; p-Chloroamphetamine (VAN); (+-)-4-Chloroamphetamine; NSC 287208; DL-p-Chloroamphetamine; LY-121860; alpha-Methyl-p-chlorophenethylamine; 4-Chloro-alpha-methylphenethylamine; Benzeneethanamine, 4-chloro-alpha-methyl-; (+-)-p-Chloro-alpha-methylphenethylamine; CHEMBL358967
DMOH75D	DT	Small molecular drug
DMOH75D	PC	3127
DMOH75D	MW	169.65
DMOH75D	FM	C9H12ClN
DMOH75D	IC	InChI=1S/C9H12ClN/c1-7(11)6-8-2-4-9(10)5-3-8/h2-5,7H,6,11H2,1H3
DMOH75D	CS	CC(CC1=CC=C(C=C1)Cl)N
DMOH75D	IK	WWPITPSIWMXDPE-UHFFFAOYSA-N
DMOH75D	IU	1-(4-chlorophenyl)propan-2-amine
DMOH75D	CA	CAS 64-12-0
DMOH75D	DE	Discovery agent

DMZY41U	ID	DMZY41U
DMZY41U	DN	Para-Isopropylaniline
DMZY41U	HS	Investigative
DMZY41U	SN	4-ISOPROPYLANILINE; 99-88-7; Cumidine; 4-Aminocumene; p-Isopropylaniline; p-Cumidine; 4-(Propan-2-Yl)Aniline; 4-Amino-1-isopropylbenzene; PARA-ISOPROPYLANILINE; Cumene, p-amino-; Aniline, p-isopropyl-; Benzenamine, 4-(1-methylethyl)-; Cumidene; UNII-0D54T7V7XL; 4-propan-2-ylaniline; 4-(2-propyl)aniline; NSC 7198; 4-Isopropylaniline, 99%; 0D54T7V7XL; .beta.-(4-Aminophenyl)propane; LRTFPLFDLJYEKT-UHFFFAOYSA-N; 4-(methylethyl)phenylamine; ss-(4-Aminophenyl)Propane; Iso; 4-(1-methylethyl)aniline; cumidin; beta-(4-Aminophenyl)propane
DMZY41U	DT	Small molecular drug
DMZY41U	PC	7464
DMZY41U	MW	135.21
DMZY41U	FM	C9H13N
DMZY41U	IC	InChI=1S/C9H13N/c1-7(2)8-3-5-9(10)6-4-8/h3-7H,10H2,1-2H3
DMZY41U	CS	CC(C)C1=CC=C(C=C1)N
DMZY41U	IK	LRTFPLFDLJYEKT-UHFFFAOYSA-N
DMZY41U	IU	4-propan-2-ylaniline
DMZY41U	CA	CAS 99-88-7
DMZY41U	CB	CHEBI:43405
DMZY41U	DE	Discovery agent

DMQVFWJ	ID	DMQVFWJ
DMQVFWJ	DN	Para-Mercury-Benzenesulfonic Acid
DMQVFWJ	HS	Investigative
DMQVFWJ	SN	(4-sulfophenyl)mercury; 4-Mercuriphenylsulfonate; PARA-MERCURY-BENZENESULFONIC ACID; p-mercuribenzenesulfonic acid; 17014-79-8; PMBS; p-Mercuriphenylsulfonate; para-Mercuriphenylsulfonate; Mercury, bis(4-sulfophenyl)-; SCHEMBL3980997; AC1L22X1; CHEBI:49823; DTXSID30168809
DMQVFWJ	DT	Small molecular drug
DMQVFWJ	PC	65258
DMQVFWJ	MW	357.76
DMQVFWJ	FM	C6H5HgO3S
DMQVFWJ	IC	InChI=1S/C6H5O3S.Hg/c7-10(8,9)6-4-2-1-3-5-6;/h2-5H,(H,7,8,9);
DMQVFWJ	CS	C1=CC(=CC=C1S(=O)(=O)O)[Hg]
DMQVFWJ	IK	KQAOIKIZSJJTII-UHFFFAOYSA-N
DMQVFWJ	IU	(4-sulfophenyl)mercury
DMQVFWJ	CA	CAS 17014-79-8
DMQVFWJ	CB	CHEBI:49823
DMQVFWJ	DE	Discovery agent

DMN4ZKC	ID	DMN4ZKC
DMN4ZKC	DN	Paraoxon
DMN4ZKC	HS	Investigative
DMN4ZKC	SN	PARAOXON; Phosphacol; Diethyl paraoxon; 311-45-5; Ethyl paraoxon; Diethyl 4-nitrophenyl phosphate; Phosphachole; Mintacol; Paraoxone; Miotisal; Fosfakol; Phosphakol; Oxyparathion; Chinorto; Diethyl p-nitrophenyl phosphate; Paroxan; Mintaco; Chinorta; Eticol; Miotisal A; Diethylparaoxon; Soluglaucit; Soluglacit; Paraoxon-ethyl; Ethyl paraoxan; p-Nitrophenyl diethyl phosphate; Phosphoric acid, diethyl 4-nitrophenyl ester; Ester 25; Pestox 101; E 600 (pesticide); Diethyl-p-nitrophenyl phosphate; Phosphoric acid diethyl 4-nitrophenyl ester
DMN4ZKC	DT	Small molecular drug
DMN4ZKC	PC	9395
DMN4ZKC	MW	275.19
DMN4ZKC	FM	C10H14NO6P
DMN4ZKC	IC	InChI=1S/C10H14NO6P/c1-3-15-18(14,16-4-2)17-10-7-5-9(6-8-10)11(12)13/h5-8H,3-4H2,1-2H3
DMN4ZKC	CS	CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+](=O)[O-]
DMN4ZKC	IK	WYMSBXTXOHUIGT-UHFFFAOYSA-N
DMN4ZKC	IU	diethyl (4-nitrophenyl) phosphate
DMN4ZKC	CA	CAS 311-45-5
DMN4ZKC	CB	CHEBI:27827
DMN4ZKC	DE	Discovery agent

DMR8O3X	ID	DMR8O3X
DMR8O3X	DN	Paraquat
DMR8O3X	HS	Investigative
DMR8O3X	SN	1,1'-dimethyl-4,4' bipyridinium dichloride
DMR8O3X	DT	Small molecular drug
DMR8O3X	PC	15939
DMR8O3X	MW	186.25
DMR8O3X	FM	C12H14N2+2
DMR8O3X	IC	InChI=1S/C12H14N2/c1-13-7-3-11(4-8-13)12-5-9-14(2)10-6-12/h3-10H,1-2H3/q+2
DMR8O3X	CS	C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C
DMR8O3X	IK	INFDPOAKFNIJBF-UHFFFAOYSA-N
DMR8O3X	IU	1-methyl-4-(1-methylpyridin-1-ium-4-yl)pyridin-1-ium
DMR8O3X	CA	CAS 4685-14-7
DMR8O3X	CB	CHEBI:34905
DMR8O3X	DE	Discovery agent

DM83C9N	ID	DM83C9N
DM83C9N	DN	Para-sirtinol
DM83C9N	HS	Investigative
DM83C9N	DT	Small molecular drug
DM83C9N	PC	135491748
DM83C9N	MW	394.5
DM83C9N	FM	C26H22N2O2
DM83C9N	IC	InChI=1S/C26H22N2O2/c1-18(19-7-3-2-4-8-19)28-26(30)21-11-14-22(15-12-21)27-17-24-23-10-6-5-9-20(23)13-16-25(24)29/h2-18,29H,1H3,(H,28,30)
DM83C9N	CS	CC(C1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)N=CC3=C(C=CC4=CC=CC=C43)O
DM83C9N	IK	IJMMXTFONLLCMY-UHFFFAOYSA-N
DM83C9N	IU	4-[(2-hydroxynaphthalen-1-yl)methylideneamino]-N-(1-phenylethyl)benzamide
DM83C9N	DE	Discovery agent

DMKJY3U	ID	DMKJY3U
DMKJY3U	DN	parathyroid hormone
DMKJY3U	HS	Investigative
DMKJY3U	SN	NPH-002; NPH-004; oral parathyroid hormone (osteoporosis), Nobex
DMKJY3U	DE	Discovery agent

DMWVPSM	ID	DMWVPSM
DMWVPSM	DN	PARCETASAL
DMWVPSM	HS	Investigative
DMWVPSM	SN	MR-897; Parcetasal; N-[4-(2-Methyl-4-oxo-1,3-benzodioxan-2-yloxy)phenyl]acetamide; Rac-4'-(2-Methyl-4-oxo-1,3-benzodioxan-2-yloxy)acetanilide
DMWVPSM	DT	Small molecular drug
DMWVPSM	PC	65656
DMWVPSM	MW	313.3
DMWVPSM	FM	C17H15NO5
DMWVPSM	IC	InChI=1S/C17H15NO5/c1-11(19)18-12-7-9-13(10-8-12)21-17(2)22-15-6-4-3-5-14(15)16(20)23-17/h3-10H,1-2H3,(H,18,19)
DMWVPSM	CS	CC(=O)NC1=CC=C(C=C1)OC2(OC3=CC=CC=C3C(=O)O2)C
DMWVPSM	IK	ZAPRLADYRFPQSH-UHFFFAOYSA-N
DMWVPSM	IU	N-[4-[(2-methyl-4-oxo-1,3-benzodioxin-2-yl)oxy]phenyl]acetamide
DMWVPSM	CA	CAS 87549-36-8
DMWVPSM	DE	Inflammation

DMVI8R2	ID	DMVI8R2
DMVI8R2	DN	Parke-Davis 1
DMVI8R2	HS	Investigative
DMVI8R2	TC	Analgesics
DMVI8R2	DE	Pain

DMMQY42	ID	DMMQY42
DMMQY42	DN	Parke-Davis 9
DMMQY42	HS	Investigative
DMMQY42	TC	Analgesics
DMMQY42	DE	Pain

DML8BT7	ID	DML8BT7
DML8BT7	DN	PAS219
DML8BT7	HS	Investigative
DML8BT7	SN	PAS219; CHEMBL24811; CYCLOHEXYLMETHYL 2-FORMYLPHENYL HYDROGEN PHOSPHATE; Fragment 15; AC1NR9QB; BDBM14685; DB03114; cyclohexylmethoxy(2-formylphenoxy)phosphinic acid; (cyclohexylmethoxy)(2-formylphenoxy)phosphinic acid; cyclohexylmethyl (2-formylphenyl) hydrogen phosphate; Phosphoric acid (cyclohexylmethyl)2-formylphenyl ester; Phosphoric acid cyclohexylmethyl ester 2-formyl-phenyl ester
DML8BT7	DT	Small molecular drug
DML8BT7	PC	5287461
DML8BT7	MW	298.27
DML8BT7	FM	C14H19O5P
DML8BT7	IC	InChI=1S/C14H19O5P/c15-10-13-8-4-5-9-14(13)19-20(16,17)18-11-12-6-2-1-3-7-12/h4-5,8-10,12H,1-3,6-7,11H2,(H,16,17)
DML8BT7	CS	C1CCC(CC1)COP(=O)(O)OC2=CC=CC=C2C=O
DML8BT7	IK	YBEVTZVQKMYQPM-UHFFFAOYSA-N
DML8BT7	IU	cyclohexylmethyl (2-formylphenyl) hydrogen phosphate
DML8BT7	DE	Discovery agent

DM7Y0G6	ID	DM7Y0G6
DM7Y0G6	DN	PASBN
DM7Y0G6	HS	Investigative
DM7Y0G6	SN	PASBN; BENZYL 2-FORMYLPHENYL HYDROGEN PHOSPHATE; AC1NRCVR; SCHEMBL4315619; CHEMBL148630; BDBM14688; DB03078; benzyl (2-formylphenyl) hydrogen phosphate; (benzyloxy)(2-formylphenoxy)phosphinic acid; benzyl 2-formylphenyl hydrogen (R)-phosphate; Phosphoric acid benzyl ester 2-formyl-phenyl ester
DM7Y0G6	DT	Small molecular drug
DM7Y0G6	PC	5289215
DM7Y0G6	MW	292.22
DM7Y0G6	FM	C14H13O5P
DM7Y0G6	IC	InChI=1S/C14H13O5P/c15-10-13-8-4-5-9-14(13)19-20(16,17)18-11-12-6-2-1-3-7-12/h1-10H,11H2,(H,16,17)
DM7Y0G6	CS	C1=CC=C(C=C1)COP(=O)(O)OC2=CC=CC=C2C=O
DM7Y0G6	IK	PWDTUFYQEUEVQD-UHFFFAOYSA-N
DM7Y0G6	IU	benzyl (2-formylphenyl) hydrogen phosphate
DM7Y0G6	DE	Discovery agent

DMRJ104	ID	DMRJ104
DMRJ104	DN	PAT5A
DMRJ104	HS	Investigative
DMRJ104	SN	PAT5A; GTPL2709
DMRJ104	DT	Small molecular drug
DMRJ104	PC	18980163
DMRJ104	MW	381.4
DMRJ104	FM	C20H19N3O3S
DMRJ104	IC	InChI=1S/C20H19N3O3S/c24-19-17(27-20(25)22-19)12-14-6-8-16(9-7-14)26-13-15-4-3-11-23(15)18-5-1-2-10-21-18/h1-2,5-10,12,15H,3-4,11,13H2,(H,22,24,25)/b17-12-
DMRJ104	CS	C1CC(N(C1)C2=CC=CC=N2)COC3=CC=C(C=C3)/C=C\\4/C(=O)NC(=O)S4
DMRJ104	IK	GRLCJTHTWOJWJS-ATVHPVEESA-N
DMRJ104	IU	(5Z)-5-[[4-[(1-pyridin-2-ylpyrrolidin-2-yl)methoxy]phenyl]methylidene]-1,3-thiazolidine-2,4-dione
DMRJ104	DE	Discovery agent

DMOXNYQ	ID	DMOXNYQ
DMOXNYQ	DN	Patuletin 3-O-beta-D-galactoside
DMOXNYQ	HS	Investigative
DMOXNYQ	SN	AC1NSZGN; CHEMBL483837
DMOXNYQ	DT	Small molecular drug
DMOXNYQ	PC	5320434
DMOXNYQ	MW	494.4
DMOXNYQ	FM	C22H22O13
DMOXNYQ	IC	InChI=1S/C22H22O13/c1-32-20-10(26)5-11-13(15(20)28)16(29)21(19(33-11)7-2-3-8(24)9(25)4-7)35-22-18(31)17(30)14(27)12(6-23)34-22/h2-5,12,14,17-18,22-28,30-31H,6H2,1H3/t12-,14+,17+,18-,22+/m1/s1
DMOXNYQ	CS	COC1=C(C2=C(C=C1O)OC(=C(C2=O)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)C4=CC(=C(C=C4)O)O)O
DMOXNYQ	IK	AFBZFRQNKMLRPU-UFJVGALSSA-N
DMOXNYQ	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMOXNYQ	DE	Discovery agent

DMZ5Q7J	ID	DMZ5Q7J
DMZ5Q7J	DN	Patuletin 3-O-beta-D-robinobioside
DMZ5Q7J	HS	Investigative
DMZ5Q7J	SN	CHEMBL442920; 6-Methoxyquercetin 3-robinobioside
DMZ5Q7J	DT	Small molecular drug
DMZ5Q7J	PC	44575854
DMZ5Q7J	MW	640.5
DMZ5Q7J	FM	C28H32O17
DMZ5Q7J	IC	InChI=1S/C28H32O17/c1-8-16(32)20(36)22(38)27(42-8)41-7-14-17(33)21(37)23(39)28(44-14)45-26-19(35)15-13(6-12(31)25(40-2)18(15)34)43-24(26)9-3-4-10(29)11(30)5-9/h3-6,8,14,16-17,20-23,27-34,36-39H,7H2,1-2H3/t8-,14+,16-,17-,20+,21-,22+,23+,27+,28-/m0/s1
DMZ5Q7J	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=C(C3=O)C(=C(C(=C4)O)OC)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O
DMZ5Q7J	IK	MLOJYABWNDVJMG-GBWWRXBVSA-N
DMZ5Q7J	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
DMZ5Q7J	DE	Discovery agent

DM0RV9C	ID	DM0RV9C
DM0RV9C	DN	PATULIN
DM0RV9C	HS	Investigative
DM0RV9C	SN	patulin; Expansin; Clavacin; Expansine; Patuline; Claviform; Clavatin; 149-29-1; Clairformin; Claviformin; Leucopin; Gigantin; Tercinin; Mycoin; Mycoine C3; Mycoin C3; Penicidin; Penatin; Mycosin; Terinin; Mycoin C; 4-Hydroxy-4H-furo[3,2-c]pyran-2(6H)-one; Sch-351633; NSC 8120; NSC 32951; 4-Hydroxy-4H-furo(3,2-C)pyran-2(6H)-one; CCRIS 4940; (2,4-Dihydroxy-2H-pyran-3(6H)-ylidene)acetic acid, 3,4-lactone; HSDB 3522; 4,6-Dihydro-4-hydroxy-2H-furo(3,2-c)pyran-2-one; NSC8120; NSC32951; EINECS 205-735-2; 4H-Furo[3,2-c]pyran-2(6H)-one, 4-hydroxy-
DM0RV9C	DT	Small molecular drug
DM0RV9C	PC	4696
DM0RV9C	MW	154.12
DM0RV9C	FM	C7H6O4
DM0RV9C	IC	InChI=1S/C7H6O4/c8-6-3-4-5(11-6)1-2-10-7(4)9/h1,3,7,9H,2H2
DM0RV9C	CS	C1C=C2C(=CC(=O)O2)C(O1)O
DM0RV9C	IK	ZRWPUFFVAOMMNM-UHFFFAOYSA-N
DM0RV9C	IU	4-hydroxy-4,6-dihydrofuro[3,2-c]pyran-2-one
DM0RV9C	CA	CAS 149-29-1
DM0RV9C	CB	CHEBI:74926
DM0RV9C	DE	Discovery agent

DMQA8N3	ID	DMQA8N3
DMQA8N3	DN	PAULLONE
DMQA8N3	HS	Investigative
DMQA8N3	SN	Paullone; 142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529
DMQA8N3	DT	Small molecular drug
DMQA8N3	PC	369401
DMQA8N3	MW	248.28
DMQA8N3	FM	C16H12N2O
DMQA8N3	IC	InChI=1S/C16H12N2O/c19-15-9-12-10-5-1-3-7-13(10)18-16(12)11-6-2-4-8-14(11)17-15/h1-8,18H,9H2,(H,17,19)
DMQA8N3	CS	C1C2=C(C3=CC=CC=C3NC1=O)NC4=CC=CC=C24
DMQA8N3	IK	VGMDAWVZNAXVDG-UHFFFAOYSA-N
DMQA8N3	IU	7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one
DMQA8N3	CA	CAS 142273-18-5
DMQA8N3	CB	CHEBI:138487
DMQA8N3	DE	Discovery agent

DMPF2N1	ID	DMPF2N1
DMPF2N1	DN	paxilline
DMPF2N1	HS	Investigative
DMPF2N1	SN	4b-Hydroxy-2-(1-hydroxy-1-methylethyl)-12b,12c-dimethyl-5,6,6a,7,12,12b,12c,13,14,14a-decahydro-2H-chromeno[5',6':6,7]indeno[1,2-b]indol-3(4bH)-one; paxillin; AC1L1IR1; GTPL2309; BDBM86263; CTK7H1286; ACNHBCIZLNNLRS-UHFFFAOYSA-N; NCGC00168476-01; CAS_57186-25-1; hydroxy-(1-hydroxy-1-methyl-ethyl)-dimethyl-[ ]one; 4b-Hydroxy-2-(1-hydroxy-1-methylethyl)-12b,12c-dimethyl-5,6,6a,7,12,12b,12c,13,14,14a-decahydro-2H-chromeno[5',6':6,7]indeno[1,2-b]indol-3(4bh)-one #
DMPF2N1	DT	Small molecular drug
DMPF2N1	PC	105008
DMPF2N1	MW	435.6
DMPF2N1	FM	C27H33NO4
DMPF2N1	IC	InChI=1S/C27H33NO4/c1-24(2,30)23-20(29)14-18-21(32-23)10-11-25(3)26(4)15(9-12-27(18,25)31)13-17-16-7-5-6-8-19(16)28-22(17)26/h5-8,14-15,21,23,28,30-31H,9-13H2,1-4H3/t15-,21-,23-,25+,26+,27+/m0/s1
DMPF2N1	CS	C[C@]12CC[C@H]3C(=CC(=O)[C@H](O3)C(C)(C)O)[C@@]1(CC[C@@H]4[C@@]2(C5=C(C4)C6=CC=CC=C6N5)C)O
DMPF2N1	IK	ACNHBCIZLNNLRS-UBGQALKQSA-N
DMPF2N1	IU	(1S,2R,5S,7R,11S,14S)-11-hydroxy-7-(2-hydroxypropan-2-yl)-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.02,11.05,10.016,24.017,22]tetracosa-9,16(24),17,19,21-pentaen-8-one
DMPF2N1	CA	CAS 57186-25-1
DMPF2N1	CB	CHEBI:34907
DMPF2N1	DE	Discovery agent

DMX7WU9	ID	DMX7WU9
DMX7WU9	DN	PB-1120
DMX7WU9	HS	Investigative
DMX7WU9	SN	Insulin-ELP
DMX7WU9	DE	Discovery agent

DMZURA2	ID	DMZURA2
DMZURA2	DN	PB-27
DMZURA2	HS	Investigative
DMZURA2	SN	PB-27; CHEMBL192244; BDBM13327; tetrahydroquinoline (THQ)-based inhibitor 4i
DMZURA2	DT	Small molecular drug
DMZURA2	PC	11271978
DMZURA2	MW	499.6
DMZURA2	FM	C26H25N7O2S
DMZURA2	IC	InChI=1S/C26H25N7O2S/c1-31-19-28-15-24(31)18-32-17-23(13-21-12-20(14-27)8-9-25(21)32)33(16-22-6-2-4-10-29-22)36(34,35)26-7-3-5-11-30-26/h2-12,15,19,23H,13,16-18H2,1H3
DMZURA2	CS	CN1C=NC=C1CN2CC(CC3=C2C=CC(=C3)C#N)N(CC4=CC=CC=N4)S(=O)(=O)C5=CC=CC=N5
DMZURA2	IK	GQLZRVHYGCXHSR-UHFFFAOYSA-N
DMZURA2	IU	N-[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2H-quinolin-3-yl]-N-(pyridin-2-ylmethyl)pyridine-2-sulfonamide
DMZURA2	DE	Discovery agent

DMMNQ1B	ID	DMMNQ1B
DMMNQ1B	DN	PB28
DMMNQ1B	HS	Investigative
DMMNQ1B	SN	Pigment Blue 28
DMMNQ1B	TC	Antiviral Agents
DMMNQ1B	DT	Small molecular drug
DMMNQ1B	PC	10474335
DMMNQ1B	MW	370.6
DMMNQ1B	FM	C24H38N2O
DMMNQ1B	IC	InChI=1S/C24H38N2O/c1-27-24-14-6-12-22-20(8-5-13-23(22)24)9-7-15-25-16-18-26(19-17-25)21-10-3-2-4-11-21/h6,12,14,20-21H,2-5,7-11,13,15-19H2,1H3
DMMNQ1B	CS	COC1=CC=CC2=C1CCCC2CCCN3CCN(CC3)C4CCCCC4
DMMNQ1B	IK	PHRCDWVPTULQMT-UHFFFAOYSA-N
DMMNQ1B	IU	1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine
DMMNQ1B	CA	CAS 172906-90-0
DMMNQ1B	DE	Coronavirus Disease 2019 (COVID-19)

DMSXZ19	ID	DMSXZ19
DMSXZ19	DN	PB-28
DMSXZ19	HS	Investigative
DMSXZ19	SN	PB-28; CHEMBL53325; PB28; 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine; 1-cyclohexyl-4-(3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl)piperazine; SCHEMBL466974; GTPL6681; BDBM50048866; API0004726; NCGC00165875-03; NCGC00165875-01; NCGC00165875-02; 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)propyl]piperazine
DMSXZ19	DT	Small molecular drug
DMSXZ19	PC	10474335
DMSXZ19	MW	370.6
DMSXZ19	FM	C24H38N2O
DMSXZ19	IC	InChI=1S/C24H38N2O/c1-27-24-14-6-12-22-20(8-5-13-23(22)24)9-7-15-25-16-18-26(19-17-25)21-10-3-2-4-11-21/h6,12,14,20-21H,2-5,7-11,13,15-19H2,1H3
DMSXZ19	CS	COC1=CC=CC2=C1CCCC2CCCN3CCN(CC3)C4CCCCC4
DMSXZ19	IK	PHRCDWVPTULQMT-UHFFFAOYSA-N
DMSXZ19	IU	1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine
DMSXZ19	CA	CAS 172906-90-0
DMSXZ19	DE	Discovery agent

DMAOIW5	ID	DMAOIW5
DMAOIW5	DN	PB-80
DMAOIW5	HS	Investigative
DMAOIW5	SN	PB-80
DMAOIW5	DT	Small molecular drug
DMAOIW5	PC	11283830
DMAOIW5	MW	521.6
DMAOIW5	FM	C26H31N7O3S
DMAOIW5	IC	InChI=1S/C26H31N7O3S/c1-26(2,3)30-25(34)17-33(37(35,36)23-6-5-9-28-14-23)21-11-20-10-19(12-27)7-8-24(20)32(15-21)16-22-13-29-18-31(22)4/h5-10,13-14,18,21H,11,15-17H2,1-4H3,(H,30,34)
DMAOIW5	CS	CC(C)(C)NC(=O)CN(C1CC2=C(C=CC(=C2)C#N)N(C1)CC3=CN=CN3C)S(=O)(=O)C4=CN=CC=C4
DMAOIW5	IK	YCXGDFGCNDASCM-UHFFFAOYSA-N
DMAOIW5	IU	N-tert-butyl-2-[[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2H-quinolin-3-yl]-pyridin-3-ylsulfonylamino]acetamide
DMAOIW5	DE	Discovery agent

DM9V807	ID	DM9V807
DM9V807	DN	PB-81
DM9V807	HS	Investigative
DM9V807	SN	PB-81
DM9V807	DT	Small molecular drug
DM9V807	PC	11214581
DM9V807	MW	521.6
DM9V807	FM	C26H31N7O3S
DM9V807	IC	InChI=1S/C26H31N7O3S/c1-26(2,3)30-25(34)17-33(37(35,36)23-7-9-28-10-8-23)21-12-20-11-19(13-27)5-6-24(20)32(15-21)16-22-14-29-18-31(22)4/h5-11,14,18,21H,12,15-17H2,1-4H3,(H,30,34)
DM9V807	CS	CC(C)(C)NC(=O)CN(C1CC2=C(C=CC(=C2)C#N)N(C1)CC3=CN=CN3C)S(=O)(=O)C4=CC=NC=C4
DM9V807	IK	VXYRLLDULVRHBY-UHFFFAOYSA-N
DM9V807	IU	N-tert-butyl-2-[[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2H-quinolin-3-yl]-pyridin-4-ylsulfonylamino]acetamide
DM9V807	DE	Discovery agent

DM39LS5	ID	DM39LS5
DM39LS5	DN	PBC-264
DM39LS5	HS	Investigative
DM39LS5	SN	pBC 264; propionyl-BC264
DM39LS5	DT	Small molecular drug
DM39LS5	PC	5491702
DM39LS5	MW	1062.2
DM39LS5	FM	C51H67N9O14S
DM39LS5	IC	InChI=1S/C51H67N9O14S/c1-5-8-18-37(52-4)46(65)57-41(28-45(63)64)47(66)56-39(25-31-15-11-10-12-16-31)49(68)60-50(69)40(27-33-29-53-36-19-14-13-17-35(33)36)58-51(70)42(61)30-54-43(20-9-6-2)59-48(67)38(55-44(62)7-3)26-32-21-23-34(24-22-32)74-75(71,72)73/h10-17,19,21-24,29,37-41,43,52-54H,5-9,18,20,25-28,30H2,1-4H3,(H,55,62)(H,56,66)(H,57,65)(H,58,70)(H,59,67)(H,63,64)(H,60,68,69)(H,71,72,73)/t37-,38-,39-,40-,41-,43-/m0/s1
DM39LS5	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)C(=O)CN[C@H](CCCC)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)CC)NC
DM39LS5	IK	VNNMDTHCFFZSSJ-HWQWZYBXSA-N
DM39LS5	IU	(3S)-4-[[(2S)-1-[[(2S)-3-(1H-indol-3-yl)-2-[[2-oxo-3-[[(1S)-1-[[(2S)-2-(propanoylamino)-3-(4-sulfooxyphenyl)propanoyl]amino]pentyl]amino]propanoyl]amino]propanoyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-(methylamino)hexanoyl]amino]-4-oxobutanoic acid
DM39LS5	CA	CAS 131167-65-2
DM39LS5	DE	Discovery agent

DM1Y2F0	ID	DM1Y2F0
DM1Y2F0	DN	PBD150
DM1Y2F0	HS	Investigative
DM1Y2F0	SN	compound 53 [PMID 16420052]
DM1Y2F0	DT	Small molecular drug
DM1Y2F0	PC	6539196
DM1Y2F0	MW	320.4
DM1Y2F0	FM	C15H20N4O2S
DM1Y2F0	IC	InChI=1S/C15H20N4O2S/c1-20-13-5-4-12(10-14(13)21-2)18-15(22)17-6-3-8-19-9-7-16-11-19/h4-5,7,9-11H,3,6,8H2,1-2H3,(H2,17,18,22)
DM1Y2F0	CS	COC1=C(C=C(C=C1)NC(=S)NCCCN2C=CN=C2)OC
DM1Y2F0	IK	FZQXMGLQANXZRP-UHFFFAOYSA-N
DM1Y2F0	IU	1-(3,4-dimethoxyphenyl)-3-(3-imidazol-1-ylpropyl)thiourea
DM1Y2F0	DE	Discovery agent

DM8Q54I	ID	DM8Q54I
DM8Q54I	DN	PBIT
DM8Q54I	HS	Investigative
DM8Q54I	SN	2514-30-9; PBIT; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21
DM8Q54I	DT	Small molecular drug
DM8Q54I	PC	935415
DM8Q54I	MW	241.31
DM8Q54I	FM	C14H11NOS
DM8Q54I	IC	InChI=1S/C14H11NOS/c1-10-6-8-11(9-7-10)15-14(16)12-4-2-3-5-13(12)17-15/h2-9H,1H3
DM8Q54I	CS	CC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3S2
DM8Q54I	IK	KRXMYBAZKJBJAB-UHFFFAOYSA-N
DM8Q54I	IU	2-(4-methylphenyl)-1,2-benzothiazol-3-one
DM8Q54I	CA	CAS 2514-30-9
DM8Q54I	DE	Discovery agent

DM8K7C4	ID	DM8K7C4
DM8K7C4	DN	PBMC
DM8K7C4	HS	Investigative
DM8K7C4	SN	PBMC; GTPL6370; [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate
DM8K7C4	DT	Small molecular drug
DM8K7C4	PC	73755215
DM8K7C4	MW	434.5
DM8K7C4	FM	C26H30N2O4
DM8K7C4	IC	InChI=1S/C26H30N2O4/c1-20(23-11-7-4-8-12-23)32-26(29)28(16-15-27)18-22-13-14-24(25(17-22)30-2)31-19-21-9-5-3-6-10-21/h3-14,17,20H,15-16,18-19,27H2,1-2H3/t20-/m1/s1
DM8K7C4	CS	C[C@H](C1=CC=CC=C1)OC(=O)N(CCN)CC2=CC(=C(C=C2)OCC3=CC=CC=C3)OC
DM8K7C4	IK	URRBLVUOXIGNQR-HXUWFJFHSA-N
DM8K7C4	IU	[(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate
DM8K7C4	DE	Discovery agent

DMD9KYN	ID	DMD9KYN
DMD9KYN	DN	PCCG-4
DMD9KYN	HS	Investigative
DMD9KYN	SN	(2S,1'S,2'S,3 R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine
DMD9KYN	DT	Small molecular drug
DMD9KYN	PC	5311344
DMD9KYN	MW	235.24
DMD9KYN	FM	C12H13NO4
DMD9KYN	IC	InChI=1S/C12H13NO4/c13-10(12(16)17)8-7(9(8)11(14)15)6-4-2-1-3-5-6/h1-5,7-10H,13H2,(H,14,15)(H,16,17)/t7-,8+,9+,10+/m1/s1
DMD9KYN	CS	C1=CC=C(C=C1)[C@@H]2[C@@H]([C@H]2C(=O)O)[C@@H](C(=O)O)N
DMD9KYN	IK	IFLWVSHRWAIVQF-KATARQTJSA-N
DMD9KYN	IU	(1S,2S,3R)-2-[(S)-amino(carboxy)methyl]-3-phenylcyclopropane-1-carboxylic acid
DMD9KYN	DE	Discovery agent

DMIMPDL	ID	DMIMPDL
DMIMPDL	DN	PCI-34051
DMIMPDL	HS	Investigative
DMIMPDL	SN	PCI-34259; PCI-34260; PCI-40505; PCI-43744; PCI-45159; PCI-47634; PCI-48000; PCI-48001; PCI-48002; PCI-48003; PCI-48004; PCI-48006; PCI-48007; PCI-48008; PCI-48009; PCI-48010; PCI-48011; PCI-48012; PCI-48013; PCI-48018; PCI-48036; PCI-48039; HDAC 8 inhibitors (cancer/inflammation); HDAC 8 inhibitors (cancer/inflammation), Pharmacyclics
DMIMPDL	CP	Pharmacyclics Inc
DMIMPDL	DT	Small molecular drug
DMIMPDL	PC	24753719
DMIMPDL	MW	296.32
DMIMPDL	FM	C17H16N2O3
DMIMPDL	IC	InChI=1S/C17H16N2O3/c1-22-15-6-2-12(3-7-15)11-19-9-8-13-4-5-14(10-16(13)19)17(20)18-21/h2-10,21H,11H2,1H3,(H,18,20)
DMIMPDL	CS	COC1=CC=C(C=C1)CN2C=CC3=C2C=C(C=C3)C(=O)NO
DMIMPDL	IK	AJRGHIGYPXNABY-UHFFFAOYSA-N
DMIMPDL	IU	N-hydroxy-1-[(4-methoxyphenyl)methyl]indole-6-carboxamide
DMIMPDL	CA	CAS 950762-95-5
DMIMPDL	CB	CHEBI:94192
DMIMPDL	DE	Solid tumour/cancer

DMGIS5Q	ID	DMGIS5Q
DMGIS5Q	DN	pCMPS
DMGIS5Q	HS	Investigative
DMGIS5Q	SN	para-Chloromercuriphenylsulfonate; p-Chloromercuribenzenesulfonate; pCMBS
DMGIS5Q	DT	Small molecular drug
DMGIS5Q	PC	11136
DMGIS5Q	MW	393.21
DMGIS5Q	FM	C6H5ClHgO3S
DMGIS5Q	IC	InChI=1S/C6H5O3S.ClH.Hg/c7-10(8,9)6-4-2-1-3-5-6;;/h2-5H,(H,7,8,9);1H;/q;;+1/p-1
DMGIS5Q	CS	C1=CC(=CC=C1S(=O)(=O)O)[Hg]Cl
DMGIS5Q	IK	XXEBDPRHFAWOND-UHFFFAOYSA-M
DMGIS5Q	IU	chloro-(4-sulfophenyl)mercury
DMGIS5Q	CA	CAS 554-77-8
DMGIS5Q	CB	CHEBI:33206
DMGIS5Q	DE	Discovery agent

DMGS6YH	ID	DMGS6YH
DMGS6YH	DN	PCNOTAXIME GROUP
DMGS6YH	HS	Investigative
DMGS6YH	SN	open; hydrolyzed; C3'-cleaved; (2r)-2-[(R)-{[(2z)-2-(2-Amino-1,3-Thiazol-4-Yl)-2-(Methoxyimino)acetyl]amino}(Carboxy)methyl]-5-Methylidene-5,6-Dihydro-2h-1,3-Thiazine-4-Carboxylic Acid; AC1O43RR; (2R)-2-[(R)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido](carboxy)methyl]-5-methylidene-2,6-dihydro-1,3-thiazine-4-carboxylic acid; (2R)-2-[(1R)-1-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-2-hydroxy-2-oxoethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
DMGS6YH	DT	Small molecular drug
DMGS6YH	PC	101666160
DMGS6YH	MW	413.4
DMGS6YH	FM	C14H15N5O6S2
DMGS6YH	IC	InChI=1S/C14H15N5O6S2/c1-5-3-26-11(18-7(5)12(21)22)9(13(23)24)17-10(20)8(19-25-2)6-4-27-14(15)16-6/h4,9,11H,1,3H2,2H3,(H2,15,16)(H,17,20)(H,21,22)(H,23,24)/b19-8+/t9-,11+/m0/s1
DMGS6YH	CS	CO/N=C(\\C1=CSC(=N1)N)/C(=O)N[C@@H]([C@@H]2N=C(C(=C)CS2)C(=O)O)C(=O)O
DMGS6YH	IK	ZRDXEERHKBZJMY-VGMFVZOQSA-N
DMGS6YH	IU	(2R)-2-[(R)-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-carboxymethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
DMGS6YH	DE	Discovery agent

DMGJSVD	ID	DMGJSVD
DMGJSVD	DN	P-Coumaric Acid
DMGJSVD	HS	Investigative
DMGJSVD	SN	p-coumaric acid; 4-Hydroxycinnamic acid; p-Hydroxycinnamic acid; 501-98-4; 4-Coumaric acid; trans-4-Hydroxycinnamic acid; 7400-08-0; trans-p-Coumaric acid; p-Cumaric acid; 3-(4-hydroxyphenyl)acrylic acid; Para-Coumaric acid; Hydroxycinnamic acid; p-Hydroxy-cinnamic acid; Naringeninic acid; p-Hydroxyphenylacrylic acid; (E)-p-Coumaric acid; trans-p-Coumarinic acid; 4'-hydroxycinnamic acid; (E)-3-(4-Hydroxyphenyl)acrylic acid; Cinnamic acid, p-hydroxy-; (E)-p-Hydroxycinnamic acid; trans-p-Hydroxycinnamic acid
DMGJSVD	DT	Small molecular drug
DMGJSVD	PC	637542
DMGJSVD	MW	164.16
DMGJSVD	FM	C9H8O3
DMGJSVD	IC	InChI=1S/C9H8O3/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-6,10H,(H,11,12)/b6-3+
DMGJSVD	CS	C1=CC(=CC=C1/C=C/C(=O)O)O
DMGJSVD	IK	NGSWKAQJJWESNS-ZZXKWVIFSA-N
DMGJSVD	IU	(E)-3-(4-hydroxyphenyl)prop-2-enoic acid
DMGJSVD	CA	CAS 501-98-4
DMGJSVD	CB	CHEBI:32374
DMGJSVD	DE	Discovery agent

DMZVJYL	ID	DMZVJYL
DMZVJYL	DN	PcTx1
DMZVJYL	HS	Investigative
DMZVJYL	SN	CIGUATOXIN; Ciguatoxin 1; Ciguatoxin CTX 1; Pacific ciguatoxin 1; CTX 1; P-CTX 1; UNII-2UKQ3B7696; HSDB 7241; 11050-21-8; 2UKQ3B7696; Pacific ciguatoxin-1; P-CTX-1; Ciguatoxins; Ciguatoxin CTX1B; Ciguatoxin I; Ciguatoxin 1B; SCHEMBL13303026; DTXSID3042637; NOCAS_42637; CHEBI:36467; LS-53705; C16762
DMZVJYL	TC	Analgesics
DMZVJYL	DT	Small molecular drug
DMZVJYL	PC	90489000
DMZVJYL	MW	4689
DMZVJYL	FM	C200H312N62O57S6
DMZVJYL	IC	InChI=1S/C200H312N62O57S6/c1-13-102(10)157-194(316)261-74-36-54-142(261)189(311)239-116(46-23-28-66-203)167(289)244-128(78-106-84-221-112-42-19-17-40-109(106)112)176(298)230-114(44-21-26-64-201)161(283)223-89-147(269)229-135-91-320-321-93-137-183(305)245-129(79-107-85-222-113-43-20-18-41-110(107)113)177(299)234-115(45-22-27-65-202)164(286)231-119(49-31-69-217-197(208)209)165(287)232-120(50-32-70-218-198(210)211)166(288)233-122(52-34-72-220-200(214)215)169(291)248-134(90-263)181(303)243-127(77-105-38-15-14-16-39-105)175(297)238-125(59-63-151(276)277)173(295)254-155(100(6)7)192(314)253-140(186(308)256-156(101(8)9)193(315)260-73-35-53-141(260)188(310)240-117(47-24-29-67-204)171(293)258-158(103(11)264)195(317)262-75-37-55-143(262)190(312)241-118(48-25-30-68-205)172(294)259-159(104(12)265)196(318)319)96-325-323-94-138(250-179(301)132(82-152(278)279)228-146(268)88-225-163(285)130(80-108-86-216-97-226-108)246-168(290)121(51-33-71-219-199(212)213)235-178(300)131(81-144(207)266)247-191(313)154(99(4)5)255-185(135)307)184(306)252-136(92-322-324-95-139(187(309)257-157)251-180(302)133(83-153(280)281)242-160(282)111(206)56-60-148(270)271)182(304)236-123(57-61-149(272)273)162(284)224-87-145(267)227-126(76-98(2)3)174(296)237-124(170(292)249-137)58-62-150(274)275/h14-20,38-43,84-86,97-104,111,114-143,154-159,221-222,263-265H,13,21-37,44-83,87-96,201-206H2,1-12H3,(H2,207,266)(H,216,226)(H,223,283)(H,224,284)(H,225,285)(H,227,267)(H,228,268)(H,229,269)(H,230,298)(H,231,286)(H,232,287)(H,233,288)(H,234,299)(H,235,300)(H,236,304)(H,237,296)(H,238,297)(H,239,311)(H,240,310)(H,241,312)(H,242,282)(H,243,303)(H,244,289)(H,245,305)(H,246,290)(H,247,313)(H,248,291)(H,249,292)(H,250,301)(H,251,302)(H,252,306)(H,253,314)(H,254,295)(H,255,307)(H,256,308)(H,257,309)(H,258,293)(H,259,294)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,318,319)(H4,208,209,217)(H4,210,211,218)(H4,212,213,219)(H4,214,215,220)
DMZVJYL	CS	CCC(C)C1C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC3CSSCC4C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)N)C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N4)CCC(=O)O)CC(C)C)CCC(=O)O)NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC3=O)C(C)C)CC(=O)N)CCCNC(=N)N)CC5=CNC=N5)CC(=O)O)C(=O)NC(C(C)C)C(=O)N6CCCC6C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N7CCCC7C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CCC(=O)O)CC8=CC=CC=C8)CO)CCCNC(=N)N)CCCNC(=N)N)CCCNC(=N)N)CCCCN)CC9=CNC1=CC=CC=C19)CCCCN)CC1=CNC2=CC=CC=C21)CCCCN
DMZVJYL	IK	LICLJUGDURFZIM-UHFFFAOYSA-N
DMZVJYL	IU	4-amino-5-[[1-[[27-[[1-[2-[[6-amino-1-[[1-[2-[[6-amino-1-[(1-carboxy-2-hydroxypropyl)amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamoyl]-51,89,95-tris(4-aminobutyl)-7-(2-amino-2-oxoethyl)-36-benzyl-80-butan-2-yl-10,42,45,48-tetrakis(3-carbamimidamidopropyl)-33,60,69-tris(2-carboxyethyl)-19-(carboxymethyl)-39-(hydroxymethyl)-13-(1H-imidazol-4-ylmethyl)-54,92-bis(1H-indol-3-ylmethyl)-63-(2-methylpropyl)-2,5,6a,8,11,14,17,20,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,78,81,87,90,93,96,99-triacontaoxo-4,30-di(propan-2-yl)-2a,3a,24,25,74,75-hexathia-a,3,5a,6,9,12,15,18,21,28,31,34,37,40,43,46,49,52,55,58,61,64,67,70,79,82,88,91,94,97-triacontazatetracyclo[55.43.4.222,72.082,86]hexahectan-77-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMZVJYL	DE	Pain

DMYC51H	ID	DMYC51H
DMYC51H	DN	PD 128907
DMYC51H	HS	Investigative
DMYC51H	SN	(4As,10bS)-4-propyl-3,4a,5,10b-tetrahydro-2H-chromeno[4,3-b][1,4]oxazin-9-ol; PBPO; PBTO; PD128907; PD-128907; CHEMBL97424; [3H]PD 128907; 123594-64-9; (4aS,10bS)-4-propyl-3,4a,5,10b-tetrahydro-2H-chromeno[4,3-b][1,4]oxazin-9-ol; trans-(+-)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol; 3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol; 2H,5H-(1)Benzopyrano(4,3-b)-1,4-oxazin-9-ol, 3,4,4a,10b-tetrahydro-4-propyl-, (4aR,10bR)-rel-; 2H,5H-(1)Benzopyrano(4,3-b)-1,4-oxazin-9-ol, 3,4,4a,10b-tetrahydro-4-propyl-, trans-(+-)-; PD-128,907;  PD128907; [3H]PD128907
DMYC51H	DT	Small molecular drug
DMYC51H	PC	115107
DMYC51H	MW	249.3
DMYC51H	FM	C14H19NO3
DMYC51H	IC	InChI=1S/C14H19NO3/c1-2-5-15-6-7-17-14-11-8-10(16)3-4-13(11)18-9-12(14)15/h3-4,8,12,14,16H,2,5-7,9H2,1H3/t12-,14-/m0/s1
DMYC51H	CS	CCCN1CCO[C@@H]2[C@@H]1COC3=C2C=C(C=C3)O
DMYC51H	IK	YOILXOMTHPUMRG-JSGCOSHPSA-N
DMYC51H	IU	(4aS,10bS)-4-propyl-3,4a,5,10b-tetrahydro-2H-chromeno[4,3-b][1,4]oxazin-9-ol
DMYC51H	CA	CAS 123594-64-9
DMYC51H	DE	Discovery agent

DM5GTHE	ID	DM5GTHE
DM5GTHE	DN	PD 154740
DM5GTHE	HS	Investigative
DM5GTHE	SN	PD-154740; PD154740
DM5GTHE	DT	Small molecular drug
DM5GTHE	PC	190945
DM5GTHE	MW	553.7
DM5GTHE	FM	C32H47N3O5
DM5GTHE	IC	InChI=1S/C32H47N3O5/c1-31(2,3)40-30(39)34-27(23-25-17-11-9-12-18-25)28(37)35-29(38)32(4,24-26-19-13-10-14-20-26)33-21-15-7-5-6-8-16-22-36/h9-14,17-20,27,33,36H,5-8,15-16,21-24H2,1-4H3,(H,34,39)(H,35,37,38)/t27-,32+/m0/s1
DM5GTHE	CS	C[C@@](CC1=CC=CC=C1)(C(=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C)NCCCCCCCCO
DM5GTHE	IK	LLSVPRQAIHTVBK-QVWWMRLHSA-N
DM5GTHE	IU	tert-butyl N-[(2S)-1-[[(2R)-2-(8-hydroxyoctylamino)-2-methyl-3-phenylpropanoyl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate
DM5GTHE	CA	CAS 159614-69-4
DM5GTHE	DE	Discovery agent

DM5J4NA	ID	DM5J4NA
DM5J4NA	DN	PD 165929
DM5J4NA	HS	Investigative
DM5J4NA	SN	PD165929; PD-165929
DM5J4NA	DT	Small molecular drug
DM5J4NA	PC	5311352
DM5J4NA	MW	593.8
DM5J4NA	FM	C37H47N5O2
DM5J4NA	IC	InChI=1S/C37H47N5O2/c1-25(2)28-15-13-16-29(26(3)4)33(28)41-35(44)42-36(5,22-27-23-39-31-17-8-7-14-30(27)31)34(43)40-24-37(19-10-6-11-20-37)32-18-9-12-21-38-32/h7-9,12-18,21,23,25-26,39H,6,10-11,19-20,22,24H2,1-5H3,(H,40,43)(H2,41,42,44)/t36-/m0/s1
DM5J4NA	CS	CC(C)C1=C(C(=CC=C1)C(C)C)NC(=O)N[C@@](C)(CC2=CNC3=CC=CC=C32)C(=O)NCC4(CCCCC4)C5=CC=CC=N5
DM5J4NA	IK	RVCSRPVACXMJEL-BHVANESWSA-N
DM5J4NA	IU	(2S)-2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-3-(1H-indol-3-yl)-2-methyl-N-[(1-pyridin-2-ylcyclohexyl)methyl]propanamide
DM5J4NA	DE	Discovery agent

DMFNQEA	ID	DMFNQEA
DMFNQEA	DN	PD 168368
DMFNQEA	HS	Investigative
DMFNQEA	SN	PD168368; PD-168368
DMFNQEA	DT	Small molecular drug
DMFNQEA	PC	9937534
DMFNQEA	MW	554.6
DMFNQEA	FM	C31H34N6O4
DMFNQEA	IC	InChI=1S/C31H34N6O4/c1-30(19-22-20-33-26-10-4-3-9-25(22)26,36-29(39)35-23-12-14-24(15-13-23)37(40)41)28(38)34-21-31(16-6-2-7-17-31)27-11-5-8-18-32-27/h3-5,8-15,18,20,33H,2,6-7,16-17,19,21H2,1H3,(H,34,38)(H2,35,36,39)/t30-/m0/s1
DMFNQEA	CS	C[C@](CC1=CNC2=CC=CC=C21)(C(=O)NCC3(CCCCC3)C4=CC=CC=N4)NC(=O)NC5=CC=C(C=C5)[N+](=O)[O-]
DMFNQEA	IK	AFDXUTWMFMAQJO-PMERELPUSA-N
DMFNQEA	IU	(2S)-3-(1H-indol-3-yl)-2-methyl-2-[(4-nitrophenyl)carbamoylamino]-N-[(1-pyridin-2-ylcyclohexyl)methyl]propanamide
DMFNQEA	DE	Discovery agent

DM7AY6K	ID	DM7AY6K
DM7AY6K	DN	PD 176252
DM7AY6K	HS	Investigative
DM7AY6K	SN	PD-176252
DM7AY6K	DT	Small molecular drug
DM7AY6K	PC	9829828
DM7AY6K	MW	584.7
DM7AY6K	FM	C32H36N6O5
DM7AY6K	IC	InChI=1S/C32H36N6O5/c1-31(18-22-19-33-27-9-5-4-8-26(22)27,37-30(40)36-23-10-12-24(13-11-23)38(41)42)29(39)35-21-32(16-6-3-7-17-32)28-15-14-25(43-2)20-34-28/h4-5,8-15,19-20,33H,3,6-7,16-18,21H2,1-2H3,(H,35,39)(H2,36,37,40)/t31-/m0/s1
DM7AY6K	CS	C[C@](CC1=CNC2=CC=CC=C21)(C(=O)NCC3(CCCCC3)C4=NC=C(C=C4)OC)NC(=O)NC5=CC=C(C=C5)[N+](=O)[O-]
DM7AY6K	IK	NNFUWNLENRUDHR-HKBQPEDESA-N
DM7AY6K	IU	(2S)-3-(1H-indol-3-yl)-N-[[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl]-2-methyl-2-[(4-nitrophenyl)carbamoylamino]propanamide
DM7AY6K	CA	CAS 204067-01-6
DM7AY6K	DE	Discovery agent

DMD2CG9	ID	DMD2CG9
DMD2CG9	DN	PD-0166326
DMD2CG9	HS	Investigative
DMD2CG9	SN	PD-166326
DMD2CG9	DT	Small molecular drug
DMD2CG9	PC	447700
DMD2CG9	MW	427.3
DMD2CG9	FM	C21H16Cl2N4O2
DMD2CG9	IC	InChI=1S/C21H16Cl2N4O2/c1-27-19-13(9-15(20(27)29)18-16(22)6-3-7-17(18)23)10-24-21(26-19)25-14-5-2-4-12(8-14)11-28/h2-10,28H,11H2,1H3,(H,24,25,26)
DMD2CG9	CS	CN1C2=NC(=NC=C2C=C(C1=O)C3=C(C=CC=C3Cl)Cl)NC4=CC=CC(=C4)CO
DMD2CG9	IK	ZIQFYVPVJZEOFS-UHFFFAOYSA-N
DMD2CG9	IU	6-(2,6-dichlorophenyl)-2-[3-(hydroxymethyl)anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one
DMD2CG9	CA	CAS 185039-91-2
DMD2CG9	DE	Discovery agent

DMSCQ9U	ID	DMSCQ9U
DMSCQ9U	DN	PD-0173952
DMSCQ9U	HS	Investigative
DMSCQ9U	SN	PD173952; PD-173952; TCMDC-137156; 305820-75-1; CHEMBL106772; SCHEMBL3458816; BDBM4213; AC1NS580; DTXSID00416167; HMS3263E07; Tox21_500983; ZINC13812765; NSC735422; CCG-222287; NSC-735422; NCGC00261668-01; PD 173952; FT-0673541; PD173952, &gt; 2-(4-morpholinophenylamino)-6-(2,3-d]pyrimidin-7(8H)-one; 6-(2,6-dichlorophenyl)-8-methyl-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-8-methyl-2-(4-morpholin-4-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
DMSCQ9U	DT	Small molecular drug
DMSCQ9U	PC	5328733
DMSCQ9U	MW	482.4
DMSCQ9U	FM	C24H21Cl2N5O2
DMSCQ9U	IC	InChI=1S/C24H21Cl2N5O2/c1-30-22-15(13-18(23(30)32)21-19(25)3-2-4-20(21)26)14-27-24(29-22)28-16-5-7-17(8-6-16)31-9-11-33-12-10-31/h2-8,13-14H,9-12H2,1H3,(H,27,28,29)
DMSCQ9U	CS	CN1C2=NC(=NC=C2C=C(C1=O)C3=C(C=CC=C3Cl)Cl)NC4=CC=C(C=C4)N5CCOCC5
DMSCQ9U	IK	XZEJMVDCQZRHLN-UHFFFAOYSA-N
DMSCQ9U	IU	6-(2,6-dichlorophenyl)-8-methyl-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidin-7-one
DMSCQ9U	CA	CAS 305820-75-1
DMSCQ9U	DE	Discovery agent

DMOZEW9	ID	DMOZEW9
DMOZEW9	DN	PD-0173955
DMOZEW9	HS	Investigative
DMOZEW9	SN	PD-17395
DMOZEW9	DT	Small molecular drug
DMOZEW9	PC	447077
DMOZEW9	MW	443.3
DMOZEW9	FM	C21H16Cl2N4OS
DMOZEW9	IC	InChI=1S/C21H16Cl2N4OS/c1-27-19-12(9-15(20(27)28)18-16(22)7-4-8-17(18)23)11-24-21(26-19)25-13-5-3-6-14(10-13)29-2/h3-11H,1-2H3,(H,24,25,26)
DMOZEW9	CS	CN1C2=NC(=NC=C2C=C(C1=O)C3=C(C=CC=C3Cl)Cl)NC4=CC(=CC=C4)SC
DMOZEW9	IK	VAARYSWULJUGST-UHFFFAOYSA-N
DMOZEW9	IU	6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidin-7-one
DMOZEW9	CA	CAS 260415-63-2
DMOZEW9	CB	CHEBI:49791
DMOZEW9	DE	Discovery agent

DM8RW92	ID	DM8RW92
DM8RW92	DN	PD-0173956
DM8RW92	HS	Investigative
DM8RW92	SN	UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; PD-0173956; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one
DM8RW92	DT	Small molecular drug
DM8RW92	PC	5330524
DM8RW92	MW	415.2
DM8RW92	FM	C20H13Cl2FN4O
DM8RW92	IC	InChI=1S/C20H13Cl2FN4O/c1-27-18-11(9-14(19(27)28)17-15(21)3-2-4-16(17)22)10-24-20(26-18)25-13-7-5-12(23)6-8-13/h2-10H,1H3,(H,24,25,26)
DM8RW92	CS	CN1C2=NC(=NC=C2C=C(C1=O)C3=C(C=CC=C3Cl)Cl)NC4=CC=C(C=C4)F
DM8RW92	IK	ZSHRAUSJZQDIJR-UHFFFAOYSA-N
DM8RW92	IU	6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one
DM8RW92	CA	CAS 305820-76-2
DM8RW92	DE	Discovery agent

DMZQ8YV	ID	DMZQ8YV
DMZQ8YV	DN	PD-0173958
DMZQ8YV	HS	Investigative
DMZQ8YV	SN	PD173958; AC1NS9BT; PD-0173958; SCHEMBL1335649; CHEMBL578006; BDBM6570; 6-(2,6-dichlorophenyl)-2-(4-ethoxyanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 2-[(4-Ethoxyphenyl)amino]-8-methyl-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidine-7(8H)-one
DMZQ8YV	DT	Small molecular drug
DMZQ8YV	PC	5330525
DMZQ8YV	MW	441.3
DMZQ8YV	FM	C22H18Cl2N4O2
DMZQ8YV	IC	InChI=1S/C22H18Cl2N4O2/c1-3-30-15-9-7-14(8-10-15)26-22-25-12-13-11-16(21(29)28(2)20(13)27-22)19-17(23)5-4-6-18(19)24/h4-12H,3H2,1-2H3,(H,25,26,27)
DMZQ8YV	CS	CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl
DMZQ8YV	IK	AFZKXALTXCNQAZ-UHFFFAOYSA-N
DMZQ8YV	IU	6-(2,6-dichlorophenyl)-2-(4-ethoxyanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one
DMZQ8YV	DE	Discovery agent

DMKO8LE	ID	DMKO8LE
DMKO8LE	DN	PD-0179483
DMKO8LE	HS	Investigative
DMKO8LE	SN	PD179483; AC1NS9BW; PD-0179483; CHEMBL573820; BDBM6571; N-[2-[4-[[6-(2,6-dichlorophenyl)-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenoxy]ethyl]-N-ethylacetamide; N-[2-(4-{[6-(2,6-dichlorophenyl)-8-methyl-7-oxo-7H,8H-pyrido[2,3-d]pyrimidin-2-yl]amino}phenoxy)ethyl]-N-ethylacetamide
DMKO8LE	DT	Small molecular drug
DMKO8LE	PC	5330526
DMKO8LE	MW	526.4
DMKO8LE	FM	C26H25Cl2N5O3
DMKO8LE	IC	InChI=1S/C26H25Cl2N5O3/c1-4-33(16(2)34)12-13-36-19-10-8-18(9-11-19)30-26-29-15-17-14-20(25(35)32(3)24(17)31-26)23-21(27)6-5-7-22(23)28/h5-11,14-15H,4,12-13H2,1-3H3,(H,29,30,31)
DMKO8LE	CS	CCN(CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl)C(=O)C
DMKO8LE	IK	ZPDSBOKGPBKXNQ-UHFFFAOYSA-N
DMKO8LE	IU	N-[2-[4-[[6-(2,6-dichlorophenyl)-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenoxy]ethyl]-N-ethylacetamide
DMKO8LE	DE	Discovery agent

DM8QMJ1	ID	DM8QMJ1
DM8QMJ1	DN	PD-068235
DM8QMJ1	HS	Investigative
DM8QMJ1	SN	CHEMBL455856; PD-068235; BDBM50266362; PD-068253
DM8QMJ1	DT	Small molecular drug
DM8QMJ1	PC	44581800
DM8QMJ1	MW	269.32
DM8QMJ1	FM	C11H15N3O3S
DM8QMJ1	IC	InChI=1S/C11H15N3O3S/c1-5-6-13-7-8(14(16)17)18-10(13)12-9(15)11(2,3)4/h5,7H,1,6H2,2-4H3
DM8QMJ1	CS	CC(C)(C)C(=O)N=C1N(C=C(S1)[N+](=O)[O-])CC=C
DM8QMJ1	IK	SPVZIILAYYBEDM-UHFFFAOYSA-N
DM8QMJ1	IU	2,2-dimethyl-N-(5-nitro-3-prop-2-enyl-1,3-thiazol-2-ylidene)propanamide
DM8QMJ1	DE	Discovery agent

DMQ4LRZ	ID	DMQ4LRZ
DMQ4LRZ	DN	PD-115199
DMQ4LRZ	HS	Investigative
DMQ4LRZ	SN	PD-115199; 107478-35-3; CHEMBL308499; N-(2-(Dimethylamino)ethyl)-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzenesulfonamide; Benzenesulfonamide,N-[2-(dimethylamino)ethyl]-N-methyl-4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-; ACMC-20mb0t; AC1L3VM5; SCHEMBL6794235; CTK4A5456; DTXSID40148056; BDBM50004562; AKOS030586456; N-(2-dimethylaminoethyl)-4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-N-methylbenzenesulfonamide
DMQ4LRZ	DT	Small molecular drug
DMQ4LRZ	PC	122978
DMQ4LRZ	MW	476.6
DMQ4LRZ	FM	C22H32N6O4S
DMQ4LRZ	IC	InChI=1S/C22H32N6O4S/c1-6-12-27-20-18(21(29)28(13-7-2)22(27)30)23-19(24-20)16-8-10-17(11-9-16)33(31,32)26(5)15-14-25(3)4/h8-11H,6-7,12-15H2,1-5H3,(H,23,24)
DMQ4LRZ	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)S(=O)(=O)N(C)CCN(C)C
DMQ4LRZ	IK	RWNRBPFXDDCJTH-UHFFFAOYSA-N
DMQ4LRZ	IU	N-[2-(dimethylamino)ethyl]-4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-N-methylbenzenesulfonamide
DMQ4LRZ	CA	CAS 107478-35-3
DMQ4LRZ	DE	Discovery agent

DM3KAY5	ID	DM3KAY5
DM3KAY5	DN	PD-117558
DM3KAY5	HS	Investigative
DM3KAY5	SN	99734-97-1
DM3KAY5	DT	Small molecular drug
DM3KAY5	PC	73366
DM3KAY5	MW	391.4
DM3KAY5	FM	C20H23F2N3O3
DM3KAY5	IC	InChI=1S/C20H23F2N3O3/c1-2-23-8-11-5-6-24(9-11)18-15(21)7-13-17(16(18)22)25(12-3-4-12)10-14(19(13)26)20(27)28/h7,10-12,23H,2-6,8-9H2,1H3,(H,27,28)
DM3KAY5	CS	CCNCC1CCN(C1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)F
DM3KAY5	IK	WDBGUJBLPRXPIX-UHFFFAOYSA-N
DM3KAY5	IU	1-cyclopropyl-7-[3-(ethylaminomethyl)pyrrolidin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
DM3KAY5	CA	CAS 99734-97-1
DM3KAY5	DE	Discovery agent

DM0E4OW	ID	DM0E4OW
DM0E4OW	DN	PD-118057
DM0E4OW	HS	Investigative
DM0E4OW	SN	PD118057; PD 118057
DM0E4OW	DT	Small molecular drug
DM0E4OW	PC	9864959
DM0E4OW	MW	386.3
DM0E4OW	FM	C21H17Cl2NO2
DM0E4OW	IC	InChI=1S/C21H17Cl2NO2/c22-18-12-9-15(13-19(18)23)6-5-14-7-10-16(11-8-14)24-20-4-2-1-3-17(20)21(25)26/h1-4,7-13,24H,5-6H2,(H,25,26)
DM0E4OW	CS	C1=CC=C(C(=C1)C(=O)O)NC2=CC=C(C=C2)CCC3=CC(=C(C=C3)Cl)Cl
DM0E4OW	IK	ZCQOSCDABPVAFB-UHFFFAOYSA-N
DM0E4OW	IU	2-[4-[2-(3,4-dichlorophenyl)ethyl]anilino]benzoic acid
DM0E4OW	CA	CAS 313674-97-4
DM0E4OW	DE	Discovery agent

DM4OQZX	ID	DM4OQZX
DM4OQZX	DN	PD123177
DM4OQZX	HS	Investigative
DM4OQZX	SN	PD 123177; PD-123177
DM4OQZX	DT	Small molecular drug
DM4OQZX	PC	114899
DM4OQZX	MW	480.6
DM4OQZX	FM	C29H28N4O3
DM4OQZX	IC	InChI=1S/C29H28N4O3/c1-19-14-20(12-13-23(19)30)16-32-18-31-24-17-33(26(29(35)36)15-25(24)32)28(34)27(21-8-4-2-5-9-21)22-10-6-3-7-11-22/h2-14,18,26-27H,15-17,30H2,1H3,(H,35,36)
DM4OQZX	CS	CC1=C(C=CC(=C1)CN2C=NC3=C2CC(N(C3)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)O)N
DM4OQZX	IK	KLVDUSUYBDMJKR-UHFFFAOYSA-N
DM4OQZX	IU	1-[(4-amino-3-methylphenyl)methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
DM4OQZX	CA	CAS 114785-12-5
DM4OQZX	CB	CHEBI:79978
DM4OQZX	DE	Discovery agent

DMV1F7U	ID	DMV1F7U
DMV1F7U	DN	PD-128763
DMV1F7U	HS	Investigative
DMV1F7U	SN	5-Methyl-3,4-dihydroisoquinolin-1(2H)-one; 129075-56-5; 5-methyl-3,4-dihydroisoquinolin-1(2H)-one; 3,4-Dihydro-5-methyl-1(2H)-isoquinolinone; 3,4-DIHYDRO-5-METHYL-ISOQUINOLINONE; 1(2H)-Isoquinolinone, 3,4-dihydro-5-methyl-; CHEBI:41928; PD128763; CHEMBL125200; 5-methyl-3,4-dihydro-2H-isoquinolin-1-one; 3,4-dihydro-5-methylisoquinolinone; 1(2H)-Isoquinolinone,3,4-dihydro-5-methyl-; 5-methyl-1,2,3,4-tetrahydroisoquinolin-1-one; DHQ; PD 128763; dihydroisoquinolinone, 1; AC1L3WIO; ACMC-1C7L4; SCHEMBL831538; AMBZ0075; KS-00000QFP; CTK4B6146; BDBM27682; 3,4-Dihydro-5-Methyl-Isoquinolinone
DMV1F7U	DT	Small molecular drug
DMV1F7U	PC	148140
DMV1F7U	MW	161.2
DMV1F7U	FM	C10H11NO
DMV1F7U	IC	InChI=1S/C10H11NO/c1-7-3-2-4-9-8(7)5-6-11-10(9)12/h2-4H,5-6H2,1H3,(H,11,12)
DMV1F7U	CS	CC1=C2CCNC(=O)C2=CC=C1
DMV1F7U	IK	RLLZPXDJYADIEU-UHFFFAOYSA-N
DMV1F7U	IU	5-methyl-3,4-dihydro-2H-isoquinolin-1-one
DMV1F7U	CA	CAS 129075-56-5
DMV1F7U	CB	CHEBI:41928
DMV1F7U	DE	Discovery agent

DMYEFAV	ID	DMYEFAV
DMYEFAV	DN	PD-135111
DMYEFAV	HS	Investigative
DMYEFAV	SN	PD-135111; CHEMBL346940; SCHEMBL9368439; BDBM50281611
DMYEFAV	DT	Small molecular drug
DMYEFAV	PC	15079637
DMYEFAV	MW	353.5
DMYEFAV	FM	C21H27N3S
DMYEFAV	IC	InChI=1S/C21H27N3S/c1-2-11-22-21(5-1)24-15-13-23(14-16-24)12-10-18-6-8-19(9-7-18)20-4-3-17-25-20/h1-5,8,11,17-18H,6-7,9-10,12-16H2
DMYEFAV	CS	C1CC(=CCC1CCN2CCN(CC2)C3=CC=CC=N3)C4=CC=CS4
DMYEFAV	IK	AAFWZBAPCZZXNP-UHFFFAOYSA-N
DMYEFAV	IU	1-pyridin-2-yl-4-[2-(4-thiophen-2-ylcyclohex-3-en-1-yl)ethyl]piperazine
DMYEFAV	DE	Discovery agent

DMUTEWI	ID	DMUTEWI
DMUTEWI	DN	PD-135118
DMUTEWI	HS	Investigative
DMUTEWI	SN	CHEMBL335914; CHEMBL353157; SCHEMBL6894174; BDBM50230684
DMUTEWI	DT	Small molecular drug
DMUTEWI	PC	14802520
DMUTEWI	MW	628.8
DMUTEWI	FM	C36H44N4O6
DMUTEWI	IC	InChI=1S/C36H44N4O6/c1-36(19-27-20-37-30-10-6-5-9-29(27)30,40-35(45)46-33-25-14-23-13-24(16-25)17-26(33)15-23)34(44)39-28(18-22-7-3-2-4-8-22)21-38-31(41)11-12-32(42)43/h2-10,20,23-26,28,33,37H,11-19,21H2,1H3,(H,38,41)(H,39,44)(H,40,45)(H,42,43)/t23?,24?,25?,26?,28-,33?,36+/m0/s1
DMUTEWI	CS	C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@@H](CC3=CC=CC=C3)CNC(=O)CCC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMUTEWI	IK	HAQJDPAHYIINDW-JWZQQOIUSA-N
DMUTEWI	IU	4-[[(2S)-2-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-3-phenylpropyl]amino]-4-oxobutanoic acid
DMUTEWI	DE	Discovery agent

DMZ4LDC	ID	DMZ4LDC
DMZ4LDC	DN	PD-135146
DMZ4LDC	HS	Investigative
DMZ4LDC	SN	PD-135146; CHEMBL349994; SCHEMBL9367241; BDBM50281608
DMZ4LDC	DT	Small molecular drug
DMZ4LDC	PC	15079636
DMZ4LDC	MW	339.5
DMZ4LDC	FM	C20H25N3S
DMZ4LDC	IC	InChI=1S/C20H25N3S/c1-2-10-21-20(5-1)23-13-11-22(12-14-23)16-17-6-8-18(9-7-17)19-4-3-15-24-19/h1-5,8,10,15,17H,6-7,9,11-14,16H2
DMZ4LDC	CS	C1CC(=CCC1CN2CCN(CC2)C3=CC=CC=N3)C4=CC=CS4
DMZ4LDC	IK	QFAVGTOUBHVISF-UHFFFAOYSA-N
DMZ4LDC	IU	1-pyridin-2-yl-4-[(4-thiophen-2-ylcyclohex-3-en-1-yl)methyl]piperazine
DMZ4LDC	DE	Discovery agent

DMA7YJV	ID	DMA7YJV
DMA7YJV	DN	PD-135158
DMA7YJV	HS	Investigative
DMA7YJV	SN	CAM 1028; PD 135158
DMA7YJV	DT	Small molecular drug
DMA7YJV	PC	122119
DMA7YJV	MW	618.8
DMA7YJV	FM	C35H46N4O6
DMA7YJV	IC	InChI=1S/C35H46N4O6/c1-33(2)24-16-17-34(33,3)28(18-24)45-32(44)39-35(4,19-23-20-36-26-13-9-8-12-25(23)26)31(43)37-21-27(22-10-6-5-7-11-22)38-29(40)14-15-30(41)42/h5-13,23-24,27-28,36H,14-21H2,1-4H3,(H,37,43)(H,38,40)(H,39,44)(H,41,42)/t23?,24-,27-,28?,34+,35+/m0/s1
DMA7YJV	CS	C[C@]12CC[C@H](C1(C)C)CC2OC(=O)N[C@](C)(CC3CNC4=CC=CC=C34)C(=O)NC[C@@H](C5=CC=CC=C5)NC(=O)CCC(=O)O
DMA7YJV	IK	VVGZQXYPBDZOLL-KROHXGCPSA-N
DMA7YJV	IU	4-[[(1R)-2-[[(2R)-3-(2,3-dihydro-1H-indol-3-yl)-2-methyl-2-[[(1S,4S)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]oxycarbonylamino]propanoyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid
DMA7YJV	DE	Discovery agent

DMSHBLF	ID	DMSHBLF
DMSHBLF	DN	PD-135188
DMSHBLF	HS	Investigative
DMSHBLF	SN	PD-135188; CHEMBL157087; SCHEMBL9367686; BDBM50281605
DMSHBLF	DT	Small molecular drug
DMSHBLF	PC	15079634
DMSHBLF	MW	325.5
DMSHBLF	FM	C19H23N3S
DMSHBLF	IC	InChI=1S/C19H23N3S/c1-2-10-20-19(5-1)22-13-11-21(12-14-22)17-8-6-16(7-9-17)18-4-3-15-23-18/h1-6,10,15,17H,7-9,11-14H2
DMSHBLF	CS	C1CC(=CCC1N2CCN(CC2)C3=CC=CC=N3)C4=CC=CS4
DMSHBLF	IK	CXONTQZSVJEICK-UHFFFAOYSA-N
DMSHBLF	IU	1-pyridin-2-yl-4-(4-thiophen-2-ylcyclohex-3-en-1-yl)piperazine
DMSHBLF	DE	Discovery agent

DM0LTNJ	ID	DM0LTNJ
DM0LTNJ	DN	PD-135222
DM0LTNJ	HS	Investigative
DM0LTNJ	SN	PD-135222; CHEMBL422187; SCHEMBL2021022; BDBM50281607
DM0LTNJ	DT	Small molecular drug
DM0LTNJ	PC	15079632
DM0LTNJ	MW	320.4
DM0LTNJ	FM	C20H24N4
DM0LTNJ	IC	InChI=1S/C20H24N4/c1-3-11-21-19(5-1)17-7-9-18(10-8-17)23-13-15-24(16-14-23)20-6-2-4-12-22-20/h1-7,11-12,18H,8-10,13-16H2
DM0LTNJ	CS	C1CC(=CCC1N2CCN(CC2)C3=CC=CC=N3)C4=CC=CC=N4
DM0LTNJ	IK	MCTSZRVXVCAAHY-UHFFFAOYSA-N
DM0LTNJ	IU	1-pyridin-2-yl-4-(4-pyridin-2-ylcyclohex-3-en-1-yl)piperazine
DM0LTNJ	DE	Discovery agent

DMX294V	ID	DMX294V
DMX294V	DN	PD-135385
DMX294V	HS	Investigative
DMX294V	SN	PD-135385; SCHEMBL9371451
DMX294V	DT	Small molecular drug
DMX294V	PC	15682881
DMX294V	MW	347.5
DMX294V	FM	C23H29N3
DMX294V	IC	InChI=1S/C23H29N3/c1-2-6-21(7-3-1)22-11-9-20(10-12-22)13-15-25-16-18-26(19-17-25)23-8-4-5-14-24-23/h1-8,11,14,20H,9-10,12-13,15-19H2
DMX294V	CS	C1CC(=CCC1CCN2CCN(CC2)C3=CC=CC=N3)C4=CC=CC=C4
DMX294V	IK	MQHGACGPMGUHSJ-UHFFFAOYSA-N
DMX294V	IU	1-[2-(4-phenylcyclohex-3-en-1-yl)ethyl]-4-pyridin-2-ylpiperazine
DMX294V	DE	Discovery agent

DM56PBI	ID	DM56PBI
DM56PBI	DN	PD-135478
DM56PBI	HS	Investigative
DM56PBI	SN	PD-135478; CHEMBL157422; SCHEMBL9367787; BDBM50281610
DM56PBI	DT	Small molecular drug
DM56PBI	PC	15079635
DM56PBI	MW	319.4
DM56PBI	FM	C21H25N3
DM56PBI	IC	InChI=1S/C21H25N3/c1-2-6-18(7-3-1)19-9-11-20(12-10-19)23-14-16-24(17-15-23)21-8-4-5-13-22-21/h1-9,13,20H,10-12,14-17H2
DM56PBI	CS	C1CC(=CCC1N2CCN(CC2)C3=CC=CC=N3)C4=CC=CC=C4
DM56PBI	IK	MBOHGQXYZVXXQF-UHFFFAOYSA-N
DM56PBI	IU	1-(4-phenylcyclohex-3-en-1-yl)-4-pyridin-2-ylpiperazine
DM56PBI	DE	Discovery agent

DMI4MPZ	ID	DMI4MPZ
DMI4MPZ	DN	PD-135540
DMI4MPZ	HS	Investigative
DMI4MPZ	SN	PD-135540; CHEMBL346075; SCHEMBL9367275; BDBM50281609
DMI4MPZ	DT	Small molecular drug
DMI4MPZ	PC	15079633
DMI4MPZ	MW	348.5
DMI4MPZ	FM	C22H28N4
DMI4MPZ	IC	InChI=1S/C22H28N4/c1-3-12-23-21(5-1)20-9-7-19(8-10-20)11-14-25-15-17-26(18-16-25)22-6-2-4-13-24-22/h1-6,9,12-13,19H,7-8,10-11,14-18H2
DMI4MPZ	CS	C1CC(=CCC1CCN2CCN(CC2)C3=CC=CC=N3)C4=CC=CC=N4
DMI4MPZ	IK	KTGXACIWWLVCPX-UHFFFAOYSA-N
DMI4MPZ	IU	1-pyridin-2-yl-4-[2-(4-pyridin-2-ylcyclohex-3-en-1-yl)ethyl]piperazine
DMI4MPZ	DE	Discovery agent

DM8N3RB	ID	DM8N3RB
DM8N3RB	DN	PD-136621
DM8N3RB	HS	Investigative
DM8N3RB	SN	CHEMBL263969; PD-136621; 4-[(S)-2-[(R)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoylamino]-1-phenylethylamino]-4-oxobutyric acid
DM8N3RB	DT	Small molecular drug
DM8N3RB	PC	44320702
DM8N3RB	MW	614.7
DM8N3RB	FM	C35H42N4O6
DM8N3RB	IC	InChI=1S/C35H42N4O6/c1-35(18-26-19-36-28-10-6-5-9-27(26)28,39-34(44)45-32-24-14-21-13-22(16-24)17-25(32)15-21)33(43)37-20-29(23-7-3-2-4-8-23)38-30(40)11-12-31(41)42/h2-10,19,21-22,24-25,29,32,36H,11-18,20H2,1H3,(H,37,43)(H,38,40)(H,39,44)(H,41,42)/t21?,22?,24?,25?,29-,32?,35?/m1/s1
DM8N3RB	CS	CC(CC1=CNC2=CC=CC=C21)(C(=O)NC[C@H](C3=CC=CC=C3)NC(=O)CCC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DM8N3RB	IK	FVQSSYMRZKLFDR-QTZXECCPSA-N
DM8N3RB	IU	4-[[(1S)-2-[[2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid
DM8N3RB	DE	Discovery agent

DMJWK0T	ID	DMJWK0T
DMJWK0T	DN	PD-137337
DMJWK0T	HS	Investigative
DMJWK0T	SN	PD-137337; CHEMBL169615; CHEMBL2304062; CAM-1241; BDBM50281735; BDBM50449747; N-{(S)-2-[(S)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-1-phenyl-ethyl}-succinamic acid
DMJWK0T	DT	Small molecular drug
DMJWK0T	PC	14802537
DMJWK0T	MW	614.7
DMJWK0T	FM	C35H42N4O6
DMJWK0T	IC	InChI=1S/C35H42N4O6/c1-35(18-26-19-36-28-10-6-5-9-27(26)28,39-34(44)45-32-24-14-21-13-22(16-24)17-25(32)15-21)33(43)37-20-29(23-7-3-2-4-8-23)38-30(40)11-12-31(41)42/h2-10,19,21-22,24-25,29,32,36H,11-18,20H2,1H3,(H,37,43)(H,38,40)(H,39,44)(H,41,42)/t21?,22?,24?,25?,29-,32?,35+/m1/s1
DMJWK0T	CS	C[C@](CC1=CNC2=CC=CC=C21)(C(=O)NC[C@H](C3=CC=CC=C3)NC(=O)CCC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMJWK0T	IK	FVQSSYMRZKLFDR-UKWUEPKQSA-N
DMJWK0T	IU	4-[[(1S)-2-[[(2S)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid
DMJWK0T	DE	Discovery agent

DMH2OV9	ID	DMH2OV9
DMH2OV9	DN	PD-137342
DMH2OV9	HS	Investigative
DMH2OV9	SN	CHEMBL2062144; PD-137342; BDBM50422043; 4-[(R)-2-[(S)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoylamino]-1-phenylethylamino]-4-oxobutyric acid
DMH2OV9	DT	Small molecular drug
DMH2OV9	PC	14802539
DMH2OV9	MW	614.7
DMH2OV9	FM	C35H42N4O6
DMH2OV9	IC	InChI=1S/C35H42N4O6/c1-35(18-26-19-36-28-10-6-5-9-27(26)28,39-34(44)45-32-24-14-21-13-22(16-24)17-25(32)15-21)33(43)37-20-29(23-7-3-2-4-8-23)38-30(40)11-12-31(41)42/h2-10,19,21-22,24-25,29,32,36H,11-18,20H2,1H3,(H,37,43)(H,38,40)(H,39,44)(H,41,42)/t21?,22?,24?,25?,29-,32?,35-/m0/s1
DMH2OV9	CS	C[C@](CC1=CNC2=CC=CC=C21)(C(=O)NC[C@@H](C3=CC=CC=C3)NC(=O)CCC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMH2OV9	IK	FVQSSYMRZKLFDR-ZTHIAPAOSA-N
DMH2OV9	IU	4-[[(1R)-2-[[(2S)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid
DMH2OV9	DE	Discovery agent

DM9ZK6L	ID	DM9ZK6L
DM9ZK6L	DN	PD-137789
DM9ZK6L	HS	Investigative
DM9ZK6L	SN	PD-137789; CHEMBL418937; BDBM50055724
DM9ZK6L	DT	Small molecular drug
DM9ZK6L	PC	10904165
DM9ZK6L	MW	347.5
DM9ZK6L	FM	C23H29N3
DM9ZK6L	IC	InChI=1S/C23H29N3/c1-2-6-21(7-3-1)22-11-9-20(10-12-22)13-15-25-16-18-26(19-17-25)23-8-4-5-14-24-23/h1-8,11,14,20H,9-10,12-13,15-19H2/t20-/m1/s1
DM9ZK6L	CS	C1CC(=CC[C@H]1CCN2CCN(CC2)C3=CC=CC=N3)C4=CC=CC=C4
DM9ZK6L	IK	MQHGACGPMGUHSJ-HXUWFJFHSA-N
DM9ZK6L	IU	1-[2-[(1S)-4-phenylcyclohex-3-en-1-yl]ethyl]-4-pyridin-2-ylpiperazine
DM9ZK6L	DE	Discovery agent

DMYMFSE	ID	DMYMFSE
DMYMFSE	DN	PD-137821
DMYMFSE	HS	Investigative
DMYMFSE	SN	PD-137821; CHEMBL348547; BDBM50281606
DMYMFSE	DT	Small molecular drug
DMYMFSE	PC	44372627
DMYMFSE	MW	347.5
DMYMFSE	FM	C23H29N3
DMYMFSE	IC	InChI=1S/C23H29N3/c1-2-6-21(7-3-1)22-11-9-20(10-12-22)13-15-25-16-18-26(19-17-25)23-8-4-5-14-24-23/h1-8,11,14,20H,9-10,12-13,15-19H2/t20-/m0/s1
DMYMFSE	CS	C1CC(=CC[C@@H]1CCN2CCN(CC2)C3=CC=CC=N3)C4=CC=CC=C4
DMYMFSE	IK	MQHGACGPMGUHSJ-FQEVSTJZSA-N
DMYMFSE	IU	1-[2-[(1R)-4-phenylcyclohex-3-en-1-yl]ethyl]-4-pyridin-2-ylpiperazine
DMYMFSE	DE	Discovery agent

DMLVRU7	ID	DMLVRU7
DMLVRU7	DN	PD-138915
DMLVRU7	HS	Investigative
DMLVRU7	SN	PD-138915; CHEMBL169616; BDBM50281734; N-{(R)-2-[(S)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-3-phenyl-propyl}-succinamic acid; 4-[(R)-2-[(S)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoylamino]-3-phenylpropylamino]-4-oxobutyric acid
DMLVRU7	DT	Small molecular drug
DMLVRU7	PC	14802521
DMLVRU7	MW	628.8
DMLVRU7	FM	C36H44N4O6
DMLVRU7	IC	InChI=1S/C36H44N4O6/c1-36(19-27-20-37-30-10-6-5-9-29(27)30,40-35(45)46-33-25-14-23-13-24(16-25)17-26(33)15-23)34(44)39-28(18-22-7-3-2-4-8-22)21-38-31(41)11-12-32(42)43/h2-10,20,23-26,28,33,37H,11-19,21H2,1H3,(H,38,41)(H,39,44)(H,40,45)(H,42,43)/t23?,24?,25?,26?,28-,33?,36+/m1/s1
DMLVRU7	CS	C[C@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@H](CC3=CC=CC=C3)CNC(=O)CCC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMLVRU7	IK	HAQJDPAHYIINDW-KMDPWDFKSA-N
DMLVRU7	IU	4-[[(2R)-2-[[(2S)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-3-phenylpropyl]amino]-4-oxobutanoic acid
DMLVRU7	DE	Discovery agent

DMIAFN5	ID	DMIAFN5
DMIAFN5	DN	PD-138916
DMIAFN5	HS	Investigative
DMIAFN5	SN	CHEMBL337661; CHEMBL355656; BDBM50007442; 4-[(R)-2-[(R)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoylamino]-3-phenylpropylamino]-4-oxobutyric acid
DMIAFN5	DT	Small molecular drug
DMIAFN5	PC	44354100
DMIAFN5	MW	628.8
DMIAFN5	FM	C36H44N4O6
DMIAFN5	IC	InChI=1S/C36H44N4O6/c1-36(19-27-20-37-30-10-6-5-9-29(27)30,40-35(45)46-33-25-14-23-13-24(16-25)17-26(33)15-23)34(44)39-28(18-22-7-3-2-4-8-22)21-38-31(41)11-12-32(42)43/h2-10,20,23-26,28,33,37H,11-19,21H2,1H3,(H,38,41)(H,39,44)(H,40,45)(H,42,43)/t23?,24?,25?,26?,28-,33?,36-/m1/s1
DMIAFN5	CS	C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@H](CC3=CC=CC=C3)CNC(=O)CCC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMIAFN5	IK	HAQJDPAHYIINDW-YUUWEXFGSA-N
DMIAFN5	IU	4-[[(2R)-2-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-3-phenylpropyl]amino]-4-oxobutanoic acid
DMIAFN5	DE	Discovery agent

DMUG2L9	ID	DMUG2L9
DMUG2L9	DN	PD-138917
DMUG2L9	HS	Investigative
DMUG2L9	SN	PD-138917; CHEMBL171806; BDBM50281733; N-{(S)-2-[(S)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-3-phenyl-propyl}-succinamic acid; 4-[(S)-2-[(S)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoylamino]-3-phenylpropylamino]-4-oxobutyric acid
DMUG2L9	DT	Small molecular drug
DMUG2L9	PC	14802522
DMUG2L9	MW	628.8
DMUG2L9	FM	C36H44N4O6
DMUG2L9	IC	InChI=1S/C36H44N4O6/c1-36(19-27-20-37-30-10-6-5-9-29(27)30,40-35(45)46-33-25-14-23-13-24(16-25)17-26(33)15-23)34(44)39-28(18-22-7-3-2-4-8-22)21-38-31(41)11-12-32(42)43/h2-10,20,23-26,28,33,37H,11-19,21H2,1H3,(H,38,41)(H,39,44)(H,40,45)(H,42,43)/t23?,24?,25?,26?,28-,33?,36-/m0/s1
DMUG2L9	CS	C[C@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@@H](CC3=CC=CC=C3)CNC(=O)CCC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMUG2L9	IK	HAQJDPAHYIINDW-HXWIKMKJSA-N
DMUG2L9	IU	4-[[(2S)-2-[[(2S)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-3-phenylpropyl]amino]-4-oxobutanoic acid
DMUG2L9	DE	Discovery agent

DMF86P3	ID	DMF86P3
DMF86P3	DN	PD-140547
DMF86P3	HS	Investigative
DMF86P3	SN	PD-140547; CHEMBL145133; CHEMBL2304064; PDSP2_000898; PDSP1_000912; BDBM50456330; BDBM50073727; (S)-3-[(S)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-4-phenyl-butyric acid; (S)-3-[(S)-2-(2-Adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoylamino]-4-phenylbutyric acid
DMF86P3	DT	Small molecular drug
DMF86P3	PC	10370499
DMF86P3	MW	557.7
DMF86P3	FM	C33H39N3O5
DMF86P3	IC	InChI=1S/C33H39N3O5/c1-33(18-25-19-34-28-10-6-5-9-27(25)28,31(39)35-26(17-29(37)38)16-20-7-3-2-4-8-20)36-32(40)41-30-23-12-21-11-22(14-23)15-24(30)13-21/h2-10,19,21-24,26,30,34H,11-18H2,1H3,(H,35,39)(H,36,40)(H,37,38)/t21?,22?,23?,24?,26-,30?,33-/m0/s1
DMF86P3	CS	C[C@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@@H](CC3=CC=CC=C3)CC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMF86P3	IK	PGOLWKTUHWHYJS-VRJYPAKCSA-N
DMF86P3	IU	(3S)-3-[[(2S)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-phenylbutanoic acid
DMF86P3	DE	Discovery agent

DMNO2EP	ID	DMNO2EP
DMNO2EP	DN	PD-140548
DMNO2EP	HS	Investigative
DMNO2EP	SN	CHEMBL356898; CHEMBL2111204; GTPL904; PDSP2_000896; PDSP1_000910; BDBM50033600; BDBM50073729; 140677-01-6; (3R)-3-[[(2S)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-phenylbutanoic acid
DMNO2EP	DT	Small molecular drug
DMNO2EP	PC	9915756
DMNO2EP	MW	557.7
DMNO2EP	FM	C33H39N3O5
DMNO2EP	IC	InChI=1S/C33H39N3O5/c1-33(18-25-19-34-28-10-6-5-9-27(25)28,31(39)35-26(17-29(37)38)16-20-7-3-2-4-8-20)36-32(40)41-30-23-12-21-11-22(14-23)15-24(30)13-21/h2-10,19,21-24,26,30,34H,11-18H2,1H3,(H,35,39)(H,36,40)(H,37,38)/t21?,22?,23?,24?,26-,30?,33+/m1/s1
DMNO2EP	CS	C[C@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@H](CC3=CC=CC=C3)CC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMNO2EP	IK	PGOLWKTUHWHYJS-KUAXMQRVSA-N
DMNO2EP	IU	(3R)-3-[[(2S)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-phenylbutanoic acid
DMNO2EP	DE	Discovery agent

DMWTOJN	ID	DMWTOJN
DMWTOJN	DN	PD-140723
DMWTOJN	HS	Investigative
DMWTOJN	SN	CHEMBL317675; CHEMBL141630; PDSP1_000911; AC1NSKGW; BDBM50281277; PDSP2_000897; BDBM50061990; (3R)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-phenylbutanoic acid; (R)-3-[(R)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-4-phenyl-butyric acid
DMWTOJN	DT	Small molecular drug
DMWTOJN	PC	5311347
DMWTOJN	MW	557.7
DMWTOJN	FM	C33H39N3O5
DMWTOJN	IC	InChI=1S/C33H39N3O5/c1-33(18-25-19-34-28-10-6-5-9-27(25)28,31(39)35-26(17-29(37)38)16-20-7-3-2-4-8-20)36-32(40)41-30-23-12-21-11-22(14-23)15-24(30)13-21/h2-10,19,21-24,26,30,34H,11-18H2,1H3,(H,35,39)(H,36,40)(H,37,38)/t21?,22?,23?,24?,26-,30?,33-/m1/s1
DMWTOJN	CS	C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@H](CC3=CC=CC=C3)CC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMWTOJN	IK	PGOLWKTUHWHYJS-HMYZUHDZSA-N
DMWTOJN	IU	(3R)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-phenylbutanoic acid
DMWTOJN	DE	Discovery agent

DMJKH28	ID	DMJKH28
DMJKH28	DN	PD-144418
DMJKH28	HS	Investigative
DMJKH28	SN	PD144418; PD 144418; ZINC5862; GTPL10731; BDBM50251208; AKOS024457192; NCGC00378668-01; HY-108512; CS-0029071; Q27456166
DMJKH28	TC	Antiviral Agents
DMJKH28	DT	Small molecular drug
DMJKH28	PC	9817231
DMJKH28	MW	282.4
DMJKH28	FM	C18H22N2O
DMJKH28	IC	InChI=1S/C18H22N2O/c1-3-10-20-11-4-5-16(13-20)18-12-17(19-21-18)15-8-6-14(2)7-9-15/h5-9,12H,3-4,10-11,13H2,1-2H3
DMJKH28	CS	CCCN1CCC=C(C1)C2=CC(=NO2)C3=CC=C(C=C3)C
DMJKH28	IK	FOQRKFCLRMMKAT-UHFFFAOYSA-N
DMJKH28	IU	3-(4-methylphenyl)-5-(1-propyl-3,6-dihydro-2H-pyridin-5-yl)-1,2-oxazole
DMJKH28	CA	CAS 154130-99-1
DMJKH28	DE	Coronavirus Disease 2019 (COVID-19)

DM03526	ID	DM03526
DM03526	DN	PD-144550
DM03526	HS	Investigative
DM03526	SN	148553-51-9; (R)-Pregabalin; (3R)-3-(aminomethyl)-5-methylhexanoic acid; PD-144550; CHEMBL167003; (R)-3-(Aminomethyl)-5-methylhexanoic acid; ent-Pregabalin; R-Pregabalin; AC1L2PDQ; BSPBio_002316; SCHEMBL263450; SPECTRUM1505816; DTXSID90276292; HMS1922H16; Pharmakon1600-01505816; HMS2093F10; ZINC5760031; TOS-0910; CCG-40213; NSC759256; AKOS027425242; NSC-759256; NCGC00178709-01; SC-94803; SBI-0206875.P001; PD 144550; FT-0674010; FT-0600823; K-4720; Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3R)-
DM03526	DT	Small molecular drug
DM03526	PC	125889
DM03526	MW	159.23
DM03526	FM	C8H17NO2
DM03526	IC	InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m1/s1
DM03526	CS	CC(C)C[C@H](CC(=O)O)CN
DM03526	IK	AYXYPKUFHZROOJ-SSDOTTSWSA-N
DM03526	IU	(3R)-3-(aminomethyl)-5-methylhexanoic acid
DM03526	CA	CAS 148553-51-9
DM03526	DE	Discovery agent

DMP65EI	ID	DMP65EI
DMP65EI	DN	PD-149164
DMP65EI	HS	Investigative
DMP65EI	SN	PD 149164; PD149164
DMP65EI	DT	Small molecular drug
DMP65EI	PC	44457632
DMP65EI	MW	575.7
DMP65EI	FM	C33H38FN3O5
DMP65EI	IC	InChI=1S/C33H38FN3O5/c1-33(17-24-18-35-28-5-3-2-4-27(24)28,31(40)36-26(16-29(38)39)15-19-6-8-25(34)9-7-19)37-32(41)42-30-22-11-20-10-21(13-22)14-23(30)12-20/h2-9,18,20-23,26,30,35H,10-17H2,1H3,(H,36,40)(H,37,41)(H,38,39)/t20?,21?,22?,23?,26?,30?,33-/m0/s1
DMP65EI	CS	C[C@](CC1=CNC2=CC=CC=C21)(C(=O)NC(CC3=CC=C(C=C3)F)CC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMP65EI	IK	UZOOGOCMUARFDV-KEZCGYQASA-N
DMP65EI	IU	3-[[(2S)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-(4-fluorophenyl)butanoic acid
DMP65EI	DE	Discovery agent

DMHD8UL	ID	DMHD8UL
DMHD8UL	DN	PD-151307
DMHD8UL	HS	Investigative
DMHD8UL	SN	PD-151307; CHEMBL135329; BDBM50076106; Benzoic acid 4-((S)-2-{(S)-2-[(azepane-1-carbonyl)-amino]-4-methyl-pentanoylamino}-2-tert-butoxycarbonyl-ethyl)-phenyl ester; (S)-2-[[(S)-2-(Hexahydro-1H-azepine-1-ylcarbonylamino)-4-methylpentanoyl]amino]-3-[4-(benzoyloxy)phenyl]propionic acid tert-butyl ester
DMHD8UL	DT	Small molecular drug
DMHD8UL	PC	44356037
DMHD8UL	MW	579.7
DMHD8UL	FM	C33H45N3O6
DMHD8UL	IC	InChI=1S/C33H45N3O6/c1-23(2)21-27(35-32(40)36-19-11-6-7-12-20-36)29(37)34-28(31(39)42-33(3,4)5)22-24-15-17-26(18-16-24)41-30(38)25-13-9-8-10-14-25/h8-10,13-18,23,27-28H,6-7,11-12,19-22H2,1-5H3,(H,34,37)(H,35,40)/t27-,28-/m0/s1
DMHD8UL	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)OC(=O)C2=CC=CC=C2)C(=O)OC(C)(C)C)NC(=O)N3CCCCCC3
DMHD8UL	IK	IFZDICMQBAJLQQ-NSOVKSMOSA-N
DMHD8UL	IU	[4-[(2S)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]phenyl] benzoate
DMHD8UL	DE	Discovery agent

DMV0EDM	ID	DMV0EDM
DMV0EDM	DN	PD-152255
DMV0EDM	HS	Investigative
DMV0EDM	SN	164917-23-1
DMV0EDM	PC	9961911
DMV0EDM	MW	723
DMV0EDM	FM	C46H54N6O2
DMV0EDM	IC	InChI=1S/C46H54N6O2/c1-7-27-49(28-8-1)31-13-35-53-39-23-19-37(20-24-39)45-47-41-15-3-5-17-43(41)51(45)33-11-12-34-52-44-18-6-4-16-42(44)48-46(52)38-21-25-40(26-22-38)54-36-14-32-50-29-9-2-10-30-50/h3-6,11-12,15-26H,1-2,7-10,13-14,27-36H2/b12-11+
DMV0EDM	CS	C1CCN(CC1)CCCOC2=CC=C(C=C2)C3=NC4=CC=CC=C4N3C/C=C/CN5C6=CC=CC=C6N=C5C7=CC=C(C=C7)OCCCN8CCCCC8
DMV0EDM	IK	RTRBUDIKCGJLKP-VAWYXSNFSA-N
DMV0EDM	IU	2-[4-(3-piperidin-1-ylpropoxy)phenyl]-1-[(E)-4-[2-[4-(3-piperidin-1-ylpropoxy)phenyl]benzimidazol-1-yl]but-2-enyl]benzimidazole
DMV0EDM	DE	Discovery agent

DMY5SX9	ID	DMY5SX9
DMY5SX9	DN	PD-156
DMY5SX9	HS	Investigative
DMY5SX9	SN	PD-503; PF-152; PF-212; PF-80; MMP-13 inhibitors (inflammation); MMP-13 inhibitors (inflammation), Pfizer
DMY5SX9	CP	Pfizer Inc
DMY5SX9	DE	Inflammation

DMHI8C9	ID	DMHI8C9
DMHI8C9	DN	PD-157672
DMHI8C9	HS	Investigative
DMHI8C9	SN	PD157672; CHEMBL444832; tert-butyl N-[(2S)-1-[[(2R)-1-[7-(carbamoylamino)heptylamino]-2-methyl-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate; AC1NSKH5; GTPL2125; BDBM50050649; PD157,672; {(S)-1-[(R)-1-Methyl-2-phenyl-1-(7-ureido-heptylcarbamoyl)-ethylcarbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester
DMHI8C9	DT	Small molecular drug
DMHI8C9	PC	5311350
DMHI8C9	MW	581.7
DMHI8C9	FM	C32H47N5O5
DMHI8C9	IC	InChI=1S/C32H47N5O5/c1-31(2,3)42-30(41)36-26(22-24-16-10-8-11-17-24)27(38)37-32(4,23-25-18-12-9-13-19-25)28(39)34-20-14-6-5-7-15-21-35-29(33)40/h8-13,16-19,26H,5-7,14-15,20-23H2,1-4H3,(H,34,39)(H,36,41)(H,37,38)(H3,33,35,40)/t26-,32+/m0/s1
DMHI8C9	CS	C[C@@](CC1=CC=CC=C1)(C(=O)NCCCCCCCNC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C
DMHI8C9	IK	BYVRLIUFCGUMSP-XYFQYJLHSA-N
DMHI8C9	IU	tert-butyl N-[(2S)-1-[[(2R)-1-[7-(carbamoylamino)heptylamino]-2-methyl-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate
DMHI8C9	DE	Discovery agent

DMQXYE9	ID	DMQXYE9
DMQXYE9	DN	PD-158780
DMQXYE9	HS	Investigative
DMQXYE9	SN	171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; PD 158780; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-
DMQXYE9	DT	Small molecular drug
DMQXYE9	PC	4707
DMQXYE9	MW	330.18
DMQXYE9	FM	C14H12BrN5
DMQXYE9	IC	InChI=1S/C14H12BrN5/c1-16-13-6-11-12(7-17-13)18-8-19-14(11)20-10-4-2-3-9(15)5-10/h2-8H,1H3,(H,16,17)(H,18,19,20)
DMQXYE9	CS	CNC1=NC=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Br
DMQXYE9	IK	KFHMLBXBRCITHF-UHFFFAOYSA-N
DMQXYE9	IU	4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine
DMQXYE9	CA	CAS 171179-06-9
DMQXYE9	CB	CHEBI:92843
DMQXYE9	DE	Discovery agent

DM6RVTO	ID	DM6RVTO
DM6RVTO	DN	PD159790
DM6RVTO	HS	Investigative
DM6RVTO	SN	PD-159790
DM6RVTO	DT	Small molecular drug
DM6RVTO	PC	9889954
DM6RVTO	MW	450.24
DM6RVTO	FM	C16H18F3IN4
DM6RVTO	IC	InChI=1S/C16H18F3IN4/c1-2-24-7-3-4-11(9-24)21-14-12-8-10(20)5-6-13(12)22-15(23-14)16(17,18)19/h5-6,8,11H,2-4,7,9H2,1H3,(H,21,22,23)
DM6RVTO	CS	CCN1CCCC(C1)NC2=NC(=NC3=C2C=C(C=C3)I)C(F)(F)F
DM6RVTO	IK	IRWWFCJIOHCTMV-UHFFFAOYSA-N
DM6RVTO	IU	N-(1-ethylpiperidin-3-yl)-6-iodo-2-(trifluoromethyl)quinazolin-4-amine
DM6RVTO	CA	CAS 179598-53-9
DM6RVTO	DE	Discovery agent

DMZYIKR	ID	DMZYIKR
DMZYIKR	DN	PD-160946
DMZYIKR	HS	Investigative
DMZYIKR	SN	CHEMBL47146; PD-160946; BDBM50050652; [(R)-2-(2-Fluoro-phenyl)-1-methyl-1-(7-ureido-heptylcarbamoyl)-ethyl]-carbamic acid (S)-2-methyl-1-phenyl-propyl ester
DMZYIKR	DT	Small molecular drug
DMZYIKR	PC	9914897
DMZYIKR	MW	528.7
DMZYIKR	FM	C29H41FN4O4
DMZYIKR	IC	InChI=1S/C29H41FN4O4/c1-21(2)25(22-14-8-7-9-15-22)38-28(37)34-29(3,20-23-16-10-11-17-24(23)30)26(35)32-18-12-5-4-6-13-19-33-27(31)36/h7-11,14-17,21,25H,4-6,12-13,18-20H2,1-3H3,(H,32,35)(H,34,37)(H3,31,33,36)/t25-,29+/m0/s1
DMZYIKR	CS	CC(C)[C@@H](C1=CC=CC=C1)OC(=O)N[C@](C)(CC2=CC=CC=C2F)C(=O)NCCCCCCCNC(=O)N
DMZYIKR	IK	ZAYADERDILOEBG-ABYGYWHVSA-N
DMZYIKR	IU	[(1S)-2-methyl-1-phenylpropyl] N-[(2R)-1-[7-(carbamoylamino)heptylamino]-3-(2-fluorophenyl)-2-methyl-1-oxopropan-2-yl]carbamate
DMZYIKR	DE	Discovery agent

DM8NV2E	ID	DM8NV2E
DM8NV2E	DN	PD-161182
DM8NV2E	HS	Investigative
DM8NV2E	SN	CHEMBL44229; GTPL5767; CAM 5187; BDBM50050670; PD161182; PD 161182; [(S)-2-(2,3-Difluoro-phenyl)-1-methyl-1-(7-ureido-heptylcarbamoyl)-ethyl]-carbamic acid (S)-2-methyl-1-phenyl-propyl ester; [(1S)-2-methyl-1-phenylpropyl] N-[(2S)-1-[7-(carbamoylamino)heptylamino]-3-(2,3-difluorophenyl)-2-methyl-1-oxopropan-2-yl]carbamate
DM8NV2E	DT	Small molecular drug
DM8NV2E	PC	9915428
DM8NV2E	MW	546.6
DM8NV2E	FM	C29H40F2N4O4
DM8NV2E	IC	InChI=1S/C29H40F2N4O4/c1-20(2)25(21-13-8-7-9-14-21)39-28(38)35-29(3,19-22-15-12-16-23(30)24(22)31)26(36)33-17-10-5-4-6-11-18-34-27(32)37/h7-9,12-16,20,25H,4-6,10-11,17-19H2,1-3H3,(H,33,36)(H,35,38)(H3,32,34,37)/t25-,29+/m0/s1
DM8NV2E	CS	CC(C)[C@@H](C1=CC=CC=C1)OC(=O)N[C@](C)(CC2=C(C(=CC=C2)F)F)C(=O)NCCCCCCCNC(=O)N
DM8NV2E	IK	IWEYVTFOHKCWJN-ABYGYWHVSA-N
DM8NV2E	IU	[(1S)-2-methyl-1-phenylpropyl] N-[(2R)-1-[7-(carbamoylamino)heptylamino]-3-(2,3-difluorophenyl)-2-methyl-1-oxopropan-2-yl]carbamate
DM8NV2E	DE	Discovery agent

DMBZ09U	ID	DMBZ09U
DMBZ09U	DN	PD-163140
DMBZ09U	HS	Investigative
DMBZ09U	SN	PD-163140; CHEMBL319452; SCHEMBL8183353; BDBM50290981; L015175; [4-Benzo[1,3]dioxol-5-yl-2-(4-methoxy-phenyl)-5-oxo-3-(3,4,5-trimethoxy-benzyl)-2,5-dihydro-furan-2-yloxycarbonylamino]-acetic acid ethyl ester
DMBZ09U	DT	Small molecular drug
DMBZ09U	PC	9960931
DMBZ09U	MW	635.6
DMBZ09U	FM	C33H33NO12
DMBZ09U	IC	InChI=1S/C33H33NO12/c1-6-42-28(35)17-34-32(37)46-33(21-8-10-22(38-2)11-9-21)23(13-19-14-26(39-3)30(41-5)27(15-19)40-4)29(31(36)45-33)20-7-12-24-25(16-20)44-18-43-24/h7-12,14-16H,6,13,17-18H2,1-5H3,(H,34,37)
DMBZ09U	CS	CCOC(=O)CNC(=O)OC1(C(=C(C(=O)O1)C2=CC3=C(C=C2)OCO3)CC4=CC(=C(C(=C4)OC)OC)OC)C5=CC=C(C=C5)OC
DMBZ09U	IK	CJWHCEUECPKIGE-UHFFFAOYSA-N
DMBZ09U	IU	ethyl 2-[[4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-5-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]furan-2-yl]oxycarbonylamino]acetate
DMBZ09U	DE	Discovery agent

DM5421R	ID	DM5421R
DM5421R	DN	PD164333
DM5421R	HS	Investigative
DM5421R	SN	LKWYYULZSFFLFK-DKJXEYTPSA-N; (Z)-2-(1,3-benzodioxol-5-yl)-3-[[3-[4-[2-(4-hydroxy-3-iodophenyl)ethylamino]-4-oxobutoxy]-4,5-dimethoxyphenyl]methyl]-4-(4-methoxyphenyl)-4-oxobut-2-enoic acid; PD 164333; GTPL3519; 1027525-70-7; P-310;  PD-164333; [125I]PD164333
DM5421R	DT	Small molecular drug
DM5421R	PC	10605470
DM5421R	MW	823.6
DM5421R	FM	C39H38INO11
DM5421R	IC	InChI=1S/C39H38INO11/c1-47-27-10-7-25(8-11-27)37(44)28(36(39(45)46)26-9-13-31-32(21-26)52-22-51-31)17-24-19-33(48-2)38(49-3)34(20-24)50-16-4-5-35(43)41-15-14-23-6-12-30(42)29(40)18-23/h6-13,18-21,42H,4-5,14-17,22H2,1-3H3,(H,41,43)(H,45,46)/b36-28-
DM5421R	CS	COC1=CC=C(C=C1)C(=O)/C(=C(/C2=CC3=C(C=C2)OCO3)\\C(=O)O)/CC4=CC(=C(C(=C4)OCCCC(=O)NCCC5=CC(=C(C=C5)O)I)OC)OC
DM5421R	IK	LKWYYULZSFFLFK-DKJXEYTPSA-N
DM5421R	IU	(Z)-2-(1,3-benzodioxol-5-yl)-3-[[3-[4-[2-(4-hydroxy-3-iodophenyl)ethylamino]-4-oxobutoxy]-4,5-dimethoxyphenyl]methyl]-4-(4-methoxyphenyl)-4-oxobut-2-enoic acid
DM5421R	DE	Discovery agent

DM9LJEP	ID	DM9LJEP
DM9LJEP	DN	PD-167341
DM9LJEP	HS	Investigative
DM9LJEP	SN	PD-167341; CHEMBL334438; BDBM50076111; Benzoic acid 4-((S)-2-{(S)-2-[(azepane-1-carbonyl)-amino]-4-methyl-pentanoylamino}-2-tert-butylcarbamoyl-ethyl)-phenyl ester
DM9LJEP	DT	Small molecular drug
DM9LJEP	PC	44356550
DM9LJEP	MW	578.7
DM9LJEP	FM	C33H46N4O5
DM9LJEP	IC	InChI=1S/C33H46N4O5/c1-23(2)21-27(35-32(41)37-19-11-6-7-12-20-37)29(38)34-28(30(39)36-33(3,4)5)22-24-15-17-26(18-16-24)42-31(40)25-13-9-8-10-14-25/h8-10,13-18,23,27-28H,6-7,11-12,19-22H2,1-5H3,(H,34,38)(H,35,41)(H,36,39)/t27-,28-/m0/s1
DM9LJEP	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)OC(=O)C2=CC=CC=C2)C(=O)NC(C)(C)C)NC(=O)N3CCCCCC3
DM9LJEP	IK	RASCVEWVRJPMSU-NSOVKSMOSA-N
DM9LJEP	IU	[4-[(2S)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(tert-butylamino)-3-oxopropyl]phenyl] benzoate
DM9LJEP	DE	Discovery agent

DMX1AY4	ID	DMX1AY4
DMX1AY4	DN	PD-168077
DMX1AY4	HS	Investigative
DMX1AY4	SN	PD-168077; 190383-31-4; CHEMBL45244; PD 168077; PD-168,077; N-[[4-(2-cyanophenyl)piperazin-1-yl]methyl]-3-methylbenzamide; Benzamide, N-[[4-(2-cyanophenyl)-1-piperazinyl]methyl]-3-methyl-; PD 168,077 maleate salt; N-((4-(2-cyanophenyl)piperazin-1-yl)methyl)-3-methylbenzamide; AC1MURTZ; Tocris-1065; NCGC00015791-01; Lopac-P-233; Biomol-NT_000050; Lopac0_000969; GTPL975; BPBio1_001301; SCHEMBL4002275; DTXSID7044007; NOCAS_44007; CHEBI:94634; BCP08352; ZINC25758996; BDBM50058225; AKOS028108749; CCG-205049; NCGC00024977-02
DMX1AY4	DT	Small molecular drug
DMX1AY4	PC	3645619
DMX1AY4	MW	334.4
DMX1AY4	FM	C20H22N4O
DMX1AY4	IC	InChI=1S/C20H22N4O/c1-16-5-4-7-17(13-16)20(25)22-15-23-9-11-24(12-10-23)19-8-3-2-6-18(19)14-21/h2-8,13H,9-12,15H2,1H3,(H,22,25)
DMX1AY4	CS	CC1=CC(=CC=C1)C(=O)NCN2CCN(CC2)C3=CC=CC=C3C#N
DMX1AY4	IK	DNULYRGWTFLJQL-UHFFFAOYSA-N
DMX1AY4	IU	N-[[4-(2-cyanophenyl)piperazin-1-yl]methyl]-3-methylbenzamide
DMX1AY4	CA	CAS 190383-31-4
DMX1AY4	CB	CHEBI:94634
DMX1AY4	DE	Discovery agent

DMN8M5P	ID	DMN8M5P
DMN8M5P	DN	PD-168393
DMN8M5P	HS	Investigative
DMN8M5P	SN	PD168393; 194423-15-9; pd 168393; PD-168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide
DMN8M5P	DT	Small molecular drug
DMN8M5P	PC	4708
DMN8M5P	MW	369.2
DMN8M5P	FM	C17H13BrN4O
DMN8M5P	IC	InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)
DMN8M5P	CS	C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Br
DMN8M5P	IK	HTUBKQUPEREOGA-UHFFFAOYSA-N
DMN8M5P	IU	N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide
DMN8M5P	CA	CAS 194423-15-9
DMN8M5P	CB	CHEBI:131504
DMN8M5P	DE	Discovery agent

DM1Z3D7	ID	DM1Z3D7
DM1Z3D7	DN	PD-169316
DM1Z3D7	HS	Investigative
DM1Z3D7	SN	PD 169316; 152121-53-4; PD-169316; PD169316; 4-(4-Fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole; 4-(4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl)pyridine; 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine; UNII-GX3Y2V80CV; PD168316; GX3Y2V80CV; CHEMBL17331; Pyridine, 4-(4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl)-; Pyridine, 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]-; C20H13FN4O2; BGIYKDUASORTBB-UHFFFAOYSA-N; PubChem23987; AC1L1ISA
DM1Z3D7	DT	Small molecular drug
DM1Z3D7	PC	4712
DM1Z3D7	MW	360.3
DM1Z3D7	FM	C20H13FN4O2
DM1Z3D7	IC	InChI=1S/C20H13FN4O2/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(8-4-15)25(26)27/h1-12H,(H,23,24)
DM1Z3D7	CS	C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)[N+](=O)[O-]
DM1Z3D7	IK	BGIYKDUASORTBB-UHFFFAOYSA-N
DM1Z3D7	IU	4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine
DM1Z3D7	CA	CAS 152121-53-4
DM1Z3D7	CB	CHEBI:93358
DM1Z3D7	DE	Discovery agent

DMU3OR1	ID	DMU3OR1
DMU3OR1	DN	PD-169469
DMU3OR1	HS	Investigative
DMU3OR1	SN	CHEMBL42420; PD-169469; SCHEMBL7404078; BDBM12074; alpha-arylsulfonylamino carboxylate 2R; (2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid
DMU3OR1	DT	Small molecular drug
DMU3OR1	PC	10549609
DMU3OR1	MW	412.3
DMU3OR1	FM	C17H18BrNO4S
DMU3OR1	IC	InChI=1S/C17H18BrNO4S/c1-11(2)16(17(20)21)19-24(22,23)15-9-5-13(6-10-15)12-3-7-14(18)8-4-12/h3-11,16,19H,1-2H3,(H,20,21)/t16-/m1/s1
DMU3OR1	CS	CC(C)[C@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)Br
DMU3OR1	IK	GJOCABIDMCKCEG-MRXNPFEDSA-N
DMU3OR1	IU	(2R)-2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid
DMU3OR1	DE	Discovery agent

DMJ3DOI	ID	DMJ3DOI
DMJ3DOI	DN	PD-171729
DMJ3DOI	HS	Investigative
DMJ3DOI	SN	PD-171729; UNII-4U96TT078E; CHEMBL290762; 4U96TT078E; PD 171729; SCHEMBL16606731; BDBM50071234; AKOS032947015; Pyrazolo(1,5-a)pyrimidin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-2,5-dimethyl-; 202579-59-7
DMJ3DOI	DT	Small molecular drug
DMJ3DOI	PC	9800614
DMJ3DOI	MW	391.3
DMJ3DOI	FM	C20H24Cl2N4
DMJ3DOI	IC	InChI=1S/C20H24Cl2N4/c1-5-7-10-25(6-2)18-11-13(3)23-20-19(14(4)24-26(18)20)16-9-8-15(21)12-17(16)22/h8-9,11-12H,5-7,10H2,1-4H3
DMJ3DOI	CS	CCCCN(CC)C1=CC(=NC2=C(C(=NN12)C)C3=C(C=C(C=C3)Cl)Cl)C
DMJ3DOI	IK	DVFPSRARRBNMBH-UHFFFAOYSA-N
DMJ3DOI	IU	N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine
DMJ3DOI	CA	CAS 202579-59-7
DMJ3DOI	DE	Discovery agent

DM29GUY	ID	DM29GUY
DM29GUY	DN	PD-172938
DM29GUY	HS	Investigative
DM29GUY	SN	PD-18126
DM29GUY	DT	Small molecular drug
DM29GUY	PC	9798466
DM29GUY	MW	349.5
DM29GUY	FM	C22H27N3O
DM29GUY	IC	InChI=1S/C22H27N3O/c1-16-7-8-18(15-17(16)2)25-13-11-24(12-14-25)10-9-21-19-5-3-4-6-20(19)22(26)23-21/h3-8,15,21H,9-14H2,1-2H3,(H,23,26)/t21-/m0/s1
DM29GUY	CS	CC1=C(C=C(C=C1)N2CCN(CC2)CC[C@H]3C4=CC=CC=C4C(=O)N3)C
DM29GUY	IK	WQEPZBNLBWDIRZ-NRFANRHFSA-N
DM29GUY	IU	(3S)-3-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]-2,3-dihydroisoindol-1-one
DM29GUY	DE	Discovery agent

DMI8JTE	ID	DMI8JTE
DMI8JTE	DN	PD-172939
DMI8JTE	HS	Investigative
DMI8JTE	SN	CHEMBL35093; PD-172939; ZINC4632541; BDBM50070518; (R)-PD-172939
DMI8JTE	DT	Small molecular drug
DMI8JTE	PC	9928335
DMI8JTE	MW	349.5
DMI8JTE	FM	C22H27N3O
DMI8JTE	IC	InChI=1S/C22H27N3O/c1-16-7-8-18(15-17(16)2)25-13-11-24(12-14-25)10-9-21-19-5-3-4-6-20(19)22(26)23-21/h3-8,15,21H,9-14H2,1-2H3,(H,23,26)/t21-/m1/s1
DMI8JTE	CS	CC1=C(C=C(C=C1)N2CCN(CC2)CC[C@@H]3C4=CC=CC=C4C(=O)N3)C
DMI8JTE	IK	WQEPZBNLBWDIRZ-OAQYLSRUSA-N
DMI8JTE	IU	(3R)-3-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]-2,3-dihydroisoindol-1-one
DMI8JTE	DE	Discovery agent

DMP0N4U	ID	DMP0N4U
DMP0N4U	DN	PD173074
DMP0N4U	HS	Investigative
DMP0N4U	DT	Small molecular drug
DMP0N4U	PC	1401
DMP0N4U	MW	523.7
DMP0N4U	FM	C28H41N7O3
DMP0N4U	IC	InChI=1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)
DMP0N4U	CS	CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C
DMP0N4U	IK	DXCUKNQANPLTEJ-UHFFFAOYSA-N
DMP0N4U	IU	1-tert-butyl-3-[2-[4-(diethylamino)butylamino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea
DMP0N4U	CA	CAS 219580-11-7
DMP0N4U	CB	CHEBI:63448
DMP0N4U	DE	Nasopharyngeal carcinoma

DMRBKW6	ID	DMRBKW6
DMRBKW6	DN	PD173212
DMRBKW6	HS	Investigative
DMRBKW6	SN	PD 173212; 217171-01-2; PD173212; CHEMBL299749; N-[[4-(1,1-dimethylethyl)phenyl]methyl]-N-methyl-L-leucyl-N-(1,1-dimethylethyl)-O-(phenylmethyl)-L-Tyrosinamide; SCHEMBL8188148; DTXSID10432752; MolPort-006-822-718; ZINC3941150; BDBM50078723; ABP000999; AKOS024457680; CS-7879; NCGC00347242-02; DB-066610; HY-103318; B7424; FT-0773764; J-014254; N-[[4-(1,1-Dimethylethyl)phenyl]methyl-N-methyl-L-leucyl-N-(1,1-dimethylethyl)-O-phenylmethyl)-L-tyrosinamide; (S)-2-[(4-tert-Butyl-benzyl)-methyl-amino]-4-methyl-pentanoic acid [(S)-2-(4-
DMRBKW6	TC	Analgesics
DMRBKW6	DT	Small molecular drug
DMRBKW6	PC	9916734
DMRBKW6	MW	599.8
DMRBKW6	FM	C38H53N3O3
DMRBKW6	IC	InChI=1S/C38H53N3O3/c1-27(2)23-34(41(9)25-29-15-19-31(20-16-29)37(3,4)5)36(43)39-33(35(42)40-38(6,7)8)24-28-17-21-32(22-18-28)44-26-30-13-11-10-12-14-30/h10-22,27,33-34H,23-26H2,1-9H3,(H,39,43)(H,40,42)/t33-,34-/m0/s1
DMRBKW6	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)OCC2=CC=CC=C2)C(=O)NC(C)(C)C)N(C)CC3=CC=C(C=C3)C(C)(C)C
DMRBKW6	IK	GCDHMGROXQUFNR-HEVIKAOCSA-N
DMRBKW6	IU	(2S)-N-[(2S)-1-(tert-butylamino)-1-oxo-3-(4-phenylmethoxyphenyl)propan-2-yl]-2-[(4-tert-butylphenyl)methyl-methylamino]-4-methylpentanamide
DMRBKW6	CA	CAS 217171-01-2
DMRBKW6	DE	Pain

DMBHIAK	ID	DMBHIAK
DMBHIAK	DN	PD-174265
DMBHIAK	HS	Investigative
DMBHIAK	SN	pd 174265; 4-aminoquinazoline, 2a; PD-174265; CHEMBL188762; 4-[(3-Bromophenyl)amino]-6-propionylamidoquinazoline; N-{4-[(3-Bromophenyl)amino]quinazolin-6-Yl}propanamide; 3lok; 2hwp; AC1L1IS1; BMC163482 Compound 3; GTPL6017; SCHEMBL2944459; BDBM31826; WUPUZEMRHDROEO-UHFFFAOYSA-N; MolPort-044-561-456; HMS3229I05; ZINC1488953; IN1163; HSCI1_000122; CCG-206770; ACM216163530; N-[4-(3-bromoanilino)quinazolin-6-yl]propanamide; J-014179; N-(4-(3-bromophenylamino)quinazolin-6-yl)propionamide
DMBHIAK	DT	Small molecular drug
DMBHIAK	PC	4709
DMBHIAK	MW	371.2
DMBHIAK	FM	C17H15BrN4O
DMBHIAK	IC	InChI=1S/C17H15BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h3-10H,2H2,1H3,(H,21,23)(H,19,20,22)
DMBHIAK	CS	CCC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Br
DMBHIAK	IK	WUPUZEMRHDROEO-UHFFFAOYSA-N
DMBHIAK	IU	N-[4-(3-bromoanilino)quinazolin-6-yl]propanamide
DMBHIAK	DE	Discovery agent

DM6XHUZ	ID	DM6XHUZ
DM6XHUZ	DN	PD176078
DM6XHUZ	HS	Investigative
DM6XHUZ	SN	CHEMBL452325; WHSQHGGETBFMLM-FTBISJDPSA-N; (S)-4-Methyl-2-methylamino-pentanoic acid [4,4-bis-(4-fluoro-phenyl)-butyl]-amide monohydrochloride; (S)-4-methyl-2-(methylamino)pentanoic acid [4,4-bis(4-fluorophenyl)butyl]amide hydrochloride
DM6XHUZ	CP	Pfizer
DM6XHUZ	TC	Analgesics
DM6XHUZ	DT	Small molecular drug
DM6XHUZ	PC	9823703
DM6XHUZ	MW	388.5
DM6XHUZ	FM	C23H30F2N2O
DM6XHUZ	IC	InChI=1S/C23H30F2N2O/c1-16(2)15-22(26-3)23(28)27-14-4-5-21(17-6-10-19(24)11-7-17)18-8-12-20(25)13-9-18/h6-13,16,21-22,26H,4-5,14-15H2,1-3H3,(H,27,28)/t22-/m0/s1
DM6XHUZ	CS	CC(C)C[C@@H](C(=O)NCCCC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)F)NC
DM6XHUZ	IK	QGJKMAIASNMXFI-QFIPXVFZSA-N
DM6XHUZ	IU	(2S)-N-[4,4-bis(4-fluorophenyl)butyl]-4-methyl-2-(methylamino)pentanamide
DM6XHUZ	DE	Pain

DMXLW4F	ID	DMXLW4F
DMXLW4F	DN	PD182905
DMXLW4F	HS	Investigative
DMXLW4F	DE	Discovery agent

DMLU9P6	ID	DMLU9P6
DMLU9P6	DN	PD-307243
DMLU9P6	HS	Investigative
DMLU9P6	SN	PD307243; PD 307243
DMLU9P6	DT	Small molecular drug
DMLU9P6	PC	54440733
DMLU9P6	MW	400.3
DMLU9P6	FM	C20H15Cl2N3O2
DMLU9P6	IC	InChI=1S/C20H15Cl2N3O2/c21-17-6-5-15(9-18(17)22)25-10-12-3-4-14(8-13(12)11-25)24-19-16(20(26)27)2-1-7-23-19/h1-9H,10-11H2,(H,23,24)(H,26,27)
DMLU9P6	CS	C1C2=C(CN1C3=CC(=C(C=C3)Cl)Cl)C=C(C=C2)NC4=C(C=CC=N4)C(=O)O
DMLU9P6	IK	WNXIPCSWXVTKQF-UHFFFAOYSA-N
DMLU9P6	IU	2-[[2-(3,4-dichlorophenyl)-1,3-dihydroisoindol-5-yl]amino]pyridine-3-carboxylic acid
DMLU9P6	DE	Discovery agent

DMBA15J	ID	DMBA15J
DMBA15J	DN	PD-32577
DMBA15J	HS	Investigative
DMBA15J	SN	PD-32577; CHEMBL421719; BDBM50080296
DMBA15J	DT	Small molecular drug
DMBA15J	PC	44460434
DMBA15J	MW	450.7
DMBA15J	FM	C29H42N2O2
DMBA15J	IC	InChI=1S/C29H42N2O2/c1-29(2,25-11-13-27(32)23(19-25)21-30-15-7-3-4-8-16-30)26-12-14-28(33)24(20-26)22-31-17-9-5-6-10-18-31/h11-14,19-20,32-33H,3-10,15-18,21-22H2,1-2H3
DMBA15J	CS	CC(C)(C1=CC(=C(C=C1)O)CN2CCCCCC2)C3=CC(=C(C=C3)O)CN4CCCCCC4
DMBA15J	IK	GHZGEEOGCPBASL-UHFFFAOYSA-N
DMBA15J	IU	2-(azepan-1-ylmethyl)-4-[2-[3-(azepan-1-ylmethyl)-4-hydroxyphenyl]propan-2-yl]phenol
DMBA15J	DE	Discovery agent

DM0OEH3	ID	DM0OEH3
DM0OEH3	DN	PD-4048
DM0OEH3	HS	Investigative
DM0OEH3	SN	NPY Y2-receptor agonist (obesity/diabetes), P2D Biosciences; Neuropeptide Y2-receptor agonist (obesity/diabetes), P2D Biosciences
DM0OEH3	CP	P2D Biosciences
DM0OEH3	DE	Diabetic complication

DM4BDEY	ID	DM4BDEY
DM4BDEY	DN	PD-4074
DM4BDEY	HS	Investigative
DM4BDEY	SN	NPY Y4-receptor agonist (obesity/diabetes), P2D Biosciences; Neuropeptide Y4-receptor agonist (obesity/diabetes), P2D Biosciences
DM4BDEY	CP	P2D Biosciences
DM4BDEY	DE	Diabetic complication

DM5SYTW	ID	DM5SYTW
DM5SYTW	DN	PD-81723
DM5SYTW	HS	Investigative
DM5SYTW	SN	132861-87-1; PD 81723; (2-amino-4,5-dimethylthiophen-3-yl)(3-(trifluoromethyl)phenyl)methanone; (2-AMINO-4,5-DIMETHYL-3-THIENYL)-[3-(TRIFLUOROMETHYL)PHENYL]METHANONE; PD-81723; CHEMBL59532; PD 81,723; PD81723; Methanone, (2-amino-4,5-dimethyl-3-thienyl)(3-(trifluoromethyl)phenyl)-; (2-amino-4,5-dimethylthiophen-3-yl)-[3-(trifluoromethyl)phenyl]methanone; (2-Amino-4,5-dimethylthiophen-3-yl)-(3-(trifluoromethyl)phenyl)methanone; C14H12F3NOS; PD-81,723; Methanone, (2-amino-4,5-dimethyl-3-thienyl)[3-(trifluoromethyl)phenyl]
DM5SYTW	DT	Small molecular drug
DM5SYTW	PC	122028
DM5SYTW	MW	299.31
DM5SYTW	FM	C14H12F3NOS
DM5SYTW	IC	InChI=1S/C14H12F3NOS/c1-7-8(2)20-13(18)11(7)12(19)9-4-3-5-10(6-9)14(15,16)17/h3-6H,18H2,1-2H3
DM5SYTW	CS	CC1=C(SC(=C1C(=O)C2=CC(=CC=C2)C(F)(F)F)N)C
DM5SYTW	IK	KKDKAWKYGCUOGR-UHFFFAOYSA-N
DM5SYTW	IU	(2-amino-4,5-dimethylthiophen-3-yl)-[3-(trifluoromethyl)phenyl]methanone
DM5SYTW	CA	CAS 132861-87-1
DM5SYTW	DE	Discovery agent

DMSIMKZ	ID	DMSIMKZ
DMSIMKZ	DN	PD-83176
DMSIMKZ	HS	Investigative
DMSIMKZ	SN	CHEMBL217423; SCHEMBL8713501; BDBM50059876; PD-83176; Cbz-His-Tyr(OBn)-Ser(OBn)-Trp-DAla-NH2; [(S)-1-[(S)-1-{(S)-2-Benzyloxy-1-[(S)-1-((R)-1-carbamoyl-ethylcarbamoyl)-2-(1H-indol-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-2-(4-benzyloxy-phenyl)-ethylcarbamoyl]-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester; [(S)-1-[(S)-1-{(S)-2-Benzyloxy-1-[(S)-1-((R)-1-carbamoyl-ethylcarbamoyl)-2-(1H-indol-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-2-(4-benzyloxy-phenyl)-ethylcarbamoyl]-2-(1H-imidazol-4-yl)-ethyl]-carbamic acid be
DMSIMKZ	DT	Small molecular drug
DMSIMKZ	PC	9919495
DMSIMKZ	MW	976.1
DMSIMKZ	FM	C54H57N9O9
DMSIMKZ	IC	InChI=1S/C54H57N9O9/c1-35(49(55)64)59-50(65)46(26-40-28-57-44-20-12-11-19-43(40)44)61-53(68)48(33-70-30-37-13-5-2-6-14-37)62-51(66)45(25-36-21-23-42(24-22-36)71-31-38-15-7-3-8-16-38)60-52(67)47(27-41-29-56-34-58-41)63-54(69)72-32-39-17-9-4-10-18-39/h2-24,28-29,34-35,45-48,57H,25-27,30-33H2,1H3,(H2,55,64)(H,56,58)(H,59,65)(H,60,67)(H,61,68)(H,62,66)(H,63,69)/t35-,45+,46+,47+,48+/m1/s1
DMSIMKZ	CS	C[C@H](C(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](COCC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)OCC5=CC=CC=C5)NC(=O)[C@H](CC6=CN=CN6)NC(=O)OCC7=CC=CC=C7
DMSIMKZ	IK	LMBPTRXCFXWLRW-ZYIGOEBISA-N
DMSIMKZ	IU	benzyl N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-amino-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylmethoxypropan-2-yl]amino]-1-oxo-3-(4-phenylmethoxyphenyl)propan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamate
DMSIMKZ	DE	Discovery agent

DMZC90M	ID	DMZC90M
DMZC90M	DN	PD98059
DMZC90M	HS	Investigative
DMZC90M	SN	167869-21-8; PD 98059; 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one; PD-98059; PD 98,059; 2-(2-amino-3-methoxyphenyl)chromen-4-one; 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 2'-AMINO-3'-METHOXYFLAVONE; PD-098059; 4H-1-Benzopyran-4-one, 2-(2-Amino-3-methoxyphenyl)-; UNII-SJE1IO5E3I; SJE1IO5E3I; CHEMBL35482; C16H13NO3; CHEBI:77954; MFCD00671789; 2-(2-Amino-3-methoxy-phenyl)-chromen-4-one; SR-01000076097; PD 098059; 2-(2-Amino-3-methoxyphenyl)-chromen-4-one; NSC 679829; Tocris-1213; PD098059; Lopac-P-215; BiomolKI_000001; 2-(2-amino-3-methoxy-phenyl)chromen-4-one; BiomolKI2_000011; PD 98,059, solid; Lopac0_001028; BMK1-B1; BSPBio_000996; KBioGR_000336; KBioSS_000336; 2-(2'-amino-3'-methoxyphenyl)oxanaphthalen-4-one; cc-461; MLS006010134; SCHEMBL157826; 4H-1-Benzopyran-4-one,2-(2-amino-3-methoxyphenyl)-; GTPL5241; QCR-14; 2''-amino-3''-methoxyflavone; BCBcMAP01_000049; KBio2_000336; KBio2_002904; KBio2_005472; KBio3_000671; KBio3_000672; AOB2598; DTXSID40168416; BCPP000123; Bio1_000475; Bio1_000964; Bio1_001453; Bio2_000338; Bio2_000818; HMS1362B17; HMS1792B17; HMS1990B17; HMS3229M08; HMS3263M17; HMS3267D03; HMS3403B17; HMS3412O09; HMS3649N14; HMS3654I16; HMS3676O09; BCP02423; EX-A2127; ZINC1420826; Tox21_501028; ABP000927; BDBM50108771; NSC679828; s1177; AKOS015995212; BCP9001060; CCG-100605; CS-0169; LP01028; NSC 679828; NSC-679828; SB16629; SDCCGSBI-0051000.P003; IDI1_002093; SMP2_000052; NCGC00015790-01; NCGC00015790-02; NCGC00015790-03; NCGC00015790-04; NCGC00015790-05; NCGC00015790-06; NCGC00015790-07; NCGC00015790-08; NCGC00025045-01; NCGC00025045-02; NCGC00025045-03; NCGC00025045-04; NCGC00025045-05; NCGC00179347-01; NCGC00261713-01; AC-28412; AK-60664; AS-19374; HY-12028; NCI60_028554; SMR001456459; AB0033706; EU-0101028; FT-0716482; P-215; PD-98059/PD98059/; SW218254-2; X7398; EC-000.2425; A25454; P-4313; PD 98059 & Z-100; InSolution PD 98059 - CAS 167869-21-8; J-505513; SR-01000076097-1; SR-01000076097-3; SR-01000076097-6; 2-(2-amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran; BRD-K62810658-001-05-6; BRD-K62810658-001-06-4; Q27088281; 2-(2-Amino-3-methoxy-phenyl)-chromen-4-one(PD98059); PD 98059 - CAS 167869-21-8; 4H-1-Benzopyran-4-one, 2-(2-amino-3-methoxyphenyl)- & Z-100
DMZC90M	DT	Small molecular drug
DMZC90M	PC	4713
DMZC90M	MW	267.28
DMZC90M	FM	C16H13NO3
DMZC90M	IC	InChI=1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3
DMZC90M	CS	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2
DMZC90M	IK	QFWCYNPOPKQOKV-UHFFFAOYSA-N
DMZC90M	IU	2-(2-amino-3-methoxyphenyl)chromen-4-one
DMZC90M	CA	CAS 167869-21-8
DMZC90M	CB	CHEBI:77954
DMZC90M	DE	Cardiac arrest

DMUDY7H	ID	DMUDY7H
DMUDY7H	DN	PDC-31
DMUDY7H	HS	Investigative
DMUDY7H	SN	PDC-31 (nasal, dysmenorrhea); PDC-31 (nasal, dysmenorrhea), PDC; THG-113 (nasal formulation, primary dysmenorrhea), PDC Biotech; THG-113.31 (nasal, primary dysmenorrhea), PDC Biotech
DMUDY7H	CP	Theratechnologies Inc
DMUDY7H	DE	Dysmenorrhea

DMSO3HM	ID	DMSO3HM
DMSO3HM	DN	PDGF gene therapy
DMSO3HM	HS	Investigative
DMSO3HM	SN	UNII-54FF09J702; 54FF09J702; Ancriviroc besylate; SCH-351125 Besylate; 565428-86-6; (1,4'-Bipiperidine)-4-methanimine, alpha-(4-bromophenyl)-1'-((2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl)-N-ethoxy-4'-methyl-, (alphaZ)-, benzenesulfonate
DMSO3HM	CP	Selective Genetics
DMSO3HM	DT	Small molecular drug
DMSO3HM	PC	9875058
DMSO3HM	MW	715.7
DMSO3HM	FM	C34H43BrN4O6S
DMSO3HM	IC	InChI=1S/C28H37BrN4O3.C6H6O3S/c1-5-36-30-26(22-6-8-24(29)9-7-22)23-11-15-32(16-12-23)28(4)13-18-31(19-14-28)27(34)25-20(2)10-17-33(35)21(25)3;7-10(8,9)6-4-2-1-3-5-6/h6-10,17,23H,5,11-16,18-19H2,1-4H3;1-5H,(H,7,8,9)/b30-26+;
DMSO3HM	CS	CCO/N=C(/C1CCN(CC1)C2(CCN(CC2)C(=O)C3=C(C=C[N+](=C3C)[O-])C)C)\\C4=CC=C(C=C4)Br.C1=CC=C(C=C1)S(=O)(=O)O
DMSO3HM	IK	RVIRPEALZXBUMV-REAKUJNMSA-N
DMSO3HM	IU	benzenesulfonic acid;[4-[4-[(Z)-C-(4-bromophenyl)-N-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone
DMSO3HM	CA	CAS 565428-86-6
DMSO3HM	DE	Diabetic foot ulcer

DMORLTH	ID	DMORLTH
DMORLTH	DN	PDGF receptor tyrosine kinase inhibitor III
DMORLTH	HS	Investigative
DMORLTH	SN	PDGFR Tyrosine Kinase Inhibitor III; PDGF Receptor Tyrosine Kinase Inhibitor III; CHEMBL102346; 205254-94-0; 4-(6,7-dimethoxyquinazolin-4-yl)-N-(4-phenoxyphenyl)piperazine-1-carboxamide; 4-(6,7-Dimethoxy-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide; N-(4-Phenoxyphenyl)-4-(6,7-dimethoxyquinazoline-4-yl)piperazine-1-carboxamide; SCHEMBL2592017; GTPL6019; CTK8E8815; DTXSID20447892; CHEBI:143127; HMS3229I09; IN1156; HSCI1_000345; BDBM50115301; CCG-206772; NCGC00185729-01; ACM205254940; RT-014972; J-013383
DMORLTH	DT	Small molecular drug
DMORLTH	PC	10907042
DMORLTH	MW	485.5
DMORLTH	FM	C27H27N5O4
DMORLTH	IC	InChI=1S/C27H27N5O4/c1-34-24-16-22-23(17-25(24)35-2)28-18-29-26(22)31-12-14-32(15-13-31)27(33)30-19-8-10-21(11-9-19)36-20-6-4-3-5-7-20/h3-11,16-18H,12-15H2,1-2H3,(H,30,33)
DMORLTH	CS	COC1=C(C=C2C(=C1)C(=NC=N2)N3CCN(CC3)C(=O)NC4=CC=C(C=C4)OC5=CC=CC=C5)OC
DMORLTH	IK	INTPTKHSGKBHHW-UHFFFAOYSA-N
DMORLTH	IU	4-(6,7-dimethoxyquinazolin-4-yl)-N-(4-phenoxyphenyl)piperazine-1-carboxamide
DMORLTH	CA	CAS 205254-94-0
DMORLTH	CB	CHEBI:143127
DMORLTH	DE	Discovery agent

DMKLRCX	ID	DMKLRCX
DMKLRCX	DN	Pedunculagin
DMKLRCX	HS	Investigative
DMKLRCX	SN	Pedunculagin; CHEMBL506204; CHEBI:7948; AC1L9D8E; C10236
DMKLRCX	DT	Small molecular drug
DMKLRCX	PC	442688
DMKLRCX	MW	784.5
DMKLRCX	FM	C34H24O22
DMKLRCX	IC	InChI=1S/C34H24O22/c35-10-1-6-15(23(43)19(10)39)16-7(2-11(36)20(40)24(16)44)31(48)54-27-14(5-52-30(6)47)53-34(51)29-28(27)55-32(49)8-3-12(37)21(41)25(45)17(8)18-9(33(50)56-29)4-13(38)22(42)26(18)46/h1-4,14,27-29,34-46,51H,5H2/t14-,27-,28+,29-,34?/m1/s1
DMKLRCX	CS	C1[C@@H]2[C@H]([C@H]3[C@H](C(O2)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O3)O)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6C7=C(C(=C(C=C7C(=O)O1)O)O)O)O)O)O
DMKLRCX	IK	IYMHVUYNBVWXKH-ZITZVVOASA-N
DMKLRCX	IU	(1R,2S,19R,22R)-7,8,9,12,13,14,20,28,29,30,33,34,35-tridecahydroxy-3,18,21,24,39-pentaoxaheptacyclo[20.17.0.02,19.05,10.011,16.026,31.032,37]nonatriaconta-5,7,9,11,13,15,26,28,30,32,34,36-dodecaene-4,17,25,38-tetrone
DMKLRCX	CB	CHEBI:7948
DMKLRCX	DE	Discovery agent

DM5GVZJ	ID	DM5GVZJ
DM5GVZJ	DN	PEG-EPO
DM5GVZJ	HS	Investigative
DM5GVZJ	SN	PEG-EPO (anemia)
DM5GVZJ	CP	Prolong Pharmaceuticals Inc
DM5GVZJ	DE	Anemia

DMY293M	ID	DMY293M
DMY293M	DN	PEG-LPA-2
DMY293M	HS	Investigative
DMY293M	SN	Leptin receptor antagonists (cancer/endometriosis); Leptin receptor antagonists (cancer/endometriosis), CRT; Leptin receptor antagonists (cancer/endometriosis), Cancer Research Technology; PEGylated leptin receptor antagonists (cancer/endometriosis), CRT; PEGylated leptin receptor antagonists (cancer/endometriosis), Cancer Research Technology
DMY293M	CP	Boston Biomedical Research Inst
DMY293M	DE	Solid tumour/cancer

DMZ01PS	ID	DMZ01PS
DMZ01PS	DN	PEGylated leptin
DMZ01PS	HS	Investigative
DMZ01PS	SN	PEG-Leptin; PEGylated leptin (obesity/type 1 diabetes); PEGylated leptin (obesity/type 1 diabetes), Ambrx
DMZ01PS	CP	Ambrx Inc
DMZ01PS	DE	Obesity

DM6K3G7	ID	DM6K3G7
DM6K3G7	DN	PEGylated PYY-3-36
DM6K3G7	HS	Investigative
DM6K3G7	SN	PEG-PYY; PEGylated PYY-3-36, Roche
DM6K3G7	CP	Hoffmann-La Roche Inc
DM6K3G7	DE	Metabolic disorder

DMAW0R7	ID	DMAW0R7
DMAW0R7	DN	PELARGONIDIN CHLORIDE
DMAW0R7	HS	Investigative
DMAW0R7	SN	Pelargonidin chloride; Pelargonidin; 134-04-3; Pelargonidol chloride; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-1-benzopyrylium chloride; UNII-DFL6200791; 3,4',5,7-Tetrahydroxyflavylium chloride; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)benzopyrylium chloride; CHEBI:28510; DFL6200791; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromenylium chloride; 1-Benzopyrylium, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-, chloride; CHEMBL591036; 2-(4-hydroxyphenyl)chromenylium-3,5,7-triol chloride; C15H11O5.Cl; EINECS 205-127-7; pelargonidine chloride
DMAW0R7	DT	Small molecular drug
DMAW0R7	PC	67249
DMAW0R7	MW	306.7
DMAW0R7	FM	C15H11ClO5
DMAW0R7	IC	InChI=1S/C15H10O5.ClH/c16-9-3-1-8(2-4-9)15-13(19)7-11-12(18)5-10(17)6-14(11)20-15;/h1-7H,(H3-,16,17,18,19);1H
DMAW0R7	CS	C1=CC(=CC=C1C2=[O+]C3=CC(=CC(=C3C=C2O)O)O)O.[Cl-]
DMAW0R7	IK	YPVZJXMTXCOTJN-UHFFFAOYSA-N
DMAW0R7	IU	2-(4-hydroxyphenyl)chromenylium-3,5,7-triol;chloride
DMAW0R7	CA	CAS 134-04-3
DMAW0R7	CB	CHEBI:28510
DMAW0R7	DE	Discovery agent

DMYIWBD	ID	DMYIWBD
DMYIWBD	DN	Pellitorin
DMYIWBD	HS	Investigative
DMYIWBD	SN	Pellitorine; Pellitorin; 18836-52-7; trans-Pellitorin; (E,E)-N-(2-Methylpropyl)-2,4-decadienamide; (E,E)-N-Isobutyl-2,4-decadienamide; N-Isobutyldeca-trans-2,trans-4-dienamide; UNII-8IS5231171; 2,4-DECADIENAMIDE, N-ISOBUTYL-, (E,E)-; 2,4-Decadienamide, N-(2-methylpropyl)-, (E,E)-; BRN 1725967; AI3-19560; CHEBI:69686; MAGQQZHFHJDIRE-BNFZFUHLSA-N; Pellitorine (6CI); 2,4-Decadienamide, N-(2-methylpropyl)-, (2E,4E)-; 8IS5231171; (2E,4E)-N-(2-methylpropyl)deca-2,4-dienamide; N-(2-Methylpropyl)-2,4-Decadienamide; Optaflow A
DMYIWBD	DT	Small molecular drug
DMYIWBD	PC	5318516
DMYIWBD	MW	223.35
DMYIWBD	FM	C14H25NO
DMYIWBD	IC	InChI=1S/C14H25NO/c1-4-5-6-7-8-9-10-11-14(16)15-12-13(2)3/h8-11,13H,4-7,12H2,1-3H3,(H,15,16)/b9-8+,11-10+
DMYIWBD	CS	CCCCC/C=C/C=C/C(=O)NCC(C)C
DMYIWBD	IK	MAGQQZHFHJDIRE-BNFZFUHLSA-N
DMYIWBD	IU	(2E,4E)-N-(2-methylpropyl)deca-2,4-dienamide
DMYIWBD	CA	CAS 18836-52-7
DMYIWBD	CB	CHEBI:69686
DMYIWBD	DE	Discovery agent

DM81AWU	ID	DM81AWU
DM81AWU	DN	Pen(Acm)AQFRKEKETFC(Acm)-OH
DM81AWU	HS	Investigative
DM81AWU	SN	CHEMBL412929
DM81AWU	PC	44403768
DM81AWU	MW	1487.7
DM81AWU	FM	C64H98N18O19S2
DM81AWU	IC	InChI=1S/C64H98N18O19S2/c1-34-52(89)73-42(21-24-48(68)84)58(95)79-45(30-36-14-5-3-6-15-36)60(97)76-41(20-13-29-71-64(69)70)56(93)74-39(18-9-11-27-65)54(91)77-43(22-25-49(85)86)57(94)75-40(19-10-12-28-66)55(92)78-44(23-26-50(87)88)59(96)82-51(35(2)83)62(99)80-46(31-37-16-7-4-8-17-37)61(98)81-47(63(100)101)33-103-102-32-38(67)53(90)72-34/h3-8,14-17,34-35,38-47,51,83H,9-13,18-33,65-67H2,1-2H3,(H2,68,84)(H,72,90)(H,73,89)(H,74,93)(H,75,94)(H,76,97)(H,77,91)(H,78,92)(H,79,95)(H,80,99)(H,81,98)(H,82,96)(H,85,86)(H,87,88)(H,100,101)(H4,69,70,71)/t34-,35-,38-,39-,40-,41+,42+,43+,44+,45-,46+,47+,51-/m1/s1
DM81AWU	CS	C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N1)N)C(=O)O)CC2=CC=CC=C2)[C@@H](C)O)CCC(=O)O)CCCCN)CCC(=O)O)CCCCN)CCCN=C(N)N)CC3=CC=CC=C3)CCC(=O)N
DM81AWU	IK	IYWWTDYPQATACO-BDUUBTEFSA-N
DM81AWU	IU	(4R,7S,10R,13S,16R,19S,22R,25S,28R,31S,34R,37S)-37-amino-16,22-bis(4-aminobutyl)-31-(3-amino-3-oxopropyl)-7,28-dibenzyl-13,19-bis(2-carboxyethyl)-25-[3-(diaminomethylideneamino)propyl]-10-[(1R)-1-hydroxyethyl]-34-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DM81AWU	DE	Discovery agent

DMZ3WPN	ID	DMZ3WPN
DMZ3WPN	DN	Penciclovir
DMZ3WPN	HS	Investigative
DMZ3WPN	SN	penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2
DMZ3WPN	TC	Antiviral Agents
DMZ3WPN	DT	Small molecular drug
DMZ3WPN	PC	135398748
DMZ3WPN	MW	253.26
DMZ3WPN	FM	C10H15N5O3
DMZ3WPN	IC	InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)
DMZ3WPN	CS	C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N
DMZ3WPN	IK	JNTOCHDNEULJHD-UHFFFAOYSA-N
DMZ3WPN	IU	2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one
DMZ3WPN	CA	CAS 39809-25-1
DMZ3WPN	CB	CHEBI:7956
DMZ3WPN	DE	Discovery agent; Human immunodeficiency virus infection; Coronavirus Disease 2019 (COVID-19)

DMIDSJ9	ID	DMIDSJ9
DMIDSJ9	DN	PENECA
DMIDSJ9	HS	Investigative
DMIDSJ9	SN	2-phenylethynyl-NECA; 2-phenylethynylNECA
DMIDSJ9	DT	Small molecular drug
DMIDSJ9	PC	9953255
DMIDSJ9	MW	408.4
DMIDSJ9	FM	C20H20N6O4
DMIDSJ9	IC	InChI=1S/C20H20N6O4/c1-2-22-19(29)16-14(27)15(28)20(30-16)26-10-23-13-17(21)24-12(25-18(13)26)9-8-11-6-4-3-5-7-11/h3-7,10,14-16,20,27-28H,2H2,1H3,(H,22,29)(H2,21,24,25)/t14-,15+,16-,20+/m0/s1
DMIDSJ9	CS	CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)C#CC4=CC=CC=C4)N)O)O
DMIDSJ9	IK	SWXXHYTUMIMRFO-KSVNGYGVSA-N
DMIDSJ9	IU	(2S,3S,4R,5R)-5-[6-amino-2-(2-phenylethynyl)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
DMIDSJ9	DE	Discovery agent

DMZUES2	ID	DMZUES2
DMZUES2	DN	PENICILLIOL A
DMZUES2	HS	Investigative
DMZUES2	SN	PENICILLIOL A; CHEMBL457041; BDBM50276865; 4-[(2E)-but-2-enoyl]-2-[(1E,3E)-5-hydroxyhexa-1,3-dien-1-yl]-5-methoxy-2-methylfuran-3(2H)-one
DMZUES2	DT	Small molecular drug
DMZUES2	PC	42629596
DMZUES2	MW	292.33
DMZUES2	FM	C16H20O5
DMZUES2	IC	InChI=1S/C16H20O5/c1-5-8-12(18)13-14(19)16(3,21-15(13)20-4)10-7-6-9-11(2)17/h5-11,17H,1-4H3/b8-5+,9-6+,10-7+
DMZUES2	CS	C/C=C/C(=O)C1=C(OC(C1=O)(C)/C=C/C=C/C(C)O)OC
DMZUES2	IK	SDJFAZYNJXZUJT-DVJWZOGQSA-N
DMZUES2	IU	4-[(E)-but-2-enoyl]-2-[(1E,3E)-5-hydroxyhexa-1,3-dienyl]-5-methoxy-2-methylfuran-3-one
DMZUES2	DE	Discovery agent

DMA13KG	ID	DMA13KG
DMA13KG	DN	Pentamycin
DMA13KG	HS	Investigative
DMA13KG	SN	Antibiotic 246; Antibiotic A-246; Cantricin; Cogomycin; Fungchromin (INN); Fungichromin; Lagosin; Lagosin (antibiotic); Moldcidin B; Pentamycin; Pentamycin (JAN); (3R,4S,6S,8S,10R,12R,14R,15R,16R,17E,19E,21E,23E,25E,27S,28R)-4,6,8,10,12,14,15,16,27-nonahydroxy-3-[(1R)-1-hydroxyhexyl]-17,28-dimethyl-1-oxacyclooctacosa-17,19,21,23,25-pentaen-2-one; 14-Hydroxyfilipin; 1JB340D58S; 6834-98-6; C35H58O12; CHEBI:31639; CHEMBL2272031; EINECS 229-913-4; NSC 105388; NSC 276732; NSC-105388; NSC-277813; S 232; S-232; UNII-1JB340D58S
DMA13KG	PC	5282200
DMA13KG	MW	670.8
DMA13KG	FM	C35H58O12
DMA13KG	IC	AGJUUQSLGVCRQA-SWOUQTJZSA-N
DMA13KG	CS	CCCCCC(C1C(CC(CC(CC(CC(CC(C(C(C(=CC=CC=CC=CC=CC(C(OC1=O)C)O)C)O)O)O)O)O)O)O)O)O
DMA13KG	IK	1S/C35H58O12/c1-4-5-11-16-29(41)32-30(42)20-26(38)18-24(36)17-25(37)19-27(39)21-31(43)34(45)33(44)22(2)14-12-9-7-6-8-10-13-15-28(40)23(3)47-35(32)46/h6-10,12-15,23-34,36-45H,4-5,11,16-21H2,1-3H3/b7-6+,10-8+,12-9+,15-13+,22-14+/t23-,24+,25-,26+,27-,28+,29-,30+,31-,32-,33-,34-/m1/s1
DMA13KG	IU	(3R,4S,6S,8S,10R,12R,14R,15R,16R,17E,19E,21E,23E,25E,27S,28R)-4,6,8,10,12,14,15,16,27-nonahydroxy-3-[(1R)-1-hydroxyhexyl]-17,28-dimethyl-1-oxacyclooctacosa-17,19,21,23,25-pentaen-2-one
DMA13KG	CA	CAS 6834-98-6
DMA13KG	CB	CHEBI:31639
DMA13KG	DE	Candidiasis

DMVPZG9	ID	DMVPZG9
DMVPZG9	DN	Pentane-1,5-diamine
DMVPZG9	HS	Investigative
DMVPZG9	SN	Pentane-1,5-diamine; 1,5-Diaminopentane; cadaverine; 462-94-2; 1,5-pentanediamine; pentamethylenediamine; Cadaverin; Animal coniine; 1,5-Pentamethylenediamine; UNII-L90BEN6OLL; AI3-26937; BRN 1697256; EINECS 207-329-0; L90BEN6OLL; CHEMBL119296; CHEBI:18127; VHRGRCVQAFMJIZ-UHFFFAOYSA-N; MFCD00008239; 1,5-Diaminopentane, 98%; N2P; Pentamethylenediamine dihydrochloride; HSDB 7866; Cadaverine, 95%; Pentane-1,5-damne; BioDex 1-; 1,5-diamino-pentane; 1,5-Amylene diamine; ACMC-1BNDU; 1,5-Diamino-n-pentane; alpha,omega-Pentanediamine
DMVPZG9	DT	Small molecular drug
DMVPZG9	PC	273
DMVPZG9	MW	102.18
DMVPZG9	FM	C5H14N2
DMVPZG9	IC	InChI=1S/C5H14N2/c6-4-2-1-3-5-7/h1-7H2
DMVPZG9	CS	C(CCN)CCN
DMVPZG9	IK	VHRGRCVQAFMJIZ-UHFFFAOYSA-N
DMVPZG9	IU	pentane-1,5-diamine
DMVPZG9	CA	CAS 462-94-2
DMVPZG9	CB	CHEBI:18127
DMVPZG9	DE	Discovery agent

DM56RAX	ID	DM56RAX
DM56RAX	DN	pentanoic acid
DM56RAX	HS	Investigative
DM56RAX	SN	n-pentanoic acid; N-valeric acid; valeric acid; pentanoate
DM56RAX	DT	Small molecular drug
DM56RAX	PC	7991
DM56RAX	MW	102.13
DM56RAX	FM	C5H10O2
DM56RAX	IC	InChI=1S/C5H10O2/c1-2-3-4-5(6)7/h2-4H2,1H3,(H,6,7)
DM56RAX	CS	CCCCC(=O)O
DM56RAX	IK	NQPDZGIKBAWPEJ-UHFFFAOYSA-N
DM56RAX	IU	pentanoic acid
DM56RAX	CA	CAS 109-52-4
DM56RAX	CB	CHEBI:17418
DM56RAX	DE	Discovery agent

DM3S790	ID	DM3S790
DM3S790	DN	Pentanoic acid (4,6-diphenylpyrimidin-2-yl)amide
DM3S790	HS	Investigative
DM3S790	SN	CHEMBL221407; 820961-66-8; N-(4,6-diphenylpyrimidin-2-yl)pentanamide; pentanoic acid (4,6-diphenylpyrimidin-2-yl)amide; CTK3E2642; DTXSID40466323; MolPort-007-705-554; BDBM50157679; ZINC13586470; AKOS001873650; MCULE-5546422381; Pentanamide, N-(4,6-diphenyl-2-pyrimidinyl)-
DM3S790	DT	Small molecular drug
DM3S790	PC	11450364
DM3S790	MW	331.4
DM3S790	FM	C21H21N3O
DM3S790	IC	InChI=1S/C21H21N3O/c1-2-3-14-20(25)24-21-22-18(16-10-6-4-7-11-16)15-19(23-21)17-12-8-5-9-13-17/h4-13,15H,2-3,14H2,1H3,(H,22,23,24,25)
DM3S790	CS	CCCCC(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DM3S790	IK	USYDGSXEKYPSDH-UHFFFAOYSA-N
DM3S790	IU	N-(4,6-diphenylpyrimidin-2-yl)pentanamide
DM3S790	CA	CAS 820961-66-8
DM3S790	DE	Discovery agent

DMAZ07T	ID	DMAZ07T
DMAZ07T	DN	Pentanoic acid (4-sulfamoyl-phenyl)-amide
DMAZ07T	HS	Investigative
DMAZ07T	SN	N-(4-sulfamoylphenyl)pentanamide; CHEMBL283097; Pentanamide, N-[4-(aminosulfonyl)phenyl]-; AC1N6D4T; Oprea1_185235; BDBM16648; aromatic sulfonamide compound 13; MolPort-006-401-342; 4-n-Pentanamido-benzenesulfonamide; ZINC5417663; STK873868; AKOS002953745; N-[4-(aminosulfonyl)phenyl]pentanamide; MCULE-5889563074
DMAZ07T	DT	Small molecular drug
DMAZ07T	PC	4258082
DMAZ07T	MW	256.32
DMAZ07T	FM	C11H16N2O3S
DMAZ07T	IC	InChI=1S/C11H16N2O3S/c1-2-3-4-11(14)13-9-5-7-10(8-6-9)17(12,15)16/h5-8H,2-4H2,1H3,(H,13,14)(H2,12,15,16)
DMAZ07T	CS	CCCCC(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DMAZ07T	IK	YLGGQMUYDSKQIG-UHFFFAOYSA-N
DMAZ07T	IU	N-(4-sulfamoylphenyl)pentanamide
DMAZ07T	DE	Discovery agent

DMD8NHB	ID	DMD8NHB
DMD8NHB	DN	pentylthio-TZTP
DMD8NHB	HS	Investigative
DMD8NHB	SN	CHEMBL130715; GTPL304; SCHEMBL6912246; BDBM50003363; ZINC13456708; 1-methyl-3-(4-pentylsulfanyl-1,2,5-thiadiazol-3-yl)-5,6-dihydro-2H-pyridine; 1-Methyl-5-(4-pentylsulfanyl-[1,2,5]thiadiazol-3-yl)-1,2,3,6-tetrahydro-pyridine; 1,2,5,6-Tetrahydro-1-methyl-3-[4-pentylthio-1,2,5-thiadiazol-3-yl]pyridine
DMD8NHB	DT	Small molecular drug
DMD8NHB	PC	10062394
DMD8NHB	MW	283.5
DMD8NHB	FM	C13H21N3S2
DMD8NHB	IC	InChI=1S/C13H21N3S2/c1-3-4-5-9-17-13-12(14-18-15-13)11-7-6-8-16(2)10-11/h7H,3-6,8-10H2,1-2H3
DMD8NHB	CS	CCCCCSC1=NSN=C1C2=CCCN(C2)C
DMD8NHB	IK	LRTWCQHCJKYNPS-UHFFFAOYSA-N
DMD8NHB	IU	3-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-4-pentylsulfanyl-1,2,5-thiadiazole
DMD8NHB	DE	Discovery agent

DMIDP1R	ID	DMIDP1R
DMIDP1R	DN	peptide 18
DMIDP1R	HS	Investigative
DMIDP1R	SN	Ac-LLLLRVK-Amba
DMIDP1R	DT	Small molecular drug
DMIDP1R	PC	75593419
DMIDP1R	MW	1027.3
DMIDP1R	FM	C51H90N14O8
DMIDP1R	IC	InChI=1S/C51H90N14O8/c1-28(2)23-38(59-33(11)66)46(69)62-40(25-30(5)6)48(71)64-41(26-31(7)8)49(72)63-39(24-29(3)4)47(70)60-37(16-14-22-57-51(55)56)45(68)65-42(32(9)10)50(73)61-36(15-12-13-21-52)44(67)58-27-34-17-19-35(20-18-34)43(53)54/h17-20,28-32,36-42H,12-16,21-27,52H2,1-11H3,(H3,53,54)(H,58,67)(H,59,66)(H,60,70)(H,61,73)(H,62,69)(H,63,72)(H,64,71)(H,65,68)(H4,55,56,57)/t36-,37-,38-,39-,40-,41-,42-/m0/s1
DMIDP1R	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC1=CC=C(C=C1)C(=N)N)NC(=O)C
DMIDP1R	IK	UFNWIBYSOUCSGW-FVMQRRFMSA-N
DMIDP1R	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-6-amino-N-[(4-carbamimidoylphenyl)methyl]hexanamide
DMIDP1R	DE	Discovery agent

DM45RTZ	ID	DM45RTZ
DM45RTZ	DN	peptide 4
DM45RTZ	HS	Investigative
DM45RTZ	SN	CHEMBL263633; GTPL8582; BDBM50376756; peptide 4 [PMID: 18294843]; (2S)-2-[[(2S)-2-[2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid
DM45RTZ	DT	Small molecular drug
DM45RTZ	PC	44450050
DM45RTZ	MW	484.6
DM45RTZ	FM	C20H36N8O6
DM45RTZ	IC	InChI=1S/C20H36N8O6/c1-9(2)14(18(32)27-12(5)19(33)34)28-16(30)11(4)25-15(29)10(3)26-17(31)13(21)7-6-8-24-20(22)23/h9-10,12-14H,4,6-8,21H2,1-3,5H3,(H,25,29)(H,26,31)(H,27,32)(H,28,30)(H,33,34)(H4,22,23,24)/t10-,12-,13-,14-/m0/s1
DM45RTZ	CS	C[C@@H](C(=O)NC(=C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N
DM45RTZ	IK	VZQHRKZCAZCACO-PYJNHQTQSA-N
DM45RTZ	IU	(2S)-2-[[(2S)-2-[2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid
DM45RTZ	DE	Discovery agent

DMC6GUA	ID	DMC6GUA
DMC6GUA	DN	Peptide alpha-keto-beta-aldehyde-based inhibitors
DMC6GUA	HS	Investigative
DMC6GUA	SN	CHEMBL48605; BDBM50090643; (3S)-3-[(Ac-L-Leu-L-Leu-)Amino]-6-guanidino-2-oxohexanal; (S)-2-Acetylamino-4-methyl-pentanoic acid {(S)-1-[(S)-4-guanidino-1-(2-oxo-acetyl)-butylcarbamoyl]-3-methyl-butyl}-amide
DMC6GUA	DT	Small molecular drug
DMC6GUA	PC	10095492
DMC6GUA	MW	454.6
DMC6GUA	FM	C21H38N6O5
DMC6GUA	IC	InChI=1S/C21H38N6O5/c1-12(2)9-16(25-14(5)29)19(31)27-17(10-13(3)4)20(32)26-15(18(30)11-28)7-6-8-24-21(22)23/h11-13,15-17H,6-10H2,1-5H3,(H,25,29)(H,26,32)(H,27,31)(H4,22,23,24)/t15-,16-,17-/m0/s1
DMC6GUA	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)C=O)NC(=O)C
DMC6GUA	IK	SDHUBIMNNXCDCV-ULQDDVLXSA-N
DMC6GUA	IU	(2S)-2-acetamido-N-[(2S)-1-[[(3S)-6-(diaminomethylideneamino)-1,2-dioxohexan-3-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide
DMC6GUA	DE	Discovery agent

DMSDFOC	ID	DMSDFOC
DMSDFOC	DN	peptide III-BTD
DMSDFOC	HS	Investigative
DMSDFOC	SN	Peptide III-BTD; AC1NSKGB; GTPL1696; (3S,6R)-6-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-cyclohexylpropanoyl]amino]-N-[(2R)-1-[[(2R)-1-amino-3-(4-chlorophenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-5-oxo-2,3,6,7,8,8a-hexahydro-[1,3]thiazolo[3,2-a]pyridine-3-carboxamide
DMSDFOC	DT	Small molecular drug
DMSDFOC	PC	5311338
DMSDFOC	MW	904.5
DMSDFOC	FM	C40H62ClN13O7S
DMSDFOC	IC	InChI=1S/C40H62ClN13O7S/c1-22(55)49-26(9-5-17-47-39(43)44)34(57)53-30(20-23-7-3-2-4-8-23)36(59)51-28-15-16-32-54(38(28)61)31(21-62-32)37(60)50-27(10-6-18-48-40(45)46)35(58)52-29(33(42)56)19-24-11-13-25(41)14-12-24/h11-14,23,26-32H,2-10,15-21H2,1H3,(H2,42,56)(H,49,55)(H,50,60)(H,51,59)(H,52,58)(H,53,57)(H4,43,44,47)(H4,45,46,48)/t26-,27+,28+,29+,30-,31+,32?/m0/s1
DMSDFOC	CS	CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H]2CCC3N(C2=O)[C@H](CS3)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CC4=CC=C(C=C4)Cl)C(=O)N
DMSDFOC	IK	TVMPRXGFXMXJRH-DLYPAOLNSA-N
DMSDFOC	IU	(3S,6R)-6-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-cyclohexylpropanoyl]amino]-N-[(2R)-1-[[(2R)-1-amino-3-(4-chlorophenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-5-oxo-2,3,6,7,8,8a-hexahydro-[1,3]thiazolo[3,2-a]pyridine-3-carboxamide
DMSDFOC	DE	Discovery agent

DM8OC9F	ID	DM8OC9F
DM8OC9F	DN	Pergularinine
DM8OC9F	HS	Investigative
DM8OC9F	SN	Tylophorinine; TYLOPHORININE; CHEMBL398325; 571-70-0; NSC100055; AC1L6CHR; (13as,14r)-3,6,7-trimethoxy-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol; AC1Q57Z0; CTK5A6391; Dibenzo(f,h)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-3,6,7-trimethoxy-, (13aS-cis)-; BDBM50213934; NSC-100055; NCI60_000003; (13aS,14R)-3,6,7-trimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol; Dibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol,9,11,12,13,13a,14-hexahydro-3,6,7-trimethoxy-,
DM8OC9F	DT	Small molecular drug
DM8OC9F	PC	264751
DM8OC9F	MW	379.4
DM8OC9F	FM	C23H25NO4
DM8OC9F	IC	InChI=1S/C23H25NO4/c1-26-13-6-7-14-15(9-13)16-10-20(27-2)21(28-3)11-17(16)18-12-24-8-4-5-19(24)23(25)22(14)18/h6-7,9-11,19,23,25H,4-5,8,12H2,1-3H3/t19-,23-/m0/s1
DM8OC9F	CS	COC1=CC2=C(C=C1)C3=C(CN4CCC[C@H]4[C@@H]3O)C5=CC(=C(C=C52)OC)OC
DM8OC9F	IK	LAWAARLALKUFQQ-CVDCTZTESA-N
DM8OC9F	IU	(13aS,14R)-3,6,7-trimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol
DM8OC9F	CA	CAS 571-70-0
DM8OC9F	DE	Discovery agent

DMZA0VD	ID	DMZA0VD
DMZA0VD	DN	Perillaldehyde
DMZA0VD	HS	Investigative
DMZA0VD	SN	PERILLALDEHYDE; Perillyl aldehyde; Perilla aldehyde; Perillal; 2111-75-3; Perillic aldehyde; P-Mentha-1,8-dien-7-al; Dihydrocuminyl aldehyde; para-Mentha-1,8-dien-7-al; l-Perillaldehyde; Perillylaldehyde; 1-Cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-; 4-Isopropenyl-1-cyclohexene-1-carboxaldehyde; 1-Cyclohexene-1-carboxaldehyde, 4-isopropenyl-; 4-Isopropenylcyclohex-1-enecarbaldehyde; FEMA No. 3557; p-Mentha-1,8-dien-7-al (natural); 1,8-p-Menthadien-7-al; NSC 138642; CCRIS 9128; CHEMBL469537; 1-Perillaldehyde
DMZA0VD	DT	Small molecular drug
DMZA0VD	PC	16441
DMZA0VD	MW	150.22
DMZA0VD	FM	C10H14O
DMZA0VD	IC	InChI=1S/C10H14O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,7,10H,1,4-6H2,2H3
DMZA0VD	CS	CC(=C)C1CCC(=CC1)C=O
DMZA0VD	IK	RUMOYJJNUMEFDD-UHFFFAOYSA-N
DMZA0VD	IU	4-prop-1-en-2-ylcyclohexene-1-carbaldehyde
DMZA0VD	CA	CAS 2111-75-3
DMZA0VD	CB	CHEBI:15421
DMZA0VD	DE	Discovery agent

DMN9W56	ID	DMN9W56
DMN9W56	DN	PERIPENTADENINE
DMN9W56	HS	Investigative
DMN9W56	SN	peripentadenine; AC1L4L4R; Hexanamide, N-(3-(2-(2-(2-hydroxy-6-methylphenyl)-2-oxoethyl)-1-pyrrolidinyl)propyl)-; CHEMBL608830; 87201-37-4
DMN9W56	DT	Small molecular drug
DMN9W56	PC	159059
DMN9W56	MW	374.5
DMN9W56	FM	C22H34N2O3
DMN9W56	IC	InChI=1S/C22H34N2O3/c1-3-4-5-12-21(27)23-13-8-15-24-14-7-10-18(24)16-20(26)22-17(2)9-6-11-19(22)25/h6,9,11,18,25H,3-5,7-8,10,12-16H2,1-2H3,(H,23,27)
DMN9W56	CS	CCCCCC(=O)NCCCN1CCCC1CC(=O)C2=C(C=CC=C2O)C
DMN9W56	IK	LZFMYZNYVOKFEE-UHFFFAOYSA-N
DMN9W56	IU	N-[3-[2-[2-(2-hydroxy-6-methylphenyl)-2-oxoethyl]pyrrolidin-1-yl]propyl]hexanamide
DMN9W56	CA	CAS 126640-99-1
DMN9W56	DE	Discovery agent

DM3RGPF	ID	DM3RGPF
DM3RGPF	DN	PERSICARIN
DM3RGPF	HS	Investigative
DM3RGPF	SN	Persicarin; Isohamnetin 3-sulfate; Isohamnetin 3-monosulfate; 549-31-5; Chromone, 2-(4-hydroxy-3-methoxyphenyl)-3,5,7-trihydroxy-, 3-sulfate (ester); 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-(sulfooxy)-; AC1NUPTX; SCHEMBL3735018; CHEMBL1207992; DTXSID40203391; LMPK12112396; LS-39598; [5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-oxochromen-3-yl] hydrogen sulfate
DM3RGPF	DT	Small molecular drug
DM3RGPF	PC	5487766
DM3RGPF	MW	396.3
DM3RGPF	FM	C16H12O10S
DM3RGPF	IC	InChI=1S/C16H12O10S/c1-24-11-4-7(2-3-9(11)18)15-16(26-27(21,22)23)14(20)13-10(19)5-8(17)6-12(13)25-15/h2-6,17-19H,1H3,(H,21,22,23)
DM3RGPF	CS	COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OS(=O)(=O)O)O
DM3RGPF	IK	CZFNXFXZXWDYMZ-UHFFFAOYSA-N
DM3RGPF	IU	[5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-oxochromen-3-yl] hydrogen sulfate
DM3RGPF	CA	CAS 549-31-5
DM3RGPF	DE	Discovery agent

DM873BS	ID	DM873BS
DM873BS	DN	Pervanadate
DM873BS	HS	Investigative
DM873BS	SN	pervanadate; POV; DTXSID2041092; NOCAS_41092; trisodium trioxido(oxo)vanadium - hydrogen peroxide (1:3)
DM873BS	DT	Small molecular drug
DM873BS	PC	24978557
DM873BS	MW	285.95
DM873BS	FM	H6Na3O10V
DM873BS	IC	InChI=1S/3Na.3H2O2.4O.V/c;;;3*1-2;;;;;/h;;;3*1-2H;;;;;/q3*+1;;;;;3*-1;
DM873BS	CS	OO.OO.OO.[O-][V](=O)([O-])[O-].[Na+].[Na+].[Na+]
DM873BS	IK	PZYFJWVGRGEWGO-UHFFFAOYSA-N
DM873BS	IU	trisodium;hydrogen peroxide;trioxido(oxo)vanadium
DM873BS	DE	Discovery agent

DM0N1DH	ID	DM0N1DH
DM0N1DH	DN	PETCM
DM0N1DH	HS	Investigative
DM0N1DH	SN	1-(trichloromethyl)-2-(4-pyridine)ethanol
DM0N1DH	DT	Small molecular drug
DM0N1DH	PC	224859
DM0N1DH	MW	240.5
DM0N1DH	FM	C8H8Cl3NO
DM0N1DH	IC	InChI=1S/C8H8Cl3NO/c9-8(10,11)7(13)5-6-1-3-12-4-2-6/h1-4,7,13H,5H2
DM0N1DH	CS	C1=CN=CC=C1CC(C(Cl)(Cl)Cl)O
DM0N1DH	IK	NGTDJJKTGRNNAU-UHFFFAOYSA-N
DM0N1DH	IU	1,1,1-trichloro-3-pyridin-4-ylpropan-2-ol
DM0N1DH	CA	CAS 10129-56-3
DM0N1DH	CB	CHEBI:91963
DM0N1DH	DE	Discovery agent

DMYIEOJ	ID	DMYIEOJ
DMYIEOJ	DN	Petrosamine
DMYIEOJ	HS	Investigative
DMYIEOJ	SN	Petrosamine; CHEMBL557422; NSC622171; AC1L7G6O
DMYIEOJ	DT	Small molecular drug
DMYIEOJ	PC	360199
DMYIEOJ	MW	458.7
DMYIEOJ	FM	C21H17BrClN3O2
DMYIEOJ	IC	InChI=1S/C21H17BrN3O2.ClH/c1-24-7-6-12-14(9-24)21(27)20-18-17(16(26)10-25(20,2)3)13-5-4-11(22)8-15(13)23-19(12)18;/h4-9H,10H2,1-3H3;1H/q+1;/p-1
DMYIEOJ	CS	CN1C=CC2=C3C4=C(C(=O)C2=C1)[N+](CC(=O)C4=C5C=CC(=CC5=N3)Br)(C)C.[Cl-]
DMYIEOJ	IK	YWXZSQALRCVSLY-UHFFFAOYSA-M
DMYIEOJ	IU	17-bromo-5,10,10-trimethyl-5,20-diaza-10-azoniapentacyclo[11.7.1.02,7.09,21.014,19]henicosa-1,3,6,9(21),13,15,17,19-octaene-8,12-dione;chloride
DMYIEOJ	DE	Discovery agent

DMR8ZBT	ID	DMR8ZBT
DMR8ZBT	DN	Petrosaspongiolide M
DMR8ZBT	HS	Investigative
DMR8ZBT	SN	petrosaspongiolide m; CHEMBL470339; SCHEMBL456053
DMR8ZBT	DT	Small molecular drug
DMR8ZBT	PC	17748437
DMR8ZBT	MW	460.6
DMR8ZBT	FM	C27H40O6
DMR8ZBT	IC	InChI=1S/C27H40O6/c1-15(28)31-24-16-7-8-21-26(4,12-9-20-25(2,3)10-6-11-27(20,21)5)18(16)14-19(32-24)17-13-22(29)33-23(17)30/h13,16,18-21,23-24,30H,6-12,14H2,1-5H3/t16-,18+,19+,20-,21-,23?,24+,26-,27-/m0/s1
DMR8ZBT	CS	CC(=O)O[C@H]1[C@H]2CC[C@@H]3[C@]4(CCCC([C@@H]4CC[C@]3([C@@H]2C[C@@H](O1)C5=CC(=O)OC5O)C)(C)C)C
DMR8ZBT	IK	RVWQZLJUVIFAOY-GQLPRRODSA-N
DMR8ZBT	IU	[(1S,3R,4aR,4bS,6aS,10aS,10bS,12aS)-3-(2-hydroxy-5-oxo-2H-furan-3-yl)-4b,7,7,10a-tetramethyl-1,3,4,4a,5,6,6a,8,9,10,10b,11,12,12a-tetradecahydronaphtho[2,1-f]isochromen-1-yl] acetate
DMR8ZBT	DE	Discovery agent

DMMVZFN	ID	DMMVZFN
DMMVZFN	DN	Petrosaspongiolide P
DMMVZFN	HS	Investigative
DMMVZFN	SN	Petrosaspongiolide P; CHEMBL470340
DMMVZFN	DT	Small molecular drug
DMMVZFN	PC	44575491
DMMVZFN	MW	418.6
DMMVZFN	FM	C25H38O5
DMMVZFN	IC	InChI=1S/C25H38O5/c1-23(2)9-5-10-25(4)18(23)8-11-24(3)16-13-17(15-12-20(26)30-22(15)28)29-21(27)14(16)6-7-19(24)25/h12,14,16-19,21-22,27-28H,5-11,13H2,1-4H3/t14-,16+,17+,18-,19-,21+,22?,24-,25-/m0/s1
DMMVZFN	CS	C[C@]12CCCC([C@@H]1CC[C@@]3([C@@H]2CC[C@H]4[C@H]3C[C@@H](O[C@H]4O)C5=CC(=O)OC5O)C)(C)C
DMMVZFN	IK	KBXIJAUSPXZGMP-IDONBMJRSA-N
DMMVZFN	IU	3-[(1R,3R,4aR,4bS,6aS,10aS,10bS,12aS)-1-hydroxy-4b,7,7,10a-tetramethyl-1,3,4,4a,5,6,6a,8,9,10,10b,11,12,12a-tetradecahydronaphtho[2,1-f]isochromen-3-yl]-2-hydroxy-2H-furan-5-one
DMMVZFN	DE	Discovery agent

DMY45K1	ID	DMY45K1
DMY45K1	DN	PF 5208766
DMY45K1	HS	Investigative
DMY45K1	SN	WAY-178357
DMY45K1	DE	Discovery agent

DMRHIMC	ID	DMRHIMC
DMRHIMC	DN	PF-00212062
DMRHIMC	HS	Investigative
DMRHIMC	SN	EP2 antagonists, Pfizer; PF-04852946
DMRHIMC	CP	Pfizer Inc
DMRHIMC	DT	Small molecular drug
DMRHIMC	PC	46213069
DMRHIMC	MW	456.5
DMRHIMC	FM	C27H24N2O5
DMRHIMC	IC	InChI=1S/C27H24N2O5/c1-33-23-10-8-22(9-11-23)25(30)29-15-14-27(17-29,26(31)32)18-34-24-12-6-21(7-13-24)20-4-2-19(16-28)3-5-20/h2-13H,14-15,17-18H2,1H3,(H,31,32)
DMRHIMC	CS	COC1=CC=C(C=C1)C(=O)N2CCC(C2)(COC3=CC=C(C=C3)C4=CC=C(C=C4)C#N)C(=O)O
DMRHIMC	IK	MDVYCLAYSVNYDS-UHFFFAOYSA-N
DMRHIMC	IU	3-[[4-(4-cyanophenyl)phenoxy]methyl]-1-(4-methoxybenzoyl)pyrrolidine-3-carboxylic acid
DMRHIMC	DE	Solid tumour/cancer

DMV43NF	ID	DMV43NF
DMV43NF	DN	PF-00356231
DMV43NF	HS	Investigative
DMV43NF	SN	PF-00356231; CHEMBL508461; (2R)-3-({[4-[(PYRIDIN-4-YL)PHENYL]-THIEN-2-YL}CARBOXAMIDO)(PHENYL)PROPANOIC ACID; 3-PHENYL-3-({[4-(4-PYRIDIN-4-YLPHENYL)THIEN-2-YL]CARBONYL}AMINO)PROPANOIC ACID; 1utz; AC1L9MIX; SCHEMBL8298104; MolPort-042-665-664; ZINC6744035; BDBM50264813; DB03367; NCGC00386512-01; (3R)-3-phenyl-3-({4-[4-(pyridin-4-yl)phenyl]thiophen-2-yl}formamido)propanoic acid; (3R)-3-phenyl-3-({[4-(4-pyridin-4-ylphenyl)thiophen-2-yl]carbonyl}amino)propanoic acid
DMV43NF	DT	Small molecular drug
DMV43NF	PC	448942
DMV43NF	MW	428.5
DMV43NF	FM	C25H20N2O3S
DMV43NF	IC	InChI=1S/C25H20N2O3S/c28-24(29)15-22(20-4-2-1-3-5-20)27-25(30)23-14-21(16-31-23)18-8-6-17(7-9-18)19-10-12-26-13-11-19/h1-14,16,22H,15H2,(H,27,30)(H,28,29)/t22-/m1/s1
DMV43NF	CS	C1=CC=C(C=C1)[C@@H](CC(=O)O)NC(=O)C2=CC(=CS2)C3=CC=C(C=C3)C4=CC=NC=C4
DMV43NF	IK	VMTJQZUZINLEKC-JOCHJYFZSA-N
DMV43NF	IU	(3R)-3-phenyl-3-[[4-(4-pyridin-4-ylphenyl)thiophene-2-carbonyl]amino]propanoic acid
DMV43NF	CA	CAS 766536-21-4
DMV43NF	DE	Discovery agent

DMWL9CU	ID	DMWL9CU
DMWL9CU	DN	PF-00614435
DMWL9CU	HS	Investigative
DMWL9CU	SN	PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer
DMWL9CU	CP	Pfizer Inc
DMWL9CU	DE	Solid tumour/cancer

DMZ5JNT	ID	DMZ5JNT
DMZ5JNT	DN	PF-02367982
DMZ5JNT	HS	Investigative
DMZ5JNT	SN	CHEMBL1083754; BDBM50318934
DMZ5JNT	DT	Small molecular drug
DMZ5JNT	PC	11964844
DMZ5JNT	MW	336.4
DMZ5JNT	FM	C19H20N4O2
DMZ5JNT	IC	InChI=1S/C19H20N4O2/c1-21-16(24)11-23-18(14-6-7-14)19(17(22-23)13-4-5-13)25-15-8-2-12(10-20)3-9-15/h2-3,8-9,13-14H,4-7,11H2,1H3,(H,21,24)
DMZ5JNT	CS	CNC(=O)CN1C(=C(C(=N1)C2CC2)OC3=CC=C(C=C3)C#N)C4CC4
DMZ5JNT	IK	PQGLAOODCQDRAR-UHFFFAOYSA-N
DMZ5JNT	IU	2-[4-(4-cyanophenoxy)-3,5-dicyclopropylpyrazol-1-yl]-N-methylacetamide
DMZ5JNT	CA	CAS 913344-84-0
DMZ5JNT	DE	Endometriosis

DMJ0936	ID	DMJ0936
DMJ0936	DN	PF-03772304
DMJ0936	HS	Investigative
DMJ0936	SN	MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth
DMJ0936	CP	Wyeth Research
DMJ0936	DE	Solid tumour/cancer

DM5NBVG	ID	DM5NBVG
DM5NBVG	DN	PF-03800130
DM5NBVG	HS	Investigative
DM5NBVG	SN	Dual dopamine D2 partial agonist/serotonin reuptake inhibitor (schizophrenia/bipolar disorder), Pfizer
DM5NBVG	CP	Pfizer Inc
DM5NBVG	DE	Bipolar disorder

DMMHQL4	ID	DMMHQL4
DMMHQL4	DN	PF-04475270
DMMHQL4	HS	Investigative
DMMHQL4	SN	EP4 agonist (glaucoma), Pfizer; Prostaglandin E receptor 4 (EP4) agonist (glaucoma) Pfizer; CP-734432-prodrug (glaucoma), Pfizer
DMMHQL4	CP	Pfizer Inc
DMMHQL4	DE	Glaucoma/ocular hypertension

DMPEZKT	ID	DMPEZKT
DMPEZKT	DN	PF-04957325
DMPEZKT	HS	Investigative
DMPEZKT	SN	GTPL9659; SCHEMBL17545207; ZINC165851270; AKOS032945026; CS-6185; HY-15426
DMPEZKT	PC	52938379
DMPEZKT	MW	400.38
DMPEZKT	FM	C14H15F3N8OS
DMPEZKT	IC	InChI=1S/C14H15F3N8OS/c15-14(16,17)13-20-11(18)10-12(21-13)25(23-22-10)6-8-5-24(2-3-26-8)7-9-19-1-4-27-9/h1,4,8H,2-3,5-7H2,(H2,18,20,21)/t8-/m1/s1
DMPEZKT	CS	C1CO[C@H](CN1CC2=NC=CS2)CN3C4=NC(=NC(=C4N=N3)N)C(F)(F)F
DMPEZKT	IK	VNLPYEMGHGDRRZ-MRVPVSSYSA-N
DMPEZKT	IU	3-[[(2R)-4-(1,3-thiazol-2-ylmethyl)morpholin-2-yl]methyl]-5-(trifluoromethyl)triazolo[4,5-d]pyrimidin-7-amine
DMPEZKT	DE	Itching; Inflammation

DMZAE97	ID	DMZAE97
DMZAE97	DN	PF-05094037
DMZAE97	HS	Investigative
DMZAE97	SN	PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer
DMZAE97	CP	Pfizer Inc
DMZAE97	DE	Solid tumour/cancer

DMOLI1E	ID	DMOLI1E
DMOLI1E	DN	PF-05313261
DMOLI1E	HS	Investigative
DMOLI1E	SN	IRAK4 inhibitors (inflammatory disease); PF-05320905; PF-05387252; PF-05387282; PF-05388169; IRAK4 inhibitors (inflammatory disease), Pfizer
DMOLI1E	CP	Pfizer Inc
DMOLI1E	DE	Inflammation

DMEUT0W	ID	DMEUT0W
DMEUT0W	DN	PF-06447475
DMEUT0W	HS	Investigative
DMEUT0W	SN	1527473-33-1; PF06447475; 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile; CHEMBL3393348; 3FE; GTPL8054; SCHEMBL15401353; EX-A560; AOB5482; BHTWDJBVZQBRKP-UHFFFAOYSA-N; MolPort-039-137-476; BCP14890; BDBM50059277; s8202; ZINC210747484; AKOS025404704; SB17260; CS-3553; NCGC00390733-02; BC600699; DA-44137; HY-12477; AK174244; QC-11808; FT-0700214; PF 06447475; PF-06447475, &gt; J-690197; 3-(4-morpholino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile
DMEUT0W	DT	Small molecular drug
DMEUT0W	PC	72706840
DMEUT0W	MW	305.33
DMEUT0W	FM	C17H15N5O
DMEUT0W	IC	InChI=1S/C17H15N5O/c18-9-12-2-1-3-13(8-12)14-10-19-16-15(14)17(21-11-20-16)22-4-6-23-7-5-22/h1-3,8,10-11H,4-7H2,(H,19,20,21)
DMEUT0W	CS	C1COCCN1C2=NC=NC3=C2C(=CN3)C4=CC=CC(=C4)C#N
DMEUT0W	IK	BHTWDJBVZQBRKP-UHFFFAOYSA-N
DMEUT0W	IU	3-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile
DMEUT0W	DE	Discovery agent

DMWIVM3	ID	DMWIVM3
DMWIVM3	DN	PF-06454589
DMWIVM3	HS	Investigative
DMWIVM3	SN	compound 28 [PMID: 25353650]
DMWIVM3	DT	Small molecular drug
DMWIVM3	PC	72706837
DMWIVM3	MW	284.32
DMWIVM3	FM	C14H16N6O
DMWIVM3	IC	InChI=1S/C14H16N6O/c1-19-8-10(6-18-19)11-7-15-13-12(11)14(17-9-16-13)20-2-4-21-5-3-20/h6-9H,2-5H2,1H3,(H,15,16,17)
DMWIVM3	CS	CN1C=C(C=N1)C2=CNC3=C2C(=NC=N3)N4CCOCC4
DMWIVM3	IK	VNWKCLDQBNSJJO-UHFFFAOYSA-N
DMWIVM3	IU	4-[5-(1-methylpyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine
DMWIVM3	DE	Discovery agent

DMBM7LU	ID	DMBM7LU
DMBM7LU	DN	PF-0998425
DMBM7LU	HS	Investigative
DMBM7LU	SN	PF-998425; 1076225-27-8; UNII-OY0E00K11M; PF 998425; OY0E00K11M; 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile; PF 0998425; 4-[(1R,2R)-2-hydroxycyclohexyl]-2-(trifluoromethyl)benzonitrile; arylcyclohexanol, (-)-6a; GTPL6698; CHEMBL458084; SCHEMBL16763727; BDBM25436; MolPort-023-276-993; MFCD17215970; ZINC40865778; AKOS024457876; SB19038; API0010282; NCGC00370969-01; KB-79880; PF0998425; FT-0673658; PF-998425, &gt; (R,R)-(-)-2-(4-Cyano-3-(trifluoromethyl)phenyl)cyclohexanol
DMBM7LU	DT	Small molecular drug
DMBM7LU	PC	25093231
DMBM7LU	MW	269.26
DMBM7LU	FM	C14H14F3NO
DMBM7LU	IC	InChI=1S/C14H14F3NO/c15-14(16,17)12-7-9(5-6-10(12)8-18)11-3-1-2-4-13(11)19/h5-7,11,13,19H,1-4H2/t11-,13-/m1/s1
DMBM7LU	CS	C1CC[C@H]([C@H](C1)C2=CC(=C(C=C2)C#N)C(F)(F)F)O
DMBM7LU	IK	MENRRRXHFQYXDW-DGCLKSJQSA-N
DMBM7LU	IU	4-[(1R,2R)-2-hydroxycyclohexyl]-2-(trifluoromethyl)benzonitrile
DMBM7LU	CA	CAS 1076225-27-8
DMBM7LU	DE	Discovery agent

DMJMU09	ID	DMJMU09
DMJMU09	DN	PF-18298
DMJMU09	HS	Investigative
DMJMU09	SN	PF-184298
DMJMU09	PC	11392888
DMJMU09	MW	315.2
DMJMU09	FM	C15H20Cl2N2O
DMJMU09	IC	InChI=1S/C15H20Cl2N2O/c1-10(2)9-19(11-6-7-18-8-11)15(20)12-4-3-5-13(16)14(12)17/h3-5,10-11,18H,6-9H2,1-2H3/t11-/m0/s1
DMJMU09	CS	CC(C)CN([C@H]1CCNC1)C(=O)C2=C(C(=CC=C2)Cl)Cl
DMJMU09	IK	PIKCALBGLDBAKK-NSHDSACASA-N
DMJMU09	IU	2,3-dichloro-N-(2-methylpropyl)-N-[(3S)-pyrrolidin-3-yl]benzamide
DMJMU09	CA	CAS 813447-40-4
DMJMU09	DE	Discovery agent

DM32FKD	ID	DM32FKD
DM32FKD	DN	PF-228
DM32FKD	HS	Investigative
DM32FKD	SN	869288-64-2; PF-573228; PF 573228; PF573228; PF-228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one
DM32FKD	DT	Small molecular drug
DM32FKD	PC	11612883
DM32FKD	MW	491.5
DM32FKD	FM	C22H20F3N5O3S
DM32FKD	IC	InChI=1S/C22H20F3N5O3S/c1-34(32,33)16-4-2-3-13(9-16)11-26-20-17(22(23,24)25)12-27-21(30-20)28-15-6-7-18-14(10-15)5-8-19(31)29-18/h2-4,6-7,9-10,12H,5,8,11H2,1H3,(H,29,31)(H2,26,27,28,30)
DM32FKD	CS	CS(=O)(=O)C1=CC=CC(=C1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)CC4
DM32FKD	IK	HESLKTSGTIBHJU-UHFFFAOYSA-N
DM32FKD	IU	6-[[4-[(3-methylsulfonylphenyl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-3,4-dihydro-1H-quinolin-2-one
DM32FKD	CA	CAS 869288-64-2
DM32FKD	CB	CHEBI:91446
DM32FKD	DE	Discovery agent

DMYSWAZ	ID	DMYSWAZ
DMYSWAZ	DN	PF-271836
DMYSWAZ	HS	Investigative
DMYSWAZ	SN	PF-2721374; PF-383965; PF-534422; PF-603059; UK-210587; UK-252820; UK-451402; Oxytocin antagonists (premature labor, prostatic hyperplasia, sexual dysfunction); Oxytocin antagonists (premature labor, prostatic hyperplasia, sexual dysfunction), Pfizer
DMYSWAZ	CP	Pfizer Inc
DMYSWAZ	DE	Female sexual arousal dysfunction

DMEZA0T	ID	DMEZA0T
DMEZA0T	DN	PF-3409409
DMEZA0T	HS	Investigative
DMEZA0T	SN	CHEMBL552338; PF-3409409; SCHEMBL5888234; BDBM50297077
DMEZA0T	DT	Small molecular drug
DMEZA0T	PC	44517677
DMEZA0T	MW	326.36
DMEZA0T	FM	C17H21F3N2O
DMEZA0T	IC	InChI=1S/C17H21F3N2O/c18-17(19,20)15-7-2-1-6-14(15)16(23)22(11-12-4-3-5-12)13-8-9-21-10-13/h1-2,6-7,12-13,21H,3-5,8-11H2/t13-/m0/s1
DMEZA0T	CS	C1CC(C1)CN([C@H]2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F
DMEZA0T	IK	SWADTMSKMJUFBO-ZDUSSCGKSA-N
DMEZA0T	IU	N-(cyclobutylmethyl)-N-[(3S)-pyrrolidin-3-yl]-2-(trifluoromethyl)benzamide
DMEZA0T	DE	Attention deficit hyperactivity disorder

DM6KVIA	ID	DM6KVIA
DM6KVIA	DN	PF-3644022
DM6KVIA	HS	Investigative
DM6KVIA	SN	PF3644022; PF 3644022
DM6KVIA	DT	Small molecular drug
DM6KVIA	PC	44631903
DM6KVIA	MW	374.5
DM6KVIA	FM	C21H18N4OS
DM6KVIA	IC	InChI=1S/C21H18N4OS/c1-11-3-4-13(10-22-11)15-6-5-14-16(25-15)7-8-17-18(14)19-20(27-17)21(26)24-12(2)9-23-19/h3-8,10,12,23H,9H2,1-2H3,(H,24,26)/t12-/m1/s1
DM6KVIA	CS	C[C@@H]1CNC2=C(C(=O)N1)SC3=C2C4=C(C=C3)N=C(C=C4)C5=CN=C(C=C5)C
DM6KVIA	IK	CMWRPDHVGMHLSZ-GFCCVEGCSA-N
DM6KVIA	IU	(15R)-15-methyl-5-(6-methylpyridin-3-yl)-11-thia-6,14,17-triazatetracyclo[8.8.0.02,7.012,18]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one
DM6KVIA	DE	Discovery agent

DMCRXAM	ID	DMCRXAM
DMCRXAM	DN	PF3845
DMCRXAM	HS	Investigative
DMCRXAM	SN	PF-3845; PF 3845
DMCRXAM	DT	Small molecular drug
DMCRXAM	PC	25154867
DMCRXAM	MW	456.5
DMCRXAM	FM	C24H23F3N4O2
DMCRXAM	IC	InChI=1S/C24H23F3N4O2/c25-24(26,27)19-6-7-22(29-15-19)33-21-5-1-3-18(14-21)13-17-8-11-31(12-9-17)23(32)30-20-4-2-10-28-16-20/h1-7,10,14-17H,8-9,11-13H2,(H,30,32)
DMCRXAM	CS	C1CN(CCC1CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=CN=CC=C4
DMCRXAM	IK	NBOJHRYUGLRASX-UHFFFAOYSA-N
DMCRXAM	IU	N-pyridin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide
DMCRXAM	CA	CAS 1196109-52-0
DMCRXAM	CB	CHEBI:95030
DMCRXAM	DE	Discovery agent

DM7E391	ID	DM7E391
DM7E391	DN	PF-3900422
DM7E391	HS	Investigative
DM7E391	SN	PF-03900422; Histamine H3 receptor antagonist (central nervous system disease), Pfizer
DM7E391	CP	Pfizer Inc
DM7E391	DE	Central nervous system disease

DMC8G4S	ID	DMC8G4S
DMC8G4S	DN	PF-4181366
DMC8G4S	HS	Investigative
DMC8G4S	SN	PDE9A inhibitor (cognitive deficit), Pfizer
DMC8G4S	CP	Pfizer Inc
DMC8G4S	DT	Small molecular drug
DMC8G4S	PC	135564899
DMC8G4S	MW	429.5
DMC8G4S	FM	C24H27N7O
DMC8G4S	IC	InChI=1S/C24H27N7O/c1-15-12-30(13-16-6-7-20-21(10-16)26-9-8-25-20)14-19(15)22-28-23-18(24(32)29-22)11-27-31(23)17-4-2-3-5-17/h6-11,15,17,19H,2-5,12-14H2,1H3,(H,28,29,32)/t15-,19-/m1/s1
DMC8G4S	CS	C[C@@H]1CN(C[C@H]1C2=NC3=C(C=NN3C4CCCC4)C(=O)N2)CC5=CC6=NC=CN=C6C=C5
DMC8G4S	IK	SNCRCEGCQVMUBS-DNVCBOLYSA-N
DMC8G4S	IU	1-cyclopentyl-6-[(3S,4S)-4-methyl-1-(quinoxalin-6-ylmethyl)pyrrolidin-3-yl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
DMC8G4S	CA	CAS 1082743-32-5
DMC8G4S	DE	Cognitive impairment

DMB0OZ3	ID	DMB0OZ3
DMB0OZ3	DN	PF-429242
DMB0OZ3	HS	Investigative
DMB0OZ3	SN	947303-87-9; PF-429242; (R)-4-((Diethylamino)methyl)-N-(2-methoxyphenethyl)-N-(pyrrolidin-3-yl)benzamide; UNII-49WB3OA7VN; 49WB3OA7VN; PF 429242; PF429242; CHEMBL233611; J-502224; C25H35N3O2; 4-[(Diethylamino)methyl]-N-[2-(2-methoxyphenyl)ethyl]-N-(3R)-3-pyrrolidinylbenzamide; (R)-4-((Diethylamino)methyl)-N-(2-methoxyphenethyl)-N-(pyrrolidin-3-yl)benz amide; (-)-PF-429242; SCHEMBL2742702; CTK8B5018; DTXSID00635376; EX-A1409; ANW-47048; ZINC28823615; BDBM50216181; AKOS015998619; RL05965; Benzamide, 4-((diethylamino)methyl)-N-(2-(
DMB0OZ3	DT	Small molecular drug
DMB0OZ3	PC	23661637
DMB0OZ3	MW	409.6
DMB0OZ3	FM	C25H35N3O2
DMB0OZ3	IC	InChI=1S/C25H35N3O2/c1-4-27(5-2)19-20-10-12-22(13-11-20)25(29)28(23-14-16-26-18-23)17-15-21-8-6-7-9-24(21)30-3/h6-13,23,26H,4-5,14-19H2,1-3H3/t23-/m1/s1
DMB0OZ3	CS	CCN(CC)CC1=CC=C(C=C1)C(=O)N(CCC2=CC=CC=C2OC)[C@@H]3CCNC3
DMB0OZ3	IK	XKPJTOHUPQWSOJ-HSZRJFAPSA-N
DMB0OZ3	IU	4-(diethylaminomethyl)-N-[2-(2-methoxyphenyl)ethyl]-N-[(3R)-pyrrolidin-3-yl]benzamide
DMB0OZ3	CA	CAS 947303-87-9
DMB0OZ3	DE	Discovery agent

DMMNEJB	ID	DMMNEJB
DMMNEJB	DN	PF-454583
DMMNEJB	HS	Investigative
DMMNEJB	SN	PF-4926965; Opioid receptor-like 1 (ORL1) antagonists (Alzheimer's disease), Pfizer
DMMNEJB	CP	Pfizer Inc
DMMNEJB	DT	Small molecular drug
DMMNEJB	PC	11690306
DMMNEJB	MW	420.9
DMMNEJB	FM	C21H26ClFN4O2
DMMNEJB	IC	InChI=1S/C21H26ClFN4O2/c1-25(2)20(28)16(12-27-13-17(22)10-24-27)11-26-7-5-21(6-8-26)19-9-18(23)4-3-15(19)14-29-21/h3-4,9-10,13,16H,5-8,11-12,14H2,1-2H3
DMMNEJB	CS	CN(C)C(=O)C(CN1CCC2(CC1)C3=C(CO2)C=CC(=C3)F)CN4C=C(C=N4)Cl
DMMNEJB	IK	BVXVLXUGXQOMEP-UHFFFAOYSA-N
DMMNEJB	IU	2-[(4-chloropyrazol-1-yl)methyl]-3-(5-fluorospiro[1H-2-benzofuran-3,4'-piperidine]-1'-yl)-N,N-dimethylpropanamide
DMMNEJB	DE	Major depressive disorder

DMI29ED	ID	DMI29ED
DMI29ED	DN	PF-4840154
DMI29ED	HS	Investigative
DMI29ED	SN	PF4840154; PF 4840154
DMI29ED	DT	Small molecular drug
DMI29ED	PC	53380803
DMI29ED	MW	466.6
DMI29ED	FM	C26H38N6O2
DMI29ED	IC	InChI=1S/C26H38N6O2/c1-20(2)15-27-24-23(25(33)28-16-21-7-4-3-5-8-21)17-29-26(30-24)32-12-10-31(11-13-32)18-22-9-6-14-34-19-22/h3-5,7-8,17,20,22H,6,9-16,18-19H2,1-2H3,(H,28,33)(H,27,29,30)
DMI29ED	CS	CC(C)CNC1=NC(=NC=C1C(=O)NCC2=CC=CC=C2)N3CCN(CC3)CC4CCCOC4
DMI29ED	IK	PPANZCQXFYBGHN-UHFFFAOYSA-N
DMI29ED	IU	N-benzyl-4-(2-methylpropylamino)-2-[4-(oxan-3-ylmethyl)piperazin-1-yl]pyrimidine-5-carboxamide
DMI29ED	DE	Discovery agent

DMV4P7S	ID	DMV4P7S
DMV4P7S	DN	PF-4957325-00
DMV4P7S	HS	Investigative
DMV4P7S	DE	Inflammation

DMSG6F1	ID	DMSG6F1
DMSG6F1	DN	PF-4989216
DMSG6F1	HS	Investigative
DMSG6F1	SN	PI3K inhibitor (cancer), Pfizer
DMSG6F1	CP	Pfizer Inc
DMSG6F1	PC	51033720
DMSG6F1	MW	380.4
DMSG6F1	FM	C18H13FN6OS
DMSG6F1	IC	InChI=1S/C18H13FN6OS/c19-14-7-11(8-20)1-2-12(14)15-13(9-21)18(25-3-5-26-6-4-25)27-16(15)17-22-10-23-24-17/h1-2,7,10H,3-6H2,(H,22,23,24)
DMSG6F1	CS	C1COCCN1C2=C(C(=C(S2)C3=NC=NN3)C4=C(C=C(C=C4)C#N)F)C#N
DMSG6F1	IK	MUENOTXSRZEFJV-UHFFFAOYSA-N
DMSG6F1	IU	4-(4-cyano-2-fluorophenyl)-2-morpholin-4-yl-5-(1H-1,2,4-triazol-5-yl)thiophene-3-carbonitrile
DMSG6F1	DE	Solid tumour/cancer

DMUOFT0	ID	DMUOFT0
DMUOFT0	DN	PF-5177624
DMUOFT0	HS	Investigative
DMUOFT0	SN	PF-05177624; 3-phosphoinositide-dependent kinase-1 inhibitor (cancer), Pfizer
DMUOFT0	CP	Pfizer Inc
DMUOFT0	DE	Solid tumour/cancer

DMD8QOZ	ID	DMD8QOZ
DMD8QOZ	DN	PF-526014
DMD8QOZ	HS	Investigative
DMD8QOZ	SN	CHEMBL403441; CHEMBL534723; PF-526014; BDBM50188098; (R)-1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine hydrochloride
DMD8QOZ	DT	Small molecular drug
DMD8QOZ	PC	16043230
DMD8QOZ	MW	310.4
DMD8QOZ	FM	C20H26N2O
DMD8QOZ	IC	InChI=1S/C20H26N2O/c1-2-23-20-11-7-6-10-18(20)16-19(17-8-4-3-5-9-17)22-14-12-21-13-15-22/h3-11,19,21H,2,12-16H2,1H3/t19-/m1/s1
DMD8QOZ	CS	CCOC1=CC=CC=C1C[C@H](C2=CC=CC=C2)N3CCNCC3
DMD8QOZ	IK	CVFBVSUFNWOPLD-LJQANCHMSA-N
DMD8QOZ	IU	1-[(1R)-2-(2-ethoxyphenyl)-1-phenylethyl]piperazine
DMD8QOZ	DE	Discovery agent

DMC4UHD	ID	DMC4UHD
DMC4UHD	DN	PF-543
DMC4UHD	HS	Investigative
DMC4UHD	SN	sphingosine kinase 1 Inhibitor II; PF 543
DMC4UHD	DT	Small molecular drug
DMC4UHD	PC	66577038
DMC4UHD	MW	465.6
DMC4UHD	FM	C27H31NO4S
DMC4UHD	IC	InChI=1S/C27H31NO4S/c1-21-14-24(20-33(30,31)27-7-3-2-4-8-27)16-26(15-21)32-19-23-11-9-22(10-12-23)17-28-13-5-6-25(28)18-29/h2-4,7-12,14-16,25,29H,5-6,13,17-20H2,1H3/t25-/m1/s1
DMC4UHD	CS	CC1=CC(=CC(=C1)OCC2=CC=C(C=C2)CN3CCC[C@@H]3CO)CS(=O)(=O)C4=CC=CC=C4
DMC4UHD	IK	NPUXORBZRBIOMQ-RUZDIDTESA-N
DMC4UHD	IU	[(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol
DMC4UHD	CA	CAS 1415562-82-1
DMC4UHD	CB	CHEBI:131144
DMC4UHD	DE	Discovery agent

DMY93GJ	ID	DMY93GJ
DMY93GJ	DN	PF-592379
DMY93GJ	HS	Investigative
DMY93GJ	SN	PF-592,379
DMY93GJ	DT	Small molecular drug
DMY93GJ	PC	10263487
DMY93GJ	MW	235.33
DMY93GJ	FM	C13H21N3O
DMY93GJ	IC	InChI=1S/C13H21N3O/c1-3-6-16-8-12(17-9-10(16)2)11-4-5-13(14)15-7-11/h4-5,7,10,12H,3,6,8-9H2,1-2H3,(H2,14,15)/t10-,12-/m0/s1
DMY93GJ	CS	CCCN1C[C@H](OC[C@@H]1C)C2=CN=C(C=C2)N
DMY93GJ	IK	DFTCYTDJDXZFSK-JQWIXIFHSA-N
DMY93GJ	IU	5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine
DMY93GJ	CA	CAS 710655-15-5
DMY93GJ	DE	Discovery agent

DMBE24Y	ID	DMBE24Y
DMBE24Y	DN	PF750
DMBE24Y	HS	Investigative
DMBE24Y	SN	PF-750; PF 750
DMBE24Y	DT	Small molecular drug
DMBE24Y	PC	25154868
DMBE24Y	MW	345.4
DMBE24Y	FM	C22H23N3O
DMBE24Y	IC	InChI=1S/C22H23N3O/c26-22(24-20-7-2-1-3-8-20)25-12-10-17(11-13-25)14-18-15-19-6-4-5-9-21(19)23-16-18/h1-9,15-17H,10-14H2,(H,24,26)
DMBE24Y	CS	C1CN(CCC1CC2=CC3=CC=CC=C3N=C2)C(=O)NC4=CC=CC=C4
DMBE24Y	IK	BIODYGOZWZNCAG-UHFFFAOYSA-N
DMBE24Y	IU	N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide
DMBE24Y	CA	CAS 959151-50-9
DMBE24Y	CB	CHEBI:95037
DMBE24Y	DE	Discovery agent

DM49MYE	ID	DM49MYE
DM49MYE	DN	PF-877423
DM49MYE	HS	Investigative
DM49MYE	SN	PF-877423; CHEMBL1095047; N-Adamantan-2-Yl-1-Ethyl-D-Prolinamide; SCHEMBL5157584; UJRJQNDIYCDCNX-BAPHQMLMSA-N; BDBM50317209; N-2-adamantyl-1-ethyl-D-prolinamide; (2R)-N-(adamantan-2-yl)-1-ethylpyrrolidine-2-carboxamide; (1S,2R)-N-(2-adamantyl)-1-ethyl-pyrrolidine-2-carboxamide; 1-ethyl-N-[(1R,3S,5R,7R)-tricyclo[3.3.1.1~3,7~]dec-2-yl]-D-prolinamide
DM49MYE	DT	Small molecular drug
DM49MYE	PC	11601544
DM49MYE	MW	276.4
DM49MYE	FM	C17H28N2O
DM49MYE	IC	InChI=1S/C17H28N2O/c1-2-19-5-3-4-15(19)17(20)18-16-13-7-11-6-12(9-13)10-14(16)8-11/h11-16H,2-10H2,1H3,(H,18,20)/t11?,12?,13?,14?,15-,16?/m1/s1
DM49MYE	CS	CCN1CCC[C@@H]1C(=O)NC2C3CC4CC(C3)CC2C4
DM49MYE	IK	UJRJQNDIYCDCNX-BAPHQMLMSA-N
DM49MYE	IU	(2R)-N-(2-adamantyl)-1-ethylpyrrolidine-2-carboxamide
DM49MYE	DE	Discovery agent

DMIUZSR	ID	DMIUZSR
DMIUZSR	DN	PF-956980
DMIUZSR	HS	Investigative
DMIUZSR	SN	Janus kinase 3 inhibitors (inflammation); JAK3 inhibitors (inflammation), Pfizer; Janus kinase 3 inhibitors (inflammation), Pfizer
DMIUZSR	CP	Pfizer Inc
DMIUZSR	DT	Small molecular drug
DMIUZSR	PC	53344620
DMIUZSR	MW	342.4
DMIUZSR	FM	C18H26N6O
DMIUZSR	IC	InChI=1S/C18H26N6O/c1-13-6-10-24(18(25)23-8-3-4-9-23)11-15(13)22(2)17-14-5-7-19-16(14)20-12-21-17/h5,7,12-13,15H,3-4,6,8-11H2,1-2H3,(H,19,20,21)/t13-,15+/m1/s1
DMIUZSR	CS	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)N4CCCC4
DMIUZSR	IK	RONMOMUOZGIDET-HIFRSBDPSA-N
DMIUZSR	IU	[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-pyrrolidin-1-ylmethanone
DMIUZSR	CB	CHEBI:144672
DMIUZSR	DE	Inflammation

DM9AZKE	ID	DM9AZKE
DM9AZKE	DN	PFFFFF
DM9AZKE	HS	Investigative
DM9AZKE	SN	CHEMBL246187
DM9AZKE	DT	Small molecular drug
DM9AZKE	PC	44440558
DM9AZKE	MW	851
DM9AZKE	FM	C50H54N6O7
DM9AZKE	IC	InChI=1S/C50H54N6O7/c57-45(39-27-16-28-51-39)52-40(29-34-17-6-1-7-18-34)46(58)53-41(30-35-19-8-2-9-20-35)47(59)54-42(31-36-21-10-3-11-22-36)48(60)55-43(32-37-23-12-4-13-24-37)49(61)56-44(50(62)63)33-38-25-14-5-15-26-38/h1-15,17-26,39-44,51H,16,27-33H2,(H,52,57)(H,53,58)(H,54,59)(H,55,60)(H,56,61)(H,62,63)/t39-,40-,41-,42-,43-,44-/m0/s1
DM9AZKE	CS	C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O
DM9AZKE	IK	GFXHQPYZLJKWEI-WGXSSYHUSA-N
DM9AZKE	IU	(2S)-3-phenyl-2-[[(2S)-3-phenyl-2-[[(2S)-3-phenyl-2-[[(2S)-3-phenyl-2-[[(2S)-3-phenyl-2-[[(2S)-pyrrolidine-2-carbonyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoic acid
DM9AZKE	DE	Discovery agent

DM9CV6S	ID	DM9CV6S
DM9CV6S	DN	p-F-HHSiD
DM9CV6S	HS	Investigative
DM9CV6S	SN	4-fluorohexahydrosiladifenidol; p-pluorohexahydrosiladyphenidol; pFHHSiD
DM9CV6S	DT	Small molecular drug
DM9CV6S	PC	3603
DM9CV6S	MW	349.6
DM9CV6S	FM	C20H32FNOSi
DM9CV6S	IC	InChI=1S/C20H32FNOSi/c21-18-10-12-20(13-11-18)24(23,19-8-3-1-4-9-19)17-7-16-22-14-5-2-6-15-22/h10-13,19,23H,1-9,14-17H2
DM9CV6S	CS	C1CCC(CC1)[Si](CCCN2CCCCC2)(C3=CC=C(C=C3)F)O
DM9CV6S	IK	ZNSZQJHTFRQUPD-UHFFFAOYSA-N
DM9CV6S	IU	cyclohexyl-(4-fluorophenyl)-hydroxy-(3-piperidin-1-ylpropyl)silane
DM9CV6S	CA	CAS 116679-83-5
DM9CV6S	DE	Discovery agent

DMVFK3J	ID	DMVFK3J
DMVFK3J	DN	PFI-1
DMVFK3J	HS	Investigative
DMVFK3J	SN	QCR-192; HY-16586; PF-6405761
DMVFK3J	DT	Small molecular drug
DMVFK3J	PC	71271629
DMVFK3J	MW	347.4
DMVFK3J	FM	C16H17N3O4S
DMVFK3J	IC	InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)
DMVFK3J	CS	CN1CC2=C(C=CC(=C2)NS(=O)(=O)C3=CC=CC=C3OC)NC1=O
DMVFK3J	IK	TXZPMHLMPKIUGK-UHFFFAOYSA-N
DMVFK3J	IU	2-methoxy-N-(3-methyl-2-oxo-1,4-dihydroquinazolin-6-yl)benzenesulfonamide
DMVFK3J	CA	CAS 1403764-72-6
DMVFK3J	CB	CHEBI:95079
DMVFK3J	DE	Discovery agent

DM619EU	ID	DM619EU
DM619EU	DN	PFI-3
DM619EU	HS	Investigative
DM619EU	SN	PFI 3; IN2080
DM619EU	DT	Small molecular drug
DM619EU	PC	78243717
DM619EU	MW	321.4
DM619EU	FM	C19H19N3O2
DM619EU	IC	InChI=1S/C19H19N3O2/c23-17-6-2-1-5-16(17)18(24)8-10-21-12-15-11-14(21)13-22(15)19-7-3-4-9-20-19/h1-10,14-15,23H,11-13H2/b10-8+/t14-,15-/m1/s1
DM619EU	CS	C1[C@@H]2CN([C@H]1CN2C3=CC=CC=N3)/C=C/C(=O)C4=CC=CC=C4O
DM619EU	IK	INAICWLVUAKEPB-QSTFCLMHSA-N
DM619EU	IU	(E)-1-(2-hydroxyphenyl)-3-[(1R,4R)-5-pyridin-2-yl-2,5-diazabicyclo[2.2.1]heptan-2-yl]prop-2-en-1-one
DM619EU	CB	CHEBI:149519
DM619EU	DE	Discovery agent

DMPKXNZ	ID	DMPKXNZ
DMPKXNZ	DN	PFI-4
DMPKXNZ	HS	Investigative
DMPKXNZ	SN	900305-37-5; PFI 4; CHEMBL3356143; N-[2,3-Dihydro-1,3-dimethyl-2-oxo-6-(1-pyrrolidinyl)-1H-benzimidazol-5-yl]-2-methoxybenzamide; N-(1,3-Dimethyl-2-oxo-6-(pyrrolidin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-2-methoxybenzamide; PFI4; GTPL8575; EX-A823; MolPort-004-921-423; BCP23818; ZINC6794685; BDBM50032927; s7906; STL436496; AKOS000482438; CS-4866; MCULE-9591292886; PFI-4, &gt; NCGC00476204-01; HY-18664; FT-0700502; N-(1,3-dimethyl-2-oxo-6-pyrrolidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide
DMPKXNZ	DT	Small molecular drug
DMPKXNZ	PC	40642506
DMPKXNZ	MW	380.4
DMPKXNZ	FM	C21H24N4O3
DMPKXNZ	IC	InChI=1S/C21H24N4O3/c1-23-17-12-15(22-20(26)14-8-4-5-9-19(14)28-3)16(25-10-6-7-11-25)13-18(17)24(2)21(23)27/h4-5,8-9,12-13H,6-7,10-11H2,1-3H3,(H,22,26)
DMPKXNZ	CS	CN1C2=C(C=C(C(=C2)NC(=O)C3=CC=CC=C3OC)N4CCCC4)N(C1=O)C
DMPKXNZ	IK	QCIJLRJBZDBVDB-UHFFFAOYSA-N
DMPKXNZ	IU	N-(1,3-dimethyl-2-oxo-6-pyrrolidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide
DMPKXNZ	DE	Discovery agent

DM2TP4Q	ID	DM2TP4Q
DM2TP4Q	DN	PG-01037
DM2TP4Q	HS	Investigative
DM2TP4Q	SN	PG-01037; PG01037; CHEMBL180010; PG 01037; GTPL6675; ZMYOIZHRXABMFZ-ONEGZZNKSA-N; BDBM50161214; ZINC52619107; NCGC00370952-01; L023518; N-[(E)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl]-4-pyridin-2-ylbenzamide; N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-enyl)-4-(pyridin-2-yl)benzamide; N-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-but-2-enyl}-4-pyridin-2-yl-benzamide
DM2TP4Q	DT	Small molecular drug
DM2TP4Q	PC	11477180
DM2TP4Q	MW	481.4
DM2TP4Q	FM	C26H26Cl2N4O
DM2TP4Q	IC	InChI=1S/C26H26Cl2N4O/c27-22-6-5-8-24(25(22)28)32-18-16-31(17-19-32)15-4-3-14-30-26(33)21-11-9-20(10-12-21)23-7-1-2-13-29-23/h1-13H,14-19H2,(H,30,33)/b4-3+
DM2TP4Q	CS	C1CN(CCN1C/C=C/CNC(=O)C2=CC=C(C=C2)C3=CC=CC=N3)C4=C(C(=CC=C4)Cl)Cl
DM2TP4Q	IK	ZMYOIZHRXABMFZ-ONEGZZNKSA-N
DM2TP4Q	IU	N-[(E)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl]-4-pyridin-2-ylbenzamide
DM2TP4Q	DE	Discovery agent

DMH4AKG	ID	DMH4AKG
DMH4AKG	DN	PG-1014491
DMH4AKG	HS	Investigative
DMH4AKG	SN	PG-1014493; Farnesyl pyrophosphate synthase (FPS) bisphosphonate inhibitors (bone disorders), Procter & Gamble
DMH4AKG	CP	The Procter & Gamble Co
DMH4AKG	DE	Bone disease

DMWP0BX	ID	DMWP0BX
DMWP0BX	DN	PG-120
DMWP0BX	HS	Investigative
DMWP0BX	SN	CD40 receptor agonist antibody (B-cell lymphoma), PanGenetics; CD40 receptor agonist antibody (B-cell mediated autoimmune disease), PanGenetics
DMWP0BX	CP	PanGenetics BV
DMWP0BX	DT	Antibody
DMWP0BX	DE	Autoimmune diabetes

DM0NBKR	ID	DM0NBKR
DM0NBKR	DN	PGC GLP-1
DM0NBKR	HS	Investigative
DM0NBKR	SN	PGC-HC/GLP-1; Glucagon-like peptide 1 (PGC, diabetes), PharmaIN
DM0NBKR	CP	PharmaIN Ltd
DM0NBKR	DE	Diabetic complication

DMYDW6J	ID	DMYDW6J
DMYDW6J	DN	PGD2
DMYDW6J	HS	Investigative
DMYDW6J	SN	Prostaglandin D2; prostaglandin D2; 11-Dehydroprostaglandin F2-alpha; 41598-07-6; BRN 2170623; UNII-RXY07S6CZ2; 11-Dehydroprostaglandin F2alpha; RXY07S6CZ2; CHEBI:15555; (5Z,13E,15S)-9alpha,15-Dihydroxy-11-oxoprosta-5,13-dienoate; (5Z,13E)-(15S)-9alpha,15-Dihydroxy-11-oxoprosta-5,13-dienoate; 9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoic acid; [3H]PGD2; (5E,13E)-9,15-DIHYDROXY-11-OXOPROSTA-5,13-DIEN-1-OIC ACID; Prosta-5,13-dien-1-oic acid, 9,15-dihydroxy-11-oxo-, (5Z,9-alpha,13E,15S)-;  11-dehydroprostaglandin F2-alpha
DMYDW6J	DT	Small molecular drug
DMYDW6J	PC	448457
DMYDW6J	MW	352.5
DMYDW6J	FM	C20H32O5
DMYDW6J	IC	InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-18,21-22H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-/m0/s1
DMYDW6J	CS	CCCCC[C@@H](/C=C/[C@@H]1[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O)O
DMYDW6J	IK	BHMBVRSPMRCCGG-OUTUXVNYSA-N
DMYDW6J	IU	(Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid
DMYDW6J	CA	CAS 41598-07-6
DMYDW6J	CB	CHEBI:15555
DMYDW6J	DE	Discovery agent

DMWNCLJ	ID	DMWNCLJ
DMWNCLJ	DN	PGD3
DMWNCLJ	HS	Investigative
DMWNCLJ	SN	GTPL1908; CTK2H7840; 71902-47-1; FT-0641375; Prosta-5,13,17-trien-1-oicacid, 9,15-dihydroxy-11-oxo-, (5Z,9a,13E,15S,17Z)-; 7-[(1R,2R,5S)-5-hydroxy-2-[(3S)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoic acid
DMWNCLJ	DT	Small molecular drug
DMWNCLJ	PC	5282260
DMWNCLJ	MW	350.4
DMWNCLJ	FM	C20H30O5
DMWNCLJ	IC	InChI=1S/C20H30O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h3-4,6-7,12-13,15-18,21-22H,2,5,8-11,14H2,1H3,(H,24,25)/b6-3-,7-4-,13-12+/t15-,16+,17+,18-/m0/s1
DMWNCLJ	CS	CC/C=C\\C[C@@H](/C=C/[C@@H]1[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O)O
DMWNCLJ	IK	ANOICLBSJIMQTA-WXGBOJPQSA-N
DMWNCLJ	IU	(Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dienyl]-3-oxocyclopentyl]hept-5-enoic acid
DMWNCLJ	CA	CAS 71902-47-1
DMWNCLJ	CB	CHEBI:34939
DMWNCLJ	DE	Discovery agent

DMNY187	ID	DMNY187
DMNY187	DN	P'-geranyl 2-fluoromevalonate 5-diphosphate
DMNY187	HS	Investigative
DMNY187	SN	P'-geranyl 2-fluoromevalonate 5-diphosphate; GTPL3207; 5-({[({[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)-2-fluoro-3-hydroxy-3-methylpentanoic acid
DMNY187	DT	Small molecular drug
DMNY187	PC	56947087
DMNY187	MW	462.34
DMNY187	FM	C16H29FO10P2
DMNY187	IC	InChI=1S/C16H29FO10P2/c1-12(2)6-5-7-13(3)8-10-25-28(21,22)27-29(23,24)26-11-9-16(4,20)14(17)15(18)19/h6,8,14,20H,5,7,9-11H2,1-4H3,(H,18,19)(H,21,22)(H,23,24)/b13-8+
DMNY187	CS	CC(=CCC/C(=C/COP(=O)(O)OP(=O)(O)OCCC(C)(C(C(=O)O)F)O)/C)C
DMNY187	IK	ACYPMTKDKJZHBJ-MDWZMJQESA-N
DMNY187	IU	5-[[[(2E)-3,7-dimethylocta-2,6-dienoxy]-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-fluoro-3-hydroxy-3-methylpentanoic acid
DMNY187	DE	Discovery agent

DMJ4SIA	ID	DMJ4SIA
DMJ4SIA	DN	P'-geranyl 3,5,7-trihydroxy-3-methylheptanate 7-diphosphate
DMJ4SIA	HS	Investigative
DMJ4SIA	SN	GTPL3208; P'-geranyl 3,5,7-trihydroxy-3-methylheptanate 7-diphosphate; 7-({[({[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)-3,5-dihydroxy-3-methylheptanoic acid
DMJ4SIA	DT	Small molecular drug
DMJ4SIA	PC	11658073
DMJ4SIA	MW	488.4
DMJ4SIA	FM	C18H34O11P2
DMJ4SIA	IC	InChI=1S/C18H34O11P2/c1-14(2)6-5-7-15(3)8-10-27-30(23,24)29-31(25,26)28-11-9-16(19)12-18(4,22)13-17(20)21/h6,8,16,19,22H,5,7,9-13H2,1-4H3,(H,20,21)(H,23,24)(H,25,26)/b15-8+
DMJ4SIA	CS	CC(=CCC/C(=C/COP(=O)(O)OP(=O)(O)OCCC(CC(C)(CC(=O)O)O)O)/C)C
DMJ4SIA	IK	WJXJJEWDRXZOEO-OVCLIPMQSA-N
DMJ4SIA	IU	7-[[[(2E)-3,7-dimethylocta-2,6-dienoxy]-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,5-dihydroxy-3-methylheptanoic acid
DMJ4SIA	DE	Discovery agent

DMO9BUR	ID	DMO9BUR
DMO9BUR	DN	P'-geranyl 3,5,8-trihydroxy-3-methyloctanate 8-diphosphate
DMO9BUR	HS	Investigative
DMO9BUR	SN	GTPL3210; P'-geranyl 3,5,8-trihydroxy-3-methyloctanate 8-diphosphate; 8-[[[(2E)-3,7-dimethylocta-2,6-dienoxy]-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,5-dihydroxy-3-methyloctanoic acid
DMO9BUR	DT	Small molecular drug
DMO9BUR	PC	11498992
DMO9BUR	MW	502.4
DMO9BUR	FM	C19H36O11P2
DMO9BUR	IC	InChI=1S/C19H36O11P2/c1-15(2)7-5-8-16(3)10-12-29-32(26,27)30-31(24,25)28-11-6-9-17(20)13-19(4,23)14-18(21)22/h7,10,17,20,23H,5-6,8-9,11-14H2,1-4H3,(H,21,22)(H,24,25)(H,26,27)/b16-10+
DMO9BUR	CS	CC(=CCC/C(=C/COP(=O)(O)OP(=O)(O)OCCCC(CC(C)(CC(=O)O)O)O)/C)C
DMO9BUR	IK	FPMYZHYONYFBNX-MHWRWJLKSA-N
DMO9BUR	IU	8-[[[(2E)-3,7-dimethylocta-2,6-dienoxy]-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,5-dihydroxy-3-methyloctanoic acid
DMO9BUR	DE	Discovery agent

DM2395E	ID	DM2395E
DM2395E	DN	P'-geranyl 3,5,9-trihydroxy-3-methylnonanate 9-diphosphate
DM2395E	HS	Investigative
DM2395E	SN	GTPL5621; P'-geranyl 3,5,9-trihydroxy-3-methylnonanate 9-diphosphate; 9-[[[(2E)-3,7-dimethylocta-2,6-dienoxy]-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,5-dihydroxy-3-methylnonanoic acid
DM2395E	DT	Small molecular drug
DM2395E	PC	11650985
DM2395E	MW	516.5
DM2395E	FM	C20H38O11P2
DM2395E	IC	InChI=1S/C20H38O11P2/c1-16(2)8-7-9-17(3)11-13-30-33(27,28)31-32(25,26)29-12-6-5-10-18(21)14-20(4,24)15-19(22)23/h8,11,18,21,24H,5-7,9-10,12-15H2,1-4H3,(H,22,23)(H,25,26)(H,27,28)/b17-11+
DM2395E	CS	CC(=CCC/C(=C/COP(=O)(O)OP(=O)(O)OCCCCC(CC(C)(CC(=O)O)O)O)/C)C
DM2395E	IK	PMUQIJKCGIYWGT-GZTJUZNOSA-N
DM2395E	IU	9-[[[(2E)-3,7-dimethylocta-2,6-dienoxy]-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,5-dihydroxy-3-methylnonanoic acid
DM2395E	DE	Discovery agent

DMUPWQT	ID	DMUPWQT
DMUPWQT	DN	PGF1alpha
DMUPWQT	HS	Investigative
DMUPWQT	SN	U 18714; prostaglandin F1alpha
DMUPWQT	DT	Small molecular drug
DMUPWQT	PC	5280939
DMUPWQT	MW	356.5
DMUPWQT	FM	C20H36O5
DMUPWQT	IC	InChI=1S/C20H36O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-19,21-23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,18-,19+/m0/s1
DMUPWQT	CS	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1CCCCCCC(=O)O)O)O)O
DMUPWQT	IK	DZUXGQBLFALXCR-CDIPTNKSSA-N
DMUPWQT	IU	7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]heptanoic acid
DMUPWQT	CA	CAS 745-62-0
DMUPWQT	CB	CHEBI:28852
DMUPWQT	DE	Discovery agent

DMZFVGC	ID	DMZFVGC
DMZFVGC	DN	PGH2
DMZFVGC	HS	Investigative
DMZFVGC	SN	Prostaglandin h2; prostaglandin h2; 9,11-Epoxymethano-pgh2; Endoperoxide H2; Prostaglandin R2; 42935-17-1; UNII-J670X3LRU2; prostaglandin-H2; J670X3LRU2; CHEBI:15554; 9S,11R-epidioxy-15S-hydroxy-5Z,13E-prostadienoic acid; (15S)Hydroxy-9alpha,11alpha-(epoxymethano)prosta-5,13-dienoic acid; 15-Hydroxy-9alpha,11alpha-peroxidoprosta-5,13-dienoic acid; (5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate; (5Z,13E)-(15S)-9alpha,11alpha-Epidioxy-15-hydroxyprosta-5,13-dienoate;  prostaglandin H2; U46609
DMZFVGC	DT	Small molecular drug
DMZFVGC	PC	445049
DMZFVGC	MW	352.5
DMZFVGC	FM	C20H32O5
DMZFVGC	IC	InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18-14-19(17)25-24-18)10-7-4-5-8-11-20(22)23/h4,7,12-13,15-19,21H,2-3,5-6,8-11,14H2,1H3,(H,22,23)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
DMZFVGC	CS	CCCCC[C@@H](/C=C/[C@H]1[C@H]2C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)OO2)O
DMZFVGC	IK	YIBNHAJFJUQSRA-YNNPMVKQSA-N
DMZFVGC	IU	(Z)-7-[(1R,4S,5R,6R)-6-[(E,3S)-3-hydroxyoct-1-enyl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
DMZFVGC	CA	CAS 42935-17-1
DMZFVGC	CB	CHEBI:15554
DMZFVGC	DE	Discovery agent

DMTVY6K	ID	DMTVY6K
DMTVY6K	DN	PGI-02749
DMTVY6K	HS	Investigative
DMTVY6K	SN	PGI-02776; ZJ-11; ZJ-17; ZJ-43; NAAG peptidase inhibitors (brain injury, schizophrenia, pain); GCPII inhibitors (brain injury, schizophrenia, pain), PsychoGenics; Glutamate carboxypeptidase II inhibitors (brain injury, schizophrenia, pain), PsychoGenics; NAAG peptidase inhibitors (brain injury, schizophrenia, pain), PsychoGenics; N-acetylaspartylglutamate peptidase inhibitors (brain injury, schizophrenia, pain), PsychoGenics
DMTVY6K	CP	Acenta Discovery
DMTVY6K	DE	Brain injury

DMR2LTC	ID	DMR2LTC
DMR2LTC	DN	PGJ2
DMR2LTC	HS	Investigative
DMR2LTC	SN	9-deoxy-delta-9-prostaglandin D2; prostaglandin J2
DMR2LTC	DT	Small molecular drug
DMR2LTC	PC	5280884
DMR2LTC	MW	334.4
DMR2LTC	FM	C20H30O4
DMR2LTC	IC	InChI=1S/C20H30O4/c1-2-3-6-10-17(21)13-14-18-16(12-15-19(18)22)9-7-4-5-8-11-20(23)24/h4,7,12-18,21H,2-3,5-6,8-11H2,1H3,(H,23,24)/b7-4-,14-13+/t16-,17-,18+/m0/s1
DMR2LTC	CS	CCCCC[C@@H](/C=C/[C@@H]1[C@H](C=CC1=O)C/C=C\\CCCC(=O)O)O
DMR2LTC	IK	UQOQENZZLBSFKO-POPPZSFYSA-N
DMR2LTC	IU	(Z)-7-[(1S,5R)-5-[(E,3S)-3-hydroxyoct-1-enyl]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
DMR2LTC	CA	CAS 60203-57-8
DMR2LTC	CB	CHEBI:27485
DMR2LTC	DE	Discovery agent

DMLMTIY	ID	DMLMTIY
DMLMTIY	DN	PGlu-His-Trp-Ser-His-D-Tyr-Leu-Arg-Pro-Gly-NH2
DMLMTIY	HS	Investigative
DMLMTIY	SN	CHEMBL436874; pGlu-His-Trp-Ser-His-D-Tyr-Leu-Arg-Pro-Gly-NH2; BDBM50180786
DMLMTIY	PC	9833530
DMLMTIY	MW	1201.3
DMLMTIY	FM	C55H76N16O15
DMLMTIY	IC	InChI=1S/C55H76N16O15/c1-29(2)19-38(49(81)66-37(9-5-17-60-55(57)58)54(86)71-18-6-10-43(71)53(85)63-26-46(77)78)65-44(74)25-62-48(80)39(20-30-11-13-33(73)14-12-30)68-52(84)42(27-72)70-50(82)40(21-31-23-61-36-8-4-3-7-34(31)36)69-51(83)41(22-32-24-59-28-64-32)67-47(79)35(56)15-16-45(75)76/h3-4,7-8,11-14,23-24,28-29,35,37-43,61,72-73H,5-6,9-10,15-22,25-27,56H2,1-2H3,(H,59,64)(H,62,80)(H,63,85)(H,65,74)(H,66,81)(H,67,79)(H,68,84)(H,69,83)(H,70,82)(H,75,76)(H,77,78)(H4,57,58,60)/t35-,37-,38-,39-,40-,41-,42-,43-/m0/s1
DMLMTIY	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)N
DMLMTIY	IK	HLUQDWRHBPWVNT-LVHVEONVSA-N
DMLMTIY	IU	(4S)-4-amino-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-(carboxymethylcarbamoyl)pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMLMTIY	DE	Discovery agent

DM40PT5	ID	DM40PT5
DM40PT5	DN	PGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
DM40PT5	HS	Investigative
DM40PT5	DE	Discovery agent

DM5GY6Z	ID	DM5GY6Z
DM5GY6Z	DN	PH-709829
DM5GY6Z	HS	Investigative
DM5GY6Z	SN	PTGWFYYEAUFEAS-ZYHUDNBSSA-N; CHEMBL403858; PHA-709829; SCHEMBL844377; GTPL3997; BDBM50377050
DM5GY6Z	DT	Small molecular drug
DM5GY6Z	PC	10107234
DM5GY6Z	MW	271.31
DM5GY6Z	FM	C15H17N3O2
DM5GY6Z	IC	InChI=1S/C15H17N3O2/c19-15(13-6-11-2-4-20-14(11)7-16-13)17-12-5-10-1-3-18(8-10)9-12/h2,4,6-7,10,12H,1,3,5,8-9H2,(H,17,19)/t10-,12-/m1/s1
DM5GY6Z	CS	C1CN2C[C@H]1C[C@H](C2)NC(=O)C3=NC=C4C(=C3)C=CO4
DM5GY6Z	IK	PTGWFYYEAUFEAS-ZYHUDNBSSA-N
DM5GY6Z	IU	N-[(3R,5R)-1-azabicyclo[3.2.1]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide
DM5GY6Z	CA	CAS 508202-22-0
DM5GY6Z	DE	Discovery agent

DMCGX9U	ID	DMCGX9U
DMCGX9U	DN	PHA-665752
DMCGX9U	HS	Investigative
DMCGX9U	SN	PHA-665752; 477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate
DMCGX9U	CP	Pfizer Inc
DMCGX9U	DT	Small molecular drug
DMCGX9U	PC	10461815
DMCGX9U	MW	641.6
DMCGX9U	FM	C32H34Cl2N4O4S
DMCGX9U	IC	InChI=1S/C32H34Cl2N4O4S/c1-19-29(35-20(2)30(19)32(40)38-14-6-7-21(38)17-37-12-3-4-13-37)16-24-23-15-22(10-11-28(23)36-31(24)39)43(41,42)18-25-26(33)8-5-9-27(25)34/h5,8-11,15-16,21,35H,3-4,6-7,12-14,17-18H2,1-2H3,(H,36,39)/b24-16-/t21-/m1/s1
DMCGX9U	CS	CC1=C(NC(=C1C(=O)N2CCC[C@@H]2CN3CCCC3)C)/C=C\\4/C5=C(C=CC(=C5)S(=O)(=O)CC6=C(C=CC=C6Cl)Cl)NC4=O
DMCGX9U	IK	OYONTEXKYJZFHA-SSHUPFPWSA-N
DMCGX9U	IU	(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one
DMCGX9U	CA	CAS 477575-56-7
DMCGX9U	CB	CHEBI:90197
DMCGX9U	DE	Solid tumour/cancer

DMHQ6KT	ID	DMHQ6KT
DMHQ6KT	DN	PHA-666859
DMHQ6KT	HS	Investigative
DMHQ6KT	SN	SC-409; SD-0006; P38-alpha kinase inhibitor (inflammation/diabetic retinopathy); P38-alpha kinase inhibitor (inflammation/diabetic retinopathy), Pfizer
DMHQ6KT	CP	Pfizer Inc
DMHQ6KT	DE	Diabetic retinopathy

DMNS70E	ID	DMNS70E
DMNS70E	DN	PHA-690509
DMNS70E	HS	Investigative
DMNS70E	SN	PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia
DMNS70E	CP	Pharmacia Inc
DMNS70E	DT	Small molecular drug
DMNS70E	PC	9902100
DMNS70E	MW	331.4
DMNS70E	FM	C17H21N3O2S
DMNS70E	IC	InChI=1S/C17H21N3O2S/c1-10(2)15-9-18-17(23-15)20-16(22)11(3)13-5-7-14(8-6-13)19-12(4)21/h5-11H,1-4H3,(H,19,21)(H,18,20,22)/t11-/m0/s1
DMNS70E	CS	C[C@@H](C1=CC=C(C=C1)NC(=O)C)C(=O)NC2=NC=C(S2)C(C)C
DMNS70E	IK	NFSKEXQRNDSSAN-NSHDSACASA-N
DMNS70E	IU	(2S)-2-(4-acetamidophenyl)-N-(5-propan-2-yl-1,3-thiazol-2-yl)propanamide
DMNS70E	DE	Solid tumour/cancer

DM4H7D5	ID	DM4H7D5
DM4H7D5	DN	PHA-767491
DM4H7D5	HS	Investigative
DM4H7D5	SN	PHA-767491; 845714-00-3; PHA 767491; CAY10572(PHA-767491); PHA-767491 (CAY10572); 2-Pyridin-4-yl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one; 1,5,6,7-Tetrahydro-2-(4-pyridinyl)-4H-pyrrolo[3,2-c]pyridin-4-one; Pyrrolopyridinone, 1; Cdc7/Cdk9 Inhibitor; Kinome_2973; JMC502647 Compound 8; MLS006011036; SCHEMBL4767679; GTPL8763; CHEMBL225519; CTK8F8505; CHEBI:95058; BDBM27344; DTXSID50471069; MolPort-009-019-436; HMS3656P19; HMS3229B21; BCP02855; PHA-767491A; PHA767491; ZINC16052718; s2742; 2651AH; AKOS026674124; SB19465; CS-1208
DM4H7D5	DT	Small molecular drug
DM4H7D5	PC	11715767
DM4H7D5	MW	213.23
DM4H7D5	FM	C12H11N3O
DM4H7D5	IC	InChI=1S/C12H11N3O/c16-12-9-7-11(8-1-4-13-5-2-8)15-10(9)3-6-14-12/h1-2,4-5,7,15H,3,6H2,(H,14,16)
DM4H7D5	CS	C1CNC(=O)C2=C1NC(=C2)C3=CC=NC=C3
DM4H7D5	IK	DKXHSOUZPMHNIZ-UHFFFAOYSA-N
DM4H7D5	IU	2-pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one
DM4H7D5	CA	CAS 845714-00-3
DM4H7D5	CB	CHEBI:95058
DM4H7D5	DE	Discovery agent

DMALRCH	ID	DMALRCH
DMALRCH	DN	Phaclofen
DMALRCH	HS	Investigative
DMALRCH	SN	Phaclofen; 114012-12-3; [3-amino-2-(4-chlorophenyl)propyl]phosphonic acid; (3-Amino-2-(4-chlorophenyl)propyl)phosphonic acid; Phosphonic acid, (3-amino-2-(4-chlorophenyl)propyl)-; 3-Amino-2-(4-chlorophenyl)propylphosphonic acid; 3-Amino-2-(4-chlorophenyl) propylphosphonic acid; Phosphonic acid,P-[3-amino-2-(4-chlorophenyl)propyl]-; SR-01000075640; Phaclofen, solid; beta-(4-Chlorophenyl)-3-aminopropylphosphonic acid; ACMC-20djlx; 108351-35-5; AC1Q3NDJ; AC1L1BWO; Biomol-NT_000256; Lopac0_000967; SCHEMBL339995; GTPL1091
DMALRCH	DT	Small molecular drug
DMALRCH	PC	1641
DMALRCH	MW	249.63
DMALRCH	FM	C9H13ClNO3P
DMALRCH	IC	InChI=1S/C9H13ClNO3P/c10-9-3-1-7(2-4-9)8(5-11)6-15(12,13)14/h1-4,8H,5-6,11H2,(H2,12,13,14)
DMALRCH	CS	C1=CC(=CC=C1C(CN)CP(=O)(O)O)Cl
DMALRCH	IK	VSGNGLJPOGUDON-UHFFFAOYSA-N
DMALRCH	IU	[3-amino-2-(4-chlorophenyl)propyl]phosphonic acid
DMALRCH	CA	CAS 114012-12-3
DMALRCH	DE	Discovery agent

DM7H5KY	ID	DM7H5KY
DM7H5KY	DN	PHASEOLIN
DM7H5KY	HS	Investigative
DM7H5KY	SN	Phaseollin; Phaseolin; 13401-40-6; (-)-Phaseollin; UNII-8OHL7771FZ; CHEMBL448350; 8OHL7771FZ; Phaseolin fungicide; (+/-)-Phaseollin; Phaseolin (pterocarpan); Phaseollin, (+/-); AC1L3MCD; AC1Q70VD; SCHEMBL33736; ZINC899892; BDBM50317438; LMPK12070020; AKOS032948435; 3h,7h-furo(3,2-c:5,4-f')bis(1)benzopyran-10-ol, 6b,12b-dihydro-3,3-dimethyl-,(6br-cis)-; C10514; 401P406; UNII-I7OEP19ZWL component LWTDZKXXJRRKDG-KXBFYZLASA-N; 3H,7H-Furo(3,2-c:5,4-f')bis(1)benzopyran-10-ol, 6b,12b-dihydro-3,3-dimethyl-, cis-
DM7H5KY	DT	Small molecular drug
DM7H5KY	PC	91572
DM7H5KY	MW	322.4
DM7H5KY	FM	C20H18O4
DM7H5KY	IC	InChI=1S/C20H18O4/c1-20(2)8-7-14-16(24-20)6-5-12-15-10-22-17-9-11(21)3-4-13(17)19(15)23-18(12)14/h3-9,15,19,21H,10H2,1-2H3/t15-,19-/m0/s1
DM7H5KY	CS	CC1(C=CC2=C(O1)C=CC3=C2O[C@@H]4[C@H]3COC5=C4C=CC(=C5)O)C
DM7H5KY	IK	LWTDZKXXJRRKDG-KXBFYZLASA-N
DM7H5KY	IU	(2R,11R)-17,17-dimethyl-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),15,20-heptaen-7-ol
DM7H5KY	CA	CAS 13401-40-6
DM7H5KY	DE	Discovery agent

DMSQ10I	ID	DMSQ10I
DMSQ10I	DN	PHASEOLLIDIN
DMSQ10I	HS	Investigative
DMSQ10I	SN	Phaseollidin; 37831-70-2; (-)-Phaseollidin; Phaseolidin; CHEMBL508534; CHEBI:17556; AC1L3OI5; AC1Q70TS; SCHEMBL1545850; DTXSID50191270; MolPort-023-298-969; ZINC895662; LMPK12070011; BDBM50311583; AKOS032948450; 6h-benzofuro(3,2-c)(1)benzopyran-3,9-diol, 6a,11a-dihydro-10-(3-methyl-2-butenyl)-,(6ar-cis)-; 4CN-1496; W2071; C05230; 6H-Benzofuro(3,2-c)(1)benzopyran-3,9-diol, 6a,11a-dihydro-10-(3-methyl-2-butenyl)-, (6aR,11aR)-; 6H-Benzofuro[3,2-c][1]benzopyran-3,9-diol,6a,11a-dihydro-10-(3-methyl-2-buten-1-yl)-, (6aR,11aR)-
DMSQ10I	DT	Small molecular drug
DMSQ10I	PC	119268
DMSQ10I	MW	324.4
DMSQ10I	FM	C20H20O4
DMSQ10I	IC	InChI=1S/C20H20O4/c1-11(2)3-5-14-17(22)8-7-13-16-10-23-18-9-12(21)4-6-15(18)20(16)24-19(13)14/h3-4,6-9,16,20-22H,5,10H2,1-2H3/t16-,20-/m0/s1
DMSQ10I	CS	CC(=CCC1=C(C=CC2=C1O[C@@H]3[C@H]2COC4=C3C=CC(=C4)O)O)C
DMSQ10I	IK	OFWYIUYVHYPQNX-JXFKEZNVSA-N
DMSQ10I	IU	(6aR,11aR)-10-(3-methylbut-2-enyl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMSQ10I	CA	CAS 37831-70-2
DMSQ10I	CB	CHEBI:17556
DMSQ10I	DE	Discovery agent

DMNJY79	ID	DMNJY79
DMNJY79	DN	PHCCC
DMNJY79	HS	Investigative
DMNJY79	SN	(-) PHCCC
DMNJY79	DT	Small molecular drug
DMNJY79	PC	5866327
DMNJY79	MW	294.3
DMNJY79	FM	C17H14N2O3
DMNJY79	IC	InChI=1S/C17H14N2O3/c20-16(18-11-6-2-1-3-7-11)17-10-13(17)15(19-21)12-8-4-5-9-14(12)22-17/h1-9,13,21H,10H2,(H,18,20)/b19-15-
DMNJY79	CS	C1C\\2C1(OC3=CC=CC=C3/C2=N/O)C(=O)NC4=CC=CC=C4
DMNJY79	IK	FPXPIEZPAXSELW-CYVLTUHYSA-N
DMNJY79	IU	(7E)-7-hydroxyimino-N-phenyl-1,7a-dihydrocyclopropa[b]chromene-1a-carboxamide
DMNJY79	CB	CHEBI:91731
DMNJY79	DE	Discovery agent

DMAP04X	ID	DMAP04X
DMAP04X	DN	PHELLIGRIDIN I
DMAP04X	HS	Investigative
DMAP04X	SN	PHELLIGRIDIN I; CHEMBL221760; BDBM50204574; 8,9-dihydroxy-3-{6,7-dihydroxy-4-(hispidin-3-yl)styryl}pyrano[4,3-c]isochromen-4-one
DMAP04X	DT	Small molecular drug
DMAP04X	PC	54689623
DMAP04X	MW	624.5
DMAP04X	FM	C33H20O13
DMAP04X	IC	InChI=1S/C33H20O13/c34-21-6-2-14(7-22(21)35)1-4-16-9-27(40)29(32(42)44-16)18-11-24(37)23(36)8-15(18)3-5-17-10-28-30(33(43)45-17)19-12-25(38)26(39)13-20(19)31(41)46-28/h1-13,34-40H/b4-1+,5-3+
DMAP04X	CS	C1=CC(=C(C=C1/C=C/C2=CC(=C(C(=O)O2)C3=CC(=C(C=C3/C=C/C4=CC5=C(C6=CC(=C(C=C6C(=O)O5)O)O)C(=O)O4)O)O)O)O)O
DMAP04X	IK	ZNLSHKJBXWCRKW-CLLRDSTBSA-N
DMAP04X	IU	3-[(E)-2-[2-[6-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxy-2-oxopyran-3-yl]-4,5-dihydroxyphenyl]ethenyl]-8,9-dihydroxypyrano[4,3-c]isochromene-1,6-dione
DMAP04X	DE	Discovery agent

DMJLUFM	ID	DMJLUFM
DMJLUFM	DN	phenamil
DMJLUFM	HS	Investigative
DMJLUFM	DT	Small molecular drug
DMJLUFM	PC	135403792
DMJLUFM	MW	305.72
DMJLUFM	FM	C12H12ClN7O
DMJLUFM	IC	InChI=1S/C12H12ClN7O/c13-8-10(15)19-9(14)7(18-8)11(21)20-12(16)17-6-4-2-1-3-5-6/h1-5H,(H4,14,15,19)(H3,16,17,20,21)
DMJLUFM	CS	C1=CC=C(C=C1)N=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N
DMJLUFM	IK	NIOHELZQFBGCEO-UHFFFAOYSA-N
DMJLUFM	IU	3,5-diamino-6-chloro-N-(N'-phenylcarbamimidoyl)pyrazine-2-carboxamide
DMJLUFM	CA	CAS 2038-35-9
DMJLUFM	CB	CHEBI:34919
DMJLUFM	DE	Discovery agent

DMYT8UG	ID	DMYT8UG
DMYT8UG	DN	Phenanthrene-2-carboxylic acid hydroxyamide
DMYT8UG	HS	Investigative
DMYT8UG	SN	Phenanthrene-2-carboxylic acid hydroxyamide; CHEMBL176285; SCHEMBL10361604; Phenanthrene-2-carbohydroximic acid; BDBM50015185
DMYT8UG	DT	Small molecular drug
DMYT8UG	PC	20227317
DMYT8UG	MW	237.25
DMYT8UG	FM	C15H11NO2
DMYT8UG	IC	InChI=1S/C15H11NO2/c17-15(16-18)12-7-8-14-11(9-12)6-5-10-3-1-2-4-13(10)14/h1-9,18H,(H,16,17)
DMYT8UG	CS	C1=CC=C2C(=C1)C=CC3=C2C=CC(=C3)C(=O)NO
DMYT8UG	IK	ADTGPCGDULHFEP-UHFFFAOYSA-N
DMYT8UG	IU	N-hydroxyphenanthrene-2-carboxamide
DMYT8UG	DE	Discovery agent

DMRYJBA	ID	DMRYJBA
DMRYJBA	DN	Phenanthrene-3-carboxylic acid hydroxyamide
DMRYJBA	HS	Investigative
DMRYJBA	SN	Phenanthrene-3-carboxylic acid hydroxyamide; CHEMBL367306; SCHEMBL10362071; Phenanthrene-3-carbohydroximic acid; ZINC28105728
DMRYJBA	DT	Small molecular drug
DMRYJBA	PC	44387129
DMRYJBA	MW	237.25
DMRYJBA	FM	C15H11NO2
DMRYJBA	IC	InChI=1S/C15H11NO2/c17-15(16-18)12-8-7-11-6-5-10-3-1-2-4-13(10)14(11)9-12/h1-9,18H,(H,16,17)
DMRYJBA	CS	C1=CC=C2C(=C1)C=CC3=C2C=C(C=C3)C(=O)NO
DMRYJBA	IK	NDIZNAOCRKZKMN-UHFFFAOYSA-N
DMRYJBA	IU	N-hydroxyphenanthrene-3-carboxamide
DMRYJBA	DE	Discovery agent

DMG8KS9	ID	DMG8KS9
DMG8KS9	DN	Phenanthrene-9,10-dione
DMG8KS9	HS	Investigative
DMG8KS9	SN	Phenanthrene-9,10-dione; 9,10-Phenanthrenequinone; 84-11-7; Phenanthrenequinone; 9,10-PHENANTHRENEDIONE; 9,10-Phenanthraquinone; Phenanthraquinone; 9,10-Phenanthroquinone; 9-10 Phenanthrene quinone; UNII-42L7BZ8H74; CCRIS 7615; Phenanthrene, 9,10-dihydro-9,10-dioxo-; HSDB 4489; EINECS 201-515-5; NSC 10446; phenanthrene-9,10-quinone; BRN 0608838; SMR000150826; CHEMBL51931; MLS000881132; MLS000571180; AI3-23739; CHEBI:37454; YYVYAPXYZVYDHN-UHFFFAOYSA-N; 42L7BZ8H74; MFCD00001163; 9,10-dihydrophenanthrene-9,10-dione; AK-96664
DMG8KS9	DT	Small molecular drug
DMG8KS9	PC	6763
DMG8KS9	MW	208.21
DMG8KS9	FM	C14H8O2
DMG8KS9	IC	InChI=1S/C14H8O2/c15-13-11-7-3-1-5-9(11)10-6-2-4-8-12(10)14(13)16/h1-8H
DMG8KS9	CS	C1=CC=C2C(=C1)C3=CC=CC=C3C(=O)C2=O
DMG8KS9	IK	YYVYAPXYZVYDHN-UHFFFAOYSA-N
DMG8KS9	IU	phenanthrene-9,10-dione
DMG8KS9	CA	CAS 84-11-7
DMG8KS9	CB	CHEBI:37454
DMG8KS9	DE	Discovery agent

DMCTVMI	ID	DMCTVMI
DMCTVMI	DN	PHENAZOCINE
DMCTVMI	HS	Investigative
DMCTVMI	SN	PHENAZOCINE HYDROBROMIDE; Narphen; Phenazocine (+-)- hydrobromide; EINECS 214-982-5; 1239-04-9; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-phenethyl-2,6-methano-3-benzazocin-8-ol hydrobromide; 2'-Hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzomorphan hydrobromide; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-phenethyl-, hydrobromide; NIH 7519 hydrobromide; AC1L24DX; C22H27NO.HBr; SCHEMBL396395; PHENETHYLAZOCINE BROMIDE; 127-35-5 (Parent); CHEMBL2107297; DTXSID20872382; AKOS022180090; LS-90611
DMCTVMI	DT	Small molecular drug
DMCTVMI	PC	14707
DMCTVMI	MW	321.5
DMCTVMI	FM	C22H27NO
DMCTVMI	IC	InChI=1S/C22H27NO/c1-16-21-14-18-8-9-19(24)15-20(18)22(16,2)11-13-23(21)12-10-17-6-4-3-5-7-17/h3-9,15-16,21,24H,10-14H2,1-2H3
DMCTVMI	CS	CC1C2CC3=C(C1(CCN2CCC4=CC=CC=C4)C)C=C(C=C3)O
DMCTVMI	IK	ZQHYKVKNPWDQSL-UHFFFAOYSA-N
DMCTVMI	IU	1,13-dimethyl-10-(2-phenylethyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMCTVMI	CA	CAS 127-35-5
DMCTVMI	DE	Discovery agent

DMCE985	ID	DMCE985
DMCE985	DN	Phenazone
DMCE985	HS	Investigative
DMCE985	SN	antipyrine; Phenazone; 60-80-0; Antipyrin; Phenazon; Analgesine; Anodynine; Fenazone; Anodynin; Azophen; 2,3-Dimethyl-1-phenyl-5-pyrazolone; Antipirin; Phenozone; Methozin; Azophene; Phenylone; Pyrazophyl; Sedatine; Apirelina; Sedatin; Dimethyloxychinizin; Dimethyloxyquinazine; Phenazonum; Antipyrinum; Oxydimethylquinazine; Azophenum; Parodyne; Phenylon; Fenazona; 3-Antipyrine; Fenazon [Czech]; Auralgan; Fenazon; Fenazona [INN-Spanish]; Phenazone (pharmaceutical); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-; Oxydimethylquinizine
DMCE985	DT	Small molecular drug
DMCE985	PC	2206
DMCE985	MW	188.23
DMCE985	FM	C11H12N2O
DMCE985	IC	InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3
DMCE985	CS	CC1=CC(=O)N(N1C)C2=CC=CC=C2
DMCE985	IK	VEQOALNAAJBPNY-UHFFFAOYSA-N
DMCE985	IU	1,5-dimethyl-2-phenylpyrazol-3-one
DMCE985	CA	CAS 60-80-0
DMCE985	CB	CHEBI:31225
DMCE985	DE	Discovery agent

DMQBEYX	ID	DMQBEYX
DMQBEYX	DN	Phencyclidine
DMQBEYX	HS	Investigative
DMQBEYX	SN	1-(1-Phenylcyclohexyl)piperidine; Angel dust; Dust; PCP (Anesthetic); Fenciclidina; Phencyclidinum; Supergrass; Cadillac; Surfer; Crystal; Tranks; Whack; Zombie dust; Magic mist; Busy bee; Piperidine, 1-(1-phenylcyclohexyl)-; Elephant tranquilizer; 1977/10/1; Superweed; Superjoint; Cycline; Sherman; Cyclones; Scuffle; Snorts; Cl-395; Sheets; Selma; Peace; Aurora borealis; Embalming fluid; Pits; Goon; Mist; Crystal joints; Wobble weed; Rocket fuel; Horse tracks; Whacky weed; Monkey dust; Killer weed; Peace weed; Peace pill
DMQBEYX	DT	Small molecular drug
DMQBEYX	PC	6468
DMQBEYX	MW	243.4
DMQBEYX	FM	C17H25N
DMQBEYX	IC	InChI=1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2
DMQBEYX	CS	C1CCC(CC1)(C2=CC=CC=C2)N3CCCCC3
DMQBEYX	IK	JTJMJGYZQZDUJJ-UHFFFAOYSA-N
DMQBEYX	IU	1-(1-phenylcyclohexyl)piperidine
DMQBEYX	CA	CAS 77-10-1
DMQBEYX	CB	CHEBI:8058
DMQBEYX	DE	Discovery agent

DMQWFO1	ID	DMQWFO1
DMQWFO1	DN	Phenethyl-(3-phenyl-propyl)-amine
DMQWFO1	HS	Investigative
DMQWFO1	SN	CHEMBL283775; Phenethyl-(3-phenyl-propyl)-amine; AC1L8VET; SCHEMBL625373; N-Phenethylbenzenepropane-1-amine; ZINC1707035; N-phenethyl-3-phenylpropan-1-amine; BDBM50041250
DMQWFO1	DT	Small molecular drug
DMQWFO1	PC	408731
DMQWFO1	MW	239.35
DMQWFO1	FM	C17H21N
DMQWFO1	IC	InChI=1S/C17H21N/c1-3-8-16(9-4-1)12-7-14-18-15-13-17-10-5-2-6-11-17/h1-6,8-11,18H,7,12-15H2
DMQWFO1	CS	C1=CC=C(C=C1)CCCNCCC2=CC=CC=C2
DMQWFO1	IK	MCXHGJLRTJKZGT-UHFFFAOYSA-N
DMQWFO1	IU	3-phenyl-N-(2-phenylethyl)propan-1-amine
DMQWFO1	DE	Discovery agent

DMFQMHK	ID	DMFQMHK
DMFQMHK	DN	Phenethyl-(4-phenyl-butyl)-amine
DMFQMHK	HS	Investigative
DMFQMHK	SN	CHEMBL280111; Phenethyl-(4-phenyl-butyl)-amine; SCHEMBL8084143; 4-Phenyl-N-phenethyl-1-butanamine; ZINC13736042
DMFQMHK	DT	Small molecular drug
DMFQMHK	PC	10708590
DMFQMHK	MW	253.4
DMFQMHK	FM	C18H23N
DMFQMHK	IC	InChI=1S/C18H23N/c1-3-9-17(10-4-1)13-7-8-15-19-16-14-18-11-5-2-6-12-18/h1-6,9-12,19H,7-8,13-16H2
DMFQMHK	CS	C1=CC=C(C=C1)CCCCNCCC2=CC=CC=C2
DMFQMHK	IK	HMGFNEMDDFFJES-UHFFFAOYSA-N
DMFQMHK	IU	4-phenyl-N-(2-phenylethyl)butan-1-amine
DMFQMHK	DE	Discovery agent

DMX0G4F	ID	DMX0G4F
DMX0G4F	DN	Phenethylamine
DMX0G4F	HS	Investigative
DMX0G4F	SN	Phenethylamine; 2-phenylethylamine; 2-Phenylethanamine; 64-04-0; Benzeneethanamine; phenylethylamine; 2-Phenethylamine; beta-phenylethylamine; beta-Phenethylamine; 1-Amino-2-phenylethane; beta-Aminoethylbenzene; (2-Aminoethyl)benzene; 2-Amino-1-phenylethane; 1-Phenyl-2-aminoethane; Ethylamine, 2-phenyl-; Ethanamine, 2-phenyl-; 2-Phenylethan-1-Amine; 1-Phenyl-2-amino-athan; 2-Fenylethylamin; 2-Amino-fenylethan; 2-Fenylethylamin [Czech]; PHENETHYLAMINE, BETA; 2-Amino-fenylethan [Czech]; beta-Phenylaethylamin [German]
DMX0G4F	DT	Small molecular drug
DMX0G4F	PC	1001
DMX0G4F	MW	121.18
DMX0G4F	FM	C8H11N
DMX0G4F	IC	InChI=1S/C8H11N/c9-7-6-8-4-2-1-3-5-8/h1-5H,6-7,9H2
DMX0G4F	CS	C1=CC=C(C=C1)CCN
DMX0G4F	IK	BHHGXPLMPWCGHP-UHFFFAOYSA-N
DMX0G4F	IU	2-phenylethanamine
DMX0G4F	CA	CAS 64-04-0
DMX0G4F	CB	CHEBI:18397
DMX0G4F	DE	Discovery agent

DMPDVG2	ID	DMPDVG2
DMPDVG2	DN	Phenethylboronic acid
DMPDVG2	HS	Investigative
DMPDVG2	SN	Phenethylboronic acid; 34420-17-2; 2-phenylethylboronic acid; Phenylethane boronic acid; PEBA; 2-Phenyl-1-ethylboronic acid; Phenylethaneboronic acid; (2-phenylethyl)boronic acid; 2-Phenylethyl-1-boronic acid; Boronic acid, (2-phenylethyl)-; 2-Phenylethyl boronic acid; PHENYLETHYLBORONIC ACID; Phenethylboronicacid; phenethyl boronic acid; PubChem14049; Alkylboronic Acid, 21; ACMC-1AFPT; (2-phenylethyl)boranediol; 2-phenylethane boronic acid; KSC489K8F; SCHEMBL129543; CHEMBL20461; AC1L235V; KS-00000ETI; BDBM26142; CTK3I9582
DMPDVG2	DT	Small molecular drug
DMPDVG2	PC	65389
DMPDVG2	MW	149.98
DMPDVG2	FM	C8H11BO2
DMPDVG2	IC	InChI=1S/C8H11BO2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-5,10-11H,6-7H2
DMPDVG2	CS	B(CCC1=CC=CC=C1)(O)O
DMPDVG2	IK	VPRUMANMDWQMNF-UHFFFAOYSA-N
DMPDVG2	IU	2-phenylethylboronic acid
DMPDVG2	CA	CAS 34420-17-2
DMPDVG2	DE	Discovery agent

DM02PAW	ID	DM02PAW
DM02PAW	DN	Phenethylcarbamic Acid Biphenyl-3-yl Ester
DM02PAW	HS	Investigative
DM02PAW	SN	Phenethylcarbamic Acid Biphenyl-3-yl Ester; CHEMBL520360
DM02PAW	DT	Small molecular drug
DM02PAW	PC	24881739
DM02PAW	MW	317.4
DM02PAW	FM	C21H19NO2
DM02PAW	IC	InChI=1S/C21H19NO2/c23-21(22-15-14-17-8-3-1-4-9-17)24-20-13-7-12-19(16-20)18-10-5-2-6-11-18/h1-13,16H,14-15H2,(H,22,23)
DM02PAW	CS	C1=CC=C(C=C1)CCNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DM02PAW	IK	SYRRFVWOILIONB-UHFFFAOYSA-N
DM02PAW	IU	(3-phenylphenyl) N-(2-phenylethyl)carbamate
DM02PAW	DE	Discovery agent

DMJD8XN	ID	DMJD8XN
DMJD8XN	DN	PHENIDONE
DMJD8XN	HS	Investigative
DMJD8XN	SN	Phenidone; 92-43-3; 1-phenylpyrazolidin-3-one; 1-Phenyl-3-pyrazolidone; 1-PHENYL-3-PYRAZOLIDINONE; Fenidon; 3-Pyrazolidinone, 1-phenyl-; 1-Phenyl-3-oxopyrazolidine; 2-Pyrazolin-3-ol, 1-phenyl-; 1-P-3-P; Pyrazolidinone, 1-phenyl-; 1-Phenyl-pyrazolidin-3-one; UNII-H0U5612P6K; CCRIS 3624; 1-Phenylpyrazolid-3-one; EINECS 202-155-1; NSC 30306; 3-Pyrazolidinone,1-phenyl-; CHEMBL7660; 1-phenyl-4,5-dihydro-1H-pyrazol-3-ol; MLS002639322; CMCWWLVWPDLCRM-UHFFFAOYSA-N; H0U5612P6K; MFCD00003094; Phenidone A (1-Phenyl-3-pyrazolidinone)
DMJD8XN	DT	Small molecular drug
DMJD8XN	PC	7090
DMJD8XN	MW	162.19
DMJD8XN	FM	C9H10N2O
DMJD8XN	IC	InChI=1S/C9H10N2O/c12-9-6-7-11(10-9)8-4-2-1-3-5-8/h1-5H,6-7H2,(H,10,12)
DMJD8XN	CS	C1CN(NC1=O)C2=CC=CC=C2
DMJD8XN	IK	CMCWWLVWPDLCRM-UHFFFAOYSA-N
DMJD8XN	IU	1-phenylpyrazolidin-3-one
DMJD8XN	CA	CAS 92-43-3
DMJD8XN	DE	Discovery agent

DMYCHTD	ID	DMYCHTD
DMYCHTD	DN	PHENMEDIPHAM
DMYCHTD	HS	Investigative
DMYCHTD	SN	Phenmedipham; 13684-63-4; 3-((Methoxycarbonyl)amino)phenyl m-tolylcarbamate; Fenmedifam; BETANAL; Phenmediphame; Kemifam; Spin-aid; Synbetan P; Schering 4072; Schering-38584; Caswell No. 648B; Morton EP 452; UNII-UJE31KXP78; Phenmediphame [ISO-French]; EP-452; SN 4075; CCRIS 6091; Phenmedipham [ANSI:BSI:ISO]; SN-38584; HSDB 1402; Methyl 3-(3-methylcarbaniloyloxy)carbanilate; Methyl 3-(m-tolylcarbamoyloxy)phenylcarbamate; EINECS 237-199-0; [3-(methoxycarbonylamino)phenyl] N-(3-methylphenyl)carbamate; 3-(Carbomethoxyamino)phenyl 3-me
DMYCHTD	DT	Small molecular drug
DMYCHTD	PC	24744
DMYCHTD	MW	300.31
DMYCHTD	FM	C16H16N2O4
DMYCHTD	IC	InChI=1S/C16H16N2O4/c1-11-5-3-6-12(9-11)18-16(20)22-14-8-4-7-13(10-14)17-15(19)21-2/h3-10H,1-2H3,(H,17,19)(H,18,20)
DMYCHTD	CS	CC1=CC(=CC=C1)NC(=O)OC2=CC=CC(=C2)NC(=O)OC
DMYCHTD	IK	IDOWTHOLJBTAFI-UHFFFAOYSA-N
DMYCHTD	IU	[3-(methoxycarbonylamino)phenyl] N-(3-methylphenyl)carbamate
DMYCHTD	CA	CAS 13684-63-4
DMYCHTD	CB	CHEBI:81734
DMYCHTD	DE	Discovery agent

DMCTUAD	ID	DMCTUAD
DMCTUAD	DN	Phenolsulfonphthalein
DMCTUAD	HS	Investigative
DMCTUAD	SN	3,3-Bis(4-hydroxyphenyl)-3H-benzo[c][1,2]oxathiole 1,1-dioxide; 4,4'-(3H-2,1-Benzoxathiol-3-ylidene)diphenol S,S-dioxide; BRN 0326470; EINECS 205-609-7; Fenolipuna; I6G9Y0J1OJ; MFCD00003552; NSC 10459; NSC10459; PHENOL RED; PSP; PSP (indicator); Phenol Red, ACS reagent; Phenol red; Phenol, 4,4'-(1,1-dioxido-3H-2,1-benzoxathiol-3-ylidene)bis-; Phenolred; Phenolsulfonephthalein; Phenolsulphonphthalein; Phenosulfophthalein; Sulfonphthal; Sulphental; Sulphonthal; UNII-I6G9Y0J1OJ; phenolsulfonphthalein
DMCTUAD	DT	Small molecular drug
DMCTUAD	PC	4766
DMCTUAD	MW	354.376
DMCTUAD	FM	C19H14O5S
DMCTUAD	IC	InChI=1S/C19H14O5S/c20-15-9-5-13(6-10-15)19(14-7-11-16(21)12-8-14)17-3-1-2-4-18(17)25(22,23)24-19/h1-12,20-21H
DMCTUAD	CS	C1=CC=C2C(=C1)C(OS2(=O)=O)(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
DMCTUAD	IK	BELBBZDIHDAJOR-UHFFFAOYSA-N
DMCTUAD	IU	4-[3-(4-hydroxyphenyl)-1,1-dioxo-2,1lambda6-benzoxathiol-3-yl]phenol
DMCTUAD	CA	CAS 143-74-8
DMCTUAD	CB	CHEBI:31991

DMZJO5V	ID	DMZJO5V
DMZJO5V	DN	Phenoxyarsonous acid
DMZJO5V	HS	Investigative
DMZJO5V	SN	phenoxyarsonous acid; CHEMBL186553; SCHEMBL11222792
DMZJO5V	DT	Small molecular drug
DMZJO5V	PC	44395086
DMZJO5V	MW	202.04
DMZJO5V	FM	C6H7AsO3
DMZJO5V	IC	InChI=1S/C6H7AsO3/c8-7(9)10-6-4-2-1-3-5-6/h1-5,8-9H
DMZJO5V	CS	C1=CC=C(C=C1)O[As](O)O
DMZJO5V	IK	NOJGJOHOYAWLBB-UHFFFAOYSA-N
DMZJO5V	IU	phenoxyarsonous acid
DMZJO5V	DE	Discovery agent

DMJ5GY7	ID	DMJ5GY7
DMJ5GY7	DN	PHENSTATIN
DMJ5GY7	HS	Investigative
DMJ5GY7	SN	PHENSTATIN; HSLFWBPRHXGUAN-UHFFFAOYSA-N; (3-hydroxy-4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone; SCHEMBL616385; CHEMBL276625; MolPort-015-162-531; STL435384; ZINC13474160; BDBM50156812; AKOS022023466; MCULE-7238289482; ST4148969; 3-hydroxy-4-methoxyphenyl 3,4,5-trimethoxyphenyl ketone
DMJ5GY7	DT	Small molecular drug
DMJ5GY7	PC	9948888
DMJ5GY7	MW	318.32
DMJ5GY7	FM	C17H18O6
DMJ5GY7	IC	InChI=1S/C17H18O6/c1-20-13-6-5-10(7-12(13)18)16(19)11-8-14(21-2)17(23-4)15(9-11)22-3/h5-9,18H,1-4H3
DMJ5GY7	CS	COC1=C(C=C(C=C1)C(=O)C2=CC(=C(C(=C2)OC)OC)OC)O
DMJ5GY7	IK	HSLFWBPRHXGUAN-UHFFFAOYSA-N
DMJ5GY7	IU	(3-hydroxy-4-methoxyphenyl)-(3,4,5-trimethoxyphenyl)methanone
DMJ5GY7	DE	Discovery agent

DMSNIBO	ID	DMSNIBO
DMSNIBO	DN	Phenyl 1-(4-butoxyphenyl)propylcarbamate
DMSNIBO	HS	Investigative
DMSNIBO	SN	phenyl 1-(4-butoxyphenyl)propylcarbamate; CHEMBL597064; SCHEMBL5218537
DMSNIBO	DT	Small molecular drug
DMSNIBO	PC	20872827
DMSNIBO	MW	327.4
DMSNIBO	FM	C20H25NO3
DMSNIBO	IC	InChI=1S/C20H25NO3/c1-3-5-15-23-17-13-11-16(12-14-17)19(4-2)21-20(22)24-18-9-7-6-8-10-18/h6-14,19H,3-5,15H2,1-2H3,(H,21,22)
DMSNIBO	CS	CCCCOC1=CC=C(C=C1)C(CC)NC(=O)OC2=CC=CC=C2
DMSNIBO	IK	FSKKTZPFXFTOGX-UHFFFAOYSA-N
DMSNIBO	IU	phenyl N-[1-(4-butoxyphenyl)propyl]carbamate
DMSNIBO	DE	Discovery agent

DM52H1D	ID	DM52H1D
DM52H1D	DN	Phenyl 10H-phenothiazine-10-carboxylate
DM52H1D	HS	Investigative
DM52H1D	SN	CHEMBL481687; 66721-07-1; 10H-Phenothiazine-10-carboxylic acid, phenyl ester; Phenyl Phenothiazine-10-carboxylate; AC1MXYWS; phenyl 10H-phenothiazine-10-carboxylate; SCHEMBL4441681; CTK1H9487; DTXSID00396233; BDBM50292620
DM52H1D	DT	Small molecular drug
DM52H1D	PC	3773589
DM52H1D	MW	319.4
DM52H1D	FM	C19H13NO2S
DM52H1D	IC	InChI=1S/C19H13NO2S/c21-19(22-14-8-2-1-3-9-14)20-15-10-4-6-12-17(15)23-18-13-7-5-11-16(18)20/h1-13H
DM52H1D	CS	C1=CC=C(C=C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM52H1D	IK	FGMRQVNHYGGLSF-UHFFFAOYSA-N
DM52H1D	IU	phenyl phenothiazine-10-carboxylate
DM52H1D	CA	CAS 66721-07-1
DM52H1D	DE	Discovery agent

DMHDWTS	ID	DMHDWTS
DMHDWTS	DN	Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate
DMHDWTS	HS	Investigative
DMHDWTS	SN	CHEMBL451230; phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate
DMHDWTS	DT	Small molecular drug
DMHDWTS	PC	44581377
DMHDWTS	MW	266.29
DMHDWTS	FM	C16H14N2O2
DMHDWTS	IC	InChI=1S/C16H14N2O2/c19-16(20-14-4-2-1-3-5-14)13-8-6-12(7-9-13)15-17-10-11-18-15/h1-9H,10-11H2,(H,17,18)
DMHDWTS	CS	C1CN=C(N1)C2=CC=C(C=C2)C(=O)OC3=CC=CC=C3
DMHDWTS	IK	KBQKAAWDURESJQ-UHFFFAOYSA-N
DMHDWTS	IU	phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate
DMHDWTS	DE	Discovery agent

DMZ03DT	ID	DMZ03DT
DMZ03DT	DN	Phenyl 4-(decyloxy)phenylcarbamate
DMZ03DT	HS	Investigative
DMZ03DT	SN	phenyl 4-(decyloxy)phenylcarbamate; CHEMBL592771; SCHEMBL5220304
DMZ03DT	DT	Small molecular drug
DMZ03DT	PC	20872829
DMZ03DT	MW	369.5
DMZ03DT	FM	C23H31NO3
DMZ03DT	IC	InChI=1S/C23H31NO3/c1-2-3-4-5-6-7-8-12-19-26-21-17-15-20(16-18-21)24-23(25)27-22-13-10-9-11-14-22/h9-11,13-18H,2-8,12,19H2,1H3,(H,24,25)
DMZ03DT	CS	CCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2
DMZ03DT	IK	ZNJJGGVTHHJCRN-UHFFFAOYSA-N
DMZ03DT	IU	phenyl N-(4-decoxyphenyl)carbamate
DMZ03DT	DE	Discovery agent

DMR1MQE	ID	DMR1MQE
DMR1MQE	DN	Phenyl 4-(dodecyloxy)phenylcarbamate
DMR1MQE	HS	Investigative
DMR1MQE	SN	phenyl 4-(dodecyloxy)phenylcarbamate; CHEMBL592772; SCHEMBL5218141
DMR1MQE	DT	Small molecular drug
DMR1MQE	PC	20872830
DMR1MQE	MW	397.5
DMR1MQE	FM	C25H35NO3
DMR1MQE	IC	InChI=1S/C25H35NO3/c1-2-3-4-5-6-7-8-9-10-14-21-28-23-19-17-22(18-20-23)26-25(27)29-24-15-12-11-13-16-24/h11-13,15-20H,2-10,14,21H2,1H3,(H,26,27)
DMR1MQE	CS	CCCCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2
DMR1MQE	IK	DFYYHKJFWVSJHM-UHFFFAOYSA-N
DMR1MQE	IU	phenyl N-(4-dodecoxyphenyl)carbamate
DMR1MQE	DE	Discovery agent

DM9UNLH	ID	DM9UNLH
DM9UNLH	DN	Phenyl 4-(heptyloxy)phenylcarbamate
DM9UNLH	HS	Investigative
DM9UNLH	SN	phenyl 4-(heptyloxy)phenylcarbamate; CHEMBL599381; SCHEMBL5214279
DM9UNLH	DT	Small molecular drug
DM9UNLH	PC	20872831
DM9UNLH	MW	327.4
DM9UNLH	FM	C20H25NO3
DM9UNLH	IC	InChI=1S/C20H25NO3/c1-2-3-4-5-9-16-23-18-14-12-17(13-15-18)21-20(22)24-19-10-7-6-8-11-19/h6-8,10-15H,2-5,9,16H2,1H3,(H,21,22)
DM9UNLH	CS	CCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2
DM9UNLH	IK	JPIYDITTWBUFSY-UHFFFAOYSA-N
DM9UNLH	IU	phenyl N-(4-heptoxyphenyl)carbamate
DM9UNLH	DE	Discovery agent

DMZ07H6	ID	DMZ07H6
DMZ07H6	DN	Phenyl 4-(hexyloxy)phenylcarbamate
DMZ07H6	HS	Investigative
DMZ07H6	SN	phenyl 4-(hexyloxy)phenylcarbamate; CHEMBL599181
DMZ07H6	DT	Small molecular drug
DMZ07H6	PC	20872832
DMZ07H6	MW	313.4
DMZ07H6	FM	C19H23NO3
DMZ07H6	IC	InChI=1S/C19H23NO3/c1-2-3-4-8-15-22-17-13-11-16(12-14-17)20-19(21)23-18-9-6-5-7-10-18/h5-7,9-14H,2-4,8,15H2,1H3,(H,20,21)
DMZ07H6	CS	CCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2
DMZ07H6	IK	ORPQZENLUNAGOE-UHFFFAOYSA-N
DMZ07H6	IU	phenyl N-(4-hexoxyphenyl)carbamate
DMZ07H6	DE	Discovery agent

DMULMWK	ID	DMULMWK
DMULMWK	DN	Phenyl 4-(octyloxy)phenylcarbamate
DMULMWK	HS	Investigative
DMULMWK	SN	phenyl 4-(octyloxy)phenylcarbamate; CHEMBL598572; SCHEMBL5219239
DMULMWK	DT	Small molecular drug
DMULMWK	PC	20872833
DMULMWK	MW	341.4
DMULMWK	FM	C21H27NO3
DMULMWK	IC	InChI=1S/C21H27NO3/c1-2-3-4-5-6-10-17-24-19-15-13-18(14-16-19)22-21(23)25-20-11-8-7-9-12-20/h7-9,11-16H,2-6,10,17H2,1H3,(H,22,23)
DMULMWK	CS	CCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2
DMULMWK	IK	IJCMIOMSKCNMQY-UHFFFAOYSA-N
DMULMWK	IU	phenyl N-(4-octoxyphenyl)carbamate
DMULMWK	DE	Discovery agent

DMSZ2CO	ID	DMSZ2CO
DMSZ2CO	DN	Phenyl 4-(undecyloxy)phenylcarbamate
DMSZ2CO	HS	Investigative
DMSZ2CO	SN	phenyl 4-(undecyloxy)phenylcarbamate; CHEMBL597923; SCHEMBL4267666
DMSZ2CO	DT	Small molecular drug
DMSZ2CO	PC	20872834
DMSZ2CO	MW	383.5
DMSZ2CO	FM	C24H33NO3
DMSZ2CO	IC	InChI=1S/C24H33NO3/c1-2-3-4-5-6-7-8-9-13-20-27-22-18-16-21(17-19-22)25-24(26)28-23-14-11-10-12-15-23/h10-12,14-19H,2-9,13,20H2,1H3,(H,25,26)
DMSZ2CO	CS	CCCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2
DMSZ2CO	IK	QJLORVSDABTRCS-UHFFFAOYSA-N
DMSZ2CO	IU	phenyl N-(4-undecoxyphenyl)carbamate
DMSZ2CO	DE	Discovery agent

DMWN9XU	ID	DMWN9XU
DMWN9XU	DN	Phenyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate
DMWN9XU	HS	Investigative
DMWN9XU	SN	CHEMBL597237
DMWN9XU	DT	Small molecular drug
DMWN9XU	PC	46230983
DMWN9XU	MW	359.4
DMWN9XU	FM	C22H17NO4
DMWN9XU	IC	InChI=1S/C22H17NO4/c1-25-19-13-12-17(15-8-4-2-5-9-15)18-14-20(27-21(18)19)23-22(24)26-16-10-6-3-7-11-16/h2-14H,1H3,(H,23,24)
DMWN9XU	CS	COC1=C2C(=C(C=C1)C3=CC=CC=C3)C=C(O2)NC(=O)OC4=CC=CC=C4
DMWN9XU	IK	LJHDOOYWZIWTJW-UHFFFAOYSA-N
DMWN9XU	IU	phenyl N-(7-methoxy-4-phenyl-1-benzofuran-2-yl)carbamate
DMWN9XU	DE	Discovery agent

DMFZH49	ID	DMFZH49
DMFZH49	DN	Phenyl Boronic acid
DMFZH49	HS	Investigative
DMFZH49	SN	Phenylboronic acid
DMFZH49	DT	Small molecular drug
DMFZH49	PC	66827
DMFZH49	MW	121.93
DMFZH49	FM	C6H7BO2
DMFZH49	IC	InChI=1S/C6H7BO2/c8-7(9)6-4-2-1-3-5-6/h1-5,8-9H
DMFZH49	CS	B(C1=CC=CC=C1)(O)O
DMFZH49	IK	HXITXNWTGFUOAU-UHFFFAOYSA-N
DMFZH49	IU	phenylboronic acid
DMFZH49	CA	CAS 98-80-6
DMFZH49	CB	CHEBI:44923
DMFZH49	DE	Discovery agent

DMDV1SN	ID	DMDV1SN
DMDV1SN	DN	Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol
DMDV1SN	HS	Investigative
DMDV1SN	SN	CHEMBL408869; SCHEMBL7226777
DMDV1SN	DT	Small molecular drug
DMDV1SN	PC	18511481
DMDV1SN	MW	303.28
DMDV1SN	FM	C17H12F3NO
DMDV1SN	IC	InChI=1S/C17H12F3NO/c18-17(19,20)15-10-13(12-8-4-5-9-14(12)21-15)16(22)11-6-2-1-3-7-11/h1-10,16,22H
DMDV1SN	CS	C1=CC=C(C=C1)C(C2=CC(=NC3=CC=CC=C32)C(F)(F)F)O
DMDV1SN	IK	CCEVSDBDTAPCRQ-UHFFFAOYSA-N
DMDV1SN	IU	phenyl-[2-(trifluoromethyl)quinolin-4-yl]methanol
DMDV1SN	DE	Discovery agent

DMDCTNU	ID	DMDCTNU
DMDCTNU	DN	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine
DMDCTNU	HS	Investigative
DMDCTNU	SN	CHEMBL383177; N,3-diphenyl-1H-indazol-6-amine; Phenyl-(3-phenyl-1H-indazol-6-yl)-amine; SCHEMBL6582340
DMDCTNU	DT	Small molecular drug
DMDCTNU	PC	10236389
DMDCTNU	MW	285.3
DMDCTNU	FM	C19H15N3
DMDCTNU	IC	InChI=1S/C19H15N3/c1-3-7-14(8-4-1)19-17-12-11-16(13-18(17)21-22-19)20-15-9-5-2-6-10-15/h1-13,20H,(H,21,22)
DMDCTNU	CS	C1=CC=C(C=C1)C2=NNC3=C2C=CC(=C3)NC4=CC=CC=C4
DMDCTNU	IK	UCZOJYXXXUINID-UHFFFAOYSA-N
DMDCTNU	IU	N,3-diphenyl-1H-indazol-6-amine
DMDCTNU	DE	Discovery agent

DMR2B4O	ID	DMR2B4O
DMR2B4O	DN	Phenyl-(5-phenyl-oxazol-2-yl)-amine
DMR2B4O	HS	Investigative
DMR2B4O	SN	N,5-diphenyl-1,3-oxazol-2-amine; 2-Oxazolamine, N,5-diphenyl-; 135307-33-4; GW549390X; aminoxazole 24; ACMC-20mvpu; AC1NS6QQ; 2-Anilino-5-aryloxazole 5; CHEMBL318728; BDBM5364; SCHEMBL3295009; CTK0B9820; DTXSID80416185; HMS3303G19; HMS3305C03; ZINC13611247; NCGC00242146-01; DA-45813; FT-0704302
DMR2B4O	DT	Small molecular drug
DMR2B4O	PC	5329404
DMR2B4O	MW	236.27
DMR2B4O	FM	C15H12N2O
DMR2B4O	IC	InChI=1S/C15H12N2O/c1-3-7-12(8-4-1)14-11-16-15(18-14)17-13-9-5-2-6-10-13/h1-11H,(H,16,17)
DMR2B4O	CS	C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=CC=C3
DMR2B4O	IK	HFICAVMUTYFODG-UHFFFAOYSA-N
DMR2B4O	IU	N,5-diphenyl-1,3-oxazol-2-amine
DMR2B4O	CA	CAS 135307-33-4
DMR2B4O	DE	Discovery agent

DMIQ18W	ID	DMIQ18W
DMIQ18W	DN	Phenyl-(9-phenyl-9H-purin-6-yl)-amine
DMIQ18W	HS	Investigative
DMIQ18W	SN	CHEMBL96015; Phenyl-(9-phenyl-9H-purin-6-yl)-amine; 6-Phenylamino-9-phenyl-9H-purine; ZINC13824421
DMIQ18W	DT	Small molecular drug
DMIQ18W	PC	12483819
DMIQ18W	MW	287.32
DMIQ18W	FM	C17H13N5
DMIQ18W	IC	InChI=1S/C17H13N5/c1-3-7-13(8-4-1)21-16-15-17(19-11-18-16)22(12-20-15)14-9-5-2-6-10-14/h1-12H,(H,18,19,21)
DMIQ18W	CS	C1=CC=C(C=C1)NC2=C3C(=NC=N2)N(C=N3)C4=CC=CC=C4
DMIQ18W	IK	UKZXHZUTIYUUII-UHFFFAOYSA-N
DMIQ18W	IU	N,9-diphenylpurin-6-amine
DMIQ18W	DE	Discovery agent

DMWEKBD	ID	DMWEKBD
DMWEKBD	DN	Phenyl-1,4-bismaleimide
DMWEKBD	HS	Investigative
DMWEKBD	SN	3278-31-7; N,N'-1,4-Phenylenedimaleimide; N,N'-p-Phenylenedimaleimide; N,N'-4-Phenylenedimaleimide; phenyl-1,4-bismaleimide; UNII-BEC7P1E6J1; 1,1'-(1,4-phenylene)bis(1h-pyrrole-2,5-dione); BEC7P1E6J1; n,n-1,4-phenylenedimaleimide; CHEMBL576594; 1,1'-Benzene-1,4-diylbis(1H-pyrrole-2,5-dione); 1-[4-(2,5-dioxopyrrol-1-yl)phenyl]pyrrole-2,5-dione; NSC81257; EINECS 221-910-6; NSC 81257; p-PDM; 1,4-Dimaleimidobenzene; ACMC-209hvr; AC1Q6MZN; 1,4-phenylene dimaleimide; 1,4-bis(maleimido)benzene; AC1L2RM9; SCHEMBL95324
DMWEKBD	DT	Small molecular drug
DMWEKBD	PC	76765
DMWEKBD	MW	268.22
DMWEKBD	FM	C14H8N2O4
DMWEKBD	IC	InChI=1S/C14H8N2O4/c17-11-5-6-12(18)15(11)9-1-2-10(4-3-9)16-13(19)7-8-14(16)20/h1-8H
DMWEKBD	CS	C1=CC(=CC=C1N2C(=O)C=CC2=O)N3C(=O)C=CC3=O
DMWEKBD	IK	AQGZJQNZNONGKY-UHFFFAOYSA-N
DMWEKBD	IU	1-[4-(2,5-dioxopyrrol-1-yl)phenyl]pyrrole-2,5-dione
DMWEKBD	CA	CAS 3278-31-7
DMWEKBD	DE	Discovery agent

DM5A8KR	ID	DM5A8KR
DM5A8KR	DN	phenylacetyl-Ala,DTrp-phenthylamide
DM5A8KR	HS	Investigative
DM5A8KR	SN	phenylacetyl-Ala,DTrp-phenthylamide; GTPL6192
DM5A8KR	DT	Small molecular drug
DM5A8KR	PC	73755184
DM5A8KR	MW	482.6
DM5A8KR	FM	C29H30N4O3
DM5A8KR	IC	InChI=1S/C29H30N4O3/c1-20(32-28(35)22-12-6-3-7-13-22)27(34)33-26(18-23-19-31-25-15-9-8-14-24(23)25)29(36)30-17-16-21-10-4-2-5-11-21/h2-15,19-20,26,31H,16-18H2,1H3,(H,30,36)(H,32,35)(H,33,34)
DM5A8KR	CS	CC(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NCCC3=CC=CC=C3)NC(=O)C4=CC=CC=C4
DM5A8KR	IK	OXMOOJYZUSQLNA-UHFFFAOYSA-N
DM5A8KR	IU	N-[1-[[3-(1H-indol-3-yl)-1-oxo-1-(2-phenylethylamino)propan-2-yl]amino]-1-oxopropan-2-yl]benzamide
DM5A8KR	DE	Discovery agent

DM16KSA	ID	DM16KSA
DM16KSA	DN	Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide
DM16KSA	HS	Investigative
DM16KSA	SN	CHEMBL566340; phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide; SCHEMBL7920067; GTPL6564; BDBM50303774
DM16KSA	DT	Small molecular drug
DM16KSA	PC	45486355
DM16KSA	MW	678.8
DM16KSA	FM	C33H50N12O4
DM16KSA	IC	InChI=1S/C33H50N12O4/c1-20(2)27(45-30(48)25(11-7-17-41-33(38)39)43-26(46)18-21-8-4-3-5-9-21)31(49)44-24(10-6-16-40-32(36)37)29(47)42-19-22-12-14-23(15-13-22)28(34)35/h3-5,8-9,12-15,20,24-25,27H,6-7,10-11,16-19H2,1-2H3,(H3,34,35)(H,42,47)(H,43,46)(H,44,49)(H,45,48)(H4,36,37,40)(H4,38,39,41)/t24-,25-,27-/m0/s1
DM16KSA	CS	CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC1=CC=C(C=C1)C(=N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CC2=CC=CC=C2
DM16KSA	IK	YGMAIAXBJLVVLI-KLJDGLGGSA-N
DM16KSA	IU	(2S)-N-[(2S)-1-[[(2S)-1-[(4-carbamimidoylphenyl)methylamino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-5-(diaminomethylideneamino)-2-[(2-phenylacetyl)amino]pentanamide
DM16KSA	DE	Discovery agent

DM29EFJ	ID	DM29EFJ
DM29EFJ	DN	phenylacetylrinvanil
DM29EFJ	HS	Investigative
DM29EFJ	SN	PhAR; IDN5890
DM29EFJ	DT	Small molecular drug
DM29EFJ	PC	73852566
DM29EFJ	MW	535.8
DM29EFJ	FM	C34H49NO4
DM29EFJ	IC	InChI=1S/C34H49NO4/c1-3-4-5-15-20-30(32(37)25-28-18-13-12-14-19-28)21-16-10-8-6-7-9-11-17-22-34(38)35-27-29-23-24-31(36)33(26-29)39-2/h10,12-14,16,18-19,23-24,26,30,36H,3-9,11,15,17,20-22,25,27H2,1-2H3,(H,35,38)/b16-10-/t30-/m1/s1
DM29EFJ	CS	CCCCCC[C@H](C/C=C\\CCCCCCCC(=O)NCC1=CC(=C(C=C1)O)OC)C(=O)CC2=CC=CC=C2
DM29EFJ	IK	STBVSPCCKFGBHG-DJVRBGHSSA-N
DM29EFJ	IU	(Z,12R)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-12-(2-phenylacetyl)octadec-9-enamide
DM29EFJ	DE	Discovery agent

DMZNFT2	ID	DMZNFT2
DMZNFT2	DN	Phenylalanylmethane
DMZNFT2	HS	Investigative
DMZNFT2	SN	PHENYLALANYLMETHANE; 2-Butanone, 3-amino-4-phenyl-, (S)-; 52735-74-7; AC1NRCRL; SCHEMBL4379939; SCHEMBL1436467; CTK1G2192; DTXSID60415353; ZINC5883734; (3S)-3-amino-4-phenylbutan-2-one; AKOS006340967
DMZNFT2	DT	Small molecular drug
DMZNFT2	PC	5289150
DMZNFT2	MW	163.22
DMZNFT2	FM	C10H13NO
DMZNFT2	IC	InChI=1S/C10H13NO/c1-8(12)10(11)7-9-5-3-2-4-6-9/h2-6,10H,7,11H2,1H3/t10-/m0/s1
DMZNFT2	CS	CC(=O)[C@H](CC1=CC=CC=C1)N
DMZNFT2	IK	RTUDQBPZFFIRAD-JTQLQIEISA-N
DMZNFT2	IU	(3S)-3-amino-4-phenylbutan-2-one
DMZNFT2	CA	CAS 52735-74-7
DMZNFT2	DE	Discovery agent

DMHVW61	ID	DMHVW61
DMHVW61	DN	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
DMHVW61	HS	Investigative
DMHVW61	SN	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE; 4-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide; 1ykr; 4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide; aminoimidazo[1,2-a]pyridine deriv. 2i; AC1NS9IQ; CHEMBL182260; BDBM6670; DB04607; 4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide
DMHVW61	DT	Small molecular drug
DMHVW61	PC	5330608
DMHVW61	MW	461.3
DMHVW61	FM	C20H14Cl2N4O3S
DMHVW61	IC	InChI=1S/C20H14Cl2N4O3S/c21-15-2-1-3-16(22)19(15)20(27)12-4-9-18-25-17(11-26(18)10-12)24-13-5-7-14(8-6-13)30(23,28)29/h1-11,24H,(H2,23,28,29)
DMHVW61	CS	C1=CC(=C(C(=C1)Cl)C(=O)C2=CN3C=C(N=C3C=C2)NC4=CC=C(C=C4)S(=O)(=O)N)Cl
DMHVW61	IK	UQAWGIKJINAKIZ-UHFFFAOYSA-N
DMHVW61	IU	4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide
DMHVW61	DE	Discovery agent

DMFRA1Y	ID	DMFRA1Y
DMFRA1Y	DN	Phenylarsonic acid
DMFRA1Y	HS	Investigative
DMFRA1Y	SN	BENZENEARSONIC ACID; 1998/5/5; Monophenylarsonic acid; Arsonic acid, phenyl-; UNII-57F9KU116M; Kyselina benzenarsonova [Czech]; HSDB 6381; EINECS 202-631-9; NSC 15566; Arsonic acid, As-phenyl-; BRN 2935741; AI3-16050; CHEMBL364571; CHEBI:29851; 57F9KU116M; Kyselina benzenarsonova; C6H7AsO3; benzenarsonic acid; Benzenearsonie acid; ACMC-20ajwq; PhAsO3H2; PhAsO(OH)2; AC1Q1HDM; AC1L1OLG; KSC489M9F; 4-16-00-01183 (Beilstein Handbook Reference); SCHEMBL707127; WLN: Q-AS-QO &amp; DTXSID6059158; CTK3I9692; BDBM26997
DMFRA1Y	DT	Small molecular drug
DMFRA1Y	PC	7365
DMFRA1Y	MW	202.04
DMFRA1Y	FM	C6H7AsO3
DMFRA1Y	IC	InChI=1S/C6H7AsO3/c8-7(9,10)6-4-2-1-3-5-6/h1-5H,(H2,8,9,10)
DMFRA1Y	CS	C1=CC=C(C=C1)[As](=O)(O)O
DMFRA1Y	IK	LVKZSFMYNWRPJX-UHFFFAOYSA-N
DMFRA1Y	IU	phenylarsonic acid
DMFRA1Y	CA	CAS 98-05-5
DMFRA1Y	CB	CHEBI:29851
DMFRA1Y	DE	Discovery agent

DMMNYXK	ID	DMMNYXK
DMMNYXK	DN	Phenylcarbamic Acid Biphenyl-3-yl Ester
DMMNYXK	HS	Investigative
DMMNYXK	SN	Phenylcarbamic Acid Biphenyl-3-yl Ester; CHEMBL487535
DMMNYXK	DT	Small molecular drug
DMMNYXK	PC	44585894
DMMNYXK	MW	289.3
DMMNYXK	FM	C19H15NO2
DMMNYXK	IC	InChI=1S/C19H15NO2/c21-19(20-17-11-5-2-6-12-17)22-18-13-7-10-16(14-18)15-8-3-1-4-9-15/h1-14H,(H,20,21)
DMMNYXK	CS	C1=CC=C(C=C1)C2=CC(=CC=C2)OC(=O)NC3=CC=CC=C3
DMMNYXK	IK	DKEGWVCCNFYZEE-UHFFFAOYSA-N
DMMNYXK	IU	(3-phenylphenyl) N-phenylcarbamate
DMMNYXK	DE	Discovery agent

DME75VC	ID	DME75VC
DME75VC	DN	PHENYLDIFLUOROMETHANESULFONAMIDE
DME75VC	HS	Investigative
DME75VC	SN	phenyldifluoromethanesulfonamide; CHEMBL371870; SCHEMBL187768; BDBM50175007
DME75VC	DT	Small molecular drug
DME75VC	PC	12195854
DME75VC	MW	207.2
DME75VC	FM	C7H7F2NO2S
DME75VC	IC	InChI=1S/C7H7F2NO2S/c8-7(9,13(10,11)12)6-4-2-1-3-5-6/h1-5H,(H2,10,11,12)
DME75VC	CS	C1=CC=C(C=C1)C(F)(F)S(=O)(=O)N
DME75VC	IK	MISDUXOMBAGVQG-UHFFFAOYSA-N
DME75VC	IU	difluoro(phenyl)methanesulfonamide
DME75VC	DE	Discovery agent

DMQD2IA	ID	DMQD2IA
DMQD2IA	DN	Phenylethanolamine
DMQD2IA	HS	Investigative
DMQD2IA	SN	Bisnorephedrine; Ethanol, 2-amino-1-phenyl-; Phenethanolamine; Phenethylamine, beta-hydroxy-; Phenylethanolamin; beta-Hydroxy-beta-phenylethylamine; beta-Hydroxyphenethylamine; beta-Phenethanolamine; phenylethanolamine; (+-)-Phenylethanolamine; (+-)-alpha-Phenylglycinol; (RS)-2-Amino-1-phenylethanol; 2-Amino-1-phenyl-1-ethanol; 2-Amino-1-phenylethanol; 2-Hydroxy-2-phenylethylamine; 2-Phenyl-2-hydroxyethylamine; 2-amino-1-phenylethan-1-ol; 7568-93-6; Benzenemethanol, .alpha.-(aminomethyl)-; alpha-(Aminomethyl)benzyl alcohol
DMQD2IA	PC	1000
DMQD2IA	MW	137.18
DMQD2IA	FM	C8H11NO
DMQD2IA	IC	ULSIYEODSMZIPX-UHFFFAOYSA-N
DMQD2IA	CS	C1=CC=C(C=C1)C(CN)O
DMQD2IA	IK	1S/C8H11NO/c9-6-8(10)7-4-2-1-3-5-7/h1-5,8,10H,6,9H2
DMQD2IA	IU	2-amino-1-phenylethanol
DMQD2IA	CA	CAS 7568-93-6
DMQD2IA	CB	CHEBI:16343
DMQD2IA	DE	Arteriosclerosis obliterans

DMHT9AR	ID	DMHT9AR
DMHT9AR	DN	phenylglycine-01
DMHT9AR	HS	Investigative
DMHT9AR	SN	PG 01
DMHT9AR	DT	Small molecular drug
DMHT9AR	PC	4695397
DMHT9AR	MW	439.5
DMHT9AR	FM	C28H29N3O2
DMHT9AR	IC	InChI=1S/C28H29N3O2/c1-19(2)20-13-15-23(16-14-20)30-28(33)27(21-9-5-4-6-10-21)31(3)26(32)17-22-18-29-25-12-8-7-11-24(22)25/h4-16,18-19,27,29H,17H2,1-3H3,(H,30,33)
DMHT9AR	CS	CC(C)C1=CC=C(C=C1)NC(=O)C(C2=CC=CC=C2)N(C)C(=O)CC3=CNC4=CC=CC=C43
DMHT9AR	IK	PQAYCXMQTUEDRD-UHFFFAOYSA-N
DMHT9AR	IU	2-[[2-(1H-indol-3-yl)acetyl]-methylamino]-2-phenyl-N-(4-propan-2-ylphenyl)acetamide
DMHT9AR	CA	CAS 853138-65-5
DMHT9AR	DE	Discovery agent

DMHW93J	ID	DMHW93J
DMHW93J	DN	Phenylglyoxal
DMHW93J	HS	Investigative
DMHW93J	SN	Benzeneacetaldehyde, .alpha.-oxo-; OJUGVDODNPJEEC-UHFFFAOYSA-N; Oxo(phenyl)acetaldehyde; Oxo-phenyl-acetaldehyde; Phenyl glyoxal; alpha-oxobenzeneacetaldehyde; benzoylcarboxaldehyde; benzoylformaldehyde; glyoxal, phenyl-; phenylethanedione; phenylglyoxal; 1074-12-0; 2-oxo-2-phenyl-acetaldehyde; 2-oxo-2-phenylacetaldehyde; AI3-22132; BRN 1854721; CCRIS 966; CHEBI:88868; EINECS 214-036-1; MFCD00006959; N45G3015PA; NSC 156299; NSC 26909; NSC627436; UNII-N45G3015PA; benzeneacetaldehyde, alpha-oxo-, monohydrate
DMHW93J	PC	14090
DMHW93J	MW	134.13
DMHW93J	FM	C8H6O2
DMHW93J	IC	OJUGVDODNPJEEC-UHFFFAOYSA-N
DMHW93J	CS	C1=CC=C(C=C1)C(=O)C=O
DMHW93J	IK	1S/C8H6O2/c9-6-8(10)7-4-2-1-3-5-7/h1-6H
DMHW93J	IU	2-oxo-2-phenylacetaldehyde
DMHW93J	CA	CAS 1074-12-0
DMHW93J	CB	CHEBI:88868
DMHW93J	DE	Discovery agent

DMJTC2B	ID	DMJTC2B
DMJTC2B	DN	Phenylmercury
DMJTC2B	HS	Investigative
DMJTC2B	SN	phenylmercury(1+); 23172-37-4; Arylmercury; CHEBI:30787; [HgPh](+); AC1L1P74; CTK1A4592; NCGC00161826-02
DMJTC2B	DT	Small molecular drug
DMJTC2B	PC	567
DMJTC2B	MW	277.7
DMJTC2B	FM	C6H5Hg
DMJTC2B	IC	InChI=1S/C6H5.Hg/c1-2-4-6-5-3-1;/h1-5H;
DMJTC2B	CS	C1=CC=C(C=C1)[Hg]
DMJTC2B	IK	DCNLOVYDMCVNRZ-UHFFFAOYSA-N
DMJTC2B	IU	phenylmercury
DMJTC2B	CA	CAS 23172-37-4
DMJTC2B	CB	CHEBI:49819
DMJTC2B	DE	Discovery agent

DMGLDFI	ID	DMGLDFI
DMGLDFI	DN	PHENYLMETHANESULFONAMIDE
DMGLDFI	HS	Investigative
DMGLDFI	SN	Phenylmethanesulfonamide; 4563-33-1; Benzenemethanesulfonamide; Benzylsulfonamide; alpha-Toluenesulfonamide; Methanesulfonamide, 1-phenyl-; .alpha.-Toluenesulfonamide; 1-phenylmethanesulfonamide; Toluene-.omega.-sulfonamide; CHEMBL369953; ABOYDMHGKWRPFD-UHFFFAOYSA-N; Toluene-alpha-sulphonamide; benzyl-sulfonamide; a-toluenesulfonamide; NSC28899; EINECS 224-935-0; NSC 28899; phenylmethansulfonamide; alphatoluenesulfonamide; PubChem10753; 1-phenylmethylsulfonamid; phenylmethane sulfonamide; phenyl-methanesulfonamide; alpha-toluene 
DMGLDFI	DT	Small molecular drug
DMGLDFI	PC	78318
DMGLDFI	MW	171.22
DMGLDFI	FM	C7H9NO2S
DMGLDFI	IC	InChI=1S/C7H9NO2S/c8-11(9,10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H2,8,9,10)
DMGLDFI	CS	C1=CC=C(C=C1)CS(=O)(=O)N
DMGLDFI	IK	ABOYDMHGKWRPFD-UHFFFAOYSA-N
DMGLDFI	IU	phenylmethanesulfonamide
DMGLDFI	CA	CAS 4563-33-1
DMGLDFI	DE	Discovery agent

DMYTS73	ID	DMYTS73
DMYTS73	DN	Phenyl-N,N-bis(tosylmethyl)methanamine
DMYTS73	HS	Investigative
DMYTS73	SN	CHEMBL399303; phenyl-N,N-bis(tosylmethyl)methanamine; Benzylbis[(4-methylbenzenesulfonyl)methyl]amine; 65950-40-5; AC1MXBV6; SCHEMBL3972986; CTK1I1277; DTXSID60396416; ZINC15776492; BDBM50232467; AKOS027445593; N,N-Bis(tosylmethyl)benzenemethanamine; N,N-bis[(4-methylphenyl)sulfonylmethyl]-1-phenylmethanamine; Benzenemethanamine, N,N-bis[[(4-methylphenyl)sulfonyl]methyl]-
DMYTS73	DT	Small molecular drug
DMYTS73	PC	3787955
DMYTS73	MW	443.6
DMYTS73	FM	C23H25NO4S2
DMYTS73	IC	InChI=1S/C23H25NO4S2/c1-19-8-12-22(13-9-19)29(25,26)17-24(16-21-6-4-3-5-7-21)18-30(27,28)23-14-10-20(2)11-15-23/h3-15H,16-18H2,1-2H3
DMYTS73	CS	CC1=CC=C(C=C1)S(=O)(=O)CN(CC2=CC=CC=C2)CS(=O)(=O)C3=CC=C(C=C3)C
DMYTS73	IK	KQKVTPWQOSNHBI-UHFFFAOYSA-N
DMYTS73	IU	N,N-bis[(4-methylphenyl)sulfonylmethyl]-1-phenylmethanamine
DMYTS73	CA	CAS 65950-40-5
DMYTS73	DE	Discovery agent

DMQ6P13	ID	DMQ6P13
DMQ6P13	DN	Phenylphosphate
DMQ6P13	HS	Investigative
DMQ6P13	SN	Phenylphosphoric acid; Phenylphosphate; Phenyl dihydrogen phosphate; 701-64-4; Phosphoric acid, monophenyl ester; Phenyl phosphate; phenol phosphate; MONOPHENYL PHOSPHATE; monophenylphosphate; Phenolic phosphate; UNII-75M88J863E; EINECS 211-857-7; CHEMBL26128; CHEBI:37548; CMPQUABWPXYYSH-UHFFFAOYSA-N; 75M88J863E; HPS; phenoxyphosphonic acid; Phosphoric acid phenyl; 1o4o; ACMC-1BB8F; Dihydrogen Phenyl Phosphate; AC1L20DG; DSSTox_RID_80630; DSSTox_CID_24981; SCHEMBL20263; DSSTox_GSID_44981; Phosphoric Acid Phenyl Ester; Phenyl dihydroge
DMQ6P13	DT	Small molecular drug
DMQ6P13	PC	12793
DMQ6P13	MW	174.09
DMQ6P13	FM	C6H7O4P
DMQ6P13	IC	InChI=1S/C6H7O4P/c7-11(8,9)10-6-4-2-1-3-5-6/h1-5H,(H2,7,8,9)
DMQ6P13	CS	C1=CC=C(C=C1)OP(=O)(O)O
DMQ6P13	IK	CMPQUABWPXYYSH-UHFFFAOYSA-N
DMQ6P13	IU	phenyl dihydrogen phosphate
DMQ6P13	CA	CAS 701-64-4
DMQ6P13	CB	CHEBI:37548
DMQ6P13	DE	Discovery agent

DMYMNBL	ID	DMYMNBL
DMYMNBL	DN	Phenyl-phosphonic acid
DMYMNBL	HS	Investigative
DMYMNBL	SN	Phenylphosphonic acid; 1571-33-1; Benzenephosphonic acid; Phosphonic acid, phenyl-; PHENYL PHOSPHONIC ACID; Phosphonic acid, P-phenyl-; UNII-BYD76T2868; NSC 145; EINECS 216-388-1; BRN 2245168; Phenylphosphonic acid, 98%; AI3-52844; NSC145; CHEMBL179801; QLZHNIAADXEJJP-UHFFFAOYSA-N; BYD76T2868; C6H7O3P; SV7; PubChem21303; Phosphonic acid,phenyl-; Dihydrogen phenylphosphonate; AC1L25LB; NCIStruc2_000427; NCIStruc1_000503; ACMC-1C27E; DSSTox_CID_24399; DSSTox_RID_80200; SCHEMBL34998
DMYMNBL	DT	Small molecular drug
DMYMNBL	PC	15295
DMYMNBL	MW	158.09
DMYMNBL	FM	C6H7O3P
DMYMNBL	IC	InChI=1S/C6H7O3P/c7-10(8,9)6-4-2-1-3-5-6/h1-5H,(H2,7,8,9)
DMYMNBL	CS	C1=CC=C(C=C1)P(=O)(O)O
DMYMNBL	IK	QLZHNIAADXEJJP-UHFFFAOYSA-N
DMYMNBL	IU	phenylphosphonic acid
DMYMNBL	CA	CAS 1571-33-1
DMYMNBL	DE	Discovery agent

DMWAK1R	ID	DMWAK1R
DMWAK1R	DN	PHENYLPIPERAZINE
DMWAK1R	HS	Investigative
DMWAK1R	SN	1-PHENYLPIPERAZINE; 92-54-6; N-Phenylpiperazine; Phenylpiperazine; Piperazine, 1-phenyl-; 1-Phenyl-piperazine; 1-Fenylpiperazin [Czech]; UNII-J9225CBI7D; n-phenyl piperazine; 1-phenyl piperazine; CCRIS 4334; N-Phenyldiethylenediamine; EINECS 202-165-6; BRN 0132157; CHEMBL9434; AI3-26332; J9225CBI7D; YZTJYBJCZXZGCT-UHFFFAOYSA-N; MFCD00005957; 1-Phenylpiperazine, 97%; 1-Fenylpiperazin; N-phenylpiperazin; N-PHENYLPIPERAZINE HYDROCHLORIDE; 1-phenylpiperazinehydrochloride; phenyl piperazine; phenyl-piperazine; N-phenylpyperazine
DMWAK1R	DT	Small molecular drug
DMWAK1R	PC	7096
DMWAK1R	MW	162.23
DMWAK1R	FM	C10H14N2
DMWAK1R	IC	InChI=1S/C10H14N2/c1-2-4-10(5-3-1)12-8-6-11-7-9-12/h1-5,11H,6-9H2
DMWAK1R	CS	C1CN(CCN1)C2=CC=CC=C2
DMWAK1R	IK	YZTJYBJCZXZGCT-UHFFFAOYSA-N
DMWAK1R	IU	1-phenylpiperazine
DMWAK1R	CA	CAS 92-54-6
DMWAK1R	DE	Discovery agent

DMRLFJV	ID	DMRLFJV
DMRLFJV	DN	PHENYLSULFAMATE
DMRLFJV	HS	Investigative
DMRLFJV	SN	phenyl sulfamate; phenylsulfamate; Sulfamic acid phenyl ester; Sulfamic acid, phenyl ester; 19792-91-7; CHEMBL24259; MLS001106216; SCHEMBL605969; CTK0E0669; DTXSID50452510; XOIYZMDJFLKIEI-UHFFFAOYSA-N; HMS3328F04; HMS2205G22; ZINC1537101; BDBM50098106; AKOS023879266; SMR000639519; DB-009256
DMRLFJV	DT	Small molecular drug
DMRLFJV	PC	11030308
DMRLFJV	MW	173.19
DMRLFJV	FM	C6H7NO3S
DMRLFJV	IC	InChI=1S/C6H7NO3S/c7-11(8,9)10-6-4-2-1-3-5-6/h1-5H,(H2,7,8,9)
DMRLFJV	CS	C1=CC=C(C=C1)OS(=O)(=O)N
DMRLFJV	IK	XOIYZMDJFLKIEI-UHFFFAOYSA-N
DMRLFJV	IU	phenyl sulfamate
DMRLFJV	CA	CAS 19792-91-7
DMRLFJV	DE	Discovery agent

DMRTHW1	ID	DMRTHW1
DMRTHW1	DN	PHENYLSULFAMIDE
DMRTHW1	HS	Investigative
DMRTHW1	SN	phenylsulfamide; N-phenylsulfamide; 15959-53-2; N-phenylaminosulfonamide; aniline sulfonic acid amide; CHEMBL168514; Sulfamide, phenyl-; Sulfamide, N-phenyl-; (Sulfamoylamino)Benzene; N-Phenylsulfuric diamide; SCHEMBL253104; CTK0E6878; DTXSID50574504; DEVUYWTZRXOMSI-UHFFFAOYSA-N; MolPort-030-912-022; ZINC13488090; BDBM50124170; AKOS029900887; 79499-EP2305698A2; 79499-EP2305697A2; 79499-EP2305695A2; 79499-EP2305696A2
DMRTHW1	DT	Small molecular drug
DMRTHW1	PC	15569631
DMRTHW1	MW	172.21
DMRTHW1	FM	C6H8N2O2S
DMRTHW1	IC	InChI=1S/C6H8N2O2S/c7-11(9,10)8-6-4-2-1-3-5-6/h1-5,8H,(H2,7,9,10)
DMRTHW1	CS	C1=CC=C(C=C1)NS(=O)(=O)N
DMRTHW1	IK	DEVUYWTZRXOMSI-UHFFFAOYSA-N
DMRTHW1	IU	(sulfamoylamino)benzene
DMRTHW1	CA	CAS 15959-53-2
DMRTHW1	DE	Discovery agent

DMM1IAU	ID	DMM1IAU
DMM1IAU	DN	PHENYLTHIOUREA
DMM1IAU	HS	Investigative
DMM1IAU	SN	Phenylthiourea; N-Phenylthiourea; 1-Phenylthiourea; 103-85-5; 1-PHENYL-2-THIOUREA; Phenylthiocarbamide; Thiourea, phenyl-; Phenyl-2-thiourea; Urea, 1-phenyl-2-thio-; phenyl-thiourea; Thiourea, N-phenyl-; Fenylthiomocovina; USAF EK-1569; RCRA waste number P093; NCI-C02017; CCRIS 514; Fenylthiomocovina [Czech]; NSC 5779; N-Phenyl-Thiourea; N-phenylisothiourea; alpha-Phenylthiourea; U 6324; UNII-6F82C6Q54C; HSDB 4105; .alpha.-Phenylthiourea; EINECS 203-151-2; RCRA waste no. P093; AI3-07549; CHEMBL263376; CHEBI:46261
DMM1IAU	DT	Small molecular drug
DMM1IAU	PC	676454
DMM1IAU	MW	152.22
DMM1IAU	FM	C7H8N2S
DMM1IAU	IC	InChI=1S/C7H8N2S/c8-7(10)9-6-4-2-1-3-5-6/h1-5H,(H3,8,9,10)
DMM1IAU	CS	C1=CC=C(C=C1)NC(=S)N
DMM1IAU	IK	FULZLIGZKMKICU-UHFFFAOYSA-N
DMM1IAU	IU	phenylthiourea
DMM1IAU	CA	CAS 103-85-5
DMM1IAU	CB	CHEBI:46261
DMM1IAU	DE	Discovery agent

DM7J0YG	ID	DM7J0YG
DM7J0YG	DN	Phenyl-Uridine-5'-Diphosphate
DM7J0YG	HS	Investigative
DM7J0YG	SN	PHENYL-URIDINE-5'-DIPHOSPHATE; UPP; AC1L9N3F; CHEMBL1199734; DB02790; 5'-O-[(R)-hydroxy{[(S)-hydroxy(phenoxy)phosphoryl]oxy}phosphoryl]uridine; [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phenyl hydrogen phosphate
DM7J0YG	DT	Small molecular drug
DM7J0YG	PC	449409
DM7J0YG	MW	480.26
DM7J0YG	FM	C15H18N2O12P2
DM7J0YG	IC	InChI=1S/C15H18N2O12P2/c18-11-6-7-17(15(21)16-11)14-13(20)12(19)10(27-14)8-26-30(22,23)29-31(24,25)28-9-4-2-1-3-5-9/h1-7,10,12-14,19-20H,8H2,(H,22,23)(H,24,25)(H,16,18,21)/t10-,12-,13-,14-/m1/s1
DM7J0YG	CS	C1=CC=C(C=C1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O
DM7J0YG	IK	ZHUWBKDWWGKIEN-FMKGYKFTSA-N
DM7J0YG	IU	[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phenyl hydrogen phosphate
DM7J0YG	DE	Discovery agent

DMJMLKA	ID	DMJMLKA
DMJMLKA	DN	Phe-Pro-Glu
DMJMLKA	HS	Investigative
DMJMLKA	SN	Phe-Pro-Glu
DMJMLKA	DT	Small molecular drug
DMJMLKA	PC	44408683
DMJMLKA	MW	391.4
DMJMLKA	FM	C19H25N3O6
DMJMLKA	IC	InChI=1S/C19H25N3O6/c20-13(11-12-5-2-1-3-6-12)18(26)22-10-4-7-15(22)17(25)21-14(19(27)28)8-9-16(23)24/h1-3,5-6,13-15H,4,7-11,20H2,(H,21,25)(H,23,24)(H,27,28)/t13-,14-,15-/m0/s1
DMJMLKA	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMJMLKA	IK	QARPMYDMYVLFMW-KKUMJFAQSA-N
DMJMLKA	IU	(2S)-2-[[(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid
DMJMLKA	CB	CHEBI:161803
DMJMLKA	DE	Discovery agent

DMWMBP3	ID	DMWMBP3
DMWMBP3	DN	PheTQS
DMWMBP3	HS	Investigative
DMWMBP3	SN	Alpha7 nicotinic acetylcholine receptor positive allosteric modulators (PAMs) (CNS disorders), GlaxoSmithKline; Alpha7 nicotinic acetylcholine receptor positive allosteric modulators (PAMs) (CNS disorders), Proximagen
DMWMBP3	CP	GlaxoSmithKline plc
DMWMBP3	DE	Central nervous system disease

DMP3MOC	ID	DMP3MOC
DMP3MOC	DN	Philanthotoxin-343
DMP3MOC	HS	Investigative
DMP3MOC	SN	Philanthotoxin 343; Philanthotoxin-343; Phtx 343; AC1Q5PFY; CHEMBL16117; 115976-93-7; CHEBI:34920; AC1L4M0L; SCHEMBL8391460; N-[1-{3-[4-(3-Amino-propylamino)-butylamino]-propylcarbamoyl}-2-(4-hydroxy-phenyl)-ethyl]-butyramide; BDBM50094298; n-[3-({4-[(3-aminopropyl)amino]butyl}amino)propyl]-n; A-butanoyl-l-tyrosinamide; C13806; Benzenepropanamide, N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-hydroxy-alpha-((1-oxobutyl)amino)-, (S)-
DMP3MOC	DT	Small molecular drug
DMP3MOC	PC	159548
DMP3MOC	MW	435.6
DMP3MOC	FM	C23H41N5O3
DMP3MOC	IC	InChI=1S/C23H41N5O3/c1-2-7-22(30)28-21(18-19-8-10-20(29)11-9-19)23(31)27-17-6-16-26-14-4-3-13-25-15-5-12-24/h8-11,21,25-26,29H,2-7,12-18,24H2,1H3,(H,27,31)(H,28,30)/t21-/m0/s1
DMP3MOC	CS	CCCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCCCNCCCCNCCCN
DMP3MOC	IK	DTWANULJDRVTFI-NRFANRHFSA-N
DMP3MOC	IU	N-[(2S)-1-[3-[4-(3-aminopropylamino)butylamino]propylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]butanamide
DMP3MOC	CA	CAS 115976-93-7
DMP3MOC	CB	CHEBI:34920
DMP3MOC	DE	Discovery agent

DM7DWZC	ID	DM7DWZC
DM7DWZC	DN	PhIP glucuronide
DM7DWZC	HS	Investigative
DM7DWZC	SN	A-D-Glucuronide; ZINC77271324; 1-Methyl-6-phenyl-N-(beta-D-glucopyranuronosyl)-1H-imidazo[4,5-b]pyridin-2-amine; 133084-70-5; 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine N-; DTXSID50747014; FT-0661931
DM7DWZC	PC	71313317
DM7DWZC	MW	400.4
DM7DWZC	FM	C19H20N4O6
DM7DWZC	IC	SQVPGYDPSLNFET-KSXIZUIISA-N
DM7DWZC	CS	CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1NC4C(C(C(C(O4)C(=O)O)O)O)O
DM7DWZC	IK	1S/C19H20N4O6/c1-23-11-7-10(9-5-3-2-4-6-9)8-20-16(11)21-19(23)22-17-14(26)12(24)13(25)15(29-17)18(27)28/h2-8,12-15,17,24-26H,1H3,(H,27,28)(H,20,21,22)/t12-,13-,14+,15-,17+/m0/s1
DM7DWZC	IU	(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[(1-methyl-6-phenylimidazo[4,5-b]pyridin-2-yl)amino]oxane-2-carboxylic acid
DM7DWZC	CA	CAS 133084-70-5
DM7DWZC	DE	Pancreatic cancer

DMYA50U	ID	DMYA50U
DMYA50U	DN	Phloretin
DMYA50U	HS	Investigative
DMYA50U	SN	phloretin; 60-82-2; 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one; Dihydronaringenin; Phloretol; 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone; NSC 407292; UNII-S5J5OE47MK; 1-Propanone, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-; CCRIS 7459; beta-(p-Hydroxyphenyl)phloropropiophenone; 2',4',6'-Trihydroxy-3-(p-hydroxyphenyl)propiophenone; 2',4',6'-Trihydroxy-3-(4-Hydroxyphenyl)propiophenone; EINECS 200-488-7; NSC407292; S5J5OE47MK; beta-(p-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone
DMYA50U	DT	Small molecular drug
DMYA50U	PC	4788
DMYA50U	MW	274.27
DMYA50U	FM	C15H14O5
DMYA50U	IC	InChI=1S/C15H14O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20H,3,6H2
DMYA50U	CS	C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O)O)O)O
DMYA50U	IK	VGEREEWJJVICBM-UHFFFAOYSA-N
DMYA50U	IU	3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one
DMYA50U	CA	CAS 60-82-2
DMYA50U	CB	CHEBI:17276
DMYA50U	DE	Discovery agent

DMNARGO	ID	DMNARGO
DMNARGO	DN	Phlorizin
DMNARGO	HS	Investigative
DMNARGO	SN	Phlorizin; Phloridzin; 60-81-1; Phlorhizin; Phlorizoside; Floridzin; Phlorrhizin; Phloretin 2'-glucoside; Phlorrhizen; Phloridzosid; Phlorizine; UNII-CU9S17279X; Phloretin-2'-O-beta-glucoside; AI3-19835; NSC 2833; Phloridzin dihydrate; EINECS 200-487-1; Phloretin-2'-beta-glucoside; CHEBI:8113; CHEMBL245067; IOUVKUPGCMBWBT-QNDFHXLGSA-N; CU9S17279X; 2'-(beta-D-Glucopyranosyloxy)-4',6'-dihydroxy-3-(4-hydroxyphenyl)propiophenone; 1-[2-(beta-D-Glucopyranosyloxy)-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)-1-propanone; 1-Propanone, 1-(2-(b
DMNARGO	DT	Small molecular drug
DMNARGO	PC	6072
DMNARGO	MW	436.4
DMNARGO	FM	C21H24O10
DMNARGO	IC	InChI=1S/C21H24O10/c22-9-16-18(27)19(28)20(29)21(31-16)30-15-8-12(24)7-14(26)17(15)13(25)6-3-10-1-4-11(23)5-2-10/h1-2,4-5,7-8,16,18-24,26-29H,3,6,9H2/t16-,18-,19+,20-,21-/m1/s1
DMNARGO	CS	C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O
DMNARGO	IK	IOUVKUPGCMBWBT-QNDFHXLGSA-N
DMNARGO	IU	1-[2,4-dihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-3-(4-hydroxyphenyl)propan-1-one
DMNARGO	CA	CAS 60-81-1
DMNARGO	CB	CHEBI:8113
DMNARGO	DE	Discovery agent

DMO1I6G	ID	DMO1I6G
DMO1I6G	DN	PHLOROFUCOFUROECKOL A
DMO1I6G	HS	Investigative
DMO1I6G	SN	Phlorofucofuroeckol A; 128129-56-6; CHEMBL510508; phlorofucofuroeckol-A; Phlorofucofuroeckol; AC1L2YD4; 1,11-Di-(3,5-dihydroxyphenoxy)benzofuro(3,2-a)dibenzo(b,e)(1,4)-dioxin-2,4,8,10,14-pentaol; SCHEMBL2230693; DTXSID40155821; BDBM50276756; Benzo(b)benzofuro(3,2-f)(1,4)benzodioxin-1,3,6,10,12-pentol, 4,9-bis(3,5-dihydroxyphenoxy)-; 4,9-bis(3,5-dihydroxyphenoxy)benzofuro[3,2-a]oxanthrene-1,3,6,10,12-pentol; 4,9-bis(3,5-dihydroxyphenoxy)-[1]benzofuro[3,2-a]oxanthrene-1,3,6,10,12-pentol
DMO1I6G	DT	Small molecular drug
DMO1I6G	PC	130976
DMO1I6G	MW	602.5
DMO1I6G	FM	C30H18O14
DMO1I6G	IC	InChI=1S/C30H18O14/c31-10-1-11(32)4-14(3-10)40-24-17(36)7-16(35)22-23-21(42-28(22)24)9-20(39)25-29(23)43-27-19(38)8-18(37)26(30(27)44-25)41-15-5-12(33)2-13(34)6-15/h1-9,31-39H
DMO1I6G	CS	C1=C(C=C(C=C1O)OC2=C(C=C(C3=C2OC4=C3C5=C(C(=C4)O)OC6=C(O5)C(=CC(=C6OC7=CC(=CC(=C7)O)O)O)O)O)O)O
DMO1I6G	IK	SLWPBUMYPRVYIJ-UHFFFAOYSA-N
DMO1I6G	IU	4,9-bis(3,5-dihydroxyphenoxy)-[1]benzofuro[3,2-a]oxanthrene-1,3,6,10,12-pentol
DMO1I6G	CA	CAS 128129-56-6
DMO1I6G	DE	Discovery agent

DMZWTY7	ID	DMZWTY7
DMZWTY7	DN	Phorbol 12,13-butyrate
DMZWTY7	HS	Investigative
DMZWTY7	SN	Phorbol 12,13-dibutyrate; PDBU; Phorbol dibutyrate; 37558-16-0; Phorbol 12,13-dibutanoate; UNII-67MX82CL58; Phorbol-12,13-dibutyrate; NSC 622507; CHEBI:17598; 67MX82CL58; (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulene-9,9a-diyl dibutanoate; Butanoic acid, (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-9aH-cyclopropa[3,4]be
DMZWTY7	DT	Small molecular drug
DMZWTY7	PC	37783
DMZWTY7	MW	504.6
DMZWTY7	FM	C28H40O8
DMZWTY7	IC	InChI=1S/C28H40O8/c1-7-9-20(30)35-24-16(4)27(34)18(22-25(5,6)28(22,24)36-21(31)10-8-2)12-17(14-29)13-26(33)19(27)11-15(3)23(26)32/h11-12,16,18-19,22,24,29,33-34H,7-10,13-14H2,1-6H3/t16-,18+,19-,22-,24-,26-,27-,28-/m1/s1
DMZWTY7	CS	CCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)CCC)O)C
DMZWTY7	IK	BQJRUJTZSGYBEZ-YVQNUNKESA-N
DMZWTY7	IU	[(1S,2S,6R,10S,11R,13S,14R,15R)-13-butanoyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] butanoate
DMZWTY7	CA	CAS 37558-16-0
DMZWTY7	CB	CHEBI:17598
DMZWTY7	DE	Discovery agent

DM096SC	ID	DM096SC
DM096SC	DN	Phorbol 12-myristate
DM096SC	HS	Investigative
DM096SC	SN	Phorbol-12-myristate; Phorbol-12-monomyristate; BRN 2319156; (1ar,1bs,4ar,7as,7bs,8r,9r,9as)-4a,7b,9a-trihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1h-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl tetradecanoate; 20839-06-9; Tetradecanoic acid, 1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-4a,7b,9a-trihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa(3,4)benz(1,2-e)azulen-9-yl ester, (1aR-(1a-alpha,1b-beta,4a-beta,7a-alpha,7b-alpha,8-alpha,9-beta,9a-alpha))-
DM096SC	DT	Small molecular drug
DM096SC	PC	107854
DM096SC	MW	574.8
DM096SC	FM	C34H54O7
DM096SC	IC	InChI=1S/C34H54O7/c1-6-7-8-9-10-11-12-13-14-15-16-17-27(36)41-30-23(3)33(39)25(28-31(4,5)34(28,30)40)19-24(21-35)20-32(38)26(33)18-22(2)29(32)37/h18-19,23,25-26,28,30,35,38-40H,6-17,20-21H2,1-5H3/t23-,25+,26-,28-,30-,32-,33-,34-/m1/s1
DM096SC	CS	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)O)O)C
DM096SC	IK	XLCISDOVNFLSGO-VONOSFMSSA-N
DM096SC	IU	[(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,13-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate
DM096SC	CA	CAS 20839-06-9
DM096SC	DE	Discovery agent

DM2USYW	ID	DM2USYW
DM2USYW	DN	Phosethanolamine
DM2USYW	HS	Investigative
DM2USYW	SN	Phosphatidylethanolamine; PHOSPHATIDYLETHANOLAMINE; Q27464388; (1s)-2-{[(2-Aminoethoxy)(Hydroxy)phosphoryl]oxy}-1-[(Palmitoyloxy)methyl]ethyl Stearate; 1-PALMITOYL-2-OLEOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE
DM2USYW	PC	16040250
DM2USYW	MW	720
DM2USYW	FM	C39H78NO8P
DM2USYW	IC	RPJZYOHZALDGKI-QNGWXLTQSA-N
DM2USYW	CS	CCCCCCCCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OCCN
DM2USYW	IK	1S/C39H78NO8P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(42)48-37(36-47-49(43,44)46-34-33-40)35-45-38(41)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h37H,3-36,40H2,1-2H3,(H,43,44)/t37-/m0/s1
DM2USYW	IU	[(2S)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadecanoate
DM2USYW	DE	Parkinsonism

DMMHQYB	ID	DMMHQYB
DMMHQYB	DN	phosphatidyl (3,5) inositol biphosphate
DMMHQYB	HS	Investigative
DMMHQYB	SN	phosphatidylinositol 3,5-bisphosphate; PI(3,5)P2
DMMHQYB	DT	Small molecular drug
DMMHQYB	PC	643961
DMMHQYB	MW	971
DMMHQYB	FM	C41H81O19P3
DMMHQYB	IC	InChI=1S/C41H81O19P3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(42)55-31-33(57-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)32-56-63(53,54)60-41-37(45)39(58-61(47,48)49)36(44)40(38(41)46)59-62(50,51)52/h33,36-41,44-46H,3-32H2,1-2H3,(H,53,54)(H2,47,48,49)(H2,50,51,52)/t33-,36?,37-,38-,39-,40+,41?/m1/s1
DMMHQYB	CS	CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC1[C@@H]([C@H](C([C@H]([C@H]1O)OP(=O)(O)O)O)OP(=O)(O)O)O)OC(=O)CCCCCCCCCCCCCCC
DMMHQYB	IK	UZMPYXSDDZXMAI-OHKKONBVSA-N
DMMHQYB	IU	[(2R)-2-hexadecanoyloxy-3-[hydroxy-[(2R,3R,5S,6R)-2,4,6-trihydroxy-3,5-diphosphonooxycyclohexyl]oxyphosphoryl]oxypropyl] hexadecanoate
DMMHQYB	CA	CAS 214282-36-7
DMMHQYB	CB	CHEBI:82954
DMMHQYB	DE	Discovery agent

DMY2RVX	ID	DMY2RVX
DMY2RVX	DN	Phosphatidylcholine
DMY2RVX	HS	Investigative
DMY2RVX	SN	Phosphatidylcholine; ZINC32792133; (7s)-4-Hydroxy-N,N,N-Trimethyl-9-Oxo-7-[(Palmitoyloxy)methyl]-3,5,8-Trioxa-4-Phosphahexacosan-1-Aminium 4-Oxide; PHOSPHATIDYLCHOLINE; 1-PALMITOYL-2-STEAROYL-PC
DMY2RVX	PC	14389436
DMY2RVX	MW	763.1
DMY2RVX	FM	C42H85NO8P+
DMY2RVX	IC	PZNPLUBHRSSFHT-FAIXQHPJSA-O
DMY2RVX	CS	CCCCCCCCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OCC[N+](C)(C)C
DMY2RVX	IK	1S/C42H84NO8P/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-42(45)51-40(39-50-52(46,47)49-37-36-43(3,4)5)38-48-41(44)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2/h40H,6-39H2,1-5H3/p+1/t40-/m0/s1
DMY2RVX	IU	2-[[(2S)-3-hexadecanoyloxy-2-octadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
DMY2RVX	DE	Discovery agent

DMOPYWF	ID	DMOPYWF
DMOPYWF	DN	Phosphatidylethanolamine
DMOPYWF	HS	Investigative
DMOPYWF	SN	cephalin
DMOPYWF	DT	Small molecular drug
DMOPYWF	PC	5327011
DMOPYWF	MW	299.21
DMOPYWF	FM	C9H18NO8P
DMOPYWF	IC	InChI=1S/C9H18NO8P/c1-7(11)15-5-9(18-8(2)12)6-17-19(13,14)16-4-3-10/h9H,3-6,10H2,1-2H3,(H,13,14)/t9-/m1/s1
DMOPYWF	CS	CC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)C
DMOPYWF	IK	CFWRDBDJAOHXSH-SECBINFHSA-N
DMOPYWF	IU	[(2R)-2-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropyl] acetate
DMOPYWF	CA	CAS 1334474-30-4
DMOPYWF	DE	Discovery agent

DM76TSG	ID	DM76TSG
DM76TSG	DN	Phosphatidylserine
DM76TSG	HS	Investigative
DM76TSG	SN	distearoylphosphatidylserine; LifeExtension PS Caps
DM76TSG	DT	Small molecular drug
DM76TSG	PC	6323481
DM76TSG	MW	385.3
DM76TSG	FM	C13H24NO10P
DM76TSG	IC	InChI=1S/C13H24NO10P/c1-3-5-12(16)24-9(6-21-11(15)4-2)7-22-25(19,20)23-8-10(14)13(17)18/h9-10H,3-8,14H2,1-2H3,(H,17,18)(H,19,20)/t9-,10+/m1/s1
DM76TSG	CS	CCCC(=O)O[C@H](COC(=O)CC)COP(=O)(O)OC[C@@H](C(=O)O)N
DM76TSG	IK	UNJJBGNPUUVVFQ-ZJUUUORDSA-N
DM76TSG	IU	(2S)-2-amino-3-[[(2R)-2-butanoyloxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
DM76TSG	CA	CAS 1446756-47-3
DM76TSG	DE	Discovery agent

DMIZLVW	ID	DMIZLVW
DMIZLVW	DN	Phosphocholine
DMIZLVW	HS	Investigative
DMIZLVW	SN	phosphocholine; PHOSPHORYLCHOLINE; O-Phosphocholine; choline phosphate; phosphoryl-choline; CHOP; CHEBI:18132; N-Trimethyl-2-aminoethylphosphonate; N,N,N-trimethyl-2-(phosphonooxy)ethanaminium; Trimethyl(2-(phosphonooxy)ethyl)ammonium; Ethanaminium, N,N,N-trimethyl-2-(phosphonooxy)-; Phosphocholine cation; AC1L1AJH; Epitope ID:115009; SCHEMBL8012; n,n,n-trim ; thyl-2-(phosphonooxy) ; thanaminium; AC1Q29R5; CHEMBL1235161; CTK1B6465; YHHSONZFOIEMCP-UHFFFAOYSA-O; ZINC1532692; trimethyl(2-phosphonooxyethyl)azanium; DB03945; Choline, di
DMIZLVW	DT	Small molecular drug
DMIZLVW	PC	1014
DMIZLVW	MW	184.15
DMIZLVW	FM	C5H15NO4P+
DMIZLVW	IC	InChI=1S/C5H14NO4P/c1-6(2,3)4-5-10-11(7,8)9/h4-5H2,1-3H3,(H-,7,8,9)/p+1
DMIZLVW	CS	C[N+](C)(C)CCOP(=O)(O)O
DMIZLVW	IK	YHHSONZFOIEMCP-UHFFFAOYSA-O
DMIZLVW	IU	trimethyl(2-phosphonooxyethyl)azanium
DMIZLVW	CA	CAS 3616-04-4
DMIZLVW	CB	CHEBI:18132
DMIZLVW	DE	Discovery agent

DM2D947	ID	DM2D947
DM2D947	DN	Phosphoenolpyruvate
DM2D947	HS	Investigative
DM2D947	SN	phosphoenolpyruvate; Phosphoenolpyruvic acid; 138-08-9; 2-(phosphonooxy)prop-2-enoic acid; Phosphopyruvic acid; 2-Propenoic acid, 2-(phosphonooxy)-; PEP; UNII-545YL308OW; 2-Phosphonooxyprop-2-enoic acid; 2-Dihydroxyphosphinoyloxyacrylic acid; CHEBI:44897; DTBNBXWJWCWCIK-UHFFFAOYSA-N; 545YL308OW; P-enol-pyruvate; Barium silver 2-(phosphonatooxy)acrylate; 2-phosphonooxyprop-2-enoate; 2-(phosphonooxy)-2-propenoic acid; 923-14-8; P-enolpyruvate; 1nhx; EINECS 213-089-8; EINECS 205-312-2; AC1L1AIQ; Phospho(enol)pyruvic acid; bmse000107
DM2D947	DT	Small molecular drug
DM2D947	PC	1005
DM2D947	MW	168.04
DM2D947	FM	C3H5O6P
DM2D947	IC	InChI=1S/C3H5O6P/c1-2(3(4)5)9-10(6,7)8/h1H2,(H,4,5)(H2,6,7,8)
DM2D947	CS	C=C(C(=O)O)OP(=O)(O)O
DM2D947	IK	DTBNBXWJWCWCIK-UHFFFAOYSA-N
DM2D947	IU	2-phosphonooxyprop-2-enoic acid
DM2D947	CA	CAS 138-08-9
DM2D947	CB	CHEBI:44897
DM2D947	DE	Discovery agent

DMAYLNO	ID	DMAYLNO
DMAYLNO	DN	PHOSPHOGLYCOLOHYDROXAMATE
DMAYLNO	HS	Investigative
DMAYLNO	SN	Phosphoglycolohydroxamic Acid; phosphoglycolohydroxamate; 2-(hydroxyamino)-2-oxoethyl dihydrogen phosphate; Acetamide, N-hydroxy-2-(phosphonooxy)-; CHEMBL371668; 51528-59-7; CHEBI:28475; 1tpw; PGH; 1trd; 1ik4; AC1L1IZ8; SCHEMBL4309631; AC1Q6S77; DTXSID90199497; O-PHOSPHOGLYCOLOHYDROXAMATE; BDBM50167777; DB02739; DB03026; Phosphoric acid monohydroxycarbamoylmethyl ester; [2-(hydroxyamino)-2-oxoethyl] dihydrogen phosphate
DMAYLNO	DT	Small molecular drug
DMAYLNO	PC	4797
DMAYLNO	MW	171.05
DMAYLNO	FM	C2H6NO6P
DMAYLNO	IC	InChI=1S/C2H6NO6P/c4-2(3-5)1-9-10(6,7)8/h5H,1H2,(H,3,4)(H2,6,7,8)
DMAYLNO	CS	C(C(=O)NO)OP(=O)(O)O
DMAYLNO	IK	BAXHHWZKQZIJID-UHFFFAOYSA-N
DMAYLNO	IU	[2-(hydroxyamino)-2-oxoethyl] dihydrogen phosphate
DMAYLNO	CA	CAS 51528-59-7
DMAYLNO	CB	CHEBI:28475
DMAYLNO	DE	Discovery agent

DM4IRU5	ID	DM4IRU5
DM4IRU5	DN	Phosphomethylphosphonic Acid Guanylate Ester
DM4IRU5	HS	Investigative
DM4IRU5	DT	Small molecular drug
DM4IRU5	PC	135440070
DM4IRU5	MW	521.21
DM4IRU5	FM	C11H18N5O13P3
DM4IRU5	IC	InChI=1S/C11H18N5O13P3/c12-11-14-8-5(9(19)15-11)13-2-16(8)10-7(18)6(17)4(28-10)1-27-30(20,21)3-31(22,23)29-32(24,25)26/h2,4,6-7,10,17-18H,1,3H2,(H,20,21)(H,22,23)(H2,24,25,26)(H3,12,14,15,19)/t4-,6-,7-,10-/m1/s1
DM4IRU5	CS	C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O)O)N=C(NC2=O)N
DM4IRU5	IK	GXTIEXDFEKYVGY-KQYNXXCUSA-N
DM4IRU5	IU	[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[hydroxy(phosphonooxy)phosphoryl]methyl]phosphinic acid
DM4IRU5	DE	Discovery agent

DMTFHPI	ID	DMTFHPI
DMTFHPI	DN	Phosphonothreonine
DMTFHPI	HS	Investigative
DMTFHPI	SN	phosphothreonine; O-phospho-L-threonine; 1114-81-4; L-Threonine O-phosphate; (2S,3R)-2-amino-3-(phosphonooxy)butanoic acid; O-Phosphothreonine; L-Threonine phosphate; Threoninium dihydrogen phosphate; O-phosphono-L-threonine; L-Threonine O-3-phosphate; O3-phosphothreonine; PHOSPHONOTHREONINE; 27530-80-9; threonine phosphate ester; (2S,3R)-2-amino-3-hydroxybutanoic acid 3-phosphate; Threonine, O-phosphono-; H-Thr(PO3H2)-OH; C4H10NO6P; phospho-l-threonine; EINECS 214-217-5; Synonyms    Sources; (S)-2-Amino-3-hydroxybutanoic acid 
DMTFHPI	DT	Small molecular drug
DMTFHPI	PC	10976469
DMTFHPI	MW	199.1
DMTFHPI	FM	C4H10NO6P
DMTFHPI	IC	InChI=1S/C4H10NO6P/c1-2(3(5)4(6)7)11-12(8,9)10/h2-3H,5H2,1H3,(H,6,7)(H2,8,9,10)/t2-,3+/m0/s1
DMTFHPI	CS	C[C@@H]([C@H](C(=O)O)N)OP(=O)(O)O
DMTFHPI	IK	USRGIUJOYOXOQJ-STHAYSLISA-N
DMTFHPI	IU	(2R,3S)-2-amino-3-phosphonooxybutanoic acid
DMTFHPI	CA	CAS 96193-69-0
DMTFHPI	DE	Discovery agent

DM09MY1	ID	DM09MY1
DM09MY1	DN	Phosphonotyrosine
DM09MY1	HS	Investigative
DM09MY1	SN	O(4)-phosphonato-L-tyrosine(2-); (2S)-2-ammonio-3-[4-(phosphonatooxy)phenyl]propanoate; Phosphotyrosine (pTyr); 4-O-phospho-L-tyrosine; CHEBI:62338; BDBM195583; CJ-23970
DM09MY1	DT	Small molecular drug
DM09MY1	PC	30819
DM09MY1	MW	261.17
DM09MY1	FM	C9H12NO6P
DM09MY1	IC	InChI=1S/C9H12NO6P/c10-8(9(11)12)5-6-1-3-7(4-2-6)16-17(13,14)15/h1-4,8H,5,10H2,(H,11,12)(H2,13,14,15)/t8-/m0/s1
DM09MY1	CS	C1=CC(=CC=C1C[C@@H](C(=O)O)N)OP(=O)(O)O
DM09MY1	IK	DCWXELXMIBXGTH-QMMMGPOBSA-N
DM09MY1	IU	(2S)-2-amino-3-(4-phosphonooxyphenyl)propanoic acid
DM09MY1	CA	CAS 21820-51-9
DM09MY1	CB	CHEBI:37788
DM09MY1	DE	Discovery agent

DM3VL7G	ID	DM3VL7G
DM3VL7G	DN	Phosphoramidon
DM3VL7G	HS	Investigative
DM3VL7G	SN	Talopeptin; 84235-60-9; L-Tryptophan, N-(N-(((6-deoxy-alpha-L-talopyranosyl)oxy)hydroxyphosphinyl)-L-leucyl)-; talopeptin (MKI); AC1Q5QPH; (2s)-2-({(2s)-2-[(hydroxy{[(2s,3r,4r,5s,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}phosphoryl)amino]-4-methylpentanoyl}amino)-3-(1h-indol-3-yl)propanoic acid(non-preferred name); SCHEMBL7155564; AC1L353S; CHEMBL1742968; LS-158133; N-(6-deoxy-alpha-talopyranosyloxyphospho)-leucyl-tryptophan; N-[N-[[(6-deoxy-
DM3VL7G	DT	Small molecular drug
DM3VL7G	PC	445114
DM3VL7G	MW	543.5
DM3VL7G	FM	C23H34N3O10P
DM3VL7G	IC	InChI=1S/C23H34N3O10P/c1-11(2)8-16(26-37(33,34)36-23-20(29)19(28)18(27)12(3)35-23)21(30)25-17(22(31)32)9-13-10-24-15-7-5-4-6-14(13)15/h4-7,10-12,16-20,23-24,27-29H,8-9H2,1-3H3,(H,25,30)(H,31,32)(H2,26,33,34)/t12-,16-,17-,18-,19+,20+,23-/m0/s1
DM3VL7G	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OP(=O)(N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)O)O)O)O
DM3VL7G	IK	ZPHBZEQOLSRPAK-XLCYBJAPSA-N
DM3VL7G	IU	(2S)-2-[[(2S)-2-[[hydroxy-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DM3VL7G	CA	CAS 36357-77-4
DM3VL7G	CB	CHEBI:45353
DM3VL7G	DE	Discovery agent

DMS57HX	ID	DMS57HX
DMS57HX	DN	Phosphoric acid mono-((E)-dec-4-enyl) ester
DMS57HX	HS	Investigative
DMS57HX	SN	CHEMBL188081; Phosphoric acid mono-((E)-dec-4-enyl) ester; SCHEMBL193089; 4-Decen-1-ol, dihydrogen phosphate; BDBM50170856
DMS57HX	DT	Small molecular drug
DMS57HX	PC	11276402
DMS57HX	MW	236.24
DMS57HX	FM	C10H21O4P
DMS57HX	IC	InChI=1S/C10H21O4P/c1-2-3-4-5-6-7-8-9-10-14-15(11,12)13/h6-7H,2-5,8-10H2,1H3,(H2,11,12,13)/b7-6+
DMS57HX	CS	CCCCC/C=C/CCCOP(=O)(O)O
DMS57HX	IK	KAHLDJCENUPBQU-VOTSOKGWSA-N
DMS57HX	IU	[(E)-dec-4-enyl] dihydrogen phosphate
DMS57HX	DE	Discovery agent

DMC873V	ID	DMC873V
DMC873V	DN	Phosphoric acid mono-((E)-dodec-9-enyl) ester
DMC873V	HS	Investigative
DMC873V	SN	CHEMBL190349; Phosphoric acid mono-((E)-dodec-9-enyl) ester; SCHEMBL194116; BDBM50170858; 9-Dodecen-1-ol, dihydrogen phosphate
DMC873V	DT	Small molecular drug
DMC873V	PC	11219269
DMC873V	MW	264.3
DMC873V	FM	C12H25O4P
DMC873V	IC	InChI=1S/C12H25O4P/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h3-4H,2,5-12H2,1H3,(H2,13,14,15)/b4-3+
DMC873V	CS	CC/C=C/CCCCCCCCOP(=O)(O)O
DMC873V	IK	FSJUVXSBVQARLY-ONEGZZNKSA-N
DMC873V	IU	[(E)-dodec-9-enyl] dihydrogen phosphate
DMC873V	DE	Discovery agent

DMET9ZC	ID	DMET9ZC
DMET9ZC	DN	Phosphoric acid mono-((E)-tetradec-11-enyl) ester
DMET9ZC	HS	Investigative
DMET9ZC	SN	CHEMBL188591; SCHEMBL193531; Phosphoric acid mono-((E)-tetradec-11-enyl) ester; ZINC13648502
DMET9ZC	DT	Small molecular drug
DMET9ZC	PC	11312382
DMET9ZC	MW	292.35
DMET9ZC	FM	C14H29O4P
DMET9ZC	IC	InChI=1S/C14H29O4P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-19(15,16)17/h3-4H,2,5-14H2,1H3,(H2,15,16,17)/b4-3+
DMET9ZC	CS	CC/C=C/CCCCCCCCCCOP(=O)(O)O
DMET9ZC	IK	VKPRWVOYFUXFAT-ONEGZZNKSA-N
DMET9ZC	IU	[(E)-tetradec-11-enyl] dihydrogen phosphate
DMET9ZC	DE	Discovery agent

DME8APC	ID	DME8APC
DME8APC	DN	Phosphoric acid mono-((E)-tetradec-9-enyl) ester
DME8APC	HS	Investigative
DME8APC	SN	CHEMBL190430; Phosphoric acid mono-((E)-tetradec-9-enyl) ester; SCHEMBL193819; ZINC13648500
DME8APC	DT	Small molecular drug
DME8APC	PC	11197104
DME8APC	MW	292.35
DME8APC	FM	C14H29O4P
DME8APC	IC	InChI=1S/C14H29O4P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-19(15,16)17/h5-6H,2-4,7-14H2,1H3,(H2,15,16,17)/b6-5+
DME8APC	CS	CCCC/C=C/CCCCCCCCOP(=O)(O)O
DME8APC	IK	UNBFYEIEMBSWCK-AATRIKPKSA-N
DME8APC	IU	[(E)-tetradec-9-enyl] dihydrogen phosphate
DME8APC	DE	Discovery agent

DMANVJY	ID	DMANVJY
DMANVJY	DN	Phosphoric acid monodec-9-enyl ester
DMANVJY	HS	Investigative
DMANVJY	SN	Phosphoric acid monodec-9-enyl ester; CHEMBL363776; 9-Decen-1-ol, 1-(dihydrogen phosphate); SCHEMBL192861; BDBM50170863
DMANVJY	DT	Small molecular drug
DMANVJY	PC	11447695
DMANVJY	MW	236.24
DMANVJY	FM	C10H21O4P
DMANVJY	IC	InChI=1S/C10H21O4P/c1-2-3-4-5-6-7-8-9-10-14-15(11,12)13/h2H,1,3-10H2,(H2,11,12,13)
DMANVJY	CS	C=CCCCCCCCCOP(=O)(O)O
DMANVJY	IK	LVTDUQMIHPQSMK-UHFFFAOYSA-N
DMANVJY	IU	dec-9-enyl dihydrogen phosphate
DMANVJY	DE	Discovery agent

DMME0VN	ID	DMME0VN
DMME0VN	DN	Phosphoric acid monododecyl ester
DMME0VN	HS	Investigative
DMME0VN	SN	Dodecyl dihydrogen phosphate; Monolauryl phosphate; Phosphoric acid, monododecyl ester; Monododecyl phosphate; 2627-35-2; Dihydrogen monolauryl phosphate; Lauryl dihydrogen phosphate; Mono-n-Dodecyl Phosphate; 12751-23-4; UNII-0K08L8GE2H; CHEMBL187711; 0K08L8GE2H; TVACALAUIQMRDF-UHFFFAOYSA-N; EINECS 220-095-4; NSC 41919; dodecylphosphoric acid; mono-Lauryl phosphate; mono-dodecyl phosphate; Momo-dodecyl phosphate; dodecyl phosphoric acid
DMME0VN	DT	Small molecular drug
DMME0VN	PC	75816
DMME0VN	MW	266.31
DMME0VN	FM	C12H27O4P
DMME0VN	IC	InChI=1S/C12H27O4P/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h2-12H2,1H3,(H2,13,14,15)
DMME0VN	CS	CCCCCCCCCCCCOP(=O)(O)O
DMME0VN	IK	TVACALAUIQMRDF-UHFFFAOYSA-N
DMME0VN	IU	dodecyl dihydrogen phosphate
DMME0VN	CA	CAS 2627-35-2
DMME0VN	DE	Discovery agent

DMG5MJL	ID	DMG5MJL
DMG5MJL	DN	Phosphoric acid monotetradecyl ester
DMG5MJL	HS	Investigative
DMG5MJL	SN	Tetradecyl dihydrogen phosphate; UNII-DF6HW7A5EB; 1-Tetradecanol, dihydrogen phosphate; 10054-29-2; Phosphoric acid monotetradecyl ester; DF6HW7A5EB; CHEMBL187633; 69029-24-9; myristyl phosphate; EINECS 233-184-8; AC1Q6T1O; SCHEMBL375578; AC1L336V; Phosphoric acid tetradecyl ester; DTXSID1073995; BDBM50170842
DMG5MJL	DT	Small molecular drug
DMG5MJL	PC	82327
DMG5MJL	MW	294.37
DMG5MJL	FM	C14H31O4P
DMG5MJL	IC	InChI=1S/C14H31O4P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-19(15,16)17/h2-14H2,1H3,(H2,15,16,17)
DMG5MJL	CS	CCCCCCCCCCCCCCOP(=O)(O)O
DMG5MJL	IK	KRIXEEBVZRZHOS-UHFFFAOYSA-N
DMG5MJL	IU	tetradecyl dihydrogen phosphate
DMG5MJL	CA	CAS 10054-29-2
DMG5MJL	DE	Discovery agent

DMN0D14	ID	DMN0D14
DMN0D14	DN	PhSO2-Gly-(Me-Gly)-Arg-(2-thiazole)
DMN0D14	HS	Investigative
DMN0D14	SN	CHEMBL403629
DMN0D14	DT	Small molecular drug
DMN0D14	PC	44453269
DMN0D14	MW	509.6
DMN0D14	FM	C20H27N7O5S2
DMN0D14	IC	InChI=1S/C20H27N7O5S2/c1-27(17(29)12-25-34(31,32)14-6-3-2-4-7-14)13-16(28)26-15(8-5-9-24-20(21)22)18(30)19-23-10-11-33-19/h2-4,6-7,10-11,15,25H,5,8-9,12-13H2,1H3,(H,26,28)(H4,21,22,24)/t15-/m0/s1
DMN0D14	CS	CN(CC(=O)N[C@@H](CCCN=C(N)N)C(=O)C1=NC=CS1)C(=O)CNS(=O)(=O)C2=CC=CC=C2
DMN0D14	IK	GJNJUHMPYZAMBU-HNNXBMFYSA-N
DMN0D14	IU	2-(benzenesulfonamido)-N-[2-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-2-oxoethyl]-N-methylacetamide
DMN0D14	DE	Discovery agent

DMI96Y3	ID	DMI96Y3
DMI96Y3	DN	PHT-427
DMI96Y3	HS	Investigative
DMI96Y3	SN	PHT 427; PHT427
DMI96Y3	DT	Small molecular drug
DMI96Y3	PC	44240850
DMI96Y3	MW	409.6
DMI96Y3	FM	C20H31N3O2S2
DMI96Y3	IC	InChI=1S/C20H31N3O2S2/c1-2-3-4-5-6-7-8-9-10-11-12-18-13-15-19(16-14-18)27(24,25)23-20-22-21-17-26-20/h13-17H,2-12H2,1H3,(H,22,23)
DMI96Y3	CS	CCCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)NC2=NN=CS2
DMI96Y3	IK	BYWWNRBKPCPJMG-UHFFFAOYSA-N
DMI96Y3	IU	4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide
DMI96Y3	CA	CAS 1191951-57-1
DMI96Y3	DE	Discovery agent

DMF9T64	ID	DMF9T64
DMF9T64	DN	Phthalic Acid
DMF9T64	HS	Investigative
DMF9T64	SN	Phthalic acid (tms); 1,2-Benzenedicarboxylic acid, bis(trimethylsilyl) ester; AC1LAT55; 2078-22-0; Phthalic acid, 2TMS derivative; Bis(trimethylsilyl) phthalate #; SCHEMBL16004864; Phthalic acid bis(trimethylsilyl); JUZOFKLPPHUUMC-UHFFFAOYSA-N; bis(trimethylsilyl) benzene-1,2-dicarboxylate; ORTHO-PHTHALIC ACID BIS(TRIMETHYLSILYL) ESTER
DMF9T64	DT	Small molecular drug
DMF9T64	PC	1017
DMF9T64	MW	166.13
DMF9T64	FM	C8H6O4
DMF9T64	IC	InChI=1S/C8H6O4/c9-7(10)5-3-1-2-4-6(5)8(11)12/h1-4H,(H,9,10)(H,11,12)
DMF9T64	CS	C1=CC=C(C(=C1)C(=O)O)C(=O)O
DMF9T64	IK	XNGIFLGASWRNHJ-UHFFFAOYSA-N
DMF9T64	IU	phthalic acid
DMF9T64	CA	CAS 88-99-3
DMF9T64	CB	CHEBI:29069
DMF9T64	DE	Discovery agent

DMBHKAV	ID	DMBHKAV
DMBHKAV	DN	PHTPP
DMBHKAV	HS	Investigative
DMBHKAV	SN	805239-56-9; 4-[2-PHENYL-5,7-BIS(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]PHENOL; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl)phenol; CHEMBL191066; GTPL3461; SCHEMBL15556029; Pyrazolo[1,5-a]pyrimidine, 2a; CTK8F1047; BDBM19452; CHEBI:93344; DTXSID10458573; AOB5403; MolPort-023-276-532; HMS3269L05; PHTPP, &gt; BCP29119; ZINC13584996; AKOS024457227; NCGC00167819-01; HY-103456; RT-015048; B7144; CS-0027927; BRD-K76568384-001-01-4
DMBHKAV	DT	Small molecular drug
DMBHKAV	PC	11201035
DMBHKAV	MW	423.3
DMBHKAV	FM	C20H11F6N3O
DMBHKAV	IC	InChI=1S/C20H11F6N3O/c21-19(22,23)14-10-15(20(24,25)26)29-18(27-14)16(11-6-8-13(30)9-7-11)17(28-29)12-4-2-1-3-5-12/h1-10,30H
DMBHKAV	CS	C1=CC=C(C=C1)C2=NN3C(=CC(=NC3=C2C4=CC=C(C=C4)O)C(F)(F)F)C(F)(F)F
DMBHKAV	IK	AEZPAUSGTAHLOQ-UHFFFAOYSA-N
DMBHKAV	IU	4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol
DMBHKAV	CA	CAS 805239-56-9
DMBHKAV	CB	CHEBI:93344
DMBHKAV	DE	Discovery agent

DMPS1Y2	ID	DMPS1Y2
DMPS1Y2	DN	P-hydroxyphenethyl trans-ferulate
DMPS1Y2	HS	Investigative
DMPS1Y2	SN	p-Hydroxyphenethyl trans-ferulate; 84873-15-4; CHEMBL481245; Hydroxyphenethylferulate; AC1LCTXZ; SCHEMBL12298709; 4-Hydroxyphenethyl trans-ferulate; DTXSID10348425; MolPort-039-063-541; BCP16493; ZINC14503833; BDBM50259746; 9566AF; (4-Hydroxyphenyl)ethyl trans-ferulate; AKOS025288299; 3-(3-Methoxy-4-hydroxyphenyl)acrylic acid 4-hydroxyphenethyl ester; 2-(4-hydroxyphenyl)ethyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate; 2-(4-hydroxyphenyl)ethyl (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
DMPS1Y2	DT	Small molecular drug
DMPS1Y2	PC	637308
DMPS1Y2	MW	314.3
DMPS1Y2	FM	C18H18O5
DMPS1Y2	IC	InChI=1S/C18H18O5/c1-22-17-12-14(4-8-16(17)20)5-9-18(21)23-11-10-13-2-6-15(19)7-3-13/h2-9,12,19-20H,10-11H2,1H3/b9-5+
DMPS1Y2	CS	COC1=C(C=CC(=C1)/C=C/C(=O)OCCC2=CC=C(C=C2)O)O
DMPS1Y2	IK	JMSFLLZUCIXALN-WEVVVXLNSA-N
DMPS1Y2	IU	2-(4-hydroxyphenyl)ethyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
DMPS1Y2	CA	CAS 84873-15-4
DMPS1Y2	DE	Discovery agent

DMU30IO	ID	DMU30IO
DMU30IO	DN	Phylomers
DMU30IO	HS	Investigative
DMU30IO	SN	PYC-35; PYC-35T; PYC-36D; PYC-36S; PYCAG-5; S-20; S-22; S-30; S-35; SP-34; SP-36; SP-71; Jun N terminal kinase inhibitors (stroke), Phylogica; Phylomers (traumatic brain injury/stroke); Phylomers (traumatic brain injury/stroke), Phylogica
DMU30IO	CP	Phylogica Ltd
DMU30IO	DT	Small molecular drug
DMU30IO	PC	56947089
DMU30IO	MW	380.5
DMU30IO	FM	C23H28N2O3
DMU30IO	IC	InChI=1S/C23H28N2O3/c1-16(2)24-21(26)23(3)14-19(23)20(18-12-8-5-9-13-18)25-22(27)28-15-17-10-6-4-7-11-17/h4-13,16,19-20H,14-15H2,1-3H3,(H,24,26)(H,25,27)
DMU30IO	CS	CC(C)NC(=O)C1(CC1C(C2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3)C
DMU30IO	IK	ONJDWAYKGBYQHM-UHFFFAOYSA-N
DMU30IO	IU	benzyl N-[[2-methyl-2-(propan-2-ylcarbamoyl)cyclopropyl]-phenylmethyl]carbamate
DMU30IO	DE	Brain injury

DM09T76	ID	DM09T76
DM09T76	DN	physalaemin
DM09T76	HS	Investigative
DM09T76	SN	Physalaemin; 2507-24-6; pGlu-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly-Leu-Met-NH2; AC1L29NZ; GTPL2094; LS-187659; LS-187047; L000921
DM09T76	DT	Small molecular drug
DM09T76	PC	17268
DM09T76	MW	1265.4
DM09T76	FM	C58H84N14O16S
DM09T76	IC	InChI=1S/C58H84N14O16S/c1-31(2)25-39(54(84)66-36(49(61)79)21-24-89-4)65-47(76)30-62-51(81)40(27-34-15-17-35(73)18-16-34)68-55(85)41(26-33-11-6-5-7-12-33)69-53(83)37(13-8-9-22-59)67-56(86)42(28-45(60)74)70-57(87)44-14-10-23-72(44)58(88)43(29-48(77)78)71-50(80)32(3)63-52(82)38-19-20-46(75)64-38/h5-7,11-12,15-18,31-32,36-44,73H,8-10,13-14,19-30,59H2,1-4H3,(H2,60,74)(H2,61,79)(H,62,81)(H,63,82)(H,64,75)(H,65,76)(H,66,84)(H,67,86)(H,68,85)(H,69,83)(H,70,87)(H,71,80)(H,77,78)
DM09T76	CS	CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C4CCC(=O)N4
DM09T76	IK	SHSUJLMLURFKID-UHFFFAOYSA-N
DM09T76	IU	4-[2-[[4-amino-1-[[6-amino-1-[[1-[[1-[[2-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-[2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoylamino]butanoic acid
DM09T76	DE	Discovery agent

DMSZ1RB	ID	DMSZ1RB
DMSZ1RB	DN	Phytanic acid
DMSZ1RB	HS	Investigative
DMSZ1RB	SN	PHYTANIC ACID; 3,7,11,15-Tetramethylhexadecanoic acid; Phytanate; 14721-66-5; Phytanoic acid; RLCKHJSFHOZMDR-UHFFFAOYSA-N; 3,7,11,15-Tetramethyl-hexadecansaeure; 3,7,11,15-tetramethyl-hexadecanoic acid; Hexadecanoic acid, 3,7,11,15-tetramethyl-; Phytanoate; NSC 108698; Methylated phytanic acid; AC1L1BZT; SCHEMBL7888; GTPL2813; CHEBI:16285; CTK6A7614; MolPort-003-959-253; HMS3649L09; BDBM119875; NSC108698; MFCD00133772; 1986AH; 3,11,15-Tetramethylhexadecanoic acid; 3,7,11,15-tetramethylhexadecoanoate; AKOS028114496; NSC-108698
DMSZ1RB	DT	Small molecular drug
DMSZ1RB	PC	26840
DMSZ1RB	MW	312.5
DMSZ1RB	FM	C20H40O2
DMSZ1RB	IC	InChI=1S/C20H40O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h16-19H,6-15H2,1-5H3,(H,21,22)
DMSZ1RB	CS	CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)O
DMSZ1RB	IK	RLCKHJSFHOZMDR-UHFFFAOYSA-N
DMSZ1RB	IU	3,7,11,15-tetramethylhexadecanoic acid
DMSZ1RB	CA	CAS 14721-66-5
DMSZ1RB	CB	CHEBI:16285
DMSZ1RB	DE	Discovery agent

DMWJCST	ID	DMWJCST
DMWJCST	DN	phytosphingosine 1-phosphate
DMWJCST	HS	Investigative
DMWJCST	SN	 phytoS1P
DMWJCST	DT	Small molecular drug
DMWJCST	PC	10883829
DMWJCST	MW	397.5
DMWJCST	FM	C18H40NO6P
DMWJCST	IC	InChI=1S/C18H40NO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(20)18(21)16(19)15-25-26(22,23)24/h16-18,20-21H,2-15,19H2,1H3,(H2,22,23,24)/t16-,17+,18-/m0/s1
DMWJCST	CS	CCCCCCCCCCCCCC[C@H]([C@H]([C@H](COP(=O)(O)O)N)O)O
DMWJCST	IK	AYGOSKULTISFCW-KSZLIROESA-N
DMWJCST	IU	[(2S,3S,4R)-2-amino-3,4-dihydroxyoctadecyl] dihydrogen phosphate
DMWJCST	CB	CHEBI:46970
DMWJCST	DE	Discovery agent

DM68JNY	ID	DM68JNY
DM68JNY	DN	PI1
DM68JNY	HS	Investigative
DM68JNY	SN	CHEMBL1801361; GTPL5814; SCHEMBL2383164; BDBM50348617
DM68JNY	DT	Small molecular drug
DM68JNY	PC	46203026
DM68JNY	MW	423.9
DM68JNY	FM	C24H26ClN3O2
DM68JNY	IC	InChI=1S/C24H26ClN3O2/c1-4-27(5-2)21(29)13-14-24(17-9-11-18(25)12-10-17)22-19(7-6-8-20(22)30-3)23-26-15-16-28(23)24/h6-12,15-16H,4-5,13-14H2,1-3H3
DM68JNY	CS	CCN(CC)C(=O)CCC1(C2=C(C=CC=C2OC)C3=NC=CN31)C4=CC=C(C=C4)Cl
DM68JNY	IK	YBTRRYYNHWVJLG-UHFFFAOYSA-N
DM68JNY	IU	3-[5-(4-chlorophenyl)-6-methoxyimidazo[1,2-b]isoindol-5-yl]-N,N-diethylpropanamide
DM68JNY	DE	Discovery agent

DMEK4TJ	ID	DMEK4TJ
DMEK4TJ	DN	PI-103
DMEK4TJ	HS	Investigative
DMEK4TJ	SN	PI-103; 371935-74-9; PI103; 3-(4-morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol; UNII-YQX02F616F; PI 103; PIK-103; Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-; YQX02F616F; CHEBI:90524; AK163162; 3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol; 3-(4-Morpholin-4-Ylpyrido[3',2':4,5]furo[3,2-D]pyrimidin-2-Yl)phenol; Phenol, 3-(4-(4-morpholinyl)pyrido(3',2':4,5)furo(3,2-d)pyrimidin-2-yl)-; 3-(4-(4-Morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol
DMEK4TJ	TC	Anticancer Agents
DMEK4TJ	DT	Small molecular drug
DMEK4TJ	PC	9884685
DMEK4TJ	MW	348.4
DMEK4TJ	FM	C19H16N4O3
DMEK4TJ	IC	InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2
DMEK4TJ	CS	C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O
DMEK4TJ	IK	TUVCWJQQGGETHL-UHFFFAOYSA-N
DMEK4TJ	IU	3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenol
DMEK4TJ	CA	CAS 371935-74-9
DMEK4TJ	CB	CHEBI:90524
DMEK4TJ	DE	Haematological malignancy

DMCQUWI	ID	DMCQUWI
DMCQUWI	DN	PI-3065
DMCQUWI	HS	Investigative
DMCQUWI	SN	PI 3065
DMCQUWI	DT	Small molecular drug
DMCQUWI	PC	24937012
DMCQUWI	MW	506.6
DMCQUWI	FM	C27H31FN6OS
DMCQUWI	IC	InChI=1S/C27H31FN6OS/c28-21-3-4-22-20(5-6-29-22)24(21)26-30-23-15-19(17-33-9-7-32(8-10-33)16-18-1-2-18)36-25(23)27(31-26)34-11-13-35-14-12-34/h3-6,15,18,29H,1-2,7-14,16-17H2
DMCQUWI	CS	C1CC1CN2CCN(CC2)CC3=CC4=C(S3)C(=NC(=N4)C5=C(C=CC6=C5C=CN6)F)N7CCOCC7
DMCQUWI	IK	YDNOHCOYQVZOMC-UHFFFAOYSA-N
DMCQUWI	IU	4-[6-[[4-(cyclopropylmethyl)piperazin-1-yl]methyl]-2-(5-fluoro-1H-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl]morpholine
DMCQUWI	DE	Discovery agent

DMQBAM6	ID	DMQBAM6
DMQBAM6	DN	PIBTU
DMQBAM6	HS	Investigative
DMQBAM6	SN	1,3-PB-ITU
DMQBAM6	DT	Small molecular drug
DMQBAM6	PC	1331
DMQBAM6	MW	282.4
DMQBAM6	FM	C12H18N4S2
DMQBAM6	IC	InChI=1S/C12H18N4S2/c13-11(14)17-6-4-9-2-1-3-10(8-9)5-7-18-12(15)16/h1-3,8H,4-7H2,(H3,13,14)(H3,15,16)
DMQBAM6	CS	C1=CC(=CC(=C1)CCSC(=N)N)CCSC(=N)N
DMQBAM6	IK	YEUSLPIIQGZHQB-UHFFFAOYSA-N
DMQBAM6	IU	2-[3-(2-carbamimidoylsulfanylethyl)phenyl]ethyl carbamimidothioate
DMQBAM6	DE	Discovery agent

DMYOP45	ID	DMYOP45
DMYOP45	DN	Piceatannol
DMYOP45	HS	Investigative
DMYOP45	SN	piceatannol; 10083-24-6; 3-Hydroxyresveratol; piceatanol; astringinin; 3,5,3',4'-Tetrahydroxystilbene; (E)-4-(3,5-dihydroxystyryl)benzene-1,2-diol; 3,3',4'5-Tetrahydroxystilbene; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; 3,3',4,5'-Tetrahydroxystilbene; UNII-6KS3LS0D4F; NSC 365798; NSC-365798; NSC 622471; 6KS3LS0D4F; CHEMBL69863; 3,3',4,5'-Stilbenetetrol; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; 4339-71-3; CHEBI:28814; C14H12O4; NSC365798; NSC622471; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-
DMYOP45	DT	Small molecular drug
DMYOP45	PC	667639
DMYOP45	MW	244.24
DMYOP45	FM	C14H12O4
DMYOP45	IC	InChI=1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+
DMYOP45	CS	C1=CC(=C(C=C1/C=C/C2=CC(=CC(=C2)O)O)O)O
DMYOP45	IK	CDRPUGZCRXZLFL-OWOJBTEDSA-N
DMYOP45	IU	4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol
DMYOP45	CA	CAS 10083-24-6
DMYOP45	CB	CHEBI:28814
DMYOP45	DE	Discovery agent

DMND2QG	ID	DMND2QG
DMND2QG	DN	PICROTIN
DMND2QG	HS	Investigative
DMND2QG	SN	picrotin; 21416-53-5; DSSTox_CID_25605; DSSTox_RID_80998; UNII-U06Z6QD7N2; DSSTox_GSID_45605; CHEMBL478523; U06Z6QD7N2; CHEBI:8205; CAS-124-87-8; ST057242; (5S,8S,12S,14S,1R,3R,9R,13R)-1-hydroxy-14-(1-hydroxy-isopropyl)-13-methyl-4,7, 10-trioxapentacyclo[6.4.1.1&lt; Pikrotin; Picrotin (from Anamirta cocculus seed); NSC 129536; BRN 5302552; NCGC00017246-02; 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1
DMND2QG	DT	Small molecular drug
DMND2QG	PC	442291
DMND2QG	MW	310.3
DMND2QG	FM	C15H18O7
DMND2QG	IC	InChI=1S/C15H18O7/c1-12(2,18)6-7-10(16)20-8(6)9-13(3)14(7,19)4-5-15(13,22-5)11(17)21-9/h5-9,18-19H,4H2,1-3H3/t5-,6+,7-,8-,9-,13-,14-,15+/m1/s1
DMND2QG	CS	C[C@@]12[C@H]3[C@H]4[C@H]([C@@H]([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O
DMND2QG	IK	RYEFFICCPKWYML-QCGISDTRSA-N
DMND2QG	IU	(1R,3R,5S,8S,9R,12S,13R,14S)-1-hydroxy-14-(2-hydroxypropan-2-yl)-13-methyl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione
DMND2QG	CA	CAS 21416-53-5
DMND2QG	CB	CHEBI:8205
DMND2QG	DE	Discovery agent

DM9BQTX	ID	DM9BQTX
DM9BQTX	DN	PIK-75
DM9BQTX	HS	Investigative
DM9BQTX	SN	PIK75; PIK 75; imidazopyridine derivative 8c [PMID 17601739]
DM9BQTX	DT	Small molecular drug
DM9BQTX	PC	10275789
DM9BQTX	MW	452.3
DM9BQTX	FM	C16H14BrN5O4S
DM9BQTX	IC	InChI=1S/C16H14BrN5O4S/c1-11-3-5-13(22(23)24)7-15(11)27(25,26)20(2)19-9-14-8-18-16-6-4-12(17)10-21(14)16/h3-10H,1-2H3/b19-9+
DM9BQTX	CS	CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N(C)/N=C/C2=CN=C3N2C=C(C=C3)Br
DM9BQTX	IK	QTHCAAFKVUWAFI-DJKKODMXSA-N
DM9BQTX	IU	N-[(E)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-N,2-dimethyl-5-nitrobenzenesulfonamide
DM9BQTX	CA	CAS 945619-31-8
DM9BQTX	CB	CHEBI:94827
DM9BQTX	DE	Discovery agent

DM3JBLK	ID	DM3JBLK
DM3JBLK	DN	PIK-93
DM3JBLK	HS	Investigative
DM3JBLK	SN	PIK93; PIK 93
DM3JBLK	DT	Small molecular drug
DM3JBLK	PC	6852167
DM3JBLK	MW	389.9
DM3JBLK	FM	C14H16ClN3O4S2
DM3JBLK	IC	InChI=1S/C14H16ClN3O4S2/c1-8-13(23-14(17-8)18-9(2)20)10-3-4-11(15)12(7-10)24(21,22)16-5-6-19/h3-4,7,16,19H,5-6H2,1-2H3,(H,17,18,20)
DM3JBLK	CS	CC1=C(SC(=N1)NC(=O)C)C2=CC(=C(C=C2)Cl)S(=O)(=O)NCCO
DM3JBLK	IK	JFVNFXCESCXMBC-UHFFFAOYSA-N
DM3JBLK	IU	N-[5-[4-chloro-3-(2-hydroxyethylsulfamoyl)phenyl]-4-methyl-1,3-thiazol-2-yl]acetamide
DM3JBLK	CA	CAS 593960-11-3
DM3JBLK	DE	Discovery agent

DMBERSG	ID	DMBERSG
DMBERSG	DN	Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMBERSG	HS	Investigative
DMBERSG	PC	73348635
DMBERSG	MW	1710
DMBERSG	FM	C81H120N28O14
DMBERSG	IC	InChI=1S/C81H120N28O14/c1-3-14-56(70(116)102-60(24-12-36-96-80(90)91)74(120)106-62(66(84)112)38-44-26-30-48(110)31-27-44)100-72(118)58(22-10-34-94-78(86)87)104-76(122)64(40-46-42-98-54-20-7-5-16-50(46)54)108-68(114)52(82)18-9-19-53(83)69(115)109-65(41-47-43-99-55-21-8-6-17-51(47)55)77(123)105-59(23-11-35-95-79(88)89)73(119)101-57(15-4-2)71(117)103-61(25-13-37-97-81(92)93)75(121)107-63(67(85)113)39-45-28-32-49(111)33-29-45/h5-8,16-17,20-21,26-33,42-43,52-53,56-65,98-99,110-111H,3-4,9-15,18-19,22-25,34-41,82-83H2,1-2H3,(H2,84,112)(H2,85,113)(H,100,118)(H,101,119)(H,102,116)(H,103,117)(H,104,122)(H,105,123)(H,106,120)(H,107,121)(H,108,114)(H,109,115)(H4,86,87,94)(H4,88,89,95)(H4,90,91,96)(H4,92,93,97)/t52-,53-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-/m0/s1
DMBERSG	CS	CCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC[C@@H](C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N)N)N
DMBERSG	IK	LTYROZHCAWVGIV-IGPFWFIDSA-N
DMBERSG	IU	(2S,6S)-2,6-diamino-N,N'-bis[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]heptanediamide
DMBERSG	DE	Discovery agent

DMHLBZR	ID	DMHLBZR
DMHLBZR	DN	P-IODOAMPHETAMINE
DMHLBZR	HS	Investigative
DMHLBZR	SN	p-IODOAMPHETAMINE; para-Iodoamphetamine; CHEMBL6368; 21894-72-4; 2-(4-Iodo-phenyl)-1-methyl-ethylamine; 4-iodoamphetamine; 1-(4-iodophenyl)propan-2-amine; AC1L3XGA; (I123)-Iodoamphetamine; SCHEMBL166055; CTK4E7914; 4-Iodo-alpha-methylphenethylamine; VZPKOWYCGWOYRF-UHFFFAOYSA-N; 1-(4-iodophenyl)propane-2-amine; Benzeneethanamine,4-iodo-a-methyl-; BDBM50003582; AKOS009158591; Benzeneethanamine, 4-iodo-alpha-methyl-
DMHLBZR	DT	Small molecular drug
DMHLBZR	PC	123870
DMHLBZR	MW	261.1
DMHLBZR	FM	C9H12IN
DMHLBZR	IC	InChI=1S/C9H12IN/c1-7(11)6-8-2-4-9(10)5-3-8/h2-5,7H,6,11H2,1H3
DMHLBZR	CS	CC(CC1=CC=C(C=C1)I)N
DMHLBZR	IK	VZPKOWYCGWOYRF-UHFFFAOYSA-N
DMHLBZR	IU	1-(4-iodophenyl)propan-2-amine
DMHLBZR	CA	CAS 21894-72-4
DMHLBZR	DE	Discovery agent

DMOZV7N	ID	DMOZV7N
DMOZV7N	DN	PIP2
DMOZV7N	HS	Investigative
DMOZV7N	SN	phosphatidylinositol-4,5-bisphosphate
DMOZV7N	DT	Small molecular drug
DMOZV7N	PC	5311358
DMOZV7N	MW	1023.1
DMOZV7N	FM	C45H85O19P3
DMOZV7N	IC	InChI=1S/C45H85O19P3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(46)59-35-37(61-39(47)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)36-60-67(57,58)64-43-40(48)41(49)44(62-65(51,52)53)45(42(43)50)63-66(54,55)56/h17-20,37,40-45,48-50H,3-16,21-36H2,1-2H3,(H,57,58)(H2,51,52,53)(H2,54,55,56)/b19-17-,20-18-/t37-,40-,41+,42+,43-,44-,45-/m1/s1
DMOZV7N	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@@H]([C@@H]([C@H]([C@@H]([C@H]1O)OP(=O)(O)O)OP(=O)(O)O)O)O)OC(=O)CCCCCCC/C=C\\CCCCCCCC
DMOZV7N	IK	IGQSAMXNWMLOOS-GGDMTQDZSA-N
DMOZV7N	IU	[(2R)-3-[hydroxy-[(1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-diphosphonooxycyclohexyl]oxyphosphoryl]oxy-2-[(Z)-octadec-9-enoyl]oxypropyl] (Z)-octadec-9-enoate
DMOZV7N	DE	Discovery agent

DMJX39N	ID	DMJX39N
DMJX39N	DN	PIP3
DMJX39N	HS	Investigative
DMJX39N	SN	phosphatidylinositol-3,4,5-trisphosphate
DMJX39N	DT	Small molecular drug
DMJX39N	PC	53477782
DMJX39N	MW	644.2
DMJX39N	FM	C12H24O22P4
DMJX39N	IC	InChI=1S/C12H24O22P4/c1-4(13)29-6(30-5(2)14)3-28-38(26,27)34-9-7(15)10(31-35(17,18)19)12(33-37(23,24)25)11(8(9)16)32-36(20,21)22/h6-12,15-16H,3H2,1-2H3,(H,26,27)(H2,17,18,19)(H2,20,21,22)(H2,23,24,25)/t7-,8-,9?,10-,11+,12?/m0/s1
DMJX39N	CS	CC(=O)OC(COP(=O)(O)OC1[C@@H]([C@H](C([C@H]([C@H]1O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)O)OC(=O)C
DMJX39N	IK	RQQIRMLGKSPXSE-WIPMOJCBSA-N
DMJX39N	IU	[1-acetyloxy-2-[[(2S,3R,5S,6S)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate
DMJX39N	DE	Discovery agent

DMN8OR2	ID	DMN8OR2
DMN8OR2	DN	Piperidin-(2E)-ylideneamine
DMN8OR2	HS	Investigative
DMN8OR2	SN	PIPERIDIN-2-IMINE; 2-Piperidinimine; Piperidin-(2E)-ylideneamine; Piperidin-(2Z)-ylideneamine; CHEMBL269058; 2-amino-4-piperidyl; 22780-54-7; EN300-77982; 2-iminopiperidine; 2IM; AMINOPIPERIDINYL; NCGC00024898-01; Tocris-0951; (2E)-piperidin-2-imine; 2-Iminopiperidine, Hydrochloride; CTK0J6105; DTXSID40275816; DHGUMNJVFYRSIG-UHFFFAOYSA-N; 3,4,5,6-tetrahydropyridine amine; ZINC2141055; AC1L3920; BDBM50049255; 2,3,4,5-tetrahydropyridin-6-amine; 3,4,5,6-Tetrahydropyridin-2-amine; AKOS005199122; AKOS002684133; MCULE-9735306041
DMN8OR2	DT	Small molecular drug
DMN8OR2	PC	85237
DMN8OR2	MW	98.15
DMN8OR2	FM	C5H10N2
DMN8OR2	IC	InChI=1S/C5H10N2/c6-5-3-1-2-4-7-5/h1-4H2,(H2,6,7)
DMN8OR2	CS	C1CCN=C(C1)N
DMN8OR2	IK	DHGUMNJVFYRSIG-UHFFFAOYSA-N
DMN8OR2	IU	2,3,4,5-tetrahydropyridin-6-amine
DMN8OR2	CA	CAS 22780-54-7
DMN8OR2	DE	Discovery agent

DMKYF5U	ID	DMKYF5U
DMKYF5U	DN	Piperidine-1-carboxamidine
DMKYF5U	HS	Investigative
DMKYF5U	SN	Piperidine-1-carboxamidine; piperidine-1-carboximidamide; 4705-39-9; 1-Piperidinecarboximidamide; piperidinecarboxamidine; 1-(aminoiminomethyl)-; CHEMBL103102; amidinopiperdine; amidinopiperidine; MRZ; AC1L4DUO; AC1Q4YZ7; SCHEMBL1228214; CTK4I9701; DTXSID50276834; MolPort-000-511-098; QUUYRYYUKNNNNS-UHFFFAOYSA-N; ZINC159755; SBB079071; HTS003411; BDBM50037981; STK210669; BBL015601; AKOS000225517; MCULE-4074763290; SC-65494; AJ-15523; Piperidine-1-Carboximidamide  Hydrobromide; KB-275095; DB-070770; FT-0742354; ST50161491
DMKYF5U	DT	Small molecular drug
DMKYF5U	PC	205051
DMKYF5U	MW	127.19
DMKYF5U	FM	C6H13N3
DMKYF5U	IC	InChI=1S/C6H13N3/c7-6(8)9-4-2-1-3-5-9/h1-5H2,(H3,7,8)
DMKYF5U	CS	C1CCN(CC1)C(=N)N
DMKYF5U	IK	QUUYRYYUKNNNNS-UHFFFAOYSA-N
DMKYF5U	IU	piperidine-1-carboximidamide
DMKYF5U	CA	CAS 4705-39-9
DMKYF5U	DE	Discovery agent

DMF375O	ID	DMF375O
DMF375O	DN	Piperidine-1-carboxylic acid adamantan-2-yl ester
DMF375O	HS	Investigative
DMF375O	SN	CHEMBL1269124; Piperidine-1-carboxylic acid adamantan-2-yl ester; SCHEMBL19248187
DMF375O	DT	Small molecular drug
DMF375O	PC	52945668
DMF375O	MW	263.37
DMF375O	FM	C16H25NO2
DMF375O	IC	InChI=1S/C16H25NO2/c18-16(17-4-2-1-3-5-17)19-15-13-7-11-6-12(9-13)10-14(15)8-11/h11-15H,1-10H2
DMF375O	CS	C1CCN(CC1)C(=O)OC2C3CC4CC(C3)CC2C4
DMF375O	IK	VAQVMFMOXWTAGF-UHFFFAOYSA-N
DMF375O	IU	2-adamantyl piperidine-1-carboxylate
DMF375O	DE	Discovery agent

DMHZFK1	ID	DMHZFK1
DMHZFK1	DN	Piperidine-1-carboxylic acid adamantan-2-ylamide
DMHZFK1	HS	Investigative
DMHZFK1	SN	CHEMBL596815; SCHEMBL4099349; BDBM50120376
DMHZFK1	DT	Small molecular drug
DMHZFK1	PC	11850038
DMHZFK1	MW	262.39
DMHZFK1	FM	C16H26N2O
DMHZFK1	IC	InChI=1S/C16H26N2O/c19-16(18-4-2-1-3-5-18)17-15-13-7-11-6-12(9-13)10-14(15)8-11/h11-15H,1-10H2,(H,17,19)
DMHZFK1	CS	C1CCN(CC1)C(=O)NC2C3CC4CC(C3)CC2C4
DMHZFK1	IK	RHMXRUDDABBEME-UHFFFAOYSA-N
DMHZFK1	IU	N-(2-adamantyl)piperidine-1-carboxamide
DMHZFK1	DE	Discovery agent

DMMIZWE	ID	DMMIZWE
DMMIZWE	DN	piperidine-4-sulphonic acid
DMMIZWE	HS	Investigative
DMMIZWE	SN	piperidine-4-sulfonic acid; Piperidine-4-sulphonic acid; 4-Piperidinesulfonic acid; 72450-62-5; CHEMBL34155; P4S; C5H11NO3S; AC1Q6WTY; Lopac-P-9159; AC1L1J2H; Lopac0_001024; MLS000069699; SCHEMBL106762; GTPL4287; DTXSID70222752; Piperidine-4-sulfonic acid (P4S); ZINC2516028; FCH838660; MFCD00055097; BDBM50087272; AKOS006272381; API0008543; CCG-205104; NCGC00093348-02; NCGC00015855-04; NCGC00093348-03; NCGC00015855-01; NCGC00015855-03; NCGC00015855-02; SMR000058505; DA-17251; AB1009736; LS-176970; FT-0688685; EU-0101024; P 9159
DMMIZWE	DT	Small molecular drug
DMMIZWE	PC	4838
DMMIZWE	MW	165.21
DMMIZWE	FM	C5H11NO3S
DMMIZWE	IC	InChI=1S/C5H11NO3S/c7-10(8,9)5-1-3-6-4-2-5/h5-6H,1-4H2,(H,7,8,9)
DMMIZWE	CS	C1CNCCC1S(=O)(=O)O
DMMIZWE	IK	UGBJGGRINDTHIH-UHFFFAOYSA-N
DMMIZWE	IU	piperidine-4-sulfonic acid
DMMIZWE	CA	CAS 72450-62-5
DMMIZWE	DE	Discovery agent

DMB3NZA	ID	DMB3NZA
DMB3NZA	DN	PIPERNONALINE
DMB3NZA	HS	Investigative
DMB3NZA	SN	CHEMBL450332; PKLGRWSJBLGIBF-JMQWPVDRSA-N; MolPort-006-668-470; ZINC14658236; Pipernonaline, &gt; 9-(3,4-Methylenedioxyphenyl)-2,8-nonadienoic acid piperidide; 1-[9-(1,3-Benzodioxol-5-yl)-1-oxo-2,8-nonadienyl]piperidine, 9CI; (2E,8E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one; (2E,8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one
DMB3NZA	DT	Small molecular drug
DMB3NZA	PC	9974595
DMB3NZA	MW	341.4
DMB3NZA	FM	C21H27NO3
DMB3NZA	IC	InChI=1S/C21H27NO3/c23-21(22-14-8-5-9-15-22)11-7-4-2-1-3-6-10-18-12-13-19-20(16-18)25-17-24-19/h6-7,10-13,16H,1-5,8-9,14-15,17H2/b10-6+,11-7+
DMB3NZA	CS	C1CCN(CC1)C(=O)/C=C/CCCC/C=C/C2=CC3=C(C=C2)OCO3
DMB3NZA	IK	PKLGRWSJBLGIBF-JMQWPVDRSA-N
DMB3NZA	IU	(2E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,8-dien-1-one
DMB3NZA	CA	CAS 88660-10-0
DMB3NZA	DE	Discovery agent

DMIHO0P	ID	DMIHO0P
DMIHO0P	DN	PIPEROXAN
DMIHO0P	HS	Investigative
DMIHO0P	SN	Piperoxan; Benodaine; Piperoxane; 59-39-2; Fourneau 933; Piperoxan [INN:BAN]; Piperoxanum [INN-Latin]; Piperoxane [INN-French]; F933; Piperoxano [INN-Spanish]; 2-Piperidinomethyl-1,4-benzodioxan; 933F; Piperidine, 1-(1,4-benzodioxan-2-ylmethyl)-; BRN 0222516; CHEMBL31836; NCGC00160643-01; Piperidine,1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-; 1,4-Benzodioxane, 2-(piperidinomethyl)-; Piperidine, 1-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-; 1,4-BENZODIOXAN, 2-(PIPERIDINOMETHYL)-
DMIHO0P	DT	Small molecular drug
DMIHO0P	PC	6040
DMIHO0P	MW	233.31
DMIHO0P	FM	C14H19NO2
DMIHO0P	IC	InChI=1S/C14H19NO2/c1-4-8-15(9-5-1)10-12-11-16-13-6-2-3-7-14(13)17-12/h2-3,6-7,12H,1,4-5,8-11H2
DMIHO0P	CS	C1CCN(CC1)CC2COC3=CC=CC=C3O2
DMIHO0P	IK	LYKMMUBOEFYJQG-UHFFFAOYSA-N
DMIHO0P	IU	1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)piperidine
DMIHO0P	CA	CAS 59-39-2
DMIHO0P	DE	Discovery agent

DMRVHWZ	ID	DMRVHWZ
DMRVHWZ	DN	PIPERROLEIN B
DMRVHWZ	HS	Investigative
DMRVHWZ	SN	Piperolein B; PIPERROLEIN B; Piperoleine B; 30505-89-6; CHEMBL256214; MEGxp0_000205; SCHEMBL15471329; ACon1_000259; FAXXHNWVMKTOFF-UXBLZVDNSA-N; MCULE-4025815326; NCGC00180733-01; BRD-K04771916-001-01-8; Piperidine, 1-[(8E)-9-(1,3-benzodioxol-5-yl)-1-oxo-8-nonenyl]-; (8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one; Piperidine, 1-[9-[3,4-(methylenedioxy)phenyl]-8-nonenoyl]-, (E)-; (E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one; Piperidine, 1-[9-(1,3-benzodioxol-5-yl)-1-oxo-8-nonenyl]-, (
DMRVHWZ	DT	Small molecular drug
DMRVHWZ	PC	21580213
DMRVHWZ	MW	343.5
DMRVHWZ	FM	C21H29NO3
DMRVHWZ	IC	InChI=1S/C21H29NO3/c23-21(22-14-8-5-9-15-22)11-7-4-2-1-3-6-10-18-12-13-19-20(16-18)25-17-24-19/h6,10,12-13,16H,1-5,7-9,11,14-15,17H2/b10-6+
DMRVHWZ	CS	C1CCN(CC1)C(=O)CCCCCC/C=C/C2=CC3=C(C=C2)OCO3
DMRVHWZ	IK	FAXXHNWVMKTOFF-UXBLZVDNSA-N
DMRVHWZ	IU	(E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnon-8-en-1-one
DMRVHWZ	CA	CAS 30505-89-6
DMRVHWZ	DE	Discovery agent

DMOE39X	ID	DMOE39X
DMOE39X	DN	Piragliatin
DMOE39X	HS	Investigative
DMOE39X	SN	GK2; R1440; RO4389620
DMOE39X	TC	Endocrine, nutritional and metabolic diseases
DMOE39X	DT	Small molecular drug
DMOE39X	PC	10432339
DMOE39X	MW	421.9
DMOE39X	FM	C19H20ClN3O4S
DMOE39X	IC	InChI=1S/C19H20ClN3O4S/c1-28(26,27)17-5-3-13(10-16(17)20)15(9-12-2-4-14(24)8-12)19(25)23-18-11-21-6-7-22-18/h3,5-7,10-12,15H,2,4,8-9H2,1H3,(H,22,23,25)/t12-,15+/m0/s1
DMOE39X	CS	CS(=O)(=O)C1=C(C=C(C=C1)[C@@H](C[C@H]2CCC(=O)C2)C(=O)NC3=NC=CN=C3)Cl
DMOE39X	IK	XEANIURBPHCHMG-SWLSCSKDSA-N
DMOE39X	IU	(2R)-2-(3-chloro-4-methylsulfonylphenyl)-3-[(1R)-3-oxocyclopentyl]-N-pyrazin-2-ylpropanamide
DMOE39X	CA	CAS 625114-41-2
DMOE39X	DE	Discovery agent

DM9T2G3	ID	DM9T2G3
DM9T2G3	DN	pirenperone
DM9T2G3	HS	Investigative
DM9T2G3	SN	R-47465
DM9T2G3	DT	Small molecular drug
DM9T2G3	PC	4847
DM9T2G3	MW	393.5
DM9T2G3	FM	C23H24FN3O2
DM9T2G3	IC	InChI=1S/C23H24FN3O2/c1-16-20(23(29)27-12-3-2-4-21(27)25-16)11-15-26-13-9-18(10-14-26)22(28)17-5-7-19(24)8-6-17/h2-8,12,18H,9-11,13-15H2,1H3
DM9T2G3	CS	CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F
DM9T2G3	IK	HXCNRYXBZNHDNE-UHFFFAOYSA-N
DM9T2G3	IU	3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-methylpyrido[1,2-a]pyrimidin-4-one
DM9T2G3	CA	CAS 75444-65-4
DM9T2G3	CB	CHEBI:92444
DM9T2G3	DE	Discovery agent

DM0SCDR	ID	DM0SCDR
DM0SCDR	DN	Piretanide
DM0SCDR	HS	Investigative
DM0SCDR	SN	piretanide; 55837-27-9; Tauliz; Arlix; 4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic acid; Piretanido [Spanish]; HOE 118; Piretanidum [INN-Latin]; Piretanido [INN-Spanish]; UNII-DQ6KK6GV93; Arelix (TN); C17H18N2O5S; EINECS 259-852-9; Hoe-118; BRN 5633965; DQ6KK6GV93; 4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic acid; 4-Phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic acid; S 734118; S 73 4118; NCGC00016878-01; 3-(Aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-benzoic acid; Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidin
DM0SCDR	DT	Small molecular drug
DM0SCDR	PC	4849
DM0SCDR	MW	362.4
DM0SCDR	FM	C17H18N2O5S
DM0SCDR	IC	InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
DM0SCDR	CS	C1CCN(C1)C2=C(C(=CC(=C2)C(=O)O)S(=O)(=O)N)OC3=CC=CC=C3
DM0SCDR	IK	UJEWTUDSLQGTOA-UHFFFAOYSA-N
DM0SCDR	IU	4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic acid
DM0SCDR	CA	CAS 55837-27-9
DM0SCDR	CB	CHEBI:32015
DM0SCDR	DE	Discovery agent

DMNP6QD	ID	DMNP6QD
DMNP6QD	DN	piribedil
DMNP6QD	HS	Investigative
DMNP6QD	SN	piribedil; 3605-01-4; Trivastal; Trivastan; 2-(4-(Benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)pyrimidine; ET 495; ET-495; EU-4200; EU 4200; 2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyrimidine; Piribedile [DCIT]; Piribedil [INN:DCF]; Piribedilum [INN-Latin]; UNII-DO22K1PRDJ; DO22K1PRDJ; 1-(2-Pyrimidyl)-4-piperonylpiperazine; 2-(4-Piperonyl-1-piperazinyl)pyrimidine; Pyrimidine, 2-(4-piperonyl-1-piperazinyl)-; OQDPVLVUJFGPGQ-UHFFFAOYSA-N; EINECS 222-764-6; 2-(4-(3,4-Methylenedioxybenzyl)piperazino)pyrimidine
DMNP6QD	DT	Small molecular drug
DMNP6QD	PC	4850
DMNP6QD	MW	298.34
DMNP6QD	FM	C16H18N4O2
DMNP6QD	IC	InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2
DMNP6QD	CS	C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4
DMNP6QD	IK	OQDPVLVUJFGPGQ-UHFFFAOYSA-N
DMNP6QD	IU	2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyrimidine
DMNP6QD	CA	CAS 3605-01-4
DMNP6QD	CB	CHEBI:92833
DMNP6QD	DE	Discovery agent

DMRDF8Z	ID	DMRDF8Z
DMRDF8Z	DN	Piridronic acid
DMRDF8Z	HS	Investigative
DMRDF8Z	SN	Piridronic acid; UNII-ADD4H8T3K9; ADD4H8T3K9; CHEMBL99369; 75755-07-6; NE-97221; (1-phosphono-2-pyridin-2-ylethyl)phosphonic acid; Acido piridronico; Acide piridronique; Acidum piridronicum; Piridronic acid [INN]; NE 97221; Acido piridronico [Spanish]; Acidum piridronicum [Latin]; Acide piridronique [French]; AC1L1NEH; AC1Q7DKX; (2-(2-Pyridyl)ethylidene)diphosphonic acid; SCHEMBL223779; GTPL3183; DTXSID50226652; ZINC1999562; BDBM50373096; NE97221; 2-(2-Pyridyl)ethylidine-1,1-bisphosphonate; Phosphonic acid, (2-(2-pyridinyl)ethylide
DMRDF8Z	DT	Small molecular drug
DMRDF8Z	PC	57637
DMRDF8Z	MW	267.11
DMRDF8Z	FM	C7H11NO6P2
DMRDF8Z	IC	InChI=1S/C7H11NO6P2/c9-15(10,11)7(16(12,13)14)5-6-3-1-2-4-8-6/h1-4,7H,5H2,(H2,9,10,11)(H2,12,13,14)
DMRDF8Z	CS	C1=CC=NC(=C1)CC(P(=O)(O)O)P(=O)(O)O
DMRDF8Z	IK	NGMZSXZBZNXBGX-UHFFFAOYSA-N
DMRDF8Z	IU	(1-phosphono-2-pyridin-2-ylethyl)phosphonic acid
DMRDF8Z	CA	CAS 75755-07-6
DMRDF8Z	DE	Discovery agent

DM7XTHD	ID	DM7XTHD
DM7XTHD	DN	Piriqualone
DM7XTHD	HS	Investigative
DM7XTHD	SN	SRC 909; BRN 0622820; 1897-90-1; 2-(2-(3-Pyridyl)-ethenyl)-3-(o-tolyl)-4(3H)-quinazolinone; 2-(beta-Pyridyl-(3'')-aethenyl)-3-(o-tolyl)chinazolinone-(4) [German]; 4(3H)-Quinazolinone, 2-(2-(3-pyridyl)ethenyl)-3-(o-tolyl)-; 3-(2-methylphenyl)-2-(2-(3-pyridinyl)ethenyl)-4(3H)-quinazolinone; 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-(2-(3-pyridinyl)ethenyl)-; SRC-909; AC1NWBSK; AC1Q6E7H; MolPort-001-954-696; MolPort-019-773-808; 2-(beta-Pyridyl-(3'')-aethenyl)-3-(o-tolyl)chinazolinone-(4); ZINC4018972; STK721935
DM7XTHD	DT	Small molecular drug
DM7XTHD	PC	6015423
DM7XTHD	MW	339.4
DM7XTHD	FM	C22H17N3O
DM7XTHD	IC	InChI=1S/C22H17N3O/c1-16-8-2-5-12-20(16)25-21(14-13-17-9-6-7-15-23-17)24-19-11-4-3-10-18(19)22(25)26/h2-15H,1H3/b14-13+
DM7XTHD	CS	CC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)/C=C/C4=CC=CC=N4
DM7XTHD	IK	MYGZNGAHFWOCLI-BUHFOSPRSA-N
DM7XTHD	IU	3-(2-methylphenyl)-2-[(E)-2-pyridin-2-ylethenyl]quinazolin-4-one
DM7XTHD	CA	CAS 1897-89-8
DM7XTHD	DE	Discovery agent

DMWLDRJ	ID	DMWLDRJ
DMWLDRJ	DN	PIROTIODECANE
DMWLDRJ	HS	Investigative
DMWLDRJ	SN	HPE-101; 1-[2-(Decylsulfanyl)ethyl]pyrrolidin-2-one
DMWLDRJ	DT	Small molecular drug
DMWLDRJ	PC	124240
DMWLDRJ	MW	285.5
DMWLDRJ	FM	C16H31NOS
DMWLDRJ	IC	InChI=1S/C16H31NOS/c1-2-3-4-5-6-7-8-9-14-19-15-13-17-12-10-11-16(17)18/h2-15H2,1H3
DMWLDRJ	CS	CCCCCCCCCCSCCN1CCCC1=O
DMWLDRJ	IK	VDPRSOCKHVPZRS-UHFFFAOYSA-N
DMWLDRJ	IU	1-(2-decylsulfanylethyl)pyrrolidin-2-one
DMWLDRJ	CA	CAS 113855-10-0
DMWLDRJ	DE	Ophthalmic graves disease

DMKHZQW	ID	DMKHZQW
DMKHZQW	DN	Pitrazepine
DMKHZQW	HS	Investigative
DMKHZQW	SN	Pitrazepin; PITRAZEPINE; 90685-01-1; AC1L3SS8; 3-(Piperazinyl)-1-9H-dibenz(c,f)triazolo(4,5-a)azepin; CHEBI:34926; 9H-Dibenzo(c,f)-1,2,4-triazolo(4,3-a)azepine, 3-(1-piperazinyl)-; CHEMBL59190; SCHEMBL5888842; DTXSID90238239; LS-182874
DMKHZQW	DT	Small molecular drug
DMKHZQW	PC	146222
DMKHZQW	MW	317.4
DMKHZQW	FM	C19H19N5
DMKHZQW	IC	InChI=1S/C19H19N5/c1-3-7-16-14(5-1)13-15-6-2-4-8-17(15)24-18(16)21-22-19(24)23-11-9-20-10-12-23/h1-8,20H,9-13H2
DMKHZQW	CS	C1CN(CCN1)C2=NN=C3N2C4=CC=CC=C4CC5=CC=CC=C53
DMKHZQW	IK	GXFWOMYQHNODFA-UHFFFAOYSA-N
DMKHZQW	IU	3-piperazin-1-yl-2,4,5-triazatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),3,5,7,9,11,14,16-octaene
DMKHZQW	CA	CAS 90685-01-1
DMKHZQW	CB	CHEBI:34926
DMKHZQW	DE	Discovery agent

DMVYNTB	ID	DMVYNTB
DMVYNTB	DN	Piv-RYYRIK-NH2
DMVYNTB	HS	Investigative
DMVYNTB	SN	CHEMBL270231
DMVYNTB	DT	Small molecular drug
DMVYNTB	PC	44456412
DMVYNTB	MW	965.2
DMVYNTB	FM	C47H76N14O8
DMVYNTB	IC	InChI=1S/C47H76N14O8/c1-6-28(2)37(43(68)56-32(38(49)63)16-10-11-23-48)61-40(65)33(17-12-24-54-45(50)51)57-41(66)36(27-30-19-21-31(62)22-20-30)59-42(67)35(26-29-14-8-7-9-15-29)58-39(64)34(18-13-25-55-46(52)53)60-44(69)47(3,4)5/h7-9,14-15,19-22,28,32-37,62H,6,10-13,16-18,23-27,48H2,1-5H3,(H2,49,63)(H,56,68)(H,57,66)(H,58,64)(H,59,67)(H,60,69)(H,61,65)(H4,50,51,54)(H4,52,53,55)/t28-,32-,33-,34-,35-,36-,37-/m0/s1
DMVYNTB	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(C)(C)C
DMVYNTB	IK	KUMVVDGHDQEFOK-KHLMYIKTSA-N
DMVYNTB	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2,2-dimethylpropanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMVYNTB	DE	Discovery agent

DMDOZPU	ID	DMDOZPU
DMDOZPU	DN	PK 11195
DMDOZPU	HS	Investigative
DMDOZPU	SN	1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide; 85532-75-8; PK-11195; PK11195; RP 52028; BRN 4264456; CHEBI:73290; N-sec-butyl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; N-(butan-2-yl)-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-; SMR000058427; SR-01000076240; Biomol-NT_000287; AC1L1B9T; DSSTox_RID_79625; Interferon alfa (IFN-alpha)
DMDOZPU	DT	Small molecular drug
DMDOZPU	PC	1345
DMDOZPU	MW	352.9
DMDOZPU	FM	C21H21ClN2O
DMDOZPU	IC	InChI=1S/C21H21ClN2O/c1-4-14(2)24(3)21(25)19-13-15-9-5-6-10-16(15)20(23-19)17-11-7-8-12-18(17)22/h5-14H,4H2,1-3H3
DMDOZPU	CS	CCC(C)N(C)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC=CC=C3Cl
DMDOZPU	IK	RAVIZVQZGXBOQO-UHFFFAOYSA-N
DMDOZPU	IU	N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide
DMDOZPU	CA	CAS 85532-75-8
DMDOZPU	CB	CHEBI:73290
DMDOZPU	DE	Discovery agent

DM40HWI	ID	DM40HWI
DM40HWI	DN	PK-44
DM40HWI	HS	Investigative
DM40HWI	SN	DPP-IV inhibitors (diabetes), PeakDale
DM40HWI	CP	Peakdale Molecular
DM40HWI	DE	Non-insulin dependent diabetes

DMIUZGY	ID	DMIUZGY
DMIUZGY	DN	PK68
DMIUZGY	HS	Investigative
DMIUZGY	SN	2173556-69-7; SCHEMBL19807982; BCP32187; EX-A4768; PK-68;PK 68; HY-128348; CS-0099048
DMIUZGY	CP	Soochow University
DMIUZGY	DT	Small molecular drug
DMIUZGY	PC	134203923
DMIUZGY	MW	424.5
DMIUZGY	FM	C22H24N4O3S
DMIUZGY	IC	InChI=1S/C22H24N4O3S/c1-13-19(26-22(28)29-17-6-4-3-5-7-17)10-16(12-23-13)15-8-9-18-20(11-15)30-21(25-18)24-14(2)27/h8-12,17H,3-7H2,1-2H3,(H,26,28)(H,24,25,27)
DMIUZGY	CS	CC1=C(C=C(C=N1)C2=CC3=C(C=C2)N=C(S3)NC(=O)C)NC(=O)OC4CCCCC4
DMIUZGY	IK	DRCNWQYEKZTTEW-UHFFFAOYSA-N
DMIUZGY	IU	cyclohexyl N-[5-(2-acetamido-1,3-benzothiazol-6-yl)-2-methylpyridin-3-yl]carbamate
DMIUZGY	DE	Inflammation

DM04C9V	ID	DM04C9V
DM04C9V	DN	PKF-241-466
DM04C9V	HS	Investigative
DM04C9V	SN	PKF-241-466; CHEMBL306090; BDBM50240611; N*4*-(2,2-Dimethyl-1-methylcarbamoyl-propyl)-N*1*-hydroxy-2-hydroxymethyl-3-p-tolyl-succinamide
DM04C9V	DT	Small molecular drug
DM04C9V	PC	9907830
DM04C9V	MW	379.5
DM04C9V	FM	C19H29N3O5
DM04C9V	IC	InChI=1S/C19H29N3O5/c1-11-6-8-12(9-7-11)14(13(10-23)16(24)22-27)17(25)21-15(18(26)20-5)19(2,3)4/h6-9,13-15,23,27H,10H2,1-5H3,(H,20,26)(H,21,25)(H,22,24)/t13-,14+,15+/m0/s1
DM04C9V	CS	CC1=CC=C(C=C1)[C@H]([C@H](CO)C(=O)NO)C(=O)N[C@H](C(=O)NC)C(C)(C)C
DM04C9V	IK	KNCYWVRUUBOHGE-RRFJBIMHSA-N
DM04C9V	IU	(2S,3R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N'-hydroxy-3-(hydroxymethyl)-2-(4-methylphenyl)butanediamide
DM04C9V	DE	Discovery agent

DMNDLAS	ID	DMNDLAS
DMNDLAS	DN	PKF-242-484
DMNDLAS	HS	Investigative
DMNDLAS	SN	TNF-484
DMNDLAS	DT	Small molecular drug
DMNDLAS	PC	9886977
DMNDLAS	MW	395.4
DMNDLAS	FM	C19H29N3O6
DMNDLAS	IC	InChI=1S/C19H29N3O6/c1-19(2,3)15(18(26)20-4)21-17(25)14(13(10-23)16(24)22-27)11-6-8-12(28-5)9-7-11/h6-9,13-15,23,27H,10H2,1-5H3,(H,20,26)(H,21,25)(H,22,24)/t13-,14+,15+/m0/s1
DMNDLAS	CS	CC(C)(C)[C@@H](C(=O)NC)NC(=O)[C@H](C1=CC=C(C=C1)OC)[C@H](CO)C(=O)NO
DMNDLAS	IK	IOLRUMINDIUCLJ-RRFJBIMHSA-N
DMNDLAS	IU	(2S,3R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N'-hydroxy-3-(hydroxymethyl)-2-(4-methoxyphenyl)butanediamide
DMNDLAS	CA	CAS 205807-59-6
DMNDLAS	DE	Discovery agent

DM6NX4H	ID	DM6NX4H
DM6NX4H	DN	PKI-402
DM6NX4H	HS	Investigative
DM6NX4H	SN	PKI-402; 1173204-81-3; PKI402; PKI 402; CHEMBL589258; 1-(4-(3-ethyl-7-morpholino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-3-(4-(4-methylpiperazine-1-carbonyl)phenyl)urea; 1-[4-[3-Ethyl-7-(morpholin-4-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl]-3-[4-[(4-methylpiperazin-1-yl)carbonyl]phenyl]urea; J-504117; ZAXFYGBKZSQBIV-UHFFFAOYSA-N; MLS006010978; SCHEMBL3401810; DTXSID30657809; EX-A040; MolPort-022-902-305; BCP02609; C29H34N10O3; s2739; BDBM50308767; ZINC49745945; ABP000110; AKOS022526182; QC-7256; RL00651
DM6NX4H	DT	Small molecular drug
DM6NX4H	PC	44187953
DM6NX4H	MW	570.6
DM6NX4H	FM	C29H34N10O3
DM6NX4H	IC	InChI=1S/C29H34N10O3/c1-3-39-27-24(34-35-39)26(37-16-18-42-19-17-37)32-25(33-27)20-4-8-22(9-5-20)30-29(41)31-23-10-6-21(7-11-23)28(40)38-14-12-36(2)13-15-38/h4-11H,3,12-19H2,1-2H3,(H2,30,31,41)
DM6NX4H	CS	CCN1C2=C(C(=NC(=N2)C3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)C(=O)N5CCN(CC5)C)N6CCOCC6)N=N1
DM6NX4H	IK	ZAXFYGBKZSQBIV-UHFFFAOYSA-N
DM6NX4H	IU	1-[4-(3-ethyl-7-morpholin-4-yltriazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[4-(4-methylpiperazine-1-carbonyl)phenyl]urea
DM6NX4H	CA	CAS 1173204-81-3
DM6NX4H	DE	Solid tumour/cancer

DMSJCKN	ID	DMSJCKN
DMSJCKN	DN	PKR-A
DMSJCKN	HS	Investigative
DMSJCKN	SN	PKR-A; SCHEMBL387975; GTPL6066; KQQGCZSZDMHKOX-UHFFFAOYSA-N; (-)-4-Benzyl-N-(3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethyl)-N-isobutylmorpholine-2-carboxamide; (+/-)-4-Benzyl-N-(3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethyl)-N-isobutylmorpholine-2-carboxamide
DMSJCKN	DT	Small molecular drug
DMSJCKN	PC	16122905
DMSJCKN	MW	438.6
DMSJCKN	FM	C26H34N2O4
DMSJCKN	IC	InChI=1S/C26H34N2O4/c1-20(2)16-28(18-22-9-10-23-24(15-22)31-13-6-12-30-23)26(29)25-19-27(11-14-32-25)17-21-7-4-3-5-8-21/h3-5,7-10,15,20,25H,6,11-14,16-19H2,1-2H3
DMSJCKN	CS	CC(C)CN(CC1=CC2=C(C=C1)OCCCO2)C(=O)C3CN(CCO3)CC4=CC=CC=C4
DMSJCKN	IK	KQQGCZSZDMHKOX-UHFFFAOYSA-N
DMSJCKN	IU	4-benzyl-N-(3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethyl)-N-(2-methylpropyl)morpholine-2-carboxamide
DMSJCKN	DE	Discovery agent

DMICVXN	ID	DMICVXN
DMICVXN	DN	PL017
DMICVXN	HS	Investigative
DMICVXN	SN	3-N-Me-Phe-morphiceptin; PL-017; PL 017
DMICVXN	DT	Small molecular drug
DMICVXN	PC	115335
DMICVXN	MW	535.6
DMICVXN	FM	C29H37N5O5
DMICVXN	IC	InChI=1S/C29H37N5O5/c1-32(25(18-19-7-3-2-4-8-19)29(39)33-15-5-9-23(33)26(31)36)28(38)24-10-6-16-34(24)27(37)22(30)17-20-11-13-21(35)14-12-20/h2-4,7-8,11-14,22-25,35H,5-6,9-10,15-18,30H2,1H3,(H2,31,36)/t22-,23+,24-,25-/m0/s1
DMICVXN	CS	CN([C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)N)C(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMICVXN	IK	JAKBYSTWCHUQOK-NDBXHCKUSA-N
DMICVXN	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-N-methylpyrrolidine-2-carboxamide
DMICVXN	CA	CAS 83397-56-2
DMICVXN	DE	Discovery agent

DMWHNZ4	ID	DMWHNZ4
DMWHNZ4	DN	Plantainoside D
DMWHNZ4	HS	Investigative
DMWHNZ4	SN	Plantainoside D; CHEMBL452413; BDBM50269518
DMWHNZ4	DT	Small molecular drug
DMWHNZ4	PC	9986606
DMWHNZ4	MW	640.6
DMWHNZ4	FM	C29H36O16
DMWHNZ4	IC	InChI=1S/C29H36O16/c30-11-19-22(36)24(38)25(39)29(43-19)45-27-23(37)20(12-42-21(35)6-3-13-1-4-15(31)17(33)9-13)44-28(26(27)40)41-8-7-14-2-5-16(32)18(34)10-14/h1-6,9-10,19-20,22-34,36-40H,7-8,11-12H2/b6-3+/t19-,20-,22-,23-,24+,25-,26-,27+,28-,29+/m1/s1
DMWHNZ4	CS	C1=CC(=C(C=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O
DMWHNZ4	IK	CBZYUWGJNYOKHT-ZKDZFUIGSA-N
DMWHNZ4	IU	[(2R,3R,4S,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,5-dihydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DMWHNZ4	DE	Discovery agent

DMV34O2	ID	DMV34O2
DMV34O2	DN	Platelet factor 4 (PF-4)
DMV34O2	HS	Investigative
DMV34O2	SN	Platelet factor 4 (59-70); 88145-47-5; PF4 (59-70); DTXSID30236855; L-Serine, N-(N-(N-(N-(N2-(N2-(N-(N-(N2-(N2-(N-L-leucyl-L-tyrosyl)-L-lysyl)-L-lysyl)-L-isoleucyl)-L-isoleucyl)-L-lysyl)-L-lysyl)-L-leucyl)-L-leucyl)-L-alpha-glutamyl)-, (6R-(6alpha,7beta(Z)))-
DMV34O2	DT	Small molecular drug
DMV34O2	PC	56842294
DMV34O2	MW	1475.9
DMV34O2	FM	C71H126N16O17
DMV34O2	IC	InChI=1S/C71H126N16O17/c1-11-43(9)58(87-70(102)59(44(10)12-2)86-65(97)51(24-16-20-34-75)78-61(93)48(21-13-17-31-72)79-68(100)55(38-45-25-27-46(89)28-26-45)82-60(92)47(76)35-40(3)4)69(101)81-50(23-15-19-33-74)62(94)77-49(22-14-18-32-73)63(95)83-54(37-42(7)8)67(99)84-53(36-41(5)6)66(98)80-52(29-30-57(90)91)64(96)85-56(39-88)71(103)104/h25-28,40-44,47-56,58-59,88-89H,11-24,29-39,72-76H2,1-10H3,(H,77,94)(H,78,93)(H,79,100)(H,80,98)(H,81,101)(H,82,92)(H,83,95)(H,84,99)(H,85,96)(H,86,97)(H,87,102)(H,90,91)(H,103,104)/t43-,44-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,58-,59-/m0/s1
DMV34O2	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(C)C)N
DMV34O2	IK	SVIMOXOHMCOIRM-UVKYVJJHSA-N
DMV34O2	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-5-oxopentanoic acid
DMV34O2	CA	CAS 88145-47-5
DMV34O2	DE	Discovery agent

DM9N0RH	ID	DM9N0RH
DM9N0RH	DN	PLATENSIMYCIN
DM9N0RH	HS	Investigative
DM9N0RH	SN	PLATENSIMYCIN; (-)-Platensimycin; UNII-Q3DQ78KOFY; Q3DQ78KOFY; CHEBI:68236; PMN; 835876-32-9; 3-({3-[(1S,4aS,6S,7S,9S,9aR)-1,6-dimethyl-2-oxo-1,2,5,6,7,8,9,9a-octahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid; CHEMBL411278; MolPort-044-561-275; ZINC29050726; DB08407; NCGC00183212-01; C20132; 34063-EP2311453A1; 34063-EP2281819A1; 34063-EP2295055A2; 34063-EP2292233A2; Benzoic acid, 3-((3-((1S,3S,4S,5aS,9S,9aR)-1,4,5,8,9,9a-hexahydro-3,9-dimethyl-8-oxo-3H-1,4:3,5a-dimethano-2-benzox
DM9N0RH	DT	Small molecular drug
DM9N0RH	PC	6857724
DM9N0RH	MW	441.5
DM9N0RH	FM	C24H27NO7
DM9N0RH	IC	InChI=1S/C24H27NO7/c1-22(7-6-17(28)25-18-14(26)4-3-13(19(18)29)21(30)31)16(27)5-8-24-10-12-9-15(20(22)24)32-23(12,2)11-24/h3-5,8,12,15,20,26,29H,6-7,9-11H2,1-2H3,(H,25,28)(H,30,31)/t12-,15+,20+,22-,23+,24+/m1/s1
DM9N0RH	CS	C[C@]12C[C@]34C[C@H]1C[C@@H]([C@H]3[C@](C(=O)C=C4)(C)CCC(=O)NC5=C(C=CC(=C5O)C(=O)O)O)O2
DM9N0RH	IK	CSOMAHTTWTVBFL-OFBLZTNGSA-N
DM9N0RH	IU	3-[3-[(1S,5S,6R,7S,9S,10S)-5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.17,10.01,6]tridec-2-en-5-yl]propanoylamino]-2,4-dihydroxybenzoic acid
DM9N0RH	CA	CAS 835876-32-9
DM9N0RH	CB	CHEBI:68236
DM9N0RH	DE	Bacterial infection

DM4MKIX	ID	DM4MKIX
DM4MKIX	DN	Ploglitazone
DM4MKIX	HS	Investigative
DM4MKIX	SN	PLOGLITAZONE
DM4MKIX	DT	Small molecular drug
DM4MKIX	PC	12944192
DM4MKIX	MW	355.5
DM4MKIX	FM	C20H21NO3S
DM4MKIX	IC	InChI=1S/C20H21NO3S/c1-2-14-3-5-15(6-4-14)11-12-24-17-9-7-16(8-10-17)13-18-19(22)21-20(23)25-18/h3-10,18H,2,11-13H2,1H3,(H,21,22,23)
DM4MKIX	CS	CCC1=CC=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DM4MKIX	IK	CZKMWGGUVIBIOI-UHFFFAOYSA-N
DM4MKIX	IU	5-[[4-[2-(4-ethylphenyl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM4MKIX	DE	Discovery agent

DMBN4V6	ID	DMBN4V6
DMBN4V6	DN	PLSQETFSDLWKLLPEN-NH2
DMBN4V6	HS	Investigative
DMBN4V6	SN	CHEMBL267823
DMBN4V6	PC	44412124
DMBN4V6	MW	2016.3
DMBN4V6	FM	C93H142N22O28
DMBN4V6	IC	InChI=1S/C93H142N22O28/c1-46(2)35-61(83(133)108-65(40-52-43-99-54-22-14-13-21-53(52)54)87(137)100-56(23-15-16-32-94)79(129)106-62(36-47(3)4)84(134)111-67(38-49(7)8)93(143)115-34-18-25-70(115)91(141)103-58(27-30-73(121)122)81(131)104-60(77(97)127)41-72(96)120)107-88(138)66(42-75(125)126)109-90(140)69(45-117)113-86(136)64(39-51-19-11-10-12-20-51)110-92(142)76(50(9)118)114-82(132)59(28-31-74(123)124)101-80(130)57(26-29-71(95)119)102-89(139)68(44-116)112-85(135)63(37-48(5)6)105-78(128)55-24-17-33-98-55/h10-14,19-22,43,46-50,55-70,76,98-99,116-118H,15-18,23-42,44-45,94H2,1-9H3,(H2,95,119)(H2,96,120)(H2,97,127)(H,100,137)(H,101,130)(H,102,139)(H,103,141)(H,104,131)(H,105,128)(H,106,129)(H,107,138)(H,108,133)(H,109,140)(H,110,142)(H,111,134)(H,112,135)(H,113,136)(H,114,132)(H,121,122)(H,123,124)(H,125,126)/t50-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,76-/m0/s1
DMBN4V6	CS	C[C@@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]5CCCN5)O
DMBN4V6	IK	JGQYEMDYGMNCJX-RDLTZJDDSA-N
DMBN4V6	IU	(4S)-4-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-3-hydroxy-2-[[(2S)-4-methyl-2-[[(2S)-pyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-5-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid
DMBN4V6	DE	Discovery agent

DM9BS50	ID	DM9BS50
DM9BS50	DN	Plumbagin
DM9BS50	HS	Investigative
DM9BS50	SN	Plumbagin; 481-42-5; Plumbagine; 5-Hydroxy-2-methyl-1,4-naphthoquinone; Plumbaein; Plumbagone; 2-Methyljuglone; 5-hydroxy-2-methylnaphthalene-1,4-dione; 5-Hydroxy-2-methyl-1,4-naphthalenedione; 5-Hydroxy-2-methyl-[1,4]naphthoquinone; 1,4-Naphthalenedione, 5-hydroxy-2-methyl-; 2-Methyl-5-hydroxy-1,4-naphthoquinone; UNII-YAS4TBQ4OQ; NSC 688284; NSC 236613; CCRIS 6671; YAS4TBQ4OQ; EINECS 207-569-6; BRN 1870475; AI3-38055; CHEBI:8273; CHEMBL295316; VCMMXZQDRFWYSE-UHFFFAOYSA-N; 1,4-NAPHTHOQUINONE, 5-HYDROXY-2-METHYL-; NSC688284
DM9BS50	DT	Small molecular drug
DM9BS50	PC	10205
DM9BS50	MW	188.18
DM9BS50	FM	C11H8O3
DM9BS50	IC	InChI=1S/C11H8O3/c1-6-5-9(13)10-7(11(6)14)3-2-4-8(10)12/h2-5,12H,1H3
DM9BS50	CS	CC1=CC(=O)C2=C(C1=O)C=CC=C2O
DM9BS50	IK	VCMMXZQDRFWYSE-UHFFFAOYSA-N
DM9BS50	IU	5-hydroxy-2-methylnaphthalene-1,4-dione
DM9BS50	CA	CAS 481-42-5
DM9BS50	CB	CHEBI:8273
DM9BS50	DE	Discovery agent

DMZG1L5	ID	DMZG1L5
DMZG1L5	DN	PLX-ORI3
DMZG1L5	HS	Investigative
DMZG1L5	SN	Omni-Raf inhibitors (cancer); Omni-Raf inhibitors (cancer), Plexxikon
DMZG1L5	CP	Plexxikon Inc
DMZG1L5	DE	Solid tumour/cancer

DMU6972	ID	DMU6972
DMU6972	DN	PMBA
DMU6972	HS	Investigative
DMU6972	SN	3-[2'-phosphonomethyl[1,1'-biphenyl]-3-yl]alanine
DMU6972	DT	Small molecular drug
DMU6972	PC	4779
DMU6972	MW	335.29
DMU6972	FM	C16H18NO5P
DMU6972	IC	InChI=1S/C16H18NO5P/c17-15(16(18)19)9-11-4-3-6-12(8-11)14-7-2-1-5-13(14)10-23(20,21)22/h1-8,15H,9-10,17H2,(H,18,19)(H2,20,21,22)
DMU6972	CS	C1=CC=C(C(=C1)CP(=O)(O)O)C2=CC=CC(=C2)CC(C(=O)O)N
DMU6972	IK	NCEGJIHRQBRVJQ-UHFFFAOYSA-N
DMU6972	IU	2-amino-3-[3-[2-(phosphonomethyl)phenyl]phenyl]propanoic acid
DMU6972	DE	Discovery agent

DMEYHWN	ID	DMEYHWN
DMEYHWN	DN	PMD38
DMEYHWN	HS	Investigative
DMEYHWN	SN	p-menthane-3,8-diol
DMEYHWN	DT	Small molecular drug
DMEYHWN	PC	19100
DMEYHWN	MW	172.26
DMEYHWN	FM	C10H20O2
DMEYHWN	IC	InChI=1S/C10H20O2/c1-7-4-5-8(9(11)6-7)10(2,3)12/h7-9,11-12H,4-6H2,1-3H3/t7-,8-,9-/m1/s1
DMEYHWN	CS	C[C@@H]1CC[C@H]([C@@H](C1)O)C(C)(C)O
DMEYHWN	IK	LMXFTMYMHGYJEI-IWSPIJDZSA-N
DMEYHWN	IU	(1R,2R,5R)-2-(2-hydroxypropan-2-yl)-5-methylcyclohexan-1-ol
DMEYHWN	CA	CAS 91739-72-9
DMEYHWN	CB	CHEBI:16053
DMEYHWN	DE	Discovery agent

DMBKVJY	ID	DMBKVJY
DMBKVJY	DN	PMEA
DMBKVJY	HS	Investigative
DMBKVJY	SN	ADEFOVIR; 106941-25-7; PMEA; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 9-(2-Phosphonylmethoxyethyl)adenine; GS-0393; GS 0393; GS 393; 9-(2-(Phosphonomethoxy)ethyl)adenine; N-(2-Phosphonylmethoxyethyl)adenine; DRG-0156; UNII-6GQP90I798; C8H12N5O4P; HSDB 8079; CHEMBL484; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; BRN 3561094; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]-; 6GQP90I798
DMBKVJY	DT	Small molecular drug
DMBKVJY	PC	60172
DMBKVJY	MW	273.19
DMBKVJY	FM	C8H12N5O4P
DMBKVJY	IC	InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)
DMBKVJY	CS	C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N
DMBKVJY	IK	SUPKOOSCJHTBAH-UHFFFAOYSA-N
DMBKVJY	IU	2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid
DMBKVJY	CA	CAS 106941-25-7
DMBKVJY	CB	CHEBI:2469
DMBKVJY	DE	Discovery agent

DMHX704	ID	DMHX704
DMHX704	DN	PMI-008
DMHX704	HS	Investigative
DMHX704	CP	Phytomedics Inc
DMHX704	DE	Obesity

DM7SDNI	ID	DM7SDNI
DM7SDNI	DN	PMID10395480C6
DM7SDNI	HS	Investigative
DM7SDNI	SN	GTPL8632
DM7SDNI	DT	Small molecular drug
DM7SDNI	PC	10336627
DM7SDNI	MW	328.41
DM7SDNI	FM	C15H28N4O4
DM7SDNI	IC	InChI=1S/C15H28N4O4/c1-8(2)7-10(16)12(20)15(23)19-6-4-5-11(19)14(22)18-9(3)13(17)21/h8-12,20H,4-7,16H2,1-3H3,(H2,17,21)(H,18,22)/t9-,10-,11-,12+/m0/s1
DM7SDNI	CS	C[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]([C@H](CC(C)C)N)O
DM7SDNI	IK	PDGQBIYMLALKTR-FIQHERPVSA-N
DM7SDNI	IU	(2S)-1-[(2R,3S)-3-amino-2-hydroxy-5-methylhexanoyl]-N-[(2S)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM7SDNI	DE	Discovery agent

DMLH73O	ID	DMLH73O
DMLH73O	DN	PMID10602705C40
DMLH73O	HS	Investigative
DMLH73O	SN	H(3)N(+)CH(CH(2)CH(2)SO(3)(-))CH(SH)CO-Ile-(3-COOH)Pro; GTPL8630
DMLH73O	DT	Small molecular drug
DMLH73O	PC	44365325
DMLH73O	MW	483.6
DMLH73O	FM	C17H29N3O9S2
DMLH73O	IC	InChI=1S/C17H29N3O9S2/c1-3-8(2)11(19-14(21)13(30)10(18)5-7-31(27,28)29)15(22)20-6-4-9(16(23)24)12(20)17(25)26/h8-13,30H,3-7,18H2,1-2H3,(H,19,21)(H,23,24)(H,25,26)(H,27,28,29)/t8-,9?,10-,11+,12+,13-/m1/s1
DMLH73O	CS	CC[C@@H](C)[C@@H](C(=O)N1CCC([C@H]1C(=O)O)C(=O)O)NC(=O)[C@@H]([C@@H](CCS(=O)(=O)O)N)S
DMLH73O	IK	HUWSZNZAROKDRZ-RRLWZMAJSA-N
DMLH73O	IU	(2S)-1-[(2S,3R)-2-[[(2R,3R)-3-amino-2-sulfanyl-5-sulfopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2,3-dicarboxylic acid
DMLH73O	DE	Discovery agent

DMU0AGE	ID	DMU0AGE
DMU0AGE	DN	PMID11934595C2
DMU0AGE	HS	Investigative
DMU0AGE	SN	GTPL8562; BDBM50111848; E8S
DMU0AGE	DT	Small molecular drug
DMU0AGE	PC	44274134
DMU0AGE	MW	490.6
DMU0AGE	FM	C22H22N2O7S2
DMU0AGE	IC	InChI=1S/C22H22N2O7S2/c1-29-16-5-7-18(8-6-16)33(27,28)24(13-15-4-9-20-21(11-15)31-14-30-20)19(22(25)23-26)12-17-3-2-10-32-17/h2-11,19,26H,12-14H2,1H3,(H,23,25)/t19-/m1/s1
DMU0AGE	CS	COC1=CC=C(C=C1)S(=O)(=O)N(CC2=CC3=C(C=C2)OCO3)[C@H](CC4=CC=CS4)C(=O)NO
DMU0AGE	IK	PGEHBYYTLWHQOM-LJQANCHMSA-N
DMU0AGE	IU	(2R)-2-[1,3-benzodioxol-5-ylmethyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxy-3-thiophen-2-ylpropanamide
DMU0AGE	DE	Discovery agent

DMFO7UC	ID	DMFO7UC
DMFO7UC	DN	PMID12014956C12 
DMFO7UC	HS	Investigative
DMFO7UC	SN	AC1NV8HB; GTPL3192; BDBM50113287
DMFO7UC	DT	Small molecular drug
DMFO7UC	PC	5473007
DMFO7UC	MW	399.36
DMFO7UC	FM	C15H31NO7P2
DMFO7UC	IC	InChI=1S/C15H31NO7P2/c1-14(2)8-5-9-15(3)10-6-11-16(4)12-7-13-22-25(20,21)23-24(17,18)19/h8,10H,5-7,9,11-13H2,1-4H3,(H,20,21)(H2,17,18,19)/b15-10+
DMFO7UC	CS	CC(=CCC/C(=C/CCN(C)CCCOP(=O)(O)OP(=O)(O)O)/C)C
DMFO7UC	IK	PNEIVJAQBZSMGD-XNTDXEJSSA-N
DMFO7UC	IU	3-[[(3E)-4,8-dimethylnona-3,7-dienyl]-methylamino]propyl phosphono hydrogen phosphate
DMFO7UC	DE	Discovery agent

DMY7W2U	ID	DMY7W2U
DMY7W2U	DN	PMID12127536C20 
DMY7W2U	HS	Investigative
DMY7W2U	SN	GTPL8650; BDBM50116264
DMY7W2U	DT	Small molecular drug
DMY7W2U	PC	44310146
DMY7W2U	MW	658.7
DMY7W2U	FM	C34H38N6O8
DMY7W2U	IC	InChI=1S/C34H38N6O8/c1-5-18(2)27(39(4)19(3)41)31(46)35-23-15-14-20-12-9-13-22-16-25(40(28(20)22)34(23)47)30(45)36-24(17-26(42)43)29(44)33-38-37-32(48-33)21-10-7-6-8-11-21/h6-13,18,23-25,27H,5,14-17H2,1-4H3,(H,35,46)(H,36,45)(H,42,43)/t18-,23-,24-,25-,27-/m0/s1
DMY7W2U	CS	CC[C@H](C)[C@@H](C(=O)N[C@H]1CCC2=C3C(=CC=C2)C[C@H](N3C1=O)C(=O)N[C@@H](CC(=O)O)C(=O)C4=NN=C(O4)C5=CC=CC=C5)N(C)C(=O)C
DMY7W2U	IK	UCXMBOHIKJZNMQ-GIYJSHOWSA-N
DMY7W2U	IU	(3S)-3-[[(2S,11S)-11-[[(2S,3S)-2-[acetyl(methyl)amino]-3-methylpentanoyl]amino]-12-oxo-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-carbonyl]amino]-4-oxo-4-(5-phenyl-1,3,4-oxadiazol-2-yl)butanoic acid
DMY7W2U	DE	Discovery agent

DMQZXMF	ID	DMQZXMF
DMQZXMF	DN	PMID12238936C3a
DMQZXMF	HS	Investigative
DMQZXMF	SN	GTPL3085; BDBM50118904
DMQZXMF	DT	Small molecular drug
DMQZXMF	PC	11082054
DMQZXMF	MW	535
DMQZXMF	FM	C26H31ClN2O8
DMQZXMF	IC	InChI=1S/C26H31ClN2O8/c1-26(2,14-30)13-29-18-9-8-15(27)10-17(18)23(16-6-5-7-19(35-3)24(16)36-4)37-20(25(29)34)11-21(31)28-12-22(32)33/h5-10,20,23,30H,11-14H2,1-4H3,(H,28,31)(H,32,33)/t20-,23-/m1/s1
DMQZXMF	CS	CC(C)(CN1C2=C(C=C(C=C2)Cl)[C@H](O[C@@H](C1=O)CC(=O)NCC(=O)O)C3=C(C(=CC=C3)OC)OC)CO
DMQZXMF	IK	CONNCFGSWRVAOP-NFBKMPQASA-N
DMQZXMF	IU	2-[[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]amino]acetic acid
DMQZXMF	CA	CAS 473987-15-4
DMQZXMF	DE	Discovery agent

DMO5J8N	ID	DMO5J8N
DMO5J8N	DN	PMID12238936C3f
DMO5J8N	HS	Investigative
DMO5J8N	SN	GTPL3111; BDBM50118906
DMO5J8N	DT	Small molecular drug
DMO5J8N	PC	11071684
DMO5J8N	MW	549
DMO5J8N	FM	C27H33ClN2O8
DMO5J8N	IC	InChI=1S/C27H33ClN2O8/c1-27(2,15-31)14-30-19-9-8-16(28)12-18(19)24(17-6-5-7-20(36-3)25(17)37-4)38-21(26(30)35)13-22(32)29-11-10-23(33)34/h5-9,12,21,24,31H,10-11,13-15H2,1-4H3,(H,29,32)(H,33,34)/t21-,24-/m1/s1
DMO5J8N	CS	CC(C)(CN1C2=C(C=C(C=C2)Cl)[C@H](O[C@@H](C1=O)CC(=O)NCCC(=O)O)C3=C(C(=CC=C3)OC)OC)CO
DMO5J8N	IK	PILXQRRCKWZQCO-ZJSXRUAMSA-N
DMO5J8N	IU	3-[[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]amino]propanoic acid
DMO5J8N	DE	Discovery agent

DMIW5TY	ID	DMIW5TY
DMIW5TY	DN	PMID12372533C20
DMIW5TY	HS	Investigative
DMIW5TY	SN	GTPL8555; BDBM50120284
DMIW5TY	DT	Small molecular drug
DMIW5TY	PC	44338671
DMIW5TY	MW	870.8
DMIW5TY	FM	C43H64BFN6O11
DMIW5TY	IC	InChI=1S/C43H64BFN6O11/c1-22(2)35(49-38(57)28(15-17-33(52)53)47-37(56)27(46)21-34(54)55)40(59)50-36(23(3)4)41(60)51-18-8-9-29(51)39(58)48-32(16-12-24-10-13-26(45)14-11-24)44-61-31-20-25-19-30(42(25,5)6)43(31,7)62-44/h10-11,13-14,22-23,25,27-32,35-36H,8-9,12,15-21,46H2,1-7H3,(H,47,56)(H,48,58)(H,49,57)(H,50,59)(H,52,53)(H,54,55)/t25-,27-,28-,29+,30-,31+,32-,35-,36-,43-/m0/s1
DMIW5TY	CS	B1(O[C@@H]2C[C@@H]3C[C@H]([C@@]2(O1)C)C3(C)C)[C@H](CCC4=CC=C(C=C4)F)NC(=O)[C@H]5CCCN5C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N
DMIW5TY	IK	JAXFJECJQZDFJS-XHEPKHHKSA-N
DMIW5TY	IU	(4S)-4-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2R)-2-[[(1R)-3-(4-fluorophenyl)-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]propyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMIW5TY	DE	Discovery agent

DM1ISJU	ID	DM1ISJU
DM1ISJU	DN	PMID12470711C3
DM1ISJU	HS	Investigative
DM1ISJU	SN	GTPL6364
DM1ISJU	DT	Small molecular drug
DM1ISJU	PC	73755211
DM1ISJU	MW	295.37
DM1ISJU	FM	C16H25NO4
DM1ISJU	IC	InChI=1S/C16H25NO4/c1-7-8-20-15(19)13-10(2)12(11(3)17-13)14(18)21-9-16(4,5)6/h17H,7-9H2,1-6H3
DM1ISJU	CS	CCCOC(=O)C1=C(C(=C(N1)C)C(=O)OCC(C)(C)C)C
DM1ISJU	IK	JFOGEVBSXYRAFN-UHFFFAOYSA-N
DM1ISJU	IU	4-O-(2,2-dimethylpropyl) 2-O-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate
DM1ISJU	DE	Discovery agent

DMXFY4P	ID	DMXFY4P
DMXFY4P	DN	PMID12614873C2b-1
DMXFY4P	HS	Investigative
DMXFY4P	SN	GTPL3696
DMXFY4P	DT	Small molecular drug
DMXFY4P	PC	73755059
DMXFY4P	MW	584.8
DMXFY4P	FM	C36H48N4O3
DMXFY4P	IC	InChI=1S/C36H48N4O3/c37-23-27-12-9-19-40(25-27)36(42)28-15-16-33-31(22-28)34(30-13-7-8-14-32(30)43-33)35(41)38-29-17-20-39(21-18-29)24-26-10-5-3-1-2-4-6-11-26/h7-8,10,13-16,22,27,29,34H,1-6,9,11-12,17-21,23-25,37H2,(H,38,41)/t27-,34?/m0/s1
DMXFY4P	CS	C1CCCC=C(CCC1)CN2CCC(CC2)NC(=O)C3C4=CC=CC=C4OC5=C3C=C(C=C5)C(=O)N6CCC[C@H](C6)CN
DMXFY4P	IK	AAPRNHKWNGDTOT-DVRVPOOOSA-N
DMXFY4P	IU	2-[(3S)-3-(aminomethyl)piperidine-1-carbonyl]-N-[1-(cyclononen-1-ylmethyl)piperidin-4-yl]-9H-xanthene-9-carboxamide
DMXFY4P	DE	Discovery agent

DMR1MCD	ID	DMR1MCD
DMR1MCD	DN	PMID12723943C12
DMR1MCD	HS	Investigative
DMR1MCD	SN	GTPL666; BDBM50127442
DMR1MCD	DT	Small molecular drug
DMR1MCD	PC	10281725
DMR1MCD	MW	579.7
DMR1MCD	FM	C34H41N7O2
DMR1MCD	IC	InChI=1S/C34H41N7O2/c1-2-19-41-30-13-7-6-12-29(30)31(25-9-4-3-5-10-25)37-32(33(41)42)38-34(43)36-26-14-16-27(17-15-26)39-20-22-40(23-21-39)28-11-8-18-35-24-28/h6-8,11-18,24-25,32H,2-5,9-10,19-23H2,1H3,(H2,36,38,43)
DMR1MCD	CS	CCCN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)NC3=CC=C(C=C3)N4CCN(CC4)C5=CN=CC=C5)C6CCCCC6
DMR1MCD	IK	AIHOVEHIRAAXQV-UHFFFAOYSA-N
DMR1MCD	IU	1-(5-cyclohexyl-2-oxo-1-propyl-3H-1,4-benzodiazepin-3-yl)-3-[4-(4-pyridin-3-ylpiperazin-1-yl)phenyl]urea
DMR1MCD	DE	Discovery agent

DM3EZ9Q	ID	DM3EZ9Q
DM3EZ9Q	DN	PMID12723954C21b
DM3EZ9Q	HS	Investigative
DM3EZ9Q	SN	GTPL630
DM3EZ9Q	DT	Small molecular drug
DM3EZ9Q	PC	10254379
DM3EZ9Q	MW	476
DM3EZ9Q	FM	C26H26ClN5O2
DM3EZ9Q	IC	InChI=1S/C26H26ClN5O2/c27-20-10-12-21(13-11-20)31-32-26(34)30-24(16-19-17-29-23-9-5-4-8-22(19)23)25(33)28-15-14-18-6-2-1-3-7-18/h1-13,17,24,29,31H,14-16H2,(H,28,33)(H2,30,32,34)/t24-/m1/s1
DM3EZ9Q	CS	C1=CC=C(C=C1)CCNC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)NNC4=CC=C(C=C4)Cl
DM3EZ9Q	IK	SLTBMTIRYMGWLX-XMMPIXPASA-N
DM3EZ9Q	IU	(2R)-2-[(4-chloroanilino)carbamoylamino]-3-(1H-indol-3-yl)-N-(2-phenylethyl)propanamide
DM3EZ9Q	DE	Discovery agent

DMYXDK5	ID	DMYXDK5
DMYXDK5	DN	PMID12812482C11
DMYXDK5	HS	Investigative
DMYXDK5	SN	GTPL665; BDBM50156455; 2-[(2R)-1-(
DMYXDK5	DT	Small molecular drug
DMYXDK5	PC	9916412
DMYXDK5	MW	586.5
DMYXDK5	FM	C27H25Cl2N5O4S
DMYXDK5	IC	InChI=1S/C27H25Cl2N5O4S/c28-20-10-9-19(15-21(20)29)39(37,38)34-23-4-2-1-3-22(23)33-27(36)24(34)16-25(35)30-12-11-17-5-7-18(8-6-17)26-31-13-14-32-26/h1-10,15,24H,11-14,16H2,(H,30,35)(H,31,32)(H,33,36)/t24-/m1/s1
DMYXDK5	CS	C1CN=C(N1)C2=CC=C(C=C2)CCNC(=O)C[C@@H]3C(=O)NC4=CC=CC=C4N3S(=O)(=O)C5=CC(=C(C=C5)Cl)Cl
DMYXDK5	IK	HYJYRDCPGUEYND-XMMPIXPASA-N
DMYXDK5	IU	2-[(2R)-1-(3,4-dichlorophenyl)sulfonyl-3-oxo-2,4-dihydroquinoxalin-2-yl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]acetamide
DMYXDK5	DE	Discovery agent

DMR2L6X	ID	DMR2L6X
DMR2L6X	DN	PMID14640538C3
DMR2L6X	HS	Investigative
DMR2L6X	SN	mergepta; 2-Mmgetpa; 2-mercaptomethyl-3-guanidinoethylthiopropanoic acid; Mergepta; Mergetpa; 77102-28-4; AC1Q5S0I; AC1L3X6V; AC1Q50E9; GTPL8675; CTK8D5675; LS-177336
DMR2L6X	DT	Small molecular drug
DMR2L6X	PC	123726
DMR2L6X	MW	237.3
DMR2L6X	FM	C7H15N3O2S2
DMR2L6X	IC	InChI=1S/C7H15N3O2S2/c8-7(9)10-1-2-14-4-5(3-13)6(11)12/h5,13H,1-4H2,(H,11,12)(H4,8,9,10)
DMR2L6X	CS	C(CSCC(CS)C(=O)O)N=C(N)N
DMR2L6X	IK	AKPKWZRKZOAAAZ-UHFFFAOYSA-N
DMR2L6X	IU	2-[2-(diaminomethylideneamino)ethylsulfanylmethyl]-3-sulfanylpropanoic acid
DMR2L6X	CA	CAS 77102-28-4
DMR2L6X	DE	Discovery agent

DMFWCAJ	ID	DMFWCAJ
DMFWCAJ	DN	PMID14697765C11a
DMFWCAJ	HS	Investigative
DMFWCAJ	SN	GTPL6426
DMFWCAJ	DT	Small molecular drug
DMFWCAJ	PC	73755219
DMFWCAJ	MW	304.3
DMFWCAJ	FM	C19H16N2O2
DMFWCAJ	IC	InChI=1S/C19H16N2O2/c1-22-18-12-13(9-10-14(18)15-6-4-5-11-20-15)19-21-16-7-2-3-8-17(16)23-19/h2-12,19,21H,1H3
DMFWCAJ	CS	COC1=C(C=CC(=C1)C2NC3=CC=CC=C3O2)C4=CC=CC=N4
DMFWCAJ	IK	DNFFCLRSKDXRKM-UHFFFAOYSA-N
DMFWCAJ	IU	2-(3-methoxy-4-pyridin-2-ylphenyl)-2,3-dihydro-1,3-benzoxazole
DMFWCAJ	DE	Discovery agent

DMFT1DO	ID	DMFT1DO
DMFT1DO	DN	PMID14697765C16a
DMFT1DO	HS	Investigative
DMFT1DO	SN	UNII-0896DN89BF; 0896DN89BF; 669091-15-0; GTPL6427
DMFT1DO	DT	Small molecular drug
DMFT1DO	PC	10380127
DMFT1DO	MW	301.3
DMFT1DO	FM	C19H15N3O
DMFT1DO	IC	InChI=1S/C19H15N3O/c1-23-18-12-14(8-9-15(18)16-6-2-4-10-20-16)17-13-22-11-5-3-7-19(22)21-17/h2-13H,1H3
DMFT1DO	CS	COC1=C(C=CC(=C1)C2=CN3C=CC=CC3=N2)C4=CC=CC=N4
DMFT1DO	IK	DNCGFJANVDVZIZ-UHFFFAOYSA-N
DMFT1DO	IU	2-(3-methoxy-4-pyridin-2-ylphenyl)imidazo[1,2-a]pyridine
DMFT1DO	CA	CAS 669091-15-0
DMFT1DO	DE	Discovery agent

DMOQ8PF	ID	DMOQ8PF
DMOQ8PF	DN	PMID15027864C8d
DMOQ8PF	HS	Investigative
DMOQ8PF	SN	GTPL8659; BDBM50143078
DMOQ8PF	DT	Small molecular drug
DMOQ8PF	PC	10043679
DMOQ8PF	MW	354.31
DMOQ8PF	FM	C15H18N2O8
DMOQ8PF	IC	InChI=1S/C15H18N2O8/c18-9-3-1-8(2-4-9)7-11(14(23)24)17-15(25)16-10(13(21)22)5-6-12(19)20/h1-4,10-11,18H,5-7H2,(H,19,20)(H,21,22)(H,23,24)(H2,16,17,25)/t10-,11-/m0/s1
DMOQ8PF	CS	C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)O
DMOQ8PF	IK	QXWVJRPYHOYHHT-QWRGUYRKSA-N
DMOQ8PF	IU	(2S)-2-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoylamino]pentanedioic acid
DMOQ8PF	DE	Discovery agent

DM9V6YK	ID	DM9V6YK
DM9V6YK	DN	PMID15055993C1a
DM9V6YK	HS	Investigative
DM9V6YK	SN	GTPL6514; BDBM50131385
DM9V6YK	DT	Small molecular drug
DM9V6YK	PC	9910222
DM9V6YK	MW	424.4
DM9V6YK	FM	C18H20N2O8S
DM9V6YK	IC	InChI=1S/C18H20N2O8S/c21-14-10-20(15(18(24)19-25)17(23)16(14)22)29(26,27)13-8-6-12(7-9-13)28-11-4-2-1-3-5-11/h1-9,14-17,21-23,25H,10H2,(H,19,24)/t14-,15+,16+,17+/m0/s1
DM9V6YK	CS	C1[C@@H]([C@H]([C@@H]([C@@H](N1S(=O)(=O)C2=CC=C(C=C2)OC3=CC=CC=C3)C(=O)NO)O)O)O
DM9V6YK	IK	WLWNRAWQDZRXMB-YLFCFFPRSA-N
DM9V6YK	IU	(2R,3R,4R,5S)-N,3,4,5-tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamide
DM9V6YK	DE	Discovery agent

DMFI4J6	ID	DMFI4J6
DMFI4J6	DN	PMID15261275C1
DMFI4J6	HS	Investigative
DMFI4J6	SN	GTPL1702; BDBM50412849
DMFI4J6	DT	Small molecular drug
DMFI4J6	PC	10046856
DMFI4J6	MW	405.3
DMFI4J6	FM	C19H21BrN2O3
DMFI4J6	IC	InChI=1S/C19H21BrN2O3/c1-19(2)24-12-16(17(25-19)13-8-4-3-5-9-13)22-18(23)21-15-11-7-6-10-14(15)20/h3-11,16-17H,12H2,1-2H3,(H2,21,22,23)/t16-,17-/m0/s1
DMFI4J6	CS	CC1(OC[C@@H]([C@@H](O1)C2=CC=CC=C2)NC(=O)NC3=CC=CC=C3Br)C
DMFI4J6	IK	ZVELNGXIEZFZIB-IRXDYDNUSA-N
DMFI4J6	IU	1-(2-bromophenyl)-3-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea
DMFI4J6	DE	Discovery agent

DM7JKLM	ID	DM7JKLM
DM7JKLM	DN	PMID1527791C29
DM7JKLM	HS	Investigative
DM7JKLM	SN	GTPL3029; BDBM50004775
DM7JKLM	DT	Small molecular drug
DM7JKLM	PC	15931922
DM7JKLM	MW	408.5
DM7JKLM	FM	C23H36O6
DM7JKLM	IC	InChI=1S/C23H36O6/c1-4-13(2)23(27)29-20-11-16(24)9-15-6-5-14(3)19(22(15)20)8-7-18-10-17(25)12-21(26)28-18/h5-6,13-20,22,24-25H,4,7-12H2,1-3H3/t13-,14-,15-,16+,17+,18?,19-,20-,22-/m0/s1
DM7JKLM	CS	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C[C@H]2[C@H]1[C@H]([C@H](C=C2)C)CCC3C[C@H](CC(=O)O3)O)O
DM7JKLM	IK	LJOOWESTVASNOG-UFJKPHDISA-N
DM7JKLM	IU	[(1S,3R,4aR,7S,8S,8aS)-3-hydroxy-8-[2-[(4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2S)-2-methylbutanoate
DM7JKLM	DE	Discovery agent

DMWDE9A	ID	DMWDE9A
DMWDE9A	DN	PMID15300839C17
DMWDE9A	HS	Investigative
DMWDE9A	SN	GTPL715; BDBM50193413
DMWDE9A	DT	Small molecular drug
DMWDE9A	PC	44415153
DMWDE9A	MW	438.6
DMWDE9A	FM	C25H30N2O3S
DMWDE9A	IC	InChI=1S/C25H30N2O3S/c1-18(22-11-7-9-19-8-3-4-10-23(19)22)26-24-12-5-6-13-25(24)27-31(28,29)21-16-14-20(30-2)15-17-21/h3-4,7-11,14-18,24-27H,5-6,12-13H2,1-2H3/t18?,24-,25-/m1/s1
DMWDE9A	CS	CC(C1=CC=CC2=CC=CC=C21)N[C@@H]3CCCC[C@H]3NS(=O)(=O)C4=CC=C(C=C4)OC
DMWDE9A	IK	AKPJKVQQBSNRID-XTEKXTAFSA-N
DMWDE9A	IU	4-methoxy-N-[(1R,2R)-2-(1-naphthalen-1-ylethylamino)cyclohexyl]benzenesulfonamide
DMWDE9A	DE	Discovery agent

DM7T8BE	ID	DM7T8BE
DM7T8BE	DN	PMID15482906C10
DM7T8BE	HS	Investigative
DM7T8BE	SN	GTPL6450; BDBM50154977
DM7T8BE	DT	Small molecular drug
DM7T8BE	PC	9967471
DM7T8BE	MW	334.31
DM7T8BE	FM	C17H11FN6O
DM7T8BE	IC	InChI=1S/C17H11FN6O/c18-12-8-13(10-15(9-12)25-14-4-3-6-19-11-14)24-22-17(21-23-24)16-5-1-2-7-20-16/h1-11H
DM7T8BE	CS	C1=CC=NC(=C1)C2=NN(N=N2)C3=CC(=CC(=C3)F)OC4=CN=CC=C4
DM7T8BE	IK	IQSMPFFGKFZZMI-UHFFFAOYSA-N
DM7T8BE	IU	2-[2-(3-fluoro-5-pyridin-3-yloxyphenyl)tetrazol-5-yl]pyridine
DM7T8BE	DE	Discovery agent

DMCPIQ4	ID	DMCPIQ4
DMCPIQ4	DN	PMID15482908C8
DMCPIQ4	HS	Investigative
DMCPIQ4	SN	507269-27-4; GTPL6448; CTK1G6178; DTXSID80439334; BDBM50151910
DMCPIQ4	DT	Small molecular drug
DMCPIQ4	PC	10400683
DMCPIQ4	MW	266.23
DMCPIQ4	FM	C13H7FN6
DMCPIQ4	IC	InChI=1S/C13H7FN6/c14-10-5-9(8-15)6-11(7-10)20-18-13(17-19-20)12-3-1-2-4-16-12/h1-7H
DMCPIQ4	CS	C1=CC=NC(=C1)C2=NN(N=N2)C3=CC(=CC(=C3)C#N)F
DMCPIQ4	IK	NNUSSUPIQZLYJW-UHFFFAOYSA-N
DMCPIQ4	IU	3-fluoro-5-(5-pyridin-2-yltetrazol-2-yl)benzonitrile
DMCPIQ4	CA	CAS 507269-27-4
DMCPIQ4	DE	Discovery agent

DMOPUIH	ID	DMOPUIH
DMOPUIH	DN	PMID15546730C2
DMOPUIH	HS	Investigative
DMOPUIH	SN	UNII-N9PH4O199D; N9PH4O199D; GTPL8136; BDBM13268
DMOPUIH	DT	Small molecular drug
DMOPUIH	PC	11153014
DMOPUIH	MW	373.9
DMOPUIH	FM	C17H16ClN5OS
DMOPUIH	IC	InChI=1S/C17H16ClN5OS/c1-9-5-4-6-12(18)15(9)23-16(24)13-8-19-17(25-13)22-14-7-10(2)20-11(3)21-14/h4-8H,1-3H3,(H,23,24)(H,19,20,21,22)
DMOPUIH	CS	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)C)C
DMOPUIH	IK	WFRLFWGASBLYTC-UHFFFAOYSA-N
DMOPUIH	IU	N-(2-chloro-6-methylphenyl)-2-[(2,6-dimethylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide
DMOPUIH	CA	CAS 302961-18-8
DMOPUIH	DE	Discovery agent

DMN5LZQ	ID	DMN5LZQ
DMN5LZQ	DN	PMID15603962Crac-16
DMN5LZQ	HS	Investigative
DMN5LZQ	SN	GTPL2333
DMN5LZQ	DT	Small molecular drug
DMN5LZQ	PC	11222922
DMN5LZQ	MW	386.7
DMN5LZQ	FM	C18H14ClF3O4
DMN5LZQ	IC	InChI=1S/C18H14ClF3O4/c1-8-5-10-7-26-17(24)15(10)14(13(8)16(23)25-2)9-3-4-12(19)11(6-9)18(20,21)22/h3-4,6,14H,5,7H2,1-2H3
DMN5LZQ	CS	CC1=C(C(C2=C(C1)COC2=O)C3=CC(=C(C=C3)Cl)C(F)(F)F)C(=O)OC
DMN5LZQ	IK	WMQUFXJLJGXXJD-UHFFFAOYSA-N
DMN5LZQ	IU	methyl 4-[4-chloro-3-(trifluoromethyl)phenyl]-6-methyl-3-oxo-4,7-dihydro-1H-2-benzofuran-5-carboxylate
DMN5LZQ	DE	Discovery agent

DM93RKC	ID	DM93RKC
DM93RKC	DN	PMID15664838C18
DM93RKC	HS	Investigative
DM93RKC	SN	GTPL6536; BDBM12195
DM93RKC	DT	Small molecular drug
DM93RKC	PC	11375559
DM93RKC	MW	504.6
DM93RKC	FM	C29H30F2N4O2
DM93RKC	IC	InChI=1S/C29H30F2N4O2/c30-24-9-5-20(6-10-24)28(21-7-11-25(31)12-8-21)34-15-13-33(14-16-34)27(36)17-26(32)29(37)35-18-22-3-1-2-4-23(22)19-35/h1-12,26,28H,13-19,32H2
DM93RKC	CS	C1CN(CCN1C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)CC(C(=O)N4CC5=CC=CC=C5C4)N
DM93RKC	IK	ZKIQFLSGMMYCGS-UHFFFAOYSA-N
DM93RKC	IU	2-amino-4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-(1,3-dihydroisoindol-2-yl)butane-1,4-dione
DM93RKC	DE	Discovery agent

DM50E6R	ID	DM50E6R
DM50E6R	DN	PMID15686906C17
DM50E6R	HS	Investigative
DM50E6R	SN	GTPL3000
DM50E6R	DT	Small molecular drug
DM50E6R	PC	14849849
DM50E6R	MW	456.5
DM50E6R	FM	C25H26F2N2O4
DM50E6R	IC	InChI=1S/C25H26F2N2O4/c1-15(2)25-28-23(16-3-7-18(26)8-4-16)24(17-5-9-19(27)10-6-17)29(25)12-11-20(30)13-21(31)14-22(32)33/h3-12,15,20-21,30-31H,13-14H2,1-2H3,(H,32,33)/b12-11+/t20-,21+/m0/s1
DM50E6R	CS	CC(C)C1=NC(=C(N1/C=C/[C@@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)F
DM50E6R	IK	GQOQQDINYJTQDY-LBNTZDJNSA-N
DM50E6R	IU	(E,3R,5R)-7-[4,5-bis(4-fluorophenyl)-2-propan-2-ylimidazol-1-yl]-3,5-dihydroxyhept-6-enoic acid
DM50E6R	DE	Discovery agent

DMBZSKJ	ID	DMBZSKJ
DMBZSKJ	DN	PMID15686906C29
DMBZSKJ	HS	Investigative
DMBZSKJ	SN	GTPL2995
DMBZSKJ	DT	Small molecular drug
DMBZSKJ	PC	44392476
DMBZSKJ	MW	455.5
DMBZSKJ	FM	C26H27F2NO4
DMBZSKJ	IC	InChI=1S/C26H27F2NO4/c1-16(2)24-15-23(17-3-7-19(27)8-4-17)26(18-5-9-20(28)10-6-18)29(24)12-11-21(30)13-22(31)14-25(32)33/h3-12,15-16,21-22,30-31H,13-14H2,1-2H3,(H,32,33)/b12-11+/t21-,22-/m1/s1
DMBZSKJ	CS	CC(C)C1=CC(=C(N1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)F
DMBZSKJ	IK	NRLBNECCSXRCMS-CXYUPCIPSA-N
DMBZSKJ	IU	(E,3R,5S)-7-[2,3-bis(4-fluorophenyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyhept-6-enoic acid
DMBZSKJ	DE	Discovery agent

DMPB7Z6	ID	DMPB7Z6
DMPB7Z6	DN	PMID15686941C13
DMPB7Z6	HS	Investigative
DMPB7Z6	SN	GTPL6447; BDBM50161031
DMPB7Z6	DT	Small molecular drug
DMPB7Z6	PC	11206949
DMPB7Z6	MW	229.24
DMPB7Z6	FM	C11H11N5O
DMPB7Z6	IC	InChI=1S/C11H11N5O/c1-7-6-14-10(12)9(15-7)11(17)16-8-4-2-3-5-13-8/h2-6H,1H3,(H2,12,14)(H,13,16,17)
DMPB7Z6	CS	CC1=CN=C(C(=N1)C(=O)NC2=CC=CC=N2)N
DMPB7Z6	IK	NAQODRYELYCKDS-UHFFFAOYSA-N
DMPB7Z6	IU	3-amino-6-methyl-N-pyridin-2-ylpyrazine-2-carboxamide
DMPB7Z6	DE	Discovery agent

DMR7UBZ	ID	DMR7UBZ
DMR7UBZ	DN	PMID15686947C(S)-3h
DMR7UBZ	HS	Investigative
DMR7UBZ	SN	2-benzylpyrridine-substituted aryloxypropanol analogue; GTPL712; ZINC14192237
DMR7UBZ	DT	Small molecular drug
DMR7UBZ	PC	11710462
DMR7UBZ	MW	370.9
DMR7UBZ	FM	C21H23ClN2O2
DMR7UBZ	IC	InChI=1S/C21H23ClN2O2/c22-20-9-4-10-21(19(20)13-23)26-15-18(25)14-24-11-5-8-17(24)12-16-6-2-1-3-7-16/h1-4,6-7,9-10,17-18,25H,5,8,11-12,14-15H2/t17-,18+/m0/s1
DMR7UBZ	CS	C1C[C@H](N(C1)C[C@H](COC2=C(C(=CC=C2)Cl)C#N)O)CC3=CC=CC=C3
DMR7UBZ	IK	HSTMYWDURDPUMY-ZWKOTPCHSA-N
DMR7UBZ	IU	2-[(2R)-3-[(2S)-2-benzylpyrrolidin-1-yl]-2-hydroxypropoxy]-6-chlorobenzonitrile
DMR7UBZ	DE	Discovery agent

DMBEHA5	ID	DMBEHA5
DMBEHA5	DN	PMID15724976C1
DMBEHA5	HS	Investigative
DMBEHA5	SN	AC1NQPIE; GTPL7507
DMBEHA5	DT	Small molecular drug
DMBEHA5	PC	5276852
DMBEHA5	MW	196.23
DMBEHA5	FM	C9H14N3O2+
DMBEHA5	IC	InChI=1S/C9H13N3O2/c10-6-3-7-11-8-4-1-2-5-9(8)12(13)14/h1-2,4-5,11H,3,6-7,10H2/p+1
DMBEHA5	CS	C1=CC=C(C(=C1)NCCC[NH3+])[N+](=O)[O-]
DMBEHA5	IK	GVGDDEYVTBKACE-UHFFFAOYSA-O
DMBEHA5	IU	3-(2-nitroanilino)propylazanium
DMBEHA5	DE	Discovery agent

DMHY95J	ID	DMHY95J
DMHY95J	DN	PMID15925511C13
DMHY95J	HS	Investigative
DMHY95J	SN	GTPL8188; BDBM50168247
DMHY95J	DT	Small molecular drug
DMHY95J	PC	11668217
DMHY95J	MW	388.5
DMHY95J	FM	C21H12N2O2S2
DMHY95J	IC	InChI=1S/C21H12N2O2S2/c24-21(25)13-6-5-12-10-15-16(11-14(12)9-13)23-20(18-4-2-8-27-18)19(22-15)17-3-1-7-26-17/h1-11H,(H,24,25)
DMHY95J	CS	C1=CSC(=C1)C2=NC3=C(C=C4C=C(C=CC4=C3)C(=O)O)N=C2C5=CC=CS5
DMHY95J	IK	GXGUVSXXUOACEX-UHFFFAOYSA-N
DMHY95J	IU	2,3-dithiophen-2-ylbenzo[g]quinoxaline-7-carboxylic acid
DMHY95J	DE	Discovery agent

DMF0ZXU	ID	DMF0ZXU
DMF0ZXU	DN	PMID15955699C24
DMF0ZXU	HS	Investigative
DMF0ZXU	SN	GTPL8131; BDBM50168854
DMF0ZXU	DT	Small molecular drug
DMF0ZXU	PC	44397277
DMF0ZXU	MW	328.37
DMF0ZXU	FM	C15H20N8O
DMF0ZXU	IC	InChI=1S/C15H20N8O/c1-2-23-13-10(9-22-5-3-17-4-6-22)7-18-8-11(13)19-15(23)12-14(16)21-24-20-12/h7-8,17H,2-6,9H2,1H3,(H2,16,21)
DMF0ZXU	CS	CCN1C2=C(C=NC=C2CN3CCNCC3)N=C1C4=NON=C4N
DMF0ZXU	IK	OXZLPOLYTISTQY-UHFFFAOYSA-N
DMF0ZXU	IU	4-[1-ethyl-7-(piperazin-1-ylmethyl)imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine
DMF0ZXU	DE	Discovery agent

DMIRSWL	ID	DMIRSWL
DMIRSWL	DN	PMID16099654C3a
DMIRSWL	HS	Investigative
DMIRSWL	SN	GTPL6205; BDBM50258139
DMIRSWL	DT	Small molecular drug
DMIRSWL	PC	44573698
DMIRSWL	MW	307.3
DMIRSWL	FM	C17H13N3O3
DMIRSWL	IC	InChI=1S/C17H13N3O3/c1-10-18-17(20-23-10)19-16(21)15-11-6-2-4-8-13(11)22-14-9-5-3-7-12(14)15/h2-9,15H,1H3,(H,19,20,21)
DMIRSWL	CS	CC1=NC(=NO1)NC(=O)C2C3=CC=CC=C3OC4=CC=CC=C24
DMIRSWL	IK	KXBNLKGEYKHKAO-UHFFFAOYSA-N
DMIRSWL	IU	N-(5-methyl-1,2,4-oxadiazol-3-yl)-9H-xanthene-9-carboxamide
DMIRSWL	DE	Discovery agent

DMV8UK1	ID	DMV8UK1
DMV8UK1	DN	PMID16099654C4b
DMV8UK1	HS	Investigative
DMV8UK1	SN	GTPL6206
DMV8UK1	DT	Small molecular drug
DMV8UK1	PC	9923127
DMV8UK1	MW	321.33
DMV8UK1	FM	C17H15N5O2
DMV8UK1	IC	InChI=1S/C17H15N5O2/c1-2-22-20-17(19-21-22)18-16(23)15-11-7-3-5-9-13(11)24-14-10-6-4-8-12(14)15/h3-10,15H,2H2,1H3,(H,18,20,23)
DMV8UK1	CS	CCN1N=C(N=N1)NC(=O)C2C3=CC=CC=C3OC4=CC=CC=C24
DMV8UK1	IK	HVTLYEBQNBWUIT-UHFFFAOYSA-N
DMV8UK1	IU	N-(2-ethyltetrazol-5-yl)-9H-xanthene-9-carboxamide
DMV8UK1	DE	Discovery agent

DMM4A7P	ID	DMM4A7P
DMM4A7P	DN	PMID16242323C15a
DMM4A7P	HS	Investigative
DMM4A7P	SN	GTPL6724
DMM4A7P	DT	Small molecular drug
DMM4A7P	PC	45265749
DMM4A7P	MW	578.1
DMM4A7P	FM	C32H40ClN5O3
DMM4A7P	IC	InChI=1S/C32H39N5O3.ClH/c1-7-8-17-37-30-24(13-10-16-34-30)27(21-11-9-12-22(18-21)40-6)29(31(37)38)36-32(39)35-28-23(19(2)3)14-15-25(33)26(28)20(4)5;/h9-16,18-20H,7-8,17,33H2,1-6H3,(H2,35,36,39);1H
DMM4A7P	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=CC(=C3C(C)C)N)C(C)C)C4=CC(=CC=C4)OC.Cl
DMM4A7P	IK	HALGUFCFUQNPBN-UHFFFAOYSA-N
DMM4A7P	IU	1-[3-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride
DMM4A7P	DE	Discovery agent

DM7U3RM	ID	DM7U3RM
DM7U3RM	DN	PMID16242323C15b
DM7U3RM	HS	Investigative
DM7U3RM	SN	GTPL6725
DM7U3RM	DT	Small molecular drug
DM7U3RM	PC	45265746
DM7U3RM	MW	578.1
DM7U3RM	FM	C32H40ClN5O3
DM7U3RM	IC	InChI=1S/C32H39N5O3.ClH/c1-7-8-15-37-30-24(13-10-14-34-30)27(21-11-9-12-23(16-21)40-6)29(31(37)38)36-32(39)35-28-25(19(2)3)17-22(33)18-26(28)20(4)5;/h9-14,16-20H,7-8,15,33H2,1-6H3,(H2,35,36,39);1H
DM7U3RM	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=C(C=C3C(C)C)N)C(C)C)C4=CC(=CC=C4)OC.Cl
DM7U3RM	IK	NPAVKCDQHSYXFT-UHFFFAOYSA-N
DM7U3RM	IU	1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride
DM7U3RM	DE	Discovery agent

DM2Q79X	ID	DM2Q79X
DM2Q79X	DN	PMID16242323C16
DM2Q79X	HS	Investigative
DM2Q79X	SN	GTPL6726
DM2Q79X	DT	Small molecular drug
DM2Q79X	PC	73755234
DM2Q79X	MW	566.1
DM2Q79X	FM	C31H40ClN5O3
DM2Q79X	IC	InChI=1S/C31H39N5O3.ClH/c1-7-8-17-36-29-24(13-10-15-33-29)25(21-11-9-12-22(18-21)39-6)28(30(36)37)35-31(38)34-27-23(19(2)3)14-16-32-26(27)20(4)5;/h9-16,18-20,26,32H,7-8,17H2,1-6H3,(H2,34,35,38);1H
DM2Q79X	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=CNC3C(C)C)C(C)C)C4=CC(=CC=C4)OC.Cl
DM2Q79X	IK	UXCQVIIRKWYPHK-UHFFFAOYSA-N
DM2Q79X	IU	1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]-3-[2,4-di(propan-2-yl)-1,2-dihydropyridin-3-yl]urea;hydrochloride
DM2Q79X	DE	Discovery agent

DMI5WPQ	ID	DMI5WPQ
DMI5WPQ	DN	PMID16242323C18a
DMI5WPQ	HS	Investigative
DMI5WPQ	SN	GTPL6727
DMI5WPQ	DT	Small molecular drug
DMI5WPQ	PC	45263291
DMI5WPQ	MW	592.2
DMI5WPQ	FM	C33H42ClN5O3
DMI5WPQ	IC	InChI=1S/C33H41N5O3.ClH/c1-7-8-15-38-31-25(13-10-14-35-31)28(23-11-9-12-24(18-23)41-6)30(32(38)39)37-33(40)36-29-26(20(2)3)16-22(19-34)17-27(29)21(4)5;/h9-14,16-18,20-21H,7-8,15,19,34H2,1-6H3,(H2,36,37,40);1H
DMI5WPQ	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=C(C=C3C(C)C)CN)C(C)C)C4=CC(=CC=C4)OC.Cl
DMI5WPQ	IK	SZCBDIVMCGFVPW-UHFFFAOYSA-N
DMI5WPQ	IU	1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride
DMI5WPQ	DE	Discovery agent

DMIS7NT	ID	DMIS7NT
DMIS7NT	DN	PMID16242323C18b
DMIS7NT	HS	Investigative
DMIS7NT	SN	GTPL6728
DMIS7NT	DT	Small molecular drug
DMIS7NT	PC	73755236
DMIS7NT	MW	620.2
DMIS7NT	FM	C35H46ClN5O3
DMIS7NT	IC	InChI=1S/C35H45N5O3.ClH/c1-9-10-17-40-33-27(15-12-16-36-33)30(25-13-11-14-26(20-25)43-8)32(34(40)41)38-35(42)37-31-28(22(2)3)18-24(21-39(6)7)19-29(31)23(4)5;/h11-16,18-20,22-23H,9-10,17,21H2,1-8H3,(H2,37,38,42);1H
DMIS7NT	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=C(C=C3C(C)C)CN(C)C)C(C)C)C4=CC(=CC=C4)OC.Cl
DMIS7NT	IK	YCGQPIRMLGEWMW-UHFFFAOYSA-N
DMIS7NT	IU	1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]-3-[4-[(dimethylamino)methyl]-2,6-di(propan-2-yl)phenyl]urea;hydrochloride
DMIS7NT	DE	Discovery agent

DMFDRMH	ID	DMFDRMH
DMFDRMH	DN	PMID16242323C22c
DMFDRMH	HS	Investigative
DMFDRMH	SN	GTPL6730
DMFDRMH	DT	Small molecular drug
DMFDRMH	PC	73755238
DMFDRMH	MW	636.2
DMFDRMH	FM	C35H46ClN5O4
DMFDRMH	IC	InChI=1S/C35H45N5O4.ClH/c1-6-7-15-40-33-27(13-9-14-37-33)30(25-11-8-12-26(20-25)44-17-10-16-41)32(34(40)42)39-35(43)38-31-28(22(2)3)18-24(21-36)19-29(31)23(4)5;/h8-9,11-14,18-20,22-23,41H,6-7,10,15-17,21,36H2,1-5H3,(H2,38,39,43);1H
DMFDRMH	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=C(C=C3C(C)C)CN)C(C)C)C4=CC(=CC=C4)OCCCO.Cl
DMFDRMH	IK	OXTVBHDILDPYAS-UHFFFAOYSA-N
DMFDRMH	IU	1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride
DMFDRMH	DE	Discovery agent

DMJICNL	ID	DMJICNL
DMJICNL	DN	PMID16242323C22d
DMJICNL	HS	Investigative
DMJICNL	SN	GTPL6731
DMJICNL	DT	Small molecular drug
DMJICNL	PC	73755240
DMJICNL	MW	608.2
DMJICNL	FM	C33H42ClN5O4
DMJICNL	IC	InChI=1S/C33H41N5O4.ClH/c1-6-7-16-38-31-25(12-9-15-35-31)28(22-10-8-11-23(19-22)42-18-17-39)30(32(38)40)37-33(41)36-29-24(20(2)3)13-14-26(34)27(29)21(4)5;/h8-15,19-21,39H,6-7,16-18,34H2,1-5H3,(H2,36,37,41);1H
DMJICNL	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=CC(=C3C(C)C)N)C(C)C)C4=CC(=CC=C4)OCCO.Cl
DMJICNL	IK	MXPCZHSTOIKVST-UHFFFAOYSA-N
DMJICNL	IU	1-[3-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(2-hydroxyethoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride
DMJICNL	DE	Discovery agent

DMD0Q7K	ID	DMD0Q7K
DMD0Q7K	DN	PMID16242323C26a
DMD0Q7K	HS	Investigative
DMD0Q7K	SN	GTPL6732
DMD0Q7K	DT	Small molecular drug
DMD0Q7K	PC	73755242
DMD0Q7K	MW	611.8
DMD0Q7K	FM	C37H49N5O3
DMD0Q7K	IC	InChI=1S/C37H49N5O3/c1-8-9-18-42-35-29(16-11-17-39-35)32(26-14-10-15-28(20-26)45-19-12-13-23(2)3)34(36(42)43)41-37(44)40-33-30(24(4)5)21-27(38)22-31(33)25(6)7/h10-11,14-17,20-25H,8-9,12-13,18-19,38H2,1-7H3,(H2,40,41,44)
DMD0Q7K	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=C(C=C3C(C)C)N)C(C)C)C4=CC(=CC=C4)OCCCC(C)C
DMD0Q7K	IK	PRCCYAKPEIWHCQ-UHFFFAOYSA-N
DMD0Q7K	IU	1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(4-methylpentoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea
DMD0Q7K	DE	Discovery agent

DMF0VLX	ID	DMF0VLX
DMF0VLX	DN	PMID16242323C26b
DMF0VLX	HS	Investigative
DMF0VLX	SN	GTPL6733
DMF0VLX	DT	Small molecular drug
DMF0VLX	PC	45263310
DMF0VLX	MW	711.8
DMF0VLX	FM	C38H52Cl2N6O3
DMF0VLX	IC	InChI=1S/C38H50N6O3.2ClH/c1-6-7-20-44-36-30(15-11-16-40-36)33(27-13-10-14-29(22-27)47-21-12-19-43-17-8-9-18-43)35(37(44)45)42-38(46)41-34-31(25(2)3)23-28(39)24-32(34)26(4)5;;/h10-11,13-16,22-26H,6-9,12,17-21,39H2,1-5H3,(H2,41,42,46);2*1H
DMF0VLX	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=C(C=C3C(C)C)N)C(C)C)C4=CC(=CC=C4)OCCCN5CCCC5.Cl.Cl
DMF0VLX	IK	YRTFLDFDKPFNCJ-UHFFFAOYSA-N
DMF0VLX	IU	1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,8-naphthyridin-3-yl]urea;dihydrochloride
DMF0VLX	DE	Discovery agent

DMT3EU2	ID	DMT3EU2
DMT3EU2	DN	PMID16242323C26c
DMT3EU2	HS	Investigative
DMT3EU2	SN	GTPL6734
DMT3EU2	DT	Small molecular drug
DMT3EU2	PC	73755243
DMT3EU2	MW	724.8
DMT3EU2	FM	C40H55Cl2N5O3
DMT3EU2	IC	InChI=1S/C40H53N5O3.2ClH/c1-6-7-21-45-38-32(19-12-20-42-38)35(29-17-11-18-31(23-29)48-22-13-16-28-14-9-8-10-15-28)37(39(45)46)44-40(47)43-36-33(26(2)3)24-30(41)25-34(36)27(4)5;;/h11-12,17-20,23-28H,6-10,13-16,21-22,41H2,1-5H3,(H2,43,44,47);2*1H
DMT3EU2	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=C(C=C3C(C)C)N)C(C)C)C4=CC(=CC=C4)OCCCC5CCCCC5.Cl.Cl
DMT3EU2	IK	ZFNNBIMQDHBELV-UHFFFAOYSA-N
DMT3EU2	IU	1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-cyclohexylpropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;dihydrochloride
DMT3EU2	DE	Discovery agent

DMIT4UN	ID	DMIT4UN
DMIT4UN	DN	PMID16250654C37
DMIT4UN	HS	Investigative
DMIT4UN	SN	AC1OCFYZ; GTPL2239; BDBM50372611
DMIT4UN	DT	Small molecular drug
DMIT4UN	PC	6918854
DMIT4UN	MW	497.6
DMIT4UN	FM	C28H33F2N3O3
DMIT4UN	IC	InChI=1S/C28H33F2N3O3/c1-15(2)11-23-26(34)32-24(19-12-17-7-5-6-8-18(17)13-19)28(36)33(23)25(27(35)31-16(3)4)21-10-9-20(29)14-22(21)30/h5-10,14-16,19,23-25H,11-13H2,1-4H3,(H,31,35)(H,32,34)/t23-,24-,25-/m1/s1
DMIT4UN	CS	CC(C)C[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(C=C(C=C2)F)F)C(=O)NC(C)C)C3CC4=CC=CC=C4C3
DMIT4UN	IK	QGSYCKKZFPLTMQ-UBFVSLLYSA-N
DMIT4UN	IU	(2R)-2-(2,4-difluorophenyl)-2-[(2R,5R)-5-(2,3-dihydro-1H-inden-2-yl)-2-(2-methylpropyl)-3,6-dioxopiperazin-1-yl]-N-propan-2-ylacetamide
DMIT4UN	DE	Discovery agent

DMOP8YM	ID	DMOP8YM
DMOP8YM	DN	PMID16290936C1b
DMOP8YM	HS	Investigative
DMOP8YM	SN	736144-17-5; GTPL8613; CTK2H1087; DTXSID70658350; BDBM50148296
DMOP8YM	DT	Small molecular drug
DMOP8YM	PC	44343301
DMOP8YM	MW	277.36
DMOP8YM	FM	C16H23NO3
DMOP8YM	IC	InChI=1S/C16H23NO3/c1-3-4-10-15(12-18)17-16(19)20-13(2)11-14-8-6-5-7-9-14/h5-9,12-13,15H,3-4,10-11H2,1-2H3,(H,17,19)/t13-,15-/m0/s1
DMOP8YM	CS	CCCC[C@@H](C=O)NC(=O)O[C@@H](C)CC1=CC=CC=C1
DMOP8YM	IK	WNKGMQLRHKONID-ZFWWWQNUSA-N
DMOP8YM	IU	[(2S)-1-phenylpropan-2-yl] N-[(2S)-1-oxohexan-2-yl]carbamate
DMOP8YM	CA	CAS 736144-17-5
DMOP8YM	DE	Discovery agent

DMI8HAV	ID	DMI8HAV
DMI8HAV	DN	PMID16439120C20
DMI8HAV	HS	Investigative
DMI8HAV	SN	GTPL6371
DMI8HAV	DT	Small molecular drug
DMI8HAV	PC	73755216
DMI8HAV	MW	258.7
DMI8HAV	FM	C14H11ClN2O
DMI8HAV	IC	InChI=1S/C14H11ClN2O/c1-10-5-13(8-16)17-14(6-10)18-9-11-3-2-4-12(15)7-11/h2-7H,9H2,1H3
DMI8HAV	CS	CC1=CC(=NC(=C1)OCC2=CC(=CC=C2)Cl)C#N
DMI8HAV	IK	IUJVMCIYVKHYBF-UHFFFAOYSA-N
DMI8HAV	IU	6-[(3-chlorophenyl)methoxy]-4-methylpyridine-2-carbonitrile
DMI8HAV	DE	Discovery agent

DMVM2XD	ID	DMVM2XD
DMVM2XD	DN	PMID16439120C26
DMVM2XD	HS	Investigative
DMVM2XD	SN	GTPL6372; BDBM50181067
DMVM2XD	DT	Small molecular drug
DMVM2XD	PC	44410045
DMVM2XD	MW	259.69
DMVM2XD	FM	C13H10ClN3O
DMVM2XD	IC	InChI=1S/C13H10ClN3O/c1-9-4-10(2-3-16-9)8-18-13-6-11(7-15)5-12(14)17-13/h2-6H,8H2,1H3
DMVM2XD	CS	CC1=NC=CC(=C1)COC2=NC(=CC(=C2)C#N)Cl
DMVM2XD	IK	MWMMUKIHNXXNGW-UHFFFAOYSA-N
DMVM2XD	IU	2-chloro-6-[(2-methylpyridin-4-yl)methoxy]pyridine-4-carbonitrile
DMVM2XD	DE	Discovery agent

DMT3RUE	ID	DMT3RUE
DMT3RUE	DN	PMID16451062C46
DMT3RUE	HS	Investigative
DMT3RUE	SN	GTPL8355; GSK-623906A; BDBM50181532
DMT3RUE	DT	Small molecular drug
DMT3RUE	PC	9916282
DMT3RUE	MW	580.7
DMT3RUE	FM	C29H33FN6O4S
DMT3RUE	IC	InChI=1S/C29H33FN6O4S/c1-39-25-14-23-24(15-26(25)40-11-3-8-36-9-6-19(17-37)7-10-36)32-18-33-28(23)35-29-31-16-22(41-29)13-27(38)34-21-5-2-4-20(30)12-21/h2,4-5,12,14-16,18-19,37H,3,6-11,13,17H2,1H3,(H,34,38)(H,31,32,33,35)
DMT3RUE	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=NC=C(S3)CC(=O)NC4=CC(=CC=C4)F)OCCCN5CCC(CC5)CO
DMT3RUE	IK	QNJAKUMXJFWQOG-UHFFFAOYSA-N
DMT3RUE	IU	N-(3-fluorophenyl)-2-[2-[[7-[3-[4-(hydroxymethyl)piperidin-1-yl]propoxy]-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]acetamide
DMT3RUE	DE	Discovery agent

DM8BKI4	ID	DM8BKI4
DM8BKI4	DN	PMID16460935C28
DM8BKI4	HS	Investigative
DM8BKI4	SN	GTPL8619; BDBM50182163
DM8BKI4	DT	Small molecular drug
DM8BKI4	PC	11948634
DM8BKI4	MW	557.5
DM8BKI4	FM	C20H15BrF2N4O2S3
DM8BKI4	IC	InChI=1S/C20H15BrF2N4O2S3/c1-30-20-17(7-16(31-20)19(24)25)32(28,29)12-5-13(21)18-15(6-12)26-9-27(18)8-10-4-11(22)2-3-14(10)23/h2-7,9H,8H2,1H3,(H3,24,25)
DM8BKI4	CS	CSC1=C(C=C(S1)C(=N)N)S(=O)(=O)C2=CC3=C(C(=C2)Br)N(C=N3)CC4=C(C=CC(=C4)F)F
DM8BKI4	IK	HEZXZGJJNMPIJM-UHFFFAOYSA-N
DM8BKI4	IU	4-[7-bromo-1-[(2,5-difluorophenyl)methyl]benzimidazol-5-yl]sulfonyl-5-methylsulfanylthiophene-2-carboximidamide
DM8BKI4	DE	Discovery agent

DM2ZYR8	ID	DM2ZYR8
DM2ZYR8	DN	PMID16516466C12c
DM2ZYR8	HS	Investigative
DM2ZYR8	SN	GTPL8663; BDBM50183711
DM2ZYR8	DT	Small molecular drug
DM2ZYR8	PC	10160968
DM2ZYR8	MW	448.5
DM2ZYR8	FM	C25H28N4O4
DM2ZYR8	IC	InChI=1S/C25H28N4O4/c1-17-14-19(21-4-2-3-5-22(21)27-17)16-33-20-8-6-18(7-9-20)24(31)28-25(15-23(30)29-32)10-12-26-13-11-25/h2-9,14,26,32H,10-13,15-16H2,1H3,(H,28,31)(H,29,30)
DM2ZYR8	CS	CC1=NC2=CC=CC=C2C(=C1)COC3=CC=C(C=C3)C(=O)NC4(CCNCC4)CC(=O)NO
DM2ZYR8	IK	BODLESUVCQEUII-UHFFFAOYSA-N
DM2ZYR8	IU	N-[4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
DM2ZYR8	DE	Discovery agent

DMU2X59	ID	DMU2X59
DMU2X59	DN	PMID16539403C15b
DMU2X59	HS	Investigative
DMU2X59	SN	GTPL8194; BDBM50184490
DMU2X59	DT	Small molecular drug
DMU2X59	PC	10361101
DMU2X59	MW	359.4
DMU2X59	FM	C21H21N5O
DMU2X59	IC	InChI=1S/C21H21N5O/c27-12-4-10-25-14-23-16-8-7-15(13-19(16)25)20-18-6-3-11-26(18)24-21(20)17-5-1-2-9-22-17/h1-2,5,7-9,13-14,27H,3-4,6,10-12H2
DMU2X59	CS	C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=CC5=C(C=C4)N=CN5CCCO
DMU2X59	IK	SYCWRTUPLPDKDX-UHFFFAOYSA-N
DMU2X59	IU	3-[6-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)benzimidazol-1-yl]propan-1-ol
DMU2X59	DE	Discovery agent

DMJ8A4I	ID	DMJ8A4I
DMJ8A4I	DN	PMID1656041C11dd
DMJ8A4I	HS	Investigative
DMJ8A4I	SN	GTPL3017; BDBM50007285
DMJ8A4I	DT	Small molecular drug
DMJ8A4I	PC	56947041
DMJ8A4I	MW	533.6
DMJ8A4I	FM	C32H31F2O5-
DMJ8A4I	IC	InChI=1S/C32H32F2O5/c1-19(2)30-27-6-4-3-5-22(27)15-28(32(30)39-18-26(36)16-25(35)17-29(37)38)31(20-7-11-23(33)12-8-20)21-9-13-24(34)14-10-21/h3-15,19,25-26,31,35-36H,16-18H2,1-2H3,(H,37,38)/p-1/t25-,26?/m1/s1
DMJ8A4I	CS	CC(C)C1=C(C(=CC2=CC=CC=C21)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OCC(C[C@H](CC(=O)[O-])O)O
DMJ8A4I	IK	KMUHRPGZKRKKCZ-DCWQJPKNSA-M
DMJ8A4I	IU	(3R)-6-[3-[bis(4-fluorophenyl)methyl]-1-propan-2-ylnaphthalen-2-yl]oxy-3,5-dihydroxyhexanoate
DMJ8A4I	DE	Discovery agent

DM20TFH	ID	DM20TFH
DM20TFH	DN	PMID1656041C11ff
DM20TFH	HS	Investigative
DM20TFH	SN	GTPL3016; BDBM50007255
DM20TFH	DT	Small molecular drug
DM20TFH	PC	56947039
DM20TFH	MW	417.5
DM20TFH	FM	C24H30FO5-
DM20TFH	IC	InChI=1S/C24H31FO5/c1-14(2)17-9-21(15(3)4)24(22(10-17)16-5-7-18(25)8-6-16)30-13-20(27)11-19(26)12-23(28)29/h5-10,14-15,19-20,26-27H,11-13H2,1-4H3,(H,28,29)/p-1/t19-,20?/m1/s1
DM20TFH	CS	CC(C)C1=CC(=C(C(=C1)C(C)C)OCC(C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F
DM20TFH	IK	GWJDCGLHTDEKGT-FIWHBWSRSA-M
DM20TFH	IU	(3R)-6-[2-(4-fluorophenyl)-4,6-di(propan-2-yl)phenoxy]-3,5-dihydroxyhexanoate
DM20TFH	DE	Discovery agent

DMLIXJW	ID	DMLIXJW
DMLIXJW	DN	PMID1656041C11jj
DMLIXJW	HS	Investigative
DMLIXJW	SN	compound 10jj [PMID: 1656041]; compound 4jj [PMID: 1656041]; GTPL3015; BDBM50007272
DMLIXJW	DT	Small molecular drug
DMLIXJW	PC	56947038
DMLIXJW	MW	501.6
DMLIXJW	FM	C27H27F2O5S-
DMLIXJW	IC	InChI=1S/C27H28F2O5S/c1-16(2)24-13-23(35-22-9-7-19(29)8-10-22)14-25(17-3-5-18(28)6-4-17)27(24)34-15-21(31)11-20(30)12-26(32)33/h3-10,13-14,16,20-21,30-31H,11-12,15H2,1-2H3,(H,32,33)/p-1/t20-,21?/m1/s1
DMLIXJW	CS	CC(C)C1=CC(=CC(=C1OCC(C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)SC3=CC=C(C=C3)F
DMLIXJW	IK	UFSXOKMGOHBXIH-VQCQRNETSA-M
DMLIXJW	IU	(3R)-6-[2-(4-fluorophenyl)-4-(4-fluorophenyl)sulfanyl-6-propan-2-ylphenoxy]-3,5-dihydroxyhexanoate
DMLIXJW	DE	Discovery agent

DMNOMCT	ID	DMNOMCT
DMNOMCT	DN	PMID1656041C11nn
DMNOMCT	HS	Investigative
DMNOMCT	SN	GTPL3014; BDBM50007271
DMNOMCT	DT	Small molecular drug
DMNOMCT	PC	56947040
DMNOMCT	MW	426.5
DMNOMCT	FM	C24H25FNO5-
DMNOMCT	IC	InChI=1S/C24H26FNO5/c1-14(2)22-19-5-3-4-6-20(19)26-23(15-7-9-16(25)10-8-15)24(22)31-13-18(28)11-17(27)12-21(29)30/h3-10,14,17-18,27-28H,11-13H2,1-2H3,(H,29,30)/p-1/t17-,18?/m1/s1
DMNOMCT	CS	CC(C)C1=C(C(=NC2=CC=CC=C21)C3=CC=C(C=C3)F)OCC(C[C@H](CC(=O)[O-])O)O
DMNOMCT	IK	WFJBUGLKYOMEIA-QNSVNVJESA-M
DMNOMCT	IU	(3R)-6-[2-(4-fluorophenyl)-4-propan-2-ylquinolin-3-yl]oxy-3,5-dihydroxyhexanoate
DMNOMCT	DE	Discovery agent

DMW90GD	ID	DMW90GD
DMW90GD	DN	PMID1656041C4ff
DMW90GD	HS	Investigative
DMW90GD	SN	GTPL2970; BDBM50007303
DMW90GD	DT	Small molecular drug
DMW90GD	PC	44331923
DMW90GD	MW	400.5
DMW90GD	FM	C24H29FO4
DMW90GD	IC	InChI=1S/C24H29FO4/c1-14(2)17-9-21(15(3)4)24(22(10-17)16-5-7-18(25)8-6-16)28-13-20-11-19(26)12-23(27)29-20/h5-10,14-15,19-20,26H,11-13H2,1-4H3/t19-,20?/m1/s1
DMW90GD	CS	CC(C)C1=CC(=C(C(=C1)C(C)C)OCC2C[C@H](CC(=O)O2)O)C3=CC=C(C=C3)F
DMW90GD	IK	JMEOINPEUMGNEF-FIWHBWSRSA-N
DMW90GD	IU	(4R)-6-[[2-(4-fluorophenyl)-4,6-di(propan-2-yl)phenoxy]methyl]-4-hydroxyoxan-2-one
DMW90GD	DE	Discovery agent

DMQGPJE	ID	DMQGPJE
DMQGPJE	DN	PMID1656041C4rr
DMQGPJE	HS	Investigative
DMQGPJE	SN	GTPL2967
DMQGPJE	DT	Small molecular drug
DMQGPJE	PC	91623350
DMQGPJE	MW	380.9
DMQGPJE	FM	C21H29ClO4
DMQGPJE	IC	InChI=1S/C21H29ClO4/c1-13-8-14(2)21(25-12-17-10-16(23)11-19(24)26-17)18(9-13)20(22)15-6-4-3-5-7-15/h8-9,15-17,20,23H,3-7,10-12H2,1-2H3/t16-,17+,20?/m1/s1
DMQGPJE	CS	CC1=CC(=C(C(=C1)C(C2CCCCC2)Cl)OC[C@@H]3C[C@H](CC(=O)O3)O)C
DMQGPJE	IK	JEIUHLQCZMJKSE-LIHHCBPRSA-N
DMQGPJE	IU	(4R,6S)-6-[[2-[chloro(cyclohexyl)methyl]-4,6-dimethylphenoxy]methyl]-4-hydroxyoxan-2-one
DMQGPJE	DE	Discovery agent

DMZVK16	ID	DMZVK16
DMZVK16	DN	PMID1656041C74
DMZVK16	HS	Investigative
DMZVK16	SN	GTPL2982
DMZVK16	DT	Small molecular drug
DMZVK16	PC	56947044
DMZVK16	MW	428.5
DMZVK16	FM	C25H31FNO4-
DMZVK16	IC	InChI=1S/C25H32FNO4/c1-15(2)24-20(11-10-18(28)12-19(29)13-23(30)31)21(14-22(27-24)25(3,4)5)16-6-8-17(26)9-7-16/h6-11,14-15,18-19,28-29H,12-13H2,1-5H3,(H,30,31)/p-1/b11-10+/t18?,19-/m1/s1
DMZVK16	CS	CC(C)C1=C(C(=CC(=N1)C(C)(C)C)C2=CC=C(C=C2)F)/C=C/C(C[C@H](CC(=O)[O-])O)O
DMZVK16	IK	SRKGZXIJDGWVAI-GVAVTCRGSA-M
DMZVK16	IU	(E,3R)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate
DMZVK16	DE	Discovery agent

DMITDEB	ID	DMITDEB
DMITDEB	DN	PMID17064898C29
DMITDEB	HS	Investigative
DMITDEB	SN	GTPL6208
DMITDEB	DT	Small molecular drug
DMITDEB	PC	73755189
DMITDEB	MW	318.4
DMITDEB	FM	C17H26N4O2
DMITDEB	IC	InChI=1S/C17H26N4O2/c22-12-13-6-8-21(9-7-13)16-11-18-15(10-19-16)17(23)20-14-4-2-1-3-5-14/h10-11,13-14,22H,1-9,12H2,(H,20,23)
DMITDEB	CS	C1CCC(CC1)NC(=O)C2=CN=C(C=N2)N3CCC(CC3)CO
DMITDEB	IK	JKQOZEOZKKMWQL-UHFFFAOYSA-N
DMITDEB	IU	N-cyclohexyl-5-[4-(hydroxymethyl)piperidin-1-yl]pyrazine-2-carboxamide
DMITDEB	DE	Discovery agent

DMLTXHJ	ID	DMLTXHJ
DMLTXHJ	DN	PMID17125263C17
DMLTXHJ	HS	Investigative
DMLTXHJ	SN	GTPL1306; BDBM50199266
DMLTXHJ	DT	Small molecular drug
DMLTXHJ	PC	11994411
DMLTXHJ	MW	486
DMLTXHJ	FM	C28H24ClN3OS
DMLTXHJ	IC	InChI=1S/C28H24ClN3OS/c29-23-9-6-20(7-10-23)26-16-25-27(34-26)28(33)32(18-30-25)24-11-8-21-14-19(4-5-22(21)15-24)17-31-12-2-1-3-13-31/h4-11,14-16,18H,1-3,12-13,17H2
DMLTXHJ	CS	C1CCN(CC1)CC2=CC3=C(C=C2)C=C(C=C3)N4C=NC5=C(C4=O)SC(=C5)C6=CC=C(C=C6)Cl
DMLTXHJ	IK	FJPBPFUKHDZYIJ-UHFFFAOYSA-N
DMLTXHJ	IU	6-(4-chlorophenyl)-3-[6-(piperidin-1-ylmethyl)naphthalen-2-yl]thieno[3,2-d]pyrimidin-4-one
DMLTXHJ	DE	Discovery agent

DMG9ZYP	ID	DMG9ZYP
DMG9ZYP	DN	PMID17189691C42
DMG9ZYP	HS	Investigative
DMG9ZYP	SN	GTPL6446
DMG9ZYP	DT	Small molecular drug
DMG9ZYP	PC	73755223
DMG9ZYP	MW	271.27
DMG9ZYP	FM	C14H13N3O3
DMG9ZYP	IC	InChI=1S/C14H13N3O3/c1-8-4-2-7-11(15-8)16-13(18)9-5-3-6-10-12(9)17-14(19)20-10/h2-4,6-7,9H,5H2,1H3,(H,17,19)(H,15,16,18)
DMG9ZYP	CS	CC1=NC(=CC=C1)NC(=O)C2CC=CC3=C2NC(=O)O3
DMG9ZYP	IK	ILTICRNSZLAODU-UHFFFAOYSA-N
DMG9ZYP	IU	N-(6-methylpyridin-2-yl)-2-oxo-4,5-dihydro-3H-1,3-benzoxazole-4-carboxamide
DMG9ZYP	DE	Discovery agent

DMWNYBV	ID	DMWNYBV
DMWNYBV	DN	PMID17276684C22
DMWNYBV	HS	Investigative
DMWNYBV	SN	GTPL6358; BDBM50204433
DMWNYBV	DT	Small molecular drug
DMWNYBV	PC	16739288
DMWNYBV	MW	306.4
DMWNYBV	FM	C19H18N2O2
DMWNYBV	IC	InChI=1S/C19H18N2O2/c1-12-9-16-15(14-7-8-20-19(22)18(14)21-16)10-17(12)23-11-13-5-3-2-4-6-13/h2-6,9-10,21H,7-8,11H2,1H3,(H,20,22)
DMWNYBV	CS	CC1=CC2=C(C=C1OCC3=CC=CC=C3)C4=C(N2)C(=O)NCC4
DMWNYBV	IK	DYTMNPUOZGPWQA-UHFFFAOYSA-N
DMWNYBV	IU	7-methyl-6-phenylmethoxy-2,3,4,9-tetrahydropyrido[3,4-b]indol-1-one
DMWNYBV	DE	Discovery agent

DMXHS4L	ID	DMXHS4L
DMXHS4L	DN	PMID17280833C30
DMXHS4L	HS	Investigative
DMXHS4L	SN	GTPL8193; BDBM50204580
DMXHS4L	DT	Small molecular drug
DMXHS4L	PC	11540659
DMXHS4L	MW	504.6
DMXHS4L	FM	C32H32N4O2
DMXHS4L	IC	InChI=1S/C32H32N4O2/c1-3-9-24(10-4-1)17-18-33-31-29-28(25-11-5-2-6-12-25)30(38-32(29)35-23-34-31)26-13-15-27(16-14-26)37-22-21-36-19-7-8-20-36/h1-6,9-16,23H,7-8,17-22H2,(H,33,34,35)
DMXHS4L	CS	C1CCN(C1)CCOC2=CC=C(C=C2)C3=C(C4=C(N=CN=C4O3)NCCC5=CC=CC=C5)C6=CC=CC=C6
DMXHS4L	IK	CYXPHNZJEDAZDD-UHFFFAOYSA-N
DMXHS4L	IU	5-phenyl-N-(2-phenylethyl)-6-[4-(2-pyrrolidin-1-ylethoxy)phenyl]furo[2,3-d]pyrimidin-4-amine
DMXHS4L	DE	Discovery agent

DMR9TYV	ID	DMR9TYV
DMR9TYV	DN	PMID17358052C5b
DMR9TYV	HS	Investigative
DMR9TYV	SN	ethyl analogue of acifran; 853260-98-7; GTPL1598; CTK3C8946; DTXSID90456956; BDBM50208125
DMR9TYV	DT	Small molecular drug
DMR9TYV	PC	11148966
DMR9TYV	MW	232.23
DMR9TYV	FM	C13H12O4
DMR9TYV	IC	InChI=1S/C13H12O4/c1-2-13(9-6-4-3-5-7-9)11(14)8-10(17-13)12(15)16/h3-8H,2H2,1H3,(H,15,16)
DMR9TYV	CS	CCC1(C(=O)C=C(O1)C(=O)O)C2=CC=CC=C2
DMR9TYV	IK	SUHZZFNDVLWPTL-UHFFFAOYSA-N
DMR9TYV	IU	5-ethyl-4-oxo-5-phenylfuran-2-carboxylic acid
DMR9TYV	CA	CAS 853260-98-7
DMR9TYV	DE	Discovery agent

DM4BZ2L	ID	DM4BZ2L
DM4BZ2L	DN	PMID1738140C9
DM4BZ2L	HS	Investigative
DM4BZ2L	SN	GTPL8677; BDBM50008431; ZINC13448941
DM4BZ2L	DT	Small molecular drug
DM4BZ2L	PC	44309732
DM4BZ2L	MW	264.36
DM4BZ2L	FM	C15H24N2O2
DM4BZ2L	IC	InChI=1S/C15H24N2O2/c1-11(2)8-9-17-15(19)14(18)13(16)10-12-6-4-3-5-7-12/h3-7,11,13-14,18H,8-10,16H2,1-2H3,(H,17,19)/t13-,14+/m1/s1
DM4BZ2L	CS	CC(C)CCNC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O
DM4BZ2L	IK	WABAJXKDQWZIOJ-KGLIPLIRSA-N
DM4BZ2L	IU	(2S,3R)-3-amino-2-hydroxy-N-(3-methylbutyl)-4-phenylbutanamide
DM4BZ2L	DE	Discovery agent

DM4IABG	ID	DM4IABG
DM4IABG	DN	PMID17480064C16
DM4IABG	HS	Investigative
DM4IABG	SN	724711-21-1; 3fhr; 2jbp; 2jbo; P4O; Pyrrolopyridine, 16; Kinome_3179; 3r2y; GTPL8177; BDBM30185; ZINC16052855; AKOS027322581; DB08358; KB-19275; DB-013997; FT-0745988
DM4IABG	DT	Small molecular drug
DM4IABG	PC	10389239
DM4IABG	MW	340.4
DM4IABG	FM	C21H16N4O
DM4IABG	IC	InChI=1S/C21H16N4O/c26-21-16-11-20(25-18(16)6-8-23-21)14-5-7-22-19(10-14)15-9-13-3-1-2-4-17(13)24-12-15/h1-5,7,9-12,25H,6,8H2,(H,23,26)
DM4IABG	CS	C1CNC(=O)C2=C1NC(=C2)C3=CC(=NC=C3)C4=CC5=CC=CC=C5N=C4
DM4IABG	IK	OWFLADWRSCINST-UHFFFAOYSA-N
DM4IABG	IU	2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one
DM4IABG	DE	Discovery agent

DMX3CYG	ID	DMX3CYG
DMX3CYG	DN	PMID17532216C2f
DMX3CYG	HS	Investigative
DMX3CYG	SN	GTPL6342; BDBM50214087
DMX3CYG	DT	Small molecular drug
DMX3CYG	PC	44442431
DMX3CYG	MW	415.9
DMX3CYG	FM	C18H14ClN5O3S
DMX3CYG	IC	InChI=1S/C18H14ClN5O3S/c1-11-22-17-16(18(25)23(11)13-4-2-12(19)3-5-13)10-21-24(17)14-6-8-15(9-7-14)28(20,26)27/h2-10H,1H3,(H2,20,26,27)
DMX3CYG	CS	CC1=NC2=C(C=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(=O)N1C4=CC=C(C=C4)Cl
DMX3CYG	IK	VRNFEVMRDQNBHD-UHFFFAOYSA-N
DMX3CYG	IU	4-[5-(4-chlorophenyl)-6-methyl-4-oxopyrazolo[3,4-d]pyrimidin-1-yl]benzenesulfonamide
DMX3CYG	DE	Discovery agent

DM7Z2WV	ID	DM7Z2WV
DM7Z2WV	DN	PMID17556356C1a
DM7Z2WV	HS	Investigative
DM7Z2WV	SN	Inverse agonist; Indole compound 1a; GTPL2833; BDBM22420; DB06833
DM7Z2WV	DT	Small molecular drug
DM7Z2WV	PC	16122612
DM7Z2WV	MW	332.5
DM7Z2WV	FM	C23H28N2
DM7Z2WV	IC	InChI=1S/C23H28N2/c1-18-11-13-21(14-12-18)25-17-20(22-9-5-6-10-23(22)25)16-24-15-19-7-3-2-4-8-19/h5-6,9-14,17,19,24H,2-4,7-8,15-16H2,1H3
DM7Z2WV	CS	CC1=CC=C(C=C1)N2C=C(C3=CC=CC=C32)CNCC4CCCCC4
DM7Z2WV	IK	MMIJMYOYKAKQPN-UHFFFAOYSA-N
DM7Z2WV	IU	1-cyclohexyl-N-[[1-(4-methylphenyl)indol-3-yl]methyl]methanamine
DM7Z2WV	DE	Discovery agent

DMLX87P	ID	DMLX87P
DMLX87P	DN	PMID17560788C29f
DMLX87P	HS	Investigative
DMLX87P	SN	GTPL2959; BDBM18382
DMLX87P	DT	Small molecular drug
DMLX87P	PC	56947057
DMLX87P	MW	538.6
DMLX87P	FM	C29H31FN2O7-2
DMLX87P	IC	InChI=1S/C29H33FN2O7/c1-3-32-24(13-12-22(33)14-23(34)15-25(35)36)26(19-8-10-21(30)11-9-19)17(2)27(32)28(37)31-16-18-4-6-20(7-5-18)29(38)39/h4-11,22-23,33-34H,3,12-16H2,1-2H3,(H,31,37)(H,35,36)(H,38,39)/p-2/t22-,23-/m1/s1
DMLX87P	CS	CCN1C(=C(C(=C1C(=O)NCC2=CC=C(C=C2)C(=O)[O-])C)C3=CC=C(C=C3)F)CC[C@H](C[C@H](CC(=O)[O-])O)O
DMLX87P	IK	MFLMXRSHJVIMRF-DHIUTWEWSA-L
DMLX87P	IU	4-[[[5-[(3R,5R)-6-carboxylato-3,5-dihydroxyhexyl]-1-ethyl-4-(4-fluorophenyl)-3-methylpyrrole-2-carbonyl]amino]methyl]benzoate
DMLX87P	DE	Discovery agent

DM6W73A	ID	DM6W73A
DM6W73A	DN	PMID17574411C41
DM6W73A	HS	Investigative
DM6W73A	SN	2q6b; GTPL3006; BDBM50215676
DM6W73A	DT	Small molecular drug
DM6W73A	PC	24916963
DM6W73A	MW	521.6
DM6W73A	FM	C30H34FN2O5-
DM6W73A	IC	InChI=1S/C30H35FN2O5/c1-19(2)33-26(15-14-23(34)17-24(35)18-27(36)37)28(20-10-12-21(31)13-11-20)25-9-6-16-32(30(38)29(25)33)22-7-4-3-5-8-22/h3-5,7-8,10-13,19,23-24,34-35H,6,9,14-18H2,1-2H3,(H,36,37)/p-1/t23-,24-/m1/s1
DM6W73A	CS	CC(C)N1C(=C(C2=C1C(=O)N(CCC2)C3=CC=CC=C3)C4=CC=C(C=C4)F)CC[C@H](C[C@H](CC(=O)[O-])O)O
DM6W73A	IK	OMBVEVHRIQULKW-DNQXCXABSA-M
DM6W73A	IU	(3R,5R)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4H-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate
DM6W73A	DE	Discovery agent

DM1YLF6	ID	DM1YLF6
DM1YLF6	DN	PMID17574411C42
DM1YLF6	HS	Investigative
DM1YLF6	SN	GTPL3001; BDBM50215672
DM1YLF6	DT	Small molecular drug
DM1YLF6	PC	56947029
DM1YLF6	MW	573.6
DM1YLF6	FM	C33H31F2N2O5-
DM1YLF6	IC	InChI=1S/C33H32F2N2O5/c1-19(2)36-28(15-14-24(38)17-25(39)18-29(40)41)30(20-10-12-21(34)13-11-20)31-26-8-3-4-9-27(26)37(33(42)32(31)36)23-7-5-6-22(35)16-23/h3-13,16,19,24-25,38-39H,14-15,17-18H2,1-2H3,(H,40,41)/p-1/t24-,25-/m1/s1
DM1YLF6	CS	CC(C)N1C(=C(C2=C1C(=O)N(C3=CC=CC=C32)C4=CC(=CC=C4)F)C5=CC=C(C=C5)F)CC[C@H](C[C@H](CC(=O)[O-])O)O
DM1YLF6	IK	BJKPZWFEYXVKOA-JWQCQUIFSA-M
DM1YLF6	IU	(3R,5R)-7-[5-(3-fluorophenyl)-1-(4-fluorophenyl)-4-oxo-3-propan-2-ylpyrrolo[2,3-c]quinolin-2-yl]-3,5-dihydroxyheptanoate
DM1YLF6	DE	Discovery agent

DM7HYPZ	ID	DM7HYPZ
DM7HYPZ	DN	PMID17574412C33
DM7HYPZ	HS	Investigative
DM7HYPZ	SN	GTPL3010; BDBM50215692
DM7HYPZ	DT	Small molecular drug
DM7HYPZ	PC	56947030
DM7HYPZ	MW	596.7
DM7HYPZ	FM	C35H35FN3O5-
DM7HYPZ	IC	InChI=1S/C35H36FN3O5/c1-22(2)39-30(17-16-28(40)18-29(41)19-31(42)43)32(26-12-14-27(36)15-13-26)33(25-6-4-3-5-7-25)34(39)35(44)38-21-24-10-8-23(20-37)9-11-24/h3-15,22,28-29,40-41H,16-19,21H2,1-2H3,(H,38,44)(H,42,43)/p-1/t28-,29-/m1/s1
DM7HYPZ	CS	CC(C)N1C(=C(C(=C1C(=O)NCC2=CC=C(C=C2)C#N)C3=CC=CC=C3)C4=CC=C(C=C4)F)CC[C@H](C[C@H](CC(=O)[O-])O)O
DM7HYPZ	IK	LRCUHVRZXKUPFJ-FQLXRVMXSA-M
DM7HYPZ	IU	(3R,5R)-7-[5-[(4-cyanophenyl)methylcarbamoyl]-3-(4-fluorophenyl)-4-phenyl-1-propan-2-ylpyrrol-2-yl]-3,5-dihydroxyheptanoate
DM7HYPZ	DE	Discovery agent

DMJFOGW	ID	DMJFOGW
DMJFOGW	DN	PMID17600705C23
DMJFOGW	HS	Investigative
DMJFOGW	SN	GTPL8146; BDBM26166
DMJFOGW	DT	Small molecular drug
DMJFOGW	PC	23657507
DMJFOGW	MW	371.4
DMJFOGW	FM	C17H17N5O3S
DMJFOGW	IC	InChI=1S/C17H17N5O3S/c1-11-5-6-13(23)10-15(11)21-16-7-8-19-17(22-16)20-12-3-2-4-14(9-12)26(18,24)25/h2-10,23H,1H3,(H2,18,24,25)(H2,19,20,21,22)
DMJFOGW	CS	CC1=C(C=C(C=C1)O)NC2=NC(=NC=C2)NC3=CC(=CC=C3)S(=O)(=O)N
DMJFOGW	IK	LKLIRPMEYRVLFV-UHFFFAOYSA-N
DMJFOGW	IU	3-[[4-(5-hydroxy-2-methylanilino)pyrimidin-2-yl]amino]benzenesulfonamide
DMJFOGW	DE	Discovery agent

DMMB6NU	ID	DMMB6NU
DMMB6NU	DN	PMID17709461C4g
DMMB6NU	HS	Investigative
DMMB6NU	SN	GTPL3077; BDBM50269921
DMMB6NU	DT	Small molecular drug
DMMB6NU	PC	44584870
DMMB6NU	MW	313.4
DMMB6NU	FM	C19H23NO3
DMMB6NU	IC	InChI=1S/C19H23NO3/c1-2-23-18(21)13-16-5-3-15(4-6-16)7-10-19(22)14-20-11-8-17(19)9-12-20/h3-6,17,22H,2,8-9,11-14H2,1H3
DMMB6NU	CS	CCOC(=O)CC1=CC=C(C=C1)C#CC2(CN3CCC2CC3)O
DMMB6NU	IK	YWKVMGDEOUPQGN-UHFFFAOYSA-N
DMMB6NU	IU	ethyl 2-[4-[2-(3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)ethynyl]phenyl]acetate
DMMB6NU	DE	Discovery agent

DMBP3O7	ID	DMBP3O7
DMBP3O7	DN	PMID17723296C18
DMBP3O7	HS	Investigative
DMBP3O7	SN	GTPL6443; BDBM50220096
DMBP3O7	DT	Small molecular drug
DMBP3O7	PC	24180510
DMBP3O7	MW	276.29
DMBP3O7	FM	C16H12N4O
DMBP3O7	IC	InChI=1S/C16H12N4O/c1-10-3-4-12-9-18-15(20-16(12)19-10)13-5-11(8-17)6-14(7-13)21-2/h3-7,9H,1-2H3
DMBP3O7	CS	CC1=NC2=NC(=NC=C2C=C1)C3=CC(=CC(=C3)C#N)OC
DMBP3O7	IK	NGRPBCOEAPBKCI-UHFFFAOYSA-N
DMBP3O7	IU	3-methoxy-5-(7-methylpyrido[2,3-d]pyrimidin-2-yl)benzonitrile
DMBP3O7	DE	Discovery agent

DMLPC17	ID	DMLPC17
DMLPC17	DN	PMID17888661C18
DMLPC17	HS	Investigative
DMLPC17	SN	GTPL3212
DMLPC17	DT	Small molecular drug
DMLPC17	PC	56947006
DMLPC17	MW	180.12
DMLPC17	FM	C6H14O2P2
DMLPC17	IC	InChI=1S/C6H14O2P2/c1-3-6(2,7)4-5-8-10-9/h7,9H,3-5H2,1-2H3
DMLPC17	CS	CCC(C)(CCOP=P)O
DMLPC17	IK	QGZAHEYJZLWZDX-UHFFFAOYSA-N
DMLPC17	IU	3-methyl-1-phosphanylidenephosphanyloxypentan-3-ol
DMLPC17	DE	Discovery agent

DMRWTHA	ID	DMRWTHA
DMRWTHA	DN	PMID17888661C19
DMRWTHA	HS	Investigative
DMRWTHA	SN	GTPL3211
DMRWTHA	DT	Small molecular drug
DMRWTHA	PC	56947005
DMRWTHA	MW	194.15
DMRWTHA	FM	C7H16O2P2
DMRWTHA	IC	InChI=1S/C7H16O2P2/c1-6(2)7(3,8)4-5-9-11-10/h6,8,10H,4-5H2,1-3H3
DMRWTHA	CS	CC(C)C(C)(CCOP=P)O
DMRWTHA	IK	VODAHBTZSLKFBN-UHFFFAOYSA-N
DMRWTHA	IU	3,4-dimethyl-1-phosphanylidenephosphanyloxypentan-3-ol
DMRWTHA	DE	Discovery agent

DMDVW4K	ID	DMDVW4K
DMDVW4K	DN	PMID17929793C11c
DMDVW4K	HS	Investigative
DMDVW4K	SN	GTPL6343
DMDVW4K	DT	Small molecular drug
DMDVW4K	PC	73755209
DMDVW4K	MW	352.4
DMDVW4K	FM	C18H16N4O2S
DMDVW4K	IC	InChI=1S/C18H16N4O2S/c1-24-12-4-2-11(3-5-12)22-9-21-15-13-14-10(6-7-19-14)8-20-17(13)25-16(15)18(22)23/h2-5,8-9,15-16,19H,6-7H2,1H3
DMDVW4K	CS	COC1=CC=C(C=C1)N2C=NC3C(C2=O)SC4=NC=C5CCNC5=C34
DMDVW4K	IK	SIUQQICXQVLRLA-UHFFFAOYSA-N
DMDVW4K	IU	13-(4-methoxyphenyl)-10-thia-3,8,13,15-tetrazatetracyclo[7.7.0.02,6.011,16]hexadeca-1,6,8,14-tetraen-12-one
DMDVW4K	DE	Discovery agent

DMIG308	ID	DMIG308
DMIG308	DN	PMID17929793C23c
DMIG308	HS	Investigative
DMIG308	SN	GTPL6345; BDBM50224405
DMIG308	DT	Small molecular drug
DMIG308	PC	16659967
DMIG308	MW	366.4
DMIG308	FM	C18H14N4O3S
DMIG308	IC	InChI=1S/C18H14N4O3S/c1-24-11-4-2-10(3-5-11)22-9-21-15-13-14-12(25-7-6-19-14)8-20-17(13)26-16(15)18(22)23/h2-5,8-9,19H,6-7H2,1H3
DMIG308	CS	COC1=CC=C(C=C1)N2C=NC3=C(C2=O)SC4=NC=C5C(=C34)NCCO5
DMIG308	IK	KUCDOJMOTMEEOF-UHFFFAOYSA-N
DMIG308	IU	14-(4-methoxyphenyl)-6-oxa-11-thia-3,9,14,16-tetrazatetracyclo[8.7.0.02,7.012,17]heptadeca-1,7,9,12(17),15-pentaen-13-one
DMIG308	DE	Discovery agent

DMOB07W	ID	DMOB07W
DMOB07W	DN	PMID17929793C23e
DMOB07W	HS	Investigative
DMOB07W	SN	GTPL6346; BDBM50224391
DMOB07W	DT	Small molecular drug
DMOB07W	PC	16659801
DMOB07W	MW	370.8
DMOB07W	FM	C17H11ClN4O2S
DMOB07W	IC	InChI=1S/C17H11ClN4O2S/c18-9-1-3-10(4-2-9)22-8-21-14-12-13-11(24-6-5-19-13)7-20-16(12)25-15(14)17(22)23/h1-4,7-8,19H,5-6H2
DMOB07W	CS	C1COC2=CN=C3C(=C2N1)C4=C(S3)C(=O)N(C=N4)C5=CC=C(C=C5)Cl
DMOB07W	IK	FODONWGPMXPGNC-UHFFFAOYSA-N
DMOB07W	IU	14-(4-chlorophenyl)-6-oxa-11-thia-3,9,14,16-tetrazatetracyclo[8.7.0.02,7.012,17]heptadeca-1,7,9,12(17),15-pentaen-13-one
DMOB07W	DE	Discovery agent

DM83Z6M	ID	DM83Z6M
DM83Z6M	DN	PMID17929793C23h
DM83Z6M	HS	Investigative
DM83Z6M	SN	GTPL6338; BDBM50224396
DM83Z6M	DT	Small molecular drug
DM83Z6M	PC	16659803
DM83Z6M	MW	384.8
DM83Z6M	FM	C18H13ClN4O2S
DM83Z6M	IC	InChI=1S/C18H13ClN4O2S/c1-9-6-20-14-12(25-9)7-21-17-13(14)15-16(26-17)18(24)23(8-22-15)11-4-2-10(19)3-5-11/h2-5,7-9,20H,6H2,1H3/t9-/m0/s1
DM83Z6M	CS	C[C@H]1CNC2=C3C4=C(C(=O)N(C=N4)C5=CC=C(C=C5)Cl)SC3=NC=C2O1
DM83Z6M	IK	LFUPTQIEOBBAJE-VIFPVBQESA-N
DM83Z6M	IU	(5S)-14-(4-chlorophenyl)-5-methyl-6-oxa-11-thia-3,9,14,16-tetrazatetracyclo[8.7.0.02,7.012,17]heptadeca-1,7,9,12(17),15-pentaen-13-one
DM83Z6M	DE	Discovery agent

DM07TVS	ID	DM07TVS
DM07TVS	DN	PMID17929793C23i
DM07TVS	HS	Investigative
DM07TVS	SN	GTPL6348; BDBM50224406
DM07TVS	DT	Small molecular drug
DM07TVS	PC	16659802
DM07TVS	MW	384.8
DM07TVS	FM	C18H13ClN4O2S
DM07TVS	IC	InChI=1S/C18H13ClN4O2S/c1-9-6-20-14-12(25-9)7-21-17-13(14)15-16(26-17)18(24)23(8-22-15)11-4-2-10(19)3-5-11/h2-5,7-9,20H,6H2,1H3/t9-/m1/s1
DM07TVS	CS	C[C@@H]1CNC2=C3C4=C(C(=O)N(C=N4)C5=CC=C(C=C5)Cl)SC3=NC=C2O1
DM07TVS	IK	LFUPTQIEOBBAJE-SECBINFHSA-N
DM07TVS	IU	(5R)-14-(4-chlorophenyl)-5-methyl-6-oxa-11-thia-3,9,14,16-tetrazatetracyclo[8.7.0.02,7.012,17]heptadeca-1,7,9,12(17),15-pentaen-13-one
DM07TVS	DE	Discovery agent

DML8ZBR	ID	DML8ZBR
DML8ZBR	DN	PMID17935989C25
DML8ZBR	HS	Investigative
DML8ZBR	SN	Kinome_2918; GTPL8122; BDBM50224883
DML8ZBR	DT	Small molecular drug
DML8ZBR	PC	44444843
DML8ZBR	MW	471.9
DML8ZBR	FM	C20H18ClN7O3S
DML8ZBR	IC	InChI=1S/C20H18ClN7O3S/c21-13-5-15-17(6-14(13)24-9-12-8-23-11-32-12)30-3-1-2-4-31-19-16(7-22)25-10-18(27-19)28-20(29)26-15/h5-6,8,10-11,24H,1-4,9H2,(H2,26,27,28,29)
DML8ZBR	CS	C1CCOC2=NC(=CN=C2C#N)NC(=O)NC3=CC(=C(C=C3OC1)NCC4=CN=CS4)Cl
DML8ZBR	IK	AZTMYWWWILJAKW-UHFFFAOYSA-N
DML8ZBR	IU	7-chloro-3-oxo-8-(1,3-thiazol-5-ylmethylamino)-11,16-dioxa-2,4,19,21-tetrazatricyclo[15.3.1.05,10]henicosa-1(20),5,7,9,17(21),18-hexaene-18-carbonitrile
DML8ZBR	DE	Discovery agent

DMEHC2I	ID	DMEHC2I
DMEHC2I	DN	PMID17936624C36
DMEHC2I	HS	Investigative
DMEHC2I	SN	GTPL6445; BDBM50224926
DMEHC2I	DT	Small molecular drug
DMEHC2I	PC	44434752
DMEHC2I	MW	280.32
DMEHC2I	FM	C17H16N2O2
DMEHC2I	IC	InChI=1S/C17H16N2O2/c1-11-4-5-12-10-18-16(9-17(12)19-11)13-6-14(20-2)8-15(7-13)21-3/h4-10H,1-3H3
DMEHC2I	CS	CC1=NC2=CC(=NC=C2C=C1)C3=CC(=CC(=C3)OC)OC
DMEHC2I	IK	AWGMVVADCJSVIO-UHFFFAOYSA-N
DMEHC2I	IU	7-(3,5-dimethoxyphenyl)-2-methyl-1,6-naphthyridine
DMEHC2I	DE	Discovery agent

DMYH36T	ID	DMYH36T
DMYH36T	DN	PMID17942791C3
DMYH36T	HS	Investigative
DMYH36T	SN	NSC1011; 5335-97-7; NSC-1011; AC1Q5TXO; AC1L570I; GTPL8556; CTK4J7742; DTXSID60277170; AKOS028111231; NCI60_000032; J3.527.038H
DMYH36T	DT	Small molecular drug
DMYH36T	PC	219564
DMYH36T	MW	370.4
DMYH36T	FM	C23H18N2O3
DMYH36T	IC	InChI=1S/C23H18N2O3/c26-22-19(13-10-16-7-4-14-24-21(16)22)20(15-5-2-1-3-6-15)25-18-11-8-17(9-12-18)23(27)28/h1-14,20,25-26H,(H,27,28)
DMYH36T	CS	C1=CC=C(C=C1)C(C2=C(C3=C(C=CC=N3)C=C2)O)NC4=CC=C(C=C4)C(=O)O
DMYH36T	IK	PSCFZETTYRDCRM-UHFFFAOYSA-N
DMYH36T	IU	4-[[(8-hydroxyquinolin-7-yl)-phenylmethyl]amino]benzoic acid
DMYH36T	CA	CAS 5335-97-7
DMYH36T	DE	Discovery agent

DMTP5OY	ID	DMTP5OY
DMTP5OY	DN	PMID17963374C31
DMTP5OY	HS	Investigative
DMTP5OY	SN	GTPL3152; BDBM50225571
DMTP5OY	DT	Small molecular drug
DMTP5OY	PC	23730136
DMTP5OY	MW	376.39
DMTP5OY	FM	C13H30O6P2S
DMTP5OY	IC	InChI=1S/C13H30O6P2S/c1-3-4-5-6-7-8-9-10-11-22(2)12-13(20(14,15)16)21(17,18)19/h13H,3-12H2,1-2H3,(H3-,14,15,16,17,18,19)
DMTP5OY	CS	CCCCCCCCCC[S+](C)CC(P(=O)(O)O)P(=O)(O)[O-]
DMTP5OY	IK	RKGOJPTZXHKAKX-UHFFFAOYSA-N
DMTP5OY	IU	[2-[decyl(methyl)sulfonio]-1-phosphonoethyl]-hydroxyphosphinate
DMTP5OY	DE	Discovery agent

DMS1QM8	ID	DMS1QM8
DMS1QM8	DN	PMID17975902C5e
DMS1QM8	HS	Investigative
DMS1QM8	SN	GTPL3169; BDBM50225999
DMS1QM8	DT	Small molecular drug
DMS1QM8	PC	12066684
DMS1QM8	MW	285.1
DMS1QM8	FM	C7H10FNO6P2
DMS1QM8	IC	InChI=1S/C7H10FNO6P2/c8-7(16(10,11)12,17(13,14)15)4-6-2-1-3-9-5-6/h1-3,5H,4H2,(H2,10,11,12)(H2,13,14,15)
DMS1QM8	CS	C1=CC(=CN=C1)CC(F)(P(=O)(O)O)P(=O)(O)O
DMS1QM8	IK	HHDUHWLBPDOLIL-UHFFFAOYSA-N
DMS1QM8	IU	(1-fluoro-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
DMS1QM8	DE	Discovery agent

DMTZQUJ	ID	DMTZQUJ
DMTZQUJ	DN	PMID18068976C25
DMTZQUJ	HS	Investigative
DMTZQUJ	SN	GTPL8568; BDBM50229655
DMTZQUJ	DT	Small molecular drug
DMTZQUJ	PC	44447430
DMTZQUJ	MW	523.6
DMTZQUJ	FM	C25H37N3O7S
DMTZQUJ	IC	InChI=1S/C25H37N3O7S/c1-18-5-2-3-6-20(18)19-9-13-28(14-10-19)36(33,34)17-25(23(30)26-32)11-15-27(16-12-25)24(31)35-22-8-4-7-21(22)29/h2-3,5-6,19,21-22,29,32H,4,7-17H2,1H3,(H,26,30)
DMTZQUJ	CS	CC1=CC=CC=C1C2CCN(CC2)S(=O)(=O)CC3(CCN(CC3)C(=O)OC4CCCC4O)C(=O)NO
DMTZQUJ	IK	JRYQAIVHIZIBOQ-UHFFFAOYSA-N
DMTZQUJ	IU	(2-hydroxycyclopentyl) 4-(hydroxycarbamoyl)-4-[[4-(2-methylphenyl)piperidin-1-yl]sulfonylmethyl]piperidine-1-carboxylate
DMTZQUJ	DE	Discovery agent

DMK5PO8	ID	DMK5PO8
DMK5PO8	DN	PMID18072721C50
DMK5PO8	HS	Investigative
DMK5PO8	SN	2r4f; GTPL3008; BDBM20708
DMK5PO8	DT	Small molecular drug
DMK5PO8	PC	44629556
DMK5PO8	MW	524.6
DMK5PO8	FM	C29H35FN3O5-
DMK5PO8	IC	InChI=1S/C29H36FN3O5/c1-18(2)27-25(15-14-23(34)16-24(35)17-26(36)37)33(22-12-10-21(30)11-13-22)31-28(27)29(38)32(4)19(3)20-8-6-5-7-9-20/h5-13,18-19,23-24,34-35H,14-17H2,1-4H3,(H,36,37)/p-1/t19-,23-,24-/m1/s1
DMK5PO8	CS	C[C@H](C1=CC=CC=C1)N(C)C(=O)C2=NN(C(=C2C(C)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F
DMK5PO8	IK	MPDDTAJMJCESGV-CTUHWIOQSA-M
DMK5PO8	IU	(3R,5R)-7-[2-(4-fluorophenyl)-5-[methyl-[(1R)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate
DMK5PO8	DE	Discovery agent

DMO21H5	ID	DMO21H5
DMO21H5	DN	PMID18078750C1b
DMO21H5	HS	Investigative
DMO21H5	SN	GTPL8627; BDBM50286724
DMO21H5	DT	Small molecular drug
DMO21H5	PC	44377139
DMO21H5	MW	405.5
DMO21H5	FM	C24H23NO3S
DMO21H5	IC	InChI=1S/C24H23NO3S/c26-23(22(29)16-17-7-3-1-4-8-17)25-21(24(27)28)15-18-11-13-20(14-12-18)19-9-5-2-6-10-19/h1-14,21-22,29H,15-16H2,(H,25,26)(H,27,28)/t21-,22+/m0/s1
DMO21H5	CS	C1=CC=C(C=C1)C[C@H](C(=O)N[C@@H](CC2=CC=C(C=C2)C3=CC=CC=C3)C(=O)O)S
DMO21H5	IK	BNECOBGISSOLPT-FCHUYYIVSA-N
DMO21H5	IU	(2S)-3-(4-phenylphenyl)-2-[[(2R)-3-phenyl-2-sulfanylpropanoyl]amino]propanoic acid
DMO21H5	DE	Discovery agent

DM2U4NW	ID	DM2U4NW
DM2U4NW	DN	PMID18155906C16f
DM2U4NW	HS	Investigative
DM2U4NW	SN	GTPL3011
DM2U4NW	DT	Small molecular drug
DM2U4NW	PC	44446672
DM2U4NW	MW	669.7
DM2U4NW	FM	C34H37F2N3O7S
DM2U4NW	IC	InChI=1S/C34H37F2N3O7S/c1-20(2)32-34(47(45,46)38-26-5-3-4-21(16-26)17-29(37)42)31(22-6-10-24(35)11-7-22)33(23-8-12-25(36)13-9-23)39(32)15-14-27(40)18-28(41)19-30(43)44/h3-13,16,20,27-28,38,40-41H,14-15,17-19H2,1-2H3,(H2,37,42)(H,43,44)/t27-,28-/m1/s1
DM2U4NW	CS	CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)S(=O)(=O)NC4=CC=CC(=C4)CC(=O)N
DM2U4NW	IK	ZXGVFUKWWWNTTQ-VSGBNLITSA-N
DM2U4NW	IU	(3R,5R)-7-[4-[[3-(2-amino-2-oxoethyl)phenyl]sulfamoyl]-2,3-bis(4-fluorophenyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
DM2U4NW	DE	Discovery agent

DMA2OWK	ID	DMA2OWK
DMA2OWK	DN	PMID18178086C15
DMA2OWK	HS	Investigative
DMA2OWK	SN	GTPL6993
DMA2OWK	DT	Small molecular drug
DMA2OWK	PC	73755255
DMA2OWK	MW	496.5
DMA2OWK	FM	C22H27Cl2N5S2
DMA2OWK	IC	InChI=1S/C22H27Cl2N5S2/c1-15-13-30-21-20(15)25-14-26-22(21)27-16(2)12-28-7-9-29(10-8-28)31(3,4)17-5-6-18(23)19(24)11-17/h5-6,11,13-14,16H,3-4,7-10,12H2,1-2H3,(H,25,26,27)/t16-/m0/s1
DMA2OWK	CS	CC1=CSC2=C1N=CN=C2N[C@@H](C)CN3CCN(CC3)S(=C)(=C)C4=CC(=C(C=C4)Cl)Cl
DMA2OWK	IK	WBVRCGUUZYPAGR-INIZCTEOSA-N
DMA2OWK	IU	N-[(2S)-1-[4-[(3,4-dichlorophenyl)-dimethylidene-lambda6-sulfanyl]piperazin-1-yl]propan-2-yl]-7-methylthieno[3,2-d]pyrimidin-4-amine
DMA2OWK	DE	Discovery agent

DM3GYNM	ID	DM3GYNM
DM3GYNM	DN	PMID18295483C2
DM3GYNM	HS	Investigative
DM3GYNM	SN	GTPL3156
DM3GYNM	DT	Small molecular drug
DM3GYNM	PC	54733935
DM3GYNM	MW	390.5
DM3GYNM	FM	C24H26N2O3
DM3GYNM	IC	InChI=1S/C24H26N2O3/c27-21-16-26(15-17-7-3-1-4-8-17)24(29)22(21)23(28)25-20-13-11-19(12-14-20)18-9-5-2-6-10-18/h1,3-4,7-8,11-14,18,27H,2,5-6,9-10,15-16H2,(H,25,28)
DM3GYNM	CS	C1CCC(CC1)C2=CC=C(C=C2)NC(=O)C3=C(CN(C3=O)CC4=CC=CC=C4)O
DM3GYNM	IK	JKRIQNNJCFTRAF-UHFFFAOYSA-N
DM3GYNM	IU	1-benzyl-N-(4-cyclohexylphenyl)-3-hydroxy-5-oxo-2H-pyrrole-4-carboxamide
DM3GYNM	DE	Discovery agent

DMCTFWE	ID	DMCTFWE
DMCTFWE	DN	PMID18324760C28
DMCTFWE	HS	Investigative
DMCTFWE	SN	GTPL6555
DMCTFWE	DT	Small molecular drug
DMCTFWE	PC	24827312
DMCTFWE	MW	452.5
DMCTFWE	FM	C22H33N2O6P
DMCTFWE	IC	InChI=1S/C22H33N2O6P/c1-15(2)12-19(23-16(3)25)21(26)24-11-7-10-20(24)31(29,30)14-18(22(27)28)13-17-8-5-4-6-9-17/h4-6,8-9,15,18-20H,7,10-14H2,1-3H3,(H,23,25)(H,27,28)(H,29,30)/t18-,19+,20+/m1/s1
DMCTFWE	CS	CC(C)C[C@@H](C(=O)N1CCC[C@@H]1P(=O)(C[C@@H](CC2=CC=CC=C2)C(=O)O)O)NC(=O)C
DMCTFWE	IK	DGMLSHVZZKUDPN-AABGKKOBSA-N
DMCTFWE	IU	(2S)-2-[[[(2S)-1-[(2S)-2-acetamido-4-methylpentanoyl]pyrrolidin-2-yl]-hydroxyphosphoryl]methyl]-3-phenylpropanoic acid
DMCTFWE	DE	Discovery agent

DM1I6AY	ID	DM1I6AY
DM1I6AY	DN	PMID18334293C15b
DM1I6AY	HS	Investigative
DM1I6AY	SN	Scios-15b; GTPL8157; BDBM50374977
DM1I6AY	DT	Small molecular drug
DM1I6AY	PC	44453784
DM1I6AY	MW	365.9
DM1I6AY	FM	C20H20ClN5
DM1I6AY	IC	InChI=1S/C20H20ClN5/c21-16-4-2-5-17(14-16)24-20-23-8-7-19(25-20)15-3-1-6-18(13-15)26-11-9-22-10-12-26/h1-8,13-14,22H,9-12H2,(H,23,24,25)
DM1I6AY	CS	C1CN(CCN1)C2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC(=CC=C4)Cl
DM1I6AY	IK	UGXVRWRXHWTSCU-UHFFFAOYSA-N
DM1I6AY	IU	N-(3-chlorophenyl)-4-(3-piperazin-1-ylphenyl)pyrimidin-2-amine
DM1I6AY	DE	Discovery agent

DMEOHLV	ID	DMEOHLV
DMEOHLV	DN	PMID18337095C27
DMEOHLV	HS	Investigative
DMEOHLV	SN	GTPL8158; BDBM50375063
DMEOHLV	DT	Small molecular drug
DMEOHLV	PC	44453397
DMEOHLV	MW	404.8
DMEOHLV	FM	C22H17ClN4O2
DMEOHLV	IC	InChI=1S/C22H17ClN4O2/c23-13-5-6-17-15(9-13)16(10-25-17)19-20(22(29)26-21(19)28)27-11-12(7-8-24)14-3-1-2-4-18(14)27/h1-6,9-11,25H,7-8,24H2,(H,26,28,29)
DMEOHLV	CS	C1=CC=C2C(=C1)C(=CN2C3=C(C(=O)NC3=O)C4=CNC5=C4C=C(C=C5)Cl)CCN
DMEOHLV	IK	UPHCEKNUUNYTFE-UHFFFAOYSA-N
DMEOHLV	IU	3-[3-(2-aminoethyl)indol-1-yl]-4-(5-chloro-1H-indol-3-yl)pyrrole-2,5-dione
DMEOHLV	DE	Discovery agent

DM6NL2B	ID	DM6NL2B
DM6NL2B	DN	PMID18412317C13b
DM6NL2B	HS	Investigative
DM6NL2B	SN	GTPL2988
DM6NL2B	DT	Small molecular drug
DM6NL2B	PC	56947036
DM6NL2B	MW	484.5
DM6NL2B	FM	C23H27FN7O4-
DM6NL2B	IC	InChI=1S/C23H28FN7O4/c1-13(2)20-18(10-9-16(32)11-17(33)12-19(34)35)21(14-5-7-15(24)8-6-14)26-22(25-20)30(3)23-27-28-29-31(23)4/h5-10,13,16-17,32-33H,11-12H2,1-4H3,(H,34,35)/p-1/b10-9+/t16-,17-/m1/s1
DM6NL2B	CS	CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)N(C)C3=NN=NN3C
DM6NL2B	IK	KOTLFRFIWUOROR-VEUZHWNKSA-M
DM6NL2B	IU	(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl-(1-methyltetrazol-5-yl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate
DM6NL2B	DE	Discovery agent

DMW7PQ8	ID	DMW7PQ8
DMW7PQ8	DN	PMID18445527C11 
DMW7PQ8	HS	Investigative
DMW7PQ8	SN	UNII-0T87WD317S; GTPL5804; 0T87WD317S; GTPL-5804; GTPL 5804; BDBM50373323; 1009082-19-2
DMW7PQ8	DT	Small molecular drug
DMW7PQ8	PC	24958668
DMW7PQ8	MW	502.9
DMW7PQ8	FM	C24H18ClF3N4O3
DMW7PQ8	IC	InChI=1S/C24H18ClF3N4O3/c1-15-14-22(32(31-15)20-8-4-2-6-18(20)25)34-21-9-5-3-7-19(21)30-23(33)29-16-10-12-17(13-11-16)35-24(26,27)28/h2-14H,1H3,(H2,29,30,33)
DMW7PQ8	CS	CC1=NN(C(=C1)OC2=CC=CC=C2NC(=O)NC3=CC=C(C=C3)OC(F)(F)F)C4=CC=CC=C4Cl
DMW7PQ8	IK	SAIPZPCGTLOMFE-UHFFFAOYSA-N
DMW7PQ8	IU	1-[2-[2-(2-chlorophenyl)-5-methylpyrazol-3-yl]oxyphenyl]-3-[4-(trifluoromethoxy)phenyl]urea
DMW7PQ8	CA	CAS 1009082-19-2
DMW7PQ8	DE	Discovery agent

DM7AXRF	ID	DM7AXRF
DM7AXRF	DN	PMID18445527C67 
DM7AXRF	HS	Investigative
DM7AXRF	SN	GTPL5805; BDBM50373304
DM7AXRF	DT	Small molecular drug
DM7AXRF	PC	24743975
DM7AXRF	MW	494.6
DM7AXRF	FM	C31H34N4O2
DM7AXRF	IC	InChI=1S/C31H34N4O2/c1-3-23-11-7-9-15-28(23)35-30(21-22(2)34-35)37-29-16-10-8-14-27(29)33-31(36)32-26-19-17-25(18-20-26)24-12-5-4-6-13-24/h7-11,14-21,24H,3-6,12-13H2,1-2H3,(H2,32,33,36)
DM7AXRF	CS	CCC1=CC=CC=C1N2C(=CC(=N2)C)OC3=CC=CC=C3NC(=O)NC4=CC=C(C=C4)C5CCCCC5
DM7AXRF	IK	BLOWXIFVYOKSMX-UHFFFAOYSA-N
DM7AXRF	IU	1-(4-cyclohexylphenyl)-3-[2-[2-(2-ethylphenyl)-5-methylpyrazol-3-yl]oxyphenyl]urea
DM7AXRF	DE	Discovery agent

DM0G42B	ID	DM0G42B
DM0G42B	DN	PMID18477808CB 
DM0G42B	HS	Investigative
DM0G42B	SN	Cpd-B; cpd B; GTPL3367; 1065478-14-9
DM0G42B	DT	Small molecular drug
DM0G42B	PC	46216676
DM0G42B	MW	416.8
DM0G42B	FM	C17H12ClF3N2O3S
DM0G42B	IC	InChI=1S/C17H12ClF3N2O3S/c1-8-4-11(3-2-9(8)5-13-14(24)23-16(25)27-13)26-15-12(18)6-10(7-22-15)17(19,20)21/h2-4,6-7,13H,5H2,1H3,(H,23,24,25)
DM0G42B	CS	CC1=C(C=CC(=C1)OC2=C(C=C(C=N2)C(F)(F)F)Cl)CC3C(=O)NC(=O)S3
DM0G42B	IK	ZAMASFSDWVSMSY-UHFFFAOYSA-N
DM0G42B	IU	5-[[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy-2-methylphenyl]methyl]-1,3-thiazolidine-2,4-dione
DM0G42B	DE	Discovery agent

DMPZSGV	ID	DMPZSGV
DMPZSGV	DN	PMID18752940C9n
DMPZSGV	HS	Investigative
DMPZSGV	SN	GTPL5795; BDBM50264264; 876I947
DMPZSGV	DT	Small molecular drug
DMPZSGV	PC	25101223
DMPZSGV	MW	428.5
DMPZSGV	FM	C26H28N4O2
DMPZSGV	IC	InChI=1S/C26H28N4O2/c1-17(2)20-10-12-21(13-11-20)24-15-28-30-19(4)23(14-27-25(24)30)26(31)29-18(3)16-32-22-8-6-5-7-9-22/h5-15,17-18H,16H2,1-4H3,(H,29,31)/t18-/m1/s1
DMPZSGV	CS	CC1=C(C=NC2=C(C=NN12)C3=CC=C(C=C3)C(C)C)C(=O)N[C@H](C)COC4=CC=CC=C4
DMPZSGV	IK	DJSWNINDPRRCLC-GOSISDBHSA-N
DMPZSGV	IU	7-methyl-N-[(2R)-1-phenoxypropan-2-yl]-3-(4-propan-2-ylphenyl)pyrazolo[1,5-a]pyrimidine-6-carboxamide
DMPZSGV	DE	Discovery agent

DMTH0PD	ID	DMTH0PD
DMTH0PD	DN	PMID1875346C18
DMTH0PD	HS	Investigative
DMTH0PD	SN	GTPL3028
DMTH0PD	DT	Small molecular drug
DMTH0PD	PC	44461899
DMTH0PD	MW	571.7
DMTH0PD	FM	C33H49NO7
DMTH0PD	IC	InChI=1S/C33H49NO7/c1-6-33(4,5)31(37)40-27-16-21(3)30(41-32(38)34-19-22-10-8-7-9-11-22)26-14-12-20(2)25(29(26)27)15-13-24-17-23(35)18-28(36)39-24/h7-11,20-21,23-27,29-30,35H,6,12-19H2,1-5H3,(H,34,38)/t20-,21+,23+,24?,25-,26+,27-,29?,30+/m0/s1
DMTH0PD	CS	CCC(C)(C)C(=O)O[C@H]1C[C@H]([C@H]([C@H]2C1[C@H]([C@H](CC2)C)CCC3C[C@H](CC(=O)O3)O)OC(=O)NCC4=CC=CC=C4)C
DMTH0PD	IK	ZUURLVDIZFDZJT-UQLLKHDVSA-N
DMTH0PD	IU	[(1S,3R,4R,4aR,7S,8S)-4-(benzylcarbamoyloxy)-8-[2-[(4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-yl] 2,2-dimethylbutanoate
DMTH0PD	DE	Discovery agent

DM1JRGI	ID	DM1JRGI
DM1JRGI	DN	PMID18754614C10
DM1JRGI	HS	Investigative
DM1JRGI	SN	GTPL3075; BDBM50253314
DM1JRGI	DT	Small molecular drug
DM1JRGI	PC	25108247
DM1JRGI	MW	366.5
DM1JRGI	FM	C21H22N2O2S
DM1JRGI	IC	InChI=1S/C21H22N2O2S/c24-21(14-23-12-4-3-5-17(23)13-25-21)16-10-8-15(9-11-16)20-22-18-6-1-2-7-19(18)26-20/h1-2,6-11,17,24H,3-5,12-14H2
DM1JRGI	CS	C1CCN2CC(OCC2C1)(C3=CC=C(C=C3)C4=NC5=CC=CC=C5S4)O
DM1JRGI	IK	ZTONOAATDZXAON-UHFFFAOYSA-N
DM1JRGI	IU	3-[4-(1,3-benzothiazol-2-yl)phenyl]-4,6,7,8,9,9a-hexahydro-1H-pyrido[2,1-c][1,4]oxazin-3-ol
DM1JRGI	DE	Discovery agent

DMSVB9D	ID	DMSVB9D
DMSVB9D	DN	PMID18754614C17
DMSVB9D	HS	Investigative
DMSVB9D	SN	GTPL3076; BDBM50253491
DMSVB9D	DT	Small molecular drug
DMSVB9D	PC	25108301
DMSVB9D	MW	348.2
DMSVB9D	FM	C17H18BrNO2
DMSVB9D	IC	InChI=1S/C17H18BrNO2/c1-19-10-11-21-17(20,12-19)15-6-2-13(3-7-15)14-4-8-16(18)9-5-14/h2-9,20H,10-12H2,1H3
DMSVB9D	CS	CN1CCOC(C1)(C2=CC=C(C=C2)C3=CC=C(C=C3)Br)O
DMSVB9D	IK	NALOOEVGTGAOHW-UHFFFAOYSA-N
DMSVB9D	IU	2-[4-(4-bromophenyl)phenyl]-4-methylmorpholin-2-ol
DMSVB9D	DE	Discovery agent

DMF7VZO	ID	DMF7VZO
DMF7VZO	DN	PMID18754614C18
DMF7VZO	HS	Investigative
DMF7VZO	SN	GTPL3071; BDBM50253492
DMF7VZO	DT	Small molecular drug
DMF7VZO	PC	25108235
DMF7VZO	MW	402.3
DMF7VZO	FM	C21H24BrNO2
DMF7VZO	IC	InChI=1S/C21H24BrNO2/c1-23-14-21(24,25-20-5-3-2-4-19(20)23)17-10-6-15(7-11-17)16-8-12-18(22)13-9-16/h6-13,19-20,24H,2-5,14H2,1H3
DMF7VZO	CS	CN1CC(OC2C1CCCC2)(C3=CC=C(C=C3)C4=CC=C(C=C4)Br)O
DMF7VZO	IK	CFDRWKHPJHJISG-UHFFFAOYSA-N
DMF7VZO	IU	2-[4-(4-bromophenyl)phenyl]-4-methyl-4a,5,6,7,8,8a-hexahydro-3H-benzo[b][1,4]oxazin-2-ol
DMF7VZO	DE	Discovery agent

DMHSE96	ID	DMHSE96
DMHSE96	DN	PMID18754614C19
DMHSE96	HS	Investigative
DMHSE96	SN	GTPL3074; BDBM50253493
DMHSE96	DT	Small molecular drug
DMHSE96	PC	25108303
DMHSE96	MW	388.3
DMHSE96	FM	C20H22BrNO2
DMHSE96	IC	InChI=1S/C20H22BrNO2/c21-18-10-6-16(7-11-18)15-4-8-17(9-5-15)20(23)14-22-12-2-1-3-19(22)13-24-20/h4-11,19,23H,1-3,12-14H2
DMHSE96	CS	C1CCN2CC(OCC2C1)(C3=CC=C(C=C3)C4=CC=C(C=C4)Br)O
DMHSE96	IK	IFRLXVCJEQULMZ-UHFFFAOYSA-N
DMHSE96	IU	3-[4-(4-bromophenyl)phenyl]-4,6,7,8,9,9a-hexahydro-1H-pyrido[2,1-c][1,4]oxazin-3-ol
DMHSE96	DE	Discovery agent

DMQFYM4	ID	DMQFYM4
DMQFYM4	DN	PMID18754614C4
DMQFYM4	HS	Investigative
DMQFYM4	SN	GTPL3080; BDBM50253935
DMQFYM4	DT	Small molecular drug
DMQFYM4	PC	25108105
DMQFYM4	MW	315.4
DMQFYM4	FM	C18H21NO2S
DMQFYM4	IC	InChI=1S/C18H21NO2S/c20-18(13-19-10-2-1-4-16(19)12-21-18)15-8-6-14(7-9-15)17-5-3-11-22-17/h3,5-9,11,16,20H,1-2,4,10,12-13H2
DMQFYM4	CS	C1CCN2CC(OCC2C1)(C3=CC=C(C=C3)C4=CC=CS4)O
DMQFYM4	IK	DXCCBGQUDIVOAH-UHFFFAOYSA-N
DMQFYM4	IU	3-(4-thiophen-2-ylphenyl)-4,6,7,8,9,9a-hexahydro-1H-pyrido[2,1-c][1,4]oxazin-3-ol
DMQFYM4	DE	Discovery agent

DMVTLO0	ID	DMVTLO0
DMVTLO0	DN	PMID18754614C7
DMVTLO0	HS	Investigative
DMVTLO0	SN	GTPL3079; BDBM50253938
DMVTLO0	DT	Small molecular drug
DMVTLO0	PC	44569287
DMVTLO0	MW	394.3
DMVTLO0	FM	C18H20BrNO2S
DMVTLO0	IC	InChI=1S/C18H20BrNO2S/c19-17-9-8-16(23-17)13-4-6-14(7-5-13)18(21)12-20-10-2-1-3-15(20)11-22-18/h4-9,15,21H,1-3,10-12H2
DMVTLO0	CS	C1CCN2CC(OCC2C1)(C3=CC=C(C=C3)C4=CC=C(S4)Br)O
DMVTLO0	IK	NQOYZHHHGSRJGT-UHFFFAOYSA-N
DMVTLO0	IU	3-[4-(5-bromothiophen-2-yl)phenyl]-4,6,7,8,9,9a-hexahydro-1H-pyrido[2,1-c][1,4]oxazin-3-ol
DMVTLO0	DE	Discovery agent

DM7SCM3	ID	DM7SCM3
DM7SCM3	DN	PMID18754614C8
DM7SCM3	HS	Investigative
DM7SCM3	SN	GTPL3078; BDBM50253939
DM7SCM3	DT	Small molecular drug
DM7SCM3	PC	25108245
DM7SCM3	MW	326.4
DM7SCM3	FM	C18H18N2O2S
DM7SCM3	IC	InChI=1S/C18H18N2O2S/c1-20-10-11-22-18(21,12-20)14-8-6-13(7-9-14)17-19-15-4-2-3-5-16(15)23-17/h2-9,21H,10-12H2,1H3
DM7SCM3	CS	CN1CCOC(C1)(C2=CC=C(C=C2)C3=NC4=CC=CC=C4S3)O
DM7SCM3	IK	PJEBUKBZVKAKLF-UHFFFAOYSA-N
DM7SCM3	IU	2-[4-(1,3-benzothiazol-2-yl)phenyl]-4-methylmorpholin-2-ol
DM7SCM3	DE	Discovery agent

DMPH7A6	ID	DMPH7A6
DMPH7A6	DN	PMID18754614C9
DMPH7A6	HS	Investigative
DMPH7A6	SN	GTPL3072; BDBM50253937
DMPH7A6	DT	Small molecular drug
DMPH7A6	PC	25147760
DMPH7A6	MW	408.4
DMPH7A6	FM	C19H22BrNO2S
DMPH7A6	IC	InChI=1S/C19H22BrNO2S/c1-21-12-19(22,23-16-5-3-2-4-15(16)21)14-8-6-13(7-9-14)17-10-11-18(20)24-17/h6-11,15-16,22H,2-5,12H2,1H3
DMPH7A6	CS	CN1CC(OC2C1CCCC2)(C3=CC=C(C=C3)C4=CC=C(S4)Br)O
DMPH7A6	IK	GFRMFVSDSQREBC-UHFFFAOYSA-N
DMPH7A6	IU	2-[4-(5-bromothiophen-2-yl)phenyl]-4-methyl-4a,5,6,7,8,8a-hexahydro-3H-benzo[b][1,4]oxazin-2-ol
DMPH7A6	DE	Discovery agent

DM613NQ	ID	DM613NQ
DM613NQ	DN	PMID18790648C10
DM613NQ	HS	Investigative
DM613NQ	SN	GTPL8665; BDBM50265077
DM613NQ	DT	Small molecular drug
DM613NQ	PC	44580457
DM613NQ	MW	728.8
DM613NQ	FM	C38H41N4O7PS
DM613NQ	IC	InChI=1S/C38H41N4O7PS/c1-48-33-18-10-11-19-34(33)51-25-29(37(44)41-32(36(39)43)21-28-22-40-31-17-9-8-16-30(28)31)24-50(46,47)35(20-26-12-4-2-5-13-26)42-38(45)49-23-27-14-6-3-7-15-27/h2-19,22,29,32,35,40H,20-21,23-25H2,1H3,(H2,39,43)(H,41,44)(H,42,45)(H,46,47)/t29-,32-,35+/m0/s1
DM613NQ	CS	COC1=CC=CC=C1SC[C@H](CP(=O)([C@H](CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3)O)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N
DM613NQ	IK	YDDMVPLLJTZTQL-LAABSITASA-N
DM613NQ	IU	[(2S)-3-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-[(2-methoxyphenyl)sulfanylmethyl]-3-oxopropyl]-[(1R)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphinic acid
DM613NQ	DE	Discovery agent

DM4UWKR	ID	DM4UWKR
DM4UWKR	DN	PMID18800762C11
DM4UWKR	HS	Investigative
DM4UWKR	SN	bisphosphonate, 11; UNII-S888WM4024; S888WM4024; 16610-63-2; Tensan AO; AC1NA3ZJ; GTPL3191; BDBM25285; DB07873
DM4UWKR	DT	Small molecular drug
DM4UWKR	PC	4395717
DM4UWKR	MW	346.29
DM4UWKR	FM	C12H28O7P2
DM4UWKR	IC	InChI=1S/C12H28O7P2/c1-2-3-4-5-6-7-8-9-10-11-12(13,20(14,15)16)21(17,18)19/h13H,2-11H2,1H3,(H2,14,15,16)(H2,17,18,19)
DM4UWKR	CS	CCCCCCCCCCCC(O)(P(=O)(O)O)P(=O)(O)O
DM4UWKR	IK	KKVZONPEMODBBG-UHFFFAOYSA-N
DM4UWKR	IU	(1-hydroxy-1-phosphonododecyl)phosphonic acid
DM4UWKR	CA	CAS 16610-63-2
DM4UWKR	DE	Discovery agent

DM5T2FR	ID	DM5T2FR
DM5T2FR	DN	PMID18800762C14
DM5T2FR	HS	Investigative
DM5T2FR	SN	bisphosphonate, 14; GTPL3194; BDBM25258
DM5T2FR	DT	Small molecular drug
DM5T2FR	PC	25023861
DM5T2FR	MW	437.4
DM5T2FR	FM	C18H33NO7P2
DM5T2FR	IC	InChI=1S/C18H33NO7P2/c1-3-4-5-6-7-8-9-10-11-26-17-12-16(14-19(2)15-17)13-18(27(20,21)22)28(23,24)25/h12,14-15,18H,3-11,13H2,1-2H3,(H3-,20,21,22,23,24,25)
DM5T2FR	CS	CCCCCCCCCCOC1=C[N+](=CC(=C1)CC(P(=O)(O)O)P(=O)(O)[O-])C
DM5T2FR	IK	PUCSJEGLZHMUSS-UHFFFAOYSA-N
DM5T2FR	IU	[2-(5-decoxy-1-methylpyridin-1-ium-3-yl)-1-phosphonoethyl]-hydroxyphosphinate
DM5T2FR	DE	Discovery agent

DM70SEQ	ID	DM70SEQ
DM70SEQ	DN	PMID18800762C16
DM70SEQ	HS	Investigative
DM70SEQ	SN	bisphosphonate, 16; GTPL3195; BDBM25260; ZINC49881424
DM70SEQ	DT	Small molecular drug
DM70SEQ	PC	25023863
DM70SEQ	MW	387.39
DM70SEQ	FM	C15H35NO6P2
DM70SEQ	IC	InChI=1S/C15H35NO6P2/c1-3-4-5-6-7-8-9-10-11-12-13-16(2)14-15(23(17,18)19)24(20,21)22/h15H,3-14H2,1-2H3,(H2,17,18,19)(H2,20,21,22)
DM70SEQ	CS	CCCCCCCCCCCCN(C)CC(P(=O)(O)O)P(=O)(O)O
DM70SEQ	IK	FQYMJTHEUPKDPQ-UHFFFAOYSA-N
DM70SEQ	IU	[2-[dodecyl(methyl)amino]-1-phosphonoethyl]phosphonic acid
DM70SEQ	DE	Discovery agent

DM1QXFI	ID	DM1QXFI
DM1QXFI	DN	PMID18800762C19
DM1QXFI	HS	Investigative
DM1QXFI	SN	bisphosphonate, 19; GTPL3193; BDBM25263
DM1QXFI	DT	Small molecular drug
DM1QXFI	PC	25023868
DM1QXFI	MW	438.4
DM1QXFI	FM	C18H32O8P2
DM1QXFI	IC	InChI=1S/C18H32O8P2/c1-2-3-4-5-6-7-8-9-13-26-17-12-10-11-16(14-17)15-18(19,27(20,21)22)28(23,24)25/h10-12,14,19H,2-9,13,15H2,1H3,(H2,20,21,22)(H2,23,24,25)
DM1QXFI	CS	CCCCCCCCCCOC1=CC=CC(=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DM1QXFI	IK	MHLLAPRPDYGFFU-UHFFFAOYSA-N
DM1QXFI	IU	[2-(3-decoxyphenyl)-1-hydroxy-1-phosphonoethyl]phosphonic acid
DM1QXFI	DE	Discovery agent

DMZDC14	ID	DMZDC14
DMZDC14	DN	PMID18800762C47
DMZDC14	HS	Investigative
DMZDC14	SN	bisphosphonate, 47; GTPL3197; BDBM25300
DMZDC14	DT	Small molecular drug
DMZDC14	PC	25023895
DMZDC14	MW	494
DMZDC14	FM	C15H14Cl4O6P2
DMZDC14	IC	InChI=1S/C15H14Cl4O6P2/c16-11-3-1-9(13(18)5-11)7-15(26(20,21)22,27(23,24)25)8-10-2-4-12(17)6-14(10)19/h1-6H,7-8H2,(H2,20,21,22)(H2,23,24,25)
DMZDC14	CS	C1=CC(=C(C=C1Cl)Cl)CC(CC2=C(C=C(C=C2)Cl)Cl)(P(=O)(O)O)P(=O)(O)O
DMZDC14	IK	HOUGVWVFZPBNCB-UHFFFAOYSA-N
DMZDC14	IU	[1,3-bis(2,4-dichlorophenyl)-2-phosphonopropan-2-yl]phosphonic acid
DMZDC14	DE	Discovery agent

DMWFGY4	ID	DMWFGY4
DMWFGY4	DN	PMID18800762C51
DMWFGY4	HS	Investigative
DMWFGY4	SN	bisphosphonate, 51; GTPL3186; BDBM25304
DMWFGY4	DT	Small molecular drug
DMWFGY4	PC	25023896
DMWFGY4	MW	263.08
DMWFGY4	FM	C3H11N3O7P2
DMWFGY4	IC	InChI=1S/C3H11N3O7P2/c4-2(5)6-1-3(7,14(8,9)10)15(11,12)13/h7H,1H2,(H4,4,5,6)(H2,8,9,10)(H2,11,12,13)
DMWFGY4	CS	C(C(O)(P(=O)(O)O)P(=O)(O)O)N=C(N)N
DMWFGY4	IK	ZZHOMRYFXNLXOZ-UHFFFAOYSA-N
DMWFGY4	IU	[2-(diaminomethylideneamino)-1-hydroxy-1-phosphonoethyl]phosphonic acid
DMWFGY4	DE	Discovery agent

DMA5P9Q	ID	DMA5P9Q
DMA5P9Q	DN	PMID1895299C1
DMA5P9Q	HS	Investigative
DMA5P9Q	SN	GTPL2975; BDBM50406568
DMA5P9Q	DT	Small molecular drug
DMA5P9Q	PC	56947047
DMA5P9Q	MW	421.5
DMA5P9Q	FM	C24H37O6-
DMA5P9Q	IC	InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28)/p-1/t14-,15-,16-,18+,19-,20-,21+,23?/m0/s1
DMA5P9Q	CS	CC[C@H](C)C(=O)O[C@@H]1C[C@H](C=C2C1[C@H]([C@H](C=C2)C)CC[C@H](C[C@@H](CC(=O)[O-])O)O)C
DMA5P9Q	IK	QLJODMDSTUBWDW-VPUMEXOFSA-M
DMA5P9Q	IU	(3S,5R)-7-[(1S,2S,6R,8R)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
DMA5P9Q	DE	Discovery agent

DMAZWHB	ID	DMAZWHB
DMAZWHB	DN	PMID1895299C4p
DMAZWHB	HS	Investigative
DMAZWHB	SN	GTPL3019
DMAZWHB	DT	Small molecular drug
DMAZWHB	PC	56947022
DMAZWHB	MW	509.5
DMAZWHB	FM	C28H29FNO5P-2
DMAZWHB	IC	InChI=1S/C28H31FNO5P/c1-4-23-26(19-10-12-21(29)13-11-19)24(14-15-36(34,35)17-22(31)16-25(32)33)27(18(2)3)30-28(23)20-8-6-5-7-9-20/h5-15,18,22,31H,4,16-17H2,1-3H3,(H,32,33)(H,34,35)/p-2/b15-14+/t22-/m1/s1
DMAZWHB	CS	CCC1=C(C(=C(N=C1C2=CC=CC=C2)C(C)C)/C=C/P(=O)(C[C@@H](CC(=O)[O-])O)[O-])C3=CC=C(C=C3)F
DMAZWHB	IK	LPNRUMVKXCLEBE-JXVRESAISA-L
DMAZWHB	IU	(3R)-4-[[(E)-2-[5-ethyl-4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-oxidophosphoryl]-3-hydroxybutanoate
DMAZWHB	DE	Discovery agent

DM384PH	ID	DM384PH
DM384PH	DN	PMID1895299C6v
DM384PH	HS	Investigative
DM384PH	SN	GTPL3018; BDBM50406579
DM384PH	DT	Small molecular drug
DM384PH	PC	56947021
DM384PH	MW	525.5
DM384PH	FM	C28H29FNO6P-2
DM384PH	IC	InChI=1S/C28H31FNO6P/c1-17(2)27-24(15-36-37(34,35)16-21(31)14-25(32)33)26(19-10-12-20(29)13-11-19)23-9-5-7-18-6-3-4-8-22(18)28(23)30-27/h3-4,6,8,10-13,17,21,31H,5,7,9,14-16H2,1-2H3,(H,32,33)(H,34,35)/p-2/t21-/m1/s1
DM384PH	CS	CC(C)C1=C(C(=C2CCCC3=CC=CC=C3C2=N1)C4=CC=C(C=C4)F)COP(=O)(C[C@@H](CC(=O)[O-])O)[O-]
DM384PH	IK	MZCZXPHMOGJQBJ-OAQYLSRUSA-L
DM384PH	IU	(3R)-4-[[6-(4-fluorophenyl)-4-propan-2-yl-3-azatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl]methoxy-oxidophosphoryl]-3-hydroxybutanoate
DM384PH	DE	Discovery agent

DMFU6AI	ID	DMFU6AI
DMFU6AI	DN	PMID18986805C9b
DMFU6AI	HS	Investigative
DMFU6AI	SN	GTPL8160; BDBM50246396; ZINC38224644
DMFU6AI	DT	Small molecular drug
DMFU6AI	PC	11675054
DMFU6AI	MW	368.4
DMFU6AI	FM	C19H21FN6O
DMFU6AI	IC	InChI=1S/C19H21FN6O/c1-11(2)26-12(3)23-10-17(26)16-7-8-22-19(25-16)24-13-5-6-14(15(20)9-13)18(27)21-4/h5-11H,1-4H3,(H,21,27)(H,22,24,25)
DMFU6AI	CS	CC1=NC=C(N1C(C)C)C2=NC(=NC=C2)NC3=CC(=C(C=C3)C(=O)NC)F
DMFU6AI	IK	OCUYCOQPRGFQEV-UHFFFAOYSA-N
DMFU6AI	IU	2-fluoro-N-methyl-4-[[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]benzamide
DMFU6AI	DE	Discovery agent

DMH70UC	ID	DMH70UC
DMH70UC	DN	PMID19097784C2
DMH70UC	HS	Investigative
DMH70UC	SN	GTPL8646
DMH70UC	DT	Small molecular drug
DMH70UC	PC	91827384
DMH70UC	MW	475.5
DMH70UC	FM	C23H20F3N3O3S
DMH70UC	IC	InChI=1S/C23H20F3N3O3S/c1-13(27)22-20(32-11-14-6-4-5-7-15(14)23(24,25)26)10-21(33-22)29-12-28-16-8-18(30-2)19(31-3)9-17(16)29/h4-10,12H,1,11,27H2,2-3H3
DMH70UC	CS	COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C(=C)N)OCC4=CC=CC=C4C(F)(F)F)OC
DMH70UC	IK	SYQIMXCJFHFKLG-UHFFFAOYSA-N
DMH70UC	IU	1-[5-(5,6-dimethoxybenzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl]methoxy]thiophen-2-yl]ethenamine
DMH70UC	DE	Discovery agent

DMVTXKI	ID	DMVTXKI
DMVTXKI	DN	PMID19111466C7d
DMVTXKI	HS	Investigative
DMVTXKI	SN	GTPL7056; BDBM50255914
DMVTXKI	DT	Small molecular drug
DMVTXKI	PC	16661454
DMVTXKI	MW	393.5
DMVTXKI	FM	C21H19N3O3S
DMVTXKI	IC	InChI=1S/C21H19N3O3S/c25-20(23-27)15-9-7-14(8-10-15)13-24-18-6-2-1-5-17(18)22-21(26)19(24)12-16-4-3-11-28-16/h1-11,19,27H,12-13H2,(H,22,26)(H,23,25)/t19-/m1/s1
DMVTXKI	CS	C1=CC=C2C(=C1)NC(=O)[C@H](N2CC3=CC=C(C=C3)C(=O)NO)CC4=CC=CS4
DMVTXKI	IK	HBEDNENASUYMPO-LJQANCHMSA-N
DMVTXKI	IU	N-hydroxy-4-[[(2R)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide
DMVTXKI	DE	Discovery agent

DMB9F2L	ID	DMB9F2L
DMB9F2L	DN	PMID19115845C89S
DMB9F2L	HS	Investigative
DMB9F2L	SN	3du8; GTPL8114; BDBM27380; DB07149
DMB9F2L	DT	Small molecular drug
DMB9F2L	PC	16757525
DMB9F2L	MW	275.28
DMB9F2L	FM	C13H14FN5O
DMB9F2L	IC	InChI=1S/C13H14FN5O/c14-3-1-7-6-17-12(20)8-5-10(18-11(7)8)9-2-4-16-13(15)19-9/h2,4-5,7,18H,1,3,6H2,(H,17,20)(H2,15,16,19)/t7-/m0/s1
DMB9F2L	CS	C1[C@@H](C2=C(C=C(N2)C3=NC(=NC=C3)N)C(=O)N1)CCF
DMB9F2L	IK	LCBAQTCTQXHTJG-ZETCQYMHSA-N
DMB9F2L	IU	(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one
DMB9F2L	DE	Discovery agent

DMG7D3I	ID	DMG7D3I
DMG7D3I	DN	PMID19191557C14
DMG7D3I	HS	Investigative
DMG7D3I	SN	GTPL3125; BDBM50292870
DMG7D3I	DT	Small molecular drug
DMG7D3I	PC	56947013
DMG7D3I	MW	355.28
DMG7D3I	FM	C14H12O7PS-3
DMG7D3I	IC	InChI=1S/C14H15O7PS/c15-22(16,17)14(23(18,19)20)10-11-5-4-8-13(9-11)21-12-6-2-1-3-7-12/h1-9,14H,10H2,(H2,15,16,17)(H,18,19,20)/p-3
DMG7D3I	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)CC(P(=O)([O-])[O-])S(=O)(=O)[O-]
DMG7D3I	IK	QZTDQEVQGQAOKB-UHFFFAOYSA-K
DMG7D3I	IU	2-(3-phenoxyphenyl)-1-phosphonatoethanesulfonate
DMG7D3I	DE	Discovery agent

DMXLVEC	ID	DMXLVEC
DMXLVEC	DN	PMID19191557C19
DMXLVEC	HS	Investigative
DMXLVEC	SN	GTPL3124; BDBM50292865
DMXLVEC	DT	Small molecular drug
DMXLVEC	PC	56947058
DMXLVEC	MW	408.4
DMXLVEC	FM	C18H19NO6PS-3
DMXLVEC	IC	InChI=1S/C18H22NO6PS/c1-2-19-16-8-4-3-7-14(16)15-12-13(10-11-17(15)19)6-5-9-18(26(20,21)22)27(23,24)25/h3-4,7-8,10-12,18H,2,5-6,9H2,1H3,(H2,20,21,22)(H,23,24,25)/p-3
DMXLVEC	CS	CCN1C2=C(C=C(C=C2)CCCC(P(=O)([O-])[O-])S(=O)(=O)[O-])C3=CC=CC=C31
DMXLVEC	IK	ZZMVEURNXXVJQQ-UHFFFAOYSA-K
DMXLVEC	IU	4-(9-ethylcarbazol-3-yl)-1-phosphonatobutane-1-sulfonate
DMXLVEC	DE	Discovery agent

DM5RIB0	ID	DM5RIB0
DM5RIB0	DN	PMID19191557C21
DM5RIB0	HS	Investigative
DM5RIB0	SN	GTPL3119; BDBM50292863
DM5RIB0	DT	Small molecular drug
DM5RIB0	PC	56947054
DM5RIB0	MW	401.3
DM5RIB0	FM	C16H15FO7PS-3
DM5RIB0	IC	InChI=1S/C16H18FO7PS/c17-14-8-1-2-9-15(14)24-13-7-3-5-12(11-13)6-4-10-16(25(18,19)20)26(21,22)23/h1-3,5,7-9,11,16H,4,6,10H2,(H2,18,19,20)(H,21,22,23)/p-3
DM5RIB0	CS	C1=CC=C(C(=C1)OC2=CC=CC(=C2)CCCC(P(=O)([O-])[O-])S(=O)(=O)[O-])F
DM5RIB0	IK	OHYIVSIWKOMZPF-UHFFFAOYSA-K
DM5RIB0	IU	4-[3-(2-fluorophenoxy)phenyl]-1-phosphonatobutane-1-sulfonate
DM5RIB0	DE	Discovery agent

DM1MEY3	ID	DM1MEY3
DM1MEY3	DN	PMID19191557C3
DM1MEY3	HS	Investigative
DM1MEY3	SN	GTPL3126; BDBM50292847
DM1MEY3	DT	Small molecular drug
DM1MEY3	PC	56947011
DM1MEY3	MW	434.24
DM1MEY3	FM	C17H15F3O6P2-4
DM1MEY3	IC	InChI=1S/C17H19F3O6P2/c18-17(19,20)15-10-8-14(9-11-15)13-6-4-12(5-7-13)2-1-3-16(27(21,22)23)28(24,25)26/h4-11,16H,1-3H2,(H2,21,22,23)(H2,24,25,26)/p-4
DM1MEY3	CS	C1=CC(=CC=C1CCCC(P(=O)([O-])[O-])P(=O)([O-])[O-])C2=CC=C(C=C2)C(F)(F)F
DM1MEY3	IK	UPZLJSDZIBONGH-UHFFFAOYSA-J
DM1MEY3	IU	dioxido-oxo-[1-phosphonato-4-[4-[4-(trifluoromethyl)phenyl]phenyl]butyl]-lambda5-phosphane
DM1MEY3	DE	Discovery agent

DMH8QRI	ID	DMH8QRI
DMH8QRI	DN	PMID19191557C32
DMH8QRI	HS	Investigative
DMH8QRI	SN	GTPL3123; BDBM50292852
DMH8QRI	DT	Small molecular drug
DMH8QRI	PC	56947050
DMH8QRI	MW	423.4
DMH8QRI	FM	C18H16O8PS-3
DMH8QRI	IC	InChI=1S/C18H19O8PS/c19-27(20,21)18(28(22,23)24)6-2-4-13-3-1-5-15(11-13)26-16-7-8-17-14(12-16)9-10-25-17/h1,3,5,7-12,18H,2,4,6H2,(H2,19,20,21)(H,22,23,24)/p-3
DMH8QRI	CS	C1=CC(=CC(=C1)OC2=CC3=C(C=C2)OC=C3)CCCC(P(=O)([O-])[O-])S(=O)(=O)[O-]
DMH8QRI	IK	ILJWMHLLBUNHIQ-UHFFFAOYSA-K
DMH8QRI	IU	4-[3-(1-benzofuran-5-yloxy)phenyl]-1-phosphonatobutane-1-sulfonate
DMH8QRI	DE	Discovery agent

DM09IEK	ID	DM09IEK
DM09IEK	DN	PMID19191557C35
DM09IEK	HS	Investigative
DM09IEK	SN	GTPL3122; BDBM50292849
DM09IEK	DT	Small molecular drug
DM09IEK	PC	56947048
DM09IEK	MW	419.3
DM09IEK	FM	C16H14F2O7PS-3
DM09IEK	IC	InChI=1S/C16H17F2O7PS/c17-12-4-6-13(7-5-12)25-14-8-9-15(18)11(10-14)2-1-3-16(26(19,20)21)27(22,23)24/h4-10,16H,1-3H2,(H2,19,20,21)(H,22,23,24)/p-3
DM09IEK	CS	C1=CC(=CC=C1OC2=CC(=C(C=C2)F)CCCC(P(=O)([O-])[O-])S(=O)(=O)[O-])F
DM09IEK	IK	GNVJUODFQNFGPT-UHFFFAOYSA-K
DM09IEK	IU	4-[2-fluoro-5-(4-fluorophenoxy)phenyl]-1-phosphonatobutane-1-sulfonate
DM09IEK	DE	Discovery agent

DMUWYA2	ID	DMUWYA2
DMUWYA2	DN	PMID19191557C8
DMUWYA2	HS	Investigative
DMUWYA2	SN	GTPL3128; BDBM50049215
DMUWYA2	DT	Small molecular drug
DMUWYA2	PC	56947052
DMUWYA2	MW	473.5
DMUWYA2	FM	C23H22O7PS-3
DMUWYA2	IC	InChI=1S/C23H25O7PS/c24-31(25,26)23(32(27,28)29)15-7-11-19-10-6-13-21(17-19)30-22-14-5-4-12-20(22)16-18-8-2-1-3-9-18/h1-6,8-10,12-14,17,23H,7,11,15-16H2,(H2,24,25,26)(H,27,28,29)/p-3
DMUWYA2	CS	C1=CC=C(C=C1)CC2=CC=CC=C2OC3=CC=CC(=C3)CCCC(P(=O)([O-])[O-])S(=O)(=O)[O-]
DMUWYA2	IK	ZMOCESLEEQXYRI-UHFFFAOYSA-K
DMUWYA2	IU	4-[3-(2-benzylphenoxy)phenyl]-1-phosphonatobutane-1-sulfonate
DMUWYA2	DE	Discovery agent

DMJRLB5	ID	DMJRLB5
DMJRLB5	DN	PMID19289283C22
DMJRLB5	HS	Investigative
DMJRLB5	SN	GTPL6349; BDBM50278288
DMJRLB5	DT	Small molecular drug
DMJRLB5	PC	11772954
DMJRLB5	MW	365.4
DMJRLB5	FM	C20H23N5O2
DMJRLB5	IC	InChI=1S/C20H23N5O2/c26-6-8-27-7-5-21-19-11-17-18(12-22-19)23-13-24-20(17)25-16-9-14-3-1-2-4-15(14)10-16/h1-4,11-13,16,26H,5-10H2,(H,21,22)(H,23,24,25)
DMJRLB5	CS	C1C(CC2=CC=CC=C21)NC3=NC=NC4=CN=C(C=C43)NCCOCCO
DMJRLB5	IK	QFBGUCZGHVJUGC-UHFFFAOYSA-N
DMJRLB5	IU	2-[2-[[4-(2,3-dihydro-1H-inden-2-ylamino)pyrido[3,4-d]pyrimidin-6-yl]amino]ethoxy]ethanol
DMJRLB5	DE	Discovery agent

DMSKGEJ	ID	DMSKGEJ
DMSKGEJ	DN	PMID19289283C32
DMSKGEJ	HS	Investigative
DMSKGEJ	SN	GTPL6351; BDBM50278407
DMSKGEJ	DT	Small molecular drug
DMSKGEJ	PC	11337722
DMSKGEJ	MW	371.5
DMSKGEJ	FM	C20H29N5O2
DMSKGEJ	IC	InChI=1S/C20H29N5O2/c1-2-4-6-16(5-3-1)24-20-17-13-19(21-14-18(17)22-15-23-20)27-12-9-25-7-10-26-11-8-25/h13-16H,1-12H2,(H,22,23,24)
DMSKGEJ	CS	C1CCCC(CC1)NC2=NC=NC3=CN=C(C=C32)OCCN4CCOCC4
DMSKGEJ	IK	OGIVDFLCEHDQBN-UHFFFAOYSA-N
DMSKGEJ	IU	N-cycloheptyl-6-(2-morpholin-4-ylethoxy)pyrido[3,4-d]pyrimidin-4-amine
DMSKGEJ	DE	Discovery agent

DMTASYN	ID	DMTASYN
DMTASYN	DN	PMID19309152C2g
DMTASYN	HS	Investigative
DMTASYN	SN	GTPL5791; BDBM50277582
DMTASYN	DT	Small molecular drug
DMTASYN	PC	11494579
DMTASYN	MW	377.4
DMTASYN	FM	C21H19N3O4
DMTASYN	IC	InChI=1S/C21H19N3O4/c25-15-7-9-18-13(11-15)5-8-19-14(12-22-24(18)19)6-10-20(26)23-17-4-2-1-3-16(17)21(27)28/h1-4,7,9,11-12,25H,5-6,8,10H2,(H,23,26)(H,27,28)
DMTASYN	CS	C1CC2=C(C=NN2C3=C1C=C(C=C3)O)CCC(=O)NC4=CC=CC=C4C(=O)O
DMTASYN	IK	PCUNTWOSLIUDRR-UHFFFAOYSA-N
DMTASYN	IU	2-[3-(7-hydroxy-4,5-dihydropyrazolo[1,5-a]quinolin-3-yl)propanoylamino]benzoic acid
DMTASYN	DE	Discovery agent

DMSE1C3	ID	DMSE1C3
DMSE1C3	DN	PMID19364658C33
DMSE1C3	HS	Investigative
DMSE1C3	SN	GTPL8163; BDBM50259563
DMSE1C3	DT	Small molecular drug
DMSE1C3	PC	25207521
DMSE1C3	MW	338.32
DMSE1C3	FM	C17H14N4O4
DMSE1C3	IC	InChI=1S/C17H14N4O4/c18-17(25)12(9-2-1-3-11(22)8-9)21-14-13(15(23)16(14)24)20-10-4-6-19-7-5-10/h1-8,12,21-22H,(H2,18,25)(H,19,20)
DMSE1C3	CS	C1=CC(=CC(=C1)O)C(C(=O)N)NC2=C(C(=O)C2=O)NC3=CC=NC=C3
DMSE1C3	IK	GPXKVULNYYNGDP-UHFFFAOYSA-N
DMSE1C3	IU	2-[[3,4-dioxo-2-(pyridin-4-ylamino)cyclobuten-1-yl]amino]-2-(3-hydroxyphenyl)acetamide
DMSE1C3	DE	Discovery agent

DMPXEIQ	ID	DMPXEIQ
DMPXEIQ	DN	PMID19433355C11q
DMPXEIQ	HS	Investigative
DMPXEIQ	SN	UNII-RWS6U82B77; RWS6U82B77; GTPL6214; BDBM50345947; 902747-93-7
DMPXEIQ	DT	Small molecular drug
DMPXEIQ	PC	23634171
DMPXEIQ	MW	366.8
DMPXEIQ	FM	C18H11ClN4OS
DMPXEIQ	IC	InChI=1S/C18H11ClN4OS/c1-2-8-20-13-7-9-21-17-14(13)15-16(25-17)18(24)23(10-22-15)12-5-3-11(19)4-6-12/h1,3-7,9-10H,8H2,(H,20,21)
DMPXEIQ	CS	C#CCNC1=C2C3=C(C(=O)N(C=N3)C4=CC=C(C=C4)Cl)SC2=NC=C1
DMPXEIQ	IK	MAYHTEHJUHRFSA-UHFFFAOYSA-N
DMPXEIQ	IU	5-(4-chlorophenyl)-13-(prop-2-ynylamino)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMPXEIQ	CA	CAS 902747-93-7
DMPXEIQ	DE	Discovery agent

DMBU0XJ	ID	DMBU0XJ
DMBU0XJ	DN	PMID19433355C11s
DMBU0XJ	HS	Investigative
DMBU0XJ	SN	UNII-3S4N4U44G8; 3S4N4U44G8; GTPL6215; BDBM50345949; 902747-98-2
DMBU0XJ	DT	Small molecular drug
DMBU0XJ	PC	23634102
DMBU0XJ	MW	362.4
DMBU0XJ	FM	C19H14N4O2S
DMBU0XJ	IC	InChI=1S/C19H14N4O2S/c1-3-9-20-14-8-10-21-18-15(14)16-17(26-18)19(24)23(11-22-16)12-4-6-13(25-2)7-5-12/h1,4-8,10-11H,9H2,2H3,(H,20,21)
DMBU0XJ	CS	COC1=CC=C(C=C1)N2C=NC3=C(C2=O)SC4=NC=CC(=C34)NCC#C
DMBU0XJ	IK	WIAAIYJUCDAKFY-UHFFFAOYSA-N
DMBU0XJ	IU	5-(4-methoxyphenyl)-13-(prop-2-ynylamino)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMBU0XJ	CA	CAS 902747-98-2
DMBU0XJ	DE	Discovery agent

DMBU9E4	ID	DMBU9E4
DMBU9E4	DN	PMID19456099C13
DMBU9E4	HS	Investigative
DMBU9E4	SN	compound 1d [PMID: 19456099]; GTPL3127
DMBU9E4	DT	Small molecular drug
DMBU9E4	PC	44185378
DMBU9E4	MW	377.4
DMBU9E4	FM	C19H24NO5P
DMBU9E4	IC	InChI=1S/C19H24NO5P/c1-19(2,26(22,23)24)18(21)20-13-7-9-15-8-6-12-17(14-15)25-16-10-4-3-5-11-16/h3-6,8,10-12,14H,7,9,13H2,1-2H3,(H,20,21)(H2,22,23,24)
DMBU9E4	CS	CC(C)(C(=O)NCCCC1=CC(=CC=C1)OC2=CC=CC=C2)P(=O)(O)O
DMBU9E4	IK	AGJZDRXKAQZWEP-UHFFFAOYSA-N
DMBU9E4	IU	[2-methyl-1-oxo-1-[3-(3-phenoxyphenyl)propylamino]propan-2-yl]phosphonic acid
DMBU9E4	DE	Discovery agent

DMPZMS0	ID	DMPZMS0
DMPZMS0	DN	PMID19456099C15
DMPZMS0	HS	Investigative
DMPZMS0	SN	compound 1j [PMID:19456099]; GTPL3120
DMPZMS0	DT	Small molecular drug
DMPZMS0	PC	44185382
DMPZMS0	MW	365.3
DMPZMS0	FM	C17H20NO6P
DMPZMS0	IC	InChI=1S/C17H20NO6P/c19-17(18-20)16(25(21,22)23)11-5-7-13-6-4-10-15(12-13)24-14-8-2-1-3-9-14/h1-4,6,8-10,12,16,20H,5,7,11H2,(H,18,19)(H2,21,22,23)
DMPZMS0	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)CCCC(C(=O)NO)P(=O)(O)O
DMPZMS0	IK	HGDWHTASNMRJMP-UHFFFAOYSA-N
DMPZMS0	IU	[1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid
DMPZMS0	DE	Discovery agent

DMTRL0X	ID	DMTRL0X
DMTRL0X	DN	PMID19502059C25d
DMTRL0X	HS	Investigative
DMTRL0X	SN	GTPL2997; BDBM50296079
DMTRL0X	DT	Small molecular drug
DMTRL0X	PC	56947033
DMTRL0X	MW	475.6
DMTRL0X	FM	C30H32FO4-
DMTRL0X	IC	InChI=1S/C30H33FO4/c1-3-30(4-2,23-8-6-5-7-9-23)24-14-10-21(13-17-26(32)19-27(33)20-29(34)35)28(18-24)22-11-15-25(31)16-12-22/h5-18,26-27,32-33H,3-4,19-20H2,1-2H3,(H,34,35)/p-1/b17-13+/t26-,27-/m1/s1
DMTRL0X	CS	CCC(CC)(C1=CC=CC=C1)C2=CC(=C(C=C2)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F
DMTRL0X	IK	VICOOSNNZUPVHM-IGPZRPDBSA-M
DMTRL0X	IU	(E,3R,5S)-7-[2-(4-fluorophenyl)-4-(3-phenylpentan-3-yl)phenyl]-3,5-dihydroxyhept-6-enoate
DMTRL0X	DE	Discovery agent

DMK5JB8	ID	DMK5JB8
DMK5JB8	DN	PMID19524438C6o
DMK5JB8	HS	Investigative
DMK5JB8	SN	GTPL5800; BDBM50414494
DMK5JB8	DT	Small molecular drug
DMK5JB8	PC	44250176
DMK5JB8	MW	319.4
DMK5JB8	FM	C14H13N3O2S2
DMK5JB8	IC	InChI=1S/C14H13N3O2S2/c18-14(19)12-5-13(16-15-12)17(6-10-1-3-20-8-10)7-11-2-4-21-9-11/h1-5,8-9H,6-7H2,(H,15,16)(H,18,19)
DMK5JB8	CS	C1=CSC=C1CN(CC2=CSC=C2)C3=NNC(=C3)C(=O)O
DMK5JB8	IK	SQUDZZYXGWLQLZ-UHFFFAOYSA-N
DMK5JB8	IU	3-[bis(thiophen-3-ylmethyl)amino]-1H-pyrazole-5-carboxylic acid
DMK5JB8	DE	Discovery agent

DMRWM24	ID	DMRWM24
DMRWM24	DN	PMID19632837C17f
DMRWM24	HS	Investigative
DMRWM24	SN	benzo[d]imidazole inhibitors of PRMT4 from BMS; GTPL7031; BDBM50301077
DMRWM24	DT	Small molecular drug
DMRWM24	PC	44622850
DMRWM24	MW	408.5
DMRWM24	FM	C24H32N4O2
DMRWM24	IC	InChI=1S/C24H32N4O2/c1-16-14-18(17-8-11-28(12-9-17)13-10-25-2)15-19-23(16)27-24(26-19)22-20(29-3)6-5-7-21(22)30-4/h5-7,14-15,17,25H,8-13H2,1-4H3,(H,26,27)
DMRWM24	CS	CC1=CC(=CC2=C1N=C(N2)C3=C(C=CC=C3OC)OC)C4CCN(CC4)CCNC
DMRWM24	IK	PFOQIHIIOLBCEQ-UHFFFAOYSA-N
DMRWM24	IU	2-[4-[2-(2,6-dimethoxyphenyl)-7-methyl-3H-benzimidazol-5-yl]piperidin-1-yl]-N-methylethanamine
DMRWM24	DE	Discovery agent

DMTX0ZJ	ID	DMTX0ZJ
DMTX0ZJ	DN	PMID19743866C51
DMTX0ZJ	HS	Investigative
DMTX0ZJ	SN	Ac-RLTbaLAR-H; GTPL8653; BDBM50314023
DMTX0ZJ	DT	Small molecular drug
DMTX0ZJ	PC	46883596
DMTX0ZJ	MW	797
DMTX0ZJ	FM	C36H68N12O8
DMTX0ZJ	IC	InChI=1S/C36H68N12O8/c1-19(2)16-25(30(52)43-21(5)28(50)45-24(33(55)56)13-11-15-42-35(39)40)47-32(54)27(18-36(7,8)9)48-31(53)26(17-20(3)4)46-29(51)23(44-22(6)49)12-10-14-41-34(37)38/h19-21,23-27H,10-18H2,1-9H3,(H,43,52)(H,44,49)(H,45,50)(H,46,51)(H,47,54)(H,48,53)(H,55,56)(H4,37,38,41)(H4,39,40,42)/t21-,23-,24-,25-,26-,27-/m0/s1
DMTX0ZJ	CS	C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DMTX0ZJ	IK	VIJSPAIQWVPKQZ-BLECARSGSA-N
DMTX0ZJ	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMTX0ZJ	DE	Discovery agent

DMCVJK9	ID	DMCVJK9
DMCVJK9	DN	PMID19788238C66
DMCVJK9	HS	Investigative
DMCVJK9	SN	1192216-03-7; GTPL8141; ZINC45245466; NSC752203; BDBM50299218; NSC-752203; KB-65160
DMCVJK9	DT	Small molecular drug
DMCVJK9	PC	44478401
DMCVJK9	MW	417.4
DMCVJK9	FM	C22H19N5O4
DMCVJK9	IC	InChI=1S/C22H19N5O4/c1-12-8-9-13(28)10-14(12)16-11-26-18-19(25(2)22(30)24-20(18)29)23-21(26)27(16)15-6-4-5-7-17(15)31-3/h4-11,28H,1-3H3,(H,24,29,30)
DMCVJK9	CS	CC1=C(C=C(C=C1)O)C2=CN3C4=C(N=C3N2C5=CC=CC=C5OC)N(C(=O)NC4=O)C
DMCVJK9	IK	JTWMOWRMSZZHDR-UHFFFAOYSA-N
DMCVJK9	IU	7-(5-hydroxy-2-methylphenyl)-6-(2-methoxyphenyl)-4-methylpurino[7,8-a]imidazole-1,3-dione
DMCVJK9	DE	Discovery agent

DMQXK4B	ID	DMQXK4B
DMQXK4B	DN	PMID19800804C12
DMQXK4B	HS	Investigative
DMQXK4B	SN	GTPL6989
DMQXK4B	DT	Small molecular drug
DMQXK4B	PC	73755253
DMQXK4B	MW	297.26
DMQXK4B	FM	C16H11NO5
DMQXK4B	IC	InChI=1S/C16H11NO5/c1-9-2-4-10(5-3-9)22-11-6-7-12-13(8-11)15(19)17(14(12)18)16(20)21/h2-8H,1H3,(H,20,21)
DMQXK4B	CS	CC1=CC=C(C=C1)OC2=CC3=C(C=C2)C(=O)N(C3=O)C(=O)O
DMQXK4B	IK	QSPCKQSNISDWOH-UHFFFAOYSA-N
DMQXK4B	IU	5-(4-methylphenoxy)-1,3-dioxoisoindole-2-carboxylic acid
DMQXK4B	DE	Discovery agent

DMIECOF	ID	DMIECOF
DMIECOF	DN	PMID19831390C14
DMIECOF	HS	Investigative
DMIECOF	SN	1116571-01-7; GTPL8151; ZINC45254830; BDBM50299583; AKOS027339246; KB-66522; AS-40572
DMIECOF	DT	Small molecular drug
DMIECOF	PC	44477445
DMIECOF	MW	453.3
DMIECOF	FM	C20H21BrN8
DMIECOF	IC	InChI=1S/C20H21BrN8/c1-13-9-23-18-17(13)19(26-12-25-18)28-6-7-29(14(2)10-28)20(24-11-22)27-16-5-3-4-15(21)8-16/h3-5,8-9,12,14H,6-7,10H2,1-2H3,(H,24,27)(H,23,25,26)/t14-/m0/s1
DMIECOF	CS	C[C@H]1CN(CCN1C(=NC2=CC(=CC=C2)Br)NC#N)C3=NC=NC4=C3C(=CN4)C
DMIECOF	IK	KSECQYDNQYAZMQ-AWEZNQCLSA-N
DMIECOF	IU	(2S)-N'-(3-bromophenyl)-N-cyano-2-methyl-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazine-1-carboximidamide
DMIECOF	DE	Discovery agent

DM8T6VG	ID	DM8T6VG
DM8T6VG	DN	PMID19831390C22m
DM8T6VG	HS	Investigative
DM8T6VG	SN	GTPL8153; BDBM50299619
DM8T6VG	DT	Small molecular drug
DM8T6VG	PC	44543082
DM8T6VG	MW	461.5
DM8T6VG	FM	C23H27N9O2
DM8T6VG	IC	InChI=1S/C23H27N9O2/c1-15-11-26-20-19(15)21(29-14-28-20)31-7-8-32(16(2)12-31)23(27-13-24)30-18-5-3-4-17(10-18)22(34)25-6-9-33/h3-5,10-11,14,16,33H,6-9,12H2,1-2H3,(H,25,34)(H,27,30)(H,26,28,29)/t16-/m0/s1
DM8T6VG	CS	C[C@H]1CN(CCN1C(=NC2=CC=CC(=C2)C(=O)NCCO)NC#N)C3=NC=NC4=C3C(=CN4)C
DM8T6VG	IK	BCNLLDVODACBHT-INIZCTEOSA-N
DM8T6VG	IU	3-[[(cyanoamino)-[(2S)-2-methyl-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl]methylidene]amino]-N-(2-hydroxyethyl)benzamide
DM8T6VG	DE	Discovery agent

DMEGPBS	ID	DMEGPBS
DMEGPBS	DN	PMID19854648C27
DMEGPBS	HS	Investigative
DMEGPBS	SN	GTPL8168; BDBM50414894
DMEGPBS	DT	Small molecular drug
DMEGPBS	PC	45375987
DMEGPBS	MW	404.2
DMEGPBS	FM	C19H15Cl2N3O3
DMEGPBS	IC	InChI=1S/C19H15Cl2N3O3/c1-26-14-6-9-10(7-15(14)27-2)18(25)16-17(9)23-24-19(16)22-8-11-12(20)4-3-5-13(11)21/h3-7H,8H2,1-2H3,(H2,22,23,24)
DMEGPBS	CS	COC1=C(C=C2C(=C1)C3=C(C2=O)C(=NN3)NCC4=C(C=CC=C4Cl)Cl)OC
DMEGPBS	IK	UUDNGLPFGYJJQX-UHFFFAOYSA-N
DMEGPBS	IU	3-[(2,6-dichlorophenyl)methylamino]-6,7-dimethoxy-1H-indeno[1,2-c]pyrazol-4-one
DMEGPBS	DE	Discovery agent

DMBTV20	ID	DMBTV20
DMBTV20	DN	PMID19899765C22
DMBTV20	HS	Investigative
DMBTV20	SN	GTPL6562; BDBM50303326
DMBTV20	DT	Small molecular drug
DMBTV20	PC	45485268
DMBTV20	MW	667.7
DMBTV20	FM	C37H38N3O7P
DMBTV20	IC	InChI=1S/C37H38N3O7P/c41-35(39-33(36(42)43)22-29-23-38-32-19-11-10-18-31(29)32)30(20-26-12-4-1-5-13-26)25-48(45,46)34(21-27-14-6-2-7-15-27)40-37(44)47-24-28-16-8-3-9-17-28/h1-19,23,30,33-34,38H,20-22,24-25H2,(H,39,41)(H,40,44)(H,42,43)(H,45,46)/t30?,33-,34+/m0/s1
DMBTV20	CS	C1=CC=C(C=C1)C[C@H](NC(=O)OCC2=CC=CC=C2)P(=O)(CC(CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)O)O
DMBTV20	IK	WWTBZEKOSBFBEM-SPWPXUSOSA-N
DMBTV20	IU	(2S)-2-[[2-benzyl-3-[hydroxy-[(1R)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMBTV20	DE	Discovery agent

DMI3PCZ	ID	DMI3PCZ
DMI3PCZ	DN	PMID1992138C8b
DMI3PCZ	HS	Investigative
DMI3PCZ	SN	GTPL2966; BDBM50011041
DMI3PCZ	DT	Small molecular drug
DMI3PCZ	PC	14229352
DMI3PCZ	MW	439.9
DMI3PCZ	FM	C25H23ClFNO3
DMI3PCZ	IC	InChI=1S/C25H23ClFNO3/c1-14(2)25-20(9-8-19-12-18(29)13-23(30)31-19)24(15-3-6-17(27)7-4-15)21-11-16(26)5-10-22(21)28-25/h3-11,14,18-19,29H,12-13H2,1-2H3/b9-8+/t18-,19-/m1/s1
DMI3PCZ	CS	CC(C)C1=NC2=C(C=C(C=C2)Cl)C(=C1/C=C/[C@@H]3C[C@H](CC(=O)O3)O)C4=CC=C(C=C4)F
DMI3PCZ	IK	FRJJJAKBRKABFA-TYFAACHXSA-N
DMI3PCZ	IU	(4R,6S)-6-[(E)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one
DMI3PCZ	DE	Discovery agent

DM2X1NY	ID	DM2X1NY
DM2X1NY	DN	PMID1992149C13
DM2X1NY	HS	Investigative
DM2X1NY	SN	GTPL2983
DM2X1NY	DT	Small molecular drug
DM2X1NY	PC	56947043
DM2X1NY	MW	456.9
DM2X1NY	FM	C25H24ClFNO4-
DM2X1NY	IC	InChI=1S/C25H25ClFNO4/c1-14(2)25-20(9-8-18(29)12-19(30)13-23(31)32)24(15-3-6-17(27)7-4-15)21-11-16(26)5-10-22(21)28-25/h3-11,14,18-19,29-30H,12-13H2,1-2H3,(H,31,32)/p-1/b9-8+/t18?,19-/m1/s1
DM2X1NY	CS	CC(C)C1=NC2=C(C=C(C=C2)Cl)C(=C1/C=C/C(C[C@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F
DM2X1NY	IK	FMCKOMPEFSASBD-FLRXWSLESA-M
DM2X1NY	IU	(E,3R)-7-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]-3,5-dihydroxyhept-6-enoate
DM2X1NY	DE	Discovery agent

DM9RENG	ID	DM9RENG
DM9RENG	DN	PMID1992149C9
DM9RENG	HS	Investigative
DM9RENG	SN	compound 10b [PMID: 1597859]; GTPL2984
DM9RENG	DT	Small molecular drug
DM9RENG	PC	14851316
DM9RENG	MW	440.5
DM9RENG	FM	C23H25FN4O4
DM9RENG	IC	InChI=1S/C23H25FN4O4/c1-14(2)22-19(8-7-17(29)11-18(30)12-21(31)32)23(15-3-5-16(24)6-4-15)28(27-22)20-13-25-9-10-26-20/h3-10,13-14,17-18,29-30H,11-12H2,1-2H3,(H,31,32)/b8-7+/t17-,18-/m1/s1
DM9RENG	CS	CC(C)C1=NN(C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=NC=CN=C3
DM9RENG	IK	DPRJPRMZJGWLHY-HNGSOEQISA-N
DM9RENG	IU	(E,3R,5S)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid
DM9RENG	DE	Discovery agent

DM3DCR9	ID	DM3DCR9
DM3DCR9	DN	PMID19931453C16m
DM3DCR9	HS	Investigative
DM3DCR9	SN	UNII-J5PMS063XX; J5PMS063XX; GTPL6429; ZINC45353419; BDBM50305056; 942510-68-1
DM3DCR9	DT	Small molecular drug
DM3DCR9	PC	23725699
DM3DCR9	MW	358.9
DM3DCR9	FM	C19H23ClN4O
DM3DCR9	IC	InChI=1S/C19H23ClN4O/c1-3-16-6-4-5-9-24(16)19(25)14-10-17(20)18(22-11-14)23-15-8-7-13(2)21-12-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,22,23)/t16-/m1/s1
DM3DCR9	CS	CC[C@@H]1CCCCN1C(=O)C2=CC(=C(N=C2)NC3=CN=C(C=C3)C)Cl
DM3DCR9	IK	QABUURICQJOWID-MRXNPFEDSA-N
DM3DCR9	IU	[5-chloro-6-[(6-methylpyridin-3-yl)amino]pyridin-3-yl]-[(2R)-2-ethylpiperidin-1-yl]methanone
DM3DCR9	CA	CAS 942510-68-1
DM3DCR9	DE	Discovery agent

DMDYZE5	ID	DMDYZE5
DMDYZE5	DN	PMID19954973C4
DMDYZE5	HS	Investigative
DMDYZE5	SN	GTPL8623; BDBM50305346
DMDYZE5	DT	Small molecular drug
DMDYZE5	PC	10286113
DMDYZE5	MW	275.3
DMDYZE5	FM	C14H17N3O3
DMDYZE5	IC	InChI=1S/C14H17N3O3/c15-6-7-20-13(14(18)19)8-11-9-17(10-16-11)12-4-2-1-3-5-12/h1-5,9-10,13H,6-8,15H2,(H,18,19)/t13-/m0/s1
DMDYZE5	CS	C1=CC=C(C=C1)N2C=C(N=C2)C[C@@H](C(=O)O)OCCN
DMDYZE5	IK	LVCATUGNENEDGZ-ZDUSSCGKSA-N
DMDYZE5	IU	(2S)-2-(2-aminoethoxy)-3-(1-phenylimidazol-4-yl)propanoic acid
DMDYZE5	DE	Discovery agent

DMMESBW	ID	DMMESBW
DMMESBW	DN	PMID20005102C1
DMMESBW	HS	Investigative
DMMESBW	SN	GTPL8181; BDBM50305878; B99
DMMESBW	DT	Small molecular drug
DMMESBW	PC	46225540
DMMESBW	MW	463.5
DMMESBW	FM	C28H25N5O2
DMMESBW	IC	InChI=1S/C28H25N5O2/c1-17-24-11-18(6-7-27(24)33-32-17)25-12-22(14-31-28(25)19-8-9-34-15-19)35-16-21(29)10-20-13-30-26-5-3-2-4-23(20)26/h2-9,11-15,21,30H,10,16,29H2,1H3,(H,32,33)/t21-/m0/s1
DMMESBW	CS	CC1=C2C=C(C=CC2=NN1)C3=C(N=CC(=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N)C6=COC=C6
DMMESBW	IK	XONRTPBYDAFIRW-NRFANRHFSA-N
DMMESBW	IU	(2S)-1-[6-(furan-3-yl)-5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxy-3-(1H-indol-3-yl)propan-2-amine
DMMESBW	DE	Discovery agent

DMV8ZFA	ID	DMV8ZFA
DMV8ZFA	DN	PMID20080612C1
DMV8ZFA	HS	Investigative
DMV8ZFA	SN	BAS 00486818; tg3-95-1; 301322-12-3; AC1LDROW; Oprea1_785181; Oprea1_405733; MLS000107338; GTPL5819; ZINC35938; MolPort-000-222-632; CHEBI:112974; HMS2485P23; CCG-17500; BDBM50016951; STK386484; AKOS000513935; MCULE-3137850852; SMR000111709; ST005800; KB-275480; SR-01000448413; SR-01000448413-1; F0817-0357; ethyl 2-(furan
DMV8ZFA	DT	Small molecular drug
DMV8ZFA	PC	673766
DMV8ZFA	MW	333.4
DMV8ZFA	FM	C17H19NO4S
DMV8ZFA	IC	InChI=1S/C17H19NO4S/c1-2-21-17(20)14-11-7-4-3-5-9-13(11)23-16(14)18-15(19)12-8-6-10-22-12/h6,8,10H,2-5,7,9H2,1H3,(H,18,19)
DMV8ZFA	CS	CCOC(=O)C1=C(SC2=C1CCCCC2)NC(=O)C3=CC=CO3
DMV8ZFA	IK	SCIMXCMXGZZKTB-UHFFFAOYSA-N
DMV8ZFA	IU	ethyl 2-(furan-2-carbonylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate
DMV8ZFA	CB	CHEBI:112974
DMV8ZFA	DE	Discovery agent

DMM49JO	ID	DMM49JO
DMM49JO	DN	PMID20121197C57
DMM49JO	HS	Investigative
DMM49JO	SN	GTPL6550; BDBM50307314
DMM49JO	DT	Small molecular drug
DMM49JO	PC	46233650
DMM49JO	MW	516.7
DMM49JO	FM	C29H32N4O3S
DMM49JO	IC	InChI=1S/C29H32N4O3S/c1-19(2)16-32-17-21-11-6-7-12-23(21)33-29(34)35-18-25(20-9-4-3-5-10-20)36-24-13-8-14-26-22(24)15-27(37-26)28(30)31/h3-15,19,25,32H,16-18H2,1-2H3,(H3,30,31)(H,33,34)
DMM49JO	CS	CC(C)CNCC1=CC=CC=C1NC(=O)OCC(C2=CC=CC=C2)OC3=C4C=C(SC4=CC=C3)C(=N)N
DMM49JO	IK	QGLTXLFHFVMPJH-UHFFFAOYSA-N
DMM49JO	IU	[2-[(2-carbamimidoyl-1-benzothiophen-4-yl)oxy]-2-phenylethyl] N-[2-[(2-methylpropylamino)methyl]phenyl]carbamate
DMM49JO	DE	Discovery agent

DM8NGEQ	ID	DM8NGEQ
DM8NGEQ	DN	PMID20167483C22e
DM8NGEQ	HS	Investigative
DM8NGEQ	SN	GTPL8504; BDBM50313751
DM8NGEQ	DT	Small molecular drug
DM8NGEQ	PC	46845425
DM8NGEQ	MW	376.5
DM8NGEQ	FM	C24H28N2O2
DM8NGEQ	IC	InChI=1S/C24H28N2O2/c1-4-24(2,3)15-19-16-25-22(26-19)14-11-17-9-12-18(13-10-17)20-7-5-6-8-21(20)23(27)28/h5-10,12-13,16H,4,11,14-15H2,1-3H3,(H,25,26)(H,27,28)
DM8NGEQ	CS	CCC(C)(C)CC1=CN=C(N1)CCC2=CC=C(C=C2)C3=CC=CC=C3C(=O)O
DM8NGEQ	IK	AXHVEQQLKVIZLO-UHFFFAOYSA-N
DM8NGEQ	IU	2-[4-[2-[5-(2,2-dimethylbutyl)-1H-imidazol-2-yl]ethyl]phenyl]benzoic acid
DM8NGEQ	DE	Discovery agent

DMKAZ1O	ID	DMKAZ1O
DMKAZ1O	DN	PMID20299227C12
DMKAZ1O	HS	Investigative
DMKAZ1O	SN	GTPL3134; BDBM50315412
DMKAZ1O	DT	Small molecular drug
DMKAZ1O	PC	46885682
DMKAZ1O	MW	392.24
DMKAZ1O	FM	C13H18N2O8P2
DMKAZ1O	IC	InChI=1S/C13H18N2O8P2/c16-24(17,18)11(25(19,20)21)8-4-5-9-22-13-12(14-23-15-13)10-6-2-1-3-7-10/h1-3,6-7,11H,4-5,8-9H2,(H2,16,17,18)(H2,19,20,21)
DMKAZ1O	CS	C1=CC=C(C=C1)C2=NON=C2OCCCCC(P(=O)(O)O)P(=O)(O)O
DMKAZ1O	IK	NPUHGRMCBDPTIW-UHFFFAOYSA-N
DMKAZ1O	IU	[5-[(4-phenyl-1,2,5-oxadiazol-3-yl)oxy]-1-phosphonopentyl]phosphonic acid
DMKAZ1O	DE	Discovery agent

DM9H6LZ	ID	DM9H6LZ
DM9H6LZ	DN	PMID20299227C20
DM9H6LZ	HS	Investigative
DM9H6LZ	SN	GTPL3133; BDBM50315414
DM9H6LZ	DT	Small molecular drug
DM9H6LZ	PC	46866079
DM9H6LZ	MW	472.3
DM9H6LZ	FM	C13H18N2O11P2S
DM9H6LZ	IC	InChI=1S/C13H18N2O11P2S/c16-13(27(17,18)19,28(20,21)22)8-4-5-9-25-11-12(15-26-14-11)29(23,24)10-6-2-1-3-7-10/h1-3,6-7,16H,4-5,8-9H2,(H2,17,18,19)(H2,20,21,22)
DM9H6LZ	CS	C1=CC=C(C=C1)S(=O)(=O)C2=NON=C2OCCCCC(O)(P(=O)(O)O)P(=O)(O)O
DM9H6LZ	IK	PSWFNEHHRVMWEJ-UHFFFAOYSA-N
DM9H6LZ	IU	[5-[[4-(benzenesulfonyl)-1,2,5-oxadiazol-3-yl]oxy]-1-hydroxy-1-phosphonopentyl]phosphonic acid
DM9H6LZ	DE	Discovery agent

DMLKFTE	ID	DMLKFTE
DMLKFTE	DN	PMID20346665C24
DMLKFTE	HS	Investigative
DMLKFTE	SN	GTPL6209; BDBM50316005
DMLKFTE	DT	Small molecular drug
DMLKFTE	PC	46866191
DMLKFTE	MW	324.4
DMLKFTE	FM	C15H12N6OS
DMLKFTE	IC	InChI=1S/C15H12N6OS/c1-7-2-4-8(5-3-7)21-6-18-10-9-12(16)19-15(17)20-13(9)23-11(10)14(21)22/h2-6H,1H3,(H4,16,17,19,20)
DMLKFTE	CS	CC1=CC=C(C=C1)N2C=NC3=C(C2=O)SC4=NC(=NC(=C34)N)N
DMLKFTE	IK	NGINYBBVZOLUBV-UHFFFAOYSA-N
DMLKFTE	IU	11,13-diamino-5-(4-methylphenyl)-8-thia-3,5,10,12-tetrazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMLKFTE	DE	Discovery agent

DMDKW6G	ID	DMDKW6G
DMDKW6G	DN	PMID20346665C27
DMDKW6G	HS	Investigative
DMDKW6G	SN	GTPL6210; BDBM50316008
DMDKW6G	DT	Small molecular drug
DMDKW6G	PC	46866192
DMDKW6G	MW	323.4
DMDKW6G	FM	C16H13N5OS
DMDKW6G	IC	InChI=1S/C16H13N5OS/c1-8-3-5-10(6-4-8)21-7-18-12-11-14(17)19-9(2)20-15(11)23-13(12)16(21)22/h3-7H,1-2H3,(H2,17,19,20)
DMDKW6G	CS	CC1=CC=C(C=C1)N2C=NC3=C(C2=O)SC4=NC(=NC(=C34)N)C
DMDKW6G	IK	RIMQNIZNDUNPQK-UHFFFAOYSA-N
DMDKW6G	IU	13-amino-11-methyl-5-(4-methylphenyl)-8-thia-3,5,10,12-tetrazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMDKW6G	DE	Discovery agent

DMCAXNU	ID	DMCAXNU
DMCAXNU	DN	PMID20363624C(+)17a
DMCAXNU	HS	Investigative
DMCAXNU	SN	GTPL5790; BDBM50318893
DMCAXNU	DT	Small molecular drug
DMCAXNU	PC	11672811
DMCAXNU	MW	188.19
DMCAXNU	FM	C8H8N6
DMCAXNU	IC	InChI=1S/C8H8N6/c1-3-2-5-6(4(1)3)9-10-7(5)8-11-13-14-12-8/h3-4H,1-2H2,(H,9,10)(H,11,12,13,14)
DMCAXNU	CS	C1C2C1C3=C(C2)C(=NN3)C4=NNN=N4
DMCAXNU	IK	DKSPRNJUDCWTID-UHFFFAOYSA-N
DMCAXNU	IU	7-(2H-tetrazol-5-yl)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene
DMCAXNU	DE	Discovery agent

DMA2Y74	ID	DMA2Y74
DMA2Y74	DN	PMID20409708C34
DMA2Y74	HS	Investigative
DMA2Y74	SN	GTPL6321; BDBM50318313
DMA2Y74	DT	Small molecular drug
DMA2Y74	PC	46830123
DMA2Y74	MW	350.4
DMA2Y74	FM	C21H22N2O3
DMA2Y74	IC	InChI=1S/C21H22N2O3/c1-21(2,3)16-7-9-18(10-8-16)25-14-19-13-23(20(24)26-19)17-6-4-5-15(11-17)12-22/h4-11,19H,13-14H2,1-3H3/t19-/m0/s1
DMA2Y74	CS	CC(C)(C)C1=CC=C(C=C1)OC[C@@H]2CN(C(=O)O2)C3=CC=CC(=C3)C#N
DMA2Y74	IK	YFJUDGZIRPWFBS-IBGZPJMESA-N
DMA2Y74	IU	3-[(5S)-5-[(4-tert-butylphenoxy)methyl]-2-oxo-1,3-oxazolidin-3-yl]benzonitrile
DMA2Y74	DE	Discovery agent

DMQFKBI	ID	DMQFKBI
DMQFKBI	DN	PMID20462760C22
DMQFKBI	HS	Investigative
DMQFKBI	SN	GTPL8205; BDBM50319635
DMQFKBI	DT	Small molecular drug
DMQFKBI	PC	24863112
DMQFKBI	MW	367.8
DMQFKBI	FM	C20H18ClN3O2
DMQFKBI	IC	InChI=1S/C20H18ClN3O2/c21-16-11-15-13(8-9-22-19(15)25)10-17(16)24-20(26)18(23-14-6-7-14)12-4-2-1-3-5-12/h1-5,8-11,14,18,23H,6-7H2,(H,22,25)(H,24,26)
DMQFKBI	CS	C1CC1NC(C2=CC=CC=C2)C(=O)NC3=C(C=C4C(=C3)C=CNC4=O)Cl
DMQFKBI	IK	SKYALJGMRAGHEN-UHFFFAOYSA-N
DMQFKBI	IU	N-(7-chloro-1-oxo-2H-isoquinolin-6-yl)-2-(cyclopropylamino)-2-phenylacetamide
DMQFKBI	DE	Discovery agent

DMBQAKO	ID	DMBQAKO
DMBQAKO	DN	PMID20471253C32
DMBQAKO	HS	Investigative
DMBQAKO	SN	GTPL8184; BDBM50319716; 3ND
DMBQAKO	DT	Small molecular drug
DMBQAKO	PC	46871820
DMBQAKO	MW	402.3
DMBQAKO	FM	C20H17Cl2N3O2
DMBQAKO	IC	InChI=1S/C20H17Cl2N3O2/c21-13-3-1-11(2-4-13)15-9-23-10-16(15)20(27)25-18-7-12-5-6-24-19(26)14(12)8-17(18)22/h1-8,15-16,23H,9-10H2,(H,24,26)(H,25,27)/t15-,16+/m0/s1
DMBQAKO	CS	C1[C@H]([C@@H](CN1)C(=O)NC2=C(C=C3C(=C2)C=CNC3=O)Cl)C4=CC=C(C=C4)Cl
DMBQAKO	IK	XBFAFSAUQFDEOK-JKSUJKDBSA-N
DMBQAKO	IU	(3S,4R)-N-(7-chloro-1-oxo-2H-isoquinolin-6-yl)-4-(4-chlorophenyl)pyrrolidine-3-carboxamide
DMBQAKO	DE	Discovery agent

DMQ918T	ID	DMQ918T
DMQ918T	DN	PMID20483621C5g
DMQ918T	HS	Investigative
DMQ918T	SN	GTPL8207; BDBM50321045
DMQ918T	DT	Small molecular drug
DMQ918T	PC	46906624
DMQ918T	MW	469.4
DMQ918T	FM	C24H26Cl2N6
DMQ918T	IC	InChI=1S/C24H26Cl2N6/c1-30-8-10-31(11-9-30)23-5-2-17(14-28-23)18-13-22-24(29-15-18)27-6-7-32(22)16-19-12-20(25)3-4-21(19)26/h2-5,12-15H,6-11,16H2,1H3,(H,27,29)
DMQ918T	CS	CN1CCN(CC1)C2=NC=C(C=C2)C3=CC4=C(NCCN4CC5=C(C=CC(=C5)Cl)Cl)N=C3
DMQ918T	IK	CSYSNPSPLOLFFI-UHFFFAOYSA-N
DMQ918T	IU	1-[(2,5-dichlorophenyl)methyl]-7-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-3,4-dihydro-2H-pyrido[2,3-b]pyrazine
DMQ918T	DE	Discovery agent

DML6OZR	ID	DML6OZR
DML6OZR	DN	PMID20483621C5m
DML6OZR	HS	Investigative
DML6OZR	SN	GTPL8206; BDBM50321053
DML6OZR	DT	Small molecular drug
DML6OZR	PC	46871638
DML6OZR	MW	584.1
DML6OZR	FM	C31H33ClF3N5O
DML6OZR	IC	InChI=1S/C31H33ClF3N5O/c32-25-7-8-27(31(33,34)35)24(17-25)20-40-16-11-36-29-28(40)18-23(19-37-29)21-3-5-22(6-4-21)30(41)39-14-9-26(10-15-39)38-12-1-2-13-38/h3-8,17-19,26H,1-2,9-16,20H2,(H,36,37)
DML6OZR	CS	C1CCN(C1)C2CCN(CC2)C(=O)C3=CC=C(C=C3)C4=CC5=C(NCCN5CC6=C(C=CC(=C6)Cl)C(F)(F)F)N=C4
DML6OZR	IK	JVVGHVJDZJSKRA-UHFFFAOYSA-N
DML6OZR	IU	[4-[1-[[5-chloro-2-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-2H-pyrido[2,3-b]pyrazin-7-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone
DML6OZR	CA	CAS 957194-90-0
DML6OZR	DE	Discovery agent

DM2BUKP	ID	DM2BUKP
DM2BUKP	DN	PMID20483621C5n
DM2BUKP	HS	Investigative
DM2BUKP	SN	GTPL8208; BDBM50321054
DM2BUKP	DT	Small molecular drug
DM2BUKP	PC	46871653
DM2BUKP	MW	488.9
DM2BUKP	FM	C24H24ClF3N6
DM2BUKP	IC	InChI=1S/C24H24ClF3N6/c25-19-1-2-20(24(26,27)28)18(11-19)15-34-10-7-31-23-21(34)12-17(14-32-23)16-3-4-30-22(13-16)33-8-5-29-6-9-33/h1-4,11-14,29H,5-10,15H2,(H,31,32)
DM2BUKP	CS	C1CN(CCN1)C2=NC=CC(=C2)C3=CC4=C(NCCN4CC5=C(C=CC(=C5)Cl)C(F)(F)F)N=C3
DM2BUKP	IK	AHZCYZMNFBGXAC-UHFFFAOYSA-N
DM2BUKP	IU	1-[[5-chloro-2-(trifluoromethyl)phenyl]methyl]-7-(2-piperazin-1-ylpyridin-4-yl)-3,4-dihydro-2H-pyrido[2,3-b]pyrazine
DM2BUKP	DE	Discovery agent

DMI30V7	ID	DMI30V7
DMI30V7	DN	PMID20527968-compound-6577871
DMI30V7	HS	Investigative
DMI30V7	SN	PMID20527968-C-6577871
DMI30V7	TC	Antiviral Agents
DMI30V7	DT	Small molecular drug
DMI30V7	DE	Severe acute respiratory syndrome (SARS)

DMS21ZP	ID	DMS21ZP
DMS21ZP	DN	PMID20598884C8
DMS21ZP	HS	Investigative
DMS21ZP	SN	GTPL6436; BDBM50323308
DMS21ZP	DT	Small molecular drug
DMS21ZP	PC	46911384
DMS21ZP	MW	261.279
DMS21ZP	FM	C12H8FN3OS
DMS21ZP	IC	InChI=1S/C12H8FN3OS/c1-7-6-18-12(15-7)16-11(17)9-2-8(5-14)3-10(13)4-9/h2-4,6H,1H3,(H,15,16,17)
DMS21ZP	CS	CC1=CSC(=N1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMS21ZP	IK	KTQZJPKEGPXLRL-UHFFFAOYSA-N
DMS21ZP	IU	3-cyano-5-fluoro-N-(4-methyl-1,3-thiazol-2-yl)benzamide
DMS21ZP	DE	Discovery agent

DMN2HXL	ID	DMN2HXL
DMN2HXL	DN	PMID20615702C8f
DMN2HXL	HS	Investigative
DMN2HXL	SN	GTPL5793; BDBM50323398
DMN2HXL	DT	Small molecular drug
DMN2HXL	PC	12003694
DMN2HXL	MW	232.24
DMN2HXL	FM	C11H12N4O2
DMN2HXL	IC	InChI=1S/C11H12N4O2/c1-15-9(2-3-12-15)6-4-7-8(5-6)13-14-10(7)11(16)17/h2-3,6H,4-5H2,1H3,(H,13,14)(H,16,17)
DMN2HXL	CS	CN1C(=CC=N1)C2CC3=C(C2)NN=C3C(=O)O
DMN2HXL	IK	ZAJBYTSUTBCMRM-UHFFFAOYSA-N
DMN2HXL	IU	5-(2-methylpyrazol-3-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylic acid
DMN2HXL	DE	Discovery agent

DMFHS4V	ID	DMFHS4V
DMFHS4V	DN	PMID20638279C11
DMFHS4V	HS	Investigative
DMFHS4V	SN	TCN 238; 125404-04-8; TCN238; GTPL6235; DTXSID00677236; MolPort-018-616-308; ZINC58593499; BDBM50323546; AKOS000278717; CS-6515; 53924-99-5; KB-69615; HY-14419; B7629; J-005224
DMFHS4V	DT	Small molecular drug
DMFHS4V	PC	46911068
DMFHS4V	MW	197.24
DMFHS4V	FM	C12H11N3
DMFHS4V	IC	InChI=1S/C12H11N3/c13-12-14-9-8-11(15-12)7-6-10-4-2-1-3-5-10/h1-9H,(H2,13,14,15)/b7-6+
DMFHS4V	CS	C1=CC=C(C=C1)/C=C/C2=NC(=NC=C2)N
DMFHS4V	IK	LNUXNUNUGIHCPA-VOTSOKGWSA-N
DMFHS4V	IU	4-[(E)-2-phenylethenyl]pyrimidin-2-amine
DMFHS4V	CA	CAS 125404-04-8
DMFHS4V	DE	Discovery agent

DMKFJP2	ID	DMKFJP2
DMKFJP2	DN	PMID20638279C7
DMKFJP2	HS	Investigative
DMKFJP2	SN	compound 7 [PMID: 20180624]; 1105039-00-6; GTPL6232; BDBM50353293
DMKFJP2	DT	Small molecular drug
DMKFJP2	PC	42645487
DMKFJP2	MW	243.29
DMKFJP2	FM	C11H9N5S
DMKFJP2	IC	InChI=1S/C11H9N5S/c1-2-4-12-10(3-1)16-11-15-9(7-17-11)8-5-13-14-6-8/h1-7H,(H,13,14)(H,12,15,16)
DMKFJP2	CS	C1=CC=NC(=C1)NC2=NC(=CS2)C3=CNN=C3
DMKFJP2	IK	WIILZWDTWZFGNO-UHFFFAOYSA-N
DMKFJP2	IU	4-(1H-pyrazol-4-yl)-N-pyridin-2-yl-1,3-thiazol-2-amine
DMKFJP2	DE	Discovery agent

DMWZK9U	ID	DMWZK9U
DMWZK9U	DN	PMID20684603C24dd
DMWZK9U	HS	Investigative
DMWZK9U	SN	GTPL8550; BDBM50324512
DMWZK9U	DT	Small molecular drug
DMWZK9U	PC	46900258
DMWZK9U	MW	455.3
DMWZK9U	FM	C22H20Cl2N6O
DMWZK9U	IC	InChI=1S/C22H20Cl2N6O/c1-13-17(11-25)20(16-6-5-14(23)10-18(16)24)30-12-19(29-22(30)28-13)21(31)27-9-7-15-4-2-3-8-26-15/h2-6,8,10,12H,7,9,11,25H2,1H3,(H,27,31)
DMWZK9U	CS	CC1=NC2=NC(=CN2C(=C1CN)C3=C(C=C(C=C3)Cl)Cl)C(=O)NCCC4=CC=CC=N4
DMWZK9U	IK	JGJABGSOYWQCSC-UHFFFAOYSA-N
DMWZK9U	IU	6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methyl-N-(2-pyridin-2-ylethyl)imidazo[1,2-a]pyrimidine-2-carboxamide
DMWZK9U	DE	Discovery agent

DMVUEZI	ID	DMVUEZI
DMVUEZI	DN	PMID20684608C35
DMVUEZI	HS	Investigative
DMVUEZI	SN	GTPL8209; BDBM50324574
DMVUEZI	DT	Small molecular drug
DMVUEZI	PC	46864283
DMVUEZI	MW	475.6
DMVUEZI	FM	C27H33N5O3
DMVUEZI	IC	InChI=1S/C27H33N5O3/c1-32-9-7-18(8-10-32)17-35-26-13-19(22-15-29-30-16-22)4-6-24(26)31-27(33)25-12-21-11-23(34-2)5-3-20(21)14-28-25/h3-6,11,13,15-16,18,25,28H,7-10,12,14,17H2,1-2H3,(H,29,30)(H,31,33)/t25-/m1/s1
DMVUEZI	CS	CN1CCC(CC1)COC2=C(C=CC(=C2)C3=CNN=C3)NC(=O)[C@H]4CC5=C(CN4)C=CC(=C5)OC
DMVUEZI	IK	GFWDPXHTWJXOEI-RUZDIDTESA-N
DMVUEZI	IU	(3R)-6-methoxy-N-[2-[(1-methylpiperidin-4-yl)methoxy]-4-(1H-pyrazol-4-yl)phenyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
DMVUEZI	DE	Discovery agent

DMKVONZ	ID	DMKVONZ
DMKVONZ	DN	PMID20690647C4b
DMKVONZ	HS	Investigative
DMKVONZ	SN	Cbz-Leu-D,L-Abu-CONH-(CH(2))(3)-2-methoxyadenin-9-yl; GTPL8614; BDBM50326300
DMKVONZ	DT	Small molecular drug
DMKVONZ	PC	25195974
DMKVONZ	MW	582.7
DMKVONZ	FM	C28H38N8O6
DMKVONZ	IC	InChI=1S/C28H38N8O6/c1-5-19(32-25(38)20(14-17(2)3)33-28(40)42-15-18-10-7-6-8-11-18)22(37)26(39)30-12-9-13-36-16-31-21-23(29)34-27(41-4)35-24(21)36/h6-8,10-11,16-17,19-20H,5,9,12-15H2,1-4H3,(H,30,39)(H,32,38)(H,33,40)(H2,29,34,35)/t19?,20-/m0/s1
DMKVONZ	CS	CCC(C(=O)C(=O)NCCCN1C=NC2=C(N=C(N=C21)OC)N)NC(=O)[C@H](CC(C)C)NC(=O)OCC3=CC=CC=C3
DMKVONZ	IK	MBPXUEHDROHPFW-ANYOKISRSA-N
DMKVONZ	IU	benzyl N-[(2S)-1-[[1-[3-(6-amino-2-methoxypurin-9-yl)propylamino]-1,2-dioxopentan-3-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate
DMKVONZ	DE	Discovery agent

DMRWZX6	ID	DMRWZX6
DMRWZX6	DN	PMID20690647C5a
DMRWZX6	HS	Investigative
DMRWZX6	SN	Cbz-Leu-D,L-Phe-CONH-(CH(2))(3)-adenin-9-yl; GTPL8615; BDBM50326304
DMRWZX6	DT	Small molecular drug
DMRWZX6	PC	46930721
DMRWZX6	MW	614.7
DMRWZX6	FM	C32H38N8O5
DMRWZX6	IC	InChI=1S/C32H38N8O5/c1-21(2)16-25(39-32(44)45-18-23-12-7-4-8-13-23)30(42)38-24(17-22-10-5-3-6-11-22)27(41)31(43)34-14-9-15-40-20-37-26-28(33)35-19-36-29(26)40/h3-8,10-13,19-21,24-25H,9,14-18H2,1-2H3,(H,34,43)(H,38,42)(H,39,44)(H2,33,35,36)/t24?,25-/m0/s1
DMRWZX6	CS	CC(C)C[C@@H](C(=O)NC(CC1=CC=CC=C1)C(=O)C(=O)NCCCN2C=NC3=C(N=CN=C32)N)NC(=O)OCC4=CC=CC=C4
DMRWZX6	IK	OVLNPOAZKHQAAD-BBMPLOMVSA-N
DMRWZX6	IU	benzyl N-[(2S)-1-[[4-[3-(6-aminopurin-9-yl)propylamino]-3,4-dioxo-1-phenylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate
DMRWZX6	DE	Discovery agent

DM0W6C9	ID	DM0W6C9
DM0W6C9	DN	PMID20809633C29b
DM0W6C9	HS	Investigative
DM0W6C9	SN	GTPL6430
DM0W6C9	DT	Small molecular drug
DM0W6C9	PC	73755220
DM0W6C9	MW	333.4
DM0W6C9	FM	C20H16FN3O
DM0W6C9	IC	InChI=1S/C20H16FN3O/c1-2-14-10-15(21)12-16(11-14)24-9-5-7-19-18(13-24)23-20(25-19)17-6-3-4-8-22-17/h1,3-4,6,8,10-12H,5,7,9,13H2
DM0W6C9	CS	C#CC1=CC(=CC(=C1)F)N2CCCC3=C(C2)N=C(O3)C4=CC=CC=N4
DM0W6C9	IK	MVXAKOGJWVQPKC-UHFFFAOYSA-N
DM0W6C9	IU	5-(3-ethynyl-5-fluorophenyl)-2-pyridin-2-yl-4,6,7,8-tetrahydro-[1,3]oxazolo[4,5-c]azepine
DM0W6C9	DE	Discovery agent

DMNEB6J	ID	DMNEB6J
DMNEB6J	DN	PMID20855207C25
DMNEB6J	HS	Investigative
DMNEB6J	SN	GTPL8159; BDBM50329197
DMNEB6J	DT	Small molecular drug
DMNEB6J	PC	46868971
DMNEB6J	MW	438.6
DMNEB6J	FM	C21H26N8OS
DMNEB6J	IC	InChI=1S/C21H26N8OS/c1-12-9-29-18(16-6-23-24-7-16)8-22-21(29)20(25-12)26-19-5-17(27-31-19)15(4)28-10-13(2)30-14(3)11-28/h5-9,13-15H,10-11H2,1-4H3,(H,23,24)(H,25,26)/t13-,14+,15-/m1/s1
DMNEB6J	CS	C[C@@H]1CN(C[C@@H](O1)C)[C@H](C)C2=NSC(=C2)NC3=NC(=CN4C3=NC=C4C5=CNN=C5)C
DMNEB6J	IK	QBWKPGNFQQJGFY-QLFBSQMISA-N
DMNEB6J	IU	3-[(1R)-1-[(2S,6R)-2,6-dimethylmorpholin-4-yl]ethyl]-N-[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine
DMNEB6J	DE	Discovery agent

DMVHR3Z	ID	DMVHR3Z
DMVHR3Z	DN	PMID20873740C18
DMVHR3Z	HS	Investigative
DMVHR3Z	SN	GTPL8191; BDBM50329427; TL80090042
DMVHR3Z	DT	Small molecular drug
DMVHR3Z	PC	24809764
DMVHR3Z	MW	279.3
DMVHR3Z	FM	C15H13N5O
DMVHR3Z	IC	InChI=1S/C15H13N5O/c16-14(21)10-8-12(11-6-7-18-15(17)20-11)19-13(10)9-4-2-1-3-5-9/h1-8,19H,(H2,16,21)(H2,17,18,20)
DMVHR3Z	CS	C1=CC=C(C=C1)C2=C(C=C(N2)C3=NC(=NC=C3)N)C(=O)N
DMVHR3Z	IK	VOQXQYXTZZHYBF-UHFFFAOYSA-N
DMVHR3Z	IU	5-(2-aminopyrimidin-4-yl)-2-phenyl-1H-pyrrole-3-carboxamide
DMVHR3Z	DE	Discovery agent

DMUGWO6	ID	DMUGWO6
DMUGWO6	DN	PMID20936789C31
DMUGWO6	HS	Investigative
DMUGWO6	SN	GTPL8180; BDBM50330575
DMUGWO6	DT	Small molecular drug
DMUGWO6	PC	49837564
DMUGWO6	MW	416.5
DMUGWO6	FM	C21H28N4O5
DMUGWO6	IC	InChI=1S/C21H28N4O5/c1-11-12(2)25(7-6-14(11)21(26)27)20-19(22)23-10-15(24-20)13-8-16(28-3)18(30-5)17(9-13)29-4/h8-12,14H,6-7H2,1-5H3,(H2,22,23)(H,26,27)/t11-,12+,14+/m0/s1
DMUGWO6	CS	C[C@H]1[C@H](N(CC[C@H]1C(=O)O)C2=NC(=CN=C2N)C3=CC(=C(C(=C3)OC)OC)OC)C
DMUGWO6	IK	YPKLAWUGDWZBMV-OUCADQQQSA-N
DMUGWO6	IU	(2R,3R,4R)-1-[3-amino-6-(3,4,5-trimethoxyphenyl)pyrazin-2-yl]-2,3-dimethylpiperidine-4-carboxylic acid
DMUGWO6	DE	Discovery agent

DM02YSE	ID	DM02YSE
DM02YSE	DN	PMID20947351C16
DM02YSE	HS	Investigative
DM02YSE	SN	GTPL7057; BDBM50331106
DM02YSE	DT	Small molecular drug
DM02YSE	PC	50908800
DM02YSE	MW	371.5
DM02YSE	FM	C18H33N3O5
DM02YSE	IC	InChI=1S/C18H33N3O5/c1-18(2,3)26-17(24)20-14(11-5-4-6-12-15(22)21-25)16(23)19-13-9-7-8-10-13/h13-14,25H,4-12H2,1-3H3,(H,19,23)(H,20,24)(H,21,22)/t14-/m0/s1
DM02YSE	CS	CC(C)(C)OC(=O)N[C@@H](CCCCCC(=O)NO)C(=O)NC1CCCC1
DM02YSE	IK	YKINZQJOQFMNPU-AWEZNQCLSA-N
DM02YSE	IU	tert-butyl N-[(2S)-1-(cyclopentylamino)-8-(hydroxyamino)-1,8-dioxooctan-2-yl]carbamate
DM02YSE	DE	Discovery agent

DMVPW1G	ID	DMVPW1G
DMVPW1G	DN	PMID21123062C27
DMVPW1G	HS	Investigative
DMVPW1G	SN	GTPL8210; BDBM50334085
DMVPW1G	DT	Small molecular drug
DMVPW1G	PC	50942314
DMVPW1G	MW	511
DMVPW1G	FM	C26H28ClFN6O2
DMVPW1G	IC	InChI=1S/C26H28ClFN6O2/c1-5-34-20-13-15(9-10-17(20)26(2,3)12-11-21(34)35)31-25-30-14-18(27)23(33-25)32-22-16(24(36)29-4)7-6-8-19(22)28/h6-10,13-14H,5,11-12H2,1-4H3,(H,29,36)(H2,30,31,32,33)
DMVPW1G	CS	CCN1C(=O)CCC(C2=C1C=C(C=C2)NC3=NC=C(C(=N3)NC4=C(C=CC=C4F)C(=O)NC)Cl)(C)C
DMVPW1G	IK	KHBUKOVUBUJCGM-UHFFFAOYSA-N
DMVPW1G	IU	2-[[5-chloro-2-[(1-ethyl-5,5-dimethyl-2-oxo-3,4-dihydro-1-benzazepin-8-yl)amino]pyrimidin-4-yl]amino]-3-fluoro-N-methylbenzamide
DMVPW1G	DE	Discovery agent

DM7I341	ID	DM7I341
DM7I341	DN	PMID21155570C14
DM7I341	HS	Investigative
DM7I341	SN	GTPL6323; BDBM50335242
DM7I341	DT	Small molecular drug
DM7I341	PC	46182736
DM7I341	MW	480
DM7I341	FM	C26H22ClNO4S
DM7I341	IC	InChI=1S/C26H22ClNO4S/c27-23-11-8-18(13-22(23)26(30)31)17-5-3-4-16(12-17)15-32-20-9-10-21-24(14-20)33-28(25(21)29)19-6-1-2-7-19/h3-5,8-14,19H,1-2,6-7,15H2,(H,30,31)
DM7I341	CS	C1CCC(C1)N2C(=O)C3=C(S2)C=C(C=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O
DM7I341	IK	ZQBPXBADOJMCRU-UHFFFAOYSA-N
DM7I341	IU	2-chloro-5-[3-[(2-cyclopentyl-3-oxo-1,2-benzothiazol-6-yl)oxymethyl]phenyl]benzoic acid
DM7I341	DE	Discovery agent

DM1BQY3	ID	DM1BQY3
DM1BQY3	DN	PMID21185185C21
DM1BQY3	HS	Investigative
DM1BQY3	SN	GTPL5789; BDBM50342520
DM1BQY3	DT	Small molecular drug
DM1BQY3	PC	53238781
DM1BQY3	MW	389.4
DM1BQY3	FM	C18H20FN5O4
DM1BQY3	IC	InChI=1S/C18H20FN5O4/c1-9-2-4-11(18(26)27)14(6-9)22-17(25)12(20)7-15-23-16(24-28-15)13-5-3-10(19)8-21-13/h3,5,8-9,12H,2,4,6-7,20H2,1H3,(H,22,25)(H,26,27)/t9-,12+/m1/s1
DM1BQY3	CS	C[C@@H]1CCC(=C(C1)NC(=O)[C@H](CC2=NC(=NO2)C3=NC=C(C=C3)F)N)C(=O)O
DM1BQY3	IK	CDYGJIFOATYSNF-SKDRFNHKSA-N
DM1BQY3	IU	(4R)-2-[[(2S)-2-amino-3-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]propanoyl]amino]-4-methylcyclohexene-1-carboxylic acid
DM1BQY3	DE	Discovery agent

DMEFUZW	ID	DMEFUZW
DMEFUZW	DN	PMID21273063C1
DMEFUZW	HS	Investigative
DMEFUZW	SN	GTPL5745; BDBM50342664
DMEFUZW	DT	Small molecular drug
DMEFUZW	PC	54580880
DMEFUZW	MW	345.5
DMEFUZW	FM	C20H31N3O2
DMEFUZW	IC	InChI=1S/C20H31N3O2/c1-20(2,3)25-19(24)23-13-8-17(9-14-23)16-6-11-22(12-7-16)18-5-4-10-21-15-18/h4-5,10,15-17H,6-9,11-14H2,1-3H3
DMEFUZW	CS	CC(C)(C)OC(=O)N1CCC(CC1)C2CCN(CC2)C3=CN=CC=C3
DMEFUZW	IK	CRZGKAWVJIDZPZ-UHFFFAOYSA-N
DMEFUZW	IU	tert-butyl 4-(1-pyridin-3-ylpiperidin-4-yl)piperidine-1-carboxylate
DMEFUZW	DE	Discovery agent

DMFYJ6O	ID	DMFYJ6O
DMFYJ6O	DN	PMID21273063C36
DMFYJ6O	HS	Investigative
DMFYJ6O	SN	GTPL5747
DMFYJ6O	DT	Small molecular drug
DMFYJ6O	PC	73755153
DMFYJ6O	MW	376.5
DMFYJ6O	FM	C22H28N6
DMFYJ6O	IC	InChI=1S/C22H28N6/c1-4-20-25-16(2)13-21(26-20)27-9-5-18(6-10-27)19-7-11-28(12-8-19)22-15-23-17(3)14-24-22/h1,13-15,18-19H,5-12H2,2-3H3
DMFYJ6O	CS	CC1=CC(=NC(=N1)C#C)N2CCC(CC2)C3CCN(CC3)C4=NC=C(N=C4)C
DMFYJ6O	IK	GIKAEVLPYSTAGY-UHFFFAOYSA-N
DMFYJ6O	IU	2-ethynyl-4-methyl-6-[4-[1-(5-methylpyrazin-2-yl)piperidin-4-yl]piperidin-1-yl]pyrimidine
DMFYJ6O	DE	Discovery agent

DMDCUYB	ID	DMDCUYB
DMDCUYB	DN	PMID21273063C58
DMDCUYB	HS	Investigative
DMDCUYB	SN	GTPL5748; BDBM50342699
DMDCUYB	DT	Small molecular drug
DMDCUYB	PC	53235534
DMDCUYB	MW	437
DMDCUYB	FM	C20H25ClN4O3S
DMDCUYB	IC	InChI=1S/C20H25ClN4O3S/c1-29(26,27)17-2-3-19(22-13-17)28-9-6-15-10-18(15)14-4-7-25(8-5-14)20-23-11-16(21)12-24-20/h2-3,11-15,18H,4-10H2,1H3/t15-,18-/m1/s1
DMDCUYB	CS	CS(=O)(=O)C1=CN=C(C=C1)OCC[C@@H]2C[C@@H]2C3CCN(CC3)C4=NC=C(C=N4)Cl
DMDCUYB	IK	XFJBGINZIMNZBW-CRAIPNDOSA-N
DMDCUYB	IU	5-chloro-2-[4-[(1R,2S)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine
DMDCUYB	DE	Discovery agent

DMYBV8Q	ID	DMYBV8Q
DMYBV8Q	DN	PMID21277783C7
DMYBV8Q	HS	Investigative
DMYBV8Q	SN	citibrasine; Citibrasine; Citbrasine; GTPL8561; BDBM50336482
DMYBV8Q	DT	Small molecular drug
DMYBV8Q	PC	19093029
DMYBV8Q	MW	331.32
DMYBV8Q	FM	C17H17NO6
DMYBV8Q	IC	InChI=1S/C17H17NO6/c1-18-11-8(6-5-7-9(11)19)13(20)10-12(18)15(22-2)17(24-4)16(23-3)14(10)21/h5-7,19,21H,1-4H3
DMYBV8Q	CS	CN1C2=C(C=CC=C2O)C(=O)C3=C1C(=C(C(=C3O)OC)OC)OC
DMYBV8Q	IK	QYPQTPVQPNLXHV-UHFFFAOYSA-N
DMYBV8Q	IU	1,5-dihydroxy-2,3,4-trimethoxy-10-methylacridin-9-one
DMYBV8Q	CA	CAS 86680-34-4
DMYBV8Q	DE	Discovery agent

DM0DNSV	ID	DM0DNSV
DM0DNSV	DN	PMID21295468C47
DM0DNSV	HS	Investigative
DM0DNSV	SN	GTPL6406; BDBM50337535; VU0459181-1
DM0DNSV	DT	Small molecular drug
DM0DNSV	PC	51003564
DM0DNSV	MW	256.3
DM0DNSV	FM	C15H16N2O2
DM0DNSV	IC	InChI=1S/C15H16N2O2/c1-17-7-8-18-14-9-12(10-16-15(14)17)11-19-13-5-3-2-4-6-13/h2-6,9-10H,7-8,11H2,1H3
DM0DNSV	CS	CN1CCOC2=C1N=CC(=C2)COC3=CC=CC=C3
DM0DNSV	IK	XAGOQHLVLYAAMO-UHFFFAOYSA-N
DM0DNSV	IU	4-methyl-7-(phenoxymethyl)-2,3-dihydropyrido[3,2-b][1,4]oxazine
DM0DNSV	DE	Discovery agent

DMTOM3E	ID	DMTOM3E
DMTOM3E	DN	PMID21310611C3
DMTOM3E	HS	Investigative
DMTOM3E	SN	GTPL5724; BDBM50337887
DMTOM3E	DT	Small molecular drug
DMTOM3E	PC	51346816
DMTOM3E	MW	416.4
DMTOM3E	FM	C20H24F4N2O3
DMTOM3E	IC	InChI=1S/C20H24F4N2O3/c1-20(6-7-20)29-19(28)26-8-4-12(5-9-26)16(23)11-25-17(27)10-13-14(21)2-3-15(22)18(13)24/h2-3,12,16H,4-11H2,1H3,(H,25,27)/t16-/m1/s1
DMTOM3E	CS	CC1(CC1)OC(=O)N2CCC(CC2)[C@@H](CNC(=O)CC3=C(C=CC(=C3F)F)F)F
DMTOM3E	IK	QCIKTRZVLCLGFT-MRXNPFEDSA-N
DMTOM3E	IU	(1-methylcyclopropyl) 4-[(1S)-1-fluoro-2-[[2-(2,3,6-trifluorophenyl)acetyl]amino]ethyl]piperidine-1-carboxylate
DMTOM3E	DE	Discovery agent

DM9YVPU	ID	DM9YVPU
DM9YVPU	DN	PMID21444206C23
DM9YVPU	HS	Investigative
DM9YVPU	SN	GTPL5740; BDBM50343444
DM9YVPU	DT	Small molecular drug
DM9YVPU	PC	54582152
DM9YVPU	MW	507.5
DM9YVPU	FM	C22H26FN5O6S
DM9YVPU	IC	InChI=1S/C22H26FN5O6S/c1-22(2,3)34-21(30)27-9-7-13(8-10-27)33-19-17-18(24-12-25-19)28(20(29)26-17)16-6-5-14(11-15(16)23)35(4,31)32/h5-6,11-13H,7-10H2,1-4H3,(H,26,29)
DM9YVPU	CS	CC(C)(C)OC(=O)N1CCC(CC1)OC2=NC=NC3=C2NC(=O)N3C4=C(C=C(C=C4)S(=O)(=O)C)F
DM9YVPU	IK	AXLNAZYMBNKFJO-UHFFFAOYSA-N
DM9YVPU	IU	tert-butyl 4-[[9-(2-fluoro-4-methylsulfonylphenyl)-8-oxo-7H-purin-6-yl]oxy]piperidine-1-carboxylate
DM9YVPU	DE	Discovery agent

DMN50B9	ID	DMN50B9
DMN50B9	DN	PMID21444206C3a
DMN50B9	HS	Investigative
DMN50B9	SN	GTPL5737; BDBM50343447; 142831-EP2292620A2; 142831-EP2287165A2; 142831-EP2287166A2
DMN50B9	DT	Small molecular drug
DMN50B9	PC	11282871
DMN50B9	MW	473.5
DMN50B9	FM	C22H27N5O5S
DMN50B9	IC	InChI=1S/C22H27N5O5S/c1-22(2,3)32-21(28)26-11-9-16(10-12-26)31-20-18-13-25-27(19(18)23-14-24-20)15-5-7-17(8-6-15)33(4,29)30/h5-8,13-14,16H,9-12H2,1-4H3
DMN50B9	CS	CC(C)(C)OC(=O)N1CCC(CC1)OC2=NC=NC3=C2C=NN3C4=CC=C(C=C4)S(=O)(=O)C
DMN50B9	IK	LZCNLEZPKDPKSO-UHFFFAOYSA-N
DMN50B9	IU	tert-butyl 4-[1-(4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate
DMN50B9	DE	Discovery agent

DMM1YBE	ID	DMM1YBE
DMM1YBE	DN	PMID21444206C3j
DMM1YBE	HS	Investigative
DMM1YBE	SN	GTPL5738; BDBM50343446; 142893-EP2287165A2; 142893-EP2292620A2; 142893-EP2287166A2
DMM1YBE	DT	Small molecular drug
DMM1YBE	PC	53630394
DMM1YBE	MW	491.5
DMM1YBE	FM	C22H26FN5O5S
DMM1YBE	IC	InChI=1S/C22H26FN5O5S/c1-22(2,3)33-21(29)27-9-7-14(8-10-27)32-20-16-12-26-28(19(16)24-13-25-20)18-6-5-15(11-17(18)23)34(4,30)31/h5-6,11-14H,7-10H2,1-4H3
DMM1YBE	CS	CC(C)(C)OC(=O)N1CCC(CC1)OC2=NC=NC3=C2C=NN3C4=C(C=C(C=C4)S(=O)(=O)C)F
DMM1YBE	IK	FEAQKOJMPVAIBR-UHFFFAOYSA-N
DMM1YBE	IU	tert-butyl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate
DMM1YBE	DE	Discovery agent

DMR21YD	ID	DMR21YD
DMR21YD	DN	PMID21444206C8g
DMR21YD	HS	Investigative
DMR21YD	SN	GTPL5739; BDBM50343443; 142925-EP2287165A2; 142925-EP2287166A2; 142925-EP2292620A2
DMR21YD	DT	Small molecular drug
DMR21YD	PC	53630410
DMR21YD	MW	507.6
DMR21YD	FM	C22H26FN5O4S2
DMR21YD	IC	InChI=1S/C22H26FN5O4S2/c1-22(2,3)32-21(29)27-9-7-14(8-10-27)33-20-16-12-26-28(19(16)24-13-25-20)18-6-5-15(11-17(18)23)34(4,30)31/h5-6,11-14H,7-10H2,1-4H3
DMR21YD	CS	CC(C)(C)OC(=O)N1CCC(CC1)SC2=NC=NC3=C2C=NN3C4=C(C=C(C=C4)S(=O)(=O)C)F
DMR21YD	IK	KRCCTTRJUJRZKA-UHFFFAOYSA-N
DMR21YD	IU	tert-butyl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]sulfanylpiperidine-1-carboxylate
DMR21YD	CA	CAS 832715-08-9
DMR21YD	DE	Discovery agent

DMFUQIT	ID	DMFUQIT
DMFUQIT	DN	PMID21493067C1d
DMFUQIT	HS	Investigative
DMFUQIT	SN	GTPL8123; BDBM50343726
DMFUQIT	DT	Small molecular drug
DMFUQIT	PC	53232451
DMFUQIT	MW	355.3
DMFUQIT	FM	C17H15F2N7
DMFUQIT	IC	InChI=1S/C17H15F2N7/c1-9-5-15(26-25-9)23-17-13(19)6-11(7-20)16(24-17)22-10(2)14-4-3-12(18)8-21-14/h3-6,8,10H,1-2H3,(H3,22,23,24,25,26)/t10-/m0/s1
DMFUQIT	CS	CC1=CC(=NN1)NC2=C(C=C(C(=N2)N[C@@H](C)C3=NC=C(C=C3)F)C#N)F
DMFUQIT	IK	HIHOEGPXVVKJPP-JTQLQIEISA-N
DMFUQIT	IU	5-fluoro-2-[[(1S)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile
DMFUQIT	DE	Discovery agent

DMUMYTB	ID	DMUMYTB
DMUMYTB	DN	PMID2153213C13b
DMUMYTB	HS	Investigative
DMUMYTB	SN	GTPL3005; BDBM50013211
DMUMYTB	DT	Small molecular drug
DMUMYTB	PC	56947025
DMUMYTB	MW	438.5
DMUMYTB	FM	C26H29FNO4-
DMUMYTB	IC	InChI=1S/C26H30FNO4/c1-17(2)26-23(13-12-21(29)14-22(30)15-25(31)32)24(18-8-10-19(27)11-9-18)16-28(26)20-6-4-3-5-7-20/h3-11,16-17,21-22,29-30H,12-15H2,1-2H3,(H,31,32)/p-1/t21-,22-/m1/s1
DMUMYTB	CS	CC(C)C1=C(C(=CN1C2=CC=CC=C2)C3=CC=C(C=C3)F)CC[C@H](C[C@H](CC(=O)[O-])O)O
DMUMYTB	IK	UBFHWBHHCSSZAB-FGZHOGPDSA-M
DMUMYTB	IU	(3R,5R)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyheptanoate
DMUMYTB	DE	Discovery agent

DM5TL2S	ID	DM5TL2S
DM5TL2S	DN	PMID2153213C13g
DM5TL2S	HS	Investigative
DM5TL2S	SN	GTPL3002; BDBM50013214
DM5TL2S	DT	Small molecular drug
DM5TL2S	PC	56947028
DM5TL2S	MW	452.5
DM5TL2S	FM	C27H31FNO4-
DM5TL2S	IC	InChI=1S/C27H32FNO4/c1-17(2)27-24(14-13-22(30)15-23(31)16-25(32)33)26(19-9-11-20(28)12-10-19)18(3)29(27)21-7-5-4-6-8-21/h4-12,17,22-23,30-31H,13-16H2,1-3H3,(H,32,33)/p-1/t22-,23-/m1/s1
DM5TL2S	CS	CC1=C(C(=C(N1C2=CC=CC=C2)C(C)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F
DM5TL2S	IK	JHURQXGATCGLIV-DHIUTWEWSA-M
DM5TL2S	IU	(3R,5R)-7-[4-(4-fluorophenyl)-5-methyl-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyheptanoate
DM5TL2S	DE	Discovery agent

DMVYB6Q	ID	DMVYB6Q
DMVYB6Q	DN	PMID2153213C1a
DMVYB6Q	HS	Investigative
DMVYB6Q	SN	GTPL2987
DMVYB6Q	DT	Small molecular drug
DMVYB6Q	PC	56947037
DMVYB6Q	MW	408.4
DMVYB6Q	FM	C24H23FNO4-
DMVYB6Q	IC	InChI=1S/C24H24FNO4/c1-16-22(12-11-20(27)13-21(28)14-24(29)30)23(17-7-9-18(25)10-8-17)15-26(16)19-5-3-2-4-6-19/h2-12,15,20-21,27-28H,13-14H2,1H3,(H,29,30)/p-1/b12-11+/t20-,21-/m1/s1
DMVYB6Q	CS	CC1=C(C(=CN1C2=CC=CC=C2)C3=CC=C(C=C3)F)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O
DMVYB6Q	IK	FQMQFMROIGKGDU-LKWCPCFXSA-M
DMVYB6Q	IU	(E,3R,5S)-7-[4-(4-fluorophenyl)-2-methyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoate
DMVYB6Q	DE	Discovery agent

DMRUJFZ	ID	DMRUJFZ
DMRUJFZ	DN	PMID2153213C1e
DMRUJFZ	HS	Investigative
DMRUJFZ	SN	GTPL2991; BDBM50013212
DMRUJFZ	DT	Small molecular drug
DMRUJFZ	PC	56947035
DMRUJFZ	MW	402.5
DMRUJFZ	FM	C23H29FNO4-
DMRUJFZ	IC	InChI=1S/C23H30FNO4/c1-14(2)23-20(10-9-18(26)11-19(27)12-22(28)29)21(13-25(23)15(3)4)16-5-7-17(24)8-6-16/h5-10,13-15,18-19,26-27H,11-12H2,1-4H3,(H,28,29)/p-1/b10-9+/t18-,19-/m1/s1
DMRUJFZ	CS	CC(C)C1=C(C(=CN1C(C)C)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O
DMRUJFZ	IK	JNPGUXGVLNJQSQ-BGGMYYEUSA-M
DMRUJFZ	IU	(E,3R,5S)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate
DMRUJFZ	DE	Discovery agent

DMOLIE1	ID	DMOLIE1
DMOLIE1	DN	PMID2153213C1f
DMOLIE1	HS	Investigative
DMOLIE1	SN	GTPL2990
DMOLIE1	DT	Small molecular drug
DMOLIE1	PC	44374901
DMOLIE1	MW	437.5
DMOLIE1	FM	C26H28FNO4
DMOLIE1	IC	InChI=1S/C26H28FNO4/c1-17(2)26-23(13-12-21(29)14-22(30)15-25(31)32)24(18-8-10-19(27)11-9-18)16-28(26)20-6-4-3-5-7-20/h3-13,16-17,21-22,29-30H,14-15H2,1-2H3,(H,31,32)/b13-12+/t21-,22-/m1/s1
DMOLIE1	CS	CC(C)C1=C(C(=CN1C2=CC=CC=C2)C3=CC=C(C=C3)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O
DMOLIE1	IK	VAVHMEQFYYBAPR-ITWZMISCSA-N
DMOLIE1	IU	(E,3R,5S)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid
DMOLIE1	DE	Discovery agent

DMJ4126	ID	DMJ4126
DMJ4126	DN	PMID2153213C2c
DMJ4126	HS	Investigative
DMJ4126	SN	GTPL3004; BDBM50013220
DMJ4126	DT	Small molecular drug
DMJ4126	PC	56947026
DMJ4126	MW	424.5
DMJ4126	FM	C25H27FNO4-
DMJ4126	IC	InChI=1S/C25H28FNO4/c1-16-23(13-12-21(28)14-22(29)15-24(30)31)25(18-8-10-19(26)11-9-18)17(2)27(16)20-6-4-3-5-7-20/h3-11,21-22,28-29H,12-15H2,1-2H3,(H,30,31)/p-1/t21-,22-/m1/s1
DMJ4126	CS	CC1=C(C(=C(N1C2=CC=CC=C2)C)C3=CC=C(C=C3)F)CC[C@H](C[C@H](CC(=O)[O-])O)O
DMJ4126	IK	QKLXBIHSGMPUQS-FGZHOGPDSA-M
DMJ4126	IU	(3R,5R)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate
DMJ4126	DE	Discovery agent

DMGAY4M	ID	DMGAY4M
DMGAY4M	DN	PMID2153213C2d
DMGAY4M	HS	Investigative
DMGAY4M	SN	GTPL3003; BDBM50013221
DMGAY4M	DT	Small molecular drug
DMGAY4M	PC	56947027
DMGAY4M	MW	376.4
DMGAY4M	FM	C21H27FNO4-
DMGAY4M	IC	InChI=1S/C21H28FNO4/c1-13(2)23-12-20(15-4-6-16(22)7-5-15)19(14(23)3)9-8-17(24)10-18(25)11-21(26)27/h4-7,12-13,17-18,24-25H,8-11H2,1-3H3,(H,26,27)/p-1/t17-,18-/m1/s1
DMGAY4M	CS	CC1=C(C(=CN1C(C)C)C2=CC=C(C=C2)F)CC[C@H](C[C@H](CC(=O)[O-])O)O
DMGAY4M	IK	LJBGBXVAGFAMLZ-QZTJIDSGSA-M
DMGAY4M	IU	(3R,5R)-7-[4-(4-fluorophenyl)-2-methyl-1-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyheptanoate
DMGAY4M	DE	Discovery agent

DM6QXYE	ID	DM6QXYE
DM6QXYE	DN	PMID2153213C2f
DM6QXYE	HS	Investigative
DM6QXYE	SN	GTPL3007; BDBM50013217
DM6QXYE	DT	Small molecular drug
DM6QXYE	PC	56947023
DM6QXYE	MW	444.6
DM6QXYE	FM	C26H35FNO4-
DM6QXYE	IC	InChI=1S/C26H36FNO4/c1-17(2)26-23(13-12-21(29)14-22(30)15-25(31)32)24(18-8-10-19(27)11-9-18)16-28(26)20-6-4-3-5-7-20/h8-11,16-17,20-22,29-30H,3-7,12-15H2,1-2H3,(H,31,32)/p-1/t21-,22-/m1/s1
DM6QXYE	CS	CC(C)C1=C(C(=CN1C2CCCCC2)C3=CC=C(C=C3)F)CC[C@H](C[C@H](CC(=O)[O-])O)O
DM6QXYE	IK	RODBEKUWCLMBSW-FGZHOGPDSA-M
DM6QXYE	IU	(3R,5R)-7-[1-cyclohexyl-4-(4-fluorophenyl)-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyheptanoate
DM6QXYE	DE	Discovery agent

DM2R94W	ID	DM2R94W
DM2R94W	DN	PMID21536437C15c
DM2R94W	HS	Investigative
DM2R94W	SN	GTPL8553; BDBM50345537
DM2R94W	DT	Small molecular drug
DM2R94W	PC	54585928
DM2R94W	MW	540.1
DM2R94W	FM	C26H38ClN3O5S
DM2R94W	IC	InChI=1S/C26H38ClN3O5S/c1-20-17-24(27)8-7-22(20)6-5-21-9-13-29(14-10-21)36(34,35)18-26(30(33)19-31)11-15-28(16-12-26)25(32)23-3-2-4-23/h7-8,17,19,21,23,33H,2-6,9-16,18H2,1H3
DM2R94W	CS	CC1=C(C=CC(=C1)Cl)CCC2CCN(CC2)S(=O)(=O)CC3(CCN(CC3)C(=O)C4CCC4)N(C=O)O
DM2R94W	IK	SIXCEPSXNLUZTE-UHFFFAOYSA-N
DM2R94W	IU	N-[4-[[4-[2-(4-chloro-2-methylphenyl)ethyl]piperidin-1-yl]sulfonylmethyl]-1-(cyclobutanecarbonyl)piperidin-4-yl]-N-hydroxyformamide
DM2R94W	DE	Discovery agent

DMHWX2O	ID	DMHWX2O
DMHWX2O	DN	PMID21536438C20f
DMHWX2O	HS	Investigative
DMHWX2O	SN	GTPL5750; BDBM50344484
DMHWX2O	DT	Small molecular drug
DMHWX2O	PC	54585570
DMHWX2O	MW	426.5
DMHWX2O	FM	C23H30N4O4
DMHWX2O	IC	InChI=1S/C23H30N4O4/c1-14-20(25-13-26-21(14)30-19-7-6-10-24-15(19)2)29-18-11-16-8-9-17(12-18)27(16)22(28)31-23(3,4)5/h6-7,10,13,16-18H,8-9,11-12H2,1-5H3/t16-,17-/m0/s1
DMHWX2O	CS	CC1=C(N=CN=C1OC2C[C@@H]3CC[C@@H](C2)N3C(=O)OC(C)(C)C)OC4=C(N=CC=C4)C
DMHWX2O	IK	YKEGUYTXACKXKS-IRXDYDNUSA-N
DMHWX2O	IU	tert-butyl (1S,5S)-3-[5-methyl-6-(2-methylpyridin-3-yl)oxypyrimidin-4-yl]oxy-8-azabicyclo[3.2.1]octane-8-carboxylate
DMHWX2O	DE	Discovery agent

DM06V1Q	ID	DM06V1Q
DM06V1Q	DN	PMID21536438C36j
DM06V1Q	HS	Investigative
DM06V1Q	SN	GTPL5755; BDBM50344511
DM06V1Q	DT	Small molecular drug
DM06V1Q	PC	54587590
DM06V1Q	MW	474
DM06V1Q	FM	C22H24ClN5O3S
DM06V1Q	IC	InChI=1S/C22H24ClN5O3S/c1-13-21(27-20-7-2-14(11-24)8-19(20)23)25-12-26-22(13)31-17-9-15-3-4-16(10-17)28(15)32(29,30)18-5-6-18/h2,7-8,12,15-18H,3-6,9-10H2,1H3,(H,25,26,27)/t15-,16-/m0/s1
DM06V1Q	CS	CC1=C(N=CN=C1OC2C[C@@H]3CC[C@@H](C2)N3S(=O)(=O)C4CC4)NC5=C(C=C(C=C5)C#N)Cl
DM06V1Q	IK	JONDVPWMQDOELC-HOTGVXAUSA-N
DM06V1Q	IU	3-chloro-4-[[6-[[(1S,5S)-8-cyclopropylsulfonyl-8-azabicyclo[3.2.1]octan-3-yl]oxy]-5-methylpyrimidin-4-yl]amino]benzonitrile
DM06V1Q	DE	Discovery agent

DMABZH6	ID	DMABZH6
DMABZH6	DN	PMID21561767C8h
DMABZH6	HS	Investigative
DMABZH6	SN	GTPL8170; BDBM50345579
DMABZH6	DT	Small molecular drug
DMABZH6	PC	46864270
DMABZH6	MW	582.6
DMABZH6	FM	C30H33F3N6O3
DMABZH6	IC	InChI=1S/C30H33F3N6O3/c1-20-4-5-22(16-21(20)7-9-25-18-35-27(37(25)3)29(42)34-2)28(41)36-24-8-6-23(26(17-24)30(31,32)33)19-39-12-10-38(11-13-39)14-15-40/h4-6,8,16-18,40H,10-15,19H2,1-3H3,(H,34,42)(H,36,41)
DMABZH6	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)CCO)C(F)(F)F)C#CC4=CN=C(N4C)C(=O)NC
DMABZH6	IK	SUXYGJZMCWKJJI-UHFFFAOYSA-N
DMABZH6	IU	5-[2-[5-[[4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-3-(trifluoromethyl)phenyl]carbamoyl]-2-methylphenyl]ethynyl]-N,1-dimethylimidazole-2-carboxamide
DMABZH6	DE	Discovery agent

DMEF8GV	ID	DMEF8GV
DMEF8GV	DN	PMID21571530C5g
DMEF8GV	HS	Investigative
DMEF8GV	SN	GTPL5514; BDBM50393143
DMEF8GV	DT	Small molecular drug
DMEF8GV	PC	53358901
DMEF8GV	MW	458.4
DMEF8GV	FM	C23H18F4N4O2
DMEF8GV	IC	InChI=1S/C23H18F4N4O2/c24-19-9-7-15(11-18(19)23(25,26)27)20-12-17(33-31-20)13-29-21(32)5-1-4-16-8-6-14-3-2-10-28-22(14)30-16/h2-3,6-12H,1,4-5,13H2,(H,29,32)
DMEF8GV	CS	C1=CC2=C(N=C1)N=C(C=C2)CCCC(=O)NCC3=CC(=NO3)C4=CC(=C(C=C4)F)C(F)(F)F
DMEF8GV	IK	SWKGPCNQBPGWNX-UHFFFAOYSA-N
DMEF8GV	IU	N-[[3-[4-fluoro-3-(trifluoromethyl)phenyl]-1,2-oxazol-5-yl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide
DMEF8GV	DE	Discovery agent

DMPBITK	ID	DMPBITK
DMPBITK	DN	PMID21571530C7e
DMPBITK	HS	Investigative
DMPBITK	SN	GTPL5515
DMPBITK	DT	Small molecular drug
DMPBITK	PC	73755126
DMPBITK	MW	533.9
DMPBITK	FM	C25H23ClF3N5O3
DMPBITK	IC	InChI=1S/C25H23ClF3N5O3/c26-19-15-17(10-12-20(19)37-25(27,28)29)24-34-33-22(36-24)8-1-2-13-30-21(35)7-3-6-18-11-9-16-5-4-14-31-23(16)32-18/h4-5,9-12,14-15H,1-3,6-8,13H2,(H,30,35)
DMPBITK	CS	C1=CC2=C(N=C1)N=C(C=C2)CCCC(=O)NCCCCC3=NN=C(O3)C4=CC(=C(C=C4)OC(F)(F)F)Cl
DMPBITK	IK	RCSBCWXPGSPJNF-UHFFFAOYSA-N
DMPBITK	IU	N-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide
DMPBITK	DE	Discovery agent

DM7JRHB	ID	DM7JRHB
DM7JRHB	DN	PMID21596927C101
DM7JRHB	HS	Investigative
DM7JRHB	SN	cmpd101; Takeda compound 101; 865608-11-3; 3pvu; QRW; GTPL8437; MolPort-039-338-070; ZINC38226912; AKOS027470239
DM7JRHB	DT	Small molecular drug
DM7JRHB	PC	11677079
DM7JRHB	MW	466.5
DM7JRHB	FM	C24H21F3N6O
DM7JRHB	IC	InChI=1S/C24H21F3N6O/c1-33-21(31-32-22(33)16-9-11-28-12-10-16)15-29-19-7-4-6-17(13-19)23(34)30-14-18-5-2-3-8-20(18)24(25,26)27/h2-13,29H,14-15H2,1H3,(H,30,34)
DM7JRHB	CS	CN1C(=NN=C1C2=CC=NC=C2)CNC3=CC=CC(=C3)C(=O)NCC4=CC=CC=C4C(F)(F)F
DM7JRHB	IK	WFOVEDJTASPCIR-UHFFFAOYSA-N
DM7JRHB	IU	3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-N-[[2-(trifluoromethyl)phenyl]methyl]benzamide
DM7JRHB	DE	Discovery agent

DMQHAIK	ID	DMQHAIK
DMQHAIK	DN	PMID21627121C2
DMQHAIK	HS	Investigative
DMQHAIK	SN	GTPL8149; BDBM50418829
DMQHAIK	DT	Small molecular drug
DMQHAIK	PC	16662746
DMQHAIK	MW	286.71
DMQHAIK	FM	C15H11ClN2O2
DMQHAIK	IC	InChI=1S/C15H11ClN2O2/c16-8-14(19)9-3-4-13-11(6-9)12(15(20)18-13)7-10-2-1-5-17-10/h1-7,17H,8H2,(H,18,20)/b12-7-
DMQHAIK	CS	C1=CNC(=C1)/C=C\\2/C3=C(C=CC(=C3)C(=O)CCl)NC2=O
DMQHAIK	IK	SEPHEVMRHYRRLS-GHXNOFRVSA-N
DMQHAIK	IU	(3Z)-5-(2-chloroacetyl)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
DMQHAIK	DE	Discovery agent

DMEBM19	ID	DMEBM19
DMEBM19	DN	PMID21688779C22a
DMEBM19	HS	Investigative
DMEBM19	SN	TC-N 22A; 1314140-00-5; GTPL6231; MolPort-023-277-166; BDBM50353290; ZINC72118775; AKOS024458120; NCGC00371008-01
DMEBM19	DT	Small molecular drug
DMEBM19	PC	46836562
DMEBM19	MW	283.35
DMEBM19	FM	C14H13N5S
DMEBM19	IC	InChI=1S/C14H13N5S/c1-2-7-15-12(6-1)17-14-18-13-9-8-16-19-10(9)4-3-5-11(13)20-14/h1-2,6-8H,3-5H2,(H,16,19)(H,15,17,18)
DMEBM19	CS	C1CC2=C(C=NN2)C3=C(C1)SC(=N3)NC4=CC=CC=N4
DMEBM19	IK	DBISXWCOHGUFSF-UHFFFAOYSA-N
DMEBM19	IU	N-pyridin-2-yl-5-thia-3,11,12-triazatricyclo[8.3.0.02,6]trideca-1(10),2(6),3,12-tetraen-4-amine
DMEBM19	DE	Discovery agent

DMXSCEA	ID	DMXSCEA
DMXSCEA	DN	PMID21692504C8
DMXSCEA	HS	Investigative
DMXSCEA	SN	SMR000042088; MLS000077901; SR-01000002103; AC1LD5G0; Oprea1_077264; GTPL8491; MolPort-006-816-887; MolPort-002-586-921; HMS2334H17; ZINC8666605; STK975536; STK649251; AKOS030520112; AKOS005580184; MCULE-9228637026; NCGC00020211-01; SR-01000002103-2; SR-01000002103-3
DMXSCEA	DT	Small molecular drug
DMXSCEA	PC	661524
DMXSCEA	MW	216.28
DMXSCEA	FM	C13H16N2O
DMXSCEA	IC	InChI=1S/C13H16N2O/c1-8(2)6-12-10-5-3-4-9(10)11(7-14)13(16)15-12/h8H,3-6H2,1-2H3,(H,15,16)
DMXSCEA	CS	CC(C)CC1=C2CCCC2=C(C(=O)N1)C#N
DMXSCEA	IK	QOUMCRXJXXVERM-UHFFFAOYSA-N
DMXSCEA	IU	1-(2-methylpropyl)-3-oxo-2,5,6,7-tetrahydrocyclopenta[c]pyridine-4-carbonitrile
DMXSCEA	DE	Discovery agent

DM8PA2V	ID	DM8PA2V
DM8PA2V	DN	PMID21741839C5
DM8PA2V	HS	Investigative
DM8PA2V	SN	GTPL8670; BDBM50324475; BJA
DM8PA2V	DT	Small molecular drug
DM8PA2V	PC	46899577
DM8PA2V	MW	556.7
DM8PA2V	FM	C26H36N8O4S
DM8PA2V	IC	InChI=1S/C26H36N8O4S/c27-23(28)20-12-10-18(11-13-20)16-32-24(35)22-9-5-15-34(22)25(36)21(8-4-14-31-26(29)30)33-39(37,38)17-19-6-2-1-3-7-19/h1-3,6-7,10-13,21-22,33H,4-5,8-9,14-17H2,(H3,27,28)(H,32,35)(H4,29,30,31)/t21-,22+/m1/s1
DM8PA2V	CS	C1C[C@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NS(=O)(=O)CC2=CC=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N
DM8PA2V	IK	QKFCYPKTTJCUSZ-YADHBBJMSA-N
DM8PA2V	IU	(2S)-1-[(2R)-2-(benzylsulfonylamino)-5-(diaminomethylideneamino)pentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide
DM8PA2V	DE	Discovery agent

DME3JMH	ID	DME3JMH
DME3JMH	DN	PMID21742770C1
DME3JMH	HS	Investigative
DME3JMH	SN	GTPL8190; BDBM50400690
DME3JMH	DT	Small molecular drug
DME3JMH	PC	71452170
DME3JMH	MW	444.5
DME3JMH	FM	C25H28N6O2
DME3JMH	IC	InChI=1S/C25H28N6O2/c1-29-12-14-30(15-13-29)22-10-5-19(16-23(22)33-3)27-24-11-4-18-17-26-31(25(18)28-24)20-6-8-21(32-2)9-7-20/h4-11,16-17H,12-15H2,1-3H3,(H,27,28)
DME3JMH	CS	CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=C3)C=NN4C5=CC=C(C=C5)OC)OC
DME3JMH	IK	LZQFMCFJCXQTTG-UHFFFAOYSA-N
DME3JMH	IU	N-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-1-(4-methoxyphenyl)pyrazolo[3,4-b]pyridin-6-amine
DME3JMH	DE	Discovery agent

DM3ELPS	ID	DM3ELPS
DM3ELPS	DN	PMID21757343C30
DM3ELPS	HS	Investigative
DM3ELPS	SN	GTPL6407; BDBM50349543
DM3ELPS	DT	Small molecular drug
DM3ELPS	PC	53380924
DM3ELPS	MW	383.9
DM3ELPS	FM	C20H18ClN3OS
DM3ELPS	IC	InChI=1S/C20H18ClN3OS/c1-13-10-17(14-4-2-5-15(21)11-14)23-12-16(13)18-6-3-8-24(18)20(25)19-22-7-9-26-19/h2,4-5,7,9-12,18H,3,6,8H2,1H3/t18-/m1/s1
DM3ELPS	CS	CC1=CC(=NC=C1[C@H]2CCCN2C(=O)C3=NC=CS3)C4=CC(=CC=C4)Cl
DM3ELPS	IK	GCSDBTCZHROCLZ-GOSISDBHSA-N
DM3ELPS	IU	[(2R)-2-[6-(3-chlorophenyl)-4-methylpyridin-3-yl]pyrrolidin-1-yl]-(1,3-thiazol-2-yl)methanone
DM3ELPS	DE	Discovery agent

DM48HR9	ID	DM48HR9
DM48HR9	DN	PMID21802293C66
DM48HR9	HS	Investigative
DM48HR9	SN	GTPL8212
DM48HR9	DT	Small molecular drug
DM48HR9	PC	53484100
DM48HR9	MW	477.4
DM48HR9	FM	C20H14F3N5O4S
DM48HR9	IC	InChI=1S/C20H14F3N5O4S/c1-32-20-13-8-11(9-24-18(13)26-27-20)25-19(29)16-14(22)5-6-15(17(16)23)28-33(30,31)12-4-2-3-10(21)7-12/h2-9,28H,1H3,(H,25,29)(H,24,26,27)
DM48HR9	CS	COC1=NNC2=C1C=C(C=N2)NC(=O)C3=C(C=CC(=C3F)NS(=O)(=O)C4=CC=CC(=C4)F)F
DM48HR9	IK	WGFNXGPBPIJYLI-UHFFFAOYSA-N
DM48HR9	IU	2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-N-(3-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)benzamide
DM48HR9	DE	Discovery agent

DMXF32O	ID	DMXF32O
DMXF32O	DN	PMID21823616C22
DMXF32O	HS	Investigative
DMXF32O	SN	ILK-IN-1; OSU-T315; 1333146-24-9; GTPL8116; BCP23690; ZINC72120050; BDBM50353484; AKOS030257532; CS-4936; HY-18676; SC-98385
DMXF32O	DT	Small molecular drug
DMXF32O	PC	51051074
DMXF32O	MW	533.6
DMXF32O	FM	C30H30F3N5O
DMXF32O	IC	InChI=1S/C30H30F3N5O/c1-34-29(39)15-10-25-20-28(38(36-25)27-13-11-26(12-14-27)37-18-16-35-17-19-37)23-4-2-21(3-5-23)22-6-8-24(9-7-22)30(31,32)33/h2-9,11-14,20,35H,10,15-19H2,1H3,(H,34,39)
DMXF32O	CS	CNC(=O)CCC1=NN(C(=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C4=CC=C(C=C4)N5CCNCC5
DMXF32O	IK	GHBUPSVATJKTRR-UHFFFAOYSA-N
DMXF32O	IU	N-methyl-3-[1-(4-piperazin-1-ylphenyl)-5-[4-[4-(trifluoromethyl)phenyl]phenyl]pyrazol-3-yl]propanamide
DMXF32O	DE	Discovery agent

DMI1FGV	ID	DMI1FGV
DMI1FGV	DN	PMID21851057C4d
DMI1FGV	HS	Investigative
DMI1FGV	SN	GTPL7516; BDBM50353596
DMI1FGV	DT	Small molecular drug
DMI1FGV	PC	54669868
DMI1FGV	MW	261.32
DMI1FGV	FM	C15H19NO3
DMI1FGV	IC	InChI=1S/C15H19NO3/c1-5-18-14-7-12(10(3)17)6-13(8-14)15-9(2)16-19-11(15)4/h6-8,10,17H,5H2,1-4H3
DMI1FGV	CS	CCOC1=CC(=CC(=C1)C(C)O)C2=C(ON=C2C)C
DMI1FGV	IK	AONNGYBECNOVTK-UHFFFAOYSA-N
DMI1FGV	IU	1-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-ethoxyphenyl]ethanol
DMI1FGV	DE	Discovery agent

DMTKJA9	ID	DMTKJA9
DMTKJA9	DN	PMID21855335C19a
DMTKJA9	HS	Investigative
DMTKJA9	SN	GTPL8186; BDBM50354414
DMTKJA9	DT	Small molecular drug
DMTKJA9	PC	56675928
DMTKJA9	MW	491
DMTKJA9	FM	C25H27ClN8O
DMTKJA9	IC	InChI=1S/C25H27ClN8O/c1-25(2)14-27-7-8-34(25)24(35)18-6-5-17(9-19(18)26)31-22-23-28-12-21(16-10-29-30-11-16)33(23)13-20(32-22)15-3-4-15/h5-6,9-13,15,27H,3-4,7-8,14H2,1-2H3,(H,29,30)(H,31,32)
DMTKJA9	CS	CC1(CNCCN1C(=O)C2=C(C=C(C=C2)NC3=NC(=CN4C3=NC=C4C5=CNN=C5)C6CC6)Cl)C
DMTKJA9	IK	MEQKJTZVPMNRIL-UHFFFAOYSA-N
DMTKJA9	IU	[2-chloro-4-[[6-cyclopropyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]amino]phenyl]-(2,2-dimethylpiperazin-1-yl)methanone
DMTKJA9	DE	Discovery agent

DMST0IN	ID	DMST0IN
DMST0IN	DN	PMID21907142CJ
DMST0IN	HS	Investigative
DMST0IN	SN	Example 1 (WO2011029803); GTPL7854; BDBM50432632
DMST0IN	DT	Small molecular drug
DMST0IN	PC	50938551
DMST0IN	MW	378.9
DMST0IN	FM	C17H16ClFN4OS
DMST0IN	IC	InChI=1S/C17H16ClFN4OS/c1-17(6-7-25-16(20)23-17)12-8-11(3-4-13(12)19)22-15(24)14-5-2-10(18)9-21-14/h2-5,8-9H,6-7H2,1H3,(H2,20,23)(H,22,24)/t17-/m0/s1
DMST0IN	CS	C[C@]1(CCSC(=N1)N)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)Cl)F
DMST0IN	IK	VVZZZUNCWSTIOI-KRWDZBQOSA-N
DMST0IN	IU	N-[3-[(4S)-2-amino-4-methyl-5,6-dihydro-1,3-thiazin-4-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide
DMST0IN	DE	Discovery agent

DMLGKD3	ID	DMLGKD3
DMLGKD3	DN	PMID21927650C18
DMLGKD3	HS	Investigative
DMLGKD3	SN	GTPL6442
DMLGKD3	DT	Small molecular drug
DMLGKD3	PC	73755222
DMLGKD3	MW	270.3
DMLGKD3	FM	C15H11FN2S
DMLGKD3	IC	InChI=1S/C15H11FN2S/c1-9-18-14-7-11(2-3-15(14)19-9)12-4-10(8-17)5-13(16)6-12/h2-7,9,18H,1H3
DMLGKD3	CS	CC1NC2=C(S1)C=CC(=C2)C3=CC(=CC(=C3)C#N)F
DMLGKD3	IK	DUFLWBPOXGXKEK-UHFFFAOYSA-N
DMLGKD3	IU	3-fluoro-5-(2-methyl-2,3-dihydro-1,3-benzothiazol-5-yl)benzonitrile
DMLGKD3	DE	Discovery agent

DMEUQFG	ID	DMEUQFG
DMEUQFG	DN	PMID21939274C1
DMEUQFG	HS	Investigative
DMEUQFG	SN	GTPL5743
DMEUQFG	DT	Small molecular drug
DMEUQFG	PC	73755151
DMEUQFG	MW	402.4
DMEUQFG	FM	C22H22N6O2
DMEUQFG	IC	InChI=1S/C22H22N6O2/c1-15(2)30-22(29)28-9-7-27(8-10-28)21-17(13-23)11-18(14-26-21)16-3-4-19-20(12-16)25-6-5-24-19/h3-6,11-12,14-15H,7-10H2,1-2H3
DMEUQFG	CS	CC(C)OC(=O)N1CCN(CC1)C2=C(C=C(C=N2)C3=CC4=NC=CN=C4C=C3)C#N
DMEUQFG	IK	UVINGSLSDLUGKX-UHFFFAOYSA-N
DMEUQFG	IU	propan-2-yl 4-(3-cyano-5-quinoxalin-6-ylpyridin-2-yl)piperazine-1-carboxylate
DMEUQFG	DE	Discovery agent

DMRCAEI	ID	DMRCAEI
DMRCAEI	DN	PMID21939274C2
DMRCAEI	HS	Investigative
DMRCAEI	SN	GTPL5744
DMRCAEI	DT	Small molecular drug
DMRCAEI	PC	73755152
DMRCAEI	MW	412.5
DMRCAEI	FM	C24H24N6O
DMRCAEI	IC	InChI=1S/C24H24N6O/c1-15(2)22-28-24(31-29-22)17-6-8-30(9-7-17)23-20(13-26)11-21(14-27-23)18-4-5-19(12-25)16(3)10-18/h4-5,10-11,14-15,17H,6-9H2,1-3H3
DMRCAEI	CS	CC1=C(C=CC(=C1)C2=CC(=C(N=C2)N3CCC(CC3)C4=NC(=NO4)C(C)C)C#N)C#N
DMRCAEI	IK	TXALYVIWRLTFFP-UHFFFAOYSA-N
DMRCAEI	IU	5-(4-cyano-3-methylphenyl)-2-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyridine-3-carbonitrile
DMRCAEI	DE	Discovery agent

DMCOHKU	ID	DMCOHKU
DMCOHKU	DN	PMID21967808CR-16
DMCOHKU	HS	Investigative
DMCOHKU	SN	GTPL8213; BDBM50361564
DMCOHKU	DT	Small molecular drug
DMCOHKU	PC	56597775
DMCOHKU	MW	595.1
DMCOHKU	FM	C29H32ClFN8O3
DMCOHKU	IC	InChI=1S/C29H32ClFN8O3/c1-29(2)14-22(36-28(42)39-11-4-5-12-39)26(41)35-21-13-16(9-10-18(21)29)34-27-33-15-19(30)24(38-27)37-23-17(25(40)32-3)7-6-8-20(23)31/h6-10,13,15,22H,4-5,11-12,14H2,1-3H3,(H,32,40)(H,35,41)(H,36,42)(H2,33,34,37,38)/t22-/m1/s1
DMCOHKU	CS	CC1(C[C@H](C(=O)NC2=C1C=CC(=C2)NC3=NC=C(C(=N3)NC4=C(C=CC=C4F)C(=O)NC)Cl)NC(=O)N5CCCC5)C
DMCOHKU	IK	HGSNUBHWAMMKIR-JOCHJYFZSA-N
DMCOHKU	IU	N-[(3R)-8-[[5-chloro-4-[2-fluoro-6-(methylcarbamoyl)anilino]pyrimidin-2-yl]amino]-5,5-dimethyl-2-oxo-3,4-dihydro-1H-1-benzazepin-3-yl]pyrrolidine-1-carboxamide
DMCOHKU	DE	Discovery agent

DM0VOXN	ID	DM0VOXN
DM0VOXN	DN	PMID21982499C14k
DM0VOXN	HS	Investigative
DM0VOXN	SN	GTPL8214; BDBM50357587
DM0VOXN	DT	Small molecular drug
DM0VOXN	PC	44222958
DM0VOXN	MW	372.8
DM0VOXN	FM	C20H13ClN6
DM0VOXN	IC	InChI=1S/C20H13ClN6/c21-16-6-1-2-7-17(16)25-20-13-8-9-22-10-15(13)12-4-3-5-14(18(12)26-20)19-23-11-24-27-19/h1-11H,(H,25,26)(H,23,24,27)
DM0VOXN	CS	C1=CC=C(C(=C1)NC2=C3C=CN=CC3=C4C=CC=C(C4=N2)C5=NC=NN5)Cl
DM0VOXN	IK	WNOHFJIMKSDPHP-UHFFFAOYSA-N
DM0VOXN	IU	N-(2-chlorophenyl)-7-(1H-1,2,4-triazol-5-yl)benzo[c][2,6]naphthyridin-5-amine
DM0VOXN	DE	Discovery agent

DMWBYNF	ID	DMWBYNF
DMWBYNF	DN	PMID22017539C15
DMWBYNF	HS	Investigative
DMWBYNF	SN	4UF; GTPL8636; BDBM50361618
DMWBYNF	DT	Small molecular drug
DMWBYNF	PC	45376872
DMWBYNF	MW	446.5
DMWBYNF	FM	C24H22N4O5
DMWBYNF	IC	InChI=1S/C24H22N4O5/c1-3-33-24(32)20-11-17-10-16(8-9-18(17)26-20)21-12-19(27-28(21)2)22(29)25-13-14-4-6-15(7-5-14)23(30)31/h4-12,26H,3,13H2,1-2H3,(H,25,29)(H,30,31)
DMWBYNF	CS	CCOC(=O)C1=CC2=C(N1)C=CC(=C2)C3=CC(=NN3C)C(=O)NCC4=CC=C(C=C4)C(=O)O
DMWBYNF	IK	MMJPVSDTLGFIQW-UHFFFAOYSA-N
DMWBYNF	IU	4-[[[5-(2-ethoxycarbonyl-1H-indol-5-yl)-1-methylpyrazole-3-carbonyl]amino]methyl]benzoic acid
DMWBYNF	DE	Discovery agent

DMX5UKA	ID	DMX5UKA
DMX5UKA	DN	PMID22115617C2c
DMX5UKA	HS	Investigative
DMX5UKA	SN	TMCB; 905105-89-7; TMCB/; GTPL8140; DTXSID50677589; MolPort-019-939-193; BS0265; BDBM50359846; ZINC58638742; ABP000318; AKOS024457742; K66
DMX5UKA	DT	Small molecular drug
DMX5UKA	PC	46943415
DMX5UKA	MW	534.82
DMX5UKA	FM	C11H9Br4N3O2
DMX5UKA	IC	InChI=1S/C11H9Br4N3O2/c1-17(2)11-16-9-7(14)5(12)6(13)8(15)10(9)18(11)3-4(19)20/h3H2,1-2H3,(H,19,20)
DMX5UKA	CS	CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br
DMX5UKA	IK	PHAOTASRLQMKBE-UHFFFAOYSA-N
DMX5UKA	IU	2-[4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazol-1-yl]acetic acid
DMX5UKA	CA	CAS 905105-89-7
DMX5UKA	DE	Discovery agent

DMZ5BHX	ID	DMZ5BHX
DMZ5BHX	DN	PMID22123324C38
DMZ5BHX	HS	Investigative
DMZ5BHX	SN	GTPL7757
DMZ5BHX	DT	Small molecular drug
DMZ5BHX	PC	86277835
DMZ5BHX	MW	466.6
DMZ5BHX	FM	C30H34N4O
DMZ5BHX	IC	InChI=1S/C30H34N4O/c1-2-15-32-26-19-30(25-9-5-3-8-23(25)26)13-16-33(17-14-30)20-21-11-12-28-24(18-21)22-7-4-6-10-27(22)34(28)29(31)35/h3-12,18,26,32H,2,13-17,19-20H2,1H3,(H2,31,35)/t26-/m1/s1
DMZ5BHX	CS	CCCN[C@@H]1CC2(CCN(CC2)CC3=CC4=C(C=C3)N(C5=CC=CC=C54)C(=O)N)C6=CC=CC=C16
DMZ5BHX	IK	LMNFAMWQPPUUNJ-AREMUKBSSA-N
DMZ5BHX	IU	3-[[(1R)-1-(propylamino)spiro[1,2-dihydroindene-3,4'-piperidine]-1'-yl]methyl]carbazole-9-carboxamide
DMZ5BHX	DE	Discovery agent

DMI8217	ID	DMI8217
DMI8217	DN	PMID22136433C20
DMI8217	HS	Investigative
DMI8217	SN	NSC748497; NSC-748497; KH-CARB13; GTPL8156; BDBM50363167
DMI8217	DT	Small molecular drug
DMI8217	PC	54613583
DMI8217	MW	363.2
DMI8217	FM	C17H16Cl2N4O
DMI8217	IC	InChI=1S/C17H16Cl2N4O/c1-23-14-9(2-3-11(18)13(14)19)12-10(8-20)17(4-6-21-7-5-17)22-16(24)15(12)23/h2-3,10,21H,4-7H2,1H3,(H,22,24)
DMI8217	CS	CN1C2=C(C=CC(=C2Cl)Cl)C3=C1C(=O)NC4(C3C#N)CCNCC4
DMI8217	IK	OWAWOKKHZNRHGV-UHFFFAOYSA-N
DMI8217	IU	7,8-dichloro-9-methyl-1-oxospiro[2,4-dihydropyrido[3,4-b]indole-3,4'-piperidine]-4-carbonitrile
DMI8217	DE	Discovery agent

DMTGVSU	ID	DMTGVSU
DMTGVSU	DN	PMID22153340C20
DMTGVSU	HS	Investigative
DMTGVSU	SN	GTPL6568; BDBM50360964
DMTGVSU	DT	Small molecular drug
DMTGVSU	PC	25122902
DMTGVSU	MW	427.5
DMTGVSU	FM	C22H21NO6S
DMTGVSU	IC	InChI=1S/C22H21NO6S/c1-12(2)21(22(24)25)23-30(26,27)15-6-7-16-17-10-14(18-8-4-13(3)28-18)5-9-19(17)29-20(16)11-15/h4-12,21,23H,1-3H3,(H,24,25)/t21-/m0/s1
DMTGVSU	CS	CC1=CC=C(O1)C2=CC3=C(C=C2)OC4=C3C=CC(=C4)S(=O)(=O)N[C@@H](C(C)C)C(=O)O
DMTGVSU	IK	LLJREHOWNIBILL-NRFANRHFSA-N
DMTGVSU	IU	(2S)-3-methyl-2-[[8-(5-methylfuran-2-yl)dibenzofuran-3-yl]sulfonylamino]butanoic acid
DMTGVSU	DE	Discovery agent

DM4NRG5	ID	DM4NRG5
DM4NRG5	DN	PMID22266036C12e
DM4NRG5	HS	Investigative
DM4NRG5	SN	GTPL6357; BDBM50364692
DM4NRG5	DT	Small molecular drug
DM4NRG5	PC	16118537
DM4NRG5	MW	363.4
DM4NRG5	FM	C20H17N3O2S
DM4NRG5	IC	InChI=1S/C20H17N3O2S/c1-25-14-6-4-13(5-7-14)23-11-9-15-17-16(22-12-2-3-12)8-10-21-19(17)26-18(15)20(23)24/h4-12H,2-3H2,1H3,(H,21,22)
DM4NRG5	CS	COC1=CC=C(C=C1)N2C=CC3=C(C2=O)SC4=NC=CC(=C34)NC5CC5
DM4NRG5	IK	ZUUBRGCTXRXCLV-UHFFFAOYSA-N
DM4NRG5	IU	13-(cyclopropylamino)-5-(4-methoxyphenyl)-8-thia-5,10-diazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DM4NRG5	DE	Discovery agent

DMFQHVL	ID	DMFQHVL
DMFQHVL	DN	PMID22266036C9a
DMFQHVL	HS	Investigative
DMFQHVL	SN	GTPL6356; BDBM50364719
DMFQHVL	DT	Small molecular drug
DMFQHVL	PC	16118119
DMFQHVL	MW	351.4
DMFQHVL	FM	C19H17N3O2S
DMFQHVL	IC	InChI=1S/C19H17N3O2S/c1-21(2)15-8-10-20-18-16(15)14-9-11-22(19(23)17(14)25-18)12-4-6-13(24-3)7-5-12/h4-11H,1-3H3
DMFQHVL	CS	CN(C)C1=C2C3=C(C(=O)N(C=C3)C4=CC=C(C=C4)OC)SC2=NC=C1
DMFQHVL	IK	KBKYZXCTHJUCOC-UHFFFAOYSA-N
DMFQHVL	IU	13-(dimethylamino)-5-(4-methoxyphenyl)-8-thia-5,10-diazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMFQHVL	DE	Discovery agent

DMVI6EX	ID	DMVI6EX
DMVI6EX	DN	PMID2231594C3j
DMVI6EX	HS	Investigative
DMVI6EX	SN	GTPL2979; BDBM50406119
DMVI6EX	DT	Small molecular drug
DMVI6EX	PC	44331788
DMVI6EX	MW	438.4
DMVI6EX	FM	C22H28FO6P
DMVI6EX	IC	InChI=1S/C22H28FO6P/c1-13(2)18-7-14(3)8-19(16-5-6-21(23)15(4)9-16)20(18)11-29-30(27,28)12-17(24)10-22(25)26/h5-9,13,17,24H,10-12H2,1-4H3,(H,25,26)(H,27,28)/t17-/m0/s1
DMVI6EX	CS	CC1=CC(=C(C(=C1)C(C)C)COP(=O)(C[C@H](CC(=O)O)O)O)C2=CC(=C(C=C2)F)C
DMVI6EX	IK	WHQUHTXULUACFD-KRWDZBQOSA-N
DMVI6EX	IU	(3S)-4-[[2-(4-fluoro-3-methylphenyl)-4-methyl-6-propan-2-ylphenyl]methoxy-hydroxyphosphoryl]-3-hydroxybutanoic acid
DMVI6EX	DE	Discovery agent

DMJYHIM	ID	DMJYHIM
DMJYHIM	DN	PMID2231594C3k
DMJYHIM	HS	Investigative
DMJYHIM	SN	GTPL2978
DMJYHIM	DT	Small molecular drug
DMJYHIM	PC	44331589
DMJYHIM	MW	436.5
DMJYHIM	FM	C23H30FO5P
DMJYHIM	IC	InChI=1S/C23H30FO5P/c1-14(2)20-9-15(3)10-21(17-5-6-22(24)16(4)11-17)19(20)7-8-30(28,29)13-18(25)12-23(26)27/h5-6,9-11,14,18,25H,7-8,12-13H2,1-4H3,(H,26,27)(H,28,29)/t18-/m0/s1
DMJYHIM	CS	CC1=CC(=C(C(=C1)C(C)C)CCP(=O)(C[C@H](CC(=O)O)O)O)C2=CC(=C(C=C2)F)C
DMJYHIM	IK	IZGDXVLRMHXOJV-SFHVURJKSA-N
DMJYHIM	IU	(3S)-4-[2-[2-(4-fluoro-3-methylphenyl)-4-methyl-6-propan-2-ylphenyl]ethyl-hydroxyphosphoryl]-3-hydroxybutanoic acid
DMJYHIM	DE	Discovery agent

DMJQ5B0	ID	DMJQ5B0
DMJQ5B0	DN	PMID2231594C3q
DMJQ5B0	HS	Investigative
DMJQ5B0	SN	GTPL2977
DMJQ5B0	DT	Small molecular drug
DMJQ5B0	PC	44331779
DMJQ5B0	MW	445.4
DMJQ5B0	FM	C23H25FNO5P
DMJQ5B0	IC	InChI=1S/C23H25FNO5P/c1-15(2)23-19-5-3-4-6-20(19)25(17-9-7-16(24)8-10-17)21(23)11-12-31(29,30)14-18(26)13-22(27)28/h3-12,15,18,26H,13-14H2,1-2H3,(H,27,28)(H,29,30)/b12-11+/t18-/m0/s1
DMJQ5B0	CS	CC(C)C1=C(N(C2=CC=CC=C21)C3=CC=C(C=C3)F)/C=C/P(=O)(C[C@H](CC(=O)O)O)O
DMJQ5B0	IK	RTTUBUXMNUJHRR-DXRVJIQQSA-N
DMJQ5B0	IU	(3S)-4-[[(E)-2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethenyl]-hydroxyphosphoryl]-3-hydroxybutanoic acid
DMJQ5B0	DE	Discovery agent

DMJ504Y	ID	DMJ504Y
DMJ504Y	DN	PMID2231594C3u
DMJ504Y	HS	Investigative
DMJ504Y	SN	GTPL2976
DMJ504Y	DT	Small molecular drug
DMJ504Y	PC	44331800
DMJ504Y	MW	456.4
DMJ504Y	FM	C25H26FO5P
DMJ504Y	IC	InChI=1S/C25H26FO5P/c26-18-9-7-17(8-10-18)24-20-5-1-2-6-21(20)25(12-3-4-13-25)22(24)11-14-32(30,31)16-19(27)15-23(28)29/h1-2,5-11,14,19,27H,3-4,12-13,15-16H2,(H,28,29)(H,30,31)/b14-11+/t19-/m0/s1
DMJ504Y	CS	C1CCC2(C1)C3=CC=CC=C3C(=C2/C=C/P(=O)(C[C@H](CC(=O)O)O)O)C4=CC=C(C=C4)F
DMJ504Y	IK	AOSODOHQJJPEAM-VUVZNRFTSA-N
DMJ504Y	IU	(3S)-4-[[(E)-2-[3'-(4-fluorophenyl)spiro[cyclopentane-1,1'-indene]-2'-yl]ethenyl]-hydroxyphosphoryl]-3-hydroxybutanoic acid
DMJ504Y	DE	Discovery agent

DMRLG7Z	ID	DMRLG7Z
DMRLG7Z	DN	PMID22364337C48
DMRLG7Z	HS	Investigative
DMRLG7Z	SN	GTPL6320; BDBM50383366
DMRLG7Z	DT	Small molecular drug
DMRLG7Z	PC	25002940
DMRLG7Z	MW	377.4
DMRLG7Z	FM	C22H20FN3O2
DMRLG7Z	IC	InChI=1S/C22H20FN3O2/c1-3-4-10-26-11-8-18(19(14-24)22(26)27)16-5-6-21(20(23)13-16)28-17-7-9-25-15(2)12-17/h5-9,11-13H,3-4,10H2,1-2H3
DMRLG7Z	CS	CCCCN1C=CC(=C(C1=O)C#N)C2=CC(=C(C=C2)OC3=CC(=NC=C3)C)F
DMRLG7Z	IK	IPTWXMISVLTMAV-UHFFFAOYSA-N
DMRLG7Z	IU	1-butyl-4-[3-fluoro-4-(2-methylpyridin-4-yl)oxyphenyl]-2-oxopyridine-3-carbonitrile
DMRLG7Z	DE	Discovery agent

DM123TU	ID	DM123TU
DM123TU	DN	PMID22420767C42
DM123TU	HS	Investigative
DM123TU	SN	GTPL5794
DM123TU	DT	Small molecular drug
DM123TU	PC	73755156
DM123TU	MW	447.4
DM123TU	FM	C22H24Cl2N4O2
DM123TU	IC	InChI=1S/C22H24Cl2N4O2/c1-14-17(22(29)25-9-10-30-16-5-3-2-4-6-16)12-26-21-18(13-27-28(14)21)15-7-8-19(23)20(24)11-15/h2-6,12-13,15,19-20H,7-11H2,1H3,(H,25,29)
DM123TU	CS	CC1=C(C=NC2=C(C=NN12)C3CCC(C(C3)Cl)Cl)C(=O)NCCOC4=CC=CC=C4
DM123TU	IK	BHDJYYFELGTSTL-UHFFFAOYSA-N
DM123TU	IU	3-(3,4-dichlorocyclohexyl)-7-methyl-N-(2-phenoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxamide
DM123TU	DE	Discovery agent

DMCDOHA	ID	DMCDOHA
DMCDOHA	DN	PMID22464687C15a
DMCDOHA	HS	Investigative
DMCDOHA	SN	GTPL7578; BDBM50388358
DMCDOHA	DT	Small molecular drug
DMCDOHA	PC	57778011
DMCDOHA	MW	539
DMCDOHA	FM	C29H31ClN2O6
DMCDOHA	IC	InChI=1S/C29H31ClN2O6/c1-36-24-7-3-5-20(29(24)37-2)28-21-16-19(30)8-9-22(21)32-12-4-6-23(32)25(38-28)17-26(33)31-13-10-18(11-14-31)15-27(34)35/h3-9,12,16,18,25,28H,10-11,13-15,17H2,1-2H3,(H,34,35)/t25-,28-/m1/s1
DMCDOHA	CS	COC1=CC=CC(=C1OC)[C@@H]2C3=C(C=CC(=C3)Cl)N4C=CC=C4[C@H](O2)CC(=O)N5CCC(CC5)CC(=O)O
DMCDOHA	IK	MSSQOQPKGAMUSY-LEAFIULHSA-N
DMCDOHA	IU	2-[1-[2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4,6-dihydropyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid
DMCDOHA	DE	Discovery agent

DMV4ZWD	ID	DMV4ZWD
DMV4ZWD	DN	PMID22465637C1
DMV4ZWD	HS	Investigative
DMV4ZWD	SN	GTPL6236
DMV4ZWD	DT	Small molecular drug
DMV4ZWD	PC	73755198
DMV4ZWD	MW	275.3
DMV4ZWD	FM	C18H17N3
DMV4ZWD	IC	InChI=1S/C18H17N3/c1-2-6-15(7-3-1)21-13-14(12-20-21)16-10-11-19-18-9-5-4-8-17(16)18/h1-11,14,20H,12-13H2
DMV4ZWD	CS	C1C(CN(N1)C2=CC=CC=C2)C3=CC=NC4=CC=CC=C34
DMV4ZWD	IK	KQNXOSZPTJGHDO-UHFFFAOYSA-N
DMV4ZWD	IU	4-(1-phenylpyrazolidin-4-yl)quinoline
DMV4ZWD	DE	Discovery agent

DMQXRCW	ID	DMQXRCW
DMQXRCW	DN	PMID22490048C(R)-10h
DMQXRCW	HS	Investigative
DMQXRCW	SN	GTPL7754; BDBM50388460
DMQXRCW	DT	Small molecular drug
DMQXRCW	PC	57523087
DMQXRCW	MW	460.6
DMQXRCW	FM	C27H32N4O3
DMQXRCW	IC	InChI=1S/C27H32N4O3/c1-17-25(31-27(33)21-6-9-24(10-7-21)34-16-20-4-5-20)11-8-22-14-23(15-30-26(17)22)18(2)28-12-13-29-19(3)32/h6-11,14-15,18,20,28H,4-5,12-13,16H2,1-3H3,(H,29,32)(H,31,33)/t18-/m1/s1
DMQXRCW	CS	CC1=C(C=CC2=CC(=CN=C12)[C@@H](C)NCCNC(=O)C)NC(=O)C3=CC=C(C=C3)OCC4CC4
DMQXRCW	IK	HRYQXLHGNOJEHH-GOSISDBHSA-N
DMQXRCW	IU	N-[3-[(1R)-1-(2-acetamidoethylamino)ethyl]-8-methylquinolin-7-yl]-4-(cyclopropylmethoxy)benzamide
DMQXRCW	DE	Discovery agent

DMYQDXO	ID	DMYQDXO
DMYQDXO	DN	PMID22521646C12
DMYQDXO	HS	Investigative
DMYQDXO	SN	GTPL8125; BDBM50420761
DMYQDXO	DT	Small molecular drug
DMYQDXO	PC	25060878
DMYQDXO	MW	364.4
DMYQDXO	FM	C21H21FN4O
DMYQDXO	IC	InChI=1S/C21H21FN4O/c1-12-16(9-14(10-17(12)22)19(27)23-15-3-4-15)13-5-8-26-18(11-13)24-25-20(26)21(2)6-7-21/h5,8-11,15H,3-4,6-7H2,1-2H3,(H,23,27)
DMYQDXO	CS	CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=CC4=NN=C(N4C=C3)C5(CC5)C
DMYQDXO	IK	REGFSKAVJRCHTE-UHFFFAOYSA-N
DMYQDXO	IU	N-cyclopropyl-3-fluoro-4-methyl-5-[3-(1-methylcyclopropyl)-[1,2,4]triazolo[4,3-a]pyridin-7-yl]benzamide
DMYQDXO	DE	Discovery agent

DMYEMWB	ID	DMYEMWB
DMYEMWB	DN	PMID22533316C1
DMYEMWB	HS	Investigative
DMYEMWB	SN	GTPL6709
DMYEMWB	DT	Small molecular drug
DMYEMWB	PC	44570860
DMYEMWB	MW	456.8
DMYEMWB	FM	C24H23BrClNO
DMYEMWB	IC	InChI=1S/C24H22BrNO.ClH/c1-3-16-26(2)17-18-4-6-19(7-5-18)20-8-10-21(11-9-20)24(27)22-12-14-23(25)15-13-22;/h3-15H,1,16-17H2,2H3;1H
DMYEMWB	CS	CN(CC=C)CC1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)Br.Cl
DMYEMWB	IK	MCMDJJBPNGLKKM-UHFFFAOYSA-N
DMYEMWB	IU	(4-bromophenyl)-[4-[4-[[methyl(prop-2-enyl)amino]methyl]phenyl]phenyl]methanone;hydrochloride
DMYEMWB	DE	Discovery agent

DMOZG0A	ID	DMOZG0A
DMOZG0A	DN	PMID22533316C3
DMOZG0A	HS	Investigative
DMOZG0A	SN	GTPL6711; BDBM50255473
DMOZG0A	DT	Small molecular drug
DMOZG0A	PC	10138707
DMOZG0A	MW	449.4
DMOZG0A	FM	C21H25BrN2O2S
DMOZG0A	IC	InChI=1S/C21H25BrN2O2S/c1-2-24(12-13-25)11-3-4-14-26-18-9-10-19-20(15-18)27-23-21(19)16-5-7-17(22)8-6-16/h5-10,15,25H,2-4,11-14H2,1H3
DMOZG0A	CS	CCN(CCCCOC1=CC2=C(C=C1)C(=NS2)C3=CC=C(C=C3)Br)CCO
DMOZG0A	IK	XHOKJNHLSGAYJL-UHFFFAOYSA-N
DMOZG0A	IU	2-[4-[[3-(4-bromophenyl)-1,2-benzothiazol-6-yl]oxy]butyl-ethylamino]ethanol
DMOZG0A	DE	Discovery agent

DMW3UHO	ID	DMW3UHO
DMW3UHO	DN	PMID22533316C4
DMW3UHO	HS	Investigative
DMW3UHO	SN	GTPL6712; BDBM50255432
DMW3UHO	DT	Small molecular drug
DMW3UHO	PC	22314173
DMW3UHO	MW	431.4
DMW3UHO	FM	C21H23BrN2OS
DMW3UHO	IC	InChI=1S/C21H23BrN2OS/c1-3-12-24(2)13-4-5-14-25-18-10-11-19-20(15-18)26-23-21(19)16-6-8-17(22)9-7-16/h3,6-11,15H,1,4-5,12-14H2,2H3
DMW3UHO	CS	CN(CCCCOC1=CC2=C(C=C1)C(=NS2)C3=CC=C(C=C3)Br)CC=C
DMW3UHO	IK	PDHRIPJKNGUCJP-UHFFFAOYSA-N
DMW3UHO	IU	4-[[3-(4-bromophenyl)-1,2-benzothiazol-6-yl]oxy]-N-methyl-N-prop-2-enylbutan-1-amine
DMW3UHO	DE	Discovery agent

DMVZQ6U	ID	DMVZQ6U
DMVZQ6U	DN	PMID22545772C42
DMVZQ6U	HS	Investigative
DMVZQ6U	SN	GTPL5735
DMVZQ6U	DT	Small molecular drug
DMVZQ6U	PC	60168163
DMVZQ6U	MW	420.5
DMVZQ6U	FM	C21H24N8O2
DMVZQ6U	IC	InChI=1S/C21H24N8O2/c1-14(2)19-26-21(27-31-19)28-6-7-29(15(3)12-28)20-24-10-18(11-25-20)30-13-16-4-5-23-9-17(16)8-22/h4-5,9-11,14-15H,6-7,12-13H2,1-3H3/t15-/m0/s1
DMVZQ6U	CS	C[C@H]1CN(CCN1C2=NC=C(C=N2)OCC3=C(C=NC=C3)C#N)C4=NOC(=N4)C(C)C
DMVZQ6U	IK	UNGZTVLHLKAKQE-HNNXBMFYSA-N
DMVZQ6U	IU	4-[[2-[(2S)-2-methyl-4-(5-propan-2-yl-1,2,4-oxadiazol-3-yl)piperazin-1-yl]pyrimidin-5-yl]oxymethyl]pyridine-3-carbonitrile
DMVZQ6U	DE	Discovery agent

DMBMYKQ	ID	DMBMYKQ
DMBMYKQ	DN	PMID22564207C25b
DMBMYKQ	HS	Investigative
DMBMYKQ	SN	CEP-28122; 1022958-60-6; GTPL8139; EX-A1541; ZINC84654307; BDBM50389154; CS-5176; NCGC00387821-03; HY-18030
DMBMYKQ	DT	Small molecular drug
DMBMYKQ	PC	57325421
DMBMYKQ	MW	539.1
DMBMYKQ	FM	C28H35ClN6O3
DMBMYKQ	IC	InChI=1S/C28H35ClN6O3/c1-37-25-20-8-7-19(35-10-12-38-13-11-35)6-4-16(20)5-9-22(25)32-28-31-15-21(29)27(34-28)33-24-18-3-2-17(14-18)23(24)26(30)36/h2-3,5,9,15,17-19,23-24H,4,6-8,10-14H2,1H3,(H2,30,36)(H2,31,32,33,34)/t17-,18+,19+,23+,24-/m1/s1
DMBMYKQ	CS	COC1=C(C=CC2=C1CC[C@H](CC2)N3CCOCC3)NC4=NC=C(C(=N4)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl
DMBMYKQ	IK	LAJAFFLJAJMYLK-CVOKMOJFSA-N
DMBMYKQ	IU	(1S,2S,3R,4R)-3-[[5-chloro-2-[[(7S)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide
DMBMYKQ	CA	CAS 1431697-87-8
DMBMYKQ	DE	Discovery agent

DM9SLUK	ID	DM9SLUK
DM9SLUK	DN	PMID22595175C4g
DM9SLUK	HS	Investigative
DM9SLUK	SN	GTPL8626; BDBM50384111
DM9SLUK	DT	Small molecular drug
DM9SLUK	PC	66561876
DM9SLUK	MW	263.25
DM9SLUK	FM	C13H13NO5
DM9SLUK	IC	InChI=1S/C13H13NO5/c1-13(2)11(16)14(12(17)19-13)10(15)8-4-6-9(18-3)7-5-8/h4-7H,1-3H3
DM9SLUK	CS	CC1(C(=O)N(C(=O)O1)C(=O)C2=CC=C(C=C2)OC)C
DM9SLUK	IK	ZYRNCIWULACSEK-UHFFFAOYSA-N
DM9SLUK	IU	3-(4-methoxybenzoyl)-5,5-dimethyl-1,3-oxazolidine-2,4-dione
DM9SLUK	DE	Discovery agent

DM7OJ5Q	ID	DM7OJ5Q
DM7OJ5Q	DN	PMID22607879CR-(-)-5f
DM7OJ5Q	HS	Investigative
DM7OJ5Q	SN	GTPL5834
DM7OJ5Q	DT	Small molecular drug
DM7OJ5Q	PC	73755161
DM7OJ5Q	MW	518.4
DM7OJ5Q	FM	C27H24BrN3O3
DM7OJ5Q	IC	InChI=1S/C27H24BrN3O3/c1-18-15-21(16-19-7-6-10-24(17-19)34-2)27(33)31(30-18)25(20-8-4-3-5-9-20)26(32)29-23-13-11-22(28)12-14-23/h3-15,17,25H,16H2,1-2H3,(H,29,32)/t25-/m1/s1
DM7OJ5Q	CS	CC1=NN(C(=O)C(=C1)CC2=CC(=CC=C2)OC)[C@H](C3=CC=CC=C3)C(=O)NC4=CC=C(C=C4)Br
DM7OJ5Q	IK	SPUZCVBKJUVZSD-RUZDIDTESA-N
DM7OJ5Q	IU	(2R)-N-(4-bromophenyl)-2-[5-[(3-methoxyphenyl)methyl]-3-methyl-6-oxopyridazin-1-yl]-2-phenylacetamide
DM7OJ5Q	DE	Discovery agent

DM19D7G	ID	DM19D7G
DM19D7G	DN	PMID22686657C(R)-26
DM19D7G	HS	Investigative
DM19D7G	SN	GTPL6535; BDBM50392215
DM19D7G	DT	Small molecular drug
DM19D7G	PC	60148519
DM19D7G	MW	380.5
DM19D7G	FM	C17H24N4O4S
DM19D7G	IC	InChI=1S/C17H24N4O4S/c1-13(2)10-26(24,25)11-15(17(23)21(4)20(3)12-18)19-16(22)14-8-6-5-7-9-14/h5-9,13,15H,10-11H2,1-4H3,(H,19,22)/t15-/m0/s1
DM19D7G	CS	CC(C)CS(=O)(=O)C[C@@H](C(=O)N(C)N(C)C#N)NC(=O)C1=CC=CC=C1
DM19D7G	IK	UGAZRSHSXNNYTK-HNNXBMFYSA-N
DM19D7G	IU	N-[(2R)-1-[[cyano(methyl)amino]-methylamino]-3-(2-methylpropylsulfonyl)-1-oxopropan-2-yl]benzamide
DM19D7G	DE	Discovery agent

DMH5RFU	ID	DMH5RFU
DMH5RFU	DN	PMID22765894C8h
DMH5RFU	HS	Investigative
DMH5RFU	SN	GTPL8175; BDBM50420996
DMH5RFU	DT	Small molecular drug
DMH5RFU	PC	67161540
DMH5RFU	MW	448
DMH5RFU	FM	C25H26ClN5O
DMH5RFU	IC	InChI=1S/C25H26ClN5O/c1-2-31-13-9-18(10-14-31)29-19-7-8-21-20(15-19)23(25(32)30-21)22(24-27-11-12-28-24)16-3-5-17(26)6-4-16/h3-8,11-12,15,18,29H,2,9-10,13-14H2,1H3,(H,27,28)(H,30,32)
DMH5RFU	CS	CCN1CCC(CC1)NC2=CC3=C(C=C2)NC(=O)C3=C(C4=CC=C(C=C4)Cl)C5=NC=CN5
DMH5RFU	IK	XHCPCYVQXFHJAU-UHFFFAOYSA-N
DMH5RFU	IU	3-[(4-chlorophenyl)-(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1H-indol-2-one
DMH5RFU	DE	Discovery agent

DM0XQZO	ID	DM0XQZO
DM0XQZO	DN	PMID22795084C1
DM0XQZO	HS	Investigative
DM0XQZO	SN	compound 1 (allosteric); GTPL7032; MolPort-019-906-830; BDBM50427768; ZINC75343937; AKOS022046525; MCULE-7514836384
DM0XQZO	DT	Small molecular drug
DM0XQZO	PC	53346504
DM0XQZO	MW	302.4
DM0XQZO	FM	C15H18N4OS
DM0XQZO	IC	InChI=1S/C15H18N4OS/c20-15(16-9-8-11-4-2-1-3-5-11)17-12-6-7-13-14(10-12)21-19-18-13/h4,6-7,10H,1-3,5,8-9H2,(H2,16,17,20)
DM0XQZO	CS	C1CCC(=CC1)CCNC(=O)NC2=CC3=C(C=C2)N=NS3
DM0XQZO	IK	GGXCUZHEJUJACD-UHFFFAOYSA-N
DM0XQZO	IU	1-(1,2,3-benzothiadiazol-6-yl)-3-[2-(cyclohexen-1-yl)ethyl]urea
DM0XQZO	DE	Discovery agent

DMVK1GT	ID	DMVK1GT
DMVK1GT	DN	PMID22802221C21
DMVK1GT	HS	Investigative
DMVK1GT	SN	C21; UNII-RC2V4W0EYC; RC2V4W0EYC; 477775-14-7; C-21; AT2R Agonist C21; GTPL6918; ZINC6467610; BDBM50156173; AKOS030231077; SB18730; NCGC00386668-01; M024/C21; M-24; butyl 3-(4-((1
DMVK1GT	DT	Small molecular drug
DMVK1GT	PC	9804984
DMVK1GT	MW	475.6
DMVK1GT	FM	C23H29N3O4S2
DMVK1GT	IC	InChI=1S/C23H29N3O4S2/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27)
DMVK1GT	CS	CCCCOC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C=CN=C3
DMVK1GT	IK	XTEOJPUYZWEXFI-UHFFFAOYSA-N
DMVK1GT	IU	butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate
DMVK1GT	CA	CAS 477775-14-7
DMVK1GT	DE	Discovery agent

DM6RY4F	ID	DM6RY4F
DM6RY4F	DN	PMID22861813C8a
DM6RY4F	HS	Investigative
DM6RY4F	SN	GTPL7891; BDBM50396558; s61
DM6RY4F	DT	Small molecular drug
DM6RY4F	PC	60182322
DM6RY4F	MW	383.4
DM6RY4F	FM	C20H18FN3O4
DM6RY4F	IC	InChI=1S/C20H18FN3O4/c1-12-6-2-3-7-13(12)15(11-19(26)27)22-20(28)16-10-18(25)24(23-16)17-9-5-4-8-14(17)21/h2-10,15,23H,11H2,1H3,(H,22,28)(H,26,27)/t15-/m0/s1
DM6RY4F	CS	CC1=CC=CC=C1[C@H](CC(=O)O)NC(=O)C2=CC(=O)N(N2)C3=CC=CC=C3F
DM6RY4F	IK	DGGLFHJMXJUSDG-HNNXBMFYSA-N
DM6RY4F	IU	(3S)-3-[[2-(2-fluorophenyl)-3-oxo-1H-pyrazole-5-carbonyl]amino]-3-(2-methylphenyl)propanoic acid
DM6RY4F	DE	Discovery agent

DMLUCSB	ID	DMLUCSB
DMLUCSB	DN	PMID22873688C3a
DMLUCSB	HS	Investigative
DMLUCSB	SN	GTPL5911
DMLUCSB	DT	Small molecular drug
DMLUCSB	PC	73755170
DMLUCSB	MW	467.1
DMLUCSB	FM	C11H16BN5O9P2S-
DMLUCSB	IC	InChI=1S/C11H16BN5O9P2S/c1-29-11-15-8(13)5-9(16-11)17(3-14-5)10-7(19)6(18)4(25-10)2-24-27(12,20)26-28(21,22)23/h3-4,6-7,10,18-19H,2H2,1H3,(H2,13,15,16)(H2,21,22,23)/q-1/t4-,6+,7+,10?,27-/m1/s1
DMLUCSB	CS	[B-][P@@](=O)(OC[C@@H]1[C@@H]([C@@H](C(O1)N2C=NC3=C(N=C(N=C32)SC)N)O)O)OP(=O)(O)O
DMLUCSB	IK	GHMYGRHRUJMVLH-CHJYMILRSA-N
DMLUCSB	DE	Discovery agent

DMXDTPL	ID	DMXDTPL
DMXDTPL	DN	PMID22902653C30
DMXDTPL	HS	Investigative
DMXDTPL	SN	GTPL8118; BDBM50390789
DMXDTPL	DT	Small molecular drug
DMXDTPL	PC	58688690
DMXDTPL	MW	503.6
DMXDTPL	FM	C26H29N7O2S
DMXDTPL	IC	InChI=1S/C26H29N7O2S/c1-6-17(7-2)35-18-10-15(3)23(16(4)11-18)20-12-19(22-14-30-26(36-22)33-25(34)27-5)31-24(32-20)21-13-28-8-9-29-21/h8-14,17H,6-7H2,1-5H3,(H2,27,30,33,34)
DMXDTPL	CS	CCC(CC)OC1=CC(=C(C(=C1)C)C2=NC(=NC(=C2)C3=CN=C(S3)NC(=O)NC)C4=NC=CN=C4)C
DMXDTPL	IK	RYXLLTGGHCFCFK-UHFFFAOYSA-N
DMXDTPL	IU	1-[5-[6-(2,6-dimethyl-4-pentan-3-yloxyphenyl)-2-pyrazin-2-ylpyrimidin-4-yl]-1,3-thiazol-2-yl]-3-methylurea
DMXDTPL	DE	Discovery agent

DMWVTAE	ID	DMWVTAE
DMWVTAE	DN	PMID22902653C31
DMWVTAE	HS	Investigative
DMWVTAE	SN	BMS 4; GTPL8117; MolPort-042-665-786; ZINC84707544; BDBM50390791; NCGC00372509-03
DMWVTAE	DT	Small molecular drug
DMWVTAE	PC	46192505
DMWVTAE	MW	461.5
DMWVTAE	FM	C23H23N7O2S
DMWVTAE	IC	InChI=1S/C23H23N7O2S/c1-5-25-22(31)30-23-27-12-19(33-23)16-10-17(20-13(2)8-15(32-4)9-14(20)3)29-21(28-16)18-11-24-6-7-26-18/h6-12H,5H2,1-4H3,(H2,25,27,30,31)
DMWVTAE	CS	CCNC(=O)NC1=NC=C(S1)C2=CC(=NC(=N2)C3=NC=CN=C3)C4=C(C=C(C=C4C)OC)C
DMWVTAE	IK	WUCYRTXFXRZKSV-UHFFFAOYSA-N
DMWVTAE	IU	1-ethyl-3-[5-[6-(4-methoxy-2,6-dimethylphenyl)-2-pyrazin-2-ylpyrimidin-4-yl]-1,3-thiazol-2-yl]urea
DMWVTAE	DE	Discovery agent

DMLVKPG	ID	DMLVKPG
DMLVKPG	DN	PMID22902653C35
DMLVKPG	HS	Investigative
DMLVKPG	SN	GTPL8119; BDBM50390795
DMLVKPG	DT	Small molecular drug
DMLVKPG	PC	58688563
DMLVKPG	MW	473.3
DMLVKPG	FM	C20H14Cl2N6O2S
DMLVKPG	IC	InChI=1S/C20H14Cl2N6O2S/c1-10(29)26-20-25-9-17(31-20)14-7-15(18-12(21)5-11(30-2)6-13(18)22)28-19(27-14)16-8-23-3-4-24-16/h3-9H,1-2H3,(H,25,26,29)
DMLVKPG	CS	CC(=O)NC1=NC=C(S1)C2=CC(=NC(=N2)C3=NC=CN=C3)C4=C(C=C(C=C4Cl)OC)Cl
DMLVKPG	IK	XACSASLXEAYEEO-UHFFFAOYSA-N
DMLVKPG	IU	N-[5-[6-(2,6-dichloro-4-methoxyphenyl)-2-pyrazin-2-ylpyrimidin-4-yl]-1,3-thiazol-2-yl]acetamide
DMLVKPG	DE	Discovery agent

DMOKZ3R	ID	DMOKZ3R
DMOKZ3R	DN	PMID2296027C25
DMOKZ3R	HS	Investigative
DMOKZ3R	SN	GTPL2965; BDBM50014729
DMOKZ3R	DT	Small molecular drug
DMOKZ3R	PC	44349317
DMOKZ3R	MW	440.5
DMOKZ3R	FM	C25H26F2N2O3
DMOKZ3R	IC	InChI=1S/C25H26F2N2O3/c1-15(2)24-22(12-11-21-13-20(30)14-23(31)32-21)25(16-3-5-17(26)6-4-16)29(28-24)19-9-7-18(27)8-10-19/h3-10,15,20-21,30H,11-14H2,1-2H3/t20-,21-/m0/s1
DMOKZ3R	CS	CC(C)C1=NN(C(=C1CC[C@H]2C[C@@H](CC(=O)O2)O)C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMOKZ3R	IK	CJOOCCJIHMSWOT-SFTDATJTSA-N
DMOKZ3R	IU	(4S,6S)-6-[2-[1,5-bis(4-fluorophenyl)-3-propan-2-ylpyrazol-4-yl]ethyl]-4-hydroxyoxan-2-one
DMOKZ3R	DE	Discovery agent

DMY267E	ID	DMY267E
DMY267E	DN	PMID2296027C29
DMY267E	HS	Investigative
DMY267E	SN	GTPL2964; BDBM50014719
DMY267E	DT	Small molecular drug
DMY267E	PC	44349330
DMY267E	MW	436.5
DMY267E	FM	C26H29FN2O3
DMY267E	IC	InChI=1S/C26H29FN2O3/c1-17(2)25-23(13-12-22-14-21(30)15-24(31)32-22)26(19-8-10-20(27)11-9-19)29(28-25)16-18-6-4-3-5-7-18/h3-11,17,21-22,30H,12-16H2,1-2H3/t21-,22-/m0/s1
DMY267E	CS	CC(C)C1=NN(C(=C1CC[C@H]2C[C@@H](CC(=O)O2)O)C3=CC=C(C=C3)F)CC4=CC=CC=C4
DMY267E	IK	SFTVYVGIXNZCEX-VXKWHMMOSA-N
DMY267E	IU	(4S,6S)-6-[2-[1-benzyl-5-(4-fluorophenyl)-3-propan-2-ylpyrazol-4-yl]ethyl]-4-hydroxyoxan-2-one
DMY267E	DE	Discovery agent

DM6VG8K	ID	DM6VG8K
DM6VG8K	DN	PMID2296036C2g
DM6VG8K	HS	Investigative
DM6VG8K	SN	GTPL2971
DM6VG8K	DT	Small molecular drug
DM6VG8K	PC	44370417
DM6VG8K	MW	411.5
DM6VG8K	FM	C25H30FNO3
DM6VG8K	IC	InChI=1S/C25H30FNO3/c1-15(2)24-20(11-10-19-12-18(28)13-23(29)30-19)21(14-22(27-24)25(3,4)5)16-6-8-17(26)9-7-16/h6-11,14-15,18-19,28H,12-13H2,1-5H3/b11-10+/t18-,19?/m1/s1
DM6VG8K	CS	CC(C)C1=C(C(=CC(=N1)C(C)(C)C)C2=CC=C(C=C2)F)/C=C/C3C[C@H](CC(=O)O3)O
DM6VG8K	IK	VPMIAOSOTOODMY-KJAPKAAFSA-N
DM6VG8K	IU	(4R)-6-[(E)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one
DM6VG8K	DE	Discovery agent

DMBXCNA	ID	DMBXCNA
DMBXCNA	DN	PMID2296036C2t
DMBXCNA	HS	Investigative
DMBXCNA	SN	GTPL2972; BDBM50014837
DMBXCNA	DT	Small molecular drug
DMBXCNA	PC	73348335
DMBXCNA	MW	398.5
DMBXCNA	FM	C23H27FN2O3
DMBXCNA	IC	InChI=1S/C23H27FN2O3/c1-13(2)21-19(10-9-18-11-17(27)12-20(28)29-18)22(26-23(25-21)14(3)4)15-5-7-16(24)8-6-15/h5-10,13-14,17-18,27H,11-12H2,1-4H3/b10-9+/t17-,18-/m1/s1
DMBXCNA	CS	CC(C)C1=NC(=NC(=C1/C=C/[C@@H]2C[C@H](CC(=O)O2)O)C3=CC=C(C=C3)F)C(C)C
DMBXCNA	IK	UTOIEVWJKDLJGE-AQRBRUGDSA-N
DMBXCNA	IU	(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-2,6-di(propan-2-yl)pyrimidin-5-yl]ethenyl]-4-hydroxyoxan-2-one
DMBXCNA	DE	Discovery agent

DMC6HQL	ID	DMC6HQL
DMC6HQL	DN	PMID2296036C4d
DMC6HQL	HS	Investigative
DMC6HQL	SN	GTPL2969; BDBM50014816
DMC6HQL	DT	Small molecular drug
DMC6HQL	PC	44370460
DMC6HQL	MW	419.5
DMC6HQL	FM	C26H26FNO3
DMC6HQL	IC	InChI=1S/C26H26FNO3/c1-2-24-22(13-12-21-14-20(29)15-26(30)31-21)23(17-8-10-19(27)11-9-17)16-25(28-24)18-6-4-3-5-7-18/h3-11,16,20-21,29H,2,12-15H2,1H3/t20-,21?/m1/s1
DMC6HQL	CS	CCC1=C(C(=CC(=N1)C2=CC=CC=C2)C3=CC=C(C=C3)F)CCC4C[C@H](CC(=O)O4)O
DMC6HQL	IK	PNHBRYIAJCYNDA-VQCQRNETSA-N
DMC6HQL	IU	(4R)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one
DMC6HQL	DE	Discovery agent

DMSJ94N	ID	DMSJ94N
DMSJ94N	DN	PMID2296036C4i
DMSJ94N	HS	Investigative
DMSJ94N	SN	GTPL2968; BDBM50014834
DMSJ94N	DT	Small molecular drug
DMSJ94N	PC	44370459
DMSJ94N	MW	433.5
DMSJ94N	FM	C27H28FNO3
DMSJ94N	IC	InChI=1S/C27H28FNO3/c1-17(2)27-23(13-12-22-14-21(30)15-26(31)32-22)24(18-8-10-20(28)11-9-18)16-25(29-27)19-6-4-3-5-7-19/h3-11,16-17,21-22,30H,12-15H2,1-2H3/t21-,22?/m1/s1
DMSJ94N	CS	CC(C)C1=C(C(=CC(=N1)C2=CC=CC=C2)C3=CC=C(C=C3)F)CCC4C[C@H](CC(=O)O4)O
DMSJ94N	IK	QVBVQHTXLPNXEY-ZMFCMNQTSA-N
DMSJ94N	IU	(4R)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one
DMSJ94N	DE	Discovery agent

DMAW86U	ID	DMAW86U
DMAW86U	DN	PMID22984835C20o
DMAW86U	HS	Investigative
DMAW86U	SN	GTPL5906; BDBM50397143; 1163793-95-0
DMAW86U	DT	Small molecular drug
DMAW86U	PC	66855377
DMAW86U	MW	637.7
DMAW86U	FM	C32H43N7O7
DMAW86U	IC	InChI=1S/C32H43N7O7/c1-2-3-19-45-32(44)37-17-15-36(16-18-37)27(40)21-33-30(42)25-20-29(39(35-25)24-11-5-4-6-12-24)46-22-28(41)38-14-8-13-26(38)31(43)34-23-9-7-10-23/h4-6,11-12,20,23,26H,2-3,7-10,13-19,21-22H2,1H3,(H,33,42)(H,34,43)/t26-/m0/s1
DMAW86U	CS	CCCCOC(=O)N1CCN(CC1)C(=O)CNC(=O)C2=NN(C(=C2)OCC(=O)N3CCC[C@H]3C(=O)NC4CCC4)C5=CC=CC=C5
DMAW86U	IK	QCKRRHRHLONWIP-SANMLTNESA-N
DMAW86U	IU	butyl 4-[2-[[5-[2-[(2S)-2-(cyclobutylcarbamoyl)pyrrolidin-1-yl]-2-oxoethoxy]-1-phenylpyrazole-3-carbonyl]amino]acetyl]piperazine-1-carboxylate
DMAW86U	DE	Discovery agent

DMMI9JE	ID	DMMI9JE
DMMI9JE	DN	PMID22984835C4
DMMI9JE	HS	Investigative
DMMI9JE	SN	GTPL5905; BDBM50397145
DMMI9JE	DT	Small molecular drug
DMMI9JE	PC	44126037
DMMI9JE	MW	599.6
DMMI9JE	FM	C29H37N5O9
DMMI9JE	IC	InChI=1S/C29H37N5O9/c1-3-41-27(39)29(13-8-14-29)43-23-19-22(31-34(23)20-9-6-5-7-10-20)25(37)30-21(11-12-24(35)36)26(38)32-15-17-33(18-16-32)28(40)42-4-2/h5-7,9-10,19,21H,3-4,8,11-18H2,1-2H3,(H,30,37)(H,35,36)/t21-/m0/s1
DMMI9JE	CS	CCOC(=O)C1(CCC1)OC2=CC(=NN2C3=CC=CC=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)N4CCN(CC4)C(=O)OCC
DMMI9JE	IK	HPSHQEAEJMOGDO-NRFANRHFSA-N
DMMI9JE	IU	(4S)-4-[[5-(1-ethoxycarbonylcyclobutyl)oxy-1-phenylpyrazole-3-carbonyl]amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid
DMMI9JE	DE	Discovery agent

DMW579R	ID	DMW579R
DMW579R	DN	PMID23083103C4
DMW579R	HS	Investigative
DMW579R	SN	GTPL6148
DMW579R	DT	Small molecular drug
DMW579R	PC	73755176
DMW579R	MW	901
DMW579R	FM	C21H29ClN10O16P4S2
DMW579R	IC	InChI=1S/C21H29ClN10O16P4S2/c22-21(49(37,38)47-51(41,53)43-1-7-11(33)13(35)19(45-7)31-5-29-9-15(23)25-3-27-17(9)31)50(39,40)48-52(42,54)44-2-8-12(34)14(36)20(46-8)32-6-30-10-16(24)26-4-28-18(10)32/h3-8,11-14,19-21,33-36H,1-2H2,(H,37,38)(H,39,40)(H,41,53)(H,42,54)(H2,23,25,27)(H2,24,26,28)/t7-,8?,11+,12+,13?,14+,19-,20-,21?,51?,52?/m1/s1
DMW579R	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@H](C(O3)COP(=O)(OP(=O)(C(P(=O)(O)OP(=S)(O)OC[C@@H]4[C@@H](C([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)Cl)O)S)O)O)N
DMW579R	IK	SQXLFBVOQBYLCG-BUWSHSPFSA-N
DMW579R	IU	[[(2R,3R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-[[[[(3R,4S,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-hydroxyphosphoryl]-chloromethyl]phosphinic acid
DMW579R	DE	Discovery agent

DMURP5Y	ID	DMURP5Y
DMURP5Y	DN	PMID23084894C10i
DMURP5Y	HS	Investigative
DMURP5Y	SN	GTPL6365; BDBM50401676
DMURP5Y	DT	Small molecular drug
DMURP5Y	PC	57559562
DMURP5Y	MW	365.4
DMURP5Y	FM	C18H15N5O2S
DMURP5Y	IC	InChI=1S/C18H15N5O2S/c1-25-12-6-4-11(5-7-12)23-9-21-14-13-16(22-10-2-3-10)19-8-20-17(13)26-15(14)18(23)24/h4-10H,2-3H2,1H3,(H,19,20,22)
DMURP5Y	CS	COC1=CC=C(C=C1)N2C=NC3=C(C2=O)SC4=NC=NC(=C34)NC5CC5
DMURP5Y	IK	DBUMITZHDMTTNX-UHFFFAOYSA-N
DMURP5Y	IU	13-(cyclopropylamino)-5-(4-methoxyphenyl)-8-thia-3,5,10,12-tetrazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMURP5Y	DE	Discovery agent

DM4ATLM	ID	DM4ATLM
DM4ATLM	DN	PMID23084894C9n
DM4ATLM	HS	Investigative
DM4ATLM	SN	GTPL6362; BDBM50401677
DM4ATLM	DT	Small molecular drug
DM4ATLM	PC	16725048
DM4ATLM	MW	371.4
DM4ATLM	FM	C17H14FN5O2S
DM4ATLM	IC	InChI=1S/C17H14FN5O2S/c1-22(2)15-12-13-14(26-16(12)20-7-19-15)17(24)23(8-21-13)11-5-4-9(25-3)6-10(11)18/h4-8H,1-3H3
DM4ATLM	CS	CN(C)C1=C2C3=C(C(=O)N(C=N3)C4=C(C=C(C=C4)OC)F)SC2=NC=N1
DM4ATLM	IK	XUSKBQJCEPMVBM-UHFFFAOYSA-N
DM4ATLM	IU	13-(dimethylamino)-5-(2-fluoro-4-methoxyphenyl)-8-thia-3,5,10,12-tetrazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DM4ATLM	DE	Discovery agent

DMWS7O9	ID	DMWS7O9
DMWS7O9	DN	PMID23099093C17d
DMWS7O9	HS	Investigative
DMWS7O9	SN	GTPL8196; ZINC95559591; BDBM50401900
DMWS7O9	DT	Small molecular drug
DMWS7O9	PC	44465558
DMWS7O9	MW	450.6
DMWS7O9	FM	C25H34N6O2
DMWS7O9	IC	InChI=1S/C25H34N6O2/c32-24(19-3-1-4-19)27-12-2-11-26-23-22(18-5-6-18)17-28-25(30-23)29-20-7-9-21(10-8-20)31-13-15-33-16-14-31/h7-10,17-19H,1-6,11-16H2,(H,27,32)(H2,26,28,29,30)
DMWS7O9	CS	C1CC(C1)C(=O)NCCCNC2=NC(=NC=C2C3CC3)NC4=CC=C(C=C4)N5CCOCC5
DMWS7O9	IK	CJPMSUUANYLPET-UHFFFAOYSA-N
DMWS7O9	IU	N-[3-[[5-cyclopropyl-2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]propyl]cyclobutanecarboxamide
DMWS7O9	DE	Discovery agent

DM3Z6F4	ID	DM3Z6F4
DM3Z6F4	DN	PMID23147077C10
DM3Z6F4	HS	Investigative
DM3Z6F4	SN	GTPL8133; BDBM50334268; ZINC43193842; MRF-0000031; NCGC00344859-04
DM3Z6F4	DT	Small molecular drug
DM3Z6F4	PC	24944925
DM3Z6F4	MW	359.4
DM3Z6F4	FM	C21H21N5O
DM3Z6F4	IC	InChI=1S/C21H21N5O/c1-21(2,3)16-6-4-15(5-7-16)20(27)24-18-13-26-12-17(8-9-19(26)23-18)25-11-10-22-14-25/h4-14H,1-3H3,(H,24,27)
DM3Z6F4	CS	CC(C)(C)C1=CC=C(C=C1)C(=O)NC2=CN3C=C(C=CC3=N2)N4C=CN=C4
DM3Z6F4	IK	SMJAMOAYGIVKRI-UHFFFAOYSA-N
DM3Z6F4	IU	4-tert-butyl-N-(6-imidazol-1-ylimidazo[1,2-a]pyridin-2-yl)benzamide
DM3Z6F4	DE	Discovery agent

DMBT92F	ID	DMBT92F
DMBT92F	DN	PMID23232060C5
DMBT92F	HS	Investigative
DMBT92F	SN	GTPL8192; BDBM50424547
DMBT92F	DT	Small molecular drug
DMBT92F	PC	71540619
DMBT92F	MW	429.5
DMBT92F	FM	C25H27N5O2
DMBT92F	IC	InChI=1S/C25H27N5O2/c1-29-10-12-30(13-11-29)22-6-5-20(16-24(22)32-3)28-25-15-19(8-9-27-25)21-14-18(17-26)4-7-23(21)31-2/h4-9,14-16H,10-13H2,1-3H3,(H,27,28)
DMBT92F	CS	CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=C3)C4=C(C=CC(=C4)C#N)OC)OC
DMBT92F	IK	GOMSKBLQVUFHHS-UHFFFAOYSA-N
DMBT92F	IU	4-methoxy-3-[2-[3-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyridin-4-yl]benzonitrile
DMBT92F	DE	Discovery agent

DMOJ8QR	ID	DMOJ8QR
DMOJ8QR	DN	PMID23312943C21
DMOJ8QR	HS	Investigative
DMOJ8QR	SN	GTPL8135; BDBM50425862
DMOJ8QR	DT	Small molecular drug
DMOJ8QR	PC	71553154
DMOJ8QR	MW	461.4
DMOJ8QR	FM	C22H26Cl2N6O
DMOJ8QR	IC	InChI=1S/C22H26Cl2N6O/c1-13-8-20(31-29-13)19-12-25-22(27-17-10-14(23)9-15(24)11-17)28-21(19)26-16-4-6-18(7-5-16)30(2)3/h8-12,16,18H,4-7H2,1-3H3,(H2,25,26,27,28)
DMOJ8QR	CS	CC1=NOC(=C1)C2=CN=C(N=C2NC3CCC(CC3)N(C)C)NC4=CC(=CC(=C4)Cl)Cl
DMOJ8QR	IK	ZTSOUDMNSOYCTG-UHFFFAOYSA-N
DMOJ8QR	IU	2-N-(3,5-dichlorophenyl)-4-N-[4-(dimethylamino)cyclohexyl]-5-(3-methyl-1,2-oxazol-5-yl)pyrimidine-2,4-diamine
DMOJ8QR	DE	Discovery agent

DM4NAC9	ID	DM4NAC9
DM4NAC9	DN	PMID23357634C24d
DM4NAC9	HS	Investigative
DM4NAC9	SN	GTPL6366
DM4NAC9	DT	Small molecular drug
DM4NAC9	PC	73755212
DM4NAC9	MW	306.79
DM4NAC9	FM	C16H19ClN2O2
DM4NAC9	IC	InChI=1S/C16H19ClN2O2/c1-11(20)19-14-6-3-7-16(9-14)10-18-15(21-16)12-4-2-5-13(17)8-12/h2,4-5,8,14H,3,6-7,9-10H2,1H3,(H,19,20)/t14-,16+/m0/s1
DM4NAC9	CS	CC(=O)N[C@H]1CCC[C@@]2(C1)CN=C(O2)C3=CC(=CC=C3)Cl
DM4NAC9	IK	NFPUARSXIMWASK-GOEBONIOSA-N
DM4NAC9	IU	N-[(5R,7S)-2-(3-chlorophenyl)-1-oxa-3-azaspiro[4.5]dec-2-en-7-yl]acetamide
DM4NAC9	DE	Discovery agent

DMPHKJI	ID	DMPHKJI
DMPHKJI	DN	PMID23368907C16 
DMPHKJI	HS	Investigative
DMPHKJI	SN	BPTU; 870544-59-5; GTPL5808; BMS-646786; MolPort-046-033-632; BCP29138; EX-A2593; ZINC95588286; BDBM50429537; AKOS032962872; CS-8114; HY-13831; DS-20243; AK689499; 1-(2-[2-
DMPHKJI	DT	Small molecular drug
DMPHKJI	PC	11510579
DMPHKJI	MW	445.4
DMPHKJI	FM	C23H22F3N3O3
DMPHKJI	IC	InChI=1S/C23H22F3N3O3/c1-22(2,3)17-7-4-5-9-19(17)31-20-18(8-6-14-27-20)29-21(30)28-15-10-12-16(13-11-15)32-23(24,25)26/h4-14H,1-3H3,(H2,28,29,30)
DMPHKJI	CS	CC(C)(C)C1=CC=CC=C1OC2=C(C=CC=N2)NC(=O)NC3=CC=C(C=C3)OC(F)(F)F
DMPHKJI	IK	AHFLGPTXSIRAQK-UHFFFAOYSA-N
DMPHKJI	IU	1-[2-(2-tert-butylphenoxy)pyridin-3-yl]-3-[4-(trifluoromethoxy)phenyl]urea
DMPHKJI	DE	Discovery agent

DMEZSHI	ID	DMEZSHI
DMEZSHI	DN	PMID23374866C31
DMEZSHI	HS	Investigative
DMEZSHI	SN	4idv; GTPL8174; BDBM50429614; 13V
DMEZSHI	DT	Small molecular drug
DMEZSHI	PC	58221375
DMEZSHI	MW	366.4
DMEZSHI	FM	C20H22N4O3
DMEZSHI	IC	InChI=1S/C20H22N4O3/c1-20(2,25)7-6-13-4-5-16-14(10-13)15(11-22-16)18-17(27-9-8-26-3)12-23-19(21)24-18/h4-5,10-12,22,25H,8-9H2,1-3H3,(H2,21,23,24)
DMEZSHI	CS	CC(C)(C#CC1=CC2=C(C=C1)NC=C2C3=NC(=NC=C3OCCOC)N)O
DMEZSHI	IK	ZZIZLABGKZWVAW-UHFFFAOYSA-N
DMEZSHI	IU	4-[3-[2-amino-5-(2-methoxyethoxy)pyrimidin-4-yl]-1H-indol-5-yl]-2-methylbut-3-yn-2-ol
DMEZSHI	DE	Discovery agent

DMRC14X	ID	DMRC14X
DMRC14X	DN	PMID23374867C24
DMRC14X	HS	Investigative
DMRC14X	SN	GTPL6419; BDBM50429651
DMRC14X	DT	Small molecular drug
DMRC14X	PC	71559428
DMRC14X	MW	431.6
DMRC14X	FM	C24H25N5OS
DMRC14X	IC	InChI=1S/C24H25N5OS/c1-4-6-17-7-5-8-20(25-17)21-22(15-9-10-19-16(12-15)13-29(3)27-19)28-31-24(21)26-23(30)18-11-14(18)2/h5,7-10,12-14,18H,4,6,11H2,1-3H3,(H,26,30)/t14-,18-/m1/s1
DMRC14X	CS	CCCC1=NC(=CC=C1)C2=C(SN=C2C3=CC4=CN(N=C4C=C3)C)NC(=O)[C@@H]5C[C@H]5C
DMRC14X	IK	DMJNZMXZSQWBRT-RDTXWAMCSA-N
DMRC14X	IU	(1R,2R)-2-methyl-N-[3-(2-methylindazol-5-yl)-4-(6-propylpyridin-2-yl)-1,2-thiazol-5-yl]cyclopropane-1-carboxamide
DMRC14X	DE	Discovery agent

DM9O8I7	ID	DM9O8I7
DM9O8I7	DN	PMID23412139C16
DM9O8I7	HS	Investigative
DM9O8I7	SN	0V6; GTPL8698; BDBM50392835
DM9O8I7	DT	Small molecular drug
DM9O8I7	PC	66575082
DM9O8I7	MW	372.9
DM9O8I7	FM	C18H17ClN4OS
DM9O8I7	IC	InChI=1S/C18H17ClN4OS/c1-4-5-11-6-12(10-21-9-11)14-7-13(19)16(25-14)18(2)8-15(24)23(3)17(20)22-18/h6-7,9-10H,8H2,1-3H3,(H2,20,22)/t18-/m0/s1
DM9O8I7	CS	CC#CC1=CC(=CN=C1)C2=CC(=C(S2)[C@@]3(CC(=O)N(C(=N3)N)C)C)Cl
DM9O8I7	IK	IJYPXSRDUPWKPB-SFHVURJKSA-N
DM9O8I7	IU	(6S)-2-amino-6-[3-chloro-5-(5-prop-1-ynylpyridin-3-yl)thiophen-2-yl]-3,6-dimethyl-5H-pyrimidin-4-one
DM9O8I7	DE	Discovery agent

DMNVQ29	ID	DMNVQ29
DMNVQ29	DN	PMID23414845C30
DMNVQ29	HS	Investigative
DMNVQ29	SN	4i4f; GTPL7864; BDBM50430287; 1BR
DMNVQ29	DT	Small molecular drug
DMNVQ29	PC	70698427
DMNVQ29	MW	410.5
DMNVQ29	FM	C22H26N4O2S
DMNVQ29	IC	InChI=1S/C22H26N4O2S/c1-22(2,3)16-8-6-15(7-9-16)13-23-17-10-11-19-18(12-17)21-20(14-24-25(21)4)29(27,28)26(19)5/h6-12,14,23H,13H2,1-5H3
DMNVQ29	CS	CC(C)(C)C1=CC=C(C=C1)CNC2=CC3=C(C=C2)N(S(=O)(=O)C4=C3N(N=C4)C)C
DMNVQ29	IK	AVFJKWOKOZKXRX-UHFFFAOYSA-N
DMNVQ29	IU	N-[(4-tert-butylphenyl)methyl]-1,5-dimethyl-4,4-dioxopyrazolo[4,3-c][2,1]benzothiazin-8-amine
DMNVQ29	DE	Discovery agent

DMZUQ7X	ID	DMZUQ7X
DMZUQ7X	DN	PMID23428964CI3
DMZUQ7X	HS	Investigative
DMZUQ7X	SN	GTPL8565; BDBM50353018
DMZUQ7X	DT	Small molecular drug
DMZUQ7X	PC	53494934
DMZUQ7X	MW	330.2
DMZUQ7X	FM	C17H16BrNO
DMZUQ7X	IC	InChI=1S/C17H16BrNO/c18-15-8-6-12(11-4-2-1-3-5-11)14-10-17(20)16(19)9-7-13(14)15/h1-6,8,16H,7,9-10,19H2
DMZUQ7X	CS	C1CC2=C(C=CC(=C2CC(=O)C1N)C3=CC=CC=C3)Br
DMZUQ7X	IK	XFZZDIHCNHYESF-UHFFFAOYSA-N
DMZUQ7X	IU	7-amino-1-bromo-4-phenyl-5,7,8,9-tetrahydrobenzo[7]annulen-6-one
DMZUQ7X	DE	Discovery agent

DMG0XC7	ID	DMG0XC7
DMG0XC7	DN	PMID23434029C41
DMG0XC7	HS	Investigative
DMG0XC7	SN	GTPL6420; BDBM50431718
DMG0XC7	DT	Small molecular drug
DMG0XC7	PC	71580330
DMG0XC7	MW	324.4
DMG0XC7	FM	C18H17FN4O
DMG0XC7	IC	InChI=1S/C18H17FN4O/c1-11-5-4-6-16(20-11)22-18(24)17-12(2)23(13(3)21-17)15-9-7-14(19)8-10-15/h4-10H,1-3H3,(H,20,22,24)
DMG0XC7	CS	CC1=NC(=CC=C1)NC(=O)C2=C(N(C(=N2)C)C3=CC=C(C=C3)F)C
DMG0XC7	IK	YQFYIHPLHNEXNE-UHFFFAOYSA-N
DMG0XC7	IU	1-(4-fluorophenyl)-2,5-dimethyl-N-(6-methylpyridin-2-yl)imidazole-4-carboxamide
DMG0XC7	DE	Discovery agent

DMG0B4N	ID	DMG0B4N
DMG0B4N	DN	PMID23434029C53
DMG0B4N	HS	Investigative
DMG0B4N	SN	GTPL6451
DMG0B4N	DT	Small molecular drug
DMG0B4N	PC	71580550
DMG0B4N	MW	327.77
DMG0B4N	FM	C16H14ClN5O
DMG0B4N	IC	InChI=1S/C16H14ClN5O/c1-10-14(15(23)20-13-8-9-18-16(17)21-13)19-11(2)22(10)12-6-4-3-5-7-12/h3-9H,1-2H3,(H,18,20,21,23)
DMG0B4N	CS	CC1=C(N=C(N1C2=CC=CC=C2)C)C(=O)NC3=NC(=NC=C3)Cl
DMG0B4N	IK	YCJZWBZJSYLMPB-UHFFFAOYSA-N
DMG0B4N	IU	N-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide
DMG0B4N	DE	Discovery agent

DMG4MLA	ID	DMG4MLA
DMG4MLA	DN	PMID23441572C24
DMG4MLA	HS	Investigative
DMG4MLA	SN	GTPL8147; BDBM50427749
DMG4MLA	DT	Small molecular drug
DMG4MLA	PC	71605047
DMG4MLA	MW	532.6
DMG4MLA	FM	C29H27F3N6O
DMG4MLA	IC	InChI=1S/C29H27F3N6O/c1-20-3-4-22(15-21(20)6-8-25-17-33-18-27-34-9-10-38(25)27)28(39)35-24-7-5-23(26(16-24)29(30,31)32)19-37-13-11-36(2)12-14-37/h3-5,7,9-10,15-18H,11-14,19H2,1-2H3,(H,35,39)
DMG4MLA	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=CC5=NC=CN45
DMG4MLA	IK	VSJSIOZQNZPUAV-UHFFFAOYSA-N
DMG4MLA	IU	3-(2-imidazo[1,2-a]pyrazin-5-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
DMG4MLA	DE	Discovery agent

DMDYC4J	ID	DMDYC4J
DMDYC4J	DN	PMID23489211C20
DMDYC4J	HS	Investigative
DMDYC4J	SN	PCM126; GTPL8124; BDBM50428059
DMDYC4J	DT	Small molecular drug
DMDYC4J	PC	71718651
DMDYC4J	MW	562.8
DMDYC4J	FM	C35H50N2O4
DMDYC4J	IC	InChI=1S/C35H50N2O4/c1-21(8-13-32(39)37-31(33(40)41)18-22-20-36-30-7-5-4-6-25(22)30)27-11-12-28-26-10-9-23-19-24(38)14-16-34(23,2)29(26)15-17-35(27,28)3/h4-7,20-21,23-24,26-29,31,36,38H,8-19H2,1-3H3,(H,37,39)(H,40,41)/t21-,23-,24-,26+,27-,28+,29+,31+,34+,35-/m1/s1
DMDYC4J	CS	C[C@H](CCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)[C@H]3CC[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@H]6[C@@]5(CC[C@H](C6)O)C)C
DMDYC4J	IK	ITOFPJRDSCGOSA-KZLRUDJFSA-N
DMDYC4J	IU	(2S)-2-[[(4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMDYC4J	DE	Discovery agent

DMFQVNL	ID	DMFQVNL
DMFQVNL	DN	PMID23517011C9
DMFQVNL	HS	Investigative
DMFQVNL	SN	GTPL7517; BDBM50430836
DMFQVNL	DT	Small molecular drug
DMFQVNL	PC	71624782
DMFQVNL	MW	337.4
DMFQVNL	FM	C20H19NO4
DMFQVNL	IC	InChI=1S/C20H19NO4/c1-12-19(13(2)25-21-12)16-9-17(11-18(10-16)24-14(3)22)20(23)15-7-5-4-6-8-15/h4-11,20,23H,1-3H3
DMFQVNL	CS	CC1=C(C(=NO1)C)C2=CC(=CC(=C2)OC(=O)C)C(C3=CC=CC=C3)O
DMFQVNL	IK	BLNKHZBHJDYSGF-UHFFFAOYSA-N
DMFQVNL	IU	[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-[hydroxy(phenyl)methyl]phenyl] acetate
DMFQVNL	DE	Discovery agent

DMPCTED	ID	DMPCTED
DMPCTED	DN	PMID23521020C7k
DMPCTED	HS	Investigative
DMPCTED	SN	GTPL8164; BDBM50430865; ZINC95592818
DMPCTED	DT	Small molecular drug
DMPCTED	PC	71624791
DMPCTED	MW	386.8
DMPCTED	FM	C22H15ClN4O
DMPCTED	IC	InChI=1S/C22H15ClN4O/c1-15-5-7-18(22(28)26-20-4-2-3-19(23)12-20)11-17(15)8-6-16-13-24-21-9-10-25-27(21)14-16/h2-5,7,9-14H,1H3,(H,26,28)
DMPCTED	CS	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC=C2)Cl)C#CC3=CN4C(=CC=N4)N=C3
DMPCTED	IK	PSBGROLQRNSAMY-UHFFFAOYSA-N
DMPCTED	IU	N-(3-chlorophenyl)-4-methyl-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)benzamide
DMPCTED	DE	Discovery agent

DMB7TE6	ID	DMB7TE6
DMB7TE6	DN	PMID23589301C1
DMB7TE6	HS	Investigative
DMB7TE6	SN	GTPL6488
DMB7TE6	DT	Small molecular drug
DMB7TE6	PC	67209274
DMB7TE6	MW	475.4
DMB7TE6	FM	C23H20Cl2N2O3S
DMB7TE6	IC	InChI=1S/C23H20Cl2N2O3S/c24-16-6-9-19(25)18(12-16)20-13-31-23(26-20)27(17-7-8-17)22(30)15(11-21(28)29)10-14-4-2-1-3-5-14/h1-6,9,12-13,15,17H,7-8,10-11H2,(H,28,29)
DMB7TE6	CS	C1CC1N(C2=NC(=CS2)C3=C(C=CC(=C3)Cl)Cl)C(=O)C(CC4=CC=CC=C4)CC(=O)O
DMB7TE6	IK	LCRQPJWEPVZEBE-UHFFFAOYSA-N
DMB7TE6	IU	3-benzyl-4-[cyclopropyl-[4-(2,5-dichlorophenyl)-1,3-thiazol-2-yl]amino]-4-oxobutanoic acid
DMB7TE6	DE	Discovery agent

DMM92IB	ID	DMM92IB
DMM92IB	DN	PMID23631440C29e
DMM92IB	HS	Investigative
DMM92IB	SN	GTPL8578; BDBM50433865
DMM92IB	DT	Small molecular drug
DMM92IB	PC	46175162
DMM92IB	MW	505.7
DMM92IB	FM	C24H31N3O5S2
DMM92IB	IC	InChI=1S/C24H31N3O5S2/c1-18(28)25-15-7-3-6-10-24(29)27-16-22(23(33)17-27)26-34(30,31)21-13-11-20(12-14-21)32-19-8-4-2-5-9-19/h2,4-5,8-9,11-14,22-23,26,33H,3,6-7,10,15-17H2,1H3,(H,25,28)/t22-,23-/m0/s1
DMM92IB	CS	CC(=O)NCCCCCC(=O)N1C[C@@H]([C@H](C1)S)NS(=O)(=O)C2=CC=C(C=C2)OC3=CC=CC=C3
DMM92IB	IK	MUWDEQLPHWVPPA-GOTSBHOMSA-N
DMM92IB	IU	N-[6-oxo-6-[(3S,4S)-3-[(4-phenoxyphenyl)sulfonylamino]-4-sulfanylpyrrolidin-1-yl]hexyl]acetamide
DMM92IB	DE	Discovery agent

DMA8UQM	ID	DMA8UQM
DMA8UQM	DN	PMID23634668C14
DMA8UQM	HS	Investigative
DMA8UQM	SN	GTPL8557
DMA8UQM	DT	Small molecular drug
DMA8UQM	PC	71663862
DMA8UQM	MW	480.6
DMA8UQM	FM	C28H28N6O2
DMA8UQM	IC	InChI=1S/C28H28N6O2/c1-20(35)30-25(19-21-9-3-2-4-10-21)28(36)34-17-15-33(16-18-34)27-22-11-5-6-12-23(22)31-26(32-27)24-13-7-8-14-29-24/h2-14,25H,15-19H2,1H3,(H,30,35)/t25-/m0/s1
DMA8UQM	CS	CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCN(CC2)C3=NC(=NC4=CC=CC=C43)C5=CC=CC=N5
DMA8UQM	IK	NHHPRDYQOKYIBK-VWLOTQADSA-N
DMA8UQM	IU	N-[(2S)-1-oxo-3-phenyl-1-[4-(2-pyridin-2-ylquinazolin-4-yl)piperazin-1-yl]propan-2-yl]acetamide
DMA8UQM	DE	Discovery agent

DMLXOAQ	ID	DMLXOAQ
DMLXOAQ	DN	PMID23639540C13a
DMLXOAQ	HS	Investigative
DMLXOAQ	SN	1435615-18-1; GTPL8155; KS-00000UBW; MolPort-044-728-919; ZINC96270778; BDBM50434751; AKOS032946391; AK687595
DMLXOAQ	DT	Small molecular drug
DMLXOAQ	PC	60182393
DMLXOAQ	MW	346.4
DMLXOAQ	FM	C19H18N6O
DMLXOAQ	IC	InChI=1S/C19H18N6O/c1-3-17(24-5-7-26-8-6-24)4-2-14(1)16-9-20-19-18(12-23-25(19)13-16)15-10-21-22-11-15/h1-4,9-13H,5-8H2,(H,21,22)
DMLXOAQ	CS	C1COCCN1C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CNN=C5)N=C3
DMLXOAQ	IK	WCDLCPLAAKUJNY-UHFFFAOYSA-N
DMLXOAQ	IU	4-[4-[3-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine
DMLXOAQ	DE	Discovery agent

DMSTQGH	ID	DMSTQGH
DMSTQGH	DN	PMID23639540C13d
DMSTQGH	HS	Investigative
DMSTQGH	SN	GTPL8120; BDBM50434752; ZINC96270779
DMSTQGH	DT	Small molecular drug
DMSTQGH	PC	60182389
DMSTQGH	MW	407.5
DMSTQGH	FM	C25H21N5O
DMSTQGH	IC	InChI=1S/C25H21N5O/c1-2-4-24-22(3-1)21(9-10-26-24)23-16-28-30-17-19(15-27-25(23)30)18-5-7-20(8-6-18)29-11-13-31-14-12-29/h1-10,15-17H,11-14H2
DMSTQGH	CS	C1COCCN1C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3
DMSTQGH	IK	SZVLDZCYMADNPG-UHFFFAOYSA-N
DMSTQGH	IU	4-[4-(3-quinolin-4-ylpyrazolo[1,5-a]pyrimidin-6-yl)phenyl]morpholine
DMSTQGH	DE	Discovery agent

DMHBZ0N	ID	DMHBZ0N
DMHBZ0N	DN	PMID23639540C13r
DMHBZ0N	HS	Investigative
DMHBZ0N	SN	GTPL8144; BDBM50434750
DMHBZ0N	DT	Small molecular drug
DMHBZ0N	PC	60182364
DMHBZ0N	MW	420.5
DMHBZ0N	FM	C26H24N6
DMHBZ0N	IC	InChI=1S/C26H24N6/c1-30-12-14-31(15-13-30)21-8-6-19(7-9-21)20-16-28-26-24(17-29-32(26)18-20)22-10-11-27-25-5-3-2-4-23(22)25/h2-11,16-18H,12-15H2,1H3
DMHBZ0N	CS	CN1CCN(CC1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3
DMHBZ0N	IK	XBGWAKUQSRNWMA-UHFFFAOYSA-N
DMHBZ0N	IU	4-[6-[4-(4-methylpiperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
DMHBZ0N	DE	Discovery agent

DM4JWMA	ID	DM4JWMA
DM4JWMA	DN	PMID23642479C17
DM4JWMA	HS	Investigative
DM4JWMA	SN	MLS004256654; GTPL8161; KUC107541N; BDBM50435449; KSC-14-92; NCGC00241335-01; SMR003081709
DM4JWMA	DT	Small molecular drug
DM4JWMA	PC	46926513
DM4JWMA	MW	374.2
DM4JWMA	FM	C18H13Cl2N3O2
DM4JWMA	IC	InChI=1S/C18H13Cl2N3O2/c19-13-5-11(6-14(20)8-13)9-22-18-21-4-3-15(23-18)12-1-2-16-17(7-12)25-10-24-16/h1-8H,9-10H2,(H,21,22,23)
DM4JWMA	CS	C1OC2=C(O1)C=C(C=C2)C3=NC(=NC=C3)NCC4=CC(=CC(=C4)Cl)Cl
DM4JWMA	IK	FFJGYBJUQCZAAY-UHFFFAOYSA-N
DM4JWMA	IU	4-(1,3-benzodioxol-5-yl)-N-[(3,5-dichlorophenyl)methyl]pyrimidin-2-amine
DM4JWMA	DE	Discovery agent

DM1T9LJ	ID	DM1T9LJ
DM1T9LJ	DN	PMID23692593C20
DM1T9LJ	HS	Investigative
DM1T9LJ	SN	Ahx-FSQn(boro)Bpg; GTPL8486; BDBM50434142
DM1T9LJ	DT	Small molecular drug
DM1T9LJ	PC	71681016
DM1T9LJ	MW	784.5
DM1T9LJ	FM	C33H55BBrN7O9
DM1T9LJ	IC	InChI=1S/C33H55BBrN7O9/c1-2-3-13-23(31(47)42-27(34(50)51)14-10-18-35)39-30(46)24(16-17-28(37)44)40-33(49)26(21-43)41-32(48)25(20-22-11-6-4-7-12-22)38-29(45)15-8-5-9-19-36/h4,6-7,11-12,23-27,43,50-51H,2-3,5,8-10,13-21,36H2,1H3,(H2,37,44)(H,38,45)(H,39,46)(H,40,49)(H,41,48)(H,42,47)/t23-,24-,25-,26-,27+/m0/s1
DM1T9LJ	CS	B([C@@H](CCCBr)NC(=O)[C@H](CCCC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CCCCCN)(O)O
DM1T9LJ	IK	AKGOAAVLALZKCN-JSLVBRCRSA-N
DM1T9LJ	IU	[(1S)-1-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-(6-aminohexanoylamino)-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]amino]-4-bromobutyl]boronic acid
DM1T9LJ	DE	Discovery agent

DM2FDJN	ID	DM2FDJN
DM2FDJN	DN	PMID23788657C1754-31
DM2FDJN	HS	Investigative
DM2FDJN	SN	GTPL6263; BDBM50097999
DM2FDJN	DT	Small molecular drug
DM2FDJN	PC	91827351
DM2FDJN	MW	721.9
DM2FDJN	FM	C43H55N5O5
DM2FDJN	IC	InChI=1S/C43H55N5O5/c1-29(2)39-24-44-40(50)41(51)48(39)27-35-13-8-20-45(35)26-36(23-32-14-17-33-11-6-7-12-34(33)21-32)47-28-37(22-30-15-18-38(49)19-16-30)46(42(52)43(47)53)25-31-9-4-3-5-10-31/h6-7,11-12,14-19,21,29,31,35-37,39,49H,3-5,8-10,13,20,22-28H2,1-2H3,(H,44,50)/t35-,36+,37+,39+/m0/s1
DM2FDJN	CS	CC(C)[C@H]1CNC(=O)C(=O)N1C[C@@H]2CCCN2C[C@@H](CC3=CC4=CC=CC=C4C=C3)N5C[C@H](N(C(=O)C5=O)CC6CCCCC6)CC7=CC=C(C=C7)O
DM2FDJN	IK	RWNPDBWKKCTTOI-WIQNKZILSA-N
DM2FDJN	IU	(5R)-4-(cyclohexylmethyl)-1-[(2R)-1-[(2S)-2-[[(6S)-2,3-dioxo-6-propan-2-ylpiperazin-1-yl]methyl]pyrrolidin-1-yl]-3-naphthalen-2-ylpropan-2-yl]-5-[(4-hydroxyphenyl)methyl]piperazine-2,3-dione
DM2FDJN	DE	Discovery agent

DMUW3MT	ID	DMUW3MT
DMUW3MT	DN	PMID23849879C3
DMUW3MT	HS	Investigative
DMUW3MT	SN	SMR000144080; MLS000537840; AC1LJ8QE; GTPL8488; cid_970375; BDBM32709; MolPort-002-093-912; HMS2464J20; HMS1593B09; ZINC609776; STK138150; AKOS001696771; MCULE-4952162555; SR-01000666149; SR-01000666149-2
DMUW3MT	DT	Small molecular drug
DMUW3MT	PC	970375
DMUW3MT	MW	279.3
DMUW3MT	FM	C15H13N5O
DMUW3MT	IC	InChI=1S/C15H13N5O/c1-10-4-6-11(7-5-10)14(21)20-15(16)18-13(19-20)12-3-2-8-17-9-12/h2-9H,1H3,(H2,16,18,19)
DMUW3MT	CS	CC1=CC=C(C=C1)C(=O)N2C(=NC(=N2)C3=CN=CC=C3)N
DMUW3MT	IK	BIEYFOHSWAIQDF-UHFFFAOYSA-N
DMUW3MT	IU	(5-amino-3-pyridin-3-yl-1,2,4-triazol-1-yl)-(4-methylphenyl)methanone
DMUW3MT	DE	Discovery agent

DM35FH8	ID	DM35FH8
DM35FH8	DN	PMID23916253C17
DM35FH8	HS	Investigative
DM35FH8	SN	GTPL8666; BDBM50439353
DM35FH8	DT	Small molecular drug
DM35FH8	PC	71817810
DM35FH8	MW	441.5
DM35FH8	FM	C23H31N5O4
DM35FH8	IC	InChI=1S/C23H31N5O4/c24-13-5-4-8-19(23(31)32)27-21(29)16-10-12-17(25)20(14-16)28-22(30)18(26)11-9-15-6-2-1-3-7-15/h1-3,6-7,10,12,14,18-19H,4-5,8-9,11,13,24-26H2,(H,27,29)(H,28,30)(H,31,32)/t18-,19-/m0/s1
DM35FH8	CS	C1=CC=C(C=C1)CC[C@@H](C(=O)NC2=C(C=CC(=C2)C(=O)N[C@@H](CCCCN)C(=O)O)N)N
DM35FH8	IK	XPUCDWKMNQBXIH-OALUTQOASA-N
DM35FH8	IU	(2S)-6-amino-2-[[4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl]amino]hexanoic acid
DM35FH8	DE	Discovery agent

DMHUWZS	ID	DMHUWZS
DMHUWZS	DN	PMID24000170C36
DMHUWZS	HS	Investigative
DMHUWZS	SN	GTPL7521
DMHUWZS	DT	Small molecular drug
DMHUWZS	PC	75124304
DMHUWZS	MW	470.4
DMHUWZS	FM	C23H17F3N4O4
DMHUWZS	IC	InChI=1S/C23H17F3N4O4/c1-10-17(11(2)34-30-10)13-8-14-20(29-22(13)32-3)19-15(9-27-14)28-21(31)18(19)12-6-4-5-7-16(12)33-23(24,25)26/h4-9,18H,1-3H3,(H,28,31)
DMHUWZS	CS	CC1=C(C(=NO1)C)C2=CC3=NC=C4C(=C3N=C2OC)C(C(=O)N4)C5=CC=CC=C5OC(F)(F)F
DMHUWZS	IK	WWSIFGSLYORAET-UHFFFAOYSA-N
DMHUWZS	IU	3-(3,5-dimethyl-1,2-oxazol-4-yl)-2-methoxy-9-[2-(trifluoromethoxy)phenyl]-7,9-dihydropyrrolo[2,3-c][1,5]naphthyridin-8-one
DMHUWZS	DE	Discovery agent

DMOLRIY	ID	DMOLRIY
DMOLRIY	DN	PMID24000170C38
DMOLRIY	HS	Investigative
DMOLRIY	SN	GTPL7522
DMOLRIY	DT	Small molecular drug
DMOLRIY	PC	75124305
DMOLRIY	MW	400.4
DMOLRIY	FM	C23H20N4O3
DMOLRIY	IC	InChI=1S/C23H20N4O3/c1-12-19(13(2)30-27-12)16-10-17-21(26-23(16)29-3)20-15(9-14-7-5-4-6-8-14)22(28)25-18(20)11-24-17/h4-8,10-11,15H,9H2,1-3H3,(H,25,28)
DMOLRIY	CS	CC1=C(C(=NO1)C)C2=CC3=NC=C4C(=C3N=C2OC)C(C(=O)N4)CC5=CC=CC=C5
DMOLRIY	IK	ZULXIHDLPPWDPC-UHFFFAOYSA-N
DMOLRIY	IU	9-benzyl-3-(3,5-dimethyl-1,2-oxazol-4-yl)-2-methoxy-7,9-dihydropyrrolo[2,3-c][1,5]naphthyridin-8-one
DMOLRIY	DE	Discovery agent

DML4KMP	ID	DML4KMP
DML4KMP	DN	PMID24044867C8
DML4KMP	HS	Investigative
DML4KMP	SN	GTPL8195; BDBM50441572
DML4KMP	DT	Small molecular drug
DML4KMP	PC	46236221
DML4KMP	MW	399.4
DML4KMP	FM	C24H21N3O3
DML4KMP	IC	InChI=1S/C24H21N3O3/c1-28-21-10-16(11-22(29-2)23(21)30-3)17-9-18-19(13-27-24(18)26-12-17)14-4-5-20-15(8-14)6-7-25-20/h4-13,25H,1-3H3,(H,26,27)
DML4KMP	CS	COC1=CC(=CC(=C1OC)OC)C2=CC3=C(NC=C3C4=CC5=C(C=C4)NC=C5)N=C2
DML4KMP	IK	UQHKXSZPEUNUDH-UHFFFAOYSA-N
DML4KMP	IU	3-(1H-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridine
DML4KMP	DE	Discovery agent

DMWOHAE	ID	DMWOHAE
DMWOHAE	DN	PMID24099220C5i
DMWOHAE	HS	Investigative
DMWOHAE	SN	GNF-PF-3777; tryptanthrin 5i; 8-Nitrotryptanthrin; AC1L9YX7; Oprea1_383200; Oprea1_416302; GTPL8223; GTPL10126; CTK5I3547; ZINC334588; BCP26220; BDBM50442991; AKOS032945018; CS-6001; HY-100687; 77603-42-0
DMWOHAE	DT	Small molecular drug
DMWOHAE	PC	478573
DMWOHAE	MW	293.23
DMWOHAE	FM	C15H7N3O4
DMWOHAE	IC	InChI=1S/C15H7N3O4/c19-13-10-7-8(18(21)22)5-6-12(10)17-14(13)16-11-4-2-1-3-9(11)15(17)20/h1-7H
DMWOHAE	CS	C1=CC=C2C(=C1)C(=O)N3C4=C(C=C(C=C4)[N+](=O)[O-])C(=O)C3=N2
DMWOHAE	IK	UFMQJYHLIUACCG-UHFFFAOYSA-N
DMWOHAE	IU	8-nitroindolo[2,1-b]quinazoline-6,12-dione
DMWOHAE	DE	Discovery agent

DMWUZP1	ID	DMWUZP1
DMWUZP1	DN	PMID24157366C35
DMWUZP1	HS	Investigative
DMWUZP1	SN	GTPL8554; BDBM50443348; US8669252, 12
DMWUZP1	DT	Small molecular drug
DMWUZP1	PC	54670056
DMWUZP1	MW	586.9
DMWUZP1	FM	C29H30BrClFN3O2
DMWUZP1	IC	InChI=1S/C29H30BrClFN3O2/c30-22-5-1-19(2-6-22)26-18-24(35-13-15-37-16-14-35)9-10-25(26)29(36)34-28(20-3-7-23(31)8-4-20)21-11-12-33-27(32)17-21/h1-8,11-12,17,24-26,28H,9-10,13-16,18H2,(H,34,36)/t24-,25-,26+,28?/m1/s1
DMWUZP1	CS	C1C[C@H]([C@@H](C[C@@H]1N2CCOCC2)C3=CC=C(C=C3)Br)C(=O)NC(C4=CC=C(C=C4)Cl)C5=CC(=NC=C5)F
DMWUZP1	IK	ABJSOROVZZKJGI-OCYUSGCXSA-N
DMWUZP1	IU	(1R,2R,4R)-2-(4-bromophenyl)-N-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide
DMWUZP1	DE	Discovery agent

DM4LEUT	ID	DM4LEUT
DM4LEUT	DN	PMID24210504C1o
DM4LEUT	HS	Investigative
DM4LEUT	SN	GTPL8143; BDBM50444090
DM4LEUT	DT	Small molecular drug
DM4LEUT	PC	44256277
DM4LEUT	MW	429.5
DM4LEUT	FM	C24H27N7O
DM4LEUT	IC	InChI=1S/C24H27N7O/c25-23-20(24-29-21-4-3-19(12-22(21)32-24)30-9-1-2-10-30)11-16(13-27-23)17-14-28-31(15-17)18-5-7-26-8-6-18/h3-4,11-15,18,26H,1-2,5-10H2,(H2,25,27)
DM4LEUT	CS	C1CCN(C1)C2=CC3=C(C=C2)N=C(O3)C4=C(N=CC(=C4)C5=CN(N=C5)C6CCNCC6)N
DM4LEUT	IK	MWVKLRSIDOXBSE-UHFFFAOYSA-N
DM4LEUT	IU	5-(1-piperidin-4-ylpyrazol-4-yl)-3-(6-pyrrolidin-1-yl-1,3-benzoxazol-2-yl)pyridin-2-amine
DM4LEUT	DE	Discovery agent

DM26JYS	ID	DM26JYS
DM26JYS	DN	PMID24359159C19a
DM26JYS	HS	Investigative
DM26JYS	SN	UNII-7N5LJ2Z26C; 7N5LJ2Z26C; GTPL6977; BDBM50446982
DM26JYS	DT	Small molecular drug
DM26JYS	PC	45275255
DM26JYS	MW	353.36
DM26JYS	FM	C16H16FN9
DM26JYS	IC	InChI=1S/C16H16FN9/c1-9(13-19-5-10(17)6-20-13)22-16-24-14-11(3-4-18-14)15(25-16)23-12-7-26(2)8-21-12/h3-9H,1-2H3,(H3,18,22,23,24,25)/t9-/m0/s1
DM26JYS	CS	C[C@@H](C1=NC=C(C=N1)F)NC2=NC3=C(C=CN3)C(=N2)NC4=CN(C=N4)C
DM26JYS	IK	QHXBWJSQXSYAGG-VIFPVBQESA-N
DM26JYS	IU	2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(1-methylimidazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
DM26JYS	CA	CAS 1220516-48-2
DM26JYS	DE	Discovery agent

DM6O7MK	ID	DM6O7MK
DM6O7MK	DN	PMID24412111C9f
DM6O7MK	HS	Investigative
DM6O7MK	SN	GTPL8508
DM6O7MK	DT	Small molecular drug
DM6O7MK	PC	91827365
DM6O7MK	MW	479.5
DM6O7MK	FM	C24H28F3N3O4
DM6O7MK	IC	InChI=1S/C24H28F3N3O4/c1-15(2)8-11-34-17-5-3-4-16(12-17)13-21(31)30-10-9-28-23-18(19(30)14-22(32)33)6-7-20(29-23)24(25,26)27/h3-7,12,15,19H,8-11,13-14H2,1-2H3,(H,28,29)(H,32,33)/t19-/m1/s1
DM6O7MK	CS	CC(C)CCOC1=CC=CC(=C1)CC(=O)N2CCNC3=C([C@H]2CC(=O)O)C=CC(=N3)C(F)(F)F
DM6O7MK	IK	DFAPMGLBHDJMNX-LJQANCHMSA-N
DM6O7MK	IU	2-[(5R)-4-[2-[3-(3-methylbutoxy)phenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid
DM6O7MK	DE	Discovery agent

DM8JQL4	ID	DM8JQL4
DM8JQL4	DN	PMID24412111C9g
DM8JQL4	HS	Investigative
DM8JQL4	SN	GTPL8509; BDBM50447475
DM8JQL4	DT	Small molecular drug
DM8JQL4	PC	72944991
DM8JQL4	MW	500.5
DM8JQL4	FM	C25H23F3N4O4
DM8JQL4	IC	InChI=1S/C25H23F3N4O4/c1-15-5-6-18(14-30-15)36-17-4-2-3-16(11-17)12-22(33)32-10-9-29-24-19(20(32)13-23(34)35)7-8-21(31-24)25(26,27)28/h2-8,11,14,20H,9-10,12-13H2,1H3,(H,29,31)(H,34,35)/t20-/m1/s1
DM8JQL4	CS	CC1=NC=C(C=C1)OC2=CC=CC(=C2)CC(=O)N3CCNC4=C([C@H]3CC(=O)O)C=CC(=N4)C(F)(F)F
DM8JQL4	IK	PPSMYAUEJRADFE-HXUWFJFHSA-N
DM8JQL4	IU	2-[(5R)-4-[2-[3-(6-methylpyridin-3-yl)oxyphenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid
DM8JQL4	DE	Discovery agent

DMG4NQV	ID	DMG4NQV
DMG4NQV	DN	PMID24418773C37
DMG4NQV	HS	Investigative
DMG4NQV	SN	GTPL8612; BDBM50447515
DMG4NQV	DT	Small molecular drug
DMG4NQV	PC	76328755
DMG4NQV	MW	522.6
DMG4NQV	FM	C28H38N6O4
DMG4NQV	IC	InChI=1S/C28H38N6O4/c29-22-12-8-19(9-13-22)15-24(27(37)33-16-20-6-10-21(11-7-20)26(30)31)34-28(38)23(32-17-25(35)36)14-18-4-2-1-3-5-18/h6-13,18,23-24,32H,1-5,14-17,29H2,(H3,30,31)(H,33,37)(H,34,38)(H,35,36)/t23-,24+/m1/s1
DMG4NQV	CS	C1CCC(CC1)C[C@H](C(=O)N[C@@H](CC2=CC=C(C=C2)N)C(=O)NCC3=CC=C(C=C3)C(=N)N)NCC(=O)O
DMG4NQV	IK	CHAFCBBAYJKFNL-RPWUZVMVSA-N
DMG4NQV	IU	2-[[(2R)-1-[[(2S)-3-(4-aminophenyl)-1-[(4-carbamimidoylphenyl)methylamino]-1-oxopropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]acetic acid
DMG4NQV	DE	Discovery agent

DMEGAZS	ID	DMEGAZS
DMEGAZS	DN	PMID24432909C8e
DMEGAZS	HS	Investigative
DMEGAZS	SN	4cd0; GTPL8137; ZINC98050687; BDBM50448785; NCGC00485046-01; P-355; AWJ
DMEGAZS	DT	Small molecular drug
DMEGAZS	PC	72710568
DMEGAZS	MW	470.5
DMEGAZS	FM	C22H23FN6O3S
DMEGAZS	IC	InChI=1S/C22H23FN6O3S/c1-12-19(33-21(28-12)22(3,31)11-30)14-8-18(20(24)25-10-14)32-13(2)16-9-15(23)4-5-17(16)29-26-6-7-27-29/h4-10,13,30-31H,11H2,1-3H3,(H2,24,25)/t13-,22-/m1/s1
DMEGAZS	CS	CC1=C(SC(=N1)[C@@](C)(CO)O)C2=CC(=C(N=C2)N)O[C@H](C)C3=C(C=CC(=C3)F)N4N=CC=N4
DMEGAZS	IK	DIXMBHMNEHPFCX-MCMMXHMISA-N
DMEGAZS	IU	(2R)-2-[5-[6-amino-5-[(1R)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol
DMEGAZS	CA	CAS 1549629-82-4
DMEGAZS	DE	Discovery agent

DMHQK54	ID	DMHQK54
DMHQK54	DN	PMID24440480C3
DMHQK54	HS	Investigative
DMHQK54	SN	99573-25-8; ACMC-20m2v2; GTPL8682; CTK3F1142; DTXSID60617875; BDBM50447757; AKOS030554829; SR-02000001193; SR-02000001140; SR-02000001193-1; SR-02000001140-2
DMHQK54	DT	Small molecular drug
DMHQK54	PC	21771691
DMHQK54	MW	251.24
DMHQK54	FM	C14H9N3O2
DMHQK54	IC	InChI=1S/C14H9N3O2/c15-9-7-12(18)8-4-5-11(17-13(8)14(9)19)10-3-1-2-6-16-10/h1-7H,15H2
DMHQK54	CS	C1=CC=NC(=C1)C2=NC3=C(C=C2)C(=O)C=C(C3=O)N
DMHQK54	IK	UMMNKCUSQIKSGP-UHFFFAOYSA-N
DMHQK54	IU	7-amino-2-pyridin-2-ylquinoline-5,8-dione
DMHQK54	CA	CAS 99573-25-8
DMHQK54	DE	Discovery agent

DMK6GAU	ID	DMK6GAU
DMK6GAU	DN	PMID24556381C10f
DMK6GAU	HS	Investigative
DMK6GAU	SN	GTPL8602; NSC748516; BDBM50449286; NSC-748516
DMK6GAU	DT	Small molecular drug
DMK6GAU	PC	54613196
DMK6GAU	MW	354.8
DMK6GAU	FM	C23H15ClN2
DMK6GAU	IC	InChI=1S/C23H15ClN2/c24-16-10-11-22-19(12-16)18(15-6-2-1-3-7-15)13-23(26-22)20-14-25-21-9-5-4-8-17(20)21/h1-14,25H
DMK6GAU	CS	C1=CC=C(C=C1)C2=CC(=NC3=C2C=C(C=C3)Cl)C4=CNC5=CC=CC=C54
DMK6GAU	IK	LTUZPODERZUPRD-UHFFFAOYSA-N
DMK6GAU	IU	6-chloro-2-(1H-indol-3-yl)-4-phenylquinoline
DMK6GAU	DE	Discovery agent

DMOH45T	ID	DMOH45T
DMOH45T	DN	PMID24556381C10l
DMOH45T	HS	Investigative
DMOH45T	SN	GTPL8603; BDBM50449284
DMOH45T	DT	Small molecular drug
DMOH45T	PC	76318115
DMOH45T	MW	365.4
DMOH45T	FM	C23H15N3O2
DMOH45T	IC	InChI=1S/C23H15N3O2/c27-26(28)16-10-11-22-19(12-16)18(15-6-2-1-3-7-15)13-23(25-22)20-14-24-21-9-5-4-8-17(20)21/h1-14,24H
DMOH45T	CS	C1=CC=C(C=C1)C2=CC(=NC3=C2C=C(C=C3)[N+](=O)[O-])C4=CNC5=CC=CC=C54
DMOH45T	IK	LQGHUZLZFHCQPO-UHFFFAOYSA-N
DMOH45T	IU	2-(1H-indol-3-yl)-6-nitro-4-phenylquinoline
DMOH45T	DE	Discovery agent

DM2HVU8	ID	DM2HVU8
DM2HVU8	DN	PMID24673130C26
DM2HVU8	HS	Investigative
DM2HVU8	SN	GTPL8134; BDBM50011536
DM2HVU8	DT	Small molecular drug
DM2HVU8	PC	86703914
DM2HVU8	MW	240.24
DM2HVU8	FM	C13H9FN4
DM2HVU8	IC	InChI=1S/C13H9FN4/c14-9-3-1-2-8(6-9)10-4-5-11-12(18-10)13(15)17-7-16-11/h1-7H,(H2,15,16,17)
DM2HVU8	CS	C1=CC(=CC(=C1)F)C2=NC3=C(C=C2)N=CN=C3N
DM2HVU8	IK	TWTLUQDFSDYZKO-UHFFFAOYSA-N
DM2HVU8	IU	6-(3-fluorophenyl)pyrido[3,2-d]pyrimidin-4-amine
DM2HVU8	DE	Discovery agent

DMJNQE1	ID	DMJNQE1
DMJNQE1	DN	PMID24749861C34
DMJNQE1	HS	Investigative
DMJNQE1	SN	GTPL8129; BDBM50013820
DMJNQE1	DT	Small molecular drug
DMJNQE1	PC	86290500
DMJNQE1	MW	287.27
DMJNQE1	FM	C14H13N3O4
DMJNQE1	IC	InChI=1S/C14H13N3O4/c15-14(16)17-4-3-7-8-1-2-11(19)10(6-18)12(8)21-13(20)9(7)5-17/h1-2,6,19H,3-5H2,(H3,15,16)
DMJNQE1	CS	C1CN(CC2=C1C3=C(C(=C(C=C3)O)C=O)OC2=O)C(=N)N
DMJNQE1	IK	YPBDMIVAGFLWPR-UHFFFAOYSA-N
DMJNQE1	IU	7-formyl-8-hydroxy-5-oxo-2,4-dihydro-1H-chromeno[3,4-c]pyridine-3-carboximidamide
DMJNQE1	DE	Discovery agent

DMDMU01	ID	DMDMU01
DMDMU01	DN	PMID24775305C7u
DMDMU01	HS	Investigative
DMDMU01	SN	GTPL8633; BDBM50015362
DMDMU01	DT	Small molecular drug
DMDMU01	PC	90656796
DMDMU01	MW	464.5
DMDMU01	FM	C25H28N4O5
DMDMU01	IC	InChI=1S/C25H28N4O5/c1-2-33-21-6-3-5-19(13-21)18-10-8-17(9-11-18)16-34-25(32)29-12-4-7-22(29)24(31)28-20(15-26)14-23(27)30/h3,5-6,8-11,13,20,22H,2,4,7,12,14,16H2,1H3,(H2,27,30)(H,28,31)/t20-,22-/m0/s1
DMDMU01	CS	CCOC1=CC=CC(=C1)C2=CC=C(C=C2)COC(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(=O)N)C#N
DMDMU01	IK	BZVXYJWEOARYIS-UNMCSNQZSA-N
DMDMU01	IU	[4-(3-ethoxyphenyl)phenyl]methyl (2S)-2-[[(1S)-3-amino-1-cyano-3-oxopropyl]carbamoyl]pyrrolidine-1-carboxylate
DMDMU01	DE	Discovery agent

DMFSJQC	ID	DMFSJQC
DMFSJQC	DN	PMID24793884C74
DMFSJQC	HS	Investigative
DMFSJQC	SN	GTPL8219; BDBM50016163
DMFSJQC	DT	Small molecular drug
DMFSJQC	PC	76072859
DMFSJQC	MW	366.2
DMFSJQC	FM	C14H9Cl2N5OS
DMFSJQC	IC	InChI=1S/C14H9Cl2N5OS/c15-6-1-2-7(8(16)5-6)10-11(12(17)22)23-13(21-10)9-3-4-19-14(18)20-9/h1-5H,(H2,17,22)(H2,18,19,20)
DMFSJQC	CS	C1=CC(=C(C=C1Cl)Cl)C2=C(SC(=N2)C3=NC(=NC=C3)N)C(=O)N
DMFSJQC	IK	CQNCHLJHIGRPDA-UHFFFAOYSA-N
DMFSJQC	IU	2-(2-aminopyrimidin-4-yl)-4-(2,4-dichlorophenyl)-1,3-thiazole-5-carboxamide
DMFSJQC	DE	Discovery agent

DMZENGX	ID	DMZENGX
DMZENGX	DN	PMID24793884C77
DMZENGX	HS	Investigative
DMZENGX	SN	GTPL8217; BDBM50016166
DMZENGX	DT	Small molecular drug
DMZENGX	PC	90643548
DMZENGX	MW	361.8
DMZENGX	FM	C15H12ClN5O2S
DMZENGX	IC	InChI=1S/C15H12ClN5O2S/c1-23-7-2-3-8(9(16)6-7)11-12(13(17)22)24-14(21-11)10-4-5-19-15(18)20-10/h2-6H,1H3,(H2,17,22)(H2,18,19,20)
DMZENGX	CS	COC1=CC(=C(C=C1)C2=C(SC(=N2)C3=NC(=NC=C3)N)C(=O)N)Cl
DMZENGX	IK	VCUXVXLUOHDHKK-UHFFFAOYSA-N
DMZENGX	IU	2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide
DMZENGX	DE	Discovery agent

DM5G1RP	ID	DM5G1RP
DM5G1RP	DN	PMID24793972C2
DM5G1RP	HS	Investigative
DM5G1RP	SN	(1R,2R)-2-PCCA; GTPL7798; BDBM50065915; HY-100013A; CS-0022096; 1287205-42-8
DM5G1RP	DT	Small molecular drug
DM5G1RP	PC	58466521
DM5G1RP	MW	455.6
DM5G1RP	FM	C30H37N3O
DM5G1RP	IC	InChI=1S/C30H37N3O/c1-4-8-22-10-12-23(13-11-22)24-14-16-25(17-15-24)33(20-28(31)21(3)5-2)30(34)27-19-26(27)29-9-6-7-18-32-29/h6-7,9-18,21,26-28H,4-5,8,19-20,31H2,1-3H3/t21-,26+,27+,28+/m0/s1
DM5G1RP	CS	CCCC1=CC=C(C=C1)C2=CC=C(C=C2)N(C[C@H]([C@@H](C)CC)N)C(=O)[C@@H]3C[C@H]3C4=CC=CC=N4
DM5G1RP	IK	OBGKRTYDTRUMGO-RFNYNIMXSA-N
DM5G1RP	IU	(1R,2R)-N-[(2S,3S)-2-amino-3-methylpentyl]-N-[4-(4-propylphenyl)phenyl]-2-pyridin-2-ylcyclopropane-1-carboxamide
DM5G1RP	DE	Discovery agent

DMI8T1Y	ID	DMI8T1Y
DMI8T1Y	DN	PMID24809814C31
DMI8T1Y	HS	Investigative
DMI8T1Y	SN	4q6r; GTPL8465; BDBM50018282; 30J
DMI8T1Y	DT	Small molecular drug
DMI8T1Y	PC	73729049
DMI8T1Y	MW	455
DMI8T1Y	FM	C26H23ClN6
DMI8T1Y	IC	InChI=1S/C26H23ClN6/c1-18-17-32(11-12-33(18)25-10-7-20(15-28)16-29-25)26-23-14-21(27)8-9-22(23)24(30-31-26)13-19-5-3-2-4-6-19/h2-10,14,16,18H,11-13,17H2,1H3/t18-/m1/s1
DMI8T1Y	CS	C[C@@H]1CN(CCN1C2=NC=C(C=C2)C#N)C3=NN=C(C4=C3C=C(C=C4)Cl)CC5=CC=CC=C5
DMI8T1Y	IK	XUZUIICAPXZZDU-GOSISDBHSA-N
DMI8T1Y	IU	6-[(2R)-4-(4-benzyl-7-chlorophthalazin-1-yl)-2-methylpiperazin-1-yl]pyridine-3-carbonitrile
DMI8T1Y	CB	CHEBI:79045
DMI8T1Y	DE	Discovery agent

DM6TFPY	ID	DM6TFPY
DM6TFPY	DN	PMID24900237C15
DM6TFPY	HS	Investigative
DM6TFPY	SN	1022957-12-5; GTPL8220; BDBM50385590; KB-75520
DM6TFPY	DT	Small molecular drug
DM6TFPY	PC	25229528
DM6TFPY	MW	497
DM6TFPY	FM	C25H29ClN6O3
DM6TFPY	IC	InChI=1S/C25H29ClN6O3/c1-3-32-18-10-9-17(22(35-2)15(18)5-4-6-19(32)33)29-25-28-12-16(26)24(31-25)30-21-14-8-7-13(11-14)20(21)23(27)34/h7-10,12-14,20-21H,3-6,11H2,1-2H3,(H2,27,34)(H2,28,29,30,31)/t13-,14+,20+,21-/m1/s1
DM6TFPY	CS	CCN1C(=O)CCCC2=C1C=CC(=C2OC)NC3=NC=C(C(=N3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)Cl
DM6TFPY	IK	GLGNXYJARSMNGJ-VKTIVEEGSA-N
DM6TFPY	IU	(1S,2S,3R,4R)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3H-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide
DM6TFPY	DE	Discovery agent

DM6TYD0	ID	DM6TYD0
DM6TYD0	DN	PMID24900283C8a
DM6TYD0	HS	Investigative
DM6TYD0	SN	GTPL8503; BDBM50394618
DM6TYD0	DT	Small molecular drug
DM6TYD0	PC	56840673
DM6TYD0	MW	489.6
DM6TYD0	FM	C25H26F3N3O2S
DM6TYD0	IC	InChI=1S/C25H26F3N3O2S/c1-15-6-12-20-22(16(15)2)31(14-17-7-13-21(25(26,27)28)30-23(17)29-20)34(32,33)19-10-8-18(9-11-19)24(3,4)5/h6-13H,14H2,1-5H3,(H,29,30)
DM6TYD0	CS	CC1=C(C2=C(C=C1)NC3=C(CN2S(=O)(=O)C4=CC=C(C=C4)C(C)(C)C)C=CC(=N3)C(F)(F)F)C
DM6TYD0	IK	OAIVSBLLDFJYMS-UHFFFAOYSA-N
DM6TYD0	IU	6-(4-tert-butylphenyl)sulfonyl-7,8-dimethyl-2-(trifluoromethyl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepine
DM6TYD0	DE	Discovery agent

DMJS0F5	ID	DMJS0F5
DMJS0F5	DN	PMID24900311C1a
DMJS0F5	HS	Investigative
DMJS0F5	SN	GTPL7799
DMJS0F5	DT	Small molecular drug
DMJS0F5	PC	86277840
DMJS0F5	MW	365.4
DMJS0F5	FM	C20H19N3O4
DMJS0F5	IC	InChI=1S/C20H19N3O4/c1-26-17-10-15(11-18(12-17)27-2)19(24)22-23-20(25)21-16-8-7-13-5-3-4-6-14(13)9-16/h3-12H,1-2H3,(H,22,24)(H2,21,23,25)
DMJS0F5	CS	COC1=CC(=CC(=C1)C(=O)NNC(=O)NC2=CC3=CC=CC=C3C=C2)OC
DMJS0F5	IK	IFQNPGNCFXITTG-UHFFFAOYSA-N
DMJS0F5	IU	1-[(3,5-dimethoxybenzoyl)amino]-3-naphthalen-2-ylurea
DMJS0F5	DE	Discovery agent

DMU4BL2	ID	DMU4BL2
DMU4BL2	DN	PMID24900428C14
DMU4BL2	HS	Investigative
DMU4BL2	SN	GTPL8154; BDBM50400754
DMU4BL2	DT	Small molecular drug
DMU4BL2	PC	71461150
DMU4BL2	MW	381.4
DMU4BL2	FM	C21H20FN3O3
DMU4BL2	IC	InChI=1S/C21H20FN3O3/c1-12-7-13(22)3-4-19(12)28-11-14-8-15(20(27-2)10-24-14)18-9-16-17(25-18)5-6-23-21(16)26/h3-4,7-10,25H,5-6,11H2,1-2H3,(H,23,26)
DMU4BL2	CS	CC1=C(C=CC(=C1)F)OCC2=CC(=C(C=N2)OC)C3=CC4=C(N3)CCNC4=O
DMU4BL2	IK	WYOFSHLAFWJJAZ-UHFFFAOYSA-N
DMU4BL2	IU	2-[2-[(4-fluoro-2-methylphenoxy)methyl]-5-methoxypyridin-4-yl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one
DMU4BL2	DE	Discovery agent

DMZ5P2K	ID	DMZ5P2K
DMZ5P2K	DN	PMID24900446C5 
DMZ5P2K	HS	Investigative
DMZ5P2K	SN	GTPL8655; BDBM50386418
DMZ5P2K	DT	Small molecular drug
DMZ5P2K	PC	18392356
DMZ5P2K	MW	548.7
DMZ5P2K	FM	C28H28N4O4S2
DMZ5P2K	IC	InChI=1S/C28H28N4O4S2/c1-36-22-9-7-20-8-11-24(16-21(20)15-22)38(34,35)32(17-19-5-3-2-4-6-19)25-13-14-31(28(25)33)18-23-10-12-26(37-23)27(29)30/h2-12,15-16,25H,13-14,17-18H2,1H3,(H3,29,30)/t25-/m0/s1
DMZ5P2K	CS	COC1=CC2=C(C=C1)C=CC(=C2)S(=O)(=O)N(CC3=CC=CC=C3)[C@H]4CCN(C4=O)CC5=CC=C(S5)C(=N)N
DMZ5P2K	IK	KKFJNRXJRRYNRJ-VWLOTQADSA-N
DMZ5P2K	IU	5-[[(3S)-3-[benzyl-(7-methoxynaphthalen-2-yl)sulfonylamino]-2-oxopyrrolidin-1-yl]methyl]thiophene-2-carboximidamide
DMZ5P2K	DE	Discovery agent

DMEWVG8	ID	DMEWVG8
DMEWVG8	DN	PMID24900526C1
DMEWVG8	HS	Investigative
DMEWVG8	SN	107491-28-1; AC1LHVED; BAS 06984707; CBKinase1_016190; CBKinase1_003790; MLS000124060; GTPL7870; CTK7J5343; MolPort-002-007-625; ZINC470145; MFCD03876460; BDBM50400562; AKOS000302705; MCULE-5295604199; SMR000124614; DB-016663; TR-042640; ST50281836
DMEWVG8	DT	Small molecular drug
DMEWVG8	PC	893637
DMEWVG8	MW	291.32
DMEWVG8	FM	C14H13NO4S
DMEWVG8	IC	InChI=1S/C14H13NO4S/c16-14(17)10-15-20(18,19)13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-9,15H,10H2,(H,16,17)
DMEWVG8	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NCC(=O)O
DMEWVG8	IK	ZIAFXLGSGMQYPL-UHFFFAOYSA-N
DMEWVG8	IU	2-[(4-phenylphenyl)sulfonylamino]acetic acid
DMEWVG8	DE	Discovery agent

DMKTBCM	ID	DMKTBCM
DMKTBCM	DN	PMID24900526C5 
DMKTBCM	HS	Investigative
DMKTBCM	SN	GTPL7869
DMKTBCM	DT	Small molecular drug
DMKTBCM	PC	66560622
DMKTBCM	MW	589.7
DMKTBCM	FM	C28H35N3O9S
DMKTBCM	IC	InChI=1S/C28H35N3O9S/c1-19(2)16-23(27(35)31(17-25(32)33)41(37,38)22-13-11-21(39-3)12-14-22)29-26(34)24-10-7-15-30(24)28(36)40-18-20-8-5-4-6-9-20/h4-6,8-9,11-14,19,23-24H,7,10,15-18H2,1-3H3,(H,29,34)(H,32,33)/t23-,24-/m0/s1
DMKTBCM	CS	CC(C)C[C@@H](C(=O)N(CC(=O)O)S(=O)(=O)C1=CC=C(C=C1)OC)NC(=O)[C@@H]2CCCN2C(=O)OCC3=CC=CC=C3
DMKTBCM	IK	QXROXWFFCFLRBZ-ZEQRLZLVSA-N
DMKTBCM	IU	2-[(4-methoxyphenyl)sulfonyl-[(2S)-4-methyl-2-[[(2S)-1-phenylmethoxycarbonylpyrrolidine-2-carbonyl]amino]pentanoyl]amino]acetic acid
DMKTBCM	DE	Discovery agent

DM5PATM	ID	DM5PATM
DM5PATM	DN	PMID24900538C2c
DM5PATM	HS	Investigative
DM5PATM	SN	GTPL8138; BDBM50392791; US8486966, 1
DM5PATM	DT	Small molecular drug
DM5PATM	PC	59627005
DM5PATM	MW	381.4
DM5PATM	FM	C19H20FN7O
DM5PATM	IC	InChI=1S/C19H20FN7O/c1-11(2)28-18-8-17(25-26-18)27-10-22-15-6-7-16(24-19(15)27)23-12(3)14-5-4-13(20)9-21-14/h4-12H,1-3H3,(H,23,24)(H,25,26)/t12-/m0/s1
DM5PATM	CS	C[C@@H](C1=NC=C(C=C1)F)NC2=NC3=C(C=C2)N=CN3C4=CC(=NN4)OC(C)C
DM5PATM	IK	FZBVNCFBCNXULH-LBPRGKRZSA-N
DM5PATM	IU	N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-3-(3-propan-2-yloxy-1H-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine
DM5PATM	DE	Discovery agent

DMCL6H3	ID	DMCL6H3
DMCL6H3	DN	PMID24900608C1
DMCL6H3	HS	Investigative
DMCL6H3	SN	GTPL7800; BDBM50443616
DMCL6H3	DT	Small molecular drug
DMCL6H3	PC	73211886
DMCL6H3	MW	352.8
DMCL6H3	FM	C18H17ClN6
DMCL6H3	IC	InChI=1S/C18H17ClN6/c19-15-2-4-18-22-16(13-25(18)11-15)12-23-5-7-24(8-6-23)17-3-1-14(9-20)10-21-17/h1-4,10-11,13H,5-8,12H2
DMCL6H3	CS	C1CN(CCN1CC2=CN3C=C(C=CC3=N2)Cl)C4=NC=C(C=C4)C#N
DMCL6H3	IK	UGDJVSURAKMIPU-UHFFFAOYSA-N
DMCL6H3	IU	6-[4-[(6-chloroimidazo[1,2-a]pyridin-2-yl)methyl]piperazin-1-yl]pyridine-3-carbonitrile
DMCL6H3	DE	Discovery agent

DM1QDG0	ID	DM1QDG0
DM1QDG0	DN	PMID24900635C21
DM1QDG0	HS	Investigative
DM1QDG0	SN	GTPL8187; BDBM50446266
DM1QDG0	DT	Small molecular drug
DM1QDG0	PC	76332060
DM1QDG0	MW	505.5
DM1QDG0	FM	C27H19F4N5O
DM1QDG0	IC	InChI=1S/C27H19F4N5O/c28-23-8-7-18(27(29,30)31)12-24(23)36-26(37)35-20-6-2-4-16(10-20)22-14-34-25-21(22)11-17(13-33-25)15-3-1-5-19(32)9-15/h1-14H,32H2,(H,33,34)(H2,35,36,37)
DM1QDG0	CS	C1=CC(=CC(=C1)N)C2=CC3=C(NC=C3C4=CC(=CC=C4)NC(=O)NC5=C(C=CC(=C5)C(F)(F)F)F)N=C2
DM1QDG0	IK	QQTPMHCXBYRWFQ-UHFFFAOYSA-N
DM1QDG0	IU	1-[3-[5-(3-aminophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]phenyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
DM1QDG0	DE	Discovery agent

DM2V4MJ	ID	DM2V4MJ
DM2V4MJ	DN	PMID24900699C68
DM2V4MJ	HS	Investigative
DM2V4MJ	SN	GTPL8165; BDBM50434356
DM2V4MJ	DT	Small molecular drug
DM2V4MJ	PC	71529752
DM2V4MJ	MW	432.3
DM2V4MJ	FM	C17H11BrFN5OS
DM2V4MJ	IC	InChI=1S/C17H11BrFN5OS/c1-25-15(20)17-24-12-5-4-11-13(14(12)26-17)16(22-7-21-11)23-10-3-2-8(18)6-9(10)19/h2-7,20H,1H3,(H,21,22,23)
DM2V4MJ	CS	COC(=N)C1=NC2=C(S1)C3=C(C=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F
DM2V4MJ	IK	ZBELDPMWYXDLNY-UHFFFAOYSA-N
DM2V4MJ	IU	methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate
DM2V4MJ	DE	Discovery agent

DMZPUSO	ID	DMZPUSO
DMZPUSO	DN	PMID24900749C1a
DMZPUSO	HS	Investigative
DMZPUSO	SN	GTPL8128; BDBM50437434
DMZPUSO	DT	Small molecular drug
DMZPUSO	PC	72163809
DMZPUSO	MW	361.4
DMZPUSO	FM	C19H19N7O
DMZPUSO	IC	InChI=1S/C19H19N7O/c1-11-3-4-15(7-16(11)22-12(2)27)23-17-8-18(24-14-5-6-14)26-19(25-17)13(9-20)10-21-26/h3-4,7-8,10,14,24H,5-6H2,1-2H3,(H,22,27)(H,23,25)
DMZPUSO	CS	CC1=C(C=C(C=C1)NC2=NC3=C(C=NN3C(=C2)NC4CC4)C#N)NC(=O)C
DMZPUSO	IK	GDSQVLMYYCNAGP-UHFFFAOYSA-N
DMZPUSO	IU	N-[5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-methylphenyl]acetamide
DMZPUSO	DE	Discovery agent

DMOSMBZ	ID	DMOSMBZ
DMOSMBZ	DN	PMID24900824C2-1-1
DMOSMBZ	HS	Investigative
DMOSMBZ	SN	GTPL8109; BDBM50011209
DMOSMBZ	DT	Small molecular drug
DMOSMBZ	PC	72202254
DMOSMBZ	MW	478.5
DMOSMBZ	FM	C25H24F2N6O2
DMOSMBZ	IC	InChI=1S/C25H24F2N6O2/c1-3-35-16-11-19(26)18(20(27)12-16)14-33-21-6-4-5-17(21)23(32-33)25-29-13-22(34-2)24(31-25)30-15-7-9-28-10-8-15/h7-13H,3-6,14H2,1-2H3,(H,28,29,30,31)
DMOSMBZ	CS	CCOC1=CC(=C(C(=C1)F)CN2C3=C(CCC3)C(=N2)C4=NC=C(C(=N4)NC5=CC=NC=C5)OC)F
DMOSMBZ	IK	UJORPFQWUKFXIE-UHFFFAOYSA-N
DMOSMBZ	IU	2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl]-5-methoxy-N-pyridin-4-ylpyrimidin-4-amine
DMOSMBZ	DE	Discovery agent

DM2FYUM	ID	DM2FYUM
DM2FYUM	DN	PMID24900824C2-13-1
DM2FYUM	HS	Investigative
DM2FYUM	SN	GTPL8112; BDBM50011188
DM2FYUM	DT	Small molecular drug
DM2FYUM	PC	72203102
DM2FYUM	MW	551.6
DM2FYUM	FM	C26H26FN7O4S
DM2FYUM	IC	InChI=1S/C26H26FN7O4S/c1-39(36,37)12-11-38-22-14-30-26(32-25(22)31-20-9-10-29-13-18(20)24(28)35)23-17-6-4-8-21(17)34(33-23)15-16-5-2-3-7-19(16)27/h2-3,5,7,9-10,13-14H,4,6,8,11-12,15H2,1H3,(H2,28,35)(H,29,30,31,32)
DM2FYUM	CS	CS(=O)(=O)CCOC1=CN=C(N=C1NC2=C(C=NC=C2)C(=O)N)C3=NN(C4=C3CCC4)CC5=CC=CC=C5F
DM2FYUM	IK	FFVPQWXBEUUBMF-UHFFFAOYSA-N
DM2FYUM	IU	4-[[2-[1-[(2-fluorophenyl)methyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl]-5-(2-methylsulfonylethoxy)pyrimidin-4-yl]amino]pyridine-3-carboxamide
DM2FYUM	DE	Discovery agent

DMC5JAT	ID	DMC5JAT
DMC5JAT	DN	PMID24900824C2-3-1
DMC5JAT	HS	Investigative
DMC5JAT	SN	GTPL8111; BDBM50011202
DMC5JAT	DT	Small molecular drug
DMC5JAT	PC	72202696
DMC5JAT	MW	535.6
DMC5JAT	FM	C28H31F2N7O2
DMC5JAT	IC	InChI=1S/C28H31F2N7O2/c1-4-38-19-14-22(29)21(23(30)15-19)17-37-24-7-5-6-20(24)26(35-37)28-32-16-25(39-13-12-36(2)3)27(34-28)33-18-8-10-31-11-9-18/h8-11,14-16H,4-7,12-13,17H2,1-3H3,(H,31,32,33,34)
DMC5JAT	CS	CCOC1=CC(=C(C(=C1)F)CN2C3=C(CCC3)C(=N2)C4=NC=C(C(=N4)NC5=CC=NC=C5)OCCN(C)C)F
DMC5JAT	IK	HDLPONLLJOSAIM-UHFFFAOYSA-N
DMC5JAT	IU	5-[2-(dimethylamino)ethoxy]-2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl]-N-pyridin-4-ylpyrimidin-4-amine
DMC5JAT	DE	Discovery agent

DMVP0Z9	ID	DMVP0Z9
DMVP0Z9	DN	PMID24900824C2-3-2
DMVP0Z9	HS	Investigative
DMVP0Z9	SN	GTPL8110; BDBM50011201
DMVP0Z9	DT	Small molecular drug
DMVP0Z9	PC	72202697
DMVP0Z9	MW	564.6
DMVP0Z9	FM	C29H30F2N6O4
DMVP0Z9	IC	InChI=1S/C29H30F2N6O4/c1-2-40-19-10-22(30)21(23(31)11-19)13-37-24-5-3-4-20(24)26(36-37)28-33-12-25(41-17-29(14-38)15-39-16-29)27(35-28)34-18-6-8-32-9-7-18/h6-12,38H,2-5,13-17H2,1H3,(H,32,33,34,35)
DMVP0Z9	CS	CCOC1=CC(=C(C(=C1)F)CN2C3=C(CCC3)C(=N2)C4=NC=C(C(=N4)NC5=CC=NC=C5)OCC6(COC6)CO)F
DMVP0Z9	IK	WIVMUEFNJYZIOY-UHFFFAOYSA-N
DMVP0Z9	IU	[3-[[2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl]oxymethyl]oxetan-3-yl]methanol
DMVP0Z9	DE	Discovery agent

DMN7QB8	ID	DMN7QB8
DMN7QB8	DN	PMID24915291C31
DMN7QB8	HS	Investigative
DMN7QB8	SN	GTPL8148; BDBM50020471
DMN7QB8	DT	Small molecular drug
DMN7QB8	PC	71519693
DMN7QB8	MW	560.5
DMN7QB8	FM	C29H23F3N6O3
DMN7QB8	IC	InChI=1S/C29H23F3N6O3/c1-3-25(39)35-20-8-5-9-21(13-20)38-28-33-15-23(16-34-28)37-27(41)24-14-22(11-10-17(24)2)36-26(40)18-6-4-7-19(12-18)29(30,31)32/h3-16H,1H2,2H3,(H,35,39)(H,36,40)(H,37,41)(H,33,34,38)
DMN7QB8	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)C(=O)NC3=CN=C(N=C3)NC4=CC(=CC=C4)NC(=O)C=C
DMN7QB8	IK	BTWVWABAWDKQNJ-UHFFFAOYSA-N
DMN7QB8	IU	2-methyl-N-[2-[3-(prop-2-enoylamino)anilino]pyrimidin-5-yl]-5-[[3-(trifluoromethyl)benzoyl]amino]benzamide
DMN7QB8	CA	CAS 1431727-00-2
DMN7QB8	DE	Discovery agent

DMBXT9J	ID	DMBXT9J
DMBXT9J	DN	PMID24915291C38
DMBXT9J	HS	Investigative
DMBXT9J	SN	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6
DMBXT9J	DT	Small molecular drug
DMBXT9J	PC	71556703
DMBXT9J	MW	617.6
DMBXT9J	FM	C31H26F3N7O4
DMBXT9J	IC	InChI=1S/C31H26F3N7O4/c1-3-26(42)35-17-27(43)38-21-8-5-9-22(13-21)41-30-36-15-24(16-37-30)40-29(45)25-14-23(11-10-18(25)2)39-28(44)19-6-4-7-20(12-19)31(32,33)34/h3-16H,1,17H2,2H3,(H,35,42)(H,38,43)(H,39,44)(H,40,45)(H,36,37,41)
DMBXT9J	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)C(=O)NC3=CN=C(N=C3)NC4=CC(=CC=C4)NC(=O)CNC(=O)C=C
DMBXT9J	IK	SMOPKEHQPPXRSH-UHFFFAOYSA-N
DMBXT9J	IU	2-methyl-N-[2-[3-[[2-(prop-2-enoylamino)acetyl]amino]anilino]pyrimidin-5-yl]-5-[[3-(trifluoromethyl)benzoyl]amino]benzamide
DMBXT9J	DE	Discovery agent

DMNPA2C	ID	DMNPA2C
DMNPA2C	DN	PMID24946214C3b
DMNPA2C	HS	Investigative
DMNPA2C	SN	GTPL8618; BDBM50021350
DMNPA2C	DT	Small molecular drug
DMNPA2C	PC	90645049
DMNPA2C	MW	330.2
DMNPA2C	FM	C17H23BN2O4
DMNPA2C	IC	InChI=1S/C17H23BN2O4/c1-12(2)11-15(18(23)24)19-16(21)8-10-20-9-7-13-5-3-4-6-14(13)17(20)22/h3-7,9,12,15,23-24H,8,10-11H2,1-2H3,(H,19,21)/t15-/m0/s1
DMNPA2C	CS	B([C@H](CC(C)C)NC(=O)CCN1C=CC2=CC=CC=C2C1=O)(O)O
DMNPA2C	IK	QCKLWTRAVKQTPI-HNNXBMFYSA-N
DMNPA2C	IU	[(1R)-3-methyl-1-[3-(1-oxoisoquinolin-2-yl)propanoylamino]butyl]boronic acid
DMNPA2C	DE	Discovery agent

DML0PFU	ID	DML0PFU
DML0PFU	DN	PMID24997608CA 
DML0PFU	HS	Investigative
DML0PFU	SN	1599477-75-4; GPR120-IN-1; GPR120 Compound A; GTPL8418; MolPort-039-136-860; EX-A1318; BCP19379; BDBM50208095; ZINC209053267; AKOS025289518; CS-6429; HY-101492
DML0PFU	DT	Small molecular drug
DML0PFU	PC	73777063
DML0PFU	MW	405.8
DML0PFU	FM	C19H23ClF3NO3
DML0PFU	IC	InChI=1S/C19H23ClF3NO3/c20-15-2-1-14(27-19(21,22)23)12-16(15)24-9-7-18(8-10-24)5-3-13(4-6-18)11-17(25)26/h1-2,12-13H,3-11H2,(H,25,26)
DML0PFU	CS	C1CC2(CCC1CC(=O)O)CCN(CC2)C3=C(C=CC(=C3)OC(F)(F)F)Cl
DML0PFU	IK	WUJVPELCYCESAP-UHFFFAOYSA-N
DML0PFU	IU	2-[3-[2-chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecan-9-yl]acetic acid
DML0PFU	DE	Discovery agent

DM5D3SN	ID	DM5D3SN
DM5D3SN	DN	PMID24999562C6b
DM5D3SN	HS	Investigative
DM5D3SN	SN	GTPL7927
DM5D3SN	DT	Small molecular drug
DM5D3SN	PC	91623353
DM5D3SN	MW	849.1
DM5D3SN	FM	C40H72N12O8
DM5D3SN	IC	InChI=1S/C40H72N12O8/c1-23(2)14-16-27(48-37(58)29(20-24(3)4)47-33(54)17-15-25-10-6-5-7-11-25)36(57)51-30(22-41)39(60)52-19-9-13-31(52)38(59)49-26(12-8-18-46-40(44)45)35(56)50-28(34(43)55)21-32(42)53/h23-31H,5-22,41H2,1-4H3,(H2,42,53)(H2,43,55)(H,47,54)(H,48,58)(H,49,59)(H,50,56)(H,51,57)(H4,44,45,46)/t26-,27-,28-,29-,30-,31-/m0/s1
DM5D3SN	CS	CC(C)CC[C@@H](C(=O)N[C@@H](CN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)CCC2CCCCC2
DM5D3SN	IK	KAFZOLYKKCWUBI-HPMAGDRPSA-N
DM5D3SN	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-3-amino-2-[[(2S)-2-[[(2S)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide
DM5D3SN	DE	Discovery agent

DMD7VOZ	ID	DMD7VOZ
DMD7VOZ	DN	PMID24999562C8d
DMD7VOZ	HS	Investigative
DMD7VOZ	SN	GTPL7926; BDBM50049424
DMD7VOZ	DT	Small molecular drug
DMD7VOZ	PC	91623352
DMD7VOZ	MW	1018.2
DMD7VOZ	FM	C51H67N15O8
DMD7VOZ	IC	InChI=1S/C51H67N15O8/c52-42(67)29-38(44(53)69)64-45(70)36(15-7-23-59-50(54)55)62-48(73)41-17-9-25-66(41)49(74)37(16-8-24-60-51(56)57)63-47(72)40(27-31-10-2-1-3-11-31)65-46(71)39(61-43(68)21-19-32-12-6-22-58-30-32)28-33-18-20-34-13-4-5-14-35(34)26-33/h1-6,10-14,18,20,22,26,30,36-41H,7-9,15-17,19,21,23-25,27-29H2,(H2,52,67)(H2,53,69)(H,61,68)(H,62,73)(H,63,72)(H,64,70)(H,65,71)(H4,54,55,59)(H4,56,57,60)/t36-,37-,38-,39-,40-,41-/m0/s1
DMD7VOZ	CS	C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC4=CC=CC=C4C=C3)NC(=O)CCC5=CN=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N
DMD7VOZ	IK	HPJGEESDHAUUQR-SKGSPYGFSA-N
DMD7VOZ	IU	(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]butanediamide
DMD7VOZ	DE	Discovery agent

DMJPR8M	ID	DMJPR8M
DMJPR8M	DN	PMID25037917C58
DMJPR8M	HS	Investigative
DMJPR8M	SN	GTPL8520; BDBM50052641
DMJPR8M	DT	Small molecular drug
DMJPR8M	PC	91827366
DMJPR8M	MW	404.9
DMJPR8M	FM	C23H21ClN4O
DMJPR8M	IC	InChI=1S/C23H21ClN4O/c24-19-4-1-3-18(13-19)16-5-7-17(8-6-16)22(29)28-20-9-10-21(28)15-27(14-20)23-25-11-2-12-26-23/h1-8,11-13,20-21H,9-10,14-15H2
DMJPR8M	CS	C1CC2CN(CC1N2C(=O)C3=CC=C(C=C3)C4=CC(=CC=C4)Cl)C5=NC=CC=N5
DMJPR8M	IK	FNHAFYQTHUKPIU-UHFFFAOYSA-N
DMJPR8M	IU	[4-(3-chlorophenyl)phenyl]-(3-pyrimidin-2-yl-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone
DMJPR8M	DE	Discovery agent

DMRFQ1W	ID	DMRFQ1W
DMRFQ1W	DN	PMID25050158C14
DMRFQ1W	HS	Investigative
DMRFQ1W	SN	CLH-304a; GTPL8539; J3.660.730K
DMRFQ1W	DT	Small molecular drug
DMRFQ1W	PC	86279004
DMRFQ1W	MW	304.4
DMRFQ1W	FM	C18H24O4
DMRFQ1W	IC	InChI=1S/C18H24O4/c1-17(2,3)12-9-11(7-8-14(19)16(21)22)10-13(15(12)20)18(4,5)6/h7-10,20H,1-6H3,(H,21,22)/b8-7+
DMRFQ1W	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C/C(=O)C(=O)O
DMRFQ1W	IK	XIQDGAUDNMVMCD-BQYQJAHWSA-N
DMRFQ1W	IU	(E)-4-(3,5-ditert-butyl-4-hydroxyphenyl)-2-oxobut-3-enoic acid
DMRFQ1W	DE	Discovery agent

DMTCGLY	ID	DMTCGLY
DMTCGLY	DN	PMID25259874C21
DMTCGLY	HS	Investigative
DMTCGLY	SN	GTPL8381; BDBM50028696
DMTCGLY	DT	Small molecular drug
DMTCGLY	PC	91827354
DMTCGLY	MW	448.5
DMTCGLY	FM	C24H28N6O3
DMTCGLY	IC	InChI=1S/C24H28N6O3/c1-15-20(22(31)29-18(23(32)33)13-8-14-27-24(25)26)30-21(28-15)19(16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2-7,9-12,18-19H,8,13-14H2,1H3,(H,28,30)(H,29,31)(H,32,33)(H4,25,26,27)/t18-/m0/s1
DMTCGLY	CS	CC1=C(N=C(N1)C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DMTCGLY	IK	RFBOIZXPIAOMAX-SFHVURJKSA-N
DMTCGLY	IU	(2S)-2-[(2-benzhydryl-5-methyl-1H-imidazole-4-carbonyl)amino]-5-(diaminomethylideneamino)pentanoic acid
DMTCGLY	DE	Discovery agent

DMZKEIH	ID	DMZKEIH
DMZKEIH	DN	PMID25259874C4
DMZKEIH	HS	Investigative
DMZKEIH	SN	GTPL8384; BDBM50028698
DMZKEIH	DT	Small molecular drug
DMZKEIH	PC	91827355
DMZKEIH	MW	428.5
DMZKEIH	FM	C22H28N4O3S
DMZKEIH	IC	InChI=1S/C22H28N4O3S/c23-22(24)25-13-7-12-19(21(28)29)26-20(27)15-30-14-18(16-8-3-1-4-9-16)17-10-5-2-6-11-17/h1-6,8-11,18-19H,7,12-15H2,(H,26,27)(H,28,29)(H4,23,24,25)/t19-/m0/s1
DMZKEIH	CS	C1=CC=C(C=C1)C(CSCC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)C2=CC=CC=C2
DMZKEIH	IK	OVJFQPIFXZBDKN-IBGZPJMESA-N
DMZKEIH	IU	(2S)-5-(diaminomethylideneamino)-2-[[2-(2,2-diphenylethylsulfanyl)acetyl]amino]pentanoic acid
DMZKEIH	DE	Discovery agent

DMDO9AJ	ID	DMDO9AJ
DMDO9AJ	DN	PMID25313322C15
DMDO9AJ	HS	Investigative
DMDO9AJ	SN	GTPL7803; BDBM50030783
DMDO9AJ	DT	Small molecular drug
DMDO9AJ	PC	86277841
DMDO9AJ	MW	360.2
DMDO9AJ	FM	C17H15Cl2N5
DMDO9AJ	IC	InChI=1S/C17H15Cl2N5/c1-20-17-23-15(14-4-2-3-7-21-14)9-16(24-17)22-10-11-5-6-12(18)8-13(11)19/h2-9H,10H2,1H3,(H2,20,22,23,24)
DMDO9AJ	CS	CNC1=NC(=CC(=N1)NCC2=C(C=C(C=C2)Cl)Cl)C3=CC=CC=N3
DMDO9AJ	IK	HOVRMCPKCWLHJS-UHFFFAOYSA-N
DMDO9AJ	IU	4-N-[(2,4-dichlorophenyl)methyl]-2-N-methyl-6-pyridin-2-ylpyrimidine-2,4-diamine
DMDO9AJ	DE	Discovery agent

DM5GL23	ID	DM5GL23
DM5GL23	DN	PMID25408830C1
DM5GL23	HS	Investigative
DM5GL23	SN	BAS 08314227; 4uyd; AC1LLXEX; ChemDiv2_002770; MLS000100042; GTPL7809; MolPort-001-912-793; HMS2483G18; HMS1376N20; ZINC812404; BDBM50032913; AKOS001788033; MCULE-4972680634; SMR000081748; V1T
DM5GL23	DT	Small molecular drug
DM5GL23	PC	1091852
DM5GL23	MW	205.21
DM5GL23	FM	C10H11N3O2
DM5GL23	IC	InChI=1S/C10H11N3O2/c1-12-7-4-3-6(9(11)14)5-8(7)13(2)10(12)15/h3-5H,1-2H3,(H2,11,14)
DM5GL23	CS	CN1C2=C(C=C(C=C2)C(=O)N)N(C1=O)C
DM5GL23	IK	BRBLVCVSNVSPMT-UHFFFAOYSA-N
DM5GL23	IU	1,3-dimethyl-2-oxobenzimidazole-5-carboxamide
DM5GL23	DE	Discovery agent

DM20E13	ID	DM20E13
DM20E13	DN	PMID25408830C2
DM20E13	HS	Investigative
DM20E13	SN	AC1LNW3E; MLS000663364; GTPL7810; MolPort-002-097-893; HMS2628P17; HMS3438L21; ZINC1063855; BDBM50032921; STL431755; AKOS000445117; MCULE-6603148725; CCG-129099; SMR000300929; SR-01000295962; SR-01000295962-1
DM20E13	DT	Small molecular drug
DM20E13	PC	1253361
DM20E13	MW	345.4
DM20E13	FM	C17H19N3O3S
DM20E13	IC	InChI=1S/C17H19N3O3S/c1-11-5-8-16(12(2)9-11)24(22,23)18-13-6-7-14-15(10-13)20(4)17(21)19(14)3/h5-10,18H,1-4H3
DM20E13	CS	CC1=CC(=C(C=C1)S(=O)(=O)NC2=CC3=C(C=C2)N(C(=O)N3C)C)C
DM20E13	IK	HVGVNYJRZJHYBS-UHFFFAOYSA-N
DM20E13	IU	N-(1,3-dimethyl-2-oxobenzimidazol-5-yl)-2,4-dimethylbenzenesulfonamide
DM20E13	DE	Discovery agent

DM8SBR2	ID	DM8SBR2
DM8SBR2	DN	PMID25408830C3
DM8SBR2	HS	Investigative
DM8SBR2	SN	GSK-5959; 901245-65-6; GSK5959; GSK 5959; 4uye; GTPL7811; MolPort-004-921-361; HMS1821D17; EX-A2263; BCP16039; ZINC8594565; BDBM50032912; AKOS000481208; MCULE-6727694163; CS-4867; NCGC00107508-01; HY-18665; C301-5895; 9F9; N-[
DM8SBR2	DT	Small molecular drug
DM8SBR2	PC	15990224
DM8SBR2	MW	394.5
DM8SBR2	FM	C22H26N4O3
DM8SBR2	IC	InChI=1S/C22H26N4O3/c1-24-18-13-16(23-21(27)15-9-5-6-10-20(15)29-3)17(26-11-7-4-8-12-26)14-19(18)25(2)22(24)28/h5-6,9-10,13-14H,4,7-8,11-12H2,1-3H3,(H,23,27)
DM8SBR2	CS	CN1C2=C(C=C(C(=C2)NC(=O)C3=CC=CC=C3OC)N4CCCCC4)N(C1=O)C
DM8SBR2	IK	LTUGYAOMCKNTGG-UHFFFAOYSA-N
DM8SBR2	IU	N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide
DM8SBR2	DE	Discovery agent

DMWZJT0	ID	DMWZJT0
DMWZJT0	DN	PMID25489658C4d
DMWZJT0	HS	Investigative
DMWZJT0	SN	GTPL8483
DMWZJT0	DT	Small molecular drug
DMWZJT0	PC	90170031
DMWZJT0	MW	393.6
DMWZJT0	FM	C17H10BrClO4
DMWZJT0	IC	InChI=1S/C17H10BrClO4/c18-9-10-4-5-15-11(6-10)7-14(17(21)23-15)16(20)22-13-3-1-2-12(19)8-13/h1-8H,9H2
DMWZJT0	CS	C1=CC(=CC(=C1)Cl)OC(=O)C2=CC3=C(C=CC(=C3)CBr)OC2=O
DMWZJT0	IK	RNWNTBMGGUARMR-UHFFFAOYSA-N
DMWZJT0	IU	(3-chlorophenyl) 6-(bromomethyl)-2-oxochromene-3-carboxylate
DMWZJT0	DE	Discovery agent

DMO6NEX	ID	DMO6NEX
DMO6NEX	DN	PMID25497965C17c
DMO6NEX	HS	Investigative
DMO6NEX	SN	GTPL8507; BDBM50041416
DMO6NEX	DT	Small molecular drug
DMO6NEX	PC	91827364
DMO6NEX	MW	493.5
DMO6NEX	FM	C24H26F3N3O5
DMO6NEX	IC	InChI=1S/C24H26F3N3O5/c1-14(2)10-22(34)35-16-5-3-4-15(11-16)12-20(31)30-9-8-28-23-17(18(30)13-21(32)33)6-7-19(29-23)24(25,26)27/h3-7,11,14,18H,8-10,12-13H2,1-2H3,(H,28,29)(H,32,33)/t18-/m1/s1
DMO6NEX	CS	CC(C)CC(=O)OC1=CC=CC(=C1)CC(=O)N2CCNC3=C([C@H]2CC(=O)O)C=CC(=N3)C(F)(F)F
DMO6NEX	IK	CJLZUKCACMUYFP-GOSISDBHSA-N
DMO6NEX	IU	2-[(5R)-4-[2-[3-(3-methylbutanoyloxy)phenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid
DMO6NEX	DE	Discovery agent

DM4PZ37	ID	DM4PZ37
DM4PZ37	DN	PMID25703523C7d
DM4PZ37	HS	Investigative
DM4PZ37	SN	43U; GTPL8304
DM4PZ37	DT	Small molecular drug
DM4PZ37	PC	90684387
DM4PZ37	MW	320.14
DM4PZ37	FM	C12H10BrN5O
DM4PZ37	IC	InChI=1S/C12H10BrN5O/c1-19-8-3-2-6(13)4-7(8)9-10-11(16-5-15-10)18-12(14)17-9/h2-5H,1H3,(H3,14,15,16,17,18)
DM4PZ37	CS	COC1=C(C=C(C=C1)Br)C2=C3C(=NC(=N2)N)N=CN3
DM4PZ37	IK	KDNVOUMYSICLPF-UHFFFAOYSA-N
DM4PZ37	IU	6-(5-bromo-2-methoxyphenyl)-7H-purin-2-amine
DM4PZ37	DE	Discovery agent

DM7AJER	ID	DM7AJER
DM7AJER	DN	PMID25719566C1
DM7AJER	HS	Investigative
DM7AJER	SN	GTPL8302; MolPort-016-611-562; ZINC65410133; BDBM50078632; MCULE-6970562839; 43C
DM7AJER	DT	Small molecular drug
DM7AJER	PC	50967109
DM7AJER	MW	354.4
DM7AJER	FM	C21H18N6
DM7AJER	IC	InChI=1S/C21H18N6/c1-16-14-27(25-24-16)12-11-26-15-23-20(18-5-3-2-4-6-18)21(26)19-9-7-17(13-22)8-10-19/h2-10,14-15H,11-12H2,1H3
DM7AJER	CS	CC1=CN(N=N1)CCN2C=NC(=C2C3=CC=C(C=C3)C#N)C4=CC=CC=C4
DM7AJER	IK	OAPIWVHFYSEARE-UHFFFAOYSA-N
DM7AJER	IU	4-[3-[2-(4-methyltriazol-1-yl)ethyl]-5-phenylimidazol-4-yl]benzonitrile
DM7AJER	DE	Discovery agent

DMGCAIO	ID	DMGCAIO
DMGCAIO	DN	PMID25719566C7
DMGCAIO	HS	Investigative
DMGCAIO	SN	GTPL8306; BDBM50078638
DMGCAIO	DT	Small molecular drug
DMGCAIO	PC	91827353
DMGCAIO	MW	358.4
DMGCAIO	FM	C19H18N8
DMGCAIO	IC	InChI=1S/C19H18N8/c1-14-11-27(24-23-14)8-7-26-13-21-18(17-10-22-25(2)12-17)19(26)16-5-3-15(9-20)4-6-16/h3-6,10-13H,7-8H2,1-2H3
DMGCAIO	CS	CC1=CN(N=N1)CCN2C=NC(=C2C3=CC=C(C=C3)C#N)C4=CN(N=C4)C
DMGCAIO	IK	YPRKVQKJNRKXFN-UHFFFAOYSA-N
DMGCAIO	IU	4-[5-(1-methylpyrazol-4-yl)-3-[2-(4-methyltriazol-1-yl)ethyl]imidazol-4-yl]benzonitrile
DMGCAIO	DE	Discovery agent

DMDYT6P	ID	DMDYT6P
DMDYT6P	DN	PMID25742366C14b
DMDYT6P	HS	Investigative
DMDYT6P	SN	GTPL8684
DMDYT6P	DT	Small molecular drug
DMDYT6P	PC	91827386
DMDYT6P	MW	437.4
DMDYT6P	FM	C21H26Cl2N4O2
DMDYT6P	IC	InChI=1S/C21H26Cl2N4O2/c22-12-19(24)25-10-4-9-18-20(28)27(21(29)26-18)13-14-5-3-6-15(11-14)16-7-1-2-8-17(16)23/h1-3,5-8,11,18-20,25,28H,4,9-10,12-13,24H2,(H,26,29)
DMDYT6P	CS	C1=CC=C(C(=C1)C2=CC=CC(=C2)CN3C(C(NC3=O)CCCNC(CCl)N)O)Cl
DMDYT6P	IK	TXEBWPPWSVMYOA-UHFFFAOYSA-N
DMDYT6P	IU	4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one
DMDYT6P	DE	Discovery agent

DMUEDBP	ID	DMUEDBP
DMUEDBP	DN	PMID25815140C48
DMUEDBP	HS	Investigative
DMUEDBP	SN	CNT2 inhibitor-1; GTPL8485; BDBM50085527; HY-112843; CS-0066911; 880155-70-4
DMUEDBP	DT	Small molecular drug
DMUEDBP	PC	59460354
DMUEDBP	MW	448.5
DMUEDBP	FM	C23H24N6O4
DMUEDBP	IC	InChI=1S/C23H24N6O4/c24-20-17-21(27-12-26-20)29(22-19(32)18(31)16(11-30)33-22)23(28-17)25-10-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-9,12,16,18-19,22,30-32H,10-11H2,(H,25,28)(H2,24,26,27)/t16-,18-,19-,22-/m1/s1
DMUEDBP	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CNC3=NC4=C(N=CN=C4N3[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMUEDBP	IK	YJLIKUSWRSEPSM-WGQQHEPDSA-N
DMUEDBP	IU	(2R,3R,4S,5R)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMUEDBP	DE	Discovery agent

DMGWZA3	ID	DMGWZA3
DMGWZA3	DN	PMID25974391C34
DMGWZA3	HS	Investigative
DMGWZA3	SN	GTPL8396; BDBM50148478; AKOS004992742; MCULE-8876093508; J3.601.438E; 4QH
DMGWZA3	DT	Small molecular drug
DMGWZA3	PC	50796983
DMGWZA3	MW	499.5
DMGWZA3	FM	C24H25N3O7S
DMGWZA3	IC	InChI=1S/C24H25N3O7S/c1-26-19-13-18(25-35(29,30)17-10-11-21(32-4)23(12-17)33-5)22(14-20(19)27(2)24(26)28)34-16-8-6-15(31-3)7-9-16/h6-14,25H,1-5H3
DMGWZA3	CS	CN1C2=C(C=C(C(=C2)NS(=O)(=O)C3=CC(=C(C=C3)OC)OC)OC4=CC=C(C=C4)OC)N(C1=O)C
DMGWZA3	IK	KNVIUMWNYXDULF-UHFFFAOYSA-N
DMGWZA3	IU	3,4-dimethoxy-N-[6-(4-methoxyphenoxy)-1,3-dimethyl-2-oxobenzimidazol-5-yl]benzenesulfonamide
DMGWZA3	DE	Discovery agent

DMHZOIU	ID	DMHZOIU
DMHZOIU	DN	PMID26061392C2
DMHZOIU	HS	Investigative
DMHZOIU	SN	caged vemurafenib prodrug; GTPL8548
DMHZOIU	DT	Small molecular drug
DMHZOIU	PC	91827370
DMHZOIU	MW	685.1
DMHZOIU	FM	C32H27ClF2N4O7S
DMHZOIU	IC	InChI=1S/C32H27ClF2N4O7S/c1-4-11-47(43,44)37-25-10-9-24(34)29(30(25)35)31(40)23-17-38(16-20-13-27(45-2)28(46-3)14-26(20)39(41)42)32-22(23)12-19(15-36-32)18-5-7-21(33)8-6-18/h5-10,12-15,17,37H,4,11,16H2,1-3H3
DMHZOIU	CS	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CN(C3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)CC5=CC(=C(C=C5[N+](=O)[O-])OC)OC)F
DMHZOIU	IK	JMMXKBJIBAVJSU-UHFFFAOYSA-N
DMHZOIU	IU	N-[3-[5-(4-chlorophenyl)-1-[(4,5-dimethoxy-2-nitrophenyl)methyl]pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide
DMHZOIU	DE	Discovery agent

DM8D6ZL	ID	DM8D6ZL
DM8D6ZL	DN	PMID26080733C7r
DM8D6ZL	HS	Investigative
DM8D6ZL	SN	GTPL8639
DM8D6ZL	DT	Small molecular drug
DM8D6ZL	PC	91827382
DM8D6ZL	MW	473.5
DM8D6ZL	FM	C27H28FN5O2
DM8D6ZL	IC	InChI=1S/C27H28FN5O2/c1-3-32-13-15-33(16-14-32)20-10-7-18(8-11-20)27(34)29-26-22-12-9-19(17-23(22)30-31-26)21-5-4-6-24(35-2)25(21)28/h4-12,17H,3,13-16H2,1-2H3,(H2,29,30,31,34)
DM8D6ZL	CS	CCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC4=C3C=CC(=C4)C5=C(C(=CC=C5)OC)F
DM8D6ZL	IK	ANMVTYAYYHHSTF-UHFFFAOYSA-N
DM8D6ZL	IU	4-(4-ethylpiperazin-1-yl)-N-[6-(2-fluoro-3-methoxyphenyl)-1H-indazol-3-yl]benzamide
DM8D6ZL	DE	Discovery agent

DM4TN73	ID	DM4TN73
DM4TN73	DN	PMID26155854C57
DM4TN73	HS	Investigative
DM4TN73	SN	GTPL8640; BDBM50096300
DM4TN73	DT	Small molecular drug
DM4TN73	PC	91827383
DM4TN73	MW	349.4
DM4TN73	FM	C20H23N5O
DM4TN73	IC	InChI=1S/C20H23N5O/c1-12-7-14(10-22-9-12)17-11-23-19(24-15-3-5-21-6-4-15)18-16(17)8-13(2)20(26)25-18/h7-11,15,21H,3-6H2,1-2H3,(H,23,24)(H,25,26)
DM4TN73	CS	CC1=CC(=CN=C1)C2=CN=C(C3=C2C=C(C(=O)N3)C)NC4CCNCC4
DM4TN73	IK	PAGDGWOISBNVEC-UHFFFAOYSA-N
DM4TN73	IU	3-methyl-5-(5-methylpyridin-3-yl)-8-(piperidin-4-ylamino)-1H-1,7-naphthyridin-2-one
DM4TN73	DE	Discovery agent

DMM5SI4	ID	DMM5SI4
DMM5SI4	DN	PMID26155854C60
DMM5SI4	HS	Investigative
DMM5SI4	SN	NP8; GTPL8641; BDBM50096282
DMM5SI4	DT	Small molecular drug
DMM5SI4	PC	91820725
DMM5SI4	MW	365.4
DMM5SI4	FM	C20H23N5O2
DMM5SI4	IC	InChI=1S/C20H23N5O2/c1-12-7-16-17(13-8-15(27-2)10-22-9-13)11-23-19(18(16)25-20(12)26)24-14-3-5-21-6-4-14/h7-11,14,21H,3-6H2,1-2H3,(H,23,24)(H,25,26)
DMM5SI4	CS	CC1=CC2=C(C(=NC=C2C3=CC(=CN=C3)OC)NC4CCNCC4)NC1=O
DMM5SI4	IK	FPQQERRFPULCIK-UHFFFAOYSA-N
DMM5SI4	IU	5-(5-methoxypyridin-3-yl)-3-methyl-8-(piperidin-4-ylamino)-1H-1,7-naphthyridin-2-one
DMM5SI4	DE	Discovery agent

DMTO95J	ID	DMTO95J
DMTO95J	DN	PMID26161824C70
DMTO95J	HS	Investigative
DMTO95J	SN	GTPL8706
DMTO95J	DT	Small molecular drug
DMTO95J	PC	46894021
DMTO95J	MW	524.4
DMTO95J	FM	C26H23Cl2N5O3
DMTO95J	IC	InChI=1S/C26H23Cl2N5O3/c27-20-9-10-23(22(28)16-20)33-25(19-7-5-18(6-8-19)4-2-1-3-11-29)21(17-34)24(30-33)26(35)31-32-12-14-36-15-13-32/h5-10,16,34H,1,3,12-15,17H2,(H,31,35)
DMTO95J	CS	C1COCCN1NC(=O)C2=NN(C(=C2CO)C3=CC=C(C=C3)C#CCCC#N)C4=C(C=C(C=C4)Cl)Cl
DMTO95J	IK	VQXIVPLXEIZJTH-UHFFFAOYSA-N
DMTO95J	IU	5-[4-(4-cyanobut-1-ynyl)phenyl]-1-(2,4-dichlorophenyl)-4-(hydroxymethyl)-N-morpholin-4-ylpyrazole-3-carboxamide
DMTO95J	DE	Discovery agent

DM9J5Q7	ID	DM9J5Q7
DM9J5Q7	DN	PMID2909732C7
DM9J5Q7	HS	Investigative
DM9J5Q7	SN	GTPL3020; BDBM50020291
DM9J5Q7	DT	Small molecular drug
DM9J5Q7	PC	44303431
DM9J5Q7	MW	236.26
DM9J5Q7	FM	C13H16O4
DM9J5Q7	IC	InChI=1S/C13H16O4/c14-11(8-12(15)9-13(16)17)7-6-10-4-2-1-3-5-10/h1-5,12,15H,6-9H2,(H,16,17)/t12-/m1/s1
DM9J5Q7	CS	C1=CC=C(C=C1)CCC(=O)C[C@H](CC(=O)O)O
DM9J5Q7	IK	AOBNEADIHQEJLV-GFCCVEGCSA-N
DM9J5Q7	IU	(3R)-3-hydroxy-5-oxo-7-phenylheptanoic acid
DM9J5Q7	DE	Discovery agent

DMOA1Y7	ID	DMOA1Y7
DMOA1Y7	DN	PMID30247903-Compound-General structure10
DMOA1Y7	HS	Investigative
DMOA1Y7	SN	PMID30247903Compound10
DMOA1Y7	DT	Small molecule immunotherapy 

DMA3ZPH	ID	DMA3ZPH
DMA3ZPH	DN	PMID30247903-Compound-General structure12
DMA3ZPH	HS	Investigative
DMA3ZPH	SN	PMID30247903Compound12
DMA3ZPH	DT	Small molecule immunotherapy 

DMJ0YZA	ID	DMJ0YZA
DMJ0YZA	DN	PMID30247903-Compound-General structure13
DMJ0YZA	HS	Investigative
DMJ0YZA	SN	PMID30247903Compound13
DMJ0YZA	DT	Small molecule immunotherapy 

DM5Z4JR	ID	DM5Z4JR
DM5Z4JR	DN	PMID30247903-Compound-General structure14
DM5Z4JR	HS	Investigative
DM5Z4JR	SN	PMID30247903Compound14
DM5Z4JR	DT	Small molecule immunotherapy 

DMCJDLO	ID	DMCJDLO
DMCJDLO	DN	PMID30247903-Compound-General structure15
DMCJDLO	HS	Investigative
DMCJDLO	SN	PMID30247903Compound15
DMCJDLO	DT	Small molecule immunotherapy 

DMVR4QH	ID	DMVR4QH
DMVR4QH	DN	PMID30247903-Compound-General structure16
DMVR4QH	HS	Investigative
DMVR4QH	SN	PMID30247903Compound16
DMVR4QH	DT	Small molecule immunotherapy 

DMC3GFI	ID	DMC3GFI
DMC3GFI	DN	PMID30247903-Compound-General structure17
DMC3GFI	HS	Investigative
DMC3GFI	SN	PMID30247903Compound17
DMC3GFI	DT	Small molecule immunotherapy 

DMZBQ5R	ID	DMZBQ5R
DMZBQ5R	DN	PMID30247903-Compound-General structure18
DMZBQ5R	HS	Investigative
DMZBQ5R	SN	PMID30247903Compound18
DMZBQ5R	DT	Small molecule immunotherapy 

DM8LS3I	ID	DM8LS3I
DM8LS3I	DN	PMID30247903-Compound-General structure19
DM8LS3I	HS	Investigative
DM8LS3I	SN	PMID30247903Compound19
DM8LS3I	DT	Small molecule immunotherapy 

DMCNXKE	ID	DMCNXKE
DMCNXKE	DN	PMID30247903-Compound-General structure20
DMCNXKE	HS	Investigative
DMCNXKE	SN	PMID30247903Compound20
DMCNXKE	DT	Small molecule immunotherapy 

DMFACRH	ID	DMFACRH
DMFACRH	DN	PMID30247903-Compound-General structure21
DMFACRH	HS	Investigative
DMFACRH	SN	PMID30247903Compound21
DMFACRH	DT	Small molecule immunotherapy 

DMLD1IU	ID	DMLD1IU
DMLD1IU	DN	PMID30247903-Compound-General structure22
DMLD1IU	HS	Investigative
DMLD1IU	SN	PMID30247903Compound22
DMLD1IU	DT	Small molecule immunotherapy 

DMMXLHW	ID	DMMXLHW
DMMXLHW	DN	PMID30247903-Compound-General structure23
DMMXLHW	HS	Investigative
DMMXLHW	SN	PMID30247903Compound23
DMMXLHW	DT	Small molecule immunotherapy 

DM8CPZB	ID	DM8CPZB
DM8CPZB	DN	PMID30247903-Compound-General structure24
DM8CPZB	HS	Investigative
DM8CPZB	SN	PMID30247903Compound24
DM8CPZB	DT	Small molecule immunotherapy 

DMEMLHR	ID	DMEMLHR
DMEMLHR	DN	PMID30247903-Compound-General structure25
DMEMLHR	HS	Investigative
DMEMLHR	SN	PMID30247903Compound25
DMEMLHR	DT	Small molecule immunotherapy 

DM4BF1P	ID	DM4BF1P
DM4BF1P	DN	PMID30247903-Compound-General structure26
DM4BF1P	HS	Investigative
DM4BF1P	SN	PMID30247903Compound26
DM4BF1P	DT	Small molecule immunotherapy 

DMYSWO4	ID	DMYSWO4
DMYSWO4	DN	PMID30247903-Compound-General structure27
DMYSWO4	HS	Investigative
DMYSWO4	SN	PMID30247903Compound27
DMYSWO4	DT	Small molecule immunotherapy 

DMALSIW	ID	DMALSIW
DMALSIW	DN	PMID30247903-Compound-General structure28
DMALSIW	HS	Investigative
DMALSIW	SN	PMID30247903Compound28
DMALSIW	DT	Small molecule immunotherapy 

DM9FEB6	ID	DM9FEB6
DM9FEB6	DN	PMID30247903-Compound-General structure29
DM9FEB6	HS	Investigative
DM9FEB6	SN	PMID30247903Compound29
DM9FEB6	DT	Small molecule immunotherapy 

DMHQ1ZD	ID	DMHQ1ZD
DMHQ1ZD	DN	PMID30247903-Compound-General structure30
DMHQ1ZD	HS	Investigative
DMHQ1ZD	SN	PMID30247903Compound30
DMHQ1ZD	DT	Small molecule immunotherapy 

DMSLWBI	ID	DMSLWBI
DMSLWBI	DN	PMID30247903-Compound-General structure31
DMSLWBI	HS	Investigative
DMSLWBI	SN	PMID30247903Compound31
DMSLWBI	DT	Small molecule immunotherapy 

DMD04TR	ID	DMD04TR
DMD04TR	DN	PMID30247903-Compound-General structure32
DMD04TR	HS	Investigative
DMD04TR	SN	PMID30247903Compound32
DMD04TR	DT	Small molecule immunotherapy 

DMFLQ96	ID	DMFLQ96
DMFLQ96	DN	PMID30247903-Compound-General structure33
DMFLQ96	HS	Investigative
DMFLQ96	SN	PMID30247903Compound33
DMFLQ96	DT	Small molecule immunotherapy 

DM1YOVG	ID	DM1YOVG
DM1YOVG	DN	PMID30247903-Compound-General structure34
DM1YOVG	HS	Investigative
DM1YOVG	SN	PMID30247903Compound34
DM1YOVG	DT	Small molecule immunotherapy 

DMF9HIJ	ID	DMF9HIJ
DMF9HIJ	DN	PMID30247903-Compound-General structure35
DMF9HIJ	HS	Investigative
DMF9HIJ	SN	PMID30247903Compound35
DMF9HIJ	DT	Small molecule immunotherapy 

DMI4EU5	ID	DMI4EU5
DMI4EU5	DN	PMID30247903-Compound-General structure36
DMI4EU5	HS	Investigative
DMI4EU5	SN	PMID30247903Compound36
DMI4EU5	DT	Small molecule immunotherapy 

DMDWHIN	ID	DMDWHIN
DMDWHIN	DN	PMID30247903-Compound-General structure37
DMDWHIN	HS	Investigative
DMDWHIN	SN	PMID30247903Compound37
DMDWHIN	DT	Small molecule immunotherapy 

DMDB9FT	ID	DMDB9FT
DMDB9FT	DN	PMID30247903-Compound-General structure38
DMDB9FT	HS	Investigative
DMDB9FT	SN	PMID30247903Compound38
DMDB9FT	DT	Small molecule immunotherapy 

DMKLATO	ID	DMKLATO
DMKLATO	DN	PMID30247903-Compound-General structure39
DMKLATO	HS	Investigative
DMKLATO	SN	PMID30247903Compound39
DMKLATO	DT	Small molecule immunotherapy 

DMPZ3AY	ID	DMPZ3AY
DMPZ3AY	DN	PMID30247903-Compound-General structure40
DMPZ3AY	HS	Investigative
DMPZ3AY	SN	PMID30247903Compound40
DMPZ3AY	DT	Small molecule immunotherapy 

DM0UMSF	ID	DM0UMSF
DM0UMSF	DN	PMID30247903-Compound-General structure41
DM0UMSF	HS	Investigative
DM0UMSF	SN	PMID30247903Compound41
DM0UMSF	DT	Small molecule immunotherapy 

DMRNF96	ID	DMRNF96
DMRNF96	DN	PMID30247903-Compound-General structure42
DMRNF96	HS	Investigative
DMRNF96	SN	PMID30247903Compound42
DMRNF96	DT	Small molecule immunotherapy 

DMY971M	ID	DMY971M
DMY971M	DN	PMID30247903-Compound-General structure43
DMY971M	HS	Investigative
DMY971M	SN	PMID30247903Compound43
DMY971M	DT	Small molecule immunotherapy 

DMRAFSB	ID	DMRAFSB
DMRAFSB	DN	PMID30247903-Compound-General structure44
DMRAFSB	HS	Investigative
DMRAFSB	SN	PMID30247903Compound44
DMRAFSB	DT	Small molecule immunotherapy 

DMHMUNB	ID	DMHMUNB
DMHMUNB	DN	PMID30247903-Compound-General structure45
DMHMUNB	HS	Investigative
DMHMUNB	SN	PMID30247903Compound45
DMHMUNB	DT	Small molecule immunotherapy 

DMWYCOB	ID	DMWYCOB
DMWYCOB	DN	PMID30247903-Compound-General structure46
DMWYCOB	HS	Investigative
DMWYCOB	SN	PMID30247903Compound46
DMWYCOB	DT	Small molecule immunotherapy 

DM7LUI2	ID	DM7LUI2
DM7LUI2	DN	PMID30247903-Compound-General structure5
DM7LUI2	HS	Investigative
DM7LUI2	SN	PMID30247903Compound5
DM7LUI2	DT	Small molecule immunotherapy 

DMHQ6C3	ID	DMHQ6C3
DMHQ6C3	DN	PMID30247903-Compound-General structure6
DMHQ6C3	HS	Investigative
DMHQ6C3	SN	PMID30247903Compound6
DMHQ6C3	DT	Small molecule immunotherapy 

DM9QMA2	ID	DM9QMA2
DM9QMA2	DN	PMID30247903-Compound-General structure7
DM9QMA2	HS	Investigative
DM9QMA2	SN	PMID30247903Compound7
DM9QMA2	DT	Small molecule immunotherapy 

DMLMYE0	ID	DMLMYE0
DMLMYE0	DN	PMID30247903-Compound-General structure8
DMLMYE0	HS	Investigative
DMLMYE0	SN	PMID30247903Compound8
DMLMYE0	DT	Small molecule immunotherapy 

DMBR7A6	ID	DMBR7A6
DMBR7A6	DN	PMID30247903-Compound-General structure9
DMBR7A6	HS	Investigative
DMBR7A6	SN	PMID30247903Compound9
DMBR7A6	DT	Small molecule immunotherapy 

DMN39V6	ID	DMN39V6
DMN39V6	DN	PMID32321856-compound-11a
DMN39V6	HS	Investigative
DMN39V6	SN	PMID32321856-C-11a
DMN39V6	TC	Antiviral Agents
DMN39V6	DT	Small molecular drug
DMN39V6	DE	Coronavirus Disease 2019 (COVID-19)

DM31QEY	ID	DM31QEY
DM31QEY	DN	PMID32321856-compound-11b
DM31QEY	HS	Investigative
DM31QEY	SN	PMID32321856-C-11b
DM31QEY	TC	Antiviral Agents
DM31QEY	DT	Small molecular drug
DM31QEY	DE	Coronavirus Disease 2019 (COVID-19)

DM3J746	ID	DM3J746
DM3J746	DN	PMID3514912C9
DM3J746	HS	Investigative
DM3J746	SN	GTPL8559; BDBM50405350; ZINC27564601
DM3J746	DT	Small molecular drug
DM3J746	PC	44365677
DM3J746	MW	269.3
DM3J746	FM	C15H15N3O2
DM3J746	IC	InChI=1S/C15H15N3O2/c1-10-2-8-13(9-3-10)20-14(19)11-4-6-12(7-5-11)18-15(16)17/h2-9H,1H3,(H4,16,17,18)
DM3J746	CS	CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
DM3J746	IK	OELAPCOUDOSGBC-UHFFFAOYSA-N
DM3J746	IU	(4-methylphenyl) 4-(diaminomethylideneamino)benzoate
DM3J746	DE	Discovery agent

DM6ZOW4	ID	DM6ZOW4
DM6ZOW4	DN	PMID3941405C3d
DM6ZOW4	HS	Investigative
DM6ZOW4	SN	GTPL8622; BDBM50026017
DM6ZOW4	DT	Small molecular drug
DM6ZOW4	PC	11241135
DM6ZOW4	MW	203.24
DM6ZOW4	FM	C11H13N3O
DM6ZOW4	IC	InChI=1S/C11H13N3O/c12-7-10(14-11(15)8-13)6-9-4-2-1-3-5-9/h1-5,10H,6,8,13H2,(H,14,15)
DM6ZOW4	CS	C1=CC=C(C=C1)CC(C#N)NC(=O)CN
DM6ZOW4	IK	QLVGHFBUSGYCCG-UHFFFAOYSA-N
DM6ZOW4	IU	2-amino-N-(1-cyano-2-phenylethyl)acetamide
DM6ZOW4	DE	Discovery agent

DMB2MQW	ID	DMB2MQW
DMB2MQW	DN	PMID7473541C11
DMB2MQW	HS	Investigative
DMB2MQW	SN	GTPL3096; BDBM50029182
DMB2MQW	DT	Small molecular drug
DMB2MQW	PC	12238216
DMB2MQW	MW	281.35
DMB2MQW	FM	C15H23NO4
DMB2MQW	IC	InChI=1S/C15H23NO4/c1-4-19-15(18)12-5-7-14(8-6-12)20-10-13(17)9-16-11(2)3/h5-8,11,13,16-17H,4,9-10H2,1-3H3
DMB2MQW	CS	CCOC(=O)C1=CC=C(C=C1)OCC(CNC(C)C)O
DMB2MQW	IK	SLTRHTRCERUIHA-UHFFFAOYSA-N
DMB2MQW	IU	ethyl 4-[2-hydroxy-3-(propan-2-ylamino)propoxy]benzoate
DMB2MQW	DE	Discovery agent

DM2CP5J	ID	DM2CP5J
DM2CP5J	DN	PMID7473541C19
DM2CP5J	HS	Investigative
DM2CP5J	SN	GTPL3112; BDBM50029177
DM2CP5J	DT	Small molecular drug
DM2CP5J	PC	10662370
DM2CP5J	MW	305.4
DM2CP5J	FM	C18H27NO3
DM2CP5J	IC	InChI=1S/C18H27NO3/c1-5-8-15-13-16(22-18(20)6-2)9-10-17(15)21-12-7-11-19-14(3)4/h5,9-10,13-14,19H,1,6-8,11-12H2,2-4H3
DM2CP5J	CS	CCC(=O)OC1=CC(=C(C=C1)OCCCNC(C)C)CC=C
DM2CP5J	IK	TYOWLIKQVJJCEX-UHFFFAOYSA-N
DM2CP5J	IU	[4-[3-(propan-2-ylamino)propoxy]-3-prop-2-enylphenyl] propanoate
DM2CP5J	DE	Discovery agent

DMMZ1LR	ID	DMMZ1LR
DMMZ1LR	DN	PMID7473541C20
DMMZ1LR	HS	Investigative
DMMZ1LR	SN	GTPL3114; ZINC13743795; BDBM50029159
DMMZ1LR	DT	Small molecular drug
DMMZ1LR	PC	10780929
DMMZ1LR	MW	305.5
DMMZ1LR	FM	C19H31NO2
DMMZ1LR	IC	InChI=1S/C19H31NO2/c1-5-7-13-21-18-10-11-19(17(15-18)9-6-2)22-14-8-12-20-16(3)4/h6,10-11,15-16,20H,2,5,7-9,12-14H2,1,3-4H3
DMMZ1LR	CS	CCCCOC1=CC(=C(C=C1)OCCCNC(C)C)CC=C
DMMZ1LR	IK	BLGFFZRIKMFSOM-UHFFFAOYSA-N
DMMZ1LR	IU	3-(4-butoxy-2-prop-2-enylphenoxy)-N-propan-2-ylpropan-1-amine
DMMZ1LR	DE	Discovery agent

DMMRSZB	ID	DMMRSZB
DMMRSZB	DN	PMID7473541C21
DMMRSZB	HS	Investigative
DMMRSZB	SN	GTPL3115; BDBM50029174
DMMRSZB	DT	Small molecular drug
DMMRSZB	PC	10591006
DMMRSZB	MW	309.4
DMMRSZB	FM	C21H27NO
DMMRSZB	IC	InChI=1S/C21H27NO/c1-4-9-20-16-19(18-10-6-5-7-11-18)12-13-21(20)23-15-8-14-22-17(2)3/h4-7,10-13,16-17,22H,1,8-9,14-15H2,2-3H3
DMMRSZB	CS	CC(C)NCCCOC1=C(C=C(C=C1)C2=CC=CC=C2)CC=C
DMMRSZB	IK	CKIDETHAWPUGOQ-UHFFFAOYSA-N
DMMRSZB	IU	3-(4-phenyl-2-prop-2-enylphenoxy)-N-propan-2-ylpropan-1-amine
DMMRSZB	DE	Discovery agent

DMOJ57D	ID	DMOJ57D
DMOJ57D	DN	PMID7629799C2d
DMOJ57D	HS	Investigative
DMOJ57D	SN	GTPL3060; BDBM50031848
DMOJ57D	DT	Small molecular drug
DMOJ57D	PC	10405846
DMOJ57D	MW	354.32
DMOJ57D	FM	C14H28O6P2
DMOJ57D	IC	InChI=1S/C14H28O6P2/c1-12(2)8-7-10-13(3)9-5-4-6-11-14(21(15,16)17)22(18,19)20/h8-9,14H,4-7,10-11H2,1-3H3,(H2,15,16,17)(H2,18,19,20)/b13-9+
DMOJ57D	CS	CC(=CCC/C(=C/CCCCC(P(=O)(O)O)P(=O)(O)O)/C)C
DMOJ57D	IK	JCYZSGYSCXRCHX-UKTHLTGXSA-N
DMOJ57D	IU	[(6E)-7,11-dimethyl-1-phosphonododeca-6,10-dienyl]phosphonic acid
DMOJ57D	DE	Discovery agent

DMBRH0Q	ID	DMBRH0Q
DMBRH0Q	DN	PMID7629799C2e
DMBRH0Q	HS	Investigative
DMBRH0Q	SN	GTPL3064; BDBM50031843
DMBRH0Q	DT	Small molecular drug
DMBRH0Q	PC	10339001
DMBRH0Q	MW	368.34
DMBRH0Q	FM	C15H30O6P2
DMBRH0Q	IC	InChI=1S/C15H30O6P2/c1-13(2)9-8-11-14(3)10-6-4-5-7-12-15(22(16,17)18)23(19,20)21/h9-10,15H,4-8,11-12H2,1-3H3,(H2,16,17,18)(H2,19,20,21)/b14-10+
DMBRH0Q	CS	CC(=CCC/C(=C/CCCCCC(P(=O)(O)O)P(=O)(O)O)/C)C
DMBRH0Q	IK	YCVCYJHGGKYDRH-GXDHUFHOSA-N
DMBRH0Q	IU	[(7E)-8,12-dimethyl-1-phosphonotrideca-7,11-dienyl]phosphonic acid
DMBRH0Q	DE	Discovery agent

DMXMF39	ID	DMXMF39
DMXMF39	DN	PMID7629799C6
DMXMF39	HS	Investigative
DMXMF39	SN	compound 3 [PMID: 8576905]; GTPL3063; BDBM50292846
DMXMF39	DT	Small molecular drug
DMXMF39	PC	56947056
DMXMF39	MW	366.24
DMXMF39	FM	C16H16O6P2-4
DMXMF39	IC	InChI=1S/C16H20O6P2/c17-23(18,19)16(24(20,21)22)8-4-5-13-9-11-15(12-10-13)14-6-2-1-3-7-14/h1-3,6-7,9-12,16H,4-5,8H2,(H2,17,18,19)(H2,20,21,22)/p-4
DMXMF39	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)CCCC(P(=O)([O-])[O-])P(=O)([O-])[O-]
DMXMF39	IK	UQVFFWAGEQWWMP-UHFFFAOYSA-J
DMXMF39	IU	dioxido-oxo-[4-(4-phenylphenyl)-1-phosphonatobutyl]-lambda5-phosphane
DMXMF39	DE	Discovery agent

DM5SU6N	ID	DM5SU6N
DM5SU6N	DN	PMID7650673C4q
DM5SU6N	HS	Investigative
DM5SU6N	SN	GTPL3108; BDBM50032836
DM5SU6N	DT	Small molecular drug
DM5SU6N	PC	10411224
DM5SU6N	MW	444.7
DM5SU6N	FM	C28H36N2OSi
DM5SU6N	IC	InChI=1S/C28H36N2OSi/c1-7-30(19-10-8-9-18-28(2,3)4)22-25-12-11-13-26(20-25)31-23-32(5,6)27-16-14-24(21-29)15-17-27/h8,10-17,20H,7,19,22-23H2,1-6H3/b10-8+
DM5SU6N	CS	CCN(C/C=C/C#CC(C)(C)C)CC1=CC(=CC=C1)OC[Si](C)(C)C2=CC=C(C=C2)C#N
DM5SU6N	IK	LIDUGWDLSDKCLM-CSKARUKUSA-N
DM5SU6N	IU	4-[[3-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]methyl-dimethylsilyl]benzonitrile
DM5SU6N	DE	Discovery agent

DM769YQ	ID	DM769YQ
DM769YQ	DN	PMID7932551C9
DM769YQ	HS	Investigative
DM769YQ	SN	(3alpha,5beta,12alpha,17xi)-3-hydroxy-21-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]pregnan-12-yl (2S)-2-methylbutanoate; GTPL3030; BDBM50037255
DM769YQ	DT	Small molecular drug
DM769YQ	PC	11756374
DM769YQ	MW	518.7
DM769YQ	FM	C31H50O6
DM769YQ	IC	InChI=1S/C31H50O6/c1-5-18(2)29(35)37-27-17-26-24(10-7-20-14-21(32)12-13-30(20,26)3)25-11-8-19(31(25,27)4)6-9-23-15-22(33)16-28(34)36-23/h18-27,32-33H,5-17H2,1-4H3/t18-,19?,20+,21+,22+,23+,24-,25-,26-,27-,30-,31+/m0/s1
DM769YQ	CS	CC[C@H](C)C(=O)O[C@H]1C[C@H]2[C@@H](CC[C@H]3[C@@]2(CC[C@H](C3)O)C)[C@H]4[C@]1(C(CC4)CC[C@@H]5C[C@H](CC(=O)O5)O)C
DM769YQ	IK	CFMOEGAYJQXZMT-UQTJVAAQSA-N
DM769YQ	IU	[(3R,5R,8R,9S,10S,12S,13R,14S)-3-hydroxy-17-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-12-yl] (2S)-2-methylbutanoate
DM769YQ	DE	Discovery agent

DMJF7OC	ID	DMJF7OC
DMJF7OC	DN	PMID7966163C3f
DMJF7OC	HS	Investigative
DMJF7OC	SN	GTPL3116; BDBM50038120
DMJF7OC	DT	Small molecular drug
DMJF7OC	PC	44352891
DMJF7OC	MW	798.9
DMJF7OC	FM	C42H54O15
DMJF7OC	IC	InChI=1S/C42H54O15/c1-27(33(54-29(3)43)28(2)26-30-18-12-10-13-19-30)23-24-40-34(45)35(42(57-40,39(50)51)41(52,38(48)49)36(56-40)37(46)47)55-32(44)22-16-8-6-4-5-7-9-17-25-53-31-20-14-11-15-21-31/h10-15,18-21,28,33-36,45,52H,1,4-9,16-17,22-26H2,2-3H3,(H,46,47)(H,48,49)(H,50,51)/t28-,33-,34-,35-,36?,40?,41?,42?/m1/s1
DMJF7OC	CS	C[C@H](CC1=CC=CC=C1)[C@@H](C(=C)CCC23[C@@H]([C@H](C(O2)(C(C(O3)C(=O)O)(C(=O)O)O)C(=O)O)OC(=O)CCCCCCCCCCOC4=CC=CC=C4)O)OC(=O)C
DMJF7OC	IK	MNIPVWXWSPXERA-IDNZQHFXSA-N
DMJF7OC	IU	(6R,7R)-1-[(4S,5R)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecanoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DMJF7OC	DE	Discovery agent

DMD524S	ID	DMD524S
DMD524S	DN	PMID7966163C4e
DMD524S	HS	Investigative
DMD524S	SN	GTPL3090; BDBM50038138
DMD524S	DT	Small molecular drug
DMD524S	PC	44352889
DMD524S	MW	827.9
DMD524S	FM	C43H57NO15
DMD524S	IC	InChI=1S/C43H57NO15/c1-28(33(56-30(3)45)29(2)27-31-19-13-11-14-20-31)23-24-41-34(46)35(43(59-41,39(51)52)42(54,38(49)50)36(58-41)37(47)48)57-40(53)44-25-17-9-7-5-4-6-8-10-18-26-55-32-21-15-12-16-22-32/h11-16,19-22,29,33-36,46,54H,1,4-10,17-18,23-27H2,2-3H3,(H,44,53)(H,47,48)(H,49,50)(H,51,52)/t29-,33-,34-,35-,36?,41?,42?,43?/m1/s1
DMD524S	CS	C[C@H](CC1=CC=CC=C1)[C@@H](C(=C)CCC23[C@@H]([C@H](C(O2)(C(C(O3)C(=O)O)(C(=O)O)O)C(=O)O)OC(=O)NCCCCCCCCCCCOC4=CC=CC=C4)O)OC(=O)C
DMD524S	IK	QOLHWXNSCZGWHK-BWBORTOCSA-N
DMD524S	IU	(6R,7R)-1-[(4S,5R)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DMD524S	DE	Discovery agent

DMUEG8O	ID	DMUEG8O
DMUEG8O	DN	PMID7966163C6c
DMUEG8O	HS	Investigative
DMUEG8O	SN	GTPL3083; BDBM50038089
DMUEG8O	DT	Small molecular drug
DMUEG8O	PC	44352782
DMUEG8O	MW	706.8
DMUEG8O	FM	C37H54O13
DMUEG8O	IC	InChI=1S/C37H54O13/c1-5-6-7-8-9-10-11-12-13-17-22-47-30-29(39)35(49-31(32(40)41)36(46,33(42)43)37(30,50-35)34(44)45)21-20-24(2)28(48-26(4)38)25(3)23-27-18-15-14-16-19-27/h14-16,18-19,25,28-31,39,46H,2,5-13,17,20-23H2,1,3-4H3,(H,40,41)(H,42,43)(H,44,45)/t25-,28-,29-,30-,31?,35?,36?,37?/m1/s1
DMUEG8O	CS	CCCCCCCCCCCCO[C@@H]1[C@H](C2(OC(C(C1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCC(=C)[C@H]([C@H](C)CC3=CC=CC=C3)OC(=O)C)O
DMUEG8O	IK	VGNCBRNRHXEODV-XXVHXNRLSA-N
DMUEG8O	IU	(6R,7R)-1-[(4S,5R)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DMUEG8O	DE	Discovery agent

DM0XU3C	ID	DM0XU3C
DM0XU3C	DN	PMID7966163C6d
DM0XU3C	HS	Investigative
DM0XU3C	SN	GTPL3086; BDBM50038092
DM0XU3C	DT	Small molecular drug
DM0XU3C	PC	44352887
DM0XU3C	MW	734.9
DM0XU3C	FM	C39H58O13
DM0XU3C	IC	InChI=1S/C39H58O13/c1-5-6-7-8-9-10-11-12-13-14-15-19-24-49-32-31(41)37(51-33(34(42)43)38(48,35(44)45)39(32,52-37)36(46)47)23-22-26(2)30(50-28(4)40)27(3)25-29-20-17-16-18-21-29/h16-18,20-21,27,30-33,41,48H,2,5-15,19,22-25H2,1,3-4H3,(H,42,43)(H,44,45)(H,46,47)/t27-,30-,31-,32-,33?,37?,38?,39?/m1/s1
DM0XU3C	CS	CCCCCCCCCCCCCCO[C@@H]1[C@H](C2(OC(C(C1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCC(=C)[C@H]([C@H](C)CC3=CC=CC=C3)OC(=O)C)O
DM0XU3C	IK	UXKLQDCALAWFIU-VKNDCNMPSA-N
DM0XU3C	IU	(6R,7R)-1-[(4S,5R)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DM0XU3C	DE	Discovery agent

DM8T41N	ID	DM8T41N
DM8T41N	DN	PMID7966163C6g
DM8T41N	HS	Investigative
DM8T41N	SN	GTPL3118; BDBM50038087
DM8T41N	DT	Small molecular drug
DM8T41N	PC	44352896
DM8T41N	MW	784.9
DM8T41N	FM	C42H56O14
DM8T41N	IC	InChI=1S/C42H56O14/c1-28(33(54-30(3)43)29(2)27-31-19-13-11-14-20-31)23-24-40-34(44)35(42(56-40,39(49)50)41(51,38(47)48)36(55-40)37(45)46)53-26-18-10-8-6-4-5-7-9-17-25-52-32-21-15-12-16-22-32/h11-16,19-22,29,33-36,44,51H,1,4-10,17-18,23-27H2,2-3H3,(H,45,46)(H,47,48)(H,49,50)/t29-,33-,34-,35-,36?,40?,41?,42?/m1/s1
DM8T41N	CS	C[C@H](CC1=CC=CC=C1)[C@@H](C(=C)CCC23[C@@H]([C@H](C(O2)(C(C(O3)C(=O)O)(C(=O)O)O)C(=O)O)OCCCCCCCCCCCOC4=CC=CC=C4)O)OC(=O)C
DM8T41N	IK	QBTROWHSMGZXCV-RQURQNPSSA-N
DM8T41N	IU	(6R,7R)-1-[(4S,5R)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecoxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DM8T41N	DE	Discovery agent

DMRGY2X	ID	DMRGY2X
DMRGY2X	DN	PMID8246233C28
DMRGY2X	HS	Investigative
DMRGY2X	SN	GTPL2985; BDBM50042631
DMRGY2X	DT	Small molecular drug
DMRGY2X	PC	44392528
DMRGY2X	MW	438.5
DMRGY2X	FM	C24H25FN3O4-
DMRGY2X	IC	InChI=1S/C24H26FN3O4/c1-15(2)24-27-22(17-4-3-10-26-14-17)23(16-5-7-18(25)8-6-16)28(24)11-9-19(29)12-20(30)13-21(31)32/h3-11,14-15,19-20,29-30H,12-13H2,1-2H3,(H,31,32)/p-1/b11-9+/t19-,20-/m1/s1
DMRGY2X	CS	CC(C)C1=NC(=C(N1/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CN=CC=C3
DMRGY2X	IK	ALLUALRNIBGJAM-MBUYQLGJSA-M
DMRGY2X	IU	(E,3R,5S)-7-[5-(4-fluorophenyl)-2-propan-2-yl-4-pyridin-3-ylimidazol-1-yl]-3,5-dihydroxyhept-6-enoate
DMRGY2X	DE	Discovery agent

DMUJ9F7	ID	DMUJ9F7
DMUJ9F7	DN	PMID8246233C35
DMUJ9F7	HS	Investigative
DMUJ9F7	SN	GTPL2999; BDBM50042629
DMUJ9F7	DT	Small molecular drug
DMUJ9F7	PC	56947031
DMUJ9F7	MW	437.5
DMUJ9F7	FM	C25H26FN2O4-
DMUJ9F7	IC	InChI=1S/C25H27FN2O4/c1-16(2)24-22(13-12-20(29)14-21(30)15-23(31)32)28(19-10-8-18(26)9-11-19)25(27-24)17-6-4-3-5-7-17/h3-13,16,20-21,29-30H,14-15H2,1-2H3,(H,31,32)/p-1/b13-12+/t20-,21-/m1/s1
DMUJ9F7	CS	CC(C)C1=C(N(C(=N1)C2=CC=CC=C2)C3=CC=C(C=C3)F)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O
DMUJ9F7	IK	ZYZCALPXKGUGJI-DDVDASKDSA-M
DMUJ9F7	IU	(E,3R,5S)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate
DMUJ9F7	DE	Discovery agent

DMETHN7	ID	DMETHN7
DMETHN7	DN	PMID8246233C5ab
DMETHN7	HS	Investigative
DMETHN7	SN	GTPL2994; BDBM50042625
DMETHN7	DT	Small molecular drug
DMETHN7	PC	44392511
DMETHN7	MW	455.5
DMETHN7	FM	C25H25F2N2O4-
DMETHN7	IC	InChI=1S/C25H26F2N2O4/c1-15(2)24-23(16-3-7-18(26)8-4-16)28-25(17-5-9-19(27)10-6-17)29(24)12-11-20(30)13-21(31)14-22(32)33/h3-12,15,20-21,30-31H,13-14H2,1-2H3,(H,32,33)/p-1/b12-11+/t20-,21-/m1/s1
DMETHN7	CS	CC(C)C1=C(N=C(N1/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)F
DMETHN7	IK	TVIKMEWXHYDWEQ-LKWCPCFXSA-M
DMETHN7	IU	(E,3R,5S)-7-[2,4-bis(4-fluorophenyl)-5-propan-2-ylimidazol-1-yl]-3,5-dihydroxyhept-6-enoate
DMETHN7	DE	Discovery agent

DMJWEXQ	ID	DMJWEXQ
DMJWEXQ	DN	PMID8246234C3h
DMJWEXQ	HS	Investigative
DMJWEXQ	SN	GTPL2956; BDBM50042653
DMJWEXQ	DT	Small molecular drug
DMJWEXQ	PC	9937377
DMJWEXQ	MW	548.4
DMJWEXQ	FM	C27H28BrF2NO4
DMJWEXQ	IC	InChI=1S/C27H28BrF2NO4/c1-16(2)26-25(28)24(17-4-8-19(29)9-5-17)27(18-6-10-20(30)11-7-18)31(26)13-12-21(32)14-22(33)15-23(34)35-3/h4-13,16,21-22,32-33H,14-15H2,1-3H3/b13-12+/t21-,22-/m1/s1
DMJWEXQ	CS	CC(C)C1=C(C(=C(N1/C=C/[C@H](C[C@H](CC(=O)OC)O)O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)Br
DMJWEXQ	IK	MUTCAPXLKRYEPR-ITWZMISCSA-N
DMJWEXQ	IU	methyl (E,3R,5S)-7-[4-bromo-2,3-bis(4-fluorophenyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyhept-6-enoate
DMJWEXQ	DE	Discovery agent

DMLOR6F	ID	DMLOR6F
DMLOR6F	DN	PMID8246237C18t
DMLOR6F	HS	Investigative
DMLOR6F	SN	GTPL2996; BDBM50042682
DMLOR6F	DT	Small molecular drug
DMLOR6F	PC	56947034
DMLOR6F	MW	539.6
DMLOR6F	FM	C33H32FN2O4-
DMLOR6F	IC	InChI=1S/C33H33FN2O4/c34-26-13-15-27(16-14-26)36-31(18-17-28(37)20-29(38)21-32(39)40)30-8-4-7-25(33(30)35-36)19-22-9-11-24(12-10-22)23-5-2-1-3-6-23/h1-3,5-6,9-18,25,28-29,37-38H,4,7-8,19-21H2,(H,39,40)/p-1/b18-17+/t25?,28-,29-/m1/s1
DMLOR6F	CS	C1CC(C2=NN(C(=C2C1)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F)CC4=CC=C(C=C4)C5=CC=CC=C5
DMLOR6F	IK	LRLBHWLNEJHHLJ-CDTDMYBXSA-M
DMLOR6F	IU	(E,3R,5S)-7-[2-(4-fluorophenyl)-7-[(4-phenylphenyl)methyl]-4,5,6,7-tetrahydroindazol-3-yl]-3,5-dihydroxyhept-6-enoate
DMLOR6F	DE	Discovery agent

DMEITGU	ID	DMEITGU
DMEITGU	DN	PMID8410973C2
DMEITGU	HS	Investigative
DMEITGU	SN	GTPL6566; BDBM50045284
DMEITGU	DT	Small molecular drug
DMEITGU	PC	15126552
DMEITGU	MW	713.9
DMEITGU	FM	C34H53F2N5O7S
DMEITGU	IC	InChI=1S/C34H53F2N5O7S/c1-4-12-27(38-32(44)29(22-26-15-10-7-11-16-26)40-49(46,47)41-17-19-48-20-18-41)31(43)39-28(21-25-13-8-6-9-14-25)30(42)34(35,36)33(45)37-23-24(3)5-2/h4,7,10-11,15-16,24-25,27-30,40,42H,1,5-6,8-9,12-14,17-23H2,2-3H3,(H,37,45)(H,38,44)(H,39,43)/t24-,27-,28-,29-,30+/m0/s1
DMEITGU	CS	CC[C@H](C)CNC(=O)C([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC=C)NC(=O)[C@H](CC2=CC=CC=C2)NS(=O)(=O)N3CCOCC3)O)(F)F
DMEITGU	IK	SXQPECMJHHMDFO-DUGYJJFCSA-N
DMEITGU	IU	(3R,4S)-5-cyclohexyl-2,2-difluoro-3-hydroxy-N-[(2S)-2-methylbutyl]-4-[[(2S)-2-[[(2S)-2-(morpholin-4-ylsulfonylamino)-3-phenylpropanoyl]amino]pent-4-enoyl]amino]pentanamide
DMEITGU	DE	Discovery agent

DM6J5KY	ID	DM6J5KY
DM6J5KY	DN	PMID8410973C3
DM6J5KY	HS	Investigative
DM6J5KY	SN	GTPL8634; BDBM50008139; 137302-35-3
DM6J5KY	DT	Small molecular drug
DM6J5KY	PC	10078814
DM6J5KY	MW	754.9
DM6J5KY	FM	C35H52F2N6O8S
DM6J5KY	IC	InChI=1S/C35H52F2N6O8S/c1-2-9-28(39-33(46)30(25-27-12-7-4-8-13-27)41-52(48,49)43-18-22-51-23-19-43)32(45)40-29(24-26-10-5-3-6-11-26)31(44)35(36,37)34(47)38-14-15-42-16-20-50-21-17-42/h2,4,7-8,12-13,26,28-30,41H,1,3,5-6,9-11,14-25H2,(H,38,47)(H,39,46)(H,40,45)/t28-,29-,30-/m0/s1
DM6J5KY	CS	C=CC[C@@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)C(C(=O)NCCN2CCOCC2)(F)F)NC(=O)[C@H](CC3=CC=CC=C3)NS(=O)(=O)N4CCOCC4
DM6J5KY	IK	MQDDTALXSBQTQP-DTXPUJKBSA-N
DM6J5KY	IU	(4S)-5-cyclohexyl-2,2-difluoro-N-(2-morpholin-4-ylethyl)-4-[[(2S)-2-[[(2S)-2-(morpholin-4-ylsulfonylamino)-3-phenylpropanoyl]amino]pent-4-enoyl]amino]-3-oxopentanamide
DM6J5KY	DE	Discovery agent

DMTURQZ	ID	DMTURQZ
DMTURQZ	DN	PMID8426367C18
DMTURQZ	HS	Investigative
DMTURQZ	SN	GTPL2961; BDBM50046561
DMTURQZ	DT	Small molecular drug
DMTURQZ	PC	44354270
DMTURQZ	MW	456.7
DMTURQZ	FM	C31H52O2
DMTURQZ	IC	InChI=1S/C31H52O2/c1-20(2)10-9-11-21(3)23-15-19-31(22(4)32)25-12-13-26-28(5,6)27(33)16-17-29(26,7)24(25)14-18-30(23,31)8/h12,20-21,23-24,26-27,33H,9-11,13-19H2,1-8H3/t21-,23-,24?,26?,27+,29-,30-,31-/m1/s1
DMTURQZ	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@]2([C@@]1(CCC3C2=CCC4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C(=O)C
DMTURQZ	IK	DZMAIPFWPZZKSY-MBDGPJGJSA-N
DMTURQZ	IU	1-[(3S,10R,13R,14S,17R)-3-hydroxy-4,4,10,13-tetramethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,5,6,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-14-yl]ethanone
DMTURQZ	DE	Discovery agent

DM8PBKQ	ID	DM8PBKQ
DM8PBKQ	DN	PMID8496919C7
DM8PBKQ	HS	Investigative
DM8PBKQ	SN	GTPL3100; BDBM50047468
DM8PBKQ	DT	Small molecular drug
DM8PBKQ	PC	10358175
DM8PBKQ	MW	312.5
DM8PBKQ	FM	C21H32N2
DM8PBKQ	IC	InChI=1S/C21H32N2/c1-18(2)8-5-9-19(3)10-6-11-20(4)13-15-23-17-21-12-7-14-22-16-21/h7-8,10,12-14,16,23H,5-6,9,11,15,17H2,1-4H3/b19-10+,20-13+
DM8PBKQ	CS	CC(=CCC/C(=C/CC/C(=C/CNCC1=CN=CC=C1)/C)/C)C
DM8PBKQ	IK	LOBKJLMNXXPMNQ-OPBVARBZSA-N
DM8PBKQ	IU	(2E,6E)-3,7,11-trimethyl-N-(pyridin-3-ylmethyl)dodeca-2,6,10-trien-1-amine
DM8PBKQ	DE	Discovery agent

DMG3ZD1	ID	DMG3ZD1
DMG3ZD1	DN	PMID8568816C56
DMG3ZD1	HS	Investigative
DMG3ZD1	SN	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010
DMG3ZD1	DT	Small molecular drug
DMG3ZD1	PC	2857
DMG3ZD1	MW	388.3
DMG3ZD1	FM	C18H18BrN3O2
DMG3ZD1	IC	InChI=1S/C18H18BrN3O2/c1-3-23-16-9-14-15(10-17(16)24-4-2)20-11-21-18(14)22-13-7-5-6-12(19)8-13/h5-11H,3-4H2,1-2H3,(H,20,21,22)
DMG3ZD1	CS	CCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Br)OCC
DMG3ZD1	IK	YXOXHAUUTIOBDA-UHFFFAOYSA-N
DMG3ZD1	IU	N-(3-bromophenyl)-6,7-diethoxyquinazolin-4-amine
DMG3ZD1	CA	CAS 171745-13-4
DMG3ZD1	DE	Discovery agent

DMUJEA4	ID	DMUJEA4
DMUJEA4	DN	PMID8576905C4
DMUJEA4	HS	Investigative
DMUJEA4	SN	GTPL3129; BDBM50049233
DMUJEA4	DT	Small molecular drug
DMUJEA4	PC	56947060
DMUJEA4	MW	405.5
DMUJEA4	FM	C18H30O6PS-3
DMUJEA4	IC	InChI=1S/C18H33O6PS/c1-15(2)9-7-11-17(4)13-8-12-16(3)10-5-6-14-18(25(19,20)21)26(22,23)24/h9-10,13,18H,5-8,11-12,14H2,1-4H3,(H2,19,20,21)(H,22,23,24)/p-3/b16-10+,17-13+
DMUJEA4	CS	CC(=CCC/C(=C/CC/C(=C/CCCC(P(=O)([O-])[O-])S(=O)(=O)[O-])/C)/C)C
DMUJEA4	IK	GAGCDEGBGYUQJJ-QKXOVSGLSA-K
DMUJEA4	IU	(5E,9E)-6,10,14-trimethyl-1-phosphonatopentadeca-5,9,13-triene-1-sulfonate
DMUJEA4	DE	Discovery agent

DMWBPOJ	ID	DMWBPOJ
DMWBPOJ	DN	PMID8709131C15
DMWBPOJ	HS	Investigative
DMWBPOJ	SN	GTPL3092; BDBM50052350; 150843-77-9
DMWBPOJ	DT	Small molecular drug
DMWBPOJ	PC	19077549
DMWBPOJ	MW	289.4
DMWBPOJ	FM	C21H23N
DMWBPOJ	IC	InChI=1S/C21H23N/c1-2-4-18(5-3-1)19-9-6-17(7-10-19)8-11-21-16-22-14-12-20(21)13-15-22/h1-11,20-21H,12-16H2/b11-8+
DMWBPOJ	CS	C1CN2CCC1C(C2)/C=C/C3=CC=C(C=C3)C4=CC=CC=C4
DMWBPOJ	IK	OBORHRVWTIDYCG-DHZHZOJOSA-N
DMWBPOJ	IU	3-[(E)-2-(4-phenylphenyl)ethenyl]-1-azabicyclo[2.2.2]octane
DMWBPOJ	CA	CAS 150843-77-9
DMWBPOJ	DE	Discovery agent

DM10IQP	ID	DM10IQP
DM10IQP	DN	PMID8709131C17
DM10IQP	HS	Investigative
DM10IQP	SN	GTPL3093; BDBM50052342
DM10IQP	DT	Small molecular drug
DM10IQP	PC	19077556
DM10IQP	MW	291.4
DM10IQP	FM	C21H25N
DM10IQP	IC	InChI=1S/C21H25N/c1-2-4-18(5-3-1)19-9-6-17(7-10-19)8-11-21-16-22-14-12-20(21)13-15-22/h1-7,9-10,20-21H,8,11-16H2
DM10IQP	CS	C1CN2CCC1C(C2)CCC3=CC=C(C=C3)C4=CC=CC=C4
DM10IQP	IK	DZTCLALNSKOSGM-UHFFFAOYSA-N
DM10IQP	IU	3-[2-(4-phenylphenyl)ethyl]-1-azabicyclo[2.2.2]octane
DM10IQP	DE	Discovery agent

DMSKJ53	ID	DMSKJ53
DMSKJ53	DN	PMID8709131C23
DMSKJ53	HS	Investigative
DMSKJ53	SN	GTPL3095; BDBM50052343
DMSKJ53	DT	Small molecular drug
DMSKJ53	PC	19077552
DMSKJ53	MW	303.4
DMSKJ53	FM	C21H21NO
DMSKJ53	IC	InChI=1S/C21H21NO/c23-21(16-22-14-11-20(21)12-15-22)13-10-17-6-8-19(9-7-17)18-4-2-1-3-5-18/h1-9,20,23H,11-12,14-16H2
DMSKJ53	CS	C1CN2CCC1C(C2)(C#CC3=CC=C(C=C3)C4=CC=CC=C4)O
DMSKJ53	IK	MWHQFRXYYJSIFR-UHFFFAOYSA-N
DMSKJ53	IU	3-[2-(4-phenylphenyl)ethynyl]-1-azabicyclo[2.2.2]octan-3-ol
DMSKJ53	DE	Discovery agent

DM1OS6M	ID	DM1OS6M
DM1OS6M	DN	PMID8709131C2a (+)
DM1OS6M	HS	Investigative
DM1OS6M	SN	BPQ-OH; GTPL3102; BDBM50052351
DM1OS6M	DT	Small molecular drug
DM1OS6M	PC	9817140
DM1OS6M	MW	279.4
DM1OS6M	FM	C19H21NO
DM1OS6M	IC	InChI=1S/C19H21NO/c21-19(14-20-12-10-18(19)11-13-20)17-8-6-16(7-9-17)15-4-2-1-3-5-15/h1-9,18,21H,10-14H2
DM1OS6M	CS	C1CN2CCC1C(C2)(C3=CC=C(C=C3)C4=CC=CC=C4)O
DM1OS6M	IK	WPCQYFUQHBLGAX-UHFFFAOYSA-N
DM1OS6M	IU	3-(4-phenylphenyl)-1-azabicyclo[2.2.2]octan-3-ol
DM1OS6M	DE	Discovery agent

DMETC8A	ID	DMETC8A
DMETC8A	DN	PMID8709131C4
DMETC8A	HS	Investigative
DMETC8A	SN	GTPL3094; BDBM50052376
DMETC8A	DT	Small molecular drug
DMETC8A	PC	9795241
DMETC8A	MW	263.4
DMETC8A	FM	C19H21N
DMETC8A	IC	InChI=1S/C19H21N/c1-2-4-15(5-3-1)16-6-8-17(9-7-16)19-14-20-12-10-18(19)11-13-20/h1-9,18-19H,10-14H2
DMETC8A	CS	C1CN2CCC1C(C2)C3=CC=C(C=C3)C4=CC=CC=C4
DMETC8A	IK	ONKAPNPOBBUQAF-UHFFFAOYSA-N
DMETC8A	IU	3-(4-phenylphenyl)-1-azabicyclo[2.2.2]octane
DMETC8A	DE	Discovery agent

DMM08LV	ID	DMM08LV
DMM08LV	DN	PMID8831774C19
DMM08LV	HS	Investigative
DMM08LV	SN	Z-Leu-Abu-CONH-CH2-CHOH-Ph; GTPL8569; BDBM50053850
DMM08LV	DT	Small molecular drug
DMM08LV	PC	44353781
DMM08LV	MW	497.6
DMM08LV	FM	C27H35N3O6
DMM08LV	IC	InChI=1S/C27H35N3O6/c1-4-21(24(32)26(34)28-16-23(31)20-13-9-6-10-14-20)29-25(33)22(15-18(2)3)30-27(35)36-17-19-11-7-5-8-12-19/h5-14,18,21-23,31H,4,15-17H2,1-3H3,(H,28,34)(H,29,33)(H,30,35)
DMM08LV	CS	CCC(C(=O)C(=O)NCC(C1=CC=CC=C1)O)NC(=O)C(CC(C)C)NC(=O)OCC2=CC=CC=C2
DMM08LV	IK	CZZWUFZBGQIPTE-UHFFFAOYSA-N
DMM08LV	IU	benzyl N-[1-[[1-[(2-hydroxy-2-phenylethyl)amino]-1,2-dioxopentan-3-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate
DMM08LV	DE	Discovery agent

DM1I578	ID	DM1I578
DM1I578	DN	PMID9003518C3
DM1I578	HS	Investigative
DM1I578	SN	GTPL6720; BDBM50055641
DM1I578	DT	Small molecular drug
DM1I578	PC	10095126
DM1I578	MW	446.8
DM1I578	FM	C29H50OS
DM1I578	IC	InChI=1S/C29H50OS/c1-23(2)13-11-18-27(6)31-22-21-26(5)15-10-9-14-24(3)16-12-17-25(4)19-20-28-29(7,8)30-28/h13-15,17,27-28H,9-12,16,18-22H2,1-8H3/b24-14+,25-17+,26-15+
DM1I578	CS	CC(CCC=C(C)C)SCC/C(=C/CC/C=C(\\C)/CC/C=C(\\C)/CCC1C(O1)(C)C)/C
DM1I578	IK	CRZHANPLXOIADK-YNWRIEOZSA-N
DM1I578	IU	2,2-dimethyl-3-[(3E,7E,11E)-3,7,12-trimethyl-14-(6-methylhept-5-en-2-ylsulfanyl)tetradeca-3,7,11-trienyl]oxirane
DM1I578	DE	Discovery agent

DMYE64O	ID	DMYE64O
DMYE64O	DN	PMID9003518C4
DMYE64O	HS	Investigative
DMYE64O	SN	GTPL6721
DMYE64O	DT	Small molecular drug
DMYE64O	PC	73755233
DMYE64O	MW	432.7
DMYE64O	FM	C28H48OS
DMYE64O	IC	InChI=1S/C28H48OS/c1-23(2)13-11-21-30-22-12-18-25(4)15-9-8-14-24(3)16-10-17-26(5)19-20-27-28(6,7)29-27/h13-15,17,27H,8-12,16,18-22H2,1-7H3/b24-14?,25-15+,26-17+
DMYE64O	CS	CC(=CCCSCCC/C(=C/CCC=C(C)CC/C=C(\\C)/CCC1C(O1)(C)C)/C)C
DMYE64O	IK	SFOVLQYHQCMFTD-VLUDVKJZSA-N
DMYE64O	IU	2,2-dimethyl-3-[(3E,11E)-3,7,12-trimethyl-15-(4-methylpent-3-enylsulfanyl)pentadeca-3,7,11-trienyl]oxirane
DMYE64O	DE	Discovery agent

DM2F81A	ID	DM2F81A
DM2F81A	DN	PMID9216829C5j
DM2F81A	HS	Investigative
DM2F81A	SN	GTPL3099; BDBM50058954
DM2F81A	DT	Small molecular drug
DM2F81A	PC	10699948
DM2F81A	MW	706.8
DM2F81A	FM	C42H46N2O8
DM2F81A	IC	InChI=1S/C42H46N2O8/c1-3-5-25-43(27-29-17-21-33(22-18-29)51-31-13-9-7-10-14-31)39(45)35-36(38(42(49)50)37(35)41(47)48)40(46)44(26-6-4-2)28-30-19-23-34(24-20-30)52-32-15-11-8-12-16-32/h7-24,35-38H,3-6,25-28H2,1-2H3,(H,47,48)(H,49,50)/t35-,36-,37-,38-/m0/s1
DM2F81A	CS	CCCCN(CC1=CC=C(C=C1)OC2=CC=CC=C2)C(=O)[C@H]3[C@@H]([C@@H]([C@H]3C(=O)O)C(=O)O)C(=O)N(CCCC)CC4=CC=C(C=C4)OC5=CC=CC=C5
DM2F81A	IK	GNPHAOQLHRZODS-ZQWQDMLBSA-N
DM2F81A	IU	(1S,2S,3S,4S)-3,4-bis[butyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid
DM2F81A	DE	Discovery agent

DM3ARWX	ID	DM3ARWX
DM3ARWX	DN	PMID9216829C5m
DM3ARWX	HS	Investigative
DM3ARWX	SN	GTPL3098; BDBM50058948
DM3ARWX	DT	Small molecular drug
DM3ARWX	PC	10818542
DM3ARWX	MW	706.8
DM3ARWX	FM	C42H46N2O8
DM3ARWX	IC	InChI=1S/C42H46N2O8/c1-27(2)23-43(25-29-15-19-33(20-16-29)51-31-11-7-5-8-12-31)39(45)35-36(38(42(49)50)37(35)41(47)48)40(46)44(24-28(3)4)26-30-17-21-34(22-18-30)52-32-13-9-6-10-14-32/h5-22,27-28,35-38H,23-26H2,1-4H3,(H,47,48)(H,49,50)/t35-,36-,37-,38-/m0/s1
DM3ARWX	CS	CC(C)CN(CC1=CC=C(C=C1)OC2=CC=CC=C2)C(=O)[C@H]3[C@@H]([C@@H]([C@H]3C(=O)O)C(=O)O)C(=O)N(CC4=CC=C(C=C4)OC5=CC=CC=C5)CC(C)C
DM3ARWX	IK	ZXCUOCHXNYWBBG-ZQWQDMLBSA-N
DM3ARWX	IU	(1S,2S,3S,4S)-3,4-bis[2-methylpropyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid
DM3ARWX	DE	Discovery agent

DMY28QM	ID	DMY28QM
DMY28QM	DN	PMID9871507C14
DMY28QM	HS	Investigative
DMY28QM	SN	GTPL3106; BDBM50068845
DMY28QM	DT	Small molecular drug
DMY28QM	PC	44382842
DMY28QM	MW	750.8
DMY28QM	FM	C43H46N2O10
DMY28QM	IC	InChI=1S/C43H46N2O10/c1-3-23-44(27-29-15-19-33(20-16-29)54-31-11-7-5-8-12-31)39(48)35-25-36(43(42(52)53,26-37(46)47)38(35)41(50)51)40(49)45(24-4-2)28-30-17-21-34(22-18-30)55-32-13-9-6-10-14-32/h5-22,35-36,38H,3-4,23-28H2,1-2H3,(H,46,47)(H,50,51)(H,52,53)/t35-,36-,38+,43-/m0/s1
DMY28QM	CS	CCCN(CC1=CC=C(C=C1)OC2=CC=CC=C2)C(=O)[C@H]3C[C@H]([C@]([C@H]3C(=O)O)(CC(=O)O)C(=O)O)C(=O)N(CCC)CC4=CC=C(C=C4)OC5=CC=CC=C5
DMY28QM	IK	SZUVGFMDDVSKSI-WIFOCOSTSA-N
DMY28QM	IU	(1S,2S,3S,5R)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid
DMY28QM	DE	Discovery agent

DMHSWT6	ID	DMHSWT6
DMHSWT6	DN	P-MPPI
DMHSWT6	HS	Investigative
DMHSWT6	SN	p-MPPI; 4-Mppi; 155204-23-2; CHEMBL29027; 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine; 4-Iodo-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-2-pyridinylbenzamide; benzamide, 4-iodo-n-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-n-2-pyridinyl-; 4-iodo-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylbenzamide; Benzamide, 4-iodo-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-2-pyridinyl-; C25H27IN4O2; NCGC00015638-01; Lopac-M-204; AC1Q4PHY; AC1L1INV; GTPL68; Lopac0_000874
DMHSWT6	DT	Small molecular drug
DMHSWT6	PC	4658
DMHSWT6	MW	542.4
DMHSWT6	FM	C25H27IN4O2
DMHSWT6	IC	InChI=1S/C25H27IN4O2/c1-32-23-7-3-2-6-22(23)29-17-14-28(15-18-29)16-19-30(24-8-4-5-13-27-24)25(31)20-9-11-21(26)12-10-20/h2-13H,14-19H2,1H3
DMHSWT6	CS	COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4=CC=C(C=C4)I
DMHSWT6	IK	DHMLNZRDVQLQBB-UHFFFAOYSA-N
DMHSWT6	IU	4-iodo-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylbenzamide
DMHSWT6	CA	CAS 155204-23-2
DMHSWT6	DE	Discovery agent

DMZCSF1	ID	DMZCSF1
DMZCSF1	DN	PMX-700
DMZCSF1	HS	Investigative
DMZCSF1	SN	SJ-005019; SJ-005059; DC-010-116; Temozolomide analogs (cancer), Pharminox
DMZCSF1	CP	Pharminox Ltd
DMZCSF1	DE	Glioblastoma multiforme

DMPUC8I	ID	DMPUC8I
DMPUC8I	DN	PNA-D-glucopyranoside
DMPUC8I	HS	Investigative
DMPUC8I	SN	P-nitrophenyl-alpha-D-glucopyranoside; A-D-glucopyranoside; p-Nitrophenyl-.beta.-galactoside; (2R,3S,4S,5S,6S)-2-(Hydroxymethyl)-6-(4-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triol; 2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol; 2-(hydroxymethyl)-6-(4-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triol; 4-Nitrophenyl-; 6-(hydroxymethyl)-2-(4-nitrophenoxy)-2H-3,4,5,6-tetrahydropyran-3,4,5-triol; p-NITROPHENYL-beta-D-GALACTOPYRANOSIDE; p-Nitrophenyl-alpha-D-glucopyranoside; p-Nitrophenyl-beta-D-glucopyranoside
DMPUC8I	PC	259380
DMPUC8I	MW	301.25
DMPUC8I	FM	C12H15NO8
DMPUC8I	IC	IFBHRQDFSNCLOZ-UHFFFAOYSA-N
DMPUC8I	CS	C1=CC(=CC=C1[N+](=O)[O-])OC2C(C(C(C(O2)CO)O)O)O
DMPUC8I	IK	1S/C12H15NO8/c14-5-8-9(15)10(16)11(17)12(21-8)20-7-3-1-6(2-4-7)13(18)19/h1-4,8-12,14-17H,5H2
DMPUC8I	IU	2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol
DMPUC8I	CA	CAS 3150-24-1
DMPUC8I	DE	Discovery agent

DMZF7RQ	ID	DMZF7RQ
DMZF7RQ	DN	PNA-l-rhamnopyranoside
DMZF7RQ	HS	Investigative
DMZF7RQ	SN	P-nitrophenyl-alpha-l-rhamnopyranoside; p-nitrophenyl-alpha-l-rhamnoside; pNP-alpha-L-rhamnoside; (2S,3R,4R,5R,6S)-2-Methyl-6-(4-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5R,6S)-2-methyl-6-(4-nitrophenoxy)oxane-3,4,5-triol; 18918-31-5; 3-Nitrophenyl a-L-rhamnopyranoside; 4-Nitrophenyl a-L-rhamnopyranoside; 4-Nitrophenyl alpha-L-rhamnopyranoside; 4-Nitrophenyl-alpha-L-rhamnoside; 4-Nitrophenylrhamnoside; alpha-L-Mannopyranoside, 4-nitrophenyl 6-deoxy-; p-NITROPHENYL alpha-L-RHAMNOPYRANOSIDE; SCHEMBL2296345; para-Nitrophenyl-alpha-L-rhamnoside
DMZF7RQ	PC	3082141
DMZF7RQ	MW	285.25
DMZF7RQ	FM	C12H15NO7
DMZF7RQ	IC	YILIDCGSXCGACV-UOAXWKJLSA-N
DMZF7RQ	CS	CC1C(C(C(C(O1)OC2=CC=C(C=C2)[N+](=O)[O-])O)O)O
DMZF7RQ	IK	1S/C12H15NO7/c1-6-9(14)10(15)11(16)12(19-6)20-8-4-2-7(3-5-8)13(17)18/h2-6,9-12,14-16H,1H3/t6-,9-,10+,11+,12-/m0/s1
DMZF7RQ	IU	(2S,3R,4R,5R,6S)-2-methyl-6-(4-nitrophenoxy)oxane-3,4,5-triol
DMZF7RQ	CA	CAS 18918-31-5
DMZF7RQ	DE	Discovery agent

DMBK8QI	ID	DMBK8QI
DMBK8QI	DN	PNB-D-glucoside
DMBK8QI	HS	Investigative
DMBK8QI	SN	P-nitrophenyl-beta-D-glucoside; Glucoside, p-nitrophenyl; IFBHRQDFSNCLOZ-RMPHRYRLSA-N; p-Nitrophenyl beta-D-glucoside; p-Nitrophenyl beta-glucoside; p-Nitrophenyl-beta-glucoside; .beta.-D-glucopyranoside, 4-nitrophenyl; 1-O-p-Nitrophenyl-D-glucose; 2492-87-7; 4-Nitrophenyl beta-D-glucopyranoside; 4-Nitrophenyl beta-D-glucoside; 4-Nitrophenyl-beta-D-glucopyranoside; 4-nitrophenyl b-d-glucopyranoside; CHEBI:90259; MFCD00006593; PNPG; beta-D-Glucopyranoside, 4-nitrophenyl; p-Nitrophenyl beta-D-glucopyranoside
DMBK8QI	PC	92930
DMBK8QI	MW	301.25
DMBK8QI	FM	C12H15NO8
DMBK8QI	IC	IFBHRQDFSNCLOZ-RMPHRYRLSA-N
DMBK8QI	CS	C1=CC(=CC=C1[N+](=O)[O-])OC2C(C(C(C(O2)CO)O)O)O
DMBK8QI	IK	1S/C12H15NO8/c14-5-8-9(15)10(16)11(17)12(21-8)20-7-3-1-6(2-4-7)13(18)19/h1-4,8-12,14-17H,5H2/t8-,9-,10+,11-,12-/m1/s1
DMBK8QI	IU	(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol
DMBK8QI	CA	CAS 2492-87-7
DMBK8QI	CB	CHEBI:90259
DMBK8QI	DE	Discovery agent

DMZ91P5	ID	DMZ91P5
DMZ91P5	DN	PNB-D-glucuronide
DMZ91P5	HS	Investigative
DMZ91P5	SN	P-nitrophenyl-beta-D-glucuronide; p-Nitrophenyl-beta-D-glucuronide; MCULE-4718455730; SY007615; (2S,3S,4S,5R,6R)-3,4,5-Trihydroxy-6-(4-nitrophenoxy)tetrahydro-2H-pyran-2-carboxylic acid; 39031-76-0; 4-Nitrophenyl beta-D-galact??uronide; AKOS024290194; DTXSID50391117; MFCD00036210; p-Nitrophenyl-beta-D-glucopyranosiduronic Acid; p-nitrophenyl ss-D-glucopyranosiduronic acid
DMZ91P5	PC	3291162
DMZ91P5	MW	315.23
DMZ91P5	FM	C12H13NO9
DMZ91P5	IC	QSUILVWOWLUOEU-UHFFFAOYSA-N
DMZ91P5	CS	C1=CC(=CC=C1[N+](=O)[O-])OC2C(C(C(C(O2)C(=O)O)O)O)O
DMZ91P5	IK	1S/C12H13NO9/c14-7-8(15)10(11(17)18)22-12(9(7)16)21-6-3-1-5(2-4-6)13(19)20/h1-4,7-10,12,14-16H,(H,17,18)
DMZ91P5	IU	3,4,5-trihydroxy-6-(4-nitrophenoxy)oxane-2-carboxylic acid
DMZ91P5	CA	CAS 39031-76-0
DMZ91P5	DE	Discovery agent

DMWPECH	ID	DMWPECH
DMWPECH	DN	PNB-D-xyloside
DMWPECH	HS	Investigative
DMWPECH	SN	P-nitrophenyl-beta-D-xyloside; Nitrophenyl-beta-D-xyloside; p-Nitrophenyl beta-D-xyloside; p-nitrophenyl ss-D-xylopyranoside; (2S,3R,4S,5R)-2-(4-Nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4S,5R)-2-(4-nitrophenoxy)oxane-3,4,5-triol; 2001-96-9; 3-Nitrophenyl b-D-xylopyranoside; 4-Nitrophenyl b-D-xylopyranoside; 4-Nitrophenyl beta-D-xylopyranoside; 4-Nitrophenyl beta-D-xyloside; 4-Nitrophenyl-Beta-D-xylopyranoside; 41721-77-1; NSC 371094; PNPX; p-Nitrophenyl beta-D-xylopyranoside; p-Nitrophenyl-beta-d-xylopyranoside
DMWPECH	PC	91509
DMWPECH	MW	271.22
DMWPECH	FM	C11H13NO7
DMWPECH	IC	MLJYKRYCCUGBBV-YTWAJWBKSA-N
DMWPECH	CS	C1C(C(C(C(O1)OC2=CC=C(C=C2)[N+](=O)[O-])O)O)O
DMWPECH	IK	1S/C11H13NO7/c13-8-5-18-11(10(15)9(8)14)19-7-3-1-6(2-4-7)12(16)17/h1-4,8-11,13-15H,5H2/t8-,9+,10-,11+/m1/s1
DMWPECH	IU	(2S,3R,4S,5R)-2-(4-nitrophenoxy)oxane-3,4,5-triol
DMWPECH	CA	CAS 2001-96-9
DMWPECH	CB	CHEBI:90148
DMWPECH	DE	Discovery agent

DMVJUOZ	ID	DMVJUOZ
DMVJUOZ	DN	P-nitrobenzoic acid
DMVJUOZ	HS	Investigative
DMVJUOZ	SN	Benzoic acid, 4-nitro-; Benzoic acid, p-nitro-; Kyselina p-nitrobenzoova; Kyselina p-nitrobenzoova [Czech]; Nitrodracylic acid; OTLNPYWUJOZPPA-UHFFFAOYSA-N; p-Nitrobenzenecarboxylic acid; p-Nitrobenzoic acid; p-Nitrodracylic acid; p-nitro benzoic acid; p-nitrobenzoicacid; para-nitrobenzoic acid; 1-Carboxy-4-nitrobenzene; 4-NITROBENZOIC ACID; 4-Nitro-benzoic acid; 4-Nitrodracylic acid; 62-23-7; AI3-00149; CCRIS 1185; CHEBI:262350; CHEMBL101263; EINECS 200-526-2; G83NWR61OW; HSDB 2140; MFCD00007352; NSC 7707; UNII-G83NWR61OW
DMVJUOZ	PC	6108
DMVJUOZ	MW	167.12
DMVJUOZ	FM	C7H5NO4
DMVJUOZ	IC	OTLNPYWUJOZPPA-UHFFFAOYSA-N
DMVJUOZ	CS	C1=CC(=CC=C1C(=O)O)[N+](=O)[O-]
DMVJUOZ	IK	1S/C7H5NO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4H,(H,9,10)
DMVJUOZ	IU	4-nitrobenzoic acid
DMVJUOZ	CA	CAS 62-23-7
DMVJUOZ	CB	CHEBI:262350
DMVJUOZ	DE	Discovery agent

DM7LPCE	ID	DM7LPCE
DM7LPCE	DN	P-nitrophenyl
DM7LPCE	HS	Investigative
DM7LPCE	SN	A-d-mannopyranoside; SCHEMBL149793; STL555800; ZINC5842327; b-D-Mannopyranoside, 4-nitrophenyl; p-Nitrophenyl ; (2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol; 35599-02-1; 4-Nitrophenyl b-D-mannopyranoside; 4-Nitrophenyl beta-D-mannopyranoside; 4-Nitrophenyl-beta-D-mannopyranoside; A-PNP; AC1L4Q9D; AC1Q20VW; BIB6133; EINECS 252-633-9; MBE; MFCD00067650; Man1-; p-Nitrophenyl beta-D-mannopyranoside; p-nitrophenyl-beta-d-mannopyranoside
DM7LPCE	PC	161880
DM7LPCE	MW	301.25
DM7LPCE	FM	C12H15NO8
DM7LPCE	IC	IFBHRQDFSNCLOZ-LDMBFOFVSA-N
DM7LPCE	CS	C1=CC(=CC=C1[N+](=O)[O-])OC2C(C(C(C(O2)CO)O)O)O
DM7LPCE	IK	1S/C12H15NO8/c14-5-8-9(15)10(16)11(17)12(21-8)20-7-3-1-6(2-4-7)13(18)19/h1-4,8-12,14-17H,5H2/t8-,9-,10+,11+,12-/m1/s1
DM7LPCE	IU	(2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol
DM7LPCE	CA	CAS 35599-02-1
DM7LPCE	DE	Discovery agent

DM29RO1	ID	DM29RO1
DM29RO1	DN	P-Nitrophenyl Glutamyl Anilide
DM29RO1	HS	Investigative
DM29RO1	SN	gamma-glutamyl-p-nitroanilide; p-nitrophenyl glutamyl anilide; AC1OF0UB; GTPL4508; (2S)-2-azaniumyl-5-(4-nitroanilino)-5-oxopentanoate
DM29RO1	DT	Small molecular drug
DM29RO1	PC	7090494
DM29RO1	MW	267.24
DM29RO1	FM	C11H13N3O5
DM29RO1	IC	InChI=1S/C11H13N3O5/c12-9(11(16)17)5-6-10(15)13-7-1-3-8(4-2-7)14(18)19/h1-4,9H,5-6,12H2,(H,13,15)(H,16,17)/t9-/m0/s1
DM29RO1	CS	C1=CC(=CC=C1NC(=O)CC[C@@H](C(=O)[O-])[NH3+])[N+](=O)[O-]
DM29RO1	IK	WMZTYIRRBCGARG-VIFPVBQESA-N
DM29RO1	IU	(2S)-2-azaniumyl-5-(4-nitroanilino)-5-oxopentanoate
DM29RO1	CA	CAS 7300-59-6
DM29RO1	DE	Discovery agent

DMDBZGP	ID	DMDBZGP
DMDBZGP	DN	PNRI-299
DMDBZGP	HS	Investigative
DMDBZGP	SN	PNRI-299; 550368-41-7; UNII-2WW6I6D1Z1; 2WW6I6D1Z1; PNRI299; ZINC1489322; BCP16043; AKOS030526844; CS-3985; HY-15131; 1H-(1,2,4)Triazolo(1,2-a)pyridazine-5-carboxamide, 2-(3-cyanophenyl)-2,3,7,8-tetrahydro-1,3,7-trioxo-N-(phenylmethyl)-
DMDBZGP	DT	Small molecular drug
DMDBZGP	PC	10318848
DMDBZGP	MW	401.4
DMDBZGP	FM	C21H15N5O4
DMDBZGP	IC	InChI=1S/C21H15N5O4/c22-11-15-7-4-8-16(9-15)25-20(29)24-13-17(27)10-18(26(24)21(25)30)19(28)23-12-14-5-2-1-3-6-14/h1-10H,12-13H2,(H,23,28)
DMDBZGP	CS	C1C(=O)C=C(N2N1C(=O)N(C2=O)C3=CC=CC(=C3)C#N)C(=O)NCC4=CC=CC=C4
DMDBZGP	IK	UPQJVNPKWQFAKQ-UHFFFAOYSA-N
DMDBZGP	IU	N-benzyl-2-(3-cyanophenyl)-1,3,6-trioxo-5H-[1,2,4]triazolo[1,2-a]pyridazine-8-carboxamide
DMDBZGP	CA	CAS 550368-41-7
DMDBZGP	DE	Discovery agent

DM8WJQ0	ID	DM8WJQ0
DM8WJQ0	DN	PNT-300
DM8WJQ0	HS	Investigative
DM8WJQ0	SN	KRAS gene inhibitor (cancer), ProNAi
DM8WJQ0	CP	ProNAi Therapeutics Inc
DM8WJQ0	DE	Solid tumour/cancer

DMIEKVB	ID	DMIEKVB
DMIEKVB	DN	PNT-500
DMIEKVB	HS	Investigative
DMIEKVB	SN	ERBB2 gene inhibitor (cancer), ProNAi
DMIEKVB	CP	ProNAi Therapeutics Inc
DMIEKVB	DE	Solid tumour/cancer

DMKBCS2	ID	DMKBCS2
DMKBCS2	DN	PNU 101017
DMKBCS2	HS	Investigative
DMKBCS2	SN	U 101017
DMKBCS2	DE	Discovery agent

DMS5XRY	ID	DMS5XRY
DMS5XRY	DN	PNU-107859
DMS5XRY	HS	Investigative
DMS5XRY	SN	PNU-107859; 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE; CHEMBL249847; ATT; 3usn; AC1N9ZM9; SCHEMBL6954588; RKWXKADYTDWZIJ-VIFPVBQESA-N; ZINC6379443; BDBM50241372; DB07390; N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-phenyl-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (S)-1-(1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)urea
DMS5XRY	DT	Small molecular drug
DMS5XRY	PC	4369084
DMS5XRY	MW	337.4
DMS5XRY	FM	C13H15N5O2S2
DMS5XRY	IC	InChI=1S/C13H15N5O2S2/c1-14-10(19)9(7-8-5-3-2-4-6-8)15-11(20)16-12-17-18-13(21)22-12/h2-6,9H,7H2,1H3,(H,14,19)(H,18,21)(H2,15,16,17,20)/t9-/m0/s1
DMS5XRY	CS	CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)NC2=NNC(=S)S2
DMS5XRY	IK	RKWXKADYTDWZIJ-VIFPVBQESA-N
DMS5XRY	IU	(2S)-N-methyl-3-phenyl-2-[(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)carbamoylamino]propanamide
DMS5XRY	DE	Discovery agent

DMYBQM7	ID	DMYBQM7
DMYBQM7	DN	PNU-120596
DMYBQM7	HS	Investigative
DMYBQM7	SN	PNU-120,596
DMYBQM7	DT	Small molecular drug
DMYBQM7	PC	311434
DMYBQM7	MW	311.72
DMYBQM7	FM	C13H14ClN3O4
DMYBQM7	IC	InChI=1S/C13H14ClN3O4/c1-7-4-12(17-21-7)16-13(18)15-9-5-8(14)10(19-2)6-11(9)20-3/h4-6H,1-3H3,(H2,15,16,17,18)
DMYBQM7	CS	CC1=CC(=NO1)NC(=O)NC2=CC(=C(C=C2OC)OC)Cl
DMYBQM7	IK	CEIIEALEIHQDBX-UHFFFAOYSA-N
DMYBQM7	IU	1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methyl-1,2-oxazol-3-yl)urea
DMYBQM7	CA	CAS 501925-31-1
DMYBQM7	CB	CHEBI:93263
DMYBQM7	DE	Discovery agent

DMEI0S7	ID	DMEI0S7
DMEI0S7	DN	PNU-142372
DMEI0S7	HS	Investigative
DMEI0S7	SN	PNU-142372; 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE; CHEMBL290140; 1usn; IN9; AC1N9ZM3; BDBM50076341; DB07988; 2,3,4,5,6-pentafluoro-N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-(pentafluorophenyl)-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (2S)-N-methyl-3-(2,3,4,5,6-pentafluorophenyl)-2-[(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)carbamoylamino]propanamide
DMEI0S7	DT	Small molecular drug
DMEI0S7	PC	4369080
DMEI0S7	MW	427.4
DMEI0S7	FM	C13H10F5N5O2S2
DMEI0S7	IC	InChI=1S/C13H10F5N5O2S2/c1-19-10(24)4(20-11(25)21-12-22-23-13(26)27-12)2-3-5(14)7(16)9(18)8(17)6(3)15/h4H,2H2,1H3,(H,19,24)(H,23,26)(H2,20,21,22,25)/t4-/m0/s1
DMEI0S7	CS	CNC(=O)[C@H](CC1=C(C(=C(C(=C1F)F)F)F)F)NC(=O)NC2=NNC(=S)S2
DMEI0S7	IK	HZAXNPDJVFUGDS-BYPYZUCNSA-N
DMEI0S7	IU	(2S)-N-methyl-3-(2,3,4,5,6-pentafluorophenyl)-2-[(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)carbamoylamino]propanamide
DMEI0S7	DE	Discovery agent

DMM0EYR	ID	DMM0EYR
DMM0EYR	DN	PNU177836
DMM0EYR	HS	Investigative
DMM0EYR	SN	PNU177836; 5-(2-{2-[(TERT-BUTOXY-HYDROXY-METHYL)-AMINO]-1-HYDROXY-3-PHENYL-PROPYLAMINO}-3-HYDROXY-3-PENTYLAMINO-PROPYL)-2-CARBOXYMETHOXY-BENZOIC ACID; AC1NRDB1; DB02977; 5-[(2S,3R)-2-{[(1S,2S)-2-{[(S)-tert-butoxy(hydroxy)methyl]amino}-1-hydroxy-3-phenylpropyl]amino}-3-hydroxy-3-(pentylamino)propyl]-2-(carboxymethoxy)benzoic acid; 2-(carboxymethyloxy)-5-[(2S,3R)-3-hydroxy-2-[[(1S,2S)-1-hydroxy-2-[[(S)-hydroxy-[(2-methylpropan-2-yl)oxy]methyl]amino]-3-phenylpropyl]amino]-3-(pentylamino)propyl]benzoic acid
DMM0EYR	DT	Small molecular drug
DMM0EYR	PC	5289442
DMM0EYR	MW	605.7
DMM0EYR	FM	C31H47N3O9
DMM0EYR	IC	InChI=1S/C31H47N3O9/c1-5-6-10-15-32-27(37)23(18-21-13-14-25(42-19-26(35)36)22(16-21)29(39)40)33-28(38)24(17-20-11-8-7-9-12-20)34-30(41)43-31(2,3)4/h7-9,11-14,16,23-24,27-28,30,32-34,37-38,41H,5-6,10,15,17-19H2,1-4H3,(H,35,36)(H,39,40)/t23-,24-,27+,28-,30-/m0/s1
DMM0EYR	CS	CCCCCN[C@@H]([C@H](CC1=CC(=C(C=C1)OCC(=O)O)C(=O)O)N[C@H]([C@H](CC2=CC=CC=C2)N[C@@H](O)OC(C)(C)C)O)O
DMM0EYR	IK	WVFJFYADATXBBE-JIFQQKSFSA-N
DMM0EYR	IU	2-(carboxymethoxy)-5-[(2S,3R)-3-hydroxy-2-[[(1S,2S)-1-hydroxy-2-[[(S)-hydroxy-[(2-methylpropan-2-yl)oxy]methyl]amino]-3-phenylpropyl]amino]-3-(pentylamino)propyl]benzoic acid
DMM0EYR	DE	Discovery agent

DMHTPSF	ID	DMHTPSF
DMHTPSF	DN	PNU-22394
DMHTPSF	HS	Investigative
DMHTPSF	SN	PNU-22394; CHEMBL6557; 6-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole; 6-Methyl-1,2,3,4,5,6-hexahydro-azepino[4,5-b]indole; AC1L1DHJ; SCHEMBL5364550; CHEBI:92297; ZINC2018607; BDBM50130095; BRD-K16551401-003-02-6; BRD-K16551401-003-01-8; 6-methyl-2,3,4,5-tetrahydro-1H-azepino[4,5-b]indole
DMHTPSF	DT	Small molecular drug
DMHTPSF	PC	27559
DMHTPSF	MW	200.28
DMHTPSF	FM	C13H16N2
DMHTPSF	IC	InChI=1S/C13H16N2/c1-15-12-5-3-2-4-10(12)11-6-8-14-9-7-13(11)15/h2-5,14H,6-9H2,1H3
DMHTPSF	CS	CN1C2=C(CCNCC2)C3=CC=CC=C31
DMHTPSF	IK	ZBXDOQWPGBISAR-UHFFFAOYSA-N
DMHTPSF	IU	6-methyl-2,3,4,5-tetrahydro-1H-azepino[4,5-b]indole
DMHTPSF	CA	CAS 15923-78-1
DMHTPSF	CB	CHEBI:92297
DMHTPSF	DE	Discovery agent

DM43K1D	ID	DM43K1D
DM43K1D	DN	PNU-248686A
DM43K1D	HS	Investigative
DM43K1D	SN	3-(4'-Chlorobiphenyl-4-ylsulfonyl)-2(R)-hydroxy-2-(phenylsulfanylmethyl)propionic acid sodium salt
DM43K1D	PC	134128286
DM43K1D	MW	486
DM43K1D	FM	C22H19ClNaO5S2
DM43K1D	IC	InChI=1S/C22H19ClO5S2.Na/c23-18-10-6-16(7-11-18)17-8-12-20(13-9-17)30(27,28)15-22(26,21(24)25)14-29-19-4-2-1-3-5-19;/h1-13,26H,14-15H2,(H,24,25);/t22-;/m1./s1
DM43K1D	CS	C1=CC=C(C=C1)SC[C@@](CS(=O)(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)Cl)(C(=O)O)O.[Na]
DM43K1D	IK	YQPKCDPUTCALSX-VZYDHVRKSA-N
DM43K1D	DE	Solid tumour/cancer

DM6SZVE	ID	DM6SZVE
DM6SZVE	DN	PNU-87663
DM6SZVE	HS	Investigative
DM6SZVE	SN	157012-18-5; U-87663; U-87663E
DM6SZVE	DE	Discovery agent

DMQMDSG	ID	DMQMDSG
DMQMDSG	DN	PO3 2-Ile-Trp-O-3K
DMQMDSG	HS	Investigative
DMQMDSG	SN	CHEMBL281785
DMQMDSG	DT	Small molecular drug
DMQMDSG	PC	91934755
DMQMDSG	MW	394.3
DMQMDSG	FM	C17H21N3O6P-3
DMQMDSG	IC	InChI=1S/C17H24N3O6P/c1-3-10(2)15(20-27(24,25)26)16(21)19-14(17(22)23)8-11-9-18-13-7-5-4-6-12(11)13/h4-7,9-10,14-15,18H,3,8H2,1-2H3,(H,19,21)(H,22,23)(H3,20,24,25,26)/p-3/t10-,14+,15+/m1/s1
DMQMDSG	CS	CC[C@@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)[O-])NP(=O)([O-])[O-]
DMQMDSG	IK	OTHKGUJBHLOAHC-ONERCXAPSA-K
DMQMDSG	IU	(2S)-3-(1H-indol-3-yl)-2-[[(2S,3R)-3-methyl-2-(phosphonatoamino)pentanoyl]amino]propanoate
DMQMDSG	DE	Discovery agent

DMY43FU	ID	DMY43FU
DMY43FU	DN	PO3 2-Leu-Nal-O-3K
DMY43FU	HS	Investigative
DMY43FU	SN	CHEMBL280917
DMY43FU	DT	Small molecular drug
DMY43FU	PC	91934756
DMY43FU	MW	405.4
DMY43FU	FM	C19H22N2O6P-3
DMY43FU	IC	InChI=1S/C19H25N2O6P/c1-12(2)10-16(21-28(25,26)27)18(22)20-17(19(23)24)11-14-8-5-7-13-6-3-4-9-15(13)14/h3-9,12,16-17H,10-11H2,1-2H3,(H,20,22)(H,23,24)(H3,21,25,26,27)/p-3/t16-,17-/m0/s1
DMY43FU	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC2=CC=CC=C21)C(=O)[O-])NP(=O)([O-])[O-]
DMY43FU	IK	RGBJIKYRFMBDCB-IRXDYDNUSA-K
DMY43FU	IU	(2S)-2-[[(2S)-4-methyl-2-(phosphonatoamino)pentanoyl]amino]-3-naphthalen-1-ylpropanoate
DMY43FU	DE	Discovery agent

DM3O78D	ID	DM3O78D
DM3O78D	DN	PO3 2-Leu-Trp-O-3K
DM3O78D	HS	Investigative
DM3O78D	SN	CHEMBL281562
DM3O78D	DT	Small molecular drug
DM3O78D	PC	91934757
DM3O78D	MW	394.3
DM3O78D	FM	C17H21N3O6P-3
DM3O78D	IC	InChI=1S/C17H24N3O6P/c1-10(2)7-14(20-27(24,25)26)16(21)19-15(17(22)23)8-11-9-18-13-6-4-3-5-12(11)13/h3-6,9-10,14-15,18H,7-8H2,1-2H3,(H,19,21)(H,22,23)(H3,20,24,25,26)/p-3/t14-,15-/m0/s1
DM3O78D	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)[O-])NP(=O)([O-])[O-]
DM3O78D	IK	GKNMEOYLZHYYGW-GJZGRUSLSA-K
DM3O78D	IU	(2S)-3-(1H-indol-3-yl)-2-[[(2S)-4-methyl-2-(phosphonatoamino)pentanoyl]amino]propanoate
DM3O78D	DE	Discovery agent

DMW1XY4	ID	DMW1XY4
DMW1XY4	DN	PO3 2-Nle-Trp-O-3K
DMW1XY4	HS	Investigative
DMW1XY4	SN	CHEMBL22509
DMW1XY4	DT	Small molecular drug
DMW1XY4	PC	91934754
DMW1XY4	MW	394.3
DMW1XY4	FM	C17H21N3O6P-3
DMW1XY4	IC	InChI=1S/C17H24N3O6P/c1-2-3-7-14(20-27(24,25)26)16(21)19-15(17(22)23)9-11-10-18-13-8-5-4-6-12(11)13/h4-6,8,10,14-15,18H,2-3,7,9H2,1H3,(H,19,21)(H,22,23)(H3,20,24,25,26)/p-3/t14-,15-/m0/s1
DMW1XY4	CS	CCCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)[O-])NP(=O)([O-])[O-]
DMW1XY4	IK	MFLINLZAVZVZNC-GJZGRUSLSA-K
DMW1XY4	IU	(2S)-3-(1H-indol-3-yl)-2-[[(2S)-2-(phosphonatoamino)hexanoyl]amino]propanoate
DMW1XY4	DE	Discovery agent

DMURB4Y	ID	DMURB4Y
DMURB4Y	DN	pobilukast
DMURB4Y	HS	Investigative
DMURB4Y	SN	SKF 104353
DMURB4Y	DT	Small molecular drug
DMURB4Y	PC	60842
DMURB4Y	MW	458.6
DMURB4Y	FM	C26H34O5S
DMURB4Y	IC	InChI=1S/C26H34O5S/c27-23(28)18-19-32-25(24(29)26(30)31)22-17-11-10-16-21(22)15-9-4-2-1-3-6-12-20-13-7-5-8-14-20/h5,7-8,10-11,13-14,16-17,24-25,29H,1-4,6,9,12,15,18-19H2,(H,27,28)(H,30,31)/t24-,25-/m1/s1
DMURB4Y	CS	C1=CC=C(C=C1)CCCCCCCCC2=CC=CC=C2[C@H]([C@H](C(=O)O)O)SCCC(=O)O
DMURB4Y	IK	PZIFPMYXXCAOCC-JWQCQUIFSA-N
DMURB4Y	IU	(2S,3R)-3-(2-carboxyethylsulfanyl)-2-hydroxy-3-[2-(8-phenyloctyl)phenyl]propanoic acid
DMURB4Y	CA	CAS 107023-41-6
DMURB4Y	DE	Discovery agent

DMXA4HY	ID	DMXA4HY
DMXA4HY	DN	Poly IC-poly arginine
DMXA4HY	HS	Investigative
DMXA4HY	SN	Poly-ICR vaccine adjuvant, Akela; Poly-ICR vaccine adjuvant, Nventa; Poly(inosinic-cytidylic) acid-poly arginine
DMXA4HY	CP	Nventa Biopharmaceuticals Corp
DMXA4HY	DT	Vaccine
DMXA4HY	DE	Keratosis

DMG7K84	ID	DMG7K84
DMG7K84	DN	Polybrominated diphenyl ether derivative
DMG7K84	HS	Investigative
DMG7K84	SN	Bastadin 7
DMG7K84	DT	Small molecular drug
DMG7K84	PC	10396070
DMG7K84	MW	938.2
DMG7K84	FM	C34H26Br4N4O8
DMG7K84	IC	InChI=1S/C34H26Br4N4O8/c35-21-9-17-1-3-27(21)49-29-15-19(11-23(37)31(29)43)6-8-40-33(45)25(41-47)13-18-2-4-28(22(36)10-18)50-30-16-20(12-24(38)32(30)44)14-26(42-48)34(46)39-7-5-17/h1-5,7,9-12,15-16,43-44,47-48H,6,8,13-14H2,(H,39,46)(H,40,45)/b7-5+,41-25+,42-26+
DMG7K84	CS	C1CNC(=O)/C(=N/O)/CC2=CC(=C(C=C2)OC3=C(C(=CC(=C3)C/C(=N\\O)/C(=O)N/C=C/C4=CC(=C(C=C4)OC5=C(C(=CC1=C5)Br)O)Br)Br)O)Br
DMG7K84	IK	ZDBNBLMYAGHTJD-HIHPLZGUSA-N
DMG7K84	IU	(12E,25E,28E)-5,16,21,32-tetrabromo-4,20-dihydroxy-12,25-bis(hydroxyimino)-2,18-dioxa-10,27-diazapentacyclo[28.2.2.214,17.13,7.119,23]octatriaconta-1(32),3,5,7(38),14,16,19,21,23(35),28,30,33,36-tridecaene-11,26-dione
DMG7K84	DE	Discovery agent

DMUTV5P	ID	DMUTV5P
DMUTV5P	DN	POLYGALATENOSIDE B
DMUTV5P	HS	Investigative
DMUTV5P	SN	CHEMBL462805; BDBM50241785
DMUTV5P	DT	Small molecular drug
DMUTV5P	PC	44559130
DMUTV5P	MW	416.4
DMUTV5P	FM	C19H28O10
DMUTV5P	IC	InChI=1S/C19H28O10/c20-6-11-14(22)15(23)13(9-26-11)29-19-17(25)18(16(24)12(7-21)28-19)27-8-10-4-2-1-3-5-10/h1-5,11-25H,6-9H2/t11-,12-,13+,14-,15-,16+,17-,18+,19-/m0/s1
DMUTV5P	CS	C1[C@H]([C@@H]([C@H]([C@@H](O1)CO)O)O)O[C@H]2[C@H]([C@@H]([C@@H]([C@@H](O2)CO)O)OCC3=CC=CC=C3)O
DMUTV5P	IK	PBKBHCJPMCMBCZ-GDLYOHBGSA-N
DMUTV5P	IU	(2S,3S,4R,5R,6S)-2-[(3R,4R,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-4-phenylmethoxyoxane-3,5-diol
DMUTV5P	DE	Discovery agent

DMV486E	ID	DMV486E
DMV486E	DN	polyIC
DMV486E	HS	Investigative
DMV486E	SN	poly(I:C); polyinosine:polycytidylic acid; polyinosine-polycytosine
DMV486E	DT	Small molecular drug
DMV486E	PC	274740
DMV486E	DE	Discovery agent

DMUMJ7B	ID	DMUMJ7B
DMUMJ7B	DN	Poly-ICR
DMUMJ7B	HS	Investigative
DMUMJ7B	SN	Poly-ICR (topical, keratosis/genital warts); Poly-ICR (topical, keratosis/genital warts), Akela; Poly-ICR (topical, keratosis/genital warts), Nventa; TLR-3 agonist (topical, acitinic keratosis/genital warts), Nventa; Poly IC-poly-arginine (topical, keratosis/genital warts), Nventa
DMUMJ7B	CP	Nventa Biopharmaceuticals Corp
DMUMJ7B	DE	Keratosis

DM4VZCW	ID	DM4VZCW
DM4VZCW	DN	Polyinosinic:polycytidylic acid
DM4VZCW	HS	Investigative
DM4VZCW	SN	NSC-120,949; PI:C; Poly 1-poly-c; Poly C poly I; Poly I:poly C; Poly IC; Poly rI:poly rC; Poly(I).poly(C); Poly(I).poly(C) complex; Poly(I:C); Poly(rI)-poly(rC); Poly(rI).(rC); Poly(rI).poly(rC); Poly(rI:rC); Polycytid; Polyinosinic acid.polycytidylic acid; Polyinosinic-polycyticylic acid complex; Polyriboinosinic acid:polyribocytidylic acid; polyinosine-polycytosine
DM4VZCW	TC	Antiviral Agents
DM4VZCW	DT	Small molecular drug
DM4VZCW	PC	135618150
DM4VZCW	MW	671.4
DM4VZCW	FM	C19H27N7O16P2
DM4VZCW	IC	InChI=1S/C10H13N4O8P.C9H14N3O8P/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,10-;4-,6-,7-,8-/m11/s1
DM4VZCW	CS	C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
DM4VZCW	IK	ACEVNMQDUCOKHT-ZLOOHWKQSA-N
DM4VZCW	IU	[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
DM4VZCW	DE	Middle East Respiratory Syndrome (MERS)

DMN6Q4E	ID	DMN6Q4E
DMN6Q4E	DN	Polyporic acid
DMN6Q4E	HS	Investigative
DMN6Q4E	SN	Polyporic acid; Polyporin; Orygameic acid; 548-59-4; 2,5-Dihydroxy-3,6-diphenyl-p-benzoquinone; NSC 44175; S 1148; NSC44175; BRN 2057889; 2,5-Dihydroxy-3,6-diphenyl-2,5-cyclohexadiene-1,4-dione; 2,5-Cyclohexadiene-1,4-dione, 2,5-dihydroxy-3,6-diphenyl-; p-BENZOQUINONE, 2,5-DIHYDROXY-3,6-DIPHENYL-; 2,5-Dihydroxy-3,6-diphenylbenzo-1,4-quinone; AC1L1WIT; 4-08-00-03298 (Beilstein Handbook Reference); SCHEMBL2445444; CTK1H0626; DTXSID50203281; MolPort-003-979-960; HZKFHDXTSAYOSN-UHFFFAOYSA-N
DMN6Q4E	DT	Small molecular drug
DMN6Q4E	PC	11056
DMN6Q4E	MW	292.3
DMN6Q4E	FM	C18H12O4
DMN6Q4E	IC	InChI=1S/C18H12O4/c19-15-13(11-7-3-1-4-8-11)16(20)18(22)14(17(15)21)12-9-5-2-6-10-12/h1-10,19,22H
DMN6Q4E	CS	C1=CC=C(C=C1)C2=C(C(=O)C(=C(C2=O)O)C3=CC=CC=C3)O
DMN6Q4E	IK	HZKFHDXTSAYOSN-UHFFFAOYSA-N
DMN6Q4E	IU	2,5-dihydroxy-3,6-diphenylcyclohexa-2,5-diene-1,4-dione
DMN6Q4E	CA	CAS 548-59-4
DMN6Q4E	CB	CHEBI:144197
DMN6Q4E	DE	Discovery agent

DMRX9E3	ID	DMRX9E3
DMRX9E3	DN	POLYSIN
DMRX9E3	HS	Investigative
DMRX9E3	SN	polysin; CHEMBL1083627
DMRX9E3	DT	Small molecular drug
DMRX9E3	PC	46871703
DMRX9E3	MW	335.5
DMRX9E3	FM	C23H29NO
DMRX9E3	IC	InChI=1S/C23H29NO/c1-21(2)18-9-12-23(4)19(22(18,3)11-10-20(21)25)14-16-13-15-7-5-6-8-17(15)24(16)23/h5-8,13,18-19H,9-12,14H2,1-4H3/t18-,19-,22-,23+/m0/s1
DMRX9E3	CS	C[C@]12CCC(=O)C([C@@H]1CC[C@@]3([C@H]2CC4=CC5=CC=CC=C5N43)C)(C)C
DMRX9E3	IK	NEPLKJAINOWIJL-DHNNRRLOSA-N
DMRX9E3	IU	(1R,12S,13S,18R)-1,13,17,17-tetramethyl-2-azapentacyclo[10.8.0.02,10.03,8.013,18]icosa-3,5,7,9-tetraen-16-one
DMRX9E3	DE	Discovery agent

DM1GV7K	ID	DM1GV7K
DM1GV7K	DN	Pomolic acid
DM1GV7K	HS	Investigative
DM1GV7K	SN	Pomolic acid; 13849-91-7; UNII-60HAB1ZK1T; 60HAB1ZK1T; CHEMBL486986; CHEBI:66772; (1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1,10-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid; AC1L8K6D; SCHEMBL1049001; Urs-12-en-28-oic acid, 3,19-dihydroxy-, (3beta)-; MolPort-028-754-128; ZINC6003698; BDBM50241553; NSC670661; AKOS032948112; NSC-670661; NCI60_024874; W2587; Urs-12-en-28-oic acid, 3,19-dihydroxy-, (3.beta.)-
DM1GV7K	DT	Small molecular drug
DM1GV7K	PC	382831
DM1GV7K	MW	472.7
DM1GV7K	FM	C30H48O4
DM1GV7K	IC	InChI=1S/C30H48O4/c1-18-10-15-30(24(32)33)17-16-27(5)19(23(30)29(18,7)34)8-9-21-26(4)13-12-22(31)25(2,3)20(26)11-14-28(21,27)6/h8,18,20-23,31,34H,9-17H2,1-7H3,(H,32,33)/t18-,20+,21-,22+,23-,26+,27-,28-,29-,30+/m1/s1
DM1GV7K	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O
DM1GV7K	IK	ZZTYPLSBNNGEIS-OPAXANQDSA-N
DM1GV7K	IU	(1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1,10-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DM1GV7K	CA	CAS 13849-91-7
DM1GV7K	CB	CHEBI:66772
DM1GV7K	DE	Discovery agent

DMGRPK8	ID	DMGRPK8
DMGRPK8	DN	PONKORANOL
DMGRPK8	HS	Investigative
DMGRPK8	SN	PONKORANOL; CHEMBL1258528
DMGRPK8	DT	Small molecular drug
DMGRPK8	PC	11710941
DMGRPK8	MW	394.4
DMGRPK8	FM	C11H22O11S2
DMGRPK8	IC	InChI=1S/C11H22O11S2/c12-1-5(14)10(18)11(22-24(19,20)21)7(16)4-23-3-6(15)9(17)8(23)2-13/h5-18H,1-4H2/t5-,6+,7+,8+,9-,10+,11+,23?/m0/s1
DMGRPK8	CS	C1[C@H]([C@@H]([C@H]([S+]1C[C@H]([C@H]([C@@H]([C@H](CO)O)O)OS(=O)(=O)[O-])O)CO)O)O
DMGRPK8	IK	YCUKGYWMYZBCGT-VLLNVTNWSA-N
DMGRPK8	IU	[(2S,3S,4R,5S)-1-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-2,4,5,6-tetrahydroxyhexan-3-yl] sulfate
DMGRPK8	DE	Discovery agent

DMVTKCX	ID	DMVTKCX
DMVTKCX	DN	POP-1
DMVTKCX	HS	Investigative
DMVTKCX	CP	Propanc Pty Ltd
DMVTKCX	DE	Solid tumour/cancer

DMQCSFV	ID	DMQCSFV
DMQCSFV	DN	Porphyran
DMQCSFV	HS	Investigative
DMQCSFV	SN	Porphyran compound; Sulphated polysaccharide porphyran
DMQCSFV	DE	Lung cancer

DMU8KTO	ID	DMU8KTO
DMU8KTO	DN	PP121
DMU8KTO	HS	Investigative
DMU8KTO	SN	PP-121; PP 121
DMU8KTO	DT	Small molecular drug
DMU8KTO	PC	24905142
DMU8KTO	MW	319.4
DMU8KTO	FM	C17H17N7
DMU8KTO	IC	InChI=1S/C17H17N7/c18-15-13-14(11-7-10-5-6-19-16(10)20-8-11)23-24(12-3-1-2-4-12)17(13)22-9-21-15/h5-9,12H,1-4H2,(H,19,20)(H2,18,21,22)
DMU8KTO	CS	C1CCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CN=C5C(=C4)C=CN5)N
DMU8KTO	IK	NVRXTLZYXZNATH-UHFFFAOYSA-N
DMU8KTO	IU	1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-4-amine
DMU8KTO	CA	CAS 1092788-83-4
DMU8KTO	CB	CHEBI:50915
DMU8KTO	DE	Discovery agent

DMYA5CB	ID	DMYA5CB
DMYA5CB	DN	PP1-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O)
DMYA5CB	HS	Investigative
DMYA5CB	DT	Small molecular drug
DMYA5CB	PC	14803041
DMYA5CB	MW	984.1
DMYA5CB	FM	C47H70N9O12P
DMYA5CB	IC	InChI=1S/C47H70N9O12P/c1-8-31(6)42(46(62)49-26-34-17-12-13-20-56(34)64)53-43(59)35(30(4)5)24-40(57)36(21-29(2)3)51-45(61)39(23-33-25-48-28-50-33)54(7)47(63)37(22-32-15-10-9-11-16-32)52-44(60)38-18-14-19-55(38)41(58)27-68-69(65,66)67/h9-13,15-17,20,25,28-31,35-40,42,57H,8,14,18-19,21-24,26-27H2,1-7H3,(H,48,50)(H,49,62)(H,51,61)(H,52,60)(H,53,59)(H2,65,66,67)
DMYA5CB	CS	CCC(C)C(C(=O)NCC1=CC=CC=[N+]1[O-])NC(=O)C(CC(C(CC(C)C)NC(=O)C(CC2=CN=CN2)N(C)C(=O)C(CC3=CC=CC=C3)NC(=O)C4CCCN4C(=O)COP(=O)(O)O)O)C(C)C
DMYA5CB	IK	APMOVMFBSHFCLN-UHFFFAOYSA-N
DMYA5CB	IU	[2-[2-[[1-[[1-[[5-hydroxy-2,8-dimethyl-7-[[3-methyl-1-[(1-oxidopyridin-1-ium-2-yl)methylamino]-1-oxopentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl] dihydrogen phosphate
DMYA5CB	DE	Discovery agent

DM2348V	ID	DM2348V
DM2348V	DN	PP-242
DM2348V	HS	Investigative
DM2348V	SN	PP242; TORKinib
DM2348V	DT	Small molecular drug
DM2348V	PC	135565635
DM2348V	MW	308.34
DM2348V	FM	C16H16N6O
DM2348V	IC	InChI=1S/C16H16N6O/c1-8(2)22-16-13(15(17)18-7-19-16)14(21-22)12-6-9-5-10(23)3-4-11(9)20-12/h3-8,20,23H,1-2H3,(H2,17,18,19)
DM2348V	CS	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(N3)C=CC(=C4)O)N
DM2348V	IK	MFAQYJIYDMLAIM-UHFFFAOYSA-N
DM2348V	IU	2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol
DM2348V	CA	CAS 1092351-67-1
DM2348V	CB	CHEBI:90679
DM2348V	DE	Discovery agent

DM3NUKX	ID	DM3NUKX
DM3NUKX	DN	PP2-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O)
DM3NUKX	HS	Investigative
DM3NUKX	PC	44372200
DM3NUKX	MW	1012.1
DM3NUKX	FM	C49H74N9O12P
DM3NUKX	IC	InChI=1S/C49H74N9O12P/c1-8-33(6)44(48(64)51-29-36-18-12-13-22-58(36)66)55-45(61)37(32(4)5)27-42(59)38(24-31(2)3)53-47(63)41(26-35-28-50-30-52-35)56(7)49(65)39(25-34-16-10-9-11-17-34)54-46(62)40-19-14-21-57(40)43(60)20-15-23-70-71(67,68)69/h9-13,16-18,22,28,30-33,37-42,44,59H,8,14-15,19-21,23-27,29H2,1-7H3,(H,50,52)(H,51,64)(H,53,63)(H,54,62)(H,55,61)(H2,67,68,69)
DM3NUKX	CS	CCC(C)C(C(=O)NCC1=CC=CC=[N+]1[O-])NC(=O)C(CC(C(CC(C)C)NC(=O)C(CC2=CN=CN2)N(C)C(=O)C(CC3=CC=CC=C3)NC(=O)C4CCCN4C(=O)CCCOP(=O)(O)O)O)C(C)C
DM3NUKX	IK	KFCDLRKAUPBHBD-UHFFFAOYSA-N
DM3NUKX	IU	[4-[2-[[1-[[1-[[5-hydroxy-2,8-dimethyl-7-[[3-methyl-1-[(1-oxidopyridin-1-ium-2-yl)methylamino]-1-oxopentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutyl] dihydrogen phosphate
DM3NUKX	DE	Discovery agent

DM86ZL2	ID	DM86ZL2
DM86ZL2	DN	PPA
DM86ZL2	HS	Investigative
DM86ZL2	DE	Discovery agent

DMWHN3T	ID	DMWHN3T
DMWHN3T	DN	PPADS
DMWHN3T	HS	Investigative
DMWHN3T	DT	Small molecular drug
DMWHN3T	PC	4881
DMWHN3T	MW	511.4
DMWHN3T	FM	C14H14N3O12PS2
DMWHN3T	IC	InChI=1S/C14H14N3O12PS2/c1-7-13(19)9(5-18)10(6-29-30(20,21)22)14(15-7)17-16-11-3-2-8(31(23,24)25)4-12(11)32(26,27)28/h2-5,19H,6H2,1H3,(H2,20,21,22)(H,23,24,25)(H,26,27,28)
DMWHN3T	CS	CC1=C(C(=C(C(=N1)N=NC2=C(C=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)COP(=O)(O)O)C=O)O
DMWHN3T	IK	PNFZSRRRZNXSMF-UHFFFAOYSA-N
DMWHN3T	IU	4-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonooxymethyl)pyridin-2-yl]diazenyl]benzene-1,3-disulfonic acid
DMWHN3T	CA	CAS 149017-66-3
DMWHN3T	CB	CHEBI:34941
DMWHN3T	DE	Discovery agent

DMWVZFK	ID	DMWVZFK
DMWVZFK	DN	PPAHV
DMWVZFK	HS	Investigative
DMWVZFK	SN	phorbol-12-phenylacetate-13-acetate-20-homovanillate
DMWVZFK	DT	Small molecular drug
DMWVZFK	PC	3035862
DMWVZFK	MW	688.8
DMWVZFK	FM	C39H44O11
DMWVZFK	IC	InChI=1S/C39H44O11/c1-21-14-30-37(45,34(21)44)19-26(20-48-31(42)18-25-12-13-28(41)29(16-25)47-6)15-27-33-36(4,5)39(33,50-23(3)40)35(22(2)38(27,30)46)49-32(43)17-24-10-8-7-9-11-24/h7-16,22,27,30,33,35,41,45-46H,17-20H2,1-6H3/t22-,27+,30-,33-,35-,37-,38-,39-/m1/s1
DMWVZFK	CS	C[C@@H]1[C@H]([C@@]2([C@@H](C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)COC(=O)CC5=CC(=C(C=C5)O)OC)O)C)O)OC(=O)C)OC(=O)CC6=CC=CC=C6
DMWVZFK	IK	OGRGWTXWAZBJKF-JXWJAAHMSA-N
DMWVZFK	IU	[(1S,2S,6R,10S,11R,13S,14R,15R)-13-acetyloxy-1,6-dihydroxy-8-[[2-(4-hydroxy-3-methoxyphenyl)acetyl]oxymethyl]-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] 2-phenylacetate
DMWVZFK	CA	CAS 175796-50-6
DMWVZFK	DE	Discovery agent

DM5IG4F	ID	DM5IG4F
DM5IG4F	DN	PPG
DM5IG4F	HS	Investigative
DM5IG4F	SN	phosphonophenylglycine
DM5IG4F	DT	Small molecular drug
DM5IG4F	PC	444843
DM5IG4F	MW	393.33
DM5IG4F	FM	C14H24N3O8P
DM5IG4F	IC	InChI=1S/C14H24N3O8P/c1-9-13(18)11(10(6-16-9)8-25-26(21,22)23)7-17-12(14(19)20)2-4-24-5-3-15/h2,4,9,12,16-17H,3,5-8,15H2,1H3,(H,19,20)(H2,21,22,23)/b4-2+
DM5IG4F	CS	CC1C(=O)C(=C(CN1)COP(=O)(O)O)CNC(/C=C/OCCN)C(=O)O
DM5IG4F	IK	YUVPJAIAVDYTLF-DUXPYHPUSA-N
DM5IG4F	IU	(E)-4-(2-aminoethoxy)-2-[[2-methyl-3-oxo-5-(phosphonooxymethyl)-2,6-dihydro-1H-pyridin-4-yl]methylamino]but-3-enoic acid
DM5IG4F	DE	Discovery agent

DML72JT	ID	DML72JT
DML72JT	DN	PPTN
DML72JT	HS	Investigative
DML72JT	SN	4-((piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid
DML72JT	DT	Small molecular drug
DML72JT	PC	42611190
DML72JT	MW	475.5
DML72JT	FM	C29H24F3NO2
DML72JT	IC	InChI=1S/C29H24F3NO2/c30-29(31,32)25-8-5-19(6-9-25)22-7-10-26-23(15-22)16-24(28(34)35)17-27(26)21-3-1-18(2-4-21)20-11-13-33-14-12-20/h1-10,15-17,20,33H,11-14H2,(H,34,35)
DML72JT	CS	C1CNCCC1C2=CC=C(C=C2)C3=C4C=CC(=CC4=CC(=C3)C(=O)O)C5=CC=C(C=C5)C(F)(F)F
DML72JT	IK	FOECKIWHCOYYFL-UHFFFAOYSA-N
DML72JT	IU	4-(4-piperidin-4-ylphenyl)-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid
DML72JT	DE	Discovery agent

DMXLPO6	ID	DMXLPO6
DMXLPO6	DN	PQ-1
DMXLPO6	HS	Investigative
DMXLPO6	SN	Substituted quinolines (cancer/ocular disease/malaria), Kansas State University
DMXLPO6	CP	Kansas State University
DMXLPO6	PC	16048421
DMXLPO6	MW	405.4
DMXLPO6	FM	C21H22F3N3O2
DMXLPO6	IC	InChI=1S/C21H22F3N3O2/c1-13-7-10-27-19-16(26-9-4-8-25)12-17(28-2)20(18(13)19)29-15-6-3-5-14(11-15)21(22,23)24/h3,5-7,10-12,26H,4,8-9,25H2,1-2H3
DMXLPO6	CS	CC1=C2C(=C(C=C(C2=NC=C1)NCCCN)OC)OC3=CC=CC(=C3)C(F)(F)F
DMXLPO6	IK	PPRRJSWOEFBRDQ-UHFFFAOYSA-N
DMXLPO6	IU	N'-[6-methoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]propane-1,3-diamine
DMXLPO6	DE	Solid tumour/cancer

DMVNHTE	ID	DMVNHTE
DMVNHTE	DN	PQ401
DMVNHTE	HS	Investigative
DMVNHTE	SN	PQ 401; IGF-1R inhibitor II; PQ-401
DMVNHTE	DT	Small molecular drug
DMVNHTE	PC	9549305
DMVNHTE	MW	341.8
DMVNHTE	FM	C18H16ClN3O2
DMVNHTE	IC	InChI=1S/C18H16ClN3O2/c1-11-9-15(13-5-3-4-6-14(13)20-11)21-18(23)22-16-10-12(19)7-8-17(16)24-2/h3-10H,1-2H3,(H2,20,21,22,23)
DMVNHTE	CS	CC1=NC2=CC=CC=C2C(=C1)NC(=O)NC3=C(C=CC(=C3)Cl)OC
DMVNHTE	IK	YBLWOZUPHDKFOT-UHFFFAOYSA-N
DMVNHTE	IU	1-(5-chloro-2-methoxyphenyl)-3-(2-methylquinolin-4-yl)urea
DMVNHTE	CA	CAS 196868-63-0
DMVNHTE	CB	CHEBI:93181
DMVNHTE	DE	Discovery agent

DMBCG31	ID	DMBCG31
DMBCG31	DN	PR-39
DMBCG31	HS	Investigative
DMBCG31	SN	PR 39; PR-39; 139637-11-9; PR-39 proline-arginine-rich peptide; PR39 proline-arginine-rich peptide; DTXSID90161139; JTJJGVCUEGCBHL-IWDHFESKSA-N
DMBCG31	PC	16198954
DMBCG31	MW	4721
DMBCG31	FM	C229H345N69O41
DMBCG31	IC	JTJJGVCUEGCBHL-IWDHFESKSA-N
DMBCG31	CS	CCC(C)C(C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CCCNC(=N)N)C(=O)NC(CC6=CC=CC=C6)C(=O)N7CCCC7C(=O)N8CCCC8C(=O)NC(CCCNC(=N)N)C(=O)NC(CC9=CC=CC=C9)C(=O)N1CCCC1C(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C1CCCN1C(=O)C1CCCN1C(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C1CCCN1C(=O)C1CCCN1C(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CC=CC=C1)NC(=O)C1CCCN1C(=O)C1CCCN1C(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C1CCCN1C(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C1CCCN1C(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)N
DMBCG31	IK	1S/C229H345N69O41/c1-7-135(6)181(218(337)297-122-50-89-178(297)216(335)283-108-33-72-161(283)190(309)261-132-180(300)262-157(128-137-54-15-9-16-55-137)206(325)293-118-46-84-173(293)212(331)284-109-37-77-166(284)192(311)265-146(65-26-98-254-223(237)238)185(304)276-158(129-138-56-17-10-18-57-138)207(326)294-119-47-85-174(294)213(332)286-111-39-78-167(286)193(312)266-147(66-27-99-255-224(239)240)186(305)277-160(131-140-60-21-12-22-61-140)209(328)298-123-51-90-179(298)219(338)339)279-187(306)148(67-28-100-256-225(241)242)267-194(313)168-79-40-112-287(168)211(330)172-83-45-117-292(172)205(324)156(125-134(4)5)274-184(303)145(64-25-97-253-222(235)236)264-191(310)165-76-38-110-285(165)214(333)175-86-48-120-295(175)208(327)159(130-139-58-19-11-20-59-139)278-189(308)153(126-136-52-13-8-14-53-136)272-198(317)170-81-42-114-289(170)215(334)177-88-49-121-296(177)217(336)176-87-44-116-291(176)203(322)152(71-32-104-260-229(249)250)271-196(315)163-74-35-106-281(163)201(320)150(69-30-102-258-227(245)246)269-197(316)164-75-36-107-282(164)204(323)155(124-133(2)3)275-188(307)154(127-141-91-93-142(299)94-92-141)273-199(318)169-80-41-113-288(169)210(329)171-82-43-115-290(171)202(321)151(70-31-103-259-228(247)248)270-195(314)162-73-34-105-280(162)200(319)149(68-29-101-257-226(243)244)268-183(302)144(63-24-96-252-221(233)234)263-182(301)143(230)62-23-95-251-220(231)232/h8-22,52-61,91-94,133-135,143-179,181,299H,7,23-51,62-90,95-132,230H2,1-6H3,(H,261,309)(H,262,300)(H,263,301)(H,264,310)(H,265,311)(H,266,312)(H,267,313)(H,268,302)(H,269,316)(H,270,314)(H,271,315)(H,272,317)(H,273,318)(H,274,303)(H,275,307)(H,276,304)(H,277,305)(H,278,308)(H,279,306)(H,338,339)(H4,231,232,251)(H4,233,234,252)(H4,235,236,253)(H4,237,238,254)(H4,239,240,255)(H4,241,242,256)(H4,243,244,257)(H4,245,246,258)(H4,247,248,259)(H4,249,250,260)/t135-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,181-/m0/s1
DMBCG31	IU	nan
DMBCG31	CA	CAS 139637-11-9
DMBCG31	DE	Ulcerative colitis

DM3XRJT	ID	DM3XRJT
DM3XRJT	DN	PRAVADOLINE
DM3XRJT	HS	Investigative
DM3XRJT	SN	Pravadoline; 92623-83-1; (4-Methoxyphenyl)(2-methyl-1-(2-morpholinoethyl)-1H-indol-3-yl)methanone; UNII-P3JW662TWA; WIN 48098; P3JW662TWA; CHEMBL13178; NCGC00160396-01; DSSTox_RID_81361; DSSTox_CID_26127; DSSTox_GSID_46127; Pravadoline, Pravadoline Maleate; Pravadolina; Pravadolinum; (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone; SMR001550504; Pravadoline [INN]; CAS-92623-83-1; Pravadolinum [INN-Latin]; Pravadolina [INN-Spanish]; AC1Q5EGD; MLS006010335; MLS004774040; SCHEMBL488940; Pravadoline(WIN 48 09
DM3XRJT	DT	Small molecular drug
DM3XRJT	PC	56463
DM3XRJT	MW	378.5
DM3XRJT	FM	C23H26N2O3
DM3XRJT	IC	InChI=1S/C23H26N2O3/c1-17-22(23(26)18-7-9-19(27-2)10-8-18)20-5-3-4-6-21(20)25(17)12-11-24-13-15-28-16-14-24/h3-10H,11-16H2,1-2H3
DM3XRJT	CS	CC1=C(C2=CC=CC=C2N1CCN3CCOCC3)C(=O)C4=CC=C(C=C4)OC
DM3XRJT	IK	MEUQWHZOUDZXHH-UHFFFAOYSA-N
DM3XRJT	IU	(4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone
DM3XRJT	CA	CAS 92623-83-1
DM3XRJT	DE	Discovery agent

DMHEV75	ID	DMHEV75
DMHEV75	DN	Preclamol
DMHEV75	HS	Investigative
DMHEV75	SN	UNII-9V2O6CRQ6Z; CHEMBL7549; 9V2O6CRQ6Z; Preclamol [INN]; Preclamolum [Latin]; 85966-89-8; Preclamolum; 3-(1-Propyl-piperidin-3-yl)-phenol; (-)-(S)-m-(1-Propyl-3-piperidyl)phenol; AC1NSK6E; Lopac0_000996; SCHEMBL1240854; DTXSID7048453; ZINC402947; 3PPP,(+); 3-PPP-(-); PDSP2_000626; BDBM50010617; PDSP1_000630; CCG-205076; NCGC00162308-01; NCGC00162310-02; (S)-3-(1-propylpiperidin-3-yl)phenol; 3-[(3S)-1-propylpiperidin-3-yl]phenol; 3-((S)-1-Propyl-piperidin-3-yl)-phenol; (-)-3-(1-Propyl-piperidin-3-yl)-phenol; FT-0770905
DMHEV75	DT	Small molecular drug
DMHEV75	PC	5311189
DMHEV75	MW	219.32
DMHEV75	FM	C14H21NO
DMHEV75	IC	InChI=1S/C14H21NO/c1-2-8-15-9-4-6-13(11-15)12-5-3-7-14(16)10-12/h3,5,7,10,13,16H,2,4,6,8-9,11H2,1H3/t13-/m1/s1
DMHEV75	CS	CCCN1CCC[C@H](C1)C2=CC(=CC=C2)O
DMHEV75	IK	HTSNFXAICLXZMA-CYBMUJFWSA-N
DMHEV75	IU	3-[(3S)-1-propylpiperidin-3-yl]phenol
DMHEV75	CA	CAS 85966-89-8
DMHEV75	DE	Discovery agent

DM2HN4D	ID	DM2HN4D
DM2HN4D	DN	Predicentrine methiodide
DM2HN4D	HS	Investigative
DM2HN4D	SN	predicentrine methiodide
DM2HN4D	DT	Small molecular drug
DM2HN4D	PC	44423690
DM2HN4D	MW	483.3
DM2HN4D	FM	C21H26INO4
DM2HN4D	IC	InChI=1S/C21H25NO4.HI/c1-22(2)7-6-12-9-16(23)21(26-5)20-14-11-18(25-4)17(24-3)10-13(14)8-15(22)19(12)20;/h9-11,15H,6-8H2,1-5H3;1H/t15-;/m0./s1
DM2HN4D	CS	C[N+]1(CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)O)C.[I-]
DM2HN4D	IK	FAVKNAGZQSEXNM-RSAXXLAASA-N
DM2HN4D	IU	(6aS)-1,9,10-trimethoxy-6,6-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-6-ium-2-ol;iodide
DM2HN4D	DE	Discovery agent

DM0LW7G	ID	DM0LW7G
DM0LW7G	DN	pregnenolone-16alpha-carbonitrile
DM0LW7G	HS	Investigative
DM0LW7G	SN	16alpha-carbonitrile, pregnenolone
DM0LW7G	DT	Small molecular drug
DM0LW7G	PC	15032
DM0LW7G	MW	341.5
DM0LW7G	FM	C22H31NO2
DM0LW7G	IC	InChI=1S/C22H31NO2/c1-13(24)20-14(12-23)10-19-17-5-4-15-11-16(25)6-8-21(15,2)18(17)7-9-22(19,20)3/h4,14,16-20,25H,5-11H2,1-3H3/t14-,16-,17+,18-,19-,20-,21-,22-/m0/s1
DM0LW7G	CS	CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C#N
DM0LW7G	IK	VSBHRRMYCDQLJF-ZDNYCOCVSA-N
DM0LW7G	IU	(3S,8S,9S,10R,13S,14S,16R,17S)-17-acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-16-carbonitrile
DM0LW7G	CA	CAS 1434-54-4
DM0LW7G	CB	CHEBI:35591
DM0LW7G	DE	Discovery agent

DMC4W03	ID	DMC4W03
DMC4W03	DN	Premafloxacin
DMC4W03	HS	Investigative
DMC4W03	SN	Premafloxacin; 143383-65-7; UNII-UOM2HMO524; UOM2HMO524; CHEMBL230599; U-95376; 1-cyclopropyl-6-fluoro-8-methoxy-7-((R)-3-((S)-1-(methylamino)ethyl)pyrrolidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Premafloxacin [USAN:INN]; Premafloxacin (USAN/INN); SCHEMBL1230382; AC1L2G72; CTK4C3611; DTXSID70162407; 3-Quinolinecarboxylicacid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(3R)-3-[(1S)-1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-; BDBM50205462; AKOS030530871; D05605; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6
DMC4W03	DT	Small molecular drug
DMC4W03	PC	71455
DMC4W03	MW	403.4
DMC4W03	FM	C21H26FN3O4
DMC4W03	IC	InChI=1S/C21H26FN3O4/c1-11(23-2)12-6-7-24(9-12)18-16(22)8-14-17(20(18)29-3)25(13-4-5-13)10-15(19(14)26)21(27)28/h8,10-13,23H,4-7,9H2,1-3H3,(H,27,28)/t11-,12+/m0/s1
DMC4W03	CS	C[C@@H]([C@@H]1CCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F)NC
DMC4W03	IK	SUQUWONDIBHQOZ-NWDGAFQWSA-N
DMC4W03	IU	1-cyclopropyl-6-fluoro-8-methoxy-7-[(3R)-3-[(1S)-1-(methylamino)ethyl]pyrrolidin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMC4W03	CA	CAS 143383-65-7
DMC4W03	DE	Discovery agent

DMVOGT4	ID	DMVOGT4
DMVOGT4	DN	PREMETREXED
DMVOGT4	HS	Investigative
DMVOGT4	SN	[3H]pemetrexed
DMVOGT4	DT	Small molecular drug
DMVOGT4	PC	394493
DMVOGT4	DE	Discovery agent

DMV8YHQ	ID	DMV8YHQ
DMV8YHQ	DN	prenalterol
DMV8YHQ	HS	Investigative
DMV8YHQ	SN	CGP 7760B
DMV8YHQ	DT	Small molecular drug
DMV8YHQ	PC	42396
DMV8YHQ	MW	225.28
DMV8YHQ	FM	C12H19NO3
DMV8YHQ	IC	InChI=1S/C12H19NO3/c1-9(2)13-7-11(15)8-16-12-5-3-10(14)4-6-12/h3-6,9,11,13-15H,7-8H2,1-2H3/t11-/m0/s1
DMV8YHQ	CS	CC(C)NC[C@@H](COC1=CC=C(C=C1)O)O
DMV8YHQ	IK	ADUKCCWBEDSMEB-NSHDSACASA-N
DMV8YHQ	IU	4-[(2S)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenol
DMV8YHQ	CA	CAS 57526-81-5
DMV8YHQ	CB	CHEBI:8391
DMV8YHQ	DE	Discovery agent

DM9HSQJ	ID	DM9HSQJ
DM9HSQJ	DN	Prenyl pyrophosphate analogue
DM9HSQJ	HS	Investigative
DM9HSQJ	DE	Discovery agent

DM5P1NZ	ID	DM5P1NZ
DM5P1NZ	DN	PREUSSOMERIN
DM5P1NZ	HS	Investigative
DM5P1NZ	SN	CHEMBL318853; PREUSSOMERIN; BDBM50059849
DM5P1NZ	DT	Small molecular drug
DM5P1NZ	PC	44332169
DM5P1NZ	MW	362.3
DM5P1NZ	FM	C20H10O7
DM5P1NZ	IC	InChI=1S/C20H10O7/c21-9-6-7-19-14-8(9)2-1-3-11(14)26-20(27-19)15-12(25-19)5-4-10(22)13(15)16(23)17-18(20)24-17/h1-7,17-18,22H/t17?,18?,19-,20+/m1/s1
DM5P1NZ	CS	C1=CC2=C3C(=C1)O[C@@]45C6C(O6)C(=O)C7=C(C=CC(=C74)O[C@@]3(O5)C=CC2=O)O
DM5P1NZ	IK	YMTRIUFFDHMDKK-TUNPWDSISA-N
DM5P1NZ	IU	(1S,12R)-7-hydroxy-3,11,21,22-tetraoxaheptacyclo[10.9.1.11,6.112,16.02,4.010,24.020,23]tetracosa-6,8,10(24),13,16(23),17,19-heptaene-5,15-dione
DM5P1NZ	DE	Discovery agent

DMLI4RF	ID	DMLI4RF
DMLI4RF	DN	Prifelone
DMLI4RF	HS	Investigative
DMLI4RF	SN	Prifelone; Prifelonum [INN-Latin]; Prifelone [USAN:INN]; Prifelona [INN-Spanish]; R-830; S-16820; UNII-0414BW860U; R-830T; BRN 3620438; CHEMBL8846; 69425-13-4; R 830; 3,5-Di-tert-butyl-4-hydroxyphenyl 2-thienyl ketone; 0414BW860U; (3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl)-2-thienylmethanone; Prifelonum; Prifelona; Methanone, (3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-2-thienyl-; Butafen; C19H24O2S; Prifelone (USAN/INN); AC1L2GQY; SCHEMBL42678; 5-18-02-00065 (Beilstein Handbook Reference); ZINC1977; DTXSID90219583; BDBM50012780
DMLI4RF	DT	Small molecular drug
DMLI4RF	PC	71751
DMLI4RF	MW	316.5
DMLI4RF	FM	C19H24O2S
DMLI4RF	IC	InChI=1S/C19H24O2S/c1-18(2,3)13-10-12(16(20)15-8-7-9-22-15)11-14(17(13)21)19(4,5)6/h7-11,21H,1-6H3
DMLI4RF	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C(=O)C2=CC=CS2
DMLI4RF	IK	WAAVMZLJRXYRMA-UHFFFAOYSA-N
DMLI4RF	IU	(3,5-ditert-butyl-4-hydroxyphenyl)-thiophen-2-ylmethanone
DMLI4RF	CA	CAS 69425-13-4
DMLI4RF	DE	Discovery agent

DMA8GI6	ID	DMA8GI6
DMA8GI6	DN	Primary alcohol metabolite of celecoxib
DMA8GI6	HS	Investigative
DMA8GI6	SN	Hydroxy Celecoxib; hydroxycelecoxib; 170571-00-3; CHEMBL745; UNII-1DIW8DT7Q3; 1DIW8DT7Q3; PRIMARY ALCOHOL METABOLITE OF CELECOXIB; Hydroxymethylcelecoxib; 4-[5-[4-(Hydroxymethyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-[4-(hydroxymethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; 4-(5-(4-Hydroxymethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4'-Hydroxycelecoxib; Celecoxib metabolite M3
DMA8GI6	DT	Small molecular drug
DMA8GI6	PC	9908776
DMA8GI6	MW	397.4
DMA8GI6	FM	C17H14F3N3O3S
DMA8GI6	IC	InChI=1S/C17H14F3N3O3S/c18-17(19,20)16-9-15(12-3-1-11(10-24)2-4-12)23(22-16)13-5-7-14(8-6-13)27(21,25)26/h1-9,24H,10H2,(H2,21,25,26)
DMA8GI6	CS	C1=CC(=CC=C1CO)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
DMA8GI6	IK	ICRSYPPLGADZKA-UHFFFAOYSA-N
DMA8GI6	IU	4-[5-[4-(hydroxymethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DMA8GI6	CA	CAS 170571-00-3
DMA8GI6	DE	Discovery agent

DMTJZQK	ID	DMTJZQK
DMTJZQK	DN	pristanic acid
DMTJZQK	HS	Investigative
DMTJZQK	SN	UNII-6P06977L1A; 6P06977L1A; (2S,6R,10R)-2,6,10,14-tetramethylpentadecanoic acid; L,d,D-pristanic acid; GTPL2676; Pristanic acid, (2S,6R,10R)-; UNII-5FMQ2908AP component PAHGJZDQXIOYTH-KURKYZTESA-N; Pentadecanoic acid, 2,6,10,14-tetramethyl-, (2S,6R,10R)-
DMTJZQK	DT	Small molecular drug
DMTJZQK	PC	123929
DMTJZQK	MW	298.5
DMTJZQK	FM	C19H38O2
DMTJZQK	IC	InChI=1S/C19H38O2/c1-15(2)9-6-10-16(3)11-7-12-17(4)13-8-14-18(5)19(20)21/h15-18H,6-14H2,1-5H3,(H,20,21)
DMTJZQK	CS	CC(C)CCCC(C)CCCC(C)CCCC(C)C(=O)O
DMTJZQK	IK	PAHGJZDQXIOYTH-UHFFFAOYSA-N
DMTJZQK	IU	2,6,10,14-tetramethylpentadecanoic acid
DMTJZQK	CA	CAS 1189-37-3
DMTJZQK	CB	CHEBI:51340
DMTJZQK	DE	Discovery agent

DMA2SBL	ID	DMA2SBL
DMA2SBL	DN	PRO-135
DMA2SBL	HS	Investigative
DMA2SBL	SN	Antisense oligonucleotide dystrophin modulator (myotonic dystrophy), Prosensa
DMA2SBL	CP	Prosensa Therapeutics BV
DMA2SBL	DT	Antisense drug
DMA2SBL	DE	Myotonic dystrophy

DMARYLK	ID	DMARYLK
DMARYLK	DN	Prochiral ketones
DMARYLK	HS	Investigative
DMARYLK	SN	4-CHLOROBENZOPHENONE; 134-85-0; (4-Chlorophenyl)(phenyl)methanone; Methanone, (4-chlorophenyl)phenyl-; Benzophenone, 4-chloro-; p-CBP; (4-chlorophenyl)-phenylmethanone; 4-chloro benzophenone; UNII-WIH1IZ728U; MFCD00000622; 4-Chlorobenzophenone, 99%; WIH1IZ728U; UGVRJVHOJNYEHR-UHFFFAOYSA-N; para-Chlorobenzophenone; HSDB 2740; 4-chlorobenzophenon; NSC 2872; p-Chlorobenzophenone; EINECS 205-160-7; PubChem3298; 4-Benzoylphenyl chloride; AI3-00705; Cetirizine Impurity (4-Chlorobenzophenone); ACMC-209bx7; p-Chlorophenyl phenyl ketone; 4-chlorophenyl phenyl ketone; DSSTox_CID_30242; DSSTox_GSID_51687; SCHEMBL50462; KSC176E1J; phenyl-(4-chlorophenyl)-ketone; CHEMBL3560455; DTXSID2051687; CTK0H6214; KS-00000IIV; Benzophenone, 4-chloro- (8CI); NSC2872; BCP27841; NSC-2872; STR01449; ZINC2504270; Tox21_304009; (4-Chlorophenyl)(phenyl)methanone #; ANW-19721; STL453116; AKOS000119405; CS-W004344; MCULE-3593125639; NE10043; PS-7925; RTR-031190; TRA0100086; NCGC00357224-01; AC-23664; AK-58316; CAS-134-85-0; AB1008297; DB-042255; TR-031190; FT-0618187; ST24026277; ST50308103; AH-034/32828041; W-108278; Q27292660; Z425389590; 4-Chlorobenzophenone, United States Pharmacopeia (USP) Reference Standard
DMARYLK	DE	Discovery agent

DMTW82E	ID	DMTW82E
DMTW82E	DN	Procyanidin B-2 3,3'-di-O-gallate
DMTW82E	HS	Investigative
DMTW82E	SN	CHEMBL506811; Bis(3,4,5-trihydroxybenzoic acid)2alpha,2'alpha-bis(3,4-dihydroxyphenyl)-5,5',7,7'-tetrahydroxy-4,8'-bichroman-3alpha,3'alpha-diyl ester
DMTW82E	DT	Small molecular drug
DMTW82E	PC	12795894
DMTW82E	MW	882.7
DMTW82E	FM	C44H34O20
DMTW82E	IC	InChI=1S/C44H34O20/c45-19-11-26(51)34-32(12-19)61-40(16-2-4-22(47)25(50)6-16)42(64-44(60)18-9-30(55)38(58)31(56)10-18)36(34)35-27(52)14-23(48)20-13-33(62-43(59)17-7-28(53)37(57)29(54)8-17)39(63-41(20)35)15-1-3-21(46)24(49)5-15/h1-12,14,33,36,39-40,42,45-58H,13H2/t33-,36?,39-,40-,42-/m1/s1
DMTW82E	CS	C1[C@H]([C@H](OC2=C1C(=CC(=C2C3[C@H]([C@H](OC4=CC(=CC(=C34)O)O)C5=CC(=C(C=C5)O)O)OC(=O)C6=CC(=C(C(=C6)O)O)O)O)O)C7=CC(=C(C=C7)O)O)OC(=O)C8=CC(=C(C(=C8)O)O)O
DMTW82E	IK	KTLUHRSHFRODPS-ZMSZJQPBSA-N
DMTW82E	IU	[(2R,3R)-2-(3,4-dihydroxyphenyl)-8-[(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-3,4-dihydro-2H-chromen-4-yl]-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMTW82E	DE	Discovery agent

DMGIF1L	ID	DMGIF1L
DMGIF1L	DN	Prodipine
DMGIF1L	HS	Investigative
DMGIF1L	SN	Prodipine; 1-Isopropyl-4,4-diphenylpiperidine; UNII-51567MYG7V; 31314-38-2; CHEMBL277382; 51567MYG7V; Prodipinum; Prodipin; Prodipina; Prodipine [INN]; Prodipinum [INN-Latin]; Prodipina [INN-Spanish]; AC1L23XQ; SCHEMBL148420; DTXSID20185247; CFOOTBBXHJHHMT-UHFFFAOYSA-N; 1-i-propyl-4,4-diphenylpiperidine; ZINC1482151; BDBM50047020; 4,4-diphenyl-1-propan-2-ylpiperidine; 1-Isopropyl-4,4-diphenyl-piperidine (prodipine)
DMGIF1L	DT	Small molecular drug
DMGIF1L	PC	65775
DMGIF1L	MW	279.4
DMGIF1L	FM	C20H25N
DMGIF1L	IC	InChI=1S/C20H25N/c1-17(2)21-15-13-20(14-16-21,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3-12,17H,13-16H2,1-2H3
DMGIF1L	CS	CC(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3
DMGIF1L	IK	CFOOTBBXHJHHMT-UHFFFAOYSA-N
DMGIF1L	IU	4,4-diphenyl-1-propan-2-ylpiperidine
DMGIF1L	CA	CAS 31314-38-2
DMGIF1L	DE	Discovery agent

DMZH0KY	ID	DMZH0KY
DMZH0KY	DN	Pro-His-Pro-His-Leu-Phe-Val-Tyr
DMZH0KY	HS	Investigative
DMZH0KY	SN	CHEMBL267446; Pro-His-Pro-His-Leu-Phe-Val-Tyr
DMZH0KY	PC	44346214
DMZH0KY	MW	1156.3
DMZH0KY	FM	C60H77N13O11
DMZH0KY	IC	InChI=1S/C60H77N13O11/c1-35(2)25-44(53(76)67-46(27-38-15-9-6-10-16-38)56(79)72-51(36(3)4)58(81)71-49(60(83)84)28-39-19-21-42(74)22-20-39)66-55(78)47(29-40-31-61-33-64-40)68-54(77)45(26-37-13-7-5-8-14-37)69-57(80)50-18-12-24-73(50)59(82)48(30-41-32-62-34-65-41)70-52(75)43-17-11-23-63-43/h5-10,13-16,19-22,31-36,43-51,63,74H,11-12,17-18,23-30H2,1-4H3,(H,61,64)(H,62,65)(H,66,78)(H,67,76)(H,68,77)(H,69,80)(H,70,75)(H,71,81)(H,72,79)(H,83,84)/t43-,44+,45+,46+,47+,48+,49+,50-,51+/m1/s1
DMZH0KY	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H]5CCCN5C(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]7CCCN7
DMZH0KY	IK	SGQUWHDGWRVGGP-XPEIQDACSA-N
DMZH0KY	IU	(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-2-[[(2R)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2R)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoic acid
DMZH0KY	DE	Discovery agent

DMD3WVO	ID	DMD3WVO
DMD3WVO	DN	Pro-His-Pro-His-Phe-Phe-Val-Tyr
DMD3WVO	HS	Investigative
DMD3WVO	SN	CHEMBL384760; Pro-His-Pro-His-Phe-Phe-Val-Tyr
DMD3WVO	PC	44346213
DMD3WVO	MW	1190.3
DMD3WVO	FM	C63H75N13O11
DMD3WVO	IC	InChI=1S/C63H75N13O11/c1-38(2)54(61(84)74-52(63(86)87)31-42-22-24-45(77)25-23-42)75-59(82)49(30-41-18-10-5-11-19-41)70-56(79)47(28-39-14-6-3-7-15-39)69-58(81)50(32-43-34-64-36-67-43)71-57(80)48(29-40-16-8-4-9-17-40)72-60(83)53-21-13-27-76(53)62(85)51(33-44-35-65-37-68-44)73-55(78)46-20-12-26-66-46/h3-11,14-19,22-25,34-38,46-54,66,77H,12-13,20-21,26-33H2,1-2H3,(H,64,67)(H,65,68)(H,69,81)(H,70,79)(H,71,80)(H,72,83)(H,73,78)(H,74,84)(H,75,82)(H,86,87)/t46-,47+,48+,49+,50+,51+,52+,53-,54+/m1/s1
DMD3WVO	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]6CCCN6C(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H]8CCCN8
DMD3WVO	IK	LZANPSMBIHLZRC-UNOFDIFTSA-N
DMD3WVO	IU	(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-2-[[(2R)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2R)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoic acid
DMD3WVO	DE	Discovery agent

DMNDUI3	ID	DMNDUI3
DMNDUI3	DN	Pro-His-Pro-His-Phe-Phe-Val-Tyr-Lys
DMNDUI3	HS	Investigative
DMNDUI3	PC	44346191
DMNDUI3	MW	1318.5
DMNDUI3	FM	C69H87N15O12
DMNDUI3	IC	InChI=1S/C69H87N15O12/c1-42(2)59(67(93)81-54(35-46-25-27-49(85)28-26-46)61(87)76-51(69(95)96)22-12-13-29-70)83-65(91)55(34-45-20-10-5-11-21-45)78-62(88)52(32-43-16-6-3-7-17-43)77-64(90)56(36-47-38-71-40-74-47)79-63(89)53(33-44-18-8-4-9-19-44)80-66(92)58-24-15-31-84(58)68(94)57(37-48-39-72-41-75-48)82-60(86)50-23-14-30-73-50/h3-11,16-21,25-28,38-42,50-59,73,85H,12-15,22-24,29-37,70H2,1-2H3,(H,71,74)(H,72,75)(H,76,87)(H,77,90)(H,78,88)(H,79,89)(H,80,92)(H,81,93)(H,82,86)(H,83,91)(H,95,96)/t50-,51+,52+,53+,54+,55+,56+,57+,58-,59+/m1/s1
DMNDUI3	CS	CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]6CCCN6C(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H]8CCCN8
DMNDUI3	IK	AIRMFERKNRDUKD-KKFBCCNDSA-N
DMNDUI3	IU	(2S)-6-amino-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-2-[[(2R)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2R)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]hexanoic acid
DMNDUI3	DE	Discovery agent

DM26VFX	ID	DM26VFX
DM26VFX	DN	Pro-His-Pro-Phe-His-Leu(CH2NH)Val-Ile-His-Lys
DM26VFX	HS	Investigative
DM26VFX	PC	44297622
DM26VFX	MW	1210.5
DM26VFX	FM	C60H91N17O10
DM26VFX	IC	InChI=1S/C60H91N17O10/c1-7-37(6)51(58(84)74-47(26-40-29-63-33-68-40)55(81)71-44(60(86)87)17-11-12-20-61)76-57(83)50(36(4)5)66-31-42(23-35(2)3)70-53(79)46(25-39-28-62-32-67-39)72-54(80)45(24-38-15-9-8-10-16-38)73-56(82)49-19-14-22-77(49)59(85)48(27-41-30-64-34-69-41)75-52(78)43-18-13-21-65-43/h8-10,15-16,28-30,32-37,42-51,65-66H,7,11-14,17-27,31,61H2,1-6H3,(H,62,67)(H,63,68)(H,64,69)(H,70,79)(H,71,81)(H,72,80)(H,73,82)(H,74,84)(H,75,78)(H,76,83)(H,86,87)/t37-,42-,43+,44-,45-,46-,47-,48-,49+,50-,51-/m0/s1
DM26VFX	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C(C)C)NC[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H]6CCCN6
DM26VFX	IK	XIZSMQBWVQNHCA-XTAHDJANSA-N
DM26VFX	IU	(2S)-6-amino-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-2-[[(2R)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2R)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]hexanoic acid
DM26VFX	DE	Discovery agent

DM82TMA	ID	DM82TMA
DM82TMA	DN	Proline
DM82TMA	HS	Investigative
DM82TMA	SN	D,L-proline; D-Pyrrolidine-2-carboxylic acid; DL proline; DL-Proline; DL-Proline, 99%; DL-Proline,(S); H-DL-Pro-OH; L-Proline, homopolymer; ONIBWKKTOPOVIA-UHFFFAOYSA-N; Poly(DL-proline); Poly(L-proline); Prolin; Proline #; Proline DL-form; Proline, DL-; PubChem20613; d,1-proline; laevo-proline; proline; proline;; pyrrolidine-2-carboxylic acid; (+/-)-Pyrrolidine-2-carboxylic acid; 2-Pyrrolidine carboxylic acid; 609-36-9; CCCu; CCRIS 8602; CHEBI:26271; CHEMBL72275; EINECS 210-189-3; Hpro; MFCD00005250; NSC 97923; NSC-97923; NSC97923
DM82TMA	PC	614
DM82TMA	MW	115.13
DM82TMA	FM	C5H9NO2
DM82TMA	IC	ONIBWKKTOPOVIA-UHFFFAOYSA-N
DM82TMA	CS	C1CC(NC1)C(=O)O
DM82TMA	IK	1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)
DM82TMA	IU	pyrrolidine-2-carboxylic acid
DM82TMA	CA	CAS 609-36-9
DM82TMA	CB	CHEBI:26271
DM82TMA	DE	Discovery agent

DMOTXE3	ID	DMOTXE3
DMOTXE3	DN	Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
DMOTXE3	HS	Investigative
DMOTXE3	SN	CHEMBL238168; 53749-61-4; Substance P(2-11); Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
DMOTXE3	PC	14535496
DMOTXE3	MW	1191.4
DMOTXE3	FM	C57H86N14O12S
DMOTXE3	IC	InChI=1S/C57H86N14O12S/c1-34(2)30-42(54(80)65-37(49(61)75)25-29-84-3)64-48(74)33-63-50(76)43(31-35-14-6-4-7-15-35)69-55(81)44(32-36-16-8-5-9-17-36)70-53(79)39(21-23-46(59)72)66-52(78)40(22-24-47(60)73)67-56(82)45-20-13-28-71(45)57(83)41(18-10-11-26-58)68-51(77)38-19-12-27-62-38/h4-9,14-17,34,37-45,62H,10-13,18-33,58H2,1-3H3,(H2,59,72)(H2,60,73)(H2,61,75)(H,63,76)(H,64,74)(H,65,80)(H,66,78)(H,67,82)(H,68,77)(H,69,81)(H,70,79)/t37-,38-,39-,40-,41-,42-,43-,44-,45-/m0/s1
DMOTXE3	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4
DMOTXE3	IK	HGUMOPZYRIFNRE-NVAZTIMOSA-N
DMOTXE3	IU	(2S)-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]pentanediamide
DMOTXE3	DE	Discovery agent

DMY3VGC	ID	DMY3VGC
DMY3VGC	DN	Promethazine
DMY3VGC	HS	Investigative
DMY3VGC	SN	Antiallersin; Aprobit; Avomine; Camergan; Dimapp; Diphergan; Diprazin; Diprazine; Diprozin; Fargan; Fenazil; Fenetazina; Fenetazine; Genphen; Hiberna; Histargan; Iergigan; Isophenergan; Isopromethazine; Lercigan; Lergigan; Metaryl; Pelpica; Phargan; Phenargan; Phenerzine; Phensedyl; Pilothia; Pilpophen; Pipolphene; Proazaimine; Proazamine; Procit; Promacot; Promazinamide; Promergan; Promesan; Prometasin; Prometazin; Prometazina; Prometazine; Prometh; Promethacon; Promethaine; Promethazin; PromethazineHcl; Promethazinum; Promethegan; Promethiazine; Promezathine; Prorex; Protazine; Prothazin; Prothazine; Provigan; Pyrethia; Pyrethiazine; Remsed; Romergan; Rumergan; Tanidil; Thiergan; Valergine; Vallergine; Lilly 01516; Lilly 1516; RP 3277; SKF 1498; WY 509; A-91033; Atosil (TN); Avomine (TN); Fargan (TN); Farganesse (TN); Lergigan (TN); Phenergan (TN); Phenoject-50; Pro-50; Prometazina [INN-Spanish]; Promethazine [INN:BAN]; Promethazinum [INN-Latin]; Promethegan (TN); Prothiazine (TN); Receptozine (TN); Romergan (TN); Zipan-25; Dimethylamino-isopropyl-phenthiazin; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN)
DMY3VGC	CP	Wyeth Pharmaceuticals
DMY3VGC	TC	Antiviral Agents
DMY3VGC	DT	Small molecular drug
DMY3VGC	PC	4927
DMY3VGC	MW	284.4
DMY3VGC	FM	C17H20N2S
DMY3VGC	IC	InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
DMY3VGC	CS	CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
DMY3VGC	IK	PWWVAXIEGOYWEE-UHFFFAOYSA-N
DMY3VGC	IU	N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
DMY3VGC	CA	CAS 60-87-7
DMY3VGC	CB	CHEBI:8461
DMY3VGC	DE	Nausea; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMIUV25	ID	DMIUV25
DMIUV25	DN	PRONTOCIL
DMIUV25	HS	Investigative
DMIUV25	DT	Small molecular drug
DMIUV25	PC	8625
DMIUV25	MW	544.5
DMIUV25	FM	C18H16N4O10S3
DMIUV25	IC	InChI=1S/C18H16N4O10S3/c1-9(23)20-14-8-13-10(6-15(14)34(27,28)29)7-16(35(30,31)32)17(18(13)24)22-21-11-2-4-12(5-3-11)33(19,25)26/h2-8,24H,1H3,(H,20,23)(H2,19,25,26)(H,27,28,29)(H,30,31,32)
DMIUV25	CS	CC(=O)NC1=C(C=C2C=C(C(=C(C2=C1)O)N=NC3=CC=C(C=C3)S(=O)(=O)N)S(=O)(=O)O)S(=O)(=O)O
DMIUV25	IK	RALNLQYPLYWQRT-UHFFFAOYSA-N
DMIUV25	IU	6-acetamido-4-hydroxy-3-[(4-sulfamoylphenyl)diazenyl]naphthalene-2,7-disulfonic acid
DMIUV25	CA	CAS 132-38-7
DMIUV25	DE	Discovery agent

DMGA53N	ID	DMGA53N
DMGA53N	DN	Prontosil
DMGA53N	HS	Investigative
DMGA53N	SN	Aseptil rojo (TN); Prontosil rubrum; Q64Q9N6Q6O; Rubiazol; SCHEMBL155098; SCHEMBL155099; Sulfamidochrysoidine; TX-017879; ob sie prontosil; prontosil; 103-12-8; 4-[(2,4-diaminophenyl)diazenyl]benzenesulfonamide; AI3-09088; Benzenesulfonamide, 4-((2,4-diaminophenyl)azo)-; CHEBI:8464; CHEMBL488279; CTK4A1757; DTXSID60145608; EINECS 203-081-2; P-[(2,4-diaminophenyl)azo]benzenesulphonamide; UNII-Q64Q9N6Q6O; p-((2,4-Diaminophenyl)azo)benzenesulphonamide; p-[(2,4-Diaminophenyl)azo]benzenesulfonamide
DMGA53N	PC	66895
DMGA53N	MW	291.33
DMGA53N	FM	C12H13N5O2S
DMGA53N	IC	ABBQGOCHXSPKHJ-UHFFFAOYSA-N
DMGA53N	CS	C1=CC(=CC=C1N=NC2=C(C=C(C=C2)N)N)S(=O)(=O)N
DMGA53N	IK	1S/C12H13N5O2S/c13-8-1-6-12(11(14)7-8)17-16-9-2-4-10(5-3-9)20(15,18)19/h1-7H,13-14H2,(H2,15,18,19)
DMGA53N	IU	4-[(2,4-diaminophenyl)diazenyl]benzenesulfonamide
DMGA53N	CA	CAS 103-12-8
DMGA53N	CB	CHEBI:8464
DMGA53N	DE	Pseudomonas infection

DM8O41M	ID	DM8O41M
DM8O41M	DN	Prop-2-ynyl 4-sulfamoylbenzoate
DM8O41M	HS	Investigative
DM8O41M	SN	O-propynylamide benzenesulphonamide
DM8O41M	DT	Small molecular drug
DM8O41M	PC	11974340
DM8O41M	MW	239.25
DM8O41M	FM	C10H9NO4S
DM8O41M	IC	InChI=1S/C10H9NO4S/c1-2-7-15-10(12)8-3-5-9(6-4-8)16(11,13)14/h1,3-6H,7H2,(H2,11,13,14)
DM8O41M	CS	C#CCOC(=O)C1=CC=C(C=C1)S(=O)(=O)N
DM8O41M	IK	IORJVPBKDUGFOJ-UHFFFAOYSA-N
DM8O41M	IU	prop-2-ynyl 4-sulfamoylbenzoate
DM8O41M	DE	Discovery agent

DMQZYW6	ID	DMQZYW6
DMQZYW6	DN	Propan-2-one O-3-butoxyphenylcarbamoyl oxime
DMQZYW6	HS	Investigative
DMQZYW6	SN	CHEMBL597130; propan-2-one O-3-butoxyphenylcarbamoyl oxime
DMQZYW6	DT	Small molecular drug
DMQZYW6	PC	20872812
DMQZYW6	MW	264.32
DMQZYW6	FM	C14H20N2O3
DMQZYW6	IC	InChI=1S/C14H20N2O3/c1-4-5-9-18-13-8-6-7-12(10-13)15-14(17)19-16-11(2)3/h6-8,10H,4-5,9H2,1-3H3,(H,15,17)
DMQZYW6	CS	CCCCOC1=CC=CC(=C1)NC(=O)ON=C(C)C
DMQZYW6	IK	GNTLUXBWYDMBFL-UHFFFAOYSA-N
DMQZYW6	IU	(propan-2-ylideneamino) N-(3-butoxyphenyl)carbamate
DMQZYW6	DE	Discovery agent

DMIQ0DF	ID	DMIQ0DF
DMIQ0DF	DN	Propan-2-one O-4-(decyloxy)phenylcarbamoyl oxime
DMIQ0DF	HS	Investigative
DMIQ0DF	SN	CHEMBL597215; propan-2-one O-4-(decyloxy)phenylcarbamoyl oxime
DMIQ0DF	DT	Small molecular drug
DMIQ0DF	PC	20872816
DMIQ0DF	MW	348.5
DMIQ0DF	FM	C20H32N2O3
DMIQ0DF	IC	InChI=1S/C20H32N2O3/c1-4-5-6-7-8-9-10-11-16-24-19-14-12-18(13-15-19)21-20(23)25-22-17(2)3/h12-15H,4-11,16H2,1-3H3,(H,21,23)
DMIQ0DF	CS	CCCCCCCCCCOC1=CC=C(C=C1)NC(=O)ON=C(C)C
DMIQ0DF	IK	VUIWYGFHHJXEAE-UHFFFAOYSA-N
DMIQ0DF	IU	(propan-2-ylideneamino) N-(4-decoxyphenyl)carbamate
DMIQ0DF	DE	Discovery agent

DM8FXM6	ID	DM8FXM6
DM8FXM6	DN	Propan-2-one O-4-(heptyloxy)phenylcarbamoyl oxime
DM8FXM6	HS	Investigative
DM8FXM6	SN	CHEMBL597294; propan-2-one O-4-(heptyloxy)phenylcarbamoyl oxime
DM8FXM6	DT	Small molecular drug
DM8FXM6	PC	20872819
DM8FXM6	MW	306.4
DM8FXM6	FM	C17H26N2O3
DM8FXM6	IC	InChI=1S/C17H26N2O3/c1-4-5-6-7-8-13-21-16-11-9-15(10-12-16)18-17(20)22-19-14(2)3/h9-12H,4-8,13H2,1-3H3,(H,18,20)
DM8FXM6	CS	CCCCCCCOC1=CC=C(C=C1)NC(=O)ON=C(C)C
DM8FXM6	IK	YXHJSUXZTSOPMI-UHFFFAOYSA-N
DM8FXM6	IU	(propan-2-ylideneamino) N-(4-heptoxyphenyl)carbamate
DM8FXM6	DE	Discovery agent

DM5J0H3	ID	DM5J0H3
DM5J0H3	DN	Propan-2-one O-4-(hexyloxy)phenylcarbamoyl oxime
DM5J0H3	HS	Investigative
DM5J0H3	SN	CHEMBL597088; propan-2-one O-4-(hexyloxy)phenylcarbamoyl oxime
DM5J0H3	DT	Small molecular drug
DM5J0H3	PC	20872820
DM5J0H3	MW	292.37
DM5J0H3	FM	C16H24N2O3
DM5J0H3	IC	InChI=1S/C16H24N2O3/c1-4-5-6-7-12-20-15-10-8-14(9-11-15)17-16(19)21-18-13(2)3/h8-11H,4-7,12H2,1-3H3,(H,17,19)
DM5J0H3	CS	CCCCCCOC1=CC=C(C=C1)NC(=O)ON=C(C)C
DM5J0H3	IK	OTUAPVMKCJEVBD-UHFFFAOYSA-N
DM5J0H3	IU	(propan-2-ylideneamino) N-(4-hexoxyphenyl)carbamate
DM5J0H3	DE	Discovery agent

DMYBH91	ID	DMYBH91
DMYBH91	DN	Propan-2-one O-4-(nonyloxy)phenylcarbamoyl oxime
DMYBH91	HS	Investigative
DMYBH91	SN	CHEMBL597014; propan-2-one O-4-(nonyloxy)phenylcarbamoyl oxime
DMYBH91	DT	Small molecular drug
DMYBH91	PC	20872821
DMYBH91	MW	334.5
DMYBH91	FM	C19H30N2O3
DMYBH91	IC	InChI=1S/C19H30N2O3/c1-4-5-6-7-8-9-10-15-23-18-13-11-17(12-14-18)20-19(22)24-21-16(2)3/h11-14H,4-10,15H2,1-3H3,(H,20,22)
DMYBH91	CS	CCCCCCCCCOC1=CC=C(C=C1)NC(=O)ON=C(C)C
DMYBH91	IK	JNUCPQPMMFLJDL-UHFFFAOYSA-N
DMYBH91	IU	(propan-2-ylideneamino) N-(4-nonoxyphenyl)carbamate
DMYBH91	DE	Discovery agent

DM6VZ4S	ID	DM6VZ4S
DM6VZ4S	DN	Propan-2-one O-4-(octyloxy)phenylcarbamoyl oxime
DM6VZ4S	HS	Investigative
DM6VZ4S	SN	CHEMBL597295; propan-2-one O-4-(octyloxy)phenylcarbamoyl oxime
DM6VZ4S	DT	Small molecular drug
DM6VZ4S	PC	20872822
DM6VZ4S	MW	320.4
DM6VZ4S	FM	C18H28N2O3
DM6VZ4S	IC	InChI=1S/C18H28N2O3/c1-4-5-6-7-8-9-14-22-17-12-10-16(11-13-17)19-18(21)23-20-15(2)3/h10-13H,4-9,14H2,1-3H3,(H,19,21)
DM6VZ4S	CS	CCCCCCCCOC1=CC=C(C=C1)NC(=O)ON=C(C)C
DM6VZ4S	IK	CZUCVARHDLBFBC-UHFFFAOYSA-N
DM6VZ4S	IU	(propan-2-ylideneamino) N-(4-octoxyphenyl)carbamate
DM6VZ4S	DE	Discovery agent

DM408U3	ID	DM408U3
DM408U3	DN	Propan-2-one O-4-(pentyloxy)phenylcarbamoyl oxime
DM408U3	HS	Investigative
DM408U3	SN	CHEMBL597087; propan-2-one O-4-(pentyloxy)phenylcarbamoyl oxime
DM408U3	DT	Small molecular drug
DM408U3	PC	20872823
DM408U3	MW	278.35
DM408U3	FM	C15H22N2O3
DM408U3	IC	InChI=1S/C15H22N2O3/c1-4-5-6-11-19-14-9-7-13(8-10-14)16-15(18)20-17-12(2)3/h7-10H,4-6,11H2,1-3H3,(H,16,18)
DM408U3	CS	CCCCCOC1=CC=C(C=C1)NC(=O)ON=C(C)C
DM408U3	IK	OBNDMPDDMGXHSO-UHFFFAOYSA-N
DM408U3	IU	(propan-2-ylideneamino) N-(4-pentoxyphenyl)carbamate
DM408U3	DE	Discovery agent

DMV13MO	ID	DMV13MO
DMV13MO	DN	Propan-2-one O-4-butoxybenzylcarbamoyl oxime
DMV13MO	HS	Investigative
DMV13MO	SN	CHEMBL597131; propan-2-one O-4-butoxybenzylcarbamoyl oxime
DMV13MO	DT	Small molecular drug
DMV13MO	PC	20872815
DMV13MO	MW	278.35
DMV13MO	FM	C15H22N2O3
DMV13MO	IC	InChI=1S/C15H22N2O3/c1-4-5-10-19-14-8-6-13(7-9-14)11-16-15(18)20-17-12(2)3/h6-9H,4-5,10-11H2,1-3H3,(H,16,18)
DMV13MO	CS	CCCCOC1=CC=C(C=C1)CNC(=O)ON=C(C)C
DMV13MO	IK	VRTSWQPAWLHCJK-UHFFFAOYSA-N
DMV13MO	IU	(propan-2-ylideneamino) N-[(4-butoxyphenyl)methyl]carbamate
DMV13MO	DE	Discovery agent

DMYJ28G	ID	DMYJ28G
DMYJ28G	DN	Propan-2-one O-4-butoxyphenylcarbamoyl oxime
DMYJ28G	HS	Investigative
DMYJ28G	SN	CHEMBL597086; propan-2-one O-4-butoxyphenylcarbamoyl oxime
DMYJ28G	DT	Small molecular drug
DMYJ28G	PC	20872814
DMYJ28G	MW	264.32
DMYJ28G	FM	C14H20N2O3
DMYJ28G	IC	InChI=1S/C14H20N2O3/c1-4-5-10-18-13-8-6-12(7-9-13)15-14(17)19-16-11(2)3/h6-9H,4-5,10H2,1-3H3,(H,15,17)
DMYJ28G	CS	CCCCOC1=CC=C(C=C1)NC(=O)ON=C(C)C
DMYJ28G	IK	DFYKIRMDPFHHCI-UHFFFAOYSA-N
DMYJ28G	IU	(propan-2-ylideneamino) N-(4-butoxyphenyl)carbamate
DMYJ28G	DE	Discovery agent

DM573UT	ID	DM573UT
DM573UT	DN	Propan-2-one O-4-ethoxyphenylcarbamoyl oxime
DM573UT	HS	Investigative
DM573UT	SN	CHEMBL591682; propan-2-one O-4-ethoxyphenylcarbamoyl oxime; propan-2-one, O-[[(4-ethoxy-phenyl)amino]carbonyl]oxime; BDBM50309759
DM573UT	DT	Small molecular drug
DM573UT	PC	20872818
DM573UT	MW	236.27
DM573UT	FM	C12H16N2O3
DM573UT	IC	InChI=1S/C12H16N2O3/c1-4-16-11-7-5-10(6-8-11)13-12(15)17-14-9(2)3/h5-8H,4H2,1-3H3,(H,13,15)
DM573UT	CS	CCOC1=CC=C(C=C1)NC(=O)ON=C(C)C
DM573UT	IK	HAJFSNBTGAUVST-UHFFFAOYSA-N
DM573UT	IU	(propan-2-ylideneamino) N-(4-ethoxyphenyl)carbamate
DM573UT	DE	Discovery agent

DMWX5Q6	ID	DMWX5Q6
DMWX5Q6	DN	Propan-2-one O-4-propoxyphenylcarbamoyl oxime
DMWX5Q6	HS	Investigative
DMWX5Q6	SN	CHEMBL609315; propan-2-one O-4-propoxyphenylcarbamoyl oxime
DMWX5Q6	DT	Small molecular drug
DMWX5Q6	PC	20872824
DMWX5Q6	MW	250.29
DMWX5Q6	FM	C13H18N2O3
DMWX5Q6	IC	InChI=1S/C13H18N2O3/c1-4-9-17-12-7-5-11(6-8-12)14-13(16)18-15-10(2)3/h5-8H,4,9H2,1-3H3,(H,14,16)
DMWX5Q6	CS	CCCOC1=CC=C(C=C1)NC(=O)ON=C(C)C
DMWX5Q6	IK	DAVIGWYJZIPGFN-UHFFFAOYSA-N
DMWX5Q6	IU	(propan-2-ylideneamino) N-(4-propoxyphenyl)carbamate
DMWX5Q6	DE	Discovery agent

DMQ9USH	ID	DMQ9USH
DMQ9USH	DN	Propandiamine
DMQ9USH	HS	Investigative
DMQ9USH	SN	1,3-Diaminopropane; Propane-1,3-diamine; Trimethylenediamine; XFNJVJPLKCPIBV-UHFFFAOYSA-N; aminopropylamine; 1,3-Propane-diamine; 1,3-Propanediamine; 1,3-Propylenediamine; 1,3-diaminepropane; 1,3-diaminopropan; 1,3-diaminopropane; 1,3-propandiamine; 1,3-propane diamine; 1,3diaminopropane; 1.3-diaminopropane; 109-76-2; 3-Aminopropylamine; AI3-25358; BRN 0605277; C00986; CB3ISL56KG; CCRIS 4054; CHEBI:15725; EINECS 203-702-7; EINECS 268-600-7; H2N(CH2)3NH2; MFCD00008228; NSC 8154; UNII-CB3ISL56KG; a,w-Propanediamine; alpha,omega-Propanediamine
DMQ9USH	PC	428
DMQ9USH	MW	74.13
DMQ9USH	FM	C3H10N2
DMQ9USH	IC	XFNJVJPLKCPIBV-UHFFFAOYSA-N
DMQ9USH	CS	C(CN)CN
DMQ9USH	IK	1S/C3H10N2/c4-2-1-3-5/h1-5H2
DMQ9USH	IU	propane-1,3-diamine
DMQ9USH	CA	CAS 109-76-2
DMQ9USH	CB	CHEBI:35411
DMQ9USH	DE	Discovery agent

DM9TN2W	ID	DM9TN2W
DM9TN2W	DN	Propanoic Acid
DM9TN2W	HS	Investigative
DM9TN2W	SN	propionic acid; Propanoic acid; 1979/9/4; ethylformic acid; methylacetic acid; Carboxyethane; Ethanecarboxylic acid; Pseudoacetic acid; Metacetonic acid; Monoprop; Luprosil; Prozoin; Propionoic acid; Acide propionique; Methyl acetic acid; Antischim B; Sentry grain preserver; C3 acid; Tenox P grain preservative; Caswell No. 707; Propionic acid grain preserver; Propionsaeure; Propcorn; Propkorn; propoic acid; Propioic acid; acide propanoique; Propionic acid (natural); Kyselina propionova; Carboxylic acids, C1-5; Acide propioniqu
DM9TN2W	DT	Small molecular drug
DM9TN2W	PC	1032
DM9TN2W	MW	74.08
DM9TN2W	FM	C3H6O2
DM9TN2W	IC	InChI=1S/C3H6O2/c1-2-3(4)5/h2H2,1H3,(H,4,5)
DM9TN2W	CS	CCC(=O)O
DM9TN2W	IK	XBDQKXXYIPTUBI-UHFFFAOYSA-N
DM9TN2W	IU	propanoic acid
DM9TN2W	CA	CAS 79-09-4
DM9TN2W	CB	CHEBI:30768
DM9TN2W	DE	Discovery agent

DMVRWL6	ID	DMVRWL6
DMVRWL6	DN	propargylglycine
DMVRWL6	HS	Investigative
DMVRWL6	SN	2-(Prop-2-ynylamino)acetic acid; Glycine,N-2-propyn-1-yl-; 58160-95-5; Acetic acid, 2-(prop-2-ynylamino)-; NSC692226; 2-[(prop-2-yn-1-yl)amino]acetic acid; (2-Propynylamino)acetic acid; Propargyl-glycine; AC1L4HR4; SCHEMBL44356; GTPL5247; CHEMBL1993296; CTK5A7939; DTXSID90206892; ZINC1858411; AKOS009210257; NSC-692226; AC-6385; SC-10419; NCI60_033077; KB-50364; SC-65650; TL8001634; FT-0764746; I04-0895; I04-0888
DMVRWL6	DT	Small molecular drug
DMVRWL6	PC	185909
DMVRWL6	MW	113.11
DMVRWL6	FM	C5H7NO2
DMVRWL6	IC	InChI=1S/C5H7NO2/c1-2-3-6-4-5(7)8/h1,6H,3-4H2,(H,7,8)
DMVRWL6	CS	C#CCNCC(=O)O
DMVRWL6	IK	XSJLQGMTIHCDSS-UHFFFAOYSA-N
DMVRWL6	IU	2-(prop-2-ynylamino)acetic acid
DMVRWL6	CA	CAS 58160-95-5
DMVRWL6	DE	Discovery agent

DMZ1FRS	ID	DMZ1FRS
DMZ1FRS	DN	Propidium
DMZ1FRS	HS	Investigative
DMZ1FRS	SN	PROPIDIUM; 36015-30-2; UNII-74NX23J96Y; CHEBI:51246; 74NX23J96Y; 3,8-DIAMINO-5[3-(DIETHYLMETHYLAMMONIO)PROPYL]-6-PHENYLPHENANTHRIDINIUM; Phenanthridinium, 3,8-diamino-5-(3-(diethylmethylammonio)propyl)-6-phenyl-; 3,8-diamino-5-{3-[diethyl(methyl)ammonio]propyl}-6-phenylphenanthridinium; CHEMBL345124; PRM; Propidium Iodide, 2; AC1Q1IXP; Prestwick1_000792; Prestwick0_000792; Prestwick2_000792; Prestwick3_000792; AC1L1J9Q; CBiol_001968; SCHEMBL55279; BSPBio_000924; KBioSS_000378; KBioGR_000378; BSPBio_001038; SPBio_002863
DMZ1FRS	DT	Small molecular drug
DMZ1FRS	PC	4939
DMZ1FRS	MW	414.6
DMZ1FRS	FM	C27H34N4+2
DMZ1FRS	IC	InChI=1S/C27H33N4/c1-4-31(3,5-2)17-9-16-30-26-19-22(29)13-15-24(26)23-14-12-21(28)18-25(23)27(30)20-10-7-6-8-11-20/h6-8,10-15,18-19,29H,4-5,9,16-17,28H2,1-3H3/q+1/p+1
DMZ1FRS	CS	CC[N+](C)(CC)CCC[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N)N
DMZ1FRS	IK	ZDWVWKDAWBGPDN-UHFFFAOYSA-O
DMZ1FRS	IU	3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propyl-diethyl-methylazanium
DMZ1FRS	CA	CAS 36015-30-2
DMZ1FRS	CB	CHEBI:51246
DMZ1FRS	DE	Discovery agent

DM0O8N6	ID	DM0O8N6
DM0O8N6	DN	Propionate
DM0O8N6	HS	Investigative
DM0O8N6	SN	propanoate; Propanoic acid, ion(1-); propanate; EtCO2 anion; UNII-AKW5EM890C; AKW5EM890C; pseudoacetate; metacetonate; ethanecarboxylate; 1972/3/7; 28488-34-8; CHEMBL500826; NCGC00159468-02; Bugle; Propionate ion; carboxylatoethane; AC1L2XEZ; Sentry Grain Preservative; AC1Q2RL9; CH3-CH2-COO(-); CHEBI:17272; CTK4G1579; DTXSID90222279; XBDQKXXYIPTUBI-UHFFFAOYSA-M; BDBM50257201; STL483862; AKOS015901051; NCGC00159468-03; NCGC00159468-04; CJ-04452; ZB014971; Propanoic acid,neodymium(3+) salt (9CI); LS-190254; 3002-EP2374454A1
DM0O8N6	DT	Small molecular drug
DM0O8N6	PC	104745
DM0O8N6	MW	73.07
DM0O8N6	FM	C3H5O2-
DM0O8N6	IC	InChI=1S/C3H6O2/c1-2-3(4)5/h2H2,1H3,(H,4,5)/p-1
DM0O8N6	CS	CCC(=O)[O-]
DM0O8N6	IK	XBDQKXXYIPTUBI-UHFFFAOYSA-M
DM0O8N6	IU	propanoate
DM0O8N6	CA	CAS 72-03-7
DM0O8N6	CB	CHEBI:17272
DM0O8N6	DE	Discovery agent

DMO325J	ID	DMO325J
DMO325J	DN	Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMO325J	HS	Investigative
DMO325J	SN	CHEMBL310558; Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMO325J	DT	Small molecular drug
DMO325J	PC	44318851
DMO325J	MW	183.25
DMO325J	FM	C10H17NO2
DMO325J	IC	InChI=1S/C10H17NO2/c1-2-10(12)13-9-6-7-4-3-5-8(9)11-7/h7-9,11H,2-6H2,1H3
DMO325J	CS	CCC(=O)OC1CC2CCCC1N2
DMO325J	IK	GSTSHGWHXRRCHO-UHFFFAOYSA-N
DMO325J	IU	8-azabicyclo[3.2.1]octan-6-yl propanoate
DMO325J	DE	Discovery agent

DMZ40RQ	ID	DMZ40RQ
DMZ40RQ	DN	Propyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine
DMZ40RQ	HS	Investigative
DMZ40RQ	SN	CHEMBL80414; 2H-Indazol-5-amine, 4,5,6,7-tetrahydro-N-propyl-; Propyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine; SCHEMBL19048481; BDBM50017539
DMZ40RQ	DT	Small molecular drug
DMZ40RQ	PC	14539719
DMZ40RQ	MW	179.26
DMZ40RQ	FM	C10H17N3
DMZ40RQ	IC	InChI=1S/C10H17N3/c1-2-5-11-9-3-4-10-8(6-9)7-12-13-10/h7,9,11H,2-6H2,1H3,(H,12,13)
DMZ40RQ	CS	CCCNC1CCC2=C(C1)C=NN2
DMZ40RQ	IK	PYXYUOJSCYNCKM-UHFFFAOYSA-N
DMZ40RQ	IU	N-propyl-4,5,6,7-tetrahydro-1H-indazol-5-amine
DMZ40RQ	DE	Discovery agent

DMTCP8K	ID	DMTCP8K
DMTCP8K	DN	propylpyrazoletriol
DMTCP8K	HS	Investigative
DMTCP8K	DT	Small molecular drug
DMTCP8K	PC	5040063
DMTCP8K	MW	386.4
DMTCP8K	FM	C24H22N2O3
DMTCP8K	IC	InChI=1S/C24H22N2O3/c1-2-3-22-23(16-4-10-19(27)11-5-16)25-26(18-8-14-21(29)15-9-18)24(22)17-6-12-20(28)13-7-17/h4-15,27-29H,2-3H2,1H3
DMTCP8K	CS	CCCC1=C(N(N=C1C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
DMTCP8K	IK	IOTXSIGGFRQYKW-UHFFFAOYSA-N
DMTCP8K	IU	4-[2,5-bis(4-hydroxyphenyl)-4-propylpyrazol-3-yl]phenol
DMTCP8K	CA	CAS 263717-53-9
DMTCP8K	CB	CHEBI:64110
DMTCP8K	DE	Discovery agent

DMXCJ7O	ID	DMXCJ7O
DMXCJ7O	DN	Prostacyclin analog
DMXCJ7O	HS	Investigative
DMXCJ7O	SN	Prostacyclin analog (deuterated, pulmonary hypertension)
DMXCJ7O	CP	CoNCERT Pharmaceuticals Inc
DMXCJ7O	DE	Pulmonary hypertension

DMWC4X8	ID	DMWC4X8
DMWC4X8	DN	Prostaglandin A2
DMWC4X8	HS	Investigative
DMWC4X8	SN	medullin; PGA2
DMWC4X8	DT	Small molecular drug
DMWC4X8	PC	5280880
DMWC4X8	MW	334.4
DMWC4X8	FM	C20H30O4
DMWC4X8	IC	InChI=1S/C20H30O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h4,7,12-18,21H,2-3,5-6,8-11H2,1H3,(H,23,24)/b7-4-,14-12+/t16-,17-,18+/m0/s1
DMWC4X8	CS	CCCCC[C@@H](/C=C/[C@H]1C=CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O
DMWC4X8	IK	MYHXHCUNDDAEOZ-FOSBLDSVSA-N
DMWC4X8	IU	(Z)-7-[(1R,2S)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopent-3-en-1-yl]hept-5-enoic acid
DMWC4X8	CA	CAS 13345-50-1
DMWC4X8	CB	CHEBI:27820
DMWC4X8	DE	Discovery agent

DME74SP	ID	DME74SP
DME74SP	DN	Prostaglandin G2
DME74SP	HS	Investigative
DME74SP	SN	prostaglandin G2; PGG2; 51982-36-6; 9S,11R-epidioxy-15S-hydroperoxy-5Z,13E-prostadienoic acid; (5Z)-7-{(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]hept-5-yl}hept-5-enoic acid; Endoperoxide G2; (5Z)-7-{(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]hept-5-yl}hept-5-enoate; GTPL5245; SCHEMBL16782384; CHEBI:27647; SGUKUZOVHSFKPH-YNNPMVKQSA-N; ZINC8220097; MFCD00036971; LMFA03010009; 2013AH; DB03866; C05956; Prostaglandin G2, &gt;=95% (HPLC), acetone solution
DME74SP	DT	Small molecular drug
DME74SP	PC	5280883
DME74SP	MW	368.5
DME74SP	FM	C20H32O6
DME74SP	IC	InChI=1S/C20H32O6/c1-2-3-6-9-15(24-23)12-13-17-16(18-14-19(17)26-25-18)10-7-4-5-8-11-20(21)22/h4,7,12-13,15-19,23H,2-3,5-6,8-11,14H2,1H3,(H,21,22)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
DME74SP	CS	CCCCC[C@@H](/C=C/[C@H]1[C@H]2C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)OO2)OO
DME74SP	IK	SGUKUZOVHSFKPH-YNNPMVKQSA-N
DME74SP	IU	(Z)-7-[(1R,4S,5R,6R)-6-[(E,3S)-3-hydroperoxyoct-1-enyl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
DME74SP	CA	CAS 51982-36-6
DME74SP	CB	CHEBI:27647
DME74SP	DE	Discovery agent

DM9GFOM	ID	DM9GFOM
DM9GFOM	DN	ProstaRex
DM9GFOM	HS	Investigative
DM9GFOM	SN	AIT (prostate cancer), AltaRex; Protate cancer therapy, ViRexx/United Therapeutics; AIT (prostate cancer), ViRexx/United Therapeutics; Anti-idiotype induction therapy (prostate cancer), Paladin; Anti-idiotype induction therapy (prostate cancer), United Therapeutics; Anti-idiotype induction therapy (prostate cancer), AltaRex/United Therapeutics
DM9GFOM	CP	AltaRex Medical Corp
DM9GFOM	DE	Prostate cancer

DMI8SH2	ID	DMI8SH2
DMI8SH2	DN	PROSTEPHABYSSINE
DMI8SH2	HS	Investigative
DMI8SH2	SN	prostephabyssine; CHEMBL1096482
DMI8SH2	DT	Small molecular drug
DMI8SH2	PC	21593990
DMI8SH2	MW	345.4
DMI8SH2	FM	C19H23NO5
DMI8SH2	IC	InChI=1S/C19H23NO5/c1-20-9-8-17-7-6-14(24-3)19(22)18(17,20)10-13(25-19)11-4-5-12(23-2)16(21)15(11)17/h4-6,13,21-22H,7-10H2,1-3H3/t13-,17+,18-,19-/m0/s1
DMI8SH2	CS	CN1CC[C@@]23[C@]14C[C@@H](C5=C2C(=C(C=C5)OC)O)O[C@]4(C(=CC3)OC)O
DMI8SH2	IK	MLEYOIRGICHLGN-PZGXJPJSSA-N
DMI8SH2	IU	(1R,8S,10S,11R)-4,12-dimethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.18,11.01,10.02,7]octadeca-2(7),3,5,12-tetraene-3,11-diol
DMI8SH2	DE	Discovery agent

DM1HMJ5	ID	DM1HMJ5
DM1HMJ5	DN	PROSTRATIN
DM1HMJ5	HS	Investigative
DM1HMJ5	DT	Small molecular drug
DM1HMJ5	PC	454217
DM1HMJ5	MW	390.5
DM1HMJ5	FM	C22H30O6
DM1HMJ5	IC	InChI=1S/C22H30O6/c1-11-6-16-20(26,18(11)25)9-14(10-23)7-15-17-19(4,5)21(17,28-13(3)24)8-12(2)22(15,16)27/h6-7,12,15-17,23,26-27H,8-10H2,1-5H3/t12-,15+,16-,17-,20-,21+,22-/m1/s1
DM1HMJ5	CS	C[C@@H]1C[C@@]2([C@@H](C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)CO)O)C)O)OC(=O)C
DM1HMJ5	IK	BOJKFRKNLSCGHY-HXGSDTCMSA-N
DM1HMJ5	IU	[(1R,2S,6R,10S,11R,13S,15R)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] acetate
DM1HMJ5	CA	CAS 60857-08-1
DM1HMJ5	CB	CHEBI:69818
DM1HMJ5	DE	Human immunodeficiency virus infection

DMWYE7A	ID	DMWYE7A
DMWYE7A	DN	Protoporphyrin IX
DMWYE7A	HS	Investigative
DMWYE7A	SN	protoporphyrin IX; protoporphyrin; 553-12-8; Ooporphyrin; Protoporpyrin IX; Porphyrinogen IX; Protoporphyrin IX disodium; Kammerer's prophyrin; ppIX; Protoporphyrin IX (VAN); H2ppIX; Kammerer's porphyrin; MLS001074731; UNII-C2K325S808; NSC2632; NSC 2632; EINECS 209-033-7; 3,7,12,17-Tetramethyl-8,13-divinyl-2,18-porphinedipropionic acid; SMR000127405; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-diethenyl-3,8,13,17-tetramethyl-; CHEMBL267548; CHEBI:15430; C34H34N4O4
DMWYE7A	DT	Small molecular drug
DMWYE7A	PC	4971
DMWYE7A	MW	562.7
DMWYE7A	FM	C34H34N4O4
DMWYE7A	IC	InChI=1S/C34H34N4O4/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25/h7-8,13-16,35-36H,1-2,9-12H2,3-6H3,(H,39,40)(H,41,42)
DMWYE7A	CS	CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C=C
DMWYE7A	IK	ZCFFYALKHPIRKJ-UHFFFAOYSA-N
DMWYE7A	IU	3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid
DMWYE7A	CA	CAS 553-12-8
DMWYE7A	CB	CHEBI:15430
DMWYE7A	DE	Discovery agent

DMJ8TP3	ID	DMJ8TP3
DMJ8TP3	DN	Protoporphyrin Ix Containing Co
DMJ8TP3	HS	Investigative
DMJ8TP3	SN	protoporphyrin ix containing co; COH; Cobalt protoporphyrin IX (CoPP)
DMJ8TP3	DT	Small molecular drug
DMJ8TP3	PC	4972
DMJ8TP3	MW	619.6
DMJ8TP3	FM	C34H32CoN4O4
DMJ8TP3	IC	InChI=1S/C34H34N4O4.Co/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);/q;+2/p-2
DMJ8TP3	CS	CC1=C(C2=CC3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C(=C3CCC(=O)O)C)CCC(=O)O.[Co+2]
DMJ8TP3	IK	AQTFKGDWFRRIHR-UHFFFAOYSA-L
DMJ8TP3	IU	3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid;cobalt(2+)
DMJ8TP3	DE	Discovery agent

DMI6TKU	ID	DMI6TKU
DMI6TKU	DN	PROTOSTEMODIOL
DMI6TKU	HS	Investigative
DMI6TKU	DT	Small molecular drug
DMI6TKU	PC	24769900
DMI6TKU	MW	435.5
DMI6TKU	FM	C23H33NO7
DMI6TKU	IC	InChI=1S/C23H33NO7/c1-11-10-17(30-22(11)27)14-7-8-15-18(16(25)6-5-9-24(14)15)12(2)19(26)21-20(29-4)13(3)23(28)31-21/h11-12,14-18,25,28H,5-10H2,1-4H3/t11-,12-,14-,15-,16-,17-,18+/m0/s1
DMI6TKU	CS	C[C@H]1C[C@H](OC1=O)[C@@H]2CC[C@@H]3N2CCC[C@@H]([C@@H]3[C@H](C)C(=O)C4=C(C(=C(O4)O)C)OC)O
DMI6TKU	IK	JQDHOVUUTIBLDW-YFIQHYBRSA-N
DMI6TKU	IU	(3S,5S)-5-[(3S,8S,9R,9aS)-8-hydroxy-9-[(2S)-1-(5-hydroxy-3-methoxy-4-methylfuran-2-yl)-1-oxopropan-2-yl]-2,3,5,6,7,8,9,9a-octahydro-1H-pyrrolo[1,2-a]azepin-3-yl]-3-methyloxolan-2-one
DMI6TKU	DE	Discovery agent

DM43ABN	ID	DM43ABN
DM43ABN	DN	Provitamin D3
DM43ABN	HS	Investigative
DM43ABN	SN	Cholesta-5,7-dien-3-ol; Cholesta-5,7-dien-3-ol, (3b)-; Cholesta-5,7-dien-3beta-ol; Dehydrocholesterin; Dehydrocholesterol; Provitamin D3; UCTLRSWJYQTBFZ-DDPQNLDTSA-N; delta5,7-Cholesterol; delta7-Cholesterol; (-)-7-Dehydrocholesterol; (3beta)-Cholesta-5,7-dien-3-ol; 434-16-2; 5,7-Cholestadien-3-beta-ol; 5,7-Cholestandien-3beta-ol; 5,7-cholestadien-3beta-ol; 7,8-Didehydrocholesterol; 7-DHC; 7-Dehydrocholesterin; 7-Dehydrocholesterol; 7-dehydro-cholesterol; CHEBI:17759; NSC 18159; BK1IU07GKF; UNII-BK1IU07GKF
DM43ABN	PC	439423
DM43ABN	MW	384.6
DM43ABN	FM	C27H44O
DM43ABN	IC	UCTLRSWJYQTBFZ-DDPQNLDTSA-N
DM43ABN	CS	CC(C)CCCC(C)C1CCC2C1(CCC3C2=CC=C4C3(CCC(C4)O)C)C
DM43ABN	IK	1S/C27H44O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9-10,18-19,21,23-25,28H,6-8,11-17H2,1-5H3/t19-,21+,23-,24+,25+,26+,27-/m1/s1
DM43ABN	IU	(3S,9S,10R,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DM43ABN	CA	CAS 434-16-2
DM43ABN	CB	CHEBI:17759
DM43ABN	DE	Discovery agent

DM72AT8	ID	DM72AT8
DM72AT8	DN	Proxyfan
DM72AT8	HS	Investigative
DM72AT8	SN	Proxyfan; proxifan; 3-(1H-imidazol-4-yl)propylphenylmethyl ether; 1H-Imidazole, 5-[3-(phenylmethoxy)propyl]-; AC1O4XL1; CHEMBL19173; GTPL1255; SCHEMBL4072620; SCHEMBL15929504; BDBM22915; CHEBI:93359; WNWALBVQAAIULR-UHFFFAOYSA-N; 4-(3-Benzyloxypropyl)-1H-imidazole; ZINC13813304; 5-[3-(benzyloxy)propyl]-1H-imidazole; 5-(3-phenylmethoxypropyl)-1H-imidazole; NCGC00159580-01; 4-[3-(phenylmethoxy)propyl]-3H-imidazole
DM72AT8	DT	Small molecular drug
DM72AT8	PC	6421522
DM72AT8	MW	216.28
DM72AT8	FM	C13H16N2O
DM72AT8	IC	InChI=1S/C13H16N2O/c1-2-5-12(6-3-1)10-16-8-4-7-13-9-14-11-15-13/h1-3,5-6,9,11H,4,7-8,10H2,(H,14,15)
DM72AT8	CS	C1=CC=C(C=C1)COCCCC2=CN=CN2
DM72AT8	IK	WNWALBVQAAIULR-UHFFFAOYSA-N
DM72AT8	IU	5-(3-phenylmethoxypropyl)-1H-imidazole
DM72AT8	CA	CAS 177708-09-7
DM72AT8	CB	CHEBI:93359
DM72AT8	DE	Discovery agent

DMKRMSP	ID	DMKRMSP
DMKRMSP	DN	Pr-RYYRIK-NH2
DMKRMSP	HS	Investigative
DMKRMSP	SN	CHEMBL403807
DMKRMSP	DT	Small molecular drug
DMKRMSP	PC	44456220
DMKRMSP	MW	937.1
DMKRMSP	FM	C45H72N14O8
DMKRMSP	IC	InChI=1S/C45H72N14O8/c1-4-27(3)37(43(67)55-31(38(47)62)15-9-10-22-46)59-40(64)33(17-12-24-53-45(50)51)56-41(65)35(26-29-18-20-30(60)21-19-29)58-42(66)34(25-28-13-7-6-8-14-28)57-39(63)32(54-36(61)5-2)16-11-23-52-44(48)49/h6-8,13-14,18-21,27,31-35,37,60H,4-5,9-12,15-17,22-26,46H2,1-3H3,(H2,47,62)(H,54,61)(H,55,67)(H,56,65)(H,57,63)(H,58,66)(H,59,64)(H4,48,49,52)(H4,50,51,53)/t27-,31-,32-,33-,34-,35-,37-/m0/s1
DMKRMSP	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CC
DMKRMSP	IK	DWZCXYUZSXSRCU-OQYWAUBWSA-N
DMKRMSP	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(propanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMKRMSP	DE	Discovery agent

DM8GCHX	ID	DM8GCHX
DM8GCHX	DN	PRS-060
DM8GCHX	HS	Investigative
DM8GCHX	SN	IL-4 alpha receptor inhibitor (Anticalin, asthma), Pieris; IL-4R alpha inhibitor (Anticalin, asthma), Pieris
DM8GCHX	CP	Pieris AG
DM8GCHX	DE	Asthma

DMB923H	ID	DMB923H
DMB923H	DN	PRS-110
DMB923H	HS	Investigative
DMB923H	SN	C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG
DMB923H	CP	Pieris AG
DMB923H	DE	Solid tumour/cancer

DM25EDB	ID	DM25EDB
DM25EDB	DN	PRT-060096
DM25EDB	HS	Investigative
DM25EDB	SN	PRT-060280; PRT-060288; PRT-060289; PRT-060392; PRT-060592; PRT-060674; PRT-061105; PRT-061106; PRT-061110; PRT-061171; Non-sulfonylurea P2Y12 antagonists (cardiovascular disease); Non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola
DM25EDB	CP	Portola Pharmaceuticals Inc
DM25EDB	DE	Cardiovascular disease

DMQPEA7	ID	DMQPEA7
DMQPEA7	DN	PRT-060318
DMQPEA7	HS	Investigative
DMQPEA7	SN	PRT-318; Syk inhibitor (oral, heparin-induced thrombocytopenia), Portola
DMQPEA7	CP	Portola Pharmaceuticals Inc
DMQPEA7	PC	11493841
DMQPEA7	MW	340.4
DMQPEA7	FM	C18H24N6O
DMQPEA7	IC	InChI=1S/C18H24N6O/c1-11-5-4-6-12(9-11)22-17-13(16(20)25)10-21-18(24-17)23-15-8-3-2-7-14(15)19/h4-6,9-10,14-15H,2-3,7-8,19H2,1H3,(H2,20,25)(H2,21,22,23,24)/t14-,15+/m0/s1
DMQPEA7	CS	CC1=CC(=CC=C1)NC2=NC(=NC=C2C(=O)N)N[C@@H]3CCCC[C@@H]3N
DMQPEA7	IK	NZNTWOVDIXCHHS-LSDHHAIUSA-N
DMQPEA7	IU	2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-(3-methylanilino)pyrimidine-5-carboxamide
DMQPEA7	DE	Thrombosis

DMOVE31	ID	DMOVE31
DMOVE31	DN	PRT-064445
DMOVE31	HS	Investigative
DMOVE31	SN	Anticoagulant antidote (bleeding), Portola; Factor Xa inhibitor antidote (bleeding), Portola
DMOVE31	CP	Portola Pharmaceuticals Inc
DMOVE31	DE	Bleeding disorder

DMPD41Q	ID	DMPD41Q
DMPD41Q	DN	prunetin
DMPD41Q	HS	Investigative
DMPD41Q	SN	4',5-dihydroxy-7-methoxyisoflavone
DMPD41Q	DT	Small molecular drug
DMPD41Q	PC	5281804
DMPD41Q	MW	284.26
DMPD41Q	FM	C16H12O5
DMPD41Q	IC	InChI=1S/C16H12O5/c1-20-11-6-13(18)15-14(7-11)21-8-12(16(15)19)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3
DMPD41Q	CS	COC1=CC(=C2C(=C1)OC=C(C2=O)C3=CC=C(C=C3)O)O
DMPD41Q	IK	KQMVAGISDHMXJJ-UHFFFAOYSA-N
DMPD41Q	IU	5-hydroxy-3-(4-hydroxyphenyl)-7-methoxychromen-4-one
DMPD41Q	CA	CAS 552-59-0
DMPD41Q	CB	CHEBI:8600
DMPD41Q	DE	Discovery agent

DMSPH30	ID	DMSPH30
DMSPH30	DN	PRX-111
DMSPH30	HS	Investigative
DMSPH30	SN	FSH variants (female infertility), Protalix Biotherapeutics/ Compugen; Follicle stimulating hormone variants (female infertility), Protalix Biotherapeutics/ Compugen
DMSPH30	CP	Protalix BioTherapeutics Inc
DMSPH30	DE	Female infertility

DMK6HMS	ID	DMK6HMS
DMK6HMS	DN	PS020990
DMK6HMS	HS	Investigative
DMK6HMS	SN	PS020990; GTPL660
DMK6HMS	DT	Small molecular drug
DMK6HMS	PC	20814785
DMK6HMS	MW	578.5
DMK6HMS	FM	C30H33Cl2N7O
DMK6HMS	IC	InChI=1S/C30H33Cl2N7O/c31-24-11-9-22(10-12-24)18-34-29(40)26(16-21-5-2-1-3-6-21)36-27-17-28(39-14-13-33-20-39)38-30(37-27)35-19-23-7-4-8-25(32)15-23/h4,7-15,17,20-21,26H,1-3,5-6,16,18-19H2,(H,34,40)(H2,35,36,37,38)
DMK6HMS	CS	C1CCC(CC1)CC(C(=O)NCC2=CC=C(C=C2)Cl)NC3=CC(=NC(=N3)NCC4=CC(=CC=C4)Cl)N5C=CN=C5
DMK6HMS	IK	HIENPNTVAACRGD-UHFFFAOYSA-N
DMK6HMS	IU	N-[(4-chlorophenyl)methyl]-2-[[2-[(3-chlorophenyl)methylamino]-6-imidazol-1-ylpyrimidin-4-yl]amino]-3-cyclohexylpropanamide
DMK6HMS	DE	Discovery agent

DMVUMWZ	ID	DMVUMWZ
DMVUMWZ	DN	PS-1145
DMVUMWZ	HS	Investigative
DMVUMWZ	SN	PS-1145; 431898-65-6; PS 1145; CHEMBL79004; N-(6-Chloro-9H-beta-carbolin-8-yl)-nicotinamide; MLS006010310; ZINC9090; SCHEMBL1420453; CTK1D2755; KS-00000TTM; CHEBI:94801; DTXSID00433238; EX-A786; MolPort-042-665-715; JZRMBDHPALEPDM-UHFFFAOYSA-N; HMS3229F21; BCP24095; s7691; BDBM50130248; AKOS030526812; CS-5415; ACN-053038; NCGC00165873-02; NCGC00165873-01; SMR004701376; HY-18008; AK547800; FT-0700478; J-690297; BRD-K93023739-001-02-9; N-{6-chloro-9H-pyrido[3,4-b]indol-8-yl}pyridine-3-carboxamide
DMVUMWZ	CP	Takeda
DMVUMWZ	DT	Small molecular drug
DMVUMWZ	PC	9949093
DMVUMWZ	MW	322.7
DMVUMWZ	FM	C17H11ClN4O
DMVUMWZ	IC	InChI=1S/C17H11ClN4O/c18-11-6-13-12-3-5-20-9-15(12)21-16(13)14(7-11)22-17(23)10-2-1-4-19-8-10/h1-9,21H,(H,22,23)
DMVUMWZ	CS	C1=CC(=CN=C1)C(=O)NC2=CC(=CC3=C2NC4=C3C=CN=C4)Cl
DMVUMWZ	IK	JZRMBDHPALEPDM-UHFFFAOYSA-N
DMVUMWZ	IU	N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)pyridine-3-carboxamide
DMVUMWZ	CA	CAS 431898-65-6
DMVUMWZ	CB	CHEBI:94801
DMVUMWZ	DE	Multiple myeloma

DMQUG0K	ID	DMQUG0K
DMQUG0K	DN	PS-154636-1
DMQUG0K	HS	Investigative
DMQUG0K	SN	PS-154636-2
DMQUG0K	DT	Small molecular drug
DMQUG0K	PC	44314268
DMQUG0K	MW	561.7
DMQUG0K	FM	C32H39N3O6
DMQUG0K	IC	InChI=1S/C32H39N3O6/c1-4-5-18-33-29(37)21-27(36)26(19-22-12-8-6-9-13-22)34-32(39)30(23-14-10-7-11-15-23)35-31(38)25-17-16-24(40-2)20-28(25)41-3/h6-17,20,26-27,30,36H,4-5,18-19,21H2,1-3H3,(H,33,37)(H,34,39)(H,35,38)/t26?,27?,30-/m0/s1
DMQUG0K	CS	CCCCNC(=O)CC(C(CC1=CC=CC=C1)NC(=O)[C@H](C2=CC=CC=C2)NC(=O)C3=C(C=C(C=C3)OC)OC)O
DMQUG0K	IK	SXBWRHFAOQVOPG-VSBJFVJKSA-N
DMQUG0K	IU	N-[(1S)-2-[[5-(butylamino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino]-2-oxo-1-phenylethyl]-2,4-dimethoxybenzamide
DMQUG0K	DE	Discovery agent

DMQVI5U	ID	DMQVI5U
DMQVI5U	DN	PS-222036
DMQVI5U	HS	Investigative
DMQVI5U	PC	44327926
DMQVI5U	MW	552.7
DMQVI5U	FM	C32H48N4O4
DMQVI5U	IC	InChI=1S/C32H48N4O4/c1-6-23(4)30(36-31(39)26-16-14-25(15-17-26)21-33-5)32(40)35-27(19-22(2)3)28(37)20-29(38)34-18-10-13-24-11-8-7-9-12-24/h7-9,11-12,14-17,22-23,27-28,30,33,37H,6,10,13,18-21H2,1-5H3,(H,34,38)(H,35,40)(H,36,39)
DMQVI5U	CS	CCC(C)C(C(=O)NC(CC(C)C)C(CC(=O)NCCCC1=CC=CC=C1)O)NC(=O)C2=CC=C(C=C2)CNC
DMQVI5U	IK	POMPAVNXKGHLHK-UHFFFAOYSA-N
DMQVI5U	IU	N-[1-[[3-hydroxy-6-methyl-1-oxo-1-(3-phenylpropylamino)heptan-4-yl]amino]-3-methyl-1-oxopentan-2-yl]-4-(methylaminomethyl)benzamide
DMQVI5U	DE	Discovery agent

DMH8YMP	ID	DMH8YMP
DMH8YMP	DN	PS-444035
DMH8YMP	HS	Investigative
DMH8YMP	SN	CHEMBL74943; PS-444035; BDBM50071556
DMH8YMP	DT	Small molecular drug
DMH8YMP	PC	44314383
DMH8YMP	MW	564.8
DMH8YMP	FM	C33H48N4O4
DMH8YMP	IC	InChI=1S/C33H48N4O4/c1-4-6-18-34-30(39)22-29(38)28(21-25-12-8-7-9-13-25)35-33(41)31(24(3)5-2)36-32(40)27-16-14-26(15-17-27)23-37-19-10-11-20-37/h7-9,12-17,24,28-29,31,38H,4-6,10-11,18-23H2,1-3H3,(H,34,39)(H,35,41)(H,36,40)/t24-,28?,29?,31-/m0/s1
DMH8YMP	CS	CCCCNC(=O)CC(C(CC1=CC=CC=C1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)C2=CC=C(C=C2)CN3CCCC3)O
DMH8YMP	IK	XZUGYLKCDURJSJ-GBIMTFRJSA-N
DMH8YMP	IU	N-[(2S,3S)-1-[[5-(butylamino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]-4-(pyrrolidin-1-ylmethyl)benzamide
DMH8YMP	DE	Discovery agent

DMT4YFR	ID	DMT4YFR
DMT4YFR	DN	PS-662477
DMT4YFR	HS	Investigative
DMT4YFR	SN	CHEMBL74562; PS-662477; BDBM50071550
DMT4YFR	DT	Small molecular drug
DMT4YFR	PC	44314223
DMT4YFR	MW	541.7
DMT4YFR	FM	C30H43N3O6
DMT4YFR	IC	InChI=1S/C30H43N3O6/c1-6-8-16-31-27(35)19-25(34)24(17-21-12-10-9-11-13-21)32-30(37)28(20(3)7-2)33-29(36)23-15-14-22(38-4)18-26(23)39-5/h9-15,18,20,24-25,28,34H,6-8,16-17,19H2,1-5H3,(H,31,35)(H,32,37)(H,33,36)/t20-,24?,25?,28-/m0/s1
DMT4YFR	CS	CCCCNC(=O)CC(C(CC1=CC=CC=C1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)C2=C(C=C(C=C2)OC)OC)O
DMT4YFR	IK	BLKHGZANZRGYRY-WUCHSTEBSA-N
DMT4YFR	IU	N-[(2S,3S)-1-[[5-(butylamino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]-2,4-dimethoxybenzamide
DMT4YFR	DE	Discovery agent

DM05DOF	ID	DM05DOF
DM05DOF	DN	PS-725074
DM05DOF	HS	Investigative
DM05DOF	SN	CHEMBL427946; PS-725074; BDBM50071551
DM05DOF	DT	Small molecular drug
DM05DOF	PC	44314315
DM05DOF	MW	527.7
DM05DOF	FM	C29H41N3O6
DM05DOF	IC	InChI=1S/C29H41N3O6/c1-6-7-15-30-26(34)18-24(33)23(16-20-11-9-8-10-12-20)31-29(36)27(19(2)3)32-28(35)22-14-13-21(37-4)17-25(22)38-5/h8-14,17,19,23-24,27,33H,6-7,15-16,18H2,1-5H3,(H,30,34)(H,31,36)(H,32,35)/t23?,24?,27-/m0/s1
DM05DOF	CS	CCCCNC(=O)CC(C(CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)NC(=O)C2=C(C=C(C=C2)OC)OC)O
DM05DOF	IK	FRRUPPDKKTVORB-CXTIUDGFSA-N
DM05DOF	IU	N-[(2S)-1-[[5-(butylamino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-2,4-dimethoxybenzamide
DM05DOF	DE	Discovery agent

DM3F7SD	ID	DM3F7SD
DM3F7SD	DN	PS-777621
DM3F7SD	HS	Investigative
DM3F7SD	SN	PS-777621; CHEMBL318055; BDBM50146527; (S)-3-(S)-Hydroxy-6-methyl-4-{(S)-3-methyl-2-[2-(naphthalen-2-yloxy)-acetylamino]-pentanoylamino}-heptanoic acid butylamide
DM3F7SD	DT	Small molecular drug
DM3F7SD	PC	44330683
DM3F7SD	MW	527.7
DM3F7SD	FM	C30H45N3O5
DM3F7SD	IC	InChI=1S/C30H45N3O5/c1-6-8-15-31-27(35)18-26(34)25(16-20(3)4)32-30(37)29(21(5)7-2)33-28(36)19-38-24-14-13-22-11-9-10-12-23(22)17-24/h9-14,17,20-21,25-26,29,34H,6-8,15-16,18-19H2,1-5H3,(H,31,35)(H,32,37)(H,33,36)/t21?,25-,26-,29-/m0/s1
DM3F7SD	CS	CCCCNC(=O)C[C@@H]([C@H](CC(C)C)NC(=O)[C@H](C(C)CC)NC(=O)COC1=CC2=CC=CC=C2C=C1)O
DM3F7SD	IK	ZOZZWZVOMAKBJD-BGRUSPQTSA-N
DM3F7SD	IU	(3S,4S)-N-butyl-3-hydroxy-6-methyl-4-[[(2S)-3-methyl-2-[(2-naphthalen-2-yloxyacetyl)amino]pentanoyl]amino]heptanamide
DM3F7SD	DE	Discovery agent

DM38JMK	ID	DM38JMK
DM38JMK	DN	PSAB-OFP
DM38JMK	HS	Investigative
DM38JMK	SN	PSAB-OFP; CHEMBL195345; SCHEMBL2184386; GTPL3968; BDBM50173944; 5''-phenyl-(2''R)-spiro[4-azabicyclo[2.2.2]octane-2,2''-furo[2,3-b]pyridine]
DM38JMK	DT	Small molecular drug
DM38JMK	PC	16727408
DM38JMK	MW	292.4
DM38JMK	FM	C19H20N2O
DM38JMK	IC	InChI=1S/C19H20N2O/c1-2-4-14(5-3-1)16-10-15-11-19(22-18(15)20-12-16)13-21-8-6-17(19)7-9-21/h1-5,10,12,17H,6-9,11,13H2/t19-/m0/s1
DM38JMK	CS	C1CN2CCC1[C@@]3(C2)CC4=C(O3)N=CC(=C4)C5=CC=CC=C5
DM38JMK	IK	GIRLVGYIIVFTLI-IBGZPJMESA-N
DM38JMK	IU	(3R)-5'-phenylspiro[1-azabicyclo[2.2.2]octane-3,2'-3H-furo[2,3-b]pyridine]
DM38JMK	DE	Discovery agent

DM6T0IQ	ID	DM6T0IQ
DM6T0IQ	DN	PSAMMAPLIN A
DM6T0IQ	HS	Investigative
DM6T0IQ	SN	Psammaplin A; 110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-
DM6T0IQ	DT	Small molecular drug
DM6T0IQ	PC	6400741
DM6T0IQ	MW	664.4
DM6T0IQ	FM	C22H24Br2N4O6S2
DM6T0IQ	IC	InChI=1S/C22H24Br2N4O6S2/c23-15-9-13(1-3-19(15)29)11-17(27-33)21(31)25-5-7-35-36-8-6-26-22(32)18(28-34)12-14-2-4-20(30)16(24)10-14/h1-4,9-10,29-30,33-34H,5-8,11-12H2,(H,25,31)(H,26,32)/b27-17+,28-18+
DM6T0IQ	CS	C1=CC(=C(C=C1C/C(=N\\O)/C(=O)NCCSSCCNC(=O)/C(=N/O)/CC2=CC(=C(C=C2)O)Br)Br)O
DM6T0IQ	IK	LMAFSGDNHVBIHU-XUIWWLCJSA-N
DM6T0IQ	IU	(2E)-3-(3-bromo-4-hydroxyphenyl)-N-[2-[2-[[(2E)-3-(3-bromo-4-hydroxyphenyl)-2-hydroxyiminopropanoyl]amino]ethyldisulfanyl]ethyl]-2-hydroxyiminopropanamide
DM6T0IQ	CA	CAS 110659-91-1
DM6T0IQ	DE	Discovery agent

DMLAFJE	ID	DMLAFJE
DMLAFJE	DN	PSB-0702
DMLAFJE	HS	Investigative
DMLAFJE	SN	CHEMBL502519
DMLAFJE	DT	Small molecular drug
DMLAFJE	PC	44157521
DMLAFJE	MW	551.5
DMLAFJE	FM	C27H18N3NaO7S
DMLAFJE	IC	InChI=1S/C27H19N3O7S.Na/c28-24-18(27(33)34)13-20(22-23(24)26(32)17-9-5-4-8-16(17)25(22)31)30-15-10-11-19(21(12-15)38(35,36)37)29-14-6-2-1-3-7-14;/h1-13,29-30H,28H2,(H,33,34)(H,35,36,37);/q;+1/p-1
DMLAFJE	CS	C1=CC=C(C=C1)NC2=C(C=C(C=C2)NC3=C4C(=C(C(=C3)C(=O)O)N)C(=O)C5=CC=CC=C5C4=O)S(=O)(=O)[O-].[Na+]
DMLAFJE	IK	PZRXTTYJQMKSRF-UHFFFAOYSA-M
DMLAFJE	IU	sodium;5-[(4-amino-3-carboxy-9,10-dioxoanthracen-1-yl)amino]-2-anilinobenzenesulfonate
DMLAFJE	DE	Discovery agent

DM3AZPD	ID	DM3AZPD
DM3AZPD	DN	PSB-0739
DM3AZPD	HS	Investigative
DM3AZPD	SN	PSB 0739; PSB-0739; GTPL5904; sodium 1-amino-9,10-dioxo-4-{[4-(phenylamino)-3-[(sodiooxy)sulfonyl]phenyl]amino}-9,10-dihydroanthracene-2-sulfonate
DM3AZPD	DT	Small molecular drug
DM3AZPD	PC	44583582
DM3AZPD	MW	609.5
DM3AZPD	FM	C26H17N3Na2O8S2
DM3AZPD	IC	InChI=1S/C26H19N3O8S2.2Na/c27-24-21(39(35,36)37)13-19(22-23(24)26(31)17-9-5-4-8-16(17)25(22)30)29-15-10-11-18(20(12-15)38(32,33)34)28-14-6-2-1-3-7-14;;/h1-13,28-29H,27H2,(H,32,33,34)(H,35,36,37);;/q;2*+1/p-2
DM3AZPD	CS	C1=CC=C(C=C1)NC2=C(C=C(C=C2)NC3=CC(=C(C4=C3C(=O)C5=CC=CC=C5C4=O)N)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+]
DM3AZPD	IK	QBLLYXXXOJUNCV-UHFFFAOYSA-L
DM3AZPD	IU	disodium;1-amino-4-(4-anilino-3-sulfonatoanilino)-9,10-dioxoanthracene-2-sulfonate
DM3AZPD	DE	Discovery agent

DM0FKV9	ID	DM0FKV9
DM0FKV9	DN	PSB-0788
DM0FKV9	HS	Investigative
DM0FKV9	SN	PSB 0788; PSB-0788; CHEMBL482436; 1027513-54-7; GTPL6561; SCHEMBL16099412; PSB0788; MolPort-023-276-691; ZINC49867711; BDBM50268129; AKOS024457473; B7313; J-000778; 8-(4-(4-(4-chlorobenzyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine; 8-[4-[4-(4-Chlorobenzyl)piperazide-1-sulfonyl)phenyl]]-1-propylxanthine; 8-(4-(4-(4-chlorobenzyl)piperazin-1-ylsulfonyl)phenyl)-1-propyl-1H-purine-2,6(3H,7H)-dione
DM0FKV9	DT	Small molecular drug
DM0FKV9	PC	44186581
DM0FKV9	MW	543
DM0FKV9	FM	C25H27ClN6O4S
DM0FKV9	IC	InChI=1S/C25H27ClN6O4S/c1-2-11-32-24(33)21-23(29-25(32)34)28-22(27-21)18-5-9-20(10-6-18)37(35,36)31-14-12-30(13-15-31)16-17-3-7-19(26)8-4-17/h3-10H,2,11-16H2,1H3,(H,27,28)(H,29,34)
DM0FKV9	CS	CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=C(C=C3)S(=O)(=O)N4CCN(CC4)CC5=CC=C(C=C5)Cl
DM0FKV9	IK	JQZJACVYMPKVDS-UHFFFAOYSA-N
DM0FKV9	IU	8-[4-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]sulfonylphenyl]-1-propyl-3,7-dihydropurine-2,6-dione
DM0FKV9	DE	Discovery agent

DMAFHLX	ID	DMAFHLX
DMAFHLX	DN	PSB-09120
DMAFHLX	HS	Investigative
DMAFHLX	SN	CHEMBL486478; PSB-09120; BDBM50268151
DMAFHLX	DT	Small molecular drug
DMAFHLX	PC	44186666
DMAFHLX	MW	562.6
DMAFHLX	FM	C25H25F3N6O4S
DMAFHLX	IC	InChI=1S/C25H25F3N6O4S/c1-2-34-23(35)20-22(31-24(34)36)30-21(29-20)17-5-9-19(10-6-17)39(37,38)33-13-11-32(12-14-33)15-16-3-7-18(8-4-16)25(26,27)28/h3-10H,2,11-15H2,1H3,(H,29,30)(H,31,36)
DMAFHLX	CS	CCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=C(C=C3)S(=O)(=O)N4CCN(CC4)CC5=CC=C(C=C5)C(F)(F)F
DMAFHLX	IK	PGUVAKMIEAFDEA-UHFFFAOYSA-N
DMAFHLX	IU	1-ethyl-8-[4-[4-[[4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]sulfonylphenyl]-3,7-dihydropurine-2,6-dione
DMAFHLX	DE	Discovery agent

DMW19LB	ID	DMW19LB
DMW19LB	DN	PSB-0952
DMW19LB	HS	Investigative
DMW19LB	SN	CHEMBL590956
DMW19LB	DT	Small molecular drug
DMW19LB	PC	45141593
DMW19LB	MW	478.4
DMW19LB	FM	C21H12FN2NaO7S
DMW19LB	IC	InChI=1S/C21H13FN2O7S.Na/c22-9-5-6-13(12(7-9)21(27)28)24-14-8-15(32(29,30)31)18(23)17-16(14)19(25)10-3-1-2-4-11(10)20(17)26;/h1-8,24H,23H2,(H,27,28)(H,29,30,31);/q;+1/p-1
DMW19LB	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3NC4=C(C=C(C=C4)F)C(=O)O)S(=O)(=O)[O-])N.[Na+]
DMW19LB	IK	MRYMOKKNOJHNGA-UHFFFAOYSA-M
DMW19LB	IU	sodium;1-amino-4-(2-carboxy-4-fluoroanilino)-9,10-dioxoanthracene-2-sulfonate
DMW19LB	DE	Discovery agent

DMBDVJ1	ID	DMBDVJ1
DMBDVJ1	DN	PSB-0963
DMBDVJ1	HS	Investigative
DMBDVJ1	SN	PSB-0963
DMBDVJ1	DT	Small molecular drug
DMBDVJ1	PC	91934096
DMBDVJ1	MW	493.5
DMBDVJ1	FM	C28H17N2O5S-
DMBDVJ1	IC	InChI=1S/C28H18N2O5S/c29-26-23(36(33,34)35)14-22(24-25(26)28(32)21-8-4-3-7-20(21)27(24)31)30-19-10-9-17-11-15-5-1-2-6-16(15)12-18(17)13-19/h1-14,30H,29H2,(H,33,34,35)/p-1
DMBDVJ1	CS	C1=CC=C2C=C3C=C(C=CC3=CC2=C1)NC4=CC(=C(C5=C4C(=O)C6=CC=CC=C6C5=O)N)S(=O)(=O)[O-]
DMBDVJ1	IK	JXFRJOYKTCEJDG-UHFFFAOYSA-M
DMBDVJ1	IU	1-amino-4-(anthracen-2-ylamino)-9,10-dioxoanthracene-2-sulfonate
DMBDVJ1	DE	Discovery agent

DMXDWO7	ID	DMXDWO7
DMXDWO7	DN	PSB-10
DMXDWO7	HS	Investigative
DMXDWO7	DT	Small molecular drug
DMXDWO7	PC	135401232
DMXDWO7	MW	398.7
DMXDWO7	FM	C16H14Cl3N5O
DMXDWO7	IC	InChI=1S/C16H14Cl3N5O/c1-3-8-6-24-15(20-8)12-14(23(2)16(24)25)22-13(21-12)9-4-7(17)5-10(18)11(9)19/h4-5,8,20H,3,6H2,1-2H3/t8-/m1/s1
DMXDWO7	CS	CC[C@@H]1CN2C(=C3C(=NC(=N3)C4=C(C(=CC(=C4)Cl)Cl)Cl)N(C2=O)C)N1
DMXDWO7	IK	QYCXKYOTLRUVFA-MRVPVSSYSA-N
DMXDWO7	IU	(8R)-8-ethyl-4-methyl-2-(2,3,5-trichlorophenyl)-8,9-dihydro-7H-imidazo[2,1-f]purin-5-one
DMXDWO7	DE	Discovery agent

DMGK2PC	ID	DMGK2PC
DMGK2PC	DN	PSB-11
DMGK2PC	HS	Investigative
DMGK2PC	DT	Small molecular drug
DMGK2PC	PC	135433658
DMGK2PC	MW	295.34
DMGK2PC	FM	C16H17N5O
DMGK2PC	IC	InChI=1S/C16H17N5O/c1-3-11-9-21-15(17-11)12-14(20(2)16(21)22)19-13(18-12)10-7-5-4-6-8-10/h4-8,11,17H,3,9H2,1-2H3/t11-/m1/s1
DMGK2PC	CS	CC[C@@H]1CN2C(=C3C(=NC(=N3)C4=CC=CC=C4)N(C2=O)C)N1
DMGK2PC	IK	XNWDEMWJNJVCBD-LLVKDONJSA-N
DMGK2PC	IU	(8R)-8-ethyl-4-methyl-2-phenyl-8,9-dihydro-7H-imidazo[2,1-f]purin-5-one
DMGK2PC	CB	CHEBI:92180
DMGK2PC	DE	Discovery agent

DMR9HYI	ID	DMR9HYI
DMR9HYI	DN	PSB1114
DMR9HYI	HS	Investigative
DMR9HYI	SN	PSB-1114; PSB 1114
DMR9HYI	DT	Small molecular drug
DMR9HYI	PC	52952605
DMR9HYI	MW	534.22
DMR9HYI	FM	C10H15F2N2O13P3S
DMR9HYI	IC	InChI=1S/C10H15F2N2O13P3S/c11-10(12,28(18,19)20)29(21,22)27-30(23,24)25-3-4-6(15)7(16)8(26-4)14-2-1-5(31)13-9(14)17/h1-2,4,6-8,15-16H,3H2,(H,21,22)(H,23,24)(H,13,17,31)(H2,18,19,20)/t4-,6-,7-,8-/m1/s1
DMR9HYI	CS	C1=CN(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(C(F)(F)P(=O)(O)O)O)O)O
DMR9HYI	IK	DFGBPSGNGNHNQM-XVFCMESISA-N
DMR9HYI	IU	[[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-oxo-4-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-difluoromethyl]phosphonic acid
DMR9HYI	DE	Discovery agent

DMOH2VC	ID	DMOH2VC
DMOH2VC	DN	PSB-1115
DMOH2VC	HS	Investigative
DMOH2VC	SN	PSB 1115; 152529-79-8; PSB-1115; CHEMBL8565; 4-(2,6-Dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-benzenesulfonic acid; 4-(2,3,6,7-TETRAHYDRO-2,6-DIOXO-1-PROPYL-1H-PURIN-8-YL)-BENZENESULFONIC ACID; 4-(2,6-dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)benzenesulfonic acid; 1-propyl-8-p-sulfophenylxanthine; PSB1115; AC1NSKPC; Tocris-2009; compound 17 [PMID: 11906291]; GTPL3286; SCHEMBL1223271; CHEBI:92848; DTXSID80415532; MolPort-003-983-852; ZINC3995486; 1-Propyl-8-(p-sulfophenyl)xanthine; BN0664; BDBM50042209
DMOH2VC	DT	Small molecular drug
DMOH2VC	PC	5311479
DMOH2VC	MW	350.35
DMOH2VC	FM	C14H14N4O5S
DMOH2VC	IC	InChI=1S/C14H14N4O5S/c1-2-7-18-13(19)10-12(17-14(18)20)16-11(15-10)8-3-5-9(6-4-8)24(21,22)23/h3-6H,2,7H2,1H3,(H,15,16)(H,17,20)(H,21,22,23)
DMOH2VC	CS	CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=C(C=C3)S(=O)(=O)O
DMOH2VC	IK	UYDRRQPGDSIMNU-UHFFFAOYSA-N
DMOH2VC	IU	4-(2,6-dioxo-1-propyl-3,7-dihydropurin-8-yl)benzenesulfonic acid
DMOH2VC	CA	CAS 152529-79-8
DMOH2VC	CB	CHEBI:92848
DMOH2VC	DE	Discovery agent

DMBGM1E	ID	DMBGM1E
DMBGM1E	DN	PSB36
DMBGM1E	HS	Investigative
DMBGM1E	SN	PSB-36
DMBGM1E	DT	Small molecular drug
DMBGM1E	PC	11689583
DMBGM1E	MW	386.5
DMBGM1E	FM	C21H30N4O3
DMBGM1E	IC	InChI=1S/C21H30N4O3/c1-2-3-5-25-18(27)16-17(24(20(25)28)6-4-7-26)23-19(22-16)21-11-13-8-14(12-21)10-15(21)9-13/h13-15,26H,2-12H2,1H3,(H,22,23)
DMBGM1E	CS	CCCCN1C(=O)C2=C(N=C(N2)C34CC5CC(C3)CC4C5)N(C1=O)CCCO
DMBGM1E	IK	CIBIXJYFYPFMTN-UHFFFAOYSA-N
DMBGM1E	IU	1-butyl-3-(3-hydroxypropyl)-8-(3-tricyclo[3.3.1.03,7]nonanyl)-7H-purine-2,6-dione
DMBGM1E	CA	CAS 524944-72-7
DMBGM1E	CB	CHEBI:91832
DMBGM1E	DE	Discovery agent

DMBIK7D	ID	DMBIK7D
DMBIK7D	DN	PSB-601
DMBIK7D	HS	Investigative
DMBIK7D	SN	CHEMBL212625; PSB-601; MolPort-003-983-848; BN0659; BDBM50190709; ZINC35923133; 8-[4-(4-benzylpiperazide-1-sulfonyl)phenyl]-1-propylxanthine
DMBIK7D	DT	Small molecular drug
DMBIK7D	PC	11605883
DMBIK7D	MW	508.6
DMBIK7D	FM	C25H28N6O4S
DMBIK7D	IC	InChI=1S/C25H28N6O4S/c1-2-12-31-24(32)21-23(28-25(31)33)27-22(26-21)19-8-10-20(11-9-19)36(34,35)30-15-13-29(14-16-30)17-18-6-4-3-5-7-18/h3-11H,2,12-17H2,1H3,(H,26,27)(H,28,33)
DMBIK7D	CS	CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=C(C=C3)S(=O)(=O)N4CCN(CC4)CC5=CC=CC=C5
DMBIK7D	IK	HHNGYTVWOXXKET-UHFFFAOYSA-N
DMBIK7D	IU	8-[4-(4-benzylpiperazin-1-yl)sulfonylphenyl]-1-propyl-3,7-dihydropurine-2,6-dione
DMBIK7D	DE	Discovery agent

DM6QERS	ID	DM6QERS
DM6QERS	DN	PSB603
DM6QERS	HS	Investigative
DM6QERS	SN	OVHCTHHFOHMNFV-UHFFFAOYSA-N; PSB 603; PSB-603; CHEMBL483688; 1092351-10-4; [3H]PSB603; 8-{4-[4-(4-chlorophenyl)piperazine-1-sulfonyl]phenyl}-1-propyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; GTPL3284; GTPL5728; SCHEMBL17387706; CTK8G2646; MolPort-023-276-690; ZINC49872110; BDBM50268232; AKOS024457472; PSB-603, &gt
DM6QERS	DT	Small molecular drug
DM6QERS	PC	44185871
DM6QERS	MW	529
DM6QERS	FM	C24H25ClN6O4S
DM6QERS	IC	InChI=1S/C24H25ClN6O4S/c1-2-11-31-23(32)20-22(28-24(31)33)27-21(26-20)16-3-9-19(10-4-16)36(34,35)30-14-12-29(13-15-30)18-7-5-17(25)6-8-18/h3-10H,2,11-15H2,1H3,(H,26,27)(H,28,33)
DM6QERS	CS	CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=C(C=C3)S(=O)(=O)N4CCN(CC4)C5=CC=C(C=C5)Cl
DM6QERS	IK	OVHCTHHFOHMNFV-UHFFFAOYSA-N
DM6QERS	IU	8-[4-[4-(4-chlorophenyl)piperazin-1-yl]sulfonylphenyl]-1-propyl-3,7-dihydropurine-2,6-dione
DM6QERS	DE	Discovery agent

DMJ9ML8	ID	DMJ9ML8
DMJ9ML8	DN	PSB-6426
DMJ9ML8	HS	Investigative
DMJ9ML8	SN	PSB-6426; CHEMBL469212; GTPL9033; SCHEMBL13210969; BDBM50262249; compound 19a [PMID: 18630897]; (2S,3S,4R,5R)-N-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide; 4-[2-((2S,3R,4S,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofurane-2-carboxamido)ethylamido-]benzylphosphonic Acid Diethyl Ester
DMJ9ML8	DT	Small molecular drug
DMJ9ML8	PC	24949079
DMJ9ML8	MW	540.5
DMJ9ML8	FM	C22H29N4O10P
DMJ9ML8	IC	InChI=1S/C22H29N4O10P/c1-3-34-37(33,35-4-2)12-13-5-7-14(8-6-13)24-16(28)11-23-20(31)19-17(29)18(30)21(36-19)26-10-9-15(27)25-22(26)32/h5-10,17-19,21,29-30H,3-4,11-12H2,1-2H3,(H,23,31)(H,24,28)(H,25,27,32)/t17-,18+,19-,21+/m0/s1
DMJ9ML8	CS	CCOP(=O)(CC1=CC=C(C=C1)NC(=O)CNC(=O)[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)OCC
DMJ9ML8	IK	AEVBPXDFDKBGLT-YOUFYPILSA-N
DMJ9ML8	IU	(2S,3S,4R,5R)-N-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide
DMJ9ML8	DE	Discovery agent

DMS2V0P	ID	DMS2V0P
DMS2V0P	DN	PSB-716
DMS2V0P	HS	Investigative
DMS2V0P	SN	78510-27-7; PSB-716; Sodium 1-amino-4-o-methoxyanilino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonate; CHEMBL257495; EINECS 278-930-3; SCHEMBL790524; DTXSID00229133; 1-Amino-2-(sodiooxysulfonyl)-4-(2-methoxyphenylamino)-9,10-anthraquinone; Sodium 1-amino-4-o-methoxyanilino-9,10-dihydro-9,10-dioxoanthracene-2-sulfonate
DMS2V0P	DT	Small molecular drug
DMS2V0P	PC	25090818
DMS2V0P	MW	446.4
DMS2V0P	FM	C21H15N2NaO6S
DMS2V0P	IC	InChI=1S/C21H16N2O6S.Na/c1-29-15-9-5-4-8-13(15)23-14-10-16(30(26,27)28)19(22)18-17(14)20(24)11-6-2-3-7-12(11)21(18)25;/h2-10,23H,22H2,1H3,(H,26,27,28);/q;+1/p-1
DMS2V0P	CS	COC1=CC=CC=C1NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)[O-].[Na+]
DMS2V0P	IK	REACUBXXZFBLMO-UHFFFAOYSA-M
DMS2V0P	IU	sodium;1-amino-4-(2-methoxyanilino)-9,10-dioxoanthracene-2-sulfonate
DMS2V0P	CA	CAS 78510-27-7
DMS2V0P	DE	Discovery agent

DMN5AE8	ID	DMN5AE8
DMN5AE8	DN	PSEUDOCOCAINE
DMN5AE8	HS	Investigative
DMN5AE8	SN	UNII-277EEP3RJA; 478-73-9; 277EEP3RJA; d-phi-Cocaine; (R)-Pseudococaine; 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(2-endo,3-exo))-; 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, [1R-(2-endo,3-exo)]-; AC1LD8EU; Pseudococaine (6CI,7CI); SCHEMBL26608; 2alpha-Carbomethoxy-3beta-benzoyloxytropane; methyl (1S,3S,4S,5R)
DMN5AE8	DT	Small molecular drug
DMN5AE8	PC	644005
DMN5AE8	MW	303.35
DMN5AE8	FM	C17H21NO4
DMN5AE8	IC	InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15-/m0/s1
DMN5AE8	CS	CN1[C@H]2CC[C@@H]1[C@@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC
DMN5AE8	IK	ZPUCINDJVBIVPJ-XGUBFFRZSA-N
DMN5AE8	IU	methyl (1R,2S,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
DMN5AE8	CA	CAS 478-73-9
DMN5AE8	DE	Discovery agent

DM0E5G9	ID	DM0E5G9
DM0E5G9	DN	Pseudocolumbamine trifluoroacetate
DM0E5G9	HS	Investigative
DM0E5G9	SN	pseudocolumbamine trifluoroacetate
DM0E5G9	DT	Small molecular drug
DM0E5G9	PC	49850520
DM0E5G9	MW	451.4
DM0E5G9	FM	C22H20F3NO6
DM0E5G9	IC	InChI=1S/C20H19NO4.C2HF3O2/c1-23-18-7-12-4-5-21-11-14-9-20(25-3)19(24-2)8-13(14)6-16(21)15(12)10-17(18)22;3-2(4,5)1(6)7/h6-11H,4-5H2,1-3H3;(H,6,7)
DM0E5G9	CS	COC1=C(C=C2C(=C1)CC[N+]3=CC4=CC(=C(C=C4C=C23)OC)OC)O.C(=O)(C(F)(F)F)[O-]
DM0E5G9	IK	NJSNVNFFIBGGAE-UHFFFAOYSA-N
DM0E5G9	IU	2,2,2-trifluoroacetate;3,10,11-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-2-ol
DM0E5G9	DE	Discovery agent

DM4HE1V	ID	DM4HE1V
DM4HE1V	DN	Pseudopalmatine trifluoroacetate
DM4HE1V	HS	Investigative
DM4HE1V	SN	Pseudopalmatine Trifluoroacetate
DM4HE1V	DT	Small molecular drug
DM4HE1V	PC	49850522
DM4HE1V	MW	465.4
DM4HE1V	FM	C23H22F3NO6
DM4HE1V	IC	InChI=1S/C21H22NO4.C2HF3O2/c1-23-18-8-13-5-6-22-12-15-10-20(25-3)19(24-2)9-14(15)7-17(22)16(13)11-21(18)26-4;3-2(4,5)1(6)7/h7-12H,5-6H2,1-4H3;(H,6,7)/q+1;/p-1
DM4HE1V	CS	COC1=C(C=C2C(=C1)CC[N+]3=CC4=CC(=C(C=C4C=C23)OC)OC)OC.C(=O)(C(F)(F)F)[O-]
DM4HE1V	IK	KUZKREKOXDJDIQ-UHFFFAOYSA-M
DM4HE1V	IU	2,3,10,11-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;2,2,2-trifluoroacetate
DM4HE1V	DE	Discovery agent

DM5ZU1V	ID	DM5ZU1V
DM5ZU1V	DN	PSI 7851
DM5ZU1V	HS	Investigative
DM5ZU1V	SN	PSI-7851
DM5ZU1V	DT	Small molecular drug
DM5ZU1V	PC	45375806
DM5ZU1V	MW	529.5
DM5ZU1V	FM	C22H29FN3O9P
DM5ZU1V	IC	InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36?/m0/s1
DM5ZU1V	CS	C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DM5ZU1V	IK	TTZHDVOVKQGIBA-IAAJYNJHSA-N
DM5ZU1V	IU	propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DM5ZU1V	CA	CAS 1064684-44-1
DM5ZU1V	DE	Hepatitis C virus infection

DMPDO49	ID	DMPDO49
DMPDO49	DN	PSILOCIN
DMPDO49	HS	Investigative
DMPDO49	SN	PSILOCIN; 4-Hydroxy-N,N-dimethyltryptamine; Psilocine; Psilotsin; 520-53-6; Psilocyn; 3-[2-(Dimethylamino)ethyl]-1H-indol-4-ol; 3-(2-(Dimethylamino)ethyl)indol-4-ol; UNII-CMS88KUW0G; N,N-Dimethyl-4-Hydroxytryptamine; CX-59; EINECS 208-296-5; CMS88KUW0G; BRN 0160503; CHEMBL65547; CHEBI:8613; DEA No. 7438; 3-(2-(Dimethylamino)ethyl)-1H-indol-4-ol; NCGC00247728-01; P-7800; 1H-Indol-4-ol, 3-[2-(dimethylamino)ethyl]-; INDOL-4-OL, 3-(2-(DIMETHYLAMINO)ETHYL)-; Indol-4-ol, 3-[2-(dimethylamino)ethyl]-; Psilocin solution; AC1L1JCI; 4-OH-DMT
DMPDO49	DT	Small molecular drug
DMPDO49	PC	4980
DMPDO49	MW	204.27
DMPDO49	FM	C12H16N2O
DMPDO49	IC	InChI=1S/C12H16N2O/c1-14(2)7-6-9-8-13-10-4-3-5-11(15)12(9)10/h3-5,8,13,15H,6-7H2,1-2H3
DMPDO49	CS	CN(C)CCC1=CNC2=C1C(=CC=C2)O
DMPDO49	IK	SPCIYGNTAMCTRO-UHFFFAOYSA-N
DMPDO49	IU	3-[2-(dimethylamino)ethyl]-1H-indol-4-ol
DMPDO49	CA	CAS 520-53-6
DMPDO49	CB	CHEBI:8613
DMPDO49	DE	Discovery agent

DMUROIY	ID	DMUROIY
DMUROIY	DN	PSN-101
DMUROIY	HS	Investigative
DMUROIY	CP	OSI Pharma
DMUROIY	DT	Small molecular drug
DMUROIY	PC	23649002
DMUROIY	MW	1006.7
DMUROIY	FM	C48H68ClN5O12S2
DMUROIY	IC	InChI=1S/C30H53N3O6.C18H15ClN2O6S2/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);3-5,7,21H,6,8H2,1-2H3/t22-,23-,24-,25-;/m0./s1
DMUROIY	CS	CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2.CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
DMUROIY	IK	FVDZRAUCUALTCQ-NATPOTRJSA-N
DMUROIY	IU	(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide;N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
DMUROIY	DE	Diabetic complication

DM2U9SR	ID	DM2U9SR
DM2U9SR	DN	PSN375963
DM2U9SR	HS	Investigative
DM2U9SR	SN	PSN 375963; PSN-375,963; PSN-375963
DM2U9SR	DT	Small molecular drug
DM2U9SR	PC	2875918
DM2U9SR	MW	285.4
DM2U9SR	FM	C17H23N3O
DM2U9SR	IC	InChI=1S/C17H23N3O/c1-2-3-4-13-5-7-15(8-6-13)17-19-16(20-21-17)14-9-11-18-12-10-14/h9-13,15H,2-8H2,1H3
DM2U9SR	CS	CCCCC1CCC(CC1)C2=NC(=NO2)C3=CC=NC=C3
DM2U9SR	IK	OAVLEYPTWABFLF-UHFFFAOYSA-N
DM2U9SR	IU	5-(4-butylcyclohexyl)-3-pyridin-4-yl-1,2,4-oxadiazole
DM2U9SR	CA	CAS 388575-52-8
DM2U9SR	DE	Discovery agent

DMJIB8N	ID	DMJIB8N
DMJIB8N	DN	PSN632408
DMJIB8N	HS	Investigative
DMJIB8N	SN	PSN 632408; PSN-632,408; PSN-632408
DMJIB8N	DT	Small molecular drug
DMJIB8N	PC	11462546
DMJIB8N	MW	360.4
DMJIB8N	FM	C18H24N4O4
DMJIB8N	IC	InChI=1S/C18H24N4O4/c1-18(2,3)25-17(23)22-10-6-14(7-11-22)24-12-15-20-16(21-26-15)13-4-8-19-9-5-13/h4-5,8-9,14H,6-7,10-12H2,1-3H3
DMJIB8N	CS	CC(C)(C)OC(=O)N1CCC(CC1)OCC2=NC(=NO2)C3=CC=NC=C3
DMJIB8N	IK	LHZWKWCEAXQUMX-UHFFFAOYSA-N
DMJIB8N	IU	tert-butyl 4-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methoxy]piperidine-1-carboxylate
DMJIB8N	CA	CAS 857652-30-3
DMJIB8N	DE	Discovery agent

DMVJDCM	ID	DMVJDCM
DMVJDCM	DN	PSX-4206
DMVJDCM	HS	Investigative
DMVJDCM	SN	PSX-4159; VAP1 inhibitor (lung disease), Pharmaxis; Vascular adhesion protein-1 inhibitor (lung disease), Pharmaxis
DMVJDCM	CP	Pharmaxis Ltd
DMVJDCM	DE	Pulmonary disease

DM47F9I	ID	DM47F9I
DM47F9I	DN	PT-101
DM47F9I	HS	Investigative
DM47F9I	SN	Thiourea, N-(2-phenylethyl)-N'-2-pyridinyl-; 5454-38-6; 1-phenethyl-3-pyridin-2-ylthiourea; NSC23099; PT-101; AC1Q7ELP; AC1LGQ0C; MLS000665556; CHEMBL316796; SCHEMBL6952754; DTXSID80202964; MolPort-001-516-695; ZINC306266; HMS2563B19; 1-phenethyl-3-(2-pyridyl)thiourea; NSC-23099; STK027846; AKOS002320458; MCULE-6942162011; NCGC00245645-01; SMR000270803; N-(2-phenylethyl)-N'-2-pyridinylthiourea; KB-219590; 1-(2-phenylethyl)-3-pyridin-2-ylthiourea; ST50594514; SR-01000246008; SR-01000246008-1
DM47F9I	DT	Small molecular drug
DM47F9I	PC	799959
DM47F9I	MW	257.36
DM47F9I	FM	C14H15N3S
DM47F9I	IC	InChI=1S/C14H15N3S/c18-14(17-13-8-4-5-10-15-13)16-11-9-12-6-2-1-3-7-12/h1-8,10H,9,11H2,(H2,15,16,17,18)
DM47F9I	CS	C1=CC=C(C=C1)CCNC(=S)NC2=CC=CC=N2
DM47F9I	IK	GVKFCKWGWXJWMN-UHFFFAOYSA-N
DM47F9I	IU	1-(2-phenylethyl)-3-pyridin-2-ylthiourea
DM47F9I	CA	CAS 5454-38-6
DM47F9I	DE	Discovery agent

DMD0K61	ID	DMD0K61
DMD0K61	DN	PT-102
DMD0K61	HS	Investigative
DMD0K61	SN	HI-275; CHEMBL317356; Thiourea, N-(5-bromo-2-pyridinyl)-N'-(2-phenylethyl)-; 149487-00-3; PETT Analog 52; PT-102; AC1M6SPL; MLS000517095; BDBM1885; SCHEMBL7624466; cid_2429552; MolPort-002-358-086; HMS2674B12; STK928015; ZINC12487116; AKOS001055750; MCULE-2726995695; NCGC00246073-01; SMR000343246; 1-(5-bromopyridin-2-yl)-3-phenethylthiourea; 1-(5-bromo-2-pyridyl)-3-phenethyl-thiourea; N-(2-Phenethyl)-N -(2-(5-bromopyridyl))thiourea; 1-(5-bromopyridin-2-yl)-3-(2-phenylethyl)thiourea
DMD0K61	DT	Small molecular drug
DMD0K61	PC	2429552
DMD0K61	MW	336.25
DMD0K61	FM	C14H14BrN3S
DMD0K61	IC	InChI=1S/C14H14BrN3S/c15-12-6-7-13(17-10-12)18-14(19)16-9-8-11-4-2-1-3-5-11/h1-7,10H,8-9H2,(H2,16,17,18,19)
DMD0K61	CS	C1=CC=C(C=C1)CCNC(=S)NC2=NC=C(C=C2)Br
DMD0K61	IK	FKDHVFZSRUETTG-UHFFFAOYSA-N
DMD0K61	IU	1-(5-bromopyridin-2-yl)-3-(2-phenylethyl)thiourea
DMD0K61	CA	CAS 149487-00-3
DMD0K61	DE	Discovery agent

DM0LTB2	ID	DM0LTB2
DM0LTB2	DN	PT-103
DM0LTB2	HS	Investigative
DM0LTB2	SN	Thiourea, N-(5-methyl-2-pyridinyl)-N'-(2-phenylethyl)-; 149486-00-0; PETT Analog 53; PT-103; AC1LJB56; MLS000671915; CHEMBL398765; cid_971434; BDBM1886; DTXSID40164296; MolPort-001-646-260; HMS2692K09; ZINC13519717; STL173974; AKOS001094581; MCULE-7559129905; NCGC00245681-01; SMR000294417; 1-Phenethyl-3-(5-methyl-2-pyridyl)thiourea; 1-(5-methyl-2-pyridyl)-3-phenethyl-thiourea; 1-(5-methylpyridin-2-yl)-3-phenethylthiourea; N-(2-Phenethyl)-N -(2-(5-methylpyridyl))thiourea; N-(5-methyl-2-pyridinyl)-N'-(2-phenylethyl)thiourea
DM0LTB2	DT	Small molecular drug
DM0LTB2	PC	971434
DM0LTB2	MW	271.4
DM0LTB2	FM	C15H17N3S
DM0LTB2	IC	InChI=1S/C15H17N3S/c1-12-7-8-14(17-11-12)18-15(19)16-10-9-13-5-3-2-4-6-13/h2-8,11H,9-10H2,1H3,(H2,16,17,18,19)
DM0LTB2	CS	CC1=CN=C(C=C1)NC(=S)NCCC2=CC=CC=C2
DM0LTB2	IK	FTLVKPIQAUANGB-UHFFFAOYSA-N
DM0LTB2	IU	1-(5-methylpyridin-2-yl)-3-(2-phenylethyl)thiourea
DM0LTB2	CA	CAS 149486-00-0
DM0LTB2	DE	Discovery agent

DMABLF7	ID	DMABLF7
DMABLF7	DN	PT-104
DMABLF7	HS	Investigative
DMABLF7	SN	149488-13-1; Thiourea, N-(5-bromo-2-pyridinyl)-N'-(2-(2,6-difluorophenyl)ethyl)-; Thiourea, N-(5-bromo-2-pyridinyl)-N'-[2-(2,6-difluorophenyl)ethyl]-; PT-104; PETT Analog 57; PETT deriv. 21; AC1MHDJX; LY300046HCl Analog 1; CHEMBL88677; BDBM1890; SCHEMBL6905477; DTXSID00164313; ZINC3832005; 1-(2,6-Difluorophenethyl)-3-(5-bromo-2-pyridinyl)thiourea; 1-(5-bromo-2-pyridyl)-3-[2-(2,6-difluorophenyl)ethyl]thiourea; 3-(5-bromopyridin-2-yl)-1-[2-(2,6-difluorophenyl)ethyl]thiourea; N-(2-(2,6-Difluorophenyl)ethyl)-N -(2-(5-bromopyri
DMABLF7	DT	Small molecular drug
DMABLF7	PC	3001078
DMABLF7	MW	372.23
DMABLF7	FM	C14H12BrF2N3S
DMABLF7	IC	InChI=1S/C14H12BrF2N3S/c15-9-4-5-13(19-8-9)20-14(21)18-7-6-10-11(16)2-1-3-12(10)17/h1-5,8H,6-7H2,(H2,18,19,20,21)
DMABLF7	CS	C1=CC(=C(C(=C1)F)CCNC(=S)NC2=NC=C(C=C2)Br)F
DMABLF7	IK	TWONRKIIQCCNQJ-UHFFFAOYSA-N
DMABLF7	IU	1-(5-bromopyridin-2-yl)-3-[2-(2,6-difluorophenyl)ethyl]thiourea
DMABLF7	CA	CAS 149488-13-1
DMABLF7	DE	Discovery agent

DMPX71O	ID	DMPX71O
DMPX71O	DN	PT-106
DMPX71O	HS	Investigative
DMPX71O	SN	Thiourea, N-(2-phenylethyl)-N'-pyrazinyl-; 149485-34-7; PETT Analog 49; PT-106; PETT Pyrazin deriv.; AC1MHDL0; BDBM1882; CHEMBL320902; SCHEMBL7082827; DTXSID50164287; 1-phenethyl-3-pyrazin-2-ylthiourea; ZINC13744909; 1-Phenethyl-3-pyrazin-2-yl-thiourea; AKOS003702467; N-(2-Phenethyl)-N -(2-pyrazinyl)thiourea
DMPX71O	DT	Small molecular drug
DMPX71O	PC	3001117
DMPX71O	MW	258.339
DMPX71O	FM	C13H14N4S
DMPX71O	IC	InChI=1S/C13H14N4S/c18-13(17-12-10-14-8-9-15-12)16-7-6-11-4-2-1-3-5-11/h1-5,8-10H,6-7H2,(H2,15,16,17,18)
DMPX71O	CS	C1=CC=C(C=C1)CCNC(=S)NC2=NC=CN=C2
DMPX71O	IK	CDHPKLQOWLHDSH-UHFFFAOYSA-N
DMPX71O	IU	1-(2-phenylethyl)-3-pyrazin-2-ylthiourea
DMPX71O	CA	CAS 149485-34-7
DMPX71O	DE	Discovery agent

DMBLAV4	ID	DMBLAV4
DMBLAV4	DN	PT-108
DMBLAV4	HS	Investigative
DMBLAV4	SN	149487-94-5; Thiourea, N-(2-(2,6-difluorophenyl)ethyl)-N'-(5-methyl-2-pyridinyl)-; 1-[2-(2,6-difluorophenyl)ethyl]-3-(5-methylpyridin-2-yl)thiourea; PETT Analog 58; Thiourea, N-[2-(2,6-difluorophenyl)ethyl]-N'-(5-methyl-2-pyridinyl)-; PT-108; AC1MHDL5; BDBM1891; CHEMBL398766; DTXSID40164312; ZINC13744917; N-(2-(2,6-Difluorophenyl)ethyl)-N -(2-(5-methylpyridyl))thiourea
DMBLAV4	DT	Small molecular drug
DMBLAV4	PC	3001122
DMBLAV4	MW	307.4
DMBLAV4	FM	C15H15F2N3S
DMBLAV4	IC	InChI=1S/C15H15F2N3S/c1-10-5-6-14(19-9-10)20-15(21)18-8-7-11-12(16)3-2-4-13(11)17/h2-6,9H,7-8H2,1H3,(H2,18,19,20,21)
DMBLAV4	CS	CC1=CN=C(C=C1)NC(=S)NCCC2=C(C=CC=C2F)F
DMBLAV4	IK	FIASQQMTLFRFPZ-UHFFFAOYSA-N
DMBLAV4	IU	1-[2-(2,6-difluorophenyl)ethyl]-3-(5-methylpyridin-2-yl)thiourea
DMBLAV4	CA	CAS 149487-94-5
DMBLAV4	DE	Discovery agent

DM8PX1T	ID	DM8PX1T
DM8PX1T	DN	PT-109
DM8PX1T	HS	Investigative
DM8PX1T	SN	1-(5-chloropyridin-2-yl)-3-[2-(2,4,6-trifluorophenyl)ethyl]thiourea; LY300046HCl Analog 29; PT-109; AC1NS2Q0; BDBM2143; CHEMBL103706
DM8PX1T	DT	Small molecular drug
DM8PX1T	PC	5327628
DM8PX1T	MW	345.8
DM8PX1T	FM	C14H11ClF3N3S
DM8PX1T	IC	InChI=1S/C14H11ClF3N3S/c15-8-1-2-13(20-7-8)21-14(22)19-4-3-10-11(17)5-9(16)6-12(10)18/h1-2,5-7H,3-4H2,(H2,19,20,21,22)
DM8PX1T	CS	C1=CC(=NC=C1Cl)NC(=S)NCCC2=C(C=C(C=C2F)F)F
DM8PX1T	IK	FSXKIIYITCFGGK-UHFFFAOYSA-N
DM8PX1T	IU	1-(5-chloropyridin-2-yl)-3-[2-(2,4,6-trifluorophenyl)ethyl]thiourea
DM8PX1T	DE	Discovery agent

DMEIW5T	ID	DMEIW5T
DMEIW5T	DN	PT-110
DMEIW5T	HS	Investigative
DMEIW5T	SN	181305-20-4; Thiourea, N-(5-chloro-2-pyridinyl)-N'-(2-(3-cyano-2,6-difluorophenyl)ethyl)-; N-(2-(3-Cyano-2,6-difluorophenethyl))-N'-(2-(5-chloropyridyl))thiourea; 1-(5-chloropyridin-2-yl)-3-[2-(3-cyano-2,6-difluorophenyl)ethyl]thiourea; N-[2-(3-Cyano-2,6-difluorophenethyl)]-N'-[2-(5-chloropyridyl)]thiourea; Thiourea, N-(5-chloro-2-pyridinyl)-N'-[2-(3-cyano-2,6-difluorophenyl)ethyl]-; PT-110; AC1MHDLU; LY300046HCl Analog 4; CHEMBL319224; BDBM2120; DTXSID20171100
DMEIW5T	DT	Small molecular drug
DMEIW5T	PC	3001147
DMEIW5T	MW	352.8
DMEIW5T	FM	C15H11ClF2N4S
DMEIW5T	IC	InChI=1S/C15H11ClF2N4S/c16-10-2-4-13(21-8-10)22-15(23)20-6-5-11-12(17)3-1-9(7-19)14(11)18/h1-4,8H,5-6H2,(H2,20,21,22,23)
DMEIW5T	CS	C1=CC(=NC=C1Cl)NC(=S)NCCC2=C(C=CC(=C2F)C#N)F
DMEIW5T	IK	OZXHOQRXBCCXFI-UHFFFAOYSA-N
DMEIW5T	IU	1-(5-chloropyridin-2-yl)-3-[2-(3-cyano-2,6-difluorophenyl)ethyl]thiourea
DMEIW5T	CA	CAS 181305-20-4
DMEIW5T	DE	Discovery agent

DMUFC6V	ID	DMUFC6V
DMUFC6V	DN	PT-113
DMUFC6V	HS	Investigative
DMUFC6V	SN	PT-113; AC1MHDJY; LY300046HCl Analog 2; CHEMBL317574; BDBM2118; N-[2-(2,6-Difluoro-3-(formamidomethyl)phenethyl)]-N'-[2-(5-bromopyridyl)]thiourea; N-[2-(2,6-Difluoro-3-(formamidomethyl)phenethyl)]-N-[2-(5-bromopyridyl)]thiourea; 3-[2-[(5-bromo-2-pyridyl)carbamothioylamino]ethyl]-2,4-difluoro-N-methyl-benzamide; 3-(2-{[(5-bromopyridin-2-yl)carbamothioyl]amino}ethyl)-2,4-difluoro-N-methylbenzamide
DMUFC6V	DT	Small molecular drug
DMUFC6V	PC	3001079
DMUFC6V	MW	429.3
DMUFC6V	FM	C16H15BrF2N4OS
DMUFC6V	IC	InChI=1S/C16H15BrF2N4OS/c1-20-15(24)11-3-4-12(18)10(14(11)19)6-7-21-16(25)23-13-5-2-9(17)8-22-13/h2-5,8H,6-7H2,1H3,(H,20,24)(H2,21,22,23,25)
DMUFC6V	CS	CNC(=O)C1=C(C(=C(C=C1)F)CCNC(=S)NC2=NC=C(C=C2)Br)F
DMUFC6V	IK	YHRQSPRSRROVMC-UHFFFAOYSA-N
DMUFC6V	IU	3-[2-[(5-bromopyridin-2-yl)carbamothioylamino]ethyl]-2,4-difluoro-N-methylbenzamide
DMUFC6V	DE	Discovery agent

DMYE1P8	ID	DMYE1P8
DMYE1P8	DN	PT-114
DMYE1P8	HS	Investigative
DMYE1P8	SN	181305-49-7; Thiourea, N-(5-chloro-2-pyridinyl)-N'-(2-(4-(dimethylamino)-2,6-difluorophenyl)ethyl)-; N-(2-(-2,6-Difluoro-4-(dimethylamino)phenethyl))-N'-(2-(5-chloropyridyl))thiourea; 1-(5-chloropyridin-2-yl)-3-[2-[4-(dimethylamino)-2,6-difluorophenyl]ethyl]thiourea; N-[2-(-2,6-Difluoro-4-(dimethylamino)phenethyl)]-N'-[2-(5-chloropyridyl)]thiourea; 1-(5-chloropyridin-2-yl)-3-{2-[4-(dimethylamino)-2,6-difluorophenyl]ethyl}thiourea; Thiourea, N-(5-chloro-2-pyridinyl)-N'-[2-[4-(dimethylamino)-2,6-difluorophenyl]ethy
DMYE1P8	DT	Small molecular drug
DMYE1P8	PC	3001133
DMYE1P8	MW	370.8
DMYE1P8	FM	C16H17ClF2N4S
DMYE1P8	IC	InChI=1S/C16H17ClF2N4S/c1-23(2)11-7-13(18)12(14(19)8-11)5-6-20-16(24)22-15-4-3-10(17)9-21-15/h3-4,7-9H,5-6H2,1-2H3,(H2,20,21,22,24)
DMYE1P8	CS	CN(C)C1=CC(=C(C(=C1)F)CCNC(=S)NC2=NC=C(C=C2)Cl)F
DMYE1P8	IK	CTKOUWBTBJGZKA-UHFFFAOYSA-N
DMYE1P8	IU	1-(5-chloropyridin-2-yl)-3-[2-[4-(dimethylamino)-2,6-difluorophenyl]ethyl]thiourea
DMYE1P8	CA	CAS 181305-49-7
DMYE1P8	DE	Discovery agent

DMS01IN	ID	DMS01IN
DMS01IN	DN	PT-115
DMS01IN	HS	Investigative
DMS01IN	SN	149488-76-6; Thiourea, N-(5-bromo-2-pyridinyl)-N'-(2-(2,6-difluoro-3-methoxyphenyl)ethyl)-; 1-(5-bromopyridin-2-yl)-3-[2-(2,6-difluoro-3-methoxyphenyl)ethyl]thiourea; N-(2-(2,6-Difluoro-3-methoxyphenethyl))-N'-(2-(5-bromopyridyl))thiourea; N-[2-(2,6-Difluoro-3-methoxyphenethyl)]-N'-[2-(5-bromopyridyl)]thiourea; Thiourea, N-(5-bromo-2-pyridinyl)-N'-[2-(2,6-difluoro-3-methoxyphenyl)ethyl]-; PT-115; AC1MHDLW; LY300046HCl Analog 7; SCHEMBL6963627; CHEMBL398890; BDBM2123; DTXSID50164323
DMS01IN	DT	Small molecular drug
DMS01IN	PC	3001149
DMS01IN	MW	402.3
DMS01IN	FM	C15H14BrF2N3OS
DMS01IN	IC	InChI=1S/C15H14BrF2N3OS/c1-22-12-4-3-11(17)10(14(12)18)6-7-19-15(23)21-13-5-2-9(16)8-20-13/h2-5,8H,6-7H2,1H3,(H2,19,20,21,23)
DMS01IN	CS	COC1=C(C(=C(C=C1)F)CCNC(=S)NC2=NC=C(C=C2)Br)F
DMS01IN	IK	HINMFTUIHCBZCY-UHFFFAOYSA-N
DMS01IN	IU	1-(5-bromopyridin-2-yl)-3-[2-(2,6-difluoro-3-methoxyphenyl)ethyl]thiourea
DMS01IN	CA	CAS 149488-76-6
DMS01IN	DE	Discovery agent

DME0N2Z	ID	DME0N2Z
DME0N2Z	DN	PT-306
DME0N2Z	HS	Investigative
DME0N2Z	SN	149485-92-7; Thiourea, N-(2-(2-fluorophenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(2-fluorophenyl)ethyl]-N'-2-thiazolyl-; PT-306; PETT Analog 2; AC1MHDM9; SCHEMBL6958232; CHEMBL253994; BDBM1895; DTXSID60164293; 1-[2-(2-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; AKOS030030936; 1-(2-Thiazolyl)-3-[2-fluorophenethyl]thiourea; 1-[2-(2-fluorophenyl)ethyl]-3-thiazol-2-yl-thiourea; N-(2-(2-Fluorophenethyl))-N -(2-thiazolyl)thiourea
DME0N2Z	DT	Small molecular drug
DME0N2Z	PC	3001162
DME0N2Z	MW	281.4
DME0N2Z	FM	C12H12FN3S2
DME0N2Z	IC	InChI=1S/C12H12FN3S2/c13-10-4-2-1-3-9(10)5-6-14-11(17)16-12-15-7-8-18-12/h1-4,7-8H,5-6H2,(H2,14,15,16,17)
DME0N2Z	CS	C1=CC=C(C(=C1)CCNC(=S)NC2=NC=CS2)F
DME0N2Z	IK	OQWSGTUKBXDUJN-UHFFFAOYSA-N
DME0N2Z	IU	1-[2-(2-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DME0N2Z	CA	CAS 149485-92-7
DME0N2Z	DE	Discovery agent

DM45HVR	ID	DM45HVR
DM45HVR	DN	PT-307
DM45HVR	HS	Investigative
DM45HVR	SN	149486-26-0; Thiourea, N-(2-(2,6-difluorophenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(2,6-difluorophenyl)ethyl]-N'-2-thiazolyl-; PETT Analog 23; PT-307; PETT di-F deriv.; AC1MHDKC; CHEMBL252136; SCHEMBL6961866; BDBM1916; DTXSID50164303; 1-[2-(2,6-difluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; 1-(2-Thiazolyl)-3-[2,6-difluorophenethyl]thiourea; N-(2-(2,6-Difluorophenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(2,6-difluorophenyl)ethyl]-3-thiazol-2-yl-thiourea
DM45HVR	DT	Small molecular drug
DM45HVR	PC	3001093
DM45HVR	MW	299.4
DM45HVR	FM	C12H11F2N3S2
DM45HVR	IC	InChI=1S/C12H11F2N3S2/c13-9-2-1-3-10(14)8(9)4-5-15-11(18)17-12-16-6-7-19-12/h1-3,6-7H,4-5H2,(H2,15,16,17,18)
DM45HVR	CS	C1=CC(=C(C(=C1)F)CCNC(=S)NC2=NC=CS2)F
DM45HVR	IK	BLZZAJBLYALRNA-UHFFFAOYSA-N
DM45HVR	IU	1-[2-(2,6-difluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DM45HVR	CA	CAS 149486-26-0
DM45HVR	DE	Discovery agent

DM7FM8V	ID	DM7FM8V
DM7FM8V	DN	PT-308
DM7FM8V	HS	Investigative
DM7FM8V	SN	149485-75-6; Thiourea, N-(2-(2-chlorophenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(2-chlorophenyl)ethyl]-N'-2-thiazolyl-; PETT Analog 12; PT-308; AC1MHDMI; SCHEMBL6953553; BDBM1905; CHEMBL102957; DTXSID80164290; 1-[2-(2-chlorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; AKOS030030937; 1-(2-Thiazolyl)-3-[2-chlorophenethyl]thiourea; 1-[2-(2-chlorophenyl)ethyl]-3-thiazol-2-yl-thiourea; N-(2-(2-Chlorophenethyl))-N -(2-thiazolyl)thiourea
DM7FM8V	DT	Small molecular drug
DM7FM8V	PC	3001171
DM7FM8V	MW	297.8
DM7FM8V	FM	C12H12ClN3S2
DM7FM8V	IC	InChI=1S/C12H12ClN3S2/c13-10-4-2-1-3-9(10)5-6-14-11(17)16-12-15-7-8-18-12/h1-4,7-8H,5-6H2,(H2,14,15,16,17)
DM7FM8V	CS	C1=CC=C(C(=C1)CCNC(=S)NC2=NC=CS2)Cl
DM7FM8V	IK	KRROCUPDKUFLSH-UHFFFAOYSA-N
DM7FM8V	IU	1-[2-(2-chlorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DM7FM8V	CA	CAS 149485-75-6
DM7FM8V	DE	Discovery agent

DM7TILD	ID	DM7TILD
DM7TILD	DN	PT-309
DM7TILD	HS	Investigative
DM7TILD	SN	149485-98-3; Thiourea, N-(2-(2-chloro-6-fluorophenyl)ethyl)-N'-2-thiazolyl-; PETT Analog 24; Thiourea, N-[2-(2-chloro-6-fluorophenyl)ethyl]-N'-2-thiazolyl-; PT-309; AC1MHDKD; PETT Cl, F deriv.; SCHEMBL6362179; CHEMBL252137; BDBM1917; DTXSID20164294; 1-[2-(2-chloro-6-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; 1-(2-Thiazolyl)-3-[2-chloro-6-fluorophenethyl]thiourea; N-(2-(2-Chloro-6-fluorophenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(2-chloro-6-fluoro-phenyl)ethyl]-3-thiazol-2-yl-thiourea
DM7TILD	DT	Small molecular drug
DM7TILD	PC	3001094
DM7TILD	MW	315.8
DM7TILD	FM	C12H11ClFN3S2
DM7TILD	IC	InChI=1S/C12H11ClFN3S2/c13-9-2-1-3-10(14)8(9)4-5-15-11(18)17-12-16-6-7-19-12/h1-3,6-7H,4-5H2,(H2,15,16,17,18)
DM7TILD	CS	C1=CC(=C(C(=C1)Cl)CCNC(=S)NC2=NC=CS2)F
DM7TILD	IK	DLYWQFUMFDBURV-UHFFFAOYSA-N
DM7TILD	IU	1-[2-(2-chloro-6-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DM7TILD	CA	CAS 149485-98-3
DM7TILD	DE	Discovery agent

DMT7G32	ID	DMT7G32
DMT7G32	DN	PT-310
DMT7G32	HS	Investigative
DMT7G32	SN	172505-79-2; Thiourea, N-(2-(2-hydroxyphenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(2-hydroxyphenyl)ethyl]-N'-2-thiazolyl-; PETT OH deriv.; PT-310; PETT Analog 11; AC1MHDMH; SCHEMBL6957663; BDBM1904; CHEMBL400684; DTXSID60169329; 1-[2-(2-hydroxyphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; 1-(2-Thiazolyl)-3-[2-hydroxyphenethyl]thiourea; 1-[2-(2-hydroxyphenyl)ethyl]-3-thiazol-2-yl-thiourea; N-(2-(2-Hydroxyphenethyl))-N -(2-thiazolyl)thiourea
DMT7G32	DT	Small molecular drug
DMT7G32	PC	3001170
DMT7G32	MW	279.4
DMT7G32	FM	C12H13N3OS2
DMT7G32	IC	InChI=1S/C12H13N3OS2/c16-10-4-2-1-3-9(10)5-6-13-11(17)15-12-14-7-8-18-12/h1-4,7-8,16H,5-6H2,(H2,13,14,15,17)
DMT7G32	CS	C1=CC=C(C(=C1)CCNC(=S)NC2=NC=CS2)O
DMT7G32	IK	PRHAOTURKTZAEQ-UHFFFAOYSA-N
DMT7G32	IU	1-[2-(2-hydroxyphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMT7G32	CA	CAS 172505-79-2
DMT7G32	DE	Discovery agent

DM9ZCGX	ID	DM9ZCGX
DM9ZCGX	DN	PT-311
DM9ZCGX	HS	Investigative
DM9ZCGX	SN	149485-76-7; Thiourea, N-(2-(2-methoxyphenyl)ethyl)-N'-2-thiazolyl-; PETT deriv. 5; Thiourea, N-[2-(2-methoxyphenyl)ethyl]-N'-2-thiazolyl-; PETT Analog 5; PT-311; AC1MHDK2; BDBM2855; CHEMBL254201; SCHEMBL6953979; DTXSID40164291; ZINC13744845; AKOS030030935; 1-(2-Methoxyphenethyl)-3-(2-thiazolyl)thiourea; 1-[2-(2-methoxyphenyl)ethyl]-3-thiazol-2-yl-thiourea; 1-[2-(2-methoxyphenyl)ethyl]-3-1,3-thiazol-2-ylthiourea
DM9ZCGX	DT	Small molecular drug
DM9ZCGX	PC	3001083
DM9ZCGX	MW	293.4
DM9ZCGX	FM	C13H15N3OS2
DM9ZCGX	IC	InChI=1S/C13H15N3OS2/c1-17-11-5-3-2-4-10(11)6-7-14-12(18)16-13-15-8-9-19-13/h2-5,8-9H,6-7H2,1H3,(H2,14,15,16,18)
DM9ZCGX	CS	COC1=CC=CC=C1CCNC(=S)NC2=NC=CS2
DM9ZCGX	IK	MRSDMFHPBHPUME-UHFFFAOYSA-N
DM9ZCGX	IU	1-[2-(2-methoxyphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DM9ZCGX	CA	CAS 149485-76-7
DM9ZCGX	DE	Discovery agent

DM7GN3E	ID	DM7GN3E
DM7GN3E	DN	PT-312
DM7GN3E	HS	Investigative
DM7GN3E	SN	Thiourea, N-(5-chloro-2-thiazolyl)-N'-(2-phenylethyl)-; 149486-85-1; PETT Analog 46; PT-312; AC1MHDKX; CHEMBL101348; SCHEMBL6951634; BDBM1879; DTXSID10164309; 1-(5-chlorothiazol-2-yl)-3-phenethyl-thiourea; N-(2-Phenethyl)-N -(2-(5-chlorothiazolyl))thiourea; 1-(5-chloro-1,3-thiazol-2-yl)-3-phenethylthiourea
DM7GN3E	DT	Small molecular drug
DM7GN3E	PC	3001114
DM7GN3E	MW	297.8
DM7GN3E	FM	C12H12ClN3S2
DM7GN3E	IC	InChI=1S/C12H12ClN3S2/c13-10-8-15-12(18-10)16-11(17)14-7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H2,14,15,16,17)
DM7GN3E	CS	C1=CC=C(C=C1)CCNC(=S)NC2=NC=C(S2)Cl
DM7GN3E	IK	FRTOQBKWAXWZAM-UHFFFAOYSA-N
DM7GN3E	IU	1-(5-chloro-1,3-thiazol-2-yl)-3-(2-phenylethyl)thiourea
DM7GN3E	CA	CAS 149486-85-1
DM7GN3E	DE	Discovery agent

DMN80XD	ID	DMN80XD
DMN80XD	DN	PT-313
DMN80XD	HS	Investigative
DMN80XD	SN	Thiourea, N-(4-methyl-2-thiazolyl)-N'-(2-phenylethyl)-; 149485-00-7; PETT Analog 37; PT-313; AC1MHDKO; SCHEMBL8885589; CHEMBL254628; BDBM1870; DTXSID50164282; ZINC13744891; AKOS030011211; 1-Phenethyl-3-(4-methyl-2-thiazolyl)thiourea; 1-(4-methylthiazol-2-yl)-3-phenethyl-thiourea; N-(2-Phenethyl)-N -(2-(4-methylthiazolyl))thiourea; 1-(4-methyl-1,3-thiazol-2-yl)-3-phenethylthiourea
DMN80XD	DT	Small molecular drug
DMN80XD	PC	3001105
DMN80XD	MW	277.4
DMN80XD	FM	C13H15N3S2
DMN80XD	IC	InChI=1S/C13H15N3S2/c1-10-9-18-13(15-10)16-12(17)14-8-7-11-5-3-2-4-6-11/h2-6,9H,7-8H2,1H3,(H2,14,15,16,17)
DMN80XD	CS	CC1=CSC(=N1)NC(=S)NCCC2=CC=CC=C2
DMN80XD	IK	ZIPXZWMTOPUETF-UHFFFAOYSA-N
DMN80XD	IU	1-(4-methyl-1,3-thiazol-2-yl)-3-(2-phenylethyl)thiourea
DMN80XD	CA	CAS 149485-00-7
DMN80XD	DE	Discovery agent

DM5C1ND	ID	DM5C1ND
DM5C1ND	DN	PT-314
DM5C1ND	HS	Investigative
DM5C1ND	SN	149485-07-4; Thiourea, N-(2-phenylethyl)-N'-(4-(trifluoromethyl)-2-thiazolyl)-; PETT Analog 43; Thiourea, N-(2-phenylethyl)-N'-[4-(trifluoromethyl)-2-thiazolyl]-; PT-314; PETT CF3 deriv.; AC1MHDKU; CHEMBL410771; SCHEMBL6962348; BDBM1876; DTXSID70164284; ZINC13744903; 1-phenethyl-3-[4-(trifluoromethyl)thiazol-2-yl]thiourea; 1-phenethyl-3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]thiourea; N-(2-Phenethyl)-N -(2-(4-(trifluoromethyl)thiazolyl))thiourea
DM5C1ND	DT	Small molecular drug
DM5C1ND	PC	3001111
DM5C1ND	MW	331.4
DM5C1ND	FM	C13H12F3N3S2
DM5C1ND	IC	InChI=1S/C13H12F3N3S2/c14-13(15,16)10-8-21-12(18-10)19-11(20)17-7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H2,17,18,19,20)
DM5C1ND	CS	C1=CC=C(C=C1)CCNC(=S)NC2=NC(=CS2)C(F)(F)F
DM5C1ND	IK	PIOSJSRPZNUBFE-UHFFFAOYSA-N
DM5C1ND	IU	1-(2-phenylethyl)-3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]thiourea
DM5C1ND	CA	CAS 149485-07-4
DM5C1ND	DE	Discovery agent

DMUK7IT	ID	DMUK7IT
DMUK7IT	DN	PT-315
DMUK7IT	HS	Investigative
DMUK7IT	SN	Thiourea, N-(4-ethyl-2-thiazolyl)-N'-(2-phenylethyl)-; 149485-47-2; PETT Analog 38; AC1MHDKP; CHEMBL254836; BDBM1871; SCHEMBL10085259; ZINC13744893; 1-Phenethyl-3-(4-ethyl-2-thiazolyl)thiourea; 1-(4-ethylthiazol-2-yl)-3-phenethyl-thiourea; 1-(4-ethyl-1,3-thiazol-2-yl)-3-phenethylthiourea; N-(2-Phenethyl)-N -(2-(4-ethylthiazolyl))thiourea
DMUK7IT	DT	Small molecular drug
DMUK7IT	PC	3001106
DMUK7IT	MW	291.4
DMUK7IT	FM	C14H17N3S2
DMUK7IT	IC	InChI=1S/C14H17N3S2/c1-2-12-10-19-14(16-12)17-13(18)15-9-8-11-6-4-3-5-7-11/h3-7,10H,2,8-9H2,1H3,(H2,15,16,17,18)
DMUK7IT	CS	CCC1=CSC(=N1)NC(=S)NCCC2=CC=CC=C2
DMUK7IT	IK	SMLAKAQKPKAWNV-UHFFFAOYSA-N
DMUK7IT	IU	1-(4-ethyl-1,3-thiazol-2-yl)-3-(2-phenylethyl)thiourea
DMUK7IT	CA	CAS 149485-47-2
DMUK7IT	DE	Discovery agent

DMXM6NT	ID	DMXM6NT
DMXM6NT	DN	PT-316
DMXM6NT	HS	Investigative
DMXM6NT	SN	Thiourea, N-(2-phenylethyl)-N'-(4-propyl-2-thiazolyl)-; 149486-74-8; PETT Pr deriv.; PT-316; PETT Analog 39; AC1MHDKQ; CHEMBL399069; BDBM1872; DTXSID30164306; ZINC13744895; 1-Phenethyl-3-(4-propyl-2-thiazolyl)thiourea; 1-phenethyl-3-(4-propylthiazol-2-yl)thiourea; N-(2-Phenethyl)-N -(2-(4-propylthiazolyl))thiourea; 1-phenethyl-3-(4-propyl-1,3-thiazol-2-yl)thiourea
DMXM6NT	DT	Small molecular drug
DMXM6NT	PC	3001107
DMXM6NT	MW	305.5
DMXM6NT	FM	C15H19N3S2
DMXM6NT	IC	InChI=1S/C15H19N3S2/c1-2-6-13-11-20-15(17-13)18-14(19)16-10-9-12-7-4-3-5-8-12/h3-5,7-8,11H,2,6,9-10H2,1H3,(H2,16,17,18,19)
DMXM6NT	CS	CCCC1=CSC(=N1)NC(=S)NCCC2=CC=CC=C2
DMXM6NT	IK	YVTPTTMDIAAXHM-UHFFFAOYSA-N
DMXM6NT	IU	1-(2-phenylethyl)-3-(4-propyl-1,3-thiazol-2-yl)thiourea
DMXM6NT	CA	CAS 149486-74-8
DMXM6NT	DE	Discovery agent

DM14XB7	ID	DM14XB7
DM14XB7	DN	PT-317
DM14XB7	HS	Investigative
DM14XB7	SN	149486-80-6; Thiourea, N-(4-(1-methylethyl)-2-thiazolyl)-N'-(2-phenylethyl)-; PETT Analog 40; Thiourea, N-[4-(1-methylethyl)-2-thiazolyl]-N'-(2-phenylethyl)-; PT-317; PETT i-Pr deriv.; AC1MHDKR; CHEMBL254839; BDBM1873; DTXSID90164307; ZINC13744897; 1-Phenethyl-3-(4-isopropyl-2-thiazolyl)thiourea; 1-(4-isopropylthiazol-2-yl)-3-phenethyl-thiourea; N-(2-Phenethyl)-N -(2-(4-isopropylthiazolyl))thiourea; 1-phenethyl-3-(4-propan-2-yl-1,3-thiazol-2-yl)thiourea
DM14XB7	DT	Small molecular drug
DM14XB7	PC	3001108
DM14XB7	MW	305.5
DM14XB7	FM	C15H19N3S2
DM14XB7	IC	InChI=1S/C15H19N3S2/c1-11(2)13-10-20-15(17-13)18-14(19)16-9-8-12-6-4-3-5-7-12/h3-7,10-11H,8-9H2,1-2H3,(H2,16,17,18,19)
DM14XB7	CS	CC(C)C1=CSC(=N1)NC(=S)NCCC2=CC=CC=C2
DM14XB7	IK	WXIISNREJKBCAO-UHFFFAOYSA-N
DM14XB7	IU	1-(2-phenylethyl)-3-(4-propan-2-yl-1,3-thiazol-2-yl)thiourea
DM14XB7	CA	CAS 149486-80-6
DM14XB7	DE	Discovery agent

DMKEPGN	ID	DMKEPGN
DMKEPGN	DN	PT-319
DMKEPGN	HS	Investigative
DMKEPGN	SN	149485-99-4; Thiourea, N-(2-(3-methoxyphenyl)ethyl)-N'-2-thiazolyl-; PETT Analog 6; Thiourea, N-[2-(3-methoxyphenyl)ethyl]-N'-2-thiazolyl-; PT-319; AC1MHDMC; SCHEMBL6963302; BDBM1899; CHEMBL400733; DTXSID80164295; ZINC13744847; AKOS030030940; 1-(2-Thiazolyl)-3-[3-methoxyphenethyl]thiourea; N-(2-(3-Methoxyphenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(3-methoxyphenyl)ethyl]-3-thiazol-2-yl-thiourea; 1-[2-(3-methoxyphenyl)ethyl]-3-1,3-thiazol-2-ylthiourea
DMKEPGN	DT	Small molecular drug
DMKEPGN	PC	3001165
DMKEPGN	MW	293.4
DMKEPGN	FM	C13H15N3OS2
DMKEPGN	IC	InChI=1S/C13H15N3OS2/c1-17-11-4-2-3-10(9-11)5-6-14-12(18)16-13-15-7-8-19-13/h2-4,7-9H,5-6H2,1H3,(H2,14,15,16,18)
DMKEPGN	CS	COC1=CC=CC(=C1)CCNC(=S)NC2=NC=CS2
DMKEPGN	IK	TXUPZNCSUKFSFG-UHFFFAOYSA-N
DMKEPGN	IU	1-[2-(3-methoxyphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMKEPGN	CA	CAS 149485-99-4
DMKEPGN	DE	Discovery agent

DMV940C	ID	DMV940C
DMV940C	DN	PT-320
DMV940C	HS	Investigative
DMV940C	SN	PETT Analog 7; PT-320; AC1MHDMD; SCHEMBL6958741; BDBM1900; CHEMBL254206; ZINC13744849; AKOS030013220; 1-(2-Thiazolyl)-3-[4-methoxyphenethyl]thiourea; N-[2-(4-Methoxyphenethyl)]-N'-(2-thiazolyl)thiourea; N-(2-(4-Methoxyphenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(4-methoxyphenyl)ethyl]-3-thiazol-2-yl-thiourea; 1-[2-(4-methoxyphenyl)ethyl]-3-1,3-thiazol-2-ylthiourea
DMV940C	DT	Small molecular drug
DMV940C	PC	3001166
DMV940C	MW	293.4
DMV940C	FM	C13H15N3OS2
DMV940C	IC	InChI=1S/C13H15N3OS2/c1-17-11-4-2-10(3-5-11)6-7-14-12(18)16-13-15-8-9-19-13/h2-5,8-9H,6-7H2,1H3,(H2,14,15,16,18)
DMV940C	CS	COC1=CC=C(C=C1)CCNC(=S)NC2=NC=CS2
DMV940C	IK	HJPBSTWTSQIWNI-UHFFFAOYSA-N
DMV940C	IU	1-[2-(4-methoxyphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMV940C	DE	Discovery agent

DMIHSEV	ID	DMIHSEV
DMIHSEV	DN	PT-322
DMIHSEV	HS	Investigative
DMIHSEV	SN	Thiourea, N-methyl-N'-(2-phenylethyl)-N-2-thiazolyl-; 172505-87-2; PETT Analog 36; PT-322; PETT N-Me deriv.; AC1MHDKN; CHEMBL317866; BDBM1869; DTXSID30169336; ZINC13744889; 1-Methyl-3-phenethyl-1-thiazol-2-yl-thiourea; 1-methyl-3-phenethyl-1-(1,3-thiazol-2-yl)thiourea
DMIHSEV	DT	Small molecular drug
DMIHSEV	PC	3001104
DMIHSEV	MW	277.4
DMIHSEV	FM	C13H15N3S2
DMIHSEV	IC	InChI=1S/C13H15N3S2/c1-16(13-15-9-10-18-13)12(17)14-8-7-11-5-3-2-4-6-11/h2-6,9-10H,7-8H2,1H3,(H,14,17)
DMIHSEV	CS	CN(C1=NC=CS1)C(=S)NCCC2=CC=CC=C2
DMIHSEV	IK	SZLHGPJAYQWUEP-UHFFFAOYSA-N
DMIHSEV	IU	1-methyl-3-(2-phenylethyl)-1-(1,3-thiazol-2-yl)thiourea
DMIHSEV	CA	CAS 172505-87-2
DMIHSEV	DE	Discovery agent

DM736T8	ID	DM736T8
DM736T8	DN	PT-401
DM736T8	HS	Investigative
DM736T8	SN	Erythropoietin dimer, Beth Israel; Erythropoietin dimer, DNAPrint; Epo-Epo dimer, Beth Israel; Epo-Epo dimer, DNAPrint
DM736T8	CP	Beth Israel Deaconess Medical Center
DM736T8	DE	Anemia

DMEJ6SK	ID	DMEJ6SK
DMEJ6SK	DN	PTAC
DMEJ6SK	HS	Investigative
DMEJ6SK	SN	CHEMBL146240; 139148-95-1; N-Hydroxy-N-(1,2,3,4-tetrahydro-6-(phenylmethoxy)-1-naphthalenyl)urea; F 107649; F-107649; AC1L53EW; SCHEMBL9488819; CTK4C1649; BDBM50055115; 6-(Benzyloxy)-1-(1-hydroxyureido)tetralin; N-Hydroxy-N-[1,2,3,4-tetrahydro-6-(benzyloxy)-1-naphthalenyl]urea; 1-hydroxy-1-(6-phenylmethoxy-1,2,3,4-tetrahydronaphthalen-1-yl)urea
DMEJ6SK	DT	Small molecular drug
DMEJ6SK	PC	15806447
DMEJ6SK	MW	269.4
DMEJ6SK	FM	C12H19N3S2
DMEJ6SK	IC	InChI=1S/C12H19N3S2/c1-2-6-16-12-11(13-17-14-12)10-8-15-5-3-4-9(10)7-15/h9-10H,2-8H2,1H3/t9-,10-/m0/s1
DMEJ6SK	CS	CCCSC1=NSN=C1[C@H]2CN3CCC[C@H]2C3
DMEJ6SK	IK	ZZGXRPGQPAPARK-UWVGGRQHSA-N
DMEJ6SK	IU	3-[(5R,6R)-1-azabicyclo[3.2.1]octan-6-yl]-4-propylsulfanyl-1,2,5-thiadiazole
DMEJ6SK	DE	Discovery agent

DMY02IR	ID	DMY02IR
DMY02IR	DN	PTBE
DMY02IR	HS	Investigative
DMY02IR	SN	CHEMBL182371; PTBE; SCHEMBL6245198; GTPL1403; BDBM50153757; 1-[2-hydroxy-3-propyl-4-[4-[4-(2H-tetrazol-5-yl)phenoxy]butoxy]phenyl]ethanone; 1-(2-Hydroxy-3-propyl-4-{4-[4-(2H-tetrazol-5-yl)-phenoxy]-butoxy}-phenyl)-ethanone; 1-(2-Hydroxy-3-propyl-4-{4-[4-(1H-tetrazol-5-yl)-phenoxy]-butoxy}-phenyl)-ethanone
DMY02IR	DT	Small molecular drug
DMY02IR	PC	10047169
DMY02IR	MW	410.5
DMY02IR	FM	C22H26N4O4
DMY02IR	IC	InChI=1S/C22H26N4O4/c1-3-6-19-20(12-11-18(15(2)27)21(19)28)30-14-5-4-13-29-17-9-7-16(8-10-17)22-23-25-26-24-22/h7-12,28H,3-6,13-14H2,1-2H3,(H,23,24,25,26)
DMY02IR	CS	CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCOC2=CC=C(C=C2)C3=NNN=N3
DMY02IR	IK	FEEONEKLFGDWHR-UHFFFAOYSA-N
DMY02IR	IU	1-[2-hydroxy-3-propyl-4-[4-[4-(2H-tetrazol-5-yl)phenoxy]butoxy]phenyl]ethanone
DMY02IR	DE	Discovery agent

DM1NM5F	ID	DM1NM5F
DM1NM5F	DN	PTeB
DM1NM5F	HS	Investigative
DM1NM5F	SN	PTeB; AC1LKKEQ; GTPL1430; ZINC682997; (2R)-N-(4-benzoylphenyl)-2-(4-methylphenoxy)propanamide
DM1NM5F	DT	Small molecular drug
DM1NM5F	PC	1019881
DM1NM5F	MW	359.4
DM1NM5F	FM	C23H21NO3
DM1NM5F	IC	InChI=1S/C23H21NO3/c1-16-8-14-21(15-9-16)27-17(2)23(26)24-20-12-10-19(11-13-20)22(25)18-6-4-3-5-7-18/h3-15,17H,1-2H3,(H,24,26)/t17-/m1/s1
DM1NM5F	CS	CC1=CC=C(C=C1)O[C@H](C)C(=O)NC2=CC=C(C=C2)C(=O)C3=CC=CC=C3
DM1NM5F	IK	XTAVVOHMWNRQKS-QGZVFWFLSA-N
DM1NM5F	IU	(2R)-N-(4-benzoylphenyl)-2-(4-methylphenoxy)propanamide
DM1NM5F	DE	Discovery agent

DM98IOX	ID	DM98IOX
DM98IOX	DN	Pterin-6-Yl-Methyl-Monophosphate
DM98IOX	HS	Investigative
DM98IOX	DT	Small molecular drug
DM98IOX	PC	135451578
DM98IOX	MW	273.14
DM98IOX	FM	C7H8N5O5P
DM98IOX	IC	InChI=1S/C7H8N5O5P/c8-7-11-5-4(6(13)12-7)10-3(1-9-5)2-17-18(14,15)16/h1H,2H2,(H2,14,15,16)(H3,8,9,11,12,13)
DM98IOX	CS	C1=C(N=C2C(=O)NC(=NC2=N1)N)COP(=O)(O)O
DM98IOX	IK	AJXFJEHKGGCFNM-UHFFFAOYSA-N
DM98IOX	IU	(2-amino-4-oxo-3H-pteridin-6-yl)methyl dihydrogen phosphate
DM98IOX	DE	Discovery agent

DMT2YNG	ID	DMT2YNG
DMT2YNG	DN	Pteroic Acid
DMT2YNG	HS	Investigative
DMT2YNG	DT	Small molecular drug
DMT2YNG	PC	135398749
DMT2YNG	MW	312.28
DMT2YNG	FM	C14H12N6O3
DMT2YNG	IC	InChI=1S/C14H12N6O3/c15-14-19-11-10(12(21)20-14)18-9(6-17-11)5-16-8-3-1-7(2-4-8)13(22)23/h1-4,6,16H,5H2,(H,22,23)(H3,15,17,19,20,21)
DMT2YNG	CS	C1=CC(=CC=C1C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
DMT2YNG	IK	JOAQINSXLLMRCV-UHFFFAOYSA-N
DMT2YNG	IU	4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoic acid
DMT2YNG	CA	CAS 119-24-4
DMT2YNG	CB	CHEBI:27623
DMT2YNG	DE	Discovery agent

DM10KIW	ID	DM10KIW
DM10KIW	DN	PTHr pepducins
DM10KIW	HS	Investigative
DM10KIW	SN	PTHr pepducins (endocrine/metabolic disorders); PTHr pepducins (endocrine/metabolic disorders), Anchor Therapeutics; Parathyroid hormone receptor-modulating pepducins (lipopeptide, endocrine/metabolic disorders), Anchor Therapeutics
DM10KIW	CP	Anchor Therapeutics Inc
DM10KIW	DE	Endocrine disease

DMQUSXK	ID	DMQUSXK
DMQUSXK	DN	PTI-601
DMQUSXK	HS	Investigative
DMQUSXK	CP	Pain Therapeutics
DMQUSXK	DE	Pain

DMAEL4C	ID	DMAEL4C
DMAEL4C	DN	PTL-101
DMAEL4C	HS	Investigative
DMAEL4C	SN	TGF beta inhibtor (IPF/ lung transplant rejection), Pacific Therapeutics/UBC
DMAEL4C	CP	University of British Columbia
DMAEL4C	DE	Pulmonary fibrosis

DMPEKTO	ID	DMPEKTO
DMPEKTO	DN	P-toluenesulfonamide
DMPEKTO	HS	Investigative
DMPEKTO	SN	4-Methylbenzenesulfonamide; P-TOLUENESULFONAMIDE; 70-55-3; 4-Toluenesulfonamide; Tosylamide; p-Tosylamide; Toluene-4-sulfonamide; p-Tolylsulfonamide; Benzenesulfonamide, 4-methyl-; Tolylsulfonamide; p-Toluenesulfamide; 4-methylbenzene-1-sulfonamide; p-Methylbenzenesulfonamide; p-Toluenesulfonylamide; Toluene-p-sulphonamide; para-Toluenesulfonamide; 4-Toluenesulfanamide; Toluene-4-sulphonamide; UNII-I8266RI90M; 4-Toluenesulfonic acid, amide; HSDB 5203; NSC 9908; EINECS 200-741-1; CHEMBL574; BRN 0472689; 4-Toluenesulfonic acid amide
DMPEKTO	DT	Small molecular drug
DMPEKTO	PC	6269
DMPEKTO	MW	171.22
DMPEKTO	FM	C7H9NO2S
DMPEKTO	IC	InChI=1S/C7H9NO2S/c1-6-2-4-7(5-3-6)11(8,9)10/h2-5H,1H3,(H2,8,9,10)
DMPEKTO	CS	CC1=CC=C(C=C1)S(=O)(=O)N
DMPEKTO	IK	LMYRWZFENFIFIT-UHFFFAOYSA-N
DMPEKTO	IU	4-methylbenzenesulfonamide
DMPEKTO	CA	CAS 70-55-3
DMPEKTO	CB	CHEBI:34435
DMPEKTO	DE	Discovery agent

DMDGUEK	ID	DMDGUEK
DMDGUEK	DN	P-tolyl 10H-phenothiazine-10-carboxylate
DMDGUEK	HS	Investigative
DMDGUEK	SN	CHEMBL481163; p-tolyl 10H-phenothiazine-10-carboxylate; SCHEMBL4449333
DMDGUEK	DT	Small molecular drug
DMDGUEK	PC	24905594
DMDGUEK	MW	333.4
DMDGUEK	FM	C20H15NO2S
DMDGUEK	IC	InChI=1S/C20H15NO2S/c1-14-10-12-15(13-11-14)23-20(22)21-16-6-2-4-8-18(16)24-19-9-5-3-7-17(19)21/h2-13H,1H3
DMDGUEK	CS	CC1=CC=C(C=C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMDGUEK	IK	HXQRAZTUUZVKLB-UHFFFAOYSA-N
DMDGUEK	IU	(4-methylphenyl) phenothiazine-10-carboxylate
DMDGUEK	DE	Discovery agent

DM8MZF4	ID	DM8MZF4
DM8MZF4	DN	P-tolylboronic acid
DM8MZF4	HS	Investigative
DM8MZF4	SN	4-Tolylboronic acid; p-Tolylboronic acid; 4-Methylphenylboronic acid; 5720-05-8; (4-methylphenyl)boronic acid; p-Tolueneboronic acid; 4-Methylbenzeneboronic acid; p-Methylbenzeneboronic acid; Boronic acid, (4-methylphenyl)-; Boronic acid, p-tolyl-; Tolyl boronic acid; 4-Methylphenylboric acid; (4-Methylphenyl)Boranediol; 4-methylphenyl boronic acid; 917814-66-5; p-Methylborophenylic acid; p-methylphenylboronic acid; UNII-YJM4GM7K66; YJM4GM7K66; 4-Methyl Phenyl Boronic Acid; CHEMBL140780; BIWQNIMLAISTBV-UHFFFAOYSA-N; NSC 62870
DM8MZF4	DT	Small molecular drug
DM8MZF4	PC	79799
DM8MZF4	MW	135.96
DM8MZF4	FM	C7H9BO2
DM8MZF4	IC	InChI=1S/C7H9BO2/c1-6-2-4-7(5-3-6)8(9)10/h2-5,9-10H,1H3
DM8MZF4	CS	B(C1=CC=C(C=C1)C)(O)O
DM8MZF4	IK	BIWQNIMLAISTBV-UHFFFAOYSA-N
DM8MZF4	IU	(4-methylphenyl)boronic acid
DM8MZF4	CA	CAS 5720-05-8
DM8MZF4	DE	Discovery agent

DMPEVQT	ID	DMPEVQT
DMPEVQT	DN	PTosyl-Glu(OtBu)-Ala-LeuVSMe
DMPEVQT	HS	Investigative
DMPEVQT	SN	CHEMBL207016; pTosyl-Glu(OtBu)-Ala-LeuVSMe
DMPEVQT	DT	Small molecular drug
DMPEVQT	PC	11621347
DMPEVQT	MW	601.8
DMPEVQT	FM	C27H43N3O8S2
DMPEVQT	IC	InChI=1S/C27H43N3O8S2/c1-18(2)17-21(15-16-39(8,34)35)29-25(32)20(4)28-26(33)23(13-14-24(31)38-27(5,6)7)30-40(36,37)22-11-9-19(3)10-12-22/h9-12,15-16,18,20-21,23,30H,13-14,17H2,1-8H3,(H,28,33)(H,29,32)/b16-15+/t20-,21+,23-/m0/s1
DMPEVQT	CS	CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C
DMPEVQT	IK	RSODQDWVGCCUGL-HSNUOWKJSA-N
DMPEVQT	IU	tert-butyl (4S)-5-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-4-[(4-methylphenyl)sulfonylamino]-5-oxopentanoate
DMPEVQT	DE	Discovery agent

DMZGFE8	ID	DMZGFE8
DMZGFE8	DN	PTR-3046
DMZGFE8	HS	Investigative
DMZGFE8	SN	CHEMBL439096
DMZGFE8	PC	71717867
DMZGFE8	MW	1100.3
DMZGFE8	FM	C59H77N11O10
DMZGFE8	IC	InChI=1S/C59H77N11O10/c1-36(2)51-59(80)70(49(33-39-17-8-5-9-18-39)58(79)69-52(37(3)71)53(61)74)30-14-22-50(73)63-29-28-62-46(31-38-15-6-4-7-16-38)55(76)66-47(32-40-23-25-42(72)26-24-40)56(77)67-48(34-41-35-64-44-20-11-10-19-43(41)44)57(78)65-45(54(75)68-51)21-12-13-27-60/h4-11,15-20,23-26,35-37,45-49,51-52,62,64,71-72H,12-14,21-22,27-34,60H2,1-3H3,(H2,61,74)(H,63,73)(H,65,78)(H,66,76)(H,67,77)(H,68,75)(H,69,79)/t37-,45+,46+,47+,48+,49+,51+,52+/m1/s1
DMZGFE8	CS	C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N2CCCC(=O)NCCN[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)C(C)C)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=C(C=C5)O)CC6=CC=CC=C6)O
DMZGFE8	IK	LRUHWPFUOBQIRY-ANYMKNSJSA-N
DMZGFE8	IU	(2S,3R)-2-[[(2S)-2-[(3S,6S,9S,12S,15S)-6-(4-aminobutyl)-15-benzyl-12-[(4-hydroxyphenyl)methyl]-9-(1H-indol-3-ylmethyl)-2,5,8,11,14,20-hexaoxo-3-propan-2-yl-1,4,7,10,13,16,19-heptazacyclotricos-1-yl]-3-phenylpropanoyl]amino]-3-hydroxybutanamide
DMZGFE8	DE	Discovery agent

DMHAJC1	ID	DMHAJC1
DMHAJC1	DN	PU24S
DMHAJC1	HS	Investigative
DMHAJC1	TC	Anticancer Agents
DMHAJC1	DE	Solid tumour/cancer

DM4SGVF	ID	DM4SGVF
DM4SGVF	DN	PUKATEINE
DM4SGVF	HS	Investigative
DM4SGVF	SN	Pukateine; UNII-Z9Y5O2QUPA; Z9Y5O2QUPA; 81-67-4; Pukatein; Pukateine [MI]; (-)-Pukateine; Pukateine, (-)-; AC1L9CMQ; SCHEMBL674930; CHEBI:8634; DTXSID00331801; ZINC898765; 5H-Benzo(g)-1,3-benzodioxolo(6,5,4-de)quinolin-12-ol, 6,7,7a,8-tetrahydro-7-methyl-, (7aR)-; C09613; UNII-8V36S7J6BB component IKMXUUHNYQWZBC-GFCCVEGCSA-N
DM4SGVF	DT	Small molecular drug
DM4SGVF	PC	442340
DM4SGVF	MW	295.3
DM4SGVF	FM	C18H17NO3
DM4SGVF	IC	InChI=1S/C18H17NO3/c1-19-6-5-11-8-14-18(22-9-21-14)17-15(11)12(19)7-10-3-2-4-13(20)16(10)17/h2-4,8,12,20H,5-7,9H2,1H3/t12-/m1/s1
DM4SGVF	CS	CN1CCC2=CC3=C(C4=C2[C@H]1CC5=C4C(=CC=C5)O)OCO3
DM4SGVF	IK	IKMXUUHNYQWZBC-GFCCVEGCSA-N
DM4SGVF	IU	(12R)-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14(19),15,17-hexaen-18-ol
DM4SGVF	CA	CAS 81-67-4
DM4SGVF	CB	CHEBI:8634
DM4SGVF	DE	Discovery agent

DMY2F6T	ID	DMY2F6T
DMY2F6T	DN	Pumiliotoxin 251D
DMY2F6T	HS	Investigative
DMY2F6T	SN	73376-35-9; AC1O5TO7; (+-)-Pumiliotoxin 251D; CHEMBL358960; PTX 251D; 8-Indolizinol, octahydro-8-methyl-6-((2R)-2-methylhexylidene)-, (6Z,8S,8aS)-; C20031
DMY2F6T	CP	Microbiotix
DMY2F6T	DT	Small molecular drug
DMY2F6T	PC	6440480
DMY2F6T	MW	251.41
DMY2F6T	FM	C16H29NO
DMY2F6T	IC	InChI=1S/C16H29NO/c1-4-5-7-13(2)10-14-11-16(3,18)15-8-6-9-17(15)12-14/h10,13,15,18H,4-9,11-12H2,1-3H3/b14-10-/t13-,15+,16+/m1/s1
DMY2F6T	CS	CCCC[C@@H](C)/C=C\\1/C[C@]([C@@H]2CCCN2C1)(C)O
DMY2F6T	IK	OKTQTXDNHCOLHT-AJKPHIATSA-N
DMY2F6T	IU	(6Z,8S,8aS)-8-methyl-6-[(2R)-2-methylhexylidene]-1,2,3,5,7,8a-hexahydroindolizin-8-ol
DMY2F6T	CA	CAS 73376-35-9
DMY2F6T	DE	Bacterial infection

DM7CWQY	ID	DM7CWQY
DM7CWQY	DN	PUNICAFOLIN
DM7CWQY	HS	Investigative
DM7CWQY	SN	Punicafolin; 88847-11-4; CHEMBL507308; 1,2,4-Tri-O-galloyl-3,6-hexahydroxydiphenoylglucose; beta-D-Glucopyranose, cyclic 3,6-(4,4',5,5',6,6')-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1,2,4-tris(3,4,5-trihydroxybenzoate), (R)-; 1,2,4-tri-O-galloyl-3,6-(R)-hexahydroxydiphenoyl-; .beta.-D-Glucopyranose, cyclic 3:6-bis[(1S)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] 1,2,4-tri(3,4,5-trihydroxybenzoate)
DM7CWQY	DT	Small molecular drug
DM7CWQY	PC	5320800
DM7CWQY	MW	938.7
DM7CWQY	FM	C41H30O26
DM7CWQY	IC	InChI=1S/C41H30O26/c42-15-1-10(2-16(43)26(15)50)36(57)64-33-23-9-62-39(60)13-7-21(48)29(53)31(55)24(13)25-14(8-22(49)30(54)32(25)56)40(61)65-34(33)35(66-37(58)11-3-17(44)27(51)18(45)4-11)41(63-23)67-38(59)12-5-19(46)28(52)20(47)6-12/h1-8,23,33-35,41-56H,9H2/t23-,33-,34+,35-,41+/m1/s1
DM7CWQY	CS	C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5C6=C(C(=C(C=C6C(=O)O1)O)O)O)O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O
DM7CWQY	IK	DPBVYZVSXAZMAY-UUUCSUBKSA-N
DM7CWQY	IU	[(1S,19R,21S,22R,23R)-6,7,8,11,12,13-hexahydroxy-3,16-dioxo-21,22-bis[(3,4,5-trihydroxybenzoyl)oxy]-2,17,20-trioxatetracyclo[17.3.1.04,9.010,15]tricosa-4,6,8,10,12,14-hexaen-23-yl] 3,4,5-trihydroxybenzoate
DM7CWQY	CA	CAS 88847-11-4
DM7CWQY	DE	Discovery agent

DMCWT4L	ID	DMCWT4L
DMCWT4L	DN	PUP-1
DMCWT4L	HS	Investigative
DMCWT4L	SN	MMP-12 inhibitor (chronic obstryctive pulmonary disorder) Abiogen
DMCWT4L	CP	Abiogen Pharma SpA
DMCWT4L	DE	Chronic obstructive pulmonary disease

DMHNS0V	ID	DMHNS0V
DMHNS0V	DN	Purine Riboside
DMHNS0V	HS	Investigative
DMHNS0V	SN	Purine riboside
DMHNS0V	DT	Small molecular drug
DMHNS0V	PC	68368
DMHNS0V	MW	252.23
DMHNS0V	FM	C10H12N4O4
DMHNS0V	IC	InChI=1S/C10H12N4O4/c15-2-6-7(16)8(17)10(18-6)14-4-13-5-1-11-3-12-9(5)14/h1,3-4,6-8,10,15-17H,2H2/t6-,7-,8-,10-/m1/s1
DMHNS0V	CS	C1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMHNS0V	IK	MRWXACSTFXYYMV-FDDDBJFASA-N
DMHNS0V	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-purin-9-yloxolane-3,4-diol
DMHNS0V	CA	CAS 550-33-4
DMHNS0V	CB	CHEBI:18255
DMHNS0V	DE	Discovery agent

DMYWRL6	ID	DMYWRL6
DMYWRL6	DN	Purpurin
DMYWRL6	HS	Investigative
DMYWRL6	SN	PURPURIN; 81-54-9; 1,2,4-Trihydroxyanthraquinone; Purpurine; Verantin; Hydroxylizaric acid; Smoke Brown G; 1,2,4-trihydroxyanthracene-9,10-dione; 1,2,4-Trihydroxy-9,10-anthracenedione; 1,2,4-Trihydroxy-9,10-anthraquinone; 1,2,4-Trihydroxyanthrachinon; C.I. 58205; 9,10-Anthracenedione, 1,2,4-trihydroxy-; 1,2,4-Trihydroxyanthra-9,10-quinone; UNII-L1GT81LS6N; Anthraquinone, 1,2,4-trihydroxy-; C.I. 75410; CHEBI:8645; CCRIS 3527; C.I. 1037; EINECS 201-359-8; NSC 10447; 1,2,4-Trihydroxyanthrachinon [Czech]; BRN 1887127; L1GT81LS6N
DMYWRL6	DT	Small molecular drug
DMYWRL6	PC	6683
DMYWRL6	MW	256.209
DMYWRL6	FM	C14H8O5
DMYWRL6	IC	InChI=1S/C14H8O5/c15-8-5-9(16)14(19)11-10(8)12(17)6-3-1-2-4-7(6)13(11)18/h1-5,15-16,19H
DMYWRL6	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3O)O)O
DMYWRL6	IK	BBNQQADTFFCFGB-UHFFFAOYSA-N
DMYWRL6	IU	1,2,4-trihydroxyanthracene-9,10-dione
DMYWRL6	CA	CAS 81-54-9
DMYWRL6	CB	CHEBI:8645
DMYWRL6	DE	Discovery agent

DMNQ7TM	ID	DMNQ7TM
DMNQ7TM	DN	Purvalanol A
DMNQ7TM	HS	Investigative
DMNQ7TM	SN	Purvalanola; AC1L1JD0; PURVALANOLA; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol
DMNQ7TM	DT	Small molecular drug
DMNQ7TM	PC	456214
DMNQ7TM	MW	388.9
DMNQ7TM	FM	C19H25ClN6O
DMNQ7TM	IC	InChI=1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)/t15-/m0/s1
DMNQ7TM	CS	CC(C)[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=CC=C3)Cl
DMNQ7TM	IK	PMXCMJLOPOFPBT-HNNXBMFYSA-N
DMNQ7TM	IU	(2R)-2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol
DMNQ7TM	CA	CAS 212844-53-6
DMNQ7TM	CB	CHEBI:47600
DMNQ7TM	DE	Discovery agent

DMF28IU	ID	DMF28IU
DMF28IU	DN	PUUPEHEDIONE
DMF28IU	HS	Investigative
DMF28IU	SN	Puupehedione; 151345-10-7; CHEMBL1163875; (4aS,6aS,12bS)-4,4,6a,12b-Tetramethyl-1,3,4,4a,5,6,6a,12b-octahydro-2H-benzo(a)xanthene-9,10-dione; (4aS,6aS,12bS)-4,4,6a,12b-tetramethyl-1,2,3,4a,5,6-hexahydrobenzo[a]xanthene-9,10-dione; (4aS,6aS,12bS)-4,4,6a,12b-Tetramethyl-1,3,4,4a,5,6,6a,12b-octahydro-2H-benzo[a]xanthene-9,10-dione; AC1LA1R0; DTXSID90164766
DMF28IU	DT	Small molecular drug
DMF28IU	PC	460087
DMF28IU	MW	326.4
DMF28IU	FM	C21H26O3
DMF28IU	IC	InChI=1S/C21H26O3/c1-19(2)7-5-8-20(3)17(19)6-9-21(4)18(20)11-13-10-14(22)15(23)12-16(13)24-21/h10-12,17H,5-9H2,1-4H3/t17-,20-,21-/m0/s1
DMF28IU	CS	C[C@]12CCCC([C@@H]1CC[C@]3(C2=CC4=CC(=O)C(=O)C=C4O3)C)(C)C
DMF28IU	IK	QLFLHSQZFRDPFM-YYWHXJBOSA-N
DMF28IU	IU	(4aS,6aS,12bS)-4,4,6a,12b-tetramethyl-1,2,3,4a,5,6-hexahydrobenzo[a]xanthene-9,10-dione
DMF28IU	CA	CAS 151345-10-7
DMF28IU	DE	Discovery agent

DMF3BCK	ID	DMF3BCK
DMF3BCK	DN	PUUPEHENONE
DMF3BCK	HS	Investigative
DMF3BCK	SN	puupehenone; NSC292446; 73573-17-8; AC1Q6CTP; AC1L1JD3; CTK5D8271; NSC-292446; 10-hydroxy-4,4,6a,12b-tetramethyl-1,2,3,4,4a,5,6,6a,12a,12b-decahydro-9h-benzo[a]xanthen-9-one; 10-hydroxy-4,4,6a,12b-tetramethyl-2,3,4a,5,6,12a-hexahydro-1H-benzo[a]xanthen-9-one
DMF3BCK	DT	Small molecular drug
DMF3BCK	PC	72536
DMF3BCK	MW	328.4
DMF3BCK	FM	C21H28O3
DMF3BCK	IC	InChI=1S/C21H28O3/c1-19(2)7-5-8-20(3)17(19)6-9-21(4)18(20)11-13-10-14(22)15(23)12-16(13)24-21/h10-12,17-18,22H,5-9H2,1-4H3/t17-,18+,20-,21-/m0/s1
DMF3BCK	CS	C[C@]12CCCC([C@@H]1CC[C@]3([C@@H]2C=C4C=C(C(=O)C=C4O3)O)C)(C)C
DMF3BCK	IK	LOCMLXSTDCXZFJ-YHELAOLJSA-N
DMF3BCK	IU	(4aS,6aS,12aR,12bS)-10-hydroxy-4,4,6a,12b-tetramethyl-2,3,4a,5,6,12a-hexahydro-1H-benzo[a]xanthen-9-one
DMF3BCK	CA	CAS 73573-17-8
DMF3BCK	DE	Discovery agent

DMRI1LF	ID	DMRI1LF
DMRI1LF	DN	PV-1019
DMRI1LF	HS	Investigative
DMRI1LF	SN	Checkpoint kinase 2 inhibitor (cancer), Provid Pharmaceuticals; Chk2 inhibitor (cancer), Provid Pharmaceuticals
DMRI1LF	CP	Provid Pharmaceuticals Inc
DMRI1LF	DE	Solid tumour/cancer

DM9JYF3	ID	DM9JYF3
DM9JYF3	DN	PX-12
DM9JYF3	HS	Investigative
DM9JYF3	SN	PX12; PX 12; IV-2
DM9JYF3	CP	Biomira
DM9JYF3	TC	Antiviral Agents
DM9JYF3	DT	Small molecular drug
DM9JYF3	PC	219104
DM9JYF3	MW	188.3
DM9JYF3	FM	C7H12N2S2
DM9JYF3	IC	InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)
DM9JYF3	CS	CCC(C)SSC1=NC=CN1
DM9JYF3	IK	BPBPYQWMFCTCNG-UHFFFAOYSA-N
DM9JYF3	IU	2-(butan-2-yldisulfanyl)-1H-imidazole
DM9JYF3	CA	CAS 141400-58-0
DM9JYF3	CB	CHEBI:94291
DM9JYF3	DE	Cancer; Coronavirus Disease 2019 (COVID-19)

DMHCEOU	ID	DMHCEOU
DMHCEOU	DN	PXS-4159
DMHCEOU	HS	Investigative
DMHCEOU	SN	Membrane copper amine oxidase modulators (asthma), Pharmaxis; SSAO/VAP-1 inhibitors (asthma), Pharmaxis
DMHCEOU	CP	Pharmaxis Ltd
DMHCEOU	DE	Asthma

DM2P0I4	ID	DM2P0I4
DM2P0I4	DN	PXVX-0103
DM2P0I4	HS	Investigative
DM2P0I4	SN	Ad4-H5-Vtn
DM2P0I4	DE	Discovery agent

DMLFJHE	ID	DMLFJHE
DMLFJHE	DN	Pycnogenol
DMLFJHE	HS	Investigative
DMLFJHE	DE	Discovery agent

DM3VNYQ	ID	DM3VNYQ
DM3VNYQ	DN	Pyr3
DM3VNYQ	HS	Investigative
DM3VNYQ	SN	1160514-60-2; GTPL4293; SCHEMBL12274132; CTK8E8091; DTXSID60719181; AOB5992; MolPort-023-276-923; Pyr3, &gt; ZINC44607934; AKOS024457787; NCGC00370970-01; HY-108465; RT-017534; CS-0028846; B7494; J-003374; ethyl 1-[4-(trichloroprop-2-enamido)phenyl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate; 1-[4-(2,3,3-Trichloro-acryloylamino)-phenyl]-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl ester; Ethyl-1-(4-(2,3,3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate
DM3VNYQ	DT	Small molecular drug
DM3VNYQ	PC	56964346
DM3VNYQ	MW	456.6
DM3VNYQ	FM	C16H11Cl3F3N3O3
DM3VNYQ	IC	InChI=1S/C16H11Cl3F3N3O3/c1-2-28-15(27)10-7-23-25(12(10)16(20,21)22)9-5-3-8(4-6-9)24-14(26)11(17)13(18)19/h3-7H,2H2,1H3,(H,24,26)
DM3VNYQ	CS	CCOC(=O)C1=C(N(N=C1)C2=CC=C(C=C2)NC(=O)C(=C(Cl)Cl)Cl)C(F)(F)F
DM3VNYQ	IK	RZHGONNSASQOAY-UHFFFAOYSA-N
DM3VNYQ	IU	ethyl 1-[4-(2,3,3-trichloroprop-2-enoylamino)phenyl]-5-(trifluoromethyl)pyrazole-4-carboxylate
DM3VNYQ	CA	CAS 1160514-60-2
DM3VNYQ	DE	Discovery agent

DMIZB81	ID	DMIZB81
DMIZB81	DN	Pyrazine-2-carboxylic acid adamantan-1-ylamide
DMIZB81	HS	Investigative
DMIZB81	SN	CHEMBL253348; Pyrazine-2-carboxylic acid adamantan-1-ylamide; BAS 03365795; AC1MG7YQ; Cambridge id 7248781; Oprea1_265306; Oprea1_647087; MLS000088554; cid_2931812; MolPort-001-540-487; HMS2379I12; ZINC4197514; N-adamantanylpyrazin-2-ylcarboxamide; N-1-adamantyl-2-pyrazinecarboxamide; BDBM50231727; STK431969; AKOS000665660; N-(1-adamantyl)pyrazine-2-carboxamide; SDCCGMLS-0024327.P002; MCULE-4724742312; SMR000071836; ST50923663
DMIZB81	DT	Small molecular drug
DMIZB81	PC	2931812
DMIZB81	MW	257.329
DMIZB81	FM	C15H19N3O
DMIZB81	IC	InChI=1S/C15H19N3O/c19-14(13-9-16-1-2-17-13)18-15-6-10-3-11(7-15)5-12(4-10)8-15/h1-2,9-12H,3-8H2,(H,18,19)
DMIZB81	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)C4=NC=CN=C4
DMIZB81	IK	RURVWNUUUXCYRB-UHFFFAOYSA-N
DMIZB81	IU	N-(1-adamantyl)pyrazine-2-carboxamide
DMIZB81	DE	Discovery agent

DMVJLSM	ID	DMVJLSM
DMVJLSM	DN	Pyrazofurin
DMVJLSM	HS	Investigative
DMVJLSM	DT	Small molecular drug
DMVJLSM	PC	135413551
DMVJLSM	MW	259.22
DMVJLSM	FM	C9H13N3O6
DMVJLSM	IC	InChI=1S/C9H13N3O6/c10-9(17)4-6(15)3(11-12-4)8-7(16)5(14)2(1-13)18-8/h2,5,7-8,13-16H,1H2,(H2,10,17)(H,11,12)/t2-,5-,7-,8+/m1/s1
DMVJLSM	CS	C([C@@H]1[C@H]([C@H]([C@@H](O1)C2=NNC(=C2O)C(=O)N)O)O)O
DMVJLSM	IK	XESARGFCSKSFID-FLLFQEBCSA-N
DMVJLSM	IU	3-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1H-pyrazole-5-carboxamide
DMVJLSM	CA	CAS 30868-30-5
DMVJLSM	CB	CHEBI:90284
DMVJLSM	DE	Discovery agent

DMUB0EJ	ID	DMUB0EJ
DMUB0EJ	DN	Pyrazolo[1,5-a]pyrimidine 3G
DMUB0EJ	HS	Investigative
DMUB0EJ	SN	KDR/Flk-1 kinase inhibitor IV; pyrazolo[1,5-a]pyrimidine 3g
DMUB0EJ	DT	Small molecular drug
DMUB0EJ	PC	5329468
DMUB0EJ	MW	307.4
DMUB0EJ	FM	C17H13N3OS
DMUB0EJ	IC	InChI=1S/C17H13N3OS/c1-21-15-4-2-12(3-5-15)14-8-18-17-16(9-19-20(17)10-14)13-6-7-22-11-13/h2-11H,1H3
DMUB0EJ	CS	COC1=CC=C(C=C1)C2=CN3C(=C(C=N3)C4=CSC=C4)N=C2
DMUB0EJ	IK	HBWLNACPIFKNIP-UHFFFAOYSA-N
DMUB0EJ	IU	6-(4-methoxyphenyl)-3-thiophen-3-ylpyrazolo[1,5-a]pyrimidine
DMUB0EJ	CA	CAS 216661-57-3
DMUB0EJ	CB	CHEBI:93078
DMUB0EJ	DE	Discovery agent

DM69LKB	ID	DM69LKB
DM69LKB	DN	Pyrazolo[1,5-a]pyrimidine-3-carboxylate
DM69LKB	HS	Investigative
DM69LKB	DE	Discovery agent

DMLFQKU	ID	DMLFQKU
DMLFQKU	DN	pyrazolone, 1
DMLFQKU	HS	Investigative
DMLFQKU	SN	compound 43 [PMID:23160941]; compound 43 [PMID:16697190]
DMLFQKU	DT	Small molecular drug
DMLFQKU	PC	24776341
DMLFQKU	MW	384.9
DMLFQKU	FM	C20H21ClN4O2
DMLFQKU	IC	InChI=1S/C20H21ClN4O2/c1-13(2)18-17(23-20(27)22-15-11-9-14(21)10-12-15)19(26)25(24(18)3)16-7-5-4-6-8-16/h4-13H,1-3H3,(H2,22,23,27)
DMLFQKU	CS	CC(C)C1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)NC3=CC=C(C=C3)Cl
DMLFQKU	IK	PAEBEUZTAPIOIO-UHFFFAOYSA-N
DMLFQKU	IU	1-(4-chlorophenyl)-3-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea
DMLFQKU	CA	CAS 903895-98-7
DMLFQKU	DE	Discovery agent

DMKTB5U	ID	DMKTB5U
DMKTB5U	DN	PYRAZOLOPYRIDAZINE 1
DMKTB5U	HS	Investigative
DMKTB5U	SN	PYRAZOLOPYRIDAZINE 1; 551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
DMKTB5U	DT	Small molecular drug
DMKTB5U	PC	6539361
DMKTB5U	MW	318.33
DMKTB5U	FM	C17H14N6O
DMKTB5U	IC	InChI=1S/C17H14N6O/c1-24-13-5-2-4-12(10-13)21-17-18-9-7-15(22-17)14-11-20-23-16(14)6-3-8-19-23/h2-11H,1H3,(H,18,21,22)
DMKTB5U	CS	COC1=CC=CC(=C1)NC2=NC=CC(=N2)C3=C4C=CC=NN4N=C3
DMKTB5U	IK	GBNWWXHUOVAUHT-UHFFFAOYSA-N
DMKTB5U	IU	N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
DMKTB5U	CA	CAS 551920-54-8
DMKTB5U	DE	Discovery agent

DMI7AUJ	ID	DMI7AUJ
DMI7AUJ	DN	PYRAZOLOPYRIDAZINE 2
DMI7AUJ	HS	Investigative
DMI7AUJ	SN	PYRAZOLOPYRIDAZINE 2; pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
DMI7AUJ	DT	Small molecular drug
DMI7AUJ	PC	6539367
DMI7AUJ	MW	348.4
DMI7AUJ	FM	C18H16N6O2
DMI7AUJ	IC	InChI=1S/C18H16N6O2/c1-25-16-6-5-12(10-17(16)26-2)22-18-19-9-7-14(23-18)13-11-21-24-15(13)4-3-8-20-24/h3-11H,1-2H3,(H,19,22,23)
DMI7AUJ	CS	COC1=C(C=C(C=C1)NC2=NC=CC(=N2)C3=C4C=CC=NN4N=C3)OC
DMI7AUJ	IK	AGAYQQLAAVQQLA-UHFFFAOYSA-N
DMI7AUJ	IU	N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
DMI7AUJ	DE	Discovery agent

DMEF6IP	ID	DMEF6IP
DMEF6IP	DN	Pyrene-1-aldehyde
DMEF6IP	HS	Investigative
DMEF6IP	SN	Pyrene-1-carbaldehyde; RCYFOPUXRMOLQM-UHFFFAOYSA-N; 1-Formylpyrene; KSC224M2B; PYRENECARBOXALDEHYDE; pyrene carboxaldehyde; pyrene-1-carboxaldehyde; pyrenecarbaldehyde; 1-PYRENECARBOXALDEHYDE; 1-Pyrene carboxaldehyde; 1-Pyrene-carboxaldehyde; 1-Pyrenealdehyde; 1-Pyrenecarbaldehyde; 3-Formylpyrene; 3-Pyrenealdehyde; 3-Pyrenecarboxaldehyde; 3-Pyrenylaldehyde; 3029-19-4; AC1L5OS9; AC1Q6PUX; AC1Q6QH9; ACMC-209hea; CCRIS 3163; EINECS 221-196-6; I9H95PVI1P; MFCD00004139; NSC 30811; SCHEMBL52121; UNII-I9H95PVI1P
DMEF6IP	PC	232848
DMEF6IP	MW	230.26
DMEF6IP	FM	C17H10O
DMEF6IP	IC	RCYFOPUXRMOLQM-UHFFFAOYSA-N
DMEF6IP	CS	C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)C=O
DMEF6IP	IK	1S/C17H10O/c18-10-14-7-6-13-5-4-11-2-1-3-12-8-9-15(14)17(13)16(11)12/h1-10H
DMEF6IP	IU	pyrene-1-carbaldehyde
DMEF6IP	CA	CAS 3029-19-4
DMEF6IP	DE	Discovery agent

DMGJ0RM	ID	DMGJ0RM
DMGJ0RM	DN	Pyrenemethanol
DMGJ0RM	HS	Investigative
DMGJ0RM	SN	4-Pyrenemethanol; (PYREN-4-YL)METHANOL; 22245-54-1; SCHEMBL975512; 4-hydroxymethylpyrene; CTK0J6579
DMGJ0RM	PC	57934637
DMGJ0RM	MW	232.28
DMGJ0RM	FM	C17H12O
DMGJ0RM	IC	LABNFNHSRBDQDP-UHFFFAOYSA-N
DMGJ0RM	CS	C1=CC2=C3C(=C1)C=C(C4=CC=CC(=C43)C=C2)CO
DMGJ0RM	IK	1S/C17H12O/c18-10-14-9-13-5-1-3-11-7-8-12-4-2-6-15(14)17(12)16(11)13/h1-9,18H,10H2
DMGJ0RM	IU	pyren-4-ylmethanol
DMGJ0RM	CA	CAS 22245-54-1
DMGJ0RM	DE	Discovery agent

DMOCG6M	ID	DMOCG6M
DMOCG6M	DN	Pyridin-3-yl 4-butoxybenzylcarbamate
DMOCG6M	HS	Investigative
DMOCG6M	SN	CHEMBL596877; pyridin-3-yl 4-butoxybenzylcarbamate
DMOCG6M	DT	Small molecular drug
DMOCG6M	PC	20872734
DMOCG6M	MW	300.35
DMOCG6M	FM	C17H20N2O3
DMOCG6M	IC	InChI=1S/C17H20N2O3/c1-2-3-11-21-15-8-6-14(7-9-15)12-19-17(20)22-16-5-4-10-18-13-16/h4-10,13H,2-3,11-12H2,1H3,(H,19,20)
DMOCG6M	CS	CCCCOC1=CC=C(C=C1)CNC(=O)OC2=CN=CC=C2
DMOCG6M	IK	CZFYUEMAFQHRFG-UHFFFAOYSA-N
DMOCG6M	IU	pyridin-3-yl N-[(4-butoxyphenyl)methyl]carbamate
DMOCG6M	DE	Discovery agent

DM4G8WX	ID	DM4G8WX
DM4G8WX	DN	Pyridine-2,4-dicarboxylic acid
DM4G8WX	HS	Investigative
DM4G8WX	SN	Pyridine-2,4-dicarboxylic acid; 499-80-9; 2,4-PYRIDINEDICARBOXYLIC ACID; Lutidinic acid; 2,4-Lutidinic acid; UNII-AFI29F0TVL; AFI29F0TVL; CHEBI:44737; EC 207-892-2; MJIVRKPEXXHNJT-UHFFFAOYSA-N; MFCD00149413; 2,4-Pyridinedicarboxylic acid hydrate, 99+%; 2,4-Pyridinedicarboxylicacid, hydrate (1:1); 4nrq; PD2; EINECS 207-892-2; NSC 403248; PubChem16314; 4-carboxypicolinic acid; 2vd7; 4ie0; 2w2i; pyridine carboxylate, 6a; AC1Q5UFW; ACMC-1BNB9; AC1L1V1N; 2,4-Pyridine-dicarboxylate; SCHEMBL72377; cid_10365; MLS000078055; GTPL8744
DM4G8WX	DT	Small molecular drug
DM4G8WX	PC	10365
DM4G8WX	MW	167.12
DM4G8WX	FM	C7H5NO4
DM4G8WX	IC	InChI=1S/C7H5NO4/c9-6(10)4-1-2-8-5(3-4)7(11)12/h1-3H,(H,9,10)(H,11,12)
DM4G8WX	CS	C1=CN=C(C=C1C(=O)O)C(=O)O
DM4G8WX	IK	MJIVRKPEXXHNJT-UHFFFAOYSA-N
DM4G8WX	IU	pyridine-2,4-dicarboxylic acid
DM4G8WX	CA	CAS 499-80-9
DM4G8WX	CB	CHEBI:44737
DM4G8WX	DE	Discovery agent

DM3PAS4	ID	DM3PAS4
DM3PAS4	DN	Pyridobenzimidazole
DM3PAS4	HS	Investigative
DM3PAS4	SN	ZINC72190057; AKOS026719278; benzo[4,5]imidazo[1,2-a]pyridin-4-ylmethanol
DM3PAS4	TC	Antifungal Agents
DM3PAS4	DT	Small molecular drug
DM3PAS4	PC	164569
DM3PAS4	MW	169.18
DM3PAS4	FM	C10H7N3
DM3PAS4	IC	InChI=1S/C10H7N3/c1-2-7-8(11-5-1)3-4-9-10(7)13-6-12-9/h1-6,11H
DM3PAS4	CS	C1=CNC2=CC=C3C(=NC=N3)C2=C1
DM3PAS4	IK	FOLSLCYDXFQZJP-UHFFFAOYSA-N
DM3PAS4	IU	6H-imidazo[4,5-f]quinoline
DM3PAS4	CA	CAS 233-55-6
DM3PAS4	DE	Fungal infection

DMQ6POC	ID	DMQ6POC
DMQ6POC	DN	Pyridoxamine-5'-Phosphate
DMQ6POC	HS	Investigative
DMQ6POC	DT	Small molecular drug
DMQ6POC	PC	1053
DMQ6POC	MW	248.17
DMQ6POC	FM	C8H13N2O5P
DMQ6POC	IC	InChI=1S/C8H13N2O5P/c1-5-8(11)7(2-9)6(3-10-5)4-15-16(12,13)14/h3,11H,2,4,9H2,1H3,(H2,12,13,14)
DMQ6POC	CS	CC1=NC=C(C(=C1O)CN)COP(=O)(O)O
DMQ6POC	IK	ZMJGSOSNSPKHNH-UHFFFAOYSA-N
DMQ6POC	IU	[4-(aminomethyl)-5-hydroxy-6-methylpyridin-3-yl]methyl dihydrogen phosphate
DMQ6POC	CA	CAS 529-96-4
DMQ6POC	CB	CHEBI:18335
DMQ6POC	DE	Discovery agent

DMFUNL1	ID	DMFUNL1
DMFUNL1	DN	Pyridoxine-5'-phosphate
DMFUNL1	HS	Investigative
DMFUNL1	SN	Pyridoxine phosphate; Pyridoxine 5-phosphate; pyridoxine-5'-phosphate; Pyridoxyl-5-phosphate; Pyridoxol 5-phosphate; 447-05-2; Pyridoxol 5'-phosphate; UNII-RG20W8WYLS; 5-Hydroxy-4-(hydroxymethyl)-6-methyl-3-pyridylmethyl dihydrogen phosphate; PYRIDOXINE 5'-PHOSPHATE; EINECS 207-179-6; NSC 83119; RG20W8WYLS; BRN 0233737; Pyridoxol, 5-(dihydrogen phosphate); [5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl dihydrogen phosphate; pyridoxine-P; pyridoxine-5P; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, alpha(3)-(dihydrog
DMFUNL1	DT	Small molecular drug
DMFUNL1	PC	1055
DMFUNL1	MW	249.16
DMFUNL1	FM	C8H12NO6P
DMFUNL1	IC	InChI=1S/C8H12NO6P/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14/h2,10-11H,3-4H2,1H3,(H2,12,13,14)
DMFUNL1	CS	CC1=NC=C(C(=C1O)CO)COP(=O)(O)O
DMFUNL1	IK	WHOMFKWHIQZTHY-UHFFFAOYSA-N
DMFUNL1	IU	[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl dihydrogen phosphate
DMFUNL1	CA	CAS 447-05-2
DMFUNL1	CB	CHEBI:28803
DMFUNL1	DE	Discovery agent

DMUVCWY	ID	DMUVCWY
DMUVCWY	DN	Pyridoxyl-Alanine-5-Phosphate
DMUVCWY	HS	Investigative
DMUVCWY	SN	N-(5'-PHOSPHOPYRIDOXYL)-L-ALANINE; ALANYL-PYRIDOXAL-5'-PHOSPHATE; CHEBI:44770; N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-L-alanine; 2-[(3-HYDROXY-2-METHYL-5-PHOSPHONOOXYMETHYL-PYRIDIN-4-YLMETHYL)-AMINO]-PROPIONIC ACID; F0G; PLP-L-Ala; Epitope ID:140625; AC1L9GV6; SCHEMBL4309695; DB04467
DMUVCWY	DT	Small molecular drug
DMUVCWY	PC	445376
DMUVCWY	MW	320.24
DMUVCWY	FM	C11H17N2O7P
DMUVCWY	IC	InChI=1S/C11H17N2O7P/c1-6-10(14)9(4-13-7(2)11(15)16)8(3-12-6)5-20-21(17,18)19/h3,7,13-14H,4-5H2,1-2H3,(H,15,16)(H2,17,18,19)
DMUVCWY	CS	CC1=NC=C(C(=C1O)CNC(C)C(=O)O)COP(=O)(O)O
DMUVCWY	IK	WACJCHFWJNNBPR-UHFFFAOYSA-N
DMUVCWY	IU	2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]propanoic acid
DMUVCWY	DE	Discovery agent

DM7AW0X	ID	DM7AW0X
DM7AW0X	DN	Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate
DM7AW0X	HS	Investigative
DM7AW0X	SN	[5-hydroxy-6-methyl-4-[[(3-oxo-1,2-oxazolidin-4-yl)amino]methyl]pyridin-3-yl]methyl dihydrogen phosphate; (5-hydroxy-6-methyl-4-{[(3-oxo-1,2-oxazolidin-4-yl)amino]methyl}pyridin-3-yl)methyl dihydrogen phosphate; AC1L1ESQ; PYRIDOXYL-N,O-CYCLOSERYLAMIDE-5-MONOPHOSPHATE; CTK7H6662; L-PYRIDOXYL-N,O-CYCLOSERYLAMIDE-5-MONOPHOSPHATE; L-[3-HYDROXY-2-METHYL-5-PHOSPHONOOXYMETHYL-PYRIDIN-4-YLMETHYL]-N,O-CYCLOSERYLAMIDE; [3-HYDROXY-2-METHYL-5-PHOSPHONOOXYMETHYL-PYRIDIN-4-YLMETHYL]-N,O-CYCLOSERYLAMIDE; Phosphoric acid [4-[[(3-o
DM7AW0X	DT	Small molecular drug
DM7AW0X	PC	2931
DM7AW0X	MW	333.23
DM7AW0X	FM	C11H16N3O7P
DM7AW0X	IC	InChI=1S/C11H16N3O7P/c1-6-10(15)8(3-13-9-5-20-14-11(9)16)7(2-12-6)4-21-22(17,18)19/h2,9,13,15H,3-5H2,1H3,(H,14,16)(H2,17,18,19)
DM7AW0X	CS	CC1=NC=C(C(=C1O)CNC2CONC2=O)COP(=O)(O)O
DM7AW0X	IK	NNRZSZJOQKAGTO-UHFFFAOYSA-N
DM7AW0X	IU	[5-hydroxy-6-methyl-4-[[(3-oxo-1,2-oxazolidin-4-yl)amino]methyl]pyridin-3-yl]methyl dihydrogen phosphate
DM7AW0X	DE	Discovery agent

DM7T2VQ	ID	DM7T2VQ
DM7T2VQ	DN	Pyrimidinyl acylthiourea
DM7T2VQ	HS	Investigative
DM7T2VQ	DE	Discovery agent

DMCTJAM	ID	DMCTJAM
DMCTJAM	DN	PYRIPYROPENE A
DMCTJAM	HS	Investigative
DMCTJAM	DT	Small molecular drug
DMCTJAM	PC	11828024
DMCTJAM	MW	583.6
DMCTJAM	FM	C31H37NO10
DMCTJAM	IC	InChI=1S/C31H37NO10/c1-16(33)38-15-30(5)22-13-24(40-18(3)35)31(6)27(29(22,4)10-9-23(30)39-17(2)34)26(36)25-21(42-31)12-20(41-28(25)37)19-8-7-11-32-14-19/h7-8,11-12,14,22-24,26-27,36H,9-10,13,15H2,1-6H3/t22-,23+,24+,26+,27-,29+,30+,31-/m1/s1
DMCTJAM	CS	CC(=O)OC[C@@]1([C@H](CC[C@]2([C@H]1C[C@@H]([C@@]3([C@@H]2[C@H](C4=C(O3)C=C(OC4=O)C5=CN=CC=C5)O)C)OC(=O)C)C)OC(=O)C)C
DMCTJAM	IK	PMMQOFWSZRQWEV-RVTXXDJVSA-N
DMCTJAM	IU	[(1S,2S,5S,6R,7R,9S,10S,18R)-5,9-diacetyloxy-18-hydroxy-2,6,10-trimethyl-16-oxo-14-pyridin-3-yl-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-12(17),13-dien-6-yl]methyl acetate
DMCTJAM	CA	CAS 147444-03-9
DMCTJAM	CB	CHEBI:64695
DMCTJAM	DE	Discovery agent

DMG5KDY	ID	DMG5KDY
DMG5KDY	DN	Pyrogallol
DMG5KDY	HS	Investigative
DMG5KDY	SN	pyrogallol; benzene-1,2,3-triol; 87-66-1; 1,2,3-trihydroxybenzene; pyrogallic acid; 1,2,3-benzenetriol; Fouramine Brown AP; fourrine PG; fourrine 85; Pyro; C.I. Oxidation Base 32; Piral; fouramine base ap; C.I. 76515; Benzenetriol; 1,2,3-Trihydroxybenzen; Benzene, 1,2,3-trihydroxy-; CI Oxidation Base 32; NSC 5035; UNII-01Y4A2QXY0; HSDB 794; CCRIS 1940; 2,3-Dihydroxyphenol; 1,2,3-Trihydroxybenzen [Czech]; 1,2,3-TRIHYDROXY-BENZENE; Pyrogallol, ACS reagent; EINECS 201-762-9; BRN 0907431; CI 76515; AI3-00709; CHEMBL307145; 01Y4A2QXY0
DMG5KDY	DT	Small molecular drug
DMG5KDY	PC	1057
DMG5KDY	MW	126.11
DMG5KDY	FM	C6H6O3
DMG5KDY	IC	InChI=1S/C6H6O3/c7-4-2-1-3-5(8)6(4)9/h1-3,7-9H
DMG5KDY	CS	C1=CC(=C(C(=C1)O)O)O
DMG5KDY	IK	WQGWDDDVZFFDIG-UHFFFAOYSA-N
DMG5KDY	IU	benzene-1,2,3-triol
DMG5KDY	CA	CAS 87-66-1
DMG5KDY	CB	CHEBI:16164
DMG5KDY	DE	Discovery agent

DMROZUA	ID	DMROZUA
DMROZUA	DN	Pyroglutamic acid
DMROZUA	HS	Investigative
DMROZUA	SN	DL-Pyroglutamic acid; 149-87-1; 5-Oxopyrrolidine-2-carboxylic acid; 2-Pyrrolidone-5-carboxylic acid; DL-Proline, 5-oxo-; 5-OXOPROLINE; 5-Oxo-DL-proline; Pyroglutamate; D-(+)-Pyroglutamic Acid; DL-Glutamic Acid Lactam; Pyrrolidonecarboxylic acid; CHEBI:16010; ODHCTXKNWHHXJC-UHFFFAOYSA-N; MFCD00064322; 5-oxoprolinate; DL-Pidolic acid; (+)-Pyroglutamic acid; 5-OXO-2-PYRROLIDINECARBOXYLIC ACID; D-Pyroglutamate; (+)-2-Pyrrolidone-5-carboxylic acid; DL-5-Oxoproline; (D-5-Oxo-2-pyrrolidinecarboxylic acid); Proline,5-oxo-; 5-Oxoproline #
DMROZUA	DT	Small molecular drug
DMROZUA	PC	7405
DMROZUA	MW	129.11
DMROZUA	FM	C5H7NO3
DMROZUA	IC	InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1
DMROZUA	CS	C1CC(=O)N[C@@H]1C(=O)O
DMROZUA	IK	ODHCTXKNWHHXJC-VKHMYHEASA-N
DMROZUA	IU	(2S)-5-oxopyrrolidine-2-carboxylic acid
DMROZUA	CA	CAS 98-79-3
DMROZUA	CB	CHEBI:18183
DMROZUA	DE	Discovery agent

DMZQ75M	ID	DMZQ75M
DMZQ75M	DN	Pyrophosphate 2-
DMZQ75M	HS	Investigative
DMZQ75M	SN	pyrophosphate 2-; dihydrogen diphosphate; diphosphate(2-); AC1L1JDO; CHEBI:45212; H2P2O7(2-)
DMZQ75M	DT	Small molecular drug
DMZQ75M	PC	4995
DMZQ75M	MW	175.96
DMZQ75M	FM	H2O7P2-2
DMZQ75M	IC	InChI=1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)/p-2
DMZQ75M	CS	OP(=O)([O-])OP(=O)(O)[O-]
DMZQ75M	IK	XPPKVPWEQAFLFU-UHFFFAOYSA-L
DMZQ75M	IU	[hydroxy(oxido)phosphoryl] hydrogen phosphate
DMZQ75M	CB	CHEBI:45212
DMZQ75M	DE	Discovery agent

DMV48S2	ID	DMV48S2
DMV48S2	DN	Pyrovalerone
DMV48S2	HS	Investigative
DMV48S2	SN	Centroton; Thymergix; PYROVALERONE HYDROCHLORIDE; Pyrovalerone HCl; Sp 1059; Pyrovalerone hydrochloride [USAN]; EINECS 214-556-9; F 1983; 1147-62-2; 4'-Methyl-2-(1-pyrrolidinyl)valerophenone hydrochloride; 1-(p-Methylphenyl)-2-pyrrolidyl-1-pentanone hydrochloride; DEA No. 1485; 1-p-Tolyl-1-oxo-2-pyrrolidino-n-pentane hydrochloride; Valerophenone, 4'-methyl-2-(1-pyrrolidinyl)-, hydrochloride; 1-Pentanone, 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-, hydrochloride; Pyrovalerone hydrochloride (USAN); AC1L23PD; SCHEMBL121638
DMV48S2	DT	Small molecular drug
DMV48S2	PC	14373
DMV48S2	MW	245.36
DMV48S2	FM	C16H23NO
DMV48S2	IC	InChI=1S/C16H23NO/c1-3-6-15(17-11-4-5-12-17)16(18)14-9-7-13(2)8-10-14/h7-10,15H,3-6,11-12H2,1-2H3
DMV48S2	CS	CCCC(C(=O)C1=CC=C(C=C1)C)N2CCCC2
DMV48S2	IK	SWUVZKWCOBGPTH-UHFFFAOYSA-N
DMV48S2	IU	1-(4-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one
DMV48S2	CA	CAS 3563-49-3
DMV48S2	CB	CHEBI:134998
DMV48S2	DE	Discovery agent

DMS4ZFU	ID	DMS4ZFU
DMS4ZFU	DN	Pyrrolidin-(2Z)-ylideneamine
DMS4ZFU	HS	Investigative
DMS4ZFU	SN	3,4-dihydro-2H-pyrrol-5-amine; 872-34-4; Pyrrolidin-2-imine; Pyrrolidin-(2Z)-ylideneamine; 4,5-DIHYDRO-3H-PYRROL-2-YLAMINE; CHEMBL161318; 2-Amino-1-pyrroline; iminopyrrolidine; 2-iminopyrrolidine; 2-imino pyrrolidine; 2-imino-pyrrolidine; 2-Amino-1-pyrrolin; PYR040; CTK5F8124; DTXSID60509645; NJBMZYSKLWQXLJ-UHFFFAOYSA-N; MolPort-004-968-713; 2-amino-4,5-dihydro-3H-pyrrole; 2H-Pyrrol-5-amine,3,4-dihydro-; BDBM50049251; BBL031757; ZINC12946088; STL283815; ANW-72957; 3788AC; 2H-Pyrrol-5-amine, 3,4-dihydro-; AKOS009098397; AKOS002684118
DMS4ZFU	DT	Small molecular drug
DMS4ZFU	PC	12778904
DMS4ZFU	MW	84.12
DMS4ZFU	FM	C4H8N2
DMS4ZFU	IC	InChI=1S/C4H8N2/c5-4-2-1-3-6-4/h1-3H2,(H2,5,6)
DMS4ZFU	CS	C1CC(=NC1)N
DMS4ZFU	IK	NJBMZYSKLWQXLJ-UHFFFAOYSA-N
DMS4ZFU	IU	3,4-dihydro-2H-pyrrol-5-amine
DMS4ZFU	CA	CAS 872-34-4
DMS4ZFU	DE	Discovery agent

DMYNZXC	ID	DMYNZXC
DMYNZXC	DN	Pyrrolidin-1-yl-thiourea
DMYNZXC	HS	Investigative
DMYNZXC	SN	CHEMBL48338; 88147-87-9; N-Pyrrolidin-1-ylthiourea; Thiourea, 1-pyrrolidinyl-; SCHEMBL5320211; CTK3B7005; DTXSID20658163
DMYNZXC	DT	Small molecular drug
DMYNZXC	PC	44291858
DMYNZXC	MW	145.23
DMYNZXC	FM	C5H11N3S
DMYNZXC	IC	InChI=1S/C5H11N3S/c6-5(9)7-8-3-1-2-4-8/h1-4H2,(H3,6,7,9)
DMYNZXC	CS	C1CCN(C1)NC(=S)N
DMYNZXC	IK	LUZJFNYVKQEEGM-UHFFFAOYSA-N
DMYNZXC	IU	pyrrolidin-1-ylthiourea
DMYNZXC	CA	CAS 88147-87-9
DMYNZXC	DE	Discovery agent

DM0BHCJ	ID	DM0BHCJ
DM0BHCJ	DN	Pyrrolidin-3-yl-acetic acid
DM0BHCJ	HS	Investigative
DM0BHCJ	SN	89203-64-5; 2-(pyrrolidin-3-yl)acetic acid; 3-PYRROLIDINEACETIC ACID; 3-Pyrrolidineaceticacid; Pyrrolidin-3-yl-acetic acid; 2-pyrrolidin-3-ylacetic Acid; pyrrolidin-3-ylacetic acid; CHEMBL351355; 2-(Pyrrolidin-3yl)acetic acid; Homo-beta-proline; ACMC-20liyx; ACMC-20mq1s; pyrrolidine-3-acetic acid; AC1N49FZ; SCHEMBL374930; CTK3E7957; OUENRUZPZZFMCA-UHFFFAOYSA-N; MolPort-001-729-044; KS-000003FH; BDBM50013224; 3-pyrrolidineacetic acid, AldrichCPR; 3-pyrrolidineacetic acid hydrochloride; AKOS005264421; MCULE-3887627276; RP19856
DM0BHCJ	DT	Small molecular drug
DM0BHCJ	PC	4125298
DM0BHCJ	MW	129.16
DM0BHCJ	FM	C6H11NO2
DM0BHCJ	IC	InChI=1S/C6H11NO2/c8-6(9)3-5-1-2-7-4-5/h5,7H,1-4H2,(H,8,9)
DM0BHCJ	CS	C1CNCC1CC(=O)O
DM0BHCJ	IK	OUENRUZPZZFMCA-UHFFFAOYSA-N
DM0BHCJ	IU	2-pyrrolidin-3-ylacetic acid
DM0BHCJ	DE	Discovery agent

DM5ZAS6	ID	DM5ZAS6
DM5ZAS6	DN	Pyrrolidine dithiocarbamate
DM5ZAS6	HS	Investigative
DM5ZAS6	SN	Pyrrolidine dithiocarbamate; Pyrrolidine-1-carbodithioic acid; Pyrrolidine dithiocarbamic acid; Pyrrolidinedithiocarbamate; 1-Pyrrolidinecarbodithioic acid; 25769-03-3; PDTC; apdc; Tetramethylenedithiocarbamic acid; Pyrrolidine-N-carbodithioic acid; Ammonium pyrrolidine dithiocarbamate; 1-Pyrrolidinecarbodithioic acid, ammonium salt; CHEBI:78782; Ammonium 1-pyrrolidinecarbodithioate; C5H9NS2; 5108-96-3; NSC298194; Pyrrolidine-N-dithiocarbamic acid ammonium salt; ammonium tetramethylene dithiocarbamate; NCIOpen2_000025
DM5ZAS6	DT	Small molecular drug
DM5ZAS6	PC	65351
DM5ZAS6	MW	147.3
DM5ZAS6	FM	C5H9NS2
DM5ZAS6	IC	InChI=1S/C5H9NS2/c7-5(8)6-3-1-2-4-6/h1-4H2,(H,7,8)
DM5ZAS6	CS	C1CCN(C1)C(=S)S
DM5ZAS6	IK	VSWDORGPIHIGNW-UHFFFAOYSA-N
DM5ZAS6	IU	pyrrolidine-1-carbodithioic acid
DM5ZAS6	CA	CAS 25769-03-3
DM5ZAS6	CB	CHEBI:78782
DM5ZAS6	DE	Discovery agent

DME6HCQ	ID	DME6HCQ
DME6HCQ	DN	pyrrolidine MCHR1 antagonist 1
DME6HCQ	HS	Investigative
DME6HCQ	SN	CHEMBL1760248; pyrrolidine MCHR1 antagonist 1; GTPL7756; BDBM50340202; N-(3-chlorophenyl)-2-((3R,4S)-1-(2-(4-hydroxytetrahydro-2H-pyran-4-yl)ethyl)-4-(4-methoxyphenyl)pyrrolidin-3-yl)acetamide
DME6HCQ	DT	Small molecular drug
DME6HCQ	PC	54579974
DME6HCQ	MW	473
DME6HCQ	FM	C26H33ClN2O4
DME6HCQ	IC	InChI=1S/C26H33ClN2O4/c1-32-23-7-5-19(6-8-23)24-18-29(12-9-26(31)10-13-33-14-11-26)17-20(24)15-25(30)28-22-4-2-3-21(27)16-22/h2-8,16,20,24,31H,9-15,17-18H2,1H3,(H,28,30)/t20-,24+/m0/s1
DME6HCQ	CS	COC1=CC=C(C=C1)[C@H]2CN(C[C@@H]2CC(=O)NC3=CC(=CC=C3)Cl)CCC4(CCOCC4)O
DME6HCQ	IK	OLINDOIRFAZHRH-GBXCKJPGSA-N
DME6HCQ	IU	N-(3-chlorophenyl)-2-[(3R,4S)-1-[2-(4-hydroxyoxan-4-yl)ethyl]-4-(4-methoxyphenyl)pyrrolidin-3-yl]acetamide
DME6HCQ	DE	Discovery agent

DM906JK	ID	DM906JK
DM906JK	DN	Pyrrolidine-1-carbonitrile
DM906JK	HS	Investigative
DM906JK	SN	Pyrrolidine-1-carbonitrile; 1530-88-7; 1-Pyrrolidinecarbonitrile; 1-Cyanopyrrolidine; N-Cyanopyrrolidine; CHEMBL262697; QJRYYOWARFCJQZ-UHFFFAOYSA-N; pyrrolidinecarbonitrile; cyanopyrrolidine; Cyano-Pyrrolidine; NSC44225; EINECS 216-234-3; Tetramethylenecyanamide; AC1L2KEM; AC1Q4SLA; 1-pyrrolidine carbonitrile; CTK0I1775; DTXSID90165192; MolPort-000-145-877; ZINC1676633; KS-00002AX2; NSC-44225; 4756AD; BDBM50095495; SBB059310; AKOS006227753; MCULE-2010942719; PS-9344; CJ-27397; AN-49391; KB-65041; FT-0607667; ST51044369; P2337; A827637
DM906JK	DT	Small molecular drug
DM906JK	PC	73737
DM906JK	MW	96.13
DM906JK	FM	C5H8N2
DM906JK	IC	InChI=1S/C5H8N2/c6-5-7-3-1-2-4-7/h1-4H2
DM906JK	CS	C1CCN(C1)C#N
DM906JK	IK	QJRYYOWARFCJQZ-UHFFFAOYSA-N
DM906JK	IU	pyrrolidine-1-carbonitrile
DM906JK	CA	CAS 1530-88-7
DM906JK	DE	Discovery agent

DM1X5JR	ID	DM1X5JR
DM1X5JR	DN	Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DM1X5JR	HS	Investigative
DM1X5JR	SN	CHEMBL370869; pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5381581
DM1X5JR	DT	Small molecular drug
DM1X5JR	PC	18382004
DM1X5JR	MW	236.22
DM1X5JR	FM	C14H8N2O2
DM1X5JR	IC	InChI=1S/C14H8N2O2/c17-13-8-5-6-10-11(12(8)14(18)16-13)7-3-1-2-4-9(7)15-10/h1-6,15H,(H,16,17,18)
DM1X5JR	CS	C1=CC=C2C(=C1)C3=C(N2)C=CC4=C3C(=O)NC4=O
DM1X5JR	IK	AGFYXNWRDSDSRA-UHFFFAOYSA-N
DM1X5JR	IU	6H-pyrrolo[3,4-c]carbazole-1,3-dione
DM1X5JR	DE	Discovery agent

DMM4CU9	ID	DMM4CU9
DMM4CU9	DN	Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione
DMM4CU9	HS	Investigative
DMM4CU9	SN	CHEMBL373066; pyrroloisoindoledione; pyrrolo[3,4-e]indole-1,3(2H,6H)-dione
DMM4CU9	DT	Small molecular drug
DMM4CU9	PC	44407700
DMM4CU9	MW	186.17
DMM4CU9	FM	C10H6N2O2
DMM4CU9	IC	InChI=1S/C10H6N2O2/c13-9-6-1-2-7-5(3-4-11-7)8(6)10(14)12-9/h1-4,11H,(H,12,13,14)
DMM4CU9	CS	C1=CC2=C(C=CN2)C3=C1C(=O)NC3=O
DMM4CU9	IK	KVIRPIKEFDXNQF-UHFFFAOYSA-N
DMM4CU9	IU	6H-pyrrolo[3,4-e]indole-1,3-dione
DMM4CU9	DE	Discovery agent

DMZLFVG	ID	DMZLFVG
DMZLFVG	DN	Pyrrolopyrimidine
DMZLFVG	HS	Investigative
DMZLFVG	PC	577022
DMZLFVG	MW	119.12
DMZLFVG	FM	C6H5N3
DMZLFVG	IC	InChI=1S/C6H5N3/c1-2-8-6-3-7-4-9-5(1)6/h1-4,8H
DMZLFVG	CS	C1=CNC2=CN=CN=C21
DMZLFVG	IK	KDOPAZIWBAHVJB-UHFFFAOYSA-N
DMZLFVG	IU	5H-pyrrolo[3,2-d]pyrimidine
DMZLFVG	DE	Discovery agent

DMUEKB3	ID	DMUEKB3
DMUEKB3	DN	pyrrolopyrimidine 48
DMUEKB3	HS	Investigative
DMUEKB3	SN	GTPL5731; pyrrolopyrimidine 48 [PMID: 22318156]; P-275; 7-benzyl-4-(1-pyridin-2-ylpiperidin-4-yl)oxypyrrolo[2,3-d]pyrimidine.
DMUEKB3	DT	Small molecular drug
DMUEKB3	PC	73755149
DMUEKB3	MW	385.5
DMUEKB3	FM	C23H23N5O
DMUEKB3	IC	InChI=1S/C23H23N5O/c1-2-6-18(7-3-1)16-28-15-11-20-22(28)25-17-26-23(20)29-19-9-13-27(14-10-19)21-8-4-5-12-24-21/h1-8,11-12,15,17,19H,9-10,13-14,16H2
DMUEKB3	CS	C1CN(CCC1OC2=NC=NC3=C2C=CN3CC4=CC=CC=C4)C5=CC=CC=N5
DMUEKB3	IK	ZMRCFNOIVYNNGH-UHFFFAOYSA-N
DMUEKB3	IU	7-benzyl-4-(1-pyridin-2-ylpiperidin-4-yl)oxypyrrolo[2,3-d]pyrimidine
DMUEKB3	DE	Discovery agent

DM725FL	ID	DM725FL
DM725FL	DN	PYY(22-36)
DM725FL	HS	Investigative
DM725FL	PC	91936050
DM725FL	MW	1889.2
DM725FL	FM	C84H137N29O21
DM725FL	IC	InChI=1S/C84H137N29O21/c1-40(2)30-56(107-79(132)62(38-114)111-68(121)44(9)85)73(126)101-52(15-12-28-97-83(91)92)71(124)109-60(35-48-37-95-39-99-48)76(129)108-59(34-47-19-23-50(117)24-20-47)75(128)105-57(31-41(3)4)74(127)110-61(36-64(87)119)77(130)106-58(32-42(5)6)78(131)112-65(43(7)8)80(133)113-66(45(10)115)81(134)103-53(16-13-29-98-84(93)94)69(122)102-54(25-26-63(86)118)72(125)100-51(14-11-27-96-82(89)90)70(123)104-55(67(88)120)33-46-17-21-49(116)22-18-46/h17-24,37,39-45,51-62,65-66,114-117H,11-16,25-36,38,85H2,1-10H3,(H2,86,118)(H2,87,119)(H2,88,120)(H,95,99)(H,100,125)(H,101,126)(H,102,122)(H,103,134)(H,104,123)(H,105,128)(H,106,130)(H,107,132)(H,108,129)(H,109,124)(H,110,127)(H,111,121)(H,112,131)(H,113,133)(H4,89,90,96)(H4,91,92,97)(H4,93,94,98)/t44-,45+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,65-,66-/m0/s1
DM725FL	CS	C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)O
DM725FL	IK	YGRCUVJOPKKCTH-PGLCTWMWSA-N
DM725FL	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DM725FL	DE	Discovery agent

DMD6ZWV	ID	DMD6ZWV
DMD6ZWV	DN	PYY(25-36)
DMD6ZWV	HS	Investigative
DMD6ZWV	PC	91936056
DMD6ZWV	MW	1617.9
DMD6ZWV	FM	C72H116N26O17
DMD6ZWV	IC	InChI=1S/C72H116N26O17/c1-35(2)27-49(93-64(110)51(30-40-16-20-43(101)21-17-40)95-65(111)52(31-41-33-83-34-87-41)92-59(105)44(73)11-8-24-84-70(77)78)63(109)96-53(32-55(75)103)66(112)94-50(28-36(3)4)67(113)97-56(37(5)6)68(114)98-57(38(7)99)69(115)90-46(13-10-26-86-72(81)82)60(106)89-47(22-23-54(74)102)62(108)88-45(12-9-25-85-71(79)80)61(107)91-48(58(76)104)29-39-14-18-42(100)19-15-39/h14-21,33-38,44-53,56-57,99-101H,8-13,22-32,73H2,1-7H3,(H2,74,102)(H2,75,103)(H2,76,104)(H,83,87)(H,88,108)(H,89,106)(H,90,115)(H,91,107)(H,92,105)(H,93,110)(H,94,112)(H,95,111)(H,96,109)(H,97,113)(H,98,114)(H4,77,78,84)(H4,79,80,85)(H4,81,82,86)/t38-,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,56+,57+/m1/s1
DMD6ZWV	CS	C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)N)O
DMD6ZWV	IK	DSTSETSWKNIEJI-UAEPIRMISA-N
DMD6ZWV	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMD6ZWV	DE	Discovery agent

DMFUYR1	ID	DMFUYR1
DMFUYR1	DN	Pyz11-D-Trp8-SRIF
DMFUYR1	HS	Investigative
DMFUYR1	PC	44400741
DMFUYR1	MW	1639.9
DMFUYR1	FM	C74H102N20O19S2
DMFUYR1	IC	InChI=1S/C74H102N20O19S2/c1-39(77)62(100)82-35-59(99)83-56-37-114-115-38-57(74(112)113)92-70(108)55(36-95)91-73(111)61(41(3)97)94-69(107)53(31-45-34-79-26-27-80-45)90-72(110)60(40(2)96)93-64(102)49(23-13-15-25-76)84-67(105)52(30-44-33-81-47-21-11-10-20-46(44)47)88-66(104)51(29-43-18-8-5-9-19-43)86-65(103)50(28-42-16-6-4-7-17-42)87-68(106)54(32-58(78)98)89-63(101)48(85-71(56)109)22-12-14-24-75/h4-11,16-21,26-27,33-34,39-41,48-57,60-61,81,95-97H,12-15,22-25,28-32,35-38,75-77H2,1-3H3,(H2,78,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t39-,40?,41?,48-,49+,50-,51+,52-,53-,54+,55-,56-,57-,60+,61+/m0/s1
DMFUYR1	CS	C[C@@H](C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCCCN)CC(=O)N)CC2=CC=CC=C2)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CCCCN)C(C)O)CC6=NC=CN=C6)C(C)O)CO)C(=O)O)N
DMFUYR1	IK	PBGRXJRISCBKBH-XNXKEXPOSA-N
DMFUYR1	IU	(4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-25,28-dibenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-13-(pyrazin-2-ylmethyl)-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DMFUYR1	DE	Discovery agent

DMDB3Q8	ID	DMDB3Q8
DMDB3Q8	DN	Pyz6-D-Trp8-SRIF
DMDB3Q8	HS	Investigative
DMDB3Q8	PC	44400602
DMDB3Q8	MW	1639.9
DMDB3Q8	FM	C74H102N20O19S2
DMDB3Q8	IC	InChI=1S/C74H102N20O19S2/c1-39(77)62(100)82-35-59(99)83-56-37-114-115-38-57(74(112)113)92-70(108)55(36-95)91-73(111)61(41(3)97)94-69(107)51(29-43-18-8-5-9-19-43)90-72(110)60(40(2)96)93-64(102)49(23-13-15-25-76)84-66(104)52(30-44-33-81-47-21-11-10-20-46(44)47)87-65(103)50(28-42-16-6-4-7-17-42)86-67(105)53(31-45-34-79-26-27-80-45)88-68(106)54(32-58(78)98)89-63(101)48(85-71(56)109)22-12-14-24-75/h4-11,16-21,26-27,33-34,39-41,48-57,60-61,81,95-97H,12-15,22-25,28-32,35-38,75-77H2,1-3H3,(H2,78,98)(H,82,100)(H,83,99)(H,84,104)(H,85,109)(H,86,105)(H,87,103)(H,88,106)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t39-,40?,41?,48-,49+,50+,51-,52-,53-,54+,55-,56-,57-,60+,61+/m0/s1
DMDB3Q8	CS	C[C@@H](C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCCCN)CC(=O)N)CC2=NC=CN=C2)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CCCCN)C(C)O)CC6=CC=CC=C6)C(C)O)CO)C(=O)O)N
DMDB3Q8	IK	JDTSWTCDRKKTPI-DOAKGFBDSA-N
DMDB3Q8	IU	(4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25-dibenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-28-(pyrazin-2-ylmethyl)-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DMDB3Q8	DE	Discovery agent

DM9D805	ID	DM9D805
DM9D805	DN	Pyz7-D-Trp8-SRIF
DM9D805	HS	Investigative
DM9D805	PC	44400603
DM9D805	MW	1639.9
DM9D805	FM	C74H102N20O19S2
DM9D805	IC	InChI=1S/C74H102N20O19S2/c1-39(77)62(100)82-35-59(99)83-56-37-114-115-38-57(74(112)113)92-70(108)55(36-95)91-73(111)61(41(3)97)94-69(107)51(29-43-18-8-5-9-19-43)90-72(110)60(40(2)96)93-64(102)49(23-13-15-25-76)84-66(104)52(30-44-33-81-47-21-11-10-20-46(44)47)87-67(105)53(31-45-34-79-26-27-80-45)88-65(103)50(28-42-16-6-4-7-17-42)86-68(106)54(32-58(78)98)89-63(101)48(85-71(56)109)22-12-14-24-75/h4-11,16-21,26-27,33-34,39-41,48-57,60-61,81,95-97H,12-15,22-25,28-32,35-38,75-77H2,1-3H3,(H2,78,98)(H,82,100)(H,83,99)(H,84,104)(H,85,109)(H,86,106)(H,87,105)(H,88,103)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t39-,40?,41?,48-,49+,50-,51-,52-,53+,54+,55-,56-,57-,60+,61+/m0/s1
DM9D805	CS	C[C@@H](C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCCCN)CC(=O)N)CC2=CC=CC=C2)CC3=NC=CN=C3)CC4=CNC5=CC=CC=C54)CCCCN)C(C)O)CC6=CC=CC=C6)C(C)O)CO)C(=O)O)N
DM9D805	IK	BUGNDGJWDYBQHT-BKUMYXSWSA-N
DM9D805	IU	(4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,28-dibenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-25-(pyrazin-2-ylmethyl)-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DM9D805	DE	Discovery agent

DME0NO8	ID	DME0NO8
DME0NO8	DN	PYZD-4409
DME0NO8	HS	Investigative
DME0NO8	DT	Small molecular drug
DME0NO8	PC	60111983
DME0NO8	MW	351.67
DME0NO8	FM	C14H7ClFN3O5
DME0NO8	IC	InChI=1S/C14H7ClFN3O5/c15-10-5-7(1-3-11(10)16)18-14(21)9(13(20)17-18)6-8-2-4-12(24-8)19(22)23/h1-6H,(H,17,20)/b9-6-
DME0NO8	CS	C1=CC(=C(C=C1N2C(=O)/C(=C\\C3=CC=C(O3)[N+](=O)[O-])/C(=O)N2)Cl)F
DME0NO8	IK	MSYMKEYWUWVZQY-TWGQIWQCSA-N
DME0NO8	IU	(4Z)-1-(3-chloro-4-fluorophenyl)-4-[(5-nitrofuran-2-yl)methylidene]pyrazolidine-3,5-dione
DME0NO8	CA	CAS 423148-78-1
DME0NO8	DE	leukaemia

DML5KMT	ID	DML5KMT
DML5KMT	DN	Q-27137207
DML5KMT	HS	Investigative
DML5KMT	SN	LMPR0103890004; 1-Deoxypentalenic acid; 1-deoxypentalenic acid; CHEBI:68832
DML5KMT	PC	10988200
DML5KMT	MW	234.33
DML5KMT	FM	C15H22O2
DML5KMT	IC	DCFDRCCHOOORSB-DSKWVYQCSA-N
DML5KMT	CS	CC1CCC2C13CC(CC3C=C2C(=O)O)(C)C
DML5KMT	IK	1S/C15H22O2/c1-9-4-5-12-11(13(16)17)6-10-7-14(2,3)8-15(9,10)12/h6,9-10,12H,4-5,7-8H2,1-3H3,(H,16,17)/t9-,10-,12+,15-/m1/s1
DML5KMT	IU	(1R,2R,5R,8S)-2,10,10-trimethyltricyclo[6.3.0.01,5]undec-6-ene-6-carboxylic acid
DML5KMT	CB	CHEBI:68832
DML5KMT	DE	Discovery agent

DM26GBV	ID	DM26GBV
DM26GBV	DN	QA1
DM26GBV	HS	Investigative
DM26GBV	SN	CHEMBL1210313; GTPL5815; SCHEMBL2407215; BDBM50322839; NCGC00189027-01; NCGC00187765-01; QA1; rac-N-(3-methyl-1-morpholinopentan-3-yl)-N-((1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)methyl)cyclohexanecarboxamide; N-(3-methyl-1-morpholinopentan-3-yl)-N-((1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)methyl)cyclohexanecarboxamide
DM26GBV	DT	Small molecular drug
DM26GBV	PC	44156964
DM26GBV	MW	467.6
DM26GBV	FM	C28H41N3O3
DM26GBV	IC	InChI=1S/C28H41N3O3/c1-4-28(2,14-15-30-16-18-34-19-17-30)31(27(33)22-10-6-5-7-11-22)21-24-20-23-12-8-9-13-25(23)29(3)26(24)32/h8-9,12-13,20,22H,4-7,10-11,14-19,21H2,1-3H3
DM26GBV	CS	CCC(C)(CCN1CCOCC1)N(CC2=CC3=CC=CC=C3N(C2=O)C)C(=O)C4CCCCC4
DM26GBV	IK	FWHNGUFKFXDMER-UHFFFAOYSA-N
DM26GBV	IU	N-(3-methyl-1-morpholin-4-ylpentan-3-yl)-N-[(1-methyl-2-oxoquinolin-3-yl)methyl]cyclohexanecarboxamide
DM26GBV	DE	Discovery agent

DM62PI8	ID	DM62PI8
DM62PI8	DN	QCP
DM62PI8	HS	Investigative
DM62PI8	SN	CHEMBL485831; BDBM50242616
DM62PI8	DT	Small molecular drug
DM62PI8	PC	11949247
DM62PI8	MW	346.41
DM62PI8	FM	C13H22N4O5S
DM62PI8	IC	InChI=1S/C13H22N4O5S/c14-7(3-4-10(15)18)11(19)16-8(6-23)12(20)17-5-1-2-9(17)13(21)22/h7-9,23H,1-6,14H2,(H2,15,18)(H,16,19)(H,21,22)/t7-,8-,9-/m0/s1
DM62PI8	CS	C1C[C@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N)C(=O)O
DM62PI8	IK	QFTRCUPCARNIPZ-CIUDSAMLSA-N
DM62PI8	IU	(2S)-1-[(2R)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
DM62PI8	DE	Discovery agent

DMSMQXZ	ID	DMSMQXZ
DMSMQXZ	DN	Qcpac
DMSMQXZ	HS	Investigative
DMSMQXZ	SN	CHEMBL486028; QCPac
DMSMQXZ	DT	Small molecular drug
DMSMQXZ	PC	44560285
DMSMQXZ	MW	331.39
DMSMQXZ	FM	C13H21N3O5S
DMSMQXZ	IC	InChI=1S/C13H21N3O5S/c1-7(11(18)15-9(6-22)13(20)21)14-12(19)10-4-3-5-16(10)8(2)17/h7,9-10,22H,3-6H2,1-2H3,(H,14,19)(H,15,18)(H,20,21)/t7-,9-,10-/m0/s1
DMSMQXZ	CS	C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)C
DMSMQXZ	IK	YFMHBFVZXDWWRU-HGNGGELXSA-N
DMSMQXZ	IU	(2R)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-sulfanylpropanoic acid
DMSMQXZ	DE	Discovery agent

DMJ38YV	ID	DMJ38YV
DMJ38YV	DN	QEDIIRNIARHLAQVGDSMDR
DMJ38YV	HS	Investigative
DMJ38YV	PC	77280325
DMJ38YV	MW	2437.7
DMJ38YV	FM	C100H169N35O34S
DMJ38YV	IC	InChI=1S/C100H169N35O34S/c1-14-46(8)75(133-90(161)61(36-68(104)139)128-82(153)54(21-18-31-113-99(107)108)124-95(166)76(47(9)15-2)135-96(167)77(48(10)16-3)134-91(162)64(39-73(147)148)130-83(154)56(25-28-70(141)142)122-80(151)52(101)23-26-66(102)137)94(165)118-50(12)79(150)120-53(20-17-30-112-98(105)106)81(152)127-60(35-51-40-111-43-116-51)87(158)126-59(34-44(4)5)86(157)117-49(11)78(149)121-55(24-27-67(103)138)85(156)132-74(45(6)7)93(164)115-41-69(140)119-62(37-71(143)144)88(159)131-65(42-136)92(163)123-57(29-33-170-13)84(155)129-63(38-72(145)146)89(160)125-58(97(168)169)22-19-32-114-100(109)110/h40,43-50,52-65,74-77,136H,14-39,41-42,101H2,1-13H3,(H2,102,137)(H2,103,138)(H2,104,139)(H,111,116)(H,115,164)(H,117,157)(H,118,165)(H,119,140)(H,120,150)(H,121,149)(H,122,151)(H,123,163)(H,124,166)(H,125,160)(H,126,158)(H,127,152)(H,128,153)(H,129,155)(H,130,154)(H,131,159)(H,132,156)(H,133,161)(H,134,162)(H,135,167)(H,141,142)(H,143,144)(H,145,146)(H,147,148)(H,168,169)(H4,105,106,112)(H4,107,108,113)(H4,109,110,114)/t46-,47-,48-,49-,50-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,74-,75-,76-,77-/m0/s1
DMJ38YV	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N
DMJ38YV	IK	LBBXBBBHAYODPZ-GVIMSCNFSA-N
DMJ38YV	IU	(4S)-5-[[(2S)-1-[[(2S,3S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[2-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]-5-oxopentanoic acid
DMJ38YV	DE	Discovery agent

DMWOSFJ	ID	DMWOSFJ
DMWOSFJ	DN	QLT-091382
DMWOSFJ	HS	Investigative
DMWOSFJ	SN	Acetyl-CoA carboxylase/sebum inhibitor (sebaceous gland disease), Valocor
DMWOSFJ	CP	Valocor Therapeutics Ltd
DMWOSFJ	DE	Sebaceous gland disease

DMTY5HP	ID	DMTY5HP
DMTY5HP	DN	QNEQCPQVSac
DMTY5HP	HS	Investigative
DMTY5HP	SN	CHEMBL506458
DMTY5HP	PC	44560287
DMTY5HP	MW	1074.1
DMTY5HP	FM	C42H67N13O18S
DMTY5HP	IC	InChI=1S/C42H67N13O18S/c1-18(2)33(54-37(67)25(16-56)47-19(3)57)40(70)50-22(7-11-29(44)59)41(71)55-14-4-5-27(55)39(69)53-26(17-74)38(68)49-20(6-10-28(43)58)34(64)48-21(9-13-32(62)63)35(65)52-24(15-31(46)61)36(66)51-23(42(72)73)8-12-30(45)60/h18,20-27,33,56,74H,4-17H2,1-3H3,(H2,43,58)(H2,44,59)(H2,45,60)(H2,46,61)(H,47,57)(H,48,64)(H,49,68)(H,50,70)(H,51,66)(H,52,65)(H,53,69)(H,54,67)(H,62,63)(H,72,73)/t20-,21-,22-,23-,24-,25-,26-,27-,33-/m0/s1
DMTY5HP	CS	CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)C
DMTY5HP	IK	GLSOSIFUCZBHCX-AYPRZOFJSA-N
DMTY5HP	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-5-amino-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-4-amino-4-oxobutanoyl]amino]-5-amino-5-oxopentanoic acid
DMTY5HP	DE	Discovery agent

DM01RZX	ID	DM01RZX
DM01RZX	DN	QNZ 46
DM01RZX	HS	Investigative
DM01RZX	SN	KB-275239
DM01RZX	DT	Small molecular drug
DM01RZX	PC	76850154
DM01RZX	MW	444.4
DM01RZX	FM	C24H18N3O6+
DM01RZX	IC	InChI=1S/C24H17N3O6/c1-33-19-10-11-21-20(14-19)23(28)26(17-8-6-16(7-9-17)24(29)30)22(25-21)12-5-15-3-2-4-18(13-15)27(31)32/h2-14,20H,1H3/p+1/b12-5+
DM01RZX	CS	COC1=CC2C(=NC(=[N+](C2=O)C3=CC=C(C=C3)C(=O)O)/C=C/C4=CC(=CC=C4)[N+](=O)[O-])C=C1
DM01RZX	IK	ZLXASDKCRPAANV-LFYBBSHMSA-O
DM01RZX	IU	4-[6-methoxy-2-[(E)-2-(3-nitrophenyl)ethenyl]-4-oxo-4aH-quinazolin-3-ium-3-yl]benzoic acid
DM01RZX	DE	Discovery agent

DMYXPF8	ID	DMYXPF8
DMYXPF8	DN	QO-58
DMYXPF8	HS	Investigative
DMYXPF8	SN	CHEMBL1689654; QO-58; GTPL7669; SCHEMBL10062354; MolPort-042-624-524; QO 58; BDBM50339281; ZINC101404854; AKOS027470159; 1259536-62-3; 5-(2,6-Dichloro-5-fluoro-3-pyridinyl)-3-phenyl-2-(trifluoromethyl)-pyrazolo[1,5-a]pyrimidin-7(4H)-one; 5-(2,6-Dichloro-5-fluoropyridin-3-yl)-3-phenyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one
DMYXPF8	DT	Small molecular drug
DMYXPF8	PC	51351551
DMYXPF8	MW	443.2
DMYXPF8	FM	C18H8Cl2F4N4O
DMYXPF8	IC	InChI=1S/C18H8Cl2F4N4O/c19-15-9(6-10(21)16(20)26-15)11-7-12(29)28-17(25-11)13(8-4-2-1-3-5-8)14(27-28)18(22,23)24/h1-7,27H
DMYXPF8	CS	C1=CC=C(C=C1)C2=C(NN3C2=NC(=CC3=O)C4=CC(=C(N=C4Cl)Cl)F)C(F)(F)F
DMYXPF8	IK	ZOLHKPWSDFSDKA-UHFFFAOYSA-N
DMYXPF8	IU	5-(2,6-dichloro-5-fluoropyridin-3-yl)-3-phenyl-2-(trifluoromethyl)-1H-pyrazolo[1,5-a]pyrimidin-7-one
DMYXPF8	DE	Discovery agent

DMJHTUG	ID	DMJHTUG
DMJHTUG	DN	QSPac
DMJHTUG	HS	Investigative
DMJHTUG	SN	CHEMBL521026; QSPac
DMJHTUG	DT	Small molecular drug
DMJHTUG	PC	44560286
DMJHTUG	MW	372.37
DMJHTUG	FM	C15H24N4O7
DMJHTUG	IC	InChI=1S/C15H24N4O7/c1-8(21)19-6-2-3-11(19)14(24)18-10(7-20)13(23)17-9(15(25)26)4-5-12(16)22/h9-11,20H,2-7H2,1H3,(H2,16,22)(H,17,23)(H,18,24)(H,25,26)/t9-,10-,11-/m0/s1
DMJHTUG	CS	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O
DMJHTUG	IK	HPQBUPGLRXIKEL-DCAQKATOSA-N
DMJHTUG	IU	(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoic acid
DMJHTUG	DE	Discovery agent

DM2Q6JY	ID	DM2Q6JY
DM2Q6JY	DN	quadazocine
DM2Q6JY	HS	Investigative
DM2Q6JY	SN	(-)-WIN 44,441; (-)-quadazocine
DM2Q6JY	DT	Small molecular drug
DM2Q6JY	PC	115077
DM2Q6JY	MW	383.6
DM2Q6JY	FM	C25H37NO2
DM2Q6JY	IC	InChI=1S/C25H37NO2/c1-24-14-15-26(3)23(16-19-9-11-21(28)17-22(19)24)25(24,2)13-12-20(27)10-8-18-6-4-5-7-18/h9,11,17-18,23,28H,4-8,10,12-16H2,1-3H3/t23-,24+,25?/m1/s1
DM2Q6JY	CS	C[C@@]12CCN([C@@H](C1(C)CCC(=O)CCC3CCCC3)CC4=C2C=C(C=C4)O)C
DM2Q6JY	IK	LOYWOYCPSWPKFH-CSIQULDISA-N
DM2Q6JY	IU	1-cyclopentyl-5-[(1S,9R)-4-hydroxy-1,10,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-13-yl]pentan-3-one
DM2Q6JY	DE	Discovery agent

DMXIU6W	ID	DMXIU6W
DMXIU6W	DN	Quercetin 3-O-neohesperidoside
DMXIU6W	HS	Investigative
DMXIU6W	SN	quercetin 3-O-neohesperidoside; q-Rha-gal; CHEMBL499824; 117611-67-3; Quercetin 3-O-alpha-rhamnopyranosyl-(1-2)-beta-galactopyranoside; AC1NX8PX; DTXSID60151840; BDBM50260169; 3',4',5,7-Tetrahydroxy-3-(2-O-alpha-L-rhamnopyranosyl-beta-D-galactopyranosyloxy)flavone; 4H-1-Benzopyran-4-one, 3-((2-O-(6-deoxy-alphal-L-manopyranosyl)-beta-D-galactopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
DMXIU6W	DT	Small molecular drug
DMXIU6W	PC	5748416
DMXIU6W	MW	610.5
DMXIU6W	FM	C27H30O16
DMXIU6W	IC	InChI=1S/C27H30O16/c1-8-17(33)20(36)22(38)26(39-8)43-25-21(37)18(34)15(7-28)41-27(25)42-24-19(35)16-13(32)5-10(29)6-14(16)40-23(24)9-2-3-11(30)12(31)4-9/h2-6,8,15,17-18,20-22,25-34,36-38H,7H2,1H3/t8-,15+,17-,18-,20+,21-,22+,25+,26-,27-/m0/s1
DMXIU6W	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)CO)O)O)O)O)O
DMXIU6W	IK	FYBMGZSDYDNBFX-KLUVJTJFSA-N
DMXIU6W	IU	3-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMXIU6W	CA	CAS 117611-67-3
DMXIU6W	DE	Discovery agent

DM1DH96	ID	DM1DH96
DM1DH96	DN	QUERCITRIN
DM1DH96	HS	Investigative
DM1DH96	SN	quercitrin; 522-12-3; Quercetrin; Quercetin 3-rhamnoside; Quercitroside; Quercimelin; Thujin; Quercetin 3-L-rhamnoside; Quercitronic acid; Quercetin 3-O-rhamnoside; UNII-2Y8906LC5P; CHEBI:17558; Quercetin 3-O-alpha-L-rhamnoside; Quercetin-3-L-rhamnoside; 3,3',4',5,7-Pentahydroxyflavone-3-L-rhamnoside; Quercetin-3-rhamnoside; NSC9221; Quercetin, 3-(6-deoxy-alpha-L-mannopyranoside); 2Y8906LC5P; Mannopyranoside, quercetin-3 6-deoxy-, alpha-L-; Quercetin 3-O-alpha-rhamnopyranoside; Usaf cf-2; Quercetrin-3-O-rham
DM1DH96	DT	Small molecular drug
DM1DH96	PC	5280459
DM1DH96	MW	448.4
DM1DH96	FM	C21H20O11
DM1DH96	IC	InChI=1S/C21H20O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-18,21-26,28-29H,1H3/t7-,15-,17+,18+,21-/m0/s1
DM1DH96	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O
DM1DH96	IK	OXGUCUVFOIWWQJ-HQBVPOQASA-N
DM1DH96	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DM1DH96	CA	CAS 522-12-3
DM1DH96	CB	CHEBI:17558
DM1DH96	DE	Discovery agent

DM9YWG8	ID	DM9YWG8
DM9YWG8	DN	Quick-acting insulin
DM9YWG8	HS	Investigative
DM9YWG8	SN	Quick-acting insulin (injectable, diabetes)
DM9YWG8	CP	Thermalin Diabetes LLC
DM9YWG8	DE	Diabetic complication

DM0BEZS	ID	DM0BEZS
DM0BEZS	DN	Quinapril analogue
DM0BEZS	HS	Investigative
DM0BEZS	SN	CHEMBL1162799
DM0BEZS	DT	Small molecular drug
DM0BEZS	PC	91934860
DM0BEZS	MW	836.2
DM0BEZS	FM	C52H78N5O2P+2
DM0BEZS	IC	InChI=1S/C52H76N5O2P/c1-4-7-35-60(36-8-5-2,37-9-6-3)40-42-29-32-47(33-30-42)53-50(58)49-38-43-23-19-20-24-44(43)39-57(49)51(59)48(34-31-41-21-13-10-14-22-41)56-52(54-45-25-15-11-16-26-45)55-46-27-17-12-18-28-46/h10,13-14,19-24,29-30,32-33,45-46,48-49H,4-9,11-12,15-18,25-28,31,34-40H2,1-3H3,(H2-,53,54,55,56,58)/p+2/t48-,49?/m0/s1
DM0BEZS	CS	CCCC[P+](CCCC)(CCCC)CC1=CC=C(C=C1)NC(=O)C2CC3=CC=CC=C3CN2C(=O)[C@H](CCC4=CC=CC=C4)NC(=[NH+]C5CCCCC5)NC6CCCCC6
DM0BEZS	IK	NILAWIULNZSYHS-GIIAILMYSA-P
DM0BEZS	IU	cyclohexyl-[(cyclohexylamino)-[[(2S)-1-oxo-4-phenyl-1-[3-[[4-(tributylphosphaniumylmethyl)phenyl]carbamoyl]-3,4-dihydro-1H-isoquinolin-2-yl]butan-2-yl]amino]methylidene]azanium
DM0BEZS	DE	Discovery agent

DMJDU5S	ID	DMJDU5S
DMJDU5S	DN	quinazoline deriv. 1
DMJDU5S	HS	Investigative
DMJDU5S	SN	Aurora Kinase Inhibitor II; quinazoline deriv 1; 331770-21-9; CHEMBL382590; -Benzamidoanilino)-6,7-dimethoxyquinazoline; N-{4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl}benzamide; N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]benzamide; Anilinoquinazoline1; K00590a; CBiol_002061; 4-(4'-Benzamidoanilino)-6,7-dimethoxyquinazoline; GTPL5930; SCHEMBL1066538; AC1O7M16; CTK8E8821; BDBM12403; DTXSID00425012; MolPort-044-561-446; Bio1_000347; ZINC590935; HMS3229A17; Bio1_001325; Bio1_000836; IN1528; CCG-206735
DMJDU5S	DT	Small molecular drug
DMJDU5S	PC	6610278
DMJDU5S	MW	400.4
DMJDU5S	FM	C23H20N4O3
DMJDU5S	IC	InChI=1S/C23H20N4O3/c1-29-20-12-18-19(13-21(20)30-2)24-14-25-22(18)26-16-8-10-17(11-9-16)27-23(28)15-6-4-3-5-7-15/h3-14H,1-2H3,(H,27,28)(H,24,25,26)
DMJDU5S	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OC
DMJDU5S	IK	IMYVCWQAHSYYOO-UHFFFAOYSA-N
DMJDU5S	IU	N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]benzamide
DMJDU5S	CA	CAS 331770-21-9
DMJDU5S	DE	Discovery agent

DMVQYWS	ID	DMVQYWS
DMVQYWS	DN	quin-C1
DMVQYWS	HS	Investigative
DMVQYWS	SN	quin-C1; Quin C1; GTPL6265; SCHEMBL19384377; MolPort-039-338-065; 4-butoxy-N-[2-(4-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]benzamide; AKOS027470217; 4-butoxy-N-(2-(4-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3(4H)-yl)benzamide; 786706-21-6; 4-butoxy-N-[2-(4-methoxyphenyl)-4-oxo-1,4-dihydro-2h-quinazolin-3-yl]benzamide
DMVQYWS	DT	Small molecular drug
DMVQYWS	PC	11751175
DMVQYWS	MW	445.5
DMVQYWS	FM	C26H27N3O4
DMVQYWS	IC	InChI=1S/C26H27N3O4/c1-3-4-17-33-21-15-11-19(12-16-21)25(30)28-29-24(18-9-13-20(32-2)14-10-18)27-23-8-6-5-7-22(23)26(29)31/h5-16,24,27H,3-4,17H2,1-2H3,(H,28,30)
DMVQYWS	CS	CCCCOC1=CC=C(C=C1)C(=O)NN2C(NC3=CC=CC=C3C2=O)C4=CC=C(C=C4)OC
DMVQYWS	IK	XORVAHQXRDLSFT-UHFFFAOYSA-N
DMVQYWS	IU	4-butoxy-N-[2-(4-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]benzamide
DMVQYWS	DE	Discovery agent

DM1CYWB	ID	DM1CYWB
DM1CYWB	DN	quin-C7
DM1CYWB	HS	Investigative
DM1CYWB	SN	Quin-C7; GTPL1039; SCHEMBL19384438
DM1CYWB	DT	Small molecular drug
DM1CYWB	PC	11647668
DM1CYWB	MW	431.5
DM1CYWB	FM	C25H25N3O4
DM1CYWB	IC	InChI=1S/C25H25N3O4/c1-2-3-16-32-20-14-10-18(11-15-20)24(30)27-28-23(17-8-12-19(29)13-9-17)26-22-7-5-4-6-21(22)25(28)31/h4-15,23,26,29H,2-3,16H2,1H3,(H,27,30)
DM1CYWB	CS	CCCCOC1=CC=C(C=C1)C(=O)NN2C(NC3=CC=CC=C3C2=O)C4=CC=C(C=C4)O
DM1CYWB	IK	URGRPHVKOQXJLZ-UHFFFAOYSA-N
DM1CYWB	IU	4-butoxy-N-[2-(4-hydroxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]benzamide
DM1CYWB	DE	Discovery agent

DMRQCK3	ID	DMRQCK3
DMRQCK3	DN	Quinizarin
DMRQCK3	HS	Investigative
DMRQCK3	SN	Quinizarin; 1,4-Dihydroxyanthraquinone; 81-64-1; 1,4-dihydroxyanthracene-9,10-dione; Quinizarine; Chinizarin; Solvent Orange 86; 1,4-Dihydroxyanthrachinon; Smoke Orange R; 1,4-Dihydroxy-9,10-anthraquinone; Macrolex Orange GG; 9,10-Anthracenedione, 1,4-dihydroxy-; Anthraquinone, 1,4-dihydroxy-; 1,4-Dioxyanthraquinone; 1,4-Dihydroxyanthra-9,10-quinone; 1,4-Doa; C.I. 58050; 1,4-Doa [Russian]; 1,4-Dihydroxy-anthraquinone; UNII-8S496ZV3CS; NSC 15367; NSC 646569; CCRIS 3524; HSDB 5242; 1,4-Dioxyanthraquinone [Russian]
DMRQCK3	DT	Small molecular drug
DMRQCK3	PC	6688
DMRQCK3	MW	240.21
DMRQCK3	FM	C14H8O4
DMRQCK3	IC	InChI=1S/C14H8O4/c15-9-5-6-10(16)12-11(9)13(17)7-3-1-2-4-8(7)14(12)18/h1-6,15-16H
DMRQCK3	CS	C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)O)O
DMRQCK3	IK	GUEIZVNYDFNHJU-UHFFFAOYSA-N
DMRQCK3	IU	1,4-dihydroxyanthracene-9,10-dione
DMRQCK3	CA	CAS 81-64-1
DMRQCK3	CB	CHEBI:37487
DMRQCK3	DE	Discovery agent

DM1QIPZ	ID	DM1QIPZ
DM1QIPZ	DN	quinoline 2
DM1QIPZ	HS	Investigative
DM1QIPZ	SN	quinoline 2; Tert-Butyl [(2s)-2-(2,5-Difluorophenyl)-3-(Quinolin-3-Yl)propyl]carbamate; GTPL8599; SCHEMBL20364499; tert-butyl N-[(2S)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate
DM1QIPZ	DT	Small molecular drug
DM1QIPZ	PC	91801114
DM1QIPZ	MW	398.4
DM1QIPZ	FM	C23H24F2N2O2
DM1QIPZ	IC	InChI=1S/C23H24F2N2O2/c1-23(2,3)29-22(28)27-14-17(19-12-18(24)8-9-20(19)25)11-15-10-16-6-4-5-7-21(16)26-13-15/h4-10,12-13,17H,11,14H2,1-3H3,(H,27,28)/t17-/m1/s1
DM1QIPZ	CS	CC(C)(C)OC(=O)NC[C@@H](CC1=CC2=CC=CC=C2N=C1)C3=C(C=CC(=C3)F)F
DM1QIPZ	IK	IRFHMTUHTBSEBK-QGZVFWFLSA-N
DM1QIPZ	IU	tert-butyl N-[(2S)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate
DM1QIPZ	DE	Discovery agent

DMDY3I2	ID	DMDY3I2
DMDY3I2	DN	Quinoline-2-carboxylic acid adamantan-1-ylamide
DMDY3I2	HS	Investigative
DMDY3I2	SN	CHEMBL399161; AC1ME9EW; quinoline-2-carboxylic acid adamantan-1-ylamide; Oprea1_069959; SCHEMBL6084070; MolPort-002-116-284; ZINC4776255; STK208477; N-1-adamantylquinoline-2-carboxamide; BDBM50231752; AKOS001569250; MCULE-4553069817; N-(1-adamantyl)quinoline-2-carboxamide; SR-01000399357; SR-01000399357-1
DMDY3I2	DT	Small molecular drug
DMDY3I2	PC	2851338
DMDY3I2	MW	306.4
DMDY3I2	FM	C20H22N2O
DMDY3I2	IC	InChI=1S/C20H22N2O/c23-19(18-6-5-16-3-1-2-4-17(16)21-18)22-20-10-13-7-14(11-20)9-15(8-13)12-20/h1-6,13-15H,7-12H2,(H,22,23)
DMDY3I2	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)C4=NC5=CC=CC=C5C=C4
DMDY3I2	IK	JRSHTOGGDUKFMC-UHFFFAOYSA-N
DMDY3I2	IU	N-(1-adamantyl)quinoline-2-carboxamide
DMDY3I2	DE	Discovery agent

DM9BIVL	ID	DM9BIVL
DM9BIVL	DN	Quinoline-3-carboxylic acid adamantan-1-ylamide
DM9BIVL	HS	Investigative
DM9BIVL	SN	CHEMBL253347; quinoline-3-carboxylic acid adamantan-1-ylamide; SCHEMBL6085211
DM9BIVL	DT	Small molecular drug
DM9BIVL	PC	12042753
DM9BIVL	MW	306.4
DM9BIVL	FM	C20H22N2O
DM9BIVL	IC	InChI=1S/C20H22N2O/c23-19(17-8-16-3-1-2-4-18(16)21-12-17)22-20-9-13-5-14(10-20)7-15(6-13)11-20/h1-4,8,12-15H,5-7,9-11H2,(H,22,23)
DM9BIVL	CS	C1C2CC3CC1CC(C2)(C3)NC(=O)C4=CC5=CC=CC=C5N=C4
DM9BIVL	IK	FVQAOJSJLLDAKM-UHFFFAOYSA-N
DM9BIVL	IU	N-(1-adamantyl)quinoline-3-carboxamide
DM9BIVL	DE	Discovery agent

DMV57OZ	ID	DMV57OZ
DMV57OZ	DN	Quinoline-8-carboxamide
DMV57OZ	HS	Investigative
DMV57OZ	SN	Quinoline-8-carboxamide; 8-Quinolinecarboxamide; 55706-61-1; CCRIS 6967; CHEMBL502330; HPQRQAOVNXWEEQ-UHFFFAOYSA-N; 8-Carbamoylquinoline; 8-Quinolinecarboxamide #; AC1L44SC; SCHEMBL460456; CTK5A4047; quinoline-8-carboxylic acid amide; DTXSID00204243; MolPort-005-722-305; ZINC6095019; BDBM50255266; AKOS008969900; NE38855; MCULE-7978956907; LS-188644; KB-259682
DMV57OZ	DT	Small molecular drug
DMV57OZ	PC	150664
DMV57OZ	MW	172.18
DMV57OZ	FM	C10H8N2O
DMV57OZ	IC	InChI=1S/C10H8N2O/c11-10(13)8-5-1-3-7-4-2-6-12-9(7)8/h1-6H,(H2,11,13)
DMV57OZ	CS	C1=CC2=C(C(=C1)C(=O)N)N=CC=C2
DMV57OZ	IK	HPQRQAOVNXWEEQ-UHFFFAOYSA-N
DMV57OZ	IU	quinoline-8-carboxamide
DMV57OZ	CA	CAS 55706-61-1
DMV57OZ	DE	Discovery agent

DMTPFLU	ID	DMTPFLU
DMTPFLU	DN	Quinoline-8-sulfonamide
DMTPFLU	HS	Investigative
DMTPFLU	SN	quinoline-8-sulfonamide; 8-Quinolinesulfonamide; 35203-91-9; 8-Sulfonamidoquinoline; Quinoline-8-sulfonic acid amide; CCRIS 7819; CHEMBL268809; SMR000009729; 8-quinoline-sulfonamide; 8-(Sulfamoyl)quinoline; AC1Q6ULO; AC1L3S9X; SCHEMBL50688; Oprea1_399346; Oprea1_819599; MLS001075858; MLS000070229; MLS001075623; CTK1C3889; DTXSID30188709; MolPort-000-398-364; ZTYZEUXZHGOXRT-UHFFFAOYSA-N; ZINC275697; HMS2220E20; HMS3356M20; ALBB-006579; NSC67458; STK387517; NSC-67458; 1294AE; BDBM50125190; AKOS000678636; MCULE-8159242011; BAS 00926056
DMTPFLU	DT	Small molecular drug
DMTPFLU	PC	94464
DMTPFLU	MW	208.24
DMTPFLU	FM	C9H8N2O2S
DMTPFLU	IC	InChI=1S/C9H8N2O2S/c10-14(12,13)8-5-1-3-7-4-2-6-11-9(7)8/h1-6H,(H2,10,12,13)
DMTPFLU	CS	C1=CC2=C(C(=C1)S(=O)(=O)N)N=CC=C2
DMTPFLU	IK	ZTYZEUXZHGOXRT-UHFFFAOYSA-N
DMTPFLU	IU	quinoline-8-sulfonamide
DMTPFLU	CA	CAS 35203-91-9
DMTPFLU	DE	Discovery agent

DM8YGOI	ID	DM8YGOI
DM8YGOI	DN	Quinolinic Acid
DM8YGOI	HS	Investigative
DM8YGOI	SN	quinolinic acid; Pyridine-2,3-dicarboxylic acid; 2,3-pyridinedicarboxylic acid; 89-00-9; quinolinate; Pyridine-2,3-dicarboxylate; 339155-13-4; UNII-F6F0HK1URN; AI3-63017; 2,3-PyridinedicarboxylicAcid; EINECS 201-874-8; pyridine-2,3-carboxylate; NSC 13127; F6F0HK1URN; CHEMBL286204; 2,3-pyridine dicarboxylic acid; CHEBI:16675; GJAWHXHKYYXBSV-UHFFFAOYSA-N; 2,3-Pyridinedicarboxylic acid, 99%; Pyridin-2,3-dicarbonsaeure; 2,3-pyridinedicarboxylate; SMR000112287; 2,3-pyridindicarbons; SR-01000075472; HSDB 7511; PubChem8035
DM8YGOI	DT	Small molecular drug
DM8YGOI	PC	1066
DM8YGOI	MW	167.12
DM8YGOI	FM	C7H5NO4
DM8YGOI	IC	InChI=1S/C7H5NO4/c9-6(10)4-2-1-3-8-5(4)7(11)12/h1-3H,(H,9,10)(H,11,12)
DM8YGOI	CS	C1=CC(=C(N=C1)C(=O)O)C(=O)O
DM8YGOI	IK	GJAWHXHKYYXBSV-UHFFFAOYSA-N
DM8YGOI	IU	pyridine-2,3-dicarboxylic acid
DM8YGOI	CA	CAS 89-00-9
DM8YGOI	CB	CHEBI:16675
DM8YGOI	DE	Discovery agent

DMRWXH4	ID	DMRWXH4
DMRWXH4	DN	Quinoxaline1
DMRWXH4	HS	Investigative
DMRWXH4	SN	quinoxaline1
DMRWXH4	DT	Small molecular drug
DMRWXH4	PC	438981
DMRWXH4	MW	185.19
DMRWXH4	FM	C9H7N5
DMRWXH4	IC	InChI=1S/C9H7N5/c10-8-7-9(14-13-8)12-6-4-2-1-3-5(6)11-7/h1-4H,(H3,10,12,13,14)
DMRWXH4	CS	C1=CC2=NC3=C(NN=C3N=C2C=C1)N
DMRWXH4	IK	DWHVZCLBMTZRQM-UHFFFAOYSA-N
DMRWXH4	IU	2H-pyrazolo[4,3-b]quinoxalin-3-amine
DMRWXH4	CA	CAS 56984-56-6
DMRWXH4	CB	CHEBI:92540
DMRWXH4	DE	Discovery agent

DMDNHEP	ID	DMDNHEP
DMDNHEP	DN	QUINPIROLE
DMDNHEP	HS	Investigative
DMDNHEP	SN	Quinpirolum; Quinpirol; Quinpirole [INN]; Quinpirolum [Latin]; Quinpirol [Spanish]; 80373-22-4; UNII-20OP60125T; CHEBI:75401; LY 156258; CHEMBL240773; (4aR-trans)-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H-pyrazolo(3,4-g)quinoline; 20OP60125T; 1H-Pyrazolo(3,4-g)quinoline, 4,4a,5,6,7,8,8a,9-octahydro-5-propyl-, (4aR-trans)-; (4aR,8aR)-5-propyl-1,4,4a,6,7,8,8a,9-octahydropyrido[2,3-f]indazole; (4aR,8aR)-5-propyl-1,4,4a,6,7,8,8a,9-octahydropyrazolo[3,4-g]quinoline
DMDNHEP	DT	Small molecular drug
DMDNHEP	PC	54562
DMDNHEP	MW	219.33
DMDNHEP	FM	C13H21N3
DMDNHEP	IC	InChI=1S/C13H21N3/c1-2-5-16-6-3-4-10-7-12-11(8-13(10)16)9-14-15-12/h9-10,13H,2-8H2,1H3,(H,14,15)/t10-,13-/m1/s1
DMDNHEP	CS	CCCN1CCC[C@H]2[C@H]1CC3=C(C2)NN=C3
DMDNHEP	IK	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N
DMDNHEP	IU	(4aR,8aR)-5-propyl-1,4,4a,6,7,8,8a,9-octahydropyrazolo[3,4-g]quinoline
DMDNHEP	CA	CAS 80373-22-4
DMDNHEP	CB	CHEBI:75401
DMDNHEP	DE	Discovery agent

DMPY6IG	ID	DMPY6IG
DMPY6IG	DN	Quipazine
DMPY6IG	HS	Investigative
DMPY6IG	SN	quipazine; 4774-24-7; 2-(piperazin-1-yl)quinoline; 2-Piperazin-1-yl-quinoline; 2-Piperazin-1-ylquinoline; Quinoline, 2-(1-piperazinyl)-; 2-(1-Piperazinyl)quinoline; Quipazine [INN]; 1-(2-Quinolinyl)piperazine; Quipazinum [INN-Latin]; Quipazina [INN-Spanish]; UNII-4WCY05C0SJ; 1-(2-Quinolyl)piperazine; 2-(1-Piperazinyl)chinolin; BRN 0196945; 4WCY05C0SJ; CHEMBL18772; 2-quinolylpiperazine; F3306-0004; Quipazinum; Quipazina; TPC-A004; MA-1291; Spectrum_001733; Tocris-0629; piperazin-1-yl-quinoline; AC1L1JEX; AC1Q4WAV; Spectrum4_001259
DMPY6IG	DT	Small molecular drug
DMPY6IG	PC	5011
DMPY6IG	MW	213.28
DMPY6IG	FM	C13H15N3
DMPY6IG	IC	InChI=1S/C13H15N3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h1-6,14H,7-10H2
DMPY6IG	CS	C1CN(CCN1)C2=NC3=CC=CC=C3C=C2
DMPY6IG	IK	XRXDAJYKGWNHTQ-UHFFFAOYSA-N
DMPY6IG	IU	2-piperazin-1-ylquinoline
DMPY6IG	CA	CAS 4774-24-7
DMPY6IG	CB	CHEBI:93368
DMPY6IG	DE	Discovery agent

DM9KMEI	ID	DM9KMEI
DM9KMEI	DN	Quizalofop
DM9KMEI	HS	Investigative
DM9KMEI	SN	Quizalofop; 76578-12-6; 2-[4-(6-chloroquinoxalin-2-yl)oxyphenoxy]propanoic acid; Quizalofop free acid; Xylafop; 95977-28-9; Quizalofop [BSI:ISO]; 2-[4-[(6-Chloroquinoxalin-2-yl)oxy]phenoxy]propanoic acid; 2-{4-[(6-chloroquinoxalin-2-yl)oxy]phenoxy}propanoic acid; CCRIS 9407; as sur-; Quizalofop (free acid); AC1L43YN; CHEMBL51789; SCHEMBL111413; AC1Q2C16; CTK3I8238; CHEBI:81943; DTXSID60273935; ABOOPXYCKNFDNJ-UHFFFAOYSA-N; CHEBI:137509; BCP07599; (RS)-2-(4-(6-Chloroquinoxalin-2-yloxy)phenoxy)propionic acid
DM9KMEI	DT	Small molecular drug
DM9KMEI	PC	178795
DM9KMEI	MW	344.7
DM9KMEI	FM	C17H13ClN2O4
DM9KMEI	IC	InChI=1S/C17H13ClN2O4/c1-10(17(21)22)23-12-3-5-13(6-4-12)24-16-9-19-15-8-11(18)2-7-14(15)20-16/h2-10H,1H3,(H,21,22)
DM9KMEI	CS	CC(C(=O)O)OC1=CC=C(C=C1)OC2=CN=C3C=C(C=CC3=N2)Cl
DM9KMEI	IK	ABOOPXYCKNFDNJ-UHFFFAOYSA-N
DM9KMEI	IU	2-[4-(6-chloroquinoxalin-2-yl)oxyphenoxy]propanoic acid
DM9KMEI	CA	CAS 76578-12-6
DM9KMEI	CB	CHEBI:81943
DM9KMEI	DE	Discovery agent

DMQ7PIL	ID	DMQ7PIL
DMQ7PIL	DN	QwFwLL-NH2
DMQ7PIL	HS	Investigative
DMQ7PIL	SN	CHEMBL499371; QwFwLL-NH2
DMQ7PIL	DT	Small molecular drug
DMQ7PIL	PC	44576253
DMQ7PIL	MW	891.1
DMQ7PIL	FM	C48H62N10O7
DMQ7PIL	IC	InChI=1S/C48H62N10O7/c1-27(2)20-37(43(51)60)54-45(62)38(21-28(3)4)56-48(65)41(24-31-26-53-36-17-11-9-15-33(31)36)58-46(63)39(22-29-12-6-5-7-13-29)57-47(64)40(55-44(61)34(49)18-19-42(50)59)23-30-25-52-35-16-10-8-14-32(30)35/h5-17,25-28,34,37-41,52-53H,18-24,49H2,1-4H3,(H2,50,59)(H2,51,60)(H,54,62)(H,55,61)(H,56,65)(H,57,64)(H,58,63)/t34-,37-,38-,39-,40+,41+/m0/s1
DMQ7PIL	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCC(=O)N)N
DMQ7PIL	IK	KUAWHJJXPITBED-QBZLXUEESA-N
DMQ7PIL	IU	(2S)-2-amino-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMQ7PIL	DE	Discovery agent

DM72ES1	ID	DM72ES1
DM72ES1	DN	R(-)amphetamine
DM72ES1	HS	Investigative
DM72ES1	SN	l-amphetamine
DM72ES1	DT	Small molecular drug
DM72ES1	PC	32893
DM72ES1	MW	135.21
DM72ES1	FM	C9H13N
DM72ES1	IC	InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m1/s1
DM72ES1	CS	C[C@H](CC1=CC=CC=C1)N
DM72ES1	IK	KWTSXDURSIMDCE-MRVPVSSYSA-N
DM72ES1	IU	(2R)-1-phenylpropan-2-amine
DM72ES1	CA	CAS 156-34-3
DM72ES1	CB	CHEBI:42724
DM72ES1	DE	Discovery agent

DM4URMA	ID	DM4URMA
DM4URMA	DN	R,R-THC
DM4URMA	HS	Investigative
DM4URMA	SN	(R,R)-THC; 138090-06-9; (R,R)-cis-Diethyl tetrahydro-2,8-chrysenediol; R,R-THC; CHEMBL282489; 221368-54-3; (5R,11R)-5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol; (R,R)-5,11-DIETHYL-5,6,11,12-TETRAHYDRO-2,8-CHRYSENEDIOL; (R,R)-cis-Diethyltetrahydro-2,8-chrysenediol; (R,R)-5,11-CIS-DIETHYL-5,6,11,12-TETRAHYDROCHRYSENE-2,8-DIOL; Lopac-D-8690; AC1L9K5Y; Lopac0_000463; MLS002153151; BIDD:ER0043; GTPL2822; DTXSID6040749; SCHEMBL13352540; CTK4E8744; MolPort-003-941-174; HMS3268D03; HMS3261M08; HMS2232C18; ZINC3940885; Tox21_500463
DM4URMA	DT	Small molecular drug
DM4URMA	PC	446849
DM4URMA	MW	320.4
DM4URMA	FM	C22H24O2
DM4URMA	IC	InChI=1S/C22H24O2/c1-3-13-9-15-11-17(23)6-8-20(15)22-14(4-2)10-16-12-18(24)5-7-19(16)21(13)22/h5-8,11-14,23-24H,3-4,9-10H2,1-2H3/t13-,14-/m1/s1
DM4URMA	CS	CC[C@@H]1CC2=C(C=CC(=C2)O)C3=C1C4=C(C[C@H]3CC)C=C(C=C4)O
DM4URMA	IK	MASYAWHPJCQLSW-ZIAGYGMSSA-N
DM4URMA	IU	(5R,11R)-5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol
DM4URMA	CA	CAS 221368-54-3
DM4URMA	DE	Discovery agent

DMK0YP7	ID	DMK0YP7
DMK0YP7	DN	R-1
DMK0YP7	HS	Investigative
DMK0YP7	SN	IBS therapeutics, Pharmagene; Irritable bowel syndrome therapeutics, Pharmagene; PGN-1091; PGN-1164; R-1 (IBS); R-1(IBS), Asterand; R-1 (IBS), Pharmagene; 5HT 2b antagonist (IBS), Pharmagene
DMK0YP7	CP	Pharmagene plc
DMK0YP7	DT	Small molecular drug
DMK0YP7	PC	5458394
DMK0YP7	MW	650.8
DMK0YP7	FM	C32H58O13
DMK0YP7	IC	InChI=1S/C32H58O13/c1-5-7-9-11-13-15-21(17-23(33)34)43-24(35)18-22(16-14-12-10-8-6-2)44-32-30(28(39)26(37)20(4)42-32)45-31-29(40)27(38)25(36)19(3)41-31/h19-22,25-32,36-40H,5-18H2,1-4H3,(H,33,34)/t19-,20-,21?,22?,25-,26-,27+,28+,29+,30+,31-,32-/m0/s1
DMK0YP7	CS	CCCCCCCC(CC(=O)O)OC(=O)CC(CCCCCCC)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O[C@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O)O)O
DMK0YP7	IK	FCBUKWWQSZQDDI-SESCQDRSSA-N
DMK0YP7	IU	3-[3-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-6-methyl-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxydecanoyloxy]decanoic acid
DMK0YP7	CA	CAS 4348-76-9
DMK0YP7	CB	CHEBI:62570
DMK0YP7	DE	Irritable bowel syndrome

DM6Y7QM	ID	DM6Y7QM
DM6Y7QM	DN	R116031
DM6Y7QM	HS	Investigative
DM6Y7QM	SN	R-116031; R 116031
DM6Y7QM	DT	Small molecular drug
DM6Y7QM	PC	9917716
DM6Y7QM	MW	660.7
DM6Y7QM	FM	C35H38F6N4O2
DM6Y7QM	IC	InChI=1S/C35H38F6N4O2/c1-23-7-6-8-24(2)32(23)42-31(46)22-43-13-15-44(16-14-43)29-11-12-45(30(21-29)17-25-9-4-3-5-10-25)33(47)26-18-27(34(36,37)38)20-28(19-26)35(39,40)41/h3-10,18-20,29-30H,11-17,21-22H2,1-2H3,(H,42,46)/t29-,30+/m0/s1
DM6Y7QM	CS	CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)[C@H]3CCN([C@@H](C3)CC4=CC=CC=C4)C(=O)C5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F
DM6Y7QM	IK	KHOXGPDKCIQOOR-XZWHSSHBSA-N
DM6Y7QM	IU	2-[4-[(2R,4S)-2-benzyl-1-[3,5-bis(trifluoromethyl)benzoyl]piperidin-4-yl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
DM6Y7QM	DE	Discovery agent

DMJ14OV	ID	DMJ14OV
DMJ14OV	DN	R-116712
DMJ14OV	HS	Investigative
DMJ14OV	CP	Janssen Pharmaceutica NV
DMJ14OV	DE	Pain

DML49FI	ID	DML49FI
DML49FI	DN	R-138727
DML49FI	HS	Investigative
DML49FI	SN	R 138727; R138727
DML49FI	DT	Small molecular drug
DML49FI	PC	10405534
DML49FI	MW	349.4
DML49FI	FM	C18H20FNO3S
DML49FI	IC	InChI=1S/C18H20FNO3S/c19-14-4-2-1-3-13(14)17(18(23)11-5-6-11)20-8-7-15(24)12(10-20)9-16(21)22/h1-4,9,11,15,17,24H,5-8,10H2,(H,21,22)/b12-9-
DML49FI	CS	C1CC1C(=O)C(C2=CC=CC=C2F)N3CCC(/C(=C\\C(=O)O)/C3)S
DML49FI	IK	ZWUQVNSJSJHFPS-XFXZXTDPSA-N
DML49FI	IU	(2Z)-2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-sulfanylpiperidin-3-ylidene]acetic acid
DML49FI	CA	CAS 204204-73-9
DML49FI	DE	Discovery agent

DMX80BL	ID	DMX80BL
DMX80BL	DN	R214127
DMX80BL	HS	Investigative
DMX80BL	SN	HXUSRWUBSYSWII-UHFFFAOYSA-N; CHEMBL369459; 409345-76-2; R 214127; Ethanone, 1-(3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-2-phenyl-; 1-(3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-2-phenylethanone; [3H]R214127; [3H]-R214127; SCHEMBL662314; R-214127; GTPL1391; GTPL6336; CTK1D4173; DTXSID20440505; ZINC3817902; PDSP2_000348; PDSP1_000350; BDBM50163606; AKOS028110267; L022369; 1-(3,4-Dihydro-2H-1-oxa-9-aza-anthracen-6-yl)-2-phenyl-ethanone;  R 214127
DMX80BL	DT	Small molecular drug
DMX80BL	PC	10470232
DMX80BL	MW	303.4
DMX80BL	FM	C20H17NO2
DMX80BL	IC	InChI=1S/C20H17NO2/c22-19(11-14-5-2-1-3-6-14)15-8-9-18-17(12-15)13-16-7-4-10-23-20(16)21-18/h1-3,5-6,8-9,12-13H,4,7,10-11H2
DMX80BL	CS	C1CC2=C(N=C3C=CC(=CC3=C2)C(=O)CC4=CC=CC=C4)OC1
DMX80BL	IK	HXUSRWUBSYSWII-UHFFFAOYSA-N
DMX80BL	IU	1-(3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-2-phenylethanone
DMX80BL	CA	CAS 409345-76-2
DMX80BL	DE	Discovery agent

DM4BP7S	ID	DM4BP7S
DM4BP7S	DN	R-226161
DM4BP7S	HS	Investigative
DM4BP7S	SN	R-226161; UNII-0878P6YAG6; CHEMBL318235; 0878P6YAG6; SCHEMBL16583684; BDBM50146518; cis-(+)-7,8-dimethoxy-3-[4-(2-methyl-3-(4-fluoro)phenyl-2(E)-propen-1-yl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole; 3H-(1)Benzopyrano(4,3-C)isoxazole, 3-((4-((2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl)-1-piperazinyl)methyl)-3a,4-dihydro-7,8-dimethoxy-, (cis)-(+)-; (3R,3aS)-3-{4-[3-(4-Fluoro-phenyl)-2-methyl-allyl]-piperazin-1-ylmethyl}-7,8-dimethoxy-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole
DM4BP7S	DT	Small molecular drug
DM4BP7S	PC	16655023
DM4BP7S	MW	481.6
DM4BP7S	FM	C27H32FN3O4
DM4BP7S	IC	InChI=1S/C27H32FN3O4/c1-18(12-19-4-6-20(28)7-5-19)15-30-8-10-31(11-9-30)16-26-22-17-34-23-14-25(33-3)24(32-2)13-21(23)27(22)29-35-26/h4-7,12-14,22,26H,8-11,15-17H2,1-3H3/b18-12+/t22-,26-/m0/s1
DM4BP7S	CS	C/C(=C\\C1=CC=C(C=C1)F)/CN2CCN(CC2)C[C@H]3[C@@H]4COC5=CC(=C(C=C5C4=NO3)OC)OC
DM4BP7S	IK	UCNOTTVNPRSTFW-XSFNXXSESA-N
DM4BP7S	IU	(3R,3aS)-3-[[4-[(E)-3-(4-fluorophenyl)-2-methylprop-2-enyl]piperazin-1-yl]methyl]-7,8-dimethoxy-3a,4-dihydro-3H-chromeno[4,3-c][1,2]oxazole
DM4BP7S	CA	CAS 452314-01-1
DM4BP7S	DE	Discovery agent

DM1OPZ9	ID	DM1OPZ9
DM1OPZ9	DN	R396
DM1OPZ9	HS	Investigative
DM1OPZ9	SN	R 396; R-396
DM1OPZ9	DT	Small molecular drug
DM1OPZ9	PC	164286
DM1OPZ9	MW	805.9
DM1OPZ9	FM	C39H51N9O10
DM1OPZ9	IC	InChI=1S/C39H51N9O10/c1-21(2)15-28(44-22(3)49)37(56)48-31(18-34(52)53)39(58)45-27(13-14-32(40)50)36(55)47-30(17-24-19-42-26-12-8-7-11-25(24)26)38(57)46-29(35(54)43-20-33(41)51)16-23-9-5-4-6-10-23/h4-12,19,21,27-31,42H,13-18,20H2,1-3H3,(H2,40,50)(H2,41,51)(H,43,54)(H,44,49)(H,45,58)(H,46,57)(H,47,55)(H,48,56)(H,52,53)/t27-,28-,29-,30-,31-/m0/s1
DM1OPZ9	CS	CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NCC(=O)N)NC(=O)C
DM1OPZ9	IK	VTQMNICJVWMKEV-QKUYTOGTSA-N
DM1OPZ9	IU	(3S)-3-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-4-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid
DM1OPZ9	CA	CAS 129809-09-2
DM1OPZ9	DE	Discovery agent

DMSHMIK	ID	DMSHMIK
DMSHMIK	DN	R-65
DMSHMIK	HS	Investigative
DMSHMIK	SN	PGN-1473; R-65 (myometrial disorders), Asterand; R-65 (myometrial disorders), Pharmagene
DMSHMIK	CP	Pharmagene plc
DMSHMIK	DE	Glaucoma/ocular hypertension

DMHX9CT	ID	DMHX9CT
DMHX9CT	DN	R-820
DMHX9CT	HS	Investigative
DMHX9CT	PC	100944274
DMHX9CT	MW	510.6
DMHX9CT	FM	C30H30N4O4
DMHX9CT	IC	InChI=1S/C30H30N4O4/c1-33(18-20-10-4-2-5-11-20)30(38)27(21-12-6-3-7-13-21)32-28(36)26-16-22(35)19-34(26)29(37)24-17-31-25-15-9-8-14-23(24)25/h2-15,17,22,26-27,31,35H,16,18-19H2,1H3,(H,32,36)/t22-,26+,27+/m1/s1
DMHX9CT	CS	CN(CC1=CC=CC=C1)C(=O)[C@H](C2=CC=CC=C2)NC(=O)[C@@H]3C[C@H](CN3C(=O)C4=CNC5=CC=CC=C54)O
DMHX9CT	IK	JSNQZGVYABLKPW-ICTDUYRTSA-N
DMHX9CT	IU	(2S,4R)-N-[(1S)-2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]-4-hydroxy-1-(1H-indole-3-carbonyl)pyrrolidine-2-carboxamide
DMHX9CT	DE	Discovery agent

DM1MIRJ	ID	DM1MIRJ
DM1MIRJ	DN	R-84
DM1MIRJ	HS	Investigative
DM1MIRJ	SN	AT-001, Affitech; VEGF receptor 2 modulator (human monoclonal antibody, cancer), Affitech; VEGF receptor 2 modulator (human monoclonal antibody, cancer), Peregrine Pharmaceuticals
DM1MIRJ	CP	Peregrine Pharmaceuticals Inc
DM1MIRJ	DT	Antibody
DM1MIRJ	DE	Solid tumour/cancer

DM2QN0S	ID	DM2QN0S
DM2QN0S	DN	R-87027
DM2QN0S	HS	Investigative
DM2QN0S	SN	Tivirapine; UNII-7WP69N3Y3Y; 8-Chloro-TIBO; 137332-54-8; CHEMBL58711; 7WP69N3Y3Y; NSC636661; 5-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE; R-87027; Tivirapine [INN]; Tivirapin; 1uwb; NSC-636661; NSC 636661; 8-ClTIBO; 8-Cl-TIBO; AC1MHD41; TBO 8; SCHEMBL377308; TIBO R86183; DTXSID00160138; TBO 8; TIBO R86183; BDBM50369418; DB08600; R86183; (5R)-5beta-Methyl-6-(3-methyl-2-butenyl)-8-chloro-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione
DM2QN0S	DT	Small molecular drug
DM2QN0S	PC	3000323
DM2QN0S	MW	321.9
DM2QN0S	FM	C16H20ClN3S
DM2QN0S	IC	InChI=1S/C16H20ClN3S/c1-10(2)6-7-19-9-12-13(17)4-5-14-15(12)20(8-11(19)3)16(21)18-14/h4-6,11H,7-9H2,1-3H3,(H,18,21)/t11-/m0/s1
DM2QN0S	CS	C[C@H]1CN2C3=C(C=CC(=C3CN1CC=C(C)C)Cl)NC2=S
DM2QN0S	IK	ZNFFMCYSMBXZQU-NSHDSACASA-N
DM2QN0S	IU	(11S)-7-chloro-11-methyl-10-(3-methylbut-2-enyl)-1,3,10-triazatricyclo[6.4.1.04,13]trideca-4(13),5,7-triene-2-thione
DM2QN0S	CA	CAS 137332-54-8
DM2QN0S	DE	Discovery agent

DMTUR6C	ID	DMTUR6C
DMTUR6C	DN	Rac-2-amino-4-phenylbutanoic acid
DMTUR6C	HS	Investigative
DMTUR6C	SN	DL-Homophenylalanine; 1012-05-1; 2-Amino-4-phenylbutanoic acid; h-dl-hophe-oh; 2-Amino-4-phenylbutyric acid; (-)-2-Amino-4-phenylbutyric acid; H-DL-HOMOPHE-OH; H-DL-HPH-OH; 2-amino-4-phenyl-butyric acid; 7636-28-4; CHEMBL203873; Benzylalanine; JTTHKOPSMAVJFE-UHFFFAOYSA-N; Benzenebutanoic acid, alpha-amino-; (RS)-2-AMINO-4-PHENYL-BUTYRIC ACID; dlhpa; MFCD00063091; rac-2-amino-4-phenylbutanoic acid; d,l-homophenylalanine; ACMC-209tws; AC1L2SZU; DL-Homophenylalanine, 98%; KSC492S1B; SCHEMBL130567; AC1Q5S74; AC1Q50B0; KS-00000FXF
DMTUR6C	DT	Small molecular drug
DMTUR6C	PC	102530
DMTUR6C	MW	179.22
DMTUR6C	FM	C10H13NO2
DMTUR6C	IC	InChI=1S/C10H13NO2/c11-9(10(12)13)7-6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)
DMTUR6C	CS	C1=CC=C(C=C1)CCC(C(=O)O)N
DMTUR6C	IK	JTTHKOPSMAVJFE-UHFFFAOYSA-N
DMTUR6C	IU	2-amino-4-phenylbutanoic acid
DMTUR6C	CA	CAS 1012-05-1
DMTUR6C	DE	Discovery agent

DMU0746	ID	DMU0746
DMU0746	DN	Rac-2-amino-5-cyclohexylpentanoic acid
DMU0746	HS	Investigative
DMU0746	SN	5-Cyclohexylnorvaline; CHEMBL380671; 5428-12-6; NSC12805; rac-2-amino-5-cyclohexylpentanoic acid; AC1Q5S7K; AC1L5D9O; SCHEMBL5843561; 2-amino-5-cyclohexyl-valeric acid; 2-amino-5-cyclohexylpentanoic acid; NSC-12805; BDBM50179718
DMU0746	DT	Small molecular drug
DMU0746	PC	224404
DMU0746	MW	199.29
DMU0746	FM	C11H21NO2
DMU0746	IC	InChI=1S/C11H21NO2/c12-10(11(13)14)8-4-7-9-5-2-1-3-6-9/h9-10H,1-8,12H2,(H,13,14)
DMU0746	CS	C1CCC(CC1)CCCC(C(=O)O)N
DMU0746	IK	LGIVZSMPEFXNLH-UHFFFAOYSA-N
DMU0746	IU	2-amino-5-cyclohexylpentanoic acid
DMU0746	CA	CAS 5428-12-6
DMU0746	DE	Discovery agent

DMD5TPH	ID	DMD5TPH
DMD5TPH	DN	Rac-2q
DMD5TPH	HS	Investigative
DMD5TPH	SN	CHEMBL246964; rac-2q; SCHEMBL1186511; MZKGVXPHEXNJSG-UHFFFAOYSA-N; BDBM50210099; [4-chloro-2-({1-[(4-chlorophenyl)sulfonyl]-3,7-dioxo-1,4-diazepan-6-yl}methyl)phenoxy]acetic acid
DMD5TPH	DT	Small molecular drug
DMD5TPH	PC	44439966
DMD5TPH	MW	501.3
DMD5TPH	FM	C20H18Cl2N2O7S
DMD5TPH	IC	InChI=1S/C20H18Cl2N2O7S/c21-14-1-4-16(5-2-14)32(29,30)24-10-18(25)23-9-13(20(24)28)7-12-8-15(22)3-6-17(12)31-11-19(26)27/h1-6,8,13H,7,9-11H2,(H,23,25)(H,26,27)
DMD5TPH	CS	C1C(C(=O)N(CC(=O)N1)S(=O)(=O)C2=CC=C(C=C2)Cl)CC3=C(C=CC(=C3)Cl)OCC(=O)O
DMD5TPH	IK	MZKGVXPHEXNJSG-UHFFFAOYSA-N
DMD5TPH	IU	2-[4-chloro-2-[[1-(4-chlorophenyl)sulfonyl-3,7-dioxo-1,4-diazepan-6-yl]methyl]phenoxy]acetic acid
DMD5TPH	DE	Discovery agent

DMTN7IU	ID	DMTN7IU
DMTN7IU	DN	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,4-diol
DMTN7IU	HS	Investigative
DMTN7IU	SN	CHEMBL551253; BDBM50295625; 4'-[1-(1H-Imidazole-1-yl)propyl]biphenyl-3,4-diol
DMTN7IU	DT	Small molecular drug
DMTN7IU	PC	42642718
DMTN7IU	MW	294.3
DMTN7IU	FM	C18H18N2O2
DMTN7IU	IC	InChI=1S/C18H18N2O2/c1-2-16(20-10-9-19-12-20)14-5-3-13(4-6-14)15-7-8-17(21)18(22)11-15/h3-12,16,21-22H,2H2,1H3
DMTN7IU	CS	CCC(C1=CC=C(C=C1)C2=CC(=C(C=C2)O)O)N3C=CN=C3
DMTN7IU	IK	AJXMMNNBZYGUFM-UHFFFAOYSA-N
DMTN7IU	IU	4-[4-(1-imidazol-1-ylpropyl)phenyl]benzene-1,2-diol
DMTN7IU	DE	Discovery agent

DMQYRAB	ID	DMQYRAB
DMQYRAB	DN	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,5-diol
DMQYRAB	HS	Investigative
DMQYRAB	SN	CHEMBL565098; BDBM50295626
DMQYRAB	DT	Small molecular drug
DMQYRAB	PC	42642719
DMQYRAB	MW	294.3
DMQYRAB	FM	C18H18N2O2
DMQYRAB	IC	InChI=1S/C18H18N2O2/c1-2-18(20-8-7-19-12-20)14-5-3-13(4-6-14)15-9-16(21)11-17(22)10-15/h3-12,18,21-22H,2H2,1H3
DMQYRAB	CS	CCC(C1=CC=C(C=C1)C2=CC(=CC(=C2)O)O)N3C=CN=C3
DMQYRAB	IK	VBHJJDVRMJRXQC-UHFFFAOYSA-N
DMQYRAB	IU	5-[4-(1-imidazol-1-ylpropyl)phenyl]benzene-1,3-diol
DMQYRAB	DE	Discovery agent

DMH2CX5	ID	DMH2CX5
DMH2CX5	DN	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3-ol
DMH2CX5	HS	Investigative
DMH2CX5	SN	CHEMBL556833; BDBM50295624
DMH2CX5	DT	Small molecular drug
DMH2CX5	PC	42642717
DMH2CX5	MW	278.3
DMH2CX5	FM	C18H18N2O
DMH2CX5	IC	InChI=1S/C18H18N2O/c1-2-18(20-11-10-19-13-20)15-8-6-14(7-9-15)16-4-3-5-17(21)12-16/h3-13,18,21H,2H2,1H3
DMH2CX5	CS	CCC(C1=CC=C(C=C1)C2=CC(=CC=C2)O)N3C=CN=C3
DMH2CX5	IK	QPIBEGYAAIVGIH-UHFFFAOYSA-N
DMH2CX5	IU	3-[4-(1-imidazol-1-ylpropyl)phenyl]phenol
DMH2CX5	DE	Discovery agent

DMUQ6FW	ID	DMUQ6FW
DMUQ6FW	DN	Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-4-ol
DMUQ6FW	HS	Investigative
DMUQ6FW	SN	CHEMBL500680; BDBM50272067; rac-4''-(1-Imidazol-1-yl-propyl)-biphenyl-4-ol; 4''-(1H -Imidazol-1-yl-propyl)-biphenyl-4-ol
DMUQ6FW	DT	Small molecular drug
DMUQ6FW	PC	42642716
DMUQ6FW	MW	278.3
DMUQ6FW	FM	C18H18N2O
DMUQ6FW	IC	InChI=1S/C18H18N2O/c1-2-18(20-12-11-19-13-20)16-5-3-14(4-6-16)15-7-9-17(21)10-8-15/h3-13,18,21H,2H2,1H3
DMUQ6FW	CS	CCC(C1=CC=C(C=C1)C2=CC=C(C=C2)O)N3C=CN=C3
DMUQ6FW	IK	LYYLXDSSMORBEQ-UHFFFAOYSA-N
DMUQ6FW	IU	4-[4-(1-imidazol-1-ylpropyl)phenyl]phenol
DMUQ6FW	DE	Discovery agent

DMR8L6O	ID	DMR8L6O
DMR8L6O	DN	Rac-cis-N-arachidonoylcyclopropanolamide
DMR8L6O	HS	Investigative
DMR8L6O	SN	cyclopropanolamide, 13a; cyclopropanolamide, rac-10a; CHEMBL474488; BDBM29078
DMR8L6O	DT	Small molecular drug
DMR8L6O	PC	42617983
DMR8L6O	MW	359.5
DMR8L6O	FM	C23H37NO2
DMR8L6O	IC	InChI=1S/C23H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)24-21-20-22(21)25/h6-7,9-10,12-13,15-16,21-22,25H,2-5,8,11,14,17-20H2,1H3,(H,24,26)/b7-6-,10-9-,13-12-,16-15-/t21-,22+/m1/s1
DMR8L6O	CS	CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N[C@@H]1C[C@@H]1O
DMR8L6O	IK	LZHCSJBKBARIFQ-NFCFDWBMSA-N
DMR8L6O	IU	(5Z,8Z,11Z,14Z)-N-[(1R,2S)-2-hydroxycyclopropyl]icosa-5,8,11,14-tetraenamide
DMR8L6O	DE	Discovery agent

DM39FSQ	ID	DM39FSQ
DM39FSQ	DN	Racemic DOI
DM39FSQ	HS	Investigative
DM39FSQ	SN	1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine; 4-DOI; 64584-34-5; 2,5-Dimethoxy-4-iodoamphetamine; DOI-P; 2,5-Dimethoxy-4-iodophenylisopropylamine; 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane; 1-(4-Iodo-2,5-dimethoxyphenyl)-2-aminopropane; 4-Iodo-2,5-dimethoxyamphetamine; C11H16INO2; 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine; CHEMBL6616; CHEBI:64629; 4-Iodo-2,5-dimethoxy-alpha-methylbenzeneethanamine; Benzeneethanamine, 4-iodo-2,5-dimethoxy-alpha-methyl-; 82830-53-3
DM39FSQ	DT	Small molecular drug
DM39FSQ	PC	1229
DM39FSQ	MW	321.15
DM39FSQ	FM	C11H16INO2
DM39FSQ	IC	InChI=1S/C11H16INO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
DM39FSQ	CS	CC(CC1=CC(=C(C=C1OC)I)OC)N
DM39FSQ	IK	BGMZUEKZENQUJY-UHFFFAOYSA-N
DM39FSQ	IU	1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine
DM39FSQ	CA	CAS 64584-34-5
DM39FSQ	CB	CHEBI:64629
DM39FSQ	DE	Discovery agent

DMNLCUH	ID	DMNLCUH
DMNLCUH	DN	Racemic DOTFM
DMNLCUH	HS	Investigative
DMNLCUH	SN	Racemic DOTFM; CHEMBL6620; 2-(2,5-Dimethoxy-4-trifluoromethyl-phenyl)-1-methyl-ethylamine; 159277-07-3; DOTFM; SCHEMBL14655679; DTXSID40439330; BDBM50038370
DMNLCUH	DT	Small molecular drug
DMNLCUH	PC	10400521
DMNLCUH	MW	263.26
DMNLCUH	FM	C12H16F3NO2
DMNLCUH	IC	InChI=1S/C12H16F3NO2/c1-7(16)4-8-5-11(18-3)9(12(13,14)15)6-10(8)17-2/h5-7H,4,16H2,1-3H3
DMNLCUH	CS	CC(CC1=CC(=C(C=C1OC)C(F)(F)F)OC)N
DMNLCUH	IK	WPGOTSORDNBMHP-UHFFFAOYSA-N
DMNLCUH	IU	1-[2,5-dimethoxy-4-(trifluoromethyl)phenyl]propan-2-amine
DMNLCUH	CA	CAS 159277-07-3
DMNLCUH	DE	Discovery agent

DM9DA8O	ID	DM9DA8O
DM9DA8O	DN	Rac-trans-N-oleoylcyclopropanolamide
DM9DA8O	HS	Investigative
DM9DA8O	SN	cyclopropanolamide, 12b; cyclopropanolamide, rac-9b; CHEMBL472662; BDBM29082
DM9DA8O	DT	Small molecular drug
DM9DA8O	PC	42617986
DM9DA8O	MW	337.5
DM9DA8O	FM	C21H39NO2
DM9DA8O	IC	InChI=1S/C21H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)22-19-18-20(19)23/h9-10,19-20,23H,2-8,11-18H2,1H3,(H,22,24)/b10-9-/t19-,20-/m1/s1
DM9DA8O	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)N[C@@H]1C[C@H]1O
DM9DA8O	IK	VCMSNKIQHBVCSW-BHGRFLGOSA-N
DM9DA8O	IU	(Z)-N-[(1R,2R)-2-hydroxycyclopropyl]octadec-9-enamide

DMNZS94	ID	DMNZS94
DMNZS94	DN	Radicicol
DMNZS94	HS	Investigative
DMNZS94	SN	AC1L1JGN; CHEMBL3972342; CTK6B6269
DMNZS94	DT	Small molecular drug
DMNZS94	PC	6323491
DMNZS94	MW	364.8
DMNZS94	FM	C18H17ClO6
DMNZS94	IC	InChI=1S/C18H17ClO6/c1-9-6-15-14(25-15)5-3-2-4-10(20)7-11-16(18(23)24-9)12(21)8-13(22)17(11)19/h2-5,8-9,14-15,21-22H,6-7H2,1H3/b4-2+,5-3-/t9-,14-,15-/m1/s1
DMNZS94	CS	C[C@@H]1C[C@@H]2[C@H](O2)/C=C\\C=C\\C(=O)CC3=C(C(=CC(=C3Cl)O)O)C(=O)O1
DMNZS94	IK	WYZWZEOGROVVHK-GTMNPGAYSA-N
DMNZS94	IU	(4R,6R,8R,9Z,11E)-16-chloro-17,19-dihydroxy-4-methyl-3,7-dioxatricyclo[13.4.0.06,8]nonadeca-1(15),9,11,16,18-pentaene-2,13-dione
DMNZS94	CA	CAS 12772-57-5
DMNZS94	CB	CHEBI:556075
DMNZS94	DE	Discovery agent

DMVHDOS	ID	DMVHDOS
DMVHDOS	DN	Raffinose
DMVHDOS	HS	Investigative
DMVHDOS	SN	D-Raffinose; Gossypose; MUPFEKGTMRGPLJ-ZQSKZDJDSA-N; Melitose; Melitriose; N5O3QU595M; RAFFINOSE; Raffinose (8CI); Raffinose, pure; d(+)-raffinose; d-(+)-Raffinose; rafinose; raflinose; 512-69-6; 6G-alpha-D-galactosylsucrose; AI3-19427; C18H32O16; CHEBI:16634; EINECS 208-146-9; NSC 170228; NSC 2025; NSC170228; UNII-N5O3QU595M; alpha-D-glucopyranoside, beta-D-fructofuranosyl O-alpha-D-galactopyranosyl-(1-&gt;6)-; beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1-&gt;6)-alpha-D-glucopyranoside
DMVHDOS	PC	439242
DMVHDOS	MW	504.4
DMVHDOS	FM	C18H32O16
DMVHDOS	IC	MUPFEKGTMRGPLJ-ZQSKZDJDSA-N
DMVHDOS	CS	C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3(C(C(C(O3)CO)O)O)CO)O)O)O)O)O)O)O
DMVHDOS	IK	1S/C18H32O16/c19-1-5-8(22)11(25)13(27)16(31-5)30-3-7-9(23)12(26)14(28)17(32-7)34-18(4-21)15(29)10(24)6(2-20)33-18/h5-17,19-29H,1-4H2/t5-,6-,7-,8+,9-,10-,11+,12+,13-,14-,15+,16+,17-,18+/m1/s1
DMVHDOS	IU	(2S,3R,4S,5R,6R)-2-[[(2R,3S,4S,5R,6R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
DMVHDOS	CA	CAS 512-69-6
DMVHDOS	CB	CHEBI:16634
DMVHDOS	DE	Discovery agent

DMI7NAF	ID	DMI7NAF
DMI7NAF	DN	ranatensin
DMI7NAF	HS	Investigative
DMI7NAF	SN	Ranatensin; 29451-71-6; GTPL618; BDBM85499; NSC_5489061; CAS_29451-71-6
DMI7NAF	DT	Small molecular drug
DMI7NAF	PC	22146595
DMI7NAF	MW	1281.5
DMI7NAF	FM	C61H84N16O13S
DMI7NAF	IC	InChI=1S/C61H84N16O13S/c1-32(2)50(60(89)66-30-49(80)70-45(27-37-29-64-31-67-37)58(87)73-43(25-35-13-8-7-9-14-35)57(86)71-40(52(63)81)22-24-91-6)75-53(82)34(5)68-56(85)44(26-36-28-65-39-16-11-10-15-38(36)39)74-54(83)42(18-20-47(62)78)72-59(88)46-17-12-23-77(46)61(90)51(33(3)4)76-55(84)41-19-21-48(79)69-41/h7-11,13-16,28-29,31-34,40-46,50-51,65H,12,17-27,30H2,1-6H3,(H2,62,78)(H2,63,81)(H,64,67)(H,66,89)(H,68,85)(H,69,79)(H,70,80)(H,71,86)(H,72,88)(H,73,87)(H,74,83)(H,75,82)(H,76,84)
DMI7NAF	CS	CC(C)C(C(=O)NCC(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCSC)C(=O)N)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)C5CCCN5C(=O)C(C(C)C)NC(=O)C6CCC(=O)N6
DMI7NAF	IK	AUOCWSNQHWTPIJ-UHFFFAOYSA-N
DMI7NAF	IU	N-[1-[[1-[[1-[[2-[[1-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[1-[3-methyl-2-[(5-oxopyrrolidine-2-carbonyl)amino]butanoyl]pyrrolidine-2-carbonyl]amino]pentanediamide
DMI7NAF	DE	Discovery agent

DM961JG	ID	DM961JG
DM961JG	DN	RAP-103
DM961JG	HS	Investigative
DM961JG	SN	RAP-103N
DM961JG	CP	RAPID Laboratories Inc
DM961JG	DE	Neuropathic pain

DMP2DMB	ID	DMP2DMB
DMP2DMB	DN	RAP-310
DMP2DMB	HS	Investigative
DMP2DMB	SN	Small stabilized receptor active peptide (Alzheimers disease), RAPID Pharmaceuticals
DMP2DMB	CP	RAPID Pharmaceuticals AG
DMP2DMB	DE	Alzheimer disease

DM8GRJK	ID	DM8GRJK
DM8GRJK	DN	Rapamycin
DM8GRJK	HS	Investigative
DM8GRJK	SN	MTOR inhibitors
DM8GRJK	CP	Genentech
DM8GRJK	TC	Antiviral Agents
DM8GRJK	DT	Small molecular drug
DM8GRJK	PC	5284616
DM8GRJK	MW	914.2
DM8GRJK	FM	C51H79NO13
DM8GRJK	IC	InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
DM8GRJK	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
DM8GRJK	IK	QFJCIRLUMZQUOT-HPLJOQBZSA-N
DM8GRJK	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM8GRJK	CA	CAS 53123-88-9
DM8GRJK	CB	CHEBI:9168
DM8GRJK	DE	Multiple myeloma; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMLBP3F	ID	DMLBP3F
DMLBP3F	DN	Rapamycin complexed with immunophilin FKBP12
DMLBP3F	HS	Investigative
DMLBP3F	DE	Discovery agent

DM678IB	ID	DM678IB
DM678IB	DN	Rapamycin Immunosuppressant Drug
DM678IB	HS	Investigative
DM678IB	SN	mTOR Inhibitor, Rapamycin
DM678IB	DT	Small molecular drug
DM678IB	PC	21944094
DM678IB	MW	914.2
DM678IB	FM	C51H79NO13
DM678IB	IC	InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
DM678IB	CS	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C\\[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
DM678IB	IK	QFJCIRLUMZQUOT-KADBNGAOSA-N
DM678IB	IU	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24Z,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM678IB	DE	Discovery agent

DM9XOE6	ID	DM9XOE6
DM9XOE6	DN	rawsonol
DM9XOE6	HS	Investigative
DM9XOE6	SN	125111-69-5
DM9XOE6	DT	Small molecular drug
DM9XOE6	PC	180306
DM9XOE6	MW	804.1
DM9XOE6	FM	C29H24Br4O7
DM9XOE6	IC	InChI=1S/C29H24Br4O7/c1-40-12-17-11-23(33)29(39)27(37)19(17)6-14-4-16(25(35)21(31)8-14)9-15-10-22(32)28(38)26(36)18(15)5-13-2-3-24(34)20(30)7-13/h2-4,7-8,10-11,34-39H,5-6,9,12H2,1H3
DM9XOE6	CS	COCC1=CC(=C(C(=C1CC2=CC(=C(C(=C2)Br)O)CC3=CC(=C(C(=C3CC4=CC(=C(C=C4)O)Br)O)O)Br)O)O)Br
DM9XOE6	IK	KCFBHVMAGOSSRA-UHFFFAOYSA-N
DM9XOE6	IU	6-bromo-4-[[3-bromo-5-[[4-bromo-2,3-dihydroxy-6-(methoxymethyl)phenyl]methyl]-2-hydroxyphenyl]methyl]-3-[(3-bromo-4-hydroxyphenyl)methyl]benzene-1,2-diol
DM9XOE6	CA	CAS 125111-69-5
DM9XOE6	DE	Discovery agent

DMPML15	ID	DMPML15
DMPML15	DN	RAZAXABAN
DMPML15	HS	Investigative
DMPML15	SN	Razaxaban Hydrochloride; UNII-7CLJ1MEZ8V; BMS-561389; 7CLJ1MEZ8V; 405940-76-3; DPC 906; Razaxaban Hydrochloride [USAN]; Razaxaban hydrochloride (USAN); CHEMBL558198; DPC-906; BMS 561389; Razaxaban HCl; AC1L4BWY; SCHEMBL6885838; DTXSID10193598; Razaxaban hydrochloride, &gt; D04029; 1H-Pyrazole-5-carboxamide, 1-(3-amino-1,2-benzisoxazol-5-yl)-N-(4-(2-((dimethylamino)methyl)-1H-imidazol-1-yl)-2-fluorophenyl)-3-(trifluoromethyl)-, monohydrochloride
DMPML15	DT	Small molecular drug
DMPML15	PC	204102
DMPML15	MW	528.5
DMPML15	FM	C24H20F4N8O2
DMPML15	IC	InChI=1S/C24H20F4N8O2/c1-34(2)12-21-30-7-8-35(21)13-3-5-17(16(25)10-13)31-23(37)18-11-20(24(26,27)28)32-36(18)14-4-6-19-15(9-14)22(29)33-38-19/h3-11H,12H2,1-2H3,(H2,29,33)(H,31,37)
DMPML15	CS	CN(C)CC1=NC=CN1C2=CC(=C(C=C2)NC(=O)C3=CC(=NN3C4=CC5=C(C=C4)ON=C5N)C(F)(F)F)F
DMPML15	IK	OFJRNBWSFXEHSA-UHFFFAOYSA-N
DMPML15	IU	2-(3-amino-1,2-benzoxazol-5-yl)-N-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMPML15	CA	CAS 218298-21-6
DMPML15	DE	Discovery agent

DMCEFUW	ID	DMCEFUW
DMCEFUW	DN	RB 2
DMCEFUW	HS	Investigative
DMCEFUW	SN	CHEMBL223344; Cibacron Blue 3GA Agarose; Cibacron Blue 3GA Agarose, saline suspension; Cibacron Blue 3GA Agarose, Type 300, saline suspension; Cibacron Blue 3GA Agarose, Type 100, saline suspension; Cibacron Blue 3GA Agarose, saline suspension, Fast flow; Cibacron Blue 3GA Agarose, Type 1000, saline suspension; Cibacron Blue 3GA Agarose, Type 3000, saline suspension; Cibacron Blue 3GA Agarose, Type 3000-CL, saline suspension; Cibacron Blue 3GA Agarose, Type 3000-L, lyophilized powder
DMCEFUW	DT	Small molecular drug
DMCEFUW	PC	9875920
DMCEFUW	MW	840.1
DMCEFUW	FM	C29H17ClN7Na3O11S3
DMCEFUW	IC	InChI=1S/C29H20ClN7O11S3.3Na/c30-27-35-28(33-13-4-3-5-15(10-13)49(40,41)42)37-29(36-27)34-18-9-8-14(11-20(18)50(43,44)45)32-19-12-21(51(46,47)48)24(31)23-22(19)25(38)16-6-1-2-7-17(16)26(23)39;;;/h1-12,32H,31H2,(H,40,41,42)(H,43,44,45)(H,46,47,48)(H2,33,34,35,36,37);;;/q;3*+1/p-3
DMCEFUW	CS	C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3NC4=CC(=C(C=C4)NC5=NC(=NC(=N5)NC6=CC(=CC=C6)S(=O)(=O)[O-])Cl)S(=O)(=O)[O-])S(=O)(=O)[O-])N.[Na+].[Na+].[Na+]
DMCEFUW	IK	VZPXDCIISFTYOM-UHFFFAOYSA-K
DMCEFUW	IU	trisodium;1-amino-4-[4-[[4-chloro-6-(3-sulfonatoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfonatoanilino]-9,10-dioxoanthracene-2-sulfonate
DMCEFUW	DE	Discovery agent

DMRK3HO	ID	DMRK3HO
DMRK3HO	DN	RB-105
DMRK3HO	HS	Investigative
DMRK3HO	SN	S-21402; S-21402-1; N-[2(S)-(Mercaptomethyl)-3(R)-phenylbutyl]-L-alanine
DMRK3HO	DT	Small molecular drug
DMRK3HO	PC	5487537
DMRK3HO	MW	281.37
DMRK3HO	FM	C14H19NO3S
DMRK3HO	IC	InChI=1S/C14H19NO3S/c1-9(11-6-4-3-5-7-11)12(8-19)13(16)15-10(2)14(17)18/h3-7,9-10,12,19H,8H2,1-2H3,(H,15,16)(H,17,18)/t9-,10-,12-/m0/s1
DMRK3HO	CS	C[C@@H](C1=CC=CC=C1)[C@H](CS)C(=O)N[C@@H](C)C(=O)O
DMRK3HO	IK	ABBSOQIXYPZCKO-NHCYSSNCSA-N
DMRK3HO	IU	(2S)-2-[[(2S,3R)-3-phenyl-2-(sulfanylmethyl)butanoyl]amino]propanoic acid
DMRK3HO	CA	CAS 155895-89-9
DMRK3HO	DE	Hypertension

DMJDE6Y	ID	DMJDE6Y
DMJDE6Y	DN	RB-400
DMJDE6Y	HS	Investigative
DMJDE6Y	SN	RB400; RB 400
DMJDE6Y	DT	Small molecular drug
DMJDE6Y	PC	5311400
DMJDE6Y	MW	678.7
DMJDE6Y	FM	C34H42N6O9
DMJDE6Y	IC	InChI=1S/C34H42N6O9/c1-3-4-14-27(33(48)39-25(17-29(42)43)32(47)38-24(31(35)46)15-20-10-6-5-7-11-20)40(2)34(49)26(37-28(41)18-30(44)45)16-21-19-36-23-13-9-8-12-22(21)23/h5-13,19,24-27,36H,3-4,14-18H2,1-2H3,(H2,35,46)(H,37,41)(H,38,47)(H,39,48)(H,42,43)(H,44,45)/t24-,25-,26-,27-/m0/s1
DMJDE6Y	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CC(=O)O
DMJDE6Y	IK	QUSCQANKQSFCGJ-FWEHEUNISA-N
DMJDE6Y	IU	(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-[(2-carboxyacetyl)amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-oxobutanoic acid
DMJDE6Y	DE	Discovery agent

DM9IQXM	ID	DM9IQXM
DM9IQXM	DN	RBI257
DM9IQXM	HS	Investigative
DM9IQXM	SN	RBI 257; RBI-257
DM9IQXM	DT	Small molecular drug
DM9IQXM	PC	5041
DM9IQXM	MW	465.4
DM9IQXM	FM	C21H28IN3O
DM9IQXM	IC	InChI=1S/C21H28IN3O/c1-16(2)26-20-5-4-12-23-21(20)24(3)19-10-13-25(14-11-19)15-17-6-8-18(22)9-7-17/h4-9,12,16,19H,10-11,13-15H2,1-3H3
DM9IQXM	CS	CC(C)OC1=C(N=CC=C1)N(C)C2CCN(CC2)CC3=CC=C(C=C3)I
DM9IQXM	IK	ZJAXDNQQFMPNAV-UHFFFAOYSA-N
DM9IQXM	IU	N-[1-[(4-iodophenyl)methyl]piperidin-4-yl]-N-methyl-3-propan-2-yloxypyridin-2-amine
DM9IQXM	DE	Discovery agent

DMNEK79	ID	DMNEK79
DMNEK79	DN	RBx-343E48F0
DMNEK79	HS	Investigative
DMNEK79	CP	Ranbaxy Laboratories Ltd
DMNEK79	DE	Chronic obstructive pulmonary disease

DM6FVZW	ID	DM6FVZW
DM6FVZW	DN	R-dimethindene
DM6FVZW	HS	Investigative
DM6FVZW	SN	CHEMBL564226; UNII-C9Z23T6963; C9Z23T6963; (R)-Dimethindene; Dimetindene, (R)-; (R)-(-)-Dimethindene; ZINC1482162; BDBM50297307; UNII-661FH77Z3P component MVMQESMQSYOVGV-HNNXBMFYSA-N; 1H-Indene-2-ethanamine, N,N-dimethyl-3-((1R)-1-(2-pyridinyl)ethyl)-; 1H-Indene-2-ethanamine, N,N-dimethyl-3-(1-(2-pyridinyl)ethyl)-, (R)-
DM6FVZW	DT	Small molecular drug
DM6FVZW	PC	12963076
DM6FVZW	MW	292.4
DM6FVZW	FM	C20H24N2
DM6FVZW	IC	InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3/t15-/m0/s1
DM6FVZW	CS	C[C@@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C
DM6FVZW	IK	MVMQESMQSYOVGV-HNNXBMFYSA-N
DM6FVZW	IU	N,N-dimethyl-2-[3-[(1R)-1-pyridin-2-ylethyl]-1H-inden-2-yl]ethanamine
DM6FVZW	CA	CAS 135821-89-5
DM6FVZW	DE	Discovery agent

DM386JM	ID	DM386JM
DM386JM	DN	Rec 15/2615
DM386JM	HS	Investigative
DM386JM	SN	CHEMBL430717; Rec 15/2615; SCHEMBL5789541; GTPL8459; ZINC602525; BDBM50057463; NCGC00370846-01; 2-[4-(6-Isopropyl-2-methoxyphenoxyacetyl)piperazino]-6,7-dimethoxyquinazoline-4-amine; 1-[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperazin-1-yl]-2-(2-isopropyl-6-methoxy-phenoxy)-ethanone
DM386JM	DT	Small molecular drug
DM386JM	PC	9891980
DM386JM	MW	495.6
DM386JM	FM	C26H33N5O5
DM386JM	IC	InChI=1S/C26H33N5O5/c1-16(2)17-7-6-8-20(33-3)24(17)36-15-23(32)30-9-11-31(12-10-30)26-28-19-14-22(35-5)21(34-4)13-18(19)25(27)29-26/h6-8,13-14,16H,9-12,15H2,1-5H3,(H2,27,28,29)
DM386JM	CS	CC(C)C1=C(C(=CC=C1)OC)OCC(=O)N2CCN(CC2)C3=NC4=CC(=C(C=C4C(=N3)N)OC)OC
DM386JM	IK	ZZMFJJDBKSYGRM-UHFFFAOYSA-N
DM386JM	IU	1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-(2-methoxy-6-propan-2-ylphenoxy)ethanone
DM386JM	DE	Discovery agent

DMJ0FCG	ID	DMJ0FCG
DMJ0FCG	DN	REC2615
DMJ0FCG	HS	Investigative
DMJ0FCG	SN	SCHEMBL6444383
DMJ0FCG	CP	Recordati
DMJ0FCG	DT	Small molecular drug
DMJ0FCG	PC	10075732
DMJ0FCG	MW	532
DMJ0FCG	FM	C26H34ClN5O5
DMJ0FCG	IC	InChI=1S/C26H33N5O5.ClH/c1-16(2)17-7-6-8-20(33-3)24(17)36-15-23(32)30-9-11-31(12-10-30)26-28-19-14-22(35-5)21(34-4)13-18(19)25(27)29-26;/h6-8,13-14,16H,9-12,15H2,1-5H3,(H2,27,28,29);1H
DMJ0FCG	CS	CC(C)C1=C(C(=CC=C1)OC)OCC(=O)N2CCN(CC2)C3=NC4=CC(=C(C=C4C(=N3)N)OC)OC.Cl
DMJ0FCG	IK	YLPWNPUPMQZIKN-UHFFFAOYSA-N
DMJ0FCG	IU	1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-(2-methoxy-6-propan-2-ylphenoxy)ethanone;hydrochloride
DMJ0FCG	DE	Female sexual arousal dysfunction

DM1P830	ID	DM1P830
DM1P830	DN	recAAT, PPL Therapeutics/Bayer
DM1P830	HS	Investigative
DM1P830	SN	AAT therapy, PPLTherapeutics/Bayer; alpha-1 antitrypsin, PPL Therapeutics/Bayer; rAAT, PPL
DM1P830	DE	Discovery agent

DM1XFE9	ID	DM1XFE9
DM1XFE9	DN	RECALL-VAX
DM1XFE9	HS	Investigative
DM1XFE9	SN	RV-01; RV-02; Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease); Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease), Intellect Neuroscience
DM1XFE9	CP	Intellect Neurosciences Inc
DM1XFE9	DT	Vaccine
DM1XFE9	DE	Alzheimer disease

DM4B6FO	ID	DM4B6FO
DM4B6FO	DN	Receptor-Fc fusion proteins
DM4B6FO	HS	Investigative
DM4B6FO	DT	Antibody
DM4B6FO	DE	Discovery agent

DMA6VCG	ID	DMA6VCG
DMA6VCG	DN	Recombinant botulinum toxin
DMA6VCG	HS	Investigative
DMA6VCG	SN	Recombinant botulinum toxin (dystonia)
DMA6VCG	CP	Syntaxin Ltd
DMA6VCG	DE	Neurological disorder

DMFAST4	ID	DMFAST4
DMFAST4	DN	Recombinant coagulation factors
DMFAST4	HS	Investigative
DMFAST4	CP	Novozymes A/S
DMFAST4	DE	Hemophilia

DMX6LV3	ID	DMX6LV3
DMX6LV3	DN	Recombinant Factor X
DMX6LV3	HS	Investigative
DMX6LV3	SN	Recombinant Factor X (hemophilia)
DMX6LV3	CP	Catalyst Biosciences Inc
DMX6LV3	DE	Hemophilia

DMNHOI3	ID	DMNHOI3
DMNHOI3	DN	Recombinant follicle stimulating hormone
DMNHOI3	HS	Investigative
DMNHOI3	CP	Itero Biopharmaceuticals Inc
DMNHOI3	DE	Female infertility

DMM3465	ID	DMM3465
DMM3465	DN	Recombinant human butyrylcholinesterase
DMM3465	HS	Investigative
DMM3465	SN	Recombinant human butyrylcholinesterase (inhaled, nerve agent exposure)
DMM3465	CP	Plant Vax Inc
DMM3465	DE	Poison intoxication

DMVJLR3	ID	DMVJLR3
DMVJLR3	DN	Recombinant human pro-urokinase
DMVJLR3	HS	Investigative
DMVJLR3	SN	Recombinant human pro-urokinase (myocardial infarction)
DMVJLR3	CP	Newsummit Biopharma Co Ltd
DMVJLR3	DE	Myocardial infarction

DMLYQWV	ID	DMLYQWV
DMLYQWV	DN	Recombinant human TNF receptor
DMLYQWV	HS	Investigative
DMLYQWV	SN	Recombinant human TNF receptor (arthritis); RhTNFR (arthritis), Shanghai/Taizhou; Recombinant human TNFreceptor (arthritis), Taizhou Fudan-Zhangjiang Pharmaceutical/ Shanghai Pharmaceuticals
DMLYQWV	CP	Taizhou Fudan-Zhangjiang Pharmaceutical Co Ltd
DMLYQWV	DE	Arthritis

DMJQ7XD	ID	DMJQ7XD
DMJQ7XD	DN	Recombinant TSH superagonists
DMJQ7XD	HS	Investigative
DMJQ7XD	SN	Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen
DMJQ7XD	CP	Trophogen Inc
DMJQ7XD	DE	Thyroid cancer

DM2S496	ID	DM2S496
DM2S496	DN	Redoxal
DM2S496	HS	Investigative
DM2S496	SN	52962-95-5; MLS000736810; NSC73735; UNII-Q0VK2156M5; N,N'-BIS(o-CARBOXYPHENYL)-o-DIANISIDINE; Q0VK2156M5; SMR000528333; 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid; Benzoic acid, 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-; 2-[4-[4-(2-carboxyanilino)-3-methoxyphenyl]-2-methoxyanilino]benzoic acid; 2-[4-[4-(2-carboxyanilino)-3-methoxy-phenyl]-2-methoxy-anilino]benzoic acid; 2-[(4-{4-[(2-carboxyphenyl)amino]-3-methoxyphenyl}-2-methoxyphenyl)amino]benzoic acid; Mini-antibody(scFv)
DM2S496	DT	Small molecular drug
DM2S496	PC	72571
DM2S496	MW	484.5
DM2S496	FM	C28H24N2O6
DM2S496	IC	InChI=1S/C28H24N2O6/c1-35-25-15-17(11-13-23(25)29-21-9-5-3-7-19(21)27(31)32)18-12-14-24(26(16-18)36-2)30-22-10-6-4-8-20(22)28(33)34/h3-16,29-30H,1-2H3,(H,31,32)(H,33,34)
DM2S496	CS	COC1=C(C=CC(=C1)C2=CC(=C(C=C2)NC3=CC=CC=C3C(=O)O)OC)NC4=CC=CC=C4C(=O)O
DM2S496	IK	IQZIRNIZQHVBMB-UHFFFAOYSA-N
DM2S496	IU	2-[4-[4-(2-carboxyanilino)-3-methoxyphenyl]-2-methoxyanilino]benzoic acid
DM2S496	CA	CAS 52962-95-5
DM2S496	DE	Discovery agent

DMQ3ER0	ID	DMQ3ER0
DMQ3ER0	DN	reglitazar
DMQ3ER0	HS	Investigative
DMQ3ER0	SN	JTT-501
DMQ3ER0	DT	Small molecular drug
DMQ3ER0	PC	154000
DMQ3ER0	MW	392.4
DMQ3ER0	FM	C22H20N2O5
DMQ3ER0	IC	InChI=1S/C22H20N2O5/c1-14-19(23-21(28-14)16-5-3-2-4-6-16)11-12-27-17-9-7-15(8-10-17)13-18-20(25)24-29-22(18)26/h2-10,18H,11-13H2,1H3,(H,24,25)
DMQ3ER0	CS	CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC4C(=O)NOC4=O
DMQ3ER0	IK	QBQLYIISSRXYKL-UHFFFAOYSA-N
DMQ3ER0	IU	4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione
DMQ3ER0	CA	CAS 170861-63-9
DMQ3ER0	DE	Discovery agent

DM3AWPB	ID	DM3AWPB
DM3AWPB	DN	Relcovaptan
DM3AWPB	HS	Investigative
DM3AWPB	SN	SR 49059; SR-49059; Relcovaptan [INN]; 150375-75-0; UNII-C1GL8G6G0O; SR49059; C1GL8G6G0O; CHEMBL419667; 1-(5-Chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl)pyrrolidine-2-carboxamide; (2S)-1-[[(2R,3S)-5-CHLORO-3-(2-CHLOROPHENYL)-1-[(3,4-DIMETHOXYPHENYL)SULFONYL]-2,3-DIHYDRO-3-HYDROXY-1H-INDOL-2-YL]CARBONYL]-2-PYRROLIDINECARBOXAMIDE; 2-Pyrrolidinecarboxamide,; [3H]relcovaptan
DM3AWPB	DT	Small molecular drug
DM3AWPB	PC	60943
DM3AWPB	MW	620.5
DM3AWPB	FM	C28H27Cl2N3O7S
DM3AWPB	IC	InChI=1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1
DM3AWPB	CS	COC1=C(C=C(C=C1)S(=O)(=O)N2[C@H]([C@](C3=C2C=CC(=C3)Cl)(C4=CC=CC=C4Cl)O)C(=O)N5CCC[C@H]5C(=O)N)OC
DM3AWPB	IK	CEBYCSRFKCEUSW-NAYZPBBASA-N
DM3AWPB	IU	(2S)-1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2H-indole-2-carbonyl]pyrrolidine-2-carboxamide
DM3AWPB	CA	CAS 150375-75-0
DM3AWPB	CB	CHEBI:93701
DM3AWPB	DE	Discovery agent

DM47TSV	ID	DM47TSV
DM47TSV	DN	Repinotan
DM47TSV	HS	Investigative
DM47TSV	SN	Repinotan; UNII-05PB82Z52L; 144980-29-0; 05PB82Z52L; Bay-x-3702; Repinotan [INN]; Repinotan (BAYx3702); GTPL95; AC1L55ZL; SCHEMBL678644; CHEMBL1614652; DTXSID80162857; YGYBFMRFXNDIPO-QGZVFWFLSA-N; ZINC1552489; 2-[4-[[(2R)-chroman-2-yl]methylamino]butyl]-1,1-dioxo-1,2-benzothiazol-3-one; (-)-2-(4-(((R)-2-Chromanylmethyl)amino)butyl)-1,2-benzisothiazolin-3-one 1,1-dioxide; (-)-2-(4-(((R)-2-Chromanylmethyl)amino)butyl)-1,2-benzisothiazolin-3-one, 1,1-dioxide, (R)-
DM47TSV	DT	Small molecular drug
DM47TSV	PC	198757
DM47TSV	MW	400.5
DM47TSV	FM	C21H24N2O4S
DM47TSV	IC	InChI=1S/C21H24N2O4S/c24-21-18-8-2-4-10-20(18)28(25,26)23(21)14-6-5-13-22-15-17-12-11-16-7-1-3-9-19(16)27-17/h1-4,7-10,17,22H,5-6,11-15H2/t17-/m1/s1
DM47TSV	CS	C1CC2=CC=CC=C2O[C@H]1CNCCCCN3C(=O)C4=CC=CC=C4S3(=O)=O
DM47TSV	IK	YGYBFMRFXNDIPO-QGZVFWFLSA-N
DM47TSV	IU	2-[4-[[(2R)-3,4-dihydro-2H-chromen-2-yl]methylamino]butyl]-1,1-dioxo-1,2-benzothiazol-3-one
DM47TSV	CA	CAS 144980-29-0
DM47TSV	DE	Discovery agent

DMQEBKF	ID	DMQEBKF
DMQEBKF	DN	RES-701-1-C-terminal analogue
DMQEBKF	HS	Investigative
DMQEBKF	DE	Discovery agent

DM2IBND	ID	DM2IBND
DM2IBND	DN	RESCOVITINE
DM2IBND	HS	Investigative
DM2IBND	SN	Rescovitine; CHEMBL1087791
DM2IBND	DT	Small molecular drug
DM2IBND	PC	46881287
DM2IBND	MW	356.5
DM2IBND	FM	C19H28N6O
DM2IBND	IC	InChI=1S/C19H28N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,13,15,21,26H,4,10-12H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
DM2IBND	CS	CC[C@H](CO)NC1=NC(=C2C(=N1)N(CN2)C(C)C)NCC3=CC=CC=C3
DM2IBND	IK	RMSINZVFNDWCCK-OAHLLOKOSA-N
DM2IBND	IU	(2R)-2-[[6-(benzylamino)-9-propan-2-yl-7,8-dihydropurin-2-yl]amino]butan-1-ol
DM2IBND	DE	Discovery agent

DMLVU6H	ID	DMLVU6H
DMLVU6H	DN	resolvin D2
DMLVU6H	HS	Investigative
DMLVU6H	SN	RvD2; GTPL5417; (4Z,7R,8E,10Z,12E,14E,17S,19Z)-7,16,17-TRIHYDROXYDOCOSA-4,8,10,12,14,19-HEXAENOIC ACID
DMLVU6H	DT	Small molecular drug
DMLVU6H	PC	11383310
DMLVU6H	MW	376.5
DMLVU6H	FM	C22H32O5
DMLVU6H	IC	InChI=1S/C22H32O5/c1-2-3-9-16-20(24)21(25)17-12-7-5-4-6-10-14-19(23)15-11-8-13-18-22(26)27/h3-12,14,17,19-21,23-25H,2,13,15-16,18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,11-8-,14-10+,17-12+/t19-,20+,21-/m1/s1
DMLVU6H	CS	CC/C=C\\C[C@@H]([C@@H](/C=C/C=C/C=C\\C=C\\[C@H](C/C=C\\CCC(=O)O)O)O)O
DMLVU6H	IK	IKFAUGXNBOBQDM-XFMPMKITSA-N
DMLVU6H	IU	(4Z,7S,8E,10Z,12E,14E,16R,17S,19Z)-7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoic acid
DMLVU6H	CB	CHEBI:81565
DMLVU6H	DE	Discovery agent

DMM37C0	ID	DMM37C0
DMM37C0	DN	Resorcinol
DMM37C0	HS	Investigative
DMM37C0	SN	resorcinol; 108-46-3; 1,3-Benzenediol; Resorcin; 1,3-Dihydroxybenzene; benzene-1,3-diol; m-Hydroquinone; 3-Hydroxyphenol; m-Hydroxyphenol; m-Dihydroxybenzene; Resorcine; m-Dioxybenzene; m-Benzenediol; Dihydroxybenzol; Resorzin; Developer O; Developer R; Developer RS; Fouramine RS; Fourrine EW; Pelagol RS; Pelagol Grey RS; Resorcinolum; Fourrine 79; Nako TGG; Durafur developer G; Phenol, m-hydroxy-; C.I. Developer 4; Benzene, m-dihydroxy-; C.I. Oxidation Base 31; Rcra waste number U201; Sulforcin; Rezamid; Resorcino; Benzene, 1,3-dihydroxy-
DMM37C0	DT	Small molecular drug
DMM37C0	PC	5054
DMM37C0	MW	110.11
DMM37C0	FM	C6H6O2
DMM37C0	IC	InChI=1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H
DMM37C0	CS	C1=CC(=CC(=C1)O)O
DMM37C0	IK	GHMLBKRAJCXXBS-UHFFFAOYSA-N
DMM37C0	IU	benzene-1,3-diol
DMM37C0	CA	CAS 108-46-3
DMM37C0	CB	CHEBI:27810
DMM37C0	DE	Discovery agent

DMN1RLA	ID	DMN1RLA
DMN1RLA	DN	Resveratrol Potassium3-Sulfate
DMN1RLA	HS	Investigative
DMN1RLA	SN	Resveratrol Potassium3-Sulfate
DMN1RLA	DT	Small molecular drug
DMN1RLA	PC	46855054
DMN1RLA	MW	346.4
DMN1RLA	FM	C14H11KO6S
DMN1RLA	IC	InChI=1S/C14H12O6S.K/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(8-11)20-21(17,18)19;/h1-9,15-16H,(H,17,18,19);/q;+1/p-1/b2-1+;
DMN1RLA	CS	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)OS(=O)(=O)[O-])O)O.[K+]
DMN1RLA	IK	ZWGAYYADLYCXQH-TYYBGVCCSA-M
DMN1RLA	IU	potassium;[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenyl] sulfate
DMN1RLA	DE	Discovery agent

DMMFP57	ID	DMMFP57
DMMFP57	DN	Resveratrol Potassium4,-Sulfate
DMMFP57	HS	Investigative
DMMFP57	SN	Resveratrol Potassium4,-Sulfate
DMMFP57	DT	Small molecular drug
DMMFP57	PC	46855201
DMMFP57	MW	346.4
DMMFP57	FM	C14H11KO6S
DMMFP57	IC	InChI=1S/C14H12O6S.K/c15-12-7-11(8-13(16)9-12)2-1-10-3-5-14(6-4-10)20-21(17,18)19;/h1-9,15-16H,(H,17,18,19);/q;+1/p-1/b2-1+;
DMMFP57	CS	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)OS(=O)(=O)[O-].[K+]
DMMFP57	IK	DBEZAQWZIMHBRG-TYYBGVCCSA-M
DMMFP57	IU	potassium;[4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl] sulfate
DMMFP57	DE	Discovery agent

DMQFSI5	ID	DMQFSI5
DMQFSI5	DN	Retagliptin
DMQFSI5	HS	Investigative
DMQFSI5	SN	DPP4 inhibitors, Shanghai Hengrui Pharmaceutical Co Ltd; SHR-1039; SHR-1040; DPPIV inhibitors (diabetes), Shanghai Hengrui Pharmaceutical Co Ltd; Dipeptidyl peptidase IV inhibitors (diabetes), Shanghai Hengrui Pharmaceutical Co Ltd
DMQFSI5	CP	Shanghai Hengrui Pharmaceutical Co Ltd
DMQFSI5	PC	44193830
DMQFSI5	MW	464.4
DMQFSI5	FM	C19H18F6N4O3
DMQFSI5	IC	InChI=1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3/t10-/m1/s1
DMQFSI5	CS	COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
DMQFSI5	IK	WIIAMRXFUJLYEF-SNVBAGLBSA-N
DMQFSI5	IU	methyl 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxylate
DMQFSI5	CA	CAS 1174122-54-3
DMQFSI5	DE	Non-insulin dependent diabetes

DMWDNOK	ID	DMWDNOK
DMWDNOK	DN	REVERSINE
DMWDNOK	HS	Investigative
DMWDNOK	SN	Reversine; 656820-32-5; 2-(4-Morpholinoanilino)-6-cyclohexylaminopurine; UNII-Z499CLJ023; CHEMBL188343; CHEBI:70723; ZFLJHSQHILSNCM-UHFFFAOYSA-N; Z499CLJ023; N~6~-Cyclohexyl-N~2~-(4-Morpholin-4-Ylphenyl)-9h-Purine-2,6-Diamine; IN1127; 9H-Purine-2,6-diamine,N6-cyclohexyl-N2-[4-(4-morpholinyl)phenyl]-; C21H27N7O; N6-cyclohexyl-N2-(4-morpholinophenyl)-7H-purine-2,6-diamine; N(6)-cyclohexyl-N(2)-[4-(morpholin-4-yl)phenyl]-9H-purine-2,6-diamine; 2vgo; Reversine(HPLC); AD5; AC1L4OI2; AC1Q4YB4; MLS006010275; SCHEMBL1800790
DMWDNOK	DT	Small molecular drug
DMWDNOK	PC	210332
DMWDNOK	MW	393.5
DMWDNOK	FM	C21H27N7O
DMWDNOK	IC	InChI=1S/C21H27N7O/c1-2-4-15(5-3-1)24-20-18-19(23-14-22-18)26-21(27-20)25-16-6-8-17(9-7-16)28-10-12-29-13-11-28/h6-9,14-15H,1-5,10-13H2,(H3,22,23,24,25,26,27)
DMWDNOK	CS	C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)NC4=CC=C(C=C4)N5CCOCC5
DMWDNOK	IK	ZFLJHSQHILSNCM-UHFFFAOYSA-N
DMWDNOK	IU	6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine
DMWDNOK	CA	CAS 656820-32-5
DMWDNOK	CB	CHEBI:70723
DMWDNOK	DE	Discovery agent

DM3IXEA	ID	DM3IXEA
DM3IXEA	DN	RF9
DM3IXEA	HS	Investigative
DM3IXEA	SN	1-Adamantanecarbonyl-RF-NH2
DM3IXEA	DT	Small molecular drug
DM3IXEA	PC	53320361
DM3IXEA	MW	482.6
DM3IXEA	FM	C26H38N6O3
DM3IXEA	IC	InChI=1S/C26H38N6O3/c27-22(33)21(12-16-5-2-1-3-6-16)31-23(34)20(7-4-8-30-25(28)29)32-24(35)26-13-17-9-18(14-26)11-19(10-17)15-26/h1-3,5-6,17-21H,4,7-15H2,(H2,27,33)(H,31,34)(H,32,35)(H4,28,29,30)/t17?,18?,19?,20-,21-,26?/m0/s1
DM3IXEA	CS	C1C2CC3CC1CC(C2)(C3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N
DM3IXEA	IK	UMKHUSRDQFQHAK-RNJMTYCLSA-N
DM3IXEA	IU	N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]adamantane-1-carboxamide
DM3IXEA	CA	CAS 876310-60-0
DM3IXEA	CB	CHEBI:140980
DM3IXEA	DE	Discovery agent

DMJG4U0	ID	DMJG4U0
DMJG4U0	DN	R-fadrozole
DMJG4U0	HS	Investigative
DMJG4U0	SN	R-FADROZOLE; CHEMBL287677; 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile; (R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile; UNII-IC1B8751F6; SCHEMBL685516; CLPFFLWZZBQMAO-CQSZACIVSA-N; IC1B8751F6; 102676-87-9; ZINC1851916; BDBM50047262; UNII-H3988M64PU component CLPFFLWZZBQMAO-CQSZACIVSA-N; Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]-
DMJG4U0	DT	Small molecular drug
DMJG4U0	PC	9815923
DMJG4U0	MW	223.27
DMJG4U0	FM	C14H13N3
DMJG4U0	IC	InChI=1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2/t14-/m1/s1
DMJG4U0	CS	C1C[C@@H](N2C=NC=C2C1)C3=CC=C(C=C3)C#N
DMJG4U0	IK	CLPFFLWZZBQMAO-CQSZACIVSA-N
DMJG4U0	IU	4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]benzonitrile
DMJG4U0	DE	Discovery agent

DMUR9LM	ID	DMUR9LM
DMUR9LM	DN	RG-50810
DMUR9LM	HS	Investigative
DMUR9LM	SN	Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; RG-50810; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215
DMUR9LM	DT	Small molecular drug
DMUR9LM	PC	2052
DMUR9LM	MW	186.17
DMUR9LM	FM	C10H6N2O2
DMUR9LM	IC	InChI=1S/C10H6N2O2/c11-5-8(6-12)3-7-1-2-9(13)10(14)4-7/h1-4,13-14H
DMUR9LM	CS	C1=CC(=C(C=C1C=C(C#N)C#N)O)O
DMUR9LM	IK	VTJXFTPMFYAJJU-UHFFFAOYSA-N
DMUR9LM	IU	2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile
DMUR9LM	CA	CAS 118409-57-7
DMUR9LM	CB	CHEBI:92862
DMUR9LM	DE	Discovery agent

DMGYWIK	ID	DMGYWIK
DMGYWIK	DN	RG6046
DMGYWIK	HS	Investigative
DMGYWIK	DE	Breast cancer

DMSTL12	ID	DMSTL12
DMSTL12	DN	RG7232
DMSTL12	HS	Investigative
DMSTL12	CP	Roche
DMSTL12	DE	Dyslipidemia

DMP08BY	ID	DMP08BY
DMP08BY	DN	RGB-286147
DMP08BY	HS	Investigative
DMP08BY	SN	pyrazolopyrimidone analog, RGB-286147
DMP08BY	DT	Small molecular drug
DMP08BY	PC	135473382
DMP08BY	MW	473.3
DMP08BY	FM	C23H22Cl2N4O3
DMP08BY	IC	InChI=1S/C23H22Cl2N4O3/c1-13(2)20-19-22(29(28-20)21-16(24)4-3-5-17(21)25)26-18(27-23(19)31)12-14-6-8-15(9-7-14)32-11-10-30/h3-9,13,30H,10-12H2,1-2H3,(H,26,27,31)
DMP08BY	CS	CC(C)C1=NN(C2=C1C(=O)NC(=N2)CC3=CC=C(C=C3)OCCO)C4=C(C=CC=C4Cl)Cl
DMP08BY	IK	RSQPNXBTPUXMQN-UHFFFAOYSA-N
DMP08BY	IU	1-(2,6-dichlorophenyl)-6-[[4-(2-hydroxyethoxy)phenyl]methyl]-3-propan-2-yl-5H-pyrazolo[3,4-d]pyrimidin-4-one
DMP08BY	CA	CAS 784211-09-2
DMP08BY	DE	Discovery agent

DMFASRB	ID	DMFASRB
DMFASRB	DN	RGD
DMFASRB	HS	Investigative
DMFASRB	PC	104802
DMFASRB	MW	346.34
DMFASRB	FM	C12H22N6O6
DMFASRB	IC	InChI=1S/C12H22N6O6/c13-6(2-1-3-16-12(14)15)10(22)17-5-8(19)18-7(11(23)24)4-9(20)21/h6-7H,1-5,13H2,(H,17,22)(H,18,19)(H,20,21)(H,23,24)(H4,14,15,16)/t6-,7-/m0/s1
DMFASRB	CS	C(C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N)CN=C(N)N
DMFASRB	IK	IYMAXBFPHPZYIK-BQBZGAKWSA-N
DMFASRB	IU	(2S)-2-[[2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]butanedioic acid
DMFASRB	CA	CAS 99896-85-2
DMFASRB	CB	CHEBI:158966
DMFASRB	DE	Discovery agent

DM0O9VG	ID	DM0O9VG
DM0O9VG	DN	RGD-039
DM0O9VG	HS	Investigative
DM0O9VG	SN	N-Ethyl-N-[4-(4-piperidyl)butyryl]-glycyl-L-aspartyl-L-(3-cyclohexyl)alanine
DM0O9VG	PC	9984308
DM0O9VG	MW	524.6
DM0O9VG	FM	C26H44N4O7
DM0O9VG	IC	InChI=1S/C26H44N4O7/c1-2-30(23(32)10-6-9-18-11-13-27-14-12-18)17-22(31)28-20(16-24(33)34)25(35)29-21(26(36)37)15-19-7-4-3-5-8-19/h18-21,27H,2-17H2,1H3,(H,28,31)(H,29,35)(H,33,34)(H,36,37)/t20-,21-/m0/s1
DM0O9VG	CS	CCN(CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)O)C(=O)CCCC2CCNCC2
DM0O9VG	IK	RCNHPBQFWAPIOX-SFTDATJTSA-N
DM0O9VG	IU	(3S)-4-[[(1S)-1-carboxy-2-cyclohexylethyl]amino]-3-[[2-[ethyl(4-piperidin-4-ylbutanoyl)amino]acetyl]amino]-4-oxobutanoic acid
DM0O9VG	DE	Thrombosis

DMX4JN6	ID	DMX4JN6
DMX4JN6	DN	RGDechi
DMX4JN6	HS	Investigative
DMX4JN6	PC	91936353
DMX4JN6	MW	2060.199
DMX4JN6	FM	C84H134N30O29S
DMX4JN6	IC	InChI=1S/C84H134N30O29S/c1-41(67(127)111-66(42(2)115)82(142)143)99-78(138)56-18-10-27-112(56)62(120)39-97-70(130)45(14-4-6-23-85)103-74(134)50(31-43-36-92-40-98-43)107-79(139)57-19-12-29-114(57)80(140)53(32-58(88)116)108-68(128)44(87)13-8-26-94-84(91)110-61(119)38-96-77(137)55-17-11-28-113(55)81(141)54(35-65(125)126)109-76(136)52(34-64(123)124)106-73(133)49(22-30-144-3)100-59(117)21-20-48-72(132)104-47(15-5-7-24-86)71(131)102-46(16-9-25-93-83(89)90)69(129)95-37-60(118)101-51(33-63(121)122)75(135)105-48/h36,40-42,44-57,66,115H,4-35,37-39,85-87H2,1-3H3,(H2,88,116)(H,92,98)(H,95,129)(H,96,137)(H,97,130)(H,99,138)(H,100,117)(H,101,118)(H,102,131)(H,103,134)(H,104,132)(H,105,135)(H,106,133)(H,107,139)(H,108,128)(H,109,136)(H,111,127)(H,121,122)(H,123,124)(H,125,126)(H,142,143)(H4,89,90,93)(H3,91,94,110,119)/t41-,42+,44-,45-,46?,47?,48?,49?,50-,51?,52?,53-,54?,55?,56-,57-,66-/m0/s1
DMX4JN6	CS	C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)NC(=O)CNC(=O)C4CCCN4C(=O)C(CC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCSC)NC(=O)CCC5C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)N5)CC(=O)O)CCCN=C(N)N)CCCCN)N)O
DMX4JN6	IK	IJKGLSUZCFGUEG-ODPTYIPQSA-N
DMX4JN6	IU	4-[[1-[2-[[2-[[N'-[(4S)-4-amino-5-[[(2S)-4-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[2-[(2S)-2-[[(2S)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-5-oxopentyl]carbamimidoyl]amino]-2-oxoethyl]carbamoyl]pyrrolidin-1-yl]-3-carboxy-1-oxopropan-2-yl]amino]-3-[[2-[3-[5-(4-aminobutyl)-14-(carboxymethyl)-8-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propanoylamino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DMX4JN6	DE	Discovery agent

DME9T0A	ID	DME9T0A
DME9T0A	DN	RGFP966
DME9T0A	HS	Investigative
DME9T0A	SN	RGFP-966
DME9T0A	DT	Small molecular drug
DME9T0A	PC	56650312
DME9T0A	MW	362.4
DME9T0A	FM	C21H19FN4O
DME9T0A	IC	InChI=1S/C21H19FN4O/c22-18-9-10-20(19(23)13-18)25-21(27)11-8-17-14-24-26(15-17)12-4-7-16-5-2-1-3-6-16/h1-11,13-15H,12,23H2,(H,25,27)/b7-4+,11-8+
DME9T0A	CS	C1=CC=C(C=C1)/C=C/CN2C=C(C=N2)/C=C/C(=O)NC3=C(C=C(C=C3)F)N
DME9T0A	IK	BLVQHYHDYFTPDV-VCABWLAWSA-N
DME9T0A	IU	(E)-N-(2-amino-4-fluorophenyl)-3-[1-[(E)-3-phenylprop-2-enyl]pyrazol-4-yl]prop-2-enamide
DME9T0A	CB	CHEBI:131163
DME9T0A	DE	Discovery agent

DM4XVLB	ID	DM4XVLB
DM4XVLB	DN	RGS4 inhibitor 13
DM4XVLB	HS	Investigative
DM4XVLB	SN	CHEMBL2037369; RGS4 inhibitor 13; GTPL8034; SCHEMBL13517588; BDBM50384771
DM4XVLB	DT	Small molecular drug
DM4XVLB	PC	57330144
DM4XVLB	MW	204.25
DM4XVLB	FM	C7H12N2O3S
DM4XVLB	IC	InChI=1S/C7H12N2O3S/c1-3-9-6(10)8(4-5-12-2)7(11)13-9/h3-5H2,1-2H3
DM4XVLB	CS	CCN1C(=O)N(C(=O)S1)CCOC
DM4XVLB	IK	NCTIMJFWDQCLDW-UHFFFAOYSA-N
DM4XVLB	IU	2-ethyl-4-(2-methoxyethyl)-1,2,4-thiadiazolidine-3,5-dione
DM4XVLB	DE	Discovery agent

DMC471Z	ID	DMC471Z
DMC471Z	DN	RHC80267
DMC471Z	HS	Investigative
DMC471Z	SN	RHC 80267; U 57908; RHC-80267
DMC471Z	DT	Small molecular drug
DMC471Z	PC	5063
DMC471Z	MW	394.5
DMC471Z	FM	C20H34N4O4
DMC471Z	IC	InChI=1S/C20H34N4O4/c25-19(27-23-17-11-5-3-6-12-17)21-15-9-1-2-10-16-22-20(26)28-24-18-13-7-4-8-14-18/h1-16H2,(H,21,25)(H,22,26)
DMC471Z	CS	C1CCC(=NOC(=O)NCCCCCCNC(=O)ON=C2CCCCC2)CC1
DMC471Z	IK	RXSVYGIGWRDVQC-UHFFFAOYSA-N
DMC471Z	IU	(cyclohexylideneamino) N-[6-[(cyclohexylideneamino)oxycarbonylamino]hexyl]carbamate
DMC471Z	CA	CAS 83654-05-1
DMC471Z	CB	CHEBI:92984
DMC471Z	DE	Discovery agent

DMS6IJ0	ID	DMS6IJ0
DMS6IJ0	DN	RHEIN
DMS6IJ0	HS	Investigative
DMS6IJ0	SN	Rhein; 478-43-3; Monorhein; Rheic acid; Rhubarb Yellow; Cassic acid; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; Chrysazin-3-carboxylic acid; 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; NSC 38629; Rheinic acid; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; dipropionyl rhein; 1,8-Dihydroxy-3-carboxyanthraquinone; UNII-YM64C2P6UX; Rhein(Monorhein); 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; CCRIS 5129; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; C15H8O6
DMS6IJ0	DT	Small molecular drug
DMS6IJ0	PC	10168
DMS6IJ0	MW	284.22
DMS6IJ0	FM	C15H8O6
DMS6IJ0	IC	InChI=1S/C15H8O6/c16-9-3-1-2-7-11(9)14(19)12-8(13(7)18)4-6(15(20)21)5-10(12)17/h1-5,16-17H,(H,20,21)
DMS6IJ0	CS	C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)C(=O)O
DMS6IJ0	IK	FCDLCPWAQCPTKC-UHFFFAOYSA-N
DMS6IJ0	IU	4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid
DMS6IJ0	CA	CAS 478-43-3
DMS6IJ0	CB	CHEBI:8825
DMS6IJ0	DE	Discovery agent

DMWP09B	ID	DMWP09B
DMWP09B	DN	RHIIP
DMWP09B	HS	Investigative
DMWP09B	CP	Baxter
DMWP09B	DE	Diabetic complication

DMH9QAF	ID	DMH9QAF
DMH9QAF	DN	RHODIOLININ
DMH9QAF	HS	Investigative
DMH9QAF	SN	Rhodiolin; Rhodiolinin; CHEMBL594871; 86831-53-0; BDBM50304348; AKOS030530361
DMH9QAF	DT	Small molecular drug
DMH9QAF	PC	14778358
DMH9QAF	MW	480.4
DMH9QAF	FM	C25H20O10
DMH9QAF	IC	InChI=1S/C25H20O10/c1-32-16-8-12(4-7-14(16)28)22-18(10-26)34-24-17(33-22)9-15(29)19-20(30)21(31)23(35-25(19)24)11-2-5-13(27)6-3-11/h2-9,18,22,26-29,31H,10H2,1H3/t18-,22-/m1/s1
DMH9QAF	CS	COC1=C(C=CC(=C1)[C@@H]2[C@H](OC3=C(O2)C=C(C4=C3OC(=C(C4=O)O)C5=CC=C(C=C5)O)O)CO)O
DMH9QAF	IK	POVCYOFRCMBMKD-XMSQKQJNSA-N
DMH9QAF	IU	(2R,3R)-6,8-dihydroxy-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-9-(4-hydroxyphenyl)-2,3-dihydropyrano[3,2-h][1,4]benzodioxin-7-one
DMH9QAF	DE	Discovery agent

DMW1VOB	ID	DMW1VOB
DMW1VOB	DN	rHuB-D2
DMW1VOB	HS	Investigative
DMW1VOB	SN	Recombinant-human-beta-defensin-2; recombinant human beta defensin 2; Beta defensin 2
DMW1VOB	DE	Discovery agent

DMSL2CM	ID	DMSL2CM
DMSL2CM	DN	Ribavirin + interferon alfa-2a
DMSL2CM	HS	Investigative
DMSL2CM	SN	Rebetol + roferon A
DMSL2CM	TC	Antiviral Agents
DMSL2CM	DT	Combination drug
DMSL2CM	DE	Middle East Respiratory Syndrome (MERS)

DMT4JCW	ID	DMT4JCW
DMT4JCW	DN	Ribavirin + interferon alfa-2b
DMT4JCW	HS	Investigative
DMT4JCW	SN	Rebetol + genferon
DMT4JCW	TC	Antiviral Agents
DMT4JCW	DT	Combination drug
DMT4JCW	DE	Middle East Respiratory Syndrome (MERS)

DMAQMXT	ID	DMAQMXT
DMAQMXT	DN	Ribavirin + interferon beta-1a
DMAQMXT	HS	Investigative
DMAQMXT	SN	Rebetol + avonex
DMAQMXT	TC	Antiviral Agents
DMAQMXT	DT	Combination drug
DMAQMXT	DE	Middle East Respiratory Syndrome (MERS)

DM7DRO4	ID	DM7DRO4
DM7DRO4	DN	Ribavirin + lopinavir + ritonavir + interferon alfa-2a
DM7DRO4	HS	Investigative
DM7DRO4	SN	Rebetol + aluviran + norvir + roferon A
DM7DRO4	TC	Antiviral Agents
DM7DRO4	DT	Combination drug
DM7DRO4	DE	Middle East Respiratory Syndrome (MERS)

DM09NGV	ID	DM09NGV
DM09NGV	DN	Ribavirin-TP
DM09NGV	HS	Investigative
DM09NGV	SN	Ribavirin 5'-triphosphate; Ribavirin-TP; Ribavirin triphosphate; 63142-71-2; CHEMBL398463; RTP; 1H-1,2,4-Triazole-3-carboxamide, 1-(5-O-(hydroxy((hydroxy(phosphonooxy)phosphinyl)oxy)phosphinyl)-beta-D-ribofuranosyl)-; 1H-1,2,4-triazole-3-carboxamide, 1-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-D-ribofuranosyl]-; 1mn9; AC1L3TZJ; [[(2R,3S,4R,5R)-5-(3-carbamoyl-1,2,4-triazol-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate
DM09NGV	DT	Small molecular drug
DM09NGV	PC	122108
DM09NGV	MW	484.14
DM09NGV	FM	C8H15N4O14P3
DM09NGV	IC	InChI=1S/C8H15N4O14P3/c9-6(15)7-10-2-12(11-7)8-5(14)4(13)3(24-8)1-23-28(19,20)26-29(21,22)25-27(16,17)18/h2-5,8,13-14H,1H2,(H2,9,15)(H,19,20)(H,21,22)(H2,16,17,18)/t3-,4-,5-,8-/m1/s1
DM09NGV	CS	C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)C(=O)N
DM09NGV	IK	MMJOCKKLRMRSEQ-AFCXAGJDSA-N
DM09NGV	IU	[[(2R,3S,4R,5R)-5-(3-carbamoyl-1,2,4-triazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM09NGV	CA	CAS 63142-71-2
DM09NGV	DE	Discovery agent

DM7V8DZ	ID	DM7V8DZ
DM7V8DZ	DN	Ribose-1-Phosphate
DM7V8DZ	HS	Investigative
DM7V8DZ	SN	ribose 1-phosphate; ribose-1-phosphate; alpha-D-Ribose 1-phosphate; CHEBI:16300; 1-O-phosphono-alpha-D-ribofuranose; alpha-D-ribofuranose 1-(dihydrogen phosphate); D-ribose-1-phosphate; alpha-D-ribose-1-phosphate; alpha-D-ribofuranose 1-phosphate; R1P; D-ribofuranose 1-(dihydrogen phosphate); 14075-00-4; D-ribose-1P; ribofuranose 1-phosphate; a-D-ribose 1-phosphate; D-ribofuranose 1-phosphate; alpha-D-Ribofuranose, 1-(dihydrogen phosphate); 1-phospho-alpha-D-ribofuranose; CHEMBL603367; SCHEMBL1995711; AC1L96Y2
DM7V8DZ	DT	Small molecular drug
DM7V8DZ	PC	439236
DM7V8DZ	MW	230.11
DM7V8DZ	FM	C5H11O8P
DM7V8DZ	IC	InChI=1S/C5H11O8P/c6-1-2-3(7)4(8)5(12-2)13-14(9,10)11/h2-8H,1H2,(H2,9,10,11)/t2-,3-,4-,5-/m1/s1
DM7V8DZ	CS	C([C@@H]1[C@H]([C@H]([C@H](O1)OP(=O)(O)O)O)O)O
DM7V8DZ	IK	YXJDFQJKERBOBM-TXICZTDVSA-N
DM7V8DZ	IU	[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl] dihydrogen phosphate
DM7V8DZ	CA	CAS 14075-00-4
DM7V8DZ	CB	CHEBI:16300
DM7V8DZ	DE	Discovery agent

DMRKO49	ID	DMRKO49
DMRKO49	DN	Ribose-5-Phosphate
DMRKO49	HS	Investigative
DMRKO49	SN	ribose-5-phosphate; Ribose phosphate; Ribose 5-monophosphate; 5-O-phosphono-D-ribose; D-ribose-5-phosphoric acid; D-Ribose 5-(dihydrogen phosphate); 4300-28-1; R-5-P; UNII-4B2428FLTO; Ribose, 5-(dihydrogen phosphate), D-; D-ribose-5-phosphate; 4B2428FLTO; aldehydo-D-ribose 5-phosphate; [(2R,3R,4R)-2,3,4-trihydroxy-5-oxopentyl] dihydrogen phosphate; R52; EINECS 224-310-2; AC1Q6RUZ; bmse000278; AC1L2U8E; D-Ribose 5-phosphoric acid; SCHEMBL21609; 3615-55-2; CTK1D6888; CHEBI:17797; Ribose, 5-(dihydrogen phosphate)
DMRKO49	DT	Small molecular drug
DMRKO49	PC	77982
DMRKO49	MW	230.11
DMRKO49	FM	C5H11O8P
DMRKO49	IC	InChI=1S/C5H11O8P/c6-1-3(7)5(9)4(8)2-13-14(10,11)12/h1,3-5,7-9H,2H2,(H2,10,11,12)/t3-,4+,5-/m0/s1
DMRKO49	CS	C([C@H]([C@H]([C@H](C=O)O)O)O)OP(=O)(O)O
DMRKO49	IK	PPQRONHOSHZGFQ-LMVFSUKVSA-N
DMRKO49	IU	[(2R,3R,4R)-2,3,4-trihydroxy-5-oxopentyl] dihydrogen phosphate
DMRKO49	CA	CAS 4300-28-1
DMRKO49	CB	CHEBI:17797
DMRKO49	DE	Discovery agent

DMXWUHA	ID	DMXWUHA
DMXWUHA	DN	Ribostamycin
DMXWUHA	HS	Investigative
DMXWUHA	SN	ribostamycin; Vistamycin; Hetangmycin; Xylostatin; Antibiotic SF 733; Ribostamycinum; Ribostamicina; Ribostamycine; Ribastamin; Dekamycin IV; SF 733; 25546-65-0; ribostamycin A; Ribostamycin [INN:BAN]; Bu 1709; Ribostamycine [INN-French]; Ribostamycinum [INN-Latin]; UNII-2Q5JOU7T53; SF-733; Ribostamicina [INN-Spanish]; C17H34N4O10; EINECS 247-091-5; NSC 138925; BRN 1357280; 2Q5JOU7T53; CHEBI:45257; NSC138925; O-2,6-Diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-&gt;4)-O-(beta-D-ribofuranosyl-(1-&gt;5))-2-deoxystreptamine
DMXWUHA	DT	Small molecular drug
DMXWUHA	PC	33042
DMXWUHA	MW	454.5
DMXWUHA	FM	C17H34N4O10
DMXWUHA	IC	InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17+/m1/s1
DMXWUHA	CS	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O)N
DMXWUHA	IK	NSKGQURZWSPSBC-VVPCINPTSA-N
DMXWUHA	IU	(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
DMXWUHA	CA	CAS 25546-65-0
DMXWUHA	CB	CHEBI:45257
DMXWUHA	DE	Discovery agent

DM6MYGX	ID	DM6MYGX
DM6MYGX	DN	Riccardin C
DM6MYGX	HS	Investigative
DM6MYGX	SN	Riccardin C; Riccardi C; CHEMBL411317; BDBM23839
DM6MYGX	DT	Small molecular drug
DM6MYGX	PC	10070992
DM6MYGX	MW	424.5
DM6MYGX	FM	C28H24O4
DM6MYGX	IC	InChI=1S/C28H24O4/c29-22-9-13-24-21(17-22)8-3-18-4-10-23(11-5-18)32-28-16-20(7-14-26(28)30)2-1-19-6-12-25(24)27(31)15-19/h4-7,9-17,29-31H,1-3,8H2
DM6MYGX	CS	C1CC2=C(C=CC(=C2)O)C3=C(C=C(CCC4=CC(=C(C=C4)O)OC5=CC=C1C=C5)C=C3)O
DM6MYGX	IK	JMKSVONWZFVEAI-UHFFFAOYSA-N
DM6MYGX	IU	14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2(7),3,5,10(29),11,13(28),15,17,19(27),22,25-dodecaene-5,16,24-triol
DM6MYGX	DE	Discovery agent

DM9HMCS	ID	DM9HMCS
DM9HMCS	DN	Ridine-5-carboxylic acid ethyl ester
DM9HMCS	HS	Investigative
DM9HMCS	SN	ridine-5-carboxylic acid ethyl ester; CHEMBL87358; SCHEMBL10960643; 1-(3-Methylpentyl)-4-amino-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester
DM9HMCS	DT	Small molecular drug
DM9HMCS	PC	14590509
DM9HMCS	MW	304.39
DM9HMCS	FM	C16H24N4O2
DM9HMCS	IC	InChI=1S/C16H24N4O2/c1-5-10(3)7-8-20-15-12(9-18-20)14(17)13(11(4)19-15)16(21)22-6-2/h9-10H,5-8H2,1-4H3,(H2,17,19)
DM9HMCS	CS	CCC(C)CCN1C2=NC(=C(C(=C2C=N1)N)C(=O)OCC)C
DM9HMCS	IK	YWSGZSUSPFMIIN-UHFFFAOYSA-N
DM9HMCS	IU	ethyl 4-amino-6-methyl-1-(3-methylpentyl)pyrazolo[3,4-b]pyridine-5-carboxylate
DM9HMCS	DE	Discovery agent

DMN98U1	ID	DMN98U1
DMN98U1	DN	Rimantadine isomer 1
DMN98U1	HS	Investigative
DMN98U1	SN	Rimantadine hydrochloride; 1501-84-4; Flumadine; Rimantadine HCL; Meradane; 1-(1-ADAMANTYL)ETHYLAMINE HYDROCHLORIDE; 1-(1-Aminoethyl)adamantane hydrochloride; alpha-Methyl-1-adamantanemethylamine hydrochloride; 1-(Adamantan-1-yl)ethanamine hydrochloride; Algirem; Meradan; Roflual; Oclovir; 1-(1-adamantyl)ethanamine hydrochloride; EXP 126; JP 61; Rimantadine (hydrochloride); Remantadine hydrochloride; NSC 206764; C12H22ClN; MLS000069661; CHEBI:8865; Adamantane, 1-(1-aminoethyl)-, hydrochloride; Rimantadine hydrochloride [USAN]
DMN98U1	DT	Small molecular drug
DMN98U1	PC	15165
DMN98U1	MW	215.76
DMN98U1	FM	C12H22ClN
DMN98U1	IC	InChI=1S/C12H21N.ClH/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12;/h8-11H,2-7,13H2,1H3;1H
DMN98U1	CS	CC(C12CC3CC(C1)CC(C3)C2)N.Cl
DMN98U1	IK	OZBDFBJXRJWNAV-UHFFFAOYSA-N
DMN98U1	IU	1-(1-adamantyl)ethanamine;hydrochloride
DMN98U1	CA	CAS 1501-84-4
DMN98U1	CB	CHEBI:8865
DMN98U1	DE	Discovery agent

DM3BEF7	ID	DM3BEF7
DM3BEF7	DN	Rimantadine isomer 2
DM3BEF7	HS	Investigative
DM3BEF7	DE	Discovery agent

DM59G40	ID	DM59G40
DM59G40	DN	Rimeporide
DM59G40	HS	Investigative
DM59G40	SN	EMD-87580; EMR-204; EMR-62204; NHE inhibitors (atrial fibrillation), Merck KGaA; Sodium/hydrogen exchange inhibitors (atrial fibrillation), Merck KGaA
DM59G40	CP	Merck KGaA
DM59G40	DT	Small molecular drug
DM59G40	PC	9799487
DM59G40	MW	333.4
DM59G40	FM	C11H15N3O5S2
DM59G40	IC	InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15)
DM59G40	CS	CC1=CC(=C(C=C1C(=O)N=C(N)N)S(=O)(=O)C)S(=O)(=O)C
DM59G40	IK	GROMEQPXDKRRIE-UHFFFAOYSA-N
DM59G40	IU	N-(diaminomethylidene)-2-methyl-4,5-bis(methylsulfonyl)benzamide
DM59G40	CA	CAS 187870-78-6
DM59G40	DE	Myocardial infarction

DM83L5Y	ID	DM83L5Y
DM83L5Y	DN	RIP
DM83L5Y	HS	Investigative
DM83L5Y	SN	beta-D-Ribopyranose; Ribose(Pyranose Form); 7296-60-8; UNII-49X539P7H4; CHEBI:27476; 49X539P7H4; (2R,3R,4R,5R)-oxane-2,3,4,5-tetrol; b-Ribopyranose; 115794-07-5; beta-D-Ribopyranose (9CI); 1ogd; 1drk; 2dri; 1drj; Ribopyranose, beta-D-; SCHEMBL625216; AC1L9B91; CHEMBL1159662; CTK4A9488; ZINC4097544; DB04286; 1577-EP2301533A1; 1577-EP2292630A1; 1577-EP2316459A1; 1577-EP2305808A1; 1577-EP2281563A1; C08353; 1577-EP2270015A1; 31308-EP2311817A1; 31308-EP2308858A1; 31308-EP2274983A1; 31308-EP2311816A1; 31308-EP2292088A1
DM83L5Y	DT	Small molecular drug
DM83L5Y	PC	441481
DM83L5Y	MW	150.13
DM83L5Y	FM	C5H10O5
DM83L5Y	IC	InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3-,4-,5-/m1/s1
DM83L5Y	CS	C1[C@H]([C@H]([C@H]([C@@H](O1)O)O)O)O
DM83L5Y	IK	SRBFZHDQGSBBOR-TXICZTDVSA-N
DM83L5Y	IU	(2R,3R,4R,5R)-oxane-2,3,4,5-tetrol
DM83L5Y	CA	CAS 7296-60-8
DM83L5Y	CB	CHEBI:27476
DM83L5Y	DE	Discovery agent

DMYIQRK	ID	DMYIQRK
DMYIQRK	DN	RIPA-56
DMYIQRK	HS	Investigative
DMYIQRK	SN	1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956
DMYIQRK	CP	National Institute of Biological Sciences
DMYIQRK	DT	Small molecular drug
DMYIQRK	PC	121439991
DMYIQRK	MW	221.29
DMYIQRK	FM	C13H19NO2
DMYIQRK	IC	InChI=1S/C13H19NO2/c1-4-13(2,3)12(15)14(16)10-11-8-6-5-7-9-11/h5-9,16H,4,10H2,1-3H3
DMYIQRK	CS	CCC(C)(C)C(=O)N(CC1=CC=CC=C1)O
DMYIQRK	IK	AVYVHIKSFXVDBG-UHFFFAOYSA-N
DMYIQRK	IU	N-benzyl-N-hydroxy-2,2-dimethylbutanamide
DMYIQRK	DE	Non-alcoholic fatty liver disease

DMTHVQD	ID	DMTHVQD
DMTHVQD	DN	RIPAZEPAM
DMTHVQD	HS	Investigative
DMTHVQD	SN	RIPAZEPAM; Pyrazapon; 26308-28-1; CI-683; Ripazepam [USAN:INN]; Ripazepamum [INN-Latin]; CCRIS 552; UNII-92000WH9C9; Cl-683; BRN 0819726; CHEBI:82529; 92000WH9C9; 1-ethyl-3-methyl-8-phenyl-4,6-dihydropyrazolo[4,3-e][1,4]diazepin-5(1H)-one; 1-Ethyl-4,6-dihydro-3-methyl-8-phenylpyrazolo(4,3-e)(1,4)diazepin-5(1H)-one; 1-Ethyl-1,4,5,6-tetrahydro-3-methyl-8-phenylpyrazolo(4,3-e)(1,4)diazepin-5-on; C15H16N4O; Ripazepamum; Pyrazolo(4,3-e)(1,4)diazepin-5(1H)-one, 4,6-dihydro-1-ethyl-3-methyl-8-phenyl-
DMTHVQD	DT	Small molecular drug
DMTHVQD	PC	33474
DMTHVQD	MW	268.31
DMTHVQD	FM	C15H16N4O
DMTHVQD	IC	InChI=1S/C15H16N4O/c1-3-19-15-13(10(2)18-19)17-12(20)9-16-14(15)11-7-5-4-6-8-11/h4-8H,3,9H2,1-2H3,(H,17,20)
DMTHVQD	CS	CCN1C2=C(C(=N1)C)NC(=O)CN=C2C3=CC=CC=C3
DMTHVQD	IK	YFHYNLHGFKXAIQ-UHFFFAOYSA-N
DMTHVQD	IU	1-ethyl-3-methyl-8-phenyl-4,6-dihydropyrazolo[4,3-e][1,4]diazepin-5-one
DMTHVQD	CA	CAS 26308-28-1
DMTHVQD	CB	CHEBI:82529
DMTHVQD	DE	Discovery agent

DMJD3WY	ID	DMJD3WY
DMJD3WY	DN	RI-TPO
DMJD3WY	HS	Investigative
DMJD3WY	DE	Discovery agent

DM2P6I8	ID	DM2P6I8
DM2P6I8	DN	RJM-0035-K002
DM2P6I8	HS	Investigative
DM2P6I8	SN	ACE inhibitor (hypertension), CDRI
DM2P6I8	CP	Central Drug Research Institute
DM2P6I8	DE	Hypertension

DM5CI2P	ID	DM5CI2P
DM5CI2P	DN	RK-682
DM5CI2P	HS	Investigative
DM5CI2P	SN	CHEMBL426373; 150627-37-5; (5R)-3-Hexadecanoyl-5-hydroxymethyltetronic acid; (R)-3-Hexadecanoyl-5-hydroxymethyltetronic acid; SCHEMBL4403663; DTXSID50715652; BDBM50093526; ZINC100031544; RK-682, &gt; (5R)-3-Hexadecanoyl-4-hydroxy-5-(hydroxymethyl)furan-2(5H)-one
DM5CI2P	DT	Small molecular drug
DM5CI2P	PC	54678922
DM5CI2P	MW	368.5
DM5CI2P	FM	C21H36O5
DM5CI2P	IC	InChI=1S/C21H36O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17(23)19-20(24)18(16-22)26-21(19)25/h18,22,24H,2-16H2,1H3/t18-/m1/s1
DM5CI2P	CS	CCCCCCCCCCCCCCCC(=O)C1=C([C@H](OC1=O)CO)O
DM5CI2P	IK	KZTSLHQKWLYYAC-GOSISDBHSA-N
DM5CI2P	IU	(2R)-4-hexadecanoyl-3-hydroxy-2-(hydroxymethyl)-2H-furan-5-one
DM5CI2P	CA	CAS 150627-37-5
DM5CI2P	DE	Discovery agent

DMGTAWC	ID	DMGTAWC
DMGTAWC	DN	RKI-1447
DMGTAWC	HS	Investigative
DMGTAWC	SN	RKI1447; compound 5g [PMID 23275831]
DMGTAWC	DT	Small molecular drug
DMGTAWC	PC	60138149
DMGTAWC	MW	326.4
DMGTAWC	FM	C16H14N4O2S
DMGTAWC	IC	InChI=1S/C16H14N4O2S/c21-13-3-1-2-11(8-13)9-18-15(22)20-16-19-14(10-23-16)12-4-6-17-7-5-12/h1-8,10,21H,9H2,(H2,18,19,20,22)
DMGTAWC	CS	C1=CC(=CC(=C1)O)CNC(=O)NC2=NC(=CS2)C3=CC=NC=C3
DMGTAWC	IK	GDVRVPIXWXOKQO-UHFFFAOYSA-N
DMGTAWC	IU	1-[(3-hydroxyphenyl)methyl]-3-(4-pyridin-4-yl-1,3-thiazol-2-yl)urea
DMGTAWC	DE	Discovery agent

DMGEDQJ	ID	DMGEDQJ
DMGEDQJ	DN	R-L3
DMGEDQJ	HS	Investigative
DMGEDQJ	SN	R-L364,373
DMGEDQJ	DT	Small molecular drug
DMGEDQJ	PC	656755
DMGEDQJ	MW	397.4
DMGEDQJ	FM	C25H20FN3O
DMGEDQJ	IC	InChI=1S/C25H20FN3O/c1-29-23-13-7-4-10-19(23)24(18-9-2-5-11-20(18)26)28-22(25(29)30)14-16-15-27-21-12-6-3-8-17(16)21/h2-13,15,22,27H,14H2,1H3/t22-/m1/s1
DMGEDQJ	CS	CN1C2=CC=CC=C2C(=N[C@@H](C1=O)CC3=CNC4=CC=CC=C43)C5=CC=CC=C5F
DMGEDQJ	IK	CGBANSGENFERAT-JOCHJYFZSA-N
DMGEDQJ	IU	(3R)-5-(2-fluorophenyl)-3-(1H-indol-3-ylmethyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMGEDQJ	CA	CAS 103342-82-1
DMGEDQJ	CB	CHEBI:34942
DMGEDQJ	DE	Discovery agent

DM87Z3Y	ID	DM87Z3Y
DM87Z3Y	DN	RM-6427
DM87Z3Y	HS	Investigative
DM87Z3Y	SN	RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark
DM87Z3Y	CP	Romark Laboratories LC
DM87Z3Y	PC	9931101
DM87Z3Y	MW	405.2
DM87Z3Y	FM	C18H13BrO6
DM87Z3Y	IC	InChI=1S/C18H13BrO6/c1-2-24-18(23)17-14(9-4-3-5-10(19)6-9)16(22)15-12(21)7-11(20)8-13(15)25-17/h3-8,20-21H,2H2,1H3
DM87Z3Y	CS	CCOC(=O)C1=C(C(=O)C2=C(C=C(C=C2O1)O)O)C3=CC(=CC=C3)Br
DM87Z3Y	IK	PXFKQPIDCKZUID-UHFFFAOYSA-N
DM87Z3Y	IU	ethyl 3-(3-bromophenyl)-5,7-dihydroxy-4-oxochromene-2-carboxylate
DM87Z3Y	DE	Cryptosporidium infection

DMJU5A9	ID	DMJU5A9
DMJU5A9	DN	RM65
DMJU5A9	HS	Investigative
DMJU5A9	SN	CHEMBL61824; RM65; GTPL7029; SCHEMBL17767405; BDBM50215479; 2-(9H-xanthen-9-ylsulfanyl)-N-{2-[2-(9H-xanthen-9-ylsulfanyl)propanamido]ethyl}propanamide
DMJU5A9	DT	Small molecular drug
DMJU5A9	PC	23656549
DMJU5A9	MW	596.8
DMJU5A9	FM	C34H32N2O4S2
DMJU5A9	IC	InChI=1S/C34H32N2O4S2/c1-21(41-31-23-11-3-7-15-27(23)39-28-16-8-4-12-24(28)31)33(37)35-19-20-36-34(38)22(2)42-32-25-13-5-9-17-29(25)40-30-18-10-6-14-26(30)32/h3-18,21-22,31-32H,19-20H2,1-2H3,(H,35,37)(H,36,38)
DMJU5A9	CS	CC(C(=O)NCCNC(=O)C(C)SC1C2=CC=CC=C2OC3=CC=CC=C13)SC4C5=CC=CC=C5OC6=CC=CC=C46
DMJU5A9	IK	KBXOGBYQKMAAIA-UHFFFAOYSA-N
DMJU5A9	IU	2-(9H-xanthen-9-ylsulfanyl)-N-[2-[2-(9H-xanthen-9-ylsulfanyl)propanoylamino]ethyl]propanamide
DMJU5A9	DE	Discovery agent

DMA3ZXM	ID	DMA3ZXM
DMA3ZXM	DN	RN1734
DMA3ZXM	HS	Investigative
DMA3ZXM	SN	RN 1734; RN-1734
DMA3ZXM	DT	Small molecular drug
DMA3ZXM	PC	3601086
DMA3ZXM	MW	353.3
DMA3ZXM	FM	C14H22Cl2N2O2S
DMA3ZXM	IC	InChI=1S/C14H22Cl2N2O2S/c1-10(2)17-7-8-18(11(3)4)21(19,20)14-6-5-12(15)9-13(14)16/h5-6,9-11,17H,7-8H2,1-4H3
DMA3ZXM	CS	CC(C)NCCN(C(C)C)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl
DMA3ZXM	IK	IHYZMEAZAIFMTN-UHFFFAOYSA-N
DMA3ZXM	IU	2,4-dichloro-N-propan-2-yl-N-[2-(propan-2-ylamino)ethyl]benzenesulfonamide
DMA3ZXM	CA	CAS 946387-07-1
DMA3ZXM	DE	Discovery agent

DMIPZTM	ID	DMIPZTM
DMIPZTM	DN	RN1747
DMIPZTM	HS	Investigative
DMIPZTM	SN	RN-1747; RN 1747
DMIPZTM	DT	Small molecular drug
DMIPZTM	PC	5068295
DMIPZTM	MW	395.9
DMIPZTM	FM	C17H18ClN3O4S
DMIPZTM	IC	InChI=1S/C17H18ClN3O4S/c18-15-6-7-17(16(12-15)21(22)23)26(24,25)20-10-8-19(9-11-20)13-14-4-2-1-3-5-14/h1-7,12H,8-11,13H2
DMIPZTM	CS	C1CN(CCN1CC2=CC=CC=C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)[N+](=O)[O-]
DMIPZTM	IK	ZNLVYSJQUMALEO-UHFFFAOYSA-N
DMIPZTM	IU	1-benzyl-4-(4-chloro-2-nitrophenyl)sulfonylpiperazine
DMIPZTM	CA	CAS 1024448-59-6
DMIPZTM	DE	Discovery agent

DML7SQH	ID	DML7SQH
DML7SQH	DN	RN486
DML7SQH	HS	Investigative
DML7SQH	SN	RN-486; compound 29 [PMID 22394077]
DML7SQH	DT	Small molecular drug
DML7SQH	PC	46908026
DML7SQH	MW	606.7
DML7SQH	FM	C35H35FN6O3
DML7SQH	IC	InChI=1S/C35H35FN6O3/c1-39-12-14-41(15-13-39)26-8-9-32(37-19-26)38-30-18-25(20-40(2)34(30)44)27-4-3-5-31(28(27)21-43)42-11-10-23-16-24(22-6-7-22)17-29(36)33(23)35(42)45/h3-5,8-11,16-20,22,43H,6-7,12-15,21H2,1-2H3,(H,37,38)
DML7SQH	CS	CN1CCN(CC1)C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=CC=C4)N5C=CC6=CC(=CC(=C6C5=O)F)C7CC7)CO
DML7SQH	IK	ZTUJNJAKTLHBEX-UHFFFAOYSA-N
DML7SQH	IU	6-cyclopropyl-8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-6-oxopyridin-3-yl]phenyl]isoquinolin-1-one
DML7SQH	CA	CAS 1242156-23-5
DML7SQH	DE	Discovery agent

DM2N3BA	ID	DM2N3BA
DM2N3BA	DN	R-N6-(phenylisopropyl)adenosine
DM2N3BA	HS	Investigative
DM2N3BA	SN	(R)-N-(1-Methyl-2-phenylethyl)adenosine; (R)-PIA; 38594-96-6; L-PIA; l-Phenylisopropyladenosine; Phenylisopropyladenosine, L-; N6-D-Phenylisopropyladenosine; (R)-(Phenylisopropyl)adenosine; (-)-(Phenylisopropyl)adenosine; N6-(R)-Phenylisopropyladenosine; (R)-N6-Phenylisopropyladenosine; (-)-PIA; L-2-N6-(Phenylisopropyl)adenosine; l-N(sup 6)-Phenylisopropyladenosine; EINECS 254-028-5; TH 162; (R)-N6-(2-Phenylisopropyl)adenosine; BRN 4912716; (-)-N-(alpha-Methylphenethyl)adensoine
DM2N3BA	DT	Small molecular drug
DM2N3BA	PC	93205
DM2N3BA	MW	385.4
DM2N3BA	FM	C19H23N5O4
DM2N3BA	IC	InChI=1S/C19H23N5O4/c1-11(7-12-5-3-2-4-6-12)23-17-14-18(21-9-20-17)24(10-22-14)19-16(27)15(26)13(8-25)28-19/h2-6,9-11,13,15-16,19,25-27H,7-8H2,1H3,(H,20,21,23)/t11-,13-,15-,16-,19-/m1/s1
DM2N3BA	CS	C[C@H](CC1=CC=CC=C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DM2N3BA	IK	RIRGCFBBHQEQQH-SSFGXONLSA-N
DM2N3BA	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(2R)-1-phenylpropan-2-yl]amino]purin-9-yl]oxolane-3,4-diol
DM2N3BA	CA	CAS 38594-96-6
DM2N3BA	DE	Discovery agent

DMGV4DS	ID	DMGV4DS
DMGV4DS	DN	R-norduloxetine
DMGV4DS	HS	Investigative
DMGV4DS	SN	CHEMBL594585; R-NORDULOXETINE; BDBM50304393
DMGV4DS	DT	Small molecular drug
DMGV4DS	PC	46227262
DMGV4DS	MW	283.4
DMGV4DS	FM	C17H17NOS
DMGV4DS	IC	InChI=1S/C17H17NOS/c18-11-10-16(17-9-4-12-20-17)19-15-8-3-6-13-5-1-2-7-14(13)15/h1-9,12,16H,10-11,18H2/t16-/m1/s1
DMGV4DS	CS	C1=CC=C2C(=C1)C=CC=C2O[C@H](CCN)C3=CC=CS3
DMGV4DS	IK	ZMXLKLOJDLMZFC-MRXNPFEDSA-N
DMGV4DS	IU	(3R)-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
DMGV4DS	DE	Discovery agent

DMXT34V	ID	DMXT34V
DMXT34V	DN	Ro 10-4548
DMXT34V	HS	Investigative
DMXT34V	SN	Ro 10-4548; GTPL982; Ro-10-4548
DMXT34V	DT	Small molecular drug
DMXT34V	PC	11429930
DMXT34V	MW	415.5
DMXT34V	FM	C22H29N3O5
DMXT34V	IC	InChI=1S/C22H29N3O5/c1-16(26)23-19-5-3-4-6-21(19)30-15-18(27)14-24-9-11-25(12-10-24)17-7-8-20(28)22(13-17)29-2/h3-8,13,18,27-28H,9-12,14-15H2,1-2H3,(H,23,26)
DMXT34V	CS	CC(=O)NC1=CC=CC=C1OCC(CN2CCN(CC2)C3=CC(=C(C=C3)O)OC)O
DMXT34V	IK	MXZGRDMOUWOERR-UHFFFAOYSA-N
DMXT34V	IU	N-[2-[2-hydroxy-3-[4-(4-hydroxy-3-methoxyphenyl)piperazin-1-yl]propoxy]phenyl]acetamide
DMXT34V	DE	Discovery agent

DMMO6PH	ID	DMMO6PH
DMMO6PH	DN	RO 116 1148
DMMO6PH	HS	Investigative
DMMO6PH	SN	RO 116-1148
DMMO6PH	DT	Small molecular drug
DMMO6PH	PC	44391713
DMMO6PH	MW	332.4
DMMO6PH	FM	C19H28N2O3
DMMO6PH	IC	InChI=1S/C19H28N2O3/c1-2-3-9-21-10-7-15(8-11-21)14-20-19(22)16-5-4-6-17-18(16)24-13-12-23-17/h4-6,15H,2-3,7-14H2,1H3,(H,20,22)
DMMO6PH	CS	CCCCN1CCC(CC1)CNC(=O)C2=C3C(=CC=C2)OCCO3
DMMO6PH	IK	VBFBEYXWJLASJA-UHFFFAOYSA-N
DMMO6PH	IU	N-[(1-butylpiperidin-4-yl)methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide
DMMO6PH	DE	Discovery agent

DM3FYUM	ID	DM3FYUM
DM3FYUM	DN	RO 244383
DM3FYUM	HS	Investigative
DM3FYUM	DE	Discovery agent

DMDC4HY	ID	DMDC4HY
DMDC4HY	DN	Ro 28-2653
DMDC4HY	HS	Investigative
DMDC4HY	SN	Ro 28-2653; Ro-28-2653; 261956-22-3; CHEMBL456911; SCHEMBL726759; SCHEMBL8471189; EX-A2614; BDBM50363130; ZINC33975062; Ro28-2653; KB-275261; 5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione
DMDC4HY	DT	Small molecular drug
DMDC4HY	PC	9832179
DMDC4HY	MW	485.5
DMDC4HY	FM	C26H23N5O5
DMDC4HY	IC	InChI=1S/C26H23N5O5/c32-23-26(24(33)28-25(34)27-23,20-8-6-19(7-9-20)18-4-2-1-3-5-18)30-16-14-29(15-17-30)21-10-12-22(13-11-21)31(35)36/h1-13H,14-17H2,(H2,27,28,32,33,34)
DMDC4HY	CS	C1CN(CCN1C2=CC=C(C=C2)[N+](=O)[O-])C3(C(=O)NC(=O)NC3=O)C4=CC=C(C=C4)C5=CC=CC=C5
DMDC4HY	IK	NJKTYSXXGARILV-UHFFFAOYSA-N
DMDC4HY	IU	5-[4-(4-nitrophenyl)piperazin-1-yl]-5-(4-phenylphenyl)-1,3-diazinane-2,4,6-trione
DMDC4HY	DE	Discovery agent

DMU2EKN	ID	DMU2EKN
DMU2EKN	DN	Ro 40-6055
DMU2EKN	HS	Investigative
DMU2EKN	SN	AM580; CD-336; Ro406055
DMU2EKN	DT	Small molecular drug
DMU2EKN	PC	2126
DMU2EKN	MW	351.4
DMU2EKN	FM	C22H25NO3
DMU2EKN	IC	InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-15(7-10-17(18)21)19(24)23-16-8-5-14(6-9-16)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)
DMU2EKN	CS	CC1(CCC(C2=C1C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)(C)C)C
DMU2EKN	IK	SZWKGOZKRMMLAJ-UHFFFAOYSA-N
DMU2EKN	IU	4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]benzoic acid
DMU2EKN	CA	CAS 102121-60-8
DMU2EKN	CB	CHEBI:64210
DMU2EKN	DE	Discovery agent

DMSJLWP	ID	DMSJLWP
DMSJLWP	DN	Ro 41-5253
DMSJLWP	HS	Investigative
DMSJLWP	SN	Ro-415253; Ro415253; LG629
DMSJLWP	DT	Small molecular drug
DMSJLWP	PC	5312120
DMSJLWP	MW	484.6
DMSJLWP	FM	C28H36O5S
DMSJLWP	IC	InChI=1S/C28H36O5S/c1-5-6-7-8-9-15-33-25-19-26-24(28(3,4)14-16-34(26,31)32)18-23(25)20(2)17-21-10-12-22(13-11-21)27(29)30/h10-13,17-19H,5-9,14-16H2,1-4H3,(H,29,30)/b20-17+
DMSJLWP	CS	CCCCCCCOC1=CC2=C(C=C1/C(=C/C3=CC=C(C=C3)C(=O)O)/C)C(CCS2(=O)=O)(C)C
DMSJLWP	IK	JEIWQRITHXYGIF-LVZFUZTISA-N
DMSJLWP	IU	4-[(E)-2-(7-heptoxy-4,4-dimethyl-1,1-dioxo-2,3-dihydrothiochromen-6-yl)prop-1-enyl]benzoic acid
DMSJLWP	CA	CAS 144092-31-9
DMSJLWP	CB	CHEBI:90706
DMSJLWP	DE	Discovery agent

DMXMSYB	ID	DMXMSYB
DMXMSYB	DN	Ro 46-8443
DMXMSYB	HS	Investigative
DMXMSYB	SN	Ro468443
DMXMSYB	DT	Small molecular drug
DMXMSYB	PC	5312146
DMXMSYB	MW	609.7
DMXMSYB	FM	C31H35N3O8S
DMXMSYB	IC	InChI=1S/C31H35N3O8S/c1-31(2,3)21-12-16-24(17-13-21)43(37,38)34-29-27(42-26-9-7-6-8-25(26)40-5)30(41-19-22(36)18-35)33-28(32-29)20-10-14-23(39-4)15-11-20/h6-17,22,35-36H,18-19H2,1-5H3,(H,32,33,34)/t22-/m1/s1
DMXMSYB	CS	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC=C(C=C3)OC)OC[C@@H](CO)O)OC4=CC=CC=C4OC
DMXMSYB	IK	DRIHNVYRUGBDHI-JOCHJYFZSA-N
DMXMSYB	IU	4-tert-butyl-N-[6-[(2R)-2,3-dihydroxypropoxy]-5-(2-methoxyphenoxy)-2-(4-methoxyphenyl)pyrimidin-4-yl]benzenesulfonamide
DMXMSYB	DE	Discovery agent

DMTQP0K	ID	DMTQP0K
DMTQP0K	DN	Ro 5-4864
DMTQP0K	HS	Investigative
DMTQP0K	SN	4'-Chlorodiazepam; 14439-61-3; 4-Chlorodiazepam; RO5-4864; UNII-2QW0IK1742; HSDB 6958; BRN 0685202; Ro-05-4864; MLS000069627; CHEMBL286346; 2QW0IK1742; Ro-5-4864; SMR000058205; 4 inverted exclamation marka-Chlorodiazepam; 7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-1-methyl-5-(p-chlorophenyl)-2H-1,4-benzodiazepin-2-one; 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-; 7-chloro-5-(4-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one; NB-3040
DMTQP0K	DT	Small molecular drug
DMTQP0K	PC	1688
DMTQP0K	MW	319.2
DMTQP0K	FM	C16H12Cl2N2O
DMTQP0K	IC	InChI=1S/C16H12Cl2N2O/c1-20-14-7-6-12(18)8-13(14)16(19-9-15(20)21)10-2-4-11(17)5-3-10/h2-8H,9H2,1H3
DMTQP0K	CS	CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl
DMTQP0K	IK	PUMYFTJOWAJIKF-UHFFFAOYSA-N
DMTQP0K	IU	7-chloro-5-(4-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMTQP0K	CA	CAS 14439-61-3
DMTQP0K	DE	Gram-positive bacterial infection

DMYVQF5	ID	DMYVQF5
DMYVQF5	DN	Ro 63-1908
DMYVQF5	HS	Investigative
DMYVQF5	SN	UNII-Q85IYK36S4; CHEMBL317229; Q85IYK36S4; 1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol; 1-(2-(4-Hydroxyphenoxy)ethyl)-4-((4-methylphenyl)methyl)-4-piperidinol; AC1OCFEC; NCGC00161413-01; SCHEMBL499394; ZINC7382; CHEBI:92975; BDBM50079385; RO-0631908; BRD-K55677650-003-01-1; 1-(2-(4-hydroxyphenoxy)ethyl)-4-(4-methylbenzyl)piperidin-4-ol; 1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]piperidin-4-ol; 4-Piperidinol, 1-(2-(4-hydroxyphenoxy)ethyl)-4-((4-methylp
DMYVQF5	DT	Small molecular drug
DMYVQF5	PC	6918426
DMYVQF5	MW	377.9
DMYVQF5	FM	C21H28ClNO3
DMYVQF5	IC	InChI=1S/C21H27NO3.ClH/c1-17-2-4-18(5-3-17)16-21(24)10-12-22(13-11-21)14-15-25-20-8-6-19(23)7-9-20;/h2-9,23-24H,10-16H2,1H3;1H
DMYVQF5	CS	CC1=CC=C(C=C1)CC2(CCN(CC2)CCOC3=CC=C(C=C3)O)O.Cl
DMYVQF5	IK	WFFZHKKSIDENAJ-UHFFFAOYSA-N
DMYVQF5	IU	1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]piperidin-4-ol;hydrochloride

DM0AC84	ID	DM0AC84
DM0AC84	DN	Ro01-6128
DM0AC84	HS	Investigative
DM0AC84	SN	Ro-016128
DM0AC84	DT	Small molecular drug
DM0AC84	PC	9903898
DM0AC84	MW	283.32
DM0AC84	FM	C17H17NO3
DM0AC84	IC	InChI=1S/C17H17NO3/c1-2-21-17(20)18-16(19)15(13-9-5-3-6-10-13)14-11-7-4-8-12-14/h3-12,15H,2H2,1H3,(H,18,19,20)
DM0AC84	CS	CCOC(=O)NC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2
DM0AC84	IK	ILSZPWZFQHSKLW-UHFFFAOYSA-N
DM0AC84	IU	ethyl N-(2,2-diphenylacetyl)carbamate
DM0AC84	DE	Discovery agent

DM6H8JM	ID	DM6H8JM
DM6H8JM	DN	Ro-04-6790
DM6H8JM	HS	Investigative
DM6H8JM	SN	Ro 04-6790; 202466-68-0; Ro-04-6790; CHEMBL433461; Ro-046790; 4-amino-N-[2,6-bis(methylamino)pyrimidin-4-yl]benzenesulfonamide; 4-Amino-N-(2,6-bis-methylamino-pyrimidin-4-yl)-benzenesulfonamide; 4-amino-N-(2,6-bis(methylamino)pyrimidin-4-yl)benzenesulfonamide; JELFWSXQTXRMAJ-UHFFFAOYSA-N; Ro 4-6790; NCGC00015885-01; 4-Amino-N-[2,6-bis(methylamino)-4-pyrimidinyl]benzenesulfonamide Dihydrobromide; Lopac-R-140; AC1NSM3L; Biomol-NT_000164; Lopac0_001045; GTPL274; SCHEMBL678897; BPBio1_000551; CTK8E8508; CHEBI:92762; ZINC23472
DM6H8JM	DT	Small molecular drug
DM6H8JM	PC	5312145
DM6H8JM	MW	308.36
DM6H8JM	FM	C12H16N6O2S
DM6H8JM	IC	InChI=1S/C12H16N6O2S/c1-14-10-7-11(17-12(15-2)16-10)18-21(19,20)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H3,14,15,16,17,18)
DM6H8JM	CS	CNC1=CC(=NC(=N1)NC)NS(=O)(=O)C2=CC=C(C=C2)N
DM6H8JM	IK	JELFWSXQTXRMAJ-UHFFFAOYSA-N
DM6H8JM	IU	4-amino-N-[2,6-bis(methylamino)pyrimidin-4-yl]benzenesulfonamide
DM6H8JM	CA	CAS 202466-68-0
DM6H8JM	CB	CHEBI:92762
DM6H8JM	DE	Discovery agent

DMLVERQ	ID	DMLVERQ
DMLVERQ	DN	Ro-0505124
DMLVERQ	HS	Investigative
DMLVERQ	SN	RO0505124
DMLVERQ	DT	Small molecular drug
DMLVERQ	PC	9911652
DMLVERQ	MW	451.5
DMLVERQ	FM	C23H25N5O3S
DMLVERQ	IC	InChI=1S/C23H25N5O3S/c1-27-8-10-28(11-9-27)17-5-3-16(4-6-17)25-23-26-22(24)21(32-23)20(29)15-2-7-18-19(14-15)31-13-12-30-18/h2-7,14H,8-13,24H2,1H3,(H,25,26)
DMLVERQ	CS	CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC(=C(S3)C(=O)C4=CC5=C(C=C4)OCCO5)N
DMLVERQ	IK	YGEYFDLYGXSZCP-UHFFFAOYSA-N
DMLVERQ	IU	[4-amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(2,3-dihydro-1,4-benzodioxin-6-yl)methanone
DMLVERQ	CA	CAS 443913-79-9
DMLVERQ	DE	Discovery agent

DM78B4A	ID	DM78B4A
DM78B4A	DN	RO-054520
DM78B4A	HS	Investigative
DM78B4A	SN	CHEMBL13095; 844-11-1; 5-(2-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; RO-054520; AC1L4W0W; SCHEMBL11858895; CTK5F2279; DTXSID00233371; ZINC3650317; BDBM50019250; AKOS030555310; Ro-05-4520; 5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one; 1-Methyl-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one
DM78B4A	DT	Small molecular drug
DM78B4A	PC	193319
DM78B4A	MW	268.28
DM78B4A	FM	C16H13FN2O
DM78B4A	IC	InChI=1S/C16H13FN2O/c1-19-14-9-5-3-7-12(14)16(18-10-15(19)20)11-6-2-4-8-13(11)17/h2-9H,10H2,1H3
DM78B4A	CS	CN1C(=O)CN=C(C2=CC=CC=C21)C3=CC=CC=C3F
DM78B4A	IK	YVTVBCWQHDDTGB-UHFFFAOYSA-N
DM78B4A	IU	5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DM78B4A	CA	CAS 844-11-1
DM78B4A	DE	Discovery agent

DMZLUAK	ID	DMZLUAK
DMZLUAK	DN	Ro0711401
DMZLUAK	HS	Investigative
DMZLUAK	SN	compound 14a [PMID: 19233648]
DMZLUAK	DT	Small molecular drug
DMZLUAK	PC	10338547
DMZLUAK	MW	360.3
DMZLUAK	FM	C18H11F3N2O3
DMZLUAK	IC	InChI=1S/C18H11F3N2O3/c19-18(20,21)14-9-25-17(22-14)23-16(24)15-10-5-1-3-7-12(10)26-13-8-4-2-6-11(13)15/h1-9,15H,(H,22,23,24)
DMZLUAK	CS	C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)C(=O)NC4=NC(=CO4)C(F)(F)F
DMZLUAK	IK	GSGDLBUOSWGZER-UHFFFAOYSA-N
DMZLUAK	IU	N-[4-(trifluoromethyl)-1,3-oxazol-2-yl]-9H-xanthene-9-carboxamide
DMZLUAK	DE	Discovery agent

DM2DXHO	ID	DM2DXHO
DM2DXHO	DN	Ro092210
DM2DXHO	HS	Investigative
DM2DXHO	DE	Discovery agent

DMOQ0CE	ID	DMOQ0CE
DMOQ0CE	DN	Ro-11-04253
DMOQ0CE	HS	Investigative
DMOQ0CE	SN	CHEMBL360688; Ro-1104253; Ro-11-04253; SCHEMBL7821569; BDBM50160164
DMOQ0CE	DT	Small molecular drug
DMOQ0CE	PC	44390740
DMOQ0CE	MW	478.4
DMOQ0CE	FM	C20H26F4N4O5
DMOQ0CE	IC	InChI=1S/C20H26F4N4O5/c1-19(32)16(29)25-18(31)28(17(19)30)6-2-5-26-7-9-27(10-8-26)14-4-3-13(21)11-15(14)33-12-20(22,23)24/h3-4,11,16,29,32H,2,5-10,12H2,1H3,(H,25,31)/t16-,19+/m1/s1
DMOQ0CE	CS	C[C@@]1([C@H](NC(=O)N(C1=O)CCCN2CCN(CC2)C3=C(C=C(C=C3)F)OCC(F)(F)F)O)O
DMOQ0CE	IK	CFECXSNWRXZHNR-APWZRJJASA-N
DMOQ0CE	IU	(5S,6R)-3-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5,6-dihydroxy-5-methyl-1,3-diazinane-2,4-dione
DMOQ0CE	DE	Discovery agent

DMAOI51	ID	DMAOI51
DMAOI51	DN	RO1138452
DMAOI51	HS	Investigative
DMAOI51	SN	Ro-1138452
DMAOI51	DT	Small molecular drug
DMAOI51	PC	9839644
DMAOI51	MW	309.4
DMAOI51	FM	C19H23N3O
DMAOI51	IC	InChI=1S/C19H23N3O/c1-14(2)23-18-9-5-16(6-10-18)13-15-3-7-17(8-4-15)22-19-20-11-12-21-19/h3-10,14H,11-13H2,1-2H3,(H2,20,21,22)
DMAOI51	CS	CC(C)OC1=CC=C(C=C1)CC2=CC=C(C=C2)NC3=NCCN3
DMAOI51	IK	GYYRMJMXXLJZAB-UHFFFAOYSA-N
DMAOI51	IU	N-[4-[(4-propan-2-yloxyphenyl)methyl]phenyl]-4,5-dihydro-1H-imidazol-2-amine
DMAOI51	CA	CAS 221529-58-4
DMAOI51	DE	Discovery agent

DMFTW0U	ID	DMFTW0U
DMFTW0U	DN	RO116-4875/608
DMFTW0U	HS	Investigative
DMFTW0U	SN	RO116-4875/608; GTPL789; SCHEMBL1223356; FQHUEFRHSWYBQS-QHCPKHFHSA-N; 1-[(2R)-1-[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]-3-methylbutan-2-yl]-3-(3,4,5-trimethoxyphenyl)urea
DMFTW0U	DT	Small molecular drug
DMFTW0U	PC	10098735
DMFTW0U	MW	538.5
DMFTW0U	FM	C27H37Cl2N3O4
DMFTW0U	IC	InChI=1S/C27H37Cl2N3O4/c1-17(2)23(31-27(33)30-20-14-24(34-3)26(36-5)25(15-20)35-4)16-32-10-8-18(9-11-32)12-19-6-7-21(28)22(29)13-19/h6-7,13-15,17-18,23H,8-12,16H2,1-5H3,(H2,30,31,33)/t23-/m0/s1
DMFTW0U	CS	CC(C)[C@H](CN1CCC(CC1)CC2=CC(=C(C=C2)Cl)Cl)NC(=O)NC3=CC(=C(C(=C3)OC)OC)OC
DMFTW0U	IK	FQHUEFRHSWYBQS-QHCPKHFHSA-N
DMFTW0U	IU	1-[(2R)-1-[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]-3-methylbutan-2-yl]-3-(3,4,5-trimethoxyphenyl)urea
DMFTW0U	DE	Discovery agent

DM6XM1D	ID	DM6XM1D
DM6XM1D	DN	RO116-9132/238
DM6XM1D	HS	Investigative
DM6XM1D	SN	RO116-9132/238; GTPL790; SCHEMBL4958779
DM6XM1D	DT	Small molecular drug
DM6XM1D	PC	9915610
DM6XM1D	MW	553.5
DM6XM1D	FM	C28H40Cl2N3O4+
DM6XM1D	IC	InChI=1S/C28H39Cl2N3O4/c1-18(2)24(32-28(34)31-21-15-25(35-4)27(37-6)26(16-21)36-5)17-33(3)11-9-19(10-12-33)13-20-7-8-22(29)23(30)14-20/h7-8,14-16,18-19,24H,9-13,17H2,1-6H3,(H-,31,32,34)/p+1/t19?,24-,33?/m0/s1
DM6XM1D	CS	CC(C)[C@H](C[N+]1(CCC(CC1)CC2=CC(=C(C=C2)Cl)Cl)C)NC(=O)NC3=CC(=C(C(=C3)OC)OC)OC
DM6XM1D	IK	INQAQQXKVUWERW-WXJUUJJFSA-O
DM6XM1D	IU	1-[(2R)-1-[4-[(3,4-dichlorophenyl)methyl]-1-methylpiperidin-1-ium-1-yl]-3-methylbutan-2-yl]-3-(3,4,5-trimethoxyphenyl)urea
DM6XM1D	DE	Discovery agent

DM0ACKJ	ID	DM0ACKJ
DM0ACKJ	DN	RO-145974
DM0ACKJ	HS	Investigative
DM0ACKJ	SN	Ethyl 11,12,13,13a-tetrahydro-9-oxo-9H-imidazo(1,5-a)pyrrolo(2,1-c)(1,4)benzodiazepine-1-carboxylate; 88552-32-3; ACMC-20lb6t; CTK3E8800
DM0ACKJ	DT	Small molecular drug
DM0ACKJ	PC	10041121
DM0ACKJ	MW	311.33
DM0ACKJ	FM	C17H17N3O3
DM0ACKJ	IC	InChI=1S/C17H17N3O3/c1-2-23-17(22)14-15-13-8-5-9-19(13)16(21)11-6-3-4-7-12(11)20(15)10-18-14/h3-4,6-7,10,13H,2,5,8-9H2,1H3/t13-/m0/s1
DM0ACKJ	CS	CCOC(=O)C1=C2[C@@H]3CCCN3C(=O)C4=CC=CC=C4N2C=N1
DM0ACKJ	IK	VUSVWZBQTTWZGJ-ZDUSSCGKSA-N
DM0ACKJ	IU	ethyl (7S)-12-oxo-2,4,11-triazatetracyclo[11.4.0.02,6.07,11]heptadeca-1(17),3,5,13,15-pentaene-5-carboxylate
DM0ACKJ	DE	Discovery agent

DMAJ6BW	ID	DMAJ6BW
DMAJ6BW	DN	RO-145975
DMAJ6BW	HS	Investigative
DMAJ6BW	SN	RO-145975; AC1LDOU9; CHEMBL269705; GXXNSEYTZVNYNW-UHFFFAOYSA-N; Ro-14-5975; Imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid, 7-chloro-9-oxo-11,12,13,13a-tetrahydro, ethyl ester; Ethyl 7-chloro-9-oxo-11,12,13,13a-tetrahydro-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate #
DMAJ6BW	DT	Small molecular drug
DMAJ6BW	PC	623268
DMAJ6BW	MW	345.8
DMAJ6BW	FM	C17H16ClN3O3
DMAJ6BW	IC	InChI=1S/C17H16ClN3O3/c1-2-24-17(23)14-15-13-4-3-7-20(13)16(22)11-8-10(18)5-6-12(11)21(15)9-19-14/h5-6,8-9,13H,2-4,7H2,1H3
DMAJ6BW	CS	CCOC(=O)C1=C2C3CCCN3C(=O)C4=C(N2C=N1)C=CC(=C4)Cl
DMAJ6BW	IK	GXXNSEYTZVNYNW-UHFFFAOYSA-N
DMAJ6BW	IU	ethyl 15-chloro-12-oxo-2,4,11-triazatetracyclo[11.4.0.02,6.07,11]heptadeca-1(17),3,5,13,15-pentaene-5-carboxylate
DMAJ6BW	DE	Discovery agent

DMX4B36	ID	DMX4B36
DMX4B36	DN	RO-147437
DMX4B36	HS	Investigative
DMX4B36	SN	Ro-14-7437; CHEMBL267665; 78756-03-3; 4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 5,6-dihydro-5-methyl-6-oxo-, ethyl ester; Ro 14-7437; RO-147437; AC1L2SAK; AC1Q6FI4; SCHEMBL7327790; CTK8D4431; HNGRWUCKESPKRC-UHFFFAOYSA-N; BDBM50034831; ethyl 5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; ethyl 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylate; ethyl 5,6-dihydro-5-methyl-6-oxo-4-H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; ethyl 5,6-dihydro-5-methyl-6-oxo-
DMX4B36	DT	Small molecular drug
DMX4B36	PC	127597
DMX4B36	MW	285.3
DMX4B36	FM	C15H15N3O3
DMX4B36	IC	InChI=1S/C15H15N3O3/c1-3-21-15(20)13-12-8-17(2)14(19)10-6-4-5-7-11(10)18(12)9-16-13/h4-7,9H,3,8H2,1-2H3
DMX4B36	CS	CCOC(=O)C1=C2CN(C(=O)C3=CC=CC=C3N2C=N1)C
DMX4B36	IK	HNGRWUCKESPKRC-UHFFFAOYSA-N
DMX4B36	IU	ethyl 5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMX4B36	CA	CAS 78756-03-3
DMX4B36	DE	Discovery agent

DM4NW3U	ID	DM4NW3U
DM4NW3U	DN	Ro-15-3505
DM4NW3U	HS	Investigative
DM4NW3U	SN	Ethyl 8-chloro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate; 78756-33-9; Ro 15-3505; CHEMBL415290; Ro-15-1310; QORLMYYHZLDYOR-UHFFFAOYSA-N; Ro-151310; AC1Q3QUM; AC1L3G5E; SCHEMBL5748925; CTK8D9399; DTXSID40229273; ZINC5114833; BDBM50034839; AKOS030600134; ethyl 8-chloro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; ethyl 8-chloro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; 4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid,;  Sarmazenil
DM4NW3U	DT	Small molecular drug
DM4NW3U	PC	71231
DM4NW3U	MW	319.74
DM4NW3U	FM	C15H14ClN3O3
DM4NW3U	IC	InChI=1S/C15H14ClN3O3/c1-3-22-15(21)13-11-7-18(2)14(20)12-9(16)5-4-6-10(12)19(11)8-17-13/h4-6,8H,3,7H2,1-2H3
DM4NW3U	CS	CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC=C3Cl)C
DM4NW3U	IK	WSDBAFQWNWJTNG-UHFFFAOYSA-N
DM4NW3U	IU	ethyl 7-chloro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DM4NW3U	CA	CAS 78771-13-8
DM4NW3U	DE	Discovery agent

DM8C2Z0	ID	DM8C2Z0
DM8C2Z0	DN	RO-194603
DM8C2Z0	HS	Investigative
DM8C2Z0	SN	Ro 19-4603; 99632-94-7; Ro-19-4603; 5,6-DIHYDRO-5-METHYL-6-OXO-4H-IMIDAZO[1,5-A]THIENO[2,3-F][1,4]DIAZEPINE-3-CARBOXYLIC ACID 1,1-DIMETHYLETHYL ESTER; Tocris-1995; AC1L2RWP; tert-butyl 5-methyl-6-oxo-5,6-dihydro-4h-imidazo[1,5-a]thieno[2,3-f][1,4]diazepine-3-carboxylate; RO-194603; CHEMBL269366; CHEBI:34952; RO19-4603; ZIGMMUKDYCABPW-UHFFFAOYSA-N; AC1Q5XKN; C13716; SCHEMBL2464268; GTPL4297; ZINC3945; CTK8D8286; DTXSID90244173; MolPort-023-276-300; HMS3268D07; PDSP1_001769; PDSP2_001752; BDBM50034835; AKOS024456899; NCGC00025337-01
DM8C2Z0	DT	Small molecular drug
DM8C2Z0	PC	127382
DM8C2Z0	MW	319.4
DM8C2Z0	FM	C15H17N3O3S
DM8C2Z0	IC	InChI=1S/C15H17N3O3S/c1-15(2,3)21-14(20)11-10-7-17(4)13(19)12-9(5-6-22-12)18(10)8-16-11/h5-6,8H,7H2,1-4H3
DM8C2Z0	CS	CC(C)(C)OC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CS3)C
DM8C2Z0	IK	ZIGMMUKDYCABPW-UHFFFAOYSA-N
DM8C2Z0	IU	tert-butyl 8-methyl-7-oxo-5-thia-1,8,12-triazatricyclo[8.3.0.02,6]trideca-2(6),3,10,12-tetraene-11-carboxylate
DM8C2Z0	CA	CAS 99632-94-7
DM8C2Z0	CB	CHEBI:34952
DM8C2Z0	DE	Discovery agent

DMOE0JX	ID	DMOE0JX
DMOE0JX	DN	Ro-21-7767
DMOE0JX	HS	Investigative
DMOE0JX	SN	Ro-21-7767; CHEMBL418791; BDBM50035644; Ro-217767
DMOE0JX	DT	Small molecular drug
DMOE0JX	PC	11778475
DMOE0JX	MW	281.3
DMOE0JX	FM	C18H19NO2
DMOE0JX	IC	InChI=1S/C18H19NO2/c1-19-10-11-4-2-3-5-12(11)17-13-7-9-16(20)18(21)14(13)6-8-15(17)19/h2-5,7,9,15,17,20-21H,6,8,10H2,1H3/t15-,17-/m1/s1
DMOE0JX	CS	CN1CC2=CC=CC=C2[C@H]3[C@H]1CCC4=C3C=CC(=C4O)O
DMOE0JX	IK	GFOJCADGVHYVJC-NVXWUHKLSA-N
DMOE0JX	IU	(6aR,12bR)-6-methyl-6a,7,8,12b-tetrahydro-5H-benzo[a]phenanthridine-9,10-diol
DMOE0JX	DE	Discovery agent

DMGL7TM	ID	DMGL7TM
DMGL7TM	DN	Ro26-4550
DMGL7TM	HS	Investigative
DMGL7TM	SN	Ro-26-4550
DMGL7TM	DT	Small molecular drug
DMGL7TM	PC	73755110
DMGL7TM	MW	446.5
DMGL7TM	FM	C26H30N4O3
DMGL7TM	IC	InChI=1S/C26H30N4O3/c1-33-26(32)24(29-25(31)17-23-8-5-15-30(18-23)19-28-27)16-22-13-11-21(12-14-22)10-9-20-6-3-2-4-7-20/h2-4,6-7,11-14,19,23-24H,5,8,15-18,27H2,1H3,(H,29,31)/t23-,24+/m1/s1
DMGL7TM	CS	COC(=O)[C@H](CC1=CC=C(C=C1)C#CC2=CC=CC=C2)NC(=O)C[C@H]3CCCN(C3)C=NN
DMGL7TM	IK	YQDXLNDLKSCQKX-RPWUZVMVSA-N
DMGL7TM	IU	methyl (2S)-2-[[2-[(3R)-1-methanehydrazonoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate
DMGL7TM	DE	Discovery agent

DMRYNJE	ID	DMRYNJE
DMRYNJE	DN	RO3
DMRYNJE	HS	Investigative
DMRYNJE	SN	RO-3
DMRYNJE	DT	Small molecular drug
DMRYNJE	PC	11289644
DMRYNJE	MW	302.37
DMRYNJE	FM	C16H22N4O2
DMRYNJE	IC	InChI=1S/C16H22N4O2/c1-9(2)12-7-14(22-4)13(21-3)6-10(12)5-11-8-19-16(18)20-15(11)17/h6-9H,5H2,1-4H3,(H4,17,18,19,20)
DMRYNJE	CS	CC(C)C1=CC(=C(C=C1CC2=CN=C(N=C2N)N)OC)OC
DMRYNJE	IK	PYNPWUIBJMVRIG-UHFFFAOYSA-N
DMRYNJE	IU	5-[(4,5-dimethoxy-2-propan-2-ylphenyl)methyl]pyrimidine-2,4-diamine
DMRYNJE	DE	Discovery agent

DMAGLPW	ID	DMAGLPW
DMAGLPW	DN	RO-316233
DMAGLPW	HS	Investigative
DMAGLPW	SN	119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3
DMAGLPW	DT	Small molecular drug
DMAGLPW	PC	2399
DMAGLPW	MW	327.3
DMAGLPW	FM	C20H13N3O2
DMAGLPW	IC	InChI=1S/C20H13N3O2/c24-19-17(13-9-21-15-7-3-1-5-11(13)15)18(20(25)23-19)14-10-22-16-8-4-2-6-12(14)16/h1-10,21-22H,(H,23,24,25)
DMAGLPW	CS	C1=CC=C2C(=C1)C(=CN2)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54
DMAGLPW	IK	DQYBRTASHMYDJG-UHFFFAOYSA-N
DMAGLPW	IU	3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione
DMAGLPW	CA	CAS 119139-23-0
DMAGLPW	CB	CHEBI:92857
DMAGLPW	DE	Discovery agent

DMDJLF0	ID	DMDJLF0
DMDJLF0	DN	Ro31-8220
DMDJLF0	HS	Investigative
DMDJLF0	SN	Bisindolylmaleimide IX; ro 31-8220; bisindolylmaleimide IX; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; Ro 31-8220 ; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl;  Ro 318220; bisindolymaleimide IX; BISINDOLYLMALEIMIDE IX
DMDJLF0	DT	Small molecular drug
DMDJLF0	PC	5083
DMDJLF0	MW	457.5
DMDJLF0	FM	C25H23N5O2S
DMDJLF0	IC	InChI=1S/C25H23N5O2S/c1-29-13-17(15-7-2-4-9-19(15)29)21-22(24(32)28-23(21)31)18-14-30(11-6-12-33-25(26)27)20-10-5-3-8-16(18)20/h2-5,7-10,13-14H,6,11-12H2,1H3,(H3,26,27)(H,28,31,32)
DMDJLF0	CS	CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CCCSC(=N)N
DMDJLF0	IK	DSXXEELGXBCYNQ-UHFFFAOYSA-N
DMDJLF0	IU	3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate
DMDJLF0	CA	CAS 125314-64-9
DMDJLF0	CB	CHEBI:38912
DMDJLF0	DE	Discovery agent

DM9GXYV	ID	DM9GXYV
DM9GXYV	DN	Ro-3201195
DM9GXYV	HS	Investigative
DM9GXYV	SN	[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE; CHEMBL203567; CHEBI:45116; Ro 320-1195; Ro-3201195; 2gfs; PQB; [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl](3-{[(2S)-2,3-dihydroxypropyl]oxy}phenyl)methanone; aminopyrazole 63; RO3201195; AC1NS1L4; SCHEMBL4108597; BDBM15754; IJDQETGUEUJVTB-HNNXBMFYSA-N; DB08424; Ro-320-1195; J3.504.577E; UNII-TE3ESF890C component IJDQETGUEUJVTB-HNNXBMFYSA-N; 5-amino-1-(4-fluorophenyl)-4-[3-{2(S),3-dihydroxypropoxy}benzoyl]pyrazole
DM9GXYV	DT	Small molecular drug
DM9GXYV	PC	5327067
DM9GXYV	MW	371.4
DM9GXYV	FM	C19H18FN3O4
DM9GXYV	IC	InChI=1S/C19H18FN3O4/c20-13-4-6-14(7-5-13)23-19(21)17(9-22-23)18(26)12-2-1-3-16(8-12)27-11-15(25)10-24/h1-9,15,24-25H,10-11,21H2/t15-/m0/s1
DM9GXYV	CS	C1=CC(=CC(=C1)OC[C@H](CO)O)C(=O)C2=C(N(N=C2)C3=CC=C(C=C3)F)N
DM9GXYV	IK	IJDQETGUEUJVTB-HNNXBMFYSA-N
DM9GXYV	IU	[5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-[3-[(2S)-2,3-dihydroxypropoxy]phenyl]methanone
DM9GXYV	CB	CHEBI:45116
DM9GXYV	DE	Discovery agent

DM8BLYO	ID	DM8BLYO
DM8BLYO	DN	RO320-2947/001
DM8BLYO	HS	Investigative
DM8BLYO	SN	RO320-2947/001; GTPL791; SCHEMBL1223391
DM8BLYO	DT	Small molecular drug
DM8BLYO	PC	10255622
DM8BLYO	MW	506
DM8BLYO	FM	C26H36ClN3O5
DM8BLYO	IC	InChI=1S/C26H36ClN3O5/c1-17(31)22(16-30-11-9-19(10-12-30)13-18-5-7-20(27)8-6-18)29-26(32)28-21-14-23(33-2)25(35-4)24(15-21)34-3/h5-8,14-15,17,19,22,31H,9-13,16H2,1-4H3,(H2,28,29,32)/t17?,22-/m0/s1
DM8BLYO	CS	CC([C@H](CN1CCC(CC1)CC2=CC=C(C=C2)Cl)NC(=O)NC3=CC(=C(C(=C3)OC)OC)OC)O
DM8BLYO	IK	JYDVJNOBDUOZJC-UGNFMNBCSA-N
DM8BLYO	IU	1-[(2S)-1-[4-[(4-chlorophenyl)methyl]piperidin-1-yl]-3-hydroxybutan-2-yl]-3-(3,4,5-trimethoxyphenyl)urea
DM8BLYO	DE	Discovery agent

DMPVKEA	ID	DMPVKEA
DMPVKEA	DN	Ro-32-0557
DMPVKEA	HS	Investigative
DMPVKEA	SN	CHEMBL538718; Ro-32-0557
DMPVKEA	DT	Small molecular drug
DMPVKEA	PC	44274749
DMPVKEA	MW	450.5
DMPVKEA	FM	C28H26N4O2
DMPVKEA	IC	InChI=1S/C28H26N4O2/c1-30-12-16-11-23-24(19-8-4-6-10-22(19)32(23)14-17(16)13-30)26-25(27(33)29-28(26)34)20-15-31(2)21-9-5-3-7-18(20)21/h3-10,15-17H,11-14H2,1-2H3,(H,29,33,34)/t16-,17+/m0/s1
DMPVKEA	CS	CN1C[C@@H]2CC3=C(C4=CC=CC=C4N3C[C@H]2C1)C5=C(C(=O)NC5=O)C6=CN(C7=CC=CC=C76)C
DMPVKEA	IK	SAYMBMAHSBYKKR-DLBZAZTESA-N
DMPVKEA	IU	3-[(11R,15R)-13-methyl-1,13-diazatetracyclo[7.7.0.02,7.011,15]hexadeca-2,4,6,8-tetraen-8-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione
DMPVKEA	DE	Discovery agent

DMBFCKD	ID	DMBFCKD
DMBFCKD	DN	RO3244794
DMBFCKD	HS	Investigative
DMBFCKD	SN	RO3244794; SCHEMBL5395501; GTPL4042; 3-(4-fluorophenyl)-2-[[5-(4-fluorophenyl)-1-benzofuran-2-yl]methoxycarbonylamino]propanoic acid
DMBFCKD	DT	Small molecular drug
DMBFCKD	PC	10204312
DMBFCKD	MW	451.4
DMBFCKD	FM	C25H19F2NO5
DMBFCKD	IC	InChI=1S/C25H19F2NO5/c26-19-6-1-15(2-7-19)11-22(24(29)30)28-25(31)32-14-21-13-18-12-17(5-10-23(18)33-21)16-3-8-20(27)9-4-16/h1-10,12-13,22H,11,14H2,(H,28,31)(H,29,30)
DMBFCKD	CS	C1=CC(=CC=C1CC(C(=O)O)NC(=O)OCC2=CC3=C(O2)C=CC(=C3)C4=CC=C(C=C4)F)F
DMBFCKD	IK	IDONYPMIPXYFLY-UHFFFAOYSA-N
DMBFCKD	IU	3-(4-fluorophenyl)-2-[[5-(4-fluorophenyl)-1-benzofuran-2-yl]methoxycarbonylamino]propanoic acid
DMBFCKD	DE	Discovery agent

DMGOPY1	ID	DMGOPY1
DMGOPY1	DN	RO330-0802/001
DMGOPY1	HS	Investigative
DMGOPY1	SN	RO330-0802/001; GTPL792; SCHEMBL1223935
DMGOPY1	DT	Small molecular drug
DMGOPY1	PC	10304110
DMGOPY1	MW	561.5
DMGOPY1	FM	C27H30Cl2N4O3S
DMGOPY1	IC	InChI=1S/C27H30Cl2N4O3S/c1-35-24-6-4-19(12-25(24)36-2)20-14-32-27(33-15-20)37-16-26(34)30-8-7-21-10-18(13-31-21)9-17-3-5-22(28)23(29)11-17/h3-6,11-12,14-15,18,21,31H,7-10,13,16H2,1-2H3,(H,30,34)/t18-,21-/m1/s1
DMGOPY1	CS	COC1=C(C=C(C=C1)C2=CN=C(N=C2)SCC(=O)NCC[C@@H]3C[C@H](CN3)CC4=CC(=C(C=C4)Cl)Cl)OC
DMGOPY1	IK	OPLAETMHSJFRBS-WIYYLYMNSA-N
DMGOPY1	IU	N-[2-[(2S,4R)-4-[(3,4-dichlorophenyl)methyl]pyrrolidin-2-yl]ethyl]-2-[5-(3,4-dimethoxyphenyl)pyrimidin-2-yl]sulfanylacetamide
DMGOPY1	DE	Discovery agent

DM83QMZ	ID	DM83QMZ
DM83QMZ	DN	Ro-37-9790
DM83QMZ	HS	Investigative
DM83QMZ	SN	Ro-37-9790; CHEMBL306412; BDBM50290086
DM83QMZ	DT	Small molecular drug
DM83QMZ	PC	44313734
DM83QMZ	MW	315.41
DM83QMZ	FM	C15H29N3O4
DM83QMZ	IC	InChI=1S/C15H29N3O4/c1-9(2)7-10(8-11(19)18-22)13(20)17-12(14(21)16-6)15(3,4)5/h9-10,12,22H,7-8H2,1-6H3,(H,16,21)(H,17,20)(H,18,19)/t10-,12+/m1/s1
DM83QMZ	CS	CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](C(=O)NC)C(C)(C)C
DM83QMZ	IK	QRXOZHSEEGNRFC-PWSUYJOCSA-N
DM83QMZ	IU	(2R)-N-[(2R)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N'-hydroxy-2-(2-methylpropyl)butanediamide
DM83QMZ	DE	Discovery agent

DM8PYAN	ID	DM8PYAN
DM8PYAN	DN	Ro-40-0655
DM8PYAN	HS	Investigative
DM8PYAN	SN	RAR-alpha agonist, Roche
DM8PYAN	CP	Roche Holding AG
DM8PYAN	DE	Colorectal cancer

DM5DMCH	ID	DM5DMCH
DM5DMCH	DN	Ro-4396686
DM5DMCH	HS	Investigative
DM5DMCH	SN	SCHEMBL5809947; CHEMBL606964
DM5DMCH	DT	Small molecular drug
DM5DMCH	PC	11396738
DM5DMCH	MW	449.5
DM5DMCH	FM	C24H24FN5O3
DM5DMCH	IC	InChI=1S/C24H24FN5O3/c1-33-21-10-7-18(8-11-21)29-14-15-13-26-23(27-17-4-2-16(25)3-5-17)28-22(15)30(24(29)32)19-6-9-20(31)12-19/h2-5,7-8,10-11,13,19-20,31H,6,9,12,14H2,1H3,(H,26,27,28)/t19-,20-/m1/s1
DM5DMCH	CS	COC1=CC=C(C=C1)N2CC3=CN=C(N=C3N(C2=O)[C@@H]4CC[C@H](C4)O)NC5=CC=C(C=C5)F
DM5DMCH	IK	KXEMINRANVTICS-WOJBJXKFSA-N
DM5DMCH	IU	7-(4-fluoroanilino)-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-4H-pyrimido[4,5-d]pyrimidin-2-one
DM5DMCH	DE	Discovery agent

DMJLSX0	ID	DMJLSX0
DMJLSX0	DN	Ro4491533
DMJLSX0	HS	Investigative
DMJLSX0	SN	Ro 4491533; Ro-4491533
DMJLSX0	DT	Small molecular drug
DMJLSX0	PC	11158623
DMJLSX0	MW	423.4
DMJLSX0	FM	C24H20F3N3O
DMJLSX0	IC	InChI=1S/C24H20F3N3O/c1-13-7-21-22(11-19(13)24(25,26)27)30-23(31)12-20(29-21)17-6-4-5-16(10-17)18-8-14(2)28-15(3)9-18/h4-11H,12H2,1-3H3,(H,30,31)
DMJLSX0	CS	CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CC(=NC(=C4)C)C
DMJLSX0	IK	LYTVXCQQTLUEQR-UHFFFAOYSA-N
DMJLSX0	IU	4-[3-(2,6-dimethylpyridin-4-yl)phenyl]-7-methyl-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one
DMJLSX0	CA	CAS 579482-31-8
DMJLSX0	DE	Discovery agent

DMC0V25	ID	DMC0V25
DMC0V25	DN	RO-4840700
DMC0V25	HS	Investigative
DMC0V25	SN	GlyT1 inhibitors (schizophrenia), Roche
DMC0V25	CP	Roche Holding AG
DMC0V25	DE	Schizophrenia

DMVGITD	ID	DMVGITD
DMVGITD	DN	Ro48-8071
DMVGITD	HS	Investigative
DMVGITD	SN	[4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone; Ro 48-8071; 161582-11-2; Ro-48-8071; [4-({6-[allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone; CHEMBL304858; R048-8071; R71; 1gsz; (4-bromophenyl)[2-fluoro-4-({6-[methyl(prop-2-en-1-yl)amino]hexyl}oxy)phenyl]methanone; C23H27BRFNO2; {4-[6-(Allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-bromo-phenyl)-methanone; (4-((6-(Allyl(methyl)amino)hexyl)oxy)-2-fluorophenyl)(4-bromophenyl)methanone; [4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl]-(4-bromo-phenyl)-methanone
DMVGITD	DT	Small molecular drug
DMVGITD	PC	1949
DMVGITD	MW	448.4
DMVGITD	FM	C23H27BrFNO2
DMVGITD	IC	InChI=1S/C23H27BrFNO2/c1-3-14-26(2)15-6-4-5-7-16-28-20-12-13-21(22(25)17-20)23(27)18-8-10-19(24)11-9-18/h3,8-13,17H,1,4-7,14-16H2,2H3
DMVGITD	CS	CN(CCCCCCOC1=CC(=C(C=C1)C(=O)C2=CC=C(C=C2)Br)F)CC=C
DMVGITD	IK	CMYCCJYVZIMDFU-UHFFFAOYSA-N
DMVGITD	IU	(4-bromophenyl)-[2-fluoro-4-[6-[methyl(prop-2-enyl)amino]hexoxy]phenyl]methanone
DMVGITD	CA	CAS 161582-11-2
DMVGITD	CB	CHEBI:101064
DMVGITD	DE	Discovery agent

DMD9SCI	ID	DMD9SCI
DMD9SCI	DN	RO-4920506
DMD9SCI	HS	Investigative
DMD9SCI	SN	MEK inhibitors (cancer); MEK inhibitors (cancer), Roche
DMD9SCI	CP	Roche Holding AG
DMD9SCI	DE	Solid tumour/cancer

DMCB2N9	ID	DMCB2N9
DMCB2N9	DN	Ro-4938581
DMCB2N9	HS	Investigative
DMCB2N9	SN	Ro-4938581; RO4938581; 883093-10-5; CHEMBL1080588; 3-bromo-10-(difluoromethyl)-9H-benzo[f]imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]diazepine; RO 4938581; 4-tert.Butylcalix[8]arene; SCHEMBL2426998; GTPL4299; EX-A856; ZINC35950127; BDBM50311045; AKOS027339432; AS-42921; HY-107489; FT-0700395; CS-0028618; J-690380
DMCB2N9	DT	Small molecular drug
DMCB2N9	PC	11624499
DMCB2N9	MW	352.14
DMCB2N9	FM	C13H8BrF2N5
DMCB2N9	IC	InChI=1S/C13H8BrF2N5/c14-7-1-2-9-8(3-7)13-17-5-19-21(13)4-10-11(12(15)16)18-6-20(9)10/h1-3,5-6,12H,4H2
DMCB2N9	CS	C1C2=C(N=CN2C3=C(C=C(C=C3)Br)C4=NC=NN41)C(F)F
DMCB2N9	IK	AFJRYPJIKHMNGL-UHFFFAOYSA-N
DMCB2N9	IU	15-bromo-5-(difluoromethyl)-2,4,8,9,11-pentazatetracyclo[11.4.0.02,6.08,12]heptadeca-1(13),3,5,9,11,14,16-heptaene
DMCB2N9	DE	Discovery agent

DM6SQ9A	ID	DM6SQ9A
DM6SQ9A	DN	RO4988546
DM6SQ9A	HS	Investigative
DM6SQ9A	SN	Ro4988546
DM6SQ9A	DT	Small molecular drug
DM6SQ9A	PC	73755205
DM6SQ9A	MW	512.4
DM6SQ9A	FM	C21H10F6N4O3S
DM6SQ9A	IC	InChI=1S/C21H10F6N4O3S/c22-20(23,24)15-5-3-13(4-6-15)17-8-18(21(25,26)27)31-19(30-17)14(10-29-31)2-1-12-7-16(11-28-9-12)35(32,33)34/h3-11H,(H,32,33,34)
DM6SQ9A	CS	C1=CC(=CC=C1C2=NC3=C(C=NN3C(=C2)C(F)(F)F)C#CC4=CC(=CN=C4)S(=O)(=O)O)C(F)(F)F
DM6SQ9A	IK	VAQSOLIIQORHSP-UHFFFAOYSA-N
DM6SQ9A	IU	5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]pyridine-3-sulfonic acid
DM6SQ9A	DE	Discovery agent

DMPXC9L	ID	DMPXC9L
DMPXC9L	DN	RO5101576
DMPXC9L	HS	Investigative
DMPXC9L	SN	Ro 5101576
DMPXC9L	DT	Small molecular drug
DMPXC9L	PC	25192022
DMPXC9L	MW	630.7
DMPXC9L	FM	C36H38O8S
DMPXC9L	IC	InChI=1S/C36H38O8S/c37-35(38)10-6-17-42-32-9-5-8-25(31(32)12-14-36(39)40)7-3-1-2-4-16-41-30-20-28(19-29(21-30)27-15-18-45-23-27)26-11-13-33-34(22-26)44-24-43-33/h5,8-9,11,13,15,18-23H,1-4,6-7,10,12,14,16-17,24H2,(H,37,38)(H,39,40)
DMPXC9L	CS	C1OC2=C(O1)C=C(C=C2)C3=CC(=CC(=C3)OCCCCCCC4=C(C(=CC=C4)OCCCC(=O)O)CCC(=O)O)C5=CSC=C5
DMPXC9L	IK	SRPFDFNVILUDAI-UHFFFAOYSA-N
DMPXC9L	IU	4-[3-[6-[3-(1,3-benzodioxol-5-yl)-5-thiophen-3-ylphenoxy]hexyl]-2-(2-carboxyethyl)phenoxy]butanoic acid
DMPXC9L	DE	Discovery agent

DM57UB9	ID	DM57UB9
DM57UB9	DN	RO5166017
DM57UB9	HS	Investigative
DM57UB9	SN	RO 5166017; RO-5166017
DM57UB9	DT	Small molecular drug
DM57UB9	PC	25016538
DM57UB9	MW	219.28
DM57UB9	FM	C12H17N3O
DM57UB9	IC	InChI=1S/C12H17N3O/c1-2-15(11-6-4-3-5-7-11)8-10-9-16-12(13)14-10/h3-7,10H,2,8-9H2,1H3,(H2,13,14)/t10-/m0/s1
DM57UB9	CS	CCN(C[C@H]1COC(=N1)N)C2=CC=CC=C2
DM57UB9	IK	PPONHQQJLWPUPH-JTQLQIEISA-N
DM57UB9	IU	(4S)-4-[(N-ethylanilino)methyl]-4,5-dihydro-1,3-oxazol-2-amine
DM57UB9	DE	Discovery agent

DM42UK5	ID	DM42UK5
DM42UK5	DN	Ro5203280
DM42UK5	HS	Investigative
DM42UK5	SN	Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394
DM42UK5	PC	25015677
DM42UK5	MW	543.6
DM42UK5	FM	C27H35F2N7O3
DM42UK5	IC	InChI=1S/C27H35F2N7O3/c1-34-12-10-18(11-13-34)31-24(37)17-8-9-20(22(14-17)39-3)32-26-30-15-21-23(33-26)36(19-6-4-5-7-19)16-27(28,29)25(38)35(21)2/h8-9,14-15,18-19H,4-7,10-13,16H2,1-3H3,(H,31,37)(H,30,32,33)
DM42UK5	CS	CN1CCC(CC1)NC(=O)C2=CC(=C(C=C2)NC3=NC=C4C(=N3)N(CC(C(=O)N4C)(F)F)C5CCCC5)OC
DM42UK5	IK	DJNZZLZKAXGMMC-UHFFFAOYSA-N
DM42UK5	IU	4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
DM42UK5	CA	CAS 1062243-51-9
DM42UK5	DE	Nasopharyngeal carcinoma

DMP0GA6	ID	DMP0GA6
DMP0GA6	DN	RO-5212651
DMP0GA6	HS	Investigative
DMP0GA6	SN	RO-5312776; RO-5328185; RO-5429374; RO-5447603; RO-5447605; RO-5461212; GPR119 agonists (type 2 diabetes), Roche
DMP0GA6	CP	Roche Holding AG
DMP0GA6	DE	Non-insulin dependent diabetes

DMHXGCO	ID	DMHXGCO
DMHXGCO	DN	RO5488608
DMHXGCO	HS	Investigative
DMHXGCO	SN	RO5488608; GTPL6325; 3-{3-[7-methyl-2-oxo-8-(trifluoromethyl)-2,3-dihydro-1H-1,5-benzodiazepin-4-yl]phenyl}benzene-1-sulfonic acid
DMHXGCO	DT	Small molecular drug
DMHXGCO	PC	73755206
DMHXGCO	MW	474.5
DMHXGCO	FM	C23H17F3N2O4S
DMHXGCO	IC	InChI=1S/C23H17F3N2O4S/c1-13-8-20-21(11-18(13)23(24,25)26)28-22(29)12-19(27-20)16-6-2-4-14(9-16)15-5-3-7-17(10-15)33(30,31)32/h2-11H,12H2,1H3,(H,28,29)(H,30,31,32)
DMHXGCO	CS	CC1=CC2=C(C=C1C(F)(F)F)NC(=O)CC(=N2)C3=CC=CC(=C3)C4=CC(=CC=C4)S(=O)(=O)O
DMHXGCO	IK	FQNZBSFUVZKONP-UHFFFAOYSA-N
DMHXGCO	IU	3-[3-[7-methyl-2-oxo-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-4-yl]phenyl]benzenesulfonic acid
DMHXGCO	DE	Discovery agent

DMXOTHC	ID	DMXOTHC
DMXOTHC	DN	Ro64-5229
DMXOTHC	HS	Investigative
DMXOTHC	SN	Ro 64-5229
DMXOTHC	DT	Small molecular drug
DMXOTHC	PC	10428048
DMXOTHC	MW	352.3
DMXOTHC	FM	C17H19Cl2N3O
DMXOTHC	IC	InChI=1S/C17H19Cl2N3O/c18-14-8-5-9-15(19)17(14)16(10-22-12-20-11-21-22)23-13-6-3-1-2-4-7-13/h5,8-13H,1-4,6-7H2/b16-10-
DMXOTHC	CS	C1CCCC(CC1)O/C(=C\\N2C=NC=N2)/C3=C(C=CC=C3Cl)Cl
DMXOTHC	IK	STCVFKBRXOEQRF-YBEGLDIGSA-N
DMXOTHC	IU	1-[(Z)-2-cycloheptyloxy-2-(2,6-dichlorophenyl)ethenyl]-1,2,4-triazole
DMXOTHC	DE	Discovery agent

DM6S742	ID	DM6S742
DM6S742	DN	Ro-65-7219
DM6S742	HS	Investigative
DM6S742	SN	Ro-65-7219; CHEMBL1276276; SCHEMBL1940750; BDBM50330350
DM6S742	DT	Small molecular drug
DM6S742	PC	52945901
DM6S742	MW	631.8
DM6S742	FM	C37H45NO8
DM6S742	IC	InChI=1S/C37H45NO8/c1-41-33-11-6-4-9-29(33)24-43-16-7-17-44-31-14-12-27(13-15-31)37-35(20-38-21-36(37)46-25-30(40)22-39)45-23-26-18-28-8-3-5-10-32(28)34(19-26)42-2/h3-6,8-15,18-19,30,35-40H,7,16-17,20-25H2,1-2H3/t30-,35+,36-,37-/m1/s1
DM6S742	CS	COC1=CC=CC=C1COCCCOC2=CC=C(C=C2)[C@@H]3[C@H](CNC[C@H]3OC[C@@H](CO)O)OCC4=CC5=CC=CC=C5C(=C4)OC
DM6S742	IK	QYBJMSXQFYUZHD-ZLWKXDTISA-N
DM6S742	IU	(2R)-3-[(3S,4R,5R)-5-[(4-methoxynaphthalen-2-yl)methoxy]-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]piperidin-3-yl]oxypropane-1,2-diol
DM6S742	DE	Discovery agent

DMPT01J	ID	DMPT01J
DMPT01J	DN	Ro-66-1168
DMPT01J	HS	Investigative
DMPT01J	SN	Ro-66-1168; CHEMBL1276275; 304025-53-4; Acetamide,N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]-; SCHEMBL5556763; YKAHCPSTICMMFK-ILFWFZRHSA-N; ZINC3985435; BDBM50330345; KB-74440; N-[2-[7-[[4beta-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidine-3alpha-yloxy]methyl]-1,2,3,4-tetrahydroquinoline-1-yl]ethyl]acetamide
DMPT01J	DT	Small molecular drug
DMPT01J	PC	9851682
DMPT01J	MW	601.8
DMPT01J	FM	C36H47N3O5
DMPT01J	IC	InChI=1S/C36H47N3O5/c1-27(40)38-18-20-39-19-5-8-30-11-10-28(23-34(30)39)25-44-36-24-37-17-16-33(36)29-12-14-32(15-13-29)43-22-6-21-42-26-31-7-3-4-9-35(31)41-2/h3-4,7,9-15,23,33,36-37H,5-6,8,16-22,24-26H2,1-2H3,(H,38,40)/t33-,36+/m1/s1
DMPT01J	CS	CC(=O)NCCN1CCCC2=C1C=C(C=C2)CO[C@H]3CNCC[C@@H]3C4=CC=C(C=C4)OCCCOCC5=CC=CC=C5OC
DMPT01J	IK	YKAHCPSTICMMFK-ILFWFZRHSA-N
DMPT01J	IU	N-[2-[7-[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]piperidin-3-yl]oxymethyl]-3,4-dihydro-2H-quinolin-1-yl]ethyl]acetamide
DMPT01J	DE	Discovery agent

DMD93NP	ID	DMD93NP
DMD93NP	DN	Ro67-4853
DMD93NP	HS	Investigative
DMD93NP	SN	Ro-67-4853
DMD93NP	DT	Small molecular drug
DMD93NP	PC	9949202
DMD93NP	MW	325.4
DMD93NP	FM	C19H19NO4
DMD93NP	IC	InChI=1S/C19H19NO4/c1-2-3-12-23-19(22)20-18(21)17-13-8-4-6-10-15(13)24-16-11-7-5-9-14(16)17/h4-11,17H,2-3,12H2,1H3,(H,20,21,22)
DMD93NP	CS	CCCCOC(=O)NC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13
DMD93NP	IK	RQBUXEUMZZQUFY-UHFFFAOYSA-N
DMD93NP	IU	butyl N-(9H-xanthene-9-carbonyl)carbamate
DMD93NP	CA	CAS 302841-89-0
DMD93NP	DE	Discovery agent

DMI95DP	ID	DMI95DP
DMI95DP	DN	Ro67-7476
DMI95DP	HS	Investigative
DMI95DP	SN	Ro-677476; Ro 677476
DMI95DP	DT	Small molecular drug
DMI95DP	PC	17950211
DMI95DP	MW	319.4
DMI95DP	FM	C17H18FNO2S
DMI95DP	IC	InChI=1S/C17H18FNO2S/c1-13-4-10-16(11-5-13)22(20,21)19-12-2-3-17(19)14-6-8-15(18)9-7-14/h4-11,17H,2-3,12H2,1H3
DMI95DP	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCCC2C3=CC=C(C=C3)F
DMI95DP	IK	DAEHFYNGSSBGSS-UHFFFAOYSA-N
DMI95DP	IU	2-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidine
DMI95DP	CA	CAS 298690-60-5
DMI95DP	DE	Discovery agent

DMASOWP	ID	DMASOWP
DMASOWP	DN	ROBINETIN
DMASOWP	HS	Investigative
DMASOWP	SN	Robinetin; 490-31-3; Norkanugin; 3,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one; 5-Hydroxyfisetin; 5-Deoxymyricetin; 4H-1-Benzopyran-4-one, 3,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-; UNII-KJ6DBC4U7E; 3,7,3',4',5'-pentahydroxyflavone; NSC 656274; NSC 407331; CCRIS 7520; EINECS 207-709-6; KJ6DBC4U7E; NSC-407331; BRN 0308905; CHEMBL170405; CHEBI:8876; FLAVONE, 3,3',4',5',7-PENTAHYDROXY-; NSC656274; 3,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-4-benzopyrone
DMASOWP	DT	Small molecular drug
DMASOWP	PC	5281692
DMASOWP	MW	302.23
DMASOWP	FM	C15H10O7
DMASOWP	IC	InChI=1S/C15H10O7/c16-7-1-2-8-11(5-7)22-15(14(21)12(8)19)6-3-9(17)13(20)10(18)4-6/h1-5,16-18,20-21H
DMASOWP	CS	C1=CC2=C(C=C1O)OC(=C(C2=O)O)C3=CC(=C(C(=C3)O)O)O
DMASOWP	IK	SOEDEYVDCDYMMH-UHFFFAOYSA-N
DMASOWP	IU	3,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
DMASOWP	CA	CAS 490-31-3
DMASOWP	CB	CHEBI:8876
DMASOWP	DE	Discovery agent

DME9VTX	ID	DME9VTX
DME9VTX	DN	ROCAGLAMIDE
DME9VTX	HS	Investigative
DME9VTX	SN	Rocaglamide; 84573-16-0; MLS002701812; CHEMBL438139; CHEBI:66309; NSC326408; NSC 326408; 1H-Cyclopenta(b)benzofuran-2-carboxamide, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-N,N-dimethyl-3-phenyl-, (1R,2R,3S,3aR,8bS)-; (1R,2R,3S,3aR,8bS)-6,8-dimethoxy-3a-(4-methoxyphenyl)-N,N-dimethyl-1,8b-bis(oxidanyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxamide
DME9VTX	DT	Small molecular drug
DME9VTX	PC	331783
DME9VTX	MW	505.6
DME9VTX	FM	C29H31NO7
DME9VTX	IC	InChI=1S/C29H31NO7/c1-30(2)27(32)23-24(17-9-7-6-8-10-17)29(18-11-13-19(34-3)14-12-18)28(33,26(23)31)25-21(36-5)15-20(35-4)16-22(25)37-29/h6-16,23-24,26,31,33H,1-5H3/t23-,24-,26-,28+,29+/m1/s1
DME9VTX	CS	CN(C)C(=O)[C@@H]1[C@H]([C@]2([C@@]([C@@H]1O)(C3=C(O2)C=C(C=C3OC)OC)O)C4=CC=C(C=C4)OC)C5=CC=CC=C5
DME9VTX	IK	DAPAQENNNINUPW-IDAMAFBJSA-N
DME9VTX	IU	(1R,2R,3S,3aR,8bS)-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-N,N-dimethyl-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxamide
DME9VTX	CA	CAS 84573-16-0
DME9VTX	CB	CHEBI:66309
DME9VTX	DE	Discovery agent

DMD4JHK	ID	DMD4JHK
DMD4JHK	DN	Roche 28-2653
DMD4JHK	HS	Investigative
DMD4JHK	DT	Small molecular drug
DMD4JHK	PC	56603788
DMD4JHK	MW	484.5
DMD4JHK	FM	C27H24N4O5
DMD4JHK	IC	InChI=1S/C27H24N4O5/c32-24-18-25(33)28-26(34)27(24,21-8-6-20(7-9-21)19-4-2-1-3-5-19)30-16-14-29(15-17-30)22-10-12-23(13-11-22)31(35)36/h1-13H,14-18H2,(H,28,33,34)
DMD4JHK	CS	C1CN(CCN1C2=CC=C(C=C2)[N+](=O)[O-])C3(C(=O)CC(=O)NC3=O)C4=CC=C(C=C4)C5=CC=CC=C5
DMD4JHK	IK	VWJFDSFQMZGQHZ-UHFFFAOYSA-N
DMD4JHK	IU	3-[4-(4-nitrophenyl)piperazin-1-yl]-3-(4-phenylphenyl)piperidine-2,4,6-trione
DMD4JHK	DE	Discovery agent

DMOTPJD	ID	DMOTPJD
DMOTPJD	DN	Rockout
DMOTPJD	HS	Investigative
DMOTPJD	SN	3-(Pyridin-4-yl)-1H-indole; 3-(4-Pyridyl)indole; rockout; 3-(pyridin-4-yl)-1H-indole; 7272-84-6; 3-Pyridin-4-yl-1H-indole; 3-(4-Pyridyl)-1H-indole; Rho Kinase Inhibitor III, Rockout; 3-(4-Pyridinyl)-1H-indole; CHEMBL380071; 1H-indole, 3-(4-pyridinyl)-; 3-(4-Pyridyl); Rho kinase inhibitor III; ChemDiv2_000332; AC1LD92F; Oprea1_292323; Oprea1_060403; CBDivE_015772; MLS000029246; SCHEMBL238277; GTPL6032; cid_644354; ZINC80555; CHEBI:93984; DTXSID90349379; 3-(PYRIDIN-4-YL)INDOLE; MolPort-001-899-519; HMS1369P02; HMS3229K13; HMS2280K08; STL331403; IN1125; BDBM50182878;  rockout
DMOTPJD	DT	Small molecular drug
DMOTPJD	PC	644354
DMOTPJD	MW	194.23
DMOTPJD	FM	C13H10N2
DMOTPJD	IC	InChI=1S/C13H10N2/c1-2-4-13-11(3-1)12(9-15-13)10-5-7-14-8-6-10/h1-9,15H
DMOTPJD	CS	C1=CC=C2C(=C1)C(=CN2)C3=CC=NC=C3
DMOTPJD	IK	LLJRXVHJOJRCSM-UHFFFAOYSA-N
DMOTPJD	IU	3-pyridin-4-yl-1H-indole
DMOTPJD	CA	CAS 7272-84-6
DMOTPJD	CB	CHEBI:93984
DMOTPJD	DE	Discovery agent

DM5HV4W	ID	DM5HV4W
DM5HV4W	DN	Rolicyclidine
DM5HV4W	HS	Investigative
DM5HV4W	SN	ROLICYCLIDINE; PCPy; 1-(1-Phenylcyclohexyl)pyrrolidine; Rolicyclidinum; Roliciclidina; 2201-39-0; Rolicyclidinum [INN-Latin]; Roliciclidina [INN-Spanish]; UNII-183O9O9JE3; DEA No. 7458; CHEBI:60805; Pyrrolidine analog of phencyclidine; 183O9O9JE3; Pyrrolidine, 1-(1-phenylcyclohexyl)-; NCGC00160464-01; Rolicyclidine [INN]; PCP pyrrolidine analog; DSSTox_RID_81398; DSSTox_CID_26167; DSSTox_GSID_46167; SCHEMBL517928; AC1L1X48; DTXSID8046167; CHEMBL1719398; HSDB 7636; FYOWWXMGDATDQY-UHFFFAOYSA-N; 1-(1-phenylcyclohexyl)-pyrrolidine
DM5HV4W	DT	Small molecular drug
DM5HV4W	PC	62436
DM5HV4W	MW	229.36
DM5HV4W	FM	C16H23N
DM5HV4W	IC	InChI=1S/C16H23N/c1-3-9-15(10-4-1)16(11-5-2-6-12-16)17-13-7-8-14-17/h1,3-4,9-10H,2,5-8,11-14H2
DM5HV4W	CS	C1CCC(CC1)(C2=CC=CC=C2)N3CCCC3
DM5HV4W	IK	FYOWWXMGDATDQY-UHFFFAOYSA-N
DM5HV4W	IU	1-(1-phenylcyclohexyl)pyrrolidine
DM5HV4W	CA	CAS 2201-39-0
DM5HV4W	CB	CHEBI:60805
DM5HV4W	DE	Discovery agent

DMJ03UM	ID	DMJ03UM
DMJ03UM	DN	ROLIPRAM
DMJ03UM	HS	Investigative
DMJ03UM	SN	61413-54-5; ZK 62711; Rolipramum; Rolipramum [Latin]; 4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone; Adeo; Rolipram [USAN:INN]; 4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one; 4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one; 4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-pyrrolidinone; (R,S)-rolipram; ZK-62711; CHEMBL63; EINECS 262-771-1; BRN 1588548; MLS000069691; CHEBI:104872; HJORMJIFDVBMOB-UHFFFAOYSA-N; 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone; [3H]rolipram
DMJ03UM	DT	Small molecular drug
DMJ03UM	PC	5092
DMJ03UM	MW	275.34
DMJ03UM	FM	C16H21NO3
DMJ03UM	IC	InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)
DMJ03UM	CS	COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3
DMJ03UM	IK	HJORMJIFDVBMOB-UHFFFAOYSA-N
DMJ03UM	IU	4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one
DMJ03UM	CA	CAS 61413-54-5
DMJ03UM	CB	CHEBI:104872
DMJ03UM	DE	Discovery agent

DMAROW1	ID	DMAROW1
DMAROW1	DN	ROMe
DMAROW1	HS	Investigative
DMAROW1	SN	(R)-FTY720-OMe
DMAROW1	DT	Small molecular drug
DMAROW1	PC	71458556
DMAROW1	MW	321.5
DMAROW1	FM	C20H35NO2
DMAROW1	IC	InChI=1S/C20H35NO2/c1-3-4-5-6-7-8-9-18-10-12-19(13-11-18)14-15-20(21,16-22)17-23-2/h10-13,22H,3-9,14-17,21H2,1-2H3/t20-/m1/s1
DMAROW1	CS	CCCCCCCCC1=CC=C(C=C1)CC[C@@](CO)(COC)N
DMAROW1	IK	YEYZALQTJCVXIJ-HXUWFJFHSA-N
DMAROW1	IU	(2R)-2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol
DMAROW1	DE	Discovery agent

DM3NBQ6	ID	DM3NBQ6
DM3NBQ6	DN	rose bengal (photoactivated)
DM3NBQ6	HS	Investigative
DM3NBQ6	SN	CHEMBL1208422; CHEBI:87202; 2,3,4,5-tetrachloro-6-(3-hydroxy-2,4,5,7-tetraiodo-6-oxo-xanthen-9-yl)benzoic acid; 2,3,4,5-tetrachloro-6-(3-hydroxy-2,4,5,7-tetraiodo-6-oxoxanthen-9-yl)benzoic acid; NSC45732; NSC10463; NSC270091; C.I.45440; Bengalrosa; rose bengal free acid; Ak-Rose Liq 1%; Tetraiodotetrachlorofluorescein; GTPL2393; SCHEMBL1464825; AC1L196L; ZINC150338646; AN-20423; LS-194354; SR-01000939637; SR-01000939637-2
DM3NBQ6	DT	Small molecular drug
DM3NBQ6	PC	25474
DM3NBQ6	MW	973.7
DM3NBQ6	FM	C20H4Cl4I4O5
DM3NBQ6	IC	InChI=1S/C20H4Cl4I4O5/c21-10-8(9(20(31)32)11(22)13(24)12(10)23)7-3-1-5(25)16(29)14(27)18(3)33-19-4(7)2-6(26)17(30)15(19)28/h1-2,29H,(H,31,32)
DM3NBQ6	CS	C1=C2C(=C3C=C(C(=O)C(=C3OC2=C(C(=C1I)O)I)I)I)C4=C(C(=C(C(=C4Cl)Cl)Cl)Cl)C(=O)O
DM3NBQ6	IK	VDNLFJGJEQUWRB-UHFFFAOYSA-N
DM3NBQ6	IU	2,3,4,5-tetrachloro-6-(3-hydroxy-2,4,5,7-tetraiodo-6-oxoxanthen-9-yl)benzoic acid
DM3NBQ6	CA	CAS 11121-48-5
DM3NBQ6	CB	CHEBI:87202
DM3NBQ6	DE	Discovery agent

DMN802V	ID	DMN802V
DMN802V	DN	ROSETTACIN
DMN802V	HS	Investigative
DMN802V	SN	ROSETTACIN; SCHEMBL4374000; CHEMBL110203; ZINC26972929
DMN802V	DT	Small molecular drug
DMN802V	PC	24813913
DMN802V	MW	284.3
DMN802V	FM	C19H12N2O
DMN802V	IC	InChI=1S/C19H12N2O/c22-19-15-7-3-1-5-12(15)10-17-18-14(11-21(17)19)9-13-6-2-4-8-16(13)20-18/h1-10H,11H2
DMN802V	CS	C1C2=CC3=CC=CC=C3N=C2C4=CC5=CC=CC=C5C(=O)N41
DMN802V	IK	JORFMKUBMHCFKA-UHFFFAOYSA-N
DMN802V	IU	3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15,17,19-nonaen-14-one
DMN802V	DE	Discovery agent

DMQ6SJT	ID	DMQ6SJT
DMQ6SJT	DN	ROSMARINIC ACID
DMQ6SJT	HS	Investigative
DMQ6SJT	SN	rosmarinic acid; 20283-92-5; Rosemary acid; (R)-rosmarinic acid; UNII-MQE6XG29YI; Rosmarinate; MQE6XG29YI; CHEMBL324842; CHEBI:50371; Labiatenic acid; C18H16O8; (R)-O-(3,4-Dihydroxycinnamoyl)-3-(3,4- dihydroxyphenyl)lactic acid; 3,4-Dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl ester; (2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid; 537-15-5; Rosemaric acid; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-propanoic acid
DMQ6SJT	DT	Small molecular drug
DMQ6SJT	PC	5281792
DMQ6SJT	MW	360.3
DMQ6SJT	FM	C18H16O8
DMQ6SJT	IC	InChI=1S/C18H16O8/c19-12-4-1-10(7-14(12)21)3-6-17(23)26-16(18(24)25)9-11-2-5-13(20)15(22)8-11/h1-8,16,19-22H,9H2,(H,24,25)/b6-3+/t16-/m1/s1
DMQ6SJT	CS	C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O
DMQ6SJT	IK	DOUMFZQKYFQNTF-WUTVXBCWSA-N
DMQ6SJT	IU	(2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxypropanoic acid
DMQ6SJT	CA	CAS 20283-92-5
DMQ6SJT	CB	CHEBI:50371
DMQ6SJT	DE	Rheumatoid arthritis

DMT0DW4	ID	DMT0DW4
DMT0DW4	DN	Rotigitine
DMT0DW4	HS	Investigative
DMT0DW4	SN	Rotigotine hydrochloride; 125572-93-2; Rotigotine HCl; Rotigotine (Hydrochloride); UNII-6Q1W9573L2; (S)-6-(Propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol hydrochloride; 6Q1W9573L2; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol hydrochloride; [14C]-Rotigotine; N-0923 hydrochloride; N 0924 hydrochloride; Rotigotine(Hydrochloride); Neupro Hydrochloride Salt; C19H26ClNOS; AC1L46ZH; (S)-5,6,7,8-Tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol hydrochlor
DMT0DW4	DT	Small molecular drug
DMT0DW4	PC	180335
DMT0DW4	MW	351.9
DMT0DW4	FM	C19H26ClNOS
DMT0DW4	IC	InChI=1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1
DMT0DW4	CS	CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O.Cl
DMT0DW4	IK	CEXBONHIOKGWNU-NTISSMGPSA-N
DMT0DW4	IU	(6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;hydrochloride
DMT0DW4	CA	CAS 125572-93-2
DMT0DW4	DE	Parkinson disease

DM751OH	ID	DM751OH
DM751OH	DN	Rotungenic acid
DM751OH	HS	Investigative
DM751OH	SN	rotungenic acid; CHEMBL493908; CHEBI:70685; SCHEMBL1051075; BDBM50253053
DM751OH	DT	Small molecular drug
DM751OH	PC	12315077
DM751OH	MW	488.7
DM751OH	FM	C30H48O5
DM751OH	IC	InChI=1S/C30H48O5/c1-18-9-14-30(24(33)34)16-15-27(4)19(23(30)29(18,6)35)7-8-21-25(2)12-11-22(32)26(3,17-31)20(25)10-13-28(21,27)5/h7,18,20-23,31-32,35H,8-17H2,1-6H3,(H,33,34)/t18-,20-,21-,22+,23-,25+,26-,27-,28-,29-,30+/m1/s1
DM751OH	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H]([C@]5(C)CO)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O
DM751OH	IK	YLHQFGOOMKJFLP-VNUPIYKRSA-N
DM751OH	IU	(1R,2R,4aS,6aR,6aS,6bR,8aR,9S,10S,12aR,14bS)-1,10-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DM751OH	CB	CHEBI:70685
DM751OH	DE	Discovery agent

DMWUAMQ	ID	DMWUAMQ
DMWUAMQ	DN	ROXIFIBAN
DMWUAMQ	HS	Investigative
DMWUAMQ	SN	Roxifiban; UNII-Q476FMZ72G; DMP754; 170902-47-3; CHEMBL18301; Q476FMZ72G; DMP-754; Roxifiban [INN]; AC1L42MF; SCHEMBL344302; DTXSID70168969; BDBM50075579; methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate; L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-; L-Alanine, 3-((((5R)-3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methy
DMWUAMQ	DT	Small molecular drug
DMWUAMQ	PC	177230
DMWUAMQ	MW	447.5
DMWUAMQ	FM	C21H29N5O6
DMWUAMQ	IC	InChI=1S/C21H29N5O6/c1-3-4-9-31-21(29)25-17(20(28)30-2)12-24-18(27)11-15-10-16(26-32-15)13-5-7-14(8-6-13)19(22)23/h5-8,15,17H,3-4,9-12H2,1-2H3,(H3,22,23)(H,24,27)(H,25,29)/t15-,17+/m1/s1
DMWUAMQ	CS	CCCCOC(=O)N[C@@H](CNC(=O)C[C@H]1CC(=NO1)C2=CC=C(C=C2)C(=N)N)C(=O)OC
DMWUAMQ	IK	IRAXRQFCCSHQDX-WBVHZDCISA-N
DMWUAMQ	IU	methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate
DMWUAMQ	CA	CAS 170902-47-3
DMWUAMQ	DE	Discovery agent

DMP2EDX	ID	DMP2EDX
DMP2EDX	DN	RP-1040
DMP2EDX	HS	Investigative
DMP2EDX	SN	RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals
DMP2EDX	CP	Incozen Therapeutics Pvt Ltd
DMP2EDX	DE	Solid tumour/cancer

DM5IXOS	ID	DM5IXOS
DM5IXOS	DN	RP-52770
DM5IXOS	HS	Investigative
DM5IXOS	SN	N-(3-Chlorophenyl)-3-pyridin-3-yl-1,3-dihydropyrrolo[1,2-c][1,3]thiazole-7-carboxamide; CHEMBL64716; 93363-02-1; N-(3-chlorophenyl)-3-pyridin-3-yl-1,3-dihydropyrrolo[1,2-c][1,3]thiazole-7-carboxamide; RP 52770; 52770 RP; [3H]52770 RP; AC1L3T5Q; GTPL1858; GTPL1839; SCHEMBL11014618; BDBM50038753; N-(3-Chlorophenyl)-3-(3-pyridinyl)-1H,3H-pyrrolo(1,2-c)thiazole-7-carboxamide; L001082; 1H,3H-Pyrrolo(1,2-c)thiazole-7-carboxamide, N-(3-chlorophenyl)-3-(3-pyridinyl)-; 3-Pyridin-3-yl-1H-pyrrolo[1,2-c]thiazole-7-carboxylic acid;  RP 52770
DM5IXOS	DT	Small molecular drug
DM5IXOS	PC	146417
DM5IXOS	MW	355.8
DM5IXOS	FM	C18H14ClN3OS
DM5IXOS	IC	InChI=1S/C18H14ClN3OS/c19-13-4-1-5-14(9-13)21-17(23)15-6-8-22-16(15)11-24-18(22)12-3-2-7-20-10-12/h1-10,18H,11H2,(H,21,23)
DM5IXOS	CS	C1C2=C(C=CN2C(S1)C3=CN=CC=C3)C(=O)NC4=CC(=CC=C4)Cl
DM5IXOS	IK	MJGVBIXLFIUPQU-UHFFFAOYSA-N
DM5IXOS	IU	N-(3-chlorophenyl)-3-pyridin-3-yl-1,3-dihydropyrrolo[1,2-c][1,3]thiazole-7-carboxamide
DM5IXOS	CA	CAS 93363-02-1
DM5IXOS	DE	Discovery agent

DM03RIT	ID	DM03RIT
DM03RIT	DN	Rp-5-OMe-UDPalphaB
DM03RIT	HS	Investigative
DM03RIT	SN	5-OMe-uridine-5'-O-(alpha-boranodiphosphate); compound 18a [PMID: 22901672]
DM03RIT	DT	Small molecular drug
DM03RIT	PC	91938091
DM03RIT	MW	433.03
DM03RIT	FM	C10H20BN2O12P2-
DM03RIT	IC	InChI=1S/C10H20BN2O12P2/c1-22-4-2-13(10(17)12-8(4)16)9-7(15)6(14)5(24-9)3-23-26(11,18)25-27(19,20)21/h4-7,9,14-15H,2-3H2,1,11H3,(H,12,16,17)(H2,19,20,21)/q-1/t4?,5-,6+,7+,9?,26-/m1/s1
DM03RIT	CS	[BH3-][P@@](=O)(OC[C@@H]1[C@@H]([C@@H](C(O1)N2CC(C(=O)NC2=O)OC)O)O)OP(=O)(O)O
DM03RIT	IK	YXHXVAMQDBFYRD-ANTPIODHSA-N
DM03RIT	IU	[[(2R,3R,4S)-3,4-dihydroxy-5-(5-methoxy-2,4-dioxo-1,3-diazinan-1-yl)oxolan-2-yl]methoxy-phosphonooxyphosphoryl]boranuide
DM03RIT	DE	Discovery agent

DMR4O3I	ID	DMR4O3I
DMR4O3I	DN	RP-66471
DMR4O3I	HS	Investigative
DMR4O3I	SN	133320-02-2
DMR4O3I	PC	9798699
DMR4O3I	MW	354.5
DMR4O3I	FM	C20H22N2O2S
DMR4O3I	IC	InChI=1S/C20H22N2O2S/c1-21-19(25)20(16-10-7-13-22-14-16)12-6-5-11-17(20)24-18(23)15-8-3-2-4-9-15/h2-4,7-10,13-14,17H,5-6,11-12H2,1H3,(H,21,25)/t17-,20+/m1/s1
DMR4O3I	CS	CNC(=S)[C@@]1(CCCC[C@H]1OC(=O)C2=CC=CC=C2)C3=CN=CC=C3
DMR4O3I	IK	UHXSGUDTSLFJNZ-XLIONFOSSA-N
DMR4O3I	IU	[(1R,2S)-2-(methylcarbamothioyl)-2-pyridin-3-ylcyclohexyl] benzoate
DMR4O3I	DE	Discovery agent

DMXMRVG	ID	DMXMRVG
DMXMRVG	DN	RP-69758
DMXMRVG	HS	Investigative
DMXMRVG	SN	RP 69758
DMXMRVG	DT	Small molecular drug
DMXMRVG	PC	9847721
DMXMRVG	MW	474.5
DMXMRVG	FM	C26H26N4O5
DMXMRVG	IC	InChI=1S/C26H26N4O5/c1-29(21-11-4-2-5-12-21)24(32)18-30(22-13-6-3-7-14-22)23(31)17-27-26(35)28-20-10-8-9-19(15-20)16-25(33)34/h2-15H,16-18H2,1H3,(H,33,34)(H2,27,28,35)
DMXMRVG	CS	CN(C1=CC=CC=C1)C(=O)CN(C2=CC=CC=C2)C(=O)CNC(=O)NC3=CC=CC(=C3)CC(=O)O
DMXMRVG	IK	CRUWRCOXWORZBA-UHFFFAOYSA-N
DMXMRVG	IU	2-[3-[[2-(N-[2-(N-methylanilino)-2-oxoethyl]anilino)-2-oxoethyl]carbamoylamino]phenyl]acetic acid
DMXMRVG	DE	Discovery agent

DMUFLNT	ID	DMUFLNT
DMUFLNT	DN	RP-71483
DMUFLNT	HS	Investigative
DMUFLNT	SN	138279-55-7
DMUFLNT	PC	101666277
DMUFLNT	MW	536.6
DMUFLNT	FM	C30H28N6O4
DMUFLNT	IC	InChI=1S/C30H28N6O4/c37-27(19-32-30(39)34-24-12-3-7-21(17-24)18-33-40)36(26-14-4-9-23-10-5-15-31-29(23)26)20-28(38)35-16-6-11-22-8-1-2-13-25(22)35/h1-5,7-10,12-15,17-18,40H,6,11,16,19-20H2,(H2,32,34,39)/b33-18-
DMUFLNT	CS	C1CC2=CC=CC=C2N(C1)C(=O)CN(C3=CC=CC4=C3N=CC=C4)C(=O)CNC(=O)NC5=CC=CC(=C5)/C=N\\O
DMUFLNT	IK	MKQFGVTYYCUUEG-OHUYPAJKSA-N
DMUFLNT	IU	N-[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]-2-[[3-[(Z)-hydroxyiminomethyl]phenyl]carbamoylamino]-N-quinolin-8-ylacetamide
DMUFLNT	DE	Discovery agent

DMWIXQS	ID	DMWIXQS
DMWIXQS	DN	RP-72540
DMWIXQS	HS	Investigative
DMWIXQS	SN	139088-45-2
DMWIXQS	DE	Discovery agent

DMLKPZ6	ID	DMLKPZ6
DMLKPZ6	DN	RP73870
DMLKPZ6	HS	Investigative
DMLKPZ6	SN	RP 73870
DMLKPZ6	DT	Small molecular drug
DMLKPZ6	PC	5311414
DMLKPZ6	MW	554.6
DMLKPZ6	FM	C27H30N4O7S
DMLKPZ6	IC	InChI=1S/C27H30N4O7S/c1-30(22-10-4-3-5-11-22)26(33)19-31(23-12-7-13-24(17-23)38-2)25(32)18-28-27(34)29-21-9-6-8-20(16-21)14-15-39(35,36)37/h3-13,16-17H,14-15,18-19H2,1-2H3,(H2,28,29,34)(H,35,36,37)
DMLKPZ6	CS	CN(C1=CC=CC=C1)C(=O)CN(C2=CC(=CC=C2)OC)C(=O)CNC(=O)NC3=CC=CC(=C3)CCS(=O)(=O)O
DMLKPZ6	IK	NGZMTMPEGDUWJQ-UHFFFAOYSA-N
DMLKPZ6	IU	2-[3-[[2-(3-methoxy-N-[2-(N-methylanilino)-2-oxoethyl]anilino)-2-oxoethyl]carbamoylamino]phenyl]ethanesulfonic acid
DMLKPZ6	DE	Discovery agent

DMJMC43	ID	DMJMC43
DMJMC43	DN	Rp-8-CPT-cGMPS
DMJMC43	HS	Investigative
DMJMC43	SN	Rp-8-[(4-chlorophenyl)thio]-guanosine-cyclic 3',5'-hydrogen phosphorothioate
DMJMC43	DT	Small molecular drug
DMJMC43	PC	136218972
DMJMC43	MW	504.9
DMJMC43	FM	C16H16ClN5O6PS2+
DMJMC43	IC	InChI=1S/C16H15ClN5O6PS2/c17-6-1-3-7(4-2-6)31-16-19-9-12(20-15(18)21-13(9)24)22(16)14-10(23)11-8(27-14)5-26-29(25,30)28-11/h1-4,8,10-11,14,23,25,30H,5H2,(H2-,18,20,21,24)/p+1/t8-,10+,11?,14?,29?/m1/s1
DMJMC43	CS	C1[C@@H]2C([C@@H](C(O2)N3C4=C(C(=O)NC(=N4)N)N=C3SC5=CC=C(C=C5)Cl)O)O[P+](O1)(O)S
DMJMC43	IK	OUBFBEIDDZMLBN-MXSLEPDVSA-O
DMJMC43	IU	9-[(4aR,7S)-2,7-dihydroxy-2-sulfanyl-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-ium-6-yl]-2-amino-8-(4-chlorophenyl)sulfanyl-1H-purin-6-one
DMJMC43	DE	Discovery agent

DM1JWGH	ID	DM1JWGH
DM1JWGH	DN	Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS)
DM1JWGH	HS	Investigative
DM1JWGH	SN	Rp-cAMPS triethylamine; Rp-Adenosine 3',5'-cyclic monophosphothioate triethylamine
DM1JWGH	DT	Small molecular drug
DM1JWGH	PC	45114047
DM1JWGH	MW	446.5
DM1JWGH	FM	C16H27N6O5PS
DM1JWGH	IC	InChI=1S/C10H12N5O5PS.C6H15N/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(19-10)1-18-21(17,22)20-7;1-4-7(5-2)6-3/h2-4,6-7,10,16H,1H2,(H,17,22)(H2,11,12,13);4-6H2,1-3H3/t4?,6-,7-,10?,21?;/m0./s1
DM1JWGH	CS	CC[NH+](CC)CC.C1C2[C@@H]([C@@H](C(O2)N3C=NC4=C(N=CN=C43)N)O)OP(=S)(O1)[O-]
DM1JWGH	IK	OXIPZMKSNMRTIV-NOFBKVLNSA-N
DM1JWGH	IU	(7S,7aR)-6-(6-aminopurin-9-yl)-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol;triethylazanium
DM1JWGH	DE	Discovery agent

DMG0S9B	ID	DMG0S9B
DMG0S9B	DN	Rp-cAMPS
DMG0S9B	HS	Investigative
DMG0S9B	SN	adenosine- 3', 5'- cyclic monophosphorothioate, Rp- isomer
DMG0S9B	DT	Small molecular drug
DMG0S9B	PC	16072219
DMG0S9B	MW	446.5
DMG0S9B	FM	C16H27N6O5PS
DMG0S9B	IC	InChI=1S/C10H12N5O5PS.C6H15N/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(19-10)1-18-21(17,22)20-7;1-4-7(5-2)6-3/h2-4,6-7,10,16H,1H2,(H,17,22)(H2,11,12,13);4-6H2,1-3H3
DMG0S9B	CS	CCN(CC)CC.C1C2C(C(C(O2)N3C=NC4=C(N=CN=C43)N)O)OP(=S)(O1)O
DMG0S9B	IK	OXIPZMKSNMRTIV-UHFFFAOYSA-N
DMG0S9B	IU	6-(6-aminopurin-9-yl)-2-hydroxy-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol;N,N-diethylethanamine
DMG0S9B	DE	Discovery agent

DMAROTU	ID	DMAROTU
DMAROTU	DN	RPKPfQwFwLL-NH2
DMAROTU	HS	Investigative
DMAROTU	SN	96736-12-8; Antagonist D; [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P; CHEMBL501261; D-Arg-Pro-Lys-Pro-D-Phe-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2; [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-Substance P; rPKPfQwFwLL-NH2; MFCD00076802; BDBM50260268; AKOS024456872; CA-1583; [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-Substance P, &gt; (D-Arg1,D-Phe5,D-Trp7 inverted exclamation mark currency9,Leu11)-Substance P
DMAROTU	PC	25091011
DMAROTU	MW	1516.8
DMAROTU	FM	C79H109N19O12
DMAROTU	IC	InChI=1S/C79H109N19O12/c1-46(2)38-59(68(83)100)91-70(102)60(39-47(3)4)92-73(105)64(43-51-45-88-56-28-14-12-25-53(51)56)95-72(104)61(40-48-20-7-5-8-21-48)93-74(106)63(42-50-44-87-55-27-13-11-24-52(50)55)94-69(101)57(32-33-67(82)99)89-71(103)62(41-49-22-9-6-10-23-49)96-76(108)66-31-19-37-98(66)78(110)58(29-15-16-34-80)90-75(107)65-30-18-36-97(65)77(109)54(81)26-17-35-86-79(84)85/h5-14,20-25,27-28,44-47,54,57-66,87-88H,15-19,26,29-43,80-81H2,1-4H3,(H2,82,99)(H2,83,100)(H,89,103)(H,90,107)(H,91,102)(H,92,105)(H,93,106)(H,94,101)(H,95,104)(H,96,108)(H4,84,85,86)/t54-,57+,58+,59+,60+,61+,62-,63-,64-,65+,66+/m1/s1
DMAROTU	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H](CC6=CC=CC=C6)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCCN)NC(=O)[C@@H]8CCCN8C(=O)[C@@H](CCCN=C(N)N)N
DMAROTU	IK	XVOCEQLNJQGCQG-ACRSGXKRSA-N
DMAROTU	IU	(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMAROTU	DE	Discovery agent

DM0HD3O	ID	DM0HD3O
DM0HD3O	DN	RPR-101511
DM0HD3O	HS	Investigative
DM0HD3O	SN	RPR-101511; CHEMBL66643; 6,7-Dimethoxy-3-(3-thienyl)quinoline; 3-(3-Thienyl)-6,7-dimethoxyquinoline; 6,7-dimethoxy-3-thiophen-3-yl-quinoline; 146535-06-0; SCHEMBL8172666; ZINC8075; BDBM50039082
DM0HD3O	DT	Small molecular drug
DM0HD3O	PC	9903563
DM0HD3O	MW	271.3
DM0HD3O	FM	C15H13NO2S
DM0HD3O	IC	InChI=1S/C15H13NO2S/c1-17-14-6-11-5-12(10-3-4-19-9-10)8-16-13(11)7-15(14)18-2/h3-9H,1-2H3
DM0HD3O	CS	COC1=CC2=CC(=CN=C2C=C1OC)C3=CSC=C3
DM0HD3O	IK	KGGRQYJJHXVWSI-UHFFFAOYSA-N
DM0HD3O	IU	6,7-dimethoxy-3-thiophen-3-ylquinoline
DM0HD3O	DE	Discovery agent

DM9ODEZ	ID	DM9ODEZ
DM9ODEZ	DN	RPR-107836
DM9ODEZ	HS	Investigative
DM9ODEZ	SN	IDDB8561
DM9ODEZ	CP	Rhone-Poulenc Rorer Inc
DM9ODEZ	DE	Anxiety disorder

DM37I92	ID	DM37I92
DM37I92	DN	RPR-108514A
DM37I92	HS	Investigative
DM37I92	SN	CHEMBL543669; RPR-108514A
DM37I92	DT	Small molecular drug
DM37I92	PC	18770833
DM37I92	MW	331.8
DM37I92	FM	C17H18ClN3O2
DM37I92	IC	InChI=1S/C17H17N3O2.ClH/c1-20(12-7-5-4-6-8-12)17-13-9-15(21-2)16(22-3)10-14(13)18-11-19-17;/h4-11H,1-3H3;1H
DM37I92	CS	CN(C1=CC=CC=C1)C2=NC=NC3=CC(=C(C=C32)OC)OC.Cl
DM37I92	IK	LPXMNVUTNCZLBT-UHFFFAOYSA-N
DM37I92	IU	6,7-dimethoxy-N-methyl-N-phenylquinazolin-4-amine;hydrochloride
DM37I92	DE	Discovery agent

DMJ6RZI	ID	DMJ6RZI
DMJ6RZI	DN	RPR-108518A
DMJ6RZI	HS	Investigative
DMJ6RZI	SN	CHEMBL543904
DMJ6RZI	DT	Small molecular drug
DMJ6RZI	PC	5330462
DMJ6RZI	MW	371.4
DMJ6RZI	FM	C19H21N3O5
DMJ6RZI	IC	InChI=1S/C19H21N3O5/c1-23-14-8-12-13(9-15(14)24-2)20-10-21-19(12)22-11-6-16(25-3)18(27-5)17(7-11)26-4/h6-10H,1-5H3,(H,20,21,22)
DMJ6RZI	CS	COC1=CC(=CC(=C1OC)OC)NC2=NC=NC3=CC(=C(C=C32)OC)OC
DMJ6RZI	IK	RNCVPFCGSMNPPO-UHFFFAOYSA-N
DMJ6RZI	IU	6,7-dimethoxy-N-(3,4,5-trimethoxyphenyl)quinazolin-4-amine
DMJ6RZI	DE	Discovery agent

DM61VHF	ID	DM61VHF
DM61VHF	DN	RPR-118071
DM61VHF	HS	Investigative
DM61VHF	SN	RPR-118071; CHEMBL93796; 186546-85-0; Benzenecarboximidamide,3-[[(3S)-3-[(2-naphthalenylsulfonyl)amino]-2-oxo-1-pyrrolidinyl]methyl]-; BDBM50080477; ZINC13800223; KB-75023; 3-[3-((S)-Naphthalene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-benzamidine; 3-[[3beta-[[(2-Naphthyl)sulfonyl]amino]-2-oxopyrrolizino]methyl]benzamidine
DM61VHF	DT	Small molecular drug
DM61VHF	PC	10574241
DM61VHF	MW	422.5
DM61VHF	FM	C22H22N4O3S
DM61VHF	IC	InChI=1S/C22H22N4O3S/c23-21(24)18-7-3-4-15(12-18)14-26-11-10-20(22(26)27)25-30(28,29)19-9-8-16-5-1-2-6-17(16)13-19/h1-9,12-13,20,25H,10-11,14H2,(H3,23,24)/t20-/m0/s1
DM61VHF	CS	C1CN(C(=O)[C@H]1NS(=O)(=O)C2=CC3=CC=CC=C3C=C2)CC4=CC(=CC=C4)C(=N)N
DM61VHF	IK	NTFWSCPFRKNWEI-FQEVSTJZSA-N
DM61VHF	IU	3-[[(3S)-3-(naphthalen-2-ylsulfonylamino)-2-oxopyrrolidin-1-yl]methyl]benzenecarboximidamide
DM61VHF	DE	Discovery agent

DMLDWCB	ID	DMLDWCB
DMLDWCB	DN	RPR-118723
DMLDWCB	HS	Investigative
DMLDWCB	SN	RPR-118723; CHEMBL80649
DMLDWCB	DT	Small molecular drug
DMLDWCB	PC	9796571
DMLDWCB	MW	306.7
DMLDWCB	FM	C14H11ClN2O4
DMLDWCB	IC	InChI=1S/C14H11ClN2O4/c1-14(5-9(18)19)8-3-2-6(15)4-7(8)10-11(14)17-13(21)12(20)16-10/h2-4H,5H2,1H3,(H,16,20)(H,17,21)(H,18,19)
DMLDWCB	CS	CC1(C2=C(C=C(C=C2)Cl)C3=C1NC(=O)C(=O)N3)CC(=O)O
DMLDWCB	IK	XNLOOYJBLRHTMX-UHFFFAOYSA-N
DMLDWCB	IU	2-(6-chloro-9-methyl-2,3-dioxo-1,4-dihydroindeno[2,3-b]pyrazin-9-yl)acetic acid
DMLDWCB	DE	Discovery agent

DM1V0MD	ID	DM1V0MD
DM1V0MD	DN	RPR-120844
DM1V0MD	HS	Investigative
DM1V0MD	SN	RPR-120844; RPR120844; sulfonamidopyrrolidinone; CHEMBL84638; CHEMBL331943; BDBM13279; 4-{[(3S)-3-[(7-methoxynaphthalene-2-)(methyl)sulfonamido]-2-oxopyrrolidin-1-yl]methyl}thiophene-2-carboximidamide
DM1V0MD	DT	Small molecular drug
DM1V0MD	PC	10322586
DM1V0MD	MW	472.6
DM1V0MD	FM	C22H24N4O4S2
DM1V0MD	IC	InChI=1S/C22H24N4O4S2/c1-25(19-7-8-26(22(19)27)12-14-9-20(21(23)24)31-13-14)32(28,29)18-6-4-15-3-5-17(30-2)10-16(15)11-18/h3-6,9-11,13,19H,7-8,12H2,1-2H3,(H3,23,24)/t19-/m0/s1
DM1V0MD	CS	CN([C@H]1CCN(C1=O)CC2=CSC(=C2)C(=N)N)S(=O)(=O)C3=CC4=C(C=CC(=C4)OC)C=C3
DM1V0MD	IK	YQYYTNCSSDRJHZ-IBGZPJMESA-N
DM1V0MD	IU	4-[[(3S)-3-[(7-methoxynaphthalen-2-yl)sulfonyl-methylamino]-2-oxopyrrolidin-1-yl]methyl]thiophene-2-carboximidamide
DM1V0MD	DE	Discovery agent

DM9DXHM	ID	DM9DXHM
DM9DXHM	DN	RPR121154
DM9DXHM	HS	Investigative
DM9DXHM	SN	RPR-121154
DM9DXHM	DT	Small molecular drug
DM9DXHM	PC	10020451
DM9DXHM	MW	345.4
DM9DXHM	FM	C22H23N3O
DM9DXHM	IC	InChI=1S/C22H23N3O/c1-24-22(23)25-19-12-13-21(20(16-19)18-10-6-3-7-11-18)26-15-14-17-8-4-2-5-9-17/h2-13,16H,14-15H2,1H3,(H3,23,24,25)
DM9DXHM	CS	CN=C(N)NC1=CC(=C(C=C1)OCCC2=CC=CC=C2)C3=CC=CC=C3
DM9DXHM	IK	QXDMVRPQHNFBSZ-UHFFFAOYSA-N
DM9DXHM	IU	2-methyl-1-[3-phenyl-4-(2-phenylethoxy)phenyl]guanidine
DM9DXHM	DE	Discovery agent

DM4T2R3	ID	DM4T2R3
DM4T2R3	DN	RPR260243
DM4T2R3	HS	Investigative
DM4T2R3	SN	RPR-260243; RPR 260243
DM4T2R3	DT	Small molecular drug
DM4T2R3	PC	11466357
DM4T2R3	MW	510.5
DM4T2R3	FM	C28H25F3N2O4
DM4T2R3	IC	InChI=1S/C28H25F3N2O4/c1-37-20-5-6-25-22(15-20)21(8-10-32-25)26(34)7-4-17-9-12-33(16-23(17)28(35)36)11-2-3-18-13-19(29)14-24(30)27(18)31/h5-6,8,10,13-15,17,23H,4,7,9,11-12,16H2,1H3,(H,35,36)/t17-,23+/m1/s1
DM4T2R3	CS	COC1=CC2=C(C=CN=C2C=C1)C(=O)CC[C@@H]3CCN(C[C@@H]3C(=O)O)CC#CC4=C(C(=CC(=C4)F)F)F
DM4T2R3	IK	VWNMWKSURFWKAL-HXOBKFHXSA-N
DM4T2R3	IU	(3R,4R)-4-[3-(6-methoxyquinolin-4-yl)-3-oxopropyl]-1-[3-(2,3,5-trifluorophenyl)prop-2-ynyl]piperidine-3-carboxylic acid
DM4T2R3	CA	CAS 668463-35-2
DM4T2R3	DE	Discovery agent

DM4LTE3	ID	DM4LTE3
DM4LTE3	DN	R-PSOP
DM4LTE3	HS	Investigative
DM4LTE3	SN	R-PSOP; GTPL3524
DM4LTE3	DT	Small molecular drug
DM4LTE3	PC	73755058
DM4LTE3	MW	350.4
DM4LTE3	FM	C20H22N4O2
DM4LTE3	IC	InChI=1S/C20H22N4O2/c25-19(22-16-4-2-1-3-5-16)23-17-10-14-11-20(26-18(14)21-12-17)13-24-8-6-15(20)7-9-24/h1-5,10,12,15H,6-9,11,13H2,(H2,22,23,25)/t20-/m0/s1
DM4LTE3	CS	C1CN2CCC1[C@@]3(C2)CC4=C(O3)N=CC(=C4)NC(=O)NC5=CC=CC=C5
DM4LTE3	IK	BUOWEYLLAFLKCW-FQEVSTJZSA-N
DM4LTE3	IU	1-phenyl-3-[(3R)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3H-furo[2,3-b]pyridine]-5'-yl]urea
DM4LTE3	DE	Discovery agent

DMP9V7U	ID	DMP9V7U
DMP9V7U	DN	RQ-00000008
DMP9V7U	HS	Investigative
DMP9V7U	SN	CJ-042794; Prostaglandin EP4 antagonists (chronic inflammatory pain), Pfizer; Prostaglandin EP4 antagonists (chronic inflammatory pain), RaQualia
DMP9V7U	CP	Pfizer Inc
DMP9V7U	DT	Small molecular drug
DMP9V7U	PC	11524454
DMP9V7U	MW	413.8
DMP9V7U	FM	C22H17ClFNO4
DMP9V7U	IC	InChI=1S/C22H17ClFNO4/c1-13(14-2-4-15(5-3-14)22(27)28)25-21(26)19-12-16(23)6-11-20(19)29-18-9-7-17(24)8-10-18/h2-13H,1H3,(H,25,26)(H,27,28)/t13-/m0/s1
DMP9V7U	CS	C[C@@H](C1=CC=C(C=C1)C(=O)O)NC(=O)C2=C(C=CC(=C2)Cl)OC3=CC=C(C=C3)F
DMP9V7U	IK	MWBNCZHVEXULBD-ZDUSSCGKSA-N
DMP9V7U	IU	4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]benzoic acid
DMP9V7U	CA	CAS 847728-01-2
DMP9V7U	DE	Inflammation

DMLN280	ID	DMLN280
DMLN280	DN	RQ-00000010
DMLN280	HS	Investigative
DMLN280	SN	CJ-033466; PF-01354082; RQ-10; 5-HT 4 receptor partial agonist (GERD), RaQualia; 5-HT4 receptor partial agonist (gastric motility disorder), Pfizer; 5-hydroxytryptamine 4 receptor partial agonist (gastric motility disorder), Pfizer; 5-hydroxytryptamine 4 receptor partial agonist (gastroesophageal reflux), RaQualia
DMLN280	CP	Pfizer Inc
DMLN280	DE	Gastric motility disorder

DM4T8KV	ID	DM4T8KV
DM4T8KV	DN	RQ-00201894
DM4T8KV	HS	Investigative
DM4T8KV	SN	Motilin receptor agonists (GERD), RaQualia; Motilin receptor agonists (gastroesophageal reflux), RaQualia
DM4T8KV	CP	RaQualia Pharma Inc
DM4T8KV	DE	Gastroesophageal reflux disease

DMTD3O8	ID	DMTD3O8
DMTD3O8	DN	RQ-00202730
DMTD3O8	HS	Investigative
DMTD3O8	SN	Cannabinoid CB2 agonists (IBS/IBD, oral), RaQualia
DMTD3O8	CP	RaQualia Pharma Inc
DMTD3O8	DE	Inflammatory bowel disease

DMAIOQB	ID	DMAIOQB
DMAIOQB	DN	RQ-00203066
DMAIOQB	HS	Investigative
DMAIOQB	SN	Nav1.3 antagonists (pain), RaQualia
DMAIOQB	CP	RaQualia Pharma Inc
DMAIOQB	DE	Pain

DM83THZ	ID	DM83THZ
DM83THZ	DN	RQ-00203078
DM83THZ	HS	Investigative
DM83THZ	SN	TRPM8 antagonists (pain), RaQualia Pharma
DM83THZ	CP	RaQualia Pharma Inc
DM83THZ	PC	49783953
DM83THZ	MW	554.8
DM83THZ	FM	C21H13ClF6N2O5S
DM83THZ	IC	InChI=1S/C21H13ClF6N2O5S/c22-17-9-14(20(23,24)25)10-29-18(17)30(11-12-1-5-15(6-2-12)35-21(26,27)28)36(33,34)16-7-3-13(4-8-16)19(31)32/h1-10H,11H2,(H,31,32)
DM83THZ	CS	C1=CC(=CC=C1CN(C2=C(C=C(C=N2)C(F)(F)F)Cl)S(=O)(=O)C3=CC=C(C=C3)C(=O)O)OC(F)(F)F
DM83THZ	IK	IJGQFZYYEHCCIZ-UHFFFAOYSA-N
DM83THZ	IU	4-[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-[[4-(trifluoromethoxy)phenyl]methyl]sulfamoyl]benzoic acid
DM83THZ	DE	Neuropathic pain

DMYK6OU	ID	DMYK6OU
DMYK6OU	DN	RQ-00310941
DMYK6OU	HS	Investigative
DMYK6OU	SN	RQ-00202065; 5-HT 2b antagonists (oral, IBS), RaQualia; 5-HT 2b antagonists (oral, irritable bowel syndrome), RaQualia
DMYK6OU	CP	RaQualia Pharma Inc
DMYK6OU	DE	Irritable bowel syndrome

DMP9RLE	ID	DMP9RLE
DMP9RLE	DN	RR(17)PZ
DMP9RLE	HS	Investigative
DMP9RLE	SN	CHEMBL220095; RR(17)PZ
DMP9RLE	PC	10463948
DMP9RLE	MW	1122.4
DMP9RLE	FM	C57H71N9O11S2
DMP9RLE	IC	InChI=1S/C57H71N9O11S2/c1-5-64(6-2)41-19-22-45-50(37-41)77-51-38-42(65(7-3)8-4)20-23-46(51)55(45)47-24-21-43(39-52(47)79(72,73)74)78(70,71)60-26-13-9-10-18-53(67)58-27-33-75-35-36-76-34-32-62-28-30-63(31-29-62)40-54(68)66-49-17-12-11-15-44(49)57(69)61-48-16-14-25-59-56(48)66/h11-12,14-17,19-25,37-39,60H,5-10,13,18,26-36,40H2,1-4H3,(H2-,58,61,67,69,72,73,74)
DMP9RLE	CS	CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCC(=O)NCCOCCOCCN5CCN(CC5)CC(=O)N6C7=CC=CC=C7C(=O)NC8=C6N=CC=C8)S(=O)(=O)[O-]
DMP9RLE	IK	ZILZAZLHMFYYBB-UHFFFAOYSA-N
DMP9RLE	IU	2-[3-(diethylamino)-6-diethylazaniumylidenexanthen-9-yl]-5-[[6-oxo-6-[2-[2-[2-[4-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]piperazin-1-yl]ethoxy]ethoxy]ethylamino]hexyl]sulfamoyl]benzenesulfonate
DMP9RLE	DE	Discovery agent

DM32ZIC	ID	DM32ZIC
DM32ZIC	DN	RS 100235
DM32ZIC	HS	Investigative
DM32ZIC	SN	RS100235; RS-100235
DM32ZIC	DT	Small molecular drug
DM32ZIC	PC	5311416
DM32ZIC	MW	503
DM32ZIC	FM	C27H35ClN2O5
DM32ZIC	IC	InChI=1S/C27H35ClN2O5/c1-32-23-8-6-19(16-24(23)33-2)4-3-11-30-12-9-18(10-13-30)5-7-22(31)20-17-21(28)25(29)27-26(20)34-14-15-35-27/h6,8,16-18H,3-5,7,9-15,29H2,1-2H3
DM32ZIC	CS	COC1=C(C=C(C=C1)CCCN2CCC(CC2)CCC(=O)C3=CC(=C(C4=C3OCCO4)N)Cl)OC
DM32ZIC	IK	UVOCSZKGWJOKNN-UHFFFAOYSA-N
DM32ZIC	IU	1-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-[1-[3-(3,4-dimethoxyphenyl)propyl]piperidin-4-yl]propan-1-one
DM32ZIC	DE	Discovery agent

DMX9W0T	ID	DMX9W0T
DMX9W0T	DN	RS 116 0086
DMX9W0T	HS	Investigative
DMX9W0T	SN	RO 116 0086; RO 116-0086; RS 116-0086
DMX9W0T	DT	Small molecular drug
DMX9W0T	PC	10404587
DMX9W0T	MW	333.4
DMX9W0T	FM	C19H27NO4
DMX9W0T	IC	InChI=1S/C19H27NO4/c1-2-3-9-20-10-7-15(8-11-20)14-24-19(21)16-5-4-6-17-18(16)23-13-12-22-17/h4-6,15H,2-3,7-14H2,1H3
DMX9W0T	CS	CCCCN1CCC(CC1)COC(=O)C2=C3C(=CC=C2)OCCO3
DMX9W0T	IK	YGXXLNHVBNARBP-UHFFFAOYSA-N
DMX9W0T	IU	(1-butylpiperidin-4-yl)methyl 2,3-dihydro-1,4-benzodioxine-5-carboxylate
DMX9W0T	DE	Discovery agent

DMD91WS	ID	DMD91WS
DMD91WS	DN	RS 57639
DMD91WS	HS	Investigative
DMD91WS	SN	AJVNZBQUOHOEQO-UHFFFAOYSA-N; RS57639; RS-57639; [1-[3-(2,3-dihydro-1,4-benzodioxin-7-yl)propyl]piperidin-4-yl]methyl 4-amino-5-chloro-2-methoxybenzoate; [3H]RS 57639; AC1NSKL9; GTPL236; GTPL239; PDSP1_001584; PDSP2_001568; [1-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)propyl]piperidin-4-yl]methyl;  RS57639
DMD91WS	DT	Small molecular drug
DMD91WS	PC	5311417
DMD91WS	MW	475
DMD91WS	FM	C25H31ClN2O5
DMD91WS	IC	InChI=1S/C25H31ClN2O5/c1-30-23-15-21(27)20(26)14-19(23)25(29)33-16-18-6-9-28(10-7-18)8-2-3-17-4-5-22-24(13-17)32-12-11-31-22/h4-5,13-15,18H,2-3,6-12,16,27H2,1H3
DMD91WS	CS	COC1=CC(=C(C=C1C(=O)OCC2CCN(CC2)CCCC3=CC4=C(C=C3)OCCO4)Cl)N
DMD91WS	IK	AJVNZBQUOHOEQO-UHFFFAOYSA-N
DMD91WS	IU	[1-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)propyl]piperidin-4-yl]methyl 4-amino-5-chloro-2-methoxybenzoate
DMD91WS	DE	Discovery agent

DMO7G94	ID	DMO7G94
DMO7G94	DN	RS 67333
DMO7G94	HS	Investigative
DMO7G94	SN	RS-67333
DMO7G94	DT	Small molecular drug
DMO7G94	PC	183782
DMO7G94	MW	352.9
DMO7G94	FM	C19H29ClN2O2
DMO7G94	IC	InChI=1S/C19H29ClN2O2/c1-3-4-9-22-10-7-14(8-11-22)5-6-18(23)15-12-16(20)17(21)13-19(15)24-2/h12-14H,3-11,21H2,1-2H3
DMO7G94	CS	CCCCN1CCC(CC1)CCC(=O)C2=CC(=C(C=C2OC)N)Cl
DMO7G94	IK	JBHLYIVFFLNISJ-UHFFFAOYSA-N
DMO7G94	IU	1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-butylpiperidin-4-yl)propan-1-one
DMO7G94	CA	CAS 160845-95-4
DMO7G94	CB	CHEBI:92807
DMO7G94	DE	Discovery agent

DM8SGTQ	ID	DM8SGTQ
DM8SGTQ	DN	RS 93520
DM8SGTQ	HS	Investigative
DM8SGTQ	SN	RS 93427-007 ; RS-93520
DM8SGTQ	DT	Small molecular drug
DM8SGTQ	PC	6438966
DM8SGTQ	MW	346.5
DM8SGTQ	FM	C21H30O4
DM8SGTQ	IC	InChI=1S/C21H30O4/c22-19(14-5-2-1-3-6-14)11-10-17-18-13-15(7-4-8-21(24)25)16(18)9-12-20(17)23/h7,14,16-20,22-23H,1-6,8-9,12-13H2,(H,24,25)/b15-7+/t16-,17-,18-,19+,20-/m0/s1
DM8SGTQ	CS	C1CCC(CC1)[C@@H](C#C[C@@H]2[C@H](CC[C@@H]\\3[C@@H]2C/C3=C\\CCC(=O)O)O)O
DM8SGTQ	IK	LOWIKMYPLIPDBI-VQWMHQLJSA-N
DM8SGTQ	IU	(4E)-4-[(1S,2R,3S,6R)-2-[(3S)-3-cyclohexyl-3-hydroxyprop-1-ynyl]-3-hydroxy-7-bicyclo[4.2.0]octanylidene]butanoic acid
DM8SGTQ	CA	CAS 105284-21-7
DM8SGTQ	DE	Discovery agent

DM63NGW	ID	DM63NGW
DM63NGW	DN	RS-100302
DM63NGW	HS	Investigative
DM63NGW	SN	UNII-XX514BJ1XW; XX514BJ1XW; 120788-07-0; Sulopenem [USAN:INN]; AC1OCF0J; SCHEMBL73397; FLSUCZWOEMTFAQ-IIOOQZKLSA-N; (5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-(((3S)-tetrahydro-3-thienyl)thio)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, (R)-S-oxide; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-((tetrahydro-3-thie
DM63NGW	CP	Roche
DM63NGW	DT	Small molecular drug
DM63NGW	PC	9805252
DM63NGW	MW	446
DM63NGW	FM	C19H28ClN3O5S
DM63NGW	IC	InChI=1S/C19H28ClN3O5S/c1-29(25,26)22-6-9-23-7-4-13(5-8-23)2-3-16(24)14-12-15(20)17(21)19-18(14)27-10-11-28-19/h12-13,22H,2-11,21H2,1H3
DM63NGW	CS	CS(=O)(=O)NCCN1CCC(CC1)CCC(=O)C2=CC(=C(C3=C2OCCO3)N)Cl
DM63NGW	IK	NBUGBCTWXCXBQD-UHFFFAOYSA-N
DM63NGW	IU	N-[2-[4-[3-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-oxopropyl]piperidin-1-yl]ethyl]methanesulfonamide
DM63NGW	CA	CAS 219757-90-1
DM63NGW	DE	Atrial fibrillation

DMDKC0J	ID	DMDKC0J
DMDKC0J	DN	RS-100329
DMDKC0J	HS	Investigative
DMDKC0J	SN	RS-100329; CHEMBL56331; RS 100329; 5-methyl-3-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1H-pyrimidine-2,4-dione; 3-(3-{4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl}propyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 3-{3-[4-(2-(2,2,2-trifluoroethoxy)phenyl)piperazin-1-yl]propyl}-5-methyl-2,4(1H,3H)-pyrimidinedione; AC1MSYDZ; Tocris-1325; NCGC00025113-01; SCHEMBL6802383; GTPL7381; CHEBI:92149; RCOBWVAGWYRNHZ-UHFFFAOYSA-N; ZINC601958; BDBM50160161; SR-01000597403; SR-01000597403-1; BRD-K08640512-003-01-5
DMDKC0J	DT	Small molecular drug
DMDKC0J	PC	3567002
DMDKC0J	MW	426.4
DMDKC0J	FM	C20H25F3N4O3
DMDKC0J	IC	InChI=1S/C20H25F3N4O3/c1-15-13-24-19(29)27(18(15)28)8-4-7-25-9-11-26(12-10-25)16-5-2-3-6-17(16)30-14-20(21,22)23/h2-3,5-6,13H,4,7-12,14H2,1H3,(H,24,29)
DMDKC0J	CS	CC1=CNC(=O)N(C1=O)CCCN2CCN(CC2)C3=CC=CC=C3OCC(F)(F)F
DMDKC0J	IK	RCOBWVAGWYRNHZ-UHFFFAOYSA-N
DMDKC0J	IU	5-methyl-3-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1H-pyrimidine-2,4-dione
DMDKC0J	CA	CAS 232953-52-5
DMDKC0J	CB	CHEBI:92149
DMDKC0J	DE	Discovery agent

DMHDYBN	ID	DMHDYBN
DMHDYBN	DN	RS-102,221
DMHDYBN	HS	Investigative
DMHDYBN	SN	RS-102221; RS102221; 185376-97-0; RS 102221 HCl; Tocris-1050; RS-102,221; Biomol-NT_000133; AC1MW45U; GTPL187; CHEMBL88402; SCHEMBL7107338; BPBio1_000243; RS102221 HCl; CHEBI:93519; BDBM85098; HZZZZODVDSHQRG-UHFFFAOYSA-N; BCP03496; ZINC26580328; PDSP1_001633; PDSP2_001617; NCGC00024967-02; NCGC00024967-01; L000523; BRD-K87048468-003-01-9; N-{5-[5-(2,4-dioxo -1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl}-4-trifluoromethylbenzenesulfonamide
DMHDYBN	DT	Small molecular drug
DMHDYBN	PC	3693566
DMHDYBN	MW	612.6
DMHDYBN	FM	C27H31F3N4O7S
DMHDYBN	IC	InChI=1S/C27H31F3N4O7S/c1-40-22-16-23(41-2)20(33-42(38,39)18-8-6-17(7-9-18)27(28,29)30)15-19(22)21(35)5-3-4-12-34-13-10-26(11-14-34)24(36)31-25(37)32-26/h6-9,15-16,33H,3-5,10-14H2,1-2H3,(H2,31,32,36,37)
DMHDYBN	CS	COC1=CC(=C(C=C1C(=O)CCCCN2CCC3(CC2)C(=O)NC(=O)N3)NS(=O)(=O)C4=CC=C(C=C4)C(F)(F)F)OC
DMHDYBN	IK	HZZZZODVDSHQRG-UHFFFAOYSA-N
DMHDYBN	IU	N-[5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)pentanoyl]-2,4-dimethoxyphenyl]-4-(trifluoromethyl)benzenesulfonamide
DMHDYBN	CA	CAS 185376-97-0
DMHDYBN	CB	CHEBI:93519
DMHDYBN	DE	Discovery agent

DMF71B3	ID	DMF71B3
DMF71B3	DN	RS-102895
DMF71B3	HS	Investigative
DMF71B3	SN	RS102895; RS-102895; GTPL779; SCHEMBL9972649; CHEMBL1593104; CHEBI:93458; ZINC2563946; BCP05302; HY-18611A; AKOS030526775; CS-3487; NCGC00092306-02; AJ-40982; KB-62464; BRD-K83063356-003-01-7; 1'-[2-[4-(trifluoromethyl)phenyl]ethyl]spiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one; 1-(4-(Trifluoromethyl)phenethyl)spiro[benzo[d][1,3]oxazine-4,4-piperidin]-2(1H)-one hydrochloride
DMF71B3	DT	Small molecular drug
DMF71B3	PC	10000456
DMF71B3	MW	390.4
DMF71B3	FM	C21H21F3N2O2
DMF71B3	IC	InChI=1S/C21H21F3N2O2/c22-21(23,24)16-7-5-15(6-8-16)9-12-26-13-10-20(11-14-26)17-3-1-2-4-18(17)25-19(27)28-20/h1-8H,9-14H2,(H,25,27)
DMF71B3	CS	C1CN(CCC12C3=CC=CC=C3NC(=O)O2)CCC4=CC=C(C=C4)C(F)(F)F
DMF71B3	IK	HIDWEYPGMLIQSN-UHFFFAOYSA-N
DMF71B3	IU	1'-[2-[4-(trifluoromethyl)phenyl]ethyl]spiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one
DMF71B3	CB	CHEBI:93458
DMF71B3	DE	Discovery agent

DMEHN2L	ID	DMEHN2L
DMEHN2L	DN	RS-136270
DMEHN2L	HS	Investigative
DMEHN2L	SN	RS-136270; 1-[(3-chlorophenyl)methyl]pyrrole-2-carboxylic Acid; AC1NNKLD; GTPL780; SCHEMBL12951306; AKOS011823849
DMEHN2L	DT	Small molecular drug
DMEHN2L	PC	5071702
DMEHN2L	MW	235.66
DMEHN2L	FM	C12H10ClNO2
DMEHN2L	IC	InChI=1S/C12H10ClNO2/c13-10-4-1-3-9(7-10)8-14-6-2-5-11(14)12(15)16/h1-7H,8H2,(H,15,16)
DMEHN2L	CS	C1=CC(=CC(=C1)Cl)CN2C=CC=C2C(=O)O
DMEHN2L	IK	VPTUTBZAHHDMAA-UHFFFAOYSA-N
DMEHN2L	IU	1-[(3-chlorophenyl)methyl]pyrrole-2-carboxylic acid
DMEHN2L	CA	CAS 702670-05-1
DMEHN2L	DE	Discovery agent

DMRW57G	ID	DMRW57G
DMRW57G	DN	RS-14491
DMRW57G	HS	Investigative
DMRW57G	SN	RS-14491; SCHEMBL7364942
DMRW57G	DT	Small molecular drug
DMRW57G	PC	19700663
DMRW57G	MW	348.8
DMRW57G	FM	C19H13ClN4O
DMRW57G	IC	InChI=1S/C19H13ClN4O/c20-15-4-1-3-14(11-15)17-18-16(5-2-8-22-18)19(25)24(23-17)12-13-6-9-21-10-7-13/h1-11H,12H2
DMRW57G	CS	C1=CC(=CC(=C1)Cl)C2=NN(C(=O)C3=C2N=CC=C3)CC4=CC=NC=C4
DMRW57G	IK	COLQUUDNEIJASV-UHFFFAOYSA-N
DMRW57G	IU	8-(3-chlorophenyl)-6-(pyridin-4-ylmethyl)pyrido[2,3-d]pyridazin-5-one
DMRW57G	DE	Discovery agent

DMKQT1Y	ID	DMKQT1Y
DMKQT1Y	DN	RS-1636
DMKQT1Y	HS	Investigative
DMKQT1Y	PC	10220452
DMKQT1Y	MW	206.24
DMKQT1Y	FM	C11H14N2O2
DMKQT1Y	IC	InChI=1S/C11H14N2O2/c1-7-3-4-8(2)10-9(7)11(13-15-10)14-6-5-12/h3-4H,5-6,12H2,1-2H3
DMKQT1Y	CS	CC1=C2C(=C(C=C1)C)ON=C2OCCN
DMKQT1Y	IK	ZTMODTQBGMQMDL-UHFFFAOYSA-N
DMKQT1Y	IU	2-[(4,7-dimethyl-1,2-benzoxazol-3-yl)oxy]ethanamine
DMKQT1Y	DE	Discovery agent

DM9D8XC	ID	DM9D8XC
DM9D8XC	DN	RS-1748
DM9D8XC	HS	Investigative
DM9D8XC	CP	Daiichi Sankyo Co Ltd
DM9D8XC	PC	46220480
DM9D8XC	MW	430.5
DM9D8XC	FM	C23H25F3N4O
DM9D8XC	IC	InChI=1S/C23H25F3N4O/c1-3-30(4-2)11-12-31-19-9-6-16(7-10-19)22-28-15-21(26)23(29-22)27-14-17-5-8-18(24)13-20(17)25/h5-10,13,15H,3-4,11-12,14H2,1-2H3,(H,27,28,29)
DM9D8XC	CS	CCN(CC)CCOC1=CC=C(C=C1)C2=NC=C(C(=N2)NCC3=C(C=C(C=C3)F)F)F
DM9D8XC	IK	QWIZBXCRZIVLRC-UHFFFAOYSA-N
DM9D8XC	IU	2-[4-[2-(diethylamino)ethoxy]phenyl]-N-[(2,4-difluorophenyl)methyl]-5-fluoropyrimidin-4-amine
DM9D8XC	DE	Asthma

DM0W2IS	ID	DM0W2IS
DM0W2IS	DN	RS-25344
DM0W2IS	HS	Investigative
DM0W2IS	SN	RS 25344
DM0W2IS	DT	Small molecular drug
DM0W2IS	PC	9842556
DM0W2IS	MW	375.3
DM0W2IS	FM	C19H13N5O4
DM0W2IS	IC	InChI=1S/C19H13N5O4/c25-18-16-5-2-8-21-17(16)23(14-3-1-4-15(11-14)24(27)28)19(26)22(18)12-13-6-9-20-10-7-13/h1-11H,12H2
DM0W2IS	CS	C1=CC(=CC(=C1)[N+](=O)[O-])N2C3=C(C=CC=N3)C(=O)N(C2=O)CC4=CC=NC=C4
DM0W2IS	IK	YLHRMVRLIOIWTO-UHFFFAOYSA-N
DM0W2IS	IU	1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4-dione
DM0W2IS	DE	Discovery agent

DMDC1B4	ID	DMDC1B4
DMDC1B4	DN	RS-30199
DMDC1B4	HS	Investigative
DMDC1B4	SN	RS-30199; CHEMBL345214; AC1L2OSK; GTPL104; SCHEMBL10467449; BDBM50228699; L004592
DMDC1B4	DT	Small molecular drug
DMDC1B4	PC	125570
DMDC1B4	MW	235.75
DMDC1B4	FM	C14H18ClN
DMDC1B4	IC	InChI=1S/C14H18ClN/c1-16-8-7-12-13(15)6-5-10-3-2-4-11(9-16)14(10)12/h5-6,11H,2-4,7-9H2,1H3
DMDC1B4	CS	CN1CCC2=C(C=CC3=C2C(C1)CCC3)Cl
DMDC1B4	IK	KELNXILYABMXFF-UHFFFAOYSA-N
DMDC1B4	IU	2-chloro-11-methyl-11-azatricyclo[7.4.1.05,14]tetradeca-1,3,5(14)-triene
DMDC1B4	DE	Discovery agent

DM2SCM7	ID	DM2SCM7
DM2SCM7	DN	RS-39066
DM2SCM7	HS	Investigative
DM2SCM7	SN	RS-39066; CHEMBL288896; GTPL8567; BDBM50287379; RS39066; RS 39066; methyl 4-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]benzoate; 4-[(S)-2-((R)-2-Hydroxycarbamoylmethyl-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-benzoic acid methyl ester
DM2SCM7	DT	Small molecular drug
DM2SCM7	PC	44288042
DM2SCM7	MW	435.5
DM2SCM7	FM	C22H33N3O6
DM2SCM7	IC	InChI=1S/C22H33N3O6/c1-13(2)10-16(12-19(26)25-30)20(27)24-18(11-14(3)4)21(28)23-17-8-6-15(7-9-17)22(29)31-5/h6-9,13-14,16,18,30H,10-12H2,1-5H3,(H,23,28)(H,24,27)(H,25,26)/t16-,18+/m1/s1
DM2SCM7	CS	CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC(C)C)C(=O)NC1=CC=C(C=C1)C(=O)OC
DM2SCM7	IK	CEEASCNCHQSPKF-AEFFLSMTSA-N
DM2SCM7	IU	methyl 4-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]benzoate
DM2SCM7	CA	CAS 169322-17-2
DM2SCM7	DE	Discovery agent

DMLI5U2	ID	DMLI5U2
DMLI5U2	DN	RS-513815
DMLI5U2	HS	Investigative
DMLI5U2	SN	RS-513815; CHEMBL181071; SCHEMBL6802944; BDBM50160162
DMLI5U2	DT	Small molecular drug
DMLI5U2	PC	22629308
DMLI5U2	MW	425.5
DMLI5U2	FM	C25H23N5O2
DMLI5U2	IC	InChI=1S/C25H23N5O2/c26-25(27-19-9-2-1-3-10-19)30-15-13-29(14-16-30)17-22-24(31)32-23(28-22)21-12-6-8-18-7-4-5-11-20(18)21/h1-12,17H,13-16H2,(H2,26,27)/b22-17+
DMLI5U2	CS	C1CN(CCN1/C=C/2\\C(=O)OC(=N2)C3=CC=CC4=CC=CC=C43)C(=NC5=CC=CC=C5)N
DMLI5U2	IK	ADANDPMLNDAKNZ-OQKWZONESA-N
DMLI5U2	IU	4-[(E)-(2-naphthalen-1-yl-5-oxo-1,3-oxazol-4-ylidene)methyl]-N'-phenylpiperazine-1-carboximidamide
DMLI5U2	DE	Discovery agent

DM89I0L	ID	DM89I0L
DM89I0L	DN	RS67506
DM89I0L	HS	Investigative
DM89I0L	SN	RS-67506
DM89I0L	DT	Small molecular drug
DM89I0L	PC	133076
DM89I0L	MW	418
DM89I0L	FM	C18H28ClN3O4S
DM89I0L	IC	InChI=1S/C18H28ClN3O4S/c1-26-18-12-16(20)15(19)11-14(18)17(23)4-3-13-5-8-22(9-6-13)10-7-21-27(2,24)25/h11-13,21H,3-10,20H2,1-2H3
DM89I0L	CS	COC1=CC(=C(C=C1C(=O)CCC2CCN(CC2)CCNS(=O)(=O)C)Cl)N
DM89I0L	IK	UATDVRSFFGFTAI-UHFFFAOYSA-N
DM89I0L	IU	N-[2-[4-[3-(4-amino-5-chloro-2-methoxyphenyl)-3-oxopropyl]piperidin-1-yl]ethyl]methanesulfonamide
DM89I0L	CB	CHEBI:92869
DM89I0L	DE	Discovery agent

DMN3ZOD	ID	DMN3ZOD
DMN3ZOD	DN	RS-PPCC
DMN3ZOD	HS	Investigative
DMN3ZOD	TC	Antiviral Agents
DMN3ZOD	DT	Small molecular drug
DMN3ZOD	DE	Coronavirus Disease 2019 (COVID-19)

DMWDXPN	ID	DMWDXPN
DMWDXPN	DN	rT3
DMWDXPN	HS	Investigative
DMWDXPN	SN	reverse T3; reverse triiodothyronine
DMWDXPN	DT	Small molecular drug
DMWDXPN	PC	644280
DMWDXPN	MW	650.97
DMWDXPN	FM	C15H12I3NO4
DMWDXPN	IC	InChI=1S/C15H12I3NO4/c16-9-3-7(4-12(19)15(21)22)1-2-13(9)23-8-5-10(17)14(20)11(18)6-8/h1-3,5-6,12,20H,4,19H2,(H,21,22)/t12-/m0/s1
DMWDXPN	CS	C1=CC(=C(C=C1C[C@@H](C(=O)O)N)I)OC2=CC(=C(C(=C2)I)O)I
DMWDXPN	IK	HZCBWYNLGPIQRK-LBPRGKRZSA-N
DMWDXPN	IU	(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3-iodophenyl]propanoic acid
DMWDXPN	CA	CAS 5817-39-0
DMWDXPN	CB	CHEBI:11684
DMWDXPN	DE	Discovery agent

DMLY4C9	ID	DMLY4C9
DMLY4C9	DN	RTA-301
DMLY4C9	HS	Investigative
DMLY4C9	SN	Peloruside; Peloruside A; Series 300, Reata; Microtubule stabilizers (cancer), Reata; Peloruside analogs (cancer), Reata
DMLY4C9	CP	University of Texas Southwestern Medical Center
DMLY4C9	DT	Small molecular drug
DMLY4C9	PC	6918506
DMLY4C9	MW	548.7
DMLY4C9	FM	C27H48O11
DMLY4C9	IC	InChI=1S/C27H48O11/c1-8-16(14-28)9-15(2)19-10-17(34-5)13-22(29)26(3,4)27(33)24(31)21(36-7)12-18(38-27)11-20(35-6)23(30)25(32)37-19/h9,16-24,28-31,33H,8,10-14H2,1-7H3/b15-9-/t16-,17-,18+,19+,20-,21-,22+,23+,24-,27+/m0/s1
DMLY4C9	CS	CC[C@H](CO)/C=C(/C)\\[C@H]1C[C@@H](C[C@H](C([C@]2([C@H]([C@H](C[C@H](O2)C[C@@H]([C@H](C(=O)O1)O)OC)OC)O)O)(C)C)O)OC
DMLY4C9	IK	NETARJWZTMGMRM-JRTPPQMASA-N
DMLY4C9	IU	(1S,3S,4R,7R,9R,11R,13S,14S,15S)-4,11,13,14-tetrahydroxy-7-[(Z,4S)-4-(hydroxymethyl)hex-2-en-2-yl]-3,9,15-trimethoxy-12,12-dimethyl-6,17-dioxabicyclo[11.3.1]heptadecan-5-one
DMLY4C9	CB	CHEBI:77692
DMLY4C9	DE	Solid tumour/cancer

DMD3ST8	ID	DMD3ST8
DMD3ST8	DN	RTI-20
DMD3ST8	HS	Investigative
DMD3ST8	SN	133627-12-0; CHEMBL288336; 2-Chloro-N11-ethyl-N5-methyl-5,11-dihydro-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; 2-Chloro-N11-ethyl-N5-methyl-5,11-dihydro-6H-dipyrido(3,2-b:2,3-e)(1,4)diazepin-6-one; RTI-20; 2-Chloro-N11-ethyl-N5-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; ACMC-20mv0r; AC1L9QW9; Dipyridodiazepinone deriv. 16; BDBM1529; SCHEMBL8889357; CTK4B8683; DTXSID70158249; 2-chloro-11-ethyl-5-methyl-dipyrido[[ ],[ ]][1,4]diazepin-6-one
DMD3ST8	DT	Small molecular drug
DMD3ST8	PC	453326
DMD3ST8	MW	288.73
DMD3ST8	FM	C14H13ClN4O
DMD3ST8	IC	InChI=1S/C14H13ClN4O/c1-3-19-12-9(5-4-8-16-12)14(20)18(2)10-6-7-11(15)17-13(10)19/h4-8H,3H2,1-2H3
DMD3ST8	CS	CCN1C2=C(C=CC=N2)C(=O)N(C3=C1N=C(C=C3)Cl)C
DMD3ST8	IK	YSEMEGXOKULCML-UHFFFAOYSA-N
DMD3ST8	IU	5-chloro-2-ethyl-9-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-10-one
DMD3ST8	CA	CAS 133627-12-0
DMD3ST8	DE	Discovery agent

DM2QYXN	ID	DM2QYXN
DM2QYXN	DN	RTI-219
DM2QYXN	HS	Investigative
DM2QYXN	SN	RTI-219; CHEMBL227179; BDBM22398; WIN 35,065-2 Analogue, 4a; 2-[(1R,2S,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-5-phenyl-1,3-thiazole
DM2QYXN	DT	Small molecular drug
DM2QYXN	PC	10524711
DM2QYXN	MW	395
DM2QYXN	FM	C23H23ClN2S
DM2QYXN	IC	InChI=1S/C23H23ClN2S/c1-26-18-11-12-20(26)22(19(13-18)15-7-9-17(24)10-8-15)23-25-14-21(27-23)16-5-3-2-4-6-16/h2-10,14,18-20,22H,11-13H2,1H3/t18-,19+,20+,22-/m0/s1
DM2QYXN	CS	CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)Cl)C4=NC=C(S4)C5=CC=CC=C5
DM2QYXN	IK	WEUZYHQNGQDGAB-HIUFNZKISA-N
DM2QYXN	IU	2-[(1R,2S,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-5-phenyl-1,3-thiazole
DM2QYXN	DE	Discovery agent

DMG6TOA	ID	DMG6TOA
DMG6TOA	DN	RTI-4229-982
DMG6TOA	HS	Investigative
DMG6TOA	SN	Metabotropic glutamate receptor 5 antagonists (neurological disease); Metabotropic glutamate receptor 5 antagonists (neurological disease), Research Triangle Institute
DMG6TOA	CP	Research Triangle Institute
DMG6TOA	DE	Neurological disorder

DMR4TM1	ID	DMR4TM1
DMR4TM1	DN	RTI-5989-23
DMR4TM1	HS	Investigative
DMR4TM1	SN	RTI-5989-23; CHEMBL50594; BDBM50064518; 3-{1-[3-(2-Chloro-phenyl)-allyl]-3,4-dimethyl-piperidin-4-yl}-phenol; 3-[(3R)-1-[(E)-3-(2-Chlorophenyl)allyl]-3alpha,4beta-dimethyl-4-piperidinyl]phenol
DMR4TM1	DT	Small molecular drug
DMR4TM1	PC	10808145
DMR4TM1	MW	355.9
DMR4TM1	FM	C22H26ClNO
DMR4TM1	IC	InChI=1S/C22H26ClNO/c1-17-16-24(13-6-8-18-7-3-4-11-21(18)23)14-12-22(17,2)19-9-5-10-20(25)15-19/h3-11,15,17,25H,12-14,16H2,1-2H3/b8-6+/t17-,22+/m0/s1
DMR4TM1	CS	C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C/C=C/C3=CC=CC=C3Cl
DMR4TM1	IK	RRGWRLNJBLFYOG-KISUKSLOSA-N
DMR4TM1	IU	3-[(3R,4R)-1-[(E)-3-(2-chlorophenyl)prop-2-enyl]-3,4-dimethylpiperidin-4-yl]phenol
DMR4TM1	DE	Discovery agent

DMQ28L9	ID	DMQ28L9
DMQ28L9	DN	RTI-5989-25
DMQ28L9	HS	Investigative
DMQ28L9	SN	RTI-5989-25; CHEMBL52451; ZINC13532660; BDBM50064515; 3-[3,4-Dimethyl-1-(3-o-tolyl-allyl)-piperidin-4-yl]-phenol; 3-[(3R,4R)-3,4-Dimethyl-1-(3-o-tolyl-allyl)-piperidin-4-yl]-phenol; 3-[(3R)-1-[(E)-3-(2-Methylphenyl)allyl]-3alpha,4beta-dimethyl-4-piperidinyl]phenol
DMQ28L9	DT	Small molecular drug
DMQ28L9	PC	9840689
DMQ28L9	MW	335.5
DMQ28L9	FM	C23H29NO
DMQ28L9	IC	InChI=1S/C23H29NO/c1-18-8-4-5-9-20(18)10-7-14-24-15-13-23(3,19(2)17-24)21-11-6-12-22(25)16-21/h4-12,16,19,25H,13-15,17H2,1-3H3/b10-7+/t19-,23+/m0/s1
DMQ28L9	CS	C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C/C=C/C3=CC=CC=C3C
DMQ28L9	IK	FJFLDQXXCJUUBR-XECBNOGISA-N
DMQ28L9	IU	3-[(3R,4R)-3,4-dimethyl-1-[(E)-3-(2-methylphenyl)prop-2-enyl]piperidin-4-yl]phenol
DMQ28L9	DE	Discovery agent

DMZO1QC	ID	DMZO1QC
DMZO1QC	DN	RTI-5989-31
DMZO1QC	HS	Investigative
DMZO1QC	SN	SCHEMBL6288083
DMZO1QC	DT	Small molecular drug
DMZO1QC	PC	22977851
DMZO1QC	MW	335.5
DMZO1QC	FM	C23H29NO
DMZO1QC	IC	InChI=1S/C23H29NO/c1-18-22-11-6-13-23(18,20-9-5-10-21(25)17-20)14-16-24(22)15-12-19-7-3-2-4-8-19/h2-5,7-10,17-18,22,25H,6,11-16H2,1H3/t18-,22?,23?/m0/s1
DMZO1QC	CS	C[C@H]1C2CCCC1(CCN2CCC3=CC=CC=C3)C4=CC(=CC=C4)O
DMZO1QC	IK	FJRARMQVERMSNJ-NWLLBJEDSA-N
DMZO1QC	IU	3-[(9R)-9-methyl-2-(2-phenylethyl)-2-azabicyclo[3.3.1]nonan-5-yl]phenol
DMZO1QC	DE	Discovery agent

DMWVBD9	ID	DMWVBD9
DMWVBD9	DN	RTU-1096
DMWVBD9	HS	Investigative
DMWVBD9	CP	R-Tech Ueno Ltd
DMWVBD9	DE	Atopic dermatitis

DMA7URH	ID	DMA7URH
DMA7URH	DN	RU26988
DMA7URH	HS	Investigative
DMA7URH	SN	RU 26988; RU-26988
DMA7URH	DT	Small molecular drug
DMA7URH	PC	123987
DMA7URH	MW	338.4
DMA7URH	FM	C22H26O3
DMA7URH	IC	InChI=1S/C22H26O3/c1-4-9-22(25)11-8-17-16-6-5-14-12-15(23)7-10-20(14,2)19(16)18(24)13-21(17,22)3/h5-7,10,12,16-19,24-25H,8,11,13H2,1-3H3/t16-,17-,18-,19+,20-,21-,22-/m0/s1
DMA7URH	CS	CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C=CC4=CC(=O)C=C[C@]34C)O)C)O
DMA7URH	IK	IXJKSIRTUSUXQC-ZXYIWLIBSA-N
DMA7URH	IU	(8S,9S,10R,11S,13S,14S,17S)-11,17-dihydroxy-10,13-dimethyl-17-prop-1-ynyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthren-3-one
DMA7URH	CA	CAS 74915-58-5
DMA7URH	DE	Discovery agent

DMN049T	ID	DMN049T
DMN049T	DN	RU28318
DMN049T	HS	Investigative
DMN049T	SN	RU 28318; RU-28318; oxprenoate
DMN049T	DT	Small molecular drug
DMN049T	PC	3034004
DMN049T	MW	402.6
DMN049T	FM	C25H38O4
DMN049T	IC	InChI=1S/C25H38O4/c1-4-5-16-14-17-15-18(26)6-10-23(17,2)19-7-11-24(3)20(22(16)19)8-12-25(24,29)13-9-21(27)28/h15-16,19-20,22,29H,4-14H2,1-3H3,(H,27,28)/t16-,19+,20+,22-,23+,24+,25-/m1/s1
DMN049T	CS	CCC[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(CCC(=O)O)O)C
DMN049T	IK	DNHCHRGCTVRAFT-JEHIOXJOSA-N
DMN049T	IU	3-[(7R,8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-7-propyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoic acid
DMN049T	CA	CAS 786592-95-8
DMN049T	DE	Discovery agent

DMAOJ0E	ID	DMAOJ0E
DMAOJ0E	DN	RU28362
DMAOJ0E	HS	Investigative
DMAOJ0E	SN	RU-28362
DMAOJ0E	DT	Small molecular drug
DMAOJ0E	PC	123790
DMAOJ0E	MW	352.5
DMAOJ0E	FM	C23H28O3
DMAOJ0E	IC	InChI=1S/C23H28O3/c1-5-8-23(26)10-7-17-16-11-14(2)18-12-15(24)6-9-21(18,3)20(16)19(25)13-22(17,23)4/h6,9,11-12,16-17,19-20,25-26H,7,10,13H2,1-4H3/t16-,17-,19-,20+,21-,22-,23-/m0/s1
DMAOJ0E	CS	CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C=C(C4=CC(=O)C=C[C@]34C)C)O)C)O
DMAOJ0E	IK	UFZKDKHLKHEFGA-ZFTCBNFESA-N
DMAOJ0E	IU	(8S,9S,10R,11S,13S,14S,17S)-11,17-dihydroxy-6,10,13-trimethyl-17-prop-1-ynyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthren-3-one
DMAOJ0E	CA	CAS 74915-64-3
DMAOJ0E	DE	Discovery agent

DMY9P85	ID	DMY9P85
DMY9P85	DN	RU-43044
DMY9P85	HS	Investigative
DMY9P85	SN	CHEMBL78704; RU-43044; SCHEMBL14289561; 136959-96-1; BDBM50113782; RU43044; 17-Hydroxy-13-methyl-10-(4-methyl-benzyl)-17-prop-1-ynyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one(RU-43044)
DMY9P85	DT	Small molecular drug
DMY9P85	PC	9823099
DMY9P85	MW	414.6
DMY9P85	FM	C29H34O2
DMY9P85	IC	InChI=1S/C29H34O2/c1-4-14-29(31)17-13-25-24-10-9-22-18-23(30)11-16-28(22,26(24)12-15-27(25,29)3)19-21-7-5-20(2)6-8-21/h5-8,12,18,24-25,31H,9-11,13,15-17,19H2,1-3H3/t24-,25-,27-,28+,29-/m0/s1
DMY9P85	CS	CC#C[C@@]1(CC[C@@H]2[C@@]1(CC=C3[C@H]2CCC4=CC(=O)CC[C@@]43CC5=CC=C(C=C5)C)C)O
DMY9P85	IK	NSUUUQRFPXZFLI-ZPCMSWJYSA-N
DMY9P85	IU	(8S,10R,13S,14S,17S)-17-hydroxy-13-methyl-10-[(4-methylphenyl)methyl]-17-prop-1-ynyl-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
DMY9P85	DE	Discovery agent

DMCASRD	ID	DMCASRD
DMCASRD	DN	RU-5135
DMCASRD	HS	Investigative
DMCASRD	SN	78774-26-2; R-5135
DMCASRD	DT	Small molecular drug
DMCASRD	PC	119544
DMCASRD	MW	304.4
DMCASRD	FM	C18H28N2O2
DMCASRD	IC	InChI=1S/C18H28N2O2/c1-17-6-5-11(21)7-10(17)3-4-12-13-8-15(19)20-18(13,2)9-14(22)16(12)17/h10-13,16,21H,3-9H2,1-2H3,(H2,19,20)/t10-,11-,12+,13+,16-,17+,18+/m1/s1
DMCASRD	CS	C[C@]12CC[C@H](C[C@H]1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC(=N4)N)C)O
DMCASRD	IK	LLAKESJIQFAQJA-NJYPJRCCSA-N
DMCASRD	IU	(3aS,3bS,5aR,7R,9aS,9bS,11aS)-2-amino-7-hydroxy-9a,11a-dimethyl-3,3a,3b,4,5,5a,6,7,8,9,9b,11-dodecahydronaphtho[2,1-e]indol-10-one
DMCASRD	CA	CAS 78774-26-2
DMCASRD	DE	Discovery agent

DMO3WEG	ID	DMO3WEG
DMO3WEG	DN	RU-56187
DMO3WEG	HS	Investigative
DMO3WEG	SN	RU-56187; 143782-25-6; CHEMBL1099140; 4-(3,4,4-Trimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-2-(trifluoromethyl)benzonitrile; Benzonitrile,2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-; RU 56187; ACMC-20n377; AC1L318J; SCHEMBL1435262; CTK4C3806; DTXSID90162545; BDBM50317664; 2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)benzonitrile; 2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile; Benzonitrile, 2-(trifluoromethyl)-4-(3,4,4-trimet
DMO3WEG	DT	Small molecular drug
DMO3WEG	PC	132581
DMO3WEG	MW	327.33
DMO3WEG	FM	C14H12F3N3OS
DMO3WEG	IC	InChI=1S/C14H12F3N3OS/c1-13(2)11(21)20(12(22)19(13)3)9-5-4-8(7-18)10(6-9)14(15,16)17/h4-6H,1-3H3
DMO3WEG	CS	CC1(C(=O)N(C(=S)N1C)C2=CC(=C(C=C2)C#N)C(F)(F)F)C
DMO3WEG	IK	HLBUAKQNKJTEIU-UHFFFAOYSA-N
DMO3WEG	IU	2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)benzonitrile
DMO3WEG	CA	CAS 143782-25-6
DMO3WEG	DE	Discovery agent

DM5D9UT	ID	DM5D9UT
DM5D9UT	DN	RU-59063
DM5D9UT	HS	Investigative
DM5D9UT	SN	155180-53-3; 4-(3-(4-Hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile; 4-[3-(4-Hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; RU-59063; RU 59063; CHEMBL331820; AK134187; AC1L53SM; SCHEMBL1714908; CTK4C8567; DTXSID50165850; MolPort-027-950-495; FIDNKDVRTLFETI-UHFFFAOYSA-N; ZINC1538191; BDBM50091400; 6064AJ; AKOS016845838; TRA0008920; RU59063; DS-4755; SY008557; CJ-05279; AJ-26835
DM5D9UT	DT	Small molecular drug
DM5D9UT	PC	197655
DM5D9UT	MW	385.4
DM5D9UT	FM	C17H18F3N3O2S
DM5D9UT	IC	InChI=1S/C17H18F3N3O2S/c1-16(2)14(25)23(15(26)22(16)7-3-4-8-24)12-6-5-11(10-21)13(9-12)17(18,19)20/h5-6,9,24H,3-4,7-8H2,1-2H3
DM5D9UT	CS	CC1(C(=O)N(C(=S)N1CCCCO)C2=CC(=C(C=C2)C#N)C(F)(F)F)C
DM5D9UT	IK	FIDNKDVRTLFETI-UHFFFAOYSA-N
DM5D9UT	IU	4-[3-(4-hydroxybutyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
DM5D9UT	CA	CAS 155180-53-3
DM5D9UT	DE	Discovery agent

DMOQE91	ID	DMOQE91
DMOQE91	DN	RU78191
DMOQE91	HS	Investigative
DMOQE91	SN	Phenylmalonic acid; 2613-89-0; 2-Phenylmalonic acid; 2-phenylpropanedioic acid; Propanedioic acid, phenyl-; Phenylmalonicacid; Phenylpropanedioc acid; Malonic acid, phenyl-; RU78191; Propanedioic acid, 2-phenyl-; phenylpropanedioic acid; CHEMBL78794; .alpha.-Carboxyphenylacetic acid; WWYDYZMNFQIYPT-UHFFFAOYSA-N; Toluene-.alpha.,.alpha.-dicarboxylic acid; phenylmalonate; alpha-Carboxyphenylacetic acid; EINECS 220-044-6; Toluene-alpha,alpha-dicarboxylic acid; NSC 41697; NSC 27164; 2-Phenyl-malonic acid; 1o4p; AC1L2PIV
DMOQE91	DT	Small molecular drug
DMOQE91	PC	75791
DMOQE91	MW	180.16
DMOQE91	FM	C9H8O4
DMOQE91	IC	InChI=1S/C9H8O4/c10-8(11)7(9(12)13)6-4-2-1-3-5-6/h1-5,7H,(H,10,11)(H,12,13)
DMOQE91	CS	C1=CC=C(C=C1)C(C(=O)O)C(=O)O
DMOQE91	IK	WWYDYZMNFQIYPT-UHFFFAOYSA-N
DMOQE91	IU	2-phenylpropanedioic acid
DMOQE91	CA	CAS 2613-89-0
DMOQE91	DE	Discovery agent

DMR8I03	ID	DMR8I03
DMR8I03	DN	RU78262
DMR8I03	HS	Investigative
DMR8I03	SN	RU78262; 2-FORMYLPHENYL DIHYDROGEN PHOSPHATE; CHEMBL286678; 2-phosphonooxy-benzaldehyde; Fragment 10; AC1NR9QH; C7H7O5P; 2-formylphenoxyphosphonic acid; SCHEMBL3514846; BDBM14680; Phosphoric acid 2-formylphenyl ester; (2-formylphenyl) dihydrogen phosphate; DB01947
DMR8I03	DT	Small molecular drug
DMR8I03	PC	5287463
DMR8I03	MW	202.1
DMR8I03	FM	C7H7O5P
DMR8I03	IC	InChI=1S/C7H7O5P/c8-5-6-3-1-2-4-7(6)12-13(9,10)11/h1-5H,(H2,9,10,11)
DMR8I03	CS	C1=CC=C(C(=C1)C=O)OP(=O)(O)O
DMR8I03	IK	BYNSFVCWJXZPOW-UHFFFAOYSA-N
DMR8I03	IU	(2-formylphenyl) dihydrogen phosphate
DMR8I03	DE	Discovery agent

DMXAK92	ID	DMXAK92
DMXAK92	DN	RU78299
DMXAK92	HS	Investigative
DMXAK92	SN	RU78299; CHEMBL421138; 2,6-DIFORMYL-4-METHYLPHENYL DIHYDROGEN PHOSPHATE; Fragment 11; AC1NR9QK; C9H9O6P; BDBM14681; DB03828; 2,6-diformyl-4-methylphenoxyphosphonic acid; (2,6-diformyl-4-methylphenyl) dihydrogen phosphate
DMXAK92	DT	Small molecular drug
DMXAK92	PC	5287465
DMXAK92	MW	244.14
DMXAK92	FM	C9H9O6P
DMXAK92	IC	InChI=1S/C9H9O6P/c1-6-2-7(4-10)9(8(3-6)5-11)15-16(12,13)14/h2-5H,1H3,(H2,12,13,14)
DMXAK92	CS	CC1=CC(=C(C(=C1)C=O)OP(=O)(O)O)C=O
DMXAK92	IK	NAYNUXXSJZLKPW-UHFFFAOYSA-N
DMXAK92	IU	(2,6-diformyl-4-methylphenyl) dihydrogen phosphate
DMXAK92	DE	Discovery agent

DM27BKD	ID	DM27BKD
DM27BKD	DN	RU78300
DM27BKD	HS	Investigative
DM27BKD	SN	RU78300; CHEMBL25186; 2-FORMYL-6-METHOXYPHENYL DIHYDROGEN PHOSPHATE; Fragment 9; AC1NR9S0; C8H9O6P; BDBM14679; DB03306; 2-formyl-6-methoxyphenoxyphosphonic acid; Phosphoric acid 2-formyl-6-methoxyphenyl ester; (2-formyl-6-methoxyphenyl) dihydrogen phosphate
DM27BKD	DT	Small molecular drug
DM27BKD	PC	5287488
DM27BKD	MW	232.13
DM27BKD	FM	C8H9O6P
DM27BKD	IC	InChI=1S/C8H9O6P/c1-13-7-4-2-3-6(5-9)8(7)14-15(10,11)12/h2-5H,1H3,(H2,10,11,12)
DM27BKD	CS	COC1=CC=CC(=C1OP(=O)(O)O)C=O
DM27BKD	IK	CGEZBCISRKFHLZ-UHFFFAOYSA-N
DM27BKD	IU	(2-formyl-6-methoxyphenyl) dihydrogen phosphate
DM27BKD	DE	Discovery agent

DMU5H4K	ID	DMU5H4K
DMU5H4K	DN	RU78783
DMU5H4K	HS	Investigative
DMU5H4K	SN	RU78783; (PHENYL-PHOSPHONO-METHYL)-PHOSPHONIC ACID; (phenylmethanediyl)bis(phosphonic acid); [phenyl(phosphono)methyl]phosphonic acid; Fragment 8; 1o4r; benzylidenebisphosphonic acid; AC1L9KY6; SCHEMBL4094661; phenyl methane diphosphonic acid; CHEMBL148732; Phenylmethylenebisphosphonic acid; BDBM14678; FRLTXWJJMCIUNT-UHFFFAOYSA-N; phenyl(phosphono)methylphosphonic acid
DMU5H4K	DT	Small molecular drug
DMU5H4K	PC	447537
DMU5H4K	MW	252.1
DMU5H4K	FM	C7H10O6P2
DMU5H4K	IC	InChI=1S/C7H10O6P2/c8-14(9,10)7(15(11,12)13)6-4-2-1-3-5-6/h1-5,7H,(H2,8,9,10)(H2,11,12,13)
DMU5H4K	CS	C1=CC=C(C=C1)C(P(=O)(O)O)P(=O)(O)O
DMU5H4K	IK	FRLTXWJJMCIUNT-UHFFFAOYSA-N
DMU5H4K	IU	[phenyl(phosphono)methyl]phosphonic acid
DMU5H4K	DE	Discovery agent

DM9GQP0	ID	DM9GQP0
DM9GQP0	DN	RU79072
DM9GQP0	HS	Investigative
DM9GQP0	SN	RU79072; 2-CYANOQUINOLIN-8-YL DIHYDROGEN PHOSPHATE; Fragment 14; 1o4h; AC1L9KXW; CHEMBL149603; BDBM14684; DB02762; (2-cyanoquinolin-8-yl)oxyphosphonic acid; Phosphoric acid 2-cyano-8-quinolinyl ester; [(2-cyanoquinolin-8-yl)oxy]phosphonic acid; (2-cyanoquinolin-8-yl) dihydrogen phosphate
DM9GQP0	DT	Small molecular drug
DM9GQP0	PC	447532
DM9GQP0	MW	250.15
DM9GQP0	FM	C10H7N2O4P
DM9GQP0	IC	InChI=1S/C10H7N2O4P/c11-6-8-5-4-7-2-1-3-9(10(7)12-8)16-17(13,14)15/h1-5H,(H2,13,14,15)
DM9GQP0	CS	C1=CC2=C(C(=C1)OP(=O)(O)O)N=C(C=C2)C#N
DM9GQP0	IK	NQLPTOOPFMPCHQ-UHFFFAOYSA-N
DM9GQP0	IU	(2-cyanoquinolin-8-yl) dihydrogen phosphate
DM9GQP0	DE	Discovery agent

DMWKTYC	ID	DMWKTYC
DMWKTYC	DN	RU79073
DMWKTYC	HS	Investigative
DMWKTYC	SN	RU79073; 1,2,3,4-TETRAHYDROQUINOLIN-8-YL DIHYDROGEN PHOSPHATE; Fragment 12; 1o4f; AC1NR9W0; CHEMBL358860; BDBM14682; DB03525; 1,2,3,4-tetrahydroquinolin-8-yloxyphosphonic acid; (1,2,3,4-tetrahydroquinolin-8-yloxy)phosphonic acid; Phosphoric acid 1,2,3,4-tetrahydroquinoline-8-yl ester
DMWKTYC	DT	Small molecular drug
DMWKTYC	PC	5287550
DMWKTYC	MW	229.17
DMWKTYC	FM	C9H12NO4P
DMWKTYC	IC	InChI=1S/C9H12NO4P/c11-15(12,13)14-8-5-1-3-7-4-2-6-10-9(7)8/h1,3,5,10H,2,4,6H2,(H2,11,12,13)
DMWKTYC	CS	C1CC2=C(C(=CC=C2)OP(=O)(O)O)NC1
DMWKTYC	IK	NSJSAHCLJYVEDM-UHFFFAOYSA-N
DMWKTYC	IU	1,2,3,4-tetrahydroquinolin-8-yl dihydrogen phosphate
DMWKTYC	DE	Discovery agent

DM06BGV	ID	DM06BGV
DM06BGV	DN	RU79256
DM06BGV	HS	Investigative
DM06BGV	SN	D-Sulfophenylacetic acid; RU79256; PHENYL(SULFO)ACETIC ACID; 39925-38-7; 1o4q; AC1L9KY4; (R)-phenyl(sulfo)acetic acid; (2R)-phenyl(sulfo)ethanoic acid; ZINC1681752; (2R)-2-phenyl-2-sulfoacetic acid; DB01866; [R,( )]-alpha-Sulfobenzeneacetic acid; AJ-29699; Benzeneacetic acid, alpha-sulfo-, (alphaR)-
DM06BGV	DT	Small molecular drug
DM06BGV	PC	447536
DM06BGV	MW	216.21
DM06BGV	FM	C8H8O5S
DM06BGV	IC	InChI=1S/C8H8O5S/c9-8(10)7(14(11,12)13)6-4-2-1-3-5-6/h1-5,7H,(H,9,10)(H,11,12,13)/t7-/m1/s1
DM06BGV	CS	C1=CC=C(C=C1)[C@H](C(=O)O)S(=O)(=O)O
DM06BGV	IK	USNMCXDGQQVYSW-SSDOTTSWSA-N
DM06BGV	IU	(2R)-2-phenyl-2-sulfoacetic acid
DM06BGV	DE	Discovery agent

DMY3X6I	ID	DMY3X6I
DMY3X6I	DN	RU81843
DMY3X6I	HS	Investigative
DMY3X6I	SN	RU81843; CHEMBL25826; N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-O-PHOSPHONOTYROSINAMIDE; Paratoulene phosphate; AC1L9KX6; BDBM14689; 1o42; DB04495; Nalpha-acetyl-N-[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]-O-phosphono-L-tyrosinamide; N-alpha-acetyl-N-[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]-O-phosphono-L-tyrosinamide; N-[(3S)-1-(4-Biphenylylmethyl)-2-oxohexahydro-1H-azepine-3beta-yl]-Nalpha-acetyl-O-phosphono-L-tyrosinamide
DMY3X6I	DT	Small molecular drug
DMY3X6I	PC	447518
DMY3X6I	MW	579.6
DMY3X6I	FM	C30H34N3O7P
DMY3X6I	IC	InChI=1S/C30H34N3O7P/c1-21(34)31-28(19-22-12-16-26(17-13-22)40-41(37,38)39)29(35)32-27-9-5-6-18-33(30(27)36)20-23-10-14-25(15-11-23)24-7-3-2-4-8-24/h2-4,7-8,10-17,27-28H,5-6,9,18-20H2,1H3,(H,31,34)(H,32,35)(H2,37,38,39)/t27-,28-/m0/s1
DMY3X6I	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N[C@H]2CCCCN(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4
DMY3X6I	IK	GGPXNASQNUOIPB-NSOVKSMOSA-N
DMY3X6I	IU	[4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]phenyl] dihydrogen phosphate
DMY3X6I	DE	Discovery agent

DMX7ZI0	ID	DMX7ZI0
DMX7ZI0	DN	RU82129
DMX7ZI0	HS	Investigative
DMX7ZI0	SN	RU82129; {4-[(1Z)-2-(acetylamino)-3-{[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]amino}-3-oxoprop-1-en-1-yl]-2-formylphenyl}acetic acid; [4-((1Z)-2-(ACETYLAMINO)-3-{[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]AMINO}-3-OXOPROP-1-ENYL)-2-FORMYLPHENYL]ACETIC ACID; Inhibitor 10; AC1NR9W6; CHEMBL356002; BDBM14698; DB03104; 2-[4-[(Z)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
DMX7ZI0	DT	Small molecular drug
DMX7ZI0	PC	5287555
DMX7ZI0	MW	567.6
DMX7ZI0	FM	C33H33N3O6
DMX7ZI0	IC	InChI=1S/C33H33N3O6/c1-22(38)34-30(18-24-12-15-27(19-31(39)40)28(17-24)21-37)32(41)35-29-9-5-6-16-36(33(29)42)20-23-10-13-26(14-11-23)25-7-3-2-4-8-25/h2-4,7-8,10-15,17-18,21,29H,5-6,9,16,19-20H2,1H3,(H,34,38)(H,35,41)(H,39,40)/b30-18-/t29-/m0/s1
DMX7ZI0	CS	CC(=O)N/C(=C\\C1=CC(=C(C=C1)CC(=O)O)C=O)/C(=O)N[C@H]2CCCCN(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4
DMX7ZI0	IK	NKMPOVPTYDXGEC-MNRBYUMSSA-N
DMX7ZI0	IU	2-[4-[(Z)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
DMX7ZI0	DE	Discovery agent

DMJG4RC	ID	DMJG4RC
DMJG4RC	DN	RU82197
DMJG4RC	HS	Investigative
DMJG4RC	SN	RU82197; 4-[(2S)-2-(acetylamino)-3-{[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]amino}-3-oxopropyl]-2-formylbenzoic acid; 4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-FORMYL-BENZOIC ACID; Inhibitor 8; AC1NR9P2; CHEMBL358866; BDBM14696; DB03268; 4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-formylbenzoic acid; 4-[(2S)-2-acetamido-2-{[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]carbamoyl}ethyl]-2-formylbenzoic acid
DMJG4RC	DT	Small molecular drug
DMJG4RC	PC	5287443
DMJG4RC	MW	555.6
DMJG4RC	FM	C32H33N3O6
DMJG4RC	IC	InChI=1S/C32H33N3O6/c1-21(37)33-29(18-23-12-15-27(32(40)41)26(17-23)20-36)30(38)34-28-9-5-6-16-35(31(28)39)19-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,17,20,28-29H,5-6,9,16,18-19H2,1H3,(H,33,37)(H,34,38)(H,40,41)/t28-,29-/m0/s1
DMJG4RC	CS	CC(=O)N[C@@H](CC1=CC(=C(C=C1)C(=O)O)C=O)C(=O)N[C@H]2CCCCN(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4
DMJG4RC	IK	WKTQBTSOHBKBRW-VMPREFPWSA-N
DMJG4RC	IU	4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-formylbenzoic acid
DMJG4RC	DE	Discovery agent

DMR3A2O	ID	DMR3A2O
DMR3A2O	DN	RU82209
DMR3A2O	HS	Investigative
DMR3A2O	SN	RU82209; N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-4-[DIFLUORO(PHOSPHONO)METHYL]PHENYLALANINAMIDE; AC1L9KXG; CHEMBL1160756; BDBM14693; 1o47; DB03591; N-alpha-acetyl-N-[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]-4-[difluoro(phosphono)methyl]-L-phenylalaninamide; [[4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]phenyl]-difluoromethyl]phosphonic acid
DMR3A2O	DT	Small molecular drug
DMR3A2O	PC	447523
DMR3A2O	MW	613.6
DMR3A2O	FM	C31H34F2N3O6P
DMR3A2O	IC	InChI=1S/C31H34F2N3O6P/c1-21(37)34-28(19-22-12-16-26(17-13-22)31(32,33)43(40,41)42)29(38)35-27-9-5-6-18-36(30(27)39)20-23-10-14-25(15-11-23)24-7-3-2-4-8-24/h2-4,7-8,10-17,27-28H,5-6,9,18-20H2,1H3,(H,34,37)(H,35,38)(H2,40,41,42)/t27-,28-/m0/s1
DMR3A2O	CS	CC(=O)N[C@@H](CC1=CC=C(C=C1)C(F)(F)P(=O)(O)O)C(=O)N[C@H]2CCCCN(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4
DMR3A2O	IK	LVZDQVATAQEMCX-NSOVKSMOSA-N
DMR3A2O	IU	[[4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]phenyl]-difluoromethyl]phosphonic acid
DMR3A2O	DE	Discovery agent

DMNGKYF	ID	DMNGKYF
DMNGKYF	DN	RU83876
DMNGKYF	HS	Investigative
DMNGKYF	SN	RU83876; CHEMBL319516; N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-3,4-DIPHOSPHONOPHENYLALANINAMIDE; Inhibitor 9; 1o4b; AC1L9KXM; BDBM14697; DB02336; 4-[(2S)-2-acetamido-2-{[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]carbamoyl}ethyl]benzene-1,2-diphosphonic acid; [4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-phosphonophenyl]phosphonic acid; Nalpha-acetyl-N-[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]-3,4-diphosphono-L-phenylalaninamide
DMNGKYF	DT	Small molecular drug
DMNGKYF	PC	447527
DMNGKYF	MW	643.6
DMNGKYF	FM	C30H35N3O9P2
DMNGKYF	IC	InChI=1S/C30H35N3O9P2/c1-20(34)31-26(17-22-12-15-27(43(37,38)39)28(18-22)44(40,41)42)29(35)32-25-9-5-6-16-33(30(25)36)19-21-10-13-24(14-11-21)23-7-3-2-4-8-23/h2-4,7-8,10-15,18,25-26H,5-6,9,16-17,19H2,1H3,(H,31,34)(H,32,35)(H2,37,38,39)(H2,40,41,42)/t25-,26-/m0/s1
DMNGKYF	CS	CC(=O)N[C@@H](CC1=CC(=C(C=C1)P(=O)(O)O)P(=O)(O)O)C(=O)N[C@H]2CCCCN(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4
DMNGKYF	IK	WCMLXBUNHNAMNH-UIOOFZCWSA-N
DMNGKYF	IU	[4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-phosphonophenyl]phosphonic acid
DMNGKYF	DE	Discovery agent

DMWK3LU	ID	DMWK3LU
DMWK3LU	DN	RU84687
DMWK3LU	HS	Investigative
DMWK3LU	SN	RU84687; CHEMBL78455; N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-3-FORMYL-O-PHOSPHONOTYROSINAMIDE; AC1NR9VO; BDBM14691; DB01678; 4-[(2S)-2-acetamido-2-{[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]carbamoyl}ethyl]-2-formylphenoxyphosphonic acid; [4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-formylphenyl] dihydrogen phosphate; N-alpha-acetyl-N-[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]-3-formyl-O-phosphono-L-tyrosinamide
DMWK3LU	DT	Small molecular drug
DMWK3LU	PC	5287544
DMWK3LU	MW	607.6
DMWK3LU	FM	C31H34N3O8P
DMWK3LU	IC	InChI=1S/C31H34N3O8P/c1-21(36)32-28(18-23-12-15-29(26(17-23)20-35)42-43(39,40)41)30(37)33-27-9-5-6-16-34(31(27)38)19-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,17,20,27-28H,5-6,9,16,18-19H2,1H3,(H,32,36)(H,33,37)(H2,39,40,41)/t27-,28-/m0/s1
DMWK3LU	CS	CC(=O)N[C@@H](CC1=CC(=C(C=C1)OP(=O)(O)O)C=O)C(=O)N[C@H]2CCCCN(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4
DMWK3LU	IK	SAFPHFWYRLLBFO-NSOVKSMOSA-N
DMWK3LU	IU	[4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-formylphenyl] dihydrogen phosphate
DMWK3LU	DE	Discovery agent

DMOA8FK	ID	DMOA8FK
DMOA8FK	DN	RU85053
DMOA8FK	HS	Investigative
DMOA8FK	SN	RU85053; CHEMBL432359; 5-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-CARBOXYMETHYL-BENZOIC ACID; 5-[(2S)-2-(acetylamino)-3-{[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]amino}-3-oxopropyl]-2-(carboxymethyl)benzoic acid; AC1L9KXI; BDBM14694; 1o48; DB03712; 5-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-(carboxymethyl)benzoic acid
DMOA8FK	DT	Small molecular drug
DMOA8FK	PC	447524
DMOA8FK	MW	585.6
DMOA8FK	FM	C33H35N3O7
DMOA8FK	IC	InChI=1S/C33H35N3O7/c1-21(37)34-29(18-23-12-15-26(19-30(38)39)27(17-23)33(42)43)31(40)35-28-9-5-6-16-36(32(28)41)20-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,17,28-29H,5-6,9,16,18-20H2,1H3,(H,34,37)(H,35,40)(H,38,39)(H,42,43)/t28-,29-/m0/s1
DMOA8FK	CS	CC(=O)N[C@@H](CC1=CC(=C(C=C1)CC(=O)O)C(=O)O)C(=O)N[C@H]2CCCCN(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4
DMOA8FK	IK	CEKLBQMULVLLTD-VMPREFPWSA-N
DMOA8FK	IU	5-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-(carboxymethyl)benzoic acid
DMOA8FK	DE	Discovery agent

DM97ZHX	ID	DM97ZHX
DM97ZHX	DN	RU85493
DM97ZHX	HS	Investigative
DM97ZHX	SN	RU85493; {4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-PHOSPHONO-PHENOXY}-ACETIC ACID; {4-[(2S)-2-(acetylamino)-3-{[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]amino}-3-oxopropyl]-2-phosphonophenoxy}acetic acid; Inhibitor 7; AC1NR9TR; CHEMBL436462; BDBM14695; 1o49; DB01908; 2-{4-[(2S)-2-acetamido-2-{[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]carbamoyl}ethyl]-2-phosphonophenoxy}acetic acid
DM97ZHX	DT	Small molecular drug
DM97ZHX	PC	5287515
DM97ZHX	MW	637.6
DM97ZHX	FM	C32H36N3O9P
DM97ZHX	IC	InChI=1S/C32H36N3O9P/c1-21(36)33-27(17-23-12-15-28(44-20-30(37)38)29(18-23)45(41,42)43)31(39)34-26-9-5-6-16-35(32(26)40)19-22-10-13-25(14-11-22)24-7-3-2-4-8-24/h2-4,7-8,10-15,18,26-27H,5-6,9,16-17,19-20H2,1H3,(H,33,36)(H,34,39)(H,37,38)(H2,41,42,43)/t26-,27-/m0/s1
DM97ZHX	CS	CC(=O)N[C@@H](CC1=CC(=C(C=C1)OCC(=O)O)P(=O)(O)O)C(=O)N[C@H]2CCCCN(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4
DM97ZHX	IK	MWEWSHNGVWABKG-SVBPBHIXSA-N
DM97ZHX	IU	2-[4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-phosphonophenoxy]acetic acid
DM97ZHX	DE	Discovery agent

DMHFKUC	ID	DMHFKUC
DMHFKUC	DN	RU90395
DMHFKUC	HS	Investigative
DMHFKUC	SN	RU90395; 2-{4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-METHOXYCARBONYL-PHENYL}-2-FLUORO-MALONIC ACID; {4-[(2S)-2-(acetylamino)-3-{[(3S)-1-(biphenyl-4-ylmethyl)-2-oxoazepan-3-yl]amino}-3-oxopropyl]-2-(methoxycarbonyl)phenyl}(fluoro)propanedioic acid; AC1L9KXE; CHEMBL357488; BDBM14692; 1o46; DB02432; 2-{4-[(2S)-2-acetamido-2-{[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]carbamoyl}ethyl]-2-(methoxycarbonyl)phenyl}-2-fluoropropanedioic acid
DMHFKUC	DT	Small molecular drug
DMHFKUC	PC	447522
DMHFKUC	MW	661.7
DMHFKUC	FM	C35H36FN3O9
DMHFKUC	IC	InChI=1S/C35H36FN3O9/c1-21(40)37-29(19-23-13-16-27(26(18-23)32(43)48-2)35(36,33(44)45)34(46)47)30(41)38-28-10-6-7-17-39(31(28)42)20-22-11-14-25(15-12-22)24-8-4-3-5-9-24/h3-5,8-9,11-16,18,28-29H,6-7,10,17,19-20H2,1-2H3,(H,37,40)(H,38,41)(H,44,45)(H,46,47)/t28-,29-/m0/s1
DMHFKUC	CS	CC(=O)N[C@@H](CC1=CC(=C(C=C1)C(C(=O)O)(C(=O)O)F)C(=O)OC)C(=O)N[C@H]2CCCCN(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4
DMHFKUC	IK	RLLAUERCSKPFGD-VMPREFPWSA-N
DMHFKUC	IU	2-[4-[(2S)-2-acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]propyl]-2-methoxycarbonylphenyl]-2-fluoropropanedioic acid
DMHFKUC	DE	Discovery agent

DMOHTC6	ID	DMOHTC6
DMOHTC6	DN	Ruthenium red
DMOHTC6	HS	Investigative
DMOHTC6	DT	Small molecular drug
DMOHTC6	PC	656819
DMOHTC6	MW	786.3
DMOHTC6	FM	Cl6H42N14O2Ru3
DMOHTC6	IC	InChI=1S/6ClH.14H3N.2O.3Ru/h6*1H;14*1H3;;;;;/q;;;;;;;;;;;;;;;;;;;;2*-2;;2*+5/p-6
DMOHTC6	CS	N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O-2].[O-2].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru].[Ru+5].[Ru+5]
DMOHTC6	IK	HURLCDYOFIWHCF-UHFFFAOYSA-H
DMOHTC6	IU	azane;oxygen(2-);ruthenium;ruthenium(5+);hexachloride
DMOHTC6	DE	Discovery agent

DMEHRAJ	ID	DMEHRAJ
DMEHRAJ	DN	Rutin
DMEHRAJ	HS	Investigative
DMEHRAJ	SN	RUTIN; 153-18-4; rutoside; Phytomelin; Quercetin 3-rutinoside; Birutan; Eldrin; Rutin trihydrate; Myrticolorin; Venoruton; Bioflavonoid; Paliuroside; Tanrutin; Osyritrin; Rutine; Rutozyd; 3-Rutinosyl quercetin; 3-Rhamnoglucosylquercetin; Quercetin 3-O-rutinoside; Rutosido; Rutosidum; Rutinum; Globularicitrin; Quercetin-3-rutinoside; Rutabion; Violaquercitrin; Globulariacitrin; Melin; Rutinic acid; Birutan Forte; Birutin; Quercetin rhamnoglucosine; Quercetin-3beta-rutinoside; UNII-5G06TVY3R7; Oxyritin; Rutosid; Ilixanthin; Rutinion acid
DMEHRAJ	DT	Small molecular drug
DMEHRAJ	PC	5280805
DMEHRAJ	MW	610.5
DMEHRAJ	FM	C27H30O16
DMEHRAJ	IC	InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,23+,26+,27-/m0/s1
DMEHRAJ	CS	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O
DMEHRAJ	IK	IKGXIBQEEMLURG-NVPNHPEKSA-N
DMEHRAJ	IU	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
DMEHRAJ	CA	CAS 153-18-4
DMEHRAJ	CB	CHEBI:28527
DMEHRAJ	DE	Discovery agent

DM8EZTM	ID	DM8EZTM
DM8EZTM	DN	RvD1-ME
DM8EZTM	HS	Investigative
DM8EZTM	SN	RvD1-methyl ester
DM8EZTM	DT	Small molecular drug
DM8EZTM	PC	71519431
DM8EZTM	MW	390.5
DM8EZTM	FM	C23H34O5
DM8EZTM	IC	InChI=1S/C23H34O5/c1-3-4-10-15-20(24)16-11-7-5-6-8-12-17-21(25)22(26)18-13-9-14-19-23(27)28-2/h4-13,16-17,20-22,24-26H,3,14-15,18-19H2,1-2H3/b7-5-,8-6+,10-4-,13-9-,16-11+,17-12+/t20-,21+,22-/m0/s1
DM8EZTM	CS	CC/C=C\\C[C@@H](/C=C/C=C\\C=C\\C=C\\[C@H]([C@H](C/C=C\\CCC(=O)OC)O)O)O
DM8EZTM	IK	WUKVAFWBFGABJN-ZXQGQRHTSA-N
DM8EZTM	IU	methyl (4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoate
DM8EZTM	DE	Discovery agent

DMAU6FN	ID	DMAU6FN
DMAU6FN	DN	RwFwLL-NH2
DMAU6FN	HS	Investigative
DMAU6FN	SN	CHEMBL500703; RwFwLL-NH2
DMAU6FN	DT	Small molecular drug
DMAU6FN	PC	44576248
DMAU6FN	MW	919.1
DMAU6FN	FM	C49H66N12O6
DMAU6FN	IC	InChI=1S/C49H66N12O6/c1-28(2)21-38(43(51)62)57-45(64)39(22-29(3)4)59-48(67)42(25-32-27-56-37-19-11-9-16-34(32)37)61-46(65)40(23-30-13-6-5-7-14-30)60-47(66)41(24-31-26-55-36-18-10-8-15-33(31)36)58-44(63)35(50)17-12-20-54-49(52)53/h5-11,13-16,18-19,26-29,35,38-42,55-56H,12,17,20-25,50H2,1-4H3,(H2,51,62)(H,57,64)(H,58,63)(H,59,67)(H,60,66)(H,61,65)(H4,52,53,54)/t35-,38-,39-,40-,41+,42+/m0/s1
DMAU6FN	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCCN=C(N)N)N
DMAU6FN	IK	GHJBYAJFOUQNRR-MQYLJLIZSA-N
DMAU6FN	IU	(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanamide
DMAU6FN	DE	Discovery agent

DMP7SI9	ID	DMP7SI9
DMP7SI9	DN	RWJ-140998
DMP7SI9	HS	Investigative
DMP7SI9	SN	4-hydroxy-1-methyl-7,8,9,10-tetrahydro-6H-[1,3]thiazocino[2,3-f]purin-2(1H)-one; RWJ-140998; AC1LIVUI; Oprea1_483450; MolPort-005-971-769; MolPort-002-544-111; ZINC496244; STK643127; AKOS005574570; AKOS030506897; MCULE-9461774198; 1-methyl-7,8,9,10-tetrahydro-6H-purino[8,7-b][1,3]thiazocine-2,4-dione; 1-methyl-7,8,9,10-tetrahydro-1H-[1,3]thiazocino[2,3-f]purine-2,4(3H,6H)-dione
DMP7SI9	CP	DuPont, Vicuron RW Johnson
DMP7SI9	DT	Small molecular drug
DMP7SI9	PC	912224
DMP7SI9	MW	266.32
DMP7SI9	FM	C11H14N4O2S
DMP7SI9	IC	InChI=1S/C11H14N4O2S/c1-14-8-7(9(16)13-10(14)17)15-5-3-2-4-6-18-11(15)12-8/h2-6H2,1H3,(H,13,16,17)
DMP7SI9	CS	CN1C2=C(C(=O)NC1=O)N3CCCCCSC3=N2
DMP7SI9	IK	IGKRUASVZKVVLL-UHFFFAOYSA-N
DMP7SI9	IU	1-methyl-7,8,9,10-tetrahydro-6H-purino[8,7-b][1,3]thiazocine-2,4-dione
DMP7SI9	DE	Gram-positive bacterial infection

DME68VT	ID	DME68VT
DME68VT	DN	RWJ-16979
DME68VT	HS	Investigative
DME68VT	DT	Small molecular drug
DME68VT	PC	11722634
DME68VT	DE	Discovery agent

DMPJTLM	ID	DMPJTLM
DMPJTLM	DN	RWJ-38063
DMPJTLM	HS	Investigative
DMPJTLM	SN	RWJ-38063; CHEMBL275469; SCHEMBL7689590; IIRJWNCOXHFIBK-UHFFFAOYSA-N; BDBM50088702; RWJ-38603; N-{2-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-ethyl}-2-(2-oxo-piperidin-1-yl)-acetamide; N-[2-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]-2-oxo-1-piperidineacetamide; N-{2-[4-(2-(2-propoxy)phenyl)-1-piperazinyl]ethyl}-2-(2-oxo-piperidin-1-yl)acetamide; N-{2-[4-(2-(2-propoxy) phenyl)-1-piperazinyl]ethyl}-2-(2-oxo-piperidin-1-yl)acetamide
DMPJTLM	DT	Small molecular drug
DMPJTLM	PC	9887378
DMPJTLM	MW	402.5
DMPJTLM	FM	C22H34N4O3
DMPJTLM	IC	InChI=1S/C22H34N4O3/c1-18(2)29-20-8-4-3-7-19(20)25-15-13-24(14-16-25)12-10-23-21(27)17-26-11-6-5-9-22(26)28/h3-4,7-8,18H,5-6,9-17H2,1-2H3,(H,23,27)
DMPJTLM	CS	CC(C)OC1=CC=CC=C1N2CCN(CC2)CCNC(=O)CN3CCCCC3=O
DMPJTLM	IK	IIRJWNCOXHFIBK-UHFFFAOYSA-N
DMPJTLM	IU	2-(2-oxopiperidin-1-yl)-N-[2-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]ethyl]acetamide
DMPJTLM	CA	CAS 216252-56-1
DMPJTLM	DE	Discovery agent

DM28IKN	ID	DM28IKN
DM28IKN	DN	RWJ-387273
DM28IKN	HS	Investigative
DM28IKN	SN	R-290629; oral PDE 5 inhibitor (erectile dysfunction), Johnson & Johnson
DM28IKN	PC	11315033
DM28IKN	MW	381.4
DM28IKN	FM	C24H19N3O2
DM28IKN	IC	InChI=1S/C24H19N3O2/c28-24-17-5-1-2-6-19(17)26-22-18(24)14-27(21-7-3-4-11-25-21)23(22)16-8-9-20-15(13-16)10-12-29-20/h1-9,11,13,23H,10,12,14H2,(H,26,28)/t23-/m1/s1
DM28IKN	CS	C1COC2=C1C=C(C=C2)[C@@H]3C4=C(CN3C5=CC=CC=N5)C(=O)C6=CC=CC=C6N4
DM28IKN	IK	NPQHDOLBQQVPMG-HSZRJFAPSA-N
DM28IKN	IU	(3R)-3-(2,3-dihydro-1-benzofuran-5-yl)-2-pyridin-2-yl-3,4-dihydro-1H-pyrrolo[3,4-b]quinolin-9-one
DM28IKN	CA	CAS 374927-41-0
DM28IKN	DE	Discovery agent

DMBVLCQ	ID	DMBVLCQ
DMBVLCQ	DN	RWJ-3981
DMBVLCQ	HS	Investigative
DMBVLCQ	SN	5-Chloro-4-phenyl-3H-1,2-dithiol-3-one; Hercules 3944; UNII-J77BU43MZU; 2425-05-0; Hercules 3944X; 3H-1,2-Dithiol-3-one, 5-chloro-4-phenyl-; J77BU43MZU; He 3944; NSC29804; 5-chloro-4-phenyldithiol-3-one; RWJ-3981; NSC 29804; 5-CHLORO-4-PHENYL-1,2-DITHIOLE-3-ONE; RWJ-3981 (compound 2); SCHEMBL6064553; 3H-1, 5-chloro-4-phenyl-; DTXSID8041537; BDBM119067; 5-chloro-4-phenyl-dithiol-3-one; ZINC1655991; AC1L2978; NSC-29804; 5-chloro-4-phenyl-[1,2]-dithiol-3-one; H 3944
DMBVLCQ	CP	DuPont, Vicuron RW Johnson
DMBVLCQ	DT	Small molecular drug
DMBVLCQ	PC	17037
DMBVLCQ	MW	228.7
DMBVLCQ	FM	C9H5ClOS2
DMBVLCQ	IC	InChI=1S/C9H5ClOS2/c10-8-7(9(11)13-12-8)6-4-2-1-3-5-6/h1-5H
DMBVLCQ	CS	C1=CC=C(C=C1)C2=C(SSC2=O)Cl
DMBVLCQ	IK	BWTGFYQZOUAOQW-UHFFFAOYSA-N
DMBVLCQ	IU	5-chloro-4-phenyldithiol-3-one
DMBVLCQ	CA	CAS 2425-05-0
DMBVLCQ	DE	Gram-positive bacterial infection

DMBOSGN	ID	DMBOSGN
DMBOSGN	DN	RWJ-49968
DMBOSGN	HS	Investigative
DMBOSGN	TC	Antifungal Agents
DMBOSGN	PC	9843779
DMBOSGN	MW	397.9
DMBOSGN	FM	C23H28ClN3O
DMBOSGN	IC	InChI=1S/C23H28ClN3O/c24-20-6-4-5-19(15-20)16-23(11-2-1-3-12-23)13-14-28-21-9-7-18(8-10-21)17-27-22(25)26/h2,4-11,15H,1,3,12-14,16-17H2,(H4,25,26,27)
DMBOSGN	CS	C1CC=CC(C1)(CCOC2=CC=C(C=C2)CN=C(N)N)CC3=CC(=CC=C3)Cl
DMBOSGN	IK	VJXVVAAVNHDMTH-UHFFFAOYSA-N
DMBOSGN	IU	2-[[4-[2-[1-[(3-chlorophenyl)methyl]cyclohex-2-en-1-yl]ethoxy]phenyl]methyl]guanidine
DMBOSGN	DE	Fungal infection

DMRPYGX	ID	DMRPYGX
DMRPYGX	DN	RWJ-50353
DMRPYGX	HS	Investigative
DMRPYGX	SN	RWJ-50353; CHEMBL270437; CHEMBL339122; BDBM50131975; BDBM50228853; (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-5-guanidino-1-oxopentan-2-yl)-1-((R)-2-(methylamino)-3-phenylpropanoyl)pyrrolidine-2-carboxamide; (S)-1-((R)-2-Methylamino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid [(S)-1-(benzothiazole-2-carbonyl)-4-guanidino-butyl]-amide; 1-(2-Methylamino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid [1-(benzothiazole-2-carbonyl)-4-guanidino-butyl]-amide
DMRPYGX	DT	Small molecular drug
DMRPYGX	PC	9872263
DMRPYGX	MW	549.7
DMRPYGX	FM	C28H35N7O3S
DMRPYGX	IC	InChI=1S/C28H35N7O3S/c1-31-21(17-18-9-3-2-4-10-18)27(38)35-16-8-13-22(35)25(37)33-20(12-7-15-32-28(29)30)24(36)26-34-19-11-5-6-14-23(19)39-26/h2-6,9-11,14,20-22,31H,7-8,12-13,15-17H2,1H3,(H,33,37)(H4,29,30,32)/t20-,21+,22-/m0/s1
DMRPYGX	CS	CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)C3=NC4=CC=CC=C4S3
DMRPYGX	IK	QRBIRSCLEVEODD-BDTNDASRSA-N
DMRPYGX	IU	(2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMRPYGX	DE	Discovery agent

DMAEWMP	ID	DMAEWMP
DMAEWMP	DN	RWJ-53419
DMAEWMP	HS	Investigative
DMAEWMP	SN	RWJ-53419; CHEMBL421547; BDBM50104598; 2-Benzyloxycarbonylamino-3-{[(R)-1-(3-piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-propionic acid
DMAEWMP	DT	Small molecular drug
DMAEWMP	PC	44322318
DMAEWMP	MW	488.6
DMAEWMP	FM	C25H36N4O6
DMAEWMP	IC	InChI=1S/C25H36N4O6/c30-22(9-8-18-10-12-26-13-11-18)29-14-4-7-20(16-29)23(31)27-15-21(24(32)33)28-25(34)35-17-19-5-2-1-3-6-19/h1-3,5-6,18,20-21,26H,4,7-17H2,(H,27,31)(H,28,34)(H,32,33)/t20-,21+/m1/s1
DMAEWMP	CS	C1C[C@H](CN(C1)C(=O)CCC2CCNCC2)C(=O)NC[C@@H](C(=O)O)NC(=O)OCC3=CC=CC=C3
DMAEWMP	IK	MUWWGBUXCFRNCO-RTWAWAEBSA-N
DMAEWMP	IU	(2S)-2-(phenylmethoxycarbonylamino)-3-[[(3R)-1-(3-piperidin-4-ylpropanoyl)piperidine-3-carbonyl]amino]propanoic acid
DMAEWMP	DE	Discovery agent

DME07AN	ID	DME07AN
DME07AN	DN	RWJ-56110
DME07AN	HS	Investigative
DME07AN	SN	RWJ56110
DME07AN	DT	Small molecular drug
DME07AN	PC	9853822
DME07AN	MW	790.7
DME07AN	FM	C41H43Cl2F2N7O3
DME07AN	IC	InChI=1S/C41H43Cl2F2N7O3/c42-32-9-6-10-33(43)31(32)25-52-24-28(23-51-17-4-5-18-51)30-13-12-29(21-38(30)52)48-41(55)50-37(20-27-11-14-34(44)35(45)19-27)40(54)49-36(15-16-46)39(53)47-22-26-7-2-1-3-8-26/h1-3,6-14,19,21,24,36-37H,4-5,15-18,20,22-23,25,46H2,(H,47,53)(H,49,54)(H2,48,50,55)/t36-,37-/m0/s1
DME07AN	CS	C1CCN(C1)CC2=CN(C3=C2C=CC(=C3)NC(=O)N[C@@H](CC4=CC(=C(C=C4)F)F)C(=O)N[C@@H](CCN)C(=O)NCC5=CC=CC=C5)CC6=C(C=CC=C6Cl)Cl
DME07AN	IK	SWPAWRHBFNDXEU-BCRBLDSWSA-N
DME07AN	IU	(2S)-4-amino-N-benzyl-2-[[(2S)-2-[[1-[(2,6-dichlorophenyl)methyl]-3-(pyrrolidin-1-ylmethyl)indol-6-yl]carbamoylamino]-3-(3,4-difluorophenyl)propanoyl]amino]butanamide
DME07AN	DE	Discovery agent

DMGUWFJ	ID	DMGUWFJ
DMGUWFJ	DN	RWJ-61907
DMGUWFJ	HS	Investigative
DMGUWFJ	TC	Antifungal Agents
DMGUWFJ	PC	47626
DMGUWFJ	MW	369.4
DMGUWFJ	FM	C22H19N5O
DMGUWFJ	IC	InChI=1S/C22H19N5O/c23-21(24)14-5-9-18(10-6-14)28-17-7-3-13(4-8-17)19-11-15-1-2-16(22(25)26)12-20(15)27-19/h1-12,27H,(H3,23,24)(H3,25,26)
DMGUWFJ	CS	C1=CC(=CC=C1C2=CC3=C(N2)C=C(C=C3)C(=N)N)OC4=CC=C(C=C4)C(=N)N
DMGUWFJ	IK	OSSYTOVYXCAWPG-UHFFFAOYSA-N
DMGUWFJ	IU	2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-6-carboximidamide
DMGUWFJ	CA	CAS 65426-89-3
DMGUWFJ	DE	Fungal infection

DMUZW80	ID	DMUZW80
DMUZW80	DN	RWJ-68141
DMUZW80	HS	Investigative
DMUZW80	SN	RWJ-68141; CHEMBL180312; BDBM50160158; 1-{4-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-2-oxo-butyl}-5-oxo-pyrrolidine-2-carboxylic acid ethyl ester
DMUZW80	DT	Small molecular drug
DMUZW80	PC	44390756
DMUZW80	MW	445.6
DMUZW80	FM	C24H35N3O5
DMUZW80	IC	InChI=1S/C24H35N3O5/c1-4-31-24(30)21-9-10-23(29)27(21)17-19(28)11-12-25-13-15-26(16-14-25)20-7-5-6-8-22(20)32-18(2)3/h5-8,18,21H,4,9-17H2,1-3H3
DMUZW80	CS	CCOC(=O)C1CCC(=O)N1CC(=O)CCN2CCN(CC2)C3=CC=CC=C3OC(C)C
DMUZW80	IK	WOLMQTMNCPQASG-UHFFFAOYSA-N
DMUZW80	IU	ethyl 5-oxo-1-[2-oxo-4-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]butyl]pyrrolidine-2-carboxylate
DMUZW80	DE	Discovery agent

DMUK7LX	ID	DMUK7LX
DMUK7LX	DN	RWJ-68157
DMUK7LX	HS	Investigative
DMUK7LX	SN	RWJ-68157; CHEMBL12603; BDBM50088703
DMUK7LX	DT	Small molecular drug
DMUK7LX	PC	9888164
DMUK7LX	MW	416.6
DMUK7LX	FM	C23H36N4O3
DMUK7LX	IC	InChI=1S/C23H36N4O3/c1-19(2)30-21-9-6-5-8-20(21)26-16-14-25(15-17-26)13-11-24-22(28)18-27-12-7-3-4-10-23(27)29/h5-6,8-9,19H,3-4,7,10-18H2,1-2H3,(H,24,28)
DMUK7LX	CS	CC(C)OC1=CC=CC=C1N2CCN(CC2)CCNC(=O)CN3CCCCCC3=O
DMUK7LX	IK	XHBOWUOETHUEOP-UHFFFAOYSA-N
DMUK7LX	IU	2-(2-oxoazepan-1-yl)-N-[2-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]ethyl]acetamide
DMUK7LX	DE	Discovery agent

DMNLVRS	ID	DMNLVRS
DMNLVRS	DN	RWJ-68354
DMNLVRS	HS	Investigative
DMNLVRS	SN	RWJ-68354; CHEMBL115769; 2-(4-FLUOROPHENYL)-4-METHOXY-3-(PYRIDIN-4-YL)-1H-PYRROLO[2,3-B]PYRIDIN-6-AMINE; rwj68354; SCHEMBL149547; BDBM15457; BDBM50215267; AKOS000280165
DMNLVRS	DT	Small molecular drug
DMNLVRS	PC	9819053
DMNLVRS	MW	334.3
DMNLVRS	FM	C19H15FN4O
DMNLVRS	IC	InChI=1S/C19H15FN4O/c1-25-14-10-15(21)23-19-17(14)16(11-6-8-22-9-7-11)18(24-19)12-2-4-13(20)5-3-12/h2-10H,1H3,(H3,21,23,24)
DMNLVRS	CS	COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N
DMNLVRS	IK	ADQZGIYHFQQPRB-UHFFFAOYSA-N
DMNLVRS	IU	2-(4-fluorophenyl)-4-methoxy-3-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-6-amine
DMNLVRS	DE	Discovery agent

DM2EOBM	ID	DM2EOBM
DM2EOBM	DN	RWJ-69736
DM2EOBM	HS	Investigative
DM2EOBM	SN	RWJ-69736; CHEMBL12062; BDBM50088706
DM2EOBM	DT	Small molecular drug
DM2EOBM	PC	9866614
DM2EOBM	MW	416.6
DM2EOBM	FM	C23H36N4O3
DM2EOBM	IC	InChI=1S/C23H36N4O3/c1-19(2)30-21-9-4-3-8-20(21)26-16-14-25(15-17-26)12-7-11-24-22(28)18-27-13-6-5-10-23(27)29/h3-4,8-9,19H,5-7,10-18H2,1-2H3,(H,24,28)
DM2EOBM	CS	CC(C)OC1=CC=CC=C1N2CCN(CC2)CCCNC(=O)CN3CCCCC3=O
DM2EOBM	IK	STMYXSKGGILJBE-UHFFFAOYSA-N
DM2EOBM	IU	2-(2-oxopiperidin-1-yl)-N-[3-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]propyl]acetamide
DM2EOBM	DE	Discovery agent

DMKYNGE	ID	DMKYNGE
DMKYNGE	DN	RX-1792
DMKYNGE	HS	Investigative
DMKYNGE	SN	EGF antagonist, Rexahn; RX-0183
DMKYNGE	CP	Rexahn Pharmaceuticals Inc
DMKYNGE	DE	Solid tumour/cancer

DMM5O30	ID	DMM5O30
DMM5O30	DN	RXP-407
DMM5O30	HS	Investigative
DMM5O30	SN	RXP 407
DMM5O30	DT	Small molecular drug
DMM5O30	PC	9827219
DMM5O30	MW	498.5
DMM5O30	FM	C21H31N4O8P
DMM5O30	IC	InChI=1S/C21H31N4O8P/c1-12(20(30)23-13(2)19(22)29)11-34(32,33)17(9-15-7-5-4-6-8-15)25-21(31)16(10-18(27)28)24-14(3)26/h4-8,12-13,16-17H,9-11H2,1-3H3,(H2,22,29)(H,23,30)(H,24,26)(H,25,31)(H,27,28)(H,32,33)/t12-,13+,16+,17-/m1/s1
DMM5O30	CS	C[C@H](CP(=O)([C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)NC(=O)C)O)C(=O)N[C@@H](C)C(=O)N
DMM5O30	IK	OCAZUTUOYLAIOA-OSRSDYAFSA-N
DMM5O30	IU	(3S)-3-acetamido-4-[[(1R)-1-[[(2S)-3-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-2-methyl-3-oxopropyl]-hydroxyphosphoryl]-2-phenylethyl]amino]-4-oxobutanoic acid
DMM5O30	DE	Discovery agent

DM5GIUY	ID	DM5GIUY
DM5GIUY	DN	RXP-470
DM5GIUY	HS	Investigative
DM5GIUY	SN	MMP-12 inhibitors (atherosclerosis); MMP-12 inhibitors (atherosclerosis), CEA; RXP-470 derivatives (atherosclerosis), CEA
DM5GIUY	CP	Commissariat a l`Energie Atomique
DM5GIUY	PC	102258832
DM5GIUY	MW	818
DM5GIUY	FM	C35H35BrClN4O10P
DM5GIUY	IC	InChI=1S/C35H35BrClN4O10P/c36-24-8-10-27(11-9-24)52(49,50)19-23(33(45)39-28(13-15-32(43)44)34(46)40-29(35(47)48)12-14-31(38)42)17-26-18-30(41-51-26)21-6-4-20(5-7-21)22-2-1-3-25(37)16-22/h1-11,16,18,23,28-29H,12-15,17,19H2,(H2,38,42)(H,39,45)(H,40,46)(H,43,44)(H,47,48)(H,49,50)/t23-,28+,29+/m1/s1
DM5GIUY	CS	C1=CC(=CC(=C1)Cl)C2=CC=C(C=C2)C3=NOC(=C3)C[C@H](CP(=O)(C4=CC=C(C=C4)Br)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O
DM5GIUY	IK	SCLRICMZGZSWFY-MGONOCMRSA-N
DM5GIUY	IU	(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(4-bromophenyl)-hydroxyphosphoryl]methyl]-3-[3-[4-(3-chlorophenyl)phenyl]-1,2-oxazol-5-yl]propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoic acid
DM5GIUY	DE	Arteriosclerosis

DMB7EGU	ID	DMB7EGU
DMB7EGU	DN	RXP470.1
DMB7EGU	HS	Investigative
DMB7EGU	SN	RXP470.1; CHEMBL507420; N-[(2s)-3-[(S)-(4-Bromophenyl)(Hydroxy)phosphoryl]-2-{[3-(3'-Chlorobiphenyl-4-Yl)-1,2-Oxazol-5-Yl]methyl}propanoyl]-L-Alpha-Glutamyl-L-Alpha-Glutamine; R47; GTPL7812; BDBM50265078; (4S)-5-amino-4-((2S)-2-((2S)-3-((4-bromophenyl)(hydroxy)phosphoryl)-2-((3-(3''-chlorobiphenyl-4-yl)isoxazol-5-yl)methyl)propanamido)-4-carboxybutanamido)-5-oxopentanoic acid
DMB7EGU	DT	Small molecular drug
DMB7EGU	PC	44580458
DMB7EGU	MW	818
DMB7EGU	FM	C35H35BrClN4O10P
DMB7EGU	IC	InChI=1S/C35H35BrClN4O10P/c36-24-8-10-27(11-9-24)52(49,50)19-23(34(47)40-29(13-15-32(44)45)35(48)39-28(33(38)46)12-14-31(42)43)17-26-18-30(41-51-26)21-6-4-20(5-7-21)22-2-1-3-25(37)16-22/h1-11,16,18,23,28-29H,12-15,17,19H2,(H2,38,46)(H,39,48)(H,40,47)(H,42,43)(H,44,45)(H,49,50)/t23-,28+,29+/m1/s1
DMB7EGU	CS	C1=CC(=CC(=C1)Cl)C2=CC=C(C=C2)C3=NOC(=C3)C[C@H](CP(=O)(C4=CC=C(C=C4)Br)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N
DMB7EGU	IK	PTUCPHGSAFOJAU-MGONOCMRSA-N
DMB7EGU	IU	(4S)-5-amino-4-[[(2S)-2-[[(2S)-2-[[(4-bromophenyl)-hydroxyphosphoryl]methyl]-3-[3-[4-(3-chlorophenyl)phenyl]-1,2-oxazol-5-yl]propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoic acid
DMB7EGU	DE	Discovery agent

DM9KXV0	ID	DM9KXV0
DM9KXV0	DN	RY024
DM9KXV0	HS	Investigative
DM9KXV0	SN	RY-024; RY 024
DM9KXV0	DT	Small molecular drug
DM9KXV0	PC	9927764
DM9KXV0	MW	337.4
DM9KXV0	FM	C19H19N3O3
DM9KXV0	IC	InChI=1S/C19H19N3O3/c1-6-12-7-8-14-13(9-12)17(23)21(5)10-15-16(20-11-22(14)15)18(24)25-19(2,3)4/h1,7-9,11H,10H2,2-5H3
DM9KXV0	CS	CC(C)(C)OC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)C#C)C
DM9KXV0	IK	YTUMMZANIYQNOM-UHFFFAOYSA-N
DM9KXV0	IU	tert-butyl 8-ethynyl-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DM9KXV0	DE	Discovery agent

DMGUX16	ID	DMGUX16
DMGUX16	DN	RY-066
DMGUX16	HS	Investigative
DMGUX16	SN	RY-066; CHEMBL130416; BDBM50067419; ethyl 9-oxo-7-(2-trimethylsilyl-1-ethynyl)-(12aS)-12,12a-dihydro-9H,11H-azeto[1,2-a]benzo[e]imidazo[5,1-c][1,4]diazepine-1-carboxylate
DMGUX16	DT	Small molecular drug
DMGUX16	PC	10715591
DMGUX16	MW	393.5
DMGUX16	FM	C21H23N3O3Si
DMGUX16	IC	InChI=1S/C21H23N3O3Si/c1-5-27-21(26)18-19-17-8-10-23(17)20(25)15-12-14(9-11-28(2,3)4)6-7-16(15)24(19)13-22-18/h6-7,12-13,17H,5,8,10H2,1-4H3/t17-/m0/s1
DMGUX16	CS	CCOC(=O)C1=C2[C@@H]3CCN3C(=O)C4=C(N2C=N1)C=CC(=C4)C#C[Si](C)(C)C
DMGUX16	IK	SNBBNIBMHQGUBE-KRWDZBQOSA-N
DMGUX16	IU	ethyl (7S)-11-oxo-14-(2-trimethylsilylethynyl)-2,4,10-triazatetracyclo[10.4.0.02,6.07,10]hexadeca-1(16),3,5,12,14-pentaene-5-carboxylate
DMGUX16	DE	Discovery agent

DMW4850	ID	DMW4850
DMW4850	DN	RY796
DMW4850	HS	Investigative
DMW4850	SN	RY 796; RY-796
DMW4850	DT	Small molecular drug
DMW4850	PC	76850157
DMW4850	MW	353.5
DMW4850	FM	C21H27N3O2
DMW4850	IC	InChI=1S/C21H27N3O2/c1-14(2)20(25)23-17-11-12-19(24(4)5)18(13-17)21(26)22-15(3)16-9-7-6-8-10-16/h6-15H,1-5H3,(H,22,26)(H,23,25)/t15-/m1/s1
DMW4850	CS	C[C@H](C1=CC=CC=C1)NC(=O)C2=C(C=CC(=C2)NC(=O)C(C)C)N(C)C
DMW4850	IK	LDXZFQWWXMRMAS-OAHLLOKOSA-N
DMW4850	IU	2-(dimethylamino)-5-(2-methylpropanoylamino)-N-[(1R)-1-phenylethyl]benzamide
DMW4850	DE	Discovery agent

DM2K6I8	ID	DM2K6I8
DM2K6I8	DN	Ryanodine
DM2K6I8	HS	Investigative
DM2K6I8	SN	ryanodine; Ryanodin; 15662-33-6; Ryania; Ryanodol, 3-(1H-pyrrole-2-carboxylate); Ryanadol; (3S,4R,4aR,6S,6aR,7S,8R,8aS,8bR,9S,9aS)-4,6,7,8a,8b,9a-hexahydroxy-7-isopropyl-3,6a,9-trimethyldodecahydro-6,9-methanobenzo[1,2]pentaleno[1,6-bc]furan-8-yl 1H-pyrrole-2-carboxylate; (3S,4R,4aR,6S,6aR,7S,8R,8aS,8bR,9S,9aS)-4,6,7,8a,8b,9a-hexahydroxy-3,6a,9-trimethyl-7-(propan-2-yl)dodecahydro-6,9-methanobenzo[1,2]pentaleno[1,6-bc]furan-8-yl 1H-pyrrole-2-carboxylate; 3-(1H-pyrrole-2-carboxylate; Ryanodine High Purity
DM2K6I8	DT	Small molecular drug
DM2K6I8	PC	11317883
DM2K6I8	MW	493.5
DM2K6I8	FM	C25H35NO9
DM2K6I8	IC	InChI=1S/C25H35NO9/c1-12(2)22(31)17(34-16(28)14-7-6-10-26-14)23(32)18(4)11-21(30)19(22,5)25(23,33)24(35-21)15(27)13(3)8-9-20(18,24)29/h6-7,10,12-13,15,17,26-27,29-33H,8-9,11H2,1-5H3/t13-,15+,17+,18-,19+,20-,21-,22+,23+,24+,25+/m0/s1
DM2K6I8	CS	C[C@H]1CC[C@@]2([C@@]3(C[C@]4([C@@]5([C@]([C@H]([C@@]3([C@]5([C@]2([C@@H]1O)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DM2K6I8	IK	JJSYXNQGLHBRRK-SFEDZAPPSA-N
DM2K6I8	IU	[(1R,2R,3S,6S,7S,9S,10R,11S,12R,13S,14R)-2,6,9,11,13,14-hexahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DM2K6I8	CA	CAS 15662-33-6
DM2K6I8	CB	CHEBI:8925
DM2K6I8	DE	Discovery agent

DM9HA8G	ID	DM9HA8G
DM9HA8G	DN	S 0957
DM9HA8G	HS	Investigative
DM9HA8G	DE	Discovery agent

DMA5GOX	ID	DMA5GOX
DMA5GOX	DN	S 1743
DMA5GOX	HS	Investigative
DMA5GOX	DE	Discovery agent

DM2FC5V	ID	DM2FC5V
DM2FC5V	DN	S 18204
DM2FC5V	HS	Investigative
DM2FC5V	DT	Small molecular drug
DM2FC5V	DE	Discovery agent

DMGEHNX	ID	DMGEHNX
DMGEHNX	DN	S 202 791
DMGEHNX	HS	Investigative
DMGEHNX	SN	Sandoz-202-791; Sdz 202-791; SAN 202791; R202-791; S 202-791; 97217-84-0; C17H18N4O5; 3-Pyridinecarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-5-nitro-, 1-methylethyl ester, (R)-; (R)-Sandoz 202-791; (-)-Sandoz 202-791; Sandoz 202-791, (-)-; (R)-(-)-Sandoz 202-791; AC1L3UBJ; AC1Q1WKA; (-)-SDZ 202-791; CBiol_001888; (-)-PN 202-791; CHEMBL487115; (R)-202-791; CTK5H9159; Bio1_001152; Bio1_000174; Bio1_000663; AKOS030532582; SDZ-202791; SDZ-202-791; NCGC00163134-01; 3-Pyridinecarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-
DMGEHNX	DT	Small molecular drug
DMGEHNX	PC	122292
DMGEHNX	MW	358.3
DMGEHNX	FM	C17H18N4O5
DMGEHNX	IC	InChI=1S/C17H18N4O5/c1-8(2)25-17(22)13-9(3)18-10(4)16(21(23)24)14(13)11-6-5-7-12-15(11)20-26-19-12/h5-8,14,18H,1-4H3/t14-/m1/s1
DMGEHNX	CS	CC1=C([C@H](C(=C(N1)C)[N+](=O)[O-])C2=CC=CC3=NON=C32)C(=O)OC(C)C
DMGEHNX	IK	LYFZEFDZKPJBJK-CQSZACIVSA-N
DMGEHNX	IU	propan-2-yl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-5-nitro-1,4-dihydropyridine-3-carboxylate
DMGEHNX	CA	CAS 97217-84-0
DMGEHNX	DE	Discovery agent

DMZN0RW	ID	DMZN0RW
DMZN0RW	DN	S 3025
DMZN0RW	HS	Investigative
DMZN0RW	SN	PMSF; Phenylmethylsulfonyl fluoride; phenylmethanesulfonyl fluoride; 329-98-6; Benzylsulfonyl fluoride; Benzenemethanesulfonyl fluoride; alpha-TOLUENESULFONYL FLUORIDE; Benzylsulphonyl fluoride; alpha-Toluenesulphonyl fluoride; Phenylmethylsulfonylfluoride; Phenylmethylsulphonyl fluoride; NSC 88499; UNII-57KD15003I; EINECS 206-350-2; BRN 2088311; CHEMBL190503; CHEBI:8102; alpha-Toluenesulfonyl fluoride; fluorobenzylsulfone; YBYRMVIVWMBXKQ-UHFFFAOYSA-N; MFCD00007424; PHENYLMETHANESULPHONYL FLUORIDE; 57KD15003I; phenyl methyl
DMZN0RW	DT	Small molecular drug
DMZN0RW	PC	4784
DMZN0RW	MW	174.19
DMZN0RW	FM	C7H7FO2S
DMZN0RW	IC	InChI=1S/C7H7FO2S/c8-11(9,10)6-7-4-2-1-3-5-7/h1-5H,6H2
DMZN0RW	CS	C1=CC=C(C=C1)CS(=O)(=O)F
DMZN0RW	IK	YBYRMVIVWMBXKQ-UHFFFAOYSA-N
DMZN0RW	IU	phenylmethanesulfonyl fluoride
DMZN0RW	CA	CAS 329-98-6
DMZN0RW	CB	CHEBI:8102
DMZN0RW	DE	Discovery agent

DMXUBIK	ID	DMXUBIK
DMXUBIK	DN	S-(-)CPB
DMXUBIK	HS	Investigative
DMXUBIK	SN	2-(4-chlorophenoxy)butanoic acid; 10310-19-7; 2-(4-Chlorophenoxy)butyric acid; 34385-92-7; Butanoic acid, 2-(4-chlorophenoxy)-; Butanoic acid,2-(4-chlorophenoxy)-; S-(-)CPB; p-chlorophenoxybutyric acid; AC1L46GO; CHEMBL23477; SCHEMBL3028298; GTPL4097; CTK4A1742; CEJKAKCQVUWNNA-UHFFFAOYSA-N; MolPort-000-889-545; ZX-AN000853; ALBB-000862; ZX-AV000272; SP4251; SBB020800; STK501060; BBL002691; 7737AC; ETHYL(4-CHLOROPHENOXY)ACETATE; AKOS000103672; AKOS016345013; MCULE-4592400851; NCGC00327569-01; (2RS)-2-(4-chlorophenoxy)butyric acid; U469
DMXUBIK	DT	Small molecular drug
DMXUBIK	PC	151501
DMXUBIK	MW	214.64
DMXUBIK	FM	C10H11ClO3
DMXUBIK	IC	InChI=1S/C10H11ClO3/c1-2-9(10(12)13)14-8-5-3-7(11)4-6-8/h3-6,9H,2H2,1H3,(H,12,13)
DMXUBIK	CS	CCC(C(=O)O)OC1=CC=C(C=C1)Cl
DMXUBIK	IK	CEJKAKCQVUWNNA-UHFFFAOYSA-N
DMXUBIK	IU	2-(4-chlorophenoxy)butanoic acid
DMXUBIK	CA	CAS 10310-19-7
DMXUBIK	DE	Discovery agent

DME9QR0	ID	DME9QR0
DME9QR0	DN	S-(-)CPP
DME9QR0	HS	Investigative
DME9QR0	SN	2-(4-CHLOROPHENOXY)PROPANOIC ACID; 3307-39-9; 2-(4-Chlorophenoxy)propionic acid; 4-CPP; 2-(p-Chlorophenoxy)propionic acid; 2-(4-chlorophenoxy) propionic acid; Propanoic acid, 2-(4-chlorophenoxy)-; 2-(4-CPP); C9H9ClO3; CHEBI:34603; DKHJWWRYTONYHB-UHFFFAOYSA-N; S-(-)CPP; EINECS 221-991-8; NSC 70174; alpha-(4-Chlorophenoxy)propionic acid; Propionic acid, 2-(p-chlorophenoxy)-; AC1L2CMI; C13701; NCIOpen2_003229; CHEMBL23629; SCHEMBL117259; AC1Q2C09; GTPL4098; ARONIS008729; Jsp006087; CTK4E4178; MolPort-000-685-652; NSC70174; SP4232
DME9QR0	DT	Small molecular drug
DME9QR0	PC	18703
DME9QR0	MW	200.62
DME9QR0	FM	C9H9ClO3
DME9QR0	IC	InChI=1S/C9H9ClO3/c1-6(9(11)12)13-8-4-2-7(10)3-5-8/h2-6H,1H3,(H,11,12)
DME9QR0	CS	CC(C(=O)O)OC1=CC=C(C=C1)Cl
DME9QR0	IK	DKHJWWRYTONYHB-UHFFFAOYSA-N
DME9QR0	IU	2-(4-chlorophenoxy)propanoic acid
DME9QR0	CA	CAS 3307-39-9
DME9QR0	CB	CHEBI:34603
DME9QR0	DE	Discovery agent

DMQG4L2	ID	DMQG4L2
DMQG4L2	DN	S-(-)-enantiomer of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP)
DMQG4L2	HS	Investigative
DMQG4L2	SN	AC1MT1CM; S-(10,13-dimethyl-17-octyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl) 3-methylpentanethioate
DMQG4L2	DT	Small molecular drug
DMQG4L2	PC	3593361
DMQG4L2	MW	500.9
DMQG4L2	FM	C33H56OS
DMQG4L2	IC	InChI=1S/C33H56OS/c1-6-8-9-10-11-12-13-25-15-17-29-28-16-14-26-23-27(35-31(34)22-24(3)7-2)18-20-33(26,5)30(28)19-21-32(25,29)4/h14,24-25,27-30H,6-13,15-23H2,1-5H3
DMQG4L2	CS	CCCCCCCCC1CCC2C1(CCC3C2CC=C4C3(CCC(C4)SC(=O)CC(C)CC)C)C
DMQG4L2	IK	LQEPAKNLJUMKSY-UHFFFAOYSA-N
DMQG4L2	IU	S-(10,13-dimethyl-17-octyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl) 3-methylpentanethioate
DMQG4L2	DE	Discovery agent

DM1D7KY	ID	DM1D7KY
DM1D7KY	DN	S-(-)-sulpiride
DM1D7KY	HS	Investigative
DM1D7KY	SN	MolPort-019-994-454; AS-12199; A816834; N-[(1-ethylpyrrolidin-2-yl)methyl]-5-methoxy-2-sulfamoylbenzamide; N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-methoxy-2-sulfamoylbenzamide; N-[(1-ethylpyrrolidin-2-yl)methyl]-5-methoxy-2-sulfamoyl-benzamide
DM1D7KY	DT	Small molecular drug
DM1D7KY	PC	44134959
DM1D7KY	MW	341.4
DM1D7KY	FM	C15H23N3O4S
DM1D7KY	IC	InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(22-2)6-7-14(13)23(16,20)21/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
DM1D7KY	CS	CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)OC)S(=O)(=O)N
DM1D7KY	IK	KRSITCLIUSFUOQ-UHFFFAOYSA-N
DM1D7KY	IU	N-[(1-ethylpyrrolidin-2-yl)methyl]-5-methoxy-2-sulfamoylbenzamide
DM1D7KY	DE	Discovery agent

DMO1R69	ID	DMO1R69
DMO1R69	DN	S-(2,4-Dichlorobenzyl)isothiourea hydrobromide
DMO1R69	HS	Investigative
DMO1R69	SN	S-(2,4-Dichlorobenzyl)isothiourea hydrobromide; CHEMBL1224483; 2,4-Dichlorobenzyl imidothiocarbamate; MLS000702775; SMR000226761; P-CHLOROBENZYLPSEUDOTHIURONIUM BROMIDE; [(2,4-dichlorophenyl)methyl]sulfanylmethanimidamide hydrobromide
DMO1R69	DT	Small molecular drug
DMO1R69	PC	15945669
DMO1R69	MW	316.04
DMO1R69	FM	C8H9BrCl2N2S
DMO1R69	IC	InChI=1S/C8H8Cl2N2S.BrH/c9-6-2-1-5(7(10)3-6)4-13-8(11)12;/h1-3H,4H2,(H3,11,12);1H
DMO1R69	CS	C1=CC(=C(C=C1Cl)Cl)CSC(=N)N.Br
DMO1R69	IK	BNMARKYIMABDPE-UHFFFAOYSA-N
DMO1R69	IU	(2,4-dichlorophenyl)methyl carbamimidothioate;hydrobromide
DMO1R69	DE	Discovery agent

DMMZQB5	ID	DMMZQB5
DMMZQB5	DN	S-(2-boronoethyl)-L-cysteine
DMMZQB5	HS	Investigative
DMMZQB5	SN	S-(2-Boronoethyl)-L-cysteine; 63107-40-4; L-Cysteine, S-(2-boronoethyl)-; (2R)-2-amino-3-{[2-(dihydroxyboranyl)ethyl]sulfanyl}propanoic acid; C5H12BNO4S; SCHEMBL439378; GTPL5264; CHEBI:59346; CTK2F2710; DTXSID00432180; MolPort-039-139-054; HMS3648G13; 1633AH; AKOS006284223; ZINC195750889; S-[2-(dihydroxyboryl)ethyl]-L-cysteine; SR-01000946213; SR-01000946213-1; (R)-2-Amino-3-((2-boronoethyl)thio)propanoic acid; (2R)-2-amino-3-{[2-boronoethyl]thio}propanoic acid; (2R)-2-amino-3-{[2-boronoethyl]sulfanyl}propanoic acid; S-2-(Boronoethyl)-L-Cysteine
DMMZQB5	DT	Small molecular drug
DMMZQB5	PC	9877608
DMMZQB5	MW	193.03
DMMZQB5	FM	C5H12BNO4S
DMMZQB5	IC	InChI=1S/C5H12BNO4S/c7-4(5(8)9)3-12-2-1-6(10)11/h4,10-11H,1-3,7H2,(H,8,9)/t4-/m0/s1
DMMZQB5	CS	B(CCSC[C@@H](C(=O)O)N)(O)O
DMMZQB5	IK	OTJHLDXXJHAZTN-BYPYZUCNSA-N
DMMZQB5	IU	(2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid
DMMZQB5	CA	CAS 63107-40-4
DMMZQB5	CB	CHEBI:59346
DMMZQB5	DE	Discovery agent

DMN62KP	ID	DMN62KP
DMN62KP	DN	S-(2-Chlorobenzyl)isothiourea hydrochloride
DMN62KP	HS	Investigative
DMN62KP	SN	3778-85-6; NSC 60041; 2-(2-Chlorobenzyl)-2-thiopseudourea hydrochloride; Pseudourea, 2-(2-chlorobenzyl)-2-thio-, hydrochloride; 2-Chlorobenzyl carbamimidothioate hydrochloride; 14122-38-4; 2-chlorobenzyl imidothiocarbamate hydrochloride; CHEMBL1224310; 2-chlorobenzyl imidothiocarbamate; 2-chlorophenylmethyl carbamimidothioate hydrochloride; AC1L56TG; MLS000698043; WLN: MUYZS1R BG &amp; DTXSID00191225; MolPort-001-529-519; S-(2-Chlorobenzyl)Isothiourea HCl; NSC60041; NSC-60041; Carbamimidothioic acid, (2-chlorophenyl)methy
DMN62KP	DT	Small molecular drug
DMN62KP	PC	199161
DMN62KP	MW	237.15
DMN62KP	FM	C8H10Cl2N2S
DMN62KP	IC	InChI=1S/C8H9ClN2S.ClH/c9-7-4-2-1-3-6(7)5-12-8(10)11;/h1-4H,5H2,(H3,10,11);1H
DMN62KP	CS	C1=CC=C(C(=C1)CSC(=N)N)Cl.Cl
DMN62KP	IK	CEICVYXCGHTEIT-UHFFFAOYSA-N
DMN62KP	IU	(2-chlorophenyl)methyl carbamimidothioate;hydrochloride
DMN62KP	CA	CAS 3778-85-6
DMN62KP	DE	Discovery agent

DMNMCQJ	ID	DMNMCQJ
DMNMCQJ	DN	S-(3,4-Dichlorobenzyl)isothiourea hydrochloride
DMNMCQJ	HS	Investigative
DMNMCQJ	SN	22816-60-0; MreB Perturbing Compound A22; 2-(3,4-Dichloro-benzyl)-isothiourea hydrochloride; S-(3,4-Dichlorobenzyl)isothiourea, HCl; 3,4-dichlorobenzyl carbamimidothioate hydrochloride; 2-[(3,4-dichlorophenyl)methyl]isothiourea hydrochloride; 2-(3,4-DICHLORO-BENZYL)-ISOTHIOUREA; {[(3,4-dichlorophenyl)methyl]sulfanyl}methanimidamide hydrochloride; CHEMBL1224484; amino[(3,4-dichlorobenzyl)sulfanyl]methaniminium chloride; A 22 hydrochloride; AC1MD4YH
DMNMCQJ	DT	Small molecular drug
DMNMCQJ	PC	2830968
DMNMCQJ	MW	271.6
DMNMCQJ	FM	C8H9Cl3N2S
DMNMCQJ	IC	InChI=1S/C8H8Cl2N2S.ClH/c9-6-2-1-5(3-7(6)10)4-13-8(11)12;/h1-3H,4H2,(H3,11,12);1H
DMNMCQJ	CS	C1=CC(=C(C=C1CSC(=N)N)Cl)Cl.Cl
DMNMCQJ	IK	VBJNMXMOMSWRDV-UHFFFAOYSA-N
DMNMCQJ	IU	(3,4-dichlorophenyl)methyl carbamimidothioate;hydrochloride
DMNMCQJ	CA	CAS 22816-60-0
DMNMCQJ	DE	Discovery agent

DMNG6JB	ID	DMNG6JB
DMNG6JB	DN	S-(3-Chlorobenzyl)isothiourea hydrochloride
DMNG6JB	HS	Investigative
DMNG6JB	SN	2-(3-Chlorobenzyl)-2-thiopseudourea hydrochloride; CHEMBL1224311; MolPort-003-912-538; S-(3-Chlorobenzyl)Isothiourea HCl; NSC201820; GEO-03858; AKOS024333709
DMNG6JB	DT	Small molecular drug
DMNG6JB	PC	13266247
DMNG6JB	MW	237.15
DMNG6JB	FM	C8H10Cl2N2S
DMNG6JB	IC	InChI=1S/C8H9ClN2S.ClH/c9-7-3-1-2-6(4-7)5-12-8(10)11;/h1-4H,5H2,(H3,10,11);1H
DMNG6JB	CS	C1=CC(=CC(=C1)Cl)CSC(=N)N.Cl
DMNG6JB	IK	YKIYRIHELXCHJD-UHFFFAOYSA-N
DMNG6JB	IU	(3-chlorophenyl)methyl carbamimidothioate;hydrochloride
DMNG6JB	DE	Discovery agent

DM0XDFG	ID	DM0XDFG
DM0XDFG	DN	S-(4-Bromobenzyl)isothiourea hydrobromide
DM0XDFG	HS	Investigative
DM0XDFG	SN	111039-41-9; 4-bromobenzyl carbamimidothioate hydrobromide; S-(4-Bromobenzyl)isothiourea hydrobromide; {[(4-Bromophenyl)methyl]sulfanyl}methanimidamide hydrobromide; CHEMBL1224314; ([(4-Bromophenyl)methyl]sulfanyl)methanimidamide hydrobromide; SCHEMBL854064; KS-00001OGW; MolPort-002-945-994; STK099425; NSC403785; AKOS005396363; NSC-403785
DM0XDFG	DT	Small molecular drug
DM0XDFG	PC	12465608
DM0XDFG	MW	326.05
DM0XDFG	FM	C8H10Br2N2S
DM0XDFG	IC	InChI=1S/C8H9BrN2S.BrH/c9-7-3-1-6(2-4-7)5-12-8(10)11;/h1-4H,5H2,(H3,10,11);1H
DM0XDFG	CS	C1=CC(=CC=C1CSC(=N)N)Br.Br
DM0XDFG	IK	PHMCIGUUXGYEBU-UHFFFAOYSA-N
DM0XDFG	IU	(4-bromophenyl)methyl carbamimidothioate;hydrobromide
DM0XDFG	DE	Discovery agent

DMWJE2X	ID	DMWJE2X
DMWJE2X	DN	S-(4-Chlorobenzyl)isothiourea hydrochloride
DMWJE2X	HS	Investigative
DMWJE2X	SN	544-47-8; UNII-UG8Z59JOWY; 2-(4-Chlorobenzyl)-2-thiopseudourea hydrochloride; S-(4-Chlorobenzyl)Isothiouronium chloride; 4-CHLOROBENZYL CARBAMIMIDOTHIOATE HYDROCHLORIDE; 2-(p-Chlorobenzyl)isothiouronium chloride; p-Chlorobenzylpseudothiuronium chloride; EINECS 208-871-0; UG8Z59JOWY; Carbamimidothioic acid, (4-chlorophenyl)methyl ester, monohydrochloride; 4-chlorobenzyl imidothiocarbamate hydrochloride; s-(p-Chlorobenzyl)-thiuronium chloride; 4-CHLOROBENZYL CARBAMIMIDOTHIOATE HCL; Pseudourea, 2-(p-chlorobenzyl)-2-thio-, 
DMWJE2X	DT	Small molecular drug
DMWJE2X	PC	68342
DMWJE2X	MW	237.15
DMWJE2X	FM	C8H10Cl2N2S
DMWJE2X	IC	InChI=1S/C8H9ClN2S.ClH/c9-7-3-1-6(2-4-7)5-12-8(10)11;/h1-4H,5H2,(H3,10,11);1H
DMWJE2X	CS	C1=CC(=CC=C1CSC(=N)N)Cl.Cl
DMWJE2X	IK	QAVHMIYSTFZJAU-UHFFFAOYSA-N
DMWJE2X	IU	(4-chlorophenyl)methyl carbamimidothioate;hydrochloride
DMWJE2X	CA	CAS 544-47-8
DMWJE2X	DE	Discovery agent

DMYGULD	ID	DMYGULD
DMYGULD	DN	S-(4-Cyanobenzyl)isothiourea hydrobromide
DMYGULD	HS	Investigative
DMYGULD	SN	S-(4-Cyanobenzyl)isothiourea hydrobromide; CHEMBL1224395; MolPort-019-952-878
DMYGULD	DT	Small molecular drug
DMYGULD	PC	49866094
DMYGULD	MW	272.17
DMYGULD	FM	C9H10BrN3S
DMYGULD	IC	InChI=1S/C9H9N3S.BrH/c10-5-7-1-3-8(4-2-7)6-13-9(11)12;/h1-4H,6H2,(H3,11,12);1H
DMYGULD	CS	C1=CC(=CC=C1CSC(=N)N)C#N.Br
DMYGULD	IK	ONSRFABKCKXUCK-UHFFFAOYSA-N
DMYGULD	IU	(4-cyanophenyl)methyl carbamimidothioate;hydrobromide
DMYGULD	DE	Discovery agent

DMNXDWV	ID	DMNXDWV
DMNXDWV	DN	S-(4-Ethylbenzyl)isothiourea hydrochloride
DMNXDWV	HS	Investigative
DMNXDWV	SN	CHEMBL1224390; S-(4-Ethylbenzyl)Isothiourea HCl
DMNXDWV	DT	Small molecular drug
DMNXDWV	PC	49866090
DMNXDWV	MW	230.76
DMNXDWV	FM	C10H15ClN2S
DMNXDWV	IC	InChI=1S/C10H14N2S.ClH/c1-2-8-3-5-9(6-4-8)7-13-10(11)12;/h3-6H,2,7H2,1H3,(H3,11,12);1H
DMNXDWV	CS	CCC1=CC=C(C=C1)CSC(=N)N.Cl
DMNXDWV	IK	FLLOBRZODSODRU-UHFFFAOYSA-N
DMNXDWV	IU	(4-ethylphenyl)methyl carbamimidothioate;hydrochloride
DMNXDWV	DE	Discovery agent

DM10MET	ID	DM10MET
DM10MET	DN	S-(4-Fluorobenzyl)isothiourea hydrochloride
DM10MET	HS	Investigative
DM10MET	SN	122305-64-0; 4-FLUOROBENZYL CARBAMIMIDOTHIOATE HYDROCHLORIDE; 4-FLUOROBENZYL CARBAMIMIDOTHIOATE HCL; CHEMBL1224313; AC1MCYW1; CTK7D2165; MolPort-000-700-596; S-(4-Fluorobenzyl)Isothiourea HCl; AR2252; AKOS027334840; 4-Fluorobenzyl carbamimidothioate, HCl; MCULE-7671257099; (4-fluorophenyl)methyl carbamimidothioate hydrochloride
DM10MET	DT	Small molecular drug
DM10MET	PC	2803022
DM10MET	MW	220.7
DM10MET	FM	C8H10ClFN2S
DM10MET	IC	InChI=1S/C8H9FN2S.ClH/c9-7-3-1-6(2-4-7)5-12-8(10)11;/h1-4H,5H2,(H3,10,11);1H
DM10MET	CS	C1=CC(=CC=C1CSC(=N)N)F.Cl
DM10MET	IK	STUFCQTWEPJJSZ-UHFFFAOYSA-N
DM10MET	IU	(4-fluorophenyl)methyl carbamimidothioate;hydrochloride
DM10MET	DE	Discovery agent

DM4XWAU	ID	DM4XWAU
DM4XWAU	DN	S-(4-Methoxybenzyl)isothiourea hydrochloride
DM4XWAU	HS	Investigative
DM4XWAU	SN	25985-08-4; 4-Methoxybenzyl imidothiocarbamate hydrochloride; S-(4-Methoxybenzyl)isothiourea hydrochloride; CHEMBL1224394; 46234-22-4; 2-(4-Methoxybenzyl)isothiourea hydrochloride; SCHEMBL489767; DTXSID10551871; QGNMUFKTLKVUHM-UHFFFAOYSA-N; NSC67155; S-(4-Methoxybenzyl)Isothiourea HCl; NSC-67155; GEO-03857; AKOS030231098; S-(4-methoxybenzyl)thiopseudourea, hydrochloride; 2-(4-methoxybenzyl)-2-thiopseudo-urea hydrochloride; 2-(4-methoxybenzyl)-2-thiopseudourea, hydrochloride; 2-((4-methoxyphenyl)methyl)-2-thiopseudourea hydr
DM4XWAU	DT	Small molecular drug
DM4XWAU	PC	13885856
DM4XWAU	MW	232.73
DM4XWAU	FM	C9H13ClN2OS
DM4XWAU	IC	InChI=1S/C9H12N2OS.ClH/c1-12-8-4-2-7(3-5-8)6-13-9(10)11;/h2-5H,6H2,1H3,(H3,10,11);1H
DM4XWAU	CS	COC1=CC=C(C=C1)CSC(=N)N.Cl
DM4XWAU	IK	QGNMUFKTLKVUHM-UHFFFAOYSA-N
DM4XWAU	IU	(4-methoxyphenyl)methyl carbamimidothioate;hydrochloride
DM4XWAU	CA	CAS 25985-08-4
DM4XWAU	DE	Discovery agent

DMAGLI8	ID	DMAGLI8
DMAGLI8	DN	S-(4-Methylbenzyl)isothiourea hydrochloride
DMAGLI8	HS	Investigative
DMAGLI8	SN	940-63-6; CHEMBL1224315; DTXSID80501388; MolPort-019-952-918; S-(4-Methylbenzyl)Isothiourea HCl; NSC77403; NSC-77403; SR-01000635084-1; (4-Methylphenyl)methyl carbamimidothioate--hydrogen chloride (1/1)
DMAGLI8	DT	Small molecular drug
DMAGLI8	PC	12526770
DMAGLI8	MW	216.73
DMAGLI8	FM	C9H13ClN2S
DMAGLI8	IC	InChI=1S/C9H12N2S.ClH/c1-7-2-4-8(5-3-7)6-12-9(10)11;/h2-5H,6H2,1H3,(H3,10,11);1H
DMAGLI8	CS	CC1=CC=C(C=C1)CSC(=N)N.Cl
DMAGLI8	IK	WTAFMQGTBRUAGV-UHFFFAOYSA-N
DMAGLI8	IU	(4-methylphenyl)methyl carbamimidothioate;hydrochloride
DMAGLI8	CA	CAS 940-63-6
DMAGLI8	DE	Discovery agent

DMYRBO0	ID	DMYRBO0
DMYRBO0	DN	S-(4-Nitrobenzyl)isothiourea hydrochloride
DMYRBO0	HS	Investigative
DMYRBO0	SN	USAF PD-23; NSC 3850; 4-nitrobenzyl imidothiocarbamate hydrochloride; 4-Nitrobenzyl thiopseudourea hydrochloride; NSC 114527; 4357-96-4; 2-(p-Nitrobenzyl)-2-thiopseudourea monohydrochloride; Pseudourea, 2-(p-nitrobenzyl)-2-thio-, hydrochloride; Pseudourea, 2-(p-nitrobenzyl)thio-, hydrochloride; EN300-31371; WLN: MUYZS1R DNW &amp; {[(4-nitrophenyl)methyl]sulfanyl}methanimidamide hydrochloride; CHEMBL1224396; AC1L2UEL; AC1Q3CS0; 4-nitrobenzyl carbamimidothioate hydrochloride(1:1); SCHEMBL5220646; AC1Q38L0; CTK8F6192
DMYRBO0	DT	Small molecular drug
DMYRBO0	PC	78062
DMYRBO0	MW	247.7
DMYRBO0	FM	C8H10ClN3O2S
DMYRBO0	IC	InChI=1S/C8H9N3O2S.ClH/c9-8(10)14-5-6-1-3-7(4-2-6)11(12)13;/h1-4H,5H2,(H3,9,10);1H
DMYRBO0	CS	C1=CC(=CC=C1CSC(=N)N)[N+](=O)[O-].Cl
DMYRBO0	IK	XLXMUFLBCRDKMJ-UHFFFAOYSA-N
DMYRBO0	IU	(4-nitrophenyl)methyl carbamimidothioate;hydrochloride
DMYRBO0	CA	CAS 4357-96-4
DMYRBO0	DE	Discovery agent

DMSCHL0	ID	DMSCHL0
DMSCHL0	DN	S-(Dimethylarsenic)Cysteine
DMSCHL0	HS	Investigative
DMSCHL0	SN	[[(S)-2-Amino-2-carboxyethyl]thio]dimethylarsenic
DMSCHL0	DT	Small molecular drug
DMSCHL0	PC	46936846
DMSCHL0	MW	225.14
DMSCHL0	FM	C5H12AsNO2S
DMSCHL0	IC	InChI=1S/C5H12AsNO2S/c1-6(2)10-3-4(7)5(8)9/h4H,3,7H2,1-2H3,(H,8,9)/t4-/m1/s1
DMSCHL0	CS	C[As](C)SC[C@H](C(=O)O)N
DMSCHL0	IK	UKLXSOVDMSQHMM-SCSAIBSYSA-N
DMSCHL0	IU	(2S)-2-amino-3-dimethylarsanylsulfanylpropanoic acid
DMSCHL0	DE	Discovery agent

DM3FXPV	ID	DM3FXPV
DM3FXPV	DN	S-(N-4bromophenyl-N-hydroxycarbamoyl)glutathione
DM3FXPV	HS	Investigative
DM3FXPV	SN	CHEMBL128872; AC1L9LM2; S-(N-4bromophenyl-N-hydroxycarbamoyl)glutathione; SCHEMBL3281589; BDBM50092826; L-gammaGlu-S-[Hydroxy(4-bromophenyl)carbamoyl]-L-Cys-Gly-OH; (2S)-2-amino-5-{[(1R)-1-[({[(4-bromophenyl)(hydroxy)amino]carbonyl}thio)methyl]-2-(carboxyamino)-2-oxoethyl]amino}-5-oxopentanoic acid; (S)-2-amino-5-((R)-3-((4-bromophenyl)hydroxycarbamoylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
DM3FXPV	DT	Small molecular drug
DM3FXPV	PC	448107
DM3FXPV	MW	521.299
DM3FXPV	FM	C17H21BrN4O8S
DM3FXPV	IC	InChI=1S/C17H21BrN4O8S/c18-9-1-3-10(4-2-9)22(30)17(29)31-8-12(15(26)20-7-14(24)25)21-13(23)6-5-11(19)16(27)28/h1-4,11-12,30H,5-8,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t11-,12-/m0/s1
DM3FXPV	CS	C1=CC(=CC=C1N(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O)Br
DM3FXPV	IK	IQPLOQWSCZRUCA-RYUDHWBXSA-N
DM3FXPV	IU	(2S)-2-amino-5-[[(2R)-3-[(4-bromophenyl)-hydroxycarbamoyl]sulfanyl-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM3FXPV	DE	Discovery agent

DMPURE8	ID	DMPURE8
DMPURE8	DN	S-(N-4chlorophenyl-N-hydroxycarbamoyl)glutathione
DMPURE8	HS	Investigative
DMPURE8	SN	CHEMBL131578; S-(N-4chlorophenyl-N-hydroxycarbamoyl)glutathione; SCHEMBL3281101; BDBM50092824; s-(n-p-chlorophenyl-n-hydroxycarbamoyl)glutathione
DMPURE8	DT	Small molecular drug
DMPURE8	PC	10322772
DMPURE8	MW	476.9
DMPURE8	FM	C17H21ClN4O8S
DMPURE8	IC	InChI=1S/C17H21ClN4O8S/c18-9-1-3-10(4-2-9)22(30)17(29)31-8-12(15(26)20-7-14(24)25)21-13(23)6-5-11(19)16(27)28/h1-4,11-12,30H,5-8,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t11-,12-/m0/s1
DMPURE8	CS	C1=CC(=CC=C1N(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O)Cl
DMPURE8	IK	AJDQQFLYKZABLT-RYUDHWBXSA-N
DMPURE8	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[(4-chlorophenyl)-hydroxycarbamoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMPURE8	DE	Discovery agent

DMU7EQV	ID	DMU7EQV
DMU7EQV	DN	S-(N-butyl-N-hydroxycarbamoyl)glutathione
DMU7EQV	HS	Investigative
DMU7EQV	SN	CHEMBL128447; S-(N-butyl-N-hydroxycarbamoyl)glutathione; SCHEMBL3281791; BDBM50092822
DMU7EQV	DT	Small molecular drug
DMU7EQV	PC	10598311
DMU7EQV	MW	422.5
DMU7EQV	FM	C15H26N4O8S
DMU7EQV	IC	InChI=1S/C15H26N4O8S/c1-2-3-6-19(27)15(26)28-8-10(13(23)17-7-12(21)22)18-11(20)5-4-9(16)14(24)25/h9-10,27H,2-8,16H2,1H3,(H,17,23)(H,18,20)(H,21,22)(H,24,25)/t9-,10-/m0/s1
DMU7EQV	CS	CCCCN(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O
DMU7EQV	IK	JHOFGABPPOTPEX-UWVGGRQHSA-N
DMU7EQV	IU	(2S)-2-amino-5-[[(2R)-3-[butyl(hydroxy)carbamoyl]sulfanyl-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMU7EQV	DE	Discovery agent

DMMETC2	ID	DMMETC2
DMMETC2	DN	S-(N-ethyl-N-hydroxycarbamoyl)glutathione
DMMETC2	HS	Investigative
DMMETC2	SN	CHEMBL128867; S-(N-ethyl-N-hydroxycarbamoyl)glutathione; SCHEMBL3287492; BDBM50092832
DMMETC2	DT	Small molecular drug
DMMETC2	PC	10810621
DMMETC2	MW	394.4
DMMETC2	FM	C13H22N4O8S
DMMETC2	IC	InChI=1S/C13H22N4O8S/c1-2-17(25)13(24)26-6-8(11(21)15-5-10(19)20)16-9(18)4-3-7(14)12(22)23/h7-8,25H,2-6,14H2,1H3,(H,15,21)(H,16,18)(H,19,20)(H,22,23)/t7-,8-/m0/s1
DMMETC2	CS	CCN(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O
DMMETC2	IK	WQKIQOZTTDZDHN-YUMQZZPRSA-N
DMMETC2	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[ethyl(hydroxy)carbamoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMMETC2	DE	Discovery agent

DMV6T1Q	ID	DMV6T1Q
DMV6T1Q	DN	S-(N-heptyl-N-hydroxycarbamoyl)glutathione
DMV6T1Q	HS	Investigative
DMV6T1Q	SN	CHEMBL128836; S-(N-heptyl-N-hydroxycarbamoyl)glutathione; BDBM50092831
DMV6T1Q	DT	Small molecular drug
DMV6T1Q	PC	10367177
DMV6T1Q	MW	464.5
DMV6T1Q	FM	C18H32N4O8S
DMV6T1Q	IC	InChI=1S/C18H32N4O8S/c1-2-3-4-5-6-9-22(30)18(29)31-11-13(16(26)20-10-15(24)25)21-14(23)8-7-12(19)17(27)28/h12-13,30H,2-11,19H2,1H3,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t12-,13-/m0/s1
DMV6T1Q	CS	CCCCCCCN(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O
DMV6T1Q	IK	BRCVFVPDJZMQPO-STQMWFEESA-N
DMV6T1Q	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[heptyl(hydroxy)carbamoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMV6T1Q	DE	Discovery agent

DMSWHMI	ID	DMSWHMI
DMSWHMI	DN	S-(N-hexyl-N-hydroxycarbamoyl)glutathione
DMSWHMI	HS	Investigative
DMSWHMI	SN	CHEMBL127840; S-(N-hexyl-N-hydroxycarbamoyl)glutathione; SCHEMBL3281719; BDBM50092827
DMSWHMI	DT	Small molecular drug
DMSWHMI	PC	10072462
DMSWHMI	MW	450.5
DMSWHMI	FM	C17H30N4O8S
DMSWHMI	IC	InChI=1S/C17H30N4O8S/c1-2-3-4-5-8-21(29)17(28)30-10-12(15(25)19-9-14(23)24)20-13(22)7-6-11(18)16(26)27/h11-12,29H,2-10,18H2,1H3,(H,19,25)(H,20,22)(H,23,24)(H,26,27)/t11-,12-/m0/s1
DMSWHMI	CS	CCCCCCN(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O
DMSWHMI	IK	VKRQPFKVQRNOCI-RYUDHWBXSA-N
DMSWHMI	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[hexyl(hydroxy)carbamoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMSWHMI	DE	Discovery agent

DM1AHIW	ID	DM1AHIW
DM1AHIW	DN	S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione
DM1AHIW	HS	Investigative
DM1AHIW	SN	S-(N-HYDROXY-N-IODOPHENYLCARBAMOYL)GLUTATHIONE; AC1L9LMI; (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[hydroxy-(N-hydroxy-4-iodoanilino)methyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM1AHIW	DT	Small molecular drug
DM1AHIW	PC	448117
DM1AHIW	MW	570.4
DM1AHIW	FM	C17H23IN4O8S
DM1AHIW	IC	InChI=1S/C17H23IN4O8S/c18-9-1-3-10(4-2-9)22(30)17(29)31-8-12(15(26)20-7-14(24)25)21-13(23)6-5-11(19)16(27)28/h1-4,11-12,17,29-30H,5-8,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t11-,12-,17?/m0/s1
DM1AHIW	CS	C1=CC(=CC=C1N(C(O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O)I
DM1AHIW	IK	SCHAHXXLASZJCD-FAGLKTCQSA-N
DM1AHIW	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[hydroxy-(N-hydroxy-4-iodoanilino)methyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM1AHIW	DE	Discovery agent

DM1C9W3	ID	DM1C9W3
DM1C9W3	DN	S-(N-methyl-N-hydroxycarbamoyl)glutathione
DM1C9W3	HS	Investigative
DM1C9W3	SN	S-Hmcg; S-(N-Hydroxy-N-methylcarbamoyl)glutathione; CHEMBL129435; 144810-23-1; AC1L2R0C; S-(N-methyl-N-hydroxycarbamoyl)glutathione; SCHEMBL3009083; DTXSID00162814; CHEBI:313255; BDBM50092823; S-(Methylhydroxycarbamoyl)glutathione; s-(n-hydroxy-n-methylcarbamoyl) glutathione; C04572; Glycine, N-(N-L-gamma-glutamyl-S-((hydroxymethylamino)carbonyl)-L-cysteinyl)-; (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[hydroxy(methyl)carbamoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM1C9W3	DT	Small molecular drug
DM1C9W3	PC	126845
DM1C9W3	MW	380.38
DM1C9W3	FM	C12H20N4O8S
DM1C9W3	IC	InChI=1S/C12H20N4O8S/c1-16(24)12(23)25-5-7(10(20)14-4-9(18)19)15-8(17)3-2-6(13)11(21)22/h6-7,24H,2-5,13H2,1H3,(H,14,20)(H,15,17)(H,18,19)(H,21,22)/t6-,7-/m0/s1
DM1C9W3	CS	CN(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O
DM1C9W3	IK	RITFSVQFPRZDHQ-BQBZGAKWSA-N
DM1C9W3	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[hydroxy(methyl)carbamoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM1C9W3	CA	CAS 144810-23-1
DM1C9W3	CB	CHEBI:313255
DM1C9W3	DE	Discovery agent

DM4E9J2	ID	DM4E9J2
DM4E9J2	DN	S-(N-pentyl-N-hydroxycarbamoyl)glutathione
DM4E9J2	HS	Investigative
DM4E9J2	SN	CHEMBL129965; S-(N-pentyl-N-hydroxycarbamoyl)glutathione; SCHEMBL3281399; BDBM50092830
DM4E9J2	DT	Small molecular drug
DM4E9J2	PC	10574926
DM4E9J2	MW	436.5
DM4E9J2	FM	C16H28N4O8S
DM4E9J2	IC	InChI=1S/C16H28N4O8S/c1-2-3-4-7-20(28)16(27)29-9-11(14(24)18-8-13(22)23)19-12(21)6-5-10(17)15(25)26/h10-11,28H,2-9,17H2,1H3,(H,18,24)(H,19,21)(H,22,23)(H,25,26)/t10-,11-/m0/s1
DM4E9J2	CS	CCCCCN(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O
DM4E9J2	IK	BRWDWFHRRYLIDE-QWRGUYRKSA-N
DM4E9J2	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[hydroxy(pentyl)carbamoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM4E9J2	DE	Discovery agent

DMECAS0	ID	DMECAS0
DMECAS0	DN	S-(N-phenyl-N-hydroxycarbamoyl)glutathione
DMECAS0	HS	Investigative
DMECAS0	SN	CHEMBL128935; S-(N-phenyl-N-hydroxycarbamoyl)glutathione; SCHEMBL3280199; BDBM50092825
DMECAS0	DT	Small molecular drug
DMECAS0	PC	10411076
DMECAS0	MW	442.4
DMECAS0	FM	C17H22N4O8S
DMECAS0	IC	InChI=1S/C17H22N4O8S/c18-11(16(26)27)6-7-13(22)20-12(15(25)19-8-14(23)24)9-30-17(28)21(29)10-4-2-1-3-5-10/h1-5,11-12,29H,6-9,18H2,(H,19,25)(H,20,22)(H,23,24)(H,26,27)/t11-,12-/m0/s1
DMECAS0	CS	C1=CC=C(C=C1)N(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O
DMECAS0	IK	GAALWJSKDIUONK-RYUDHWBXSA-N
DMECAS0	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[hydroxy(phenyl)carbamoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMECAS0	DE	Discovery agent

DMRFKZ6	ID	DMRFKZ6
DMRFKZ6	DN	S-(N-propyl-N-hydroxycarbamoyl)glutathione
DMRFKZ6	HS	Investigative
DMRFKZ6	SN	CHEMBL129597; S-(N-propyl-N-hydroxycarbamoyl)glutathione; SCHEMBL3286977; BDBM50092829
DMRFKZ6	DT	Small molecular drug
DMRFKZ6	PC	10740201
DMRFKZ6	MW	408.43
DMRFKZ6	FM	C14H24N4O8S
DMRFKZ6	IC	InChI=1S/C14H24N4O8S/c1-2-5-18(26)14(25)27-7-9(12(22)16-6-11(20)21)17-10(19)4-3-8(15)13(23)24/h8-9,26H,2-7,15H2,1H3,(H,16,22)(H,17,19)(H,20,21)(H,23,24)/t8-,9-/m0/s1
DMRFKZ6	CS	CCCN(C(=O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O
DMRFKZ6	IK	MWNYPJZEPXNOON-IUCAKERBSA-N
DMRFKZ6	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[hydroxy(propyl)carbamoyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMRFKZ6	DE	Discovery agent

DMLPAD8	ID	DMLPAD8
DMLPAD8	DN	S,S-(2-Hydroxyethyl)Thiocysteine
DMLPAD8	HS	Investigative
DMLPAD8	SN	AC1OAH3S
DMLPAD8	DT	Small molecular drug
DMLPAD8	PC	170018
DMLPAD8	MW	197.3
DMLPAD8	FM	C5H11NO3S2
DMLPAD8	IC	InChI=1S/C5H11NO3S2/c6-4(5(8)9)3-11-10-2-1-7/h4,7H,1-3,6H2,(H,8,9)/t4-/m0/s1
DMLPAD8	CS	C(CSSC[C@@H](C(=O)O)N)O
DMLPAD8	IK	YPUBRSXDQSFQBA-BYPYZUCNSA-N
DMLPAD8	IU	(2R)-2-amino-3-(2-hydroxyethyldisulfanyl)propanoic acid
DMLPAD8	CA	CAS 38254-63-6
DMLPAD8	CB	CHEBI:74104
DMLPAD8	DE	Discovery agent

DMT36AB	ID	DMT36AB
DMT36AB	DN	S-024
DMT36AB	HS	Investigative
DMT36AB	SN	Chk1 inhibitors (cancer); S-144; Chk1 inhibitors (cancer), Sentinel
DMT36AB	CP	Sentinel Oncology Ltd
DMT36AB	DE	Solid tumour/cancer

DMANSCK	ID	DMANSCK
DMANSCK	DN	S-070
DMANSCK	HS	Investigative
DMANSCK	SN	S-158; Targeted synergy program (solid tumor), Sentinel Oncology; Chk1/PARP-1 inhibitors (cancer); Chk1/PARP-1 inhibitors (cancer), Sentinel Oncology
DMANSCK	CP	Sentinel Oncology Ltd
DMANSCK	DE	Solid tumour/cancer

DMIBEY6	ID	DMIBEY6
DMIBEY6	DN	S-1,2-propanediol
DMIBEY6	HS	Investigative
DMIBEY6	SN	L-1,2-propanediol; Propylene glycol #; Propylene glycol, (S)-; PubChem5853; S(+)-Propylene glycol; S-1,2-PROPANEDIOL; (+)-1,2-Propanediol; (2S)-propane-1,2-diol; (2S)-propane-1,2diol; (S)-(+)-1,2-Dihydroxypropane; (S)-(+)-1,2-Propanediol; (S)-(+)-Propylene Glycol; (S)-(+)-Propylene glycerol; (S)-(+)-Propylene oxide; (S)-1,2-Propanediol; (S)-1,2-dihydroxypropane; (S)-1,2-propane-diol; DNIAPMSPPWPWGF-VKHMYHEASA-N; KSC489M6N; (S)-Propane-1,2-diol; (S)-Propylene glycol; 4254-15-3; 942194N4TD; MFCD00004539; PGO; UNII-942194N4TD
DMIBEY6	PC	439846
DMIBEY6	MW	76.09
DMIBEY6	FM	C3H8O2
DMIBEY6	IC	DNIAPMSPPWPWGF-VKHMYHEASA-N
DMIBEY6	CS	CC(CO)O
DMIBEY6	IK	1S/C3H8O2/c1-3(5)2-4/h3-5H,2H2,1H3/t3-/m0/s1
DMIBEY6	IU	(2S)-propane-1,2-diol
DMIBEY6	CA	CAS 4254-15-3
DMIBEY6	CB	CHEBI:29002
DMIBEY6	DE	Discovery agent

DM2JYQA	ID	DM2JYQA
DM2JYQA	DN	S109
DM2JYQA	HS	Investigative
DM2JYQA	SN	oxapium iodide; 6577-41-9; Cyclonium; Cyclonium iodide; UNII-682380CG4N; SH 100; 682380CG4N; DSSTox_CID_26925; DSSTox_RID_82021; DSSTox_GSID_46925; Esperan; Oxapii iodidum; Ciclonium iodide; Iodure d'oxapium; Ioduro de oxapio; 1-[(2-cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl]-1-methylpiperidin-1-ium;iodide; CAS-6577-41-9; NCGC00181356-01; Oxapium iodide [INN:JAN]; Oxapii iodidum [INN-Latin]; C22H34INO2; Iodure d'oxapium [INN-French]; Ioduro de oxapio [INN-Spanish]; ANC 113; Espalexan (TN); Oxapium iodide (JP17/INN); SCHEMBL1316687; CHEMBL2107009; DTXSID6046925; s109; Tox21_112814; 2-Cyclohexyl-2-phenyl-4-piperidinomethyl-dioxolane-1,3 methiodide; AC-669; AKOS015969034; Tox21_112814_1; VA11456; N-Methyl-N-(2-cyclohexyl-2-phenyl-1,3 dioxolan-4-yl-methyl)-piperidinium iodide; NCGC00181356-02; DB-080725; FT-0656107; D01815; Q10859610; 1-((2-Cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl)-1-methylpiperidin-1-ium iodide; 1-((2-Cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl)-1-methylpiperidinium iodide; Piperidinium, 1-((2-cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl)-1-methyl-, iodide
DM2JYQA	DT	Small molecular drug
DM2JYQA	PC	168884
DM2JYQA	MW	471.4
DM2JYQA	FM	C22H34INO2
DM2JYQA	IC	InChI=1S/C22H34NO2.HI/c1-23(15-9-4-10-16-23)17-21-18-24-22(25-21,19-11-5-2-6-12-19)20-13-7-3-8-14-20;/h2,5-6,11-12,20-21H,3-4,7-10,13-18H2,1H3;1H/q+1;/p-1
DM2JYQA	CS	C[N+]1(CCCCC1)CC2COC(O2)(C3CCCCC3)C4=CC=CC=C4.[I-]
DM2JYQA	IK	YHEWVHONOOWLMW-UHFFFAOYSA-M
DM2JYQA	IU	1-[(2-cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl]-1-methylpiperidin-1-ium;iodide
DM2JYQA	CA	CAS 6577-41-9
DM2JYQA	DE	Solid tumour/cancer

DMRVUCY	ID	DMRVUCY
DMRVUCY	DN	S-111
DMRVUCY	HS	Investigative
DMRVUCY	SN	PARP1 inhibitor (cancer), Sentinel Oncology
DMRVUCY	CP	Sentinel Oncology Ltd
DMRVUCY	DE	Solid tumour/cancer

DMN6HE3	ID	DMN6HE3
DMN6HE3	DN	S136492
DMN6HE3	HS	Investigative
DMN6HE3	SN	(E)-2-(2-(quinolin-2-yl)vinyl)phenol; CHEMBL127545; 2-[(E)-2-(quinolin-2-yl)ethenyl]phenol; 143816-42-6; Quininib; 2-(2-(quinolin-2-yl)vinyl)phenol; (6E)-6-[(2E)-2-(1H-quinolin-2-ylidene)ethylidene]cyclohexa-2,4-dien-1-one; AC1OATYA; AC1NW9KR; Cambridge id 5719593; AC1NZV89; AC1Q791J; Quininib, &gt; SCHEMBL10325190; CHEBI:133170; MolPort-001-824-964; MolPort-000-712-889; ZINC3882963; STL044348; BDBM50001270; 2-(2-Quinolin-2-yl-vinyl)-phenol; AKOS015955311; AKOS005697868; 2-[(E)-2-(quinolin-2-yl)vinyl]phenol
DMN6HE3	DT	Small molecular drug
DMN6HE3	PC	135411330
DMN6HE3	MW	247.29
DMN6HE3	FM	C17H13NO
DMN6HE3	IC	InChI=1S/C17H13NO/c19-17-8-4-2-6-14(17)10-12-15-11-9-13-5-1-3-7-16(13)18-15/h1-12,19H/b12-10+
DMN6HE3	CS	C1=CC=C2C(=C1)C=CC(=N2)/C=C/C3=CC=CC=C3O
DMN6HE3	IK	NXNDEWNGCMCWMA-ZRDIBKRKSA-N
DMN6HE3	IU	2-[(E)-2-quinolin-2-ylethenyl]phenol
DMN6HE3	CB	CHEBI:133170
DMN6HE3	DE	Discovery agent

DMHVEJF	ID	DMHVEJF
DMHVEJF	DN	S-14671
DMHVEJF	HS	Investigative
DMHVEJF	SN	S-14,671; S 14671
DMHVEJF	DT	Small molecular drug
DMHVEJF	PC	131907
DMHVEJF	MW	395.5
DMHVEJF	FM	C22H25N3O2S
DMHVEJF	IC	InChI=1S/C22H25N3O2S/c1-27-18-8-7-17-4-2-5-20(19(17)16-18)25-13-11-24(12-14-25)10-9-23-22(26)21-6-3-15-28-21/h2-8,15-16H,9-14H2,1H3,(H,23,26)
DMHVEJF	CS	COC1=CC2=C(C=CC=C2N3CCN(CC3)CCNC(=O)C4=CC=CS4)C=C1
DMHVEJF	IK	YFNZHCXOYLKDGU-UHFFFAOYSA-N
DMHVEJF	IU	N-[2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl]thiophene-2-carboxamide
DMHVEJF	CA	CAS 135722-27-9
DMHVEJF	DE	Discovery agent

DMD4KLQ	ID	DMD4KLQ
DMD4KLQ	DN	S1627
DMD4KLQ	HS	Investigative
DMD4KLQ	SN	Piperazine, 1-benzoyl-4-[2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-1,2-dioxoethyl]- &amp
DMD4KLQ	DT	Small molecular drug
DMD4KLQ	PC	16186132
DMD4KLQ	MW	5459
DMD4KLQ	FM	C257H363N61O72
DMD4KLQ	IC	InChI=1S/C235H341N57O67.C22H22N4O5/c1-20-120(13)194(290-218(342)155(69-83-184(246)303)258-198(322)122(15)254-201(325)149(63-77-178(240)297)263-211(335)157(71-85-187(307)308)270-221(345)166(97-117(7)8)280-222(346)164(95-115(3)4)277-199(323)124(17)256-235(359)196(125(18)294)292-234(358)195(121(14)21-2)291-217(341)148(58-38-42-94-239)261-205(329)150(64-78-179(241)298)265-212(336)158(72-86-188(309)310)272-227(351)172(104-131-111-251-142-52-32-27-47-137(131)142)284-215(339)159(73-87-189(311)312)267-208(332)153(67-81-182(244)301)269-226(350)170(257-126(19)295)102-129-109-249-140-50-30-25-45-135(129)140)233(357)275-154(68-82-183(245)302)209(333)264-151(65-79-180(242)299)207(331)266-156(70-84-186(305)306)210(334)260-146(56-36-40-92-237)204(328)287-175(107-185(247)304)230(354)274-161(75-89-191(315)316)214(338)282-169(101-128-59-61-134(296)62-60-128)225(349)271-160(74-88-190(313)314)213(337)279-165(96-116(5)6)220(344)268-152(66-80-181(243)300)206(330)259-145(55-35-39-91-236)202(326)278-167(98-118(9)10)224(348)288-176(108-193(319)320)231(355)262-147(57-37-41-93-238)203(327)283-171(103-130-110-250-141-51-31-26-46-136(130)141)219(343)255-123(16)200(324)289-177(114-293)232(356)281-168(99-119(11)12)223(347)286-173(105-132-112-252-143-53-33-28-48-138(132)143)228(352)273-162(76-90-192(317)318)216(340)285-174(106-133-113-253-144-54-34-29-49-139(133)144)229(353)276-163(197(248)321)100-127-43-23-22-24-44-127;1-30-16-13-24-20(31-2)18-17(16)15(12-23-18)19(27)22(29)26-10-8-25(9-11-26)21(28)14-6-4-3-5-7-14/h22-34,43-54,59-62,109-113,115-125,145-177,194-196,249-253,293-294,296H,20-21,35-42,55-58,63-108,114,236-239H2,1-19H3,(H2,240,297)(H2,241,298)(H2,242,299)(H2,243,300)(H2,244,301)(H2,245,302)(H2,246,303)(H2,247,304)(H2,248,321)(H,254,325)(H,255,343)(H,256,359)(H,257,295)(H,258,322)(H,259,330)(H,260,334)(H,261,329)(H,262,355)(H,263,335)(H,264,333)(H,265,336)(H,266,331)(H,267,332)(H,268,344)(H,269,350)(H,270,345)(H,271,349)(H,272,351)(H,273,352)(H,274,354)(H,275,357)(H,276,353)(H,277,323)(H,278,326)(H,279,337)(H,280,346)(H,281,356)(H,282,338)(H,283,327)(H,284,339)(H,285,340)(H,286,347)(H,287,328)(H,288,348)(H,289,324)(H,290,342)(H,291,341)(H,292,358)(H,305,306)(H,307,308)(H,309,310)(H,311,312)(H,313,314)(H,315,316)(H,317,318)(H,319,320);3-7,12-13,23H,8-11H2,1-2H3/t120-,121-,122-,123-,124-,125+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,194-,195-,196-;/m0./s1
DMD4KLQ	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC9=CNC1=CC=CC=C19)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C.COC1=CN=C(C2=C1C(=CN2)C(=O)C(=O)N3CCN(CC3)C(=O)C4=CC=CC=C4)OC
DMD4KLQ	IK	HFYONINHPQMPNL-BENXRZQJSA-N
DMD4KLQ	IU	(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-aminohexanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid;1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione
DMD4KLQ	DE	Discovery agent

DM589XM	ID	DM589XM
DM589XM	DN	S-19528
DM589XM	HS	Investigative
DM589XM	CP	Servier
DM589XM	PC	10393643
DM589XM	MW	591.8
DM589XM	FM	C38H49N5O
DM589XM	IC	InChI=1S/C38H49N5O/c44-38(41-36-27-42-24-22-31(36)23-25-42)43(37(39-32-12-3-1-4-13-32)40-33-14-5-2-6-15-33)26-28-18-20-30(21-19-28)35-17-9-11-29-10-7-8-16-34(29)35/h7-11,16-21,31-33,36H,1-6,12-15,22-27H2,(H,39,40)(H,41,44)
DM589XM	CS	C1CCC(CC1)NC(=NC2CCCCC2)N(CC3=CC=C(C=C3)C4=CC=CC5=CC=CC=C54)C(=O)NC6CN7CCC6CC7
DM589XM	IK	PNYOQUZLCMAUQE-UHFFFAOYSA-N
DM589XM	IU	3-(1-azabicyclo[2.2.2]octan-3-yl)-1-(N,N'-dicyclohexylcarbamimidoyl)-1-[(4-naphthalen-1-ylphenyl)methyl]urea
DM589XM	DE	Eating disorder

DMU9F7K	ID	DMU9F7K
DMU9F7K	DN	S-2-(o-toluidino)-2-oxoethyl carbamothioate
DMU9F7K	HS	Investigative
DMU9F7K	SN	5429-04-9; carbamoylsulfanyl-acetic acid o-toluidide; NSC13347; AC1L5DGT; AC1Q5NMD; Oprea1_302154; MLS000085728; CHEMBL236685; ZINC69645; MolPort-002-702-780; HMS2293B23; STK795741; carbamothioic acid, s-[2-[(2-methylphenyl)amino]-2-oxoethyl] ester; NSC-13347; AKOS001735942; MCULE-9952660100; SMR000020857; EU-0051903; SR-01000520769; SR-01000520769-1; S-[2-(2-methylanilino)-2-oxoethyl] carbamothioate; S-{2-[(2-methylphenyl)amino]-2-oxoethyl} thiocarbamate; S-{2-[(2-methylphenyl)amino]-2-oxoethyl} carbamothioate; A1844/0077558
DMU9F7K	DT	Small molecular drug
DMU9F7K	PC	224667
DMU9F7K	MW	224.28
DMU9F7K	FM	C10H12N2O2S
DMU9F7K	IC	InChI=1S/C10H12N2O2S/c1-7-4-2-3-5-8(7)12-9(13)6-15-10(11)14/h2-5H,6H2,1H3,(H2,11,14)(H,12,13)
DMU9F7K	CS	CC1=CC=CC=C1NC(=O)CSC(=O)N
DMU9F7K	IK	AGIYBDIJVLUNFI-UHFFFAOYSA-N
DMU9F7K	IU	S-[2-(2-methylanilino)-2-oxoethyl] carbamothioate
DMU9F7K	CA	CAS 5429-04-9
DMU9F7K	DE	Discovery agent

DMTH15E	ID	DMTH15E
DMTH15E	DN	S-2,9-dioxo-9-(phenylamino)nonyl ethanethioate
DMTH15E	HS	Investigative
DMTH15E	SN	CHEMBL272613
DMTH15E	DT	Small molecular drug
DMTH15E	PC	11964504
DMTH15E	MW	321.4
DMTH15E	FM	C17H23NO3S
DMTH15E	IC	InChI=1S/C17H23NO3S/c1-14(19)22-13-16(20)11-7-2-3-8-12-17(21)18-15-9-5-4-6-10-15/h4-6,9-10H,2-3,7-8,11-13H2,1H3,(H,18,21)
DMTH15E	CS	CC(=O)SCC(=O)CCCCCCC(=O)NC1=CC=CC=C1
DMTH15E	IK	OCDCFMXSXAYLLI-UHFFFAOYSA-N
DMTH15E	IU	S-(9-anilino-2,9-dioxononyl) ethanethioate
DMTH15E	DE	Discovery agent

DMOJ9N6	ID	DMOJ9N6
DMOJ9N6	DN	S-21007
DMOJ9N6	HS	Investigative
DMOJ9N6	SN	153628-86-5
DMOJ9N6	PC	9863146
DMOJ9N6	MW	348.5
DMOJ9N6	FM	C20H20N4S
DMOJ9N6	IC	InChI=1S/C20H20N4S/c1-2-5-16(6-3-1)15-22-10-12-23(13-11-22)19-18-7-4-9-24(18)20-17(21-19)8-14-25-20/h1-9,14H,10-13,15H2
DMOJ9N6	CS	C1CN(CCN1CC2=CC=CC=C2)C3=NC4=C(N5C3=CC=C5)SC=C4
DMOJ9N6	IK	QYWDOJXSLBBWLE-UHFFFAOYSA-N
DMOJ9N6	IU	8-(4-benzylpiperazin-1-yl)-3-thia-1,7-diazatricyclo[7.3.0.02,6]dodeca-2(6),4,7,9,11-pentaene
DMOJ9N6	DE	Discovery agent

DM4S5TQ	ID	DM4S5TQ
DM4S5TQ	DN	S22153
DM4S5TQ	HS	Investigative
DM4S5TQ	SN	S 22153; S-22153
DM4S5TQ	DT	Small molecular drug
DM4S5TQ	PC	9816339
DM4S5TQ	MW	247.36
DM4S5TQ	FM	C14H17NOS
DM4S5TQ	IC	InChI=1S/C14H17NOS/c1-3-11-4-5-14-13(8-11)12(9-17-14)6-7-15-10(2)16/h4-5,8-9H,3,6-7H2,1-2H3,(H,15,16)
DM4S5TQ	CS	CCC1=CC2=C(C=C1)SC=C2CCNC(=O)C
DM4S5TQ	IK	PICRXJDULXLJCZ-UHFFFAOYSA-N
DM4S5TQ	IU	N-[2-(5-ethyl-1-benzothiophen-3-yl)ethyl]acetamide
DM4S5TQ	DE	Discovery agent

DM3GS2X	ID	DM3GS2X
DM3GS2X	DN	S-2238
DM3GS2X	HS	Investigative
DM3GS2X	SN	D-Phenylalanyl-L-2-piperidinecarbonyl-N-(4-nitro phenyl)-L-argininamide; H-D-Phe-pip-arg-pna; Chromogenic substrate S-2238; D-Phe-Pip-Arg-PNA; D-F-Pip-R-PNA; H-Phe-pip-arg-pna; D-Phe-Pip-Arg-paranitroanilide; H-Phe-pip-arg-p-nitroanilide; S 2238; H-D-Phenylalanyl-pip-arg-p-nitroanilide; AC1Q5KFD; AC1L3XF1; H-D-Phenylalanyl-L-pipecolyl-arginine-nitroanilide; (2s)-n-{(2s)-5-[(diaminomethylidene)amino]-1-[(4-nitrophenyl)amino]-1-oxopentan-2-yl}-1-(d-phenylalanyl)piperidine-2-carboxamidato(3-); BDBM12678; YDMBNDUHUNWWRP-VJBWXMMDSA-N; BDBM233013; ZINC14950391
DM3GS2X	DT	Small molecular drug
DM3GS2X	PC	123853
DM3GS2X	MW	552.6
DM3GS2X	FM	C27H36N8O5
DM3GS2X	IC	InChI=1S/C27H36N8O5/c28-21(17-18-7-2-1-3-8-18)26(38)34-16-5-4-10-23(34)25(37)33-22(9-6-15-31-27(29)30)24(36)32-19-11-13-20(14-12-19)35(39)40/h1-3,7-8,11-14,21-23H,4-6,9-10,15-17,28H2,(H,32,36)(H,33,37)(H4,29,30,31)/t21-,22+,23+/m1/s1
DM3GS2X	CS	C1CCN([C@@H](C1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-])C(=O)[C@@H](CC3=CC=CC=C3)N
DM3GS2X	IK	YDMBNDUHUNWWRP-VJBWXMMDSA-N
DM3GS2X	IU	(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(2S)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide
DM3GS2X	CA	CAS 64815-81-2
DM3GS2X	DE	Discovery agent

DM9RU46	ID	DM9RU46
DM9RU46	DN	S24014
DM9RU46	HS	Investigative
DM9RU46	SN	S-24014; S 24014
DM9RU46	DT	Small molecular drug
DM9RU46	PC	9998187
DM9RU46	MW	353.4
DM9RU46	FM	C21H23NO4
DM9RU46	IC	InChI=1S/C21H23NO4/c1-14(23)22-10-9-18-19-13-17(25-3)7-8-20(19)26-21(18)12-15-5-4-6-16(11-15)24-2/h4-8,11,13H,9-10,12H2,1-3H3,(H,22,23)
DM9RU46	CS	CC(=O)NCCC1=C(OC2=C1C=C(C=C2)OC)CC3=CC(=CC=C3)OC
DM9RU46	IK	GNWDMICUDNQPEK-UHFFFAOYSA-N
DM9RU46	IU	N-[2-[5-methoxy-2-[(3-methoxyphenyl)methyl]-1-benzofuran-3-yl]ethyl]acetamide
DM9RU46	DE	Discovery agent

DM1HAD0	ID	DM1HAD0
DM1HAD0	DN	S24773
DM1HAD0	HS	Investigative
DM1HAD0	SN	S-24773; S 24773
DM1HAD0	DT	Small molecular drug
DM1HAD0	PC	22133318
DM1HAD0	MW	334.4
DM1HAD0	FM	C21H22N2O2
DM1HAD0	IC	InChI=1S/C21H22N2O2/c1-14(24)23-9-8-17-11-18(15-4-3-5-19(22)12-15)10-16-6-7-20(25-2)13-21(16)17/h3-7,10-13H,8-9,22H2,1-2H3,(H,23,24)
DM1HAD0	CS	CC(=O)NCCC1=C2C=C(C=CC2=CC(=C1)C3=CC(=CC=C3)N)OC
DM1HAD0	IK	RUYDBTKHRKQOLY-UHFFFAOYSA-N
DM1HAD0	IU	N-[2-[3-(3-aminophenyl)-7-methoxynaphthalen-1-yl]ethyl]acetamide
DM1HAD0	CA	CAS 225786-69-6
DM1HAD0	DE	Discovery agent

DMBUD1M	ID	DMBUD1M
DMBUD1M	DN	S-25585
DMBUD1M	HS	Investigative
DMBUD1M	CP	Servier
DMBUD1M	DT	Small molecular drug
DMBUD1M	PC	9871791
DMBUD1M	MW	534.6
DMBUD1M	FM	C22H29F3N4O6S
DMBUD1M	IC	InChI=1S/C22H29F3N4O6S/c23-22(24,25)17-10-11-19(18(12-17)29(32)33)36(34,35)26-13-14-6-8-16(9-7-14)21(31)28-27-20(30)15-4-2-1-3-5-15/h1-5,14,16-19,26H,6-13H2,(H,27,30)(H,28,31)
DMBUD1M	CS	C1CC(CCC1CNS(=O)(=O)C2CCC(CC2[N+](=O)[O-])C(F)(F)F)C(=O)NNC(=O)C3=CC=CC=C3
DMBUD1M	IK	MODMVZPKMVZXFO-UHFFFAOYSA-N
DMBUD1M	IU	N-[[4-(benzamidocarbamoyl)cyclohexyl]methyl]-2-nitro-4-(trifluoromethyl)cyclohexane-1-sulfonamide
DMBUD1M	DE	Eating disorder

DMCJ86U	ID	DMCJ86U
DMCJ86U	DN	S26131
DMCJ86U	HS	Investigative
DMCJ86U	SN	S 26131; S-26131
DMCJ86U	DT	Small molecular drug
DMCJ86U	PC	9870523
DMCJ86U	MW	498.6
DMCJ86U	FM	C31H34N2O4
DMCJ86U	IC	InChI=1S/C31H34N2O4/c1-22(34)32-16-14-26-8-3-6-24-10-12-28(20-30(24)26)36-18-5-19-37-29-13-11-25-7-4-9-27(31(25)21-29)15-17-33-23(2)35/h3-4,6-13,20-21H,5,14-19H2,1-2H3,(H,32,34)(H,33,35)
DMCJ86U	CS	CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OCCCOC3=CC4=C(C=CC=C4CCNC(=O)C)C=C3
DMCJ86U	IK	NSXBZYDTTKLTOH-UHFFFAOYSA-N
DMCJ86U	IU	N-[2-[7-[3-[8-(2-acetamidoethyl)naphthalen-2-yl]oxypropoxy]naphthalen-1-yl]ethyl]acetamide
DMCJ86U	DE	Discovery agent

DMLJITC	ID	DMLJITC
DMLJITC	DN	S26284
DMLJITC	HS	Investigative
DMLJITC	SN	S 26284
DMLJITC	DT	Small molecular drug
DMLJITC	PC	9806449
DMLJITC	MW	512.6
DMLJITC	FM	C32H36N2O4
DMLJITC	IC	InChI=1S/C32H36N2O4/c1-23(35)33-17-15-27-9-5-7-25-11-13-29(21-31(25)27)37-19-3-4-20-38-30-14-12-26-8-6-10-28(32(26)22-30)16-18-34-24(2)36/h5-14,21-22H,3-4,15-20H2,1-2H3,(H,33,35)(H,34,36)
DMLJITC	CS	CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OCCCCOC3=CC4=C(C=CC=C4CCNC(=O)C)C=C3
DMLJITC	IK	AGGOYESCDGTCOY-UHFFFAOYSA-N
DMLJITC	IU	N-[2-[7-[4-[8-(2-acetamidoethyl)naphthalen-2-yl]oxybutoxy]naphthalen-1-yl]ethyl]acetamide
DMLJITC	DE	Discovery agent

DM3Z6TI	ID	DM3Z6TI
DM3Z6TI	DN	S33005
DM3Z6TI	HS	Investigative
DM3Z6TI	SN	S33005; SCHEMBL945666; BDBM85805; PDSP2_000811; PDSP1_000824
DM3Z6TI	CP	Servier
DM3Z6TI	TC	Psychiatric
DM3Z6TI	DT	Small molecular drug
DM3Z6TI	PC	9925999
DM3Z6TI	MW	289.4
DM3Z6TI	FM	C18H27NO2
DM3Z6TI	IC	InChI=1S/C18H27NO2/c1-19(2)13-17(18(20)9-5-4-6-10-18)12-14-7-8-15(21-3)11-16(14)17/h7-8,11,20H,4-6,9-10,12-13H2,1-3H3
DM3Z6TI	CS	CN(C)CC1(CC2=C1C=C(C=C2)OC)C3(CCCCC3)O
DM3Z6TI	IK	UBIQMAFTTDZGEX-UHFFFAOYSA-N
DM3Z6TI	IU	1-[7-[(dimethylamino)methyl]-4-methoxy-7-bicyclo[4.2.0]octa-1(6),2,4-trienyl]cyclohexan-1-ol
DM3Z6TI	CA	CAS 242473-59-2
DM3Z6TI	DE	Depression

DMZLQ5W	ID	DMZLQ5W
DMZLQ5W	DN	S-34324
DMZLQ5W	HS	Investigative
DMZLQ5W	SN	CHEMBL90997; S-34324; SCHEMBL6949357; BDBM50131357; 4-(5-Fluoro-2-indanylmethyl)-2-imidazoline; L001645
DMZLQ5W	DT	Small molecular drug
DMZLQ5W	PC	10220053
DMZLQ5W	MW	218.27
DMZLQ5W	FM	C13H15FN2
DMZLQ5W	IC	InChI=1S/C13H15FN2/c14-12-2-1-10-3-9(4-11(10)6-12)5-13-7-15-8-16-13/h1-2,6,8-9,13H,3-5,7H2,(H,15,16)
DMZLQ5W	CS	C1C(CC2=C1C=CC(=C2)F)CC3CN=CN3
DMZLQ5W	IK	HBMJQYDGBNSZMC-UHFFFAOYSA-N
DMZLQ5W	IU	5-[(5-fluoro-2,3-dihydro-1H-inden-2-yl)methyl]-4,5-dihydro-1H-imidazole
DMZLQ5W	DE	Discovery agent

DM84DMW	ID	DM84DMW
DM84DMW	DN	S3969
DM84DMW	HS	Investigative
DM84DMW	SN	S 3969
DM84DMW	DT	Small molecular drug
DM84DMW	PC	46861536
DM84DMW	MW	320.5
DM84DMW	FM	C17H24N2O2S
DM84DMW	IC	InChI=1S/C17H24N2O2S/c1-11(2)9-14(17(21)18-7-8-20)22-15-10-19-13-6-4-5-12(3)16(13)15/h4-6,10-11,14,19-20H,7-9H2,1-3H3,(H,18,21)
DM84DMW	CS	CC1=C2C(=CC=C1)NC=C2SC(CC(C)C)C(=O)NCCO
DM84DMW	IK	FTNIWEHRMFLJKE-UHFFFAOYSA-N
DM84DMW	IU	N-(2-hydroxyethyl)-4-methyl-2-[(4-methyl-1H-indol-3-yl)sulfanyl]pentanamide
DM84DMW	DE	Discovery agent

DME5HIR	ID	DME5HIR
DME5HIR	DN	S-4048
DME5HIR	HS	Investigative
DME5HIR	DT	Small molecular drug
DME5HIR	PC	9873573
DME5HIR	MW	604
DME5HIR	FM	C32H30ClN3O7
DME5HIR	IC	InChI=1S/C32H30ClN3O7/c33-22-10-8-19(9-11-22)23-13-21(23)17-42-32(31(40)41)15-26(37)29(39)27(16-32)43-28(38)14-25(20-5-2-1-3-6-20)36-18-35-30-24(36)7-4-12-34-30/h1-12,14,18,21,23,26-27,29,37,39H,13,15-17H2,(H,40,41)/b25-14-/t21-,23+,26+,27+,29+,32-/m0/s1
DME5HIR	CS	C1[C@H]([C@H]1C2=CC=C(C=C2)Cl)CO[C@]3(C[C@H]([C@H]([C@@H](C3)OC(=O)/C=C(/C4=CC=CC=C4)\\N5C=NC6=C5C=CC=N6)O)O)C(=O)O
DME5HIR	IK	MYXPHMOLFCUDIL-MLFVSVOESA-N
DME5HIR	IU	(1S,3R,4R,5R)-1-[[(1R,2S)-2-(4-chlorophenyl)cyclopropyl]methoxy]-3,4-dihydroxy-5-[(Z)-3-imidazo[4,5-b]pyridin-1-yl-3-phenylprop-2-enoyl]oxycyclohexane-1-carboxylic acid
DME5HIR	DE	Discovery agent

DMFC430	ID	DMFC430
DMFC430	DN	S-41744
DMFC430	HS	Investigative
DMFC430	SN	Dual 5-HT reuptake inhibitor/NK1 antagonist (depression); Dual 5-HT reuptake inhibitor/NK1 antagonist(depression), Servier
DMFC430	CP	Servier
DMFC430	DE	Major depressive disorder

DMML1HC	ID	DMML1HC
DMML1HC	DN	S6716
DMML1HC	HS	Investigative
DMML1HC	SN	3-amidinobenzylindole carboxamide 23
DMML1HC	DT	Small molecular drug
DMML1HC	PC	9803617
DMML1HC	MW	446.5
DMML1HC	FM	C29H26N4O
DMML1HC	IC	InChI=1S/C29H26N4O/c1-19-7-4-14-26-25(19)16-27(33(26)18-20-8-5-11-22(15-20)28(30)31)29(34)32-17-23-12-6-10-21-9-2-3-13-24(21)23/h2-16H,17-18H2,1H3,(H3,30,31)(H,32,34)
DMML1HC	CS	CC1=C2C=C(N(C2=CC=C1)CC3=CC(=CC=C3)C(=N)N)C(=O)NCC4=CC=CC5=CC=CC=C54
DMML1HC	IK	IDKGPACCMPKKQB-UHFFFAOYSA-N
DMML1HC	IU	1-[(3-carbamimidoylphenyl)methyl]-4-methyl-N-(naphthalen-1-ylmethyl)indole-2-carboxamide
DMML1HC	DE	Discovery agent

DMIKJNL	ID	DMIKJNL
DMIKJNL	DN	S6-nitrobenzyl mercaptopurine riboside
DMIKJNL	HS	Investigative
DMIKJNL	SN	NBMPR; 38048-32-7; 4-Nitrobenzylthioinosine; NBTI; 6-(p-Nitrobenzylthio)inosine; EINECS 253-753-4; UNII-GV1L2DZM2Z; GV1L2DZM2Z; BRN 1191080; 6-((4-Nitrobenzyl)thio)-9-beta-D-ribofuranosylpurine; CHEMBL418509; (2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-((4-nitrobenzyl)thio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol; 6-(((4-Nitrophenyl)methyl)thio)-9-beta-D-ribofuranosyl-9H-purine; 9H-Purine, 6-(((4-nitrophenyl)methyl)thio)-9-beta-D-ribofuranosyl-
DMIKJNL	DT	Small molecular drug
DMIKJNL	PC	65407
DMIKJNL	MW	419.4
DMIKJNL	FM	C17H17N5O6S
DMIKJNL	IC	InChI=1S/C17H17N5O6S/c23-5-11-13(24)14(25)17(28-11)21-8-20-12-15(21)18-7-19-16(12)29-6-9-1-3-10(4-2-9)22(26)27/h1-4,7-8,11,13-14,17,23-25H,5-6H2/t11-,13-,14-,17-/m1/s1
DMIKJNL	CS	C1=CC(=CC=C1CSC2=NC=NC3=C2N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)[N+](=O)[O-]
DMIKJNL	IK	DYCJFJRCWPVDHY-LSCFUAHRSA-N
DMIKJNL	IU	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[(4-nitrophenyl)methylsulfanyl]purin-9-yl]oxolane-3,4-diol
DMIKJNL	CA	CAS 38048-32-7
DMIKJNL	CB	CHEBI:138859
DMIKJNL	DE	Discovery agent

DMHB6UY	ID	DMHB6UY
DMHB6UY	DN	S-9947
DMHB6UY	HS	Investigative
DMHB6UY	SN	S9947; CHEMBL148159; AC1LCVHN; CHEBI:34965; 2'-(Benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide; SureCN498662; S-9947; SCHEMBL498662; GTPL2562; FLOLVFLAXFXKBU-UHFFFAOYSA-N; MolPort-042-665-732; CHEBI:342860; ZINC1491423; BDBM50123508; NCGC00386602-01; C13771; benzyl N-[[2-[2-(2-pyridin-2-ylethylcarbamoyl)phenyl]phenyl]methyl]carbamate; benzyl N-[[2-[2-[2-(2-pyridyl)ethylcarbamoyl]phenyl]phenyl]methyl]carbamate; [2''-(2-Pyridin-2-yl-ethylcarbamoyl)-biphenyl-2-ylmethyl]-carbamic acid benzyl este
DMHB6UY	CP	Aventis
DMHB6UY	DT	Small molecular drug
DMHB6UY	PC	656730
DMHB6UY	MW	465.5
DMHB6UY	FM	C29H27N3O3
DMHB6UY	IC	InChI=1S/C29H27N3O3/c33-28(31-19-17-24-13-8-9-18-30-24)27-16-7-6-15-26(27)25-14-5-4-12-23(25)20-32-29(34)35-21-22-10-2-1-3-11-22/h1-16,18H,17,19-21H2,(H,31,33)(H,32,34)
DMHB6UY	CS	C1=CC=C(C=C1)COC(=O)NCC2=CC=CC=C2C3=CC=CC=C3C(=O)NCCC4=CC=CC=N4
DMHB6UY	IK	FLOLVFLAXFXKBU-UHFFFAOYSA-N
DMHB6UY	IU	benzyl N-[[2-[2-(2-pyridin-2-ylethylcarbamoyl)phenyl]phenyl]methyl]carbamate
DMHB6UY	CB	CHEBI:34965
DMHB6UY	DE	Atrial fibrillation

DMVA5FE	ID	DMVA5FE
DMVA5FE	DN	SA-6541
DMVA5FE	HS	Investigative
DMVA5FE	SN	SA-6541; CHEMBL457317; SCHEMBL4565424; BDBM50266074
DMVA5FE	DT	Small molecular drug
DMVA5FE	PC	9906720
DMVA5FE	MW	356.5
DMVA5FE	FM	C16H24N2O3S2
DMVA5FE	IC	InChI=1S/C16H24N2O3S2/c1-11(8-22)15(19)17-14(16(20)21)10-23-9-12-4-6-13(7-5-12)18(2)3/h4-7,11,14,22H,8-10H2,1-3H3,(H,17,19)(H,20,21)/t11-,14+/m1/s1
DMVA5FE	CS	C[C@H](CS)C(=O)N[C@@H](CSCC1=CC=C(C=C1)N(C)C)C(=O)O
DMVA5FE	IK	HLSVAMGQMKPXOP-RISCZKNCSA-N
DMVA5FE	IU	(2R)-3-[[4-(dimethylamino)phenyl]methylsulfanyl]-2-[[(2S)-2-methyl-3-sulfanylpropanoyl]amino]propanoic acid
DMVA5FE	DE	Inflammation

DM5MBX7	ID	DM5MBX7
DM5MBX7	DN	Sabadinine
DM5MBX7	HS	Investigative
DM5MBX7	DT	Small molecular drug
DM5MBX7	PC	264634
DM5MBX7	MW	509.6
DM5MBX7	FM	C27H43NO8
DM5MBX7	IC	InChI=1S/C27H43NO8/c1-14-4-7-18-22(3,31)26(34)17(12-28(18)11-14)24(33)13-25-16(23(24,32)10-20(26)30)6-5-15-21(25,2)9-8-19(29)27(15,35)36-25/h14-20,29-35H,4-13H2,1-3H3
DM5MBX7	CS	CC1CCC2C(C3(C(CC4(C5CCC6C7(C5(CC4(C3CN2C1)O)OC6(C(CC7)O)O)C)O)O)O)(C)O
DM5MBX7	IK	MZHXYVMEVBEFAL-UHFFFAOYSA-N
DM5MBX7	IU	6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosane-1,10,11,12,14,22,23-heptol
DM5MBX7	CA	CAS 5876-23-3
DM5MBX7	DE	Discovery agent

DMRA736	ID	DMRA736
DMRA736	DN	Saccharin
DMRA736	HS	Investigative
DMRA736	SN	saccharin; 81-07-2; o-Sulfobenzimide; Saccharine; o-Benzoic sulfimide; Saccharimide; Benzosulfimide; o-Benzosulfimide; Benzoic sulfimide; Benzosulphimide; Saccharinose; Garantose; Saccharinol; Gluside; Saccharin acid; Benzosulfinide; Hermesetas; Saccharol; Sweeta; Saccharin insoluble; Glucid; Benzoic sulphimide; 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide; Saccharina; Zaharina; Sucrette; Sacarina; Kandiset; Sykose; Saxin; o-Benzoyl sulfimide; Benzo-2-sulphimide; Sucre edulcor; o-Benzoic sulphimide; Benzoylsulfonic Imide; o-Sulfobenzoic acid im
DMRA736	DT	Small molecular drug
DMRA736	PC	5143
DMRA736	MW	183.19
DMRA736	FM	C7H5NO3S
DMRA736	IC	InChI=1S/C7H5NO3S/c9-7-5-3-1-2-4-6(5)12(10,11)8-7/h1-4H,(H,8,9)
DMRA736	CS	C1=CC=C2C(=C1)C(=O)NS2(=O)=O
DMRA736	IK	CVHZOJJKTDOEJC-UHFFFAOYSA-N
DMRA736	IU	1,1-dioxo-1,2-benzothiazol-3-one
DMRA736	CA	CAS 128-44-9
DMRA736	CB	CHEBI:32111
DMRA736	DE	Discovery agent

DM3TO27	ID	DM3TO27
DM3TO27	DN	saclofen
DM3TO27	HS	Investigative
DM3TO27	SN	saclofen; 125464-42-8; 3-amino-2-(4-chlorophenyl)propane-1-sulfonic acid; beta-(Aminomethyl)-4-chlorobenzeneethanesulfonic acid; CHEMBL312403; (RS)-3-amino-2-(4-chlorophenyl)propylsulfonic acid; AK-86940; Benzeneethanesulfonic acid, beta-(aminomethyl)-4-chloro-; 3-AMINO-2-(4-CHLOROPHENYL)-PROPANE SULFONIC ACID; Saclofen, solid; Saclofen HCl; Biomol-NT_000242; SCHEMBL339757; BPBio1_000705; GTPL1078; AC1L3U31; CHEBI:91596; CTK8B4660; MolPort-003-824-767; HMS3266E05; BCP16740; BN0452; ANW-45829; MFCD00216817; BDBM50286225
DM3TO27	DT	Small molecular drug
DM3TO27	PC	122150
DM3TO27	MW	249.72
DM3TO27	FM	C9H12ClNO3S
DM3TO27	IC	InChI=1S/C9H12ClNO3S/c10-9-3-1-7(2-4-9)8(5-11)6-15(12,13)14/h1-4,8H,5-6,11H2,(H,12,13,14)
DM3TO27	CS	C1=CC(=CC=C1C(CN)CS(=O)(=O)O)Cl
DM3TO27	IK	JYLNVJYYQQXNEK-UHFFFAOYSA-N
DM3TO27	IU	3-amino-2-(4-chlorophenyl)propane-1-sulfonic acid
DM3TO27	CA	CAS 125464-42-8
DM3TO27	CB	CHEBI:91596
DM3TO27	DE	Discovery agent

DMZWGVP	ID	DMZWGVP
DMZWGVP	DN	Saframycin A
DMZWGVP	HS	Investigative
DMZWGVP	SN	AC1MHXXG
DMZWGVP	DT	Small molecular drug
DMZWGVP	PC	100594
DMZWGVP	MW	562.6
DMZWGVP	FM	C29H30N4O8
DMZWGVP	IC	InChI=1S/C29H30N4O8/c1-11-23(35)14-8-17-22-21-15(24(36)12(2)28(41-6)26(21)38)7-16(32(22)4)18(9-30)33(17)19(10-31-29(39)13(3)34)20(14)25(37)27(11)40-5/h16-19,22H,7-8,10H2,1-6H3,(H,31,39)/t16-,17-,18-,19-,22-/m0/s1
DMZWGVP	CS	CC1=C(C(=O)C2=C(C1=O)C[C@H]3[C@H]4C5=C(C[C@H](N4C)[C@@H](N3[C@H]2CNC(=O)C(=O)C)C#N)C(=O)C(=C(C5=O)OC)C)OC
DMZWGVP	IK	JNEGMBHBUAJRSX-SHUHUVMISA-N
DMZWGVP	IU	N-[[(1R,2S,10R,12R,13S)-12-cyano-7,18-dimethoxy-6,17,21-trimethyl-5,8,16,19-tetraoxo-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),6,15(20),17-tetraen-10-yl]methyl]-2-oxopropanamide
DMZWGVP	CA	CAS 66082-27-7
DMZWGVP	DE	Discovery agent

DMHOG7W	ID	DMHOG7W
DMHOG7W	DN	SAG
DMHOG7W	HS	Investigative
DMHOG7W	SN	1-stearoyl-2-arachidonoyl-sn-glycerol
DMHOG7W	DT	Small molecular drug
DMHOG7W	PC	5284330
DMHOG7W	MW	490.1
DMHOG7W	FM	C28H28ClN3OS
DMHOG7W	IC	InChI=1S/C28H28ClN3OS/c1-30-22-9-11-23(12-10-22)32(28(33)27-26(29)24-7-2-3-8-25(24)34-27)18-19-5-4-6-21(17-19)20-13-15-31-16-14-20/h2-8,13-17,22-23,30H,9-12,18H2,1H3
DMHOG7W	CS	CNC1CCC(CC1)N(CC2=CC(=CC=C2)C3=CC=NC=C3)C(=O)C4=C(C5=CC=CC=C5S4)Cl
DMHOG7W	IK	VFSUUTYAEQOIMW-UHFFFAOYSA-N
DMHOG7W	IU	3-chloro-N-[4-(methylamino)cyclohexyl]-N-[(3-pyridin-4-ylphenyl)methyl]-1-benzothiophene-2-carboxamide
DMHOG7W	CA	CAS 364590-63-6
DMHOG7W	CB	CHEBI:138438
DMHOG7W	DE	Discovery agent

DMLU6J0	ID	DMLU6J0
DMLU6J0	DN	SAIT301
DMLU6J0	HS	Investigative
DMLU6J0	DT	Antibody
DMLU6J0	DE	Nasopharyngeal carcinoma

DMUAQYZ	ID	DMUAQYZ
DMUAQYZ	DN	sakuranetin
DMUAQYZ	HS	Investigative
DMUAQYZ	DT	Small molecular drug
DMUAQYZ	PC	73571
DMUAQYZ	MW	286.28
DMUAQYZ	FM	C16H14O5
DMUAQYZ	IC	InChI=1S/C16H14O5/c1-20-11-6-12(18)16-13(19)8-14(21-15(16)7-11)9-2-4-10(17)5-3-9/h2-7,14,17-18H,8H2,1H3/t14-/m0/s1
DMUAQYZ	CS	COC1=CC(=C2C(=O)C[C@H](OC2=C1)C3=CC=C(C=C3)O)O
DMUAQYZ	IK	DJOJDHGQRNZXQQ-AWEZNQCLSA-N
DMUAQYZ	IU	(2S)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMUAQYZ	CA	CAS 2957-21-3
DMUAQYZ	CB	CHEBI:28927
DMUAQYZ	DE	Discovery agent

DMGLSPC	ID	DMGLSPC
DMGLSPC	DN	Salicylhydroxamic acid
DMGLSPC	HS	Investigative
DMGLSPC	SN	Salicylhydroxamic acid; N,2-Dihydroxybenzamide; 89-73-6; 2-Hydroxybenzohydroxamic acid; Salicylohydroxamic acid; SHAM; Salicylohydroximic acid; Benzamide, N,2-dihydroxy-; 2-Hydroxybenzhydroxamic acid; O-Hydroxybenzohydroxamic acid; SalicylhydroxaMicacid; SHA; 2,N-Dihydroxy-benzamide; NSC 5088; NSC 193440; Saliaylhydroxamic acid; UNII-8Q07182D0T; 2-hydroxybenzenecarbohydroxamic acid; Salicylic Hydroxamic Acid; EINECS 201-934-3; Salicylhydroxamic acid, 99%; MLS000069410; CHEMBL309339; CHEBI:45615; NSC5088
DMGLSPC	DT	Small molecular drug
DMGLSPC	PC	66644
DMGLSPC	MW	153.14
DMGLSPC	FM	C7H7NO3
DMGLSPC	IC	InChI=1S/C7H7NO3/c9-6-4-2-1-3-5(6)7(10)8-11/h1-4,9,11H,(H,8,10)
DMGLSPC	CS	C1=CC=C(C(=C1)C(=O)NO)O
DMGLSPC	IK	HBROZNQEVUILML-UHFFFAOYSA-N
DMGLSPC	IU	N,2-dihydroxybenzamide
DMGLSPC	CA	CAS 89-73-6
DMGLSPC	CB	CHEBI:45615
DMGLSPC	DE	Discovery agent

DMUPCA6	ID	DMUPCA6
DMUPCA6	DN	s-allylglycine
DMUPCA6	HS	Investigative
DMUPCA6	SN	L-Allylglycine; 16338-48-0; (S)-2-aminopent-4-enoic acid; H-Gly(Ally)-OH; (2S)-2-aminopent-4-enoic acid; (S)-(-)-2-Amino-4-pentenoic acid; (S)-2-Amino-4-pentenoic acid; L-alpha-Allyl-Gly; L-2-Amino-4-pentenoic acid; (S)-2-Amino-4- Pentenoic Acid; (S)-ALLYLGLYCINE; 3-VINYL-L-ALANINE; 4-Pentenoic acid, 2-amino-, (2S)-; (2S)-2-amino-4-pentenoic acid; (S)-2-Amino-pent-4-enoic acid; MFCD00002627; s-allylglycine; D-Allylglycine hydrochloride; (-)-Allylglycine; H-Gly(allyl)-OH; (S)-(-)-alpha-Allylglycine, 98%, 98% ee; C5H9NO2
DMUPCA6	DT	Small molecular drug
DMUPCA6	PC	167529
DMUPCA6	MW	115.13
DMUPCA6	FM	C5H9NO2
DMUPCA6	IC	InChI=1S/C5H9NO2/c1-2-3-4(6)5(7)8/h2,4H,1,3,6H2,(H,7,8)/t4-/m0/s1
DMUPCA6	CS	C=CC[C@@H](C(=O)O)N
DMUPCA6	IK	WNNNWFKQCKFSDK-BYPYZUCNSA-N
DMUPCA6	IU	(2S)-2-aminopent-4-enoic acid
DMUPCA6	CA	CAS 16338-48-0
DMUPCA6	DE	Discovery agent

DM8T1Y4	ID	DM8T1Y4
DM8T1Y4	DN	Salvinicin A
DM8T1Y4	HS	Investigative
DM8T1Y4	SN	salvinicin A; CHEMBL560302; SCHEMBL13312917
DM8T1Y4	DT	Small molecular drug
DM8T1Y4	PC	11466688
DM8T1Y4	MW	528.5
DM8T1Y4	FM	C25H36O12
DM8T1Y4	IC	InChI=1S/C25H36O12/c1-11(26)35-14-9-13(19(29)32-4)23(2)8-7-12-20(30)36-15(10-24(12,3)17(23)16(14)27)25(31)18(28)21(33-5)37-22(25)34-6/h12-15,17-18,21-22,28,31H,7-10H2,1-6H3/t12-,13-,14-,15-,17-,18+,21-,22+,23-,24-,25+/m0/s1
DM8T1Y4	CS	CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)[C@]4([C@@H]([C@H](O[C@H]4OC)OC)O)O)C)C(=O)OC
DM8T1Y4	IK	QEBAQEQKIKWXTO-QYGCUGILSA-N
DM8T1Y4	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-[(2R,3S,4S,5S)-3,4-dihydroxy-2,5-dimethoxyoxolan-3-yl]-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM8T1Y4	DE	Discovery agent

DMB70T3	ID	DMB70T3
DMB70T3	DN	SALVINICIN B
DMB70T3	HS	Investigative
DMB70T3	DT	Small molecular drug
DMB70T3	PC	44425153
DMB70T3	MW	528.5
DMB70T3	FM	C25H36O12
DMB70T3	IC	InChI=1S/C25H36O12/c1-11(26)35-14-9-13(19(29)32-4)23(2)8-7-12-20(30)36-15(10-24(12,3)17(23)16(14)27)25(31)18(28)21(33-5)37-22(25)34-6/h12-15,17-18,21-22,28,31H,7-10H2,1-6H3/t12-,13-,14-,15?,17-,18+,21+,22-,23-,24-,25+/m0/s1
DMB70T3	CS	CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)OC(C[C@@]3([C@H]2C1=O)C)[C@]4([C@@H]([C@@H](O[C@@H]4OC)OC)O)O)C)C(=O)OC
DMB70T3	IK	QEBAQEQKIKWXTO-CKKULBRGSA-N
DMB70T3	IU	methyl (4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-dimethoxyoxolan-3-yl]-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMB70T3	DE	Discovery agent

DMYH9Q5	ID	DMYH9Q5
DMYH9Q5	DN	Salvinorin A (ester)
DMYH9Q5	HS	Investigative
DMYH9Q5	SN	Salvinorin A (ester); CHEMBL435108; BDBM50159169; (2S,4aalpha,10abeta)-2beta-(3-Furyl)-4,10-dioxo-6aalpha,10balpha-dimethyl-9alpha-acetoxydodecahydro-2H-naphtho[2,1-c]pyran-7alpha-carboxylic acid methyl ester; (3S,4aR,4bS,6S,8R,8aR,10aS)-6-Acetoxy-3-furan-3-yl-4a,8a-dimethyl-1,5-dioxo-dodecahydro-2-oxa-phenanthrene-8-carboxylic acid methyl ester
DMYH9Q5	DT	Small molecular drug
DMYH9Q5	PC	21589297
DMYH9Q5	MW	432.5
DMYH9Q5	FM	C23H28O8
DMYH9Q5	IC	InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15+,16+,17+,19+,22+,23+/m1/s1
DMYH9Q5	CS	CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DMYH9Q5	IK	OBSYBRPAKCASQB-FBCTZMOOSA-N
DMYH9Q5	IU	methyl (2S,4aS,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMYH9Q5	DE	Discovery agent

DMBR7O0	ID	DMBR7O0
DMBR7O0	DN	SALVINORIN B
DMBR7O0	HS	Investigative
DMBR7O0	SN	Salvinorin B; CHEMBL424698; 92545-30-7; Divinorin B; (-)-Salvinorin B; SCHEMBL3144611; DTXSID50465988; BLTMVAIOAAGYAR-CEFSSPBYSA-N; (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(3-Furanyl)dodecahydro-9-hydroxy-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic Acid Methyl Ester; ZINC15449154; BDBM50189136; Salvinorin B, &gt; =93.0% (HPLC); AKOS027326793; NCGC00181787-01; Salvinorin B solution, 1.0 mg/mL in acetonitrile: water (9:1), ampule of 1 mL, certified reference material; [2S-(2; A,4a; A,6a; A,9; A,10a; A,10b
DMBR7O0	DT	Small molecular drug
DMBR7O0	PC	11440685
DMBR7O0	MW	390.4
DMBR7O0	FM	C21H26O7
DMBR7O0	IC	InChI=1S/C21H26O7/c1-20-6-4-12-19(25)28-15(11-5-7-27-10-11)9-21(12,2)17(20)16(23)14(22)8-13(20)18(24)26-3/h5,7,10,12-15,17,22H,4,6,8-9H2,1-3H3/t12-,13-,14-,15-,17-,20-,21-/m0/s1
DMBR7O0	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)O)C)C4=COC=C4
DMBR7O0	IK	BLTMVAIOAAGYAR-CEFSSPBYSA-N
DMBR7O0	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-9-hydroxy-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMBR7O0	CA	CAS 92545-30-7
DMBR7O0	DE	Discovery agent

DM5ZE7F	ID	DM5ZE7F
DM5ZE7F	DN	Salvinorin B 1-ethoxyethyl ether
DM5ZE7F	HS	Investigative
DM5ZE7F	SN	CHEMBL257922; CHEMBL556996; salvinorin B 1-ethoxyethyl ether; BDBM50374630
DM5ZE7F	DT	Small molecular drug
DM5ZE7F	PC	45266000
DM5ZE7F	MW	499
DM5ZE7F	FM	C25H35ClO8
DM5ZE7F	IC	InChI=1S/C25H34O8.ClH/c1-6-31-14(2)32-18-11-17(22(27)29-5)24(3)9-7-16-23(28)33-19(15-8-10-30-13-15)12-25(16,4)21(24)20(18)26;/h8,10,13-14,16-19,21H,6-7,9,11-12H2,1-5H3;1H/t14?,16-,17-,18-,19-,21-,24-,25-;/m0./s1
DM5ZE7F	CS	CCOC(C)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC.Cl
DM5ZE7F	IK	ZGLSOBCUTUFGHE-LMEMKYRVSA-N
DM5ZE7F	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(1-ethoxyethoxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate;hydrochloride
DM5ZE7F	DE	Discovery agent

DM1DE3F	ID	DM1DE3F
DM1DE3F	DN	Salvinorin B 2,2,2-trifluoroethoxymethyl ether
DM1DE3F	HS	Investigative
DM1DE3F	SN	CHEMBL272482; salvinorin B 2,2,2-trifluoroethoxymethyl ether
DM1DE3F	DT	Small molecular drug
DM1DE3F	PC	44456346
DM1DE3F	MW	502.5
DM1DE3F	FM	C24H29F3O8
DM1DE3F	IC	InChI=1S/C24H29F3O8/c1-22-6-4-14-21(30)35-17(13-5-7-32-10-13)9-23(14,2)19(22)18(28)16(8-15(22)20(29)31-3)34-12-33-11-24(25,26)27/h5,7,10,14-17,19H,4,6,8-9,11-12H2,1-3H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1
DM1DE3F	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OCOCC(F)(F)F)C)C4=COC=C4
DM1DE3F	IK	RUKCGYZDLPIDHQ-AGQYDFLVSA-N
DM1DE3F	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-(2,2,2-trifluoroethoxymethoxy)-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM1DE3F	DE	Discovery agent

DMBAXDU	ID	DMBAXDU
DMBAXDU	DN	Salvinorin B 2-fluoroethoxymethyl ether
DMBAXDU	HS	Investigative
DMBAXDU	SN	CHEMBL271077; salvinorin B 2-fluoroethoxymethyl ether
DMBAXDU	DT	Small molecular drug
DMBAXDU	PC	44456375
DMBAXDU	MW	466.5
DMBAXDU	FM	C24H31FO8
DMBAXDU	IC	InChI=1S/C24H31FO8/c1-23-6-4-15-22(28)33-18(14-5-8-30-12-14)11-24(15,2)20(23)19(26)17(32-13-31-9-7-25)10-16(23)21(27)29-3/h5,8,12,15-18,20H,4,6-7,9-11,13H2,1-3H3/t15-,16-,17-,18-,20-,23-,24-/m0/s1
DMBAXDU	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OCOCCF)C)C4=COC=C4
DMBAXDU	IK	BESVDGAGHUYOPY-WFOQEEKOSA-N
DMBAXDU	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(2-fluoroethoxymethoxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMBAXDU	DE	Discovery agent

DMD9A08	ID	DMD9A08
DMD9A08	DN	Salvinorin B 2-methoxy-2-propyl ether
DMD9A08	HS	Investigative
DMD9A08	SN	CHEMBL429026
DMD9A08	DT	Small molecular drug
DMD9A08	PC	44456105
DMD9A08	MW	462.5
DMD9A08	FM	C25H34O8
DMD9A08	IC	InChI=1S/C25H34O8/c1-23(2,30-6)33-17-11-16(21(27)29-5)24(3)9-7-15-22(28)32-18(14-8-10-31-13-14)12-25(15,4)20(24)19(17)26/h8,10,13,15-18,20H,7,9,11-12H2,1-6H3/t15-,16-,17-,18-,20-,24-,25-/m0/s1
DMD9A08	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OC(C)(C)OC)C)C4=COC=C4
DMD9A08	IK	CRCQUPUJAMIWQE-AZKXBNKQSA-N
DMD9A08	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-9-(2-methoxypropan-2-yloxy)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMD9A08	DE	Discovery agent

DM8UATD	ID	DM8UATD
DM8UATD	DN	Salvinorin B 2-methoxyethoxymethyl ether
DM8UATD	HS	Investigative
DM8UATD	SN	CHEMBL272483; salvinorin B 2-methoxyethoxymethyl ether
DM8UATD	DT	Small molecular drug
DM8UATD	PC	44456347
DM8UATD	MW	478.5
DM8UATD	FM	C25H34O9
DM8UATD	IC	InChI=1S/C25H34O9/c1-24-7-5-16-23(28)34-19(15-6-8-31-13-15)12-25(16,2)21(24)20(26)18(11-17(24)22(27)30-4)33-14-32-10-9-29-3/h6,8,13,16-19,21H,5,7,9-12,14H2,1-4H3/t16-,17-,18-,19-,21-,24-,25-/m0/s1
DM8UATD	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OCOCCOC)C)C4=COC=C4
DM8UATD	IK	PIISJSXOJJEJHX-BYDLNXCSSA-N
DM8UATD	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-9-(2-methoxyethoxymethoxy)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM8UATD	DE	Discovery agent

DMKXEQ6	ID	DMKXEQ6
DMKXEQ6	DN	Salvinorin B benzyloxymethyl ether
DMKXEQ6	HS	Investigative
DMKXEQ6	SN	CHEMBL271061; salvinorin B benzyloxymethyl ether
DMKXEQ6	DT	Small molecular drug
DMKXEQ6	PC	44456309
DMKXEQ6	MW	510.6
DMKXEQ6	FM	C29H34O8
DMKXEQ6	IC	InChI=1S/C29H34O8/c1-28-11-9-20-27(32)37-23(19-10-12-34-16-19)14-29(20,2)25(28)24(30)22(13-21(28)26(31)33-3)36-17-35-15-18-7-5-4-6-8-18/h4-8,10,12,16,20-23,25H,9,11,13-15,17H2,1-3H3/t20-,21-,22-,23-,25-,28-,29-/m0/s1
DMKXEQ6	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OCOCC4=CC=CC=C4)C)C5=COC=C5
DMKXEQ6	IK	UEIIMJAHRTUJMW-ZZIVESEQSA-N
DMKXEQ6	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-(phenylmethoxymethoxy)-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMKXEQ6	DE	Discovery agent

DM7Q12B	ID	DM7Q12B
DM7Q12B	DN	Salvinorin B butoxymethyl ether
DM7Q12B	HS	Investigative
DM7Q12B	SN	CHEMBL255139; salvinorin B butoxymethyl ether
DM7Q12B	DT	Small molecular drug
DM7Q12B	PC	44456421
DM7Q12B	MW	476.6
DM7Q12B	FM	C26H36O8
DM7Q12B	IC	InChI=1S/C26H36O8/c1-5-6-10-32-15-33-19-12-18(23(28)30-4)25(2)9-7-17-24(29)34-20(16-8-11-31-14-16)13-26(17,3)22(25)21(19)27/h8,11,14,17-20,22H,5-7,9-10,12-13,15H2,1-4H3/t17-,18-,19-,20-,22-,25-,26-/m0/s1
DM7Q12B	CS	CCCCOCO[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DM7Q12B	IK	SWDPRRWCLDGMFD-VHPHCEBOSA-N
DM7Q12B	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(butoxymethoxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM7Q12B	DE	Discovery agent

DMP5WNL	ID	DMP5WNL
DMP5WNL	DN	Salvinorin B ethoxymethyl ether
DMP5WNL	HS	Investigative
DMP5WNL	SN	CHEMBL272939; salvinorin B ethoxymethyl ether
DMP5WNL	DT	Small molecular drug
DMP5WNL	PC	24873526
DMP5WNL	MW	448.5
DMP5WNL	FM	C24H32O8
DMP5WNL	IC	InChI=1S/C24H32O8/c1-5-29-13-31-17-10-16(21(26)28-4)23(2)8-6-15-22(27)32-18(14-7-9-30-12-14)11-24(15,3)20(23)19(17)25/h7,9,12,15-18,20H,5-6,8,10-11,13H2,1-4H3/t15-,16-,17-,18-,20-,23-,24-/m0/s1
DMP5WNL	CS	CCOCO[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DMP5WNL	IK	ICVTXAUKIHJDGV-WFOQEEKOSA-N
DMP5WNL	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(ethoxymethoxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMP5WNL	DE	Discovery agent

DM01WOF	ID	DM01WOF
DM01WOF	DN	Salvinorin B fluoromethyl ether
DM01WOF	HS	Investigative
DM01WOF	SN	CHEMBL270844; salvinorin B fluoromethyl ether
DM01WOF	DT	Small molecular drug
DM01WOF	PC	44456305
DM01WOF	MW	422.4
DM01WOF	FM	C22H27FO7
DM01WOF	IC	InChI=1S/C22H27FO7/c1-21-6-4-13-20(26)30-16(12-5-7-28-10-12)9-22(13,2)18(21)17(24)15(29-11-23)8-14(21)19(25)27-3/h5,7,10,13-16,18H,4,6,8-9,11H2,1-3H3/t13-,14-,15-,16-,18-,21-,22-/m0/s1
DM01WOF	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OCF)C)C4=COC=C4
DM01WOF	IK	DDPYLPBMPHWVGO-VOVNARLJSA-N
DM01WOF	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(fluoromethoxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM01WOF	DE	Discovery agent

DMSFXA3	ID	DMSFXA3
DMSFXA3	DN	Salvinorin B isopropoxymethyl ether
DMSFXA3	HS	Investigative
DMSFXA3	SN	CHEMBL271078; salvinorin B isopropoxymethyl ether
DMSFXA3	DT	Small molecular drug
DMSFXA3	PC	44456377
DMSFXA3	MW	462.5
DMSFXA3	FM	C25H34O8
DMSFXA3	IC	InChI=1S/C25H34O8/c1-14(2)31-13-32-18-10-17(22(27)29-5)24(3)8-6-16-23(28)33-19(15-7-9-30-12-15)11-25(16,4)21(24)20(18)26/h7,9,12,14,16-19,21H,6,8,10-11,13H2,1-5H3/t16-,17-,18-,19-,21-,24-,25-/m0/s1
DMSFXA3	CS	CC(C)OCO[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DMSFXA3	IK	FRUCKVROBALDJE-BYDLNXCSSA-N
DMSFXA3	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-(propan-2-yloxymethoxy)-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMSFXA3	DE	Discovery agent

DMZ51IE	ID	DMZ51IE
DMZ51IE	DN	Salvinorin B methoxymethyl ether
DMZ51IE	HS	Investigative
DMZ51IE	SN	CHEMBL258098; salvinorin B methoxymethyl ether
DMZ51IE	DT	Small molecular drug
DMZ51IE	PC	44456192
DMZ51IE	MW	434.5
DMZ51IE	FM	C23H30O8
DMZ51IE	IC	InChI=1S/C23H30O8/c1-22-7-5-14-21(26)31-17(13-6-8-29-11-13)10-23(14,2)19(22)18(24)16(30-12-27-3)9-15(22)20(25)28-4/h6,8,11,14-17,19H,5,7,9-10,12H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1
DMZ51IE	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OCOC)C)C4=COC=C4
DMZ51IE	IK	KFVUSZPWUZBAPF-AGQYDFLVSA-N
DMZ51IE	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-9-(methoxymethoxy)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMZ51IE	DE	Discovery agent

DMKDMPL	ID	DMKDMPL
DMKDMPL	DN	Salvinorin B methylthiomethyl ether
DMKDMPL	HS	Investigative
DMKDMPL	SN	CHEMBL403658; salvinorin B methylthiomethyl ether
DMKDMPL	DT	Small molecular drug
DMKDMPL	PC	44456307
DMKDMPL	MW	450.5
DMKDMPL	FM	C23H30O7S
DMKDMPL	IC	InChI=1S/C23H30O7S/c1-22-7-5-14-21(26)30-17(13-6-8-28-11-13)10-23(14,2)19(22)18(24)16(29-12-31-4)9-15(22)20(25)27-3/h6,8,11,14-17,19H,5,7,9-10,12H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1
DMKDMPL	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OCSC)C)C4=COC=C4
DMKDMPL	IK	IEZYEEBKOXBUJC-AGQYDFLVSA-N
DMKDMPL	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-9-(methylsulfanylmethoxy)-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMKDMPL	DE	Discovery agent

DMKCUY6	ID	DMKCUY6
DMKCUY6	DN	Salvinorin B propoxymethyl ether
DMKCUY6	HS	Investigative
DMKCUY6	SN	CHEMBL258285; salvinorin B propoxymethyl ether
DMKCUY6	DT	Small molecular drug
DMKCUY6	PC	44456420
DMKCUY6	MW	462.5
DMKCUY6	FM	C25H34O8
DMKCUY6	IC	InChI=1S/C25H34O8/c1-5-9-31-14-32-18-11-17(22(27)29-4)24(2)8-6-16-23(28)33-19(15-7-10-30-13-15)12-25(16,3)21(24)20(18)26/h7,10,13,16-19,21H,5-6,8-9,11-12,14H2,1-4H3/t16-,17-,18-,19-,21-,24-,25-/m0/s1
DMKCUY6	CS	CCCOCO[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DMKCUY6	IK	WNDQODUGHMFWNT-BYDLNXCSSA-N
DMKCUY6	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-(propoxymethoxy)-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMKCUY6	DE	Discovery agent

DM8H6AT	ID	DM8H6AT
DM8H6AT	DN	Salvinorin B tert-butoxymethyl ether
DM8H6AT	HS	Investigative
DM8H6AT	SN	CHEMBL271285; salvinorin B tert-butoxymethyl ether
DM8H6AT	DT	Small molecular drug
DM8H6AT	PC	44456378
DM8H6AT	MW	476.6
DM8H6AT	FM	C26H36O8
DM8H6AT	IC	InChI=1S/C26H36O8/c1-24(2,3)33-14-32-18-11-17(22(28)30-6)25(4)9-7-16-23(29)34-19(15-8-10-31-13-15)12-26(16,5)21(25)20(18)27/h8,10,13,16-19,21H,7,9,11-12,14H2,1-6H3/t16-,17-,18-,19-,21-,25-,26-/m0/s1
DM8H6AT	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OCOC(C)(C)C)C)C4=COC=C4
DM8H6AT	IK	CWFMTHRKTLKOGU-PEVIRZATSA-N
DM8H6AT	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-9-[(2-methylpropan-2-yl)oxymethoxy]-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM8H6AT	DE	Discovery agent

DM3UPAE	ID	DM3UPAE
DM3UPAE	DN	Salvinorin B tetrahydropyran-2-yl ether
DM3UPAE	HS	Investigative
DM3UPAE	SN	CHEMBL403137; salvinorin B tetrahydropyran-2-yl ether
DM3UPAE	DT	Small molecular drug
DM3UPAE	PC	44456106
DM3UPAE	MW	474.5
DM3UPAE	FM	C26H34O8
DM3UPAE	IC	InChI=1S/C26H34O8/c1-25-9-7-16-24(29)34-19(15-8-11-31-14-15)13-26(16,2)22(25)21(27)18(12-17(25)23(28)30-3)33-20-6-4-5-10-32-20/h8,11,14,16-20,22H,4-7,9-10,12-13H2,1-3H3/t16-,17-,18-,19-,20?,22-,25-,26-/m0/s1
DM3UPAE	CS	C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OC4CCCCO4)C)C5=COC=C5
DM3UPAE	IK	QFGJOBZLFYQWNI-UBPYUYODSA-N
DM3UPAE	IU	methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-9-(oxan-2-yloxy)-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM3UPAE	DE	Discovery agent

DMTRMX8	ID	DMTRMX8
DMTRMX8	DN	Sanfetrinem cilexetil
DMTRMX8	HS	Investigative
DMTRMX8	SN	GV 118819
DMTRMX8	DT	Small molecular drug
DMTRMX8	PC	6918217
DMTRMX8	MW	451.5
DMTRMX8	FM	C23H33NO8
DMTRMX8	IC	InChI=1S/C23H33NO8/c1-12(25)17-19-15-10-7-11-16(29-3)18(15)20(24(19)21(17)26)22(27)30-13(2)31-23(28)32-14-8-5-4-6-9-14/h12-17,19,25H,4-11H2,1-3H3/t12-,13?,15+,16+,17-,19-/m1/s1
DMTRMX8	CS	C[C@H]([C@@H]1[C@H]2[C@H]3CCC[C@@H](C3=C(N2C1=O)C(=O)OC(C)OC(=O)OC4CCCCC4)OC)O
DMTRMX8	IK	QFEICXCLIGZEJB-IRVPUMQPSA-N
DMTRMX8	IU	1-cyclohexyloxycarbonyloxyethyl (1S,5S,8aS,8bR)-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-5,6,7,8,8a,8b-hexahydro-1H-azeto[1,2-b]isoindole-4-carboxylate
DMTRMX8	CA	CAS 141646-08-4
DMTRMX8	DE	Discovery agent

DMSF5DW	ID	DMSF5DW
DMSF5DW	DN	Sanggenon C
DMSF5DW	HS	Investigative
DMSF5DW	SN	Sanggenon C; 80651-76-9; 2-[(1S,5S,6R)-6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-1,3,8,10a-tetrahydroxy-5a-(3-methylbut-2-enyl)-[1]benzofuro[3,2-b]chromen-11-one; AC1L9CVB; Sanggenone-C; C09834; CHEBI:9020; DTXSID20230468
DMSF5DW	DT	Small molecular drug
DMSF5DW	PC	442458
DMSF5DW	MW	708.7
DMSF5DW	FM	C40H36O12
DMSF5DW	IC	InChI=1S/C40H36O12/c1-18(2)10-11-39-27-9-6-22(43)16-31(27)52-40(39,50)38(49)35-32(51-39)17-30(46)34(37(35)48)26-13-19(3)12-25(23-7-4-20(41)14-28(23)44)33(26)36(47)24-8-5-21(42)15-29(24)45/h4-10,13-17,25-26,33,41-46,48,50H,11-12H2,1-3H3/t25-,26+,33-,39?,40?/m1/s1
DMSF5DW	CS	CC1=C[C@@H]([C@@H]([C@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C(C5=C(C=C4O)OC6(C7=C(C=C(C=C7)O)OC6(C5=O)O)CC=C(C)C)O
DMSF5DW	IK	XETHJOZXBVWLLM-QAHMVTMMSA-N
DMSF5DW	IU	2-[(1S,5S,6R)-6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-1,3,8,10a-tetrahydroxy-5a-(3-methylbut-2-enyl)-[1]benzofuro[3,2-b]chromen-11-one
DMSF5DW	CA	CAS 80651-76-9
DMSF5DW	CB	CHEBI:9020
DMSF5DW	DE	Discovery agent

DMNHUOD	ID	DMNHUOD
DMNHUOD	DN	Sanggenon G
DMNHUOD	HS	Investigative
DMNHUOD	SN	CHEMBL382338
DMNHUOD	DT	Small molecular drug
DMNHUOD	PC	42608053
DMNHUOD	MW	694.7
DMNHUOD	FM	C40H38O11
DMNHUOD	IC	InChI=1S/C40H38O11/c1-19(2)4-3-5-20-12-27(24-9-6-21(41)14-29(24)44)36(39(49)26-11-8-23(43)16-31(26)46)28(13-20)37-32(47)18-35-38(40(37)50)33(48)17-34(51-35)25-10-7-22(42)15-30(25)45/h4,6-11,13-16,18,27-28,34,36,41-47,50H,3,5,12,17H2,1-2H3/t27-,28?,34?,36-/m1/s1
DMNHUOD	CS	CC(=CCCC1=CC([C@@H]([C@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C(C5=C(C=C4O)OC(CC5=O)C6=C(C=C(C=C6)O)O)O)C
DMNHUOD	IK	VYCKCQBOVSSJSK-CFQOWUBYSA-N
DMNHUOD	IU	6-[(5S,6R)-6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-(4-methylpent-3-enyl)cyclohex-2-en-1-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one
DMNHUOD	DE	Discovery agent

DM9XV16	ID	DM9XV16
DM9XV16	DN	Sanguiin H-6
DM9XV16	HS	Investigative
DM9XV16	SN	Sanguiin H-6; CHEMBL508647; CHEMBL3734788; BDBM50250999; [[5-[dodecahydroxy(tetraoxo)[ ]yl]oxycarbonyl-2,3-dihydroxy-phenoxy]-dodecahydroxy-tetraoxo-[ ]yl] 3,4,5-trihydroxybenzoate; .alpha.-D-Glucopyranose, cyclic 4,6-[3-[5-[[[2,3:4,6-bis-O-[(4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-diyl)dicarbonyl]-.beta.-D-glucopyranosyl]oxy]carbonyl]-2,3-dihydroxyphenoxy]-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] cyclic 2,3-(4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate) 1-(3,4,5- trih
DM9XV16	PC	16130897
DM9XV16	MW	1871.3
DM9XV16	FM	C82H54O52
DM9XV16	IC	InChI=1S/C82H54O52/c83-23-1-14(2-24(84)45(23)93)71(112)133-81-70-68(130-77(118)20-9-30(90)50(98)57(105)39(20)41-22(79(120)132-70)11-32(92)52(100)59(41)107)65-35(126-81)13-123-74(115)17-6-27(87)53(101)60(108)42(17)43-44(80(121)128-65)66(63(111)62(110)61(43)109)124-33-4-15(3-25(85)46(33)94)72(113)134-82-69-67(129-76(117)19-8-29(89)49(97)56(104)38(19)40-21(78(119)131-69)10-31(91)51(99)58(40)106)64-34(125-82)12-122-73(114)16-5-26(86)47(95)54(102)36(16)37-18(75(116)127-64)7-28(88)48(96)55(37)103/h1-11,34-35,64-65,67-70,81-111H,12-13H2/t34-,35-,64-,65-,67+,68+,69-,70-,81-,82+/m1/s1
DM9XV16	CS	C1[C@@H]2[C@H]([C@H]3[C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)OC5=C(C(=C(C6=C5C(=O)O[C@@H]7[C@@H](COC(=O)C8=CC(=C(C(=C86)O)O)O)O[C@@H]([C@H]9[C@H]7OC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)O9)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)O3)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)O1)O)O)O)O)O)O
DM9XV16	IK	FFZOOOCGCNFHAQ-GWOIDVGPSA-N
DM9XV16	IU	[(1R,2S,19R,20R,22R)-36-[5-[[(1R,2S,19R,20S,22R)-7,8,9,12,13,14,28,29,30,33,34,35-dodecahydroxy-4,17,25,38-tetraoxo-3,18,21,24,39-pentaoxaheptacyclo[20.17.0.02,19.05,10.011,16.026,31.032,37]nonatriaconta-5,7,9,11,13,15,26,28,30,32,34,36-dodecaen-20-yl]oxycarbonyl]-2,3-dihydroxyphenoxy]-7,8,9,12,13,14,28,29,30,33,34,35-dodecahydroxy-4,17,25,38-tetraoxo-3,18,21,24,39-pentaoxaheptacyclo[20.17.0.02,19.05,10.011,16.026,31.032,37]nonatriaconta-5,7,9,11,13,15,26,28,30,32(37),33,35-dodecaen-20-yl] 3,4,5-trihydroxybenzoate
DM9XV16	DE	Discovery agent

DM9CV4P	ID	DM9CV4P
DM9CV4P	DN	Sant7
DM9CV4P	HS	Investigative
DM9CV4P	SN	beta-Methylene tad; BETA-METHYLENE-THIAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE; 102977-57-1; beta-Tad; NSC617998; 1lrt; NSC 617998; beta-Methylene thiazole-4-carboxamide adenine dinucleotide; .beta.-Methylene TAD; AC1L2TER; Adenosine, 5'-(hydrogen (phosphonomethyl)phosphonate), 5'-ester with 2-beta-D-ribofuranosyl-4-thiazolecarboxamide
DM9CV4P	CP	Sigma-Tau
DM9CV4P	DT	Small molecular drug
DM9CV4P	PC	128225
DM9CV4P	MW	667.5
DM9CV4P	FM	C20H27N7O13P2S
DM9CV4P	IC	InChI=1S/C20H27N7O13P2S/c21-16-10-18(24-4-23-16)27(5-25-10)20-14(31)12(29)9(40-20)2-38-42(35,36)6-41(33,34)37-1-8-11(28)13(30)15(39-8)19-26-7(3-43-19)17(22)32/h3-5,8-9,11-15,20,28-31H,1-2,6H2,(H2,22,32)(H,33,34)(H,35,36)(H2,21,23,24)/t8-,9-,11-,12-,13-,14-,15-,20-/m1/s1
DM9CV4P	CS	C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(CP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)O)C(=O)N
DM9CV4P	IK	CRWWKLKZKYLFQV-HVIRUEHBSA-N
DM9CV4P	IU	[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[[(2R,3S,4R,5R)-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methyl]phosphinic acid
DM9CV4P	CA	CAS 102977-57-1
DM9CV4P	DE	Multiple myeloma

DMFAM7P	ID	DMFAM7P
DMFAM7P	DN	santacruzamate A
DMFAM7P	HS	Investigative
DMFAM7P	SN	CAY10683
DMFAM7P	DT	Small molecular drug
DMFAM7P	PC	72946782
DMFAM7P	MW	278.35
DMFAM7P	FM	C15H22N2O3
DMFAM7P	IC	InChI=1S/C15H22N2O3/c1-2-20-15(19)17-11-6-9-14(18)16-12-10-13-7-4-3-5-8-13/h3-5,7-8H,2,6,9-12H2,1H3,(H,16,18)(H,17,19)
DMFAM7P	CS	CCOC(=O)NCCCC(=O)NCCC1=CC=CC=C1
DMFAM7P	IK	HTOYBIILVCHURC-UHFFFAOYSA-N
DMFAM7P	IU	ethyl N-[4-oxo-4-(2-phenylethylamino)butyl]carbamate
DMFAM7P	DE	Discovery agent

DMYZFNH	ID	DMYZFNH
DMYZFNH	DN	Sapanisertib
DMYZFNH	HS	Investigative
DMYZFNH	SN	INK-128; MLN0128; INK 128; INK128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; MLN-0128; JGH0DF1U03
DMYZFNH	TC	Antiviral Agents
DMYZFNH	DT	Small molecular drug
DMYZFNH	PC	45375953
DMYZFNH	MW	309.33
DMYZFNH	FM	C15H15N7O
DMYZFNH	IC	InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)
DMYZFNH	CS	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N
DMYZFNH	IK	GYLDXIAOMVERTK-UHFFFAOYSA-N
DMYZFNH	IU	5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
DMYZFNH	CA	CAS 1224844-38-5
DMYZFNH	CB	CHEBI:91450
DMYZFNH	DE	Coronavirus Disease 2019 (COVID-19)

DM6GE21	ID	DM6GE21
DM6GE21	DN	Sapropterin
DM6GE21	HS	Investigative
DM6GE21	SN	L-erythro-tetrahydrobiopterin; R-THBP; Sapropterin; Sapropterin (INN); Sapropterin [INN]; Sapropterina; Sapropterinum; tetrahydro-l-biopterin; (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydropteridin-4(3H)-one; (6R)-L-erythro-tetrahydrobiopterin; 2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone; 62989-33-7; 6R-5,6,7,8-Tetrahydrobiopterin; 6R-BH4; 6R-L-5,6,7,8-Tetrahydrobiopterin; Kuvan; UNII-EGX657432I
DM6GE21	PC	135398654
DM6GE21	MW	241.25
DM6GE21	FM	C9H15N5O3
DM6GE21	IC	FNKQXYHWGSIFBK-RPDRRWSUSA-N
DM6GE21	CS	CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DM6GE21	IK	1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4+,6-/m0/s1
DM6GE21	IU	(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one
DM6GE21	CA	CAS 62989-33-7
DM6GE21	CB	CHEBI:59560
DM6GE21	DE	Discovery agent

DM2J0UN	ID	DM2J0UN
DM2J0UN	DN	SAR-106881
DM2J0UN	HS	Investigative
DM2J0UN	SN	FGF agonist (ischemia), sanofi-aventis
DM2J0UN	CP	Sanofi
DM2J0UN	DE	Peripheral arterial disease

DMSYE4W	ID	DMSYE4W
DMSYE4W	DN	SAR-131675
DMSYE4W	HS	Investigative
DMSYE4W	SN	VEGFR3 tyrosine kinase inhibitor (cancer), sanofi-aventis
DMSYE4W	CP	Sanofi
DMSYE4W	DT	Small molecular drug
DMSYE4W	PC	71295845
DMSYE4W	MW	358.4
DMSYE4W	FM	C18H22N4O4
DMSYE4W	IC	InChI=1S/C18H22N4O4/c1-5-22-15(19)13(17(24)20-3)14(23)12-7-6-11(21-16(12)22)8-9-18(2,25)10-26-4/h6-7,25H,5,10,19H2,1-4H3,(H,20,24)/t18-/m1/s1
DMSYE4W	CS	CCN1C(=C(C(=O)C2=C1N=C(C=C2)C#C[C@](C)(COC)O)C(=O)NC)N
DMSYE4W	IK	PFMPOBVAYMTUOX-GOSISDBHSA-N
DMSYE4W	IU	2-amino-1-ethyl-7-[(3R)-3-hydroxy-4-methoxy-3-methylbut-1-ynyl]-N-methyl-4-oxo-1,8-naphthyridine-3-carboxamide
DMSYE4W	DE	Solid tumour/cancer

DM0RDC4	ID	DM0RDC4
DM0RDC4	DN	Sarafotoxin 6C
DM0RDC4	HS	Investigative
DM0RDC4	SN	Sarafotoxin 6c; Sarafotoxin S 6c; Endothelin 1 (pig), 2-L-threonine-4-L-asparagine-5-L-aspartic acid-6-L-methionine-7-L-threonine-9-L-glutamic acid-12-L-leucine-13-L-asparagine-17-L-glutamine-19-L-valine-; SARAFOTOXINS6C; Sarafotoxin S6c, &gt; LS-184473
DM0RDC4	DT	Small molecular drug
DM0RDC4	PC	16132429
DM0RDC4	MW	2515.8
DM0RDC4	FM	C103H147N27O37S5
DM0RDC4	IC	InChI=1S/C103H147N27O37S5/c1-10-46(6)80(100(163)123-67(103(166)167)30-50-37-109-54-19-15-14-18-52(50)54)128-99(162)79(45(4)5)127-95(158)66(36-78(144)145)120-85(148)55(20-23-71(105)133)112-90(153)61(31-51-38-108-43-110-51)117-97(160)69-40-170-169-39-53(104)83(146)129-81(47(7)131)102(165)126-70-42-172-171-41-68(96(159)115-59(28-44(2)3)88(151)118-62(32-72(106)134)91(154)116-60(89(152)125-69)29-49-16-12-11-13-17-49)124-86(149)57(22-25-75(138)139)111-84(147)56(21-24-74(136)137)113-94(157)65(35-77(142)143)122-101(164)82(48(8)132)130-87(150)58(26-27-168-9)114-93(156)64(34-76(140)141)121-92(155)63(33-73(107)135)119-98(70)161/h11-19,37-38,43-48,53,55-70,79-82,109,131-132H,10,20-36,39-42,104H2,1-9H3,(H2,105,133)(H2,106,134)(H2,107,135)(H,108,110)(H,111,147)(H,112,153)(H,113,157)(H,114,156)(H,115,159)(H,116,154)(H,117,160)(H,118,151)(H,119,161)(H,120,148)(H,121,155)(H,122,164)(H,123,163)(H,124,149)(H,125,152)(H,126,165)(H,127,158)(H,128,162)(H,129,146)(H,130,150)(H,136,137)(H,138,139)(H,140,141)(H,142,143)(H,144,145)(H,166,167)
DM0RDC4	CS	CCC(C)C(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CN=CN3)NC(=O)C4CSSCC(C(=O)NC(C(=O)NC5CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4)CC6=CC=CC=C6)CC(=O)N)CC(C)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC5=O)CC(=O)N)CC(=O)O)CCSC)C(C)O)CC(=O)O)CCC(=O)O)CCC(=O)O)C(C)O)N
DM0RDC4	IK	LXPHPKVWHQLBBA-UHFFFAOYSA-N
DM0RDC4	IU	3-[[5-amino-2-[[2-[[31-amino-22,42-bis(2-amino-2-oxoethyl)-39-benzyl-4,7-bis(2-carboxyethyl)-10,19-bis(carboxymethyl)-13,28-bis(1-hydroxyethyl)-45-(2-methylpropyl)-16-(2-methylsulfanylethyl)-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecazabicyclo[23.22.4]henpentacontane-36-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-[[1-[[1-[[1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM0RDC4	CA	CAS 121695-87-2
DM0RDC4	DE	Discovery agent

DMR6PJ5	ID	DMR6PJ5
DMR6PJ5	DN	sarafotoxin S6b
DMR6PJ5	HS	Investigative
DMR6PJ5	SN	SRTX-b; GTPL995; AKOS024456438; Sarafotoxin S6b Atractaspis engaddensis sequence; Sarafotoxin S6b Atractaspis engaddensis sequence, &gt
DMR6PJ5	DT	Small molecular drug
DMR6PJ5	PC	74969379
DMR6PJ5	MW	2563.9
DMR6PJ5	FM	C110H159N27O34S5
DMR6PJ5	IC	InChI=1S/C110H159N27O34S5/c1-9-55(6)88(108(168)130-77(110(170)171)40-59-45-116-64-22-14-13-21-62(59)64)136-107(167)87(54(4)5)135-102(162)76(44-86(148)149)128-93(153)67(29-31-82(114)141)121-99(159)73(41-60-46-115-52-117-60)126-106(166)81-49-174-173-48-63(113)90(150)131-78(47-138)103(163)134-79-50-175-176-51-80(105(165)123-70(37-53(2)3)96(156)124-72(39-58-25-27-61(140)28-26-58)97(157)125-71(98(158)133-81)38-57-19-11-10-12-20-57)132-94(154)68(30-32-83(142)143)120-91(151)65(23-15-17-34-111)118-101(161)75(43-85(146)147)129-109(169)89(56(7)139)137-95(155)69(33-36-172-8)122-100(160)74(42-84(144)145)127-92(152)66(119-104(79)164)24-16-18-35-112/h10-14,19-22,25-28,45-46,52-56,63,65-81,87-89,116,138-140H,9,15-18,23-24,29-44,47-51,111-113H2,1-8H3,(H2,114,141)(H,115,117)(H,118,161)(H,119,164)(H,120,151)(H,121,159)(H,122,160)(H,123,165)(H,124,156)(H,125,157)(H,126,166)(H,127,152)(H,128,153)(H,129,169)(H,130,168)(H,131,150)(H,132,154)(H,133,158)(H,134,163)(H,135,162)(H,136,167)(H,137,155)(H,142,143)(H,144,145)(H,146,147)(H,148,149)(H,170,171)
DMR6PJ5	CS	CCC(C)C(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CNC=N3)NC(=O)C4CSSCC(C(=O)NC(C(=O)NC5CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4)CC6=CC=CC=C6)CC7=CC=C(C=C7)O)CC(C)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC5=O)CCCCN)CC(=O)O)CCSC)C(C)O)CC(=O)O)CCCCN)CCC(=O)O)CO)N
DMR6PJ5	IK	ZHRYDGYRZIWZPS-UHFFFAOYSA-N
DMR6PJ5	IU	3-[[5-amino-2-[[2-[[31-amino-7,22-bis(4-aminobutyl)-39-benzyl-4-(2-carboxyethyl)-10,19-bis(carboxymethyl)-13-(1-hydroxyethyl)-28-(hydroxymethyl)-42-[(4-hydroxyphenyl)methyl]-45-(2-methylpropyl)-16-(2-methylsulfanylethyl)-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecazabicyclo[23.22.4]henpentacontane-36-carbonyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-[[1-[[1-[[1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMR6PJ5	DE	Discovery agent

DMCNOJV	ID	DMCNOJV
DMCNOJV	DN	Sar-Arg-Val-Tyr-Ile-His-Pro-Ala
DMCNOJV	HS	Investigative
DMCNOJV	SN	Sar-Arg-Val-Tyr-Ile-His-Pro-Ala; 53935-10-7; [Sar1,Ala8]-ANGIOTENSIN II; DTXSID10657524; N-Methylglycyl-N~5~-(diaminomethylidene)ornithylvalyltyrosylisoleucylhistidylprolylalanine--acetic acid (1/1)
DMCNOJV	DT	Small molecular drug
DMCNOJV	PC	44134544
DMCNOJV	MW	986.1
DMCNOJV	FM	C45H71N13O12
DMCNOJV	IC	InChI=1S/C43H67N13O10.C2H4O2/c1-7-24(4)35(40(63)53-31(19-27-20-47-22-49-27)41(64)56-17-9-11-32(56)38(61)50-25(5)42(65)66)55-37(60)30(18-26-12-14-28(57)15-13-26)52-39(62)34(23(2)3)54-36(59)29(51-33(58)21-46-6)10-8-16-48-43(44)45;1-2(3)4/h12-15,20,22-25,29-32,34-35,46,57H,7-11,16-19,21H2,1-6H3,(H,47,49)(H,50,61)(H,51,58)(H,52,62)(H,53,63)(H,54,59)(H,55,60)(H,65,66)(H4,44,45,48);1H3,(H,3,4)
DMCNOJV	CS	CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(C)C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)CNC.CC(=O)O
DMCNOJV	IK	RWZZWAGPSKCDPN-UHFFFAOYSA-N
DMCNOJV	IU	acetic acid;2-[[1-[2-[[2-[[2-[[2-[[5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid
DMCNOJV	CA	CAS 53935-10-7
DMCNOJV	DE	Discovery agent

DMS0FQC	ID	DMS0FQC
DMS0FQC	DN	Sar-Arg-Val-Tyr-Ile-His-Pro-Ile
DMS0FQC	HS	Investigative
DMS0FQC	SN	Sar-Arg-Val-Tyr-Ile-His-Pro-Ile; 67724-27-0; DTXSID80553928
DMS0FQC	DT	Small molecular drug
DMS0FQC	PC	13996240
DMS0FQC	MW	968.2
DMS0FQC	FM	C46H73N13O10
DMS0FQC	IC	InChI=1S/C46H73N13O10/c1-8-26(5)37(43(66)55-33(21-29-22-50-24-52-29)44(67)59-19-11-13-34(59)41(64)58-38(45(68)69)27(6)9-2)57-40(63)32(20-28-14-16-30(60)17-15-28)54-42(65)36(25(3)4)56-39(62)31(53-35(61)23-49-7)12-10-18-51-46(47)48/h14-17,22,24-27,31-34,36-38,49,60H,8-13,18-21,23H2,1-7H3,(H,50,52)(H,53,61)(H,54,65)(H,55,66)(H,56,62)(H,57,63)(H,58,64)(H,68,69)(H4,47,48,51)
DMS0FQC	CS	CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(C(C)CC)C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)CNC
DMS0FQC	IK	ZVUNAQTWOGAJRE-UHFFFAOYSA-N
DMS0FQC	IU	2-[[1-[2-[[2-[[2-[[2-[[5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid
DMS0FQC	CA	CAS 67724-27-0
DMS0FQC	DE	Discovery agent

DMD6SJT	ID	DMD6SJT
DMD6SJT	DN	Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
DMD6SJT	HS	Investigative
DMD6SJT	SN	CHEMBL216061; 51833-69-3; (Sar1)-Angiotensin II; Sar-Arg-Val-Tyr-Ile-His-Pro-Phe; Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH; (Sar1)angiotensin II
DMD6SJT	PC	10373777
DMD6SJT	MW	1002.2
DMD6SJT	FM	C49H71N13O10
DMD6SJT	IC	InChI=1S/C49H71N13O10/c1-6-29(4)41(46(69)58-36(24-32-25-53-27-55-32)47(70)62-21-11-15-38(62)44(67)59-37(48(71)72)23-30-12-8-7-9-13-30)61-43(66)35(22-31-16-18-33(63)19-17-31)57-45(68)40(28(2)3)60-42(65)34(56-39(64)26-52-5)14-10-20-54-49(50)51/h7-9,12-13,16-19,25,27-29,34-38,40-41,52,63H,6,10-11,14-15,20-24,26H2,1-5H3,(H,53,55)(H,56,64)(H,57,68)(H,58,69)(H,59,67)(H,60,65)(H,61,66)(H,71,72)(H4,50,51,54)/t29-,34-,35-,36-,37-,38-,40-,41-/m0/s1
DMD6SJT	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMD6SJT	IK	WCYZYYURIHACQW-KOTWUFNXSA-N
DMD6SJT	IU	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMD6SJT	DE	Discovery agent

DMZR4FX	ID	DMZR4FX
DMZR4FX	DN	Sarcodictyin A
DMZR4FX	HS	Investigative
DMZR4FX	SN	Sarcodictyin A; sarcodictyin-a; CHEMBL370543
DMZR4FX	DT	Small molecular drug
DMZR4FX	PC	5478977
DMZR4FX	MW	496.6
DMZR4FX	FM	C28H36N2O6
DMZR4FX	IC	InChI=1S/C28H36N2O6/c1-17(2)20-9-7-18(3)21-14-24(35-25(31)10-8-19-15-30(5)16-29-19)27(4)11-12-28(33,36-27)23(13-22(20)21)26(32)34-6/h7-8,10-13,15-17,20-22,24,33H,9,14H2,1-6H3/b10-8+,23-13-/t20-,21+,22-,24+,27+,28-/m1/s1
DMZR4FX	CS	CC1=CC[C@@H]([C@@H]/2[C@H]1C[C@@H]([C@@]3(C=C[C@@](O3)(/C(=C2)/C(=O)OC)O)C)OC(=O)/C=C/C4=CN(C=N4)C)C(C)C
DMZR4FX	IK	VHZOZCRALQEBDG-BEMXCNERSA-N
DMZR4FX	IU	methyl (1R,2E,4S,5R,9R,11S,12S)-1-hydroxy-8,12-dimethyl-11-[(E)-3-(1-methylimidazol-4-yl)prop-2-enoyl]oxy-5-propan-2-yl-15-oxatricyclo[10.2.1.04,9]pentadeca-2,7,13-triene-2-carboxylate
DMZR4FX	DE	Discovery agent

DMIVGOR	ID	DMIVGOR
DMIVGOR	DN	Sarcosine
DMIVGOR	HS	Investigative
DMIVGOR	SN	sarcosine; 107-97-1; N-methylglycine; Sarcosinic acid; Methylglycine; Glycine, N-methyl-; Methylaminoacetic acid; 2-(methylamino)acetic acid; N-Methylaminoacetic acid; Sarcosin; (Methylamino)acetic acid; (Methylamino)ethanoic acid; Sargosine hydrochloride; N-Methyl glycine; Acetic acid, (methylamino)-; Cocoylsarcosine; Polysarcosine; N-methyl-Glycine; H-Sar-OH; UNII-Z711V88R5F; BRN 1699442; Sarcosine, 98%; AI3-15410; Methylamino-Acetic Acid; EINECS 203-538-6; SAR; CHEMBL304383; CHEBI:15611; FSYKKLYZXJSNPZ-UHFFFAOYSA-N; Z711V88R5F
DMIVGOR	DT	Small molecular drug
DMIVGOR	PC	1088
DMIVGOR	MW	89.09
DMIVGOR	FM	C3H7NO2
DMIVGOR	IC	InChI=1S/C3H7NO2/c1-4-2-3(5)6/h4H,2H2,1H3,(H,5,6)
DMIVGOR	CS	CNCC(=O)O
DMIVGOR	IK	FSYKKLYZXJSNPZ-UHFFFAOYSA-N
DMIVGOR	IU	2-(methylamino)acetic acid
DMIVGOR	CA	CAS 107-97-1
DMIVGOR	CB	CHEBI:15611
DMIVGOR	DE	Discovery agent

DMILBO9	ID	DMILBO9
DMILBO9	DN	SARMs
DMILBO9	HS	Investigative
DMILBO9	SN	SARMs (cancer); SARMs (cancer), CEAMED; Selective androgen receptor modulators (cancer), CEAMED
DMILBO9	CP	CEAMED SA
DMILBO9	DE	Solid tumour/cancer

DMJQVAG	ID	DMJQVAG
DMJQVAG	DN	S-ATPO
DMJQVAG	HS	Investigative
DMJQVAG	SN	CHEMBL594840; (S)-2-Amino-3-(5-Tert-Butyl-3-(Phosphonomethoxy)-4-Isoxazolyl)propionic Acid; 2-AMINO-3-(5-TERT-BUTYL-3-(PHOSPHONOMETHOXY)-4-ISOXAZOLYL)PROPIONIC ACID; (2S)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid; AT1; 1n0t; AC1L9KN0; (S)-ATPO; SCHEMBL5457168; BCP16890; ZINC2047684; BDBM50304093; AKOS032960456; DB02347; A-330; 3-[5-tert-butyl-3-(phosphonomethoxy)isoxazol-4-yl]-L-alanine; (S)-2-amino-3-[5-tertbutyl-3-(phosphono-methoxy)-4-isoxazolyl]-propionic acid
DMJQVAG	DT	Small molecular drug
DMJQVAG	PC	447249
DMJQVAG	MW	322.25
DMJQVAG	FM	C11H19N2O7P
DMJQVAG	IC	InChI=1S/C11H19N2O7P/c1-11(2,3)8-6(4-7(12)10(14)15)9(13-20-8)19-5-21(16,17)18/h7H,4-5,12H2,1-3H3,(H,14,15)(H2,16,17,18)/t7-/m0/s1
DMJQVAG	CS	CC(C)(C)C1=C(C(=NO1)OCP(=O)(O)O)C[C@@H](C(=O)O)N
DMJQVAG	IK	AGSOOCUNMTYPSE-ZETCQYMHSA-N
DMJQVAG	IU	(2S)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid
DMJQVAG	DE	Discovery agent

DMF8O62	ID	DMF8O62
DMF8O62	DN	SAVX-1
DMF8O62	HS	Investigative
DMF8O62	CP	Genfit SA
DMF8O62	DE	Central nervous system disease

DMLX8RW	ID	DMLX8RW
DMLX8RW	DN	Saxitoxin
DMLX8RW	HS	Investigative
DMLX8RW	DT	Small molecular drug
DMLX8RW	PC	56947150
DMLX8RW	MW	299.29
DMLX8RW	FM	C10H17N7O4
DMLX8RW	IC	InChI=1S/C10H17N7O4/c11-6-15-5-4(3-21-8(13)18)14-7(12)17-2-1-9(19,20)10(5,17)16-6/h4-5,19-20H,1-3H2,(H2,12,14)(H2,13,18)(H3,11,15,16)/t4-,5-,10-/m0/s1
DMLX8RW	CS	C1CN2C(=N[C@H]([C@H]3[C@]2(C1(O)O)NC(=N3)N)COC(=O)N)N
DMLX8RW	IK	RPQXVSUAYFXFJA-HGRQIUPRSA-N
DMLX8RW	IU	[(3aS,4R,10aS)-2,6-diamino-10,10-dihydroxy-3a,4,8,9-tetrahydro-1H-pyrrolo[1,2-c]purin-4-yl]methyl carbamate
DMLX8RW	CA	CAS 35523-89-8
DMLX8RW	CB	CHEBI:34970
DMLX8RW	DE	Discovery agent

DM68JI5	ID	DM68JI5
DM68JI5	DN	Sazetidine-A
DM68JI5	HS	Investigative
DM68JI5	SN	AMOP-H-OH; Nicotinic ligands (depression, pain, nicotine dependence); Nicotinic ligands (depression, pain, nicotine dependence), PsychoGenics
DM68JI5	CP	University of Illinois
DM68JI5	DT	Small molecular drug
DM68JI5	PC	11983356
DM68JI5	MW	260.329
DM68JI5	FM	C15H20N2O2
DM68JI5	IC	InChI=1S/C15H20N2O2/c18-8-4-2-1-3-5-13-9-15(11-16-10-13)19-12-14-6-7-17-14/h9-11,14,17-18H,1-2,4,6-8,12H2/t14-/m0/s1
DM68JI5	CS	C1CN[C@@H]1COC2=CN=CC(=C2)C#CCCCCO
DM68JI5	IK	WONBUILDJNKYCB-AWEZNQCLSA-N
DM68JI5	IU	6-[5-[[(2S)-azetidin-2-yl]methoxy]pyridin-3-yl]hex-5-yn-1-ol
DM68JI5	CA	CAS 820231-95-6
DM68JI5	DE	Major depressive disorder

DMQAO5B	ID	DMQAO5B
DMQAO5B	DN	SB 203106
DMQAO5B	HS	Investigative
DMQAO5B	DE	Discovery agent

DM43K85	ID	DM43K85
DM43K85	DN	SB 204070
DM43K85	HS	Investigative
DM43K85	SN	SB-204070A; SB204070; SB-204,070
DM43K85	DT	Small molecular drug
DM43K85	PC	121880
DM43K85	MW	419.3
DM43K85	FM	C19H28Cl2N2O4
DM43K85	IC	InChI=1S/C19H27ClN2O4.ClH/c1-2-3-6-22-7-4-13(5-8-22)12-26-19(23)14-11-15(20)16(21)18-17(14)24-9-10-25-18;/h11,13H,2-10,12,21H2,1H3;1H
DM43K85	CS	CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)Cl.Cl
DM43K85	IK	YEQGKAOSYSXEPU-UHFFFAOYSA-N
DM43K85	IU	(1-butylpiperidin-4-yl)methyl 5-amino-6-chloro-2,3-dihydro-1,4-benzodioxine-8-carboxylate;hydrochloride
DM43K85	CA	CAS 148688-01-1
DM43K85	DE	Discovery agent

DM3LQF4	ID	DM3LQF4
DM3LQF4	DN	SB 204741
DM3LQF4	HS	Investigative
DM3LQF4	SN	SB-204741; SB-204,741
DM3LQF4	DT	Small molecular drug
DM3LQF4	PC	3277600
DM3LQF4	MW	286.35
DM3LQF4	FM	C14H14N4OS
DM3LQF4	IC	InChI=1S/C14H14N4OS/c1-9-7-13(20-17-9)16-14(19)15-11-3-4-12-10(8-11)5-6-18(12)2/h3-8H,1-2H3,(H2,15,16,19)
DM3LQF4	CS	CC1=NSC(=C1)NC(=O)NC2=CC3=C(C=C2)N(C=C3)C
DM3LQF4	IK	USFUFHFQWXDVMH-UHFFFAOYSA-N
DM3LQF4	IU	1-(1-methylindol-5-yl)-3-(3-methyl-1,2-thiazol-5-yl)urea
DM3LQF4	CA	CAS 152239-46-8
DM3LQF4	CB	CHEBI:140936
DM3LQF4	DE	Discovery agent

DMCM4LT	ID	DMCM4LT
DMCM4LT	DN	SB 215505
DMCM4LT	HS	Investigative
DMCM4LT	SN	SB-215505; SB-215,505
DMCM4LT	DT	Small molecular drug
DMCM4LT	PC	10449757
DMCM4LT	MW	337.8
DMCM4LT	FM	C19H16ClN3O
DMCM4LT	IC	InChI=1S/C19H16ClN3O/c1-12-10-13-7-9-23(18(13)11-15(12)20)19(24)22-17-6-2-5-16-14(17)4-3-8-21-16/h2-6,8,10-11H,7,9H2,1H3,(H,22,24)
DMCM4LT	CS	CC1=CC2=C(C=C1Cl)N(CC2)C(=O)NC3=CC=CC4=C3C=CC=N4
DMCM4LT	IK	HOVMHIRTZYQSKM-UHFFFAOYSA-N
DMCM4LT	IU	6-chloro-5-methyl-N-quinolin-5-yl-2,3-dihydroindole-1-carboxamide
DMCM4LT	CA	CAS 162100-15-4
DMCM4LT	DE	Discovery agent

DMB3R4Z	ID	DMB3R4Z
DMB3R4Z	DN	SB 216641
DMB3R4Z	HS	Investigative
DMB3R4Z	SN	SB-216,641; SB-216641
DMB3R4Z	DT	Small molecular drug
DMB3R4Z	PC	3292447
DMB3R4Z	MW	486.6
DMB3R4Z	FM	C28H30N4O4
DMB3R4Z	IC	InChI=1S/C28H30N4O4/c1-18-16-22(27-29-19(2)36-31-27)10-12-24(18)20-6-8-21(9-7-20)28(33)30-23-11-13-25(34-5)26(17-23)35-15-14-32(3)4/h6-13,16-17H,14-15H2,1-5H3,(H,30,33)
DMB3R4Z	CS	CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)OCCN(C)C
DMB3R4Z	IK	JRNUKVFYILMMLX-UHFFFAOYSA-N
DMB3R4Z	IU	N-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]-4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]benzamide
DMB3R4Z	CA	CAS 170230-39-4
DMB3R4Z	CB	CHEBI:92537
DMB3R4Z	DE	Discovery agent

DMN1G5S	ID	DMN1G5S
DMN1G5S	DN	SB 218078
DMN1G5S	HS	Investigative
DMN1G5S	SN	SB-218078
DMN1G5S	DT	Small molecular drug
DMN1G5S	PC	3387354
DMN1G5S	MW	393.4
DMN1G5S	FM	C24H15N3O3
DMN1G5S	IC	InChI=1S/C24H15N3O3/c28-23-19-17-11-5-1-3-7-13(11)26-15-9-10-16(30-15)27-14-8-4-2-6-12(14)18(22(27)21(17)26)20(19)24(29)25-23/h1-8,15-16H,9-10H2,(H,25,28,29)
DMN1G5S	CS	C1CC2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N(C1O2)C7=C53)C(=O)NC6=O
DMN1G5S	IK	OTPNDVKVEAIXTI-UHFFFAOYSA-N
DMN1G5S	IU	28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-3,5-dione
DMN1G5S	CA	CAS 135897-06-2
DMN1G5S	CB	CHEBI:91500
DMN1G5S	DE	Discovery agent

DM8DVY2	ID	DM8DVY2
DM8DVY2	DN	SB 221284
DM8DVY2	HS	Investigative
DM8DVY2	SN	SB-221284; SB221284
DM8DVY2	DT	Small molecular drug
DM8DVY2	PC	443389
DM8DVY2	MW	353.4
DM8DVY2	FM	C16H14F3N3OS
DM8DVY2	IC	InChI=1S/C16H14F3N3OS/c1-24-14-7-10-4-6-22(13(10)8-12(14)16(17,18)19)15(23)21-11-3-2-5-20-9-11/h2-3,5,7-9H,4,6H2,1H3,(H,21,23)
DM8DVY2	CS	CSC1=C(C=C2C(=C1)CCN2C(=O)NC3=CN=CC=C3)C(F)(F)F
DM8DVY2	IK	OQZOXHCRSXYSPM-UHFFFAOYSA-N
DM8DVY2	IU	5-methylsulfanyl-N-pyridin-3-yl-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide
DM8DVY2	CA	CAS 196965-14-7
DM8DVY2	CB	CHEBI:8978
DM8DVY2	DE	Discovery agent

DMIS8JQ	ID	DMIS8JQ
DMIS8JQ	DN	SB 224289
DMIS8JQ	HS	Investigative
DMIS8JQ	SN	180083-23-2; (2'-Methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)(1'-methyl-6,7-dihydrospiro[furo[2,3-f]indole-3,4'-piperidin]-5(2H)-yl)methanone; SB224289; SB-224289; SB 224289; UNII-F95C648W4N; CHEMBL281350; CHEBI:64069; F95C648W4N; (4-(2-Methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)phenyl)-(1'-methylspiro(6,7-dihydro-2H-furo(2,3-f)indole-3,4'-piperidine)-5-yl)methanone
DMIS8JQ	DT	Small molecular drug
DMIS8JQ	PC	3378093
DMIS8JQ	MW	520.6
DMIS8JQ	FM	C32H32N4O3
DMIS8JQ	IC	InChI=1S/C32H32N4O3/c1-20-16-25(30-33-21(2)39-34-30)8-9-26(20)22-4-6-23(7-5-22)31(37)36-13-10-24-17-29-27(18-28(24)36)32(19-38-29)11-14-35(3)15-12-32/h4-9,16-18H,10-15,19H2,1-3H3
DMIS8JQ	CS	CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)N4CCC5=CC6=C(C=C54)C7(CCN(CC7)C)CO6
DMIS8JQ	IK	ATQMRMGXINTJHV-UHFFFAOYSA-N
DMIS8JQ	IU	[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]-(1'-methylspiro[6,7-dihydro-2H-furo[2,3-f]indole-3,4'-piperidine]-5-yl)methanone
DMIS8JQ	CA	CAS 180083-23-2
DMIS8JQ	CB	CHEBI:64069
DMIS8JQ	DE	Discovery agent

DM7S63O	ID	DM7S63O
DM7S63O	DN	SB 227122
DM7S63O	HS	Investigative
DM7S63O	SN	CHEMBL64322; SCHEMBL3031616; AYXBAIULRDEVAS-UHFFFAOYSA-N; N,N-dimethyl-N-(4-((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)aminobenzyl)-N-(4-tetrahydropyranyl)ammonium iodide; N,N-dimethyl-N-(4-((2-(4-methylphenyl)-6,7-dihydro-5 H-benzocyclohepten-8-yl)carbonyl)aminobenzyl)-N-(4-tetrahydropyranyl)ammonium iodide
DM7S63O	DT	Small molecular drug
DM7S63O	PC	9873888
DM7S63O	MW	622.6
DM7S63O	FM	C33H39IN2O2
DM7S63O	IC	InChI=1S/C33H38N2O2.HI/c1-24-7-11-27(12-8-24)28-14-13-26-5-4-6-29(22-30(26)21-28)33(36)34-31-15-9-25(10-16-31)23-35(2,3)32-17-19-37-20-18-32;/h7-16,21-22,32H,4-6,17-20,23H2,1-3H3;1H
DM7S63O	CS	CC1=CC=C(C=C1)C2=CC3=C(CCCC(=C3)C(=O)NC4=CC=C(C=C4)C[N+](C)(C)C5CCOCC5)C=C2.[I-]
DM7S63O	IK	AYXBAIULRDEVAS-UHFFFAOYSA-N
DM7S63O	IU	dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7H-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;iodide
DM7S63O	DE	Discovery agent

DMKA8R4	ID	DMKA8R4
DMKA8R4	DN	SB 228357
DMKA8R4	HS	Investigative
DMKA8R4	SN	SB-228357; SB228357
DMKA8R4	DT	Small molecular drug
DMKA8R4	PC	443390
DMKA8R4	MW	431.4
DMKA8R4	FM	C22H17F4N3O2
DMKA8R4	IC	InChI=1S/C22H17F4N3O2/c1-31-20-9-13-4-6-29(19(13)11-18(20)22(24,25)26)21(30)28-17-8-15(7-16(23)10-17)14-3-2-5-27-12-14/h2-3,5,7-12H,4,6H2,1H3,(H,28,30)
DMKA8R4	CS	COC1=C(C=C2C(=C1)CCN2C(=O)NC3=CC(=CC(=C3)C4=CN=CC=C4)F)C(F)(F)F
DMKA8R4	IK	RRJLJKRFFRZRAF-UHFFFAOYSA-N
DMKA8R4	IU	N-(3-fluoro-5-pyridin-3-ylphenyl)-5-methoxy-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide
DMKA8R4	CA	CAS 181629-93-6
DMKA8R4	CB	CHEBI:8979
DMKA8R4	DE	Discovery agent

DM201Q7	ID	DM201Q7
DM201Q7	DN	SB 239063
DM201Q7	HS	Investigative
DM201Q7	SN	SB 239063; 193551-21-2; SB239063; SB-239063; UNII-HII3DC8CPI; HII3DC8CPI; CHEMBL97162; trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole; CHEBI:90681; TRANS-1-(4-HYDROXYCYCLOHEXYL)-4-(4-FLUOROPHENYL)-5-(2-METHOXYPYRIMIDIN-4-YL) IMIDAZOLE; trans-4-[4-(4-Fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol; 4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol
DM201Q7	TC	Analgesics
DM201Q7	DT	Small molecular drug
DM201Q7	PC	5166
DM201Q7	MW	368.4
DM201Q7	FM	C20H21FN4O2
DM201Q7	IC	InChI=1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3
DM201Q7	CS	COC1=NC=CC(=N1)C2=C(N=CN2C3CCC(CC3)O)C4=CC=C(C=C4)F
DM201Q7	IK	ZQUSFAUAYSEREK-UHFFFAOYSA-N
DM201Q7	IU	4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol
DM201Q7	CA	CAS 193551-21-2
DM201Q7	CB	CHEBI:90681
DM201Q7	DE	Pain

DMISBDC	ID	DMISBDC
DMISBDC	DN	SB 242084
DMISBDC	HS	Investigative
DMISBDC	SN	SB-242,084; SB242084
DMISBDC	DT	Small molecular drug
DMISBDC	PC	3644637
DMISBDC	MW	394.9
DMISBDC	FM	C21H19ClN4O2
DMISBDC	IC	InChI=1S/C21H19ClN4O2/c1-13-10-15-7-9-26(18(15)11-17(13)22)21(27)25-16-5-6-20(24-12-16)28-19-4-3-8-23-14(19)2/h3-6,8,10-12H,7,9H2,1-2H3,(H,25,27)
DMISBDC	CS	CC1=CC2=C(C=C1Cl)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C
DMISBDC	IK	GIUZEIJUFOPTMR-UHFFFAOYSA-N
DMISBDC	IU	6-chloro-5-methyl-N-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-2,3-dihydroindole-1-carboxamide
DMISBDC	CA	CAS 181632-25-7
DMISBDC	DE	Discovery agent

DMAFWRT	ID	DMAFWRT
DMAFWRT	DN	SB 243213
DMAFWRT	HS	Investigative
DMAFWRT	SN	SB-243213; SB 243213; AC1L9EKT; UNII-R6MR8DB4PZ; R6MR8DB4PZ; CHEMBL14460; CHEBI:8980; sb 243213 dihydrochloride; 200940-22-3; 5-methyl-N-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide; 5-methyl-N-(6-((2-methylpyridin-3-yl)oxy)pyridin-3-yl)-6-(trifluoromethyl)indoline-1-carboxamide; 5-Methyl-N-(6-((2-methylpyridin-3-yl)oxy)pyridin-3-yl)-6-(trifluoromethyl)-2,3-dihydro-1H-indole-1-carboxamide
DMAFWRT	DT	Small molecular drug
DMAFWRT	PC	443391
DMAFWRT	MW	428.4
DMAFWRT	FM	C22H19F3N4O2
DMAFWRT	IC	InChI=1S/C22H19F3N4O2/c1-13-10-15-7-9-29(18(15)11-17(13)22(23,24)25)21(30)28-16-5-6-20(27-12-16)31-19-4-3-8-26-14(19)2/h3-6,8,10-12H,7,9H2,1-2H3,(H,28,30)
DMAFWRT	CS	CC1=CC2=C(C=C1C(F)(F)F)N(CC2)C(=O)NC3=CN=C(C=C3)OC4=C(N=CC=C4)C
DMAFWRT	IK	ZETBBVYSBABLHL-UHFFFAOYSA-N
DMAFWRT	IU	5-methyl-N-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide
DMAFWRT	CA	CAS 200940-22-3
DMAFWRT	CB	CHEBI:8980
DMAFWRT	DE	Discovery agent

DM2QJKZ	ID	DM2QJKZ
DM2QJKZ	DN	SB 258585
DM2QJKZ	HS	Investigative
DM2QJKZ	SN	SB-258585; SB258585; SB-258,585; Tocris-1961; NCGC00025328-01; AC1MN2NM; SCHEMBL678180; CHEMBL60264; GTPL3232; CHEBI:93418; BDBM86428; ZINC3923836; NCGC00025328-02; BRD-K80639402-003-01-1; 4-iodo-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzenesulfonamide; 4-iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide; Benzenesulfonamide, 4-iodo-N-(4-methoxy-3-(4-methyl-1-piperazinyl)phenyl)-
DM2QJKZ	DT	Small molecular drug
DM2QJKZ	PC	3248571
DM2QJKZ	MW	487.4
DM2QJKZ	FM	C18H22IN3O3S
DM2QJKZ	IC	InChI=1S/C18H22IN3O3S/c1-21-9-11-22(12-10-21)17-13-15(5-8-18(17)25-2)20-26(23,24)16-6-3-14(19)4-7-16/h3-8,13,20H,9-12H2,1-2H3
DM2QJKZ	CS	CN1CCN(CC1)C2=C(C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)I)OC
DM2QJKZ	IK	BDHMSYNBSBZCAF-UHFFFAOYSA-N
DM2QJKZ	IU	4-iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide
DM2QJKZ	CA	CAS 209480-63-7
DM2QJKZ	CB	CHEBI:93418
DM2QJKZ	DE	Discovery agent

DMFHUGC	ID	DMFHUGC
DMFHUGC	DN	SB 269970-A
DMFHUGC	HS	Investigative
DMFHUGC	SN	SB-269970 hydrochloride; 261901-57-9; SB 269970 hydrochloride; SB269970 HCl; (R)-3-((2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)phenol hydrochloride; SB-269970 (hydrochloride); (R)-3-[2-[2-(4-Methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol hydrochloride; SR-01000076135; EU-0101059; SB269970 hydrochloride; C18H29ClN2O3S; MLS002153418; SB 269970 hcl; SCHEMBL2719586; CHEMBL1256844; KS-00000XMZ; CTK8B9470; SB-269970 HCl; MolPort-003-959-592; BCP14529; Tox21_501059; MFCD03788020; ANW-62575; s2849
DMFHUGC	DT	Small molecular drug
DMFHUGC	PC	11957684
DMFHUGC	MW	389
DMFHUGC	FM	C18H29ClN2O3S
DMFHUGC	IC	InChI=1S/C18H28N2O3S.ClH/c1-15-7-11-19(12-8-15)13-9-16-4-3-10-20(16)24(22,23)18-6-2-5-17(21)14-18;/h2,5-6,14-16,21H,3-4,7-13H2,1H3;1H/t16-;/m1./s1
DMFHUGC	CS	CC1CCN(CC1)CC[C@H]2CCCN2S(=O)(=O)C3=CC=CC(=C3)O.Cl
DMFHUGC	IK	XQCJOYZLWFNDIO-PKLMIRHRSA-N
DMFHUGC	IU	3-[(2R)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol;hydrochloride
DMFHUGC	DE	Discovery agent

DMOLNQX	ID	DMOLNQX
DMOLNQX	DN	SB 272183
DMOLNQX	HS	Investigative
DMOLNQX	SN	SB-272183
DMOLNQX	DT	Small molecular drug
DMOLNQX	PC	9870500
DMOLNQX	MW	498
DMOLNQX	FM	C29H28ClN5O
DMOLNQX	IC	InChI=1S/C29H28ClN5O/c1-33-14-16-34(17-15-33)28-19-27-21(18-25(28)30)10-13-35(27)29(36)32-26-7-6-22(20-8-11-31-12-9-20)23-4-2-3-5-24(23)26/h2-9,11-12,18-19H,10,13-17H2,1H3,(H,32,36)
DMOLNQX	CS	CN1CCN(CC1)C2=C(C=C3CCN(C3=C2)C(=O)NC4=CC=C(C5=CC=CC=C54)C6=CC=NC=C6)Cl
DMOLNQX	IK	DAPBIPAGJXKFCI-UHFFFAOYSA-N
DMOLNQX	IU	5-chloro-6-(4-methylpiperazin-1-yl)-N-(4-pyridin-4-ylnaphthalen-1-yl)-2,3-dihydroindole-1-carboxamide
DMOLNQX	DE	Discovery agent

DMVO8P5	ID	DMVO8P5
DMVO8P5	DN	SB 272844
DMVO8P5	HS	Investigative
DMVO8P5	SN	Tallimustine hydrochloride; UNII-JWV8AC9E4V; JWV8AC9E4V; FCE-24517; 118438-45-2; 1H-Pyrrole-2-carboxamide, N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1- methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-, hydrochloride (1:1); AC1OCF0Z; SCHEMBL1230144; CHEMBL545612; PNU-152241
DMVO8P5	DT	Small molecular drug
DMVO8P5	PC	6918104
DMVO8P5	MW	734.1
DMVO8P5	FM	C32H39Cl3N10O4
DMVO8P5	IC	InChI=1S/C32H38Cl2N10O4.ClH/c1-41-18-22(14-25(41)30(46)37-11-8-28(35)36)39-32(48)27-16-23(19-43(27)3)40-31(47)26-15-21(17-42(26)2)38-29(45)20-4-6-24(7-5-20)44(12-9-33)13-10-34;/h4-7,14-19H,8-13H2,1-3H3,(H3,35,36)(H,37,46)(H,38,45)(H,39,48)(H,40,47);1H
DMVO8P5	CS	CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CN(C(=C3)C(=O)NCCC(=N)N)C)C)NC(=O)C4=CC=C(C=C4)N(CCCl)CCCl.Cl
DMVO8P5	IK	BLSOATWWAGIRGE-UHFFFAOYSA-N
DMVO8P5	IU	N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide;hydrochloride
DMVO8P5	CA	CAS 118438-45-2
DMVO8P5	DE	Discovery agent

DM21Z6H	ID	DM21Z6H
DM21Z6H	DN	SB 649915
DM21Z6H	HS	Investigative
DM21Z6H	SN	SB-649915
DM21Z6H	DT	Small molecular drug
DM21Z6H	PC	10296414
DM21Z6H	MW	431.5
DM21Z6H	FM	C26H29N3O3
DM21Z6H	IC	InChI=1S/C26H29N3O3/c1-18-5-7-21-22(27-18)3-2-4-24(21)31-14-13-29-11-9-19(10-12-29)15-20-6-8-25-23(16-20)28-26(30)17-32-25/h2-8,16,19H,9-15,17H2,1H3,(H,28,30)
DM21Z6H	CS	CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCC(CC3)CC4=CC5=C(C=C4)OCC(=O)N5
DM21Z6H	IK	PJSUYRBCBFPCQW-UHFFFAOYSA-N
DM21Z6H	IU	6-[[1-[2-(2-methylquinolin-5-yl)oxyethyl]piperidin-4-yl]methyl]-4H-1,4-benzoxazin-3-one
DM21Z6H	CA	CAS 420785-70-2
DM21Z6H	DE	Discovery agent

DM82GH9	ID	DM82GH9
DM82GH9	DN	SB 699551
DM82GH9	HS	Investigative
DM82GH9	SN	SB-699,551; SB699551
DM82GH9	DT	Small molecular drug
DM82GH9	PC	11983346
DM82GH9	MW	584.7
DM82GH9	FM	C34H47Cl2N3O
DM82GH9	IC	InChI=1S/C34H45N3O.2ClH/c1-36(2)24-25-37(34(38)21-16-28-10-6-7-11-28)27-31-14-19-33(20-15-31)32-17-12-30(13-18-32)26-35-23-22-29-8-4-3-5-9-29;;/h3-5,8-9,12-15,17-20,28,35H,6-7,10-11,16,21-27H2,1-2H3;2*1H
DM82GH9	CS	CN(C)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)CNCCC3=CC=CC=C3)C(=O)CCC4CCCC4.Cl.Cl
DM82GH9	IK	QJMKBIHLMPTYTI-UHFFFAOYSA-N
DM82GH9	IU	3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[[4-[4-[(2-phenylethylamino)methyl]phenyl]phenyl]methyl]propanamide;dihydrochloride
DM82GH9	CA	CAS 791789-61-2
DM82GH9	DE	Discovery agent

DMGHRY0	ID	DMGHRY0
DMGHRY0	DN	SB 714786
DMGHRY0	HS	Investigative
DMGHRY0	SN	SB-714786; SB714786
DMGHRY0	DT	Small molecular drug
DMGHRY0	PC	10287730
DMGHRY0	MW	412.5
DMGHRY0	FM	C26H28N4O
DMGHRY0	IC	InChI=1S/C26H28N4O/c1-20-10-11-23-24(28-20)8-3-9-25(23)31-18-17-29-13-15-30(16-14-29)19-22-6-2-5-21-7-4-12-27-26(21)22/h2-12H,13-19H2,1H3
DMGHRY0	CS	CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCN(CC3)CC4=CC=CC5=C4N=CC=C5
DMGHRY0	IK	RMCSKUADBRROSI-UHFFFAOYSA-N
DMGHRY0	IU	2-methyl-5-[2-[4-(quinolin-8-ylmethyl)piperazin-1-yl]ethoxy]quinoline
DMGHRY0	CA	CAS 584555-10-2
DMGHRY0	DE	Discovery agent

DMOZX0D	ID	DMOZX0D
DMOZX0D	DN	SB-0304
DMOZX0D	HS	Investigative
DMOZX0D	SN	SB-0304; CHEMBL409225
DMOZX0D	DT	Small molecular drug
DMOZX0D	PC	11641503
DMOZX0D	MW	479.5
DMOZX0D	FM	C25H29N5O5
DMOZX0D	IC	InChI=1S/C25H29N5O5/c1-14(30-12-18-8-19(31)7-6-16(18)9-20(26)24(30)34)23(33)28-21-10-15-4-2-3-5-17(15)11-29(25(21)35)13-22(27)32/h2-8,14,20-21,31H,9-13,26H2,1H3,(H2,27,32)(H,28,33)/t14-,20+,21+/m1/s1
DMOZX0D	CS	C[C@H](C(=O)N[C@H]1CC2=CC=CC=C2CN(C1=O)CC(=O)N)N3CC4=C(C[C@@H](C3=O)N)C=CC(=C4)O
DMOZX0D	IK	ACFTTXWQZSBVGL-OREJSRFESA-N
DMOZX0D	IU	(2R)-2-[(4S)-4-amino-8-hydroxy-3-oxo-4,5-dihydro-1H-2-benzazepin-2-yl]-N-[(4S)-2-(2-amino-2-oxoethyl)-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]propanamide
DMOZX0D	DE	Discovery agent

DM9O0AR	ID	DM9O0AR
DM9O0AR	DN	SB-13
DM9O0AR	HS	Investigative
DM9O0AR	SN	CARBAMIC ACID, DIMETHYL-, 2-(DIMETHYLAMINO)-p-TOLYL ESTER, HYDROCHLORIDE; Carbamic acid, N,N-dimethyl-, 2-dimethylamino-4-methylphenyl ester, hydrochloride; AC1L2CX4; LS-49497; 63884-75-3; [2-(dimethylcarbamoyloxy)-5-methylphenyl]-dimethylazanium chloride
DM9O0AR	DT	Small molecular drug
DM9O0AR	PC	10013901
DM9O0AR	MW	225.28
DM9O0AR	FM	C15H15NO
DM9O0AR	IC	InChI=1S/C15H15NO/c1-16-14-8-4-12(5-9-14)2-3-13-6-10-15(17)11-7-13/h2-11,16-17H,1H3/b3-2+
DM9O0AR	CS	CNC1=CC=C(C=C1)/C=C/C2=CC=C(C=C2)O
DM9O0AR	IK	ZWIARAQZLULYPG-NSCUHMNNSA-N
DM9O0AR	IU	4-[(E)-2-[4-(methylamino)phenyl]ethenyl]phenol
DM9O0AR	CA	CAS 866475-34-5
DM9O0AR	DE	Discovery agent

DMKLWSG	ID	DMKLWSG
DMKLWSG	DN	SB-201076
DMKLWSG	HS	Investigative
DMKLWSG	SN	CHEMBL324097; 154566-05-9; SB-201076; SCHEMBL2622309; ZINC13781097; BDBM50066692; KB-145947; (S)-2-((S)-8-(2,4-dichlorophenyl)-2-hydroxyoctyl)-2-hydroxysuccinic acid; (S)-2-[(S)-8-(2,4-Dichloro-phenyl)-2-hydroxy-octyl]-2-hydroxy-succinic acid
DMKLWSG	DT	Small molecular drug
DMKLWSG	PC	10835222
DMKLWSG	MW	407.3
DMKLWSG	FM	C18H24Cl2O6
DMKLWSG	IC	InChI=1S/C18H24Cl2O6/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14(21)10-18(26,17(24)25)11-16(22)23/h7-9,14,21,26H,1-6,10-11H2,(H,22,23)(H,24,25)/t14-,18+/m1/s1
DMKLWSG	CS	C1=CC(=C(C=C1Cl)Cl)CCCCCC[C@H](C[C@](CC(=O)O)(C(=O)O)O)O
DMKLWSG	IK	NPZOIISFQXTCQN-KDOFPFPSSA-N
DMKLWSG	IU	(2S)-2-[(2R)-8-(2,4-dichlorophenyl)-2-hydroxyoctyl]-2-hydroxybutanedioic acid
DMKLWSG	DE	Discovery agent

DM09UIS	ID	DM09UIS
DM09UIS	DN	SB-202235
DM09UIS	HS	Investigative
DM09UIS	SN	139149-55-6; SB-202236
DM09UIS	DT	Small molecular drug
DM09UIS	PC	101930499
DM09UIS	MW	224.21
DM09UIS	FM	C10H12N2O4
DM09UIS	IC	InChI=1S/C10H12N2O4/c1-15-6-2-3-7-8(12(14)10(11)13)5-16-9(7)4-6/h2-4,8,14H,5H2,1H3,(H2,11,13)/t8-/m1/s1
DM09UIS	CS	COC1=CC2=C(C=C1)[C@@H](CO2)N(C(=O)N)O
DM09UIS	IK	KQTIJEDPTHQHRM-MRVPVSSYSA-N
DM09UIS	IU	1-hydroxy-1-[(3S)-6-methoxy-2,3-dihydro-1-benzofuran-3-yl]urea
DM09UIS	DE	Discovery agent

DM3AWMF	ID	DM3AWMF
DM3AWMF	DN	SB-203347
DM3AWMF	HS	Investigative
DM3AWMF	SN	169527-42-8
DM3AWMF	PC	9808192
DM3AWMF	MW	573.4
DM3AWMF	FM	C22H12F9NO5S
DM3AWMF	IC	InChI=1S/C22H12F9NO5S/c23-20(24,25)11-5-6-18(37-17-4-2-1-3-15(17)19(33)34)16(10-11)32-38(35,36)14-8-12(21(26,27)28)7-13(9-14)22(29,30)31/h1-10,32H,(H,33,34)
DM3AWMF	CS	C1=CC=C(C(=C1)C(=O)O)OC2=C(C=C(C=C2)C(F)(F)F)NS(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DM3AWMF	IK	VWKSVPJJPNTCFZ-UHFFFAOYSA-N
DM3AWMF	IU	2-[2-[[3,5-bis(trifluoromethyl)phenyl]sulfonylamino]-4-(trifluoromethyl)phenoxy]benzoic acid
DM3AWMF	DE	Discovery agent

DM704TL	ID	DM704TL
DM704TL	DN	SB-207043
DM704TL	HS	Investigative
DM704TL	SN	SB-207043; CHEMBL606910
DM704TL	PC	52942958
DM704TL	MW	1012.3
DM704TL	FM	C47H69N11O10S2
DM704TL	IC	InChI=1S/C47H69N11O10S2/c1-44(2)21-28(22-45(3,4)57(44)67)52-36(60)26-69-33-18-12-10-15-30(33)41(64)56(9)32(17-14-20-50-43(48)49)39(62)51-25-35(59)55-38(42(65)66)40(63)54-31-16-11-13-19-34(31)70-27-37(61)53-29-23-46(5,6)58(68)47(7,8)24-29/h10-13,15-16,18-19,28-29,32,38H,14,17,20-27H2,1-9H3,(H,51,62)(H,52,60)(H,53,61)(H,54,63)(H,55,59)(H,65,66)(H4,48,49,50)/t32-,38+/m0/s1
DM704TL	CS	CC1(CC(CC(N1[O])(C)C)NC(=O)CSC2=CC=CC=C2C(=O)N(C)[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](C(=O)NC3=CC=CC=C3SCC(=O)NC4CC(N(C(C4)(C)C)[O])(C)C)C(=O)O)C
DM704TL	IK	GUCPTRJTGNVVHA-SCAVLVJOSA-N
DM704TL	DE	Discovery agent

DMVQKMC	ID	DMVQKMC
DMVQKMC	DN	SB-207710
DMVQKMC	HS	Investigative
DMVQKMC	SN	SB207710; SB-207710; CHEMBL114112; (1-butylpiperidin-4-yl)methyl 5-amino-6-iodo-2,3-dihydro-1,4-benzodioxine-8-carboxylate; AC1NSKLR; GTPL257; SCHEMBL2939430; BDBM50327858; 148703-08-6; SB 207710; L008862; (1-butyl-4-piperidinyl)-methyl-8-amino-7-iodo-1,4-benzodioxan-5-carboxyl-ate; (1-Butylpiperidin-4-yl)methyl 8-amino-7-iodo-2,3-dihydrobenzo-[b][1,4]dioxine-5-carboxylate; 8-Amino-7-iodo-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid 1-butyl-piperidin-4-ylmethyl ester
DMVQKMC	DT	Small molecular drug
DMVQKMC	PC	5311423
DMVQKMC	MW	474.3
DMVQKMC	FM	C19H27IN2O4
DMVQKMC	IC	InChI=1S/C19H27IN2O4/c1-2-3-6-22-7-4-13(5-8-22)12-26-19(23)14-11-15(20)16(21)18-17(14)24-9-10-25-18/h11,13H,2-10,12,21H2,1H3
DMVQKMC	CS	CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)I
DMVQKMC	IK	FCKKCDRMGKXQDK-UHFFFAOYSA-N
DMVQKMC	IU	(1-butylpiperidin-4-yl)methyl 5-amino-6-iodo-2,3-dihydro-1,4-benzodioxine-8-carboxylate
DMVQKMC	DE	Discovery agent

DM5EWQN	ID	DM5EWQN
DM5EWQN	DN	SB-210313
DM5EWQN	HS	Investigative
DM5EWQN	SN	SB-210313; CHEMBL14112; SCHEMBL4918397; HMS3303P01; HMS3305H01; BDBM50053424; NCGC00241904-01; AB01092380-01
DM5EWQN	DT	Small molecular drug
DM5EWQN	PC	9885504
DM5EWQN	MW	366.4
DM5EWQN	FM	C21H23FN4O
DM5EWQN	IC	InChI=1S/C21H23FN4O/c22-19-4-2-17(3-5-19)20-21(18-6-8-23-9-7-18)26(16-24-20)11-1-10-25-12-14-27-15-13-25/h2-9,16H,1,10-15H2
DM5EWQN	CS	C1COCCN1CCCN2C=NC(=C2C3=CC=NC=C3)C4=CC=C(C=C4)F
DM5EWQN	IK	ANWALZPQHPAZFO-UHFFFAOYSA-N
DM5EWQN	IU	4-[3-[4-(4-fluorophenyl)-5-pyridin-4-ylimidazol-1-yl]propyl]morpholine
DM5EWQN	DE	Discovery agent

DMUCHNP	ID	DMUCHNP
DMUCHNP	DN	SB-213068
DMUCHNP	HS	Investigative
DMUCHNP	SN	SB-213068; CHEMBL306229; SCHEMBL7822831; FJENKDXEWRLENI-UHFFFAOYSA-N; BDBM50085043; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid; alpha-Ethoxy-4-[2-[methyl(benzoxazole-2-yl)amino]ethoxy]benzenepropanoic acid; 3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-ethoxypropanoic acid; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid(SB-213068)
DMUCHNP	DT	Small molecular drug
DMUCHNP	PC	9843045
DMUCHNP	MW	384.4
DMUCHNP	FM	C21H24N2O5
DMUCHNP	IC	InChI=1S/C21H24N2O5/c1-3-26-19(20(24)25)14-15-8-10-16(11-9-15)27-13-12-23(2)21-22-17-6-4-5-7-18(17)28-21/h4-11,19H,3,12-14H2,1-2H3,(H,24,25)
DMUCHNP	CS	CCOC(CC1=CC=C(C=C1)OCCN(C)C2=NC3=CC=CC=C3O2)C(=O)O
DMUCHNP	IK	FJENKDXEWRLENI-UHFFFAOYSA-N
DMUCHNP	IU	3-[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]-2-ethoxypropanoic acid
DMUCHNP	DE	Discovery agent

DMH1CFX	ID	DMH1CFX
DMH1CFX	DN	SB-214111
DMH1CFX	HS	Investigative
DMH1CFX	SN	209480-37-5
DMH1CFX	DT	Small molecular drug
DMH1CFX	PC	6918647
DMH1CFX	MW	440.4
DMH1CFX	FM	C18H22BrN3O3S
DMH1CFX	IC	InChI=1S/C18H22BrN3O3S/c1-21-9-11-22(12-10-21)17-13-15(5-8-18(17)25-2)20-26(23,24)16-6-3-14(19)4-7-16/h3-8,13,20H,9-12H2,1-2H3
DMH1CFX	CS	CN1CCN(CC1)C2=C(C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)Br)OC
DMH1CFX	IK	OZYPUQNRUYTZDI-UHFFFAOYSA-N
DMH1CFX	IU	4-bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide
DMH1CFX	DE	Discovery agent

DMIYFQ5	ID	DMIYFQ5
DMIYFQ5	DN	SB216763
DMIYFQ5	HS	Investigative
DMIYFQ5	SN	280744-09-4; SB 216763; 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; SB216763; SB-216763; 3-(2,4-dichlorophenyl)-4-(1-methylindol-3-yl)pyrrole-2,5-dione; 1H-Pyrrole-2,5-dione, 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-; CHEMBL102714; 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; SR-01000076052; Tocris-1616; Lopac-S-3442; AC1L41YI; Lopac0_000934; SCHEMBL30251; MLS001074894; cid_176158; BDBM8296; GTPL8015; CTK8B4807; CHEBI:91421; AOB5004; SYN1075; EX-A291
DMIYFQ5	DT	Small molecular drug
DMIYFQ5	PC	176158
DMIYFQ5	MW	371.2
DMIYFQ5	FM	C19H12Cl2N2O2
DMIYFQ5	IC	InChI=1S/C19H12Cl2N2O2/c1-23-9-13(11-4-2-3-5-15(11)23)17-16(18(24)22-19(17)25)12-7-6-10(20)8-14(12)21/h2-9H,1H3,(H,22,24,25)
DMIYFQ5	CS	CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C(C=C(C=C4)Cl)Cl
DMIYFQ5	IK	JCSGFHVFHSKIJH-UHFFFAOYSA-N
DMIYFQ5	IU	3-(2,4-dichlorophenyl)-4-(1-methylindol-3-yl)pyrrole-2,5-dione
DMIYFQ5	CA	CAS 280744-09-4
DMIYFQ5	CB	CHEBI:91421
DMIYFQ5	DE	Discovery agent

DMOH9TA	ID	DMOH9TA
DMOH9TA	DN	SB-216995
DMOH9TA	HS	Investigative
DMOH9TA	SN	PYRIDINYLIMIDAZOLE; CHEMBL96741; sb216995; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyridine; 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE; SB6; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine; 1bl6; SB-216995; AC1L1JR9; SCHEMBL4915662; CTK7C0283; BDBM15237; ZINC2047872; DB08522; SB216995; PYRIDINYLIMIDAZOLE
DMOH9TA	DT	Small molecular drug
DMOH9TA	PC	5171
DMOH9TA	MW	293.3
DMOH9TA	FM	C18H16FN3
DMOH9TA	IC	InChI=1S/C18H16FN3/c19-16-5-3-14(4-6-16)17-18(15-7-9-20-10-8-15)22(12-21-17)11-13-1-2-13/h3-10,12-13H,1-2,11H2
DMOH9TA	CS	C1CC1CN2C=NC(=C2C3=CC=NC=C3)C4=CC=C(C=C4)F
DMOH9TA	IK	ROKOFZNQCIIJMI-UHFFFAOYSA-N
DMOH9TA	IU	4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine
DMOH9TA	DE	Discovery agent

DM7LARD	ID	DM7LARD
DM7LARD	DN	SB218078
DM7LARD	HS	Investigative
DM7LARD	SN	REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE; (5R,8S)-7,8-dihydro-5H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacene-13,15(6H,14H)-dione; 1nvs; CHEMBL289422; SCHEMBL14040957; ZINC18183490; DB08683; UCM; Q27097872; UNII-S6U3J3UP11 component OTPNDVKVEAIXTI-IYBDPMFKSA-N; (5R,8S)-5,6,7,8-tetrahydro-13H-5,8-epoxy-4b,8a,14-triazadibenzo[b,h]cycloocta[1,2,3,4-jkl]cyclopenta[e]-as-indacene-13,15(14H)-dione
DM7LARD	DT	Small molecular drug
DM7LARD	PC	447446
DM7LARD	MW	393.4
DM7LARD	FM	C24H15N3O3
DM7LARD	IC	InChI=1S/C24H15N3O3/c28-23-19-17-11-5-1-3-7-13(11)26-15-9-10-16(30-15)27-14-8-4-2-6-12(14)18(22(27)21(17)26)20(19)24(29)25-23/h1-8,15-16H,9-10H2,(H,25,28,29)/t15-,16+
DM7LARD	CS	C1C[C@H]2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N([C@@H]1O2)C7=C53)C(=O)NC6=O
DM7LARD	IK	OTPNDVKVEAIXTI-IYBDPMFKSA-N
DM7LARD	IU	(15S,18R)-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-3,5-dione
DM7LARD	DE	Triple negative breast cancer

DMJKE4M	ID	DMJKE4M
DMJKE4M	DN	SB-218655
DMJKE4M	HS	Investigative
DMJKE4M	SN	1bmk; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyrimidin-2-amine; SB-218655; 4-(FLUOROPHENYL)-1-CYCLOPROPYLMETHYL-5-(2-AMINO-4-PYRIMIDINYL)IMIDAZOLE; 165806-51-9; SB 218655; C14316; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine; SB5; AC1L1JRC; AC1Q4ON9; SCHEMBL4323457; CHEMBL590753; BDBM15238; CTK4D2173; DTXSID50274456; sb218655; AKOS030547879
DMJKE4M	DT	Small molecular drug
DMJKE4M	PC	5172
DMJKE4M	MW	309.34
DMJKE4M	FM	C17H16FN5
DMJKE4M	IC	InChI=1S/C17H16FN5/c18-13-5-3-12(4-6-13)15-16(14-7-8-20-17(19)22-14)23(10-21-15)9-11-1-2-11/h3-8,10-11H,1-2,9H2,(H2,19,20,22)
DMJKE4M	CS	C1CC1CN2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F
DMJKE4M	IK	DFEYXQGDDCDXJK-UHFFFAOYSA-N
DMJKE4M	IU	4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine
DMJKE4M	CA	CAS 165806-51-9
DMJKE4M	DE	Discovery agent

DMMWCLV	ID	DMMWCLV
DMMWCLV	DN	SB-221420-A
DMMWCLV	HS	Investigative
DMMWCLV	SN	SB-221420-A
DMMWCLV	TC	Analgesics
DMMWCLV	DT	Small molecular drug
DMMWCLV	PC	9843561
DMMWCLV	MW	393.9
DMMWCLV	FM	C25H28ClNO
DMMWCLV	IC	InChI=1S/C25H27NO.ClH/c1-25(2,19-10-5-4-6-11-19)20-13-15-21(16-14-20)27-24-22-12-8-7-9-18(22)17-23(24)26-3;/h4-16,23-24,26H,17H2,1-3H3;1H/t23-,24+;/m1./s1
DMMWCLV	CS	CC(C)(C1=CC=CC=C1)C2=CC=C(C=C2)O[C@@H]3[C@@H](CC4=CC=CC=C34)NC.Cl
DMMWCLV	IK	GWFDWCZMDDKZDV-ITNPDYSASA-N
DMMWCLV	IU	(1S,2R)-N-methyl-1-[4-(2-phenylpropan-2-yl)phenoxy]-2,3-dihydro-1H-inden-2-amine;hydrochloride
DMMWCLV	DE	Pain

DMO1WI8	ID	DMO1WI8
DMO1WI8	DN	SB-227931
DMO1WI8	HS	Investigative
DMO1WI8	SN	SB-227931; CHEMBL371720; BDBM50173166
DMO1WI8	DT	Small molecular drug
DMO1WI8	PC	44404442
DMO1WI8	MW	549.4
DMO1WI8	FM	C24H20IN7O
DMO1WI8	IC	InChI=1S/C24H20IN7O/c25-20-7-5-18(6-8-20)24(33)28-11-2-14-32-16-29-22(23(32)17-9-12-27-13-10-17)19-3-1-4-21(15-19)30-31-26/h1,3-10,12-13,15-16H,2,11,14H2,(H,28,33)
DMO1WI8	CS	C1=CC(=CC(=C1)N=[N+]=[N-])C2=C(N(C=N2)CCCNC(=O)C3=CC=C(C=C3)I)C4=CC=NC=C4
DMO1WI8	IK	LUMGXWHASLYPJW-UHFFFAOYSA-N
DMO1WI8	IU	N-[3-[4-(3-azidophenyl)-5-pyridin-4-ylimidazol-1-yl]propyl]-4-iodobenzamide
DMO1WI8	DE	Discovery agent

DMIBS95	ID	DMIBS95
DMIBS95	DN	SB-2280
DMIBS95	HS	Investigative
DMIBS95	SN	SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO
DMIBS95	CP	S*BIO Pte Ltd
DMIBS95	DE	Solid tumour/cancer

DMYQDPM	ID	DMYQDPM
DMYQDPM	DN	SB236057
DMYQDPM	HS	Investigative
DMYQDPM	SN	WXAKEEQOWUHGCI-UHFFFAOYSA-N; SB-236057; SB 236057; AC1NSKM0; 180083-49-2; SCHEMBL7831487; GTPL3231; CHEMBL1628625; DTXSID0047321; NCGC00247934-01; L000541; 1'-ethyl-7-({4-[2-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]phenyl}carbonyl)-2,5,6,7-tetrahydrospiro[furo[2,3-f]indole-1,4'-piperidine]; 1'-Ethyl-5-[2'-methyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine];  SB 236057; SB 236057-A
DMYQDPM	DT	Small molecular drug
DMYQDPM	PC	5311426
DMYQDPM	MW	534.6
DMYQDPM	FM	C33H34N4O3
DMYQDPM	IC	InChI=1S/C33H34N4O3/c1-4-36-15-12-33(13-16-36)20-39-30-18-25-11-14-37(29(25)19-28(30)33)32(38)24-7-5-23(6-8-24)27-10-9-26(17-21(27)2)31-35-34-22(3)40-31/h5-10,17-19H,4,11-16,20H2,1-3H3
DMYQDPM	CS	CCN1CCC2(CC1)COC3=C2C=C4C(=C3)CCN4C(=O)C5=CC=C(C=C5)C6=C(C=C(C=C6)C7=NN=C(O7)C)C
DMYQDPM	IK	WXAKEEQOWUHGCI-UHFFFAOYSA-N
DMYQDPM	IU	(1'-ethylspiro[6,7-dihydro-2H-furo[2,3-f]indole-3,4'-piperidine]-5-yl)-[4-[2-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]phenyl]methanone
DMYQDPM	CA	CAS 180083-49-2
DMYQDPM	DE	Discovery agent

DMLZDK6	ID	DMLZDK6
DMLZDK6	DN	SB251023
DMLZDK6	HS	Investigative
DMLZDK6	SN	SB-251023
DMLZDK6	DT	Small molecular drug
DMLZDK6	PC	9958026
DMLZDK6	MW	511.5
DMLZDK6	FM	C28H34NO6P
DMLZDK6	IC	InChI=1S/C28H34NO6P/c30-23-10-14-25(15-11-23)34-20-24(31)19-29-28(16-4-5-17-28)18-22-8-12-26(13-9-22)35-21-36(32,33)27-6-2-1-3-7-27/h1-3,6-15,24,29-31H,4-5,16-21H2,(H,32,33)/t24-/m0/s1
DMLZDK6	CS	C1CCC(C1)(CC2=CC=C(C=C2)OCP(=O)(C3=CC=CC=C3)O)NC[C@@H](COC4=CC=C(C=C4)O)O
DMLZDK6	IK	MKEFUSOCGOBQMJ-DEOSSOPVSA-N
DMLZDK6	IU	[4-[[1-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]cyclopentyl]methyl]phenoxy]methyl-phenylphosphinic acid
DMLZDK6	DE	Discovery agent

DMO01AG	ID	DMO01AG
DMO01AG	DN	SB-258719
DMO01AG	HS	Investigative
DMO01AG	SN	SB 258719; SB258719; CHEMBL12264; N,3-dimethyl-N-[(2R)-4-(4-methylpiperidin-1-yl)butan-2-yl]benzenesulfonamide; 195199-95-2; SB-258,719; AC1NSM3U; GTPL281; ZINC7275; SCHEMBL2471088; HY-U00443; BDBM50098550; CS-0035396; SB-258719, &gt; 4-Methyl-1-[(R)-3-methyl-4-(toluene-3-sulfonyl)-pentyl]-piperidine; Benzenesulfonamide, N,3-dimethyl-N-(1-methyl-3-(4-methyl-1-piperidinyl)propyl)-, (R)-; 3,N-Dimethyl-N-[(R)-1-methyl-3-(4-methyl-piperidin-1-yl)-propyl]-benzenesulfonamide
DMO01AG	DT	Small molecular drug
DMO01AG	PC	5312148
DMO01AG	MW	338.5
DMO01AG	FM	C18H30N2O2S
DMO01AG	IC	InChI=1S/C18H30N2O2S/c1-15-8-11-20(12-9-15)13-10-17(3)19(4)23(21,22)18-7-5-6-16(2)14-18/h5-7,14-15,17H,8-13H2,1-4H3/t17-/m1/s1
DMO01AG	CS	CC1CCN(CC1)CC[C@@H](C)N(C)S(=O)(=O)C2=CC=CC(=C2)C
DMO01AG	IK	AGVNHDNTFYHZNL-QGZVFWFLSA-N
DMO01AG	IU	N,3-dimethyl-N-[(2R)-4-(4-methylpiperidin-1-yl)butan-2-yl]benzenesulfonamide
DMO01AG	CA	CAS 195199-95-2
DMO01AG	DE	Discovery agent

DM0HK6L	ID	DM0HK6L
DM0HK6L	DN	SB-258741
DM0HK6L	HS	Investigative
DM0HK6L	SN	SB-258741; CHEMBL12624; SCHEMBL4454954; ZINC4393149; BDBM50130279; NCGC00386485-01; 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine; 4-Methyl-1-{2-[(S)-1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine; 4-Methyl-1-{2-[(R)-1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine; (R)-4-Methyl-1-(2-(1-toluene-3-sulfonyl)-pyrrolidin-2-yl)-ethyl)-piperidine (Oxalate salt)
DM0HK6L	DT	Small molecular drug
DM0HK6L	PC	9863250
DM0HK6L	MW	350.5
DM0HK6L	FM	C19H30N2O2S
DM0HK6L	IC	InChI=1S/C19H30N2O2S/c1-16-8-12-20(13-9-16)14-10-18-6-4-11-21(18)24(22,23)19-7-3-5-17(2)15-19/h3,5,7,15-16,18H,4,6,8-14H2,1-2H3/t18-/m1/s1
DM0HK6L	CS	CC1CCN(CC1)CC[C@H]2CCCN2S(=O)(=O)C3=CC=CC(=C3)C
DM0HK6L	IK	YVWGGGGMRDLOGA-GOSISDBHSA-N
DM0HK6L	IU	4-methyl-1-[2-[(2R)-1-(3-methylphenyl)sulfonylpyrrolidin-2-yl]ethyl]piperidine
DM0HK6L	DE	Discovery agent

DM8UKH7	ID	DM8UKH7
DM8UKH7	DN	SB-265123
DM8UKH7	HS	Investigative
DM8UKH7	SN	SB-265123; CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid
DM8UKH7	DT	Small molecular drug
DM8UKH7	PC	9952958
DM8UKH7	MW	402.5
DM8UKH7	FM	C25H26N2O3
DM8UKH7	IC	InChI=1S/C25H26N2O3/c28-25(29)17-21-14-18-9-10-22(16-20(18)15-19-6-1-2-7-23(19)21)30-13-5-12-27-24-8-3-4-11-26-24/h1-4,6-11,16,21H,5,12-15,17H2,(H,26,27)(H,28,29)/t21-/m0/s1
DM8UKH7	CS	C1[C@H](C2=CC=CC=C2CC3=C1C=CC(=C3)OCCCNC4=CC=CC=N4)CC(=O)O
DM8UKH7	IK	HODBWQCCKYDYPY-NRFANRHFSA-N
DM8UKH7	IU	2-[(9S)-14-[3-(pyridin-2-ylamino)propoxy]-9-tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaenyl]acetic acid
DM8UKH7	DE	Discovery agent

DMEGNJK	ID	DMEGNJK
DMEGNJK	DN	SB269652
DMEGNJK	HS	Investigative
DMEGNJK	SN	SB-269652; SB-269,652
DMEGNJK	DT	Small molecular drug
DMEGNJK	PC	9910352
DMEGNJK	MW	426.6
DMEGNJK	FM	C27H30N4O
DMEGNJK	IC	InChI=1S/C27H30N4O/c28-17-20-5-8-21-12-14-31(18-23(21)15-20)13-11-19-6-9-24(10-7-19)29-27(32)26-16-22-3-1-2-4-25(22)30-26/h1-5,8,15-16,19,24,30H,6-7,9-14,18H2,(H,29,32)
DMEGNJK	CS	C1CC(CCC1CCN2CCC3=C(C2)C=C(C=C3)C#N)NC(=O)C4=CC5=CC=CC=C5N4
DMEGNJK	IK	JGLGOAQPUQITLD-UHFFFAOYSA-N
DMEGNJK	IU	N-[4-[2-(7-cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]cyclohexyl]-1H-indole-2-carboxamide
DMEGNJK	DE	Discovery agent

DM5VJAF	ID	DM5VJAF
DM5VJAF	DN	SB-271046
DM5VJAF	HS	Investigative
DM5VJAF	SN	209481-20-9; SB-271046; SB271046; Sb 271046; 5-chloro-N-(4-methoxy-3-(piperazin-1-yl)phenyl)-3-methylbenzo[b]thiophene-2-sulfonamide; UNII-L3SK5KX24S; L3SK5KX24S; CHEMBL431298; SB-271,046; C20H22ClN3O3S2; 5-Chloro-N-[4-methoxy-3-(1-piperazinyl)phenyl]-3-methylbenzo[b]thiophene-2-sulfonamide; 5-chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)-3-methyl-1-benzothiophene-2-sulfonamide; 5-Chloro-N-(4-methoxy-3-(1-piperazinyl)phenyl)-3-methylbenzo(b)thiophene-2-sulfonamide; AC1NSM3X; GTPL276; SCHEMBL194700; SB271046 HCl; BDBM28583; SB 
DM5VJAF	DT	Small molecular drug
DM5VJAF	PC	5312149
DM5VJAF	MW	452
DM5VJAF	FM	C20H22ClN3O3S2
DM5VJAF	IC	InChI=1S/C20H22ClN3O3S2/c1-13-16-11-14(21)3-6-19(16)28-20(13)29(25,26)23-15-4-5-18(27-2)17(12-15)24-9-7-22-8-10-24/h3-6,11-12,22-23H,7-10H2,1-2H3
DM5VJAF	CS	CC1=C(SC2=C1C=C(C=C2)Cl)S(=O)(=O)NC3=CC(=C(C=C3)OC)N4CCNCC4
DM5VJAF	IK	LOCQRDBFWSXQQI-UHFFFAOYSA-N
DM5VJAF	IU	5-chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)-3-methyl-1-benzothiophene-2-sulfonamide
DM5VJAF	CA	CAS 209481-20-9
DM5VJAF	DE	Discovery agent

DM28K0E	ID	DM28K0E
DM28K0E	DN	SB290157
DM28K0E	HS	Investigative
DM28K0E	SN	SB-290157
DM28K0E	DT	Small molecular drug
DM28K0E	PC	5311120
DM28K0E	MW	412.5
DM28K0E	FM	C22H28N4O4
DM28K0E	IC	InChI=1S/C22H28N4O4/c23-22(24)25-13-7-12-19(21(28)29)26-20(27)15-30-14-18(16-8-3-1-4-9-16)17-10-5-2-6-11-17/h1-6,8-11,18-19H,7,12-15H2,(H,26,27)(H,28,29)(H4,23,24,25)/t19-/m0/s1
DM28K0E	CS	C1=CC=C(C=C1)C(COCC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)C2=CC=CC=C2
DM28K0E	IK	RRKKJYBCPXAJAO-IBGZPJMESA-N
DM28K0E	IU	(2S)-5-(diaminomethylideneamino)-2-[[2-(2,2-diphenylethoxy)acetyl]amino]pentanoic acid
DM28K0E	DE	Discovery agent

DMU2J3K	ID	DMU2J3K
DMU2J3K	DN	SB-298
DMU2J3K	HS	Investigative
DMU2J3K	SN	SB-298; CHEMBL490262; BDBM50268085
DMU2J3K	DT	Small molecular drug
DMU2J3K	PC	44583036
DMU2J3K	MW	400.4
DMU2J3K	FM	C20H24N4O5
DMU2J3K	IC	InChI=1S/C20H24N4O5/c1-3-9-24-19(27)18-16(23(2)20(24)28)11-15(22-18)13-4-6-14(7-5-13)29-12-17(26)21-8-10-25/h4-7,11,22,25H,3,8-10,12H2,1-2H3,(H,21,26)
DMU2J3K	CS	CCCN1C(=O)C2=C(C=C(N2)C3=CC=C(C=C3)OCC(=O)NCCO)N(C1=O)C
DMU2J3K	IK	DLDXAAWYBLTTEM-UHFFFAOYSA-N
DMU2J3K	IU	N-(2-hydroxyethyl)-2-[4-(1-methyl-2,4-dioxo-3-propyl-5H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetamide
DMU2J3K	DE	Discovery agent

DMT1KFL	ID	DMT1KFL
DMT1KFL	DN	SB-328872
DMT1KFL	HS	Investigative
DMT1KFL	SN	SB-328872; CHEMBL190533; BDBM50240962; N-((S)-1-((S)-1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-ylamino)-4-methyl-1-oxopentan-2-yl)benzo[b]thiophene-2-carboxamide; Benzo[b]thiophene-2-carboxylic acid ((S)-1-{(R)-1-[4-(3-dimethylamino-propoxy)-benzyl]-pyrrolidin-3-ylcarbamoyl}-3-methyl-butyl)-amide
DMT1KFL	DT	Small molecular drug
DMT1KFL	PC	10120078
DMT1KFL	MW	550.8
DMT1KFL	FM	C31H42N4O3S
DMT1KFL	IC	InChI=1S/C31H42N4O3S/c1-22(2)18-27(33-31(37)29-19-24-8-5-6-9-28(24)39-29)30(36)32-25-14-16-35(21-25)20-23-10-12-26(13-11-23)38-17-7-15-34(3)4/h5-6,8-13,19,22,25,27H,7,14-18,20-21H2,1-4H3,(H,32,36)(H,33,37)/t25-,27-/m0/s1
DMT1KFL	CS	CC(C)C[C@@H](C(=O)N[C@H]1CCN(C1)CC2=CC=C(C=C2)OCCCN(C)C)NC(=O)C3=CC4=CC=CC=C4S3
DMT1KFL	IK	HLMWNBIZKQIDFC-BDYUSTAISA-N
DMT1KFL	IU	N-[(2S)-1-[[(3S)-1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]pyrrolidin-3-yl]amino]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide
DMT1KFL	DE	Discovery agent

DMDZKWJ	ID	DMDZKWJ
DMDZKWJ	DN	SB-334867
DMDZKWJ	HS	Investigative
DMDZKWJ	SN	SB334867A; SB-334,867
DMDZKWJ	DT	Small molecular drug
DMDZKWJ	PC	6604926
DMDZKWJ	MW	319.32
DMDZKWJ	FM	C17H13N5O2
DMDZKWJ	IC	InChI=1S/C17H13N5O2/c1-10-20-12-5-4-11(9-15(12)24-10)21-17(23)22-14-6-8-18-13-3-2-7-19-16(13)14/h2-9H,1H3,(H2,18,21,22,23)
DMDZKWJ	CS	CC1=NC2=C(O1)C=C(C=C2)NC(=O)NC3=C4C(=NC=C3)C=CC=N4
DMDZKWJ	IK	AKMNUCBQGHFICM-UHFFFAOYSA-N
DMDZKWJ	IU	1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea
DMDZKWJ	CB	CHEBI:92733
DMDZKWJ	DE	Discovery agent

DMFTO8R	ID	DMFTO8R
DMFTO8R	DN	SB-357134
DMFTO8R	HS	Investigative
DMFTO8R	SN	SB-357134; CHEMBL329383; SB-357,134; AC1OCFKU; SCHEMBL678563; GTPL3235; PDSP1_001374; PDSP2_001358; BDBM50130268; SB357134; SB 357134; L020233; N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide; N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-(piperazin-1-yl)benzene-1-sulfonamide; N-(2,5-dibromo-3-fluorophe-nyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide; N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-(piperazin-1-yl)benzenesulfonamide
DMFTO8R	DT	Small molecular drug
DMFTO8R	PC	6918553
DMFTO8R	MW	523.2
DMFTO8R	FM	C17H18Br2FN3O3S
DMFTO8R	IC	InChI=1S/C17H18Br2FN3O3S/c1-26-16-3-2-12(10-15(16)23-6-4-21-5-7-23)27(24,25)22-14-9-11(18)8-13(20)17(14)19/h2-3,8-10,21-22H,4-7H2,1H3
DMFTO8R	CS	COC1=C(C=C(C=C1)S(=O)(=O)NC2=C(C(=CC(=C2)Br)F)Br)N3CCNCC3
DMFTO8R	IK	BLWHAZZXRHTFJE-UHFFFAOYSA-N
DMFTO8R	IU	N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide
DMFTO8R	DE	Discovery agent

DM3BV5S	ID	DM3BV5S
DM3BV5S	DN	SB-381320
DM3BV5S	HS	Investigative
DM3BV5S	SN	CHEMBL56954; SB-381320; BDBM50102161; 1-{2-[4-(3,4-Dichloro-phenyl)-piperazin-1-yl]-2-oxo-ethyl}-2-(4-fluoro-benzylsulfanyl)-5-(2-methoxy-pyrimidin-5-ylmethyl)-1H-pyrimidin-4-one
DM3BV5S	DT	Small molecular drug
DM3BV5S	PC	9939109
DM3BV5S	MW	629.5
DM3BV5S	FM	C29H27Cl2FN6O3S
DM3BV5S	IC	InChI=1S/C29H27Cl2FN6O3S/c1-41-28-33-14-20(15-34-28)12-21-16-38(29(35-27(21)40)42-18-19-2-4-22(32)5-3-19)17-26(39)37-10-8-36(9-11-37)23-6-7-24(30)25(31)13-23/h2-7,13-16H,8-12,17-18H2,1H3
DM3BV5S	CS	COC1=NC=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)CC(=O)N4CCN(CC4)C5=CC(=C(C=C5)Cl)Cl
DM3BV5S	IK	ATFLNJHGWNOVTM-UHFFFAOYSA-N
DM3BV5S	IU	1-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]-2-oxoethyl]-2-[(4-fluorophenyl)methylsulfanyl]-5-[(2-methoxypyrimidin-5-yl)methyl]pyrimidin-4-one
DM3BV5S	DE	Discovery agent

DMFMK89	ID	DMFMK89
DMFMK89	DN	SB399885
DMFMK89	HS	Investigative
DMFMK89	SN	SB-399885; SB-399,885; SB 399885
DMFMK89	DT	Small molecular drug
DMFMK89	PC	6918649
DMFMK89	MW	446.3
DMFMK89	FM	C18H21Cl2N3O4S
DMFMK89	IC	InChI=1S/C18H21Cl2N3O4S/c1-26-17-4-3-13(11-16(17)23-7-5-21-6-8-23)28(24,25)22-15-10-12(19)9-14(20)18(15)27-2/h3-4,9-11,21-22H,5-8H2,1-2H3
DMFMK89	CS	COC1=C(C=C(C=C1)S(=O)(=O)NC2=C(C(=CC(=C2)Cl)Cl)OC)N3CCNCC3
DMFMK89	IK	ATKZKAYWARYLBW-UHFFFAOYSA-N
DMFMK89	IU	N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide
DMFMK89	CA	CAS 402713-80-8
DMFMK89	DE	Discovery agent

DMB8XZP	ID	DMB8XZP
DMB8XZP	DN	SB-408124
DMB8XZP	HS	Investigative
DMB8XZP	SN	SB 408124; SB408124
DMB8XZP	DT	Small molecular drug
DMB8XZP	PC	4331799
DMB8XZP	MW	356.4
DMB8XZP	FM	C19H18F2N4O
DMB8XZP	IC	InChI=1S/C19H18F2N4O/c1-11-8-17(15-9-12(20)10-16(21)18(15)22-11)24-19(26)23-13-4-6-14(7-5-13)25(2)3/h4-10H,1-3H3,(H2,22,23,24,26)
DMB8XZP	CS	CC1=CC(=C2C=C(C=C(C2=N1)F)F)NC(=O)NC3=CC=C(C=C3)N(C)C
DMB8XZP	IK	JTARFZSNUAGHRB-UHFFFAOYSA-N
DMB8XZP	IU	1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea
DMB8XZP	CA	CAS 288150-92-5
DMB8XZP	CB	CHEBI:92941
DMB8XZP	DE	Discovery agent

DMQLHE8	ID	DMQLHE8
DMQLHE8	DN	SB-410220
DMQLHE8	HS	Investigative
DMQLHE8	SN	SB-410220; CHEMBL522758; GTPL1705; SCHEMBL3101355; 1-(5,8-difluoroquinolin-4-yl)-3-(4-dimethylaminophenyl)urea; BDBM50423650
DMQLHE8	DT	Small molecular drug
DMQLHE8	PC	10065953
DMQLHE8	MW	342.3
DMQLHE8	FM	C18H16F2N4O
DMQLHE8	IC	InChI=1S/C18H16F2N4O/c1-24(2)12-5-3-11(4-6-12)22-18(25)23-15-9-10-21-17-14(20)8-7-13(19)16(15)17/h3-10H,1-2H3,(H2,21,22,23,25)
DMQLHE8	CS	CN(C)C1=CC=C(C=C1)NC(=O)NC2=CC=NC3=C(C=CC(=C23)F)F
DMQLHE8	IK	AZFKSWSBVCFBCG-UHFFFAOYSA-N
DMQLHE8	IU	1-(5,8-difluoroquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea
DMQLHE8	DE	Discovery agent

DMMAL3I	ID	DMMAL3I
DMMAL3I	DN	SB-415286
DMMAL3I	HS	Investigative
DMMAL3I	SN	SB 415286; 264218-23-7; SB-415286; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855
DMMAL3I	DT	Small molecular drug
DMMAL3I	PC	4210951
DMMAL3I	MW	359.72
DMMAL3I	FM	C16H10ClN3O5
DMMAL3I	IC	InChI=1S/C16H10ClN3O5/c17-10-7-8(5-6-12(10)21)18-14-13(15(22)19-16(14)23)9-3-1-2-4-11(9)20(24)25/h1-7,21H,(H2,18,19,22,23)
DMMAL3I	CS	C1=CC=C(C(=C1)C2=C(C(=O)NC2=O)NC3=CC(=C(C=C3)O)Cl)[N+](=O)[O-]
DMMAL3I	IK	PQCXVIPXISBFPN-UHFFFAOYSA-N
DMMAL3I	IU	3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione
DMMAL3I	CA	CAS 264218-23-7
DMMAL3I	CB	CHEBI:91107
DMMAL3I	DE	Discovery agent

DMJW72O	ID	DMJW72O
DMJW72O	DN	SB-416
DMJW72O	HS	Investigative
DMJW72O	SN	UNII-344PKU9JSY; 344PKU9JSY; 63589-10-6; SB-416; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-4-[(4-methoxyphenyl)amino]-9,10-dioxo-, monosodium salt; CHEMBL401735; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-4-[(4-methoxyphenyl)amino]-9,10-dioxo-, sodium salt (1:1); 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-4-((4-methoxyphenyl)amino)-9,10-dioxo-, monosodium salt; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-4-((4-methoxyphenyl)amino)-9,10-dioxo-, sodium salt (1:1); EINECS 264-344-5; AC1Q1VH1
DMJW72O	DT	Small molecular drug
DMJW72O	PC	23680506
DMJW72O	MW	446.4
DMJW72O	FM	C21H15N2NaO6S
DMJW72O	IC	InChI=1S/C21H16N2O6S.Na/c1-29-12-8-6-11(7-9-12)23-15-10-16(30(26,27)28)19(22)18-17(15)20(24)13-4-2-3-5-14(13)21(18)25;/h2-10,23H,22H2,1H3,(H,26,27,28);/q;+1/p-1
DMJW72O	CS	COC1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)[O-].[Na+]
DMJW72O	IK	UKZVMBMYDRZSBX-UHFFFAOYSA-M
DMJW72O	IU	sodium;1-amino-4-(4-methoxyanilino)-9,10-dioxoanthracene-2-sulfonate
DMJW72O	CA	CAS 63589-10-6
DMJW72O	DE	Discovery agent

DMUFV4O	ID	DMUFV4O
DMUFV4O	DN	SB452533
DMUFV4O	HS	Investigative
DMUFV4O	SN	SB-452533; SB 452533
DMUFV4O	DT	Small molecular drug
DMUFV4O	PC	9842609
DMUFV4O	MW	376.3
DMUFV4O	FM	C18H22BrN3O
DMUFV4O	IC	InChI=1S/C18H22BrN3O/c1-3-22(15-8-6-7-14(2)13-15)12-11-20-18(23)21-17-10-5-4-9-16(17)19/h4-10,13H,3,11-12H2,1-2H3,(H2,20,21,23)
DMUFV4O	CS	CCN(CCNC(=O)NC1=CC=CC=C1Br)C2=CC=CC(=C2)C
DMUFV4O	IK	IFJYEGJUQIBBQV-UHFFFAOYSA-N
DMUFV4O	IU	1-(2-bromophenyl)-3-[2-(N-ethyl-3-methylanilino)ethyl]urea
DMUFV4O	DE	Discovery agent

DM4G09S	ID	DM4G09S
DM4G09S	DN	SB-505124
DM4G09S	HS	Investigative
DM4G09S	SN	SB-505124; 694433-59-5; SB505124; SB 505124; 2-(4-(benzo[d][1,3]dioxol-5-yl)-2-tert-butyl-1H-imidazol-5-yl)-6-methylpyridine; CHEMBL226838; 2-[4-(1,3-Benzodioxol-5-yl)-2-(tert-butyl)-1H-imidazol-5-yl]-6-methylpyridine; 2-[5-(1,3-Benzodioxol-5-yl)-2-(1,1-dimethylethyl)-1H-imidazol-4-yl]-6-methylpyridine; 2-[4-(2H-1,3-benzodioxol-5-yl)-2-tert-butyl-1H-imidazol-5-yl]-6-methylpyridine; MLS006010969; SCHEMBL373422; GTPL6049; CTK8E3615; KS-00000XPS; EX-A217; DTXSID50431926; AOB1766; AOB5688; MolPort-021-804-897; CHEBI:100922
DM4G09S	DT	Small molecular drug
DM4G09S	PC	9858940
DM4G09S	MW	335.4
DM4G09S	FM	C20H21N3O2
DM4G09S	IC	InChI=1S/C20H21N3O2/c1-12-6-5-7-14(21-12)18-17(22-19(23-18)20(2,3)4)13-8-9-15-16(10-13)25-11-24-15/h5-10H,11H2,1-4H3,(H,22,23)
DM4G09S	CS	CC1=NC(=CC=C1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=C(C=C3)OCO4
DM4G09S	IK	WGZOTBUYUFBEPZ-UHFFFAOYSA-N
DM4G09S	IU	2-[4-(1,3-benzodioxol-5-yl)-2-tert-butyl-1H-imidazol-5-yl]-6-methylpyridine
DM4G09S	CA	CAS 694433-59-5
DM4G09S	CB	CHEBI:100922
DM4G09S	DE	Discovery agent

DM0PETL	ID	DM0PETL
DM0PETL	DN	SB-525334
DM0PETL	HS	Investigative
DM0PETL	SN	356559-20-1; SB 525334; SB-525334; SB525334; 6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline; 6-[2-TERT-BUTYL-5-(6-METHYL-PYRIDIN-2-YL)-1H-IMIDAZOL-4-YL]-QUINOXALINE; CHEMBL401570; 6-[2-(1,1-DiMethylethyl)-5-(6-Methyl-2-pyridinyl)-1H-iMidazol-4-yl]quinoxaline; C21H21N5; 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline; 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline; MLS006011134; SCHEMBL373474; QCR-68; SCHEMBL10000768; CTK4H5088; CHEBI:91391; AOB5969
DM0PETL	DT	Small molecular drug
DM0PETL	PC	9967941
DM0PETL	MW	343.4
DM0PETL	FM	C21H21N5
DM0PETL	IC	InChI=1S/C21H21N5/c1-13-6-5-7-16(24-13)19-18(25-20(26-19)21(2,3)4)14-8-9-15-17(12-14)23-11-10-22-15/h5-12H,1-4H3,(H,25,26)
DM0PETL	CS	CC1=NC(=CC=C1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=NC=CN=C4C=C3
DM0PETL	IK	DKPQHFZUICCZHF-UHFFFAOYSA-N
DM0PETL	IU	6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline
DM0PETL	CA	CAS 356559-20-1
DM0PETL	CB	CHEBI:91391
DM0PETL	DE	Discovery agent

DM0OLYF	ID	DM0OLYF
DM0OLYF	DN	SB-559457
DM0OLYF	HS	Investigative
DM0OLYF	CP	GlaxoSmithKline plc
DM0OLYF	DE	Acute myeloid leukaemia

DMBIF42	ID	DMBIF42
DMBIF42	DN	SB-568849
DMBIF42	HS	Investigative
DMBIF42	SN	GTPL1312
DMBIF42	DT	Small molecular drug
DMBIF42	PC	10300618
DMBIF42	MW	500.6
DMBIF42	FM	C28H31F3N2O3
DMBIF42	IC	InChI=1S/C28H31F3N2O3/c1-5-33(6-2)17-18-36-25-16-15-24(19-26(25)35-4)32(3)27(34)22-9-7-20(8-10-22)21-11-13-23(14-12-21)28(29,30)31/h7-16,19H,5-6,17-18H2,1-4H3
DMBIF42	CS	CCN(CC)CCOC1=C(C=C(C=C1)N(C)C(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)OC
DMBIF42	IK	JAIIZWCZERLWEK-UHFFFAOYSA-N
DMBIF42	IU	N-[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]-N-methyl-4-[4-(trifluoromethyl)phenyl]benzamide
DMBIF42	DE	Discovery agent

DMASQV4	ID	DMASQV4
DMASQV4	DN	SB-611812
DMASQV4	HS	Investigative
DMASQV4	SN	SB611812
DMASQV4	DT	Small molecular drug
DMASQV4	PC	10278166
DMASQV4	MW	491.7
DMASQV4	FM	C17H16Cl3F3N2O3S
DMASQV4	IC	InChI=1S/C17H16Cl3F3N2O3S/c1-25(2)5-6-28-15-9-11(3-4-12(15)18)24-29(26,27)16-13(19)7-10(8-14(16)20)17(21,22)23/h3-4,7-9,24H,5-6H2,1-2H3
DMASQV4	CS	CN(C)CCOC1=C(C=CC(=C1)NS(=O)(=O)C2=C(C=C(C=C2Cl)C(F)(F)F)Cl)Cl
DMASQV4	IK	UIZHOFJFIOCYLH-UHFFFAOYSA-N
DMASQV4	IU	2,6-dichloro-N-[4-chloro-3-[2-(dimethylamino)ethoxy]phenyl]-4-(trifluoromethyl)benzenesulfonamide
DMASQV4	DE	Discovery agent

DM2SZ3F	ID	DM2SZ3F
DM2SZ3F	DN	SB-612111
DM2SZ3F	HS	Investigative
DM2SZ3F	SN	N/OFQ receptor antagonist (inflammatory disease), SRI International
DM2SZ3F	CP	SRI International
DM2SZ3F	DT	Small molecular drug
DM2SZ3F	PC	10047612
DM2SZ3F	MW	418.4
DM2SZ3F	FM	C24H29Cl2NO
DM2SZ3F	IC	InChI=1S/C24H29Cl2NO/c1-16-4-2-5-20-19(16)9-8-17(14-23(20)28)15-27-12-10-18(11-13-27)24-21(25)6-3-7-22(24)26/h2-7,17-18,23,28H,8-15H2,1H3/t17-,23-/m0/s1
DM2SZ3F	CS	CC1=C2CC[C@@H](C[C@@H](C2=CC=C1)O)CN3CCC(CC3)C4=C(C=CC=C4Cl)Cl
DM2SZ3F	IK	OHRDCQFCAWLDBP-SBUREZEXSA-N
DM2SZ3F	IU	(5S,7S)-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol
DM2SZ3F	CA	CAS 371980-98-2
DM2SZ3F	DE	Inflammation

DMVOIL5	ID	DMVOIL5
DMVOIL5	DN	SB-656104
DMVOIL5	HS	Investigative
DMVOIL5	SN	CHEMBL95104; CHEMBL538029; SCHEMBL6810550; GTPL3237; BDBM50130261; SB656104; 6-[(2R)-2-[2-[4-(4-chlorophenoxy)piperidin-1-yl]ethyl]pyrrolidin-1-yl]sulfonyl-1H-indole; 6-(2-{2-[4-(4-Chloro-phenoxy)-piperidin-1-yl]-ethyl}-pyrrolidine-1-sulfonyl)-1H-indole
DMVOIL5	DT	Small molecular drug
DMVOIL5	PC	10028436
DMVOIL5	MW	488
DMVOIL5	FM	C25H30ClN3O3S
DMVOIL5	IC	InChI=1S/C25H30ClN3O3S/c26-20-4-6-22(7-5-20)32-23-11-16-28(17-12-23)15-10-21-2-1-14-29(21)33(30,31)24-8-3-19-9-13-27-25(19)18-24/h3-9,13,18,21,23,27H,1-2,10-12,14-17H2/t21-/m1/s1
DMVOIL5	CS	C1C[C@@H](N(C1)S(=O)(=O)C2=CC3=C(C=C2)C=CN3)CCN4CCC(CC4)OC5=CC=C(C=C5)Cl
DMVOIL5	IK	QEGMGDYIJDZJCI-OAQYLSRUSA-N
DMVOIL5	IU	6-[(2R)-2-[2-[4-(4-chlorophenoxy)piperidin-1-yl]ethyl]pyrrolidin-1-yl]sulfonyl-1H-indole
DMVOIL5	DE	Discovery agent

DMLW8BI	ID	DMLW8BI
DMLW8BI	DN	SB-699551-A
DMLW8BI	HS	Investigative
DMLW8BI	DE	Discovery agent

DM9ZYNJ	ID	DM9ZYNJ
DM9ZYNJ	DN	SB-706375
DM9ZYNJ	HS	Investigative
DM9ZYNJ	SN	733734-61-7; SB 706375; SB-706375; CHEMBL522770; Benzenesulfonamide,2-bromo-4,5-dimethoxy-N-[3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]-4-(trifluoromethyl)phenyl]-; SCHEMBL5835165; GTPL2165; MolPort-035-765-788; ZINC1553794; BDBM50249878; AKOS024458280; NCGC00379177-01; SB706375; KB-75256; B5677; 2-Bromo-4,5-dimethoxy-N-[3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]-4-(trifluoromethyl)phenyl]benzenesulfonamide; 2-bromo-4,5-dimethoxy-N-[3-[(3R)-1-methylpyrrolidin-3-yl]oxy-4-(trifluoromethyl)phenyl]benzenesulfonamide
DM9ZYNJ	DT	Small molecular drug
DM9ZYNJ	PC	21023902
DM9ZYNJ	MW	539.4
DM9ZYNJ	FM	C20H22BrF3N2O5S
DM9ZYNJ	IC	InChI=1S/C20H22BrF3N2O5S/c1-26-7-6-13(11-26)31-16-8-12(4-5-14(16)20(22,23)24)25-32(27,28)19-10-18(30-3)17(29-2)9-15(19)21/h4-5,8-10,13,25H,6-7,11H2,1-3H3/t13-/m1/s1
DM9ZYNJ	CS	CN1CC[C@H](C1)OC2=C(C=CC(=C2)NS(=O)(=O)C3=C(C=C(C(=C3)OC)OC)Br)C(F)(F)F
DM9ZYNJ	IK	BPOWQJYAMDEAFF-CYBMUJFWSA-N
DM9ZYNJ	IU	2-bromo-4,5-dimethoxy-N-[3-[(3R)-1-methylpyrrolidin-3-yl]oxy-4-(trifluoromethyl)phenyl]benzenesulfonamide
DM9ZYNJ	CA	CAS 733734-61-7
DM9ZYNJ	DE	Discovery agent

DMO2EXW	ID	DMO2EXW
DMO2EXW	DN	SB-731489
DMO2EXW	HS	Investigative
DMO2EXW	SN	SB-731489; CHEMBL436624; N-(3-Aminopropyl)-N-{(1R)-1-[7-chloro-4-oxo-3-(phenylmethyl)-3,4-dihydro-2-quinazolinyl]-2-methylpropyl}-3-fluoro-4-methylbenzamide; BDBM50220156
DMO2EXW	DT	Small molecular drug
DMO2EXW	PC	16034829
DMO2EXW	MW	535
DMO2EXW	FM	C30H32ClFN4O2
DMO2EXW	IC	InChI=1S/C30H32ClFN4O2/c1-19(2)27(35(15-7-14-33)29(37)22-11-10-20(3)25(32)16-22)28-34-26-17-23(31)12-13-24(26)30(38)36(28)18-21-8-5-4-6-9-21/h4-6,8-13,16-17,19,27H,7,14-15,18,33H2,1-3H3/t27-/m1/s1
DMO2EXW	CS	CC1=C(C=C(C=C1)C(=O)N(CCCN)[C@@H](C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4)C(C)C)F
DMO2EXW	IK	FSWMJRIVQDJZRP-HHHXNRCGSA-N
DMO2EXW	IU	N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-3-fluoro-4-methylbenzamide
DMO2EXW	DE	Discovery agent

DM20Q5O	ID	DM20Q5O
DM20Q5O	DN	SB-747651A
DM20Q5O	HS	Investigative
DM20Q5O	SN	SB-747651A; CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine
DM20Q5O	DT	Small molecular drug
DM20Q5O	PC	11393719
DM20Q5O	MW	342.4
DM20Q5O	FM	C16H22N8O
DM20Q5O	IC	InChI=1S/C16H22N8O/c1-2-24-14-10(8-20-11-3-5-18-6-4-11)7-19-9-12(14)21-16(24)13-15(17)23-25-22-13/h7,9,11,18,20H,2-6,8H2,1H3,(H2,17,23)
DM20Q5O	CS	CCN1C2=C(C=NC=C2CNC3CCNCC3)N=C1C4=NON=C4N
DM20Q5O	IK	MBCJUIJWPYUEBX-UHFFFAOYSA-N
DM20Q5O	IU	4-[1-ethyl-7-[(piperidin-4-ylamino)methyl]imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine
DM20Q5O	DE	Discovery agent

DMYL56F	ID	DMYL56F
DMYL56F	DN	SB-782443
DMYL56F	HS	Investigative
DMYL56F	SN	SB-782443; CHEMBL514691; 6-(4-fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide; SCHEMBL4388633; QBATWTOFDFHEDZ-UHFFFAOYSA-N
DMYL56F	DT	Small molecular drug
DMYL56F	PC	9951636
DMYL56F	MW	377.4
DMYL56F	FM	C21H16FN3OS
DMYL56F	IC	InChI=1S/C21H16FN3OS/c1-12-17(8-9-18(23-12)14-3-5-15(22)6-4-14)21(26)25-16-7-10-20-19(11-16)24-13(2)27-20/h3-11H,1-2H3,(H,25,26)
DMYL56F	CS	CC1=C(C=CC(=N1)C2=CC=C(C=C2)F)C(=O)NC3=CC4=C(C=C3)SC(=N4)C
DMYL56F	IK	QBATWTOFDFHEDZ-UHFFFAOYSA-N
DMYL56F	IU	6-(4-fluorophenyl)-2-methyl-N-(2-methyl-1,3-benzothiazol-5-yl)pyridine-3-carboxamide
DMYL56F	DE	Discovery agent

DMU8KGB	ID	DMU8KGB
DMU8KGB	DN	SBB007833
DMU8KGB	HS	Investigative
DMU8KGB	SN	NSC 10120; NSC 105303; NSC 170724
DMU8KGB	DT	Small molecular drug
DMU8KGB	PC	672296
DMU8KGB	MW	193.16
DMU8KGB	FM	C9H7NO4
DMU8KGB	IC	InChI=1S/C9H7NO4/c11-10(12)4-3-7-1-2-8-9(5-7)14-6-13-8/h1-5H,6H2/b4-3+
DMU8KGB	CS	C1OC2=C(O1)C=C(C=C2)/C=C/[N+](=O)[O-]
DMU8KGB	IK	KFLWBZPSJQPRDD-ONEGZZNKSA-N
DMU8KGB	IU	5-[(E)-2-nitroethenyl]-1,3-benzodioxole
DMU8KGB	CA	CAS 22568-48-5
DMU8KGB	DE	Discovery agent

DMCRQ29	ID	DMCRQ29
DMCRQ29	DN	S-benzo[d]oxazol-2-yl O-butyl carbonothioate
DMCRQ29	HS	Investigative
DMCRQ29	SN	MLS000105935; butyl 1,3-benzoxazol-2-ylsulfanylformate; SMR000102909; AC1M2XFY; CHEMBL1253382; cid_2202888; BDBM33627; MolPort-002-144-521; HMS2405D05; HMS1580J19; ZINC2848864; MCULE-9572612001; butyl 1,3-benzoxazol-2-ylsulfanylmethanoate; AB00080574-01; (1,3-benzoxazol-2-ylthio)formic acid butyl ester
DMCRQ29	DT	Small molecular drug
DMCRQ29	PC	2202888
DMCRQ29	MW	251.3
DMCRQ29	FM	C12H13NO3S
DMCRQ29	IC	InChI=1S/C12H13NO3S/c1-2-3-8-15-12(14)17-11-13-9-6-4-5-7-10(9)16-11/h4-7H,2-3,8H2,1H3
DMCRQ29	CS	CCCCOC(=O)SC1=NC2=CC=CC=C2O1
DMCRQ29	IK	MJTKQBGLMBYWSU-UHFFFAOYSA-N
DMCRQ29	IU	butyl 1,3-benzoxazol-2-ylsulfanylformate
DMCRQ29	DE	Discovery agent

DMDUC2X	ID	DMDUC2X
DMDUC2X	DN	S-benzyl phenylmethanesulfinothioate
DMDUC2X	HS	Investigative
DMDUC2X	SN	S-benzyl phenylmethanesulfinothioate; CHEMBL1224167; 16302-98-0; S-benzyl phenylmethanethiosulfinate; Benzenemethanesulfinothioic acid, S-(phenylmethyl) ester; petivericin; benzylsulfinylsulfanylmethylbenzene; Benzyl(benzylthio) sulfoxide; SCHEMBL10391146; CTK0E6161; DTXSID90437280; BDBM50325648; S-benzyl phenylmethanesulfinothioate (Petivericin)
DMDUC2X	DT	Small molecular drug
DMDUC2X	PC	10244468
DMDUC2X	MW	262.4
DMDUC2X	FM	C14H14OS2
DMDUC2X	IC	InChI=1S/C14H14OS2/c15-17(12-14-9-5-2-6-10-14)16-11-13-7-3-1-4-8-13/h1-10H,11-12H2
DMDUC2X	CS	C1=CC=C(C=C1)CSS(=O)CC2=CC=CC=C2
DMDUC2X	IK	VUJONJHZKSZFSA-UHFFFAOYSA-N
DMDUC2X	IU	benzylsulfinylsulfanylmethylbenzene
DMDUC2X	CA	CAS 16302-98-0
DMDUC2X	DE	Discovery agent

DM2RLXF	ID	DM2RLXF
DM2RLXF	DN	S-Benzyl-brassinin
DM2RLXF	HS	Investigative
DM2RLXF	SN	S-Benzyl-brassinin; 917986-01-7; CHEMBL203477; CTK3H8792; DTXSID10658773; AKOS030611376; 2-(S-benzyldithiocarbamoylaminomethyl)indole; Benzyl [(1H-indol-2-yl)methyl]carbamodithioate; Carbamodithioic acid, N-(1H-indol-2-ylmethyl)-, phenylmethyl ester
DM2RLXF	DT	Small molecular drug
DM2RLXF	PC	44406807
DM2RLXF	MW	312.5
DM2RLXF	FM	C17H16N2S2
DM2RLXF	IC	InChI=1S/C17H16N2S2/c20-17(21-12-13-6-2-1-3-7-13)18-11-15-10-14-8-4-5-9-16(14)19-15/h1-10,19H,11-12H2,(H,18,20)
DM2RLXF	CS	C1=CC=C(C=C1)CSC(=S)NCC2=CC3=CC=CC=C3N2
DM2RLXF	IK	PHBHIYCWGKONRK-UHFFFAOYSA-N
DM2RLXF	IU	benzyl N-(1H-indol-2-ylmethyl)carbamodithioate
DM2RLXF	CA	CAS 917986-01-7
DM2RLXF	DE	Discovery agent

DMIQU8D	ID	DMIQU8D
DMIQU8D	DN	S-Benzyl-Glutathione
DMIQU8D	HS	Investigative
DMIQU8D	SN	AC1Q5QKZ; AC1L4ODA; s-benzyl-l-cysteinyl-n-l-; A-glutamylglycine; Glycine, N-(N-L-gamma-glutamyl-S-(phenylmethyl)-L-cysteinyl)-; (2S)-2-amino-5-[[(2R)-2-amino-3-benzylsulfanylpropanoyl]-(carboxymethyl)amino]-5-oxopentanoic acid
DMIQU8D	DT	Small molecular drug
DMIQU8D	PC	46936726
DMIQU8D	MW	397.4
DMIQU8D	FM	C17H23N3O6S
DMIQU8D	IC	InChI=1S/C17H23N3O6S/c18-12(17(25)26)6-7-14(21)20-13(16(24)19-8-15(22)23)10-27-9-11-4-2-1-3-5-11/h1-5,12-13H,6-10,18H2,(H,19,24)(H,20,21)(H,22,23)(H,25,26)/t12-,13+/m0/s1
DMIQU8D	CS	C1=CC=C(C=C1)CSC[C@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N
DMIQU8D	IK	XYJWEQWNNKNSFU-QWHCGFSZSA-N
DMIQU8D	IU	(2S)-2-amino-5-[[(2S)-3-benzylsulfanyl-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMIQU8D	DE	Discovery agent

DMDBLGQ	ID	DMDBLGQ
DMDBLGQ	DN	SBTI
DMDBLGQ	HS	Investigative
DMDBLGQ	DE	Discovery agent

DMD2WEQ	ID	DMD2WEQ
DMD2WEQ	DN	SC-0030
DMD2WEQ	HS	Investigative
DMD2WEQ	SN	SC0030
DMD2WEQ	DT	Small molecular drug
DMD2WEQ	PC	10295883
DMD2WEQ	MW	423.6
DMD2WEQ	FM	C20H26FN3O2S2
DMD2WEQ	IC	InChI=1S/C20H26FN3O2S2/c1-20(2,3)16-8-5-14(6-9-16)12-22-19(27)23-13-15-7-10-18(17(21)11-15)24-28(4,25)26/h5-11,24H,12-13H2,1-4H3,(H2,22,23,27)
DMD2WEQ	CS	CC(C)(C)C1=CC=C(C=C1)CNC(=S)NCC2=CC(=C(C=C2)NS(=O)(=O)C)F
DMD2WEQ	IK	DUHBVFMCIJLUJX-UHFFFAOYSA-N
DMD2WEQ	IU	1-[(4-tert-butylphenyl)methyl]-3-[[3-fluoro-4-(methanesulfonamido)phenyl]methyl]thiourea
DMD2WEQ	CA	CAS 401907-26-4
DMD2WEQ	DE	Discovery agent

DMU2C9W	ID	DMU2C9W
DMU2C9W	DN	SC-19220
DMU2C9W	HS	Investigative
DMU2C9W	SN	SC 19220; SC19220
DMU2C9W	DT	Small molecular drug
DMU2C9W	PC	4336830
DMU2C9W	MW	331.75
DMU2C9W	FM	C16H14ClN3O3
DMU2C9W	IC	InChI=1S/C16H14ClN3O3/c1-10(21)18-19-16(22)20-9-11-4-2-3-5-14(11)23-15-7-6-12(17)8-13(15)20/h2-8H,9H2,1H3,(H,18,21)(H,19,22)
DMU2C9W	CS	CC(=O)NNC(=O)N1CC2=CC=CC=C2OC3=C1C=C(C=C3)Cl
DMU2C9W	IK	KNURFLJTOUGOOQ-UHFFFAOYSA-N
DMU2C9W	IU	N'-acetyl-3-chloro-6H-benzo[b][1,4]benzoxazepine-5-carbohydrazide
DMU2C9W	CA	CAS 19395-87-0
DMU2C9W	CB	CHEBI:92916
DMU2C9W	DE	Discovery agent

DMCWZ84	ID	DMCWZ84
DMCWZ84	DN	SC-41661A
DMCWZ84	HS	Investigative
DMCWZ84	SN	105357-16-2; 105357-17-3; Propanamide, 3-[(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-methyl-N-[2-(2-pyridinyl)ethyl]-
DMCWZ84	DT	Small molecular drug
DMCWZ84	PC	188930
DMCWZ84	MW	465.1
DMCWZ84	FM	C25H37ClN2O2S
DMCWZ84	IC	InChI=1S/C25H36N2O2S.ClH/c1-24(2,3)20-16-19(17-21(23(20)29)25(4,5)6)30-15-12-22(28)27(7)14-11-18-10-8-9-13-26-18;/h8-10,13,16-17,29H,11-12,14-15H2,1-7H3;1H
DMCWZ84	CS	CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SCCC(=O)N(C)CCC2=CC=CC=N2.Cl
DMCWZ84	IK	MCQQQXHGLCUPHW-UHFFFAOYSA-N
DMCWZ84	IU	3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide;hydrochloride
DMCWZ84	CA	CAS 105357-17-3
DMCWZ84	DE	Discovery agent

DMVZ9Q0	ID	DMVZ9Q0
DMVZ9Q0	DN	Sc-43076
DMVZ9Q0	HS	Investigative
DMVZ9Q0	DT	siRNA drug
DMVZ9Q0	DE	Discovery agent

DMYDS5Z	ID	DMYDS5Z
DMYDS5Z	DN	Sc-43077
DMYDS5Z	HS	Investigative
DMYDS5Z	DT	siRNA drug
DMYDS5Z	DE	Discovery agent

DM6AS0P	ID	DM6AS0P
DM6AS0P	DN	SC46275
DM6AS0P	HS	Investigative
DM6AS0P	SN	SC-46275
DM6AS0P	DT	Small molecular drug
DM6AS0P	PC	5311427
DM6AS0P	MW	416.5
DM6AS0P	FM	C25H36O5
DM6AS0P	IC	InChI=1S/C25H36O5/c1-25(29,17-15-19-10-7-8-11-19)16-9-13-21-20(22(26)18-23(21)27)12-5-3-4-6-14-24(28)30-2/h3-4,9-10,13,15,17,20-21,23,27,29H,5-8,11-12,14,16,18H2,1-2H3/b4-3-,13-9+,17-15+/t20-,21-,23-,25-/m1/s1
DM6AS0P	CS	C[C@@](C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CC/C=C\\CCC(=O)OC)O)(/C=C/C2=CCCC2)O
DM6AS0P	IK	ZZVPHCPLTZTOBC-ZNJGPPGCSA-N
DM6AS0P	IU	methyl (Z)-7-[(1R,2R,3R)-2-[(1E,4R,5E)-6-(cyclopenten-1-yl)-4-hydroxy-4-methylhexa-1,5-dienyl]-3-hydroxy-5-oxocyclopentyl]hept-4-enoate
DM6AS0P	CA	CAS 110902-56-2
DM6AS0P	DE	Discovery agent

DM2DU80	ID	DM2DU80
DM2DU80	DN	SC-5003
DM2DU80	HS	Investigative
DM2DU80	SN	SC-5003; CHEMBL445631; BDBM50084660; {1-[1-(1-Cyclohexylmethyl-2,5-dihydroxy-4-methyl-nonylcarbamoyl)-3-methyl-butylcarbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester(SC-5003)
DM2DU80	DT	Small molecular drug
DM2DU80	PC	44342336
DM2DU80	MW	645.9
DM2DU80	FM	C37H63N3O6
DM2DU80	IC	InChI=1S/C37H63N3O6/c1-8-9-20-32(41)26(4)22-33(42)29(23-27-16-12-10-13-17-27)38-34(43)30(21-25(2)3)39-35(44)31(24-28-18-14-11-15-19-28)40-36(45)46-37(5,6)7/h11,14-15,18-19,25-27,29-33,41-42H,8-10,12-13,16-17,20-24H2,1-7H3,(H,38,43)(H,39,44)(H,40,45)/t26-,29+,30+,31+,32?,33+/m1/s1
DM2DU80	CS	CCCCC([C@H](C)C[C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C)O)O
DM2DU80	IK	DZSFYDAIURXYOI-YFUMYMLSSA-N
DM2DU80	IU	tert-butyl N-[(2S)-1-[[(2S)-1-[[(2S,3S,5R)-1-cyclohexyl-3,6-dihydroxy-5-methyldecan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate
DM2DU80	DE	Discovery agent

DMU2WIS	ID	DMU2WIS
DMU2WIS	DN	SC-50073
DMU2WIS	HS	Investigative
DMU2WIS	SN	SC-50073; CHEMBL167804; SCHEMBL8941432; CIIUJGWVQJRIPP-UHFFFAOYSA-N; BDBM50284123; 3,4-Dihydro-7-[3-[3-methoxy-2-propyl-4-[(methylamino)carbonyl]phenoxy]propoxy]-8-propyl-2H-1-benzopyran-2-carboxylic acid; 7-[3-(3-Methoxy-4-methylcarbamoyl-2-propyl-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid
DMU2WIS	DT	Small molecular drug
DMU2WIS	PC	15817161
DMU2WIS	MW	499.6
DMU2WIS	FM	C28H37NO7
DMU2WIS	IC	InChI=1S/C28H37NO7/c1-5-8-19-22(13-10-18-11-14-24(28(31)32)36-25(18)19)34-16-7-17-35-23-15-12-21(27(30)29-3)26(33-4)20(23)9-6-2/h10,12-13,15,24H,5-9,11,14,16-17H2,1-4H3,(H,29,30)(H,31,32)
DMU2WIS	CS	CCCC1=C(C=CC2=C1OC(CC2)C(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)NC)OC)CCC
DMU2WIS	IK	CIIUJGWVQJRIPP-UHFFFAOYSA-N
DMU2WIS	IU	7-[3-[3-methoxy-4-(methylcarbamoyl)-2-propylphenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromene-2-carboxylic acid
DMU2WIS	DE	Discovery agent

DMI2KE7	ID	DMI2KE7
DMI2KE7	DN	SC-50135
DMI2KE7	HS	Investigative
DMI2KE7	SN	SC-50135; CHEMBL355401
DMI2KE7	DT	Small molecular drug
DMI2KE7	PC	44379679
DMI2KE7	MW	539.7
DMI2KE7	FM	C31H41NO7
DMI2KE7	IC	InChI=1S/C31H41NO7/c1-4-9-22-25(14-11-21-12-15-27(31(34)35)39-28(21)22)37-19-8-20-38-26-16-13-24(29(36-3)23(26)10-5-2)30(33)32-17-6-7-18-32/h11,13-14,16,27H,4-10,12,15,17-20H2,1-3H3,(H,34,35)
DMI2KE7	CS	CCCC1=C(C=CC2=C1OC(CC2)C(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)N4CCCC4)OC)CCC
DMI2KE7	IK	POSHDLOOHKRLEK-UHFFFAOYSA-N
DMI2KE7	IU	7-[3-[3-methoxy-2-propyl-4-(pyrrolidine-1-carbonyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromene-2-carboxylic acid
DMI2KE7	DE	Discovery agent

DM8RJ0V	ID	DM8RJ0V
DM8RJ0V	DN	SC-50676
DM8RJ0V	HS	Investigative
DM8RJ0V	SN	SC-50676; CHEMBL167474; SCHEMBL8941563; SSLKTPMFZMERSJ-UHFFFAOYSA-N; BDBM50284121; 7-[3-[2-(Cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoyl-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid
DM8RJ0V	DT	Small molecular drug
DM8RJ0V	PC	15237280
DM8RJ0V	MW	511.6
DM8RJ0V	FM	C29H37NO7
DM8RJ0V	IC	InChI=1S/C29H37NO7/c1-4-6-20-23(12-9-19-10-13-25(29(32)33)37-26(19)20)35-15-5-16-36-24-14-11-21(28(31)30-2)27(34-3)22(24)17-18-7-8-18/h9,11-12,14,18,25H,4-8,10,13,15-17H2,1-3H3,(H,30,31)(H,32,33)
DM8RJ0V	CS	CCCC1=C(C=CC2=C1OC(CC2)C(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)NC)OC)CC4CC4
DM8RJ0V	IK	SSLKTPMFZMERSJ-UHFFFAOYSA-N
DM8RJ0V	IU	7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromene-2-carboxylic acid
DM8RJ0V	DE	Discovery agent

DMBQ16F	ID	DMBQ16F
DMBQ16F	DN	SC-50998
DMBQ16F	HS	Investigative
DMBQ16F	SN	SC-50998; GTPL883; SCHEMBL9302290; 4-(1H-indole-3-carbonylamino)-5-oxo-1-phenylpyrrolidine-3-carboxylic acid
DMBQ16F	DT	Small molecular drug
DMBQ16F	PC	19023535
DMBQ16F	MW	363.4
DMBQ16F	FM	C20H17N3O4
DMBQ16F	IC	InChI=1S/C20H17N3O4/c24-18(14-10-21-16-9-5-4-8-13(14)16)22-17-15(20(26)27)11-23(19(17)25)12-6-2-1-3-7-12/h1-10,15,17,21H,11H2,(H,22,24)(H,26,27)
DMBQ16F	CS	C1C(C(C(=O)N1C2=CC=CC=C2)NC(=O)C3=CNC4=CC=CC=C43)C(=O)O
DMBQ16F	IK	TUYVXFVSHUIIJR-UHFFFAOYSA-N
DMBQ16F	IU	4-(1H-indole-3-carbonylamino)-5-oxo-1-phenylpyrrolidine-3-carboxylic acid
DMBQ16F	DE	Discovery agent

DM0LWUV	ID	DM0LWUV
DM0LWUV	DN	SC-51322
DM0LWUV	HS	Investigative
DM0LWUV	SN	146032-79-3
DM0LWUV	DT	Small molecular drug
DM0LWUV	PC	9933831
DM0LWUV	MW	457.9
DM0LWUV	FM	C22H20ClN3O4S
DM0LWUV	IC	InChI=1S/C22H20ClN3O4S/c23-16-7-8-20-18(12-16)26(13-15-4-1-2-6-19(15)30-20)22(28)25-24-21(27)9-11-31-14-17-5-3-10-29-17/h1-8,10,12H,9,11,13-14H2,(H,24,27)(H,25,28)
DM0LWUV	CS	C1C2=CC=CC=C2OC3=C(N1C(=O)NNC(=O)CCSCC4=CC=CO4)C=C(C=C3)Cl
DM0LWUV	IK	CQBVTZDISUKDSX-UHFFFAOYSA-N
DM0LWUV	IU	3-chloro-N'-[3-(furan-2-ylmethylsulfanyl)propanoyl]-6H-benzo[b][1,4]benzoxazepine-5-carbohydrazide
DM0LWUV	CA	CAS 146032-79-3
DM0LWUV	DE	Discovery agent

DMAWI4M	ID	DMAWI4M
DMAWI4M	DN	SC-514
DMAWI4M	HS	Investigative
DMAWI4M	SN	354812-17-2; Sc 514; SC514; 4-Amino-[2,3'-bithiophene]-5-carboxamide; 3-amino-5-(thiophen-3-yl)thiophene-2-carboxamide; CHEMBL193093; IKK-2 Inhibitor, SC-514; 5-(Thien-3-yl)-3-aminothiophene-2-carboxamide; C9H8N2OS2; GK 01140; Curator_000007; 4-Amino-[2,3-bithiophene]-5-carboxamide; BiomolKI_000076; BiomolKI2_000080; AC1MD9M6; 3-amino-5-thiophen-3-ylthiophene-2-carboxamide; Oprea1_591652; SCHEMBL4082097; KS-00000XLB; CHEBI:92464; ZINC81904; CTK8E9458; BDBM26098; SYN5231
DMAWI4M	DT	Small molecular drug
DMAWI4M	PC	2807869
DMAWI4M	MW	224.3
DMAWI4M	FM	C9H8N2OS2
DMAWI4M	IC	InChI=1S/C9H8N2OS2/c10-6-3-7(5-1-2-13-4-5)14-8(6)9(11)12/h1-4H,10H2,(H2,11,12)
DMAWI4M	CS	C1=CSC=C1C2=CC(=C(S2)C(=O)N)N
DMAWI4M	IK	BMUACLADCKCNKZ-UHFFFAOYSA-N
DMAWI4M	IU	3-amino-5-thiophen-3-ylthiophene-2-carboxamide
DMAWI4M	CA	CAS 354812-17-2
DMAWI4M	CB	CHEBI:92464
DMAWI4M	DE	Discovery agent

DM0E2SM	ID	DM0E2SM
DM0E2SM	DN	SC-52073
DM0E2SM	HS	Investigative
DM0E2SM	SN	SC-52073; CHEMBL422388; BDBM50284125; 7-[3-(4-Isopropylcarbamoyl-3-methoxy-2-propyl-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid
DM0E2SM	DT	Small molecular drug
DM0E2SM	PC	44379678
DM0E2SM	MW	527.6
DM0E2SM	FM	C30H41NO7
DM0E2SM	IC	InChI=1S/C30H41NO7/c1-6-9-21-24(14-11-20-12-15-26(30(33)34)38-27(20)21)36-17-8-18-37-25-16-13-23(29(32)31-19(3)4)28(35-5)22(25)10-7-2/h11,13-14,16,19,26H,6-10,12,15,17-18H2,1-5H3,(H,31,32)(H,33,34)
DM0E2SM	CS	CCCC1=C(C=CC2=C1OC(CC2)C(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)NC(C)C)OC)CCC
DM0E2SM	IK	LCOBFNPHFDALDJ-UHFFFAOYSA-N
DM0E2SM	IU	7-[3-[3-methoxy-4-(propan-2-ylcarbamoyl)-2-propylphenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromene-2-carboxylic acid
DM0E2SM	DE	Discovery agent

DMJ576C	ID	DMJ576C
DMJ576C	DN	SC-52491
DMJ576C	HS	Investigative
DMJ576C	SN	147600-74-6; 175773-85-0; SC-52490; SC-52491A
DMJ576C	DT	Small molecular drug
DMJ576C	PC	9885123
DMJ576C	MW	321.8
DMJ576C	FM	C16H20ClN3O2
DMJ576C	IC	InChI=1S/C16H20ClN3O2/c1-22-14-4-13(18)12(17)3-10(14)16(21)19-15-9-2-8-5-20(6-9)7-11(8)15/h3-4,8-9,11,15H,2,5-7,18H2,1H3,(H,19,21)
DMJ576C	CS	COC1=CC(=C(C=C1C(=O)NC2C3CC4C2CN(C4)C3)Cl)N
DMJ576C	IK	MRKYTIJPEALHEE-UHFFFAOYSA-N
DMJ576C	IU	4-amino-N-(1-azatricyclo[3.3.1.03,7]nonan-4-yl)-5-chloro-2-methoxybenzamide
DMJ576C	DE	Discovery agent

DMLOJ42	ID	DMLOJ42
DMLOJ42	DN	SC-52569
DMLOJ42	HS	Investigative
DMLOJ42	SN	SC-52569; CHEMBL167350; BDBM50284122; 7-[3-(4-Dimethylcarbamoyl-3-methoxy-2-propyl-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid
DMLOJ42	DT	Small molecular drug
DMLOJ42	PC	44379453
DMLOJ42	MW	513.6
DMLOJ42	FM	C29H39NO7
DMLOJ42	IC	InChI=1S/C29H39NO7/c1-6-9-20-23(14-11-19-12-15-25(29(32)33)37-26(19)20)35-17-8-18-36-24-16-13-22(28(31)30(3)4)27(34-5)21(24)10-7-2/h11,13-14,16,25H,6-10,12,15,17-18H2,1-5H3,(H,32,33)
DMLOJ42	CS	CCCC1=C(C=CC2=C1OC(CC2)C(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)N(C)C)OC)CCC
DMLOJ42	IK	DHAATERTHLJWHW-UHFFFAOYSA-N
DMLOJ42	IU	7-[3-[4-(dimethylcarbamoyl)-3-methoxy-2-propylphenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromene-2-carboxylic acid
DMLOJ42	DE	Discovery agent

DMXA6LU	ID	DMXA6LU
DMXA6LU	DN	SC-52892
DMXA6LU	HS	Investigative
DMXA6LU	SN	CHEMBL9642; SC-52892; SCHEMBL7679693; MIKRUZGZQMVMAG-UHFFFAOYSA-N; BDBM50281814; L007546; 1,4-Dibutyl-3-{6-[2-(1H-tetrazol-5-yl)-phenyl]-pyridin-3-ylmethyl}-1,3-dihydro-imidazol-2-one
DMXA6LU	DT	Small molecular drug
DMXA6LU	PC	9932483
DMXA6LU	MW	431.5
DMXA6LU	FM	C24H29N7O
DMXA6LU	IC	InChI=1S/C24H29N7O/c1-3-5-9-19-17-30(14-6-4-2)24(32)31(19)16-18-12-13-22(25-15-18)20-10-7-8-11-21(20)23-26-28-29-27-23/h7-8,10-13,15,17H,3-6,9,14,16H2,1-2H3,(H,26,27,28,29)
DMXA6LU	CS	CCCCC1=CN(C(=O)N1CC2=CN=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CCCC
DMXA6LU	IK	MIKRUZGZQMVMAG-UHFFFAOYSA-N
DMXA6LU	IU	1,4-dibutyl-3-[[6-[2-(2H-tetrazol-5-yl)phenyl]pyridin-3-yl]methyl]imidazol-2-one
DMXA6LU	DE	Discovery agent

DMYH12X	ID	DMYH12X
DMYH12X	DN	SC-53229
DMYH12X	HS	Investigative
DMYH12X	SN	SC-53229; CHEMBL167669; BDBM50284124; 3-{(R)-7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoyl-phenoxy)-propoxy]-8-propyl-chroman-2-yl}-propionic acid
DMYH12X	DT	Small molecular drug
DMYH12X	PC	9958915
DMYH12X	MW	539.7
DMYH12X	FM	C31H41NO7
DMYH12X	IC	InChI=1S/C31H41NO7/c1-4-6-23-26(14-10-21-9-11-22(39-29(21)23)12-16-28(33)34)37-17-5-18-38-27-15-13-24(31(35)32-2)30(36-3)25(27)19-20-7-8-20/h10,13-15,20,22H,4-9,11-12,16-19H2,1-3H3,(H,32,35)(H,33,34)/t22-/m1/s1
DMYH12X	CS	CCCC1=C(C=CC2=C1O[C@H](CC2)CCC(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)NC)OC)CC4CC4
DMYH12X	IK	YWYUQSGYKDEAMJ-JOCHJYFZSA-N
DMYH12X	IU	3-[(2R)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid
DMYH12X	DE	Discovery agent

DM3BEKV	ID	DM3BEKV
DM3BEKV	DN	SC-54701A
DM3BEKV	HS	Investigative
DM3BEKV	SN	UNII-TN585Y92BI; SC-54701A; SC-54701; CHEMBL311572; TN585Y92BI; Xemilofiban acid; Xemilofiban acid [MI]; SCHEMBL7080314; BDBM50031565; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, (3S)-; 149193-61-3; (S)-3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid ethyl ester; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid (SC-54701A)
DM3BEKV	DT	Small molecular drug
DM3BEKV	PC	9862322
DM3BEKV	MW	330.34
DM3BEKV	FM	C16H18N4O4
DM3BEKV	IC	InChI=1S/C16H18N4O4/c1-2-11(9-15(23)24)19-13(21)7-8-14(22)20-12-5-3-10(4-6-12)16(17)18/h1,3-6,11H,7-9H2,(H3,17,18)(H,19,21)(H,20,22)(H,23,24)/t11-/m1/s1
DM3BEKV	CS	C#C[C@H](CC(=O)O)NC(=O)CCC(=O)NC1=CC=C(C=C1)C(=N)N
DM3BEKV	IK	OUZLOTRPGMFLPN-LLVKDONJSA-N
DM3BEKV	IU	(3S)-3-[[4-(4-carbamimidoylanilino)-4-oxobutanoyl]amino]pent-4-ynoic acid
DM3BEKV	CA	CAS 149193-61-3
DM3BEKV	DE	Discovery agent

DMEUTXG	ID	DMEUTXG
DMEUTXG	DN	SC-54750
DMEUTXG	HS	Investigative
DMEUTXG	PC	43550116
DMEUTXG	MW	248.32
DMEUTXG	FM	C14H20N2O2
DMEUTXG	IC	InChI=1S/C14H20N2O2/c1-9-7-10-8-11(15)5-6-12(10)16(9)13(17)18-14(2,3)4/h5-6,8-9H,7,15H2,1-4H3
DMEUTXG	CS	CC1CC2=C(N1C(=O)OC(C)(C)C)C=CC(=C2)N
DMEUTXG	IK	YOELJPDARJMOOO-UHFFFAOYSA-N
DMEUTXG	IU	tert-butyl 5-amino-2-methyl-2,3-dihydroindole-1-carboxylate
DMEUTXG	DE	Discovery agent

DMLJ8T7	ID	DMLJ8T7
DMLJ8T7	DN	SC-55634
DMLJ8T7	HS	Investigative
DMLJ8T7	SN	CHEMBL9599; SC-55634; BDBM50281823
DMLJ8T7	DT	Small molecular drug
DMLJ8T7	PC	9935096
DMLJ8T7	MW	485.6
DMLJ8T7	FM	C28H35N7O
DMLJ8T7	IC	InChI=1S/C28H35N7O/c1-4-5-11-22-18-35(26-19(2)9-8-10-20(26)3)28(36)34(22)17-21-14-15-25(29-16-21)23-12-6-7-13-24(23)27-30-32-33-31-27/h6-7,12-16,18-20,26H,4-5,8-11,17H2,1-3H3,(H,30,31,32,33)/t19-,20+,26?
DMLJ8T7	CS	CCCCC1=CN(C(=O)N1CC2=CN=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C5[C@@H](CCC[C@@H]5C)C
DMLJ8T7	IK	GBXQWPCVQAHRBS-NJEHHLDASA-N
DMLJ8T7	IU	4-butyl-1-[(2S,6R)-2,6-dimethylcyclohexyl]-3-[[6-[2-(2H-tetrazol-5-yl)phenyl]pyridin-3-yl]methyl]imidazol-2-one
DMLJ8T7	DE	Discovery agent

DMAZLKX	ID	DMAZLKX
DMAZLKX	DN	SC-558
DMAZLKX	HS	Investigative
DMAZLKX	SN	CHEMBL602951; BDBM50308509
DMAZLKX	DT	Small molecular drug
DMAZLKX	PC	1396
DMAZLKX	MW	446.2
DMAZLKX	FM	C16H11BrF3N3O2S
DMAZLKX	IC	InChI=1S/C16H11BrF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)
DMAZLKX	CS	C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)Br
DMAZLKX	IK	OYZKFVIVPRQRQQ-UHFFFAOYSA-N
DMAZLKX	IU	4-[5-(4-bromophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DMAZLKX	DE	Discovery agent

DMT1GJL	ID	DMT1GJL
DMT1GJL	DN	SC-560
DMT1GJL	HS	Investigative
DMT1GJL	SN	SC-560; 188817-13-2; SC 560; 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole; razole; SC560; 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole; CHEMBL26915; CHEBI:76274; 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazole; 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethyl pyrazole; Lopac-S-2064; AC1N7Q9I; Lopac0_001086; SCHEMBL676921; GTPL10240; CTK8E8897; BDBM13065; DTXSID00401775; QCR-133; MolPort-003-959-517; HMS3268E05; ZINC2391787; BCP07005; EX-A1507; CS-006
DMT1GJL	DT	Small molecular drug
DMT1GJL	PC	4306515
DMT1GJL	MW	352.7
DMT1GJL	FM	C17H12ClF3N2O
DMT1GJL	IC	InChI=1S/C17H12ClF3N2O/c1-24-14-8-6-13(7-9-14)23-15(10-16(22-23)17(19,20)21)11-2-4-12(18)5-3-11/h2-10H,1H3
DMT1GJL	CS	COC1=CC=C(C=C1)N2C(=CC(=N2)C(F)(F)F)C3=CC=C(C=C3)Cl
DMT1GJL	IK	PQUGCKBLVKJMNT-UHFFFAOYSA-N
DMT1GJL	IU	5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazole
DMT1GJL	CA	CAS 188817-13-2
DMT1GJL	CB	CHEBI:76274
DMT1GJL	DE	Discovery agent

DMZJQ1D	ID	DMZJQ1D
DMZJQ1D	DN	SC-58272
DMZJQ1D	HS	Investigative
DMZJQ1D	SN	SC-58272; SC 58272; CHEMBL6269; [CYCLOHEXYLETHYL]-[[[[4-[2-METHYL-1-IMIDAZOLYL-BUTYL]PHENYL]ACETYL]-SERYL]-LYSINYL]-AMINE; 164931-25-3; L-Lysinamide, N-((4-(4-(2-methyl-1H-imidazol-1-yl)butyl)phenyl)acetyl)-L-seryl-N1-(2-cyclohexylethyl)-; MIM; (2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[[2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]acetyl]amino]propanoyl]amino]hexanamide; L-Lysinamide, N-[[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetyl]-L-seryl-N1-(2-cyclohexylethyl)-; AC1L9JM6; DTXSID00167824
DMZJQ1D	DT	Small molecular drug
DMZJQ1D	PC	446385
DMZJQ1D	MW	596.8
DMZJQ1D	FM	C33H52N6O4
DMZJQ1D	IC	InChI=1S/C33H52N6O4/c1-25-35-20-22-39(25)21-8-6-11-27-13-15-28(16-14-27)23-31(41)37-30(24-40)33(43)38-29(12-5-7-18-34)32(42)36-19-17-26-9-3-2-4-10-26/h13-16,20,22,26,29-30,40H,2-12,17-19,21,23-24,34H2,1H3,(H,36,42)(H,37,41)(H,38,43)/t29-,30-/m0/s1
DMZJQ1D	CS	CC1=NC=CN1CCCCC2=CC=C(C=C2)CC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCCC3CCCCC3
DMZJQ1D	IK	WHLPIOSHBKQGHA-KYJUHHDHSA-N
DMZJQ1D	IU	(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[[2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]acetyl]amino]propanoyl]amino]hexanamide
DMZJQ1D	CA	CAS 164931-25-3
DMZJQ1D	DE	Discovery agent

DMNI91Z	ID	DMNI91Z
DMNI91Z	DN	SC-74020
DMNI91Z	HS	Investigative
DMNI91Z	SN	sc-74020; CHEMBL1233506; N-{4-[(1-HYDROXYCARBAMOYL-2-METHYL-PROPYL)-(2-MORPHOLIN-4-YL-ETHYL)-SULFAMOYL]-4-PENTYL-BENZAMIDE; I52; SC 74020; AC1NRBR8; BDBM50026872; DB01630; SC74020; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl](2-morpholin-4-ylethyl)sulfamoyl}phenyl)-4-pentylbenzamide; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide
DMNI91Z	DT	Small molecular drug
DMNI91Z	PC	5288596
DMNI91Z	MW	574.7
DMNI91Z	FM	C29H42N4O6S
DMNI91Z	IC	InChI=1S/C29H42N4O6S/c1-4-5-6-7-23-8-10-24(11-9-23)28(34)30-25-12-14-26(15-13-25)40(37,38)33(27(22(2)3)29(35)31-36)17-16-32-18-20-39-21-19-32/h8-15,22,27,36H,4-7,16-21H2,1-3H3,(H,30,34)(H,31,35)/t27-/m1/s1
DMNI91Z	CS	CCCCCC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)N(CCN3CCOCC3)[C@H](C(C)C)C(=O)NO
DMNI91Z	IK	YJNCFXPJICILOK-HHHXNRCGSA-N
DMNI91Z	IU	N-[4-[[(2R)-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-(2-morpholin-4-ylethyl)sulfamoyl]phenyl]-4-pentylbenzamide
DMNI91Z	DE	Discovery agent

DMD71VB	ID	DMD71VB
DMD71VB	DN	SC-79407
DMD71VB	HS	Investigative
DMD71VB	DT	Small molecular drug
DMD71VB	PC	24755617
DMD71VB	DE	Discovery agent

DMZN7YT	ID	DMZN7YT
DMZN7YT	DN	SC-795
DMZN7YT	HS	Investigative
DMZN7YT	SN	SC-795; CHEMBL303954; SCHEMBL992314; XNYMOOHZPFZFJE-OAQYLSRUSA-N; 1,1,1-Trifluoro-3-{(3-phenoxy-phenyl)-[3-(1,1,2,2-tetrafluoro-ethoxy)-benzyl]-amino}-propan-2-ol; BDBM50094519; (2R)-3-[(3-phenoxyphenyl)-[[3-(1,1,2,2-tetrafluoroethoxy) phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol; (R)-3-((3-(1,1,2,2-tetrafluoroethoxy)benzyl)(3-phenoxyphenyl)amino)-1,1,1-trifluoropropan-2-ol; (R)-1,1,1-trifluoro-3-((3-phenoxyphenyl)(3-(1,1,2,2-tetrafluoroethoxy)benzyl)amino)propan-2-ol
DMZN7YT	DT	Small molecular drug
DMZN7YT	PC	9806102
DMZN7YT	MW	503.4
DMZN7YT	FM	C24H20F7NO3
DMZN7YT	IC	InChI=1S/C24H20F7NO3/c25-22(26)24(30,31)35-20-11-4-6-16(12-20)14-32(15-21(33)23(27,28)29)17-7-5-10-19(13-17)34-18-8-2-1-3-9-18/h1-13,21-22,33H,14-15H2/t21-/m1/s1
DMZN7YT	CS	C1=CC=C(C=C1)OC2=CC=CC(=C2)N(CC3=CC(=CC=C3)OC(C(F)F)(F)F)C[C@H](C(F)(F)F)O
DMZN7YT	IK	XNYMOOHZPFZFJE-OAQYLSRUSA-N
DMZN7YT	IU	(2R)-1,1,1-trifluoro-3-[3-phenoxy-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]propan-2-ol
DMZN7YT	CA	CAS 315229-16-4
DMZN7YT	DE	Discovery agent

DM96ATK	ID	DM96ATK
DM96ATK	DN	SC-83157
DM96ATK	HS	Investigative
DM96ATK	DT	Small molecular drug
DM96ATK	PC	177285
DM96ATK	DE	Discovery agent

DMX40NM	ID	DMX40NM
DMX40NM	DN	SCANDENOLIDE
DMX40NM	HS	Investigative
DMX40NM	SN	Scandenolide; 23758-16-9; AC1Q62GG; AC1L40IU; NSC145911; NSC-145911; 10a-methyl-3-methylidene-2,6-dioxodecahydro-4,7-(metheno)furo[3,2-c]oxireno[f]oxacycloundecin-8(6h)-yl acetate; 5H-7,4-Methenofuro(3,2-c)oxireno(f)oxacycloundecin-5,9(7H)-dione, 3-(acetyloxy)-1a,2,3,7a,8,10a,11,11a-octahydro-11a-methyl-8-methylene-, (1aS-(1aR*,3R*,7S*,7aS*,10aR*,11aR*))-
DMX40NM	DT	Small molecular drug
DMX40NM	PC	98927
DMX40NM	MW	334.3
DMX40NM	FM	C17H18O7
DMX40NM	IC	InChI=1S/C17H18O7/c1-7-14-11-4-9(16(20)22-11)10(21-8(2)18)5-13-17(3,24-13)6-12(14)23-15(7)19/h4,10-14H,1,5-6H2,2-3H3
DMX40NM	CS	CC(=O)OC1CC2C(O2)(CC3C(C4C=C1C(=O)O4)C(=C)C(=O)O3)C
DMX40NM	IK	SLIMCFUYVZKJTC-UHFFFAOYSA-N
DMX40NM	IU	(8-methyl-3-methylidene-4,14-dioxo-5,9,15-trioxatetracyclo[11.2.1.02,6.08,10]hexadec-13(16)-en-12-yl) acetate
DMX40NM	CA	CAS 23758-16-9
DMX40NM	DE	Discovery agent

DMRC4LE	ID	DMRC4LE
DMRC4LE	DN	Sch 202596
DMRC4LE	HS	Investigative
DMRC4LE	SN	Sch 202596; GTPL6128; Sch-202596; (1S)-3',4-Dioxo-4'-[[(1R)-2-(methoxycarbonyl)-4beta,5beta,6alpha-trihydroxy-2-cyclohexen-1alpha-yl]oxy]-5',7'-dichloro-6-methoxy-6'-methylspiro[2,5-cyclohexadiene-1,2'(3'H)-benzofuran]-2-carboxylic acid methyl ester; methyl (2S)-5,7-dichloro-5'-methoxy-6-methyl-3,3'-dioxo-4-[[(1R,4R,5R,6S)-4,5,6-trihydroxy-2-methoxycarbonyl-1-cyclohex-2-enyl]oxy]spiro[1-benzofuran-2,6'-cyclohexa-1,4-diene]-1'-carboxylate
DMRC4LE	DT	Small molecular drug
DMRC4LE	PC	11758032
DMRC4LE	MW	585.3
DMRC4LE	FM	C25H22Cl2O12
DMRC4LE	IC	InChI=1S/C25H22Cl2O12/c1-8-15(26)20(38-19-10(23(33)36-3)7-12(29)17(30)18(19)31)14-21(16(8)27)39-25(22(14)32)11(24(34)37-4)5-9(28)6-13(25)35-2/h5-7,12,17-19,29-31H,1-4H3/t12-,17-,18+,19-,25+/m1/s1
DMRC4LE	CS	CC1=C(C2=C(C(=C1Cl)O[C@H]3[C@H]([C@@H]([C@@H](C=C3C(=O)OC)O)O)O)C(=O)[C@]4(O2)C(=CC(=O)C=C4OC)C(=O)OC)Cl
DMRC4LE	IK	LNGFWDFUPRZMJI-VEHFIHCQSA-N
DMRC4LE	IU	methyl (2S)-5,7-dichloro-5'-methoxy-6-methyl-3,3'-dioxo-4-[(1R,4R,5R,6S)-4,5,6-trihydroxy-2-methoxycarbonylcyclohex-2-en-1-yl]oxyspiro[1-benzofuran-2,6'-cyclohexa-1,4-diene]-1'-carboxylate
DMRC4LE	CA	CAS 196615-89-1
DMRC4LE	DE	Discovery agent

DMD1M24	ID	DMD1M24
DMD1M24	DN	SCH 206272
DMD1M24	HS	Investigative
DMD1M24	SN	SCH-206272
DMD1M24	DT	Small molecular drug
DMD1M24	PC	56947091
DMD1M24	MW	713.5
DMD1M24	FM	C33H41Cl4N5O4
DMD1M24	IC	InChI=1S/C33H41Cl4N5O4/c1-38-31(43)18-22-5-4-11-42(33(22)45)26-8-12-41(13-9-26)14-10-27(21-6-7-28(36)29(37)17-21)30(39-46-3)20-40(2)32(44)23-15-24(34)19-25(35)16-23/h6-7,15-17,19,22,26-27H,4-5,8-14,18,20H2,1-3H3,(H,38,43)/b39-30-/t22-,27-/m1/s1
DMD1M24	CS	CNC(=O)C[C@H]1CCCN(C1=O)C2CCN(CC2)CC[C@H](C3=CC(=C(C=C3)Cl)Cl)/C(=N\\OC)/CN(C)C(=O)C4=CC(=CC(=C4)Cl)Cl
DMD1M24	IK	UITMLIVWRRGLLR-MSBPVHBISA-N
DMD1M24	IU	3,5-dichloro-N-[(2E,3R)-3-(3,4-dichlorophenyl)-2-methoxyimino-5-[4-[(3R)-3-[2-(methylamino)-2-oxoethyl]-2-oxopiperidin-1-yl]piperidin-1-yl]pentyl]-N-methylbenzamide
DMD1M24	DE	Discovery agent

DMNLD6W	ID	DMNLD6W
DMNLD6W	DN	SCH 44643
DMNLD6W	HS	Investigative
DMNLD6W	SN	SCH 44643; 133330-43-5; AC1L466E
DMNLD6W	DT	Small molecular drug
DMNLD6W	PC	179927
DMNLD6W	MW	432.9
DMNLD6W	FM	C25H23ClN3O2-
DMNLD6W	IC	InChI=1S/C25H23ClN3O2/c26-21-5-6-22-20(16-21)4-3-18-2-1-11-27-24(18)23(22)17-7-12-28(13-8-17)25(30)19-9-14-29(31)15-10-19/h1-2,5-6,9-11,14,16H,3-4,7-8,12-13,15H2/q-1
DMNLD6W	CS	C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)C(=O)C4=CCN(C=C4)[O-])C5=C1C=CC=N5
DMNLD6W	IK	IJTLWVCXERQDJL-UHFFFAOYSA-N
DMNLD6W	IU	[4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidin-1-yl]-(1-oxido-2H-pyridin-4-yl)methanone
DMNLD6W	CA	CAS 133330-43-5
DMNLD6W	DE	Discovery agent

DMIKJLP	ID	DMIKJLP
DMIKJLP	DN	Sch-036
DMIKJLP	HS	Investigative
DMIKJLP	SN	Cannabinoid CB2 inverse agonists (immune disorders); Cannabinoid CB2 inverse agonists (immune disorders), Schering-Plough
DMIKJLP	CP	Schering-Plough Research Institute
DMIKJLP	DE	Immune System disease

DMP8OKA	ID	DMP8OKA
DMP8OKA	DN	SCH-12679
DMP8OKA	HS	Investigative
DMP8OKA	SN	Trimopam; Sch-12679; 20012-08-2; CHEMBL343569; N-Methyl-1-phenyl-7,8-dimethoxy-2,3,4,5-tetrahydro-3-benzazepine; 7,8-Dimethoxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; AC1L1JG0; SCHEMBL11704977; ICPHJSKVAZMKIV-UHFFFAOYSA-N; AC1Q5689; BDBM50067817; 2,3,4,5-Tetrahydro-7,8-dimethoxy-3-methyl-1-phenyl-1H-3-benzazepine; d-7,8-Dimethoxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; NCGC00162352-01; N-methyl-1-phenyl-7,8-dimethoxy-2,3,4,5-tetra-hydro-3-benzazepine
DMP8OKA	DT	Small molecular drug
DMP8OKA	PC	5024
DMP8OKA	MW	297.4
DMP8OKA	FM	C19H23NO2
DMP8OKA	IC	InChI=1S/C19H23NO2/c1-20-10-9-15-11-18(21-2)19(22-3)12-16(15)17(13-20)14-7-5-4-6-8-14/h4-8,11-12,17H,9-10,13H2,1-3H3
DMP8OKA	CS	CN1CCC2=CC(=C(C=C2C(C1)C3=CC=CC=C3)OC)OC
DMP8OKA	IK	ICPHJSKVAZMKIV-UHFFFAOYSA-N
DMP8OKA	IU	7,8-dimethoxy-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepine
DMP8OKA	CA	CAS 20012-08-2
DMP8OKA	DE	Discovery agent

DM584T6	ID	DM584T6
DM584T6	DN	SCH-205831
DM584T6	HS	Investigative
DM584T6	SN	SCH-205831; CHEMBL371069; SCHEMBL1106195; BDBM50173419; (3R,3aS,4S,4aR,8aS,9aR)-3-Methyl-4-{(E)-2-[5-(3-trifluoromethyl-phenyl)-pyridin-2-yl]-vinyl}-decahydro-naphtho[2,3-c]furan-1-one; (3R,3aS,4S,4aR,8aS,9aR)-3-methyl-4-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)-decahydronaphtho[2,3-c]furan-1(3H)-one
DM584T6	DT	Small molecular drug
DM584T6	PC	9804049
DM584T6	MW	455.5
DM584T6	FM	C27H28F3NO2
DM584T6	IC	InChI=1S/C27H28F3NO2/c1-16-25-23(22-8-3-2-5-18(22)14-24(25)26(32)33-16)12-11-21-10-9-19(15-31-21)17-6-4-7-20(13-17)27(28,29)30/h4,6-7,9-13,15-16,18,22-25H,2-3,5,8,14H2,1H3/b12-11+/t16-,18+,22-,23+,24-,25+/m1/s1
DM584T6	CS	C[C@@H]1[C@@H]2[C@@H](C[C@@H]3CCCC[C@H]3[C@@H]2/C=C/C4=NC=C(C=C4)C5=CC(=CC=C5)C(F)(F)F)C(=O)O1
DM584T6	IK	PQLBJVPZXNPVOS-HLBWOJLBSA-N
DM584T6	IU	(3R,3aS,4S,4aR,8aS,9aR)-3-methyl-4-[(E)-2-[5-[3-(trifluoromethyl)phenyl]pyridin-2-yl]ethenyl]-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f][2]benzofuran-1-one
DM584T6	DE	Thrombosis

DM42A1F	ID	DM42A1F
DM42A1F	DN	SCH-210971
DM42A1F	HS	Investigative
DM42A1F	DT	Small molecular drug
DM42A1F	PC	54726677
DM42A1F	DE	Discovery agent

DMHOUSR	ID	DMHOUSR
DMHOUSR	DN	SCH-221510
DMHOUSR	HS	Investigative
DMHOUSR	SN	SCH-225288; SCH-655842; Nociceptin receptor ligands (pain/anxiety/cough/urinary incontinence); NOP agonists (pain, anxiety, cough, urinary incontinence), Merck & Co; NOP receptor ligands (pain/anxiety/cough/urinary incontinence), Schering-Plough; Nociceptin opioid peptide receptor ligands (pain/anxiety/cough/urinary incontinence), Schering-Plough; Nociceptin receptor ligands (pain/anxiety/cough/urinary incontinence), Merck & Co; Nociceptin receptor ligands (pain/anxiety/cough/urinary incontinence),Schering-Plough; ORL1 receptor ligands (pain/anxiety/cough/urinary incontinence), Schering-Plough; Opioid receptor-like 1 receptor ligands (pain/anxiety/cough/urinary incontinence), Schering-Plough
DMHOUSR	CP	Schering-Plough Corp
DMHOUSR	DT	Small molecular drug
DMHOUSR	PC	9887077
DMHOUSR	MW	397.6
DMHOUSR	FM	C28H31NO
DMHOUSR	IC	InChI=1S/C28H31NO/c1-20-10-6-8-14-25(20)27(26-15-9-7-11-21(26)2)29-23-16-17-24(29)19-28(30,18-23)22-12-4-3-5-13-22/h3-15,23-24,27,30H,16-19H2,1-2H3
DMHOUSR	CS	CC1=CC=CC=C1C(C2=CC=CC=C2C)N3C4CCC3CC(C4)(C5=CC=CC=C5)O
DMHOUSR	IK	LOSJNRBXNQTUNT-UHFFFAOYSA-N
DMHOUSR	IU	8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol
DMHOUSR	CA	CAS 322473-89-2
DMHOUSR	DE	Anxiety disorder

DMH7EWZ	ID	DMH7EWZ
DMH7EWZ	DN	SCH-225336
DMH7EWZ	HS	Investigative
DMH7EWZ	SN	SCH-225336
DMH7EWZ	DT	Small molecular drug
DMH7EWZ	PC	46880729
DMH7EWZ	MW	538.6
DMH7EWZ	FM	C23H25NO8S3
DMH7EWZ	IC	InChI=1S/C23H25NO8S3/c1-16(24-33(4,25)26)17-5-10-20(11-6-17)34(27,28)22-14-9-19(32-3)15-23(22)35(29,30)21-12-7-18(31-2)8-13-21/h5-16,24H,1-4H3/i2-1
DMH7EWZ	CS	CC(C1=CC=C(C=C1)S(=O)(=O)C2=C(C=C(C=C2)OC)S(=O)(=O)C3=CC=C(C=C3)O[11CH3])NS(=O)(=O)C
DMH7EWZ	IK	NXODIUKWAVUFGF-JVVVGQRLSA-N
DMH7EWZ	IU	N-[1-[4-[4-methoxy-2-(4-(111C)methoxyphenyl)sulfonylphenyl]sulfonylphenyl]ethyl]methanesulfonamide
DMH7EWZ	DE	Discovery agent

DMT1OAH	ID	DMT1OAH
DMT1OAH	DN	SCH-23390
DMT1OAH	HS	Investigative
DMT1OAH	SN	Sch-23388; Lopac-D-054; AC1O7G1X; GTPL956; CHEMBL63321; SCH 23388 (S-enantiomer); SCHEMBL11107859; BDBM82248; GOTMKOSCLKVOGG-HNNXBMFYSA-N; ZINC2017840; PDSP1_001624; PDSP2_001608; PDSP2_000613; PDSP1_000616; NCGC00015301-01; (+)-SCH-23390; CAS_73445-63-3; (5S)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol; (1S)-7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol
DMT1OAH	DT	Small molecular drug
DMT1OAH	PC	5018
DMT1OAH	MW	287.8
DMT1OAH	FM	C17H18ClNO
DMT1OAH	IC	InChI=1S/C17H18ClNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3
DMT1OAH	CS	CN1CCC2=CC(=C(C=C2C(C1)C3=CC=CC=C3)O)Cl
DMT1OAH	IK	GOTMKOSCLKVOGG-UHFFFAOYSA-N
DMT1OAH	IU	8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
DMT1OAH	CB	CHEBI:73297

DM6SC5K	ID	DM6SC5K
DM6SC5K	DN	SCH-24518
DM6SC5K	HS	Investigative
DM6SC5K	SN	CHEMBL292418; CHEMBL540857; Sch-24518; 8-Chloro-2,3,4,5-tetrahydro-5-phenyl-1H-3-benzazepin-7-ol; ACMC-20mac5; AC1L3SVB; SCHEMBL13007204; BDBM50004796; 8-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol; 8-Chloro-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol
DM6SC5K	DT	Small molecular drug
DM6SC5K	PC	146265
DM6SC5K	MW	354.7
DM6SC5K	FM	C16H17BrClNO
DM6SC5K	IC	InChI=1S/C16H16ClNO.BrH/c17-15-8-12-6-7-18-10-14(13(12)9-16(15)19)11-4-2-1-3-5-11;/h1-5,8-9,14,18-19H,6-7,10H2;1H
DM6SC5K	CS	C1CNCC(C2=CC(=C(C=C21)Cl)O)C3=CC=CC=C3.Br
DM6SC5K	IK	XSWVQBLZJAURQF-UHFFFAOYSA-N
DM6SC5K	IU	8-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol;hydrobromide
DM6SC5K	CA	CAS 90955-43-4
DM6SC5K	DE	Discovery agent

DMOEB8M	ID	DMOEB8M
DMOEB8M	DN	SCH-356036
DMOEB8M	HS	Investigative
DMOEB8M	SN	SCH-356036; CHEMBL382728; SCHEMBL8137174; BDBM50172158; (S)-N-(1-(4-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)phenyl)ethyl)methanesulfonamide
DMOEB8M	DT	Small molecular drug
DMOEB8M	PC	9893254
DMOEB8M	MW	532
DMOEB8M	FM	C21H19ClFNO6S3
DMOEB8M	IC	InChI=1S/C21H19ClFNO6S3/c1-14(24-31(2,25)26)15-7-10-17(11-8-15)32(27,28)20-12-9-16(22)13-21(20)33(29,30)19-6-4-3-5-18(19)23/h3-14,24H,1-2H3/t14-/m0/s1
DMOEB8M	CS	C[C@@H](C1=CC=C(C=C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)S(=O)(=O)C3=CC=CC=C3F)NS(=O)(=O)C
DMOEB8M	IK	BQYPKXDCTROOHB-AWEZNQCLSA-N
DMOEB8M	IU	N-[(1S)-1-[4-[4-chloro-2-(2-fluorophenyl)sulfonylphenyl]sulfonylphenyl]ethyl]methanesulfonamide
DMOEB8M	DE	Discovery agent

DM0J937	ID	DM0J937
DM0J937	DN	SCH-48375
DM0J937	HS	Investigative
DM0J937	SN	SCH-48678
DM0J937	DT	Small molecular drug
DM0J937	PC	10318874
DM0J937	MW	401.5
DM0J937	FM	C26H27NO3
DM0J937	IC	InChI=1S/C26H27NO3/c1-29-22-15-11-20(12-16-22)25-24(10-6-9-19-7-4-3-5-8-19)26(28)27(25)21-13-17-23(30-2)18-14-21/h3-5,7-8,11-18,24-25H,6,9-10H2,1-2H3/t24-,25+/m0/s1
DM0J937	CS	COC1=CC=C(C=C1)[C@@H]2[C@@H](C(=O)N2C3=CC=C(C=C3)OC)CCCC4=CC=CC=C4
DM0J937	IK	IMNTVVOUWFPRSB-LOSJGSFVSA-N
DM0J937	IU	(3S,4S)-1,4-bis(4-methoxyphenyl)-3-(3-phenylpropyl)azetidin-2-one
DM0J937	DE	Discovery agent

DMCWSJP	ID	DMCWSJP
DMCWSJP	DN	SCH51866
DMCWSJP	HS	Investigative
DMCWSJP	SN	SCH 51866; SCH-51866
DMCWSJP	DT	Small molecular drug
DMCWSJP	PC	5311355
DMCWSJP	MW	389.4
DMCWSJP	FM	C19H18F3N5O
DMCWSJP	IC	InChI=1S/C19H18F3N5O/c1-26-17(28)15-16(27-13-4-2-3-12(13)23-18(26)27)25-14(24-15)9-10-5-7-11(8-6-10)19(20,21)22/h5-8,12-13H,2-4,9H2,1H3,(H,24,25)/t12-,13+/m0/s1
DMCWSJP	CS	CN1C(=O)C2=C(N=C(N2)CC3=CC=C(C=C3)C(F)(F)F)N4C1=N[C@@H]5[C@H]4CCC5
DMCWSJP	IK	JOSMPBVYYKRYLG-QWHCGFSZSA-N
DMCWSJP	IU	(11S,15R)-8-methyl-4-[[4-(trifluoromethyl)phenyl]methyl]-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one
DMCWSJP	CA	CAS 167298-74-0
DMCWSJP	DE	Discovery agent

DMMXIB4	ID	DMMXIB4
DMMXIB4	DN	SCH-546909
DMMXIB4	HS	Investigative
DMMXIB4	SN	CDK2 inhibitors (cancer), Merck & Co; CDK2 inhibitors (cancer), Schering-Plough; Cyclindependent kinase 2 inhibitors (cancer), Schering-Plough
DMMXIB4	CP	Schering-Plough Corp
DMMXIB4	DT	Small molecular drug
DMMXIB4	PC	10356352
DMMXIB4	MW	281.26
DMMXIB4	FM	C16H11NO4
DMMXIB4	IC	InChI=1S/C16H11NO4/c1-21-15-12(19)6-10-13-11(17-16(10)20)4-7-2-3-8(18)5-9(7)14(13)15/h2-6,18-19H,1H3,(H,17,20)
DMMXIB4	CS	COC1=C(C=C2C3=C(C=C4C=CC(=CC4=C31)O)NC2=O)O
DMMXIB4	IK	PFXGXKFPTAJYHV-UHFFFAOYSA-N
DMMXIB4	IU	4,14-dihydroxy-15-methoxy-10-azatetracyclo[7.6.1.02,7.012,16]hexadeca-1,3,5,7,9(16),12,14-heptaen-11-one
DMMXIB4	DE	Solid tumour/cancer

DMDK8TR	ID	DMDK8TR
DMDK8TR	DN	SCH-57726
DMDK8TR	HS	Investigative
DMDK8TR	SN	SCH-57726; CHEMBL28676; BDBM50289464
DMDK8TR	DT	Small molecular drug
DMDK8TR	PC	44278378
DMDK8TR	MW	493.6
DMDK8TR	FM	C31H35N5O
DMDK8TR	IC	InChI=1S/C31H35N5O/c1-34-29(37)26-28(36-21-31(33-30(34)36)18-8-9-19-31)32-27(35(26)20-22-10-4-2-5-11-22)25-16-14-24(15-17-25)23-12-6-3-7-13-23/h2,4-5,10-11,14-17,23H,3,6-9,12-13,18-21H2,1H3
DMDK8TR	CS	CN1C(=O)C2=C(N=C(N2CC3=CC=CC=C3)C4=CC=C(C=C4)C5CCCCC5)N6C1=NC7(C6)CCCC7
DMDK8TR	IK	COWBACSJPXQWNS-UHFFFAOYSA-N
DMDK8TR	IU	3-benzyl-2-(4-cyclohexylphenyl)-5-methylspiro[8H-imidazo[2,1-b]purine-7,1'-cyclopentane]-4-one
DMDK8TR	DE	Discovery agent

DMRDM9S	ID	DMRDM9S
DMRDM9S	DN	SCH-602539
DMRDM9S	HS	Investigative
DMRDM9S	SN	SCH-602539; UNII-7467O90MW3; CHEMBL1270738; 7467O90MW3; SCH602539; 618385-42-5; SCHEMBL8058894; BDBM50329618; Carbamic acid, N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)furan-6-yl)-, ethyl ester; Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(2,3'-bipyridin-6'-yl)vinyl)-1-methyl-3-oxododecahydronaphtho(2,3-C)furan-6-yl}carbamate; Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)fura
DMRDM9S	CP	Schering-Plough Corp
DMRDM9S	DT	Small molecular drug
DMRDM9S	PC	16214871
DMRDM9S	MW	475.6
DMRDM9S	FM	C28H33N3O4
DMRDM9S	IC	InChI=1S/C28H33N3O4/c1-3-34-28(33)31-21-10-11-22-19(14-21)15-24-26(17(2)35-27(24)32)23(22)12-9-20-8-7-18(16-30-20)25-6-4-5-13-29-25/h4-9,12-13,16-17,19,21-24,26H,3,10-11,14-15H2,1-2H3,(H,31,33)/b12-9+/t17-,19+,21-,22-,23+,24-,26+/m1/s1
DMRDM9S	CS	CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/C4=NC=C(C=C4)C5=CC=CC=N5)[C@H](OC3=O)C
DMRDM9S	IK	IHWKYASJAJITBL-MSGZWQTISA-N
DMRDM9S	IU	ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-1-methyl-3-oxo-9-[(E)-2-(5-pyridin-2-ylpyridin-2-yl)ethenyl]-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
DMRDM9S	CA	CAS 618385-42-5
DMRDM9S	DE	Arteriosclerosis

DMAUB9F	ID	DMAUB9F
DMAUB9F	DN	SCH-63390
DMAUB9F	HS	Investigative
DMAUB9F	SN	SCH-63390; CHEMBL17121; SCHEMBL5823548; Sch 63390; BDBM50051241; 2-(2-Furanyl)-7-(3-phenylpropyl)-3-aza-7H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-amine; 5-amino-7-(3-phenylpropyl)-2-(2-furyl)pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine; 2-Furan-2-yl-7-(3-phenyl-propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine(SCH 63390); 7H-Pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)-
DMAUB9F	DT	Small molecular drug
DMAUB9F	PC	9798914
DMAUB9F	MW	359.4
DMAUB9F	FM	C19H17N7O
DMAUB9F	IC	InChI=1S/C19H17N7O/c20-19-23-17-14(18-22-16(24-26(18)19)15-9-5-11-27-15)12-21-25(17)10-4-8-13-6-2-1-3-7-13/h1-3,5-7,9,11-12H,4,8,10H2,(H2,20,23)
DMAUB9F	CS	C1=CC=C(C=C1)CCCN2C3=C(C=N2)C4=NC(=NN4C(=N3)N)C5=CC=CO5
DMAUB9F	IK	XMXGGIWSFRIOKL-UHFFFAOYSA-N
DMAUB9F	IU	4-(furan-2-yl)-10-(3-phenylpropyl)-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
DMAUB9F	CA	CAS 174648-45-4
DMAUB9F	DE	Discovery agent

DM4CI57	ID	DM4CI57
DM4CI57	DN	SCH-68631
DM4CI57	HS	Investigative
DM4CI57	SN	Sch-68631; CHEMBL179197; 3-Butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione; Sch68631; AC1LA66R; SCHEMBL16010694; CTK6D3164; BDBM50158807; SF-2418; PKF118-744; 100843-91-2; 3-Butyryl-1,8-dihydroxy-2-methyl-phenanthrene-9,10-dione; 3-butyryl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione
DM4CI57	DT	Small molecular drug
DM4CI57	PC	482190
DM4CI57	MW	324.3
DM4CI57	FM	C19H16O5
DM4CI57	IC	InChI=1S/C19H16O5/c1-3-5-13(20)11-8-12-10-6-4-7-14(21)15(10)18(23)19(24)16(12)17(22)9(11)2/h4,6-8,21-22H,3,5H2,1-2H3
DM4CI57	CS	CCCC(=O)C1=C(C(=C2C(=C1)C3=C(C(=CC=C3)O)C(=O)C2=O)O)C
DM4CI57	IK	YJQYHFMKGAVKDP-UHFFFAOYSA-N
DM4CI57	IU	3-butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione
DM4CI57	DE	Discovery agent

DM9YJI8	ID	DM9YJI8
DM9YJI8	DN	SCH-725737
DM9YJI8	HS	Investigative
DM9YJI8	SN	SCH-725737
DM9YJI8	PC	44435593
DM9YJI8	MW	1347.5
DM9YJI8	FM	C61H102O30S
DM9YJI8	IC	InChI=1S/C61H102O30S/c1-23(2)11-10-16-61(9,75)36-13-12-30-29-20-34(32-19-28(91-92(76,77)78)14-17-59(32,7)31(29)15-18-60(30,36)8)85-56-48(74)50(39(65)26(5)83-56)88-57-51(89-54-45(71)42(68)37(63)24(3)81-54)41(67)35(22-80-57)86-58-52(90-55-46(72)43(69)38(64)25(4)82-55)47(73)49(27(6)84-58)87-53-44(70)40(66)33(62)21-79-53/h15,23-30,32-58,62-75H,10-14,16-22H2,1-9H3,(H,76,77,78)/t24-,25-,26-,27-,28+,29+,30+,32-,33+,34+,35-,36+,37-,38+,39-,40+,41+,42+,43+,44-,45-,46-,47+,48-,49-,50+,51-,52-,53+,54+,55+,56+,57+,58+,59-,60+,61-/m1/s1
DM9YJI8	CS	C[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](CO[C@H]2O[C@H]3[C@@H]([C@H](O[C@H]([C@@H]3O)O[C@H]4C[C@H]5[C@@H]6CC[C@@H]([C@]6(CC=C5[C@@]7([C@@H]4C[C@H](CC7)OS(=O)(=O)O)C)C)[C@@](C)(CCCC(C)C)O)C)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@H](CO9)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)C)O)O)O)O)O)O)O
DM9YJI8	IK	YGJYYDTWXBCDRA-MIRNQWDESA-N
DM9YJI8	IU	[(3S,5S,6S,8S,10S,13S,14S,17S)-6-[(2R,3R,4S,5R,6R)-3,5-dihydroxy-4-[(2S,3R,4S,5R)-4-hydroxy-5-[(2S,3R,4S,5S,6R)-4-hydroxy-6-methyl-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-5-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-17-[(2R)-2-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DM9YJI8	DE	Discovery agent

DMYKB0S	ID	DMYKB0S
DMYKB0S	DN	SCH-725739
DMYKB0S	HS	Investigative
DMYKB0S	SN	SCH-725739
DMYKB0S	PC	44435595
DMYKB0S	MW	1361.5
DMYKB0S	FM	C62H104O30S
DMYKB0S	IC	InChI=1S/C62H104O30S/c1-23(2)12-11-17-62(10,76)36-14-13-31-30-21-35(33-20-29(92-93(77,78)79)15-18-60(33,8)32(30)16-19-61(31,36)9)86-57-48(75)51(39(66)26(5)83-57)89-59-53(91-56-45(72)42(69)38(65)25(4)82-56)47(74)50(28(7)85-59)88-58-52(90-55-44(71)41(68)37(64)24(3)81-55)46(73)49(27(6)84-58)87-54-43(70)40(67)34(63)22-80-54/h16,23-31,33-59,63-76H,11-15,17-22H2,1-10H3,(H,77,78,79)/t24-,25-,26-,27-,28-,29+,30+,31+,33-,34+,35+,36+,37+,38-,39-,40+,41+,42+,43-,44-,45-,46+,47+,48-,49-,50-,51+,52-,53-,54+,55+,56+,57+,58+,59+,60-,61+,62-/m1/s1
DMYKB0S	CS	C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C)O)O)O)O[C@H]5[C@@H]([C@H](O[C@H]([C@@H]5O)O[C@H]6C[C@H]7[C@@H]8CC[C@@H]([C@]8(CC=C7[C@@]9([C@@H]6C[C@H](CC9)OS(=O)(=O)O)C)C)[C@@](C)(CCCC(C)C)O)C)O)C)C)O[C@H]1[C@@H]([C@H]([C@H](CO1)O)O)O)O)O)O)O
DMYKB0S	IK	RRDLUYKZNPWVNX-HVARHZHCSA-N
DMYKB0S	IU	[(3S,5S,6S,8S,10S,13S,14S,17S)-6-[(2R,3R,4S,5R,6R)-3,5-dihydroxy-4-[(2S,3R,4S,5S,6R)-4-hydroxy-5-[(2S,3R,4S,5S,6R)-4-hydroxy-6-methyl-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-5-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-6-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-17-[(2R)-2-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMYKB0S	DE	Discovery agent

DMWVH62	ID	DMWVH62
DMWVH62	DN	SCH772984
DMWVH62	HS	Investigative
DMWVH62	SN	SCH-772984
DMWVH62	DT	Small molecular drug
DMWVH62	PC	24866313
DMWVH62	MW	587.7
DMWVH62	FM	C33H33N9O2
DMWVH62	IC	InChI=1S/C33H33N9O2/c43-30(42-18-16-41(17-19-42)27-5-2-24(3-6-27)32-35-11-1-12-36-32)22-40-15-10-25(21-40)33(44)37-26-4-7-29-28(20-26)31(39-38-29)23-8-13-34-14-9-23/h1-9,11-14,20,25H,10,15-19,21-22H2,(H,37,44)(H,38,39)/t25-/m1/s1
DMWVH62	CS	C1CN(C[C@@H]1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7
DMWVH62	IK	HDAJDNHIBCDLQF-RUZDIDTESA-N
DMWVH62	IU	(3R)-1-[2-oxo-2-[4-(4-pyrimidin-2-ylphenyl)piperazin-1-yl]ethyl]-N-(3-pyridin-4-yl-1H-indazol-5-yl)pyrrolidine-3-carboxamide
DMWVH62	DE	Discovery agent

DM5ZEPD	ID	DM5ZEPD
DM5ZEPD	DN	SCH79687
DM5ZEPD	HS	Investigative
DM5ZEPD	SN	CHEMBL366977; 224585-45-9; SCHEMBL7860131; BDBM86188; DTXSID20430941; SCH 79687; PDSP1_001301; SCH-79687; PDSP2_001285; L018853
DM5ZEPD	DT	Small molecular drug
DM5ZEPD	PC	9801743
DM5ZEPD	MW	375.2
DM5ZEPD	FM	C18H16Cl2N4O
DM5ZEPD	IC	InChI=1S/C18H16Cl2N4O/c19-14-6-15(20)8-16(7-14)24-18(25)22-9-13-3-1-12(2-4-13)5-17-10-21-11-23-17/h1-4,6-8,10-11H,5,9H2,(H,21,23)(H2,22,24,25)
DM5ZEPD	CS	C1=CC(=CC=C1CC2=CN=CN2)CNC(=O)NC3=CC(=CC(=C3)Cl)Cl
DM5ZEPD	IK	CXNCQFJNXQAFND-UHFFFAOYSA-N
DM5ZEPD	IU	1-(3,5-dichlorophenyl)-3-[[4-(1H-imidazol-5-ylmethyl)phenyl]methyl]urea
DM5ZEPD	CA	CAS 224585-45-9
DM5ZEPD	DE	Central nervous system disease

DM346KA	ID	DM346KA
DM346KA	DN	Sch-900875
DM346KA	HS	Investigative
DM346KA	SN	CXCR3 antagonists (inflammatory diseases), Schering-Plough/Ligand/Merck & Co
DM346KA	CP	Ligand Pharmaceuticals Inc
DM346KA	PC	11997335
DM346KA	MW	553.1
DM346KA	FM	C28H37ClN8O2
DM346KA	IC	InChI=1S/C28H37ClN8O2/c1-5-22-17-36(25-19(4)32-24(15-31-25)26-33-34-28(39-26)30-6-2)18(3)16-37(22)23-11-13-35(14-12-23)27(38)20-7-9-21(29)10-8-20/h7-10,15,18,22-23H,5-6,11-14,16-17H2,1-4H3,(H,30,34)/t18-,22+/m1/s1
DM346KA	CS	CC[C@H]1CN([C@@H](CN1C2CCN(CC2)C(=O)C3=CC=C(C=C3)Cl)C)C4=NC=C(N=C4C)C5=NN=C(O5)NCC
DM346KA	IK	MDHIGNOFHUSPMA-GCJKJVERSA-N
DM346KA	IU	(4-chlorophenyl)-[4-[(2S,5R)-2-ethyl-4-[5-[5-(ethylamino)-1,3,4-oxadiazol-2-yl]-3-methylpyrazin-2-yl]-5-methylpiperazin-1-yl]piperidin-1-yl]methanone
DM346KA	CA	CAS 907206-98-8
DM346KA	DE	Inflammation

DMWQ480	ID	DMWQ480
DMWQ480	DN	schisandrin A
DMWQ480	HS	Investigative
DMWQ480	SN	(-)-deoxyschisandrin; (-)-dimethylgomisin J
DMWQ480	DT	Small molecular drug
DMWQ480	PC	155256
DMWQ480	MW	416.5
DMWQ480	FM	C24H32O6
DMWQ480	IC	InChI=1S/C24H32O6/c1-13-9-15-11-17(25-3)21(27-5)23(29-7)19(15)20-16(10-14(13)2)12-18(26-4)22(28-6)24(20)30-8/h11-14H,9-10H2,1-8H3/t13-,14+
DMWQ480	CS	C[C@@H]1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3C[C@@H]1C)OC)OC)OC)OC)OC)OC
DMWQ480	IK	JEJFTTRHGBKKEI-OKILXGFUSA-N
DMWQ480	IU	(9R,10S)-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaene
DMWQ480	CA	CAS 61281-38-7
DMWQ480	DE	Discovery agent

DM645FP	ID	DM645FP
DM645FP	DN	SCOPOLETIN
DM645FP	HS	Investigative
DM645FP	SN	scopoletin; 92-61-5; Gelseminic acid; 6-Methylesculetin; 7-Hydroxy-6-methoxy-2H-chromen-2-one; Chrysatropic acid; Scopoletine; 7-Hydroxy-6-methoxycoumarin; Scopoletol; Murrayetin; 6-O-Methylesculetin; Escopoletin; 6-Methoxy-7-hydroxycoumarin; 7-Hydroxy-6-methoxy-2H-1-benzopyran-2-one; 6-Methoxyumbelliferone; 2H-1-Benzopyran-2-one, 7-hydroxy-6-methoxy-; Esculetin 6-methyl ether; beta-Methylesculetin; Esculetin-6-methyl ether; .beta.-Methylesculetin; Buxuletin; UNII-KLF1HS0SXJ; COUMARIN, 7-HYDROXY-6-METHOXY-
DM645FP	DT	Small molecular drug
DM645FP	PC	5280460
DM645FP	MW	192.17
DM645FP	FM	C10H8O4
DM645FP	IC	InChI=1S/C10H8O4/c1-13-9-4-6-2-3-10(12)14-8(6)5-7(9)11/h2-5,11H,1H3
DM645FP	CS	COC1=C(C=C2C(=C1)C=CC(=O)O2)O
DM645FP	IK	RODXRVNMMDRFIK-UHFFFAOYSA-N
DM645FP	IU	7-hydroxy-6-methoxychromen-2-one
DM645FP	CA	CAS 92-61-5
DM645FP	CB	CHEBI:17488
DM645FP	DE	Discovery agent

DMJD03I	ID	DMJD03I
DMJD03I	DN	SCUTELLAREIN
DMJD03I	HS	Investigative
DMJD03I	SN	Scutellarein; 529-53-3; 6-Hydroxyapigenin; 5,6,7,4'-Tetrahydroxyflavone; SCUTELLARTLN; 4',5,6,7-tetrahydroxyflavone; 4',5,6,7-Tetrahydroxyflavanone; UNII-P460GTI853; 5,6,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 5,6,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; CHEBI:9062; 5,6,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; JVXZRQGOGOXCEC-UHFFFAOYSA-N; P460GTI853; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-(4-hydroxyphenyl)-; Q-100602; 2-(4-hydroxyphenyl)-5,6,7-tris(oxidanyl)chromen-4-one; AC1NQYX1
DMJD03I	DT	Small molecular drug
DMJD03I	PC	5281697
DMJD03I	MW	286.24
DMJD03I	FM	C15H10O6
DMJD03I	IC	InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)11-5-9(17)13-12(21-11)6-10(18)14(19)15(13)20/h1-6,16,18-20H
DMJD03I	CS	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O)O
DMJD03I	IK	JVXZRQGOGOXCEC-UHFFFAOYSA-N
DMJD03I	IU	5,6,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one
DMJD03I	CA	CAS 529-53-3
DMJD03I	CB	CHEBI:9062
DMJD03I	DE	Discovery agent

DMQXUYH	ID	DMQXUYH
DMQXUYH	DN	SD-208
DMQXUYH	HS	Investigative
DMQXUYH	SN	SCI-208
DMQXUYH	DT	Small molecular drug
DMQXUYH	PC	10316032
DMQXUYH	MW	352.8
DMQXUYH	FM	C17H10ClFN6
DMQXUYH	IC	InChI=1S/C17H10ClFN6/c18-10-1-2-13(19)12(9-10)15-24-16-14(21-7-8-22-16)17(25-15)23-11-3-5-20-6-4-11/h1-9H,(H,20,22,23,24,25)
DMQXUYH	CS	C1=CC(=C(C=C1Cl)C2=NC3=NC=CN=C3C(=N2)NC4=CC=NC=C4)F
DMQXUYH	IK	BERLXWPRSBJFHO-UHFFFAOYSA-N
DMQXUYH	IU	2-(5-chloro-2-fluorophenyl)-N-pyridin-4-ylpteridin-4-amine
DMQXUYH	CA	CAS 627536-09-8
DMQXUYH	DE	Discovery agent

DMP3EXG	ID	DMP3EXG
DMP3EXG	DN	SDZ-205-557
DMP3EXG	HS	Investigative
DMP3EXG	SN	137196-67-9
DMP3EXG	DT	Small molecular drug
DMP3EXG	PC	5191
DMP3EXG	MW	300.78
DMP3EXG	FM	C14H21ClN2O3
DMP3EXG	IC	InChI=1S/C14H21ClN2O3/c1-4-17(5-2)6-7-20-14(18)10-8-11(15)12(16)9-13(10)19-3/h8-9H,4-7,16H2,1-3H3
DMP3EXG	CS	CCN(CC)CCOC(=O)C1=CC(=C(C=C1OC)N)Cl
DMP3EXG	IK	FFNWMBDISAYHDC-UHFFFAOYSA-N
DMP3EXG	IU	2-(diethylamino)ethyl 4-amino-5-chloro-2-methoxybenzoate
DMP3EXG	CA	CAS 137196-67-9
DMP3EXG	CB	CHEBI:92288
DMP3EXG	DE	Discovery agent

DMLPRU4	ID	DMLPRU4
DMLPRU4	DN	SDZ-208911
DMLPRU4	HS	Investigative
DMLPRU4	SN	SDZ-HAC-911; N-[(8alpha)-2,6-Dimethylergolin-8-yl]-2,2-dimethylpropanamide; N-(5,7-Dimethyl-4,6,6abeta,7,8,9,10,10aalpha-octahydroindolo[4,3-fg]quinolin-9alpha-yl)-2,2-dimethylpropanamide; 2,6-Dimethyl-8alpha-(2,2-dimethyl-1-oxopropylamino)ergoline
DMLPRU4	DT	Small molecular drug
DMLPRU4	PC	14277536
DMLPRU4	MW	339.5
DMLPRU4	FM	C21H29N3O
DMLPRU4	IC	InChI=1S/C21H29N3O/c1-12-15-10-18-16(14-7-6-8-17(22-12)19(14)15)9-13(11-24(18)5)23-20(25)21(2,3)4/h6-8,13,16,18,22H,9-11H2,1-5H3,(H,23,25)
DMLPRU4	CS	CC1=C2CC3C(CC(CN3C)NC(=O)C(C)(C)C)C4=C2C(=CC=C4)N1
DMLPRU4	IK	ZNMWUMGOSWLWOH-UHFFFAOYSA-N
DMLPRU4	IU	N-(5,7-dimethyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl)-2,2-dimethylpropanamide
DMLPRU4	DE	Psychotic disorder

DM3GJ07	ID	DM3GJ07
DM3GJ07	DN	SDZ-PDI-747
DM3GJ07	HS	Investigative
DM3GJ07	DE	Discovery agent

DMBYSEM	ID	DMBYSEM
DMBYSEM	DN	SDZ-PTS-893
DMBYSEM	HS	Investigative
DMBYSEM	SN	155383-07-6; PTH agonist, Sandoz
DMBYSEM	DE	Discovery agent

DMYSKI0	ID	DMYSKI0
DMYSKI0	DN	SE RNA
DMYSKI0	HS	Investigative
DMYSKI0	DT	Aptamer
DMYSKI0	DE	Human immunodeficiency virus infection

DMSB4WO	ID	DMSB4WO
DMSB4WO	DN	SEA
DMSB4WO	HS	Investigative
DMSB4WO	SN	N-stearoylethanolamine; stearoylethanolamide
DMSB4WO	DT	Small molecular drug
DMSB4WO	PC	27902
DMSB4WO	MW	327.5
DMSB4WO	FM	C20H41NO2
DMSB4WO	IC	InChI=1S/C20H41NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h22H,2-19H2,1H3,(H,21,23)
DMSB4WO	CS	CCCCCCCCCCCCCCCCCC(=O)NCCO
DMSB4WO	IK	OTGQIQQTPXJQRG-UHFFFAOYSA-N
DMSB4WO	IU	N-(2-hydroxyethyl)octadecanamide
DMSB4WO	CA	CAS 111-57-9
DMSB4WO	CB	CHEBI:85299
DMSB4WO	DE	Discovery agent

DME69PI	ID	DME69PI
DME69PI	DN	SEA-0400
DME69PI	HS	Investigative
DME69PI	SN	SEA0400; 223104-29-8; SEA-0400; SEA 0400; 2-(4-((2,5-DIFLUOROBENZYL)OXY)PHENOXY)-5-ETHOXYANILINE; 2-[4-[(2,5-Difluorophenyl)methoxy]phenoxy]-5-ethoxybenzenamine; 2-[4-[(2,5-Difluorobenzyl)oxy]phenoxy]-5-ethoxyaniline; 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline; 2-(4-(2,5-difluorobenzyloxy)phenoxy)-5-ethoxyaniline; 2-[4-(2,5-Difluorobenzyloxy)phenoxy]-5-ethoxyaniline; 2-{4-[(2,5-Difluorobenzyl)oxy]phenoxy}-5-ethoxyaniline; 2-{4-[(2,5-difluorophenyl)methoxy]phenoxy}-5-ethoxyaniline
DME69PI	CP	Taisho Pharmaceutical Co Ltd
DME69PI	DT	Small molecular drug
DME69PI	PC	644100
DME69PI	MW	371.4
DME69PI	FM	C21H19F2NO3
DME69PI	IC	InChI=1S/C21H19F2NO3/c1-2-25-18-8-10-21(20(24)12-18)27-17-6-4-16(5-7-17)26-13-14-11-15(22)3-9-19(14)23/h3-12H,2,13,24H2,1H3
DME69PI	CS	CCOC1=CC(=C(C=C1)OC2=CC=C(C=C2)OCC3=C(C=CC(=C3)F)F)N
DME69PI	IK	YSUBLPUJDOWYDP-UHFFFAOYSA-N
DME69PI	IU	2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline
DME69PI	CA	CAS 223104-29-8
DME69PI	DE	Cerebrovascular ischaemia

DM3VOPQ	ID	DM3VOPQ
DM3VOPQ	DN	SEBACIC ACID
DM3VOPQ	HS	Investigative
DM3VOPQ	SN	sebacic acid; DECANEDIOIC ACID; 111-20-6; 1,8-Octanedicarboxylic acid; 1,10-Decanedioic acid; Sebacic acids; Decanedicarboxylic acid; Sebacinsaure; n-Decanedioic acid; Acide sebacique; sebacate; Sebacinsaeure; USAF HC-1; Sebacinsaure [German]; Seracic acid; Acide sebacique [French]; UNII-97AN39ICTC; NSC 19492; Ipomic acid; CCRIS 2290; NSC19492; EINECS 203-845-5; BRN 1210591; 97AN39ICTC; AI3-09127; CHEBI:41865; CXMXRPHRNRROMY-UHFFFAOYSA-N; MFCD00004440; Sebacic acid, 98%; DSSTox_CID_6867; DSSTox_RID_78231; DSSTox_GSID_26867; Decanedioic ac
DM3VOPQ	DT	Small molecular drug
DM3VOPQ	PC	5192
DM3VOPQ	MW	202.25
DM3VOPQ	FM	C10H18O4
DM3VOPQ	IC	InChI=1S/C10H18O4/c11-9(12)7-5-3-1-2-4-6-8-10(13)14/h1-8H2,(H,11,12)(H,13,14)
DM3VOPQ	CS	C(CCCCC(=O)O)CCCC(=O)O
DM3VOPQ	IK	CXMXRPHRNRROMY-UHFFFAOYSA-N
DM3VOPQ	IU	decanedioic acid
DM3VOPQ	CA	CAS 111-20-6
DM3VOPQ	CB	CHEBI:41865
DM3VOPQ	DE	Discovery agent

DM9QSDC	ID	DM9QSDC
DM9QSDC	DN	Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9QSDC	HS	Investigative
DM9QSDC	SN	CHEMBL1269061; sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9QSDC	DT	Small molecular drug
DM9QSDC	PC	14151061
DM9QSDC	MW	268.31
DM9QSDC	FM	C16H16N2O2
DM9QSDC	IC	InChI=1S/C16H16N2O2/c1-3-10(2)20-16(19)14-8-12-11-6-4-5-7-13(11)18-15(12)9-17-14/h4-10,18H,3H2,1-2H3
DM9QSDC	CS	CCC(C)OC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DM9QSDC	IK	HRNSOLSYHZMSCD-UHFFFAOYSA-N
DM9QSDC	IU	butan-2-yl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9QSDC	DE	Discovery agent

DM76CUP	ID	DM76CUP
DM76CUP	DN	SECOCULARIDINE
DM76CUP	HS	Investigative
DM76CUP	SN	secocularidine; CHEMBL508081
DM76CUP	DT	Small molecular drug
DM76CUP	PC	44559879
DM76CUP	MW	341.4
DM76CUP	FM	C20H23NO4
DM76CUP	IC	InChI=1S/C20H23NO4/c1-21(2)10-9-13-6-8-16(22)20-15(13)7-5-14-11-18(23-3)19(24-4)12-17(14)25-20/h5-8,11-12,22H,9-10H2,1-4H3
DM76CUP	CS	CN(C)CCC1=C2C=CC3=CC(=C(C=C3OC2=C(C=C1)O)OC)OC
DM76CUP	IK	DBGGUODEECPLSS-UHFFFAOYSA-N
DM76CUP	IU	7-[2-(dimethylamino)ethyl]-2,3-dimethoxybenzo[b][1]benzoxepin-10-ol
DM76CUP	DE	Discovery agent

DMY7IVZ	ID	DMY7IVZ
DMY7IVZ	DN	Seco-exiguamine
DMY7IVZ	HS	Investigative
DMY7IVZ	DT	Small molecular drug
DMY7IVZ	PC	24856336
DMY7IVZ	DE	Discovery agent

DM9BJ27	ID	DM9BJ27
DM9BJ27	DN	Se-Ethyl-Isoselenourea
DM9BJ27	HS	Investigative
DM9BJ27	SN	SE-ETHYL-ISOSELENOUREA; ISU; ethyl imidoselenocarbamate; ethyl carbamimidoselenoate; AC1L9NBX; SCHEMBL5003626
DM9BJ27	DT	Small molecular drug
DM9BJ27	PC	449633
DM9BJ27	MW	151.08
DM9BJ27	FM	C3H8N2Se
DM9BJ27	IC	InChI=1S/C3H8N2Se/c1-2-6-3(4)5/h2H2,1H3,(H3,4,5)
DM9BJ27	CS	CC[Se]C(=N)N
DM9BJ27	IK	FFKYNFXDBBLWGF-UHFFFAOYSA-N
DM9BJ27	IU	ethyl carbamimidoselenoate
DM9BJ27	DE	Discovery agent

DMCQNT9	ID	DMCQNT9
DMCQNT9	DN	SE-ET-TP020d
DMCQNT9	HS	Investigative
DMCQNT9	CP	NascaCell GmbH
DMCQNT9	DE	Thrombocytopenia

DMFKE6C	ID	DMFKE6C
DMFKE6C	DN	SEL-73
DMFKE6C	HS	Investigative
DMFKE6C	SN	Antipsychotic, Selvita
DMFKE6C	CP	Selvita Life Sciences Solutions
DMFKE6C	DE	Psychiatric disorder

DMKSIVL	ID	DMKSIVL
DMKSIVL	DN	Selenazofurin
DMKSIVL	HS	Investigative
DMKSIVL	SN	Selenazofurin; 83705-13-9; UNII-I5R2V02E8Z; CI-935; 4-Selenazolecarboxamide, 2-beta-D-ribofuranosyl-; NSC 340847; BRN 4198668; I5R2V02E8Z; 2-beta-D-Ribofuranosyl-4-selenazolecarboxamide; 2-beta-D-Ribofuranosylselenazole-4-Carboxamide; C9H12N2O5Se; NSC340847; NSC-340847; RSC II; AC1L2P7R; SCHEMBL3051767; CHEMBL3144001; DTXSID80232569; CKMBACZHCFMPLQ-DBRKOABJSA-N; 2-ribofuranosylselenazole-4-carboxamide; PD-111232; LS-144766; 2 beta-ribofuranosylselenazole-4-carboxamide
DMKSIVL	DT	Small molecular drug
DMKSIVL	PC	100665
DMKSIVL	MW	307.17
DMKSIVL	FM	C9H12N2O5Se
DMKSIVL	IC	InChI=1S/C9H12N2O5Se/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1
DMKSIVL	CS	C1=C(N=C([Se]1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DMKSIVL	IK	CKMBACZHCFMPLQ-DBRKOABJSA-N
DMKSIVL	IU	2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-selenazole-4-carboxamide
DMKSIVL	CA	CAS 83705-13-9
DMKSIVL	DE	Discovery agent

DMXERWD	ID	DMXERWD
DMXERWD	DN	Selenazole-4-Carboxyamide-Adenine Dinucleotide
DMXERWD	HS	Investigative
DMXERWD	SN	SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE; SAE; AC1L9GCG; CHEMBL451855; DB03070; Selenazole-4-carboxamide adenine dinucleotide; 2-[5-O-(5'-Adenylyloxyphosphonyl)-beta-D-ribofuranosyl]selenazole-4-carboxamide; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(4-carbamoyl-1,3-selenazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl [(2R,3S,4R,5R)-5-(4-carbamoyl-1,
DMXERWD	DT	Small molecular drug
DMXERWD	PC	444451
DMXERWD	MW	716.4
DMXERWD	FM	C19H25N7O14P2Se
DMXERWD	IC	InChI=1S/C19H25N7O14P2Se/c20-15-9-17(23-4-22-15)26(5-24-9)19-13(30)11(28)8(39-19)2-37-42(34,35)40-41(32,33)36-1-7-10(27)12(29)14(38-7)18-25-6(3-43-18)16(21)31/h3-5,7-8,10-14,19,27-30H,1-2H2,(H2,21,31)(H,32,33)(H,34,35)(H2,20,22,23)/t7-,8-,10-,11-,12-,13-,14-,19-/m1/s1
DMXERWD	CS	C1=C(N=C([Se]1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N
DMXERWD	IK	SKNBJMQZTZPCPF-QZTLEVGFSA-N
DMXERWD	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(4-carbamoyl-1,3-selenazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMXERWD	DE	Discovery agent

DMB7GPA	ID	DMB7GPA
DMB7GPA	DN	Selenious acid
DMB7GPA	HS	Investigative
DMB7GPA	SN	Monohydrated selenium dioxide; SELENIOUS ACID; Selenious acid (H2SeO3); Selenious acid (USP); Selenious acid [USP]; Selenious acid, 98%; Selenite (SeO32-); Selenite ion(2-); Selenium dioxide, monohydrated; Selenous acid; Selenous acid, 98%; dihydroxidooxidoselenium; selenige Saeure; selenige Saure; 7783-00-8; AC1L1APE; CCRIS 5530; CHEBI:26642; DSSTox_CID_4300; EINECS 231-974-7; F6A27P4Q4R; HSDB 6065; MFCD00011331; Selenium, Reference Standard Solution; UNII-F6A27P4Q4R; selenious acid,selenous acid,monohydrated selenium dioxide
DMB7GPA	PC	1091
DMB7GPA	MW	128.99
DMB7GPA	FM	H2O3Se
DMB7GPA	IC	MCAHWIHFGHIESP-UHFFFAOYSA-N
DMB7GPA	CS	O[Se](=O)O
DMB7GPA	IK	1S/H2O3Se/c1-4(2)3/h(H2,1,2,3)
DMB7GPA	IU	selenous acid
DMB7GPA	CA	CAS 7783-00-8
DMB7GPA	CB	CHEBI:26642
DMB7GPA	DE	Discovery agent

DMBJ1E0	ID	DMBJ1E0
DMBJ1E0	DN	Selumetinib
DMBJ1E0	HS	Investigative
DMBJ1E0	SN	Selumetinib; AZD-6244; ARRY142886; AZD6244; ARRY142886; AZD 6244; AZD-6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
DMBJ1E0	CP	AstraZeneca
DMBJ1E0	TC	Antiviral Agents
DMBJ1E0	DT	Small molecular drug
DMBJ1E0	PC	10127622
DMBJ1E0	MW	457.7
DMBJ1E0	FM	C17H15BrClFN4O3
DMBJ1E0	IC	InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
DMBJ1E0	CS	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
DMBJ1E0	IK	CYOHGALHFOKKQC-UHFFFAOYSA-N
DMBJ1E0	IU	6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
DMBJ1E0	CA	CAS 606143-52-6
DMBJ1E0	CB	CHEBI:90227
DMBJ1E0	DE	Pediatric neurofibromatosis type 1; Discovery agent; Melanoma; Non-small-cell lung cancer; Thyroid cancer; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMDIZUT	ID	DMDIZUT
DMDIZUT	DN	SEM-606
DMDIZUT	HS	Investigative
DMDIZUT	SN	SEM-304; Abeta amyloid synthesis inhibitors (neurological disorders), University of Manchester
DMDIZUT	CP	University of Manchester
DMDIZUT	DE	Neurological disorder

DMW5SIQ	ID	DMW5SIQ
DMW5SIQ	DN	SEMIPLENAMIDE A
DMW5SIQ	HS	Investigative
DMW5SIQ	SN	semiplenamide A; CHEMBL459704
DMW5SIQ	DT	Small molecular drug
DMW5SIQ	PC	10384247
DMW5SIQ	MW	365.6
DMW5SIQ	FM	C23H43NO2
DMW5SIQ	IC	InChI=1S/C23H43NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(2)23(26)24-20-21-25/h15-16,19,25H,3-14,17-18,20-21H2,1-2H3,(H,24,26)/b16-15+,22-19+
DMW5SIQ	CS	CCCCCCCCCCCCC/C=C/CC/C=C(\\C)/C(=O)NCCO
DMW5SIQ	IK	SJZSLZDOZDKKND-JWGQYYPISA-N
DMW5SIQ	IU	(2E,6E)-N-(2-hydroxyethyl)-2-methylicosa-2,6-dienamide
DMW5SIQ	DE	Discovery agent

DMHWCFJ	ID	DMHWCFJ
DMHWCFJ	DN	SEMIPLENAMIDE B
DMHWCFJ	HS	Investigative
DMHWCFJ	SN	Semiplenamide B; CHEMBL465162
DMHWCFJ	DT	Small molecular drug
DMHWCFJ	PC	10454085
DMHWCFJ	MW	407.6
DMHWCFJ	FM	C25H45NO3
DMHWCFJ	IC	InChI=1S/C25H45NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23(2)25(28)26-21-22-29-24(3)27/h16-17,20H,4-15,18-19,21-22H2,1-3H3,(H,26,28)/b17-16+,23-20+
DMHWCFJ	CS	CCCCCCCCCCCCC/C=C/CC/C=C(\\C)/C(=O)NCCOC(=O)C
DMHWCFJ	IK	QXKJTHBWYQHGEY-UEAIFQQQSA-N
DMHWCFJ	IU	2-[[(2E,6E)-2-methylicosa-2,6-dienoyl]amino]ethyl acetate
DMHWCFJ	DE	Discovery agent

DM4RP0A	ID	DM4RP0A
DM4RP0A	DN	Semiplenamide G
DM4RP0A	HS	Investigative
DM4RP0A	SN	Semiplenamide G; CHEMBL466777
DM4RP0A	DT	Small molecular drug
DM4RP0A	PC	21589501
DM4RP0A	MW	411.6
DM4RP0A	FM	C24H45NO4
DM4RP0A	IC	InChI=1S/C24H45NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-22-24(4,29-22)23(27)25-20(2)19-28-21(3)26/h20,22H,5-19H2,1-4H3,(H,25,27)/t20?,22-,24+/m1/s1
DM4RP0A	CS	CCCCCCCCCCCCCCC[C@@H]1[C@@](O1)(C)C(=O)NC(C)COC(=O)C
DM4RP0A	IK	MILXVDLKZSMGBO-ZUBLCLOHSA-N
DM4RP0A	IU	2-[[(2S,3R)-2-methyl-3-pentadecyloxirane-2-carbonyl]amino]propyl acetate
DM4RP0A	DE	Discovery agent

DM1C5GZ	ID	DM1C5GZ
DM1C5GZ	DN	Semorphone
DM1C5GZ	HS	Investigative
DM1C5GZ	SN	(-)-4,5alpha-Epoxy-3,14-dihydroxy-17-(2-methoxyethyl)morphinan-6-one hydrochloride; (-)-4,5alpha-Epoxy-3,14-dihydroxy-N-(2-methoxyethyl)morphinan-6-one hydrochloride; MR-2264 (free base); MRZ-2264 (free base); N-(2-Methoxyethyl)noroxymorphone hydrochloride; Semorphone hydrochloride 
DM1C5GZ	DT	Small molecular drug
DM1C5GZ	PC	5491906
DM1C5GZ	MW	345.4
DM1C5GZ	FM	C19H23NO5
DM1C5GZ	IC	InChI=1S/C19H23NO5/c1-24-9-8-20-7-6-18-15-11-2-3-12(21)16(15)25-17(18)13(22)4-5-19(18,23)14(20)10-11/h2-3,14,17,21,23H,4-10H2,1H3/t14-,17+,18+,19-/m1/s1
DM1C5GZ	CS	COCCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
DM1C5GZ	IK	PBGIBLLOMGURPS-GRGSLBFTSA-N
DM1C5GZ	IU	(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-(2-methoxyethyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM1C5GZ	CA	88939-40-6
DM1C5GZ	DE	Discovery agent

DMKB2IJ	ID	DMKB2IJ
DMKB2IJ	DN	SEN-1500
DMKB2IJ	HS	Investigative
DMKB2IJ	SN	SEN-1576; Beta-amyloid aggregation inhibitors (Alzheimer's disease); Beta-amyloid aggregation inhibitors (Alzheimer's disease), Senexis
DMKB2IJ	CP	Senexis Ltd
DMKB2IJ	PC	54589394
DMKB2IJ	MW	391.4
DMKB2IJ	FM	C21H18FN5O2
DMKB2IJ	IC	InChI=1S/C21H18FN5O2/c22-20-5-4-16(10-15(20)12-23)26-21-24-13-19(14-25-21)29-18-3-1-2-17(11-18)27-6-8-28-9-7-27/h1-5,10-11,13-14H,6-9H2,(H,24,25,26)
DMKB2IJ	CS	C1COCCN1C2=CC(=CC=C2)OC3=CN=C(N=C3)NC4=CC(=C(C=C4)F)C#N
DMKB2IJ	IK	RQBIQZWMNRERQQ-UHFFFAOYSA-N
DMKB2IJ	IU	2-fluoro-5-[[5-(3-morpholin-4-ylphenoxy)pyrimidin-2-yl]amino]benzonitrile
DMKB2IJ	DE	Alzheimer disease

DMRJIP4	ID	DMRJIP4
DMRJIP4	DN	Septide
DMRJIP4	HS	Investigative
DMRJIP4	SN	Septide; 5-Oxo-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-leucyl-L-methioninamide; Glp-phe-phe-pro-leu-met-NH2; Pglu-phe-phe-pro-leu-met-NH2; Pglu(6)-pro(9)-SP(6-11); 6-Glp-9-pro-substance P (6-11); Substance P (6-11), glp(6)-pro(9)-; Substance P (6-11), pyroglutamyl(6)-proline(9)-; 79775-19-2; L-Methioninamide, 5-oxo-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-leucyl-
DMRJIP4	DT	Small molecular drug
DMRJIP4	PC	119137
DMRJIP4	MW	763.9
DMRJIP4	FM	C39H53N7O7S
DMRJIP4	IC	InChI=1S/C39H53N7O7S/c1-24(2)21-29(36(50)42-27(34(40)48)18-20-54-3)44-38(52)32-15-10-19-46(32)39(53)31(23-26-13-8-5-9-14-26)45-37(51)30(22-25-11-6-4-7-12-25)43-35(49)28-16-17-33(47)41-28/h4-9,11-14,24,27-32H,10,15-23H2,1-3H3,(H2,40,48)(H,41,47)(H,42,50)(H,43,49)(H,44,52)(H,45,51)/t27-,28-,29-,30-,31-,32-/m0/s1
DMRJIP4	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCC(=O)N4
DMRJIP4	IK	UUZURPUIMYJOIL-JNRWAQIZSA-N
DMRJIP4	IU	(2S)-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMRJIP4	CA	CAS 79775-19-2
DMRJIP4	DE	Discovery agent

DMIKT7W	ID	DMIKT7W
DMIKT7W	DN	SER-203
DMIKT7W	HS	Investigative
DMIKT7W	SN	Pendant POZ conjugate (cancer/inflammation), Serina
DMIKT7W	CP	Serina Therapeutics Inc
DMIKT7W	DE	Solid tumour/cancer

DMF8GAX	ID	DMF8GAX
DMF8GAX	DN	sergliflozin
DMF8GAX	HS	Investigative
DMF8GAX	SN	Sergliflozin; Sergliflozin etabonate; 408504-26-7; UNII-4HY3523466; GW869682X; 4HY3523466; 2-(4-Methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-beta-D-glucopyranoside; 2-[(4-Methoxyphenyl)methyl]phenyl-beta-D-glucopyranoside-6-(ethyl carbonate); CHEMBL450044; Sergliflozin etabonate [USAN:INN]; SCHEMBL621807; Sergliflozin etabonate (USAN); GTPL4587; gsk-869682; QLXKHBNJTPICNF-QMCAAQAGSA-N; ZINC3974200; AN-28459; D06641; 504M267; 2-(4-methoxybenzyl)phenyl 6-O-ethoxycarbonyl-beta-D-glucopyranoside; beta-D-Glucopyranoside, 2-((4-methoxy
DMF8GAX	DT	Small molecular drug
DMF8GAX	PC	9824918
DMF8GAX	MW	448.5
DMF8GAX	FM	C23H28O9
DMF8GAX	IC	InChI=1S/C23H28O9/c1-3-29-23(27)30-13-18-19(24)20(25)21(26)22(32-18)31-17-7-5-4-6-15(17)12-14-8-10-16(28-2)11-9-14/h4-11,18-22,24-26H,3,12-13H2,1-2H3/t18-,19-,20+,21-,22-/m1/s1
DMF8GAX	CS	CCOC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=CC=CC=C2CC3=CC=C(C=C3)OC)O)O)O
DMF8GAX	IK	QLXKHBNJTPICNF-QMCAAQAGSA-N
DMF8GAX	IU	ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate
DMF8GAX	CA	CAS 408504-26-7
DMF8GAX	DE	Discovery agent

DM6FVCE	ID	DM6FVCE
DM6FVCE	DN	Sergliflozin A
DM6FVCE	HS	Investigative
DM6FVCE	SN	SERGLIFLOZIN A; UNII-AR34521QFL; CHEMBL270766; AR34521QFL; O-glucoside, 4a; SCHEMBL2574820; BDBM20878; beta-D-Glucopyranoside, 2-((4-methoxyphenyl)methyl)phenyl; HFLCZNNDZKKXCS-OUUBHVDSSA-N; J3.551.075C; 2-(4-methoxybenzyl)phenyl betaD-glucopyranoside; 2-(4-methoxybenzyl)phenyl beta-D-glucopyranoside; 2-(4-methoxybenzyl)-phenyl beta-D-glucopyranoside; 2-(4-methoxy-benzyl)phenyl beta-D-glucopyranoside; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-{2-[(4-methoxyphenyl)methyl]phenoxy}oxane-3,4,5-triol
DM6FVCE	DT	Small molecular drug
DM6FVCE	PC	10177526
DM6FVCE	MW	376.4
DM6FVCE	FM	C20H24O7
DM6FVCE	IC	InChI=1S/C20H24O7/c1-25-14-8-6-12(7-9-14)10-13-4-2-3-5-15(13)26-20-19(24)18(23)17(22)16(11-21)27-20/h2-9,16-24H,10-11H2,1H3/t16-,17-,18+,19-,20-/m1/s1
DM6FVCE	CS	COC1=CC=C(C=C1)CC2=CC=CC=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
DM6FVCE	IK	HFLCZNNDZKKXCS-OUUBHVDSSA-N
DM6FVCE	IU	(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxane-3,4,5-triol
DM6FVCE	CA	CAS 360775-96-8
DM6FVCE	DE	Discovery agent

DM4ZYKV	ID	DM4ZYKV
DM4ZYKV	DN	SERMs
DM4ZYKV	HS	Investigative
DM4ZYKV	SN	SERMs (cancer); SERMs (cancer), CEAMED; Selective estrogen receptor modulators (cancer), CEAMAD
DM4ZYKV	CP	CEAMED SA
DM4ZYKV	DE	Solid tumour/cancer

DMOFCRY	ID	DMOFCRY
DMOFCRY	DN	Serotonin
DMOFCRY	HS	Investigative
DMOFCRY	SN	serotonin; 5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Serotonine; Thrombotonin; Thrombocytin; Antemovis; Ds substance; Hippophain; Antemoqua; Substance DS; Substanz DS; 1H-Indol-5-ol, 3-(2-aminoethyl)-; 5-Hta; Tryptamine, 5-hydroxy-; 3-(2-Aminoethyl)indol-5-ol; Enteramin; UNII-333DO1RDJY; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxy-3-(beta-aminoethyl)indole; 3-(beta-Aminoethyl)-5-hydroxyindole; EINECS 200-058-9; 3-(2-Amino-ethyl)-1H-indol-5-ol; BRN 0143524; 333DO1RDJY; CHEBI:28790
DMOFCRY	DT	Small molecular drug
DMOFCRY	PC	5202
DMOFCRY	MW	176.21
DMOFCRY	FM	C10H12N2O
DMOFCRY	IC	InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2
DMOFCRY	CS	C1=CC2=C(C=C1O)C(=CN2)CCN
DMOFCRY	IK	QZAYGJVTTNCVMB-UHFFFAOYSA-N
DMOFCRY	IU	3-(2-aminoethyl)-1H-indol-5-ol
DMOFCRY	CA	CAS 50-67-9
DMOFCRY	CB	CHEBI:28790
DMOFCRY	DE	Discovery agent

DMS509U	ID	DMS509U
DMS509U	DN	Ser-Tyr-Ser-Nle-Glu-His-Dphe-Arg
DMS509U	HS	Investigative
DMS509U	PC	91971100
DMS509U	MW	1605.8
DMS509U	FM	C76H108N20O19
DMS509U	IC	InChI=1S/C76H108N20O19/c1-4-5-18-51(88-72(111)59(40-98)94-70(109)55(90-64(103)49(78)39-97)33-44-23-25-47(99)26-24-44)66(105)89-53(27-28-62(101)102)68(107)93-58(35-46-37-81-41-85-46)71(110)91-56(32-43-15-7-6-8-16-43)69(108)87-52(21-13-30-82-76(79)80)67(106)92-57(34-45-36-83-50-19-10-9-17-48(45)50)65(104)84-38-61(100)86-54(20-11-12-29-77)74(113)96-31-14-22-60(96)73(112)95-63(42(2)3)75(114)115/h6-10,15-17,19,23-26,36-37,41-42,49,51-60,63,83,97-99H,4-5,11-14,18,20-22,27-35,38-40,77-78H2,1-3H3,(H,81,85)(H,84,104)(H,86,100)(H,87,108)(H,88,111)(H,89,105)(H,90,103)(H,91,110)(H,92,106)(H,93,107)(H,94,109)(H,95,112)(H,101,102)(H,114,115)(H4,79,80,82)/t49-,51-,52-,53-,54-,55-,56+,57-,58-,59-,60-,63-/m0/s1
DMS509U	CS	CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)N
DMS509U	IK	RLJQBYDPIVYMOS-PVTUMTKLSA-N
DMS509U	IU	(4S)-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(1S)-1-carboxy-2-methylpropyl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoic acid
DMS509U	DE	Discovery agent

DM49AYM	ID	DM49AYM
DM49AYM	DN	S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
DM49AYM	HS	Investigative
DM49AYM	SN	TFPI hydrochloride; ETPI HCl; 163490-78-6; s-ethyl-n-[4-(trifluoromethyl)phenyl]isothiourea hydrochloride; S-Ethyl N-[4-Triflurormethyl)phenyl]isothio Urea, Hydrochloride; CHEMBL542855; SR-01000076170; EU-0101170; AC1MBZ30; C10H11F3N2S.HCl; SCHEMBL4425282; MolPort-027-641-133; 1762AH; NCGC00094428-04; NCGC00094428-03; NCGC00094428-02; NCGC00094428-01; FT-0668409; T 7188; J-010049; SR-01000076170-4; SR-01000076170-1; S-Ethyl N-[4-(trifluoromethyl)phenyl]isothiourea hydrochloride; ethyl 4-(trifluoromethyl)phenylcarbamimidothioate h
DM49AYM	DT	Small molecular drug
DM49AYM	PC	3311
DM49AYM	MW	248.27
DM49AYM	FM	C10H11F3N2S
DM49AYM	IC	InChI=1S/C10H11F3N2S/c1-2-16-9(14)15-8-5-3-7(4-6-8)10(11,12)13/h3-6H,2H2,1H3,(H2,14,15)
DM49AYM	CS	CCSC(=NC1=CC=C(C=C1)C(F)(F)F)N
DM49AYM	IK	LCMOXIFARISMOH-UHFFFAOYSA-N
DM49AYM	IU	ethyl N'-[4-(trifluoromethyl)phenyl]carbamimidothioate
DM49AYM	CA	CAS 163490-40-2
DM49AYM	DE	Discovery agent

DM6DT9Z	ID	DM6DT9Z
DM6DT9Z	DN	S-Ethyl-N-Phenyl-Isothiourea
DM6DT9Z	HS	Investigative
DM6DT9Z	SN	S-ETHYL-N-PHENYL-ISOTHIOUREA; 19801-34-4; 2-ETHYL-1-PHENYL-ISOTHIOUREA; S-Ethyl N-Phenylisothiourea; CHEMBL451666; Carbamimidothioic acid,N-phenyl-, ethyl ester; CHEMBL545673; S-Ethyl N-Phenylisothio Urea; S-ethyl-N-phenylisothiourea; AC1L87NW; 1-Phenyl-2-ethylisothiourea; SCHEMBL1387773; CTK4E2382; ethyl N'-phenylimidothiocarbamate; ethyl N'-phenylcarbamimidothioate; DTXSID00324314; LAXNJIWNBHHMDO-UHFFFAOYSA-N; ZINC6001367; FCH829155; BDBM50058459; 2-Ethyl-1-phenyl-2-thio-pseudourea; N-phenyl(ethylsulfanyl)methanimidamide
DM6DT9Z	DT	Small molecular drug
DM6DT9Z	PC	347590
DM6DT9Z	MW	180.27
DM6DT9Z	FM	C9H12N2S
DM6DT9Z	IC	InChI=1S/C9H12N2S/c1-2-12-9(10)11-8-6-4-3-5-7-8/h3-7H,2H2,1H3,(H2,10,11)
DM6DT9Z	CS	CCSC(=NC1=CC=CC=C1)N
DM6DT9Z	IK	LAXNJIWNBHHMDO-UHFFFAOYSA-N
DM6DT9Z	IU	ethyl N'-phenylcarbamimidothioate
DM6DT9Z	CA	CAS 19801-34-4
DM6DT9Z	DE	Discovery agent

DMJBW7X	ID	DMJBW7X
DMJBW7X	DN	SEW2871
DMJBW7X	HS	Investigative
DMJBW7X	SN	SEW-2871; SEW 2871
DMJBW7X	DT	Small molecular drug
DMJBW7X	PC	4077460
DMJBW7X	MW	440.4
DMJBW7X	FM	C20H10F6N2OS
DMJBW7X	IC	InChI=1S/C20H10F6N2OS/c21-19(22,23)13-8-4-7-12(9-13)17-27-18(29-28-17)15-10-14(11-5-2-1-3-6-11)16(30-15)20(24,25)26/h1-10H
DMJBW7X	CS	C1=CC=C(C=C1)C2=C(SC(=C2)C3=NC(=NO3)C4=CC(=CC=C4)C(F)(F)F)C(F)(F)F
DMJBW7X	IK	OYMNPJXKQVTQTR-UHFFFAOYSA-N
DMJBW7X	IU	5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
DMJBW7X	CA	CAS 256414-75-2
DMJBW7X	CB	CHEBI:92283
DMJBW7X	DE	Discovery agent

DMVI2H9	ID	DMVI2H9
DMVI2H9	DN	SF-11
DMVI2H9	HS	Investigative
DMVI2H9	SN	TCMDC-124500; MLS001111122; SMR000457056; 3-(4-chlorophenyl)-5-methyl-4-[2-(4-methylphenyl)sulfonylpyrazol-3-yl]-1,2-oxazole; 3-(4-chlorophenyl)-5-methyl-4-{1-[(4-methylphenyl)sulfonyl]-1H-pyrazol-5-yl}isoxazole; SR-01000768170; AC1MCJZ0; CHEMBL548708; GTPL6404; cid_2745583; BDBM46991; HMS1669J02; SR-01000768170-4; SR-01000768170-3; SR-01000768170-2; 3-(4-chlorophenyl)-5-methyl-4-(2-tosylpyrazol-3-yl)isoxazole
DMVI2H9	DT	Small molecular drug
DMVI2H9	PC	2745583
DMVI2H9	MW	413.9
DMVI2H9	FM	C20H16ClN3O3S
DMVI2H9	IC	InChI=1S/C20H16ClN3O3S/c1-13-3-9-17(10-4-13)28(25,26)24-18(11-12-22-24)19-14(2)27-23-20(19)15-5-7-16(21)8-6-15/h3-12H,1-2H3
DMVI2H9	CS	CC1=CC=C(C=C1)S(=O)(=O)N2C(=CC=N2)C3=C(ON=C3C4=CC=C(C=C4)Cl)C
DMVI2H9	IK	WFFKVDICECGSHN-UHFFFAOYSA-N
DMVI2H9	IU	3-(4-chlorophenyl)-5-methyl-4-[2-(4-methylphenyl)sulfonylpyrazol-3-yl]-1,2-oxazole
DMVI2H9	DE	Discovery agent

DMI6SNQ	ID	DMI6SNQ
DMI6SNQ	DN	SF-21
DMI6SNQ	HS	Investigative
DMI6SNQ	SN	MLS000713637; 4-chloro-N-(2-morpholin-4-ylcyclohexyl)benzenesulfonamide; SMR000273118; SR-01000500139; SF-21; AC1MEZXV; BAS 03787124; Oprea1_235657; Oprea1_704083; GTPL6405; CHEMBL1521361; cid_2911646; CHEBI:91729; BDBM46952; MolPort-000-302-377; HMS2652F10; ML123; STL298589; AKOS000622769; AKOS022139764; CCG-143112; MCULE-3861940652; 384352-24-3; UNM000000650501; SR-01000500139-1; SR-01000500139-3; 4-chloro-N-(2-morpholinocyclohexyl)benzenesulfonamide; 4-chloro-N-(2-morpholinocyclohexyl)-1-benzenesulfonamide
DMI6SNQ	DT	Small molecular drug
DMI6SNQ	PC	2911646
DMI6SNQ	MW	358.9
DMI6SNQ	FM	C16H23ClN2O3S
DMI6SNQ	IC	InChI=1S/C16H23ClN2O3S/c17-13-5-7-14(8-6-13)23(20,21)18-15-3-1-2-4-16(15)19-9-11-22-12-10-19/h5-8,15-16,18H,1-4,9-12H2
DMI6SNQ	CS	C1CCC(C(C1)NS(=O)(=O)C2=CC=C(C=C2)Cl)N3CCOCC3
DMI6SNQ	IK	AYQCZQKMGKDZPS-UHFFFAOYSA-N
DMI6SNQ	IU	4-chloro-N-(2-morpholin-4-ylcyclohexyl)benzenesulfonamide
DMI6SNQ	CB	CHEBI:91729
DMI6SNQ	DE	Discovery agent

DMH36A9	ID	DMH36A9
DMH36A9	DN	SF303
DMH36A9	HS	Investigative
DMH36A9	DT	Small molecular drug
DMH36A9	PC	6918369
DMH36A9	DE	Discovery agent

DMP35VS	ID	DMP35VS
DMP35VS	DN	SGC0946
DMP35VS	HS	Investigative
DMP35VS	SN	SGC0946; 1561178-17-3; SGC 0946; CHEMBL3087498; SGC-0946; 5-Bromo-7-{5-[(3-{[(4-Tert-Butylphenyl)carbamoyl]amino}propyl)(Propan-2-Yl)amino]-5-Deoxy-Beta-D-Ribofuranosyl}-7h-Pyrrolo[2,3-D]pyrimidin-4-Amine; 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea; MLS006011035; C28H40BrN7O4; GTPL7020; SCHEMBL17433345; AOB3554; EX-A321; MolPort-028-720-498; ZINC97956664; s7079; BDBM50443016; 2714AH; AKOS024458211
DMP35VS	DT	Small molecular drug
DMP35VS	PC	56962337
DMP35VS	MW	618.6
DMP35VS	FM	C28H40BrN7O4
DMP35VS	IC	InChI=1S/C28H40BrN7O4/c1-16(2)35(12-6-11-31-27(39)34-18-9-7-17(8-10-18)28(3,4)5)14-20-22(37)23(38)26(40-20)36-13-19(29)21-24(30)32-15-33-25(21)36/h7-10,13,15-16,20,22-23,26,37-38H,6,11-12,14H2,1-5H3,(H2,30,32,33)(H2,31,34,39)/t20-,22-,23-,26-/m1/s1
DMP35VS	CS	CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)C[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=C(C4=C(N=CN=C43)N)Br)O)O
DMP35VS	IK	IQCKJUKAQJINMK-HUBRGWSESA-N
DMP35VS	IU	1-[3-[[(2R,3S,4R,5R)-5-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea
DMP35VS	CA	CAS 1561178-17-3
DMP35VS	DE	Discovery agent

DMGINBT	ID	DMGINBT
DMGINBT	DN	SGC707
DMGINBT	HS	Investigative
DMGINBT	SN	1687736-54-4; SGC 707; SGC-707; 1-Isoquinolin-6-Yl-3-[2-Oxo-2-(Pyrrolidin-1-Yl)ethyl]urea; GTPL8552; KS-00000THM; AOB5757; MolPort-039-101-300; EX-A1304; BCP16746; s7832; ZINC220951188; AKOS025142099; CS-5370; ACN-053041; NCGC00384204-04; HY-19715; AK546586; SGC707, &gt; AS-16917; FT-0700238; J-690235; 1-isoquinolin-6-yl-3-(2-oxo-2-pyrrolidin-1-ylethyl)urea; 1-(isoquinolin-6-yl)-3-[2-oxo-2-(pyrrolidin-1-yl)ethyl]urea; 1-(Isoquinolin-6-yl)-3-[2-oxo-2-(pyrrolidin-1-yl)ethyl] urea
DMGINBT	DT	Small molecular drug
DMGINBT	PC	90642938
DMGINBT	MW	298.34
DMGINBT	FM	C16H18N4O2
DMGINBT	IC	InChI=1S/C16H18N4O2/c21-15(20-7-1-2-8-20)11-18-16(22)19-14-4-3-13-10-17-6-5-12(13)9-14/h3-6,9-10H,1-2,7-8,11H2,(H2,18,19,22)
DMGINBT	CS	C1CCN(C1)C(=O)CNC(=O)NC2=CC3=C(C=C2)C=NC=C3
DMGINBT	IK	DMIDPTCQPIJYFE-UHFFFAOYSA-N
DMGINBT	IU	1-isoquinolin-6-yl-3-(2-oxo-2-pyrrolidin-1-ylethyl)urea
DMGINBT	DE	Discovery agent

DMTLRGZ	ID	DMTLRGZ
DMTLRGZ	DN	SGC-CBP30
DMTLRGZ	HS	Investigative
DMTLRGZ	SN	SGC-CBP30; 1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256
DMTLRGZ	DT	Small molecular drug
DMTLRGZ	PC	72201027
DMTLRGZ	MW	509
DMTLRGZ	FM	C28H33ClN4O3
DMTLRGZ	IC	InChI=1S/C28H33ClN4O3/c1-18(32-11-13-35-14-12-32)17-33-25-8-7-22(28-19(2)31-36-20(28)3)16-24(25)30-27(33)10-6-21-5-9-26(34-4)23(29)15-21/h5,7-9,15-16,18H,6,10-14,17H2,1-4H3/t18-/m0/s1
DMTLRGZ	CS	CC1=C(C(=NO1)C)C2=CC3=C(C=C2)N(C(=N3)CCC4=CC(=C(C=C4)OC)Cl)C[C@H](C)N5CCOCC5
DMTLRGZ	IK	GEPYBHCJBORHCE-SFHVURJKSA-N
DMTLRGZ	IU	4-[(2S)-1-[2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)benzimidazol-1-yl]propan-2-yl]morpholine
DMTLRGZ	DE	Discovery agent

DMZ20A5	ID	DMZ20A5
DMZ20A5	DN	SGI-1252
DMZ20A5	HS	Investigative
DMZ20A5	SN	JAK2 inhibitors (cancer), SuperGen; Janus-activated kinase-2 inhibitors (cancer), SuperGen
DMZ20A5	CP	SuperGen Inc
DMZ20A5	DE	Solid tumour/cancer

DMW7E32	ID	DMW7E32
DMW7E32	DN	SHA 68
DMW7E32	HS	Investigative
DMW7E32	SN	SHA-68; SHA68
DMW7E32	DT	Small molecular drug
DMW7E32	PC	11374217
DMW7E32	MW	445.5
DMW7E32	FM	C26H24FN3O3
DMW7E32	IC	InChI=1S/C26H24FN3O3/c27-22-13-11-19(12-14-22)17-28-24(31)29-15-16-30-23(18-29)26(33-25(30)32,20-7-3-1-4-8-20)21-9-5-2-6-10-21/h1-14,23H,15-18H2,(H,28,31)
DMW7E32	CS	C1CN2C(CN1C(=O)NCC3=CC=C(C=C3)F)C(OC2=O)(C4=CC=CC=C4)C5=CC=CC=C5
DMW7E32	IK	SFRQIPRTNYHJHP-UHFFFAOYSA-N
DMW7E32	IU	N-[(4-fluorophenyl)methyl]-3-oxo-1,1-diphenyl-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide
DMW7E32	DE	Discovery agent

DMODS9A	ID	DMODS9A
DMODS9A	DN	S-hexyl hexane-1-sulfinothioate
DMODS9A	HS	Investigative
DMODS9A	SN	S-hexyl hexane-1-sulfinothioate; CHEMBL1224171; 131904-37-5; BDBM50325651; Hexane-1-thiosulfinic acid S-hexyl ester
DMODS9A	DT	Small molecular drug
DMODS9A	PC	14849212
DMODS9A	MW	250.5
DMODS9A	FM	C12H26OS2
DMODS9A	IC	InChI=1S/C12H26OS2/c1-3-5-7-9-11-14-15(13)12-10-8-6-4-2/h3-12H2,1-2H3
DMODS9A	CS	CCCCCCSS(=O)CCCCCC
DMODS9A	IK	FBPVGCZBKKKGRF-UHFFFAOYSA-N
DMODS9A	IU	1-hexylsulfinylsulfanylhexane
DMODS9A	DE	Discovery agent

DMNWP02	ID	DMNWP02
DMNWP02	DN	S-hexylglutathione
DMNWP02	HS	Investigative
DMNWP02	DT	Small molecular drug
DMNWP02	PC	97536
DMNWP02	MW	391.5
DMNWP02	FM	C16H29N3O6S
DMNWP02	IC	InChI=1S/C16H29N3O6S/c1-2-3-4-5-8-26-10-12(15(23)18-9-14(21)22)19-13(20)7-6-11(17)16(24)25/h11-12H,2-10,17H2,1H3,(H,18,23)(H,19,20)(H,21,22)(H,24,25)/t11-,12-/m0/s1
DMNWP02	CS	CCCCCCSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N
DMNWP02	IK	HXJDWCWJDCOHDG-RYUDHWBXSA-N
DMNWP02	IU	(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-hexylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMNWP02	CA	CAS 24425-56-7
DMNWP02	CB	CHEBI:27704
DMNWP02	DE	Discovery agent

DMBE0CT	ID	DMBE0CT
DMBE0CT	DN	Shikimate-3-Phosphate
DMBE0CT	HS	Investigative
DMBE0CT	SN	shikimate-3-phosphate; 3-phosphoshikimic acid; Shikimate 5-phosphate; Shikimate 3-phosphate; 63959-45-5; CHEBI:17052; (3R,4S,5R)-4,5-dihydroxy-3-phosphonooxycyclohexene-1-carboxylic acid; rel-(3R,4S,5R)-4,5-dihydroxy-3-(phosphonooxy)cyclohex-1-ene-1-carboxylic acid; S3P; AC1L3TPD; Shikimic acid 3-phosphate; AC1Q6RU9; SCHEMBL67425; CHEMBL95193; CTK2F4097; BDBM100283; ZINC3870237; DB04328; 1-cyclohexene-1-carboxylic acid, 4,5-dihydroxy-3-(phosphonooxy)-,(3r,4s,5r)-; FT-0674570; C03175; 3-Phosphoshikimic acid lithium salt, &gt
DMBE0CT	DT	Small molecular drug
DMBE0CT	PC	121947
DMBE0CT	MW	254.13
DMBE0CT	FM	C7H11O8P
DMBE0CT	IC	InChI=1S/C7H11O8P/c8-4-1-3(7(10)11)2-5(6(4)9)15-16(12,13)14/h2,4-6,8-9H,1H2,(H,10,11)(H2,12,13,14)/t4-,5-,6+/m1/s1
DMBE0CT	CS	C1[C@H]([C@@H]([C@@H](C=C1C(=O)O)OP(=O)(O)O)O)O
DMBE0CT	IK	QYOJSKGCWNAKGW-PBXRRBTRSA-N
DMBE0CT	IU	(3R,4S,5R)-4,5-dihydroxy-3-phosphonooxycyclohexene-1-carboxylic acid
DMBE0CT	CA	CAS 63959-45-5
DMBE0CT	CB	CHEBI:17052
DMBE0CT	DE	Discovery agent

DMTKHR3	ID	DMTKHR3
DMTKHR3	DN	ShRNA molecule silencing DNAPK radiosensitizer
DMTKHR3	HS	Investigative
DMTKHR3	SN	ShRNA molecule silencing DNAPK radiosensitizer (PSMA-targeting RNA aptamer-based delivery, prostate cancer)
DMTKHR3	CP	Johns Hopkins University School of Medicine
DMTKHR3	DT	Aptamer
DMTKHR3	DE	Prostate cancer

DMT62LS	ID	DMT62LS
DMT62LS	DN	SHU9119
DMT62LS	HS	Investigative
DMT62LS	SN	Shu 9119; (2S)-2-acetamido-N-[(3S,6S,13E)-14-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(2,3-dihydro-1H-indol-3-yl)propanoyl]amino]-3-(4H-imidazol-4-ylmethyl)-2,5,8,15-tetraoxo-1,4,9-triazacyclopentadec-13-en-6-yl]hexanamide; SHU9119; AC1O5TWM; GTPL1325; Ac-Nle(4)-c(asp(5)-2'-nal(7)-lys(10))alpha-msh(4-10)-NH2; Acetyl-norisoleucyl(4)-cyclo(aspartyl(5)-2'-naphthylalanyl(7)-lysyl(10))alpha-msh(4-10)-amide
DMT62LS	DT	Small molecular drug
DMT62LS	PC	6440621
DMT62LS	MW	1074.2
DMT62LS	FM	C54H71N15O9
DMT62LS	IC	InChI=1S/C54H71N15O9/c1-3-4-15-40(63-31(2)70)48(73)68-45-27-46(71)59-21-10-9-17-41(50(75)69-53(78)44(67-52(45)77)26-36-29-58-30-62-36)65-51(76)43(25-35-28-61-39-16-8-7-14-37(35)39)66-49(74)42(18-11-22-60-54(56)57)64-47(72)38(55)24-32-19-20-33-12-5-6-13-34(33)23-32/h5-8,12-14,16-17,19-20,23,29-30,35-36,38,40,42-45,61H,3-4,9-11,15,18,21-22,24-28,55H2,1-2H3,(H,59,71)(H,63,70)(H,64,72)(H,65,76)(H,66,74)(H,67,77)(H,68,73)(H4,56,57,60)(H,69,75,78)/b41-17+/t35?,36?,38-,40+,42+,43+,44+,45+/m1/s1
DMT62LS	CS	CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCC/C=C(\\C(=O)NC(=O)[C@@H](NC1=O)CC2C=NC=N2)/NC(=O)[C@H](CC3CNC4=CC=CC=C34)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)NC(=O)C
DMT62LS	IK	ORTUTLYEGOSCRP-ATNXLWBUSA-N
DMT62LS	IU	(2S)-2-acetamido-N-[(3S,6S,13E)-14-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(2,3-dihydro-1H-indol-3-yl)propanoyl]amino]-3-(4H-imidazol-4-ylmethyl)-2,5,8,15-tetraoxo-1,4,9-triazacyclopentadec-13-en-6-yl]hexanamide
DMT62LS	CA	CAS 168482-23-3
DMT62LS	DE	Discovery agent

DMAEY9X	ID	DMAEY9X
DMAEY9X	DN	Sialic acid
DMAEY9X	HS	Investigative
DMAEY9X	SN	Lactaminic acid; N-Acetyl-a-neuraminate; Neuraminic acid N-acetate; Neuraminic acid, N-acetyl-; O-sialic acid; Oprea1_149877; SCHEMBL2619258; SQVRNKJHWKZAKO-UHFFFAOYSA-N; SY012200; TRA-0206530; sialic acid; (-)-N-Acetylneuraminic acid,synthetic; 131-48-6; 489-46-3; 9724BDBF-717D-4312-8E53-2EC71ECF2DE6; AKOS025243615; CHEMBL112030; D-glycero-D-galacto-2-Nonulosonic acid, 5-(acetylamino)-3,5-dideoxy-; DB-042034; DTXSID80964136; MFCD00006620; N-Acetylneuraminic Acid, Synthetic; NSC-111756; NSC111756; SCHEMBL11936589
DMAEY9X	PC	906
DMAEY9X	MW	309.27
DMAEY9X	FM	C11H19NO9
DMAEY9X	IC	SQVRNKJHWKZAKO-UHFFFAOYSA-N
DMAEY9X	CS	CC(=O)NC1C(CC(OC1C(C(CO)O)O)(C(=O)O)O)O
DMAEY9X	IK	1S/C11H19NO9/c1-4(14)12-7-5(15)2-11(20,10(18)19)21-9(7)8(17)6(16)3-13/h5-9,13,15-17,20H,2-3H2,1H3,(H,12,14)(H,18,19)
DMAEY9X	IU	5-acetamido-2,4-dihydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylic acid
DMAEY9X	CA	CAS 489-46-3
DMAEY9X	DE	Discovery agent

DMR5FD9	ID	DMR5FD9
DMR5FD9	DN	Sib-1533A
DMR5FD9	HS	Investigative
DMR5FD9	SN	Telavancin Hydrochloride; Td 6424; 560130-42-9; TD-6424; UNII-0701472ZG0; Telavancin hydrochloride [USAN]; 0701472ZG0; Telavancin hydrochloride (USAN); Telavancin HCl; Vibativ (TN); CHEMBL3301680; CHEBI:71226; D06057; Vancomycin, N3'-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-, monohydrochloride
DMR5FD9	DT	Small molecular drug
DMR5FD9	PC	9812715
DMR5FD9	MW	1792.1
DMR5FD9	FM	C80H107Cl3N11O27P
DMR5FD9	IC	InChI=1S/C80H106Cl2N11O27P.ClH/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39;/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114);1H/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-;/m0./s1
DMR5FD9	CS	CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)C.Cl
DMR5FD9	IK	GSSIWSIRBWAZHG-ACOPVEIWSA-N
DMR5FD9	IU	(1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-[2-(decylamino)ethylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-36-[(phosphonomethylamino)methyl]-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid;hydrochloride
DMR5FD9	CA	CAS 560130-42-9
DMR5FD9	CB	CHEBI:71226
DMR5FD9	DE	Discovery agent

DMFOGE2	ID	DMFOGE2
DMFOGE2	DN	SIB-1757
DMFOGE2	HS	Investigative
DMFOGE2	DT	Small molecular drug
DMFOGE2	PC	5218788
DMFOGE2	MW	213.23
DMFOGE2	FM	C12H11N3O
DMFOGE2	IC	InChI=1S/C12H11N3O/c1-9-7-8-11(16)12(13-9)15-14-10-5-3-2-4-6-10/h2-8,16H,1H3
DMFOGE2	CS	CC1=NC(=C(C=C1)O)N=NC2=CC=CC=C2
DMFOGE2	IK	LOCPVWIREQIGNQ-UHFFFAOYSA-N
DMFOGE2	IU	6-methyl-2-phenyldiazenylpyridin-3-ol
DMFOGE2	CA	CAS 31993-01-8
DMFOGE2	CB	CHEBI:93722
DMFOGE2	DE	Discovery agent

DMAVBKP	ID	DMAVBKP
DMAVBKP	DN	SIB-1893
DMAVBKP	HS	Investigative
DMAVBKP	SN	SIB 1893; SIB-1893; 2-methyl-6-(2-phenylethenyl)pyridine; 6266-99-5; SIB1893; 2-methyl-6-[(E)-2-phenylethenyl]pyridine; 7370-21-0; CHEMBL88612; MLS002607995; (E)-2-methyl-6-styrylpyridine; [E]-2-Methyl-6-[2-phenylethenyl]pyridine; (E)-2-Methyl-6-[2-phenylethenyl]pyridine; SR-01000076143; Lopac0_001171; Pyridine,2-methyl-6-(2-phenylethenyl)-; AC1NSKMI; AC1Q4VO3; GTPL1432; CHEBI:93178; BDBM86715; MolPort-003-959-634; HMS3263L03; ZINC3941522; 2-[(E)-Styryl]-6-methylpyridine; NSC36665; SIB 1893, &gt;99%, solid; Tox21_501171
DMAVBKP	DT	Small molecular drug
DMAVBKP	PC	5311432
DMAVBKP	MW	195.26
DMAVBKP	FM	C14H13N
DMAVBKP	IC	InChI=1S/C14H13N/c1-12-6-5-9-14(15-12)11-10-13-7-3-2-4-8-13/h2-11H,1H3/b11-10+
DMAVBKP	CS	CC1=NC(=CC=C1)/C=C/C2=CC=CC=C2
DMAVBKP	IK	SISOFUCTXZKSOQ-ZHACJKMWSA-N
DMAVBKP	IU	2-methyl-6-[(E)-2-phenylethenyl]pyridine
DMAVBKP	CA	CAS 6266-99-5
DMAVBKP	CB	CHEBI:93178
DMAVBKP	DE	Discovery agent

DMEIBTY	ID	DMEIBTY
DMEIBTY	DN	SIDEROXYLONAL A
DMEIBTY	HS	Investigative
DMEIBTY	SN	sideroxylonal A; 145382-68-9; CHEMBL453012; MolPort-035-706-114; ZINC38749900; BDBM50241599; AKOS032948111; W1943
DMEIBTY	DT	Small molecular drug
DMEIBTY	PC	10391273
DMEIBTY	MW	500.5
DMEIBTY	FM	C26H28O10
DMEIBTY	IC	InChI=1S/C26H28O10/c1-10(2)5-12-17(11(3)4)26(19-23(34)13(6-27)20(31)14(7-28)24(19)35)36-25-16(9-30)21(32)15(8-29)22(33)18(12)25/h6-12,17,26,31-35H,5H2,1-4H3/t12-,17+,26+/m0/s1
DMEIBTY	CS	CC(C)C[C@H]1[C@H]([C@@H](OC2=C(C(=C(C(=C12)O)C=O)O)C=O)C3=C(C(=C(C(=C3O)C=O)O)C=O)O)C(C)C
DMEIBTY	IK	PHQDMQGEKNBIPF-FLFOAQQMSA-N
DMEIBTY	IU	(2R,3R,4S)-2-(3,5-diformyl-2,4,6-trihydroxyphenyl)-5,7-dihydroxy-4-(2-methylpropyl)-3-propan-2-yl-3,4-dihydro-2H-chromene-6,8-dicarbaldehyde
DMEIBTY	DE	Discovery agent

DMDP7Y5	ID	DMDP7Y5
DMDP7Y5	DN	SIDEROXYLONAL B
DMDP7Y5	HS	Investigative
DMDP7Y5	SN	sideroxylonal B; CHEMBL509880
DMDP7Y5	DT	Small molecular drug
DMDP7Y5	PC	9848832
DMDP7Y5	MW	500.5
DMDP7Y5	FM	C26H28O10
DMDP7Y5	IC	InChI=1S/C26H28O10/c1-10(2)5-12-17(11(3)4)26(19-23(34)13(6-27)20(31)14(7-28)24(19)35)36-25-16(9-30)21(32)15(8-29)22(33)18(12)25/h6-12,17,26,31-35H,5H2,1-4H3/t12-,17-,26+/m0/s1
DMDP7Y5	CS	CC(C)C[C@H]1[C@@H]([C@@H](OC2=C(C(=C(C(=C12)O)C=O)O)C=O)C3=C(C(=C(C(=C3O)C=O)O)C=O)O)C(C)C
DMDP7Y5	IK	PHQDMQGEKNBIPF-GKZOTJLQSA-N
DMDP7Y5	IU	(2R,3S,4S)-2-(3,5-diformyl-2,4,6-trihydroxyphenyl)-5,7-dihydroxy-4-(2-methylpropyl)-3-propan-2-yl-3,4-dihydro-2H-chromene-6,8-dicarbaldehyde
DMDP7Y5	DE	Discovery agent

DMSGNM1	ID	DMSGNM1
DMSGNM1	DN	Sideroxylonal C
DMSGNM1	HS	Investigative
DMSGNM1	SN	sideroxylonal C; CHEMBL453538; BDBM50241601
DMSGNM1	DT	Small molecular drug
DMSGNM1	PC	10413640
DMSGNM1	MW	500.5
DMSGNM1	FM	C26H28O10
DMSGNM1	IC	InChI=1S/C26H28O10/c1-10(2)5-12-17(11(3)4)26(19-23(34)13(6-27)20(31)14(7-28)24(19)35)36-25-16(9-30)21(32)15(8-29)22(33)18(12)25/h6-12,17,26,31-35H,5H2,1-4H3/t12-,17-,26-/m1/s1
DMSGNM1	CS	CC(C)C[C@@H]1[C@H]([C@@H](OC2=C(C(=C(C(=C12)O)C=O)O)C=O)C3=C(C(=C(C(=C3O)C=O)O)C=O)O)C(C)C
DMSGNM1	IK	PHQDMQGEKNBIPF-RAFFTOIBSA-N
DMSGNM1	IU	(2R,3R,4R)-2-(3,5-diformyl-2,4,6-trihydroxyphenyl)-5,7-dihydroxy-4-(2-methylpropyl)-3-propan-2-yl-3,4-dihydro-2H-chromene-6,8-dicarbaldehyde
DMSGNM1	DE	Discovery agent

DMB70NK	ID	DMB70NK
DMB70NK	DN	SIGMOIDIN A
DMB70NK	HS	Investigative
DMB70NK	SN	Sigmoidin A; 87746-48-3; CHEMBL229506; CHEBI:66482; (2s)-2-[3,4-dihydroxy-2,5-bis(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-2,3-dihydro-4h-chromen-4-one; Sigmoidin-A; (2S)-2-[3,4-dihydroxy-2,5-bis(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-2,3-dihydrochromen-4-one; AC1Q6KI8; AC1L2JG5; CTK5F8963; DTXSID20236607; ZINC689691; BDBM50212392; AKOS030553599; 5,7,3',4'-tetrahydroxy-2',5'-diprenylflavone; (2S)-2-[3,4-dihydroxy-2,5-bis(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-chroman-4-one
DMB70NK	DT	Small molecular drug
DMB70NK	PC	73204
DMB70NK	MW	424.5
DMB70NK	FM	C25H28O6
DMB70NK	IC	InChI=1S/C25H28O6/c1-13(2)5-7-15-9-18(17(8-6-14(3)4)25(30)24(15)29)21-12-20(28)23-19(27)10-16(26)11-22(23)31-21/h5-6,9-11,21,26-27,29-30H,7-8,12H2,1-4H3/t21-/m0/s1
DMB70NK	CS	CC(=CCC1=CC(=C(C(=C1O)O)CC=C(C)C)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)C
DMB70NK	IK	BVHLNRAYBCPKOY-NRFANRHFSA-N
DMB70NK	IU	(2S)-2-[3,4-dihydroxy-2,5-bis(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-2,3-dihydrochromen-4-one
DMB70NK	CA	CAS 87746-48-3
DMB70NK	CB	CHEBI:66482
DMB70NK	DE	Discovery agent

DMVH5WK	ID	DMVH5WK
DMVH5WK	DN	SIGMOIDIN B
DMVH5WK	HS	Investigative
DMVH5WK	SN	Sigmoidin B; 87746-47-2; CHEMBL229454; CHEBI:66483; (2s)-2-[3,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-2,3-dihydro-4h-chromen-4-one; Sigmoidin-B; (2S)-2-[3,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-2,3-dihydrochromen-4-one; AC1L2JG8; AC1Q6KI9; CTK5F8962; DTXSID60236606; BDBM50212399; AKOS030553600; 5,7,3',4'-tetrahydroxy-5'-prenylflavone; (2S)-2-[3,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-chroman-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxy-5-(3-methyl-2-butenyl)phenyl)-2,3
DMVH5WK	DT	Small molecular drug
DMVH5WK	PC	73205
DMVH5WK	MW	356.4
DMVH5WK	FM	C20H20O6
DMVH5WK	IC	InChI=1S/C20H20O6/c1-10(2)3-4-11-5-12(6-16(24)20(11)25)17-9-15(23)19-14(22)7-13(21)8-18(19)26-17/h3,5-8,17,21-22,24-25H,4,9H2,1-2H3/t17-/m0/s1
DMVH5WK	CS	CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O)O)C
DMVH5WK	IK	SFQIGPZCFNTPOD-KRWDZBQOSA-N
DMVH5WK	IU	(2S)-2-[3,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-2,3-dihydrochromen-4-one
DMVH5WK	CA	CAS 87746-47-2
DMVH5WK	CB	CHEBI:66483
DMVH5WK	DE	Discovery agent

DM8E62L	ID	DM8E62L
DM8E62L	DN	Sigmoidin F
DM8E62L	HS	Investigative
DM8E62L	SN	Sigmoidin F; CHEMBL229222; 126005-97-8; AC1L4UEV; AC1Q6NL6; (2,6'-bi-2h-1-benzopyran)-4(3h)-one, 5,7,8'-trihydroxy-2',2'-dimethyl-7'-(3-methyl-2-butenyl)-,(r)-; BDBM50212398; (2R)-5,7-dihydroxy-2-[8-hydroxy-2,2-dimethyl-7-(3-methylbut-2-enyl)chromen-6-yl]-2,3-dihydrochromen-4-one; (2,6'-Bi-2H-1-benzopyran)-4(3H)-one, 5,7,8'-trihydroxy-2',2'-dimethyl-7'-(3-methyl-2-butenyl)-, (R)-
DM8E62L	DT	Small molecular drug
DM8E62L	PC	164215
DM8E62L	MW	422.5
DM8E62L	FM	C25H26O6
DM8E62L	IC	InChI=1S/C25H26O6/c1-13(2)5-6-16-17(9-14-7-8-25(3,4)31-24(14)23(16)29)20-12-19(28)22-18(27)10-15(26)11-21(22)30-20/h5,7-11,20,26-27,29H,6,12H2,1-4H3/t20-/m1/s1
DM8E62L	CS	CC(=CCC1=C(C=C2C=CC(OC2=C1O)(C)C)[C@H]3CC(=O)C4=C(C=C(C=C4O3)O)O)C
DM8E62L	IK	WPVMLODCRMLWMB-HXUWFJFHSA-N
DM8E62L	IU	(2R)-5,7-dihydroxy-2-[8-hydroxy-2,2-dimethyl-7-(3-methylbut-2-enyl)chromen-6-yl]-2,3-dihydrochromen-4-one
DM8E62L	CA	CAS 126005-97-8
DM8E62L	DE	Discovery agent

DM4VDMP	ID	DM4VDMP
DM4VDMP	DN	silahexocyclium
DM4VDMP	HS	Investigative
DM4VDMP	SN	Silahexocyclium; 124393-85-7; Sila-hexocyclium; cyclohexyl-[(4,4-dimethylpiperazin-4-ium-1-yl)methyl]-hydroxy-phenylsilane; AC1L2WWH; GTPL331; L001247; Piperazinium, 4-((cyclohexylhydroxyphenylsilyl)methyl)-1,1-dimethyl-
DM4VDMP	DT	Small molecular drug
DM4VDMP	PC	130169
DM4VDMP	MW	333.6
DM4VDMP	FM	C19H33N2OSi+
DM4VDMP	IC	InChI=1S/C19H33N2OSi/c1-21(2)15-13-20(14-16-21)17-23(22,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3,5-6,9-10,19,22H,4,7-8,11-17H2,1-2H3/q+1
DM4VDMP	CS	C[N+]1(CCN(CC1)C[Si](C2CCCCC2)(C3=CC=CC=C3)O)C
DM4VDMP	IK	GBISIIAKUATURW-UHFFFAOYSA-N
DM4VDMP	IU	cyclohexyl-[(4,4-dimethylpiperazin-4-ium-1-yl)methyl]-hydroxy-phenylsilane
DM4VDMP	CA	CAS 124393-85-7
DM4VDMP	DE	Discovery agent

DM5ZILV	ID	DM5ZILV
DM5ZILV	DN	Silicon-modified indomethacin
DM5ZILV	HS	Investigative
DM5ZILV	SN	Silexsyn; RND-100; SiM-100; Silicon-modified indomethacin (cancer); Silicon-modified indometacin (cancer), Silamed; Silicon-modified indomethacin (cancer), Silamed
DM5ZILV	CP	Silamed Inc
DM5ZILV	DE	Arthritis

DMQIBZD	ID	DMQIBZD
DMQIBZD	DN	Silmitasertib
DMQIBZD	HS	Investigative
DMQIBZD	SN	CX-4945; CX4945; CX-4945 (Silmitasertib); CX 4945; UNII-C6RWP0N0L2; W-204393
DMQIBZD	TC	Antiviral Agents
DMQIBZD	DT	Small molecular drug
DMQIBZD	PC	24748573
DMQIBZD	MW	349.8
DMQIBZD	FM	C19H12ClN3O2
DMQIBZD	IC	InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)
DMQIBZD	CS	C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4
DMQIBZD	IK	MUOKSQABCJCOPU-UHFFFAOYSA-N
DMQIBZD	IU	5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid
DMQIBZD	CA	CAS 1009820-21-6
DMQIBZD	DE	Coronavirus Disease 2019 (COVID-19)

DM5JKNF	ID	DM5JKNF
DM5JKNF	DN	Silvestrol
DM5JKNF	HS	Investigative
DM5JKNF	SN	Naturally derived compounds (cancer); Naturally derived compounds (cancer), Bristol-Myers Squibb/National Cancer Institute
DM5JKNF	CP	Bristol-Myers Squibb Co
DM5JKNF	TC	Antiviral Agents
DM5JKNF	DT	Small molecular drug
DM5JKNF	PC	11787114
DM5JKNF	MW	654.7
DM5JKNF	FM	C34H38O13
DM5JKNF	IC	InChI=1S/C34H38O13/c1-40-20-12-10-19(11-13-20)34-27(18-8-6-5-7-9-18)26(30(38)42-3)29(37)33(34,39)28-23(41-2)14-21(15-24(28)47-34)45-32-31(43-4)44-17-25(46-32)22(36)16-35/h5-15,22,25-27,29,31-32,35-37,39H,16-17H2,1-4H3/t22-,25-,26-,27-,29-,31-,32-,33+,34+/m1/s1
DM5JKNF	CS	CO[C@H]1[C@@H](O[C@H](CO1)[C@@H](CO)O)OC2=CC3=C(C(=C2)OC)[C@@]4([C@@H]([C@@H]([C@H]([C@@]4(O3)C5=CC=C(C=C5)OC)C6=CC=CC=C6)C(=O)OC)O)O
DM5JKNF	IK	GVKXFVCXBFGBCD-QKDMMWSPSA-N
DM5JKNF	IU	methyl (1R,2R,3S,3aR,8bS)-6-[[(2S,3R,6R)-6-[(1R)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate
DM5JKNF	CA	CAS 697235-38-4
DM5JKNF	CB	CHEBI:66484
DM5JKNF	DE	Cancer; Middle East Respiratory Syndrome (MERS)

DMS7EHF	ID	DMS7EHF
DMS7EHF	DN	Silvestrol
DMS7EHF	HS	Investigative
DMS7EHF	SN	Naturally derived compounds (cancer); Naturally derived compounds (cancer), Bristol-Myers Squibb/National Cancer Institute
DMS7EHF	CP	Bristol-Myers Squibb Co
DMS7EHF	DT	Small molecular drug
DMS7EHF	PC	11787114
DMS7EHF	MW	654.7
DMS7EHF	FM	C34H38O13
DMS7EHF	IC	InChI=1S/C34H38O13/c1-40-20-12-10-19(11-13-20)34-27(18-8-6-5-7-9-18)26(30(38)42-3)29(37)33(34,39)28-23(41-2)14-21(15-24(28)47-34)45-32-31(43-4)44-17-25(46-32)22(36)16-35/h5-15,22,25-27,29,31-32,35-37,39H,16-17H2,1-4H3/t22-,25-,26-,27-,29-,31-,32-,33+,34+/m1/s1
DMS7EHF	CS	CO[C@H]1[C@@H](O[C@H](CO1)[C@@H](CO)O)OC2=CC3=C(C(=C2)OC)[C@@]4([C@@H]([C@@H]([C@H]([C@@]4(O3)C5=CC=C(C=C5)OC)C6=CC=CC=C6)C(=O)OC)O)O
DMS7EHF	IK	GVKXFVCXBFGBCD-QKDMMWSPSA-N
DMS7EHF	IU	methyl (1R,2R,3S,3aR,8bS)-6-[[(2S,3R,6R)-6-[(1R)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate
DMS7EHF	CA	CAS 697235-38-4
DMS7EHF	CB	CHEBI:66484
DMS7EHF	DE	Solid tumour/cancer

DM3LDFB	ID	DM3LDFB
DM3LDFB	DN	Simoctocog alfa
DM3LDFB	HS	Investigative
DM3LDFB	SN	Factor VIII - Octapharma; Human-cl rhFVIII - Octapharma; Nuwiq
DM3LDFB	DE	Discovery agent

DMNWM8H	ID	DMNWM8H
DMNWM8H	DN	Sinefungin
DMNWM8H	HS	Investigative
DMNWM8H	SN	sinefungin; ADENOSYL-ORNITHINE; Sinefunginum; Sinefungina; Sinefungine; Antibiotic A 9145; Compound 57926; Adenosylornithine; 58944-73-3; A 9145; Antibiotic 32232 RP; Sinefungin [USAN:INN]; Sinefungine [INN-French]; Sinefunginum [INN-Latin]; UNII-W2U467CIIL; Sinefungina [INN-Spanish]; 6,9-Diamino-1-(6-amino-9H-purin-9-yl)-1,5,6,7,8,9-hexadeoxydecofuranuronic acid; 6,9-Diamino-1-(6-amino-9H-purin-9-yl)-1,5,6,7,8,9-hexadeoxy-beta-D-ribo-decofuranuronic acid; BRN 3574678; W2U467CIIL; RP 32232; LY 57926; CHEBI:45453; Decofuranuronic 
DMNWM8H	DT	Small molecular drug
DMNWM8H	PC	65482
DMNWM8H	MW	381.39
DMNWM8H	FM	C15H23N7O5
DMNWM8H	IC	InChI=1S/C15H23N7O5/c16-6(1-2-7(17)15(25)26)3-8-10(23)11(24)14(27-8)22-5-21-9-12(18)19-4-20-13(9)22/h4-8,10-11,14,23-24H,1-3,16-17H2,(H,25,26)(H2,18,19,20)/t6-,7-,8+,10+,11+,14+/m0/s1
DMNWM8H	CS	C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)C[C@H](CC[C@@H](C(=O)O)N)N)O)O)N
DMNWM8H	IK	LMXOHSDXUQEUSF-YECHIGJVSA-N
DMNWM8H	IU	(2S,5S)-2,5-diamino-6-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]hexanoic acid
DMNWM8H	CA	CAS 58944-73-3
DMNWM8H	CB	CHEBI:45453
DMNWM8H	DE	Discovery agent

DM1NXFL	ID	DM1NXFL
DM1NXFL	DN	S-isopentyl 3-methylbutane-1-sulfinothioate
DM1NXFL	HS	Investigative
DM1NXFL	SN	S-isopentyl 3-methylbutane-1-sulfinothioate; CHEMBL1224170; 56527-87-8
DM1NXFL	DT	Small molecular drug
DM1NXFL	PC	49865939
DM1NXFL	MW	222.4
DM1NXFL	FM	C10H22OS2
DM1NXFL	IC	InChI=1S/C10H22OS2/c1-9(2)5-7-12-13(11)8-6-10(3)4/h9-10H,5-8H2,1-4H3
DM1NXFL	CS	CC(C)CCSS(=O)CCC(C)C
DM1NXFL	IK	PPSCLEFHDJTMFD-UHFFFAOYSA-N
DM1NXFL	IU	3-methyl-1-(3-methylbutylsulfinylsulfanyl)butane
DM1NXFL	DE	Discovery agent

DMZ30AM	ID	DMZ30AM
DMZ30AM	DN	S-Isopropyl-Isothiourea
DMZ30AM	HS	Investigative
DMZ30AM	SN	S-Isopropylisothiourea hydrobromide; 4269-97-0; S-Isopropylthiourea hydrobromide; 57200-31-4; SR-01000597878; IPITU hydrobromide; C4H10N2S.HBr; S-Isopropylthiuronium bromide; S-Isopropyl-ITU hydrobromide; SCHEMBL7532633; S-ISOPROPYLISOTHIOUREA HBR; DTXSID10431048; MolPort-003-937-638; 2036AH; AKOS024458684; ACM4269970; B6494; SR-01000597878-2
DMZ30AM	DT	Small molecular drug
DMZ30AM	PC	445319
DMZ30AM	MW	118.2
DMZ30AM	FM	C4H10N2S
DMZ30AM	IC	InChI=1S/C4H10N2S/c1-3(2)7-4(5)6/h3H,1-2H3,(H3,5,6)
DMZ30AM	CS	CC(C)SC(=N)N
DMZ30AM	IK	XSSNABKEYXKKMK-UHFFFAOYSA-N
DMZ30AM	IU	propan-2-yl carbamimidothioate
DMZ30AM	CA	CAS 6913-17-3
DMZ30AM	DE	Discovery agent

DMCMIUG	ID	DMCMIUG
DMCMIUG	DN	SITS
DMCMIUG	HS	Investigative
DMCMIUG	SN	4'-isothiocyanostilbene-2,2'-disulphonic acid
DMCMIUG	DT	Small molecular drug
DMCMIUG	PC	5282250
DMCMIUG	MW	454.5
DMCMIUG	FM	C17H14N2O7S3
DMCMIUG	IC	InChI=1S/C17H14N2O7S3/c1-11(20)19-15-7-5-13(17(9-15)29(24,25)26)3-2-12-4-6-14(18-10-27)8-16(12)28(21,22)23/h2-9H,1H3,(H,19,20)(H,21,22,23)(H,24,25,26)/b3-2+
DMCMIUG	CS	CC(=O)NC1=CC(=C(C=C1)/C=C/C2=C(C=C(C=C2)N=C=S)S(=O)(=O)O)S(=O)(=O)O
DMCMIUG	IK	YJCCSLGGODRWKK-NSCUHMNNSA-N
DMCMIUG	IU	5-acetamido-2-[(E)-2-(4-isothiocyanato-2-sulfophenyl)ethenyl]benzenesulfonic acid
DMCMIUG	CA	CAS 27816-59-7
DMCMIUG	CB	CHEBI:34383
DMCMIUG	DE	Discovery agent

DMEQBU2	ID	DMEQBU2
DMEQBU2	DN	SJ-8002
DMEQBU2	HS	Investigative
DMEQBU2	SN	Piperazine derivative (anticancer), Samjin/ImQuest
DMEQBU2	CP	Samjin Pharmaceutical Co Ltd
DMEQBU2	DE	Solid tumour/cancer

DMU1P3T	ID	DMU1P3T
DMU1P3T	DN	SK&F 107649
DMU1P3T	HS	Investigative
DMU1P3T	SN	ZINC5266
DMU1P3T	DT	Small molecular drug
DMU1P3T	PC	197400
DMU1P3T	MW	312.4
DMU1P3T	FM	C18H20N2O3
DMU1P3T	IC	InChI=1S/C18H20N2O3/c19-18(21)20(22)17-8-4-7-14-11-15(9-10-16(14)17)23-12-13-5-2-1-3-6-13/h1-3,5-6,9-11,17,22H,4,7-8,12H2,(H2,19,21)
DMU1P3T	CS	C1CC(C2=C(C1)C=C(C=C2)OCC3=CC=CC=C3)N(C(=O)N)O
DMU1P3T	IK	HGXVXGSOOPCMHM-UHFFFAOYSA-N
DMU1P3T	IU	1-hydroxy-1-(6-phenylmethoxy-1,2,3,4-tetrahydronaphthalen-1-yl)urea
DMU1P3T	CA	CAS 139148-95-1
DMU1P3T	DE	Discovery agent

DMYRKEJ	ID	DMYRKEJ
DMYRKEJ	DN	SK&F-105854
DMYRKEJ	HS	Investigative
DMYRKEJ	SN	SK-105854
DMYRKEJ	DT	Small molecular drug
DMYRKEJ	PC	9839317
DMYRKEJ	MW	300.58
DMYRKEJ	FM	C12H11BrClNO
DMYRKEJ	IC	InChI=1S/C12H11BrClNO/c1-15-5-4-7-9(14)2-3-10-11(7)8(6-15)12(13)16-10/h2-3H,4-6H2,1H3
DMYRKEJ	CS	CN1CCC2=C(C=CC3=C2C(=C(O3)Br)C1)Cl
DMYRKEJ	IK	NYGANYRUZQPPGP-UHFFFAOYSA-N
DMYRKEJ	IU	2-bromo-7-chloro-11-methyl-3-oxa-11-azatricyclo[6.4.1.04,13]trideca-1,4(13),5,7-tetraene
DMYRKEJ	DE	Discovery agent

DMHETY7	ID	DMHETY7
DMHETY7	DN	SK&F-106686
DMHETY7	HS	Investigative
DMHETY7	SN	SK-106686
DMHETY7	DT	Small molecular drug
DMHETY7	PC	10946567
DMHETY7	MW	265.8
DMHETY7	FM	C14H16ClNS
DMHETY7	IC	InChI=1S/C14H16ClNS/c1-3-12-10-8-16(2)7-6-9-11(15)4-5-13(17-12)14(9)10/h4-5H,3,6-8H2,1-2H3
DMHETY7	CS	CCC1=C2CN(CCC3=C(C=CC(=C32)S1)Cl)C
DMHETY7	IK	BAAUEDJUTZLMAN-UHFFFAOYSA-N
DMHETY7	IU	7-chloro-2-ethyl-11-methyl-3-thia-11-azatricyclo[6.4.1.04,13]trideca-1,4(13),5,7-tetraene
DMHETY7	DE	Discovery agent

DM2KFQ5	ID	DM2KFQ5
DM2KFQ5	DN	SK&F-29661
DM2KFQ5	HS	Investigative
DM2KFQ5	SN	SK-29661
DM2KFQ5	DT	Small molecular drug
DM2KFQ5	PC	5226
DM2KFQ5	MW	212.27
DM2KFQ5	FM	C9H12N2O2S
DM2KFQ5	IC	InChI=1S/C9H12N2O2S/c10-14(12,13)9-2-1-7-3-4-11-6-8(7)5-9/h1-2,5,11H,3-4,6H2,(H2,10,12,13)
DM2KFQ5	CS	C1CNCC2=C1C=CC(=C2)S(=O)(=O)N
DM2KFQ5	IK	UGLLZXSYRBMNOS-UHFFFAOYSA-N
DM2KFQ5	IU	1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
DM2KFQ5	CA	CAS 31404-61-2
DM2KFQ5	DE	Discovery agent

DM60Y3Q	ID	DM60Y3Q
DM60Y3Q	DN	SK&F-64139
DM60Y3Q	HS	Investigative
DM60Y3Q	SN	SK-64139
DM60Y3Q	DT	Small molecular drug
DM60Y3Q	PC	123920
DM60Y3Q	MW	202.08
DM60Y3Q	FM	C9H9Cl2N
DM60Y3Q	IC	InChI=1S/C9H9Cl2N/c10-8-2-1-6-3-4-12-5-7(6)9(8)11/h1-2,12H,3-5H2
DM60Y3Q	CS	C1CNCC2=C1C=CC(=C2Cl)Cl
DM60Y3Q	IK	WFPUBEDBBOGGIQ-UHFFFAOYSA-N
DM60Y3Q	IU	7,8-dichloro-1,2,3,4-tetrahydroisoquinoline
DM60Y3Q	CA	CAS 61563-24-4
DM60Y3Q	CB	CHEBI:160129
DM60Y3Q	DE	Discovery agent

DM4RHEZ	ID	DM4RHEZ
DM4RHEZ	DN	SK&F-86466
DM4RHEZ	HS	Investigative
DM4RHEZ	SN	SK-86466
DM4RHEZ	DT	Small molecular drug
DM4RHEZ	PC	123981
DM4RHEZ	MW	195.69
DM4RHEZ	FM	C11H14ClN
DM4RHEZ	IC	InChI=1S/C11H14ClN/c1-13-7-5-9-3-2-4-11(12)10(9)6-8-13/h2-4H,5-8H2,1H3
DM4RHEZ	CS	CN1CCC2=C(CC1)C(=CC=C2)Cl
DM4RHEZ	IK	RSRUDTPYRBLHEO-UHFFFAOYSA-N
DM4RHEZ	IU	6-chloro-3-methyl-1,2,4,5-tetrahydro-3-benzazepine
DM4RHEZ	CA	CAS 73943-10-9
DM4RHEZ	CB	CHEBI:8986
DM4RHEZ	DE	Discovery agent

DM3SUKX	ID	DM3SUKX
DM3SUKX	DN	SK&F-89626
DM3SUKX	HS	Investigative
DM3SUKX	SN	SK-89626
DM3SUKX	PC	6604005
DM3SUKX	MW	247.31
DM3SUKX	FM	C13H13NO2S
DM3SUKX	IC	InChI=1S/C13H13NO2S/c15-11-2-1-8(5-12(11)16)10-6-14-7-13-9(10)3-4-17-13/h1-5,10,14-16H,6-7H2/t10-/m0/s1
DM3SUKX	CS	C1[C@H](C2=C(CN1)SC=C2)C3=CC(=C(C=C3)O)O
DM3SUKX	IK	QDKUSZZMIFQVPN-JTQLQIEISA-N
DM3SUKX	IU	4-[(4S)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-4-yl]benzene-1,2-diol
DM3SUKX	DE	Discovery agent

DMMYX7C	ID	DMMYX7C
DMMYX7C	DN	SK1-I
DMMYX7C	HS	Investigative
DMMYX7C	SN	BML-258
DMMYX7C	DT	Small molecular drug
DMMYX7C	PC	44815217
DMMYX7C	MW	277.4
DMMYX7C	FM	C17H27NO2
DMMYX7C	IC	InChI=1S/C17H27NO2/c1-3-4-5-6-14-7-9-15(10-8-14)11-12-17(20)16(13-19)18-2/h7-12,16-20H,3-6,13H2,1-2H3/b12-11+/t16-,17+/m1/s1
DMMYX7C	CS	CCCCCC1=CC=C(C=C1)/C=C/[C@@H]([C@@H](CO)NC)O
DMMYX7C	IK	JYEXUQKROPHSEF-SFDDJJRUSA-N
DMMYX7C	IU	(E,2R,3S)-2-(methylamino)-5-(4-pentylphenyl)pent-4-ene-1,3-diol
DMMYX7C	DE	Discovery agent

DM73SC6	ID	DM73SC6
DM73SC6	DN	SK509
DM73SC6	HS	Investigative
DM73SC6	SN	Tetrachlorosalicylanilide; 7426/7/5; 2,3,4,5-tetrachloro-6-hydroxy-n-phenylbenzamide; AC1L3YOY; C11274; AC1Q3L4M; SCHEMBL999269; CHEBI:9473; CTK2H9174; DTXSID90225265; 2-Hydroxy-3,4,5,6-tetrachlorobenzanilide; 2,3,4,5-tetrachloro-6-hydroxy-N-phenyl-benzamide
DM73SC6	DT	Small molecular drug
DM73SC6	PC	124579
DM73SC6	MW	351
DM73SC6	FM	C13H7Cl4NO2
DM73SC6	IC	InChI=1S/C13H7Cl4NO2/c14-8-7(12(19)11(17)10(16)9(8)15)13(20)18-6-4-2-1-3-5-6/h1-5,19H,(H,18,20)
DM73SC6	CS	C1=CC=C(C=C1)NC(=O)C2=C(C(=C(C(=C2Cl)Cl)Cl)Cl)O
DM73SC6	IK	BDOBMVIEWHZYDL-UHFFFAOYSA-N
DM73SC6	IU	2,3,4,5-tetrachloro-6-hydroxy-N-phenylbenzamide
DM73SC6	CA	CAS 7426-07-5
DM73SC6	CB	CHEBI:9473
DM73SC6	DE	Discovery agent

DMK1OP2	ID	DMK1OP2
DMK1OP2	DN	SK549
DMK1OP2	HS	Investigative
DMK1OP2	DE	Discovery agent

DMUTBZ8	ID	DMUTBZ8
DMUTBZ8	DN	SK554
DMUTBZ8	HS	Investigative
DMUTBZ8	DE	Discovery agent

DMM32CF	ID	DMM32CF
DMM32CF	DN	SK-683
DMM32CF	HS	Investigative
DMM32CF	SN	SK-683; CHEMBL116620; SCHEMBL8089576; BDBM50148757
DMM32CF	DT	Small molecular drug
DMM32CF	PC	9888071
DMM32CF	MW	415.4
DMM32CF	FM	C24H21N3O4
DMM32CF	IC	InChI=1S/C24H21N3O4/c28-21(27-31)15-14-17-8-7-9-18(16-17)22(23(29)25-19-10-3-1-4-11-19)24(30)26-20-12-5-2-6-13-20/h1-16,22,31H,(H,25,29)(H,26,30)(H,27,28)/b15-14+
DMM32CF	CS	C1=CC=C(C=C1)NC(=O)C(C2=CC=CC(=C2)/C=C/C(=O)NO)C(=O)NC3=CC=CC=C3
DMM32CF	IK	SQGNVWSNUGLNRK-CCEZHUSRSA-N
DMM32CF	IU	2-[3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]-N,N'-diphenylpropanediamide
DMM32CF	DE	Discovery agent

DMBL7YN	ID	DMBL7YN
DMBL7YN	DN	SKA-121
DMBL7YN	HS	Investigative
DMBL7YN	SN	SKA121; SKA 121
DMBL7YN	DT	Small molecular drug
DMBL7YN	PC	91827362
DMBL7YN	MW	198.22
DMBL7YN	FM	C12H10N2O
DMBL7YN	IC	InChI=1S/C12H10N2O/c1-7-6-10-11(15-12(13)14-10)9-5-3-2-4-8(7)9/h2-6H,1H3,(H2,13,14)
DMBL7YN	CS	CC1=CC2=C(C3=CC=CC=C13)OC(=N2)N
DMBL7YN	IK	JEGUERWMMMQFJV-UHFFFAOYSA-N
DMBL7YN	IU	5-methylbenzo[g][1,3]benzoxazol-2-amine
DMBL7YN	DE	Discovery agent

DMX34F1	ID	DMX34F1
DMX34F1	DN	SKA-31
DMX34F1	HS	Investigative
DMX34F1	SN	2-aminonaphthiazole; 2-amino-beta-naphthothiazole
DMX34F1	DT	Small molecular drug
DMX34F1	PC	94880
DMX34F1	MW	200.26
DMX34F1	FM	C11H8N2S
DMX34F1	IC	InChI=1S/C11H8N2S/c12-11-13-10-8-4-2-1-3-7(8)5-6-9(10)14-11/h1-6H,(H2,12,13)
DMX34F1	CS	C1=CC=C2C(=C1)C=CC3=C2N=C(S3)N
DMX34F1	IK	FECQXVPRUCCUIL-UHFFFAOYSA-N
DMX34F1	IU	benzo[e][1,3]benzothiazol-2-amine
DMX34F1	CA	CAS 40172-65-4
DMX34F1	DE	Discovery agent

DMWODHR	ID	DMWODHR
DMWODHR	DN	SKF 89748
DMWODHR	HS	Investigative
DMWODHR	SN	SK&F 89748; SK&F 89748-A; SK&F-89748
DMWODHR	DT	Small molecular drug
DMWODHR	PC	128805
DMWODHR	MW	223.34
DMWODHR	FM	C12H17NOS
DMWODHR	IC	InChI=1S/C12H17NOS/c1-14-11-5-6-12(15-2)9-4-3-8(13)7-10(9)11/h5-6,8H,3-4,7,13H2,1-2H3
DMWODHR	CS	COC1=C2CC(CCC2=C(C=C1)SC)N
DMWODHR	IK	YCSXMTWSPWKFIE-UHFFFAOYSA-N
DMWODHR	IU	8-methoxy-5-methylsulfanyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMWODHR	CA	CAS 86287-13-0
DMWODHR	DE	Discovery agent

DMQ6YXF	ID	DMQ6YXF
DMQ6YXF	DN	SKF-75670
DMQ6YXF	HS	Investigative
DMQ6YXF	SN	Skf 75670; 3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol; SKF-75670; AC1L5AM7; Lopac0_001087; GTPL936; SCHEMBL11712694; CHEMBL1193571; BDBM81986; NSC_173870; CCG-205164; CAS_173870; NCGC00162337-01; NCGC00015942-03; NCGC00015942-02; L000564; 3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol; 2,3,4,5-Tetrahydro-3-methyl-1-phenyl-1H-3-benzazepine-7,8-diol; 3-Methyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol
DMQ6YXF	DT	Small molecular drug
DMQ6YXF	PC	173871
DMQ6YXF	MW	269.34
DMQ6YXF	FM	C17H19NO2
DMQ6YXF	IC	InChI=1S/C17H19NO2/c1-18-8-7-13-9-16(19)17(20)10-14(13)15(11-18)12-5-3-2-4-6-12/h2-6,9-10,15,19-20H,7-8,11H2,1H3
DMQ6YXF	CS	CN1CCC2=CC(=C(C=C2C(C1)C3=CC=CC=C3)O)O
DMQ6YXF	IK	LIHCKGZEDBNUJG-UHFFFAOYSA-N
DMQ6YXF	IU	3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol
DMQ6YXF	DE	Discovery agent

DMCMQH8	ID	DMCMQH8
DMCMQH8	DN	SKF-83556
DMCMQH8	HS	Investigative
DMCMQH8	SN	SK-83566; SK&F-83566
DMCMQH8	DT	Small molecular drug
DMCMQH8	PC	1243
DMCMQH8	MW	332.2
DMCMQH8	FM	C17H18BrNO
DMCMQH8	IC	InChI=1S/C17H18BrNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3
DMCMQH8	CS	CN1CCC2=CC(=C(C=C2C(C1)C3=CC=CC=C3)O)Br
DMCMQH8	IK	XFTVOHWWEQGXLS-UHFFFAOYSA-N
DMCMQH8	IU	8-bromo-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
DMCMQH8	CA	CAS 99295-33-7
DMCMQH8	CB	CHEBI:91747
DMCMQH8	DE	Discovery agent

DMWC6RU	ID	DMWC6RU
DMWC6RU	DN	SKF-83959
DMWC6RU	HS	Investigative
DMWC6RU	SN	SKF83959; SKF 83959
DMWC6RU	DT	Small molecular drug
DMWC6RU	PC	133538
DMWC6RU	MW	317.8
DMWC6RU	FM	C18H20ClNO2
DMWC6RU	IC	InChI=1S/C18H20ClNO2/c1-11-4-3-5-12(8-11)15-10-20(2)7-6-13-14(15)9-16(21)18(22)17(13)19/h3-5,8-9,15,21-22H,6-7,10H2,1-2H3
DMWC6RU	CS	CC1=CC(=CC=C1)C2CN(CCC3=C(C(=C(C=C23)O)O)Cl)C
DMWC6RU	IK	JXMYTVOBSFOHAF-UHFFFAOYSA-N
DMWC6RU	IU	9-chloro-3-methyl-5-(3-methylphenyl)-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol
DMWC6RU	CA	CAS 80751-85-5
DMWC6RU	CB	CHEBI:64001
DMWC6RU	DE	Discovery agent

DMNUQ9P	ID	DMNUQ9P
DMNUQ9P	DN	SKF-89124A
DMNUQ9P	HS	Investigative
DMNUQ9P	SN	F 89124; CHEMBL587; 7-HYDROXY ROPINIROLE; 81654-62-8; 4-[2-(dipropylamino)ethyl]-7-hydroxy-1,3-dihydro-2h-indol-2-one; Skf-18924A; Skf 89124A; Skf 89124; F-89124; AC1Q6M2P; AC1L33CC; SCHEMBL2914813; 4-(2-Di-n-propylaminoethyl)-7-hydroxy-2-(3H)indolone; CTK8D5316; DTXSID60231232; 4-[2-(dipropylamino)ethyl]-7-hydroxy-1,3-dihydroindol-2-one; ZINC5832868; BDBM50019393; 4-(N,N-Dipropyl-2-aminoethyl)-7-hydroxy-2(3H)-indolone hydrochloride; AKOS030547943; 4-(2-di-n-propylaminoethyl)-7-hydroxy-2-(3h)-indolone
DMNUQ9P	DT	Small molecular drug
DMNUQ9P	PC	133741
DMNUQ9P	MW	276.37
DMNUQ9P	FM	C16H24N2O2
DMNUQ9P	IC	InChI=1S/C16H24N2O2/c1-3-8-18(9-4-2)10-7-12-5-6-14(19)16-13(12)11-15(20)17-16/h5-6,19H,3-4,7-11H2,1-2H3,(H,17,20)
DMNUQ9P	CS	CCCN(CCC)CCC1=C2CC(=O)NC2=C(C=C1)O
DMNUQ9P	IK	PVIICBUWKXYFAA-UHFFFAOYSA-N
DMNUQ9P	IU	4-[2-(dipropylamino)ethyl]-7-hydroxy-1,3-dihydroindol-2-one
DMNUQ9P	CA	CAS 81654-62-8
DMNUQ9P	DE	Discovery agent

DM0WNHQ	ID	DM0WNHQ
DM0WNHQ	DN	SKF89976A
DM0WNHQ	HS	Investigative
DM0WNHQ	SN	SKF-89976A; SKF 89976A
DM0WNHQ	DT	Small molecular drug
DM0WNHQ	PC	92409
DM0WNHQ	MW	335.4
DM0WNHQ	FM	C22H25NO2
DM0WNHQ	IC	InChI=1S/C22H25NO2/c24-22(25)20-13-7-15-23(17-20)16-8-14-21(18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-6,9-12,14,20H,7-8,13,15-17H2,(H,24,25)
DM0WNHQ	CS	C1CC(CN(C1)CCC=C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)O
DM0WNHQ	IK	TXQKSMSLZVKQBI-UHFFFAOYSA-N
DM0WNHQ	IU	1-(4,4-diphenylbut-3-enyl)piperidine-3-carboxylic acid
DM0WNHQ	CA	CAS 85375-85-5
DM0WNHQ	CB	CHEBI:91734
DM0WNHQ	DE	Discovery agent

DMJL6HX	ID	DMJL6HX
DMJL6HX	DN	SKI-2852
DMJL6HX	HS	Investigative
DMJL6HX	CP	SK Chemicals Co Ltd
DMJL6HX	DE	Metabolic syndrome x

DMXS9V8	ID	DMXS9V8
DMXS9V8	DN	SKL-18287
DMXS9V8	HS	Investigative
DMXS9V8	SN	GLP analog (sustained-release formulation, type 2 diabetes), Sanwa Kagaku Kenkyusho
DMXS9V8	CP	Sanwa Kagaku Kenkyusho Co Ltd
DMXS9V8	DE	Non-insulin dependent diabetes

DM5T4Y1	ID	DM5T4Y1
DM5T4Y1	DN	SKL-19014
DM5T4Y1	HS	Investigative
DM5T4Y1	SN	Glucokinase activator (oral, type 2 diabetes), Sanwa Kagaku Kenkyusho
DM5T4Y1	CP	Sanwa Kagaku Kenkyusho Co Ltd
DM5T4Y1	DE	Non-insulin dependent diabetes

DMUVAFO	ID	DMUVAFO
DMUVAFO	DN	SKLB-010
DMUVAFO	HS	Investigative
DMUVAFO	SN	Thiazolidinediones (inflammation), Sichuan University
DMUVAFO	CP	Sichuan University
DMUVAFO	PC	5373936
DMUVAFO	MW	235.26
DMUVAFO	FM	C11H9NO3S
DMUVAFO	IC	InChI=1S/C11H9NO3S/c1-15-8-4-2-7(3-5-8)6-9-10(13)12-11(14)16-9/h2-6H,1H3,(H,12,13,14)/b9-6-
DMUVAFO	CS	COC1=CC=C(C=C1)/C=C\\2/C(=O)NC(=O)S2
DMUVAFO	IK	VRUKGUBMRBLJJW-TWGQIWQCSA-N
DMUVAFO	IU	(5Z)-5-[(4-methoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
DMUVAFO	CA	CAS 6320-51-0
DMUVAFO	DE	Inflammation

DM4X2GH	ID	DM4X2GH
DM4X2GH	DN	SKL-PD
DM4X2GH	HS	Investigative
DM4X2GH	SN	SKA-PD-01; Monoamine oxidase B inhibitor (Parkinson's disease), SK Life Science
DM4X2GH	CP	SK Life Science
DM4X2GH	DE	Central nervous system disease

DMGQ9Z5	ID	DMGQ9Z5
DMGQ9Z5	DN	SKS-927
DMGQ9Z5	HS	Investigative
DMGQ9Z5	SN	SKS-927; CHEMBL391738; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[4-(4-methylpiperazin-1-yl)but-1-ynyl]-3-quinolinecarbonitrile; SCHEMBL4961809; ZJDFSJYCAFMEGH-UHFFFAOYSA-N
DMGQ9Z5	DT	Small molecular drug
DMGQ9Z5	PC	11656591
DMGQ9Z5	MW	524.4
DMGQ9Z5	FM	C27H27Cl2N5O2
DMGQ9Z5	IC	InChI=1S/C27H27Cl2N5O2/c1-33-8-10-34(11-9-33)7-5-4-6-18-12-23-20(13-25(18)35-2)27(19(16-30)17-31-23)32-24-15-26(36-3)22(29)14-21(24)28/h12-15,17H,5,7-11H2,1-3H3,(H,31,32)
DMGQ9Z5	CS	CN1CCN(CC1)CCC#CC2=CC3=NC=C(C(=C3C=C2OC)NC4=CC(=C(C=C4Cl)Cl)OC)C#N
DMGQ9Z5	IK	ZJDFSJYCAFMEGH-UHFFFAOYSA-N
DMGQ9Z5	IU	4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[4-(4-methylpiperazin-1-yl)but-1-ynyl]quinoline-3-carbonitrile
DMGQ9Z5	DE	Discovery agent

DMEIZ20	ID	DMEIZ20
DMEIZ20	DN	SL125
DMEIZ20	HS	Investigative
DMEIZ20	DE	Hyperaldosteronism; Myocardial fibrosis; Congestive heart failure

DM0UE28	ID	DM0UE28
DM0UE28	DN	SL-3111
DM0UE28	HS	Investigative
DM0UE28	SN	SL-3111; CHEMBL143592; SCHEMBL9881223; BDBM50068132
DM0UE28	DT	Small molecular drug
DM0UE28	PC	9909743
DM0UE28	MW	414.6
DM0UE28	FM	C28H34N2O
DM0UE28	IC	InChI=1S/C28H34N2O/c1-28(2,3)25-14-12-23(13-15-25)27(24-10-7-11-26(31)20-24)30-18-16-29(17-19-30)21-22-8-5-4-6-9-22/h4-15,20,27,31H,16-19,21H2,1-3H3
DM0UE28	CS	CC(C)(C)C1=CC=C(C=C1)C(C2=CC(=CC=C2)O)N3CCN(CC3)CC4=CC=CC=C4
DM0UE28	IK	PNVIEMCZBRMSPB-UHFFFAOYSA-N
DM0UE28	IU	3-[(4-benzylpiperazin-1-yl)-(4-tert-butylphenyl)methyl]phenol
DM0UE28	DE	Discovery agent

DMYJV4I	ID	DMYJV4I
DMYJV4I	DN	SL-327
DMYJV4I	HS	Investigative
DMYJV4I	SN	SL327
DMYJV4I	DT	Small molecular drug
DMYJV4I	PC	9549284
DMYJV4I	MW	335.3
DMYJV4I	FM	C16H12F3N3S
DMYJV4I	IC	InChI=1S/C16H12F3N3S/c17-16(18,19)14-4-2-1-3-12(14)13(9-20)15(22)23-11-7-5-10(21)6-8-11/h1-8H,21-22H2/b15-13+
DMYJV4I	CS	C1=CC=C(C(=C1)/C(=C(\\N)/SC2=CC=C(C=C2)N)/C#N)C(F)(F)F
DMYJV4I	IK	JLOXTZFYJNCPIS-FYWRMAATSA-N
DMYJV4I	IU	(Z)-3-amino-3-(4-aminophenyl)sulfanyl-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile
DMYJV4I	CA	CAS 305350-87-2
DMYJV4I	CB	CHEBI:92211
DMYJV4I	DE	Discovery agent

DM3I2US	ID	DM3I2US
DM3I2US	DN	SL422
DM3I2US	HS	Investigative
DM3I2US	SN	analogue 55f [PMID: 11472217]
DM3I2US	DT	Small molecular drug
DM3I2US	PC	10344307
DM3I2US	MW	462.5
DM3I2US	FM	C23H34N4O6
DM3I2US	IC	InChI=1S/C23H34N4O6/c1-14(2)11-18-17(22(30)27-32)5-4-10-33-16-8-6-15(7-9-16)12-19(26-21(18)29)23(31)25-13-20(28)24-3/h6-9,14,17-19,32H,4-5,10-13H2,1-3H3,(H,24,28)(H,25,31)(H,26,29)(H,27,30)/t17-,18+,19-/m0/s1
DM3I2US	CS	CC(C)C[C@@H]1[C@H](CCCOC2=CC=C(C[C@H](NC1=O)C(=O)NCC(=O)NC)C=C2)C(=O)NO
DM3I2US	IK	HFAGTNGCAZYYLZ-OTWHNJEPSA-N
DM3I2US	IU	(6S,7R,10S)-6-N-hydroxy-10-N-[2-(methylamino)-2-oxoethyl]-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide
DM3I2US	DE	Discovery agent

DMEBPCO	ID	DMEBPCO
DMEBPCO	DN	SLG
DMEBPCO	HS	Investigative
DMEBPCO	SN	1-stearoyl-2-linoleoyl-sn-glycerol
DMEBPCO	DT	Small molecular drug
DMEBPCO	PC	6441562
DMEBPCO	MW	621
DMEBPCO	FM	C39H72O5
DMEBPCO	IC	InChI=1S/C39H72O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(41)43-36-37(35-40)44-39(42)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12,14,18,20,37,40H,3-11,13,15-17,19,21-36H2,1-2H3/b14-12-,20-18-/t37-/m0/s1
DMEBPCO	CS	CCCCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC/C=C\\C/C=C\\CCCCC
DMEBPCO	IK	AJMZUFBKADIAKC-SKTOPKGQSA-N
DMEBPCO	IU	[(2S)-3-hydroxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropyl] octadecanoate
DMEBPCO	CA	CAS 34487-26-8
DMEBPCO	CB	CHEBI:77097
DMEBPCO	DE	Discovery agent

DMBD6TC	ID	DMBD6TC
DMBD6TC	DN	slotoxin
DMBD6TC	HS	Investigative
DMBD6TC	SN	Potassium channel toxin alpha-KTx 1.11; SloTx
DMBD6TC	DT	Small molecular drug
DMBD6TC	PC	16133816
DMBD6TC	MW	4092
DMBD6TC	FM	C177H281N47O50S7
DMBD6TC	IC	InChI=1S/C177H281N47O50S7/c1-17-92(10)141(222-159(256)116(71-99-42-22-19-23-43-99)207-169(266)136(184)96(14)226)173(270)210-120(76-135(238)239)160(257)219-138(89(4)5)171(268)209-119(75-134(236)237)157(254)216-127(87-280)167(264)223-142(97(15)227)174(271)220-139(90(6)7)172(269)211-121(81-225)161(258)199-109(49-29-35-64-181)151(248)202-112(58-59-132(232)233)154(251)215-125(85-278)166(263)206-117(73-101-77-188-104-45-25-24-44-103(101)104)155(252)194-95(13)175(272)224-68-39-53-128(224)168(265)217-126(86-279)164(261)200-108(48-28-34-63-180)148(245)193-93(11)143(240)192-94(12)144(241)204-114(70-98-40-20-18-21-41-98)147(244)191-80-131(231)218-137(88(2)3)170(267)208-118(74-133(234)235)156(253)197-105(52-38-67-187-177(185)186)145(242)189-78-129(229)196-107(47-27-33-62-179)150(247)212-123(83-276)163(260)203-113(60-69-281-16)146(243)190-79-130(230)195-106(46-26-32-61-178)149(246)198-110(50-30-36-65-182)152(249)213-122(82-275)162(259)201-111(51-31-37-66-183)153(250)214-124(84-277)165(262)205-115(72-100-54-56-102(228)57-55-100)158(255)221-140(91(8)9)176(273)274/h18-25,40-45,54-57,77,88-97,105-128,136-142,188,225-228,275-280H,17,26-39,46-53,58-76,78-87,178-184H2,1-16H3,(H,189,242)(H,190,243)(H,191,244)(H,192,240)(H,193,245)(H,194,252)(H,195,230)(H,196,229)(H,197,253)(H,198,246)(H,199,258)(H,200,261)(H,201,259)(H,202,248)(H,203,260)(H,204,241)(H,205,262)(H,206,263)(H,207,266)(H,208,267)(H,209,268)(H,210,270)(H,211,269)(H,212,247)(H,213,249)(H,214,250)(H,215,251)(H,216,254)(H,217,265)(H,218,231)(H,219,257)(H,220,271)(H,221,255)(H,222,256)(H,223,264)(H,232,233)(H,234,235)(H,236,237)(H,238,239)(H,273,274)(H4,185,186,187)/t92-,93-,94-,95-,96+,97+,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,136-,137-,138-,139-,140-,141-,142-/m0/s1
DMBD6TC	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)N
DMBD6TC	IK	IYKSHBADGOZWIF-UTPLJIOFSA-N
DMBD6TC	IU	(4S)-5-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[[(2R)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2R)-1-[[(2S)-6-amino-1-[[(2R)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoic acid
DMBD6TC	DE	Discovery agent

DMPETL7	ID	DMPETL7
DMPETL7	DN	SLV-314
DMPETL7	HS	Investigative
DMPETL7	SN	Lensiprazine; 327026-93-7; SLV-314; UNII-N47MW76OGX; N47MW76OGX; CHEMBL196514; Lensiprazine [INN]; DTXSID60186379; ZINC11689014; BDBM50176019; API0013978; ACM327026937; 026L937; (R)-8-{4-[3-(5-Fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one; (R)-8-(4-(3-(5-fluoro-1H-indol-3-yl)propyl)piperazin-1-yl)-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one
DMPETL7	DT	Small molecular drug
DMPETL7	PC	9954003
DMPETL7	MW	422.5
DMPETL7	FM	C24H27FN4O2
DMPETL7	IC	InChI=1S/C24H27FN4O2/c1-16-24(30)27-21-5-2-6-22(23(21)31-16)29-12-10-28(11-13-29)9-3-4-17-15-26-20-8-7-18(25)14-19(17)20/h2,5-8,14-16,26H,3-4,9-13H2,1H3,(H,27,30)/t16-/m1/s1
DMPETL7	CS	C[C@@H]1C(=O)NC2=C(O1)C(=CC=C2)N3CCN(CC3)CCCC4=CNC5=C4C=C(C=C5)F
DMPETL7	IK	SDAMYSWGWHXMRT-MRXNPFEDSA-N
DMPETL7	IU	(2R)-8-[4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazin-1-yl]-2-methyl-4H-1,4-benzoxazin-3-one
DMPETL7	CA	CAS 327026-93-7
DMPETL7	DE	Discovery agent

DM7MSGK	ID	DM7MSGK
DM7MSGK	DN	SM 21
DM7MSGK	HS	Investigative
DM7MSGK	SN	SM-21; (RS)-SM21; (+/-)-SM21
DM7MSGK	DT	Small molecular drug
DM7MSGK	PC	4679312
DM7MSGK	MW	337.8
DM7MSGK	FM	C18H24ClNO3
DM7MSGK	IC	InChI=1S/C18H24ClNO3/c1-3-17(22-15-8-4-12(19)5-9-15)18(21)23-16-10-13-6-7-14(11-16)20(13)2/h4-5,8-9,13-14,16-17H,3,6-7,10-11H2,1-2H3
DM7MSGK	CS	CCC(C(=O)OC1CC2CCC(C1)N2C)OC3=CC=C(C=C3)Cl
DM7MSGK	IK	WTPAXDRULIZRDJ-UHFFFAOYSA-N
DM7MSGK	IU	(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(4-chlorophenoxy)butanoate
DM7MSGK	CA	CAS 155058-71-2
DM7MSGK	CB	CHEBI:104235
DM7MSGK	DE	Discovery agent

DMC7YQE	ID	DMC7YQE
DMC7YQE	DN	SM-122
DMC7YQE	HS	Investigative
DMC7YQE	SN	SM-122; CHEMBL481422; Smac peptide mimetic 20; GTPL8855; SCHEMBL12105346; BDBM26218; bicyclic Smac peptide mimetic, 20; (3S,6S,10aS)-N-benzhydryl-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-2,3,6,7,8,9,10,10a-octahydro-1H-pyrrolo[1,2-a]azocine-3-carboxamide
DMC7YQE	DT	Small molecular drug
DMC7YQE	PC	24754886
DMC7YQE	MW	476.6
DMC7YQE	FM	C28H36N4O3
DMC7YQE	IC	InChI=1S/C28H36N4O3/c1-19(29-2)26(33)30-23-16-10-9-15-22-17-18-24(32(22)28(23)35)27(34)31-25(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,19,22-25,29H,9-10,15-18H2,1-2H3,(H,30,33)(H,31,34)/t19-,22-,23-,24-/m0/s1
DMC7YQE	CS	C[C@@H](C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)NC
DMC7YQE	IK	XBTLZUHJBOBKRG-HCUBDLJJSA-N
DMC7YQE	IU	(3S,6S,10aS)-N-benzhydryl-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-2,3,6,7,8,9,10,10a-octahydro-1H-pyrrolo[1,2-a]azocine-3-carboxamide
DMC7YQE	DE	Discovery agent

DMKZVEQ	ID	DMKZVEQ
DMKZVEQ	DN	SM-130,686
DMKZVEQ	HS	Investigative
DMKZVEQ	SN	SM 130686
DMKZVEQ	DT	Small molecular drug
DMKZVEQ	PC	9890863
DMKZVEQ	MW	469.9
DMKZVEQ	FM	C22H23ClF3N3O3
DMKZVEQ	IC	InChI=1S/C22H23ClF3N3O3/c1-3-28(4-2)9-10-29-17-12-13(19(27)30)11-15(22(24,25)26)18(17)21(32,20(29)31)14-7-5-6-8-16(14)23/h5-8,11-12,32H,3-4,9-10H2,1-2H3,(H2,27,30)
DMKZVEQ	CS	CCN(CC)CCN1C2=CC(=CC(=C2C(C1=O)(C3=CC=CC=C3Cl)O)C(F)(F)F)C(=O)N
DMKZVEQ	IK	YSSPGXCFFITNCE-UHFFFAOYSA-N
DMKZVEQ	IU	3-(2-chlorophenyl)-1-[2-(diethylamino)ethyl]-3-hydroxy-2-oxo-4-(trifluoromethyl)indole-6-carboxamide
DMKZVEQ	DE	Discovery agent

DMP8VO6	ID	DMP8VO6
DMP8VO6	DN	SM-131
DMP8VO6	HS	Investigative
DMP8VO6	SN	CHEMBL514738
DMP8VO6	DT	Small molecular drug
DMP8VO6	PC	44589292
DMP8VO6	MW	462.6
DMP8VO6	FM	C27H34N4O3
DMP8VO6	IC	InChI=1S/C27H34N4O3/c1-3-22(28-2)25(32)29-23-16-10-15-21-17-18-24(31(21)26(23)33)27(34)30(19-11-6-4-7-12-19)20-13-8-5-9-14-20/h4-9,11-14,21-24,28H,3,10,15-18H2,1-2H3,(H,29,32)/t21-,22-,23-,24-/m0/s1
DMP8VO6	CS	CC[C@@H](C(=O)N[C@H]1CCC[C@H]2CC[C@H](N2C1=O)C(=O)N(C3=CC=CC=C3)C4=CC=CC=C4)NC
DMP8VO6	IK	MIWHOUGMEANWCH-ZJZGAYNASA-N
DMP8VO6	IU	(3S,6S,9aS)-6-[[(2S)-2-(methylamino)butanoyl]amino]-5-oxo-N,N-diphenyl-1,2,3,6,7,8,9,9a-octahydropyrrolo[1,2-a]azepine-3-carboxamide
DMP8VO6	DE	Discovery agent

DMOSTP9	ID	DMOSTP9
DMOSTP9	DN	SM-337
DMOSTP9	HS	Investigative
DMOSTP9	SN	SM-337; CHEMBL504559; GTPL7732; SCHEMBL12851753; BDBM50273699; (5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-3-(2-phenylacetyl)-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
DMOSTP9	DT	Small molecular drug
DMOSTP9	PC	25172871
DMOSTP9	MW	595.7
DMOSTP9	FM	C35H41N5O4
DMOSTP9	IC	InChI=1S/C35H41N5O4/c1-24(36-2)33(42)37-29-23-39(31(41)22-25-12-6-3-7-13-25)21-20-28-18-19-30(40(28)35(29)44)34(43)38-32(26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17,24,28-30,32,36H,18-23H2,1-2H3,(H,37,42)(H,38,43)/t24-,28+,29-,30-/m0/s1
DMOSTP9	CS	C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC5=CC=CC=C5)NC
DMOSTP9	IK	YBYZHVZWINISJO-XPSCAIQQSA-N
DMOSTP9	IU	(5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-3-(2-phenylacetyl)-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
DMOSTP9	CA	CAS 1071992-61-4
DMOSTP9	DE	Discovery agent

DMWJ70Q	ID	DMWJ70Q
DMWJ70Q	DN	Small molecule 34
DMWJ70Q	HS	Investigative
DMWJ70Q	SN	3-(2-(4-pyridyl)ethyl)indole; 3-(2-PYRIDIN-4-YLETHYL)-1H-INDOLE; INHIBITOR OF P38 KINASE; 3-(2-(Pyridin-4-yl)ethyl)-1H-indole; 3-[2-(pyridin-4-yl)ethyl]-1H-indole; 3-(2-Pyridin-4-yl-ethyl)-1H-indole; L12; Maybridge1_000718; Cambridge id 5373101; AC1L1E9J; Oprea1_574113; Oprea1_420786; SCHEMBL735580; CHEMBL193156; HMS543I14; ZINC94256; BDBM13346; UUEYCHLWAOBOHG-UHFFFAOYSA-N; 1w84; MolPort-001-886-488; HMS3604M06; 3-[2-(4-pyridyl)-ethyl]-indole; STL328644; CCG-45397; 3-[2-(4-Pyridyl)ethyl]-1H-indole; AKOS000545583; MCULE-4657429599
DMWJ70Q	DT	Small molecular drug
DMWJ70Q	PC	27934
DMWJ70Q	MW	222.28
DMWJ70Q	FM	C15H14N2
DMWJ70Q	IC	InChI=1S/C15H14N2/c1-2-4-15-14(3-1)13(11-17-15)6-5-12-7-9-16-10-8-12/h1-4,7-11,17H,5-6H2
DMWJ70Q	CS	C1=CC=C2C(=C1)C(=CN2)CCC3=CC=NC=C3
DMWJ70Q	IK	UUEYCHLWAOBOHG-UHFFFAOYSA-N
DMWJ70Q	IU	3-(2-pyridin-4-ylethyl)-1H-indole
DMWJ70Q	DE	Discovery agent

DMGJTL3	ID	DMGJTL3
DMGJTL3	DN	SMaRT FVIII
DMGJTL3	HS	Investigative
DMGJTL3	SN	SMaRT FVIII (hemophilia A); Factor VIII modulator (SMaRT), Intronn; Factor VIII modulator (SMaRT), VIRxSYS; Hemophilia therapeutic (SMaRT), Intronn; Hemophilia therapeutic (SMaRT), VIRxSYS; SMaRT FVIII (hemophilia A), Intronn; SMaRT FVIII (hemophilia A), VIRxSYS
DMGJTL3	CP	Intronn Inc
DMGJTL3	DE	Hemophilia

DMZC2BT	ID	DMZC2BT
DMZC2BT	DN	SMEATHXANTHONE A
DMZC2BT	HS	Investigative
DMZC2BT	SN	smeathxanthone A; CHEMBL480158; BDBM50325675; 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-1,3,5,8-tetrahydroxy-xanthen-9-one
DMZC2BT	DT	Small molecular drug
DMZC2BT	PC	11509473
DMZC2BT	MW	396.4
DMZC2BT	FM	C23H24O6
DMZC2BT	IC	InChI=1S/C23H24O6/c1-12(2)5-4-6-13(3)7-8-14-17(26)11-18-20(21(14)27)22(28)19-15(24)9-10-16(25)23(19)29-18/h5,7,9-11,24-27H,4,6,8H2,1-3H3/b13-7+
DMZC2BT	CS	CC(=CCC/C(=C/CC1=C(C2=C(C=C1O)OC3=C(C=CC(=C3C2=O)O)O)O)/C)C
DMZC2BT	IK	TWEXJIOSYZXWGT-NTUHNPAUSA-N
DMZC2BT	IU	2-[(2E)-3,7-dimethylocta-2,6-dienyl]-1,3,5,8-tetrahydroxyxanthen-9-one
DMZC2BT	DE	Discovery agent

DM79QC2	ID	DM79QC2
DM79QC2	DN	S-methyl 4-methyl-4-morpholinopent-2-ynethioate
DM79QC2	HS	Investigative
DM79QC2	SN	CHEMBL447917; SCHEMBL18768283; 4-methyl-4-morpholin-4-ylpent-2-ynthioic acid S-methyl ester
DM79QC2	DT	Small molecular drug
DM79QC2	PC	9964593
DM79QC2	MW	227.33
DM79QC2	FM	C11H17NO2S
DM79QC2	IC	InChI=1S/C11H17NO2S/c1-11(2,5-4-10(13)15-3)12-6-8-14-9-7-12/h6-9H2,1-3H3
DM79QC2	CS	CC(C)(C#CC(=O)SC)N1CCOCC1
DM79QC2	IK	XEVZURDMZKIWMB-UHFFFAOYSA-N
DM79QC2	IU	S-methyl 4-methyl-4-morpholin-4-ylpent-2-ynethioate
DM79QC2	DE	Discovery agent

DMAMRKS	ID	DMAMRKS
DMAMRKS	DN	S-Methylcysteine
DMAMRKS	HS	Investigative
DMAMRKS	SN	7728-98-5; H-DL-Cys(Me)-OH; H-D-HoCys-OH; S-Methyl-DL-cysteine; USAF CB-24; Methylcysteine; 2-amino-3-(methylsulfanyl)propanoic acid; 19651-44-6; 1-carboxy-2-methylthioethylamine; Methylcysteine, L-; ALANINE, 3-(METHYLTHIO)-, L-; EINECS 231-787-0; Methylcysteine #; S-Methyl cysteine; DL-S-Methylcysteine; DL-S-Methyl-Cys-OH; DL-Cysteine, S-methyl-; AC1Q5S9H; AC1L5E8F; SCHEMBL110459; ACMC-209a03; IDIDJDIHTAOVLG-UHFFFAOYSA-; CTK0E0884; IDIDJDIHTAOVLG-UHFFFAOYSA-N; MolPort-003-876-437; NSC15387; NSC-15387; AKOS022154885
DMAMRKS	DT	Small molecular drug
DMAMRKS	PC	24417
DMAMRKS	MW	135.19
DMAMRKS	FM	C4H9NO2S
DMAMRKS	IC	InChI=1S/C4H9NO2S/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1
DMAMRKS	CS	CSC[C@@H](C(=O)O)N
DMAMRKS	IK	IDIDJDIHTAOVLG-VKHMYHEASA-N
DMAMRKS	IU	(2R)-2-amino-3-methylsulfanylpropanoic acid
DMAMRKS	CA	CAS 1187-84-4
DMAMRKS	CB	CHEBI:45658
DMAMRKS	DE	Discovery agent

DMBLWMS	ID	DMBLWMS
DMBLWMS	DN	SMI-4a
DMBLWMS	HS	Investigative
DMBLWMS	SN	438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione
DMBLWMS	DT	Small molecular drug
DMBLWMS	PC	1361334
DMBLWMS	MW	273.23
DMBLWMS	FM	C11H6F3NO2S
DMBLWMS	IC	InChI=1S/C11H6F3NO2S/c12-11(13,14)7-3-1-2-6(4-7)5-8-9(16)15-10(17)18-8/h1-5H,(H,15,16,17)/b8-5-
DMBLWMS	CS	C1=CC(=CC(=C1)C(F)(F)F)/C=C\\2/C(=O)NC(=O)S2
DMBLWMS	IK	NGJLOFCOEOHFKQ-YVMONPNESA-N
DMBLWMS	IU	(5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione
DMBLWMS	DE	Non-small cell lung cancer

DMABIX1	ID	DMABIX1
DMABIX1	DN	SMOi2-17
DMABIX1	HS	Investigative
DMABIX1	SN	SMOi2-20; SMO antagonist (lipidated peptide, cancer), NCI; Smoothened antagonist (lipidated peptide, cancer), NCI
DMABIX1	CP	National Cancer Institute
DMABIX1	DE	Solid tumour/cancer

DMSI95J	ID	DMSI95J
DMSI95J	DN	SMP-797
DMSI95J	HS	Investigative
DMSI95J	SN	compound 22b [PMID: 16242323]
DMSI95J	DT	Small molecular drug
DMSI95J	PC	9938311
DMSI95J	MW	585.7
DMSI95J	FM	C34H43N5O4
DMSI95J	IC	InChI=1S/C34H43N5O4/c1-6-7-15-39-32-26(13-9-14-36-32)29(23-11-8-12-25(18-23)43-17-10-16-40)31(33(39)41)38-34(42)37-30-27(21(2)3)19-24(35)20-28(30)22(4)5/h8-9,11-14,18-22,40H,6-7,10,15-17,35H2,1-5H3,(H2,37,38,42)
DMSI95J	CS	CCCCN1C2=C(C=CC=N2)C(=C(C1=O)NC(=O)NC3=C(C=C(C=C3C(C)C)N)C(C)C)C4=CC(=CC=C4)OCCCO
DMSI95J	IK	HNRUUMLUBDTZHX-UHFFFAOYSA-N
DMSI95J	IU	1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea
DMSI95J	CA	CAS 437763-85-4
DMSI95J	DE	Discovery agent

DMO8G39	ID	DMO8G39
DMO8G39	DN	S-MTC
DMO8G39	HS	Investigative
DMO8G39	SN	L-S-Methylthiocitrulline; S-Methyl-L-thiocitrulline; S-Methyl-l-thiocitrulline; S-Methylthiocitrulline; (2S)-2-amino-5-[[amino(methylsulfanyl)methylidene]amino]pentanoic acid; 156719-41-4; CHEBI:90712; CHEMBL106516; L-Ornithine, N5-(imino(methylthio)methyl)-; L-Ornithine, N5-[imino(methylthio)methyl]-; N(delta)-(S-Methylisothioureido)norvaline; N5-(Imino(methylthio)methyl)-L-ornithine; N5-[Imino(methylthio)methyl]-L-ornithine; M790X706JV; NGVMVBQRKZPFLB-YFKPBYRVSA-N; S-Me-TC; N~5~-[(E)-imino(methylsulfanyl)methyl]-L-ornithine; S-MTC; UNII-M790X706JV
DMO8G39	PC	107968
DMO8G39	MW	205.28
DMO8G39	FM	C7H15N3O2S
DMO8G39	IC	NGVMVBQRKZPFLB-YFKPBYRVSA-N
DMO8G39	CS	CSC(=NCCCC(C(=O)O)N)N
DMO8G39	IK	1S/C7H15N3O2S/c1-13-7(9)10-4-2-3-5(8)6(11)12/h5H,2-4,8H2,1H3,(H2,9,10)(H,11,12)/t5-/m0/s1
DMO8G39	IU	(2S)-2-amino-5-[[amino(methylsulfanyl)methylidene]amino]pentanoic acid
DMO8G39	CA	CAS 156719-41-4
DMO8G39	CB	CHEBI:90712
DMO8G39	DE	Discovery agent

DM9SF48	ID	DM9SF48
DM9SF48	DN	SMTP-0
DM9SF48	HS	Investigative
DM9SF48	SN	SMTP compounds (cancer/metabolic disorder/thromboembolism/organ failure); SMTP compounds (cancer/metabolic disorder/thromboembolism/organ failure), TMS; Triprenyl phenols (cancer/metabolic disorder/thromboembolism/organ failure), TMS
DM9SF48	CP	Tokyo University Of Agriculture & Technology Co Ltd
DM9SF48	PC	102326821
DM9SF48	MW	399.5
DM9SF48	FM	C24H33NO4
DM9SF48	IC	InChI=1S/C24H33NO4/c1-15(2)8-6-9-16(3)10-7-11-24(4)21(27)13-18-20(26)12-17-19(22(18)29-24)14-25(5)23(17)28/h8,10,12,21,26-27H,6-7,9,11,13-14H2,1-5H3/b16-10+/t21-,24-/m0/s1
DM9SF48	CS	CC(=CCC/C(=C/CC[C@]1([C@H](CC2=C(C=C3C(=C2O1)CN(C3=O)C)O)O)C)/C)C
DM9SF48	IK	QIEGDUWARWIZQX-IRTPIHDWSA-N
DM9SF48	IU	(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2,8-dimethyl-4,9-dihydro-3H-pyrano[2,3-e]isoindol-7-one
DM9SF48	DE	Solid tumour/cancer

DMWCSQH	ID	DMWCSQH
DMWCSQH	DN	SN-1
DMWCSQH	HS	Investigative
DMWCSQH	DT	Small molecular drug
DMWCSQH	PC	135419200
DMWCSQH	MW	461.6
DMWCSQH	FM	C22H31N5O4S
DMWCSQH	IC	InChI=1S/C22H31N5O4S/c1-9-31-15-11-10-13(32(29,30)26-22(5,6)7)12-14(15)19-23-16-17(20(28)24-19)27(8)25-18(16)21(2,3)4/h10-12,26H,9H2,1-8H3,(H,23,24,28)
DMWCSQH	CS	CCOC1=C(C=C(C=C1)S(=O)(=O)NC(C)(C)C)C2=NC3=C(C(=O)N2)N(N=C3C(C)(C)C)C
DMWCSQH	IK	VMVZVLPMWCBOFI-UHFFFAOYSA-N
DMWCSQH	IU	N-tert-butyl-3-(3-tert-butyl-1-methyl-7-oxo-6H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxybenzenesulfonamide
DMWCSQH	CB	CHEBI:120653
DMWCSQH	DE	Discovery agent

DMA0JZM	ID	DMA0JZM
DMA0JZM	DN	SN-11
DMA0JZM	HS	Investigative
DMA0JZM	SN	SN-11; CHEMBL559518
DMA0JZM	DT	Small molecular drug
DMA0JZM	PC	23642304
DMA0JZM	MW	396.5
DMA0JZM	FM	C27H28N2O
DMA0JZM	IC	InChI=1S/C27H28N2O/c30-21-8-7-18-13-26-23-12-20-11-19-3-1-2-4-24(19)28-25(20)15-27(23,22(18)14-21)9-10-29(26)16-17-5-6-17/h1-4,7-8,11,14,17,23,26,30H,5-6,9-10,12-13,15-16H2/t23-,26+,27+/m0/s1
DMA0JZM	CS	C1CC1CN2CC[C@]34CC5=NC6=CC=CC=C6C=C5C[C@H]3[C@H]2CC7=C4C=C(C=C7)O
DMA0JZM	IK	FTJYQAMRGYACMS-HUROMRQRSA-N
DMA0JZM	IU	(1S,14R,15R)-25-(cyclopropylmethyl)-4,25-diazahexacyclo[13.7.3.01,14.03,12.05,10.017,22]pentacosa-3,5,7,9,11,17(22),18,20-octaen-20-ol
DMA0JZM	DE	Discovery agent

DMYVIBW	ID	DMYVIBW
DMYVIBW	DN	SN-2
DMYVIBW	HS	Investigative
DMYVIBW	SN	SN 2; 823218-99-1; MLS000700355; 5-mesityl-3-oxa-4-azatricyclo[5.2.1.0~2,6~]dec-4-ene; SMR000225039; 5-mesityl-3-oxa-4-azatricyclo[5.2.1.02,6]dec-4-ene; AE-842/34023054; GTPL6402; CHEMBL1430530; BDBM46936; CTK6B4503; MolPort-002-801-812; cid_11834987; HMS2568I08; 4052AH; AKOS024458411; CS-3229; HY-16696; 5-Mesityl-3-oxa-4-azatricyclo[5.2.1.0(2,6)]dec-4-ene
DMYVIBW	DT	Small molecular drug
DMYVIBW	PC	11834987
DMYVIBW	MW	255.35
DMYVIBW	FM	C17H21NO
DMYVIBW	IC	InChI=1S/C17H21NO/c1-9-6-10(2)14(11(3)7-9)16-15-12-4-5-13(8-12)17(15)19-18-16/h6-7,12-13,15,17H,4-5,8H2,1-3H3
DMYVIBW	CS	CC1=CC(=C(C(=C1)C)C2=NOC3C2C4CCC3C4)C
DMYVIBW	IK	WKLZNTYMDOPBSE-UHFFFAOYSA-N
DMYVIBW	IU	5-(2,4,6-trimethylphenyl)-3-oxa-4-azatricyclo[5.2.1.02,6]dec-4-ene
DMYVIBW	DE	Discovery agent

DM6O0PD	ID	DM6O0PD
DM6O0PD	DN	SN-23
DM6O0PD	HS	Investigative
DM6O0PD	SN	SN-23; CHEMBL564538
DM6O0PD	DT	Small molecular drug
DM6O0PD	PC	45270599
DM6O0PD	MW	398.5
DM6O0PD	FM	C27H30N2O
DM6O0PD	IC	InChI=1S/C27H30N2O/c1-17(2)16-29-10-9-27-15-25-20(11-19-5-3-4-6-24(19)28-25)12-23(27)26(29)13-18-7-8-21(30)14-22(18)27/h3-8,11,14,17,23,26,30H,9-10,12-13,15-16H2,1-2H3/t23-,26+,27+/m0/s1
DM6O0PD	CS	CC(C)CN1CC[C@]23CC4=NC5=CC=CC=C5C=C4C[C@H]2[C@H]1CC6=C3C=C(C=C6)O
DM6O0PD	IK	LRXLXNDXXNBZCL-HUROMRQRSA-N
DM6O0PD	IU	(1S,14R,15R)-25-(2-methylpropyl)-4,25-diazahexacyclo[13.7.3.01,14.03,12.05,10.017,22]pentacosa-3,5,7,9,11,17(22),18,20-octaen-20-ol
DM6O0PD	DE	Discovery agent

DMB8TJC	ID	DMB8TJC
DMB8TJC	DN	SN-28
DMB8TJC	HS	Investigative
DMB8TJC	SN	CHEMBL552308; SN-28; SCHEMBL16248949
DMB8TJC	DT	Small molecular drug
DMB8TJC	PC	44467662
DMB8TJC	MW	356.5
DMB8TJC	FM	C24H24N2O
DMB8TJC	IC	InChI=1S/C24H24N2O/c1-26-9-8-24-14-22-17(10-16-4-2-3-5-21(16)25-22)11-20(24)23(26)12-15-6-7-18(27)13-19(15)24/h2-7,10,13,20,23,27H,8-9,11-12,14H2,1H3/t20-,23+,24+/m0/s1
DMB8TJC	CS	CN1CC[C@]23CC4=NC5=CC=CC=C5C=C4C[C@H]2[C@H]1CC6=C3C=C(C=C6)O
DMB8TJC	IK	HDRKKGULQPRYBL-TUACAJSNSA-N
DMB8TJC	IU	(1S,14R,15R)-25-methyl-4,25-diazahexacyclo[13.7.3.01,14.03,12.05,10.017,22]pentacosa-3,5,7,9,11,17(22),18,20-octaen-20-ol
DMB8TJC	DE	Discovery agent

DM2UVNB	ID	DM2UVNB
DM2UVNB	DN	SN-38G
DM2UVNB	HS	Investigative
DM2UVNB	SN	SN-38 Glucuronide; SN-38G; J-004437; RT-015725; SN38 glucuronide; ZINC4099104; 121080-63-5; AC1L9E4E; AKOS025394253; C11376; CHEBI:8990; CHEMBL3526803; CTK8E7286
DM2UVNB	PC	443154
DM2UVNB	MW	568.5
DM2UVNB	FM	C28H28N2O11
DM2UVNB	IC	SSJQVDUAKDRWTA-CAYKMONMSA-N
DM2UVNB	CS	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC6C(C(C(C(O6)C(=O)O)O)O)O
DM2UVNB	IK	1S/C28H28N2O11/c1-3-12-13-7-11(40-26-22(33)20(31)21(32)23(41-26)25(35)36)5-6-17(13)29-19-14(12)9-30-18(19)8-16-15(24(30)34)10-39-27(37)28(16,38)4-2/h5-8,20-23,26,31-33,38H,3-4,9-10H2,1-2H3,(H,35,36)/t20-,21-,22+,23-,26+,28-/m0/s1
DM2UVNB	IU	(2S,3S,4S,5R,6S)-6-[[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DM2UVNB	CA	CAS 121080-63-5
DM2UVNB	CB	CHEBI:8990
DM2UVNB	DE	Colorectal cancer

DMP4IJ6	ID	DMP4IJ6
DMP4IJ6	DN	SN429
DMP4IJ6	HS	Investigative
DMP4IJ6	SN	CHEMBL37251; SN-429; 209954-52-9; 1H-Pyrazole-5-carboxamide,1-[3-(aminoiminomethyl)phenyl]-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl-; SCHEMBL14534861; BDBM12751; ZINC2006270; KB-65315
DMP4IJ6	DT	Small molecular drug
DMP4IJ6	PC	9869498
DMP4IJ6	MW	474.5
DMP4IJ6	FM	C24H22N6O3S
DMP4IJ6	IC	InChI=1S/C24H22N6O3S/c1-15-13-21(30(29-15)19-6-4-5-17(14-19)23(25)26)24(31)28-18-11-9-16(10-12-18)20-7-2-3-8-22(20)34(27,32)33/h2-14H,1H3,(H3,25,26)(H,28,31)(H2,27,32,33)
DMP4IJ6	CS	CC1=NN(C(=C1)C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3S(=O)(=O)N)C4=CC=CC(=C4)C(=N)N
DMP4IJ6	IK	APFKCRTWNKCURW-UHFFFAOYSA-N
DMP4IJ6	IU	2-(3-carbamimidoylphenyl)-5-methyl-N-[4-(2-sulfamoylphenyl)phenyl]pyrazole-3-carboxamide
DMP4IJ6	DE	Thrombosis

DMS1AFL	ID	DMS1AFL
DMS1AFL	DN	SNAP 398299
DMS1AFL	HS	Investigative
DMS1AFL	SN	SNAP-398299; SNAP398299
DMS1AFL	DT	Small molecular drug
DMS1AFL	PC	11698643
DMS1AFL	MW	479.5
DMS1AFL	FM	C27H24F3N3O2
DMS1AFL	IC	InChI=1S/C27H24F3N3O2/c28-27(29,30)19-7-5-8-20(17-19)31-25-23-11-1-2-12-24(23)33(26(25)34)21-9-6-10-22(18-21)35-16-15-32-13-3-4-14-32/h1-2,5-12,17-18H,3-4,13-16H2
DMS1AFL	CS	C1CCN(C1)CCOC2=CC=CC(=C2)N3C4=CC=CC=C4C(=NC5=CC=CC(=C5)C(F)(F)F)C3=O
DMS1AFL	IK	HXCJZIBJTFITNI-UHFFFAOYSA-N
DMS1AFL	IU	1-[3-(2-pyrrolidin-1-ylethoxy)phenyl]-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one
DMS1AFL	DE	Discovery agent

DMEJ5CP	ID	DMEJ5CP
DMEJ5CP	DN	SNAP-5036
DMEJ5CP	HS	Investigative
DMEJ5CP	SN	SNAP-5036; CHEMBL282214; SCHEMBL7034334; NJWKVUCAVMYELV-UHFFFAOYSA-N; BDBM50160147; 2-[(4-Methoxyphenethyl)aminomethyl]-1,2,3,4-tetrahydronaphthalene; 2- [(4-Methoxyphenethyl)aminomethyl]-1,2,3,4-tetrahydronaphthalene
DMEJ5CP	DT	Small molecular drug
DMEJ5CP	PC	9817640
DMEJ5CP	MW	295.4
DMEJ5CP	FM	C20H25NO
DMEJ5CP	IC	InChI=1S/C20H25NO/c1-22-20-10-7-16(8-11-20)12-13-21-15-17-6-9-18-4-2-3-5-19(18)14-17/h2-5,7-8,10-11,17,21H,6,9,12-15H2,1H3
DMEJ5CP	CS	COC1=CC=C(C=C1)CCNCC2CCC3=CC=CC=C3C2
DMEJ5CP	IK	NJWKVUCAVMYELV-UHFFFAOYSA-N
DMEJ5CP	IU	2-(4-methoxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)ethanamine
DMEJ5CP	DE	Discovery agent

DMFM19S	ID	DMFM19S
DMFM19S	DN	SNAP-5114
DMFM19S	HS	Investigative
DMFM19S	SN	157604-55-2; (S)-SNAP-5114; (S)-SNAP 5114; CHEMBL75035; (S)-1-[2-[TRIS(4-METHOXYPHENYL)METHOXY]ETHYL]-3-PIPERIDINECARBOXYLIC ACID; GTPL4677; SCHEMBL18187570; CTK0H0672; DTXSID40440224; MolPort-003-983-686; HMS3268E15; ZINC3995954; MFCD06411702; BN0494; BDBM50039246; AKOS024456666; NCGC00025217-02; B6792; SR-01000597587; (S)-SNAP-5114, &gt; SR-01000597587-1; (S)-1-(2-(tris(4-methoxyphenyl)methoxy)ethyl)piperidine-3-carboxylic acid; (3S)-1-{2-[tris(4-methoxyphenyl)methoxy]ethyl}piperidine-3-carboxylic
DMFM19S	DT	Small molecular drug
DMFM19S	PC	10458835
DMFM19S	MW	505.6
DMFM19S	FM	C30H35NO6
DMFM19S	IC	InChI=1S/C30H35NO6/c1-34-26-12-6-23(7-13-26)30(24-8-14-27(35-2)15-9-24,25-10-16-28(36-3)17-11-25)37-20-19-31-18-4-5-22(21-31)29(32)33/h6-17,22H,4-5,18-21H2,1-3H3,(H,32,33)/t22-/m0/s1
DMFM19S	CS	COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)(C3=CC=C(C=C3)OC)OCCN4CCC[C@@H](C4)C(=O)O
DMFM19S	IK	VDLDUZLDZBVOAS-QFIPXVFZSA-N
DMFM19S	IU	(3S)-1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]piperidine-3-carboxylic acid
DMFM19S	CA	CAS 157604-55-2
DMFM19S	DE	Discovery agent

DM2OLGQ	ID	DM2OLGQ
DM2OLGQ	DN	SNAP-5150
DM2OLGQ	HS	Investigative
DM2OLGQ	DT	Small molecular drug
DM2OLGQ	PC	9894818
DM2OLGQ	MW	593.7
DM2OLGQ	FM	C35H39N5O4
DM2OLGQ	IC	InChI=1S/C35H39N5O4/c1-24-30(33(36)41)32(26-14-16-29(17-15-26)40(43)44)31(25(2)38-24)34(42)37-20-9-21-39-22-18-35(19-23-39,27-10-5-3-6-11-27)28-12-7-4-8-13-28/h3-8,10-17,32,38H,9,18-23H2,1-2H3,(H2,36,41)(H,37,42)
DM2OLGQ	CS	CC1=C(C(C(=C(N1)C)C(=O)NCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC=C(C=C5)[N+](=O)[O-])C(=O)N
DM2OLGQ	IK	OZQHHXAYNRRVBN-UHFFFAOYSA-N
DM2OLGQ	IU	5-N-[3-(4,4-diphenylpiperidin-1-yl)propyl]-2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxamide
DM2OLGQ	DE	Discovery agent

DM3KN2F	ID	DM3KN2F
DM3KN2F	DN	SNAP-7915
DM3KN2F	HS	Investigative
DM3KN2F	SN	SNAP-7915; CHEMBL96467; SNAP7915; SCHEMBL7658901; DTYAFBJXWWLRMA-QMHKHESXSA-N; BDBM50090647; (4S,5S)-4-(3,4-Difluorophenyl)-N-[3-[4-(4-fluorophenyl)-1-piperidinyl]propyl]-5-methyl-2-oxo-3-oxazolidine carboxamide; 4-(3,4-Difluoro-phenyl)-5-methyl-2-oxo-oxazolidine-3-carboxylic acid {3-[4-(4-fluoro-phenyl)-piperidin-1-yl]-propyl}-amide; (4S,5S)-4-(3,4-difluorophenyl)-N-(3-(4-(4-fluorophenyl)piperidin-1-yl)propyl)-5-methyl-2-oxooxazolidine-3-carboxamide
DM3KN2F	DT	Small molecular drug
DM3KN2F	PC	9830741
DM3KN2F	MW	475.5
DM3KN2F	FM	C25H28F3N3O3
DM3KN2F	IC	InChI=1S/C25H28F3N3O3/c1-16-23(19-5-8-21(27)22(28)15-19)31(25(33)34-16)24(32)29-11-2-12-30-13-9-18(10-14-30)17-3-6-20(26)7-4-17/h3-8,15-16,18,23H,2,9-14H2,1H3,(H,29,32)/t16-,23+/m0/s1
DM3KN2F	CS	C[C@H]1[C@@H](N(C(=O)O1)C(=O)NCCCN2CCC(CC2)C3=CC=C(C=C3)F)C4=CC(=C(C=C4)F)F
DM3KN2F	IK	DTYAFBJXWWLRMA-QMHKHESXSA-N
DM3KN2F	IU	(4S,5S)-4-(3,4-difluorophenyl)-N-[3-[4-(4-fluorophenyl)piperidin-1-yl]propyl]-5-methyl-2-oxo-1,3-oxazolidine-3-carboxamide
DM3KN2F	DE	Discovery agent

DMCHPMA	ID	DMCHPMA
DMCHPMA	DN	SNAP-8719
DMCHPMA	HS	Investigative
DMCHPMA	SN	CHEMBL98241; SNAP-8719; SCHEMBL6753278; WCWNYVYNQAPOOX-OAHLLOKOSA-N; BDBM50122803; 8-{(1R)-2-[4-(2,4,5-Trifluorophenyl)piperazin-1-yl]-1-methylethyl}-8-azaspiro[4.5]decane-7,9-dione; 8-{1-Methyl-2-[4-(2,4,5-trifluoro-phenyl)-piperazin-1-yl]-ethyl}-8-aza-spiro[4.5]decane-7,9-dione; 8-{(R)-1-Methyl-2-[4-(2,4,5-trifluoro-phenyl)-piperazin-1-yl]-ethyl}-8-aza-spiro[4.5]decane-7,9-dione
DMCHPMA	DT	Small molecular drug
DMCHPMA	PC	9845181
DMCHPMA	MW	423.5
DMCHPMA	FM	C22H28F3N3O2
DMCHPMA	IC	InChI=1S/C22H28F3N3O2/c1-15(28-20(29)12-22(13-21(28)30)4-2-3-5-22)14-26-6-8-27(9-7-26)19-11-17(24)16(23)10-18(19)25/h10-11,15H,2-9,12-14H2,1H3/t15-/m1/s1
DMCHPMA	CS	C[C@H](CN1CCN(CC1)C2=CC(=C(C=C2F)F)F)N3C(=O)CC4(CCCC4)CC3=O
DMCHPMA	IK	WCWNYVYNQAPOOX-OAHLLOKOSA-N
DMCHPMA	IU	8-[(2R)-1-[4-(2,4,5-trifluorophenyl)piperazin-1-yl]propan-2-yl]-8-azaspiro[4.5]decane-7,9-dione
DMCHPMA	DE	Discovery agent

DMMHQDX	ID	DMMHQDX
DMMHQDX	DN	SNAP-94847
DMMHQDX	HS	Investigative
DMMHQDX	SN	SNAP-94847; CHEMBL242004; N-(3-{1-[4-(3,4-DIFLUOROPHENOXY)BENZYL]-4-PIPERIDINYL}-4-METHYLPHENYL)-2-METHYLPROPANAMIDE; N-(3-{1-[4-(3,4-DIFLUOROPHENOXY)BENZYL]-4-PIPERIDINYL)-4-METHYLPHENYL)-2-METHYLPROPANAMIDE; SCHEMBL5660385; VMLZFUVIKCGATC-UHFFFAOYSA-N; ZINC3961758; BDBM50219053; NCGC00370900-01
DMMHQDX	DT	Small molecular drug
DMMHQDX	PC	16756754
DMMHQDX	MW	478.6
DMMHQDX	FM	C29H32F2N2O2
DMMHQDX	IC	InChI=1S/C29H32F2N2O2/c1-19(2)29(34)32-23-7-4-20(3)26(16-23)22-12-14-33(15-13-22)18-21-5-8-24(9-6-21)35-25-10-11-27(30)28(31)17-25/h4-11,16-17,19,22H,12-15,18H2,1-3H3,(H,32,34)
DMMHQDX	CS	CC1=C(C=C(C=C1)NC(=O)C(C)C)C2CCN(CC2)CC3=CC=C(C=C3)OC4=CC(=C(C=C4)F)F
DMMHQDX	IK	VMLZFUVIKCGATC-UHFFFAOYSA-N
DMMHQDX	IU	N-[3-[1-[[4-(3,4-difluorophenoxy)phenyl]methyl]piperidin-4-yl]-4-methylphenyl]-2-methylpropanamide
DMMHQDX	CA	CAS 487051-12-7
DMMHQDX	DE	Discovery agent

DMJI5H0	ID	DMJI5H0
DMJI5H0	DN	SNC-80
DMJI5H0	HS	Investigative
DMJI5H0	SN	Snc 80; Snc-80; 156727-74-1; CHEMBL13470; SNC80; NSC707484; 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide; NCGC00024777-02; DSSTox_RID_81039; DSSTox_CID_25662; DSSTox_GSID_45662; 4-((2,5-Dimethyl-4-(2-propenyl)-1-piperazinyl)(3-methoxyphenyl)methyl)-N,N-diethylbenzamide (2S-(1(S*),2alpha,5beta))-; Benzamide, 4-((2,5-dimethyl-4-(2-propenyl)-1-piperazinyl)(3-methoxyphenyl)methyl)-N,N-diethyl-, (2S-(1(S*),2alpha,5bet))-
DMJI5H0	DT	Small molecular drug
DMJI5H0	PC	123924
DMJI5H0	MW	449.6
DMJI5H0	FM	C28H39N3O2
DMJI5H0	IC	InChI=1S/C28H39N3O2/c1-7-17-30-19-22(5)31(20-21(30)4)27(25-11-10-12-26(18-25)33-6)23-13-15-24(16-14-23)28(32)29(8-2)9-3/h7,10-16,18,21-22,27H,1,8-9,17,19-20H2,2-6H3/t21-,22+,27-/m1/s1
DMJI5H0	CS	CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)OC)N3C[C@H](N(C[C@@H]3C)CC=C)C
DMJI5H0	IK	KQWVAUSXZDRQPZ-UMTXDNHDSA-N
DMJI5H0	IU	4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide
DMJI5H0	CA	CAS 156727-74-1
DMJI5H0	CB	CHEBI:109556
DMJI5H0	DE	Discovery agent

DMYUH62	ID	DMYUH62
DMYUH62	DN	SNEWIQPRLPQH
DMYUH62	HS	Investigative
DMYUH62	SN	CHEMBL448652; SNEWIQPRLPQH
DMYUH62	PC	44560069
DMYUH62	MW	1504.6
DMYUH62	FM	C67H101N21O19
DMYUH62	IC	InChI=1S/C67H101N21O19/c1-5-34(4)54(86-60(100)44(26-35-29-76-39-12-7-6-11-37(35)39)83-57(97)42(18-21-53(93)94)78-59(99)45(28-52(71)92)82-55(95)38(68)31-89)63(103)81-43(17-20-51(70)91)64(104)87-23-9-14-48(87)61(101)79-40(13-8-22-75-67(72)73)56(96)84-46(25-33(2)3)65(105)88-24-10-15-49(88)62(102)80-41(16-19-50(69)90)58(98)85-47(66(106)107)27-36-30-74-32-77-36/h6-7,11-12,29-30,32-34,38,40-49,54,76,89H,5,8-10,13-28,31,68H2,1-4H3,(H2,69,90)(H2,70,91)(H2,71,92)(H,74,77)(H,78,99)(H,79,101)(H,80,102)(H,81,103)(H,82,95)(H,83,97)(H,84,96)(H,85,98)(H,86,100)(H,93,94)(H,106,107)(H4,72,73,75)/t34-,38-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,54-/m0/s1
DMYUH62	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)NC(=O)[C@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N
DMYUH62	IK	BMZQNOXMUPLPCR-PBLORMCUSA-N
DMYUH62	IU	(4S)-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-1-[[(1S)-1-carboxy-2-(1H-imidazol-5-yl)ethyl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMYUH62	DE	Discovery agent

DMOLQNK	ID	DMOLQNK
DMOLQNK	DN	SNG-163
DMOLQNK	HS	Investigative
DMOLQNK	SN	SGIC-163; ER-a36 inhibitor (cancer), Shenogen
DMOLQNK	CP	Shenogen Pharma Group Ltd
DMOLQNK	DE	Solid tumour/cancer

DMCT02Q	ID	DMCT02Q
DMCT02Q	DN	SNG-8006
DMCT02Q	HS	Investigative
DMCT02Q	SN	Estrogen receptor alpha-36 antagonist (osteoporosis), Shenogen Pharma
DMCT02Q	CP	Shenogen Pharma Group Ltd
DMCT02Q	DE	Osteoporosis

DM6O9DQ	ID	DM6O9DQ
DM6O9DQ	DN	SNG-8023
DM6O9DQ	HS	Investigative
DM6O9DQ	SN	Estrogen receptor alpha 36 inhibitor (breast cancer), Shenogen Pharma; Monoclonal antibody (breast cancer), Shenogen Pharma
DM6O9DQ	CP	Shenogen Pharma Group Ltd
DM6O9DQ	DT	Antibody
DM6O9DQ	DE	Breast cancer

DM0W54R	ID	DM0W54R
DM0W54R	DN	SNG-8033
DM0W54R	HS	Investigative
DM0W54R	SN	Estrogen receptor alpha 36 inhibitor (leukemia), Shenogen Pharma
DM0W54R	CP	Shenogen Pharma Group Ltd
DM0W54R	DE	leukaemia

DMB5A80	ID	DMB5A80
DMB5A80	DN	SNX-2112
DMB5A80	HS	Investigative
DMB5A80	SN	SNX-2112; 908112-43-6; SNX 2112; 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide; UNII-10C9P3FFOW; PF-04928473; 10C9P3FFOW; CHEMBL560895; SNX-2112 (PF-04928473); 945626-71-1; 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide; 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(cis-4-hydroxycyclohexyl)amino]benzamide
DMB5A80	DT	Small molecular drug
DMB5A80	PC	24772860
DMB5A80	MW	464.5
DMB5A80	FM	C23H27F3N4O3
DMB5A80	IC	InChI=1S/C23H27F3N4O3/c1-22(2)10-17-19(18(32)11-22)20(23(24,25)26)29-30(17)13-5-8-15(21(27)33)16(9-13)28-12-3-6-14(31)7-4-12/h5,8-9,12,14,28,31H,3-4,6-7,10-11H2,1-2H3,(H2,27,33)
DMB5A80	CS	CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)O)C(F)(F)F)C
DMB5A80	IK	ZFVRYNYOPQZKDG-UHFFFAOYSA-N
DMB5A80	IU	4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide
DMB5A80	CA	CAS 908112-43-6
DMB5A80	DE	Discovery agent

DMSRM49	ID	DMSRM49
DMSRM49	DN	Sodium 2,3,5,6-tetrafluorobenzoate
DMSRM49	HS	Investigative
DMSRM49	SN	sodium 2,3,5,6-tetrafluorobenzoate; CHEMBL368444; Sodium 2,3,5,6-Tetrafluoro-Benzoate
DMSRM49	DT	Small molecular drug
DMSRM49	PC	23675285
DMSRM49	MW	216.06
DMSRM49	FM	C7HF4NaO2
DMSRM49	IC	InChI=1S/C7H2F4O2.Na/c8-2-1-3(9)6(11)4(5(2)10)7(12)13;/h1H,(H,12,13);/q;+1/p-1
DMSRM49	CS	C1=C(C(=C(C(=C1F)F)C(=O)[O-])F)F.[Na+]
DMSRM49	IK	ZESSIGXSSUUGNU-UHFFFAOYSA-M
DMSRM49	IU	sodium;2,3,5,6-tetrafluorobenzoate
DMSRM49	DE	Discovery agent

DMHPD2Y	ID	DMHPD2Y
DMHPD2Y	DN	SODIUM CITRATE
DMHPD2Y	HS	Investigative
DMHPD2Y	SN	Sodium citrate; 68-04-2; TRISODIUM CITRATE; Citrosodine; Sodium citrate anhydrous; Citrosodina; Natrocitral; Citrosodna; Citreme; Citnatin; sodium citrate, anhydrous; Sodium 2-hydroxypropane-1,2,3-tricarboxylate; Trisodium citrate anhydrous; Citric acid, trisodium salt; Trisodium citrate, anhydrous; Citric acid trisodium salt; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trisodium salt; UNII-RS7A450LGA; FEMA No. 3026; CCRIS 3293; Sodium citrate (Na3C6H5O7); HSDB 5201; EINECS 200-675-3; RS7A450LGA; CHEBI:53258; Trisodium 2-hydroxy-1
DMHPD2Y	DT	Small molecular drug
DMHPD2Y	PC	6224
DMHPD2Y	MW	258.07
DMHPD2Y	FM	C6H5Na3O7
DMHPD2Y	IC	InChI=1S/C6H8O7.3Na/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
DMHPD2Y	CS	C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Na+].[Na+].[Na+]
DMHPD2Y	IK	HRXKRNGNAMMEHJ-UHFFFAOYSA-K
DMHPD2Y	IU	trisodium;2-hydroxypropane-1,2,3-tricarboxylate
DMHPD2Y	CA	CAS 68-04-2
DMHPD2Y	CB	CHEBI:53258
DMHPD2Y	DE	Discovery agent

DM2WUZA	ID	DM2WUZA
DM2WUZA	DN	Sodium maleate
DM2WUZA	HS	Investigative
DM2WUZA	SN	disodium but-2-enedioate; 371-47-1; disodiumfumarate; 2-Butenedioic acid (2Z)-, sodium salt (1:2); ACMC-209ir7; ACMC-209e0o; AC1L1TP7; AC1N5G1J; CTK4D3501; CTK8B1559; CTK4D7533; DTXSID10168802; KS-00000WA6; ANW-22438; ANW-28577; AKOS030228400; AN-18678; 2-Butenedioic acid(2Z)-, sodium salt (1: ); 2-Butenedioic acid(2E)-, sodium salt (1:2)
DM2WUZA	DT	Small molecular drug
DM2WUZA	PC	6364608
DM2WUZA	MW	160.04
DM2WUZA	FM	C4H2Na2O4
DM2WUZA	IC	InChI=1S/C4H4O4.2Na/c5-3(6)1-2-4(7)8;;/h1-2H,(H,5,6)(H,7,8);;/q;2*+1/p-2/b2-1-;;
DM2WUZA	CS	C(=C\\C(=O)[O-])\\C(=O)[O-].[Na+].[Na+]
DM2WUZA	IK	MSJMDZAOKORVFC-UAIGNFCESA-L
DM2WUZA	IU	disodium;(Z)-but-2-enedioate
DM2WUZA	CA	CAS 371-47-1
DM2WUZA	CB	CHEBI:91263
DM2WUZA	DE	Discovery agent

DMBVQI4	ID	DMBVQI4
DMBVQI4	DN	Sodium N-methylphenylaminomethanesulfonate
DMBVQI4	HS	Investigative
DMBVQI4	SN	Sodium N-methylphenylaminomethanesulfonate; CHEMBL571598
DMBVQI4	DT	Small molecular drug
DMBVQI4	PC	23665438
DMBVQI4	MW	223.23
DMBVQI4	FM	C8H10NNaO3S
DMBVQI4	IC	InChI=1S/C8H11NO3S.Na/c1-9(7-13(10,11)12)8-5-3-2-4-6-8;/h2-6H,7H2,1H3,(H,10,11,12);/q;+1/p-1
DMBVQI4	CS	CN(CS(=O)(=O)[O-])C1=CC=CC=C1.[Na+]
DMBVQI4	IK	XIDHWXUDYZMZID-UHFFFAOYSA-M
DMBVQI4	IU	sodium;(N-methylanilino)methanesulfonate
DMBVQI4	DE	Discovery agent

DM8CLG2	ID	DM8CLG2
DM8CLG2	DN	Sodium orthovanadate
DM8CLG2	HS	Investigative
DM8CLG2	SN	13721-39-6; Trisodium vanadate; Sodium pervanadate; Sodium o-vanadate; Sodium vanadate (ortho); Trisodium tetraoxovanadate; Sodium tetraoxovanadate(3-); Vanadic acid, trisodium salt; TRISODIUM ORTHOVANADATE; Vanadic acid (H3VO4), sodium salt; UNII-7845MV6C8V; trisodium trioxido(oxo)vanadium; CCRIS 9063; Vanadic(II) acid, trisodium salt; EINECS 237-287-9; NSC 79534; Vanadate (VO43-), trisodium, (T-4)-; AI3-52157; Vanadate(VO4(3-)), trisodium; CHEBI:35607; 7845MV6C8V; Vanadic (II) Acid, Trisodium
DM8CLG2	DT	Small molecular drug
DM8CLG2	PC	61671
DM8CLG2	MW	183.908
DM8CLG2	FM	Na3O4V
DM8CLG2	IC	InChI=1S/3Na.4O.V/q3*+1;;3*-1;
DM8CLG2	CS	[O-][V](=O)([O-])[O-].[Na+].[Na+].[Na+]
DM8CLG2	IK	IHIXIJGXTJIKRB-UHFFFAOYSA-N
DM8CLG2	IU	trisodium;trioxido(oxo)vanadium
DM8CLG2	CA	CAS 13721-39-6
DM8CLG2	CB	CHEBI:35607
DM8CLG2	DE	Discovery agent

DMESHV2	ID	DMESHV2
DMESHV2	DN	SODIUM PERFLUOROHEXANESULFONAMIDE
DMESHV2	HS	Investigative
DMESHV2	SN	CHEMBL1076889; Sodium perfluorohexane sulfonamide
DMESHV2	DT	Small molecular drug
DMESHV2	PC	46865217
DMESHV2	MW	421.11
DMESHV2	FM	C6HF13NNaO2S
DMESHV2	IC	InChI=1S/C6HF13NO2S.Na/c7-1(8,3(11,12)5(15,16)17)2(9,10)4(13,14)6(18,19)23(20,21)22;/h(H-,20,21,22);/q-1;+1
DMESHV2	CS	C(C(C(C(F)(F)S(=O)(=O)[NH-])(F)F)(F)F)(C(C(F)(F)F)(F)F)(F)F.[Na+]
DMESHV2	IK	WEVJDFCVPBPCIK-UHFFFAOYSA-N
DMESHV2	IU	sodium;1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexylsulfonylazanide
DMESHV2	DE	Discovery agent

DMJ7I4U	ID	DMJ7I4U
DMJ7I4U	DN	Sodium phenylaminomethanesulfonate
DMJ7I4U	HS	Investigative
DMJ7I4U	SN	Sodium anilinomethanesulfonate; Sodium anilinomethanesulphonate; Methanesulfonic acid, (phenylamino)-, monosodium salt; 26021-90-9; Aniline-N-methylsulfonic acid,Na salt; Methanesulfonic acid, 1-(phenylamino)-, sodium salt (1:1); Anilinomethanesulfonate sodium salt; Anilinomethanesulfonic acid, sodium salt; W-110647; (Phenylamino)methanesulfonic acid, sodium salt; Phenylaminomethanesulfonic acid, monosodium salt; Sodium phenylaminomethanesulfonate; EINECS 247-417-6; NSC 57030; Anilinomethanesulfonic acid, monosodium salt
DMJ7I4U	DT	Small molecular drug
DMJ7I4U	PC	23680200
DMJ7I4U	MW	209.2
DMJ7I4U	FM	C7H8NNaO3S
DMJ7I4U	IC	InChI=1S/C7H9NO3S.Na/c9-12(10,11)6-8-7-4-2-1-3-5-7;/h1-5,8H,6H2,(H,9,10,11);/q;+1/p-1
DMJ7I4U	CS	C1=CC=C(C=C1)NCS(=O)(=O)[O-].[Na+]
DMJ7I4U	IK	AJSINQAAKNYUDA-UHFFFAOYSA-M
DMJ7I4U	IU	sodium;anilinomethanesulfonate
DMJ7I4U	CA	CAS 26021-90-9
DMJ7I4U	DE	Discovery agent

DMXELBI	ID	DMXELBI
DMXELBI	DN	Sodium phenylarsonate
DMXELBI	HS	Investigative
DMXELBI	SN	sodium phenylarsonate
DMXELBI	DT	Small molecular drug
DMXELBI	PC	44593649
DMXELBI	MW	246
DMXELBI	FM	C6H5AsNa2O3
DMXELBI	IC	InChI=1S/C6H7AsO3.2Na/c8-7(9,10)6-4-2-1-3-5-6;;/h1-5H,(H2,8,9,10);;/q;2*+1/p-2
DMXELBI	CS	C1=CC=C(C=C1)[As](=O)([O-])[O-].[Na+].[Na+]
DMXELBI	IK	IDQWLYXYOJVSLB-UHFFFAOYSA-L
DMXELBI	IU	disodium;dioxido-oxo-phenyl-lambda5-arsane
DMXELBI	DE	Discovery agent

DM1G4S9	ID	DM1G4S9
DM1G4S9	DN	Sodium Phosphate, Dibasic, Anhydrous
DM1G4S9	HS	Investigative
DM1G4S9	SN	7558-79-4; DISODIUM PHOSPHATE; Disodium hydrogen phosphate; Disodium hydrogenorthophosphate; Sodium phosphate dibasic; Acetest; Soda phosphate; Disodium orthophosphate; Sodium hydrogenphosphate; Sodium hydrogen phosphate; Phosphoric acid, disodium salt; Disodium acid phosphate; Phosphate of soda; sec-Sodium phosphate; Disodium acid orthophosphate; Sodium monohydrogen phosphate; Caswell No. 778; Disodium hydrophosphate; Disodium monohydrogen phosphate; Disodium phosphoric acid; FEMA Number 2398
DM1G4S9	DT	Small molecular drug
DM1G4S9	PC	24203
DM1G4S9	MW	141.959
DM1G4S9	FM	HNa2O4P
DM1G4S9	IC	InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2
DM1G4S9	CS	OP(=O)([O-])[O-].[Na+].[Na+]
DM1G4S9	IK	BNIILDVGGAEEIG-UHFFFAOYSA-L
DM1G4S9	IU	disodium;hydrogen phosphate
DM1G4S9	CA	CAS 7558-79-4
DM1G4S9	CB	CHEBI:34683
DM1G4S9	DE	Discovery agent

DMAMV6T	ID	DMAMV6T
DMAMV6T	DN	Sodium sulfamate
DMAMV6T	HS	Investigative
DMAMV6T	SN	Sodium sulfamate; 13845-18-6; Monosodium sulfamate; Sulfamic Acid Sodium Salt; Sulfamic acid, sodium salt; Sulfamic acid, monosodium salt; Sulfamic acid monosodium salt; Aminosulfonic Acid Sodium Salt; Sodium sulphamidate; Sulfamic acid, sodium salt (1:1); Sulphamic acid, sodium salt; Sodium Sulphamate; Sodium amidosulfate; EINECS 237-572-8; EINECS 247-584-5; Sodium aminosulfonate; ACMC-209chs; Sulfamicacidmonosodiumsalt; Na.H2NSO3; EC 237-572-8; 26288-34-6; KSC910O5T; DTXSID8065664; KS-00000VNX; CTK8B0759; MolPort-006-120-135
DMAMV6T	DT	Small molecular drug
DMAMV6T	PC	23700090
DMAMV6T	MW	119.08
DMAMV6T	FM	H2NNaO3S
DMAMV6T	IC	InChI=1S/H3NO3S.Na/c1-5(2,3)4;/h(H3,1,2,3,4);/q;+1/p-1
DMAMV6T	CS	NS(=O)(=O)[O-].[Na+]
DMAMV6T	IK	QDWYPRSFEZRKDK-UHFFFAOYSA-M
DMAMV6T	IU	sodium;sulfamate
DMAMV6T	CA	CAS 13845-18-6
DMAMV6T	DE	Discovery agent

DM6WYGC	ID	DM6WYGC
DM6WYGC	DN	Sodium trithiocarbonate
DM6WYGC	HS	Investigative
DM6WYGC	SN	Sodium trithiocarbonate; Carbonotrithioic acid, disodium salt; disodium carbonotrithioate; UNII-Y01PT1AS4O; 534-18-9; Y01PT1AS4O; Carbonotrithioic acid, sodium salt (1:2); CHEMBL471245; EINECS 208-592-4; Sodium Carbonotrithioate; disodium trithiocarbonate; AC1Q1UXB; AC1L2RHE; AC1MC2O4; SCHEMBL1492384; DTXSID7060203; Trithiocarbonic acid disodium salt; USAIOOFEIMNEDN-UHFFFAOYSA-L; AKOS006229270; AN-21294
DM6WYGC	DT	Small molecular drug
DM6WYGC	PC	101753
DM6WYGC	MW	154.2
DM6WYGC	FM	CNa2S3
DM6WYGC	IC	InChI=1S/CH2S3.2Na/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2
DM6WYGC	CS	C(=S)([S-])[S-].[Na+].[Na+]
DM6WYGC	IK	USAIOOFEIMNEDN-UHFFFAOYSA-L
DM6WYGC	IU	disodium;carbonotrithioate
DM6WYGC	CA	CAS 534-18-9
DM6WYGC	DE	Discovery agent

DMX6PLV	ID	DMX6PLV
DMX6PLV	DN	Sodium valproate
DMX6PLV	HS	Investigative
DMX6PLV	SN	Sodium valproate; Sodium 2-propylpentanoate; 1069-66-5; Valproate sodium; Valproic acid sodium salt; Labazene; Eurekene; Orfiril; Valproic acid sodium; Epilim; Valerin; Natrium valproat; Sodium 2-propylvalerate; 2-Propylvaleric acid sodium salt; Pentanoic acid, 2-propyl-, sodium salt; 2-Propylpentanoic acid sodium salt; DEPACON; Sodium dipropylacetate; Dipropylacetate sodium; Sodium bispropylacetate; Valproinsaeure, natrium; Sodium n-dipropylacetate; UNII-5VOM6GYJ0D; Valproic Acid, Sodium Salt; Valproic Acid (sodium salt); Sodium 2
DMX6PLV	DT	Small molecular drug
DMX6PLV	PC	16760703
DMX6PLV	MW	166.19
DMX6PLV	FM	C8H15NaO2
DMX6PLV	IC	InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1
DMX6PLV	CS	CCCC(CCC)C(=O)[O-].[Na+]
DMX6PLV	IK	AEQFSUDEHCCHBT-UHFFFAOYSA-M
DMX6PLV	IU	sodium;2-propylpentanoate
DMX6PLV	CA	CAS 1069-66-5
DMX6PLV	CB	CHEBI:9925
DMX6PLV	DE	Discovery agent

DMEZAPR	ID	DMEZAPR
DMEZAPR	DN	SODIUM ZINC DIHYDROLIPOYLHISTIDINATE
DMEZAPR	HS	Investigative
DMEZAPR	SN	CHEMBL226494; SODIUM ZINC DIHYDROLIPOYLHISTIDINATE
DMEZAPR	DT	Small molecular drug
DMEZAPR	PC	44423423
DMEZAPR	MW	430.8
DMEZAPR	FM	C14H20N3NaO3S2Zn
DMEZAPR	IC	InChI=1S/C14H23N3O3S2.Na.Zn/c18-13(4-2-1-3-11(22)5-6-21)17-12(14(19)20)7-10-8-15-9-16-10;;/h8-9,11-12,21-22H,1-7H2,(H,15,16)(H,17,18)(H,19,20);;/q;+1;+2/p-3
DMEZAPR	CS	C1=C(NC=N1)CC(C(=O)[O-])NC(=O)CCCCC(CC[S-])[S-].[Na+].[Zn+2]
DMEZAPR	IK	GLGKCICLFLDJDO-UHFFFAOYSA-K
DMEZAPR	IU	sodium;zinc;2-(6,8-disulfidooctanoylamino)-3-(1H-imidazol-5-yl)propanoate
DMEZAPR	DE	Discovery agent

DMJXN1G	ID	DMJXN1G
DMJXN1G	DN	Soluble ErbB3 theragnostics
DMJXN1G	HS	Investigative
DMJXN1G	SN	Soluble ErbB3 theragnostics (cancer); SErbB3 theragnostics (cancer), TBIG; SHer theragnostics (cancer), TBIG;Soluble ErbB3 theragnostics (cancer), TBIG; Soluble Her theragnostics (cancer), TBIG; P85-sErbB3 (cancer), TBIG
DMJXN1G	CP	Tumor Biology Investment Group Inc
DMJXN1G	DE	Solid tumour/cancer

DMIOFQE	ID	DMIOFQE
DMIOFQE	DN	SOMATOSTATIN
DMIOFQE	HS	Investigative
DMIOFQE	SN	51110-01-1; Somiaton; Panhibin; Aminopan; Somatostatin acetate; SRIF; Somatotropin release-inhibiting factor; Somatotropin release-inhibiting hormone; Growth hormone release-inhibiting factor; CCRIS 7071; EINECS 256-969-7; Growth hormone release-inhibiting hormone; AY 24910; Growth hormone release inhibiting factor; Somatostatin 1-14; Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys; NCGC00181005-01; 61950-59-2; [D-Trp8]-SOMATOSTATIN; SCHEMBL3046327
DMIOFQE	PC	16129706
DMIOFQE	MW	1637.9
DMIOFQE	FM	C76H104N18O19S2
DMIOFQE	IC	InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t41-,42+,43+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-,63-/m0/s1
DMIOFQE	CS	C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)O)CO)[C@@H](C)O)CC6=CC=CC=C6)O
DMIOFQE	IK	NHXLMOGPVYXJNR-ATOGVRKGSA-N
DMIOFQE	IU	(4R,7S,10S,13S,16S,19S,22S,25S,28S,31S,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DMIOFQE	CA	CAS 38916-34-6
DMIOFQE	CB	CHEBI:64628
DMIOFQE	DE	Discovery agent

DMH6JI8	ID	DMH6JI8
DMH6JI8	DN	S-OOPP
DMH6JI8	HS	Investigative
DMH6JI8	SN	CHEMBL1214256; S-OOPP; SCHEMBL3768627; GTPL6493; UUEMOTWYJKOUPP-JTQLQIEISA-N; BDBM50416509; (S)-N-(2-oxooxetan-3-yl)-3-phenylpropionamide; N-[(3s)-2-oxo-3-oxetanyl]-3-phenylpropanamide; N-[(3S)-2-oxooxetan-3-yl]-3-phenylpropanamide
DMH6JI8	DT	Small molecular drug
DMH6JI8	PC	25227533
DMH6JI8	MW	219.24
DMH6JI8	FM	C12H13NO3
DMH6JI8	IC	InChI=1S/C12H13NO3/c14-11(13-10-8-16-12(10)15)7-6-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,13,14)/t10-/m0/s1
DMH6JI8	CS	C1[C@@H](C(=O)O1)NC(=O)CCC2=CC=CC=C2
DMH6JI8	IK	UUEMOTWYJKOUPP-JTQLQIEISA-N
DMH6JI8	IU	N-[(3S)-2-oxooxetan-3-yl]-3-phenylpropanamide
DMH6JI8	DE	Discovery agent

DM8Y1S7	ID	DM8Y1S7
DM8Y1S7	DN	SOPHOFLAVESCENOL
DM8Y1S7	HS	Investigative
DM8Y1S7	SN	SOPHOFLAVESCENOL; 216450-65-6; CHEMBL77651; SCHEMBL14563970; MolPort-039-339-033; ZINC4199939; HY-N2284; BCP24815; LMPK12112538; BDBM50116711; AKOS032945037; CS-6033; 3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)-4H-chromen-4-one
DM8Y1S7	DT	Small molecular drug
DM8Y1S7	PC	9929189
DM8Y1S7	MW	368.4
DM8Y1S7	FM	C21H20O6
DM8Y1S7	IC	InChI=1S/C21H20O6/c1-11(2)4-9-14-15(23)10-16(26-3)17-18(24)19(25)20(27-21(14)17)12-5-7-13(22)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3
DM8Y1S7	CS	CC(=CCC1=C2C(=C(C=C1O)OC)C(=O)C(=C(O2)C3=CC=C(C=C3)O)O)C
DM8Y1S7	IK	VMLJAWUWVVHRNG-UHFFFAOYSA-N
DM8Y1S7	IU	3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)chromen-4-one
DM8Y1S7	DE	Discovery agent

DMUVKX5	ID	DMUVKX5
DMUVKX5	DN	SOPHORAFLAVANONE B
DMUVKX5	HS	Investigative
DMUVKX5	SN	8-Prenylnaringenin; 53846-50-7; Sophoraflavanone B; Flavaprenin; (-)-(2S)-8-dimethylallylnaringenin; (S)-8-dimethylallylnaringenin; YS04; CHEMBL376915; CHEBI:50207; (-)-(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-4H-chromen-4-one; (s)-8-prenylnaringenin; 8-dimethylallylnaringenin; AC1LA3DM; UNII-5L872SZR8X; 8-prenylnaringenin (8-PN); BIDD:ER0149; cid_509245; SCHEMBL1171435; 5L872SZR8X; ZINC39452; CTK5J8800; BDBM19460
DMUVKX5	DT	Small molecular drug
DMUVKX5	PC	509245
DMUVKX5	MW	340.4
DMUVKX5	FM	C20H20O5
DMUVKX5	IC	InChI=1S/C20H20O5/c1-11(2)3-8-14-15(22)9-16(23)19-17(24)10-18(25-20(14)19)12-4-6-13(21)7-5-12/h3-7,9,18,21-23H,8,10H2,1-2H3
DMUVKX5	CS	CC(=CCC1=C2C(=C(C=C1O)O)C(=O)CC(O2)C3=CC=C(C=C3)O)C
DMUVKX5	IK	LPEPZZAVFJPLNZ-UHFFFAOYSA-N
DMUVKX5	IU	5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
DMUVKX5	CA	CAS 68682-02-0
DMUVKX5	DE	Discovery agent

DMBTMN5	ID	DMBTMN5
DMBTMN5	DN	Sophoraflavanone G
DMBTMN5	HS	Investigative
DMBTMN5	SN	Sophoraflavanone G; Vexibinol; 97938-30-2; (2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-2,3-dihydro-4H-chromen-4-one; norkurarinone; CHEMBL243148; CHEBI:50209; (2S)-5,7,2',4'-tetrahydroxy-8-lavandulylflavanone; Kushnol F; (2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(2,4-dihydroxyphenyl)-8-(5-methyl-2-(1-methylethenyl)-4-hexenyl)-, (S-(R*,S*))-
DMBTMN5	DT	Small molecular drug
DMBTMN5	PC	72936
DMBTMN5	MW	424.5
DMBTMN5	FM	C25H28O6
DMBTMN5	IC	InChI=1S/C25H28O6/c1-13(2)5-6-15(14(3)4)9-18-20(28)11-21(29)24-22(30)12-23(31-25(18)24)17-8-7-16(26)10-19(17)27/h5,7-8,10-11,15,23,26-29H,3,6,9,12H2,1-2,4H3/t15-,23+/m1/s1
DMBTMN5	CS	CC(=CC[C@H](CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)O)C(=C)C)C
DMBTMN5	IK	XRYVAQQLDYTHCL-CMJOXMDJSA-N
DMBTMN5	IU	(2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
DMBTMN5	CA	CAS 97938-30-2
DMBTMN5	CB	CHEBI:50209
DMBTMN5	DE	Discovery agent

DM4A0NP	ID	DM4A0NP
DM4A0NP	DN	SOPHORICOSIDE
DM4A0NP	HS	Investigative
DM4A0NP	SN	Sophoricoside; 152-95-4; UNII-J0407L5MGM; J0407L5MGM; CHEMBL486626; 5,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one; 5',7'-Dihydroxy-4'-glucosyloxyisoflavone; 4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenyl beta-D-glucopyranoside; 5,7-dihydroxy-3-(4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)-4H-chromen-4-one; 3-{4-[(2S,4S,5S,3R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)(2H-3,4,5,6-tetrahydr opyran-2-yloxy)]phenyl}-5,7-d
DM4A0NP	DT	Small molecular drug
DM4A0NP	PC	5321398
DM4A0NP	MW	432.4
DM4A0NP	FM	C21H20O10
DM4A0NP	IC	InChI=1S/C21H20O10/c22-7-15-18(26)19(27)20(28)21(31-15)30-11-3-1-9(2-4-11)12-8-29-14-6-10(23)5-13(24)16(14)17(12)25/h1-6,8,15,18-24,26-28H,7H2/t15-,18-,19+,20-,21-/m1/s1
DM4A0NP	CS	C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DM4A0NP	IK	ISQRJFLLIDGZEP-CMWLGVBASA-N
DM4A0NP	IU	5,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
DM4A0NP	CA	CAS 152-95-4
DM4A0NP	DE	Discovery agent

DM18IKZ	ID	DM18IKZ
DM18IKZ	DN	Soraphen A
DM18IKZ	HS	Investigative
DM18IKZ	SN	122547-72-2; Soraphen A(1alpha); AC1O5R15; (1S,2S,3Z,5R,6S,11S,14S,15R,16R,17S,18S)-15,17-dihydroxy-5,6,16-trimethoxy-2,14,18-trimethyl-11-phenyl-12,19-dioxabicyclo[13.3.1]nonadec-3-en-13-one; 4,19-Dioxabicyclo(13.3.1)nonadec-12-en-3-one, 1,17-dihydroxy-10,11,18-trimethoxy-2,14,16-trimethyl-5-phenyl-, (1R-(1R*,2S*,5S*,10S*,11R*,12E,14S*,15S*,16S*,17S*,18R*))-
DM18IKZ	DT	Small molecular drug
DM18IKZ	PC	5281897
DM18IKZ	MW	520.7
DM18IKZ	FM	C29H44O8
DM18IKZ	IC	InChI=1S/C29H44O8/c1-18-16-17-24(34-5)23(33-4)15-11-10-14-22(21-12-8-7-9-13-21)36-28(31)20(3)29(32)27(35-6)25(30)19(2)26(18)37-29/h7-9,12-13,16-20,22-27,30,32H,10-11,14-15H2,1-6H3/b17-16+/t18-,19-,20+,22-,23-,24+,25-,26-,27+,29+/m0/s1
DM18IKZ	CS	C[C@H]1/C=C/[C@H]([C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC)OC
DM18IKZ	IK	WPMGNXPRKGXGBO-OFQQMTDKSA-N
DM18IKZ	IU	(1R,2S,5S,10S,11R,12E,14S,15S,16S,17S,18R)-1,17-dihydroxy-10,11,18-trimethoxy-2,14,16-trimethyl-5-phenyl-4,19-dioxabicyclo[13.3.1]nonadec-12-en-3-one
DM18IKZ	CA	CAS 122547-72-2
DM18IKZ	CB	CHEBI:9200
DM18IKZ	DE	Discovery agent

DM2TRIZ	ID	DM2TRIZ
DM2TRIZ	DN	SP-08
DM2TRIZ	HS	Investigative
DM2TRIZ	SN	SP-008
DM2TRIZ	CP	Georgetown University
DM2TRIZ	DE	Alzheimer disease

DM6VQZ7	ID	DM6VQZ7
DM6VQZ7	DN	SP203
DM6VQZ7	HS	Investigative
DM6VQZ7	SN	SP 203; SP-203
DM6VQZ7	DT	Small molecular drug
DM6VQZ7	PC	16737207
DM6VQZ7	MW	260.26
DM6VQZ7	FM	C13H6F2N2S
DM6VQZ7	IC	InChI=1S/C13H6F2N2S/c14-6-13-17-12(8-18-13)2-1-9-3-10(7-16)5-11(15)4-9/h3-5,8H,6H2
DM6VQZ7	CS	C1=C(C=C(C=C1C#N)F)C#CC2=CSC(=N2)CF
DM6VQZ7	IK	WTLBLIGPXACYET-UHFFFAOYSA-N
DM6VQZ7	IU	3-fluoro-5-[2-[2-(fluoromethyl)-1,3-thiazol-4-yl]ethynyl]benzonitrile
DM6VQZ7	CA	CAS 945933-41-5
DM6VQZ7	DE	Discovery agent

DM5HUY0	ID	DM5HUY0
DM5HUY0	DN	SP2456
DM5HUY0	HS	Investigative
DM5HUY0	SN	SP2456; CHEMBL106187; 2-CYCLOHEXYL-N-(2-{4-[5-(2,3-DICHLORO-PHENYL)-2H-PYRAZOL-3-YL]-PIPERIDIN-1-YL}-2-OXO-ETHYL)-2-GUANIDINO-ACETAMIDE; FRB; AC1L9LF4; BDBM50148008; DB03957; 2-(R)-Cyclohexyl-N-(2-{4-[5-(2,3-dichloro-phenyl)-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethyl)-2-guanidino-acetamide; (R)-2-Cyclohexyl-N-(2-{4-[5-(2,3-dichloro-phenyl)-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethyl)-2-guanidino-acetamide
DM5HUY0	DT	Small molecular drug
DM5HUY0	PC	447945
DM5HUY0	MW	534.5
DM5HUY0	FM	C25H33Cl2N7O2
DM5HUY0	IC	InChI=1S/C25H33Cl2N7O2/c26-18-8-4-7-17(22(18)27)20-13-19(32-33-20)15-9-11-34(12-10-15)21(35)14-30-24(36)23(31-25(28)29)16-5-2-1-3-6-16/h4,7-8,13,15-16,23H,1-3,5-6,9-12,14H2,(H,30,36)(H,32,33)(H4,28,29,31)/t23-/m1/s1
DM5HUY0	CS	C1CCC(CC1)[C@H](C(=O)NCC(=O)N2CCC(CC2)C3=CC(=NN3)C4=C(C(=CC=C4)Cl)Cl)N=C(N)N
DM5HUY0	IK	SSSXBBASYYVGCI-HSZRJFAPSA-N
DM5HUY0	IU	(2R)-2-cyclohexyl-2-(diaminomethylideneamino)-N-[2-[4-[3-(2,3-dichlorophenyl)-1H-pyrazol-5-yl]piperidin-1-yl]-2-oxoethyl]acetamide
DM5HUY0	DE	Discovery agent

DMLA3WY	ID	DMLA3WY
DMLA3WY	DN	SP4160
DMLA3WY	HS	Investigative
DMLA3WY	SN	SP4160; FRI; 2-GUANIDINO-4-METHYL-PENTANOIC ACID [2-(4-{5-[4-(4-ACETYLAMINO-BENZYLOXY)-2,3-DICHLORO-PHENYL]-2-METHYL-2H-PYRAZOL-3-YL}-PIPERIDIN-1-YL)-2-OXO-ETHYL]-AMIDE; AC1LCVU4; SP-4160; DB02555; (2R)-N-[2-[4-[5-[4-[(4-acetamidophenyl)methoxy]-2,3-dichlorophenyl]-2-methylpyrazol-3-yl]piperidin-1-yl]-2-oxoethyl]-2-(diaminomethylideneamino)-4-methylpentanamide; N-(2-{4-[3-(4-{[4-(acetylamino)benzyl]oxy}-2,3-dichlorophenyl)-1-methyl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethyl)-N~2~-carbamimidoyl-D-leucinamide
DMLA3WY	DT	Small molecular drug
DMLA3WY	PC	656989
DMLA3WY	MW	685.6
DMLA3WY	FM	C33H42Cl2N8O4
DMLA3WY	IC	InChI=1S/C33H42Cl2N8O4/c1-19(2)15-26(40-33(36)37)32(46)38-17-29(45)43-13-11-22(12-14-43)27-16-25(41-42(27)4)24-9-10-28(31(35)30(24)34)47-18-21-5-7-23(8-6-21)39-20(3)44/h5-10,16,19,22,26H,11-15,17-18H2,1-4H3,(H,38,46)(H,39,44)(H4,36,37,40)/t26-/m1/s1
DMLA3WY	CS	CC(C)C[C@H](C(=O)NCC(=O)N1CCC(CC1)C2=CC(=NN2C)C3=C(C(=C(C=C3)OCC4=CC=C(C=C4)NC(=O)C)Cl)Cl)N=C(N)N
DMLA3WY	IK	VCXMTWSYQSVWRK-AREMUKBSSA-N
DMLA3WY	IU	(2R)-N-[2-[4-[5-[4-[(4-acetamidophenyl)methoxy]-2,3-dichlorophenyl]-2-methylpyrazol-3-yl]piperidin-1-yl]-2-oxoethyl]-2-(diaminomethylideneamino)-4-methylpentanamide
DMLA3WY	DE	Discovery agent

DM4SXIT	ID	DM4SXIT
DM4SXIT	DN	SP-650003
DM4SXIT	HS	Investigative
DM4SXIT	DE	Discovery agent

DMV1W4M	ID	DMV1W4M
DMV1W4M	DN	Sp-722
DMV1W4M	HS	Investigative
DMV1W4M	SN	SP-722; 4-[[glutamic acid]-carbonyl]-benzene-sulfonyl-d-proline; CHEMBL325414; CHEBI:46068; N-[4-(D-prolinosulfonyl)benzoyl]-L-glutamic acid; TP3; 1f4f; AC1L9I40; SCHEMBL7082354; BDBM50149202; DB04503; N-[(4-{[(2R)-2-carboxypyrrolidin-1-yl]sulfonyl}phenyl)carbonyl]-L-glutamic acid; (2S)-2-({4-[(2R)-2-carboxypyrrolidin-1-ylsulfonyl]phenyl}formamido)pentanedioic acid; (2S)-2-[[4-[(2R)-2-carboxypyrrolidin-1-yl]sulfonylbenzoyl]amino]pentanedioic acid
DMV1W4M	DT	Small molecular drug
DMV1W4M	PC	445505
DMV1W4M	MW	428.4
DMV1W4M	FM	C17H20N2O9S
DMV1W4M	IC	InChI=1S/C17H20N2O9S/c20-14(21)8-7-12(16(23)24)18-15(22)10-3-5-11(6-4-10)29(27,28)19-9-1-2-13(19)17(25)26/h3-6,12-13H,1-2,7-9H2,(H,18,22)(H,20,21)(H,23,24)(H,25,26)/t12-,13+/m0/s1
DMV1W4M	CS	C1C[C@@H](N(C1)S(=O)(=O)C2=CC=C(C=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O
DMV1W4M	IK	NDDOUBGQRWFVQM-QWHCGFSZSA-N
DMV1W4M	IU	(2S)-2-[[4-[(2R)-2-carboxypyrrolidin-1-yl]sulfonylbenzoyl]amino]pentanedioic acid
DMV1W4M	CB	CHEBI:46068
DMV1W4M	DE	Discovery agent

DML2V1I	ID	DML2V1I
DML2V1I	DN	Sp7343-Sp7964
DML2V1I	HS	Investigative
DML2V1I	SN	SP7343-SP7964; 3-(4-{2-[2-(2-BROMO-ACETYLAMINO)-ETHYLDISULFANYL]-ETHYLCARBAMOYL}-CYCLOHEXYLCARBAMOYL)-PYRAZINE-2-CARBOXYLIC ACID; 1nwl; AC1L9KVK; DB02620; 3-[[4-[2-(2-acetamidoethyldisulfanyl)ethylcarbamoyl]cyclohexyl]carbamoyl]pyrazine-2-carboxylic acid; 3-({cis-4-[(2-{[2-(acetylamino)ethyl]disulfanyl}ethyl)carbamoyl]cyclohexyl}carbamoyl)pyrazine-2-carboxylic acid; 3-{[(1r,4r)-4-({2-[(2-acetamidoethyl)disulfanyl]ethyl}carbamoyl)cyclohexyl]carbamoyl}pyrazine-2-carboxylic acid
DML2V1I	DT	Small molecular drug
DML2V1I	PC	447450
DML2V1I	MW	469.6
DML2V1I	FM	C19H27N5O5S2
DML2V1I	IC	InChI=1S/C19H27N5O5S2/c1-12(25)20-8-10-30-31-11-9-23-17(26)13-2-4-14(5-3-13)24-18(27)15-16(19(28)29)22-7-6-21-15/h6-7,13-14H,2-5,8-11H2,1H3,(H,20,25)(H,23,26)(H,24,27)(H,28,29)
DML2V1I	CS	CC(=O)NCCSSCCNC(=O)C1CCC(CC1)NC(=O)C2=NC=CN=C2C(=O)O
DML2V1I	IK	OMSKFAYIWROESZ-UHFFFAOYSA-N
DML2V1I	IU	3-[[4-[2-(2-acetamidoethyldisulfanyl)ethylcarbamoyl]cyclohexyl]carbamoyl]pyrazine-2-carboxylic acid
DML2V1I	DE	Discovery agent

DMJZKEH	ID	DMJZKEH
DMJZKEH	DN	Sp-876
DMJZKEH	HS	Investigative
DMJZKEH	SN	SP-876; CHEMBL418875; n-[4-[[glutamic acid]-carbonyl]-benzene-sulfonyl-d-prolinyl]-3-amino-propanoic acid; 1f4g; AC1L9I43; SCHEMBL7085784; BDBM50149206; DB03558; 1-[(4-{[(1S)-1,3-dicarboxypropyl]carbamoyl}phenyl)sulfonyl]-D-prolyl-beta-alanine; (2S)-2-[[4-[(2R)-2-(2-carboxyethylcarbamoyl)pyrrolidin-1-yl]sulfonylbenzoyl]amino]pentanedioic acid; (S)-2-{4-[(R)-2-(2-Carboxy-ethylcarbamoyl)-pyrrolidine-1-sulfonyl]-benzoylamino}-pentanedioic acid
DMJZKEH	DT	Small molecular drug
DMJZKEH	PC	445506
DMJZKEH	MW	499.5
DMJZKEH	FM	C20H25N3O10S
DMJZKEH	IC	InChI=1S/C20H25N3O10S/c24-16(25)8-7-14(20(30)31)22-18(28)12-3-5-13(6-4-12)34(32,33)23-11-1-2-15(23)19(29)21-10-9-17(26)27/h3-6,14-15H,1-2,7-11H2,(H,21,29)(H,22,28)(H,24,25)(H,26,27)(H,30,31)/t14-,15+/m0/s1
DMJZKEH	CS	C1C[C@@H](N(C1)S(=O)(=O)C2=CC=C(C=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)NCCC(=O)O
DMJZKEH	IK	SRAHBOKVSSZEHQ-LSDHHAIUSA-N
DMJZKEH	IU	(2S)-2-[[4-[(2R)-2-(2-carboxyethylcarbamoyl)pyrrolidin-1-yl]sulfonylbenzoyl]amino]pentanedioic acid
DMJZKEH	DE	Discovery agent

DM1VQ4K	ID	DM1VQ4K
DM1VQ4K	DN	Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate
DM1VQ4K	HS	Investigative
DM1VQ4K	SN	AC1NRD1K
DM1VQ4K	DT	Small molecular drug
DM1VQ4K	PC	46936216
DM1VQ4K	MW	345.27
DM1VQ4K	FM	C10H12N5O5PS
DM1VQ4K	IC	InChI=1S/C10H12N5O5PS/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(19-10)1-18-21(17,22)20-7/h2-4,6-7,10,16H,1H2,(H,17,22)(H2,11,12,13)/t4-,6+,7+,10+,21?/m1/s1
DM1VQ4K	CS	C1[C@@H]2[C@@H]([C@@H]([C@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=S)(O1)O
DM1VQ4K	IK	SMPNJFHAPJOHPP-LSSDEPPKSA-N
DM1VQ4K	IU	(4aR,6S,7S,7aR)-6-(6-aminopurin-9-yl)-2-hydroxy-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol
DM1VQ4K	DE	Discovery agent

DMV63IP	ID	DMV63IP
DMV63IP	DN	SPANTIDE
DMV63IP	HS	Investigative
DMV63IP	SN	Spantide; [D-Arg1,D-Trp7,9,Leu11]-SUBSTANCE P; D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2; D- Arg-Pro-Lys-Pro-Gln-Gln-D- Trp-Phe-D- Trp-Leu-Leu-NH2
DMV63IP	PC	25079075
DMV63IP	MW	1497.8
DMV63IP	FM	C75H108N20O13
DMV63IP	IC	InChI=1S/C75H108N20O13/c1-42(2)35-55(64(80)98)89-67(101)56(36-43(3)4)90-69(103)59(39-46-41-85-51-23-11-9-20-48(46)51)93-68(102)57(37-44-17-6-5-7-18-44)91-70(104)58(38-45-40-84-50-22-10-8-19-47(45)50)92-66(100)52(27-29-62(78)96)86-65(99)53(28-30-63(79)97)87-71(105)61-26-16-34-95(61)74(108)54(24-12-13-31-76)88-72(106)60-25-15-33-94(60)73(107)49(77)21-14-32-83-75(81)82/h5-11,17-20,22-23,40-43,49,52-61,84-85H,12-16,21,24-39,76-77H2,1-4H3,(H2,78,96)(H2,79,97)(H2,80,98)(H,86,99)(H,87,105)(H,88,106)(H,89,101)(H,90,103)(H,91,104)(H,92,100)(H,93,102)(H4,81,82,83)/t49-,52+,53+,54+,55+,56+,57+,58-,59-,60+,61+/m1/s1
DMV63IP	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCCN)NC(=O)[C@@H]7CCCN7C(=O)[C@@H](CCCN=C(N)N)N
DMV63IP	IK	SAPCBHPQLCZCDV-CHPWDEGWSA-N
DMV63IP	IU	(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DMV63IP	DE	Discovery agent

DMKC6IX	ID	DMKC6IX
DMKC6IX	DN	spantide II
DMKC6IX	HS	Investigative
DMKC6IX	SN	Spantide II; Npcatn-SP; 1-Niclys-3-(3-pal)-5-Cl2Phe-6-asn-7,9-trp-11-nle-substance P; Substance P, nic-lys(1)-3-pal(3)-Cl2-phe(5)-asn(6)-trp(7,9)-nle(11)-; 1-Nicotinyl-lysyl-3-pyridyl-alanyl-5-dichloro-phenylalanyl-6-asparaginyl-7,9-tryptophyl-11-norleucine-substance P; Substance P, nicotinyllysyl(1)-3-pyridylalanyl(3)-dichlorophenyl(5)-asparaginyl(6)-tryptophyl(7,9)-norleucine-; L-Norleucinamide, N6-(3-pyridinylcarbonyl)-D-lysyl-L-prolyl-3-(3-pyridinyl)-L-alanyl-L-prolyl-3,4-dichloro-D-phenylalanyl-L-asparaginyl
DMKC6IX	DT	Small molecular drug
DMKC6IX	PC	16131028
DMKC6IX	MW	1668.8
DMKC6IX	FM	C86H104Cl2N18O13
DMKC6IX	IC	InChI=1S/C86H104Cl2N18O13/c1-4-5-26-66(84(117)106(86(119)73-30-18-37-105(73)83(116)63(91)41-53-21-15-33-93-46-53)85(118)72-29-17-36-104(72)82(115)61(89)25-13-14-35-95-75(108)54-22-16-34-94-47-54)98-77(110)67(38-50(2)3)100-79(112)69(43-55-48-96-64-27-11-9-23-57(55)64)102-78(111)68(42-51-19-7-6-8-20-51)101-80(113)70(44-56-49-97-65-28-12-10-24-58(56)65)103-81(114)71(45-74(92)107)99-76(109)62(90)40-52-31-32-59(87)60(88)39-52/h6-12,15-16,19-24,27-28,31-34,39,46-50,61-63,66-73,96-97H,4-5,13-14,17-18,25-26,29-30,35-38,40-45,89-91H2,1-3H3,(H2,92,107)(H,95,108)(H,98,110)(H,99,109)(H,100,112)(H,101,113)(H,102,111)(H,103,114)/t61-,62-,63+,66+,67+,68+,69-,70-,71+,72+,73+/m1/s1
DMKC6IX	CS	CCCC[C@@H](C(=O)N(C(=O)[C@@H]1CCCN1C(=O)[C@@H](CCCCNC(=O)C2=CN=CC=C2)N)C(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CN=CC=C4)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H](CC1=CC(=C(C=C1)Cl)Cl)N
DMKC6IX	IK	AZZJAARMZMEIHY-BBKUSFMUSA-N
DMKC6IX	IU	(2S)-2-[[(2R)-2-amino-3-(3,4-dichlorophenyl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2R)-2-amino-6-(pyridine-3-carbonylamino)hexanoyl]pyrrolidine-2-carbonyl]-[(2S)-1-[(2S)-2-amino-3-pyridin-3-ylpropanoyl]pyrrolidine-2-carbonyl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]butanediamide
DMKC6IX	CA	CAS 129176-97-2
DMKC6IX	DE	Discovery agent

DMWCIMG	ID	DMWCIMG
DMWCIMG	DN	Sparteine
DMWCIMG	HS	Investigative
DMWCIMG	SN	Esparteina; Esparteina [INN-Spanish]; Genisteine Alkaloid; L-SPARTEINE; Lupinidin; Spartein; Sparteina [DCIT]; Sparteine; Sparteine [INN]; Sparteinum; Sparteinum [INN-Latin]; lupinidine; (-)-Lupinidine; (-)-Sparteine; 298897D62S; 6-beta,7-alpha,9-alpha,11-alpha-Pachycarpine; 6beta,7alpha,9alpha,11alpha-Pachycarpine; 90-39-1; CHEBI:28827; DSSTox_CID_3591; DSSTox_RID_77098; UNII-298897D62S; [7S-(7alpha,7aalpha,14alpha,14abeta)]-Dodecahydro-7,14-methano-2H,6H-dipyrido[1,2-a:1',2'-e][1,5]diazocine
DMWCIMG	PC	644020
DMWCIMG	MW	234.38
DMWCIMG	FM	C15H26N2
DMWCIMG	IC	SLRCCWJSBJZJBV-ZQDZILKHSA-N
DMWCIMG	CS	C1CCN2CC3CC(C2C1)CN4C3CCCC4
DMWCIMG	IK	1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m0/s1
DMWCIMG	IU	(1S,2R,9S,10S)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane
DMWCIMG	CA	CAS 90-39-1
DMWCIMG	CB	CHEBI:28827
DMWCIMG	DE	Cardiac arrhythmia

DMJ6WNK	ID	DMJ6WNK
DMJ6WNK	DN	Spathodic acid
DMJ6WNK	HS	Investigative
DMJ6WNK	SN	spathodic acid; CHEMBL493893; CHEBI:69529; BDBM50253200; 3beta,19alpha,24-trihydroxyolean-12-en-28-oic acid
DMJ6WNK	DT	Small molecular drug
DMJ6WNK	PC	21594148
DMJ6WNK	MW	488.7
DMJ6WNK	FM	C30H48O5
DMJ6WNK	IC	InChI=1S/C30H48O5/c1-25(2)13-15-30(24(34)35)16-14-28(5)18(22(30)23(25)33)7-8-20-26(3)11-10-21(32)27(4,17-31)19(26)9-12-29(20,28)6/h7,19-23,31-33H,8-17H2,1-6H3,(H,34,35)/t19-,20-,21+,22-,23+,26+,27-,28-,29-,30+/m1/s1
DMJ6WNK	CS	C[C@]12CC[C@@H]([C@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4[C@@H](C(CC5)(C)C)O)C(=O)O)C)C)(C)CO)O
DMJ6WNK	IK	TUOYZAJHBIXONX-CGSJAQJOSA-N
DMJ6WNK	IU	(1S,4aR,6aR,6aS,6bR,8aR,9S,10S,12aR,14bS)-1,10-dihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMJ6WNK	CB	CHEBI:69529
DMJ6WNK	DE	Discovery agent

DMFXJKB	ID	DMFXJKB
DMFXJKB	DN	S-p-bromobenzyl glutatione
DMFXJKB	HS	Investigative
DMFXJKB	SN	S-P-Bromobenzylglutathione; S-p-bromobenzyl glutatione; S-(p-Bromobenzyl)glutathione; S-(4-Bromobenzyl)glutathione; 31702-37-1; CHEMBL218644; (2S)-2-amino-5-[[(2R)-3-[(4-bromophenyl)methylsulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid; NSC 131115; ILG-PBB-GLY; AC1L3YPU; 0HG; SCHEMBL3280215; CTK4G7613; ZINC4962303; BDBM50241121; Glycine, L-g-glutamyl-S-[(4-bromophenyl)methyl]-L-cysteinyl-; N-(S-((4-Bromophenyl)methyl)-N-L-gamma-glutamyl-L-cysteinyl)glycine
DMFXJKB	DT	Small molecular drug
DMFXJKB	PC	97537
DMFXJKB	MW	476.3
DMFXJKB	FM	C17H22BrN3O6S
DMFXJKB	IC	InChI=1S/C17H22BrN3O6S/c18-11-3-1-10(2-4-11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)6-5-12(19)17(26)27/h1-4,12-13H,5-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1
DMFXJKB	CS	C1=CC(=CC=C1CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)Br
DMFXJKB	IK	HMNYAPVDRLKBJH-STQMWFEESA-N
DMFXJKB	IU	(2S)-2-amino-5-[[(2R)-3-[(4-bromophenyl)methylsulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMFXJKB	CA	CAS 31702-37-1
DMFXJKB	DE	Discovery agent

DM9ZBLE	ID	DM9ZBLE
DM9ZBLE	DN	Sphinganine
DM9ZBLE	HS	Investigative
DM9ZBLE	SN	dihydrosphingosine; dihydro-D-erythrosphingosine
DM9ZBLE	DT	Small molecular drug
DM9ZBLE	PC	91486
DM9ZBLE	MW	301.5
DM9ZBLE	FM	C18H39NO2
DM9ZBLE	IC	InChI=1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3/t17-,18+/m0/s1
DM9ZBLE	CS	CCCCCCCCCCCCCCC[C@H]([C@H](CO)N)O
DM9ZBLE	IK	OTKJDMGTUTTYMP-ZWKOTPCHSA-N
DM9ZBLE	IU	(2S,3R)-2-aminooctadecane-1,3-diol
DM9ZBLE	CA	CAS 764-22-7
DM9ZBLE	CB	CHEBI:16566
DM9ZBLE	DE	Discovery agent

DM7ZIMS	ID	DM7ZIMS
DM7ZIMS	DN	sphingosylphosphorylcholine
DM7ZIMS	HS	Investigative
DM7ZIMS	SN	sphingosyl phosphorylcholine
DM7ZIMS	DT	Small molecular drug
DM7ZIMS	PC	9847290
DM7ZIMS	MW	464.6
DM7ZIMS	FM	C23H49N2O5P
DM7ZIMS	IC	InChI=1S/C23H49N2O5P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(26)22(24)21-30-31(27,28)29-20-19-25(2,3)4/h17-18,22-23,26H,5-16,19-21,24H2,1-4H3/b18-17+/t22-,23+/m0/s1
DM7ZIMS	CS	CCCCCCCCCCCCC/C=C/[C@H]([C@H](COP(=O)([O-])OCC[N+](C)(C)C)N)O
DM7ZIMS	IK	JLVSPVFPBBFMBE-HXSWCURESA-N
DM7ZIMS	IU	[(E,2S,3R)-2-amino-3-hydroxyoctadec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
DM7ZIMS	CA	CAS 1670-26-4
DM7ZIMS	CB	CHEBI:17689
DM7ZIMS	DE	Discovery agent

DM8MNVX	ID	DM8MNVX
DM8MNVX	DN	Spingomyelin
DM8MNVX	HS	Investigative
DM8MNVX	SN	Spingomyelin compound; Spingomyelin active compound; SPH
DM8MNVX	DE	Discovery agent

DMDZIV5	ID	DMDZIV5
DMDZIV5	DN	spiradoline
DMDZIV5	HS	Investigative
DMDZIV5	SN	U62066; U-62066; U 62066
DMDZIV5	DT	Small molecular drug
DMDZIV5	PC	55652
DMDZIV5	MW	425.4
DMDZIV5	FM	C22H30Cl2N2O2
DMDZIV5	IC	InChI=1S/C22H30Cl2N2O2/c1-25(21(27)14-16-5-6-17(23)18(24)13-16)19-7-9-22(8-4-12-28-22)15-20(19)26-10-2-3-11-26/h5-6,13,19-20H,2-4,7-12,14-15H2,1H3/t19-,20-,22-/m0/s1
DMDZIV5	CS	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl
DMDZIV5	IK	NYKCGQQJNVPOLU-ONTIZHBOSA-N
DMDZIV5	IU	2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
DMDZIV5	CA	CAS 87151-85-7
DMDZIV5	DE	Discovery agent

DM5KNMD	ID	DM5KNMD
DM5KNMD	DN	spiramide
DM5KNMD	HS	Investigative
DM5KNMD	SN	AMI-193; R-5808
DM5KNMD	DT	Small molecular drug
DM5KNMD	PC	68186
DM5KNMD	MW	383.5
DM5KNMD	FM	C22H26FN3O2
DM5KNMD	IC	InChI=1S/C22H26FN3O2/c23-18-7-9-20(10-8-18)28-16-4-13-25-14-11-22(12-15-25)21(27)24-17-26(22)19-5-2-1-3-6-19/h1-3,5-10H,4,11-17H2,(H,24,27)
DM5KNMD	CS	C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCOC4=CC=C(C=C4)F
DM5KNMD	IK	FJUKDAZEABGEIH-UHFFFAOYSA-N
DM5KNMD	IU	8-[3-(4-fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DM5KNMD	CA	CAS 510-74-7
DM5KNMD	CB	CHEBI:64207
DM5KNMD	DE	Discovery agent

DMGFC8D	ID	DMGFC8D
DMGFC8D	DN	Spiro[cyclopropane-1,2-adamantan]-2-amine
DMGFC8D	HS	Investigative
DMGFC8D	DT	Small molecular drug
DMGFC8D	PC	56603794
DMGFC8D	MW	205.34
DMGFC8D	FM	C14H23N
DMGFC8D	IC	InChI=1S/C14H23N/c1-13(15-2)8-14(13)11-4-9-3-10(6-11)7-12(14)5-9/h9-12,15H,3-8H2,1-2H3
DMGFC8D	CS	CC1(CC12C3CC4CC(C3)CC2C4)NC
DMGFC8D	IK	LMLBGVHUFCZMCI-UHFFFAOYSA-N
DMGFC8D	IU	N,1'-dimethylspiro[adamantane-2,2'-cyclopropane]-1'-amine
DMGFC8D	DE	Discovery agent

DMWU9PV	ID	DMWU9PV
DMWU9PV	DN	Spiro[piperidine-2,2-adamantane]
DMWU9PV	HS	Investigative
DMWU9PV	SN	Spiro[adamantane-2,2'-piperidine]; SCHEMBL587914; CHEMBL323842; SCHEMBL15922506
DMWU9PV	DT	Small molecular drug
DMWU9PV	PC	10398047
DMWU9PV	MW	205.34
DMWU9PV	FM	C14H23N
DMWU9PV	IC	InChI=1S/C14H23N/c1-2-4-15-14(3-1)12-6-10-5-11(8-12)9-13(14)7-10/h10-13,15H,1-9H2
DMWU9PV	CS	C1CCNC2(C1)C3CC4CC(C3)CC2C4
DMWU9PV	IK	MAKUVZBPESPZLP-UHFFFAOYSA-N
DMWU9PV	IU	spiro[adamantane-2,2'-piperidine]
DMWU9PV	DE	Discovery agent

DMW48JD	ID	DMW48JD
DMW48JD	DN	Spiro[pyrrolidine-2,2-adamantane]
DMW48JD	HS	Investigative
DMW48JD	SN	1'-methylspiro[adamantane-2,2'-pyrrolidine]; AC1LA6HK; CHEMBL45505; SCHEMBL17352425; SCHEMBL15922378; ZINC3639976; 1-Methylspiro[pyrrolidine-2,2'-adamantane]; Spiro[pyrrolidine-2,2'-tricyclo[3.3.1.13,7]decane], 1-methyl-
DMW48JD	DT	Small molecular drug
DMW48JD	PC	508064
DMW48JD	MW	205.34
DMW48JD	FM	C14H23N
DMW48JD	IC	InChI=1S/C14H23N/c1-15-4-2-3-14(15)12-6-10-5-11(8-12)9-13(14)7-10/h10-13H,2-9H2,1H3
DMW48JD	CS	CN1CCCC12C3CC4CC(C3)CC2C4
DMW48JD	IK	NEVKUUKTVIGMHH-UHFFFAOYSA-N
DMW48JD	IU	1'-methylspiro[adamantane-2,2'-pyrrolidine]
DMW48JD	DE	Discovery agent

DMNJVZU	ID	DMNJVZU
DMNJVZU	DN	SPIROINDANYLOXYMORPHONE
DMNJVZU	HS	Investigative
DMNJVZU	SN	7-Spiroindanyloxymorphone; SIOM; 7-(Spiroindano)Oxymorphone; CHEMBL399708; SPIROINDANYLOXYMORPHONE; 150380-34-0; SCHEMBL12013205; 7-(2'-spiroindanyl)oxymorphone; 7-(2''-spiroindanyl)oxymorphone; BDBM50297170; 1',3',7,7a,8,9-Hexahydro-3,7a-dihydroxy-12-methylspiro(6H-8,9c-(iminoethano)phenanthro(4,5-bcd)furan-6,2'-(2H)inden)-5(4aH)-one (4aR-(4aalpha,7aalpha,8alpha,9calpha))-; Spiro(6H-8,9c-(iminoethano)phenanthro(4,5-bcd)furan-6,2'-(2H)inden)-5(4aH)-one, 1',3',7,7a,8,9-hexahydro-3,7a-dihydroxy-12-methyl-, (4aR-(4aalpha
DMNJVZU	DT	Small molecular drug
DMNJVZU	PC	44444966
DMNJVZU	MW	403.5
DMNJVZU	FM	C25H25NO4
DMNJVZU	IC	InChI=1S/C25H25NO4/c1-26-9-8-24-19-14-6-7-17(27)20(19)30-22(24)21(28)23(13-25(24,29)18(26)10-14)11-15-4-2-3-5-16(15)12-23/h2-7,18,22,27,29H,8-13H2,1H3/t18-,22+,24+,25-/m1/s1
DMNJVZU	CS	CN1CC[C@]23[C@@H]4C(=O)C5(CC6=CC=CC=C6C5)C[C@]2([C@H]1CC7=C3C(=C(C=C7)O)O4)O
DMNJVZU	IK	YJWDKWRVFJZBCJ-QVJDATKISA-N
DMNJVZU	IU	(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methylspiro[1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6,2'-1,3-dihydroindene]-7-one
DMNJVZU	CA	CAS 150380-34-0
DMNJVZU	DE	Discovery agent

DMPHRXQ	ID	DMPHRXQ
DMPHRXQ	DN	spiroxatrine
DMPHRXQ	HS	Investigative
DMPHRXQ	SN	spiroxamide
DMPHRXQ	DT	Small molecular drug
DMPHRXQ	PC	5268
DMPHRXQ	MW	379.5
DMPHRXQ	FM	C22H25N3O3
DMPHRXQ	IC	InChI=1S/C22H25N3O3/c26-21-22(25(16-23-21)17-6-2-1-3-7-17)10-12-24(13-11-22)14-18-15-27-19-8-4-5-9-20(19)28-18/h1-9,18H,10-16H2,(H,23,26)
DMPHRXQ	CS	C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CC4COC5=CC=CC=C5O4
DMPHRXQ	IK	JVGBTTIJPBFLTE-UHFFFAOYSA-N
DMPHRXQ	IU	8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DMPHRXQ	CA	CAS 1054-88-2
DMPHRXQ	CB	CHEBI:91845
DMPHRXQ	DE	Discovery agent

DMCLHZ5	ID	DMCLHZ5
DMCLHZ5	DN	splitomicin
DMCLHZ5	HS	Investigative
DMCLHZ5	SN	splitomicin; 5690-03-9; 1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398
DMCLHZ5	DT	Small molecular drug
DMCLHZ5	PC	5269
DMCLHZ5	MW	198.22
DMCLHZ5	FM	C13H10O2
DMCLHZ5	IC	InChI=1S/C13H10O2/c14-13-8-6-11-10-4-2-1-3-9(10)5-7-12(11)15-13/h1-5,7H,6,8H2
DMCLHZ5	CS	C1CC(=O)OC2=C1C3=CC=CC=C3C=C2
DMCLHZ5	IK	ISFPDBUKMJDAJH-UHFFFAOYSA-N
DMCLHZ5	IU	1,2-dihydrobenzo[f]chromen-3-one
DMCLHZ5	CA	CAS 5690-03-9
DMCLHZ5	CB	CHEBI:75272
DMCLHZ5	DE	Discovery agent

DMYBCEG	ID	DMYBCEG
DMYBCEG	DN	S-P-Nitrobenzyloxycarbonylglutathione
DMYBCEG	HS	Investigative
DMYBCEG	SN	S-P-NITROBENZYLOXYCARBONYLGLUTATHIONE
DMYBCEG	DT	Small molecular drug
DMYBCEG	PC	46936582
DMYBCEG	MW	488.5
DMYBCEG	FM	C18H24N4O10S
DMYBCEG	IC	InChI=1S/C18H24N4O10S/c19-12(17(27)28)5-6-14(23)21-13(16(26)20-7-15(24)25)9-33-18(29)32-8-10-1-3-11(4-2-10)22(30)31/h1-4,12-13,18,29H,5-9,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/t12-,13+,18+/m0/s1
DMYBCEG	CS	C1=CC(=CC=C1CO[C@@H](O)SC[C@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)[N+](=O)[O-]
DMYBCEG	IK	QYFGPQQSJQOGEO-VEVIJQCQSA-N
DMYBCEG	IU	(2S)-2-amino-5-[[(2S)-1-(carboxymethylamino)-3-[(R)-hydroxy-[(4-nitrophenyl)methoxy]methyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMYBCEG	DE	Discovery agent

DM0GJVS	ID	DM0GJVS
DM0GJVS	DN	SPONGIADIOXIN A
DM0GJVS	HS	Investigative
DM0GJVS	SN	SPONGIADIOXIN A; CHEMBL185828; 329040-77-9; Dibenzo[b,e][1,4]dioxin-1-ol, 3,4,6,8-tetrabromo-; BDBM50150784
DM0GJVS	DT	Small molecular drug
DM0GJVS	PC	10029508
DM0GJVS	MW	515.77
DM0GJVS	FM	C12H4Br4O3
DM0GJVS	IC	InChI=1S/C12H4Br4O3/c13-4-1-6(15)10-8(2-4)18-11-7(17)3-5(14)9(16)12(11)19-10/h1-3,17H
DM0GJVS	CS	C1=C(C=C(C2=C1OC3=C(O2)C(=C(C=C3O)Br)Br)Br)Br
DM0GJVS	IK	SSCRQJOLSHUSSG-UHFFFAOYSA-N
DM0GJVS	IU	3,4,6,8-tetrabromodibenzo-p-dioxin-1-ol
DM0GJVS	DE	Discovery agent

DMP5VN2	ID	DMP5VN2
DMP5VN2	DN	SPP-800
DMP5VN2	HS	Investigative
DMP5VN2	SN	Renin inhibitors, Locus/Novartis; Renin inhibitors, Locus/Speedel
DMP5VN2	CP	Locus Pharmaceuticals Inc
DMP5VN2	DE	Hypertension

DMFTLY9	ID	DMFTLY9
DMFTLY9	DN	S-propyl propane-1-sulfinothioate
DMFTLY9	HS	Investigative
DMFTLY9	SN	s-propyl propane-1-sulfinothioate; 1948-52-3; 1-Propanesulfinothioic acid, S-propyl ester; S-Propyl 1-propanesulfinothioate; S-Propyl propane-1-thiosulphinate; CHEMBL1224166; S-Propyl propane-1-thiosulfinate; 1-propylsulfinylsulfanylpropane; EINECS 217-755-9; NSC 23131; dipropyl thiosulfinate; propyl propylthiosulfinate; AC1L2MLV; AC1Q6YQN; Propyl(propylthio) sulfoxide; S-propyl propanethiosulfinate; SCHEMBL7033573; CHEBI:91021; CTK4E1637; XPRZAEWSYWTDSQ-UHFFFAOYSA-N; NSC23131; NSC-23131; BDBM50325647; S-Propyl 1-propanesulfinoth
DMFTLY9	DT	Small molecular drug
DMFTLY9	PC	74761
DMFTLY9	MW	166.3
DMFTLY9	FM	C6H14OS2
DMFTLY9	IC	InChI=1S/C6H14OS2/c1-3-5-8-9(7)6-4-2/h3-6H2,1-2H3
DMFTLY9	CS	CCCSS(=O)CCC
DMFTLY9	IK	XPRZAEWSYWTDSQ-UHFFFAOYSA-N
DMFTLY9	IU	1-propylsulfinylsulfanylpropane
DMFTLY9	CA	CAS 1948-52-3
DMFTLY9	CB	CHEBI:91021
DMFTLY9	DE	Discovery agent

DMKCJQW	ID	DMKCJQW
DMKCJQW	DN	SP-SAP
DMKCJQW	HS	Investigative
DMKCJQW	SN	NK1-saporin conjugate, Advanced Targeting Systems; Neurokinin NK1-saporin conjugate, ATS; SP-SAP, APT; SP-SAP, Advanced Pain Therapeutics; SP-SAP, Advanced Targeting Systems; Substance P-saporin conjugate, ATS; Substance P-saporin conjugate, Advanced Targeting Systems
DMKCJQW	CP	Advanced Targeting Systems Inc
DMKCJQW	DE	Cancer related pain

DM94RJW	ID	DM94RJW
DM94RJW	DN	SPT
DM94RJW	HS	Investigative
DM94RJW	SN	8-Pspt; 8-(p-Sulfophenyl)theophylline hydrate; MLS000859938; CHEMBL1697922; HMS3373H03; HMS2230M12; AKOS024360233; SMR000326799; 8-(p-Sulfophenyl)theophylline hydrate, solid; ST50990065; 4-(1,3-dimethyl-2,6-dioxo-1,3-dihydropurin-8-yl)benzenesulfonic acid, hydrate; 4-(1,3-Dimethyl-2,6-dioxo-2,3,6,9-tetrahydro-1H-purin-8-yl)benzenesulfonic acid hemihydrate
DM94RJW	DT	Small molecular drug
DM94RJW	PC	18528136
DM94RJW	MW	354.34
DM94RJW	FM	C13H14N4O6S
DM94RJW	IC	InChI=1S/C13H12N4O5S.H2O/c1-16-11-9(12(18)17(2)13(16)19)14-10(15-11)7-3-5-8(6-4-7)23(20,21)22;/h3-6H,1-2H3,(H,14,15)(H,20,21,22);1H2
DM94RJW	CS	CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C3=CC=C(C=C3)S(=O)(=O)O.O
DM94RJW	IK	AYQOEZBHENEBEJ-UHFFFAOYSA-N
DM94RJW	IU	4-(1,3-dimethyl-2,6-dioxo-7H-purin-8-yl)benzenesulfonic acid;hydrate
DM94RJW	DE	Discovery agent

DMRP42B	ID	DMRP42B
DMRP42B	DN	SQ 26655
DMRP42B	HS	Investigative
DMRP42B	SN	SQ-26,655; SQ-26655
DMRP42B	DT	Small molecular drug
DMRP42B	PC	73755172
DMRP42B	MW	350.5
DMRP42B	FM	C21H34O4
DMRP42B	IC	InChI=1S/C21H34O4/c1-2-3-6-9-17(22)13-12-16-14-18-15-20(25-18)19(16)10-7-4-5-8-11-21(23)24/h4,7,12-13,16-20,22H,2-3,5-6,8-11,14-15H2,1H3,(H,23,24)/b7-4-,13-12+/t16-,17-,18-,19+,20-/m0/s1
DMRP42B	CS	CCCCC[C@@H](/C=C/[C@H]1C[C@H]2C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O2)O
DMRP42B	IK	HAJUMEFPOWPAQL-IGUVKOCZSA-N
DMRP42B	IU	(Z)-7-[(1S,2R,3R,5S)-3-[(E,3S)-3-hydroxyoct-1-enyl]-6-oxabicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid
DMRP42B	DE	Discovery agent

DMJW8NV	ID	DMJW8NV
DMJW8NV	DN	SQ-14603
DMJW8NV	HS	Investigative
DMJW8NV	SN	2-Benzyl-3-mercaptopropanoic acid; SQ-14603; CHEMBL58957; 2-benzyl-3-sulfanylpropanoic acid; 69734-01-6; SQ 14,603; Benzenepropanoic acid, alpha-(mercaptomethyl)-; AC1Q5S0H; AC1L4Y1D; SCHEMBL1559014; CTK2F3831; ZUEBVBPVXLQMQR-UHFFFAOYSA-N; 2-Benzyl-3-mercapto-propionic acid; BDBM50109593; AKOS022645473; 2-mercaptomethyl-3-phenylpropionic acid; 2-Mercaptomethyl-3-phenyl-propionic acid; 81110-55-6; 3-Phenyl-2-(mercaptomethyl)propionic acid; Benzenepropanoic acid, alpha-(mercaptomethyl)-, (+-)-
DMJW8NV	DT	Small molecular drug
DMJW8NV	PC	194327
DMJW8NV	MW	196.27
DMJW8NV	FM	C10H12O2S
DMJW8NV	IC	InChI=1S/C10H12O2S/c11-10(12)9(7-13)6-8-4-2-1-3-5-8/h1-5,9,13H,6-7H2,(H,11,12)
DMJW8NV	CS	C1=CC=C(C=C1)CC(CS)C(=O)O
DMJW8NV	IK	ZUEBVBPVXLQMQR-UHFFFAOYSA-N
DMJW8NV	IU	2-benzyl-3-sulfanylpropanoic acid
DMJW8NV	CA	CAS 69734-01-6
DMJW8NV	DE	Discovery agent

DMW7Y9L	ID	DMW7Y9L
DMW7Y9L	DN	SQ-24798
DMW7Y9L	HS	Investigative
DMW7Y9L	SN	2-Mercaptomethyl-5-guanidinopentanoic acid; SQ-24798; CHEMBL236822; 5-carbamimidamido-2-(sulfanylmethyl)pentanoic acid; 69734-02-7; 5-(diaminomethylideneamino)-2-(sulfanylmethyl)pentanoic acid; SQ 24798; SQ 24,798; AC1Q5RYU; AC1L4Y1G; GTPL8656; SCHEMBL5415499; CTK5D1141; BDBM50201438; AKOS030556047; SQ-24,798; 5-guanidino-2-(mercaptomethyl)pentanoic acid; (+/-)-5-guanidino-2-(mercaptomethyl)pentanoic acid
DMW7Y9L	DT	Small molecular drug
DMW7Y9L	PC	194328
DMW7Y9L	MW	205.28
DMW7Y9L	FM	C7H15N3O2S
DMW7Y9L	IC	InChI=1S/C7H15N3O2S/c8-7(9)10-3-1-2-5(4-13)6(11)12/h5,13H,1-4H2,(H,11,12)(H4,8,9,10)
DMW7Y9L	CS	C(CC(CS)C(=O)O)CN=C(N)N
DMW7Y9L	IK	JOVIPJZDTSYNNW-UHFFFAOYSA-N
DMW7Y9L	IU	5-(diaminomethylideneamino)-2-(sulfanylmethyl)pentanoic acid
DMW7Y9L	CA	CAS 69734-02-7
DMW7Y9L	DE	Discovery agent

DMLPN95	ID	DMLPN95
DMLPN95	DN	SQ-27986
DMLPN95	HS	Investigative
DMLPN95	SN	SQ27986; SQ 27986
DMLPN95	DT	Small molecular drug
DMLPN95	PC	6439022
DMLPN95	MW	362.5
DMLPN95	FM	C22H34O4
DMLPN95	IC	InChI=1S/C22H34O4/c23-19(16-8-4-3-5-9-16)13-12-18-17(20-14-15-21(18)26-20)10-6-1-2-7-11-22(24)25/h1,6,12-13,16-21,23H,2-5,7-11,14-15H2,(H,24,25)/b6-1-,13-12+/t17-,18-,19+,20-,21+/m0/s1
DMLPN95	CS	C1CCC(CC1)[C@@H](/C=C/[C@@H]2[C@H]3CC[C@@H]([C@H]2C/C=C\\CCCC(=O)O)O3)O
DMLPN95	IK	CEHGUSRXHYTTPN-ZSMXBAJYSA-N
DMLPN95	IU	(Z)-7-[(1S,2S,3S,4R)-3-[(E,3S)-3-cyclohexyl-3-hydroxyprop-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DMLPN95	DE	Discovery agent

DM9G3UD	ID	DM9G3UD
DM9G3UD	DN	SQ-29548
DM9G3UD	HS	Investigative
DM9G3UD	SN	7-(3-((2-((Phenylamino)carbonyl)hydrazino)methyl)-7-oxabicyclo(221)hept-2-yl)-5-heptenoic acid; SQ 28053; (Z)-7-[(1R,4S,5R,6R)-5-[(2-(phenylcarbamoyl)hydrazinyl)methyl]-7-oxabicyclo[221]heptan-6-yl]hept-5-enoic acid; 98672-91-4; 98299-61-7; [3H]SQ29548; SQ-28053; [3H]SQ-29548; [3H]-SQ29548; [3H]SQ-28053; GTPL1985; GTPL1980; 5-Heptenoic acid, 7-((1R,2R,3R,4S)-3-((2-((phenylamino)carbonyl)hydrazino)methyl)-7-oxabicyclo(221)hept-2-yl)-, (5Z)-rel-; 5-Heptenoic acid,
DM9G3UD	DT	Small molecular drug
DM9G3UD	PC	6437074
DM9G3UD	MW	387.5
DM9G3UD	FM	C21H29N3O4
DM9G3UD	IC	InChI=1S/C21H29N3O4/c25-20(26)11-7-2-1-6-10-16-17(19-13-12-18(16)28-19)14-22-24-21(27)23-15-8-4-3-5-9-15/h1,3-6,8-9,16-19,22H,2,7,10-14H2,(H,25,26)(H2,23,24,27)/b6-1-/t16-,17+,18-,19+/m1/s1
DM9G3UD	CS	C1C[C@H]2[C@H]([C@H]([C@@H]1O2)C/C=C\\CCCC(=O)O)CNNC(=O)NC3=CC=CC=C3
DM9G3UD	IK	RJNDVCNWVBWHLY-OQMICVBCSA-N
DM9G3UD	IU	(Z)-7-[(1R,2R,3R,4S)-3-[[2-(phenylcarbamoyl)hydrazinyl]methyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DM9G3UD	CA	CAS 98299-61-7
DM9G3UD	DE	Discovery agent

DML6SIE	ID	DML6SIE
DML6SIE	DN	SQ32,910
DML6SIE	HS	Investigative
DML6SIE	SN	SQ 32910; SQ-32,910; 138335-21-4; 1-(2-(Dimethylamino)ethyl)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-6-(trifluoromethyl)-2H-1-benzazepine-2-one; 2H-1-Benzazepin-2-one, 1-(2-(dimethylamino)ethyl)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-6-(trifluoromethyl)-, cis-(+-)-
DML6SIE	DT	Small molecular drug
DML6SIE	PC	15612142
DML6SIE	MW	420.5
DML6SIE	FM	C23H27F3N2O2
DML6SIE	IC	InChI=1S/C23H27F3N2O2/c1-15-18(16-8-10-17(30-4)11-9-16)14-19-20(23(24,25)26)6-5-7-21(19)28(22(15)29)13-12-27(2)3/h5-11,15,18H,12-14H2,1-4H3
DML6SIE	CS	CC1C(CC2=C(C=CC=C2N(C1=O)CCN(C)C)C(F)(F)F)C3=CC=C(C=C3)OC
DML6SIE	IK	ZBCRNIFALVNVKY-UHFFFAOYSA-N
DML6SIE	IU	1-[2-(dimethylamino)ethyl]-4-(4-methoxyphenyl)-3-methyl-6-(trifluoromethyl)-4,5-dihydro-3H-1-benzazepin-2-one
DML6SIE	CA	CAS 138335-21-4
DML6SIE	DE	Discovery agent

DMBA297	ID	DMBA297
DMBA297	DN	SR11254
DMBA297	HS	Investigative
DMBA297	SN	SR11254; SCHEMBL5712126; DB02258; SR-11254; MM-11254; 6-[(1Z)-(hydroxyimino)(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)methyl]naphthalene-2-carboxylic acid
DMBA297	DT	Small molecular drug
DMBA297	PC	9887304
DMBA297	MW	401.5
DMBA297	FM	C26H27NO3
DMBA297	IC	InChI=1S/C26H27NO3/c1-25(2)11-12-26(3,4)22-15-19(9-10-21(22)25)23(27-30)18-7-5-17-14-20(24(28)29)8-6-16(17)13-18/h5-10,13-15,30H,11-12H2,1-4H3,(H,28,29)/b27-23+
DMBA297	CS	CC1(CCC(C2=C1C=CC(=C2)/C(=N/O)/C3=CC4=C(C=C3)C=C(C=C4)C(=O)O)(C)C)C
DMBA297	IK	RNZIUDLOJHVHLZ-SLEBQGDGSA-N
DMBA297	IU	6-[(E)-N-hydroxy-C-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbonimidoyl]naphthalene-2-carboxylic acid
DMBA297	DE	Discovery agent

DMPN3Q0	ID	DMPN3Q0
DMPN3Q0	DN	SR-14136
DMPN3Q0	HS	Investigative
DMPN3Q0	SN	ORL1 ligands (pain); SR-14148; SR-14150; SR-14159; SR-16430; SR-16435; SR-16506; SR-16507; SR-16835; NOP receptor modulators (pain), SRI; ORL1 ligands (pain), SRI; Nociceptin/orphanin FQ modulators (pain), SRI
DMPN3Q0	CP	SRI International
DMPN3Q0	DT	Small molecular drug
DMPN3Q0	PC	10066285
DMPN3Q0	MW	347.5
DMPN3Q0	FM	C22H25N3O
DMPN3Q0	IC	InChI=1S/C22H25N3O/c26-22-23-19-10-4-5-11-21(19)25(22)18-13-14-24-17(15-18)9-6-12-20(24)16-7-2-1-3-8-16/h1-5,7-8,10-11,17-18,20H,6,9,12-15H2,(H,23,26)/t17-,18-,20+/m1/s1
DMPN3Q0	CS	C1C[C@@H]2C[C@@H](CCN2[C@@H](C1)C3=CC=CC=C3)N4C5=CC=CC=C5NC4=O
DMPN3Q0	IK	KMUYAJQKQQUKSQ-GGPKGHCWSA-N
DMPN3Q0	IU	3-[(2R,6S,9aR)-6-phenyl-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-2-yl]-1H-benzimidazol-2-one
DMPN3Q0	DE	Pain

DMMXU6R	ID	DMMXU6R
DMMXU6R	DN	SR142948A
DMMXU6R	HS	Investigative
DMMXU6R	SN	SR-142948A
DMMXU6R	DT	Small molecular drug
DMMXU6R	PC	5311451
DMMXU6R	MW	685.9
DMMXU6R	FM	C39H51N5O6
DMMXU6R	IC	InChI=1S/C39H51N5O6/c1-23(2)29-21-26(37(46)43(5)15-9-14-42(3)4)12-13-31(29)44-32(35-33(49-6)10-8-11-34(35)50-7)22-30(41-44)36(45)40-39(38(47)48)27-17-24-16-25(19-27)20-28(39)18-24/h8,10-13,21-25,27-28H,9,14-20H2,1-7H3,(H,40,45)(H,47,48)
DMMXU6R	CS	CC(C)C1=C(C=CC(=C1)C(=O)N(C)CCCN(C)C)N2C(=CC(=N2)C(=O)NC3(C4CC5CC(C4)CC3C5)C(=O)O)C6=C(C=CC=C6OC)OC
DMMXU6R	IK	LWULHXVBLMWCHO-UHFFFAOYSA-N
DMMXU6R	IU	2-[[5-(2,6-dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
DMMXU6R	CA	CAS 184162-64-9
DMMXU6R	CB	CHEBI:93589
DMMXU6R	DE	Discovery agent

DMBRVXY	ID	DMBRVXY
DMBRVXY	DN	SR144528
DMBRVXY	HS	Investigative
DMBRVXY	SN	SR 144528; SR144528; 192703-06-3; SR-144528; CHEMBL381791; 5-(4-Chloro-3-methylphenyl)-1-((4-methylphenyl)methyl)-N-(1,3,3-trimethylbicyclo(2.2.1)hept-2-yl)-1H-pyrazole-3-carboxamide (1S-endo)-; SR144,528; (1S-endo)-5-(4-Chloro-3-methylphenyl)-1-((4-methylphenyl)methyl)-N-(1,3,3-trimethylbicyclo(2.2.1)hept-2-yl)-1H-pyrazole-3-carboxamide; 5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-pyrazole-3-carboxamide; 1H-Pyrazole-3-carboxamide, 5-(4-chloro-3-methylphe
DMBRVXY	DT	Small molecular drug
DMBRVXY	PC	3081355
DMBRVXY	MW	476.1
DMBRVXY	FM	C29H34ClN3O
DMBRVXY	IC	InChI=1S/C29H34ClN3O/c1-18-6-8-20(9-7-18)17-33-25(21-10-11-23(30)19(2)14-21)15-24(32-33)26(34)31-27-28(3,4)22-12-13-29(27,5)16-22/h6-11,14-15,22,27H,12-13,16-17H2,1-5H3,(H,31,34)/t22-,27-,29+/m1/s1
DMBRVXY	CS	CC1=CC=C(C=C1)CN2C(=CC(=N2)C(=O)N[C@H]3[C@]4(CC[C@H](C4)C3(C)C)C)C5=CC(=C(C=C5)Cl)C
DMBRVXY	IK	SUGVYNSRNKFXQM-XRHWURSXSA-N
DMBRVXY	IU	5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethyl-2-bicyclo[2.2.1]heptanyl]pyrazole-3-carboxamide
DMBRVXY	CA	CAS 192703-06-3
DMBRVXY	CB	CHEBI:146245
DMBRVXY	DE	Discovery agent

DMPO4WX	ID	DMPO4WX
DMPO4WX	DN	SR-33805A
DMPO4WX	HS	Investigative
DMPO4WX	SN	3-Isopropyl-2-[4-[3-[N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylamino]propoxy]phenylsulfonyl]-1-methylindole oxalate
DMPO4WX	DT	Small molecular drug
DMPO4WX	PC	21256218
DMPO4WX	MW	654.8
DMPO4WX	FM	C34H42N2O9S
DMPO4WX	IC	InChI=1S/C32H40N2O5S.C2H2O4/c1-23(2)31-27-10-7-8-11-28(27)34(4)32(31)40(35,36)26-15-13-25(14-16-26)39-21-9-19-33(3)20-18-24-12-17-29(37-5)30(22-24)38-6;3-1(4)2(5)6/h7-8,10-17,22-23H,9,18-21H2,1-6H3;(H,3,4)(H,5,6)
DMPO4WX	CS	CC(C)C1=C(N(C2=CC=CC=C21)C)S(=O)(=O)C3=CC=C(C=C3)OCCCN(C)CCC4=CC(=C(C=C4)OC)OC.C(=O)(C(=O)O)O
DMPO4WX	IK	MZWPPDAHWIKZID-UHFFFAOYSA-N
DMPO4WX	IU	N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-3-propan-2-ylindol-2-yl)sulfonylphenoxy]propan-1-amine;oxalic acid
DMPO4WX	CA	CAS 121346-33-6
DMPO4WX	DE	Hypertension

DM3Y09Z	ID	DM3Y09Z
DM3Y09Z	DN	SR-3850
DM3Y09Z	HS	Investigative
DM3Y09Z	SN	Rho kinase inhibitors (hypertension, glaucoma, cancer); Rho kinase inhibitors (hypertension, glaucoma, cancer), Scripps
DM3Y09Z	CP	Scripps Research Institute
DM3Y09Z	DE	Solid tumour/cancer

DMUHQS9	ID	DMUHQS9
DMUHQS9	DN	SR48527
DMUHQS9	HS	Investigative
DMUHQS9	SN	SR-48527; SR 48527
DMUHQS9	DT	Small molecular drug
DMUHQS9	PC	9915499
DMUHQS9	MW	549
DMUHQS9	FM	C29H29ClN4O5
DMUHQS9	IC	InChI=1S/C29H29ClN4O5/c1-38-24-9-6-10-25(39-2)26(24)23-16-21(28(35)32-27(29(36)37)17-7-4-3-5-8-17)33-34(23)22-13-14-31-20-15-18(30)11-12-19(20)22/h6,9-17,27H,3-5,7-8H2,1-2H3,(H,32,35)(H,36,37)/t27-/m0/s1
DMUHQS9	CS	COC1=C(C(=CC=C1)OC)C2=CC(=NN2C3=C4C=CC(=CC4=NC=C3)Cl)C(=O)N[C@@H](C5CCCCC5)C(=O)O
DMUHQS9	IK	PXNTUYAGLGTUKX-MHZLTWQESA-N
DMUHQS9	IU	(2S)-2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]-2-cyclohexylacetic acid
DMUHQS9	DE	Discovery agent

DMCRVM2	ID	DMCRVM2
DMCRVM2	DN	SR-59026
DMCRVM2	HS	Investigative
DMCRVM2	DE	Discovery agent

DM2WIGO	ID	DM2WIGO
DM2WIGO	DN	SR9238
DM2WIGO	HS	Investigative
DM2WIGO	SN	SR9238; SR 9238; 1416153-62-2; GTPL8692; SCHEMBL15773678; MolPort-042-624-584; AKOS027470306; ZINC145690538; HY-101442; CS-0021352; ethyl 5-[[[4-(3-methylsulfonylphenyl)phenyl]methyl-(2,4,6-trimethylphenyl)sulfonylamino]methyl]furan-2-carboxylate; Ethyl 5-[[[[3'-(Methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl][(2,4,6-trimethylphenyl)sulfonyl]amino]methyl]-2-furancarboxylate
DM2WIGO	DT	Small molecular drug
DM2WIGO	PC	71478195
DM2WIGO	MW	595.7
DM2WIGO	FM	C31H33NO7S2
DM2WIGO	IC	InChI=1S/C31H33NO7S2/c1-6-38-31(33)29-15-14-27(39-29)20-32(41(36,37)30-22(3)16-21(2)17-23(30)4)19-24-10-12-25(13-11-24)26-8-7-9-28(18-26)40(5,34)35/h7-18H,6,19-20H2,1-5H3
DM2WIGO	CS	CCOC(=O)C1=CC=C(O1)CN(CC2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C)S(=O)(=O)C4=C(C=C(C=C4C)C)C
DM2WIGO	IK	HDZWHJYZJWLTAG-UHFFFAOYSA-N
DM2WIGO	IU	ethyl 5-[[[4-(3-methylsulfonylphenyl)phenyl]methyl-(2,4,6-trimethylphenyl)sulfonylamino]methyl]furan-2-carboxylate
DM2WIGO	DE	Discovery agent

DMA28ZX	ID	DMA28ZX
DMA28ZX	DN	SR95531
DMA28ZX	HS	Investigative
DMA28ZX	SN	SMR000326943; Prestwick_764; AC1O4W6K; MLS000862180; MLS002222260; MLS002153143; SCHEMBL593922; C15H17N3O3.BrH; HMS1569I08; HMS3370G11; HMS3713I08; HMS3263H05; HMS2231I20; HMS2096I08; Tox21_501152; AKOS015913760; LP01152; CCG-222456; API0000574; CCG-220443; NCGC00261837-01; NCGC00094415-01; SR-95531, &gt; X6865; EU-0101152; SR-01000780583; SR-01000076238; SR-01000780583-2; SR-01000076238-1; I14-44993; 4-[6-amino-3-(4-methoxyphenyl)pyridazin-1-ium-1-yl]butanoic acid bromide
DMA28ZX	DT	Small molecular drug
DMA28ZX	PC	107896
DMA28ZX	MW	287.31
DMA28ZX	FM	C15H17N3O3
DMA28ZX	IC	InChI=1S/C15H17N3O3/c1-21-12-6-4-11(5-7-12)13-8-9-14(16)18(17-13)10-2-3-15(19)20/h4-9,16H,2-3,10H2,1H3,(H,19,20)
DMA28ZX	CS	COC1=CC=C(C=C1)C2=NN(C(=N)C=C2)CCCC(=O)O
DMA28ZX	IK	ACVGNKYJVGNLIL-UHFFFAOYSA-N
DMA28ZX	IU	4-[6-imino-3-(4-methoxyphenyl)pyridazin-1-yl]butanoic acid
DMA28ZX	CA	CAS 105538-73-6
DMA28ZX	CB	CHEBI:34968

DMU48OD	ID	DMU48OD
DMU48OD	DN	SR-973
DMU48OD	HS	Investigative
DMU48OD	SN	SR-973; CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide
DMU48OD	DT	Small molecular drug
DMU48OD	PC	9849669
DMU48OD	MW	523.7
DMU48OD	FM	C30H41N3O5
DMU48OD	IC	InChI=1S/C30H41N3O5/c1-4-11-25(29(35)32-37)26(18-21(2)3)28(34)31-27-16-8-9-17-33(30(27)36)20-22-12-10-15-24(19-22)38-23-13-6-5-7-14-23/h5-7,10,12-15,19,21,25-27,37H,4,8-9,11,16-18,20H2,1-3H3,(H,31,34)(H,32,35)/t25-,26+,27-/m0/s1
DMU48OD	CS	CCC[C@@H]([C@@H](CC(C)C)C(=O)N[C@H]1CCCCN(C1=O)CC2=CC(=CC=C2)OC3=CC=CC=C3)C(=O)NO
DMU48OD	IK	WICQDDCNCVTFDX-VJGNERBWSA-N
DMU48OD	IU	(2S,3R)-N-hydroxy-3-(2-methylpropyl)-N'-[(3S)-2-oxo-1-[(3-phenoxyphenyl)methyl]azepan-3-yl]-2-propylbutanediamide
DMU48OD	DE	Discovery agent

DM37YJH	ID	DM37YJH
DM37YJH	DN	SRA880
DM37YJH	HS	Investigative
DM37YJH	SN	NVP-SRA880; obelin
DM37YJH	DT	Small molecular drug
DM37YJH	PC	5311377
DM37YJH	MW	464.6
DM37YJH	FM	C26H32N4O4
DM37YJH	IC	InChI=1S/C26H32N4O4/c1-27-17-20(14-19-15-23-18(16-24(19)27)4-3-5-25(23)34-2)26(31)29-12-10-28(11-13-29)21-6-8-22(9-7-21)30(32)33/h3-9,19-20,24H,10-17H2,1-2H3/t19-,20-,24-/m1/s1
DM37YJH	CS	CN1C[C@@H](C[C@H]2[C@H]1CC3=C(C2)C(=CC=C3)OC)C(=O)N4CCN(CC4)C5=CC=C(C=C5)[N+](=O)[O-]
DM37YJH	IK	INULNSAIIZKOQE-YOSAUDMPSA-N
DM37YJH	IU	[(3R,4aR,10aR)-6-methoxy-1-methyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-3-yl]-[4-(4-nitrophenyl)piperazin-1-yl]methanone
DM37YJH	DE	Discovery agent

DMUZP9V	ID	DMUZP9V
DMUZP9V	DN	Src kinase inhibitor I
DMUZP9V	HS	Investigative
DMUZP9V	SN	Src Kinase Inhibitor I; 179248-59-0; Src I1; Src Inhibitor 1; Src I 1; Src Inhibitor-1; Src-l1; 6,7-dimethoxy-N-(4-phenoxyphenyl)quinazolin-4-amine; SKI-1; CHEMBL97771; CHEBI:78332; 6,7-dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine; 4-Quinazolinamine, 6,7-dimethoxy-N-(4-phenoxyphenyl)-; 4-(4'-PHENOXYANILINO)-6,7-DIMETHOXYQUINAZOLINE; -Phenoxyanilino)-6,7-dimethoxyquinazoline; Src-I1; AC1LT1HN; Bionet1_003516; Oprea1_231056; GTPL6042; SCHEMBL1387206; KS-00002WRA; HMS578L18; CTK0E3319; AOB5689; DTXSID50363056
DMUZP9V	DT	Small molecular drug
DMUZP9V	PC	1474853
DMUZP9V	MW	373.4
DMUZP9V	FM	C22H19N3O3
DMUZP9V	IC	InChI=1S/C22H19N3O3/c1-26-20-12-18-19(13-21(20)27-2)23-14-24-22(18)25-15-8-10-17(11-9-15)28-16-6-4-3-5-7-16/h3-14H,1-2H3,(H,23,24,25)
DMUZP9V	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)OC4=CC=CC=C4)OC
DMUZP9V	IK	DMWVGXGXHPOEPT-UHFFFAOYSA-N
DMUZP9V	IU	6,7-dimethoxy-N-(4-phenoxyphenyl)quinazolin-4-amine
DMUZP9V	CA	CAS 179248-59-0
DMUZP9V	CB	CHEBI:78332
DMUZP9V	DE	Discovery agent

DM35NF6	ID	DM35NF6
DM35NF6	DN	SRI-224
DM35NF6	HS	Investigative
DM35NF6	SN	SRI-224; CHEMBL223505; [(E)-1-(4-methoxyphenyl)ethylideneamino]thiourea; p-Methoxyacetophenone thiosemicarbazone; 1-(4-methoxyphenyl)ethanone thiosemicarbazone; MolPort-000-248-698; ZINC15224175; BDBM50302754; AKOS000506378; p-methoxyphenyl(methyl)thiosemicarbazone; KB-89903; ST085316; BAS 00232870; 9P-047; SR-01000310617; [(E)-[1-(4-methoxyphenyl)ethylidene]amino]thiourea; SR-01000310617-1; (1E)-1-(4-methoxyphenyl)ethanone thiosemicarbazone
DM35NF6	DT	Small molecular drug
DM35NF6	PC	9561005
DM35NF6	MW	223.3
DM35NF6	FM	C10H13N3OS
DM35NF6	IC	InChI=1S/C10H13N3OS/c1-7(12-13-10(11)15)8-3-5-9(14-2)6-4-8/h3-6H,1-2H3,(H3,11,13,15)/b12-7+
DM35NF6	CS	C/C(=N\\NC(=S)N)/C1=CC=C(C=C1)OC
DM35NF6	IK	JPXKIPVPEBSPLT-KPKJPENVSA-N
DM35NF6	IU	[(E)-1-(4-methoxyphenyl)ethylideneamino]thiourea
DM35NF6	DE	Discovery agent

DM8GDZS	ID	DM8GDZS
DM8GDZS	DN	SRI-63-675
DM8GDZS	HS	Investigative
DM8GDZS	SN	109516-82-7; SDZ-63-675
DM8GDZS	DT	Small molecular drug
DM8GDZS	PC	122013
DM8GDZS	MW	690.9
DM8GDZS	FM	C38H63N2O7P
DM8GDZS	IC	InChI=1S/C38H63N2O7P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21-28-39-36(41)44-32-37(2)26-27-38(3,47-37)33-46-48(42,43)45-31-30-40-29-22-24-34-23-19-20-25-35(34)40/h19-20,22-25,29H,4-18,21,26-28,30-33H2,1-3H3,(H-,39,41,42,43)/t37-,38+/m0/s1
DM8GDZS	CS	CCCCCCCCCCCCCCCCCCNC(=O)OC[C@@]1(CC[C@](O1)(C)COP(=O)([O-])OCC[N+]2=CC=CC3=CC=CC=C32)C
DM8GDZS	IK	JANHWNKOVXOFLY-QPPIDDCLSA-N
DM8GDZS	IU	[(2R,5S)-2,5-dimethyl-5-(octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl 2-quinolin-1-ium-1-ylethyl phosphate
DM8GDZS	CA	CAS 109516-82-7
DM8GDZS	DE	Discovery agent

DM5GILS	ID	DM5GILS
DM5GILS	DN	Sri-9439
DM5GILS	HS	Investigative
DM5GILS	SN	SRI-9439; CHEMBL151958; 6-([5-QUINOLYLAMINO]METHYL)-2,4-DIAMINO-5-METHYLPYRIDO[2,3-D]PYRIMIDINE; 5-methyl-6-[(quinolin-5-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine; AC1L9K2A; BDBM50107995; ZINC12503486; DB03351; 5-methyl-6-[(5-quinolylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine; 5-Methyl-6-(quinolin-5-ylaminomethyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; 2,4-Diamino-5-methylpyrido[2,3-d]pyrimidine, 6-[(5-quinolylamino]methyl)-
DM5GILS	DT	Small molecular drug
DM5GILS	PC	446752
DM5GILS	MW	331.4
DM5GILS	FM	C18H17N7
DM5GILS	IC	InChI=1S/C18H17N7/c1-10-11(9-23-17-15(10)16(19)24-18(20)25-17)8-22-14-6-2-5-13-12(14)4-3-7-21-13/h2-7,9,22H,8H2,1H3,(H4,19,20,23,24,25)
DM5GILS	CS	CC1=C2C(=NC(=NC2=NC=C1CNC3=CC=CC4=C3C=CC=N4)N)N
DM5GILS	IK	KMSATRJZEXNGDP-UHFFFAOYSA-N
DM5GILS	IU	5-methyl-6-[(quinolin-5-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
DM5GILS	DE	Discovery agent

DMYO4A3	ID	DMYO4A3
DMYO4A3	DN	Sri-9662
DMYO4A3	HS	Investigative
DMYO4A3	SN	SRI-9662; 6-[(Z)-2-(2,5-dimethoxyphenyl)ethenyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; (Z)-6-(2-[2,5-DIMETHOXYPHENYL]ETHEN-1-YL)-2,4-DIAMINO-5-METHYLPYRIDO[2,3-D]PYRIMIDINE; 1kmv; AC1L9K2C
DMYO4A3	DT	Small molecular drug
DMYO4A3	PC	446753
DMYO4A3	MW	337.4
DMYO4A3	FM	C18H19N5O2
DMYO4A3	IC	InChI=1S/C18H19N5O2/c1-10-12(9-21-17-15(10)16(19)22-18(20)23-17)5-4-11-8-13(24-2)6-7-14(11)25-3/h4-9H,1-3H3,(H4,19,20,21,22,23)/b5-4-
DMYO4A3	CS	CC1=C2C(=NC(=NC2=NC=C1/C=C\\C3=C(C=CC(=C3)OC)OC)N)N
DMYO4A3	IK	WNDJHUNKXPAREB-PLNGDYQASA-N
DMYO4A3	IU	6-[(Z)-2-(2,5-dimethoxyphenyl)ethenyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
DMYO4A3	DE	Discovery agent

DMDY1M7	ID	DMDY1M7
DMDY1M7	DN	SRIF-14
DMDY1M7	HS	Investigative
DMDY1M7	SN	SST-14; SS14
DMDY1M7	DT	Small molecular drug
DMDY1M7	PC	44386062
DMDY1M7	MW	1389.6
DMDY1M7	FM	C63H88N16O16S2
DMDY1M7	IC	InChI=1S/C63H88N16O16S2/c1-34(66)53(84)69-30-51(83)70-48-32-96-97-33-49(63(94)95)78-60(91)47(31-80)77-62(93)52(35(2)81)79-55(86)42(22-12-14-24-65)71-58(89)45(27-38-29-68-40-20-10-9-19-39(38)40)75-57(88)44(26-37-17-7-4-8-18-37)73-56(87)43(25-36-15-5-3-6-16-36)74-59(90)46(28-50(67)82)76-54(85)41(72-61(48)92)21-11-13-23-64/h3-10,15-20,29,34-35,41-49,52,68,80-81H,11-14,21-28,30-33,64-66H2,1-2H3,(H2,67,82)(H,69,84)(H,70,83)(H,71,89)(H,72,92)(H,73,87)(H,74,90)(H,75,88)(H,76,85)(H,77,93)(H,78,91)(H,79,86)(H,94,95)/t34-,35+,41+,42-,43+,44-,45+,46-,47-,48+,49-,52+/m0/s1
DMDY1M7	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)O)CO)O
DMDY1M7	IK	VVEJUSYNERNRME-XGFVQVCISA-N
DMDY1M7	IU	(4R,7S,10R,13S,16R,19S,22R,25S,28R,31S)-13,28-bis(4-aminobutyl)-25-(2-amino-2-oxoethyl)-31-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-19,22-dibenzyl-10-[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carboxylic acid
DMDY1M7	DE	Discovery agent

DM0OM9L	ID	DM0OM9L
DM0OM9L	DN	SRIF-28
DM0OM9L	HS	Investigative
DM0OM9L	SN	Somatostatin 28; somatostatin 1-28; Somatostatin 28,cyclic; GTPL2020; AKOS024456430
DM0OM9L	DT	Small molecular drug
DM0OM9L	PC	44388117
DM0OM9L	MW	3148.6
DM0OM9L	FM	C137H207N41O39S3
DM0OM9L	IC	InChI=1S/C137H207N41O39S3/c1-69(154-113(194)82(37-19-22-47-138)159-115(196)85(40-25-50-149-136(145)146)160-118(199)87(44-45-106(188)189)163-116(197)86(41-26-51-150-137(147)148)164-130(211)101-43-27-52-177(101)133(214)72(4)156-114(195)88(46-54-218-7)158-110(191)71(3)155-129(210)100-42-28-53-178(100)134(215)95(61-104(144)186)171-126(207)96(65-180)172-124(205)93(59-102(142)184)165-111(192)70(2)153-112(193)80(141)64-179)109(190)152-63-105(187)157-98-67-219-220-68-99(135(216)217)174-127(208)97(66-181)173-132(213)108(74(6)183)176-125(206)91(57-77-33-15-10-16-34-77)170-131(212)107(73(5)182)175-119(200)84(39-21-24-49-140)161-122(203)92(58-78-62-151-81-36-18-17-35-79(78)81)168-121(202)90(56-76-31-13-9-14-32-76)166-120(201)89(55-75-29-11-8-12-30-75)167-123(204)94(60-103(143)185)169-117(198)83(162-128(98)209)38-20-23-48-139/h8-18,29-36,62,69-74,80,82-101,107-108,151,179-183H,19-28,37-61,63-68,138-141H2,1-7H3,(H2,142,184)(H2,143,185)(H2,144,186)(H,152,190)(H,153,193)(H,154,194)(H,155,210)(H,156,195)(H,157,187)(H,158,191)(H,159,196)(H,160,199)(H,161,203)(H,162,209)(H,163,197)(H,164,211)(H,165,192)(H,166,201)(H,167,204)(H,168,202)(H,169,198)(H,170,212)(H,171,207)(H,172,205)(H,173,213)(H,174,208)(H,175,200)(H,176,206)(H,188,189)(H,216,217)(H4,145,146,149)(H4,147,148,150)/t69-,70-,71-,72-,73+,74+,80-,82-,83+,84-,85-,86-,87-,88-,89+,90-,91-,92+,93-,94-,95-,96-,97-,98+,99-,100-,101-,107+,108+/m0/s1
DM0OM9L	CS	C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)N)C(=O)O)CO)[C@@H](C)O)CC8=CC=CC=C8)O
DM0OM9L	IK	GGYTXJNZMFRSLX-OKOIUDDXSA-N
DM0OM9L	IU	(4R,7S,10R,13S,16R,19S,22R,25S,28R,31S,34R,37S)-37-[[2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-carboxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DM0OM9L	DE	Discovery agent

DMUKVHQ	ID	DMUKVHQ
DMUKVHQ	DN	SRT1720
DMUKVHQ	HS	Investigative
DMUKVHQ	SN	925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; SRT1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N
DMUKVHQ	DT	Small molecular drug
DMUKVHQ	PC	25232708
DMUKVHQ	MW	506
DMUKVHQ	FM	C25H24ClN7OS
DMUKVHQ	IC	InChI=1S/C25H23N7OS.ClH/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31;/h1-8,13,15-16,26H,9-12,14H2,(H,29,33);1H
DMUKVHQ	CS	C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl
DMUKVHQ	IK	DTGRRMPPXCRRIM-UHFFFAOYSA-N
DMUKVHQ	IU	N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide;hydrochloride
DMUKVHQ	CA	CAS 1001645-58-4
DMUKVHQ	DE	Discovery agent

DMF0X2S	ID	DMF0X2S
DMF0X2S	DN	SSR126768A
DMF0X2S	HS	Investigative
DMF0X2S	SN	SSR-126768A
DMF0X2S	DT	Small molecular drug
DMF0X2S	PC	10461270
DMF0X2S	MW	604.5
DMF0X2S	FM	C33H31Cl2N3O4
DMF0X2S	IC	InChI=1S/C33H31Cl2N3O4/c1-5-37(19-21-7-6-14-36-18-21)31(39)22-9-12-28(35)26(15-22)33(2)27-16-24(34)10-13-29(27)38(32(33)40)20-23-8-11-25(41-3)17-30(23)42-4/h6-18H,5,19-20H2,1-4H3/t33-/m0/s1
DMF0X2S	CS	CCN(CC1=CN=CC=C1)C(=O)C2=CC(=C(C=C2)Cl)[C@]3(C4=C(C=CC(=C4)Cl)N(C3=O)CC5=C(C=C(C=C5)OC)OC)C
DMF0X2S	IK	UENRBNCNIZQNTR-XIFFEERXSA-N
DMF0X2S	IU	4-chloro-3-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)methyl]-3-methyl-2-oxoindol-3-yl]-N-ethyl-N-(pyridin-3-ylmethyl)benzamide
DMF0X2S	DE	Discovery agent

DMDIYWV	ID	DMDIYWV
DMDIYWV	DN	S-sulpho-L-cysteine
DMDIYWV	HS	Investigative
DMDIYWV	SN	S-Sulfocysteine; S-Sulphocysteine; L-Cysteine S-sulfate; Cysteine-S-sulfate; S-Sulfo-L-cysteine; Cysteine-S-sulfonate; Cysteinyl-S-sulfonate; 1637-71-4; Cysteinyl-S-sulfonic acid; S-sulpho-L-cysteine; 3-(sulfosulfanyl)-l-alanine; Cysteine-S-Sulfonic Acid; UNII-885F2S42LL; L-Cysteine, S-sulfo-; CHEMBL457665; CHEBI:27891; 885F2S42LL; cysteine s-sulfate; Cysteine-S-sulphate; L-Cysteine, hydrogen sulfate (ester); L-Cysteine S-sulphate; S-Cysteinesulfonic acid; L-Cysteinesulfonic acid; L-Cysteine-S-sulfonate; Alaninethiosulfuric acid
DMDIYWV	DT	Small molecular drug
DMDIYWV	PC	115015
DMDIYWV	MW	201.2
DMDIYWV	FM	C3H7NO5S2
DMDIYWV	IC	InChI=1S/C3H7NO5S2/c4-2(3(5)6)1-10-11(7,8)9/h2H,1,4H2,(H,5,6)(H,7,8,9)/t2-/m0/s1
DMDIYWV	CS	C([C@@H](C(=O)O)N)SS(=O)(=O)O
DMDIYWV	IK	NOKPBJYHPHHWAN-REOHCLBHSA-N
DMDIYWV	IU	(2R)-2-amino-3-sulfosulfanylpropanoic acid
DMDIYWV	CA	CAS 1637-71-4
DMDIYWV	CB	CHEBI:27891
DMDIYWV	DE	Discovery agent

DMO7WRU	ID	DMO7WRU
DMO7WRU	DN	ST074946
DMO7WRU	HS	Investigative
DMO7WRU	SN	ST074946; 3-Amino-6,6-dimethyl-2-phenyl-2,8-dihydro-6H-pyrano[3,4-c]pyridazine-4-carbonitrile; AC1LENQ2; CHEMBL171632; GTPL6539; ZINC173901; HMS1685F16; AKOS000506326; MCULE-9779696514; BAS 00288764; SR-01000803010; SR-01000803010-2; 3-amino-6,6-dimethyl-2-phenyl-8H-pyrano[4,5-e]pyridazine-4-carbonitrile; 3-amino-6,6-dimethyl-2-phenyl-2,6-dihydro-8H-pyrano[3,4-c]pyridazine-4-carboni trile
DMO7WRU	DT	Small molecular drug
DMO7WRU	PC	738951
DMO7WRU	MW	280.32
DMO7WRU	FM	C16H16N4O
DMO7WRU	IC	InChI=1S/C16H16N4O/c1-16(2)8-12-13(9-17)15(18)20(19-14(12)10-21-16)11-6-4-3-5-7-11/h3-8H,10,18H2,1-2H3
DMO7WRU	CS	CC1(C=C2C(=NN(C(=C2C#N)N)C3=CC=CC=C3)CO1)C
DMO7WRU	IK	XQJQZTOXHGIQCA-UHFFFAOYSA-N
DMO7WRU	IU	3-amino-6,6-dimethyl-2-phenyl-8H-pyrano[3,4-c]pyridazine-4-carbonitrile
DMO7WRU	DE	Discovery agent

DM14PLC	ID	DM14PLC
DM14PLC	DN	ST-1025
DM14PLC	HS	Investigative
DM14PLC	SN	ST-1025; CHEMBL1257584; BDBM50327232
DM14PLC	DT	Small molecular drug
DM14PLC	PC	46898078
DM14PLC	MW	378.5
DM14PLC	FM	C23H26N2OS
DM14PLC	IC	InChI=1S/C23H26N2OS/c1-4-11-19(12-5-1)21-22(20-13-6-2-7-14-20)27-23(24-21)26-18-10-17-25-15-8-3-9-16-25/h1-2,4-7,11-14H,3,8-10,15-18H2
DM14PLC	CS	C1CCN(CC1)CCCOC2=NC(=C(S2)C3=CC=CC=C3)C4=CC=CC=C4
DM14PLC	IK	QRGQBMVHLMCOKC-UHFFFAOYSA-N
DM14PLC	IU	4,5-diphenyl-2-(3-piperidin-1-ylpropoxy)-1,3-thiazole
DM14PLC	DE	Discovery agent

DMKZJWV	ID	DMKZJWV
DMKZJWV	DN	ST-1093
DMKZJWV	HS	Investigative
DMKZJWV	SN	ST-1093; CHEMBL1257934; BDBM50327233
DMKZJWV	DT	Small molecular drug
DMKZJWV	PC	52940790
DMKZJWV	MW	406.6
DMKZJWV	FM	C22H38N4OS
DMKZJWV	IC	InChI=1S/C22H38N4OS/c1-3-10-24(11-4-1)14-7-15-26-17-9-20-21(19-26)28-22(23-20)27-18-8-16-25-12-5-2-6-13-25/h1-19H2
DMKZJWV	CS	C1CCN(CC1)CCCN2CCC3=C(C2)SC(=N3)OCCCN4CCCCC4
DMKZJWV	IK	SYMZYURRALQTPH-UHFFFAOYSA-N
DMKZJWV	IU	2-(3-piperidin-1-ylpropoxy)-5-(3-piperidin-1-ylpropyl)-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine
DMKZJWV	DE	Discovery agent

DMUTC9Z	ID	DMUTC9Z
DMUTC9Z	DN	ST-1535
DMUTC9Z	HS	Investigative
DMUTC9Z	SN	ST-1535; 496955-42-1; CHEMBL197669; 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine; 9H-Purin-6-amine, 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-; 2-butyl-9-methyl-8-(triazol-2-yl)purin-6-amine; ST1535; ST 1535; GTPL5613; SCHEMBL5362208; CTK1D0597; DTXSID60432000; ZINC1554291; BDBM50176058; AKOS030562134; SB16783; AS-35290; L001675; 2-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine
DMUTC9Z	DT	Small molecular drug
DMUTC9Z	PC	9860294
DMUTC9Z	MW	272.31
DMUTC9Z	FM	C12H16N8
DMUTC9Z	IC	InChI=1S/C12H16N8/c1-3-4-5-8-16-10(13)9-11(17-8)19(2)12(18-9)20-14-6-7-15-20/h6-7H,3-5H2,1-2H3,(H2,13,16,17)
DMUTC9Z	CS	CCCCC1=NC(=C2C(=N1)N(C(=N2)N3N=CC=N3)C)N
DMUTC9Z	IK	CYYQMAWUIRPCNW-UHFFFAOYSA-N
DMUTC9Z	IU	2-butyl-9-methyl-8-(triazol-2-yl)purin-6-amine
DMUTC9Z	CA	CAS 496955-42-1
DMUTC9Z	DE	Discovery agent

DMR1G40	ID	DMR1G40
DMR1G40	DN	ST-1646
DMR1G40	HS	Investigative
DMR1G40	SN	CHEMBL392303
DMR1G40	DT	Small molecular drug
DMR1G40	PC	44439175
DMR1G40	MW	479.5
DMR1G40	FM	C21H33N7O6
DMR1G40	IC	InChI=1S/C21H33N7O6/c22-21(23)24-8-2-5-12-18(32)15-7-6-11-3-1-4-13(20(34)28(11)15)26-14(9-17(30)31)19(33)25-10-16(29)27-12/h11-15,26H,1-10H2,(H,25,33)(H,27,29)(H,30,31)(H4,22,23,24)/t11-,12-,13-,14+,15+/m0/s1
DMR1G40	CS	C1C[C@H]2CC[C@H]3N2C(=O)[C@H](C1)N[C@@H](C(=O)NCC(=O)N[C@H](C3=O)CCCN=C(N)N)CC(=O)O
DMR1G40	IK	MYSBVCKSODARFZ-BTFPBAQTSA-N
DMR1G40	IU	2-[(1S,3R,9S,11R,14S)-9-[3-(diaminomethylideneamino)propyl]-4,7,10,18-tetraoxo-2,5,8,19-tetrazatricyclo[9.6.2.014,19]nonadecan-3-yl]acetic acid
DMR1G40	DE	Discovery agent

DM73E0G	ID	DM73E0G
DM73E0G	DN	ST-2741
DM73E0G	HS	Investigative
DM73E0G	SN	ST-2741; CHEMBL564876; SCHEMBL1306499; BDBM50297444
DM73E0G	DT	Small molecular drug
DM73E0G	PC	11993691
DM73E0G	MW	375.5
DM73E0G	FM	C23H25N3O2
DM73E0G	IC	InChI=1S/C23H25N3O2/c27-23(26-28)13-3-1-2-8-16(19-14-24-21-11-6-4-9-17(19)21)20-15-25-22-12-7-5-10-18(20)22/h4-7,9-12,14-16,24-25,28H,1-3,8,13H2,(H,26,27)
DM73E0G	CS	C1=CC=C2C(=C1)C(=CN2)C(CCCCCC(=O)NO)C3=CNC4=CC=CC=C43
DM73E0G	IK	ZWBFOQJCRGCPED-UHFFFAOYSA-N
DM73E0G	IU	N-hydroxy-7,7-bis(1H-indol-3-yl)heptanamide
DM73E0G	DE	Discovery agent

DMNERM6	ID	DMNERM6
DMNERM6	DN	ST-2986
DMNERM6	HS	Investigative
DMNERM6	SN	ST-2986; CHEMBL471041; SCHEMBL3444455; BDBM50278219
DMNERM6	DT	Small molecular drug
DMNERM6	PC	44138031
DMNERM6	MW	386.27
DMNERM6	FM	C17H11F5N2O3
DMNERM6	IC	InChI=1S/C17H11F5N2O3/c18-13-11(14(19)16(21)17(22)15(13)20)8-27-23-7-10-3-1-9(2-4-10)5-6-12(25)24-26/h1-7,26H,8H2,(H,24,25)/b6-5+,23-7+
DMNERM6	CS	C1=CC(=CC=C1/C=C/C(=O)NO)/C=N/OCC2=C(C(=C(C(=C2F)F)F)F)F
DMNERM6	IK	ATRIOAVZXXVRHX-UDVGQSQZSA-N
DMNERM6	IU	(E)-N-hydroxy-3-[4-[(E)-(2,3,4,5,6-pentafluorophenyl)methoxyiminomethyl]phenyl]prop-2-enamide
DMNERM6	DE	Discovery agent

DMWXTM8	ID	DMWXTM8
DMWXTM8	DN	ST-2987
DMWXTM8	HS	Investigative
DMWXTM8	SN	ST-2987; CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220
DMWXTM8	DT	Small molecular drug
DMWXTM8	PC	44138032
DMWXTM8	MW	341.32
DMWXTM8	FM	C17H15N3O5
DMWXTM8	IC	InChI=1S/C17H15N3O5/c21-17(19-22)10-7-13-1-3-14(4-2-13)11-18-25-12-15-5-8-16(9-6-15)20(23)24/h1-11,22H,12H2,(H,19,21)/b10-7+,18-11+
DMWXTM8	CS	C1=CC(=CC=C1CO/N=C/C2=CC=C(C=C2)/C=C/C(=O)NO)[N+](=O)[O-]
DMWXTM8	IK	IWWFFHDXUHSRDM-PFMZDYLOSA-N
DMWXTM8	IU	(E)-N-hydroxy-3-[4-[(E)-(4-nitrophenyl)methoxyiminomethyl]phenyl]prop-2-enamide
DMWXTM8	DE	Solid tumour/cancer

DM19K2D	ID	DM19K2D
DM19K2D	DN	ST-3050
DM19K2D	HS	Investigative
DM19K2D	SN	ST-3050; CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222
DM19K2D	DT	Small molecular drug
DM19K2D	PC	44591988
DM19K2D	MW	319.36
DM19K2D	FM	C16H21N3O4
DM19K2D	IC	InChI=1S/C16H21N3O4/c20-16(18-21)6-5-14-1-3-15(4-2-14)13-17-23-12-9-19-7-10-22-11-8-19/h1-6,13,21H,7-12H2,(H,18,20)/b6-5+,17-13+
DM19K2D	CS	C1COCCN1CCO/N=C/C2=CC=C(C=C2)/C=C/C(=O)NO
DM19K2D	IK	KKMCPDKFGBXVNL-WDGODYKHSA-N
DM19K2D	IU	(E)-N-hydroxy-3-[4-[(E)-2-morpholin-4-ylethoxyiminomethyl]phenyl]prop-2-enamide
DM19K2D	DE	Discovery agent

DM9FYPM	ID	DM9FYPM
DM9FYPM	DN	ST-5732
DM9FYPM	HS	Investigative
DM9FYPM	SN	ST-5732; CHEMBL561604; BDBM50297446
DM9FYPM	DT	Small molecular drug
DM9FYPM	PC	45269423
DM9FYPM	MW	465.5
DM9FYPM	FM	C23H23N5O6
DM9FYPM	IC	InChI=1S/C23H23N5O6/c29-23(26-30)5-3-1-2-4-16(19-12-24-21-8-6-14(27(31)32)10-17(19)21)20-13-25-22-9-7-15(28(33)34)11-18(20)22/h6-13,16,24-25,30H,1-5H2,(H,26,29)
DM9FYPM	CS	C1=CC2=C(C=C1[N+](=O)[O-])C(=CN2)C(CCCCCC(=O)NO)C3=CNC4=C3C=C(C=C4)[N+](=O)[O-]
DM9FYPM	IK	VSVDNXSUROYWOP-UHFFFAOYSA-N
DM9FYPM	IU	N-hydroxy-7,7-bis(5-nitro-1H-indol-3-yl)heptanamide
DM9FYPM	DE	Discovery agent

DMIYJ2M	ID	DMIYJ2M
DMIYJ2M	DN	STA2
DMIYJ2M	HS	Investigative
DMIYJ2M	SN	11alpha-carba-9alpha,11beta-thia-Txa2
DMIYJ2M	DT	Small molecular drug
DMIYJ2M	PC	5311453
DMIYJ2M	MW	366.6
DMIYJ2M	FM	C21H34O3S
DMIYJ2M	IC	InChI=1S/C21H34O3S/c1-2-3-6-9-17(22)13-12-16-14-18-15-20(25-18)19(16)10-7-4-5-8-11-21(23)24/h4,7,12-13,16-20,22H,2-3,5-6,8-11,14-15H2,1H3,(H,23,24)/b7-4-,13-12+/t16-,17+,18-,19+,20-/m0/s1
DMIYJ2M	CS	CCCCC[C@H](/C=C/[C@H]1C[C@H]2C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)S2)O
DMIYJ2M	IK	OVGWMUWIRHGGJP-WVDJAODQSA-N
DMIYJ2M	IU	(Z)-7-[(1S,2R,3R,5S)-3-[(E,3R)-3-hydroxyoct-1-enyl]-6-thiabicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid
DMIYJ2M	DE	Discovery agent

DMIZESL	ID	DMIZESL
DMIZESL	DN	Stachyflin
DMIZESL	HS	Investigative
DMIZESL	SN	Stachyflin; dihydroxy(tetramethyl)[ ]one; (+)-Stachyflin; AC1LAQMJ; 3H-Naphtho[1',8a':5,6]pyrano[2,3-e]isoindol-3-one, 1,2,6,6a,7,8,9,9a,10,11,12,13-dodecahydro-5,11-dihydroxy-6a,7,10,10-tetramethyl-, (6aR,7S,9aS,11S,13aS)-
DMIZESL	DT	Small molecular drug
DMIZESL	PC	493326
DMIZESL	MW	385.5
DMIZESL	FM	C23H31NO4
DMIZESL	IC	InChI=1S/C23H31NO4/c1-12-5-6-17-21(2,3)18(26)7-8-23(17)22(12,4)10-14-16(25)9-13-15(19(14)28-23)11-24-20(13)27/h9,12,17-18,25-26H,5-8,10-11H2,1-4H3,(H,24,27)/t12-,17-,18-,22+,23-/m0/s1
DMIZESL	CS	C[C@H]1CC[C@@H]2[C@]3([C@@]1(CC4=C(C=C5C(=C4O3)CNC5=O)O)C)CC[C@@H](C2(C)C)O
DMIZESL	IK	KUWCILGWLAWLGB-SFJHCMNLSA-N
DMIZESL	IU	(1S,13R,14S,17S,19S)-10,19-dihydroxy-13,14,18,18-tetramethyl-2-oxa-6-azapentacyclo[11.8.0.01,17.03,11.04,8]henicosa-3,8,10-trien-7-one
DMIZESL	DE	Discovery agent

DM1R9GV	ID	DM1R9GV
DM1R9GV	DN	Stachyose
DM1R9GV	HS	Investigative
DM1R9GV	SN	D-Stachyose; Lupeose; Manneotetrose; Stachyose; Stachyose n-Hydrate; UQZIYBXSHAGNOE-XNSRJBNMSA-N; ZINC85544384; 470-55-3; 54261-98-2; AK111270; AKOS016009597; C01613; CC-34534; CHEBI:17164; CHEMBL1625803; Epitope ID:150068; MFCD00149457; NCGC00246978-01; O-alpha-D-galactopyranosyl-(1-&gt;6)o-alpha-D-galactopyranosyl-(1-&gt;6)O-alpha-D-galactopyranosyl-beta-D-fructofuranoside; SCHEMBL32922; Stachyose hydrate from Stachys tuberifera; alpha-D-Galp-(1-&gt;6)-alpha-D-Galp-(1-&gt;6)-alpha-D-Glcp-(1&lt;-&gt;2)-beta-D-Fruf; bmse000240
DM1R9GV	PC	439531
DM1R9GV	MW	666.6
DM1R9GV	FM	C24H42O21
DM1R9GV	IC	UQZIYBXSHAGNOE-XNSRJBNMSA-N
DM1R9GV	CS	C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC3C(C(C(C(O3)OC4(C(C(C(O4)CO)O)O)CO)O)O)O)O)O)O)O)O)O)O
DM1R9GV	IK	1S/C24H42O21/c25-1-6-10(28)14(32)17(35)21(41-6)39-3-8-11(29)15(33)18(36)22(42-8)40-4-9-12(30)16(34)19(37)23(43-9)45-24(5-27)20(38)13(31)7(2-26)44-24/h6-23,25-38H,1-5H2/t6-,7-,8-,9-,10+,11+,12-,13-,14+,15+,16+,17-,18-,19-,20+,21+,22+,23-,24+/m1/s1
DM1R9GV	IU	(2S,3R,4S,5R,6R)-2-[[(2R,3R,4S,5R,6S)-6-[[(2R,3S,4S,5R,6R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
DM1R9GV	CA	CAS 470-55-3
DM1R9GV	CB	CHEBI:17164
DM1R9GV	DE	Discovery agent

DM4WQHU	ID	DM4WQHU
DM4WQHU	DN	Statin
DM4WQHU	HS	Investigative
DM4WQHU	SN	Statin (MedinGel, hypercholesterolemia)
DM4WQHU	CP	MedinCell SA
DM4WQHU	DT	Small molecular drug
DM4WQHU	PC	4677798
DM4WQHU	MW	418.6
DM4WQHU	FM	C25H38O5
DM4WQHU	IC	InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3
DM4WQHU	CS	CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
DM4WQHU	IK	RYMZZMVNJRMUDD-UHFFFAOYSA-N
DM4WQHU	IU	[8-[2-(4-hydroxy-6-oxooxan-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
DM4WQHU	CB	CHEBI:91894
DM4WQHU	DE	Hypercholesterolaemia

DM0E9BR	ID	DM0E9BR
DM0E9BR	DN	Staurosporine
DM0E9BR	HS	Investigative
DM0E9BR	SN	staurosporine; Staurosporin; (+)-Staurosporine; Antibiotic 230; 62996-74-1; Antibiotic AM 2282; CCRIS 3272; AM-2282; UNII-H88EPA0A3N; Alkaloid AM-2282 from Streptomyces; H88EPA0A3N; CHEMBL388978; CHEBI:15738; CGP 39360; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-
DM0E9BR	DT	Small molecular drug
DM0E9BR	PC	44259
DM0E9BR	MW	466.5
DM0E9BR	FM	C28H26N4O3
DM0E9BR	IC	InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1
DM0E9BR	CS	C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC
DM0E9BR	IK	HKSZLNNOFSGOKW-FYTWVXJKSA-N
DM0E9BR	IU	(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one
DM0E9BR	CA	CAS 62996-74-1
DM0E9BR	CB	CHEBI:15738
DM0E9BR	DE	Discovery agent

DMU2H4K	ID	DMU2H4K
DMU2H4K	DN	STAUROSPORINONE
DMU2H4K	HS	Investigative
DMU2H4K	DE	Discovery agent

DMGMXQC	ID	DMGMXQC
DMGMXQC	DN	STEPHOLIDINE
DMGMXQC	HS	Investigative
DMGMXQC	SN	l-Stepholidine; 16562-13-3; (-)-Stepholidine; stepholidine; (S)-3,9-Dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline-2,10-diol; S-Stepholidine; UNII-0UPX3E69W8; 0UPX3E69W8; Q-100198; (13aS)-3,9-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,10-diol; 3,9-Dimethoxy-13a-alpha-berbine-2,10-diol; l-2,10-Dihydroxy-3,9-dimethyloxytetrahydropseudoberberine; L-(S)-Stepholidine; l-SPD; AC1OCEV4; 13a-alpha-BERBINE-2,10-DIOL, 3,9-DIMETHOXY-; GTPL8370; DIB014; CHEMBL487387; SCHEMBL10001966
DMGMXQC	DT	Small molecular drug
DMGMXQC	PC	6917970
DMGMXQC	MW	327.4
DMGMXQC	FM	C19H21NO4
DMGMXQC	IC	InChI=1S/C19H21NO4/c1-23-18-8-12-5-6-20-10-14-11(3-4-16(21)19(14)24-2)7-15(20)13(12)9-17(18)22/h3-4,8-9,15,21-22H,5-7,10H2,1-2H3/t15-/m0/s1
DMGMXQC	CS	COC1=C(C=C2[C@@H]3CC4=C(CN3CCC2=C1)C(=C(C=C4)O)OC)O
DMGMXQC	IK	JKPISQIIWUONPB-HNNXBMFYSA-N
DMGMXQC	IU	(13aS)-3,9-dimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline-2,10-diol
DMGMXQC	CA	CAS 16562-13-3
DMGMXQC	DE	Discovery agent

DM1PMR3	ID	DM1PMR3
DM1PMR3	DN	Sterculic acid
DM1PMR3	HS	Investigative
DM1PMR3	SN	STERCULIC ACID; 738-87-4; Sterculinic acid; UNII-MXV06G5ROK; 9,10-methylene-9-octadecenoic acid; MXV06G5ROK; 2-octyl-1-cyclopropene-1-octanoic acid; 8-(2-octylcyclopropen-1-yl)octanoic acid; omega-(2-n-octylcycloprop-1-enyl)octanoic acid; Sterculinsaeure; ster-culic acid; Sterculia-Saeure; HSDB 3904; PubChem20404; 1-Cyclopropene-1-octanoic acid, 2-octyl-; FA(19:1)(cyclo); AC1L20NB; SCHEMBL31295; 55088-60-3; 2-Octyl-1-cyclopropene-1-octanoic acid homopolymer; CHEBI:9261; US8962837, Sterculic acid; CHEMBL3677268
DM1PMR3	DT	Small molecular drug
DM1PMR3	PC	12921
DM1PMR3	MW	294.5
DM1PMR3	FM	C19H34O2
DM1PMR3	IC	InChI=1S/C19H34O2/c1-2-3-4-5-7-10-13-17-16-18(17)14-11-8-6-9-12-15-19(20)21/h2-16H2,1H3,(H,20,21)
DM1PMR3	CS	CCCCCCCCC1=C(C1)CCCCCCCC(=O)O
DM1PMR3	IK	PQRKPYLNZGDCFH-UHFFFAOYSA-N
DM1PMR3	IU	8-(2-octylcyclopropen-1-yl)octanoic acid
DM1PMR3	CA	CAS 738-87-4
DM1PMR3	CB	CHEBI:9261
DM1PMR3	DE	Discovery agent

DMZSOG2	ID	DMZSOG2
DMZSOG2	DN	STO609
DMZSOG2	HS	Investigative
DMZSOG2	SN	STO-609; STO 609
DMZSOG2	DT	Small molecular drug
DMZSOG2	PC	3467590
DMZSOG2	MW	314.3
DMZSOG2	FM	C19H10N2O3
DMZSOG2	IC	InChI=1S/C19H10N2O3/c22-18-13-5-3-4-10-11(19(23)24)8-9-12(16(10)13)17-20-14-6-1-2-7-15(14)21(17)18/h1-9H,(H,23,24)
DMZSOG2	CS	C1=CC=C2C(=C1)N=C3N2C(=O)C4=CC=CC5=C(C=CC3=C54)C(=O)O
DMZSOG2	IK	MYKOWOGZBMOVBJ-UHFFFAOYSA-N
DMZSOG2	IU	11-oxo-3,10-diazapentacyclo[10.7.1.02,10.04,9.016,20]icosa-1(20),2,4,6,8,12,14,16,18-nonaene-17-carboxylic acid
DMZSOG2	CB	CHEBI:92918
DMZSOG2	DE	Discovery agent

DM0HOEA	ID	DM0HOEA
DM0HOEA	DN	streptonigrin
DM0HOEA	HS	Investigative
DM0HOEA	SN	rufocromomycin; bruneomycin; nigrin; valacidin; NSC-45383
DM0HOEA	DT	Small molecular drug
DM0HOEA	PC	5298
DM0HOEA	MW	506.5
DM0HOEA	FM	C25H22N4O8
DM0HOEA	IC	InChI=1S/C25H22N4O8/c1-9-14(10-6-8-13(35-2)23(36-3)20(10)30)15(26)19(29-17(9)25(33)34)12-7-5-11-18(28-12)22(32)16(27)24(37-4)21(11)31/h5-8,30H,26-27H2,1-4H3,(H,33,34)
DM0HOEA	CS	CC1=C(C(=C(N=C1C(=O)O)C2=NC3=C(C=C2)C(=O)C(=C(C3=O)N)OC)N)C4=C(C(=C(C=C4)OC)OC)O
DM0HOEA	IK	PVYJZLYGTZKPJE-UHFFFAOYSA-N
DM0HOEA	IU	5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpyridine-2-carboxylic acid
DM0HOEA	CA	CAS 3930-19-6
DM0HOEA	CB	CHEBI:9287
DM0HOEA	DE	Discovery agent

DM5BATX	ID	DM5BATX
DM5BATX	DN	STS-T4
DM5BATX	HS	Investigative
DM5BATX	SN	TPO mimetic (oral, thrombocytopenia), STATegics
DM5BATX	CP	STATegics Inc
DM5BATX	DE	Thrombocytopenia

DM9UHCY	ID	DM9UHCY
DM9UHCY	DN	S-tubercidinylhomocysteine
DM9UHCY	HS	Investigative
DM9UHCY	SN	S-tubercidinylhomocysteine; CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid
DM9UHCY	DT	Small molecular drug
DM9UHCY	PC	124349
DM9UHCY	MW	383.4
DM9UHCY	FM	C15H21N5O5S
DM9UHCY	IC	InChI=1S/C15H21N5O5S/c16-8(15(23)24)2-4-26-5-9-10(21)11(22)14(25-9)20-3-1-7-12(17)18-6-19-13(7)20/h1,3,6,8-11,14,21-22H,2,4-5,16H2,(H,23,24)(H2,17,18,19)/t8-,9+,10+,11+,14+/m0/s1
DM9UHCY	CS	C1=CN(C2=NC=NC(=C21)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CSCC[C@@H](C(=O)O)N)O)O
DM9UHCY	IK	VIRPSVXGKGPXDV-NDXSAKOMSA-N
DM9UHCY	IU	(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid
DM9UHCY	CA	CAS 57344-98-6
DM9UHCY	DE	Discovery agent

DM7LZJ3	ID	DM7LZJ3
DM7LZJ3	DN	STX
DM7LZJ3	HS	Investigative
DM7LZJ3	SN	Selective estrogen receptor modulator (menopause-associated symptoms), Oregon Health & Science University
DM7LZJ3	CP	Oregon Health Sciences University
DM7LZJ3	DT	Small molecular drug
DM7LZJ3	PC	6852124
DM7LZJ3	MW	197.23
DM7LZJ3	FM	C9H15N3O2
DM7LZJ3	IC	InChI=1S/C9H15N3O2/c1-9(2,3)8-12-11-7(14-8)6(13)5-10-4/h10H,5H2,1-4H3
DM7LZJ3	CS	CC(C)(C)C1=NN=C(O1)C(=O)CNC
DM7LZJ3	IK	CLBJJWUUSJAAPJ-UHFFFAOYSA-N
DM7LZJ3	IU	1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2-(methylamino)ethanone
DM7LZJ3	DE	Estrogen deficiency

DMO9VWJ	ID	DMO9VWJ
DMO9VWJ	DN	STYLISSADINE A
DMO9VWJ	HS	Investigative
DMO9VWJ	SN	Stylissadine A
DMO9VWJ	PC	16121949
DMO9VWJ	MW	2094.3
DMO9VWJ	FM	C52H50Br8F12N20O17
DMO9VWJ	IC	InChI=1S/C44H46Br8N20O9.4C2HF3O2/c45-13-1-17(61-25(13)49)29(73)57-5-9-11(7-59-31(75)19-3-15(47)27(51)63-19)23(41-21(9)43(77)35(67-39(55)71-43)80-33(41)65-37(53)69-41)79-24-12(8-60-32(76)20-4-16(48)28(52)64-20)10(6-58-30(74)18-2-14(46)26(50)62-18)22-42(24)34(66-38(54)70-42)81-36-44(22,78)72-40(56)68-36;4*3-2(4,5)1(6)7/h1-4,9-12,21-24,33-36,61-64,77-78H,5-8H2,(H,57,73)(H,58,74)(H,59,75)(H,60,76)(H3,53,65,69)(H3,54,66,70)(H3,55,67,71)(H3,56,68,72);4*(H,6,7)/t9-,10-,11-,12-,21+,22+,23+,24+,33+,34+,35-,36-,41+,42+,43-,44-;;;;/m1..../s1
DMO9VWJ	CS	C1=C(NC(=C1Br)Br)C(=O)NC[C@@H]2[C@H]([C@@H]([C@@]34[C@H]2[C@]5([C@H](N=C(N5)N)O[C@@H]3N=C(N4)N)O)O[C@H]6[C@@H]([C@H]([C@H]7[C@@]68[C@@H](N=C(N8)N)O[C@@H]9[C@]7(NC(=N9)N)O)CNC(=O)C1=CC(=C(N1)Br)Br)CNC(=O)C1=CC(=C(N1)Br)Br)CNC(=O)C1=CC(=C(N1)Br)Br.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O
DMO9VWJ	IK	PWAQCZXQKIUIBJ-AACIOKPJSA-N
DMO9VWJ	IU	4,5-dibromo-N-[[(1S,2S,3S,4R,5S,6R,10R,12S)-8,14-diamino-2-[[(1S,2S,3S,4R,5S,6R,10R,12S)-8,14-diamino-3,4-bis[[(4,5-dibromo-1H-pyrrole-2-carbonyl)amino]methyl]-6-hydroxy-11-oxa-7,9,13,15-tetrazatetracyclo[10.3.0.01,5.06,10]pentadeca-8,13-dien-2-yl]oxy]-3-[[(4,5-dibromo-1H-pyrrole-2-carbonyl)amino]methyl]-6-hydroxy-11-oxa-7,9,13,15-tetrazatetracyclo[10.3.0.01,5.06,10]pentadeca-8,13-dien-4-yl]methyl]-1H-pyrrole-2-carboxamide;2,2,2-trifluoroacetic acid
DMO9VWJ	DE	Discovery agent

DMNAYEP	ID	DMNAYEP
DMNAYEP	DN	STYLISSADINE B
DMNAYEP	HS	Investigative
DMNAYEP	SN	Stylissadine B
DMNAYEP	PC	16121950
DMNAYEP	MW	2094.3
DMNAYEP	FM	C52H50Br8F12N20O17
DMNAYEP	IC	InChI=1S/C44H46Br8N20O9.4C2HF3O2/c45-13-1-17(61-25(13)49)29(73)57-5-9-11(7-59-31(75)19-3-15(47)27(51)63-19)23(41-21(9)43(77)35(67-39(55)71-43)80-33(41)65-37(53)69-41)79-24-12(8-60-32(76)20-4-16(48)28(52)64-20)10(6-58-30(74)18-2-14(46)26(50)62-18)22-42(24)34(66-38(54)70-42)81-36-44(22,78)72-40(56)68-36;4*3-2(4,5)1(6)7/h1-4,9-12,21-24,33-36,61-64,77-78H,5-8H2,(H,57,73)(H,58,74)(H,59,75)(H,60,76)(H3,53,65,69)(H3,54,66,70)(H3,55,67,71)(H3,56,68,72);4*(H,6,7)/t9-,10-,11-,12-,21-,22+,23+,24+,33+,34+,35-,36-,41+,42+,43-,44-;;;;/m1..../s1
DMNAYEP	CS	C1=C(NC(=C1Br)Br)C(=O)NC[C@@H]2[C@H]([C@@H]([C@@]34[C@@H]2[C@]5([C@H](N=C(N5)N)O[C@@H]3N=C(N4)N)O)O[C@H]6[C@@H]([C@H]([C@H]7[C@@]68[C@@H](N=C(N8)N)O[C@@H]9[C@]7(NC(=N9)N)O)CNC(=O)C1=CC(=C(N1)Br)Br)CNC(=O)C1=CC(=C(N1)Br)Br)CNC(=O)C1=CC(=C(N1)Br)Br.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O
DMNAYEP	IK	PWAQCZXQKIUIBJ-JGPXLICKSA-N
DMNAYEP	IU	4,5-dibromo-N-[[(1S,2S,3S,4R,5S,6R,10R,12S)-8,14-diamino-2-[[(1S,2S,3S,4R,5R,6R,10R,12S)-8,14-diamino-3,4-bis[[(4,5-dibromo-1H-pyrrole-2-carbonyl)amino]methyl]-6-hydroxy-11-oxa-7,9,13,15-tetrazatetracyclo[10.3.0.01,5.06,10]pentadeca-8,13-dien-2-yl]oxy]-3-[[(4,5-dibromo-1H-pyrrole-2-carbonyl)amino]methyl]-6-hydroxy-11-oxa-7,9,13,15-tetrazatetracyclo[10.3.0.01,5.06,10]pentadeca-8,13-dien-4-yl]methyl]-1H-pyrrole-2-carboxamide;2,2,2-trifluoroacetic acid
DMNAYEP	DE	Discovery agent

DMJ4Z7W	ID	DMJ4Z7W
DMJ4Z7W	DN	Styrylboronic acid
DMJ4Z7W	HS	Investigative
DMJ4Z7W	SN	styrylboronic acid; 6783-05-7; (E)-Styrylboronic acid; trans-2-Phenylvinylboronic acid; E-Phenylethenylboronic acid; 2-Phenylvinylboronic Acid; [(E)-2-phenylethenyl]boronic acid; 4363-35-3; trans-Phenylvinylboronic acid; (E)-Phenylethenylboronic acid; CHEMBL559289; Trans-Beta-Styreneboronic Acid; Boronic acid, [(1E)-2-phenylethenyl]-; [(E)-styryl]boronic acid; 2-phenylethenylboronic Acid; ((E)-Styryl)boronic acid; [(E)-2-phenylvinyl]boronic acid; trans-styryl boronic acid; AC1NWBO3; (E)-phenylvinylboronic acid
DMJ4Z7W	DT	Small molecular drug
DMJ4Z7W	PC	5702628
DMJ4Z7W	MW	147.97
DMJ4Z7W	FM	C8H9BO2
DMJ4Z7W	IC	InChI=1S/C8H9BO2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-7,10-11H/b7-6+
DMJ4Z7W	CS	B(/C=C/C1=CC=CC=C1)(O)O
DMJ4Z7W	IK	VKIJXFIYBAYHOE-VOTSOKGWSA-N
DMJ4Z7W	IU	[(E)-2-phenylethenyl]boronic acid
DMJ4Z7W	DE	Discovery agent

DMF1P6W	ID	DMF1P6W
DMF1P6W	DN	SU 6656
DMF1P6W	HS	Investigative
DMF1P6W	SN	su6656; 330161-87-0; SU-6656; SU6656; CHEMBL605003; (3z)-N,N-Dimethyl-2-Oxo-3-(4,5,6,7-Tetrahydro-1h-Indol-2-Ylmethylidene)-2,3-Dihydro-1h-Indole-5-Sulfonamide; (3Z)-N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonamide; SR-01000076237; 2,3-Dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indole-5-sulfonamide; AC1NSM2X; Lopac-S-9692; Lopac0_000979; MLS002153475; GTPL6044; EX-A584; MolPort-003-959-609; HMS3229I04; HMS2232C04
DMF1P6W	DT	Small molecular drug
DMF1P6W	PC	5312137
DMF1P6W	MW	371.5
DMF1P6W	FM	C19H21N3O3S
DMF1P6W	IC	InChI=1S/C19H21N3O3S/c1-22(2)26(24,25)14-7-8-18-15(11-14)16(19(23)21-18)10-13-9-12-5-3-4-6-17(12)20-13/h7-11,20H,3-6H2,1-2H3,(H,21,23)/b16-10-
DMF1P6W	CS	CN(C)S(=O)(=O)C1=CC\\2=C(C=C1)NC(=O)/C2=C\\C3=CC4=C(N3)CCCC4
DMF1P6W	IK	LOGJQOUIVKBFGH-YBEGLDIGSA-N
DMF1P6W	IU	(3Z)-N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonamide
DMF1P6W	DE	Discovery agent

DMASP9Z	ID	DMASP9Z
DMASP9Z	DN	SU11274
DMASP9Z	HS	Investigative
DMASP9Z	SN	Met kinase Inhibitor; SU-11274
DMASP9Z	DT	Small molecular drug
DMASP9Z	PC	9549297
DMASP9Z	MW	568.1
DMASP9Z	FM	C28H30ClN5O4S
DMASP9Z	IC	InChI=1S/C28H30ClN5O4S/c1-17-25(30-18(2)26(17)28(36)34-12-10-32(3)11-13-34)16-23-22-15-21(8-9-24(22)31-27(23)35)39(37,38)33(4)20-7-5-6-19(29)14-20/h5-9,14-16,30H,10-13H2,1-4H3,(H,31,35)/b23-16-
DMASP9Z	CS	CC1=C(NC(=C1C(=O)N2CCN(CC2)C)C)/C=C\\3/C4=C(C=CC(=C4)S(=O)(=O)N(C)C5=CC(=CC=C5)Cl)NC3=O
DMASP9Z	IK	FPYJSJDOHRDAMT-KQWNVCNZSA-N
DMASP9Z	IU	(3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide
DMASP9Z	CA	CAS 658084-23-2
DMASP9Z	DE	Discovery agent

DMGQXN7	ID	DMGQXN7
DMGQXN7	DN	SU-11652
DMGQXN7	HS	Investigative
DMGQXN7	SN	SU11652; SU-11652; 5-[(Z)-(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; UNII-1C7AZL970U; CHEMBL13485; 1C7AZL970U; 326914-10-7; 5-[(E)-(5-Chloro-2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]-N-[2-(Diethylamino)ethyl]-2,4-Dimethyl-1h-Pyrrole-3-Carboxamide; 5-{[(3Z)-5-chloro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; AC1NS62M; SU11248 analog 12c; GTPL6043; BDBM4815; SCHEMBL2114096
DMGQXN7	DT	Small molecular drug
DMGQXN7	PC	5329103
DMGQXN7	MW	414.9
DMGQXN7	FM	C22H27ClN4O2
DMGQXN7	IC	InChI=1S/C22H27ClN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
DMGQXN7	CS	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)Cl)NC2=O)C
DMGQXN7	IK	XPLJEFSRINKZLC-ATVHPVEESA-N
DMGQXN7	IU	5-[(Z)-(5-chloro-2-oxo-1H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DMGQXN7	CA	CAS 326914-10-7
DMGQXN7	CB	CHEBI:94073
DMGQXN7	DE	Discovery agent

DMWVN8R	ID	DMWVN8R
DMWVN8R	DN	SU4984
DMWVN8R	HS	Investigative
DMWVN8R	SN	SU-4984; CHEMBL315546; 3[4-(1-Formylpiperazin-4-yl)benzylidenyl]-2-indolinone; (Z)-4-(4-((2-Oxoindolin-3-ylidene)methyl)phenyl)piperazine-1-carbaldehyde; 186610-89-9; AC1NZT45; SCHEMBL141892; BDBM50065306; ZINC12832813; 4-[4-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]phenyl]piperazine-1-carbaldehyde
DMWVN8R	DT	Small molecular drug
DMWVN8R	PC	5941540
DMWVN8R	MW	333.4
DMWVN8R	FM	C20H19N3O2
DMWVN8R	IC	InChI=1S/C20H19N3O2/c24-14-22-9-11-23(12-10-22)16-7-5-15(6-8-16)13-18-17-3-1-2-4-19(17)21-20(18)25/h1-8,13-14H,9-12H2,(H,21,25)/b18-13-
DMWVN8R	CS	C1CN(CCN1C=O)C2=CC=C(C=C2)/C=C\\3/C4=CC=CC=C4NC3=O
DMWVN8R	IK	ZNFJBJDODKHWED-AQTBWJFISA-N
DMWVN8R	IU	4-[4-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]phenyl]piperazine-1-carbaldehyde
DMWVN8R	DE	Discovery agent

DM9JON3	ID	DM9JON3
DM9JON3	DN	SU5402
DM9JON3	HS	Investigative
DM9JON3	SN	su5402; 215543-92-3; SU 5402; SU-5402; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; CHEMBL89363; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE; J-502595; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid
DM9JON3	CP	Sugen Inc
DM9JON3	DT	Small molecular drug
DM9JON3	PC	5289418
DM9JON3	MW	296.32
DM9JON3	FM	C17H16N2O3
DM9JON3	IC	InChI=1S/C17H16N2O3/c1-10-9-18-15(11(10)6-7-16(20)21)8-13-12-4-2-3-5-14(12)19-17(13)22/h2-5,8-9,18H,6-7H2,1H3,(H,19,22)(H,20,21)/b13-8-
DM9JON3	CS	CC1=CNC(=C1CCC(=O)O)/C=C\\2/C3=CC=CC=C3NC2=O
DM9JON3	IK	JNDVEAXZWJIOKB-JYRVWZFOSA-N
DM9JON3	IU	3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
DM9JON3	CA	CAS 215543-92-3
DM9JON3	CB	CHEBI:63449
DM9JON3	DE	Multiple myeloma

DMV1408	ID	DMV1408
DMV1408	DN	SU5403
DMV1408	HS	Investigative
DMV1408	SN	189894-57-3; 1-((1S,2S)-1-Hydroxy-1-(4-hydroxyphenyl)propan-2-yl)-4-phenylpiperidin-4-ol methanesulfonate trihydrate; UNII-BD2A56I30W; BD2A56I30W; Traxoprodil mesylate, CP-101606-27; Traxoprodil mesylate [USAN:INN]; (1S,2S)-1-(4-HYDROXYPHENYL)-2-(4-HYDROXY-4-PHENYLPIPERIDIN-1-YL)-1-PROPANOL METHANESULFONATE TRIHYDRATE; Traxoprodil mesylate hydrate; CHEMBL3989673; KS-00000REE; MolPort-023-219-113; AKOS025396623; RL02411; DS-5988; BCP9000543
DMV1408	DT	Small molecular drug
DMV1408	PC	9826324
DMV1408	MW	477.6
DMV1408	FM	C21H35NO9S
DMV1408	IC	InChI=1S/C20H25NO3.CH4O3S.3H2O/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17;1-5(2,3)4;;;/h2-10,15,19,22-24H,11-14H2,1H3;1H3,(H,2,3,4);3*1H2/t15-,19+;;;;/m0..../s1
DMV1408	CS	C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O.CS(=O)(=O)O.O.O.O
DMV1408	IK	LUILKELNVBKKTG-ZOZJKLBQSA-N
DMV1408	IU	1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol;methanesulfonic acid;trihydrate
DMV1408	CA	CAS 189894-57-3
DMV1408	DE	Discovery agent

DMDNA23	ID	DMDNA23
DMDNA23	DN	SU-6689
DMDNA23	HS	Investigative
DMDNA23	SN	SU-6689; CHEMBL426078; Indolinone based inhibitor, 2f; SCHEMBL5203211; BDBM17028
DMDNA23	DT	Small molecular drug
DMDNA23	PC	10131254
DMDNA23	MW	254.28
DMDNA23	FM	C15H14N2O2
DMDNA23	IC	InChI=1S/C15H14N2O2/c1-8-5-9(2)16-14(8)7-12-11-6-10(18)3-4-13(11)17-15(12)19/h3-7,16,18H,1-2H3,(H,17,19)/b12-7-
DMDNA23	CS	CC1=CC(=C(N1)/C=C\\2/C3=C(C=CC(=C3)O)NC2=O)C
DMDNA23	IK	GUXYHZUGDWFOBA-GHXNOFRVSA-N
DMDNA23	IU	(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-5-hydroxy-1H-indol-2-one
DMDNA23	DE	Discovery agent

DMQHG0R	ID	DMQHG0R
DMQHG0R	DN	SU9516
DMQHG0R	HS	Investigative
DMQHG0R	SN	SU9516; 377090-84-1; SU 9516; SU-9516; AC1NRD9P; 666837-93-0; (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE; (Z)-3-((1H-imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one; 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one; SU9; (Z)-1,3-DIHYDRO-3-(1H-IMIDAZOL-4-YLMETHYLENE)-5-METHOXY-2H-INDOL-2-ONE; 3py1; 3py0; imidazole indolinone driv.; MLS001074893; SCHEMBL1170686; BDBM7238; SCHEMBL1170687; CHEMBL258805
DMQHG0R	DT	Small molecular drug
DMQHG0R	PC	5289419
DMQHG0R	MW	241.24
DMQHG0R	FM	C13H11N3O2
DMQHG0R	IC	InChI=1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-7H,1H3,(H,14,15)(H,16,17)/b11-4-
DMQHG0R	CS	COC1=CC\\2=C(C=C1)NC(=O)/C2=C\\C3=CN=CN3
DMQHG0R	IK	QNUKRWAIZMBVCU-WCIBSUBMSA-N
DMQHG0R	IU	(3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-1H-indol-2-one
DMQHG0R	CA	CAS 377090-84-1
DMQHG0R	CB	CHEBI:113546
DMQHG0R	DE	Discovery agent

DM4SWQA	ID	DM4SWQA
DM4SWQA	DN	Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DM4SWQA	HS	Investigative
DM4SWQA	PC	73347134
DM4SWQA	MW	1724
DM4SWQA	FM	C82H122N28O14
DM4SWQA	IC	InChI=1S/C82H122N28O14/c1-3-15-57(71(117)103-61(25-13-37-97-81(91)92)75(121)107-63(67(85)113)39-45-27-31-49(111)32-28-45)101-73(119)59(23-11-35-95-79(87)88)105-77(123)65(41-47-43-99-55-21-9-5-17-51(47)55)109-69(115)53(83)19-7-8-20-54(84)70(116)110-66(42-48-44-100-56-22-10-6-18-52(48)56)78(124)106-60(24-12-36-96-80(89)90)74(120)102-58(16-4-2)72(118)104-62(26-14-38-98-82(93)94)76(122)108-64(68(86)114)40-46-29-33-50(112)34-30-46/h5-6,9-10,17-18,21-22,27-34,43-44,53-54,57-66,99-100,111-112H,3-4,7-8,11-16,19-20,23-26,35-42,83-84H2,1-2H3,(H2,85,113)(H2,86,114)(H,101,119)(H,102,120)(H,103,117)(H,104,118)(H,105,123)(H,106,124)(H,107,121)(H,108,122)(H,109,115)(H,110,116)(H4,87,88,95)(H4,89,90,96)(H4,91,92,97)(H4,93,94,98)/t53-,54-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-/m0/s1
DM4SWQA	CS	CCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCCC[C@@H](C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N)N)N
DM4SWQA	IK	OWXAFDOATMPIJT-ITDOKHEHSA-N
DM4SWQA	IU	(2S,7S)-2,7-diamino-N,N'-bis[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]octanediamide
DM4SWQA	DE	Discovery agent

DM56MOV	ID	DM56MOV
DM56MOV	DN	Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2
DM56MOV	HS	Investigative
DM56MOV	PC	73354703
DM56MOV	MW	1708
DM56MOV	FM	C80H122N24O18
DM56MOV	IC	InChI=1S/C80H122N24O18/c1-43(2)37-59(71(115)95-57(15-9-35-93-79(87)88)69(113)103-63(75(119)120)41-47-21-29-51(107)30-22-47)101-67(111)55(13-7-33-91-77(83)84)97-73(117)61(39-45-17-25-49(105)26-18-45)99-65(109)53(81)11-5-6-12-54(82)66(110)100-62(40-46-19-27-50(106)28-20-46)74(118)98-56(14-8-34-92-78(85)86)68(112)102-60(38-44(3)4)72(116)96-58(16-10-36-94-80(89)90)70(114)104-64(76(121)122)42-48-23-31-52(108)32-24-48/h17-32,43-44,53-64,105-108H,5-16,33-42,81-82H2,1-4H3,(H,95,115)(H,96,116)(H,97,117)(H,98,118)(H,99,109)(H,100,110)(H,101,111)(H,102,112)(H,103,113)(H,104,114)(H,119,120)(H,121,122)(H4,83,84,91)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1
DM56MOV	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCC[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)N)N
DM56MOV	IK	FPKKOJOGVASCPV-ODXRWUIZSA-N
DM56MOV	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,7S)-2,7-diamino-8-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-8-oxooctanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM56MOV	DE	Discovery agent

DMKH9IE	ID	DMKH9IE
DMKH9IE	DN	subalin
DMKH9IE	HS	Investigative
DMKH9IE	SN	172451-91-1; IFN (alpha-2), NPO Vector; alfa-2 interferon, NPO Vector; alfa-2 interferon, SRC VB Vector; alpha-2 interferon, NPO Vector; alpha-2 interferon, SRC VB Vector
DMKH9IE	DE	Discovery agent

DM235XH	ID	DM235XH
DM235XH	DN	Suberic bishydroxamic acid
DM235XH	HS	Investigative
DM235XH	DE	Discovery agent

DM8BLXT	ID	DM8BLXT
DM8BLXT	DN	Subersic acid
DM8BLXT	HS	Investigative
DM8BLXT	SN	(+)-subersic acid; CHEMBL455101; CHEBI:66532; 4-hydroxy-3-{(2E)-3-methyl-5-[(4aS,8aS)-2,5,5,8a-tetramethyl-3,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]pent-2-en-1-yl}benzoic acid; BDBM50242189
DM8BLXT	DT	Small molecular drug
DM8BLXT	PC	44584380
DM8BLXT	MW	394.5
DM8BLXT	FM	C26H34O3
DM8BLXT	IC	InChI=1S/C26H34O3/c1-25(2)13-4-14-26(3)21-10-6-17(15-18(21)9-12-23(25)26)5-7-19-16-20(24(28)29)8-11-22(19)27/h5,8,11,16,23,27H,4,6-7,9-10,12-15H2,1-3H3,(H,28,29)/b17-5-/t23-,26+/m1/s1
DM8BLXT	CS	C[C@@]12CCCC([C@H]1CCC3=C2CC/C(=C/CC4=C(C=CC(=C4)C(=O)O)O)/C3)(C)C
DM8BLXT	IK	DJADSIGWJIXULZ-IJOJHBLOSA-N
DM8BLXT	IU	3-[(2Z)-2-[(4bR,8aR)-4b,8,8-trimethyl-3,4,5,6,7,8a,9,10-octahydro-1H-phenanthren-2-ylidene]ethyl]-4-hydroxybenzoic acid
DM8BLXT	DE	Discovery agent

DMQ6W4I	ID	DMQ6W4I
DMQ6W4I	DN	Substance P
DMQ6W4I	HS	Investigative
DMQ6W4I	SN	Substance P; 33507-63-0; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2; CCRIS 7229; UNII-675VGV5J1D; EINECS 251-545-8; CHEMBL235363; 675VGV5J1D; 12769-48-1; P substance; Neurokinin P; Substanz-P; C63H98N18O13S; Substance P analogue; AC1Q5IQE; AC1L1VX3; tachykinin substance P (SP); SCHEMBL1116347; GTPL2098; ArgProLysProGlnGlnPhePheGlyLeuMet; MolPort-023-276-010; ADNPLDHMAVUMIW-CUZNLEPHSA-N; 2053AH; BDBM50001450; AKOS024456424; NCGC00167123-01; 11035-08-8; LS-147256; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-amine
DMQ6W4I	DT	Small molecular drug
DMQ6W4I	SQ	DE = Substance P: RPKPQQFFGLM
DMQ6W4I	PC	36511
DMQ6W4I	MW	1347.6
DMQ6W4I	FM	C63H98N18O13S
DMQ6W4I	IC	InChI=1S/C63H98N18O13S/c1-37(2)33-45(57(89)74-41(53(68)85)27-32-95-3)73-52(84)36-72-54(86)46(34-38-15-6-4-7-16-38)78-58(90)47(35-39-17-8-5-9-18-39)79-56(88)42(23-25-50(66)82)75-55(87)43(24-26-51(67)83)76-59(91)49-22-14-31-81(49)62(94)44(20-10-11-28-64)77-60(92)48-21-13-30-80(48)61(93)40(65)19-12-29-71-63(69)70/h4-9,15-18,37,40-49H,10-14,19-36,64-65H2,1-3H3,(H2,66,82)(H2,67,83)(H2,68,85)(H,72,86)(H,73,84)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,88)(H4,69,70,71)/t40-,41-,42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
DMQ6W4I	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DMQ6W4I	IK	ADNPLDHMAVUMIW-CUZNLEPHSA-N
DMQ6W4I	IU	(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DMQ6W4I	CA	CAS 33507-63-0
DMQ6W4I	DE	Discovery agent

DMPY09A	ID	DMPY09A
DMPY09A	DN	Succinate
DMPY09A	HS	Investigative
DMPY09A	DT	Small molecular drug
DMPY09A	PC	160419
DMPY09A	MW	116.072
DMPY09A	FM	C4H4O4-2
DMPY09A	CS	C(CC(=O)[O-])C(=O)[O-]
DMPY09A	IK	KDYFGRWQOYBRFD-UHFFFAOYSA-L
DMPY09A	IU	butanedioate
DMPY09A	CA	CAS 56-14-4
DMPY09A	CB	CHEBI:30031
DMPY09A	DE	Dietary supplements

DMVWUCF	ID	DMVWUCF
DMVWUCF	DN	Sucrose
DMVWUCF	HS	Investigative
DMVWUCF	SN	sucrose; saccharose; 57-50-1; Cane sugar; sugar; Table sugar; White sugar; D-Sucrose; Saccharum; Rohrzucker; Amerfand; Sucrose, pure; Sucrose, dust; D(+)-Saccharose; sacarosa; D(+)-Sucrose; D-(+)-Saccharose; beta-D-Fructofuranosyl alpha-D-glucopyranoside; Microse; Amerfond; Granulated sugar; Rock candy; Beet sugar; Sucraloxum [INN-Latin]; beta-D-Fructofuranosyl-alpha-D-glucopyranoside; Confectioner's sugar; HSDB 500; Sacharose; CCRIS 2120; Sucrose [USAN:JAN]; alpha-D-Glucopyranosyl beta-D-fructofuranoside; CHEBI:17992; D-Saccharose
DMVWUCF	DT	Small molecular drug
DMVWUCF	PC	5988
DMVWUCF	MW	342.3
DMVWUCF	FM	C12H22O11
DMVWUCF	IC	InChI=1S/C12H22O11/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12/h4-11,13-20H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1
DMVWUCF	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO)O)O)O)O
DMVWUCF	IK	CZMRCDWAGMRECN-UGDNZRGBSA-N
DMVWUCF	IU	(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMVWUCF	CA	CAS 57-50-1
DMVWUCF	CB	CHEBI:17992
DMVWUCF	DE	Discovery agent

DMET64R	ID	DMET64R
DMET64R	DN	Sucrose Octasulfate
DMET64R	HS	Investigative
DMET64R	SN	SCHEMBL145070
DMET64R	DT	Small molecular drug
DMET64R	PC	444237
DMET64R	MW	982.8
DMET64R	FM	C12H22O35S8
DMET64R	IC	InChI=1S/C12H22O35S8/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36)/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1
DMET64R	CS	C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O
DMET64R	IK	WEPNHBQBLCNOBB-UGDNZRGBSA-N
DMET64R	IU	[(2R,3R,4S,5R,6R)-2-[(2S,3S,4R,5R)-3,4-disulfooxy-2,5-bis(sulfooxymethyl)oxolan-2-yl]oxy-3,5-disulfooxy-6-(sulfooxymethyl)oxan-4-yl] hydrogen sulfate
DMET64R	CA	CAS 57680-56-5
DMET64R	DE	Discovery agent

DMF1589	ID	DMF1589
DMF1589	DN	SULFAMATE
DMF1589	HS	Investigative
DMF1589	PC	177700
DMF1589	MW	96.09
DMF1589	FM	H2NO3S-
DMF1589	IC	InChI=1S/H3NO3S/c1-5(2,3)4/h(H3,1,2,3,4)/p-1
DMF1589	CS	NS(=O)(=O)[O-]
DMF1589	IK	IIACRCGMVDHOTQ-UHFFFAOYSA-M
DMF1589	IU	sulfamate
DMF1589	CA	CAS 15853-39-1
DMF1589	DE	Discovery agent

DM9XNSK	ID	DM9XNSK
DM9XNSK	DN	Sulfamic acid 12-sulfamoyloxy-dodecyl ester
DM9XNSK	HS	Investigative
DM9XNSK	SN	CHEMBL361421; Sulfamic acid 12-sulfamoyloxy-dodecyl ester
DM9XNSK	DT	Small molecular drug
DM9XNSK	PC	44391576
DM9XNSK	MW	360.5
DM9XNSK	FM	C12H28N2O6S2
DM9XNSK	IC	InChI=1S/C12H28N2O6S2/c13-21(15,16)19-11-9-7-5-3-1-2-4-6-8-10-12-20-22(14,17)18/h1-12H2,(H2,13,15,16)(H2,14,17,18)
DM9XNSK	CS	C(CCCCCCOS(=O)(=O)N)CCCCCOS(=O)(=O)N
DM9XNSK	IK	ZTCHMZGWTCOWRR-UHFFFAOYSA-N
DM9XNSK	IU	12-sulfamoyloxydodecyl sulfamate
DM9XNSK	DE	Discovery agent

DM7VBSY	ID	DM7VBSY
DM7VBSY	DN	Sulfamic acid 16-sulfamoyloxy-hexadecyl ester
DM7VBSY	HS	Investigative
DM7VBSY	SN	CHEMBL181753; Sulfamic acid 16-sulfamoyloxy-hexadecyl ester
DM7VBSY	DT	Small molecular drug
DM7VBSY	PC	44391592
DM7VBSY	MW	416.6
DM7VBSY	FM	C16H36N2O6S2
DM7VBSY	IC	InChI=1S/C16H36N2O6S2/c17-25(19,20)23-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-24-26(18,21)22/h1-16H2,(H2,17,19,20)(H2,18,21,22)
DM7VBSY	CS	C(CCCCCCCCOS(=O)(=O)N)CCCCCCCOS(=O)(=O)N
DM7VBSY	IK	HZFWMHWDIQYXCO-UHFFFAOYSA-N
DM7VBSY	IU	16-sulfamoyloxyhexadecyl sulfamate
DM7VBSY	DE	Discovery agent

DMM70K1	ID	DMM70K1
DMM70K1	DN	Sulfamic acid 2-nonyl-4-oxo-4H-chromen-6-yl ester
DMM70K1	HS	Investigative
DMM70K1	SN	CHEMBL137692; Sulfamic acid 2-nonyl-4-oxo-4H-chromen-6-yl ester; ZINC36338395
DMM70K1	DT	Small molecular drug
DMM70K1	PC	9864028
DMM70K1	MW	367.5
DMM70K1	FM	C18H25NO5S
DMM70K1	IC	InChI=1S/C18H25NO5S/c1-2-3-4-5-6-7-8-9-14-13-17(20)16-12-15(24-25(19,21)22)10-11-18(16)23-14/h10-13H,2-9H2,1H3,(H2,19,21,22)
DMM70K1	CS	CCCCCCCCCC1=CC(=O)C2=C(O1)C=CC(=C2)OS(=O)(=O)N
DMM70K1	IK	ATSLCAISNROVSQ-UHFFFAOYSA-N
DMM70K1	IU	(2-nonyl-4-oxochromen-6-yl) sulfamate
DMM70K1	DE	Discovery agent

DMSZ50N	ID	DMSZ50N
DMSZ50N	DN	Sulfamic acid 3-(3-hydroxy-benzoyl)-phenyl ester
DMSZ50N	HS	Investigative
DMSZ50N	SN	CHEMBL63397; Sulfamic acid 3-(3-hydroxy-benzoyl)-phenyl ester
DMSZ50N	DT	Small molecular drug
DMSZ50N	PC	44306759
DMSZ50N	MW	293.3
DMSZ50N	FM	C13H11NO5S
DMSZ50N	IC	InChI=1S/C13H11NO5S/c14-20(17,18)19-12-6-2-4-10(8-12)13(16)9-3-1-5-11(15)7-9/h1-8,15H,(H2,14,17,18)
DMSZ50N	CS	C1=CC(=CC(=C1)O)C(=O)C2=CC(=CC=C2)OS(=O)(=O)N
DMSZ50N	IK	JDCIQZXDYFJKSG-UHFFFAOYSA-N
DMSZ50N	IU	[3-(3-hydroxybenzoyl)phenyl] sulfamate
DMSZ50N	DE	Discovery agent

DMIQWAH	ID	DMIQWAH
DMIQWAH	DN	Sulfamic acid 3-(3-methoxy-benzoyl)-phenyl ester
DMIQWAH	HS	Investigative
DMIQWAH	SN	CHEMBL305077; Sulfamic acid 3-(3-methoxy-benzoyl)-phenyl ester
DMIQWAH	DT	Small molecular drug
DMIQWAH	PC	44306686
DMIQWAH	MW	307.32
DMIQWAH	FM	C14H13NO5S
DMIQWAH	IC	InChI=1S/C14H13NO5S/c1-19-12-6-2-4-10(8-12)14(16)11-5-3-7-13(9-11)20-21(15,17)18/h2-9H,1H3,(H2,15,17,18)
DMIQWAH	CS	COC1=CC=CC(=C1)C(=O)C2=CC(=CC=C2)OS(=O)(=O)N
DMIQWAH	IK	WHDKAZSQSIKUGW-UHFFFAOYSA-N
DMIQWAH	IU	[3-(3-methoxybenzoyl)phenyl] sulfamate
DMIQWAH	DE	Discovery agent

DMH71N6	ID	DMH71N6
DMH71N6	DN	Sulfamic acid 3-(4-hydroxy-benzoyl)-phenyl ester
DMH71N6	HS	Investigative
DMH71N6	SN	CHEMBL63504; Sulfamic acid 3-(4-hydroxy-benzoyl)-phenyl ester
DMH71N6	DT	Small molecular drug
DMH71N6	PC	44306775
DMH71N6	MW	293.3
DMH71N6	FM	C13H11NO5S
DMH71N6	IC	InChI=1S/C13H11NO5S/c14-20(17,18)19-12-3-1-2-10(8-12)13(16)9-4-6-11(15)7-5-9/h1-8,15H,(H2,14,17,18)
DMH71N6	CS	C1=CC(=CC(=C1)OS(=O)(=O)N)C(=O)C2=CC=C(C=C2)O
DMH71N6	IK	VGINQGIMAOLOBO-UHFFFAOYSA-N
DMH71N6	IU	[3-(4-hydroxybenzoyl)phenyl] sulfamate
DMH71N6	DE	Discovery agent

DMFVE3N	ID	DMFVE3N
DMFVE3N	DN	Sulfamic acid 3-(4-methoxy-benzoyl)-phenyl ester
DMFVE3N	HS	Investigative
DMFVE3N	SN	CHEMBL434211; Sulfamic acid 3-(4-methoxy-benzoyl)-phenyl ester
DMFVE3N	DT	Small molecular drug
DMFVE3N	PC	44306687
DMFVE3N	MW	307.32
DMFVE3N	FM	C14H13NO5S
DMFVE3N	IC	InChI=1S/C14H13NO5S/c1-19-12-7-5-10(6-8-12)14(16)11-3-2-4-13(9-11)20-21(15,17)18/h2-9H,1H3,(H2,15,17,18)
DMFVE3N	CS	COC1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)OS(=O)(=O)N
DMFVE3N	IK	ARBLJGHHCKHHLN-UHFFFAOYSA-N
DMFVE3N	IU	[3-(4-methoxybenzoyl)phenyl] sulfamate
DMFVE3N	DE	Discovery agent

DMLXHAI	ID	DMLXHAI
DMLXHAI	DN	Sulfamic acid 3-benzoyl-phenyl ester
DMLXHAI	HS	Investigative
DMLXHAI	SN	CHEMBL63838; Sulfamic acid 3-benzoyl-phenyl ester; SCHEMBL9451288; WRPUJPPBHRVDQK-UHFFFAOYSA-N; Sulfamic acid 3-benzoylphenyl ester
DMLXHAI	DT	Small molecular drug
DMLXHAI	PC	44306685
DMLXHAI	MW	277.3
DMLXHAI	FM	C13H11NO4S
DMLXHAI	IC	InChI=1S/C13H11NO4S/c14-19(16,17)18-12-8-4-7-11(9-12)13(15)10-5-2-1-3-6-10/h1-9H,(H2,14,16,17)
DMLXHAI	CS	C1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)OS(=O)(=O)N
DMLXHAI	IK	WRPUJPPBHRVDQK-UHFFFAOYSA-N
DMLXHAI	IU	(3-benzoylphenyl) sulfamate
DMLXHAI	DE	Discovery agent

DMA0MEV	ID	DMA0MEV
DMA0MEV	DN	Sulfamic acid 3-sulfamoyloxy-phenyl ester
DMA0MEV	HS	Investigative
DMA0MEV	SN	CHEMBL182429; Sulfamic acid 3-sulfamoyloxy-phenyl ester; SCHEMBL9451263
DMA0MEV	DT	Small molecular drug
DMA0MEV	PC	44391650
DMA0MEV	MW	268.3
DMA0MEV	FM	C6H8N2O6S2
DMA0MEV	IC	InChI=1S/C6H8N2O6S2/c7-15(9,10)13-5-2-1-3-6(4-5)14-16(8,11)12/h1-4H,(H2,7,9,10)(H2,8,11,12)
DMA0MEV	CS	C1=CC(=CC(=C1)OS(=O)(=O)N)OS(=O)(=O)N
DMA0MEV	IK	NORJAZQSJATXMQ-UHFFFAOYSA-N
DMA0MEV	IU	(3-sulfamoyloxyphenyl) sulfamate
DMA0MEV	DE	Discovery agent

DMSYXHF	ID	DMSYXHF
DMSYXHF	DN	Sulfamic acid 4-(2-hydroxy-benzoyl)-phenyl ester
DMSYXHF	HS	Investigative
DMSYXHF	SN	CHEMBL65399; Sulfamic acid 4-(2-hydroxy-benzoyl)-phenyl ester
DMSYXHF	DT	Small molecular drug
DMSYXHF	PC	44306269
DMSYXHF	MW	293.3
DMSYXHF	FM	C13H11NO5S
DMSYXHF	IC	InChI=1S/C13H11NO5S/c14-20(17,18)19-10-7-5-9(6-8-10)13(16)11-3-1-2-4-12(11)15/h1-8,15H,(H2,14,17,18)
DMSYXHF	CS	C1=CC=C(C(=C1)C(=O)C2=CC=C(C=C2)OS(=O)(=O)N)O
DMSYXHF	IK	LJZUGMLIVIPULP-UHFFFAOYSA-N
DMSYXHF	IU	[4-(2-hydroxybenzoyl)phenyl] sulfamate
DMSYXHF	DE	Discovery agent

DM8LWM3	ID	DM8LWM3
DM8LWM3	DN	Sulfamic acid 4-(2-methoxy-benzoyl)-phenyl ester
DM8LWM3	HS	Investigative
DM8LWM3	SN	CHEMBL65446; Sulfamic acid 4-(2-methoxy-benzoyl)-phenyl ester
DM8LWM3	DT	Small molecular drug
DM8LWM3	PC	44306292
DM8LWM3	MW	307.32
DM8LWM3	FM	C14H13NO5S
DM8LWM3	IC	InChI=1S/C14H13NO5S/c1-19-13-5-3-2-4-12(13)14(16)10-6-8-11(9-7-10)20-21(15,17)18/h2-9H,1H3,(H2,15,17,18)
DM8LWM3	CS	COC1=CC=CC=C1C(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DM8LWM3	IK	IREHNQRSDKSAOR-UHFFFAOYSA-N
DM8LWM3	IU	[4-(2-methoxybenzoyl)phenyl] sulfamate
DM8LWM3	DE	Discovery agent

DMK97WC	ID	DMK97WC
DMK97WC	DN	Sulfamic acid 4-(3-methoxy-benzoyl)-phenyl ester
DMK97WC	HS	Investigative
DMK97WC	SN	CHEMBL63345; Sulfamic acid 4-(3-methoxy-benzoyl)-phenyl ester
DMK97WC	DT	Small molecular drug
DMK97WC	PC	44306276
DMK97WC	MW	307.32
DMK97WC	FM	C14H13NO5S
DMK97WC	IC	InChI=1S/C14H13NO5S/c1-19-13-4-2-3-11(9-13)14(16)10-5-7-12(8-6-10)20-21(15,17)18/h2-9H,1H3,(H2,15,17,18)
DMK97WC	CS	COC1=CC=CC(=C1)C(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMK97WC	IK	MCDUCTBYYJRLMG-UHFFFAOYSA-N
DMK97WC	IU	[4-(3-methoxybenzoyl)phenyl] sulfamate
DMK97WC	DE	Discovery agent

DMDUW9F	ID	DMDUW9F
DMDUW9F	DN	Sulfamic acid 4-benzoyl-phenyl ester
DMDUW9F	HS	Investigative
DMDUW9F	SN	CHEMBL304708; Sulfamic acid 4-benzoyl-phenyl ester; SCHEMBL9451248; 4-(Aminosulfonyloxy)benzophenone; LWUJBMNPWUQTGS-UHFFFAOYSA-N; Sulfamic acid 4-benzoylphenyl ester
DMDUW9F	DT	Small molecular drug
DMDUW9F	PC	9817055
DMDUW9F	MW	277.3
DMDUW9F	FM	C13H11NO4S
DMDUW9F	IC	InChI=1S/C13H11NO4S/c14-19(16,17)18-12-8-6-11(7-9-12)13(15)10-4-2-1-3-5-10/h1-9H,(H2,14,16,17)
DMDUW9F	CS	C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMDUW9F	IK	LWUJBMNPWUQTGS-UHFFFAOYSA-N
DMDUW9F	IU	(4-benzoylphenyl) sulfamate
DMDUW9F	DE	Discovery agent

DMQZGNJ	ID	DMQZGNJ
DMQZGNJ	DN	Sulfamic acid 4-sulfamoyloxy-butyl ester
DMQZGNJ	HS	Investigative
DMQZGNJ	SN	1,4-Butanediyl sulfamate; Sulfamic acid, tetramethylene ester; 1,4-Butanediol, bissulfamate (ester); BRN 2275335; CHEMBL353258; 60548-62-1; Sulfamic acid 4-sulfamoyloxy-butyl ester; 4-sulfamoyloxybutyl sulfamate; AC1L3Y05; SCHEMBL11593067; DTXSID40209297; XHCZRWMTVBHWQT-UHFFFAOYSA-N; Bissulfamideoic acid 1,4-butanediyl; BDBM50159801; 1,4-Bis-O-sulfamyl-1,4-butanediol
DMQZGNJ	DT	Small molecular drug
DMQZGNJ	PC	148886
DMQZGNJ	MW	248.3
DMQZGNJ	FM	C4H12N2O6S2
DMQZGNJ	IC	InChI=1S/C4H12N2O6S2/c5-13(7,8)11-3-1-2-4-12-14(6,9)10/h1-4H2,(H2,5,7,8)(H2,6,9,10)
DMQZGNJ	CS	C(CCOS(=O)(=O)N)COS(=O)(=O)N
DMQZGNJ	IK	XHCZRWMTVBHWQT-UHFFFAOYSA-N
DMQZGNJ	IU	4-sulfamoyloxybutyl sulfamate
DMQZGNJ	CA	CAS 60548-62-1
DMQZGNJ	DE	Discovery agent

DMFJR0S	ID	DMFJR0S
DMFJR0S	DN	Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester
DMFJR0S	HS	Investigative
DMFJR0S	SN	CHEMBL360714; Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester
DMFJR0S	DT	Small molecular drug
DMFJR0S	PC	44391625
DMFJR0S	MW	296.3
DMFJR0S	FM	C8H12N2O6S2
DMFJR0S	IC	InChI=1S/C8H12N2O6S2/c9-17(11,12)15-5-7-1-2-8(4-3-7)6-16-18(10,13)14/h1-4H,5-6H2,(H2,9,11,12)(H2,10,13,14)
DMFJR0S	CS	C1=CC(=CC=C1COS(=O)(=O)N)COS(=O)(=O)N
DMFJR0S	IK	YOXOVPXRAUISQE-UHFFFAOYSA-N
DMFJR0S	IU	[4-(sulfamoyloxymethyl)phenyl]methyl sulfamate
DMFJR0S	DE	Discovery agent

DMT3U2D	ID	DMT3U2D
DMT3U2D	DN	Sulfamic acid 6-sulfamoyloxy-hexyl ester
DMT3U2D	HS	Investigative
DMT3U2D	SN	CHEMBL182276; Sulfamic acid 6-sulfamoyloxy-hexyl ester; SCHEMBL10486465
DMT3U2D	DT	Small molecular drug
DMT3U2D	PC	20043771
DMT3U2D	MW	276.3
DMT3U2D	FM	C6H16N2O6S2
DMT3U2D	IC	InChI=1S/C6H16N2O6S2/c7-15(9,10)13-5-3-1-2-4-6-14-16(8,11)12/h1-6H2,(H2,7,9,10)(H2,8,11,12)
DMT3U2D	CS	C(CCCOS(=O)(=O)N)CCOS(=O)(=O)N
DMT3U2D	IK	AEARVEODHXFSKG-UHFFFAOYSA-N
DMT3U2D	IU	6-sulfamoyloxyhexyl sulfamate
DMT3U2D	DE	Discovery agent

DMVWEN3	ID	DMVWEN3
DMVWEN3	DN	Sulfamic acid 7-sulfamoyloxy-heptyl ester
DMVWEN3	HS	Investigative
DMVWEN3	SN	Hepsulfam; 1,7-Heptanediol disulfamate; 96892-57-8; Sulfamic acid, 1,7-heptanediyl ester; 7-sulfamoyloxyheptyl sulfamate; heptane-1,7-diyl disulfamate; NSC 329680; Sulfamic acid 7-sulfamoyloxy-heptyl ester; UNII-971DU2GQ51; CHEMBL182440; GOJJWDOZNKBUSR-UHFFFAOYSA-N; 971DU2GQ51; sulfamic acid 1,7-heptanediyl ester; NSC329680; NSC-329680; AC1L2P3I; AC1Q6YA4; 1,7-Heptanediol bissulfamate; SCHEMBL5409150; C7H18N2O6S2; CTK8D8639; DTXSID90242619; ZINC1574758; HY-U00095; BDBM50154471; CS-7131; SULFAMIC ACID,7-HEPTANEDIYL ESTER
DMVWEN3	DT	Small molecular drug
DMVWEN3	PC	100606
DMVWEN3	MW	290.4
DMVWEN3	FM	C7H18N2O6S2
DMVWEN3	IC	InChI=1S/C7H18N2O6S2/c8-16(10,11)14-6-4-2-1-3-5-7-15-17(9,12)13/h1-7H2,(H2,8,10,11)(H2,9,12,13)
DMVWEN3	CS	C(CCCOS(=O)(=O)N)CCCOS(=O)(=O)N
DMVWEN3	IK	GOJJWDOZNKBUSR-UHFFFAOYSA-N
DMVWEN3	IU	7-sulfamoyloxyheptyl sulfamate
DMVWEN3	CA	CAS 96892-57-8
DMVWEN3	DE	Discovery agent

DMFVQYI	ID	DMFVQYI
DMFVQYI	DN	Sulfamic acid benzo[1,3]dioxol-2-ylmethyl ester
DMFVQYI	HS	Investigative
DMFVQYI	SN	CHEMBL175786; Sulfamic acid benzo[1,3]dioxol-2-ylmethyl ester
DMFVQYI	DT	Small molecular drug
DMFVQYI	PC	11264735
DMFVQYI	MW	231.23
DMFVQYI	FM	C8H9NO5S
DMFVQYI	IC	InChI=1S/C8H9NO5S/c9-15(10,11)12-5-8-13-6-3-1-2-4-7(6)14-8/h1-4,8H,5H2,(H2,9,10,11)
DMFVQYI	CS	C1=CC=C2C(=C1)OC(O2)COS(=O)(=O)N
DMFVQYI	IK	UAXDMVNWVLYKAY-UHFFFAOYSA-N
DMFVQYI	IU	1,3-benzodioxol-2-ylmethyl sulfamate
DMFVQYI	DE	Discovery agent

DMN0Q71	ID	DMN0Q71
DMN0Q71	DN	Sulfamic acid chroman-2-ylmethyl ester
DMN0Q71	HS	Investigative
DMN0Q71	SN	CHEMBL180475; 835894-63-8; Sulfamic acid, (3,4-dihydro-2H-1-benzopyran-2-yl)methyl ester; Sulfamic acid chroman-2-ylmethyl ester; SCHEMBL5274616; CTK3D1605; DTXSID80463432; BDBM50163317; (3,4-dihydro-2H-chromen-2-yl)methyl sulfamate
DMN0Q71	DT	Small molecular drug
DMN0Q71	PC	11356944
DMN0Q71	MW	243.28
DMN0Q71	FM	C10H13NO4S
DMN0Q71	IC	InChI=1S/C10H13NO4S/c11-16(12,13)14-7-9-6-5-8-3-1-2-4-10(8)15-9/h1-4,9H,5-7H2,(H2,11,12,13)
DMN0Q71	CS	C1CC2=CC=CC=C2OC1COS(=O)(=O)N
DMN0Q71	IK	OXNGFJDSVRPPCH-UHFFFAOYSA-N
DMN0Q71	IU	3,4-dihydro-2H-chromen-2-ylmethyl sulfamate
DMN0Q71	CA	CAS 835894-63-8
DMN0Q71	DE	Discovery agent

DMW0ZBF	ID	DMW0ZBF
DMW0ZBF	DN	Sulfate
DMW0ZBF	HS	Investigative
DMW0ZBF	SN	sulfate; Sulfate ion; Sulphate; Sulfate(2-); Sulfate ions; Sulfate (ion); Sulfate radical anion; 14808-79-8; Sulfate dianion; Sulfate anion; UNII-7IS9N8KPMG; tetraoxosulfate(2-); Sulfate anion(2-); 7IS9N8KPMG; Sulfate (7CI,8CI,9CI); SO4(2-); Sulfate-35S; SULFATE STANDARD; Sulfate (S-35); Sulphate Ion; tetraoxosulfate(VI); tetraoxidosulfate(2-); Zirconium Basic sulfate; AC1L1ARH; sulfuric acid, ion(2-); Colistin Sulfate (mixture); CHEMBL183495; CHEBI:16189; CTK0H6976; BDBM26992; QAOWNCQODCNURD-UHFFFAOYSA-L; SO42-; SO4-2; SO4--
DMW0ZBF	DT	Small molecular drug
DMW0ZBF	PC	1117
DMW0ZBF	MW	96.07
DMW0ZBF	FM	O4S-2
DMW0ZBF	IC	InChI=1S/H2O4S/c1-5(2,3)4/h(H2,1,2,3,4)/p-2
DMW0ZBF	CS	[O-]S(=O)(=O)[O-]
DMW0ZBF	IK	QAOWNCQODCNURD-UHFFFAOYSA-L
DMW0ZBF	IU	sulfate
DMW0ZBF	CA	CAS 14808-79-8
DMW0ZBF	CB	CHEBI:16189
DMW0ZBF	DE	Discovery agent

DM8KYUE	ID	DM8KYUE
DM8KYUE	DN	SULFOARECOLINE
DM8KYUE	HS	Investigative
DM8KYUE	SN	SULFOARECOLINE IODIDE
DM8KYUE	DT	Small molecular drug
DM8KYUE	PC	44275767
DM8KYUE	MW	173.25
DM8KYUE	FM	C8H13O2S+
DM8KYUE	IC	InChI=1S/C8H13O2S/c1-10-8(9)7-4-3-5-11(2)6-7/h4H,3,5-6H2,1-2H3/q+1
DM8KYUE	CS	COC(=O)C1=CCC[S+](C1)C
DM8KYUE	IK	RPAWRCUXEGWRMJ-UHFFFAOYSA-N
DM8KYUE	IU	methyl 1-methyl-3,6-dihydro-2H-thiopyran-1-ium-5-carboxylate
DM8KYUE	DE	Discovery agent

DMU0BW9	ID	DMU0BW9
DMU0BW9	DN	sulfonamide-01
DMU0BW9	HS	Investigative
DMU0BW9	SN	sulfonamide-01; Oprea1_687396; GTPL4313; SCHEMBL1864265; SF-01; EU-0032819; SR-01000593746; SR-01000593746-1
DMU0BW9	DT	Small molecular drug
DMU0BW9	PC	11532283
DMU0BW9	MW	441.5
DMU0BW9	FM	C22H23N3O5S
DMU0BW9	IC	InChI=1S/C22H23N3O5S/c1-4-12-23-22(27)17-14-24-18-11-10-15(13-16(18)21(17)26)31(28,29)25(3)19-8-6-7-9-20(19)30-5-2/h4,6-11,13-14H,1,5,12H2,2-3H3,(H,23,27)(H,24,26)
DMU0BW9	CS	CCOC1=CC=CC=C1N(C)S(=O)(=O)C2=CC3=C(C=C2)NC=C(C3=O)C(=O)NCC=C
DMU0BW9	IK	IVIJZILSKWHMIO-UHFFFAOYSA-N
DMU0BW9	IU	6-[(2-ethoxyphenyl)-methylsulfamoyl]-4-oxo-N-prop-2-enyl-1H-quinoline-3-carboxamide
DMU0BW9	DE	Discovery agent

DMBG0H1	ID	DMBG0H1
DMBG0H1	DN	Sulfonylthioureas
DMBG0H1	HS	Investigative
DMBG0H1	DT	Small molecular drug
DMBG0H1	PC	9579193
DMBG0H1	DE	Discovery agent

DMQY3L0	ID	DMQY3L0
DMQY3L0	DN	Sulforaphane
DMQY3L0	HS	Investigative
DMQY3L0	SN	Sulforafan; DL-Sulforaphane; 1-Isothiocyanato-4-(methylsulfinyl)butane; D,L-Sulforaphane; L-Sulforaphane; Sulforaphane (unspecified); R,S-Sulforaphane; C6H11NOS2; 1-isothiocyanato-4-methylsulfinylbutane; Sulforaphane Racemate; CCRIS 7221; 1-Isothiocyanato-4-(methylsulfinyl)-butane; Butane, 1-isothiocyanato-4-(methylsulfinyl)-; SUVMJBTUFCVSAD-UHFFFAOYSA-N; 4-(Methylsulfinyl)Butyl Isothiocyanate
DMQY3L0	PC	5350
DMQY3L0	MW	177.3
DMQY3L0	FM	C6H11NOS2
DMQY3L0	IC	InChI=1S/C6H11NOS2/c1-10(8)5-3-2-4-7-6-9/h2-5H2,1H3
DMQY3L0	CS	CS(=O)CCCCN=C=S
DMQY3L0	IK	SUVMJBTUFCVSAD-UHFFFAOYSA-N
DMQY3L0	IU	1-isothiocyanato-4-methylsulfinylbutane
DMQY3L0	CA	CAS 4478-93-7
DMQY3L0	CB	CHEBI:47807
DMQY3L0	DE	Solid tumour/cancer; Skin disease

DMYPM2D	ID	DMYPM2D
DMYPM2D	DN	SULFURETIN
DMYPM2D	HS	Investigative
DMYPM2D	SN	Sulfuretin; 120-05-8; Sulphuretin; UNII-M6410VY6MI; MLS000863576; M6410VY6MI; CHEBI:9355; SMR000440743; (Z)-2-[(3,4-dihydroxyphenyl)methylene]-6-hydroxy-2H-benzofuran-3-one; (2Z)-2-(3,4-Dihydroxybenzylidene)-6-hydroxy-1-benzofuran-3(2H)-one; 6,3',4'-Trihydroxyaurone; (2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-6-hydroxy-1-benzofuran-3-one; (Z)-2-((3,4-Dihydroxyphenyl)methylene)-6-hydroxy-2H-benzofuran-3-one; Aurone, 6,3',4'-trihydroxy-; EINECS 204-366-4; AC1NQYB9; SCHEMBL634006; SCHEMBL634007
DMYPM2D	DT	Small molecular drug
DMYPM2D	PC	5281295
DMYPM2D	MW	270.24
DMYPM2D	FM	C15H10O5
DMYPM2D	IC	InChI=1S/C15H10O5/c16-9-2-3-10-13(7-9)20-14(15(10)19)6-8-1-4-11(17)12(18)5-8/h1-7,16-18H/b14-6-
DMYPM2D	CS	C1=CC(=C(C=C1/C=C\\2/C(=O)C3=C(O2)C=C(C=C3)O)O)O
DMYPM2D	IK	RGNXWPVNPFAADO-NSIKDUERSA-N
DMYPM2D	IU	(2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-6-hydroxy-1-benzofuran-3-one
DMYPM2D	CA	CAS 120-05-8
DMYPM2D	CB	CHEBI:9355
DMYPM2D	DE	Discovery agent

DMTEU0L	ID	DMTEU0L
DMTEU0L	DN	Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp
DMTEU0L	HS	Investigative
DMTEU0L	PC	23712949
DMTEU0L	MW	1129.4
DMTEU0L	FM	C56H85N10NaO11S
DMTEU0L	IC	InChI=1S/C56H86N10O11S.Na/c1-9-39(6)51(55(73)59-35-41-22-17-18-26-58-41)63-52(70)43(38(4)5)33-48(67)44(30-37(2)3)61-54(72)47(32-42-34-57-36-60-42)65(8)56(74)45(31-40-20-13-12-14-21-40)62-53(71)46-23-19-27-66(46)50(69)25-16-11-10-15-24-49(68)64(7)28-29-78(75,76)77;/h12-14,17-18,20-22,26,34,36-39,43-48,51,67H,9-11,15-16,19,23-25,27-33,35H2,1-8H3,(H,57,60)(H,59,73)(H,61,72)(H,62,71)(H,63,70)(H,75,76,77);/q;+1/p-1
DMTEU0L	CS	CCC(C)C(C(=O)NCC1=CC=CC=N1)NC(=O)C(CC(C(CC(C)C)NC(=O)C(CC2=CN=CN2)N(C)C(=O)C(CC3=CC=CC=C3)NC(=O)C4CCCN4C(=O)CCCCCCC(=O)N(C)CCS(=O)(=O)[O-])O)C(C)C.[Na+]
DMTEU0L	IK	RCOSBSCBKACBAF-UHFFFAOYSA-M
DMTEU0L	IU	sodium;2-[[8-[2-[[1-[[1-[[5-hydroxy-2,8-dimethyl-7-[[3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-8-oxooctanoyl]-methylamino]ethanesulfonate
DMTEU0L	DE	Discovery agent

DMQB2CN	ID	DMQB2CN
DMQB2CN	DN	Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O)
DMQB2CN	HS	Investigative
DMQB2CN	PC	14803031
DMQB2CN	MW	1145.4
DMQB2CN	FM	C56H85N10NaO12S
DMQB2CN	IC	InChI=1S/C56H86N10O12S.Na/c1-9-39(6)51(55(73)58-35-42-22-17-18-27-66(42)75)62-52(70)43(38(4)5)33-48(67)44(30-37(2)3)60-54(72)47(32-41-34-57-36-59-41)64(8)56(74)45(31-40-20-13-12-14-21-40)61-53(71)46-23-19-26-65(46)50(69)25-16-11-10-15-24-49(68)63(7)28-29-79(76,77)78;/h12-14,17-18,20-22,27,34,36-39,43-48,51,67H,9-11,15-16,19,23-26,28-33,35H2,1-8H3,(H,57,59)(H,58,73)(H,60,72)(H,61,71)(H,62,70)(H,76,77,78);/q;+1/p-1
DMQB2CN	CS	CCC(C)C(C(=O)NCC1=CC=CC=[N+]1[O-])NC(=O)C(CC(C(CC(C)C)NC(=O)C(CC2=CN=CN2)N(C)C(=O)C(CC3=CC=CC=C3)NC(=O)C4CCCN4C(=O)CCCCCCC(=O)N(C)CCS(=O)(=O)[O-])O)C(C)C.[Na+]
DMQB2CN	IK	RWEIQAJIARNFKO-UHFFFAOYSA-M
DMQB2CN	IU	sodium;2-[[8-[2-[[1-[[1-[[5-hydroxy-2,8-dimethyl-7-[[3-methyl-1-[(1-oxidopyridin-1-ium-2-yl)methylamino]-1-oxopentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-8-oxooctanoyl]-methylamino]ethanesulfonate
DMQB2CN	DE	Discovery agent

DM26KQG	ID	DM26KQG
DM26KQG	DN	SUN-C8257
DM26KQG	HS	Investigative
DM26KQG	DE	Discovery agent

DMVZWCI	ID	DMVZWCI
DMVZWCI	DN	super cinnamaldehyde
DMVZWCI	HS	Investigative
DMVZWCI	SN	supercinnamaldehyde; CHEMBL402589; 1-methyl-3-(2-oxopropylidene)indolin-2-one; 1,3-DIHYDRO-1-METHYL-3-(2-OXOPROPYLIDENE)-2H-INDOL-2-ONE; SCHEMBL1078803; GTPL6270; 70351-51-8; MFCD08530327; ZINC29043655; BDBM50203070; Supercinnamaldehyde, &gt
DMVZWCI	DT	Small molecular drug
DMVZWCI	PC	12480411
DMVZWCI	MW	201.22
DMVZWCI	FM	C12H11NO2
DMVZWCI	IC	InChI=1S/C12H11NO2/c1-8(14)7-10-9-5-3-4-6-11(9)13(2)12(10)15/h3-7H,1-2H3/b10-7+
DMVZWCI	CS	CC(=O)/C=C/1\\C2=CC=CC=C2N(C1=O)C
DMVZWCI	IK	CZKBLHCEDVWPRN-JXMROGBWSA-N
DMVZWCI	IU	(3E)-1-methyl-3-(2-oxopropylidene)indol-2-one
DMVZWCI	DE	Discovery agent

DMN4IW5	ID	DMN4IW5
DMN4IW5	DN	Suramin
DMN4IW5	HS	Investigative
DMN4IW5	SN	Antrypol; Belganyl; Farma; Fourneau; Germanin; Moranyl; Naganil; Naganin; Naganine; Naganol; Naphuride; SVR; Suramine; SURAMIN SODIUM; Sodium suramin; Suramine sodium; Farma 939; Naganol 6 Na; Germanin (TN); SGCTO-001
DMN4IW5	CP	Bayer Pharmaceuticals Corporation
DMN4IW5	TC	Antiviral Agents
DMN4IW5	DT	Small molecular drug
DMN4IW5	PC	5361
DMN4IW5	MW	1297.3
DMN4IW5	FM	C51H40N6O23S6
DMN4IW5	IC	InChI=1S/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)
DMN4IW5	CS	CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C
DMN4IW5	IK	FIAFUQMPZJWCLV-UHFFFAOYSA-N
DMN4IW5	IU	8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonic acid
DMN4IW5	CA	CAS 145-63-1
DMN4IW5	CB	CHEBI:45906
DMN4IW5	DE	African trypanosomiasis; Coronavirus Disease 2019 (COVID-19)

DMQ5GMV	ID	DMQ5GMV
DMQ5GMV	DN	SUVN-1004028
DMQ5GMV	HS	Investigative
DMQ5GMV	SN	SUVN-D1003019
DMQ5GMV	CP	Suven Life Sciences Ltd
DMQ5GMV	DE	Neurodegenerative disorder

DMT8PKC	ID	DMT8PKC
DMT8PKC	DN	SUVN-501
DMT8PKC	HS	Investigative
DMT8PKC	SN	SUVN-623; SUVN-901; SUVN-976
DMT8PKC	CP	Suven Life Sciences Ltd
DMT8PKC	DE	Neurological disorder

DMZCKDH	ID	DMZCKDH
DMZCKDH	DN	SUVN-504
DMZCKDH	HS	Investigative
DMZCKDH	SN	SUVN-503; SUVN-51005; 5-HT 6 antagonists (emesis), Suven; 5-HT 6 antagonists (obesity), Suven
DMZCKDH	CP	Suven Life Sciences Ltd
DMZCKDH	PC	11744001
DMZCKDH	MW	441.3
DMZCKDH	FM	C18H18BrFN2O3S
DMZCKDH	IC	InChI=1S/C18H18BrFN2O3S/c1-21(2)9-10-25-18-12-22(17-8-3-13(19)11-16(17)18)26(23,24)15-6-4-14(20)5-7-15/h3-8,11-12H,9-10H2,1-2H3
DMZCKDH	CS	CN(C)CCOC1=CN(C2=C1C=C(C=C2)Br)S(=O)(=O)C3=CC=C(C=C3)F
DMZCKDH	IK	GTFCQLBBMSYCFM-UHFFFAOYSA-N
DMZCKDH	IU	2-[5-bromo-1-(4-fluorophenyl)sulfonylindol-3-yl]oxy-N,N-dimethylethanamine
DMZCKDH	DE	Vomiting

DM2UMK8	ID	DM2UMK8
DM2UMK8	DN	SUVN-507
DM2UMK8	HS	Investigative
DM2UMK8	SN	5-HT 6 antagonist (cognitive disorder), Suven
DM2UMK8	CP	Suven Life Sciences Ltd
DM2UMK8	DE	Neurological disorder

DMVDHBT	ID	DMVDHBT
DMVDHBT	DN	SUVN-G1031
DMVDHBT	HS	Investigative
DMVDHBT	SN	Histamine-3 antagonists (metabolic disorders/neurodegenerative diseases); Histamine-3 antagonists (metabolic disorders/neurodegenerative diseases), Suven
DMVDHBT	CP	Suven Life Sciences Ltd
DMVDHBT	DE	Metabolic disorder

DMZGX48	ID	DMZGX48
DMZGX48	DN	SX-517
DMZGX48	HS	Investigative
DMZGX48	SN	SX-517; GTPL8501; SCHEMBL13197143; CHEMBL3342269; BDBM150811; US8981106, 1 (SX-517); N-(4-Fluorophenyl)-6-[2-(dihydroxyboryl)benzylthio]nicotinamide; [2-[[5-[(4-fluorophenyl)carbamoyl]pyridin-2-yl]sulfanylmethyl]phenyl]boronic acid
DMZGX48	DT	Small molecular drug
DMZGX48	PC	46897162
DMZGX48	MW	382.2
DMZGX48	FM	C19H16BFN2O3S
DMZGX48	IC	InChI=1S/C19H16BFN2O3S/c21-15-6-8-16(9-7-15)23-19(24)13-5-10-18(22-11-13)27-12-14-3-1-2-4-17(14)20(25)26/h1-11,25-26H,12H2,(H,23,24)
DMZGX48	CS	B(C1=CC=CC=C1CSC2=NC=C(C=C2)C(=O)NC3=CC=C(C=C3)F)(O)O
DMZGX48	IK	VZRIHFZJVIOJBE-UHFFFAOYSA-N
DMZGX48	IU	[2-[[5-[(4-fluorophenyl)carbamoyl]pyridin-2-yl]sulfanylmethyl]phenyl]boronic acid
DMZGX48	DE	Discovery agent

DMEA36L	ID	DMEA36L
DMEA36L	DN	SX-ARPC
DMEA36L	HS	Investigative
DMEA36L	SN	ADR-L09; Androgen receptor antagonists (small peptide mimetic, androgen independent prostate cancer),Serometrix
DMEA36L	CP	Serometrix LLC
DMEA36L	DE	Prostate cancer

DMT53U6	ID	DMT53U6
DMT53U6	DN	SX-GLP1
DMT53U6	HS	Investigative
DMT53U6	SN	GLP-1 agonists (small peptide mimetics, type II diabetes), Serometrix; Glucagon-like peptide-1 agonists (small peptide mimetics, type II diabetes), Serometrix
DMT53U6	CP	Serometrix LLC
DMT53U6	DE	Non-insulin dependent diabetes

DMJGZ79	ID	DMJGZ79
DMJGZ79	DN	SX-MTR1
DMJGZ79	HS	Investigative
DMJGZ79	SN	MTOR modulators (small peptide mimetics, bladder cancer), Serometrix
DMJGZ79	CP	Serometrix LLC
DMJGZ79	DE	Bladder cancer

DM7YB08	ID	DM7YB08
DM7YB08	DN	SYL-040003
DM7YB08	HS	Investigative
DM7YB08	SN	SYL-04003; Carbonic anhydrase targeting siRNA (ocular hypertension), Sylentis
DM7YB08	CP	Sylentis Sau
DM7YB08	DT	siRNA drug
DM7YB08	DE	Ocular hypertension

DMKIDRY	ID	DMKIDRY
DMKIDRY	DN	SYM-011
DMKIDRY	HS	Investigative
DMKIDRY	SN	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h
DMKIDRY	CP	Receptor BioLogix Inc
DMKIDRY	DE	Solid tumour/cancer

DM30WDL	ID	DM30WDL
DM30WDL	DN	SYM2081
DM30WDL	HS	Investigative
DM30WDL	SN	KRKRAOXTGDJWNI-DMTCNVIQSA-L; (2S,4R)-2-amino-4-methylpentanedioate; [3H](2S,4R)-4-methylglutamate; [3H]SYM2081; [(3)H]4MG; (2S,4R)-Me-Glu; GTPL4317; GTPL4075; compound 52 [PMID:
DM30WDL	DT	Small molecular drug
DM30WDL	PC	21117106
DM30WDL	MW	159.14
DM30WDL	FM	C6H9NO4-2
DM30WDL	IC	InChI=1S/C6H11NO4/c1-3(5(8)9)2-4(7)6(10)11/h3-4H,2,7H2,1H3,(H,8,9)(H,10,11)/p-2/t3-,4+/m1/s1
DM30WDL	CS	C[C@H](C[C@@H](C(=O)[O-])N)C(=O)[O-]
DM30WDL	IK	KRKRAOXTGDJWNI-DMTCNVIQSA-L
DM30WDL	IU	(2S,4R)-2-amino-4-methylpentanedioate
DM30WDL	DE	Discovery agent

DM28TXP	ID	DM28TXP
DM28TXP	DN	SYMBIOPOLYOL
DM28TXP	HS	Investigative
DM28TXP	SN	SYMBIOPOLYOL
DM28TXP	PC	46872950
DM28TXP	MW	1243.5
DM28TXP	FM	C60H99NaO23S
DM28TXP	IC	InChI=1S/C60H100O23S.Na/c1-5-6-7-8-9-10-11-12-13-14-17-20-26-44(65)54(73)59-57(76)48(69)36-50(83-59)58(77)51(70)38(3)29-31-42(63)49-35-47(68)56(75)60(82-49)55(74)45(66)33-37(2)28-30-41(62)34-46(67)53(72)39(4)52(71)43(64)27-22-21-25-40(61)24-19-16-15-18-23-32-81-84(78,79)80;/h5,8-13,19-22,24,26,33,39-77H,1,3,6-7,14-18,23,25,27-32,34-36H2,2,4H3,(H,78,79,80);/q;+1/p-1/b9-8+,11-10+,13-12+,22-21+,24-19+,26-20+,37-33+;/t39?,40?,41-,42+,43?,44+,45+,46-,47+,48+,49+,50+,51-,52?,53+,54-,55-,56+,57+,58-,59-,60-;/m0./s1
DM28TXP	CS	CC([C@H]([C@H](C[C@H](CC/C(=C/[C@H]([C@@H]([C@H]1[C@@H]([C@@H](C[C@@H](O1)[C@@H](CCC(=C)[C@@H]([C@H]([C@H]2C[C@H]([C@H]([C@@H](O2)[C@H]([C@@H](/C=C/CC/C=C/C=C/C=C/CCC=C)O)O)O)O)O)O)O)O)O)O)O)/C)O)O)O)C(C(C/C=C/CC(/C=C/CCCCCOS(=O)(=O)[O-])O)O)O.[Na+]
DM28TXP	IK	FTLCRLMIOGRCRI-ZJJHBUFWSA-M
DM28TXP	IU	sodium;[(6E,10E,16R,17S,19S,22E,24R,25S)-25-[(2R,3R,4R,6R)-6-[(1R,5S,6R)-6-[(2R,4R,5R,6R)-6-[(1S,2R,3E,7E,9E,11E)-1,2-dihydroxyhexadeca-3,7,9,11,15-pentaenyl]-4,5-dihydroxyoxan-2-yl]-1,5,6-trihydroxy-4-methylidenehexyl]-3,4-dihydroxyoxan-2-yl]-8,13,14,16,17,19,24,25-octahydroxy-15,22-dimethylpentacosa-6,10,22-trienyl] sulfate
DM28TXP	DE	Discovery agent

DMYTEXB	ID	DMYTEXB
DMYTEXB	DN	Syn-1020
DMYTEXB	HS	Investigative
DMYTEXB	SN	NOP agonist peptide (pain), SynVax; ORL1 agonist peptide (pain), SynVax; Ac-RY(3-Cl)YRWR-NH2
DMYTEXB	CP	Synvax Pharmaceuticals Inc
DMYTEXB	DE	Pain

DMFNR75	ID	DMFNR75
DMFNR75	DN	SYN-1327
DMFNR75	HS	Investigative
DMFNR75	SN	SYN-1327; CHEMBL443697
DMFNR75	PC	25090771
DMFNR75	MW	1513.8
DMFNR75	FM	C70H100N18O16S2
DMFNR75	IC	InChI=1S/C70H100N18O16S2/c1-39(2)28-53(64(99)82-50(31-43-22-24-45(90)25-23-43)67(102)88-27-15-21-52(88)63(98)83-51(37-105)68(103)104)87(7)56(93)36-86(6)55(92)35-77-60(95)47(29-41-16-10-8-11-17-41)81-61(96)49(32-44-33-74-38-78-44)79-54(91)34-76-65(100)57(40(3)89)84-66(101)58(70(4,5)106)85-62(97)48(30-42-18-12-9-13-19-42)80-59(94)46(71)20-14-26-75-69(72)73/h8-13,16-19,22-25,33,38-40,46-53,57-58,89-90,105-106H,14-15,20-21,26-32,34-37,71H2,1-7H3,(H,74,78)(H,76,100)(H,77,95)(H,79,91)(H,80,94)(H,81,96)(H,82,99)(H,83,98)(H,84,101)(H,85,97)(H,103,104)(H4,72,73,75)/t40-,46+,47+,48+,49+,50+,51+,52+,53+,57+,58-/m1/s1
DMFNR75	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)(C)S)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCN=C(N)N)N)O
DMFNR75	IK	AJONUWHGRIXLLX-SCOIVGQKSA-N
DMFNR75	IU	(2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methyl-3-sulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]-methylamino]acetyl]-methylamino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoic acid
DMFNR75	DE	Discovery agent

DMM5PVL	ID	DMM5PVL
DMM5PVL	DN	syn-BrP-LPA
DMM5PVL	HS	Investigative
DMM5PVL	SN	syn-BrP-LPA; SCHEMBL1555937; GTPL6986; CHEMBL3621355; [(1R,3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]phosphonic acid
DMM5PVL	DT	Small molecular drug
DMM5PVL	PC	24771259
DMM5PVL	MW	487.4
DMM5PVL	FM	C20H40BrO6P
DMM5PVL	IC	InChI=1S/C20H40BrO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20(23)27-17-18(22)16-19(21)28(24,25)26/h18-19,22H,2-17H2,1H3,(H2,24,25,26)/t18-,19-/m0/s1
DMM5PVL	CS	CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@H](P(=O)(O)O)Br)O
DMM5PVL	IK	HLVKVWDSLLFMSX-OALUTQOASA-N
DMM5PVL	IU	[(1R,3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]phosphonic acid
DMM5PVL	DE	Discovery agent

DM802V7	ID	DM802V7
DM802V7	DN	Syringic Acid
DM802V7	HS	Investigative
DM802V7	SN	SYRINGIC ACID; 530-57-4; 4-Hydroxy-3,5-dimethoxybenzoic acid; 3,5-Dimethoxy-4-hydroxybenzoic acid; Cedar acid; Gallic acid 3,5-dimethyl ether; Benzoic acid, 4-hydroxy-3,5-dimethoxy-; 3,5-Dimethoxy-4-hydroxybenzyl acid; UNII-E390O181H5; NSC 2129; EINECS 208-486-8; 4-Hydroxy-3,5-dimethoxy-benzoic acid; BRN 2115262; CHEMBL1414; AI3-24376; CHEBI:68329; JMSVCTWVEWCHDZ-UHFFFAOYSA-N; MFCD00002552; E390O181H5; Syringic acid, 97%; Syringlicacid; Syringicacid; PubChem2673; SpecPlus_000485; AC1L1VUN; Spectrum3_001866; Spectrum5_000963
DM802V7	DT	Small molecular drug
DM802V7	PC	10742
DM802V7	MW	198.17
DM802V7	FM	C9H10O5
DM802V7	IC	InChI=1S/C9H10O5/c1-13-6-3-5(9(11)12)4-7(14-2)8(6)10/h3-4,10H,1-2H3,(H,11,12)
DM802V7	CS	COC1=CC(=CC(=C1O)OC)C(=O)O
DM802V7	IK	JMSVCTWVEWCHDZ-UHFFFAOYSA-N
DM802V7	IU	4-hydroxy-3,5-dimethoxybenzoic acid
DM802V7	CA	CAS 530-57-4
DM802V7	CB	CHEBI:68329
DM802V7	DE	Discovery agent

DM8L6ZF	ID	DM8L6ZF
DM8L6ZF	DN	SZ(+)-(S)-202-791
DM8L6ZF	HS	Investigative
DM8L6ZF	SN	propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-5-nitro-1,4-dihydropyridine-3-carboxylate; 97217-83-9; AC1L1JG6; SZ(+)-(S)-202-791; GTPL4318; SCHEMBL9187081; CTK3I7196; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-5-nitro-3-pyridinecarboxylate; AKOS030605399; SDZ-202 791 R(-); isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-5-nitro-3-pyridine carboxylate
DM8L6ZF	DT	Small molecular drug
DM8L6ZF	PC	5026
DM8L6ZF	MW	358.3
DM8L6ZF	FM	C17H18N4O5
DM8L6ZF	IC	InChI=1S/C17H18N4O5/c1-8(2)25-17(22)13-9(3)18-10(4)16(21(23)24)14(13)11-6-5-7-12-15(11)20-26-19-12/h5-8,14,18H,1-4H3
DM8L6ZF	CS	CC1=C(C(C(=C(N1)C)[N+](=O)[O-])C2=CC=CC3=NON=C32)C(=O)OC(C)C
DM8L6ZF	IK	LYFZEFDZKPJBJK-UHFFFAOYSA-N
DM8L6ZF	IU	propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-5-nitro-1,4-dihydropyridine-3-carboxylate
DM8L6ZF	DE	Discovery agent

DMTKSVO	ID	DMTKSVO
DMTKSVO	DN	T0070907
DMTKSVO	HS	Investigative
DMTKSVO	SN	2-Chloro-5-nitro-N-4-pyridinylbenzamide; 313516-66-4; 2-CHLORO-5-NITRO-N-4-PYRIDINYLBENZAMIDE; 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide; T 0070907; T-0070907; 2-chloro-5-nitro-N-pyridin-4-ylbenzamide; 2-Chloro-5-nitro-N-(4-pyridyl)benzamide; CHEMBL510698; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; 2-chloro-5-nitro-n-4-pyridinyl-benzamide; SR-01000392700; AC1MCROG; Oprea1_586106; ZINC3381; GTPL3444; SCHEMBL2128178; CTK6H1028; KS-00000MYU; CHEBI:92553; DTXSID30380504; MolPort-001-763-336; FRPJSHKMZHWJBE-UHFFFAOYSA-N; HMS3268J16; HMS3651P21; HMS3262J21;  T 0070907
DMTKSVO	DT	Small molecular drug
DMTKSVO	PC	2777391
DMTKSVO	MW	277.66
DMTKSVO	FM	C12H8ClN3O3
DMTKSVO	IC	InChI=1S/C12H8ClN3O3/c13-11-2-1-9(16(18)19)7-10(11)12(17)15-8-3-5-14-6-4-8/h1-7H,(H,14,15,17)
DMTKSVO	CS	C1=CC(=C(C=C1[N+](=O)[O-])C(=O)NC2=CC=NC=C2)Cl
DMTKSVO	IK	FRPJSHKMZHWJBE-UHFFFAOYSA-N
DMTKSVO	IU	2-chloro-5-nitro-N-pyridin-4-ylbenzamide
DMTKSVO	CA	CAS 313516-66-4
DMTKSVO	CB	CHEBI:92553
DMTKSVO	DE	Discovery agent

DMZE9TW	ID	DMZE9TW
DMZE9TW	DN	T0156
DMZE9TW	HS	Investigative
DMZE9TW	SN	T-0156
DMZE9TW	DT	Small molecular drug
DMZE9TW	PC	5368
DMZE9TW	MW	583.6
DMZE9TW	FM	C31H29N5O7
DMZE9TW	IC	InChI=1S/C31H29N5O7/c1-18-13-19(7-11-32-18)16-36-27(31(38)42-5)25(20-14-22(39-2)28(41-4)23(15-20)40-3)21-8-12-35-29(26(21)30(36)37)43-17-24-33-9-6-10-34-24/h6-15H,16-17H2,1-5H3
DMZE9TW	CS	CC1=NC=CC(=C1)CN2C(=C(C3=C(C2=O)C(=NC=C3)OCC4=NC=CC=N4)C5=CC(=C(C(=C5)OC)OC)OC)C(=O)OC
DMZE9TW	IK	JEMJAABFSYOLAP-UHFFFAOYSA-N
DMZE9TW	IU	methyl 2-[(2-methylpyridin-4-yl)methyl]-1-oxo-8-(pyrimidin-2-ylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2,7-naphthyridine-3-carboxylate
DMZE9TW	CB	CHEBI:93111
DMZE9TW	DE	Discovery agent

DMSVLXQ	ID	DMSVLXQ
DMSVLXQ	DN	T-0509
DMSVLXQ	HS	Investigative
DMSVLXQ	SN	RP333
DMSVLXQ	DT	Small molecular drug
DMSVLXQ	PC	173382
DMSVLXQ	MW	333.4
DMSVLXQ	FM	C18H23NO5
DMSVLXQ	IC	InChI=1S/C18H23NO5/c1-23-17-6-3-12(9-18(17)24-2)7-8-19-11-16(22)13-4-5-14(20)15(21)10-13/h3-6,9-10,16,19-22H,7-8,11H2,1-2H3
DMSVLXQ	CS	COC1=C(C=C(C=C1)CCNCC(C2=CC(=C(C=C2)O)O)O)OC
DMSVLXQ	IK	DIPGFXJERHNAQQ-UHFFFAOYSA-N
DMSVLXQ	IU	4-[2-[2-(3,4-dimethoxyphenyl)ethylamino]-1-hydroxyethyl]benzene-1,2-diol
DMSVLXQ	CA	CAS 75241-20-2
DMSVLXQ	DE	Discovery agent

DMZQVDI	ID	DMZQVDI
DMZQVDI	DN	T0901317
DMZQVDI	HS	Investigative
DMZQVDI	SN	T0901317; 293754-55-9; T 0901317; TO-901317; TO901317; UNII-A07663A39I; T-0901317; CHEMBL62136; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide; A07663A39I; N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE; N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]benzenesulfonamide; T-1317
DMZQVDI	DT	Small molecular drug
DMZQVDI	PC	447912
DMZQVDI	MW	481.3
DMZQVDI	FM	C17H12F9NO3S
DMZQVDI	IC	InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2
DMZQVDI	CS	C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O
DMZQVDI	IK	SGIWFELWJPNFDH-UHFFFAOYSA-N
DMZQVDI	IU	N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide
DMZQVDI	CA	CAS 293754-55-9
DMZQVDI	DE	Discovery agent

DMGPQ0Y	ID	DMGPQ0Y
DMGPQ0Y	DN	T-1105
DMGPQ0Y	HS	Investigative
DMGPQ0Y	SN	3-Hydroxypyrazine-2-carboxamide; 55321-99-8; 2-oxo-1H-pyrazine-3-carboxamide; 3-Oxo-3,4-dihydropyrazine-2-carboxamide; Pyrazinecarboxamide, 3,4-dihydro-3-oxo-; NSC163503; SZPBAPFUXAADQV-UHFFFAOYSA-N; Pyrazine-2-carboxamide, 3-hydroxy-; t6mv dnj cvz[wln]; 3-HYDROXYPYRAZINE-2-CARBOXAMINE; AC1Q6FTJ; AC1L6MD7; KSC273I6F; SCHEMBL1338425; ZINC8657; 3-Hydroxy-2-pyrazinecarboxamide; CTK1H3462; DTXSID10203888; 3-hydroxy-pyrazine-2-carboxamide; MolPort-005-980-549; 3-Hydroxy-2-pyrazinecarboxamide #
DMGPQ0Y	DT	Small molecular drug
DMGPQ0Y	PC	294642
DMGPQ0Y	MW	139.11
DMGPQ0Y	FM	C5H5N3O2
DMGPQ0Y	IC	InChI=1S/C5H5N3O2/c6-4(9)3-5(10)8-2-1-7-3/h1-2H,(H2,6,9)(H,8,10)
DMGPQ0Y	CS	C1=CN=C(C(=O)N1)C(=O)N
DMGPQ0Y	IK	SZPBAPFUXAADQV-UHFFFAOYSA-N
DMGPQ0Y	IU	2-oxo-1H-pyrazine-3-carboxamide
DMGPQ0Y	CA	CAS 55321-99-8
DMGPQ0Y	DE	Discovery agent

DMPA2E9	ID	DMPA2E9
DMPA2E9	DN	T-1106
DMPA2E9	HS	Investigative
DMPA2E9	SN	AC1NRS1H; T-1106; SCHEMBL6384698; CHEMBL261459; XVXWUBIIHFDOJO-KQYNXXCUSA-N; 4-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-oxopyrazine-2-carboxamide; 4-((2R,3R,4S,5R)-3,4-Dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-3-oxo-3,4-dihydro-pyrazine-2-carboxylic acid amide; 4-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-3-oxo-3,4-dihydro-2-pyrazinecarboxamide
DMPA2E9	DT	Small molecular drug
DMPA2E9	PC	5271819
DMPA2E9	MW	271.23
DMPA2E9	FM	C10H13N3O6
DMPA2E9	IC	InChI=1S/C10H13N3O6/c11-8(17)5-9(18)13(2-1-12-5)10-7(16)6(15)4(3-14)19-10/h1-2,4,6-7,10,14-16H,3H2,(H2,11,17)/t4-,6-,7-,10-/m1/s1
DMPA2E9	CS	C1=CN(C(=O)C(=N1)C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
DMPA2E9	IK	XVXWUBIIHFDOJO-KQYNXXCUSA-N
DMPA2E9	IU	4-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-oxopyrazine-2-carboxamide
DMPA2E9	DE	Virus infection

DMSA3U4	ID	DMSA3U4
DMSA3U4	DN	T1117
DMSA3U4	HS	Investigative
DMSA3U4	SN	tocrifluor T1117
DMSA3U4	DT	Small molecular drug
DMSA3U4	PC	57369426
DMSA3U4	MW	975
DMSA3U4	FM	C56H53Cl2N7O5
DMSA3U4	IC	InChI=1S/C56H53Cl2N7O5/c1-34-51(54(67)61-64-28-7-6-8-29-64)60-65(48-26-20-40(57)31-47(48)58)52(34)38-17-15-37(16-18-38)36-13-11-35(12-14-36)10-9-27-59-53(66)39-19-23-44-43(30-39)55(68)70-56(44)45-24-21-41(62(2)3)32-49(45)69-50-33-42(63(4)5)22-25-46(50)56/h11-26,30-33H,6-10,27-29H2,1-5H3,(H,59,66)(H,61,67)
DMSA3U4	CS	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)C5=CC=C(C=C5)CCCNC(=O)C6=CC7=C(C=C6)C8(C9=C(C=C(C=C9)N(C)C)OC1=C8C=CC(=C1)N(C)C)OC7=O
DMSA3U4	IK	RNAPRXIZPJDYPH-UHFFFAOYSA-N
DMSA3U4	IU	5-[4-[4-[3-[[3',6'-bis(dimethylamino)-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carbonyl]amino]propyl]phenyl]phenyl]-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMSA3U4	CA	CAS 1186195-59-4
DMSA3U4	DE	Discovery agent

DMVRJEL	ID	DMVRJEL
DMVRJEL	DN	T13
DMVRJEL	HS	Investigative
DMVRJEL	SN	GTPL6984; [(3R,4S)-3-[(Z)-octadec-9-enoyl]oxyoxan-4-yl]oxy-sulfidophosphinic acid
DMVRJEL	DT	Small molecular drug
DMVRJEL	PC	73755252
DMVRJEL	MW	500.6
DMVRJEL	FM	C23H42NaO6PS
DMVRJEL	IC	InChI=1S/C23H43O6PS.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(24)28-22-20-27-19-18-21(22)29-30(25,26)31;/h9-10,21-22H,2-8,11-20H2,1H3,(H2,25,26,31);/q;+1/p-1/b10-9-;/t21-,22+;/m0./s1
DMVRJEL	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)O[C@@H]1COCC[C@@H]1OP(=O)(O)[S-].[Na+]
DMVRJEL	IK	DFEVXZSENXLXQQ-LYOQJJATSA-M
DMVRJEL	IU	sodium;[(3R,4S)-3-[(Z)-octadec-9-enoyl]oxyoxan-4-yl]oxy-sulfidophosphinic acid
DMVRJEL	DE	Discovery agent

DM6HZVC	ID	DM6HZVC
DM6HZVC	DN	T134
DM6HZVC	HS	Investigative
DM6HZVC	SN	T134; GTPL852
DM6HZVC	DT	Small molecular drug
DM6HZVC	PC	16197445
DM6HZVC	MW	2182.6
DM6HZVC	FM	C94H152N38O19S2
DM6HZVC	IC	InChI=1S/C94H152N38O19S2/c95-35-5-3-18-59-76(138)125-65(19-4-6-36-96)86(148)132-44-14-26-72(132)85(147)129-68(46-52-29-33-55(134)34-30-52)81(143)123-62(22-10-40-114-91(104)105)75(137)121-64(24-12-43-117-94(110)151)79(141)130-71(84(146)126-66(87(149)150)25-13-42-116-93(108)109)50-153-152-49-70(83(145)124-63(23-11-41-115-92(106)107)78(140)127-67(45-51-27-31-54(133)32-28-51)80(142)122-61(74(136)120-59)21-9-39-113-90(102)103)131-82(144)69(47-53-48-118-58-17-2-1-15-56(53)58)128-77(139)60(20-8-38-112-89(100)101)119-73(135)57(97)16-7-37-111-88(98)99/h1-2,15,17,27-34,48,57,59-72,118,133-134H,3-14,16,18-26,35-47,49-50,95-97H2,(H,119,135)(H,120,136)(H,121,137)(H,122,142)(H,123,143)(H,124,145)(H,125,138)(H,126,146)(H,127,140)(H,128,139)(H,129,147)(H,130,141)(H,131,144)(H,149,150)(H4,98,99,111)(H4,100,101,112)(H4,102,103,113)(H4,104,105,114)(H4,106,107,115)(H4,108,109,116)(H3,110,117,151)/t57-,59-,60-,61-,62-,63-,64-,65+,66-,67-,68-,69-,70-,71-,72-/m0/s1
DM6HZVC	CS	C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=N)N)CC3=CC=C(C=C3)O)CCCNC(=N)N)NC(=O)[C@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)CCCNC(=O)N)CCCNC(=N)N)CC6=CC=C(C=C6)O
DM6HZVC	IK	ZFIUCXJWTNZDRW-UYROLUPNSA-N
DM6HZVC	IU	(2S)-2-[[(3R,6S,9S,12S,15S,18R,23R,26S,29S,32S,35S)-3,6-bis(4-aminobutyl)-18-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-9,15,29-tris(3-carbamimidamidopropyl)-26-[3-(carbamoylamino)propyl]-12,32-bis[(4-hydroxyphenyl)methyl]-2,5,8,11,14,17,25,28,31,34-decaoxo-20,21-dithia-1,4,7,10,13,16,24,27,30,33-decazabicyclo[33.3.0]octatriacontane-23-carbonyl]amino]-5-carbamimidamidopentanoic acid
DM6HZVC	DE	Discovery agent

DMIHBC5	ID	DMIHBC5
DMIHBC5	DN	T140
DMIHBC5	HS	Investigative
DMIHBC5	SN	[L-3-(2-naphthyl)-alanine3]-T134
DMIHBC5	DT	Small molecular drug
DMIHBC5	PC	16130395
DMIHBC5	MW	2037.4
DMIHBC5	FM	C90H141N33O18S2
DMIHBC5	IC	InChI=1S/C90H141N33O18S2/c91-35-5-3-17-58-74(129)116-63(18-4-6-36-92)83(138)123-43-13-24-70(123)82(137)120-66(46-51-28-33-56(125)34-29-51)78(133)115-61(21-10-40-108-88(100)101)73(128)113-62(22-11-42-110-90(104)141)76(131)121-68(80(135)117-64(84(139)140)23-12-41-109-89(102)103)48-142-143-49-69(81(136)119-65(45-50-26-31-55(124)32-27-50)77(132)114-60(72(127)112-58)20-9-39-107-87(98)99)122-79(134)67(47-52-25-30-53-14-1-2-15-54(53)44-52)118-75(130)59(19-8-38-106-86(96)97)111-71(126)57(93)16-7-37-105-85(94)95/h1-2,14-15,25-34,44,57-70,124-125H,3-13,16-24,35-43,45-49,91-93H2,(H,111,126)(H,112,127)(H,113,128)(H,114,132)(H,115,133)(H,116,129)(H,117,135)(H,118,130)(H,119,136)(H,120,137)(H,121,131)(H,122,134)(H,139,140)(H4,94,95,105)(H4,96,97,106)(H4,98,99,107)(H4,100,101,108)(H4,102,103,109)(H3,104,110,141)/t57-,58-,59-,60-,61-,62-,63+,64-,65-,66-,67-,68-,69-,70-/m0/s1
DMIHBC5	CS	C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=N)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC5=CC=CC=C5C=C4)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)CCCNC(=O)N)CCCNC(=N)N)CC6=CC=C(C=C6)O
DMIHBC5	IK	IMOHHNXUCDZLKM-ADZSTZGASA-N
DMIHBC5	IU	(2S)-2-[[(3R,6S,9S,12S,15R,20R,23S,26S,29S,32S)-3,6-bis(4-aminobutyl)-15-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-9,26-bis(3-carbamimidamidopropyl)-23-[3-(carbamoylamino)propyl]-12,29-bis[(4-hydroxyphenyl)methyl]-2,5,8,11,14,22,25,28,31-nonaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-20-carbonyl]amino]-5-carbamimidamidopentanoic acid
DMIHBC5	CA	CAS 229030-20-0
DMIHBC5	DE	Discovery agent

DMBIH8A	ID	DMBIH8A
DMBIH8A	DN	T22
DMBIH8A	HS	Investigative
DMBIH8A	SN	[Tyr5,12,Lys7]-polyphemusin II
DMBIH8A	DT	Small molecular drug
DMBIH8A	PC	16197316
DMBIH8A	MW	2487
DMBIH8A	FM	C109H164N38O22S4
DMBIH8A	IC	InChI=1S/C109H164N38O22S4/c110-40-6-3-17-72-90(155)131-54-87(152)132-78(48-59-24-32-64(148)33-25-59)96(161)146-85-57-172-171-56-84(102(167)140-79(97(162)135-72)49-60-26-34-65(149)35-27-60)145-95(160)74(19-5-8-42-112)137-92(157)77(23-13-47-129-109(123)124)139-99(164)81(51-62-30-38-67(151)39-31-62)142-104(169)86(147-100(165)82(52-63-53-130-70-16-2-1-14-68(63)70)143-93(158)75(21-11-45-127-107(119)120)134-89(154)69(113)15-9-43-125-105(115)116)58-173-170-55-83(101(166)133-71(88(114)153)20-10-44-126-106(117)118)144-94(159)73(18-4-7-41-111)136-91(156)76(22-12-46-128-108(121)122)138-98(163)80(141-103(85)168)50-61-28-36-66(150)37-29-61/h1-2,14,16,24-39,53,69,71-86,130,148-151H,3-13,15,17-23,40-52,54-58,110-113H2,(H2,114,153)(H,131,155)(H,132,152)(H,133,166)(H,134,154)(H,135,162)(H,136,156)(H,137,157)(H,138,163)(H,139,164)(H,140,167)(H,141,168)(H,142,169)(H,143,158)(H,144,159)(H,145,160)(H,146,161)(H,147,165)(H4,115,116,125)(H4,117,118,126)(H4,119,120,127)(H4,121,122,128)(H4,123,124,129)/t69-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-/m0/s1
DMBIH8A	CS	C1[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CCCCN)CCCNC(=N)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CCCCN)CCCNC(=N)N)CC6=CC=C(C=C6)O)CC7=CC=C(C=C7)O)CCCCN)CC8=CC=C(C=C8)O
DMBIH8A	IK	MJULKHZUJYASFR-FQPMSUGVSA-N
DMBIH8A	IU	(1R,4S,7S,10S,13R,18R,21S,24S,27S,30R,33S,39S,42S)-4,21,39-tris(4-aminobutyl)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-13-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-7,24-bis(3-carbamimidamidopropyl)-10,27,33,42-tetrakis[(4-hydroxyphenyl)methyl]-3,6,9,12,20,23,26,29,32,35,38,41,44-tridecaoxo-15,16,46,47-tetrathia-2,5,8,11,19,22,25,28,31,34,37,40,43-tridecazabicyclo[28.14.4]octatetracontane-18-carboxamide
DMBIH8A	DE	Discovery agent

DMCWE90	ID	DMCWE90
DMCWE90	DN	T2328
DMCWE90	HS	Investigative
DMCWE90	SN	T-2328; T 2328
DMCWE90	DT	Small molecular drug
DMCWE90	PC	10158788
DMCWE90	MW	415.5
DMCWE90	FM	C26H26FN3O
DMCWE90	IC	InChI=1S/C26H26FN3O/c1-31-25-12-10-20(22-11-9-18(16-28)14-23(22)27)15-21(25)17-30-24-8-5-13-29-26(24)19-6-3-2-4-7-19/h2-4,6-7,9-12,14-15,24,26,29-30H,5,8,13,17H2,1H3/t24-,26-/m0/s1
DMCWE90	CS	COC1=C(C=C(C=C1)C2=C(C=C(C=C2)C#N)F)CN[C@H]3CCCN[C@H]3C4=CC=CC=C4
DMCWE90	IK	BJOOHYLOKXAENV-AHWVRZQESA-N
DMCWE90	IU	3-fluoro-4-[4-methoxy-3-[[[(2S,3S)-2-phenylpiperidin-3-yl]amino]methyl]phenyl]benzonitrile
DMCWE90	DE	Discovery agent

DMFKQ1W	ID	DMFKQ1W
DMFKQ1W	DN	T-98475
DMFKQ1W	HS	Investigative
DMFKQ1W	SN	T 98475; T-98475; UNII-F1KLT23O3A; 192887-28-8; F1KLT23O3A; CHEMBL71917; CHEMBL544440; 7-[(2,6-Difluorophenyl)methyl]-4,7-dihydro-2-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-4-oxo-thieno[2,3-b]pyridine-5-carboxylic acid 1-methylethyl ester; 199119-18-1; GTPL1184; SCHEMBL7497514; CTK8E7257; CHEBI:93085; DTXSID90432134; MolPort-023-276-465; HMS3269M21; ZINC4424097; BDBM50067485; AKOS024457145; NCGC00167759-01; Isopropyl 3-(N-benzyl-N-methylaminomethyl)-7-(2,6-difluorobenzyl)-4,7-dihydro-2-(4-i
DMFKQ1W	DT	Small molecular drug
DMFKQ1W	PC	9874838
DMFKQ1W	MW	657.8
DMFKQ1W	FM	C37H37F2N3O4S
DMFKQ1W	IC	InChI=1S/C37H37F2N3O4S/c1-22(2)35(44)40-26-16-14-25(15-17-26)34-28(19-41(5)18-24-10-7-6-8-11-24)32-33(43)29(37(45)46-23(3)4)21-42(36(32)47-34)20-27-30(38)12-9-13-31(27)39/h6-17,21-23H,18-20H2,1-5H3,(H,40,44)
DMFKQ1W	CS	CC(C)C(=O)NC1=CC=C(C=C1)C2=C(C3=C(S2)N(C=C(C3=O)C(=O)OC(C)C)CC4=C(C=CC=C4F)F)CN(C)CC5=CC=CC=C5
DMFKQ1W	IK	RANJJVIMTOIWIN-UHFFFAOYSA-N
DMFKQ1W	IU	propan-2-yl 3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-2-[4-(2-methylpropanoylamino)phenyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate
DMFKQ1W	CA	CAS 192887-28-8
DMFKQ1W	CB	CHEBI:93085
DMFKQ1W	DE	Discovery agent

DME2PFQ	ID	DME2PFQ
DME2PFQ	DN	TA-106
DME2PFQ	HS	Investigative
DME2PFQ	SN	FAb antibody fragment (inflammation), Taligen Therapeutics; Anti-factor B FAb (inflammation), Alexion
DME2PFQ	CP	Taligen Therapeutics Inc
DME2PFQ	DT	Antibody
DME2PFQ	DE	Asthma

DMP2016	ID	DMP2016
DMP2016	DN	TA1-RTA
DMP2016	HS	Investigative
DMP2016	SN	CHEMBL8197; 8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate; 89565-68-4; 124583-47-7; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1H-indole-3-carboxylate; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-; NCGC00015984-03; ACMC-20mr3z; ACMC-20bn7f; Enamine_001310; Biomol-NT_000158; AC1L1KP5; REGID_for_CID_5595; Oprea1_655173; Lopac0_001253; Oprea1_462281; MLS000055682; SCHEMBL463128; AC1Q625H; SCHEMBL8946882
DMP2016	DT	Small molecular drug
DMP2016	PC	5595
DMP2016	MW	284.35
DMP2016	FM	C17H20N2O2
DMP2016	IC	InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3
DMP2016	CS	CN1C2CCC1CC(C2)OC(=O)C3=CNC4=CC=CC=C43
DMP2016	IK	ZNRGQMMCGHDTEI-UHFFFAOYSA-N
DMP2016	IU	(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1H-indole-3-carboxylate
DMP2016	CA	CAS 89565-68-4
DMP2016	CB	CHEBI:91913
DMP2016	DE	Discovery agent

DMOWHER	ID	DMOWHER
DMOWHER	DN	TACRINE(8)-4-AMINOQUINOLINE
DMOWHER	HS	Investigative
DMOWHER	SN	TACRINE(8)-4-AMINOQUINOLINE; CHEMBL1082738; A8B; N-quinolin-4-yl-N'-(1,2,3,4-tetrahydroacridin-9-yl)octane-1,8-diamine; AC1LCVTY; BDBM9441; SCHEMBL20553457; DB04616; Heterodimeric Tacrine-Based Inhibitor 8g; N-(1,2,3,4-Tetrahydroacridine-9-yl)-N'-(4-quinolyl)-1,8-octanediamine; N-[8-(1,2,3,4-tetrahydroacridin-9-ylamino)octyl]quinolin-4-amine trihydrochloride; N-4-Quinolyl-N-9-(1,2,3,4-tetrahydroacridinyl)-1,8-diaminooctane Hydrochloride Salt; N-4'-QUINOLYL-N'-9"-(1",2",3",4"-TETRAHYDRO-ACRIDINYL)-1,8-DIAMINOOCTANE DIHY
DMOWHER	DT	Small molecular drug
DMOWHER	PC	656986
DMOWHER	MW	452.6
DMOWHER	FM	C30H36N4
DMOWHER	IC	InChI=1S/C30H36N4/c1(3-11-20-31-27-19-22-32-26-16-8-5-13-23(26)27)2-4-12-21-33-30-24-14-6-9-17-28(24)34-29-18-10-7-15-25(29)30/h5-6,8-9,13-14,16-17,19,22H,1-4,7,10-12,15,18,20-21H2,(H,31,32)(H,33,34)
DMOWHER	CS	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCCNC4=CC=NC5=CC=CC=C54
DMOWHER	IK	UNVOAAWEEGAXTN-UHFFFAOYSA-N
DMOWHER	IU	N-quinolin-4-yl-N'-(1,2,3,4-tetrahydroacridin-9-yl)octane-1,8-diamine
DMOWHER	DE	Discovery agent

DMCIEQO	ID	DMCIEQO
DMCIEQO	DN	TAD
DMCIEQO	HS	Investigative
DMCIEQO	SN	glutathione sodium salt; 34212-83-4; Tad (TN); SCHEMBL680296; AKOS027382818
DMCIEQO	DT	Small molecular drug
DMCIEQO	PC	46174090
DMCIEQO	MW	330.32
DMCIEQO	FM	C10H17N3NaO6S
DMCIEQO	IC	InChI=1S/C10H17N3O6S.Na/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16;/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19);/t5-,6-;/m0./s1
DMCIEQO	CS	C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)N.[Na]
DMCIEQO	IK	KJQNSWHBRKOGHW-GEMLJDPKSA-N
DMCIEQO	CA	CAS 34212-83-4
DMCIEQO	DE	Discovery agent

DM3B8R1	ID	DM3B8R1
DM3B8R1	DN	Tagetitoxin
DM3B8R1	HS	Investigative
DM3B8R1	SN	Tagetitoxin; (1R,4R,5R,6R,7S,8R)-6-ACETOXY-7-AMINO-4-CARBAMOYL-4-HYDROXY-8-(PHOSPHONOOXY)-9-OXA-3-THIABICYCLO[3.3.1]NONANE-1-CARBOXYLIC ACID; 87913-21-1; DB04788; (1R,4R,5R,6R,7S,8R)-6-(acetyloxy)-7-amino-4-carbamoyl-4-hydroxy-8-(phosphonooxy)-9-oxa-3-thiabicyclo[3.3.1]nonane-1-carboxylic acid (non-preferred name)
DM3B8R1	DT	Small molecular drug
DM3B8R1	PC	5327077
DM3B8R1	MW	416.3
DM3B8R1	FM	C11H17N2O11PS
DM3B8R1	IC	InChI=1S/C11H17N2O11PS/c1-3(14)22-5-4(12)6(24-25(19,20)21)10(9(16)17)2-26-11(18,8(13)15)7(5)23-10/h4-7,18H,2,12H2,1H3,(H2,13,15)(H,16,17)(H2,19,20,21)/t4-,5+,6+,7+,10+,11+/m0/s1
DM3B8R1	CS	CC(=O)O[C@@H]1[C@@H]([C@H]([C@]2(CS[C@]([C@@H]1O2)(C(=O)N)O)C(=O)O)OP(=O)(O)O)N
DM3B8R1	IK	UVAAUIDYGIWLMB-HGNFPZBQSA-N
DM3B8R1	IU	(1R,4R,5R,6R,7S,8R)-6-acetyloxy-7-amino-4-carbamoyl-4-hydroxy-8-phosphonooxy-9-oxa-3-thiabicyclo[3.3.1]nonane-1-carboxylic acid
DM3B8R1	CA	CAS 87913-21-1
DM3B8R1	DE	Discovery agent

DM2RN0S	ID	DM2RN0S
DM2RN0S	DN	tagitinin A
DM2RN0S	HS	Investigative
DM2RN0S	SN	tagitinin A; 59979-61-2; GTPL8701; CHEMBL518700; AC1L48P2; MEGxp0_000075; ACon0_000437; ACon1_000272; BDBM50394802; NCGC00180721-01
DM2RN0S	DT	Small molecular drug
DM2RN0S	PC	181254
DM2RN0S	MW	368.4
DM2RN0S	FM	C19H28O7
DM2RN0S	IC	InChI=1S/C19H28O7/c1-9(2)16(21)25-13-7-18(5)14(20)8-19(23,26-18)10(3)6-12-15(13)11(4)17(22)24-12/h9-10,12-15,20,23H,4,6-8H2,1-3,5H3/t10-,12+,13+,14-,15-,18+,19+/m0/s1
DM2RN0S	CS	C[C@H]1C[C@@H]2[C@@H]([C@@H](C[C@@]3([C@H](C[C@]1(O3)O)O)C)OC(=O)C(C)C)C(=C)C(=O)O2
DM2RN0S	IK	HREHFPZHVCNOMQ-XNNFIIJVSA-N
DM2RN0S	IU	[(1R,2S,4R,8S,9R,11R,12S)-1,12-dihydroxy-2,11-dimethyl-7-methylidene-6-oxo-5,14-dioxatricyclo[9.2.1.04,8]tetradecan-9-yl] 2-methylpropanoate
DM2RN0S	CA	CAS 59979-61-2
DM2RN0S	DE	Discovery agent

DMLOAZB	ID	DMLOAZB
DMLOAZB	DN	TAK-075
DMLOAZB	HS	Investigative
DMLOAZB	SN	Calcium-sensing receptor antagonists (osteoporosis), Takeda
DMLOAZB	CP	Takeda Pharmaceutical Co Ltd
DMLOAZB	DT	Small molecular drug
DMLOAZB	PC	135565722
DMLOAZB	MW	630.8
DMLOAZB	FM	C36H46N4O4S
DMLOAZB	IC	InChI=1S/C29H38N4O.C7H8O3S/c1-7-21-15-17-23(18-16-21)29(8-2,9-3)31-27(34)25-20(4)32-33-26(25)30-24(19-28(33,5)6)22-13-11-10-12-14-22;1-6-2-4-7(5-3-6)11(8,9)10/h10-18,24,30H,7-9,19H2,1-6H3,(H,31,34);2-5H,1H3,(H,8,9,10)/t24-;/m1./s1
DMLOAZB	CS	CCC1=CC=C(C=C1)C(CC)(CC)NC(=O)C2=C3N[C@H](CC(N3N=C2C)(C)C)C4=CC=CC=C4.CC1=CC=C(C=C1)S(=O)(=O)O
DMLOAZB	IK	NDWLAPXXXCPRNP-GJFSDDNBSA-N
DMLOAZB	IU	(5R)-N-[3-(4-ethylphenyl)pentan-3-yl]-2,7,7-trimethyl-5-phenyl-5,6-dihydro-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide;4-methylbenzenesulfonic acid
DMLOAZB	CA	CAS 667931-33-1
DMLOAZB	DE	Osteoporosis

DMW24JP	ID	DMW24JP
DMW24JP	DN	TALAROFLAVONE
DMW24JP	HS	Investigative
DMW24JP	SN	CHEMBL408995; NCGC00381160-01; NCGC00381160-01_C14H12O6_Spiro[cyclopent-4-ene-1,1'(3'H)-isobenzofuran]-3,3'-dione, 2,4'-dihydroxy-6'-methoxy-5-methyl-
DMW24JP	DT	Small molecular drug
DMW24JP	PC	14824655
DMW24JP	MW	276.24
DMW24JP	FM	C14H12O6
DMW24JP	IC	InChI=1S/C14H12O6/c1-6-3-10(16)12(17)14(6)8-4-7(19-2)5-9(15)11(8)13(18)20-14/h3-5,12,15,17H,1-2H3
DMW24JP	CS	CC1=CC(=O)C(C12C3=C(C(=CC(=C3)OC)O)C(=O)O2)O
DMW24JP	IK	ISNKGHIHBITAEG-UHFFFAOYSA-N
DMW24JP	IU	5',7-dihydroxy-5-methoxy-3'-methylspiro[2-benzofuran-3,4'-cyclopent-2-ene]-1,1'-dione
DMW24JP	DE	Discovery agent

DMRTD16	ID	DMRTD16
DMRTD16	DN	Talinolol
DMRTD16	HS	Investigative
DMRTD16	SN	Talinolol; 57460-41-0; Cordanum; Racemic talinolol; 1-(4-(3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY)PHENYL)-3-CYCLOHEXYLUREA; Talinolol [INN]; (+-)-Talinolol; Talinololum [INN-Latin]; 38649-73-9; 1-(4-Cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane; Talinolol (INN); (+-)-N-Cyclohexyl-N'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)urea; NCGC00164542-01; 1-(4-(cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(3-(3-Cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol
DMRTD16	DT	Small molecular drug
DMRTD16	PC	68770
DMRTD16	MW	363.5
DMRTD16	FM	C20H33N3O3
DMRTD16	IC	InChI=1S/C20H33N3O3/c1-20(2,3)21-13-17(24)14-26-18-11-9-16(10-12-18)23-19(25)22-15-7-5-4-6-8-15/h9-12,15,17,21,24H,4-8,13-14H2,1-3H3,(H2,22,23,25)
DMRTD16	CS	CC(C)(C)NCC(COC1=CC=C(C=C1)NC(=O)NC2CCCCC2)O
DMRTD16	IK	MXFWWQICDIZSOA-UHFFFAOYSA-N
DMRTD16	IU	1-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-3-cyclohexylurea
DMRTD16	CA	CAS 57460-41-0
DMRTD16	CB	CHEBI:135533
DMRTD16	DE	Discovery agent

DMMTSL2	ID	DMMTSL2
DMMTSL2	DN	Talmapimod
DMMTSL2	HS	Investigative
DMMTSL2	SN	Talmapimod; SCIO-469; 309913-83-5; Scios 469; UNII-B1E00KQ6NT; SCIO 469; B1E00KQ6NT; CHEMBL514201; SCIO 469 hydrochloride; CHEBI:90683; Talmapimod hydrochloride; 2-(6-Chloro-5-{[(2r,5s)-4-(4-Fluorobenzyl)-2,5-Dimethylpiperazin-1-Yl]carbonyl}-1-Methyl-1h-Indol-3-Yl)-N,N-Dimethyl-2-Oxoacetamide; 2-[6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methylindol-3-yl]-N,N-dimethyl-2-oxoacetamide; 750646-72-1; Talmapimod [USAN]; Talmapimod [USAN:INN]
DMMTSL2	DT	Small molecular drug
DMMTSL2	PC	9871074
DMMTSL2	MW	513
DMMTSL2	FM	C27H30ClFN4O3
DMMTSL2	IC	InChI=1S/C27H30ClFN4O3/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28/h6-11,15-17H,12-14H2,1-5H3/t16-,17+/m0/s1
DMMTSL2	CS	C[C@@H]1CN([C@H](CN1C(=O)C2=C(C=C3C(=C2)C(=CN3C)C(=O)C(=O)N(C)C)Cl)C)CC4=CC=C(C=C4)F
DMMTSL2	IK	ZMELOYOKMZBMRB-DLBZAZTESA-N
DMMTSL2	IU	2-[6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methylindol-3-yl]-N,N-dimethyl-2-oxoacetamide
DMMTSL2	CA	CAS 309913-83-5
DMMTSL2	CB	CHEBI:90683
DMMTSL2	DE	Discovery agent

DM26SE7	ID	DM26SE7
DM26SE7	DN	TAM-67
DM26SE7	HS	Investigative
DM26SE7	SN	CHEMBL16410; UNII-929J96FO8T; 82668-33-5; JPC-211; U-99194A maleate; 929J96FO8T; PNU-99194A free base; 5,6-dimethoxy-n,n-dipropylindan-2-amine; JPC 211; Tocris-1357; NCGC00016073-01; 2-Di-n-propylamino-5,6-dimethoxyindane; Lopac-U-116; 1H-Inden-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-; AC1L1KRQ; Biomol-NT_000031; AC1Q56MX; Lopac0_001207; ZINC7459; SCHEMBL2640137; BPBio1_001223; CHEBI:93232; DTXSID50274471; BDBM50107876; CCG-205281; PNU-99,194; API0008965; NCGC00025123-03; NCGC00025123-01; NCGC00016073-02
DM26SE7	DT	Small molecular drug
DM26SE7	PC	5626
DM26SE7	MW	277.4
DM26SE7	FM	C17H27NO2
DM26SE7	IC	InChI=1S/C17H27NO2/c1-5-7-18(8-6-2)15-9-13-11-16(19-3)17(20-4)12-14(13)10-15/h11-12,15H,5-10H2,1-4H3
DM26SE7	CS	CCCN(CCC)C1CC2=CC(=C(C=C2C1)OC)OC
DM26SE7	IK	UOLJKAPABHXFRE-UHFFFAOYSA-N
DM26SE7	IU	5,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine
DM26SE7	CA	CAS 82668-33-5
DM26SE7	CB	CHEBI:93232
DM26SE7	DE	Discovery agent

DM0EP51	ID	DM0EP51
DM0EP51	DN	TAMARIXETIN
DM0EP51	HS	Investigative
DM0EP51	SN	Tamarixetin; 603-61-2; 4'-Methoxyquercetin; 4'-O-Methylquercetin; Quercetin 4'-methyl ether; UNII-73WRA8Z8M8; 3,3',5,7-Tetrahydroxy-4'-methoxyflavone; 4'-O-Methyl Quercetin; Quercetin-4'-methylether; 73WRA8Z8M8; CHEMBL226034; CHEBI:67492; 3,5,7-Trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 4'-Methoxy-3,3',5,7-tetrahydroxyflavone; Tamaraxetin; 3-O-rhamnopyranosyl-1-2-glucopyranoside; 3-O-alpha-L-rhamnopyranosyl-1-2-beta-D-glucopyranoside; AC1NQYX7
DM0EP51	DT	Small molecular drug
DM0EP51	PC	5281699
DM0EP51	MW	316.26
DM0EP51	FM	C16H12O7
DM0EP51	IC	InChI=1S/C16H12O7/c1-22-11-3-2-7(4-9(11)18)16-15(21)14(20)13-10(19)5-8(17)6-12(13)23-16/h2-6,17-19,21H,1H3
DM0EP51	CS	COC1=C(C=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
DM0EP51	IK	FPLMIPQZHHQWHN-UHFFFAOYSA-N
DM0EP51	IU	3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one
DM0EP51	CA	CAS 603-61-2
DM0EP51	CB	CHEBI:67492
DM0EP51	DE	Discovery agent

DM17JFO	ID	DM17JFO
DM17JFO	DN	Tamarixetin 3-glucoside-7-sulfate
DM17JFO	HS	Investigative
DM17JFO	SN	Tamarixetin 3-glucoside-7-sulfate; LMPK12112409; Quercetin 4'-methyl ether 3-glucoside-7-sulfate
DM17JFO	DT	Small molecular drug
DM17JFO	PC	44259416
DM17JFO	MW	558.5
DM17JFO	FM	C22H22O15S
DM17JFO	IC	InChI=1S/C22H22O15S/c1-33-12-3-2-8(4-10(12)24)20-21(36-22-19(29)18(28)16(26)14(7-23)35-22)17(27)15-11(25)5-9(6-13(15)34-20)37-38(30,31)32/h2-6,14,16,18-19,22-26,28-29H,7H2,1H3,(H,30,31,32)/t14-,16-,18?,19?,22+/m1/s1
DM17JFO	CS	COC1=C(C=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)OS(=O)(=O)O)O)O[C@H]4C(C([C@@H]([C@H](O4)CO)O)O)O)O
DM17JFO	IK	HDCDAUMQECHFOE-VZIAGGLWSA-N
DM17JFO	IU	[5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-3-[(2S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-7-yl] hydrogen sulfate
DM17JFO	DE	Discovery agent

DMBKL5O	ID	DMBKL5O
DMBKL5O	DN	Tamoxifen butyl bromide
DMBKL5O	HS	Investigative
DMBKL5O	SN	Tamoxifen butyl bromide
DMBKL5O	DT	Small molecular drug
DMBKL5O	PC	11547961
DMBKL5O	MW	508.5
DMBKL5O	FM	C30H38BrNO
DMBKL5O	IC	InChI=1S/C30H38NO.BrH/c1-5-7-22-31(3,4)23-24-32-28-20-18-27(19-21-28)30(26-16-12-9-13-17-26)29(6-2)25-14-10-8-11-15-25;/h8-21H,5-7,22-24H2,1-4H3;1H/q+1;/p-1/b30-29-;
DMBKL5O	CS	CCCC[N+](C)(C)CCOC1=CC=C(C=C1)/C(=C(/CC)\\C2=CC=CC=C2)/C3=CC=CC=C3.[Br-]
DMBKL5O	IK	XHYMZYZWHWNTMN-DHKWPOFJSA-M
DMBKL5O	IU	butyl-[2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl]-dimethylazanium;bromide
DMBKL5O	DE	Discovery agent

DM76BXY	ID	DM76BXY
DM76BXY	DN	Tamoxifen ethyl bromide
DM76BXY	HS	Investigative
DM76BXY	SN	Tamoxifen ethyl bromide
DM76BXY	DT	Small molecular drug
DM76BXY	PC	49863610
DM76BXY	MW	480.5
DM76BXY	FM	C28H34BrNO
DM76BXY	IC	InChI=1S/C28H34NO.BrH/c1-5-27(23-13-9-7-10-14-23)28(24-15-11-8-12-16-24)25-17-19-26(20-18-25)30-22-21-29(3,4)6-2;/h7-20H,5-6,21-22H2,1-4H3;1H/q+1;/p-1/b28-27-;
DM76BXY	CS	CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCC[N+](C)(C)CC)/C3=CC=CC=C3.[Br-]
DM76BXY	IK	BXPXDYCXXNBOQW-LXCLTORNSA-M
DM76BXY	IU	2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-ethyl-dimethylazanium;bromide
DM76BXY	DE	Discovery agent

DMBKWUZ	ID	DMBKWUZ
DMBKWUZ	DN	Tamoxifen isopropyl bromide
DMBKWUZ	HS	Investigative
DMBKWUZ	SN	Tamoxifen isopropyl bromide
DMBKWUZ	DT	Small molecular drug
DMBKWUZ	PC	46919124
DMBKWUZ	MW	494.5
DMBKWUZ	FM	C29H36BrNO
DMBKWUZ	IC	InChI=1S/C29H36NO.BrH/c1-6-28(24-13-9-7-10-14-24)29(25-15-11-8-12-16-25)26-17-19-27(20-18-26)31-22-21-30(4,5)23(2)3;/h7-20,23H,6,21-22H2,1-5H3;1H/q+1;/p-1/b29-28-;
DMBKWUZ	CS	CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCC[N+](C)(C)C(C)C)/C3=CC=CC=C3.[Br-]
DMBKWUZ	IK	VSVUDCODHCQATR-FJBFXRHMSA-M
DMBKWUZ	IU	2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-dimethyl-propan-2-ylazanium;bromide
DMBKWUZ	DE	Discovery agent

DMQCW7V	ID	DMQCW7V
DMQCW7V	DN	Tanaproget
DMQCW7V	HS	Investigative
DMQCW7V	SN	Tanaproget; 304853-42-7; NSP-989; UNII-W9F9H8GXWR; W9F9H8GXWR; 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile; T98; Tanaproget [USAN:INN]; 1zuc; NSP 989; Tanaproget (USAN/INN); AC1NA08O; SCHEMBL62188; CHEMBL539163; GTPL7416; DTXSID00184556; PYVFWTPEBMRKSR-UHFFFAOYSA-N; ZINC6245719; BDBM50375821; AKOS030526776; SB17247; DB04787; CS-1550; NSP-989;NSP 989;NSP989; HY-15606; KB-145966; FT-0735521; W-5758; D06003
DMQCW7V	DT	Small molecular drug
DMQCW7V	PC	4369524
DMQCW7V	MW	297.4
DMQCW7V	FM	C16H15N3OS
DMQCW7V	IC	InChI=1S/C16H15N3OS/c1-16(2)12-8-10(4-6-13(12)18-15(21)20-16)14-7-5-11(9-17)19(14)3/h4-8H,1-3H3,(H,18,21)
DMQCW7V	CS	CC1(C2=C(C=CC(=C2)C3=CC=C(N3C)C#N)NC(=S)O1)C
DMQCW7V	IK	PYVFWTPEBMRKSR-UHFFFAOYSA-N
DMQCW7V	IU	5-(4,4-dimethyl-2-sulfanylidene-1H-3,1-benzoxazin-6-yl)-1-methylpyrrole-2-carbonitrile
DMQCW7V	CA	CAS 304853-42-7
DMQCW7V	DE	Estrogen deficiency

DM52WGH	ID	DM52WGH
DM52WGH	DN	tannic acid
DM52WGH	HS	Investigative
DM52WGH	SN	TANNIC ACID; Glycerite; 1401-55-4; Gallotannic acid; MLS001335996; CHEBI:81066; 5424-20-4; SMR000857330; DSSTox_CID_6076; DSSTox_RID_78006; DSSTox_GSID_26076; Quebracho extract; CAS-1401-55-4; Tannic acid, ACS reagent; Tanninum; MFCD00066397; Chinese gallotannin; NCGC00095101-01; Gallotannin; EINECS 226-562-9; C76H52O46; Tannin (Tannic acid); Tannic acid, technical; Tannic acid, technical grade; MLS001335995; SCHEMBL409692; Tannic acid, SAJ first grade; GTPL4319; CHEMBL506247; BDBM60986; Tannic acid, puriss., 95.0%
DM52WGH	DT	Small molecular drug
DM52WGH	PC	16129778
DM52WGH	MW	1701.2
DM52WGH	FM	C76H52O46
DM52WGH	IC	InChI=1S/C76H52O46/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26/h1-20,52,63-65,76-101H,21H2/t52-,63-,64+,65-,76+/m1/s1
DM52WGH	CS	C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O
DM52WGH	IK	LRBQNJMCXXYXIU-PPKXGCFTSA-N
DM52WGH	IU	[2,3-dihydroxy-5-[[(2R,3R,4S,5R,6S)-3,4,5,6-tetrakis[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy]oxan-2-yl]methoxycarbonyl]phenyl] 3,4,5-trihydroxybenzoate
DM52WGH	CA	CAS 1401-55-4
DM52WGH	CB	CHEBI:81066
DM52WGH	DE	Discovery agent

DMTFHRI	ID	DMTFHRI
DMTFHRI	DN	TANNIN
DMTFHRI	HS	Investigative
DMTFHRI	DE	Discovery agent

DM07FBL	ID	DM07FBL
DM07FBL	DN	TAS-203
DM07FBL	HS	Investigative
DM07FBL	SN	PDE 4 inhibitor (airway inflammation), Taiho; Phosphodiesterase 4 inhibitor (airway inflammation), Taiho
DM07FBL	CP	Taiho Pharmaceutical Co Ltd
DM07FBL	DE	Respiratory tract inflammation

DM9S5DV	ID	DM9S5DV
DM9S5DV	DN	TASPINE
DM9S5DV	HS	Investigative
DM9S5DV	SN	Taspine; Thaspine; 602-07-3; UNII-V53XN9L07O; V53XN9L07O; CHEMBL470867; 74578-01-1; 1-(2-(Dimethylamino)ethyl)-3,8-dimethoxychromeno[5,4,3-cde]chromene-5,10-dione; NSC76022; NSC618155; NSC-76022; 1-(2-(Dimethylamino)ethyl)-3,8-dimethoxychromeno(5,4,3-cde)chromene-5,10-dione hydrochloride; Taspin; AC1L4Y9B; ZINC1702514; NSC688259; BDBM50241808; AKOS027326755; NSC 688259; NSC-688259; 2-dimethylaminoethyl(dimethoxy)[ ]dione; NCI60_041671; NCI60_031857; FT-0674816
DM9S5DV	DT	Small molecular drug
DM9S5DV	PC	215159
DM9S5DV	MW	369.4
DM9S5DV	FM	C20H19NO6
DM9S5DV	IC	InChI=1S/C20H19NO6/c1-21(2)8-7-10-9-13(25-4)18-16-14(10)20(23)27-17-12(24-3)6-5-11(15(16)17)19(22)26-18/h5-6,9H,7-8H2,1-4H3
DM9S5DV	CS	CN(C)CCC1=CC(=C2C3=C1C(=O)OC4=C(C=CC(=C34)C(=O)O2)OC)OC
DM9S5DV	IK	MTAWKURMWOXCEO-UHFFFAOYSA-N
DM9S5DV	IU	5-[2-(dimethylamino)ethyl]-7,14-dimethoxy-2,9-dioxatetracyclo[6.6.2.04,16.011,15]hexadeca-1(14),4(16),5,7,11(15),12-hexaene-3,10-dione
DM9S5DV	CA	CAS 602-07-3
DM9S5DV	DE	Discovery agent

DML01Y7	ID	DML01Y7
DML01Y7	DN	TAT-120
DML01Y7	HS	Investigative
DML01Y7	SN	MIP-120, Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease); Peptide Mst-1 inhibitors (ischemia), Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease), Vasade
DML01Y7	CP	Vasade Biosciences Inc
DML01Y7	DE	Ischemic heart disease

DMVW7N3	ID	DMVW7N3
DMVW7N3	DN	Taurine
DMVW7N3	HS	Investigative
DMVW7N3	SN	taurine; 2-aminoethanesulfonic acid; 107-35-7; tauphon; L-Taurine; Ethanesulfonic acid, 2-amino-; 2-Aminoethylsulfonic acid; O-Due; 2-Sulfoethylamine; taufon; Aminoethanesulfonic acid; aminoethylsulfonic acid; beta-Aminoethylsulfonic acid; 2-aminoethane-1-sulfonic acid; Taurinum [Latin]; Taurina [Spanish]; Taurine [INN]; FEMA No. 3813; CCRIS 4721; UNII-1EQV5MLY3D; NCI-C60606; AI3-18307; NSC32428; EINECS 203-483-8; NSC 32428; 1EQV5MLY3D; .beta.-Aminoethylsulfonic acid; 1-Aminoethane-2-sulfonic acid; CHEBI:15891
DMVW7N3	DT	Small molecular drug
DMVW7N3	PC	1123
DMVW7N3	MW	125.15
DMVW7N3	FM	C2H7NO3S
DMVW7N3	IC	InChI=1S/C2H7NO3S/c3-1-2-7(4,5)6/h1-3H2,(H,4,5,6)
DMVW7N3	CS	C(CS(=O)(=O)O)N
DMVW7N3	IK	XOAAWQZATWQOTB-UHFFFAOYSA-N
DMVW7N3	IU	2-aminoethanesulfonic acid
DMVW7N3	CA	CAS 107-35-7
DMVW7N3	CB	CHEBI:15891
DMVW7N3	DE	Discovery agent

DMEL9UT	ID	DMEL9UT
DMEL9UT	DN	Taurochenodeoxycholic acid
DMEL9UT	HS	Investigative
DMEL9UT	SN	taurochenodeoxycholate
DMEL9UT	DT	Small molecular drug
DMEL9UT	PC	387316
DMEL9UT	MW	499.7
DMEL9UT	FM	C26H45NO6S
DMEL9UT	IC	InChI=1S/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17+,18-,19-,20+,21+,22-,24+,25+,26-/m1/s1
DMEL9UT	CS	C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMEL9UT	IK	BHTRKEVKTKCXOH-BJLOMENOSA-N
DMEL9UT	IU	2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
DMEL9UT	CA	CAS 516-35-8
DMEL9UT	CB	CHEBI:16525
DMEL9UT	DE	Discovery agent

DMFKRQE	ID	DMFKRQE
DMFKRQE	DN	Tauroursodeoxycholic acid
DMFKRQE	HS	Investigative
DMFKRQE	SN	tauroursodeoxycholate; TUDCA
DMFKRQE	DT	Small molecular drug
DMFKRQE	PC	9848818
DMFKRQE	MW	499.7
DMFKRQE	FM	C26H45NO6S
DMFKRQE	IC	InChI=1S/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17+,18-,19-,20+,21+,22+,24+,25+,26-/m1/s1
DMFKRQE	CS	C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMFKRQE	IK	BHTRKEVKTKCXOH-LBSADWJPSA-N
DMFKRQE	IU	2-[[(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
DMFKRQE	CA	CAS 14605-22-2
DMFKRQE	CB	CHEBI:80774
DMFKRQE	DE	Discovery agent

DMC92DQ	ID	DMC92DQ
DMC92DQ	DN	TAUTOMYCIN
DMC92DQ	HS	Investigative
DMC92DQ	SN	Tautomycin; AC1L99OL; CHEBI:9414; CHEMBL505512; CTK8E8541; 109946-35-2; Tautomycin from Streptomyces spiroverticillatus; SCHEMBL83891; DNC014580; BDBM50366883; RT-015883; C05372; J-002353; [(1R,2R,3R,6S,7S,10R)-10-[(2S,3S,6R,8S,9R)-3,9-dimethyl-8-[(3S)-3-methyl-4-oxo-pentyl]-1,7-dioxaspiro[5.5]undecan-2-yl]-3,7-dihydroxy-1-isopropyl-2-methoxy-6-methyl-5-oxo-undecyl] (3R)-3-hydroxy-3-(4-methyl-2,5-dioxo-3-furyl)propanoate
DMC92DQ	DT	Small molecular drug
DMC92DQ	PC	440646
DMC92DQ	MW	767
DMC92DQ	FM	C41H66O13
DMC92DQ	IC	InChI=1S/C41H66O13/c1-21(2)36(51-34(47)20-31(45)35-27(8)39(48)52-40(35)49)38(50-10)32(46)19-30(44)26(7)29(43)13-11-24(5)37-25(6)16-18-41(54-37)17-15-23(4)33(53-41)14-12-22(3)28(9)42/h21-26,29,31-33,36-38,43,45-46H,11-20H2,1-10H3/t22-,23+,24+,25-,26-,29-,31+,32+,33-,36+,37-,38+,41+/m0/s1
DMC92DQ	CS	C[C@@H]1CC[C@@]2(CC[C@@H]([C@@H](O2)[C@H](C)CC[C@@H]([C@H](C)C(=O)C[C@H]([C@H]([C@@H](C(C)C)OC(=O)C[C@H](C3=C(C(=O)OC3=O)C)O)OC)O)O)C)O[C@H]1CC[C@H](C)C(=O)C
DMC92DQ	IK	RFCWHQNNCOJYTR-IRCAEPKSSA-N
DMC92DQ	IU	[(3R,4R,5R,8S,9S,12R)-12-[(2S,3S,6R,8S,9R)-3,9-dimethyl-8-[(3S)-3-methyl-4-oxopentyl]-1,7-dioxaspiro[5.5]undecan-2-yl]-5,9-dihydroxy-4-methoxy-2,8-dimethyl-7-oxotridecan-3-yl] (3R)-3-hydroxy-3-(4-methyl-2,5-dioxofuran-3-yl)propanoate
DMC92DQ	CB	CHEBI:9414
DMC92DQ	DE	Discovery agent

DMCZIFS	ID	DMCZIFS
DMCZIFS	DN	TB-101
DMCZIFS	HS	Investigative
DMCZIFS	CP	TROBIO AB
DMCZIFS	DE	Bleeding disorder

DMUN8CG	ID	DMUN8CG
DMUN8CG	DN	TB-102
DMUN8CG	HS	Investigative
DMUN8CG	CP	TROBIO AB
DMUN8CG	DE	Bleeding disorder

DMFC3XP	ID	DMFC3XP
DMFC3XP	DN	TBPS
DMFC3XP	HS	Investigative
DMFC3XP	SN	tert-butylbicyclophosphorothionate
DMFC3XP	DT	Small molecular drug
DMFC3XP	PC	104781
DMFC3XP	MW	222.24
DMFC3XP	FM	C8H15O3PS
DMFC3XP	IC	InChI=1S/C8H15O3PS/c1-7(2,3)8-4-9-12(13,10-5-8)11-6-8/h4-6H2,1-3H3
DMFC3XP	CS	CC(C)(C)C12COP(=S)(OC1)OC2
DMFC3XP	IK	VTBHBNXGFPTBJL-UHFFFAOYSA-N
DMFC3XP	IU	4-tert-butyl-1-sulfanylidene-2,6,7-trioxa-1lambda5-phosphabicyclo[2.2.2]octane
DMFC3XP	CA	CAS 70636-86-1
DMFC3XP	DE	Discovery agent

DMKAX76	ID	DMKAX76
DMKAX76	DN	T-BuAc-RYYRIK-NH2
DMKAX76	HS	Investigative
DMKAX76	SN	CHEMBL270216
DMKAX76	DT	Small molecular drug
DMKAX76	PC	44456299
DMKAX76	MW	979.2
DMKAX76	FM	C48H78N14O8
DMKAX76	IC	InChI=1S/C48H78N14O8/c1-6-29(2)39(45(70)58-33(40(50)65)16-10-11-23-49)62-42(67)35(18-13-25-56-47(53)54)59-43(68)37(27-31-19-21-32(63)22-20-31)61-44(69)36(26-30-14-8-7-9-15-30)60-41(66)34(17-12-24-55-46(51)52)57-38(64)28-48(3,4)5/h7-9,14-15,19-22,29,33-37,39,63H,6,10-13,16-18,23-28,49H2,1-5H3,(H2,50,65)(H,57,64)(H,58,70)(H,59,68)(H,60,66)(H,61,69)(H,62,67)(H4,51,52,55)(H4,53,54,56)/t29-,33-,34-,35-,36-,37-,39-/m0/s1
DMKAX76	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CC(C)(C)C
DMKAX76	IK	MBLODLLZWHUJED-INYUMPDKSA-N
DMKAX76	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(3,3-dimethylbutanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMKAX76	DE	Discovery agent

DMLNVH8	ID	DMLNVH8
DMLNVH8	DN	TC-2559
DMLNVH8	HS	Investigative
DMLNVH8	SN	TC2559
DMLNVH8	DT	Small molecular drug
DMLNVH8	PC	9823180
DMLNVH8	MW	206.28
DMLNVH8	FM	C12H18N2O
DMLNVH8	IC	InChI=1S/C12H18N2O/c1-3-15-12-8-11(9-14-10-12)6-4-5-7-13-2/h4,6,8-10,13H,3,5,7H2,1-2H3/b6-4+
DMLNVH8	CS	CCOC1=CN=CC(=C1)/C=C/CCNC
DMLNVH8	IK	HFZDMKMXPGRKCK-GQCTYLIASA-N
DMLNVH8	IU	(E)-4-(5-ethoxypyridin-3-yl)-N-methylbut-3-en-1-amine
DMLNVH8	CB	CHEBI:93177
DMLNVH8	DE	Discovery agent

DM06DI1	ID	DM06DI1
DM06DI1	DN	TCI15
DM06DI1	HS	Investigative
DM06DI1	SN	TCI15; GTPL6582; (2S)-2-{[(4S)-3-(benzenesulfonyl)-5,5-dimethyl-1,3-thiazolidin-4-yl]formamido}-3-[(benzylcarbamoyl)amino]propanoic acid
DM06DI1	DT	Small molecular drug
DM06DI1	PC	73755228
DM06DI1	MW	520.6
DM06DI1	FM	C23H28N4O6S2
DM06DI1	IC	InChI=1S/C23H28N4O6S2/c1-23(2)19(27(15-34-23)35(32,33)17-11-7-4-8-12-17)20(28)26-18(21(29)30)14-25-22(31)24-13-16-9-5-3-6-10-16/h3-12,18-19H,13-15H2,1-2H3,(H,26,28)(H,29,30)(H2,24,25,31)/t18-,19-/m0/s1
DM06DI1	CS	CC1([C@@H](N(CS1)S(=O)(=O)C2=CC=CC=C2)C(=O)N[C@@H](CNC(=O)NCC3=CC=CC=C3)C(=O)O)C
DM06DI1	IK	XKLHCUGVLCGKKX-OALUTQOASA-N
DM06DI1	IU	(2S)-2-[[(4S)-3-(benzenesulfonyl)-5,5-dimethyl-1,3-thiazolidine-4-carbonyl]amino]-3-(benzylcarbamoylamino)propanoic acid
DM06DI1	DE	Discovery agent

DMMT2GP	ID	DMMT2GP
DMMT2GP	DN	TCN-201
DMMT2GP	HS	Investigative
DMMT2GP	SN	QCR-22
DMMT2GP	DT	Small molecular drug
DMMT2GP	PC	4787937
DMMT2GP	MW	461.9
DMMT2GP	FM	C21H17ClFN3O4S
DMMT2GP	IC	InChI=1S/C21H17ClFN3O4S/c22-18-12-17(10-11-19(18)23)31(29,30)24-13-14-6-8-16(9-7-14)21(28)26-25-20(27)15-4-2-1-3-5-15/h1-12,24H,13H2,(H,25,27)(H,26,28)
DMMT2GP	CS	C1=CC=C(C=C1)C(=O)NNC(=O)C2=CC=C(C=C2)CNS(=O)(=O)C3=CC(=C(C=C3)F)Cl
DMMT2GP	IK	FYIBXBFDXNPBSF-UHFFFAOYSA-N
DMMT2GP	IU	N-[[4-(benzamidocarbamoyl)phenyl]methyl]-3-chloro-4-fluorobenzenesulfonamide
DMMT2GP	CA	CAS 852918-02-6
DMMT2GP	DE	Discovery agent

DMTF4VI	ID	DMTF4VI
DMTF4VI	DN	TCPA
DMTF4VI	HS	Investigative
DMTF4VI	SN	N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine
DMTF4VI	DT	Small molecular drug
DMTF4VI	PC	10391170
DMTF4VI	DE	Discovery agent

DMKVF5Q	ID	DMKVF5Q
DMKVF5Q	DN	TCPOBOP
DMKVF5Q	HS	Investigative
DMKVF5Q	SN	tcpobop; 76150-91-9; 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene; 1,4-BDPOB; CCRIS 3521; 2,2'-[1,4-phenylenebis(oxy)]bis(3,5-dichloropyridine); 1,4-Bis(2-(3,5-dichloropyridyloxy))benzene; 3,5-DICHLORO-2-{4-[(3,5-DICHLOROPYRIDIN-2-YL)OXY]PHENOXY}PYRIDINE; MLS000532100; 2,2'-[benzene-1,4-diylbis(oxy)]bis(3,5-dichloropyridine); 1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene; 1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene; Pyridine,2,2'-[1,4-phenylenebis(oxy)]bis[3,5-dichloro-
DMKVF5Q	DT	Small molecular drug
DMKVF5Q	PC	5382
DMKVF5Q	MW	402.1
DMKVF5Q	FM	C16H8Cl4N2O2
DMKVF5Q	IC	InChI=1S/C16H8Cl4N2O2/c17-9-5-13(19)15(21-7-9)23-11-1-2-12(4-3-11)24-16-14(20)6-10(18)8-22-16/h1-8H
DMKVF5Q	CS	C1=CC(=CC=C1OC2=C(C=C(C=N2)Cl)Cl)OC3=C(C=C(C=N3)Cl)Cl
DMKVF5Q	IK	BAFKRPOFIYPKBQ-UHFFFAOYSA-N
DMKVF5Q	IU	3,5-dichloro-2-[4-(3,5-dichloropyridin-2-yl)oxyphenoxy]pyridine
DMKVF5Q	CA	CAS 76150-91-9
DMKVF5Q	DE	Discovery agent

DMOLJRH	ID	DMOLJRH
DMOLJRH	DN	TCS 2510
DMOLJRH	HS	Investigative
DMOLJRH	SN	TCS-2510
DMOLJRH	DT	Small molecular drug
DMOLJRH	PC	9864831
DMOLJRH	MW	383.5
DMOLJRH	FM	C21H29N5O2
DMOLJRH	IC	InChI=1S/C21H29N5O2/c27-19(16-17-8-4-3-5-9-17)13-11-18-12-14-21(28)26(18)15-7-2-1-6-10-20-22-24-25-23-20/h3-5,8-9,11,13,18-19,27H,1-2,6-7,10,12,14-16H2,(H,22,23,24,25)/b13-11+/t18-,19+/m0/s1
DMOLJRH	CS	C1CC(=O)N([C@H]1/C=C/[C@H](CC2=CC=CC=C2)O)CCCCCCC3=NNN=N3
DMOLJRH	IK	JWYPJSNXPZTEHL-VJKINUSGSA-N
DMOLJRH	IU	(5R)-5-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-1-[6-(2H-tetrazol-5-yl)hexyl]pyrrolidin-2-one
DMOLJRH	CA	CAS 346673-06-1
DMOLJRH	DE	Discovery agent

DMMUFSQ	ID	DMMUFSQ
DMMUFSQ	DN	TCS 5861528
DMMUFSQ	HS	Investigative
DMMUFSQ	SN	TCS 5861528; 332117-28-9; chembridge-5861528; TCS5861528; CHEMBL1086339; N-(4-butan-2-ylphenyl)-2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetamide; CheMbridge 5861528; AC1MFLDN; Oprea1_547219; Oprea1_106027; GTPL6276; SCHEMBL10113882; CTK8E7524; DTXSID60386817; MolPort-001-509-243; N-[4-[(2R)-butan-2-yl]phenyl]-2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetamide; BCP16176; EX-A2273; STK138446; BDBM50318464; AKOS017008161; AKOS000677516; MCULE-9341057356; NCGC00285960-01; NCGC00285960-02; KB-76039; BC600780; BAS 01129942; HY-15065; C-235
DMMUFSQ	DT	Small molecular drug
DMMUFSQ	PC	2873523
DMMUFSQ	MW	369.4
DMMUFSQ	FM	C19H23N5O3
DMMUFSQ	IC	InChI=1S/C19H23N5O3/c1-5-12(2)13-6-8-14(9-7-13)21-15(25)10-24-11-20-17-16(24)18(26)23(4)19(27)22(17)3/h6-9,11-12H,5,10H2,1-4H3,(H,21,25)
DMMUFSQ	CS	CCC(C)C1=CC=C(C=C1)NC(=O)CN2C=NC3=C2C(=O)N(C(=O)N3C)C
DMMUFSQ	IK	ZUTUWJYMCADJHD-UHFFFAOYSA-N
DMMUFSQ	IU	N-(4-butan-2-ylphenyl)-2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetamide
DMMUFSQ	CA	CAS 332117-28-9
DMMUFSQ	DE	Discovery agent

DMBVYQR	ID	DMBVYQR
DMBVYQR	DN	TCS2314
DMBVYQR	HS	Investigative
DMBVYQR	SN	TCS-2314; TCS 2314
DMBVYQR	DT	Small molecular drug
DMBVYQR	PC	11226207
DMBVYQR	MW	522.6
DMBVYQR	FM	C28H34N4O6
DMBVYQR	IC	InChI=1S/C28H34N4O6/c1-19-4-2-3-5-23(19)30-28(37)29-22-8-6-20(7-9-22)16-25(33)32-14-15-38-18-24(32)27(36)31-12-10-21(11-13-31)17-26(34)35/h2-9,21,24H,10-18H2,1H3,(H,34,35)(H2,29,30,37)/t24-/m0/s1
DMBVYQR	CS	CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N3CCOC[C@H]3C(=O)N4CCC(CC4)CC(=O)O
DMBVYQR	IK	ITXAAOWFOURIHK-DEOSSOPVSA-N
DMBVYQR	IU	2-[1-[(3S)-4-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]morpholine-3-carbonyl]piperidin-4-yl]acetic acid
DMBVYQR	DE	Discovery agent

DMH6UN8	ID	DMH6UN8
DMH6UN8	DN	TCS-359
DMH6UN8	HS	Investigative
DMH6UN8	SN	TCS 359
DMH6UN8	DT	Small molecular drug
DMH6UN8	PC	1048845
DMH6UN8	MW	360.4
DMH6UN8	FM	C18H20N2O4S
DMH6UN8	IC	InChI=1S/C18H20N2O4S/c1-23-12-8-7-10(9-13(12)24-2)17(22)20-18-15(16(19)21)11-5-3-4-6-14(11)25-18/h7-9H,3-6H2,1-2H3,(H2,19,21)(H,20,22)
DMH6UN8	CS	COC1=C(C=C(C=C1)C(=O)NC2=C(C3=C(S2)CCCC3)C(=O)N)OC
DMH6UN8	IK	FSPQCTGGIANIJZ-UHFFFAOYSA-N
DMH6UN8	IU	2-[(3,4-dimethoxybenzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide
DMH6UN8	CA	CAS 301305-73-7
DMH6UN8	CB	CHEBI:93427
DMH6UN8	DE	Discovery agent

DML8RTO	ID	DML8RTO
DML8RTO	DN	TCS-OX2-29
DML8RTO	HS	Investigative
DML8RTO	SN	compound 29 [PMID: 14643355]; TCS OX2 29; KB-11822
DML8RTO	DT	Small molecular drug
DML8RTO	PC	10408514
DML8RTO	MW	397.5
DML8RTO	FM	C23H31N3O3
DML8RTO	IC	InChI=1S/C23H31N3O3/c1-23(2,3)21(25-14-16-6-9-24-10-7-16)22(27)26-11-8-17-12-19(28-4)20(29-5)13-18(17)15-26/h6-7,9-10,12-13,21,25H,8,11,14-15H2,1-5H3/t21-/m1/s1
DML8RTO	CS	CC(C)(C)[C@@H](C(=O)N1CCC2=CC(=C(C=C2C1)OC)OC)NCC3=CC=NC=C3
DML8RTO	IK	COFVZFLCAOUMJT-OAQYLSRUSA-N
DML8RTO	IU	(2S)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3,3-dimethyl-2-(pyridin-4-ylmethylamino)butan-1-one
DML8RTO	CA	CAS 372523-75-6
DML8RTO	DE	Discovery agent

DMQ7VDM	ID	DMQ7VDM
DMQ7VDM	DN	TDI-0033
DMQ7VDM	HS	Investigative
DMQ7VDM	SN	Gene therapy program (NGF receptor agonist); TDI-0034; TDI-0035; TDI-0036; TDI-0038; TDI-0041; Gene therapy program (NGF receptor agonist), ALS Therapy Development Foundation
DMQ7VDM	CP	ALS Therapy Development Foundation Inc
DMQ7VDM	DE	Motor neurone disease

DMSI9QM	ID	DMSI9QM
DMSI9QM	DN	TDI-0059
DMSI9QM	HS	Investigative
DMSI9QM	CP	ALS Therapy Development Foundation Inc
DMSI9QM	DE	Motor neurone disease

DMXHWAY	ID	DMXHWAY
DMXHWAY	DN	TDI-0060
DMXHWAY	HS	Investigative
DMXHWAY	CP	ALS Therapy Development Foundation Inc
DMXHWAY	DE	Motor neurone disease

DM5HEIR	ID	DM5HEIR
DM5HEIR	DN	TDI-0079
DM5HEIR	HS	Investigative
DM5HEIR	SN	Superoxide dismutase-1 (SOD1) gene modulator (amyotrophic lateral sclerosis), ALS Therapy Development Foundation
DM5HEIR	CP	ALS Therapy Development Foundation Inc
DM5HEIR	DE	Motor neurone disease

DMWGDXF	ID	DMWGDXF
DMWGDXF	DN	TDI-0107
DMWGDXF	HS	Investigative
DMWGDXF	SN	Gene therapy (SOD1 gene inhibitor), ALS Therapy Development Foundation
DMWGDXF	CP	ALS Therapy Development Foundation Inc
DMWGDXF	DE	Motor neurone disease

DMRU8WT	ID	DMRU8WT
DMRU8WT	DN	TDT-044
DMRU8WT	HS	Investigative
DMRU8WT	SN	IDEA-044; Corticosteroid (Transfersome, chloracetophenone dermatitis/psoriasis), Celtic; Corticosteroid (Transfersome, chloracetophenone dermatitis/psoriasis), Idea
DMRU8WT	CP	Idea AG
DMRU8WT	DE	Dermatological disease

DM0HJD4	ID	DM0HJD4
DM0HJD4	DN	tedisamil
DM0HJD4	HS	Investigative
DM0HJD4	SN	KC-8857
DM0HJD4	DT	Small molecular drug
DM0HJD4	PC	65825
DM0HJD4	MW	288.5
DM0HJD4	FM	C19H32N2
DM0HJD4	IC	InChI=1S/C19H32N2/c1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16/h15-18H,1-14H2
DM0HJD4	CS	C1CCC2(C1)C3CN(CC2CN(C3)CC4CC4)CC5CC5
DM0HJD4	IK	CTIRHWCPXYGDGF-UHFFFAOYSA-N
DM0HJD4	IU	3,7-bis(cyclopropylmethyl)spiro[3,7-diazabicyclo[3.3.1]nonane-9,1'-cyclopentane]
DM0HJD4	CA	CAS 90961-53-8
DM0HJD4	CB	CHEBI:134747
DM0HJD4	DE	Discovery agent

DMRPFCS	ID	DMRPFCS
DMRPFCS	DN	TEFLUDAZINE
DMRPFCS	HS	Investigative
DMRPFCS	SN	Tefludazine; Tefludazine [INN]; Tefludazinum [Latin]; Tefludazina [Spanish]; Lu 18-012; CHEMBL95636; trans-4-[3-(p-fluorophenyl)-6-(trifluoromethyl)-1-indanyl]-1-piperazineethanol; 2-(4-(trans-3-(4-Fluorphenyl-6-trifluormethyl-1-indanyl)-1-piperazinyl)ethanol; 80273-79-6; Tefludazinum; Tefludazina; trans-4-(3-(p-Fluorophenyl)-6-(trifluoromethyl)-1-indanyl)-1-piperazineethanol; 1-Piperazineethanol, 4-(3-(4-fluorophenyl)-2,3-dihydro-6-(trifluoromethyl)-1H-indel-1-yl)-, trans-(+-)-; (1R,3S)-Tefludazine; AC1L2FT8; AC1Q4JR0
DMRPFCS	DT	Small molecular drug
DMRPFCS	PC	71240
DMRPFCS	MW	408.4
DMRPFCS	FM	C22H24F4N2O
DMRPFCS	IC	InChI=1S/C22H24F4N2O/c23-17-4-1-15(2-5-17)19-14-21(28-9-7-27(8-10-28)11-12-29)20-13-16(22(24,25)26)3-6-18(19)20/h1-6,13,19,21,29H,7-12,14H2/t19-,21+/m0/s1
DMRPFCS	CS	C1CN(CCN1CCO)[C@@H]2C[C@H](C3=C2C=C(C=C3)C(F)(F)F)C4=CC=C(C=C4)F
DMRPFCS	IK	JSBWGXQXCRYYTG-PZJWPPBQSA-N
DMRPFCS	IU	2-[4-[(1R,3S)-3-(4-fluorophenyl)-6-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]piperazin-1-yl]ethanol
DMRPFCS	CA	CAS 80273-79-6
DMRPFCS	DE	Discovery agent

DMBNYJW	ID	DMBNYJW
DMBNYJW	DN	TEI-8362
DMBNYJW	HS	Investigative
DMBNYJW	DT	Small molecular drug
DMBNYJW	PC	9894678
DMBNYJW	MW	540.5
DMBNYJW	FM	C26H28N4O9
DMBNYJW	IC	InChI=1S/C26H28N4O9/c1-15-12-17(13-19-22(15)24(36)39-25(29-19)27-11-5-8-20(31)32)28-23(35)18(9-10-21(33)34)30-26(37)38-14-16-6-3-2-4-7-16/h2-4,6-7,12-13,18H,5,8-11,14H2,1H3,(H,27,29)(H,28,35)(H,30,37)(H,31,32)(H,33,34)/t18-/m0/s1
DMBNYJW	CS	CC1=CC(=CC2=C1C(=O)OC(=N2)NCCCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)OCC3=CC=CC=C3
DMBNYJW	IK	JLDVWXAMNKPCJI-SFHVURJKSA-N
DMBNYJW	IU	(4S)-5-[[2-(3-carboxypropylamino)-5-methyl-4-oxo-3,1-benzoxazin-7-yl]amino]-5-oxo-4-(phenylmethoxycarbonylamino)pentanoic acid
DMBNYJW	DE	Discovery agent

DMGQLYR	ID	DMGQLYR
DMGQLYR	DN	TEI-9063
DMGQLYR	HS	Investigative
DMGQLYR	SN	TEI 9063
DMGQLYR	DT	Small molecular drug
DMGQLYR	PC	73755022
DMGQLYR	MW	378.5
DMGQLYR	FM	C23H38O4
DMGQLYR	IC	InChI=1S/C23H38O4/c1-3-4-7-16(2)12-19(24)10-11-20-21-14-17(8-5-6-9-23(26)27)13-18(21)15-22(20)25/h10-11,13,16,18-22,24-25H,3-9,12,14-15H2,1-2H3,(H,26,27)/b11-10+/t16-,18?,19+,20+,21?,22+/m0/s1
DMGQLYR	CS	CCCC[C@H](C)C[C@@H](/C=C/[C@H]1[C@@H](CC2C1CC(=C2)CCCCC(=O)O)O)O
DMGQLYR	IK	BPNIWRLPDMCZPC-ASUUCAAFSA-N
DMGQLYR	IU	5-[(5R,6R)-5-hydroxy-6-[(E,3S,5S)-3-hydroxy-5-methylnon-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoic acid
DMGQLYR	DE	Discovery agent

DMLDAR4	ID	DMLDAR4
DMLDAR4	DN	TEI-9647
DMLDAR4	HS	Investigative
DMLDAR4	SN	TEI9647
DMLDAR4	DT	Small molecular drug
DMLDAR4	PC	9547692
DMLDAR4	MW	426.6
DMLDAR4	FM	C27H38O4
DMLDAR4	IC	InChI=1S/C27H38O4/c1-16(12-22-13-17(2)26(30)31-22)23-9-10-24-19(6-5-11-27(23,24)4)7-8-20-14-21(28)15-25(29)18(20)3/h7-8,16,21-25,28-29H,2-3,5-6,9-15H2,1,4H3/b19-7+,20-8-/t16-,21-,22+,23-,24+,25+,27-/m1/s1
DMLDAR4	CS	C[C@H](C[C@H]1CC(=C)C(=O)O1)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DMLDAR4	IK	SAODSJHDCZTVAT-CZADFQNYSA-N
DMLDAR4	IU	(5S)-5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]propyl]-3-methylideneoxolan-2-one
DMLDAR4	CA	CAS 173388-20-0
DMLDAR4	CB	CHEBI:156177
DMLDAR4	DE	Discovery agent

DMSMLRB	ID	DMSMLRB
DMSMLRB	DN	Teijin-lead_cmp_5
DMSMLRB	HS	Investigative
DMSMLRB	SN	CHEMBL337246; Teijin-lead_cmp_5; GTPL785; SCHEMBL9912177; BDBM50133112; (R)-N-(2-(1-(2,4-dimethylbenzyl)pyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide; N-{[(R)-1-(2,4-Dimethyl-benzyl)-pyrrolidin-3-ylcarbamoyl]-methyl}-3-trifluoromethyl-benzamide
DMSMLRB	DT	Small molecular drug
DMSMLRB	PC	44353447
DMSMLRB	MW	433.5
DMSMLRB	FM	C23H26F3N3O2
DMSMLRB	IC	InChI=1S/C23H26F3N3O2/c1-15-6-7-18(16(2)10-15)13-29-9-8-20(14-29)28-21(30)12-27-22(31)17-4-3-5-19(11-17)23(24,25)26/h3-7,10-11,20H,8-9,12-14H2,1-2H3,(H,27,31)(H,28,30)/t20-/m1/s1
DMSMLRB	CS	CC1=CC(=C(C=C1)CN2CC[C@H](C2)NC(=O)CNC(=O)C3=CC(=CC=C3)C(F)(F)F)C
DMSMLRB	IK	MRRGKBBDXLJMCV-HXUWFJFHSA-N
DMSMLRB	IU	N-[2-[[(3R)-1-[(2,4-dimethylphenyl)methyl]pyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide
DMSMLRB	DE	Discovery agent

DM60HU5	ID	DM60HU5
DM60HU5	DN	Tellimagrandin II
DM60HU5	HS	Investigative
DM60HU5	SN	CHEMBL510512
DM60HU5	DT	Small molecular drug
DM60HU5	PC	151590
DM60HU5	MW	938.7
DM60HU5	FM	C41H30O26
DM60HU5	IC	InChI=1S/C41H30O26/c42-15-1-10(2-16(43)26(15)50)36(57)65-34-33-23(9-62-39(60)13-7-21(48)29(53)31(55)24(13)25-14(40(61)64-33)8-22(49)30(54)32(25)56)63-41(67-38(59)12-5-19(46)28(52)20(47)6-12)35(34)66-37(58)11-3-17(44)27(51)18(45)4-11/h1-8,23,33-35,41-56H,9H2
DM60HU5	CS	C1C2C(C(C(C(O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)OC(=O)C6=CC(=C(C(=C6C7=C(C(=C(C=C7C(=O)O1)O)O)O)O)O)O
DM60HU5	IK	JCGHAEBIBSEQAD-UHFFFAOYSA-N
DM60HU5	IU	[3,4,5,21,22,23-hexahydroxy-8,18-dioxo-12,13-bis[(3,4,5-trihydroxybenzoyl)oxy]-9,14,17-trioxatetracyclo[17.4.0.02,7.010,15]tricosa-1(23),2,4,6,19,21-hexaen-11-yl] 3,4,5-trihydroxybenzoate
DM60HU5	CA	CAS 81571-72-4
DM60HU5	DE	Discovery agent

DMGD0HT	ID	DMGD0HT
DMGD0HT	DN	Tellurium
DMGD0HT	HS	Investigative
DMGD0HT	SN	Tellurium; 13494-80-9; Telloy; Tellur; Aurum paradoxum; Tellurium element; Tellur [Polish]; Metallum problematum; Tellurium, metallic; Tellurium, elemental; Tellurium Atom; UNII-NQA0O090ZJ; Tellurium and compounds; HSDB 2532; NCI-C60117; EINECS 236-813-4; NQA0O090ZJ; teluro; Tellurium, 99+%, (trace metal basis), powder; Tellurium, 99.999%, (trace metal basis), powder; tellure; Tellurium compounds, n.o.s.; Tellurium, 99.8%, (trace metal basis), powder, -200 mesh; Tellurium powder; Tellurium compounds; ACMC-1BQVR; 52Te; EC 236-813-4
DMGD0HT	DT	Small molecular drug
DMGD0HT	PC	6327182
DMGD0HT	MW	127.6
DMGD0HT	FM	Te
DMGD0HT	IC	InChI=1S/Te
DMGD0HT	CS	[Te]
DMGD0HT	IK	PORWMNRCUJJQNO-UHFFFAOYSA-N
DMGD0HT	IU	tellurium
DMGD0HT	CA	CAS 13494-80-9
DMGD0HT	CB	CHEBI:30452
DMGD0HT	DE	Discovery agent

DM6EIVM	ID	DM6EIVM
DM6EIVM	DN	Telomestatin
DM6EIVM	HS	Investigative
DM6EIVM	SN	YVSQVYZBDXIXCC-UHFFFAOYSA-N; AC1L9EVW; CHEMBL443683; CHEBI:29689; Telomestatin (TMS); gm95; SureCN10025441; SCHEMBL10025441; CHEBI:601758; BDBM213233; DCL000983
DM6EIVM	CP	Geron Corp
DM6EIVM	DT	Small molecular drug
DM6EIVM	PC	443590
DM6EIVM	MW	582.5
DM6EIVM	FM	C26H14N8O7S
DM6EIVM	IC	InChI=1S/C26H14N8O7S/c1-9-17-24-30-14(6-39-24)21-28-12(4-37-21)19-27-11(3-35-19)20-29-13(5-36-20)22-31-15(7-38-22)26-32-16(8-42-26)23-33-18(10(2)40-23)25(34-17)41-9/h3-7,16H,8H2,1-2H3
DM6EIVM	CS	CC1=C2C3=NC(=C(O3)C)C4=NC(=CO4)C5=NC(=CO5)C6=NC(=CO6)C7=NC(=CO7)C8=NC(=CO8)C9=NC(CS9)C(=N2)O1
DM6EIVM	IK	YVSQVYZBDXIXCC-UHFFFAOYSA-N
DM6EIVM	IU	4,8-dimethyl-3,7,11,15,19,23,27-heptaoxa-31-thia-33,34,35,36,37,38,39,40-octazanonacyclo[28.2.1.12,5.16,9.110,13.114,17.118,21.122,25.126,29]tetraconta-2(40),4,6(39),8,10(38),12,14(37),16,18(36),20,22(35),24,26(34),28,30(33)-pentadecaene
DM6EIVM	CA	CAS 265114-54-3
DM6EIVM	CB	CHEBI:29689
DM6EIVM	DE	Multiple myeloma

DMT4NWX	ID	DMT4NWX
DMT4NWX	DN	TELUDIPINE HYDROCHLORIDE
DMT4NWX	HS	Investigative
DMT4NWX	SN	Former USAN >; GR-53992B; GX-1296B; Taludipine hydrochloride < former INNM; Teludipine hydrochloride< Rec INNM; Rac-4-[o-[(E)-2-Carboxyvinyl]phenyl]-2-[(dimethylamino)methyl]-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid 4-tert-butyl diethyl ester monohydrochloride; Rac-2-(Dimethylaminomethyl)-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1(E)-propenyl]phenyl]-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester monohydrochloride
DMT4NWX	DT	Small molecular drug
DMT4NWX	PC	9893335
DMT4NWX	MW	535.1
DMT4NWX	FM	C28H39ClN2O6
DMT4NWX	IC	InChI=1S/C28H38N2O6.ClH/c1-9-34-26(32)23-18(3)29-21(17-30(7)8)25(27(33)35-10-2)24(23)20-14-12-11-13-19(20)15-16-22(31)36-28(4,5)6;/h11-16,24,29H,9-10,17H2,1-8H3;1H/b16-15+;
DMT4NWX	CS	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)CN(C)C)C.Cl
DMT4NWX	IK	VMZCXIGDNRMWGI-GEEYTBSJSA-N
DMT4NWX	IU	diethyl 2-[(dimethylamino)methyl]-6-methyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride
DMT4NWX	CA	CAS 108700-03-4
DMT4NWX	DE	Hypertension

DML53GP	ID	DML53GP
DML53GP	DN	Tendamistat
DML53GP	HS	Investigative
DML53GP	SN	Tendamistat (12-26); 135307-06-1; Glycine, L-valyl-L-threonyl-L-leucyl-L-tyrosyl-L-glutaminyl-L-seryl-L-tryptophyl-L-arginyl-L-tyrosyl-L-seryl-L-glutaminyl-L-alanyl-L-alpha-aspartyl-L-asparaginyl-
DML53GP	DT	Small molecular drug
DML53GP	PC	16131388
DML53GP	MW	1787.9
DML53GP	FM	C79H114N22O26
DML53GP	IC	InChI=1S/C79H114N22O26/c1-36(2)26-50(98-78(127)64(39(6)104)101-77(126)63(83)37(3)4)70(119)95-51(27-40-13-17-43(105)18-14-40)71(120)91-49(22-24-59(81)108)69(118)99-57(35-103)76(125)96-53(29-42-32-87-46-11-8-7-10-45(42)46)73(122)90-47(12-9-25-86-79(84)85)68(117)94-52(28-41-15-19-44(106)20-16-41)72(121)100-56(34-102)75(124)92-48(21-23-58(80)107)67(116)89-38(5)65(114)93-55(31-61(110)111)74(123)97-54(30-60(82)109)66(115)88-33-62(112)113/h7-8,10-11,13-20,32,36-39,47-57,63-64,87,102-106H,9,12,21-31,33-35,83H2,1-6H3,(H2,80,107)(H2,81,108)(H2,82,109)(H,88,115)(H,89,116)(H,90,122)(H,91,120)(H,92,124)(H,93,114)(H,94,117)(H,95,119)(H,96,125)(H,97,123)(H,98,127)(H,99,118)(H,100,121)(H,101,126)(H,110,111)(H,112,113)(H4,84,85,86)/t38-,39+,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,63-,64-/m0/s1
DML53GP	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N)O
DML53GP	IK	QFVHHVFVZLFPHM-UCEBDAAVSA-N
DML53GP	IU	(3S)-3-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]-4-[[(2S)-4-amino-1-(carboxymethylamino)-1,4-dioxobutan-2-yl]amino]-4-oxobutanoic acid
DML53GP	CA	CAS 135307-06-1
DML53GP	DE	Discovery agent

DM1S209	ID	DM1S209
DM1S209	DN	TENELLONE A
DM1S209	HS	Investigative
DM1S209	SN	Tenellone A; CHEMBL457810
DM1S209	DT	Small molecular drug
DM1S209	PC	44583991
DM1S209	MW	442.5
DM1S209	FM	C25H30O7
DM1S209	IC	InChI=1S/C25H30O7/c1-14(2)6-7-16-8-9-19(27)18(12-26)22(16)24(30)17-10-15(3)11-20(23(17)29)32-13-21(28)25(4,5)31/h6,8-12,21,27-29,31H,7,13H2,1-5H3
DM1S209	CS	CC1=CC(=C(C(=C1)OCC(C(C)(C)O)O)O)C(=O)C2=C(C=CC(=C2C=O)O)CC=C(C)C
DM1S209	IK	AXMCRMUBMNEKLN-UHFFFAOYSA-N
DM1S209	IU	2-[3-(2,3-dihydroxy-3-methylbutoxy)-2-hydroxy-5-methylbenzoyl]-6-hydroxy-3-(3-methylbut-2-enyl)benzaldehyde
DM1S209	DE	Discovery agent

DM9ZVJ7	ID	DM9ZVJ7
DM9ZVJ7	DN	TENELLONE B
DM9ZVJ7	HS	Investigative
DM9ZVJ7	SN	Tenellone B; CHEMBL515063
DM9ZVJ7	DT	Small molecular drug
DM9ZVJ7	PC	44583992
DM9ZVJ7	MW	424.5
DM9ZVJ7	FM	C25H28O6
DM9ZVJ7	IC	InChI=1S/C25H28O6/c1-14(2)6-7-16-8-9-19(27)18(12-26)22(16)23(28)17-10-15(3)11-20-24(17)31-21(13-30-20)25(4,5)29/h6,8-12,21,27,29H,7,13H2,1-5H3
DM9ZVJ7	CS	CC1=CC(=C2C(=C1)OCC(O2)C(C)(C)O)C(=O)C3=C(C=CC(=C3C=O)O)CC=C(C)C
DM9ZVJ7	IK	DYNXQZCWMXLZCW-UHFFFAOYSA-N
DM9ZVJ7	IU	6-hydroxy-2-[3-(2-hydroxypropan-2-yl)-7-methyl-2,3-dihydro-1,4-benzodioxine-5-carbonyl]-3-(3-methylbut-2-enyl)benzaldehyde
DM9ZVJ7	DE	Discovery agent

DMRM1QV	ID	DMRM1QV
DMRM1QV	DN	Tenocyclidine
DMRM1QV	HS	Investigative
DMRM1QV	SN	TENOCYCLIDINE; thienyl cyclohexylpiperidine; Tenocyclidinum; Tenociclidina; 1-(1-(2-Thienyl)cyclohexyl)piperidine; Tenocyclidine [INN]; 21500-98-1; UNII-8BQ45Q6VCL; Tenocyclidinum [INN-Latin]; 1-[1-(2-thienyl)cyclohexyl]piperidine; 8BQ45Q6VCL; Tenociclidina [INN-Spanish]; CHEMBL279676; Piperidine, 1-(1-(2-thienyl)cyclohexyl)-; DEA No. 7470; Thiophene analog of phencyclidine; CHEBI:64610; 2-Thienyl analog of phencyclidine; JUZZEWSCNBCFRL-UHFFFAOYSA-N; BRN 1246605; 1-(1-[2-Thienyl]cyclohexyl)piperidine; NCGC00160467-01
DMRM1QV	DT	Small molecular drug
DMRM1QV	PC	62751
DMRM1QV	MW	249.4
DMRM1QV	FM	C15H23NS
DMRM1QV	IC	InChI=1S/C15H23NS/c1-3-9-15(10-4-1,14-8-7-13-17-14)16-11-5-2-6-12-16/h7-8,13H,1-6,9-12H2
DMRM1QV	CS	C1CCC(CC1)(C2=CC=CS2)N3CCCCC3
DMRM1QV	IK	JUZZEWSCNBCFRL-UHFFFAOYSA-N
DMRM1QV	IU	1-(1-thiophen-2-ylcyclohexyl)piperidine
DMRM1QV	CA	CAS 21500-98-1
DMRM1QV	CB	CHEBI:64610
DMRM1QV	DE	Discovery agent

DMMLSZ4	ID	DMMLSZ4
DMMLSZ4	DN	TENOSAL
DMMLSZ4	HS	Investigative
DMMLSZ4	SN	MR-Y134; Tenosal; 2-(2-Thienoyloxy)benzoic acid; 2-Thiophenecarboxylic acid salicyl ester
DMMLSZ4	DT	Small molecular drug
DMMLSZ4	PC	65838
DMMLSZ4	MW	248.26
DMMLSZ4	FM	C12H8O4S
DMMLSZ4	IC	InChI=1S/C12H8O4S/c13-11(14)8-4-1-2-5-9(8)16-12(15)10-6-3-7-17-10/h1-7H,(H,13,14)
DMMLSZ4	CS	C1=CC=C(C(=C1)C(=O)O)OC(=O)C2=CC=CS2
DMMLSZ4	IK	JCUTZUSPPNNLDC-UHFFFAOYSA-N
DMMLSZ4	IU	2-(thiophene-2-carbonyloxy)benzoic acid
DMMLSZ4	CA	CAS 95232-68-1
DMMLSZ4	DE	Rheumatoid arthritis

DMROS5K	ID	DMROS5K
DMROS5K	DN	TEPA (possesses cytotoxic activity)
DMROS5K	HS	Investigative
DMROS5K	SN	TEPA; Triethylenephosphoramide; Aphoxide; 545-55-1; Tris(1-aziridinyl)phosphine oxide; TAPO; Imperon fixer T; Triaziridinophosphine oxide; Triethylenephosphorotriamide; Triaziridinylphosphine oxide; Triethylene phophoramide; Triethylene phosphoramide; Phosphoric acid triethylene imide; Tris(1-aziridine)phosphine oxide; Triethylenephosphoric triamide; ENT 24915; Tris(aziridinyl)phosphine oxide; Tri-1-aziridinylphosphine oxide; Triethylenepyrophosphoramide; Tri(aziridin-1-yl)phosphine oxide; TEPA (VAN)
DMROS5K	DT	Small molecular drug
DMROS5K	PC	11016
DMROS5K	MW	173.15
DMROS5K	FM	C6H12N3OP
DMROS5K	IC	InChI=1S/C6H12N3OP/c10-11(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2
DMROS5K	CS	C1CN1P(=O)(N2CC2)N3CC3
DMROS5K	IK	FYAMXEPQQLNQDM-UHFFFAOYSA-N
DMROS5K	IU	1-[bis(aziridin-1-yl)phosphoryl]aziridine
DMROS5K	CA	CAS 545-55-1
DMROS5K	CB	CHEBI:82546
DMROS5K	DE	Discovery agent

DMPX7QS	ID	DMPX7QS
DMPX7QS	DN	TERRITREM B
DMPX7QS	HS	Investigative
DMPX7QS	SN	Territrem B; Territreme B; CHEMBL24686; 70407-20-4; 4H,11H-Naphtho(2,1-b)pyrano(3,4-e)pyran-1,11(5H)-dione, 4a,6,6a,12,12a,12b-hexahydro-4a,12a-dihydroxy-4,4,6a,12b-tetramethyl-9-(3,4,5-trimethoxyphenyl)-, (4aR,6aR,12aS,12bS)-; 4H,11H-Naphtho(2,1-b)pyrano(3,4-e)pyran-1,11(5H)-dione, 4a,6,6a,12,12a,12b-hexahydro-4a,12a-dihydroxy-4,4,6a,12b-tetramethyl-9-(3,4,5-trimethoxyphenyl)-, (4aR-(4a-alpha,6a-beta,12a-alpha,12b-beta))-; TERRITREMB(RG); 4m0f; AC1L3FVE
DMPX7QS	DT	Small molecular drug
DMPX7QS	PC	114734
DMPX7QS	MW	526.6
DMPX7QS	FM	C29H34O9
DMPX7QS	IC	InChI=1S/C29H34O9/c1-25(2)9-8-22(30)27(4)28(25,32)11-10-26(3)29(27,33)15-17-19(38-26)14-18(37-24(17)31)16-12-20(34-5)23(36-7)21(13-16)35-6/h8-9,12-14,32-33H,10-11,15H2,1-7H3/t26-,27+,28-,29-/m1/s1
DMPX7QS	CS	C[C@@]12CC[C@@]3([C@@]([C@]1(CC4=C(O2)C=C(OC4=O)C5=CC(=C(C(=C5)OC)OC)OC)O)(C(=O)C=CC3(C)C)C)O
DMPX7QS	IK	PBXNNDFKPQPJBB-VJLHXPKFSA-N
DMPX7QS	IU	(1S,2S,7R,10R)-1,7-dihydroxy-2,6,6,10-tetramethyl-14-(3,4,5-trimethoxyphenyl)-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-4,12(17),13-triene-3,16-dione
DMPX7QS	CA	CAS 70407-20-4
DMPX7QS	DE	Discovery agent

DM8LI1K	ID	DM8LI1K
DM8LI1K	DN	Tert-butyl (2S)-1-cyanopyrrolidine-2-carboxylate
DM8LI1K	HS	Investigative
DM8LI1K	SN	CHEMBL363610; tert-butyl (2S)-1-cyanopyrrolidine-2-carboxylate
DM8LI1K	DT	Small molecular drug
DM8LI1K	PC	44398742
DM8LI1K	MW	196.25
DM8LI1K	FM	C10H16N2O2
DM8LI1K	IC	InChI=1S/C10H16N2O2/c1-10(2,3)14-9(13)8-5-4-6-12(8)7-11/h8H,4-6H2,1-3H3
DM8LI1K	CS	CC(C)(C)OC(=O)C1CCCN1C#N
DM8LI1K	IK	BFXLWVDZNFZGJO-UHFFFAOYSA-N
DM8LI1K	IU	tert-butyl 1-cyanopyrrolidine-2-carboxylate
DM8LI1K	DE	Discovery agent

DMW2X5V	ID	DMW2X5V
DMW2X5V	DN	Tert-butyl 10H-phenothiazine-10-carboxylate
DMW2X5V	HS	Investigative
DMW2X5V	SN	CHEMBL444507; tert-butyl 10H-phenothiazine-10-carboxylate
DMW2X5V	DT	Small molecular drug
DMW2X5V	PC	44568319
DMW2X5V	MW	299.4
DMW2X5V	FM	C17H17NO2S
DMW2X5V	IC	InChI=1S/C17H17NO2S/c1-17(2,3)20-16(19)18-12-8-4-6-10-14(12)21-15-11-7-5-9-13(15)18/h4-11H,1-3H3
DMW2X5V	CS	CC(C)(C)OC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMW2X5V	IK	ZJCHCPTZZNZOLM-UHFFFAOYSA-N
DMW2X5V	IU	tert-butyl phenothiazine-10-carboxylate
DMW2X5V	DE	Discovery agent

DMWQFY6	ID	DMWQFY6
DMWQFY6	DN	Tert-Butyl 2-(2-oxohexadecanamido)acetate
DMWQFY6	HS	Investigative
DMWQFY6	SN	CHEMBL487220
DMWQFY6	DT	Small molecular drug
DMWQFY6	PC	16118319
DMWQFY6	MW	383.6
DMWQFY6	FM	C22H41NO4
DMWQFY6	IC	InChI=1S/C22H41NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-19(24)21(26)23-18-20(25)27-22(2,3)4/h5-18H2,1-4H3,(H,23,26)
DMWQFY6	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCC(=O)OC(C)(C)C
DMWQFY6	IK	DQZNHZUPVFCAKC-UHFFFAOYSA-N
DMWQFY6	IU	tert-butyl 2-(2-oxohexadecanoylamino)acetate
DMWQFY6	DE	Discovery agent

DMZG5I7	ID	DMZG5I7
DMZG5I7	DN	TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE
DMZG5I7	HS	Investigative
DMZG5I7	SN	TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE; AC1NRDAA; DB08594; tert-butyl N-[cyano(methyl)amino]carbamate
DMZG5I7	DT	Small molecular drug
DMZG5I7	PC	5289428
DMZG5I7	MW	171.2
DMZG5I7	FM	C7H13N3O2
DMZG5I7	IC	InChI=1S/C7H13N3O2/c1-7(2,3)12-6(11)9-10(4)5-8/h1-4H3,(H,9,11)
DMZG5I7	CS	CC(C)(C)OC(=O)NN(C)C#N
DMZG5I7	IK	SWELYBAPJHIOQT-UHFFFAOYSA-N
DMZG5I7	IU	tert-butyl N-[cyano(methyl)amino]carbamate
DMZG5I7	DE	Discovery agent

DMNU9WV	ID	DMNU9WV
DMNU9WV	DN	Tert-Butyl 3-(2-oxo-8-phenyloctanamido)propanoate
DMNU9WV	HS	Investigative
DMNU9WV	SN	CHEMBL488918
DMNU9WV	DT	Small molecular drug
DMNU9WV	PC	44563077
DMNU9WV	MW	361.5
DMNU9WV	FM	C21H31NO4
DMNU9WV	IC	InChI=1S/C21H31NO4/c1-21(2,3)26-19(24)15-16-22-20(25)18(23)14-10-5-4-7-11-17-12-8-6-9-13-17/h6,8-9,12-13H,4-5,7,10-11,14-16H2,1-3H3,(H,22,25)
DMNU9WV	CS	CC(C)(C)OC(=O)CCNC(=O)C(=O)CCCCCCC1=CC=CC=C1
DMNU9WV	IK	BTVXYIHQAQOQLT-UHFFFAOYSA-N
DMNU9WV	IU	tert-butyl 3-[(2-oxo-8-phenyloctanoyl)amino]propanoate
DMNU9WV	DE	Discovery agent

DMYQXPB	ID	DMYQXPB
DMYQXPB	DN	Tert-Butyl 3-(2-oxohexadecanamido)propanoate
DMYQXPB	HS	Investigative
DMYQXPB	SN	CHEMBL488922
DMYQXPB	DT	Small molecular drug
DMYQXPB	PC	16118318
DMYQXPB	MW	397.6
DMYQXPB	FM	C23H43NO4
DMYQXPB	IC	InChI=1S/C23H43NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-20(25)22(27)24-19-18-21(26)28-23(2,3)4/h5-19H2,1-4H3,(H,24,27)
DMYQXPB	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCCC(=O)OC(C)(C)C
DMYQXPB	IK	WSQKSMQAQMMUAU-UHFFFAOYSA-N
DMYQXPB	IU	tert-butyl 3-(2-oxohexadecanoylamino)propanoate
DMYQXPB	DE	Discovery agent

DM1ALTR	ID	DM1ALTR
DM1ALTR	DN	Tert-Butyl 5-(2-oxohexadecanamido)pentanoate
DM1ALTR	HS	Investigative
DM1ALTR	SN	CHEMBL529887
DM1ALTR	DT	Small molecular drug
DM1ALTR	PC	16118459
DM1ALTR	MW	425.6
DM1ALTR	FM	C25H47NO4
DM1ALTR	IC	InChI=1S/C25H47NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-19-22(27)24(29)26-21-18-17-20-23(28)30-25(2,3)4/h5-21H2,1-4H3,(H,26,29)
DM1ALTR	CS	CCCCCCCCCCCCCCC(=O)C(=O)NCCCCC(=O)OC(C)(C)C
DM1ALTR	IK	RXNGZFCASMDLGP-UHFFFAOYSA-N
DM1ALTR	IU	tert-butyl 5-(2-oxohexadecanoylamino)pentanoate
DM1ALTR	DE	Discovery agent

DM42WFH	ID	DM42WFH
DM42WFH	DN	Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate
DM42WFH	HS	Investigative
DM42WFH	SN	TERT-BUTYL(1S)-1-CYCLOHEXYL-2-OXOETHYLCARBAMATE; CHEMBL92567; tert-butyl N-[(1S)-1-cyclohexyl-2-oxoethyl]carbamate; 1q6k; AC1L9LIG; SCHEMBL8259018; BDBM50137816; DB04523; (S)-tert-butyl (1-cyclohexyl-2-oxoethyl)carbamate; tert-butyl [(1S)-1-cyclohexyl-2-oxoethyl]carbamate; ((S)-1-Cyclohexyl-2-oxo-ethyl)-carbamic acid tert-butyl ester
DM42WFH	DT	Small molecular drug
DM42WFH	PC	448022
DM42WFH	MW	241.33
DM42WFH	FM	C13H23NO3
DM42WFH	IC	InChI=1S/C13H23NO3/c1-13(2,3)17-12(16)14-11(9-15)10-7-5-4-6-8-10/h9-11H,4-8H2,1-3H3,(H,14,16)/t11-/m1/s1
DM42WFH	CS	CC(C)(C)OC(=O)N[C@H](C=O)C1CCCCC1
DM42WFH	IK	BDSGOSWEKUGHOV-LLVKDONJSA-N
DM42WFH	IU	tert-butyl N-[(1S)-1-cyclohexyl-2-oxoethyl]carbamate
DM42WFH	DE	Discovery agent

DMQKOUZ	ID	DMQKOUZ
DMQKOUZ	DN	Tert-butyloxy carbonyl-D-Phe-pro-Arg-H
DMQKOUZ	HS	Investigative
DMQKOUZ	SN	CHEMBL104472; LY-178207; tert-butyloxy carbonyl-D-Phe-pro-Arg-H; AC1OCEOE; SCHEMBL7371676; BDBM50046360; BDBM50029511; {1-Benzyl-2-[2-(1-formyl-4-guanidino-butylcarbamoyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-carbamic acid tert-butyl ester; {(R)-1-Benzyl-2-[(S)-2-((S)-1-formyl-4-guanidino-butylcarbamoyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-carbamic acid tert-butyl ester; tert-butyl N-[(2R)-1-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamate
DMQKOUZ	DT	Small molecular drug
DMQKOUZ	PC	6917805
DMQKOUZ	MW	502.6
DMQKOUZ	FM	C25H38N6O5
DMQKOUZ	IC	InChI=1S/C25H38N6O5/c1-25(2,3)36-24(35)30-19(15-17-9-5-4-6-10-17)22(34)31-14-8-12-20(31)21(33)29-18(16-32)11-7-13-28-23(26)27/h4-6,9-10,16,18-20H,7-8,11-15H2,1-3H3,(H,29,33)(H,30,35)(H4,26,27,28)/t18-,19+,20-/m0/s1
DMQKOUZ	CS	CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O
DMQKOUZ	IK	JDXUSWQJCGTBLN-ZCNNSNEGSA-N
DMQKOUZ	IU	tert-butyl N-[(2R)-1-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamate
DMQKOUZ	DE	Discovery agent

DMQDVNZ	ID	DMQDVNZ
DMQDVNZ	DN	Testetrol
DMQDVNZ	HS	Investigative
DMQDVNZ	SN	Testetrol (oral, hypogonadism); T2 (oral, hypogonadism), Pantarhei; Testetrol (oral, hypogonadism), Pantarhei; Testosterone agonist (oral, hypogonadism), Pantarhei
DMQDVNZ	CP	Pantarhei Bioscience BV
DMQDVNZ	DE	Hypogonadism

DMKLIXZ	ID	DMKLIXZ
DMKLIXZ	DN	Tetrabromocinnamic acid
DMKLIXZ	HS	Investigative
DMKLIXZ	SN	TBCA; tetrabromocinnamic acid
DMKLIXZ	DT	Small molecular drug
DMKLIXZ	PC	16760346
DMKLIXZ	MW	463.74
DMKLIXZ	FM	C9H4Br4O2
DMKLIXZ	IC	InChI=1S/C9H4Br4O2/c10-5-3-4(1-2-6(14)15)7(11)9(13)8(5)12/h1-3H,(H,14,15)/b2-1+
DMKLIXZ	CS	C1=C(C(=C(C(=C1Br)Br)Br)Br)/C=C/C(=O)O
DMKLIXZ	IK	SVJQCVOKYJWUBC-OWOJBTEDSA-N
DMKLIXZ	IU	(E)-3-(2,3,4,5-tetrabromophenyl)prop-2-enoic acid
DMKLIXZ	CA	CAS 934358-00-6
DMKLIXZ	DE	Discovery agent

DMX5MAU	ID	DMX5MAU
DMX5MAU	DN	Tetrabutylammonium Ion
DMX5MAU	HS	Investigative
DMX5MAU	SN	Tetrabutylammonium; TETRABUTYLAMMONIUM ION; N,N,N-tributylbutan-1-aminium; UNII-CBU2X6BBJR; 1-Butanaminium, N,N,N-tributyl-; 10549-76-5; CBU2X6BBJR; CHEMBL1236196; CHEBI:45825; tetrabutylamine; tetrabutylazanium; tetrabutyammonium; tetrabutyl ammonium; tetrabutyl-ammonium; tetra-butylammonium; tetra-butyl ammonium; tetra butyl-ammonium; tetra-n-butylammonium; tetra-n-butyl ammonium; tetra(n-butyl)ammonium; TETRABUTHYLAMMONIUM; Bu4N+; tetra (n-butyl) ammonium; SCHEMBL22384; 429-41-4 (fluoride); 311-28-4 (iodide); 993-22-6 (azide)
DMX5MAU	DT	Small molecular drug
DMX5MAU	PC	16028
DMX5MAU	MW	242.46
DMX5MAU	FM	C16H36N+
DMX5MAU	IC	InChI=1S/C16H36N/c1-5-9-13-17(14-10-6-2,15-11-7-3)16-12-8-4/h5-16H2,1-4H3/q+1
DMX5MAU	CS	CCCC[N+](CCCC)(CCCC)CCCC
DMX5MAU	IK	DZLFLBLQUQXARW-UHFFFAOYSA-N
DMX5MAU	IU	tetrabutylazanium
DMX5MAU	CA	CAS 10549-76-5
DMX5MAU	CB	CHEBI:45825
DMX5MAU	DE	Discovery agent

DMK8P61	ID	DMK8P61
DMK8P61	DN	Tetradecane
DMK8P61	HS	Investigative
DMK8P61	SN	629-59-4; N-TETRADECANE; Alkanes, C14-16; Tridecane, methyl-; CCRIS 715; Tetradecane, 99%; UNII-03LY784Y58; HSDB 5728; EINECS 211-096-0; NSC 72440; C14H30; BRN 1733859; AI3-04240; CHEBI:41253; BGHCVCJVXZWKCC-UHFFFAOYSA-N; MFCD00008986; 03LY784Y58; 90622-46-1; Tetradecane, analytical standard; Alkanes, C14-30; Tetradekan; n-Teradecane; Tetradecane olefine; EINECS 292-448-0; Paraffinic hydrocarbons (C14-C30); Tetradecane, &gt; AC1L1ZHO; DSSTox_CID_7267; EC 211-096-0; DSSTox_RID_78378; ACMC-1B07Q; DSSTox_GSID_27267
DMK8P61	DT	Small molecular drug
DMK8P61	PC	12389
DMK8P61	MW	198.39
DMK8P61	FM	C14H30
DMK8P61	IC	InChI=1S/C14H30/c1-3-5-7-9-11-13-14-12-10-8-6-4-2/h3-14H2,1-2H3
DMK8P61	CS	CCCCCCCCCCCCCC
DMK8P61	IK	BGHCVCJVXZWKCC-UHFFFAOYSA-N
DMK8P61	IU	tetradecane
DMK8P61	CA	CAS 629-59-4
DMK8P61	CB	CHEBI:41253
DMK8P61	DE	Discovery agent

DMABITD	ID	DMABITD
DMABITD	DN	Tetradecyl-phosphonic acid
DMABITD	HS	Investigative
DMABITD	SN	Tetradecylphosphonic acid; 4671-75-4; Phosphonic acid, tetradecyl-; 1-Tetradecanephosphonic acid; Tetradecanephosphonic acid; Tetradecyl phosphonic acid; n-Tetradecylphosphonic acid; 1-Tetradecylphosphonic Acid; Phosphonic acid, P-tetradecyl-; EINECS 225-118-1; BRN 1784271; CHEMBL190999; P-tetradecyl-Phosphonic acid; C14H31O3P; tetradecylphosphonate; AC1L2V5G; 14; SCHEMBL19906; 4-04-00-03566 (Beilstein Handbook Reference); Tetradecylphosphonic acid, 97%; DTXSID7063550; CTK3J7960
DMABITD	DT	Small molecular drug
DMABITD	PC	78401
DMABITD	MW	278.37
DMABITD	FM	C14H31O3P
DMABITD	IC	InChI=1S/C14H31O3P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18(15,16)17/h2-14H2,1H3,(H2,15,16,17)
DMABITD	CS	CCCCCCCCCCCCCCP(=O)(O)O
DMABITD	IK	BVQJQTMSTANITJ-UHFFFAOYSA-N
DMABITD	IU	tetradecylphosphonic acid
DMABITD	CA	CAS 4671-75-4
DMABITD	DE	Discovery agent

DMH4AGL	ID	DMH4AGL
DMH4AGL	DN	Tetraethylene Glycol
DMH4AGL	HS	Investigative
DMH4AGL	SN	TETRAETHYLENE GLYCOL; 112-60-7; Tetraglycol; 2,2'-((Oxybis(ethane-2,1-diyl))bis(oxy))diethanol; HI-Dry; Carbitol, diethyl; 3,6,9-Trioxaundecane-1,11-diol; Ethanol, 2,2'-[oxybis(2,1-ethanediyloxy)]bis-; Tetra(ethylene glycol); NSC 1262; 2,2'-[oxybis(ethane-2,1-diyloxy)]diethanol; Bis[2-(2-hydroxyethoxy)ethyl] ether; HSDB 843; Ethanol, 2,2'-(oxybis(ethyleneoxy))di-; 3,6,9-Trioxaundecan-1,11-diol; EINECS 203-989-9; BRN 1634320; PEG-4; AI3-01838; 2,2'-[oxybis(2,1-ethanediyloxy)]diethanol; CHEBI:44920; UWHCKJMYHZGTIT-UHFFFAOYSA-N
DMH4AGL	DT	Small molecular drug
DMH4AGL	PC	8200
DMH4AGL	MW	194.23
DMH4AGL	FM	C8H18O5
DMH4AGL	IC	InChI=1S/C8H18O5/c9-1-3-11-5-7-13-8-6-12-4-2-10/h9-10H,1-8H2
DMH4AGL	CS	C(COCCOCCOCCO)O
DMH4AGL	IK	UWHCKJMYHZGTIT-UHFFFAOYSA-N
DMH4AGL	IU	2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethanol
DMH4AGL	CA	CAS 112-60-7
DMH4AGL	CB	CHEBI:44920
DMH4AGL	DE	Discovery agent

DMDWUCX	ID	DMDWUCX
DMDWUCX	DN	Tetragastrin
DMDWUCX	HS	Investigative
DMDWUCX	SN	Trp-Met-Asp-Phe-NH2; CCK 30-33; 3-[[2-[[2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-oxobutanoic acid; Gastrin tetrapeptide amide; 35144-91-3; Cholecystokinin Fragment 30-33 Amide; AC1N7MCV; GTPL861; GASTRIN I, Fragment 14-17; CHOLECYSTOKININ,Fragment 30-33; L000162; 3-{2-[2-amino-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido}-3-[(1-carbamoyl-2-phenylethyl)carbamoyl]propanoic acid
DMDWUCX	DT	Small molecular drug
DMDWUCX	PC	446569
DMDWUCX	MW	596.7
DMDWUCX	FM	C29H36N6O6S
DMDWUCX	IC	InChI=1S/C29H36N6O6S/c1-42-12-11-22(33-27(39)20(30)14-18-16-32-21-10-6-5-9-19(18)21)28(40)35-24(15-25(36)37)29(41)34-23(26(31)38)13-17-7-3-2-4-8-17/h2-10,16,20,22-24,32H,11-15,30H2,1H3,(H2,31,38)(H,33,39)(H,34,41)(H,35,40)(H,36,37)/t20-,22-,23-,24-/m0/s1
DMDWUCX	CS	CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N
DMDWUCX	IK	RGYLYUZOGHTBRF-BIHRQFPBSA-N
DMDWUCX	IU	(3S)-3-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMDWUCX	CA	CAS 1947-37-1
DMDWUCX	CB	CHEBI:32210
DMDWUCX	DE	Discovery agent

DM2QKOU	ID	DM2QKOU
DM2QKOU	DN	Tetrahydroaldosterone
DM2QKOU	HS	Investigative
DM2QKOU	SN	A-Tetrahydro-aldosterone; A-pregnan-20-one; 3Alpha,5beta-tetrahydroaldosterone; Tetrahydro Aldosterone; tetrahydroaldosterone; (3; (3)rihydroxy-5; 13489-75-3; 3,18,21-Trihydroxy-11,18-epoxypregnan-20-one; 3alpha,5alpha-Tetrahydroaldosterone; 3alpha,5beta-Tetrahydroaldosterone; A)-11,18-Epoxy-3,18,21-trihydroxypregnan-20-one; A,11; A,18,21-; A,18-Epoxy-3; A,5; AC1L3U1S; DTXSID10928807
DM2QKOU	PC	122135
DM2QKOU	MW	364.5
DM2QKOU	FM	C21H32O5
DM2QKOU	IC	JDEYOKPHRJVBQO-FPXQBPFJSA-N
DM2QKOU	CS	CC12CCC(CC1CCC3C2C4CC5(C3CCC5C(=O)CO)C(O4)O)O
DM2QKOU	IK	1S/C21H32O5/c1-20-7-6-12(23)8-11(20)2-3-13-14-4-5-15(16(24)10-22)21(14)9-17(18(13)20)26-19(21)25/h11-15,17-19,22-23,25H,2-10H2,1H3/t11-,12-,13+,14+,15-,17+,18-,19?,20+,21-/m1/s1
DM2QKOU	IU	1-[(1R,2S,5S,6S,9R,11R,14S,15S,16S)-11,18-dihydroxy-14-methyl-17-oxapentacyclo[14.2.1.01,5.06,15.09,14]nonadecan-2-yl]-2-hydroxyethanone
DM2QKOU	CA	13489-75-3
DM2QKOU	DE	Discovery agent

DMNURE0	ID	DMNURE0
DMNURE0	DN	TETRAHYDROBENXIMIDAZOLE
DMNURE0	HS	Investigative
DMNURE0	SN	CHEMBL282765; TETRAHYDROBENXIMIDAZOLE; SCHEMBL10625034; KDEKNYKHIZTSLE-UHFFFAOYSA-N; BDBM50016839; 4,5-dihydro-6-[4-(4,5,6,7-tetrahydro-1H-benzimidazol-1-yl)phenyl]-5-methyl-3(2H)-pyridazinone
DMNURE0	DT	Small molecular drug
DMNURE0	PC	14032753
DMNURE0	MW	308.4
DMNURE0	FM	C18H20N4O
DMNURE0	IC	InChI=1S/C18H20N4O/c1-12-10-17(23)20-21-18(12)13-6-8-14(9-7-13)22-11-19-15-4-2-3-5-16(15)22/h6-9,11-12H,2-5,10H2,1H3,(H,20,23)
DMNURE0	CS	CC1CC(=O)NN=C1C2=CC=C(C=C2)N3C=NC4=C3CCCC4
DMNURE0	IK	KDEKNYKHIZTSLE-UHFFFAOYSA-N
DMNURE0	IU	4-methyl-3-[4-(4,5,6,7-tetrahydrobenzimidazol-1-yl)phenyl]-4,5-dihydro-1H-pyridazin-6-one
DMNURE0	DE	Discovery agent

DMDY1MZ	ID	DMDY1MZ
DMDY1MZ	DN	tetrahydrocannabivarin
DMDY1MZ	HS	Investigative
DMDY1MZ	SN	Delta9-tetrahydrocannabivarin
DMDY1MZ	DT	Small molecular drug
DMDY1MZ	PC	93147
DMDY1MZ	MW	286.4
DMDY1MZ	FM	C19H26O2
DMDY1MZ	IC	InChI=1S/C19H26O2/c1-5-6-13-10-16(20)18-14-9-12(2)7-8-15(14)19(3,4)21-17(18)11-13/h9-11,14-15,20H,5-8H2,1-4H3/t14-,15-/m1/s1
DMDY1MZ	CS	CCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
DMDY1MZ	IK	ZROLHBHDLIHEMS-HUUCEWRRSA-N
DMDY1MZ	IU	(6aR,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
DMDY1MZ	CA	CAS 31262-37-0
DMDY1MZ	DE	Discovery agent

DMF8M0W	ID	DMF8M0W
DMF8M0W	DN	tetrahydrodeoxycorticosterone
DMF8M0W	HS	Investigative
DMF8M0W	SN	Tetrahydrodeoxycorticosterone; 567-02-2; 3alpha,21-Dihydroxy-5alpha-pregnan-20-one; Allotetrahydrodeoxycorticosterone; 5alpha-THDOC; 5-alpha-THDOC; 5alpha-Pregnane-3alpha,21-diol-20-one; CHEMBL1256760; 21-Hydroxyallopregnanolone; CHEBI:34461; 3a,21-dihydroxy-5a-pregnan-20-one; 2-hydroxy-1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone; THDOC; A-Pregnane-3; A,21-diol-20-one; A,21-Dihydroxy-5; A-pregnan-20-one; EINECS 209-
DMF8M0W	DT	Small molecular drug
DMF8M0W	PC	101771
DMF8M0W	MW	334.5
DMF8M0W	FM	C21H34O3
DMF8M0W	IC	InChI=1S/C21H34O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h13-18,22-23H,3-12H2,1-2H3/t13-,14+,15-,16-,17-,18+,20-,21-/m0/s1
DMF8M0W	CS	C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C(=O)CO)C)O
DMF8M0W	IK	CYKYBWRSLLXBOW-GDYGHMJCSA-N
DMF8M0W	IU	2-hydroxy-1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DMF8M0W	CA	CAS 567-02-2
DMF8M0W	CB	CHEBI:34461
DMF8M0W	DE	Discovery agent

DMNH3ST	ID	DMNH3ST
DMNH3ST	DN	Tetrahydroimidazo[4,5,1-jk]-[1,4]benzodiazepin-2(1H)-one
DMNH3ST	HS	Investigative
DMNH3ST	DE	Discovery agent

DMMU6WQ	ID	DMMU6WQ
DMMU6WQ	DN	Tetrahydro-pyrimidin-2-ylideneamine
DMMU6WQ	HS	Investigative
DMMU6WQ	SN	1,4,5,6-tetrahydropyrimidin-2-amine; 41078-65-3; 1,4,5,6-tetrahydro-2-Pyrimidinamine; 1,4,5,6-tetrahydro-pyrimidin-2-ylamine; 2-amino-1,4,5,6-tetrahydropyrimidine; CHEMBL158626; Tetrahydro-pyrimidin-2-ylideneamine; Tetrahydropyrimidinimin; 2(1h)-pyrimidinimine; AC1MMKIU; tetrahydro-2(1H)-pyrimidinimine; DTXSID90391075; PEHDFSFYZKSKGH-UHFFFAOYSA-N; ZINC1728936; hexahydro-pyrimidin-2-ylidene-amine; BDBM50049248; AKOS024618750; AKOS011559938; MCULE-1407334516; 2-amino-3,4,5,6-tetrahydropyrimidine
DMMU6WQ	DT	Small molecular drug
DMMU6WQ	PC	3287412
DMMU6WQ	MW	99.13
DMMU6WQ	FM	C4H9N3
DMMU6WQ	IC	InChI=1S/C4H9N3/c5-4-6-2-1-3-7-4/h1-3H2,(H3,5,6,7)
DMMU6WQ	CS	C1CNC(=NC1)N
DMMU6WQ	IK	PEHDFSFYZKSKGH-UHFFFAOYSA-N
DMMU6WQ	IU	1,4,5,6-tetrahydropyrimidin-2-amine
DMMU6WQ	CA	CAS 41078-65-3
DMMU6WQ	DE	Discovery agent

DMWRZJX	ID	DMWRZJX
DMWRZJX	DN	TETRAHYDROQUINOLINE A
DMWRZJX	HS	Investigative
DMWRZJX	SN	CHEMBL490868; TETRAHYDROQUINOLINE A; Tetrahydroquinline A
DMWRZJX	DT	Small molecular drug
DMWRZJX	PC	44591717
DMWRZJX	MW	565.4
DMWRZJX	FM	C26H20F9NO3
DMWRZJX	IC	InChI=1S/C26H20F9NO3/c27-24(28,29)23(37)14-36-21(16-5-2-7-18(13-16)39-26(33,34)35)11-10-20-19(8-3-9-22(20)36)15-4-1-6-17(12-15)38-25(30,31)32/h1-9,12-13,21,23,37H,10-11,14H2/t21-,23+/m1/s1
DMWRZJX	CS	C1CC2=C(C=CC=C2N([C@H]1C3=CC(=CC=C3)OC(F)(F)F)C[C@@H](C(F)(F)F)O)C4=CC(=CC=C4)OC(F)(F)F
DMWRZJX	IK	CMOJRCASVGGDKQ-GGAORHGYSA-N
DMWRZJX	IU	(2S)-3-[(2R)-2,5-bis[3-(trifluoromethoxy)phenyl]-3,4-dihydro-2H-quinolin-1-yl]-1,1,1-trifluoropropan-2-ol
DMWRZJX	DE	Discovery agent

DMHT61V	ID	DMHT61V
DMHT61V	DN	TETRAHYDROQUINOLINE B
DMHT61V	HS	Investigative
DMHT61V	SN	Tetrahydroquinoline B; CHEMBL491072
DMHT61V	DT	Small molecular drug
DMHT61V	PC	44591718
DMHT61V	MW	565.4
DMHT61V	FM	C26H20F9NO3
DMHT61V	IC	InChI=1S/C26H20F9NO3/c27-24(28,29)23(37)14-36-21(16-5-2-7-18(13-16)39-26(33,34)35)11-10-20-19(8-3-9-22(20)36)15-4-1-6-17(12-15)38-25(30,31)32/h1-9,12-13,21,23,37H,10-11,14H2/t21-,23-/m1/s1
DMHT61V	CS	C1CC2=C(C=CC=C2N([C@H]1C3=CC(=CC=C3)OC(F)(F)F)C[C@H](C(F)(F)F)O)C4=CC(=CC=C4)OC(F)(F)F
DMHT61V	IK	CMOJRCASVGGDKQ-FYYLOGMGSA-N
DMHT61V	IU	(2R)-3-[(2R)-2,5-bis[3-(trifluoromethoxy)phenyl]-3,4-dihydro-2H-quinolin-1-yl]-1,1,1-trifluoropropan-2-ol
DMHT61V	DE	Discovery agent

DMWOBAE	ID	DMWOBAE
DMWOBAE	DN	tetralin_urea analogue (7o)
DMWOBAE	HS	Investigative
DMWOBAE	SN	CHEMBL384701; tetralin_urea analogue (7o); 3-(3-chloro-4-fluorophenyl)-1-(7-cyano-1,2,3,4-tetrahydronaphthalen-2-yl)-1-[3-(4-methylpiperazin-1-yl)propyl]urea; 3-(3-chloro-4-fluorophenyl)-1-(7-cyano-1,2,3,4-tetrahydronaphthalen-2-yl)-1-(3-(4-methylpiperazin-1-yl)propyl)urea; SCHEMBL3990193; GTPL1319; GQGGDNLJDZHJKN-UHFFFAOYSA-N; BDBM50203352
DMWOBAE	DT	Small molecular drug
DMWOBAE	PC	11691555
DMWOBAE	MW	484
DMWOBAE	FM	C26H31ClFN5O
DMWOBAE	IC	InChI=1S/C26H31ClFN5O/c1-31-11-13-32(14-12-31)9-2-10-33(26(34)30-22-6-8-25(28)24(27)17-22)23-7-5-20-4-3-19(18-29)15-21(20)16-23/h3-4,6,8,15,17,23H,2,5,7,9-14,16H2,1H3,(H,30,34)
DMWOBAE	CS	CN1CCN(CC1)CCCN(C2CCC3=C(C2)C=C(C=C3)C#N)C(=O)NC4=CC(=C(C=C4)F)Cl
DMWOBAE	IK	GQGGDNLJDZHJKN-UHFFFAOYSA-N
DMWOBAE	IU	3-(3-chloro-4-fluorophenyl)-1-(7-cyano-1,2,3,4-tetrahydronaphthalen-2-yl)-1-[3-(4-methylpiperazin-1-yl)propyl]urea
DMWOBAE	DE	Discovery agent

DMLEPYN	ID	DMLEPYN
DMLEPYN	DN	Tetramethylammonium Ion
DMLEPYN	HS	Investigative
DMLEPYN	SN	Tetramethylammonium; TETRAMETHYLAMMONIUM ION; tetramethylazanium; 51-92-3; N,N,N-trimethylmethanaminium; UNII-H0W55235FC; Tetramethylammonium octahydrotriborate; EINECS 235-626-5; CHEMBL46486; Methanaminium, N,N,N-trimethyl-, octahydrotriborate(1-); CHEBI:46020; Methanaminium, N,N,N-trimethyl-; H0W55235FC; Tetramethylammonium pentaiodide; Tetramethyl-Ammonium; Ammonium, (pentaiodide); AC1L1MEF; 19269-48-8; bmse000780; 64-20-0 (bromide); 75-59-2 (hydroxide); 75-57-0 (chloride); 75-58-1 (iodide); 12386-10-6; 373-68-2 (fluoride)
DMLEPYN	DT	Small molecular drug
DMLEPYN	PC	6380
DMLEPYN	MW	74.14
DMLEPYN	FM	C4H12N+
DMLEPYN	IC	InChI=1S/C4H12N/c1-5(2,3)4/h1-4H3/q+1
DMLEPYN	CS	C[N+](C)(C)C
DMLEPYN	IK	QEMXHQIAXOOASZ-UHFFFAOYSA-N
DMLEPYN	IU	tetramethylazanium
DMLEPYN	CA	CAS 51-92-3
DMLEPYN	CB	CHEBI:46020
DMLEPYN	DE	Discovery agent

DMW9CH2	ID	DMW9CH2
DMW9CH2	DN	Tetramethylbutylphenol
DMW9CH2	HS	Investigative
DMW9CH2	SN	P-T-Octylphenol; Phenol, p-(tert-octyl)-; p-Octylphenol (VAN); p-Terc.oktylfenol; p-terc.Oktylfenol [Czech]; p-tert-Octylphenol; para-tert-Octylphenol; 4-(1,1,3,3-Tetramethylbutyl)phenol; tert-Octylphenol, flaked; 140-66-9; 4-(1,1,3,3-TETRAMETHYLBUTYL)PHENOL; 4-(2,4,4-trimethylpentan-2-yl)phenol; 4-(TERT-OCTYL)PHENOL; 4-t-Octylphenol; 4-tert-Octylphenol; BRN 0513992; EINECS 205-426-2; HSDB 5411; NSC 5427; Phenol, 4-(1,1,3,3-tetramethylbutyl)-; Phenol, p-(1,1,3,3-tetramethylbutyl)-; IOY9FVU3J3; UNII-IOY9FVU3J3; p-(1,1,3,3-Tetramethylbutyl)phenol
DMW9CH2	PC	8814
DMW9CH2	MW	206.32
DMW9CH2	FM	C14H22O
DMW9CH2	IC	ISAVYTVYFVQUDY-UHFFFAOYSA-N
DMW9CH2	CS	CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O
DMW9CH2	IK	1S/C14H22O/c1-13(2,3)10-14(4,5)11-6-8-12(15)9-7-11/h6-9,15H,10H2,1-5H3
DMW9CH2	IU	4-(2,4,4-trimethylpentan-2-yl)phenol
DMW9CH2	CA	CAS 140-66-9
DMW9CH2	CB	CHEBI:34445
DMW9CH2	DE	Discovery agent

DM8T7CG	ID	DM8T7CG
DM8T7CG	DN	tetronothiodin
DM8T7CG	HS	Investigative
DM8T7CG	SN	Tetronothiodin; CHEMBL3576924; 139643-79-1; GTPL910; BDBM50088529; 3a,4,5,8,9,10,15,15a,18,19,23,23a-Dodecahydro-9,24-dihydroxy-4,17,18-trimethyl-alpha,21,23-trioxo-3H,21H-19a,22-metheno-1H-thieno(3,4-e)(1)benzoxacycloeicosin-3-acetic acid; 2-[(8Z,10E,15E)-13,26-dihydroxy-3,4,18-trimethyl-24,28-dioxo-27-oxa-21-thiatetracyclo[23.2.1.0^{1,6}.0^{19,23}]octacosa-4,8,10,15,25-pentaen-20-yl]-2-oxoacetic acid; 3H,21H-19a,22-Metheno-1H-thieno(3,4-e)(1)benzoxacycloeicosin-3-acetic acid, 3a,4,5,8,9,10,15,15a,18,19,23,23a-do
DM8T7CG	DT	Small molecular drug
DM8T7CG	PC	54695534
DM8T7CG	MW	570.7
DM8T7CG	FM	C31H38O8S
DM8T7CG	IC	InChI=1S/C31H38O8S/c1-17-10-8-9-13-21(32)12-7-5-4-6-11-20-14-18(2)19(3)15-31(20)28(35)24(30(38)39-31)25(33)22-16-40-27(23(17)22)26(34)29(36)37/h4-9,14,17,19-23,27,32,35H,10-13,15-16H2,1-3H3,(H,36,37)/b6-4+,7-5+,9-8+
DM8T7CG	CS	CC1C/C=C/CC(C/C=C/C=C/CC2C=C(C(CC23C(=C(C(=O)C4C1C(SC4)C(=O)C(=O)O)C(=O)O3)O)C)C)O
DM8T7CG	IK	WWHAZVYADWRKPA-SFYXYOTASA-N
DM8T7CG	IU	2-[(8E,10E,15E)-13,28-dihydroxy-3,4,18-trimethyl-24,26-dioxo-27-oxa-21-thiatetracyclo[23.2.1.01,6.019,23]octacosa-4,8,10,15,25(28)-pentaen-20-yl]-2-oxoacetic acid
DM8T7CG	CA	CAS 139643-79-1
DM8T7CG	DE	Discovery agent

DMHBMJZ	ID	DMHBMJZ
DMHBMJZ	DN	Textilinin
DMHBMJZ	HS	Investigative
DMHBMJZ	SN	Q-8008; Fibrinolysis inhibitor (bleeding), QRxPharma; Kunitz type serine protease inhibitor (bleeding), QRxPharma; Plasmin inhibitor (bleeding), QRxPharma
DMHBMJZ	CP	University of Queensland
DMHBMJZ	DE	Bleeding disorder

DMAC8TP	ID	DMAC8TP
DMAC8TP	DN	TFMPP
DMAC8TP	HS	Investigative
DMAC8TP	SN	1-[3-(Trifluoromethyl)phenyl]piperazine; 15532-75-9; 1-(3-(Trifluoromethyl)phenyl)piperazine; 1-(3-Trifluoromethylphenyl)piperazine; N-(3-trifluoromethylphenyl)piperazine; 3-trifluoromethylphenylpiperazine; Legal E [Street Name]; Piperazine, 1-[3-(trifluoromethyl)phenyl]-; UNII-25R3ONU51C; 1-(m-trifluoromethylphenyl)piperazine; 1-(3-Trifluoromethyl-phenyl)-piperazine; EINECS 239-574-4; N-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazine; NSC 128882; N-(alpha,alpha,alpha-Trifluoro-3-tolyl)piperazine;  3-trifluoromethylphenylpiperazine
DMAC8TP	DT	Small molecular drug
DMAC8TP	PC	4296
DMAC8TP	MW	230.23
DMAC8TP	FM	C11H13F3N2
DMAC8TP	IC	InChI=1S/C11H13F3N2/c12-11(13,14)9-2-1-3-10(8-9)16-6-4-15-5-7-16/h1-3,8,15H,4-7H2
DMAC8TP	CS	C1CN(CCN1)C2=CC=CC(=C2)C(F)(F)F
DMAC8TP	IK	KKIMDKMETPPURN-UHFFFAOYSA-N
DMAC8TP	IU	1-[3-(trifluoromethyl)phenyl]piperazine
DMAC8TP	CA	CAS 15532-75-9
DMAC8TP	CB	CHEBI:83536
DMAC8TP	DE	Discovery agent

DMIR3X2	ID	DMIR3X2
DMIR3X2	DN	TG-100435
DMIR3X2	HS	Investigative
DMIR3X2	SN	TG-100435; CHEMBL230686; SCHEMBL4266197; ZINC28702706; BDBM50198782; US8481536, 367; US8481536, 575; ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine); 7-(2,6-dichlorophenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine
DMIR3X2	DT	Small molecular drug
DMIR3X2	PC	11562302
DMIR3X2	MW	494.4
DMIR3X2	FM	C26H25Cl2N5O
DMIR3X2	IC	InChI=1S/C26H25Cl2N5O/c1-17-15-18(24-21(27)5-4-6-22(24)28)16-23-25(17)30-26(32-31-23)29-19-7-9-20(10-8-19)34-14-13-33-11-2-3-12-33/h4-10,15-16H,2-3,11-14H2,1H3,(H,29,30,32)
DMIR3X2	CS	CC1=CC(=CC2=C1N=C(N=N2)NC3=CC=C(C=C3)OCCN4CCCC4)C5=C(C=CC=C5Cl)Cl
DMIR3X2	IK	OTTCBLPTHPBEEX-UHFFFAOYSA-N
DMIR3X2	IU	7-(2,6-dichlorophenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine
DMIR3X2	CA	CAS 867330-68-5
DMIR3X2	DE	Discovery agent

DMSG0TL	ID	DMSG0TL
DMSG0TL	DN	TG-1022
DMSG0TL	HS	Investigative
DMSG0TL	SN	AMP activated protein kinase stimulator (obesity), TG Biotech; AMPK activator (obesity), TG Biotech
DMSG0TL	CP	TG Biotech Inc
DMSG0TL	DE	Obesity

DM5VJQP	ID	DM5VJQP
DM5VJQP	DN	TG-1031
DM5VJQP	HS	Investigative
DM5VJQP	SN	VV-MUC1-IL-2, Transgene; breast cancer vaccine, Transgene; pTG-1031; pox virus-MUC1-IL-2, Transgene; vaccina virus-MUC1-IL-2, Transgene
DM5VJQP	DE	Discovery agent

DMRFAVG	ID	DMRFAVG
DMRFAVG	DN	TG-2001
DMRFAVG	HS	Investigative
DMRFAVG	SN	Vero-IL-2, Transgene; gene therapy (interleukin-2, melanoma/mesothelioma), Transgene
DMRFAVG	DE	Discovery agent

DMHTEMP	ID	DMHTEMP
DMHTEMP	DN	TG-3003
DMHTEMP	HS	Investigative
DMHTEMP	SN	Anti-colony stimulating factor 1 receptor (CSF1-R/CD115) humanized mAb (cancer), Transgene
DMHTEMP	CP	Transgene SA
DMHTEMP	DT	Antibody
DMHTEMP	DE	Solid tumour/cancer

DM8RSDE	ID	DM8RSDE
DM8RSDE	DN	TG-3030
DM8RSDE	HS	Investigative
DM8RSDE	SN	GABA B receptor agonist (smoking cessation), TG Biotech
DM8RSDE	CP	TG Biotech Inc
DM8RSDE	DE	Nicotine dependence

DM862TI	ID	DM862TI
DM862TI	DN	TG4-155
DM862TI	HS	Investigative
DM862TI	SN	TG4-155; 1164462-05-8; (E)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide; CHEMBL1368005; (E)-N-[2-(2-methylindol-1-yl)ethyl]-3-(3,4,5-trimethoxyphenyl)prop-2-enamide; YBHUXHFZLMFETJ-MDZDMXLPSA-N; AC1NYOOW; SMR000237431; MLS000724641; GTPL5818; SCHEMBL14333686; AOB1790; SYN5120; MolPort-007-612-333; HMS2242E03; ZINC4801017; BCP25837; BDBM50016949; TG4155; AKOS001816787; TG4 155; AS-16484; TG 4-155; (2E)-N-[2-(2-methyl-1H-indol-1-yl)ethyl]-3-(3,4,5-trimethoxyphenyl)acrylamide
DM862TI	DT	Small molecular drug
DM862TI	PC	5886965
DM862TI	MW	394.5
DM862TI	FM	C23H26N2O4
DM862TI	IC	InChI=1S/C23H26N2O4/c1-16-13-18-7-5-6-8-19(18)25(16)12-11-24-22(26)10-9-17-14-20(27-2)23(29-4)21(15-17)28-3/h5-10,13-15H,11-12H2,1-4H3,(H,24,26)/b10-9+
DM862TI	CS	CC1=CC2=CC=CC=C2N1CCNC(=O)/C=C/C3=CC(=C(C(=C3)OC)OC)OC
DM862TI	IK	YBHUXHFZLMFETJ-MDZDMXLPSA-N
DM862TI	IU	(E)-N-[2-(2-methylindol-1-yl)ethyl]-3-(3,4,5-trimethoxyphenyl)prop-2-enamide
DM862TI	DE	Discovery agent

DM0OHL3	ID	DM0OHL3
DM0OHL3	DN	TG7-171
DM0OHL3	HS	Investigative
DM0OHL3	SN	TG7-171; GTPL8546
DM0OHL3	DT	Small molecular drug
DM0OHL3	PC	91827368
DM0OHL3	MW	377.5
DM0OHL3	FM	C24H31N3O
DM0OHL3	IC	InChI=1S/C24H31N3O/c1-4-26(5-2)22-13-11-20(12-14-22)18-24(28)25-15-8-16-27-19(3)17-21-9-6-7-10-23(21)27/h6-7,9-14,17H,4-5,8,15-16,18H2,1-3H3,(H,25,28)
DM0OHL3	CS	CCN(CC)C1=CC=C(C=C1)CC(=O)NCCCN2C(=CC3=CC=CC=C32)C
DM0OHL3	IK	NBHMEDLJHJCMEZ-UHFFFAOYSA-N
DM0OHL3	IU	2-[4-(diethylamino)phenyl]-N-[3-(2-methylindol-1-yl)propyl]acetamide
DM0OHL3	DE	Discovery agent

DMBFX7S	ID	DMBFX7S
DMBFX7S	DN	TgBSSL
DMBFX7S	HS	Investigative
DMBFX7S	CP	PPL Therapeutics
DMBFX7S	DE	Pancreatic malfunction

DMOX3AH	ID	DMOX3AH
DMOX3AH	DN	TGF alpha
DMOX3AH	HS	Investigative
DMOX3AH	SN	TGF alpha (neurological damage)
DMOX3AH	CP	NeuroRepair Inc
DMOX3AH	DE	Cerebrovascular ischaemia

DMUP34S	ID	DMUP34S
DMUP34S	DN	TGF-beta Shield
DMUP34S	HS	Investigative
DMUP34S	SN	TGF-beta antagonist (fibrosis/cancer), Resverlogix
DMUP34S	CP	Resverlogix Corp
DMUP34S	DE	Solid tumour/cancer

DM1BVW3	ID	DM1BVW3
DM1BVW3	DN	TGSC01AA(4)
DM1BVW3	HS	Investigative
DM1BVW3	SN	Benzodiazepine receptor binder (anxiety), Fabre Kramer Pharmaceuticals; TGSC01AA series (anxiety), Fabre Kramer Pharmaceuticals
DM1BVW3	CP	Fabre Kramer Pharmaceuticals Inc
DM1BVW3	DE	Anxiety disorder

DMM0LRE	ID	DMM0LRE
DMM0LRE	DN	TGX-221
DMM0LRE	HS	Investigative
DMM0LRE	SN	TGX 221
DMM0LRE	DT	Small molecular drug
DMM0LRE	PC	9907093
DMM0LRE	MW	364.4
DMM0LRE	FM	C21H24N4O2
DMM0LRE	IC	InChI=1S/C21H24N4O2/c1-15-12-18(16(2)22-17-6-4-3-5-7-17)21-23-19(13-20(26)25(21)14-15)24-8-10-27-11-9-24/h3-7,12-14,16,22H,8-11H2,1-2H3
DMM0LRE	CS	CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3)N4CCOCC4
DMM0LRE	IK	CPRAGQJXBLMUEL-UHFFFAOYSA-N
DMM0LRE	IU	9-(1-anilinoethyl)-7-methyl-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one
DMM0LRE	CA	CAS 663619-89-4
DMM0LRE	CB	CHEBI:91428
DMM0LRE	DE	Discovery agent

DMLC8PX	ID	DMLC8PX
DMLC8PX	DN	TH-1320
DMLC8PX	HS	Investigative
DMLC8PX	SN	Topoisomerase I modulators (cancer), Threshold Pharmaceuticals; 14-Aminocamptothecin
DMLC8PX	CP	Threshold Pharmaceuticals Inc
DMLC8PX	DE	Solid tumour/cancer

DMKCY0X	ID	DMKCY0X
DMKCY0X	DN	THA-902
DMKCY0X	HS	Investigative
DMKCY0X	SN	TH-902
DMKCY0X	CP	Theralpha SAS
DMKCY0X	DE	Fibromyalgia

DMQSO7V	ID	DMQSO7V
DMQSO7V	DN	THA-904
DMQSO7V	HS	Investigative
DMQSO7V	SN	Amiloride sensitive cation channel 1a/1b antagonist (neuropathic pain), Theralpha
DMQSO7V	CP	Theralpha SAS
DMQSO7V	DE	Neuropathic pain

DMG6S2V	ID	DMG6S2V
DMG6S2V	DN	THEASINENSIN A
DMG6S2V	HS	Investigative
DMG6S2V	SN	Theasinensin A; Theasinensin D; BGCDG; Spectrum_000210; SpecPlus_000187; CHEBI:9518; CHEMBL349197; 89064-31-3; 2',2'-BISEPIGALLOCATECHIN DIGALLATE; [(2R,3R)-2-[2-[6-[(2R,3R)-5,7-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-chroman-2-yl]-2,3,4-trihydroxy-phenyl]-3,4,5-trihydroxy-phenyl]-5,7-dihydroxy-chroman-3-yl] 3,4,5-trihydroxybenzoate; theasinensin A (D); Spectrum4_000886; Spectrum5_000886; Spectrum3_001800; Spectrum2_000166; AC1L9D1Q; KBioSS_000690; KBioGR_001292; BSPBio_003359; DivK1c_006283; SCHEMBL449649; SPBio_000031
DMG6S2V	DT	Small molecular drug
DMG6S2V	PC	442543
DMG6S2V	MW	914.7
DMG6S2V	FM	C44H34O22
DMG6S2V	IC	InChI=1S/C44H34O22/c45-15-5-21(47)17-11-31(65-43(61)13-1-23(49)35(55)24(50)2-13)41(63-29(17)7-15)19-9-27(53)37(57)39(59)33(19)34-20(10-28(54)38(58)40(34)60)42-32(12-18-22(48)6-16(46)8-30(18)64-42)66-44(62)14-3-25(51)36(56)26(52)4-14/h1-10,31-32,41-42,45-60H,11-12H2/t31-,32-,41-,42-/m1/s1
DMG6S2V	CS	C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3C4=C(C(=C(C=C4[C@@H]5[C@@H](CC6=C(C=C(C=C6O5)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)O)O)O
DMG6S2V	IK	YUULFXAQUWEYNP-GXAWFILRSA-N
DMG6S2V	IU	[(2R,3R)-2-[2-[6-[(2R,3R)-5,7-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-3,4-dihydro-2H-chromen-2-yl]-2,3,4-trihydroxyphenyl]-3,4,5-trihydroxyphenyl]-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMG6S2V	CA	CAS 89064-31-3
DMG6S2V	CB	CHEBI:9518
DMG6S2V	DE	Discovery agent

DMRCD3O	ID	DMRCD3O
DMRCD3O	DN	THEBAINE
DMRCD3O	HS	Investigative
DMRCD3O	SN	THEBAINE; Paramorphine; 3-O-Methyl-oripavin; 115-37-7; UNII-2P9MKG8GX7; Thebain; 4,5alpha-Epoxy-3,6-dimethoxy-17-methyl-6,8-morphinadien; EINECS 204-084-1; 2P9MKG8GX7; (5R,9R,13S)-4,5-Epoxy-3,6-dimethoxy-9alpha-methyl-6,8-morphinadien; CHEBI:9519; DEA No. 9333; NCGC00160239-01; DSSTox_RID_81337; DSSTox_CID_26099; DSSTox_GSID_46099; Morphinan, 6,7,8,14-tetradehydro-4,5-alpha-epoxy-3,6-dimethoxy-17-methyl-; 3,6-dimethoxy-17-methyl-6,7,8,14-tetradehydro-4,5alpha-epoxymorphinan
DMRCD3O	DT	Small molecular drug
DMRCD3O	PC	5324289
DMRCD3O	MW	311.4
DMRCD3O	FM	C19H21NO3
DMRCD3O	IC	InChI=1S/C19H21NO3/c1-20-9-8-19-12-5-7-15(22-3)18(19)23-17-14(21-2)6-4-11(16(17)19)10-13(12)20/h4-7,13,18H,8-10H2,1-3H3/t13-,18+,19+/m1/s1
DMRCD3O	CS	CN1CC[C@]23[C@@H]4C(=CC=C2[C@H]1CC5=C3C(=C(C=C5)OC)O4)OC
DMRCD3O	IK	FQXXSQDCDRQNQE-VMDGZTHMSA-N
DMRCD3O	IU	(4R,7aR,12bS)-7,9-dimethoxy-3-methyl-2,4,7a,13-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline
DMRCD3O	CA	CAS 115-37-7
DMRCD3O	CB	CHEBI:9519
DMRCD3O	DE	Discovery agent

DMRVXFN	ID	DMRVXFN
DMRVXFN	DN	Theliatinib
DMRVXFN	HS	Investigative
DMRVXFN	SN	HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma
DMRVXFN	CP	Hutchison Medipharma Enterprises Ltd
DMRVXFN	PC	54759275
DMRVXFN	MW	442.5
DMRVXFN	FM	C25H26N6O2
DMRVXFN	IC	InChI=1S/C25H26N6O2/c1-4-16-6-5-7-18(10-16)28-24-19-11-21(23(33-3)12-20(19)26-15-27-24)29-25(32)31-13-17-8-9-30(2)22(17)14-31/h1,5-7,10-12,15,17,22H,8-9,13-14H2,2-3H3,(H,29,32)(H,26,27,28)/t17-,22+/m1/s1
DMRVXFN	CS	CN1CC[C@H]2[C@@H]1CN(C2)C(=O)NC3=C(C=C4C(=C3)C(=NC=N4)NC5=CC=CC(=C5)C#C)OC
DMRVXFN	IK	FSXCKIBROURMFT-VGSWGCGISA-N
DMRVXFN	IU	(3aR,6aR)-N-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]-1-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-5-carboxamide
DMRVXFN	CA	CAS 1353644-70-8
DMRVXFN	DE	Solid tumour/cancer

DM54OKX	ID	DM54OKX
DM54OKX	DN	Thenoyltrifluoroacetone
DM54OKX	HS	Investigative
DM54OKX	SN	thenoyl trifluoro acetone; MolPort-001-660-116; STK312921; AKOS005437067; ST45092067; (2E)-1,1,1-trifluoro-4-oxo-4-(thiophen-2-yl)but-2-en-2-olate
DM54OKX	DT	Small molecular drug
DM54OKX	PC	5601
DM54OKX	MW	222.19
DM54OKX	FM	C8H5F3O2S
DM54OKX	IC	InChI=1S/C8H5F3O2S/c9-8(10,11)7(13)4-5(12)6-2-1-3-14-6/h1-3H,4H2
DM54OKX	CS	C1=CSC(=C1)C(=O)CC(=O)C(F)(F)F
DM54OKX	IK	TXBBUSUXYMIVOS-UHFFFAOYSA-N
DM54OKX	IU	4,4,4-trifluoro-1-thiophen-2-ylbutane-1,3-dione
DM54OKX	CA	CAS 326-91-0
DM54OKX	DE	Discovery agent

DM9CF45	ID	DM9CF45
DM9CF45	DN	thiadiazolidinone (TDZD) deriv. 6
DM9CF45	HS	Investigative
DM9CF45	SN	Thiadiazolidinone (TDZD) deriv. 6; 4-butyl-2-ethyl-1,2,4-thiadiazolidine-3,5-dione; RGS4 inhibitor 11b; CCG 203769; AC1O6Z6H; CHEMBL24773; GTPL8033; BDBM7779; SCHEMBL13517142; HY-U00431; 410074-60-1; CS-0035365; 2-ethyl-4-butyl-1,2,4-thiadiazolidine-3,5-dione
DM9CF45	DT	Small molecular drug
DM9CF45	PC	6539137
DM9CF45	MW	202.28
DM9CF45	FM	C8H14N2O2S
DM9CF45	IC	InChI=1S/C8H14N2O2S/c1-3-5-6-9-7(11)10(4-2)13-8(9)12/h3-6H2,1-2H3
DM9CF45	CS	CCCCN1C(=O)N(SC1=O)CC
DM9CF45	IK	WTFFYZGCISALRI-UHFFFAOYSA-N
DM9CF45	IU	4-butyl-2-ethyl-1,2,4-thiadiazolidine-3,5-dione
DM9CF45	DE	Discovery agent

DMKRG2C	ID	DMKRG2C
DMKRG2C	DN	Thiadiazolo[2,3-a]pyrimidine
DMKRG2C	HS	Investigative
DMKRG2C	DE	Discovery agent

DM3F25L	ID	DM3F25L
DM3F25L	DN	Thiamin Diphosphate
DM3F25L	HS	Investigative
DM3F25L	SN	thiamin diphosphate; thiamine diphosphate; thiamin pyrophosphate; AC1O7464; [2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethoxy-oxidophosphoryl] hydrogen phosphate
DM3F25L	DT	Small molecular drug
DM3F25L	PC	1132
DM3F25L	MW	425.32
DM3F25L	FM	C12H19N4O7P2S+
DM3F25L	IC	InChI=1S/C12H18N4O7P2S/c1-8-11(3-4-22-25(20,21)23-24(17,18)19)26-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7H,3-4,6H2,1-2H3,(H4-,13,14,15,17,18,19,20,21)/p+1
DM3F25L	CS	CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCOP(=O)(O)OP(=O)(O)O
DM3F25L	IK	AYEKOFBPNLCAJY-UHFFFAOYSA-O
DM3F25L	IU	2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl phosphono hydrogen phosphate
DM3F25L	CA	CAS 136-08-3
DM3F25L	CB	CHEBI:9532
DM3F25L	DE	Discovery agent

DM5WYJ6	ID	DM5WYJ6
DM5WYJ6	DN	Thiamine pyrophosphate
DM5WYJ6	HS	Investigative
DM5WYJ6	SN	B-Neurox; Berolase; Biosyth; Bioxylasi; Bivitasi; Co-Bi; Co-carboxylase; Cocarbina; Cocarboxil; Cocarboxilasa; Cocarboxylasum; Cocarboxylasum [INN-Latin]; Coenbione; Coxylase; Diphosphothiamin; Diphosphothiamine; Farmaneurina; Metabolase; Nutrase; Pyrolase; Pyruvodehydrase; TDP (thiamin ester); TPP (coenzyme); Thiamine pyrophosphate; Thiamine pyrophosphate chloride; Thiamine pyrophosphoric ester; Thiamine-PP; Thiaminediphosphate; Thiaminepyrophosphate; Thiaminpyrophosphate; UNII-XMK8K8EVIU; cocarboxylase
DM5WYJ6	DT	Small molecular drug
DM5WYJ6	PC	9068
DM5WYJ6	MW	460.763
DM5WYJ6	FM	C12H19ClN4O7P2S
DM5WYJ6	IC	InChI=1S/C12H18N4O7P2S.ClH/c1-8-11(3-4-22-25(20,21)23-24(17,18)19)26-7-16(8)6-10-5-14-9(2)15-12(10)13;/h5,7H,3-4,6H2,1-2H3,(H4-,13,14,15,17,18,19,20,21);1H
DM5WYJ6	CS	CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCOP(=O)(O)OP(=O)(O)O.[Cl-]
DM5WYJ6	IK	YXVCLPJQTZXJLH-UHFFFAOYSA-N
DM5WYJ6	IU	2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl phosphono hydrogen phosphate;chloride
DM5WYJ6	CA	CAS 154-87-0
DM5WYJ6	CB	ChEBI:18290

DMIOTHG	ID	DMIOTHG
DMIOTHG	DN	Thieno analogue of kenpaullone
DMIOTHG	HS	Investigative
DMIOTHG	SN	Thieno analogue of kenpaullone; Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one
DMIOTHG	DT	Small molecular drug
DMIOTHG	PC	6538761
DMIOTHG	MW	333.2
DMIOTHG	FM	C14H9BrN2OS
DMIOTHG	IC	InChI=1S/C14H9BrN2OS/c15-7-1-2-10-8(5-7)9-6-12(18)16-11-3-4-19-14(11)13(9)17-10/h1-5,17H,6H2,(H,16,18)
DMIOTHG	CS	C1C2=C(C3=C(C=CS3)NC1=O)NC4=C2C=C(C=C4)Br
DMIOTHG	IK	XLKHCIUFNPNLIE-UHFFFAOYSA-N
DMIOTHG	IU	13-bromo-3-thia-7,17-diazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),2(6),4,11(16),12,14-hexaen-8-one
DMIOTHG	DE	Discovery agent

DMUL2FW	ID	DMUL2FW
DMUL2FW	DN	Thieno[2,3-B]Pyridine-2-Carboxamidine
DMUL2FW	HS	Investigative
DMUL2FW	SN	thieno[2,3-b]pyridine-2-carboxamidine; amino(thieno[2,3-b]pyridin-2-yl)methaniminium; [amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium; AC1L1KCT; BDBM14171; CTK7D1810; APC-7538
DMUL2FW	DT	Small molecular drug
DMUL2FW	PC	5438
DMUL2FW	MW	178.24
DMUL2FW	FM	C8H8N3S+
DMUL2FW	IC	InChI=1S/C8H7N3S/c9-7(10)6-4-5-2-1-3-11-8(5)12-6/h1-4H,(H3,9,10)/p+1
DMUL2FW	CS	C1=CC2=C(N=C1)SC(=C2)C(=[NH2+])N
DMUL2FW	IK	GZEJMYFXZMUAEC-UHFFFAOYSA-O
DMUL2FW	IU	[amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium
DMUL2FW	DE	Discovery agent

DMT74N6	ID	DMT74N6
DMT74N6	DN	Thieno[3,2-e][1]benzothiophene-4,5-dione
DMT74N6	HS	Investigative
DMT74N6	SN	Benzo[1,2-b:4,3-b']dithiophene-4,5-dione; 24243-31-0; CHEMBL398109; 4,5-Dihydrobenzo[1,2-b:4,3-b']dithiophene-4,5-dione
DMT74N6	DT	Small molecular drug
DMT74N6	PC	44435802
DMT74N6	MW	220.3
DMT74N6	FM	C10H4O2S2
DMT74N6	IC	InChI=1S/C10H4O2S2/c11-7-8(12)10-6(2-4-14-10)5-1-3-13-9(5)7/h1-4H
DMT74N6	CS	C1=CSC2=C1C3=C(C(=O)C2=O)SC=C3
DMT74N6	IK	MOUQKENTDKBOQJ-UHFFFAOYSA-N
DMT74N6	IU	thieno[3,2-e][1]benzothiole-4,5-dione
DMT74N6	DE	Discovery agent

DMFDROW	ID	DMFDROW
DMFDROW	DN	Thieno-phenanthridin-6-one
DMFDROW	HS	Investigative
DMFDROW	DE	Brain ischaemia

DMQ0YB5	ID	DMQ0YB5
DMQ0YB5	DN	Thiethylperazine
DMQ0YB5	HS	Investigative
DMQ0YB5	SN	ETHYLTHIOPERAZINE; Theithylperazine; Thiethylperazinum; Thiethylpipezazine; Thioethylperazine; Tietilperazina; Torecan; Tietilperazina [DCIT]; Thiethylperazinum [INN-Latin]; Torecan (TN); Thiethylperazine (USAN/INN); Thiethylperazine [USAN:INN:BAN]; Norzine (*Dimaleate*); GS-95 (*Dimaleate*)
DMQ0YB5	CP	Norvatis Phamaceuticals Corporation
DMQ0YB5	TC	Antiviral Agents
DMQ0YB5	DT	Small molecular drug
DMQ0YB5	PC	5440
DMQ0YB5	MW	399.6
DMQ0YB5	FM	C22H29N3S2
DMQ0YB5	IC	InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3
DMQ0YB5	CS	CCSC1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C
DMQ0YB5	IK	XCTYLCDETUVOIP-UHFFFAOYSA-N
DMQ0YB5	IU	2-ethylsulfanyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DMQ0YB5	CA	CAS 1420-55-9
DMQ0YB5	CB	CHEBI:9544
DMQ0YB5	DE	Nausea; Middle East Respiratory Syndrome (MERS)

DM3KU46	ID	DM3KU46
DM3KU46	DN	THIIC
DM3KU46	HS	Investigative
DM3KU46	SN	THIIC; SCHEMBL1828988; GTPL6259; RYINQFMHVVYWNS-UHFFFAOYSA-N; N-({4-[3-hydroxy-4-(2-methylpropanoyl)-2-(trifluoromethyl)phenoxymethyl]phenyl}methyl)-1-methyl-1H-imidazole-4-carboxamide; 1-Methyl-1H-imidazole-4-carboxylic acid 4-(3-hydroxy-4-isobutyryl-2-trifluoromethyl-phenoxymethyl)-benzylamide; N-(4-{[3-hydroxy-4-(2-methylpropanoyl)-2-(trifluoromethyl)phenoxy]methyl}benzyl)-1-methyl-1 h-imidazole-4-carboxamide
DM3KU46	DT	Small molecular drug
DM3KU46	PC	44595851
DM3KU46	MW	475.5
DM3KU46	FM	C24H24F3N3O4
DM3KU46	IC	InChI=1S/C24H24F3N3O4/c1-14(2)21(31)17-8-9-19(20(22(17)32)24(25,26)27)34-12-16-6-4-15(5-7-16)10-28-23(33)18-11-30(3)13-29-18/h4-9,11,13-14,32H,10,12H2,1-3H3,(H,28,33)
DM3KU46	CS	CC(C)C(=O)C1=C(C(=C(C=C1)OCC2=CC=C(C=C2)CNC(=O)C3=CN(C=N3)C)C(F)(F)F)O
DM3KU46	IK	RYINQFMHVVYWNS-UHFFFAOYSA-N
DM3KU46	IU	N-[[4-[[3-hydroxy-4-(2-methylpropanoyl)-2-(trifluoromethyl)phenoxy]methyl]phenyl]methyl]-1-methylimidazole-4-carboxamide
DM3KU46	DE	Discovery agent

DMBOKSF	ID	DMBOKSF
DMBOKSF	DN	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester
DMBOKSF	HS	Investigative
DMBOKSF	SN	CHEMBL111806; SCHEMBL14812153
DMBOKSF	DT	Small molecular drug
DMBOKSF	PC	11254470
DMBOKSF	MW	279.4
DMBOKSF	FM	C15H21NO2S
DMBOKSF	IC	InChI=1S/C15H21NO2S/c1-13(17)19-12-8-3-2-7-11-15(18)16-14-9-5-4-6-10-14/h4-6,9-10H,2-3,7-8,11-12H2,1H3,(H,16,18)
DMBOKSF	CS	CC(=O)SCCCCCCC(=O)NC1=CC=CC=C1
DMBOKSF	IK	BNRRQLIZKKTJIO-UHFFFAOYSA-N
DMBOKSF	IU	S-(7-anilino-7-oxoheptyl) ethanethioate
DMBOKSF	DE	Discovery agent

DM76EPH	ID	DM76EPH
DM76EPH	DN	thio-BCTC
DM76EPH	HS	Investigative
DM76EPH	SN	thio-BCTC; GTPL2473; SCHEMBL13930765
DM76EPH	DT	Small molecular drug
DM76EPH	PC	21037647
DM76EPH	MW	389
DM76EPH	FM	C20H25ClN4S
DM76EPH	IC	InChI=1S/C20H25ClN4S/c1-20(2,3)15-6-8-16(9-7-15)23-19(26)25-13-11-24(12-14-25)18-17(21)5-4-10-22-18/h4-10H,11-14H2,1-3H3,(H,23,26)
DM76EPH	CS	CC(C)(C)C1=CC=C(C=C1)NC(=S)N2CCN(CC2)C3=C(C=CC=N3)Cl
DM76EPH	IK	ODPJGEXSZMHIBU-UHFFFAOYSA-N
DM76EPH	IU	N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carbothioamide
DM76EPH	DE	Discovery agent

DMP7LJH	ID	DMP7LJH
DMP7LJH	DN	Thiocarbamate
DMP7LJH	HS	Investigative
DMP7LJH	SN	GNVMUORYQLCPJZ-UHFFFAOYSA-M
DMP7LJH	DT	Small molecular drug
DMP7LJH	PC	21226412
DMP7LJH	MW	76.1
DMP7LJH	FM	CH2NOS-
DMP7LJH	IC	InChI=1S/CH3NOS/c2-1(3)4/h(H3,2,3,4)/p-1
DMP7LJH	CS	C(=O)(N)[S-]
DMP7LJH	IK	GNVMUORYQLCPJZ-UHFFFAOYSA-M
DMP7LJH	IU	carbamothioate
DMP7LJH	DE	Discovery agent

DML4TQ5	ID	DML4TQ5
DML4TQ5	DN	thiochrome
DML4TQ5	HS	Investigative
DML4TQ5	SN	thiachrome
DML4TQ5	DT	Small molecular drug
DML4TQ5	PC	66706
DML4TQ5	MW	262.33
DML4TQ5	FM	C12H14N4OS
DML4TQ5	IC	InChI=1S/C12H14N4OS/c1-7-10(3-4-17)18-12-15-11-9(6-16(7)12)5-13-8(2)14-11/h5,17H,3-4,6H2,1-2H3
DML4TQ5	CS	CC1=C(SC2=NC3=NC(=NC=C3CN12)C)CCO
DML4TQ5	IK	GTQXMAIXVFLYKF-UHFFFAOYSA-N
DML4TQ5	IU	2-(6,12-dimethyl-4-thia-2,7,11,13-tetrazatricyclo[7.4.0.03,7]trideca-1(13),2,5,9,11-pentaen-5-yl)ethanol
DML4TQ5	CA	CAS 92-35-3
DML4TQ5	DE	Discovery agent

DM7X8MH	ID	DM7X8MH
DM7X8MH	DN	THIOCITRULLINE
DM7X8MH	HS	Investigative
DM7X8MH	SN	Thiocitrulline; 2-amino-5-(carbamothioylamino)pentanoic acid; AC1MNJZG; Lopac0_001244; SCHEMBL3276661; CHEMBL1608298; CHEBI:139389; CCG-205318; NCGC00094485-01; NCGC00015991-03; NCGC00015991-02; NCGC00094485-02; EU-0101244; T-173; SR-01000075525
DM7X8MH	DT	Small molecular drug
DM7X8MH	PC	3353976
DM7X8MH	MW	191.25
DM7X8MH	FM	C6H13N3O2S
DM7X8MH	IC	InChI=1S/C6H13N3O2S/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)
DM7X8MH	CS	C(CC(C(=O)O)N)CNC(=S)N
DM7X8MH	IK	BKGWACHYAMTLAF-UHFFFAOYSA-N
DM7X8MH	IU	2-amino-5-(carbamothioylamino)pentanoic acid
DM7X8MH	CB	CHEBI:139389
DM7X8MH	DE	Discovery agent

DMJSKIP	ID	DMJSKIP
DMJSKIP	DN	Thiocolchicine
DMJSKIP	HS	Investigative
DMJSKIP	SN	Thiocolchicine; Thiocholchicine; 2730-71-4; Colchicine, 10-thio-; NSC 186301; UNII-47541468FI; Colchicine, 10-demethoxy-10-(methylthio)-; EINECS 220-346-8; NSC186301; 10-Demethoxy-10-methylthiocolchicine; CHEMBL18981; 47541468FI; COLCHICINE, 10-DEMETHOXY-10-METHYLTHIO-; Acetamide, N-(5,6,7,9-tetrahydro-1,2,3-trimethoxy-10-(methylthio)-9-oxobenzo(a)heptalen-7-yl)-; N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMJSKIP	DT	Small molecular drug
DMJSKIP	PC	17648
DMJSKIP	MW	415.5
DMJSKIP	FM	C22H25NO5S
DMJSKIP	IC	InChI=1S/C22H25NO5S/c1-12(24)23-16-8-6-13-10-18(26-2)21(27-3)22(28-4)20(13)14-7-9-19(29-5)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1
DMJSKIP	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)OC
DMJSKIP	IK	CMEGANPVAXDBPL-INIZCTEOSA-N
DMJSKIP	IU	N-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMJSKIP	CA	CAS 2730-71-4
DMJSKIP	DE	Discovery agent

DMPTSN0	ID	DMPTSN0
DMPTSN0	DN	Thiocoumarin
DMPTSN0	HS	Investigative
DMPTSN0	SN	THIOCOUMARIN; FC1; AC1LCVZG; SCHEMBL929244; DB02462; 4-[3-(dimethylamino)propoxy]thiochromen-2-one
DMPTSN0	DT	Small molecular drug
DMPTSN0	PC	657073
DMPTSN0	MW	263.36
DMPTSN0	FM	C14H17NO2S
DMPTSN0	IC	InChI=1S/C14H17NO2S/c1-15(2)8-5-9-17-12-10-14(16)18-13-7-4-3-6-11(12)13/h3-4,6-7,10H,5,8-9H2,1-2H3
DMPTSN0	CS	CN(C)CCCOC1=CC(=O)SC2=CC=CC=C21
DMPTSN0	IK	DIOZFKOOIBATNZ-UHFFFAOYSA-N
DMPTSN0	IU	4-[3-(dimethylamino)propoxy]thiochromen-2-one
DMPTSN0	DE	Discovery agent

DMNFCXW	ID	DMNFCXW
DMNFCXW	DN	THIOCTIC ACID
DMNFCXW	HS	Investigative
DMNFCXW	SN	dl-Thioctic acid; thioctic acid; 1077-28-7; 5-(1,2-Dithiolan-3-yl)pentanoic acid; DL-alpha-Lipoic acid; 1,2-dithiolane-3-pentanoic acid; Thioctacid; 6,8-Thioctic acid; 6-Thioctic acid; Lipothion; Biletan; dl-Lipoic acid; Tioctacid; Thioctsan; Liposan; Rac-lipoate; 1,2-Dithiolane-3-valeric acid; DL-6,8-Thioctic acid; alpha-Liponsaeure; DL-6-Thioctic acid; alpha-liponic acid; Thioktsaeure; Tioctidasi; (RS)-Lipoic acid; 6,8-Dithiooctanoic acid; espa-lipon; Thioctic acid dl-form; 62-46-4
DMNFCXW	DT	Small molecular drug
DMNFCXW	PC	864
DMNFCXW	MW	206.3
DMNFCXW	FM	C8H14O2S2
DMNFCXW	IC	InChI=1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)
DMNFCXW	CS	C1CSSC1CCCCC(=O)O
DMNFCXW	IK	AGBQKNBQESQNJD-UHFFFAOYSA-N
DMNFCXW	IU	5-(dithiolan-3-yl)pentanoic acid
DMNFCXW	CA	CAS 1077-28-7
DMNFCXW	CB	CHEBI:16494
DMNFCXW	DE	Discovery agent

DMK2J5L	ID	DMK2J5L
DMK2J5L	DN	THIOGENISTEIN
DMK2J5L	HS	Investigative
DMK2J5L	DT	Small molecular drug
DMK2J5L	PC	135520257
DMK2J5L	MW	286.3
DMK2J5L	FM	C15H10O4S
DMK2J5L	IC	InChI=1S/C15H10O4S/c16-9-3-1-8(2-4-9)11-7-19-13-6-10(17)5-12(18)14(13)15(11)20/h1-7,16-18H
DMK2J5L	CS	C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=S)O)O)O
DMK2J5L	IK	RPDMOSIZAIBSRV-UHFFFAOYSA-N
DMK2J5L	IU	5,7-dihydroxy-3-(4-hydroxyphenyl)chromene-4-thione
DMK2J5L	DE	Discovery agent

DMBAWDG	ID	DMBAWDG
DMBAWDG	DN	Thiolactomycin
DMBAWDG	HS	Investigative
DMBAWDG	SN	Antibiotic 2-200; 82079-32-1; (R)-(+)-Thiolactomycin; (+)-Thiolactomycin; BRN 4423670; 4-HYDROXY-3,5-DIMETHYL-5-(2-METHYL-BUTA-1,3-DIENYL)-5H-THIOPHEN-2-ONE; 2(5H)-Thiophenone, 3,5-dimethyl-4-hydroxy-5-(2-methyl-1,3-butadienyl)-, (R-(E))-; (R-(E))-3,5-Dimethyl-4-hydroxy-5-(2-methyl-1,3-butadienyl)-2(5H)-thiophenone; TLM; 2(5H)-Thiophenone, 4-hydroxy-3,5-dimethyl-5-(2-methyl-1,3-butadienyl)-, (S-(E))-; (2R)-5-hydroxy-2,4-dimethyl-2-[(1E)-2-methylbuta-1,3-dienyl]thiophen-3-one; (5R)-Thiolactomycin; 2vb8
DMBAWDG	DT	Small molecular drug
DMBAWDG	PC	135403829
DMBAWDG	MW	210.29
DMBAWDG	FM	C11H14O2S
DMBAWDG	IC	InChI=1S/C11H14O2S/c1-5-7(2)6-11(4)9(12)8(3)10(13)14-11/h5-6,12H,1H2,2-4H3/b7-6+/t11-/m1/s1
DMBAWDG	CS	CC1=C([C@@](SC1=O)(C)/C=C(\\C)/C=C)O
DMBAWDG	IK	SYQNUQSGEWNWKV-XUIVZRPNSA-N
DMBAWDG	IU	(5R)-4-hydroxy-3,5-dimethyl-5-[(1E)-2-methylbuta-1,3-dienyl]thiophen-2-one
DMBAWDG	CA	CAS 82079-32-1
DMBAWDG	DE	Malaria; Urinary tract infection

DMAKW2S	ID	DMAKW2S
DMAKW2S	DN	Thiophene sulfonamide
DMAKW2S	HS	Investigative
DMAKW2S	SN	MLS000048634; AC1O9WJ4; AC1NX3H6; AC1NT7F3; N-(2-hydroxybenzylidene)-2-thiophenesulfonamide; CHEMBL3193745; MolPort-035-831-874; MolPort-000-689-338; CCG-13754; AKOS001033013; SMR000060871; ST021762; BIM-0024487P001; SR-01000030268; AS-871/40346888; SR-01000030268-1; 2-{[(1E)-2-(2-hydroxyphenyl)-1-azavinyl]sulfonyl}thiophene; N-[(Z)-(6-oxocyclohexa-2,4-dien-1-ylidene)methyl]thiophene-2-sulfonamide; N-[(6-oxocyclohexa-2,4-dien-1-ylidene)methyl]thiophene-2-sulfonamide
DMAKW2S	DT	Small molecular drug
DMAKW2S	PC	72881
DMAKW2S	MW	163.2
DMAKW2S	FM	C4H5NO2S2
DMAKW2S	IC	InChI=1S/C4H5NO2S2/c5-9(6,7)4-2-1-3-8-4/h1-3H,(H2,5,6,7)
DMAKW2S	CS	C1=CSC(=C1)S(=O)(=O)N
DMAKW2S	IK	KTFDYVNEGTXQCV-UHFFFAOYSA-N
DMAKW2S	IU	thiophene-2-sulfonamide
DMAKW2S	CA	CAS 6339-87-3
DMAKW2S	CB	CHEBI:79403
DMAKW2S	DE	Malaria

DML3OHW	ID	DML3OHW
DML3OHW	DN	Thiophene-2-ylboronic acid
DML3OHW	HS	Investigative
DML3OHW	SN	thiophene-2-ylboronic acid; CHEMBL236759; SCHEMBL13630729
DML3OHW	DT	Small molecular drug
DML3OHW	PC	44435718
DML3OHW	MW	129.979
DML3OHW	FM	C4H7BO2S
DML3OHW	IC	InChI=1S/C4H7BO2S/c6-5(7)4-2-1-3-8-4/h2,6-7H,1,3H2
DML3OHW	CS	B(C1=CCCS1)(O)O
DML3OHW	IK	HBWATGYSAHIWIX-UHFFFAOYSA-N
DML3OHW	IU	2,3-dihydrothiophen-5-ylboronic acid
DML3OHW	DE	Discovery agent

DMZ4FCB	ID	DMZ4FCB
DMZ4FCB	DN	Thiophosphoric acid (E)-dodec-9-enyl ester
DMZ4FCB	HS	Investigative
DMZ4FCB	SN	CHEMBL190484; Thiophosphoric acid (E)-dodec-9-enyl ester; SCHEMBL193155; BDBM50170847; 9-Dodecen-1-ol, dihydrogen phosphorothioate
DMZ4FCB	DT	Small molecular drug
DMZ4FCB	PC	11208266
DMZ4FCB	MW	280.37
DMZ4FCB	FM	C12H25O3PS
DMZ4FCB	IC	InChI=1S/C12H25O3PS/c1-2-3-4-5-6-7-8-9-10-11-12-15-16(13,14)17/h3-4H,2,5-12H2,1H3,(H2,13,14,17)/b4-3+
DMZ4FCB	CS	CC/C=C/CCCCCCCCOP(=S)(O)O
DMZ4FCB	IK	WIHXFYRABDDREX-ONEGZZNKSA-N
DMZ4FCB	IU	[(E)-dodec-9-enoxy]-dihydroxy-sulfanylidene-lambda5-phosphane
DMZ4FCB	DE	Discovery agent

DMYOXJ4	ID	DMYOXJ4
DMYOXJ4	DN	Thiophosphoric acid (E)-tetradec-9-enyl ester
DMYOXJ4	HS	Investigative
DMYOXJ4	SN	CHEMBL187402; Thiophosphoric acid (E)-tetradec-9-enyl ester
DMYOXJ4	DT	Small molecular drug
DMYOXJ4	PC	11220562
DMYOXJ4	MW	308.42
DMYOXJ4	FM	C14H29O3PS
DMYOXJ4	IC	InChI=1S/C14H29O3PS/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-18(15,16)19/h5-6H,2-4,7-14H2,1H3,(H2,15,16,19)/b6-5+
DMYOXJ4	CS	CCCC/C=C/CCCCCCCCOP(=S)(O)O
DMYOXJ4	IK	JIUMNBPJJCCLAG-AATRIKPKSA-N
DMYOXJ4	IU	dihydroxy-sulfanylidene-[(E)-tetradec-9-enoxy]-lambda5-phosphane
DMYOXJ4	DE	Discovery agent

DM12NGE	ID	DM12NGE
DM12NGE	DN	Thiophosphoric acid dec-9-enyl ester
DM12NGE	HS	Investigative
DM12NGE	SN	Thiophosphoric acid dec-9-enyl ester; CHEMBL363935; 9-Decen-1-ol, dihydrogen phosphorothioate; SCHEMBL192854; BDBM50170855
DM12NGE	DT	Small molecular drug
DM12NGE	PC	11288209
DM12NGE	MW	252.31
DM12NGE	FM	C10H21O3PS
DM12NGE	IC	InChI=1S/C10H21O3PS/c1-2-3-4-5-6-7-8-9-10-13-14(11,12)15/h2H,1,3-10H2,(H2,11,12,15)
DM12NGE	CS	C=CCCCCCCCCOP(=S)(O)O
DM12NGE	IK	LWVBJTXDTCXEJG-UHFFFAOYSA-N
DM12NGE	IU	dec-9-enoxy-dihydroxy-sulfanylidene-lambda5-phosphane
DM12NGE	DE	Discovery agent

DM36KW9	ID	DM36KW9
DM36KW9	DN	Thiophosphoric acid decyl ester
DM36KW9	HS	Investigative
DM36KW9	SN	Thiophosphoric acid decyl ester; CHEMBL187795; Phosphorothioic acid, O-decyl ester; SCHEMBL194339
DM36KW9	DT	Small molecular drug
DM36KW9	PC	11242245
DM36KW9	MW	254.33
DM36KW9	FM	C10H23O3PS
DM36KW9	IC	InChI=1S/C10H23O3PS/c1-2-3-4-5-6-7-8-9-10-13-14(11,12)15/h2-10H2,1H3,(H2,11,12,15)
DM36KW9	CS	CCCCCCCCCCOP(=S)(O)O
DM36KW9	IK	ISIPUCJUDOMIDU-UHFFFAOYSA-N
DM36KW9	IU	decoxy-dihydroxy-sulfanylidene-lambda5-phosphane
DM36KW9	CA	CAS 849721-54-6
DM36KW9	DE	Discovery agent

DM86LFB	ID	DM86LFB
DM86LFB	DN	Thiorphan
DM86LFB	HS	Investigative
DM86LFB	SN	(S)-THIORPHAN; (2-MERCAPTOMETHYL-3-PHENYL-PROPIONYL)-GLYCINE; CHEMBL298827; 95909-00-5; 1zdp; AC1N9ZZO; Lopac-T-6031; SCHEMBL49662; GTPL5278; Glycine, N-[(2S)-2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-; ZINC3872336; BDBM50024102; DB08626; NCGC00016033-01; NCGC00016933-01; CAS-76721-89-6; N-[(2S)-2-benzyl-3-sulfanylpropanoyl]glycine; 2-[(2S)-2-benzyl-3-sulfanylpropanamido]acetic acid; (S) (2-Mercaptomethyl-3-phenyl-propionylamino)-acetic acid; 2-[[(2S)-2-benzyl-3-sulfanylpropanoyl]amino]acetic acid; UNII-B79L7B5X3Z component LJJ
DM86LFB	DT	Small molecular drug
DM86LFB	PC	3132
DM86LFB	MW	253.32
DM86LFB	FM	C12H15NO3S
DM86LFB	IC	InChI=1S/C12H15NO3S/c14-11(15)7-13-12(16)10(8-17)6-9-4-2-1-3-5-9/h1-5,10,17H,6-8H2,(H,13,16)(H,14,15)
DM86LFB	CS	C1=CC=C(C=C1)CC(CS)C(=O)NCC(=O)O
DM86LFB	IK	LJJKNPQAGWVLDQ-UHFFFAOYSA-N
DM86LFB	IU	2-[(2-benzyl-3-sulfanylpropanoyl)amino]acetic acid
DM86LFB	CA	CAS 76721-89-6
DM86LFB	CB	CHEBI:9568
DM86LFB	DE	Discovery agent

DML7Y1R	ID	DML7Y1R
DML7Y1R	DN	Thiostrepton
DML7Y1R	HS	Investigative
DML7Y1R	SN	thiostrepton; Thiostrepton from Streptomyces azureus; Bryamycin; Thiactin; Alaninamide,; 1393-48-2; NSC81722; NSC170365; NSC 81722; NSC 170365; CHEMBL1981887; CHEBI:94340; MolPort-003-939-599; NSC-81722; NSC-170365; NCGC00485235-01; Thiostrepton from Streptomyces azureus, &gt
DML7Y1R	DT	Small molecular drug
DML7Y1R	PC	16129666
DML7Y1R	MW	1664.9
DML7Y1R	FM	C72H85N19O18S5
DML7Y1R	IC	InChI=1S/C72H85N19O18S5/c1-14-26(3)47-63(105)78-30(7)57(99)75-28(5)56(98)76-31(8)58(100)91-72-19-18-40(66-85-43(22-111-66)59(101)77-29(6)55(97)74-27(4)54(73)96)81-52(72)42-21-112-67(83-42)49(34(11)109-69(107)41-20-37(32(9)92)36-16-17-39(79-47)51(95)50(36)80-41)89-60(102)44-24-113-68(86-44)53(71(13,108)35(12)94)90-62(104)45-23-110-65(84-45)38(15-2)82-64(106)48(33(10)93)88-61(103)46-25-114-70(72)87-46/h15-17,20-22,24-26,30-35,39,45,47-49,51-53,79,92-95,108H,4-6,14,18-19,23H2,1-3,7-13H3,(H2,73,96)(H,74,97)(H,75,99)(H,76,98)(H,77,101)(H,78,105)(H,82,106)(H,88,103)(H,89,102)(H,90,104)(H,91,100)/b38-15+
DML7Y1R	CS	CCC(C)C1C(=O)NC(C(=O)NC(=C)C(=O)NC(C(=O)NC23CCC(=NC2C4=CSC(=N4)C(C(OC(=O)C5=NC6=C(C=CC(C6O)N1)C(=C5)C(C)O)C)NC(=O)C7=CSC(=N7)C(NC(=O)C8CSC(=N8)/C(=C\\C)/NC(=O)C(NC(=O)C9=CSC3=N9)C(C)O)C(C)(C(C)O)O)C1=NC(=CS1)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)C)C
DML7Y1R	IK	NSFFHOGKXHRQEW-DVRIZHICSA-N
DML7Y1R	IU	N-[3-[(3-amino-3-oxoprop-1-en-2-yl)amino]-3-oxoprop-1-en-2-yl]-2-[(11E)-37-butan-2-yl-18-(2,3-dihydroxybutan-2-yl)-11-ethylidene-59-hydroxy-8,31-bis(1-hydroxyethyl)-26,40,46-trimethyl-43-methylidene-6,9,16,23,28,38,41,44,47-nonaoxo-27-oxa-3,13,20,56-tetrathia-7,10,17,24,36,39,42,45,48,52,58,61,62,63,64-pentadecazanonacyclo[23.23.9.329,35.12,5.112,15.119,22.154,57.01,53.032,60]tetrahexaconta-2(64),4,12(63),19(62),21,29(61),30,32(60),33,51,54,57-dodecaen-51-yl]-1,3-thiazole-4-carboxamide
DML7Y1R	CA	CAS 1393-48-2
DML7Y1R	DE	Discovery agent

DMUELHN	ID	DMUELHN
DMUELHN	DN	Thiourea
DMUELHN	HS	Investigative
DMUELHN	SN	2-Thiopseudourea; 2-Thiourea; Carbamimidothioic acid; Caswell No. 855; Isothiourea; Pseudothiourea; Pseudourea, 2-thio-; RCRA waste no. U219;.beta.-Thiopseudourea; RCRA waste number U219; Sulfourea; Sulfouren; Sulourea; THIOUREA; Thiocarbamid; Thiocarbamide; Thiocarbonic acid diamide; Thioharnstoff; Thiokarbamid; Thiomocovina; Thiomocovina [Czech]; Thiurea; Thiuronium; Tsizp 34; Urea, 2-thio-; Urea, thio-; beta-Thiopseudourea; carbonothioic diamide; sulfocarbamide; thio-urea
DMUELHN	DT	Small molecular drug
DMUELHN	PC	2723790
DMUELHN	MW	76.117
DMUELHN	FM	CH4N2S
DMUELHN	IC	InChI=1S/CH4N2S/c2-1(3)4/h(H4,2,3,4)
DMUELHN	CS	C(=S)(N)N
DMUELHN	IK	UMGDCJDMYOKAJW-UHFFFAOYSA-N
DMUELHN	IU	thiourea
DMUELHN	CA	CAS 62-56-6
DMUELHN	CB	ChEBI:36946

DM8WYEM	ID	DM8WYEM
DM8WYEM	DN	Thioureido sulfonamide
DM8WYEM	HS	Investigative
DM8WYEM	DE	Discovery agent

DMP8LSF	ID	DMP8LSF
DMP8LSF	DN	THIQ
DMP8LSF	HS	Investigative
DMP8LSF	SN	MB-243; MC4 receptor agonists (obesity); MK-0489; MZ-767; PG-917; PG-946; RY-764; Anti-obesity therapy, Merck &Co; MC4 receptor agonists (obesity), Merck & Co; Melanocortin agonists (obesity/erectile dysfunction), Merck & Co
DMP8LSF	CP	Merck & Co Inc
DMP8LSF	DT	Small molecular drug
DMP8LSF	PC	9938402
DMP8LSF	MW	589.2
DMP8LSF	FM	C33H41ClN6O2
DMP8LSF	IC	InChI=1S/C33H41ClN6O2/c34-28-12-10-24(11-13-28)18-30(38-31(41)29-19-25-6-4-5-7-26(25)20-36-29)32(42)39-16-14-33(15-17-39,21-40-23-35-22-37-40)27-8-2-1-3-9-27/h4-7,10-13,22-23,27,29-30,36H,1-3,8-9,14-21H2,(H,38,41)/t29-,30-/m1/s1
DMP8LSF	CS	C1CCC(CC1)C2(CCN(CC2)C(=O)[C@@H](CC3=CC=C(C=C3)Cl)NC(=O)[C@H]4CC5=CC=CC=C5CN4)CN6C=NC=N6
DMP8LSF	IK	HLCHESOMJVGDSJ-LOYHVIPDSA-N
DMP8LSF	IU	(3R)-N-[(2R)-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-oxopropan-2-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
DMP8LSF	CA	CAS 312637-48-2
DMP8LSF	DE	Erectile dysfunction

DMD1G6R	ID	DMD1G6R
DMD1G6R	DN	THPG
DMD1G6R	HS	Investigative
DMD1G6R	SN	(RS)-3,4,5-trihydroxyphenylglycine
DMD1G6R	DT	Small molecular drug
DMD1G6R	PC	18941399
DMD1G6R	MW	199.16
DMD1G6R	FM	C8H9NO5
DMD1G6R	IC	InChI=1S/C8H9NO5/c10-5-1-4(9-3-7(12)13)2-6(11)8(5)14/h1-2,9-11,14H,3H2,(H,12,13)
DMD1G6R	CS	C1=C(C=C(C(=C1O)O)O)NCC(=O)O
DMD1G6R	IK	ZXXHFFMAINKZSZ-UHFFFAOYSA-N
DMD1G6R	IU	2-(3,4,5-trihydroxyanilino)acetic acid
DMD1G6R	DE	Discovery agent

DMJD479	ID	DMJD479
DMJD479	DN	THPO
DMJD479	HS	Investigative
DMJD479	SN	THPO; 53602-00-9; 4,5,6,7-Tetrahydroisoxazolo(4,5-c)pyridin-3-ol; 4,5,6,7-Tetrahydroisoxazolo[4,5-c]pyridin-3-ol; CHEMBL150830; Isoxazolo(4,5-d)pyridin-3(2H)-one, 4,5,6,7-tetrahydro-; 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3(2H)-one; AC1Q6C1M; SCHEMBL455554; GTPL4727; AC1L1C13; isoxazolo[4,5-c]pyridin-3-ol, 4,5,6,7-tetrahydro-; CTK4J8459; DTXSID90201822; SXXLKZCNJHJYFL-UHFFFAOYSA-N; FCH907083; BDBM50226145; ZINC13803345; AKOS022718554; AKOS006371191; API0009745; DA-05117; LS-183574; FT-0754243
DMJD479	DT	Small molecular drug
DMJD479	PC	1695
DMJD479	MW	140.14
DMJD479	FM	C6H8N2O2
DMJD479	IC	InChI=1S/C6H8N2O2/c9-6-4-3-7-2-1-5(4)10-8-6/h7H,1-3H2,(H,8,9)
DMJD479	CS	C1CNCC2=C1ONC2=O
DMJD479	IK	SXXLKZCNJHJYFL-UHFFFAOYSA-N
DMJD479	IU	4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-3-one
DMJD479	CA	CAS 53602-00-9
DMJD479	DE	Discovery agent

DM4W1E8	ID	DM4W1E8
DM4W1E8	DN	Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride
DM4W1E8	HS	Investigative
DM4W1E8	SN	CHEMBL537206
DM4W1E8	DT	Small molecular drug
DM4W1E8	PC	16720951
DM4W1E8	MW	215.33
DM4W1E8	FM	C15H21N
DM4W1E8	IC	InChI=1S/C15H21N/c1-2-7-13(8-3-1)14-9-6-12-16-11-5-4-10-15(14)16/h1-3,7-8,14-15H,4-6,9-12H2/t14-,15-/m1/s1
DM4W1E8	CS	C1CCN2CCC[C@@H]([C@H]2C1)C3=CC=CC=C3
DM4W1E8	IK	OUZYKKYJPBLWGM-HUUCEWRRSA-N
DM4W1E8	IU	(1R,9aR)-1-phenyl-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizine
DM4W1E8	DE	Discovery agent

DMA7GTH	ID	DMA7GTH
DMA7GTH	DN	Threo-3,4-dichlororitalinol hydrochloride
DMA7GTH	HS	Investigative
DMA7GTH	SN	Threo-3,4-Dichlororitalinol HCl
DMA7GTH	DT	Small molecular drug
DMA7GTH	PC	16719669
DMA7GTH	MW	274.18
DMA7GTH	FM	C13H17Cl2NO
DMA7GTH	IC	InChI=1S/C13H17Cl2NO/c14-11-5-4-9(7-12(11)15)10(8-17)13-3-1-2-6-16-13/h4-5,7,10,13,16-17H,1-3,6,8H2/t10-,13-/m1/s1
DMA7GTH	CS	C1CCN[C@H](C1)[C@H](CO)C2=CC(=C(C=C2)Cl)Cl
DMA7GTH	IK	VBLILHAGVIRWHD-ZWNOBZJWSA-N
DMA7GTH	IU	(2R)-2-(3,4-dichlorophenyl)-2-[(2R)-piperidin-2-yl]ethanol

DMOE3IJ	ID	DMOE3IJ
DMOE3IJ	DN	Threo-3-methylglutamate
DMOE3IJ	HS	Investigative
DMOE3IJ	SN	(+/-)-threo-3-methylglutamic acid
DMOE3IJ	DT	Small molecular drug
DMOE3IJ	PC	237657
DMOE3IJ	MW	161.16
DMOE3IJ	FM	C6H11NO4
DMOE3IJ	IC	InChI=1S/C6H11NO4/c1-3(2-4(8)9)5(7)6(10)11/h3,5H,2,7H2,1H3,(H,8,9)(H,10,11)
DMOE3IJ	CS	CC(CC(=O)O)C(C(=O)O)N
DMOE3IJ	IK	FHJNAFIJPFGZRI-UHFFFAOYSA-N
DMOE3IJ	IU	2-amino-3-methylpentanedioic acid
DMOE3IJ	CA	CAS 2445-97-8
DMOE3IJ	DE	Discovery agent

DMEVT7S	ID	DMEVT7S
DMEVT7S	DN	Threo-N-ethylritalinol hydrochloride
DMEVT7S	HS	Investigative
DMEVT7S	SN	Threo-N-Ethylritalinol HCl
DMEVT7S	DT	Small molecular drug
DMEVT7S	PC	16719767
DMEVT7S	MW	233.35
DMEVT7S	FM	C15H23NO
DMEVT7S	IC	InChI=1S/C15H23NO/c1-2-16-11-7-6-10-15(16)14(12-17)13-8-4-3-5-9-13/h3-5,8-9,14-15,17H,2,6-7,10-12H2,1H3/t14-,15-/m1/s1
DMEVT7S	CS	CCN1CCCC[C@@H]1[C@H](CO)C2=CC=CC=C2
DMEVT7S	IK	BHAGCFGXKSMVPG-HUUCEWRRSA-N
DMEVT7S	IU	(2R)-2-[(2R)-1-ethylpiperidin-2-yl]-2-phenylethanol

DM4MPVE	ID	DM4MPVE
DM4MPVE	DN	Threo-ritalinol hydrochloride
DM4MPVE	HS	Investigative
DM4MPVE	SN	Threo-Ritalinol HCl
DM4MPVE	DT	Small molecular drug
DM4MPVE	PC	10726933
DM4MPVE	MW	205.3
DM4MPVE	FM	C13H19NO
DM4MPVE	IC	InChI=1S/C13H19NO/c15-10-12(11-6-2-1-3-7-11)13-8-4-5-9-14-13/h1-3,6-7,12-15H,4-5,8-10H2/t12-,13-/m1/s1
DM4MPVE	CS	C1CCN[C@H](C1)[C@H](CO)C2=CC=CC=C2
DM4MPVE	IK	IKNCLLOBJQVKNP-CHWSQXEVSA-N
DM4MPVE	IU	(2R)-2-phenyl-2-[(2R)-piperidin-2-yl]ethanol

DMV0CZ5	ID	DMV0CZ5
DMV0CZ5	DN	Threo-ritalinol methyl ether hydrochloride
DMV0CZ5	HS	Investigative
DMV0CZ5	SN	Threo-Ritalinol Methyl Ether HCl
DMV0CZ5	DT	Small molecular drug
DMV0CZ5	PC	16719668
DMV0CZ5	MW	219.32
DMV0CZ5	FM	C14H21NO
DMV0CZ5	IC	InChI=1S/C14H21NO/c1-16-11-13(12-7-3-2-4-8-12)14-9-5-6-10-15-14/h2-4,7-8,13-15H,5-6,9-11H2,1H3/t13-,14-/m1/s1
DMV0CZ5	CS	COC[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2
DMV0CZ5	IK	DNWCZLGJLQABLG-ZIAGYGMSSA-N
DMV0CZ5	IU	(2R)-2-[(1R)-2-methoxy-1-phenylethyl]piperidine

DMRVXH7	ID	DMRVXH7
DMRVXH7	DN	ThromboMer
DMRVXH7	HS	Investigative
DMRVXH7	SN	TPO peptide mimetic (thrombocytopenia), AplaGen; Thrombopoietin peptide mimetic (thrombocytopenia), AplaGen
DMRVXH7	CP	AplaGen GmbH
DMRVXH7	DE	Thrombocytopenia

DMY07CA	ID	DMY07CA
DMY07CA	DN	THRX160209
DMY07CA	HS	Investigative
DMY07CA	SN	THRX-160209; THRX 160209
DMY07CA	DT	Small molecular drug
DMY07CA	PC	11354367
DMY07CA	MW	668.9
DMY07CA	FM	C42H60N4O3
DMY07CA	IC	InChI=1S/C42H60N4O3/c1-4-26-46(37-24-30-45(31-25-37)33-38-39(48-2)21-16-22-40(38)49-3)28-15-7-5-6-14-27-44-29-23-36(32-44)42(41(43)47,34-17-10-8-11-18-34)35-19-12-9-13-20-35/h8-13,16-22,36-37H,4-7,14-15,23-33H2,1-3H3,(H2,43,47)/t36-/m1/s1
DMY07CA	CS	CCCN(CCCCCCCN1CC[C@H](C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)C4CCN(CC4)CC5=C(C=CC=C5OC)OC
DMY07CA	IK	AXSAVLPYCZEECW-PSXMRANNSA-N
DMY07CA	IU	2-[(3S)-1-[7-[[1-[(2,6-dimethoxyphenyl)methyl]piperidin-4-yl]-propylamino]heptyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
DMY07CA	DE	Discovery agent

DMUDGSN	ID	DMUDGSN
DMUDGSN	DN	THYMELEATOXIN
DMUDGSN	HS	Investigative
DMUDGSN	SN	thymeleatoxin; 94482-56-1
DMUDGSN	DT	Small molecular drug
DMUDGSN	PC	90477734
DMUDGSN	MW	628.7
DMUDGSN	FM	C36H36O10
DMUDGSN	IC	InChI=1S/C36H36O10/c1-19(2)34-28(42-25(38)16-15-22-11-7-5-8-12-22)21(4)35-24-17-20(3)27(39)33(24,41)31(40)32(18-37)29(43-32)26(35)30(34)44-36(45-34,46-35)23-13-9-6-10-14-23/h5-17,21,24,26,28-31,37,40-41H,1,18H2,2-4H3/b16-15+/t21-,24-,26-,28-,29+,30-,31-,32+,33-,34+,35-,36-/m1/s1
DMUDGSN	CS	C[C@@H]1[C@H]([C@]2([C@H]3[C@@H]4[C@@]1([C@@H]5C=C(C(=O)[C@]5([C@@H]([C@@]6([C@H]4O6)CO)O)O)C)O[C@](O3)(O2)C7=CC=CC=C7)C(=C)C)OC(=O)/C=C/C8=CC=CC=C8
DMUDGSN	IK	OTTFLYUONKAFGT-KSFWXGPWSA-N
DMUDGSN	IU	[(1S,2R,6S,7S,8R,10S,11R,12R,14S,16S,17R,18R)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-14-phenyl-16-prop-1-en-2-yl-9,13,15,19-tetraoxahexacyclo[12.4.1.01,11.02,6.08,10.012,16]nonadec-3-en-17-yl] (E)-3-phenylprop-2-enoate
DMUDGSN	DE	Discovery agent

DMKM6NQ	ID	DMKM6NQ
DMKM6NQ	DN	Thymidine-5'-Phosphate
DMKM6NQ	HS	Investigative
DMKM6NQ	SN	Thymidine 5'-monophosphate; dTMP(-); thymidine 5'-phosphate(1-); CHEBI:46960; thymidine 5'-(hydrogen phosphate)
DMKM6NQ	DT	Small molecular drug
DMKM6NQ	PC	9700
DMKM6NQ	MW	322.21
DMKM6NQ	FM	C10H15N2O8P
DMKM6NQ	IC	InChI=1S/C10H15N2O8P/c1-5-3-12(10(15)11-9(5)14)8-2-6(13)7(20-8)4-19-21(16,17)18/h3,6-8,13H,2,4H2,1H3,(H,11,14,15)(H2,16,17,18)/t6-,7+,8+/m0/s1
DMKM6NQ	CS	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O)O
DMKM6NQ	IK	GYOZYWVXFNDGLU-XLPZGREQSA-N
DMKM6NQ	IU	[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMKM6NQ	CA	CAS 365-07-1
DMKM6NQ	CB	CHEBI:17013
DMKM6NQ	DE	Discovery agent

DMKGXB9	ID	DMKGXB9
DMKGXB9	DN	Thymine
DMKGXB9	HS	Investigative
DMKGXB9	SN	5-methyluracil; 65-71-4; 2,4-Dihydroxy-5-methylpyrimidine; Thymin; 5-methylpyrimidine-2,4(1H,3H)-dione; Thymine anhydrate; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-; 5-methyl-2,4(1H,3H)-pyrimidinedione; Thymin (purine base); 5-Methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione; 5-methyl-1H-pyrimidine-2,4-dione; CCRIS 5584; UNII-QR26YLT7LT; 5-Methyl Uracil; 5-Methylpyrimidine-2,4-dione; 4-Hydroxy-5-methylpyrimidin-2(1H)-one; CHEBI:17821; AI3-25479; NSC14705; EINECS 200-616-1; NSC 14705; QR26YLT7LT; CHEMBL993
DMKGXB9	DT	Small molecular drug
DMKGXB9	PC	1135
DMKGXB9	MW	126.11
DMKGXB9	FM	C5H6N2O2
DMKGXB9	IC	InChI=1S/C5H6N2O2/c1-3-2-6-5(9)7-4(3)8/h2H,1H3,(H2,6,7,8,9)
DMKGXB9	CS	CC1=CNC(=O)NC1=O
DMKGXB9	IK	RWQNBRDOKXIBIV-UHFFFAOYSA-N
DMKGXB9	IU	5-methyl-1H-pyrimidine-2,4-dione
DMKGXB9	CA	CAS 65-71-4
DMKGXB9	CB	CHEBI:17821
DMKGXB9	DE	Discovery agent

DMU10FE	ID	DMU10FE
DMU10FE	DN	THZ1
DMU10FE	HS	Investigative
DMU10FE	SN	HY-80013
DMU10FE	DT	Small molecular drug
DMU10FE	PC	73602827
DMU10FE	MW	566.1
DMU10FE	FM	C31H28ClN7O2
DMU10FE	IC	InChI=1S/C31H28ClN7O2/c1-39(2)16-6-11-28(40)35-21-14-12-20(13-15-21)30(41)36-22-7-5-8-23(17-22)37-31-34-19-26(32)29(38-31)25-18-33-27-10-4-3-9-24(25)27/h3-15,17-19,33H,16H2,1-2H3,(H,35,40)(H,36,41)(H,34,37,38)/b11-6+
DMU10FE	CS	CN(C)C/C=C/C(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl
DMU10FE	IK	OBJNFLYHUXWUPF-IZZDOVSWSA-N
DMU10FE	IU	N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
DMU10FE	DE	Nasopharyngeal carcinoma

DMBZ2MF	ID	DMBZ2MF
DMBZ2MF	DN	THZ531
DMBZ2MF	HS	Investigative
DMBZ2MF	SN	1702809-17-3; THZ-531; (R,E)-N-(4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)-4-(dimethylamino)but-2-enamide; CHEMBL4163879; THZ531 HCl; THZ-531 HCl; SCHEMBL16655248; SCHEMBL16655252; CHEBI:143122; THZ531; THZ 531; (E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide; AMY16834; BCP28996; EX-A1532; BDBM50528813; NSC821656; s6595; NSC-821656; SB18810; AC-31604; BS-16034; HY-103618; CS-0015451; J3.623.785F; CN(C)CC=CC(=O)Nc1ccc(cc1)C(=O)N1CCC[C@H](C1)Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12; (2E)-N-(4-{[(3R)-3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}piperidin-1-yl]carbonyl}phenyl)-4-(dimethylamino)but-2-enamide
DMBZ2MF	DT	Small molecular drug
DMBZ2MF	PC	118025540
DMBZ2MF	MW	558.1
DMBZ2MF	FM	C30H32ClN7O2
DMBZ2MF	IC	InChI=1S/C30H32ClN7O2/c1-37(2)15-6-10-27(39)34-21-13-11-20(12-14-21)29(40)38-16-5-7-22(19-38)35-30-33-18-25(31)28(36-30)24-17-32-26-9-4-3-8-23(24)26/h3-4,6,8-14,17-18,22,32H,5,7,15-16,19H2,1-2H3,(H,34,39)(H,33,35,36)/b10-6+/t22-/m1/s1
DMBZ2MF	CS	CN(C)C/C=C/C(=O)NC1=CC=C(C=C1)C(=O)N2CCC[C@H](C2)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl
DMBZ2MF	IK	RUBYHLPRZRMTJO-MOVYNIQHSA-N
DMBZ2MF	IU	(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide
DMBZ2MF	CB	CHEBI:143122
DMBZ2MF	DE	Solid tumour/cancer

DMGXSTB	ID	DMGXSTB
DMGXSTB	DN	TI3
DMGXSTB	HS	Investigative
DMGXSTB	SN	RB106; CHEMBL419499; [(2S)-2-SULFANYL-3-PHENYLPROPANOYL]-GLY-(5-PHENYLPROLINE); TI3; 1qf2; AC1L9LL2; BDBM50051785; DB02669; N-[(S)-2-Mercapto-3-phenylpropionyl]-Gly-[(5R)-5-phenyl-L-Pro-]-OH; N-[(2S)-3-phenyl-2-sulfanylpropanoyl]glycyl-(5R)-5-phenyl-L-proline; (2S,5R)-5-phenyl-1-[2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid; (2S,5R)-1-[2-((S)-2-Mercapto-3-phenyl-propionylamino)-acetyl]-5-phenyl-pyrrolidine-2-carboxylic acid
DMGXSTB	DT	Small molecular drug
DMGXSTB	PC	448087
DMGXSTB	MW	412.5
DMGXSTB	FM	C22H24N2O4S
DMGXSTB	IC	InChI=1S/C22H24N2O4S/c25-20(14-23-21(26)19(29)13-15-7-3-1-4-8-15)24-17(11-12-18(24)22(27)28)16-9-5-2-6-10-16/h1-10,17-19,29H,11-14H2,(H,23,26)(H,27,28)/t17-,18+,19+/m1/s1
DMGXSTB	CS	C1C[C@H](N([C@H]1C2=CC=CC=C2)C(=O)CNC(=O)[C@H](CC3=CC=CC=C3)S)C(=O)O
DMGXSTB	IK	ZWDQTNWLXALTOV-QYZOEREBSA-N
DMGXSTB	IU	(2S,5R)-5-phenyl-1-[2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid
DMGXSTB	DE	Discovery agent

DMOXINT	ID	DMOXINT
DMOXINT	DN	TI4
DMOXINT	HS	Investigative
DMOXINT	DT	Small molecular drug
DMOXINT	PC	91808049
DMOXINT	MW	214.31
DMOXINT	FM	C14H18N2
DMOXINT	IC	InChI=1S/C14H18N2/c1-2-12(7-15-3-1)14-13-5-10-4-11(6-13)9-16(14)8-10/h1-3,7,10-11,13-14H,4-6,8-9H2/t10-,11+,13?,14-/m0/s1
DMOXINT	CS	C1[C@@H]2CC3C[C@H]1CN(C2)[C@H]3C4=CN=CC=C4
DMOXINT	IK	INDYXBQOPZTSTJ-OWZDMKDPSA-N
DMOXINT	IU	(2R,5S,7R)-2-pyridin-3-yl-1-azatricyclo[3.3.1.13,7]decane
DMOXINT	DE	Discovery agent

DMWSI0H	ID	DMWSI0H
DMWSI0H	DN	Tiapamil
DMWSI0H	HS	Investigative
DMWSI0H	SN	ORE-5002; Tiapamil (CNS disease); Tiapamil (CNS disease), Ore Pharmaceuticals
DMWSI0H	CP	Roche Holding AG
DMWSI0H	DT	Small molecular drug
DMWSI0H	PC	42107
DMWSI0H	MW	555.7
DMWSI0H	FM	C26H37NO8S2
DMWSI0H	IC	InChI=1S/C26H37NO8S2/c1-27(15-12-20-8-10-22(32-2)24(18-20)34-4)14-6-13-26(36(28,29)16-7-17-37(26,30)31)21-9-11-23(33-3)25(19-21)35-5/h8-11,18-19H,6-7,12-17H2,1-5H3
DMWSI0H	CS	CN(CCCC1(S(=O)(=O)CCCS1(=O)=O)C2=CC(=C(C=C2)OC)OC)CCC3=CC(=C(C=C3)OC)OC
DMWSI0H	IK	ZROUQTNYPCANTN-UHFFFAOYSA-N
DMWSI0H	IU	N-[2-(3,4-dimethoxyphenyl)ethyl]-3-[2-(3,4-dimethoxyphenyl)-1,1,3,3-tetraoxo-1,3-dithian-2-yl]-N-methylpropan-1-amine
DMWSI0H	CA	CAS 57010-31-8
DMWSI0H	CB	CHEBI:35016
DMWSI0H	DE	Cardiovascular disease

DMEFVPH	ID	DMEFVPH
DMEFVPH	DN	Tiazofurin adenine dinucleotide
DMEFVPH	HS	Investigative
DMEFVPH	SN	Tiazofurin adenine dinucleotide; TCAD; NSC 358285; Thiazole-4-carboxamide adenine dinucleotide; CHEMBL394276; 83285-83-0; Adenosine 5'-(trihydrogen diphosphate), 5'-5'-ester with 2-beta-D-ribofuranosyl-4-thiazolecarboxamide; NSC358285; C19H25N7O14P2S; AC1L2KAD; BDBM19253; Tiazofurin Adenine Dinucleotide (TAD); LS-177745; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMEFVPH	DT	Small molecular drug
DMEFVPH	PC	73680
DMEFVPH	MW	669.5
DMEFVPH	FM	C19H25N7O14P2S
DMEFVPH	IC	InChI=1S/C19H25N7O14P2S/c20-15-9-17(23-4-22-15)26(5-24-9)19-13(30)11(28)8(39-19)2-37-42(34,35)40-41(32,33)36-1-7-10(27)12(29)14(38-7)18-25-6(3-43-18)16(21)31/h3-5,7-8,10-14,19,27-30H,1-2H2,(H2,21,31)(H,32,33)(H,34,35)(H2,20,22,23)/t7-,8-,10-,11-,12-,13-,14-,19-/m1/s1
DMEFVPH	CS	C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N
DMEFVPH	IK	INQLNSVYIFCUML-QZTLEVGFSA-N
DMEFVPH	IU	[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMEFVPH	CA	CAS 83285-83-0
DMEFVPH	DE	Discovery agent

DMMFCHU	ID	DMMFCHU
DMMFCHU	DN	Tic-D-Phe-Arg-2-Nal-NHCH3
DMMFCHU	HS	Investigative
DMMFCHU	SN	CHEMBL381357; Tic-D-Phe-Arg-2-Nal-NHCH3
DMMFCHU	DT	Small molecular drug
DMMFCHU	PC	44409257
DMMFCHU	MW	690.8
DMMFCHU	FM	C39H46N8O4
DMMFCHU	IC	InChI=1S/C39H46N8O4/c1-42-35(48)33(22-26-17-18-27-12-5-6-13-28(27)20-26)46-36(49)31(16-9-19-43-39(40)41)45-38(51)34(21-25-10-3-2-4-11-25)47-37(50)32-23-29-14-7-8-15-30(29)24-44-32/h2-8,10-15,17-18,20,31-34,44H,9,16,19,21-24H2,1H3,(H,42,48)(H,45,51)(H,46,49)(H,47,50)(H4,40,41,43)/t31-,32-,33-,34+/m0/s1
DMMFCHU	CS	CNC(=O)[C@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CC5=CC=CC=C5CN4
DMMFCHU	IK	MCHDZFRIUNRJGL-GZXHTMMISA-N
DMMFCHU	IU	(3S)-N-[(2R)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1-(methylamino)-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
DMMFCHU	DE	Discovery agent

DM71HQL	ID	DM71HQL
DM71HQL	DN	Tideglusib
DM71HQL	HS	Investigative
DM71HQL	SN	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)
DM71HQL	TC	Antiviral Agents
DM71HQL	DT	Small molecular drug
DM71HQL	PC	11313622
DM71HQL	MW	334.4
DM71HQL	FM	C19H14N2O2S
DM71HQL	IC	InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2
DM71HQL	CS	C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43
DM71HQL	IK	PMJIHLSCWIDGMD-UHFFFAOYSA-N
DM71HQL	IU	4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
DM71HQL	CA	CAS 865854-05-3
DM71HQL	CB	CHEBI:147398
DM71HQL	DE	Osteosarcoma; Coronavirus Disease 2019 (COVID-19)

DM4QK0T	ID	DM4QK0T
DM4QK0T	DN	tifluadom
DM4QK0T	HS	Investigative
DM4QK0T	SN	Tifluadom; dl-Tifluadom; Tifluadom [INN]; 83386-35-0; KC 5103; EINECS 280-380-4; Tifluadom (INN); C22H20FN3OS; CHEBI:9591; CHEMBL169703; 81656-30-6; 3-Thiophenecarboxamide, N-((5-(2-fluorophenyl)-2,3-dihydro-1-methyl-1H-1,4-benzodiazepin-2-yl)methyl)-; N-[[5-(2-fluorophenyl)-1-methyl-2,3-dihydro-1,4-benzodiazepin-2-yl]methyl]thiophene-3-carboxamide; 3-Thiophenecarboxamide,N-[[5-(2-fluorophenyl)- 2,3-dihydro-1-methyl-1H-1,4- benzodiazepin-2-yl]methyl]-; titfluadom
DM4QK0T	DT	Small molecular drug
DM4QK0T	PC	115208
DM4QK0T	MW	393.5
DM4QK0T	FM	C22H20FN3OS
DM4QK0T	IC	InChI=1S/C22H20FN3OS/c1-26-16(13-25-22(27)15-10-11-28-14-15)12-24-21(17-6-2-4-8-19(17)23)18-7-3-5-9-20(18)26/h2-11,14,16H,12-13H2,1H3,(H,25,27)
DM4QK0T	CS	CN1C(CN=C(C2=CC=CC=C21)C3=CC=CC=C3F)CNC(=O)C4=CSC=C4
DM4QK0T	IK	NPGABYHTDVGGJK-UHFFFAOYSA-N
DM4QK0T	IU	N-[[5-(2-fluorophenyl)-1-methyl-2,3-dihydro-1,4-benzodiazepin-2-yl]methyl]thiophene-3-carboxamide
DM4QK0T	CA	CAS 83386-35-0
DM4QK0T	CB	CHEBI:9591
DM4QK0T	DE	Discovery agent

DMLNTB5	ID	DMLNTB5
DMLNTB5	DN	TILIROSIDE
DMLNTB5	HS	Investigative
DMLNTB5	SN	Tiliroside; 20316-62-5; Tribuloside; Trans-Tiliroside; UNII-15M04TXR9M; CHEMBL266564; 15M04TXR9M; CHEBI:80944; 22153-44-2; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, 6'-ester with 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; AC1NSZRJ; SCHEMBL23597; Tiliroside, analytical standard; MEGxp0_000169; MolPort-001-740-347; ZINC17654711; BDBM50241244; AKOS015896718; MCULE-6075035042; NCGC00163634-01; LS-123660; W1685; kaempferol 3-O-(6"-O-p-coumaroyl)-glucoside; C17140
DMLNTB5	DT	Small molecular drug
DMLNTB5	PC	5320686
DMLNTB5	MW	594.5
DMLNTB5	FM	C30H26O13
DMLNTB5	IC	InChI=1S/C30H26O13/c31-16-6-1-14(2-7-16)3-10-22(35)40-13-21-24(36)26(38)27(39)30(42-21)43-29-25(37)23-19(34)11-18(33)12-20(23)41-28(29)15-4-8-17(32)9-5-15/h1-12,21,24,26-27,30-34,36,38-39H,13H2/b10-3+/t21-,24-,26+,27-,30+/m1/s1
DMLNTB5	CS	C1=CC(=CC=C1/C=C/C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O)O)O)O
DMLNTB5	IK	DVGGLGXQSFURLP-VWMSDXGPSA-N
DMLNTB5	IU	[(2R,3S,4S,5R,6S)-6-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl (E)-3-(4-hydroxyphenyl)prop-2-enoate
DMLNTB5	CA	CAS 20316-62-5
DMLNTB5	CB	CHEBI:80944
DMLNTB5	DE	Discovery agent

DMTXJ5S	ID	DMTXJ5S
DMTXJ5S	DN	Tin protoporphyrin
DMTXJ5S	HS	Investigative
DMTXJ5S	SN	AC1NUFJX; 3-[(1Z,4Z,10Z,14Z)-18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,22,23,24-tetraid-2-yl]propanoic acid
DMTXJ5S	DT	Small molecular drug
DMTXJ5S	PC	24197550
DMTXJ5S	MW	679.4
DMTXJ5S	FM	C34H32N4O4Sn
DMTXJ5S	IC	InChI=1S/C34H32N4O4.Sn/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H,39,40)(H,41,42);/q-4;+4/b25-13-,26-13?,27-14?,28-15-,29-14-,30-15?,31-16?,32-16-;
DMTXJ5S	CS	CC\\1=C(/C/2=C/C3=C(C(=C([N-]3)/C=C\\4/C(=C(/C(=C/C5=C(C(=C([N-]5)/C=C1\\[N-]2)C=C)C)/[N-]4)C=C)C)C)CCC(=O)O)CCC(=O)O.[Sn+4]
DMTXJ5S	IK	VWEYNEFKXXWVHZ-QPPPNFCJSA-N
DMTXJ5S	IU	3-[(1Z,4Z,10Z,14Z)-18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,22,23,24-tetraid-2-yl]propanoic acid;tin(4+)
DMTXJ5S	DE	Discovery agent

DMEV7FY	ID	DMEV7FY
DMEV7FY	DN	TINGENIN B
DMEV7FY	HS	Investigative
DMEV7FY	SN	Tingenin B; 22-Hydroxytingenone; 50656-68-3; (6aS,6bS,8aR,9S,11R,12aS,14aR)-3,9-dihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione; AC1L2JCW; AC1Q6P5G; (6bs,8ar,9s,11r,12as,12bs,14ar)-3,9-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,8a,11,12,12a,12b,13,14,14a-decahydropicene-2,10(6bh,9h)-dione; CTK4J2949; D:A-Friedo-24,30-dinoroleana-1(10),3,5,7-tetraene-2,21-dione, 3,22-dihydroxy-, (20beta,22beta)-
DMEV7FY	DT	Small molecular drug
DMEV7FY	PC	73147
DMEV7FY	MW	436.6
DMEV7FY	FM	C28H36O4
DMEV7FY	IC	InChI=1S/C28H36O4/c1-15-13-21-26(4,24(32)22(15)30)10-12-27(5)20-8-7-17-16(2)23(31)19(29)14-18(17)25(20,3)9-11-28(21,27)6/h7-8,14-15,21,24,31-32H,9-13H2,1-6H3/t15-,21-,24-,25+,26-,27-,28+/m1/s1
DMEV7FY	CS	C[C@@H]1C[C@@H]2[C@@](CC[C@]3([C@]2(CC[C@@]4(C3=CC=C5C4=CC(=O)C(=C5C)O)C)C)C)([C@@H](C1=O)O)C
DMEV7FY	IK	QIRUFAFQGKOTKA-ZRWKYKNNSA-N
DMEV7FY	IU	(6aS,6bS,8aR,9S,11R,12aS,14aR)-3,9-dihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
DMEV7FY	CA	CAS 50656-68-3
DMEV7FY	DE	Discovery agent

DMH3NTP	ID	DMH3NTP
DMH3NTP	DN	TINGENONE
DMH3NTP	HS	Investigative
DMH3NTP	SN	Maitenin; Tingenone; Tingenin A; Tingenon; Maytenin; 50802-21-6; maitenine; D:A-Friedo-24,30-dinoroleana-1(10),3,5,7-tetraene-2,21-dione, 3-hydroxy-, (20-beta)-; 20-decarboxy-20-oxocelastrol; NSC608781; AC1Q6P7B; (20b)-3-hydroxy-d:a-friedo-24,30-dinoroleana-1(10),3,5,7-tetraene-2,21-dione; SCHEMBL17064; AC1L2R07; C29H38O2; LS-69745
DMH3NTP	DT	Small molecular drug
DMH3NTP	PC	101520
DMH3NTP	MW	420.6
DMH3NTP	FM	C28H36O3
DMH3NTP	IC	InChI=1S/C28H36O3/c1-16-13-23-25(3,15-21(16)30)9-11-27(5)22-8-7-18-17(2)24(31)20(29)14-19(18)26(22,4)10-12-28(23,27)6/h7-8,14,16,23,31H,9-13,15H2,1-6H3/t16-,23-,25+,26+,27-,28+/m1/s1
DMH3NTP	CS	C[C@@H]1C[C@@H]2[C@@](CC[C@]3([C@]2(CC[C@@]4(C3=CC=C5C4=CC(=O)C(=C5C)O)C)C)C)(CC1=O)C
DMH3NTP	IK	WSTYNZDAOAEEKG-GWJSGULQSA-N
DMH3NTP	IU	(6aS,6bS,8aS,11R,12aR,14aR)-3-hydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
DMH3NTP	CA	CAS 50802-21-6
DMH3NTP	DE	Discovery agent

DM81KD2	ID	DM81KD2
DM81KD2	DN	tiotidine
DM81KD2	HS	Investigative
DM81KD2	SN	Tiotidine; TIOTIDINE; 69014-14-8; [3H]tiotidine; ICI 125,211; ICI-125211; Tiotidine [USAN:INN]; Tiotidinum [INN-Latin]; UNII-EZU9AIZ69M; Tiotidina [INN-Spanish]; EZU9AIZ69M; NCGC00163256-01; DSSTox_CID_26341; 2-Cyano-1-(2-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)ethyl)-3-methylguanidine; DSSTox_RID_81545; DSSTox_GSID_46341; Tiotidinum; Tiotidina; 2-guanidino-4-(2-(2-cyano-3-methylguanidino)ethylthiomethyl)thiazole; [3H]-tiotidine; Guanidine,;  ICI 125,211
DM81KD2	DT	Small molecular drug
DM81KD2	PC	50287
DM81KD2	MW	312.4
DM81KD2	FM	C10H16N8S2
DM81KD2	IC	InChI=1S/C10H16N8S2/c1-14-9(16-6-11)15-2-3-19-4-7-5-20-10(17-7)18-8(12)13/h5H,2-4H2,1H3,(H2,14,15,16)(H4,12,13,17,18)
DM81KD2	CS	CN=C(NCCSCC1=CSC(=N1)N=C(N)N)NC#N
DM81KD2	IK	YDDXVAXDYKBWDX-UHFFFAOYSA-N
DM81KD2	IU	1-cyano-3-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-2-methylguanidine
DM81KD2	CA	CAS 69014-14-8
DM81KD2	CB	CHEBI:92190
DM81KD2	DE	Discovery agent

DMZO1FJ	ID	DMZO1FJ
DMZO1FJ	DN	TIP
DMZO1FJ	HS	Investigative
DMZO1FJ	SN	oxide; 16833-27-5; Oxide anion; Oxide ion; Atomic oxygen(2-); Oxygen, ion(O2-); oxide(2-); AC1L4Q4G; AC1Q22UN; CTK4D2966; CHEBI:29356; O(2-)
DMZO1FJ	DT	Small molecular drug
DMZO1FJ	PC	190217
DMZO1FJ	MW	15.999
DMZO1FJ	FM	O-2
DMZO1FJ	IC	InChI=1S/O/q-2
DMZO1FJ	CS	[O-2]
DMZO1FJ	IK	AHKZTVQIVOEVFO-UHFFFAOYSA-N
DMZO1FJ	IU	oxygen(2-)
DMZO1FJ	CA	CAS 16833-27-5
DMZO1FJ	CB	CHEBI:29356
DMZO1FJ	DE	Discovery agent

DM9FNQ6	ID	DM9FNQ6
DM9FNQ6	DN	TIPPpsi
DM9FNQ6	HS	Investigative
DM9FNQ6	SN	TIPP-psi
DM9FNQ6	DT	Small molecular drug
DM9FNQ6	PC	5311481
DM9FNQ6	MW	620.7
DM9FNQ6	FM	C37H40N4O5
DM9FNQ6	IC	InChI=1S/C37H40N4O5/c38-32(19-27-15-17-31(42)18-16-27)36(44)41-24-29-14-8-7-13-28(29)22-30(41)23-39-33(20-25-9-3-1-4-10-25)35(43)40-34(37(45)46)21-26-11-5-2-6-12-26/h1-18,30,32-34,39,42H,19-24,38H2,(H,40,43)(H,45,46)/t30-,32-,33-,34-/m0/s1
DM9FNQ6	CS	C1[C@H](N(CC2=CC=CC=C21)C(=O)[C@H](CC3=CC=C(C=C3)O)N)CN[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O
DM9FNQ6	IK	RPKMHCAOERKVEC-DYTOPAQESA-N
DM9FNQ6	IU	(2S)-2-[[(2S)-2-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-3,4-dihydro-1H-isoquinolin-3-yl]methylamino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
DM9FNQ6	CA	CAS 159992-07-1
DM9FNQ6	DE	Discovery agent

DMQ4GBO	ID	DMQ4GBO
DMQ4GBO	DN	tirotundin
DMQ4GBO	HS	Investigative
DMQ4GBO	SN	Tirotundin; 56377-67-4; MEGxp0_000078; GTPL8700; CHEMBL464453; MolPort-039-052-526; ZINC40393738; BDBM50394803; AKOS032948657
DMQ4GBO	DT	Small molecular drug
DMQ4GBO	PC	9975297
DMQ4GBO	MW	352.4
DMQ4GBO	FM	C19H28O6
DMQ4GBO	IC	InChI=1S/C19H28O6/c1-10(2)16(20)24-14-9-18(5)6-7-19(22,25-18)11(3)8-13-15(14)12(4)17(21)23-13/h10-11,13-15,22H,4,6-9H2,1-3,5H3/t11-,13+,14+,15-,18-,19+/m0/s1
DMQ4GBO	CS	C[C@H]1C[C@@H]2[C@@H]([C@@H](C[C@@]3(CC[C@]1(O3)O)C)OC(=O)C(C)C)C(=C)C(=O)O2
DMQ4GBO	IK	VKWNXJLVNFOOOS-QNIDSSLUSA-N
DMQ4GBO	IU	[(1R,2S,4R,8S,9R,11S)-1-hydroxy-2,11-dimethyl-7-methylidene-6-oxo-5,14-dioxatricyclo[9.2.1.04,8]tetradecan-9-yl] 2-methylpropanoate
DMQ4GBO	DE	Discovery agent

DMKV52P	ID	DMKV52P
DMKV52P	DN	TK-112690
DMKV52P	HS	Investigative
DMKV52P	SN	TK-112690 (mucositis); TK-112690 (mucositis), Tosk
DMKV52P	CP	Tosk Inc
DMKV52P	DE	Mucositis

DMYGXHK	ID	DMYGXHK
DMYGXHK	DN	T-kinin
DMYGXHK	HS	Investigative
DMYGXHK	SN	[Ile,Ser]bradykinin; Ile-Ser-BK
DMYGXHK	DT	Small molecular drug
DMYGXHK	PC	123643
DMYGXHK	MW	1260.4
DMYGXHK	FM	C59H89N17O14
DMYGXHK	IC	InChI=1S/C59H89N17O14/c1-3-34(2)47(60)53(85)72-41(32-77)50(82)69-37(19-10-24-65-58(61)62)54(86)76-28-14-23-45(76)56(88)75-27-12-21-43(75)51(83)67-31-46(79)68-39(29-35-15-6-4-7-16-35)48(80)73-42(33-78)55(87)74-26-13-22-44(74)52(84)71-40(30-36-17-8-5-9-18-36)49(81)70-38(57(89)90)20-11-25-66-59(63)64/h4-9,15-18,34,37-45,47,77-78H,3,10-14,19-33,60H2,1-2H3,(H,67,83)(H,68,79)(H,69,82)(H,70,81)(H,71,84)(H,72,85)(H,73,80)(H,89,90)(H4,61,62,65)(H4,63,64,66)/t34-,37-,38-,39-,40-,41-,42-,43-,44-,45-,47-/m0/s1
DMYGXHK	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N
DMYGXHK	IK	GKCWYHPGFSRBQV-WRBAKOPXSA-N
DMYGXHK	IU	(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMYGXHK	CA	CAS 86030-63-9
DMYGXHK	CB	CHEBI:80238
DMYGXHK	DE	Discovery agent

DMDBUXR	ID	DMDBUXR
DMDBUXR	DN	TKP-1001
DMDBUXR	HS	Investigative
DMDBUXR	SN	Amyloid-beta modulator (Alzheimer's disease), EUSA Pharma; Amyloid-beta modulator (Alzheimer's disease), Talisker Pharma; Amyloid-beta synthesis modulator (Alzheimer's disease), The Open University
DMDBUXR	CP	The Open University
DMDBUXR	DE	Alzheimer disease

DMZU4O8	ID	DMZU4O8
DMZU4O8	DN	TKP-1002
DMZU4O8	HS	Investigative
DMZU4O8	SN	Antipsychotics (schizophrenia), EUSA Pharma; Antipsychotics (schizophrenia), Talisker Pharma; Antipsychotics (schizophrenia), University of Liege
DMZU4O8	CP	University of Liege
DMZU4O8	DE	Schizophrenia

DMAHG9E	ID	DMAHG9E
DMAHG9E	DN	TL-1892
DMAHG9E	HS	Investigative
DMAHG9E	SN	Taxane analog (oral, cancer), Taxolog
DMAHG9E	CP	Taxolog Inc
DMAHG9E	DE	Solid tumour/cancer

DMCN2B8	ID	DMCN2B8
DMCN2B8	DN	TMB-8
DMCN2B8	HS	Investigative
DMCN2B8	SN	TMB-8; 8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate; TMB 8; 57818-92-5; TM-8; 8-(N,N-Diethylamino)octyl-3,4,5-trimethoxybenzoate; 3,4,5-Trimethoxybenzoic acid, 8-(diethylamino)octyl ester; C22H37NO5; AC1L1KGS; AC1Q67GP; Lopac-861804; Lopac0_000022; BSPBio_001503; GTPL4323; CHEMBL258764; SCHEMBL2173737; CTK5A7496; DTXSID70206532; CHEBI:107633; HMS1989L05; HMS1791L05; HMS3402L05; 53464-72-5 (hydrochloride); ZINC3875139; EI-110; AKOS030559942; MCULE-5343453436; CCG-204118; NCGC00162047-03; NCGC00162047-01; NCGC00014998-06
DMCN2B8	DT	Small molecular drug
DMCN2B8	PC	5494
DMCN2B8	MW	395.5
DMCN2B8	FM	C22H37NO5
DMCN2B8	IC	InChI=1S/C22H37NO5/c1-6-23(7-2)14-12-10-8-9-11-13-15-28-22(24)18-16-19(25-3)21(27-5)20(17-18)26-4/h16-17H,6-15H2,1-5H3
DMCN2B8	CS	CCN(CC)CCCCCCCCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC
DMCN2B8	IK	IBQMHBGFMLHHLE-UHFFFAOYSA-N
DMCN2B8	IU	8-(diethylamino)octyl 3,4,5-trimethoxybenzoate
DMCN2B8	CA	CAS 57818-92-5
DMCN2B8	CB	CHEBI:107633
DMCN2B8	DE	Discovery agent

DMSMQE7	ID	DMSMQE7
DMSMQE7	DN	TMP269
DMSMQE7	HS	Investigative
DMSMQE7	SN	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269
DMSMQE7	DT	Small molecular drug
DMSMQE7	PC	53344908
DMSMQE7	MW	514.5
DMSMQE7	FM	C25H21F3N4O3S
DMSMQE7	IC	InChI=1S/C25H21F3N4O3S/c26-25(27,28)22-31-20(32-35-22)17-7-4-8-18(13-17)21(33)29-15-24(9-11-34-12-10-24)23-30-19(14-36-23)16-5-2-1-3-6-16/h1-8,13-14H,9-12,15H2,(H,29,33)
DMSMQE7	CS	C1COCCC1(CNC(=O)C2=CC=CC(=C2)C3=NOC(=N3)C(F)(F)F)C4=NC(=CS4)C5=CC=CC=C5
DMSMQE7	IK	HORXBWNTEDOVKN-UHFFFAOYSA-N
DMSMQE7	IU	N-[[4-(4-phenyl-1,3-thiazol-2-yl)oxan-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
DMSMQE7	DE	Discovery agent

DMWO85H	ID	DMWO85H
DMWO85H	DN	TMPyP4
DMWO85H	HS	Investigative
DMWO85H	SN	TMPP; AC1L1HPJ; N-Methylpyridylylporphyrin; AC1Q29RK; CHEMBL65606; ABCGFHPGHXSVKI-UHFFFAOYSA-O; BDBM50107609; 4,4',4'',4'''-(5,10,15,20-porphyrintetrayl)tetrakis(1-methylpyridinium); J2.096.016G; 5,10,15,20-tetra(1-methyl-4-pyridyl)-porphyrin; 5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin
DMWO85H	CP	Geron Corp
DMWO85H	DT	Small molecular drug
DMWO85H	PC	135398505
DMWO85H	MW	678.8
DMWO85H	FM	C44H38N8+4
DMWO85H	IC	InChI=1S/C44H37N8/c1-49-21-13-29(14-22-49)41-33-5-7-35(45-33)42(30-15-23-50(2)24-16-30)37-9-11-39(47-37)44(32-19-27-52(4)28-20-32)40-12-10-38(48-40)43(36-8-6-34(41)46-36)31-17-25-51(3)26-18-31/h5-28H,1-4H3,(H,45,46,47,48)/q+3/p+1
DMWO85H	CS	C[N+]1=CC=C(C=C1)C2=C3C=CC(=C(C4=NC(=C(C5=CC=C(N5)C(=C6C=CC2=N6)C7=CC=[N+](C=C7)C)C8=CC=[N+](C=C8)C)C=C4)C9=CC=[N+](C=C9)C)N3
DMWO85H	IK	ABCGFHPGHXSVKI-UHFFFAOYSA-O
DMWO85H	IU	5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,23-dihydroporphyrin
DMWO85H	CA	CAS 38673-65-3
DMWO85H	DE	Multiple myeloma

DMULO0V	ID	DMULO0V
DMULO0V	DN	TMX-201
DMULO0V	HS	Investigative
DMULO0V	SN	TLR7-modulating vaccine adjuvant, Telormedix
DMULO0V	CP	University of California San Diego
DMULO0V	DT	Vaccine
DMULO0V	DE	Autoimmune diabetes

DMPX3WT	ID	DMPX3WT
DMPX3WT	DN	TMX-202
DMPX3WT	HS	Investigative
DMPX3WT	SN	TMX-20X
DMPX3WT	CP	University of California San Diego
DMPX3WT	DE	Bladder cancer

DMSEAMU	ID	DMSEAMU
DMSEAMU	DN	TMX-30X
DMSEAMU	HS	Investigative
DMSEAMU	SN	TMX-301
DMSEAMU	CP	Telormedix SA
DMSEAMU	DE	Autoimmune diabetes

DME0I7O	ID	DME0I7O
DME0I7O	DN	TN-14003
DME0I7O	HS	Investigative
DME0I7O	SN	UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4-&gt;13)-disulfide
DME0I7O	PC	16130647
DME0I7O	MW	2037.4
DME0I7O	FM	C90H141N33O18S2
DME0I7O	IC	InChI=1S/C90H141N33O18S2/c91-35-5-3-17-59-75(130)117-64(18-4-6-36-92)84(139)123-43-13-24-70(123)83(138)120-66(46-51-28-33-56(125)34-29-51)79(134)116-61(21-10-40-108-88(101)102)74(129)114-63(23-12-42-110-90(104)141)77(132)121-68(81(136)111-58(71(94)126)19-8-38-106-86(97)98)48-142-143-49-69(82(137)119-65(45-50-26-31-55(124)32-27-50)78(133)115-62(73(128)113-59)22-11-41-109-89(103)140)122-80(135)67(47-52-25-30-53-14-1-2-15-54(53)44-52)118-76(131)60(20-9-39-107-87(99)100)112-72(127)57(93)16-7-37-105-85(95)96/h1-2,14-15,25-34,44,57-70,124-125H,3-13,16-24,35-43,45-49,91-93H2,(H2,94,126)(H,111,136)(H,112,127)(H,113,128)(H,114,129)(H,115,133)(H,116,134)(H,117,130)(H,118,131)(H,119,137)(H,120,138)(H,121,132)(H,122,135)(H4,95,96,105)(H4,97,98,106)(H4,99,100,107)(H4,101,102,108)(H3,103,109,140)(H3,104,110,141)/t57-,58-,59-,60-,61-,62-,63-,64+,65-,66-,67-,68-,69-,70-/m0/s1
DME0I7O	CS	C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC5=CC=CC=C5C=C4)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC6=CC=C(C=C6)O
DME0I7O	IK	DGQKRQOCJFODHN-OIHVMPBRSA-N
DME0I7O	IU	(3R,6S,9S,12S,15R,20R,23S,26S,29S,32S)-3,6-bis(4-aminobutyl)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-15-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-26-(3-carbamimidamidopropyl)-9,23-bis[3-(carbamoylamino)propyl]-12,29-bis[(4-hydroxyphenyl)methyl]-2,5,8,11,14,22,25,28,31-nonaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-20-carboxamide
DME0I7O	CA	CAS 368874-31-1
DME0I7O	DE	Acute lymphoblastic leukaemia

DMAGI7K	ID	DMAGI7K
DMAGI7K	DN	TNFcept
DMAGI7K	HS	Investigative
DMAGI7K	SN	TNFcept (rheumatoid arthritis)
DMAGI7K	CP	LG Life Sciences Ltd
DMAGI7K	DE	Rheumatoid arthritis

DM4T0ZF	ID	DM4T0ZF
DM4T0ZF	DN	TNFmab
DM4T0ZF	HS	Investigative
DM4T0ZF	SN	TNFmab (rheumatoid arthritis)
DM4T0ZF	CP	LG Life Sciences Ltd
DM4T0ZF	DT	Antibody
DM4T0ZF	DE	Rheumatoid arthritis

DMPTQEG	ID	DMPTQEG
DMPTQEG	DN	TNFR1 NAM
DMPTQEG	HS	Investigative
DMPTQEG	SN	TNFR1 negative allosteric modulators, Addex
DMPTQEG	CP	Addex Pharmaceuticals SA
DMPTQEG	DE	Multiple sclerosis

DMC958O	ID	DMC958O
DMC958O	DN	TNK-651
DMC958O	HS	Investigative
DMC958O	SN	175739-42-1
DMC958O	DT	Small molecular drug
DMC958O	PC	446515
DMC958O	MW	364.4
DMC958O	FM	C22H24N2O3
DMC958O	IC	InChI=1S/C22H24N2O3/c1-16(2)20-19(13-17-9-5-3-6-10-17)24(22(26)23-21(20)25)15-27-14-18-11-7-4-8-12-18/h3-12,16H,13-15H2,1-2H3,(H,23,25,26)
DMC958O	CS	CC(C)C1=C(N(C(=O)NC1=O)COCC2=CC=CC=C2)CC3=CC=CC=C3
DMC958O	IK	KSAAUHMSLCPIEX-UHFFFAOYSA-N
DMC958O	IU	6-benzyl-1-(phenylmethoxymethyl)-5-propan-2-ylpyrimidine-2,4-dione
DMC958O	CA	CAS 175739-42-1
DMC958O	CB	CHEBI:45910
DMC958O	DE	Discovery agent

DMVZY0X	ID	DMVZY0X
DMVZY0X	DN	TNP-ATP
DMVZY0X	HS	Investigative
DMVZY0X	SN	2',3'-O-(2,4,6-trinitrophenyl)-ATP
DMVZY0X	DT	Small molecular drug
DMVZY0X	PC	3035228
DMVZY0X	MW	713.2
DMVZY0X	FM	C16H12N8O19P3-
DMVZY0X	IC	InChI=1S/C16H13N8O19P3/c17-13-10-14(19-4-18-13)21(5-20-10)15-12-11(7(39-15)3-38-45(34,35)43-46(36,37)42-44(31,32)33)40-16(41-12)8(23(27)28)1-6(22(25)26)2-9(16)24(29)30/h1-2,4-5,8,10,17H,3H2,(H4,31,32,33,34,35,36,37)/p-1
DMVZY0X	CS	C1=C(C=C(C2(C1[N+](=O)[O-])OC3=C(OC(=C3O2)[N+]4=C5C(C(=NC=N5)N)N=C4)COP(=O)(O)OP(=O)(O)OP(=O)([O-])[O-])[N+](=O)[O-])[N+](=O)[O-]
DMVZY0X	IK	NHXFSKZBEIIARS-UHFFFAOYSA-M
DMVZY0X	IU	[[[4'-(6-amino-5H-purin-9-ium-9-yl)-1,3,5-trinitrospiro[cyclohexa-1,3-diene-6,2'-furo[3,4-d][1,3]dioxole]-6'-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] phosphate
DMVZY0X	CA	CAS 61368-63-6
DMVZY0X	DE	Discovery agent

DMHV5NK	ID	DMHV5NK
DMHV5NK	DN	TOLOXATONE
DMHV5NK	HS	Investigative
DMHV5NK	SN	Toloxatone; 29218-27-7; Humoryl; Perenum; 5-(Hydroxymethyl)-3-(m-tolyl)oxazolidin-2-one; Toloxatone [INN]; Delalande 69276; Toloxatonum [INN-Latin]; Toloxatona [INN-Spanish]; 5-(Hydroxymethyl)-3-(3-methylphenyl)-2-oxazolidinone; EINECS 249-522-2; BRN 0527506; 69276 MD; CHEMBL18116; 2-oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)-; 5-Hydroxymethyl-3-(m-tolyl)-2-oxazolidinone; 5-(Hydroxymethyl)-3-m-tolyl-2-oxazolidinone; Toloxatone (INN); 5-(hydroxymethyl)-3-m-tolyloxazolidin-2-one; 2-Oxazolidinone, 5-hydroxymethyl-3-(m-t
DMHV5NK	DT	Small molecular drug
DMHV5NK	PC	34521
DMHV5NK	MW	207.23
DMHV5NK	FM	C11H13NO3
DMHV5NK	IC	InChI=1S/C11H13NO3/c1-8-3-2-4-9(5-8)12-6-10(7-13)15-11(12)14/h2-5,10,13H,6-7H2,1H3
DMHV5NK	CS	CC1=CC(=CC=C1)N2CC(OC2=O)CO
DMHV5NK	IK	MXUNKHLAEDCYJL-UHFFFAOYSA-N
DMHV5NK	IU	5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one
DMHV5NK	CA	CAS 29218-27-7
DMHV5NK	CB	CHEBI:156575
DMHV5NK	DE	Discovery agent

DMPTM6V	ID	DMPTM6V
DMPTM6V	DN	TOLSERINE
DMPTM6V	HS	Investigative
DMPTM6V	SN	tolserine.tartaric acid; 2-methylphenserine; CHEMBL130458; SCHEMBL8920175; BDBM10959; (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-(2-methylphenyl)carbamate
DMPTM6V	DT	Small molecular drug
DMPTM6V	PC	9928397
DMPTM6V	MW	351.4
DMPTM6V	FM	C21H25N3O2
DMPTM6V	IC	InChI=1S/C21H25N3O2/c1-14-7-5-6-8-17(14)22-20(25)26-15-9-10-18-16(13-15)21(2)11-12-23(3)19(21)24(18)4/h5-10,13,19H,11-12H2,1-4H3,(H,22,25)/t19-,21+/m1/s1
DMPTM6V	CS	CC1=CC=CC=C1NC(=O)OC2=CC3=C(C=C2)N([C@@H]4[C@]3(CCN4C)C)C
DMPTM6V	IK	JGAGHIIOCADQOV-CTNGQTDRSA-N
DMPTM6V	IU	[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(2-methylphenyl)carbamate
DMPTM6V	DE	Discovery agent

DMAYUV6	ID	DMAYUV6
DMAYUV6	DN	Toluene-1-diazonium-3-sulfonic acid anion
DMAYUV6	HS	Investigative
DMAYUV6	SN	m-azobenzenesulfonate; m-azobenzenesulphonate; meta-azobenzenesulfonate; m-diazoniobenzenesulfonate; 3-diazoniobenzenesulfonate; 1-benzenediazonium-3-sulfonate; m-sulfanilic acid diazonium salt; CHEBI:64458
DMAYUV6	DT	Small molecular drug
DMAYUV6	PC	13948283
DMAYUV6	MW	184.17
DMAYUV6	FM	C6H4N2O3S
DMAYUV6	IC	InChI=1S/C6H4N2O3S/c7-8-5-2-1-3-6(4-5)12(9,10)11/h1-4H
DMAYUV6	CS	C1=CC(=CC(=C1)S(=O)(=O)[O-])[N+]#N
DMAYUV6	IK	MQAGWJGGLKPBSC-UHFFFAOYSA-N
DMAYUV6	IU	3-diazoniobenzenesulfonate
DMAYUV6	CA	CAS 618-06-4
DMAYUV6	CB	CHEBI:64458
DMAYUV6	DE	Discovery agent

DMA3U15	ID	DMA3U15
DMA3U15	DN	Tomatine
DMA3U15	HS	Investigative
DMA3U15	SN	(3beta,5alpha,22beta,25S)-Spirosolan-3-yl O-beta-D-glucopyranosyl-(1-2)-O-(beta-D-xylopyranosyl)-(1-3))-O-(beta-D-glucopyranosyl-(1-4)-beta-D-Galactopyr; A''-Tomatidine; Lycopersicin; Tomatidine, glycoside; Tomatin; Tomatine; alpha-Tomatine; beta-D-Galactopyranoside, (3beta,5alpha,22beta,25S)-spirosolan-3-yl O-beta-D-glucopyranosyl-(1-2)-O-(beta-D-xylopyranosyl-(1-3))-O-beta-D-glucopyranosyl-(1-4)-
DMA3U15	TC	Antimicrobial Agents
DMA3U15	PC	28523
DMA3U15	MW	1034.2
DMA3U15	FM	C50H83NO21
DMA3U15	IC	InChI=1S/C50H83NO21/c1-20-7-12-50(51-15-20)21(2)32-28(72-50)14-26-24-6-5-22-13-23(8-10-48(22,3)25(24)9-11-49(26,32)4)65-45-40(63)37(60)41(31(18-54)68-45)69-47-43(71-46-39(62)36(59)34(57)29(16-52)66-46)42(35(58)30(17-53)67-47)70-44-38(61)33(56)27(55)19-64-44/h20-47,51-63H,5-19H2,1-4H3/t20-,21-,22-,23-,24+,25-,26-,27+,28-,29+,30+,31+,32-,33-,34+,35+,36-,37+,38+,39+,40+,41-,42-,43+,44-,45+,46-,47-,48-,49-,50-/m0/s1
DMA3U15	CS	CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)CO)O)OC9C(C(C(CO9)O)O)O)OC2C(C(C(C(O2)CO)O)O)O)O)O)C)C)C)NC1
DMA3U15	IK	REJLGAUYTKNVJM-SGXCCWNXSA-N
DMA3U15	IU	(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1R,2S,4S,5'S,6S,7S,8R,9S,12S,13S,16S,18S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-piperidine]-16-yl]oxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMA3U15	CA	CAS 17406-45-0
DMA3U15	CB	ChEBI:9630

DMROZL8	ID	DMROZL8
DMROZL8	DN	Tonazocine mesylate
DMROZL8	HS	Investigative
DMROZL8	DT	Small molecular drug
DMROZL8	PC	76965006
DMROZL8	MW	453.6
DMROZL8	FM	C24H39NO5S
DMROZL8	IC	InChI=1S/C23H35NO2.CH4O3S/c1-5-6-7-8-18(25)11-12-23(3)21-15-17-9-10-19(26)16-20(17)22(23,2)13-14-24(21)4;1-5(2,3)4/h9-10,16,21,26H,5-8,11-15H2,1-4H3;1H3,(H,2,3,4)/t21-,22+,23-;/m1./s1
DMROZL8	CS	CCCCCC(=O)CC[C@@]1([C@H]2CC3=C([C@@]1(CCN2C)C)C=C(C=C3)O)C.CS(=O)(=O)O
DMROZL8	IK	CQSTVPYARYSBNS-HZLAGBECSA-N
DMROZL8	IU	1-[(1S,9R,13S)-4-hydroxy-1,10,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-13-yl]octan-3-one;methanesulfonic acid
DMROZL8	CA	CAS 73789-00-1
DMROZL8	DE	Discovery agent

DMNZQO9	ID	DMNZQO9
DMNZQO9	DN	TOPOSTATIN
DMNZQO9	HS	Investigative
DMNZQO9	SN	topostatin; CHEMBL505529
DMNZQO9	DT	Small molecular drug
DMNZQO9	PC	44559995
DMNZQO9	MW	754.9
DMNZQO9	FM	C36H58N4O11S
DMNZQO9	IC	InChI=1S/C36H58N4O11S/c1-8-9-10-11-12-13-22(2)14-15-23(3)16-18-29(41)24(4)17-19-30-26(6)34(44)39-27(7)35(45)38-21-25(5)33(43)40-28(36(46)50-30)20-31(32(37)42)51-52(47,48)49/h15-16,18,22,24-26,28,30-31H,7-14,17,19-21H2,1-6H3,(H2,37,42)(H,38,45)(H,39,44)(H,40,43)(H,47,48,49)/b18-16+,23-15+/t22?,24?,25-,26?,28-,30?,31?/m0/s1
DMNZQO9	CS	CCCCCCCC(C)C/C=C(\\C)/C=C/C(=O)C(C)CCC1C(C(=O)NC(=C)C(=O)NC[C@@H](C(=O)N[C@H](C(=O)O1)CC(C(=O)N)OS(=O)(=O)O)C)C
DMNZQO9	IK	XLDIAUNLPWGNHO-NUPNHORYSA-N
DMNZQO9	IU	[1-amino-3-[(3S,6S)-6,13-dimethyl-10-methylidene-2,5,9,12-tetraoxo-14-[(5E,7E)-3,7,10-trimethyl-4-oxoheptadeca-5,7-dienyl]-1-oxa-4,8,11-triazacyclotetradec-3-yl]-1-oxopropan-2-yl] hydrogen sulfate
DMNZQO9	DE	Discovery agent

DMKD6GA	ID	DMKD6GA
DMKD6GA	DN	Toremifene
DMKD6GA	HS	Investigative
DMKD6GA	SN	Farestone; Z-Toremifene; Toremifeno; Toremifenum; Toremifenum [Latin]; Toremifeno [Spanish]; FC-1157a; GTx 006; Toremifene [INN:BAN]; UNII-7NFE54O27T; GTx-006
DMKD6GA	TC	Antiviral Agents
DMKD6GA	DT	Small molecular drug
DMKD6GA	PC	3005573
DMKD6GA	MW	406
DMKD6GA	FM	C26H28ClNO
DMKD6GA	IC	InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
DMKD6GA	CS	CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\\C2=CC=CC=C2)/C3=CC=CC=C3
DMKD6GA	IK	XFCLJVABOIYOMF-QPLCGJKRSA-N
DMKD6GA	IU	2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
DMKD6GA	CA	CAS 89778-26-7
DMKD6GA	CB	CHEBI:9635
DMKD6GA	DE	Coronavirus Disease 2019 (COVID-19)

DMZD0NA	ID	DMZD0NA
DMZD0NA	DN	torin 1
DMZD0NA	HS	Investigative
DMZD0NA	SN	Torin-1
DMZD0NA	DT	Small molecular drug
DMZD0NA	PC	49836027
DMZD0NA	MW	607.6
DMZD0NA	FM	C35H28F3N5O2
DMZD0NA	IC	InChI=1S/C35H28F3N5O2/c1-2-32(44)42-15-13-41(14-16-42)31-11-9-26(19-28(31)35(36,37)38)43-33(45)12-8-24-20-40-30-10-7-22(18-27(30)34(24)43)25-17-23-5-3-4-6-29(23)39-21-25/h3-12,17-21H,2,13-16H2,1H3
DMZD0NA	CS	CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F
DMZD0NA	IK	AKCRNFFTGXBONI-UHFFFAOYSA-N
DMZD0NA	IU	1-[4-(4-propanoylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-quinolin-3-ylbenzo[h][1,6]naphthyridin-2-one
DMZD0NA	CA	CAS 1222998-36-8
DMZD0NA	CB	CHEBI:84327
DMZD0NA	DE	Discovery agent

DMC6U93	ID	DMC6U93
DMC6U93	DN	Torin2
DMC6U93	HS	Investigative
DMC6U93	SN	Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE
DMC6U93	DT	Small molecular drug
DMC6U93	PC	51358113
DMC6U93	MW	432.4
DMC6U93	FM	C24H15F3N4O
DMC6U93	IC	InChI=1S/C24H15F3N4O/c25-24(26,27)17-2-1-3-18(11-17)31-22(32)9-6-16-13-29-20-7-4-14(10-19(20)23(16)31)15-5-8-21(28)30-12-15/h1-13H,(H2,28,30)
DMC6U93	CS	C1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CN=C(C=C5)N)C(F)(F)F
DMC6U93	IK	GUXXEUUYCAYESJ-UHFFFAOYSA-N
DMC6U93	IU	9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one
DMC6U93	CA	CAS 1223001-51-1
DMC6U93	CB	CHEBI:90682
DMC6U93	DE	T-cell leukaemia

DMDG0HK	ID	DMDG0HK
DMDG0HK	DN	Tormentic acid methyl ester
DMDG0HK	HS	Investigative
DMDG0HK	SN	Tormentic acid methyl ester; CHEMBL600614; 13850-15-2
DMDG0HK	DT	Small molecular drug
DMDG0HK	PC	14314585
DMDG0HK	MW	502.7
DMDG0HK	FM	C31H50O5
DMDG0HK	IC	InChI=1S/C31H50O5/c1-18-11-14-31(25(34)36-8)16-15-28(5)19(23(31)30(18,7)35)9-10-22-27(4)17-20(32)24(33)26(2,3)21(27)12-13-29(22,28)6/h9,18,20-24,32-33,35H,10-17H2,1-8H3/t18-,20-,21+,22-,23-,24+,27+,28-,29-,30-,31+/m1/s1
DMDG0HK	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H](C5(C)C)O)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)OC
DMDG0HK	IK	RQWXHGLRDYGNGZ-BPKREVGBSA-N
DMDG0HK	IU	methyl (1R,2R,4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-1,10,11-trihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMDG0HK	DE	Discovery agent

DMNC2A5	ID	DMNC2A5
DMNC2A5	DN	Tosyl-D-Proline
DMNC2A5	HS	Investigative
DMNC2A5	SN	TOSYL-D-PROLINE; TOS-D-PRO-OH; 110771-95-4; N-tosyl-D-proline; CHEMBL334226; TPR; (2R)-1-(4-methylphenyl)sulfonylpyrrolidine-2-carboxylic acid; 1f4e; AC1L9I3X; SCHEMBL2636629; ZINC63280; CTK8E6464; DTXSID60332192; CGPHGPCHVUSFFA-LLVKDONJSA-N; MolPort-014-930-952; BDBM50149243; 7792AH; AKOS006162662; DB02752; 1-[(4-methylphenyl)sulfonyl]-D-proline; AS-46804; D-Proline,1-[(4-methylphenyl)sulfonyl]-; D-Proline, 1-[(4-methylphenyl)sulfonyl]-; RT-016051; K-0696; (2R)-1-Tosylpyrrolidine-2beta-carboxylic acid; J-002477
DMNC2A5	DT	Small molecular drug
DMNC2A5	PC	445504
DMNC2A5	MW	269.32
DMNC2A5	FM	C12H15NO4S
DMNC2A5	IC	InChI=1S/C12H15NO4S/c1-9-4-6-10(7-5-9)18(16,17)13-8-2-3-11(13)12(14)15/h4-7,11H,2-3,8H2,1H3,(H,14,15)/t11-/m1/s1
DMNC2A5	CS	CC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@@H]2C(=O)O
DMNC2A5	IK	CGPHGPCHVUSFFA-LLVKDONJSA-N
DMNC2A5	IU	(2R)-1-(4-methylphenyl)sulfonylpyrrolidine-2-carboxylic acid
DMNC2A5	CA	CAS 110771-95-4
DMNC2A5	DE	Discovery agent

DM4R657	ID	DM4R657
DM4R657	DN	toxaphene
DM4R657	HS	Investigative
DM4R657	SN	octachlorocamphene
DM4R657	DT	Small molecular drug
DM4R657	PC	5284469
DM4R657	MW	411.8
DM4R657	FM	C10H8Cl8
DM4R657	IC	InChI=1S/C10H8Cl8/c1-4-7(2-11,3-12)9(16)6(14)5(13)8(4,15)10(9,17)18/h5-6H,1-3H2
DM4R657	CS	C=C1C(C2(C(C(C1(C2(Cl)Cl)Cl)Cl)Cl)Cl)(CCl)CCl
DM4R657	IK	OEJNXTAZZBRGDN-UHFFFAOYSA-N
DM4R657	IU	1,4,5,6,7,7-hexachloro-2,2-bis(chloromethyl)-3-methylidenebicyclo[2.2.1]heptane
DM4R657	CA	CAS 8001-35-2
DM4R657	DE	Discovery agent

DMJHTQK	ID	DMJHTQK
DMJHTQK	DN	TOXIFERINE
DMJHTQK	HS	Investigative
DMJHTQK	SN	TOXIFERINE; UNII-9M7D9K3OJI; Toxiferine I; 9M7D9K3OJI; CHEBI:9644; Toxiferine I, 2,2',16,16'-tetradehydro-16,16',17,17'-tetrahydro-; C-Toxiferine I; 302-30-7; C40H46N4O2; SCHEMBL3132546; CHEMBL1184078; LS-174284
DMJHTQK	DT	Small molecular drug
DMJHTQK	PC	5281411
DMJHTQK	MW	614.8
DMJHTQK	FM	C40H46N4O2+2
DMJHTQK	IC	InChI=1S/C40H46N4O2/c1-43-15-13-39-31-7-3-5-9-33(31)41-22-30-28-20-36-40(14-16-44(36,2)24-26(28)12-18-46)32-8-4-6-10-34(32)42(38(30)40)21-29(37(39)41)27(19-35(39)43)25(23-43)11-17-45/h3-12,21-22,27-28,35-38,45-46H,13-20,23-24H2,1-2H3/q+2/b25-11-,26-12-,29-21-,30-22-/t27-,28-,35-,36-,37-,38-,39+,40+,43-,44-/m0/s1
DMJHTQK	CS	C[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)C)/[C@@H](C3)/C(=C\\CO)/C1)CC2
DMJHTQK	IK	IIYHWTVUYIYKKG-QQRSFBQTSA-N
DMJHTQK	IU	(2E)-2-[(1S,9Z,11S,13S,14S,17S,25Z,27S,30S,33S,35S,36S,38E)-38-(2-hydroxyethylidene)-14,30-dimethyl-8,24-diaza-14,30-diazoniaundecacyclo[25.5.2.211,14.11,26.110,17.02,7.013,17.018,23.030,33.08,35.024,36]octatriaconta-2,4,6,9,18,20,22,25-octaen-28-ylidene]ethanol
DMJHTQK	CA	CAS 302-30-7
DMJHTQK	CB	CHEBI:9644
DMJHTQK	DE	Discovery agent

DMRHDGN	ID	DMRHDGN
DMRHDGN	DN	TP003
DMRHDGN	HS	Investigative
DMRHDGN	SN	TP-003; TP 003
DMRHDGN	DT	Small molecular drug
DMRHDGN	PC	10001434
DMRHDGN	MW	407.4
DMRHDGN	FM	C23H16F3N3O
DMRHDGN	IC	InChI=1S/C23H16F3N3O/c1-23(2,30)18-7-8-29-20(12-28-22(29)21(18)26)13-3-6-19(25)17(10-13)16-5-4-15(24)9-14(16)11-27/h3-10,12,30H,1-2H3
DMRHDGN	CS	CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O
DMRHDGN	IK	SJMMDWXJSSJHOQ-UHFFFAOYSA-N
DMRHDGN	IU	5-fluoro-2-[2-fluoro-5-[8-fluoro-7-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl]benzonitrile
DMRHDGN	CA	CAS 628690-75-5
DMRHDGN	DE	Discovery agent

DMM41O9	ID	DMM41O9
DMM41O9	DN	TP-680
DMM41O9	HS	Investigative
DMM41O9	SN	TP 680
DMM41O9	DT	Small molecular drug
DMM41O9	PC	9873836
DMM41O9	MW	619.7
DMM41O9	FM	C35H33N5O4S
DMM41O9	IC	InChI=1S/C35H33N5O4S/c41-32(29-22-26-14-7-8-16-28(26)37-29)38-30(23-45-33-27(35(43)44)15-9-17-36-33)34(42)40-20-18-39(19-21-40)31(24-10-3-1-4-11-24)25-12-5-2-6-13-25/h1-17,22,30-31,37H,18-21,23H2,(H,38,41)(H,43,44)/t30-/m0/s1
DMM41O9	CS	C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)[C@H](CSC4=C(C=CC=N4)C(=O)O)NC(=O)C5=CC6=CC=CC=C6N5
DMM41O9	IK	JWXZKQOPZVEJHR-PMERELPUSA-N
DMM41O9	IU	2-[(2R)-3-(4-benzhydrylpiperazin-1-yl)-2-(1H-indole-2-carbonylamino)-3-oxopropyl]sulfanylpyridine-3-carboxylic acid
DMM41O9	DE	Discovery agent

DM4WTCE	ID	DM4WTCE
DM4WTCE	DN	TP-801
DM4WTCE	HS	Investigative
DM4WTCE	SN	C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech
DM4WTCE	CP	Tiger Pharmatech
DM4WTCE	DE	Solid tumour/cancer

DMA14PR	ID	DMA14PR
DMA14PR	DN	TPCA-1
DMA14PR	HS	Investigative
DMA14PR	SN	TPCA1
DMA14PR	DT	Small molecular drug
DMA14PR	PC	9903786
DMA14PR	MW	279.29
DMA14PR	FM	C12H10FN3O2S
DMA14PR	IC	InChI=1S/C12H10FN3O2S/c13-7-3-1-6(2-4-7)9-5-8(10(14)17)11(19-9)16-12(15)18/h1-5H,(H2,14,17)(H3,15,16,18)
DMA14PR	CS	C1=CC(=CC=C1C2=CC(=C(S2)NC(=O)N)C(=O)N)F
DMA14PR	IK	SAYGKHKXGCPTLX-UHFFFAOYSA-N
DMA14PR	IU	2-(carbamoylamino)-5-(4-fluorophenyl)thiophene-3-carboxamide
DMA14PR	CA	CAS 507475-17-4
DMA14PR	CB	CHEBI:91403
DMA14PR	DE	Discovery agent

DMW2FTP	ID	DMW2FTP
DMW2FTP	DN	TPI-1361-17
DMW2FTP	HS	Investigative
DMW2FTP	SN	MCH1 receptor antagonist (obesity), Mixture Sciences
DMW2FTP	CP	Mixture Sciences Inc
DMW2FTP	DT	Small molecular drug
DMW2FTP	PC	11305934
DMW2FTP	MW	470.7
DMW2FTP	FM	C25H35FN6S
DMW2FTP	IC	InChI=1S/C25H35FN6S/c1-19(16-29-17-21-7-3-2-4-8-21)32-18-23(11-6-13-30-24(27)28)31(25(32)33)14-12-20-9-5-10-22(26)15-20/h2-5,7-10,15,19,23,29H,6,11-14,16-18H2,1H3,(H4,27,28,30)/t19-,23-/m0/s1
DMW2FTP	CS	C[C@@H](CNCC1=CC=CC=C1)N2C[C@@H](N(C2=S)CCC3=CC(=CC=C3)F)CCCN=C(N)N
DMW2FTP	IK	DSJVYEAOYVHUJW-CVDCTZTESA-N
DMW2FTP	IU	2-[3-[(4S)-1-[(2S)-1-(benzylamino)propan-2-yl]-3-[2-(3-fluorophenyl)ethyl]-2-sulfanylideneimidazolidin-4-yl]propyl]guanidine
DMW2FTP	CA	CAS 1055030-06-2
DMW2FTP	DE	Obesity

DMHATCZ	ID	DMHATCZ
DMHATCZ	DN	Tpl2 kinase inhibitor
DMHATCZ	HS	Investigative
DMHATCZ	SN	Tpl2 Kinase Inhibitor; 871307-18-5; 4-((3-Chloro-4-fluorophenyl)amino)-6-((pyridin-3-ylmethyl)amino)-1,7-naphthyridine-3-carbonitrile; CHEMBL200381; 4-[(3-CHLORO-4-FLUOROPHENYL)AMINO]-6-[(3-PYRIDINYLMETHYL)AMINO]-1,7-NAPHTHYRIDINE-3-CARBONITRILE; 4-(3-Chloro-4-fluorophenylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-[1,7]-naphthyridine; K00599a; 4-[(3-chloro-4-fluorophenyl)amino]-6-[(pyridin-3-ylmethyl)amino]-1,7-naphthyridine-3-carbonitrile
DMHATCZ	DT	Small molecular drug
DMHATCZ	PC	9549300
DMHATCZ	MW	404.8
DMHATCZ	FM	C21H14ClFN6
DMHATCZ	IC	InChI=1S/C21H14ClFN6/c22-17-6-15(3-4-18(17)23)29-21-14(8-24)11-26-19-12-28-20(7-16(19)21)27-10-13-2-1-5-25-9-13/h1-7,9,11-12H,10H2,(H,26,29)(H,27,28)
DMHATCZ	CS	C1=CC(=CN=C1)CNC2=NC=C3C(=C2)C(=C(C=N3)C#N)NC4=CC(=C(C=C4)F)Cl
DMHATCZ	IK	NMEUKWOOQOHUNA-UHFFFAOYSA-N
DMHATCZ	IU	4-(3-chloro-4-fluoroanilino)-6-(pyridin-3-ylmethylamino)-1,7-naphthyridine-3-carbonitrile
DMHATCZ	CA	CAS 871307-18-5
DMHATCZ	DE	Discovery agent

DMBF6KS	ID	DMBF6KS
DMBF6KS	DN	TPMPA
DMBF6KS	HS	Investigative
DMBF6KS	SN	(1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid
DMBF6KS	DT	Small molecular drug
DMBF6KS	PC	5521
DMBF6KS	MW	161.14
DMBF6KS	FM	C6H12NO2P
DMBF6KS	IC	InChI=1S/C6H12NO2P/c1-10(8,9)6-2-4-7-5-3-6/h2,7H,3-5H2,1H3,(H,8,9)
DMBF6KS	CS	CP(=O)(C1=CCNCC1)O
DMBF6KS	IK	MFUKVPOVVKKLRQ-UHFFFAOYSA-N
DMBF6KS	IU	methyl(1,2,3,6-tetrahydropyridin-4-yl)phosphinic acid
DMBF6KS	CA	CAS 182485-36-5
DMBF6KS	DE	Discovery agent

DMW9G7H	ID	DMW9G7H
DMW9G7H	DN	TPN-729
DMW9G7H	HS	Investigative
DMW9G7H	SN	TPN-729B; PDE5 inhibitors (erectile dysfunction/pulmonary arterial hypertension), Shanghai Institute of Materia Medica/Topharman Shanghai
DMW9G7H	CP	Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
DMW9G7H	DE	Erectile dysfunction

DMFL5XU	ID	DMFL5XU
DMFL5XU	DN	TPO gene plasmid
DMFL5XU	HS	Investigative
DMFL5XU	SN	TPO gene plasmid (thrombocytopenia)
DMFL5XU	CP	InvivoGen Therapeutics
DMFL5XU	DE	Thrombocytopenia

DMEF32D	ID	DMEF32D
DMEF32D	DN	TQ-1017
DMEF32D	HS	Investigative
DMEF32D	CP	TheraQuest
DMEF32D	DE	Pain

DMZA6X3	ID	DMZA6X3
DMZA6X3	DN	TQX-173
DMZA6X3	HS	Investigative
DMZA6X3	SN	TQX-173; CHEMBL267276; SCHEMBL2038719; BDBM50092637; 7-Chloro-4-oxo-8-[1,2,4]triazol-4-yl-4,5-dihydro-[1,2,4]triazolo[1,5-a]quinoxaline-2-carboxylic acid
DMZA6X3	DT	Small molecular drug
DMZA6X3	PC	9840540
DMZA6X3	MW	331.67
DMZA6X3	FM	C12H6ClN7O3
DMZA6X3	IC	InChI=1S/C12H6ClN7O3/c13-5-1-6-8(2-7(5)19-3-14-15-4-19)20-10(11(21)16-6)17-9(18-20)12(22)23/h1-4H,(H,16,21)(H,22,23)
DMZA6X3	CS	C1=C2C(=CC(=C1Cl)N3C=NN=C3)N4C(=NC(=N4)C(=O)O)C(=O)N2
DMZA6X3	IK	QYMZRTSHYZACQA-UHFFFAOYSA-N
DMZA6X3	IU	7-chloro-4-oxo-8-(1,2,4-triazol-4-yl)-5H-[1,2,4]triazolo[1,5-a]quinoxaline-2-carboxylic acid
DMZA6X3	DE	Discovery agent

DM18CV3	ID	DM18CV3
DM18CV3	DN	TRACIZOLINE
DM18CV3	HS	Investigative
DM18CV3	SN	65295-26-3; AC1O5AS5; 2-[(E)-2-phenylethenyl]-4,5-dihydro-1H-imidazole; AKOS030531161; 1H-Imidazole, 4,5-dihydro-2-(2-phenylethenyl)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
DM18CV3	DT	Small molecular drug
DM18CV3	PC	6455104
DM18CV3	MW	172.23
DM18CV3	FM	C11H12N2
DM18CV3	IC	InChI=1S/C11H12N2/c1-2-4-10(5-3-1)6-7-11-12-8-9-13-11/h1-7H,8-9H2,(H,12,13)/b7-6+
DM18CV3	CS	C1CN=C(N1)/C=C/C2=CC=CC=C2
DM18CV3	IK	IGISUADTPSLENQ-VOTSOKGWSA-N
DM18CV3	IU	2-[(E)-2-phenylethenyl]-4,5-dihydro-1H-imidazole
DM18CV3	DE	Discovery agent

DM3ML0N	ID	DM3ML0N
DM3ML0N	DN	Tramazoline
DM3ML0N	HS	Investigative
DM3ML0N	SN	Tramazoline; 1082-57-1; UNII-SLE31693IV; Towk; CHEMBL32573; SLE31693IV; QQJLHRRUATVHED-UHFFFAOYSA-N; 4,5-Dihydro-N-(5,6,7,8-tetrahydro-1-naphthalenyl)-1H-imidazol-2-amine; Rhinol; 1H-Imidazol-2-amine, 4,5-dihydro-N-(5,6,7,8-tetrahydro-1-naphthalenyl)-; N-(5,6,7,8-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine; Tramazolina; Rhynaspray; Tramazolinum; Tobispray; Tramazoline [INN:BAN]; Tramazolinum [INN-Latin]; Tramazolina [INN-Spanish]; Muconasal (TN); EINECS 214-105-6; Tramazoline (INN); TRAMAZOLIN; AC1Q4UQJ; AC1L1KJB
DM3ML0N	DT	Small molecular drug
DM3ML0N	PC	5524
DM3ML0N	MW	215.29
DM3ML0N	FM	C13H17N3
DM3ML0N	IC	InChI=1S/C13H17N3/c1-2-6-11-10(4-1)5-3-7-12(11)16-13-14-8-9-15-13/h3,5,7H,1-2,4,6,8-9H2,(H2,14,15,16)
DM3ML0N	CS	C1CCC2=C(C1)C=CC=C2NC3=NCCN3
DM3ML0N	IK	QQJLHRRUATVHED-UHFFFAOYSA-N
DM3ML0N	IU	N-(5,6,7,8-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine
DM3ML0N	CA	CAS 1082-57-1
DM3ML0N	CB	CHEBI:134893
DM3ML0N	DE	Discovery agent

DMRTASL	ID	DMRTASL
DMRTASL	DN	Trametinib
DMRTASL	HS	Investigative
DMRTASL	SN	GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN
DMRTASL	CP	GlaxoSmithKline
DMRTASL	TC	Antiviral Agents
DMRTASL	DT	Small molecular drug
DMRTASL	PC	11707110
DMRTASL	MW	615.4
DMRTASL	FM	C26H23FIN5O4
DMRTASL	IC	InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
DMRTASL	CS	CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5
DMRTASL	IK	LIRYPHYGHXZJBZ-UHFFFAOYSA-N
DMRTASL	IU	N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
DMRTASL	CA	CAS 871700-17-3
DMRTASL	CB	CHEBI:75998
DMRTASL	DE	Discovery agent; Melanoma; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DM27TPM	ID	DM27TPM
DM27TPM	DN	Trans-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine
DM27TPM	HS	Investigative
DM27TPM	SN	CHEMBL511601; trans-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine
DM27TPM	DT	Small molecular drug
DM27TPM	PC	44577750
DM27TPM	MW	227.28
DM27TPM	FM	C15H14FN
DM27TPM	IC	InChI=1S/C15H14FN/c16-14(12-7-3-1-4-8-12)11-15(14,17)13-9-5-2-6-10-13/h1-10H,11,17H2/t14-,15-/m0/s1
DM27TPM	CS	C1[C@@]([C@]1(C2=CC=CC=C2)F)(C3=CC=CC=C3)N
DM27TPM	IK	OGVYLPHSSJTUKP-GJZGRUSLSA-N
DM27TPM	IU	(1S,2S)-2-fluoro-1,2-diphenylcyclopropan-1-amine
DM27TPM	DE	Discovery agent

DMYVJHN	ID	DMYVJHN
DMYVJHN	DN	Trans-(1S(R),2S(R))-2-Hydroxycyclooctyl nitrate
DMYVJHN	HS	Investigative
DMYVJHN	SN	CHEMBL556256; trans-(1S(R),2S(R))-2-Hydroxycyclooctyl nitrate; BDBM50293661
DMYVJHN	DT	Small molecular drug
DMYVJHN	PC	45273021
DMYVJHN	MW	189.21
DMYVJHN	FM	C8H15NO4
DMYVJHN	IC	InChI=1S/C8H15NO4/c10-7-5-3-1-2-4-6-8(7)13-9(11)12/h7-8,10H,1-6H2/t7-,8-/m0/s1
DMYVJHN	CS	C1CCC[C@@H]([C@H](CC1)O)O[N+](=O)[O-]
DMYVJHN	IK	IWKAONCFSJZOOC-YUMQZZPRSA-N
DMYVJHN	IU	[(1S,2S)-2-hydroxycyclooctyl] nitrate
DMYVJHN	DE	Discovery agent

DMXC98D	ID	DMXC98D
DMXC98D	DN	Trans-(R(S))-2-Hydroxy-1-phenylethyl nitrate
DMXC98D	HS	Investigative
DMXC98D	SN	CHEMBL563619; trans-(R(S))-2-Hydroxy-1-phenylethyl nitrate; BDBM50293660
DMXC98D	DT	Small molecular drug
DMXC98D	PC	45273020
DMXC98D	MW	183.16
DMXC98D	FM	C8H9NO4
DMXC98D	IC	InChI=1S/C8H9NO4/c10-6-8(13-9(11)12)7-4-2-1-3-5-7/h1-5,8,10H,6H2/t8-/m0/s1
DMXC98D	CS	C1=CC=C(C=C1)[C@H](CO)O[N+](=O)[O-]
DMXC98D	IK	HJZAIMHRCPGGNJ-QMMMGPOBSA-N
DMXC98D	IU	[(1R)-2-hydroxy-1-phenylethyl] nitrate
DMXC98D	DE	Discovery agent

DMHD1XM	ID	DMHD1XM
DMHD1XM	DN	Trans,trans-1,3-bis-(4-hydroxycyclohexyl)urea
DMHD1XM	HS	Investigative
DMHD1XM	SN	CHEMBL231584; 1,3-bis(4-hydroxycyclohexyl)urea; trans,trans-1,3-bis-(4-hydroxycyclohexyl)urea; SCHEMBL3195592; SCHEMBL3195603; MolPort-005-690-989; BDBM50217480; ZINC24975985; AKOS034042111; ZINC253654706
DMHD1XM	DT	Small molecular drug
DMHD1XM	PC	11644572
DMHD1XM	MW	256.339
DMHD1XM	FM	C13H24N2O3
DMHD1XM	IC	InChI=1S/C13H24N2O3/c16-11-5-1-9(2-6-11)14-13(18)15-10-3-7-12(17)8-4-10/h9-12,16-17H,1-8H2,(H2,14,15,18)
DMHD1XM	CS	C1CC(CCC1NC(=O)NC2CCC(CC2)O)O
DMHD1XM	IK	CHWFTRBAEVNHFK-UHFFFAOYSA-N
DMHD1XM	IU	1,3-bis(4-hydroxycyclohexyl)urea
DMHD1XM	DE	Discovery agent

DMH1S57	ID	DMH1S57
DMH1S57	DN	Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine
DMH1S57	HS	Investigative
DMH1S57	SN	CHEMBL466770; trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine
DMH1S57	DT	Small molecular drug
DMH1S57	PC	11241513
DMH1S57	MW	185.62
DMH1S57	FM	C9H9ClFN
DMH1S57	IC	InChI=1S/C9H9ClFN/c10-7-3-1-6(2-4-7)9(11)5-8(9)12/h1-4,8H,5,12H2/t8-,9-/m0/s1
DMH1S57	CS	C1[C@@H]([C@]1(C2=CC=C(C=C2)Cl)F)N
DMH1S57	IK	UTADHPUNQUNGFZ-IUCAKERBSA-N
DMH1S57	IU	(1S,2S)-2-(4-chlorophenyl)-2-fluorocyclopropan-1-amine
DMH1S57	DE	Discovery agent

DMO01T8	ID	DMO01T8
DMO01T8	DN	Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine
DMO01T8	HS	Investigative
DMO01T8	SN	CHEMBL447729; trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine
DMO01T8	DT	Small molecular drug
DMO01T8	PC	11171752
DMO01T8	MW	169.17
DMO01T8	FM	C9H9F2N
DMO01T8	IC	InChI=1S/C9H9F2N/c10-7-3-1-6(2-4-7)9(11)5-8(9)12/h1-4,8H,5,12H2/t8-,9-/m0/s1
DMO01T8	CS	C1[C@@H]([C@]1(C2=CC=C(C=C2)F)F)N
DMO01T8	IK	JCUGJWBVZNWAIJ-IUCAKERBSA-N
DMO01T8	IU	(1S,2S)-2-fluoro-2-(4-fluorophenyl)cyclopropan-1-amine
DMO01T8	DE	Discovery agent

DMVGAFR	ID	DMVGAFR
DMVGAFR	DN	Trans-2-fluoro-2-phenylcyclopropylamin
DMVGAFR	HS	Investigative
DMVGAFR	SN	CHEMBL455782; trans-2-fluoro-2-phenylcyclopropylamin; SCHEMBL15542348; ZINC13559954
DMVGAFR	DT	Small molecular drug
DMVGAFR	PC	10374615
DMVGAFR	MW	151.18
DMVGAFR	FM	C9H10FN
DMVGAFR	IC	InChI=1S/C9H10FN/c10-9(6-8(9)11)7-4-2-1-3-5-7/h1-5,8H,6,11H2/t8-,9-/m0/s1
DMVGAFR	CS	C1[C@@H]([C@]1(C2=CC=CC=C2)F)N
DMVGAFR	IK	UJTQURLMCYMANH-IUCAKERBSA-N
DMVGAFR	IU	(1S,2S)-2-fluoro-2-phenylcyclopropan-1-amine
DMVGAFR	DE	Discovery agent

DM392QT	ID	DM392QT
DM392QT	DN	Trans-2-fluoro-2-p-tolylcyclopropanamine
DM392QT	HS	Investigative
DM392QT	SN	CHEMBL468852; trans-2-fluoro-2-p-tolylcyclopropanamine
DM392QT	DT	Small molecular drug
DM392QT	PC	11816512
DM392QT	MW	165.21
DM392QT	FM	C10H12FN
DM392QT	IC	InChI=1S/C10H12FN/c1-7-2-4-8(5-3-7)10(11)6-9(10)12/h2-5,9H,6,12H2,1H3/t9-,10-/m0/s1
DM392QT	CS	CC1=CC=C(C=C1)[C@]2(C[C@@H]2N)F
DM392QT	IK	JEBMWAUALYWCIW-UWVGGRQHSA-N
DM392QT	IU	(1S,2S)-2-fluoro-2-(4-methylphenyl)cyclopropan-1-amine
DM392QT	DE	Discovery agent

DMHJM0B	ID	DMHJM0B
DMHJM0B	DN	trans-2-methylcrotonic acid
DMHJM0B	HS	Investigative
DMHJM0B	SN	tiglic acid
DMHJM0B	DT	Small molecular drug
DMHJM0B	PC	125468
DMHJM0B	MW	100.12
DMHJM0B	FM	C5H8O2
DMHJM0B	IC	InChI=1S/C5H8O2/c1-3-4(2)5(6)7/h3H,1-2H3,(H,6,7)/b4-3+
DMHJM0B	CS	C/C=C(\\C)/C(=O)O
DMHJM0B	IK	UIERETOOQGIECD-ONEGZZNKSA-N
DMHJM0B	IU	(E)-2-methylbut-2-enoic acid
DMHJM0B	CA	CAS 80-59-1
DMHJM0B	CB	CHEBI:9592
DMHJM0B	DE	Discovery agent

DMEDC5I	ID	DMEDC5I
DMEDC5I	DN	Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine
DMEDC5I	HS	Investigative
DMEDC5I	SN	CHEMBL486043; trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine
DMEDC5I	DT	Small molecular drug
DMEDC5I	PC	44560674
DMEDC5I	MW	239.31
DMEDC5I	FM	C16H17NO
DMEDC5I	IC	InChI=1S/C16H17NO/c1-11-6-2-5-9-15(11)18-16-10-14(17)12-7-3-4-8-13(12)16/h2-9,14,16H,10,17H2,1H3/t14-,16-/m0/s1
DMEDC5I	CS	CC1=CC=CC=C1O[C@H]2C[C@@H](C3=CC=CC=C23)N
DMEDC5I	IK	VQMGCAXPAOTPQE-HOCLYGCPSA-N
DMEDC5I	IU	(1S,3S)-3-(2-methylphenoxy)-2,3-dihydro-1H-inden-1-amine
DMEDC5I	DE	Discovery agent

DM6HI8W	ID	DM6HI8W
DM6HI8W	DN	trans-3-ACPBPA
DM6HI8W	HS	Investigative
DM6HI8W	SN	trans-3-ACPBPA; SCHEMBL4586130; GTPL4099; [(1R,3R)-3-aminocyclopentyl](butyl)phosphinic acid
DM6HI8W	DT	Small molecular drug
DM6HI8W	PC	11629817
DM6HI8W	MW	205.23
DM6HI8W	FM	C9H20NO2P
DM6HI8W	IC	InChI=1S/C9H20NO2P/c1-2-3-6-13(11,12)9-5-4-8(10)7-9/h8-9H,2-7,10H2,1H3,(H,11,12)/t8-,9-/m1/s1
DM6HI8W	CS	CCCCP(=O)([C@@H]1CC[C@H](C1)N)O
DM6HI8W	IK	UQGQAMARAMOEID-RKDXNWHRSA-N
DM6HI8W	IU	[(1R,3R)-3-aminocyclopentyl]-butylphosphinic acid
DM6HI8W	DE	Discovery agent

DM8E9YS	ID	DM8E9YS
DM8E9YS	DN	Trans-dimethyl gababutin
DM8E9YS	HS	Investigative
DM8E9YS	SN	ATAGABALIN; 223445-75-8; UNII-JT7957Q2FB; CHEMBL593430; JT7957Q2FB; PD-0200390; 2-[(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid; trans-dimethyl gababutin; Atagabalin [USAN:INN]; 2-((3S,4S)-1-(Aminomethyl)-3,4-dimethylcyclopentyl)acetic acid; Atagabalin (USAN/INN); SCHEMBL121610; CTK1A0230; BDBM50305887; AKOS030591721; DB12032; AN-5147; CS-0003598; PD 0200390; D09581; ((3S,4S)-1-(Aminomethyl)-3,4-dimethylcyclopentyl)acetic acid; 3,4-trans-2-(1-(aminomethyl)-3,4-dimethylcyclopentyl)acetic acid
DM8E9YS	DT	Small molecular drug
DM8E9YS	PC	9794485
DM8E9YS	MW	185.26
DM8E9YS	FM	C10H19NO2
DM8E9YS	IC	InChI=1S/C10H19NO2/c1-7-3-10(6-11,4-8(7)2)5-9(12)13/h7-8H,3-6,11H2,1-2H3,(H,12,13)/t7-,8-/m0/s1
DM8E9YS	CS	C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN
DM8E9YS	IK	IUVMAUQEZFTTFB-YUMQZZPRSA-N
DM8E9YS	IU	2-[(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
DM8E9YS	CA	CAS 223445-75-8
DM8E9YS	DE	Discovery agent

DMBU4KJ	ID	DMBU4KJ
DMBU4KJ	DN	Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH
DMBU4KJ	HS	Investigative
DMBU4KJ	SN	tDADAE(9); trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH; CHEMBL229440; BDBM21126; (5S,8R,10E,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid
DMBU4KJ	DT	Small molecular drug
DMBU4KJ	PC	16733487
DMBU4KJ	MW	551.6
DMBU4KJ	FM	C28H33N5O7
DMBU4KJ	IC	InChI=1S/C28H33N5O7/c29-20(14-18-10-12-19(34)13-11-18)25(36)32-21-8-4-5-9-22(28(39)40)33-27(38)23(15-17-6-2-1-3-7-17)31-24(35)16-30-26(21)37/h1-7,10-13,20-23,34H,8-9,14-16,29H2,(H,30,37)(H,31,35)(H,32,36)(H,33,38)(H,39,40)/b5-4+/t20-,21+,22+,23-/m0/s1
DMBU4KJ	CS	C1/C=C/C[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]1NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CC=CC=C3)C(=O)O
DMBU4KJ	IK	VNZCTJLIVONUDE-KLGXLVMCSA-N
DMBU4KJ	IU	(5S,8R,10E,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid
DMBU4KJ	DE	Discovery agent

DMXS8LN	ID	DMXS8LN
DMXS8LN	DN	Trans-hydroxytamoxifen
DMXS8LN	HS	Investigative
DMXS8LN	PC	5284643
DMXS8LN	MW	387.5
DMXS8LN	FM	C26H29NO2
DMXS8LN	IC	InChI=1S/C26H29NO2/c1-4-25(20-10-14-23(28)15-11-20)26(21-8-6-5-7-9-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-
DMXS8LN	CS	CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=C(C=C3)O
DMXS8LN	IK	DODQJNMQWMSYGS-QPLCGJKRSA-N
DMXS8LN	IU	4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol
DMXS8LN	CA	CAS 82413-23-8
DMXS8LN	DE	Discovery agent

DMP4T87	ID	DMP4T87
DMP4T87	DN	TRANSTORINE
DMP4T87	HS	Investigative
DMP4T87	SN	kynurenic acid; 492-27-3; 4-Hydroxyquinoline-2-carboxylic acid; 13593-94-7; Kynurenate; Quinurenic acid; 4-oxo-1,4-dihydroquinoline-2-carboxylic acid; Transtorine; Kynuronic acid; Kinurenic acid; 4-Hydroxyquinaldic acid; 4-Hydroxy-2-quinolincarboxylic acid; 1,4-Dihydro-4-oxoquinoline-2-carboxylic acid; 2-Quinolinecarboxylic acid, 4-hydroxy-; 4-Hydroxyquinaldinic acid; 4-Hydroxy-2-quinolinecarboxylic acid; Quinaldic acid, 4-hydroxy-; NSC 58973; 4-oxo-1H-quinoline-2-carboxylic acid; UNII-H030S2S85J; KYNA; CCRIS 4428; NSC58973
DMP4T87	DT	Small molecular drug
DMP4T87	PC	3845
DMP4T87	MW	189.17
DMP4T87	FM	C10H7NO3
DMP4T87	IC	InChI=1S/C10H7NO3/c12-9-5-8(10(13)14)11-7-4-2-1-3-6(7)9/h1-5H,(H,11,12)(H,13,14)
DMP4T87	CS	C1=CC=C2C(=C1)C(=O)C=C(N2)C(=O)O
DMP4T87	IK	HCZHHEIFKROPDY-UHFFFAOYSA-N
DMP4T87	IU	4-oxo-1H-quinoline-2-carboxylic acid
DMP4T87	CA	CAS 492-27-3
DMP4T87	CB	CHEBI:18344
DMP4T87	DE	Discovery agent

DMXZAH6	ID	DMXZAH6
DMXZAH6	DN	Trapoxin
DMXZAH6	HS	Investigative
DMXZAH6	SN	trapoxin A; C34H42N4O6; Cyclo((S)-phenylalanyl-(S)-phenylalanyl-(R)-pipecolinyl-(2S,9S)-2-amino-8-oxo-9,10-epoxydecanoyl); 133155-89-2; Cyclo((S)-gamma-oxo-L-alpha-aminooxiraneoctanoyl-L-phenylalanyl-L-phenylalanyl-D-2-piperidinecarbonyl); AC1L3TK4; SCHEMBL4787967; CHEBI:84057; RF 1023A; LS-172860; J-006317; UNII-GSS8DX555X component GXVXXETYXSPSOA-UFEOFEBPSA-N; (3S,6S,9S,15aR)-6,9-dibenzyl-3-{6-[(2S)-oxiran-2-yl]-6-oxohexyl}octahydro-2H-pyrido[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10(3H,12H)-tetrone
DMXZAH6	DT	Small molecular drug
DMXZAH6	PC	395803
DMXZAH6	MW	588.7
DMXZAH6	FM	C33H40N4O6
DMXZAH6	IC	InChI=1S/C33H40N4O6/c38-28(29-21-43-29)17-9-3-8-15-24-30(39)35-25(19-22-11-4-1-5-12-22)31(40)36-26(20-23-13-6-2-7-14-23)33(42)37-18-10-16-27(37)32(41)34-24/h1-2,4-7,11-14,24-27,29H,3,8-10,15-21H2,(H,34,41)(H,35,39)(H,36,40)/t24-,25-,26-,27+,29-/m0/s1
DMXZAH6	CS	C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CC=CC=C4)CCCCCC(=O)[C@@H]5CO5
DMXZAH6	IK	LLOKIGWPNVSDGJ-AFBVCZJXSA-N
DMXZAH6	IU	(3S,6S,9S,12R)-3,6-dibenzyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMXZAH6	DE	Discovery agent

DMDX0VI	ID	DMDX0VI
DMDX0VI	DN	Trecadrine
DMDX0VI	HS	Investigative
DMDX0VI	SN	90845-56-0; AC1L241B; SCHEMBL10553786; HY-U00303; CS-7288; KB-124998; L001625; Sulfenamido-sulfonamides
DMDX0VI	DT	Small molecular drug
DMDX0VI	PC	65823
DMDX0VI	MW	383.5
DMDX0VI	FM	C27H29NO
DMDX0VI	IC	InChI=1S/C27H29NO/c1-20(27(29)23-12-4-3-5-13-23)28(2)19-18-26-24-14-8-6-10-21(24)16-17-22-11-7-9-15-25(22)26/h3-15,18,20,27,29H,16-17,19H2,1-2H3
DMDX0VI	CS	CC(C(C1=CC=CC=C1)O)N(C)CC=C2C3=CC=CC=C3CCC4=CC=CC=C42
DMDX0VI	IK	BHVGOYREXHCFOE-UHFFFAOYSA-N
DMDX0VI	IU	2-[methyl-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)ethyl]amino]-1-phenylpropan-1-ol
DMDX0VI	DE	Discovery agent

DME94KO	ID	DME94KO
DME94KO	DN	Trecetilide fumarate
DME94KO	HS	Investigative
DME94KO	SN	PNU-108342E; Trecetilide fumarate < Prop INNM; (-)-N-[4-[4-[N-Ethyl-N-(6-fluoro-6-methylheptyl)amino]-1(S)-hydroxybutyl]phenyl]methanesulfonamide fumarate (2:1)
DME94KO	DT	Small molecular drug
DME94KO	PC	6441132
DME94KO	MW	949.3
DME94KO	FM	C46H78F2N4O10S2
DME94KO	IC	InChI=1S/2C21H37FN2O3S.C4H4O4/c2*1-5-24(16-8-6-7-15-21(2,3)22)17-9-10-20(25)18-11-13-19(14-12-18)23-28(4,26)27;5-3(6)1-2-4(7)8/h2*11-14,20,23,25H,5-10,15-17H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*20-;/m00./s1
DME94KO	CS	CCN(CCCCCC(C)(C)F)CCC[C@@H](C1=CC=C(C=C1)NS(=O)(=O)C)O.CCN(CCCCCC(C)(C)F)CCC[C@@H](C1=CC=C(C=C1)NS(=O)(=O)C)O.C(=C/C(=O)O)\\C(=O)O
DME94KO	IK	ODFOUAATRQAOLG-MMSVOLSESA-N
DME94KO	IU	(E)-but-2-enedioic acid;N-[4-[(1S)-4-[ethyl-(6-fluoro-6-methylheptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide
DME94KO	CA	CAS 191349-60-7
DME94KO	DE	Cardiac arrhythmias

DM8LYSB	ID	DM8LYSB
DM8LYSB	DN	Triazine
DM8LYSB	HS	Investigative
DM8LYSB	SN	Anilazine; DYRENE; Zinochlor; Anilazin; Kemate; 101-05-3; Bortrysan; Triazin; Triasyn; Triasym; Direz; Dyrene 50W; Aniyaline; Dyrene Flussig; Triazine (pesticide); 4,6-Dichloro-N-(2-chlorophenyl)-1,3,5-triazin-2-amine; 2,4-Dichloro-6-(o-chloroanilino)-s-triazine; NCI-C08684; (o-Chloroanilino)dichlorotriazine; Triazine (VAN); NSC 3851; Caswell No. 302; 2,4-Dichloro-6-(2-chloroanilino)-1,3,5-triazine; Dairene; Anilazine [BSI:ISO]; ENT 26,058; 1,3,5-Triazin-2-amine, 4,6-dichloro-N-(2-chlorophenyl)-; UNII-C6E8Y03ZJN; B-622; CCRIS 43
DM8LYSB	DT	Small molecular drug
DM8LYSB	PC	123047
DM8LYSB	MW	81.08
DM8LYSB	FM	C3H3N3
DM8LYSB	IC	InChI=1S/C3H3N3/c1-2-4-6-5-3-1/h1-3H
DM8LYSB	CS	C1=CN=NN=C1
DM8LYSB	IK	JYEUMXHLPRZUAT-UHFFFAOYSA-N
DM8LYSB	IU	triazine
DM8LYSB	CA	CAS 12654-97-6
DM8LYSB	CB	CHEBI:38058
DM8LYSB	DE	Discovery agent

DMCLA2D	ID	DMCLA2D
DMCLA2D	DN	triazine compound PC10
DMCLA2D	HS	Investigative
DMCLA2D	DT	Small molecular drug
DMCLA2D	PC	73755221
DMCLA2D	MW	563.6
DMCLA2D	FM	C28H27F2N7O4
DMCLA2D	IC	InChI=1S/C28H27F2N7O4/c1-41-23-12-4-19(5-13-23)16-36-26(35-27(39)37(28(36)40)17-18-2-8-21(29)9-3-18)33-15-14-32-25(31)34-24(38)20-6-10-22(30)11-7-20/h2-13H,14-17H2,1H3,(H,33,35,39)(H3,31,32,34,38)
DMCLA2D	CS	COC1=CC=C(C=C1)CN2C(=NC(=O)N(C2=O)CC3=CC=C(C=C3)F)NCCN=C(N)NC(=O)C4=CC=C(C=C4)F
DMCLA2D	IK	XZNHZFUKGYYVMQ-UHFFFAOYSA-N
DMCLA2D	IU	4-fluoro-N-[N'-[2-[[5-[(4-fluorophenyl)methyl]-1-[(4-methoxyphenyl)methyl]-4,6-dioxo-1,3,5-triazin-2-yl]amino]ethyl]carbamimidoyl]benzamide
DMCLA2D	DE	Discovery agent

DM1F2K0	ID	DM1F2K0
DM1F2K0	DN	Triazolopyridine
DM1F2K0	HS	Investigative
DM1F2K0	SN	CP-808844; 6-[4-(4-FLUOROPHENYL)-1,3-OXAZOL-5-YL]-3-ISOPROPYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE; 1zzl; AC1NRDFA; Triazolopyridine deriv. 25; SCHEMBL40860; CHEMBL194322; BDBM15414; DB04797; 6-[4-(4-fluorophenyl)-1,3-oxazol-5-yl]-3-(1-methylethyl)[1,2,4]triazolo[4,3-a]pyridine; 6-[4-(4-Fluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine; 4-(4-fluorophenyl)-5-[3-(propan-2-yl)-[1,2,4]triazolo[3,4-a]pyridin-6-yl]-1,3-oxazole
DM1F2K0	DT	Small molecular drug
DM1F2K0	PC	5289514
DM1F2K0	MW	322.3
DM1F2K0	FM	C18H15FN4O
DM1F2K0	IC	InChI=1S/C18H15FN4O/c1-11(2)18-22-21-15-8-5-13(9-23(15)18)17-16(20-10-24-17)12-3-6-14(19)7-4-12/h3-11H,1-2H3
DM1F2K0	CS	CC(C)C1=NN=C2N1C=C(C=C2)C3=C(N=CO3)C4=CC=C(C=C4)F
DM1F2K0	IK	OVCXRBARSPBVMC-UHFFFAOYSA-N
DM1F2K0	IU	4-(4-fluorophenyl)-5-(3-propan-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-1,3-oxazole
DM1F2K0	DE	Discovery agent

DM5ZBF3	ID	DM5ZBF3
DM5ZBF3	DN	TRIAZOLOPYRIMIDINE
DM5ZBF3	HS	Investigative
DM5ZBF3	SN	8-Azapurine; 273-40-5; 2H-triazolo[4,5-d]pyrimidine; 179268-22-5; 6H-1,2,3-Triazolo[4,5-d]pyrimidine; 2H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-[1,2,3]triazolo[4,5-d]pyrimidine; triazolo[4,5-d]pyrimidine; triazolo(4,5-d)pyrimidine; 273-39-2; 99331-25-6; 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDINE; ACMC-1CNOM; AC1L22AZ; SCHEMBL26606; 179268-21-4; SCHEMBL11026556; CTK1A0899; CTK0H1173; CTK0H1170; CTK3G7531; CTK0H1174; DTXSID80181745; GIIGHSIIKVOWKZ-UHFFFAOYSA-N; ZINC2020258; ACM273405; FCH907879; AKOS006372727
DM5ZBF3	DT	Small molecular drug
DM5ZBF3	PC	64962
DM5ZBF3	MW	121.1
DM5ZBF3	FM	C4H3N5
DM5ZBF3	IC	InChI=1S/C4H3N5/c1-3-4(6-2-5-1)8-9-7-3/h1-2H,(H,5,6,7,8,9)
DM5ZBF3	CS	C1=NC=NC2=NNN=C21
DM5ZBF3	IK	GIIGHSIIKVOWKZ-UHFFFAOYSA-N
DM5ZBF3	IU	2H-triazolo[4,5-d]pyrimidine
DM5ZBF3	CA	CAS 273-40-5
DM5ZBF3	DE	Discovery agent

DMYSX0K	ID	DMYSX0K
DMYSX0K	DN	Tribenzyl 2-aminopropane-1,2,3-tricarboxylate
DMYSX0K	HS	Investigative
DMYSX0K	SN	CHEMBL561821; Tribenzyl 2-aminopropane-1,2,3-tricarboxylate
DMYSX0K	DT	Small molecular drug
DMYSX0K	PC	44511346
DMYSX0K	MW	461.5
DMYSX0K	FM	C27H27NO6
DMYSX0K	IC	InChI=1S/C27H27NO6/c28-27(26(31)34-20-23-14-8-3-9-15-23,16-24(29)32-18-21-10-4-1-5-11-21)17-25(30)33-19-22-12-6-2-7-13-22/h1-15H,16-20,28H2
DMYSX0K	CS	C1=CC=C(C=C1)COC(=O)CC(CC(=O)OCC2=CC=CC=C2)(C(=O)OCC3=CC=CC=C3)N
DMYSX0K	IK	LEIRLWNRJKDALU-UHFFFAOYSA-N
DMYSX0K	IU	tribenzyl 2-aminopropane-1,2,3-tricarboxylate
DMYSX0K	DE	Discovery agent

DMHN7CB	ID	DMHN7CB
DMHN7CB	DN	Tributylstannanyl
DMHN7CB	HS	Investigative
DMHN7CB	SN	Tributyltin; tributylstannanyl; Tributlytin; Tributylstannic hydride; TRIBUTYL TIN; Tri-n-butylstannane hydride; UNII-4XDX163P3D; Tin, tri-n-butyl-, hydride; HSDB 6362; EINECS 211-704-4; BRN 3587329; 4XDX163P3D; Stannane, tri-n-butyl-, hydride; 20763-88-6; Tri-n-butyltin hydride, 97%; tri-n-butylstannyl radical; tributyl-tin; TBY; TBTH; AC1MHUMB; AC1Q2UP8; ACMC-1B91A; DTXSID0040709; CTK1A6693; MolPort-003-928-307; PIILXFBHQILWPS-UHFFFAOYSA-N; MolPort-035-869-643; EBD10558; ANW-35557; MFCD00009416; ZINC169748512; AKOS015909735
DMHN7CB	DT	Small molecular drug
DMHN7CB	PC	3032732
DMHN7CB	MW	290.05
DMHN7CB	FM	C12H27Sn
DMHN7CB	IC	InChI=1S/3C4H9.Sn/c3*1-3-4-2;/h3*1,3-4H2,2H3;
DMHN7CB	CS	CCCC[Sn](CCCC)CCCC
DMHN7CB	IK	PIILXFBHQILWPS-UHFFFAOYSA-N
DMHN7CB	CA	CAS 688-73-3
DMHN7CB	DE	Discovery agent

DMLKWTG	ID	DMLKWTG
DMLKWTG	DN	Tricarballylic Acid
DMLKWTG	HS	Investigative
DMLKWTG	SN	Tricarballylic acid; 99-14-9; 1,2,3-Propanetricarboxylic acid; Propane-1,2,3-tricarboxylic acid; Carballylic acid; Tricarballylate; beta-Carboxyglutaric acid; 3-carboxyglutaric acid; 1,2,3-Propanetricarboxylicacid; NSC2347; Propane 1,2,3-tricarboxylic acid; UNII-RA5QH2J020; CHEBI:45969; Tricarballylic acid, 99%; .beta.-Carboxyglutaric acid; RA5QH2J020; KQTIIICEAUMSDG-UHFFFAOYSA-N; NSC-2347; 1,2,3-Tripropanetricarboxylic acid; TRC; NSC 2347; EINECS 202-733-3; ACMC-209sbq; AI3-52246; carboxymethylsuccinic acid; 3-carboxypentanedioic 
DMLKWTG	DT	Small molecular drug
DMLKWTG	PC	14925
DMLKWTG	MW	176.12
DMLKWTG	FM	C6H8O6
DMLKWTG	IC	InChI=1S/C6H8O6/c7-4(8)1-3(6(11)12)2-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMLKWTG	CS	C(C(CC(=O)O)C(=O)O)C(=O)O
DMLKWTG	IK	KQTIIICEAUMSDG-UHFFFAOYSA-N
DMLKWTG	IU	propane-1,2,3-tricarboxylic acid
DMLKWTG	CA	CAS 99-14-9
DMLKWTG	CB	CHEBI:45969
DMLKWTG	DE	Discovery agent

DMNALMF	ID	DMNALMF
DMNALMF	DN	trichloroethanol
DMNALMF	HS	Investigative
DMNALMF	SN	2,2,2-TRICHLOROETHANOL; Trichloroethanol; 115-20-8; Trichlorethanol; Trichloroethyl alcohol; Ethanol, 2,2,2-trichloro-; 2,2,2-Trichloro-1-ethanol; (Hydroxymethyl)trichloromethane; 2,2,2-Trichloroethyl alcohol; 2,2,2-Trichloroethan-1-ol; C2H3Cl3O; UNII-AW835AJ62N; NSC 66407; beta-trichloroethanol; CCRIS 6763; CCl3CH2OH; EINECS 204-071-0; 2,2,2-trichloro-ethanol; 2,2,2-tris-chloroethanol; BRN 1697495; AW835AJ62N; CHEBI:28094; KPWDGTGXUYRARH-UHFFFAOYSA-N; .beta.,.beta.,.beta-Trichloroethanol; 2,2,2-Trichloroethanol, 99%; 4yas
DMNALMF	DT	Small molecular drug
DMNALMF	PC	8259
DMNALMF	MW	149.4
DMNALMF	FM	C2H3Cl3O
DMNALMF	IC	InChI=1S/C2H3Cl3O/c3-2(4,5)1-6/h6H,1H2
DMNALMF	CS	C(C(Cl)(Cl)Cl)O
DMNALMF	IK	KPWDGTGXUYRARH-UHFFFAOYSA-N
DMNALMF	IU	2,2,2-trichloroethanol
DMNALMF	CA	CAS 115-20-8
DMNALMF	CB	CHEBI:28094
DMNALMF	DE	Discovery agent

DM9C8NX	ID	DM9C8NX
DM9C8NX	DN	Trichostatin A
DM9C8NX	HS	Investigative
DM9C8NX	SN	trichostatin A; 58880-19-6; Trichostatin A (TSA); TSA; Trichostatin; Tricostatin A; UNII-3X2S926L3Z; CHEBI:46024; (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide; GNF-PF-1011; RTKIYFITIVXBLE-QEQCGCAPSA-N; 3X2S926L3Z; 7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-; 7-[4-(DIMETHYLAMINO)PHENYL]-N-HYDROXY-4,6-DIMETHYL-7-OXO-2,4-HEPTADIENAMIDE
DM9C8NX	DT	Small molecular drug
DM9C8NX	PC	444732
DM9C8NX	MW	302.37
DM9C8NX	FM	C17H22N2O3
DM9C8NX	IC	InChI=1S/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)19(3)4/h5-11,13,22H,1-4H3,(H,18,20)/b10-5+,12-11+/t13-/m1/s1
DM9C8NX	CS	C[C@H](/C=C(\\C)/C=C/C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C
DM9C8NX	IK	RTKIYFITIVXBLE-QEQCGCAPSA-N
DM9C8NX	IU	(2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide
DM9C8NX	CA	CAS 58880-19-6
DM9C8NX	CB	CHEBI:46024
DM9C8NX	DE	Solid tumour/cancer

DMYB57J	ID	DMYB57J
DMYB57J	DN	Triclosan monophosphate
DMYB57J	HS	Investigative
DMYB57J	SN	Triclosan monophosphate; SCHEMBL121443; [5-chloro-2-(2,4-dichlorophenoxy)phenyl] dihydrogen phosphate; UWGXJEHVYAWNIK-UHFFFAOYSA-N
DMYB57J	PC	9929261
DMYB57J	MW	369.5
DMYB57J	FM	C12H8Cl3O5P
DMYB57J	IC	UWGXJEHVYAWNIK-UHFFFAOYSA-N
DMYB57J	CS	C1=CC(=C(C=C1Cl)OP(=O)(O)O)OC2=C(C=C(C=C2)Cl)Cl
DMYB57J	IK	1S/C12H8Cl3O5P/c13-7-1-3-10(9(15)5-7)19-11-4-2-8(14)6-12(11)20-21(16,17)18/h1-6H,(H2,16,17,18)
DMYB57J	IU	[5-chloro-2-(2,4-dichlorophenoxy)phenyl] dihydrogen phosphate
DMYB57J	DE	Discovery agent

DM5Q7K8	ID	DM5Q7K8
DM5Q7K8	DN	Triethyl 2-aminopropane-1,2,3-tricarboxylate
DM5Q7K8	HS	Investigative
DM5Q7K8	SN	CHEMBL509901
DM5Q7K8	DT	Small molecular drug
DM5Q7K8	PC	44561272
DM5Q7K8	MW	275.3
DM5Q7K8	FM	C12H21NO6
DM5Q7K8	IC	InChI=1S/C12H21NO6/c1-4-17-9(14)7-12(13,11(16)19-6-3)8-10(15)18-5-2/h4-8,13H2,1-3H3
DM5Q7K8	CS	CCOC(=O)CC(CC(=O)OCC)(C(=O)OCC)N
DM5Q7K8	IK	OUTCCXFGNSXCFR-UHFFFAOYSA-N
DM5Q7K8	IU	triethyl 2-aminopropane-1,2,3-tricarboxylate
DM5Q7K8	DE	Discovery agent

DMUPK6G	ID	DMUPK6G
DMUPK6G	DN	Triethylcholine
DMUPK6G	HS	Investigative
DMUPK6G	SN	Triethylcholine; UNII-9B2PFY5LLZ; 9B2PFY5LLZ; triethyl(2-hydroxyethyl)azanium; 302-61-4; CHEMBL555023; Triethylaminoethanol; Triethyl (2-hydroxyethyl)ammonium chloride; AC1L2YNS; 152-22-7 (chloride); SCHEMBL476985; GTPL4760; CHEMBL318993; 5957-17-5 (iodide); ZINC394634; BDBM50366913; MCULE-9715160196; Ethanaminium, N,N,N-triethyl-2-hydroxy-
DMUPK6G	DT	Small molecular drug
DMUPK6G	PC	80058
DMUPK6G	MW	146.25
DMUPK6G	FM	C8H20NO+
DMUPK6G	IC	InChI=1S/C8H20NO/c1-4-9(5-2,6-3)7-8-10/h10H,4-8H2,1-3H3/q+1
DMUPK6G	CS	CC[N+](CC)(CC)CCO
DMUPK6G	IK	GZBUMTPCIKCWFW-UHFFFAOYSA-N
DMUPK6G	IU	triethyl(2-hydroxyethyl)azanium
DMUPK6G	CA	CAS 302-61-4
DMUPK6G	DE	Discovery agent

DMAWTUL	ID	DMAWTUL
DMAWTUL	DN	Trifluoroethanol
DMAWTUL	HS	Investigative
DMAWTUL	SN	2,2,2-TRIFLUOROETHANOL; 75-89-8; Trifluoroethanol; Ethanol, 2,2,2-trifluoro-; Trifluoroethyl alcohol; 2,2,2-Trifluoroethan-1-Ol; Fluorinol 85; 2,2,2-Trifluoroethyl alcohol; trifluoro ethanol; TFE; Perfluoro-1,1-dihydroethanol; tfetoh; NSC 451; CF3CH2OH; 2,2,2-trifluoro-ethanol; beta,beta,beta-Trifluoroethyl alcohol; UNII-8T8I76KYF1; TFEA; 2,2,2-TRIFLUORETHANOL; 1h,1h-trifluoroethanol; EINECS 200-913-6; BRN 1733203; ethanol, 2,2,2-trifluoro; AI3-25486; 8T8I76KYF1; CHEBI:42330; RHQDFWAXVIIEBN-UHFFFAOYSA-N; MFCD00004672
DMAWTUL	DT	Small molecular drug
DMAWTUL	PC	6409
DMAWTUL	MW	100.04
DMAWTUL	FM	C2H3F3O
DMAWTUL	IC	InChI=1S/C2H3F3O/c3-2(4,5)1-6/h6H,1H2
DMAWTUL	CS	C(C(F)(F)F)O
DMAWTUL	IK	RHQDFWAXVIIEBN-UHFFFAOYSA-N
DMAWTUL	IU	2,2,2-trifluoroethanol
DMAWTUL	CA	CAS 75-89-8
DMAWTUL	CB	CHEBI:42330
DMAWTUL	DE	Discovery agent

DM4IKBV	ID	DM4IKBV
DM4IKBV	DN	Trifluoromethionine
DM4IKBV	HS	Investigative
DM4IKBV	SN	Trifluoro-l-methionine; 764-52-3; 2-AMINO-4-TRIFLUOROMETHYLSULFANYL-BUTYRIC ACID; (S)-2-Amino-4-((trifluoromethyl)thio)butanoic acid; YLJLTSVBCXYTQK-VKHMYHEASA-N; S-Trifluoromethyl-L-homocysteine; MF3; (2S)-2-amino-4-(trifluoromethylsulfanyl)butanoic acid; AC1Q4KJQ; AC1Q4U8O; SCHEMBL245986; (Trifluoromethyl)homocysteine #; AC1L4W93; CHEBI:43978; ZINC1698833; L-Homocysteine,S-(trifluoromethyl)-; AKOS027393884; DB03799; AK432011
DM4IKBV	DT	Small molecular drug
DM4IKBV	PC	165196
DM4IKBV	MW	203.19
DM4IKBV	FM	C5H8F3NO2S
DM4IKBV	IC	InChI=1S/C5H8F3NO2S/c6-5(7,8)12-2-1-3(9)4(10)11/h3H,1-2,9H2,(H,10,11)/t3-/m0/s1
DM4IKBV	CS	C(CSC(F)(F)F)[C@@H](C(=O)O)N
DM4IKBV	IK	YLJLTSVBCXYTQK-VKHMYHEASA-N
DM4IKBV	IU	(2S)-2-amino-4-(trifluoromethylsulfanyl)butanoic acid
DM4IKBV	CA	CAS 764-52-3
DM4IKBV	CB	CHEBI:43978
DM4IKBV	DE	Discovery agent

DMEPFAB	ID	DMEPFAB
DMEPFAB	DN	Trifluoromethylketone
DMEPFAB	HS	Investigative
DMEPFAB	DE	Discovery agent

DMIZX8P	ID	DMIZX8P
DMIZX8P	DN	Triflupromazine
DMIZX8P	HS	Investigative
DMIZX8P	SN	Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN)
DMIZX8P	CP	Bristol-Myers Squibb
DMIZX8P	TC	Antiviral Agents
DMIZX8P	DT	Small molecular drug
DMIZX8P	PC	5568
DMIZX8P	MW	352.4
DMIZX8P	FM	C18H19F3N2S
DMIZX8P	IC	InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
DMIZX8P	CS	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F
DMIZX8P	IK	XSCGXQMFQXDFCW-UHFFFAOYSA-N
DMIZX8P	IU	N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine
DMIZX8P	CA	CAS 146-54-3
DMIZX8P	CB	CHEBI:9711
DMIZX8P	DE	Psychosis; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)

DMSP56N	ID	DMSP56N
DMSP56N	DN	trihydroxycholestane
DMSP56N	HS	Investigative
DMSP56N	SN	5beta-Cholestane-3alpha,7alpha,12alpha-triol; Trihydroxycoprostane; 3,7,12-Trihydroxycholestane; 547-96-6; 5-b-Cholestane-3a ,7a ,12a-triol; (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol; 3alpha,7alpha,12alpha-Trihydroxycoprostane; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestane; 3,7,12-Trihydroxycoprostane; A,5; A)-cholestane-3,7,12-triol; AC1L4NRJ; 3,7,12-trihydroxycholestane; trihydroxycoprostane; 5beta-cholestane-3alpha,7alpha,12alpha-triol
DMSP56N	DT	Small molecular drug
DMSP56N	PC	160520
DMSP56N	MW	420.7
DMSP56N	FM	C27H48O3
DMSP56N	IC	InChI=1S/C27H48O3/c1-16(2)7-6-8-17(3)20-9-10-21-25-22(15-24(30)27(20,21)5)26(4)12-11-19(28)13-18(26)14-23(25)29/h16-25,28-30H,6-15H2,1-5H3/t17-,18+,19-,20-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DMSP56N	CS	C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
DMSP56N	IK	RIVQQZVHIVNQFH-XJZYBRFWSA-N
DMSP56N	IU	(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol
DMSP56N	CA	CAS 547-96-6
DMSP56N	CB	CHEBI:16496
DMSP56N	DE	Discovery agent

DMVJD1A	ID	DMVJD1A
DMVJD1A	DN	Triiodo-l-thyronine
DMVJD1A	HS	Investigative
DMVJD1A	SN	Reverse Tri-Iodothyronine; Triiodothyronine, reverse; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3-iodophenyl]propanoic acid; (S)-2-Amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3-iodophenyl)propanoic acid; 3,3',5'-Triiodo-L-thyronine; 3,3',5'-Triiodothyronine; 5817-39-0; 3,3',5'-Triiodo-l-thyronine; REVERSE TRIIODOTHYRONINE; Reverse T3; 8NZ4Y08T96; CHEBI:11684; DSSTox_CID_26908; DSSTox_GSID_46908; DSSTox_RID_82006; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3-iodo-; Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3-iodo-; UNII-8NZ4Y08T96
DMVJD1A	PC	644280
DMVJD1A	MW	650.97
DMVJD1A	FM	C15H12I3NO4
DMVJD1A	IC	HZCBWYNLGPIQRK-LBPRGKRZSA-N
DMVJD1A	CS	C1=CC(=C(C=C1CC(C(=O)O)N)I)OC2=CC(=C(C(=C2)I)O)I
DMVJD1A	IK	1S/C15H12I3NO4/c16-9-3-7(4-12(19)15(21)22)1-2-13(9)23-8-5-10(17)14(20)11(18)6-8/h1-3,5-6,12,20H,4,19H2,(H,21,22)/t12-/m0/s1
DMVJD1A	IU	(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3-iodophenyl]propanoic acid
DMVJD1A	CA	CAS 5817-39-0
DMVJD1A	CB	CHEBI:11684
DMVJD1A	DE	Discovery agent

DMNHU4M	ID	DMNHU4M
DMNHU4M	DN	TRIM
DMNHU4M	HS	Investigative
DMNHU4M	SN	Trim; 25371-96-4; 1-[2-(trifluoromethyl)phenyl]imidazole; 1-(2-Trifluoromethylphenyl)imidazole; 1-(2-(Trifluoromethyl)phenyl)-1H-imidazole; 1-[2-(Trifluoromethyl)phenyl]-1H-imidazole; CHEMBL277525; WZBWBNCQUTXYEL-UHFFFAOYSA-N; NCGC00016047-03; 1H-Imidazole,1-[2-(trifluoromethyl)phenyl]-; DSSTox_RID_80756; DSSTox_CID_25217; DSSTox_GSID_45217; [2-(trifluoromethyl)phenyl]imidazole; 1-TRIM; CAS-25371-96-4; SR-01000076173; PubChem6489; Tocris-0919; ACMC-1CKKY; AC1L1BAW; AC1Q4JVD; Lopac-T-7313; Lopac0_001200; KBioSS_000064
DMNHU4M	DT	Small molecular drug
DMNHU4M	PC	1359
DMNHU4M	MW	212.17
DMNHU4M	FM	C10H7F3N2
DMNHU4M	IC	InChI=1S/C10H7F3N2/c11-10(12,13)8-3-1-2-4-9(8)15-6-5-14-7-15/h1-7H
DMNHU4M	CS	C1=CC=C(C(=C1)C(F)(F)F)N2C=CN=C2
DMNHU4M	IK	WZBWBNCQUTXYEL-UHFFFAOYSA-N
DMNHU4M	IU	1-[2-(trifluoromethyl)phenyl]imidazole
DMNHU4M	CA	CAS 25371-96-4
DMNHU4M	CB	CHEBI:109530
DMNHU4M	DE	Discovery agent

DMPXHTY	ID	DMPXHTY
DMPXHTY	DN	TRIMEDOXIME
DMPXHTY	HS	Investigative
DMPXHTY	DT	Small molecular drug
DMPXHTY	PC	135565598
DMPXHTY	MW	446.14
DMPXHTY	FM	C15H18Br2N4O2
DMPXHTY	IC	InChI=1S/C15H16N4O2.2BrH/c20-16-12-14-2-8-18(9-3-14)6-1-7-19-10-4-15(5-11-19)13-17-21;;/h2-5,8-13H,1,6-7H2;2*1H
DMPXHTY	CS	C1=C[N+](=CC=C1/C=N/O)CCC[N+]2=CC=C(C=C2)/C=N/O.[Br-].[Br-]
DMPXHTY	IK	JHZHWVQTOXIXIV-UHFFFAOYSA-N
DMPXHTY	IU	(NE)-N-[[1-[3-[4-[(E)-hydroxyiminomethyl]pyridin-1-ium-1-yl]propyl]pyridin-1-ium-4-yl]methylidene]hydroxylamine;dibromide
DMPXHTY	CA	CAS 56-97-3
DMPXHTY	DE	Discovery agent

DMQXPMB	ID	DMQXPMB
DMQXPMB	DN	Trimethyl-(3-nitro-phenyl)-ammonium iodide
DMQXPMB	HS	Investigative
DMQXPMB	DE	Discovery agent

DMJ4I98	ID	DMJ4I98
DMJ4I98	DN	Trimethyl-(4-oxo-pentyl)-ammonium iodide
DMJ4I98	HS	Investigative
DMJ4I98	DE	Discovery agent

DM8LJ3C	ID	DM8LJ3C
DM8LJ3C	DN	trimethylamine
DM8LJ3C	HS	Investigative
DM8LJ3C	SN	trimethylamine; N,N-dimethylmethanamine; 75-50-3; Methanamine, N,N-dimethyl-; N-Trimethylamine; Dimethylmethaneamine; Trimethylamine solution; (CH3)3N; TRIMETHYL AMINE; Trimethylamin; Trimethylamine anhydrous; trimethyl-amine; FEMA Number 3241; UNII-LHH7G8O305; UN1297; UN1083; FEMA No. 3241; HSDB 808; CCRIS 6283; N,N,N-trimethylamine; NMe3; AI3-15639; Trimethylamine, in aqueous solution; EINECS 200-875-0; Trimethylamine solution (30% or less); trimethylamino; Methylamine, N,N-dimethyl-; LHH7G8O305; CHEBI:18139
DM8LJ3C	DT	Small molecular drug
DM8LJ3C	PC	1146
DM8LJ3C	MW	59.11
DM8LJ3C	FM	C3H9N
DM8LJ3C	IC	InChI=1S/C3H9N/c1-4(2)3/h1-3H3
DM8LJ3C	CS	CN(C)C
DM8LJ3C	IK	GETQZCLCWQTVFV-UHFFFAOYSA-N
DM8LJ3C	IU	N,N-dimethylmethanamine
DM8LJ3C	CA	CAS 75-50-3
DM8LJ3C	CB	CHEBI:18139
DM8LJ3C	DE	Discovery agent

DMK9743	ID	DMK9743
DMK9743	DN	Trimetoquinol
DMK9743	HS	Investigative
DMK9743	SN	Trimetoquinol; Trimethoquinol; Inolin; Trimetoquinol-hydrochloride; AQL 208; Trikvinol (triquinol) hydrochloride; l-Trimetoquinol; Trimetoquinol (VAN); Trimethoquinol (VAN); AQ-110; CCRIS 1913; Tretoquinol l-form hydrochloride; Tetroquinol; EINECS 242-423-5; NSC 288748; TRETOQUINOL HYDROCHLORIDE; (-)-Trimethoquinol; AC1L1GTS; C19H23NO5.HCl; CHEMBL542101; SCHEMBL1630263; L-1-(3,4,5-Trimethylbenzyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; AQL-208; 1-(3,4,5-Trimethoxybenzyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline hydroch
DMK9743	DT	Small molecular drug
DMK9743	PC	29137
DMK9743	MW	381.8
DMK9743	FM	C19H24ClNO5
DMK9743	IC	InChI=1S/C19H23NO5.ClH/c1-23-17-7-11(8-18(24-2)19(17)25-3)6-14-13-10-16(22)15(21)9-12(13)4-5-20-14;/h7-10,14,20-22H,4-6H2,1-3H3;1H
DMK9743	CS	COC1=CC(=CC(=C1OC)OC)CC2C3=CC(=C(C=C3CCN2)O)O.Cl
DMK9743	IK	UHSXRTHJCJGEKG-UHFFFAOYSA-N
DMK9743	IU	1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride
DMK9743	CA	CAS 18559-63-2
DMK9743	DE	Discovery agent

DML3OYH	ID	DML3OYH
DML3OYH	DN	TriMixDC
DML3OYH	HS	Investigative
DML3OYH	SN	Dendritic cell vaccine (melanoma), Vrije Universiteit Brussel; TriMixDC (melanoma, intrademal), Universite Libre de Bruxelles
DML3OYH	CP	Universite Libre de Bruxelles
DML3OYH	DT	Vaccine
DML3OYH	DE	Melanoma

DM2VIDK	ID	DM2VIDK
DM2VIDK	DN	Triphenylacetic acid methyl ester
DM2VIDK	HS	Investigative
DM2VIDK	SN	methyl triphenylacetate; methyl 2,2,2-triphenylacetate; 5467-21-0; triphenylacetic acid methyl ester; CHEMBL270495; 2-TRIPHENYL METHYL ACETIC ACID; NSC28082; methyl triphenyl-acetate; AC1Q5YRI; SCHEMBL7258414; AC1L5M42; CTK5A2196; DTXSID30282812; ZPGOQUZHRVSLML-UHFFFAOYSA-N; ZINC4696706; BDBM50371380; NSC-28082; Benzeneacetic acid, a,a-diphenyl-, methyl ester; benzeneacetic acid, .alpha.,.alpha.-diphenyl-, methyl ester
DM2VIDK	DT	Small molecular drug
DM2VIDK	PC	231627
DM2VIDK	MW	302.4
DM2VIDK	FM	C21H18O2
DM2VIDK	IC	InChI=1S/C21H18O2/c1-23-20(22)21(17-11-5-2-6-12-17,18-13-7-3-8-14-18)19-15-9-4-10-16-19/h2-16H,1H3
DM2VIDK	CS	COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3
DM2VIDK	IK	ZPGOQUZHRVSLML-UHFFFAOYSA-N
DM2VIDK	IU	methyl 2,2,2-triphenylacetate
DM2VIDK	CA	CAS 5467-21-0
DM2VIDK	DE	Discovery agent

DM3CQIZ	ID	DM3CQIZ
DM3CQIZ	DN	Triphenylmethanamine
DM3CQIZ	HS	Investigative
DM3CQIZ	SN	Tritylamine; Triphenylmethanamine; 5824-40-8; Triphenylmethylamine; Benzenemethanamine, .alpha.,.alpha.-diphenyl-; BZVJOYBTLHNRDW-UHFFFAOYSA-N; tritylamin; trityl amine; NSC1154; Aminotriphenylmethane; Triphenylaminomethane; triphenyl methylamine; Triphenylmethanamine #; Aminotrityl, polymer-bound; Triphenylmethylamine, 99%; 1,1,1-triphenylmethanamine; Aminotrityl polystyrene resin; Methylamine,1,1-triphenyl-; KSC490G4B; SCHEMBL115149; ACMC-209m39; AC1Q506E; CHEMBL272255; AC1Q506F; BEN104; AC1L3D64; BDBM23786; Methylamine, 1,1,1-trip
DM3CQIZ	DT	Small molecular drug
DM3CQIZ	PC	138598
DM3CQIZ	MW	259.3
DM3CQIZ	FM	C19H17N
DM3CQIZ	IC	InChI=1S/C19H17N/c20-19(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h1-15H,20H2
DM3CQIZ	CS	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)N
DM3CQIZ	IK	BZVJOYBTLHNRDW-UHFFFAOYSA-N
DM3CQIZ	IU	triphenylmethanamine
DM3CQIZ	CA	CAS 5824-40-8
DM3CQIZ	DE	Discovery agent

DMF8QR6	ID	DMF8QR6
DMF8QR6	DN	TRIPHLOROETHOL A
DMF8QR6	HS	Investigative
DMF8QR6	SN	Triphloroethol A; CHEMBL1083394; BDBM50319628
DMF8QR6	DT	Small molecular drug
DMF8QR6	PC	21626545
DMF8QR6	MW	374.3
DMF8QR6	FM	C18H14O9
DMF8QR6	IC	InChI=1S/C18H14O9/c19-8-1-9(20)3-12(2-8)26-18-15(25)6-11(22)7-16(18)27-17-13(23)4-10(21)5-14(17)24/h1-7,19-25H
DMF8QR6	CS	C1=C(C=C(C=C1O)OC2=C(C=C(C=C2OC3=C(C=C(C=C3O)O)O)O)O)O
DMF8QR6	IK	OXFVHFABBAINFL-UHFFFAOYSA-N
DMF8QR6	IU	2-[2-(3,5-dihydroxyphenoxy)-3,5-dihydroxyphenoxy]benzene-1,3,5-triol
DMF8QR6	DE	Discovery agent

DMWZ5FB	ID	DMWZ5FB
DMWZ5FB	DN	tripitramine
DMWZ5FB	HS	Investigative
DMWZ5FB	SN	Tripitramine; 152429-64-6; AC1L31VO; GTPL361; CHEMBL265256; SCHEMBL20584784; BDBM82423; DTXSID30165030; PDSP1_000934; PDSP2_000920; NSC_132947; CAS_132947; L000604; 11-[2-[6-[methyl-[8-[methyl-[6-[[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]amino]hexyl]amino]octyl]amino]hexyl-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]amino]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 6H-Pyrido(2,3-b)(1,4)benzodiazepin-6-one, 11,11'-(3-(2-(5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-1
DMWZ5FB	DT	Small molecular drug
DMWZ5FB	PC	132947
DMWZ5FB	MW	1124.4
DMWZ5FB	FM	C64H77N13O6
DMWZ5FB	IC	InChI=1S/C64H77N13O6/c1-72(41-20-8-5-17-35-65-44-56(78)75-53-32-14-11-26-47(53)62(81)69-50-29-23-36-66-59(50)75)39-18-6-3-4-7-19-40-73(2)42-21-9-10-22-43-74(45-57(79)76-54-33-15-12-27-48(54)63(82)70-51-30-24-37-67-60(51)76)46-58(80)77-55-34-16-13-28-49(55)64(83)71-52-31-25-38-68-61(52)77/h11-16,23-34,36-38,65H,3-10,17-22,35,39-46H2,1-2H3,(H,69,81)(H,70,82)(H,71,83)
DMWZ5FB	CS	CN(CCCCCCCCN(C)CCCCCCN(CC(=O)N1C2=CC=CC=C2C(=O)NC3=C1N=CC=C3)CC(=O)N4C5=CC=CC=C5C(=O)NC6=C4N=CC=C6)CCCCCCNCC(=O)N7C8=CC=CC=C8C(=O)NC9=C7N=CC=C9
DMWZ5FB	IK	YUJOQEAGGUIMED-UHFFFAOYSA-N
DMWZ5FB	IU	11-[2-[6-[8-[6-[bis[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]amino]hexyl-methylamino]octyl-methylamino]hexylamino]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMWZ5FB	CA	CAS 152429-64-6
DMWZ5FB	DE	Discovery agent

DMBYV3M	ID	DMBYV3M
DMBYV3M	DN	TRIPTOCALLINE A
DMBYV3M	HS	Investigative
DMBYV3M	SN	Triptocalline A; 201534-10-3
DMBYV3M	DT	Small molecular drug
DMBYV3M	PC	44559634
DMBYV3M	MW	442.6
DMBYV3M	FM	C28H42O4
DMBYV3M	IC	InChI=1S/C28H42O4/c1-15-13-21-26(4,24(32)22(15)30)10-12-27(5)20-8-7-17-16(2)23(31)19(29)14-18(17)25(20,3)9-11-28(21,27)6/h15,18-21,24,29,32H,7-14H2,1-6H3/t15-,18-,19+,20+,21-,24-,25+,26-,27-,28+/m1/s1
DMBYV3M	CS	C[C@@H]1C[C@@H]2[C@@](CC[C@]3([C@]2(CC[C@@]4([C@@H]3CCC5=C(C(=O)[C@H](C[C@H]54)O)C)C)C)C)([C@@H](C1=O)O)C
DMBYV3M	IK	UUGCGHAFZPEHIC-OIOGIDCRSA-N
DMBYV3M	IU	(2R,4S,4aR,6aS,6aR,6bS,11S,12aS,14aS,14bS)-4,11-dihydroxy-2,4a,6a,6a,9,14a-hexamethyl-1,2,4,5,6,6b,7,8,11,12,12a,13,14,14b-tetradecahydropicene-3,10-dione
DMBYV3M	CA	CAS 201534-10-3
DMBYV3M	DE	Discovery agent

DM6USPC	ID	DM6USPC
DM6USPC	DN	TRISMETHOXYRESVERATROL
DM6USPC	HS	Investigative
DM6USPC	SN	22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; TRISMETHOXYRESVERATROL; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene
DM6USPC	DT	Small molecular drug
DM6USPC	PC	5388063
DM6USPC	MW	270.32
DM6USPC	FM	C17H18O3
DM6USPC	IC	InChI=1S/C17H18O3/c1-18-15-8-6-13(7-9-15)4-5-14-10-16(19-2)12-17(11-14)20-3/h4-12H,1-3H3/b5-4+
DM6USPC	CS	COC1=CC=C(C=C1)/C=C/C2=CC(=CC(=C2)OC)OC
DM6USPC	IK	GDHNBPHYVRHYCC-SNAWJCMRSA-N
DM6USPC	IU	1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene
DM6USPC	CA	CAS 22255-22-7
DM6USPC	DE	Discovery agent

DMQVH3J	ID	DMQVH3J
DMQVH3J	DN	Trisnorsqualene alcohol
DMQVH3J	HS	Investigative
DMQVH3J	SN	trisnorsqualene alcohol; CHEMBL47899; Trinorsqualene alcohol; SCHEMBL2587286; SCHEMBL2587282; BDBM50015507; 4,8,13,17,21-Pentamethyl-docosa-4,8,12,16,20-pentaen-1-ol
DMQVH3J	DT	Small molecular drug
DMQVH3J	PC	14379145
DMQVH3J	MW	386.7
DMQVH3J	FM	C27H46O
DMQVH3J	IC	InChI=1S/C27H46O/c1-23(2)13-9-16-26(5)19-10-17-24(3)14-7-8-15-25(4)18-11-20-27(6)21-12-22-28/h13-15,19-20,28H,7-12,16-18,21-22H2,1-6H3/b24-14+,25-15+,26-19+,27-20+
DMQVH3J	CS	CC(=CCC/C(=C/CC/C(=C/CC/C=C(\\C)/CC/C=C(\\C)/CCCO)/C)/C)C
DMQVH3J	IK	WAMKRSMPERYEBH-OGDZRKEVSA-N
DMQVH3J	IU	(4E,8E,12E,16E)-4,8,13,17,21-pentamethyldocosa-4,8,12,16,20-pentaen-1-ol
DMQVH3J	DE	Discovery agent

DM0G2IR	ID	DM0G2IR
DM0G2IR	DN	Trisnorsqualene cyclopropylamine
DM0G2IR	HS	Investigative
DM0G2IR	SN	Trisnorsqualene CA; AC1O5R3E; 123594-76-3; Cyclopropanamine, N-(4,8,13,17,21-pentamethyl-4,8,12,16,20-docosapentaenyl)-, (all-E)-
DM0G2IR	DT	Small molecular drug
DM0G2IR	PC	6505320
DM0G2IR	MW	425.7
DM0G2IR	FM	C30H51N
DM0G2IR	IC	InChI=1S/C30H51N/c1-25(2)13-9-16-28(5)19-10-17-26(3)14-7-8-15-27(4)18-11-20-29(6)21-12-24-31-30-22-23-30/h13-15,19-20,30-31H,7-12,16-18,21-24H2,1-6H3/b26-14+,27-15+,28-19+,29-20+
DM0G2IR	CS	CC(=CCC/C(=C/CC/C(=C/CC/C=C(\\C)/CC/C=C(\\C)/CCCNC1CC1)/C)/C)C
DM0G2IR	IK	AWTJYTFLSJBJTO-CQNOQWDGSA-N
DM0G2IR	IU	N-[(4E,8E,12E,16E)-4,8,13,17,21-pentamethyldocosa-4,8,12,16,20-pentaenyl]cyclopropanamine
DM0G2IR	CA	CAS 123594-76-3
DM0G2IR	DE	Discovery agent

DMQA7ZS	ID	DMQA7ZS
DMQA7ZS	DN	Trisnorsqualene difluoromethylidene
DMQA7ZS	HS	Investigative
DMQA7ZS	SN	Trisnorsqualene difluoromethylidene; CHEMBL457687; SCHEMBL9152042; SCHEMBL9152035
DMQA7ZS	DT	Small molecular drug
DMQA7ZS	PC	15119643
DMQA7ZS	MW	418.6
DMQA7ZS	FM	C28H44F2
DMQA7ZS	IC	InChI=1S/C28H44F2/c1-23(2)13-9-16-26(5)19-10-17-24(3)14-7-8-15-25(4)18-11-20-27(6)21-12-22-28(29)30/h13-15,19-20,22H,7-12,16-18,21H2,1-6H3/b24-14+,25-15+,26-19+,27-20+
DMQA7ZS	CS	CC(=CCC/C(=C/CC/C(=C/CC/C=C(\\C)/CC/C=C(\\C)/CCC=C(F)F)/C)/C)C
DMQA7ZS	IK	VSXSIZULFIRURF-OGDZRKEVSA-N
DMQA7ZS	IU	(5E,9E,13E,17E)-1,1-difluoro-5,9,14,18,22-pentamethyltricosa-1,5,9,13,17,21-hexaene
DMQA7ZS	DE	Discovery agent

DMPVI3A	ID	DMPVI3A
DMPVI3A	DN	Trisodium phosphate
DMPVI3A	HS	Investigative
DMPVI3A	SN	TRISODIUM PHOSPHATE; 7601-54-9; Sodium orthophosphate; Tromete; Tribasic sodium phosphate; Phosphoric acid, trisodium salt; Oakite; Trisodium orthophosphate; Phosphoric acid trisodium salt; Trinatriumphosphat; Nutrifos STP; Tertiary sodium phosphate; Dri-Tri; Antisal 4; Sodium phosphate, anhydrous; Tribasic sodium orthophosphate; Caswell No. 898; Sodium tertiary phosphate; Sodium phosphate (VAN); UNII-SX01TZO3QZ; Emulsiphos 440/660; Trinatriumphosphat [German]; Trisodium phosphate anhydrous; Sodium phosphate (Na3PO4); Sodium ortho
DMPVI3A	DT	Small molecular drug
DMPVI3A	PC	24243
DMPVI3A	MW	163.941
DMPVI3A	FM	Na3O4P
DMPVI3A	IC	InChI=1S/3Na.H3O4P/c;;;1-5(2,3)4/h;;;(H3,1,2,3,4)/q3*+1;/p-3
DMPVI3A	CS	[O-]P(=O)([O-])[O-].[Na+].[Na+].[Na+]
DMPVI3A	IK	RYFMWSXOAZQYPI-UHFFFAOYSA-K
DMPVI3A	IU	trisodium;phosphate
DMPVI3A	CA	CAS 7601-54-9
DMPVI3A	CB	CHEBI:37583
DMPVI3A	DE	Discovery agent

DMBZI5F	ID	DMBZI5F
DMBZI5F	DN	TrkB NAM
DMBZI5F	HS	Investigative
DMBZI5F	SN	TrkB negative allosteric modulators (neurodegenerative diseases); TrkB NAM program (neurodegenerative diseases), Addex; TrkB negative allosteric modulators (neurodegenerative diseases), Addex
DMBZI5F	CP	Addex Pharmaceuticals SA
DMBZI5F	DE	Neurodegenerative disorder

DMU3E1M	ID	DMU3E1M
DMU3E1M	DN	TRL-382
DMU3E1M	HS	Investigative
DMU3E1M	SN	COX-1 inhibitor (neuropathic pain), Toray Industries
DMU3E1M	CP	Toray Industries Inc
DMU3E1M	DE	Neuropathic pain

DMXNSTF	ID	DMXNSTF
DMXNSTF	DN	TRN-101
DMXNSTF	HS	Investigative
DMXNSTF	SN	Dual ROCK1/ROCK2 inhibitor (inhalant, COPD), Theron Pharmaceuticals; Dual Rho kinase 1/ Rho kinase2 inhibitor (inhalant, COPD), Theron Pharmaceuticals
DMXNSTF	CP	Theron Pharmaceuticals Inc
DMXNSTF	DE	Chronic obstructive pulmonary disease

DMOMXP7	ID	DMOMXP7
DMOMXP7	DN	TROPOLONE
DMOMXP7	HS	Investigative
DMOMXP7	SN	Tropolone; 533-75-5; 2-Hydroxycyclohepta-2,4,6-trienone; Purpurocatechol; 2-Hydroxy-2,4,6-cycloheptatrien-1-one; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-; 2-hydroxycyclohepta-2,4,6-trien-1-one; 2-Hydroxytropone; 2-Hydroxy-2,4,6-cycloheptatrienone; UNII-7L6DL16P1T; Tropolone, 98%; CCRIS 6609; NSC89303; EINECS 208-577-2; NSC 89303; BRN 1904978; CHEMBL121188; 7L6DL16P1T; CHEBI:79966; MDYOLVRUBBJPFM-UHFFFAOYSA-N; MFCD00004158; Tropomyosins; 0TR; PubChem6330; NCIMech_000829; AC1L1VY5; DSSTox_RID_83491; DSSTox_CID_29376; DSSTox_GSID_49416
DMOMXP7	DT	Small molecular drug
DMOMXP7	PC	10789
DMOMXP7	MW	122.12
DMOMXP7	FM	C7H6O2
DMOMXP7	IC	InChI=1S/C7H6O2/c8-6-4-2-1-3-5-7(6)9/h1-5H,(H,8,9)
DMOMXP7	CS	C1=CC=C(C(=O)C=C1)O
DMOMXP7	IK	MDYOLVRUBBJPFM-UHFFFAOYSA-N
DMOMXP7	IU	2-hydroxycyclohepta-2,4,6-trien-1-one
DMOMXP7	CA	CAS 533-75-5
DMOMXP7	CB	CHEBI:79966
DMOMXP7	DE	Discovery agent

DMIF6NS	ID	DMIF6NS
DMIF6NS	DN	TROX-1
DMIF6NS	HS	Investigative
DMIF6NS	SN	GTPL7766; ZINC43203633; AJ-108280
DMIF6NS	DT	Small molecular drug
DMIF6NS	PC	25256198
DMIF6NS	MW	434.9
DMIF6NS	FM	C22H16ClFN6O
DMIF6NS	IC	InChI=1S/C22H16ClFN6O/c1-22(8-13-9-25-11-26-10-13)16-6-14(15-2-4-18(24)17(23)7-15)3-5-19(16)30(20(22)31)21-27-12-28-29-21/h2-7,9-12H,8H2,1H3,(H,27,28,29)
DMIF6NS	CS	CC1(C2=C(C=CC(=C2)C3=CC(=C(C=C3)F)Cl)N(C1=O)C4=NC=NN4)CC5=CN=CN=C5
DMIF6NS	IK	OABSWPUPIHULMQ-UHFFFAOYSA-N
DMIF6NS	IU	5-(3-chloro-4-fluorophenyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1-(1H-1,2,4-triazol-5-yl)indol-2-one
DMIF6NS	CA	CAS 1141080-15-0
DMIF6NS	DE	Discovery agent

DM48QTG	ID	DM48QTG
DM48QTG	DN	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys)
DM48QTG	HS	Investigative
DM48QTG	SN	CHEMBL408141
DM48QTG	PC	44368903
DM48QTG	MW	1496.8
DM48QTG	FM	C71H97N15O17S2
DM48QTG	IC	InChI=1S/C71H97N15O17S2/c1-9-38(7)58(69(100)81-53(71(102)103)27-42-30-74-47-19-15-14-18-45(42)47)86-70(101)59(39(8)10-2)85-65(96)52(29-56(89)90)79-61(92)48(24-36(3)4)76-64(95)51(28-43-31-73-35-75-43)78-67(98)55-34-105-104-33-46(72)60(91)82-54(32-87)66(97)84-57(37(5)6)68(99)80-50(26-41-20-22-44(88)23-21-41)62(93)77-49(63(94)83-55)25-40-16-12-11-13-17-40/h11-23,30-31,35-39,46,48-55,57-59,74,87-88H,9-10,24-29,32-34,72H2,1-8H3,(H,73,75)(H,76,95)(H,77,93)(H,78,98)(H,79,92)(H,80,99)(H,81,100)(H,82,91)(H,83,94)(H,84,97)(H,85,96)(H,86,101)(H,89,90)(H,102,103)/t38-,39-,46-,48-,49-,50+,51-,52-,53-,54-,55+,57-,58-,59-/m0/s1
DM48QTG	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N4)CC5=CC=CC=C5)CC6=CC=C(C=C6)O)C(C)C)CO)N
DM48QTG	IK	NFALCSTYLUFIHX-TWAFHRHTSA-N
DM48QTG	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(4S,7S,10R,13S,16S,19R)-19-amino-7-benzyl-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DM48QTG	DE	Discovery agent

DMOZX8M	ID	DMOZX8M
DMOZX8M	DN	Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys)
DMOZX8M	HS	Investigative
DMOZX8M	SN	CHEMBL436884; Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys)
DMOZX8M	PC	44368904
DMOZX8M	MW	1409.7
DMOZX8M	FM	C68H92N14O15S2
DMOZX8M	IC	InChI=1S/C68H92N14O15S2/c1-9-37(7)56(66(94)78-52(68(96)97)27-41-30-71-46-19-15-14-18-44(41)46)82-67(95)57(38(8)10-2)81-63(91)51(29-54(84)85)76-59(87)47(24-35(3)4)73-62(90)50(28-42-31-70-34-72-42)75-64(92)53-33-99-98-32-45(69)58(86)80-55(36(5)6)65(93)77-49(26-40-20-22-43(83)23-21-40)60(88)74-48(61(89)79-53)25-39-16-12-11-13-17-39/h11-23,30-31,34-38,45,47-53,55-57,71,83H,9-10,24-29,32-33,69H2,1-8H3,(H,70,72)(H,73,90)(H,74,88)(H,75,92)(H,76,87)(H,77,93)(H,78,94)(H,79,89)(H,80,86)(H,81,91)(H,82,95)(H,84,85)(H,96,97)/t37-,38-,45-,47-,48-,49+,50-,51-,52-,53+,55-,56-,57-/m0/s1
DMOZX8M	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N4)CC5=CC=CC=C5)CC6=CC=C(C=C6)O)C(C)C)N
DMOZX8M	IK	OETKRDJJNWJFOP-OUBBGVQJSA-N
DMOZX8M	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(4S,7S,10R,13S,16R)-16-amino-7-benzyl-10-[(4-hydroxyphenyl)methyl]-6,9,12,15-tetraoxo-13-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMOZX8M	DE	Discovery agent

DMDUGQ1	ID	DMDUGQ1
DMDUGQ1	DN	Trypanothione
DMDUGQ1	HS	Investigative
DMDUGQ1	DT	Small molecular drug
DMDUGQ1	PC	115098
DMDUGQ1	MW	721.9
DMDUGQ1	FM	C27H47N9O10S2
DMDUGQ1	IC	InChI=1S/C27H47N9O10S2/c28-16(26(43)44)4-6-20(37)35-18-14-47-48-15-19(36-21(38)7-5-17(29)27(45)46)25(42)34-13-23(40)32-11-3-9-30-8-1-2-10-31-22(39)12-33-24(18)41/h16-19,30H,1-15,28-29H2,(H,31,39)(H,32,40)(H,33,41)(H,34,42)(H,35,37)(H,36,38)(H,43,44)(H,45,46)/t16-,17-,18-,19-/m0/s1
DMDUGQ1	CS	C1CCNC(=O)CNC(=O)[C@H](CSSC[C@@H](C(=O)NCC(=O)NCCCNC1)NC(=O)CC[C@@H](C(=O)O)N)NC(=O)CC[C@@H](C(=O)O)N
DMDUGQ1	IK	LZMSXDHGHZKXJD-VJANTYMQSA-N
DMDUGQ1	IU	(2S)-2-amino-5-[[(4R,23R)-4-[[(4S)-4-amino-4-carboxybutanoyl]amino]-5,8,19,22-tetraoxo-1,2-dithia-6,9,13,18,21-pentazacyclotetracos-23-yl]amino]-5-oxopentanoic acid
DMDUGQ1	CA	CAS 96304-42-6
DMDUGQ1	CB	CHEBI:35490
DMDUGQ1	DE	Discovery agent

DMTRYCI	ID	DMTRYCI
DMTRYCI	DN	tryptanthrin
DMTRYCI	HS	Investigative
DMTRYCI	SN	GNF-PF-2691; couroupitine a
DMTRYCI	DT	Small molecular drug
DMTRYCI	PC	73549
DMTRYCI	MW	248.24
DMTRYCI	FM	C15H8N2O2
DMTRYCI	IC	InChI=1S/C15H8N2O2/c18-13-10-6-2-4-8-12(10)17-14(13)16-11-7-3-1-5-9(11)15(17)19/h1-8H
DMTRYCI	CS	C1=CC=C2C(=C1)C(=O)N3C4=CC=CC=C4C(=O)C3=N2
DMTRYCI	IK	VQQVWGVXDIPORV-UHFFFAOYSA-N
DMTRYCI	IU	indolo[2,1-b]quinazoline-6,12-dione
DMTRYCI	CA	CAS 13220-57-0
DMTRYCI	CB	CHEBI:9768
DMTRYCI	DE	Discovery agent

DMV19K7	ID	DMV19K7
DMV19K7	DN	TRYPTOLINE
DMV19K7	HS	Investigative
DMV19K7	SN	16502-01-5; Tryptoline; 2,3,4,9-tetrahydro-1H-Pyrido[3,4-b]indole; Noreleagnine; 1,2,3,4-Tetrahydro-9H-pyrido[3,4-b]indole; 1,2,3,4-Tetrahydro-beta-carboline; Tetrahydro-beta-carboline; THBC; Tetrahydronorharman; UNII-65027TMI0H; 1H,2H,3H,4H,9H-Pyrido[3,4-B]Indole; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-; 2,3,4,9-tetrahydro-1H-beta-carboline; MLS000069483; CHEMBL269236; 65027TMI0H; SMR000059115; Triptoline; Tetrahydronorharmane; Tetrahydro-beta-carboline, 98%; 1,2,3,4-tetrahydrobeta-carboline
DMV19K7	DT	Small molecular drug
DMV19K7	PC	107838
DMV19K7	MW	172.23
DMV19K7	FM	C11H12N2
DMV19K7	IC	InChI=1S/C11H12N2/c1-2-4-10-8(3-1)9-5-6-12-7-11(9)13-10/h1-4,12-13H,5-7H2
DMV19K7	CS	C1CNCC2=C1C3=CC=CC=C3N2
DMV19K7	IK	CFTOTSJVQRFXOF-UHFFFAOYSA-N
DMV19K7	IU	2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMV19K7	CA	CAS 16502-01-5
DMV19K7	CB	CHEBI:92568
DMV19K7	DE	Discovery agent

DMIV75Q	ID	DMIV75Q
DMIV75Q	DN	TS antisense + raltitrexed
DMIV75Q	HS	Investigative
DMIV75Q	TC	Antisense
DMIV75Q	DT	Combination drug (Antisense drug)
DMIV75Q	PC	104758
DMIV75Q	DE	Solid tumour/cancer

DM6JF7T	ID	DM6JF7T
DM6JF7T	DN	TSERaM
DM6JF7T	HS	Investigative
DM6JF7T	SN	TSERaM (menopausal weight gain); TSERaM (menopausal weight gain), Bionovo; Tissue-selective estrogen receptor alpha modulators (menopausal weight gain), Bionovo
DM6JF7T	CP	Bionovo Inc
DM6JF7T	DE	Menopause symptom

DM6NZFH	ID	DM6NZFH
DM6NZFH	DN	TTH 03-001
DM6NZFH	HS	Investigative
DM6NZFH	CP	Tetra Therapeutics SL
DM6NZFH	DE	Pain

DMDM7C6	ID	DMDM7C6
DMDM7C6	DN	TTL-1177
DMDM7C6	HS	Investigative
DMDM7C6	SN	TH-1177; Cav3 inhibitors (Cytostatic Checkpoint Therapy, cancer), Tau Therapeutics
DMDM7C6	CP	University of Virginia
DMDM7C6	DE	Solid tumour/cancer

DMSABD0	ID	DMSABD0
DMSABD0	DN	TTNPB
DMSABD0	HS	Investigative
DMSABD0	SN	Arotinoid acid; 71441-28-6; Arotinoic acid; Ro 13-7410; CCRIS 3297; UNII-673M8C29UR; 4-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid; Tocris-0761; Lopac-T-3757; TTNPB (Arotinoid Acid); BRN 2008247; CHEMBL275311; CHEBI:75261; 673M8C29UR; 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid; (E)-4-(2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propen-1-yl)benzoic acid
DMSABD0	DT	Small molecular drug
DMSABD0	PC	5289501
DMSABD0	MW	348.5
DMSABD0	FM	C24H28O2
DMSABD0	IC	InChI=1S/C24H28O2/c1-16(14-17-6-8-18(9-7-17)22(25)26)19-10-11-20-21(15-19)24(4,5)13-12-23(20,2)3/h6-11,14-15H,12-13H2,1-5H3,(H,25,26)/b16-14+
DMSABD0	CS	C/C(=C\\C1=CC=C(C=C1)C(=O)O)/C2=CC3=C(C=C2)C(CCC3(C)C)(C)C
DMSABD0	IK	FOIVPCKZDPCJJY-JQIJEIRASA-N
DMSABD0	IU	4-[(E)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid
DMSABD0	CA	CAS 71441-28-6
DMSABD0	CB	CHEBI:75261
DMSABD0	DE	Discovery agent

DMUR0TF	ID	DMUR0TF
DMUR0TF	DN	Tu-514
DMUR0TF	HS	Investigative
DMUR0TF	SN	TU-514; 1,5-ANHYDRO-2-C-(CARBOXYMETHYL-N-HYDROXYAMIDE)-2-DEOXY-3-O-MYRISTOYL-D-GLUCITOL; TUX; 1xxe; 2go4; AC1L9MVN; CHEMBL1236446; DB01991; 1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-tetradecanoyl-D-glucitol; [(2R,3S,4R,5S)-3-hydroxy-5-[2-(hydroxyamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-4-yl] tetradecanoate
DMUR0TF	DT	Small molecular drug
DMUR0TF	PC	449223
DMUR0TF	MW	431.6
DMUR0TF	FM	C22H41NO7
DMUR0TF	IC	InChI=1S/C22H41NO7/c1-2-3-4-5-6-7-8-9-10-11-12-13-20(26)30-22-17(14-19(25)23-28)16-29-18(15-24)21(22)27/h17-18,21-22,24,27-28H,2-16H2,1H3,(H,23,25)/t17-,18+,21+,22+/m0/s1
DMUR0TF	CS	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H](CO[C@@H]([C@H]1O)CO)CC(=O)NO
DMUR0TF	IK	INAPDIIIYSWKOC-XHIHJMKYSA-N
DMUR0TF	IU	[(2R,3S,4R,5S)-3-hydroxy-5-[2-(hydroxyamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-4-yl] tetradecanoate
DMUR0TF	DE	Discovery agent

DMYR8SG	ID	DMYR8SG
DMYR8SG	DN	Tubacin
DMYR8SG	HS	Investigative
DMYR8SG	SN	Tubacin; 537049-40-4; AC1O7Y2P; CHEMBL356769; 1350555-93-9; N1-(4-((2R,4R,6S)-4-(((4,5-Diphenyloxazol-2-yl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxyoctanediamide; Tubacin (BML-GR362); Octanediamide, N1-(4-((2R,4R,6S)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxy-, rel-; N-[4-[(2R,4R,6S)-4-[[(4,5-Diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide; SCHEMBL4741166
DMYR8SG	CP	Broad Institute
DMYR8SG	DT	Small molecular drug
DMYR8SG	PC	6675804
DMYR8SG	MW	721.9
DMYR8SG	FM	C41H43N3O7S
DMYR8SG	IC	InChI=1S/C41H43N3O7S/c45-26-28-17-19-29(20-18-28)35-25-34(27-52-41-43-38(30-11-5-3-6-12-30)39(51-41)31-13-7-4-8-14-31)49-40(50-35)32-21-23-33(24-22-32)42-36(46)15-9-1-2-10-16-37(47)44-48/h3-8,11-14,17-24,34-35,40,45,48H,1-2,9-10,15-16,25-27H2,(H,42,46)(H,44,47)/t34-,35+,40+/m1/s1
DMYR8SG	CS	C1[C@@H](O[C@@H](O[C@@H]1C2=CC=C(C=C2)CO)C3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO)CSC4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6
DMYR8SG	IK	BHUZLJOUHMBZQY-YXQOSMAKSA-N
DMYR8SG	IU	N-[4-[(2R,4R,6S)-4-[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide
DMYR8SG	CA	CAS 537049-40-4
DMYR8SG	CB	CHEBI:94166
DMYR8SG	DE	Multiple myeloma

DMHICK8	ID	DMHICK8
DMHICK8	DN	Tubercidin
DMHICK8	HS	Investigative
DMHICK8	SN	sparsamycin A
DMHICK8	DT	Small molecular drug
DMHICK8	PC	6245
DMHICK8	MW	266.25
DMHICK8	FM	C11H14N4O4
DMHICK8	IC	InChI=1S/C11H14N4O4/c12-9-5-1-2-15(10(5)14-4-13-9)11-8(18)7(17)6(3-16)19-11/h1-2,4,6-8,11,16-18H,3H2,(H2,12,13,14)/t6-,7-,8-,11-/m1/s1
DMHICK8	CS	C1=CN(C2=NC=NC(=C21)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMHICK8	IK	HDZZVAMISRMYHH-KCGFPETGSA-N
DMHICK8	IU	(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMHICK8	CA	CAS 69-33-0
DMHICK8	CB	CHEBI:48267
DMHICK8	DE	Discovery agent

DM2H0PQ	ID	DM2H0PQ
DM2H0PQ	DN	TUG-424
DM2H0PQ	HS	Investigative
DM2H0PQ	SN	TUG424
DM2H0PQ	DT	Small molecular drug
DM2H0PQ	PC	25150014
DM2H0PQ	MW	264.3
DM2H0PQ	FM	C18H16O2
DM2H0PQ	IC	InChI=1S/C18H16O2/c1-14-4-2-3-5-17(14)12-10-15-6-8-16(9-7-15)11-13-18(19)20/h2-9H,11,13H2,1H3,(H,19,20)
DM2H0PQ	CS	CC1=CC=CC=C1C#CC2=CC=C(C=C2)CCC(=O)O
DM2H0PQ	IK	FODHWOBAQBTTFS-UHFFFAOYSA-N
DM2H0PQ	IU	3-[4-[2-(2-methylphenyl)ethynyl]phenyl]propanoic acid
DM2H0PQ	CA	CAS 1082058-99-8
DM2H0PQ	DE	Discovery agent

DM8YN42	ID	DM8YN42
DM8YN42	DN	TUG-469
DM8YN42	HS	Investigative
DM8YN42	SN	Free fatty acid receptor 1 agonist (type 2 diabetes), University of Souther Denmark
DM8YN42	CP	University of Southern Denmark
DM8YN42	PC	46941175
DM8YN42	MW	345.4
DM8YN42	FM	C23H23NO2
DM8YN42	IC	InChI=1S/C23H23NO2/c1-17-5-2-3-8-22(17)20-7-4-6-19(15-20)16-24-21-12-9-18(10-13-21)11-14-23(25)26/h2-10,12-13,15,24H,11,14,16H2,1H3,(H,25,26)
DM8YN42	CS	CC1=CC=CC=C1C2=CC=CC(=C2)CNC3=CC=C(C=C3)CCC(=O)O
DM8YN42	IK	RUPXKSLKGSSZCP-UHFFFAOYSA-N
DM8YN42	IU	3-[4-[[3-(2-methylphenyl)phenyl]methylamino]phenyl]propanoic acid
DM8YN42	DE	Non-insulin dependent diabetes

DM487HF	ID	DM487HF
DM487HF	DN	TUG-770
DM487HF	HS	Investigative
DM487HF	SN	TUG770
DM487HF	DT	Small molecular drug
DM487HF	PC	66553168
DM487HF	MW	307.3
DM487HF	FM	C19H14FNO2
DM487HF	IC	InChI=1S/C19H14FNO2/c20-18-13-14(6-8-17(18)9-10-19(22)23)5-7-15-3-1-2-4-16(15)11-12-21/h1-4,6,8,13H,9-11H2,(H,22,23)
DM487HF	CS	C1=CC=C(C(=C1)CC#N)C#CC2=CC(=C(C=C2)CCC(=O)O)F
DM487HF	IK	KIZUBVPJNPVIIN-UHFFFAOYSA-N
DM487HF	IU	3-[4-[2-[2-(cyanomethyl)phenyl]ethynyl]-2-fluorophenyl]propanoic acid
DM487HF	CA	CAS 1402601-82-4
DM487HF	DE	Discovery agent

DMJRGZT	ID	DMJRGZT
DMJRGZT	DN	TUG-891
DMJRGZT	HS	Investigative
DMJRGZT	SN	TUG 891; TUG891
DMJRGZT	DT	Small molecular drug
DMJRGZT	PC	57522038
DMJRGZT	MW	364.4
DMJRGZT	FM	C23H21FO3
DMJRGZT	IC	InChI=1S/C23H21FO3/c1-16-2-7-18(8-3-16)22-12-9-20(24)14-19(22)15-27-21-10-4-17(5-11-21)6-13-23(25)26/h2-5,7-12,14H,6,13,15H2,1H3,(H,25,26)
DMJRGZT	CS	CC1=CC=C(C=C1)C2=C(C=C(C=C2)F)COC3=CC=C(C=C3)CCC(=O)O
DMJRGZT	IK	LPGBXHWIQNZEJB-UHFFFAOYSA-N
DMJRGZT	IU	3-[4-[[5-fluoro-2-(4-methylphenyl)phenyl]methoxy]phenyl]propanoic acid
DMJRGZT	DE	Discovery agent

DMIRQ65	ID	DMIRQ65
DMIRQ65	DN	Tumor vascular thrombogen
DMIRQ65	HS	Investigative
DMIRQ65	SN	Tumor vascular thrombogen (cancer)
DMIRQ65	CP	Medbiocom
DMIRQ65	DE	Solid tumour/cancer

DMAUTRP	ID	DMAUTRP
DMAUTRP	DN	TUPICHINOL C
DMAUTRP	HS	Investigative
DMAUTRP	SN	TUPICHINOL C; CHEMBL463804; (2R)-7,4'-Dihydroxylflavan; (2R)-7,4''-Dihydroxylflavan; BDBM50320309; (R)-2-(4-hydroxyphenyl)chroman-7-ol
DMAUTRP	DT	Small molecular drug
DMAUTRP	PC	11064571
DMAUTRP	MW	242.27
DMAUTRP	FM	C15H14O3
DMAUTRP	IC	InChI=1S/C15H14O3/c16-12-5-1-10(2-6-12)14-8-4-11-3-7-13(17)9-15(11)18-14/h1-3,5-7,9,14,16-17H,4,8H2/t14-/m1/s1
DMAUTRP	CS	C1CC2=C(C=C(C=C2)O)O[C@H]1C3=CC=C(C=C3)O
DMAUTRP	IK	YXMLGIGHGPSEKA-CQSZACIVSA-N
DMAUTRP	IU	(2R)-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol
DMAUTRP	DE	Discovery agent

DMLDYVB	ID	DMLDYVB
DMLDYVB	DN	TURBINATINE
DMLDYVB	HS	Investigative
DMLDYVB	SN	Turbinatine
DMLDYVB	DT	Small molecular drug
DMLDYVB	PC	44559633
DMLDYVB	MW	530.6
DMLDYVB	FM	C27H34N2O9
DMLDYVB	IC	InChI=1S/C27H34N2O9/c1-3-13-16(17(11-30)26(35)36-2)10-19-21-15(14-6-4-5-7-18(14)28-21)8-9-29(19)25(13)38-27-24(34)23(33)22(32)20(12-31)37-27/h3-7,11,13,16,19-20,22-25,27-28,30-34H,1,8-10,12H2,2H3/b17-11-/t13-,16-,19-,20-,22-,23+,24-,25-,27+/m0/s1
DMLDYVB	CS	COC(=O)/C(=C\\O)/[C@H]1C[C@H]2C3=C(CCN2[C@H]([C@H]1C=C)O[C@@H]4[C@H]([C@@H]([C@H]([C@@H](O4)CO)O)O)O)C5=CC=CC=C5N3
DMLDYVB	IK	XAYUCVICBPYPRE-LPRPFWDGSA-N
DMLDYVB	IU	methyl (Z)-2-[(2S,3S,4S,12bS)-3-ethenyl-4-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-hydroxyprop-2-enoate
DMLDYVB	DE	Discovery agent

DM3QE8P	ID	DM3QE8P
DM3QE8P	DN	Turmeric extracts
DM3QE8P	HS	Investigative
DM3QE8P	SN	HSS-808; HSS-818; HSS-838; HSS-848; HSS-888; Turmeric extracts (Alzheimer's disease); Turmeric extracts (Alzheimer's disease), HerbalScience
DM3QE8P	CP	HerbalScience LLC
DM3QE8P	DE	Alzheimer disease

DMDE8YS	ID	DMDE8YS
DMDE8YS	DN	TW-37
DMDE8YS	HS	Investigative
DMDE8YS	SN	TW-37; 877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide
DMDE8YS	DT	Small molecular drug
DMDE8YS	PC	11455910
DMDE8YS	MW	573.7
DMDE8YS	FM	C33H35NO6S
DMDE8YS	IC	InChI=1S/C33H35NO6S/c1-20(2)25-11-7-6-10-21(25)18-22-19-26(30(36)31(37)29(22)35)32(38)34-23-14-16-24(17-15-23)41(39,40)28-13-9-8-12-27(28)33(3,4)5/h6-17,19-20,35-37H,18H2,1-5H3,(H,34,38)
DMDE8YS	CS	CC(C)C1=CC=CC=C1CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C
DMDE8YS	IK	PQAPVTKIEGUPRN-UHFFFAOYSA-N
DMDE8YS	IU	N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide
DMDE8YS	CA	CAS 877877-35-5
DMDE8YS	CB	CHEBI:95008
DMDE8YS	DE	Discovery agent

DMS29M4	ID	DMS29M4
DMS29M4	DN	TWS-119
DMS29M4	HS	Investigative
DMS29M4	SN	TWS119; 601514-19-6; TWS-119; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB
DMS29M4	DT	Small molecular drug
DMS29M4	PC	9549289
DMS29M4	MW	318.3
DMS29M4	FM	C18H14N4O2
DMS29M4	IC	InChI=1S/C18H14N4O2/c19-12-4-1-3-11(7-12)16-9-15-17(22-16)20-10-21-18(15)24-14-6-2-5-13(23)8-14/h1-10,23H,19H2,(H,20,21,22)
DMS29M4	CS	C1=CC(=CC(=C1)N)C2=CC3=C(N2)N=CN=C3OC4=CC=CC(=C4)O
DMS29M4	IK	VPVLEBIVXZSOMQ-UHFFFAOYSA-N
DMS29M4	IU	3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol
DMS29M4	CA	CAS 601514-19-6
DMS29M4	CB	CHEBI:91384
DMS29M4	DE	Discovery agent

DMHFCZA	ID	DMHFCZA
DMHFCZA	DN	Tylophorinidine
DMHFCZA	HS	Investigative
DMHFCZA	SN	AC1LCEK3; 3,7-dimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[10,9-f]indolizine-6,14-diol
DMHFCZA	DT	Small molecular drug
DMHFCZA	PC	161749
DMHFCZA	MW	365.4
DMHFCZA	FM	C22H23NO4
DMHFCZA	IC	InChI=1S/C22H23NO4/c1-26-12-5-6-13-14(8-12)15-9-19(24)20(27-2)10-16(15)17-11-23-7-3-4-18(23)22(25)21(13)17/h5-6,8-10,18,22,24-25H,3-4,7,11H2,1-2H3/t18-,22+/m0/s1
DMHFCZA	CS	COC1=CC2=C(C=C1)C3=C(CN4CCC[C@H]4[C@H]3O)C5=CC(=C(C=C52)O)OC
DMHFCZA	IK	CMFIDYCYVJWPPL-PGRDOPGGSA-N
DMHFCZA	IU	(13aS,14S)-3,7-dimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[10,9-f]indolizine-6,14-diol
DMHFCZA	CA	CAS 32523-69-6
DMHFCZA	DE	Discovery agent

DMIWPKB	ID	DMIWPKB
DMIWPKB	DN	Tyr-(NMe)Ala-L-Phe-D-Pro-NH2
DMIWPKB	HS	Investigative
DMIWPKB	DT	Small molecular drug
DMIWPKB	PC	44376180
DMIWPKB	MW	509.6
DMIWPKB	FM	C27H35N5O5
DMIWPKB	IC	InChI=1S/C27H35N5O5/c1-17(31(2)26(36)21(28)15-19-10-12-20(33)13-11-19)25(35)30-22(16-18-7-4-3-5-8-18)27(37)32-14-6-9-23(32)24(29)34/h3-5,7-8,10-13,17,21-23,33H,6,9,14-16,28H2,1-2H3,(H2,29,34)(H,30,35)/t17?,21?,22-,23+/m0/s1
DMIWPKB	CS	CC(C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)N)N(C)C(=O)C(CC3=CC=C(C=C3)O)N
DMIWPKB	IK	PAVMQNDNZSJTHU-LLLIPXRLSA-N
DMIWPKB	IU	(2R)-1-[(2S)-2-[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]-methylamino]propanoylamino]-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMIWPKB	DE	Discovery agent

DMDQJUO	ID	DMDQJUO
DMDQJUO	DN	Tyr-(R)-Aba-Gly-Phe-NH2
DMDQJUO	HS	Investigative
DMDQJUO	SN	CHEMBL250448; Tyr-(R)-Aba-Gly-Phe-NH2
DMDQJUO	DT	Small molecular drug
DMDQJUO	PC	24755140
DMDQJUO	MW	543.6
DMDQJUO	FM	C30H33N5O5
DMDQJUO	IC	InChI=1S/C30H33N5O5/c31-24(14-20-10-12-23(36)13-11-20)29(39)34-26-16-21-8-4-5-9-22(21)17-35(30(26)40)18-27(37)33-25(28(32)38)15-19-6-2-1-3-7-19/h1-13,24-26,36H,14-18,31H2,(H2,32,38)(H,33,37)(H,34,39)/t24-,25-,26+/m0/s1
DMDQJUO	CS	C1[C@H](C(=O)N(CC2=CC=CC=C21)CC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMDQJUO	IK	XIRBKSHTAOQLGM-KKUQBAQOSA-N
DMDQJUO	IU	(2S)-2-amino-N-[(4R)-2-[2-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]-3-(4-hydroxyphenyl)propanamide
DMDQJUO	DE	Discovery agent

DMHNM3K	ID	DMHNM3K
DMHNM3K	DN	Tyr-(R)-spiro-Aba-Gly-Phe-NH2
DMHNM3K	HS	Investigative
DMHNM3K	SN	CHEMBL401142; Tyr-(R)-spiro-Aba-Gly-Phe-NH2
DMHNM3K	DT	Small molecular drug
DMHNM3K	PC	24755139
DMHNM3K	MW	583.7
DMHNM3K	FM	C33H37N5O5
DMHNM3K	IC	InChI=1S/C33H37N5O5/c34-27(17-23-11-13-26(39)14-12-23)31(42)38-16-6-15-33(38)19-24-9-4-5-10-25(24)20-37(32(33)43)21-29(40)36-28(30(35)41)18-22-7-2-1-3-8-22/h1-5,7-14,27-28,39H,6,15-21,34H2,(H2,35,41)(H,36,40)/t27-,28-,33+/m0/s1
DMHNM3K	CS	C1C[C@]2(CC3=CC=CC=C3CN(C2=O)CC(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N)N(C1)C(=O)[C@H](CC5=CC=C(C=C5)O)N
DMHNM3K	IK	XXSVWIUHNDWFND-NTBNWUQQSA-N
DMHNM3K	IU	(2S)-2-[[2-[(4R)-1'-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-3-oxospiro[1,5-dihydro-2-benzazepine-4,2'-pyrrolidine]-2-yl]acetyl]amino]-3-phenylpropanamide
DMHNM3K	DE	Discovery agent

DMYZ792	ID	DMYZ792
DMYZ792	DN	Tyr-(S)-Aba-Gly-Phe-NH2
DMYZ792	HS	Investigative
DMYZ792	SN	CHEMBL399796; Tyr-(S)-Aba-Gly-Phe-NH2
DMYZ792	DT	Small molecular drug
DMYZ792	PC	24755070
DMYZ792	MW	543.6
DMYZ792	FM	C30H33N5O5
DMYZ792	IC	InChI=1S/C30H33N5O5/c31-24(14-20-10-12-23(36)13-11-20)29(39)34-26-16-21-8-4-5-9-22(21)17-35(30(26)40)18-27(37)33-25(28(32)38)15-19-6-2-1-3-7-19/h1-13,24-26,36H,14-18,31H2,(H2,32,38)(H,33,37)(H,34,39)/t24-,25-,26-/m0/s1
DMYZ792	CS	C1[C@@H](C(=O)N(CC2=CC=CC=C21)CC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMYZ792	IK	XIRBKSHTAOQLGM-GSDHBNRESA-N
DMYZ792	IU	(2S)-2-amino-N-[(4S)-2-[2-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]-3-(4-hydroxyphenyl)propanamide
DMYZ792	DE	Discovery agent

DMT316S	ID	DMT316S
DMT316S	DN	Tyr-(S)-spiro-Aba-Gly-Phe-NH2
DMT316S	HS	Investigative
DMT316S	SN	CHEMBL401143; Tyr-(S)-spiro-Aba-Gly-Phe-NH2
DMT316S	DT	Small molecular drug
DMT316S	PC	24755069
DMT316S	MW	583.7
DMT316S	FM	C33H37N5O5
DMT316S	IC	InChI=1S/C33H37N5O5/c34-27(17-23-11-13-26(39)14-12-23)31(42)38-16-6-15-33(38)19-24-9-4-5-10-25(24)20-37(32(33)43)21-29(40)36-28(30(35)41)18-22-7-2-1-3-8-22/h1-5,7-14,27-28,39H,6,15-21,34H2,(H2,35,41)(H,36,40)/t27-,28-,33-/m0/s1
DMT316S	CS	C1C[C@@]2(CC3=CC=CC=C3CN(C2=O)CC(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N)N(C1)C(=O)[C@H](CC5=CC=C(C=C5)O)N
DMT316S	IK	XXSVWIUHNDWFND-DRVYDUGISA-N
DMT316S	IU	(2S)-2-[[2-[(4S)-1'-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-3-oxospiro[1,5-dihydro-2-benzazepine-4,2'-pyrrolidine]-2-yl]acetyl]amino]-3-phenylpropanamide
DMT316S	DE	Discovery agent

DM4UXT1	ID	DM4UXT1
DM4UXT1	DN	Tyramine
DM4UXT1	HS	Investigative
DM4UXT1	SN	Tyramine; 4-(2-Aminoethyl)phenol; 51-67-2; 4-Hydroxyphenethylamine; p-Tyramine; 2-(4-Hydroxyphenyl)ethylamine; Uteramine; Tyramin; Tyrosamine; Tocosine; 4-Hydroxyphenylethylamine; Systogene; Phenol, 4-(2-aminoethyl)-; p-Hydroxyphenethylamine; Tenosin-wirkstoff; p-Hydroxyphenylethylamine; p-(2-Aminoethyl)phenol; 2-(p-Hydroxyphenyl)ethylamine; Phenethylamine, p-hydroxy-; p-beta-Aminoethylphenol; Phenol, p-(2-aminoethyl)-; Benzeneethanamine, 4-hydroxy-; Tyramine base; beta-Hydroxyphenylethylamine; NSC 249188;  p-tyramine; [3H]tyramine
DM4UXT1	DT	Small molecular drug
DM4UXT1	PC	5610
DM4UXT1	MW	137.18
DM4UXT1	FM	C8H11NO
DM4UXT1	IC	InChI=1S/C8H11NO/c9-6-5-7-1-3-8(10)4-2-7/h1-4,10H,5-6,9H2
DM4UXT1	CS	C1=CC(=CC=C1CCN)O
DM4UXT1	IK	DZGWFCGJZKJUFP-UHFFFAOYSA-N
DM4UXT1	IU	4-(2-aminoethyl)phenol
DM4UXT1	CA	CAS 51-67-2
DM4UXT1	CB	CHEBI:15760
DM4UXT1	DE	Discovery agent

DM0D1Z5	ID	DM0D1Z5
DM0D1Z5	DN	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2
DM0D1Z5	HS	Investigative
DM0D1Z5	SN	Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2; CCK-Opioid Peptide, 14; CHEMBL383458; BDBM21144; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DM0D1Z5	DT	Small molecular drug
DM0D1Z5	PC	11520765
DM0D1Z5	MW	870
DM0D1Z5	FM	C44H55N9O10
DM0D1Z5	IC	InChI=1S/C44H55N9O10/c1-3-4-13-33(42(61)53-36(22-38(56)57)44(63)52-34(39(46)58)20-26-10-6-5-7-11-26)51-43(62)35(21-28-23-47-32-14-9-8-12-30(28)32)50-37(55)24-48-40(59)25(2)49-41(60)31(45)19-27-15-17-29(54)18-16-27/h5-12,14-18,23,25,31,33-36,47,54H,3-4,13,19-22,24,45H2,1-2H3,(H2,46,58)(H,48,59)(H,49,60)(H,50,55)(H,51,62)(H,52,63)(H,53,61)(H,56,57)/t25-,31+,33+,34+,35-,36+/m1/s1
DM0D1Z5	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DM0D1Z5	IK	LTNSZIYAGMZDDY-GUNATADUSA-N
DM0D1Z5	IU	(3S)-3-[[(2S)-2-[[(2R)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DM0D1Z5	DE	Discovery agent

DMPH1G0	ID	DMPH1G0
DMPH1G0	DN	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMPH1G0	HS	Investigative
DMPH1G0	SN	Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2; CCK-Opioid Peptide, 11; CHEMBL206974; BDBM21141; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMPH1G0	DT	Small molecular drug
DMPH1G0	PC	11556976
DMPH1G0	MW	884
DMPH1G0	FM	C45H57N9O10
DMPH1G0	IC	InChI=1S/C45H57N9O10/c1-4-5-15-37(44(63)53-35(23-39(57)58)43(62)52-34(40(47)59)21-27-11-7-6-8-12-27)54(3)45(64)36(22-29-24-48-33-14-10-9-13-31(29)33)51-38(56)25-49-41(60)26(2)50-42(61)32(46)20-28-16-18-30(55)19-17-28/h6-14,16-19,24,26,32,34-37,48,55H,4-5,15,20-23,25,46H2,1-3H3,(H2,47,59)(H,49,60)(H,50,61)(H,51,56)(H,52,62)(H,53,63)(H,57,58)/t26-,32+,34+,35+,36-,37+/m1/s1
DMPH1G0	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMPH1G0	IK	LFIFGNCFEBAIHA-JCOUAQLOSA-N
DMPH1G0	IU	(3S)-3-[[(2S)-2-[[(2R)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMPH1G0	DE	Discovery agent

DM2XRZL	ID	DM2XRZL
DM2XRZL	DN	Tyr-D-Ala-Gly-NMePhe
DM2XRZL	HS	Investigative
DM2XRZL	SN	CHEMBL583426; Tyr-D-Ala-Gly-NMePhe
DM2XRZL	DT	Small molecular drug
DM2XRZL	PC	45483974
DM2XRZL	MW	398.5
DM2XRZL	FM	C21H26N4O4
DM2XRZL	IC	InChI=1S/C21H26N4O4/c1-14(24-21(29)18(22)12-15-8-10-17(26)11-9-15)20(28)23-13-19(27)25(2)16-6-4-3-5-7-16/h3-11,14,18,26H,12-13,22H2,1-2H3,(H,23,28)(H,24,29)/t14-,18+/m1/s1
DM2XRZL	CS	C[C@H](C(=O)NCC(=O)N(C)C1=CC=CC=C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DM2XRZL	IK	OPRBFENCQHCQFV-KDOFPFPSSA-N
DM2XRZL	IU	(2S)-2-amino-3-(4-hydroxyphenyl)-N-[(2R)-1-[[2-(N-methylanilino)-2-oxoethyl]amino]-1-oxopropan-2-yl]propanamide
DM2XRZL	DE	Discovery agent

DMC7LND	ID	DMC7LND
DMC7LND	DN	Tyr-D-Ala-Gly-Phe-Met-NH2
DMC7LND	HS	Investigative
DMC7LND	SN	Tyr-DAla-Gly-Phe-Met-NH2
DMC7LND	DT	Small molecular drug
DMC7LND	PC	10371120
DMC7LND	MW	586.7
DMC7LND	FM	C28H38N6O6S
DMC7LND	IC	InChI=1S/C28H38N6O6S/c1-17(32-27(39)21(29)14-19-8-10-20(35)11-9-19)26(38)31-16-24(36)33-23(15-18-6-4-3-5-7-18)28(40)34-22(25(30)37)12-13-41-2/h3-11,17,21-23,35H,12-16,29H2,1-2H3,(H2,30,37)(H,31,38)(H,32,39)(H,33,36)(H,34,40)/t17-,21+,22+,23+/m1/s1
DMC7LND	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMC7LND	IK	ANZXICRKKYOVMY-SZOBAZRNSA-N
DMC7LND	IU	(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide
DMC7LND	DE	Discovery agent

DMWOP9N	ID	DMWOP9N
DMWOP9N	DN	Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl
DMWOP9N	HS	Investigative
DMWOP9N	SN	CHEMBL448998; Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl
DMWOP9N	PC	25129135
DMWOP9N	MW	1073.3
DMWOP9N	FM	C57H72N10O9S
DMWOP9N	IC	InChI=1S/C57H72N10O9S/c1-35(2)28-46(54(73)65-48(53(72)60-32-39-16-9-6-10-17-39)31-40-33-59-44-19-12-11-18-42(40)44)66-56(75)49-20-13-26-67(49)57(76)45(25-27-77-4)64-55(74)47(30-37-14-7-5-8-15-37)63-50(69)34-61-51(70)36(3)62-52(71)43(58)29-38-21-23-41(68)24-22-38/h5-12,14-19,21-24,33,35-36,43,45-49,59,68H,13,20,25-32,34,58H2,1-4H3,(H,60,72)(H,61,70)(H,62,71)(H,63,69)(H,64,74)(H,65,73)(H,66,75)/t36-,43+,45+,46+,47+,48+,49+/m1/s1
DMWOP9N	CS	C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DMWOP9N	IK	VUSRUVIDWSRKBU-POSUKJBFSA-N
DMWOP9N	IU	(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]-N-[(2S)-1-[[(2S)-1-(benzylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMWOP9N	DE	Discovery agent

DMB2TCF	ID	DMB2TCF
DMB2TCF	DN	Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc
DMB2TCF	HS	Investigative
DMB2TCF	SN	CHEMBL374325; Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc
DMB2TCF	PC	44408526
DMB2TCF	MW	1148.3
DMB2TCF	FM	C59H73N9O15
DMB2TCF	IC	InChI=1S/C59H73N9O15/c1-7-8-22-48(54(76)64-46(57(80)81)31-39-34-68(58(82)83-59(3,4)5)47-23-16-15-21-41(39)47)67(6)55(77)44(32-50(71)72)62-53(75)43(29-37-19-13-10-14-20-37)66-65-42(28-36-17-11-9-12-18-36)52(74)60-33-49(70)61-35(2)51(73)63-45(56(78)79)30-38-24-26-40(69)27-25-38/h9-21,23-27,34-35,42-46,48,65-66,69H,7-8,22,28-33H2,1-6H3,(H,60,74)(H,61,70)(H,62,75)(H,63,73)(H,64,76)(H,71,72)(H,78,79)(H,80,81)/t35-,42+,43+,44+,45+,46-,48+/m1/s1
DMB2TCF	CS	CCCC[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C(=O)OC(C)(C)C)C(=O)O)N(C)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NN[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DMB2TCF	IK	CHVZZDMXXHMJNM-BPYPMLAUSA-N
DMB2TCF	IU	(3S)-3-[[(2S)-2-[2-[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]hydrazinyl]-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(1R)-1-carboxy-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]ethyl]amino]-1-oxohexan-2-yl]-methylamino]-4-oxobutanoic acid
DMB2TCF	DE	Discovery agent

DMUXMVQ	ID	DMUXMVQ
DMUXMVQ	DN	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2
DMUXMVQ	HS	Investigative
DMUXMVQ	SN	Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2; CCK-Opioid Peptide, 8; CHEMBL262172; BDBM21138; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMUXMVQ	DT	Small molecular drug
DMUXMVQ	PC	10909103
DMUXMVQ	MW	870
DMUXMVQ	FM	C44H55N9O10
DMUXMVQ	IC	InChI=1S/C44H55N9O10/c1-3-4-13-33(42(61)53-36(22-38(56)57)44(63)52-34(39(46)58)20-26-10-6-5-7-11-26)51-43(62)35(21-28-23-47-32-14-9-8-12-30(28)32)50-37(55)24-48-40(59)25(2)49-41(60)31(45)19-27-15-17-29(54)18-16-27/h5-12,14-18,23,25,31,33-36,47,54H,3-4,13,19-22,24,45H2,1-2H3,(H2,46,58)(H,48,59)(H,49,60)(H,50,55)(H,51,62)(H,52,63)(H,53,61)(H,56,57)/t25-,31+,33+,34+,35+,36+/m1/s1
DMUXMVQ	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMUXMVQ	IK	LTNSZIYAGMZDDY-QMXRFRSXSA-N
DMUXMVQ	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMUXMVQ	DE	Discovery agent

DMREJ69	ID	DMREJ69
DMREJ69	DN	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2
DMREJ69	HS	Investigative
DMREJ69	SN	Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2; CCK-Opioid Peptide, 2; CHEMBL382349; BDBM21132; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMREJ69	DT	Small molecular drug
DMREJ69	PC	11040230
DMREJ69	MW	884
DMREJ69	FM	C45H57N9O10
DMREJ69	IC	InChI=1S/C45H57N9O10/c1-4-5-15-37(44(63)53-35(23-39(57)58)43(62)52-34(40(47)59)21-27-11-7-6-8-12-27)54(3)45(64)36(22-29-24-48-33-14-10-9-13-31(29)33)51-38(56)25-49-41(60)26(2)50-42(61)32(46)20-28-16-18-30(55)19-17-28/h6-14,16-19,24,26,32,34-37,48,55H,4-5,15,20-23,25,46H2,1-3H3,(H2,47,59)(H,49,60)(H,50,61)(H,51,56)(H,52,62)(H,53,63)(H,57,58)/t26-,32+,34+,35+,36+,37+/m1/s1
DMREJ69	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMREJ69	IK	LFIFGNCFEBAIHA-XSAWFYHVSA-N
DMREJ69	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMREJ69	DE	Discovery agent

DMTPLNZ	ID	DMTPLNZ
DMTPLNZ	DN	Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2
DMTPLNZ	HS	Investigative
DMTPLNZ	PC	73346987
DMTPLNZ	MW	1032.099
DMTPLNZ	FM	C47H69N9O17
DMTPLNZ	IC	InChI=1S/C47H69N9O17/c1-21(2)34(45(70)55-35(22(3)4)46(71)56-36(44(69)50-19-32(49)59)24(6)72-47-39(64)38(63)37(62)31(20-57)73-47)54-43(68)30(18-33(60)61)53-42(67)29(17-25-10-8-7-9-11-25)52-40(65)23(5)51-41(66)28(48)16-26-12-14-27(58)15-13-26/h7-15,21-24,28-31,34-39,47,57-58,62-64H,16-20,48H2,1-6H3,(H2,49,59)(H,50,69)(H,51,66)(H,52,65)(H,53,67)(H,54,68)(H,55,70)(H,56,71)(H,60,61)/t23-,24-,28+,29+,30+,31-,34+,35+,36+,37-,38+,39-,47+/m1/s1
DMTPLNZ	CS	C[C@H]([C@@H](C(=O)NCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
DMTPLNZ	IK	QTEVIWGWCOWBNP-CNGXOXJSSA-N
DMTPLNZ	IU	(3S)-3-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMTPLNZ	DE	Discovery agent

DMC4NO5	ID	DMC4NO5
DMC4NO5	DN	Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2
DMC4NO5	HS	Investigative
DMC4NO5	SN	CHEMBL29078; Tyr-Ala-Phe-Asp-Val-Val-Gly; GTPL1615
DMC4NO5	DT	Small molecular drug
DMC4NO5	PC	10033203
DMC4NO5	MW	782.9
DMC4NO5	FM	C38H54N8O10
DMC4NO5	IC	InChI=1S/C38H54N8O10/c1-20(2)31(37(55)41-19-29(40)48)46-38(56)32(21(3)4)45-35(53)27(15-16-30(49)50)43-36(54)28(18-23-9-7-6-8-10-23)44-33(51)22(5)42-34(52)26(39)17-24-11-13-25(47)14-12-24/h6-14,20-22,26-28,31-32,47H,15-19,39H2,1-5H3,(H2,40,48)(H,41,55)(H,42,52)(H,43,54)(H,44,51)(H,45,53)(H,46,56)(H,49,50)/t22-,26+,27+,28+,31+,32+/m1/s1
DMC4NO5	CS	C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMC4NO5	IK	NUNBRHVOPFWRRG-RCEFDBTISA-N
DMC4NO5	IU	(4S)-4-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMC4NO5	CB	CHEBI:81498
DMC4NO5	DE	Discovery agent

DM4FASR	ID	DM4FASR
DM4FASR	DN	Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2
DM4FASR	HS	Investigative
DM4FASR	PC	44331204
DM4FASR	MW	1036.099
DM4FASR	FM	C49H65N9O16
DM4FASR	IC	InChI=1S/C49H65N9O16/c1-25(54-44(68)32(50)19-28-10-14-30(60)15-11-28)43(67)56-33(20-27-7-4-3-5-8-27)45(69)53-23-38(63)55-34(21-29-12-16-31(61)17-13-29)48(72)58-18-6-9-35(58)46(70)57-39(47(71)52-22-37(51)62)26(2)73-49-42(66)41(65)40(64)36(24-59)74-49/h3-5,7-8,10-17,25-26,32-36,39-42,49,59-61,64-66H,6,9,18-24,50H2,1-2H3,(H2,51,62)(H,52,71)(H,53,69)(H,54,68)(H,55,63)(H,56,67)(H,57,70)/t25-,26?,32+,33+,34+,35+,36?,39+,40?,41?,42?,49?/m1/s1
DM4FASR	CS	C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)OC4C(C(C(C(O4)CO)O)O)O)C(=O)NCC(=O)N)NC(=O)[C@H](CC5=CC=C(C=C5)O)N
DM4FASR	IK	ZXTWNLGGKJOAMK-XUDWIOABSA-N
DM4FASR	IU	(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutan-2-yl]pyrrolidine-2-carboxamide
DM4FASR	DE	Discovery agent

DMB9A46	ID	DMB9A46
DMB9A46	DN	Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2
DMB9A46	HS	Investigative
DMB9A46	PC	73345456
DMB9A46	MW	1009.1
DMB9A46	FM	C48H64N8O16
DMB9A46	IC	InChI=1S/C48H64N8O16/c1-24(51-43(66)31(49)19-27-10-14-29(59)15-11-27)42(65)52-32(20-26-7-4-3-5-8-26)44(67)55-37(25(2)71-48-40(63)39(62)38(61)36(23-58)72-48)46(69)53-33(21-28-12-16-30(60)17-13-28)47(70)56-18-6-9-35(56)45(68)54-34(22-57)41(50)64/h3-5,7-8,10-17,24-25,31-40,48,57-63H,6,9,18-23,49H2,1-2H3,(H2,50,64)(H,51,66)(H,52,65)(H,53,69)(H,54,68)(H,55,67)/t24-,25-,31+,32+,33+,34+,35+,36-,37+,38-,39+,40-,48+/m1/s1
DMB9A46	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O
DMB9A46	IK	SAWFTOJFOXCLCQ-MHOYXDTBSA-N
DMB9A46	IU	(2S)-N-[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]-1-[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DMB9A46	DE	Discovery agent

DMLC0NW	ID	DMLC0NW
DMLC0NW	DN	Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2
DMLC0NW	HS	Investigative
DMLC0NW	PC	73345457
DMLC0NW	MW	1177.2
DMLC0NW	FM	C56H72N8O20
DMLC0NW	IC	InChI=1S/C56H72N8O20/c1-28(59-51(74)39(57)23-35-14-18-37(70)19-15-35)50(73)60-40(24-34-11-8-7-9-12-34)52(75)63-45(29(2)80-56-48(83-33(6)69)47(82-32(5)68)46(81-31(4)67)44(84-56)27-79-30(3)66)54(77)61-41(25-36-16-20-38(71)21-17-36)55(78)64-22-10-13-43(64)53(76)62-42(26-65)49(58)72/h7-9,11-12,14-21,28-29,39-48,56,65,70-71H,10,13,22-27,57H2,1-6H3,(H2,58,72)(H,59,74)(H,60,73)(H,61,77)(H,62,76)(H,63,75)/t28-,29-,39+,40+,41+,42+,43+,44-,45+,46+,47-,48-,56+/m1/s1
DMLC0NW	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)O[C@@H]5[C@@H]([C@@H]([C@H]([C@H](O5)COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C
DMLC0NW	IK	OATORUSDYAEZJF-CARIVLHESA-N
DMLC0NW	IU	[(2R,3S,4R,5R,6S)-3,4,5-triacetyloxy-6-[(2R,3S)-4-[[(2S)-1-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutan-2-yl]oxyoxan-2-yl]methyl acetate
DMLC0NW	DE	Discovery agent

DM4YTFP	ID	DM4YTFP
DM4YTFP	DN	Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2
DM4YTFP	HS	Investigative
DM4YTFP	SN	CHEMBL32202; BDBM50009180; 3-(2-{2-[2-(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-4-methylsulfanyl-butyrylamino}-3-phenyl-propionylamino)-3-(1H-imidazol-4-yl)-propionylamino]-4-methyl-pentanoylamino}-4-methylsulfanyl-butyrylamino)-succinamic ac
DM4YTFP	DT	Small molecular drug
DM4YTFP	PC	14504437
DM4YTFP	MW	955.2
DM4YTFP	FM	C44H62N10O10S2
DM4YTFP	IC	InChI=1S/C44H62N10O10S2/c1-25(2)18-34(42(62)50-32(15-17-66-4)40(60)51-33(38(46)58)22-37(56)57)52-44(64)36(21-28-23-47-24-48-28)54-43(63)35(20-26-8-6-5-7-9-26)53-41(61)31(14-16-65-3)49-39(59)30(45)19-27-10-12-29(55)13-11-27/h5-13,23-25,30-36,55H,14-22,45H2,1-4H3,(H2,46,58)(H,47,48)(H,49,59)(H,50,62)(H,51,60)(H,52,64)(H,53,61)(H,54,63)(H,56,57)/t30-,31-,32-,33-,34-,35-,36-/m0/s1
DM4YTFP	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM4YTFP	IK	BHSURCCZOBVHJJ-QJCLFNHPSA-N
DM4YTFP	IU	(3S)-4-amino-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DM4YTFP	DE	Discovery agent

DMY9NIJ	ID	DMY9NIJ
DMY9NIJ	DN	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2
DMY9NIJ	HS	Investigative
DMY9NIJ	SN	Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2; CCK-Opioid Peptide, 15; CHEMBL205306; BDBM21145; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMY9NIJ	DT	Small molecular drug
DMY9NIJ	PC	11722088
DMY9NIJ	MW	912
DMY9NIJ	FM	C47H61N9O10
DMY9NIJ	IC	InChI=1S/C47H61N9O10/c1-3-5-15-35(53-43(62)33(48)22-29-18-20-31(57)21-19-29)44(63)51-27-40(58)52-38(24-30-26-50-34-17-11-10-14-32(30)34)46(65)54-36(16-6-4-2)45(64)56-39(25-41(59)60)47(66)55-37(42(49)61)23-28-12-8-7-9-13-28/h7-14,17-21,26,33,35-39,50,57H,3-6,15-16,22-25,27,48H2,1-2H3,(H2,49,61)(H,51,63)(H,52,58)(H,53,62)(H,54,65)(H,55,66)(H,56,64)(H,59,60)/t33-,35+,36-,37-,38+,39-/m0/s1
DMY9NIJ	CS	CCCC[C@H](C(=O)NCC(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMY9NIJ	IK	YVOYRMXNVINXII-PREDZLEHSA-N
DMY9NIJ	IU	(3S)-3-[[(2S)-2-[[(2R)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMY9NIJ	DE	Discovery agent

DMQREP2	ID	DMQREP2
DMQREP2	DN	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DMQREP2	HS	Investigative
DMQREP2	SN	Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2; CCK-Opioid Peptide, 12; CHEMBL408083; BDBM21142; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMQREP2	DT	Small molecular drug
DMQREP2	PC	11614928
DMQREP2	MW	926.1
DMQREP2	FM	C48H63N9O10
DMQREP2	IC	InChI=1S/C48H63N9O10/c1-4-6-16-36(54-44(63)34(49)23-30-19-21-32(58)22-20-30)45(64)52-28-41(59)53-39(25-31-27-51-35-17-12-11-15-33(31)35)48(67)57(3)40(18-7-5-2)47(66)56-38(26-42(60)61)46(65)55-37(43(50)62)24-29-13-9-8-10-14-29/h8-15,17,19-22,27,34,36-40,51,58H,4-7,16,18,23-26,28,49H2,1-3H3,(H2,50,62)(H,52,64)(H,53,59)(H,54,63)(H,55,65)(H,56,66)(H,60,61)/t34-,36+,37-,38-,39+,40-/m0/s1
DMQREP2	CS	CCCC[C@H](C(=O)NCC(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMQREP2	IK	KJQHRGYUFQCLJG-KOPATMAISA-N
DMQREP2	IU	(3S)-3-[[(2S)-2-[[(2R)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMQREP2	DE	Discovery agent

DMZ24LN	ID	DMZ24LN
DMZ24LN	DN	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2
DMZ24LN	HS	Investigative
DMZ24LN	SN	Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2; CCK-Opioid Peptide, 9; CHEMBL208479; BDBM21139; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMZ24LN	DT	Small molecular drug
DMZ24LN	PC	11564210
DMZ24LN	MW	912
DMZ24LN	FM	C47H61N9O10
DMZ24LN	IC	InChI=1S/C47H61N9O10/c1-3-5-15-35(53-43(62)33(48)22-29-18-20-31(57)21-19-29)44(63)51-27-40(58)52-38(24-30-26-50-34-17-11-10-14-32(30)34)46(65)54-36(16-6-4-2)45(64)56-39(25-41(59)60)47(66)55-37(42(49)61)23-28-12-8-7-9-13-28/h7-14,17-21,26,33,35-39,50,57H,3-6,15-16,22-25,27,48H2,1-2H3,(H2,49,61)(H,51,63)(H,52,58)(H,53,62)(H,54,65)(H,55,66)(H,56,64)(H,59,60)/t33-,35+,36-,37-,38-,39-/m0/s1
DMZ24LN	CS	CCCC[C@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMZ24LN	IK	YVOYRMXNVINXII-ULSNPNCNSA-N
DMZ24LN	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMZ24LN	DE	Discovery agent

DMPSJ72	ID	DMPSJ72
DMPSJ72	DN	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2
DMPSJ72	HS	Investigative
DMPSJ72	SN	Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2; CCK-Opioid Peptide, 3; CHEMBL408330; BDBM21133; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMPSJ72	DT	Small molecular drug
DMPSJ72	PC	11528076
DMPSJ72	MW	926.1
DMPSJ72	FM	C48H63N9O10
DMPSJ72	IC	InChI=1S/C48H63N9O10/c1-4-6-16-36(54-44(63)34(49)23-30-19-21-32(58)22-20-30)45(64)52-28-41(59)53-39(25-31-27-51-35-17-12-11-15-33(31)35)48(67)57(3)40(18-7-5-2)47(66)56-38(26-42(60)61)46(65)55-37(43(50)62)24-29-13-9-8-10-14-29/h8-15,17,19-22,27,34,36-40,51,58H,4-7,16,18,23-26,28,49H2,1-3H3,(H2,50,62)(H,52,64)(H,53,59)(H,54,63)(H,55,65)(H,56,66)(H,60,61)/t34-,36+,37-,38-,39-,40-/m0/s1
DMPSJ72	CS	CCCC[C@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMPSJ72	IK	KJQHRGYUFQCLJG-ACEPAJJMSA-N
DMPSJ72	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMPSJ72	DE	Discovery agent

DMIWMN6	ID	DMIWMN6
DMIWMN6	DN	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2
DMIWMN6	HS	Investigative
DMIWMN6	SN	Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2; CCK-Opioid Peptide, 13; CHEMBL379405; BDBM21143; (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMIWMN6	DT	Small molecular drug
DMIWMN6	PC	11136782
DMIWMN6	MW	946.1
DMIWMN6	FM	C50H59N9O10
DMIWMN6	IC	InChI=1S/C50H59N9O10/c1-2-3-17-38(48(67)59-42(27-44(62)63)50(69)57-39(45(52)64)24-30-12-6-4-7-13-30)56-49(68)41(26-33-28-53-37-18-11-10-16-35(33)37)55-43(61)29-54-47(66)40(25-31-14-8-5-9-15-31)58-46(65)36(51)23-32-19-21-34(60)22-20-32/h4-16,18-22,28,36,38-42,53,60H,2-3,17,23-27,29,51H2,1H3,(H2,52,64)(H,54,66)(H,55,61)(H,56,68)(H,57,69)(H,58,65)(H,59,67)(H,62,63)/t36-,38-,39-,40+,41+,42-/m0/s1
DMIWMN6	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)N
DMIWMN6	IK	DWHRPZRXNRDAQF-KCTXSUAESA-N
DMIWMN6	IU	(3S)-3-[[(2S)-2-[[(2R)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMIWMN6	DE	Discovery agent

DM2CEWT	ID	DM2CEWT
DM2CEWT	DN	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2
DM2CEWT	HS	Investigative
DM2CEWT	SN	Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2; CCK-Opioid Peptide, 10; CHEMBL218327; BDBM21140; H-Tyr-DPhe-Gly-DTrp-NMeNle-Asp-Phe-NH(2); (3S)-3-[(2S)-2-[(2R)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DM2CEWT	DT	Small molecular drug
DM2CEWT	PC	10942040
DM2CEWT	MW	960.1
DM2CEWT	FM	C51H61N9O10
DM2CEWT	IC	InChI=1S/C51H61N9O10/c1-3-4-19-43(50(69)59-41(28-45(63)64)49(68)57-39(46(53)65)25-31-13-7-5-8-14-31)60(2)51(70)42(27-34-29-54-38-18-12-11-17-36(34)38)56-44(62)30-55-48(67)40(26-32-15-9-6-10-16-32)58-47(66)37(52)24-33-20-22-35(61)23-21-33/h5-18,20-23,29,37,39-43,54,61H,3-4,19,24-28,30,52H2,1-2H3,(H2,53,65)(H,55,67)(H,56,62)(H,57,68)(H,58,66)(H,59,69)(H,63,64)/t37-,39-,40+,41-,42+,43-/m0/s1
DM2CEWT	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)N
DM2CEWT	IK	KKPFQTRKARZYLE-YKEIYGJZSA-N
DM2CEWT	IU	(3S)-3-[[(2S)-2-[[(2R)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DM2CEWT	DE	Discovery agent

DMKM81A	ID	DMKM81A
DMKM81A	DN	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2
DMKM81A	HS	Investigative
DMKM81A	SN	Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2; CCK-Opioid Peptide, 7; CHEMBL382051; BDBM21137; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMKM81A	DT	Small molecular drug
DMKM81A	PC	11051303
DMKM81A	MW	946.1
DMKM81A	FM	C50H59N9O10
DMKM81A	IC	InChI=1S/C50H59N9O10/c1-2-3-17-38(48(67)59-42(27-44(62)63)50(69)57-39(45(52)64)24-30-12-6-4-7-13-30)56-49(68)41(26-33-28-53-37-18-11-10-16-35(33)37)55-43(61)29-54-47(66)40(25-31-14-8-5-9-15-31)58-46(65)36(51)23-32-19-21-34(60)22-20-32/h4-16,18-22,28,36,38-42,53,60H,2-3,17,23-27,29,51H2,1H3,(H2,52,64)(H,54,66)(H,55,61)(H,56,68)(H,57,69)(H,58,65)(H,59,67)(H,62,63)/t36-,38-,39-,40+,41-,42-/m0/s1
DMKM81A	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)N
DMKM81A	IK	DWHRPZRXNRDAQF-GEQJWKGNSA-N
DMKM81A	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMKM81A	DE	Discovery agent

DMZOTGM	ID	DMZOTGM
DMZOTGM	DN	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2
DMZOTGM	HS	Investigative
DMZOTGM	SN	Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2; CCK-Opioid Peptide, 1; CHEMBL218763; BDBM21131; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMZOTGM	DT	Small molecular drug
DMZOTGM	PC	9811733
DMZOTGM	MW	960.1
DMZOTGM	FM	C51H61N9O10
DMZOTGM	IC	InChI=1S/C51H61N9O10/c1-3-4-19-43(50(69)59-41(28-45(63)64)49(68)57-39(46(53)65)25-31-13-7-5-8-14-31)60(2)51(70)42(27-34-29-54-38-18-12-11-17-36(34)38)56-44(62)30-55-48(67)40(26-32-15-9-6-10-16-32)58-47(66)37(52)24-33-20-22-35(61)23-21-33/h5-18,20-23,29,37,39-43,54,61H,3-4,19,24-28,30,52H2,1-2H3,(H2,53,65)(H,55,67)(H,56,62)(H,57,68)(H,58,66)(H,59,69)(H,63,64)/t37-,39-,40+,41-,42-,43-/m0/s1
DMZOTGM	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)N
DMZOTGM	IK	KKPFQTRKARZYLE-NOGCUKNYSA-N
DMZOTGM	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMZOTGM	DE	Discovery agent

DMM9H07	ID	DMM9H07
DMM9H07	DN	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2
DMM9H07	HS	Investigative
DMM9H07	SN	Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2; CCK-Opioid Peptide, 4; CHEMBL205965; BDBM21134; (3S)-3-[(2S)-2-[(2S)-2-(2-{[(2R)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}acetamido)-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMM9H07	DT	Small molecular drug
DMM9H07	PC	11693641
DMM9H07	MW	910
DMM9H07	FM	C47H59N9O10
DMM9H07	IC	InChI=1S/C47H59N9O10/c1-3-4-15-38(45(64)54-36(25-41(59)60)43(62)53-35(42(49)61)23-28-11-6-5-7-12-28)55(2)47(66)37(24-30-26-50-34-14-9-8-13-32(30)34)52-40(58)27-51-44(63)39-16-10-21-56(39)46(65)33(48)22-29-17-19-31(57)20-18-29/h5-9,11-14,17-20,26,33,35-39,50,57H,3-4,10,15-16,21-25,27,48H2,1-2H3,(H2,49,61)(H,51,63)(H,52,58)(H,53,62)(H,54,64)(H,59,60)/t33-,35-,36-,37-,38-,39+/m0/s1
DMM9H07	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N
DMM9H07	IK	XMLJSDGQSNTHPG-TVUSJDTQSA-N
DMM9H07	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMM9H07	DE	Discovery agent

DMKND2R	ID	DMKND2R
DMKND2R	DN	Tyr-Gly-Gly-Phe-c(Cys-Arg-Arg-Ile-Cys)-Arg-lys
DMKND2R	HS	Investigative
DMKND2R	SN	CHEMBL415406; Tyr-Gly-Gly-Phe-c(Cys-Arg-Arg-Ile-Cys)-Arg-lys
DMKND2R	PC	44377416
DMKND2R	MW	1356.6
DMKND2R	FM	C58H93N21O13S2
DMKND2R	IC	InChI=1S/C58H93N21O13S2/c1-3-32(2)46-54(90)78-43(53(89)75-38(16-10-24-68-57(63)64)49(85)76-40(55(91)92)14-7-8-22-59)31-94-93-30-42(52(88)74-37(15-9-23-67-56(61)62)48(84)73-39(50(86)79-46)17-11-25-69-58(65)66)77-51(87)41(27-33-12-5-4-6-13-33)72-45(82)29-70-44(81)28-71-47(83)36(60)26-34-18-20-35(80)21-19-34/h4-6,12-13,18-21,32,36-43,46,80H,3,7-11,14-17,22-31,59-60H2,1-2H3,(H,70,81)(H,71,83)(H,72,82)(H,73,84)(H,74,88)(H,75,89)(H,76,85)(H,77,87)(H,78,90)(H,79,86)(H,91,92)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t32-,36-,37+,38+,39-,40+,41-,42+,43+,46+/m0/s1
DMKND2R	CS	CC[C@H](C)[C@@H]1C(=O)N[C@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CCCN=C(N)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCCN)C(=O)O
DMKND2R	IK	MRWXDNZOCJXRHP-KCSCKQEISA-N
DMKND2R	IU	(2R)-6-amino-2-[[(2R)-2-[[(4S,7R,10S,13R,16S)-16-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-7-[(2S)-butan-2-yl]-10,13-bis[3-(diaminomethylideneamino)propyl]-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoic acid
DMKND2R	DE	Discovery agent

DMG6NDA	ID	DMG6NDA
DMG6NDA	DN	Tyr-Gly-Gly-Phe-leu-c(Cys-Arg-Ile-Arg-Cys)-lys
DMG6NDA	HS	Investigative
DMG6NDA	SN	CHEMBL265241; Tyr-Gly-Gly-Phe-leu-c(Cys-Arg-Ile-Arg-Cys)-lys
DMG6NDA	PC	44377415
DMG6NDA	MW	1313.6
DMG6NDA	FM	C58H92N18O13S2
DMG6NDA	IC	InChI=1S/C58H92N18O13S2/c1-5-33(4)47-55(87)71-38(16-11-23-65-57(61)62)49(81)74-44(54(86)72-40(56(88)89)15-9-10-22-59)31-91-90-30-43(53(85)70-39(50(82)76-47)17-12-24-66-58(63)64)75-51(83)41(25-32(2)3)73-52(84)42(27-34-13-7-6-8-14-34)69-46(79)29-67-45(78)28-68-48(80)37(60)26-35-18-20-36(77)21-19-35/h6-8,13-14,18-21,32-33,37-44,47,77H,5,9-12,15-17,22-31,59-60H2,1-4H3,(H,67,78)(H,68,80)(H,69,79)(H,70,85)(H,71,87)(H,72,86)(H,73,84)(H,74,81)(H,75,83)(H,76,82)(H,88,89)(H4,61,62,65)(H4,63,64,66)/t33-,37-,38-,39-,40-,41-,42-,43-,44-,47+/m0/s1
DMG6NDA	CS	CC[C@H](C)[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)N[C@@H](CCCCN)C(=O)O)CCCN=C(N)N
DMG6NDA	IK	JYEKWXODJFQZIP-HSIOXNDMSA-N
DMG6NDA	IU	(2S)-6-amino-2-[[(4R,7S,10R,13S,16R)-16-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-10-[(2S)-butan-2-yl]-7,13-bis[3-(diaminomethylideneamino)propyl]-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carbonyl]amino]hexanoic acid
DMG6NDA	DE	Discovery agent

DMN7290	ID	DMN7290
DMN7290	DN	Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2
DMN7290	HS	Investigative
DMN7290	SN	CHEMBL336381; Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2; CCK-Opioid Peptide, 6; BDBM21136; (3S)-3-[(2S)-2-[(2S)-2-(2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}acetamido)-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DMN7290	DT	Small molecular drug
DMN7290	PC	11061906
DMN7290	MW	870
DMN7290	FM	C44H55N9O10
DMN7290	IC	InChI=1S/C44H55N9O10/c1-3-4-14-36(43(62)52-34(22-39(57)58)42(61)51-33(40(46)59)20-26-10-6-5-7-11-26)53(2)44(63)35(21-28-23-47-32-13-9-8-12-30(28)32)50-38(56)25-48-37(55)24-49-41(60)31(45)19-27-15-17-29(54)18-16-27/h5-13,15-18,23,31,33-36,47,54H,3-4,14,19-22,24-25,45H2,1-2H3,(H2,46,59)(H,48,55)(H,49,60)(H,50,56)(H,51,61)(H,52,62)(H,57,58)/t31-,33-,34-,35-,36-/m0/s1
DMN7290	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMN7290	IK	KSAGKPZDJHLHBS-AWSJBNSNSA-N
DMN7290	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMN7290	DE	Discovery agent

DM91UKB	ID	DM91UKB
DM91UKB	DN	Tyropanoic acid
DM91UKB	HS	Investigative
DM91UKB	SN	Acidum tyropanoicum; Bilopac; Bilopaque; LS-187166; SCHEMBL2788021; Sodium Tyropanoate (USAN); TYROPANIC ACID; Tyropanoate sodium(USAN; Tyropanoic acid; Tyropanoic acid sodium salt; Tyropaque; WIN 8851-2; tyropanoate; 2-(3-(Butyrylamino)-2,4,6-triiodobenzyl)butanoic acid; 2-(3-(Butyrylamino)-2,4,6-triiodobenzyl)butyric acid; 2-[3-(butyrylamino)-2,4,6-triiodobenzyl]butanoic acid; 27293-82-9; AC1L1KQH; AC1Q4PCM; API0012761; CHEBI:135862; CHEMBL1201261; CTK4F9414; DB09340; DTXSID5048269; EINECS 248-389-8; NSC107434
DM91UKB	PC	5611
DM91UKB	MW	641.02
DM91UKB	FM	C15H18I3NO3
DM91UKB	IC	YMOXVLQZFAUUKI-UHFFFAOYSA-N
DM91UKB	CS	CCCC(=O)NC1=C(C=C(C(=C1I)CC(CC)C(=O)O)I)I
DM91UKB	IK	1S/C15H18I3NO3/c1-3-5-12(20)19-14-11(17)7-10(16)9(13(14)18)6-8(4-2)15(21)22/h7-8H,3-6H2,1-2H3,(H,19,20)(H,21,22)
DM91UKB	IU	2-[[3-(butanoylamino)-2,4,6-triiodophenyl]methyl]butanoic acid
DM91UKB	CA	CAS 27293-82-9
DM91UKB	CB	CHEBI:135862
DM91UKB	DE	Discovery agent

DM87ZIH	ID	DM87ZIH
DM87ZIH	DN	Tyrphostin Ag-1478
DM87ZIH	HS	Investigative
DM87ZIH	SN	AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; Tyrphostin AG-1478; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255
DM87ZIH	DT	Small molecular drug
DM87ZIH	PC	2051
DM87ZIH	MW	315.75
DM87ZIH	FM	C16H14ClN3O2
DM87ZIH	IC	InChI=1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)
DM87ZIH	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC
DM87ZIH	IK	GFNNBHLJANVSQV-UHFFFAOYSA-N
DM87ZIH	IU	N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine
DM87ZIH	CA	CAS 153436-53-4
DM87ZIH	CB	CHEBI:75404
DM87ZIH	DE	Discovery agent

DMDCJWU	ID	DMDCJWU
DMDCJWU	DN	Tyr-Pro-3,5Dmp-Phe-NH2
DMDCJWU	HS	Investigative
DMDCJWU	SN	CHEMBL413892; Tyr-Pro-3,5Dmp-Phe-NH2
DMDCJWU	DT	Small molecular drug
DMDCJWU	PC	16736272
DMDCJWU	MW	599.7
DMDCJWU	FM	C34H41N5O5
DMDCJWU	IC	InChI=1S/C34H41N5O5/c1-21-15-22(2)17-25(16-21)20-29(32(42)37-28(31(36)41)19-23-7-4-3-5-8-23)38-33(43)30-9-6-14-39(30)34(44)27(35)18-24-10-12-26(40)13-11-24/h3-5,7-8,10-13,15-17,27-30,40H,6,9,14,18-20,35H2,1-2H3,(H2,36,41)(H,37,42)(H,38,43)/t27-,28-,29-,30-/m0/s1
DMDCJWU	CS	CC1=CC(=CC(=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N)C
DMDCJWU	IK	WGUOAUNVYIRMQJ-KRCBVYEFSA-N
DMDCJWU	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(3,5-dimethylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMDCJWU	DE	Discovery agent

DMH08O3	ID	DMH08O3
DMH08O3	DN	Tyr-Pro-D-(NMe)Phe-D-Pro-NH2
DMH08O3	HS	Investigative
DMH08O3	SN	Tyr-Pro-D-(NMe)Phe-D-Pro-NH2; CHEMBL163808
DMH08O3	DT	Small molecular drug
DMH08O3	PC	44375783
DMH08O3	MW	535.6
DMH08O3	FM	C29H37N5O5
DMH08O3	IC	InChI=1S/C29H37N5O5/c1-32(25(18-19-7-3-2-4-8-19)29(39)33-15-5-9-23(33)26(31)36)28(38)24-10-6-16-34(24)27(37)22(30)17-20-11-13-21(35)14-12-20/h2-4,7-8,11-14,22-25,35H,5-6,9-10,15-18,30H2,1H3,(H2,31,36)/t22?,23-,24?,25-/m1/s1
DMH08O3	CS	CN([C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)N)C(=O)C3CCCN3C(=O)C(CC4=CC=C(C=C4)O)N
DMH08O3	IK	JAKBYSTWCHUQOK-RULIFZQXSA-N
DMH08O3	IU	1-[2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-N-methylpyrrolidine-2-carboxamide
DMH08O3	DE	Discovery agent

DMNXCHT	ID	DMNXCHT
DMNXCHT	DN	Tyr-Pro-Dmp-Phe-NH2
DMNXCHT	HS	Investigative
DMNXCHT	SN	CHEMBL266122; Tyr-Pro-Dmp-Phe-NH2
DMNXCHT	DT	Small molecular drug
DMNXCHT	PC	10371367
DMNXCHT	MW	599.7
DMNXCHT	FM	C34H41N5O5
DMNXCHT	IC	InChI=1S/C34H41N5O5/c1-21-8-6-9-22(2)26(21)20-29(32(42)37-28(31(36)41)19-23-10-4-3-5-11-23)38-33(43)30-12-7-17-39(30)34(44)27(35)18-24-13-15-25(40)16-14-24/h3-6,8-11,13-16,27-30,40H,7,12,17-20,35H2,1-2H3,(H2,36,41)(H,37,42)(H,38,43)/t27-,28-,29-,30-/m0/s1
DMNXCHT	CS	CC1=C(C(=CC=C1)C)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMNXCHT	IK	HJYUYBYISGYHKS-KRCBVYEFSA-N
DMNXCHT	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2,6-dimethylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMNXCHT	DE	Discovery agent

DMOU43H	ID	DMOU43H
DMOU43H	DN	Tyr-Pro-Dmt-Phe-NH2
DMOU43H	HS	Investigative
DMOU43H	SN	CHEMBL228512; Tyr-Pro-Dmt-Phe-NH2
DMOU43H	DT	Small molecular drug
DMOU43H	PC	44424809
DMOU43H	MW	601.7
DMOU43H	FM	C33H39N5O6
DMOU43H	IC	InChI=1S/C33H39N5O6/c1-20-16-25(40)14-11-23(20)19-28(31(42)36-27(30(35)41)18-21-6-3-2-4-7-21)37-32(43)29-8-5-15-38(29)33(44)26(34)17-22-9-12-24(39)13-10-22/h2-4,6-7,9-14,16,26-29,39-40H,5,8,15,17-19,34H2,1H3,(H2,35,41)(H,36,42)(H,37,43)/t26-,27-,28-,29-/m0/s1
DMOU43H	CS	CC1=C(C=CC(=C1)O)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMOU43H	IK	NGVFBRDVYVEPFY-DZUOILHNSA-N
DMOU43H	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxy-2-methylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMOU43H	DE	Discovery agent

DM4ZJR5	ID	DM4ZJR5
DM4ZJR5	DN	Tyr-Pro-D-Phe-D-Pro-NH2
DM4ZJR5	HS	Investigative
DM4ZJR5	DT	Small molecular drug
DM4ZJR5	PC	44375820
DM4ZJR5	MW	521.6
DM4ZJR5	FM	C28H35N5O5
DM4ZJR5	IC	InChI=1S/C28H35N5O5/c29-21(16-19-10-12-20(34)13-11-19)27(37)33-15-5-9-24(33)26(36)31-22(17-18-6-2-1-3-7-18)28(38)32-14-4-8-23(32)25(30)35/h1-3,6-7,10-13,21-24,34H,4-5,8-9,14-17,29H2,(H2,30,35)(H,31,36)/t21?,22-,23-,24?/m1/s1
DM4ZJR5	CS	C1C[C@@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C3CCCN3C(=O)C(CC4=CC=C(C=C4)O)N)C(=O)N
DM4ZJR5	IK	LSQXZIUREIDSHZ-BIELFDCTSA-N
DM4ZJR5	IU	1-[2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM4ZJR5	DE	Discovery agent

DMCTSNE	ID	DMCTSNE
DMCTSNE	DN	Tyr-Pro-D-Phe-Pro-NH2
DMCTSNE	HS	Investigative
DMCTSNE	SN	Tyr-Pro-D-Phe-Pro-NH2; CHEMBL162564
DMCTSNE	DT	Small molecular drug
DMCTSNE	PC	44376104
DMCTSNE	MW	521.6
DMCTSNE	FM	C28H35N5O5
DMCTSNE	IC	InChI=1S/C28H35N5O5/c29-21(16-19-10-12-20(34)13-11-19)27(37)33-15-5-9-24(33)26(36)31-22(17-18-6-2-1-3-7-18)28(38)32-14-4-8-23(32)25(30)35/h1-3,6-7,10-13,21-24,34H,4-5,8-9,14-17,29H2,(H2,30,35)(H,31,36)/t21?,22-,23?,24?/m1/s1
DMCTSNE	CS	C1CC(N(C1)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C3CCCN3C(=O)C(CC4=CC=C(C=C4)O)N)C(=O)N
DMCTSNE	IK	LSQXZIUREIDSHZ-NJEQKKOJSA-N
DMCTSNE	IU	1-[2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2R)-1-(2-carbamoylpyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMCTSNE	DE	Discovery agent

DMEDVRN	ID	DMEDVRN
DMEDVRN	DN	Tyr-Pro-D-Phg-Phe-NH2
DMEDVRN	HS	Investigative
DMEDVRN	SN	CHEMBL210247; Tyr-Pro-D-Phg-Phe-NH2
DMEDVRN	DT	Small molecular drug
DMEDVRN	PC	44413216
DMEDVRN	MW	557.6
DMEDVRN	FM	C31H35N5O5
DMEDVRN	IC	InChI=1S/C31H35N5O5/c32-24(18-21-13-15-23(37)16-14-21)31(41)36-17-7-12-26(36)29(39)35-27(22-10-5-2-6-11-22)30(40)34-25(28(33)38)19-20-8-3-1-4-9-20/h1-6,8-11,13-16,24-27,37H,7,12,17-19,32H2,(H2,33,38)(H,34,40)(H,35,39)/t24-,25-,26-,27+/m0/s1
DMEDVRN	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@H](C3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N
DMEDVRN	IK	CLTFAZZUUWSIAO-YIPNQBBMSA-N
DMEDVRN	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(1R)-2-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-2-oxo-1-phenylethyl]pyrrolidine-2-carboxamide
DMEDVRN	DE	Discovery agent

DMUKE43	ID	DMUKE43
DMUKE43	DN	Tyr-Pro-Emp-Phe-NH2
DMUKE43	HS	Investigative
DMUKE43	SN	CHEMBL375274; Tyr-Pro-Emp-Phe-NH2
DMUKE43	DT	Small molecular drug
DMUKE43	PC	16736708
DMUKE43	MW	613.7
DMUKE43	FM	C35H43N5O5
DMUKE43	IC	InChI=1S/C35H43N5O5/c1-3-25-12-7-9-22(2)27(25)21-30(33(43)38-29(32(37)42)20-23-10-5-4-6-11-23)39-34(44)31-13-8-18-40(31)35(45)28(36)19-24-14-16-26(41)17-15-24/h4-7,9-12,14-17,28-31,41H,3,8,13,18-21,36H2,1-2H3,(H2,37,42)(H,38,43)(H,39,44)/t28-,29-,30-,31-/m0/s1
DMUKE43	CS	CCC1=CC=CC(=C1C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N)C
DMUKE43	IK	AAXFHBRSEVMRCW-ORYMTKCHSA-N
DMUKE43	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2-ethyl-6-methylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMUKE43	DE	Discovery agent

DM8THU2	ID	DM8THU2
DM8THU2	DN	Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2
DM8THU2	HS	Investigative
DM8THU2	SN	Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2; CCK-Opioid Peptide, 5; CHEMBL382409; BDBM21135; (3S)-3-[(2S)-2-[(2S)-2-(2-{[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}acetamido)-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DM8THU2	DT	Small molecular drug
DM8THU2	PC	11629355
DM8THU2	MW	910
DM8THU2	FM	C47H59N9O10
DM8THU2	IC	InChI=1S/C47H59N9O10/c1-3-4-15-38(45(64)54-36(25-41(59)60)43(62)53-35(42(49)61)23-28-11-6-5-7-12-28)55(2)47(66)37(24-30-26-50-34-14-9-8-13-32(30)34)52-40(58)27-51-44(63)39-16-10-21-56(39)46(65)33(48)22-29-17-19-31(57)20-18-29/h5-9,11-14,17-20,26,33,35-39,50,57H,3-4,10,15-16,21-25,27,48H2,1-2H3,(H2,49,61)(H,51,63)(H,52,58)(H,53,62)(H,54,64)(H,59,60)/t33-,35-,36-,37-,38-,39-/m0/s1
DM8THU2	CS	CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N
DM8THU2	IK	XMLJSDGQSNTHPG-WYLSNLDWSA-N
DM8THU2	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DM8THU2	DE	Discovery agent

DME5HIS	ID	DME5HIS
DME5HIS	DN	Tyr-Pro-Hfe-Phe-NH2
DME5HIS	HS	Investigative
DME5HIS	SN	CHEMBL378466; Tyr-Pro-Hfe-Phe-NH2
DME5HIS	DT	Small molecular drug
DME5HIS	PC	14991618
DME5HIS	MW	585.7
DME5HIS	FM	C33H39N5O5
DME5HIS	IC	InChI=1S/C33H39N5O5/c34-26(20-24-13-16-25(39)17-14-24)33(43)38-19-7-12-29(38)32(42)36-27(18-15-22-8-3-1-4-9-22)31(41)37-28(30(35)40)21-23-10-5-2-6-11-23/h1-6,8-11,13-14,16-17,26-29,39H,7,12,15,18-21,34H2,(H2,35,40)(H,36,42)(H,37,41)/t26-,27-,28-,29-/m0/s1
DME5HIS	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CCC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N
DME5HIS	IK	FNDQFOCGSSQYSF-DZUOILHNSA-N
DME5HIS	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-4-phenylbutan-2-yl]pyrrolidine-2-carboxamide
DME5HIS	DE	Discovery agent

DMJBR75	ID	DMJBR75
DMJBR75	DN	Tyr-Pro-Hfe-Pro-NH2
DMJBR75	HS	Investigative
DMJBR75	SN	CHEMBL380286; Tyr-Pro-Hfe-Pro-NH2
DMJBR75	DT	Small molecular drug
DMJBR75	PC	44413086
DMJBR75	MW	535.6
DMJBR75	FM	C29H37N5O5
DMJBR75	IC	InChI=1S/C29H37N5O5/c30-22(18-20-10-13-21(35)14-11-20)28(38)34-17-5-9-25(34)27(37)32-23(15-12-19-6-2-1-3-7-19)29(39)33-16-4-8-24(33)26(31)36/h1-3,6-7,10-11,13-14,22-25,35H,4-5,8-9,12,15-18,30H2,(H2,31,36)(H,32,37)/t22-,23-,24-,25-/m0/s1
DMJBR75	CS	C1C[C@H](N(C1)C(=O)[C@H](CCC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N)C(=O)N
DMJBR75	IK	SJJQQBJUOIMODQ-QORCZRPOSA-N
DMJBR75	IU	(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-phenylbutanoyl]pyrrolidine-2-carboxamide
DMJBR75	DE	Discovery agent

DMUV3ZW	ID	DMUV3ZW
DMUV3ZW	DN	Tyr-Pro-Imp-Phe-NH2
DMUV3ZW	HS	Investigative
DMUV3ZW	SN	CHEMBL434559; Tyr-Pro-Imp-Phe-NH2
DMUV3ZW	DT	Small molecular drug
DMUV3ZW	PC	16736710
DMUV3ZW	MW	627.8
DMUV3ZW	FM	C36H45N5O5
DMUV3ZW	IC	InChI=1S/C36H45N5O5/c1-22(2)27-12-7-9-23(3)28(27)21-31(34(44)39-30(33(38)43)20-24-10-5-4-6-11-24)40-35(45)32-13-8-18-41(32)36(46)29(37)19-25-14-16-26(42)17-15-25/h4-7,9-12,14-17,22,29-32,42H,8,13,18-21,37H2,1-3H3,(H2,38,43)(H,39,44)(H,40,45)/t29-,30-,31-,32-/m0/s1
DMUV3ZW	CS	CC1=C(C(=CC=C1)C(C)C)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMUV3ZW	IK	ZMMDWGMVKHLYTG-YDPTYEFTSA-N
DMUV3ZW	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2-methyl-6-propan-2-ylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMUV3ZW	DE	Discovery agent

DMI65GV	ID	DMI65GV
DMI65GV	DN	Tyr-Pro-L-(NMe)Phe-D-Pro-NH2
DMI65GV	HS	Investigative
DMI65GV	DT	Small molecular drug
DMI65GV	PC	44376060
DMI65GV	MW	535.6
DMI65GV	FM	C29H37N5O5
DMI65GV	IC	InChI=1S/C29H37N5O5/c1-32(25(18-19-7-3-2-4-8-19)29(39)33-15-5-9-23(33)26(31)36)28(38)24-10-6-16-34(24)27(37)22(30)17-20-11-13-21(35)14-12-20/h2-4,7-8,11-14,22-25,35H,5-6,9-10,15-18,30H2,1H3,(H2,31,36)/t22?,23-,24?,25+/m1/s1
DMI65GV	CS	CN([C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)N)C(=O)C3CCCN3C(=O)C(CC4=CC=C(C=C4)O)N
DMI65GV	IK	JAKBYSTWCHUQOK-DZIFKCOOSA-N
DMI65GV	IU	1-[2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-N-methylpyrrolidine-2-carboxamide
DMI65GV	DE	Discovery agent

DM1NITL	ID	DM1NITL
DM1NITL	DN	Tyr-Pro-L-(NMe)Phe-Pro-NH2
DM1NITL	HS	Investigative
DM1NITL	DT	Small molecular drug
DM1NITL	PC	44375819
DM1NITL	MW	535.6
DM1NITL	FM	C29H37N5O5
DM1NITL	IC	InChI=1S/C29H37N5O5/c1-32(25(18-19-7-3-2-4-8-19)29(39)33-15-5-9-23(33)26(31)36)28(38)24-10-6-16-34(24)27(37)22(30)17-20-11-13-21(35)14-12-20/h2-4,7-8,11-14,22-25,35H,5-6,9-10,15-18,30H2,1H3,(H2,31,36)/t22?,23?,24?,25-/m0/s1
DM1NITL	CS	CN([C@@H](CC1=CC=CC=C1)C(=O)N2CCCC2C(=O)N)C(=O)C3CCCN3C(=O)C(CC4=CC=C(C=C4)O)N
DM1NITL	IK	JAKBYSTWCHUQOK-DGGBHQDZSA-N
DM1NITL	IU	1-[2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-(2-carbamoylpyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-N-methylpyrrolidine-2-carboxamide
DM1NITL	DE	Discovery agent

DMUVHGS	ID	DMUVHGS
DMUVHGS	DN	Tyr-Pro-L-Phe-D-Pro-NH2
DMUVHGS	HS	Investigative
DMUVHGS	DT	Small molecular drug
DMUVHGS	PC	44376061
DMUVHGS	MW	521.6
DMUVHGS	FM	C28H35N5O5
DMUVHGS	IC	InChI=1S/C28H35N5O5/c29-21(16-19-10-12-20(34)13-11-19)27(37)33-15-5-9-24(33)26(36)31-22(17-18-6-2-1-3-7-18)28(38)32-14-4-8-23(32)25(30)35/h1-3,6-7,10-13,21-24,34H,4-5,8-9,14-17,29H2,(H2,30,35)(H,31,36)/t21?,22-,23+,24?/m0/s1
DMUVHGS	CS	C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)C3CCCN3C(=O)C(CC4=CC=C(C=C4)O)N)C(=O)N
DMUVHGS	IK	LSQXZIUREIDSHZ-JULQRDMDSA-N
DMUVHGS	IU	1-[2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMUVHGS	DE	Discovery agent

DM8VW3Z	ID	DM8VW3Z
DM8VW3Z	DN	Tyr-Pro-L-Phe-Pro-NH2
DM8VW3Z	HS	Investigative
DM8VW3Z	DT	Small molecular drug
DM8VW3Z	PC	44375782
DM8VW3Z	MW	521.6
DM8VW3Z	FM	C28H35N5O5
DM8VW3Z	IC	InChI=1S/C28H35N5O5/c29-21(16-19-10-12-20(34)13-11-19)27(37)33-15-5-9-24(33)26(36)31-22(17-18-6-2-1-3-7-18)28(38)32-14-4-8-23(32)25(30)35/h1-3,6-7,10-13,21-24,34H,4-5,8-9,14-17,29H2,(H2,30,35)(H,31,36)/t21?,22-,23?,24?/m0/s1
DM8VW3Z	CS	C1CC(N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)C3CCCN3C(=O)C(CC4=CC=C(C=C4)O)N)C(=O)N
DM8VW3Z	IK	LSQXZIUREIDSHZ-REDCPHJYSA-N
DM8VW3Z	IU	1-[2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-(2-carbamoylpyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM8VW3Z	DE	Discovery agent

DMRE7G3	ID	DMRE7G3
DMRE7G3	DN	Tyr-Pro-Mmp-Phe-NH
DMRE7G3	HS	Investigative
DMRE7G3	SN	CHEMBL413676; Tyr-Pro-Mmp-Phe-NH
DMRE7G3	DT	Small molecular drug
DMRE7G3	PC	16736675
DMRE7G3	MW	585.7
DMRE7G3	FM	C33H39N5O5
DMRE7G3	IC	InChI=1S/C33H39N5O5/c1-21-8-5-6-11-24(21)20-28(31(41)36-27(30(35)40)19-22-9-3-2-4-10-22)37-32(42)29-12-7-17-38(29)33(43)26(34)18-23-13-15-25(39)16-14-23/h2-6,8-11,13-16,26-29,39H,7,12,17-20,34H2,1H3,(H2,35,40)(H,36,41)(H,37,42)/t26-,27-,28-,29-/m0/s1
DMRE7G3	CS	CC1=CC=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMRE7G3	IK	LJUZIHDRCVUPHL-DZUOILHNSA-N
DMRE7G3	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2-methylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMRE7G3	DE	Discovery agent

DMIE4U5	ID	DMIE4U5
DMIE4U5	DN	Tyr-Pro-Phe-Ala-Bn
DMIE4U5	HS	Investigative
DMIE4U5	SN	CHEMBL577749; Tyr-Pro-Phe-Ala-Bn
DMIE4U5	DT	Small molecular drug
DMIE4U5	PC	45487602
DMIE4U5	MW	585.7
DMIE4U5	FM	C33H39N5O5
DMIE4U5	IC	InChI=1S/C33H39N5O5/c1-22(30(40)35-21-25-11-6-3-7-12-25)36-31(41)28(20-23-9-4-2-5-10-23)37-32(42)29-13-8-18-38(29)33(43)27(34)19-24-14-16-26(39)17-15-24/h2-7,9-12,14-17,22,27-29,39H,8,13,18-21,34H2,1H3,(H,35,40)(H,36,41)(H,37,42)/t22-,27-,28-,29-/m0/s1
DMIE4U5	CS	C[C@@H](C(=O)NCC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMIE4U5	IK	FFJZWXQQTXSXFM-OCDVNBFTSA-N
DMIE4U5	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-(benzylamino)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMIE4U5	DE	Discovery agent

DMLQ3PR	ID	DMLQ3PR
DMLQ3PR	DN	Tyr-Pro-Phe-D-2-Nal-NH2
DMLQ3PR	HS	Investigative
DMLQ3PR	SN	CHEMBL375070; Tyr-Pro-Phe-D-2-Nal-NH2
DMLQ3PR	DT	Small molecular drug
DMLQ3PR	PC	11498201
DMLQ3PR	MW	621.7
DMLQ3PR	FM	C36H39N5O5
DMLQ3PR	IC	InChI=1S/C36H39N5O5/c37-29(20-24-13-16-28(42)17-14-24)36(46)41-18-6-11-32(41)35(45)40-31(21-23-7-2-1-3-8-23)34(44)39-30(33(38)43)22-25-12-15-26-9-4-5-10-27(26)19-25/h1-5,7-10,12-17,19,29-32,42H,6,11,18,20-22,37H2,(H2,38,43)(H,39,44)(H,40,45)/t29-,30+,31-,32-/m0/s1
DMLQ3PR	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CC5=CC=CC=C5C=C4)C(=O)N
DMLQ3PR	IK	UHSIKTZSFPWTDC-RACKDBBVSA-N
DMLQ3PR	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMLQ3PR	DE	Discovery agent

DMLEUF6	ID	DMLEUF6
DMLEUF6	DN	Tyr-Pro-Phe-D-Ala-Bn
DMLEUF6	HS	Investigative
DMLEUF6	SN	CHEMBL577748; Tyr-Pro-Phe-D-Ala-Bn
DMLEUF6	DT	Small molecular drug
DMLEUF6	PC	45487600
DMLEUF6	MW	585.7
DMLEUF6	FM	C33H39N5O5
DMLEUF6	IC	InChI=1S/C33H39N5O5/c1-22(30(40)35-21-25-11-6-3-7-12-25)36-31(41)28(20-23-9-4-2-5-10-23)37-32(42)29-13-8-18-38(29)33(43)27(34)19-24-14-16-26(39)17-15-24/h2-7,9-12,14-17,22,27-29,39H,8,13,18-21,34H2,1H3,(H,35,40)(H,36,41)(H,37,42)/t22-,27+,28+,29+/m1/s1
DMLEUF6	CS	C[C@H](C(=O)NCC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMLEUF6	IK	FFJZWXQQTXSXFM-GDNYIZLESA-N
DMLEUF6	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-(benzylamino)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMLEUF6	DE	Discovery agent

DM6YRVT	ID	DM6YRVT
DM6YRVT	DN	Tyr-Pro-Phe-D-Phg-NH2
DM6YRVT	HS	Investigative
DM6YRVT	SN	CHEMBL208990; Tyr-Pro-Phe-D-Phg-NH2
DM6YRVT	DT	Small molecular drug
DM6YRVT	PC	44413117
DM6YRVT	MW	557.6
DM6YRVT	FM	C31H35N5O5
DM6YRVT	IC	InChI=1S/C31H35N5O5/c32-24(18-21-13-15-23(37)16-14-21)31(41)36-17-7-12-26(36)30(40)34-25(19-20-8-3-1-4-9-20)29(39)35-27(28(33)38)22-10-5-2-6-11-22/h1-6,8-11,13-16,24-27,37H,7,12,17-19,32H2,(H2,33,38)(H,34,40)(H,35,39)/t24-,25-,26-,27+/m0/s1
DM6YRVT	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](C4=CC=CC=C4)C(=O)N
DM6YRVT	IK	UUUCKSPURQXDKV-YIPNQBBMSA-N
DM6YRVT	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(1R)-2-amino-2-oxo-1-phenylethyl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM6YRVT	DE	Discovery agent

DM1QZ9X	ID	DM1QZ9X
DM1QZ9X	DN	Tyr-Pro-Phe-D-Val-Bn
DM1QZ9X	HS	Investigative
DM1QZ9X	SN	CHEMBL577746; Tyr-Pro-Phe-D-Val-Bn
DM1QZ9X	DT	Small molecular drug
DM1QZ9X	PC	44555371
DM1QZ9X	MW	613.7
DM1QZ9X	FM	C35H43N5O5
DM1QZ9X	IC	InChI=1S/C35H43N5O5/c1-23(2)31(34(44)37-22-26-12-7-4-8-13-26)39-32(42)29(21-24-10-5-3-6-11-24)38-33(43)30-14-9-19-40(30)35(45)28(36)20-25-15-17-27(41)18-16-25/h3-8,10-13,15-18,23,28-31,41H,9,14,19-22,36H2,1-2H3,(H,37,44)(H,38,43)(H,39,42)/t28-,29-,30-,31+/m0/s1
DM1QZ9X	CS	CC(C)[C@H](C(=O)NCC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DM1QZ9X	IK	XAWPZZPZRCUIDR-XHPANXIASA-N
DM1QZ9X	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM1QZ9X	DE	Discovery agent

DM71P2O	ID	DM71P2O
DM71P2O	DN	Tyr-Pro-Phe-Hfe-NH2
DM71P2O	HS	Investigative
DM71P2O	SN	CHEMBL211147; Tyr-Pro-Phe-Hfe-NH2
DM71P2O	DT	Small molecular drug
DM71P2O	PC	14991612
DM71P2O	MW	585.7
DM71P2O	FM	C33H39N5O5
DM71P2O	IC	InChI=1S/C33H39N5O5/c34-26(20-24-13-16-25(39)17-14-24)33(43)38-19-7-12-29(38)32(42)37-28(21-23-10-5-2-6-11-23)31(41)36-27(30(35)40)18-15-22-8-3-1-4-9-22/h1-6,8-11,13-14,16-17,26-29,39H,7,12,15,18-21,34H2,(H2,35,40)(H,36,41)(H,37,42)/t26-,27-,28-,29-/m0/s1
DM71P2O	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCC4=CC=CC=C4)C(=O)N
DM71P2O	IK	KEZWZCZPOVYKBN-DZUOILHNSA-N
DM71P2O	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-4-phenylbutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM71P2O	DE	Discovery agent

DM5DRIZ	ID	DM5DRIZ
DM5DRIZ	DN	Tyr-Pro-Phe-Phe-N(CH3)2
DM5DRIZ	HS	Investigative
DM5DRIZ	SN	CHEMBL505975; Tyr-Pro-Phe-Phe-N(CH3)2
DM5DRIZ	DT	Small molecular drug
DM5DRIZ	PC	44586190
DM5DRIZ	MW	599.7
DM5DRIZ	FM	C34H41N5O5
DM5DRIZ	IC	InChI=1S/C34H41N5O5/c1-38(2)34(44)29(22-24-12-7-4-8-13-24)37-31(41)28(21-23-10-5-3-6-11-23)36-32(42)30-14-9-19-39(30)33(43)27(35)20-25-15-17-26(40)18-16-25/h3-8,10-13,15-18,27-30,40H,9,14,19-22,35H2,1-2H3,(H,36,42)(H,37,41)/t27-,28-,29-,30-/m0/s1
DM5DRIZ	CS	CN(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DM5DRIZ	IK	KRABRQBOUFODOG-KRCBVYEFSA-N
DM5DRIZ	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-(dimethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM5DRIZ	DE	Discovery agent

DM2U4VI	ID	DM2U4VI
DM2U4VI	DN	Tyr-Pro-Phe-Phe-NHCH3
DM2U4VI	HS	Investigative
DM2U4VI	SN	CHEMBL453689; Tyr-Pro-Phe-Phe-NHCH3
DM2U4VI	DT	Small molecular drug
DM2U4VI	PC	44586189
DM2U4VI	MW	585.7
DM2U4VI	FM	C33H39N5O5
DM2U4VI	IC	InChI=1S/C33H39N5O5/c1-35-30(40)27(20-22-9-4-2-5-10-22)36-31(41)28(21-23-11-6-3-7-12-23)37-32(42)29-13-8-18-38(29)33(43)26(34)19-24-14-16-25(39)17-15-24/h2-7,9-12,14-17,26-29,39H,8,13,18-21,34H2,1H3,(H,35,40)(H,36,41)(H,37,42)/t26-,27-,28-,29-/m0/s1
DM2U4VI	CS	CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DM2U4VI	IK	WEITVBLLGNOHNQ-DZUOILHNSA-N
DM2U4VI	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM2U4VI	DE	Discovery agent

DMY6V9R	ID	DMY6V9R
DMY6V9R	DN	Tyr-Pro-Phe-Phe-NHNH2
DMY6V9R	HS	Investigative
DMY6V9R	SN	CHEMBL180777; Tyr-Pro-Phe-Phe-NHNH2
DMY6V9R	DT	Small molecular drug
DMY6V9R	PC	24857892
DMY6V9R	MW	586.7
DMY6V9R	FM	C32H38N6O5
DMY6V9R	IC	InChI=1S/C32H38N6O5/c33-25(18-23-13-15-24(39)16-14-23)32(43)38-17-7-12-28(38)31(42)36-26(19-21-8-3-1-4-9-21)29(40)35-27(30(41)37-34)20-22-10-5-2-6-11-22/h1-6,8-11,13-16,25-28,39H,7,12,17-20,33-34H2,(H,35,40)(H,36,42)(H,37,41)/t25-,26-,27-,28-/m0/s1
DMY6V9R	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)NN
DMY6V9R	IK	JZSLBNUKUIAYPN-LJWNLINESA-N
DMY6V9R	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-hydrazinyl-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMY6V9R	DE	Discovery agent

DMS4P1E	ID	DMS4P1E
DMS4P1E	DN	Tyr-Pro-Phe-Phe-OC(CH3)3
DMS4P1E	HS	Investigative
DMS4P1E	SN	CHEMBL500195; Tyr-Pro-Phe-Phe-OC(CH3)3
DMS4P1E	DT	Small molecular drug
DMS4P1E	PC	44586192
DMS4P1E	MW	628.8
DMS4P1E	FM	C36H44N4O6
DMS4P1E	IC	InChI=1S/C36H44N4O6/c1-36(2,3)46-35(45)30(23-25-13-8-5-9-14-25)39-32(42)29(22-24-11-6-4-7-12-24)38-33(43)31-15-10-20-40(31)34(44)28(37)21-26-16-18-27(41)19-17-26/h4-9,11-14,16-19,28-31,41H,10,15,20-23,37H2,1-3H3,(H,38,43)(H,39,42)/t28-,29-,30-,31-/m0/s1
DMS4P1E	CS	CC(C)(C)OC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMS4P1E	IK	MUCJBMLSOAIPBH-ORYMTKCHSA-N
DMS4P1E	IU	tert-butyl (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoate
DMS4P1E	DE	Discovery agent

DMZNHEC	ID	DMZNHEC
DMZNHEC	DN	Tyr-Pro-Phe-Phe-OCH2CH3
DMZNHEC	HS	Investigative
DMZNHEC	SN	CHEMBL505502; Tyr-Pro-Phe-Phe-OCH2CH3
DMZNHEC	DT	Small molecular drug
DMZNHEC	PC	44586191
DMZNHEC	MW	600.7
DMZNHEC	FM	C34H40N4O6
DMZNHEC	IC	InChI=1S/C34H40N4O6/c1-2-44-34(43)29(22-24-12-7-4-8-13-24)37-31(40)28(21-23-10-5-3-6-11-23)36-32(41)30-14-9-19-38(30)33(42)27(35)20-25-15-17-26(39)18-16-25/h3-8,10-13,15-18,27-30,39H,2,9,14,19-22,35H2,1H3,(H,36,41)(H,37,40)/t27-,28-,29-,30-/m0/s1
DMZNHEC	CS	CCOC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMZNHEC	IK	JKMFJIMTIXQDHF-KRCBVYEFSA-N
DMZNHEC	IU	ethyl (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoate
DMZNHEC	DE	Discovery agent

DMFV7NI	ID	DMFV7NI
DMFV7NI	DN	Tyr-Pro-Phe-Phe-OCH2OH
DMFV7NI	HS	Investigative
DMFV7NI	SN	CHEMBL522293; Tyr-Pro-Phe-Phe-OCH2OH
DMFV7NI	DT	Small molecular drug
DMFV7NI	PC	24857893
DMFV7NI	MW	558.7
DMFV7NI	FM	C32H38N4O5
DMFV7NI	IC	InChI=1S/C32H38N4O5/c33-27(19-24-13-15-26(38)16-14-24)32(41)36-17-7-12-29(36)31(40)35-28(20-23-10-5-2-6-11-23)30(39)34-25(21-37)18-22-8-3-1-4-9-22/h1-6,8-11,13-16,25,27-29,37-38H,7,12,17-21,33H2,(H,34,39)(H,35,40)/t25-,27-,28-,29-/m0/s1
DMFV7NI	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)CO
DMFV7NI	IK	PZNSQIAIDOIARA-AMEOFWRWSA-N
DMFV7NI	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMFV7NI	DE	Discovery agent

DMRQXHO	ID	DMRQXHO
DMRQXHO	DN	Tyr-Pro-Phe-Phe-OCH3
DMRQXHO	HS	Investigative
DMRQXHO	SN	CHEMBL361922; Tyr-Pro-Phe-Phe-OCH3; Tyr-Pro-Phe-Phe-OMe
DMRQXHO	DT	Small molecular drug
DMRQXHO	PC	44390652
DMRQXHO	MW	586.7
DMRQXHO	FM	C33H38N4O6
DMRQXHO	IC	InChI=1S/C33H38N4O6/c1-43-33(42)28(21-23-11-6-3-7-12-23)36-30(39)27(20-22-9-4-2-5-10-22)35-31(40)29-13-8-18-37(29)32(41)26(34)19-24-14-16-25(38)17-15-24/h2-7,9-12,14-17,26-29,38H,8,13,18-21,34H2,1H3,(H,35,40)(H,36,39)/t26-,27-,28-,29-/m0/s1
DMRQXHO	CS	COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMRQXHO	IK	YYNCXEIEPLRPCR-DZUOILHNSA-N
DMRQXHO	IU	methyl (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoate
DMRQXHO	DE	Discovery agent

DM70HYT	ID	DM70HYT
DM70HYT	DN	Tyr-Pro-Phe-Phg-NH2
DM70HYT	HS	Investigative
DM70HYT	SN	CHEMBL378111; Tyr-Pro-Phe-Phg-NH2
DM70HYT	DT	Small molecular drug
DM70HYT	PC	44413074
DM70HYT	MW	557.6
DM70HYT	FM	C31H35N5O5
DM70HYT	IC	InChI=1S/C31H35N5O5/c32-24(18-21-13-15-23(37)16-14-21)31(41)36-17-7-12-26(36)30(40)34-25(19-20-8-3-1-4-9-20)29(39)35-27(28(33)38)22-10-5-2-6-11-22/h1-6,8-11,13-16,24-27,37H,7,12,17-19,32H2,(H2,33,38)(H,34,40)(H,35,39)/t24-,25-,26-,27-/m0/s1
DM70HYT	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C4=CC=CC=C4)C(=O)N
DM70HYT	IK	UUUCKSPURQXDKV-FWEHEUNISA-N
DM70HYT	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM70HYT	DE	Discovery agent

DMVDM73	ID	DMVDM73
DMVDM73	DN	Tyr-Pro-Phg-Phe-NH2
DMVDM73	HS	Investigative
DMVDM73	SN	CHEMBL211119; Tyr-Pro-Phg-Phe-NH2
DMVDM73	DT	Small molecular drug
DMVDM73	PC	44413203
DMVDM73	MW	557.6
DMVDM73	FM	C31H35N5O5
DMVDM73	IC	InChI=1S/C31H35N5O5/c32-24(18-21-13-15-23(37)16-14-21)31(41)36-17-7-12-26(36)29(39)35-27(22-10-5-2-6-11-22)30(40)34-25(28(33)38)19-20-8-3-1-4-9-20/h1-6,8-11,13-16,24-27,37H,7,12,17-19,32H2,(H2,33,38)(H,34,40)(H,35,39)/t24-,25-,26-,27-/m0/s1
DMVDM73	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](C3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N
DMVDM73	IK	CLTFAZZUUWSIAO-FWEHEUNISA-N
DMVDM73	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(1S)-2-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-2-oxo-1-phenylethyl]pyrrolidine-2-carboxamide
DMVDM73	DE	Discovery agent

DMSGMPU	ID	DMSGMPU
DMSGMPU	DN	Tyr-Pro-Phg-Pro-NH2
DMSGMPU	HS	Investigative
DMSGMPU	SN	CHEMBL425421; Tyr-Pro-Phg-Pro-NH2
DMSGMPU	DT	Small molecular drug
DMSGMPU	PC	44413146
DMSGMPU	MW	507.6
DMSGMPU	FM	C27H33N5O5
DMSGMPU	IC	InChI=1S/C27H33N5O5/c28-20(16-17-10-12-19(33)13-11-17)26(36)32-15-5-9-22(32)25(35)30-23(18-6-2-1-3-7-18)27(37)31-14-4-8-21(31)24(29)34/h1-3,6-7,10-13,20-23,33H,4-5,8-9,14-16,28H2,(H2,29,34)(H,30,35)/t20-,21-,22-,23-/m0/s1
DMSGMPU	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](C3=CC=CC=C3)C(=O)N4CCC[C@H]4C(=O)N
DMSGMPU	IK	QTYFABXBYBNUEU-MLCQCVOFSA-N
DMSGMPU	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(1S)-2-[(2S)-2-carbamoylpyrrolidin-1-yl]-2-oxo-1-phenylethyl]pyrrolidine-2-carboxamide
DMSGMPU	DE	Discovery agent

DMR3IVB	ID	DMR3IVB
DMR3IVB	DN	Tyr-Pro-Tmp-Phe-NH
DMR3IVB	HS	Investigative
DMR3IVB	SN	CHEMBL389023; Tyr-Pro-Tmp-Phe-NH
DMR3IVB	DT	Small molecular drug
DMR3IVB	PC	16736706
DMR3IVB	MW	613.7
DMR3IVB	FM	C35H43N5O5
DMR3IVB	IC	InChI=1S/C35H43N5O5/c1-21-16-22(2)27(23(3)17-21)20-30(33(43)38-29(32(37)42)19-24-8-5-4-6-9-24)39-34(44)31-10-7-15-40(31)35(45)28(36)18-25-11-13-26(41)14-12-25/h4-6,8-9,11-14,16-17,28-31,41H,7,10,15,18-20,36H2,1-3H3,(H2,37,42)(H,38,43)(H,39,44)/t28-,29-,30-,31-/m0/s1
DMR3IVB	CS	CC1=CC(=C(C(=C1)C)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N)C
DMR3IVB	IK	KFLSQRYJYCLKBS-ORYMTKCHSA-N
DMR3IVB	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-(2,4,6-trimethylphenyl)propan-2-yl]pyrrolidine-2-carboxamide
DMR3IVB	DE	Discovery agent

DMFIPXA	ID	DMFIPXA
DMFIPXA	DN	Tyr-Pro-Trp-D-Ala-Bn
DMFIPXA	HS	Investigative
DMFIPXA	SN	CHEMBL577747; Tyr-Pro-Trp-D-Ala-Bn
DMFIPXA	DT	Small molecular drug
DMFIPXA	PC	44555372
DMFIPXA	MW	624.7
DMFIPXA	FM	C35H40N6O5
DMFIPXA	IC	InChI=1S/C35H40N6O5/c1-22(32(43)38-20-24-8-3-2-4-9-24)39-33(44)30(19-25-21-37-29-11-6-5-10-27(25)29)40-34(45)31-12-7-17-41(31)35(46)28(36)18-23-13-15-26(42)16-14-23/h2-6,8-11,13-16,21-22,28,30-31,37,42H,7,12,17-20,36H2,1H3,(H,38,43)(H,39,44)(H,40,45)/t22-,28+,30+,31+/m1/s1
DMFIPXA	CS	C[C@H](C(=O)NCC1=CC=CC=C1)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N
DMFIPXA	IK	IRQJYTHTLNHEDS-QVBNWNEOSA-N
DMFIPXA	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-(benzylamino)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMFIPXA	DE	Discovery agent

DMY5HX6	ID	DMY5HX6
DMY5HX6	DN	Tyr-Pro-Trp-D-Val-Bn
DMY5HX6	HS	Investigative
DMY5HX6	SN	CHEMBL577745; Tyr-Pro-Trp-D-Val-Bn
DMY5HX6	DT	Small molecular drug
DMY5HX6	PC	44555370
DMY5HX6	MW	652.8
DMY5HX6	FM	C37H44N6O5
DMY5HX6	IC	InChI=1S/C37H44N6O5/c1-23(2)33(36(47)40-21-25-9-4-3-5-10-25)42-34(45)31(20-26-22-39-30-12-7-6-11-28(26)30)41-35(46)32-13-8-18-43(32)37(48)29(38)19-24-14-16-27(44)17-15-24/h3-7,9-12,14-17,22-23,29,31-33,39,44H,8,13,18-21,38H2,1-2H3,(H,40,47)(H,41,46)(H,42,45)/t29-,31-,32-,33+/m0/s1
DMY5HX6	CS	CC(C)[C@H](C(=O)NCC1=CC=CC=C1)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N
DMY5HX6	IK	FBLJJMPPZKDLDJ-DMBLRCPMSA-N
DMY5HX6	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMY5HX6	DE	Discovery agent

DMKLDWF	ID	DMKLDWF
DMKLDWF	DN	Tyr-Pro-Trp-Gly-Bn
DMKLDWF	HS	Investigative
DMKLDWF	SN	CHEMBL570634; Tyr-Pro-Trp-Gly-Bn
DMKLDWF	DT	Small molecular drug
DMKLDWF	PC	45487601
DMKLDWF	MW	610.7
DMKLDWF	FM	C34H38N6O5
DMKLDWF	IC	InChI=1S/C34H38N6O5/c35-27(17-22-12-14-25(41)15-13-22)34(45)40-16-6-11-30(40)33(44)39-29(18-24-20-36-28-10-5-4-9-26(24)28)32(43)38-21-31(42)37-19-23-7-2-1-3-8-23/h1-5,7-10,12-15,20,27,29-30,36,41H,6,11,16-19,21,35H2,(H,37,42)(H,38,43)(H,39,44)/t27-,29-,30-/m0/s1
DMKLDWF	CS	C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NCC5=CC=CC=C5
DMKLDWF	IK	BDVRZLFOEXKBFR-BKHJTQGXSA-N
DMKLDWF	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[2-(benzylamino)-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMKLDWF	DE	Discovery agent

DMIZB25	ID	DMIZB25
DMIZB25	DN	Tyr-Sar-Phe-D-2-Nal-NH2
DMIZB25	HS	Investigative
DMIZB25	SN	CHEMBL254926; Tyr-Sar-Phe-D-2-Nal-NH2
DMIZB25	DT	Small molecular drug
DMIZB25	PC	44447367
DMIZB25	MW	595.7
DMIZB25	FM	C34H37N5O5
DMIZB25	IC	InChI=1S/C34H37N5O5/c1-39(34(44)28(35)18-23-12-15-27(40)16-13-23)21-31(41)37-30(19-22-7-3-2-4-8-22)33(43)38-29(32(36)42)20-24-11-14-25-9-5-6-10-26(25)17-24/h2-17,28-30,40H,18-21,35H2,1H3,(H2,36,42)(H,37,41)(H,38,43)/t28-,29+,30-/m0/s1
DMIZB25	CS	CN(CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N)C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMIZB25	IK	GNWOYARHUGPZGJ-JBOQNHBVSA-N
DMIZB25	IU	(2S)-2-amino-N-[2-[[(2S)-1-[[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-3-(4-hydroxyphenyl)-N-methylpropanamide
DMIZB25	DE	Discovery agent

DMVCHOX	ID	DMVCHOX
DMVCHOX	DN	TZD18
DMVCHOX	HS	Investigative
DMVCHOX	SN	TZD 18; TZD-18
DMVCHOX	DT	Small molecular drug
DMVCHOX	PC	9827261
DMVCHOX	MW	477.6
DMVCHOX	FM	C27H27NO5S
DMVCHOX	IC	InChI=1S/C27H27NO5S/c1-2-8-19-17-23(33-21-10-4-3-5-11-21)13-14-24(19)32-16-7-15-31-22-12-6-9-20(18-22)25-26(29)28-27(30)34-25/h3-6,9-14,17-18,25H,2,7-8,15-16H2,1H3,(H,28,29,30)
DMVCHOX	CS	CCCC1=C(C=CC(=C1)OC2=CC=CC=C2)OCCCOC3=CC=CC(=C3)C4C(=O)NC(=O)S4
DMVCHOX	IK	ZNLPWBJCSSSCCR-UHFFFAOYSA-N
DMVCHOX	IU	5-[3-[3-(4-phenoxy-2-propylphenoxy)propoxy]phenyl]-1,3-thiazolidine-2,4-dione
DMVCHOX	DE	Discovery agent

DMSI0HE	ID	DMSI0HE
DMSI0HE	DN	TZI-41127
DMSI0HE	HS	Investigative
DMSI0HE	SN	Tzi-41127; 104007-80-9; 2-(4-Hydroxy-3,5-dimethylphenyl)-5-methoxy-3-methylindole; CHEMBL76586; Phenol,4-(5-methoxy-3-methyl-1H-indol-2-yl)-2,6-dimethyl-; OZFHUMGEWVYBRM-UHFFFAOYSA-N; ACMC-1BUG2; AC1L2TV9; SCHEMBL10459430; CTK4A2589; DTXSID20146217; Phenol, 4-(5-methoxy-3-methyl-1H-indol-2-yl)-2,6-dimethyl-; BDBM50283452; 4-(5-methoxy-3-methyl-1H-indol-2-yl)-2,6-dimethylphenol
DMSI0HE	DT	Small molecular drug
DMSI0HE	PC	128480
DMSI0HE	MW	281.3
DMSI0HE	FM	C18H19NO2
DMSI0HE	IC	InChI=1S/C18H19NO2/c1-10-7-13(8-11(2)18(10)20)17-12(3)15-9-14(21-4)5-6-16(15)19-17/h5-9,19-20H,1-4H3
DMSI0HE	CS	CC1=CC(=CC(=C1O)C)C2=C(C3=C(N2)C=CC(=C3)OC)C
DMSI0HE	IK	OZFHUMGEWVYBRM-UHFFFAOYSA-N
DMSI0HE	IU	4-(5-methoxy-3-methyl-1H-indol-2-yl)-2,6-dimethylphenol
DMSI0HE	CA	CAS 104007-80-9
DMSI0HE	DE	Discovery agent

DMD6CLG	ID	DMD6CLG
DMD6CLG	DN	TZP-201
DMD6CLG	HS	Investigative
DMD6CLG	SN	JTZ-2002; IBS-D therapeutic, Tranzyme; Irritable bowel syndrome (diarrhea type) therapeutic, Tranzyme; Motilin antagonists (IBS/ fuctional dyspepsia), Tranzyme; Motilin receptor antagonists (irritable bowel syndrome/ functional dyspepsia), Tranzyme; Motilin receptor antagonists (irritable bowel syndrome/diarrhea), Tranzyme
DMD6CLG	CP	Tranzyme Pharma Inc
DMD6CLG	DE	Diarrhea

DM31OGF	ID	DM31OGF
DM31OGF	DN	U0126
DM31OGF	HS	Investigative
DM31OGF	SN	U0126; 109511-58-2; U-0126; U 0126; 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene; UNII-8027P94HLL; CHEBI:64208; 8027P94HLL; (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylidene}butanedinitrile; FT-1069-1; 218601-62-8; Succinonitrile, bis(amino(o-aminophenylthio)methylene)-; Butanedinitrile, bis(amino((2-aminophenyl)thio)methylene)-; C18H16N6S2; (2z)-Bis{amino[(2-Aminophenyl)sulfanyl]methylidene}butanedinitrile; (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylene}succinonitrile
DM31OGF	DT	Small molecular drug
DM31OGF	PC	3006531
DM31OGF	MW	380.5
DM31OGF	FM	C18H16N6S2
DM31OGF	IC	InChI=1S/C18H16N6S2/c19-9-11(17(23)25-15-7-3-1-5-13(15)21)12(10-20)18(24)26-16-8-4-2-6-14(16)22/h1-8H,21-24H2/b17-11+,18-12+
DM31OGF	CS	C1=CC=C(C(=C1)N)S/C(=C(/C(=C(/SC2=CC=CC=C2N)\\N)/C#N)\\C#N)/N
DM31OGF	IK	DVEXZJFMOKTQEZ-JYFOCSDGSA-N
DM31OGF	IU	(2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanylmethylidene]butanedinitrile
DM31OGF	CA	CAS 218601-62-8
DM31OGF	CB	CHEBI:64208
DM31OGF	DE	Discovery agent

DM9GOAV	ID	DM9GOAV
DM9GOAV	DN	U101958
DM9GOAV	HS	Investigative
DM9GOAV	SN	U-101958; U 101958
DM9GOAV	DT	Small molecular drug
DM9GOAV	PC	5615
DM9GOAV	MW	339.5
DM9GOAV	FM	C21H29N3O
DM9GOAV	IC	InChI=1S/C21H29N3O/c1-17(2)25-20-10-7-13-22-21(20)23(3)19-11-14-24(15-12-19)16-18-8-5-4-6-9-18/h4-10,13,17,19H,11-12,14-16H2,1-3H3
DM9GOAV	CS	CC(C)OC1=C(N=CC=C1)N(C)C2CCN(CC2)CC3=CC=CC=C3
DM9GOAV	IK	WFLHEXUTTRRXFJ-UHFFFAOYSA-N
DM9GOAV	IU	N-(1-benzylpiperidin-4-yl)-N-methyl-3-propan-2-yloxypyridin-2-amine
DM9GOAV	CA	CAS 170856-57-2
DM9GOAV	DE	Discovery agent

DM0DMNS	ID	DM0DMNS
DM0DMNS	DN	U-44069
DM0DMNS	HS	Investigative
DM0DMNS	SN	5-trans U-44069; U-44069; CTK8G3685
DM0DMNS	DT	Small molecular drug
DM0DMNS	PC	5311386
DM0DMNS	MW	350.5
DM0DMNS	FM	C21H34O4
DM0DMNS	IC	InChI=1S/C21H34O4/c1-2-3-6-9-17(22)12-13-18-16-14-20(25-15-16)19(18)10-7-4-5-8-11-21(23)24/h4,7,12-13,16-20,22H,2-3,5-6,8-11,14-15H2,1H3,(H,23,24)/b7-4-,13-12+/t16-,17-,18-,19+,20-/m0/s1
DM0DMNS	CS	CCCCC[C@@H](/C=C/[C@H]1[C@H]2C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)OC2)O
DM0DMNS	IK	DJKDIKIDYDXHDD-IGUVKOCZSA-N
DM0DMNS	IU	(Z)-7-[(1S,4R,5S,6R)-5-[(E,3S)-3-hydroxyoct-1-enyl]-2-oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid
DM0DMNS	CA	CAS 56985-32-1
DM0DMNS	DE	Discovery agent

DM13FX4	ID	DM13FX4
DM13FX4	DN	U46619
DM13FX4	HS	Investigative
DM13FX4	SN	(Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-Hydroxyoct-1-enyl]-3-oxabicyclo[221]heptan-6-yl]hept-5-enoic acid; U 46619; MLS000028857; CHEMBL521784; U-46619; 56985-40-1; SMR000058897; (5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[221]hept-5-yl]-5-heptenoic acid; 9a,11a-Methanoepoxy-15-hydroxyprosta-5,13-dienoic acid; 9,11-Methanoepoxy PGH2; 11alpha,9alpha-epoxymethano-PGH2; 9alpha-PGM; (Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxabicyclo[221]heptan-6-yl]hept-5-enoic acid; 9alpha,11alpha-Methanoepoxy-PGF2alpha; Opera_ID_380; [3H]U46619; 9,11-Dideoxy-9alpha,11alpha-methanoepoxy PGF2alpha;  U 46619
DM13FX4	DT	Small molecular drug
DM13FX4	PC	5311493
DM13FX4	MW	350.5
DM13FX4	FM	C21H34O4
DM13FX4	IC	InChI=1S/C21H34O4/c1-2-3-6-9-17(22)12-13-19-18(16-14-20(19)25-15-16)10-7-4-5-8-11-21(23)24/h4,7,12-13,16-20,22H,2-3,5-6,8-11,14-15H2,1H3,(H,23,24)/b7-4-,13-12+/t16-,17+,18+,19-,20-/m1/s1
DM13FX4	CS	CCCCC[C@@H](/C=C/[C@H]1[C@H]2C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)CO2)O
DM13FX4	IK	LQANGKSBLPMBTJ-BRSNVKEHSA-N
DM13FX4	IU	(Z)-7-[(1R,4S,5S,6R)-6-[(E,3S)-3-hydroxyoct-1-enyl]-2-oxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
DM13FX4	CA	CAS 56985-40-1
DM13FX4	DE	Discovery agent

DMYW1VP	ID	DMYW1VP
DMYW1VP	DN	U50,488H
DMYW1VP	HS	Investigative
DMYW1VP	SN	U50488; U-50488; U 50488; U50,488; U-50488H; U50488H; U-50,488; U 50,488; CHEMBL441765; CHEBI:73358; 67198-13-4; trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzeneacetamide; 2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide; 2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-(pyrrolidin-1-yl)cyclohexyl]acetamide; Benzeneacetamide, 3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-, trans-; NIH 10533; Lopac-U-110; Lopac-U-111; AC1MI0XE; 83913-05-7; C11796
DMYW1VP	DT	Small molecular drug
DMYW1VP	PC	135349
DMYW1VP	MW	465.4
DMYW1VP	FM	C20H30Cl2N2O4S
DMYW1VP	IC	InChI=1S/C19H26Cl2N2O.CH4O3S/c1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23;1-5(2,3)4/h8-9,12,17-18H,2-7,10-11,13H2,1H3;1H3,(H,2,3,4)/t17-,18-;/m1./s1
DMYW1VP	CS	CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl.CS(=O)(=O)O
DMYW1VP	IK	OJPHNZCUXUUVKU-JAXOOIEVSA-N
DMYW1VP	IU	2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide;methanesulfonic acid
DMYW1VP	CA	CAS 83913-06-8
DMYW1VP	DE	Discovery agent

DMQT6AH	ID	DMQT6AH
DMQT6AH	DN	U-89267
DMQT6AH	HS	Investigative
DMQT6AH	SN	CHEMBL142750; U-89267; SCHEMBL8883956; BDBM50040717; (S)-1-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-10,11,12,12a-tetrahydroimidazo[1,5-a]pyrrolo[2,1-c]quinoxalin-10-one; 1-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-10,11,12,12a-tetrahydroimidazo[1,5-a]pyrrolo[2,1-c]quinoxalin-10-one
DMQT6AH	DT	Small molecular drug
DMQT6AH	PC	9840599
DMQT6AH	MW	333.3
DMQT6AH	FM	C18H15N5O2
DMQT6AH	IC	InChI=1S/C18H15N5O2/c24-14-8-7-13-16-15(17-20-18(25-21-17)10-5-6-10)19-9-22(16)11-3-1-2-4-12(11)23(13)14/h1-4,9-10,13H,5-8H2
DMQT6AH	CS	C1CC1C2=NC(=NO2)C3=C4C5CCC(=O)N5C6=CC=CC=C6N4C=N3
DMQT6AH	IK	KIGZWNHARYMTNM-UHFFFAOYSA-N
DMQT6AH	IU	5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-2,4,11-triazatetracyclo[10.4.0.02,6.07,11]hexadeca-1(16),3,5,12,14-pentaen-10-one
DMQT6AH	DE	Discovery agent

DMI6VAX	ID	DMI6VAX
DMI6VAX	DN	U-89854
DMI6VAX	HS	Investigative
DMI6VAX	CP	Pharmacia & Upjohn Co
DMI6VAX	DE	Anxiety disorder

DM7CJNE	ID	DM7CJNE
DM7CJNE	DN	U92016A
DM7CJNE	HS	Investigative
DM7CJNE	SN	U-92,016-A; U-92016A
DM7CJNE	DT	Small molecular drug
DM7CJNE	PC	9904242
DM7CJNE	MW	295.4
DM7CJNE	FM	C19H25N3
DM7CJNE	IC	InChI=1S/C19H25N3/c1-3-9-22(10-4-2)16-7-5-14-6-8-19-18(17(14)12-16)11-15(13-20)21-19/h6,8,11,16,21H,3-5,7,9-10,12H2,1-2H3/t16-/m1/s1
DM7CJNE	CS	CCCN(CCC)[C@@H]1CCC2=C(C1)C3=C(C=C2)NC(=C3)C#N
DM7CJNE	IK	WDDZPZKGLZNGEH-MRXNPFEDSA-N
DM7CJNE	IU	(8R)-8-(dipropylamino)-6,7,8,9-tetrahydro-3H-benzo[e]indole-2-carbonitrile
DM7CJNE	CA	CAS 149654-41-1
DM7CJNE	DE	Discovery agent

DMLUP30	ID	DMLUP30
DMLUP30	DN	UBIQUINONE-2
DMLUP30	HS	Investigative
DMLUP30	SN	Ubiquinone-2; Coenzyme Q2; Ubiquinone Q2; 606-06-4; Ubiquinone 2; UNII-I7T5V2W47R; I7T5V2W47R; CHEBI:46372; 2,3-Dimethoxy-5-geranyl-6-methyl-1,4-benzoquinone; (E)-2-(3,7-Dimethyl-2,6-octadienyl)-5,6-dimethoxy-3-methyl-p-benzoquinone; 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; 2,5-Cyclohexadiene-1,4-dione, 2-(3,7-dimethyl-2,6-octadienyl)-5,6-dimethoxy-3-methyl-; p-Benzoquinone, 2-(3,7-dimethyl-2,6-octadienyl)-5,6-dimethoxy-3-methyl-, (E)-
DMLUP30	DT	Small molecular drug
DMLUP30	PC	5280346
DMLUP30	MW	318.4
DMLUP30	FM	C19H26O4
DMLUP30	IC	InChI=1S/C19H26O4/c1-12(2)8-7-9-13(3)10-11-15-14(4)16(20)18(22-5)19(23-6)17(15)21/h8,10H,7,9,11H2,1-6H3/b13-10+
DMLUP30	CS	CC1=C(C(=O)C(=C(C1=O)OC)OC)C/C=C(\\C)/CCC=C(C)C
DMLUP30	IK	SQQWBSBBCSFQGC-JLHYYAGUSA-N
DMLUP30	IU	2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
DMLUP30	CA	CAS 606-06-4
DMLUP30	CB	CHEBI:46372
DMLUP30	DE	Discovery agent

DM6IG5J	ID	DM6IG5J
DM6IG5J	DN	UBP141
DM6IG5J	HS	Investigative
DM6IG5J	SN	UBP 141; UBP-141
DM6IG5J	DT	Small molecular drug
DM6IG5J	PC	9864550
DM6IG5J	MW	378.4
DM6IG5J	FM	C21H18N2O5
DM6IG5J	IC	InChI=1S/C21H18N2O5/c24-19(23-10-9-22-17(20(25)26)18(23)21(27)28)14-8-7-13-6-5-12-3-1-2-4-15(12)16(13)11-14/h1-8,11,17-18,22H,9-10H2,(H,25,26)(H,27,28)/t17-,18+/m0/s1
DM6IG5J	CS	C1CN([C@H]([C@H](N1)C(=O)O)C(=O)O)C(=O)C2=CC3=C(C=CC4=CC=CC=C43)C=C2
DM6IG5J	IK	VVUAQPXBYDYTDF-ZWKOTPCHSA-N
DM6IG5J	IU	(2R,3S)-1-(phenanthrene-3-carbonyl)piperazine-2,3-dicarboxylic acid
DM6IG5J	DE	Discovery agent

DMSJLX0	ID	DMSJLX0
DMSJLX0	DN	UBP-302
DMSJLX0	HS	Investigative
DMSJLX0	SN	UBP 302; (S)-1-(2-AMINO-2-CARBOXYETHYL)-3-(2-CARBOXYBENZYL)PYRIMIDINE-2,4-DIONE; UBP302; CHEMBL372797; 745055-91-8; UBC; Tocris-2079; AC1O4WKY; SCHEMBL2265710; GTPL4333; DTXSID80423571; MolPort-003-983-705; 2f35; ZINC3996041; BDBM50178136; BN0533; AKOS024456932; NCGC00025352-01; UBP302, &gt; B6942; SR-01000597533; SR-01000597533-1; (S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)-pyrimidine-2,4-dione; 2-[[3-[(2S)-2-amino-3-hydroxy-3-oxopropyl]-2,6-dioxopyrimidin-1-yl]methyl]benzoic acid
DMSJLX0	DT	Small molecular drug
DMSJLX0	PC	6420161
DMSJLX0	MW	333.3
DMSJLX0	FM	C15H15N3O6
DMSJLX0	IC	InChI=1S/C15H15N3O6/c16-11(14(22)23)8-17-6-5-12(19)18(15(17)24)7-9-3-1-2-4-10(9)13(20)21/h1-6,11H,7-8,16H2,(H,20,21)(H,22,23)/t11-/m0/s1
DMSJLX0	CS	C1=CC=C(C(=C1)CN2C(=O)C=CN(C2=O)C[C@@H](C(=O)O)N)C(=O)O
DMSJLX0	IK	UUIYULWYHDSXHL-NSHDSACASA-N
DMSJLX0	IU	2-[[3-[(2S)-2-amino-2-carboxyethyl]-2,6-dioxopyrimidin-1-yl]methyl]benzoic acid
DMSJLX0	CA	CAS 745055-91-8
DMSJLX0	DE	Discovery agent

DMVQL3J	ID	DMVQL3J
DMVQL3J	DN	UBP310
DMVQL3J	HS	Investigative
DMVQL3J	SN	(S)-1-(2-Amino-2-carboxyethyl)-3(2-carboxythiophene-3-YL-methyl)-5-methylpyrimidine-2,4-dione; UBP 310; UBP-310; CHEMBL373428; (S)-1-(2-AMINO-2-CARBOXYETHYL)-3(2-CARBOXYTHIOPHENE-3-YL-METHYL)-5-METHYLPYRIMIDINE-2,4-DIONE; UBA; 3-[[3-[(2S)-2-amino-3-hydroxy-3-oxopropyl]-5-methyl-2,6-dioxopyrimidin-1-yl]methyl]thiophene-2-carboxylic acid; [3H]UBP310; AC1O4WKX; GTPL4334; GTPL4092; SCHEMBL15959446; ZTAZUCRXCRXNSU-VIFPVBQESA-N; MolPort-006-069-045; 2f34; ZINC16052001; BDBM50207593; AKOS024457719; NCGC00370889-01;  UBP-310
DMVQL3J	DT	Small molecular drug
DMVQL3J	PC	6420160
DMVQL3J	MW	353.35
DMVQL3J	FM	C14H15N3O6S
DMVQL3J	IC	InChI=1S/C14H15N3O6S/c1-7-4-16(6-9(15)12(19)20)14(23)17(11(7)18)5-8-2-3-24-10(8)13(21)22/h2-4,9H,5-6,15H2,1H3,(H,19,20)(H,21,22)/t9-/m0/s1
DMVQL3J	CS	CC1=CN(C(=O)N(C1=O)CC2=C(SC=C2)C(=O)O)C[C@@H](C(=O)O)N
DMVQL3J	IK	ZTAZUCRXCRXNSU-VIFPVBQESA-N
DMVQL3J	IU	3-[[3-[(2S)-2-amino-2-carboxyethyl]-5-methyl-2,6-dioxopyrimidin-1-yl]methyl]thiophene-2-carboxylic acid
DMVQL3J	DE	Discovery agent

DMCRFT5	ID	DMCRFT5
DMCRFT5	DN	UC-1011
DMCRFT5	HS	Investigative
DMCRFT5	SN	UC-2021; UC-2025; GABA A receptor antagonists (Alzheimer's disease); GABA A receptor antagonists (Alzheimer's disease), Umecrine; 3beta-20beta-dihydroxy-5alpha-pregnane; 3beta-20beta-dihydroxy-5alpha-pregnane (Alzheimer's disease), Umecrine
DMCRFT5	CP	Umecrine AB
DMCRFT5	DE	Alzheimer disease

DMJVT4K	ID	DMJVT4K
DMJVT4K	DN	UC-2024
DMJVT4K	HS	Investigative
DMJVT4K	CP	Umecrine AB
DMJVT4K	DE	Premenstrual syndrome

DMGSOZ7	ID	DMGSOZ7
DMGSOZ7	DN	UC-2029
DMGSOZ7	HS	Investigative
DMGSOZ7	CP	Umecrine AB
DMGSOZ7	DE	Premenstrual syndrome

DMHYORU	ID	DMHYORU
DMHYORU	DN	UCB-101333-3
DMHYORU	HS	Investigative
DMHYORU	SN	UCB-101333-3; CHEMBL205654; SCHEMBL460823; XMDRTFUFPOAGDR-UHFFFAOYSA-N; BDBM50181089; 6-(1-azepanyl)-N,2-dicyclopropyl-5-methyl-4-pyrimidinamine
DMHYORU	DT	Small molecular drug
DMHYORU	PC	10125445
DMHYORU	MW	286.4
DMHYORU	FM	C17H26N4
DMHYORU	IC	InChI=1S/C17H26N4/c1-12-15(18-14-8-9-14)19-16(13-6-7-13)20-17(12)21-10-4-2-3-5-11-21/h13-14H,2-11H2,1H3,(H,18,19,20)
DMHYORU	CS	CC1=C(N=C(N=C1N2CCCCCC2)C3CC3)NC4CC4
DMHYORU	IK	XMDRTFUFPOAGDR-UHFFFAOYSA-N
DMHYORU	IU	6-(azepan-1-yl)-N,2-dicyclopropyl-5-methylpyrimidin-4-amine
DMHYORU	DE	Discovery agent

DMFUE43	ID	DMFUE43
DMFUE43	DN	UCB-1277763
DMFUE43	HS	Investigative
DMFUE43	SN	P38 kinase inhibitors (inflammation), UCB
DMFUE43	CP	UCB SA
DMFUE43	DE	Inflammation

DMQ20A4	ID	DMQ20A4
DMQ20A4	DN	UCB-2892
DMQ20A4	HS	Investigative
DMQ20A4	SN	H3 antagonist (cognitive disorders); H3 antagonist (cognitive disorders), UCB
DMQ20A4	CP	UCB SA
DMQ20A4	DE	Cognitive impairment

DMQB8C3	ID	DMQB8C3
DMQB8C3	DN	UCB35625
DMQB8C3	HS	Investigative
DMQB8C3	SN	UCB 35625; UCB-35625
DMQB8C3	DT	Small molecular drug
DMQB8C3	PC	458342
DMQB8C3	MW	502.5
DMQB8C3	FM	C28H35Cl2N2O2+
DMQB8C3	IC	InChI=1S/C28H34Cl2N2O2/c1-32(18-19-6-4-2-3-5-7-19)14-12-22(13-15-32)31-28(33)27-23-16-20(29)8-10-25(23)34-26-11-9-21(30)17-24(26)27/h8-11,16-17,19,22,27H,2-7,12-15,18H2,1H3/p+1
DMQB8C3	CS	C[N+]1(CCC(CC1)NC(=O)C2C3=C(C=CC(=C3)Cl)OC4=C2C=C(C=C4)Cl)CC5CCCCCC5
DMQB8C3	IK	AHYGVFSLUXGXSH-UHFFFAOYSA-O
DMQB8C3	IU	2,7-dichloro-N-[1-(cycloheptylmethyl)-1-methylpiperidin-1-ium-4-yl]-9H-xanthene-9-carboxamide
DMQB8C3	DE	Discovery agent

DMO9S5P	ID	DMO9S5P
DMO9S5P	DN	UCCF-029
DMO9S5P	HS	Investigative
DMO9S5P	SN	2-Pyridin-4-yl-benzo[h]chromen-4-one; UCCF-029; 2110-25-0; CHEMBL177991; 2-(pyridin-4-yl)-4H-benzo[h]chromen-4-one; BAS 12813734; AC1MKUU0; MLS001209162; ZINC9006; SCHEMBL4069839; GTPL4335; CTK7H2722; DTXSID20390354; CHEBI:116557; HMS2841G23; BDBM50159612; 2-(4-pyridyl)benzo[h]chromen-4-one; 2-pyridin-4-ylbenzo[h]chromen-4-one; AKOS000507523; MCULE-4590967836; 2-(pyridin-4-yl)benzo[h]chromen-4-one; SMR000525005; TR-043515; ST50294170; EC-000.1914; 4-(4-Oxo-4H-benzo[h]chromen-2-yl)-pyridinium; J-013846
DMO9S5P	DT	Small molecular drug
DMO9S5P	PC	3163532
DMO9S5P	MW	273.3
DMO9S5P	FM	C18H11NO2
DMO9S5P	IC	InChI=1S/C18H11NO2/c20-16-11-17(13-7-9-19-10-8-13)21-18-14-4-2-1-3-12(14)5-6-15(16)18/h1-11H
DMO9S5P	CS	C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CC=NC=C4
DMO9S5P	IK	LZCOBWKVDSSOBB-UHFFFAOYSA-N
DMO9S5P	IU	2-pyridin-4-ylbenzo[h]chromen-4-one
DMO9S5P	CA	CAS 2110-25-0
DMO9S5P	CB	CHEBI:116557
DMO9S5P	DE	Discovery agent

DM3I9JG	ID	DM3I9JG
DM3I9JG	DN	UCCF-339
DM3I9JG	HS	Investigative
DM3I9JG	SN	652138-15-3; UCCF-339; GTPL4337; CTK1J8227; DTXSID60799206; 6-(furan-2-yl)-2-(pyridin-4-yl)-4H-benzo[h]chromen-4-one; 4H-Naphtho[1,2-b]pyran-4-one, 6-(2-furanyl)-2-(4-pyridinyl)-
DM3I9JG	DT	Small molecular drug
DM3I9JG	PC	71376521
DM3I9JG	MW	339.3
DM3I9JG	FM	C22H13NO3
DM3I9JG	IC	InChI=1S/C22H13NO3/c24-19-13-21(14-7-9-23-10-8-14)26-22-16-5-2-1-4-15(16)17(12-18(19)22)20-6-3-11-25-20/h1-13H
DM3I9JG	CS	C1=CC=C2C(=C1)C(=CC3=C2OC(=CC3=O)C4=CC=NC=C4)C5=CC=CO5
DM3I9JG	IK	YYRINQRAIIGEQV-UHFFFAOYSA-N
DM3I9JG	IU	6-(furan-2-yl)-2-pyridin-4-ylbenzo[h]chromen-4-one
DM3I9JG	CA	CAS 652138-15-3
DM3I9JG	DE	Discovery agent

DMN9QO4	ID	DMN9QO4
DMN9QO4	DN	UCCF-853
DMN9QO4	HS	Investigative
DMN9QO4	SN	UCCF-853; 625458-06-2; 1-(3-chlorophenyl)-5-trifluoromethyl-3-hydrobenzimidazol-2-one; GTPL4338; SCHEMBL15070016; DTXSID40590778; ZINC22115075; 1-(3-Chloro-phenyl)-5-trifluoromethyl-1,3-dihydro-benzoimidazol-2-one; KB-08685; KB-08684; EC-000.1912; 1-(3-chlorophenyl)-5-trifluoromethyl-1,3-dihydrobenzoimidazol-2-one; 1-(3-Chlorophenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-benzimidazol-2-one
DMN9QO4	DT	Small molecular drug
DMN9QO4	PC	17750928
DMN9QO4	MW	312.67
DMN9QO4	FM	C14H8ClF3N2O
DMN9QO4	IC	InChI=1S/C14H8ClF3N2O/c15-9-2-1-3-10(7-9)20-12-5-4-8(14(16,17)18)6-11(12)19-13(20)21/h1-7H,(H,19,21)
DMN9QO4	CS	C1=CC(=CC(=C1)Cl)N2C3=C(C=C(C=C3)C(F)(F)F)NC2=O
DMN9QO4	IK	NMPJFFWYEIIGFW-UHFFFAOYSA-N
DMN9QO4	IU	3-(3-chlorophenyl)-6-(trifluoromethyl)-1H-benzimidazol-2-one
DMN9QO4	CA	CAS 625458-06-2
DMN9QO4	DE	Discovery agent

DMZNJFU	ID	DMZNJFU
DMZNJFU	DN	UCL1684
DMZNJFU	HS	Investigative
DMZNJFU	SN	UCL-1684
DMZNJFU	DT	Small molecular drug
DMZNJFU	PC	656733
DMZNJFU	MW	494.6
DMZNJFU	FM	C34H30N4+2
DMZNJFU	IC	InChI=1S/C34H28N4/c1-3-10-33-29(8-1)31-16-18-37(33)23-27-6-5-7-28(20-27)24-38-19-17-32(30-9-2-4-11-34(30)38)36-22-26-14-12-25(13-15-26)21-35-31/h1-20H,21-24H2/p+2
DMZNJFU	CS	C1C2=CC=C(CNC3=CC=[N+](CC4=CC=CC(=C4)C[N+]5=CC=C(N1)C6=CC=CC=C65)C7=CC=CC=C37)C=C2
DMZNJFU	IK	HZWVJPDDZQOYGA-UHFFFAOYSA-P
DMZNJFU	IU	17,24-diaza-1,9-diazoniaheptacyclo[23.6.2.29,16.219,22.13,7.010,15.026,31]octatriaconta-1(32),3(38),4,6,9(37),10,12,14,16(36),19,21,25(33),26,28,30,34-hexadecaene
DMZNJFU	CB	CHEBI:35040
DMZNJFU	DE	Discovery agent

DM2CN0A	ID	DM2CN0A
DM2CN0A	DN	UCL1848
DM2CN0A	HS	Investigative
DM2CN0A	SN	UCL-1848
DM2CN0A	DT	Small molecular drug
DM2CN0A	PC	9811445
DM2CN0A	MW	426.6
DM2CN0A	FM	C28H34N4+2
DM2CN0A	IC	InChI=1S/C28H32N4/c1-7-17-29-25-15-21-31(27-13-5-3-11-23(25)27)19-9-2-10-20-32-22-16-26(30-18-8-1)24-12-4-6-14-28(24)32/h3-6,11-16,21-22H,1-2,7-10,17-20H2/p+2
DM2CN0A	CS	C1CCNC2=CC=[N+](CCCCC[N+]3=CC=C(C4=CC=CC=C43)NCC1)C5=CC=CC=C25
DM2CN0A	IK	IOXVWOJJNCBJBX-UHFFFAOYSA-P
DM2CN0A	IU	15,21-diaza-1,7-diazoniapentacyclo[20.6.2.27,14.08,13.023,28]dotriaconta-1(29),7(32),8,10,12,14(31),22(30),23,25,27-decaene
DM2CN0A	CA	CAS 201147-53-7
DM2CN0A	DE	Discovery agent

DM0P5Z9	ID	DM0P5Z9
DM0P5Z9	DN	UCL1972
DM0P5Z9	HS	Investigative
DM0P5Z9	SN	CHEMBL289855; UCL-1972; 1-[5-(4-nitrophenoxy)pentyl]pyrrolidine; 1-(5-(4-nitrophenoxy)pentyl)pyrrolidine; SCHEMBL490968; BDBM50089295; 1-[5-(4-Nitro-phenoxy)-pentyl]-pyrrolidine; L019446
DM0P5Z9	DT	Small molecular drug
DM0P5Z9	PC	9925627
DM0P5Z9	MW	278.35
DM0P5Z9	FM	C15H22N2O3
DM0P5Z9	IC	InChI=1S/C15H22N2O3/c18-17(19)14-6-8-15(9-7-14)20-13-5-1-2-10-16-11-3-4-12-16/h6-9H,1-5,10-13H2
DM0P5Z9	CS	C1CCN(C1)CCCCCOC2=CC=C(C=C2)[N+](=O)[O-]
DM0P5Z9	IK	ITOJPDNONZGUKB-UHFFFAOYSA-N
DM0P5Z9	IU	1-[5-(4-nitrophenoxy)pentyl]pyrrolidine
DM0P5Z9	DE	Discovery agent

DM15CJZ	ID	DM15CJZ
DM15CJZ	DN	UCL-2138
DM15CJZ	HS	Investigative
DM15CJZ	SN	UCL-2138; CHEMBL129257; 4-(3-piperidin-1-ylpropoxy)benzonitrile; Benzonitrile, 4-[3-(1-piperidinyl)propoxy]-; 146440-20-2; AC1MGZLJ; ACMC-20n4tz; SCHEMBL491825; GTPL1257; CTK0B2418; DTXSID60388154; UCL2138; ZINC2009079; UCL 2138; PDSP2_000689; BDBM50133003; PDSP1_000699; AKOS009440882; MCULE-6416627117; 4-[3-(1-Piperidinyl)propoxy]benzonitrile; 4-(3-Piperidin-1-yl-propoxy)-benzonitrile; 4-(3-(piperidin-1-yl)propoxy)benzonitrile
DM15CJZ	DT	Small molecular drug
DM15CJZ	PC	2994072
DM15CJZ	MW	244.33
DM15CJZ	FM	C15H20N2O
DM15CJZ	IC	InChI=1S/C15H20N2O/c16-13-14-5-7-15(8-6-14)18-12-4-11-17-9-2-1-3-10-17/h5-8H,1-4,9-12H2
DM15CJZ	CS	C1CCN(CC1)CCCOC2=CC=C(C=C2)C#N
DM15CJZ	IK	RHMNKKOAWUCDRK-UHFFFAOYSA-N
DM15CJZ	IU	4-(3-piperidin-1-ylpropoxy)benzonitrile
DM15CJZ	CA	CAS 146440-20-2
DM15CJZ	DE	Discovery agent

DMFYUMX	ID	DMFYUMX
DMFYUMX	DN	UCL-67022
DMFYUMX	HS	Investigative
DMFYUMX	SN	HDAC inhibitor (multiple myeloma), ST Barts/UCL
DMFYUMX	CP	University College London
DMFYUMX	DE	Multiple myeloma

DM9JG1L	ID	DM9JG1L
DM9JG1L	DN	UCM 549
DM9JG1L	HS	Investigative
DM9JG1L	SN	UCM-549; UCM549
DM9JG1L	DT	Small molecular drug
DM9JG1L	PC	11185529
DM9JG1L	MW	295.4
DM9JG1L	FM	C19H21NO2
DM9JG1L	IC	InChI=1S/C19H21NO2/c1-13(21)20-12-17-10-15-6-4-3-5-14(15)9-16-7-8-18(22-2)11-19(16)17/h3-8,11,17H,9-10,12H2,1-2H3,(H,20,21)
DM9JG1L	CS	CC(=O)NCC1CC2=CC=CC=C2CC3=C1C=C(C=C3)OC
DM9JG1L	IK	PQZZGTZTKGECDT-UHFFFAOYSA-N
DM9JG1L	IU	N-[(6-methoxy-9-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)methyl]acetamide
DM9JG1L	DE	Discovery agent

DMCKSYQ	ID	DMCKSYQ
DMCKSYQ	DN	UCM 724
DMCKSYQ	HS	Investigative
DMCKSYQ	SN	UCM-724; UCM724
DMCKSYQ	DT	Small molecular drug
DMCKSYQ	PC	86277838
DMCKSYQ	MW	296.4
DMCKSYQ	FM	C18H20N2O2
DMCKSYQ	IC	InChI=1S/C18H20N2O2/c1-22-16-7-6-14-8-12-4-2-3-5-13(12)9-15(17(14)10-16)11-20-18(19)21/h2-7,10,15H,8-9,11H2,1H3,(H3,19,20,21)
DMCKSYQ	CS	COC1=CC2=C(CC3=CC=CC=C3CC2CNC(=O)N)C=C1
DMCKSYQ	IK	DIXNMQKCFFPTKU-UHFFFAOYSA-N
DMCKSYQ	IU	(6-methoxy-9-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)methylurea
DMCKSYQ	DE	Discovery agent

DMD16MH	ID	DMD16MH
DMD16MH	DN	UCM 765
DMD16MH	HS	Investigative
DMD16MH	SN	UCM-765; UCM765
DMD16MH	DT	Small molecular drug
DMD16MH	PC	24749950
DMD16MH	MW	284.35
DMD16MH	FM	C17H20N2O2
DMD16MH	IC	InChI=1S/C17H20N2O2/c1-14(20)18-12-13-19(15-6-4-3-5-7-15)16-8-10-17(21-2)11-9-16/h3-11H,12-13H2,1-2H3,(H,18,20)
DMD16MH	CS	CC(=O)NCCN(C1=CC=CC=C1)C2=CC=C(C=C2)OC
DMD16MH	IK	PWTCGLHUMIIRML-UHFFFAOYSA-N
DMD16MH	IU	N-[2-(N-(4-methoxyphenyl)anilino)ethyl]acetamide
DMD16MH	DE	Discovery agent

DM8J41W	ID	DM8J41W
DM8J41W	DN	UCM 793
DM8J41W	HS	Investigative
DM8J41W	SN	UCM-793; UCM793
DM8J41W	DT	Small molecular drug
DM8J41W	PC	24750192
DM8J41W	MW	222.28
DM8J41W	FM	C12H18N2O2
DM8J41W	IC	InChI=1S/C12H18N2O2/c1-10(15)13-7-8-14(2)11-5-4-6-12(9-11)16-3/h4-6,9H,7-8H2,1-3H3,(H,13,15)
DM8J41W	CS	CC(=O)NCCN(C)C1=CC(=CC=C1)OC
DM8J41W	IK	FAWOXVGCBAVSFR-UHFFFAOYSA-N
DM8J41W	IU	N-[2-(3-methoxy-N-methylanilino)ethyl]acetamide
DM8J41W	DE	Discovery agent

DMSVJFG	ID	DMSVJFG
DMSVJFG	DN	UCM-454
DMSVJFG	HS	Investigative
DMSVJFG	SN	CHEMBL33185; UCM454; GTPL7783; UCM 454; BDBM50240442; N-[[1-[(4-chlorophenyl)methyl]-4-methoxyindol-2-yl]methyl]propanamide; N-[[1-(4-Chlorobenzyl)-4-methoxy-1H-indole-2-yl]methyl]propionamide; N-((1-(4-chlorobenzyl)-4-methoxy-1H-indol-2-yl)methyl)propionamide
DMSVJFG	DT	Small molecular drug
DMSVJFG	PC	10244841
DMSVJFG	MW	309.4
DMSVJFG	FM	C20H23NO2
DMSVJFG	IC	InChI=1S/C20H23NO2/c1-3-20(22)21-13-17-11-15-7-5-4-6-14(15)10-16-8-9-18(23-2)12-19(16)17/h4-9,12,17H,3,10-11,13H2,1-2H3,(H,21,22)
DMSVJFG	CS	CCC(=O)NCC1CC2=CC=CC=C2CC3=C1C=C(C=C3)OC
DMSVJFG	IK	FRJHLFANQUOSEH-UHFFFAOYSA-N
DMSVJFG	IU	N-[(6-methoxy-9-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)methyl]propanamide
DMSVJFG	DE	Discovery agent

DMOJ4TG	ID	DMOJ4TG
DMOJ4TG	DN	UCM-5600
DMOJ4TG	HS	Investigative
DMOJ4TG	SN	UCM-5600; CHEMBL12259; BDBM50240359; 1-[5-(4-Phenylpiperazino)pentyl]-1,2-dihydrobenzo[cd]indole-2-one; 1-(5-(4-phenylpiperazin-1-yl)pentyl)benzo[cd]indol-2(1H)-one
DMOJ4TG	DT	Small molecular drug
DMOJ4TG	PC	9843889
DMOJ4TG	MW	399.5
DMOJ4TG	FM	C26H29N3O
DMOJ4TG	IC	InChI=1S/C26H29N3O/c30-26-23-13-7-9-21-10-8-14-24(25(21)23)29(26)16-6-2-5-15-27-17-19-28(20-18-27)22-11-3-1-4-12-22/h1,3-4,7-14H,2,5-6,15-20H2
DMOJ4TG	CS	C1CN(CCN1CCCCCN2C3=CC=CC4=C3C(=CC=C4)C2=O)C5=CC=CC=C5
DMOJ4TG	IK	UPZHUDFDXXFEKG-UHFFFAOYSA-N
DMOJ4TG	IU	1-[5-(4-phenylpiperazin-1-yl)pentyl]benzo[cd]indol-2-one
DMOJ4TG	DE	Discovery agent

DMTQEDA	ID	DMTQEDA
DMTQEDA	DN	UCPH-101
DMTQEDA	HS	Investigative
DMTQEDA	SN	UCPH-101; UCPH 101; 1118460-77-7; UCPH101; 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile; 2-AMINO-5,6,7,8-TETRAHYDRO-4-(4-METHOXYPHENYL)-7-(NAPHTHALEN-1-YL)-5-OXO-4H-CHROMENE-3-CARBONITRILE; YBMGNDPBARCLFT-UHFFFAOYSA-N; SCHEMBL562822; GTPL4609; CTK8E8875; DTXSID80649375; MolPort-023-276-814; BCP29137; EX-A2602; AKOS024457635; CS-7960; HY-10914; RT-017609; J-002643; 2-Amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyran-3-carbonitrile
DMTQEDA	DT	Small molecular drug
DMTQEDA	PC	25223366
DMTQEDA	MW	422.5
DMTQEDA	FM	C27H22N2O3
DMTQEDA	IC	InChI=1S/C27H22N2O3/c1-31-19-11-9-17(10-12-19)25-22(15-28)27(29)32-24-14-18(13-23(30)26(24)25)21-8-4-6-16-5-2-3-7-20(16)21/h2-12,18,25H,13-14,29H2,1H3
DMTQEDA	CS	COC1=CC=C(C=C1)C2C(=C(OC3=C2C(=O)CC(C3)C4=CC=CC5=CC=CC=C54)N)C#N
DMTQEDA	IK	YBMGNDPBARCLFT-UHFFFAOYSA-N
DMTQEDA	IU	2-amino-4-(4-methoxyphenyl)-7-naphthalen-1-yl-5-oxo-4,6,7,8-tetrahydrochromene-3-carbonitrile
DMTQEDA	CA	CAS 1118460-77-7
DMTQEDA	DE	Discovery agent

DMMWHAV	ID	DMMWHAV
DMMWHAV	DN	UDP-beta-S
DMMWHAV	HS	Investigative
DMMWHAV	SN	UDP-beta-S; CHEMBL2086770; SCHEMBL2705698; GTPL1750; BDBM50421169; dihydroxyphosphinothioyl [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMMWHAV	DT	Small molecular drug
DMMWHAV	PC	22960366
DMMWHAV	MW	420.23
DMMWHAV	FM	C9H14N2O11P2S
DMMWHAV	IC	InChI=1S/C9H14N2O11P2S/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(21-8)3-20-23(16,17)22-24(18,19)25/h1-2,4,6-8,13-14H,3H2,(H,16,17)(H,10,12,15)(H2,18,19,25)/t4-,6-,7-,8-/m1/s1
DMMWHAV	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=S)(O)O)O)O
DMMWHAV	IK	HFPQTPQWHHTLHT-XVFCMESISA-N
DMMWHAV	IU	dihydroxyphosphinothioyl [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMMWHAV	DE	Discovery agent

DMLT4JA	ID	DMLT4JA
DMLT4JA	DN	UDP-glucose
DMLT4JA	HS	Investigative
DMLT4JA	SN	Uridine-5'-diphosphate-glucose; URIDINE DIPHOSPHATE GLUCOSE; UDPG; UDP-alpha-D-Glucose; 133-89-1; UNII-V50K1D7P4Y; URIDINE-5'-DIPHOSPHATE-GLUCOSE; 5'-Diphosphoglucose; UDP-D-glucose; GLUCOSE-URIDINE-C1,5'-DIPHOSPHATE; UDPglucose; V50K1D7P4Y; CHEBI:46229; URIDINE-5'-DIPHOSPHOGLUCOSE; UDP-Glc; Uridine diphosphoglucose; Uridine 5'-diphosphoglucose; co-waldenase; URIDINE-5'-MONOPHOSPHATE GLUCOPYRANOSYL-MONOPHOSPHATE ESTER; co-galactoisomerase; [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl];  uridine diphosphate glucose; Glucose-Uridine-C1,5'-Diphosphate
DMLT4JA	DT	Small molecular drug
DMLT4JA	PC	8629
DMLT4JA	MW	566.3
DMLT4JA	FM	C15H24N2O17P2
DMLT4JA	IC	InChI=1S/C15H24N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8-,9-,10+,11-,12-,13-,14-/m1/s1
DMLT4JA	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O
DMLT4JA	IK	HSCJRCZFDFQWRP-JZMIEXBBSA-N
DMLT4JA	IU	[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
DMLT4JA	CA	CAS 133-89-1
DMLT4JA	CB	CHEBI:46229
DMLT4JA	DE	Discovery agent

DMW16X2	ID	DMW16X2
DMW16X2	DN	UDP-glucuronic acid
DMW16X2	HS	Investigative
DMW16X2	SN	UDP glucuronic acid; UDP-glucuronate; UDPGA; uridine diphosphate glucuronic acid
DMW16X2	DT	Small molecular drug
DMW16X2	PC	17473
DMW16X2	MW	580.28
DMW16X2	FM	C15H22N2O18P2
DMW16X2	IC	InChI=1S/C15H22N2O18P2/c18-5-1-2-17(15(26)16-5)12-9(22)6(19)4(32-12)3-31-36(27,28)35-37(29,30)34-14-10(23)7(20)8(21)11(33-14)13(24)25/h1-2,4,6-12,14,19-23H,3H2,(H,24,25)(H,27,28)(H,29,30)(H,16,18,26)/t4-,6-,7+,8+,9-,10-,11+,12-,14-/m1/s1
DMW16X2	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)O)O
DMW16X2	IK	HDYANYHVCAPMJV-LXQIFKJMSA-N
DMW16X2	IU	(2S,3S,4S,5R,6R)-6-[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMW16X2	CA	CAS 2616-64-0
DMW16X2	CB	CHEBI:17200
DMW16X2	DE	Discovery agent

DMVE7MZ	ID	DMVE7MZ
DMVE7MZ	DN	UDP-xylose
DMVE7MZ	HS	Investigative
DMVE7MZ	SN	Udp xylose; UDP-xylose; UDP-ALPHA-D-XYLOPYRANOSE; URIDINE-5'-DIPHOSPHATE-XYLOPYRANOSE; URIDINE DIPHOSPHATE XYLOSE; UDP-alpha-D-xylose; Uridine 5'-(trihydrogen diphosphate), P'-alpha-D-xylopyranosyl ester; 3616-06-6; UDP-D-xylose; uridine 5'-[3-(alpha-D-xylopyranosyl) dihydrogen diphosphate]; UDX; UDPxylose; UDP-a-D-xylose; AC1L2DQI; P1-a-D-xylopyranosyl ester; Mono-a-D-xylopyranosyl ester; GTPL4730; CHEBI:16082; ZINC8551129; DB01713; Uridine 51-pyrophosphate, a-D-xylopyranosyl ester; J-700264; Uridine 5'-diphosphoric acid beta-a
DMVE7MZ	DT	Small molecular drug
DMVE7MZ	PC	19235
DMVE7MZ	MW	536.28
DMVE7MZ	FM	C14H22N2O16P2
DMVE7MZ	IC	InChI=1S/C14H22N2O16P2/c17-5-3-28-13(11(22)8(5)19)31-34(26,27)32-33(24,25)29-4-6-9(20)10(21)12(30-6)16-2-1-7(18)15-14(16)23/h1-2,5-6,8-13,17,19-22H,3-4H2,(H,24,25)(H,26,27)(H,15,18,23)/t5-,6-,8+,9-,10-,11-,12-,13-/m1/s1
DMVE7MZ	CS	C1[C@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)O)O)O
DMVE7MZ	IK	DQQDLYVHOTZLOR-OCIMBMBZSA-N
DMVE7MZ	IU	[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl] hydrogen phosphate
DMVE7MZ	CA	CAS 3616-06-6
DMVE7MZ	CB	CHEBI:16082
DMVE7MZ	DE	Discovery agent

DMKZF01	ID	DMKZF01
DMKZF01	DN	UFP-101
DMKZF01	HS	Investigative
DMKZF01	SN	[Nphe1,Arg14,Lys15]N/OFQ-NH2; UFP101; [Nphe1,Arg14,Lys15]nociceptin-NH2; UFP 101
DMKZF01	DT	Small molecular drug
DMKZF01	PC	25081457
DMKZF01	MW	1665.9
DMKZF01	FM	C73H124N28O17
DMKZF01	IC	InChI=1S/C73H124N28O17/c1-42(91-57(106)40-90-70(118)59(44(3)103)101-68(116)53(35-45-19-6-4-7-20-45)93-58(107)39-89-56(105)38-88-55(104)37-84-36-46-21-8-5-9-22-46)61(109)95-50(26-16-32-85-71(78)79)65(113)98-49(25-12-15-31-76)67(115)100-54(41-102)69(117)92-43(2)62(110)96-51(27-17-33-86-72(80)81)66(114)97-48(24-11-14-30-75)64(112)99-52(28-18-34-87-73(82)83)63(111)94-47(60(77)108)23-10-13-29-74/h4-9,19-22,42-44,47-54,59,84,102-103H,10-18,23-41,74-76H2,1-3H3,(H2,77,108)(H,88,104)(H,89,105)(H,90,118)(H,91,106)(H,92,117)(H,93,107)(H,94,111)(H,95,109)(H,96,110)(H,97,114)(H,98,113)(H,99,112)(H,100,115)(H,101,116)(H4,78,79,85)(H4,80,81,86)(H4,82,83,87)/t42-,43-,44+,47-,48-,49-,50-,51-,52-,53-,54-,59-/m0/s1
DMKZF01	CS	C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)CNCC2=CC=CC=C2)O
DMKZF01	IK	JEXLNFNIIVBCHM-OSMJMQRHSA-N
DMKZF01	IU	(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[2-(benzylamino)acetyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanamide
DMKZF01	DE	Discovery agent

DMENTMP	ID	DMENTMP
DMENTMP	DN	UFP-112
DMENTMP	HS	Investigative
DMENTMP	SN	[(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2; UFP112; UFP 112
DMENTMP	DT	Small molecular drug
DMENTMP	PC	44430609
DMENTMP	MW	1940.2
DMENTMP	FM	C83H139FN32O21
DMENTMP	IC	InChI=1S/C83H139FN32O21/c1-44(67(125)107-54(22-14-34-98-80(92)93)70(128)108-51(19-8-11-31-85)69(127)111-55(23-15-35-99-81(94)95)71(129)109-52(20-9-12-32-86)72(130)112-58(39-61(90)120)75(133)106-50(66(91)124)29-30-60(89)119)104-77(135)59(43-117)113-73(131)53(21-10-13-33-87)110-74(132)56(24-16-36-100-82(96)97)114-79(137)83(3,4)116-64(123)42-103-78(136)65(45(2)118)115-76(134)57(38-47-25-27-48(84)28-26-47)105-63(122)41-101-62(121)40-102-68(126)49(88)37-46-17-6-5-7-18-46/h5-7,17-18,25-28,44-45,49-59,65,117-118H,8-16,19-24,29-43,85-88H2,1-4H3,(H2,89,119)(H2,90,120)(H2,91,124)(H,101,121)(H,102,126)(H,103,136)(H,104,135)(H,105,122)(H,106,133)(H,107,125)(H,108,128)(H,109,129)(H,110,132)(H,111,127)(H,112,130)(H,113,131)(H,114,137)(H,115,134)(H,116,123)(H4,92,93,98)(H4,94,95,99)(H4,96,97,100)/t44-,45+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,65-/m0/s1
DMENTMP	CS	C[C@H]([C@@H](C(=O)NCC(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMENTMP	IK	GVIRJSRJRJCCJE-HCYVKCTOSA-N
DMENTMP	IU	(2S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-(4-fluorophenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-2-methylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMENTMP	DE	Discovery agent

DMD8BRG	ID	DMD8BRG
DMD8BRG	DN	UFP-502
DMD8BRG	HS	Investigative
DMD8BRG	SN	UFP-502; CHEMBL109390; H-Dmt-Tic-NH-CH2-Bid; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (1H-benzoimidazol-2-ylmethyl)-amide; BDBM50179191; (S)-N-((1H-benzo[d]imidazol-2-yl)methyl)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
DMD8BRG	DT	Small molecular drug
DMD8BRG	PC	10345770
DMD8BRG	MW	497.6
DMD8BRG	FM	C29H31N5O3
DMD8BRG	IC	InChI=1S/C29H31N5O3/c1-17-11-21(35)12-18(2)22(17)14-23(30)29(37)34-16-20-8-4-3-7-19(20)13-26(34)28(36)31-15-27-32-24-9-5-6-10-25(24)33-27/h3-12,23,26,35H,13-16,30H2,1-2H3,(H,31,36)(H,32,33)/t23-,26-/m0/s1
DMD8BRG	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=NC5=CC=CC=C5N4)N)C)O
DMD8BRG	IK	XRZTZWCPHAJWJQ-OZXSUGGESA-N
DMD8BRG	IU	(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(1H-benzimidazol-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMD8BRG	DE	Discovery agent

DMYPVSJ	ID	DMYPVSJ
DMYPVSJ	DN	UFP-512
DMYPVSJ	HS	Investigative
DMYPVSJ	SN	UFP-512; CHEMBL442577; GTPL9006; BDBM50272169; H-Dmt-Tic-NH-CH(CH2-COOH)-Bid; H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid; (3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1H-benzimidazol-2-yl)propanoic acid; (S)-3-((S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-3-(1H-benzo[d]imidazol-2-yl)propanoic acid
DMYPVSJ	DT	Small molecular drug
DMYPVSJ	PC	10918703
DMYPVSJ	MW	555.6
DMYPVSJ	FM	C31H33N5O5
DMYPVSJ	IC	InChI=1S/C31H33N5O5/c1-17-11-21(37)12-18(2)22(17)14-23(32)31(41)36-16-20-8-4-3-7-19(20)13-27(36)30(40)35-26(15-28(38)39)29-33-24-9-5-6-10-25(24)34-29/h3-12,23,26-27,37H,13-16,32H2,1-2H3,(H,33,34)(H,35,40)(H,38,39)/t23-,26-,27-/m0/s1
DMYPVSJ	CS	CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC(=O)O)C4=NC5=CC=CC=C5N4)N)C)O
DMYPVSJ	IK	USVQTDLSVBRMCR-YGPDHOBYSA-N
DMYPVSJ	IU	(3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1H-benzimidazol-2-yl)propanoic acid
DMYPVSJ	DE	Discovery agent

DM5K6ZE	ID	DM5K6ZE
DM5K6ZE	DN	UH-232
DM5K6ZE	HS	Investigative
DM5K6ZE	SN	UH232; (1S,2R)-5-methoxy-1-methyl-N,N-dipropyl-1,2-dihydronaphthalen-2-amine; AC1NSK6H; GTPL957
DM5K6ZE	DT	Small molecular drug
DM5K6ZE	PC	6604756
DM5K6ZE	MW	275.4
DM5K6ZE	FM	C18H29NO
DM5K6ZE	IC	InChI=1S/C18H29NO/c1-5-12-19(13-6-2)17-11-10-16-15(14(17)3)8-7-9-18(16)20-4/h7-9,14,17H,5-6,10-13H2,1-4H3/t14-,17+/m0/s1
DM5K6ZE	CS	CCCN(CCC)[C@@H]1CCC2=C([C@@H]1C)C=CC=C2OC
DM5K6ZE	IK	BTOJYCTUJJHANF-WMLDXEAASA-N
DM5K6ZE	IU	(1S,2R)-5-methoxy-1-methyl-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine
DM5K6ZE	CA	CAS 95999-12-5
DM5K6ZE	CB	CHEBI:114198
DM5K6ZE	DE	Discovery agent

DM5NYWV	ID	DM5NYWV
DM5NYWV	DN	UH-301
DM5NYWV	HS	Investigative
DM5NYWV	SN	UNII-44B1597K8X; CHEMBL41716; 44B1597K8X; 127126-18-5; (R)-7-(Dipropylamino)-4-fluoro-5,6,7,8-tetrahydronaphthalen-1-ol; UH-301 free base, (R)-; Lopac0_001246; (R)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralin; GTPL3218; SCHEMBL7749343; (R)-(+)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralin; 1-Naphthalenol, 7-(dipropylamino)-4-fluoro-5,6,7,8-tetrahydro-, (R)-; CTK0C1981; ZINC3874894; BDBM50013020; 1-Naphthalenol, 7-(dipropylamino)-4-fluoro-5,6,7,8-tetrahydro-, (7R)-
DM5NYWV	DT	Small molecular drug
DM5NYWV	PC	122187
DM5NYWV	MW	265.37
DM5NYWV	FM	C16H24FNO
DM5NYWV	IC	InChI=1S/C16H24FNO/c1-3-9-18(10-4-2)12-5-6-13-14(11-12)16(19)8-7-15(13)17/h7-8,12,19H,3-6,9-11H2,1-2H3/t12-/m0/s1
DM5NYWV	CS	CCCN(CCC)[C@H]1CCC2=C(C=CC(=C2C1)O)F
DM5NYWV	IK	FNKBVTBXFLSTPB-LBPRGKRZSA-N
DM5NYWV	IU	(7S)-7-(dipropylamino)-4-fluoro-5,6,7,8-tetrahydronaphthalen-1-ol
DM5NYWV	CA	CAS 127126-21-0

DMT5UMG	ID	DMT5UMG
DMT5UMG	DN	UH-AH 37
DMT5UMG	HS	Investigative
DMT5UMG	SN	1-chloro-11-[2-(1-methylpiperidin-4-yl)acetyl]-5H-benzo[b][1,4]benzodiazepin-6-one; AC1L2V2Z; GTPL8583; SCHEMBL6746859; UFJWXHOFKIGIAF-UHFFFAOYSA-N; 6-Chloro-5-[(1-methylpiperidin-4-yl)acetyl]-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
DMT5UMG	DT	Small molecular drug
DMT5UMG	PC	129140
DMT5UMG	MW	383.9
DMT5UMG	FM	C21H22ClN3O2
DMT5UMG	IC	InChI=1S/C21H22ClN3O2/c1-24-11-9-14(10-12-24)13-19(26)25-18-8-3-2-5-15(18)21(27)23-17-7-4-6-16(22)20(17)25/h2-8,14H,9-13H2,1H3,(H,23,27)
DMT5UMG	CS	CN1CCC(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2C(=CC=C4)Cl
DMT5UMG	IK	UFJWXHOFKIGIAF-UHFFFAOYSA-N
DMT5UMG	IU	1-chloro-11-[2-(1-methylpiperidin-4-yl)acetyl]-5H-benzo[b][1,4]benzodiazepin-6-one
DMT5UMG	CA	CAS 120382-14-1
DMT5UMG	DE	Discovery agent

DMOVY6L	ID	DMOVY6L
DMOVY6L	DN	Uinagolide
DMOVY6L	HS	Investigative
DMOVY6L	SN	Quinagolidum [INN-Latin]; Quinagolida [INN-Spanish]; 3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline; Quinagolide [BAN:INN]; BRN 6074559; AC1L1JHQ; SCHEMBL678170; quinagolide, (3alpha,4aalpha,10abeta)-(+-)-isomer; CHEMBL2218861
DMOVY6L	DT	Small molecular drug
DMOVY6L	PC	55645
DMOVY6L	MW	395.6
DMOVY6L	FM	C20H33N3O3S
DMOVY6L	IC	InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3
DMOVY6L	CS	CCCN1CC(CC2C1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC
DMOVY6L	IK	GDFGTRDCCWFXTG-UHFFFAOYSA-N
DMOVY6L	IU	3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
DMOVY6L	DE	Discovery agent

DM6GLSF	ID	DM6GLSF
DM6GLSF	DN	UK-129485
DM6GLSF	HS	Investigative
DM6GLSF	SN	UK-129485; CHEMBL42906; 8-Ethyl-6-methoxy-3-methyl-8H-1,3a,7,8,9-pentaaza-dibenzo[e,h]azulene; AC1L9UO4; CTK7A8639; BDBM50050632; UK-129,485
DM6GLSF	DT	Small molecular drug
DM6GLSF	PC	476263
DM6GLSF	MW	307.35
DM6GLSF	FM	C17H17N5O
DM6GLSF	IC	InChI=1S/C17H17N5O/c1-4-21-15-12(6-5-9-18-15)16-19-10-11(2)22(16)13-7-8-14(23-3)20-17(13)21/h5-10H,4H2,1-3H3
DM6GLSF	CS	CCN1C2=C(C=CC=N2)C3=NC=C(N3C4=C1N=C(C=C4)OC)C
DM6GLSF	IK	WCIBELXOPRCLEG-UHFFFAOYSA-N
DM6GLSF	IU	13-ethyl-16-methoxy-3-methyl-2,5,11,13,15-pentazatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),3,5,7(12),8,10,15,17-octaene
DM6GLSF	DE	Discovery agent

DM02FGH	ID	DM02FGH
DM02FGH	DN	UK-356618
DM02FGH	HS	Investigative
DM02FGH	SN	UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide
DM02FGH	DT	Small molecular drug
DM02FGH	PC	10370504
DM02FGH	MW	557.7
DM02FGH	FM	C34H43N3O4
DM02FGH	IC	InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1
DM02FGH	CS	CC1=C(C=CC(=C1)CCC[C@H](CC(=O)NO)C(=O)N[C@H](C(=O)N[C@H](C)C2=CC=CC=C2)C(C)(C)C)C3=CC=CC=C3
DM02FGH	IK	JJHRUUKMPWUYIB-HVOSOHGQSA-N
DM02FGH	IU	(2R)-N-[(2S)-3,3-dimethyl-1-oxo-1-[[(1R)-1-phenylethyl]amino]butan-2-yl]-N'-hydroxy-2-[3-(3-methyl-4-phenylphenyl)propyl]butanediamide
DM02FGH	CA	CAS 230961-08-7
DM02FGH	CB	CHEBI:94305
DM02FGH	DE	Discovery agent

DME7VG6	ID	DME7VG6
DME7VG6	DN	UK-383367
DME7VG6	HS	Investigative
DME7VG6	SN	UK 383367; 348622-88-8; UK-383367; CHEMBL226630; 5-[(1R)-4-Cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazole-3-carboxamide; (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide; ARJCBSRIPGJMAD-LLVKDONJSA-N; UK383367; 5-{(1R)-4-cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl}-1,2,4-oxadiazole-3-carboxamide; MLS006011234; SCHEMBL6430715; CTK8F1316; SYN3014; DTXSID30431303; MolPort-016-633-322; ZINC3818556; s2224; BDBM50216795; AKOS024458022; SB19579; RL03300; CS-0414
DME7VG6	DT	Small molecular drug
DME7VG6	PC	9818682
DME7VG6	MW	324.38
DME7VG6	FM	C15H24N4O4
DME7VG6	IC	InChI=1S/C15H24N4O4/c16-13(21)14-17-15(23-19-14)11(9-12(20)18-22)8-4-7-10-5-2-1-3-6-10/h10-11,22H,1-9H2,(H2,16,21)(H,18,20)/t11-/m1/s1
DME7VG6	CS	C1CCC(CC1)CCC[C@H](CC(=O)NO)C2=NC(=NO2)C(=O)N
DME7VG6	IK	ARJCBSRIPGJMAD-LLVKDONJSA-N
DME7VG6	IU	5-[(3R)-6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl]-1,2,4-oxadiazole-3-carboxamide
DME7VG6	CA	CAS 348622-88-8
DME7VG6	DE	Discovery agent

DMXSTF2	ID	DMXSTF2
DMXSTF2	DN	UNC0006
DMXSTF2	HS	Investigative
DMXSTF2	SN	CHEMBL2165126; UNC0006; SCHEMBL253164; GTPL7651; NGCKUAWDNUFNBB-UHFFFAOYSA-N; BDBM50395587; 7-(4-(4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
DMXSTF2	DT	Small molecular drug
DMXSTF2	PC	56597938
DMXSTF2	MW	462.4
DMXSTF2	FM	C24H29Cl2N3O2
DMXSTF2	IC	InChI=1S/C24H29Cl2N3O2/c25-20-5-3-6-22(24(20)26)29-13-4-12-28(14-15-29)11-1-2-16-31-19-9-7-18-8-10-23(30)27-21(18)17-19/h3,5-7,9,17H,1-2,4,8,10-16H2,(H,27,30)
DMXSTF2	CS	C1CN(CCN(C1)C2=C(C(=CC=C2)Cl)Cl)CCCCOC3=CC4=C(CCC(=O)N4)C=C3
DMXSTF2	IK	NGCKUAWDNUFNBB-UHFFFAOYSA-N
DMXSTF2	IU	7-[4-[4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
DMXSTF2	DE	Discovery agent

DMCVU1T	ID	DMCVU1T
DMCVU1T	DN	UNC0321
DMCVU1T	HS	Investigative
DMCVU1T	SN	UNC-0321; UNC 0321
DMCVU1T	DT	Small molecular drug
DMCVU1T	PC	46901937
DMCVU1T	MW	515.7
DMCVU1T	FM	C27H45N7O3
DMCVU1T	IC	InChI=1S/C27H45N7O3/c1-31(2)15-16-36-17-18-37-25-20-23-22(19-24(25)35-5)26(28-21-7-11-33(4)12-8-21)30-27(29-23)34-10-6-9-32(3)13-14-34/h19-21H,6-18H2,1-5H3,(H,28,29,30)
DMCVU1T	CS	CN1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)NC4CCN(CC4)C)OC)OCCOCCN(C)C
DMCVU1T	IK	AULLUGALUBVBDD-UHFFFAOYSA-N
DMCVU1T	IU	7-[2-[2-(dimethylamino)ethoxy]ethoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine
DMCVU1T	CB	CHEBI:94307
DMCVU1T	DE	Discovery agent

DM4A1KJ	ID	DM4A1KJ
DM4A1KJ	DN	UNC0638
DM4A1KJ	HS	Investigative
DM4A1KJ	SN	UNC0638; 1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine
DM4A1KJ	DT	Small molecular drug
DM4A1KJ	PC	46224516
DM4A1KJ	MW	509.7
DM4A1KJ	FM	C30H47N5O2
DM4A1KJ	IC	InChI=1S/C30H47N5O2/c1-22(2)35-17-12-24(13-18-35)31-30-25-20-27(36-3)28(37-19-9-16-34-14-7-8-15-34)21-26(25)32-29(33-30)23-10-5-4-6-11-23/h20-24H,4-19H2,1-3H3,(H,31,32,33)
DM4A1KJ	CS	CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)C5CCCCC5
DM4A1KJ	IK	QOECJCJVIMVJGX-UHFFFAOYSA-N
DM4A1KJ	IU	2-cyclohexyl-6-methoxy-N-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine
DM4A1KJ	CA	CAS 1255580-76-7
DM4A1KJ	CB	CHEBI:95074
DM4A1KJ	DE	Discovery agent

DM7Y1SO	ID	DM7Y1SO
DM7Y1SO	DN	UNC0642
DM7Y1SO	HS	Investigative
DM7Y1SO	SN	1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448
DM7Y1SO	DT	Small molecular drug
DM7Y1SO	PC	53315878
DM7Y1SO	MW	546.7
DM7Y1SO	FM	C29H44F2N6O2
DM7Y1SO	IC	InChI=1S/C29H44F2N6O2/c1-21(2)36-14-7-22(8-15-36)32-27-23-19-25(38-3)26(39-18-6-13-35-11-4-5-12-35)20-24(23)33-28(34-27)37-16-9-29(30,31)10-17-37/h19-22H,4-18H2,1-3H3,(H,32,33,34)
DM7Y1SO	CS	CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)N5CCC(CC5)(F)F
DM7Y1SO	IK	RNAMYOYQYRYFQY-UHFFFAOYSA-N
DM7Y1SO	IU	2-(4,4-difluoropiperidin-1-yl)-6-methoxy-N-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine
DM7Y1SO	DE	Discovery agent

DMWMRLS	ID	DMWMRLS
DMWMRLS	DN	UNC1215
DMWMRLS	HS	Investigative
DMWMRLS	SN	UNC1215; 1415800-43-9; UNC-1215; UNC 1215; (2-(phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone); CHEMBL2426364; 2-Phenylamino-1,4-bis(4-(pyrrolidinyl)piperidinyl)benzamide; [2-(Phenylamino)benzene-1,4-Diyl]bis{[4-(Pyrrolidin-1-Yl)piperidin-1-Yl]methanone}; MLS006011024; GTPL8232; SCHEMBL19730381; CHEBI:95086; EX-A193; AOB4333; MolPort-028-720-812; HMS3652P22; KS-00000T6B; BCP07393; ZINC83253967; s7088; BDBM50440614; 2782AH; AKOS024458279; SB19337; CS-1646; NCGC00344623-12; NCGC00344623-02; SMR004702819
DMWMRLS	DT	Small molecular drug
DMWMRLS	PC	57339144
DMWMRLS	MW	529.7
DMWMRLS	FM	C32H43N5O2
DMWMRLS	IC	InChI=1S/C32H43N5O2/c38-31(36-20-12-27(13-21-36)34-16-4-5-17-34)25-10-11-29(30(24-25)33-26-8-2-1-3-9-26)32(39)37-22-14-28(15-23-37)35-18-6-7-19-35/h1-3,8-11,24,27-28,33H,4-7,12-23H2
DMWMRLS	CS	C1CCN(C1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)C(=O)N4CCC(CC4)N5CCCC5)NC6=CC=CC=C6
DMWMRLS	IK	PQOOIERVZAXHBP-UHFFFAOYSA-N
DMWMRLS	IU	[3-anilino-4-(4-pyrrolidin-1-ylpiperidine-1-carbonyl)phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone
DMWMRLS	CA	CAS 1415800-43-9
DMWMRLS	CB	CHEBI:95086
DMWMRLS	DE	Discovery agent

DMOPCBD	ID	DMOPCBD
DMOPCBD	DN	UNC1999
DMOPCBD	HS	Investigative
DMOPCBD	SN	UNC 1999; UNC-1999
DMOPCBD	DT	Small molecular drug
DMOPCBD	PC	72551585
DMOPCBD	MW	569.7
DMOPCBD	FM	C33H43N7O2
DMOPCBD	IC	InChI=1S/C33H43N7O2/c1-7-8-24-15-23(6)37-33(42)28(24)19-35-32(41)27-16-26(17-30-29(27)20-36-40(30)22(4)5)25-9-10-31(34-18-25)39-13-11-38(12-14-39)21(2)3/h9-10,15-18,20-22H,7-8,11-14,19H2,1-6H3,(H,35,41)(H,37,42)
DMOPCBD	CS	CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CN=C(C=C4)N5CCN(CC5)C(C)C)C(C)C
DMOPCBD	IK	DPJNKUOXBZSZAI-UHFFFAOYSA-N
DMOPCBD	IU	N-[(6-methyl-2-oxo-4-propyl-1H-pyridin-3-yl)methyl]-1-propan-2-yl-6-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]indazole-4-carboxamide
DMOPCBD	CA	CAS 1431612-23-5
DMOPCBD	DE	Discovery agent

DMCU59W	ID	DMCU59W
DMCU59W	DN	UNC2025
DMCU59W	HS	Investigative
DMCU59W	SN	1429881-91-3; UNC-2025; mrx-6313; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; CHEMBL3326006; 4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol; UNC2025A; SCHEMBL14854194; SCHEMBL15978986; SCHEMBL21797957; BDBM350845; BCP16544; EX-A1030; BDBM50055496; MFCD28142874; s9662; AKOS025289796; ZINC210464182; ZINC249857461; CS-3354; SB16838; NCGC00390618-01; NCGC00482875-01; AK171371; AS-52179; DA-44845; HY-12344; US9795606, B4; B8016; FT-0743029; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 2109176-09-0; 4-(2-(Butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 4beta-[2-(Butylamino)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-7-yl]cyclohexane-1alpha-ol; R6N
DMCU59W	CP	University of North Carolina
DMCU59W	DT	Small molecular drug
DMCU59W	PC	73425588
DMCU59W	MW	476.7
DMCU59W	FM	C28H40N6O
DMCU59W	IC	InChI=1S/C28H40N6O/c1-3-4-13-29-28-30-18-25-26(20-34(27(25)31-28)23-9-11-24(35)12-10-23)22-7-5-21(6-8-22)19-33-16-14-32(2)15-17-33/h5-8,18,20,23-24,35H,3-4,9-17,19H2,1-2H3,(H,29,30,31)
DMCU59W	CS	CCCCNC1=NC=C2C(=CN(C2=N1)C3CCC(CC3)O)C4=CC=C(C=C4)CN5CCN(CC5)C
DMCU59W	IK	MJSHVHLADKXCML-UHFFFAOYSA-N
DMCU59W	IU	4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol
DMCU59W	DE	Glioblastoma of brain

DMJL6ZM	ID	DMJL6ZM
DMJL6ZM	DN	UNC569
DMJL6ZM	HS	Investigative
DMJL6ZM	SN	unc569; 1350547-65-7; 1-[(Trans-4-Aminocyclohexyl)methyl]-N-Butyl-3-(4-Fluorophenyl)-1h-Pyrazolo[3,4-D]pyrimidin-6-Amine; CHEMBL2036808; 1-(((1r,4r)-4-aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; SCHEMBL12185720; SCHEMBL14755115; SCHEMBL17173901; SCHEMBL17178092; UNC 569; UNC-569; BDBM336260; UNC-569;UNC 569; BCP27883; EX-A2464; BDBM50384576; ZINC101508966; ZINC254077925; NCGC00386692-01; AS-35154; US9744172, Compound UNC00000569A; Q27458844; 1-[(4-aminocyclohexyl)methyl]-N-butyl-3-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-6-amine; 1-((4-aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; CKJ; rel-1-(((1r,4r)-4-Aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine
DMJL6ZM	DT	Small molecular drug
DMJL6ZM	PC	53355503
DMJL6ZM	MW	396.5
DMJL6ZM	FM	C22H29FN6
DMJL6ZM	IC	InChI=1S/C22H29FN6/c1-2-3-12-25-22-26-13-19-20(16-6-8-17(23)9-7-16)28-29(21(19)27-22)14-15-4-10-18(24)11-5-15/h6-9,13,15,18H,2-5,10-12,14,24H2,1H3,(H,25,26,27)
DMJL6ZM	CS	CCCCNC1=NC=C2C(=NN(C2=N1)CC3CCC(CC3)N)C4=CC=C(C=C4)F
DMJL6ZM	IK	OGEBRHQLRGFBNV-UHFFFAOYSA-N
DMJL6ZM	IU	1-[(4-aminocyclohexyl)methyl]-N-butyl-3-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-6-amine
DMJL6ZM	DE	Acute lymphoblastic leukaemia

DM4RDVO	ID	DM4RDVO
DM4RDVO	DN	UNC9975
DM4RDVO	HS	Investigative
DM4RDVO	SN	CHEMBL2165119; 7-(4-(4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)butoxy)-3,4-dihydro-1,8-naphthyridin-2(1h)-one; UNC9975; SCHEMBL252358; GTPL7650; JQSRFMXTGAVHIR-UHFFFAOYSA-N; BDBM50395569; 7-[4-[4-(2,3-Dichlorophenyl)hexahydro-1H-1,4-diazepine-1-yl]butoxy]-3,4-dihydro-1,8-naphthyridine-2(1H)-one
DM4RDVO	DT	Small molecular drug
DM4RDVO	PC	56593482
DM4RDVO	MW	463.4
DM4RDVO	FM	C23H28Cl2N4O2
DM4RDVO	IC	InChI=1S/C23H28Cl2N4O2/c24-18-5-3-6-19(22(18)25)29-13-4-12-28(14-15-29)11-1-2-16-31-21-10-8-17-7-9-20(30)26-23(17)27-21/h3,5-6,8,10H,1-2,4,7,9,11-16H2,(H,26,27,30)
DM4RDVO	CS	C1CN(CCN(C1)C2=C(C(=CC=C2)Cl)Cl)CCCCOC3=NC4=C(CCC(=O)N4)C=C3
DM4RDVO	IK	JQSRFMXTGAVHIR-UHFFFAOYSA-N
DM4RDVO	IU	7-[4-[4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl]butoxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one
DM4RDVO	DE	Discovery agent

DMDK86V	ID	DMDK86V
DMDK86V	DN	UNC9994
DMDK86V	HS	Investigative
DMDK86V	SN	CHEMBL2165138; UNC9994; SCHEMBL248630; GTPL7652; URYZTMIOHYGTNJ-UHFFFAOYSA-N; BDBM50395577; 5-{3-[4-(2,3-dichlorophenyl)piperidin-1-yl]propoxy}-1,3-benzothiazole
DMDK86V	DT	Small molecular drug
DMDK86V	PC	56599142
DMDK86V	MW	421.4
DMDK86V	FM	C21H22Cl2N2OS
DMDK86V	IC	InChI=1S/C21H22Cl2N2OS/c22-18-4-1-3-17(21(18)23)15-7-10-25(11-8-15)9-2-12-26-16-5-6-20-19(13-16)24-14-27-20/h1,3-6,13-15H,2,7-12H2
DMDK86V	CS	C1CN(CCC1C2=C(C(=CC=C2)Cl)Cl)CCCOC3=CC4=C(C=C3)SC=N4
DMDK86V	IK	URYZTMIOHYGTNJ-UHFFFAOYSA-N
DMDK86V	IU	5-[3-[4-(2,3-dichlorophenyl)piperidin-1-yl]propoxy]-1,3-benzothiazole
DMDK86V	DE	Discovery agent

DMFOIPL	ID	DMFOIPL
DMFOIPL	DN	undecanoic acid
DMFOIPL	HS	Investigative
DMFOIPL	SN	undecanoate; undecoic acid
DMFOIPL	DT	Small molecular drug
DMFOIPL	PC	8180
DMFOIPL	MW	186.29
DMFOIPL	FM	C11H22O2
DMFOIPL	IC	InChI=1S/C11H22O2/c1-2-3-4-5-6-7-8-9-10-11(12)13/h2-10H2,1H3,(H,12,13)
DMFOIPL	CS	CCCCCCCCCCC(=O)O
DMFOIPL	IK	ZDPHROOEEOARMN-UHFFFAOYSA-N
DMFOIPL	IU	undecanoic acid
DMFOIPL	CA	CAS 112-37-8
DMFOIPL	CB	CHEBI:32368
DMFOIPL	DE	Discovery agent

DM4AYC2	ID	DM4AYC2
DM4AYC2	DN	Undecylamine-n,n-dimethyl-n-oxide
DM4AYC2	HS	Investigative
DM4AYC2	SN	UNDECYLAMINE-N,N-DIMETHYL-N-OXIDE; N,N-Dimethylundecylamine N-oxide; 15178-71-9; N,N-dimethylundecan-1-amine oxide; aminodimethylundecyl-1-ol; Undecyldimethylamine oxide; AC1N3GI3; dimethyl(undecyl)amine oxide; SCHEMBL80683; N,N-dimethylundecylamine-N-oxide; CTK4C7202; DTXSID30399439; MolPort-003-931-480; ZINC2516963; AKOS024386385; DB07646; 1-Undecanamine,N,N-dimethyl-, N-oxide; FT-0747513; ST51037582; C-56601
DM4AYC2	DT	Small molecular drug
DM4AYC2	PC	4112111
DM4AYC2	MW	215.38
DM4AYC2	FM	C13H29NO
DM4AYC2	IC	InChI=1S/C13H29NO/c1-4-5-6-7-8-9-10-11-12-13-14(2,3)15/h4-13H2,1-3H3
DM4AYC2	CS	CCCCCCCCCCC[N+](C)(C)[O-]
DM4AYC2	IK	OZHBUVQCJMARBN-UHFFFAOYSA-N
DM4AYC2	IU	N,N-dimethylundecan-1-amine oxide
DM4AYC2	CA	CAS 15178-71-9
DM4AYC2	DE	Discovery agent

DMD9KEB	ID	DMD9KEB
DMD9KEB	DN	Undecyl-Phosphinic Acid Butyl Ester
DMD9KEB	HS	Investigative
DMD9KEB	DE	Discovery agent

DMFH79T	ID	DMFH79T
DMFH79T	DN	UNIFLORINE B
DMFH79T	HS	Investigative
DMFH79T	SN	uniflorine B; CHEMBL1082047
DMFH79T	DT	Small molecular drug
DMFH79T	PC	46879415
DMFH79T	MW	205.21
DMFH79T	FM	C8H15NO5
DMFH79T	IC	InChI=1S/C8H15NO5/c10-3-1-5(12)9-2-4(11)8(14)6(9)7(3)13/h3-8,10-14H,1-2H2/t3-,4-,5-,6+,7-,8-/m1/s1
DMFH79T	CS	C1[C@H]([C@H]([C@H]2[C@@H]([C@@H](CN2[C@@H]1O)O)O)O)O
DMFH79T	IK	HHLGVTQXFOVXKK-CVBHLRHXSA-N
DMFH79T	IU	(1S,2R,5R,7R,8S,8aS)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,5,7,8-pentol
DMFH79T	DE	Discovery agent

DMKQWSB	ID	DMKQWSB
DMKQWSB	DN	Up3U
DMKQWSB	HS	Investigative
DMKQWSB	SN	Up3U; GTPL1751; [[(2R,3R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[(2S,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate
DMKQWSB	DT	Small molecular drug
DMKQWSB	PC	73755005
DMKQWSB	MW	707.3
DMKQWSB	FM	C18H22N4O20P3-3
DMKQWSB	IC	InChI=1S/C18H25N4O20P3/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(39-15)5-37-43(31,32)41-45(35,36)42-44(33,34)38-6-8-12(26)14(28)16(40-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,19,23,29)(H,20,24,30)/p-3/t7-,8+,11+,12-,13?,14?,15-,16-/m1/s1
DMKQWSB	CS	C1=CN(C(=O)NC1=O)[C@H]2C([C@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3[C@H](C([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O
DMKQWSB	IK	JPNWHMPVXHYIKN-VRXVDWQRSA-K
DMKQWSB	IU	[[(2R,3R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[(2S,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate
DMKQWSB	DE	Discovery agent

DMR46C8	ID	DMR46C8
DMR46C8	DN	UPA-targeted oncolytic Sendai virus
DMR46C8	HS	Investigative
DMR46C8	SN	BioKnife; RSeV/Fct14(uPA2)dM; UPA-targeted oncolytic Sendai virus, DNAVEC
DMR46C8	CP	DNAVEC Corp
DMR46C8	DE	Solid tumour/cancer

DMPF1VU	ID	DMPF1VU
DMPF1VU	DN	UR-10324
DMPF1VU	HS	Investigative
DMPF1VU	SN	136408-45-2
DMPF1VU	DE	Discovery agent

DM8G9NY	ID	DM8G9NY
DM8G9NY	DN	UR-11353
DM8G9NY	HS	Investigative
DM8G9NY	SN	138060-13-6
DM8G9NY	DT	Small molecular drug
DM8G9NY	PC	132114
DM8G9NY	MW	611.3
DM8G9NY	FM	C34H59ClN2O5
DM8G9NY	IC	InChI=1S/C34H59N2O5.ClH/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22-25-39-33-26-31(28-40-33)29-41-34(38)36(30(3)37)27-32-23-20-21-24-35(32)5-2;/h20-21,23-24,31,33H,4-19,22,25-29H2,1-3H3;1H/q+1;/p-1
DM8G9NY	CS	CCCCCCCCCCCCCCCCCCOC1CC(CO1)COC(=O)N(CC2=CC=CC=[N+]2CC)C(=O)C.[Cl-]
DM8G9NY	IK	KFNNWINXWGVOQN-UHFFFAOYSA-M
DM8G9NY	IU	(5-octadecoxyoxolan-3-yl)methyl N-acetyl-N-[(1-ethylpyridin-1-ium-2-yl)methyl]carbamate;chloride
DM8G9NY	CA	CAS 138060-13-6
DM8G9NY	DE	Discovery agent

DM2HVUW	ID	DM2HVUW
DM2HVUW	DN	UR-12510
DM2HVUW	HS	Investigative
DM2HVUW	CP	Grupo Uriach
DM2HVUW	DE	Allergy

DMVZQ47	ID	DMVZQ47
DMVZQ47	DN	UR-12519
DMVZQ47	HS	Investigative
DMVZQ47	SN	149692-09-1
DMVZQ47	DT	Small molecular drug
DMVZQ47	PC	3025824
DMVZQ47	MW	421.5
DMVZQ47	FM	C23H27N5O3
DMVZQ47	IC	InChI=1S/C23H27N5O3/c1-17-19(9-6-10-25-17)21(16-24)27-11-13-28(14-12-27)22(29)15-20(26-23(30)31-2)18-7-4-3-5-8-18/h3-10,20-21H,11-15H2,1-2H3,(H,26,30)
DMVZQ47	CS	CC1=C(C=CC=N1)C(C#N)N2CCN(CC2)C(=O)CC(C3=CC=CC=C3)NC(=O)OC
DMVZQ47	IK	PMKMCABYJLILBB-UHFFFAOYSA-N
DMVZQ47	IU	methyl N-[3-[4-[cyano-(2-methylpyridin-3-yl)methyl]piperazin-1-yl]-3-oxo-1-phenylpropyl]carbamate
DMVZQ47	CA	CAS 149692-09-1
DMVZQ47	DE	Discovery agent

DM3YE5X	ID	DM3YE5X
DM3YE5X	DN	UR-60427
DM3YE5X	HS	Investigative
DM3YE5X	SN	Histamine H4 inverse agonist (asthma), Palau Pharma
DM3YE5X	CP	Palau Pharma SA
DM3YE5X	DE	Asthma

DMNPO9Q	ID	DMNPO9Q
DMNPO9Q	DN	Uracil
DMNPO9Q	HS	Investigative
DMNPO9Q	SN	Xyfid; Uracil topical
DMNPO9Q	DT	Small molecular drug
DMNPO9Q	PC	1174
DMNPO9Q	MW	112.09
DMNPO9Q	FM	C4H4N2O2
DMNPO9Q	IC	InChI=1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)
DMNPO9Q	CS	C1=CNC(=O)NC1=O
DMNPO9Q	IK	ISAKRJDGNUQOIC-UHFFFAOYSA-N
DMNPO9Q	IU	1H-pyrimidine-2,4-dione
DMNPO9Q	CA	CAS 66-22-8
DMNPO9Q	CB	CHEBI:17568
DMNPO9Q	DE	Discovery agent

DMA1MKT	ID	DMA1MKT
DMA1MKT	DN	Uric acid
DMA1MKT	HS	Investigative
DMA1MKT	SN	urate
DMA1MKT	DT	Small molecular drug
DMA1MKT	PC	1175
DMA1MKT	MW	168.11
DMA1MKT	FM	C5H4N4O3
DMA1MKT	IC	InChI=1S/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(H4,6,7,8,9,10,11,12)
DMA1MKT	CS	C12=C(NC(=O)N1)NC(=O)NC2=O
DMA1MKT	IK	LEHOTFFKMJEONL-UHFFFAOYSA-N
DMA1MKT	IU	7,9-dihydro-3H-purine-2,6,8-trione
DMA1MKT	CA	CAS 69-93-2
DMA1MKT	CB	CHEBI:17775
DMA1MKT	DE	Discovery agent

DMPA0BJ	ID	DMPA0BJ
DMPA0BJ	DN	Uridine diphosphate galactose
DMPA0BJ	HS	Investigative
DMPA0BJ	SN	Udp galactose; uridine diphosphate galactose; UDP-D-galactopyranose; Uridine pyrophosphogalactose; Uridinediphosphogalactose; UDP-galactose; Udpgal; Uridine diphosphogalactose; UDP-alpha-D-Galactose; Uridine diphosphategalactose; GALACTOSE-URIDINE-5'-DIPHOSPHATE; 2956-16-3; UDP-Gal; CHEMBL439009; CHEBI:67119; UDP-D-galactose; UDP-alpha-D-galactopyranose; UDP-galactopyranose; Uridine-5'-diphosphate-alpha-D-galactose; Uridinediphosphate galactose; Uridine 5'-diphosphogalactose; GDU; UDPgalactose; Uridine 5'-(alpha-D-galactopyranosy
DMPA0BJ	DT	Small molecular drug
DMPA0BJ	PC	18068
DMPA0BJ	MW	566.3
DMPA0BJ	FM	C15H24N2O17P2
DMPA0BJ	IC	InChI=1S/C15H24N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8+,9-,10+,11-,12-,13-,14-/m1/s1
DMPA0BJ	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)O)O
DMPA0BJ	IK	HSCJRCZFDFQWRP-ABVWGUQPSA-N
DMPA0BJ	IU	[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
DMPA0BJ	CA	CAS 2956-16-3
DMPA0BJ	CB	CHEBI:67119
DMPA0BJ	DE	Discovery agent

DMDQKJB	ID	DMDQKJB
DMDQKJB	DN	Uridine-5'-Diphosphate
DMDQKJB	HS	Investigative
DMDQKJB	SN	Uridine 5'-diphosphate; URIDINE DIPHOSPHATE; 58-98-0; Uridine 5'-(trihydrogen diphosphate); uridine-5'-diphosphate; UDP; UNII-5G0F599A1Y; 5'-UDP; Uridine 5'-pyrophosphate; EINECS 200-409-6; Uridine 5'-pyrophosphoric acid; CHEMBL130266; CHEBI:17659; 5G0F599A1Y; uridine-diphosphate; ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl trihydrogen diphosphate; [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate; Uridine Pyrophosp
DMDQKJB	DT	Small molecular drug
DMDQKJB	PC	6031
DMDQKJB	MW	404.16
DMDQKJB	FM	C9H14N2O12P2
DMDQKJB	IC	InChI=1S/C9H14N2O12P2/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(22-8)3-21-25(19,20)23-24(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DMDQKJB	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)O)O
DMDQKJB	IK	XCCTYIAWTASOJW-XVFCMESISA-N
DMDQKJB	IU	[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMDQKJB	CA	CAS 58-98-0
DMDQKJB	CB	CHEBI:17659
DMDQKJB	DE	Discovery agent

DMAYCQU	ID	DMAYCQU
DMAYCQU	DN	Uridine-5'-Diphosphate-Mannose
DMAYCQU	HS	Investigative
DMAYCQU	SN	URIDINE-5'-DIPHOSPHATE-MANNOSE; CHEMBL227711; UFM; UDP-Mannose; AC1L9MFS; SCHEMBL1520993; BDBM50209666; DB02421; URIDINE-5''-DIPHOSPHATE-MANNOSE; [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate; [(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl (2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl dihydrogen diphosphat
DMAYCQU	DT	Small molecular drug
DMAYCQU	PC	448873
DMAYCQU	MW	566.3
DMAYCQU	FM	C15H24N2O17P2
DMAYCQU	IC	InChI=1S/C15H24N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8-,9-,10+,11-,12+,13-,14-/m1/s1
DMAYCQU	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O
DMAYCQU	IK	HSCJRCZFDFQWRP-NYYOCOOHSA-N
DMAYCQU	IU	[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
DMAYCQU	CA	CAS 16375-64-7
DMAYCQU	DE	Discovery agent

DMG1NM7	ID	DMG1NM7
DMG1NM7	DN	Uridine-5'-Monophosphate
DMG1NM7	HS	Investigative
DMG1NM7	SN	5'-URIDYLIC ACID; Uridine 5'-monophosphate; Uridylic acid; Uridine monophosphate; 58-97-9; uridine-5'-monophosphate; Uridine phosphate; Uridine 5'-phosphate; Uridine 5'-phosphoric acid; 5'-UMP; UMP; UMP (nucleic acid); Uridine 5'-(dihydrogen phosphate); 5'Uridylic acid; uridylate; UNII-E2OU15WN0N; BRN 0047486; CHEBI:16695; Uridine 5-monophosphate; EINECS 200-408-0; E2OU15WN0N; CHEMBL214393; U 5'-P; AK113761; 27416-86-0; 2,4(1H,3H)-pyrimidinedione, 1-(5-O-phosphono-beta-D-ribofuranosyl)-; Polyuridylic acids
DMG1NM7	DT	Small molecular drug
DMG1NM7	PC	6030
DMG1NM7	MW	324.18
DMG1NM7	FM	C9H13N2O9P
DMG1NM7	IC	InChI=1S/C9H13N2O9P/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DMG1NM7	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O
DMG1NM7	IK	DJJCXFVJDGTHFX-XVFCMESISA-N
DMG1NM7	IU	[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMG1NM7	CA	CAS 58-97-9
DMG1NM7	CB	CHEBI:16695
DMG1NM7	DE	Discovery agent

DMXHO6J	ID	DMXHO6J
DMXHO6J	DN	Uridine-Diphosphate-N-Acetylgalactosamine
DMXHO6J	HS	Investigative
DMXHO6J	SN	UDP-N-acetyl-D-galactosamine; uridine 5'-[3-(2-acetamido-2-deoxy-D-galactopyranosyl) dihydrogen diphosphate]; Uridine 5'-(trihydrogen diphosphate), P'-(2-(acetylamino)-2-deoxy-alpha-D-galactopyranosyl) ester; AC1O4WBS; CHEBI:16650; [(3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DMXHO6J	DT	Small molecular drug
DMXHO6J	PC	23700
DMXHO6J	MW	607.4
DMXHO6J	FM	C17H27N3O17P2
DMXHO6J	IC	InChI=1S/C17H27N3O17P2/c1-6(22)18-10-13(26)11(24)7(4-21)35-16(10)36-39(31,32)37-38(29,30)33-5-8-12(25)14(27)15(34-8)20-3-2-9(23)19-17(20)28/h2-3,7-8,10-16,21,24-27H,4-5H2,1H3,(H,18,22)(H,29,30)(H,31,32)(H,19,23,28)/t7-,8-,10-,11+,12-,13-,14-,15-,16-/m1/s1
DMXHO6J	CS	CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O)O
DMXHO6J	IK	LFTYTUAZOPRMMI-NESSUJCYSA-N
DMXHO6J	IU	[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DMXHO6J	CA	CAS 7277-98-7
DMXHO6J	CB	CHEBI:67168

DMEQSTP	ID	DMEQSTP
DMEQSTP	DN	Uridine-Diphosphate-N-Acetylglucosamine
DMEQSTP	HS	Investigative
DMEQSTP	SN	UDP-N-acetylglucosamine; UDP-GlcNAc; UDP-N-acetyl-D-glucosamine; URIDINE-DIPHOSPHATE-N-ACETYLGLUCOSAMINE; UPPAG; UDP-acetylglucosamine; uridine diphosphate N-acetylglucosamine; UDP-N-acetyl-alpha-D-glucosamine; Uridine diphosphate-N-acetylglucosamine; 528-04-1; UDP-acetyl-D-glucosamine; Uridine diphospho-N-acetylglucosamine; Uridine 5'-diphospho-N-acetylglucosamine; [(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxy
DMEQSTP	DT	Small molecular drug
DMEQSTP	PC	445675
DMEQSTP	MW	607.4
DMEQSTP	FM	C17H27N3O17P2
DMEQSTP	IC	InChI=1S/C17H27N3O17P2/c1-6(22)18-10-13(26)11(24)7(4-21)35-16(10)36-39(31,32)37-38(29,30)33-5-8-12(25)14(27)15(34-8)20-3-2-9(23)19-17(20)28/h2-3,7-8,10-16,21,24-27H,4-5H2,1H3,(H,18,22)(H,29,30)(H,31,32)(H,19,23,28)/t7-,8-,10-,11-,12-,13-,14-,15-,16-/m1/s1
DMEQSTP	CS	CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O)O
DMEQSTP	IK	LFTYTUAZOPRMMI-CFRASDGPSA-N
DMEQSTP	IU	[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DMEQSTP	CA	CAS 528-04-1
DMEQSTP	CB	CHEBI:16264
DMEQSTP	DE	Discovery agent

DMCJXWK	ID	DMCJXWK
DMCJXWK	DN	URMC-099
DMCJXWK	HS	Investigative
DMCJXWK	SN	compound 1 [PMID 24044867]
DMCJXWK	DT	Small molecular drug
DMCJXWK	PC	54764565
DMCJXWK	MW	421.5
DMCJXWK	FM	C27H27N5
DMCJXWK	IC	InChI=1S/C27H27N5/c1-31-10-12-32(13-11-31)18-19-2-4-20(5-3-19)23-15-24-25(17-30-27(24)29-16-23)21-6-7-26-22(14-21)8-9-28-26/h2-9,14-17,28H,10-13,18H2,1H3,(H,29,30)
DMCJXWK	CS	CN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(NC=C4C5=CC6=C(C=C5)NC=C6)N=C3
DMCJXWK	IK	QKKIWEILHCXECO-UHFFFAOYSA-N
DMCJXWK	IU	3-(1H-indol-5-yl)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine
DMCJXWK	DE	Discovery agent

DMCE3PJ	ID	DMCE3PJ
DMCE3PJ	DN	urotensin II-related peptide
DMCE3PJ	HS	Investigative
DMCE3PJ	SN	urotensin-related peptide
DMCE3PJ	DT	Small molecular drug
DMCE3PJ	PC	11995575
DMCE3PJ	MW	1023.3
DMCE3PJ	FM	C49H70N10O10S2
DMCE3PJ	IC	InChI=1S/C49H70N10O10S2/c1-27(2)41(49(68)69)59-48(67)40-26-71-70-25-39(57-42(61)28(3)51)47(66)55-36(21-29-11-5-4-6-12-29)44(63)56-38(23-31-24-52-34-14-8-7-13-33(31)34)46(65)53-35(15-9-10-20-50)43(62)54-37(45(64)58-40)22-30-16-18-32(60)19-17-30/h7-8,13-14,16-19,24,27-29,35-41,52,60H,4-6,9-12,15,20-23,25-26,50-51H2,1-3H3,(H,53,65)(H,54,62)(H,55,66)(H,56,63)(H,57,61)(H,58,64)(H,59,67)(H,68,69)/t28-,35-,36-,37-,38-,39-,40-,41-/m0/s1
DMCE3PJ	CS	C[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2CCCCC2)CC3=CNC4=CC=CC=C43)CCCCN)CC5=CC=C(C=C5)O)C(=O)N[C@@H](C(C)C)C(=O)O)N
DMCE3PJ	IK	BKBNRUZZGBUWOM-KOOAXUMWSA-N
DMCE3PJ	IU	(2S)-2-[[(4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-19-[[(2S)-2-aminopropanoyl]amino]-16-(cyclohexylmethyl)-7-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-methylbutanoic acid
DMCE3PJ	DE	Discovery agent

DM2C6GB	ID	DM2C6GB
DM2C6GB	DN	UR-PG131A
DM2C6GB	HS	Investigative
DM2C6GB	SN	CHEMBL470563; UR-PG131A; GTPL1198; BDBM50413183
DM2C6GB	DT	Small molecular drug
DM2C6GB	PC	25149704
DM2C6GB	MW	401.4
DM2C6GB	FM	C19H21F2N7O
DM2C6GB	IC	InChI=1S/C19H21F2N7O/c20-15-4-3-12(8-16(15)21)14(18-24-6-7-25-18)9-17(29)28-19(22)26-5-1-2-13-10-23-11-27-13/h3-4,6-8,10-11,14H,1-2,5,9H2,(H,23,27)(H,24,25)(H3,22,26,28,29)
DM2C6GB	CS	C1=CC(=C(C=C1C(CC(=O)NC(=NCCCC2=CN=CN2)N)C3=NC=CN3)F)F
DM2C6GB	IK	DGJMWXIXZSWRLP-UHFFFAOYSA-N
DM2C6GB	IU	3-(3,4-difluorophenyl)-3-(1H-imidazol-2-yl)-N-[N'-[3-(1H-imidazol-5-yl)propyl]carbamimidoyl]propanamide
DM2C6GB	DE	Discovery agent

DMQCL6Y	ID	DMQCL6Y
DMQCL6Y	DN	UR-PG146
DMQCL6Y	HS	Investigative
DMQCL6Y	SN	CHEMBL513056; UR-PG146; GTPL1200; BDBM50413173
DMQCL6Y	DT	Small molecular drug
DMQCL6Y	PC	25149519
DMQCL6Y	MW	335.43
DMQCL6Y	FM	C14H21N7OS
DMQCL6Y	IC	InChI=1S/C14H21N7OS/c1-10-12(20-9-18-10)6-23-7-13(22)21-14(15)17-4-2-3-11-5-16-8-19-11/h5,8-9H,2-4,6-7H2,1H3,(H,16,19)(H,18,20)(H3,15,17,21,22)
DMQCL6Y	CS	CC1=C(N=CN1)CSCC(=O)NC(=NCCCC2=CN=CN2)N
DMQCL6Y	IK	ZOBGKPFWPWGQOI-UHFFFAOYSA-N
DMQCL6Y	IU	N-[N'-[3-(1H-imidazol-5-yl)propyl]carbamimidoyl]-2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]acetamide
DMQCL6Y	CA	CAS 888491-51-8
DMQCL6Y	DE	Discovery agent

DM3VTLG	ID	DM3VTLG
DM3VTLG	DN	UR-PG153
DM3VTLG	HS	Investigative
DM3VTLG	SN	CHEMBL499301; UR-PG153; GTPL1201; BDBM50413181
DM3VTLG	DT	Small molecular drug
DM3VTLG	PC	25150700
DM3VTLG	MW	361.4
DM3VTLG	FM	C21H23N5O
DM3VTLG	IC	InChI=1S/C21H23N5O/c22-21(24-12-11-18-14-23-15-25-18)26-20(27)13-19(16-7-3-1-4-8-16)17-9-5-2-6-10-17/h1-10,14-15,19H,11-13H2,(H,23,25)(H3,22,24,26,27)
DM3VTLG	CS	C1=CC=C(C=C1)C(CC(=O)NC(=NCCC2=CN=CN2)N)C3=CC=CC=C3
DM3VTLG	IK	BCIVIRNJAROBHW-UHFFFAOYSA-N
DM3VTLG	IU	N-[N'-[2-(1H-imidazol-5-yl)ethyl]carbamimidoyl]-3,3-diphenylpropanamide
DM3VTLG	DE	Discovery agent

DM6SM4N	ID	DM6SM4N
DM6SM4N	DN	UR-PG55B
DM6SM4N	HS	Investigative
DM6SM4N	SN	CHEMBL513883; UR-PG55B; GTPL1202; BDBM50413176
DM6SM4N	DT	Small molecular drug
DM6SM4N	PC	25150704
DM6SM4N	MW	411.4
DM6SM4N	FM	C22H23F2N5O
DM6SM4N	IC	InChI=1S/C22H23F2N5O/c23-17-7-3-15(4-8-17)20(16-5-9-18(24)10-6-16)12-21(30)29-22(25)27-11-1-2-19-13-26-14-28-19/h3-10,13-14,20H,1-2,11-12H2,(H,26,28)(H3,25,27,29,30)
DM6SM4N	CS	C1=CC(=CC=C1C(CC(=O)NC(=NCCCC2=CN=CN2)N)C3=CC=C(C=C3)F)F
DM6SM4N	IK	BRPONMOKDIJLJF-UHFFFAOYSA-N
DM6SM4N	IU	3,3-bis(4-fluorophenyl)-N-[N'-[3-(1H-imidazol-5-yl)propyl]carbamimidoyl]propanamide
DM6SM4N	DE	Discovery agent

DMCQ8AL	ID	DMCQ8AL
DMCQ8AL	DN	USIMINE A
DMCQ8AL	HS	Investigative
DMCQ8AL	SN	Usimine A; CHEMBL514108
DMCQ8AL	DT	Small molecular drug
DMCQ8AL	PC	101865652
DMCQ8AL	MW	487.5
DMCQ8AL	FM	C24H25NO10
DMCQ8AL	IC	InChI=1S/C24H25NO10/c1-9-19(29)17(11(3)26)21-18(20(9)30)24(4)14(35-21)8-13(27)16(22(24)31)10(2)25-12(23(32)33)6-7-15(28)34-5/h8,12,25,29-30H,6-7H2,1-5H3,(H,32,33)/t12-,24-/m0/s1
DMCQ8AL	CS	CC1=C(C(=C2C(=C1O)[C@@]3(C(=CC(=O)C(=C(C)N[C@@H](CCC(=O)OC)C(=O)O)C3=O)O2)C)C(=O)C)O
DMCQ8AL	IK	KSWPDJNHLSRGKZ-MCFWBGNESA-N
DMCQ8AL	IU	(2S)-2-[1-[(9bR)-6-acetyl-7,9-dihydroxy-8,9b-dimethyl-1,3-dioxodibenzofuran-2-ylidene]ethylamino]-5-methoxy-5-oxopentanoic acid
DMCQ8AL	DE	Discovery agent

DMGOURX	ID	DMGOURX
DMGOURX	DN	USNIC ACID
DMGOURX	HS	Investigative
DMGOURX	SN	usnic acid; 125-46-2; Usniacin; Usno; Usninsaeure [German]; (+-)-Uanic acid; usnic-acid; Usinic acid; L-Usnic acid; NSC 8517; CCRIS 5518; HSDB 7170; NSC5890; 1,3(2H,9bH)-Dibenzofurandione, 2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-; C18H16O7; EINECS 204-740-7; BRN 1299865; 2,6-Diacetyl-7,9-dihydroxy-8,9b-dimethyl-1,3(2H,9bH)-dibenzofurandione; AI3-50457; CHEBI:2264; NSC8517; NSC5889; 2,6-Diacetyl-7,9-dihydroxy-8,9b-dimethyldibenzo[b,d]furan-1,3(2H,9bh)-dione
DMGOURX	DT	Small molecular drug
DMGOURX	PC	5646
DMGOURX	MW	344.3
DMGOURX	FM	C18H16O7
DMGOURX	IC	InChI=1S/C18H16O7/c1-6-14(22)12(8(3)20)16-13(15(6)23)18(4)10(25-16)5-9(21)11(7(2)19)17(18)24/h5,11,22-23H,1-4H3
DMGOURX	CS	CC1=C(C(=C2C(=C1O)C3(C(=CC(=O)C(C3=O)C(=O)C)O2)C)C(=O)C)O
DMGOURX	IK	CUCUKLJLRRAKFN-UHFFFAOYSA-N
DMGOURX	IU	2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyldibenzofuran-1,3-dione
DMGOURX	CA	CAS 125-46-2
DMGOURX	CB	CHEBI:2264
DMGOURX	DE	Discovery agent

DMZP32O	ID	DMZP32O
DMZP32O	DN	USTILOXIN A
DMZP32O	HS	Investigative
DMZP32O	SN	Ustiloxin A; 143557-93-1; AC1L4UT4; CHEMBL212074; Glycine, 2-((4-amino-4-carboxy-2-hydroxybutyl)sulfinyl)-threo-beta,5-dihydroxy-N-methyl-L-tyrosyl-L-valyl-3-hydroxy-L-isoleucyl-, cyclic (15-3)-ether, (2S-(1(S*),2R*,4R*))-; (2S,4S)-2-amino-5-[[(2R,3S,6S,9S,10R)-9-(carboxymethylcarbamoyl)-10-ethyl-2,13-dihydroxy-10-methyl-3-(methylamino)-4,7-dioxo-6-propan-2-yl-11-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-15-yl]sulfinyl]-4-hydroxypentanoic acid
DMZP32O	DT	Small molecular drug
DMZP32O	PC	164454
DMZP32O	MW	673.7
DMZP32O	FM	C28H43N5O12S
DMZP32O	IC	InChI=1S/C28H43N5O12S/c1-6-28(4)23(26(41)31-10-19(36)37)33-24(39)20(12(2)3)32-25(40)21(30-5)22(38)14-8-17(45-28)16(35)9-18(14)46(44)11-13(34)7-15(29)27(42)43/h8-9,12-13,15,20-23,30,34-35,38H,6-7,10-11,29H2,1-5H3,(H,31,41)(H,32,40)(H,33,39)(H,36,37)(H,42,43)/t13-,15-,20-,21-,22+,23+,28+,46?/m0/s1
DMZP32O	CS	CC[C@@]1([C@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](C2=CC(=C(C=C2S(=O)C[C@H](C[C@@H](C(=O)O)N)O)O)O1)O)NC)C(C)C)C(=O)NCC(=O)O)C
DMZP32O	IK	QRLBQXQEGMBXFM-MWFNQMQISA-N
DMZP32O	IU	(2S,4S)-2-amino-5-[[(3R,4S,7S,10S,11R)-4-(carboxymethylcarbamoyl)-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-propan-2-yl-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(15),12(16),13-trien-13-yl]sulfinyl]-4-hydroxypentanoic acid
DMZP32O	CA	CAS 143557-93-1
DMZP32O	DE	Discovery agent

DMA8JH7	ID	DMA8JH7
DMA8JH7	DN	Ustiloxin D
DMA8JH7	HS	Investigative
DMA8JH7	SN	Ustiloxin D; 158243-18-6; AC1L4IRQ; CHEMBL386110; DTXSID90166386; (beta-R)-beta,3-Dihydroxy-N-methyl-L-tyrosyl-L-valyl-3-hydroxy-L-isoleucylglycine cyclic (1(sup 3)-3)-ether; Glycine, threo-beta,3-dihydroxy-N-methyl-L-tyrosyl-L-valyl-3-hydroxy-L-isoleucyl-, cyclic (1(3)-3)-ether; Glycine, (beta-R)-beta,3-dihydroxy-N-methyl-L-tyrosyl-L-valyl-3-hydroxy-L-isoleucyl-, cyclic (1(sup 3)-3)-ether
DMA8JH7	DT	Small molecular drug
DMA8JH7	PC	157840
DMA8JH7	MW	494.5
DMA8JH7	FM	C23H34N4O8
DMA8JH7	IC	InChI=1S/C23H34N4O8/c1-6-23(4)19(22(34)25-10-15(29)30)27-20(32)16(11(2)3)26-21(33)17(24-5)18(31)12-7-8-13(28)14(9-12)35-23/h7-9,11,16-19,24,28,31H,6,10H2,1-5H3,(H,25,34)(H,26,33)(H,27,32)(H,29,30)/t16-,17-,18+,19+,23+/m0/s1
DMA8JH7	CS	CC[C@@]1([C@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](C2=CC(=C(C=C2)O)O1)O)NC)C(C)C)C(=O)NCC(=O)O)C
DMA8JH7	IK	GDXLZSYACWZHOC-ZNRYNLAGSA-N
DMA8JH7	IU	2-[[(3R,4S,7S,10S,11R)-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-propan-2-yl-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(15),12(16),13-triene-4-carbonyl]amino]acetic acid
DMA8JH7	CA	CAS 158243-18-6
DMA8JH7	DE	Discovery agent

DMT1LS0	ID	DMT1LS0
DMT1LS0	DN	Ustiloxin F
DMT1LS0	HS	Investigative
DMT1LS0	SN	Ustiloxin F
DMT1LS0	DT	Small molecular drug
DMT1LS0	PC	10367264
DMT1LS0	MW	466.5
DMT1LS0	FM	C21H30N4O8
DMT1LS0	IC	InChI=1S/C21H30N4O8/c1-5-21(3)17(20(32)23-9-14(27)28)25-18(30)10(2)24-19(31)15(22-4)16(29)11-6-7-12(26)13(8-11)33-21/h6-8,10,15-17,22,26,29H,5,9H2,1-4H3,(H,23,32)(H,24,31)(H,25,30)(H,27,28)/t10-,15-,16+,17+,21+/m0/s1
DMT1LS0	CS	CC[C@@]1([C@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](C2=CC(=C(C=C2)O)O1)O)NC)C)C(=O)NCC(=O)O)C
DMT1LS0	IK	XAJYTGHEDODUTC-KILRJQPKSA-N
DMT1LS0	IU	2-[[(3R,4S,7S,10S,11R)-3-ethyl-11,15-dihydroxy-3,7-dimethyl-10-(methylamino)-6,9-dioxo-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(15),12(16),13-triene-4-carbonyl]amino]acetic acid
DMT1LS0	DE	Discovery agent

DMKLB4O	ID	DMKLB4O
DMKLB4O	DN	UTPgammaS
DMKLB4O	HS	Investigative
DMKLB4O	SN	UTP-Gamma-S; CHEMBL220200; UTPgammaS; UTP..gamma..S; AC1NSKQ9; SCHEMBL338166; GTPL1735; BDBM50205417; (dihydroxyphosphinothioyloxy-hydroxyphosphoryl) [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; dihydroxyphosphinothioyl [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DMKLB4O	DT	Small molecular drug
DMKLB4O	PC	5311494
DMKLB4O	MW	500.21
DMKLB4O	FM	C9H15N2O14P3S
DMKLB4O	IC	InChI=1S/C9H15N2O14P3S/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(23-8)3-22-26(16,17)24-27(18,19)25-28(20,21)29/h1-2,4,6-8,13-14H,3H2,(H,16,17)(H,18,19)(H,10,12,15)(H2,20,21,29)/t4-,6-,7-,8-/m1/s1
DMKLB4O	CS	C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O
DMKLB4O	IK	DUDALCZPYHIGIR-XVFCMESISA-N
DMKLB4O	IU	dihydroxyphosphinothioyl [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DMKLB4O	DE	Discovery agent

DMAFQE1	ID	DMAFQE1
DMAFQE1	DN	UVAOL
DMAFQE1	HS	Investigative
DMAFQE1	SN	Uvaol; 545-46-0; Urs-12-ene-3beta,28-diol; Urs-12-ene-3,28-diol; UNII-W599R31ROT; W599R31ROT; CHEMBL399873; CHEBI:67894; (3beta)-Urs-12-ene-3,28-diol; (3S,4aR,6aR,6bS,8aS,11R,12S,12aS,14aR,14bR)-8a-(hydroxymethyl)-4,4,6a,6b,11,12,14b-heptamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picen-3-ol; EINECS 208-888-3; NSC 159627; Uvaol, &gt; AC1L3OV7; SCHEMBL337913; BCBcMAP01_000233; MolPort-003-959-866; 3-beta,28-Dihydroxy-urs-12-ene; ZINC3978797
DMAFQE1	DT	Small molecular drug
DMAFQE1	PC	92802
DMAFQE1	MW	442.7
DMAFQE1	FM	C30H50O2
DMAFQE1	IC	InChI=1S/C30H50O2/c1-19-10-15-30(18-31)17-16-28(6)21(25(30)20(19)2)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h8,19-20,22-25,31-32H,9-18H2,1-7H3/t19-,20+,22+,23-,24+,25+,27+,28-,29-,30-/m1/s1
DMAFQE1	CS	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)CO
DMAFQE1	IK	XUARCIYIVXVTAE-ZAPOICBTSA-N
DMAFQE1	IU	(3S,4aR,6aR,6bS,8aS,11R,12S,12aS,14aR,14bR)-8a-(hydroxymethyl)-4,4,6a,6b,11,12,14b-heptamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picen-3-ol
DMAFQE1	CA	CAS 545-46-0
DMAFQE1	CB	CHEBI:67894
DMAFQE1	DE	Discovery agent

DM95UI1	ID	DM95UI1
DM95UI1	DN	UVI3003
DM95UI1	HS	Investigative
DM95UI1	SN	UVI 3003
DM95UI1	DT	Small molecular drug
DM95UI1	PC	44566108
DM95UI1	MW	436.6
DM95UI1	FM	C28H36O4
DM95UI1	IC	InChI=1S/C28H36O4/c1-6-7-8-15-32-25-18-23-22(27(2,3)13-14-28(23,4)5)17-21(25)20-16-19(9-11-24(20)29)10-12-26(30)31/h9-12,16-18,29H,6-8,13-15H2,1-5H3,(H,30,31)/b12-10+
DM95UI1	CS	CCCCCOC1=CC2=C(C=C1C3=C(C=CC(=C3)/C=C/C(=O)O)O)C(CCC2(C)C)(C)C
DM95UI1	IK	APJSHECCIRQQDV-ZRDIBKRKSA-N
DM95UI1	IU	(E)-3-[4-hydroxy-3-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid
DM95UI1	DE	Discovery agent

DM0KSFN	ID	DM0KSFN
DM0KSFN	DN	V-103
DM0KSFN	HS	Investigative
DM0KSFN	SN	Peri-procedural bruising therapy (topical), Vicept
DM0KSFN	CP	Vicept Therapeutics Inc
DM0KSFN	DE	Contusion

DMXLHIO	ID	DMXLHIO
DMXLHIO	DN	V158411
DMXLHIO	HS	Investigative
DMXLHIO	SN	1174664-88-0; 1-Benzyl-N-(5-{5-[3-(Dimethylamino)-2,2-Dimethylpropoxy]-1h-Indol-2-Yl}-6-Oxo-1,6-Dihydropyridin-3-Yl)-1h-Pyrazole-4-Carboxamide; VER-00158411; 1-Benzyl-N-(5-(5-(3-(dimethylamino)-2,2-dimethylpropoxy)-1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3-yl)-1H-pyrazole-4-carboxamide; VER-158411; SCHEMBL950079; BCP25319; HY-18942; CS-0014655; Q27455647; V 158411; V-158411; VER00158411; VER 00158411; VER-00158411; 1-benzyl-N-[5-[5-[3-(dimethylamino)-2,2-dimethylpropoxy]-1H-indol-2-yl]-6-oxo-1H-pyridin-3-yl]pyrazole-4-carboxamide; 5CV
DMXLHIO	DT	Small molecular drug
DMXLHIO	PC	44198296
DMXLHIO	MW	538.6
DMXLHIO	FM	C31H34N6O3
DMXLHIO	IC	InChI=1S/C31H34N6O3/c1-31(2,19-36(3)4)20-40-25-10-11-27-22(12-25)13-28(35-27)26-14-24(16-32-30(26)39)34-29(38)23-15-33-37(18-23)17-21-8-6-5-7-9-21/h5-16,18,35H,17,19-20H2,1-4H3,(H,32,39)(H,34,38)
DMXLHIO	CS	CC(C)(CN(C)C)COC1=CC2=C(C=C1)NC(=C2)C3=CC(=CNC3=O)NC(=O)C4=CN(N=C4)CC5=CC=CC=C5
DMXLHIO	IK	REQMZUHAMVOEON-UHFFFAOYSA-N
DMXLHIO	IU	1-benzyl-N-[5-[5-[3-(dimethylamino)-2,2-dimethylpropoxy]-1H-indol-2-yl]-6-oxo-1H-pyridin-3-yl]pyrazole-4-carboxamide
DMXLHIO	DE	Triple negative breast cancer

DM8SWVN	ID	DM8SWVN
DM8SWVN	DN	V-165
DM8SWVN	HS	Investigative
DM8SWVN	SN	V-165; 223393-69-9; 5-(4-nitrophenyl)-2,8-dithioxo-5,7,8,9-tetrahydro-2H-pyrano[2,3-d:6,5-d']dipyrimidine-4,6(1H,3H)-dione; NSC705851; AC1MFLNX; V 165; CHEMBL178865; SCHEMBL13788910; MolPort-000-782-351; MolPort-000-751-505; ZINC13799665; STL349538; STL150551; AKOS005750605; AKOS022142146; NSC-705851; MCULE-8450455381; NCI60_037697; ST51021506; 4-(4-nitrophenyl)-2,2-bis(sulfanyl)[ ]-4,4-diol; 2,8-Dimercapto-5-(4-nitro-phenyl)-5H-pyrano[2,3-d; 2,8-dimercapto-5-(4-nitrophenyl)-5h-pyrano[2,3-d:6,5-d']dipyrimidine-4,6-diol
DM8SWVN	DT	Small molecular drug
DM8SWVN	PC	2921179
DM8SWVN	MW	403.4
DM8SWVN	FM	C15H9N5O5S2
DM8SWVN	IC	InChI=1S/C15H9N5O5S2/c21-10-8-7(5-1-3-6(4-2-5)20(23)24)9-11(22)17-15(27)19-13(9)25-12(8)18-14(26)16-10/h1-4,7H,(H2,16,18,21,26)(H2,17,19,22,27)
DM8SWVN	CS	C1=CC(=CC=C1C2C3=C(NC(=S)NC3=O)OC4=C2C(=O)NC(=S)N4)[N+](=O)[O-]
DM8SWVN	IK	UYLYXNZSRMQYRO-UHFFFAOYSA-N
DM8SWVN	IU	9-(4-nitrophenyl)-5,13-bis(sulfanylidene)-2-oxa-4,6,12,14-tetrazatricyclo[8.4.0.03,8]tetradeca-1(10),3(8)-diene-7,11-dione
DM8SWVN	CA	CAS 223393-69-9
DM8SWVN	DE	Discovery agent

DMH971B	ID	DMH971B
DMH971B	DN	V1A F/U
DMH971B	HS	Investigative
DMH971B	SN	Vasopressin 1a antagonist (infertility), Vantia
DMH971B	CP	Vantia Therapeutics
DMH971B	DE	Infertility

DM65GQD	ID	DM65GQD
DM65GQD	DN	VA-118020
DM65GQD	HS	Investigative
DM65GQD	SN	KKI; FE-999155; Kallikrein 1 inhibitor (oral, respiratory disorders), Vantia
DM65GQD	CP	Vantia Therapeutics
DM65GQD	DE	Respiratory disease

DMG53XV	ID	DMG53XV
DMG53XV	DN	VA-119930
DMG53XV	HS	Investigative
DMG53XV	SN	Fibroblast activation protein inhibitors (IBD), Vantia; Seprase inhibitor (IBD), Vantia
DMG53XV	CP	Vantia Therapeutics
DMG53XV	DE	Inflammatory bowel disease

DMEOJ89	ID	DMEOJ89
DMEOJ89	DN	VAGANINE D
DMEOJ89	HS	Investigative
DMEOJ89	SN	CHEMBL460447; ( )-vaganine D; SCHEMBL15861466; BDBM50242345; [(20S)-20-(N,N-dimethylamino)-3 beta-(senecioylamino)-5 alpha-pregn-16-en-4 beta-yl acetate]
DMEOJ89	DT	Small molecular drug
DMEOJ89	PC	10051046
DMEOJ89	MW	484.7
DMEOJ89	FM	C30H48N2O3
DMEOJ89	IC	InChI=1S/C30H48N2O3/c1-18(2)17-27(34)31-26-14-16-30(6)24-13-15-29(5)22(19(3)32(7)8)11-12-23(29)21(24)9-10-25(30)28(26)35-20(4)33/h11,17,19,21,23-26,28H,9-10,12-16H2,1-8H3,(H,31,34)/t19-,21-,23-,24-,25-,26-,28+,29+,30+/m0/s1
DMEOJ89	CS	C[C@@H](C1=CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@H]([C@@H]4OC(=O)C)NC(=O)C=C(C)C)C)C)N(C)C
DMEOJ89	IK	SYWAOYCXRQDRLP-ULERWODGSA-N
DMEOJ89	IU	[(3S,4R,5R,8R,9S,10R,13S,14S)-17-[(1S)-1-(dimethylamino)ethyl]-10,13-dimethyl-3-(3-methylbut-2-enoylamino)-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-4-yl] acetate
DMEOJ89	DE	Discovery agent

DMW4TYV	ID	DMW4TYV
DMW4TYV	DN	Valinomycin
DMW4TYV	HS	Investigative
DMW4TYV	SN	Antibiotic N-329 B; Cyclic(D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl); Potassium ionophore I; UNII-N561YS75MN; Valinomicin; cyclo[-D-O-Val-D-Val-L-O-Ala-L-Val]3; valino; valinomycin
DMW4TYV	TC	Antibiotics
DMW4TYV	DT	Small molecular drug
DMW4TYV	PC	3000706
DMW4TYV	MW	1111.338
DMW4TYV	FM	C54H90N6O18
DMW4TYV	IC	InChI=1S/C54H90N6O18/c1-22(2)34-49(67)73-31(19)43(61)55-38(26(9)10)53(71)77-41(29(15)16)47(65)59-36(24(5)6)51(69)75-33(21)45(63)57-39(27(11)12)54(72)78-42(30(17)18)48(66)60-35(23(3)4)50(68)74-32(20)44(62)56-37(25(7)8)52(70)76-40(28(13)14)46(64)58-34/h22-42H,1-21H3,(H,55,61)(H,56,62)(H,57,63)(H,58,64)(H,59,65)(H,60,66)/t31-,32-,33-,34+,35+,36+,37-,38-,39-,40+,41+,42+/m0/s1
DMW4TYV	CS	CC1C(=O)NC(C(=O)OC(C(=O)NC(C(=O)OC(C(=O)NC(C(=O)OC(C(=O)NC(C(=O)OC(C(=O)NC(C(=O)OC(C(=O)NC(C(=O)O1)C(C)C)C(C)C)C(C)C)C)C(C)C)C(C)C)C(C)C)C)C(C)C)C(C)C)C(C)C
DMW4TYV	IK	FCFNRCROJUBPLU-DNDCDFAISA-N
DMW4TYV	IU	(3S,6S,9R,12R,15S,18S,21R,24R,27S,30S,33R,36R)-6,18,30-trimethyl-3,9,12,15,21,24,27,33,36-nona(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone
DMW4TYV	CA	CAS 2001-95-8
DMW4TYV	CB	ChEBI:28545

DM2VQN5	ID	DM2VQN5
DM2VQN5	DN	VALIOLAMINE
DM2VQN5	HS	Investigative
DM2VQN5	SN	Valiolamine; 83465-22-9; Valinolamine; (1S,2S,3R,4S,5S)-5-Amino-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol; Valiolamine hydrate; (1S,2S,3R,4S,5S)-5-amino-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; CHEMBL222396; AK109366; 4-Amino-3,4-dideoxy-2-C-(hydroxymethyl)-D-epi-inositol hydrate; C7H15NO5; BDBM50241137; D-epi-Inositol, 4-amino-3,4-dideoxy-2-C-(hydroxymethyl)-, hydrate; AC1L5B2J; CHEMBL9216; VDLOJRUTNRJDJO-ZYNSJIGGSA-N; MolPort-005-935-511; ZINC5157081; FCH856530; BDBM50024129; AKOS006287538; API0004565; AC-1555
DM2VQN5	DT	Small molecular drug
DM2VQN5	PC	174312
DM2VQN5	MW	193.2
DM2VQN5	FM	C7H15NO5
DM2VQN5	IC	InChI=1S/C7H15NO5/c8-3-1-7(13,2-9)6(12)5(11)4(3)10/h3-6,9-13H,1-2,8H2/t3-,4-,5+,6-,7-/m0/s1
DM2VQN5	CS	C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)N
DM2VQN5	IK	VDLOJRUTNRJDJO-ZYNSJIGGSA-N
DM2VQN5	IU	(1S,2S,3R,4S,5S)-5-amino-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
DM2VQN5	CA	CAS 83465-22-9
DM2VQN5	DE	Discovery agent

DM30E56	ID	DM30E56
DM30E56	DN	Vapill
DM30E56	HS	Investigative
DM30E56	SN	BTT-2026; BTT-2027; BTT-2052; SzV-1287; SzV-1928; SzV-2007; SzV-626; VAP-1 SSAO inhibitor, BioTie; VAP-1 SSAO inhibitors (inflammatory diseases); VAP-1 SSAO inhibitors (inflammatory diseases), BioTie/Seikagaku
DM30E56	CP	BioTie Therapies Corp
DM30E56	DE	Diabetic complication

DMD7M9L	ID	DMD7M9L
DMD7M9L	DN	VAR-10200
DMD7M9L	HS	Investigative
DMD7M9L	SN	HLA-20
DMD7M9L	CP	Varinel Inc
DMD7M9L	DT	Small molecular drug
DMD7M9L	PC	6918819
DMD7M9L	MW	281.35
DMD7M9L	FM	C17H19N3O
DMD7M9L	IC	InChI=1S/C17H19N3O/c1-2-8-19-9-11-20(12-10-19)13-14-5-6-16(21)17-15(14)4-3-7-18-17/h1,3-7,21H,8-13H2
DMD7M9L	CS	C#CCN1CCN(CC1)CC2=C3C=CC=NC3=C(C=C2)O
DMD7M9L	IK	JWUOZHTYFQHGAB-UHFFFAOYSA-N
DMD7M9L	IU	5-[(4-prop-2-ynylpiperazin-1-yl)methyl]quinolin-8-ol
DMD7M9L	CA	CAS 686722-53-2
DMD7M9L	DE	Neurodegenerative disorder

DMFKTPO	ID	DMFKTPO
DMFKTPO	DN	VAR-10300
DMFKTPO	HS	Investigative
DMFKTPO	SN	M-30; M-32; Dual iron chelator/monoamine oxidase inhibitor compounds (neurodegenerative disease), Technion/Weizmann Institute/Varinel
DMFKTPO	CP	Weizmann Institute of Science
DMFKTPO	DT	Small molecular drug
DMFKTPO	PC	6918822
DMFKTPO	MW	226.27
DMFKTPO	FM	C14H14N2O
DMFKTPO	IC	InChI=1S/C14H14N2O/c1-3-9-16(2)10-11-6-7-13(17)14-12(11)5-4-8-15-14/h1,4-8,17H,9-10H2,2H3
DMFKTPO	CS	CN(CC#C)CC1=C2C=CC=NC2=C(C=C1)O
DMFKTPO	IK	FQFLPZZATVCNLA-UHFFFAOYSA-N
DMFKTPO	IU	5-[[methyl(prop-2-ynyl)amino]methyl]quinolin-8-ol
DMFKTPO	CA	CAS 766454-72-2
DMFKTPO	DE	Neurodegenerative disorder

DMVBO78	ID	DMVBO78
DMVBO78	DN	VARIECOLIN
DMVBO78	HS	Investigative
DMVBO78	SN	Variecolin; CHEMBL519317; CHEBI:66349; BDBM50260106; isopropenyl-trimethyl-oxo-[ ]carbaldehyde; Cyclopenta[4,5]cyclooct[1,2-e]indene-8-carboxaldehyde, 1,2,2a,3,4,5,5a,5b,6,8a,9,10,11,11a,12,12a-hexadecahydro-2a,11,12a-trimethyl-5-(1-methylethenyl)-9-oxo-, (2aS,5S,5aS,5bS,8aR,11S,11aS,12aR)-
DMVBO78	DT	Small molecular drug
DMVBO78	PC	6480205
DMVBO78	MW	368.6
DMVBO78	FM	C25H36O2
DMVBO78	IC	InChI=1S/C25H36O2/c1-15(2)18-8-9-24(4)10-11-25(5)13-19-16(3)12-21(27)22(19)17(14-26)6-7-20(25)23(18)24/h6,14,16,18-20,22-23H,1,7-13H2,2-5H3/b17-6-/t16-,18+,19-,20-,22-,23-,24-,25+/m0/s1
DMVBO78	CS	C[C@H]1CC(=O)[C@@H]/2[C@H]1C[C@]3(CC[C@@]4(CC[C@@H]([C@H]4[C@@H]3C/C=C2/C=O)C(=C)C)C)C
DMVBO78	IK	XAYQASOMEVLRKN-NOJNFTMQSA-N
DMVBO78	IU	(1R,3S,4S,7R,8E,11S,12S,13S,16S)-1,4,16-trimethyl-6-oxo-13-prop-1-en-2-yltetracyclo[9.7.0.03,7.012,16]octadec-8-ene-8-carbaldehyde
DMVBO78	CB	CHEBI:66349
DMVBO78	DE	Discovery agent

DM3K8PT	ID	DM3K8PT
DM3K8PT	DN	Va-RYYRIK-NH2
DM3K8PT	HS	Investigative
DM3K8PT	SN	CHEMBL272084
DM3K8PT	DT	Small molecular drug
DM3K8PT	PC	44456101
DM3K8PT	MW	965.2
DM3K8PT	FM	C47H76N14O8
DM3K8PT	IC	InChI=1S/C47H76N14O8/c1-4-6-19-38(63)56-34(17-12-25-54-46(50)51)41(65)59-36(27-30-14-8-7-9-15-30)44(68)60-37(28-31-20-22-32(62)23-21-31)43(67)58-35(18-13-26-55-47(52)53)42(66)61-39(29(3)5-2)45(69)57-33(40(49)64)16-10-11-24-48/h7-9,14-15,20-23,29,33-37,39,62H,4-6,10-13,16-19,24-28,48H2,1-3H3,(H2,49,64)(H,56,63)(H,57,69)(H,58,67)(H,59,65)(H,60,68)(H,61,66)(H4,50,51,54)(H4,52,53,55)/t29-,33-,34-,35-,36-,37-,39-/m0/s1
DM3K8PT	CS	CCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N
DM3K8PT	IK	JKNVIONDDVKVIP-INYUMPDKSA-N
DM3K8PT	IU	(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(pentanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DM3K8PT	DE	Discovery agent

DM8ACIF	ID	DM8ACIF
DM8ACIF	DN	VBY- 285
DM8ACIF	HS	Investigative
DM8ACIF	SN	VBY-285; Cathepsin S inhibitor (neuropathic pain, oral), Virobay
DM8ACIF	CP	Virobay Inc
DM8ACIF	DE	Neuropathic pain

DMG1YZQ	ID	DMG1YZQ
DMG1YZQ	DN	VCP-28
DMG1YZQ	HS	Investigative
DMG1YZQ	SN	VCP-28; CHEMBL399774; BDBM50292322; N6-(2,2,5,5-tetramethylpyrrolidin-1-yloxyl-3-ylmethyl)adenosine
DMG1YZQ	DT	Small molecular drug
DMG1YZQ	PC	44442164
DMG1YZQ	MW	421.5
DMG1YZQ	FM	C19H29N6O5
DMG1YZQ	IC	InChI=1S/C19H29N6O5/c1-18(2)5-10(19(3,4)25(18)29)6-20-15-12-16(22-8-21-15)24(9-23-12)17-14(28)13(27)11(7-26)30-17/h8-11,13-14,17,26-28H,5-7H2,1-4H3,(H,20,21,22)/t10?,11-,13-,14-,17-/m1/s1
DMG1YZQ	CS	CC1(CC(C(N1[O])(C)C)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)C
DMG1YZQ	IK	QFFVFNDFHJHEHU-QIFOKDCASA-N
DMG1YZQ	DE	Discovery agent

DMN62VE	ID	DMN62VE
DMN62VE	DN	VDA-1124
DMN62VE	HS	Investigative
DMN62VE	SN	Granzyme B inhibitors (abdominal aortic aneurysms), viDA Therapeutics
DMN62VE	CP	ViDA Therapeutics Inc
DMN62VE	DE	Aortic aneurysm

DM3GADP	ID	DM3GADP
DM3GADP	DN	VE-04051645
DM3GADP	HS	Investigative
DM3GADP	SN	Direct thrombin inhibitors (cardiovascular diseases/cancer/neurodegenerative disease); Direct thrombin inhibitors (cardiovascular diseases/cancer/neurodegenerative disease), Verseon; Small molecule allosteric thrombin inhibitors (cancer/neurodegenerative/cardiovascular disease), Verseon
DM3GADP	CP	Verseon
DM3GADP	DE	Solid tumour/cancer

DM0UXNF	ID	DM0UXNF
DM0UXNF	DN	VE-821
DM0UXNF	HS	Investigative
DM0UXNF	SN	ATR serine/threonine protein kinase inhibitors (cancer), Oxford University; ATR serine/threonine protein kinase inhibitors (cancer), Vertex Pharmaceuticals
DM0UXNF	CP	University of Oxford
DM0UXNF	DT	Small molecular drug
DM0UXNF	PC	51000408
DM0UXNF	MW	368.4
DM0UXNF	FM	C18H16N4O3S
DM0UXNF	IC	InChI=1S/C18H16N4O3S/c1-26(24,25)14-9-7-12(8-10-14)15-11-20-17(19)16(22-15)18(23)21-13-5-3-2-4-6-13/h2-11H,1H3,(H2,19,20)(H,21,23)
DM0UXNF	CS	CS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CC=CC=C3)N
DM0UXNF	IK	DUIHHZKTCSNTGM-UHFFFAOYSA-N
DM0UXNF	IU	3-amino-6-(4-methylsulfonylphenyl)-N-phenylpyrazine-2-carboxamide
DM0UXNF	CA	CAS 1232410-49-9
DM0UXNF	CB	CHEBI:124916
DM0UXNF	DE	Solid tumour/cancer

DMWXCYA	ID	DMWXCYA
DMWXCYA	DN	VEGF receptor 2 kinase inhibitor I
DMWXCYA	HS	Investigative
DMWXCYA	SN	VEGF Receptor 2 Kinase Inhibitor I; UNII-U07H877HUF; CHEMBL86943; U07H877HUF; 15966-93-5; (Z)-3-[(2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]indolin-2-one; Vegfr-2 inhi; ethyl 2,4-dimethyl-5-{[(3Z)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-1H-pyrrole-3-carboxylate; Ethyl 2,4-dimethyl-5-(((3Z)-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl)-1H-pyrrole-3-carboxylate; AC1O4WEX; K00004; Vegfr 2 kinase inhibitor I; SCHEMBL378979; VEGFR2 KiN/Ase Inhibitor I; GTPL6053; MolPort-044-561-167; HMS3229O05; ZINC3875265
DMWXCYA	DT	Small molecular drug
DMWXCYA	PC	6419834
DMWXCYA	MW	310.3
DMWXCYA	FM	C18H18N2O3
DMWXCYA	IC	InChI=1S/C18H18N2O3/c1-4-23-18(22)16-10(2)15(19-11(16)3)9-13-12-7-5-6-8-14(12)20-17(13)21/h5-9,19H,4H2,1-3H3,(H,20,21)/b13-9-
DMWXCYA	CS	CCOC(=O)C1=C(NC(=C1C)/C=C\\2/C3=CC=CC=C3NC2=O)C
DMWXCYA	IK	PMUJUSJUVIXDQC-LCYFTJDESA-N
DMWXCYA	IU	ethyl 2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrole-3-carboxylate
DMWXCYA	CA	CAS 15966-93-5
DMWXCYA	DE	Discovery agent

DMFZMA2	ID	DMFZMA2
DMFZMA2	DN	VER-156084
DMFZMA2	HS	Investigative
DMFZMA2	SN	VER-156084; CHEMBL555563; BDBM50296484
DMFZMA2	DT	Small molecular drug
DMFZMA2	PC	44243144
DMFZMA2	MW	420.3
DMFZMA2	FM	C21H23Cl2N3O2
DMFZMA2	IC	InChI=1S/C21H23Cl2N3O2/c22-16-8-6-15(7-9-16)19(18-5-4-10-24-20(18)23)28-17-13-26(14-17)21(27)25-11-2-1-3-12-25/h4-10,17,19H,1-3,11-14H2/t19-/m0/s1
DMFZMA2	CS	C1CCN(CC1)C(=O)N2CC(C2)O[C@@H](C3=CC=C(C=C3)Cl)C4=C(N=CC=C4)Cl
DMFZMA2	IK	QEKKZTBXSULKCC-IBGZPJMESA-N
DMFZMA2	IU	[3-[(S)-(4-chlorophenyl)-(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]-piperidin-1-ylmethanone
DMFZMA2	DE	Neuropathic pain

DMCRHOA	ID	DMCRHOA
DMCRHOA	DN	VER-156085
DMCRHOA	HS	Investigative
DMCRHOA	SN	VER-156085; CHEMBL558709; BDBM50296485
DMCRHOA	DT	Small molecular drug
DMCRHOA	PC	44250208
DMCRHOA	MW	420.3
DMCRHOA	FM	C21H23Cl2N3O2
DMCRHOA	IC	InChI=1S/C21H23Cl2N3O2/c22-16-8-6-15(7-9-16)19(18-5-4-10-24-20(18)23)28-17-13-26(14-17)21(27)25-11-2-1-3-12-25/h4-10,17,19H,1-3,11-14H2/t19-/m1/s1
DMCRHOA	CS	C1CCN(CC1)C(=O)N2CC(C2)O[C@H](C3=CC=C(C=C3)Cl)C4=C(N=CC=C4)Cl
DMCRHOA	IK	QEKKZTBXSULKCC-LJQANCHMSA-N
DMCRHOA	IU	[3-[(R)-(4-chlorophenyl)-(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]-piperidin-1-ylmethanone
DMCRHOA	DE	Discovery agent

DM5WAM8	ID	DM5WAM8
DM5WAM8	DN	VER-2692
DM5WAM8	HS	Investigative
DM5WAM8	SN	VER-2692; CHEMBL201930; SCHEMBL6605040; SDEXYLCQNBTWLI-JTQLQIEISA-N; BDBM50176272; (S)-1-(1H-pyrrolo[2,3-f]quinolin-1-yl)-2-propylamine
DM5WAM8	DT	Small molecular drug
DM5WAM8	PC	10198431
DM5WAM8	MW	225.29
DM5WAM8	FM	C14H15N3
DM5WAM8	IC	InChI=1S/C14H15N3/c1-10(15)9-17-8-6-11-4-5-13-12(14(11)17)3-2-7-16-13/h2-8,10H,9,15H2,1H3/t10-/m0/s1
DM5WAM8	CS	C[C@@H](CN1C=CC2=C1C3=C(C=C2)N=CC=C3)N
DM5WAM8	IK	SDEXYLCQNBTWLI-JTQLQIEISA-N
DM5WAM8	IU	(2S)-1-pyrrolo[2,3-f]quinolin-1-ylpropan-2-amine
DM5WAM8	DE	Discovery agent

DM7O2K1	ID	DM7O2K1
DM7O2K1	DN	VER-3323
DM7O2K1	HS	Investigative
DM7O2K1	SN	VER-3323; Lopac-V-1889; CHEMBL309760; 259857-99-3; (2S)-1-(6-bromo-2,3-dihydroindol-1-yl)propan-2-amine; (S)-2-(6-Bromo-2,3-dihydro-indol-1-yl)-1-methyl-ethylamine; SR-01000075153; NCGC00016082-01; AC1O7G7U; Lopac0_000659; GTPL168; SCHEMBL7674586; BDBM50144840; 1H-Indole-1-ethanamine, 6-bromo-2,3-dihydro-alpha-methyl-, (alphaS)-; CCG-204745; NCGC00162213-01; NCGC00162213-02; LS-193647; SR-01000075153-5
DM7O2K1	DT	Small molecular drug
DM7O2K1	PC	6604042
DM7O2K1	MW	255.15
DM7O2K1	FM	C11H15BrN2
DM7O2K1	IC	InChI=1S/C11H15BrN2/c1-8(13)7-14-5-4-9-2-3-10(12)6-11(9)14/h2-3,6,8H,4-5,7,13H2,1H3/t8-/m0/s1
DM7O2K1	CS	C[C@@H](CN1CCC2=C1C=C(C=C2)Br)N
DM7O2K1	IK	QGRQJMXAQYGAKK-QMMMGPOBSA-N
DM7O2K1	IU	(2S)-1-(6-bromo-2,3-dihydroindol-1-yl)propan-2-amine
DM7O2K1	DE	Discovery agent

DMF1KDX	ID	DMF1KDX
DMF1KDX	DN	VER-49009
DMF1KDX	HS	Investigative
DMF1KDX	DT	Small molecular drug
DMF1KDX	PC	4369536
DMF1KDX	MW	387.8
DMF1KDX	FM	C19H18ClN3O4
DMF1KDX	IC	InChI=1S/C19H18ClN3O4/c1-3-21-19(26)18-16(10-4-6-11(27-2)7-5-10)17(22-23-18)12-8-13(20)15(25)9-14(12)24/h4-9,24-25H,3H2,1-2H3,(H,21,26)(H,22,23)
DMF1KDX	CS	CCNC(=O)C1=C(C(=NN1)C2=CC(=C(C=C2O)O)Cl)C3=CC=C(C=C3)OC
DMF1KDX	IK	HUNAOTXNHVALTN-UHFFFAOYSA-N
DMF1KDX	IU	3-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)-1H-pyrazole-5-carboxamide
DMF1KDX	CA	CAS 940289-57-6
DMF1KDX	CB	CHEBI:47273
DMF1KDX	DE	Discovery agent

DMC2EO9	ID	DMC2EO9
DMC2EO9	DN	VER-5384
DMC2EO9	HS	Investigative
DMC2EO9	SN	VER-5384; CHEMBL77880; SCHEMBL905999; BDBM50144842; LS-193617
DMC2EO9	DT	Small molecular drug
DMC2EO9	PC	9859257
DMC2EO9	MW	218.29
DMC2EO9	FM	C13H18N2O
DMC2EO9	IC	InChI=1S/C13H18N2O/c1-9(14)8-15-6-4-10-2-3-12-11(13(10)15)5-7-16-12/h2-3,9H,4-8,14H2,1H3/t9-/m0/s1
DMC2EO9	CS	C[C@@H](CN1CCC2=C1C3=C(C=C2)OCC3)N
DMC2EO9	IK	OBQZQQHWYDPMDY-VIFPVBQESA-N
DMC2EO9	IU	(2S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)propan-2-amine
DMC2EO9	DE	Discovery agent

DMYD7P5	ID	DMYD7P5
DMYD7P5	DN	VER-54505
DMYD7P5	HS	Investigative
DMYD7P5	SN	Cdk2 inhibitors, Vernalis; RBT-0049985
DMYD7P5	CP	Vernalis plc
DMYD7P5	DE	Solid tumour/cancer

DMZ2V0A	ID	DMZ2V0A
DMZ2V0A	DN	VER-5593
DMZ2V0A	HS	Investigative
DMZ2V0A	SN	VER-5593; CHEMBL76474; SCHEMBL10199665; BDBM50144846; LS-193648
DMZ2V0A	DT	Small molecular drug
DMZ2V0A	PC	11264955
DMZ2V0A	MW	240.34
DMZ2V0A	FM	C12H17FN2S
DMZ2V0A	IC	InChI=1S/C12H17FN2S/c1-8(14)7-15-4-3-9-5-10(13)12(16-2)6-11(9)15/h5-6,8H,3-4,7,14H2,1-2H3/t8-/m0/s1
DMZ2V0A	CS	C[C@@H](CN1CCC2=CC(=C(C=C21)SC)F)N
DMZ2V0A	IK	IGAAICGMRRWZJW-QMMMGPOBSA-N
DMZ2V0A	IU	(2S)-1-(5-fluoro-6-methylsulfanyl-2,3-dihydroindol-1-yl)propan-2-amine
DMZ2V0A	DE	Discovery agent

DMJRVBS	ID	DMJRVBS
DMJRVBS	DN	VERAGUENSIN
DMJRVBS	HS	Investigative
DMJRVBS	SN	Veraguensin; CHEMBL112481; ( )-Veraguensin; SCHEMBL10900486; BDBM50002830; (2R,3R,4R,5S)-2,5-Bis-(3,4-dimethoxy-phenyl)-3,4-dimethyl-tetrahydro-furan
DMJRVBS	DT	Small molecular drug
DMJRVBS	PC	443026
DMJRVBS	MW	372.5
DMJRVBS	FM	C22H28O5
DMJRVBS	IC	InChI=1S/C22H28O5/c1-13-14(2)22(16-8-10-18(24-4)20(12-16)26-6)27-21(13)15-7-9-17(23-3)19(11-15)25-5/h7-14,21-22H,1-6H3/t13-,14-,21-,22+/m0/s1
DMJRVBS	CS	C[C@H]1[C@@H]([C@H](O[C@H]1C2=CC(=C(C=C2)OC)OC)C3=CC(=C(C=C3)OC)OC)C
DMJRVBS	IK	JLJAVUZBHSLLJL-GKHNXXNSSA-N
DMJRVBS	IU	(2R,3S,4S,5S)-2,5-bis(3,4-dimethoxyphenyl)-3,4-dimethyloxolane
DMJRVBS	CA	CAS 19950-55-1
DMJRVBS	CB	CHEBI:69669
DMJRVBS	DE	Discovery agent

DMUF8JZ	ID	DMUF8JZ
DMUF8JZ	DN	Veratridine
DMUF8JZ	HS	Investigative
DMUF8JZ	SN	veratrine; 3-veratroylveracevine
DMUF8JZ	DT	Small molecular drug
DMUF8JZ	PC	6280
DMUF8JZ	MW	673.8
DMUF8JZ	FM	C36H51NO11
DMUF8JZ	IC	InChI=1S/C36H51NO11/c1-19-6-11-26-31(3,40)35(43)25(17-37(26)16-19)33(42)18-34-24(32(33,41)15-27(35)38)10-9-23-30(34,2)13-12-28(36(23,44)48-34)47-29(39)20-7-8-21(45-4)22(14-20)46-5/h7-8,14,19,23-28,38,40-44H,6,9-13,15-18H2,1-5H3/t19-,23-,24-,25-,26-,27-,28-,30-,31+,32+,33+,34+,35-,36-/m0/s1
DMUF8JZ	CS	C[C@H]1CC[C@H]2[C@@]([C@]3([C@H](C[C@]4([C@@H]5CC[C@H]6[C@]7([C@]5(C[C@]4([C@@H]3CN2C1)O)O[C@@]6([C@H](CC7)OC(=O)C8=CC(=C(C=C8)OC)OC)O)C)O)O)O)(C)O
DMUF8JZ	IK	FVECELJHCSPHKY-YFUMOZOISA-N
DMUF8JZ	IU	[(1R,2S,6S,9S,10R,11S,12S,14R,15S,18S,19S,22S,23S,25R)-1,10,11,12,14,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] 3,4-dimethoxybenzoate
DMUF8JZ	CA	CAS 71-62-5
DMUF8JZ	CB	CHEBI:28051
DMUF8JZ	DE	Discovery agent

DM7NRK5	ID	DM7NRK5
DM7NRK5	DN	Verdoheme
DM7NRK5	HS	Investigative
DM7NRK5	DT	Small molecular drug
DM7NRK5	PC	11963948
DM7NRK5	MW	549.4
DM7NRK5	FM	C30H29FeN4O3+3
DM7NRK5	IC	InChI=1S/C30H30N4O3.Fe/c1-8-20-19(7)29-34-27(20)15-25-18(6)22(10-11-28(35)36)23(32-25)12-13-31-24(16(3)4)14-26-17(5)21(9-2)30(33-26)37-29;/h8-9,12-15H,1-3,10-11H2,4-7H3,(H2-,31,32,33,34,35,36);/q;+4/p-1
DM7NRK5	CS	CC1=C(C2=[O+]C3=NC(=CC4=C(C(=C([N-]4)C=CN=C(C=C1[N-]2)C(=C)C)CCC(=O)O)C)C(=C3C)C=C)C=C.[Fe+4]
DM7NRK5	IK	QNHRNHLUNLNYAK-UHFFFAOYSA-M
DM7NRK5	IU	3-[5,19-bis(ethenyl)-4,9,18-trimethyl-15-prop-1-en-2-yl-2-oxonia-14,22-diaza-20,21-diazanidatetracyclo[15.2.1.13,6.18,11]docosa-1,3(22),4,6,8,10,12,14,16,18-decaen-10-yl]propanoic acid;iron(4+)
DM7NRK5	DE	Discovery agent

DMD1C6S	ID	DMD1C6S
DMD1C6S	DN	Verongamine
DMD1C6S	HS	Investigative
DMD1C6S	SN	Verongamine; 150036-88-7; CHEBI:66355; L008857; Benzenepropanamide, 3-bromo-alpha-(hydroxyimino)-N-(2-(1H-imidazol-4-yl)ethyl)-4-methoxy-, (E)-; (E)-3-bromo-alpha-(hydroxyimino)-N-(2-(1H-imidazol-4-yl)ethyl)-4-methoxy-benzenepropanamide
DMD1C6S	DT	Small molecular drug
DMD1C6S	PC	9578063
DMD1C6S	MW	381.22
DMD1C6S	FM	C15H17BrN4O3
DMD1C6S	IC	InChI=1S/C15H17BrN4O3/c1-23-14-3-2-10(6-12(14)16)7-13(20-22)15(21)18-5-4-11-8-17-9-19-11/h2-3,6,8-9,22H,4-5,7H2,1H3,(H,17,19)(H,18,21)/b20-13+
DMD1C6S	CS	COC1=C(C=C(C=C1)C/C(=N\\O)/C(=O)NCCC2=CN=CN2)Br
DMD1C6S	IK	MFMMJKGZEGTTSV-DEDYPNTBSA-N
DMD1C6S	IU	(2E)-3-(3-bromo-4-methoxyphenyl)-2-hydroxyimino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide
DMD1C6S	CA	CAS 150036-88-7
DMD1C6S	CB	CHEBI:66355
DMD1C6S	DE	Discovery agent

DMUHEJ3	ID	DMUHEJ3
DMUHEJ3	DN	Very low dose (VLD) cyclobenzaprine
DMUHEJ3	HS	Investigative
DMUHEJ3	CP	Pharmos
DMUHEJ3	DE	Fibromyalgia

DMHKUBG	ID	DMHKUBG
DMHKUBG	DN	Vesamicol
DMHKUBG	HS	Investigative
DMHKUBG	SN	vesamicol; VESAMICOL HYDROCHLORIDE; 22232-64-0; CHEMBL20943; MLS000554350; 2-(4-Phenyl-piperidin-1-yl)-cyclohexanol; Cyclohexanol, 2-(4-phenyl-1-piperidinyl)-; 2-(4-phenylpiperidin-1-yl)cyclohexan-1-ol; AH-5183; 2-(4-Phenyl-1-piperidinyl)cyclohexanol; SMR000146667; 2-(4-Phenylpiperidino)cyclohexanol; 23965-53-9; V-100; Spectrum_000292; Opera_ID_322; AC1Q7BAI; AC1L1KUQ; Prestwick1_000920; Spectrum3_001861; Prestwick0_000920; Prestwick2_000920; Oprea1_778558; Lopac0_001228; Oprea1_695768; KBioSS_000772; BSPBio_003302; MLS001201728
DMHKUBG	DT	Small molecular drug
DMHKUBG	PC	5662
DMHKUBG	MW	259.399
DMHKUBG	FM	C17H25NO
DMHKUBG	IC	InChI=1S/C17H25NO/c19-17-9-5-4-8-16(17)18-12-10-15(11-13-18)14-6-2-1-3-7-14/h1-3,6-7,15-17,19H,4-5,8-13H2
DMHKUBG	CS	C1CCC(C(C1)N2CCC(CC2)C3=CC=CC=C3)O
DMHKUBG	IK	YSSBJODGIYRAMI-UHFFFAOYSA-N
DMHKUBG	IU	2-(4-phenylpiperidin-1-yl)cyclohexan-1-ol
DMHKUBG	CA	CAS 22232-64-0
DMHKUBG	CB	CHEBI:103974
DMHKUBG	DE	Discovery agent

DMO4GBK	ID	DMO4GBK
DMO4GBK	DN	vinburnine
DMO4GBK	HS	Investigative
DMO4GBK	SN	eburnamonine
DMO4GBK	DT	Small molecular drug
DMO4GBK	PC	71203
DMO4GBK	MW	294.4
DMO4GBK	FM	C19H22N2O
DMO4GBK	IC	InChI=1S/C19H22N2O/c1-2-19-9-5-10-20-11-8-14-13-6-3-4-7-15(13)21(16(22)12-19)17(14)18(19)20/h3-4,6-7,18H,2,5,8-12H2,1H3/t18-,19+/m1/s1
DMO4GBK	CS	CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=O)C2
DMO4GBK	IK	WYJAPUKIYAZSEM-MOPGFXCFSA-N
DMO4GBK	IU	(15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-one
DMO4GBK	CA	CAS 4880-88-0
DMO4GBK	CB	CHEBI:4740
DMO4GBK	DE	Discovery agent

DMNFVO7	ID	DMNFVO7
DMNFVO7	DN	Vinylsulphones
DMNFVO7	HS	Investigative
DMNFVO7	DE	Infection of P. falciparum

DMAXOPS	ID	DMAXOPS
DMAXOPS	DN	viral macrophage inflammatory protein-II
DMAXOPS	HS	Investigative
DMAXOPS	SN	CFLTKRGRQVC; vMIP-II; Viral macrophage inflammatory protein-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMAXOPS	DT	Small molecular drug
DMAXOPS	PC	486830
DMAXOPS	MW	1308.6
DMAXOPS	FM	C55H93N19O14S2
DMAXOPS	IC	InChI=1S/C55H93N19O14S2/c1-28(2)23-37-50(84)74-43(30(5)75)52(86)69-35(15-9-10-20-56)47(81)67-33(16-11-21-63-54(59)60)45(79)65-25-41(77)66-34(17-12-22-64-55(61)62)46(80)68-36(18-19-40(58)76)48(82)73-42(29(3)4)51(85)72-39(53(87)88)27-90-89-26-32(57)44(78)70-38(49(83)71-37)24-31-13-7-6-8-14-31/h6-8,13-14,28-30,32-39,42-43,75H,9-12,15-27,56-57H2,1-5H3,(H2,58,76)(H,65,79)(H,66,77)(H,67,81)(H,68,80)(H,69,86)(H,70,78)(H,71,83)(H,72,85)(H,73,82)(H,74,84)(H,87,88)(H4,59,60,63)(H4,61,62,64)/t30-,32+,33+,34+,35+,36+,37+,38+,39+,42+,43+/m1/s1
DMAXOPS	CS	C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(C)C)CC2=CC=CC=C2)N)C(=O)O)C(C)C)CCC(=O)N)CCCN=C(N)N)CCCN=C(N)N)CCCCN)O
DMAXOPS	IK	JOEHPBQVSCDCHE-BKGQOYFSSA-N
DMAXOPS	IU	(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMAXOPS	DE	Discovery agent

DMCSHE8	ID	DMCSHE8
DMCSHE8	DN	visnagin
DMCSHE8	HS	Investigative
DMCSHE8	SN	desmethoxykhellin
DMCSHE8	DT	Small molecular drug
DMCSHE8	PC	6716
DMCSHE8	MW	230.22
DMCSHE8	FM	C13H10O4
DMCSHE8	IC	InChI=1S/C13H10O4/c1-7-5-9(14)12-11(17-7)6-10-8(3-4-16-10)13(12)15-2/h3-6H,1-2H3
DMCSHE8	CS	CC1=CC(=O)C2=C(O1)C=C3C(=C2OC)C=CO3
DMCSHE8	IK	NZVQLVGOZRELTG-UHFFFAOYSA-N
DMCSHE8	IU	4-methoxy-7-methylfuro[3,2-g]chromen-5-one
DMCSHE8	CA	CAS 82-57-5
DMCSHE8	CB	CHEBI:10002
DMCSHE8	DE	Discovery agent

DMN6EZY	ID	DMN6EZY
DMN6EZY	DN	Vitamin K
DMN6EZY	HS	Investigative
DMN6EZY	SN	12001-79-5; MBWXNTAXLNYFJB-LKUDQCMESA-N; 81818-54-4
DMN6EZY	DT	Small molecular drug
DMN6EZY	PC	5280483
DMN6EZY	MW	450.7
DMN6EZY	FM	C31H46O2
DMN6EZY	IC	InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+
DMN6EZY	CS	CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CCCC(C)CCCC(C)CCCC(C)C
DMN6EZY	IK	MBWXNTAXLNYFJB-LKUDQCMESA-N
DMN6EZY	IU	2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
DMN6EZY	CA	CAS 12001-79-5
DMN6EZY	CB	CHEBI:94399
DMN6EZY	DE	Discovery agent

DMJB3E1	ID	DMJB3E1
DMJB3E1	DN	VITAMIN K2
DMJB3E1	HS	Investigative
DMJB3E1	SN	menaquinone-2; MK-2; menaquinone(2); AC1NQWYQ; Prestwick3_001100; BSPBio_001180; SCHEMBL416517; 2-(3,7-dimethylocta-2,6-dienyl)-3-methylnaphthalene-1,4-dione; CHEMBL263382; BPBio1_001298; GTPL2771; PTWSIIUEOFZCHW-NTCAYCPXSA-N; HMS2098K22; 2-(3,7-Dimethyl-2,6-octadienyl)-3-methyl-1,4-naphthoquinone; 1,4-Naphthoquinone, 2-(3,7-dimethyl-2,6-octadienyl)-3-methyl-; ZINC1532757; AKOS015899893; CJ-24250; 1163-13-9; 7421-23-0; AB00514047; C00828; I14-11159; 2-Methyl-3-(3,7-dimethyl-2,6-octadienyl)-1,4-naphthoquinone
DMJB3E1	DT	Small molecular drug
DMJB3E1	PC	5282367
DMJB3E1	MW	444.6
DMJB3E1	FM	C31H40O2
DMJB3E1	IC	InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+
DMJB3E1	CS	CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DMJB3E1	IK	DKHGMERMDICWDU-GHDNBGIDSA-N
DMJB3E1	IU	2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]naphthalene-1,4-dione
DMJB3E1	CA	CAS 863-61-6
DMJB3E1	CB	CHEBI:78277
DMJB3E1	DE	Discovery agent

DM7FQD0	ID	DM7FQD0
DM7FQD0	DN	VK-11
DM7FQD0	HS	Investigative
DM7FQD0	SN	Imaging agent (Alzheimer's disease), Prana
DM7FQD0	CP	Prana Biotechnology Ltd
DM7FQD0	DE	Alzheimer disease

DMRQBEW	ID	DMRQBEW
DMRQBEW	DN	VK-12
DMRQBEW	HS	Investigative
DMRQBEW	SN	Anticancer/neuroprotectant (cancer/Parkinsons/Alzheimer's disease), Prana
DMRQBEW	CP	Prana Biotechnology Ltd
DMRQBEW	DE	Solid tumour/cancer

DMKW5YL	ID	DMKW5YL
DMKW5YL	DN	VL-0395
DMKW5YL	HS	Investigative
DMKW5YL	SN	CHEMBL137814; GTPL886; BDBM50061836; 3-{3-[(5-Carbamimidoyl-1H-indole-2-carbonyl)-amino]-benzoylamino}-3-phenyl-propionic acid; beta-[[3-[(5-Amidino-1H-indol-2-yl)carbonylamino]benzoyl]amino]benzenepropanoic acid; 3-[[3-[(5-carbamimidoyl1H-indole-2-carbonyl)amino]benzoyl]amino]-3-phenylpropanoic acid
DMKW5YL	DT	Small molecular drug
DMKW5YL	PC	10742947
DMKW5YL	MW	469.5
DMKW5YL	FM	C26H23N5O4
DMKW5YL	IC	InChI=1S/C26H23N5O4/c27-24(28)16-9-10-20-18(11-16)13-22(30-20)26(35)29-19-8-4-7-17(12-19)25(34)31-21(14-23(32)33)15-5-2-1-3-6-15/h1-13,21,30H,14H2,(H3,27,28)(H,29,35)(H,31,34)(H,32,33)
DMKW5YL	CS	C1=CC=C(C=C1)C(CC(=O)O)NC(=O)C2=CC(=CC=C2)NC(=O)C3=CC4=C(N3)C=CC(=C4)C(=N)N
DMKW5YL	IK	RVWSCZNGPOUASU-UHFFFAOYSA-N
DMKW5YL	IU	3-[[3-[(5-carbamimidoyl-1H-indole-2-carbonyl)amino]benzoyl]amino]-3-phenylpropanoic acid
DMKW5YL	DE	Discovery agent

DM2XAUY	ID	DM2XAUY
DM2XAUY	DN	VL-0494
DM2XAUY	HS	Investigative
DM2XAUY	DT	Small molecular drug
DM2XAUY	PC	136060576
DM2XAUY	MW	571.6
DM2XAUY	FM	C38H25N3O3
DM2XAUY	IC	InChI=1S/C38H25N3O3/c42-34-21-20-28-27(19-16-24-14-17-26(18-15-24)25-8-2-1-3-9-25)22-35-39-32-12-6-7-13-33(32)41(35)36(28)31(34)23-40-37(43)29-10-4-5-11-30(29)38(40)44/h1-22,42H,23H2/b19-16+
DM2XAUY	CS	C1=CC=C(C=C1)C2=CC=C(C=C2)/C=C/C3=CC4=NC5=CC=CC=C5N4C6=C3C=CC(=C6CN7C(=O)C8=CC=CC=C8C7=O)O
DM2XAUY	IK	XCVOBDZXSDXTNL-KNTRCKAVSA-N
DM2XAUY	IU	2-[[2-hydroxy-5-[(E)-2-(4-phenylphenyl)ethenyl]benzimidazolo[1,2-a]quinolin-1-yl]methyl]isoindole-1,3-dione
DM2XAUY	DE	Discovery agent

DMCZNB3	ID	DMCZNB3
DMCZNB3	DN	VL-0699
DMCZNB3	HS	Investigative
DMCZNB3	SN	CHEMBL208171; VL-0699; BDBM50185263; 2(R,S)-{2-[(2-acetylaminocinnamoyl)amino]benzoylamino}-3-phenylpropionic acid
DMCZNB3	DT	Small molecular drug
DMCZNB3	PC	11442807
DMCZNB3	MW	471.5
DMCZNB3	FM	C27H25N3O5
DMCZNB3	IC	InChI=1S/C27H25N3O5/c1-18(31)28-23(16-19-10-4-2-5-11-19)26(33)29-22-15-9-8-14-21(22)25(32)30-24(27(34)35)17-20-12-6-3-7-13-20/h2-16,24H,17H2,1H3,(H,28,31)(H,29,33)(H,30,32)(H,34,35)/b23-16+
DMCZNB3	CS	CC(=O)N/C(=C/C1=CC=CC=C1)/C(=O)NC2=CC=CC=C2C(=O)NC(CC3=CC=CC=C3)C(=O)O
DMCZNB3	IK	GKGZJDOSLXUABF-XQNSMLJCSA-N
DMCZNB3	IU	2-[[2-[[(E)-2-acetamido-3-phenylprop-2-enoyl]amino]benzoyl]amino]-3-phenylpropanoic acid
DMCZNB3	DE	Discovery agent

DMU9VQJ	ID	DMU9VQJ
DMU9VQJ	DN	VL-1499
DMU9VQJ	HS	Investigative
DMU9VQJ	SN	CHEMBL377157; VL-1499; BDBM50185260; (+/-)-2-(2-cinnamamidobenzamido)-3-phenylpropanoic acid; 3-phenyl-2(R,S)-[2-(cinnamoylamino)benzoylamino]propionic acid
DMU9VQJ	DT	Small molecular drug
DMU9VQJ	PC	11200806
DMU9VQJ	MW	414.5
DMU9VQJ	FM	C25H22N2O4
DMU9VQJ	IC	InChI=1S/C25H22N2O4/c28-23(16-15-18-9-3-1-4-10-18)26-21-14-8-7-13-20(21)24(29)27-22(25(30)31)17-19-11-5-2-6-12-19/h1-16,22H,17H2,(H,26,28)(H,27,29)(H,30,31)/b16-15+
DMU9VQJ	CS	C1=CC=C(C=C1)CC(C(=O)O)NC(=O)C2=CC=CC=C2NC(=O)/C=C/C3=CC=CC=C3
DMU9VQJ	IK	GKKJCDQBYJQSQR-FOCLMDBBSA-N
DMU9VQJ	IU	3-phenyl-2-[[2-[[(E)-3-phenylprop-2-enoyl]amino]benzoyl]amino]propanoic acid
DMU9VQJ	DE	Discovery agent

DMBEV4W	ID	DMBEV4W
DMBEV4W	DN	VL-2799
DMBEV4W	HS	Investigative
DMBEV4W	SN	CHEMBL380355; VL-2799; BDBM50185259; AKOS030589696; 2(R,S)-{2-[(1H-indole-2-carbonyl)amino]-benzoylamino}propionic acid; 2-(R,S)-{2-[(1H-Indole-2-carbonyl)-amino]-benzoylamino}-propionic acid
DMBEV4W	DT	Small molecular drug
DMBEV4W	PC	44409521
DMBEV4W	MW	351.4
DMBEV4W	FM	C19H17N3O4
DMBEV4W	IC	InChI=1S/C19H17N3O4/c1-11(19(25)26)20-17(23)13-7-3-5-9-15(13)22-18(24)16-10-12-6-2-4-8-14(12)21-16/h2-11,21H,1H3,(H,20,23)(H,22,24)(H,25,26)
DMBEV4W	CS	CC(C(=O)O)NC(=O)C1=CC=CC=C1NC(=O)C2=CC3=CC=CC=C3N2
DMBEV4W	IK	GNVBTLURHXQVAD-UHFFFAOYSA-N
DMBEV4W	IU	2-[[2-(1H-indole-2-carbonylamino)benzoyl]amino]propanoic acid
DMBEV4W	CA	CAS 657432-67-2
DMBEV4W	DE	Discovery agent

DM95KRY	ID	DM95KRY
DM95KRY	DN	VLI-27
DM95KRY	HS	Investigative
DM95KRY	SN	AKT inhibitor (pancreatic cancer), NovaLead Pharma
DM95KRY	CP	NovaLead Pharma
DM95KRY	DE	Pancreatic cancer

DMYH3A0	ID	DMYH3A0
DMYH3A0	DN	VLTS-582
DMYH3A0	HS	Investigative
DMYH3A0	SN	gene therapy (MnSOD), Valentis; gene therapy (manganese superoxide dismutase), Valentis
DMYH3A0	DE	Discovery agent

DMJRI6A	ID	DMJRI6A
DMJRI6A	DN	VN/107-1
DMJRI6A	HS	Investigative
DMJRI6A	SN	CYP17 inhibitors (prostate cancer); CYP17 inhibitors (prostate cancer), University of Maryland; VN/108-1; VN/109-1; VN/125-1; VN/85-1; VN/87-1
DMJRI6A	CP	University of Maryland
DMJRI6A	PC	10593052
DMJRI6A	MW	337.5
DMJRI6A	FM	C21H27N3O
DMJRI6A	IC	InChI=1S/C21H27N3O/c1-20-9-7-15(25)11-14(20)3-4-16-17-5-6-19(24-13-22-12-23-24)21(17,2)10-8-18(16)20/h6,11-13,16-18H,3-5,7-10H2,1-2H3/t16-,17-,18-,20-,21-/m0/s1
DMJRI6A	CS	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4N5C=NC=N5)C
DMJRI6A	IK	OPPZNEHAUJDDQH-OEUJLIAZSA-N
DMJRI6A	IU	(8R,9S,10R,13S,14S)-10,13-dimethyl-17-(1,2,4-triazol-1-yl)-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one
DMJRI6A	DE	Prostate cancer

DMA106W	ID	DMA106W
DMA106W	DN	Voacangine
DMA106W	HS	Investigative
DMA106W	SN	Voacangine; CHEMBL182120; Carbomethoxyibogaine; (-)-Voacangine; 510-22-5; methyl ethyl(methoxy)[ ]carboxylate; AC1L2JJV; 12-Methoxyibogamine-18-carboxylic acid methyl ester; MMAYTCMMKJYIAM-RUGRQLENSA-N; BDBM50329104; ZINC100392804; Methyl (1S)-3,13-diaza-17-ethyl-7-methoxypentacyclo[13.3.1.0&lt; 2,10&gt; 4,9&gt; 13,18&gt; ]nonadeca-2(10),4,6,8-tetraenecarboxylate
DMA106W	DT	Small molecular drug
DMA106W	PC	73255
DMA106W	MW	368.5
DMA106W	FM	C22H28N2O3
DMA106W	IC	InChI=1S/C22H28N2O3/c1-4-14-9-13-11-22(21(25)27-3)19-16(7-8-24(12-13)20(14)22)17-10-15(26-2)5-6-18(17)23-19/h5-6,10,13-14,20,23H,4,7-9,11-12H2,1-3H3/t13-,14-,20-,22+/m0/s1
DMA106W	CS	CC[C@H]1C[C@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC)C(=O)OC
DMA106W	IK	MMAYTCMMKJYIAM-RUGRQLENSA-N
DMA106W	IU	methyl (1S,15S,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene-1-carboxylate
DMA106W	CA	CAS 510-22-5
DMA106W	CB	CHEBI:141966
DMA106W	DE	Discovery agent

DMT03VB	ID	DMT03VB
DMT03VB	DN	VP-343
DMT03VB	HS	Investigative
DMT03VB	SN	VP-343
DMT03VB	DT	Small molecular drug
DMT03VB	PC	9914030
DMT03VB	MW	503.6
DMT03VB	FM	C32H29N3O3
DMT03VB	IC	InChI=1S/C32H29N3O3/c1-21-10-12-22(13-11-21)27-6-2-3-7-28(27)31(37)33-24-16-14-23(15-17-24)32(38)35-19-25-18-26(36)20-34(25)29-8-4-5-9-30(29)35/h2-17,25-26,36H,18-20H2,1H3,(H,33,37)/t25-,26+/m1/s1
DMT03VB	CS	CC1=CC=C(C=C1)C2=CC=CC=C2C(=O)NC3=CC=C(C=C3)C(=O)N4C[C@H]5C[C@@H](CN5C6=CC=CC=C64)O
DMT03VB	IK	UACMTQPSUBFZOR-FTJBHMTQSA-N
DMT03VB	IU	N-[4-[(2S,3aR)-2-hydroxy-2,3,3a,4-tetrahydro-1H-pyrrolo[1,2-a]quinoxaline-5-carbonyl]phenyl]-2-(4-methylphenyl)benzamide
DMT03VB	DE	Discovery agent

DMIXUM3	ID	DMIXUM3
DMIXUM3	DN	VPC03090-P
DMIXUM3	HS	Investigative
DMIXUM3	SN	VPC-03090-P; VPC 03090-P
DMIXUM3	DT	Small molecular drug
DMIXUM3	PC	73755254
DMIXUM3	MW	369.4
DMIXUM3	FM	C19H32NO4P
DMIXUM3	IC	InChI=1S/C19H32NO4P/c1-2-3-4-5-6-7-9-16-10-8-11-17(12-16)18-13-19(20,14-18)15-24-25(21,22)23/h8,10-12,18H,2-7,9,13-15,20H2,1H3,(H2,21,22,23)
DMIXUM3	CS	CCCCCCCCC1=CC(=CC=C1)C2CC(C2)(COP(=O)(O)O)N
DMIXUM3	IK	LNMFICMTNRORPU-UHFFFAOYSA-N
DMIXUM3	IU	[1-amino-3-(3-octylphenyl)cyclobutyl]methyl dihydrogen phosphate
DMIXUM3	DE	Discovery agent

DM6F0VR	ID	DM6F0VR
DM6F0VR	DN	VPC12249
DM6F0VR	HS	Investigative
DM6F0VR	SN	VPC 12249; VPC-12249
DM6F0VR	DT	Small molecular drug
DM6F0VR	PC	10282223
DM6F0VR	MW	601.8
DM6F0VR	FM	C34H52NO6P
DM6F0VR	IC	InChI=1S/C34H52NO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-34(36)35-32(29-41-42(37,38)39)27-30-23-25-33(26-24-30)40-28-31-20-17-16-18-21-31/h9-10,16-18,20-21,23-26,32H,2-8,11-15,19,22,27-29H2,1H3,(H,35,36)(H2,37,38,39)/b10-9-/t32-/m1/s1
DM6F0VR	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)N[C@H](CC1=CC=C(C=C1)OCC2=CC=CC=C2)COP(=O)(O)O
DM6F0VR	IK	NJLPYJKKKSBCSK-MJPIYRIWSA-N
DM6F0VR	IU	[(2R)-2-[[(Z)-octadec-9-enoyl]amino]-3-(4-phenylmethoxyphenyl)propyl] dihydrogen phosphate
DM6F0VR	DE	Discovery agent

DMVQFY4	ID	DMVQFY4
DMVQFY4	DN	VPC23019
DMVQFY4	HS	Investigative
DMVQFY4	SN	VPC 23019; VPC-23019
DMVQFY4	DT	Small molecular drug
DMVQFY4	PC	11588811
DMVQFY4	MW	372.4
DMVQFY4	FM	C17H29N2O5P
DMVQFY4	IC	InChI=1S/C17H29N2O5P/c1-2-3-4-5-6-7-9-14-10-8-11-15(12-14)19-17(20)16(18)13-24-25(21,22)23/h8,10-12,16H,2-7,9,13,18H2,1H3,(H,19,20)(H2,21,22,23)/t16-/m1/s1
DMVQFY4	CS	CCCCCCCCC1=CC(=CC=C1)NC(=O)[C@@H](COP(=O)(O)O)N
DMVQFY4	IK	MRUSUGVVWGNKFE-MRXNPFEDSA-N
DMVQFY4	IU	[(2R)-2-amino-3-(3-octylanilino)-3-oxopropyl] dihydrogen phosphate
DMVQFY4	CB	CHEBI:144948
DMVQFY4	DE	Discovery agent

DMLK3I9	ID	DMLK3I9
DMLK3I9	DN	VPC32183
DMLK3I9	HS	Investigative
DMLK3I9	SN	compound 10t [PMID: 15125924]
DMLK3I9	DT	Small molecular drug
DMLK3I9	PC	44392752
DMLK3I9	MW	602.7
DMLK3I9	FM	C33H51N2O6P
DMLK3I9	IC	InChI=1S/C33H51N2O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-33(36)35-31(28-41-42(37,38)39)25-29-20-22-32(23-21-29)40-27-30-18-17-24-34-26-30/h9-10,17-18,20-24,26,31H,2-8,11-16,19,25,27-28H2,1H3,(H,35,36)(H2,37,38,39)/b10-9-/t31-/m1/s1
DMLK3I9	CS	CCCCCCCC/C=C\\CCCCCCCC(=O)N[C@H](CC1=CC=C(C=C1)OCC2=CN=CC=C2)COP(=O)(O)O
DMLK3I9	IK	KMTDWYLEJRZIJN-HWNQJZBBSA-N
DMLK3I9	IU	[(2R)-2-[[(Z)-octadec-9-enoyl]amino]-3-[4-(pyridin-3-ylmethoxy)phenyl]propyl] dihydrogen phosphate
DMLK3I9	DE	Discovery agent

DMQ4OTJ	ID	DMQ4OTJ
DMQ4OTJ	DN	VPC44116
DMQ4OTJ	HS	Investigative
DMQ4OTJ	SN	VPC-44116
DMQ4OTJ	DT	Small molecular drug
DMQ4OTJ	PC	11545181
DMQ4OTJ	MW	370.4
DMQ4OTJ	FM	C18H31N2O4P
DMQ4OTJ	IC	InChI=1S/C18H31N2O4P/c1-2-3-4-5-6-7-9-15-10-8-11-16(14-15)20-18(21)17(19)12-13-25(22,23)24/h8,10-11,14,17H,2-7,9,12-13,19H2,1H3,(H,20,21)(H2,22,23,24)/t17-/m1/s1
DMQ4OTJ	CS	CCCCCCCCC1=CC(=CC=C1)NC(=O)[C@@H](CCP(=O)(O)O)N
DMQ4OTJ	IK	FMLHSOGKNHADEE-QGZVFWFLSA-N
DMQ4OTJ	IU	[(3R)-3-amino-4-(3-octylanilino)-4-oxobutyl]phosphonic acid
DMQ4OTJ	DE	Discovery agent

DM20AJ4	ID	DM20AJ4
DM20AJ4	DN	VPC-94075
DM20AJ4	HS	Investigative
DM20AJ4	SN	Sphingosine kinase inhibitor (vascular disease); Sphingosine kinase inhibitor (vascular disease), University of Virgina
DM20AJ4	CP	University of Virginia
DM20AJ4	DT	Small molecular drug
DM20AJ4	PC	753704
DM20AJ4	MW	302.8
DM20AJ4	FM	C15H11ClN2OS
DM20AJ4	IC	InChI=1S/C15H11ClN2OS/c16-11-3-1-10(2-4-11)14-9-20-15(18-14)17-12-5-7-13(19)8-6-12/h1-9,19H,(H,17,18)
DM20AJ4	CS	C1=CC(=CC=C1C2=CSC(=N2)NC3=CC=C(C=C3)O)Cl
DM20AJ4	IK	ZFGXZJKLOFCECI-UHFFFAOYSA-N
DM20AJ4	IU	4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol
DM20AJ4	CA	CAS 312636-16-1
DM20AJ4	CB	CHEBI:92375
DM20AJ4	DE	Vascular disease

DM1QKVL	ID	DM1QKVL
DM1QKVL	DN	VRC3375
DM1QKVL	HS	Investigative
DM1QKVL	SN	VRC3375; AC1LAH4D; CTK6D4143; tert-butyl 1-{(2r)-2-[2-(hydroxyamino)-2-oxoethyl]hexanoyl}-l-prolinate; tert-butyl (2S)-1-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]hexanoyl]pyrrolidine-2-carboxylate; 1-[(R)-2-[2-Oxo-2-(hydroxyamino)ethyl]hexanoyl]-L-proline tert-butyl ester; L-Proline, 1-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-1-oxohexyl]-, 1,1-dimethylethyl ester; tert-butyl (2S)-1-[(2R)-2-[2-(hydroxyamino)-2-oxo-ethyl]hexanoyl]pyrrolidine-2-carboxylate
DM1QKVL	DT	Small molecular drug
DM1QKVL	PC	488029
DM1QKVL	MW	342.4
DM1QKVL	FM	C17H30N2O5
DM1QKVL	IC	InChI=1S/C17H30N2O5/c1-5-6-8-12(11-14(20)18-23)15(21)19-10-7-9-13(19)16(22)24-17(2,3)4/h12-13,23H,5-11H2,1-4H3,(H,18,20)/t12-,13+/m1/s1
DM1QKVL	CS	CCCC[C@H](CC(=O)NO)C(=O)N1CCC[C@H]1C(=O)OC(C)(C)C
DM1QKVL	IK	XNOOIEVKOZAJEO-OLZOCXBDSA-N
DM1QKVL	IU	tert-butyl (2S)-1-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]hexanoyl]pyrrolidine-2-carboxylate
DM1QKVL	DE	Discovery agent

DMFT49S	ID	DMFT49S
DMFT49S	DN	VRT-750018
DMFT49S	HS	Investigative
DMFT49S	SN	Syk tyrosine kinase inhibitors (asthma/allergy); Syk tyrosine kinase inhibitors (asthma/allergy), Vertex
DMFT49S	CP	Vertex Pharmaceuticals Inc
DMFT49S	DE	Allergy

DMCXZGU	ID	DMCXZGU
DMCXZGU	DN	VRX-03011
DMCXZGU	HS	Investigative
DMCXZGU	SN	5-HT4 agonist (cognition/neuroprotectant), EPIX
DMCXZGU	PC	23673468
DMCXZGU	MW	415.6
DMCXZGU	FM	C19H26KN3O3S
DMCXZGU	IC	InChI=1S/C19H27N3O3S.K/c1-13(2)22-18(25)15(16(23)14-7-12-26-19(14)22)17(24)20-8-6-11-21-9-4-3-5-10-21;/h7,12-13,23H,3-6,8-11H2,1-2H3,(H,20,24);/q;+1/p-1
DMCXZGU	CS	CC(C)N1C2=C(C=CS2)C(=C(C1=O)C(=O)NCCCN3CCCCC3)[O-].[K+]
DMCXZGU	IK	JWRDEPYIIBDWDI-UHFFFAOYSA-M
DMCXZGU	IU	potassium;6-oxo-5-(3-piperidin-1-ylpropylcarbamoyl)-7-propan-2-ylthieno[2,3-b]pyridin-4-olate
DMCXZGU	DE	Discovery agent

DMRP2IN	ID	DMRP2IN
DMRP2IN	DN	VS-12343
DMRP2IN	HS	Investigative
DMRP2IN	SN	Hesperetin 7-O-rutinoside; LMPK12140451; MCULE-6401179754; QUQPHWDTPGMPEX-SGHBVPQBSA-N; STK801624; Hesperetin-7-O-rutinoside; hesperidin; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 6-O-(6-deoxyhexopyranosyl)hexopyranoside; 520-26-3; AB0013409; AKOS004119862; AKOS016357494; Flavanone, 3',5,7-trihydroxy-4'-methoxy-, 7-(6-O-.alpha.-L-rhamnosyl-D-glucoside); H6243; H992; ALBB-028539; BBL033922; SCHEMBL13886768
DMRP2IN	PC	16394497
DMRP2IN	MW	610.6
DMRP2IN	FM	C28H34O15
DMRP2IN	IC	QUQPHWDTPGMPEX-SGHBVPQBSA-N
DMRP2IN	CS	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O
DMRP2IN	IK	1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10?,17-,19?,21?,22?,23?,24?,25?,26?,27?,28?/m0/s1
DMRP2IN	IU	(2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
DMRP2IN	CA	CAS 520-26-3
DMRP2IN	DE	Sickle-cell anaemia

DMB7I0A	ID	DMB7I0A
DMB7I0A	DN	VT-224
DMB7I0A	HS	Investigative
DMB7I0A	SN	Cc-chemokine binding protein (inflammation), Viron
DMB7I0A	CP	Viron Therapeutics Inc
DMB7I0A	DE	Inflammation

DM1QBXM	ID	DM1QBXM
DM1QBXM	DN	VT-310
DM1QBXM	HS	Investigative
DM1QBXM	SN	VT-310 (inflammation); IL-10 homologue (inflammation), Viron; VT-310 (inflammation), Viron
DM1QBXM	CP	Viron Therapeutics Inc
DM1QBXM	DE	Inflammation

DMG1Q0W	ID	DMG1Q0W
DMG1Q0W	DN	VT-362
DMG1Q0W	HS	Investigative
DMG1Q0W	SN	CD30 homologue (inflammation), Viron
DMG1Q0W	CP	Cambridge University
DMG1Q0W	DE	Autoimmune diabetes

DMJ2PG1	ID	DMJ2PG1
DMJ2PG1	DN	VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2
DMJ2PG1	HS	Investigative
DMJ2PG1	SN	CHEMBL525571; alpha-Cgrp (8-37); Val(8)-phe(37)-cgrp; CGRP8-37; CGRP-(8-37); Calcitonin gene-related peptide (8-37); h alpha-CGRP8-37; 8-Val-37-phe-calcitonin gene-related peptide; Calcitonin gene-related peptide, val(8)-phe(37)-; Calcitonin gene-related peptide, valyl(8)-phenylalanine(37)-; BDBM50000743; NCGC00167246-01; CALCITONIN GENE RELATED PEPTIDE (8-37); [Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2] hC; alpha-Calcitonin gene-r
DMJ2PG1	PC	16134896
DMJ2PG1	MW	3125.6
DMJ2PG1	FM	C139H230N44O38
DMJ2PG1	IC	InChI=1S/C139H230N44O38/c1-66(2)48-86(161-102(193)60-155-113(197)74(17)159-120(204)87(49-67(3)4)168-118(202)83(40-31-45-152-138(147)148)163-123(207)90(53-80-57-151-65-158-80)173-136(220)111(77(20)188)182-131(215)105(145)69(7)8)121(205)169-88(50-68(5)6)122(206)176-96(64-186)129(213)165-84(41-32-46-153-139(149)150)119(203)175-94(62-184)115(199)156-58-101(192)154-59-104(195)177-107(71(11)12)134(218)179-108(72(13)14)133(217)166-82(39-28-30-44-141)117(201)171-91(54-98(142)189)125(209)172-92(55-99(143)190)124(208)170-89(52-79-36-25-22-26-37-79)126(210)180-109(73(15)16)137(221)183-47-33-42-97(183)130(214)181-110(76(19)187)135(219)174-93(56-100(144)191)127(211)178-106(70(9)10)132(216)157-61-103(194)162-95(63-185)128(212)164-81(38-27-29-43-140)116(200)160-75(18)114(198)167-85(112(146)196)51-78-34-23-21-24-35-78/h21-26,34-37,57,65-77,81-97,105-111,184-188H,27-33,38-56,58-64,140-141,145H2,1-20H3,(H2,142,189)(H2,143,190)(H2,144,191)(H2,146,196)(H,151,158)(H,154,192)(H,155,197)(H,156,199)(H,157,216)(H,159,204)(H,160,200)(H,161,193)(H,162,194)(H,163,207)(H,164,212)(H,165,213)(H,166,217)(H,167,198)(H,168,202)(H,169,205)(H,170,208)(H,171,201)(H,172,209)(H,173,220)(H,174,219)(H,175,203)(H,176,206)(H,177,195)(H,178,211)(H,179,218)(H,180,210)(H,181,214)(H,182,215)(H4,147,148,152)(H4,149,150,153)/t74-,75-,76+,77+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,105-,106-,107-,108-,109-,110-,111-/m0/s1
DMJ2PG1	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N)O
DMJ2PG1	IK	NDACAFBDTQIYCQ-YVQXRMNASA-N
DMJ2PG1	IU	(2S)-N-[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]butanediamide
DMJ2PG1	CA	CAS 119911-68-1
DMJ2PG1	DE	Discovery agent

DMT967L	ID	DMT967L
DMT967L	DN	VTT-201
DMT967L	HS	Investigative
DMT967L	SN	Thriva Prostate; PSA modulator (prostate cancer/neoplasia), Vitala
DMT967L	CP	Genyous Biomed International Inc
DMT967L	DE	Prostate cancer

DMEVAIF	ID	DMEVAIF
DMEVAIF	DN	VTX-744
DMEVAIF	HS	Investigative
DMEVAIF	SN	VTX-744 (adjuvant, vaccination), VentiRx
DMEVAIF	CP	VentiRx Pharmaceuticals Inc
DMEVAIF	DE	Discovery agent

DMGTB95	ID	DMGTB95
DMGTB95	DN	VTX-763
DMGTB95	HS	Investigative
DMGTB95	SN	TLR-8 antagonist (autoimmune/inflammatory disease), VentiRx Pharmaceuticals
DMGTB95	CP	VentiRx Pharmaceuticals Inc
DMGTB95	DE	Autoimmune diabetes

DMDF2U3	ID	DMDF2U3
DMDF2U3	DN	VU0001171
DMDF2U3	HS	Investigative
DMDF2U3	DT	Small molecular drug
DMDF2U3	PC	135773804
DMDF2U3	MW	278.31
DMDF2U3	FM	C16H14N4O
DMDF2U3	IC	InChI=1S/C16H14N4O/c1-11-16(19-15-5-3-2-4-14(15)18-11)20-17-10-12-6-8-13(21)9-7-12/h2-10,21H,1H3,(H,19,20)/b17-10-
DMDF2U3	CS	CC1=NC2=CC=CC=C2N=C1N/N=C\\C3=CC=C(C=C3)O
DMDF2U3	IK	WDPUHMPVZBSBGB-YVLHZVERSA-N
DMDF2U3	IU	4-[(Z)-[(3-methylquinoxalin-2-yl)hydrazinylidene]methyl]phenol
DMDF2U3	DE	Discovery agent

DMXD3T7	ID	DMXD3T7
DMXD3T7	DN	VU0010010
DMXD3T7	HS	Investigative
DMXD3T7	SN	VU0010010; GTPL7633
DMXD3T7	DT	Small molecular drug
DMXD3T7	PC	86277832
DMXD3T7	MW	347.9
DMXD3T7	FM	C17H18ClN3OS
DMXD3T7	IC	InChI=1S/C17H18ClN3OS/c1-9-7-13-14(19)15(23-17(13)21-10(9)2)16(22)20-8-11-3-5-12(18)6-4-11/h3-7,14-15H,8,19H2,1-2H3,(H,20,22)
DMXD3T7	CS	CC1=CC2=C(N=C1C)SC(C2N)C(=O)NCC3=CC=C(C=C3)Cl
DMXD3T7	IK	VUEHIWNVURDJMB-UHFFFAOYSA-N
DMXD3T7	IU	3-amino-N-[(4-chlorophenyl)methyl]-5,6-dimethyl-2,3-dihydrothieno[2,3-b]pyridine-2-carboxamide
DMXD3T7	DE	Discovery agent

DMRNLGW	ID	DMRNLGW
DMRNLGW	DN	VU0029767
DMRNLGW	HS	Investigative
DMRNLGW	DT	Small molecular drug
DMRNLGW	PC	135411347
DMRNLGW	MW	363.4
DMRNLGW	FM	C21H21N3O3
DMRNLGW	IC	InChI=1S/C21H21N3O3/c1-2-27-17-10-8-16(9-11-17)22-14-21(26)24-23-13-19-18-6-4-3-5-15(18)7-12-20(19)25/h3-13,22,25H,2,14H2,1H3,(H,24,26)/b23-13+
DMRNLGW	CS	CCOC1=CC=C(C=C1)NCC(=O)N/N=C/C2=C(C=CC3=CC=CC=C32)O
DMRNLGW	IK	JWRJGCUSLSJMMD-YDZHTSKRSA-N
DMRNLGW	IU	2-(4-ethoxyanilino)-N-[(E)-(2-hydroxynaphthalen-1-yl)methylideneamino]acetamide
DMRNLGW	DE	Discovery agent

DMUMOV1	ID	DMUMOV1
DMUMOV1	DN	VU0080241
DMUMOV1	HS	Investigative
DMUMOV1	SN	VU0080241; 1-(2,4-dimethylphenyl)-4-(3-methylpiperidin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine; CHEMBL477396; SMR000017000; 393845-24-4; AC1MMGFZ; Oprea1_199133; Oprea1_698469; MLS000100825; MLS000419668; GTPL6227; cid_3260619; MolPort-000-728-354; HMS2252F08; BDBM50263670; STL336201; AKOS021898571; AKOS002088041; MCULE-8819330672; NCGC00081401-02; EU-0028524; SR-01000566242; SR-01000566242-1; BRD-A99482020-001-07-0; F0518-0125; 1-(2,4-dimethylphenyl)-4-(3-methylpiperidin-1-yl)pyrazolo[3,4-d]pyrimidine
DMUMOV1	DT	Small molecular drug
DMUMOV1	PC	3260619
DMUMOV1	MW	321.4
DMUMOV1	FM	C19H23N5
DMUMOV1	IC	InChI=1S/C19H23N5/c1-13-6-7-17(15(3)9-13)24-19-16(10-22-24)18(20-12-21-19)23-8-4-5-14(2)11-23/h6-7,9-10,12,14H,4-5,8,11H2,1-3H3
DMUMOV1	CS	CC1CCCN(C1)C2=NC=NC3=C2C=NN3C4=C(C=C(C=C4)C)C
DMUMOV1	IK	CLQVVBPDAXJGBV-UHFFFAOYSA-N
DMUMOV1	IU	1-(2,4-dimethylphenyl)-4-(3-methylpiperidin-1-yl)pyrazolo[3,4-d]pyrimidine
DMUMOV1	DE	Discovery agent

DMGFTVI	ID	DMGFTVI
DMGFTVI	DN	VU0090157
DMGFTVI	HS	Investigative
DMGFTVI	SN	cyclopentyl 1,6-dimethyl-4-(6-nitrobenzo[d][1,3]-dioxol-5-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
DMGFTVI	DT	Small molecular drug
DMGFTVI	PC	2882724
DMGFTVI	MW	403.4
DMGFTVI	FM	C19H21N3O7
DMGFTVI	IC	InChI=1S/C19H21N3O7/c1-10-16(18(23)29-11-5-3-4-6-11)17(20-19(24)21(10)2)12-7-14-15(28-9-27-14)8-13(12)22(25)26/h7-8,11,17H,3-6,9H2,1-2H3,(H,20,24)
DMGFTVI	CS	CC1=C(C(NC(=O)N1C)C2=CC3=C(C=C2[N+](=O)[O-])OCO3)C(=O)OC4CCCC4
DMGFTVI	IK	GUFKDOZSNUQIAS-UHFFFAOYSA-N
DMGFTVI	IU	cyclopentyl 3,4-dimethyl-6-(6-nitro-1,3-benzodioxol-5-yl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate
DMGFTVI	DE	Discovery agent

DMVMXKP	ID	DMVMXKP
DMVMXKP	DN	VU0092145
DMVMXKP	HS	Investigative
DMVMXKP	SN	VU 0092145
DMVMXKP	DT	Small molecular drug
DMVMXKP	PC	4052597
DMVMXKP	MW	342.4
DMVMXKP	FM	C23H22N2O
DMVMXKP	IC	InChI=1S/C23H22N2O/c1-16-12-14-19(15-13-16)25-22(17(2)18-8-4-3-5-9-18)24-21-11-7-6-10-20(21)23(25)26/h3-15,17,22,24H,1-2H3
DMVMXKP	CS	CC1=CC=C(C=C1)N2C(NC3=CC=CC=C3C2=O)C(C)C4=CC=CC=C4
DMVMXKP	IK	QZAOSZVJAXUJFE-UHFFFAOYSA-N
DMVMXKP	IU	3-(4-methylphenyl)-2-(1-phenylethyl)-1,2-dihydroquinazolin-4-one
DMVMXKP	DE	Discovery agent

DMT76JS	ID	DMT76JS
DMT76JS	DN	VU0092273
DMT76JS	HS	Investigative
DMT76JS	SN	VU 0092273
DMT76JS	DT	Small molecular drug
DMT76JS	PC	16000100
DMT76JS	MW	305.4
DMT76JS	FM	C20H19NO2
DMT76JS	IC	InChI=1S/C20H19NO2/c22-19-12-14-21(15-13-19)20(23)18-10-8-17(9-11-18)7-6-16-4-2-1-3-5-16/h1-5,8-11,19,22H,12-15H2
DMT76JS	CS	C1CN(CCC1O)C(=O)C2=CC=C(C=C2)C#CC3=CC=CC=C3
DMT76JS	IK	FPDBSDNGFNDSSK-UHFFFAOYSA-N
DMT76JS	IU	(4-hydroxypiperidin-1-yl)-[4-(2-phenylethynyl)phenyl]methanone
DMT76JS	DE	Discovery agent

DMPSI10	ID	DMPSI10
DMPSI10	DN	VU0119498
DMPSI10	HS	Investigative
DMPSI10	SN	1-(4-Bromobenzyl)indole-2,3-dione; VU0119498; 79183-37-2; 1-(4-bromobenzyl)-1H-indole-2,3-dione; CHEMBL523685; 1-[(4-bromophenyl)methyl]indole-2,3-dione; 1-[(4-bromophenyl)methyl]-2,3-dihydro-1H-indole-2,3-dione; STK215777; 1-(4-bromobenzyl)indoline-2,3-dione; AC1Q24VD; AC1MHO09; GTPL7632; SCHEMBL5430888; cid_3008304; MolPort-002-341-984; ZINC2454837; BDBM50258439; AKOS000245456; CCG-198352; NE20417; MCULE-6184534031; VU 0119498; ST50892639; VU-0119498; EU-0067620; VU0119498-2; 1-[(4-bromophenyl)methyl]indoline-2,3-dione
DMPSI10	DT	Small molecular drug
DMPSI10	PC	3008304
DMPSI10	MW	316.15
DMPSI10	FM	C15H10BrNO2
DMPSI10	IC	InChI=1S/C15H10BrNO2/c16-11-7-5-10(6-8-11)9-17-13-4-2-1-3-12(13)14(18)15(17)19/h1-8H,9H2
DMPSI10	CS	C1=CC=C2C(=C1)C(=O)C(=O)N2CC3=CC=C(C=C3)Br
DMPSI10	IK	DELLOEULSHGYCG-UHFFFAOYSA-N
DMPSI10	IU	1-[(4-bromophenyl)methyl]indole-2,3-dione
DMPSI10	DE	Discovery agent

DM1UAQT	ID	DM1UAQT
DM1UAQT	DN	VU0152099
DM1UAQT	HS	Investigative
DM1UAQT	SN	3-amino-N-(benzo[d][1,3]dioxol-5-ylmethyl)-4,6-dimethylthieno[2,3-b]pyridine carboxamide
DM1UAQT	DT	Small molecular drug
DM1UAQT	PC	1541501
DM1UAQT	MW	355.4
DM1UAQT	FM	C18H17N3O3S
DM1UAQT	IC	InChI=1S/C18H17N3O3S/c1-9-5-10(2)21-18-14(9)15(19)16(25-18)17(22)20-7-11-3-4-12-13(6-11)24-8-23-12/h3-6H,7-8,19H2,1-2H3,(H,20,22)
DM1UAQT	CS	CC1=CC(=NC2=C1C(=C(S2)C(=O)NCC3=CC4=C(C=C3)OCO4)N)C
DM1UAQT	IK	AZOGCTMOKNTHIU-UHFFFAOYSA-N
DM1UAQT	IU	3-amino-N-(1,3-benzodioxol-5-ylmethyl)-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide
DM1UAQT	DE	Discovery agent

DM04HUC	ID	DM04HUC
DM04HUC	DN	VU0152100
DM04HUC	HS	Investigative
DM04HUC	SN	VU-0152100; VU 0152100
DM04HUC	DT	Small molecular drug
DM04HUC	PC	864492
DM04HUC	MW	341.4
DM04HUC	FM	C18H19N3O2S
DM04HUC	IC	InChI=1S/C18H19N3O2S/c1-10-8-11(2)21-18-14(10)15(19)16(24-18)17(22)20-9-12-4-6-13(23-3)7-5-12/h4-8H,9,19H2,1-3H3,(H,20,22)
DM04HUC	CS	CC1=CC(=NC2=C1C(=C(S2)C(=O)NCC3=CC=C(C=C3)OC)N)C
DM04HUC	IK	MDNWGCQSCGNTKH-UHFFFAOYSA-N
DM04HUC	IU	3-amino-N-[(4-methoxyphenyl)methyl]-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide
DM04HUC	CA	CAS 409351-28-6
DM04HUC	DE	Discovery agent

DMPKSTD	ID	DMPKSTD
DMPKSTD	DN	VU0155041
DMPKSTD	HS	Investigative
DMPKSTD	SN	VU-0155041; VU 0155041
DMPKSTD	DT	Small molecular drug
DMPKSTD	PC	888023
DMPKSTD	MW	316.2
DMPKSTD	FM	C14H15Cl2NO3
DMPKSTD	IC	InChI=1S/C14H15Cl2NO3/c15-8-5-9(16)7-10(6-8)17-13(18)11-3-1-2-4-12(11)14(19)20/h5-7,11-12H,1-4H2,(H,17,18)(H,19,20)/t11-,12+/m0/s1
DMPKSTD	CS	C1CC[C@H]([C@H](C1)C(=O)NC2=CC(=CC(=C2)Cl)Cl)C(=O)O
DMPKSTD	IK	VSMUYYFJVFSVCA-NWDGAFQWSA-N
DMPKSTD	IU	(1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
DMPKSTD	DE	Discovery agent

DMOPLQI	ID	DMOPLQI
DMOPLQI	DN	VU0238429
DMOPLQI	HS	Investigative
DMOPLQI	SN	VU 0238429; 1160247-92-6; VU0238429; 1-(4-METHOXYBENZYL)-5-TRIFLUOROMETHOXYISATIN; CHEMBL466253; VU-0238429; 1-[(4-Methoxyphenyl)methyl]-5-(trifluoromethoxy)-1H-indole-2,3-dione; GTPL3257; CTK8E8884; DTXSID40655290; MolPort-023-276-878; cid_42633508; ML129; MFCD16618396; BDBM50258656; ZINC40875741; AKOS024457724; API0008325; HY-12157; KB-81463; RT-017613; B7448; CS-0003122; VU0238429-1; VU0238429, solubility: &gt;=20 mg/mL in DMSO; J-003368; 1-(4-methoxybenzyl)-5-(trifluoromethoxy)indoline-2,3-dione
DMOPLQI	DT	Small molecular drug
DMOPLQI	PC	42633508
DMOPLQI	MW	351.28
DMOPLQI	FM	C17H12F3NO4
DMOPLQI	IC	InChI=1S/C17H12F3NO4/c1-24-11-4-2-10(3-5-11)9-21-14-7-6-12(25-17(18,19)20)8-13(14)15(22)16(21)23/h2-8H,9H2,1H3
DMOPLQI	CS	COC1=CC=C(C=C1)CN2C3=C(C=C(C=C3)OC(F)(F)F)C(=O)C2=O
DMOPLQI	IK	CKLGZXFOLMHCMC-UHFFFAOYSA-N
DMOPLQI	IU	1-[(4-methoxyphenyl)methyl]-5-(trifluoromethoxy)indole-2,3-dione
DMOPLQI	CA	CAS 1160247-92-6
DMOPLQI	DE	Discovery agent

DMH720P	ID	DMH720P
DMH720P	DN	VU0240382
DMH720P	HS	Investigative
DMH720P	SN	CHEMBL1682799; VU0240382; SCHEMBL504253; GTPL6422; 1(2H)-Isoquinolinone, 3,4-dihydro-6-(2-phenylethynyl)-; BDBM50337503; 1092550-36-1; VU0240382-4; 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2h)-one
DMH720P	DT	Small molecular drug
DMH720P	PC	51346799
DMH720P	MW	247.29
DMH720P	FM	C17H13NO
DMH720P	IC	InChI=1S/C17H13NO/c19-17-16-9-8-14(12-15(16)10-11-18-17)7-6-13-4-2-1-3-5-13/h1-5,8-9,12H,10-11H2,(H,18,19)
DMH720P	CS	C1CNC(=O)C2=C1C=C(C=C2)C#CC3=CC=CC=C3
DMH720P	IK	BOVJHNHRQNCDEQ-UHFFFAOYSA-N
DMH720P	IU	6-(2-phenylethynyl)-3,4-dihydro-2H-isoquinolin-1-one
DMH720P	DE	Discovery agent

DMU3YRH	ID	DMU3YRH
DMU3YRH	DN	VU0240551
DMU3YRH	HS	Investigative
DMU3YRH	SN	893990-34-6; VU 0240551; VU0240551; N-(4-Methyl-2-thiazolyl)-2-[(6-phenyl-3-pyridazinyl)thio]-acetamide; VU0240551-2-D4; N-(4-methylthiazol-2-yl)-2-(6-phenylpyridazin-3-ylthio)acetamide; VU-0240551; n-(4-methyl-2-thiazolyl)-2-[(6-phenyl-3-pyridazinyl)thio]acetamide; VU0240551-1; N-(4-methyl-1,3-thiazol-2-yl)-2-[(6-phenylpyridazin-3-yl)thio]acetamide; C16H14N4OS2; C26H30N2O5; N-(4-methyl-1,3-thiazol-2-yl)-2-(6-phenylpyridazin-3-yl)sulfanylacetamide; AC1OHJ6T; MLS000621247; GTPL4665; CHEMBL1491962; SCHEMBL20240442; BDBM43891
DMU3YRH	DT	Small molecular drug
DMU3YRH	PC	7211972
DMU3YRH	MW	342.4
DMU3YRH	FM	C16H14N4OS2
DMU3YRH	IC	InChI=1S/C16H14N4OS2/c1-11-9-23-16(17-11)18-14(21)10-22-15-8-7-13(19-20-15)12-5-3-2-4-6-12/h2-9H,10H2,1H3,(H,17,18,21)
DMU3YRH	CS	CC1=CSC(=N1)NC(=O)CSC2=NN=C(C=C2)C3=CC=CC=C3
DMU3YRH	IK	WJRWSLORVIHRNX-UHFFFAOYSA-N
DMU3YRH	IU	N-(4-methyl-1,3-thiazol-2-yl)-2-(6-phenylpyridazin-3-yl)sulfanylacetamide
DMU3YRH	CA	CAS 893990-34-6
DMU3YRH	CB	CHEBI:92476
DMU3YRH	DE	Discovery agent

DMRKE6W	ID	DMRKE6W
DMRKE6W	DN	VU0255035
DMRKE6W	HS	Investigative
DMRKE6W	SN	1135243-19-4; VU 0255035; N-(3-Oxo-3-(4-(pyridin-4-yl)piperazin-1-yl)propyl)benzo[c][1,2,5]thiadiazole-4-sulfonamide; VU0255035; CHEMBL1628667; N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide; SCHEMBL2730708; GTPL3274; CHEBI:93015; MolPort-023-276-911; BDBM50362367; ZINC43207362; AKOS024457774; AK163845; AX8294949; ST24048355; J-002979; BRD-K58033748-001-01-2
DMRKE6W	DT	Small molecular drug
DMRKE6W	PC	24768606
DMRKE6W	MW	432.5
DMRKE6W	FM	C18H20N6O3S2
DMRKE6W	IC	InChI=1S/C18H20N6O3S2/c25-17(24-12-10-23(11-13-24)14-4-7-19-8-5-14)6-9-20-29(26,27)16-3-1-2-15-18(16)22-28-21-15/h1-5,7-8,20H,6,9-13H2
DMRKE6W	CS	C1CN(CCN1C2=CC=NC=C2)C(=O)CCNS(=O)(=O)C3=CC=CC4=NSN=C43
DMRKE6W	IK	WXDHQWPQLKGANZ-UHFFFAOYSA-N
DMRKE6W	IU	N-[3-oxo-3-(4-pyridin-4-ylpiperazin-1-yl)propyl]-2,1,3-benzothiadiazole-4-sulfonamide
DMRKE6W	CB	CHEBI:93015
DMRKE6W	DE	Discovery agent

DM7VCDF	ID	DM7VCDF
DM7VCDF	DN	VU0285683
DM7VCDF	HS	Investigative
DM7VCDF	SN	327056-22-4; VU0285683; VU 0285683; CHEMBL2164544; 3-Fluoro-5-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)benzonitrile; GELAFISMURFRCA-UHFFFAOYSA-N; SCHEMBL4197981; GTPL6398; MolPort-035-765-727; 3-fluoro-5-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)benzonitrile; ZINC95554357; BDBM50395943; AKOS024458130; NCGC00379115-01; KB-276106; B5569; 3-(2-Pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole; 3-Fluoro-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-benzonitrile
DM7VCDF	DT	Small molecular drug
DM7VCDF	PC	9816778
DM7VCDF	MW	266.23
DM7VCDF	FM	C14H7FN4O
DM7VCDF	IC	InChI=1S/C14H7FN4O/c15-11-6-9(8-16)5-10(7-11)14-18-13(19-20-14)12-3-1-2-4-17-12/h1-7H
DM7VCDF	CS	C1=CC=NC(=C1)C2=NOC(=N2)C3=CC(=CC(=C3)C#N)F
DM7VCDF	IK	GELAFISMURFRCA-UHFFFAOYSA-N
DM7VCDF	IU	3-fluoro-5-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)benzonitrile
DM7VCDF	DE	Discovery agent

DMETUHS	ID	DMETUHS
DMETUHS	DN	VU0357121
DMETUHS	HS	Investigative
DMETUHS	SN	VU 0357121
DMETUHS	DT	Small molecular drug
DMETUHS	PC	2296132
DMETUHS	MW	305.32
DMETUHS	FM	C17H17F2NO2
DMETUHS	IC	InChI=1S/C17H17F2NO2/c1-2-3-10-22-14-7-4-12(5-8-14)17(21)20-16-9-6-13(18)11-15(16)19/h4-9,11H,2-3,10H2,1H3,(H,20,21)
DMETUHS	CS	CCCCOC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)F)F
DMETUHS	IK	AHCYOTLTLQTPSU-UHFFFAOYSA-N
DMETUHS	IU	4-butoxy-N-(2,4-difluorophenyl)benzamide
DMETUHS	CA	CAS 433967-28-3
DMETUHS	DE	Discovery agent

DM9V01W	ID	DM9V01W
DM9V01W	DN	VU0359516
DM9V01W	HS	Investigative
DM9V01W	SN	VU0359516; GTPL6230
DM9V01W	DT	Small molecular drug
DM9V01W	PC	73755197
DM9V01W	MW	295.29
DM9V01W	FM	C16H13N3O3
DM9V01W	IC	InChI=1S/C16H13N3O3/c20-15(18-13-7-3-4-8-17-13)16-9-11(16)14(19-21)10-5-1-2-6-12(10)22-16/h1-8,11,21H,9H2,(H,17,18,20)/b19-14+
DM9V01W	CS	C1C\\2C1(OC3=CC=CC=C3/C2=N\\O)C(=O)NC4=CC=CC=N4
DM9V01W	IK	NAPZSTOOVHXHKA-XMHGGMMESA-N
DM9V01W	IU	(7Z)-7-hydroxyimino-N-pyridin-2-yl-1,7a-dihydrocyclopropa[b]chromene-1a-carboxamide
DM9V01W	DE	Discovery agent

DM3NXMB	ID	DM3NXMB
DM3NXMB	DN	VU0360172
DM3NXMB	HS	Investigative
DM3NXMB	SN	CHEMBL1684242; VU0360172; N-cyclobutyl-6-((3-fluorophenyl)ethynyl)nicotinamide; GTPL6400; SCHEMBL19411346; ZINC66138253; BDBM50337958; NCGC00379106-01; VU-0360172
DM3NXMB	DT	Small molecular drug
DM3NXMB	PC	53318624
DM3NXMB	MW	294.3
DM3NXMB	FM	C18H15FN2O
DM3NXMB	IC	InChI=1S/C18H15FN2O/c19-15-4-1-3-13(11-15)7-9-16-10-8-14(12-20-16)18(22)21-17-5-2-6-17/h1,3-4,8,10-12,17H,2,5-6H2,(H,21,22)
DM3NXMB	CS	C1CC(C1)NC(=O)C2=CN=C(C=C2)C#CC3=CC(=CC=C3)F
DM3NXMB	IK	NEMHWVUKNWAKTM-UHFFFAOYSA-N
DM3NXMB	IU	N-cyclobutyl-6-[2-(3-fluorophenyl)ethynyl]pyridine-3-carboxamide
DM3NXMB	DE	Discovery agent

DME71ON	ID	DME71ON
DME71ON	DN	VU0361737
DME71ON	HS	Investigative
DME71ON	SN	VU-0361737; VU 0361737; compound 9b [PMID: 19469556]
DME71ON	DT	Small molecular drug
DME71ON	PC	44191096
DME71ON	MW	262.69
DME71ON	FM	C13H11ClN2O2
DME71ON	IC	InChI=1S/C13H11ClN2O2/c1-18-12-8-9(5-6-10(12)14)16-13(17)11-4-2-3-7-15-11/h2-8H,1H3,(H,16,17)
DME71ON	CS	COC1=C(C=CC(=C1)NC(=O)C2=CC=CC=N2)Cl
DME71ON	IK	ARYUXFNGXHNNDM-UHFFFAOYSA-N
DME71ON	IU	N-(4-chloro-3-methoxyphenyl)pyridine-2-carboxamide
DME71ON	CA	CAS 1161205-04-4
DME71ON	DE	Discovery agent

DM3ZUH2	ID	DM3ZUH2
DM3ZUH2	DN	VU0361747
DM3ZUH2	HS	Investigative
DM3ZUH2	SN	VU0361747; 1309976-66-6; GTPL6423; CHEMBL2431185; ZINC96933575; KB-276109; VU0361747-2; 1-({6-[2-(3-fluorophenyl)ethynyl]pyridin-3-yl}carbonyl)piperidin-4-ol
DM3ZUH2	DT	Small molecular drug
DM3ZUH2	PC	53384841
DM3ZUH2	MW	324.3
DM3ZUH2	FM	C19H17FN2O2
DM3ZUH2	IC	InChI=1S/C19H17FN2O2/c20-16-3-1-2-14(12-16)4-6-17-7-5-15(13-21-17)19(24)22-10-8-18(23)9-11-22/h1-3,5,7,12-13,18,23H,8-11H2
DM3ZUH2	CS	C1CN(CCC1O)C(=O)C2=CN=C(C=C2)C#CC3=CC(=CC=C3)F
DM3ZUH2	IK	ZKKOJUZGUBLAJQ-UHFFFAOYSA-N
DM3ZUH2	IU	[6-[2-(3-fluorophenyl)ethynyl]pyridin-3-yl]-(4-hydroxypiperidin-1-yl)methanone
DM3ZUH2	DE	Discovery agent

DM8TR1Y	ID	DM8TR1Y
DM8TR1Y	DN	VU0364289
DM8TR1Y	HS	Investigative
DM8TR1Y	SN	VU 0364289
DM8TR1Y	DT	Small molecular drug
DM8TR1Y	PC	46865097
DM8TR1Y	MW	335.4
DM8TR1Y	FM	C20H21N3O2
DM8TR1Y	IC	InChI=1S/C20H21N3O2/c21-14-18-8-4-5-9-19(18)22-10-12-23(13-11-22)20(24)16-25-15-17-6-2-1-3-7-17/h1-9H,10-13,15-16H2
DM8TR1Y	CS	C1CN(CCN1C2=CC=CC=C2C#N)C(=O)COCC3=CC=CC=C3
DM8TR1Y	IK	LTPGKAICNBCBPT-UHFFFAOYSA-N
DM8TR1Y	IU	2-[4-(2-phenylmethoxyacetyl)piperazin-1-yl]benzonitrile
DM8TR1Y	DE	Discovery agent

DMXY980	ID	DMXY980
DMXY980	DN	VU0364770
DMXY980	HS	Investigative
DMXY980	SN	61350-00-3; VU 0364770; VU0364770; N-(3-chlorophenyl)picolinamide; N-(3-chlorophenyl)-2-pyridinecarboxamide; N-(3-chlorophenyl)pyridine-2-carboxamide; CHEMBL556667; 2-Pyridinecarboxamide, N-(3-chlorophenyl)-; AC1LHD0L; GTPL6234; SCHEMBL2530324; cid_836002; KS-00001CNQ; CTK2E1861; DTXSID00356877; MolPort-002-826-420; ZINC362766; HMS3651P19; EX-A1099; BCP19097; s2862; 2565AH; BDBM50293743; AKOS003020541; CS-6072; KB-276111; HY-100588; VU-0364770; N-(3-chloro-phenyl)-pyridine-2-carboxamide; SW219537-1
DMXY980	DT	Small molecular drug
DMXY980	PC	836002
DMXY980	MW	232.66
DMXY980	FM	C12H9ClN2O
DMXY980	IC	InChI=1S/C12H9ClN2O/c13-9-4-3-5-10(8-9)15-12(16)11-6-1-2-7-14-11/h1-8H,(H,15,16)
DMXY980	CS	C1=CC=NC(=C1)C(=O)NC2=CC(=CC=C2)Cl
DMXY980	IK	SUYUTNCKIOLMAJ-UHFFFAOYSA-N
DMXY980	IU	N-(3-chlorophenyl)pyridine-2-carboxamide
DMXY980	CA	CAS 61350-00-3
DMXY980	DE	Discovery agent

DMA6CLO	ID	DMA6CLO
DMA6CLO	DN	VU0366058
DMA6CLO	HS	Investigative
DMA6CLO	SN	CHEMBL3759200; 1369344-82-0; 2-(benzooxazol-2-ylamino)-4-(4-fluorophenyl)pyrimidine-5-carbonitrile; VU0366058; GTPL6438; BDBM50143543; ZINC200480443; KB-267312
DMA6CLO	DT	Small molecular drug
DMA6CLO	PC	57328392
DMA6CLO	MW	331.3
DMA6CLO	FM	C18H10FN5O
DMA6CLO	IC	InChI=1S/C18H10FN5O/c19-13-7-5-11(6-8-13)16-12(9-20)10-21-17(23-16)24-18-22-14-3-1-2-4-15(14)25-18/h1-8,10H,(H,21,22,23,24)
DMA6CLO	CS	C1=CC=C2C(=C1)N=C(O2)NC3=NC=C(C(=N3)C4=CC=C(C=C4)F)C#N
DMA6CLO	IK	OBFRNKSPNQSVFR-UHFFFAOYSA-N
DMA6CLO	IU	2-(1,3-benzoxazol-2-ylamino)-4-(4-fluorophenyl)pyrimidine-5-carbonitrile
DMA6CLO	DE	Discovery agent

DM7L51U	ID	DM7L51U
DM7L51U	DN	VU0400195
DM7L51U	HS	Investigative
DM7L51U	SN	ML182
DM7L51U	DT	Small molecular drug
DM7L51U	PC	46869947
DM7L51U	MW	393.8
DM7L51U	FM	C21H16ClN3O3
DM7L51U	IC	InChI=1S/C21H16ClN3O3/c22-14-10-13(24-19(26)15-3-1-2-8-23-15)6-7-16(14)25-20(27)17-11-4-5-12(9-11)18(17)21(25)28/h1-8,10-12,17-18H,9H2,(H,24,26)/t11-,12+,17-,18?/m1/s1
DM7L51U	CS	C1[C@H]2C=C[C@@H]1C3[C@@H]2C(=O)N(C3=O)C4=C(C=C(C=C4)NC(=O)C5=CC=CC=N5)Cl
DM7L51U	IK	LJUABYFUJVRUSJ-KNGMQDLYSA-N
DM7L51U	IU	N-[3-chloro-4-[(1S,2R,7R)-3,5-dioxo-4-azatricyclo[5.2.1.02,6]dec-8-en-4-yl]phenyl]pyridine-2-carboxamide
DM7L51U	DE	Discovery agent

DMZRE6X	ID	DMZRE6X
DMZRE6X	DN	VU0404251
DMZRE6X	HS	Investigative
DMZRE6X	SN	1276013-77-4; CHEMBL2151817; (r)-6-(3-fluorobenzyloxy)-n-(1,2,2-trimethylpropyl)nicotinamide; VU0404251; SCHEMBL6928852; GTPL6410; ZINC68267021; BDBM50392432; AKOS027446878; KB-186257; (R)-6-(3-Fluoro-benzyloxy)-N-(1,2,2-trimethyl-propyl)-nicotinamide
DMZRE6X	DT	Small molecular drug
DMZRE6X	PC	58368068
DMZRE6X	MW	330.4
DMZRE6X	FM	C19H23FN2O2
DMZRE6X	IC	InChI=1S/C19H23FN2O2/c1-13(19(2,3)4)22-18(23)15-8-9-17(21-11-15)24-12-14-6-5-7-16(20)10-14/h5-11,13H,12H2,1-4H3,(H,22,23)/t13-/m1/s1
DMZRE6X	CS	C[C@H](C(C)(C)C)NC(=O)C1=CN=C(C=C1)OCC2=CC(=CC=C2)F
DMZRE6X	IK	VOYBJCDMLJODRK-CYBMUJFWSA-N
DMZRE6X	IU	N-[(2R)-3,3-dimethylbutan-2-yl]-6-[(3-fluorophenyl)methoxy]pyridine-3-carboxamide
DMZRE6X	DE	Discovery agent

DMLPMAY	ID	DMLPMAY
DMLPMAY	DN	VU0405601
DMLPMAY	HS	Investigative
DMLPMAY	SN	VU 0405601; VU-0405601
DMLPMAY	DT	Small molecular drug
DMLPMAY	PC	1301094
DMLPMAY	MW	357.2
DMLPMAY	FM	C17H13BrN2O2
DMLPMAY	IC	InChI=1S/C17H13BrN2O2/c18-17-14-6-2-1-4-12(14)7-8-15(17)22-11-16(21)20-13-5-3-9-19-10-13/h1-10H,11H2,(H,20,21)
DMLPMAY	CS	C1=CC=C2C(=C1)C=CC(=C2Br)OCC(=O)NC3=CN=CC=C3
DMLPMAY	IK	WLLRAGBPCSOJNH-UHFFFAOYSA-N
DMLPMAY	IU	2-(1-bromonaphthalen-2-yl)oxy-N-pyridin-3-ylacetamide
DMLPMAY	DE	Discovery agent

DMZDIVL	ID	DMZDIVL
DMZDIVL	DN	VU0424465
DMZDIVL	HS	Investigative
DMZDIVL	SN	ML273
DMZDIVL	DT	Small molecular drug
DMZDIVL	PC	53384864
DMZDIVL	MW	326.4
DMZDIVL	FM	C19H19FN2O2
DMZDIVL	IC	InChI=1S/C19H19FN2O2/c1-13(19(2,3)24)22-18(23)17-10-9-15(12-21-17)8-7-14-5-4-6-16(20)11-14/h4-6,9-13,24H,1-3H3,(H,22,23)/t13-/m1/s1
DMZDIVL	CS	C[C@H](C(C)(C)O)NC(=O)C1=NC=C(C=C1)C#CC2=CC(=CC=C2)F
DMZDIVL	IK	ZPKZAFDYFVJULO-CYBMUJFWSA-N
DMZDIVL	IU	5-[2-(3-fluorophenyl)ethynyl]-N-[(2R)-3-hydroxy-3-methylbutan-2-yl]pyridine-2-carboxamide
DMZDIVL	DE	Discovery agent

DM96FQ2	ID	DM96FQ2
DM96FQ2	DN	VU0463597
DM96FQ2	HS	Investigative
DM96FQ2	SN	ML289; (R)-VU0463597
DM96FQ2	DT	Small molecular drug
DM96FQ2	PC	56587994
DM96FQ2	MW	349.4
DM96FQ2	FM	C22H23NO3
DM96FQ2	IC	InChI=1S/C22H23NO3/c1-26-21-12-8-18(9-13-21)5-4-17-6-10-20(11-7-17)22(25)23-14-2-3-19(15-23)16-24/h6-13,19,24H,2-3,14-16H2,1H3/t19-/m1/s1
DM96FQ2	CS	COC1=CC=C(C=C1)C#CC2=CC=C(C=C2)C(=O)N3CCC[C@H](C3)CO
DM96FQ2	IK	VSLWUPHHCFQTDB-LJQANCHMSA-N
DM96FQ2	IU	[(3R)-3-(hydroxymethyl)piperidin-1-yl]-[4-[2-(4-methoxyphenyl)ethynyl]phenyl]methanone
DM96FQ2	DE	Discovery agent

DMDW9MS	ID	DMDW9MS
DMDW9MS	DN	VU0463841
DMDW9MS	HS	Investigative
DMDW9MS	SN	VU0463841; GTPL6393
DMDW9MS	DT	Small molecular drug
DMDW9MS	PC	73755217
DMDW9MS	MW	290.68
DMDW9MS	FM	C13H8ClFN4O
DMDW9MS	IC	InChI=1S/C13H8ClFN4O/c14-9-1-2-12(17-7-9)19-13(20)18-11-4-8(6-16)3-10(15)5-11/h1-5,7H,(H2,17,18,19,20)
DMDW9MS	CS	C1=CC(=NC=C1Cl)NC(=O)NC2=CC(=CC(=C2)C#N)F
DMDW9MS	IK	KDANLHLWAYNCMV-UHFFFAOYSA-N
DMDW9MS	IU	1-(5-chloropyridin-2-yl)-3-(3-cyano-5-fluorophenyl)urea
DMDW9MS	DE	Discovery agent

DM1H5DL	ID	DM1H5DL
DM1H5DL	DN	VU0469650
DM1H5DL	HS	Investigative
DM1H5DL	SN	3-[(3R)-3-methyl-4-[(4-methyladamantan-1-yl)carbonyl]piperazin-1-yl]pyridine-2-carbonitrile; VU0469650; GTPL6337
DM1H5DL	DT	Small molecular drug
DM1H5DL	PC	73755207
DM1H5DL	MW	378.5
DM1H5DL	FM	C23H30N4O
DM1H5DL	IC	InChI=1S/C23H30N4O/c1-15-14-26(21-4-3-5-25-20(21)13-24)6-7-27(15)22(28)23-10-17-8-18(11-23)16(2)19(9-17)12-23/h3-5,15-19H,6-12,14H2,1-2H3/t15-,16?,17?,18?,19?,23?/m1/s1
DM1H5DL	CS	C[C@@H]1CN(CCN1C(=O)C23CC4CC(C2)C(C(C4)C3)C)C5=C(N=CC=C5)C#N
DM1H5DL	IK	HPOKCTFUFZGTGF-ABYMYHKNSA-N
DM1H5DL	IU	3-[(3R)-3-methyl-4-(4-methyladamantane-1-carbonyl)piperazin-1-yl]pyridine-2-carbonitrile
DM1H5DL	DE	Discovery agent

DM31V7K	ID	DM31V7K
DM31V7K	DN	VU10007
DM31V7K	HS	Investigative
DM31V7K	SN	(S)-3-Amino-4,6-dimethyl-N-(1-phenylethyl)thieno[2,3-b]pyridine-2-carboxamide 2,2,2-trifluoroacetate; VU10007; AC1LEQT2; CHEMBL1212991; ZINC61353
DM31V7K	DT	Small molecular drug
DM31V7K	PC	690842
DM31V7K	MW	325.4
DM31V7K	FM	C18H19N3OS
DM31V7K	IC	InChI=1S/C18H19N3OS/c1-10-9-11(2)20-18-14(10)15(19)16(23-18)17(22)21-12(3)13-7-5-4-6-8-13/h4-9,12H,19H2,1-3H3,(H,21,22)/t12-/m0/s1
DM31V7K	CS	CC1=CC(=NC2=C1C(=C(S2)C(=O)N[C@@H](C)C3=CC=CC=C3)N)C
DM31V7K	IK	MCAYWJFTDPUQKE-LBPRGKRZSA-N
DM31V7K	IU	3-amino-4,6-dimethyl-N-[(1S)-1-phenylethyl]thieno[2,3-b]pyridine-2-carboxamide
DM31V7K	DE	Discovery agent

DM2HGCB	ID	DM2HGCB
DM2HGCB	DN	VU10010
DM2HGCB	HS	Investigative
DM2HGCB	SN	633283-39-3; VU 10010; 3-amino-N-[(4-chlorophenyl)methyl]-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide; VU-10010; CHEMBL1212994; VU10010; 3-amino-N-(4-chlorobenzyl)-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide; FPRULFHDSFKYBV-UHFFFAOYSA-N; 2fLI; 2-Fly; f-LIGRLO-NH2; AC1LEM0C; 2-fAP; 2-f-LIGRLO-NH2; MLS002474501; cid_714286; CTK5B8654; DTXSID30351931; MolPort-002-722-568; HMS3431D09; ZINC109066; STL227650; BDBM50323691; AKOS000282930; MCULE-8947006791; NCGC00378784-01; KB-81468; SMR001398666; RT-016241; B7285
DM2HGCB	DT	Small molecular drug
DM2HGCB	PC	714286
DM2HGCB	MW	345.8
DM2HGCB	FM	C17H16ClN3OS
DM2HGCB	IC	InChI=1S/C17H16ClN3OS/c1-9-7-10(2)21-17-13(9)14(19)15(23-17)16(22)20-8-11-3-5-12(18)6-4-11/h3-7H,8,19H2,1-2H3,(H,20,22)
DM2HGCB	CS	CC1=CC(=NC2=C1C(=C(S2)C(=O)NCC3=CC=C(C=C3)Cl)N)C
DM2HGCB	IK	FPRULFHDSFKYBV-UHFFFAOYSA-N
DM2HGCB	IU	3-amino-N-[(4-chlorophenyl)methyl]-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide
DM2HGCB	CA	CAS 633283-39-3
DM2HGCB	DE	Discovery agent

DMCRF48	ID	DMCRF48
DMCRF48	DN	VU-1545
DMCRF48	HS	Investigative
DMCRF48	SN	VU1545
DMCRF48	DT	Small molecular drug
DMCRF48	PC	11625520
DMCRF48	MW	402.4
DMCRF48	FM	C22H15FN4O3
DMCRF48	IC	InChI=1S/C22H15FN4O3/c23-18-8-4-5-9-20(18)26-21(14-19(25-26)15-6-2-1-3-7-15)24-22(28)16-10-12-17(13-11-16)27(29)30/h1-14H,(H,24,28)
DMCRF48	CS	C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC=C(C=C3)[N+](=O)[O-])C4=CC=CC=C4F
DMCRF48	IK	BRAZLURTFMCAHU-UHFFFAOYSA-N
DMCRF48	IU	N-[2-(2-fluorophenyl)-5-phenylpyrazol-3-yl]-4-nitrobenzamide
DMCRF48	CA	CAS 890764-63-3
DMCRF48	DE	Discovery agent

DMX9ED1	ID	DMX9ED1
DMX9ED1	DN	VU591
DMX9ED1	HS	Investigative
DMX9ED1	SN	VU 591; VU-591
DMX9ED1	DT	Small molecular drug
DMX9ED1	PC	44123657
DMX9ED1	MW	368.3
DMX9ED1	FM	C16H12N6O5
DMX9ED1	IC	InChI=1S/C16H12N6O5/c23-21(24)9-1-3-11-13(5-9)19-15(17-11)7-27-8-16-18-12-4-2-10(22(25)26)6-14(12)20-16/h1-6H,7-8H2,(H,17,19)(H,18,20)
DMX9ED1	CS	C1=CC2=C(C=C1[N+](=O)[O-])NC(=N2)COCC3=NC4=C(N3)C=C(C=C4)[N+](=O)[O-]
DMX9ED1	IK	ZQPXNYLXYNRFNP-UHFFFAOYSA-N
DMX9ED1	IU	6-nitro-2-[(6-nitro-1H-benzimidazol-2-yl)methoxymethyl]-1H-benzimidazole
DMX9ED1	CA	CAS 1222810-74-3
DMX9ED1	DE	Discovery agent

DMHX1KJ	ID	DMHX1KJ
DMHX1KJ	DN	VU-71
DMHX1KJ	HS	Investigative
DMHX1KJ	SN	VU71
DMHX1KJ	DT	Small molecular drug
DMHX1KJ	PC	11523834
DMHX1KJ	MW	384.4
DMHX1KJ	FM	C22H16N4O3
DMHX1KJ	IC	InChI=1S/C22H16N4O3/c27-22(17-11-13-19(14-12-17)26(28)29)24-21-20(16-7-3-1-4-8-16)15-23-25(21)18-9-5-2-6-10-18/h1-15H,(H,24,27)
DMHX1KJ	CS	C1=CC=C(C=C1)C2=C(N(N=C2)C3=CC=CC=C3)NC(=O)C4=CC=C(C=C4)[N+](=O)[O-]
DMHX1KJ	IK	UCQCMSNDKYLLFD-UHFFFAOYSA-N
DMHX1KJ	IU	N-(2,4-diphenylpyrazol-3-yl)-4-nitrobenzamide
DMHX1KJ	DE	Discovery agent

DMFPNRD	ID	DMFPNRD
DMFPNRD	DN	VUF 4904
DMFPNRD	HS	Investigative
DMFPNRD	SN	VUF-4904; VUF4904
DMFPNRD	DT	Small molecular drug
DMFPNRD	PC	11492393
DMFPNRD	MW	235.37
DMFPNRD	FM	C14H25N3
DMFPNRD	IC	InChI=1S/C14H25N3/c1-3-7-13(8-4-1)16-10-6-2-5-9-14-11-15-12-17-14/h11-13,16H,1-10H2,(H,15,17)
DMFPNRD	CS	C1CCC(CC1)NCCCCCC2=CN=CN2
DMFPNRD	IK	XFSHNAXXKOSENG-UHFFFAOYSA-N
DMFPNRD	IU	N-[5-(1H-imidazol-5-yl)pentyl]cyclohexanamine
DMFPNRD	DE	Discovery agent

DMMNVGJ	ID	DMMNVGJ
DMMNVGJ	DN	VUF 5207
DMMNVGJ	HS	Investigative
DMMNVGJ	SN	VUF-5207; VUF5207
DMMNVGJ	DT	Small molecular drug
DMMNVGJ	PC	11672774
DMMNVGJ	MW	181.28
DMMNVGJ	FM	C10H19N3
DMMNVGJ	IC	InChI=1S/C10H19N3/c1-13(2)7-5-3-4-6-10-8-11-9-12-10/h8-9H,3-7H2,1-2H3,(H,11,12)
DMMNVGJ	CS	CN(C)CCCCCC1=CN=CN1
DMMNVGJ	IK	MVHBNHUOEFGIBK-UHFFFAOYSA-N
DMMNVGJ	IU	5-(1H-imidazol-5-yl)-N,N-dimethylpentan-1-amine
DMMNVGJ	CA	CAS 397248-39-4
DMMNVGJ	DE	Discovery agent

DMVFJR4	ID	DMVFJR4
DMVFJR4	DN	VUF 5681
DMVFJR4	HS	Investigative
DMVFJR4	SN	CHEMBL78498; 4-[3-(1h-imidazol-4-yl)propyl]piperidine; 768358-61-8; VUF-5681; 4-[3-(1H-IMIDAZOL-4-YL)-PROPYL]-PIPERIDINE; SCHEMBL15139142; CHEBI:93084; ZINC13530263; BDBM50409817; AKOS006290761; NCGC00167742-01; KB-333611
DMVFJR4	DT	Small molecular drug
DMVFJR4	PC	10330240
DMVFJR4	MW	193.29
DMVFJR4	FM	C11H19N3
DMVFJR4	IC	InChI=1S/C11H19N3/c1(3-11-8-13-9-14-11)2-10-4-6-12-7-5-10/h8-10,12H,1-7H2,(H,13,14)
DMVFJR4	CS	C1CNCCC1CCCC2=CN=CN2
DMVFJR4	IK	YPGRNKJNOSUCLY-UHFFFAOYSA-N
DMVFJR4	IU	4-[3-(1H-imidazol-5-yl)propyl]piperidine
DMVFJR4	CA	CAS 768358-61-8
DMVFJR4	CB	CHEBI:93084
DMVFJR4	DE	Discovery agent

DMI6GD0	ID	DMI6GD0
DMI6GD0	DN	VUF 8328
DMI6GD0	HS	Investigative
DMI6GD0	SN	VUF 8328; 3-(1H-imidazol-5-yl)propyl carbamimidothioate; 102203-17-8; CHEMBL281576; GTPL1246; BDBM22912; CTK8G4476; VUF8328; VUF-8328; PDSP2_000279; PDSP1_000280
DMI6GD0	DT	Small molecular drug
DMI6GD0	PC	10176414
DMI6GD0	MW	184.26
DMI6GD0	FM	C7H12N4S
DMI6GD0	IC	InChI=1S/C7H12N4S/c8-7(9)12-3-1-2-6-4-10-5-11-6/h4-5H,1-3H2,(H3,8,9)(H,10,11)
DMI6GD0	CS	C1=C(NC=N1)CCCSC(=N)N
DMI6GD0	IK	QJUVWGBVEFRHCN-UHFFFAOYSA-N
DMI6GD0	IU	3-(1H-imidazol-5-yl)propyl carbamimidothioate
DMI6GD0	DE	Discovery agent

DMJC0UH	ID	DMJC0UH
DMJC0UH	DN	VUF 8430
DMJC0UH	HS	Investigative
DMJC0UH	SN	VUF8430; VUF-8430
DMJC0UH	DT	Small molecular drug
DMJC0UH	PC	3063228
DMJC0UH	MW	161.23
DMJC0UH	FM	C4H11N5S
DMJC0UH	IC	InChI=1S/C4H11N5S/c5-3(6)9-1-2-10-4(7)8/h1-2H2,(H3,7,8)(H4,5,6,9)
DMJC0UH	CS	C(CSC(=N)N)N=C(N)N
DMJC0UH	IK	GSYGTVNTZHFQQH-UHFFFAOYSA-N
DMJC0UH	IU	2-(diaminomethylideneamino)ethyl carbamimidothioate
DMJC0UH	CA	CAS 98021-17-1
DMJC0UH	DE	Discovery agent

DM89PMC	ID	DM89PMC
DM89PMC	DN	VUF-10148
DM89PMC	HS	Investigative
DM89PMC	SN	VUF-10148; CHEMBL261551; 1001065-53-7; VUF 10148; 3-Benzyl-2-(4-methylpiperazinyl)-quinoxaline; SCHEMBL602972; MolPort-027-564-855; PQQUQVYOCGJWAX-UHFFFAOYSA-N; KS-00002WX1; ZINC29054164; BDBM50412496; AKOS016340709; MG-0235
DM89PMC	DT	Small molecular drug
DM89PMC	PC	24759623
DM89PMC	MW	318.4
DM89PMC	FM	C20H22N4
DM89PMC	IC	InChI=1S/C20H22N4/c1-23-11-13-24(14-12-23)20-19(15-16-7-3-2-4-8-16)21-17-9-5-6-10-18(17)22-20/h2-10H,11-15H2,1H3
DM89PMC	CS	CN1CCN(CC1)C2=NC3=CC=CC=C3N=C2CC4=CC=CC=C4
DM89PMC	IK	PQQUQVYOCGJWAX-UHFFFAOYSA-N
DM89PMC	IU	2-benzyl-3-(4-methylpiperazin-1-yl)quinoxaline
DM89PMC	DE	Discovery agent

DMADEOQ	ID	DMADEOQ
DMADEOQ	DN	VUF-10214
DMADEOQ	HS	Investigative
DMADEOQ	SN	VUF-10214; CHEMBL260549; SCHEMBL602698; BDBM50361014; 6,7-dichloro-3-(4-methylpiperazin-1-yl)quinoxalin-2(1 h)-one
DMADEOQ	DT	Small molecular drug
DMADEOQ	PC	11301441
DMADEOQ	MW	313.18
DMADEOQ	FM	C13H14Cl2N4O
DMADEOQ	IC	InChI=1S/C13H14Cl2N4O/c1-18-2-4-19(5-3-18)12-13(20)17-11-7-9(15)8(14)6-10(11)16-12/h6-7H,2-5H2,1H3,(H,17,20)
DMADEOQ	CS	CN1CCN(CC1)C2=NC3=CC(=C(C=C3NC2=O)Cl)Cl
DMADEOQ	IK	MFJVHWQDKIEBCM-UHFFFAOYSA-N
DMADEOQ	IU	6,7-dichloro-3-(4-methylpiperazin-1-yl)-1H-quinoxalin-2-one
DMADEOQ	DE	Discovery agent

DM3G6OK	ID	DM3G6OK
DM3G6OK	DN	VUF-5297
DM3G6OK	HS	Investigative
DM3G6OK	SN	CHEMBL13795; SCHEMBL7508989; BDBM50127605; AKOS006351626; (1S,2S)-2-(3H-Imidazol-4-yl)-cyclopropylamine
DM3G6OK	DT	Small molecular drug
DM3G6OK	PC	10374457
DM3G6OK	MW	123.16
DM3G6OK	FM	C6H9N3
DM3G6OK	IC	InChI=1S/C6H9N3/c7-5-1-4(5)6-2-8-3-9-6/h2-5H,1,7H2,(H,8,9)/t4-,5-/m0/s1
DM3G6OK	CS	C1[C@@H]([C@H]1N)C2=CN=CN2
DM3G6OK	IK	OWWNABDDYQLERE-WHFBIAKZSA-N
DM3G6OK	IU	(1S,2S)-2-(1H-imidazol-5-yl)cyclopropan-1-amine
DM3G6OK	DE	Discovery agent

DMF1O0Z	ID	DMF1O0Z
DMF1O0Z	DN	VUF5391
DMF1O0Z	HS	Investigative
DMF1O0Z	DE	Discovery agent

DMUA751	ID	DMUA751
DMUA751	DN	VUF5574
DMUA751	HS	Investigative
DMUA751	SN	VUF 5574; VUF-5574
DMUA751	DT	Small molecular drug
DMUA751	PC	4046493
DMUA751	MW	371.4
DMUA751	FM	C21H17N5O2
DMUA751	IC	InChI=1S/C21H17N5O2/c1-28-18-11-5-4-10-17(18)24-21(27)26-20-15-8-2-3-9-16(15)23-19(25-20)14-7-6-12-22-13-14/h2-13H,1H3,(H2,23,24,25,26,27)
DMUA751	CS	COC1=CC=CC=C1NC(=O)NC2=NC(=NC3=CC=CC=C32)C4=CN=CC=C4
DMUA751	IK	YRAFEJSZTVWUMD-UHFFFAOYSA-N
DMUA751	IU	1-(2-methoxyphenyl)-3-(2-pyridin-3-ylquinazolin-4-yl)urea
DMUA751	CA	CAS 280570-45-8
DMUA751	DE	Discovery agent

DM8OTAG	ID	DM8OTAG
DM8OTAG	DN	VUF-8504
DM8OTAG	HS	Investigative
DM8OTAG	SN	CHEMBL130499; GTPL475; 4-methoxy-N-(2-pyridin-2-ylquinazolin-4-yl)benzamide; VUF8504; VUF 8504; BDBM50067117; 4-Methoxy-N-[2-(2-pyridinyl)quinazoline-4-yl]benzamide
DM8OTAG	DT	Small molecular drug
DM8OTAG	PC	10247610
DM8OTAG	MW	355.4
DM8OTAG	FM	C22H17N3O2
DM8OTAG	IC	InChI=1S/C22H17N3O2/c1-27-17-11-9-15(10-12-17)22(26)25-21-18-7-3-2-6-16(18)14-20(24-21)19-8-4-5-13-23-19/h2-14H,1H3,(H,24,25,26)
DM8OTAG	CS	COC1=CC=C(C=C1)C(=O)NC2=NC(=CC3=CC=CC=C32)C4=CC=CC=N4
DM8OTAG	IK	VLGYXUZBVKQWQO-UHFFFAOYSA-N
DM8OTAG	IU	4-methoxy-N-(3-pyridin-2-ylisoquinolin-1-yl)benzamide
DM8OTAG	DE	Discovery agent

DMQFWV7	ID	DMQFWV7
DMQFWV7	DN	VUF-8507
DMQFWV7	HS	Investigative
DMQFWV7	SN	VUF-8507; CHEMBL71053; N-(3-pyridin-2-ylisoquinolin-1-yl)benzamide; GTPL476; SCHEMBL1003046; VUF8507; VUF 8507; BDBM50067096; N-[3-(2-pyridinyl)-1-isoquinolinyl]benzamide; N-(3-(pyridin-2-yl)isoquinolin-1-yl)benzamide; N-(3-Pyridin-2-yl-isoquinolin-1-yl)-benzamide; N-(3-Pyridin-2-yl-isoquinolin-1-yl)-benzamide(VUF8507)
DMQFWV7	DT	Small molecular drug
DMQFWV7	PC	10448986
DMQFWV7	MW	325.4
DMQFWV7	FM	C21H15N3O
DMQFWV7	IC	InChI=1S/C21H15N3O/c25-21(15-8-2-1-3-9-15)24-20-17-11-5-4-10-16(17)14-19(23-20)18-12-6-7-13-22-18/h1-14H,(H,23,24,25)
DMQFWV7	CS	C1=CC=C(C=C1)C(=O)NC2=NC(=CC3=CC=CC=C32)C4=CC=CC=N4
DMQFWV7	IK	FWRPUFITEHOETQ-UHFFFAOYSA-N
DMQFWV7	IU	N-(3-pyridin-2-ylisoquinolin-1-yl)benzamide
DMQFWV7	DE	Discovery agent

DMWRX4T	ID	DMWRX4T
DMWRX4T	DN	VULM-1457
DMWRX4T	HS	Investigative
DMWRX4T	SN	Acyl CoA cholesterol acyltransferase inhibitor (dyslipidemia/atherosclerosis), Univerzity Komenskeho v Bratislave
DMWRX4T	CP	Univerzity Komenskeho v Bratislave
DMWRX4T	DE	Arteriosclerosis

DMEZAND	ID	DMEZAND
DMEZAND	DN	VVP-100X
DMEZAND	HS	Investigative
DMEZAND	CP	Verva Pharmaceuticals Ltd
DMEZAND	DE	Non-insulin dependent diabetes

DM4Q5DO	ID	DM4Q5DO
DM4Q5DO	DN	VX-467
DM4Q5DO	HS	Investigative
DM4Q5DO	SN	JAK 3 inhibitor (inflammation), Vertex
DM4Q5DO	CP	Vertex Pharmaceuticals Inc
DM4Q5DO	DE	Inflammation

DMDYTSW	ID	DMDYTSW
DMDYTSW	DN	W146
DMDYTSW	HS	Investigative
DMDYTSW	SN	W146_02-01; W 146; W-146
DMDYTSW	DT	Small molecular drug
DMDYTSW	PC	6857802
DMDYTSW	MW	342.37
DMDYTSW	FM	C16H27N2O4P
DMDYTSW	IC	InChI=1S/C16H27N2O4P/c1-2-3-4-5-7-13-8-6-9-14(12-13)18-16(19)15(17)10-11-23(20,21)22/h6,8-9,12,15H,2-5,7,10-11,17H2,1H3,(H,18,19)(H2,20,21,22)/t15-/m1/s1
DMDYTSW	CS	CCCCCCC1=CC(=CC=C1)NC(=O)[C@@H](CCP(=O)(O)O)N
DMDYTSW	IK	FWJRVGZWNDOOFH-OAHLLOKOSA-N
DMDYTSW	IU	[(3R)-3-amino-4-(3-hexylanilino)-4-oxobutyl]phosphonic acid
DMDYTSW	CA	CAS 909725-61-7
DMDYTSW	DE	Discovery agent

DMQI7BA	ID	DMQI7BA
DMQI7BA	DN	W54011
DMQI7BA	HS	Investigative
DMQI7BA	SN	W-54011; W 54011
DMQI7BA	DT	Small molecular drug
DMQI7BA	PC	5311122
DMQI7BA	MW	456.6
DMQI7BA	FM	C30H36N2O2
DMQI7BA	IC	InChI=1S/C30H36N2O2/c1-21(2)23-11-16-26(17-12-23)32(20-22-9-14-25(15-10-22)31(3)4)30(33)28-8-6-7-24-13-18-27(34-5)19-29(24)28/h9-19,21,28H,6-8,20H2,1-5H3
DMQI7BA	CS	CC(C)C1=CC=C(C=C1)N(CC2=CC=C(C=C2)N(C)C)C(=O)C3CCCC4=C3C=C(C=C4)OC
DMQI7BA	IK	DVYASSBBADJRAS-UHFFFAOYSA-N
DMQI7BA	IU	N-[[4-(dimethylamino)phenyl]methyl]-7-methoxy-N-(4-propan-2-ylphenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide
DMQI7BA	DE	Discovery agent

DMMBI9Y	ID	DMMBI9Y
DMMBI9Y	DN	W-84
DMMBI9Y	HS	Investigative
DMMBI9Y	SN	Hdmppa; W84
DMMBI9Y	DT	Small molecular drug
DMMBI9Y	PC	167962
DMMBI9Y	MW	548.7
DMMBI9Y	FM	C32H44N4O4+2
DMMBI9Y	IC	InChI=1S/C32H44N4O4/c1-35(2,23-13-19-33-29(37)25-15-7-8-16-26(25)30(33)38)21-11-5-6-12-22-36(3,4)24-14-20-34-31(39)27-17-9-10-18-28(27)32(34)40/h7-10,15-18H,5-6,11-14,19-24H2,1-4H3/q+2
DMMBI9Y	CS	C[N+](C)(CCCCCC[N+](C)(C)CCCN1C(=O)C2=CC=CC=C2C1=O)CCCN3C(=O)C4=CC=CC=C4C3=O
DMMBI9Y	IK	WDAXQFXYXWPELC-UHFFFAOYSA-N
DMMBI9Y	IU	3-(1,3-dioxoisoindol-2-yl)propyl-[6-[3-(1,3-dioxoisoindol-2-yl)propyl-dimethylazaniumyl]hexyl]-dimethylazanium
DMMBI9Y	DE	Discovery agent

DMNRBDP	ID	DMNRBDP
DMNRBDP	DN	WA-8242-A1
DMNRBDP	HS	Investigative
DMNRBDP	SN	171272-08-5; 204272-98-0; 204273-00-7; WA-8242-A2; WA-8242-B
DMNRBDP	DE	Discovery agent

DMB6H35	ID	DMB6H35
DMB6H35	DN	waixenicin A
DMB6H35	HS	Investigative
DMB6H35	SN	waixenicin A; GTPL6359; (2E,5S)-5-[(1R,4aS,11aR)-1-Acetoxy-7-methyl-11-methylene-1,4a,5,6,9,10,11,11a-octahydrocyclonona[c]pyran-4-yl]-2-methyl-2-pentene-1,5-diyl diacetate
DMB6H35	DT	Small molecular drug
DMB6H35	PC	73755210
DMB6H35	MW	460.6
DMB6H35	FM	C26H36O7
DMB6H35	IC	InChI=1S/C26H36O7/c1-16-8-7-9-18(3)25-22(12-10-16)23(15-31-26(25)33-21(6)29)24(32-20(5)28)13-11-17(2)14-30-19(4)27/h8,11,15,22,24-26H,3,7,9-10,12-14H2,1-2,4-6H3/b16-8?,17-11+/t22-,24+,25+,26-/m1/s1
DMB6H35	CS	CC1=CCCC(=C)[C@H]2[C@H](CC1)C(=CO[C@@H]2OC(=O)C)[C@H](C/C=C(\\C)/COC(=O)C)OC(=O)C
DMB6H35	IK	DCZJIZRGTZFSQY-VWQHOESYSA-N
DMB6H35	IU	[(E,5S)-5-[(1R,4aS,11aR)-1-acetyloxy-7-methyl-11-methylidene-4a,5,6,9,10,11a-hexahydro-1H-cyclonona[c]pyran-4-yl]-5-acetyloxy-2-methylpent-2-enyl] acetate
DMB6H35	DE	Discovery agent

DMC6KYF	ID	DMC6KYF
DMC6KYF	DN	WAY 100135
DMC6KYF	HS	Investigative
DMC6KYF	SN	CHEMBL38288; (2S)-N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide; Tocris-1253; AC1O7GY4; GTPL126; SCHEMBL4087689; BDBM82369; ZINC52957106; BDBM50047471; NCGC00025081-01; AJ-112145; CAS_133025-23-7; (s)-N-t-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide; (S)-N-tert-Butyl-2-phenyl-3-[4-(2-methoxyphenyl)piperazino]propanamide
DMC6KYF	DT	Small molecular drug
DMC6KYF	PC	115111
DMC6KYF	MW	395.5
DMC6KYF	FM	C24H33N3O2
DMC6KYF	IC	InChI=1S/C24H33N3O2/c1-24(2,3)25-23(28)20(19-10-6-5-7-11-19)18-26-14-16-27(17-15-26)21-12-8-9-13-22(21)29-4/h5-13,20H,14-18H2,1-4H3,(H,25,28)
DMC6KYF	CS	CC(C)(C)NC(=O)C(CN1CCN(CC1)C2=CC=CC=C2OC)C3=CC=CC=C3
DMC6KYF	IK	UMTDAKAAYOXIKU-UHFFFAOYSA-N
DMC6KYF	IU	N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide
DMC6KYF	CA	CAS 133025-23-7
DMC6KYF	CB	CHEBI:104131
DMC6KYF	DE	Discovery agent

DMCSZG0	ID	DMCSZG0
DMCSZG0	DN	WAY-125971
DMCSZG0	HS	Investigative
DMCSZG0	SN	Way 125971; 139047-48-6; Way-125,971; AC1L53ET; SCHEMBL9736383; CHEMBL109351; DTXSID80160878; N-(2-((Methyl-3-(4-((methylsulfonyl)amino)phenoxy)propyl)amino)methyl)-6-quinolinylmethanesulfonamide
DMCSZG0	DT	Small molecular drug
DMCSZG0	PC	101617951
DMCSZG0	MW	492.6
DMCSZG0	FM	C22H28N4O5S2
DMCSZG0	IC	InChI=1S/C22H28N4O5S2/c1-23-33(29,30)21-11-12-22-17(15-21)5-6-19(24-22)16-26(2)13-4-14-31-20-9-7-18(8-10-20)25-32(3,27)28/h5-12,15,23,25H,4,13-14,16H2,1-3H3
DMCSZG0	CS	CNS(=O)(=O)C1=CC2=C(C=C1)N=C(C=C2)CN(C)CCCOC3=CC=C(C=C3)NS(=O)(=O)C
DMCSZG0	IK	YENONGAXQMSIAO-UHFFFAOYSA-N
DMCSZG0	IU	2-[[3-[4-(methanesulfonamido)phenoxy]propyl-methylamino]methyl]-N-methylquinoline-6-sulfonamide
DMCSZG0	DE	Discovery agent

DMRWG0C	ID	DMRWG0C
DMRWG0C	DN	WAY-151693
DMRWG0C	HS	Investigative
DMRWG0C	SN	WAY-151693; CHEMBL70176; n-hydroxy-2-[(4-methoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-3-methyl-benzamide; 1fls; WAY; AC1L1I0A; SCHEMBL6129930; BDBM50096463; DB02071; WAY 151693; N-hydroxy-3-methyl-2-[N-(pyridin-3-ylmethyl)4-methoxybenzenesulfonamido]benzamide; N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbenzamide; N-hydroxy-2-{[(4-methoxyphenyl)sulfonyl](pyridin-3-ylmethyl)amino}-3-methylbenzamide
DMRWG0C	DT	Small molecular drug
DMRWG0C	PC	4368
DMRWG0C	MW	427.5
DMRWG0C	FM	C21H21N3O5S
DMRWG0C	IC	InChI=1S/C21H21N3O5S/c1-15-5-3-7-19(21(25)23-26)20(15)24(14-16-6-4-12-22-13-16)30(27,28)18-10-8-17(29-2)9-11-18/h3-13,26H,14H2,1-2H3,(H,23,25)
DMRWG0C	CS	CC1=C(C(=CC=C1)C(=O)NO)N(CC2=CN=CC=C2)S(=O)(=O)C3=CC=C(C=C3)OC
DMRWG0C	IK	AINJYWXKBKRQSX-UHFFFAOYSA-N
DMRWG0C	IU	N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbenzamide
DMRWG0C	DE	Discovery agent

DMNMO4Q	ID	DMNMO4Q
DMNMO4Q	DN	WAY-163909
DMNMO4Q	HS	Investigative
DMNMO4Q	SN	WAY163909
DMNMO4Q	DT	Small molecular drug
DMNMO4Q	PC	10130594
DMNMO4Q	MW	214.31
DMNMO4Q	FM	C14H18N2
DMNMO4Q	IC	InChI=1S/C14H18N2/c1-3-10-9-15-7-8-16-13-6-2-4-11(13)12(5-1)14(10)16/h1,3,5,11,13,15H,2,4,6-9H2/t11-,13-/m1/s1
DMNMO4Q	CS	C1C[C@H]2[C@@H](C1)N3CCNCC4=C3C2=CC=C4
DMNMO4Q	IK	XOSKJKGKWRIMGV-DGCLKSJQSA-N
DMNMO4Q	IU	(11R,15R)-7,10-diazatetracyclo[8.5.1.05,16.011,15]hexadeca-1,3,5(16)-triene
DMNMO4Q	CA	CAS 428868-32-0
DMNMO4Q	DE	Discovery agent

DM94KWA	ID	DM94KWA
DM94KWA	DN	WAY-169916
DM94KWA	HS	Investigative
DM94KWA	DT	Small molecular drug
DM94KWA	PC	135461982
DM94KWA	MW	334.29
DM94KWA	FM	C17H13F3N2O2
DM94KWA	IC	InChI=1S/C17H13F3N2O2/c1-2-8-22-16-12(4-3-5-13(16)17(18,19)20)15(21-22)11-7-6-10(23)9-14(11)24/h2-7,9,23-24H,1,8H2
DM94KWA	CS	C=CCN1C2=C(C=CC=C2C(F)(F)F)C(=N1)C3=C(C=C(C=C3)O)O
DM94KWA	IK	ZDUDMCQPFKPISO-UHFFFAOYSA-N
DM94KWA	IU	4-[1-prop-2-enyl-7-(trifluoromethyl)indazol-3-yl]benzene-1,3-diol
DM94KWA	CA	CAS 669764-18-5
DM94KWA	DE	Discovery agent

DMZT8LI	ID	DMZT8LI
DMZT8LI	DN	WAY170523
DMZT8LI	HS	Investigative
DMZT8LI	SN	WAY-170523; WAY 170523
DMZT8LI	DT	Small molecular drug
DMZT8LI	PC	9830392
DMZT8LI	MW	613.7
DMZT8LI	FM	C33H31N3O7S
DMZT8LI	IC	InChI=1S/C33H31N3O7S/c1-22-18-23(2)31(28(19-22)32(37)35-39)36(21-24-8-4-3-5-9-24)44(40,41)27-14-12-26(13-15-27)42-17-16-34-33(38)30-20-25-10-6-7-11-29(25)43-30/h3-15,18-20,39H,16-17,21H2,1-2H3,(H,34,38)(H,35,37)
DMZT8LI	CS	CC1=CC(=C(C(=C1)C(=O)NO)N(CC2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)OCCNC(=O)C4=CC5=CC=CC=C5O4)C
DMZT8LI	IK	FARMEEAGJWMFSZ-UHFFFAOYSA-N
DMZT8LI	IU	N-[2-[4-[benzyl-[2-(hydroxycarbamoyl)-4,6-dimethylphenyl]sulfamoyl]phenoxy]ethyl]-1-benzofuran-2-carboxamide
DMZT8LI	CB	CHEBI:92636
DMZT8LI	DE	Discovery agent

DMNH0CM	ID	DMNH0CM
DMNH0CM	DN	WAY-196025
DMNH0CM	HS	Investigative
DMNH0CM	SN	CHEMBL404529; SCHEMBL1501417; YOFBEFNLUYVWRR-UHFFFAOYSA-N; BDBM50226793; 4-(3-{1-Benzhydryl-5-chloro-2-[2-(2,6-dimethyl-phenylmethanesulfonylamino)-ethyl]-1H-indol-3 -yl}-propyl)-benzoic Acid; 4-{3-[5-Chloro-2-(2-{[(2,6-dimethylbenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic Acid; 4-(3-(1-benzhydryl-5-chloro-2-(2-((2,6-dimethylphenyl)methylsulfonamido)ethyl)indolin-3-yl)propyl)benzoic acid
DMNH0CM	DT	Small molecular drug
DMNH0CM	PC	10290302
DMNH0CM	MW	705.3
DMNH0CM	FM	C42H41ClN2O4S
DMNH0CM	IC	InChI=1S/C42H41ClN2O4S/c1-29-11-9-12-30(2)38(29)28-50(48,49)44-26-25-40-36(18-10-13-31-19-21-34(22-20-31)42(46)47)37-27-35(43)23-24-39(37)45(40)41(32-14-5-3-6-15-32)33-16-7-4-8-17-33/h3-9,11-12,14-17,19-24,27,41,44H,10,13,18,25-26,28H2,1-2H3,(H,46,47)
DMNH0CM	CS	CC1=C(C(=CC=C1)C)CS(=O)(=O)NCCC2=C(C3=C(N2C(C4=CC=CC=C4)C5=CC=CC=C5)C=CC(=C3)Cl)CCCC6=CC=C(C=C6)C(=O)O
DMNH0CM	IK	YOFBEFNLUYVWRR-UHFFFAOYSA-N
DMNH0CM	IU	4-[3-[1-benzhydryl-5-chloro-2-[2-[(2,6-dimethylphenyl)methylsulfonylamino]ethyl]indol-3-yl]propyl]benzoic acid
DMNH0CM	DE	Discovery agent

DMBHXTL	ID	DMBHXTL
DMBHXTL	DN	WAY200070
DMBHXTL	HS	Investigative
DMBHXTL	SN	WAY 200070; 440122-66-7; WAY-200070; CHEMBL188528; 7-BROMO-2-(4-HYDROXYPHENYL)-1,3-BENZOXAZOL-5-OL; 7-Bromo-2-(4-hydroxy-phenyl)-benzooxazol-5-ol; SCHEMBL3930187; ZINC9308; GTPL4052; CTK1D2551; DTXSID80432027; MolPort-023-276-777; BAAILVWEAXFTSF-UHFFFAOYSA-N; BCP28989; WAY-00005; BDBM50154088; ZINC138816775; AKOS024457585; CS-6398; HY-101271; RT-016254; B7386; 7-bromo-2-(4-hydroxyphenyl)-5-benzoxazolol; 5-Benzoxazolol, 7-bromo-2-(4-hydroxyphenyl)-; 7-bromo-2-(4-hydroxyphenyl)benzo[d]oxazol-5-ol; WAY-200070, &gt
DMBHXTL	DT	Small molecular drug
DMBHXTL	PC	135418373
DMBHXTL	MW	306.11
DMBHXTL	FM	C13H8BrNO3
DMBHXTL	IC	InChI=1S/C13H8BrNO3/c14-10-5-9(17)6-11-12(10)18-13(15-11)7-1-3-8(16)4-2-7/h1-6,16-17H
DMBHXTL	CS	C1=CC(=CC=C1C2=NC3=C(O2)C(=CC(=C3)O)Br)O
DMBHXTL	IK	BAAILVWEAXFTSF-UHFFFAOYSA-N
DMBHXTL	IU	7-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMBHXTL	CA	CAS 440122-66-7
DMBHXTL	DE	Discovery agent

DMJ14NE	ID	DMJ14NE
DMJ14NE	DN	WAY-207024
DMJ14NE	HS	Investigative
DMJ14NE	SN	WAY-207024; CHEMBL474991; 872002-72-7; GTPL5582; SCHEMBL3275225; SCHEMBL13324654; BDBM50256882; ZINC35923465; WAY 207024; NCGC00370941-01; KB-81482; 6-((4-(2-(4-tert-butylphenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)methyl)quinoxaline
DMJ14NE	DT	Small molecular drug
DMJ14NE	PC	11496610
DMJ14NE	MW	476.6
DMJ14NE	FM	C30H32N6
DMJ14NE	IC	InChI=1S/C30H32N6/c1-30(2,3)23-10-8-22(9-11-23)29-33-25-5-4-6-27(28(25)34-29)36-17-15-35(16-18-36)20-21-7-12-24-26(19-21)32-14-13-31-24/h4-14,19H,15-18,20H2,1-3H3,(H,33,34)
DMJ14NE	CS	CC(C)(C)C1=CC=C(C=C1)C2=NC3=C(N2)C=CC=C3N4CCN(CC4)CC5=CC6=NC=CN=C6C=C5
DMJ14NE	IK	AVEVJMZJJJDOCI-UHFFFAOYSA-N
DMJ14NE	IU	6-[[4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl]methyl]quinoxaline
DMJ14NE	DE	Discovery agent

DM9K2LU	ID	DM9K2LU
DM9K2LU	DN	WAY-208466
DM9K2LU	HS	Investigative
DM9K2LU	SN	UNII-0AXW9ALG9W; 0AXW9ALG9W; CHEMBL571858; SCHEMBL3892710; GTPL8429; BDBM50300828; ZINC38542752; NCGC00370934-02; WAY-208466 dihydrochloride, &gt; 3-((3-Fluorophenyl)sulfonyl)-N,N-dimethyl-1H-pyrrolo(2,3-b)pyridine-1-ethanamine; 2-(3-(3-fluorophenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-N,N-dimethylethanamine; 1H-Pyrrolo(2,3-b)pyridine-1-ethanamine, 3-((3-fluorophenyl)sulfonyl)-N,N-dimethyl-; 2-[3-(3-fluorophenyl)sulfonylpyrrolo[2,3-b]pyridin-1-yl]-N,N-dimethylethanamine
DM9K2LU	DT	Small molecular drug
DM9K2LU	PC	10337743
DM9K2LU	MW	347.4
DM9K2LU	FM	C17H18FN3O2S
DM9K2LU	IC	InChI=1S/C17H18FN3O2S/c1-20(2)9-10-21-12-16(15-7-4-8-19-17(15)21)24(22,23)14-6-3-5-13(18)11-14/h3-8,11-12H,9-10H2,1-2H3
DM9K2LU	CS	CN(C)CCN1C=C(C2=C1N=CC=C2)S(=O)(=O)C3=CC=CC(=C3)F
DM9K2LU	IK	SFSFIDVAEMDPIP-UHFFFAOYSA-N
DM9K2LU	IU	2-[3-(3-fluorophenyl)sulfonylpyrrolo[2,3-b]pyridin-1-yl]-N,N-dimethylethanamine
DM9K2LU	CA	CAS 633304-27-5
DM9K2LU	DE	Discovery agent

DMMXL4E	ID	DMMXL4E
DMMXL4E	DN	WAY-213613
DMMXL4E	HS	Investigative
DMMXL4E	SN	WAY-213,613
DMMXL4E	DT	Small molecular drug
DMMXL4E	PC	11531745
DMMXL4E	MW	415.19
DMMXL4E	FM	C16H13BrF2N2O4
DMMXL4E	IC	InChI=1S/C16H13BrF2N2O4/c17-10-5-11(18)12(19)6-14(10)25-9-3-1-8(2-4-9)21-15(22)7-13(20)16(23)24/h1-6,13H,7,20H2,(H,21,22)(H,23,24)/t13-/m0/s1
DMMXL4E	CS	C1=CC(=CC=C1NC(=O)C[C@@H](C(=O)O)N)OC2=CC(=C(C=C2Br)F)F
DMMXL4E	IK	BNYDDAAZMBUFRG-ZDUSSCGKSA-N
DMMXL4E	IU	(2S)-2-amino-4-[4-(2-bromo-4,5-difluorophenoxy)anilino]-4-oxobutanoic acid
DMMXL4E	CA	CAS 868359-05-1
DMMXL4E	DE	Discovery agent

DM8ODI7	ID	DM8ODI7
DM8ODI7	DN	WAY-214950
DM8ODI7	HS	Investigative
DM8ODI7	SN	WAY-214950; SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067
DM8ODI7	DT	Small molecular drug
DM8ODI7	PC	25113722
DM8ODI7	MW	388.3
DM8ODI7	FM	C21H13F5N2
DM8ODI7	IC	InChI=1S/C21H13F5N2/c22-15-10-8-13(9-11-15)20-16-5-3-6-17(21(24,25)26)19(16)27-28(20)12-14-4-1-2-7-18(14)23/h1-11H,12H2
DM8ODI7	CS	C1=CC=C(C(=C1)CN2C(=C3C=CC=C(C3=N2)C(F)(F)F)C4=CC=C(C=C4)F)F
DM8ODI7	IK	NHSFDMDEDPAKNH-UHFFFAOYSA-N
DM8ODI7	IU	3-(4-fluorophenyl)-2-[(2-fluorophenyl)methyl]-7-(trifluoromethyl)indazole
DM8ODI7	CA	CAS 875787-08-9
DM8ODI7	DE	Discovery agent

DMC83HA	ID	DMC83HA
DMC83HA	DN	WAY-254011
DMC83HA	HS	Investigative
DMC83HA	DE	Discovery agent

DMSLNWA	ID	DMSLNWA
DMSLNWA	DN	WAY-255348
DMSLNWA	HS	Investigative
DMSLNWA	SN	WAY-255348; 872141-23-6; CHEMBL407848; WAY255348; KIOOLNRTWPFVHX-UHFFFAOYSA-N; GTPL8664; SCHEMBL1537222; BCP21063; ZINC29133439; BDBM50375827; WAY 255348; SB18886; KB-81484; 5-(7-fluoro-3,3-dimethyl-2-oxo-1H-indol-5-yl)-1-methylpyrrole-2-carbonitrile
DMSLNWA	DT	Small molecular drug
DMSLNWA	PC	11543746
DMSLNWA	MW	283.3
DMSLNWA	FM	C16H14FN3O
DMSLNWA	IC	InChI=1S/C16H14FN3O/c1-16(2)11-6-9(7-12(17)14(11)19-15(16)21)13-5-4-10(8-18)20(13)3/h4-7H,1-3H3,(H,19,21)
DMSLNWA	CS	CC1(C2=C(C(=CC(=C2)C3=CC=C(N3C)C#N)F)NC1=O)C
DMSLNWA	IK	KIOOLNRTWPFVHX-UHFFFAOYSA-N
DMSLNWA	IU	5-(7-fluoro-3,3-dimethyl-2-oxo-1H-indol-5-yl)-1-methylpyrrole-2-carbonitrile
DMSLNWA	DE	Solid tumour/cancer

DM48MC3	ID	DM48MC3
DM48MC3	DN	WAY-256805
DM48MC3	HS	Investigative
DM48MC3	SN	WAY-256805; CHEMBL469668
DM48MC3	DT	Small molecular drug
DM48MC3	PC	24894910
DM48MC3	MW	459.4
DM48MC3	FM	C20H31Cl2F3N2O2
DM48MC3	IC	InChI=1S/C20H29F3N2O2.2ClH/c1-24-10-12-25(13-11-24)15-18(19(26)8-3-2-4-9-19)16-6-5-7-17(14-16)27-20(21,22)23;;/h5-7,14,18,26H,2-4,8-13,15H2,1H3;2*1H/t18-;;/m1../s1
DM48MC3	CS	CN1CCN(CC1)C[C@H](C2=CC(=CC=C2)OC(F)(F)F)C3(CCCCC3)O.Cl.Cl
DM48MC3	IK	DJVJRXDBDBMWFD-JPKZNVRTSA-N
DM48MC3	IU	1-[(1S)-2-(4-methylpiperazin-1-yl)-1-[3-(trifluoromethoxy)phenyl]ethyl]cyclohexan-1-ol;dihydrochloride
DM48MC3	DE	Pain

DMMOH51	ID	DMMOH51
DMMOH51	DN	WAY-466
DMMOH51	HS	Investigative
DMMOH51	SN	BDBM34144
DMMOH51	DT	Small molecular drug
DMMOH51	PC	11431598
DMMOH51	MW	481.4
DMMOH51	FM	C19H20IN3O2S
DMMOH51	IC	InChI=1S/C19H20IN3O2S/c20-17-5-1-2-6-19(17)26(24,25)23-15-7-8-18-16(11-15)13(12-22-18)10-14-4-3-9-21-14/h1-2,5-8,11-12,14,21-23H,3-4,9-10H2/t14-/m1/s1
DMMOH51	CS	C1C[C@@H](NC1)CC2=CNC3=C2C=C(C=C3)NS(=O)(=O)C4=CC=CC=C4I
DMMOH51	IK	ZLTKHJVPOSETMR-CQSZACIVSA-N
DMMOH51	IU	2-iodo-N-[3-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indol-5-yl]benzenesulfonamide
DMMOH51	DE	Discovery agent

DMNCZEQ	ID	DMNCZEQ
DMNCZEQ	DN	WAY-644
DMNCZEQ	HS	Investigative
DMNCZEQ	SN	MMP-12 inhibitor (aortic abdominal aneurysm), Pfizer; MMP-12 inhibitor (aortic abdominal aneurysm), Wyeth
DMNCZEQ	CP	Wyeth
DMNCZEQ	DE	Aortic aneurysm

DME10AL	ID	DME10AL
DME10AL	DN	WBZ-7
DME10AL	HS	Investigative
DME10AL	SN	Imatinib analog (cancer), MD Anderson Cancer Center/Rice University
DME10AL	CP	MD Anderson Cancer Center
DME10AL	DE	Solid tumour/cancer

DMWU5PK	ID	DMWU5PK
DMWU5PK	DN	WDuo3
DMWU5PK	HS	Investigative
DMWU5PK	SN	1,1'-Trimethylenebis[4-(phthalimidylmethoxyiminomethyl)pyridinium]
DMWU5PK	DT	Small molecular drug
DMWU5PK	PC	44381306
DMWU5PK	MW	604.6
DMWU5PK	FM	C33H28N6O6+2
DMWU5PK	IC	InChI=1S/C33H28N6O6/c40-30-26-6-1-2-7-27(26)31(41)38(30)22-44-34-20-24-10-16-36(17-11-24)14-5-15-37-18-12-25(13-19-37)21-35-45-23-39-32(42)28-8-3-4-9-29(28)33(39)43/h1-4,6-13,16-21H,5,14-15,22-23H2/q+2/b34-20+,35-21+
DMWU5PK	CS	C1=CC=C2C(=O)N(C(=O)C2=C1)CO/N=C/C3=CC=[N+](C=C3)CCC[N+]4=CC=C(C=C4)/C=N/OCN5C(=O)C6=CC=CC=C6C5=O
DMWU5PK	IK	OLTRDACQFPTOSK-VQGAUUQYSA-N
DMWU5PK	IU	2-[[(E)-[1-[3-[4-[(E)-(1,3-dioxoisoindol-2-yl)methoxyiminomethyl]pyridin-1-ium-1-yl]propyl]pyridin-1-ium-4-yl]methylideneamino]oxymethyl]isoindole-1,3-dione
DMWU5PK	DE	Discovery agent

DMHL3YV	ID	DMHL3YV
DMHL3YV	DN	WEDELOLACTONE
DMHL3YV	HS	Investigative
DMHL3YV	SN	Wedelolactone; 524-12-9; UNII-0K6L725GNS; 7-Methoxy-5,11,12-trihydroxycoumestan; 7-Methoxy-5,11,12-trihydroxy-coumestan; 1,8,9-Trihydroxy-3-methoxycoumestan; Wedelolactone, Eclipta alba; CHEMBL97453; 0K6L725GNS; CHEBI:10037; IKK Inhibitor II, Wedelolactone; 1,8,9-Trihydroxy-3-methoxy-6H-benzofuro[3,2-c][1]benzopyran-6-one; 1,8,9-trihydroxy-3-methoxy-benzofuro[3,2-c]chromen-6-one; 1,8,9-Trihydroxy-3-methoxy-6H-[1]benzofuro[3,2-c]chromen-6-one; AC1NQZ4Z; SCHEMBL601220; GTPL5551; CTK8G3781; DTXSID60200408; Wedelolactone, analyti
DMHL3YV	DT	Small molecular drug
DMHL3YV	PC	5281813
DMHL3YV	MW	314.25
DMHL3YV	FM	C16H10O7
DMHL3YV	IC	InChI=1S/C16H10O7/c1-21-6-2-10(19)14-12(3-6)23-16(20)13-7-4-8(17)9(18)5-11(7)22-15(13)14/h2-5,17-19H,1H3
DMHL3YV	CS	COC1=CC(=C2C(=C1)OC(=O)C3=C2OC4=CC(=C(C=C43)O)O)O
DMHL3YV	IK	XQDCKJKKMFWXGB-UHFFFAOYSA-N
DMHL3YV	IU	1,8,9-trihydroxy-3-methoxy-[1]benzofuro[3,2-c]chromen-6-one
DMHL3YV	CA	CAS 524-12-9
DMHL3YV	CB	CHEBI:10037
DMHL3YV	DE	Discovery agent

DMK0OVE	ID	DMK0OVE
DMK0OVE	DN	WEHI-0103122
DMK0OVE	HS	Investigative
DMK0OVE	SN	BH3 mimetics (cancer), WEHI; Bcl-xL inhibitors (cancer); Bcl-xL inhibitors (cancer), WEHI/ Genentech
DMK0OVE	CP	Walter and Eliza Hall Institute of Medical Research
DMK0OVE	DE	Solid tumour/cancer

DMAXOIS	ID	DMAXOIS
DMAXOIS	DN	W-F-F-N--Y-Y-W
DMAXOIS	HS	Investigative
DMAXOIS	SN	CHEMBL413880; W-F-F-N--Y-Y-W
DMAXOIS	PC	44371672
DMAXOIS	MW	1126.2
DMAXOIS	FM	C62H63N9O12
DMAXOIS	IC	InChI=1S/C62H63N9O12/c63-55(74)33-52(70-58(77)49(28-37-13-5-2-6-14-37)67-56(75)48(27-36-11-3-1-4-12-36)66-53(61(80)81)31-40-34-64-46-17-9-7-15-44(40)46)60(79)69-50(29-38-19-23-42(72)24-20-38)57(76)68-51(30-39-21-25-43(73)26-22-39)59(78)71-54(62(82)83)32-41-35-65-47-18-10-8-16-45(41)47/h1-26,34-35,48-54,64-66,72-73H,27-33H2,(H2,63,74)(H,67,75)(H,68,76)(H,69,79)(H,70,77)(H,71,78)(H,80,81)(H,82,83)/t48-,49-,50-,51-,52-,53+,54-/m0/s1
DMAXOIS	CS	C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)O)N[C@H](CC7=CNC8=CC=CC=C87)C(=O)O
DMAXOIS	IK	NXCOTRHNIBGFLM-ZYWWURNJSA-N
DMAXOIS	IU	(2R)-2-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)propanoic acid
DMAXOIS	DE	Discovery agent

DMQS7BT	ID	DMQS7BT
DMQS7BT	DN	WFwGG-NH2
DMQS7BT	HS	Investigative
DMQS7BT	SN	CHEMBL444131; wFwGG-NH2
DMQS7BT	DT	Small molecular drug
DMQS7BT	PC	44576255
DMQS7BT	MW	650.7
DMQS7BT	FM	C35H38N8O5
DMQS7BT	IC	InChI=1S/C35H38N8O5/c36-26(15-22-17-38-27-12-6-4-10-24(22)27)33(46)42-29(14-21-8-2-1-3-9-21)35(48)43-30(34(47)41-20-32(45)40-19-31(37)44)16-23-18-39-28-13-7-5-11-25(23)28/h1-13,17-18,26,29-30,38-39H,14-16,19-20,36H2,(H2,37,44)(H,40,45)(H,41,47)(H,42,46)(H,43,48)/t26-,29+,30-/m1/s1
DMQS7BT	CS	C1=CC=C(C=C1)C[C@@H](C(=O)N[C@H](CC2=CNC3=CC=CC=C32)C(=O)NCC(=O)NCC(=O)N)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)N
DMQS7BT	IK	WIJADCOBFJYNSF-JJZPZGAKSA-N
DMQS7BT	IU	(2S)-2-[[(2R)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[2-[(2-amino-2-oxoethyl)amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-3-phenylpropanamide
DMQS7BT	DE	Discovery agent

DMOBXVL	ID	DMOBXVL
DMOBXVL	DN	WFwLL-NH2
DMOBXVL	HS	Investigative
DMOBXVL	SN	CHEMBL450217; wFwLL-NH2; BDBM50260269
DMOBXVL	DT	Small molecular drug
DMOBXVL	PC	10190715
DMOBXVL	MW	762.9
DMOBXVL	FM	C43H54N8O5
DMOBXVL	IC	InChI=1S/C43H54N8O5/c1-25(2)18-35(39(45)52)48-41(54)36(19-26(3)4)50-43(56)38(22-29-24-47-34-17-11-9-15-31(29)34)51-42(55)37(20-27-12-6-5-7-13-27)49-40(53)32(44)21-28-23-46-33-16-10-8-14-30(28)33/h5-17,23-26,32,35-38,46-47H,18-22,44H2,1-4H3,(H2,45,52)(H,48,54)(H,49,53)(H,50,56)(H,51,55)/t32-,35+,36+,37+,38-/m1/s1
DMOBXVL	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)N
DMOBXVL	IK	YFSSMBIPKDBQSL-CLZHSDMDSA-N
DMOBXVL	IU	(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanamide
DMOBXVL	DE	Discovery agent

DMJS8VQ	ID	DMJS8VQ
DMJS8VQ	DN	WH-4-023
DMJS8VQ	HS	Investigative
DMJS8VQ	SN	WH-4-023; 837422-57-8; 2,6-dimethylphenyl (2,4-dimethoxyphenyl)(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)carbamate; KIN001-112; 2,6-dimethylphenyl N-(2,4-dimethoxyphenyl)-N-(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)carbamate; SCHEMBL5755186; KIN112; CHEMBL213100; GTPL8068; CHEBI:94644; 2-aminopyrimidine carbamate, 28; KS-00001CWM; BDBM17729; AOB6574; MolPort-035-789-690; HMS3653D15; C32H36N6O4; EX-A1078; BCP10090; s7565; ZINC14965418; 2801AH; AKOS025142111; CS-3292; NCGC00346959-01
DMJS8VQ	DT	Small molecular drug
DMJS8VQ	PC	11844351
DMJS8VQ	MW	568.7
DMJS8VQ	FM	C32H36N6O4
DMJS8VQ	IC	InChI=1S/C32H36N6O4/c1-22-7-6-8-23(2)30(22)42-32(39)38(27-14-13-26(40-4)21-28(27)41-5)29-15-16-33-31(35-29)34-24-9-11-25(12-10-24)37-19-17-36(3)18-20-37/h6-16,21H,17-20H2,1-5H3,(H,33,34,35)
DMJS8VQ	CS	CC1=C(C(=CC=C1)C)OC(=O)N(C2=C(C=C(C=C2)OC)OC)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCN(CC5)C
DMJS8VQ	IK	NBTNHSGBRGTFJS-UHFFFAOYSA-N
DMJS8VQ	IU	(2,6-dimethylphenyl) N-(2,4-dimethoxyphenyl)-N-[2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]carbamate
DMJS8VQ	CB	CHEBI:94644
DMJS8VQ	DE	Discovery agent

DMYHWS1	ID	DMYHWS1
DMYHWS1	DN	WHI-P154
DMYHWS1	HS	Investigative
DMYHWS1	DT	Small molecular drug
DMYHWS1	PC	3795
DMYHWS1	MW	376.2
DMYHWS1	FM	C16H14BrN3O3
DMYHWS1	IC	InChI=1S/C16H14BrN3O3/c1-22-14-6-10-12(7-15(14)23-2)18-8-19-16(10)20-9-3-4-13(21)11(17)5-9/h3-8,21H,1-2H3,(H,18,19,20)
DMYHWS1	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)O)Br)OC
DMYHWS1	IK	CBIAKDAYHRWZCU-UHFFFAOYSA-N
DMYHWS1	IU	2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol
DMYHWS1	CA	CAS 211555-04-3
DMYHWS1	DE	Diffuse large B-cell lymphoma

DMZ703W	ID	DMZ703W
DMZ703W	DN	WilVent
DMZ703W	HS	Investigative
DMZ703W	SN	PG-670
DMZ703W	CP	Pharmagenesis Inc
DMZ703W	DE	Pulmonary disease

DMY5LOB	ID	DMY5LOB
DMY5LOB	DN	WIN 51,708
DMY5LOB	HS	Investigative
DMY5LOB	SN	WIN51,708; WIN-51708
DMY5LOB	DT	Small molecular drug
DMY5LOB	PC	9803245
DMY5LOB	MW	439.6
DMY5LOB	FM	C29H33N3O
DMY5LOB	IC	InChI=1S/C29H33N3O/c1-4-29(33)14-12-22-20-10-9-19-15-24-18(16-27(19,2)21(20)11-13-28(22,29)3)17-32-25-8-6-5-7-23(25)30-26(32)31-24/h1,5-8,17,19-22,33H,9-16H2,2-3H3/t19-,20+,21-,22-,27-,28-,29-/m0/s1
DMY5LOB	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CC[C@@H]4[C@@]3(CC5=CN6C7=CC=CC=C7N=C6N=C5C4)C
DMY5LOB	IK	AIIXYCDTEGICEE-HZVAOYAWSA-N
DMY5LOB	IU	(3S,4S,7S,8R,11S,12R,15S)-8-ethynyl-3,7-dimethyl-18,20,27-triazaheptacyclo[15.11.0.03,15.04,12.07,11.019,27.021,26]octacosa-1(28),17,19,21,23,25-hexaen-8-ol
DMY5LOB	CA	CAS 144177-30-0
DMY5LOB	DE	Discovery agent

DMGOQY2	ID	DMGOQY2
DMGOQY2	DN	WIN 62,577
DMGOQY2	HS	Investigative
DMGOQY2	SN	WIN62,577; WIN-62577
DMGOQY2	DT	Small molecular drug
DMGOQY2	PC	15118529
DMGOQY2	MW	437.6
DMGOQY2	FM	C29H31N3O
DMGOQY2	IC	InChI=1S/C29H31N3O/c1-4-29(33)14-12-22-20-10-9-19-15-24-18(16-27(19,2)21(20)11-13-28(22,29)3)17-32-25-8-6-5-7-23(25)30-26(32)31-24/h1,5-8,15,17,20-22,33H,9-14,16H2,2-3H3/t20-,21+,22+,27+,28+,29+/m1/s1
DMGOQY2	CS	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=NC6=NC7=CC=CC=C7N6C=C5C[C@]34C
DMGOQY2	IK	YBCYJDNOPAFFOW-XOAARHKISA-N
DMGOQY2	IU	(3R,4S,7S,8R,11S,12R)-8-ethynyl-3,7-dimethyl-18,20,27-triazaheptacyclo[15.11.0.03,15.04,12.07,11.019,27.021,26]octacosa-1(28),15,17,19,21,23,25-heptaen-8-ol
DMGOQY2	CA	CAS 138091-43-7
DMGOQY2	DE	Discovery agent

DMTE0YJ	ID	DMTE0YJ
DMTE0YJ	DN	WIN 64338
DMTE0YJ	HS	Investigative
DMTE0YJ	SN	WIN-64338
DMTE0YJ	DT	Small molecular drug
DMTE0YJ	PC	132927
DMTE0YJ	MW	747.5
DMTE0YJ	FM	C45H68ClN4OP
DMTE0YJ	IC	InChI=1S/C45H67N4OP.ClH/c1-4-7-30-51(31-8-5-2,32-9-6-3)35-36-25-28-42(29-26-36)46-44(50)43(34-37-24-27-38-18-16-17-19-39(38)33-37)49-45(47-40-20-12-10-13-21-40)48-41-22-14-11-15-23-41;/h16-19,24-29,33,40-41,43H,4-15,20-23,30-32,34-35H2,1-3H3,(H2-,46,47,48,49,50);1H/t43-;/m0./s1
DMTE0YJ	CS	CCCC[P+](CCCC)(CCCC)CC1=CC=C(C=C1)NC(=O)[C@H](CC2=CC3=CC=CC=C3C=C2)NC(=NC4CCCCC4)NC5CCCCC5.[Cl-]
DMTE0YJ	IK	MJWYKJXHACNJCD-SXWPEPABSA-N
DMTE0YJ	IU	tributyl-[[4-[[(2S)-2-[(N,N'-dicyclohexylcarbamimidoyl)amino]-3-naphthalen-2-ylpropanoyl]amino]phenyl]methyl]phosphanium;chloride
DMTE0YJ	CA	CAS 151039-63-3
DMTE0YJ	DE	Discovery agent

DM6IH4F	ID	DM6IH4F
DM6IH4F	DN	WIN-35065
DM6IH4F	HS	Investigative
DM6IH4F	SN	UNII-AH3LC885W8; WIN 350650-2; AH3LC885W8; 50372-80-0; (1R-(exo,exo))-8-Methyl-3-phenyl-8-azabicyclo(3.2.1)octane-2-carboxylic acid methyl ester; 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 8-methyl-3-phenyl-, methyl ester, (1R-(exo,exo))-; CHEMBL494786; OMBOXYLBBHNWHL-YJNKXOJESA-N; SCHEMBL729026; AC1L56C5; CHEMBL390742; troparil, 1R-(exo,exo)-isomer; BDBM22396; ZINC5996016; BDBM50260903; AKOS027446315; 2beta-Carbomethoxy-3beta-phenyltropane; 2beta-carbomethoxy-3beta-phenyl trop
DM6IH4F	DT	Small molecular drug
DM6IH4F	PC	170832
DM6IH4F	MW	259.339
DM6IH4F	FM	C16H21NO2
DM6IH4F	IC	InChI=1S/C16H21NO2/c1-17-12-8-9-14(17)15(16(18)19-2)13(10-12)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14+,15-/m0/s1
DM6IH4F	CS	CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC
DM6IH4F	IK	OMBOXYLBBHNWHL-YJNKXOJESA-N
DM6IH4F	IU	methyl (1R,2S,3S,5S)-8-methyl-3-phenyl-8-azabicyclo[3.2.1]octane-2-carboxylate
DM6IH4F	CA	CAS 50372-80-0
DM6IH4F	DE	Discovery agent

DMOX1S0	ID	DMOX1S0
DMOX1S0	DN	WIN-35066-2
DMOX1S0	HS	Investigative
DMOX1S0	DT	Small molecular drug
DMOX1S0	PC	44462219
DMOX1S0	MW	259.339
DMOX1S0	FM	C16H21NO2
DMOX1S0	IC	InChI=1S/C16H21NO2/c1-17-12-8-9-14(17)15(16(18)19-2)13(10-12)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13-,14?,15+/m1/s1
DMOX1S0	CS	CN1[C@@H]2CCC1[C@H]([C@H](C2)C3=CC=CC=C3)C(=O)OC
DMOX1S0	IK	OMBOXYLBBHNWHL-VOFREWHGSA-N
DMOX1S0	IU	methyl (2S,3S,5R)-8-methyl-3-phenyl-8-azabicyclo[3.2.1]octane-2-carboxylate

DMNM50K	ID	DMNM50K
DMNM50K	DN	WIN-63395
DMNM50K	HS	Investigative
DMNM50K	SN	WIN-63395; CHEMBL98422; SCHEMBL7307414; LZCQHGLOTYILCS-UHFFFAOYSA-N; BDBM50029703; 2-(1-phenyltetrazol-5-yl)thiomethyl-4-isopropyl-6-methoxysaccharin
DMNM50K	DT	Small molecular drug
DMNM50K	PC	9889727
DMNM50K	MW	445.5
DMNM50K	FM	C19H19N5O4S2
DMNM50K	IC	InChI=1S/C19H19N5O4S2/c1-12(2)15-9-14(28-3)10-16-17(15)18(25)23(30(16,26)27)11-29-19-20-21-22-24(19)13-7-5-4-6-8-13/h4-10,12H,11H2,1-3H3
DMNM50K	CS	CC(C)C1=C2C(=CC(=C1)OC)S(=O)(=O)N(C2=O)CSC3=NN=NN3C4=CC=CC=C4
DMNM50K	IK	LZCQHGLOTYILCS-UHFFFAOYSA-N
DMNM50K	IU	6-methoxy-1,1-dioxo-2-[(1-phenyltetrazol-5-yl)sulfanylmethyl]-4-propan-2-yl-1,2-benzothiazol-3-one
DMNM50K	DE	Discovery agent

DMQ1B2Y	ID	DMQ1B2Y
DMQ1B2Y	DN	WIN-64745
DMQ1B2Y	HS	Investigative
DMQ1B2Y	SN	150881-28-0; Q-20547C
DMQ1B2Y	PC	101651924
DMQ1B2Y	MW	630.7
DMQ1B2Y	FM	C37H38N6O4
DMQ1B2Y	IC	InChI=1S/C37H38N6O4/c1-20(2)16-26-32(46)42-28(30(44)38-26)18-36(22-12-6-8-14-24(22)40-34(36)42)37-19-29-31(45)39-27(17-21-10-4-3-5-11-21)33(47)43(29)35(37)41-25-15-9-7-13-23(25)37/h3-15,20,26-29,34-35,40-41H,16-19H2,1-2H3,(H,38,44)(H,39,45)/t26-,27-,28-,29-,34+,35+,36?,37?/m0/s1
DMQ1B2Y	CS	CC(C)C[C@H]1C(=O)N2[C@@H](CC3([C@@H]2NC4=CC=CC=C43)C56C[C@H]7C(=O)N[C@H](C(=O)N7[C@H]5NC8=CC=CC=C68)CC9=CC=CC=C9)C(=O)N1
DMQ1B2Y	IK	QQLUWDJRGUSAKT-PEFRYSBJSA-N
DMQ1B2Y	IU	(1R,4S,7S)-4-benzyl-9-[(1R,4S,7S)-4-(2-methylpropyl)-3,6-dioxo-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-trien-9-yl]-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-triene-3,6-dione
DMQ1B2Y	DE	Discovery agent

DMUM5LV	ID	DMUM5LV
DMUM5LV	DN	WIN-66306
DMUM5LV	HS	Investigative
DMUM5LV	SN	151928-32-4
DMUM5LV	DT	Small molecular drug
DMUM5LV	PC	192562
DMUM5LV	MW	800.9
DMUM5LV	FM	C41H52N8O9
DMUM5LV	IC	InChI=1S/C41H52N8O9/c1-23(2)11-12-25-16-26(13-14-33(25)51)38(55)31(22-50)47-35(53)20-45-40(57)37(24(3)4)48-36(54)21-44-39(56)32-10-7-15-49(32)41(58)30(46-34(52)18-42)17-27-19-43-29-9-6-5-8-28(27)29/h5-9,11,13-16,19,22,24,30-32,37-38,43,51,55H,10,12,17-18,20-21,42H2,1-4H3,(H,44,56)(H,45,57)(H,46,52)(H,47,53)(H,48,54)/t30-,31+,32-,37-,38+/m0/s1
DMUM5LV	CS	CC(C)[C@@H](C(=O)NCC(=O)N[C@H](C=O)[C@@H](C1=CC(=C(C=C1)O)CC=C(C)C)O)NC(=O)CNC(=O)[C@@H]2CC=CN2C(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CN
DMUM5LV	IK	MZGWPVIVGCXMPX-QFXPHGGCSA-N
DMUM5LV	IU	(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]-N-[2-[[(2S)-1-[[2-[[(1R,2S)-1-hydroxy-1-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-3-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]-2,3-dihydropyrrole-2-carboxamide
DMUM5LV	CA	CAS 151928-32-4
DMUM5LV	DE	Discovery agent

DMJHG1O	ID	DMJHG1O
DMJHG1O	DN	WIN-68577
DMJHG1O	HS	Investigative
DMJHG1O	SN	151928-33-5
DMJHG1O	PC	9961991
DMJHG1O	MW	732.8
DMJHG1O	FM	C36H44N8O9
DMJHG1O	IC	InChI=1S/C36H44N8O9/c1-19(2)30-34(51)39-18-29(48)43-31(32(49)20-9-11-22(45)12-10-20)35(52)40-16-27(46)41-25(14-21-15-37-24-7-4-3-6-23(21)24)36(53)44-13-5-8-26(44)33(50)38-17-28(47)42-30/h3-4,6-7,9-12,15,19,25-26,30-32,37,45,49H,5,8,13-14,16-18H2,1-2H3,(H,38,50)(H,39,51)(H,40,52)(H,41,46)(H,42,47)(H,43,48)/t25-,26-,30-,31-,32?/m0/s1
DMJHG1O	CS	CC(C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)NCC(=O)N1)CC3=CNC4=CC=CC=C43)C(C5=CC=C(C=C5)O)O
DMJHG1O	IK	SYBLQDYULNRQHI-ZTRORRTFSA-N
DMJHG1O	IU	(3S,9S,15S,21S)-9-[hydroxy-(4-hydroxyphenyl)methyl]-3-(1H-indol-3-ylmethyl)-15-propan-2-yl-1,4,7,10,13,16,19-heptazabicyclo[19.3.0]tetracosane-2,5,8,11,14,17,20-heptone
DMJHG1O	CA	CAS 151928-33-5
DMJHG1O	DE	Discovery agent

DMX0ZBC	ID	DMX0ZBC
DMX0ZBC	DN	WK-X-34
DMX0ZBC	HS	Investigative
DMX0ZBC	DE	Discovery agent

DM8SEHO	ID	DM8SEHO
DM8SEHO	DN	WL-276
DM8SEHO	HS	Investigative
DM8SEHO	CP	University of Minnesota
DM8SEHO	DE	Solid tumour/cancer

DMOZATX	ID	DMOZATX
DMOZATX	DN	WO2012007375C1
DMOZATX	HS	Investigative
DMOZATX	SN	GTPL8084; BDBM50040728
DMOZATX	DT	Small molecular drug
DMOZATX	PC	58056241
DMOZATX	MW	400.9
DMOZATX	FM	C19H21ClN6O2
DMOZATX	IC	InChI=1S/C19H21ClN6O2/c20-13-1-2-17(25-5-3-12(8-21)4-6-25)16(7-13)24-19(28)15-10-23-26-11-14(27)9-22-18(15)26/h1-2,7,9-12,27H,3-6,8,21H2,(H,24,28)
DMOZATX	CS	C1CN(CCC1CN)C2=C(C=C(C=C2)Cl)NC(=O)C3=C4N=CC(=CN4N=C3)O
DMOZATX	IK	BNVZRFQNZWYPQH-UHFFFAOYSA-N
DMOZATX	IU	N-[2-[4-(aminomethyl)piperidin-1-yl]-5-chlorophenyl]-6-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxamide
DMOZATX	DE	Discovery agent

DMPI2MA	ID	DMPI2MA
DMPI2MA	DN	WO2012007375C7 
DMPI2MA	HS	Investigative
DMPI2MA	SN	GTPL8085; BDBM50040727
DMPI2MA	DT	Small molecular drug
DMPI2MA	PC	58056092
DMPI2MA	MW	408.5
DMPI2MA	FM	C20H20N6O2S
DMPI2MA	IC	InChI=1S/C20H20N6O2S/c1-26(7-5-21)20-23-10-17-18(25-20)13(11-29-17)19(27)24-15-8-12-4-3-6-22-14(12)9-16(15)28-2/h3-4,6,8-11H,5,7,21H2,1-2H3,(H,24,27)
DMPI2MA	CS	CN(CCN)C1=NC=C2C(=N1)C(=CS2)C(=O)NC3=C(C=C4C(=C3)C=CC=N4)OC
DMPI2MA	IK	BUJSZRICYLPWCM-UHFFFAOYSA-N
DMPI2MA	IU	2-[2-aminoethyl(methyl)amino]-N-(7-methoxyquinolin-6-yl)thieno[3,2-d]pyrimidine-7-carboxamide
DMPI2MA	DE	Discovery agent

DM21WOP	ID	DM21WOP
DM21WOP	DN	WO2013026806C72 
DM21WOP	HS	Investigative
DM21WOP	SN	EHT 5372; compound 8c [PMID 25264830]; GTPL8166; BDBM50434338
DM21WOP	DT	Small molecular drug
DM21WOP	PC	71529770
DM21WOP	MW	369.8
DM21WOP	FM	C17H12ClN5OS
DM21WOP	IC	InChI=1S/C17H12ClN5OS/c1-24-15(19)17-23-12-7-6-11-13(14(12)25-17)16(21-8-20-11)22-10-4-2-9(18)3-5-10/h2-8,19H,1H3,(H,20,21,22)
DM21WOP	CS	COC(=N)C1=NC2=C(S1)C3=C(C=C2)N=CN=C3NC4=CC=C(C=C4)Cl
DM21WOP	IK	BGXZIBSLBRKDTP-UHFFFAOYSA-N
DM21WOP	IU	methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate
DM21WOP	DE	Discovery agent

DMDPN4E	ID	DMDPN4E
DMDPN4E	DN	WO2013110309CA127
DMDPN4E	HS	Investigative
DMDPN4E	SN	A-127; GTPL8169; BDBM50011235
DMDPN4E	DT	Small molecular drug
DMDPN4E	PC	90655897
DMDPN4E	MW	408.5
DMDPN4E	FM	C20H24N8O2
DMDPN4E	IC	InChI=1S/C20H24N8O2/c1-4-27-10-9-17(25-27)22-19-21-13-16-18(23-19)24-26-28(16)15-7-5-14(6-8-15)20(2,3)30-12-11-29/h5-10,13,29H,4,11-12H2,1-3H3,(H,21,22,23,25)
DMDPN4E	CS	CCN1C=CC(=N1)NC2=NC=C3C(=N2)N=NN3C4=CC=C(C=C4)C(C)(C)OCCO
DMDPN4E	IK	XNAMZBCMLZQBIC-UHFFFAOYSA-N
DMDPN4E	IU	2-[2-[4-[5-[(1-ethylpyrazol-3-yl)amino]triazolo[4,5-d]pyrimidin-1-yl]phenyl]propan-2-yloxy]ethanol
DMDPN4E	DE	Discovery agent

DMGCF51	ID	DMGCF51
DMGCF51	DN	Wogonin
DMGCF51	HS	Investigative
DMGCF51	SN	Wogonin; 632-85-9; 5,7-Dihydroxy-8-methoxyflavone; Vogonin; Norwogonin 8-methyl ether; UNII-POK93PO28W; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; BRN 0287152; POK93PO28W; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one; CHEMBL16171; FLAVONE, 5,7-DIHYDROXY-8-METHOXY-; CHEBI:10043; XLTFNNCXVBYBSX-UHFFFAOYSA-N; 5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one; 5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-one; ST077088; Q-100730; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one
DMGCF51	DT	Small molecular drug
DMGCF51	PC	5281703
DMGCF51	MW	284.26
DMGCF51	FM	C16H12O5
DMGCF51	IC	InChI=1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3
DMGCF51	CS	COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)O
DMGCF51	IK	XLTFNNCXVBYBSX-UHFFFAOYSA-N
DMGCF51	IU	5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one
DMGCF51	CA	CAS 632-85-9
DMGCF51	CB	CHEBI:10043
DMGCF51	DE	Discovery agent

DMUCGK8	ID	DMUCGK8
DMUCGK8	DN	WR-080539
DMUCGK8	HS	Investigative
DMUCGK8	SN	4'-Acetamidochalcone; CCRIS 2216; NSC 40307; WR-080539; CHEMBL187926; 19337-19-0; N-{4-[(2E)-3-phenylprop-2-enoyl]phenyl}acetamide; AC1NS7QX; N-(4-cinnamoylphenyl)acetamide; MolPort-018-573-532; NSC40307; ZINC4612934; STL426808; BBL035434; NSC-40307; BDBM50154614; AKOS003620252; N-[4-(trans-Cinnamoyl)phenyl]acetamide; LS-188491; N-[4-(3-Phenyl-acryloyl)-phenyl]-acetamide
DMUCGK8	DT	Small molecular drug
DMUCGK8	PC	5355577
DMUCGK8	MW	265.31
DMUCGK8	FM	C17H15NO2
DMUCGK8	IC	InChI=1S/C17H15NO2/c1-13(19)18-16-10-8-15(9-11-16)17(20)12-7-14-5-3-2-4-6-14/h2-12H,1H3,(H,18,19)/b12-7+
DMUCGK8	CS	CC(=O)NC1=CC=C(C=C1)C(=O)/C=C/C2=CC=CC=C2
DMUCGK8	IK	CUYJTAUCYGHYLW-KPKJPENVSA-N
DMUCGK8	IU	N-[4-[(E)-3-phenylprop-2-enoyl]phenyl]acetamide
DMUCGK8	CA	CAS 19337-19-0
DMUCGK8	DE	Discovery agent

DMT9WPJ	ID	DMT9WPJ
DMT9WPJ	DN	WR-089120
DMT9WPJ	HS	Investigative
DMT9WPJ	SN	1-(3-nitrophenyl)-3-phenylprop-2-en-1-one; 16619-21-9; 3'-Nitrochalcone; CHEMBL187682; WR-089120; NSC186962; AC1NWTRO; (2E)-1-(3-nitrophenyl)-3-phenylprop-2-en-1-one; 2-Propen-1-one, 1-(3-nitrophenyl)-3-phenyl-; SCHEMBL9779522; DTXSID60420806; MolPort-000-653-504; ZINC4159317; BDBM50154604; SBB055406; 5324AD; AKOS002346621; NSC-186962; ACM16619219; KB-147050; (E)-1-(3-Nitro-phenyl)-3-phenyl-propenone
DMT9WPJ	DT	Small molecular drug
DMT9WPJ	PC	5712110
DMT9WPJ	MW	253.25
DMT9WPJ	FM	C15H11NO3
DMT9WPJ	IC	InChI=1S/C15H11NO3/c17-15(10-9-12-5-2-1-3-6-12)13-7-4-8-14(11-13)16(18)19/h1-11H/b10-9+
DMT9WPJ	CS	C1=CC=C(C=C1)/C=C/C(=O)C2=CC(=CC=C2)[N+](=O)[O-]
DMT9WPJ	IK	MJXRQBATDWPDNF-MDZDMXLPSA-N
DMT9WPJ	IU	(E)-1-(3-nitrophenyl)-3-phenylprop-2-en-1-one
DMT9WPJ	CA	CAS 16619-21-9
DMT9WPJ	DE	Discovery agent

DM3TI6L	ID	DM3TI6L
DM3TI6L	DN	WR-190706
DM3TI6L	HS	Investigative
DM3TI6L	SN	WR-190706; CHEMBL506696; AC1NXLQG; 1-(4-methoxyphenyl)-3-(pyridin-2-yl)prop-2-en-1-one; ZINC6544999; BDBM50278866; AKOS022265236; 1-(4-Methoxyphenyl)-3-(2-pyridyl)-2-propene-1-one; (E)-1-(4-methoxyphenyl)-3-pyridin-2-ylprop-2-en-1-one
DM3TI6L	DT	Small molecular drug
DM3TI6L	PC	5784790
DM3TI6L	MW	239.27
DM3TI6L	FM	C15H13NO2
DM3TI6L	IC	InChI=1S/C15H13NO2/c1-18-14-8-5-12(6-9-14)15(17)10-7-13-4-2-3-11-16-13/h2-11H,1H3/b10-7+
DM3TI6L	CS	COC1=CC=C(C=C1)C(=O)/C=C/C2=CC=CC=N2
DM3TI6L	IK	PUUXTLUBRGYYIL-JXMROGBWSA-N
DM3TI6L	IU	(E)-1-(4-methoxyphenyl)-3-pyridin-2-ylprop-2-en-1-one
DM3TI6L	DE	Discovery agent

DM9M1UO	ID	DM9M1UO
DM9M1UO	DN	WR-203581
DM9M1UO	HS	Investigative
DM9M1UO	SN	WR-203581; CHEMBL471252; BDBM50278195; ZINC40895928
DM9M1UO	DT	Small molecular drug
DM9M1UO	PC	44591969
DM9M1UO	MW	254.24
DM9M1UO	FM	C14H10N2O3
DM9M1UO	IC	InChI=1S/C14H10N2O3/c17-14(8-7-12-5-1-2-9-15-12)11-4-3-6-13(10-11)16(18)19/h1-10H/b8-7+
DM9M1UO	CS	C1=CC=NC(=C1)/C=C/C(=O)C2=CC(=CC=C2)[N+](=O)[O-]
DM9M1UO	IK	BXQJHMCMOWDXJO-BQYQJAHWSA-N
DM9M1UO	IU	(E)-1-(3-nitrophenyl)-3-pyridin-2-ylprop-2-en-1-one
DM9M1UO	DE	Discovery agent

DM5W9GR	ID	DM5W9GR
DM5W9GR	DN	WR-289009
DM5W9GR	HS	Investigative
DM5W9GR	SN	WR-289009; CHEMBL446640; 1-(4-methoxyphenyl)-3-(pyridin-4-yl)prop-2-en-1-one; 1-(4-methoxyphenyl)-3-(4-pyridyl)prop-2-en-1-one; AC1NWTYG; MolPort-039-015-455; ZX-AT028226; ZINC4280782; BDBM50278069; AKOS005199414; KB-147400; 1-(4-Methoxyphenyl)-3-(4-pyridyl)-2-propene-1-one; (E)-1-(4-methoxyphenyl)-3-pyridin-4-ylprop-2-en-1-one; (E)-1-(4-methoxyphenyl)-3-(4-pyridyl)prop-2-en-1-one; 2-Propen-1-one, 1-(4-methoxyphenyl)-3-(4-pyridinyl)-, (2E)-
DM5W9GR	DT	Small molecular drug
DM5W9GR	PC	5712235
DM5W9GR	MW	239.27
DM5W9GR	FM	C15H13NO2
DM5W9GR	IC	InChI=1S/C15H13NO2/c1-18-14-5-3-13(4-6-14)15(17)7-2-12-8-10-16-11-9-12/h2-11H,1H3/b7-2+
DM5W9GR	CS	COC1=CC=C(C=C1)C(=O)/C=C/C2=CC=NC=C2
DM5W9GR	IK	OHXOJKQHTRABPQ-FARCUNLSSA-N
DM5W9GR	IU	(E)-1-(4-methoxyphenyl)-3-pyridin-4-ylprop-2-en-1-one
DM5W9GR	CA	CAS 72512-24-4
DM5W9GR	DE	Discovery agent

DMS2QUL	ID	DMS2QUL
DMS2QUL	DN	WR-289010
DMS2QUL	HS	Investigative
DMS2QUL	SN	WR-289010; CHEMBL470424; BDBM50278194
DMS2QUL	DT	Small molecular drug
DMS2QUL	PC	44591968
DMS2QUL	MW	299.32
DMS2QUL	FM	C17H17NO4
DMS2QUL	IC	InChI=1S/C17H17NO4/c1-20-15-7-5-13(16(21-2)17(15)22-3)14(19)6-4-12-8-10-18-11-9-12/h4-11H,1-3H3/b6-4+
DMS2QUL	CS	COC1=C(C(=C(C=C1)C(=O)/C=C/C2=CC=NC=C2)OC)OC
DMS2QUL	IK	MPCORTUZMOUOQN-GQCTYLIASA-N
DMS2QUL	IU	(E)-3-pyridin-4-yl-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one
DMS2QUL	DE	Discovery agent

DMG2LVM	ID	DMG2LVM
DMG2LVM	DN	WR-289012
DMG2LVM	HS	Investigative
DMG2LVM	SN	WR-289012; CHEMBL385631; 3-(naphthalen-2-yl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one
DMG2LVM	DT	Small molecular drug
DMG2LVM	PC	44419435
DMG2LVM	MW	348.4
DMG2LVM	FM	C22H20O4
DMG2LVM	IC	InChI=1S/C22H20O4/c1-24-20-13-11-18(21(25-2)22(20)26-3)19(23)12-9-15-8-10-16-6-4-5-7-17(16)14-15/h4-14H,1-3H3/b12-9+
DMG2LVM	CS	COC1=C(C(=C(C=C1)C(=O)/C=C/C2=CC3=CC=CC=C3C=C2)OC)OC
DMG2LVM	IK	RUDVXNBRAYSKEY-FMIVXFBMSA-N
DMG2LVM	IU	(E)-3-naphthalen-2-yl-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one
DMG2LVM	CA	CAS 914383-91-8
DMG2LVM	DE	Discovery agent

DMT08ZH	ID	DMT08ZH
DMT08ZH	DN	WR-289016
DMT08ZH	HS	Investigative
DMT08ZH	SN	WR-289016; CHEMBL139856; AC1NX4XU; MolPort-002-144-127; ZINC3998043; BDBM50107296; AB00080136-01; 1-(2,4-Dimethoxy-phenyl)-3-naphthalen-1-yl-propenone; 1-(2,4-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one; (E)-1-(2,4-dimethoxyphenyl)-3-naphthalen-1-ylprop-2-en-1-one
DMT08ZH	DT	Small molecular drug
DMT08ZH	PC	5720587
DMT08ZH	MW	318.4
DMT08ZH	FM	C21H18O3
DMT08ZH	IC	InChI=1S/C21H18O3/c1-23-17-11-12-19(21(14-17)24-2)20(22)13-10-16-8-5-7-15-6-3-4-9-18(15)16/h3-14H,1-2H3/b13-10+
DMT08ZH	CS	COC1=CC(=C(C=C1)C(=O)/C=C/C2=CC=CC3=CC=CC=C32)OC
DMT08ZH	IK	MLJPSPKBQRTVGK-JLHYYAGUSA-N
DMT08ZH	IU	(E)-1-(2,4-dimethoxyphenyl)-3-naphthalen-1-ylprop-2-en-1-one
DMT08ZH	DE	Discovery agent

DM9V0KP	ID	DM9V0KP
DM9V0KP	DN	WR85915
DM9V0KP	HS	Investigative
DM9V0KP	SN	azasetron hydrochloride; 123040-16-4; Azasetron HCl; Serotone; Azasetron (hydrochloride); Y-25130 hydrochloride; 141922-90-9; C17H20ClN3O3.HCl; Azasetron hydrochloride [JAN]; 6-chloro-4-methyl-3-oxo-N-(quinuclidin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide hydrochloride; Azasetron hydrochloride (JAN); N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide hydrochloride; 2H-1,4-Benzoxazine-8-carboxamide, 3,4-dihydro-N-1-azabicyclo(2.2.2)oct-3-yl-6-chloro-
DM9V0KP	DT	Small molecular drug
DM9V0KP	PC	115000
DM9V0KP	MW	386.3
DM9V0KP	FM	C17H21Cl2N3O3
DM9V0KP	IC	InChI=1S/C17H20ClN3O3.ClH/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21;/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23);1H
DM9V0KP	CS	CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4.Cl
DM9V0KP	IK	DBMKBKPJYAHLQP-UHFFFAOYSA-N
DM9V0KP	IU	N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide;hydrochloride
DM9V0KP	CA	CAS 123040-16-4
DM9V0KP	CB	CHEBI:31246
DM9V0KP	DE	Discovery agent

DM1U29V	ID	DM1U29V
DM1U29V	DN	WRC-0571
DM1U29V	HS	Investigative
DM1U29V	SN	WRC-0571; GTPL8419
DM1U29V	DT	Small molecular drug
DM1U29V	PC	91827359
DM1U29V	MW	330.4
DM1U29V	FM	C17H26N6O
DM1U29V	IC	InChI=1S/C17H26N6O/c1-9(2)22(3)17-21-14-15(18-8-19-16(14)23(17)4)20-12-6-11-5-10(12)7-13(11)24/h8-13,24H,5-7H2,1-4H3,(H,18,19,20)/t10?,11?,12-,13?/m1/s1
DM1U29V	CS	CC(C)N(C)C1=NC2=C(N=CN=C2N1C)N[C@@H]3CC4CC3CC4O
DM1U29V	IK	FTVZUYADPTUEKI-AYNROABZSA-N
DM1U29V	IU	(5R)-5-[[9-methyl-8-[methyl(propan-2-yl)amino]purin-6-yl]amino]bicyclo[2.2.1]heptan-2-ol
DM1U29V	DE	Discovery agent

DMP761U	ID	DMP761U
DMP761U	DN	WRR-112
DMP761U	HS	Investigative
DMP761U	SN	WRR-112; N-[3-CARBOXY-2-HYDROXY-PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE; AC1NRD12; DB03691; (3S)-3-hydroxy-4-({(2S)-1-[(3-methylbutyl)amino]-1-oxo-4-phenylbutan-2-yl}amino)-4-oxobutanoic acid; (3S)-3-hydroxy-3-{[(1S)-1-[(3-methylbutyl)carbamoyl]-3-phenylpropyl]carbamoyl}propanoic acid; (3S)-3-hydroxy-4-[[(2S)-1-(3-methylbutylamino)-1-oxo-4-phenylbutan-2-yl]amino]-4-oxobutanoic acid
DMP761U	DT	Small molecular drug
DMP761U	PC	5289294
DMP761U	MW	364.4
DMP761U	FM	C19H28N2O5
DMP761U	IC	InChI=1S/C19H28N2O5/c1-13(2)10-11-20-18(25)15(9-8-14-6-4-3-5-7-14)21-19(26)16(22)12-17(23)24/h3-7,13,15-16,22H,8-12H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t15-,16-/m0/s1
DMP761U	CS	CC(C)CCNC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)O
DMP761U	IK	KVZMXOVSHIMGNA-HOTGVXAUSA-N
DMP761U	IU	(3S)-3-hydroxy-4-[[(2S)-1-(3-methylbutylamino)-1-oxo-4-phenylbutan-2-yl]amino]-4-oxobutanoic acid
DMP761U	DE	Discovery agent

DMRVAH1	ID	DMRVAH1
DMRVAH1	DN	WRR-204
DMRVAH1	HS	Investigative
DMRVAH1	SN	AC1NRDI1; (3S)-5-phenyl-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentane-1-sulfonic acid
DMRVAH1	DT	Small molecular drug
DMRVAH1	PC	17754216
DMRVAH1	MW	600.7
DMRVAH1	FM	C34H36N2O6S
DMRVAH1	IC	InChI=1S/C34H36N2O6S/c37-33(32(25-28-15-7-2-8-16-28)36-34(38)41-26-29-17-9-3-10-18-29)35-30(22-21-27-13-5-1-6-14-27)23-24-43(39,40)42-31-19-11-4-12-20-31/h1-20,30,32H,21-26H2,(H,35,37)(H,36,38)/t30-,32-/m0/s1
DMRVAH1	CS	C1=CC=C(C=C1)CC[C@@H](CCS(=O)(=O)OC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CC=CC=C4
DMRVAH1	IK	SUGQHICXCRBQOI-CDZUIXILSA-N
DMRVAH1	IU	phenyl (3S)-5-phenyl-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentane-1-sulfonate
DMRVAH1	DE	Discovery agent

DMPYGMO	ID	DMPYGMO
DMPYGMO	DN	WRR605
DMPYGMO	HS	Investigative
DMPYGMO	DE	Amoebiasis

DM8ZA6K	ID	DM8ZA6K
DM8ZA6K	DN	WRR-99
DM8ZA6K	HS	Investigative
DM8ZA6K	SN	WRR-99; N-[3-CARBOXY-2-HYDROXY-PROPIONYL]-D-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE; AC1NRCYX; DB03573; (3S)-3-hydroxy-4-[[(2R)-1-(3-methylbutylamino)-1-oxo-4-phenylbutan-2-yl]amino]-4-oxobutanoic acid; (3S)-3-hydroxy-4-({(2R)-1-[(3-methylbutyl)amino]-1-oxo-4-phenylbutan-2-yl}amino)-4-oxobutanoic acid; (3S)-3-hydroxy-3-{[(1R)-1-[(3-methylbutyl)carbamoyl]-3-phenylpropyl]carbamoyl}propanoic acid
DM8ZA6K	DT	Small molecular drug
DM8ZA6K	PC	5289258
DM8ZA6K	MW	364.4
DM8ZA6K	FM	C19H28N2O5
DM8ZA6K	IC	InChI=1S/C19H28N2O5/c1-13(2)10-11-20-18(25)15(9-8-14-6-4-3-5-7-14)21-19(26)16(22)12-17(23)24/h3-7,13,15-16,22H,8-12H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t15-,16+/m1/s1
DM8ZA6K	CS	CC(C)CCNC(=O)[C@@H](CCC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)O
DM8ZA6K	IK	KVZMXOVSHIMGNA-CVEARBPZSA-N
DM8ZA6K	IU	(3S)-3-hydroxy-4-[[(2R)-1-(3-methylbutylamino)-1-oxo-4-phenylbutan-2-yl]amino]-4-oxobutanoic acid
DM8ZA6K	DE	Discovery agent

DMYNIG5	ID	DMYNIG5
DMYNIG5	DN	WS-070117
DMYNIG5	HS	Investigative
DMYNIG5	CP	Institute of Materia Medica Chinese Academy of Medical Science
DMYNIG5	PC	45377904
DMYNIG5	MW	485.4
DMYNIG5	FM	C22H23N5O8
DMYNIG5	IC	InChI=1S/C22H23N5O8/c1-11(28)32-8-16-18(33-12(2)29)19(34-13(3)30)22(35-16)27-10-25-17-20(23-9-24-21(17)27)26-14-5-4-6-15(31)7-14/h4-7,9-10,16,18-19,22,31H,8H2,1-3H3,(H,23,24,26)/t16-,18-,19-,22-/m1/s1
DMYNIG5	CS	CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NC4=CC(=CC=C4)O)OC(=O)C)OC(=O)C
DMYNIG5	IK	IUDLPZTURGVXEA-WGQQHEPDSA-N
DMYNIG5	IU	[(2R,3R,4R,5R)-3,4-diacetyloxy-5-[6-(3-hydroxyanilino)purin-9-yl]oxolan-2-yl]methyl acetate
DMYNIG5	DE	Hyperlipidaemia

DM48MHL	ID	DM48MHL
DM48MHL	DN	WS-12
DM48MHL	HS	Investigative
DM48MHL	SN	WS 12
DM48MHL	DT	Small molecular drug
DM48MHL	PC	11266244
DM48MHL	MW	289.4
DM48MHL	FM	C18H27NO2
DM48MHL	IC	InChI=1S/C18H27NO2/c1-12(2)16-10-5-13(3)11-17(16)18(20)19-14-6-8-15(21-4)9-7-14/h6-9,12-13,16-17H,5,10-11H2,1-4H3,(H,19,20)/t13-,16+,17-/m1/s1
DM48MHL	CS	C[C@@H]1CC[C@H]([C@@H](C1)C(=O)NC2=CC=C(C=C2)OC)C(C)C
DM48MHL	IK	HNSGVPAAXJJOPQ-XOKHGSTOSA-N
DM48MHL	IU	(1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-propan-2-ylcyclohexane-1-carboxamide
DM48MHL	CA	CAS 68489-09-8
DM48MHL	DE	Discovery agent

DMT5SXR	ID	DMT5SXR
DMT5SXR	DN	WS-23
DMT5SXR	HS	Investigative
DMT5SXR	SN	WS 23
DMT5SXR	DT	Small molecular drug
DMT5SXR	PC	65300
DMT5SXR	MW	171.28
DMT5SXR	FM	C10H21NO
DMT5SXR	IC	InChI=1S/C10H21NO/c1-7(2)10(5,8(3)4)9(12)11-6/h7-8H,1-6H3,(H,11,12)
DMT5SXR	CS	CC(C)C(C)(C(C)C)C(=O)NC
DMT5SXR	IK	RWAXQWRDVUOOGG-UHFFFAOYSA-N
DMT5SXR	IU	N,2,3-trimethyl-2-propan-2-ylbutanamide
DMT5SXR	CA	CAS 51115-67-4
DMT5SXR	DE	Discovery agent

DM1R8MW	ID	DM1R8MW
DM1R8MW	DN	WS-3
DM1R8MW	HS	Investigative
DM1R8MW	SN	WS 3
DM1R8MW	DT	Small molecular drug
DM1R8MW	PC	62907
DM1R8MW	MW	211.34
DM1R8MW	FM	C13H25NO
DM1R8MW	IC	InChI=1S/C13H25NO/c1-5-14-13(15)12-8-10(4)6-7-11(12)9(2)3/h9-12H,5-8H2,1-4H3,(H,14,15)
DM1R8MW	CS	CCNC(=O)C1CC(CCC1C(C)C)C
DM1R8MW	IK	VUNOFAIHSALQQH-UHFFFAOYSA-N
DM1R8MW	IU	N-ethyl-5-methyl-2-propan-2-ylcyclohexane-1-carboxamide
DM1R8MW	CA	CAS 39711-79-0
DM1R8MW	DE	Discovery agent

DMX1JR0	ID	DMX1JR0
DMX1JR0	DN	WS-5
DMX1JR0	HS	Investigative
DMX1JR0	SN	GTPL6368; SCHEMBL15257792; ethyl N-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexanecarbonyl]carbamate
DMX1JR0	DT	Small molecular drug
DMX1JR0	PC	56929299
DMX1JR0	MW	255.35
DMX1JR0	FM	C14H25NO3
DMX1JR0	IC	InChI=1S/C14H25NO3/c1-5-18-14(17)15-13(16)12-8-10(4)6-7-11(12)9(2)3/h9-12H,5-8H2,1-4H3,(H,15,16,17)/t10-,11+,12-/m1/s1
DMX1JR0	CS	CCOC(=O)NC(=O)[C@@H]1C[C@@H](CC[C@H]1C(C)C)C
DMX1JR0	IK	AOTWCRSILVRYCS-GRYCIOLGSA-N
DMX1JR0	IU	ethyl N-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexanecarbonyl]carbamate
DMX1JR0	DE	Discovery agent

DM6A08D	ID	DM6A08D
DM6A08D	DN	WS-50030
DM6A08D	HS	Investigative
DM6A08D	SN	Dual dopamine D2 partial agonist/serotonin reuptake inhibitor (schizophrenia); Dual dopamine D2 partial agonist/serotonin reuptake inhibitor (schizophrenia), Pfizer/Solvay
DM6A08D	CP	Wyeth
DM6A08D	DT	Small molecular drug
DM6A08D	PC	44540845
DM6A08D	MW	375.5
DM6A08D	FM	C23H25N3O2
DM6A08D	IC	InChI=1S/C23H25N3O2/c27-23-24-20-8-3-9-21(22(20)28-23)26-15-13-25(14-16-26)12-4-6-18-11-10-17-5-1-2-7-19(17)18/h1-3,5,7-9,11H,4,6,10,12-16H2,(H,24,27)
DM6A08D	CS	C1CN(CCN1CCCC2=CCC3=CC=CC=C32)C4=CC=CC5=C4OC(=O)N5
DM6A08D	IK	NBEGULJEDOLHOO-UHFFFAOYSA-N
DM6A08D	IU	7-[4-[3-(3H-inden-1-yl)propyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
DM6A08D	DE	Schizophrenia

DMF9SOV	ID	DMF9SOV
DMF9SOV	DN	WTLNSAGYLL-CONH2
DMF9SOV	HS	Investigative
DMF9SOV	SN	AR-M 1896; 367518-31-8; CHEMBL578710; WTLNSAGYLL-CONH2; Galanin-2-11-NH..2..; Gal(2-11)amide; galanin(2-11); AC1O44IJ; Galanin(2-11)porcine,rat; BDBM50307252; AKOS024457247; GALANIN (2-11) (PORCINE, RAT); Galanin (2-11) porcine, rat, &gt;=97% (HPLC), lyophilized powder
DMF9SOV	PC	6324638
DMF9SOV	MW	1136.3
DMF9SOV	FM	C54H81N13O14
DMF9SOV	IC	InChI=1S/C54H81N13O14/c1-26(2)17-37(46(57)73)62-49(76)38(18-27(3)4)63-51(78)40(20-31-13-15-33(70)16-14-31)61-44(72)24-59-47(74)29(7)60-53(80)42(25-68)66-52(79)41(22-43(56)71)64-50(77)39(19-28(5)6)65-54(81)45(30(8)69)67-48(75)35(55)21-32-23-58-36-12-10-9-11-34(32)36/h9-16,23,26-30,35,37-42,45,58,68-70H,17-22,24-25,55H2,1-8H3,(H2,56,71)(H2,57,73)(H,59,74)(H,60,80)(H,61,72)(H,62,76)(H,63,78)(H,64,77)(H,65,81)(H,66,79)(H,67,75)/t29-,30+,35-,37-,38-,39-,40-,41-,42-,45-/m0/s1
DMF9SOV	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)O
DMF9SOV	IK	SUJPPMXJCZETOA-ZKEPBWIVSA-N
DMF9SOV	IU	(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMF9SOV	DE	Discovery agent

DMB3567	ID	DMB3567
DMB3567	DN	WTLNSAGYLLGPHAVGNHPSFSDKNGLTS-CONH2
DMB3567	HS	Investigative
DMB3567	PC	91934076
DMB3567	MW	3100.4
DMB3567	FM	C137H207N41O42
DMB3567	IC	InChI=1S/C137H207N41O42/c1-64(2)38-84(162-120(203)86(40-66(5)6)163-122(205)88(43-74-31-33-78(185)34-32-74)158-104(189)54-149-112(195)69(11)155-129(212)96(58-179)172-126(209)94(49-103(142)188)167-121(204)87(41-67(7)8)170-134(217)110(71(13)183)176-114(197)80(139)44-75-51-148-81-27-19-18-26-79(75)81)115(198)152-57-107(192)178-37-23-30-100(178)132(215)169-90(45-76-52-145-62-153-76)119(202)156-70(12)113(196)175-109(68(9)10)133(216)151-56-106(191)159-93(48-102(141)187)125(208)165-91(46-77-53-146-63-154-77)124(207)161-83(29-22-36-147-137(143)144)118(201)171-97(59-180)130(213)164-89(42-73-24-16-15-17-25-73)123(206)173-98(60-181)131(214)168-95(50-108(193)194)127(210)160-82(28-20-21-35-138)117(200)166-92(47-101(140)186)116(199)150-55-105(190)157-85(39-65(3)4)128(211)177-111(72(14)184)135(218)174-99(61-182)136(219)220/h15-19,24-27,31-34,51-53,62-72,80,82-100,109-111,148,179-185H,20-23,28-30,35-50,54-61,138-139H2,1-14H3,(H2,140,186)(H2,141,187)(H2,142,188)(H,145,153)(H,146,154)(H,149,195)(H,150,199)(H,151,216)(H,152,198)(H,155,212)(H,156,202)(H,157,190)(H,158,189)(H,159,191)(H,160,210)(H,161,207)(H,162,203)(H,163,205)(H,164,213)(H,165,208)(H,166,200)(H,167,204)(H,168,214)(H,169,215)(H,170,217)(H,171,201)(H,172,209)(H,173,206)(H,174,218)(H,175,196)(H,176,197)(H,177,211)(H,193,194)(H,219,220)(H4,143,144,147)/t69-,70-,71+,72+,80-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,109-,110-,111-/m0/s1
DMB3567	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC4=CN=CN4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC6=CNC7=CC=CC=C76)N)O
DMB3567	IK	UTHJXLJHUIVFLB-TYEKMZLMSA-N
DMB3567	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-oxobutanoic acid
DMB3567	DE	Discovery agent

DMVZB8U	ID	DMVZB8U
DMVZB8U	DN	WVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2
DMVZB8U	HS	Investigative
DMVZB8U	SN	CHEMBL500283; WVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2
DMVZB8U	PC	44563409
DMVZB8U	MW	3311.8
DMVZB8U	FM	C150H240N46O39
DMVZB8U	IC	InChI=1S/C150H240N46O39/c1-72(2)52-96(173-112(206)66-167-123(210)80(17)171-131(218)97(53-73(3)4)180-129(216)93(44-33-49-163-149(158)159)175-134(221)100(58-87-63-162-71-170-87)185-147(234)121(83(20)201)195-145(232)118(78(13)14)190-125(212)89(153)57-86-62-165-90-41-28-27-40-88(86)90)132(219)181-98(54-74(5)6)133(220)188-106(70-199)140(227)177-94(45-34-50-164-150(160)161)130(217)187-104(68-197)126(213)168-64-111(205)166-65-114(208)189-116(76(9)10)144(231)192-117(77(11)12)143(230)178-92(43-30-32-48-152)128(215)183-101(59-108(154)202)136(223)184-102(60-109(155)203)135(222)182-99(56-85-38-25-22-26-39-85)137(224)193-119(79(15)16)148(235)196-51-35-46-107(196)141(228)194-120(82(19)200)146(233)186-103(61-110(156)204)138(225)191-115(75(7)8)142(229)169-67-113(207)174-105(69-198)139(226)176-91(42-29-31-47-151)127(214)172-81(18)124(211)179-95(122(157)209)55-84-36-23-21-24-37-84/h21-28,36-41,62-63,71-83,89,91-107,115-121,165,197-201H,29-35,42-61,64-70,151-153H2,1-20H3,(H2,154,202)(H2,155,203)(H2,156,204)(H2,157,209)(H,162,170)(H,166,205)(H,167,210)(H,168,213)(H,169,229)(H,171,218)(H,172,214)(H,173,206)(H,174,207)(H,175,221)(H,176,226)(H,177,227)(H,178,230)(H,179,211)(H,180,216)(H,181,219)(H,182,222)(H,183,215)(H,184,223)(H,185,234)(H,186,233)(H,187,217)(H,188,220)(H,189,208)(H,190,212)(H,191,225)(H,192,231)(H,193,224)(H,194,228)(H,195,232)(H4,158,159,163)(H4,160,161,164)/t80-,81-,82+,83+,89-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,115-,116-,117-,118-,119-,120-,121-/m0/s1
DMVZB8U	CS	C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)N)O
DMVZB8U	IK	KABRZBKCOKQUKE-CFPQMTSYSA-N
DMVZB8U	IU	(2S)-N-[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]butanediamide
DMVZB8U	DE	Discovery agent

DM6J7OQ	ID	DM6J7OQ
DM6J7OQ	DN	WX-037
DM6J7OQ	HS	Investigative
DM6J7OQ	SN	PI3K inhibitors (cancer), Wilex
DM6J7OQ	CP	UCB SA
DM6J7OQ	DE	Solid tumour/cancer

DM0AZLE	ID	DM0AZLE
DM0AZLE	DN	WY-46016
DM0AZLE	HS	Investigative
DM0AZLE	SN	104325-55-5; 3-(2-Quinolinylmethoxy)benzeneacetic acid; Wy-46016; WY-46,016; AC1L2TZC; 2-[3-(quinolin-2-ylmethoxy)phenyl]acetic acid; [3-(Quinolin-2-ylmethoxy)-phenyl]-acetic acid; CHEMBL310611; SCHEMBL9053241; CTK8G4858; DTXSID00146391; VTTJDSVAGYOMKY-UHFFFAOYSA-N; ZINC5162878; 3-(2-Quinolinylmethoxy)phenylacetic acid; 3-[(2-Quinolinyl)methoxy]benzeneacetic acid; Benzeneacetic acid, 3-(2-quinolinylmethoxy)-
DM0AZLE	DT	Small molecular drug
DM0AZLE	PC	128543
DM0AZLE	MW	293.3
DM0AZLE	FM	C18H15NO3
DM0AZLE	IC	InChI=1S/C18H15NO3/c20-18(21)11-13-4-3-6-16(10-13)22-12-15-9-8-14-5-1-2-7-17(14)19-15/h1-10H,11-12H2,(H,20,21)
DM0AZLE	CS	C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=CC(=C3)CC(=O)O
DM0AZLE	IK	VTTJDSVAGYOMKY-UHFFFAOYSA-N
DM0AZLE	IU	2-[3-(quinolin-2-ylmethoxy)phenyl]acetic acid
DM0AZLE	CA	CAS 104325-55-5
DM0AZLE	DE	Discovery agent

DMBWUR0	ID	DMBWUR0
DMBWUR0	DN	WZ-3146
DMBWUR0	HS	Investigative
DMBWUR0	SN	WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals
DMBWUR0	CP	Gatekeeper Pharmaceuticals Inc
DMBWUR0	DT	Small molecular drug
DMBWUR0	PC	44607360
DMBWUR0	MW	464.9
DMBWUR0	FM	C24H25ClN6O2
DMBWUR0	IC	InChI=1S/C24H25ClN6O2/c1-3-22(32)27-18-5-4-6-20(15-18)33-23-21(25)16-26-24(29-23)28-17-7-9-19(10-8-17)31-13-11-30(2)12-14-31/h3-10,15-16H,1,11-14H2,2H3,(H,27,32)(H,26,28,29)
DMBWUR0	CS	CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)OC4=CC=CC(=C4)NC(=O)C=C)Cl
DMBWUR0	IK	APHGZZPEOCCYNO-UHFFFAOYSA-N
DMBWUR0	IU	N-[3-[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
DMBWUR0	CA	CAS 1214265-56-1
DMBWUR0	CB	CHEBI:94728
DMBWUR0	DE	Lung cancer

DMP9RBK	ID	DMP9RBK
DMP9RBK	DN	WZ4003
DMP9RBK	HS	Investigative
DMP9RBK	SN	WZ-4003
DMP9RBK	DT	Small molecular drug
DMP9RBK	PC	72200024
DMP9RBK	MW	497
DMP9RBK	FM	C25H29ClN6O3
DMP9RBK	IC	InChI=1S/C25H29ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h5-9,14-16H,4,10-13H2,1-3H3,(H,28,33)(H,27,29,30)
DMP9RBK	CS	CCC(=O)NC1=CC(=CC=C1)OC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCN(CC4)C)OC
DMP9RBK	IK	SDGJBAUIGHSMRI-UHFFFAOYSA-N
DMP9RBK	IU	N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]propanamide
DMP9RBK	CA	CAS 1214265-58-3
DMP9RBK	DE	Discovery agent

DMZ0TDL	ID	DMZ0TDL
DMZ0TDL	DN	X-387
DMZ0TDL	HS	Investigative
DMZ0TDL	SN	MTOR inhibitors (cancer), Shanghai Institute of Materia Medica
DMZ0TDL	CP	Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
DMZ0TDL	DE	Solid tumour/cancer

DMOVJP3	ID	DMOVJP3
DMOVJP3	DN	xamoterol
DMOVJP3	HS	Investigative
DMOVJP3	SN	ICI-118587
DMOVJP3	DT	Small molecular drug
DMOVJP3	PC	155774
DMOVJP3	MW	339.39
DMOVJP3	FM	C16H25N3O5
DMOVJP3	IC	InChI=1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)
DMOVJP3	CS	C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O
DMOVJP3	IK	DXPOSRCHIDYWHW-UHFFFAOYSA-N
DMOVJP3	IU	N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide
DMOVJP3	CA	CAS 81801-12-9
DMOVJP3	CB	CHEBI:10055
DMOVJP3	DE	Discovery agent

DMGYVFD	ID	DMGYVFD
DMGYVFD	DN	xanthine amine congener
DMGYVFD	HS	Investigative
DMGYVFD	SN	N-(2-Aminoethyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; Xanthine amine congener; 96865-92-8; Papaxac; XAC; CHEMBL273094; 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine; n-(2-aminoethyl)-2-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1h-purin-8-yl)phenoxy]acetamide; N-(2-aminoethyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; Xanthine amine congener xac; 8-[4-[[[[(2-Aminoethyl)amino]carbonyl]methyl]oxy]phenyl]-1,3-dipropylxanthine; [3H]xanthine amine congener; [3H]XAC;  papaxac
DMGYVFD	DT	Small molecular drug
DMGYVFD	PC	5697
DMGYVFD	MW	428.5
DMGYVFD	FM	C21H28N6O4
DMGYVFD	IC	InChI=1S/C21H28N6O4/c1-3-11-26-19-17(20(29)27(12-4-2)21(26)30)24-18(25-19)14-5-7-15(8-6-14)31-13-16(28)23-10-9-22/h5-8H,3-4,9-13,22H2,1-2H3,(H,23,28)(H,24,25)
DMGYVFD	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)NCCN
DMGYVFD	IK	FIQGIOAELHTLHM-UHFFFAOYSA-N
DMGYVFD	IU	N-(2-aminoethyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide
DMGYVFD	CA	CAS 96865-92-8
DMGYVFD	DE	Discovery agent

DM1GJX8	ID	DM1GJX8
DM1GJX8	DN	Xanthosine-5'-monophosphate disodium salt
DM1GJX8	HS	Investigative
DM1GJX8	SN	EINECS 247-324-0; sodium 5'-o-(hydroxyphosphinato)xanthosine; AC1Q1VBC; CHEMBL1627079; xanthosine-5'-monophosphate disodium salt; A818576; sodium [(2R,3S,4R,5R)-5-[2,6-bis(oxidanylidene)-3H-purin-9-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate; sodium [(2R,3S,4R,5R)-5-(2,6-dioxo-3H-purin-9-yl)-3,4-dihydroxy-2-oxolanyl]methyl hydrogen phosphate
DM1GJX8	DT	Small molecular drug
DM1GJX8	PC	23677998
DM1GJX8	MW	386.19
DM1GJX8	FM	C10H12N4NaO9P
DM1GJX8	IC	InChI=1S/C10H13N4O9P.Na/c15-5-3(1-22-24(19,20)21)23-9(6(5)16)14-2-11-4-7(14)12-10(18)13-8(4)17;/h2-3,5-6,9,15-16H,1H2,(H2,19,20,21)(H2,12,13,17,18);/q;+1/p-1/t3-,5-,6-,9-;/m1./s1
DM1GJX8	CS	C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)[O-])O)O)NC(=O)NC2=O.[Na+]
DM1GJX8	IK	FVWNNNBCIYRTSW-GWTDSMLYSA-M
DM1GJX8	IU	sodium;[(2R,3S,4R,5R)-5-(2,6-dioxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM1GJX8	CA	CAS 25899-70-1
DM1GJX8	DE	Discovery agent

DM38TLN	ID	DM38TLN
DM38TLN	DN	XANTHOSTIGMINE
DM38TLN	HS	Investigative
DM38TLN	SN	Xanthostigmine; CHEMBL340427; aminoalkoxyheteroaryl deriv. 8; BDBM10692; 3-{[methyl({3-[(9-oxo-9H-xanthen-3-yl)oxy]propyl})amino]methyl}phenyl N-methylcarbamate
DM38TLN	DT	Small molecular drug
DM38TLN	PC	10765787
DM38TLN	MW	446.5
DM38TLN	FM	C26H26N2O5
DM38TLN	IC	InChI=1S/C26H26N2O5/c1-27-26(30)32-20-8-5-7-18(15-20)17-28(2)13-6-14-31-19-11-12-22-24(16-19)33-23-10-4-3-9-21(23)25(22)29/h3-5,7-12,15-16H,6,13-14,17H2,1-2H3,(H,27,30)
DM38TLN	CS	CNC(=O)OC1=CC=CC(=C1)CN(C)CCCOC2=CC3=C(C=C2)C(=O)C4=CC=CC=C4O3
DM38TLN	IK	DNSUFPJFKSCBRT-UHFFFAOYSA-N
DM38TLN	IU	[3-[[methyl-[3-(9-oxoxanthen-3-yl)oxypropyl]amino]methyl]phenyl] N-methylcarbamate
DM38TLN	DE	Discovery agent

DMLTVI6	ID	DMLTVI6
DMLTVI6	DN	XAP044
DMLTVI6	HS	Investigative
DMLTVI6	SN	7-hydroxy-3-(4-iodophenoxy)-4H-chromen-4-one
DMLTVI6	DT	Small molecular drug
DMLTVI6	PC	5428913
DMLTVI6	MW	380.13
DMLTVI6	FM	C15H9IO4
DMLTVI6	IC	InChI=1S/C15H9IO4/c16-9-1-4-11(5-2-9)20-14-8-19-13-7-10(17)3-6-12(13)15(14)18/h1-8,17H
DMLTVI6	CS	C1=CC(=CC=C1OC2=COC3=C(C2=O)C=CC(=C3)O)I
DMLTVI6	IK	XXZKJJYWINSUMJ-UHFFFAOYSA-N
DMLTVI6	IU	7-hydroxy-3-(4-iodophenoxy)chromen-4-one
DMLTVI6	DE	Discovery agent

DMYT5DI	ID	DMYT5DI
DMYT5DI	DN	XB-05
DMYT5DI	HS	Investigative
DMYT5DI	CP	University of Louisville
DMYT5DI	DE	Solid tumour/cancer

DMBN7UX	ID	DMBN7UX
DMBN7UX	DN	XB-387
DMBN7UX	HS	Investigative
DMBN7UX	SN	PDGFRB-targeted mAb (cancer), X-BODY; Platelet-derived growth factor receptor beta-targeted monoclonal antibody (cancer), X-BODY
DMBN7UX	CP	X-BODY BioSciences
DMBN7UX	DT	Antibody
DMBN7UX	DE	Non-small-cell lung cancer

DM8PADV	ID	DM8PADV
DM8PADV	DN	XCC
DM8PADV	HS	Investigative
DM8PADV	SN	QTMMGCYGCFXBFI-UHFFFAOYSA-N; CHEMBL27041; [4-(2,6-Dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)phenoxy]acetic acid; 2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetic acid; PDSP1_000315; AC1Q5WRT; AC1L2PQ2; GTPL451; SCHEMBL7235224; CTK8E0623; MolPort-023-277-106; ZINC5114736; PDSP2_000313; PDSP2_001238; PDSP1_001254; BDBM50008405; AKOS024458041; NCGC00370927-01; L000656; 1,3-dipropyl-8-(4-carboxymethyloxy)phenylxanthine; 8-(4-Carboxymethyloxy)phenyl-1,3-dipropylxanthine
DM8PADV	DT	Small molecular drug
DM8PADV	PC	126079
DM8PADV	MW	386.4
DM8PADV	FM	C19H22N4O5
DM8PADV	IC	InChI=1S/C19H22N4O5/c1-3-9-22-17-15(18(26)23(10-4-2)19(22)27)20-16(21-17)12-5-7-13(8-6-12)28-11-14(24)25/h5-8H,3-4,9-11H2,1-2H3,(H,20,21)(H,24,25)
DM8PADV	CS	CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)O
DM8PADV	IK	QTMMGCYGCFXBFI-UHFFFAOYSA-N
DM8PADV	IU	2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetic acid
DM8PADV	CA	CAS 96865-83-7
DM8PADV	DE	Discovery agent

DMZ7N8D	ID	DMZ7N8D
DMZ7N8D	DN	XCT790
DMZ7N8D	HS	Investigative
DMZ7N8D	SN	XCT 790; XCT-790
DMZ7N8D	DT	Small molecular drug
DMZ7N8D	PC	6918788
DMZ7N8D	MW	596.4
DMZ7N8D	FM	C23H13F9N4O3S
DMZ7N8D	IC	InChI=1S/C23H13F9N4O3S/c1-38-17-7-11(6-13(9-33)18(37)34-20-36-35-19(40-20)23(30,31)32)2-5-16(17)39-10-12-3-4-14(21(24,25)26)8-15(12)22(27,28)29/h2-8H,10H2,1H3,(H,34,36,37)/b13-6+
DMZ7N8D	CS	COC1=C(C=CC(=C1)/C=C(\\C#N)/C(=O)NC2=NN=C(S2)C(F)(F)F)OCC3=C(C=C(C=C3)C(F)(F)F)C(F)(F)F
DMZ7N8D	IK	HQFNFOOGGLSBBT-AWNIVKPZSA-N
DMZ7N8D	IU	(E)-3-[4-[[2,4-bis(trifluoromethyl)phenyl]methoxy]-3-methoxyphenyl]-2-cyano-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]prop-2-enamide
DMZ7N8D	CA	CAS 725247-18-7
DMZ7N8D	CB	CHEBI:79999
DMZ7N8D	DE	Discovery agent

DMS3TZ5	ID	DMS3TZ5
DMS3TZ5	DN	XD1
DMS3TZ5	HS	Investigative
DMS3TZ5	SN	colchicein; colchiceine; NSC33411
DMS3TZ5	DT	Small molecular drug
DMS3TZ5	PC	234105
DMS3TZ5	MW	385.4
DMS3TZ5	FM	C21H23NO6
DMS3TZ5	IC	InChI=1S/C21H23NO6/c1-11(23)22-15-7-5-12-9-18(26-2)20(27-3)21(28-4)19(12)13-6-8-16(24)17(25)10-14(13)15/h6,8-10,15H,5,7H2,1-4H3,(H,22,23)(H,24,25)/t15-/m0/s1
DMS3TZ5	CS	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)O)OC)OC)OC
DMS3TZ5	IK	PRGILOMAMBLWNG-HNNXBMFYSA-N
DMS3TZ5	IU	N-[(7S)-10-hydroxy-1,2,3-trimethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMS3TZ5	CA	CAS 477-27-0
DMS3TZ5	DE	Discovery agent

DMUMACD	ID	DMUMACD
DMUMACD	DN	XD14
DMUMACD	HS	Investigative
DMUMACD	SN	XD14; 1370888-71-3; XD 14; 4-acetyl-N-[5-(diethylsulfamoyl)-2-hydroxyphenyl]-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; CHEMBL3787231; 4-acetyl-N-(5-(N,N-diethylsulfamoyl)-2-hydroxyphenyl)-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; 4lyw; GTPL7524; SCHEMBL16181763; AOB6049; MolPort-010-365-022; XD-14; EX-A1864; ZINC59367920; BDBM50158909; AKOS025293503; NE41584; MCULE-3472066147; Z606699744
DMUMACD	DT	Small molecular drug
DMUMACD	PC	52670832
DMUMACD	MW	421.5
DMUMACD	FM	C20H27N3O5S
DMUMACD	IC	InChI=1S/C20H27N3O5S/c1-6-15-18(13(5)24)12(4)21-19(15)20(26)22-16-11-14(9-10-17(16)25)29(27,28)23(7-2)8-3/h9-11,21,25H,6-8H2,1-5H3,(H,22,26)
DMUMACD	CS	CCC1=C(NC(=C1C(=O)C)C)C(=O)NC2=C(C=CC(=C2)S(=O)(=O)N(CC)CC)O
DMUMACD	IK	DPBKLIVPNYGQQG-UHFFFAOYSA-N
DMUMACD	IU	4-acetyl-N-[5-(diethylsulfamoyl)-2-hydroxyphenyl]-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide
DMUMACD	DE	Discovery agent

DMLH1PK	ID	DMLH1PK
DMLH1PK	DN	XE991
DMLH1PK	HS	Investigative
DMLH1PK	SN	LS-190926
DMLH1PK	DT	Small molecular drug
DMLH1PK	PC	656732
DMLH1PK	MW	376.4
DMLH1PK	FM	C26H20N2O
DMLH1PK	IC	InChI=1S/C26H20N2O/c29-25-21-5-1-3-7-23(21)26(17-19-9-13-27-14-10-19,18-20-11-15-28-16-12-20)24-8-4-2-6-22(24)25/h1-16H,17-18H2
DMLH1PK	CS	C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2(CC4=CC=NC=C4)CC5=CC=NC=C5
DMLH1PK	IK	KHJFBUUFMUBONL-UHFFFAOYSA-N
DMLH1PK	IU	10,10-bis(pyridin-4-ylmethyl)anthracen-9-one
DMLH1PK	CA	CAS 122955-42-4
DMLH1PK	CB	CHEBI:35046
DMLH1PK	DE	Discovery agent

DMZ24P1	ID	DMZ24P1
DMZ24P1	DN	XEN-907
DMZ24P1	HS	Investigative
DMZ24P1	SN	NaV1.7 inhibitors (pain); NaV1.7 inhibitors (pain), Xenon Pharmaceuticals
DMZ24P1	CP	Xenon Pharmaceuticals Inc
DMZ24P1	DT	Small molecular drug
DMZ24P1	PC	11998198
DMZ24P1	MW	351.4
DMZ24P1	FM	C21H21NO4
DMZ24P1	IC	InChI=1S/C21H21NO4/c1-2-3-6-9-22-16-8-5-4-7-14(16)21(20(22)23)12-24-17-11-19-18(10-15(17)21)25-13-26-19/h4-5,7-8,10-11H,2-3,6,9,12-13H2,1H3
DMZ24P1	CS	CCCCCN1C2=CC=CC=C2C3(C1=O)COC4=CC5=C(C=C34)OCO5
DMZ24P1	IK	PHMRUZIIERITEP-UHFFFAOYSA-N
DMZ24P1	IU	1'-pentylspiro[6H-furo[2,3-f][1,3]benzodioxole-7,3'-indole]-2'-one
DMZ24P1	DE	Pain

DM1EHG5	ID	DM1EHG5
DM1EHG5	DN	XEN-D0104
DM1EHG5	HS	Investigative
DM1EHG5	CP	Xention Ltd
DM1EHG5	DE	Atrial fibrillation

DMAPRNO	ID	DMAPRNO
DMAPRNO	DN	xenin
DMAPRNO	HS	Investigative
DMAPRNO	SN	xenin-25
DMAPRNO	DT	Small molecular drug
DMAPRNO	PC	16131039
DMAPRNO	MW	2971.6
DMAPRNO	FM	C139H224N38O32S
DMAPRNO	IC	InChI=1S/C139H224N38O32S/c1-15-79(10)111(132(203)169-103(137(208)209)64-77(6)7)173-126(197)101(67-85-69-152-89-41-23-22-40-87(85)89)167-130(201)107-49-34-59-176(107)135(206)96(47-33-58-151-139(147)148)163-117(188)91(43-25-29-54-141)159-129(200)106-48-35-60-177(106)136(207)102(68-86-70-149-74-154-86)168-124(195)100(66-84-38-20-17-21-39-84)166-128(199)105(73-179)171-122(193)97(62-75(2)3)156-108(182)71-153-116(187)90(42-24-28-53-140)160-131(202)110(78(8)9)172-120(191)94(46-32-57-150-138(145)146)157-114(185)80(11)155-127(198)104(72-178)170-119(190)93(45-27-31-56-143)162-133(204)112(81(12)180)174-121(192)95(50-51-109(183)184)158-123(194)99(65-83-36-18-16-19-37-83)165-118(189)92(44-26-30-55-142)161-134(205)113(82(13)181)175-125(196)98(63-76(4)5)164-115(186)88(144)52-61-210-14/h16-23,36-41,69-70,74-82,88,90-107,110-113,152,178-181H,15,24-35,42-68,71-73,140-144H2,1-14H3,(H,149,154)(H,153,187)(H,155,198)(H,156,182)(H,157,185)(H,158,194)(H,159,200)(H,160,202)(H,161,205)(H,162,204)(H,163,188)(H,164,186)(H,165,189)(H,166,199)(H,167,201)(H,168,195)(H,169,203)(H,170,190)(H,171,193)(H,172,191)(H,173,197)(H,174,192)(H,175,196)(H,183,184)(H,208,209)(H4,145,146,150)(H4,147,148,151)/t79-,80-,81+,82+,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,110-,111-,112-,113-/m0/s1
DMAPRNO	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)N
DMAPRNO	IK	IDHVLSACPFUBDY-QCDLPZBNSA-N
DMAPRNO	IU	(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DMAPRNO	CA	CAS 144092-28-4
DMAPRNO	DE	Discovery agent

DMVTCZ1	ID	DMVTCZ1
DMVTCZ1	DN	XEP-018
DMVTCZ1	HS	Investigative
DMVTCZ1	SN	Conus consors venom (pain/anesthesia), Atheris
DMVTCZ1	CP	Atheris Laboratories
DMVTCZ1	DE	Pain

DM4YQR2	ID	DM4YQR2
DM4YQR2	DN	xestospongin C
DM4YQR2	HS	Investigative
DM4YQR2	SN	xestospongin c; 88903-69-9; Xestospongin; (-)-xestospongin C; C28H50N2O2; KBioGR_000612; BSPBio_001272; KBioSS_000612; SCHEMBL5163114; GTPL4344; KBio2_003180; KBio2_005748; KBio3_001084; KBio3_001083; KBio2_000612; HMS1990P13; Bio2_000476; HMS1792P13; CA409; Bio2_000956; HMS1362P13; XeC; ZINC33822036; 2102AH; MFCD01862629; IDI1_002231; NCGC00163490-02; C-22436
DM4YQR2	DT	Small molecular drug
DM4YQR2	PC	5311502
DM4YQR2	MW	446.7
DM4YQR2	FM	C28H50N2O2
DM4YQR2	IC	InChI=1S/C28H50N2O2/c1-3-7-15-25-17-21-30-20-10-14-24(28(30)31-25)12-6-2-4-8-16-26-18-22-29-19-9-13-23(11-5-1)27(29)32-26/h23-28H,1-22H2/t23-,24+,25-,26-,27+,28+/m0/s1
DM4YQR2	CS	C1CCC[C@H]2CCN3CCC[C@@H]([C@H]3O2)CCCCCC[C@H]4CCN5CCC[C@H]([C@H]5O4)CC1
DM4YQR2	IK	PQYOPBRFUUEHRC-MUJQFDPKSA-N
DM4YQR2	IU	(1R,8S,10R,15S,22S,29R)-9,30-dioxa-11,25-diazapentacyclo[20.6.2.28,11.010,15.025,29]dotriacontane
DM4YQR2	DE	Discovery agent

DM96FTS	ID	DM96FTS
DM96FTS	DN	XGP-110
DM96FTS	HS	Investigative
DM96FTS	SN	Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen
DM96FTS	CP	Xaragen Pharma Ltd
DM96FTS	DE	Arthritis

DMBLR73	ID	DMBLR73
DMBLR73	DN	XGP-510
DMBLR73	HS	Investigative
DMBLR73	SN	CysLT1 antagonist + repositioned compound (allergy), Xaragen
DMBLR73	CP	Xaragen Pharma Ltd
DMBLR73	DE	Allergy

DMZIHKY	ID	DMZIHKY
DMZIHKY	DN	XMD8-92
DMZIHKY	HS	Investigative
DMZIHKY	SN	XMD 8-92
DMZIHKY	DT	Small molecular drug
DMZIHKY	PC	46843772
DMZIHKY	MW	474.6
DMZIHKY	FM	C26H30N6O3
DMZIHKY	IC	InChI=1S/C26H30N6O3/c1-4-35-23-15-17(32-13-11-18(33)12-14-32)9-10-20(23)28-26-27-16-22-24(29-26)30(2)21-8-6-5-7-19(21)25(34)31(22)3/h5-10,15-16,18,33H,4,11-14H2,1-3H3,(H,27,28,29)
DMZIHKY	CS	CCOC1=C(C=CC(=C1)N2CCC(CC2)O)NC3=NC=C4C(=N3)N(C5=CC=CC=C5C(=O)N4C)C
DMZIHKY	IK	QAPAJIZPZGWAND-UHFFFAOYSA-N
DMZIHKY	IU	2-[2-ethoxy-4-(4-hydroxypiperidin-1-yl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one
DMZIHKY	CA	CAS 1234480-50-2
DMZIHKY	CB	CHEBI:60325
DMZIHKY	DE	Discovery agent

DMHWTCY	ID	DMHWTCY
DMHWTCY	DN	XMetD
DMHWTCY	HS	Investigative
DMHWTCY	SN	Insulin receptor antagonist antibody (hypoglycemia), XOMA
DMHWTCY	CP	XOMA Ltd
DMHWTCY	DT	Antibody
DMHWTCY	DE	Hypoglycemia

DM6JKL7	ID	DM6JKL7
DM6JKL7	DN	XMetS
DM6JKL7	HS	Investigative
DM6JKL7	SN	Insulin receptor sensitizing antibody (diabetes), XOMA
DM6JKL7	CP	XOMA Ltd
DM6JKL7	DT	Antibody
DM6JKL7	DE	Non-insulin dependent diabetes

DM5TR49	ID	DM5TR49
DM5TR49	DN	XMT-1191
DM5TR49	HS	Investigative
DM5TR49	SN	XMT-1191; GTPL6486
DM5TR49	DT	Small molecular drug
DM5TR49	PC	25227633
DM5TR49	MW	544.6
DM5TR49	FM	C29H40N2O8
DM5TR49	IC	InChI=1S/C29H40N2O8/c1-18(2)8-13-22-28(3,39-22)26-25(36-4)21(14-15-29(26)17-37-29)38-27(35)30-16-19-9-11-20(12-10-19)31-23(32)6-5-7-24(33)34/h8-12,21-22,25-26H,5-7,13-17H2,1-4H3,(H,30,35)(H,31,32)(H,33,34)/t21-,22-,25-,26-,28+,29+/m1/s1
DM5TR49	CS	CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)NCC4=CC=C(C=C4)NC(=O)CCCC(=O)O)OC)C
DM5TR49	IK	HRLDHINFRLTOEQ-UZHVHHFFSA-N
DM5TR49	IU	5-[4-[[[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl]oxycarbonylamino]methyl]anilino]-5-oxopentanoic acid
DM5TR49	DE	Discovery agent

DMXH6DL	ID	DMXH6DL
DMXH6DL	DN	XN-0502
DMXH6DL	HS	Investigative
DMXH6DL	SN	MZ-3; Combretastatin-A4 analogs (cancer); Combretastatin-A4 analogs (cancer), Zhejiang University
DMXH6DL	CP	Zhejiang University
DMXH6DL	DT	Small molecular drug
DMXH6DL	PC	46183322
DMXH6DL	MW	355.4
DMXH6DL	FM	C19H21N3O4
DMXH6DL	IC	InChI=1S/C19H21N3O4/c1-23-13-7-5-11(6-8-13)16-17(21-22-19(16)20)12-9-14(24-2)18(26-4)15(10-12)25-3/h5-10H,1-4H3,(H3,20,21,22)
DMXH6DL	CS	COC1=CC=C(C=C1)C2=C(NN=C2N)C3=CC(=C(C(=C3)OC)OC)OC
DMXH6DL	IK	SITNEARYBVAYKV-UHFFFAOYSA-N
DMXH6DL	IU	4-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-amine
DMXH6DL	DE	Solid tumour/cancer

DMPOGXU	ID	DMPOGXU
DMPOGXU	DN	XNT
DMPOGXU	HS	Investigative
DMPOGXU	SN	86456-22-6; NSC354677; 9H-Xanthen-9-one, 1-((2-(dimethylamino)ethyl)amino)-4-(hydroxymethyl)-7-(((4-methylphenyl)sulfonyl)oxy)-; [8-(2-dimethylaminoethylamino)-5-(hydroxymethyl)-9-oxoxanthen-2-yl] 4-methylbenzenesulfonate; 8-((2-(Dimethylamino)ethyl)amino)-5-(hydroxymethyl)-9-oxo-9H-xanthen-2-yl 4-methylbenzenesulfonate; 9H-Xanthen-9-one, 1-[[2-(dimethylamino)ethyl]amino]-4-(hydroxymethyl)-7-[[(4-methylphenyl)sulfonyl]oxy]-
DMPOGXU	DT	Small molecular drug
DMPOGXU	PC	337294
DMPOGXU	MW	482.5
DMPOGXU	FM	C25H26N2O6S
DMPOGXU	IC	InChI=1S/C25H26N2O6S/c1-16-4-8-19(9-5-16)34(30,31)33-18-7-11-22-20(14-18)24(29)23-21(26-12-13-27(2)3)10-6-17(15-28)25(23)32-22/h4-11,14,26,28H,12-13,15H2,1-3H3
DMPOGXU	CS	CC1=CC=C(C=C1)S(=O)(=O)OC2=CC3=C(C=C2)OC4=C(C=CC(=C4C3=O)NCCN(C)C)CO
DMPOGXU	IK	SEVKFSGZVZFIMA-UHFFFAOYSA-N
DMPOGXU	IU	[8-[2-(dimethylamino)ethylamino]-5-(hydroxymethyl)-9-oxoxanthen-2-yl] 4-methylbenzenesulfonate
DMPOGXU	CA	CAS 86456-22-6
DMPOGXU	DE	Discovery agent

DMGOMYN	ID	DMGOMYN
DMGOMYN	DN	XP-21510
DMGOMYN	HS	Investigative
DMGOMYN	SN	XP-27B; Tranexamic acid prodrug (menorrhagia), Xenoport/Xanodyne
DMGOMYN	CP	XenoPort Inc
DMGOMYN	DE	Menorrhagia

DMTUFI1	ID	DMTUFI1
DMTUFI1	DN	XR-9456
DMTUFI1	HS	Investigative
DMTUFI1	SN	XR-9456; CHEMBL346292; SCHEMBL7170174; BDBM50375810
DMTUFI1	DT	Small molecular drug
DMTUFI1	PC	15511439
DMTUFI1	MW	535.6
DMTUFI1	FM	C33H33N3O4
DMTUFI1	IC	InChI=1S/C33H33N3O4/c1-39-30-20-25-17-19-36(22-26(25)21-31(30)40-2)18-16-23-12-14-27(15-13-23)34-33(38)28-10-6-7-11-29(28)35-32(37)24-8-4-3-5-9-24/h3-15,20-21H,16-19,22H2,1-2H3,(H,34,38)(H,35,37)
DMTUFI1	CS	COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4NC(=O)C5=CC=CC=C5)OC
DMTUFI1	IK	AEXVPZYELNSRFS-UHFFFAOYSA-N
DMTUFI1	IU	2-benzamido-N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]benzamide
DMTUFI1	DE	Discovery agent

DMIQP69	ID	DMIQP69
DMIQP69	DN	XR-9504
DMIQP69	HS	Investigative
DMIQP69	SN	XR-9504; CHEMBL258896; SCHEMBL7168501
DMIQP69	DT	Small molecular drug
DMIQP69	PC	22004473
DMIQP69	MW	549.7
DMIQP69	FM	C34H35N3O4
DMIQP69	IC	InChI=1S/C34H35N3O4/c1-23-8-12-25(13-9-23)33(38)36-30-7-5-4-6-29(30)34(39)35-28-14-10-24(11-15-28)16-18-37-19-17-26-20-31(40-2)32(41-3)21-27(26)22-37/h4-15,20-21H,16-19,22H2,1-3H3,(H,35,39)(H,36,38)
DMIQP69	CS	CC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2C(=O)NC3=CC=C(C=C3)CCN4CCC5=CC(=C(C=C5C4)OC)OC
DMIQP69	IK	YKXTXQJFMGBJLD-UHFFFAOYSA-N
DMIQP69	IU	N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-2-[(4-methylbenzoyl)amino]benzamide
DMIQP69	DE	Discovery agent

DM1OZPN	ID	DM1OZPN
DM1OZPN	DN	XR-9544
DM1OZPN	HS	Investigative
DM1OZPN	SN	XR-9544; CHEMBL444075; SCHEMBL14290581; BDBM50375811
DM1OZPN	DT	Small molecular drug
DM1OZPN	PC	15511440
DM1OZPN	MW	586.7
DM1OZPN	FM	C36H34N4O4
DM1OZPN	IC	InChI=1S/C36H34N4O4/c1-43-33-20-25-16-18-40(23-28(25)21-34(33)44-2)17-15-24-11-13-29(14-12-24)38-36(42)30-8-4-6-10-32(30)39-35(41)27-19-26-7-3-5-9-31(26)37-22-27/h3-14,19-22H,15-18,23H2,1-2H3,(H,38,42)(H,39,41)
DM1OZPN	CS	COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC
DM1OZPN	IK	TZASTBIDWCFCGN-UHFFFAOYSA-N
DM1OZPN	IU	N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]phenyl]quinoline-3-carboxamide
DM1OZPN	DE	Discovery agent

DMIZV6T	ID	DMIZV6T
DMIZV6T	DN	XR-9577
DMIZV6T	HS	Investigative
DMIZV6T	SN	XR-9577; CHEMBL428402
DMIZV6T	DT	Small molecular drug
DMIZV6T	PC	15950351
DMIZV6T	MW	526.6
DMIZV6T	FM	C34H30N4O2
DMIZV6T	IC	InChI=1S/C34H30N4O2/c39-33(28-21-26-8-3-5-11-31(26)35-22-28)37-32-12-6-4-10-30(32)34(40)36-29-15-13-24(14-16-29)17-19-38-20-18-25-7-1-2-9-27(25)23-38/h1-16,21-22H,17-20,23H2,(H,36,40)(H,37,39)
DMIZV6T	CS	C1CN(CC2=CC=CC=C21)CCC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4NC(=O)C5=CC6=CC=CC=C6N=C5
DMIZV6T	IK	JCKRZMGEVAGHHV-UHFFFAOYSA-N
DMIZV6T	IU	N-[2-[[4-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]phenyl]quinoline-3-carboxamide
DMIZV6T	DE	Discovery agent

DM7BTNF	ID	DM7BTNF
DM7BTNF	DN	XT-101
DM7BTNF	HS	Investigative
DM7BTNF	CP	Xalud Therapeutics Inc
DM7BTNF	DE	Neuropathic pain

DML1K07	ID	DML1K07
DML1K07	DN	XV454
DML1K07	HS	Investigative
DML1K07	DE	Discovery agent

DMSXJUW	ID	DMSXJUW
DMSXJUW	DN	xylazine
DMSXJUW	HS	Investigative
DMSXJUW	SN	Bayer 1470; Narcoxyl; Rompun; Xylapan; Xylasol; Xylzin; BAY-VA-1470
DMSXJUW	DT	Small molecular drug
DMSXJUW	PC	5707
DMSXJUW	MW	220.34
DMSXJUW	FM	C12H16N2S
DMSXJUW	IC	InChI=1S/C12H16N2S/c1-9-5-3-6-10(2)11(9)14-12-13-7-4-8-15-12/h3,5-6H,4,7-8H2,1-2H3,(H,13,14)
DMSXJUW	CS	CC1=C(C(=CC=C1)C)NC2=NCCCS2
DMSXJUW	IK	BPICBUSOMSTKRF-UHFFFAOYSA-N
DMSXJUW	IU	N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine
DMSXJUW	CA	CAS 7361-61-7
DMSXJUW	CB	CHEBI:92386
DMSXJUW	DE	Discovery agent

DMZKPSQ	ID	DMZKPSQ
DMZKPSQ	DN	Y-26763
DMZKPSQ	HS	Investigative
DMZKPSQ	SN	127408-31-5
DMZKPSQ	DT	Small molecular drug
DMZKPSQ	PC	121878
DMZKPSQ	MW	276.29
DMZKPSQ	FM	C14H16N2O4
DMZKPSQ	IC	InChI=1S/C14H16N2O4/c1-8(17)16(19)12-10-6-9(7-15)4-5-11(10)20-14(2,3)13(12)18/h4-6,12-13,18-19H,1-3H3/t12-,13+/m1/s1
DMZKPSQ	CS	CC(=O)N([C@H]1[C@@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O)O
DMZKPSQ	IK	IWTCFIIOUXJOOV-OLZOCXBDSA-N
DMZKPSQ	IU	N-[(3S,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-N-hydroxyacetamide
DMZKPSQ	CA	CAS 127408-31-5
DMZKPSQ	CB	CHEBI:92788
DMZKPSQ	DE	Discovery agent

DMC95YB	ID	DMC95YB
DMC95YB	DN	Y-39041
DMC95YB	HS	Investigative
DMC95YB	SN	SCHEMBL4603503
DMC95YB	DT	Small molecular drug
DMC95YB	PC	10151575
DMC95YB	MW	452
DMC95YB	FM	C27H30ClNO3
DMC95YB	IC	InChI=1S/C27H29NO3.ClH/c1-3-8-22(9-4-1)27(23-10-5-2-6-11-23)31-24-12-7-16-28(19-24)17-15-21-13-14-25-26(18-21)30-20-29-25;/h1-6,8-11,13-14,18,24,27H,7,12,15-17,19-20H2;1H/t24-;/m1./s1
DMC95YB	CS	C1C[C@H](CN(C1)CCC2=CC3=C(C=C2)OCO3)OC(C4=CC=CC=C4)C5=CC=CC=C5.Cl
DMC95YB	IK	OUTBWXJALMTPND-GJFSDDNBSA-N
DMC95YB	IU	(3R)-3-benzhydryloxy-1-[2-(1,3-benzodioxol-5-yl)ethyl]piperidine;hydrochloride
DMC95YB	DE	Discovery agent

DM412IV	ID	DM412IV
DM412IV	DN	Y-40613
DM412IV	HS	Investigative
DM412IV	SN	CHEMBL281124; Y-40613; SCHEMBL7152045; BDBM50098847; 2-(2-{2-[5-Amino-2-(4-fluoro-phenyl)-6-oxo-6H-pyrimidin-1-yl]-acetylamino}-3-phenyl-propionyl)-benzooxazole-5-carboxylic acid methyl ester
DM412IV	DT	Small molecular drug
DM412IV	PC	9829503
DM412IV	MW	569.5
DM412IV	FM	C30H24FN5O6
DM412IV	IC	InChI=1S/C30H24FN5O6/c1-41-30(40)19-9-12-24-22(14-19)35-28(42-24)26(38)23(13-17-5-3-2-4-6-17)34-25(37)16-36-27(33-15-21(32)29(36)39)18-7-10-20(31)11-8-18/h2-12,14-15,23H,13,16,32H2,1H3,(H,34,37)
DM412IV	CS	COC(=O)C1=CC2=C(C=C1)OC(=N2)C(=O)C(CC3=CC=CC=C3)NC(=O)CN4C(=NC=C(C4=O)N)C5=CC=C(C=C5)F
DM412IV	IK	YGRSMPVCBHOYMS-UHFFFAOYSA-N
DM412IV	IU	methyl 2-[2-[[2-[5-amino-2-(4-fluorophenyl)-6-oxopyrimidin-1-yl]acetyl]amino]-3-phenylpropanoyl]-1,3-benzoxazole-5-carboxylate
DM412IV	DE	Discovery agent

DMUW4KG	ID	DMUW4KG
DMUW4KG	DN	YAWF-NH2
DMUW4KG	HS	Investigative
DMUW4KG	SN	CHEMBL445690; YAWF-NH2
DMUW4KG	DT	Small molecular drug
DMUW4KG	PC	44577306
DMUW4KG	MW	584.7
DMUW4KG	FM	C32H36N6O5
DMUW4KG	IC	InChI=1S/C32H36N6O5/c1-19(36-31(42)25(33)15-21-11-13-23(39)14-12-21)30(41)38-28(17-22-18-35-26-10-6-5-9-24(22)26)32(43)37-27(29(34)40)16-20-7-3-2-4-8-20/h2-14,18-19,25,27-28,35,39H,15-17,33H2,1H3,(H2,34,40)(H,36,42)(H,37,43)(H,38,41)/t19-,25-,27-,28-/m0/s1
DMUW4KG	CS	C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMUW4KG	IK	AXMWRKQKSXEZPQ-VCJXGGRGSA-N
DMUW4KG	IU	(2S)-2-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
DMUW4KG	DE	Discovery agent

DMAC65P	ID	DMAC65P
DMAC65P	DN	Y-c[D-Pen-(2')Nal-GSFC]KR-NH2
DMAC65P	HS	Investigative
DMAC65P	SN	CHEMBL405681; BDBM50064832
DMAC65P	PC	44312289
DMAC65P	MW	1064.3
DMAC65P	FM	C49H69N13O10S2
DMAC65P	IC	InChI=1S/C49H69N13O10S2/c1-28(64)56-40-47(72)61-35(24-30-18-19-31-14-7-8-15-32(31)22-30)42(67)55-25-39(65)57-37(26-63)45(70)60-36(23-29-12-5-4-6-13-29)44(69)62-38(27-73-74-49(40,2)3)46(71)59-34(16-9-10-20-50)43(68)58-33(41(51)66)17-11-21-54-48(52)53/h4-8,12-15,18-19,22,33-38,40,63H,9-11,16-17,20-21,23-27,50H2,1-3H3,(H2,51,66)(H,55,67)(H,56,64)(H,57,65)(H,58,68)(H,59,71)(H,60,70)(H,61,72)(H,62,69)(H4,52,53,54)/t33-,34-,35-,36+,37-,38+,40-/m0/s1
DMAC65P	CS	CC(=O)N[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC1(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)CC2=CC=CC=C2)CO)CC3=CC4=CC=CC=C4C=C3
DMAC65P	IK	RLMDVJMHWZVFEI-BQQBDQLKSA-N
DMAC65P	IU	(4S,7R,10S,16S,19S)-19-acetamido-N-[(2S)-6-amino-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]-7-benzyl-10-(hydroxymethyl)-20,20-dimethyl-16-(naphthalen-2-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMAC65P	DE	Discovery agent

DMEL4UN	ID	DMEL4UN
DMEL4UN	DN	Y-c[D-Pen-(2R,3R)-2-Me-(2')Nal-GSFC]KR-NH2
DMEL4UN	HS	Investigative
DMEL4UN	SN	CHEMBL412218; BDBM50064828
DMEL4UN	PC	44312287
DMEL4UN	MW	1199.5
DMEL4UN	FM	C57H78N14O11S2
DMEL4UN	IC	InChI=1S/C57H78N14O11S2/c1-32(36-21-20-35-14-7-8-15-37(35)28-36)46-54(81)64-29-45(74)65-43(30-72)52(79)68-42(27-33-12-5-4-6-13-33)51(78)69-44(53(80)67-41(16-9-10-24-58)50(77)66-40(48(60)75)17-11-25-63-56(61)62)31-83-84-57(2,3)47(55(82)70-46)71-49(76)39(59)26-34-18-22-38(73)23-19-34/h4-8,12-15,18-23,28,32,39-44,46-47,72-73H,9-11,16-17,24-27,29-31,58-59H2,1-3H3,(H2,60,75)(H,64,81)(H,65,74)(H,66,77)(H,67,80)(H,68,79)(H,69,78)(H,70,82)(H,71,76)(H4,61,62,63)/t32-,39-,40-,41-,42+,43-,44+,46+,47-/m0/s1
DMEL4UN	CS	C[C@H]([C@@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC([C@H](C(=O)N1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)CC3=CC=CC=C3)CO)C4=CC5=CC=CC=C5C=C4
DMEL4UN	IK	HWTDVIKHJPOWJP-YOGAMANKSA-N
DMEL4UN	IU	(4S,7R,10S,16R,19S)-N-[(2S)-6-amino-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]-19-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-10-(hydroxymethyl)-20,20-dimethyl-16-[(1S)-1-naphthalen-2-ylethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMEL4UN	DE	Discovery agent

DM7P0H6	ID	DM7P0H6
DM7P0H6	DN	Y-c[D-Pen-(2R,3S)-2-Me-(2')Nal-GSFC]KR-NH2
DM7P0H6	HS	Investigative
DM7P0H6	SN	CHEMBL262212; BDBM50064837
DM7P0H6	PC	44312309
DM7P0H6	MW	1199.5
DM7P0H6	FM	C57H78N14O11S2
DM7P0H6	IC	InChI=1S/C57H78N14O11S2/c1-32(36-21-20-35-14-7-8-15-37(35)28-36)46-54(81)64-29-45(74)65-43(30-72)52(79)68-42(27-33-12-5-4-6-13-33)51(78)69-44(53(80)67-41(16-9-10-24-58)50(77)66-40(48(60)75)17-11-25-63-56(61)62)31-83-84-57(2,3)47(55(82)70-46)71-49(76)39(59)26-34-18-22-38(73)23-19-34/h4-8,12-15,18-23,28,32,39-44,46-47,72-73H,9-11,16-17,24-27,29-31,58-59H2,1-3H3,(H2,60,75)(H,64,81)(H,65,74)(H,66,77)(H,67,80)(H,68,79)(H,69,78)(H,70,82)(H,71,76)(H4,61,62,63)/t32-,39+,40+,41+,42-,43+,44-,46-,47+/m1/s1
DM7P0H6	CS	C[C@@H]([C@@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC([C@H](C(=O)N1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)CC3=CC=CC=C3)CO)C4=CC5=CC=CC=C5C=C4
DM7P0H6	IK	HWTDVIKHJPOWJP-JDMNTRJUSA-N
DM7P0H6	IU	(4S,7R,10S,16R,19S)-N-[(2S)-6-amino-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]-19-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-10-(hydroxymethyl)-20,20-dimethyl-16-[(1R)-1-naphthalen-2-ylethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM7P0H6	DE	Discovery agent

DMBNM85	ID	DMBNM85
DMBNM85	DN	Y-c[D-Pen-(2S,3R)-2-Me-(2')Nal-GSFC]KR-NH2
DMBNM85	HS	Investigative
DMBNM85	SN	CHEMBL413670; BDBM50064847
DMBNM85	PC	44312307
DMBNM85	MW	1199.5
DMBNM85	FM	C57H78N14O11S2
DMBNM85	IC	InChI=1S/C57H78N14O11S2/c1-32(36-21-20-35-14-7-8-15-37(35)28-36)46-54(81)64-29-45(74)65-43(30-72)52(79)68-42(27-33-12-5-4-6-13-33)51(78)69-44(53(80)67-41(16-9-10-24-58)50(77)66-40(48(60)75)17-11-25-63-56(61)62)31-83-84-57(2,3)47(55(82)70-46)71-49(76)39(59)26-34-18-22-38(73)23-19-34/h4-8,12-15,18-23,28,32,39-44,46-47,72-73H,9-11,16-17,24-27,29-31,58-59H2,1-3H3,(H2,60,75)(H,64,81)(H,65,74)(H,66,77)(H,67,80)(H,68,79)(H,69,78)(H,70,82)(H,71,76)(H4,61,62,63)/t32-,39-,40-,41-,42+,43-,44+,46-,47-/m0/s1
DMBNM85	CS	C[C@H]([C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC([C@H](C(=O)N1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)CC3=CC=CC=C3)CO)C4=CC5=CC=CC=C5C=C4
DMBNM85	IK	HWTDVIKHJPOWJP-WISPORKVSA-N
DMBNM85	IU	(4S,7R,10S,16S,19S)-N-[(2S)-6-amino-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]-19-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-10-(hydroxymethyl)-20,20-dimethyl-16-[(1S)-1-naphthalen-2-ylethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMBNM85	DE	Discovery agent

DME1BGO	ID	DME1BGO
DME1BGO	DN	Y-c[D-Pen-(2S,3S)-2-Me-(2')Nal-GSFC]KR-NH2
DME1BGO	HS	Investigative
DME1BGO	SN	CHEMBL414159; BDBM50064843
DME1BGO	PC	44312308
DME1BGO	MW	1199.5
DME1BGO	FM	C57H78N14O11S2
DME1BGO	IC	InChI=1S/C57H78N14O11S2/c1-32(36-21-20-35-14-7-8-15-37(35)28-36)46-54(81)64-29-45(74)65-43(30-72)52(79)68-42(27-33-12-5-4-6-13-33)51(78)69-44(53(80)67-41(16-9-10-24-58)50(77)66-40(48(60)75)17-11-25-63-56(61)62)31-83-84-57(2,3)47(55(82)70-46)71-49(76)39(59)26-34-18-22-38(73)23-19-34/h4-8,12-15,18-23,28,32,39-44,46-47,72-73H,9-11,16-17,24-27,29-31,58-59H2,1-3H3,(H2,60,75)(H,64,81)(H,65,74)(H,66,77)(H,67,80)(H,68,79)(H,69,78)(H,70,82)(H,71,76)(H4,61,62,63)/t32-,39+,40+,41+,42-,43+,44-,46+,47+/m1/s1
DME1BGO	CS	C[C@@H]([C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC([C@H](C(=O)N1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)CC3=CC=CC=C3)CO)C4=CC5=CC=CC=C5C=C4
DME1BGO	IK	HWTDVIKHJPOWJP-DRSDNMEYSA-N
DME1BGO	IU	(4S,7R,10S,16S,19S)-N-[(2S)-6-amino-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]-19-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-10-(hydroxymethyl)-20,20-dimethyl-16-[(1R)-1-naphthalen-2-ylethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DME1BGO	DE	Discovery agent

DMF7S54	ID	DMF7S54
DMF7S54	DN	Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2
DMF7S54	HS	Investigative
DMF7S54	SN	CHEMBL216490; Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2
DMF7S54	PC	44312580
DMF7S54	MW	1403.2
DMF7S54	FM	C52H72I2N14O12S2
DMF7S54	IC	InChI=1S/C52H72I2N14O12S2/c1-52(2)42(68-44(74)33(56)21-28-13-15-30(70)16-14-28)50(80)66-36(23-29-19-31(53)41(72)32(54)20-29)45(75)61-24-40(71)62-38(25-69)48(78)65-37(22-27-9-4-3-5-10-27)47(77)67-39(26-81-82-52)49(79)64-35(11-6-7-17-55)46(76)63-34(43(57)73)12-8-18-60-51(58)59/h3-5,9-10,13-16,19-20,33-39,42,69-70,72H,6-8,11-12,17-18,21-26,55-56H2,1-2H3,(H2,57,73)(H,61,75)(H,62,71)(H,63,76)(H,64,79)(H,65,78)(H,66,80)(H,67,77)(H,68,74)(H4,58,59,60)/t33-,34-,35-,36-,37+,38-,39+,42-/m0/s1
DMF7S54	CS	CC1([C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSS1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)CC2=CC=CC=C2)CO)CC3=CC(=C(C(=C3)I)O)I)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)C
DMF7S54	IK	ZHARLIJAVUCVJG-YLYTWGDESA-N
DMF7S54	IU	(4S,7R,10S,16S,19S)-N-[(2S)-6-amino-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]-19-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-16-[(4-hydroxy-3,5-diiodophenyl)methyl]-10-(hydroxymethyl)-20,20-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMF7S54	DE	Discovery agent

DMW1PSO	ID	DMW1PSO
DMW1PSO	DN	Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2
DMW1PSO	HS	Investigative
DMW1PSO	SN	CHEMBL436961; Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2
DMW1PSO	PC	44312363
DMW1PSO	MW	1277.3
DMW1PSO	FM	C52H73IN14O12S2
DMW1PSO	IC	InChI=1S/C52H73IN14O12S2/c1-52(2)42(67-44(73)33(55)22-29-13-16-31(69)17-14-29)50(79)65-36(24-30-15-18-40(70)32(53)21-30)45(74)60-25-41(71)61-38(26-68)48(77)64-37(23-28-9-4-3-5-10-28)47(76)66-39(27-80-81-52)49(78)63-35(11-6-7-19-54)46(75)62-34(43(56)72)12-8-20-59-51(57)58/h3-5,9-10,13-18,21,33-39,42,68-70H,6-8,11-12,19-20,22-27,54-55H2,1-2H3,(H2,56,72)(H,60,74)(H,61,71)(H,62,75)(H,63,78)(H,64,77)(H,65,79)(H,66,76)(H,67,73)(H4,57,58,59)/t33-,34-,35-,36-,37+,38-,39+,42-/m0/s1
DMW1PSO	CS	CC1([C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSS1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)CC2=CC=CC=C2)CO)CC3=CC(=C(C=C3)O)I)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)C
DMW1PSO	IK	NXLJKZAAHWHFCS-YLYTWGDESA-N
DMW1PSO	IU	(4S,7R,10S,16S,19S)-N-[(2S)-6-amino-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]-19-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-16-[(4-hydroxy-3-iodophenyl)methyl]-10-(hydroxymethyl)-20,20-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMW1PSO	DE	Discovery agent

DM2ILAH	ID	DM2ILAH
DM2ILAH	DN	Y-c[D-Pen-D-(2')Nal-GSFC]KR-NH2
DM2ILAH	HS	Investigative
DM2ILAH	SN	CHEMBL404595; BDBM50064829
DM2ILAH	PC	44312288
DM2ILAH	MW	1064.3
DM2ILAH	FM	C49H69N13O10S2
DM2ILAH	IC	InChI=1S/C49H69N13O10S2/c1-28(64)56-40-47(72)61-35(24-30-18-19-31-14-7-8-15-32(31)22-30)42(67)55-25-39(65)57-37(26-63)45(70)60-36(23-29-12-5-4-6-13-29)44(69)62-38(27-73-74-49(40,2)3)46(71)59-34(16-9-10-20-50)43(68)58-33(41(51)66)17-11-21-54-48(52)53/h4-8,12-15,18-19,22,33-38,40,63H,9-11,16-17,20-21,23-27,50H2,1-3H3,(H2,51,66)(H,55,67)(H,56,64)(H,57,65)(H,58,68)(H,59,71)(H,60,70)(H,61,72)(H,62,69)(H4,52,53,54)/t33-,34-,35+,36+,37-,38+,40-/m0/s1
DM2ILAH	CS	CC(=O)N[C@H]1C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC1(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)CC2=CC=CC=C2)CO)CC3=CC4=CC=CC=C4C=C3
DM2ILAH	IK	RLMDVJMHWZVFEI-LNZYVXNRSA-N
DM2ILAH	IU	(4S,7R,10S,16R,19S)-19-acetamido-N-[(2S)-6-amino-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]-7-benzyl-10-(hydroxymethyl)-20,20-dimethyl-16-(naphthalen-2-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM2ILAH	DE	Discovery agent

DM5LYKW	ID	DM5LYKW
DM5LYKW	DN	YGGWL-NH2
DM5LYKW	HS	Investigative
DM5LYKW	SN	CHEMBL504973; YGGWL-NH2
DM5LYKW	DT	Small molecular drug
DM5LYKW	PC	44577308
DM5LYKW	MW	593.7
DM5LYKW	FM	C30H39N7O6
DM5LYKW	IC	InChI=1S/C30H39N7O6/c1-17(2)11-24(28(32)41)37-30(43)25(13-19-14-33-23-6-4-3-5-21(19)23)36-27(40)16-34-26(39)15-35-29(42)22(31)12-18-7-9-20(38)10-8-18/h3-10,14,17,22,24-25,33,38H,11-13,15-16,31H2,1-2H3,(H2,32,41)(H,34,39)(H,35,42)(H,36,40)(H,37,43)/t22-,24-,25-/m0/s1
DM5LYKW	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM5LYKW	IK	GNLQCAGQAYEHAM-HVCNVCAESA-N
DM5LYKW	IU	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanamide
DM5LYKW	DE	Discovery agent

DMV89B4	ID	DMV89B4
DMV89B4	DN	YGRKKRRQRRR-KLSSIESDV
DMV89B4	HS	Investigative
DMV89B4	SN	UNII-D45TI2TWMA; D45TI2TWMA; 500992-11-0; L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-alpha-glutamyl-L-seryl-L-alpha-aspartyl-L-valine; L-Valine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-alpha-glutamyl-L-seryl-L-alpha-aspartyl-
DMV89B4	PC	91935893
DMV89B4	MW	2518.9
DMV89B4	FM	C105H188N42O30
DMV89B4	IC	InChI=1S/C105H188N42O30/c1-7-55(6)80(98(175)140-69(34-36-77(154)155)92(169)143-72(50-148)95(172)142-71(48-78(156)157)94(171)146-79(54(4)5)99(176)177)147-97(174)74(52-150)145-96(173)73(51-149)144-93(170)70(46-53(2)3)141-90(167)62(22-10-13-39-108)133-85(162)63(24-15-41-124-101(113)114)135-87(164)65(26-17-43-126-103(117)118)136-88(165)66(27-18-44-127-104(119)120)138-91(168)68(33-35-75(110)152)139-89(166)67(28-19-45-128-105(121)122)137-86(163)64(25-16-42-125-102(115)116)134-84(161)61(21-9-12-38-107)132-83(160)60(20-8-11-37-106)131-82(159)59(23-14-40-123-100(111)112)130-76(153)49-129-81(158)58(109)47-56-29-31-57(151)32-30-56/h29-32,53-55,58-74,79-80,148-151H,7-28,33-52,106-109H2,1-6H3,(H2,110,152)(H,129,158)(H,130,153)(H,131,159)(H,132,160)(H,133,162)(H,134,161)(H,135,164)(H,136,165)(H,137,163)(H,138,168)(H,139,166)(H,140,175)(H,141,167)(H,142,172)(H,143,169)(H,144,170)(H,145,173)(H,146,171)(H,147,174)(H,154,155)(H,156,157)(H,176,177)(H4,111,112,123)(H4,113,114,124)(H4,115,116,125)(H4,117,118,126)(H4,119,120,127)(H4,121,122,128)/t55-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,79-,80-/m0/s1
DMV89B4	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N
DMV89B4	IK	XWQVQFBTSBCKLI-FKXNDIMNSA-N
DMV89B4	IU	(4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMV89B4	DE	Discovery agent

DMQ2EYJ	ID	DMQ2EYJ
DMQ2EYJ	DN	YGWFL-NH2
DMQ2EYJ	HS	Investigative
DMQ2EYJ	SN	CHEMBL455502; YGWFL-NH2
DMQ2EYJ	DT	Small molecular drug
DMQ2EYJ	PC	44577349
DMQ2EYJ	MW	683.8
DMQ2EYJ	FM	C37H45N7O6
DMQ2EYJ	IC	InChI=1S/C37H45N7O6/c1-22(2)16-30(34(39)47)43-36(49)31(18-23-8-4-3-5-9-23)44-37(50)32(19-25-20-40-29-11-7-6-10-27(25)29)42-33(46)21-41-35(48)28(38)17-24-12-14-26(45)15-13-24/h3-15,20,22,28,30-32,40,45H,16-19,21,38H2,1-2H3,(H2,39,47)(H,41,48)(H,42,46)(H,43,49)(H,44,50)/t28-,30-,31-,32-/m0/s1
DMQ2EYJ	CS	CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMQ2EYJ	IK	VGMSMMKQRJOPQL-MCEBTLFFSA-N
DMQ2EYJ	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanamide
DMQ2EYJ	DE	Discovery agent

DM6FEMV	ID	DM6FEMV
DM6FEMV	DN	YH-1238
DM6FEMV	HS	Investigative
DM6FEMV	SN	195889-55-5
DM6FEMV	DE	Discovery agent

DML1JY4	ID	DML1JY4
DML1JY4	DN	YIL781
DML1JY4	HS	Investigative
DML1JY4	SN	YIL-781; YIL 781
DML1JY4	DT	Small molecular drug
DML1JY4	PC	23631116
DML1JY4	MW	409.5
DML1JY4	FM	C24H28FN3O2
DML1JY4	IC	InChI=1S/C24H28FN3O2/c1-16(2)27-12-4-5-18(14-27)15-28-17(3)26-23-11-10-21(13-22(23)24(28)29)30-20-8-6-19(25)7-9-20/h6-11,13,16,18H,4-5,12,14-15H2,1-3H3/t18-/m0/s1
DML1JY4	CS	CC1=NC2=C(C=C(C=C2)OC3=CC=C(C=C3)F)C(=O)N1C[C@H]4CCCN(C4)C(C)C
DML1JY4	IK	FRKXOBMDEXCHHD-SFHVURJKSA-N
DML1JY4	IU	6-(4-fluorophenoxy)-2-methyl-3-[[(3S)-1-propan-2-ylpiperidin-3-yl]methyl]quinazolin-4-one
DML1JY4	DE	Discovery agent

DMU0NHX	ID	DMU0NHX
DMU0NHX	DN	YK-3237
DMU0NHX	HS	Investigative
DMU0NHX	SN	Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University
DMU0NHX	CP	Georgetown University
DMU0NHX	DE	Solid tumour/cancer

DMPYM3J	ID	DMPYM3J
DMPYM3J	DN	YM 218
DMPYM3J	HS	Investigative
DMPYM3J	SN	YM-218
DMPYM3J	DT	Small molecular drug
DMPYM3J	PC	9917025
DMPYM3J	MW	616.7
DMPYM3J	FM	C35H38F2N4O4
DMPYM3J	IC	InChI=1S/C35H38F2N4O4/c1-24-28(15-22-45-24)33(43)38-26-11-9-25(10-12-26)34(44)41-21-16-35(36,37)30(29-7-3-4-8-31(29)41)23-32(42)40-19-13-27(14-20-40)39-17-5-2-6-18-39/h3-4,7-12,15,22-23,27H,2,5-6,13-14,16-21H2,1H3,(H,38,43)/b30-23-
DMPYM3J	CS	CC1=C(C=CO1)C(=O)NC2=CC=C(C=C2)C(=O)N3CCC(/C(=C\\C(=O)N4CCC(CC4)N5CCCCC5)/C6=CC=CC=C63)(F)F
DMPYM3J	IK	VDUUABBYYOPFAW-WMMMYUQOSA-N
DMPYM3J	IU	N-[4-[(5Z)-4,4-difluoro-5-[2-oxo-2-(4-piperidin-1-ylpiperidin-1-yl)ethylidene]-2,3-dihydro-1-benzazepine-1-carbonyl]phenyl]-2-methylfuran-3-carboxamide
DMPYM3J	CA	CAS 425375-94-6
DMPYM3J	DE	Discovery agent

DM5BFL4	ID	DM5BFL4
DM5BFL4	DN	YM 471
DM5BFL4	HS	Investigative
DM5BFL4	SN	YM-471
DM5BFL4	DT	Small molecular drug
DM5BFL4	PC	9810140
DM5BFL4	MW	648.7
DM5BFL4	FM	C39H38F2N4O3
DM5BFL4	IC	InChI=1S/C39H38F2N4O3/c1-43(2)30-20-23-44(24-21-30)36(46)26-34-33-14-8-9-15-35(33)45(25-22-39(34,40)41)38(48)28-16-18-29(19-17-28)42-37(47)32-13-7-6-12-31(32)27-10-4-3-5-11-27/h3-19,26,30H,20-25H2,1-2H3,(H,42,47)/b34-26-
DM5BFL4	CS	CN(C)C1CCN(CC1)C(=O)/C=C\\2/C3=CC=CC=C3N(CCC2(F)F)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
DM5BFL4	IK	ICRPTZMWRJGNQI-CLIDGEQKSA-N
DM5BFL4	IU	N-[4-[(5Z)-5-[2-[4-(dimethylamino)piperidin-1-yl]-2-oxoethylidene]-4,4-difluoro-2,3-dihydro-1-benzazepine-1-carbonyl]phenyl]-2-phenylbenzamide
DM5BFL4	DE	Discovery agent

DMMW3L1	ID	DMMW3L1
DMMW3L1	DN	YM-175735
DMMW3L1	HS	Investigative
DMMW3L1	SN	YM-175735; CHEMBL202990; BDBM18634; (2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,4-difluorophenyl)-2,5-dimethylpiperazine-1-carboxamide
DMMW3L1	DT	Small molecular drug
DMMW3L1	PC	11178122
DMMW3L1	MW	438.4
DMMW3L1	FM	C21H19F5N4O
DMMW3L1	IC	InChI=1S/C21H19F5N4O/c1-12-11-30(20(31)28-19-6-4-15(22)7-18(19)23)13(2)10-29(12)16-5-3-14(9-27)17(8-16)21(24,25)26/h3-8,12-13H,10-11H2,1-2H3,(H,28,31)/t12-,13+/m0/s1
DMMW3L1	CS	C[C@@H]1CN([C@H](CN1C(=O)NC2=C(C=C(C=C2)F)F)C)C3=CC(=C(C=C3)C#N)C(F)(F)F
DMMW3L1	IK	WTZSNQXSDYHCRV-QWHCGFSZSA-N
DMMW3L1	IU	(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,4-difluorophenyl)-2,5-dimethylpiperazine-1-carboxamide
DMMW3L1	DE	Discovery agent

DM3IOLR	ID	DM3IOLR
DM3IOLR	DN	YM-202074
DM3IOLR	HS	Investigative
DM3IOLR	SN	SCHEMBL658904; GTPL6361
DM3IOLR	DT	Small molecular drug
DM3IOLR	PC	10409562
DM3IOLR	MW	414.6
DM3IOLR	FM	C22H30N4O2S
DM3IOLR	IC	InChI=1S/C22H30N4O2S/c1-24(11-12-28-3)14-16-9-10-19-18(13-16)23-22-26(19)15-20(29-22)21(27)25(2)17-7-5-4-6-8-17/h9-10,13,15,17H,4-8,11-12,14H2,1-3H3
DM3IOLR	CS	CN(CCOC)CC1=CC2=C(C=C1)N3C=C(SC3=N2)C(=O)N(C)C4CCCCC4
DM3IOLR	IK	YDAIWUAWYILYPH-UHFFFAOYSA-N
DM3IOLR	IU	N-cyclohexyl-6-[[2-methoxyethyl(methyl)amino]methyl]-N-methyl-[1,3]thiazolo[3,2-a]benzimidazole-2-carboxamide
DM3IOLR	DE	Discovery agent

DMUYDXT	ID	DMUYDXT
DMUYDXT	DN	YM298198
DMUYDXT	HS	Investigative
DMUYDXT	SN	7-Amino-N-cyclohexyl-N,1-dimethyl-[1,3]thiazolo[3,2-a]benzimidazole-2-carboxamide; YM-298198; 748758-45-4; [3H]YM298198; [3H]-YM298198; SCHEMBL3371668; GTPL1389; GTPL5392; CHEMBL1517556; KS-00002WSU; CHEBI:93046; MolPort-016-581-183; ZINC11687445; AKOS015994566; ES-0033; NCGC00161412-01; L023814; BRD-K59650319-003-01-7; 7-amino-N-cyclohexyl-N,1-dimethyl-[1,3]thiazolo[3,2-a]benzimidazole-2-carboxamide;  YM298198
DMUYDXT	DT	Small molecular drug
DMUYDXT	PC	9819432
DMUYDXT	MW	342.5
DMUYDXT	FM	C18H22N4OS
DMUYDXT	IC	InChI=1S/C18H22N4OS/c1-11-16(17(23)21(2)13-6-4-3-5-7-13)24-18-20-14-9-8-12(19)10-15(14)22(11)18/h8-10,13H,3-7,19H2,1-2H3
DMUYDXT	CS	CC1=C(SC2=NC3=C(N12)C=C(C=C3)N)C(=O)N(C)C4CCCCC4
DMUYDXT	IK	KCBXOMYXOBVLED-UHFFFAOYSA-N
DMUYDXT	IU	7-amino-N-cyclohexyl-N,1-dimethyl-[1,3]thiazolo[3,2-a]benzimidazole-2-carboxamide
DMUYDXT	CA	CAS 748758-45-4
DMUYDXT	CB	CHEBI:93046
DMUYDXT	DE	Discovery agent

DM38F9T	ID	DM38F9T
DM38F9T	DN	YM-348
DM38F9T	HS	Investigative
DM38F9T	SN	YM348; YM-348; YM 348; 372163-84-3; CHEMBL407909; (2S)-1-(7-ethylfuro[2,3-g]indazol-1-yl)propan-2-amine; (S)-2-(7-Ethyl-1H-furo(2,3-g)indazol-1-yl)-1-methylethylamine; (S)-2-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine; AC1MIIFB; GTPL230; SCHEMBL1981665; DTXSID50190708; BDBM50375450; HY-100330; LS-193532; CS-0018481; 1H-Furo(2,3-g)indazole-1-ethanamine, 7-ethyl-alpha-methyl-, (S)-; 1H-Furo(2,3-g)indazole-1-ethanamine, 7-ethyl-alpha-methyl-, (alphaS)-
DM38F9T	DT	Small molecular drug
DM38F9T	PC	3045225
DM38F9T	MW	243.3
DM38F9T	FM	C14H17N3O
DM38F9T	IC	InChI=1S/C14H17N3O/c1-3-11-6-12-13(18-11)5-4-10-7-16-17(14(10)12)8-9(2)15/h4-7,9H,3,8,15H2,1-2H3/t9-/m0/s1
DM38F9T	CS	CCC1=CC2=C(O1)C=CC3=C2N(N=C3)C[C@H](C)N
DM38F9T	IK	QLOOWOVVZLBYHU-VIFPVBQESA-N
DM38F9T	IU	(2S)-1-(7-ethylfuro[2,3-g]indazol-1-yl)propan-2-amine
DM38F9T	CA	CAS 372163-84-3
DM38F9T	DE	Discovery agent

DMXRZ6N	ID	DMXRZ6N
DMXRZ6N	DN	YM-35278
DMXRZ6N	HS	Investigative
DMXRZ6N	SN	YM-35278; CHEMBL506235
DMXRZ6N	DT	Small molecular drug
DMXRZ6N	PC	44520886
DMXRZ6N	MW	628.7
DMXRZ6N	FM	C38H30F2N4O3
DMXRZ6N	IC	InChI=1S/C38H30F2N4O3/c39-38(40)21-23-44(34-16-7-6-15-32(34)33(38)24-35(45)42-25-29-12-8-9-22-41-29)37(47)27-17-19-28(20-18-27)43-36(46)31-14-5-4-13-30(31)26-10-2-1-3-11-26/h1-20,22,24H,21,23,25H2,(H,42,45)(H,43,46)/b33-24-
DMXRZ6N	CS	C1CN(C2=CC=CC=C2/C(=C/C(=O)NCC3=CC=CC=N3)/C1(F)F)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
DMXRZ6N	IK	OPEZXZINWZCBQD-GIBOGKFOSA-N
DMXRZ6N	IU	N-[4-[(5Z)-4,4-difluoro-5-[2-oxo-2-(pyridin-2-ylmethylamino)ethylidene]-2,3-dihydro-1-benzazepine-1-carbonyl]phenyl]-2-phenylbenzamide
DMXRZ6N	DE	Discovery agent

DMDOR2L	ID	DMDOR2L
DMDOR2L	DN	YM44778
DMDOR2L	HS	Investigative
DMDOR2L	SN	YM-44778
DMDOR2L	DT	Small molecular drug
DMDOR2L	PC	9852373
DMDOR2L	MW	640.6
DMDOR2L	FM	C34H39Cl2N3O5
DMDOR2L	IC	InChI=1S/C34H39Cl2N3O5/c1-38(33(41)25-18-29(42-2)32(44-4)30(19-25)43-3)21-24(22-9-10-27(35)28(36)17-22)11-14-39-15-12-34(13-16-39)26-8-6-5-7-23(26)20-31(40)37-34/h5-10,17-19,24H,11-16,20-21H2,1-4H3,(H,37,40)
DMDOR2L	CS	CN(CC(CCN1CCC2(CC1)C3=CC=CC=C3CC(=O)N2)C4=CC(=C(C=C4)Cl)Cl)C(=O)C5=CC(=C(C(=C5)OC)OC)OC
DMDOR2L	IK	RMRHFQVHSFCBEO-UHFFFAOYSA-N
DMDOR2L	IU	N-[2-(3,4-dichlorophenyl)-4-(3-oxospiro[2,4-dihydroisoquinoline-1,4'-piperidine]-1'-yl)butyl]-3,4,5-trimethoxy-N-methylbenzamide
DMDOR2L	DE	Discovery agent

DM73AEL	ID	DM73AEL
DM73AEL	DN	YM44781
DM73AEL	HS	Investigative
DM73AEL	SN	YM-44781; YM 44781
DM73AEL	DT	Small molecular drug
DM73AEL	PC	10483085
DM73AEL	MW	568.5
DM73AEL	FM	C31H32Cl2FN3O2
DM73AEL	IC	InChI=1S/C31H32Cl2FN3O2/c1-36(30(39)21-6-9-25(34)10-7-21)20-24(22-8-11-27(32)28(33)18-22)12-15-37-16-13-31(14-17-37)26-5-3-2-4-23(26)19-29(38)35-31/h2-11,18,24H,12-17,19-20H2,1H3,(H,35,38)
DM73AEL	CS	CN(CC(CCN1CCC2(CC1)C3=CC=CC=C3CC(=O)N2)C4=CC(=C(C=C4)Cl)Cl)C(=O)C5=CC=C(C=C5)F
DM73AEL	IK	MIXOPBNZLJBQJH-UHFFFAOYSA-N
DM73AEL	IU	N-[2-(3,4-dichlorophenyl)-4-(3-oxospiro[2,4-dihydroisoquinoline-1,4'-piperidine]-1'-yl)butyl]-4-fluoro-N-methylbenzamide
DM73AEL	DE	Discovery agent

DMTYSUN	ID	DMTYSUN
DMTYSUN	DN	YM49598
DMTYSUN	HS	Investigative
DMTYSUN	SN	YM-49598
DMTYSUN	DT	Small molecular drug
DMTYSUN	PC	10327625
DMTYSUN	MW	608.7
DMTYSUN	FM	C36H45Cl2N2O2+
DMTYSUN	IC	InChI=1S/C36H45Cl2N2O2/c1-27(2)42-32-12-7-9-28(23-32)24-35(41)39-19-8-17-36(26-39,31-13-14-33(37)34(38)25-31)18-22-40(3)20-15-30(16-21-40)29-10-5-4-6-11-29/h4-7,9-14,23,25,27,30H,8,15-22,24,26H2,1-3H3/q+1
DMTYSUN	CS	CC(C)OC1=CC=CC(=C1)CC(=O)N2CCCC(C2)(CC[N+]3(CCC(CC3)C4=CC=CC=C4)C)C5=CC(=C(C=C5)Cl)Cl
DMTYSUN	IK	QRSSYNAUQYYMPH-UHFFFAOYSA-N
DMTYSUN	IU	1-[3-(3,4-dichlorophenyl)-3-[2-(1-methyl-4-phenylpiperidin-1-ium-1-yl)ethyl]piperidin-1-yl]-2-(3-propan-2-yloxyphenyl)ethanone
DMTYSUN	DE	Discovery agent

DMMCXWQ	ID	DMMCXWQ
DMMCXWQ	DN	YM-75440
DMMCXWQ	HS	Investigative
DMMCXWQ	SN	YM75440; YM 75440
DMMCXWQ	DT	Small molecular drug
DMMCXWQ	PC	11372147
DMMCXWQ	MW	370.5
DMMCXWQ	FM	C25H26N2O
DMMCXWQ	IC	InChI=1S/C25H26N2O/c1-2-9-22-24(28-17-8-16-26-18-19-10-4-3-5-11-19)15-14-21-20-12-6-7-13-23(20)27-25(21)22/h2-7,10-15,26-27H,1,8-9,16-18H2
DMMCXWQ	CS	C=CCC1=C(C=CC2=C1NC3=CC=CC=C23)OCCCNCC4=CC=CC=C4
DMMCXWQ	IK	UPGXTVJBIFAVHT-UHFFFAOYSA-N
DMMCXWQ	IU	N-benzyl-3-[(1-prop-2-enyl-9H-carbazol-2-yl)oxy]propan-1-amine
DMMCXWQ	DE	Discovery agent

DML5DU0	ID	DML5DU0
DML5DU0	DN	YM90709
DML5DU0	HS	Investigative
DML5DU0	SN	YM-90709; YM 90709
DML5DU0	DT	Small molecular drug
DML5DU0	PC	1103147
DML5DU0	MW	359.4
DML5DU0	FM	C22H21N3O2
DML5DU0	IC	InChI=1S/C22H21N3O2/c1-22(2)12-13-9-19(26-3)20(27-4)10-14(13)18-11-17-21(25(18)22)24-16-8-6-5-7-15(16)23-17/h5-11H,12H2,1-4H3
DML5DU0	CS	CC1(CC2=CC(=C(C=C2C3=CC4=NC5=CC=CC=C5N=C4N31)OC)OC)C
DML5DU0	IK	HIXSPVQXXDULHS-UHFFFAOYSA-N
DML5DU0	IU	16,17-dimethoxy-21,21-dimethyl-1,3,10-triazapentacyclo[11.8.0.02,11.04,9.014,19]henicosa-2,4,6,8,10,12,14,16,18-nonaene
DML5DU0	CA	CAS 163769-88-8
DML5DU0	CB	CHEBI:92125
DML5DU0	DE	Discovery agent

DMPU5TC	ID	DMPU5TC
DMPU5TC	DN	YM-96765
DMPU5TC	HS	Investigative
DMPU5TC	SN	SCHEMBL7334410
DMPU5TC	DT	Small molecular drug
DMPU5TC	PC	102207029
DMPU5TC	MW	537.6
DMPU5TC	FM	C26H31N7O4S
DMPU5TC	IC	InChI=1S/C26H31N7O4S/c27-25(28)20-5-4-19-3-2-18(14-21(19)15-20)16-33(38(36,37)17-24(34)35)23-8-6-22(7-9-23)31-10-1-11-32(13-12-31)26(29)30/h2-9,14-15H,1,10-13,16-17H2,(H3,27,28)(H3,29,30)(H,34,35)
DMPU5TC	CS	C1CN(CCN(C1)C(=N)N)C2=CC=C(C=C2)N(CC3=CC4=C(C=C3)C=CC(=C4)C(=N)N)S(=O)(=O)CC(=O)O
DMPU5TC	IK	WDFHCLOWHSYIFO-UHFFFAOYSA-N
DMPU5TC	IU	2-[[4-(4-carbamimidoyl-1,4-diazepan-1-yl)phenyl]-[(7-carbamimidoylnaphthalen-2-yl)methyl]sulfamoyl]acetic acid
DMPU5TC	DE	Discovery agent

DMC3DK5	ID	DMC3DK5
DMC3DK5	DN	YPAA-NH2
DMC3DK5	HS	Investigative
DMC3DK5	SN	CHEMBL466147; YPAA-NH2
DMC3DK5	DT	Small molecular drug
DMC3DK5	PC	44577307
DMC3DK5	MW	419.5
DMC3DK5	FM	C20H29N5O5
DMC3DK5	IC	InChI=1S/C20H29N5O5/c1-11(17(22)27)23-18(28)12(2)24-19(29)16-4-3-9-25(16)20(30)15(21)10-13-5-7-14(26)8-6-13/h5-8,11-12,15-16,26H,3-4,9-10,21H2,1-2H3,(H2,22,27)(H,23,28)(H,24,29)/t11-,12-,15-,16-/m0/s1
DMC3DK5	CS	C[C@@H](C(=O)N)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)N
DMC3DK5	IK	UTONSZTXKQBYQC-APYUEPQZSA-N
DMC3DK5	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMC3DK5	DE	Discovery agent

DMOTHAC	ID	DMOTHAC
DMOTHAC	DN	YPWA-NH2
DMOTHAC	HS	Investigative
DMOTHAC	SN	CHEMBL512955; YPWA-NH2
DMOTHAC	DT	Small molecular drug
DMOTHAC	PC	44577305
DMOTHAC	MW	534.6
DMOTHAC	FM	C28H34N6O5
DMOTHAC	IC	InChI=1S/C28H34N6O5/c1-16(25(30)36)32-26(37)23(14-18-15-31-22-6-3-2-5-20(18)22)33-27(38)24-7-4-12-34(24)28(39)21(29)13-17-8-10-19(35)11-9-17/h2-3,5-6,8-11,15-16,21,23-24,31,35H,4,7,12-14,29H2,1H3,(H2,30,36)(H,32,37)(H,33,38)/t16-,21-,23-,24-/m0/s1
DMOTHAC	CS	C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMOTHAC	IK	FMYKJNQXBIJPPV-DFQATESRSA-N
DMOTHAC	IU	(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMOTHAC	DE	Discovery agent

DMXOJIB	ID	DMXOJIB
DMXOJIB	DN	YRFB
DMXOJIB	HS	Investigative
DMXOJIB	SN	CHEMBL215513; YRFB
DMXOJIB	DT	Small molecular drug
DMXOJIB	PC	44416268
DMXOJIB	MW	555.6
DMXOJIB	FM	C27H37N7O6
DMXOJIB	IC	InChI=1S/C27H37N7O6/c28-20(15-18-8-10-19(35)11-9-18)24(38)33-21(7-4-13-32-27(29)30)26(40)34-22(16-17-5-2-1-3-6-17)25(39)31-14-12-23(36)37/h1-3,5-6,8-11,20-22,35H,4,7,12-16,28H2,(H,31,39)(H,33,38)(H,34,40)(H,36,37)(H4,29,30,32)/t20-,21-,22-/m0/s1
DMXOJIB	CS	C1=CC=C(C=C1)C[C@@H](C(=O)NCCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMXOJIB	IK	XNBYETXMULNTPG-FKBYEOEOSA-N
DMXOJIB	IU	3-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]propanoic acid
DMXOJIB	DE	Discovery agent

DMTURZ6	ID	DMTURZ6
DMTURZ6	DN	YS110 mAb clone
DMTURZ6	HS	Investigative
DMTURZ6	SN	YS110
DMTURZ6	TC	Antiviral Agents
DMTURZ6	DT	Monoclonal antibody
DMTURZ6	DE	Middle East Respiratory Syndrome (MERS)

DM24LNB	ID	DM24LNB
DM24LNB	DN	YVAD
DM24LNB	HS	Investigative
DM24LNB	DT	Small molecular drug
DM24LNB	PC	9847365
DM24LNB	MW	466.5
DM24LNB	FM	C21H30N4O8
DM24LNB	IC	InChI=1S/C21H30N4O8/c1-10(2)17(25-19(30)14(22)8-12-4-6-13(26)7-5-12)20(31)23-11(3)18(29)24-15(21(32)33)9-16(27)28/h4-7,10-11,14-15,17,26H,8-9,22H2,1-3H3,(H,23,31)(H,24,29)(H,25,30)(H,27,28)(H,32,33)/t11-,14-,15-,17-/m0/s1
DM24LNB	CS	C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
DM24LNB	IK	XVZUMQAMCYSUMS-SIUGBPQLSA-N
DM24LNB	IU	(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]butanedioic acid
DM24LNB	DE	Discovery agent

DMFT51X	ID	DMFT51X
DMFT51X	DN	Z 944
DMFT51X	HS	Investigative
DMFT51X	SN	Z-944
DMFT51X	PC	44540045
DMFT51X	MW	383.9
DMFT51X	FM	C19H27ClFN3O2
DMFT51X	IC	InChI=1S/C19H27ClFN3O2/c1-19(2,3)23-17(25)12-24-6-4-13(5-7-24)11-22-18(26)14-8-15(20)10-16(21)9-14/h8-10,13H,4-7,11-12H2,1-3H3,(H,22,26)(H,23,25)
DMFT51X	CS	CC(C)(C)NC(=O)CN1CCC(CC1)CNC(=O)C2=CC(=CC(=C2)Cl)F
DMFT51X	IK	JOCLITFYIMJMNK-UHFFFAOYSA-N
DMFT51X	IU	N-[[1-[2-(tert-butylamino)-2-oxoethyl]piperidin-4-yl]methyl]-3-chloro-5-fluorobenzamide
DMFT51X	CA	CAS 1199236-64-0
DMFT51X	DE	Discovery agent

DMMP0DT	ID	DMMP0DT
DMMP0DT	DN	Z-Ala-Leu-His-Agly-Ile-Val-OMe
DMMP0DT	HS	Investigative
DMMP0DT	DT	Small molecular drug
DMMP0DT	PC	44355524
DMMP0DT	MW	757.9
DMMP0DT	FM	C36H55N9O9
DMMP0DT	IC	InChI=1S/C36H55N9O9/c1-9-22(6)29(33(49)42-28(21(4)5)34(50)53-8)43-35(51)45-44-32(48)27(16-25-17-37-19-38-25)41-31(47)26(15-20(2)3)40-30(46)23(7)39-36(52)54-18-24-13-11-10-12-14-24/h10-14,17,19-23,26-29H,9,15-16,18H2,1-8H3,(H,37,38)(H,39,52)(H,40,46)(H,41,47)(H,42,49)(H,44,48)(H2,43,45,51)
DMMP0DT	CS	CCC(C)C(C(=O)NC(C(C)C)C(=O)OC)NC(=O)NNC(=O)C(CC1=CN=CN1)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)OCC2=CC=CC=C2
DMMP0DT	IK	IVHANADPEKMLMO-UHFFFAOYSA-N
DMMP0DT	IU	methyl 2-[[2-[[[3-(1H-imidazol-5-yl)-2-[[4-methyl-2-[2-(phenylmethoxycarbonylamino)propanoylamino]pentanoyl]amino]propanoyl]amino]carbamoylamino]-3-methylpentanoyl]amino]-3-methylbutanoate
DMMP0DT	DE	Discovery agent

DM7IGRT	ID	DM7IGRT
DM7IGRT	DN	Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl
DM7IGRT	HS	Investigative
DM7IGRT	DT	Small molecular drug
DM7IGRT	PC	44355522
DM7IGRT	MW	809
DM7IGRT	FM	C42H64N8O8
DM7IGRT	IC	InChI=1S/C42H64N8O8/c1-10-28(8)35(40(55)47-34(27(6)7)39(54)43-23-30-17-13-11-14-18-30)48-41(56)50-49-38(53)33(22-26(4)5)46-37(52)32(21-25(2)3)45-36(51)29(9)44-42(57)58-24-31-19-15-12-16-20-31/h11-20,25-29,32-35H,10,21-24H2,1-9H3,(H,43,54)(H,44,57)(H,45,51)(H,46,52)(H,47,55)(H,49,53)(H2,48,50,56)
DM7IGRT	CS	CCC(C)C(C(=O)NC(C(C)C)C(=O)NCC1=CC=CC=C1)NC(=O)NNC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)OCC2=CC=CC=C2
DM7IGRT	IK	XSXSYDVWNYPPNF-UHFFFAOYSA-N
DM7IGRT	IU	benzyl N-[1-[[1-[[1-[2-[[1-[[1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]carbamate
DM7IGRT	DE	Discovery agent

DMVEUOL	ID	DMVEUOL
DMVEUOL	DN	Z-Ala-Leu-lle-Agly-Ile-Val-OMe
DMVEUOL	HS	Investigative
DMVEUOL	DT	Small molecular drug
DMVEUOL	PC	44355206
DMVEUOL	MW	733.9
DMVEUOL	FM	C36H59N7O9
DMVEUOL	IC	InChI=1S/C36H59N7O9/c1-11-22(7)28(32(46)39-27(21(5)6)34(48)51-10)41-35(49)43-42-33(47)29(23(8)12-2)40-31(45)26(18-20(3)4)38-30(44)24(9)37-36(50)52-19-25-16-14-13-15-17-25/h13-17,20-24,26-29H,11-12,18-19H2,1-10H3,(H,37,50)(H,38,44)(H,39,46)(H,40,45)(H,42,47)(H2,41,43,49)
DMVEUOL	CS	CCC(C)C(C(=O)NNC(=O)NC(C(C)CC)C(=O)NC(C(C)C)C(=O)OC)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)OCC1=CC=CC=C1
DMVEUOL	IK	HGMOIJOFHZHWKH-UHFFFAOYSA-N
DMVEUOL	IU	methyl 3-methyl-2-[[3-methyl-2-[[[3-methyl-2-[[4-methyl-2-[2-(phenylmethoxycarbonylamino)propanoylamino]pentanoyl]amino]pentanoyl]amino]carbamoylamino]pentanoyl]amino]butanoate
DMVEUOL	DE	Discovery agent

DM3209T	ID	DM3209T
DM3209T	DN	Z-Ala-Leu-Nal-Agly-Ile-Val-OMe
DM3209T	HS	Investigative
DM3209T	DT	Small molecular drug
DM3209T	PC	44355523
DM3209T	MW	818
DM3209T	FM	C43H59N7O9
DM3209T	IC	InChI=1S/C43H59N7O9/c1-9-27(6)36(40(54)47-35(26(4)5)41(55)58-8)48-42(56)50-49-39(53)34(23-31-20-15-19-30-18-13-14-21-32(30)31)46-38(52)33(22-25(2)3)45-37(51)28(7)44-43(57)59-24-29-16-11-10-12-17-29/h10-21,25-28,33-36H,9,22-24H2,1-8H3,(H,44,57)(H,45,51)(H,46,52)(H,47,54)(H,49,53)(H2,48,50,56)
DM3209T	CS	CCC(C)C(C(=O)NC(C(C)C)C(=O)OC)NC(=O)NNC(=O)C(CC1=CC=CC2=CC=CC=C21)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)OCC3=CC=CC=C3
DM3209T	IK	KMJURIDKPLGXEZ-UHFFFAOYSA-N
DM3209T	IU	methyl 3-methyl-2-[[3-methyl-2-[[[2-[[4-methyl-2-[2-(phenylmethoxycarbonylamino)propanoylamino]pentanoyl]amino]-3-naphthalen-1-ylpropanoyl]amino]carbamoylamino]pentanoyl]amino]butanoate
DM3209T	DE	Discovery agent

DML16BT	ID	DML16BT
DML16BT	DN	Z-Ala-Leu-Phe-Agly-Ile-Val-OMe
DML16BT	HS	Investigative
DML16BT	DT	Small molecular drug
DML16BT	PC	44355205
DML16BT	MW	767.9
DML16BT	FM	C39H57N7O9
DML16BT	IC	InChI=1S/C39H57N7O9/c1-9-25(6)32(36(50)43-31(24(4)5)37(51)54-8)44-38(52)46-45-35(49)30(21-27-16-12-10-13-17-27)42-34(48)29(20-23(2)3)41-33(47)26(7)40-39(53)55-22-28-18-14-11-15-19-28/h10-19,23-26,29-32H,9,20-22H2,1-8H3,(H,40,53)(H,41,47)(H,42,48)(H,43,50)(H,45,49)(H2,44,46,52)
DML16BT	CS	CCC(C)C(C(=O)NC(C(C)C)C(=O)OC)NC(=O)NNC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)OCC2=CC=CC=C2
DML16BT	IK	ONHOINLCWRTXCR-UHFFFAOYSA-N
DML16BT	IU	methyl 3-methyl-2-[[3-methyl-2-[[[2-[[4-methyl-2-[2-(phenylmethoxycarbonylamino)propanoylamino]pentanoyl]amino]-3-phenylpropanoyl]amino]carbamoylamino]pentanoyl]amino]butanoate
DML16BT	DE	Discovery agent

DMIB5O3	ID	DMIB5O3
DMIB5O3	DN	Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe
DMIB5O3	HS	Investigative
DMIB5O3	DT	Small molecular drug
DMIB5O3	PC	44355267
DMIB5O3	MW	797.9
DMIB5O3	FM	C40H59N7O10
DMIB5O3	IC	InChI=1S/C40H59N7O10/c1-10-25(6)33(37(51)44-32(24(4)5)38(52)56-9)45-39(53)47-46-36(50)31(21-27-16-18-29(55-8)19-17-27)43-35(49)30(20-23(2)3)42-34(48)26(7)41-40(54)57-22-28-14-12-11-13-15-28/h11-19,23-26,30-33H,10,20-22H2,1-9H3,(H,41,54)(H,42,48)(H,43,49)(H,44,51)(H,46,50)(H2,45,47,53)
DMIB5O3	CS	CCC(C)C(C(=O)NC(C(C)C)C(=O)OC)NC(=O)NNC(=O)C(CC1=CC=C(C=C1)OC)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)OCC2=CC=CC=C2
DMIB5O3	IK	QZSSZOWDSLCTPA-UHFFFAOYSA-N
DMIB5O3	IU	methyl 2-[[2-[[[3-(4-methoxyphenyl)-2-[[4-methyl-2-[2-(phenylmethoxycarbonylamino)propanoylamino]pentanoyl]amino]propanoyl]amino]carbamoylamino]-3-methylpentanoyl]amino]-3-methylbutanoate
DMIB5O3	DE	Discovery agent

DMM4ZKU	ID	DMM4ZKU
DMM4ZKU	DN	ZAPOTIN
DMM4ZKU	HS	Investigative
DMM4ZKU	SN	Zapotin; 14813-19-5; CHEMBL375582; 5,6,2',6'-tetramethoxyflavone; 2-(2,6-dimethoxyphenyl)-5,6-dimethoxychromen-4-one; Flavone, 2',5,6,6'-tetramethoxy-; AC1LCGQ2; SCHEMBL3307703; 2',6',5,6-Tetramethoxyflavon; DTXSID80348078; 2-(2,6-Dimethoxyphenyl)-5,6-dimethoxy-4H-chromen-4-one; PBQMALAAFQMDSP-UHFFFAOYSA-N; 2',5,6,6'-Tetramethoxyflavone; MolPort-005-945-165; 4H-1-Benzopyran-4-one, 2-(2,6-dimethoxyphenyl)-5,6-dimethoxy-; 5,6,2'',6''-tetramethoxyflavone; ZINC14756841; LMPK12110091; Flavone,2',5,6,6'-tetramethoxy-; BDBM50202558
DMM4ZKU	DT	Small molecular drug
DMM4ZKU	PC	629965
DMM4ZKU	MW	342.3
DMM4ZKU	FM	C19H18O6
DMM4ZKU	IC	InChI=1S/C19H18O6/c1-21-12-6-5-7-13(22-2)18(12)16-10-11(20)17-14(25-16)8-9-15(23-3)19(17)24-4/h5-10H,1-4H3
DMM4ZKU	CS	COC1=C(C(=CC=C1)OC)C2=CC(=O)C3=C(O2)C=CC(=C3OC)OC
DMM4ZKU	IK	PBQMALAAFQMDSP-UHFFFAOYSA-N
DMM4ZKU	IU	2-(2,6-dimethoxyphenyl)-5,6-dimethoxychromen-4-one
DMM4ZKU	CA	CAS 14813-19-5
DMM4ZKU	DE	Discovery agent

DMYRLA0	ID	DMYRLA0
DMYRLA0	DN	ZARAGOZIC ACID B
DMYRLA0	HS	Investigative
DMYRLA0	SN	Zaragozic acid B; UNII-2AF560R2HC; 2AF560R2HC; CHEMBL504845; 146389-61-9; SCHEMBL6130350; GTPL6061; BDBM50292415; L-glycero-D-altro-Pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13,14,15-heptadeoxy-10,12-dimethyl-15-phenyl-, 5-(6,12-tetradecadienoate), (5(6E,12E),7S,10xi,11xi,12xi)-; (1R,2S,3S,5S,6R,7R)-2,6-dihydroxy-5-[(E)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-enyl]-7-[(6E,12E)-tetradeca-6,12-dienoyl]oxy-4,8-dioxabicyclo[3.2.1]octane-1,2,3-tricarboxylic acid
DMYRLA0	DT	Small molecular drug
DMYRLA0	PC	9940176
DMYRLA0	MW	730.8
DMYRLA0	FM	C39H54O13
DMYRLA0	IC	InChI=1S/C39H54O13/c1-4-5-6-7-8-9-10-11-12-13-17-23-29(40)50-32-31(42)37(51-33(34(43)44)38(49,35(45)46)39(32,52-37)36(47)48)25-24-27(3)30(41)26(2)19-18-22-28-20-15-14-16-21-28/h4-5,10-11,14-16,18,20-22,26-27,30-33,41-42,49H,6-9,12-13,17,19,23-25H2,1-3H3,(H,43,44)(H,45,46)(H,47,48)/b5-4+,11-10+,22-18+/t26?,27?,30?,31-,32-,33-,37+,38-,39+/m1/s1
DMYRLA0	CS	C/C=C/CCCC/C=C/CCCCC(=O)O[C@@H]1[C@H]([C@]2(O[C@@H]([C@]([C@@]1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCC(C)C(C(C)C/C=C/C3=CC=CC=C3)O)O
DMYRLA0	IK	VFZAKIFLDMCTJV-NZHUAJKLSA-N
DMYRLA0	IU	(1S,3S,4S,5R,6R,7R)-4,7-dihydroxy-1-[(E)-4-hydroxy-3,5-dimethyl-8-phenyloct-7-enyl]-6-[(6E,12E)-tetradeca-6,12-dienoyl]oxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DMYRLA0	CA	CAS 146389-61-9
DMYRLA0	DE	Discovery agent

DMUQWP1	ID	DMUQWP1
DMUQWP1	DN	Zaragozic Acid C
DMUQWP1	HS	Investigative
DMUQWP1	SN	zaragozic acid C; UNII-04ISX24T1B; 04ISX24T1B; CHEMBL505374; CHEBI:83934; L-697350; 146389-62-0; Zaragozic acid C [MI]; GTPL3073; BDBM50292333; L-Erythro-L-glycero-D-altro-7-trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-c-carboxy-8,9,10,12,13-pentadeoxy-12-(phenylmethyl)-, 11-acetate 5-((4E,6R)-6-methyl-9-phenyl-4-nonenoate), (7S)-
DMUQWP1	DT	Small molecular drug
DMUQWP1	PC	11814656
DMUQWP1	MW	754.8
DMUQWP1	FM	C40H50O14
DMUQWP1	IC	InChI=1S/C40H50O14/c1-25(15-12-20-28-16-6-4-7-17-28)14-10-11-22-31(42)52-33-32(43)38(53-34(35(44)45)39(50,36(46)47)40(33,54-38)37(48)49)23-13-21-30(51-27(3)41)26(2)24-29-18-8-5-9-19-29/h4-10,14,16-19,25-26,30,32-34,43,50H,11-13,15,20-24H2,1-3H3,(H,44,45)(H,46,47)(H,48,49)/b14-10+/t25-,26+,30+,32+,33+,34+,38-,39+,40-/m0/s1
DMUQWP1	CS	C[C@H](CCCC1=CC=CC=C1)/C=C/CCC(=O)O[C@@H]2[C@H]([C@]3(O[C@@H]([C@]([C@@]2(O3)C(=O)O)(C(=O)O)O)C(=O)O)CCC[C@H]([C@H](C)CC4=CC=CC=C4)OC(=O)C)O
DMUQWP1	IK	KQMNJFMTGHRJHM-ZFSXNWTMSA-N
DMUQWP1	IU	(1S,3S,4S,5R,6R,7R)-1-[(4R,5R)-4-acetyloxy-5-methyl-6-phenylhexyl]-4,7-dihydroxy-6-[(E,6R)-6-methyl-9-phenylnon-4-enoyl]oxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DMUQWP1	CA	CAS 146389-62-0
DMUQWP1	CB	CHEBI:83934
DMUQWP1	DE	Discovery agent

DMMTJE3	ID	DMMTJE3
DMMTJE3	DN	Zaragozic Acid D
DMMTJE3	HS	Investigative
DMMTJE3	SN	Zaragozic acid D; UNII-N34668EC9D; CHEMBL502872; N34668EC9D; 155179-14-9; BDBM50292414; (7S,11xi,12xi,14E)-2,7-Anhydro-3,4-di-C-carboxy-8,9,10,12,13,14,15-heptadeoxy-12-methyl-15-phenyl-L-glycero-D-altro-pentadec-14-en-7-ulo-7,4-furanosonic acid 11-acetate 5-octanoate; L-glycero-D-altro-Pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13,14,15-heptadeoxy-12-methyl-15-phenyl-, 11-acetate 5-octanoate, (7S,11xi,12xi,14E)-
DMMTJE3	DT	Small molecular drug
DMMTJE3	PC	9917905
DMMTJE3	MW	678.7
DMMTJE3	FM	C34H46O14
DMMTJE3	IC	InChI=1S/C34H46O14/c1-4-5-6-7-11-19-25(36)46-27-26(37)32(47-28(29(38)39)33(44,30(40)41)34(27,48-32)31(42)43)20-13-18-24(45-22(3)35)21(2)14-12-17-23-15-9-8-10-16-23/h8-10,12,15-17,21,24,26-28,37,44H,4-7,11,13-14,18-20H2,1-3H3,(H,38,39)(H,40,41)(H,42,43)/b17-12+/t21?,24?,26-,27-,28-,32+,33-,34+/m1/s1
DMMTJE3	CS	CCCCCCCC(=O)O[C@@H]1[C@H]([C@]2(O[C@@H]([C@]([C@@]1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCCC(C(C)C/C=C/C3=CC=CC=C3)OC(=O)C)O
DMMTJE3	IK	CGQGIYLITCUENM-FRHZWACMSA-N
DMMTJE3	IU	(1S,3S,4S,5R,6R,7R)-1-[(E)-4-acetyloxy-5-methyl-8-phenyloct-7-enyl]-4,7-dihydroxy-6-octanoyloxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DMMTJE3	CA	CAS 155179-14-9
DMMTJE3	DE	Discovery agent

DML4WQJ	ID	DML4WQJ
DML4WQJ	DN	Zaragozic Acid D2
DML4WQJ	HS	Investigative
DML4WQJ	SN	Zaragozic acid D2; UNII-W832OVP6BY; W832OVP6BY; CHEMBL502210; 155179-15-0; Zaragozic acid D(2); BDBM50292413; L-glycero-D-altro-Pentadec-14-en-7-ulo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13,14,15-hexptadeoxy-12-methyl-15-phenyl-, 11-acetate 5-decanoate, (7S,11xi,12xi,14E)-
DML4WQJ	DT	Small molecular drug
DML4WQJ	PC	23376020
DML4WQJ	MW	706.8
DML4WQJ	FM	C36H50O14
DML4WQJ	IC	InChI=1S/C36H50O14/c1-4-5-6-7-8-9-13-21-27(38)48-29-28(39)34(49-30(31(40)41)35(46,32(42)43)36(29,50-34)33(44)45)22-15-20-26(47-24(3)37)23(2)16-14-19-25-17-11-10-12-18-25/h10-12,14,17-19,23,26,28-30,39,46H,4-9,13,15-16,20-22H2,1-3H3,(H,40,41)(H,42,43)(H,44,45)/b19-14+/t23?,26?,28-,29-,30-,34+,35-,36+/m1/s1
DML4WQJ	CS	CCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2(O[C@@H]([C@]([C@@]1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCCC(C(C)C/C=C/C3=CC=CC=C3)OC(=O)C)O
DML4WQJ	IK	WDLYATMIWWDJQY-FYSMYQDTSA-N
DML4WQJ	IU	(1S,3S,4S,5R,6R,7R)-1-[(E)-4-acetyloxy-5-methyl-8-phenyloct-7-enyl]-6-decanoyloxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DML4WQJ	CA	CAS 155179-15-0
DML4WQJ	DE	Discovery agent

DM69FKN	ID	DM69FKN
DM69FKN	DN	Z-Arg-Leu-Val-Agly-Ala-Gly-NH2
DM69FKN	HS	Investigative
DM69FKN	DT	Small molecular drug
DM69FKN	PC	44355110
DM69FKN	MW	705.8
DM69FKN	FM	C31H51N11O8
DM69FKN	IC	InChI=1S/C31H51N11O8/c1-17(2)14-22(27(46)40-24(18(3)4)28(47)41-42-30(48)37-19(5)25(44)36-15-23(32)43)38-26(45)21(12-9-13-35-29(33)34)39-31(49)50-16-20-10-7-6-8-11-20/h6-8,10-11,17-19,21-22,24H,9,12-16H2,1-5H3,(H2,32,43)(H,36,44)(H,38,45)(H,39,49)(H,40,46)(H,41,47)(H4,33,34,35)(H2,37,42,48)
DM69FKN	CS	CC(C)CC(C(=O)NC(C(C)C)C(=O)NNC(=O)NC(C)C(=O)NCC(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)OCC1=CC=CC=C1
DM69FKN	IK	QPGAIIGEIAEEEV-UHFFFAOYSA-N
DM69FKN	IU	benzyl N-[1-[[1-[[1-[2-[[1-[(2-amino-2-oxoethyl)amino]-1-oxopropan-2-yl]carbamoyl]hydrazinyl]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamate
DM69FKN	DE	Discovery agent

DMT0UZ1	ID	DMT0UZ1
DMT0UZ1	DN	Z-Arg-Leu-Val-Agly-Ileu-Val-OMe
DMT0UZ1	HS	Investigative
DMT0UZ1	DT	Small molecular drug
DMT0UZ1	PC	44355092
DMT0UZ1	MW	805
DMT0UZ1	FM	C38H64N10O9
DMT0UZ1	IC	InChI=1S/C38H64N10O9/c1-10-24(8)30(33(51)45-29(23(6)7)35(53)56-9)46-37(54)48-47-34(52)28(22(4)5)44-32(50)27(19-21(2)3)42-31(49)26(17-14-18-41-36(39)40)43-38(55)57-20-25-15-12-11-13-16-25/h11-13,15-16,21-24,26-30H,10,14,17-20H2,1-9H3,(H,42,49)(H,43,55)(H,44,50)(H,45,51)(H,47,52)(H4,39,40,41)(H2,46,48,54)
DMT0UZ1	CS	CCC(C)C(C(=O)NC(C(C)C)C(=O)OC)NC(=O)NNC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)OCC1=CC=CC=C1
DMT0UZ1	IK	ZLXFGUGFOLETFJ-UHFFFAOYSA-N
DMT0UZ1	IU	methyl 2-[[2-[[[2-[[2-[[5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]carbamoylamino]-3-methylpentanoyl]amino]-3-methylbutanoate
DMT0UZ1	DE	Discovery agent

DM9SXMB	ID	DM9SXMB
DM9SXMB	DN	Z-Arg-Leu-Val-Agly-Ile-Val-OMe
DM9SXMB	HS	Investigative
DM9SXMB	SN	Z-Arg-Leu-Val-Azagly-Ile-Val-OMe; CHEMBL2028907; 464883-21-4; Z-Arg-Leu-Val-Agly-Ile-Val-OMe; GTPL6534; BDBM50409586; ZINC95550984; 883Z214; methyl (2S)-2-[[(2S,3S)-2-[[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]carbamoylamino]-3-methylpentanoyl]amino]-3-methylbutanoate
DM9SXMB	DT	Small molecular drug
DM9SXMB	PC	10033311
DM9SXMB	MW	805
DM9SXMB	FM	C38H64N10O9
DM9SXMB	IC	InChI=1S/C38H64N10O9/c1-10-24(8)30(33(51)45-29(23(6)7)35(53)56-9)46-37(54)48-47-34(52)28(22(4)5)44-32(50)27(19-21(2)3)42-31(49)26(17-14-18-41-36(39)40)43-38(55)57-20-25-15-12-11-13-16-25/h11-13,15-16,21-24,26-30H,10,14,17-20H2,1-9H3,(H,42,49)(H,43,55)(H,44,50)(H,45,51)(H,47,52)(H4,39,40,41)(H2,46,48,54)/t24-,26-,27-,28-,29-,30-/m0/s1
DM9SXMB	CS	CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)OC)NC(=O)NNC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)OCC1=CC=CC=C1
DM9SXMB	IK	ZLXFGUGFOLETFJ-POPCVQDUSA-N
DM9SXMB	IU	methyl (2S)-2-[[(2S,3S)-2-[[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]carbamoylamino]-3-methylpentanoyl]amino]-3-methylbutanoate
DM9SXMB	DE	Discovery agent

DMZDGJO	ID	DMZDGJO
DMZDGJO	DN	Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2
DMZDGJO	HS	Investigative
DMZDGJO	DT	Small molecular drug
DMZDGJO	PC	44355091
DMZDGJO	MW	991.2
DMZDGJO	FM	C49H74N12O10
DMZDGJO	IC	InChI=1S/C49H74N12O10/c1-10-30(8)40(44(65)58-38(28(4)5)43(64)55-37(46(67)70-9)24-32-25-53-34-20-15-14-19-33(32)34)59-48(68)61-60-45(66)39(29(6)7)57-42(63)36(23-27(2)3)54-41(62)35(21-16-22-52-47(50)51)56-49(69)71-26-31-17-12-11-13-18-31/h11-15,17-20,25,27-30,35-40,53H,10,16,21-24,26H2,1-9H3,(H,54,62)(H,55,64)(H,56,69)(H,57,63)(H,58,65)(H,60,66)(H4,50,51,52)(H2,59,61,68)
DMZDGJO	CS	CCC(C)C(C(=O)NC(C(C)C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)OC)NC(=O)NNC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)OCC3=CC=CC=C3
DMZDGJO	IK	LIQDTPYQUQZTGR-UHFFFAOYSA-N
DMZDGJO	IU	methyl 2-[[2-[[2-[[[2-[[2-[[5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]carbamoylamino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoate
DMZDGJO	DE	Discovery agent

DMM5O2V	ID	DMM5O2V
DMM5O2V	DN	Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2
DMM5O2V	HS	Investigative
DMM5O2V	DT	Small molecular drug
DMM5O2V	PC	44355268
DMM5O2V	MW	934.1
DMM5O2V	FM	C45H67N13O9
DMM5O2V	IC	InChI=1S/C45H67N13O9/c1-24(2)20-33(52-38(60)32(18-13-19-49-43(47)48)54-45(66)67-23-28-14-9-8-10-15-28)39(61)56-36(26(5)6)42(64)57-58-44(65)53-34(21-29-22-50-31-17-12-11-16-30(29)31)40(62)55-35(25(3)4)41(63)51-27(7)37(46)59/h8-12,14-17,22,24-27,32-36,50H,13,18-21,23H2,1-7H3,(H2,46,59)(H,51,63)(H,52,60)(H,54,66)(H,55,62)(H,56,61)(H,57,64)(H4,47,48,49)(H2,53,58,65)
DMM5O2V	CS	CC(C)CC(C(=O)NC(C(C)C)C(=O)NNC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(C(C)C)C(=O)NC(C)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)OCC3=CC=CC=C3
DMM5O2V	IK	TXGCKASBHJKJOM-UHFFFAOYSA-N
DMM5O2V	IU	benzyl N-[1-[[1-[[1-[2-[[1-[[1-[(1-amino-1-oxopropan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]hydrazinyl]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamate
DMM5O2V	DE	Discovery agent

DMTWNH7	ID	DMTWNH7
DMTWNH7	DN	Z-Arg-Leu-Val-Agly-Val-Ala-NH2
DMTWNH7	HS	Investigative
DMTWNH7	DT	Small molecular drug
DMTWNH7	PC	44355111
DMTWNH7	MW	747.9
DMTWNH7	FM	C34H57N11O8
DMTWNH7	IC	InChI=1S/C34H57N11O8/c1-18(2)16-24(40-28(47)23(14-11-15-38-32(36)37)41-34(52)53-17-22-12-9-8-10-13-22)29(48)42-26(20(5)6)31(50)44-45-33(51)43-25(19(3)4)30(49)39-21(7)27(35)46/h8-10,12-13,18-21,23-26H,11,14-17H2,1-7H3,(H2,35,46)(H,39,49)(H,40,47)(H,41,52)(H,42,48)(H,44,50)(H4,36,37,38)(H2,43,45,51)
DMTWNH7	CS	CC(C)CC(C(=O)NC(C(C)C)C(=O)NNC(=O)NC(C(C)C)C(=O)NC(C)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)OCC1=CC=CC=C1
DMTWNH7	IK	OILQRSUIXCAKPE-UHFFFAOYSA-N
DMTWNH7	IU	benzyl N-[1-[[1-[[1-[2-[[1-[(1-amino-1-oxopropan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]hydrazinyl]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamate
DMTWNH7	DE	Discovery agent

DMLI8GZ	ID	DMLI8GZ
DMLI8GZ	DN	ZD1604
DMLI8GZ	HS	Investigative
DMLI8GZ	DE	Discovery agent

DM8MXS6	ID	DM8MXS6
DM8MXS6	DN	ZD-6021
DM8MXS6	HS	Investigative
DM8MXS6	SN	255049-08-2
DM8MXS6	DT	Small molecular drug
DM8MXS6	PC	9852253
DM8MXS6	MW	632.6
DM8MXS6	FM	C35H35Cl2N3O2S
DM8MXS6	IC	InChI=1S/C35H35Cl2N3O2S/c1-39(35(41)31-20-24(22-38)19-27-7-3-4-8-29(27)31)23-28(26-11-12-32(36)33(37)21-26)15-18-40-16-13-25(14-17-40)30-9-5-6-10-34(30)43(2)42/h3-12,19-21,25,28H,13-18,23H2,1-2H3/t28-,43+/m1/s1
DM8MXS6	CS	CN(C[C@@H](CCN1CCC(CC1)C2=CC=CC=C2[S@@](=O)C)C3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC(=CC5=CC=CC=C54)C#N
DM8MXS6	IK	SJHZTGDJTIZMSK-KPRDSAADSA-N
DM8MXS6	IU	3-cyano-N-[(2S)-2-(3,4-dichlorophenyl)-4-[4-[2-[(S)-methylsulfinyl]phenyl]piperidin-1-yl]butyl]-N-methylnaphthalene-1-carboxamide
DM8MXS6	DE	Discovery agent

DMI5WF1	ID	DMI5WF1
DMI5WF1	DN	ZEARALANONE
DMI5WF1	HS	Investigative
DMI5WF1	SN	Zearalanone; Zanone; 5975-78-0; (S)-Zearalanone; UNII-133DU2F2VS; CCRIS 9235; MLS000069626; P 1502; SMR000058193; CHEMBL491499; 133DU2F2VS; CHEBI:35051; beta-Resorcylic acid, 6-(10-hydroxy-6-oxoundecyl)-, mu-lactone; (S)-3,4,5,6,9,10,11,12-Octahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,5,6,9,10,11,12-octahydro-14,16-dihydroxy-3-methyl-, (S)-; 2,4-DIHYDROXY-6-[10-HYDROXY-6-OXO-UNDECYL]BENZOIC ACID MICRO-LACTONE
DMI5WF1	DT	Small molecular drug
DMI5WF1	PC	108003
DMI5WF1	MW	320.4
DMI5WF1	FM	C18H24O5
DMI5WF1	IC	InChI=1S/C18H24O5/c1-12-6-5-9-14(19)8-4-2-3-7-13-10-15(20)11-16(21)17(13)18(22)23-12/h10-12,20-21H,2-9H2,1H3/t12-/m0/s1
DMI5WF1	CS	C[C@H]1CCCC(=O)CCCCCC2=C(C(=CC(=C2)O)O)C(=O)O1
DMI5WF1	IK	APJDQUGPCJRQRJ-LBPRGKRZSA-N
DMI5WF1	IU	(4S)-16,18-dihydroxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),15,17-triene-2,8-dione
DMI5WF1	CA	CAS 5975-78-0
DMI5WF1	CB	CHEBI:35051
DMI5WF1	DE	Discovery agent

DMF0CRA	ID	DMF0CRA
DMF0CRA	DN	zinc pyrithione
DMF0CRA	HS	Investigative
DMF0CRA	SN	BCP13412
DMF0CRA	DT	Small molecular drug
DMF0CRA	PC	26041
DMF0CRA	MW	317.7
DMF0CRA	FM	C10H8N2O2S2Zn
DMF0CRA	IC	InChI=1S/2C5H5NOS.Zn/c2*7-6-4-2-1-3-5(6)8;/h2*1-4,8H;/q;;+2/p-2
DMF0CRA	CS	C1=CC=[N+](C(=C1)[S-])[O-].C1=CC=[N+](C(=C1)[S-])[O-].[Zn+2]
DMF0CRA	IK	OTPSWLRZXRHDNX-UHFFFAOYSA-L
DMF0CRA	IU	zinc;1-oxidopyridin-1-ium-2-thiolate
DMF0CRA	CA	CAS 13463-41-7
DMF0CRA	DE	Discovery agent

DMKETL5	ID	DMKETL5
DMKETL5	DN	zinterol
DMKETL5	HS	Investigative
DMKETL5	SN	ZINTEROL; 37000-20-7; Zinterol [INN]; Zinterolum [INN-Latin]; N-(2-HYDROXY-5-(1-HYDROXY-2-(2-METHYL-1-PHENYLPROPAN-2-YLAMINO)ETHYL)PHENYL)METHANESULFONAMIDE; CHEMBL1243407; C19H26N2O4S; MJ-9184-1; MJ 9184; N-[2-hydroxy-5-[1-hydroxy-2-[(2-methyl-1-phenylpropan-2-yl)amino]ethyl]phenyl]methanesulfonamide; Zinterolum; 2'-Hydroxy-5'-(l-hydroxy-2-(2-methyl-1-phenyl-2-propylamino)ethyl)methanesulfonanilide; Methanesulfonamide, N-(5-(2-((1,1-dimethyl-2-phenylethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)-; NSC-284704; AC1Q6VSI
DMKETL5	DT	Small molecular drug
DMKETL5	PC	37990
DMKETL5	MW	378.5
DMKETL5	FM	C19H26N2O4S
DMKETL5	IC	InChI=1S/C19H26N2O4S/c1-19(2,12-14-7-5-4-6-8-14)20-13-18(23)15-9-10-17(22)16(11-15)21-26(3,24)25/h4-11,18,20-23H,12-13H2,1-3H3
DMKETL5	CS	CC(C)(CC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)NS(=O)(=O)C)O
DMKETL5	IK	XJBCFFLVLOPYBV-UHFFFAOYSA-N
DMKETL5	IU	N-[2-hydroxy-5-[1-hydroxy-2-[(2-methyl-1-phenylpropan-2-yl)amino]ethyl]phenyl]methanesulfonamide
DMKETL5	CA	CAS 37000-20-7
DMKETL5	DE	Discovery agent

DMP089G	ID	DMP089G
DMP089G	DN	ZK 756326
DMP089G	HS	Investigative
DMP089G	SN	ZK-756326; ZK756326
DMP089G	DT	Small molecular drug
DMP089G	PC	56972201
DMP089G	MW	429.4
DMP089G	FM	C21H30Cl2N2O3
DMP089G	IC	InChI=1S/C21H28N2O3.2ClH/c24-14-16-25-15-13-22-9-11-23(12-10-22)18-19-5-4-8-21(17-19)26-20-6-2-1-3-7-20;;/h1-8,17,24H,9-16,18H2;2*1H
DMP089G	CS	C1CN(CCN1CCOCCO)CC2=CC(=CC=C2)OC3=CC=CC=C3.Cl.Cl
DMP089G	IK	MPACCEKWFGWZHS-UHFFFAOYSA-N
DMP089G	IU	2-[2-[4-[(3-phenoxyphenyl)methyl]piperazin-1-yl]ethoxy]ethanol;dihydrochloride
DMP089G	DE	Discovery agent

DMY3SUZ	ID	DMY3SUZ
DMY3SUZ	DN	ZK110841
DMY3SUZ	HS	Investigative
DMY3SUZ	SN	ZK 110841; ZK-110841
DMY3SUZ	DT	Small molecular drug
DMY3SUZ	PC	5311503
DMY3SUZ	MW	384.9
DMY3SUZ	FM	C21H33ClO4
DMY3SUZ	IC	InChI=1S/C21H33ClO4/c22-18-14-20(24)17(12-13-19(23)15-8-4-3-5-9-15)16(18)10-6-1-2-7-11-21(25)26/h1,6,12-13,15-20,23-24H,2-5,7-11,14H2,(H,25,26)/b6-1-,13-12+/t16?,17-,18-,19-,20-/m1/s1
DMY3SUZ	CS	C1CCC(CC1)[C@@H](/C=C/[C@H]2[C@@H](C[C@H](C2C/C=C\\CCCC(=O)O)Cl)O)O
DMY3SUZ	IK	ZOQXTNLUBHPZOZ-GZFHOOQWSA-N
DMY3SUZ	IU	(Z)-7-[(2R,3R,5R)-5-chloro-2-[(E,3S)-3-cyclohexyl-3-hydroxyprop-1-enyl]-3-hydroxycyclopentyl]hept-5-enoic acid
DMY3SUZ	DE	Discovery agent

DM8JN45	ID	DM8JN45
DM8JN45	DN	ZK-112993
DM8JN45	HS	Investigative
DM8JN45	SN	105114-63-4
DM8JN45	DT	Small molecular drug
DM8JN45	PC	121874
DM8JN45	MW	428.6
DM8JN45	FM	C29H32O3
DM8JN45	IC	InChI=1S/C29H32O3/c1-4-14-29(32)15-13-26-24-11-9-21-16-22(31)10-12-23(21)27(24)25(17-28(26,29)3)20-7-5-19(6-8-20)18(2)30/h5-8,16,24-26,32H,9-13,15,17H2,1-3H3/t24-,25+,26-,28-,29-/m0/s1
DM8JN45	CS	CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)C(=O)C)C)O
DM8JN45	IK	OPKMKRUFBKTTRF-GCNJZUOMSA-N
DM8JN45	IU	(8S,11R,13S,14S,17S)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DM8JN45	CA	CAS 105114-63-4
DM8JN45	DE	Discovery agent

DMBCPKE	ID	DMBCPKE
DMBCPKE	DN	ZK-114043
DMBCPKE	HS	Investigative
DMBCPKE	SN	105120-95-4
DMBCPKE	DT	Small molecular drug
DMBCPKE	PC	9911439
DMBCPKE	MW	446.6
DMBCPKE	FM	C29H34O4
DMBCPKE	IC	InChI=1S/C29H34O4/c1-18(31)19-4-6-20(7-5-19)25-17-28(2)26(12-14-29(28,33)13-3-15-30)24-10-8-21-16-22(32)9-11-23(21)27(24)25/h3-7,13,16,24-26,30,33H,8-12,14-15,17H2,1-2H3/b13-3-/t24-,25+,26-,28-,29-/m0/s1
DMBCPKE	CS	CC(=O)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(/C=C\\CO)O)[C@H]4C2=C5CCC(=O)C=C5CC4)C
DMBCPKE	IK	QRFXQUJABMFXNM-VRQKHSNCSA-N
DMBCPKE	IU	(8S,11R,13S,14S,17R)-11-(4-acetylphenyl)-17-hydroxy-17-[(Z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMBCPKE	DE	Discovery agent

DMCQYBE	ID	DMCQYBE
DMCQYBE	DN	ZK-136798
DMCQYBE	HS	Investigative
DMCQYBE	SN	176175-63-6
DMCQYBE	PC	102069237
DMCQYBE	MW	519.7
DMCQYBE	FM	C35H37NO3
DMCQYBE	IC	InChI=1S/C35H37NO3/c1-33-20-30-28-9-7-24(23-5-3-22(21-36)4-6-23)17-25(28)19-34-14-11-27(38)18-26(34)8-10-29(32(30)34)31(33)12-15-35(33,39)13-2-16-37/h2-7,9,13,17-18,29-32,37,39H,8,10-12,14-16,19-20H2,1H3/b13-2+/t29-,30-,31+,32-,33+,34-,35+/m1/s1
DMCQYBE	CS	C[C@]12C[C@H]3[C@H]4[C@@H]([C@@H]1CC[C@]2(/C=C/CO)O)CCC5=CC(=O)CC[C@]45CC6=C3C=CC(=C6)C7=CC=C(C=C7)C#N
DMCQYBE	IK	QHTHVOAGHYSJSF-DVNFVMEUSA-N
DMCQYBE	IU	4-[(1S,9S,11S,12R,15S,16R,24R)-12-hydroxy-12-[(E)-3-hydroxyprop-1-enyl]-11-methyl-21-oxo-5-hexacyclo[14.7.1.01,19.03,8.09,24.011,15]tetracosa-3(8),4,6,19-tetraenyl]benzonitrile
DMCQYBE	DE	Discovery agent

DMNMD0J	ID	DMNMD0J
DMNMD0J	DN	ZK-158252
DMNMD0J	HS	Investigative
DMNMD0J	SN	ZK158252; ZK 158252
DMNMD0J	DT	Small molecular drug
DMNMD0J	PC	9824142
DMNMD0J	MW	432.6
DMNMD0J	FM	C29H36O3
DMNMD0J	IC	InChI=1S/C29H36O3/c30-27(29(22-11-23-29)21-10-14-24-12-2-1-3-13-24)19-8-6-17-25-15-4-5-16-26(25)18-7-9-20-28(31)32/h1-3,6,8,12-13,17-19,25,27,30H,4-5,7,9,11,15-16,20-23H2,(H,31,32)/b17-6+,19-8+,26-18+
DMNMD0J	CS	C1CC/C(=C\\CCCC(=O)O)/C(C1)/C=C/C=C/C(C2(CCC2)CC#CC3=CC=CC=C3)O
DMNMD0J	IK	HILRZHRCCODTSA-AHQVELJISA-N
DMNMD0J	IU	(5E)-5-[2-[(1E,3E)-5-hydroxy-5-[1-(3-phenylprop-2-ynyl)cyclobutyl]penta-1,3-dienyl]cyclohexylidene]pentanoic acid
DMNMD0J	DE	Discovery agent

DMYRHK6	ID	DMYRHK6
DMYRHK6	DN	ZK159222
DMYRHK6	HS	Investigative
DMYRHK6	SN	C410228; ZK 159222
DMYRHK6	DT	Small molecular drug
DMYRHK6	PC	9936230
DMYRHK6	MW	512.7
DMYRHK6	FM	C32H48O5
DMYRHK6	IC	InChI=1S/C32H48O5/c1-5-6-18-37-30(36)32(16-17-32)29(35)14-9-21(2)26-12-13-27-23(8-7-15-31(26,27)4)10-11-24-19-25(33)20-28(34)22(24)3/h9-11,14,21,25-29,33-35H,3,5-8,12-13,15-20H2,1-2,4H3/b14-9+,23-10+,24-11-/t21-,25-,26-,27+,28+,29-,31-/m1/s1
DMYRHK6	CS	CCCCOC(=O)C1(CC1)[C@@H](/C=C/[C@@H](C)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C)O
DMYRHK6	IK	SPARTCPUGRJFRS-PBDCIXLPSA-N
DMYRHK6	IU	butyl 1-[(E,1R,4R)-4-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-1-hydroxypent-2-enyl]cyclopropane-1-carboxylate
DMYRHK6	DE	Discovery agent

DMROWV8	ID	DMROWV8
DMROWV8	DN	ZK-164015
DMROWV8	HS	Investigative
DMROWV8	SN	ZK 164015; 177583-70-9; ZK-164015; 2-(4-HYDROXYPHENYL)-3-METHYL-1-[10-(PENTYLSULFONYL)DECYL]-1H-INDOL-5-OL; CHEMBL184074; SCHEMBL7133598; CHEBI:92087; CTK4D6535; DTXSID00430964; MolPort-006-822-606; HMS3268P09; ZINC8022535; AKOS024456974; NCGC00092322-01; RT-016336; B6960; J-011295; BRD-K05151076-001-01-8
DMROWV8	DT	Small molecular drug
DMROWV8	PC	9806489
DMROWV8	MW	513.7
DMROWV8	FM	C30H43NO4S
DMROWV8	IC	InChI=1S/C30H43NO4S/c1-3-4-12-21-36(34,35)22-13-10-8-6-5-7-9-11-20-31-29-19-18-27(33)23-28(29)24(2)30(31)25-14-16-26(32)17-15-25/h14-19,23,32-33H,3-13,20-22H2,1-2H3
DMROWV8	CS	CCCCCS(=O)(=O)CCCCCCCCCCN1C2=C(C=C(C=C2)O)C(=C1C3=CC=C(C=C3)O)C
DMROWV8	IK	LYJSJVYJLZOMCD-UHFFFAOYSA-N
DMROWV8	IU	2-(4-hydroxyphenyl)-3-methyl-1-(10-pentylsulfonyldecyl)indol-5-ol
DMROWV8	CA	CAS 177583-70-9
DMROWV8	CB	CHEBI:92087
DMROWV8	DE	Discovery agent

DMNOWAQ	ID	DMNOWAQ
DMNOWAQ	DN	ZK-810388
DMNOWAQ	HS	Investigative
DMNOWAQ	SN	3-chloro-N-{4-chloro-2-[(5-chloropyridin-2-yl)carbamoyl]-6-methoxyphenyl}-4-{[4,5-dihydro-1,3-oxazol-2-yl(methyl)amino]methyl}thiophene-2-carboxamide; 3-chloro-N-[4-chloro-2-[(5-chloropyridin-2-yl)carbamoyl]-6-methoxyphenyl]-4-[[4,5-dihydro-1,3-oxazol-2-yl(methyl)amino]methyl]thiophene-2-carboxamide; AC1MOUJH; 1mq6; ZK-810388; Thiophene-Anthranilamide, 13a; CHEMBL173994; BDBM17111; ZK810388; ZK 810388; N-[2-(5-Chloro-2-pyridinylcarbamoyl)-4-chloro-6-methoxyphenyl]-3-chloro-4-(methyl 2-oxazoline-2-ylaminomethyl)thioph
DMNOWAQ	DT	Small molecular drug
DMNOWAQ	PC	3400921
DMNOWAQ	MW	568.9
DMNOWAQ	FM	C23H20Cl3N5O4S
DMNOWAQ	IC	InChI=1S/C23H20Cl3N5O4S/c1-31(23-27-5-6-35-23)10-12-11-36-20(18(12)26)22(33)30-19-15(7-14(25)8-16(19)34-2)21(32)29-17-4-3-13(24)9-28-17/h3-4,7-9,11H,5-6,10H2,1-2H3,(H,30,33)(H,28,29,32)
DMNOWAQ	CS	CN(CC1=CSC(=C1Cl)C(=O)NC2=C(C=C(C=C2OC)Cl)C(=O)NC3=NC=C(C=C3)Cl)C4=NCCO4
DMNOWAQ	IK	FBXIHZSULWMHJY-UHFFFAOYSA-N
DMNOWAQ	IU	3-chloro-N-[4-chloro-2-[(5-chloropyridin-2-yl)carbamoyl]-6-methoxyphenyl]-4-[[4,5-dihydro-1,3-oxazol-2-yl(methyl)amino]methyl]thiophene-2-carboxamide
DMNOWAQ	DE	Discovery agent

DMIC4HJ	ID	DMIC4HJ
DMIC4HJ	DN	ZK-813039
DMIC4HJ	HS	Investigative
DMIC4HJ	SN	DE-00684; Factor Xa inhibitor (oral), Schering AG/Pfizer
DMIC4HJ	DT	Small molecular drug
DMIC4HJ	PC	18376720
DMIC4HJ	MW	565.9
DMIC4HJ	FM	C23H19Cl3N6O3S
DMIC4HJ	IC	InChI=1S/C23H19Cl3N6O3S/c1-27-23-28-5-6-32(23)10-12-11-36-20(18(12)26)22(34)31-19-15(7-14(25)8-16(19)35-2)21(33)30-17-4-3-13(24)9-29-17/h3-9,11H,10H2,1-2H3,(H,27,28)(H,31,34)(H,29,30,33)
DMIC4HJ	CS	CNC1=NC=CN1CC2=CSC(=C2Cl)C(=O)NC3=C(C=C(C=C3OC)Cl)C(=O)NC4=NC=C(C=C4)Cl
DMIC4HJ	IK	LLHSZBPXQIOQJJ-UHFFFAOYSA-N
DMIC4HJ	IU	3-chloro-N-[4-chloro-2-[(5-chloropyridin-2-yl)carbamoyl]-6-methoxyphenyl]-4-[[2-(methylamino)imidazol-1-yl]methyl]thiophene-2-carboxamide
DMIC4HJ	CA	CAS 229336-92-9
DMIC4HJ	DE	Discovery agent

DMCBV5F	ID	DMCBV5F
DMCBV5F	DN	ZK-814048
DMCBV5F	HS	Investigative
DMCBV5F	SN	ZK-814048; Thiophene-Anthranilamide, 10b; SCHEMBL6589576; CHEMBL227222; BDBM17090; CYFNXPSIQONWKY-UHFFFAOYSA-N; ZK814048; ZK 814048; N-(5-chloropyridin-2-yl)-2-[((4-((methylamino)methyl)-3-chlorothiophen-2-yl)carbonyl)amino]-3-methoxy-5-chlorobenzamide
DMCBV5F	DT	Small molecular drug
DMCBV5F	PC	16731825
DMCBV5F	MW	499.8
DMCBV5F	FM	C20H17Cl3N4O3S
DMCBV5F	IC	InChI=1S/C20H17Cl3N4O3S/c1-24-7-10-9-31-18(16(10)23)20(29)27-17-13(5-12(22)6-14(17)30-2)19(28)26-15-4-3-11(21)8-25-15/h3-6,8-9,24H,7H2,1-2H3,(H,27,29)(H,25,26,28)
DMCBV5F	CS	CNCC1=CSC(=C1Cl)C(=O)NC2=C(C=C(C=C2OC)Cl)C(=O)NC3=NC=C(C=C3)Cl
DMCBV5F	IK	CYFNXPSIQONWKY-UHFFFAOYSA-N
DMCBV5F	IU	3-chloro-N-[4-chloro-2-[(5-chloropyridin-2-yl)carbamoyl]-6-methoxyphenyl]-4-(methylaminomethyl)thiophene-2-carboxamide
DMCBV5F	DE	Discovery agent

DM24OIX	ID	DM24OIX
DM24OIX	DN	ZL006
DM24OIX	HS	Investigative
DM24OIX	SN	4-((3,5-dichloro-2-hydroxybenzyl)amino)-2-hydroxybenzoic acid; SCHEMBL15367533; ZINC68267234; ZL-006; AKOS032945012; CS-5881; ZL006, &gt; HY-100456; J3.550.774D
DM24OIX	PC	44207238
DM24OIX	MW	328.1
DM24OIX	FM	C14H11Cl2NO4
DM24OIX	IC	InChI=1S/C14H11Cl2NO4/c15-8-3-7(13(19)11(16)4-8)6-17-9-1-2-10(14(20)21)12(18)5-9/h1-5,17-19H,6H2,(H,20,21)
DM24OIX	CS	C1=CC(=C(C=C1NCC2=C(C(=CC(=C2)Cl)Cl)O)O)C(=O)O
DM24OIX	IK	RTEYSQSXRFVKTJ-UHFFFAOYSA-N
DM24OIX	IU	4-[(3,5-dichloro-2-hydroxyphenyl)methylamino]-2-hydroxybenzoic acid
DM24OIX	DE	Fear-related disorder

DMEFHQI	ID	DMEFHQI
DMEFHQI	DN	Z-LEHD-fmk
DMEFHQI	HS	Investigative
DMEFHQI	DT	Small molecular drug
DMEFHQI	PC	10032582
DMEFHQI	MW	690.7
DMEFHQI	FM	C32H43FN6O10
DMEFHQI	IC	InChI=1S/C32H43FN6O10/c1-19(2)12-24(39-32(46)49-17-20-8-6-5-7-9-20)30(44)36-22(10-11-27(41)47-3)29(43)38-25(13-21-16-34-18-35-21)31(45)37-23(26(40)15-33)14-28(42)48-4/h5-9,16,18-19,22-25H,10-15,17H2,1-4H3,(H,34,35)(H,36,44)(H,37,45)(H,38,43)(H,39,46)/t22-,23-,24-,25-/m0/s1
DMEFHQI	CS	CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)OC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)OC)C(=O)CF)NC(=O)OCC2=CC=CC=C2
DMEFHQI	IK	YXRKBEPGVHOXSV-QORCZRPOSA-N
DMEFHQI	IU	methyl (4S)-5-[[(2S)-1-[[(3S)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-5-oxopentanoate
DMEFHQI	CA	CAS 210345-04-3
DMEFHQI	DE	Discovery agent

DM6OGR9	ID	DM6OGR9
DM6OGR9	DN	Z-leu-Val-Agly-Val-OBzl
DM6OGR9	HS	Investigative
DM6OGR9	SN	Z-leu-Val-Agly-Val-OBzl; CHEMBL263061
DM6OGR9	DT	Small molecular drug
DM6OGR9	PC	44355152
DM6OGR9	MW	611.7
DM6OGR9	FM	C32H45N5O7
DM6OGR9	IC	InChI=1S/C32H45N5O7/c1-20(2)17-25(33-32(42)44-19-24-15-11-8-12-16-24)28(38)34-26(21(3)4)29(39)36-37-31(41)35-27(22(5)6)30(40)43-18-23-13-9-7-10-14-23/h7-16,20-22,25-27H,17-19H2,1-6H3,(H,33,42)(H,34,38)(H,36,39)(H2,35,37,41)
DM6OGR9	CS	CC(C)CC(C(=O)NC(C(C)C)C(=O)NNC(=O)NC(C(C)C)C(=O)OCC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2
DM6OGR9	IK	QYEUFPXQJIQXLI-UHFFFAOYSA-N
DM6OGR9	IU	benzyl 3-methyl-2-[[[3-methyl-2-[[4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]butanoyl]amino]carbamoylamino]butanoate
DM6OGR9	DE	Discovery agent

DM1H865	ID	DM1H865
DM1H865	DN	ZL-N-91
DM1H865	HS	Investigative
DM1H865	CP	Zhejiang University
DM1H865	DE	Lung inflammation

DMA3M9H	ID	DMA3M9H
DMA3M9H	DN	ZM 253270
DMA3M9H	HS	Investigative
DMA3M9H	SN	ZM-253270; ZM253270
DMA3M9H	DT	Small molecular drug
DMA3M9H	PC	9826055
DMA3M9H	MW	471.9
DMA3M9H	FM	C22H26ClN7O3
DMA3M9H	IC	InChI=1S/C22H26ClN7O3/c1-13(2)30-12-17-18(21(30)32)25-22(26-19(17)24-16-6-4-15(23)5-7-16)29-10-8-28(9-11-29)20(31)14(3)27-33/h4-7,13,33H,8-12H2,1-3H3,(H,24,25,26)/b27-14-
DMA3M9H	CS	CC(C)N1CC2=C(C1=O)N=C(N=C2NC3=CC=C(C=C3)Cl)N4CCN(CC4)C(=O)/C(=N\\O)/C
DMA3M9H	IK	OYOSXTKSOATNNB-VYYCAZPPSA-N
DMA3M9H	IU	4-(4-chloroanilino)-2-[4-[(2Z)-2-hydroxyiminopropanoyl]piperazin-1-yl]-6-propan-2-yl-5H-pyrrolo[3,4-d]pyrimidin-7-one
DMA3M9H	DE	Discovery agent

DMC46RQ	ID	DMC46RQ
DMC46RQ	DN	ZM 325802
DMC46RQ	HS	Investigative
DMC46RQ	DE	Discovery agent

DMD0NFL	ID	DMD0NFL
DMD0NFL	DN	ZM-274773
DMD0NFL	HS	Investigative
DMD0NFL	SN	M-274773
DMD0NFL	DT	Small molecular drug
DMD0NFL	PC	9871234
DMD0NFL	MW	517.5
DMD0NFL	FM	C27H34Cl2N4O2
DMD0NFL	IC	InChI=1S/C27H34Cl2N4O2/c1-31(26(34)20-6-3-2-4-7-20)19-22(21-8-9-24(28)25(29)18-21)10-15-32-16-11-23(12-17-32)33-14-5-13-30-27(33)35/h2-4,6-9,18,22-23H,5,10-17,19H2,1H3,(H,30,35)/t22-/m1/s1
DMD0NFL	CS	CN(C[C@@H](CCN1CCC(CC1)N2CCCNC2=O)C3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=CC=C4
DMD0NFL	IK	SCMPVSAUZONHCN-JOCHJYFZSA-N
DMD0NFL	IU	N-[(2S)-2-(3,4-dichlorophenyl)-4-[4-(2-oxo-1,3-diazinan-1-yl)piperidin-1-yl]butyl]-N-methylbenzamide
DMD0NFL	DE	Discovery agent

DMD5JYQ	ID	DMD5JYQ
DMD5JYQ	DN	ZM-336372
DMD5JYQ	HS	Investigative
DMD5JYQ	SN	ZM 336372; 208260-29-1; ZM336372; ZM-336372; 3-(dimethylamino)-N-(3-(4-hydroxybenzamido)-4-methylphenyl)benzamide; N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; CHEMBL186526; n-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide; 3-(dimethylamino)-N-{3-[(4-hydroxybenzoyl)amino]-4-methylphenyl}benzamide; 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide; 3-(dimethylamino)-N-[3-(4-hydroxybenzamido)-4-methylphenyl]benzamide; Bio1_001346; compound 1 [PMID: 15454231
DMD5JYQ	DT	Small molecular drug
DMD5JYQ	PC	5730
DMD5JYQ	MW	389.4
DMD5JYQ	FM	C23H23N3O3
DMD5JYQ	IC	InChI=1S/C23H23N3O3/c1-15-7-10-18(24-23(29)17-5-4-6-19(13-17)26(2)3)14-21(15)25-22(28)16-8-11-20(27)12-9-16/h4-14,27H,1-3H3,(H,24,29)(H,25,28)
DMD5JYQ	CS	CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)N(C)C)NC(=O)C3=CC=C(C=C3)O
DMD5JYQ	IK	PYEFPDQFAZNXLI-UHFFFAOYSA-N
DMD5JYQ	IU	3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide
DMD5JYQ	CA	CAS 208260-29-1
DMD5JYQ	CB	CHEBI:95033
DMD5JYQ	DE	Discovery agent

DMTMVYH	ID	DMTMVYH
DMTMVYH	DN	ZM-39923
DMTMVYH	HS	Investigative
DMTMVYH	SN	ZM39923; 273727-89-2; ZM-39923; UNII-M0ZX82000S; M0ZX82000S; 3-[benzyl(propan-2-yl)amino]-1-(naphthalen-2-yl)propan-1-one; 3-(Benzyl(propan-2-yl)amino)-1-(naphthalen-2-yl)propan-1-one; JSASWRWALCMOQP-UHFFFAOYSA-N; Tocris-1367; NCGC00025126-01; AC1L1GQH; Lopac-Z-4626; Lopac0_000844; SCHEMBL2891331; GTPL5994; CHEMBL596674; CHEBI:92715; BDBM81346; CTK6A9359; M9440 (Me-3,4-dephostatin); ZINC1487934; HY-12589A; HSCI1_000104; AKOS030526763; CS-4952; CCG-204927; NCGC00025126-02; NCGC00016107-05; NCGC00016107-02; NCGC00016107-09
DMTMVYH	DT	Small molecular drug
DMTMVYH	PC	3797
DMTMVYH	MW	331.4
DMTMVYH	FM	C23H25NO
DMTMVYH	IC	InChI=1S/C23H25NO/c1-18(2)24(17-19-8-4-3-5-9-19)15-14-23(25)22-13-12-20-10-6-7-11-21(20)16-22/h3-13,16,18H,14-15,17H2,1-2H3
DMTMVYH	CS	CC(C)N(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC3=CC=CC=C3
DMTMVYH	IK	JSASWRWALCMOQP-UHFFFAOYSA-N
DMTMVYH	IU	3-[benzyl(propan-2-yl)amino]-1-naphthalen-2-ylpropan-1-one
DMTMVYH	CA	CAS 273727-89-2
DMTMVYH	CB	CHEBI:92715
DMTMVYH	DE	Discovery agent

DMFP8WE	ID	DMFP8WE
DMFP8WE	DN	ZM-447439
DMFP8WE	HS	Investigative
DMFP8WE	SN	331771-20-1; ZM-447439; ZM447439; ZM 447439; N-[4-[[6-METHOXY-7-[3-(4-MORPHOLINYL)PROPOXY]-4-QUINAZOLINYL]AMINO]PHENYL]BENZAMIDE; TCMDC-125873; UNII-RSN3P9776R; CHEMBL202721; RSN3P9776R; N-(4-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)benzamide; C29H31N5O4; N-[4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl}amino)phenyl]benzamide; N-(4-{[6-Methoxy-7-(3-Morpholin-4-Ylpropoxy)quinazolin-4-Yl]amino}phenyl)benzamide
DMFP8WE	DT	Small molecular drug
DMFP8WE	PC	9914412
DMFP8WE	MW	513.6
DMFP8WE	FM	C29H31N5O4
DMFP8WE	IC	InChI=1S/C29H31N5O4/c1-36-26-18-24-25(19-27(26)38-15-5-12-34-13-16-37-17-14-34)30-20-31-28(24)32-22-8-10-23(11-9-22)33-29(35)21-6-3-2-4-7-21/h2-4,6-11,18-20H,5,12-17H2,1H3,(H,33,35)(H,30,31,32)
DMFP8WE	CS	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5
DMFP8WE	IK	OGNYUTNQZVRGMN-UHFFFAOYSA-N
DMFP8WE	IU	N-[4-[[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino]phenyl]benzamide
DMFP8WE	CA	CAS 331771-20-1
DMFP8WE	CB	CHEBI:91376
DMFP8WE	DE	Discovery agent

DMEC1I9	ID	DMEC1I9
DMEC1I9	DN	Zn2+
DMEC1I9	HS	Investigative
DMEC1I9	SN	zinc ion; Zinc cation; zinc(2+); Zinc, ion (Zn2+); 23713-49-7; Zn(II); Velmanase Alfa; UNII-13S1S8SF37; Zinc (II) ion; zinc(2+) ion; Zinc (II); Velmanase Alfa [INN]; Zn+2; CHEBI:29105; Zn(2+); 13S1S8SF37; 9025-42-7; Microheterogeneityzinc Ion; alpha-Mannanase; Zinc ions; alpha-Mannosidase; Zinc(2+)ions; Mannosidase, alpha-; alpha-Mannopyranosidase; Zinc 2+; Rhlaman; dietary zinc; UNII-M91TG242P2; Zinc dication; zinc(II) cation; Zinc divalent ion; alpha-Mannosidase recombinant human; Recombinant Human Alpha-mannosidase
DMEC1I9	DT	Small molecular drug
DMEC1I9	PC	32051
DMEC1I9	MW	65.4
DMEC1I9	FM	Zn+2
DMEC1I9	IC	InChI=1S/Zn/q+2
DMEC1I9	CS	[Zn+2]
DMEC1I9	IK	PTFCDOFLOPIGGS-UHFFFAOYSA-N
DMEC1I9	IU	zinc(2+)
DMEC1I9	CA	CAS 23713-49-7
DMEC1I9	CB	CHEBI:29105
DMEC1I9	DE	Discovery agent

DMY2V37	ID	DMY2V37
DMY2V37	DN	ZNCCNCSSKWCRDHSRCC
DMY2V37	HS	Investigative
DMY2V37	SN	ZNCCNCSSKWCRDHSRCC
DMY2V37	PC	44560052
DMY2V37	MW	2109.4
DMY2V37	FM	C79H117N31O26S6
DMY2V37	IC	InChI=1S/C79H117N31O26S6/c80-14-4-3-9-38-61(120)97-42(17-34-22-91-37-8-2-1-7-36(34)37)65(124)107-51-28-139-142-32-55(109-67(126)44(19-56(81)114)99-64(123)41-12-13-58(116)93-41)77(136)110-52-29-140-141-31-54(76(135)105-50(60(83)119)27-137-138-30-53(108-68(127)45(20-57(82)115)100-74(52)133)75(134)104-49(26-113)72(131)103-48(25-112)71(130)94-38)106-63(122)40(11-6-16-90-79(86)87)95-70(129)47(24-111)102-66(125)43(18-35-23-88-33-92-35)98-69(128)46(21-59(117)118)101-62(121)39(96-73(51)132)10-5-15-89-78(84)85/h1-2,7-8,22-23,33,38-55,91,111-113H,3-6,9-21,24-32,80H2,(H2,81,114)(H2,82,115)(H2,83,119)(H,88,92)(H,93,116)(H,94,130)(H,95,129)(H,96,132)(H,97,120)(H,98,128)(H,99,123)(H,100,133)(H,101,121)(H,102,125)(H,103,131)(H,104,134)(H,105,135)(H,106,122)(H,107,124)(H,108,127)(H,109,126)(H,110,136)(H,117,118)(H4,84,85,89)(H4,86,87,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-/m0/s1
DMY2V37	CS	C1CC(=O)N[C@@H]1C(=O)N[C@@H](CC(=O)N)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]4CSSC[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](NC4=O)C(=O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC5=CNC6=CC=CC=C65)CCCCN)CO)CO)CC(=O)N)NC2=O)CCCNC(=N)N)CO)CC7=CN=CN7)CC(=O)O)CCCNC(=N)N
DMY2V37	IK	ZZZNHYZYRLIYMB-JPPSNFOMSA-N
DMY2V37	IU	2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-47-[[(2S)-4-amino-4-oxo-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]butanoyl]amino]-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-12,33,36-tris(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMY2V37	DE	Discovery agent

DM8WRAU	ID	DM8WRAU
DM8WRAU	DN	ZP-2307
DM8WRAU	HS	Investigative
DM8WRAU	SN	Parathyroid hormone PTH(1-17) analog (osteoporosis), Zealand
DM8WRAU	CP	Zealand Pharma A/S
DM8WRAU	DE	Osteoporosis

DMJ16AD	ID	DMJ16AD
DMJ16AD	DN	ZP-3022
DMJ16AD	HS	Investigative
DMJ16AD	SN	Dual glucagon-like peptide 1/gastrin peptide agonist (diabetes), Zealand Pharma
DMJ16AD	CP	Zealand Pharma A/S
DMJ16AD	DE	Diabetic complication

DM9XFYZ	ID	DM9XFYZ
DM9XFYZ	DN	ZP-G-CSF
DM9XFYZ	HS	Investigative
DM9XFYZ	SN	Filgrastim (transdermal, Macroflux technology, neutropenia), Zosano
DM9XFYZ	CP	Zosano Pharma Inc
DM9XFYZ	DE	Neutropenia

DM43O2U	ID	DM43O2U
DM43O2U	DN	Z-Pro-Prolinal
DM43O2U	HS	Investigative
DM43O2U	SN	Z-Pro-prolinal; N-Benzyloxycarbonyl-prolyl-prolinal; n-benzyloxycarbonyl-l-prolyl-l-prolinal; CHEMBL79993; BRN 4821785; Prolyl Endopeptidase Inhibitor II; 86925-97-5; z-prolyl-prolinal; benzyl (2S)-2-[(2S)-2-formylpyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate; ZPR; 2-Pyrrolidinecarboxylic acid, 2-((2-formyl-1-pyrrolidinyl)carbonyl)-, phenylmethyl ester, (S-(R*,R*))-; AC1L3UY7; AC1Q6A8G; KBioSS_000265; KBioGR_000265; BSPBio_001545; SCHEMBL1219336; KBio3_000529; KBio2_005401; KBio3_000530; KBio2_002833; KBio2_000265; CTK3E8930
DM43O2U	DT	Small molecular drug
DM43O2U	PC	122623
DM43O2U	MW	330.4
DM43O2U	FM	C18H22N2O4
DM43O2U	IC	InChI=1S/C18H22N2O4/c21-12-15-8-4-10-19(15)17(22)16-9-5-11-20(16)18(23)24-13-14-6-2-1-3-7-14/h1-3,6-7,12,15-16H,4-5,8-11,13H2/t15-,16-/m0/s1
DM43O2U	CS	C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)OCC3=CC=CC=C3)C=O
DM43O2U	IK	ORZXYSPOAVJYRU-HOTGVXAUSA-N
DM43O2U	IU	benzyl (2S)-2-[(2S)-2-formylpyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate
DM43O2U	CA	CAS 88795-32-8
DM43O2U	DE	Discovery agent

DM1YZJ3	ID	DM1YZJ3
DM1YZJ3	DN	ZRCCNCSSKWCRDHSRCC
DM1YZJ3	HS	Investigative
DM1YZJ3	SN	ZRCCNCSSKWCRDHSRCC
DM1YZJ3	PC	44560053
DM1YZJ3	MW	2151.5
DM1YZJ3	FM	C81H123N33O25S6
DM1YZJ3	IC	InChI=1S/C81H123N33O25S6/c82-16-4-3-10-40-62(123)102-45(20-36-24-95-39-9-2-1-8-38(36)39)67(128)112-53-30-142-145-34-57(111-64(125)42(12-6-18-93-80(87)88)98-66(127)44-14-15-59(119)97-44)78(139)114-54-31-143-144-33-56(77(138)109-52(61(84)122)29-140-141-32-55(113-69(130)47(22-58(83)118)104-75(54)136)76(137)108-51(28-117)73(134)107-50(27-116)72(133)99-40)110-65(126)43(13-7-19-94-81(89)90)100-71(132)49(26-115)106-68(129)46(21-37-25-91-35-96-37)103-70(131)48(23-60(120)121)105-63(124)41(101-74(53)135)11-5-17-92-79(85)86/h1-2,8-9,24-25,35,40-57,95,115-117H,3-7,10-23,26-34,82H2,(H2,83,118)(H2,84,122)(H,91,96)(H,97,119)(H,98,127)(H,99,133)(H,100,132)(H,101,135)(H,102,123)(H,103,131)(H,104,136)(H,105,124)(H,106,129)(H,107,134)(H,108,137)(H,109,138)(H,110,126)(H,111,125)(H,112,128)(H,113,130)(H,114,139)(H,120,121)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t40-,41-,42-,43-,44-,45-,46-,47+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-/m0/s1
DM1YZJ3	CS	C1CC(=O)N[C@@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]4CSSC[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](NC4=O)C(=O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC5=CNC6=CC=CC=C65)CCCCN)CO)CO)CC(=O)N)NC2=O)CCCNC(=N)N)CO)CC7=CN=CN7)CC(=O)O)CCCNC(=N)N
DM1YZJ3	IK	BDKVNCLFYNBTCE-RQJANPMLSA-N
DM1YZJ3	IU	2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-47-[[(2S)-5-carbamimidamido-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-12,33,36-tris(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DM1YZJ3	DE	Discovery agent

DM60N3C	ID	DM60N3C
DM60N3C	DN	ztz240
DM60N3C	HS	Investigative
DM60N3C	SN	ZTZ240; N-(6-chloropyridin-3-yl)-4-fluorobenzamide; 325457-98-5; N-(6-chloro-3-pyridinyl)-4-fluorobenzenecarboxamide; AC1MWVXA; SCHEMBL5214418; GTPL7668; CHEMBL1454208; cid_3780776; BDBM64871; MolPort-002-886-592; KS-00003O7V; ZINC4106322; AKOS005282280; MS-1427; MCULE-1248614968; N-(6-Chloro-3-pyridyl)-4-fluorobenzamide; KB-276144; N-(6-chloro-3-pyridyl)-4-fluoro-benzamide; N-(6-chloro-3-pyridinyl)-4-fluorobenzamide; VU0409859-1
DM60N3C	DT	Small molecular drug
DM60N3C	PC	3780776
DM60N3C	MW	250.65
DM60N3C	FM	C12H8ClFN2O
DM60N3C	IC	InChI=1S/C12H8ClFN2O/c13-11-6-5-10(7-15-11)16-12(17)8-1-3-9(14)4-2-8/h1-7H,(H,16,17)
DM60N3C	CS	C1=CC(=CC=C1C(=O)NC2=CN=C(C=C2)Cl)F
DM60N3C	IK	URPKVELJRWKNQS-UHFFFAOYSA-N
DM60N3C	IU	N-(6-chloropyridin-3-yl)-4-fluorobenzamide
DM60N3C	DE	Discovery agent

DMCE8K1	ID	DMCE8K1
DMCE8K1	DN	Z-VAD-CHO
DMCE8K1	HS	Investigative
DMCE8K1	SN	CHEMBL320954; Z-VAD-CHO; ZVAD-CHO; BDBM50176519; (S)-3-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-oxo-butyric acid
DMCE8K1	DT	Small molecular drug
DMCE8K1	PC	10112904
DMCE8K1	MW	421.4
DMCE8K1	FM	C20H27N3O7
DMCE8K1	IC	InChI=1S/C20H27N3O7/c1-12(2)17(23-20(29)30-11-14-7-5-4-6-8-14)19(28)21-13(3)18(27)22-15(10-24)9-16(25)26/h4-8,10,12-13,15,17H,9,11H2,1-3H3,(H,21,28)(H,22,27)(H,23,29)(H,25,26)/t13-,15-,17-/m0/s1
DMCE8K1	CS	C[C@@H](C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1
DMCE8K1	IK	YYQWNJQKDSNAES-QRTARXTBSA-N
DMCE8K1	IU	(3S)-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
DMCE8K1	DE	Discovery agent

DM4Y0NI	ID	DM4Y0NI
DM4Y0NI	DN	ZX-AP000068
DM4Y0NI	HS	Investigative
DM4Y0NI	SN	DL-3-Fluoro-beta-alanine; OJQNRNQELNLWHH-UHFFFAOYSA-N; PC3387E; Propanoic acid, 3-amino-2-fluoro-; SCHEMBL637248; 2-Fluoro-beta-alanine; a-fluoro-b-alanine; a-fluoro-beta-alanine; alpha-Fluoro-beta-alanine; dl-2-Fluoro-3-alanine; (R)-3-amino-2-fluoropropanoic acid; (S)-3-Amino-2-fluoropropanoic acid; 130695-34-0; 2-Fluoro-.beta.-alanine; 2-Fluoro-beta-alanine #; 3-Amino-2-fluoropropionic acid; 3-amino-2-fluoropropanoic acid; 3821-81-6; AC1L21K0; CHEBI:80626; CHEMBL3544571; CTK8E9543; DTXSID00959160; EINECS 223-318-3
DM4Y0NI	PC	13351
DM4Y0NI	MW	107.08
DM4Y0NI	FM	C3H6FNO2
DM4Y0NI	IC	OJQNRNQELNLWHH-UHFFFAOYSA-N
DM4Y0NI	CS	C(C(C(=O)O)F)N
DM4Y0NI	IK	1S/C3H6FNO2/c4-2(1-5)3(6)7/h2H,1,5H2,(H,6,7)
DM4Y0NI	IU	3-amino-2-fluoropropanoic acid
DM4Y0NI	CA	CAS 3821-81-6
DM4Y0NI	CB	CHEBI:80626
DM4Y0NI	DE	Discovery agent

DMN9UCI	ID	DMN9UCI
DMN9UCI	DN	ZY H2
DMN9UCI	HS	Investigative
DMN9UCI	SN	ZYH2
DMN9UCI	DE	Discovery agent

DM0S5PE	ID	DM0S5PE
DM0S5PE	DN	ZYKLOPHIN
DM0S5PE	HS	Investigative
DM0S5PE	SN	zyklophin; GTPL9193; CHEMBL574568
DM0S5PE	PC	45483651
DM0S5PE	MW	1365.6
DM0S5PE	FM	C65H96N20O13
DM0S5PE	IC	InChI=1S/C65H96N20O13/c1-3-38(2)54-62(97)83-49(60(95)81-45(21-13-29-73-65(70)71)63(98)85-30-14-22-50(85)61(96)79-43(55(67)90)19-10-11-27-66)35-75-51(87)33-48(59(94)80-44(57(92)84-54)20-12-28-72-64(68)69)82-58(93)47(32-39-15-6-4-7-16-39)78-53(89)37-76-52(88)36-77-56(91)46(31-40-23-25-42(86)26-24-40)74-34-41-17-8-5-9-18-41/h4-9,15-18,23-26,38,43-50,54,74,86H,3,10-14,19-22,27-37,66H2,1-2H3,(H2,67,90)(H,75,87)(H,76,88)(H,77,91)(H,78,89)(H,79,96)(H,80,94)(H,81,95)(H,82,93)(H,83,97)(H,84,92)(H4,68,69,72)(H4,70,71,73)/t38?,43-,44-,45-,46-,47-,48-,49-,50-,54-/m0/s1
DM0S5PE	CS	CCC(C)[C@H]1C(=O)N[C@@H](CNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)NCC4=CC=CC=C4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N
DM0S5PE	IK	UWLIKQFWZOPOAX-HRFULILYSA-N
DM0S5PE	IU	(3S,6S,9S,12S)-12-[[(2S)-2-[[2-[[2-[[(2S)-2-(benzylamino)-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-6-butan-2-yl-N-[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-[[(2S)-1,6-diamino-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]-9-[3-(diaminomethylideneamino)propyl]-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carboxamide
DM0S5PE	DE	Discovery agent

DM0TP2R	ID	DM0TP2R
DM0TP2R	DN	Z-YVAD-CHO
DM0TP2R	HS	Investigative
DM0TP2R	SN	CHEMBL159822; Z-YVAD-CHO
DM0TP2R	DT	Small molecular drug
DM0TP2R	PC	44407073
DM0TP2R	MW	584.6
DM0TP2R	FM	C29H36N4O9
DM0TP2R	IC	InChI=1S/C29H36N4O9/c1-17(2)25(28(40)30-18(3)26(38)31-21(15-34)14-24(36)37)33-27(39)23(13-19-9-11-22(35)12-10-19)32-29(41)42-16-20-7-5-4-6-8-20/h4-12,15,17-18,21,23,25,35H,13-14,16H2,1-3H3,(H,30,40)(H,31,38)(H,32,41)(H,33,39)(H,36,37)/t18-,21-,23-,25-/m0/s1
DM0TP2R	CS	C[C@@H](C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)OCC2=CC=CC=C2
DM0TP2R	IK	NEIVVNHQVHXDKP-RCGJGYDGSA-N
DM0TP2R	IU	(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-(phenylmethoxycarbonylamino)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
DM0TP2R	DE	Discovery agent

DMFTBPI	ID	DMFTBPI
DMFTBPI	DN	Z-YVAD-FMK
DMFTBPI	HS	Investigative
DMFTBPI	SN	benzyloxycarbonyl-Tyr-Val-Ala-Asp(OMe)-fluoromethylketone; caspase-1 Inhibitor VI
DMFTBPI	DT	Small molecular drug
DMFTBPI	PC	644196
DMFTBPI	MW	630.7
DMFTBPI	FM	C31H39FN4O9
DMFTBPI	IC	InChI=1S/C31H39FN4O9/c1-18(2)27(30(42)33-19(3)28(40)34-23(25(38)16-32)15-26(39)44-4)36-29(41)24(14-20-10-12-22(37)13-11-20)35-31(43)45-17-21-8-6-5-7-9-21/h5-13,18-19,23-24,27,37H,14-17H2,1-4H3,(H,33,42)(H,34,40)(H,35,43)(H,36,41)/t19-,23-,24-,27-/m0/s1
DMFTBPI	CS	C[C@@H](C(=O)N[C@@H](CC(=O)OC)C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)OCC2=CC=CC=C2
DMFTBPI	IK	MVPQJUFFTWWKBT-LBDWYMBGSA-N
DMFTBPI	IU	methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-(phenylmethoxycarbonylamino)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxopentanoate
DMFTBPI	DE	Discovery agent